Get more medical books and resources at

www.medicalbr.com
Medicines Information Services

Information on drug therapy
Information on any aspect of drug therapy can be obtained from Regional and District Medicines Information Services. Details regarding the local services provided within your Region can be obtained by telephoning the following numbers.

<table>
<thead>
<tr>
<th>Region</th>
<th>Telephone Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>England</strong></td>
<td></td>
</tr>
<tr>
<td>Birmingham</td>
<td>(0121) 424 7298</td>
</tr>
<tr>
<td>Bristol</td>
<td>(0117) 342 2867</td>
</tr>
<tr>
<td>Ipswich</td>
<td>(01473) 704 431</td>
</tr>
<tr>
<td>Leeds</td>
<td>(0113) 206 5377</td>
</tr>
<tr>
<td>Leicester</td>
<td>(0116) 258 6491</td>
</tr>
<tr>
<td>Liverpool</td>
<td>(0151) 794 8113/7, (0151) 794 8118</td>
</tr>
<tr>
<td>London</td>
<td></td>
</tr>
<tr>
<td>• Guy’s Hospital</td>
<td>(020) 7188 8750, (020) 7188 3849, (020) 7188 3855</td>
</tr>
<tr>
<td>• Northwick Park Hospital</td>
<td>(020) 8669 2761, (020) 8669 3973</td>
</tr>
<tr>
<td>Newcastle</td>
<td>(0191) 282 4631</td>
</tr>
<tr>
<td>Southampton</td>
<td>(023) 8120 6908/9</td>
</tr>
<tr>
<td><strong>Scotland</strong></td>
<td></td>
</tr>
<tr>
<td>Aberdeen</td>
<td>(01224) 552 316</td>
</tr>
<tr>
<td>Dundee</td>
<td>(01382) 632 351, (01382) 660 111 Extn 32351</td>
</tr>
<tr>
<td>Edinburgh</td>
<td>(0131) 242 2920</td>
</tr>
<tr>
<td>Glasgow</td>
<td>(0141) 211 4407</td>
</tr>
<tr>
<td><strong>Northern Ireland</strong></td>
<td></td>
</tr>
<tr>
<td>Belfast</td>
<td>(028) 9504 0558</td>
</tr>
<tr>
<td><strong>Republic of Ireland</strong></td>
<td></td>
</tr>
<tr>
<td>Dublin</td>
<td>(01) 473 0589, (01) 453 7941 Extn 2348</td>
</tr>
</tbody>
</table>

United Kingdom Medicines Information Pharmacists Group (UKMIPG) website
www.ukmi.nhs.uk

Proprietary Manufacturers
Telephone numbers and email addresses of proprietary manufacturers listed in BNF Publications are shown in the Index of proprietary manufacturers p. 1488

UK Teratology Information Service
Information on drug and chemical exposures in pregnancy.
Tel: 0344 892 0909
www.uktis.org

UK Drugs in Lactation Advisory Service (UKDILAS)
Information on the compatibility of drugs with breastfeeding.
Tel: (0116) 258 6491, or (0121) 424 7298
www.ukmi.nhs.uk/ukdilas

Medicines in Dentistry Specialist Advisory Service
Information on drug therapy relating to dental treatment.
Liverpool: (0151) 794 8206

Driver and Vehicle Licensing Agency (DVLA)
Information on the national medical guidelines of fitness to drive is available from:
www.gov.uk/government/publications/at-a-glance

Patient Information Lines
NHS Urgent Care Services 111

Poisons Information Services
UK National Poisons Information Service 0344 892 0111
www.toxbase.org

Sport
- Information regarding the use of medicines in sport is available from UK Anti-Doping:
  www.ukad.org.uk
  Tel: (020) 7842 3450
  ukad@ukad.org.uk
  UK Anti-Doping
  Fleetbank House
  2-6 Salisbury Square
  London
  EC4Y 8AE
- Information about the prohibited status of specific medicines based on the current World Anti-Doping Agency Prohibited List is available from Global Drug Reference Online: www.globaldro.com/UK/search

Travel Immunisation
Up-to-date information on travel immunisation requirements may be obtained from:
- National Travel Health Network and Centre (for healthcare professionals only) 0845 602 6712 Monday – Friday (closed Wednesday afternoons and Bank Holidays): 09:00–11:45 and 13:00–15:45
- Travel Medicine Team, Health Protection Scotland (0141) 300 1100 (14.00–16.00 hours weekdays) www.travax.nhs.uk (for registered users of the NHS website Travax only)
- Welsh Government Switchboard English language 0300 0603300 (09.00–17.30 hours weekdays only)
- Welsh Government Switchboard Yr Iaith Gymraeg 0300 0604400 (09.00–17.30 hours weekdays only)
- Department of Health and Social Services (Belfast) (028) 9052 2118 (weekdays)

List of Registered Medical Practitioners
Details on whether doctors are registered and hold a licence to practise medicine in the UK can be obtained from the General Medical Council.
Tel: (0161) 923 6602
www.gmc-uk.org/register
Access the BNF your way

The *British National Formulary* (BNF) and *BNF for Children* are updated monthly online via MedicinesComplete, ensuring healthcare professionals always have the latest prescribing advice.

**ONLINE**

**BNF on MedicinesComplete**
Access BNF and *BNF for Children* on MedicinesComplete and receive the very latest drug information through monthly online updates.

**FormularyComplete** Create, edit and manage your own local formulary content built upon the trusted prescribing advice of the BNF and *BNF for Children*.

**BNF on Evidence Search**
Search the BNF and *BNF for Children* alongside other authoritative clinical and non-clinical evidence and best practice at www.evidence.nhs.uk from NICE.

**PRINT**

Eligible health professionals will now receive one print copy a year – the September issue – to supplement online access. If you are entitled to an NHS copy please refer to page ii for full details on distribution, call 01268 495 609 or email bnf@binleys.com.

*Turn the page for more details...*
How to purchase

**Buy direct from Pharmaceutical Press** by visiting
www.pharmpress.com/bnf

For enquiries about the BNF or BNFC in print, contact
direct@macmillan.co.uk
Tel: +44 (0) 1256 302 699

For enquiries concerning MedicinesComplete,
FormularyComplete, or bulk orders of the print edition, contact
pharmpress-support@rpharms.com
Tel: +44 (0) 20 7572 2266

Download mobile apps by visiting your appropriate app store.
Available for iOS, Android and Blackberry

For pricing information please visit the website at
www.pharmpress.com/bnf

For international sales contact your local sales agent.
Contact details at www.pharmpress.com/agents

Stay up to date – sign up to the BNF
eNewsletter at www.bnf.org/newsletter
Preface

The BNF is a joint publication of the British Medical Association and the Royal Pharmaceutical Society. It is published under the authority of a Joint Formulary Committee which comprises representatives of the two professional bodies, the UK Health Departments, the Medicines and Healthcare products Regulatory Agency, and a national guideline producer. The Dental Advisory Group oversees the preparation of advice on the drug management of dental and oral conditions; the Group includes representatives of the British Dental Association and a representative from the UK Health Departments. The Nurse Prescribers’ Advisory Group advises on the content relevant to nurses and includes representatives from different parts of the nursing community and from the UK Health Departments.

The BNF aims to provide prescribers, pharmacists, and other healthcare professionals with sound up-to-date information about the use of medicines.

The BNF includes key information on the selection, prescribing, dispensing and administration of medicines. Medicines generally prescribed in the UK are covered and those considered less suitable for prescribing are clearly identified. Little or no information is included on medicines promoted for purchase by the public.

Information on drugs is drawn from the manufacturers’ product literature, medical and pharmaceutical literature, UK health departments, regulatory authorities, and professional bodies. Advice is constructed from clinical literature and reflects, as far as possible, an evaluation of the evidence from diverse sources. The BNF also takes account of authoritative national guidelines and emerging safety concerns. In addition, the editorial team receives advice on all therapeutic areas from expert clinicians; this ensures that the BNF’s recommendations are relevant to practice.

The BNF is designed as a digest for rapid reference and it may not always include all the information necessary for prescribing and dispensing. Also, less detail is given on areas such as obstetrics, malignant disease, and anaesthesia since it is expected that those undertaking treatment will have specialist knowledge and access to specialist literature. BNF for Children should be consulted for detailed information on the use of medicines in children. The BNF should be interpreted in the light of professional knowledge and supplemented as necessary by specialised publications and by reference to the product literature. Information is also available from medicines information services, see Medicines Information Services (see inside front cover).

It is important to use the most recent BNF information for making clinical decisions. The print edition of the BNF is updated in March and September each year. Monthly updates are provided online via Medicines Complete and the NHS Evidence portal. The more important changes are listed under Changes; changes listed online are cumulative (from one print edition to the next), and can be printed off each month to show the main changes since the last print edition as an aide memoire for those using print copies.

The BNF Publications website (www.bnf.org) includes additional information of relevance to healthcare professionals. Other digital formats of the BNF—including versions for mobile devices and integration into local formularies—are also available.

BNF Publications welcomes comments from healthcare professionals. Comments and constructive criticism should be sent to:

British National Formulary,
Royal Pharmaceutical Society,
66–68 East Smithfield
London
E1W 1AW
editor@bnf.org

The contact email for manufacturers or pharmaceutical companies wishing to contact BNF Publications is manufacturerinfo@bnf.org
## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preface</td>
<td>iii</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>v</td>
</tr>
<tr>
<td>How BNF publications are constructed</td>
<td>ix</td>
</tr>
<tr>
<td>How to use BNF Publications in print</td>
<td>xii</td>
</tr>
<tr>
<td>Changes</td>
<td>xix</td>
</tr>
<tr>
<td>Guidance on Prescribing</td>
<td>1</td>
</tr>
<tr>
<td>Prescription writing</td>
<td>5</td>
</tr>
<tr>
<td>Emergency supply of medicines</td>
<td>7</td>
</tr>
<tr>
<td>Controlled drugs and drug dependence</td>
<td>8</td>
</tr>
<tr>
<td>Adverse reactions to drugs</td>
<td>12</td>
</tr>
<tr>
<td>Guidance on intravenous infusions</td>
<td>16</td>
</tr>
<tr>
<td>Prescribing for children</td>
<td>18</td>
</tr>
<tr>
<td>Prescribing in hepatic impairment</td>
<td>19</td>
</tr>
<tr>
<td>Prescribing in renal impairment</td>
<td>19</td>
</tr>
<tr>
<td>Prescribing in pregnancy</td>
<td>22</td>
</tr>
<tr>
<td>Prescribing in breast-feeding</td>
<td>22</td>
</tr>
<tr>
<td>Prescribing in palliative care</td>
<td>23</td>
</tr>
<tr>
<td>Prescribing for the elderly</td>
<td>28</td>
</tr>
<tr>
<td>Drugs and sport</td>
<td>29</td>
</tr>
<tr>
<td>Prescribing in dental practice</td>
<td>30</td>
</tr>
</tbody>
</table>

## NOTES ON DRUGS AND PREPARATIONS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Gastro-intestinal system</td>
<td>35</td>
</tr>
<tr>
<td>2 Cardiovascular system</td>
<td>96</td>
</tr>
<tr>
<td>3 Respiratory system</td>
<td>229</td>
</tr>
<tr>
<td>4 Nervous system</td>
<td>287</td>
</tr>
<tr>
<td>5 Infection</td>
<td>479</td>
</tr>
<tr>
<td>6 Endocrine system</td>
<td>627</td>
</tr>
<tr>
<td>7 Genito-urinary system</td>
<td>731</td>
</tr>
<tr>
<td>8 Immune system and malignant disease</td>
<td>785</td>
</tr>
<tr>
<td>9 Blood and nutrition</td>
<td>922</td>
</tr>
<tr>
<td>10 Musculoskeletal system</td>
<td>998</td>
</tr>
<tr>
<td>11 Eye</td>
<td>1057</td>
</tr>
<tr>
<td>12 Ear, nose and oropharynx</td>
<td>1093</td>
</tr>
<tr>
<td>13 Skin</td>
<td>1117</td>
</tr>
<tr>
<td>14 Vaccines</td>
<td>1183</td>
</tr>
<tr>
<td>15 Anaesthesia</td>
<td>1218</td>
</tr>
<tr>
<td>16 Emergency treatment of poisoning</td>
<td>1249</td>
</tr>
</tbody>
</table>

## APPENDICES AND INDICES

| Appendix 1 Interactions                                               | 1262 |
| Appendix 2 Borderline substances                                      | 1420 |
| Appendix 3 Cautionary and advisory labels for dispensed medicines     | 1454 |
| Appendix 4 Wound management products and elasticated garments         | 1457 |
| Dental Practitioners' Formulary                                       | 1482 |
| Nurse Prescribers' Formulary                                          | 1484 |
| Non-medical prescribing                                               | 1487 |
| Index of proprietary manufacturers                                   | 1488 |
| Special-order Manufacturers                                          | 1493 |
| Index                                                                  | 1495 |
| Medical emergencies in the community                                 | inside back cover |
Acknowledgements

The Joint Formulary Committee is grateful to individuals and organisations that have provided advice and information to the BNF.

The principal contributors for this update were:

Expert advice on the management of oral and dental conditions was kindly provided by M. Addy, P. Coulthard, A. Crighton, M.A.O. Lewis, J.G. Meechan, N.D. Robb, C. Scully, R.A. Seymour, R. Welbury, and J.M. Zakrzewska.

S. Kaur provided valuable advice on dental prescribing policy.


Members of the Advisory Committee on Malaria Prevention, R.H. Behrens, D. Bell, P.L. Chiodini, V. Field, F. Genasi, L. Goodyer, A. Green, J. Jones, G. Kassianos, D.G. Lalloo, D. Patel, H. Patel, M. Powell, D.V. Shingadia, N.O. Subair, C.J.M. Whitty, M. Blaze (Secretariat), and V. Smith (Secretariat) have provided valuable advice.

The UK Ophthalmic Pharmacy Group have also provided valuable advice.

The MHRA have provided valuable assistance.

Correspondents in the pharmaceutical industry have provided information on new products and commented on products in the BNF.

Numerous doctors, pharmacists, nurses, and others have sent comments and suggestions.

BNF interactions are provided by C.L. Preston, S.L. Jones, H.K. Sandhu, and S. Sutton.

The BNF has valuable access to the Martindale data banks by courtesy of A. Brayfield and staff.


BNF interactions are provided by C.L. Preston, S.L. Jones, H.K. Sandhu, and S. Sutton.

The BNF has valuable access to the Martindale data banks by courtesy of A. Brayfield and staff.


The Joint Formulary Committee is grateful to individuals and organisations that have provided advice and information to the BNF.

The principal contributors for this update were:

Expert advice on the management of oral and dental conditions was kindly provided by M. Addy, P. Coulthard, A. Crighton, M.A.O. Lewis, J.G. Meechan, N.D. Robb, C. Scully, R.A. Seymour, R. Welbury, and J.M. Zakrzewska.

S. Kaur provided valuable advice on dental prescribing policy.


Members of the Advisory Committee on Malaria Prevention, R.H. Behrens, D. Bell, P.L. Chiodini, V. Field, F. Genasi, L. Goodyer, A. Green, J. Jones, G. Kassianos, D.G. Lalloo, D. Patel, H. Patel, M. Powell, D.V. Shingadia, N.O. Subair, C.J.M. Whitty, M. Blaze (Secretariat), and V. Smith (Secretariat) have provided valuable advice.

The UK Ophthalmic Pharmacy Group have also provided valuable advice.

The MHRA have provided valuable assistance.

Correspondents in the pharmaceutical industry have provided information on new products and commented on products in the BNF.

Numerous doctors, pharmacists, nurses, and others have sent comments and suggestions.

BNF interactions are provided by C.L. Preston, S.L. Jones, H.K. Sandhu, and S. Sutton.

The BNF has valuable access to the Martindale data banks by courtesy of A. Brayfield and staff.


BNF Staff

BNF DIRECTOR
Karen Baxter
BSc, MSc, MRPharmS

HEAD OF CONTENT
Kate Towers
BPharm (AU), GCClinPharm

CONTENT MANAGERS
Thomas F. Corbett
BScPharm (IRL), MPharm (IRL)
Kristina Fowlie
MPharm, CertPharmPract, MRPharmS
Claire McSherry
BPharm (NZ), PGCertClinPharm (NZ)
Heenaben Patel
MPharm, DipClinPharm, MRPharmS

QUALITY AND PROCESS MANAGER
Angela M.G. McFarlane
BSc, DipClinPharm

CLINICAL WRITERS
Abby Calder
BPharm (NZ), PGCertClinPharm (NZ)
Naimah Callachand
MPharm
Holly Hayne
BSc (Pharmacology) (NZ), BPharm (NZ)
Angela L. Kam
BPharm (NZ), PGDipPharmPrac (NZ), PGCertPharmPres (NZ)
Philip D. Lee
BSc, PhD
Kirsty Luck
BPharm (AU)
Nafeesa Mussa
BPharm (NZ), PGCertClinPharm (NZ)
Kere Odumah
MPharm
Paridhi K. Prashar
MPharm, MRPharmS
Jacob M. Warner
BPharm (AU)
Sharyn Young
BPharm (NZ), PGDipClinPharm (NZ)

CLINICAL ASSISTANTS
Elizabeth King

EDITORIAL ASSISTANTS
Hima Bhatt
BSc, MA
Jaya Venkitachalam
BSc, MRes

SENIOR BNF ADMINISTRATOR
Heidi Homar
BA

MANAGING DIRECTOR, PHARMACEUTICAL PRESS
Alina Lourie
B.Ed, MSc

SENIOR MEDICAL ADVISER
Derek G. Waller
BSc, MB, BS, DM, FRCP
Joint Formulary Committee 2017–2018

CHAIR
Derek G. Waller
BSc, MB BS, DM, FRCP

DEPUTY CHAIR
Alison Blenkinsopp
BPPharm, PhD, FRPharmS, OBE

COMMITTEE MEMBERS
Julie Beynon
MB ChB, FRCA, FFPM
Carmel M. Darcy
BSc, MSc, IP, MPSNI, MRPharmS
Sue Faulding
BPPharm, MSc, FRPharmS
Tracy Hall
BSc, MSc, Cert N, Dip N, RGN, DN
Simon Hurding
MB, ChB, MRCGP
W. Moira Kinnear
BSc, MSc, MRPharmS
Mark P. Lythgoe
MB BS, MRPharmS
Louise Picton
BSc, DipCommPharm, MSc, MRPharmS
Michael J. Stewart
MB ChB, MD, FRCP(Ed), FRCP
Esther Wong
BSc, MPharm, MSc, DipEthics, DipPharmPract, IP, MRPharmS

LAY MEMBERS
Andy Burman

EXECUTIVE SECRETARY
Heidi Homar
BA

Dental Advisory Group 2017–2018

CHAIR
Sarah Manton
BDS, FDSRCS Ed, FHEA, PhD

COMMITTEE MEMBERS
Karen Baxter
BSc, MSc, MRPharmS
Andrew K. Brewer
BSc, BchD
Alexander Crighton
Kristina Fowlie
MPPharm, CertPharmPract, MRPharmS
Michelle Moffat
BDS, MFDS RCS Ed, M Paed Dent RCPS, FDS (Paed Dent) RCS Ed
Kate Towers
BPPharm (AU), GCClinPharm

SECRETARY
Arianne J. Matlin
MA, MSc, PhD

EXECUTIVE SECRETARY
Heidi Homar
BA

ADVICE ON DENTAL PRACTICE
The British Dental Association has contributed to the advice on medicines for dental practice through its representatives on the Dental Advisory Group.
Nurse Prescribers’ Advisory Group 2017-2018

CHAIR
Molly Courtenay
PhD, MSc, Cert Ed, BSc, RGN

COMMITTEE MEMBERS
Karen Baxter
BSc, MSc, MRPharmS
Kristina Fowlie
MPharm, CertPharmPract, MRPharmS
Penny M. Franklin
RN, RCN, RSCPHN(HV), MA, PGCE
Matt Griffiths
BA (Hons), FAETC, RGN, Cert A&E, NISP, PHECC
Tracy Hall
BSc, MSc, RGN, DN, Dip N, Cert N
Penny Harrison
BSc (Hons)
Julie MacAngus
BSc (Hons), RGN, RM, PGCE
Joan Myers
MSc, BSc, RGN, RSCN, Dip DN
Fiona Peniston-Bird
BSc (Hons), NIP, RHV, RGN
Kathy Radley
BSc, RGN
Kate Towers
BPharm (AU), GCClinPharm

EXECUTIVE SECRETARY
Heidi Homar
BA
How BNF Publications are constructed

Overview
The BNF is an independent professional publication that addresses the day-to-day prescribing information needs of healthcare professionals. Use of this resource throughout the health service helps to ensure that medicines are used safely, effectively, and appropriately.

Hundreds of changes are made between print editions, and are published monthly in a number of digital formats. The most clinically significant updates are listed under Changes p. xix.

The BNF is unique in bringing together authoritative, independent guidance on best practice with clinically validated drug information. Validation of information follows a standardised process, reviewing emerging evidence, best-practice guidelines, and advice from a network of clinical experts. Where the evidence base is weak, further validation is undertaken through a process of peer review. The process and its governance are outlined in greater detail in the sections that follow.

Joint Formulary Committee
The Joint Formulary Committee (JFC) is responsible for the content of the BNF. The JFC includes pharmacy, medical, nursing, and lay representatives; there are also representatives from the Medicines and Healthcare products Regulatory Agency (MHRA), the UK Health Departments, and a national guideline producer. The JFC decides on matters of policy and reviews amendments to the BNF in the light of new evidence and expert advice.

Dental Advisory Group
The Dental Advisory Group oversees the preparation of advice on the drug management of dental and oral conditions; the group includes representatives from the British Dental Association and a representative from the UK Health Departments.

Nurse Prescribers’ Advisory Group
The Nurse Prescribers’ Advisory Group oversees the list of drugs approved for inclusion in the Nurse Prescribers’ Formulary; the group includes representatives from a range of nursing disciplines and stakeholder organisations.

Expert advisers
The BNF uses about 60 expert clinical advisers (including doctors, pharmacists, nurses, and dentists) throughout the UK to help with clinical content. The role of these expert advisers is to review existing text and to comment on amendments drafted by the clinical writers. These clinical experts help to ensure that the BNF remains reliable by:
- commenting on the relevance of the text in the context of best clinical practice in the UK;
- checking draft amendments for appropriate interpretation of any new evidence;
- providing expert opinion in areas of controversy or when reliable evidence is lacking;
- providing independent advice on drug interactions, prescribing in hepatic impairment, renal impairment, pregnancy, breast-feeding, children, the elderly, palliative care, and the emergency treatment of poisoning.

In addition to consulting with regular advisers, the BNF calls on other clinical specialists for specific developments when particular expertise is required.

The BNF works closely with a number of expert bodies that produce clinical guidelines. Drafts or pre-publication copies of guidelines are often received for comment and assimilation into the BNF.

Editorial team
BNF clinical writers have all worked as pharmacists or possess a pharmacy degree and a further, relevant postgraduate qualification, and have a sound understanding of how drugs are used in clinical practice. As a team, the clinical writers are responsible for editing, maintaining, and updating BNF content. They follow a systematic prioritisation process in response to updates to the evidence base in order to ensure the most clinically important topics are reviewed as quickly as possible. In parallel the team of clinical writers undertakes a process of rolling revalidation, aiming to review all of the content in the BNF over a 3- to 4-year period.

Amendments to the text are drafted when the clinical writers are satisfied that any new information is reliable and relevant. A set of standard criteria define when content is referred to expert advisers, the Joint Formulary Committee or other advisory groups, or submitted for peer review.

Clinical writers prepare the text for publication and undertake a number of validation checks on the knowledge at various stages of the production process.

Sources of BNF information
The BNF uses a variety of sources for its information; the main ones are shown below.

Summaries of product characteristics
The BNF reviews summaries of product characteristics (SPCs) of all new products as well as revised SPCs for existing products. The SPCs are the principal source of product information and are carefully processed. Such processing involves:
- verifying the approved names of all relevant ingredients including ‘non-active’ ingredients (the BNF is committed to using approved names and descriptions as laid down by the Human Medicine Regulations 2012);
- comparing the indications, cautions, contra-indications, and side-effects with similar existing drugs. Where these are different from the expected pattern, justification is sought for their inclusion or exclusion;
- seeking independent data on the use of drugs in pregnancy and breast-feeding;
- incorporating the information into the BNF using established criteria for the presentation and inclusion of the data;
- checking interpretation of the information by a second clinical writer before submitting to a content manager; changes relating to doses receive a further check;
- identifying potential clinical problems or omissions and seeking further information from manufacturers or from expert advisers;
- constructing, with the help of expert advisers, a comment on the role of the drug in the context of similar drugs.

Much of this processing is applicable to the following sources as well.

Literature
Clinical writers monitor core medical and pharmaceutical journals. Research papers and reviews relating to drug therapy are carefully processed. When a difference between the advice in the BNF and the paper is noted, the new information is assessed for reliability (using tools based on SIGN methodology) and relevance to UK clinical practice. If necessary, new text is drafted and discussed with expert advisers and the Joint Formulary Committee. The BNF enjoys a close working relationship with a number of national information providers.

In addition to the routine process, which is used to identify ‘triggers’ for changing the content, systematic literature searches are used to identify the best quality evidence available to inform an update. Clinical writers receive training in critical appraisal, literature evaluation, and search strategies.
Consensus guidelines
The advice in the BNF is checked against consensus guidelines produced by expert bodies. The quality of the guidelines is assessed using adapted versions of the AGREE II tool. A number of bodies make drafts or pre-publication copies of the guidelines available to the BNF; it is therefore possible to ensure that a consistent message is disseminated. The BNF routinely processes guidelines from the National Institute for Health and Care Excellence (NICE), the All Wales Medicines Strategy Group (AWMSG), the Scottish Medicines Consortium (SMC), and the Scottish Intercollegiate Guidelines Network (SIGN).

Reference sources
Textbooks and reference sources are used to provide background information for the review of existing text or for the construction of new text. The BNF team works closely with the editorial team that produces Martindale: The Complete Drug Reference. The BNF has access to Martindale information resources and each team keeps the other informed of significant developments and shifts in the trends of drug usage.

Peer review
Although every effort is made to identify the most robust data available, inevitably there are areas where the evidence base is weak or contradictory. While the BNF has the valuable support of expert advisers and the Joint Formulary Committee, the recommendations made may be subject to a further level of scrutiny through peer review to ensure they reflect best practice.

Content for peer review is posted on bnf.org and interested parties are notified via a number of channels, including the BNF e-newsletter.

Statutory information
The BNF routinely processes relevant information from various Government bodies including Statutory Instruments and regulations affecting the Prescriptions only Medicines Order. Official compendia such as the British Pharmacopoeia and its addenda are processed routinely to ensure that the BNF complies with the relevant sections of the Human Medicines Regulations 2012.

The BNF maintains close links with the Home Office (in relation to controlled drug regulations) and the Medicines and Healthcare products Regulatory Agency (including the British Pharmacopoeia Commission). Safety warnings issued by the Commission on Human Medicines (CHM) and guidelines on drug are issued by the UK health departments are processed as a matter of routine.

Relevant professional statements issued by the Royal Pharmaceutical Society are included in the BNF as are guidelines from bodies such as the Royal College of General Practitioners.

Medicines and devices
NHS Prescription Services (from the NHS Business Services Authority) provides non-clinical, categorial information (including prices) on the medicines and devices included in the BNF.

Comments from readers
Readers of the BNF are invited to send in comments. Numerous letters and emails are received by the BNF team. Such feedback helps to ensure that the BNF provides practical and clinically relevant information. Many changes in the presentation and scope of the BNF have resulted from comments sent in by users.

Comments from industry
Close scrutiny of BNF by the manufacturers provides an additional check and allows them an opportunity to raise issues about BNF’s presentation of the role of various drugs; this is yet another check on the balance of BNF’s advice. All comments are looked at with care and, where necessary, additional information and expert advice are sought.

Market research
Market research is conducted at regular intervals to gather feedback on specific areas of development.

Assessing the evidence
From January 2016, recommendations made in BNF publications have been evidence graded to reflect the strength of the recommendation. The addition of evidence grading is to support clinical decision making based on the best available evidence.

Evidence used to make a recommendation is assessed for validity using standardised methodology tools based on AGREE II and assigned a level of evidence. The recommendation is then given a grade that is extrapolated from the level of evidence, and an assessment of the body of evidence and its applicability.

Evidence assigned a level 1- or 2- score has an unacceptable level of bias or confounding and is not used to form recommendations.

Levels of evidence
- **Level 1++**: High quality meta-analyses, systematic reviews of randomised controlled trials (RCTs), or RCTs with a very low risk of bias.
- **Level 1+**: Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias.
- **Level 1-**: Meta-analyses, systematic reviews, or RCTs with a high risk of bias.
- **Level 2++**: High quality systematic reviews of case control or cohort studies; or high quality case control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal.
- **Level 2+**: Well-conducted case control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal.
- **Level 2-**: Case control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal.
- **Level 3**: Non-analytic studies, e.g. case reports, case series.
- **Level 4**: Expert advice or clinical experience from respected authorities.

Grades of recommendation
- **Grade A: High strength**: NICE-accredited guidelines; or guidelines that pass AGREE II assessment; or at least one meta-analysis, systematic review, or RCT rated as 1++, and directly applicable to the target population; or a body of evidence consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results.
● **Grade B: Moderate strength**
A body of evidence including studies rated as 2++, directly applicable to the target population, and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 1++ or 1+.

● **Grade C: Low strength**
A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 2++.

● **Grade D: Very low strength**
Evidence level 3; or extrapolated evidence from studies rated as 2+; or tertiary reference source created by a transparent, defined methodology, where the basis for recommendation is clear.

● **Grade E: Practice point**
Evidence level 4.
How to use BNF Publications in print

How to use the BNF

This edition of the BNF continues to display the fundamental change to the structure of the content that was first shown in BNF 70. The changes were made to bring consistency and clarity to BNF content, and to the way that the content is arranged within print and digital products, increasing the ease with which information can be found.

For reference, the most notable changes to the structure of the content include:

- Drug monographs – where possible, all information that relates to a single drug is contained within its drug monograph, moving information previously contained in the prescribing notes. Drug monographs have also changed structurally: additional sections have been added, ensuring greater regularity around where information is located within the publication.
- Drug class monographs – where substantial amounts of information are common to all drugs within a drug class (e.g. macrolides p. 507), a drug class monograph has been created to contain the common information.
- Medicinal forms – categorical information about marketed medicines, such as price and pack size, continues to be sourced directly from the Dictionary of Medicines and Devices provided by the NHS Business Services Authority. However, clinical information curated by the BNF team has been clearly separated from the categorical pricing and pack size information and is included in the relevant section of the drug monograph.
- Section numbering – the BNF section numbering has been removed. This section numbering tied the content to a rigid structure and enforced the retention of defunct classifications, such as mercurial diuretics, and hindered the relocation of drugs where therapeutic use had altered. It also caused constraints between the BNF and BNF for Children, where drugs had different therapeutic uses in children.
- Appendix 4 – the content has been moved to individual drug monographs. The introductory notes have been replaced with a new guidance section, Guidance on intravenous infusions p. 16.

Introduction

In order to achieve the safe, effective, and appropriate use of medicines, healthcare professionals must be able to use the BNF effectively, and keep up to date with significant changes in the BNF that are relevant to their clinical practice. This How to Use the BNF is key in reinforcing the details of the new structure of the BNF to all healthcare professionals involved with prescribing, monitoring, supplying, and administering medicines, as well as supporting the learning of students training to join these professions.

Structure of the BNF

This BNF edition continues to broadly follows the high-level structure of earlier editions of the BNF (i.e. those published before BNF 70):

- Front matter, comprising information on how to use the BNF, the significant content changes in each edition, and guidance on various prescribing matters (e.g. prescription writing, the use of intravenous drugs, particular considerations for special patient populations).
- Chapters, containing drug monographs describing the uses, doses, safety issues and other considerations involved in the use of drugs; drug class monographs; and treatment summaries, covering guidance on the selection of drugs. Monographs and treatment summaries are divided into chapters based on specific aspects of medical care, such as Chapter 5, Infections, or Chapter 16, Emergency treatment of poisoning; or drug use related to a particular system of the body, such as Chapter 2, Cardiovascular.

Within each chapter, content is organised alphabetically by therapeutic use (e.g. Airways disease, obstructive), with the treatment summaries first, (e.g. asthma), followed by the monographs of the drugs used to manage the conditions discussed in the treatment summary. Within each therapeutic use, the drugs are organised alphabetically by classification (e.g. Antimuscarinics, Beta 2-agonist bronchodilators) and then alphabetically within each classification (e.g. Aclidinium bromide, Glycopyrronium bromide, Ipratropium bromide).

Appendices, covering interactions, borderline substances, cautionary and advisory labels, and woundcare.

Back matter, covering the lists of medicines approved by the NHS for Dental and Nurse Practitioner prescribing, proprietary and specials manufacturers’ contact details, and the index. Yellow cards are also included, to facilitate the reporting of adverse events, as well as quick reference guides for life support and key drug doses in medical emergencies, for ease of access.

Navigating the BNF

The contents page provides the high-level layout of information within the BNF; and in addition, each chapter begins with a small contents section, describing the therapeutic uses covered within that chapter. Once in a chapter, location is guided by the side of the page showing the chapter number (the thumbnail), alongside the chapter title. The top of the page includes the therapeutic use (the running head) alongside the page number.

Once on a page, visual cues aid navigation: treatment summary information is in black type, with therapeutic use titles similarly styled in black, whereas the use of colour indicates drug-related information, including drug classification titles, drug class monographs, and drug monographs.

Although navigation is possible by browsing, primarily access to the information is via the index, which covers the titles of drug class monographs, drug monographs, and treatment summaries. The index also includes the names of branded medicines and other topics of relevance, such as abbreviations, guidance sections, tables, and images.

Content types

Treatment summaries

Treatment summaries are of three main types:

- an overview of delivering a drug to a particular body system (e.g. Skin conditions, management p. 1117)
- a comparison between a group or groups of drugs (e.g. beta-adrenoceptor blockers (systemic) p. 142)
- an overview of the drug management or prophylaxis of common conditions intended to facilitate rapid appraisal of options (e.g. Hypertension p. 135, or Malaria, prophylaxis p. 574).

In order to select safe and effective medicines for individual patients, information in the treatment summaries must be used in conjunction with other prescribing details about the drugs and knowledge of the patient’s medical and drug history.

Monographs

Overview

In earlier editions (i.e. before BNF 70), a systemically administered drug with indications for use in different body systems was split across the chapters relating to those body systems. So, for example, codeine phosphate p. 431 was found in chapter 1, for its antimotility effects and chapter 4 for its analgesic effects. However, the monograph in chapter
1 contained only the dose and some selected safety precautions.

Now, all of the information for the systemic use of a drug is contained within one monograph, so codeine phosphate is now included in chapter 4. This carries the advantage of providing all of the information in one place, so the user does not need to flick back and forth across several pages to find all of the relevant information for that drug. Cross references are included in chapter 1, where the management of diarrhoea is discussed, to the drug monograph to assist navigation.

Where drugs have systemic and local uses, for example, chloramphenicol p. 537, 1072, 1095 and the considerations around drug use are markedly different according to the route of administration, the monograph is split, as with earlier editions, into the relevant chapters.

This means that the majority of drugs are still placed in the same chapters and sections as earlier editions, and although there may be some variation in order, all of the relevant information will be easier to locate.

One of the most significant changes to the monograph structure is the increased granularity, with a move from around 9 sections to over 20 sections; sections are only included when relevant information has been identified. The following information describes these sections and their uses in more detail.

Nomenclature
Monograph titles follow the convention of recommended international non-proprietary names (rINNs), or, in the absence of a rINN, British Approved Names. Relevant synonyms are included below the title and, in some instances a brief description of the drug action is included. Over future editions these drug action statements will be rolled out for all drugs.

In some monographs, immediately below the nomenclature or drug action, there are a number of cross references or flags used to signpost the user to any additional information they need to consider about a drug.

This is most common for drugs formulated in combinations, where users will be signposted to the monographs for the individual ingredients (e.g. senna with ispaghula husk p. 62) or for drugs that are related to a drug class monograph (see Drug class monographs, below).

Indication and dose
User feedback has highlighted that one of the main uses of the BNF is identifying indications and doses of drugs. Therefore, indication and dose information has been promoted to the top of the monograph and highlighted by a coloured panel to aid quick reference.

The indication and dose section is more highly structured than in earlier editions, giving greater clarity around which doses should be used for which indications and by which route. In addition, if the dose varies with a specific preparation or formulation, that dosing information has been moved out of the preparations section and in to the indication and dose panel, under a heading of the preparation name.

Doses are either expressed in terms of a definite frequency (e.g. 1 g 4 times daily) or in the total daily dose format (e.g. 6 g daily in 3 divided doses); the total daily dose should be divided into individual doses (in the second example, the patient should receive 2 g 3 times daily).

Doses for specific patient groups (e.g. the elderly) may be included if they are different to the standard dose. Doses for children can be identified by the relevant age range and may vary according to their age or body-weight.

In earlier editions of the BNF, age ranges and weight ranges overlapped. For clarity and to aid selection of the correct dose, wherever possible these age and weight ranges now do not overlap. When interpreting age ranges it is important to understand that a patient is considered to be 64 up until the point of their 65th birthday, meaning that an age range of adult 18 to 64 is applicable to a patient from the day of their 18th birthday until the day before their 65th birthday. All age ranges should be interpreted in this way. Similarly, when interpreting weight ranges, it should be understood that a weight of up to 30 kg is applicable to a patient up to, but not including, the point that they tip the scales at 30 kg and a weight range of 35 to 59 kg is applicable to a patient as soon as they tip the scales at 35 kg right up until, but not including, the point that they tip the scales at 60 kg. All weight ranges should be interpreted in this way.

In all circumstances, it is important to consider the patient in question and their physical condition, and select the dose most appropriate for the individual.

Other information relevant to Indication and dose
The dose panel also contains, where known, an indication of pharmacokinetic considerations that may affect the choice of dose, and dose equivalence information, which may aid the selection of dose when switching between drugs or preparations.

The BNF includes unlicensed use of medicines when the clinical need cannot be met by licensed medicines; such use should be supported by appropriate evidence and experience. When the BNF recommends an unlicensed medicine or the ‘off-label’ use of a licensed medicine, this is shown below the indication and dose panel in the unlicensed use section.

Minimising harm and drug safety
The drug chosen to treat a particular condition should minimise the patient’s susceptibility to adverse effects and, where co-morbidities exist, have minimal detrimental effects on the patient’s other diseases. To achieve this, the Contra-indications, Cautions and Side-effects of the relevant drug should be reviewed.

The information under Cautions can be used to assess the risks of using a drug in a patient who has co-morbidities that are also included in the Cautions for that drug—if a safer alternative cannot be found, the drug may be prescribed while monitoring the patient for adverse-effects or deterioration in the co-morbidity. Contra-indications are far more restrictive than Cautions and mean that the drug should be avoided in a patient with a condition that is contra-indicated.

The impact that potential side-effects may have on a patient’s quality of life should also be assessed. For instance, in a patient who has difficulty sleeping, it may be preferable to avoid a drug that frequently causes insomnia.

Clinically relevant side-effects for drugs are included in the monographs or class monographs. Side-effects are listed in order of frequency, where known, and arranged alphabetically. The frequency of side-effects follows the regulatory standard:

- Very common — occurs more frequently than 1 in 10 administrations of a drug
- Common — occurs between 1 in 10 and 1 in 100 administrations of a drug
- Uncommon — between 1 in 100 and 1 in 1,000 administrations of a drug
- Rare — between 1 in 1,000 and 1 in 10,000 administrations of a drug
- Very rare — occurs less than 1 in 10,000 administrations of a drug
- Frequency not known

An exhaustive list of side-effects is not included, particularly for drugs that are used by specialists (e.g. cytotoxic drugs and drugs used in anaesthesia). The BNF also omits effects that are likely to have little clinical consequence (e.g. transient increase in liver enzymes).

Recognising that hypersensitivity reactions can occur with virtually all medicines, this effect is generally not listed, unless the drug carries an increased risk of such reactions,
Typical layout of a monograph and associated medicinal forms

1 Class Monographs and drug monographs
In most cases, all information that relates to an individual drug is contained in its drug monograph and there is no symbol. Class monographs have been created where substantial amounts of information are common to all drugs within a drug class, these are indicated by a flag symbol in a circle:

Drug monographs with a corresponding class monograph are indicated by a tab with a flag symbol:

The page number of the corresponding class monograph is indicated within the tab. For further information, see How to use BNF Publications

2 Drug classifications
Used to inform users of the class of a drug and to assist in finding other drugs of the same class. May be based on pharmacological class (e.g. opioids) but can also be associated with the use of the drug (e.g. cough suppressants)

3 Review date
The date of last review of the content

4 Specific preparation name
If the dose varies with a specific preparation or formulation it appears under a heading of the preparation name

5 Evidence grading
Evidence grading to reflect the strengths of recommendations will be applied as content goes through the revalidation process. A five level evidence grading system based on the former SIGN grading system has been adopted. The grades A, B, C, D, E are displayed next to the recommendations within the text, and are preceded by the symbol:

For further information, see How BNF Publications are constructed

Class monograph

CLASSIFICATION

Drug monograph

(Synonym) another name by which a drug may be known

DRUG ACTION how a drug exerts its effect in the body

INDICATIONS AND DOSE
Indications are the clinical reasons a drug is used. The dose of a drug will often depend on the indications

Indication
- ROUTE
- Age groups: [Child/Adult/Elderly]
  Dose and frequency of administration (max. dose)

SPECIFIC PREPARATION NAME

Indication
- ROUTE
- Age groups: [Child/Adult/Elderly]
  Dose and frequency of administration (max. dose)

DOSE EQUIVALENCE AND CONVERSION information around the bioequivalence between formulations of the same drug, or equivalent doses of drugs that are members of the same class

PHARMACOKINETICS how the body affects a drug (absorption, distribution, metabolism, and excretion)

POTENCY a measure of drug activity expressed in terms of the concentration required to produce an effect of given intensity

DOSES AT EXTREMES OF BODY-WEIGHT dosing information for patients who are overweight or underweight

UNLICENSED USE describes the use of medicines outside the terms of their UK licence (off-label use), or of medicines that have no licence for use in the UK

IMPORTANT SAFETY INFORMATION
Information produced and disseminated by drug regulators often highlights serious risks associated with the use of a drug, and may include advice that is mandatory

CONTRA-INDICATIONS circumstances when a drug should be avoided

CAUTIONS details of precautions required

INTERACTIONS when one drug changes the effects of another drug; the mechanisms underlying drug interactions are explained in Appendix 1

SIDE-EFFECTS listed in order of frequency, where known, and arranged alphabetically

ALLERGY AND CROSS-SENSITIVITY for drugs that carry an increased risk of hypersensitivity reactions

CONCEPTION AND CONTRACEPTION potential for a drug to have harmful effects on an unborn child when prescribing for a woman of childbearing age or for a man trying to father a child; information on the effect of drugs on the efficacy of latex condoms or diaphragms

PREGNANCY advice on the use of a drug during pregnancy

BREAST FEEDING advice on the use of a drug during breast feeding
- **HEPATIC IMPAIRMENT** advice on the use of a drug in hepatic impairment
- **RENAL IMPAIRMENT** advice on the use of a drug in renal impairment
- **PRE-TREATMENT SCREENING** covers one off tests required to assess the suitability of a patient for a particular drug
- **MONITORING REQUIREMENTS** specifies any special monitoring requirements, including information on monitoring the plasma concentration of drugs with a narrow therapeutic index
- **EFFECTS ON LABORATORY TESTS** for drugs that can interfere with the accuracy of seemingly unrelated laboratory tests
- **TREATMENT CESSATION** specifies whether further monitoring or precautions are advised when the drug is withdrawn
- **DIRECTIONS FOR ADMINISTRATION** practical information on the preparation of intravenous drug infusions; general advice relevant to other routes of administration
- **PRESCRIBING AND DISPENSING INFORMATION** practical information around how a drug can be prescribed and dispensed including details of when brand prescribing is necessary
- **HANDLING AND STORAGE** includes information on drugs that can cause adverse effects to those who handle them before they are taken by, or administered to, a patient; advice on storage conditions
- **PARENT AND CARER ADVICE** for drugs with a special need for counselling
- **PROFESSION SPECIFIC INFORMATION** provides details of the restrictions certain professions such as dental practitioners or nurse prescribers need to be aware of when prescribing on the NHS
- **NATIONAL FUNDING/ACCESS DECISIONS** details of NICE Technology Appraisals and SMC advice
- **LESS SUITABLE FOR PRESCRIBING** preparations that are considered by the Joint Formulary Committee to be less suitable for prescribing
- **EXCEPTION TO LEGAL CATEGORY** advice and information on drugs which may be sold without a prescription under specific conditions

### Legal categories

[P] This symbol has been placed against those preparations that are available only on a prescription issued by an appropriate practitioner. For more detailed information see *Medicines, Ethics and Practice*, London, Pharmaceutical Press (always consult latest edition)

[CD1 CD2 CD3 CD4-1 CD4-2 CD5] These symbols indicate that the preparations are subject to the prescription requirements of the Misuse of Drugs Act

For regulations governing prescriptions for such preparations, see Controlled Drugs and Drug Dependence

Not all monographs include all possible sections; sections are only included when relevant information has been identified

### MEDICINAL FORMS

**Form**

- **CAUTIONARY AND ADVISORY LABELS** if applicable
- **EXCIPIENTS** clinically important but not comprehensive [consult manufacturer information for full details]
- **ELECTROLYTES** if clinically significant quantities occur

#### Preparation name (Manufacturer/Non-proprietary)

- Drug name and strength pack sizes

#### Combinations available

This indicates a combination preparation is available and a cross reference page number is provided to locate this preparation
when the information is included under Allergy and cross sensitivity.

The Important safety advice section in the BNF, delineated by a coloured outline box, highlights important safety concerns, often those raised by regulatory authorities or guideline producers. Safety warnings issued by the Commission on Human Medicines (CHM) or Medicines and Healthcare products Regulatory Agency (MHRA) are found here.

Drug selection should aim to minimise drug interactions. If it is necessary to prescribe a potentially serious combination of drugs, patients should be monitored appropriately. The mechanisms underlying drug interactions are explained in Appendix 1, followed by details of drug interactions.

**Use of drugs in specific patient populations**

Drug selection should aim to minimise the potential for drug accumulation, adverse drug reactions, and exacerbation of pre-existing hepatic or renal disease. If it is necessary to prescribe drugs whose effect is altered by hepatic or renal disease, appropriate drug dose adjustments should be made, and patients should be monitored adequately. The general principles for prescribing are outlined under Prescribing in hepatic impairment p. 19, and Prescribing in renal impairment p. 19. Information about drugs that should be avoided or used with caution in hepatic disease or renal impairment can be found in drug monographs under Hepatic impairment and Renal impairment (e.g. fluconazole p. 562).

Similarly, drug selection should aim to minimise harm to the fetus, nursing infant, and mother. The infant should be monitored for potential side-effects of drugs used by the mother during pregnancy or breast-feeding. The general principles for prescribing are outlined under Prescribing in pregnancy p. 22 and Prescribing in breast-feeding p. 22. The Treatment Summaries provide guidance on the drug treatment of common conditions that can occur during pregnancy and breast-feeding (e.g. Asthma p. 230). Information about the use of specific drugs during pregnancy and breast-feeding can be found in their drug monographs under Pregnancy, and Breast-feeding (e.g. fluconazole p. 562).

A section, Conception and contraception, containing information around considerations for females of childbearing potential or men who might father a child (e.g. isotretinoin p. 1166) has been included.

**Administration and monitoring**

When selecting the most appropriate drug, it may be necessary to screen the patient for certain genetic markers or metabolic states. This information is included within a section called Pre-treatment screening (e.g. abacavir p. 610). This section covers one-off tests required to assess the suitability of a patient for a particular drug.

Once the drug has been selected, it needs to be given in the most appropriate manner. A Directions for administration section contains the information about intravenous administration previously located in Appendix 4. This provides practical information on the preparation of intravenous drug infusions, including compatibility of drugs with standard intravenous infusion fluids, method of dilution or reconstitution, and administration rates. In addition, general advice relevant to other routes of administration is provided within this section (e.g. fentanyl p. 434).

After selecting and administering the most appropriate drug by the most appropriate route, patients should be monitored to ensure they are achieving the expected benefits from drug treatment without any unwanted side-effects. The Monitoring section specifies any special monitoring requirements, including information on monitoring the plasma concentration of drugs with a narrow therapeutic index (e.g. theophylline p. 263). Monitoring may, in certain cases, be affected by the impact of a drug on laboratory tests (e.g. hydroxocobalamin p. 938), and this information is included in Effects on laboratory tests.

In some cases, when a drug is withdrawn, further monitoring or precautions may be advised (e.g. clonidine hydrochloride p. 139); these are covered under Treatment cessation.

**Choice and supply**

The prescriber and the patient should agree on the health outcomes that the patient desires and on the strategy for achieving them (see Taking Medicines to Best Effect). Taking the time to explain to the patient (and carers) the rationale and the potential adverse effects of treatment may improve adherence. For some medicines there is a special need for counselling (e.g. appropriate posture during administration of doxycycline p. 534); this is shown in Patient and carer advice.

Other information contained in the latter half of the monograph also helps prescribers and those dispensing medicines choose medicinal forms (by indicating information such as flavour or when branded products may not be interchangeable (e.g. diltiliazem hydrochloride p. 152), assess the suitability of a drug for prescribing, understand the NHS funding status for a drug (e.g. sildenafil p. 766), or assess when a patient may be able to purchase a drug without prescription (e.g. loperamide hydrochloride p. 65).

**Medicinal forms**

In the BNF, preparations follow immediately after the monograph for the drug that is their main ingredient.

In earlier editions, when a particular preparation had safety information, dose advice or other clinical information specific to the product, it was contained within the preparations section. This information has been moved to the relevant section in the main body of the monograph under a heading of the name of the specific medicinal form (e.g. peppermint oil p. 46).

The medicinal forms (formerly preparations) section provides information on the type of formulation (e.g. tablet), the amount of active drug in a solid dosage form, and the concentration of active drug in a liquid dosage form. The legal status is shown for prescription-only medicines and controlled drugs, as well as pharmacy medicines and medicines on the general sales list. Practitioners are reminded, by a statement under the heading of "Medicinal Forms" that not all products containing a specific drug ingredient may be similarly licensed. To be clear on the precise licensing status of specific medicinal forms, practitioners should check the product literature for the particular product being prescribed or dispensed.

Details of all medicinal forms available on the dm+d for each drug in BNF Publications appears online on MedicinesComplete. In print editions, due to space constraints, only certain branded products are included in detail. Where medicinal forms are listed they should not be inferred as equivalent to the other brands listed under the same form heading. For example, all the products listed under a heading of "Modified release capsule" will be available as modified release capsules, however, the brands listed under that form heading may have different release profiles, the available strengths may vary and/or the products may have different licensing information. As with earlier editions of the BNF, practitioners must ensure that the particular product being prescribed or dispensed is appropriate.

As medicinal forms are derived from dm+d data, some drugs may appear under names derived from that data; this may vary slightly from those in previous BNF versions, e.g. sodium acid phosphate, is now sodium dihydrogen phosphate anhydrous.

Patients should be prescribed a preparation that complements their daily routine, and that provides the right dose of drug for the right indication and route of administration. When dispensing liquid preparations, a
sugar-free preparation should always be used in preference to one containing sugar. Patients receiving medicines containing cariogenic sugars should be advised of appropriate dental hygiene measures to prevent caries.

In earlier editions, the BNF only included excipients and electrolyte information for proprietary medicines. This information is now covered at the level of the dose form (e.g. tablet). It is not possible to keep abreast of all of the generic products available on the UK market, and so this information serves as a reminder to the healthcare professional that, if the presence of a particular excipient is of concern, they should check the product literature for the particular product being prescribed or dispensed.

Cautionary and advisory labels that pharmacists are recommended to add when dispensing are included in the medicinal forms section. Details of these labels can be found in Appendix 3, Guidance for cautionary and advisory labels p. 1454. As these labels have now been applied at the level of the dose form, a full list of medicinal products with their relevant labels would be extensive. This list has therefore been removed, but the information is retained within the monograph.

In the case of compound preparations, the prescribing information for all constituents should be taken into account.

**Prices in the BNF**

Basic NHS net prices are given in the BNF to provide an indication of relative cost. Where there is a choice of suitable preparations for a particular disease or condition the relative cost may be used in making a selection. Cost-effective prescribing must, however, take into account other factors (such as dose frequency and duration of treatment) that affect the total cost. The use of more expensive drugs is justified if it will result in better treatment of the patient, or a reduction of the length of an illness, or the time spent in hospital.

Prices are regularly updated using the Drug Tariff and proprietary price information published by the NHS dictionary of medicines and devices (dm+d, www.dmd.nhs.uk). The weekly updated dm+d data (including prices) can be accessed using the dm+d browser of the NHS Business Services Authority (apps.nhsbsa.nhs.uk/DMDBrowser). Prices have been calculated from the net cost used in pricing NHS prescriptions and generally reflect whole dispensing packs. Prices for extemporaneously prepared preparations are not provided in the BNF as prices vary between different manufacturers. In Appendix 4, prices stated are per dressing or bandage.

BNF prices are not suitable for quoting to patients seeking net prices (e.g. metropolan tartrate p. 149). Within this flag, the page number of the drug class monograph is provided (e.g. 1234), to help navigate the user to this information. This is particularly useful where occasionally, due to differences in therapeutic use, the drug monograph may not directly follow the drug class monograph (e.g. sotalol hydrochloride p. 105).

**Evidence grading**

The BNF has adopted a five level evidence grading system (see How BNF Publications are constructed p. ix). Recommendations that are evidence graded can be identified by a symbol appearing immediately before the recommendation. The evidence grade is displayed at the end of the recommendation.

**Other content**

**Nutrition**

Appendix 2, Borderline substances p. 1420, includes tables of ACBS-approved enteral feeds and nutritional supplements based on their energy and protein content. There are separate tables for specialised formulae for specific clinical conditions. Classified sections on foods for special diets and nutritional supplements for metabolic diseases are also included.

**Wound dressings**

A table on wound dressings in Appendix 4, Wound management products and elasticated garments p. 1457, allows an appropriate dressing to be selected based on the appearance and condition of the wound. Further information about the dressing can be found by following the cross-reference to the relevant classified section in the Appendix. Advanced wound contact dressings have been classified in order of increasing absorbency.

**Other useful information**

**Finding significant changes in the BNF**

- **Changes**, provides a list of significant changes, dose changes, classification changes, new names, and new preparations that have been incorporated into the BNF, as well as a list of preparations that have been discontinued and removed from the BNF. Changes listed online are cumulative (from one print edition to the next), and can be printed off each month to show the main changes since the last print edition as an aide memoir for those using print copies. So many changes are made for each update of the BNF, that not all of them can be accommodated in the Changes section. We encourage healthcare professionals to regularly review the prescribing information on drugs that they encounter frequently;

- **Changes to the Dental Practitioners’ Formulary**, are located at the end of the Dental List;

- **E-newsletter**, the BNF & BNFC e-newsletter service is available free of charge. It alerts healthcare professionals to details of significant changes in the clinical content of these publications and to the way that this information is delivered. Newsletters also review clinical case studies, provide tips on using these publications effectively, and highlight forthcoming changes to the publications. To sign up for e-newsletters go to www.bnf.org.

- An e-learning programme developed in collaboration with the Centre for Pharmacy Postgraduate Education (CPPE), enables pharmacists to identify and assess how significant changes in the BNF affect their clinical practice. The module can be found at www.cppe.ac.uk.

**Using other sources for medicines information**

The BNF is designed as a digest for rapid reference. Less detail is given on areas such as obstetrics, malignant disease, and anaesthesia since it is expected that those undertaking treatment will have specialist knowledge and access to
specialist literature. *BNF for Children* should be consulted for detailed information on the use of medicines in children. The BNF should be interpreted in the light of professional knowledge and supplemented as necessary by specialised publications and by reference to the product literature. Information is also available from medicines information services.
Changes

Monthly updates are provided online via MedicinesComplete and the NHS Evidence portal. The changes listed below are cumulative (from one print edition to the next).

**Significant changes**

Significant changes that appear in the print edition of BNF 74 (September 2017–March 2018):

- Acetylcysteine p. 1065 for paracetamol overdose [MHRA advice].
- Adalimumab p. 1008 for treating moderate-to-severe hidradenitis suppurativa [NICE guidance].
- Affibirecept p. 921 for treating visual impairment caused by macular oedema after branch retinal vein occlusion [NICE guidance].
- Antibacterials, principles of therapy p. 479: new guidance on early management of sepsis.
- Apremilast p. 1018 for treating moderate to severe plaque psoriasis [NICE guidance].
- Apremilast p. 1018 for treating active psoriatic arthritis [NICE guidance].
- Brimonidine tartrate p. 1086 gel (Mirvaso®): risk of exacerbation of rosacea [MHRA/CHM advice].
- Canagliflozin p. 661: increased risk of lower-limb amputation (mainly toes) [MHRA/CHM advice].
- Canagliflozin p. 661, dapagliflozin p. 662 or empagliflozin p. 664: risk of diabetic ketoacidosis [MHRA/CHM advice].
- Certolizumab pegol p. 1011 for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor [NICE guidance].
- Cholestasis p. 85: updated guidance on management.
- Cobimetinib p. 895 in combination with vemurafenib p. 917 for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [NICE guidance].
- Constipation p. 51: updated guidance on management.
- Contraceptive, interactions p. 747: updated guidance.
- Crizotinib p. 896 for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer [NICE guidance update].
- Crizotinib p. 896 for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer [NICE guidance].
- Crohn’s disease p. 36: updated guidance on management.
- Dapagliflozin p. 662 in combination therapy for treating type 2 diabetes [NICE guidance].
- Dapagliflozin p. 662 in triple therapy for treating type 2 diabetes [NICE guidance].
- Dasatinib p. 898, nilotinib p. 907 and high-dose imatinib p. 904 for treating imatinib-resistant or intolerant chronic myeloid leukaemia (CML) [NICE guidance].
- Dasatinib p. 898, nilotinib p. 907 and imatinib p. 904 for untreated chronic myeloid leukaemia (CML) [NICE guidance].
- Degarelix p. 875 for treating advanced hormone-dependent prostate cancer [NICE guidance].
- Diabetes p. 643: updated guidance on management.
- Elbasvir with grazoprevir p. 591 for treating chronic hepatitis C [NICE guidance].
- Epilepsy p. 292: updated guidance on epilepsy and driving.
- Erectile dysfunction p. 765: updated guidance on management.
- Eribulin p. 862 for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens [NICE guidance].
- Everolimus p. 900 with exemestane p. 880 for treating advanced breast cancer after endocrine therapy [NICE guidance].
- Everolimus p. 900 for advanced renal cell carcinoma after previous treatment [NICE guidance].
- Evolocumab p. 200 for treating primary hypercholesterolaemia and mixed dyslipidaemia [NICE guidance].
- Fingolimod p. 802: signal of rebound effect after stopping or switching therapy [MHRA/CHM advice].
- Finasteride p. 742: rare reports of depression and suicidal thoughts [MHRA/CHM advice].
- Food allergy p. 82: updated guidance on management.
- Gallstones p. 85: updated guidance on management.
- Haemorrhoids p. 89: new guidance on management.
- Hyoscine butylbromide p. 83 (Buscopan®) injection: risk of serious adverse effects in patients with underlying cardiac disease [MHRA/CHM advice].
- Ibrutinib p. 902 for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation [NICE guidance].
- Imatinib p. 904 for chronic myeloid leukaemia [updated NICE guidance].
- Low back pain and sciatica p. 1028: new guidance on management.
- Pegylated liposomal irinotecan hydrochloride p. 856 for treating pancreatic cancer after gemcitabine [NICE guidance].
- Inborn errors of primary bile acid synthesis p. 85: updated guidance on management.
- Mepolizumab p. 256 for treating severe refractory eosinophilic asthma [NICE guidance].
- Motor neurone disease p. 385: new guidance on management.
- Multiple sclerosis p. 797: new guidance on management.
- Necitumumab p. 812 for untreated advanced or metastatic squamous non-small-cell lung cancer [NICE guidance].
- Nivolumab p. 813 for previously treated advanced renal cell carcinoma [NICE guidance].
- Osimertinib p. 908 for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer [NICE guidance].
- Pegaspargase p. 865 for treating acute lymphoblastic leukaemia [NICE guidance].
- Pembrolizumab p. 816 for treating PD-L1-positive non-small-cell lung cancer after chemotherapy [NICE guidance].
- Pertuzumab p. 817 for the neoadjuvant treatment of HER2-positive breast cancer [NICE guidance].
- Pomalidomide p. 886 for multiple myeloma previously treated with lenalidomide and bortezomib [NICE guidance].
- Ponatinib p. 911: risk of vascular occlusive events—updated advice on possible dose reduction [MHRA/CHM advice].
- Primary biliary cholangitis p. 86: updated guidance on management.
- Secukinumab p. 1004 for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors [NICE guidance].
- Sodium valproate p. 312: resources to support the safety of girls and women who are being treated with valproate [NHS improvement patient safety alert].
● Direct-acting antiviral interferon-free regimens to treat chronic hepatitis C: risk of hepatitis B reactivation [MHRA/CHM advice], see sofosbuvir p. 595.
● Sofosbuvir with velpatavir p. 596 for treating chronic hepatitis C [NICE guidance].
● Talimogene laherparepvec p. 881 for treating unresectable metastatic melanoma [NICE guidance].
● Ticagrelor p. 208 for preventing atherothrombotic events after myocardial infarction [NICE guidance].
● Trametinib p. 915 in combination with dabrafenib p. 897 for treating unresectable or metastatic melanoma [NICE guidance].
● Trametinib p. 915: risk of gastrointestinal perforation and colitis [MHRA/CHM advice].
● Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR [MHRA/CHM advice], see sofosbuvir p. 595.
● Tuberculosis p. 546: updated guidance on management.
● Ulcerative colitis p. 37: updated guidance on management.
● Urinary retention p. 736: updated guidance on management.
● Valproic acid p. 337: resources to support the safety of girls and women who are being treated with valproate [NHS improvement patient safety alert].

Dose changes
Changes in dose statements that appear in the print edition of BNF 74 (September 2017–March 2018):
● Atorvastatin p. 196 fluvastatin p. 196 simvastatin p. 198 [with concomitant elbasvir with grazoprevir]; rosuvastatin p. 197 [with concomitant elbasvir with grazoprevir or with concomitant sofosbuvir with velpatavir].
● Bicalutamide p. 874: prostate cancer (metastatic) with the aim of retaining sexual function [unlicensed use].
● Fenofibrate p. 193 [dose in renal impairment].
● Lansoprazole p. 77: severe oesophagitis, refractory to initial treatment [unlicensed use].
● Lithium citrate p. 341 [Li-Liquid®].
● Medroxyprogesterone acetate p. 763: hot flushes caused by long-term androgen suppression in men with prostate cancer [unlicensed use].
● Nystatin p. 1116
● Pantoprazole p. 79: severe oesophagitis, refractory to initial treatment [unlicensed use].
● Phytoxy p. 308 [rate of intravenous administration in adults].
● Rabeprazole sodium p. 80: severe oesophagitis, refractory to initial treatment [unlicensed use].
● Tranexamic acid p. 107: prevention and treatment of significant haemorrhage following trauma [unlicensed use].

Classification changes
Classification changes that appear in the print edition of BNF 74 (September 2017–March 2018):

New names
Name changes that appear in the print edition of BNF 74 (September 2017–March 2018):

Deleted preparations
Preparations discontinued in the print edition of BNF 74 (September 2017–March 2018):
● Incivo® [telaprevir].
● Vikrius® [boceprevir].
● Trobalt® [retigabin].
● Prempak-C® [conjugated oestrogens with norgestrel].

New preparations
New preparations that appear in the print edition of BNF 74 (September 2017–March 2018):
● Adasuve® [loxapine p. 370].
● AirFluSal Forspiro® [fluticasone with salmeterol p. 255].
● Amsidine® [amsacrine p. 860].
● Benepali® [etanercept p. 1012].
● Blincyto® [blinatumomab p. 809].
● Bupepe® [buprenorphine p. 425].
● Buplast® [buprenorphine p. 425].
● Butec® [buprenorphine p. 425].
● Catephyn® [camellia sinensis p. 1179].
● Cilodex® [dexamethasone with ciprofloxacin p. 1096].
● Cingaero® [resizumab p. 257].
● Cleveryrex® [clevidipine p. 151].
● Coteflo® [cobimetinib p. 895].
● Cortint® [budesonide p. 43].
● Dazaralex® [daratumumab p. 811].
● Delmosart® [modified release tablet [methylphenidate hydrochloride p. 331]]
● Descovy® [emricitabine with tenofovir alafenamide p. 615].
● Duavive® [conjugated oestrogens with bazedoxifene acetate p. 711].
● Emlipirci® [elotuzumab p. 811].
● Ensitil® [calcioprotet with benzamethasone p. 1141].
● Eplusa® [sofosbuvir with velpatavir p. 596].
● Evotax® [etatanaivir with cobicistat p. 618].
● Exjade® [film-coated tablets [deferasirox p. 939].
● Feracaura® [ferric maltol p. 933].
● Fiasp® [insulin aspart p. 673].
● Fluomizin® [dexamethasone chloride p. 780].
● Genvoya® [elvetigavir with cobicistat, emricitabine and tenofovir alafenamide p. 613].
● Ibrance® [palbociclib p. 909].
● Imlyctic® [talimogene laherparepvec p. 881].
● Invicorp® [aviparatid with phenolamine mesilate p. 772].
● Kyrotil® [carfilzomib p. 890].
● Kyplyx® [lenalidomib p. 906].
● Lenvima® [lenvatinib p. 906].
● Lonsaur® [trifluridine with tipiracil p. 848].
● Lutjes® [progesterone p. 721].
● Mekinisi® [trameitinib p. 915].
● Nucala® [mepolizumab p. 256].
● Ninlaro® [ixazomicin p. 891].
● Noqdir® [desmopressin p. 628].
● Odfev® [emricitabine with rilpivirine and tenofovir alafenamide p. 614].
● Oncaspar® [pegaspargase p. 865].
● Ongents® [opicapone p. 393].
● Onixysde® [irinotecan hydrochloride p. 856].
● Panitax® [buprenorphine p. 425].
● Portrazza® [necitumumab p. 812].
● Praxbind® [idarucizumab p. 116].
● Prenotrix® [buprenorphine p. 425].
● Raxone® [idebenone p. 1091].
● Reletrans® [buprenorphine p. 425].
● Relevtec® [buprenorphine p. 425].
● Repathia® [evolocumab p. 200].
● Reolosta® [darunavir with cobicistat p. 619].
● Sevodone® [buprenorphine p. 425].
● Sereflo® [fluticasone with salmeterol p. 255].
● Soolantra® [ivermectin p. 571].
● Spectral® [asparaginase p. 861].
● Taltz® [ixekizumab p. 1155].
● Tagrisso® [osimertinib p. 908].
● Translarra® [ataluren p. 1024].
● Uptravi® [slexiopag p. 178].
● Venclyxo® [venetoclax p. 919].
● Votubia® [dispersible tablets [everolimus p. 900].
● Wakix® [pitolisant p. 467].
● Xadago® [safinamide p. 407].
● Zalviso® [sufentanil p. 446].
● Zepatier® [elbasvir with grazoprevir p. 591].
● Zerbaxa® [ceftolozane with tazobactam p. 502].
● Zinbryta® [dalcizumab p. 803].
Guidance on prescribing

General guidance
Medicines should be prescribed only when they are necessary, and in all cases the benefit of administering the medicine should be considered in relation to the risk involved. This is particularly important during pregnancy, when the risk to both mother and fetus must be considered. It is important to discuss treatment options carefully with the patient to ensure that the patient is content to take the medicine as prescribed. In particular, the patient should be helped to distinguish the adverse effects of prescribed drugs from the effects of the medical disorder. When the beneficial effects of the medicine are likely to be delayed, the patient should be advised of this.

Prescribing competency framework
The Royal Pharmaceutical Society has published a Prescribing Competency Framework that includes a common set of competencies that form the basis for prescribing, regardless of professional background. The competencies have been developed to help healthcare professionals to be safe and effective prescribers, with the aim of supporting patients to get the best outcomes from their medicines. It is available at www.rpharms.com/resources/frameworks/prescribers-competency-framework.

Multimorbidity
The presence of two or more long-term health conditions in a patient (multimorbidity) is associated with reduced quality of life, higher mortality, higher rates of adverse drug reactions, greater use of the health service, and a higher treatment burden (due to polypharmacy or multiple appointments). Treatment decisions in these patients should involve consideration of the patient’s needs, preferences for treatment, health priorities, and lifestyle with the aim of improving quality of life by reducing treatment burden, adverse events, and unplanned or uncoordinated care.

Prescribing in patients with multimorbidity
Prescribers should consider the risks and benefits of treatments recommended for patients with multimorbidity from guidance for single health conditions; evidence for these recommendations is commonly drawn from patients without multimorbidity or who are taking fewer prescribed regular medicines.

Treatments intended to relieve symptoms should be reviewed for effectiveness, including reducing or stopping the treatment and monitoring the effects. Alternatively, non-pharmacological treatments may be offered or treatments of limited benefit can be considered for discontinuation. Risks factors for future disease can be a major treatment burden for patients with multimorbidity and is not always appropriate.

Deprescribing
Deprescribing is the process of discontinuing or reducing the dose of medicines, supervised by a healthcare professional, with the aim of managing polypharmacy and improving outcomes. Deprescribing requires careful counselling and shared decision-making with patients, and is considered part of routine clinical care.

Taking medicines to best effect
Difficulties in adherence to drug treatment occur regardless of age. Factors contributing to poor compliance with prescribed medicines include:

- perceived lack of efficacy;
- real or perceived adverse effects;
- patients’ perception of the risk and severity of side-effects may differ from that of the prescriber;
- instructions for administration not clear;
- physical difficulty in taking medicines (e.g. swallowing the medicine, handling small tablets, or opening medicine containers);
- unattractive formulation (e.g. unpleasant taste);
- complicated regimen.

The prescriber and the patient should agree on the health outcomes that the patient desires and on the strategy for achieving them (’concordance’). The prescriber should be sensitive to religious, cultural, and personal beliefs that can affect a patient’s acceptance of medicines.

Taking the time to explain to the patient (and relatives) the rationale and the potential adverse effects of treatment may improve adherence. Reinforcement and elaboration of the physician’s instructions by the pharmacist and other members of the healthcare team also helps. Advising the patient of the possibility of alternative treatments may encourage the patient to seek advice rather than merely abandon unacceptable treatment.

Simplifying the drug regimen may help; the need for frequent administration may reduce adherence, although there appears to be little difference in adherence between once-daily and twice-daily administration. Combination products reduce the number of drugs taken but at the expense of the ability to titrate individual doses.

Biological medicines
Biological medicines are medicines that are made by or derived from a biological source using biotechnology processes, such as recombinant DNA technology. The size and complexity of biological medicines, as well as the way they are produced, may result in a degree of natural variability in molecules of the same active substance, particularly in different batches of the medicine. This variation is maintained within strict acceptable limits. Examples of biological medicines include insulins and monoclonal antibodies. Biological medicines must be prescribed by brand name and the brand name specified on the prescription should be dispensed in order to avoid inadvertent switching. Automatic substitution of brands at the point of dispensing is not appropriate for biological medicines.

Biosimilar medicines
A biosimilar medicine is a biological medicine that is highly similar and clinically equivalent (in terms of quality, safety, and efficacy) to an existing biological medicine that has already been authorised in the European Union (known as the reference biological medicine or originator medicine). The active substance of a biosimilar medicine is similar, but not identical, to the originator biological medicine. Once the patent for a biological medicine has expired, a biosimilar medicine may be authorised by the European Medicines Agency (EMA). A biosimilar medicine is not the same as a generic medicine, which contains a simpler molecular structure that is identical to the originator medicine.

Therapeutic equivalence
Biosimilar medicines should be considered to be therapeutically equivalent to the originator biological medicine within their authorised indications. Biosimilar medicines are usually licensed for all the indications of the originator biological medicine, but this depends on the evidence submitted to the EMA for...
**Guidance on prescribing**

**Prescribing and dispensing** The choice of whether to prescribe a biosimilar medicine or the originator biological medicine rests with the clinician in consultation with the patient. Biological medicines (including biosimilar medicines) must be prescribed by brand name and the brand name specified on the prescription should be dispensed in order to avoid inadvertent switching. Automatic substitution of brands at the point of dispensing is not appropriate for biological medicines.

**Safety monitoring** Biosimilar medicines are subject to a black triangle status at the time of initial authorisation. It is important to report suspected adverse reactions using the Yellow Card Scheme (see Adverse reactions to drugs p. 12). For all biological medicines, adverse reaction reports should clearly state the brand name and the batch number of the suspected medicine. UK Medicines Information centres have developed a validated tool to determine potential safety issues associated with all new medicines. These ‘in-use product safety assessment reports’ will be published for new biosimilar medicines as they become available, see www.ukmhi.nhs.uk/activities/patientSafety/default.asp?pageRef=20.

**National funding/access decisions** The Department of Health has confirmed that, in England, NICE can decide to apply the same remit, and the resulting technology appraisal guidance, to relevant biosimilar medicines which appear on the market subsequent to their originator biological medicine. In other circumstances, where a review of the evidence for a particular biosimilar medicine is necessary, NICE will consider producing an evidence summary: 

**Marketing authorisation and BNF advice** In general the *doses, indications, cautions, contra-indications, and side-effects* in the BNF reflect those in the manufacturers’ data sheets or Summaries of Product Characteristics (SPCs) which, in turn, reflect those in the corresponding marketing authorisations (formerly known as Product Licences). The BNF does not generally include proprietary medicines that are not supported by a valid Summary of Product Characteristics or when the marketing authorisation holder has not been able to supply essential information. When a preparation is available from more than one manufacturer, the BNF reflects advice that is the most clinically relevant regardless of any variation in the marketing authorisations. Unlicensed products can be obtained from ‘special-order’ manufacturers or specialist importing companies.

**Non-proprietary titles** Where non-proprietary (‘generic’) titles are given, they should be used in prescribing. This will enable any suitable product to be dispensed, thereby saving delay to the patient and sometimes expense to the health service. The only exception is where there is a demonstrable difference in clinical effect between each manufacturer’s version of the formulation, making it important that the patient should always receive the same brand; in such cases, the brand name or the manufacturer should be stated. Non-proprietary titles should not be invented for the purposes of prescribing generically since this can lead to confusion, particularly in the case of compound and modified-release preparations.

**Proprietary titles** Names followed by the symbol® are or have been used as proprietary names in the United Kingdom. These names may in general be applied only to products supplied by the owners of the trade marks.

**Availability** The following drugs are available as a biosimilar medicine:

- Epoetin alfa p. 925
- Epoetin zeta p. 928
- Etanercept p. 1012
- Filgrastim p. 942
- Filgrastim alfa p. 702
- Infliximab p. 1016
- Insulin glargine p. 672
- Somatropin p. 705

**Complementary and alternative medicine** An increasing amount of information on complementary and alternative medicine is becoming available. The scope of the BNF is restricted to the discussion of conventional medicines but reference is made to complementary treatments if they affect conventional therapy (e.g. interactions with St John’s wort). Further information on herbal medicines is available at www.mhra.gov.uk.

**Abbreviation of titles** In general, titles of drugs and preparations should be written in full. Unofficial abbreviations should not be used as they may be misinterpreted.
may also be available). It is provided with an adaptor and an instruction leaflet. The 5–mL spoon is used for doses of 5 mL (or multiples thereof).

**Important** To avoid inadvertent intravenous administration of oral liquid medicines, only an appropriate oral or enteral syringe should be used to measure an oral liquid medicine (if a medicine spoon or graduated measure cannot be used); these syringes should not be compatible with intravenous or other parenteral devices. Oral or enteral syringes should be clearly labelled ‘Oral’ or ‘Enteral’ in a large font size; it is the healthcare practitioner’s responsibility to label the syringe with this information if the manufacturer has not done so.

**Excipients**

Branded oral liquid preparations that do not contain fructose, glucose, or sucrose are described as ‘sugar-free’ in the BNF. Preparations containing hydrogenated glucose syrup, mannitol, maltitol, sorbitol, or xylitol are also marked ‘sugar-free’ since there is evidence that they do not cause dental caries. Patients receiving medicines containing cariogenic sugars should be advised of appropriate dental hygiene measures to prevent caries. Sugar-free preparations should be used whenever possible.

Where information on the presence of aspartame, gluten, sulfites, tartrazine, arachis (peanut) oil or sesame oil is available, this is indicated in the BNF against the relevant preparation.

Information is provided on selected excipients in skin preparations, in vaccines, and on selected preservatives and excipients in eye drops and injections. The presence of benzyl alcohol and polyoxyl castor oil (polyethoxylated castor oil) in injections is indicated in the BNF. Benzyl alcohol has been associated with a fatal toxic syndrome in preterm neonates, and therefore, parenteral preparations containing the preservative should not be used in neonates. Polyoxyl castor oils, used as vehicles in intravenous injections, have been associated with severe anaphylactoid reactions.

The presence of propylene glycol in oral or parenteral medicines is indicated in the BNF; it can cause adverse effects if its elimination is impaired, e.g. in renal failure, in neonates and young children, and in slow metabolisers of the substance. It may interact with disulfiram p. 471 and metronidazole p. 512. The lactose content in most medicines is too small to cause problems in most lactose-intolerant patients. However in severe lactose intolerance, the lactose content should be determined before prescribing. The amount of lactose varies according to manufacturer, product, formulation, and strength.

**Important** In the absence of information on excipients in the BNF and in the product literature (available at www.medicines.org.uk/emc), contact the manufacturer (see Index of Proprietary Manufacturers) if it is essential to check details.

**Extemporaneous preparation**

A product should be dispensed extemporaneously only when no product with a marketing authorisation is available. The BP direction that a preparation must be freshly prepared indicates that it must be made not more than 24 hours before it is issued for use. The direction that a preparation should be recently prepared indicates that deterioration is likely if the preparation is stored for longer than about 4 weeks at 15–25°C.

The term water used without qualification means either potable water freshly drawn direct from the public supply and suitable for drinking or freshly boiled and cooled purified water. The latter should be used if the public supply is from a local storage tank or if the potable water is unsuitable for a particular preparation (Water for injections).

**Drugs and driving**

Prescribers and other healthcare professionals should advise patients if treatment is likely to affect their ability to perform skilled tasks (e.g. driving). This applies especially to drugs with sedative effects; patients should be warned that these effects are increased by alcohol. General information about a patient’s fitness to drive is available from the Driver and Vehicle Licensing Agency at www.dvla.gov.uk.

A new offence of driving, attempting to drive, or being in charge of a vehicle, with certain specified controlled drugs in excess of specified limits, came into force on 2nd March 2015. This offence is in addition to the existing rules on drug impaired driving and fitness to drive, and applies to two groups of drugs—commonly abused drugs, including amfetamines, cannabis, cocaine, and ketamine p. 1234, and drugs used mainly for medical reasons, such as opioids and benzodiazepines. Anyone found to have any of the drugs (including related drugs, for example, apomorphine hydrochloride p. 398) above specified limits in their blood will be guilty of an offence, whether their driving was impaired or not. This also includes prescribed drugs which metabolise to those included in the offence, for example, selegiline hydrochloride p. 407. However, the legislation provides a statutory “medical defence” for patients taking drugs for medical reasons in accordance with instructions, if their driving was not impaired—it continues to be an offence to drive if actually impaired. Patients should therefore be advised to continue taking their medicines as prescribed, and when driving, to carry suitable evidence that the drug was prescribed, or sold, to treat a medical or dental problem, and that it was taken according to the instructions given by the prescriber, or information provided with the medicine (e.g. a repeat prescription form or the medicine’s patient information leaflet). Further information is available from the Department for Transport at www.gov.uk/government/collections/drug-driving.

**Patents**

In the BNF, certain drugs have been included notwithstanding the existence of actual or potential patent rights. In so far as such substances are protected by Letters Patent, their inclusion in this Formulary neither conveys, nor implies, licence to manufacture.

**Health and safety**

When handling chemical or biological materials particular attention should be given to the possibility of allergy, fire, explosion, radiation, or poisoning. Substances such as corticosteroids, some antimicrobials, phenothiazines, and many cytotoxics, are irritant or very potent and should be handled with caution. Contact with the skin and inhalation of dust should be avoided.

**Safety in the home**

Patients must be warned to keep all medicines out of the reach of children. All solid dose and all oral and external liquid preparations must be dispensed in a reclosable child-resistant container unless:

- the medicine is in an original pack or patient pack such as to make this inadvisable;
- the patient will have difficulty in opening a child-resistant container;
- a specific request is made that the product shall not be dispensed in a child-resistant container;
- no suitable child-resistant container exists for a particular liquid preparation.

All patients should be advised to dispose of unwanted medicines by returning them to a supplier for destruction.
Labelling of prescribed medicines
There is a legal requirement for the following to appear on the label of any prescribed medicine:
- name of the patient;
- name and address of the supplying pharmacy;
- date of dispensing;
- name of the medicine;
- directions for use of the medicine;
- precautions relating to the use of the medicine.

The Royal Pharmaceutical Society recommends that the following also appears on the label:
- the words ‘Keep out of the sight and reach of children’;
- where applicable, the words ‘Use this medicine only on your skin’.

A pharmacist can exercise professional skill and judgement to amend or include more appropriate wording for the name of the medicine, the directions for use, or the precautions relating to the use of the medicine.

Non-proprietary names of compound preparations
Non-proprietary names of compound preparations which appear in the BNF are those that have been compiled by the British Pharmacopoeia Commission or another recognised body; whenever possible they reflect the names of the active ingredients.

Prescribers should avoid creating their own compound names for the purposes of generic prescribing; such names do not have an approved definition and can be misinterpreted.

Special care should be taken to avoid errors when prescribing compound preparations; in particular the hyphen ‘co-’ should be retained.

Special care should also be taken to avoid creating generic names for modified-release preparations where the use of these names could lead to confusion between formulations with different lengths of action.

EEA and Swiss prescriptions
Pharmacists can dispense prescriptions issued by doctors and dentists from the European Economic Area (EEA) or Switzerland (except prescriptions for controlled drugs in Schedules 1, 2, or 3, or for drugs without a UK marketing authorisation). Prescriptions should be written in ink or otherwise so as to be indelible, should be dated, should state the name of the patient, should state the address of the prescriber, should contain particulars indicating whether the prescriber is a doctor or dentist, and should be signed by the prescriber.

Security and validity of prescriptions
The Councils of the British Medical Association and the Royal Pharmaceutical Society have issued a joint statement on the security and validity of prescriptions.

In particular, prescription forms should:
- not be left unattended at reception desks;
- not be left in a car where they may be visible; and
- when not in use, be kept in a locked drawer within the surgery and at home.

Where there is any doubt about the authenticity of a prescription, the pharmacist should contact the prescriber. If this is done by telephone, the number should be obtained from the directory rather than relying on the information on the prescription form, which may be false.

Patient group direction (PGD)
In most cases, the most appropriate clinical care will be provided on an individual basis by a prescriber to a specific individual patient. However, a Patient Group Direction for supply and administration of medicines by other healthcare professionals can be used where it would benefit patient care without compromising safety.

A Patient Group Direction is a written direction relating to the supply and administration (or administration only) of a licensed prescription-only medicine (including some Controlled Drugs in specific circumstances) by certain classes of healthcare professionals; the Direction is signed by a doctor (or dentist) and by a pharmacist. Further information on Patient Group Directions is available in Health Service Circular HSC 2000/026 (England), HDL (2001) 7 (Scotland), and WHC (2000) 116 (Wales); see also the Human Medicines Regulations 2012.

NICE, Scottish Medicines Consortium and All Wales Medicines Strategy Group
Advice issued by the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group (AWMSG) is included in the BNF when relevant. Details of the advice together with updates can be obtained from: www.nice.org.uk, www.scottishmedicines.org.uk and www.awmsg.org.
Shared care

In its guidelines on responsibility for prescribing (circular EL (91) 127) between hospitals and general practitioners, the Department of Health has advised that legal responsibility for prescribing lies with the doctor who signs the prescription.

Requirements

Prescriptions should be written legibly in ink or otherwise so as to be indelible (it is permissible to issue carbon copies of NHS prescriptions as long as they are signed in ink), should be dated, should state the name and address of the patient, the address of the prescriber, an indication of the type of prescriber, and should be signed in ink by the prescriber (computer-generated facsimile signatures do not meet the legal requirement). The age and the date of birth of the patient should preferably be stated, and it is a legal requirement. The age and the date of birth of the patient should preferably be stated, and it is a legal requirement in the case of prescription-only medicines to state the age for children under 12 years. These recommendations are acceptable for prescription-only medicines. Prescriptions for controlled drugs have additional legal requirements.

Wherever appropriate the prescriber should state the current weight of the child to enable the dose prescribed to be checked. Consideration should also be given to including the dose per unit mass e.g. mg/kg or the dose per m² body-surface area e.g. mg /m² where this would reduce error. The following should be noted:

- The strength or quantity to be contained in capsules, lozenges, tablets etc. should be stated by the prescriber. In particular, strength of liquid preparations should be clearly stated (e.g. 125 mg/5 mL).
- The unnecessary use of decimal points should be avoided, e.g. 3 mg, not 3.0 mg. Quantities of 1 gram or more should be written as 1 g etc. Quantities less than 1 gram should be written in milligrams, e.g. 500 mg, not 0.5 g. Quantities less than 1 mg should be written in micrograms, e.g. 100 micrograms, not 0.1 mg. When decimals are unavoidable a zero should be written in front of the decimal point where there is no other figure, e.g. 0.5 mL, not 5 mL. Use of the decimal point is acceptable to express a range, e.g. 0.5 to 1 g.
- ‘Micrograms’ and ‘nanograms’ should not be abbreviated. Similarly ‘units’ should not be abbreviated.
- The term ‘millilitre’ (mL or mL) is used in medicine and pharmacy, and cubic centimetre, c.c., or cm³ should not be used. (The use of capital ‘L’ in mL is a printing convention throughout the BNF; both ‘mL’ and ‘ml’ are recognised SI abbreviations).
- Dose and dose frequency should be stated; in the case of preparations to be taken ‘as required’ a minimum dose interval should be specified. Care should be taken to ensure children receive the correct dose of the active drug. Therefore, the dose should normally be stated in terms of the mass of the active drug (e.g. ‘125 mg 3 times daily’); terms such as ‘5 mL’ or ‘1 tablet’ should be avoided except for compound preparations. When doses other than multiples of 5 mL are prescribed for oral liquid preparations the dose-volume will be provided by means of an oral syringe, (except for preparations intended to be measured with a pipette). Suitable quantities:
  - Elixirs, Linctuses, and Paediatric Mixtures (5-mL dose), 50, 100, or 150 mL
  - Adult Mixtures (10-mL dose), 200 or 300 mL
  - Ear Drops, Eye drops, and Nasal Drops, 10 mL (or the manufacturer’s pack)
  - Eye Lotions, Gargles, and Mouthwashes, 200 mL
- The names of drugs and preparations should be written clearly and not abbreviated, using approved titles only; avoid creating generic titles for modified-release preparations.
- The quantity to be supplied may be stated by indicating the number of days of treatment required in the box provided on NHS forms. In most cases the exact amount will be supplied. This does not apply to items directed to be used as required—if the dose and frequency are not given then the quantity to be supplied needs to be stated. When several items are ordered on one form the box can be marked with the number of days of treatment provided the quantity is added for any item for which the amount cannot be calculated.
- Although directions should preferably be in English without abbreviation, it is recognised that some Latin abbreviations are used.

Sample prescription

Prescribing by dentists

Until new prescribing arrangements are in place for NHS prescriptions, dentists should use form FP10D (GP14 in Scotland, WP10D in Wales) to prescribe only those items listed in the Dental Practitioners’ Formulary. The Human Medicines Regulations 2012 does not set any limitations upon the number and variety of substances which the dentist may administer to patients in the surgery or may order by private prescription—provided the relevant legal requirements are observed the dentist may use or order whatever is required for the clinical situation. There is no statutory requirement for the dentist to communicate with a patient’s medical practitioner when prescribing for dental use. There are, however, occasions when this would be in the patient’s interest and such communication is to be encouraged. For legal requirements relating to prescriptions
of Controlled Drugs, see Controlled drugs and drug dependence p. 8.

Computer-issued prescriptions

For computer-issued prescriptions the following advice, based on the recommendations of the Joint GP Information Technology Committee, should also be noted:

1. The computer must print out the date, the patient’s surname, one forename, other initials, and address, and may also print out the patient’s title and date of birth. The age of children under 12 years and of adults over 60 years must be printed in the box available; the age of children under 5 years should be printed in years and months. A facility may also exist to print out the age of patients between 12 and 60 years.

2. The doctor’s name must be printed at the bottom of the prescription form; this will be the name of the doctor responsible for the prescription (who will normally sign it). The doctor’s surgery address, reference number, and Primary Care Trust (PCT, Health Board in Scotland, Local Health Board in Wales) are also necessary. In addition, the surgery telephone number should be printed.

3. When prescriptions are to be signed by general practitioner registrars, assistants, locums, or deputising doctors, the name of the doctor printed at the bottom of the form must still be that of the responsible principal.

4. Names of medicines must come from a dictionary held in the computer memory, to provide a check on the spelling and to ensure that the name is written in full. The computer can be programmed to recognise both the non-proprietary and the proprietary name of a particular drug and to print out the preferred choice, but must not print out both names. For medicines not in the dictionary, separate checks are required—the user must be warned that no check was possible and the entire prescription must be entered in the lexicon.

5. The dictionary may contain information on the usual doses, formulations, and pack sizes to produce standard predetermined prescriptions for common preparations, and to provide a check on the validity of an individual prescription on entry.

6. The prescription must be printed in English without abbreviation; information may be entered or stored in abbreviated form. The dose must be in numbers, the frequency in words, and the quantity in numbers in brackets, thus: 40 mg four times daily (112). It must also be possible to prescribe by indicating the length of treatment required.

7. The BNF recommendations should be followed as listed above.

8. Checks may be incorporated to ensure that all the information required for dispensing a particular drug has been filled in. For instructions such as ‘as directed’ and ‘when required’, the maximum daily dose should normally be specified.

9. Numbers and codes used in the system for organising and retrieving data must never appear on the form.

10. Supplementary warnings or advice should be written in full, should not interfere with the clarity of the prescription itself, and should be in line with any warnings or advice in the BNF; numerical codes should not be used.

11. A mechanism (such as printing a series of nonspecific characters) should be incorporated to cancel out unused space, or wording such as ‘no more items on this prescription’ may be added after the last item. Otherwise the doctor should delete the space manually.

12. To avoid forgery the computer may print on the form the number of items to be dispensed (somewhere separate from the box for the pharmacist). The number

13. Handwritten alterations should only be made in exceptional circumstances—it is preferable to print out a new prescription. Any alterations must be made in the doctor’s own handwriting and countersigned; computer records should be updated to fully reflect any alteration. Prescriptions for drugs used for contraceptive purposes (but which are not promoted as contraceptives) may need to be marked in handwriting with the symbol ‘C’ (or endorsed in another way to indicate that the item is prescribed for contraceptive purposes).

14. Prescriptions for controlled drugs can be printed from the computer, but the prescriber’s signature must be handwritten (See Controlled Drugs and Drug Dependence; the prescriber may use a date stamp).

15. The strip of paper on the side of the FP10SS (GP10SS in Scotland, WP10SS in Wales) may be used for various purposes but care should be taken to avoid including confidential information. It may be advisable for the patient’s name to appear at the top, but this should be preceded by ‘confidential’.

16. In rural dispensing practices prescription requests (or details of medicines dispensed) will normally be entered in one surgery. The prescriptions (or dispensed medicines) may then need to be delivered to another surgery or location; if possible the computer should hold up to 10 alternatives.

17. Prescription forms that are reprinted or issued as a duplicate should be labelled clearly as such.
Emergency supply of medicines

Emergency supply requested by member of the public
Pharmacists are sometimes called upon by members of the public to make an emergency supply of medicines. The Human Medicines Regulations 2012 allows exemptions from the Prescription Only requirements for emergency supply to be made by a person lawfully conducting a retail pharmacy business provided:

a) that the pharmacist has interviewed the person requesting the prescription-only medicine and is satisfied:
   i) that there is immediate need for the prescription-only medicine and that it is impracticable in the circumstances to obtain a prescription without undue delay;
   ii) that treatment with the prescription-only medicine has on a previous occasion been prescribed for the person requesting it;
   iii) as to the dose that it would be appropriate for the person to take;

b) that no greater quantity shall be supplied than will provide 5 days' treatment of phenobarbital p. 318, phenobarbital sodium, or Controlled Drugs in Schedules 4 or 5 (doctors or dentists from the European Economic Area and Switzerland, or their patients, cannot request an emergency supply of Controlled Drugs in Schedules 1, 2, or 3, or drugs that do not have a UK marketing authorisation) or 30 days' treatment for other prescription-only medicines, except when the prescription-only medicine is:
   i) insulin, an ointment or cream, or a preparation for the relief of asthma in an aerosol dispenser when the smallest pack can be supplied;
   ii) an oral contraceptive when a full cycle may be supplied;
   iii) an antibiotic in liquid form for oral administration when the smallest quantity that will provide a full course of treatment can be supplied;

c) that an entry shall be made by the pharmacist in the prescription book stating:
   i) the date of supply;
   ii) the name, quantity and, where appropriate, the pharmaceutical form and strength;
   iii) the name and address of the patient;
   iv) the nature of the emergency;

d) that the container or package must be labelled to show:
   i) the date of supply;
   ii) the name, quantity and, where appropriate, the pharmaceutical form and strength;
   iii) the name of the patient;
   iv) the name and address of the pharmacy;
   v) the words 'Emergency supply';
   vi) the words 'Keep out of the reach of children' (or similar warning);

e) that the prescription-only medicine is not a substance specifically excluded from the emergency supply provision, and does not contain a Controlled Drug specified in Schedules 1, 2, or 3 to the Misuse of Drugs Regulations 2001 except for phenobarbital p. 318 or phenobarbital sodium for the treatment of epilepsy: for details see Medicines, Ethics and Practice, London, Pharmaceutical Press (always consult latest edition); (Doctors or dentists from the European Economic Area and Switzerland, or their patients, cannot request an emergency supply of Controlled Drugs in Schedules 1, 2, or 3, or drugs that do not have a UK marketing authorisation).

Emergency supply requested by prescriber
Emergency supply of a prescription-only medicine may also be made at the request of a doctor, a dentist, a supplementary prescriber, a community practitioner nurse prescriber, a nurse, pharmacist, or optometrist independent prescriber, or a doctor or dentist from the European Economic Area or Switzerland, provided:

a) that the pharmacist is satisfied that the prescriber by reason of some emergency is unable to furnish a prescription immediately;

b) that the prescriber has undertaken to furnish a prescription within 72 hours;

c) that the medicine is supplied in accordance with the directions of the prescriber requesting it;

d) that the medicine is not a Controlled Drug specified in Schedules 1, 2, or 3 to the Misuse of Drugs Regulations 2001 except for phenobarbital p. 318 or phenobarbital sodium for the treatment of epilepsy: for details see Medicines, Ethics and Practice, London, Pharmaceutical Press (always consult latest edition); (Doctors or dentists from the European Economic Area and Switzerland, or their patients, cannot request an emergency supply of Controlled Drugs in Schedules 1, 2, or 3, or drugs that do not have a UK marketing authorisation).

e) that an entry shall be made in the prescription book stating:
   i) the date of supply;
   ii) the name, quantity and, where appropriate, the pharmaceutical form and strength;
   iii) the name and address of the practitioner requesting the emergency supply;
   iv) the name and address of the patient;
   v) the date on the prescription;
   vi) when the prescription is received the entry should be amended to include the date on which it is received.

Royal Pharmaceutical Society’s guidelines
1. The pharmacist should consider the medical consequences of not supplying a medicine in an emergency.
2. If the pharmacist is unable to make an emergency supply of a medicine the pharmacist should advise the patient how to obtain essential medical care.

For conditions that apply to supplies made at the request of a patient see Medicines, Ethics and Practice, London Pharmaceutical Press, (always consult latest edition).
Controlled drugs and drug dependence

Regulations and classification

The Misuse of Drugs Act, 1971 prohibits certain activities in relation to 'Controlled Drugs', in particular their manufacture, supply, and possession. The penalties applicable to offences involving the different drugs are graded broadly according to the harmlessness attributable to a drug when it is misused and for this purpose the drugs are defined in the following three classes:


- **Class C** includes: certain drugs related to the amfetamines such as benzphetamine and chlorphenetermine, buparephrine p. 425, mazindol, meprobamate p. 330, pempoline, pipradrol, most benzodiazepines, tramadol hydrochloride p. 447, zaleplon p. 465, zolpidem tartrate p. 465, zopiclone p. 466, androgenic and anabolic steroids, clenbuterol, choric gonadotrophin (HCG), non-human choric gonadotrophin, somatropin, somatrem, and somatropin p. 705.

The Misuse of Drugs Regulations 2001 (and subsequent amendments) define the classes of person who are authorised to supply and possess controlled drugs while acting in their professional capacities and lay down the conditions under which these activities may be carried out. In the regulations drugs are divided into five schedules each specifying the requirements governing such activities as import, export, production, supply, possession, prescribing, and record keeping which apply to them.

- **Schedule 1** includes drugs such as lysierge which is not used medicinally. Possession and supply are prohibited except in accordance with Home Office authority.

- **Schedule 2** includes drugs such as diamorphine hydrochloride (heroin) p. 433, morphine p. 439, nabilone p. 410, remifentanil p. 1233, pethidine hydrochloride p. 445, secoecobarbital, glutethimide, the amfetamines, sodium oxybate and cocaine and are subject to the full controlled drug requirements relating to prescriptions, safe custody (except for secoecobarbital), the need to keep registers, etc. (unless exempted in Schedule 5).

- **Schedule 3** includes the barbiturates (except secoecobarbital, now Schedule 2), buparephrine p. 425, mazindol, meprobamate p. 330, midazolam p. 323, pentazocine p. 445, phentermine, temazepam p. 463, and tramadol hydrochloride p. 447. They are subject to the special prescription requirements. Safe custody requirements do apply, except for any 5,5 disubstituted barbituric acid (e.g. phenobarbital), mazindol, meprobamate, midazolam, pentazocine, phentermine, tramadol hydrochloride, or any stereoisomeric form or salts of the above. Records in registers do not need to be kept (although there are requirements for the retention of invoices for 2 years).

- **Schedule 4** includes in Part I benzodiazepines (except temazepam p. 463 and midazolam p. 323, which are in Schedule 3), zaleplon p. 465, zolpidem tartrate p. 465, and zopiclone p. 466 which are subject to minimal control. Part II includes androgenic and anabolic steroids, clenbuterol, choric gonadotrophin (HCG), non-human choric gonadotrophin, somatotropin, somatrem, and somatropin p. 705. Controlled drug prescription requirements do not apply and Schedule 4 Controlled Drugs are not subject to safe custody requirements.

- **Schedule 5** includes those preparations which, because of their strength, are exempt from virtually all Controlled Drug requirements other than retention of invoices for two years.

Prescriptions

Preparations in Schedules 1, 2, 3, and 4 of the Misuse of Drugs Regulations 2001 (and subsequent amendments) are identified throughout the BNF and BNF for children using the following symbols:

- **CD1** for preparations in Schedule 1
- **CD2** for preparations in Schedule 2
- **CD3** for preparations in Schedule 3
- **CD4-1** for preparations in Schedule 4 (Part I)
- **CD4-2** for preparations in Schedule 4 (Part II)
- **CD5** for preparations in Schedule 5

The principal legal requirements relating to medical prescriptions are listed below (see also Department of Health Guidance).

**Prescription requirements** Prescriptions for Controlled Drugs that are subject to prescription requirements (all preparations in Schedules 2 and 3) must be indelible and must be signed by the prescriber, be dated, and specify the prescriber’s address. A machine-written prescription is acceptable, but the prescriber’s signature must be handwritten. Advanced electronic signatures can be accepted for Schedule 2 and 3 Controlled Drugs where the Electronic Prescribing Service (EPS) is used. All prescriptions for Controlled Drugs that are subject to the prescription requirements must always state:

- the name and address of the patient;
- in the case of a preparation, the form, (the dosage form e.g. tablets must be included on a Controlled Drugs prescription irrespective of whether it is implicit in the proprietary name e.g. MST Continus or whether only one form is available), and where appropriate the strength of the preparation (when more than one strength of a preparation exists the strength required must be specified);
- for liquids, the total volume in millilitres (in both words and figures) of the Controlled Drug to be supplied; for dosage units, the number (in both words and figures) of dosage units to be supplied; in any other case, the total quantity (in both words and figures) of the Controlled Drug to be supplied;
- the dose (the instruction ‘one as directed’ constitutes a dose but ‘as directed’ does not);
- the words ‘for dental treatment only’ if issued by a dentist.

A pharmacist is not allowed to dispense a Controlled Drug unless all the information required by law is given on the prescription. In the case of a prescription for a Controlled Drug in Schedule 2 or 3, a pharmacist can amend the prescription if it specifies the total quantity only in words or in figures if it contains minor typographical errors, provided that such amendments are indelible and clearly attributable to the pharmacist (implementation date for N. Ireland not confirmed). Failure to comply with the
regulations concerning the writing of prescriptions will result in inconvenience to patients and carers and delay in supplying the necessary medicine. A prescription for a Controlled Drug in Schedules 2, 3, or 4 is valid for 28 days from the date stated thereon (the prescriber may forward-date the prescription; the start date may also be specified in the body of the prescription).

**Instalments and ‘repeats’**
A prescription may order a Controlled Drug to be dispensed by instalments; the amount of instalments and the intervals to be observed must be specified. A total of 14 days’ treatment by instalment of any drug listed in Schedule 2 of the Misuse of Drugs Regulations, buprenorphine p. 425, and diazepam p. 327 may be prescribed in England. In England, forms FP10 (MDA) (blue) and FP10H (MDA) (blue) should be used. In Scotland, forms GP10 (peach), HBP (blue), or HBPA (pink) should be used. In Wales a total of 14 days’ treatment by instalment of any drug listed in Schedules 2–5 of the Misuse of Drugs Regulations may be prescribed. In Wales, form WP10 (MDA) or form WP10HP (AD) should be used. Instalment prescriptions must be dispensed in accordance with the directions in the prescription. However, the Home Office has approved specific wording which may be included in an instalment prescription to cover certain situations; for example, if a pharmacy is closed on the day when an instalment is due. For details, see Medicines, Ethics and Practice, London, Pharmaceutical Press (always consult latest edition) or see Home Office approved wording for instalment prescribing (Circular 027/2015), available at www.gov.uk/.

Prescriptions ordering ‘repeats’ on the same form are not permitted for Controlled Drugs in Schedules 2 or 3.

**Private prescriptions**
Private prescriptions for Controlled Drugs in Schedules 2 and 3 must be written on specially designated forms provided by Primary Care Trusts in England, Health Boards in Scotland, Local Health Boards in Wales, or the Northern Ireland Central Services Agency; in addition, prescriptions must specify the prescriber’s identification number. Prescriptions to be supplied by a pharmacist in hospital are exempt from the requirements for private prescriptions.

**Department of Health guidance**
Guidance (June 2006) issued by the Department of Health in England on prescribing and dispensing of Controlled Drugs requires:

- in general, prescriptions for Controlled Drugs in Schedules 2, 3, and 4 to be limited to a supply of up to 30 days’ treatment; exceptionally, to cover a justifiable clinical need and after consideration of any risk, a prescription can be issued for a longer period, but the reasons for the decision should be recorded on the patient’s notes;
- the patient’s identifier to be shown on NHS and private prescriptions for Controlled Drugs in Schedules 2 and 3.

Further information is available at www.gov.uk/dh.

**Dependence and misuse**
The most serious drugs of addiction are **cocaine**, **diamorphine hydrochloride** (heroin) p. 433, **morphine** p. 439, and the **synthetic opioids**. For arrangements for prescribing of diamorphine, dipipanone, or cocaine for addicts, see Prescribing of diamorphine, dipipanone, or cocaine for addicts, Available at www.gov.uk/dh

**Benzo Diazepines** are commonly misused. However, the misuse of **barbiturates** is now uncommon, in line with declining medicinal use and consequent availability. **Cannabis** (Indian hemp) has no approved medicinal use and cannot be prescribed by doctors. Its use is illegal but widespread. Cannabis is a mild hallucinogen seldom accompanied by a desire to increase the dose; withdrawal symptoms are unusual. However, cannabis extract is licensed as a medicinal product. **Lysergide** (lysergic acid diethylamide, LSD) is a much more potent hallucinogen; its use can lead to severe psychotic states which can be life-threatening. There are concerns over increases in the availability and misuse of other drugs with variously combined hallucinogenic, anaesthetic, or sedative properties. These include ketamine p. 1234 and gamma-hydroxybutyrate (sodium oxybate, GHB).

**Supervised consumption**
Individuals prescribed opioid substitution therapy can take their daily dose under the supervision of a doctor, nurse, or pharmacist during the dose stabilisation phase (usually the first 3 months of treatment), after a relapse or period of...
instability, or if there is a significant increase in the dose of methadone. Supervised consumption should continue (in accordance with local protocols) until the prescriber is confident that the patient is compliant with their treatment.

**Prescribing drugs likely to cause dependence or misuse**

The prescriber has three main responsibilities:

- To avoid creating dependence by introducing drugs to patients without sufficient reason. In this context, the proper use of the morphine-like drugs is well understood. The dangers of other Controlled Drugs are less clear because recognition of dependence is not easy and its effects, and those of withdrawal, are less obvious.
- To see that the patient does not gradually increase the dose of a drug, given for good medical reasons, to the point where dependence becomes more likely. This tendency is seen especially with hypnotics and anxiolytics. The prescriber should keep a close eye on the amount prescribed to prevent patients from accumulating stocks. A minimal amount should be prescribed in the first instance, or when seeing a new patient for the first time.
- To avoid being used as an unwitting source of supply for addicts and being vigilant to methods for obtaining medicines. Methods include visiting more than one doctor, fabricating stories, and forging prescriptions.

Patients under temporary care should be given only small supplies of drugs unless they present an unequivocal letter from their own doctor. Doctors should also remember that their own patients may be attempting to collect prescriptions from other prescribers, especially in hospitals. It is sensible to reduce dosages steadily or to issue weekly or even daily prescriptions for small amounts if it is apparent that dependence is occurring. The stealing and misuse of prescription forms could be minimised by the following precautions:

- do not leave unattended if called away from the consulting room or at reception desks; do not leave in a car where they may be visible; when not in use, keep in a locked drawer within the surgery and at home;
- draw a diagonal line across the blank part of the form under the prescription;
- write the quantity in words and figures when prescribing drugs prone to abuse; this is obligatory for controlled drugs;
- alterations are best avoided but if any are made they should be clear and unambiguous; add initials against altered items;
- if prescriptions are left for collection they should be left in a safe place in a sealed envelope.

**Travelling abroad**

Prescribed drugs listed in Schedule 4 Part II (CD Anab) and Schedule 5 of the Misuse of Drugs Regulations 2001 are not subject to export or import licensing. However, patients intending to travel abroad for more than 3 months carrying any amount of drugs listed in Schedules 2, 3, or 4 Part I (CD Benz) will require a personal export/import licence. Further details can be obtained at www.gov.uk/guidance/controlled-drugs-licences-fees-and-returns or from the Home Office by contacting DFLU.ie@homeoffice.gsi.gov.uk. In cases of emergency, telephone (020) 7035 6330. Applications must be supported by a covering letter from the prescriber and should give details of:

- the patient’s name and address;
- the quantities of drugs to be carried;
- the strength and form in which the drugs will be dispensed;
- the country or countries of destination;
- the dates of travel to and from the United Kingdom.

Applications for licences should be sent to the Home Office, Drugs Licensing & Compliance Unit, Fry Building, 2 Marsham Street, London, SW1P 4DF. Alternatively, completed application forms can be emailed to dlcucommsofficer@homeoffice.gsi.gov.uk with a copy of the covering letter from the prescriber as a pdf. A minimum of two weeks should be allowed for processing the application. Patients travelling for less than 3 months do not require a personal export/import licence for carrying Controlled Drugs, but are advised to carry a letter from the prescribing doctor. Those travelling for more than 3 months are advised to make arrangements to have their medication prescribed by a practitioner in the country they are visiting.

Doctors who want to take Controlled Drugs abroad while accompanying patients may similarly be issued with licences. Licences are not normally issued to doctors who want to take Controlled Drugs abroad solely in case a family emergency should arise.

Personal export/import licences do not have any legal status outside the UK and are issued only to comply with the Misuse of Drugs Act and to facilitate passage through UK Customs and Excise control. For clearance in the country to be visited it is necessary to approach that country’s consulate in the UK.

**Notification of patients receiving structured drug treatment for substance dependence**

In England, doctors should report cases where they are providing structured drug treatment for substance dependence to their local National Drug Treatment Monitoring System (NDTMS) Team. General information about NDTMS can be found at www.nta.nhs.uk/ndtms.aspx. Enquiries about NDTMS, and how to submit data, should initially be directed to:

- EvidenceApplicationTeam@phe.gov.uk

In Scotland, doctors should report cases to the Substance Misuse Programme (SMP).

Tel: (0131) 275 6348

In Northern Ireland, the Misuse of Drugs (Notification of and Supply to Addicts) (Northern Ireland) Regulations 1973 require doctors to send particulars of persons whom they consider to be addicted to certain controlled drugs to the Chief Medical Officer of the Department of Health and Social Services. The Northern Ireland contacts are:

Medical contact:
Dr Ian McMaster, C3 Castle Buildings, Belfast, BT4 3FQ
Tel: (028) 9052 2421, Fax: (028) 9052 0718
ian.mcmaster@dhsspni.gov.uk

Administrative contact:
Public Health Information & Research Branch, Department of Health, Annexe 2, Castle Building, Stormont, Belfast BT4 3SQ
Tel: (028) 9052 2504

Public Health Information & Research Branch also maintains the Northern Ireland Drug Misuse Database (NIDMD) which collects detailed information on those presenting for treatment, on drugs misused and injecting behaviour; participation is not a statutory requirement.

In Wales, doctors should report cases where they are providing structured drug treatment for substance dependence on the Welsh National Database for Substance Misuse; enquiries should be directed to: substance.misuse-queries@wales.nhs.uk.
Prescribing of diamorphine (heroin), dipipanone, and cocaine for addicts

The Misuse of Drugs (Supply to Addicts) Regulations 1997 require that only medical practitioners who hold a special licence issued by the Home Secretary may prescribe, administer, or supply diamorphine hydrochloride p. 433, dipipanone (Diconal®), or cocaine in the treatment of drug addiction; other practitioners must refer any addict who requires these drugs to a treatment centre. Whenever possible the addict will be introduced by a member of staff from the treatment centre to a pharmacist whose agreement has been obtained and whose pharmacy is conveniently sited for the patient. Prescriptions for weekly supplies will be sent to the pharmacy by post and will be dispensed on a daily basis as indicated by the doctor. If any alterations of the arrangements are requested by the addict, the portion of the prescription affected must be represcribed and not merely altered.

General practitioners and other doctors do not require a special licence for prescribing diamorphine hydrochloride p. 433, dipipanone, and cocaine for patients (including addicts) for relieving pain from organic disease or injury.
Adverse reactions to drugs

Yellow card scheme
Any drug may produce unwanted or unexpected adverse reactions. Rapid detection and recording of adverse drug reactions is of vital importance so that unrecognised hazards are identified promptly and appropriate regulatory action is taken to ensure that medicines are used safely. Healthcare professionals and coroners are asked to report suspected adverse drug reactions directly to the Medicines and Healthcare products Regulatory Agency (MHRA) through the Yellow Card Scheme using the electronic form at www.mhra.gov.uk/yellowcard. Alternatively, prepaid Yellow Cards for reporting are available from the address below and are also bound in the inside back cover of the BNF.

Send Yellow Cards to:
FREEPOST YELLOW CARD
(No other address details required).
Tel: 0800 731 6789

Suspected adverse drug reactions to any therapeutic agent should be reported, including drugs (self-medication as well as those prescribed), blood products, vaccines, radiographic contrast media, complementary and herbal products. For biosimilar medicines and vaccines, adverse reaction reports should clearly state the brand name and the batch number of the suspected medicine or vaccine.

Suspected adverse drug reactions should be reported through the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. Yellow Cards can be used for reporting suspected adverse drug reactions to medicines, vaccines, herbal or complementary products, whether self-medicated or prescribed. This includes suspected adverse drug reactions associated with misuse, overdose, medication errors or from use of unlicensed and off-label medicines. Yellow Cards can also be used to report medical device incidents, defective medicines, and suspected fake medicines.

Spontaneous reporting is particularly valuable for recognising possible new hazards rapidly. An adverse reaction should be reported even if it is not certain that the drug has caused it, or if the reaction is well recognised, or if other drugs have been given at the same time. Reports of overdoses (deliberate or accidental) can complicate the assessment of adverse drug reactions, but provide important information on the potential toxicity of drugs.

A freephone service is available to all parts of the UK for advice and information on suspected adverse drug reactions; contact the National Yellow Card Information Service at the MHRA on 0800 731 6789. Outside office hours a telephone-answering machine will take messages.

The following Yellow Card Centres can be contacted for further information:

Yellow Card Centre Northwest
2nd Floor, 70 Pembroke Place, Liverpool, L69 3GF
Tel: (0151) 794 8122

Yellow Card Centre Wales
All Wales Therapeutics and Toxicology Centre, Academic Building, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan, CF64 2XX
Tel: (029) 2074 5831

Yellow Card Centre Northern & Yorkshire
Regional Drug and Therapeutics Centre, 16/17 Framlington Place, Newcastle upon Tyne, NE2 4AB
Tel: (0191) 213 7855

Yellow Card Centre West Midlands
City Hospital, Dudley Road, Birmingham, B18 7QH
Tel: (0121) 507 5672

Yellow Card Centre Scotland
CARDS, Royal Infirmary of Edinburgh, 51 Little France Crescent, Old Dalkeith Road, Edinburgh, EH16 4SA
Tel: (0131) 242 2919
YCCScotland@luht.scot.nhs.uk

The MHRA’s database facilitates the monitoring of adverse drug reactions. More detailed information on reporting and a list of products currently under additional monitoring can be found on the MHRA website: www.mhra.gov.uk.

MHRA Drug Safety Update
Drug Safety Update is a monthly newsletter from the MHRA and the Commission on Human Medicines (CHM); it is available at www.gov.uk/drug-safety-update.

Self-reporting
Patients and their carers can also report suspected adverse drug reactions to the MHRA. Reports can be submitted directly to the MHRA through the Yellow Card Scheme using the electronic form at www.mhra.gov.uk/yellowcard, by telephone on 0808 100 3352, or by downloading the Yellow Card form from www.mhra.gov.uk. Alternatively, patients can use Yellow Cards available form pharmacies and GP surgeries. Information for patients about the Yellow Card Scheme is available in other languages at www.mhra.gov.uk/yellowcard.

Prescription-event monitoring
In addition to the MHRA’s Yellow Card Scheme, an independent scheme monitors the safety of new medicines using a different approach. The Drug Safety Research Unit identifies patients who have been prescribed selected new medicines and collects data on clinical events in these patients. The data are submitted on a voluntary basis by general practitioners on green forms. More information about the scheme and the Unit’s educational material is available from www.dsru.org.

Newer drugs and vaccines
Only limited information is available from clinical trials on the safety of new medicines. Further understanding about the safety of medicines depends on the availability of information from routine clinical practice. The black triangle symbol identifies newly licensed medicines that require additional monitoring by the European Medicines Agency. Such medicines include new active substances, biosimilar medicines, and medicines that the European Medicines Agency consider require additional monitoring. The black triangle symbol also appears in the Patient Information Leaflets for relevant medicines, with a brief explanation of what it means. Products usually retain a black triangle for 5 years, but this can be extended if required.

Spontaneous reporting is particularly valuable for recognising possible new hazards rapidly. For medicines showing the black triangle symbol, the MHRA asks that all suspected reactions (including those considered not to be serious) are reported through the Yellow Card Scheme. An adverse reaction should be reported even if it is not certain that the drug has caused it, or if the reaction is well recognised, or if other drugs have been given at the same time.

Established drugs and vaccines
Healthcare professionals and coroners are asked to report all suspected reactions to established drugs (including over-the-counter, herbal, and unlicensed medicines and medicines used off-label) and vaccines that are serious, medically significant, or result in harm. Serious reactions include those that are fatal, life-threatening, disabling,
incapacitating, or which result in or prolong hospitalisation, or a congenital abnormality; they should be reported even if the effect is well recognised. Examples include anaphylaxis, blood disorders, endocrine disturbances, effects on fertility, haemorrhage from any site, renal impairment, jaundice, ophthalmic disorders, severe CNS effects, severe skin reactions, reactions in pregnant women, and any drug interactions. Reports of serious adverse reactions are required to enable comparison with other drugs of a similar class. Reports of overdoses (deliberate or accidental) can complicate the assessment of adverse drug reactions, but provide important information on the potential toxicity of drugs.

For established drugs there is no need to report well-known, relatively minor side-effects, such as dry mouth with tricyclic antidepressants or constipation with opioids.

**Medication errors**

Adverse drug reactions where harm occurs as a result of a medication error are reportable as a Yellow Card or through the local risk management systems into the National Reporting and Learning System (NRLS). If reported to the NRLS, these will be shared with the MHRA. If the NRLS is not available and harm occurs, report using a Yellow Card.

**Adverse reactions to medical devices**

Suspected adverse reactions to medical devices including dental or surgical materials, intra-uterine devices, and contact lens fluids should be reported. Information on reporting these can be found at: [www.mhra.gov.uk](http://www.mhra.gov.uk).

**Side-effects in the BNF**

The BNF includes clinically relevant side-effects for most drugs; an exhaustive list is not included for drugs that are used by specialists (e.g. cytotoxic drugs and drugs used in anaesthesia). Where causality has not been established, side-effects in the manufacturers’ literature may be omitted from the BNF.

Recognising that hypersensitivity reactions can occur with virtually all medicines, this effect is not generally listed, unless the drug carries an increased risk of such reactions. The BNF also omits effects that are likely to have little clinical consequence (e.g. transient increase in liver enzymes).

Side-effects are generally listed in order of frequency and arranged broadly by body systems. Occasionally a rare side-effect might be listed first if it is considered to be particularly important because of its seriousness. In the product literature the frequency of side-effects is generally described as follows:

<table>
<thead>
<tr>
<th>Description of the frequency of side-effects</th>
<th>Very common</th>
<th>greater than 1 in 10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common</td>
<td>1 in 100 to 1 in 10</td>
<td></td>
</tr>
<tr>
<td>Uncommon [formerly ‘less commonly’ in BNF publications]</td>
<td>1 in 1000 to 1 in 100</td>
<td></td>
</tr>
<tr>
<td>Rare</td>
<td>1 in 10 000 to 1 in 1000</td>
<td></td>
</tr>
<tr>
<td>Very rare</td>
<td>less than 1 in 10 000</td>
<td></td>
</tr>
</tbody>
</table>

**Special problems**

**Delayed drug effects** Some reactions (e.g. cancers, chloroquine retinopathy, and retroperitoneal fibrosis) may become manifest months or years after exposure. Any suspicion of such an association should be reported directly to the MHRA through the Yellow Card Scheme.

**The elderly** Particular vigilance is required to identify adverse reactions in the elderly.

**Congenital abnormalities** When an infant is born with a congenital abnormality or there is a malformed aborted fetus doctors are asked to consider whether this might be an adverse reaction to a drug and to report all drugs (including self-medication) taken during pregnancy.

**Children** Particular vigilance is required to identify and report adverse reactions in children, including those resulting from the unlicensed use of medicines; all suspected reactions should be reported directly to the MHRA through the Yellow Card Scheme (see also Adverse Drug Reactions in Children).

**Prevention of adverse reactions**

Adverse reactions may be prevented as follows:

- never use any drug unless there is a good indication. If the patient is pregnant do not use a drug unless the need for it is imperative;
- allergy and idiosyncrasy are important causes of adverse drug reactions. Ask if the patient had previous reactions to the drug or formulation;
- ask if the patient is already taking other drugs including self-medication drugs, health supplements, complementary and alternative therapies; interactions may occur;
- age and hepatic or renal disease may alter the metabolism or excretion of drugs, so that much smaller doses may be needed. Genetic factors may also be responsible for variations in metabolism, and therefore for the adverse effect of the drug; notably of isoniazid p. 554 and the tricyclic antidepressants;
- prescribe as few drugs as possible and give very clear instructions to the elderly or any patient likely to misunderstand complicated instructions;
- whenever possible use a familiar drug; with a new drug, be particularly alert for adverse reactions or unexpected events;
- consider if excipients (e.g. colouring agents) may be contributing to the adverse reaction. If the reaction is minor, a trial of an alternative formulation of the same drug may be considered before abandoning the drug;
- warn the patient if serious adverse reactions are liable to occur.

**Drug allergy (suspected or confirmed)**

Suspected drug allergy is any reaction caused by a drug with clinical features compatible with an immunological mechanism. All drugs have the potential to cause adverse drug reactions, but not all of these are allergic in nature. A reaction is more likely to be caused by drug allergy if:

- The reaction occurred while the patient was being treated with the drug, or
- The drug is known to cause this pattern of reaction, or
- The patient has had a similar reaction to the same drug or drug-class previously.

A suspected reaction is less likely to be caused by a drug allergy if there is a possible non-drug cause or if there are only gastro-intestinal symptoms present.

The following signs, allergic patterns and timing of onset can be used to help decide whether to suspect drug allergy: **Immediate, rapidly-evolving reactions** (onset usually less than 1 hour after drug exposure)

- Anaphylaxis, with erythema, urticaria or angioedema, and hypotension and/or bronchospasm. See also Antihistamines, allergen immunotherapy and allergic emergencies p. 265
- Urticaria or angioedema without systemic features
- Exacerbation of asthma e.g. with non-steroidal anti-inflammatory drugs (NSAIDs)

**Non-immediate reactions, without systemic involvement** (onset usually 6–10 days after first drug exposure or 3 days after second exposure)

- Cutaneous reactions, e.g. widespread red macules and/or papules, or, fixed drug eruption (localised inflamed skin)
Adverse reactions to drugs

Non-immediate reactions, with systemic involvement (onset may be variable, usually 3 days to 6 weeks after first drug exposure, depending on features, or 3 days after second exposure)

- Cutaneous reactions with systemic features, e.g. drug reaction with eosinophilia and systemic signs (DRESS) or drug hypersensitivity syndrome (DHS), characterised by widespread red macules, papules or erythrodema, fever, lymphadenopathy, liver dysfunction or eosinophilia
- Toxic epidermal necrolysis or Stevens–Johnson syndrome
- Acute generalised exanthesmatous pustulosis (AGEP)

Suspicious drug allergy information should be clearly and accurately documented in clinical notes and prescriptions, and shared among all healthcare professionals. Patients should be given information about which drugs and drug-classes to avoid and encouraged to share their drug allergy status.

If a drug allergy is suspected, consider stopping the suspected drug and advising the patient or carer to avoid this drug in future. Symptoms of the acute reaction should be treated, in hospital if severe. Patients presenting with a suspected anaphylactic reaction, or a severe or non-immediate cutaneous reaction, should be referred to a specialist drug allergy service. Patients presenting with a suspected drug allergic reaction or anaphylaxis to NSAIDs, and local and general anaesthetics may also need to be referred to a specialist drug allergy service, e.g. in cases of anaphylactic reactions or to determine future treatment options. Patients presenting with a suspected drug allergic reaction or anaphylaxis associated with beta-lactam antibiotics should be referred to a specialist drug allergy service if their disease or condition can only be treated by a beta-lactam antibiotic or they are likely to need beta-lactam antibiotics frequently in the future (e.g. immunodeficient patients). For further information see Drug allergy: diagnosis and management. NICE Clinical Guideline 183 (September 2014) www.nice.org.uk/guidance/cg183.

Oral side-effects of drugs

Drug-induced disorders of the mouth may be due to a local reaction on the mouth or to a systemic effect manifested by oral changes. In the latter case urgent referral to the patient’s medical practitioner may be necessary.

Oral mucosa

Medicaments left in contact with or applied directly to the oral mucosa can lead to inflammation or ulceration; the possibility of allergy should also be borne in mind. Aspirin tablets p. 117 allowed to dissolve in the sulcus for the treatment of toothache can lead to a white patch followed by ulceration.

Flavouring agents, particularly essential oils, may sensitise the skin, but mucosal swelling is not usually prominent. The oral mucosa is particularly vulnerable to ulceration in patients treated with cytotoxic drugs, e.g. methotrexate p. 844. Other drugs capable of causing oral ulceration include ACE inhibitors, gold, nicorandil p. 206, NSAIDs, pancreatin p. 93, penicillamine p. 1002, proguanil hydrochloride p. 585, and protease inhibitors.

Erythema multiforme or Stevens–Johnson syndrome may follow the use of a wide range of drugs including antibacterials, antiretrovirals, sulfonamide derivatives, and anticonvulsants; the oral mucosa may be extensively ulcerated, with characteristic target lesions on the skin. Oral lesions of toxic epidermal necrolysis have been reported with a similar range of drugs.

Lichenoid eruptions are associated with ACE inhibitors, NSAIDs, methyldopa p. 140, chloroquine p. 582, oral antidiabetics, thiazide diuretics, and gold. Candidiasis can complicate treatment with antibacterials and immunosuppressants and is an occasional side-effect of corticosteroid inhalers.

Teeth and jaw

Brown staining of the teeth frequently follows the use of chlorhexidine mouthwash, spray or gel p. 1108, but can readily be removed by polishing. Iron salts in liquid form can stain the enamel black. Superficial staining has been reported rarely with co-amoxiclav suspension p. 521. Intrinsic staining of the teeth is most commonly caused by tetracyclines. They will affect the teeth if given at any time from about the fourth month in utero until the age of twelve years; they are contra-indicated during pregnancy, in breast-feeding women, and in children under 12 years. All tetracyclines can cause permanent, unsightly staining in children, the colour varying from yellow to grey. Excessive ingestion of fluoride leads to dental fluorosis with mottling of the enamel and areas of hypoplasia or pitting; fluoride supplements occasionally cause mild mottling (white patches) if the dose is too large for the child’s age (taking into account the fluoride content of the local drinking water and of toothpaste).

The risk of osteonecrosis of the jaw is substantially greater for patients receiving intravenous bisphosphonates in the treatment of cancer than for patients receiving oral bisphosphonates for osteoporosis or Paget’s disease. All patients receiving bisphosphonates should have a dental check-up (and any necessary remedial work should be performed) before bisphosphonate treatment, or as soon as possible after starting treatment. Patients with cancer receiving bevacizumab p. 807 or sunitinib p. 914 may also be at risk of osteonecrosis of the jaw.

Periodontium

Gingival overgrowth (gingival hyperplasia) is a side-effect of phenytoin p. 308 and sometimes of cyclosporin p. 788 or of nifedipine p. 157 (and some other calcium-channel blockers).

Thrombocytopenia may be drug related and may cause bleeding at the gingival margins, which may be spontaneous or may follow mild trauma (such as toothbrushing).

Salivary glands

The most common effect that drugs have on the salivary glands is to reduce flow (xerostomia). Patients with a persistently dry mouth may have poor oral hygiene; they are at an increased risk of dental caries and oral infections (particularly candidiasis). Many drugs have been implicated in xerostomia, particularly antimuscarinics (anticholinergics), antidepressants (including tricyclic antidepressants, and selective serotonin re-uptake inhibitors), alpha-blockers, antihistamines, antipsychotics, bacoferen p. 1026, bupropion hydrochloride p. 473, clonidine hydrochloride p. 139, SHT, agonists, opioids and tizanidine p. 1027. Excessive use of diuretics can also result in xerostomia.

Some drugs (e.g. clozapine p. 377, neostigmine p. 1024) can increase saliva production but this is rarely a problem unless the patient has associated difficulty in swallowing. Pain in the salivary glands has been reported with some antihypertensives (e.g. clonidine hydrochloride p. 139, methyldopa p. 140) and with vinca alkaloids.

Swelling of the salivary glands can occur with iodides, antithyroid drugs, phenothiazines, and sulfonamides.

Taste

There can be decreased taste acuity or alteration in taste sensation. Many drugs are implicated, including amiodarone hydrochloride p. 102, calcitonin, ACE inhibitors, carbamazepine p. 727, clarithromycin p. 508, gold, griseofulvin p. 568, lithium salts, metformin hydrochloride p. 652, metronidazole p. 512, penicillamine p. 1002, phenindione p. 101, propafenone hydrochloride p. 101, protease inhibitors, terbinafine p. 1132, and zopiclone p. 466.

Defective medicines

During the manufacture or distribution of a medicine an error or accident may occur whereby the finished product does not conform to its specification. While such a defect may impair the therapeutic effect of the product and could
adversely affect the health of a patient, it should **not** be confused with an Adverse Drug Reaction where the product conforms to its specification.
The Defective Medicines Report Centre assists with the investigation of problems arising from licensed medicinal products thought to be defective and co-ordinates any necessary protective action. Reports on suspect defective medicinal products should include the brand or the non-proprietary name, the name of the manufacturer or supplier, the strength and dosage form of the product, the product licence number, the batch number or numbers of the product, the nature of the defect, and an account of any action already taken in consequence. The Centre can be contacted at:
The Defective Medicines Report Centre
Medicines and Healthcare products Regulatory Agency,
151 Buckingham Palace Road, London, SW1W 9SZ
Tel: (020) 3080 6574
dmrc@mhra.gsi.gov.uk
Intravenous additives policies
A local policy on the addition of drugs to intravenous fluids should be drawn up by a multi-disciplinary team and issued as a document to the members of staff concerned. Centralised additive services are provided in a number of hospital pharmacy departments and should be used in preference to making additions on wards. The information that follows should be read in conjunction with local policy documents.

Guidelines
- Drugs should only be added to infusion containers when constant plasma concentrations are needed or when the administration of a more concentrated solution would be harmful.
- In general, only one drug should be added to any infusion container and the components should be compatible. Ready-prepared solutions should be used whenever possible. Drugs should not normally be added to blood products, mannitol, or sodium bicarbonate. Only specially formulated additives should be used with fat emulsions or amino-acid solutions.
- Solutions should be thoroughly mixed by shaking and checked for absence of particulate matter before use.
- Strict asepsis should be maintained throughout and in general the giving set should not be used for more than 24 hours (for drug admixtures).
- The infusion container should be labelled with the patient’s name, the name and quantity of additives, and the date and time of addition (and the new expiry date or time). Such additional labelling should not interfere with information on the manufacturer’s label that is still valid. When possible, containers should be retained for a period after use in case they are needed for investigation.
- It is good practice to examine intravenous infusions from time to time while they are running. If cloudiness, crystallisation, change of colour, or any other sign of interaction or contamination is observed the infusion should be discontinued.

Problems
Microbial contamination The accidental entry and subsequent growth of micro-organisms converts the infusion fluid pathway into a potential vehicle for infection with micro-organisms, particularly species of *Candida*, *Enterobacter*, and *Klebsiella*. Ready-prepared infusions containing the additional drugs, or infusions prepared by an additive service (when available) should therefore be used in preference to making extemporaneous additions to infusion containers on wards etc. However, when this is necessary strict aseptic procedure should be followed.

Incompatibility Physical and chemical incompatibilities may occur with loss of potency, increase in toxicity, or other adverse effect. The solutions may become opalescent or precipitation may occur, but in many instances there is no visual indication of incompatibility. Interaction may take place at any point in the infusion fluid pathway, and the potential for incompatibility is increased when more than one substance is added to the infusion fluid.

Common incompatibilities Precipitation reactions are numerous and varied and may occur as a result of pH, concentration changes, ‘salting-out’ effects, complexation or other chemical changes. Precipitation or other particle formation must be avoided since, apart from lack of control of dosage on administration, it may initiate or exacerbate adverse effects. This is particularly important in the case of drugs which have been implicated in either thrombophlebitis (e.g. diazepam) or in skin sloughing or necrosis caused by extravasation (e.g. sodium bicarbonate and certain cytotoxic drugs). It is also especially important to effect solution of colloidal drugs and to prevent their subsequent precipitation in order to avoid a pyrogenic reaction (e.g. amphotericin). It is considered undesirable to mix β-lactam antibiotics, such as semi-synthetic penicillins and cephalosporins, with proteinaceous materials on the grounds that immunogenic and allergenic conjugates could be formed. A number of preparations undergo significant loss of potency when added singly or in combination to large volume infusions. Examples include ampicillin in infusions that contain glucose or lactates. The breakdown products of dacarbazine have been implicated in adverse effects.

Blood Because of the large number of incompatibilities, drugs should not normally be added to blood and blood products for infusion purposes. Examples of incompatibility with blood include hypertonic mannitol solutions (irreversible crenation of red cells), dextran (rouleaux formation and interference with cross-matching), glucose (clumping of red cells), and oxytocin (inactivated). If the giving set is not changed after the administration of blood, but used for other infusion fluids, a fibrin clot may form which, apart from blocking the set, increases the likelihood of microbial growth.

Intravenous fat emulsions These may break down with coalescence of fat globules and separation of phases when additions such as antibacterials or electrolytes are made, thus increasing the possibility of embolism. Only specially formulated products such as *Vitlipid N*® may be added to appropriate intravenous fat emulsions.

Other infusions Infusions that frequently give rise to incompatibility include amino acids, mannitol, and sodium bicarbonate.

Bactericides Bactericides such as chlororesol 0.1% or phenylmercuric nitrate 0.001% are present in some injection solutions. The total volume of such solutions added to a container for infusion on one occasion should not exceed 15 mL.

Method
Ready-prepared infusions should be used whenever available. *Potassium chloride* is usually available in concentrations of 20, 27, and 40 mmol/litre in sodium chloride intravenous infusion (0.9%), glucose intravenous infusion (5%) or sodium chloride and glucose intravenous infusion. *Lidocaine hydrochloride* is usually available in concentrations of 0.1 or 0.2% in glucose intravenous infusion (5%). When addition is required to be made extemporaneously, any product reconstitution instructions such as those relating to concentration, vehicle, mixing, and handling precautions should be strictly followed using an aseptic technique throughout. Once the product has been reconstituted, addition to the infusion fluid should be made immediately in order to minimise microbial contamination and, with certain products, to prevent degradation or other formulation change which may occur; e.g. reconstituted ampicillin injection degrades rapidly on standing, and also may form polymers which could cause sensitivity reactions. It is also important in certain instances that an infusion fluid of specific pH be used (e.g. *furosemide* injection requires dilution in infusions of pH greater than 5.5).

When drug additions are made it is important to mix thoroughly; additions should not be made to an infusion container that has been connected to a giving set, as mixing is hampered. If the solutions are not thoroughly mixed a concentrated layer of the additive may form owing to
differences in density. **Potassium chloride** is particularly prone to this 'layering' effect when added without adequate mixing to infusions packed in non-rigid infusion containers; if such a mixture is administered it may have a serious effect on the heart.

A time limit between addition and completion of administration must be imposed for certain admixtures to guarantee satisfactory drug potency and compatibility. For admixtures in which degradation occurs without the formation of toxic substances, an acceptable limit is the time taken for 10% decomposition of the drug. When toxic substances are produced stricter limits may be imposed. Because of the risk of microbial contamination a maximum time limit of 24 hours may be appropriate for additions made elsewhere than in hospital pharmacies offering central additive service.

Certain injections must be protected from light during continuous infusion to minimise oxidation, e.g. dacarbazine and sodium nitroprusside.

Dilution with a small volume of an appropriate vehicle and administration using a motorised infusion pump is advocated for preparations such as unfractionated heparin where strict control over administration is required. In this case the appropriate dose may be dissolved in a convenient volume (e.g. 24–48 mL) of sodium chloride intravenous infusion (0.9%).

### Information provided in the BNF

The BNF gives information about preparations given by three methods:

- continuous infusion;
- intermittent infusion;
- addition via the drip tubing.

**Drugs given by continuous infusion** The BNF includes information on addition to **Glucose intravenous infusion 5 and 10%**, and **Sodium chloride intravenous infusion 0.9%**. Compatibility with glucose 5% and with sodium chloride 0.9% indicates compatibility with **Sodium chloride and glucose intravenous infusion**. Infusion of a large volume of hypotonic solution should be avoided therefore care should be taken if water for injections is used. The information relates to the proprietary preparations indicated; for other preparations suitability should be checked with the manufacturer.

Drugs for **continuous infusion** must be diluted in a large volume infusion. Penicillins and cephalosporins are not usually given by continuous infusion because of stability problems and because adequate plasma and tissue concentrations are best obtained by intermittent infusion. Where it is necessary to administer them by continuous infusion, detailed literature should be consulted.

Drugs that are both compatible and clinically suitable may be given by **intermittent infusion** in a relatively small volume of infusion over a short period of time, e.g. 100 mL in 30 minutes. The method is used if the product is incompatible or unstable over the period necessary for continuous infusion; the limited stability of ampicillin or amoxicillin in large volume glucose or lactate infusions may be overcome in this way.

Intermittent infusion is also used if adequate plasma and tissue concentrations are not produced by continuous infusion as in the case of drugs such as dacarbazine, gentamicin, and ticarcillin.

An in-line burette may be used for intermittent infusion techniques in order to achieve strict control over the time and rate of administration, especially for infants and children and in intensive care units. Intermittent infusion may also make use of the 'piggy-back' technique provided that no additions are made to the primary infusion. In this method the drug is added to a small secondary container connected to a Y-type injection site on the primary infusion giving set; the secondary solution is usually infused within 30 minutes.

**Addition via the drip tubing** is indicated for a number of cytotoxic drugs in order to minimise extravasation. The preparation is added aseptically via the rubber septum of the injection site of a fast-running infusion. In general, drug preparations intended for a bolus effect should be given directly into a separate vein where possible. Failing this, administration may be made via the drip tubing provided that the preparation is compatible with the infusion fluid when given in this manner.
Prescribing in children

Overview
For detailed advice on medicines used for children, consult BNF for Children.
Children, and particularly neonates, differ from adults in their response to drugs. Special care is needed in the neonatal period (first 28 days of life) and doses should always be calculated with care. At this age, the risk of toxicity is increased by reduced drug clearance and differing target organ sensitivity.
Whenever possible, intramuscular injections should be avoided in children because they are painful.
Where possible, medicines for children should be prescribed within the terms of the marketing authorisation (product licence). However, many children may require medicines not specifically licensed for paediatric use.
Although medicines cannot be promoted outside the limits of the licence, the Human Medicines Regulations 2012 does not prohibit the use of unlicensed medicines. It is recognised that the informed use of unlicensed medicines or of licensed medicines for unlicensed applications (‘off-label’ use) is often necessary in paediatric practice.

Adverse drug reactions in children
Suspected adverse drug reactions in children and young adults under 18 years should be reported through the Yellow Card Scheme. Yellow cards can be used for reporting suspected adverse drug reactions to medicines, vaccines, herbal or complementary products, whether self-medicated or prescribed. This includes suspected adverse drug reactions associated with misuse, overdose, medication errors or from use of unlicensed and off-label medicines. Yellow Cards can also be used to report medical device incidents, defective medicines, and suspected fake medicines.

Report all suspected adverse drug reactions that are:
- serious, medically significant or result in harm.
- associated with newer drugs and vaccines; the most up to date list of black triangle medicines is available at: www.mhra.gov.uk/blacktriangle

If in doubt whether to report a suspected adverse drug reaction, please complete a Yellow Card. The identification and reporting of adverse reactions to drugs in children and neonates is particularly important because:
- the action of the drug and its pharmacokinetics in children (especially in the very young) may be different from that in adults;
- drugs may not have been extensively tested in children;
- many drugs are not specifically licensed for use in children and are used either ‘off-label’ or as unlicensed products;
- drugs may affect the way a child grows and develops or may cause delayed adverse reactions which do not occur in adults;
- suitable formulations may not be available to allow precise dosing in children or they may contain excipients that should be used with caution in children;
- the nature and course of illnesses and adverse drug reactions may differ between adults and children.

Even if reported through the British Paediatric Surveillance Unit’s Orange Card Scheme, any identified suspected adverse drug reactions should also be submitted to the Yellow Card Scheme.

Prescription writing
Prescriptions should be written according to the guidelines in Prescription Writing. Inclusion of age is a legal requirement in the case of prescription-only medicines for children under 12 years of age, but it is preferable to state the age for all prescriptions for children.
It is particularly important to state the strengths of capsules or tablets. Although liquid preparations are particularly suitable for children, they may contain sugar which encourages dental decay. Sugar-free medicines are preferred for long-term treatment.
Many children are able to swallow tablets or capsules and may prefer a solid dose form; involving the child and parents in choosing the formulation is helpful.

Dosage in children
Children’s doses in the BNF are stated in the individual drug entries.
Doses are generally based on body-weight (in kilograms) or specific age ranges. In the BNF and BNF for Children, the term neonate is used to describe a newborn infant aged 0–28 days. The terms child or children are used generically to describe the entire range from infant to adolescent (1 month–17 years). An age range is specified when the dose information applies to a narrower age range than a child from 1 month–17 years.

Dose calculation
Many children’s doses are standardised by weight (and therefore require multiplying by the body-weight in kilograms to determine the child’s dose); occasionally, the doses have been standardised by body surface area (in m²). These methods should be used rather than attempting to calculate a child’s dose on the basis of doses used in adults.
For most drugs the adult maximum dose should not be exceeded. For example if the dose is stated as 8 mg/kg (max. 300 mg), a child weighing 10 kg should receive 80 mg but a child weighing 40 kg should receive 300 mg (rather than 320 mg).
Young children may require a higher dose per kilogram than adults because of their higher metabolic rates. Other problems need to be considered. For example, calculation by body-weight in the overweight child may result in much higher doses being administered than necessary; in such
cases, dose should be calculated from an ideal weight, related to height and age. **Body surface area (BSA) estimates** are sometimes preferable to body-weight for calculation of paediatric doses since many physiological phenomena correlate better with body surface area. Body surface area can be estimated from weight. For more information, refer to *BNF for Children*. Where the dose for children is not stated, prescribers should consult *BNF for Children* or seek advice from a medicines information centre.

**Dose frequency**
Antibacterials are generally given at regular intervals throughout the day. Some flexibility should be allowed in children to avoid waking them during the night. For example, the night-time dose may be given at the child’s bedtime. Where new or potentially toxic drugs are used, the manufacturers’ recommended doses should be carefully followed.

**Prescribing in hepatic impairment**

**Overview**
Liver disease may alter the response to drugs in several ways as indicated below, and drug prescribing should be kept to a minimum in all patients with severe liver disease. The main problems occur in patients with jaundice, ascites, or evidence of encephalopathy.

**Impaired drug metabolism**
Metabolism by the liver is the main route of elimination for many drugs, but hepatic reserve is large and liver disease has to be severe before important changes in drug metabolism occur. Routine liver-function tests are a poor guide to the capacity of the liver to metabolise drugs, and in the individual patient it is not possible to predict the extent to which the metabolism of a particular drug may be impaired. A few drugs, e.g. rifampicin p. 549 and fusidic acid p. 539, are excreted in the bile unchanged and can accumulate in patients with intrahepatic or extrahepatic obstructive jaundice.

**Hypoproteinaemia**
The hypoalbuminaemia in severe liver disease is associated with reduced protein binding and increased toxicity of some highly protein-bound drugs such as phenytoin p. 308 and prednisolone p. 639.

**Reduced clotting**
Reduced hepatic synthesis of blood-clotting factors, indicated by a prolonged prothrombin time, increases the sensitivity to oral anticoagulants such as warfarin sodium p. 135 and phenindione p. 134.

**Hepatic encephalopathy**
In severe liver disease many drugs can further impair cerebral function and may precipitate hepatic encephalopathy. These include all sedative drugs, opioid analgesics, those diuretics that produce hypokalaemia, and drugs that cause constipation.

**Fluid overload**
Oedema and ascites in chronic liver disease can be exacerbated by drugs that give rise to fluid retention e.g. NSAIDs and corticosteroids.

**Hepatotoxic drugs**
Hepatotoxicity is either dose-related or unpredictable (idiosyncratic). Drugs that cause dose-related toxicity may do so at lower doses in the presence of hepatic impairment than in individuals with normal liver function, and some drugs that produce reactions of the idiosyncratic kind do so more frequently in patients with liver disease. These drugs should be avoided or used very carefully in patients with liver disease. Where care is needed when prescribing in hepatic impairment, this is indicated under the relevant drug in the BNF.

**Prescribing in renal impairment**

**Issues encountered in renal impairment**
The use of drugs in patients with reduced renal function can give rise to problems for several reasons:
- reduced renal excretion of a drug or its metabolites may cause toxicity;
- sensitivity to some drugs is increased even if elimination is unimpaired;
- many side-effects are tolerated poorly by patients with renal impairment;
- some drugs are not effective when renal function is reduced.

Many of these problems can be avoided by reducing the dose or by using alternative drugs.

If even mild renal impairment is considered likely on clinical grounds, renal function should be checked before prescribing any drug which requires dose modification.

**General guidance**
Where care is needed when prescribing in renal impairment, this is indicated under the relevant drug monograph in the BNF. When both efficacy and toxicity are closely related to plasma-drug concentration, recommended regimens should be regarded only as a guide to initial treatment; subsequent doses must be adjusted according to clinical response and plasma-drug concentration. Dose recommendations are based on the severity of renal impairment. The total daily maintenance dose of a drug can
be reduced either by reducing the size of the individual doses or by increasing the interval between doses. For some drugs, although the size of the maintenance dose is reduced it is important to give a loading dose if an immediate effect is required. This is because it takes about five times the half-life of the drug to achieve steady-state plasma concentrations. Because the plasma half-life of drugs excreted by the kidney is prolonged in renal impairment it can take many doses for the reduced dosage to achieve a therapeutic plasma concentration.

**Important: dosage adjustment advice in the BNF** Clinical laboratories routinely report renal function in adults based on *estimated glomerular filtration rate* (eGFR) normalised to a body surface area of 1.73 m² — this is derived from either the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula or the Modification of Diet in Renal disease (MDRD) formula. However, in product literature, the effects of renal impairment on drug elimination is usually stated in terms of *creatinine clearance* as a surrogate for GFR. The information on dosage adjustment in the BNF is usually expressed in terms of eGFR. Exceptions to the use of eGFR include toxic drugs, in elderly patients and in patients at extremes of muscle mass (see *Estimating renal function in patients at extremes of muscle mass* and *Estimating renal function in elderly patients*, below) where calculation of CrCl is recommended. Although these two measures of renal function are not interchangeable, for most drugs and for most adult patients of average build and height, eGFR (rather than CrCl) can be used to determine dosage adjustments.

**Nephrotoxic drugs** Nephrotoxic drugs should, if possible, be avoided in patients with renal disease because the consequences of nephrotoxicity are likely to be more serious when renal reserve is already reduced. During intercurrent illness the risk of acute kidney injury is increased in patients with an eGFR of less than 60 mL/min/1.73 m²; potentially nephrotoxic or renally excreted drugs may require dose reduction or temporary discontinuation.

**Renal replacement therapy and transplantation** For prescribing in patients who have received a renal transplant or who are on renal replacement therapy (peritoneal dialysis or haemodialysis), consult specialist literature.

### Estimating renal function

Direct measure of Glomerular filtration rate (GFR) using plasma or urinary clearance is considered the best overall index of renal function. However, this is difficult to do in practice. As an alternative, the *estimated* Glomerular filtration rate (eGFR) based on serum creatinine is used to assess renal function. Creatinine clearance (CrCl) is also used as an estimate of GFR. Various equations for estimating glomerular filtration rate exist, however there is no compelling evidence to support the superiority of any given method for drug dosing in all patient populations or clinical situations. There is also insufficient evidence to provide definitive guidance about dosage adjustment of all drugs in patients with reduced renal function. Therefore, an understanding of drug pharmacokinetics is necessary in order to make appropriate dosing decisions.

Using serum creatinine to derive eGFR has a number of limitations; serum creatinine levels are dependent on muscle mass and diet, therefore estimates should be interpreted with caution in certain individuals (such as the elderly, body builders, amputees, in muscle-wasting disorders and vegans)—estimates will be higher or lower than the true value. Creatinine-derived measurements are also not useful in periods of rapidly changing renal function or in patients with AKI.

**Estimated glomerular filtration rate**

**Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula** The CKD-EPI formula is the recommended method for estimating GFR and calculating drug doses in most patients with renal impairment. CKD-EPI is adjusted for body surface area (BSA) and utilises serum creatinine, age, sex and race as variables. Clinical laboratories should use the CKD-EPI formula to routinely report eGFR.

**CKD-EPI equation**

\[
eGFR \text{ (ml/min/1.73 m}^2\text{)} = 141 \times \min(S_{Cr}/K, \ 1)^{1.209} \times 0.993^{\text{age}} \times \text{max}(S_{Cr}/K, \ 1) \times 1.159 \text{ if female} \times 0.85 \text{ if black}
\]

Where:
- \(S_{Cr}\) = serum creatinine in mg/dL;
- \(K = 0.7\) for females and 0.9 for males;
- \(\text{age} = -0.329\) for females and \(-0.411\) for males;
- \(\min(S_{Cr}/K, \ 1)\) indicates the minimum of \(S_{Cr}/K\) or 1;
- \(\max(S_{Cr}/K, \ 1)\) indicates the maximum of \(S_{Cr}/K\) or 1.

**Modification of Diet in Renal disease (MDRD)** The MDRD formula, like CKD-EPI, is expressed in terms of body surface area. It is less accurate than the CKD-EPI formula when eGFR is greater than 60 mL/min/1.73 m². It also overestimates GFR in elderly patients.

**Estimated creatinine clearance**

**Cockcroft and Gault** The Cockcroft and Gault formula is the preferred method for estimating renal function or calculating drug doses in patients with renal impairment who are elderly or at extremes of muscle mass (see below); it provides an estimate of CrCl (which is not equivalent to eGFR).

\[
\text{Estimated Creatinine Clearance} = \frac{186 \times \text{Age} \times \text{Weight}}{\text{Serum creatinine} \times \text{Ideal body weight (kilograms)}}
\]

- \(\text{Age in years}\)
- \(\text{Weight in kilograms (use ideal body weight where fat is likely to be the major contributor to body mass)}\)
- \(\text{Serum creatinine in micromol/litre}\)
- \(\text{Ideal body weight} = \text{Constant + 0.018 \times \text{Height in centimetres}}\)

Where:
- \(\text{Constant} = 50\) for men; 45.5 for women
- \(\text{Height in centimetres}\)

**Estimated renal function in patients at extremes of muscle mass** In patients at both extremes of muscle mass, eGFR should be interpreted with caution. Reduced muscle mass will lead to overestimation of GFR and increased muscle mass will lead to underestimation of the GFR.

**Creatinine clearance or absolute glomerular filtration rate** should be used to adjust drug doses in patients with a BMI less than 18 kg/m² or greater than 40 kg/m². Ideal body weight should be used to calculate the CrCl. Where the patient’s actual body weight is less than their ideal body weight, actual body weight should be used instead.

The absolute glomerular filtration rate is determined by removing the normalisation for BSA from the eGFR using the following formula:

\[
\text{GFR (Absolute)} = \text{eGFR} \times (\text{individual’s body surface area} / 1.73)
\]

The ideal body weight is calculated as follows:

**Ideal body weight (kilograms) = Constant + 0.91 \times (Height - 152.4)**

Where:
- \(\text{Constant} = 50\) for men; 45.5 for women
- \(\text{Height in centimetres}\)

**Estimated renal function in elderly patients** The Cockcroft and Gault formula is the preferred method for estimating renal function in elderly patients aged 75 years and over.
**Chronic kidney disease**  
**Classification of chronic kidney disease using GFR and ACR**  
Chronic kidney disease is classified using a combination of GFR and albumin:creatinine ratio (ACR). A decreased GFR and an increased ACR is associated with an increased risk of adverse outcomes. For example, a person with an eGFR of 25 ml/min/1.73 m² and an ACR of 15 mg/mmol has a CKD classification of G4A2.

<table>
<thead>
<tr>
<th>GFR and ACR categories and risk of adverse outcomes</th>
<th>ACR categories (mg/mmol), description and range</th>
</tr>
</thead>
<tbody>
<tr>
<td>GFR (ml/min/1.73 m²)</td>
<td>&lt;3 Normal to mild increase</td>
</tr>
<tr>
<td>≥90 Normal or high</td>
<td>A1</td>
</tr>
<tr>
<td>60–89 Mild reduction relative to normal range for a young adult</td>
<td>No CKD in the absence of markers of kidney damage</td>
</tr>
<tr>
<td>45–59 Mild-moderate reduction</td>
<td>G3a</td>
</tr>
<tr>
<td>30–44 Moderate-severe reduction</td>
<td>G3b</td>
</tr>
<tr>
<td>15–29 Severe reduction</td>
<td>G4</td>
</tr>
<tr>
<td>&lt;15 Kidney failure</td>
<td>G5</td>
</tr>
</tbody>
</table>

**Abbreviations:** ACR, albumin:creatinine ratio; CKD, chronic kidney disease; GFR, glomerular filtration rate

Adapted with the kind permission of the Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, 2013.
Prescribing in pregnancy

Overview
Drugs can have harmful effects on the embryo or fetus at any time during pregnancy. It is important to bear this in mind when prescribing for a woman of childbearing age or for men trying to father a child. During the first trimester drugs can produce congenital malformations (teratogenesis), and the period of greatest risk is from the third to the eleventh week of pregnancy. During the second and third trimesters drugs can affect the growth or functional development of the fetus, or they can have toxic effects on fetal tissues. Drugs given shortly before term or during labour can have adverse effects on labour or on the neonate after delivery. Not all the damaging effects of intra-uterine exposure to drugs are obvious at birth, some may only manifest later in life. Such late-onset effects include malignancy, e.g. adenocarcinoma of the vagina after puberty in females exposed to diethylstilbestrol in the womb, and adverse effects on intellectual, social, and functional development. The BNF and BNF for Children identifies drugs which:

- may have harmful effects in pregnancy and indicates the trimester of risk
- are not known to be harmful in pregnancy

The information is based on human data, but information from animal studies has been included for some drugs when its omission might be misleading. Maternal drug doses may require adjustment during pregnancy due to changes in maternal physiology but this is beyond the scope of the BNF and BNF for Children.

Where care is needed when prescribing in pregnancy, this is indicated under the relevant drug in the BNF and BNF for Children.

Important
Drugs should be prescribed in pregnancy only if the expected benefit to the mother is thought to be greater than the risk to the fetus, and all drugs should be avoided if possible during the first trimester. Drugs which have been extensively used in pregnancy and appear to be usually safe should be prescribed in preference to new or untried drugs; and the smallest effective dose should be used. Few drugs have been shown conclusively to be teratogenic in humans, but no drug is safe beyond all doubt in early pregnancy. Screening procedures are available when there is a known risk of certain defects.

Absence of information does not imply safety. It should be noted that the BNF and BNF for Children provide independent advice and may not always agree with the product literature.

Information on drugs and pregnancy is also available from the UK Teratology Information Service. www.uktis.org. Tel: 0344 892 0909 (09.00–17:00 Monday to Friday; urgent enquiries only outside these hours).

Prescribing in breast-feeding

Overview
Breast-feeding is beneficial; the immunological and nutritional value of breast milk to the infant is greater than that of formula feeds. Although there is concern that drugs taken by the mother might affect the infant, there is very little information on this. In the absence of evidence of an effect, the potential for harm to the infant can be inferred from:

- the amount of drug or active metabolite of the drug delivered to the infant (dependent on the pharmacokinetic characteristics of the drug in the mother);
- the efficiency of absorption, distribution, and elimination of the drug by the infant (infant pharmacokinetics);
- the nature of the effect of the drug on the infant (pharmacodynamic properties of the drug in the infant).

The amount of drug transferred in breast milk is rarely sufficient to produce a discernible effect on the infant. This applies particularly to drugs that are poorly absorbed and need to be given parenterally. However, there is a theoretical possibility that a small amount of drug present in breast milk can induce a hypersensitivity reaction. A clinical effect can occur in the infant if a pharmacologically significant quantity of the drug is present in milk. For some drugs (e.g. fluvastatin p. 196), the ratio between the concentration in milk and that in maternal plasma may be high enough to expose the infant to adverse effects. Some infants, such as those born prematurely or who have jaundice, are at a slightly higher risk of toxicity.

Some drugs inhibit the infant’s sucking reflex (e.g. phenobarbital p. 318) while others can affect lactation (e.g. bromocriptine p. 399).

The BNF identifies drugs:

- that should be used with caution or are contra-indicated in breast-feeding;
- that can be given to the mother during breastfeeding because they are present in milk in amounts which are too small to be harmful to the infant;
- that might be present in milk in significant amount but are not known to be harmful.

Where care is needed when prescribing in breast-feeding, this is indicated under the relevant drug in the BNF.

Important
For many drugs insufficient evidence is available to provide guidance and it is advisable to administer only essential drugs to a mother during breast-feeding. Because of the inadequacy of information on drugs in breast-feeding, absence of information does not imply safety.
Prescribing in palliative care

Overview
Palliative care is an approach that improves the quality of life of patients and their families facing life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychological, and spiritual. Careful assessment of symptoms and needs of the patient should be undertaken by a multidisciplinary team.

Specialist palliative care is available in most areas as day hospice care, home-care teams (often known as Macmillan teams), in-patient hospice care, and hospital teams. Many acute hospitals and teaching centres now have consultative, hospital-based teams.

Hospice care of terminally ill patients has shown the importance of symptom control and psychosocial support of the patient and family. Families should be included in the care of the patient if they wish.

Many patients wish to remain at home with their families. Although some families may at first be afraid of caring for the patient at home, support can be provided by community nursing services, social services, voluntary agencies and hospices together with the general practitioner. The family may be reassured by the knowledge that the patient will be admitted to a hospital or hospice if the family cannot cope.

Drug treatment
The number of drugs should be as few as possible, for even the taking of medicine may be an effort. Oral medication is usually satisfactory unless there is severe nausea and vomiting, dysphagia, weakness, or coma, when parenteral medication may be necessary.

Pain
Pain management in palliative care is focused on achieving control of pain by administering the right drug in the right dose at the right time. Analgesics can be divided into three broad classes: non-opioid (paracetamol p. 422, NSAID), opioid (e.g. codeine phosphate ‘weak’ p. 431, morphine ‘strong’ p. 439) and adjuvant (e.g. antidepressants, antiepileptics). Drugs from the different classes are used alone or in combination according to the type of pain and response to treatment. Analgesics are more effective in preventing pain than in the relief of established pain; it is important that they are given regularly.

Paracetamol p. 422 or a NSAID given regularly will often be sufficient to manage mild pain. If non-opioid analgesics alone are not sufficient, then an opioid analgesic alone or in combination with a non-opioid analgesic at an adequate dosage, may be helpful in the control of moderate pain. Codeine phosphate p. 431 or tramadol hydrochloride p. 447 can be considered for moderate pain. If these preparations do not control the pain then morphine p. 439 is the most useful opioid analgesic. Alternatives to morphine including transdermal buprenorphine p. 425, transdermal fentanyl p. 434, hydrocode (crude) hydrochloride p. 439, methadone hydrochloride p. 476, or oxycodone hydrochloride p. 442, should be initiated by those with experience in palliative care. Initiation of an opioid analgesic should not be delayed by concern over a theoretical likelihood of psychological dependence (addiction).

Bone metastases
In addition to the above approach, radiotherapy, bisphosphonates, and radioactive isotopes of strontium ranelate p. 690 (Metastron® available from GE Healthcare) may be useful for pain due to bone metastases.

Neuropathic pain
Patients with neuropathic pain may benefit from a trial of a tricyclic antidepressant. An antiepileptic may be added or substituted if pain persists; gabapentin p. 301 and pregabalin p. 310 are licensed for neuropathic pain. Ketamine p. 1234 is sometimes used under specialist supervision for neuropathic pain that responds poorly to opioid analgesics. Pain due to nerve compression may be reduced by a corticosteroid such as dexamethasone p. 635, which reduces oedema around the tumour, thus reducing compression. Nerve blocks or regional anaesthesia techniques (including the use of epidural and intrathecal catheters) can be considered when pain is localised to a specific area.

Pain management with opioids

Oral route
Treatment with morphine p. 439 is given by mouth as immediate-release or modified-release preparations. During the titration phase the initial dose is based on the previous medication used, the severity of the pain, and other factors such as presence of renal impairment, increasing age, or frailty. The dose is given either as an immediate-release preparation 4-hourly or as a modified-release preparation 12-hourly, in addition to rescue doses.

If pain occurs between regular doses of morphine (‘breakthrough pain’), an additional dose (‘rescue dose’) of immediate-release morphine should be given. An additional dose should also be given 30 minutes before an activity that causes pain, such as wound dressing. The standard dose of a strong opioid for breakthrough pain is usually one-tenth to one-sixth of the regular 24-hour dose, repeated every 2–4 hours as required (up to hourly may be needed if pain is severe or in the last days of life). Review pain management if rescue analgesic is required frequently (twice daily or more). Each patient should be assessed on an individual basis.

Formulations of fentanyl p. 434 that are administered nasally, buccally or sublingually are also licensed for breakthrough pain.

When adjusting the dose of morphine, the number of rescue doses required and the response to them should be taken into account; increments of morphine should not exceed one-third to one-half of the total daily dose every 24 hours. Thereafter, the dose should be adjusted with careful assessment of the pain, and the use of adjuvant analgesics should also be considered. Upward titration of the dose of morphine stops when either the pain is relieved or unacceptable adverse effects occur, after which it is necessary to consider alternative measures.

Morphine immediate-release 30mg 4-hourly (or modified-release 100mg 12-hourly) is usually adequate for most patients; some patients require morphine immediate-release up to 200mg 4-hourly (or modified-release 600mg 12-hourly), occasionally more is needed.

Once their pain is controlled, patients started on 4-hourly immediate-release morphine can be transferred to the same total 24-hour dose of morphine given as the modified-release preparation for 12-hourly or 24-hourly administration. The first dose of the modified-release preparation is given with, or within 4 hours of, the last dose of the immediate-release preparation. For preparations suitable for 12-hourly or 24-hourly administration see modified-release preparations under morphine p. 439. Increments should be made to the dose, not to the frequency of administration. The patient must be monitored closely for efficacy and side-effects, particularly constipation, and nausea and vomiting. A suitable laxative should be prescribed routinely.

Oxycodone hydrochloride p. 442 can be used in patients who require an opioid but cannot tolerate morphine. If the patient is already receiving an opioid, oxycodone hydrochloride should be started at a dose equivalent to the current analgesic (see below). Oxycodone hydrochloride immediate-release preparations can be given for breakthrough pain.

Neuropathic pain
Patients with neuropathic pain may benefit from a trial of a tricyclic antidepressant. An antiepileptic may be added or substituted if pain persists; gabapentin p. 301 and pregabalin p. 310 are licensed for neuropathic pain. Ketamine p. 1234 is sometimes used under specialist supervision for neuropathic pain that responds poorly to opioid analgesics. Pain due to nerve compression may be reduced by a corticosteroid such as dexamethasone p. 635, which reduces oedema around the tumour, thus reducing compression. Nerve blocks or regional anaesthesia techniques (including the use of epidural and intrathecal catheters) can be considered when pain is localised to a specific area.

Pain management with opioids

Oral route
Treatment with morphine p. 439 is given by mouth as immediate-release or modified-release preparations. During the titration phase the initial dose is based on the previous medication used, the severity of the pain, and other factors such as presence of renal impairment, increasing age, or frailty. The dose is given either as an immediate-release preparation 4-hourly or as a modified-release preparation 12-hourly, in addition to rescue doses.

If pain occurs between regular doses of morphine (‘breakthrough pain’), an additional dose (‘rescue dose’) of immediate-release morphine should be given. An additional dose should also be given 30 minutes before an activity that causes pain, such as wound dressing. The standard dose of a strong opioid for breakthrough pain is usually one-tenth to one-sixth of the regular 24-hour dose, repeated every 2–4 hours as required (up to hourly may be needed if pain is severe or in the last days of life). Review pain management if rescue analgesic is required frequently (twice daily or more). Each patient should be assessed on an individual basis.

Formulations of fentanyl p. 434 that are administered nasally, buccally or sublingually are also licensed for breakthrough pain.

When adjusting the dose of morphine, the number of rescue doses required and the response to them should be taken into account; increments of morphine should not exceed one-third to one-half of the total daily dose every 24 hours. Thereafter, the dose should be adjusted with careful assessment of the pain, and the use of adjuvant analgesics should also be considered. Upward titration of the dose of morphine stops when either the pain is relieved or unacceptable adverse effects occur, after which it is necessary to consider alternative measures.

Morphine immediate-release 30mg 4-hourly (or modified-release 100mg 12-hourly) is usually adequate for most patients; some patients require morphine immediate-release up to 200mg 4-hourly (or modified-release 600mg 12-hourly), occasionally more is needed.

Once their pain is controlled, patients started on 4-hourly immediate-release morphine can be transferred to the same total 24-hour dose of morphine given as the modified-release preparation for 12-hourly or 24-hourly administration. The first dose of the modified-release preparation is given with, or within 4 hours of, the last dose of the immediate-release preparation. For preparations suitable for 12-hourly or 24-hourly administration see modified-release preparations under morphine p. 439. Increments should be made to the dose, not to the frequency of administration. The patient must be monitored closely for efficacy and side-effects, particularly constipation, and nausea and vomiting. A suitable laxative should be prescribed routinely.

Oxycodone hydrochloride p. 442 can be used in patients who require an opioid but cannot tolerate morphine. If the patient is already receiving an opioid, oxycodone hydrochloride should be started at a dose equivalent to the current analgesic (see below). Oxycodone hydrochloride immediate-release preparations can be given for breakthrough pain.
Equivalent doses of opioid analgesics.

<table>
<thead>
<tr>
<th>Analgesic/Route</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Codeine: PO</td>
<td>100 mg</td>
</tr>
<tr>
<td>Diamorphine: IM, IV, SC</td>
<td>3 mg</td>
</tr>
<tr>
<td>Dihydrocodeine: PO</td>
<td>100 mg</td>
</tr>
<tr>
<td>Hydromorphone: PO</td>
<td>2 mg</td>
</tr>
<tr>
<td>Morphine: PO</td>
<td>10 mg</td>
</tr>
<tr>
<td>Morphine: IM, IV, SC</td>
<td>5 mg</td>
</tr>
<tr>
<td>Oxycodeone: PO</td>
<td>6.6 mg</td>
</tr>
<tr>
<td>Tramadol: PO</td>
<td>100 mg</td>
</tr>
</tbody>
</table>
| PO = by mouth; IM = intramuscular; IV = intravenous; SC = subcutaneous

**Parenteral route** The equivalent parenteral dose of morphine p. 439 (subcutaneous, intramuscular, or intravenous) is about half of the oral dose. If the patient becomes unable to swallow, generally morphine is administered as a continuous subcutaneous infusion (for details, see Continuous Subcutaneous Infusions below). Diamorphine hydrochloride p. 433 is sometimes preferred, because being more soluble, it can be given in a smaller volume. The equivalent subcutaneous dose of diamorphine hydrochloride is about one-third of the oral dose of morphine.

If the patient can resume taking medicines by mouth, then oral morphine may be substituted for subcutaneous infusion of morphine or diamorphine hydrochloride, see table above of approximate equivalent doses of morphine and diamorphine hydrochloride. The infusion is discontinued when the first oral dose of morphine is given.

**Rectal route** Morphine is also available for rectal administration as suppositories; alternatively oxycodone hydrochloride suppositories p. 442 can be obtained on special order.

**Transdermal route** Transdermal preparations of fentanyl p. 434 and buprenorphine p. 425 are available, they are not suitable for acute pain or in patients whose analgesic requirements are changing rapidly because the long time to steady state prevents rapid titration of the dose. Prescribers should ensure that they are familiar with the correct use of transdermal preparations, see under buprenorphine p. 425 and fentanyl p. 434 (inappropriate use has caused fatalities). Immediate-release morphine p. 439 can be given for breakthrough pain. The following 24-hour oral doses of morphine are considered to be approximately equivalent to the buprenorphine and fentanyl patches shown, however when switching due to possible opioid-induced hyperalgesia, reduce the calculated equivalent dose of the new opioid by one-quarter to one-half.

### Buprenorphine patches are approximately equivalent to the following 24-hour doses of oral morphine

- morphine salt 12 mg daily = buprenorphine ’5’ patch
- morphine salt 24 mg daily = buprenorphine ’10’ patch
- morphine salt 36 mg daily = buprenorphine ’15’ patch
- morphine salt 48 mg daily = buprenorphine ’20’ patch
- morphine salt 84 mg daily = buprenorphine ’35’ patch
- morphine salt 126 mg daily = buprenorphine ’52.5’ patch
- morphine salt 168 mg daily = buprenorphine ’70’ patch

Formulations of transdermal patches are available as 72-hourly, 96-hourly and 7-day patches, for further information see buprenorphine p. 425. Conversion ratios vary and these figures are a guide only. Morphine equivalences for transdermal opioid preparations have been approximated to allow comparison with available preparations of oral morphine.

### 72-hour Fentanyl patches are approximately equivalent to the following 24-hour doses of oral morphine

- morphine salt 30 mg daily = fentanyl ’12’ patch
- morphine salt 60 mg daily = fentanyl ’25’ patch
- morphine salt 120 mg daily = fentanyl ’50’ patch
- morphine salt 180 mg daily = fentanyl ’75’ patch
- morphine salt 240 mg daily = fentanyl ’100’ patch

Fentanyl equivalences in this table are for patients on well-tolerated opioid therapy for long periods; for patients who are opioid naive or who have been stable on oral morphine or other immediate release opioid for only several weeks, see Transdermal Route. Conversion ratios vary and these figures are a guide only. Morphine equivalences for transdermal opioid preparations have been approximated to allow comparison with available preparations of oral morphine.

### Symptom control

Several recommendations in this section involve unlicensed indications or routes.

**Anorexia** Anorexia may be helped by prednisolone p. 639 or dexamethasone p. 635.

**Bowel colic and excessive respiratory secretions** Bowel colic and excessive respiratory secretions may be reduced by a subcutaneous injection of hyoscine hydrobromide p. 417, hyoscine butylbromide p. 83, or glycopyrronium bromide p. 238. These antimuscarinics are generally given every 4 hours when required, but hourly use is occasionally necessary, particularly in excessive respiratory secretions. If symptoms persist, they can be given regularly via a continuous infusion device. Care is required to avoid the discomfort of dry mouth.

**Capillary bleeding** Capillary bleeding can be treated with tranexamic acid p. 107 by mouth; treatment is usually discontinued one week after the bleeding has stopped, or, if necessary, it can be continued at a reduced dose. Alternatively, gauze soaked in tranexamic acid 100 mg/mL p. 107 or adrenaline/epinephrine solution 1 mg/mL (1 in 1000) p. 216 can be applied to the affected area.

Vitamin K may be useful for the treatment and prevention of bleeding associated with prolonged clotting in liver disease. In severe chronic cholestasis, absorption of vitamin K may be impaired; either parenteral or water-soluble oral vitamin K (see phytomenadione p. 997 and menadion sodium phosphate p. 996) should be considered.

**Constipation** Constipation is a common cause of distress and is almost invariably after administration of an opioid.
analgesic. It should be prevented if possible by the regular administration of laxatives; a faecal softener with a peristaltic stimulant (e.g. co-danthramer p. 60) or lactulose solution p. 55 with a senna preparation p. 61 should be used. Methylprednisolone p. 62 is licensed for the treatment of opioid-induced constipation.

Convolutions Patients with cerebral tumours or uraemia may be susceptible to convulsions. Prophylactic treatment with phenytoin p. 308 or carbamazepine p. 297 should be considered. When oral medication is no longer possible, diazepam p. 327 given rectally, or phenobarbital p. 318 by injection is continued as prophylaxis. For the use of midazolam p. 323 by subcutaneous infusion using a continuous infusion device see below.

Dry mouth Dry mouth may be relieved by good mouth care and measures such as chewing sugar-free gum, sucking ice or pineapple chunks, or the use of artificial saliva, dry mouth associated with candidiasis can be treated by oral preparations of nystatin p. 1116 or miconazole p. 782, alternatively, fluconazole p. 562 can be given by mouth. Dry mouth may be caused by certain medications including opioids, antimuscarinic drugs (e.g. hyoscine), antidepressants and some antiepileptics; if possible, an alternative preparation should be considered.

Dysphagia A corticosteroid such as dexamethasone p. 635 may help, temporarily, if there is an obstruction due to tumour. See also Dry mouth, above.

Dyspnoea Breathlessness at rest may be relieved by regular oral morphine p. 439 in carefully titrated doses. Diazepam p. 327 may be helpful for dyspnoea associated with anxiety. A corticosteroid, such as dexamethasone p. 635, may also be helpful if there is bronchospasm or partial obstruction.

Fungating tumours Fungating tumours can be treated by regular dressing and antibacterial drugs; systemic treatment with metronidazole p. 512 is often required to reduce malodour but topical metronidazole p. 512 is also used.

Gastro-intestinal pain The pain of bowel colic may be reduced by loperamide hydrochloride p. 65. Hyoscine butylbromide p. 83, hyoscine hydrobromide p. 417, and glycopyrronium bromide p. 238 can also be used to treat bowel colic. Gastric distension pain due to pressure on the stomach may be caused by certain medications including opioids, antimuscarinic drugs (e.g. hyoscine), antidepressants and some antiepileptics; if possible, an alternative preparation should be considered.

Hiccups Hiccups may be relieved by moist inhalations or by regular administration of oral morphine p. 439. Methadone hydrochloride linctus p. 476 should be avoided because it has a long duration of action and tends to accumulate.

Muscle spasm The pain of muscle spasm can be helped by a muscle relaxant such as diazepam p. 327 or baclofen p. 1026.

Nausea and vomiting Nausea and vomiting are common in patients with advanced cancer. Ideally, the cause should be determined before treatment with an antiemetic is started. A prokinetic antiemetic may be a preferred choice for first-line therapy. Nausea and vomiting may occur with opioid therapy particularly in the initial stages but can be prevented by giving an antiemetic such as haloperidol p. 368 or metoclopramide hydrochloride p. 411. An antiemetic is usually necessary only for the first 4 or 5 days and therefore combined preparations containing an opioid with an antiemetic are not recommended because they lead to unnecessary antiemetic therapy (and associated side-effects when used long-term). Metoclopramide hydrochloride p. 411 has a prokinetic action and is used by mouth for nausea and vomiting associated with gastritis, gastric stasis, and functional bowel obstruction. Drugs with antimuscarinic effects antagonise prokinetic drugs and, if possible, should not be used concurrently.

Metoclopramide hydrochloride p. 411 has a prokinetic action and is used by mouth for nausea and vomiting associated with gastritis, gastric stasis, and functional bowel obstruction. Drugs with antimuscarinic effects antagonise prokinetic drugs and, if possible, should not be used concurrently.

Haloperidol p. 368 is used by mouth for most metabolic causes of vomiting (e.g. hypercalcaemia, renal failure). Cyclizine p. 409 is given by mouth. It is used for nausea and vomiting due to mechanical bowel obstruction, raised intracranial pressure, and motion sickness. Levomepromazine p. 419 is used as an antiemetic; it is given by mouth or by subcutaneous injection at bedtime. For the dose by subcutaneous infusion see below. Dexamethasone p. 635 by mouth can be used as an adjunct. Antiemetic therapy should be reviewed every 24 hours; it may be necessary to substitute the antiemetic or to add another one.

For the administration of antiemetics by subcutaneous infusion using a continuous infusion device, see below. For the treatment of nausea and vomiting associated with cancer chemotherapy see Cytotoxic drugs p. 824.

Pruritus Pruritus, even when associated with obstructive jaundice, often responds to simple measures such as application of emollients. In the case of obstructive jaundice, further measures include administration of colestyramine p. 191.

Raised intracranial pressure Headache due to raised intracranial pressure often responds to a high dose of a corticosteroid, such as dexamethasone p. 635 and should be given before 6 p.m. to reduce the risk of insomnia.

Restlessness and confusion Restlessness and confusion may require treatment with an antipsychotic, e.g. haloperidol p. 368 or levomepromazine p. 419, by mouth or by subcutaneous injection, both repeated every 2 hours if required. The dose and frequency is adjusted according to the level of patient distress and the response. A regular maintenance dose should also be considered, given twice daily either by mouth or by subcutaneous injection; alternatively use a continuous infusion device.

Levomepromazine is licensed to treat pain in palliative care—this use is reserved for distressed patients with severe pain unresponsive to other measures (seek specialist advice).

Continuous subcutaneous infusions Although drugs can usually be administered by mouth to control the symptoms of advanced cancer, the parenteral route may sometimes be necessary. Repeated administration of intramuscular injections can be difficult in a cachectic patient. This has led to the use of portable continuous infusion devices, such as syringe drivers, to give a continuous subcutaneous infusion, which can provide good control of symptoms with little discomfort or inconvenience to the patient.

Indications for the parenteral route are:

- the patient is unable to take medicines by mouth owing to nausea and vomiting, dysphagia, severe weakness, or coma
- there is malignant bowel obstruction in patients for whom further surgery is inappropriate (avoiding the need for
an intravenous infusion or for insertion of a nasogastric tube.

- occasionally when the patient does not wish to take regular medication by mouth.

**Syringe driver rate settings** Staff using syringe drivers should be adequately trained and different rate settings should be clearly identified and differentiated; incorrect use of syringe drivers is a common cause of medication errors.

**Bowel colic and excessive respiratory secretions** Hyoscine hydrobromide p. 417 effectively reduces respiratory secretions and bowel colic and is sedative (but occasionally causes paradoxical agitation).

Hyoscine butylbromide p. 83 is used for bowel colic and for excessive respiratory secretions, and is less sedative than hyoscine hydrobromide.

Glycopyrronium bromide p. 238 may also be used to treat bowel colic or excessive respiratory secretions.

**Confusion and restlessness** Haloperidol p. 368 has little sedative effect.

Levomepromazine p. 419 has a sedative effect.

Midazolam p. 323 is a sedative and an antiepileptic that may be used in addition to an antipsychotic drug in a very restless patient. Midazolam is also used for myoclonus.

**Convulsions** If a patient has previously been receiving an antiepileptic drug or has a primary or secondary cerebral tumour or is at risk of convulsion (e.g. owing to uraemia) antiepileptic medication should not be stopped. Midazolam p. 323 is the benzodiazepine antiepileptic of choice for continuous subcutaneous infusion.

**Nausea and vomiting** Haloperidol p. 368 and levomepromazine p. 419 can both be given as a subcutaneous infusion but sedation can limit the dose of levomepromazine.

Cyclizine is particularly likely to precipitate if mixed with diamorphine or other drugs (see under Mixing and Compatibility, below)

Metoclopramide hydrochloride p. 411 can cause skin reactions.

Octreotide p. 877, which stimulates water and electrolyte absorption and inhibits water secretion in the small bowel, can be used by subcutaneous infusion to reduce intestinal secretions and to reduce vomiting due to bowel obstruction.

**Pain control** Diamorphine hydrochloride p. 433 is the preferred opioid since its high solubility permits a large dose to be given in a small volume (see under Mixing and Compatibility, below). The table shows approximate equivalent doses of morphine and diamorphine hydrochloride.

**Mixing and compatibility** The general principle that injections should be given into separate sites (and should not be mixed) does not apply to the use of syringe drivers in palliative care. Provided that there is evidence of compatibility, selected injections can be mixed in syringe drivers. Not all types of medication can be used in a subcutaneous infusion. In particular, chlorpromazine hydrochloride p. 367, prochlorperazine p. 371, and diazepam p. 327 are contra-indicated as they cause skin reactions at the injection site; to a lesser extent cyclizine p. 409 and levomepromazine p. 419 also sometimes cause local irritation.

In theory injections dissolved in water for injections are more likely to be associated with pain (possibly owing to their hypotonicity). The use of physiological saline (sodium chloride 0.9% p. 953) however increases the likelihood of precipitation when more than one drug is used; moreover subcutaneous infusion rates are so slow (0.1–0.3 mL/hour) that pain is not usually a problem when water is used as a diluent.

**Compatibility with diamorphine** Diamorphine can be given by subcutaneous infusion in a strength of up to 250 mg/mL; up to a strength of 40 mg/mL either water for injections or physiological saline (sodium chloride 0.9%) is a suitable diluent—above that strength only water for injections is used (to avoid precipitation).

The following can be mixed with diamorphine:

- **Cyclizine**, may precipitate at concentrations above 10 mg/mL or in the presence of sodium chloride 0.9% or as the concentration of diamorphine relative to cyclizine increases; mixtures of diamorphine and cyclizine are also likely to precipitate after 24 hours.

- **Dexamethasone**, special care is needed to avoid precipitation of dexamethasone when preparing it.

- **Haloperidol**, mixtures of haloperidol and diamorphine are likely to precipitate after 24 hours if haloperidol concentration is above 2 mg/mL.

- **Hyoscine butylbromide**

- **Hyoscine hydrobromide**

- **Levomepromazine**

- **Metoclopramide**, under some conditions infusions containing metoclopramide become discoloured; such solutions should be discarded.

**Midazolam**

Subcutaneous infusion solution should be monitored regularly both to check for precipitation (and discolouration) and to ensure that the infusion is running at the correct rate.

**Problems encountered with syringe drivers** The following are problems that may be encountered with syringe drivers and the action that should be taken:

- if the subcutaneous infusion runs too quickly check the rate setting and the calculation;

- if the subcutaneous infusion runs too slowly check the start button, the battery, the syringe driver, the cannula, and make sure that the injection site is not inflamed;

- if there is an injection site reaction make sure that the site does not need to be changed—firmness or swelling at the site of injection is not in itself an indication for change, but pain or obvious inflammation is.
Equivalent doses of morphine sulfate and diamorphine hydrochloride given over 24 hours

These equivalences are *approximate only* and should be adjusted according to response

<table>
<thead>
<tr>
<th>Oral morphine sulfate over 24 hours</th>
<th>Subcutaneous infusion of morphine sulfate over 24 hours</th>
<th>Subcutaneous infusion of diamorphine hydrochloride over 24 hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 mg</td>
<td>15 mg</td>
<td>10 mg</td>
</tr>
<tr>
<td>60 mg</td>
<td>30 mg</td>
<td>20 mg</td>
</tr>
<tr>
<td>90 mg</td>
<td>45 mg</td>
<td>30 mg</td>
</tr>
<tr>
<td>120 mg</td>
<td>60 mg</td>
<td>40 mg</td>
</tr>
<tr>
<td>180 mg</td>
<td>90 mg</td>
<td>60 mg</td>
</tr>
<tr>
<td>240 mg</td>
<td>120 mg</td>
<td>80 mg</td>
</tr>
<tr>
<td>360 mg</td>
<td>180 mg</td>
<td>120 mg</td>
</tr>
<tr>
<td>480 mg</td>
<td>240 mg</td>
<td>160 mg</td>
</tr>
<tr>
<td>600 mg</td>
<td>300 mg</td>
<td>200 mg</td>
</tr>
<tr>
<td>780 mg</td>
<td>390 mg</td>
<td>260 mg</td>
</tr>
<tr>
<td>960 mg</td>
<td>480 mg</td>
<td>320 mg</td>
</tr>
<tr>
<td>1200 mg</td>
<td>600 mg</td>
<td>400 mg</td>
</tr>
</tbody>
</table>

If breakthrough pain occurs give a subcutaneous (preferable) or intramuscular injection equivalent to one-tenth to one-sixth of the total 24-hour subcutaneous infusion dose. It is kinder to give an intermittent bolus injection subcutaneously—absorption is smoother so that the risk of adverse effects at peak absorption is avoided (an even better method is to use a subcutaneous butterfly needle). To minimise the risk of infection no individual subcutaneous infusion solution should be used for longer than 24 hours.
Prescribing in the elderly

Overview
Old people, especially the very old, require special care and consideration from prescribers. Medicines for Older People, a component document of the National Service Framework for Older People (Department of Health. National Service Framework for Older People. London: Department of Health, March 2001), describes how to maximise the benefits of medicines and how to avoid excessive, inappropriate, or inadequate consumption of medicines by older people.

Appropriate prescribing
Elderly patients often receive multiple drugs for their multiple diseases. This greatly increases the risk of drug interactions as well as adverse reactions, and may affect compliance. The balance of benefit and harm of some medicines may be altered in the elderly. Therefore, elderly patients’ medicines should be reviewed regularly and medicines which are not of benefit should be stopped. Non-pharmacological measures may be more appropriate for symptoms such as headache, sleeplessness, and light-headedness when associated with social stress as in widowhood, loneliness, and family dispersal.

In some cases prophylactic drugs are inappropriate if they are likely to complicate existing treatment or introduce unnecessary side-effects, especially in elderly patients with poor prognosis or with poor overall health. However, elderly patients should not be denied medicines which may help them, such as anticoagulants or antiplatelet drugs for atrial fibrillation, antihypertensives, statins, and drugs for osteoporosis.

Form of medicine
Frail elderly patients may have difficulty swallowing tablets; if left in the mouth, ulceration may develop. They should always be encouraged to take their tablets or capsules with enough fluid, and whilst in an upright position to avoid the possibility of oesophageal ulceration. It can be helpful to discuss with the patient the possibility of taking the drug as a liquid if available.

Manifestations of ageing
In the very old, manifestations of normal ageing may be mistaken for disease and lead to inappropriate prescribing. In addition, age-related muscle weakness and difficulty in maintaining balance should not be confused with neurological disease. Disorders such as light-headedness not associated with postural or postprandial hypotension are unlikely to be helped by drugs.

Sensitivity
The nervous system of elderly patients is more sensitive to many commonly used drugs, such as opioid analgesics, benzodiazepines, antipsychotics, and antiparkinsonian drugs, all of which must be used with caution. Similarly, other organs may also be more susceptible to the effects of drugs such as anti-hypertensives and NSAIDs.

Pharmacokinetics
Pharmacokinetic changes can markedly increase the tissue concentration of a drug in the elderly, especially in debilitated patients. The most important effect of age is reduced renal clearance. Many aged patients thus excrete drugs slowly, and are highly susceptible to nephrotoxic drugs. Acute illness can lead to rapid reduction in renal clearance, especially if accompanied by dehydration. Hence, a patient stabilised on a drug with a narrow margin between the therapeutic and the toxic dose (e.g. digoxin p. 106) can rapidly develop adverse effects in the aftermath of a myocardial infarction or a respiratory-tract infection. The hepatic metabolism of lipid soluble drugs is reduced in elderly patients because there is a reduction in liver volume. This is important for drugs with a narrow therapeutic window.

Adverse reactions
Adverse reactions often present in the elderly in a vague and non-specific fashion. Confusion is often the presenting symptom (caused by almost any of the commonly used drugs). Other common manifestations are constipation (with antimuscarinics and many tranquillisers) and postural hypotension and falls (with diuretics and many psychotropics).

Hypnotics
Many hypnotics with long half-lives have serious hangover effects, including drowsiness, unsteady gait, slurred speech, and confusion. Hypnotics with short half-lives should be used but they too can present problems. Short courses of hypnotics are occasionally useful for helping a patient through an acute illness or some other crisis but every effort must be made to avoid dependence. Benzodiazepines impair balance, which can result in falls.

Diuretics
Diuretics are overprescribed in old age and should not be used on a long-term basis to treat simple gravitational oedema which will usually respond to increased movement, raising the legs, and support stockings. A few days of diuretic treatment may speed the clearing of the oedema but it should rarely need continued drug therapy.

NSAIDs
Bleeding associated with aspirin and other NSAIDs is more common in the elderly who are more likely to have a fatal or serious outcome. NSAIDs are also a special hazard in patients with cardiac disease or renal impairment which may again place older patients at particular risk. Owing to the increased susceptibility of the elderly to the side-effects of NSAIDs the following recommendations are made:
- for osteoarthritis, soft-tissue lesions, and back pain, first try measures such as weight reduction (if obese), warmth, exercise, and use of a walking stick;
- for osteoarthritis, soft-tissue lesions, back pain, and pain in rheumatoid arthritis, paracetamol p. 422 should be used first and can often provide adequate pain relief;
- alternatively, a low-dose NSAID (e.g. ibuprofen p. 1041 up to 1.2 g daily) may be given;
- for pain relief when either drug is inadequate, paracetamol in a full dose plus a low-dose NSAID may be given;
- if necessary, the NSAID dose can be increased or an opioid analgesic given with paracetamol;
- do not give two NSAIDs at the same time.

Prophylaxis of NSAID-induced peptic ulcers may be required if continued NSAID treatment is necessary. NSAID-associated ulcers under Peptic ulceration p. 70.

Other drugs
Other drugs which commonly cause adverse reactions are antiparkinsonian drugs, antihypertensives, psychotropics, and digoxin p. 106. The usual maintenance dose of digoxin in very old patients is 125 micrograms daily (62.5 micrograms in those with renal disease); lower doses are often inadequate but toxicity is common in those given 250 micrograms daily. Drug-induced blood disorders are much more common in the elderly. Therefore drugs with a tendency to cause bone marrow depression (e.g. co-trimoxazole p. 531, mianserin...
hydrochloride p. 353) should be avoided unless there is no acceptable alternative.
The elderly generally require a lower maintenance dose of warfarin sodium p. 135 than younger adults; once again, the outcome of bleeding tends to be more serious.

**Guidelines**
Always consider whether a drug is indicated at all.

**Limit range**  It is a sensible policy to prescribe from a limited range of drugs and to be thoroughly familiar with their effects in the elderly.

**Reduce dose**  Dosage should generally be substantially lower than for younger patients and it is common to start with about 50% of the adult dose. Some drugs (e.g. long-acting antidiabetic drugs such as glibenclamide p. 665) should be avoided altogether.

**Review regularly**  Review repeat prescriptions regularly. In many patients it may be possible to stop some drugs, provided that clinical progress is monitored. It may be necessary to reduce the dose of some drugs as renal function declines.

**Simplify regimens**  Elderly patients benefit from simple treatment regimens. Only drugs with a clear indication should be prescribed and whenever possible given once or twice daily. In particular, regimens which call for a confusing array of dosage intervals should be avoided.

**Explain clearly**  Write full instructions on every prescription (including repeat prescriptions) so that containers can be properly labelled with full directions. Avoid imprecisions like ‘as directed’. Child-resistant containers may be unsuitable.

**Repeats and disposal**  Instruct patients what to do when drugs run out, and also how to dispose of any that are no longer necessary. Try to prescribe matching quantities. If these guidelines are followed most elderly people will cope adequately with their own medicines. If not then it is essential to enrol the help of a third party, usually a relative or a friend.

---

**Drugs and sport**

**Anti-doping**
UK Anti-Doping, the national body responsible for the UK’s anti-doping policy, advises that athletes are personally responsible should a prohibited substance be detected in their body. Information regarding the use of medicines in sport is available from:

UK Anti-doping
Fleetbank House
2-6 Salisbury Square
London
EC4Y 8AE
(020) 7842 3450
ukad@ukad.org.uk
www.ukad.org.uk

Information about the prohibited status of specific medications based on the current World Anti-Doping Agency Prohibited List is available from Global Drug Reference Online: www.globaldro.com/UK/search

**General Medical Council’s advice**
Doctors who prescribe or collude in the provision of drugs or treatment with the intention of improperly enhancing an individual’s performance in sport contravene the GMC’s guidance, and such actions would usually raise a question of a doctor’s continued registration. This does not preclude the provision of any care or treatment where the doctor’s intention is to protect or improve the patient’s health.
Prescribing in dental practice

General guidance
Advice on the drug management of dental and oral conditions has been integrated into the main text. For ease of access, guidance on such conditions is usually identified by means of a relevant heading (e.g. Dental and Orofacial Pain) in the appropriate sections of the BNF. The following is a list of topics of particular relevance to dentists:
- Prescribing by dentists, see Prescription writing p. 5
- Oral side-effects of drugs, see Adverse reactions to drugs p. 12
- Medical emergencies in dental practice, see below
- Medical problems in dental practice, see below

Drug management of dental and oral conditions

Dental and orofacial pain
- Neuropathic pain p. 457
- Non-opioid analgesics and compound analgesic preparations, see Analgesics p. 420
- Opioid analgesics, see Analgesics p. 420
- Non-steroidal anti-inflammatory drugs p. 1028

Oral infections
- Bacterial infections, see Antibacterials, principles of therapy p. 479
  - Phenoxymethylpenicillin p. 518
  - Broad-spectrum penicillins (amoxicillin p. 518 and ampicillin p. 520)
  - Cephalexins (cefelexin p. 497 and cefradine p. 497)
  - Tetracyclines p. 533
  - Macrolides (clarithromycin p. 508, erythromycin p. 510 and azithromycin p. 507)
  - Clindamycin p. 506
  - Metronidazole p. 512
  - Fusidic acid p. 539

Fungal infections
- Local treatment, see Oropharyngeal fungal infections p. 1115
- Systemic treatment, see Antifungals, systemic use p. 558

Viral infections
- Herpetic gingivostomatitis, local treatment, see Oropharyngeal viral infections p. 1116
- Herpetic gingivostomatitis, systemic treatment, see Oropharyngeal viral infections p. 1116 and Herpesvirus infections p. 598
- Herpes labialis, see Skin infections p. 1125

Anaesthetics, anxiolytics and hypnotics
- Sedation, anaesthesia, and resuscitation in dental practice p. 1219
- Hypnotics, see Hypnotics and anxiolytics p. 459
- Sedation for dental procedures, see Hypnotics and anxiolytics p. 459
- Local anaesthesia p. 1236

Minerals
- Fluorides

Oral ulceration and inflammation p. 1111
- Mouthwashes, gargles and dentifrices, see Mouthwashes and other preparations for ooropharyngeal use p. 1107
- Dry mouth, see Treatment of dry mouth p. 1105
- Aromatic inhalations, see Aromatic inhalations, cough preparations and systemic nasal decongestants p. 282
- Nasal decongestants, see Aromatic inhalations, cough preparations and systemic nasal decongestants p. 282
- Dental Practitioners’ Formulary p. 1482

Medical emergencies in dental practice
This section provides guidelines on the management of the more common medical emergencies which may arise in dental practice. Dentists and their staff should be familiar with standard resuscitation procedures, but in all circumstances it is advisable to summon medical assistance as soon as possible. See also algorithm of the procedure for Cardiopulmonary resuscitation p. 1533.

The drugs referred to in this section include:
- Adrenaline/epinephrine Injection p. 216, adrenaline 1 in 1000, (adrenaline 1 mg/mL as acid tartrate), 1 mL amps
- Aspirin Dispersible Tablets 300 mg p. 117
- Glucagon Injection p. 681, glucagon (as hydrochloride), 1–unit vial (with solvent) p. 681
- Oxygen
- Midazolam Oromucosal Solution p. 323, midazolam 5 mg/mL p. 323
- Salbutamol Aerosol Inhalation p. 244, salbutamol 100 micrograms/metered inhalation p. 244

Adrenal insufficiency
Adrenal insufficiency may follow prolonged therapy with corticosteroids and can persist for years after stopping. A patient with adrenal insufficiency may become hypotensive under the stress of a dental visit (important: see individual monographs for details of corticosteroid cover before dental surgical procedures under general anaesthesia).

Management
- Lay the patient flat
- Give oxygen
- Transfer patient urgently to hospital

Anaphylaxis
A severe allergic reaction may follow oral or parenteral administration of a drug. Anaphylactic reactions in dentistry may follow the administration of a drug or contact with substances such as latex in surgical gloves. In general, the more rapid the onset of the reaction the more profound it tends to be. Symptoms may develop within minutes and rapid treatment is essential. Anaphylactic reactions may also be associated with additives and excipients in foods and medicines. Refined arachis (peanut) oil, which may be present in some medicinal products, is unlikely to cause an allergic reaction—nevertheless it is wise to check the full formula of preparations which may contain allergens (including those for topical application, particularly if they are intended for use in the mouth or for application to the nasal mucosa).

Symptoms and signs
- Paraesthesia, flushing, and swelling of face
- Generalised itching, especially of hands and feet
- Bronchospasm and laryngospasm (with wheezing and difficulty in breathing)
- Rapid weak pulse together with fall in blood pressure and pallor; finally cardiac arrest

Management
First-line treatment includes securing the airway, restoration of blood pressure (laying the patient flat and raising the feet, or in the recovery position if unconscious or nauseous and at risk of vomiting), and administration of adrenaline/epinephrine injection p. 216. This is given intramuscularly in a dose of 500 micrograms (0.5 mL adrenaline injection 1 in 1000); a dose of 300 micrograms (0.3 mL adrenaline injection 1 in 1000) may be appropriate for immediate self-administration. The dose is repeated if...
necessary at 5-minute intervals according to blood pressure, pulse, and respiratory function. Oxygen administration is also of primary importance. Arrangements should be made to transfer the patient to hospital urgently.

**Asthma**

Patients with asthma may have an attack while at the dental surgery. Most attacks will respond to 2 puffs of the patient’s short-acting beta agonist inhaler such as salbutamol 100 micrograms/puff p. 244; further puffs are required if the patient does not respond rapidly. If the patient is unable to use the inhaler effectively, further puffs should be given through a large-volume spacer device (or, if not available, through a plastic or paper cup with a hole in the bottom for the inhaler mouthpiece). If the response remains unsatisfactory, or if further deterioration occurs, then the patient should be transferred urgently to hospital. Whilst awaiting transfer, oxygen should be given with salbutamol 5 mg or terbutaline sulfate 100 micrograms/puff p. 246 by nebuliser; if a nebuliser is unavailable, then 2–10 puffs of salbutamol 100 micrograms/metered inhalation should be given (preferably by a large-volume spacer), and repeated every 5 mg or terbutaline sulfate

Reassure the patient as much as possible to relieve further anxiety. If available, aspirin p. 117 in a single dose of 300 mg should be given. A note (to say that aspirin has been given) should be sent with the patient to the hospital. For further details on the initial management of myocardial infarction, see Management of ST-Segment Elevation Myocardial Infarction.

If the patient collapses and loses consciousness attempt standard resuscitation measures. See also algorithm of the procedure for Cardiopulmonary resuscitation p. 1533.

**Epileptic seizures**

Patients with epilepsy must continue with their normal dosage of anticonvulsant drugs when attending for dental treatment. It is not uncommon for epileptic patients not to volunteer the information that they are epileptic but there should be little difficulty in recognising a tonic-clonic (grand mal) seizure.

**Symptoms and signs**

- There may be a brief warning (but variable)
- Sudden loss of consciousness, the patient becomes rigid, falls, may give a cry, and becomes cyanotic (tonic phase)
- After 30 seconds, there are jerking movements of the limbs; the tongue may be bitten (clonic phase)
- There may be frothing from mouth and urinary incontinence
- The seizure typically lasts a few minutes; the patient may then become flaccid but remain unconscious. After a variable time the patient regains consciousness but may remain confused for a while

**Management**

During a convulsion try to ensure that the patient is not at risk from injury but make no attempt to put anything in the mouth or between the teeth (in mistaken belief that this will protect the tongue). Give oxygen to support respiration if necessary. Do not attempt to restrain convulsive movements. After convulsive movements have subsided place the patient in the coma (recovery) position and check the airway. After convulsive movements have subsided place the patient in the coma (recovery) position and check the airway. Again, the patient should be little dif volunteer the information that they are epileptic but there may not have such prominent changes but may appear unduly lethargic.

**Cardiac emergencies**

If there is a history of angina the patient will probably carry glyceryl trinitrate spray or tablets p. 212 (or isosorbide dinitrate tablets p. 214) and should be allowed to use them. Hospital admission is not necessary if symptoms are mild and resolve rapidly with the patient’s own medication. See also Coronary Artery Disease below.

Arrhythmias may lead to a sudden reduction in cardiac output with loss of consciousness. Medical assistance should be summoned. For advice on pacemaker interference, see also Pacemakers below.

The pain of myocardial infarction is similar to that of angina but generally more severe and more prolonged. For general advice see also Coronary Artery Disease below.

**Symptoms and signs of myocardial infarction:**

- Progressive onset of severe, crushing pain across front of chest; pain may radiate towards the shoulder and down arm, or into neck and jaw
- Skin becomes pale and clammy
- Nausea and vomiting are common
- Pulse may be weak and blood pressure may fall
- Breathlessness

**Initial management of myocardial infarction:**

Call immediately for medical assistance and an ambulance, as appropriate.

Allow the patient to rest in the position that feels most comfortable; in the presence of breathlessness this is likely to be sitting position, whereas the syncopal patient should be laid flat; often an intermediate position (dictated by the patient) will be most appropriate. Oxygen may be administered.

Sublingual glyceryl trinitrate p. 212 may relieve pain. Intramuscular injection of drugs should be avoided because absorption may be too slow (particularly when cardiac output is reduced) and pain relief is inadequate. Intramuscular injection also increases the risk of local bleeding into the muscle if the patient is given a thrombolytic drug.

Dental procedure. This should be discussed with the patient as appropriate.

Hospital admission is not necessary if symptoms are mild and resolve rapidly with the patient’s own medication. See also Coronary Artery Disease below.

**Hypoglycaemia**

Insulin-treated diabetic patients attending for dental treatment under local anaesthesia should inject insulin and eat meals as normal. If food is omitted the blood glucose will fall to an abnormally low level (hypoglycaemia). Patients can often recognise the symptoms themselves and this state responds to sugar in water or a few lumps of sugar. Children may not have such prominent changes but may appear unduly lethargic.
Symptoms and signs
- Shaking and trembling
- Sweating
- 'Pins and needles' in lips and tongue
- Hunger
- Palpitation
- Headache (occasionally)
- Double vision
- Difficulty in concentration
- Slurring of speech
- Confusion
- Change of behaviour; truculence
- Convulsions
- Unconsciousness

Management
Initially glucose 10–20 g is given by mouth either in liquid form or as granulated sugar or sugar lumps. Approximately 10 g of glucose is available from non-diet versions of Lucozade® Energy Original 55 mL, Coca-Cola® 100 mL, Ribena® Blackcurrent 19 mL (to be diluted), 2 teaspoons sugar, and also from 3 sugar lumps. (Proprietary products of quick-acting carbohydrate (e.g. GlucoGel®, Dextrogel®, GSF-Syrup®, Rapilose® gel) are available on prescription for the patient to keep to hand in case of hypoglycaemia). If necessary this may be repeated in 10–15 minutes. If glucose cannot be given by mouth, if it is ineffective, or if the hypoglycaemia causes unconsciousness, glucagon 1 mg (1 unit) should be given by intramuscular (or subcutaneous) injection; a child under 8 years or of body-weight under 25 kg should be given 500 micrograms. Once the patient regains consciousness oral glucose should be administered as above. If glucagon is ineffective or contra-indicated, the patient should be transferred urgently to hospital. The patient must also be admitted to hospital if hypoglycaemia is caused by an oral antidiabetic drug.

Syncope
Insufficient blood supply to the brain results in loss of consciousness. The commonest cause is a vasovagal attack or simple faint (syncope) due to emotional stress.

Symptoms and signs
- Patient feels faint
- Low blood pressure
- Pallor and sweating
- Yawning and slow pulse
- Nausea and vomiting
- Dilated pupils
- Muscular twitching

Management
- Lay the patient as flat as is reasonably comfortable and, in the absence of associated breathlessness, raise the legs to improve cerebral circulation
- Loosen any tight clothing around the neck
- Once consciousness is regained, give sugar in water or a cup of sweet tea

Other possible causes
Postural hypotension can be a consequence of rising abruptly or of standing upright for too long; antihypertensive drugs predispose to this. When rising, susceptible patients should take their time. Management is as for a vasovagal attack. Under stressful circumstances, some patients hyperventilate. This gives rise to feelings of faintness but does not usually result in syncope. In most cases reassurance is all that is necessary; rebreathing from cupped hands or a bag may be helpful but calls for careful supervision. Adrenal insufficiency or arrhythmias are other possible causes of syncope.

Medical problems in dental practice
Individuals presenting at the dental surgery may also suffer from an unrelated medical condition; this may require modification to the management of their dental condition. If the patient has systemic disease or is taking other medication, the matter may need to be discussed with the patient’s general practitioner or hospital consultant.

Allergy
Patients should be asked about any history of allergy; those with a history of atopic allergy (asthma, eczema, hay fever, etc.) are at special risk. Those with a history of a severe allergy or of anaphylactic reactions are at high risk—it is essential to confirm that they are not allergic to any medication, or to any dental materials or equipment (including latex gloves). See also Anaphylaxis above.

Arrhythmias
Patients, especially those who suffer from heart failure or who have sustained a myocardial infarction, may have irregular cardiac rhythm. Atrial fibrillation is a common arrhythmia even in patients with normal hearts and is of little concern except that dentists should be aware that such patients may be receiving anticoagulant therapy. The patient’s medical practitioner should be asked whether any special precautions are necessary. Premedication (e.g. with temazepam p. 463) may be useful in some instances for very anxious patients. See also Cardiac emergencies above, and Dental Anaesthesia (Local anaesthesia p. 1236).

Cardiac prostheses
For an account of the risk of infective endocarditis in patients with prosthetic heart valves, see Infective Endocarditis below. For advice on patients receiving anticoagulants, see Thromboembolic disease below.

Coronary artery disease
Patients are vulnerable for at least 4 weeks following a myocardial infarction or following any sudden increase in the symptoms of angina. It would be advisable to check with the patient’s medical practitioner before commencing treatment. See also Cardiac Emergencies above. Treatment with low-dose aspirin (75 mg daily), clopidogrel p. 119, or dipyridamole p. 120 should not be stopped routinely nor should the dose be altered before dental procedures.
A Working Party of the British Society for Antimicrobial Chemotherapy has not recommended antibiotic prophylaxis for patients following coronary artery bypass surgery.

Cyanotic heart disease
Patients with cyanotic heart disease are at risk in the dental chair, particularly if they have pulmonary hypertension. In such patients a syncopal reaction increases the shunt away from the lungs, causing more hypoxia which worsens the syncopal reaction—a vicious circle that may prove fatal. The advice of the cardiologist should be sought on any patient with congenital cyanotic heart disease. Treatment in hospital is more appropriate for some patients with this condition.

Hypertension
Patients with hypertension are likely to be receiving antihypertensive drugs. Their blood pressure may fall dangerously low under general anaesthesia, see also under Dental Anaesthesia (Local anaesthesia p. 1236).

Immunosuppression and indwelling intraperitoneal catheters
Advice of a Working Party of the British Society for Antimicrobial Chemotherapy is that patients who are
immunosuppressed (including transplant patients) and patients with indwelling intraperitoneal catheters do not require antibiotic prophylaxis for dental treatment provided there is no other indication for prophylaxis. The Working Party has commented that there is little evidence that dental treatment is followed by infection in immunosuppressed and immunodeficient patients nor is there evidence that dental treatment is followed by infection in patients with indwelling intraperitoneal catheters.

**Infective endocarditis**
While almost any dental procedure can cause bacteraemia, there is no clear association with the development of infective endocarditis. Routine daily activities such as tooth brushing also produce a bacteraemia and may present a risk for infective endocarditis. While almost any dental procedure can cause bacteraemia, there is no clear association with the development of infective endocarditis. Routine daily activities such as tooth brushing also produce a bacteraemia and may present a risk for infective endocarditis.

Antibacterial prophylaxis and chlorhexidine p. 1108 mouthwash are not recommended for the prevention of endocarditis in patients undergoing dental procedures. Such prophylaxis may expose patients to the adverse effects of antimicrobials when the evidence of benefit has not been proven.

**Reduction of oral bacteraemia**
Patients at risk of endocarditis including those with valve replacement, acquired valvular heart disease with stenosis or regurgitation, structural congenital heart disease (including surgically corrected or palliated structural conditions, but excluding isolated atrial septal defect, fully repaired ventricular septal defect, fully repaired patent ductus arteriosus, and closure devices considered to be endothelialised), hypertrophic cardiomyopathy, or a previous episode of infective endocarditis, should be advised to maintain the highest possible standards of oral hygiene in order to reduce the:

- need for dental extractions or other surgery;
- chances of severe bacteraemia if dental surgery is needed;
- possibility of ‘spontaneous’ bacteraemia.

**Postoperative care**
Patients at risk of endocarditis including those with valve replacement, acquired valvular heart disease with stenosis or regurgitation, structural congenital heart disease (including surgically corrected or palliated structural conditions, but excluding isolated atrial septal defect, fully repaired ventricular septal defect, fully repaired patent ductus arteriosus, and closure devices considered to be endothelialised), hypertrophic cardiomyopathy, or a previous episode of infective endocarditis, should be advised to maintain the highest possible standards of oral hygiene in order to reduce the:

- need for dental extractions or other surgery;
- chances of severe bacteraemia if dental surgery is needed;
- possibility of ‘spontaneous’ bacteraemia.

**Patients on anticoagulant therapy**
For general advice on dental surgery in patients receiving oral anticoagulant therapy see Thromboembolic Disease below.

**Joint prostheses**
Advice of a Working Party of the British Society for Antimicrobial Chemotherapy is that patients with prosthetic joint implants (including total hip replacements) do not require antibiotic prophylaxis for dental treatment. The Working Party considers that it is unacceptable to expose patients to the adverse effects of antibiotics when there is no evidence that such prophylaxis is of any benefit, but that those who develop any intercurrent infection require prompt treatment with antibiotics to which the infecting organisms are sensitive. The Working Party has commented that joint infections have rarely been shown to follow dental procedures and are even more rarely caused by oral streptococci.

**Pacemakers**
Pacemakers prevent asystole or severe bradycardia. Some ultrasonic scalers, electronic apex locators, electro-analgesic devices, and electrocautery devices interfere with the normal function of pacemakers (including shielded pacemakers) and should not be used. The manufacturer’s literature should be consulted whenever possible. If severe bradycardia occurs in a patient fitted with a pacemaker, electrical equipment should be switched off and the patient placed supine with the legs elevated. If the patient loses consciousness and the pulse remains slow or is absent, cardiopulmonary resuscitation may be needed. Call immediately for medical assistance and an ambulance, as appropriate.


**Thromboembolic disease**
Patients receiving a heparin or an oral anticoagulant such as warfarin sodium p. 135, acenocoumarol (nicoumalone) p. 134, phenindione p. 134, apixaban p. 121, dabigatran etexilate p. 131 or rivaroxaban p. 123 may be liable to excessive bleeding after extraction of teeth or other dental surgery. Often dental surgery can be delayed until the anticoagulant therapy has been completed. For a patient requiring long-term therapy with warfarin sodium, the patient’s medical practitioner should be consulted and the International Normalised Ratio (INR) should be assessed 72 hours before the dental procedure. This allows sufficient time for dose modification if necessary. In those with an unstable INR (including those who require weekly monitoring of their INR, or those who have had some INR measurements greater than 4.0 in the last 2 months), the INR should be assessed within 24 hours of the dental procedure. Patients requiring minor dental procedures (including extractions) who have an INR below 4.0 may continue warfarin sodium without dose adjustment. There is no need to check the INR for a patient requiring a non-invasive dental procedure. If it is necessary to remove several teeth, a single extraction should be done first; if this goes well further teeth may be extracted at subsequent visits (two or three at a time). Measures should be taken to minimise bleeding during and after the procedure. This includes the use of sutures and a haemostatic such as oxidised cellulose, collagen sponge or resorbable gelatin sponge. Scaling and root planing should initially be restricted to a limited area to assess the potential for bleeding.

For a patient on long-term warfarin sodium, the advice of the clinician responsible for the patient’s anticoagulation should be sought if:

- the INR is unstable, or if the INR is greater than 4.0;
- the patient has thrombocytopenia, haemophilia, or other disorders of haemostasis, or suffers from liver impairment, alcoholism, or renal failure;
- the patient is receiving antiplatelet drugs, cytotoxic drugs or radiotherapy.

Intramuscular injections are contra-indicated in patients taking anticoagulants with an INR above the therapeutic range, and in those with any disorder of haemostasis. In patients taking anticoagulants who have a stable INR within the therapeutic range, intramuscular injections should be avoided if possible; if an intramuscular injection is necessary, the patient should be informed of the increased risk of localised bleeding and monitored carefully.
A local anaesthetic containing a vasoconstrictor should be given by infiltration, or by intraligamentary or mental nerve injection if possible. If regional nerve blocks cannot be avoided the local anaesthetic should be given cautiously using an aspirating syringe.

Drugs which have potentially serious interactions with anticoagulants include aspirin and other NSAIDs, carbamazepine p. 297, imidazole and triazole antifungals (including miconazole p. 782), erythromycin p. 510, clarithromycin p. 508, and metronidazole p. 512; for details of these and other interactions with anticoagulants, see Appendix 1 (dabigatran etexilate, heparins, phenindione, rivaroxaban, and coumarins).

Although studies have failed to demonstrate an interaction, common experience in anticoagulant clinics is that the INR can be altered following a course of an oral broad-spectrum antibiotic, such as ampicillin p. 520 or amoxicillin p. 518. Information on the treatment of patients who take anticoagulants is available at www.npsa.nhs.uk/patientsafety/alerts-and-directives/alerts/anticoagulant.

Liver disease
Liver disease may alter the response to drugs and drug prescribing should be kept to a minimum in patients with severe liver disease. Problems are likely mainly in patients with jaundice, ascites, or evidence of encephalopathy. For guidance on prescribing for patients with hepatic impairment, see Prescribing in hepatic impairment p. 19. Where care is needed when prescribing in hepatic impairment, this is indicated under the relevant drug in the BNF.

Renal impairment
The use of drugs in patients with reduced renal function can give rise to many problems. Many of these problems can be avoided by reducing the dose or by using alternative drugs. Special care is required in renal transplantation and immunosuppressed patients; if necessary such patients should be referred to specialists. For guidance on prescribing in patients with renal impairment, see Prescribing in renal impairment p. 19. Where care is needed when prescribing in renal impairment, this is indicated under the relevant drug in the BNF.

Pregnancy
Drugs taken during pregnancy can be harmful to the fetus and should be prescribed only if the expected benefit to the mother is thought to be greater than the risk to the fetus; all drugs should be avoided if possible during the first trimester. For guidance on prescribing in pregnancy, see Prescribing in pregnancy p. 22. Where care is needed when prescribing in pregnancy, this is indicated under the relevant drug in the BNF.

Breast-feeding
Some drugs taken by the mother whilst breast-feeding can be transferred to the breast milk, and may affect the infant. For guidance on prescribing in breast-feeding, see Prescribing in breast-feeding p. 22. Where care is needed when prescribing in breast-feeding, this is indicated under the relevant drug in the BNF.
Chapter 1
Gastro-intestinal system

Contents

1 Chronic bowel disorders
   1.1 Coeliac disease
   1.2 Diverticular disease and diverticulitis
   1.3 Inflammatory bowel disease
   1.4 Irritable bowel syndrome
   1.5 Short bowel syndrome

2 Constipation and bowel cleansing
   2.1 Bowel cleansing
   2.2 Constipation

3 Diarrhoea

4 Disorders of gastric acid and ulceration
   4.1 Dyspepsia
   4.2 Gastric and duodenal ulceration
   4.3 Gastro-oesophageal reflux disease

5 Food allergy

6 Gastro-intestinal smooth muscle spasm

7 Liver disorders and related conditions
   7.1 Biliary disorders
   7.2 Oesophageal varices

8 Obesity

9 Rectal and anal disorders
   9.1 Anal fissures
   9.2 Haemorrhoids

10 Reduced exocrine secretions

11 Stoma care

1 Chronic bowel disorders

Chronic bowel disorders

Overview

Once tumours are ruled out individual symptoms of chronic bowel disorders need specific treatment including dietary manipulation as well as drug treatment and the maintenance of a liberal fluid intake.

Clostridium difficile infection

Clostridium difficile infection is caused by colonisation of the colon with Clostridium difficile and production of toxin. It often follows antibiotic therapy and is usually of acute onset, but may become chronic. It is a particular hazard of ampicillin p. 520, amoxicillin p. 518, co-amoxiclav p. 521, second- and third-generation cephalosporins, clindamycin p. 506, and quinolones, but few antibiotics are free of this side-effect. Treatment options include metronidazole p. 512, vancomycin p. 505, and fidaxomicin p. 538.

1.1 Coeliac disease

Coeliac disease

Description of condition

Coeliac disease is an autoimmune condition which is associated with chronic inflammation of the small intestine. Dietary proteins known as gluten, which are present in wheat, barley and rye, activate an abnormal immune response in the intestinal mucosa, which can lead to malabsorption of nutrients.

Aims of treatment

The management of coeliac disease is aimed at eliminating symptoms (such as diarrhoea, bloating and abdominal pain) and reducing the risk of complications, including those resulting from malabsorption.

Non-drug treatment

The only effective treatment for coeliac disease is a strict, life-long, gluten-free diet. A range of gluten-free products is available for prescription (see Borderline substances).

Drug treatment

Patients who have coeliac disease are at an increased risk of malabsorption of key nutrients (such as calcium and vitamin D). Their risk of osteoporosis and the need for active treatment of bone disease should form part of the ongoing management of coeliac disease. Supplementation of key nutrients may be required if dietary intake is insufficient.

Patients who have coeliac disease should be advised not to self-medicate with over-the-counter vitamins or mineral supplements. Initiation of supplementation should involve a discussion with a member of the patient’s healthcare team in order to identify the individual needs of the patient and to allow for appropriate ongoing monitoring.

Confirmed cases of refractory coeliac disease should be referred to a specialist centre. Treatment with prednisolone p. 639 can be considered for initial management while awaiting specialist advice.

Useful Resources


1.2 Diverticular disease and diverticulitis

Diverticular disease and diverticulitis

Description of condition

Diverticular disease is a condition where diverticula (sac-like protrusions of mucosa through the muscular colonic...
wall) cause intermittent lower abdominal pain in the absence of inflammation or infection. The prevalence of diverticula increases with age, with the majority of patients older than 50 years.

**Diverticulitis** occurs when the diverticula become inflamed and infected, causing marked lower abdominal pain usually accompanied by fever and general malaise, and occasionally, with large rectal bleeds. Complicated diverticulitis includes episodes associated with an abscess, free perforation, fistula, obstruction, or stricture.

To ensure that an accurate diagnosis of diverticulitis and diverticular disease is made, consider and exclude all other causes of lower abdominal pain prior to treatment.

### Aims of treatment

The aim of treatment is to relieve symptoms of diverticular disease, cure episodes of diverticulitis, and reduce the risk of recurrences and complications.

### Drug treatment

A high-fibre diet is recommended for the treatment of symptomatic diverticular disease, although evidence supporting this is inconsistent and of low quality. Bulk-forming drugs have also been used, but evidence of their effectiveness is lacking.

Treatment of uncomplicated diverticulitis includes a low residue diet and bowel rest. Antibacterials are recommended only when the patient presents with signs of infection or is immunocompromised, as there is no evidence to support routine administration.

Patients with complicated diverticulitis or with severe presentation, require hospital admission, treatment with intravenous antibacterials (covering Gram-negative organisms and anaerobes), and bowel rest.

There is insufficient evidence to justify the role of fibre, rifaximin p. 543, antispasmodics, mesalazine p. 39, and probiotics in the prevention or treatment of diverticulitis. Elective surgery to provide symptomatic relief or prevent recurrence, should be considered for patients following recovery from an episode of complicated diverticulitis. This includes episodes associated with free perforation, abscess, fistula, obstruction, or stricture. Urgent sigmoid colectomy is required for patients with diffuse peritonitis or for those in whom non-operative management of acute diverticulitis fails.

### 1.3 Inflammatory bowel disease

#### Inflammatory bowel disease

Chronic inflammatory bowel diseases include Crohn’s disease below and Ulcerative colitis p. 37.

#### Drugs used in chronic bowel disorders

**Aminosalicylates**

Sulfasalazine p. 42 is a combination of 5-aminosalicylic acid (‘5-ASA’) and sulfapyridine; sulfapyridine acts only as a carrier to the colonic site of action but still causes side-effects. In the newer aminosalicylates, mesalazine p. 39 (5-aminosalicylic acid), balsalazine sodium p. 39 (a pro-drug of 5-aminosalicylic acid) and olsalazine sodium p. 42 (a dimer of 5-aminosalicylic acid which cleaves in the lower bowel), the sulfonamide-related side-effects of sulfasalazine are avoided, but 5-aminosalicylic acid alone can still cause side-effects including blood disorders and lupus-like syndrome also seen with sulfasalazine.

**Drugs affecting the immune response**

Folic acid p. 937 should be given to reduce the possibility of methotrexate p. 844 toxicity [unlicensed indication]. Folic acid is usually given once weekly on a different day to the methotrexate; alternative regimens may be used in some settings.

**Cytokine modulators**

Infliximab p. 1016, adalimumab p. 1008, and golimumab p. 1014 are monoclonal antibodies which inhibit the pro-inflammatory cytokine, tumour necrosis factor alpha. They should be used under specialist supervision.

### Crohn’s disease

#### Description of condition

Crohn’s disease is a chronic, inflammatory bowel disease that mainly affects the gastro-intestinal tract. It is characterised by thickened areas of the gastro-intestinal wall with inflammation extending through all layers, deep ulceration and fissuring of the mucosa, and the presence of granulomas; affected areas may occur in any part of the gastro-intestinal tract, interspersed with areas of relatively normal tissue. Crohn’s disease may present as recurrent attacks, with acute exacerbations combined with periods of remission or less active disease. Symptoms depend on the site of disease but may include abdominal pain, diarrhoea, fever, weight loss and rectal bleeding.

Complications of Crohn’s disease include intestinal strictures, abscesses in the wall of the intestine or adjacent structures, fistulae, anaemia, malnutrition, colorectal and small bowel cancers, and growth failure and delayed puberty in children. Crohn’s disease may also be associated with extra-intestinal manifestation: the most common are arthritis and abnormalities of the joints, eyes, liver and skin. Crohn’s disease is also a cause of secondary osteoporosis and those at greatest risk should be monitored for osteopenia and assessed for the risk of fractures.

**Fistulating Crohn’s disease**

Fistulating Crohn’s disease is a complication that involves the formation of a fistula between the intestine and adjacent structures, such as perianal skin, bladder, and vagina. It occurs in about one quarter of patients, mostly when the disease involves the ileocolonic area.

#### Aims of treatment

Treatment is largely directed at the induction and maintenance of remission and the relief of symptoms. Active treatment of acute Crohn’s disease should be distinguished from preventing relapse. The aims of drug treatment are to reduce symptoms and maintain or improve quality of life, while minimising toxicity related to drugs over both the short and long term.

In fistulating Crohn’s disease, surgery and medical treatment aim to close and maintain closure of the fistula.

#### Non-drug treatment

In addition to drug treatment, management options for Crohn’s disease include smoking cessation and attention to nutrition, which plays an important role in supportive care. Surgery may be considered in certain patients with early disease limited to the distal ileum and in severe or chronic active disease.

#### Drug treatment

**Treatment of acute disease**

**Monotherapy**

A corticosteroid (either prednisolone p. 639 or methylprednisolone p. 638 or intravenous hydrocortisone p. 637), is used to induce remission in patients with a first presentation or a single inflammatory exacerbation of Crohn’s disease in a 12-month period.

In patients with distal ileal, ileocaecal or right-sided colonic disease, in whom a conventional corticosteroid is unsuitable or contra-indicated, budesonide p. 43 may be
Considered. Budesonide is less effective but may cause fewer side-effects than other corticosteroids, as systemic exposure is limited. Aminosalicylates (such as sulfasalazine p. 42 and mesalazine p. 39) are an alternative option in these patients. They are less effective than a corticosteroid or budesonide, but may be preferred because they have fewer side-effects. Aminosalicylates and budesonide are not appropriate for severe presentations or exacerbations.

Add-on treatment

Add on treatment is prescribed if there are two or more inflammatory exacerbations in a 12-month period, or the corticosteroid dose cannot be reduced.

Azathioprine p. 787 or mercaptopurine p. 844 [unlicensed indications] can be added to a corticosteroid or budesonide to induce remission. In patients who cannot tolerate azathioprine or mercaptopurine or in whom thiopurine methyltransferase (TPMT) activity is deficient, methotrexate p. 844 can be added to a corticosteroid.

Under specialist supervision, monoclonal antibody therapies, adalimumab p. 1008 and infliximab p. 1016, are options for the treatment of severe, active Crohn’s disease, following inadequate response to conventional therapies or in those who are intolerant of or have contra-indications to conventional therapy. Vedolizumab p. 44 is recommended as a treatment option for moderate to severely active Crohn’s disease when therapy with adalimumab or infliximab is unsuccessful, is contra-indicated or not tolerated. See also National funding/access decisions for adalimumab, infliximab and vedolizumab.

Adalimumab and infliximab can be used as mono-therapy or combined with an immunosuppressant although there is uncertainty about the comparative effectiveness and long-term side-effects of therapy.

Maintenance of remission

Patients who choose not to receive maintenance treatment during remission should be made aware of the symptoms that may suggest a relapse (most frequently unintended weight loss, abdominal pain, diarrhoea and general ill-health). For those who choose not to receive maintenance treatment during remission, a suitable follow-up plan should be agreed upon and information provided on how to access healthcare if a relapse should occur.

Azathioprine or mercaptopurine [unlicensed indications] as monotherapy can be used to maintain remission when previously used with a corticosteroid to induce remission. They may also be used in patients who have not previously received these drugs (particularly those with adverse prognostic factors such as early age of onset, perianal disease, corticosteroid use at presentation, and severe presentations). Methotrexate can be used to maintain remission only in patients who required methotrexate to induce remission, or who are intolerant of or are not suitable for azathioprine or mercaptopurine for maintenance. Corticosteroids or budesonide should not be used.

Fistulating Crohn’s disease

Perianal fistulae are the most common occurrence in patients with fistulating Crohn’s disease. Treatment may not be necessary for simple, asymptomatic perianal fistulae. When fistulae are symptomatic, local drainage and surgery may be required in conjunction with the medical therapy.

Metronidazole p. 512 or ciprofloxacin p. 527 [unlicensed indications], alone or in combination, can improve symptoms of fistulating Crohn’s disease but complete healing occurs rarely. Metronidazole is usually given for 1 month, but no longer than 3 months because of concerns about peripheral neuropathy. Other antibacterials should be given if specifically indicated (e.g. in sepsis associated with fistulae and perianal disease) and for managing bacterial overgrowth in the small bowel.

Either azathioprine or mercaptopurine [unlicensed indications] is used to control the inflammation in fistulating Crohn’s disease and they are continued for maintenance.

Infliximab p. 1016 is recommended for patients with active fistulating Crohn’s disease who have not responded to conventional therapy (including antibacterials, drainage and immunosuppressive treatments), or who are intolerant of or have contra-indications to conventional therapy. Infliximab should be used after ensuring that all sepsis is actively draining.

Abscess drainage, fistulotomy, and seton insertion may be appropriate, particularly before infliximab treatment.

Azathioprine p. 787, mercaptopurine p. 844, or infliximab should be continued as maintenance treatment for at least one year.

For the management of non-perianal fistulating Crohn’s disease (including entero-gynaecological and enterovesical fistulae) surgery is the only recommended approach.

Useful Resources


www.nice.org.uk/guidance/cg152

Ulcerative colitis

Description of condition

Ulcerative colitis is a chronic inflammatory condition, characterised by diffuse mucosal inflammation—it has a relapsing–remitting pattern. It is a life-long disease that is associated with significant morbidity. It most commonly presents between the ages of 15 and 25 years, although diagnosis can be made at any age.

The pattern of inflammation is continuous, extending from the rectum upwards to a varying degree. Inflammation of the rectum is referred to as proctitis, and inflammation of the rectum and sigmoid colon as proctosigmoiditis. Left-sided colitis refers to disease involving the colon distal to the splenic flexure. Extensive colitis affects the colon proximal to the splenic flexure, and includes pan–colitis, where the whole colon is involved. Common symptoms of active disease or relapse include bloody diarrhoea, an urgent need to defaecate, and abdominal pain.

Ulcerative colitis is classified as subacute if it is moderate-to–severely active disease which can be managed in an outpatient setting, and does not require hospitalisation or consideration of urgent surgical intervention.

Complications associated with ulcerative colitis include an increased risk of colorectal cancer, secondary osteoporosis, venous thromboembolism and toxic megacolon.

Aims of treatment

Treatment is focussed on treating active disease to manage symptoms and to induce and maintain remission.
Drug treatment

**Overview**
Management of ulcerative colitis is dependent on factors such as clinical severity, extent of disease, and patient preference. Clinical and laboratory investigations are used to determine the extent and severity of disease and to guide treatment. Severity is classified as mild, moderate or severe by using the Truelove and Witts’ Severity Index to assess bowel movements, heart rate, erythrocyte sedimentation rate and the presence of pyrexia, melaena or anaemia—see the NICE guideline for Ulcerative Colitis for further information (Useful resources below).

The extent of disease should be considered when choosing the route of administration for aminosalicylates and corticosteroids; whether oral treatment, topical treatment or both are to be used. If the inflammation is distal, a rectal preparation is adequate but if the inflammation is extended, systemic medication is required. Either suppositories or enemas can be offered, taking into account the patient’s preferences. 

Rectal foam preparations and suppositories can be used when patients have difficulty retaining liquid enemas. Diarrhoea associated with ulcerative colitis is sometimes treated with anti-diarrhoeal drugs (such as loperamide hydrochloride p. 65 or codeine phosphate p. 431) on the advice of a specialist; however their use is contra-indicated in acute ulcerative colitis as they can increase the risk of toxic megacolon. A macrogol-containing osmotic laxative (such as macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride p. 55) may be useful for proximal faecal loading in proctitis. 

Oral aminosalicylates for the treatment of ulcerative colitis are available in different preparations and release forms. The preparation and dosing schedule should be chosen taking into account the delivery characteristics and suitability for the patient. When used to maintain remission, single daily doses of oral aminosalicylates can be more effective than multiple daily dosing, but may result in more side-effects.

**Treatment of acute mild-to-moderate ulcerative colitis**
Acute treatment to induce remission generally consists of an aminosalicylate with or without a corticosteroid. Oral and rectal aminosalicylate in combination can be used as first line treatment in patients with acute, mild-to-moderate extensive ulcerative colitis; as this is associated with higher rates of improvement in disease activity.

**Proctitis and proctosigmoiditis**
Aminosalicylates are recommended as first-line treatment for patients with a mild-to-moderate initial presentation or inflammatory exacerbation. Using a rectal aminosalicylate (mesalazine p. 39 or sulfasalazine p. 42) alone is likely to be more effective for patients with proctitis and proctosigmoiditis. Monotherapy with an oral aminosalicylate (balsalazide sodium p. 39, mesalazine, olsalazine sodium p. 42, sulfasalazine) can be considered for patients who prefer not to use enemas or suppositories, although this may not be as effective.

A rectal corticosteroid (budesonide p. 43, hydrocortisone p. 637 or prednisolone p. 639) or oral prednisolone can be considered in patients who are intolerant to, decline, or have a contra-indication to aminosalicylates.

Oral prednisolone should be considered for the treatment of patients with subacute proctitis or proctosigmoiditis.

**Left-sided or extensive ulcerative colitis**
First-line treatment in patients with left-sided or extensive ulcerative colitis is a high induction dose of an oral aminosalicylate, with addition of a rectal aminosalicylate or oral beclometasone dipropionate if necessary. Oral prednisolone alone is recommended for patients who cannot tolerate or who decline aminosalicylates, in whom aminosalicylates are contra-indicated or in patients with subacute left-sided or extensive ulcerative colitis.

**Initial treatment failure in all extents of mild-to-moderate disease**
In all patients who are treated with an aminosalicylate, if there are no improvements within four weeks of initial treatment or if symptoms worsen, addition of oral prednisolone to aminosalicylate therapy can be considered (discontinue beclometasone dipropionate p. 43 if adding oral prednisolone). If there is still no response after 2–4 weeks of prednisolone, consider adding oral tacrolimus p. 791 [unlicensed indication] to induce remission. Budesonide multiformix (a corticosteroid that is taken orally but exerts its action topically in the colon) is licensed for inducing remission in mild-to-moderate active ulcerative colitis in adults for whom aminosalicylate treatment is not sufficient and can be considered as an additional therapeutic option.

Moderate disease may require treatment with a monoclonal antibody due to inadequate response to conventional treatment or if conventional treatment is not tolerated or contra-indicated (see Monoclonal antibodies for ulcerative colitis below).

**Treatment of acute severe ulcerative colitis**
Acute severe ulcerative colitis of any extent can be life-threatening and is regarded as a medical emergency. Immediate hospital admission is required for treatment.

Intravenous corticosteroids (such as hydrocortisone or methylprednisolone p. 638) should be given to induce remission in patients with acute severe ulcerative colitis (at first presentation or an exacerbation) while assessing the need for surgery. If intravenous corticosteroids are contra-indicated, declined or cannot be tolerated, then intravenous ciclosporin p. 788 [unlicensed indication] or surgery should be considered. A combination of intravenous ciclosporin with intravenous corticosteroids, or surgery is second line therapy for patients who have little or no improvement within 72 hours of starting intravenous corticosteroids or whose symptoms worsen despite treatment.

Research has shown that infliximab p. 1016 is as effective as ciclosporin and, in practice, it is commonly used in these patients instead of ciclosporin—see also Monoclonal antibodies for acute ulcerative colitis, below.

In patients who experience an initial response to steroids followed by deterioration, stool cultures should be taken to exclude the presence of pathogens; cytomegalovirus activation should be considered.

**Monoclonal antibodies for acute ulcerative colitis**
Adalimumab p. 1008, golimumab p. 1014, infliximab p. 1016 and vedolizumab p. 44 can be used to treat moderate-to-severe active ulcerative colitis following an inadequate response to conventional treatment options, or if conventional treatment options are not tolerated or contra-indicated. Treatment with these agents is continued into the maintenance phase, if effective and tolerated. See also National funding/access decisions for adalimumab, golimumab, infliximab and vedolizumab.

Infliximab can be used to treat acute exacerbations of severely active ulcerative colitis if ciclosporin p. 788 is contra-indicated or clinically inappropriate.

**Maintaining remission in mild, moderate or severe ulcerative colitis**
To reduce the chances of relapse occurring, maintenance therapy with an aminosalicylate is recommended in most patients. Corticosteroids are not suitable for maintenance treatment because of their side-effects.

After a mild-to-moderate inflammatory exacerbation of proctitis or proctosigmoiditis, a rectal aminosalicylate can be started alone or in combination with an oral aminosalicylate, administered daily or as part of an intermittent regimen.
(such as twice to three times weekly or the first seven days of each month). An oral aminosalicylate can be used alone in patients who prefer not to use enemas or suppositories, although, this may not be as effective.

A low-dose of oral aminosalicylate is given to maintain remission in patients after a mild-to-moderate inflammatory exacerbation of left-sided or extensive ulcerative colitis.

When used to maintain remission, single daily doses of oral aminosalicylates can be more effective than multiple daily dosing, but may result in more side-effects.

Oral azathioprine p. 787 or mercaptopurine p. 844 [unlicensed indications] can be considered to maintain remission, if there has been two or more inflammatory exacerbations in a 12-month period that required treatment with systemic corticosteroids, or if remission is not maintained by aminosalicylates, or following a single acute severe episode.

There is no evidence to support the use of methotrexate p. 844 to induce or maintain remission in ulcerative colitis, though its use is common in clinical practice.

Monoclonal antibodies for maintaining remission of ulcerative colitis

Treatment with these agents is continued into the maintenance phase, if effective and tolerated in acute disease. See also National funding/access decisions for adalimumab, golimumab, infliximab and vedolizumab.

Non-drug treatment

Surgery may be necessary as emergency treatment for severe ulcerative colitis that does not respond to drug treatment. Patients can also choose to have elective surgery for unresponsive or frequently relapsing disease that is affecting their quality of life.

Useful Resources


AMINOSALICYLATES

Aminosalicylates

- **SIDE-EFFECTS**
  - Rare Acute pancreatitis • agranulocytosis • alopecia • aplastic anaemia • arthralgia • blood disorders • eosinophilia • fibrosing alveolitis • hepatitis • interstitial nephritis • leucopenia • lupus erythematosus-like syndrome • methaemoglobinemia • myalgia • myocarditis • nephrotic syndrome • neutropenia • pericarditis • peripheral neuropathy • renal dysfunction • skin reactions • Stevens-Johnson syndrome • thrombocytopenia
  - Frequency not known Abdominal pain • diarrhoea • exacerbation of symptoms of colitis • headache • hypersensitivity reactions • nausea • rash • urticaria • vomiting

SIDE-EFFECTS, FURTHER INFORMATION

- Blood Disorders A blood count should be performed and the drug stopped immediately if there is suspicion of a blood dyscrasia.
- **ALLERGY AND CROSS-SENSITIVITY** Contra-indicated in salicylate hypersensitivity.
- **RENAL IMPAIRMENT** Renal function should be monitored more frequently in renal impairment.
- **MONITORING REQUIREMENTS** Renal function should be monitored before starting an oral aminosalicylate, at 3 months of treatment, and then annually during treatment.

- **PATIENT AND CARER ADVICE**
  - Blood disorders Patients receiving aminosalicylates, and their carers, should be advised to report any unexplained bleeding, bruising, purpura, sore throat, fever or malaise that occurs during treatment.

Balsalazide sodium

- **INDICATIONS AND DOSE**
  - Treatment of mild to moderate ulcerative colitis, acute attack
    - **BY MOUTH**
    - Adult: 2.25 g 3 times a day until remission occurs or for up to maximum of 12 weeks
  - **Maintenance of remission of ulcerative colitis**
    - **BY MOUTH**
    - Adult: 1.5 g twice daily (max. per dose 3 g), adjusted according to response; maximum 6 g per day

- **CAUTIONS** History of asthma
- **INTERACTIONS** Appendix 1: balsalazide
- **SIDE-EFFECTS** Cholelithiasis
- **PREGNANCY** Manufacturer advises avoid.
- **BREAST FEEDING** Diarrhoea may develop in the infant. Monitor breast-fed infants for diarrhoea.
- **HEPATIC IMPAIRMENT** Avoid in severe impairment.
- **RENAL IMPAIRMENT** Manufacturer advises avoid in moderate to severe impairment.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

  **Capsule**
  - CAUTIONARY AND ADVISORY LABELS 21, 25
  - Colazide (Almirall Ltd) Balsalazide disodium 750 mg Colazide 750mg capsules 130 capsule POM £30.42 DT price = £30.42

Mesalazine

- **INDICATIONS AND DOSE**
  - **ASACOL® MR 400MG TABLETS**
    - Treatment of mild to moderate ulcerative colitis, acute attack
      - **BY MOUTH**
      - Child 12-17 years: 800 mg 3 times a day
      - Adult: 2.4 g daily in divided doses
    - **Maintenance of remission of ulcerative colitis and Crohn's ileo-colitis**
      - **BY MOUTH**
      - Child 12-17 years: 400–800 mg 2–3 times a day
      - Adult: 1.2–2.4 g daily in divided doses
    - **ASACOL® MR 800MG TABLETS**
      - Treatment of mild to moderate ulcerative colitis, acute attack
        - **BY MOUTH**
        - Adult: 2.4–4.8 g daily in divided doses
    - **Maintenance of remission of ulcerative colitis**
      - **BY MOUTH**
      - Adult: Up to 2.4 g once daily, alternatively up to 2.4 g daily in divided doses
    - **Maintenance of remission of Crohn's ileo-colitis**
      - **BY MOUTH**
      - Adult: Up to 2.4 g daily in divided doses
### ASACOL® FOAM ENEMA
- **Treatment of acute attack of mild to moderate ulcerative colitis affecting the rectosigmoid region**
  - **By Rectum**
  - Adult: 1 g daily for 4–6 weeks, to be administered into the rectum

- **Treatment of acute attack of mild to moderate ulcerative colitis, affecting the descending colon**
  - **By Rectum**
  - Adult: 2 g once daily for 4–6 weeks, to be administered into the rectum

### ASACOL® SUPPOSITORIES
- **Treatment of acute attack of mild to moderate ulcerative colitis and maintenance of remission**
  - **By Rectum**
  - Adult: 0.75–1.5 g daily in divided doses, last dose to be administered at bedtime

### IPOCOL®
- **Treatment of mild to moderate ulcerative colitis, acute attack**
  - **By Mouth**
  - Adult: 2.4 g daily in divided doses

### Maintenance of remission of ulcerative colitis
- **By Mouth**
  - Adult: 1.2–2.4 g daily in divided doses

### MEZAVANT® XL
- **Treatment of mild to moderate ulcerative colitis, acute attack**
  - **By Mouth**
  - Adult: 2.4 g daily in divided doses
  - Up to 500 mg/kg 5–10 times a day

### OCTASA®
- **Treatment of mild to moderate ulcerative colitis, acute attack**
  - **By Mouth**
  - Adult: 2.4–4.8 g once daily, alternatively 2.4–4.8 g daily in divided doses, dose over 2.4 g daily in divided doses only

### Maintenance of remission of ulcerative colitis and Crohn's ileo-colitis
- **By Mouth**
  - Adult: 1.2–2.4 g once daily, alternatively daily in divided doses

### PENTASA® GRANULES
- **Treatment of mild to moderate ulcerative colitis, acute attack**
  - **By Mouth**
  - Child 5–17 years (body-weight up to 40 kg): 10–20 mg/kg 3 times a day
  - Child 5–17 years (body-weight 40 kg and above): 1–2 g twice daily, total daily dose may alternatively be given in 3–4 divided doses
  - Adult: Up to 4 g once daily, alternatively up to 4 g daily in 2–4 divided doses

### Maintenance of remission of ulcerative colitis
- **By Mouth**
  - Child 5–17 years (body-weight up to 40 kg): 7.5–15 mg/kg twice daily, total daily dose may alternatively be given in 3 divided doses
  - Child 5–17 years (body-weight 40 kg and above): 2 g once daily
  - Adult: 2 g once daily

### PENTASA® RETENTION ENEMA
- **Treatment of acute attack of mild to moderate ulcerative colitis or maintenance of remission**
  - **By Rectum**
  - Adult: 1 g once daily, dose to be administered at bedtime

### PENTASA® SUPPOSITORIES
- **Treatment of acute attack of mild to moderate ulcerative colitis affecting the rectosigmoid region**
  - **By Rectum**
  - Child 12–17 years: 1 g once daily, dose to be administered at bedtime

### PENTASA® TABLETS
- **Treatment of mild to moderate ulcerative colitis, acute attack**
  - **By Mouth**
  - Adult: Up to 4 g once daily, alternatively up to 4 g daily in 2–3 divided doses

### Maintenance of remission of ulcerative colitis
- **By Mouth**
  - Adult: 2 g once daily

### SALOFALK® ENEMA
- **Treatment of acute attack of mild to moderate ulcerative colitis or maintenance of remission**
  - **By Rectum**
  - Adult: 2 g once daily

### SALOFALK® GRANULES
- **Treatment of mild to moderate ulcerative colitis, acute attack**
  - **By Mouth**
  - Child 5–17 years (body-weight up to 40 kg): 30–50 mg/kg once daily, dose preferably given in the morning, alternatively 10–20 mg/kg 3 times a day
  - Child 5–17 years (body-weight 40 kg and above): 1.5–3 g once daily, dose preferably given in the morning, alternatively 0.5–1 g 3 times a day
  - Adult: 1.5–3 g once daily, dose preferably taken in the morning, alternatively 0.5–1 g 3 times a day

### SALOFALK® RETENTION ENEMA
- **Treatment of acute attack of mild to moderate ulcerative colitis affecting sigmoid colon and rectum**
  - **By Rectum**
  - Child 12–17 years: 2 g once daily, dose to be administered into the rectum at bedtime, alternatively 2 g daily in 2 divided doses
  - Adult: 2 g once daily, dose to be administered into the rectum at bedtime, alternatively 2 g daily in 2 divided doses

### RETENTION ENEMA
- **Treatment of acute attack of mild to moderate ulcerative colitis affecting the rectosigmoid region**
  - **By Rectum**
  - Adult: 1 g once daily, dose to be administered at bedtime

### Maintenance, ulcerative proctitis
- **By Rectum**
  - Adult: 1 g daily
**Salofalk® Suppositories**
Treatment of acute attack of mild to moderate ulcerative colitis affecting the rectum, sigmoid colon and descending colon
- **By Rectum**
  - Adult: 0.5–1 g 2–3 times a day, adjusted according to response, dose to be given using 500 mg suppositories

Treatment of acute attack of mild to moderate ulcerative colitis affecting the rectum
- **By Rectum**
  - Adult: 1 g daily, preferably at bedtime, dose to be given using 1 g suppositories

**Salofalk® Tablets**
Treatment of mild to moderate ulcerative colitis, acute attack
- **By Mouth**
  - Child 5–17 years (body-weight up to 40 kg): 10–20 mg/kg 3 times a day
  - Child 5–17 years (body-weight 40 kg and above): 0.5–1 g 3 times a day
  - Adult: 0.5–1 g 3 times a day

Maintenance of remission of ulcerative colitis
- **By Mouth**
  - Child 5–17 years (body-weight up to 40 kg): 7.5–15 mg/kg twice daily, total daily dose may alternatively be given in 3 divided doses
  - Child 5–17 years (body-weight 40 kg and above): 500 mg 3 times a day
  - Adult: 500 mg 3 times a day

**Dose Equivalence and Conversion**
- There is no evidence to show that any one oral preparation of mesalazine is more effective than another; however, the delivery characteristics of oral mesalazine preparations may vary.

- **Unlicensed Use**
  - With oral use in children **Asacol®** (all preparations) not licensed for use in children under 18 years. **Pentasa®** granules and **Salofalk®** tablets and granules not licensed for use in children under 6 years.
  - With rectal use in children **Salofalk®** rectal foam no dose recommendations for children (age range not specified by manufacturer).

- **Contra-Indications** Blood clotting abnormalities (in children)

- **Caution**
  - Elderly: pulmonary disease

- **Interactions**
  - Appendix 1: mesalazine

- **Side-Effects**
  - Rare: Dizziness
  - Very rare: Oligospermia (reversible)

- **Pregnancy** Negligible quantities cross placenta.

- **Breast Feeding** Diarrhoea reported in breast-fed infants, but negligible amounts of mesalazine detected in breast milk.

- **Hepatic Impairment** Avoid in severe impairment.

- **Renal Impairment**
  - In adults Use with caution. Avoid if eGFR less than 20 mL/minute/1.73 m².
  - In children Use with caution. Avoid if estimated glomerular filtration rate less than 20 mL/minute/1.73 m².

- **Directions for Administration**

  **Pentasa® Tablets** Tablets may be halved, quartered, or dispersed in water, but should not be chewed.

  **Salofalk® Granules** Granules should be placed on tongue and washed down with water without chewing.

  **Pentasa® Granules** Granules should be placed on tongue and washed down with water or orange juice without chewing.

In children Contents of one sachet should be weighed and divided immediately before use; discard any remaining granules.

**Prescribing and Dispensing Information**
There is no evidence to show that any one oral preparation of mesalazine is more effective than another; however, the delivery characteristics of oral mesalazine preparations may vary.

Flavours of granule formulations of **Salofalk®** may include vanilla.

**Patient and Carer Advice**
If it is necessary to switch a patient to a different brand of mesalazine, the patient should be advised to report any changes in symptoms.

Some products may require special administration advice; patients and carers should be informed.


**Medicinal Forms**
There can be variation in the licensing of different medicines containing the same drug.

**Modified-release Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>21 (does not apply to Pentasa® tablets)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mezavant XL (Shire Pharmaceuticals Ltd)</td>
<td></td>
</tr>
<tr>
<td>Mesalazine 1.2 gram Mezavant XL 1200mg tablets</td>
<td>60 tablet</td>
</tr>
<tr>
<td>Pentasa (Ferring Pharmaceuticals Ltd)</td>
<td></td>
</tr>
<tr>
<td>Mesalazine 500 mg Pentasa 500mg modified-release tablets</td>
<td>100 tablet</td>
</tr>
<tr>
<td>Mesalazine 1 gram Pentasa 1g modified-release tablets</td>
<td>60 tablet</td>
</tr>
<tr>
<td><strong>Foam</strong></td>
<td></td>
</tr>
<tr>
<td>EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), disodium edetate, hydroxybenzoates (parabens), polysorbates, propylene glycol, sodium metabisulphite</td>
<td></td>
</tr>
<tr>
<td>Asacol (Allergan Ltd)</td>
<td></td>
</tr>
<tr>
<td>Mesalazine 1 gram per 1 application Asacol 1g/application foam enema</td>
<td>14 dose</td>
</tr>
<tr>
<td>Salofalk (Dr. Falk Pharma UK Ltd)</td>
<td></td>
</tr>
<tr>
<td>Mesalazine 1 gram per 1 application Salofalk 1g/application foam enema</td>
<td>14 dose</td>
</tr>
<tr>
<td><strong>Gastro-resistant Tablet</strong></td>
<td></td>
</tr>
<tr>
<td>CAUTIONARY AND ADVISORY LABELS</td>
<td>5 (does not apply to Octasa®)</td>
</tr>
<tr>
<td>Asacol MR (Allergan Ltd)</td>
<td></td>
</tr>
<tr>
<td>Mesalazine 400 mg Asacol 400mg MR gastro-resistant tablets</td>
<td>84 tablet</td>
</tr>
<tr>
<td>Mesalazine 800 mg Asacol 800mg MR gastro-resistant tablets</td>
<td>84 tablet</td>
</tr>
<tr>
<td><strong>Octasa MR</strong> (Tillotsons Pharma Ltd)</td>
<td></td>
</tr>
<tr>
<td>Mesalazine 400 mg Octasa 400mg MR gastro-resistant tablets</td>
<td>90 tablet</td>
</tr>
<tr>
<td>Mesalazine 800 mg Octasa 800mg MR gastro-resistant tablets</td>
<td>90 tablet</td>
</tr>
<tr>
<td>Salofalk (Dr. Falk Pharma UK Ltd)</td>
<td></td>
</tr>
<tr>
<td>Mesalazine 250 mg Salofalk 250mg gastro-resistant tablets</td>
<td>100 tablet</td>
</tr>
<tr>
<td>Mesalazine 500 mg Salofalk 500mg gastro-resistant tablets</td>
<td>100 tablet</td>
</tr>
</tbody>
</table>

**Suppository**

| Asacol (Allergan Ltd) |
| Mesalazine 250 mg Asacol 250mg suppositories | 20 suppository | £4.82 DT price = £4.82 |
Gastro-intestinal system

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS 21</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Olsalazine sodium (Non-proprietary)</td>
<td></td>
</tr>
<tr>
<td>Olsalazine sodium 500 mg</td>
<td>Olsalazine 500mg tablets</td>
</tr>
</tbody>
</table>

**Capsule**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS 21</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Olsalazine sodium (Non-proprietary)</td>
<td></td>
</tr>
<tr>
<td>Olsalazine sodium 250 mg</td>
<td>Olsalazine 250mg capsules</td>
</tr>
</tbody>
</table>

---

**Sulfasalazine (Sulphasalazine)**

**Indications and dose**

**Treatment of acute attack of mild to moderate and severe ulcerative colitis / Active Crohn’s disease**

- **By mouth**
  - Adult: 1–2 g 4 times a day until remission occurs, corticosteroids may also be given, if necessary

- **By rectum**
  - Adult: 0.5–1 g twice daily, administered alone or in conjunction with oral therapy, morning and night after a bowel movement

**Maintenance of remission of mild to moderate and severe ulcerative colitis**

- **By mouth**
  - Adult: 500 mg 4 times a day

- **By rectum**
  - Adult: 0.5–1 g twice daily, administered alone or in conjunction with oral therapy, morning and night after a bowel movement

**Active rheumatoid arthritis (administered on expert advice)**

- **By mouth**
  - Adult: Initially 500 mg daily, increased in steps of 500 mg every week, increased to 2–3 g daily in divided doses, enteric coated tablets to be administered

**Caution**

Acute porphyrias p. 969 · G6PD deficiency · history of allergy · history of asthma · maintain adequate fluid intake · risk of haematological toxicity · risk of hepatic toxicity · slow acetylator status

**Interactions**

Appendix 1: sulfasalazine

**Side-effects**

- **Common or very common** Blood disorders · cough · dizziness · fever · Heinz body anaemia · insomnia · megaloblastic anaemia · proteinuria · pruritus · stomatitis · taste disturbances · tinnitus

- **Uncommon** Alopecia · convulsions · depression · dyspnoea · vasculitis

**Frequency not known** Anaphylaxis · aseptic meningitis · ataxia · crystalluria · disturbances of smell · epidermal necrosis · exfoliative dermatitis · gastro-intestinal intolerance · hallucinations · hypersensitivity reactions · leucopenia (especially in patients with rheumatoid arthritis) · loss of appetite · neutropenia (especially in patients with rheumatoid arthritis) · oligospermia · parotitis · photosensitivity · rashes · serum sickness · some soft contact lenses may be stained · thrombocytopenia (especially in patients with rheumatoid arthritis) · yellow-orange discoloration of other body fluids · yellow-orange discoloration of skin · yellow-orange discoloration of urine

**Side-effects, further information**

- **Gastro-intestinal side effects** Upper gastro-intestinal side-effects common over 4 g daily.

---

**Olsalazine sodium**

**Indications and dose**

**Treatment of acute attack of mild ulcerative colitis**

- **By mouth**
  - Adult: 1 g daily in divided doses, doses to be taken after meals, then increased if necessary up to 3 g daily in divided doses (max. per dose 1 g), dose to be increased over 1 week

**Maintenance of remission of mild ulcerative colitis**

- **By mouth**
  - Adult: Maintenance 500 mg twice daily, dose to be taken after food

**Side-effects**

- **Common or very common** Watery diarrhoea

**Pregnancy**

- **Pregnancy** Manufacturer advises avoid unless potential benefit outweighs risk.

**Breast feeding**

- **Breast feeding** Monitor breast-fed infants for diarrhoea.

**Renal impairment**

- **Renal Impairment** Use with caution; manufacturer advises avoid in significant impairment.

**Directions for administration**

- **Directions for administration** Capsules can be opened and contents sprinkled on food.

---

**Medications**

- **Medications**
  - **Medications**
  - **Medications**

**Additional information**

- **Additional information**

---

**Gastro-intestinal system**

**42 Chronic bowl disorders**

**Olsalazine sodium**

**Indications and dose**

**Treatment of acute attack of mild ulcerative colitis**

- **By mouth**
  - Adult: 1 g daily in divided doses, doses to be taken after meals, then increased if necessary up to 3 g daily in divided doses (max. per dose 1 g), dose to be increased over 1 week

**Maintenance of remission of mild ulcerative colitis**

- **By mouth**
  - Adult: Maintenance 500 mg twice daily, dose to be taken after food

**Interactions**

Appendix 1: olsalazine

**Side-effects**

- **Common or very common** Watery diarrhoea

**Frequency not known**

- **Frequency not known** Blurred vision · palpitation · photosensitivity · pyrexia · tachycardia

**Pregnancy**

- **Pregnancy** Manufacturer advises avoid unless potential benefit outweighs risk.

**Breast feeding**

- **Breast feeding** Monitor breast-fed infants for diarrhoea.

**Renal impairment**

- **Renal Impairment** Use with caution; manufacturer advises avoid in significant impairment.

**Directions for administration**

- **Directions for administration** Capsules can be opened and contents sprinkled on food.

---

**Olsalazine sodium**

**Indications and dose**

**Treatment of acute attack of mild ulcerative colitis**

- **By mouth**
  - Adult: 1 g daily in divided doses, doses to be taken after meals, then increased if necessary up to 3 g daily in divided doses (max. per dose 1 g), dose to be increased over 1 week

**Maintenance of remission of mild ulcerative colitis**

- **By mouth**
  - Adult: Maintenance 500 mg twice daily, dose to be taken after food

**Interactions**

Appendix 1: olsalazine

**Side-effects**

- **Common or very common** Watery diarrhoea

**Frequency not known**

- **Frequency not known** Blurred vision · palpitation · photosensitivity · pyrexia · tachycardia

**Pregnancy**

- **Pregnancy** Manufacturer advises avoid unless potential benefit outweighs risk.

**Breast feeding**

- **Breast feeding** Monitor breast-fed infants for diarrhoea.

**Renal impairment**

- **Renal Impairment** Use with caution; manufacturer advises avoid in significant impairment.

**Directions for administration**

- **Directions for administration** Capsules can be opened and contents sprinkled on food.

---

**Olsalazine sodium**

**Indications and dose**

**Treatment of acute attack of mild ulcerative colitis**

- **By mouth**
  - Adult: 1 g daily in divided doses, doses to be taken after meals, then increased if necessary up to 3 g daily in divided doses (max. per dose 1 g), dose to be increased over 1 week

**Maintenance of remission of mild ulcerative colitis**

- **By mouth**
  - Adult: Maintenance 500 mg twice daily, dose to be taken after food

**Interactions**

Appendix 1: olsalazine

**Side-effects**

- **Common or very common** Watery diarrhoea

**Frequency not known**

- **Frequency not known** Blurred vision · palpitation · photosensitivity · pyrexia · tachycardia

**Pregnancy**

- **Pregnancy** Manufacturer advises avoid unless potential benefit outweighs risk.

**Breast feeding**

- **Breast feeding** Monitor breast-fed infants for diarrhoea.

**Renal impairment**

- **Renal Impairment** Use with caution; manufacturer advises avoid in significant impairment.

**Directions for administration**

- **Directions for administration** Capsules can be opened and contents sprinkled on food.
Corticosteroids

Beclometasone dipropionate
(Beclometasone dipropionate)

- **INDICATIONS AND DOSE**
  
  **Adjunct to aminosalicylates in acute mild to moderate ulcerative colitis**
  
  - **BY MOUTH**
  - Adult: 5 mg daily maximum duration of treatment of 4 weeks, dose to be taken in the morning

- **INTERACTIONS**  Appendix 1: corticosteroids
- **SIDE-EFFECTS**  Constipation, drowsiness
- **HEPATIC IMPAIRMENT**  Manufacturer advises avoid in severe impairment—no information available.

<table>
<thead>
<tr>
<th>Medicinal forms</th>
</tr>
</thead>
<tbody>
<tr>
<td>There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension</td>
</tr>
</tbody>
</table>

**Oral suspension**

- **CAUTIONARY AND ADVISORY LABELS**  14
- **EXCIPIENTS:** May contain Alcohol
  
  - **Sulfasalazine (Non-proprietary)**
    
    Sulfasalazine 500 mg per 1 ml  Sulfasalazine 250mg/5ml oral suspension free sugar-free 500 ml  **PO**  £42.92 DT price = £42.92

**Gastro-resistant tablet**

- **CAUTIONARY AND ADVISORY LABELS**  5, 14, 25
  
  - **Sulfasalazine (Non-proprietary)**
    
    Sulfasalazine 500 mg  Sulfasalazine 500mg gastro-resistant tablets 100 tablet  **PO**  no price available  112 tablet  **PO**  £11.18 DT price = £11.18
  
  - **Salazopyrin EN (Pfizer Ltd)**
    
    Sulfasalazine 500 mg  Salazopyrin EN-Tabs 500mg  112 tablet  **PO**  £8.43 DT price = £11.18
  
  - **Sulazine EC (Genesis Pharmaceuticals Ltd)**
    
    Sulfasalazine 500 mg  Sulazine EC 500mg tablets  112 tablet  **PO**  £8.00 DT price = £11.18

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS**  14
  
  - **Sulfasalazine (Non-proprietary)**
    
    Sulfasalazine 500 mg  Sulfasalazine 500mg tablets  112 tablet  **PO**  £9.00 DT price = £7.37
  
  - **Salazopyrin (Pfizer Ltd)**
    
    Sulfasalazine 500 mg  Salazopyrin gastro-resistant tablets  112 tablet  **PO**  £6.97 DT price = £7.37

**Suppository**

- **CAUTIONARY AND ADVISORY LABELS**  14
  
  - **Salazopyrin (Pfizer Ltd)**
    
    Sulfasalazine 500 mg  Salazopyrin suppositories  10 suppository  **PO**  £3.30
ENTOCORT® CAPSULES
Mild to moderate Crohn’s disease affecting the ileum or ascending colon
▶ BY MOUTH
▶ Adult: 9 mg once daily for up to 8 weeks; reduce dose for the last 2–4 weeks of treatment, to be taken in the morning

ENTOCORT® ENEMA
Ulcerative colitis involving rectal and recto-sigmoid disease
▶ BY RECTUM
▶ Adult: 1 enema daily for 4 weeks, to be administered at bedtime

● CAUTIONS
▶ With systemic use Autoimmune hepatitis

● INTERACTIONS → Appendix 1: corticosteroids

● HEPATIC IMPAIRMENT
▶ With systemic use When used in autoimmune hepatitis liver function tests should be monitored every 2 weeks for 1 month, then at least every 3 months.

● DIRECTIONS FOR ADMINISTRATION
Granules should be placed on tongue and washed down with water without chewing.

● PRESCRIBING AND DISPENSING INFORMATION
Flavours of granule formulations may include lemon.

ENTOCORT® CAPSULES
Dispense modified-release capsules in original container (contains desiccant).

● PATIENT AND CARER ADVICE
Patients or carers should be given advice on how to administer budesonide granules.

● NATIONAL FUNDING/ACCESS DECISIONS

CORTIMENT®
Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (October 2016) that budesonide (Cortiment®) is accepted for restricted use within NHS Scotland for induction of remission of mild-to-moderate active ulcerative colitis where aminosalicylate treatment is not sufficient, and only if patients present with active left-sided disease and/or proctitis who are not suitable for oral prednisolone, as an alternative to budesonide rectal formulations or off-label oral budesonide.

BUDENOFALK® CAPSULES
Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (April 2015) that Budenofalk® gastro-resistant capsules are accepted for restricted use within NHS Scotland for the treatment of autoimmune hepatitis in non-cirrhotic patients who are intolerant of conventional oral corticosteroids (prednisolone) with severe corticosteroid-related side effects (actual or anticipated) such as psychosis, poorly controlled diabetes or osteoporosis.

● MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Modified-release tablet
CAUTIONARY AND ADVISORY LABELS 25
▶ CORTIMENT (Ferring Pharmaceuticals Ltd)
Budesonide 9 mg Cortiment 9mg modified-release tablets | 30 tablet (POD) £75.00 DT price = £75.00

Gastro-resistant capsule
CAUTIONARY AND ADVISORY LABELS 5, 10, 22, 25
▶ BUDENOFALK (Dr. Falk Pharma UK Ltd)
Budesonide 3 mg Budenofalk 3mg gastro-resistant capsules | 100 capsule (POD) £75.05 DT price = £75.05

Foam
EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), disodium edetate, propylene glycol, sorbic acid

▶ Budenofalk (Dr. Falk Pharma UK Ltd)
Budesonide 2 mg per 1 actuation Budenofalk 2mg foam enema | 14 dose (POD) £57.11

Modified-release capsule
CAUTIONARY AND ADVISORY LABELS 5, 10, 25
▶ Entocort CR (Tillotts Pharma Ltd)
Budesonide 3 mg Entocort CR 3mg capsules | 100 capsule (POD) £84.15 DT price = £84.15

Gastro-resistant granules
CAUTIONARY AND ADVISORY LABELS 5, 10, 22, 25
▶ Budenofalk (Dr. Falk Pharma UK Ltd)
Budesonide 9 mg Budenofalk 9mg gastro-resistant granules sachets | 60 sachet (POD) £135.00

Enema
▶ Entocort (Tillotts Pharma Ltd)
Budesonide 20 microgram per 1 ml Entocort 2mg/100ml enema | 7 enema (POD) £33.66

IMMUNOSUPPRESSANTS → MONOCLONAL ANTIBODIES, ANTI-LYMPHOCYTE

Vedolizumab

04-Apr-2016

▶ DRUG ACTION
Vedolizumab is a monoclonal antibody that binds specifically to the α4β7 integrin, which is expressed on gut homing T helper lymphocytes and causes a reduction in gastrointestinal inflammation.

▶ INDICATIONS AND DOSE
Moderate to severe active ulcerative colitis in patients who have had an inadequate response with, lost response to, or are intolerant to either conventional therapy or a tumour necrosis factor alpha inhibitor (under expert supervision)
▶ BY INTRAVENOUS INFUSION
▶ Adult: Initially 300 mg, then 300 mg after 2 weeks, followed by 300 mg after 4 weeks, followed by 300 mg every 8 weeks, dose to be given over 30 minutes, if treatment is interrupted or response decreases, dosing frequency may be increased—consult product literature; review treatment if no response within 10 weeks of initial dose

Moderate to severe active Crohn’s disease in patients who have had an inadequate response with, lost response to, or are intolerant to either conventional therapy or a tumour necrosis factor alpha inhibitor (under expert supervision)
▶ BY INTRAVENOUS INFUSION
▶ Adult: Initially 300 mg, then 300 mg after 2 weeks, followed by 300 mg after 4 weeks, followed by 300 mg every 8 weeks, dose to be given over 30 minutes, if no response is observed, an additional dose of 300 mg may be given 10 weeks after initial dose; if treatment is interrupted or response decreases, dosing frequency may be increased—consult product literature; review treatment if no response within 14 weeks of initial dose

▶ CONTRA-INDICATIONS
Severe active infection

▶ CAUTIONS
Controlled chronic severe infection · history of recurring severe infection · previous treatment with natalizumab (wait at least 12 weeks between natalizumab use and initiation of vedolizumab unless potential benefit outweighs risk) · previous treatment with rituximab

CAUTIONS, FURTHER INFORMATION
▶ Risk of infection Patients must be screened for tuberculosis before starting treatment; if latent tuberculosis is diagnosed, appropriate treatment must be initiated prior to vedolizumab treatment; if tuberculosis is diagnosed during treatment, discontinue vedolizumab until infection is resolved.

Patients should be brought up to date with current immunisation schedule before initiating treatment.

▶ INTERACTIONS → Appendix 1: monoclonal antibodies
**SIDE-EFFECTS**

- **Common or very common** Acne, arthralgia, back pain, constipation, cough, dyspepsia, eczema, erythema, flatulence, gastroenteritis, headache, hypertension, infection (increased susceptibility to viral, fungal and bacterial infections), malaise, muscle spasms, muscular weakness, nasal congestion, nasopharyngitis, nosebleed, night sweats, oropharyngeal pain, paraesthesia, pharyngitis, pruritus, pyrexia, rash, sinusitis.

- **Uncommon** Folliculitis, infusion-related reactions.

- **Frequency not known** Dizziness.

**SIDE-EFFECTS, FURTHER INFORMATION**

Infusion-related reactions, infusion-related and hypersensitivity reactions have been reported. Patients should be observed continuously during each infusion for signs and symptoms of acute hypersensitivity reactions; they should also be observed for 2 hours after the initial two infusions, and for 1 hour after subsequent infusions. Discontinue treatment if a severe infusion-related or other severe reaction occurs and initiate appropriate treatment (e.g. adrenaline and antihistamines); if a mild to moderate infusion-related reaction occurs, interrupt infusion or reduce infusion rate and initiate appropriate treatment (if reaction subsides the infusion may be continued)—consider pretreatment with an antihistamine, hydrocortisone, and/or paracetamol prior to subsequent infusions in patients who experience mild to moderate infusion-related reactions.

**CONCEPTION AND CONTRACEPTION** Manufacturer advises effective contraception required during and for at least 18 weeks after treatment.

**PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk.

**BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.

**MONITORING REQUIREMENTS**

- Manufacturer advises monitor closely for infection before, during and after treatment—potential increased risk of opportunistic infection.

- Manufacturer advises monitor for new onset or worsening neurological signs and symptoms ( withhold treatment if progressive multifocal leukoencephalopathy (PML) is suspected).

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Entyvio®), give intermittently in Sodium chloride 0.9%; allow vial to reach room temperature then reconstitute with 4.8 mL of water for injection (using a syringe with a 21–25 gauge needle); gently swirl vial for at least 15 seconds, do not shake vigorously or invert; allow to stand for up to 20 minutes (gently swirl vial if needed), leave for an additional 10 minutes if not dissolved; gently invert vial three times, withdraw 5 mL of reconstituted solution (using a syringe with a 21–25 gauge needle), and add to 250 mL of infusion fluid; gently mix and give over 30 minutes.

**PATIENT AND CARER ADVICE** Patients should be provided with a patient alert card.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- **Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy (August 2015)** NICE TA352

Vedolizumab is recommended as an option for the treatment of moderate to severe active Crohn’s disease in adults if:

- a tumour necrosis factor-alpha inhibitor has failed (that is, the disease has responded inadequately or has lost response to treatment) or

- a tumour necrosis factor-alpha inhibitor cannot be tolerated or is contra-indicated,

and the manufacturer provides vedolizumab with the discount agreed in the patient access scheme.

Vedolizumab should be given as a planned course of treatment until treatment fails, or surgery is needed, or until 12 months after starting treatment, whichever is the shorter. Treatment should be continued only if there is clear evidence of a response. Patients who continue treatment should be reassessed at least every 12 months to determine whether ongoing treatment is still clinically appropriate.

Patients currently receiving vedolizumab whose disease does not meet the above criteria should be able to continue treatment until they and their clinician consider it appropriate to stop.

**Scottish Medicines Consortium (SMC) Decisions**

The **Scottish Medicines Consortium** has advised (July 2015) that vedolizumab (Entyvio®) is accepted for restricted use within NHS Scotland for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to a TNF antagonist; it is also accepted for use in NHS Scotland for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF antagonist.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for infusion**

- **Entyvio (Takeda UK Ltd)** ▼ Vedolizumab 300 mg Entyvio 300mg powder for concentrate for solution for infusion vials | 1 vial (£50) £2,050.00

---

**1.4 Irritable bowel syndrome**

**Irritable bowel syndrome**

**Description of condition**

**Irritable bowel syndrome** (IBS) is a common, chronic, relapsing, and often life-long condition, mainly affecting people aged between 20 and 30 years. It is more common in women. Symptoms include abdominal pain or discomfort, disordered defaecation (either diarrhoea, or constipation with straining, urgency, and incomplete evacuation), passage of mucus, and bloating. Symptoms are usually relieved by defaecation. Obtaining an accurate clinical diagnosis of IBS prior to treatment is crucial.

**Aims of treatment**

The treatment of IBS is focused on symptom control, in order to improve quality of life.

**Non-drug treatment**

Diet and lifestyle changes are important for effective self-management of IBS. Patients should be encouraged to increase physical activity, and advised to eat regularly, without missing meals or leaving long gaps between meals. Dietary advice should also include, limiting fresh fruit consumption to no more than 3 portions per day. The fibre intake of patients with IBS should be reviewed. If an increase in dietary fibre is required, soluble fibre such as ispaghula husk p. 53, or foods high in soluble fibre such as oats, are recommended. Intake of insoluble fibre (e.g. bran) and ‘resistant starch’ should be reduced or discouraged as they may exacerbate symptoms. Fluid intake (mostly water) should be increased to at least 8 cups each day and the intake of caffeine, alcohol and fizzy drinks reduced. The artificial sweetener sorbitol should be avoided in patients with...
diarrhoea. Where probiotics are being used, continue for at least 4 weeks while monitoring the effect.

If a patient’s symptoms persist following lifestyle and dietary advice, single food avoidance and exclusion diets may be an option under the supervision of a dietitian or medical specialist.

**Drug treatment**

The choice of drug treatment depends on the nature and severity of the symptoms. Many drug treatment options for IBS are available over-the-counter.

Antispasmodic drugs (such as alverine citrate p. 84, mebeverine hydrochloride p. 84 and peppermint oil below) can be taken in addition to dietary and lifestyle changes. A laxative (excluding lactulose p. 55 as it may cause bloating) can be used to treat constipation. Patients who have not responded to laxatives from the different classes and who have had constipation for at least 12 months, can be treated with linaclotide p. 47. Loperamide hydrochloride p. 65 is the first-line choice of anti-motility drug for relief of diarrhoea. Patients with IBS should be advised how on to adjust their dose of laxative or anti-motility drug according to stool consistency, with the aim of achieving a soft, well-formed stool. See Constipation p. 51, for information on other drugs used for chronic constipation.

A low-dose tricyclic antidepressant, such as amitriptyline hydrochloride p. 355 [unlicensed indication], can be used for abdominal pain or discomfort as a second-line option in patients who have not responded to antispasmodics, anti-motility drugs, or laxatives. A selective serotonin reuptake inhibitor may be considered in those who do not respond to a tricyclic antidepressant [unlicensed indication].

Psychological intervention can be offered to patients who have no relief of IBS symptoms after 12 months of drug treatment.

**Useful Resources**


www.nice.org.uk/guidance/cg61

**ANTISPASMODICS**

**Mebeverine with ispaghula husk**

04-Feb-2016

The properties listed below are those particular to the combination only. For the properties of the components please consider, mebeverine hydrochloride p. 84, ispaghula husk p. 53.

**INDICATIONS AND DOSE**

**Irritable bowel syndrome**

- **BY MOUTH**
  - Child 12-17 years: 1 sachet twice daily, in water, morning and evening, 30 minutes before food and 1 sachet daily if required, taken 30 minutes before midday meal
  - Adult: 1 sachet twice daily, in water, morning and evening, 30 minutes before food and 1 sachet daily if required, taken 30 minutes before midday meal

**DIRECTIONS FOR ADMINISTRATION**

Contents of one sachet should be stirred into a glass (approx. 150 mL) of cold water and drunk immediately.

**PATIENT AND CARER ADVICE**

Patients or carers should be given advice on how to administer ispaghula husk with mebeverine granules.

**Peppermint oil**

**INDICATIONS AND DOSE**

**COLPERMIN®**

Relief of abdominal colic and distension, particularly in irritable bowel syndrome

- **BY MOUTH**
  - Child 15-17 years: 1–2 capsules 3 times a day for up to 3 months if necessary, capsule to be swallowed whole with water
  - Adult: 1–2 capsules 3 times a day for up to 3 months if necessary, capsule to be swallowed whole with water

**MINTEC®**

Relief of abdominal colic and distension, particularly in irritable bowel syndrome

- **BY MOUTH**
  - Adult: 1–2 capsules 3 times a day for up to 2–3 months if necessary, dose to be taken before meals, swallowed whole with water

**CAUTIONS**

- Sensitivity to menthol

**INTERACTIONS**

Appendix 1: peppermint oil

**SIDE-EFFECTS**

- Rare Allergic reactions - ataxia - bradycardia - headache - muscle tremor - rash
- Frequency not known Heartburn - perianal irritation

**PREGNANCY**

Not known to be harmful.

**BREAST FEEDING**

Significant levels of menthol in breast milk unlikely.

**DIRECTIONS FOR ADMINISTRATION**

Capsules should not be broken or chewed because peppermint oil may irritate mouth or oesophagus.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Gastro-resistant capsule**

- **CAUTIONARY AND ADVISORY LABELS** 13, 22
- **EXCIPIENTS:** May contain Aspartame
- **ELECTROLYTES:** May contain Potassium
- **Fybogel Mebeverine** (Reckitt Benckiser Healthcare (UK) Ltd)
  - Mebeverine hydrochloride 135 mg, Ispaghula husk
  - 3.5 gram Fybogel Mebeverine effervescent granules sachets orange sugar-free 10 sachet £4.64 DT price = £4.64
1.5 Short bowel syndrome

Description of condition
Patients with a shortened bowel due to large surgical resection (with or without stoma formation) may require medical management to ensure adequate absorption of nutrients and fluid. Absorption of oral medication is also often impaired.

Aims of treatment
The management of short bowel syndrome focuses on ensuring adequate nutrition and drug absorption, thereby reducing the risk of complications resulting from these effects.

Drug treatment

Nutritional deficiencies

Patients with a short bowel may require replacement of vitamins and minerals depending on the extent and position of the bowel resection. Deficiencies in vitamins A, B12, D, E, and K, essential fatty acids, zinc, and selenium can occur.

Hypomagnesaemia is common and is treated with oral or intravenous magnesium supplementation (see under Magnesium, in Minerals p. 962), though administration of oral magnesium may cause diarrhoea. Occasionally the use of oral alfalcacidol p. 991 and correction of sodium depletion may be useful. Nutritional support can range from oral supplements to parenteral nutrition, depending on the severity of intestinal failure.

Diarrhoea and high output stomas

Diarrhoea is common in short bowel syndrome and can be due to multiple factors. Use of oral rehydration salts can be considered in order to promote adequate hydration. Oral intake influences the volume of stool passed, so reducing food intake will lessen diarrhoea, but will also exacerbate the problems of undernutrition. A patient may require parenteral nutrition to allow them to eat less, if the extent of diarrhoea is unacceptable.

Pharmacological treatment may be necessary, with the choice of drug depending on the potential for side-effects and the degree of resection.

Antimotility drugs

Loperamide hydrochloride p. 65 and codeine phosphate p. 431 reduce intestinal motility and thus exert antidiarrhoeal actions. Loperamide hydrochloride is preferred as it is not sedative and does not cause dependence or fat malabsorption. High doses of loperamide hydrochloride [unlicensed] may be required in patients with a short bowel due to disrupted enterohepatic circulation and rapid gastrointestinal transit time. If the desired response is not obtained with loperamide hydrochloride, codeine phosphate may be added to therapy.

Co-phenoton p. 64 has traditionally been used alone or in combination with other medications to help decrease faecal output. Co-phenoton crosses the blood–brain barrier and can produce central nervous system side-effects, which may limit its use; the potential for dependence and anticholinergic effects may also restrict its use.

Colestyramine

In patients with an intact colon and less than 100 cm of ileum resected, colestyramine p. 191 can be used to bind the unabsorbed bile salts and reduce diarrhoea. When colestyramine is given to these patients, it is important to monitor for evidence of fat malabsorption (steatorrhoea) or fat-soluble vitamin deficiencies.

Antisecretory drugs

Drugs that reduce gastric acid secretion reduce jejunalostomy output. Omeprazole p. 78 is rarely absorbed in the duodenum and upper small bowel, but if less than 50 cm of jejunal remains, it may need to be given intravenously. Use of a proton pump inhibitor alone does not eliminate the need for further intervention for fluid control (such as antimotility agents, intravenous fluids, or oral rehydration salts).

Octreotide [unlicensed indication] reduces ileostomy diarrhoea and large volume jejunalostomy output by inhibiting multiple pro-secretory substances. There is insufficient evidence to establish its role in the management of short bowel syndrome.

Growth factors

Growth factors can be used to facilitate intestinal adaptation after surgery in patients with short bowel syndrome, thus enhancing fluid, electrolyte, and micronutrient absorption.

Teduglutide p. 48 is an analogue of endogenous human glucagon-like peptide 2 (GLP-2) which is licensed for use in the management of short bowel syndrome. It may be...
considered after a period of stabilisation following surgery, during which intravenous fluids and nutritional support should have been optimised.

**Drug absorption**

For *Prescribing in patients with stoma*, see Stoma care p. 94.

Many drugs are incompletely absorbed by patients with a short bowel and may need to be prescribed in much higher doses than usual (such as levothyroxine, warfarin, oral contraceptives, and digoxin) or may need to be given intravenously.

Several factors can alter the absorption of drugs taken by mouth in patients with a compromised gastrointestinal system. The most important factors are the length of intestine available for drug absorption, and which section has been removed. The small intestine, with its large surface area and high blood flow, is the most important site of drug absorption. The larger the amount of the small intestine that has been removed, the higher the possibility that drug absorption will be affected. Other factors, such as gastric emptying and gastric transit time, also affect drug handling.

Dosage forms with quick dissolution (soluble tablets) should be used. Uncoated tablets and liquid formulations may also be suitable. Before prescribing liquid formulations, prescribers should consider the osmolarity, excipient content and volume required. Hypersmolar liquids and some excipients (such as sorbitol) can result in fluid loss. The calorie density of oral supplements should also be considered, as it will influence the volume to be taken.

Other drugs used for Short bowel syndrome

Cimetidine, p. 72

**AMINO ACIDS AND DERIVATIVES**

**Teduglutide**

- **DRUG ACTION** Teduglutide is an analogue of human glucagon-like peptide-2 (GLP-2), which preserves mucosal integrity by promoting growth and repair of the intestine.

- **INDICATIONS AND DOSE**
  
  **Short bowel syndrome (initiated under specialist supervision)**
  
  - **BY SUBCUTANEOUS INJECTION**
  - **Adult:** 0.05 mg/kg once daily, dose to be administered to alternating quadrants of the abdomen; alternatively the thigh can be used, for optimal injection volume per body weight, consult product literature. Review treatment after 6 months

- **CONTRA-INDICATIONS** Active or suspected malignancy • history of gastro-intestinal malignancy (in previous 5 years)

- **CAUTIONS** Abrupt withdrawal of parenteral support (reduce gradually with concomitant monitoring of fluid status) • cardiac insufficiency • cardiovascular disease • colo-rectal polyps • hypertension

- **SIDE-EFFECTS**
  
  - **Common or very common** Abdominal distension • abdominal pain • allergic dermatitis • anxiety • arthralgia • chest pain • cholecystitis • cholostasis • congestive heart failure • cough • decreased appetite • dyspnoea • flushing • headache • intestinal obstruction • nausea • night sweats • pancreatitis • paraesthesia • peripheral oedema • rash • renal colic • sleep disorder • vomiting
  
  - **Uncommon** Syncope

- **Frequency not known** Gastro-intestinal neoplasia • pancreatic duct stenosis • pancreatic infection

- **ALLERGY AND CROSS-SENSITIVITY** Manufacturer advises caution in patients with tetracycline hypersensitivity.

- **PREGNANCY** Specialist sources indicate use if necessary—no human data available.

- **BREAST FEEDING** Manufacturer advises avoid—toxicity in animal studies.

- **RENAI IMPAIRMENT** Manufacturer advises use half the daily dose in moderate or severe impairment and end-stage renal disease.

- **MONITORING REQUIREMENTS** Manufacturer advises monitoring of small bowel function, gall bladder, bile ducts and pancreas during treatment.

- **TREATMENT CESSATION** Caution when discontinuing treatment—risk of dehydration.

- **PATIENT AND CARER ADVICE** Patients with cardiovascular disease should seek medical attention if they notice sudden weight gain, swollen ankles or dyspnoea—may indicate increased fluid absorption.

**CONTRA-INDICATIONS**

- Gastro-intestinal neoplasia
- Pancreatic duct stenosis
- Pancreatic infection

**ALLERGY AND CROSS-SENSITIVITY**

- Tetracycline hypersensitivity

**PREGNANCY**

- Specialist sources indicate use if necessary

**BREAST FEEDING**

- Avoid—risk of toxicity in animal studies

**RENAI IMPAIRMENT**

- Use half the daily dose in moderate or severe impairment and end-stage renal disease

**MONITORING REQUIREMENTS**

- Monitoring of small bowel function, gall bladder, bile ducts and pancreas during treatment

**TREATMENT CESSATION**

- Caution when discontinuing treatment—risk of dehydration

**PATIENT AND CARER ADVICE**

- Seek medical attention if sudden weight gain, swollen ankles or dyspnoea

**MEDIcINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

**Powder and solvent for solution for injection**

- **Revestive** (Shire Pharmaceuticals Ltd)
  
  - **Teduglutide 5 mg**
  
  - **Revestive 5 mg powder and solvent for solution for injection vials**

  - **28 vial**

  - **No price available**

- **Other drugs used for Bowel cleansing**

  - Bisacodyl, p. 59 • Docusate sodium, p. 58 • Magnesium sulfate, p. 963

**2 Constipation and bowel cleansing**

**2.1 Bowel cleansing**

- **Other drugs used for Bowel cleansing**

  - Bisacodyl, p. 59 • Docusate sodium, p. 58 • Magnesium sulfate, p. 963

**LAXATIVES > OSMOTIC LAXATIVES**

**Citric acid with magnesium carbonate**

(Formulated as a bowel cleansing preparation)

- **INDICATIONS AND DOSE**
  
  - **Bowel evacuation for surgery, colonoscopy or radiological examination**
  
  - **BY MOUTH**
  
  - **Child 5–9 years:** One-third of a sachet to be given at 8 a.m. the day before the procedure and, one-third of a sachet to be given between 2 and 4 p.m. the day before the procedure
  
  - **Child 10–17 years:** 0.5–1 sachet, given at 8 a.m. the day before the procedure and 0.5–1 sachet, given between 2 and 4 p.m. the day before the procedure
  
  - **Adult:** 1 sachet, given 8 a.m. the day before the procedure and 1 sachet, given between 2 and 4 p.m. the day before the procedure, use half the dose in frail elderly patients

- **CONTRA-INDICATIONS** Acute severe colitis • gastric retention • gastro-intestinal obstruction • gastro-intestinal perforation • toxic megalocolon

- **CAUTIONS** Children • colitis (avoid if acute severe colitis) • debilitated • elderly • hypovolaemia (should be corrected before administration of bowel cleansing preparations) • impaired gag reflex or possibility of regurgitation or aspiration • patients with fluid and electrolyte disturbances
CAUTIONS, FURTHER INFORMATION
Adequate hydration should be maintained during treatment.

- **INTERACTIONS** → Appendix 1: bowel cleansing preparations

- **SIDE-EFFECTS**
  - Common or very common: Abdominal distension, abdominal pain, nausea, vomiting
  - Uncommon: Dehydration, dizziness, electrolyte disturbances, headache

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Abdominal pain: Abdominal pain is usually transient and can be reduced by taking preparation more slowly.

- **PREGNANCY** Use with caution.

- **BREAST FEEDING** Use with caution.

- **HEPATIC IMPAIRMENT** Avoid in hepatic coma if risk of renal failure.

- **RENAL IMPAIRMENT**
  - In adults: Avoid if eGFR less than 30 mL/minute/1.73 m² — risk of hypermagnesaemia.
  - In children: Avoid if estimated glomerular filtration rate less than 30 mL/minute/1.73 m² — risk of hypermagnesaemia.

- **MONITORING REQUIREMENTS** Renal function should be measured before starting treatment in patients at risk of fluid and electrolyte disturbances.

- **DIRECTIONS FOR ADMINISTRATION** One sachet should be reconstituted with 200 mL of hot water; the solution should be allowed to cool for approx. 30 minutes before drinking.

- **PRESCRIBING AND DISPENSING INFORMATION**
  - Reconstitution of one sachet containing 11.57 g magnesium carbonate and 17.79 g anhydrous citric acid provides a solution containing magnesium citrate with 118 mmol Mg²⁺.
  - Flavours of oral powders may include lemon and lime.

- **PATIENT AND CARER ADVICE** Low residue or fluid only diet (e.g. water, fruit squash, clear soup, black tea or coffee) recommended before procedure (according to prescriber’s advice) and copious intake of clear fluids recommended until procedure. Patient or carers should be given advice on how to administer oral powder.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  **Effervescent powder**
  - **CAUTIONARY AND ADVISORY LABELS** 13, 10
  - **ELECTROLYTES:** May contain Magnesium

  **Citramag** (Sanochemia Diagnostics UK Ltd)
  - Magnesium carbonate heavy 11.57 gram, Citric acid anhydrous 17.79 gram Citramag effervescent powder sachets sugar-free | 10 sachet £18.92

---

**Macrogol 3350 with anhydrous sodium sulfate, ascorbic acid, potassium chloride, sodium ascorbate and sodium chloride**

(Polyethylene glycols)

- **INDICATIONS AND DOSE**
  - **MOVIPREP®**
    - Bowel evacuation for surgery, colonoscopy or radiological examination
      - **BY MOUTH**
      - **Adult:** 1 litre daily for 2 doses: first dose of reconstituted solution taken on the evening before procedure and the second dose on the morning of procedure, alternatively 2 litres daily for 1 dose; reconstituted solution to be taken on the evening before the procedure, treatment should be completed at least 1 hour before colonoscopy.

  - **CONTRA-INDICATIONS**
    - Acute severe colitis - G6PD deficiency - gastric retention - gastro-intestinal obstruction - gastro-intestinal perforation - toxic megacolon

  - **CAUTIONS**
    - Colitis (avoid if acute severe colitis) - debilitated patients - elderly - fluid and electrolyte disturbances - heart failure - hypovolaemia (should be corrected before administration of bowel cleansing preparations) - impaired gag reflex or possibility of regurgitation or aspiration

  - **INTERACTIONS** → Appendix 1: bowel cleansing preparations

  - **SIDE-EFFECTS**
    - Common or very common: Abdominal distension, abdominal pain, nausea, vomiting
    - Uncommon: Dehydration, dizziness, electrolyte disturbances, headache

  - **SIDE-EFFECTS, FURTHER INFORMATION**
    - Abdominal pain: Abdominal pain is usually transient and can be reduced by taking preparation more slowly.

  - **PREGNANCY** Manufacturers advise use only if essential — no information available.

  - **BREAST FEEDING** Manufacturers advise use only if essential — no information available.

  - **RENAL IMPAIRMENT** Caution if eGFR less than 30 mL/minute/1.73 m².

  - **MONITORING REQUIREMENTS** Renal function should be measured before starting treatment in patients at risk of fluid and electrolyte disturbances.

  - **DIRECTIONS FOR ADMINISTRATION**
    - **MOVIPREP®** One pair of sachets (A and B) should be reconstituted in 1 litre of water and taken over 1–2 hours. 1 litre of other clear fluid should also be taken during treatment.

  - **PRESCRIBING AND DISPENSING INFORMATION**
    - Flavours of oral powder formulations may include lemon or orange.

  **MOVIPREP®** 1 pair of sachets (A+B) when reconstituted with 1 litre of water provides Na⁺ 181.6 mmol (Na⁺ 56.2 mmol absorbable), K⁺ 14.2 mmol, Cl⁻ 59.8 mmol.

  - **PATIENT AND CARER ADVICE** Patient information leaflet.
    - Solid food should not be taken during treatment until procedure completed. Treatment can be stopped if bowel motions become watery and clear.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  **Powder**
  - **CAUTIONARY AND ADVISORY LABELS** 10, 13
  - **EXCIPIENTS:** May contain Aspartame
  - **ELECTROLYTES:** May contain Chloride, potassium, sodium

  **Moviprep** (Norgine Pharmaceuticals Ltd)
  - Moviprep oral powder sachets sugar-free | 4 sachet £9.87

---

**BNF 74**

1

Gastro-intestinal system
Macrogol 3350 with anhydrous sodium sulfate, potassium chloride, sodium bicarbonate and sodium chloride

(Formulated as a bowel cleansing preparation)

**INDICATIONS AND DOSE**

**Bowel cleansing before radiological examination, colonoscopy, or surgery**

- **INITIALLY BY MOUTH**
  - **Adult:** Initially 2 litres daily for 2 doses: first dose of reconstituted solution taken on the evening before procedure and the second dose on the morning of procedure, alternatively (by mouth) initially 250 mL every 10–15 minutes, reconstituted solution to be administered, alternatively (by nasogastric tube) initially 20–30 mL/minute, starting on the day before procedure until 4 litres have been consumed

**SIDE-EFFECTS** → Appendix 1: bowel cleansing preparations

**SIDE-EFFECTS, FURTHER INFORMATION**

- Abdominal pain
- Abdominal distention
- Anal discomfort
- Constipation
- Dehydration
- Fatigue
- Headache
- Nausea
- Vomiting

**PREGNANCY**

Manufacturers advise use only if essential—no information available.

**PEDIATRICS**

- Adult: 1 sachet taken before 8 a.m, then 1 sachet after 6–8 hours

**PHARMACOKINETICS**

For CitraFleet®: Acts within 3 hours of first dose.

**CONTRA-INDICATIONS**

- Acute severe colitis
- Gastric retention
- Gastro-intestinal obstruction
- Gastro-intestinal perforation
- Toxic megacolon

**CAUTIONS**

- Colitis (avoid if acute severe colitis)
- Debilitated patients
- Elderly
- Fluid and electrolyte disturbances
- Heart failure
- Hypovolaemia (should be corrected before administration of bowel cleansing preparations)
- Impaired gag reflex or possibility of regurgitation or aspiration

**INTERACTIONS**

- **LAXATIVES**

**LAXATIVES > STIMULANT LAXATIVES**

**Magnesium citrate with sodium picosulfate**

(Formulated as a bowel cleansing preparation)

**INDICATIONS AND DOSE**

**CITRAFLEET® SACHETS**

**Bowel evacuation on day before radiological examination, endoscopy, or surgery**

- **BY MOUTH**
  - **Adult:** 1 sachet taken before 8 a.m, then 1 sachet after 6–8 hours

**PHARMACOKINETICS**

For Picolax®: Acts within 3 hours of first dose.

**CONTRA-INDICATIONS**

- Acute severe colitis
- Ascites
- Congestive cardiac failure
- Gastric retention
- Gastro-intestinal obstruction
- Gastro-intestinal perforation
- Gastro-intestinal ulceration
- Toxic megacolon

**CAUTIONS**

- Cardiac disease (avoid in congestive cardiac failure)
- Children
- Colitis (avoid if acute severe colitis)
- Debilitated patients
- Elderly
- Fluid and electrolyte disturbances
- Hypovolaemia (should be corrected before administration)
- Impaired gag reflex or possibility of regurgitation or aspiration
- Recent gastro-intestinal surgery

**SIDE-EFFECTS**

- **Common or very common** Abdominal distention
- Abdominal pain
- Anal discomfort
- Constipation
- Dehydration
- Fatigue
- Headache
- Nausea
- Vomiting

**PREGNANCY**

Caution.

**BREAST FEEDING**

Caution.

**HEPATIC IMPAIRMENT**

Avoid in hepatic coma if risk of renal failure.
Constipation

2.2 Constipation

Description of condition

Constipation is defaecation that is unsatisfactory because of infrequent stools, difficult stool passage, or seemingly incomplete defaecation. It can occur at any age and is commonly seen in women, the elderly, and during pregnancy.

It is important for those who complain of constipation to understand that bowel habit can vary considerably in frequency without doing harm. Some people erroneously consider themselves constipated if they do not have a bowel movement each day.

New onset constipation, especially in patients over 50 years of age, or accompanying symptoms such as anaemia, abdominal pain, weight loss, or overt or occult blood in the stool should provoke urgent investigation because of the risk of malignancy or other serious bowel disorder. In those patients with secondary constipation caused by a drug, the drug should be reviewed.

Overview

In all patients with constipation, an increase in dietary fibre, adequate fluid intake and exercise is advised. Diet should be balanced and contain whole grains, fruits and vegetables. Fibre intake should be increased gradually (to minimise flatulence and bloating). The effects of a high-fibre diet may be seen in a few days although it can take as long as 4 weeks. Adequate fluid intake is important (particularly with a high-fibre diet or fibre supplements), but can be difficult for some people (for example, the frail or elderly).

Fruits high in fibre and sorbitol, and fruit juices high in sorbitol, can help prevent and treat constipation. Misconceptions about bowel habits have led to excessive laxative use. Laxative abuse may lead to hypokalaemia.

Before prescribing laxatives it is important to be sure that the patient is constipated and that the constipation is not secondary to an underlying undiagnosed complaint.

Laxatives

Bulk-forming laxatives

Bulk-forming laxatives include bran, ispaghula husk p. 53, methylcellulose p. 53 and sterculia p. 54. They are of particular value in adults with small hard stools if fibre cannot be increased in the diet. Onset of action is up to 72 hours. Symptoms of flatulence, bloating, and cramping may be exacerbated. Adequate fluid intake must be maintained to avoid intestinal obstruction.

Methylcellulose, ispaghula husk and sterculia may be used in patients who cannot tolerate bran. Methylcellulose also acts as a faecal softener.

Stimulant laxatives

Stimulant laxatives include bisacodyl p. 59, sodium picosulfate p. 62, and members of the anthraquinone group (senna p. 61, co-danthramer p. 60 and co-danthrusate p. 60). Stimulant laxatives increase intestinal motility and often cause abdominal cramp; manufacturer advises they should be avoided in intestinal obstruction.

The use of co-danthramer and co-danthrusate is limited to constipation in terminally ill patients because of potential carcinogenicity (based on animal studies) and evidence of genotoxicity.

Docusate sodium p. 58 is believed to act as both a stimulant laxative and as a faecal softener (below). Glycerol suppositories act as a lubricant and as a rectal stimulant by virtue of the mildly irritant action of glycerol.

Faecal softeners

Faecal softeners are claimed to act by decreasing surface tension and increasing penetration of intestinal fluid into the faecal mass. Docusate sodium and glycerol p. 61 suppositories have softening properties. Enemas containing arachis oil p. 58 (ground-nut oil, peanut oil) lubricate and soften impacted faeces and promote a bowel movement. Liquid paraffin p. 59 has also been used as a lubricant for the passage of stools but manufacturer advises that it should be used with caution because of its adverse effects, which include anal seepage and the risks of granulomatous disease of the gastro-intestinal tract or of lipid pneumonia on aspiration.

Osmotic laxatives

Osmotic laxatives increase the amount of water in the large bowel, either by drawing fluid from the body into the bowel or by retaining the fluid they were administered with. Lactulose p. 55 is a semi-synthetic disaccharide which is not absorbed from the gastro-intestinal tract. It produces an osmotic diarrhoea of low faecal pH, and discourages the proliferation of ammonia-producing organisms. It is
therefore useful in the treatment of hepatic encephalopathy. Macrogols (such as macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride p. 55) are inert polymers of ethylene glycol which sequester fluid in the bowel; giving fluid with macrogols may reduce the dehydrating effect sometimes seen with osmotic laxatives.

**Other drugs used in constipation**

Linaclotide p. 47 is a guanylate cyclase-C receptor agonist that is licensed for the treatment of moderate to severe irritable bowel syndrome associated with constipation. It increases intestinal fluid secretion and transit, and decreases visceral pain.

Lubiprostone p. 54 is a chloride-channel activator that is licensed for the treatment of chronic idiopathic constipation in adults whose condition has not responded adequately to lifestyle changes (including dietary changes).

Prucalopride p. 58 is a selective serotonin 5HT₄-receptor agonist with prokinetic properties. It is licensed for the treatment of chronic constipation in women, when other laxatives have failed to provide an adequate response.

**Bowel cleansing preparations**

Bowel cleansing preparations are used before colonic surgery, colonoscopy or radiological examination to ensure the bowel is free of solid contents; examples include macrogol 3350 with anhydrous sodium sulphate, potassium chloride, sodium bicarbonate and sodium chloride p. 50, citric acid with magnesium carbonate p. 48, magnesium citrate with sodium picosulfate p. 50 and sodium acid phosphate with sodium phosphate p. 57. Bowel cleansing treatments are not treatments for constipation.

**Management**

**Short-duration constipation**

In the management of short-duration constipation (where dietary measures are ineffective) treatment should be started with a bulk-forming laxative, ensuring adequate fluid intake. If stools remain hard, add or switch to an osmotic laxative. If stools are soft but difficult to pass or the person complains of inadequate emptying, a stimulant laxative should be added.

**Opioid-induced constipation**

See also **Constipation** under Prescribing in palliative care p. 23. In patients with opioid-induced constipation, an osmotic laxative (or docusate sodium to soften the stools) and a stimulant laxative is recommended. Bulk-forming laxatives should be avoided.

Naloxegol p. 63 is recommended for the treatment of opioid-induced constipation when response to other laxatives is inadequate.

Methylnaltrexone bromide p. 62 is licensed for the treatment of opioid-induced constipation when response to other laxatives is inadequate. Manufacturer advises that in patients receiving palliative care, methylnaltrexone bromide should be used as an adjunct to existing laxative therapy.

**Faecal impaction**

The treatment of faecal impaction depends on the stool consistency. In patients with hard stools, a high dose of an oral macrogol (such as macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride) may be considered. In those with soft stools, or with hard stools after a few days treatment with a macrogol, an oral stimulant laxative should be started or added to the previous treatment. If the response to oral laxatives is inadequate, for soft stools consider rectal administration of bisacodyl, and for hard stools rectal administration of glycerol alone, or glycerol plus bisacodyl. Alternatively, a docusate sodium p. 58 or sodium citrate p. 743 enema may be tried.

If the response is still insufficient, a sodium acid phosphate with sodium phosphate p. 57 or arachis oil p. 58 retention enema may be necessary. For hard faeces it can be helpful to give the arachis oil enema overnight before giving a sodium acid phosphate with sodium phosphate or sodium citrate enema the following day. Enemas may need to be repeated several times to clear hard impacted faeces.

**Chronic constipation**

In the management of chronic constipation, treatment should be started with a bulk-forming laxative, whilst ensuring good hydration. If stools remain hard, add or change to an osmotic laxative such as a macrogol. Lactulose p. 55 is an alternative if macrogols are not effective, or not tolerated. If the response is inadequate, a stimulant laxative can be added. The dose of laxative should be adjusted gradually to produce one or two soft, formed stools per day.

If at least two laxatives (from different classes) have been tried at the highest tolerated recommended doses for at least 6 months, the use of prucalopride p. 58 (in women only) or lubiprostone p. 54 should be considered. If treatment with prucalopride is not effective after 4 weeks, or lubiprostone is not effective after 2 weeks, the patient should be re-examined and the benefit of continuing treatment reconsidered.

Laxatives can be slowly withdrawn when regular bowel movements occur without difficulty, according to the frequency and consistency of the stools. If a combination of laxatives has been used, reduce and stop one laxative at a time; if possible, the stimulant laxative should be reduced first. However, it may be necessary to also adjust the dose of the osmotic laxative to compensate.

**Constipation in pregnancy and breast-feeding**

If dietary and lifestyle changes fail to control constipation in pregnancy, fibre supplements in the form of bran or wheat are likely to help women experiencing constipation in pregnancy, and raise no serious concerns about side-effects to the mother or foetus. A bulk-forming laxative is the first choice during pregnancy if fibre supplements fail. An osmotic laxative, such as lactulose, can also be used. Bisacodyl p. 59 or senna p. 61 may be suitable if a stimulant effect is necessary but use of senna should be avoided near term or if there is a history of unstable pregnancy. Stimulant laxatives are more effective than bulk-forming laxatives but are more likely to cause side-effects (diarrhoea and abdominal discomfort), reducing their acceptability to patients. Docusate sodium and glycerol p. 61 suppositories can also be used.

A bulk-forming laxative is the first choice during breast-feeding, if dietary measures fail. Lactulose or a macrogol may be used if stools remain hard. As an alternative, a short course of a stimulant laxative such as bisacodyl or senna can be considered.

**Constipation in children**

Early identification of constipation and effective treatment can improve outcomes for children. Without early diagnosis and treatment, an acute episode of constipation can lead to anal fissure and become chronic. The first-line treatment for children with constipation requires the use of a laxative in combination with dietary modification or with behavioural interventions. Diet modification alone is not recommended as first-line treatment.

In children an increase in dietary fibre, adequate fluid intake, and exercise is advised. Diet should be balanced and contain fruits, and vegetables, high-fibre bread, baked beans, and wholegrain breakfast cereals. Unprocessed bran (which may cause bloating and flatulence and reduces the absorption of micronutrients) is not recommended. If faecal impaction is not present (or has been treated), the child should be treated promptly with a laxative. A macrogol (such as macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride p. 55) is preferred as first-line management. If the response is inadequate, add
Faecal impaction in children

- **Drugs Action**: Treatment of faecal impaction may initially increase symptoms of soiling and abdominal pain. In children over 1 year of age with faecal impaction, an oral preparation containing a macrogol (such as macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride) is used to clear faecal mass and to establish and maintain soft well-formed stools, using an escalating dose regimen depending on symptoms and response. If disimpaction does not occur after 2 weeks, a stimulant laxative can be added or if stools are hard, used in combination with an osmotic laxative such as lactulose.

**LAXATIVES** > **BULK-FORMING LAXATIVES**

**Ispaghula husk**

- **Drug Action**: Bulk-forming laxatives relieve constipation by increasing faecal mass which stimulates peristalsis.

- **Indications and Dose**
  - **Constipation**
    - **Adult**: 1 sachet or 3 capsule daily, dose to be taken two to three times daily, preferably after meals.
    - **Child**: 1 sachet or capsule daily, dose to be taken two to three times daily, preferably after meals.

- **Contra-Indications**: Colonotony - difficulty in swallowing - faecal impaction - infective bowel disease - intestinal obstruction.

- **Caution**: Adequate fluid intake should be maintained to avoid intestinal obstruction.

- **Side-Effects**: Abdominal distension - flatulence - gastro-intestinal impaction - gastro-intestinal obstruction - hypersensitivity.

- **Prescribing and Dispensing Information**: Flavours of soluble granules formulations may include lemon, orange, or banana.

- **Handling and Storage**: Ispaghula husk contains potent allergens. Individuals exposed to the product (including those handling the product) can develop hypersensitivity reactions such as rhinitis, conjunctivitis, bronchospasm and in some cases, anaphylaxis.

- **Patient and Carer Advice**: Manufacturer advises that preparations that swell in contact with liquid should always be carefully swallowed with water and should not be taken immediately before going to bed. Patients and their carers should be advised that the full effect may take some days to develop and should be given advice on how to administer ispaghula husk.

- **Medicinal Forms**: There can be variation in the licensing of different medicines containing the same drug.

**Effervescent granules**

- **Drug Action**: Ispaghula 3.5g effervescent granules sachets gluten free sugar free sugar-free 30 sachet DT price = £2.72.
- **Indications and Dose**
  - **Adult**: 1 sachet twice daily, dose to be given in water preferably taken after food, morning and evening.
  - **Child**: 1 sachet twice daily, dose to be given in water preferably taken after food, morning and evening.

**Granules**

- **Drug Action**: Ispaghula 3.5g effervescent granules sachets gluten free sugar-free 30 sachet DT price = £2.72.

**Methyldroxide**

- **Drug Action**: Bulk-forming laxatives relieve constipation by increasing faecal mass which stimulates peristalsis.

- **Indications and Dose**
  - **Constipation**: 1 sachet or capsule daily, dose to be taken two to three times daily, preferably after meals.

- **Contra-Indications**: Colonotony - difficulty in swallowing - faecal impaction - infective bowel disease - intestinal obstruction.

- **Caution**: Adequate fluid intake should be maintained to avoid intestinal obstruction.

- **Side-Effects**: Abdominal distension (especially during the first few days of treatment) - flatulence (especially during the first few days of treatment) - gastro-intestinal impaction - gastro-intestinal obstruction - hypersensitivity.

- **Prescribing and Dispensing Information**: In constipation the dose should be taken with at least 300 mL liquid. In diarrhoea, ileostomy, and colostomy control, avoid liquid intake for 30 minutes before and after dose.

- **Handling and Storage**: Ispaghula husk contains potent allergens. Individuals exposed to the product (including those handling the product) can develop hypersensitivity reactions such as rhinitis, conjunctivitis, bronchospasm and in some cases, anaphylaxis.

- **Patient and Carer Advice**: Patients and their carers should be advised that the full effect may take some days to develop and should be given advice on how to administer ispaghula husk.

**Gastro-intestinal system**

- **Drug Action**: Bulk-forming laxatives relieve constipation by increasing faecal mass which stimulates peristalsis.

- **Indications and Dose**
  - **Adult**: 1 sachet or capsule daily, dose to be taken two to three times daily, preferably after meals.
  - **Child**: 1 sachet or capsule daily, dose to be taken two to three times daily, preferably after meals.

- **Contra-Indications**: Colonotony - difficulty in swallowing - faecal impaction - infective bowel disease - intestinal obstruction.

- **Caution**: Adequate fluid intake should be maintained to avoid intestinal obstruction.

- **Side-Effects**: Abdominal distension (especially during the first few days of treatment) - flatulence (especially during the first few days of treatment) - gastro-intestinal impaction - gastro-intestinal obstruction - hypersensitivity.

- **Prescribing and Dispensing Information**: In constipation the dose should be taken with at least 300 mL liquid. In diarrhoea, ileostomy, and colostomy control, avoid liquid intake for 30 minutes before and after dose.

- **Handling and Storage**: Ispaghula husk contains potent allergens. Individuals exposed to the product (including those handling the product) can develop hypersensitivity reactions such as rhinitis, conjunctivitis, bronchospasm and in some cases, anaphylaxis.

- **Patient and Carer Advice**: Patients and their carers should be advised that the full effect may take some days to develop and should be given advice on how to administer ispaghula husk.

**Related documents**

- **BNF**
  - **74**
  - Issue 31 (2016)
  - 24-Feb-2016

**Combinations available**: Senna with ispaghula husk. p. 62

---

*Note: The above text is a excerpt from a medical reference and is not an actual document.*
to develop. Preparations that swell in contact with liquid should always be carefully swallowed with water and should not be taken immediately before going to bed.

- **MEDICINAL FORMS**
  - **Tablet**
    - **Celevac** (AMCo)
    - Methylcellulose "450" 500 mg
  - **Granules**
    - **Normacol**
    - Frangula 80 mg per 1 gram, Sterculia 620 mg per 1 gram
    - Normalac Plus granules
    - Normalac granules

- **INDICATIONS AND DOSE**
  - **Constipation**
    - **BY MOUTH**
      - Child 6–11 years: 0.5–1 sachet 1–2 times a day, alternatively, half to one heaped 5–6 mL spoonfuls once or twice a day; washed down without chewing with plenty of liquid after meals.
      - Child 12–17 years: 1–2 sachets 1–2 times a day, alternatively, one to two heaped 5–6 mL spoonfuls once or twice a day; washed down without chewing with plenty of liquid after meals.
      - Adult: 1–2 sachets 1–2 times a day, alternatively, one to two heaped 5–6 mL spoonfuls once or twice a day; washed down without chewing with plenty of liquid after meals.

- **CONTRA-INDICATIONS**
  - Colonic atony · difficulty in swallowing · faecal impaction · intestinal obstruction

- **CAUTIONS**
  - Adequate fluid intake should be maintained to avoid intestinal obstruction

- **CAUTIONS, FURTHER INFORMATION**
  - In adults, it may be necessary to supervise elderly or debilitated patients or those with intestinal narrowing or decreased motility to ensure adequate fluid intake.

- **SIDE-EFFECTS**
  - Abdominal distension (especially during the first few days of treatment) · flatulence (especially during the first few days of treatment) · gastro-intestinal impaction · gastro-intestinal obstruction · hypersensitivity

- **DIRECTIONS FOR ADMINISTRATION**
  - May be mixed with soft food (e.g. yoghurt) before swallowing, followed by plenty of liquid.

- **PATIENT AND CARER ADVICE**
  - Patients and their carers should be advised that the full effect may take some days to develop. Preparations that swell in contact with liquid should always be carefully swallowed with water and should not be taken immediately before going to bed.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

- **Granules**
  - Normalac Plus (Norgine Pharmaceuticals Ltd)
    - Frangula 80 mg per 1 gram, Sterculia 620 mg per 1 gram
    - Normalac Plus granules
    - Normalac granules

- **LAXATIVES**
  - **CHLORIDE-CHANNEL AGONISTS**

<table>
<thead>
<tr>
<th>Lubiprostone</th>
<th>23-Mar-2016</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DRUG ACTION</strong></td>
<td>Lubiprostone is a chloride-channel activator that acts locally in the gut to increase intestinal fluid secretion and intestinal motility, resulting in a laxative effect.</td>
</tr>
<tr>
<td><strong>INDICATIONS AND DOSE</strong></td>
<td>Chronic idiopathic constipation when response to lifestyle changes (including diet) inadequate</td>
</tr>
<tr>
<td><strong>BY MOUTH</strong></td>
<td>Adult: 24 micrograms twice daily for 2–4 weeks, discontinue if no response after initial 2 weeks</td>
</tr>
</tbody>
</table>

| **CONTRA-INDICATIONS** | Gastro-intestinal obstruction |
| **SIDE-EFFECTS** | Common or very common · Abdominal discomfort · abdominal distension · abdominal pain · diarrhoea · dizziness · dyspepsia · dysphagia · flatulence · headache · hot flush · hyperhidrosis · nausea · oedema · palpitation |
| **Uncommon** | Chest pain · muscle spasm · syncope · vomiting |
| **Frequency not known** | Influenza-like symptoms · rash · tachycardia |
| **PREGNANCY** | Manufacturer advises avoid—toxicity in animal studies. |
| **BREAST FEEDING** | Unknown if excreted in milk. |
| **HEPATIC IMPAIRMENT** | In moderate to severe impairment initially 24 micrograms once daily; if tolerated, and if necessary, increased to 24 micrograms twice daily. |
| **PRESCRIBING AND DISPENSING INFORMATION** | Dispense capsules in original container; discard any capsules remaining 4 weeks after opening. |
MACROGL 3350 WITH POTASSIUM CHLORIDE, SODIUM BICARBONATE AND SODIUM CHLORIDE

INDICATIONS AND DOSE
Chronic constipation (dose for non-proprietary ‘full-strength’ sachets)
- **BY MOUTH**
  - Child 12–17 years: 4 sachets on first day, then increased in steps of 2 sachets daily, total daily dose to be drunk within a 6 hour period, after disimpaction, switch to maintenance laxative therapy if required; maximum 8 sachets per day
  - Adult: 4 sachets on first day, then increased in steps of 2 sachets daily, total daily dose to be drunk within a 6 hour period, after disimpaction, switch to maintenance laxative therapy if required; maximum 8 sachets per day

Faecal impaction (dose for non-proprietary ‘full-strength’ sachets)
- **BY MOUTH**
  - Child 12–17 years: 2–6 sachets daily in divided doses usually for up to 2 weeks; maintenance 2–4 sachets daily
  - Adult: 2–6 sachets daily in divided doses usually for up to 2 weeks; maintenance 2–4 sachets daily

MOVICOL-HALF®
Chronic constipation
- **BY MOUTH**
  - Child 12–17 years: 2–6 sachets daily in divided doses usually for up to 2 weeks; maintenance 2–4 sachets daily
  - Adult: 2–6 sachets daily in divided doses usually for up to 2 weeks; maintenance 2–4 sachets daily

Faecal impaction
- **BY MOUTH**
  - Child 12–17 years: Initially 8 sachets daily on first day, then increased in steps of 4 sachets daily, total daily dose to be drunk within 6 hours, after disimpaction, switch to maintenance laxative therapy; maximum 16 sachets per day
  - Adult: Initially 8 sachets daily on first day, then increased in steps of 4 sachets daily, total daily dose to be drunk within 6 hours, after disimpaction, switch to maintenance laxative therapy; maximum 16 sachets per day

MOVICOL-PAEDIATRIC®
Chronic constipation | Prevention of faecal impaction
- **BY MOUTH**
  - Child 2–5 years: 1 sachet daily, adjust dose to produce regular soft stools; maximum 4 sachets per day

continued →
Constipation and bowel cleansing

56

Gastro-intestinal system

- Child 6–11 years: 2 sachets daily, adjust dose to produce regular soft stools; maximum 4 sachets per day

Faecal impaction
- BY MOUTH
- Child 5–11 years: Initially 4 sachets daily on first day, then increased in steps of 2 sachets daily, total daily dose to be taken over a 12-hour period, after disimpaction, switch to maintenance laxative therapy; maximum 12 sachets per day

Movicol Paediatric not licensed for use in faecal impaction in children under 5 years, or for chronic constipation in children under 2 years.

CONTRA-INDICATIONS Crohn’s disease • Intestinal obstruction • Intestinal perforation • Paralytic ileus • Severe inflammatory conditions of the intestinal tract • Toxic megacolon • Ulcerative colitis

Movicol Paediatric not licensed for use in faecal impaction in children under 5 years, or for chronic constipation in children under 2 years.

CAUTIONS Cardiovascular impairment (should not take more than 2 ‘full-strength’ sachets or 4 ‘half-strength’ sachets in any one hour) • Discontinue if symptoms of fluid and electrolyte disturbance

Movicol Paediatric not licensed for use in faecal impaction in children under 5 years, or for chronic constipation in children under 2 years.

SIDE-EFFECTS Abdominal distention • Abdominal pain • Flatulence • Nausea

PREGNANCY Limited data, but manufacturer advises that it can be used.

BREAST FEEDING Manufacturer advises that it can be used.

RENAI IMPAIRMENT Movicol Paediatric not licensed for use in faecal impaction in children under 5 years, or for chronic constipation in children under 2 years.

DIRECTIONS FOR ADMINISTRATION Contents of each ‘full strength’ sachet of oral powder to be dissolved in half a glass (approx. 125 mL) of water; after reconstitution the solution should be kept in a refrigerator and discarded if unused after 6 hours.

Movicol Paediatric not licensed for use in faecal impaction in children under 5 years, or for chronic constipation in children under 2 years.

Movicol Paediatric not licensed for use in faecal impaction in children under 5 years, or for chronic constipation in children under 2 years.

Movicol Paediatric not licensed for use in faecal impaction in children under 5 years, or for chronic constipation in children under 2 years.

Movicol Paediatric not licensed for use in faecal impaction in children under 5 years, or for chronic constipation in children under 2 years.

Movicol Paediatric not licensed for use in faecal impaction in children under 5 years, or for chronic constipation in children under 2 years.

Movicol Paediatric not licensed for use in faecal impaction in children under 5 years, or for chronic constipation in children under 2 years.

Movicol Paediatric not licensed for use in faecal impaction in children under 5 years, or for chronic constipation in children under 2 years.

Cautions Cardiovascular impairment (should not take more than 2 ‘full-strength’ sachets or 4 ‘half-strength’ sachets in any one hour) • Discontinue if symptoms of fluid and electrolyte disturbance

Movicol Paediatric not licensed for use in faecal impaction in children under 5 years, or for chronic constipation in children under 2 years.

Electrolytes: May contain Bicarbonate, chloride, potassium, sodium

Movicol (Norgine Pharmaceuticals Ltd)

Movicol 3350 105 gram per 1 litre, Potassium 5.4 mmol per 1 litre, Bicarbonate 17 mmol per 1 litre, Chloride 53 mmol per 1 litre, Sodium 65 mmol per 1 litre

Movicol Liquid sugar-free | 500 mL £ 3.15 DT price = £5.15

Movicol Half oral powder 6.9 g sachets sugar-free | 20 sachet £ 3.37 sugar-free | 30 sachet £ 5.06 DT price = £4.38

Movicol Half oral powder 6.9 g sachets sugar-free | 30 sachet £ 4.38 DT price = £4.38

Movicol Half oral powder 6.9 g sachets sugar-free | 30 sachet £ 4.38 DT price = £4.38

Movicol 3350 105 gram per 1 litre, Potassium 5.4 mmol per 1 litre, Bicarbonate 17 mmol per 1 litre, Chloride 53 mmol per 1 litre, Sodium 65 mmol per 1 litre

Movicol Chocolate oral powder 13.7 g sachets sugar-free | 30 sachet £ 7.72 DT price = £4.27 sugar-free | 50 sachet £ 12.85

Movicol Chocolate oral powder 13.9 g sachets sugar-free | 30 sachet £ 7.72 DT price = £4.27

Movicol oral powder 13.8 g sachets lemon & lime sugar-free | 20 sachet £ 5.15 sugar-free | 30 sachet £ 7.72 DT price = £4.27 sugar-free | 50 sachet £ 12.85

Movicol Half oral powder 6.9 g sachets sugar-free | 30 sachet £ 4.38 DT price = £4.38

Movicol-Half oral powder

Patients or carers should be counselled on how to take Movicol® oral solution.

Patients or carers should be counselled on how to take Movicol® oral solution.

Patients or carers should be counselled on how to take Movicol® oral solution.

Patients or carers should be counselled on how to take Movicol® oral solution.

There can be variation in the licensing of different medicines containing the same drug.

Movicol Paediatric not licensed for use in faecal impaction in children under 5 years, or for chronic constipation in children under 2 years.
MAGNESIUM HYDROXIDE

INDICATIONS AND DOSE

Constipation
- By mouth
- Adult: 30–45 mL as required, dose to be given mixed with water at bedtime

CONTRA-INDICATIONS
- Acute gastro-intestinal conditions
- Debilitated patients - elderly
- INTERACTIONS
- Appendix 1: magnesium
- SIDE-EFFECTS
- Colic
- HEPATIC IMPAIRMENT
- Avoid in hepatic coma if risk of renal failure.
- RENAL IMPAIRMENT
- Avoid or reduce dose. Increased risk of toxicity in renal impairment.
- PRESCRIBING AND DISPENSING INFORMATION
- When prepared extemporaneously, the BP states Magnesium Hydroxide Mixture, BP consists of an aqueous suspension containing about 8% hydrated magnesium oxide.

MEDICINAL FORMS
- There can be variation in the licensing of different medicines containing the same drug.
- Oral suspension
  - Phillips’ Milk of Magnesia (Omega Pharma Ltd)
    - Magnesium hydroxide 83 mg per 1 mL Phillips’ Milk of Magnesia
    - 415 mg/5 mL oral suspension sugar-free £2.32
  - Combinations available: Liquid paraffin with magnesium hydroxide, p. 59

SODIUM ACID PHOSPHATE WITH SODIUM PHOSPHATE

INDICATIONS AND DOSE

Constipation (using Phosphates Enema BP Formula B) | Bowel evacuation before abdominal radiological procedures, endoscopy, and surgery (using Phosphates Enema BP Formula B)
- By rectum
  - Child 3–6 years: 45–65 mL once daily
  - Child 7–11 years: 65–100 mL once daily
  - Child 12–17 years: 100–128 mL once daily
  - Adult: 128 mL daily

FLEET® READY-TO-USE ENEMA
- Constipation | Bowel evacuation before abdominal radiological procedures | Bowel evacuation before endoscopy | Bowel evacuation before surgery
- By rectum
- Adult: 118 mL

FLEET® PHOSPHO-SODA
- Bowel evacuation before colonoscopic surgery | Bowel evacuation before colonoscopy | Bowel evacuation before radiological examination
- By mouth
- Adult: 45 mL twice daily, each dose must be diluted with half a glass (120 mL) of cold water, followed by one full glass (240 mL) of cold water, timing of doses is dependent on the time of the procedure, for morning procedure, the first dose should be taken at 7 a.m. and second at 7 p.m. on day before the procedure; for afternoon procedure, first dose should be taken at 7 p.m. on day before and second dose at 7 a.m. on day of the procedure

PHARMACOKINETICS
- For Fleet® Phospho-soda: Onset of action is within half to 6 hours of first dose.
LAXATIVES > SELECTIVE 5-HT₄ RECEPTOR AGONISTS

Prucalopride

**DRUG ACTION** A selective serotonin 5HT₄-receptor agonist with prokinetic properties.

**INDICATIONS AND DOSE**

- **Chronic constipation when other laxatives fail to provide an adequate response**
  - **BY MOUTH**
  - Adult: 2 mg once daily, review treatment if no response after 4 weeks
  - Elderly: Initially 1 mg once daily, increased if necessary to 2 mg once daily, review treatment if no response after 4 weeks

**CONTRA-INDICATIONS** Crohn’s disease · intestinal obstruction · intestinal perforation · toxic megacolon · ulcerative colitis

**CAUTIONS** History of arrhythmias · history of ischaemic heart disease

**SIDE-EFFECTS**

- Common or very common Abdominal pain · decreased appetite · diarrhoea · dizziness · dyspepsia · fatigue · flatulence · headache · nausea · polyuria · rectal bleeding · vomiting
- Uncommon Fever · malaise · palpitation · tremor

**SIDE-EFFECTS, FURTHER INFORMATION**

Manufacturer advises that side-effects generally occur at the start of treatment and are usually transient.

**CONCEPTION AND CONTRACEPTION** Manufacturer recommends effective contraception during treatment.

**PREGNANCY**

Manufacturer advises avoid—limited data available.

**BREAST FEEDING**

Manufacturer advises avoid—present in milk.

**HEPATIC IMPAIRMENT** In severe impairment, manufacturer advises reduced dose of 1 mg once daily; increased if necessary to 2 mg once daily.

**RENAL IMPAIRMENT** Manufacturer recommends a reduced dose of 1 mg daily if eGFR less than 30 mL/minute/1.73 m².

**PATIENT AND CARER ADVICE**

Driving and skilled tasks

Manufacturer advises that dizziness and fatigue may initially affect ability to drive or operate machinery.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Prucalopride for the treatment of chronic constipation in women (December 2010) NICE TA211

Prucalopride is recommended as an option for the treatment of chronic constipation in women for whom treatment with at least 2 laxatives from different classes, at the highest tolerated recommended doses for at least 6 months, has failed to provide adequate relief and invasive treatment for constipation is being considered. If treatment with prucalopride is not effective after 4 weeks, the patient should be re-examined and the benefit of continuing treatment reconsidered.

Prucalopride should only be prescribed by a clinician with experience of treating chronic constipation, after careful review of the patient’s previous courses of laxative treatments.

www.nice.org.uk/TA211

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (June 2011) that prucalopride (Resolor®) is not recommended for use within NHS Scotland for the symptomatic treatment of chronic constipation of women in whom laxatives fail to provide adequate relief.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Resolor** (Shire Pharmaceuticals Ltd)
  - Prucalopride (as Prucalopride succinate) 1 mg Resolor tablets 28 tablet [Pres] £8.69 DT price = £4.69
  - Prucalopride (as Prucalopride succinate) 2 mg Resolor tablets 28 tablet [Pres] £9.52 DT price = £5.52

LAXATIVES > SOFTENING LAXATIVES

Arachis oil

**INDICATIONS AND DOSE**

To soften impacted faeces

- **BY RECTUM**
  - Adult: 130 mL as required

**CAUTIONS**

- Hypersensitivity to soya · intestinal obstruction

**ALLERGY AND CROSS-SENSITIVITY**

Contra-indicated if history of hypersensitivity to arachis oil or peanuts.

**DIRECTIONS FOR ADMINISTRATION**

Warm enema in warm water before use.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Enema**

- **Arachis oil (Non-proprietary)**
  - Arachis oil 1 ml per 1 ml Arachis oil 130ml enema 1 enema [Pres] £47.50 DT price = £47.50

Docusate sodium

**(Diocyl sodium sulphasuccinate)**

**INDICATIONS AND DOSE**

- **Chronic constipation**
  - **BY MOUTH**
    - Child 6 months-1 year: 12.5 mg 3 times a day, adjusted according to response, use paediatric oral solution
    - Child 2-11 years: 12.5–25 mg 3 times a day, adjusted according to response, use paediatric oral solution
    - Child 12-17 years: Up to 500 mg daily in divided doses, adjusted according to response
Adult: Up to 500 mg daily in divided doses, adjusted according to response

**By rectum**

Adult: 120 mg for 1 dose

**Contraindications**

**Indications and dose**

**Constipation**

**By mouth**

Adult: 400 mg, to be administered with barium meal

**By rectum**

Adult: 120 mg for 1 dose

**Pharmacokinetics**

Oral preparations act within 1–2 days; response to rectal administration usually occurs within 20 minutes.

**Unlicensed use**

*Adult oral solution and capsules* not licensed for use in children under 12 years.

**Contra-indications**

Avoid in intestinal obstruction.

**Caution**

Do not give with liquid paraffin - excessive use of stimulant laxatives can cause diarrhoea and related effects such as hypokalaemia - rectal preparations not indicated if haemorrhoids or anal fissure.

**Interactions**

*Appendix 1: docusate sodium*

**Side-effects**

Abdominal cramp - diarrhea (excessive use) - hypokalaemia - rash

**Pregnancy**

Not known to be harmful - manufacturer advises caution.

**Breastfeeding**

With oral use: Present in milk following oral administration - manufacturer advises caution.

With rectal use: Rectal administration not known to be harmful.

**Directions for administration**

With oral use in children: For administration by mouth, solution may be mixed with milk or squash.

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug.

**Oral solution**

- **Docusate sodium (Non-proprietary)**
  - Docusate sodium 2.5 mg per 1 ml: Docusate 12.5mg/5ml oral solution sugar-free free sugar-free | 300 ml [P] £7.79 DT price = £5.29
  - Docusate sodium 10 mg per 1 ml: Docusate 50mg/5ml oral solution sugar-free free sugar-free | 300 ml [P] £7.99 DT price = £7.99
- **Docusol** (Typharm Ltd)
  - Docusate sodium 2.5 mg per 1 ml: Docusol Paediatric 12.5mg/5ml oral solution sugar-free free | 300 ml [P] £5.29 DT price = £5.29

**Enema**

- **Norgalax** (Essential Pharma Ltd)
  - Docusate sodium 12 mg per 1 gram: Norgalax 120mg/10g enema | 6 enema [P] £28.00

**Capsule**

- **Dicotyl** (UCB Pharma Ltd)
  - Docusate sodium 100 mg: Dicotyl 100mg capsules | 30 capsule [P] £2.09 DT price = £2.09 | 100 capsule [P] £6.98
- **DulcoEase** (Boehringer Ingelheim Self-Medication Division)
  - Docusate sodium 100 mg: DulcoEase 100mg capsules | 30 capsule CSL £3.20 DT price = £2.09

**Combinations available:** *Co-danthrusate*, p. 60

**Liquid paraffin with magnesium hydroxide**

The properties listed below are those particular to the combination only. For the properties of the components please consider, liquid paraffin above, magnesium hydroxide p. 57.

**Indications and dose**

**Constipation**

**By mouth**

Adult: 5–20 mL as required

**Prescribing and dispensing information**

Liquid paraffin and magnesium hydroxide preparations are on sale to the public.

When prepared extemporaneously, the BP states Liquid Paraffin and Magnesium Hydroxide Oral Emulsion, BP consists of 25% liquid paraffin in aqueous suspension containing 6% hydrated magnesium oxide.

**Less suitable for prescribing**

Liquid paraffin with magnesium hydroxide is less suitable for prescribing.

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug. No licensed medicines listed.

**Laxatives**

**Stimulant laxatives**

**Bisacodyl**

**Indications and dose**

**Constipation**

**By mouth**

- Child 4–17 years: 5–20 mg once daily, adjusted according to response, dose to be taken at night
- Adult: 5–10 mg once daily increased if necessary up to 20 mg once daily, dose to be taken at night

**By rectum**

- Child 2–17 years: 5–10 mg once daily, adjusted according to response
- Adult: 10 mg once daily, dose to be taken in the morning

**Bowel clearance before radiological procedures and surgery**

**Initially by mouth**

- Adult: 10 mg twice daily, doses to be taken in the morning and evening on the day before... continued →
Co-danthramer

INDICATIONS AND DOSE

Constitution in terminally ill patients (standard strength capsules)
- By mouth using capsules
  - Child 6–11 years: 1 capsule once daily, dose should be taken at night
  - Child 12–17 years: 1–2 capsules once daily, dose should be taken at night
  - Adult: 1–2 capsules once daily, dose should be taken at night

Constitution in terminally ill patients (strong capsules)
- By mouth using capsules
  - Child 6–11 years: 1–2 capsules once daily, dose should be given at night
  - Adult: 1–2 capsules once daily, dose should be given at night

PHARMACOKINETICS

Tablets act in 10–12 hours; suppositories act in 20–60 minutes.

CONTRA-INDICATIONS

Acute abdominal conditions (in children) • acute inflammatory bowel disease • acute surgical abdominal conditions (in adults) • intestinal obstruction • severe dehydration

CAUTIONS

Excessive use of stimulant laxatives can cause diarrhoea and related effects such as hypokalaemia • risk of electrolyte imbalance with prolonged use (in children)

INTERACTIONS

Appendix 1: bisacodyl

SIDE-EFFECTS

Abdominal cramp • diarrhoea and vomiting

CAUTIONARY AND ADVISORY LABELS

May be suitable for constipation in pregnancy, if a stimulant effect is necessary.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, suppository, enema

Gastro-resistant tablet

Cautionary and advisory labels 5, 25

Bisacodyl (non-proprietary)
- Bisacodyl 5 mg: Bisacodyl 5 mg gastro-resistant tablets | 60 tablet | £3.25 DT price = £1.96 | 100 tablet | £5.40 | 500 tablet | £25.73 | 1000 tablet | £51.45
- Dulco-Lax (bisacodyl) (Boehringer Ingelheim Self-Medication Division)
  - Bisacodyl 5 mg: Dulcolax 5 mg gastro-resistant tablets | 40 tablet | £2.44 | 100 tablet | £3.60

Enema

Bisacodyl (non-proprietary)
- Bisacodyl 333.333 microgram per 1 ml: Fleet Bisacodyl 10 mg/30 ml enema | 1 enema | No price available

Suppository

Bisacodyl (non-proprietary)
- Bisacodyl 10 mg: Bisacodyl 10 mg suppositories | 12 suppository | £3.53 DT price = £3.53
- Dulco-Lax (bisacodyl) (Boehringer Ingelheim Self-Medication Division)
  - Bisacodyl 5 mg: Dulcolax 5 mg suppositories for children | 5 suppository | £1.04 DT price = £1.04
  - Bisacodyl 10 mg: Dulcolax 10 mg suppositories | 12 suppository | £2.35 DT price = £3.53

Co-danthrusate

INDICATIONS AND DOSE

Constitution in terminally ill patients
- By mouth using capsules
  - Child 6–11 years: 1 capsule once daily, to be taken at night

20-Apr-2016
Child 12-17 years: 1–3 capsules once daily, to be taken at night
Adult: 1–3 capsules once daily, to be taken at night
**LOCAL IRRITATION**

**MEDICINAL FORMS**

**DOSE EQUIVALENCE AND CONVERSION**

- Co-danthrusate capsules contain dantron 50 mg and docusate 50 mg per 5 mL.
- Co-danthrusate capsules contain dantron 50 mg and docusate 60 mg per capsule.

- CONTRA-INDICATIONS Acute abdominal conditions (in children) - acute inflammatory bowel disease - acute surgical abdominal conditions (in adults) - intestinal obstruction - severe dehydration
- **CAUTIONS** Excessive use of stimulant laxatives can cause diarrhea and related effects such as hypokalaemia - may cause local irritation - *rodent* studies indicate potential carcinogenic risk

- INTERACTIONS → Appendix 1: dantron, docusate sodium
- **SIDE-EFFECTS** Abdominal cramp - urine may be coloured red
- **PREGNANCY** Manufacturers advise avoid - limited information available.
- **BREAST FEEDING** Manufacturers advise avoid—no information available.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Oral suspension**

**CAUTIONARY AND ADVISORY LABELS** 14 (urine red)
- Co-danthrusate (Non-proprietary)
  - Dantron 10 mg per 1 mL, Docusate sodium 12 mg per 1 mL Co-danthrusate 50mg/60mg/5ml oral suspension sugar free sugar-free 200 mL [POM] £89.92 DT price = £89.92

**Capsule**

**CAUTIONARY AND ADVISORY LABELS** 14 (urine red)
- Co-danthrusate (Non-proprietary)
  - Dantron 50 mg, Docusate sodium 60 mg Co-danthrusate 50mg/60mg capsules | 63 capsule [POM] no price available DT price = £52.50

**Glycerol**

**(Glycerin)**

**INDICATIONS AND DOSE**

**Constipation**

- **BY MOUTH USING TABLETS**
  - Child 6–17 years: 7.5–30 mg once daily, adjusted according to response
  - Adult: 7.5–15 mg daily (max. per dose 30 mg daily), dose usually taken at bedtime; initial dose should be low then gradually increased, higher doses may be prescribed under medical supervision
- **BY MOUTH USING SYRUP**
  - Child 1 month–3 years: 3.75–15 mg once daily, adjusted according to response
  - Child 4–17 years: 3.75–30 mg once daily, adjusted according to response
  - Adult: 7.5–15 mg once daily (max. per dose 30 mg daily), dose usually taken at bedtime, higher doses may be prescribed under medical supervision

**PHARMACOKINETICS**

Onset of action 8–12 hours.

**UNLICENSED USE** Tablets not licensed for use in children under 6 years. Syrup not licensed for use in children under 2 years.

Doses in BNF adhere to national guidelines and may differ from those in product literature.

**CONTRA-INDICATIONS** Intestinal obstruction - undiagnosed abdominal pain

**INTERACTIONS** → Appendix 1: senna

**SIDE-EFFECTS** Abdominal spasm - discoloration of urine - pruritus

**SIDE-EFFECTS, FURTHER INFORMATION** Prolonged or excessive use of stimulant laxatives can cause diarrhea and related effects such as hypokalaemia.

**PREGNANCY** [G6] Specialist sources indicate suitable for use in pregnancy. [D]

**BREAST FEEDING** [G6] Specialist sources indicate suitable for use in breast-feeding in infants over 1 month. [D]

**PATIENT AND CARER ADVICE**

Medicines for Children leaflet: Senna for constipation www.medicinesforchildren.org.uk/senna-for-constipation

**NATIONAL FUNDING/ACCESS DECISIONS** NHS restrictions Senokot® tablets.

**EXCEPTIONS TO LEGAL CATEGORY** Senna is on sale to the public for use in children over 12 years; doses on packs may vary from those in BNF Publications.
### Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug.

**Oral solution**

- **Senokot** (Forum Health Products Ltd, Reckitt Benckiser Healthcare (UK) Ltd)
  - **Sennoside B (as Sennosides)** 1.5 mg per ml Senokot 7.5mg/5ml Syrup Pharmacy sugar free sugar-free | 500 ml | £4.76 DT price = £4.76

**Tablet**

- **Senna (Non-proprietary)**
  - **Sennoside B (as Sennosides)** 7.5 mg Senna 7.5mg tablets | 20 tablet | £1.00 | 60 tablet | £2.50 DT price = £2.01 |
  - **Senna** (Non-proprietary) 7.5 mg Senna 7.5mg tablets | 20 tablet | £1.00 |

- **Ex-Lax Senna** (Novartis Consumer Health UK Ltd)
  - **Sennoside B (as Sennosides)** 12 mg Ex-Lax Senna 12mg pills | 20 tablet GSSL | £1.54

- **Senokot** (Reckitt Benckiser Healthcare (UK) Ltd, Forum Health Products Ltd)
  - **Sennoside B (as Sennosides)** 7.5 mg Senokot 7.5mg tablets | 20 tablet GSL | £1.61 | 60 tablet GSSL | £4.20 DT price = £2.01 |
  - **Senna** (Non-proprietary) 7.5 mg Senokot 7.5mg tablets | 20 tablet GSSL | £5.49 | 500 tablet GSSL | £12.50

- **Sennoside B (as Sennosides)** 15 mg Senokot Max Strength 15mg tablets | 24 tablet GSSL | £3.23 | 48 tablet GSSL | £5.69 DT price = £5.69

### Senna with ispaghula husk

The properties listed below are those particular to the combination only. For the properties of the components please consider, senna p. 61, ispaghula husk p. 53.

- **Indications and dose**
  - **Constipation**
    - **By mouth**
      - Child 12–17 years: 5–10 g once daily, to be taken at night, 5 g equivalent to one level spoonful of granules
      - Adult: 5–10 g once daily, to be taken at night, 5 g equivalent to one level spoonful of granules
  - **Side-effects**
    - **Common or very common** Abdominal cramp
    - **Uncommon** Dizziness, nausea, vomiting
    - **Frequency not known** Angioedema, pruritus, rash, syncope

- **Interactions**
  - **Appendix 1: senna**

- **Pregnancy**
  - Manufacturer advises avoid during pregnancy.

- **Directions for administration**
  - Take at night with at least 150 mL liquid.

- **Medicinal forms**
  - There can be variation in the licensing of different medicines containing the same drug.

### Sodium picosulfate

**Sodium picosulfate** (Sodium picosulfate)

- **Drug action** Sodium picosulfate is a stimulant laxative. After metabolism in the colon it stimulates the mucosa thereby increasing the motility of the large intestine.

- **Indications and dose**
  - **Constipation**
    - **By mouth**
      - Child 1 month–3 years: 2.5–10 mg once daily, adjusted according to response
      - Child 4–17 years: 2.5–20 mg once daily, adjusted according to response
      - Adult: 5–10 mg once daily, dose to be taken at bedtime

### Opioid Receptor Antagonists

**Methylnaltrexone bromide**

- **Drug action** Methylnaltrexone bromide is a peripherally acting opioid-receptor antagonist. It therefore blocks the gastro-intestinal (constipating) effects of opioids without altering their central analgesic effects.

- **Indications and dose**
  - **Opioid-induced constipation in patients with chronic pain (except palliative care patients with advanced illness)**
    - **By subcutaneous injection**
      - Adult: 12 mg once daily if required, to be given as 4–7 doses weekly
  - **Adjunct to other laxatives in opioid-induced constipation in advanced illness (palliative care patients)**
    - **By subcutaneous injection**
      - Adult (body-weight up to 38 kg): 150 micrograms/kg once daily on alternate days for maximum duration of treatment 4 months, two consecutive doses may be given 24 hours apart if no response to treatment on the preceding day
      - Adult (body-weight 38–61 kg): 8 mg once daily on alternate days for maximum duration of treatment 4 months, two consecutive doses may be given 24 hours apart if no response to treatment on the preceding day
      - Adult (body-weight 62–114 kg): 12 mg once daily on alternate days for maximum duration of treatment 4 months, two consecutive doses may be given 24 hours apart if no response to treatment on the preceding day
Naloxegol

20-Jun-2016

**DRUG ACTION**

Naloxegol is a peripherally acting opioid receptor antagonist. It therefore decreases the constipating effects of opioids without altering their central analgesic effects.

**INDICATIONS AND DOSE**

**Opioid-induced constipation when response to laxatives inadequate**

- **BY MOUTH**

- **Adult:** 25 mg once daily, to be taken in the morning

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**

Manufacturer advises reduce initial dose to 12.5 mg daily with concurrent use of moderate inhibitors of CYP3A4, increasing to 25 mg daily if well tolerated.

**CONTRA-INDICATIONS**

Gastro-intestinal or peritoneum malignancy (risk of gastro-intestinal perforation) · known or suspected gastro-intestinal obstruction · patients at risk of recurrent gastro-intestinal obstruction · recurrent or advanced ovarian cancer (risk of gastro-intestinal perforation) · vascular endothelial growth factor (VEGF) inhibitor treatment (risk of gastro-intestinal perforation)

**CAUTIONS**

Alzheimer’s disease (advanced) · cardiovascular disease · CNS metastases · congestive heart failure (symptomatic) · Crohn’s disease · diverticulitis (active or recurrent) · multiple sclerosis (active) · peptic ulcer disease (severe) · primary brain malignancies · QT interval over 500 milliseconds · recent history of myocardial infarction (within 6 months)

**CAUTIONS, FURTHER INFORMATION**

- Disruptions to blood-brain barrier Manufacturer advises caution in patients with clinically important disruptions to the blood-brain barrier (e.g., advanced Alzheimer’s disease, active multiple sclerosis, primary brain malignancies) — risk of uptake into the CNS.

- Cardiovascular disorders Safety and efficacy has not been established in patients with these conditions.

**INTERACTIONS**

- **Appendix 1: naloxegol**

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain · diarrhoea · dizziness · flatulence · injection site reactions · nausea · opioid withdrawal symptoms (usually mild to moderate) · vomiting

**FURTHER INFORMATION**

- Palliative care see www.palliativedrugs.com/formulary/en/opioid-antagonists.html

**HANDLING AND STORAGE**

- Protect from light.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Relistor (Swedish Orphan Biovitrum Ltd)**

  - Methyltnaltrexone bromide 20 mg per 1 ml Relistor 12mg/0.6ml solution for injection vials | 1 vial [P] £21.05 | 7 vial [P] £147.35

**NATIONAL FUNDING/ACCESS DECISIONS**

- **NICE technology appraisals (TAs)**

  - Naloxegol for treating opioid induced constipation (July 2015) NICE TA345

  Naloxegol is recommended as a possible treatment for opioid induced constipation in patients whose response to laxatives is inadequate.

  www.nice.org.uk/TA345

- **MEDICINAL FORMS**

  - There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS**

  - **Moventig (Kyowa Kirin Ltd)**

    - Naloxegol (as Naloxegol oxalate) 12.5 mg Moventig 12.5mg tablets | 30 tablet [P] £55.20 DT price = £55.20

    - Naloxegol (as Naloxegol oxalate) 25 mg Moventig 25mg tablets | 30 tablet [P] £55.20 DT price = £55.20
3 Diarrhoea

Acute diarrhoea

Management of acute diarrhoea

The priority in acute diarrhoea, as in gastro-enteritis, is the prevention or reversal of fluid and electrolyte depletion. This is particularly important in infants and in frail and elderly patients. Oral rehydration preparations are used in the prevention or reversal of fluid and electrolyte depletion. Severe depletion of fluid and electrolytes requires immediate admission to hospital and urgent replacement.

Antimotility drugs

Antimotility drugs relieve symptoms of acute diarrhoea by binding to opioid receptors in the gastrointestinal tract and thereby prolonging the duration of intestinal transit. They are used in the management of uncomplicated acute diarrhoea in adults, however, are not recommended for acute diarrhoea in young children; fluid and electrolyte replacement are of primary importance in severe cases of acute diarrhoea and may also be necessary in cases of dehydration.

Loperamide hydrochloride p. 65 is used due to its action on opioid receptors in the gastrointestinal tract and because it does not readily cross the blood-brain barrier. Loperamide hydrochloride can also be used for faecal incontinence [unlicensed indication] after the underlying cause of incontinence has been addressed.

Antimotility drugs have a role in Inflammatory bowel disease p. 36 and in Stoma care p. 94.

Antispasmodics

Antispasmodics are occasionally of value in treating abdominal cramp associated with diarrhoea but they should not be used for primary treatment. Antispasmodics and antiemetics should be avoided in young children with gastro-enteritis because they are rarely effective and have troublesome side-effects.

Antibacterial drugs

Antibacterial drugs are generally unnecessary in simple gastro-enteritis because the complaint usually resolves quickly without them, and infective diarrhoeas in the UK often have a viral cause. Systemic bacterial infection does, however, need appropriate systemic treatment.

Ciprofloxacin p. 527 is occasionally used for prophylaxis against travellers’ diarrhoea, but routine use is not recommended. Lactobacillus preparations have not been shown to be effective.

Adsorbents and bulk-forming drugs

Adsorbents such as kaolin p. 66 are not recommended for acute diarrhoeas. Bulk-forming drugs, such as ispaghula husk p. 53, methylcellulose p. 53, and sterculia p. 54 are useful in controlling diarrhoea associated with diverticular disease. Colestryramine p. 191 binds unabsorbed bile salts and provides symptomatic relief of diarrhoea following ileal disease or resection.

Enkephalinase inhibitors

Racecadotril p. 66 is a pro-drug of thiorphan. Thiorphan is an enkephalinase inhibitor that inhibits the breakdown of endogenous opioids, thereby reducing intestinal secretions. Racecadotril is licensed, as an adjunct to rehydration, for the symptomatic treatment of uncomplicated acute diarrhoea; it should only be used in children over 3 months of age when usual supportive measures, including oral rehydration, are insufficient to control the condition. Racecadotril does not affect the duration of intestinal transit.

Other drugs used for Diarrhoea: Codeine phosphate, p. 431

Co-phenotre

INDICATIONS AND DOSE

Adjucent to rehydration in acute diarrhoea

BY MOUTH

- Child 4-8 years: 1 tablet 3 times a day
- Child 9-11 years: 1 tablet 4 times a day
- Child 12-15 years: 2 tablets 3 times a day
- Child 16-17 years: Initially 4 tablets, followed by 2 tablets every 6 hours until diarrhoea controlled
- Adult: Initially 4 tablets, followed by 2 tablets every 6 hours until diarrhoea controlled

Control of faecal consistency after colostomy or ileostomy

BY MOUTH

- Child 4-8 years: 1 tablet 3 times a day
- Child 9-11 years: 1 tablet 4 times a day
- Child 12-15 years: 2 tablets 3 times a day
- Child 16-17 years: Initially 4 tablets, then 2 tablets 4 times a day
- Adult: Initially 4 tablets, then 2 tablets 4 times a day

• UNLICENSED USE: Not licensed for use in children under 4 years.
• CONTRA-INDICATIONS: Gastro-intestinal obstruction • intestinal atony • myasthenia gravis (but some antimuscarinics may be used to decrease muscarinic side-effects of anticholinesterases) • paralytic ileus • prostatic enlargement (in adults) • pyloric stenosis • severe ulcerative colitis • significant bladder outflow obstruction • toxic megacolon • urinary retention

• CAUTIONS: Presence of subclinical doses of atropine may give rise to atropine side-effects in susceptible individuals or in overdosage. Young children are particularly susceptible to overdosage. Symptoms may be delayed and observation is needed for at least 48 hours after ingestion.

• INTERACTIONS: Appendix 1: atropine, opioids

• SIDE-EFFECTS

- Very rare: Angle-closure glaucoma
- Frequency not known: Abdominal pain • anorexia • confusion (particularly in the elderly) • constipation • dilation of the pupils with loss of accommodation • dry mouth • dryness of the skin • fever • flushing • giddiness • nausea • photophobia • reduced bronchial secretions • transient bradycardia (followed by tachycardia, palpitation and arrhythmias) • urinary retention • urinary urgency • vomiting

• PREGNANCY: Manufacturer advises caution.
• BREAST FEEDING: May be present in milk.
• HEPATIC IMPAIRMENT: Avoid in jaundice.
• DIRECTIONS FOR ADMINISTRATION: For administration by mouth tablets may be crushed.
• PRESCRIBING AND DISPENSING INFORMATION: A mixture of diphenoxylate hydrochloride and atropine sulfate in the mass proportions 100 parts to 1 part respectively.

• EXCEPTIONS TO LEGAL CATEGORY: Co-phenotre 2.5/0.025 can be sold to the public for adults and children over 16 years (provided packs do not contain more than 20 tablets) as an adjunct to rehydration in acute diarrhoea (max. daily dose 10 tablets).
**Contraindications**

- Acute abdomen · delayed gastric emptying · heart failure secondary to chronic lung disease · phaeochromocytoma

**Cautions**

Cardiac arrhythmias · pancreatitis · severe cor pulmonale

**Interactions**

- Abdominal pain · agitation · amenorrhoea · anorexia · asthenia · bronchospasm · delirium · disorientation · dyspepsia · exacerbation of pancreatitis · excitation · hypotension · hypothermia · inhibition of cough reflex · malaise · muscle fasciculation · myoclonus · nystagmus · paraesthesia · paralytic ileus · raised intracranial pressure · restlessness · rhabdomyolysis · seizures · syncope · taste disturbance

**Breastfeeding**

Therapeutic doses unlikely to affect infant.

**Renal Impairment**

Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.

**Prescribing and Dispensing Information**

When prepared extemporaneously, the BP states Kaolin and Morphine Mixture, BP consists of light kaolin or light kaolin (natural) 20%, sodium bicarbonate 5%, and chloroform and morphine tincture 4% in a suitable vehicle. Contains anhydrous morphine 550–800 micrograms/10 mL.

**Less Suitable for Prescribing**

Kaolin and Morphine Mixture, BP (Kaolin and Morphine Oral Suspension) is less suitable for prescribing.

**Medicinal Forms**

There can be variation in the licensing of different medicines containing the same drug.

**Oral Suspension**

- **Kaolin with morphine (Non-proprietary)**
  - Morphine hydrochloride 91.6 microgram per 1 mL, Sodium bicarbonate 50 mg per 1 mL, Kaolin light 200 mg per 1 mL, Chlorof orm 5 mL per 1 litre Kaolin and Morphine mixture 1 200 ml  
  - £1.67 DT price = £1.67 (GS)

**Loperamide Hydrochloride**

**Indications and Dose**

Symptomatic treatment of acute diarrhoea

- **By mouth**
  - Child 4-7 years: 1 mg 3–4 times a day for up to 3 days only
  - Child 8-11 years: 2 mg 4 times a day for up to 5 days
  - Child 12-17 years: Initially 4 mg, followed by 2 mg for up to 5 days, dose to be taken after each loose stool; usual dose 6–8 mg daily; maximum 16 mg per day

**Chronic diarrhoea**

- **By mouth**
  - Adult: Initially 4–8 mg daily in divided doses, adjusted according to response; maintenance up to 16 mg daily in 2 divided doses

**Faecal incontinence**

- **By mouth**
  - Adult: Initially 500 micrograms daily, adjusted according to response, maximum daily dose to be given in divided doses; maximum 16 mg per day

**Pain of bowel colic in palliative care**

- **By mouth**
  - Adult: 2–4 mg 4 times a day

**Unlicensed Use**

- In children **Capsules** not licensed for use in children under 8 years. **Syrup** not licensed for use in children under 4 years.

- In adults Use for faecal incontinence is an unlicensed indication.

**Contra-Indications**

Active ulcerative colitis · antibiotic-associated colitis · conditions where abdominal distension develops · conditions where inhibition of peristalsis should be avoided

**Cautions**

Not recommended for children under 12 years (in children)

**Interactions**

- **Common or very common**
  - Dizziness · flatulence · headache · nausea

- **Uncommon**
  - Abdominal pain · drowsiness · dry mouth · dyspepsia · rash · vomiting

- **Rare**
  - Fatigue · hypotonia · paralytic ileus · Stevens-Johnson syndrome · toxic epidermal necrolysis · urinary retention

**Pregnancy**

Manufacturers advise avoid—not information available.

**Breastfeeding**

Amount probably too small to be harmful.

**Hepatic Impairment**

Risk of accumulation—manufacturer advises caution.

**Prescribing and Dispensing Information**

Palliative care


**Patient and Carer Advice**

Medicines for Children leaflet: Loperamide for diarrhoea [www.medicinesforchildren.org.uk/loperamide-for-diarrhoea](http://www.medicinesforchildren.org.uk/loperamide-for-diarrhoea)

**Exceptions to Legal Category**

Loperamide can be sold to the public, for use in adults and children over 12 years, provided it is licensed and labelled for the treatment of acute diarrhoea.

In adults Loperamide can be sold to the public, provided it is licensed and labelled for the treatment of acute diarrhoea associated with irritable bowel syndrome (after initial diagnosis by a doctor) in adults over 18 years of age.

**Medicinal Forms**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Tablet**

- **Loperamide hydrochloride (Non-proprietary)**
  - Loperamide hydrochloride 2 mg Loperamide 2mg tablets  | 30 tablet  
  - £2.15 DT price = £2.15
Loperamide with simeticone

The properties listed below are those particular to the combination only. For the properties of the components please consider, loperamide hydrochloride p. 65, simeticone p. 70.

**INDICATIONS AND DOSE**

**Acute diarrhoea with abdominal colic**
- **By mouth**
  - Child 12-17 years: Initially 1 tablet, then 1 tablet, after each loose stool, for up to 2 days; maximum 4 tablets per day
  - Adult: Initially 2 tablets, then 1 tablet, after each loose stool, for up to 2 days; maximum 4 tablets per day

**INTERACTIONS** → Appendix 1: loperamide

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- **Imodium Plus** (McNeil Products Ltd)
  - Loperamide hydrochloride 2 mg, Simeticone (as Simeticone)
    - 125 mg Imodium Plus caplets | 12 tablet (£3.66

ANTIDIARRHOEALS > ENKEPHALINASE INHIBITORS

**Racecadotril**

**INDICATIONS AND DOSE**

Adjuvact to rehydration, for the symptomatic treatment of uncomplicated acute diarrhoea
- **By mouth using capsules**
  - Adult: Initially 100 mg, then 100 mg 3 times a day until diarrhoea stops; maximum duration of treatment 7 days, dose to be taken preferably before food
  - **By mouth using granules**
    - Child 3 months-17 years (body-weight up to 9 kg): 10 mg 3 times a day until diarrhoea stops; maximum duration of treatment 7 days
    - Child 3 months-17 years (body-weight 9-12 kg): 20 mg 3 times a day until diarrhoea stops; maximum duration of treatment 7 days
    - Child 3 months-17 years (body-weight 13-27 kg): 30 mg 3 times a day until diarrhoea stops; maximum duration of treatment 7 days
    - Child 3 months-17 years (body-weight 28 kg and above): 60 mg 3 times a day until diarrhoea stops; maximum duration of treatment 7 days

**SIDE-EFFECTS**
- **Common or very common** Headache (in adults)
- **Uncommon** Erythema, rash
- **Frequency not known** Angioedema, pruritus, urticaria

**SIDE-EFFECTS, FURTHER INFORMATION**

Skin reactions Severe skin reactions have been reported—discontinue treatment immediately.

**PREGNANCY**

Manufacturer advises avoid—no information available.

**BREAST FEEDING**

Manufacturer advises avoid—no information available.

**HEPATIC IMPAIRMENT**

- In adults: Manufacturer advises caution.
- In children: Manufacturer advises avoid.

**RENAL IMPAIRMENT**

- In adults: Manufacturer advises caution.
- In children: Manufacturer advises avoid.

**DIRECTIONS FOR ADMINISTRATION**

Granules may be added to food or mixed with water or bottle feeds and then taken immediately.

**PATIENT AND CARER ADVICE**

Patients and carers should be given advice on how to administer racecadotril capsules.

**NATIONAL FUNDING/ACCESS DECISIONS**

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium, has advised (July 2014) that racecadotril (Hidrasec®) is not recommended for use within NHS Scotland for the treatment of acute diarrhoea in children because there is insufficient evidence that it improves the recovery rate.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Granules**
- **EXCIPIENTS:** May contain Sucrose
  - Hidrasec (Lincoln Medical Ltd)
    - Racecadotril 10 mg: Hidrasec infants 10mg granules sachets | 20 sachet (£8.42
    - Racecadotril 30 mg: Hidrasec Children 30mg granules sachets | 20 sachet (£8.42

ANTIDIARRHOEALS > INTESTINAL ADSORBENTS

**Kaolin**

**INDICATIONS AND DOSE**

Diarrhoea (not recommended for acute diarrhoea)
- **By mouth**
  - Adult: 10–20 ml every 4 hours

**INTERACTIONS** → Appendix 1: kaolin

**DIRECTIONS FOR ADMINISTRATION**

Warm and apply poultice directly or between layers of muslin; avoid application of overheated poultice.

**PRESCRIBING AND DISPENSING INFORMATION**

Flavours of oral liquid formulations may include peppermint.

When prepared extemporaneously, the BP states Kaolin mixture, BP consists of light kaolin or light kaolin (natural) 20%, light magnesium carbonate 5%, sodium bicarbonate 5% in a suitable vehicle with a peppermint flavour.

**LESS SUITABLE FOR PRESCRIBING**

Kaolin Mixture BP is less suitable for prescribing.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. No licensed medicines listed.
4 Disorders of gastric acid and ulceration

4.1 Dyspepsia

**Dyspepsia**

**Overview**

Dyspepsia covers upper abdominal pain, fullness, early satiety, bloating, and nausea. It can occur with gastric and duodenal ulceration and, gastric cancer, but most commonly it is of uncertain origin.

Urgent endoscopic investigation is required if dyspepsia is accompanied by ‘alarm features’ (e.g. bleeding, dysphagia, recurrent vomiting, or weight loss). Urgent investigation should also be considered for patients over 55 years with unexplained, recent-onset dyspepsia that has not responded to treatment.

Patients with dyspepsia should be advised about lifestyle changes (avoidance of excess alcohol and of aggravating foods such as fats); other measures include weight reduction, smoking cessation, and raising the head of the bed. Some medications may cause dyspepsia—these should be stopped, if possible.

Antacids may provide some symptomatic relief, however if symptoms persist in uninvestigated dyspepsia, treatment involves a proton pump inhibitor for up to 4 weeks. A proton pump inhibitor can be used intermittently to control symptoms long term. Patients with uninvestigated dyspepsia, who do not respond to an initial trial with a proton pump inhibitor, should be tested for Helicobacter pylori and given eradication therapy if *H. pylori* is present. Alternatively, particularly in populations where *H. pylori* infection is more likely, the ‘test and treat’ strategy for *H. pylori* can be used before a trial with a proton pump inhibitor.

If *H. pylori* is present in patients with functional (investigated, non-ulcer) dyspepsia, eradication therapy should be provided. If symptoms persist, treatment with either a proton pump inhibitor or a histamine H₂-receptor antagonist can be given for 4 weeks. These antisecretory drugs can be used intermittently to control symptoms long term. However, most patients with functional dyspepsia do not benefit symptomatically from *H. pylori* eradication therapy or antisecretory drugs.

**Antacids**

Antacids (usually containing aluminium or magnesium compounds) can often relieve symptoms in ulcer dyspepsia and in non-erosive gastro-oesophageal reflux; they are also sometimes used in functional (non-ulcer) dyspepsia but the evidence of benefit is uncertain. Antacids are best given when symptoms occur or are expected, usually between meals and at bedtime, although additional doses may be required. Conventional doses of liquid magnesium–aluminium antacids promote ulcer healing, but less well than antisecretory drugs; proof of a relationship between healing and neutralising capacity is lacking. Liquid preparations are more effective than tablet preparations.

Aluminium- and magnesium-containing antacids (e.g. aluminium hydroxide p. 964, magnesium carbonate p. 69, co-magdalrox p. 68 and magnesium trisilicate p. 69), being relatively insoluble in water, are long-acting if retained in the stomach. They are suitable for most antacid purposes. Magnesium-containing antacids tend to be laxative whereas aluminium-containing antacids may be constipating; antacids containing both magnesium and aluminium may reduce these colonic side-effects. Aluminium accumulation does not appear to be a risk if renal function is normal.

The acid-neutralising capacity of preparations that contain more than one antacid may be the same as simpler preparations. Complexes such as hydrotalcite confer no special advantage.

Sodium bicarbonate p. 950 should no longer be prescribed alone for the relief of dyspepsia but it is present as an ingredient in many indigestion remedies. However, it retains a place in the management of urinary-tract disorders and acidosis.

Bismuth-containing antacids (unless chelates) are not recommended because absorbed bismuth can be neurotoxic, causing encephalopathy; they tend to be constipating.

Calcium-containing antacids can induce rebound acid secretion: with modest doses the clinical significance is doubtful, but prolonged high doses also cause hypercalcaemia and alkalosis, and can precipitate the milk-alkali syndrome.

**Simeticone**

Simeticone p. 70 (activated dimeticone p. 1134) is added to an antacid as an antifoaming agent to relieve flatulence. These preparations may be useful for the relief of hiccup in palliative care.

**Alginates**

Alginates taken in combination with an antacid increases the viscosity of stomach contents and can protect the oesophageal mucosa from acid reflux. Some alginate-containing preparations form a viscous gel (‘raft’) that floats on the surface of the stomach contents, thereby reducing symptoms of reflux. The amount of additional ingredient or antacid in individual preparations varies widely, as does their sodium content, so that preparations may not be freely interchangeable.

**ANTACIDS > ALGINATE**

**Alginic acid**

+ INDICATIONS AND DOSE
+ **GAVISCON INFANT® POWDER SACHETS**

Management of gastro-oesophageal reflux disease

▶ BY MOUTH

- Child 1–23 months (body-weight 4.5 kg and above): 1 dose as required, to be mixed with feeds (or water, for breast-fed infants); maximum 6 doses per day
- Child 1–23 months (body-weight 4.5 kg and above): 2 doses as required, to be mixed with feeds (or water, for breast-fed infants); maximum 12 doses per day

+ CONTRA-INDICATIONS

- Intestinal obstruction • preterm neonates • where excessive water loss likely (e.g. fever, diarrhoea, vomiting, high room temperature)

**GAVISCON INFANT® POWDER SACHETS**

Concurrent use of preparations containing thickening agents

+ **HEPATIC IMPAIRMENT**

In patients with fluid retention, avoid antacids containing large amounts of sodium. Avoid antacids containing magnesium salts in hepatic coma if there is a risk of renal failure.

+ **RENAL IMPAIRMENT**

In patients with fluid retention, avoid antacids containing large amounts of sodium.

+ **PRESCRIBING AND DISPENSING INFORMATION**

Each half of the dual-sachet is identified as ‘one dose’. To avoid errors prescribe with directions in terms of ‘dose’.
ANTACIDS > ALUMINIUM AND MAGNESIUM

Co-magaldrox

The properties listed below are those particular to the combination only. For the properties of the components please consider, aluminium hydroxide p. 964, magnesium hydroxide p. 57.

● INDICATIONS AND DOSE

MAALOX 

Dyspepsia

▷ BY MOUTH
  ▷ Child 14–17 years: 10–20 mL, to be taken 20–60 minutes after meals, and at bedtime or when required
  ▷ Adult: 10–20 mL, to be taken 20–60 minutes after meals, and at bedtime or when required

MUCOGEL®

Dyspepsia

▷ BY MOUTH
  ▷ Child 12–17 years: 10–20 mL 3 times a day, to be taken 20–60 minutes after meals, and at bedtime, or when required
  ▷ Adult: 10–20 mL 3 times a day, to be taken 20–60 minutes after meals, and at bedtime, or when required

● INTERACTIONS → Appendix 1: antacids

● PRESCRIBING AND DISPENSING INFORMATION

Co-magaldrox is a mixture of aluminium hydroxide and magnesium hydroxide; the proportions are expressed in the form x/y where x and y are the strengths in milligrams per unit dose of magnesium hydroxide and aluminium hydroxide respectively.

MUCOGEL® Mucogel® suspension is low in sodium.

MAALOX® Maalox® suspension is low in sodium.

● MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Oral suspension

ELECTROLYTES: May contain Potassium, sodium
  ▷ Acidex Advance (Pinewood Healthcare) Magnesium bicarbonate 20 mg per 1 mL, Sodium alginate 100 mg per 1 mL Acidex Advance oral suspension dried peppermint sugar-free | 250 mL [P] £0.21 sugar-free | 500 mL [P] £0.42 DT price = £0.12
  ▷ Gaviscon Infant (Chemidex Pharma Ltd) Magnesium bicarbonate 25 mg per 1 mL, Sodium alginate 225 mg Gaviscon Infant oral powder sachets sugar-free | 15 dual dose sachet [GL] £0.82 DT price = £0.82

Chewable tablet

EXCIPIENTS: May contain Aspartame
ELECTROLYTES: May contain Potassium, sodium
  ▷ Sodium alginate with potassium bicarbonate (Non-proprietary) Potassium bicarbonate 100 mg, Sodium alginate 500 mg Sodium alginate 500mg / Potassium bicarbonate 100mg chewable tablets sugar free sugar-free | 60 tablet [GL] no price available DT price = £3.07
  ▷ Brands may include Gaviscon Advance

Co-simalcite

● INDICATIONS AND DOSE

Dyspepsia

▷ BY MOUTH
  ▷ Child 8–11 years: 5 mL 4 times a day as required, to be taken between meals and at bedtime
  ▷ Child 12–17 years: 10 mL 4 times a day as required, to be taken between meals and at bedtime
  ▷ Adult: 10 mL 4 times a day as required, to be taken between meals and at bedtime

● CONTRA-INDICATIONS

Hypophosphataemia · infants · neonates
CONTRA-INDICATIONS, FURTHER INFORMATION
  ▷ Aluminium-containing antacids Aluminium-containing antacids should not be used in neonates and infants because accumulation may lead to increased plasma-aluminium concentrations.
**SIDE-EFFECTS**

**SIDE-EFFECTS, FURTHER INFORMATION**

- Constipation and diarrhoea: Magnesium-containing antacids tend to be laxative whereas aluminium-containing antacids may be constipating; antacids containing both magnesium and aluminium may reduce these colonic side-effects.

**HEPATIC IMPAIRMENT** Avoid; can cause constipation which can precipitate coma. Avoid in hepatic coma; risk of renal failure.

**RENAL IMPAIRMENT** Antacids containing magnesium salts should be avoided or used at a reduced dose because there is an increased risk of toxicity.

- In adults: There is a risk of accumulation and aluminium toxicity with antacids containing aluminium salts. Absorption of aluminium from aluminium salts is increased by citrates, which are contained in many effervescent preparations (such as effervescent analgesics).
- In children: Aluminium-containing antacids should not be used in children with renal impairment, because accumulation may lead to increased plasma-aluminium concentrations.

**PRESCRIBING AND DISPENSING INFORMATION**

**Magnesium trisilicate**

- **INDICATIONS AND DOSE**
  - **Dyspepsia**
    - **BY MOUTH USING CHEWABLE TABLETS**
      - Adult: 1–2 tablets as required

- **CONTRA-INDICATIONS**
  - Hypophosphataemia

- **INTERACTIONS**
  - Appendix 1: antacids

**Magnesium carbonate with magnesium hydroxide and aluminium hydroxide**

The properties listed below are those particular to the combination only. For the properties of the components please consider, simeticone p. 70, aluminium hydroxide p. 964.

- **INDICATIONS AND DOSE**
  - **Dyspepsia**
    - **BY MOUTH**
      - Child 12-17 years: 5–10 mL 4 times a day, to be taken after meals and at bedtime, or when required
      - Adult: 5–10 mL 4 times a day, to be taken after meals and at bedtime, or when required

- **INTERACTIONS**
  - Appendix 1: antacids

**Médicinales**

There can be variation in the licensing of different medicines containing the same drug.

**Oral suspension**

- **Altacite Plus** (Peckforton Pharmaceuticals Ltd)
  - Simeticone 25 mg per 1 mL, Hydrotalcite 100 mg per 1 mL
  - Alumina lactate oral suspension sugar-free: 100 mL £4.00 sugar-free / 500 ml £5.20 DT price = £5.20

**Antacids > Magnesium**

**Magnesium carbonate**

- **INDICATIONS AND DOSE**
  - **Dyspepsia**
    - **BY MOUTH USING ORAL SUSPENSION**
      - Adult: 10 mL 3 times a day, dose to be taken in water

- **CONTRA-INDICATIONS**
  - Hypophosphataemia

**Magnesium trisilicate with magnesium carbonate and sodium bicarbonate**

The properties listed below are those particular to the combination only. For the properties of the components please consider, magnesium trisilicate above, magnesium carbonate above, sodium bicarbonate p. 950.

- **INDICATIONS AND DOSE**
  - **Dyspepsia**
    - **BY MOUTH**
      - Child 5-11 years: 5–10 mL 3 times a day, alternatively as required, dose to be made up with water
      - Child 12-17 years: 10–20 mL 3 times a day, alternatively as required, dose to be made up with water
      - Adult: 10–20 mL 3 times a day, alternatively as required, dose to be made up with water

- **CONTRA-INDICATIONS**
  - Hypophosphataemia • Severe renal failure

- **CAUTIONS**
  - Heart failure • Hypomagnesaemia • Hypertension • Metabolic alkalosis • Respiratory alkalosis

- **INTERACTIONS**
  - Appendix 1: antacids

- **SIDE-EFFECTS**
  - Belching due to liberated carbon dioxide • Diarrhoea
**Gastro-intestinal system**

- **HEPATIC IMPAIRMENT** In patients with fluid retention avoid antacids containing large amounts of sodium. Avoid antacids containing magnesium salts in hepatic coma if there is a risk of renal failure.
- **RENAAL IMPAIRMENT** Magnesium trisilicate and magnesium carbonate mixtures have high sodium content; avoid in patients with fluid retention.
- **PRESCRIBING AND DISPENSING INFORMATION** When prepared extemporaneously, the BP states Magnesium Trisilicate Mixture, BP consists of 5% each of magnesium trisilicate, light magnesium carbonate, and sodium bicarbonate in a suitable vehicle with a peppermint flavour.

**MEDITCINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Oral suspension**

- Magnesium trisilicate with magnesium carbonate and sodium bicarbonate (Non-proprietary).
- Magnesium carbonate light 50 mg per 1 ml, Magnesium trisilicate 50 mg per 1 ml, Sodium bicarbonate 50 mg per 1 ml Magnesium trisilicate oral suspension | 200 ml £1.65 DT price = £1.65

**MEDITCINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Oral suspension**

- Magnesium trisilicate with magnesium carbonate and sodium bicarbonate (Non-proprietary).
- Magnesium carbonate light 50 mg per 1 ml, Magnesium trisilicate 50 mg per 1 ml, Sodium bicarbonate 50 mg per 1 ml Magnesium trisilicate oral suspension | 200 ml £1.65 DT price = £1.65

**ANTIOFOAMING DRUGS**

**Simeticone (Activated dimeticone)**

- **DRUG ACTION** Simeticone (activated dimeticone) is an antifoaming agent.

- **INDICATIONS AND DOSE**
  - **DENTINOX®**
    - **Colic / Wind pains**
      - **BY MOUTH**
        - Child 1 month–1 year: 2.5 mL, to be taken with or after each feed; may be added to bottle feed; maximum 6 doses per day
      - **INFACOL®**
        - **Colic / Wind pains**
          - **BY MOUTH**
            - Child 1 month–1 year: 0.5–1 mL, to be taken before feeds

- **PRESCRIBING AND DISPENSING INFORMATION**
  - **DENTINOX®** The brand name Dentinox® is also used for other preparations including teething gel.
  - **PATIENT AND CARER ADVICE**
    - **INFACOL®** Patients or carers should be given advice on use of the Infacol® dropper.
  - **LESS SUITABLE FOR PRESCRIBING**
    - **INFACOL®** Infacol® is less suitable for prescribing (evidence of benefit in infantile colic uncertain).
    - **DENTINOX®** Dentinox® colic drops are less suitable for prescribing (evidence of benefit in infantile colic uncertain).

- **MEDITCINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Oral suspension**

- **Infacol** (Teva UK Ltd)
  - Simeticone 40 mg per 1 ml Infacol 40mg/ml oral suspension sugar-free | 50 ml £2.71 DT price = £2.71
- **Dentinox Infant** (Dendron Ltd)
  - Simeticone 8.4 mg per 1 ml Dentinox infant colic drops | 100 ml £1.73

Combinations available: Co-similacite, p. 68 · Simeticone with aluminium hydroxide and magnesium hydroxide, p. 69

---

**4.2 Gastric and duodenal ulceration**

**Peptic ulceration**

**Overview**

Peptic ulceration commonly involves the stomach, duodenum, and lower oesophagus; after gastric surgery it involves the gastro-enterostomy stoma. Healing can be promoted by general measures, stopping smoking and taking antacids and by antisecretory drug treatment, but relapse is common when treatment ceases. Nearly all duodenal ulcers and most gastric ulcers not associated with NSAIDs are caused by Helicobacter pylori.

**Helicobacter pylori infection**

Eradication of Helicobacter pylori reduces recurrence of gastric and duodenal ulcers and the risk of rebleeding. It also causes regression of most localised gastric mucosa associated lymphoid-tissue (MALT) lymphomas. The presence of H. pylori should be confirmed before starting eradication treatment. Acid inhibition combined with antibacterial treatment is highly effective in the eradication of H. pylori; reinfection is rare. Antibiotic associated colitis is an uncommon risk.

For initial treatment, a one-week triple-therapy regimen that comprises a proton pump inhibitor, clarithromycin p. 508, and either amoxicillin p. 518 or metronidazole p. 512 can be used. However, if a patient has been treated with metronidazole for other infections, a regimen containing a proton pump inhibitor, amoxicillin and clarithromycin is preferred for initial therapy. If a patient has been treated with a macrolide for other infections, a regimen containing a proton pump inhibitor, amoxicillin and metronidazole is preferred for initial therapy. These regimens eradicate H. pylori in about 85% of cases. There is usually no need to continue antisecretory treatment (with a proton pump inhibitor or H2-receptor antagonist), however, if the ulcer is large, or complicated by haemorrhage or perforation, then antisecretory treatment is continued for a further 3 weeks. Treatment failure usually indicates antibacterial resistance or poor compliance. Resistance to amoxicillin is rare. However, resistance to clarithromycin and metronidazole is common and can develop during treatment.

Two-week triple-therapy regimens offer the possibility of higher eradication rates compared to one-week regimens, but adverse effects are common and poor compliance is likely to offset any possible gain.

Two-week dual-therapy regimens using a proton pump inhibitor and a single antibacterial are licensed, but produce low rates of H. pylori eradication and are not recommended. Tinidazole p. 514 is also used occasionally for H. pylori eradication as an alternative to metronidazole; tinidazole should be combined with antisecretory drugs and other antibacterials.

Routine retesting, to confirm eradication, is not necessary unless the patient has gastric MALT lymphoma or complicated H. pylori associated peptic ulcer.

A two-week regimen comprising a proton pump inhibitor plus tripotassium dicitratobismuthate, plus tetracycline p. 536, plus metronidazole can be used for eradication failure. Alternatively, the patient can be referred for endoscopy and treatment based on the results of culture and sensitivity testing.

See under NSAID-associated ulcers for the role of H. pylori eradication therapy in patients starting or taking a NSAID. Also see Dyspepsia p. 67 for H. pylori eradication in patients with dyspepsia.
Recommended regimens for *Helicobacter pylori* eradication in adults

<table>
<thead>
<tr>
<th>Acid suppressant</th>
<th>Antibacterial</th>
<th>Metronidazole</th>
<th>Price for 7-day course</th>
</tr>
</thead>
<tbody>
<tr>
<td>Esomeprazole 20 mg twice daily</td>
<td>1 g twice daily</td>
<td>500 mg twice daily</td>
<td>£6.63</td>
</tr>
<tr>
<td></td>
<td>250 mg twice daily</td>
<td>400 mg twice daily</td>
<td>£4.30</td>
</tr>
<tr>
<td>Lansoprazole 30 mg twice daily</td>
<td>1 g twice daily</td>
<td>500 mg twice daily</td>
<td>£5.52</td>
</tr>
<tr>
<td></td>
<td>1 g twice daily</td>
<td>250 mg twice daily</td>
<td>£3.70</td>
</tr>
<tr>
<td>Omeprazole 20 mg twice daily</td>
<td>1 g twice daily</td>
<td>500 mg twice daily</td>
<td>£5.36</td>
</tr>
<tr>
<td></td>
<td>500 mg 3 times a day</td>
<td>400 mg 3 times a day</td>
<td>£3.03</td>
</tr>
<tr>
<td>Pantoprazole 40 mg twice daily</td>
<td>1 g twice daily</td>
<td>500 mg twice daily</td>
<td>£5.48</td>
</tr>
<tr>
<td></td>
<td>250 mg twice daily</td>
<td>400 mg twice daily</td>
<td>£3.15</td>
</tr>
<tr>
<td>Rabeprazole sodium 20 mg twice daily</td>
<td>1 g twice daily</td>
<td>500 mg twice daily</td>
<td>£6.04</td>
</tr>
<tr>
<td></td>
<td>250 mg twice daily</td>
<td>400 mg twice daily</td>
<td>£3.71</td>
</tr>
</tbody>
</table>

**Test for *Helicobacter pylori***

13C-Urea breath test kits are available for the diagnosis of gastro-duodenal infection with *Helicobacter pylori*. The test involves collection of breath samples before and after ingestion of an oral solution of 13C-urea; the samples are sent for analysis by an appropriate laboratory. The test should not be performed within 4 weeks of treatment with an antibacterial or within 2 weeks of treatment with an antisecretory drug. A specific 13C-urea breath test kit for children is available (*Helicobacter Test INFAI* for children of the age 3–11). However, the appropriateness of testing for *H. pylori* infection in children has not been established.

**NSAID-associated ulcers**

Gastro-intestinal bleeding and ulceration can occur with NSAID use. The risk of serious upper gastro-intestinal side-effects varies between individual NSAIDs. Whenever possible, the NSAID should be withdrawn if an ulcer occurs.

Patients at high risk of developing gastro-intestinal complications with a NSAID include those aged over 65 years, those with a history of peptic ulcer disease or serious gastro-intestinal complication, those taking other medicines that increase the risk of gastro-intestinal side-effects, or those with serious co-morbidity (e.g. cardiovascular disease, diabetes, renal or hepatic impairment). In those at risk of ulceration, a proton pump inhibitor can be considered for protection against gastric and duodenal ulcers associated with non-selective NSAIDs; a H2-receptor antagonist such as ranitidine p. 74 given at twice the usual dose or misoprostol p. 75 are alternatives. Colic and diarrhoea may limit the dose of misoprostol. Its use is most appropriate for the frail or very elderly from whom NSAIDs cannot be withdrawn. A combination of a cyclo-oxygenase-2 selective inhibitor with a proton pump inhibitor may be more appropriate for those with a history of upper gastro-intestinal bleeding or 3 or more risk factors for gastro-intestinal ulceration, but see NSAIDs and Cardiovascular Events.

NSAID use and *H. pylori* infection are independent risk factors for gastro-intestinal bleeding and ulceration. In patients already taking a NSAID, eradication of *H. pylori* is unlikely to reduce the risk of NSAID-induced bleeding or ulceration. However, in patients with dyspepsia or a history of gastric or duodenal ulcer, who are *H. pylori* positive, and who are about to start long-term treatment with a non-selective NSAID, eradication of *H. pylori* may reduce the overall risk of ulceration.

In a patient who has developed an ulcer, if the NSAID can be discontinued, a proton pump inhibitor usually produces the most rapid healing; alternatively, the ulcer can be treated with a H2-receptor antagonist or misoprostol. On healing, patients should be tested for *H. pylori* and given eradication therapy if *H. pylori* is present (see also Test for *Helicobacter pylori*).

If treatment with a non-selective NSAID needs to continue, the following options are suitable:

- Treat ulcer with a proton pump inhibitor and on healing continue the proton pump inhibitor (dose not normally reduced because asymptomatic ulcer recurrence may occur);
- Treat ulcer with a proton pump inhibitor and on healing switch to misoprostol for maintenance therapy (colic and diarrhoea may limit the dose of misoprostol);
- Treat ulcer with a proton pump inhibitor and switch non-selective NSAID to a cyclo-oxygenase-2 selective inhibitor, but see NSAIDs and Cardiovascular Events; on healing, continuation of the proton pump inhibitor in patients with a history of upper gastro-intestinal bleeding may provide further protection against recurrence.

If treatment with a cyclo-oxygenase-2 selective inhibitor needs to continue, treat ulcer with a proton pump inhibitor; on healing continuation of the proton pump inhibitor in patients with a history of upper gastro-intestinal bleeding may provide further protection against recurrence.

**GASTROPROTECTIVE COMPLEXES AND CHELATORS**

**Chelates and complexes**

**Overview**

Sucralfate below may act by protecting the mucosa from acid-pepsin attack in gastric and duodenal ulcers. It is a complex of aluminium hydroxide and sulfated sucrose but has minimal antacid properties.

**Sucralfate**

- **INDICATIONS AND DOSE**

  **Benign gastric ulceration | Benign duodenal ulceration**

  - By mouth
    - Child 15–17 years: 2 g twice daily, dose to be taken on rising and at bedtime, alternatively 1 g 4 times a day for 4–6 weeks, or in resistant cases up to 12 weeks, dose to be taken 1 hour before meals and at bedtime; maximum 8 g per day
    - Adult: 2 g twice daily, dose to be taken on rising and at bedtime, alternatively 1 g 4 times a day for 4–6 weeks, or in resistant cases up to 12 weeks, dose to be taken 1 hour before meals and at bedtime; maximum 8 g per day
Chronic gastritis
- **BY MOUTH**
- **Adult**: 2 g twice daily, dose to be taken on rising and at bedtime, alternatively 1 g 4 times a day for 4–6 weeks or in resistant cases up to 12 weeks, dose to be taken 1 hour before meals and at bedtime; maximum 8 g per day

**Prophylaxis of stress ulceration in child under intensive care**
- **BY MOUTH**
- **Child 15-17 years**: 1 g 6 times a day; maximum 8 g per day

**Prophylaxis of stress ulceration**
- **BY MOUTH**
- **Adult**: 1 g 6 times a day; maximum 8 g per day

**UNLICENSED USE**

**CAUTIONS**
Patients under intensive care (Important: reports of bezoar formation)

**CAUTIONS, FURTHER INFORMATION**
Bezoar formation Following reports of bezoar formation associated with sucralfate, caution is advised in seriously ill patients, especially those receiving concomitant enteral feeds or those with predisposing conditions such as delayed gastric emptying.

**INTERACTIONS** → Appendix 1: sucralfate

**SIDE-EFFECTS**
- **Common or very common** Constipation
- **Uncommon** Back pain · bezoar formation · diarrhoea · dizziness · drowsiness · dry mouth · earache · flatulence · gastric discomfort · indigestion · nausea · rash

**PREGNANCY**
No evidence of harm; absorption from gastrointestinal tract negligible.

**BREAST FEEDING**
Amount probably too small to be harmful.

**RENAL IMPAIRMENT**
Use with caution; aluminium is absorbed and may accumulate.

**DIRECTIONS FOR ADMINISTRATION**
Administration of sucralfate and enteral feeds should be separated by 1 hour and for administration by mouth, sucralfate should be given 1 hour before meals. *Oral suspension* blocks fine-bore feeding tubes. Crushed *tablets* may be dispersed in water.

**PRESCRIBING AND DISPENSING INFORMATION**
Flavours of oral liquid formulations may include aniseed and caramel.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, oral suspension

*Tablet*
CAUTIONYAR AND ADVISORY LABELS 5
- *Sucralfate (Non-proprietary)*
- *Sucralfate 1 gram* Sulcrate 1g tablets | 100 tablet no price available Carafate 1g tablets | 100 tablet no price available

### H$_2$-RECEPTOR ANTAGONISTS

#### H$_2$-receptor antagonists

**Overview**
Histamine H$_2$-receptor antagonists heal gastric and duodenal ulcers by reducing gastric acid output as a result of histamine H$_2$-receptor blockade; they are also used to relieve symptoms of gastro-oesophageal reflux disease. H$_2$-receptor antagonists should not normally be used for Zollinger-Ellison syndrome because proton pump inhibitors are more effective.

**H$_2$-receptor antagonists**

<table>
<thead>
<tr>
<th><strong>H$_2$-receptor antagonists</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Overview</strong></td>
</tr>
<tr>
<td>Histamine H$_2$-receptor antagonists heal gastric and duodenal ulcers by reducing gastric acid output as a result of histamine H$_2$-receptor blockade; they are also used to relieve symptoms of gastro-oesophageal reflux disease. H$_2$-receptor antagonists should not normally be used for Zollinger-Ellison syndrome because proton pump inhibitors are more effective.</td>
</tr>
</tbody>
</table>

**Maintenance treatment with low doses for the prevention of peptic ulcer disease has largely been replaced in *Helicobacter pylori* positive patients by eradication regimens.**

In adults, H$_2$-receptor antagonists are used for the treatment of functional dyspepsia and may be used for the treatment of uninvestigated dyspepsia without alarm features. H$_2$-receptor antagonist therapy can promote healing of NSAID-associated ulcers (particularly duodenal).

Treatment with a H$_2$-receptor antagonist has not been shown to be beneficial in haematemesis and melaena, but prophylactic use reduces the frequency of bleeding from gastroduodenal erosions in hepatic coma, and possibly in other conditions requiring intensive care. H$_2$-receptor antagonists also reduce the risk of acid aspiration in obstetric patients at delivery (Mendelson’s syndrome).

**H$_2$-receptor antagonists**

- **CAUTIONS** Signs and symptoms of gastric cancer (in adults)

**CAUTIONS, FURTHER INFORMATION**
- **Gastric cancer**
  - In adults H$_2$-receptor antagonists might mask symptoms of gastric cancer; particular care is required in patients presenting with ‘alarm features’ in such cases gastric malignancy should be ruled out before treatment.

**SIDE-EFFECTS**
- **Common or very common** Diarrhoea · dizziness · headache
- **Uncommon** Erythema multiforme · rash · toxic epidermal necrolysis
- **Rare** Arthralgia · blood disorders · bradycardia · cholestatic jaundice · confusion · depression · hallucinations · hepatitis · leucopenia · myalgia · pancytopenia · psychiatric reactions · thrombocytopenia
- **Frequency not known** Gynaecomastia · impotence

**SIDE-EFFECTS, FURTHER INFORMATION**
Psychiatric reactions, including confusion, depression, and hallucinations occur particularly in the elderly or the very ill.

**Cimetidine**

**INDICATIONS AND DOSE**

**Benign duodenal ulceration**
- **BY MOUTH**
  - Adult: 400 mg twice daily for at least 4 weeks, to be taken with breakfast and at night, alternatively 800 mg once daily for at least 4 weeks, to be taken at night; increased if necessary up to 400 mg 4 times a day; maintenance 400 mg once daily, to be taken at night, alternatively maintenance 400 mg twice daily, to be taken in the morning and at night

**Benign gastric ulceration**
- **BY MOUTH**
  - Adult: 400 mg twice daily for 6 weeks, to be taken with breakfast and at night, alternatively 800 mg daily for 6 weeks, to be taken at night; increased if necessary up to 400 mg 4 times a day; maintenance 400 mg once daily, to be taken at night, alternatively maintenance 400 mg twice daily, to be taken in the morning and at night

**NSAID-associated ulceration**
- **BY MOUTH**
  - Adult: 400 mg twice daily for 8 weeks, to be taken with breakfast and at night, alternatively 800 mg daily for 8 weeks, to be taken at night; increased if necessary up to 400 mg 4 times a day; maintenance 400 mg daily, to be taken at night, alternatively maintenance 400 mg twice daily, to be taken in the morning and at night
Gastric and duodenal ulceration

**Reflex oesophagitis**
- **BY MOUTH**
  - Adult: 400 mg 4 times a day for 4–8 weeks

**Prophylaxis of stress ulceration**
- **BY MOUTH**
  - Adult: 200–400 mg every 4–6 hours

**Gastric acid reduction in obstetrics**
- **BY MOUTH**
  - Adult: Initially 400 mg, to be administered at start of labour, then increased if necessary up to 400 mg every 4 hours, do not use syrup in prophylaxis of acid aspiration; maximum 2.4 g per day

**Gastric acid reduction during surgical procedures**
- **BY MOUTH**
  - Adult: 400 mg, to be given 90–120 minutes before induction of general anaesthesia

**Short-bowel syndrome**
- **BY MOUTH**
  - Adult: 400 mg twice daily, adjusted according to response, to be taken with breakfast and at bedtime

**To reduce degradation of pancreatic enzyme supplements**
- **BY MOUTH**
  - Adult: 0.8–1.6 g daily in 4 divided doses, to be taken 1–1½ hours before meals

**INTERACTIONS** 
- Appendix 1: H₂ receptor antagonists

**SIDE-EFFECTS**
- Common or very common: Malaise
- Uncommon: Tachycardia
- Rare: Intestinal nephritis
- Very rare: Alopecia, galactorrhoea, pancreatitis, vasculitis

**PREGNANCY**
- Manufacturer advises avoid unless essential.

**NURSING AND BREASTFEEDING**
- Significant amount present in milk—not known to be harmful, but manufacturer advises avoid.

**HEPATIC IMPAIRMENT**
- Reduce dose. Increased risk of confusion.

**RENAL IMPAIRMENT**
- Reduce dose to 200 mg 4 times daily if eGFR 30–50 mL/minute/1.73 m². Reduce dose to 200 mg 3 times daily if eGFR 15–30 mL/minute/1.73 m². Reduce dose to 200 mg twice daily if eGFR less than 15 mL/minute/1.73 m². Occasional risk of confusion.

**EXCEPTIONS TO LEGAL CATEGORY**
- Cimetidine can be sold to the public for adults and children over 16 years (provided packs do not contain more than 2 weeks’ supply) for the short-term symptomatic relief of heartburn, dyspepsia, and hyperacidity (max. single dose 200 mg, max. daily dose 800 mg), and for the prophylactic management of nocturnal heartburn (single night-time dose 100 mg).

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Oral solution**
- May contain Propylene glycol
  - Cimetidine (Non-proprietary)
    - Cimetidine 40 mg per 1 ml Cimetidine 200mg/5ml oral solution sugar free sugar-free | 300 ml [Pom] £14.24–£14.25 DT price = £14.25
  - Tagamet (Essential Pharma Ltd)
    - Cimetidine 40 mg per 1 ml Tagamet 200mg/5ml syrup | 600 ml [Pom] £28.49 DT price = £28.49

**Tablet**
- Cimetidine (Non-proprietary)
  - Cimetidine 200 mg Cimetidine 200mg tablets | 60 tablet [Pom] £45.59 | 120 tablet [Pom] £120.00
  - Cimetidine 400 mg Cimetidine 400mg tablets | 60 tablet [Pom] £120.00 DT price = £15.31
  - Cimetidine 800 mg Cimetidine 800mg tablets | 30 tablet [Pom] no price available DT price = £9.09

**Tagamet** (Chemidex Pharma Ltd)
- Cimetidine 200 mg Tagamet 200mg tablets | 120 tablet [Pom] £19.58
- Cimetidine 400 mg Tagamet 400mg tablets | 60 tablet [Pom] £22.62 DT price = £15.31
- Cimetidine 800 mg Tagamet 800mg tablets | 30 tablet [Pom] £22.62 DT price = £9.09

**Famotidine**

**INDICATIONS AND DOSE**
- Treatment of benign gastric and duodenal ulceration
  - **BY MOUTH**
    - Adult: 40 mg once daily for 4–8 weeks, dose to be taken at night

- Maintenance treatment of duodenal ulceration
  - **BY MOUTH**
    - Adult: 20 mg once daily, dose to be taken at night

**Reflex oesophagitis**
- **BY MOUTH**
  - Adult: 20–40 mg twice daily for 6–12 weeks; maintenance 20 mg twice daily

**INTERACTIONS**
- Appendix 1: H₂ receptor antagonists

**SIDE-EFFECTS**
- Common or very common: Constipation
- Uncommon: Fatigue, vomiting, anorexia, dry mouth, flatulence, nausea, taste disorders
- Very rare: Chest tightness, interstitial pneumonia, paraesthesia, seizures

**PREGNANCY**
- Manufacturer advises avoid unless potential benefit outweighs risk.

**NURSING AND BREASTFEEDING**
- Present in milk—not known to be harmful but manufacturer advises avoid.

**RENAL IMPAIRMENT**
- Use normal dose every 36–48 hours or use half normal dose if eGFR less than 50 mL/minute/1.73 m². Seizures reported very rarely.

**EXCEPTIONS TO LEGAL CATEGORY**
- Famotidine can be sold to the public for adults and children over 16 years (provided packs do not contain more than 2 weeks’ supply) for the short-term symptomatic relief of heartburn, dyspepsia, and hyperacidity, and for the prevention of these symptoms when associated with consumption of food or drink including when they cause sleep disturbance (max. single dose 10 mg, max. daily dose 20 mg).

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- Famotidine (Non-proprietary)
  - Famotidine 20 mg Famotidine 20mg tablets | 28 tablet [Pom] £22.00 DT price = £21.79
  - Famotidine 40 mg Famotidine 40mg tablets | 28 tablet [Pom] £39.00 DT price = £38.98

**Nizatidine**

**INDICATIONS AND DOSE**
- Benign gastric, duodenal or NSAID-associated ulceration
  - **BY MOUTH**
    - Adult: 300 mg once daily for 4–8 weeks, dose to be taken in the evening, alternatively 150 mg twice daily for 4–8 weeks; maintenance 150 mg once daily, dose to be taken at night

- Gastro-oesophageal reflux disease
  - **BY MOUTH**
    - Adult: 150–300 mg twice daily for up to 12 weeks

**INTERACTIONS**
- Appendix 1: H₂ receptor antagonists
**Gastro-intestinal system**

**PREGNANCY**  
Manufacturer advises avoid unless essential.

**BREAST FEEDING**  
Amount too small to be harmful.

**HEPATIC IMPAIRMENT**  
Manufacturer advises caution.

**RENAL IMPAIRMENT**  
Use half normal dose if eGFR less than 20 mL/minute/1.73 m². Use one-quarter normal dose if eGFR less than 20 mL/minute/1.73 m².

**EXCEPTIONS TO LEGAL CATEGORY**  
Nizatidine can be sold to the public for the prevention and treatment of symptoms of food-related heartburn and meal-induced indigestion in adults and children over 16 years; max. single dose 75 mg, max. daily dose 150 mg for max. 14 days.

**SID-E-EFFECTS**  
Common or very common  
Sweating

**INTERACTIONS**  
**Nizatidine** (Non-proprietary)  
Nizatidine 300 mg Nizatidine 300 mg capsules | 30 capsule  
£15.43 DT price = £15.43

**INDICATIONS AND DOSE**  
**Benign gastric ulceration | Duodenal ulceration**

- **BY MOUTH**
  - Child 1–5 months: 1 mg/kg 3 times a day
  - Child 6 months–2 years: 2–4 mg/kg twice daily
  - Child 3–11 years: 2–4 mg/kg twice daily (max. per dose 150 mg)
  - Child 12–17 years: 150 mg twice daily, alternatively 300 mg once daily, dose to be taken at night
  - Adult: 150 mg twice daily for 4–8 weeks, alternatively 300 mg once daily for 4–8 weeks, dose to be taken at night

**Chronic episodic dyspepsia**
- **BY MOUTH**
  - Adult: 150 mg twice daily for 6 weeks, alternatively 300 mg once daily for 6 weeks, dose to be taken at night

**NSAID-associated gastric ulceration**
- **BY MOUTH**
  - Adult: 150 mg twice daily for up to 8 weeks, alternatively 300 mg once daily for up to 8 weeks, dose to be taken at night

**NSAID-associated duodenal ulcer**
- **BY MOUTH**
  - Adult: 300 mg twice daily for 4 weeks, to achieve a higher healing rate

**Prophylaxis of NSAID-associated gastric ulcer** | **Prophylaxis of NSAID-associated duodenal ulcer**

- **BY MOUTH**
  - Adult: 300 mg twice daily

**Gastro-oesophageal reflux disease**

- **BY MOUTH**
  - Adult: 150 mg twice daily for up to 8 weeks or if necessary 12 weeks, alternatively 300 mg once daily for up to 8 weeks or if necessary 12 weeks, dose to be taken at night

**Moderate to severe gastro-oesophageal reflux disease**
- **BY MOUTH**
  - Adult: 600 mg daily in 2–4 divided doses for up to 12 weeks

**Long-term treatment of healed gastro-oesophageal reflux disease**

- **BY MOUTH**
  - Adult: 150 mg twice daily

**Gastric acid reduction (prophylaxis of acid aspiration) in obstetrics**
- **BY MOUTH**
  - Adult: 150 mg, dose to be given at onset of labour, then 150 mg every 6 hours

**Gastric acid reduction (prophylaxis of acid aspiration) in surgical procedures**

- **INITIALLY BY INTRAMUSCULAR INJECTION, OR BY SLOW INTRAVENOUS INJECTION**
  - Adult: 50 mg, to be given 45–60 minutes before induction of anaesthesia, intravenous injection diluted to 20 mL and given over at least 2 minutes, alternatively (by mouth) 150 mg, to be given 2 hours before induction of anaesthesia and also when possible on the preceding evening

**Prophylaxis of stress ulceration**

- **INITIALLY BY SLOW INTRAVENOUS INJECTION**
  - Adult: 50 mg every 8 hours, dose to be diluted to 20 mL and given over at least 2 minutes, then (by mouth) 150 mg twice daily, may be given when oral feeding commences

**Reflux oesophagitis and other conditions where gastric acid reduction is beneficial**

- **BY MOUTH**
  - Child 1–5 months: 1 mg/kg 3 times a day (max. per dose 3 mg/kg 3 times a day)
  - Child 6 months–2 years: 2–4 mg/kg twice daily
  - Child 3–11 years: 2–4 mg/kg twice daily (max. per dose 150 mg)
  - Child 12–17 years: 150 mg twice daily, alternatively 300 mg once daily, dose to be taken at night
  - Adult: 150 mg twice daily for 4–8 weeks, alternatively 300 mg once daily for 4–8 weeks, dose to be taken at night

**Conditions where reduction of gastric acidity is beneficial and oral route not available**

- **BY INTRAMUSCULAR INJECTION**
  - Adult: 50 mg every 6–8 hours
  - **BY SLOW INTRAVENOUS INJECTION**
  - Adult: 50 mg, dose to be diluted to 20 mL and given over at least 2 minutes; may be repeated every 6–8 hours

**UNLICENSED USE**  
Oral preparations not licensed for use in children under 3 years. Injection not licensed for use in children under 6 months. Doses given for prophylaxis of NSAID-associated gastric or duodenal ulcer, and prophylaxis of stress ulceration, are not licensed.

**INTERACTIONS**  
Appendix 1: H₂ receptor antagonists

**SIDE-EFFECTS**  
Uncommon  
Blurred vision

**INTERVENTIONS**  
Alopecia · interstitial nephritis · involuntary movement disorders · pancreatitis

**PREGNANCY**  
Manufacturer advises avoid unless essential, but not known to be harmful.

**BREAST FEEDING**  
In adults Use half normal dose if eGFR less than 50 mL/minute/1.73 m².
PROSTAGLANDIN ANALOGUES AND PROSTAMIDES

GASTROPROTECTIVE

Misoprostol

- **DRUG ACTION** Misoprostol is a synthetic prostaglandin analogue that has antisecretory and protective properties, promoting healing of gastric and duodenal ulcers. It also acts as a potent uterine stimulant.

- **INDICATIONS AND DOSAGE**
  - Benign gastric ulceration
  - Benign duodenal ulceration
  - NSAID-associated ulceration
    - **BY MOUTH**
      - Adult: 800 micrograms daily in 2–4 divided doses continued for at least 4 weeks or may be continued for up to 8 weeks if required, dose to be taken with breakfast (or main meals) and at bedtime

- **Prophylaxis of NSAID-induced gastric ulcer** | **Prophylaxis of duodenal ulcer**
  - **BY MOUTH**
  - Adult: 200 micrograms 4 times a day, reduced if not tolerated to 200 micrograms 2–3 times a day, use lower dose is less effective

- **CAUTIONS** Conditions where hypotension might precipitate severe complications (e.g. cerebrovascular disease, cardiovascular disease) - inflammatory bowel disease

- **SIDE-EFFECTS**
  - Common or very common: Diarrhoea
  - Frequency not known: Abdominal pain - abnormal vaginal bleeding - dizziness - dyspepsia - flatulence - intermenstrual bleeding - menorrhagia - nausea - postmenopausal bleeding - rashes - vomiting

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Diarrhoea: May occasionally be severe and require withdrawal, reduced by giving single doses not exceeding 200 micrograms and by avoiding magnesium-containing antacids.

- **CONCEPTION AND CONTRACEPTION**
  - Manufacturer advises that misoprostol should not be used in women of childbearing age unless pregnancy has been excluded. In such patients it is advised that misoprostol should only be used if the patient takes effective contraceptive measures and has been advised of the risks of taking misoprostol if pregnant.

- **PREGNANCY**
  - Avoid—potent uterine stimulant (has been used to induce abortion). Teratogenic risk in first trimester.

- **BREAST FEEDING**
  - Present in milk, but amount probably too small to be harmful.
Proton pump inhibitors

**DRUG ACTION** Proton pump inhibitors inhibit gastric acid secretion by blocking the hydrogen-potassium adenosine triphosphatase enzyme system (the ‘proton pump’) of the gastric parietal cell.

**IMPORTANT SAFETY INFORMATION**

**MHRA ADVICE: PROTON PUMP INHIBITORS (PPIs): VERY LOW RISK OF SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SEPTEMBER 2015)**

Very infrequent cases of subacute cutaneous lupus erythematosus (SCLE) have been reported in patients taking PPIs. Drug-induced SCLE can occur weeks, months or even years after exposure to the drug.

If a patient treated with a PPI develops lesions—especially in sun-exposed areas of the skin—and it is accompanied by arthralgia:

- Advise them to avoid exposing the skin to sunlight;
- Consider SCLE as a possible diagnosis;
- Consider discontinuing PPI treatment unless it is imperative for a serious acid-related condition; a patient who develops SCLE with a particular PPI may be at risk of the same reaction with another;
- In most cases, symptoms resolve on PPI withdrawal; topical or systemic steroids might be necessary for treatment of SCLE only if there are no signs of remission after a few weeks or months.

**CAUTIONS** Can increase the risk of fractures (particularly when used at high doses for over a year in the elderly) — may increase the risk of gastro-intestinal infections (including Clostridium difficile infection) — may mask the symptoms of gastric cancer (in adults) — patients at risk of osteoporosis.

**CAUTIONS, FURTHER INFORMATION**

- Risk of osteoporosis Patients at risk of osteoporosis should maintain an adequate intake of calcium and vitamin D, and if necessary, receive other preventative therapy.
- Gastric cancer Particular care is required in those presenting with ‘alarm features’, in such cases gastric malignancy should be ruled out before treatment.

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain · constipation · diarrhoea · flatulence · gastro-intestinal disturbances · headache · nausea · vomiting
- **Uncommon** Arthralgia · dizziness · dry mouth · fatigue · myalgia · paraesthesia · peripheral oedema · pruritus · rash · sleep disturbances
- **Rare** Alopecia · anaphylaxis · blood disorders · bronchospasm · confusion · depression · fever · gynaecomastia · hallucinations · hepatitis · hypersensitivity reactions · hypomagnesaemia (usually after 1 year of treatment, but sometimes after 3 months of treatment) · hyponatraemia · interstitial nephritis · jaundice · leucocytosis · leucopenia · pancytopenia · photosensitivity · Stevens-Johnson syndrome · stomatitis · sweating · taste disturbance · thrombocytopenia · toxic epidermal necrolysis · visual disturbances

**SIDE-EFFECTS, FURTHER INFORMATION**

Rebound acid hypersecretion and protracted dyspepsia may occur after stopping prolonged treatment with a proton pump inhibitor.

**MONITORING REQUIREMENTS** Measurement of serum-magnesium concentrations should be considered before and during prolonged treatment with a proton pump inhibitor, especially when used with other drugs that cause hypomagnesaemia or with digoxin.

**PRESCRIBING AND DISPENSING INFORMATION** A proton pump inhibitor should be prescribed for appropriate indications at the lowest effective dose for the shortest period; the need for long-term treatment should be reviewed periodically.

---

**Esomeprazole**

**INDICATIONS AND DOSE**

**NSAID-associated gastric ulcer**

- **BY MOUTH**
  - Adult: 20 mg once daily for 4–8 weeks
  - **BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
    - Adult: 20 mg daily continue until oral administration possible, injection to be given over at least 3 minutes

**Prophylaxis of NSAID-associated gastric ulcer in patients with an increased risk of gastroduodenal complications who require continued NSAID treatment**

- **BY MOUTH**
  - Adult: 20 mg daily

**Prophylaxis of NSAID-associated gastric or duodenal ulcer**

- **BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
  - Adult: 20 mg daily continue until oral administration possible, injection to be given over at least 3 minutes

**Gastro-oesophageal reflux disease (in the presence of erosive reflux oesophagitis)**

- **BY MOUTH**
  - Child 1–11 years (body-weight 10–19 kg): 10 mg once daily for 8 weeks
  - Child 11–17 years: 20 mg once daily for 8 weeks
  - Child 12–17 years: Initially 40 mg once daily for 4 weeks, continued for further 4 weeks if not fully healed or symptoms persist; maintenance 20 mg daily
  - Adult: Initially 40 mg once daily for 4 weeks, continued for further 4 weeks if not fully healed or symptoms persist; maintenance 20 mg daily

**SYMPTOMATIC TREATMENT OF GASTRO-OESOPHAGEAL REFUX DISEASE IN THE ABSENCE OF OESOPHAGITIS**

- **BY MOUTH**
  - Child 1–11 years (body-weight 10 kg and above): 10 mg once daily for up to 8 weeks
  - Child 12–17 years: 20 mg once daily for up to 4 weeks
  - Adult: 20 mg once daily for up to 4 weeks, then 20 mg daily if required

**BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**

- Adult: 20 mg once daily continue until oral administration is possible, injection to be given over at least 3 minutes
Zollinger–Ellison syndrome

▶ BY MOUTH

▶ Adult: Initially 40 mg twice daily, adjusted according to response; usual dose 80–160 mg daily, daily doses above 80 mg should be given in 2 divided doses

Severe peptic ulcer bleeding (following endoscopic treatment)

▶ INITIALLY BY INTRAVENOUS INFUSION

▶ Adult: Initially 80 mg, to be given over 30 minutes, then (by continuous intravenous infusion) 8 mg/hour for 72 hours, then (by mouth) 40 mg once daily for 4 weeks

Helicobacter pylori eradication in combination with clarithromycin and amoxicillin or metronidazole

▶ BY MOUTH

▶ Adult: 20 mg twice daily

UNLICENSED USE Tablets and capsules not licensed for use in children 1–11 years.

INTERACTIONS ▶ Appendix 1: proton pump inhibitors

PREGNANCY ▶ Appendix 1: clarithromycin

BREAST FEEDING Manufacturer advises caution—no information available.

HEPATIC IMPAIRMENT

▶ In adults In severe hepatic impairment max. 20 mg daily. Severe peptic ulcer bleeding in severe hepatic impairment, initial intravenous infusion of 80 mg, then by continuous intravenous infusion, 4 mg/hour for 72 hours.

▶ In children 1–11 years max. 10 mg daily in severe impairment. 12–17 years max. 20 mg daily in severe impairment.

RENAL IMPAIRMENT Manufacturer advises caution in severe renal insufficiency.

DIRECTIONS FOR ADMINISTRATION

▶ With intravenous use in adults For intravenous infusion (Nexium®), give continuously or intermittently in Sodium Chloride 0.9%; reconstitute 40–80 mg with up to 100 mL infusion fluid; for intermittent infusion, give requisite dose over 10–30 minutes; stable for 12 hours in Sodium Chloride 0.9%.

▶ With oral use Do not chew or crush capsules; swallow whole or mix capsule contents in water and drink within 30 minutes. Do not crush or chew tablets; swallow whole or disperse in water and drink within 30 minutes. Disperse the contents of each sachet of gastro-resistant granules in approx. 15 mL water. Stir and leave to thicken for a few minutes; stir again before administration and use within 30 minutes; rinse container with 15 mL water to obtain full dose. For administration through a gastric tube, consult product literature.

PATIENT AND CARER ADVICE

▶ With oral use Counselling on administration of gastro-resistant capsules, tablets, and granules advised.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

Gastro-resistant capsule

▶ Esomeprazole (Non-proprietary)

Esomeprazole (as Esomeprazole magnesiuim dihydrate)

20 mg Esomeprazole 20mg gastro-resistant capsules | 28 capsule | £12.95 DT price = £2.64

Esomeprazole (as Esomeprazole magnesium dihydrate)

40 mg Esomeprazole 40mg gastro-resistant capsules | 28 capsule | £17.63 DT price = £3.30

▶ Emozul (Consilient Health Ltd)

Esomeprazole (as Esomeprazole magnesium dihydrate)

20 mg Emozul 20mg gastro-resistant capsules | 28 capsule | £2.64 DT price = £2.64

Gastro-resistant tablet

▶ Esomeprazole (Non-proprietary)

Esomeprazole (as Esomeprazole magnesium trihydrate)

20 mg Esomeprazole 20mg gastro-resistant tablets | 28 tablet | £18.50 DT price = £2.65

Esomeprazole (as Esomeprazole magnesium trihydrate)

40 mg Esomeprazole 40mg gastro-resistant tablets | 28 tablet | £25.19 DT price = £3.31

Nexium (AstraZeneca UK Ltd, Pfizer Consumer Healthcare Ltd)

Esomeprazole (as Esomeprazole magnesium trihydrate)

20 mg Nexium 20mg gastro-resistant tablets | 28 tablet | £18.50 DT price = £2.65

Esomeprazole (as Esomeprazole magnesium trihydrate)

40 mg Nexium 40mg gastro-resistant tablets | 28 tablet | £25.19 DT price = £3.31

Powder for solution for injection

▶ Esomeprazole (Non-proprietary)

Esomeprazole (as Esomeprazole sodium) 40 mg Esomeprazole 40mg powder for solution for injection vials | 1 vial | £3.07–£3.13 (Hospital only)

Nexium (AstraZeneca UK Ltd)

Esomeprazole (as Esomeprazole sodium) 40 mg Nexium I.V 40mg powder for solution for injection vials | 1 vial | £4.25 (Hospital only)

Gastro-resistant granules

CAUTIONARY AND ADVISORY LABELS 25

Nexium (AstraZeneca UK Ltd)

Esomeprazole (as Esomeprazole magnesium trihydrate)

10 mg Nexium 10mg gastro-resistant granules sachets | 28 sachet | £25.19 DT price = £25.19

Lansoprazole

INDICATIONS AND DOSE

Helicobacter pylori eradication in combination with amoxicillin and clarithromycin; or in combination with amoxicillin and metronidazole; or in combination with clarithromycin and metronidazole

▶ BY MOUTH

▶ Adult: 30 mg twice daily

Benign gastric ulcer

▶ BY MOUTH

▶ Adult: 30 mg once daily for 8 weeks, dose to be taken in the morning

Duodenal ulcer

▶ BY MOUTH

▶ Adult: 30 mg once daily for 4 weeks, dose to be taken in the morning; maintenance 15 mg once daily

NSAID-associated duodenal ulcer | NSAID-associated gastric ulcer

▶ BY MOUTH

▶ Adult: 30 mg once daily for 4 weeks, continued for further 4 weeks if not fully healed

Prophylaxis of NSAID-associated duodenal ulcer | Prophylaxis of NSAID-associated gastric ulcer

▶ BY MOUTH

▶ Adult: 15–30 mg once daily

Zollinger–Ellison syndrome (and other hypersecretory conditions)

▶ BY MOUTH

▶ Adult: Initially 60 mg once daily, adjusted according to response, daily doses of 120 mg or more given in two divided doses continued
Gastro-intestinal system

Disorders of gastric acid and ulceration

JSICINAL FORMS

PROFESSION SPECIFIC INFORMATION

TIENT AND CARER ADVICE

HEPATIC IMPAIRMENT

BR EAST FEEDING

▶ UNLICENSED USE

Lansoprazole doses in BNF may differ from those in product literature. Not licensed at 30 mg twice daily for severe oesophagitis refractory to initial treatment.

▶ INTERACTIONS

Appendix 1: proton pump inhibitors

▶ SIDE-EFFECTS

Very rare: Colitis - raised serum cholesterol - raised triglycerides

Frequency not known: Anorexia - glossitis - impotence - pancreatitis - petechiae - purpura - restlessness - tremor

▶ PREGNANCY

Manufacturer advises avoid.

▶ BREAST FEEDING

Avoid—present in milk in animal studies.

▶ HEPATIC IMPAIRMENT

Use half normal dose in moderate to severe liver disease.

▶ DIRECTIONS FOR ADMINISTRATION

Orodispersible tablets should be placed on the tongue, allowed to disperse and swallowed, or may be swallowed whole with a glass of water. Alternatively, tablets can be dispersed in a small amount of water and administered by an oral syringe or nasogastric tube.

▶ PATIENT AND CARER ADVICE

Counselling on administration of orodispersible tablet advised.

▶ PROFESSION SPECIFIC INFORMATION

Dental practitioners’ formulary

Lansoprazole capsules may be prescribed.

▶ MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Gastro-resistant capsule

CAUTIONARY AND ADVISORY LABELS 5, 22, 25

▶ Lansoprazole (Non-proprietary)

Lansoprazole 15 mg Lansoprazole 15mg gastro-resistant capsules | 28 capsule | £12.92 DT price = £0.84
Lansoprazole 30 mg Lansoprazole 30mg gastro-resistant capsules | 28 capsule | £23.63 DT price = £1.11

Orodispersible tablet

CAUTIONARY AND ADVISORY LABELS 5, 22

EXCIPIENTS: May contain Aspartame

▶ Lansoprazole (Non-proprietary)

Lansoprazole 15 mg Lansoprazole 15mg orodispersible tablets | 28 tablet | £3.99 DT price = £0.14
Lansoprazole 30 mg Lansoprazole 30mg orodispersible tablets | 28 tablet | £6.99 DT price = £0.34

Zoton FasTab (Pfizer Ltd)

Lansoprazole 15 mg Zoton FasTab 15mg | 28 tablet | £2.99 DT price = £0.10
Lansoprazole 30 mg Zoton FasTab 30mg | 28 tablet | £5.50 DT price = £0.20

Omeprazole

▶ INDICATIONS AND DOSE

Helicobacter pylori eradication in combination with amoxicillin and clarithromycin; or in combination with amoxicillin and metronidazole; or in combination with clarithromycin and metronidazole

▶ BY MOUTH

Adult: 20 mg twice daily

Benign gastric ulceration

▶ BY MOUTH

Adult: 20 mg once daily for 4 weeks, increased if necessary to 40 mg once daily, in severe or recurrent cases

Prevention of relapse in gastric ulcer

▶ BY MOUTH

Adult: 20 mg once daily, increased if necessary to 40 mg once daily

Prevention of relapse in duodenal ulcer

▶ BY MOUTH

Adult: 20 mg once daily, dose may range between 10–40 mg daily

NSAID-associated duodenal ulcer | NSAID-associated gastric ulcer | NSAID-associated gastroduodenal erosions

▶ BY MOUTH

Adult: 20 mg once daily for 4 weeks, continued for a further 4 weeks if not fully healed

Prophylaxis in patients with a history of NSAID-associated duodenal ulcer who require continued NSAID treatment | Prophylaxis in patients with a history of NSAID-associated gastric ulcer who require continued NSAID treatment | Prophylaxis in patients with a history of NSAID-associated gastroduodenal lesions who require continued NSAID treatment | Prophylaxis in patients with a history of NSAID-associated dyspeptic symptoms who require continued NSAID treatment

▶ BY MOUTH

Adult: 20 mg twice daily

Zollinger–Ellison syndrome

▶ BY MOUTH

Adult: Initially 60 mg once daily; usual dose 20–120 mg daily, total daily doses greater than 80 mg should be given in 2 divided doses

BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION

Adult: Initially 60 mg once daily, adjusted according to response, total daily doses greater than 60 mg should be given in 2 divided doses, injection to be given over 5 minutes, infusion to be given over 20–30 minutes

Gastro-oesophageal reflux disease

▶ BY MOUTH

Adult: 20 mg once daily for 4 weeks, continued for a further 4–8 weeks if not fully healed; maintenance 20 mg once daily

Gastro-oesophageal reflux disease refractory to other treatment

▶ BY MOUTH

Adult: 40 mg once daily for 8 weeks; maintenance 20 mg once daily

Acid reflux disease (long-term management)

▶ BY MOUTH

Adult: 10 mg once daily, increased to 20 mg once daily, dose only increased if symptoms return
Acid-related dyspepsia
▶ BY MOUTH
▶ Adult: 10–20 mg once daily for 2–4 weeks according to response

Treatment and prevention of benign gastric ulcers
Treatment and prevention of duodenal ulcers
Treatment and prevention of NSAID-associated ulcers
Treatment and prevention of gastro-oesophageal reflux disease
▶ BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION
▶ Adult: 40 mg once daily until oral administration possible, injection to be given over 5 minutes, infusion to be given over 20–30 minutes

Major peptic ulcer bleeding (following endoscopic treatment)
▶ INITIALLY BY INTRAVENOUS INFUSION
▶ Adult: Initially 80 mg, to be given over 40–60 minutes, then (by continuous intravenous infusion) 8 mg/hour for 72 hours, subsequent dose then changed to oral therapy

UNLICENSED USE Treatment of major peptic ulcer bleeding (following endoscopic treatment) is an unlicensed indication.

INTERACTIONS ➔ Appendix 1: proton pump inhibitors

SIDE-EFFECTS Agitation - impotence

PREGNANCY Not known to be harmful.

BREAST FEEDING Present in milk but not known to be harmful.

HEPATIC IMPAIRMENT Not more than 20 mg daily should be needed.

DIRECTIONS FOR ADMINISTRATION For administration by mouth, swallow whole, or disperse Losec MUPS® tablets in water, or mix capsule contents or Losec MUPS® tablets with fruit juice or yoghurt. Preparations consisting of an e/c tablet within a capsule should not be opened.

With intravenous use For intravenous infusion (Losec®), give intermittently or continuously in Glucose 5% or Sodium chloride 0.9%; reconstitute each 40 mg vial with infusion fluid and dilute to 100 mL; for intermittent infusion give 40 mg over 20–30 minutes; stable for 3 hours in glucose 5% or 12 hours in sodium chloride 0.9%.

PATIENT AND CARER ADVICE
With oral use Counselling on administration advised.

PROFESSION SPECIFIC INFORMATION
Dental practitioners’ formulary
Gastro-resistant omeprazole capsules may be prescribed.

EXCEPTIONS TO LEGAL CATEGORY
With oral use Omeprazole 10 mg tablets can be sold to the public for the short-term relief of reflux-like symptoms (e.g. heartburn) in adults over 18 years, max. daily dose 20 mg for max. 4 weeks, and a pack size of 28 tablets.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Gastro-resistant capsule
▶ Omeprazole (Non-proprietary)
Omeprazole 10 mg Omeprazole 10 mg gastro-resistant capsules | 28 capsule (POM) £9.30 DT price = £0.89
Omeprazole 20 mg Omeprazole 20 mg gastro-resistant capsules | 28 capsule (POM) £13.50 DT price = £0.91
Omeprazole 40 mg Omeprazole 40 mg gastro-resistant capsules | 7 capsule (POM) £6.96 DT price = £0.91
Losec (AstraZeneca UK Ltd)
Omeprazole 10 mg Losec 10 mg gastro-resistant capsules | 28 capsule (POM) £9.30 DT price = £0.89
Omeprazole 20 mg Losec 20 mg gastro-resistant capsules | 28 capsule (POM) £13.92 DT price = £0.91
Omeprazole 40 mg Losec 40 mg gastro-resistant capsules | 7 capsule (POM) £6.96 DT price = £0.91

Mepradec (Discovery Pharmaceuticals)
Omeprazole 10 mg Mepradec 10 mg gastro-resistant capsules | 28 capsule (POM) £0.83 DT price = £0.89
Omeprazole 20 mg Mepradec 20 mg gastro-resistant capsules | 28 capsule (POM) £0.83 DT price = £0.91

Gastro-resistant tablet
CAUTIONARY AND ADVISORY LABELS 25
▶ Omeprazole (Non-proprietary)
Omeprazole 10 mg Omeprazole 10 mg gastro-resistant tablets | 28 tablet (POM) £11.89 DT price = £7.90
Omeprazole (as Omeprazole magnesium) 10 mg Omeprazole 10 mg dispersible gastro-resistant tablets | 28 tablet (POM) £8.06 DT price = £7.75
Omeprazole 20 mg Omeprazole 20 mg gastro-resistant tablets | 28 tablet (POM) £28.56 DT price = £6.01
Omeprazole (as Omeprazole magnesium) 20 mg Omeprazole 20 mg dispersible gastro-resistant tablets | 28 tablet (POM) £11.60 DT price = £11.60
Omeprazole 40 mg Omeprazole 40 mg gastro-resistant tablets | 7 tablet (POM) £15.00 DT price = £6.02
Omeprazole (as Omeprazole magnesium) 40 mg Omeprazole 40 mg gastro-resistant tablets | 7 tablet (POM) £6.30 DT price = £5.80
Losec (AstraZeneca UK Ltd)
Omeprazole (as Omeprazole magnesium) 10 mg Losec MUPS 10 mg gastro-resistant tablets | 28 tablet (POM) £7.75 DT price = £7.75
Omeprazole (as Omeprazole magnesium) 20 mg Losec MUPS 20 mg gastro-resistant tablets | 28 tablet (POM) £11.60 DT price = £11.60
Omeprazole (as Omeprazole magnesium) 40 mg Losec MUPS 40 mg gastro-resistant tablets | 7 tablet (POM) £5.80 DT price = £5.80
Mezopram (Sandolz Ltd)
Omeprazole (as Omeprazole magnesium) 10 mg Mezopram 10 mg gastro-resistant tablets | 28 tablet (POM) £6.58 DT price = £7.75
Omeprazole (as Omeprazole magnesium) 20 mg Mezopram 20 mg gastro-resistant tablets | 28 tablet (POM) £9.86 DT price = £11.60
Omeprazole (as Omeprazole magnesium) 40 mg Mezopram 40 mg gastro-resistant tablets | 7 tablet (POM) £4.93 DT price = £5.80

Powder for solution for infusion
▶ Omeprazole (Non-proprietary)
Omeprazole (as Omeprazole sodium) 40 mg Omeprazole 40 mg powder for solution for infusion vials | 5 vial (POM) £32.45 (Hospital only) | 5 vial (POM) £16.54

Pantoprazole

INDICATIONS AND DOSE
Helicobacter pylori eradication in combination with amoxicillin and clarithromycin; or in combination with clarithromycin and metronidazole
▶ BY MOUTH
▶ Adult: 40 mg twice daily

Benign gastric ulcer
▶ BY MOUTH
▶ Adult: 40 mg daily for 8 weeks; increased if necessary up to 80 mg daily, dose increased in severe cases

Gastric ulcer
▶ BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION
▶ Adult: 40 mg daily until oral administration can be resumed, injection to be given over at least 2 minutes

Duodenal ulcer
▶ BY MOUTH
▶ Adult: 40 mg daily for 4 weeks; increased if necessary up to 80 mg daily, dose increased in severe cases
▶ BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION
▶ Adult: 40 mg daily until oral administration can be resumed, injection to be given over at least 2 minutes

continued →
Prophylaxis of NSAID-associated gastric ulcer in patients with an increased risk of gastro-duodenal complications who require continued NSAID treatment.

**INDICATIONS AND DOSE**

**Benign gastric ulcer**
- **BY MOUTH**
  - Adult: 20 mg daily for 8 weeks, dose to be taken in the morning

**Duodenal ulcer**
- **BY MOUTH**
  - Adult: 20 mg daily for 4 weeks, dose to be taken in the morning

**Gastro-oesophageal reflux disease**
- **BY MOUTH**
  - Adult: 20–80 mg daily for 4 weeks, continued for further 4 weeks if not fully healed, dose to be taken in the morning; maintenance 20 mg daily and increased to 40 mg daily, increased only if symptoms return.

**SIDE-EFFECTS**
- **BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
  - Adult: 40 mg daily until oral administration can be resumed, injection to be given over at least 2 minutes

**Zollinger–Ellison syndrome (and other hypersecretory conditions)**
- **BY MOUTH**
  - Adult: Initially 80 mg daily (max. per dose 80 mg), adjusted according to response
  - Elderly: 40 mg daily

**BR EAS T FEEDING**
- **BY MOUTH**
  - Adult: 80 mg once daily for 8–12 weeks; maintenance 10–20 mg daily

**Gastro-oesophageal reflux disease (symptomatic treatment in the absence of oesophagitis)**
- **BY MOUTH**
  - Adult: 10 mg daily for up to 4 weeks, then 10 mg daily if required

**Severe oesophagitis**
- **BY MOUTH**
  - Adult: 20 mg once daily for 8 weeks, continue as maintenance treatment if appropriate

**Severe oesophagitis, refractory to initial treatment**
- **BY MOUTH**
  - Adult: 20 mg twice daily

**Zollinger–Ellison syndrome**
- **BY MOUTH**
  - Adult: 20 mg twice daily

**Medicinal forms**
- **Rabeprazole sodium**
  - **Pantoprazole** (as Pantoprazole sodium sesquihydrate)
    - 20 mg Pantoprazole 20 mg gastro-resistant tablets | 28 tablet [Pos] £11.83 DT price = £0.95
    - 40 mg Pantoprazole 40 mg gastro-resistant tablets | 28 tablet [Pos] £20.57 DT price = £1.12

**Powder for solution for injection**
- **Pantoprazole** (as Pantoprazole sodium sesquihydrate)
  - 40 mg Pantoprazole 40mg powder for solution for injection vials | 1 vial [Pos] £5.00 | 5 vial [Pos] £25.25
  - **Protium** (Takeda UK Ltd)
  - Pantoprazole (as Pantoprazole sodium sesquihydrate)
    - 40 mg Protium IV. 40mg powder for solution for injection vials | 5 vial [Pos] £25.53
4.3 Gastro-oesophageal reflux disease

Management
Gastro-oesophageal reflux disease (including non-erosive gastro-oesophageal reflux and erosive oesophagitis) is associated with heartburn, acid regurgitation, and sometimes, difficulty in swallowing (dysphagia); oesophageal inflammation (oesophagitis), ulceration, and stricture formation may occur and there is an association with asthma.

The management of gastro-oesophageal reflux disease includes drug treatment, lifestyle changes and, in some cases, surgery. Initial treatment is guided by the severity of symptoms and treatment is then adjusted according to response. The extent of healing depends on the severity of the disease, the treatment chosen, and the duration of therapy.

Patients with gastro-oesophageal reflux disease should be advised about lifestyle changes (avoidance of excess alcohol and of aggravating foods such as fats); other measures include weight reduction, smoking cessation, and raising the head of the bed.

For mild symptoms of gastro-oesophageal reflux disease, initial management may include the use of antacids and alginites. Alginate-containing antacids can form a ‘raft’ that floats on the surface of the stomach contents to reduce reflux and protect the oesophageal mucosa. Histamine H₂-receptor antagonists may relieve symptoms and permit reduction in antacid consumption. However, proton pump inhibitors provide more effective relief of symptoms than H2-receptor antagonists. When symptoms abate, treatment is titrated down to a level which maintains remission (e.g. by giving treatment intermittently).

For severe symptoms of gastro-oesophageal reflux disease or for patients with a proven or severe pathology (e.g. oesophagitis, oesophageal ulceration, oesophagopharyngeal reflux, Barrett’s oesophagus), initial management involves the use of a proton pump inhibitor; patients need to be reassessed if symptoms persist despite treatment for 4–6 weeks with a proton pump inhibitor. When symptoms abate, treatment is titrated down to a level which maintains remission (e.g. by reducing the dose of the proton pump inhibitor or by giving it intermittently, or by substituting treatment with a histamine H₂-receptor antagonist). However, for endoscopically confirmed erosive, ulcerative, or strictureing disease, or Barrett’s oesophagus, treatment with a proton pump inhibitor usually needs to be maintained at the minimum effective dose.

Pregnancy
If dietary and lifestyle changes fail to control gastro-oesophageal reflux disease in pregnancy, an antacid or an alginate can be used. If this is ineffective, ranitidine p. 74 can be tried. Omeprazole p. 78 is reserved for women with severe or complicated reflux disease.

Gastro-oesophageal reflux disease in children
Gastro-oesophageal reflux disease is common in infancy but most symptoms resolve without treatment between 12 and 18 months of age. In infants, mild or moderate reflux without complications can be managed initially by changing the frequency and volume of feed; a feed thicker or thickened formula feed can be used (with advice of a dietitian). If necessary, a suitable alginate-containing preparation can be used instead of thickened feeds. For older children, life-style changes similar to those for adults may be helpful followed if necessary by treatment with an alginate-containing preparation.

Children who do not respond to these measures or who have problems such as respiratory disorders or suspected oesophagitis need to be referred to hospital; an H₂-receptor antagonist may be needed to reduce acid secretion. If the oesophagitis is resistant to H₂-receptor blockade, the proton pump inhibitor omeprazole can be tried.

ANTACIDS → ALGINATE

Sodium alginate with calcium carbonate and sodium bicarbonate

The properties listed below are those particular to the combination only. For the properties of the components please consider, alginic acid p. 67, sodium bicarbonate p. 950, calcium carbonate p. 958.

- INDICATIONS AND DOSE
  Mild symptoms of gastro-oesophageal reflux disease
    - BY MOUTH
      - Child 6–11 years: 5–10 mL, to be taken after meals and at bedtime
      - Child 12–17 years: 10–20 mL, to be taken after meals and at bedtime
      - Adult: 10–20 mL, to be taken after meals and at bedtime

- INTERACTIONS → Appendix 1: calcium salts, sodium bicarbonate
- PRESCRIBING AND DISPENSING INFORMATION Flavours of oral liquid formulations may include aniseed or peppermint.

- PATIENT AND CARER ADVICE
  Medicines for Children leaflet: Gaviscon for gastro-oesophageal reflux disease www.medicinesforchildren.org.uk/gaviscon-gastro-oesophageal-reflux-disease

- MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug.

  Oral suspension
  ELECTROLYTES: May contain Sodium
    - Sodium alginate with calcium carbonate and sodium bicarbonate (Non-proprietary)
      - Calcium carbonate 16 mg per 1 mL, Sodium bicarbonate 26.7 mg per 1 mL, Sodium alginate 50 mg per 1 mL

- RELIEF
  Alginic acid 50 mg per 1 mL, Sodium alginate 40 mg per 1 mL, Calcium carbonate 16 mg per 1 mL, Sodium bicarbonate 26.7 mg per 1 mL

- BRANDS
  - 'Sodium alginate with calcium carbonate and sodium bicarbonate' Alginic acid 50 mg per 1 mL, Sodium alginate 40 mg per 1 mL, Calcium carbonate 16 mg per 1 mL, Sodium bicarbonate 26.7 mg per 1 mL
  - 'Gaviscon Alginate' Alginic acid 50 mg per 1 mL, Sodium alginate 40 mg per 1 mL, Calcium carbonate 16 mg per 1 mL, Sodium bicarbonate 26.7 mg per 1 mL

4.4 Helicobacter pylori diagnosis

DIAGNOSTIC AGENTS

Urea (13C)

- INDICATIONS AND DOSE
  Diagnosis of gastro-duodenal Helicobacter pylori infection
    - BY MOUTH
    - Adult: (consult product literature)
Gastro-intestinal system

5  Food allergy

Food allergy 15-Dec-2016

Description of condition
Food allergy is an adverse immune response to a food, commonly associated with cutaneous and gastro-intestinal reactions, and less frequently associated with respiratory reactions and anaphylaxis. It is distinct from food intolerance which is non-immunological. Cow's milk, hen's eggs, soy, wheat, peanuts, tree nuts, and shellfish are the most common allergens. Cross-reactivity between similar foods can occur (e.g. allergy to other mammalian milk in patients with cow's milk allergy).

Management of food allergy
Expt Allergy caused by specific foods should be managed by strict avoidance of the causal food. Sodium cromoglicate p. 260 is licensed as an adjunct to dietary avoidance in patients with food allergy. Educating patients about appropriate nutrition, food preparation, and the risks of accidental exposure is recommended, such as food and drinks to avoid, ensuring adequate nutritional intake, and interpreting food labels. A

Drug treatment
Expt There is low quality evidence to support the use of antihistamines to treat acute, non-life-threatening symptoms (such as flushing and urticaria) if accidental ingestion of allergenic food has occurred (see Antihistamines, under Antihistamines, allergen immunotherapy and allergic emergencies p. 265). Chlorphenamine maleate p. 272 is licensed for the symptomatic control of food allergy. In case of food-induced anaphylaxis, adrenaline/epinephrine p. 15 is the first-line immediate treatment (see also Allergic emergencies, under Antihistamines, allergen immunotherapy and allergic emergencies p. 265). Patients who are at risk of anaphylaxis should be trained to use self-injectable adrenaline/epinephrine. A

6  Gastro-intestinal smooth muscle spasm

Antispasmodics

Antimuscarinics
The intestinal smooth muscle relaxant properties of antimuscarinic and other antispasmodic drugs may be useful in irritable bowel syndrome. Antimuscarinics (formerly termed ‘anticholinergics’) reduce intestinal motility. They can be used for the management of irritable bowel syndrome.

Antimuscarinics that are used for gastro-intestinal smooth muscle spasm include the tertiary amines atropine sulfate p. 1224 and dicycloverine hydrochloride below and the quaternary ammonium compounds propantheline bromide p. 84 and hyoscine butylbromide p. 83. The quaternary ammonium compounds are less lipid soluble than atropine sulfate and are less likely to cross the blood–brain barrier; they are also less well absorbed from the gastro-intestinal tract.

Dicycloverine hydrochloride has a much less marked antimuscarinic action than atropine sulfate and may also have some direct action on smooth muscle. Hyoscine butylbromide is advocated as a gastro-intestinal antispasmodic, but it is poorly absorbed; the injection is useful in endoscopy and radiology. Atropine sulfate and the belladonna alkaloids are outmoded treatments, any clinical virtues being outweighed by atropinic side-effects.

Other antispasmodics
Alverine citrate p. 84, mebeverine hydrochloride p. 84, and peppermint oil p. 46 are believed to be direct relaxants of intestinal smooth muscle and may relieve pain in irritable bowel syndrome. They have no serious adverse effects but, like all antispasmodics, should be avoided in paralytic ileus.

ANTIMUSCARINICS

I Dicycloverine hydrochloride

(Dicyclomine hydrochloride)

- INDICATIONS AND DOSE
Symptomatic relief of gastro-intestinal disorders characterised by smooth muscle spasm
  ▶ BY MOUTH
  - Child 6–23 months: 5–10 mg 3–4 times a day, dose to be taken 15 minutes before feeds
  - Child 2–11 years: 10 mg 3 times a day
  - Child 12–17 years: 10–20 mg 3 times a day
  - Adult: 10–20 mg 3 times a day

- CONTRA-INDICATIONS  Child under 6 months
- INTERACTIONS  → Appendix 1: dicycloverine
- PREGNANCY  Not known to be harmful; manufacturer advises use only if essential.
- BREAST FEEDING  Avoid—present in milk; apnoea reported in infant.
- EXCEPTIONS TO LEGAL CATEGORY  Dicycloverine hydrochloride can be sold to the public provided that max. single dose is 10 mg and max. daily dose is 60 mg.

- MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Oral solution
- Dicycloverine hydrochloride (Non-proprietary)
  Dicycloverine hydrochloride 2 mg per 1 ml Dicycloverine hydrochloride 10mg/5ml oral solution 100 ml (Pos) no price available
  Dicycloverine hydrochloride 2 mg per 1 ml Dicycloverine hydrochloride 2 mg per 1 ml
  10mg/5ml oral solution 100 ml (Pos) no price available
  120 ml (Pos) £196.36 DT price + £319.75 300 ml (Pos) no price available

Tablet
- Dicycloverine hydrochloride (Non-proprietary)
  Dicycloverine hydrochloride 10 mg Dicycloverine 10mg tablets 100 tablet (Pos) £201.22 DT price = £184.25
Dicycloverine hydrochloride with aluminium hydroxide, magnesium oxide and simeticone

The properties listed below are those particular to the combination only. For the properties of the components please consider, dicycloverine hydrochloride p. 82, aluminium hydroxide p. 964, simeticone p. 70.

- **INDICATIONS AND DOSE**
  - Symptomatic relief of gastro-intestinal disorders characterised by smooth muscle spasm
    - **BY MOUTH**
      - Child 12-17 years: 10–20 mL every 4 hours as required
      - Adult: 10–20 mL every 4 hours as required
  - **INTERACTIONS** → Appendix 1: antacids, dicycloverine

- **MEDICINAL FORMS**
  - Oral suspension
    - Kolanticon (Peckforton Pharmaceuticals Ltd)
      - Dicycloverine hydrochloride 500 microgram per 1 ml, Simeticone 4 mg per 1 ml, Magnesium oxide light 20 mg per 1 ml, Aluminium hydroxide dried 40 mg per 1 ml. Kolanticon gel sugar-free | 200 ml £4.00 sugar-free | 500 ml £6.00

Hyoscine butylbromide

- **INDICATIONS AND DOSE**
  - Symptomatic relief of gastro-intestinal or genito-urinary disorders characterised by smooth muscle spasm
    - **BY MOUTH**
      - Child 6-11 years: 10 mg 3 times a day
      - Child 12-17 years: 20 mg 4 times a day
      - Adult: 20 mg 4 times a day
  - **IRRITABLE BOWEL SYNDROME**
    - **BY MOUTH**
      - Adult: 10 mg 3 times a day; increased if necessary up to 20 mg 4 times a day
  - **ACUTE SPASM | SPASM IN DIAGNOSTIC PROCEDURES**
    - Initially by intramuscular injection, or by slow intravenous injection
      - Adult: 20 mg, then (by intramuscular injection or by slow intravenous injection) 20 mg after 30 minutes if required, dose may be repeated more frequently in endoscopy; maximum 100 mg per day
  - **EXCESSIVE RESPIRATORY SECRETIONS IN PALLIATIVE CARE**
    - **BY MOUTH**
      - Child 1 month-1 year: 300–500 micrograms/kg 3–4 times a day (max. per dose 5 mg)
      - Child 2–4 years: 5 mg 3–4 times a day
      - Child 5–11 years: 10 mg 3–4 times a day
      - Child 12–17 years: 20–20 mg 3–4 times a day
    - **BY INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INJECTION**
      - Child 1 month-4 years: 300–500 micrograms/kg 3–4 times a day (max. per dose 5 mg)
      - Child 5–11 years: 5–10 mg 3–4 times a day
      - Child 12–17 years: 10–20 mg 3–4 times a day
    - **BY SUBCUTANEOUS INJECTION**
      - Adult: 20 mg every 4 hours if required, adjusted according to response to up to 20 mg every 1 hour
    - **BY SUBCUTANEOUS INFUSION**
      - Adult: 20–120 mg/24 hours

**BOWEL COLIC (IN PALLIATIVE CARE)**

- **BY MOUTH**
  - Child 1 month-1 year: 300–500 micrograms/kg 3–4 times a day (max. per dose 5 mg)
  - Child 2–4 years: 5 mg 3–4 times a day
  - Child 5–11 years: 10 mg 3–4 times a day
  - Child 12–17 years: 20–20 mg 3–4 times a day
- **BY INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INJECTION**
  - Child 1 month-4 years: 300–500 micrograms/kg 3–4 times a day (max. per dose 5 mg)
  - Child 5–11 years: 5–10 mg 3–4 times a day
  - Child 12–17 years: 10–20 mg 3–4 times a day
  - **BY SUBCUTANEOUS INJECTION**
    - Adult: 20 mg every 4 hours if required, adjusted according to response to up to 20 mg every 1 hour
  - **BY SUBCUTANEOUS INFUSION**
    - Adult: 60–300 mg/24 hours

**PHARMACOKINETICS**

Administration by mouth is associated with poor absorption.

**UNLICENSED USE** Tablets not licensed for use in children under 6 years. Injection not licensed for use in children (age range not specified by manufacturer).

**IMPORTANT SAFETY INFORMATION**

MHRA/CHM ADVICE: HYOSCINE BUTYLBROMIDE (BUSCOPAN®) INJECTION: RISK OF SERIOUS ADVERSE EFFECTS IN PATIENTS WITH UNDERLYING CARDIAC DISEASE (FEBRUARY 2017)

The MHRA advises that hyoscine butylbromide injection can cause serious adverse effects including tachycardia, hypotension, and anaphylaxis; several reports have noted that anaphylaxis is more likely to be fatal in patients with underlying coronary heart disease. Hyoscine butylbromide injection is contra-indicated in patients with tachycardia and should be used with caution in patients with cardiac disease; the MHRA recommends that these patients are monitored and that resuscitation equipment and trained personnel are readily available.

**CONTRA-INDICATIONS**

- With intramuscular use or intravenous use or subcutaneous use Tachycardia

**INTERACTIONS** → Appendix 1: hyoscine

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**

Anaphylaxis

**SPECIFIC SIDE-EFFECTS**

- **Common or very common**
  - With intramuscular use or intravenous use or subcutaneous use Tachycardia
  - Uncommon
    - With oral use Tachycardia
    - Frequency not known
      - With intramuscular use or intravenous use or subcutaneous use Hypotension
  - **PREGNANCY** Manufacturer advises avoid.
  - **BREAST FEEDING** Amount too small to be harmful.

**DIRECTIONS FOR ADMINISTRATION**

- With oral use in children For administration by mouth, injection solution may be used; content of ampoule may be stored in a refrigerator for up to 24 hours after opening.
- With intravenous use in children For intravenous injection, may be diluted with Glucose 5% or Sodium Chloride 0.9%; give over at least 1 minute.
## Propantheline bromide

### INDICATIONS AND DOSE
**Symptomatic relief of gastro-intestinal disorders characterised by smooth muscle spasm**
- **Adult enuresis**
  - **By mouth**
    - Child 12-17 years: 15 mg 3 times a day, dose to be taken at least one hour before food and 30 mg, dose to be taken at night; maximum 120 mg per day
    - Adult: Initially 15 mg 3 times a day, dose to be taken at least one hour before food and 30 mg, dose to be taken at bedtime, subsequently adjusted according to response; maximum 120 mg per day

### SIDE-EFFECTS
- **Allergic reactions**
- **Dizziness**
- **Driving and skilled tasks**
- **Gastro-intestinal smooth muscle spasm**
- **Irritable bowel syndrome**
- **Jaundice**
- **Wheezing**

### MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, tablets and liquid.

#### Tablets
- **Pro-Banthine** (Kyowa Kirin Ltd)
  - Propantheline bromide 15 mg Pro-Banthine 15mg tablets | 112 tablet [Pkt] £20.74 DT price = £20.74
- **Propantheline bromide (Non-proprietary)**
  - Propantheline bromide 15 mg Propantheline bromide 15mg tablets | 100 tablet [Pkt] no price available

### PREGNANCY
Manufacturer advises caution.

### UNLICENSED USE
Tablets not licensed for use in children under 12 years.

### INTERACTIONS
- Appendix 1: propantheline

### MEDICATIONS TO BE AVOIDED
- Hyoscine butylbromide

### NOTIFICATION REQUIREMENTS
- No information available.

### PATIENT AND CARER ADVICE
Driving and skilled tasks

## Mebeverine hydrochloride

### INDICATIONS AND DOSE
**Adjunct in gastro-intestinal disorders characterised by smooth muscle spasm**
- **By mouth using immediate-release medicines**
  - Child 10-17 years: 135–150 mg 3 times a day, dose preferably taken 20 minutes before meals
  - Adult: 135–150 mg 3 times a day, dose preferably taken 20 minutes before meals

### SIDE-EFFECTS
- **Allergic reactions**
- **Contraindications** Paralytic ileus
- **Dizziness**
- **Driving and skilled tasks**
- **Irritable bowel syndrome**
- **Jaundice**

### MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

#### Capsules
- **Alverine citrate (Non-proprietary)**
  - Alverine citrate 60 mg Alverine 60mg capsules | 10 capsule [P] £19.45 DT price = £19.45
  - Alverine citrate 120 mg Alverine 120mg capsules | 60 capsule [P] £23.28 DT price = £23.28
  - Audmonal (Teva UK Ltd)
    - Alverine citrate 60 mg Audmonal 60mg capsules | 10 capsule [P] £14.80 DT price = £14.80
  - Alverine citrate 120 mg Audmonal Forte 120mg capsules | 60 capsule [P] £17.75 DT price = £17.75
- **Gielism** (HFA Healthcare Products Ltd)
  - Alverine citrate 60 mg Gielism 60mg capsules | 100 capsule [P] £19.48 DT price = £19.48
- **Spasmonal** (Meda Pharmaceuticals Ltd)
  - Alverine citrate 60 mg Spasmonal 60mg capsules | 100 capsule [P] £16.45 DT price = £16.45

## Antispasmodics

### Alverine citrate

#### INDICATIONS AND DOSE
**Symptomatic relief of gastro-intestinal disorders characterised by smooth muscle spasm**
- **Dysmenorrhoea**
  - Child 12-17 years: 60–120 mg 1–3 times a day
  - Adult: 60–120 mg 1–3 times a day

#### CONTRA-INDICATIONS
- Intestinal obstruction
- Paraletic ileus

#### SIDE-EFFECTS
- Dizziness
- Dyspnoea
- Headache

#### PREGNANCY
Manufacturer advises caution.

### BREAST FEEDING
Manufacturer advises caution.

### PATIENT AND CARER ADVICE
Driving and skilled tasks

**Dizziness may affect performance of skilled tasks (e.g. driving).**
PREGNANCY Not known to be harmful—manufacturers advise avoid.

BREAST FEEDING Manufacturers advise avoid—no information available.

PATIENT AND CARER ADVICE

In adults Mebeverine hydrochloride can be sold to the public for symptomatic relief of irritable bowel syndrome provided that max. single dose is 135 mg and max. daily dose is 405 mg; for uses other than symptomatic relief of irritable bowel syndrome provided that max. single dose is 100 mg and max. daily dose is 300 mg.

EXCEPTIONS TO LEGAL CATEGORY

GALLSTONES

Description of condition

Gallstones (cholelithiasis) occur when hard mineral or fatty deposits form in the gallbladder. Gallstone disease is a general term that describes the presence of one or more stones in the gallbladder or in the bile duct, and the symptoms and complications that they may cause.

The majority of patients with gallstones remain asymptomatic. When the stones irritate the gallbladder or block part of the biliary system, the patient can experience symptoms such as pain, or infection and inflammation that if left untreated, can lead to severe complications such as biliary colic, acute cholecystitis, cholangitis, pancreatitis, and obstructive jaundice.

Non-drug treatment

Asymptomatic gallbladder stones do not need to be treated unless symptoms develop.

Drug treatment

Analgesia should be offered to control pain symptoms. Paracetamol p. 422 or nonsteroidal anti-inflammatory drugs (see Non-steroidal anti-inflammatory drugs p. 1028) are recommended for intermittent mild-to-moderate pain. Intramuscular diclofenac sodium p. 1034 can be given for severe pain or, if not suitable, an intramuscular opioid (such as morphine p. 439 or pethidine hydrochloride p. 445).

Although ursodeoxycholic acid p. 86 has been used for the management of gallstone disease, there is no evidence to support its use.

USEFUL RESOURCES


INBORN ERRORS OF PRIMARY BILE ACID SYNTHESIS

Description of condition

Inborn errors of primary bile acid synthesis are a group of diseases in which the liver does not produce enough primary bile acids due to enzyme deficiencies. These acids are the main components of the bile, and include cholic acid and chenodeoxycholic acid.
**Primary biliary cholangitis**  
30-May-2017

**Description of condition**
Primary biliary cholangitis (or primary biliary cirrhosis) is a chronic cholestatic disease which develops due to progressive destruction of small and intermediate bile ducts within the liver, subsequently evolving to fibrosis and cirrhosis.

**Treatment**
Ursodeoxycholic acid below is recommended for the management of primary biliary cholangitis, including those with asymptomatic disease. It slows disease progression, but the effect on overall survival is uncertain. Liver transplantation can be considered in patients with advanced primary biliary cholangitis.

**BILE ACIDS**

**Cholic acid**  
21-Mar-2016

- **Drug Action** Cholic acid is the predominant primary bile acid in humans, which can be used to provide a source of bile acid in patients with inborn deficiencies in bile acid synthesis.

- **Indications and Dose**
  
  **Indications of primary bile acid synthesis (initiated by a specialist)**
  
  - **by mouth**
    - Adult: Usual dose 5–15 mg/kg daily; increased in steps of 50 mg daily in divided doses if required, dose to be given with food at the same time each day; Usual maximum 500 mg/24 hours

- **Interactions** → Appendix 1: cholic acid
- **Side-effects** Diarrhoea · gallstones (long term use) · pruritus

**Side-effects, Further Information**
Patients presenting with pruritus and/or persistent diarrhoea should be investigated for potential overdose by a serum and/or urine bile acid assay.

- **Pregnancy** Limited data available—not known to be harmful, manufacturer advises continue treatment.
  
  Manufacturer advises monitor patient parameters more frequently in pregnancy.

- **Breast Feeding** Present in milk but not known to be harmful.

- **Hepatic Impairment** Manufacturer advises monitor closely.

- **Monitoring Requirements** Manufacturer advises monitor serum and/or urine bile-acid concentrations every 3 months for the first year, then every 6 months for three years, then annually; monitor liver function tests at the same or greater frequency.

- **Directions for Administration** Manufacturer advises capsules may be opened and the content added to infant formula, juice, fruit compote, or yoghurt for administration.

- **Patient and Carer Advice** Counselling advised on administration.

**Medicinal Forms**
There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>25</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>▶ Kolbam (Retrophin Inc) ▼</td>
<td></td>
</tr>
<tr>
<td>Cholic acid 50 mg Kolbam 50mg capsules</td>
<td>90 capsule [PsM] £3.240.00</td>
</tr>
<tr>
<td>Cholic acid 250 mg Kolbam 250mg capsules</td>
<td>90 capsule [PsM] £11.340.00</td>
</tr>
<tr>
<td>▶ Orphacol (Laboratoires CTRS) ▼</td>
<td></td>
</tr>
<tr>
<td>Cholic acid 50 mg Orphacol 50mg capsules</td>
<td>30 capsule [PsM] £1.860.00</td>
</tr>
<tr>
<td>Cholic acid 250 mg Orphacol 250mg capsules</td>
<td>30 capsule [PsM] £6.630.00</td>
</tr>
</tbody>
</table>

**Ursodeoxycholic acid**

- **Indications and Dose**
  
  **Dissolution of gallstones**
  
  - **by mouth**
    - Adult: 8–12 mg/kg once daily, dose to be taken at bedtime, alternatively 8–12 mg/kg daily in 2 divided doses for up to 2 years; treatment is continued for 3–4 months after stones dissolve

- **Primary biliary cirrhosis**
  
  - **by mouth**
    - Adult: 12–16 mg/kg daily in 3 divided doses for 3 months, then 12–16 mg/kg once daily, dose to be taken at bedtime

- **Contra-Indications** Acute inflammation of the gall bladder · frequent episodes of biliary colic · inflammatory diseases and other conditions of the colon, liver or small intestine which interfere with enterohepatic circulation of bile salts · non-functioning gall bladder · radio-opaque stones

- **Caution** Liver disease

- **Interactions** → Appendix 1: ursodeoxycholic acid

- **Side-Effects**
  
  - Common or very common Diarrhoea
  
  - Very rare Abdominal pain · gallstone calcification · urticaria

- **Frequency not known** Nausea · pruritus · vomiting

- **Pregnancy** No evidence of harm but manufacturer advises avoid.

- **Breast Feeding** Not known to be harmful but manufacturer advises avoid.

- **Hepatic Impairment** Avoid in chronic liver disease (but used in primary biliary cirrhosis).

- **Monitoring Requirements** In primary biliary cirrhosis, monitor liver function every 4 weeks for 3 months, then every 3 months.

- **Patient and Carer Advice** Patients should be given dietary advice (including avoidance of excessive cholesterol and calories).
MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Oral suspension**
CAUTIONARY AND ADVISORY LABELS 21
▶ Ursodiol (Dr. Falk Pharma UK Ltd)
Ursodeoxycholic acid 50 mg per 1 ml Ursodiol 250mg/5ml oral suspension sugar-free | 250 ml [PO] £26.98 DT price = £26.98

**Tablet**
CAUTIONARY AND ADVISORY LABELS 21
▶ Ursodeoxycholic acid (Non-proprietary)
Ursodeoxycholic acid 150 mg Ursodeoxycholic acid 150mg tablets | 60 tablet [PO] £19.02 DT price = £19.02
Ursodeoxycholic acid 300 mg Ursodeoxycholic acid 300mg tablets | 60 tablet [PO] £47.63 DT price = £47.63
▶ Cholusor (HFA Healthcare Products Ltd)
Ursodeoxycholic acid 250 mg Cholusor 250mg tablets | 60 tablet [PO] £18.00
Ursodeoxycholic acid 500 mg Cholusor 500mg tablets | 60 tablet [PO] £45.00
▶ Destolit (Norgine Pharmaceuticals Ltd)
Ursodeoxycholic acid 150 mg Destolit 150mg tablets | 60 tablet [PO] £18.39 DT price = £19.02
▶ Ursodil (Dr. Falk Pharma UK Ltd)
Ursodeoxycholic acid 500 mg Ursodil 500mg tablets | 100 tablet [PO] £80.00

**Capsule**
CAUTIONARY AND ADVISORY LABELS 21
▶ Ursodeoxycholic acid (Non-proprietary)
Ursodeoxycholic acid 250 mg Ursodeoxycholic acid 250mg capsules | 60 capsule [PO] £31.50 DT price = £25.29
▶ Ursodil (Dr. Falk Pharma UK Ltd)
Ursodeoxycholic acid 250 mg Ursodil 250mg capsules | 60 capsule [PO] £30.17 DT price = £25.29 | 100 capsule [PO] £31.88

PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES ➤ VASOPRESSIN AND ANALOGUES

Terlipressin acetate

**INDICATIONS AND DOSE**

**GLYPRESSIN® INJECTION**

**Bleeding from oesophageal varices**
▶ BY INTRAVENOUS INJECTION
Adult (body-weight up to 50 kg): Initially 2 mg every 4 hours until bleeding controlled, then reduced to 1 mg every 4 hours if required, maximum duration 48 hours
Adult (body-weight 50 kg and above): Initially 2 mg every 4 hours until bleeding controlled, reduced if not tolerated to 1 mg every 4 hours, maximum duration 48 hours

**VARIQUEL® INJECTION**

**Bleeding from oesophageal varices**
▶ BY INTRAVENOUS INJECTION
Adult (body-weight up to 50 kg): Initially 1 mg, then 1 mg every 4–6 hours for up to 72 hours, to be administered over 1 minute
Adult (body-weight 50–69 kg): Initially 1.5 mg, then 1 mg every 4–6 hours for up to 72 hours, to be administered over 1 minute
Adult (body-weight 70 kg and above): Initially 2 mg, then 1 mg every 4–6 hours for up to 72 hours, to be administered over 1 minute

**CAUTIONS**
Arrhythmia • elderly • electrolyte and fluid disturbances • heart disease • history of QT-interval prolongation • respiratory disease • septic shock • uncontrolled hypertension • vascular disease

**SIDE-EFFECTS**
▶ Common or very common Abdominal cramps • arrhythmia • bradycardia • diarrhoea • headache • hypertension • hypotension • pallor • peripheral ischaemia
▶ Uncommon Angina • bronchospasm • convulsions • hot flushes • hyponatraemia • intestinal ischaemia • myocardial infarction • nausea • pulmonary oedema • respiratory failure • tachycardia • vomiting
▶ Rare Dyspnoea
▶ Very rare Hyperglycaemia • stroke
▶ Frequency not known Heart failure • skin necrosis

**PREGNANCY**
Avoid unless benefits outweigh risk—uterine contractions and increased intra-uterine pressure in early pregnancy, and decreased uterine blood flow reported.

**BREAST FEEDING**
Avoid unless benefits outweigh risk—no information available.

**RENAL IMPAIRMENT**
Use with caution in chronic renal failure.

TERPENES

Borneol with camphene, cineole, menthol, menthone and pinene

**INDICATIONS AND DOSE**

**Biliary disorders**
▶ BY MOUTH
Adult: 1–2 capsules 3 times a day, to be taken before food

**LESS SUITABLE FOR PRESCRIBING** Rowachol® is less suitable for prescribing.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Gastro-resistant capsule**
CAUTIONARY AND ADVISORY LABELS 22
▶ Rowachol (Meadow Laboratories Ltd)
Cineole 2 mg, Borneol 5 mg, Camphene 5 mg, Menthone 6 mg, Pinene 17 mg, Menthol 32 mg Rowachol gastro-resistant capsules | 50 capsule [PO] £7.35

7.2 Oesophageal varices

Other drugs used for Oesophageal varices Vasopressin, p. 630

**Solution for injection**
▶ Glypressin (Ferring Pharmaceuticals Ltd)
Terlipressin acetate 120 microgram per 1 ml Glypressin 1mg/8.5ml solution for injection ampoules | 5 ampoule [PO] no price available
▶ Variquel (Sinclair IS Pharma Plc)
Terlipressin acetate 200 microgram per 1 ml Variquel 1mg/5ml solution for injection vials | 5 vial [PO] £89.98 (Hospital only)

**Powder and solvent for solution for injection**
▶ Glypressin (Ferring Pharmaceuticals Ltd)
Terlipressin acetate 1 mg Glypressin 1mg powder and solvent for solution for injection vials | 5 vial [PO] £92.33
▶ Variquel (Alliance Pharmaceuticals Ltd)
Terlipressin acetate 1 mg Variquel 1mg powder and solvent for solution for injection vials | 5 vial [PO] £89.48
Obesity should be managed in an appropriate setting.

Patients should be encouraged to engage in a lifestyle change-related health problems. A waist circumference of 80 cm (90 cm for Asian men), and women with a waist circumference of 80 cm are at increased risk of obesity-related health problems. A waist circumference of >102 cm in men and >88 cm in women indicates a very high risk of obesity-related health problems.

**Aims of treatment**

Management should be aimed at modest, sustainable weight loss and maintenance of a healthy weight, to reduce the risk factors associated with obesity.

**Overview**

Obesity should be managed in an appropriate setting by staff who have been trained in the management of obesity. Patients should be monitored for changes in weight, as well as changes in blood pressure and blood lipids, and for other associated conditions.

An initial assessment should consider potential underlying causes (e.g. hypothyroidism) and a review of the appropriateness of current medications which are known to cause weight gain, e.g. atypical antipsychotics, beta-adrenoceptor blocking drugs, insulin (when used in the treatment of type 2 diabetes), lithium carbonate, lithium citrate, sodium valproate, sulphonylureas, thiazolidinediones, and tricyclic antidepressants.

**Lifestyle changes**

Patients should be encouraged to engage in a sustainable weight management programme which includes strategies to change behaviour, increase physical activity, and improve diet and eating behaviour.

**Drug treatment**

Drug treatment should never be used as the sole element of treatment and should be used as part of an overall weight management plan. An anti-obesity drug should be considered only for those with a BMI of >30 kg/m², in whom diet, exercise and behaviour changes fail to achieve a realistic reduction in weight. In the presence of associated risk factors, it may be appropriate to prescribe an anti-obesity drug to individuals with a BMI of >28 kg/m². A vitamin and mineral supplement may also be considered if there is concern about inadequate micronutrient intake, particularly for vulnerable groups such as the elderly and younger patients.

The effect of management should be monitored on a regular basis with reinforcement of supporting lifestyle advice. Rates of weight loss may be slower in patients with type 2 diabetes, so less strict goals than in those without diabetes may be appropriate.

Orlistat, a lipase inhibitor, reduces the absorption of dietary fat.

**INDICATIONS AND DOSE**

Adjunct in obesity (in conjunction with a mildly hypocaloric diet in individuals with a body mass index (BMI) of 30 kg/m² or more or in individuals with a BMI of 28 kg/m² or more in the presence of other risk factors such as type 2 diabetes, hypertension, or hypercholesterolaemia).

**CONTRA-INDICATIONS** Cholestasis · chronic malabsorption syndrome

**CAUTIONS** Chronic kidney disease · may impair absorption of fat-soluble vitamins · volume depletion

**INTERACTIONS** Appendix 1: orlistat

**SIDE-EFFECTS**

Common or very common Abdominal distension (gastro-intestinal effects minimised by reduced fat intake) · abdominal pain (gastro-intestinal effects minimised by reduced fat intake) · anxiety · faecal incontinence · faecal...
9 Rectal and anal disorders

9.1 Anal fissures

**Anal fissure**

**Description of condition**

An anal fissure is a tear or ulcer in the lining of the anal canal, immediately within the anal margin. Clinical features of anal fissure include bleeding and persistent pain on defecation, and a linear split in the anal mucosa.

**Aims of treatment**

The aim of treatment is to relieve pain and promote healing of the fissure.

**Drug treatment**

**Acute anal fissure**

Initial management of acute anal fissures (present for less than 6 weeks) should focus on ensuring that stools are soft and easily passed. Bulk-forming laxatives (such as ispaghula husk p. 53) are recommended and an osmotic laxative (such as lactulose p. 55) can be considered as an alternative—see also Constipation p. 51, for further information about these laxatives. Short-term use of a topical preparation containing a local anaesthetic (such as lidocaine hydrochloride p. 1242) or a simple analgesic (such as paracetamol p. 422 or ibuprofen p. 1041) may be offered for prolonged burning pain following defecation. If these measures are inadequate, the patient should be referred for specialist treatment in hospital.

**Chronic anal fissure**

Chronic anal fissures (present for 6 weeks or longer, and associated pain, may be treated with glyceryl trinitrate p. 212 rectal ointment 0.4% or 0.2% [unlicensed] (available from Special-order manufacturers p. 1493 or specialist importing companies). Limited evidence suggests that the strength used does not influence the effectiveness, but that the higher strength potentially increases the incidence of side-effects. Healing rates with topical glyceryl trinitrate are marginally superior to placebo, but the incidence of headache as an adverse effect is quite high (about 20-30% of patients). Recurrence of the fissure after treatment is common.

As an alternative to glyceryl trinitrate rectal ointment, chronic anal fissure may also be treated with topical diltiazem hydrochloride 2% p. 152 [unlicensed] or nifedipine 0.2-0.5% p. 157 [unlicensed] (available from Special-order manufacturers p. 1493 or specialist importing companies), which have a lower incidence of adverse effects than topical glyceryl trinitrate. Oral nifedipine [unlicensed indication] and oral diltiazem hydrochloride [unlicensed indication] may be as effective as topical treatment, but the incidence of adverse effects are likely to be higher and topical preparations are preferred.

Patients who do not respond to first-line treatment may be referred to a specialist for local injection of botulinum toxin type A [unlicensed indication].

**Non-drug treatment**

Surgery is an effective option for the management of chronic anal fissure in adults but is generally reserved for those who do not respond to drug treatment.

9.2 Haemorrhoids

**Haemorrhoids**

**Description of condition**

Haemorrhoids, or piles, are abnormal swellings of the vascular mucosal anal cushions around the anus. Internal haemorrhoids arise above the dentate line and are usually painless unless they become strangulated. External haemorrhoids originate below the dentate line and can be itchy or painful. Women are predisposed to developing haemorrhoids during pregnancy.

**Aims of treatment**

The aims of treatment are to reduce the symptoms (pain, bleeding and swelling), promote healing, and prevent recurrence.

**Non-drug treatment**

Stools should be kept soft and easy to pass (to minimise straining) by increasing dietary fibre and fluid intake. Advice about perianal hygiene is helpful to aid healing and reduce irritation and itching.

**Drug treatment**

If constipation is reported, it should be treated. A bulk-forming laxative can be prescribed (see Constipation p. 51) A simple analgesic such as paracetamol p. 422 can be used for pain relief. Opioid analgesics should be avoided as they can cause constipation, and NSAIDs should be avoided if rectal bleeding is present.

Topical preparations that contain a combination of local anaesthetics, corticosteroids, astringents, lubricants, and antiseptics are available—see Related drugs below. They can offer symptomatic relief of local pain and itching but evidence does not suggest that any preparation is more effective than any other.

Topical preparations containing local anaesthetics (lidocaine, benzocaine, cinchocaine and pramocaine) should only be used for a few days as they may cause sensitisation of the anal skin. Local anaesthetics can be absorbed through the rectal mucosa (with a theoretical risk of systemic side effects) and very rarely may cause increased irritation; therefore excessive application should be avoided.

Topical preparations combining corticosteroids with local anaesthetics and soothing agents are available for the management of haemorrhoids. They may ameliorate local perianal inflammation, but no data suggest that they actually reduce haemorrhoidal swelling, bleeding, or protrusion.
Topical corticosteroids are suitable for occasional short-term use (no more than 7 days) after exclusion of infections (such as perianal streptococcal infection, herpes simplex or perianal thrush). Long-term use of corticosteroid creams can cause ulceration or permanent damage due to thinning of the perianal skin and should be avoided. Continuous or excessive use carries a risk of adrenal suppression and systemic corticosteroid effects.

Treatments available from specialists include rubber band ligation, injection sclerotherapy (using phenol p. 92 in oil), infrared coagulation/photocoagulation, bipolar diathermy and direct-current electrotherapy, haemorrhoidectomy, stapled haemorrhoidectomy, and haemorrhoidal artery ligation.

Pregnancy

Bulk forming laxatives are not absorbed, and are therefore safe for use in pregnant women (see Pregnancy, under Constipation p. 51). No topical haemorrhoidal preparations are licensed for use during pregnancy.

If treatment with a topical haemorrhoidal preparation is required, a soothing preparation containing simple, soothing products (not local anaesthetics or corticosteroids) can be considered.

Corticosteroids

Benzyl benzoate with bismuth oxide, bismuth subgallate, hydrocortisone acetate, peru balsam and zinc oxide

---

**INDICATIONS AND DOSE**

**Haemorrhoids | Pruritus ani**

- **BY RECTUM USING OINTMENT**
  - Adult: Apply twice daily for no longer than 7 days, to be applied morning and night and after a bowel movement

- **BY RECTUM USING SUPPOSITORIES**
  - Adult: 1 suppository twice daily for no longer than 7 days, to be inserted night and morning, additional dose after a bowel movement

---

**CAUTIONS**

Local anaesthetic component can be absorbed through the rectal mucosa (avoid excessive application, particularly in children and infants) - local anaesthetic component may cause sensitisation (use for short periods only—no longer than a few days)

---

**PRESCRIBING AND DISPENSING INFORMATION**

A proprietary brand Anusol Plus HC® (ointment and suppositories) is on sale to the public.

---

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Ointment**

- **Anusol-Hc** (McNeil Products Ltd)
  - Hydrocortisone acetate 2.5 mg per 1 gram, Bismuth oxide 8.75 mg per 1 gram, Benzyl benzoate 12.5 mg per 1 gram, Peru Balsam 18.75 mg per 1 gram, Bismuth subgallate 22.5 mg per 1 gram, Zinc oxide 107.5 mg per 1 gram
  - Anusol Hc ointment | 30 gram [POM] £2.49

- **Suppository**
  - **Anusol-Hc** (McNeil Products Ltd)
    - Hydrocortisone acetate 10 mg, Bismuth oxide 24 mg, Benzyl benzoate 33 mg, Peru Balsam 49 mg, Bismuth subgallate 59 mg, Zinc oxide 296 mg
    - Anusol HC suppositories | 12 suppository [POM] £1.74
Cinchoacaine with hydrocortisone

- **INDICATIONS AND DOSE**

  **PROCSEDEYL® OINTMENT**
  **Haemorrhoids | Pruritus ani**
  - **TO THE SKIN, OR BY RECTUM**
  - Child: Apply twice daily, to be administered morning and night and after a bowel movement. Do not use for longer than 7 days
  - Adult: Apply twice daily, to be administered morning and night and after a bowel movement. Apply externally or by rectum. Do not use for longer than 7 days

  **PROCSEDEYL® SUPPOSITORIES**
  **Haemorrhoids | Pruritus ani**
  - **BY RECTUM**
  - Child 12-17 years: 1 suppository, insert suppository night and morning and after a bowel movement. Do not use for longer than 7 days
  - Adult: 1 suppository, insert suppository night and morning and after a bowel movement. Do not use for longer than 7 days

  **UNIROID-HC® OINTMENT**
  **Haemorrhoids | Pruritus ani**
  - **TO THE SKIN, OR BY RECTUM**
  - Child 12-17 years: Apply twice daily, and apply after a bowel movement, apply externally or by rectum, do not use for longer than 7 days
  - Adult: Apply twice daily, and apply after a bowel movement, apply externally or by rectum, do not use for longer than 7 days

  **UNIROID-HC® SUPPOSITORIES**
  **Haemorrhoids | Pruritus ani**
  - **BY RECTUM**
  - Child 12-17 years: 1 suppository, insert twice daily and after a bowel movement. Do not use for longer than 7 days
  - Adult: 1 suppository, insert twice daily and after a bowel movement. Do not use for longer than 7 days

- **CAUTIONS**
  - Local anaesthetic component may cause sensitisation (use for short periods only—no longer than a few days)
  - There can be variation in the licensing of different medicines containing the same drug.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Ointment**
    - **Proctosedyl** (Sanofi)
      - Cinchoacaine hydrochloride 5 mg per 1 gram, Hydrocortisone 5 mg per 1 gram Proctosedyl ointment | 30 gram | £10.34
    - **Uniroid HC** (Chemidex Pharma Ltd)
      - Cinchoacaine hydrochloride 5 mg per 1 gram, Hydrocortisone 5 mg per 1 gram Uniroid HC ointment | 30 gram | £4.23
  - **Suppository**
    - **Proctosedyl** (Sanofi)
      - Cinchoacaine hydrochloride 5 mg, Hydrocortisone 5 mg Proctosedyl suppositories | 12 suppository | £5.08
    - **Uniroid HC** (Chemidex Pharma Ltd)
      - Cinchoacaine hydrochloride 5 mg, Hydrocortisone 5 mg Uniroid HC suppositories | 12 suppository | £1.31

Cinchoacaine with prednisolone

- **INDICATIONS AND DOSE**

  **PROCSEDEYL® OINTMENT**
  **Haemorrhoids | Pruritus ani**
  - **BY RECTUM USING OINTMENT**
    - Adult: Apply twice daily for 5–7 days, apply 3–4 times a day on the first day if necessary, then apply once daily for a few days after symptoms have cleared
    - **BY RECTUM USING SUPPOSITORIES**
      - Adult: 1 suppository daily for 5–7 days, to be inserted after a bowel movement

  **Haemorrhoids (severe cases) | Pruritus ani (severe cases)**
  - **BY RECTUM USING SUPPOSITORIES**
    - Adult: Initially 1 suppository 2–3 times a day, then 1 suppository daily for a total of 5–7 days, to be inserted after a bowel movement

- **CAUTIONS**
  - Local anaesthetic component can be absorbed through the rectal mucosa (avoid excessive application) - local anaesthetic component may cause sensitisation (use for short periods only—no longer than a few days)

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  **Ointment**
  - **Scheriproct** (Bayer Plc)
    - Prednisolone hexanoate 1.9 mg per 1 gram, Cinchoacaine hydrochloride 5 mg per 1 gram Scheriproct ointment | 30 gram | £2.94 DT price = £2.94
  - **Suppository**
    - **Scheriproct** (Bayer Plc)
      - Cinchoacaine hydrochloride 1 mg, Prednisolone hexanoate 1.3 mg Scheriproct suppositories | 12 suppository | £1.38 DT price = £1.38

Hydrocortisone with lidocaine

- **INDICATIONS AND DOSE**

  **Haemorrhoids | Pruritus ani**
  - **BY RECTUM USING AEROSOL SPRAY**
    - Adult: 1 spray up to 3 times a day for no longer than 7 days without medical advice, spray once over the affected area
    - **BY RECTUM USING OINTMENT**
      - Adult: Apply several times daily, for short term use only

- **CAUTIONS**
  - Local anaesthetic component can be absorbed through the rectal mucosa (avoid excessive application) - local anaesthetic component may cause sensitisation (use for short periods only—no longer than a few days)

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  **Ointment**
  - **Hydrocortisone with lidocaine (Non-proprietary)**
    - Hydrocortisone acetate 0.200% / Lidocaine 0.275% ointment | 20 gram | £4.19 DT price = £4.19
    - **Xyloproct** (Aspen Pharma Trading Ltd)
      - Hydrocortisone acetate 2.75 mg per 1 gram, Lidocaine 50 mg per 1 gram Xyloproct 5%/0.275% ointment | 20 gram | £4.19 DT price = £4.19
  - **Spray**
    - **Perinal** (Dermal Laboratories Ltd)
      - Hydrocortisone 2 mg per 1 gram, Lidocaine hydrochloride 10 mg per 1 gram Perinal spray | 30 ml | £6.11
## Reduced exocrine secretions

### Exocrine pancreatic insufficiency

**Description of condition**

Exocrine pancreatic insufficiency is characterised by reduced secretion of pancreatic enzymes into the duodenum. The main clinical manifestations are malabsorption and malnutrition, associated with low circulating levels of lipids, fat-soluble vitamins and micronutrients. Patients also present with gastro-intestinal symptoms such as diarrhoea, abdominal cramps and steatorrhoea.

Exocrine pancreatic insufficiency can result from chronic pancreatitis, cystic fibrosis, obstructive pancreatic tumours, coeliac disease, Zollinger-Ellison syndrome, and gastro-intestinal or pancreatic surgical resection.

### Aims of treatment

The aim of treatment is to relieve gastro-intestinal symptoms and to achieve a normal nutritional status.

### Drug treatment

Pancreatic enzyme replacement therapy with pancreatin p. 93 is the mainstay of treatment for exocrine pancreatic insufficiency. Pancreatin contains the three main groups of digestive enzymes: lipase, amylase and protease. These enzymes respectively digest fats, carbohydrates and proteins in their basic components so that they can be absorbed and utilised by the body. Pancreatin should be administered with meals and snacks. The dose should be adjusted, as necessary, to the lowest effective dose according to the symptoms of malabsorption.

There is limited evidence that acid suppression may improve the effectiveness of pancreatin. Acid-suppressing drugs (proton pump inhibitors or H2-receptor antagonists) may be trialled in patients who continue to experience symptoms despite high doses of pancreatin.

## Phenol

### Indications and dose

**Haemorrhoids** (particularly when unprolapsed)

- **By submusosal injection**
  - Adult: 2–3 mL, dose (using phenol 5%) to be injected into the submuscular layer at the base of the pile; several injections may be given at different sites, max. total injected 10 mL at any one time

### Side-effects

- Irritation · tissue necrosis

### Prescribing and dispensing information

When prepared extemporaneously, the BP states Oily Phenol Injection, BP consists of phenol 5% in a suitable fixed oil.

### Medicinal forms

There can be variation in the licensing of different medicines containing the same drug.

#### Foam

- **Proctofoam HC** (Meda Pharmaceuticals Ltd)
  - Hydrocortisone acetate 10 mg per 1 gram, Pramocaine hydrochloride 10 mg per 1 gram
  - Proctofoam HC foam enema | 40 dose
  - **Price**: £6.07

## Sclerosants

### Phenol

**Indications and dose**

- **Haemorrhoids**
  - **By rectum**
  - Adult: 1 applicatorful 2–3 times a day and 1 applicatorful, after a bowel movement, do not use for longer than 7 days; maximum 4 applicatorfuls per day

**Caution**

Local anaesthetic component can be absorbed through the rectal mucosa (avoid excessive application) · local anaesthetic component may cause sensitisation (use for short periods only—no longer than a few days)

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug.

#### Solution for injection

- **Phenol (Non-proprietary)**
  - Phenol 50 mg per 1 mL
  - Oily phenol 5% solution for injection 5 mL ampoules | 10 ampoule
  - **Price**: £56.73

#### Foam

- **Proctofoam HC** (Meda Pharmaceuticals Ltd)
  - Hydrocortisone acetate 10 mg per 1 gram, Pramocaine hydrochloride 10 mg per 1 gram
  - Proctofoam HC foam enema | 40 dose
  - **Price**: £6.07

### 10 Reduced exocrine secretions

**Exocrine pancreatic insufficiency**

**Description of condition**

Exocrine pancreatic insufficiency is characterised by reduced secretion of pancreatic enzymes into the duodenum. The main clinical manifestations are malabsorption and malnutrition, associated with low circulating levels of lipids, fat-soluble vitamins and micronutrients. Patients also present with gastro-intestinal symptoms such as diarrhoea, abdominal cramps and steatorrhoea.

Exocrine pancreatic insufficiency can result from chronic pancreatitis, cystic fibrosis, obstructive pancreatic tumours, coeliac disease, Zollinger-Ellison syndrome, and gastro-intestinal or pancreatic surgical resection.
three snacks. Food that is difficult to digest should be avoided, such as legumes (peas, beans, lentils) and high-fibre foods. Alcohol should be avoided completely. Reduced fat diets are not recommended.

Medium-chain triglycerides (see MCT oil, in Borderline mucosa, were thought to be useful in some patients. However evidence has shown that MCT-enriched preparations offer no advantage over a normal balanced diet.

**PANCREATIC ENZYMES**

**Pancreatin**

- **DRUG ACTION** Supplements of pancreatin are given to compensate for reduced or absent exocrine secretion. They assist the digestion of starch, fat, and protein.

- **INDICATIONS AND DOSE**

  **CREON® 10000**
  **Pancreatic insufficiency**
  ▶ **BY MOUTH**
  - Child: Initially 1–2 capsules, dose to be taken with each meal either taken whole or contents mixed with acidic fluid or soft food (then swallowed immediately without chewing)
  - Adult: Initially 1–2 capsules, dose to be taken with each meal either taken whole or contents mixed with acidic fluid or soft food (then swallowed immediately without chewing)

  **CREON® 25000**
  **Pancreatic insufficiency**
  ▶ **BY MOUTH**
  - Child 2–17 years: Initially 1–2 capsules, dose to be taken with each meal either taken whole or contents mixed with acidic fluid or soft food (then swallowed immediately without chewing)
  - Adult: Initially 1–2 capsules, dose to be taken with each meal either taken whole or contents mixed with acidic fluid or soft food (then swallowed immediately without chewing)

  **CREON® 40000**
  **Pancreatic insufficiency**
  ▶ **BY MOUTH**
  - Child 2–17 years: Initially 1–2 capsules, dose to be taken with each meal either taken whole or contents mixed with acidic fluid or soft food (then swallowed immediately without chewing)
  - Adult: Initially 1–2 capsules, dose to be taken with each meal either taken whole or contents mixed with acidic fluid or soft food (then swallowed immediately without chewing)

  **CREON® MICRO**
  **Pancreatic insufficiency**
  ▶ **BY MOUTH**
  - Child: Initially 100 mg, for administration advice, see Directions for administration
  - Adult: Initially 100 mg, for administration advice, see Directions for administration

  **DOSE EQUIVALENCE AND CONVERSION**
  ▶ For Creon® Micro: 100 mg granules = one measured scoopful (scoop supplied with product).

  **NUTRIZYM 22® GASTRO-RESISTANT CAPSULES**
  **Pancreatic insufficiency**
  ▶ **BY MOUTH**
  - Adult: Initially 1–2 capsules, dose to be taken with meals and 1 capsule as required, dose to be taken with snacks, doses should be swallowed whole or contents taken with water, or mixed with acidic fluid or soft food (then swallowed immediately without chewing)

**PANCREASE HL®**

**Pancreatic insufficiency**

▶ **BY MOUTH**

- Child 15–17 years: Initially 1–2 capsules, dose to be taken during each meal and 1 capsule, to be taken with snacks, all doses either taken whole or contents mixed with slightly acidic liquid or soft food (then swallowed immediately without chewing)
- Adult: Initially 1–2 capsules, dose to be taken during each meal and 1 capsule, to be taken with snacks, all doses either taken whole or contents mixed with slightly acidic liquid or soft food (then swallowed immediately without chewing)

**PANCREX®**

**Pancreatic insufficiency**

▶ **BY MOUTH**

- Child 2–17 years: 5–10 g, to be taken just before meals, washed down or mixed with milk or water
- Adult: 5–10 g, to be taken just before meals; washed down or mixed with milk or water

**PANCREX® V**

**Pancreatic insufficiency**

▶ **BY MOUTH**

- Child 1–11 months: 1–2 capsules, contents of capsule to be mixed with feeds
- Child 1–17 years: 2–6 capsules, dose to be taken with each meal either swallowed whole or sprinkled on food
- Adult: 2–6 capsules, dose to be taken with each meal either swallowed whole or sprinkled on food

**PANCREX® V POWDER**

**Pancreatic insufficiency**

▶ **BY MOUTH**

- Child: 0.5–2 g, to be taken before or with meals, washed down or mixed with milk or water
- Adult: 0.5–2 g, to be taken before or with meals, washed down or mixed with milk or water

**PANCREX® V TABLETS**

**Pancreatic insufficiency**

▶ **BY MOUTH**

- Child 2–17 years: 5–15 tablets, to be taken before meals
- Adult: 5–15 tablets, to be taken before meals

**PANCREX® V TABLETS FORTE**

**Pancreatic insufficiency**

▶ **BY MOUTH**

- Child 2–17 years: 6–10 tablets, to be taken before meals
- Adult: 6–10 tablets, to be taken before meals

**CONTRA-INDICATIONS**

**PANCREASE HL®** Should not be used in children aged 15 years or less with cystic fibrosis

**NUTRIZYM 22® GASTRO-RESISTANT CAPSULES** Should not be used in children aged 15 years or less with cystic fibrosis

**CAUTIONS** Can irritate the perioral skin and buccal mucosa if retained in the mouth. Excessive doses can cause perianal irritation

**INTERACTIONS** → Appendix 1: pancreatin

**SIDE-EFFECTS** Abdominal discomfort - hyperuricaemia (associated with very high doses) - hyperuricosuria (associated with very high doses) - mucosal irritation - nausea - skin irritation - vomiting

**PREGNANCY** Not known to be harmful.

**DIRECTIONS FOR ADMINISTRATION** Pancreatin is inactivated by gastric acid therefore manufacturer advises pancreatin preparations are best taken with food (or immediately before or after food). Since pancreatin is inactivated by heat, excessive heat should be avoided if preparations are mixed with liquids or food; manufacturer advises the resulting mixtures should not be kept for more

---

**BNF 74**

**Reduced exocrine secretions**

---

**Gastro-intestinal system**

---
than one hour and any left-over food or liquid containing pancreatin should be discarded. Enteric-coated preparations deliver a higher enzyme concentration in the duodenum (provided the capsule contents are swallowed whole without chewing). Manufacturer advises gastro-resistant granules should be mixed with slightly acidic soft food or liquid such as apple juice, and then swallowed immediately without chewing. Capsules containing enteric-coated granules can be opened and the granules administered in the same way. For infants, Creon Micro® granules can be mixed with a small amount of milk on a spoon and administered immediately — gastro-resistant granules should not be added to the baby’s bottle. Manufacturer advises Pancrex® V powder may be administered via nasogastric tube or gastrostomy tube — consult local and national official guidelines.

**PRESCRIBING AND DISPENSING INFORMATION**
Preparations may contain pork pancreatin — consult product literature.

**HANDLING AND STORAGE**
Hypersensitivity reactions occur occasionally and may affect those handling the powder.

**PATIENT AND CARER ADVICE**
Patients or carers should be given advice on administration.

It is important to ensure adequate hydration at all times in patients receiving higher-strength pancreatin preparations.

Medicines for Children leaflet: Pancreatin for pancreatic insufficiency [www.medicinesforchildren.org.uk](http://www.medicinesforchildren.org.uk)/pancreatin-for-pancreatic-insufficiency

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

### Gastro-resistant capsule
- **Creon** (Mylan Ltd)
  - Protease 600 unit, Amylase 8000 unit, Lipase 10000 unit Creon 10000 gastro-resistant capsules | 100 capsule [P] £12.93
  - Protease 1000 unit, Amylase 18000 unit, Lipase 25000 unit Creon 25000 gastro-resistant capsules | 100 capsule [P] £28.25
  - Protease 1600 unit, Amylase 25000 unit, Lipase 40000 unit Creon 40000 gastro-resistant capsules | 100 capsule [P] £41.80
- **Nutrizym** (Merck Serono Ltd)
  - Protease 1100 unit, Amylase 19800 unit, Lipase 22000 unit Nutrizym 22 gastro-resistant capsules | 100 capsule [P] £33.33
- **Pancrease** (Janssen-Cilag Ltd)
  - Protease 1250 unit, Amylase 22500 unit, Lipase 25000 unit Pancrease Ht gastro-resistant capsules | 100 capsule [P] £40.38

### Gastro-resistant tablet
**CAUTIONARY AND ADVISORY LABELS** 5, 25
- **Pancrex** (Essential Pharmaceuticals Ltd)
  - Protease 110 unit, Amylase 1700 unit, Lipase 1900 unit Pancrex V gastro-resistant tablets | 300 tablet [P] £38.79
  - Protease 330 unit, Amylase 5000 unit Pancrease 5600 unit Pancrex V Forte gastro-resistant tablets | 300 tablet [P] £48.11

### Gastro-resistant granules
**CAUTIONARY AND ADVISORY LABELS** 25
- **Creon** (Mylan Ltd)
  - Protease 200 unit, Amylase 3600 unit, Lipase 5000 unit Creon Micro Pancreatin 60.12mg gastro-resistant granules | 20 gram [P] £31.50
- **Pancrex** (Essential Pharmaceuticals Ltd)
  - Protease 300 unit, Amylase 4000 unit, Lipase 5000 unit Pancrex gastro-resistant granules | 300 gram [P] £57.00

### Powder
- **Pancrex** (Essential Pharmaceuticals Ltd)
  - Protease 1400 unit, Lipase 25000 unit, Amylase 30000 unit Pancrex V oral powder sugar-free | 300 gram [P] £58.88

---

### 11 Stoma care

#### Description of condition
A stoma is an artificial opening on the abdomen to divert flow of faeces or urine into an external pouch located outside of the body. This procedure may be temporary or permanent.

Colostomy and ileostomy are the most common forms of stoma but a gastrostomy, jejunostomy, duodenostomy or caecostomy may also be performed. Understanding the type and extent of surgical intervention in each patient is crucial in managing the patient’s pharmaceutical needs correctly.

**Overview**
Prescribing for patients with stoma calls for special care due to modifications in drug delivery, resulting in a higher risk of sub-optimal absorption. The following is a brief account of some of the main points to be borne in mind.

Enteric-coated and modified-release medicines are unsuitable, particularly in patients with an ileostomy, as there may not be sufficient release of active ingredient. Soluble tablets, liquids, capsules or uncoated tablets are more suitable due to their quicker dissolution. When a solid-dose form such as a capsule or a tablet is given, the contents of the ostomy bag should be checked for any remnants.

Preparations containing sorbitol as an excipient should be avoided, due to its laxative side effects.

#### Analgesics
Opioid analgesics may cause troublesome constipation in colostomy patients. When a non-opioid analgesic is required, paracetamol is usually suitable. Anti-inflammatory analgesics may cause gastric irritation and bleeding; faecal output should be monitored for traces of blood.

#### Antacids
The tendency to diarrhoea from magnesium salts or constipation from aluminium or calcium salts may be increased in patients with stoma.

#### Antisecretory drugs
The gastric acid secretion often increases stoma output. Proton pump inhibitors and somatostatin analogues (octreotide p. 877 and lanreotide p. 876) are often used to reduce this risk.

#### Antidiarrhoeal drugs
Loperamide hydrochloride p. 65 and codeine phosphate p. 431 reduce intestinal motility and decrease water and sodium output from an ileostomy. Loperamide hydrochloride circulates through the enterohepatic circulation, which is disrupted in patients with a short bowel; high doses of loperamide hydrochloride may be required. Codeine phosphate can be added if response with loperamide hydrochloride alone is inadequate.

#### Digoxin
Patients with a stoma are particularly susceptible to hypokalaemia if taking digoxin p. 106, due to fluid and sodium depletion. Potassium supplements or a potassium-sparing diuretic may be advisable with monitoring for early signs of toxicity.
Diuretics
Diuretics should be used with caution in patients with an ileostomy or with urostomy as they may become excessively dehydrated and potassium depletion may easily occur. It is usually advisable to use a potassium-sparing diuretic.

Iron preparations
Iron preparations may cause loose stools and sore skin in these patients. If this is troublesome and if iron is definitely indicated, an intramuscular iron preparation should be used. Modified-release preparations should be avoided for the reasons given above.

Laxatives
Laxatives should not be used in patients with an ileostomy where possible as they may cause rapid and severe loss of water and electrolytes.

Colostomy patients may suffer from constipation and whenever possible should be treated by increasing fluid intake or dietary fibre. Bulk-forming drugs can be tried. If they are insufficient, as small a dose as possible of a stimulant laxative such as senna p. 61 can be used with caution.

Potassium supplements
Liquid formulations are preferred to modified-release formulations. The daily dose should be split to avoid osmotic diarrhoea.

Care of stoma
Patients and their carers are usually given advice about the use of cleansing agents, protective creams, lotions, deodorants, or sealants whilst in hospital, either by the surgeon or by stoma care nurses. Voluntary organisations offer help and support to patients with stoma.
Chapter 2
Cardiovascular system

CONTENTS
1 Arrhythmias page 96
2 Bleeding disorders 107
2.1 Coagulation factor deficiencies 108
2.2 Subarachnoid haemorrhage 111
3 Blood clots 112
3.1 Blocked catheters and lines 112
3.2 Thromboembolism 112
4 Blood pressure conditions 135
4.1 Hypertension 135
4.1a Hypertension associated with pheochromocytoma 176
4.1b Hypertensive crises 177
4.1c Pulmonary hypertension page 178
4.2 Hypotension and shock 181
5 Heart failure 184
6 Hyperlipidaemia 188
7 Myocardial ischaemia 202
7.1 Acute coronary syndromes 206
7.1a Cardiac arrest 216
8 Oedema 218
9 Vascular disease 226
9.1 Vein malformations 228

1 Arrhythmias

Arrhythmias

Overview
Management of an arrhythmia requires precise diagnosis of the type of arrhythmia, and electrocardiography is essential; underlying causes such as heart failure require appropriate treatment.

Ectopic beats
If ectopic beats are spontaneous and the patient has a normal heart, treatment is rarely required and reassurance to the patient will often suffice. If they are particularly troublesome, beta-blockers are sometimes effective and may be safer than other suppressant drugs.

Atrial fibrillation
Treatment of patients with atrial fibrillation aims to reduce symptoms and prevent complications, especially stroke. All patients with atrial fibrillation should be assessed for their risk of stroke and thromboembolism. Atrial fibrillation can be managed by either controlling the ventricular rate (‘rate control’) or by attempting to restore and maintain sinus rhythm (‘rhythm control’). At any stage if treatment fails to control symptoms, or, if symptoms reoccur after cardioversion and specialised management is required, referral should be made within 4 weeks. If drug treatment fails to control the symptoms of atrial fibrillation or is unsuitable, ablation strategies can be considered. Review anticoagulation, stroke, and bleeding risk at least annually in all patients with atrial fibrillation.

Acute presentation
All patients with life-threatening haemodynamic instability caused by new-onset atrial fibrillation should undergo emergency electrical cardioversion without delaying to achieve anticoagulation. In patients presenting acutely but without life-threatening haemodynamic instability, rate or rhythm control can be offered if the onset of arrhythmia is less than 48 hours; rate control is preferred if onset is more than 48 hours or uncertain. Consideration of pharmacological or electrical cardioversion should be based on clinical circumstances. If pharmacological cardioversion has been agreed, intravenous amiodarone hydrochloride p. 102, or alternatively flecainide acetate p. 100, can be used (amiodarone hydrochloride is preferred if there is structural heart disease). If urgent rate control is required, a beta-blocker or verapamil hydrochloride p. 159 can be given intravenously.

Cardioversion
Sinus rhythm can be restored by electrical cardioversion, or pharmacological cardioversion with an oral or intravenous antiarrhythmic drug e.g. flecainide acetate or amiodarone hydrochloride. If atrial fibrillation has been present for more than 48 hours, electrical cardioversion is preferred and should not be attempted until the patient has been fully anticoagulated for at least 3 weeks; if this is not possible, parenteral anticoagulation should be commenced, and a left atrial thrombus ruled out immediately before cardioversion; oral anticoagulation should be given after cardioversion and continued for at least 4 weeks; prior to cardioversion, offer rate control as appropriate.

Drug treatment
Rate control is the preferred first-line drug treatment strategy for atrial fibrillation except in patients with new-onset atrial fibrillation, heart failure secondary to atrial fibrillation, atrial flutter suitable for an ablation strategy, atrial fibrillation with a reversible cause, or if rhythm control is more suitable based on clinical judgement. Ventricular rate can be controlled with a standard beta-blocker (not sotalol hydrochloride p. 105) or a rate-limiting calcium channel blocker such as diltiazem hydrochloride p. 152 [unlicensed indication], or verapamil hydrochloride as monotherapy. Choice of drug should be based on individual symptoms, heart rate, comorbidities, and patient preference. Digoxin p. 106 is usually only effective for controlling the ventricular rate at rest, and should therefore only be used as monotherapy in predominantly sedentary patients with non-paroxysmal atrial fibrillation. When a single drug fails to adequately control the ventricular rate, a combination of two drugs including a beta-blocker, digoxin, or diltiazem hydrochloride can be used. If symptoms are not controlled with a combination of two drugs, a rhythm-control strategy should be considered. If ventricular function is diminished, the combination of a beta-blocker (that is licensed for use in heart failure) and digoxin is preferred. Digoxin is also used when atrial fibrillation is accompanied by congestive heart failure.
If drug treatment is required to maintain sinus rhythm (‘rhythm control’) post-cardioversion, a standard beta-blocker is used. If a standard beta-blocker is not appropriate or is ineffective, consider an oral anti-arrhythmic drug such as sotalol hydrochloride, flecainide acetate, propafenone hydrochloride p. 101, or amiodarone hydrochloride; dronedarone p. 103 may be considered in paroxysmal or persistent atrial fibrillation (see NICE guidance). If necessary, amiodarone hydrochloride can be started 4 weeks before and continuing for up to 12 months after electrical cardioversion to increase success of the procedure, and to maintain sinus rhythm. Flecainide acetate or propafenone hydrochlorides should not be given when there is known ischaemic or structural heart disease. Consider amiodarone hydrochloride in patients with left ventricular impairment or heart failure.

**Paroxysmal atrial fibrillation**

In symptomatic paroxysmal atrial fibrillation, ventricular rhythm is controlled with a standard beta-blocker. Alternatively, if symptoms persist or a standard beta-blocker is not appropriate, an oral anti-arrhythmic drug such as sotalol (see NICE guidance), sotalol hydrochloride, flecainide acetate, propafenone hydrochloride, or amiodarone hydrochloride can be given (see also Paroxysmal supraventricular tachycardia and Supraventricular arrhythmias). In selected patients with infrequent episodes of symptomatic paroxysmal atrial fibrillation, sinus rhythm can be restored using the ‘pill-in-the-pocket’ approach; this involves the patient taking oral flecainide acetate or propafenone hydrochloride to self-treat an episode of atrial fibrillation when it occurs.

**Stroke prevention**

All patients with atrial fibrillation should be assessed for their risk of stroke and the need for thromboprophylaxis; this needs to be balanced with the patient’s risk of bleeding; a NICE guideline (NICE clinical guideline 180 (June 2014). Atrial fibrillation: The management of atrial fibrillation) recommends using the CHA2DS2-VASc assessment tool for stroke risk and the HAS-BLED tool for bleeding risk prior to and during anticoagulation. Risk factors for stroke taken into account by CHA2DS2-VASc include prior ischaemic stroke, transient ischaemic attacks, or thromboembolic events, heart failure, left ventricular systolic dysfunction, vascular disease, diabetes, hypertension, females, and patients over 65 years. Patients with a very low risk of stroke (CHA2DS2-VASc score of 0 for men or 1 for women) do not require an anticoagulant. Oral anticoagulants are contra-indicated for stroke prevention. Parenteral anticoagulation should be offered to patients with new-onset atrial fibrillation who are receiving subtherapeutic or no anticoagulation therapy until assessment is made, and appropriate anticoagulation is started. Oral anticoagulation should be offered to patients with confirmed diagnosis of atrial fibrillation in whom sinus rhythm has not been successfully restored within 48 hours of onset, patients who have had, or are at high risk of recurrence of atrial fibrillation such as those with structural heart disease, prolonged history of atrial fibrillation (more than 12 months), a history of failed attempts at cardioversion, and patients whom the risk of stroke outweighs the risk of bleeding. Anticoagulation treatment should not be withheld solely because of the risk of falls, and choice of treatment should be based on clinical features and patient preferences. Oral anticoagulation may be with a vitamin K antagonist (e.g. warfarin sodium p. 135), or in non-valvular atrial fibrillation with apixaban p. 121, dabigatran etexilate p. 131, or rivaroxaban p. 123. Anticoagulants are also indicated during cardioversion procedures. Aspirin p. 117 is less effective than warfarin sodium at preventing emboli; the modest benefit is offset by the risk of bleeding, and aspirin should not be offered as monotherapy solely for stroke prevention in atrial fibrillation. If anticoagulant treatment is contra-indicated or not tolerated, left atrial appendage occlusion can be considered.

**Atrial flutter**

Like atrial fibrillation, treatment options for atrial flutter involve either controlling the ventricular rate or attempting to restore and maintain sinus rhythm. However, atrial flutter generally responds less well to drug treatment than atrial fibrillation.

Control of the ventricular rate is usually an interim measure pending restoration of sinus rhythm. Ventricular rate can be controlled by administration of a beta-blocker, diltiazem hydrochloride p. 152 [unlicensed indication], or verapamil hydrochloride p. 159; an intravenous beta-blocker or verapamil hydrochloride is preferred for rapid control. Digoxin p. 106 can be added if rate control remains inadequate, and may be particularly useful in those with heart failure.

Conversion to sinus rhythm can be achieved by electrical cardioversion (by cardiac pacing or direct current), pharmacological cardioversion, or catheter ablation. If the duration of atrial flutter is unknown, or it has lasted for over 48 hours, cardioversion should not be attempted until the patient has been fully anticoagulated for at least 3 weeks; if this is not possible, parenteral anticoagulation should be commenced and a left atrial thrombus ruled out immediately before cardioversion; oral anticoagulation should be given after cardioversion and continued for at least 4 weeks. Direct current cardioversion is usually the treatment of choice when rapid conversion to sinus rhythm is necessary (e.g. when atrial flutter is associated with haemodynamic compromise); catheter ablation is preferred for the treatment of recurrent atrial flutter. There is a limited role for anti-arrhythmic drugs as their use is not always successful. Flecainide acetate p. 100 or propafenone hydrochloride p. 101 can slow atrial flutter, resulting in 1:1 conduction to the ventricles, and should therefore be prescribed in conjunction with a ventricular rate controlling drug such as a beta-blocker, diltiazem hydrochloride [unlicensed indication], or verapamil hydrochloride.

Amiodarone hydrochloride p. 102 can be used when other drug treatments are contra-indicated or ineffective. All patients should be assessed for their risk of stroke and the need for thromboprophylaxis; the choice of anticoagulant is based on the same criteria as for atrial fibrillation.

**Paroxysmal supraventricular tachycardia**

This will often terminate spontaneously or with reflex vagal stimulation such as a Valsalva manoeuvre, immersing the face in ice-cold water, or carotid sinus massage; such manoeuvres should be performed with ECG monitoring.

If the effects of reflex vagal stimulation are transient or ineffective, or if the arrhythmia is causing severe symptoms, intravenous adenosine p. 104 should be given. If adenosine is ineffective or contra-indicated, intravenous verapamil hydrochloride is an alternative, but it should be avoided in patients recently treated with beta-blockers.

Failure to terminate paroxysmal supraventricular tachycardia with reflex vagal stimulation or drug treatment may suggest an arrhythmia of atrial origin, such as focal atrial tachycardia or atrial flutter.

Treatment with direct current cardioversion is needed in haemodynamically unstable patients or when the above measures have failed to restore sinus rhythm (and an alternative diagnosis has not been found).

Recurrent episodes of paroxysmal supraventricular tachycardia can be treated by catheter ablation, or prevented with drugs such as diltiazem hydrochloride, verapamil hydrochloride, beta-blockers including sotalol hydrochloride p. 105, flecainide acetate or propafenone hydrochloride.
Arrhythmias after myocardial infarction
In patients with a paroxysmal tachycardia or rapid irregularity of the pulse it is best not to administer an anti-arrhythmic until an ECG record has been obtained.
Bradycardia, particularly if complicated by hypotension, should be treated with an intravenous dose of atropine sulfate p. 1224 the dose may be repeated if necessary. If there is a risk of asystole, or if the patient is unstable and has failed to respond to atropine sulfate, adrenaline/epinephrine p. 216 should be given by intravenous infusion, and the dose adjusted according to response.

For further advice, refer to the most recent recommendations of the Resuscitation Council (UK) available at www.resus.org.uk.

Ventricular tachycardia
Pulseless ventricular tachycardia or ventricular fibrillation should be treated with immediate defibrillation (see Cardiopulmonary resuscitation).
 Patients with unstable sustained ventricular tachycardia, who continue to deteriorate with signs of hypotension or reduced cardiac output, should receive direct current cardioversion to restore sinus rhythm. If this fails, intravenous amiodarone hydrochloride should be administered and direct current cardioversion repeated.
 Patients with sustained ventricular tachycardia who are haemodynamically stable can be treated with intravenous anti-arrhythmic drugs. Amiodarone hydrochloride is the preferred drug. Flecainide acetate, propafenone hydrochloride, and, although less effective, lidocaine hydrochloride p. 1242 have all been used. If sinus rhythm is not restored, direct current cardioversion or pacing should be considered. Catheter ablation is an alternative if cessation of the arrhythmia is not urgent. Non-sustained ventricular tachycardia can be treated with a beta-blocker.

All patients presenting with ventricular tachycardia should be referred to a specialist. Following restoration of sinus rhythm, patients who remain at high risk of cardiac arrest will require maintenance therapy. Most patients will be treated with an implantable cardioverter defibrillator. Beta-blockers or sotalol hydrochloride (in place of a standard beta-blocker), or amiodarone hydrochloride (in combination with a standard beta-blocker), can be used in addition to the device in some patients; alternatively, they can be used alone when use of an implantable cardioverter defibrillator is not appropriate.

Torsade de pointes
Torsade de pointes is a form of ventricular tachycardia associated with a long QT syndrome (usually drug-induced, but other factors including hypokalaemia, severe bradycardia, and genetic predisposition are also implicated). Episodes are usually self-limiting, but are frequently recurrent and can cause impairment or loss of consciousness. If not controlled, the arrhythmia can progress to ventricular fibrillation and sometimes death.
 Intravenous infusion of magnesium sulfate p. 963 is usually effective. A beta-blocker (but not sotalol hydrochloride) and atrial (or ventricular) pacing can be considered. Anti-arrhythmics can further prolong the QT interval, thus worsening the condition.

Drugs for arrhythmias
Anti-arrhythmic drugs can be classified clinically into those that act on supraventricular arrhythmias (e.g. verapamil hydrochloride), those that act on both supraventricular and ventricular arrhythmias (e.g. amiodarone hydrochloride), and those that act on ventricular arrhythmias (e.g. lidocaine hydrochloride).

Anti-arrhythmic drugs can also be classified according to their effects on the electrical behaviour of myocardial cells during activity (the Vaughan Williams classification) although this classification is of less clinical significance:
- Class I: membrane stabilising drugs (e.g. lidocaine, flecainide)
- Class II: beta-blockers
- Class III: amiodarone; sotalol (also Class II)
- Class IV: calcium-channel blockers (includes verapamil but not dihydropyridines)

The negative inotropic effects of anti-arrhythmic drugs tend to be additive. Therefore special care should be taken if two or more are used, especially if myocardial function is impaired. Most drugs that are effective in countering arrhythmias can also provoke them in some circumstances; moreover, hypokalaemia enhances the arrhythmogenic (pro-arrhythmic) effect of many drugs.

Supraventricular arrhythmias
Adenosine p. 104 is usually the treatment of choice for terminating paroxysmal supraventricular tachycardia. As it has a very short duration of action (half-life only about 8 to 10 seconds, but prolonged in those taking dipyridamole p. 120), most side-effects are short lived. Unlike verapamil hydrochloride p. 159, adenosine can be used after a beta-blocker. Verapamil hydrochloride may be preferable to adenosine in asthma.

Oral administration of a cardiac glycoside (such as digoxin p. 106) slows the ventricular response in cases of atrial fibrillation and atrial flutter. However, intravenous infusion of digoxin is rarely effective for rapid control of ventricular rate. Cardiac glycosides are contra-indicated in supraventricular arrhythmias associated with accessory conducting pathways (e.g. Wolf-Parkinson-White syndrome).

Verapamil hydrochloride is usually effective for supraventricular tachycardias. An initial intravenous dose (important: serious beta-blocker interaction hazard) may be followed by oral treatment; hypotension may occur with large doses. It should not be used for tachyarrhythmias where the QRS complex is wide (i.e. broad complex) unless a supraventricular origin has been established beyond reasonable doubt. It is also contra-indicated in atrial fibrillation or atrial flutter associated with accessory conducting pathways (e.g. Wolf-Parkinson-White syndrome). It should not be used in children with arrhythmias without specialist advice; some supraventricular arrhythmias in childhood can be accelerated by verapamil hydrochloride with dangerous consequences.

Intravenous administration of a beta-blocker such as esmolol hydrochloride p. 149 or propranolol hydrochloride p. 145, can achieve rapid control of the ventricular rate.

Drugs for both supraventricular and ventricular arrhythmias include amiodarone hydrochloride p. 102, beta-blockers, disopyramide p. 99, flecainide acetate p. 100, procainamide (available from special-order manufacturers or specialist importing companies), and propafenone hydrochloride p. 101.

Supraventricular and ventricular arrhythmias
Amiodarone hydrochloride is used in the treatment of arrhythmias, particularly when other drugs are ineffective or contra-indicated. It can be used for paroxysmal supraventricular, nodal and ventricular tachycardias, atrial fibrillation and flutter, and ventricular fibrillation. It can also be used for tachyarrhythmias associated with Wolff-Parkinson-White syndrome. It should be initiated only under hospital or specialist supervision. Amiodarone hydrochloride may be given by intravenous infusion as well as by mouth, and has the advantage of causing little or no myocardial depression. Unlike oral amiodarone hydrochloride, intravenous amiodarone hydrochloride acts relatively rapidly.

Intravenous injection of amiodarone hydrochloride can be used in cardiopulmonary resuscitation for ventricular
fibrillation or pulseless tachycardia unresponsive to other interventions.

Amiodarone hydrochloride has a very long half-life (extending to several weeks) and only needs to be given once daily (but high doses can cause nausea unless divided). Many weeks or months may be required to achieve steady-state plasma-amiodarone concentration; this is particularly important when drug interactions are likely.

**Beta-blockers** act as anti-arrhythmic drugs principally by attenuating the effects of the sympathetic system on automatism and conductivity within the heart. Sotalol has a role in the management of ventricular arrhythmias.

Disopyramide can be given by intravenous injection to control arrhythmias after myocardial infarction (including those not responding to lidocaine hydrochloride p. 1242), but it impairs cardiac contractility. Oral administration of disopyramide is useful, but it has an antimuscarinic effect which limits its use in patients susceptible to angle-closure glaucoma or with prostatic hyperplasia.

Flecainide acetate belongs to the same general class as lidocaine hydrochloride and may be of value for serious symptomatic ventricular arrhythmias. It may also be indicated for junctional re-entry tachycardias and for paroxysmal atrial fibrillation. However, it can precipitate serious arrhythmias in a small minority of patients (including those with otherwise normal hearts).

Propafenone hydrochloride is used for the prophylaxis and treatment of ventricular arrhythmias and also for some supraventricular arrhythmias. It has complex mechanisms of action, including weak beta-blocking activity (therefore caution is needed in obstructive airways disease—contra indicated if severe).

Drugs for supraventricular arrhythmias include adenosine, **cardiac glycosides**, and verapamil hydrochloride. Drugs for ventricular arrhythmias include lidocaine hydrochloride.

*Mexiletine* and procainamide are both available from ‘special-order’ manufacturers or specialist importing companies. (*Mexiletine* can be used for life-threatening ventricular arrhythmias; *procainamide* is given by intravenous injection to control ventricular arrhythmias.

**Ventricular arrhythmias**

Intravenous lidocaine hydrochloride can be used for the treatment of ventricular tachycardia in haemodynamically stable patients, and ventricular fibrillation and pulseless ventricular tachycardia in cardiac arrest refractory to defibrillation, however it is no longer the anti-arrhythmic drug of first choice.

Drugs for both supraventricular and ventricular arrhythmias include amiodarone hydrochloride, **beta-blockers**, disopyramide, flecainide acetate, **procainamide** (available from ‘special-order’ manufacturers or specialist importing companies), and propafenone hydrochloride.

*Mexiletine* is available from ‘special-order’ manufacturers or specialist importing companies for treatment of life-threatening ventricular arrhythmias.

---

**ANTIARRHYTHMICS > CLASS IA**

### Disopyramide

**INDICATIONS AND DOSE**

Prevention and treatment of ventricular and supraventricular arrhythmias, including after myocardial infarction | Maintenance of sinus rhythm after cardioversion

- **By mouth using immediate-release medicines**
  - Adult: 300–800 mg daily in divided doses
- **By mouth using modified-release medicines**
  - Adult: 250–375 mg every 12 hours

**CONTRA-INDICATIONS** Bundle-branch block associated with first-degree AV block · second- and third-degree AV block or bifascicular block (unless pacemaker fitted) · severe heart failure (unless secondary to arrhythmia) · severe sinus node dysfunction

**CAUTIONS**

- Atrial flutter or atrial tachycardia with partial block · avoid in acute porphyrias p. 969 · elderly · heart failure (avoid if severe) · myasthenia gravis · prostatic enlargement · structural heart disease · susceptibility to angle-closure glaucoma

**INTERACTIONS**

Appendix 1: antiarrhythmics

**SIDE-EFFECTS**

- Angle-closure glaucoma · antimuscarinic effects · AV block · blurred vision · cholestatic jaundice · dry mouth · gastro-intestinal irritation · hypoglycaemia · hypotension · myocardial depression · psychosis · urinary retention · ventricular tachycardia, ventricular fibrillation or torsade de pointes (usually associated with prolongation of QRS complex or QT interval)

**PREGNANCY**

Manufacturer advises use only if potential benefit outweighs risk; may induce labour if used in third trimester.

**BREAST FEEDING**

Present in milk—use only if essential.

Monitor infant for antimuscarinic effects.

**HEPATIC IMPAIRMENT**

Half-life prolonged—may need dose reduction. Avoid modified-release preparation.

**RENAL IMPAIRMENT**

Reduce dose by increasing dose interval; adjust according to response. Avoid modified-release preparation.

**MONITORING REQUIREMENTS**

- Monitor for hypotension, hypoglycaemia, ventricular tachycardia, ventricular fibrillation or torsade de pointes (discontinue if occur).
- Monitor serum potassium.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule, oral suspension, oral solution

**Modified-release tablet**

**CAUTIONARY AND ADVISORY LABELS**

- 25

**Rythmodan Retard** (Sanofi)

Disopyramide (as Disopyramide phosphate) 250 mg | Rythmodan Retard 250 mg tablets | 60 tablet | £32.08 DT price | £32.08

**Capsule**

- **Disopyramide (Non-proprietary)**
  - Disopyramide 100 mg | Disopyramide 100 mg capsules | 84
    - Capsule | £25.00 DT price | £22.09
  - Disopyramide 150 mg | Disopyramide 150 mg capsules | 84
    - Capsule | £33.40 DT price | £27.58
- **Rythmodan** (Sanofi)
  - Disopyramide 100 mg | Rythmodan 100 mg capsules | 84
    - Capsule | £14.14 DT price | £12.09

---

**Other drugs used for Arrhythmias**

- Acebutolol, p. 146
- Atenolol, p. 147
- Metoprolol tartrate, p. 149
- Nadolol, p. 144
- Oxprenolol hydrochloride, p. 144

---

**Arrhythmias**

Cardiovascular system

---

downloaded from www.medicalbr.com
**ANTIARRHYTHMICS > CLASS IB**

**Lidocaine hydrochloride**

*(Lignocaine hydrochloride)*

- **INDICATIONS AND DOSE**
  - Cardiopulmonary resuscitation (as an alternative if amiodarone is not available)
    - **BY INTRAVENOUS INJECTION**
    - Adult: 1 mg/kg, do not exceed 3 mg/kg over the first hour

- **CONTRAINICATIONS**
  - All grades of atrioventricular block
  - Severe myocardial depression
  - Sino-atrial disorders

- **CAUTIONS**
  - Acute porphyria (consider infusion with glucose for its anti-porphyrinogenic effects)
  - Congestive cardiac failure (consider lower dose)
  - Post cardiac surgery (consider lower dose)

- **INTERACTIONS**
  - **Appendix 1: antiarrhythmics**

- **SIDE-EFFECTS**
  - **Common or very common**
    - Bradycardia (may lead to cardiac arrest)
    - Confusion
    - Convulsions
    - Dizziness (particularly if injection too rapid)
    - Drowsiness (particularly if injection too rapid)
    - Hypotension (may lead to cardiac arrest)
    - Parasthesia (particularly if injection too rapid)
  - **Rare**
    - Anaphylaxis

- **PREGNANCY**
  - Crosses the placenta but not known to be harmful in animal studies—use if benefit outweighs risk.

- **BREAST FEEDING**
  - Present in milk but amount too small to be harmful.

- **HEPATIC IMPAIRMENT**
  - Caution—increased risk of side-effects.

- **RENAL IMPAIRMENT**
  - Possible accumulation of lidocaine and active metabolite; caution in severe impairment.

- **MONITORING REQUIREMENTS**
  - Monitor ECG and have resuscitation facilities available.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

- **Solution for injection**
  - **Lidocaine hydrochloride (Non-proprietary)**
    - Lidocaine hydrochloride 5 mg per 1 ml
      - Lidocaine 50mg/10ml (0.5%) solution for injection ampoules | 10 ampoule [£1.40]
      - Lidocaine hydrochloride 10 mg per 1 ml
        - Lidocaine 100mg/10ml (1%) solution for injection Mini-Plasco ampoules | 20 ampoule [£1.09]
        - Lidocaine 100mg/10ml (1%) solution for injection Mini-Plasco ampoules | 10 ampoule [PD]
        - Lidocaine 4.40 DT price = £4.36
        - Lidocaine 100mg/10ml (1%) solution for injection Sure-Amp ampoules | 20 ampoule [PD]
        - Lidocaine 200mg/20ml (1%) solution for injection vials | 10 vial [PD]
        - Lidocaine 200mg/20ml (1%) solution for injection vials | 10 vial [PD]
        - Lidocaine 200mg/20ml (1%) solution for injection vials | 10 vial [PD]
        - Lidocaine 200mg/20ml (1%) solution for injection vials | 10 vial [PD]
        - Lidocaine 200mg/20ml (1%) solution for injection vials | 10 vial [PD]
        - Lidocaine 200mg/20ml (1%) solution for injection vials | 10 vial [PD]
        - Lidocaine 200mg/20ml (1%) solution for injection vials | 10 vial [PD]
        - Lidocaine 200mg/20ml (1%) solution for injection vials | 10 vial [PD]
        - Lidocaine 200mg/20ml (1%) solution for injection vials | 10 vial [PD]
    - Lidocaine hydrochloride 20 mg per 1 ml
      - Lidocaine 100mg/5ml (2%) solution for injection ampoules | 10 ampoule [PD]
      - Lidocaine 100mg/5ml (2%) solution for injection ampoules | 10 ampoule [PD]
      - Lidocaine 100mg/5ml (2%) solution for injection ampoules | 10 ampoule [PD]
      - Lidocaine 100mg/5ml (2%) solution for injection ampoules | 10 ampoule [PD]
      - Lidocaine 100mg/5ml (2%) solution for injection ampoules | 10 ampoule [PD]
      - Lidocaine 100mg/5ml (2%) solution for injection ampoules | 10 ampoule [PD]
      - Lidocaine 100mg/5ml (2%) solution for injection ampoules | 10 ampoule [PD]
      - Lidocaine 100mg/5ml (2%) solution for injection ampoules | 10 ampoule [PD]
      - Lidocaine 100mg/5ml (2%) solution for injection ampoules | 10 ampoule [PD]
      - Lidocaine 100mg/5ml (2%) solution for injection ampoules | 10 ampoule [PD]

- **ANTIARRHYTHMICS > CLASS IC**

**Flecainide acetate**

- **INDICATIONS AND DOSE**
  - AV nodal reciprocating tachycardia, arrhythmias associated with accessory conducting pathways (e.g. Wolff-Parkinson-White syndrome), disabling symptoms of paroxysmal atrial fibrillation in patients without left ventricular dysfunction (arrhythmias of recent onset will respond more readily) (specialist supervision in hospital)
  - Ventricular tachyarrhythmias resistant to other treatment (specialist supervision in hospital)
  - **INITIALLY BY SLOW INTRAVENOUS INJECTION**
  - Adult: Initially 2 mg/kg (max. per dose 150 mg), to be given over 10–30 minutes with ECG monitoring, followed by (by intravenous infusion) 1.5 mg/kg/hour if required for 1 hour, then (by intravenous infusion) reduced to 100–250 micrograms/kg/hour for up to 24 hours, maximum cumulative dose of 600 mg in first 24 hours, then transfer to oral treatment

- **SUPRAVENTRICULAR ARRHYTHMIAS**
  - **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
    - Adult: Initially 50 mg twice daily, increased if necessary up to 300 mg daily
  - **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
    - Adult: 200 mg daily

- **VENTRICULAR ARRHYTHMIAS (INITIATED UNDER DIRECTION OF HOSPITAL CONSULTANT)**
  - **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
    - Adult: Initially 100 mg twice daily for 3–5 days, maximum 400 mg daily reserved for rapid control or in heavily built patients; for maintenance, reduce to the lowest dose that controls the arrhythmia
Glucose 5% or Sodium Chloride 0.9%. Minimum volume in infusion fluids containing chlorides 500 mL.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Tablet**

- **Flecainide acetate (Non-proprietary)**
  - **Flecainide acetate 50 mg** Flecainide 50mg tablets | 60 tablet £13.50 DT price = £8.64
  - **Flecainide acetate 100 mg** Flecainide 100mg tablets | 60 tablet £19.63 DT price = £10.10
- **Tambocor (Meda Pharmaceuticals Ltd)**
  - **Flecainide acetate 50 mg** Tambocor 50mg tablets | 60 tablet £11.57 DT price = £8.64
  - **Flecainide acetate 100 mg** Tambocor 100mg tablets | 60 tablet £16.53 DT price = £10.10

**Solution for injection**

- **Tambocor (Meda Pharmaceuticals Ltd)**
  - **Flecainide acetate 10 mg per 1 ml** Tambocor 150mg/15ml solution for injection ampoules | 5 ampoule £21.99

**Modified-release capsule**

- **Tambocor XL (Meda Pharmaceuticals Ltd)**
  - **Flecainide acetate 200 mg** Tambocor XL 200mg capsules | 30 capsule £14.77

### Propafenone hydrochloride

**INDICATIONS AND DOSE**

Ventricular arrhythmias (specialist supervision in hospital) | Paroxysmal supraventricular tachyarrhythmias which include paroxysmal atrial flutter or fibrillation and paroxysmal re-entrant tachycardias involving the AV node or accessory pathway, where standard therapy ineffective or contra-indicated (specialist supervision in hospital)

- **BY MOUTH**
  - **Adult**: Initially 150 mg 3 times a day, dose to be taken after food, monitor ECG and blood pressure, if QRS interval prolonged by more than 20%, reduce dose or discontinue until ECG returns to normal limits; increased if necessary to 300 mg twice daily (max. per dose 300 mg 3 times a day), dose to be increased at intervals of at least 3 days, reduce total daily dose for patients under 70 kg
  - **Elderly**: Initially 150 mg 3 times a day, dose to be taken after food, monitor ECG and blood pressure, if QRS interval prolonged by more than 20%, reduce dose or discontinue until ECG returns to normal limits; increased if necessary to 300 mg twice daily (max. per dose 300 mg 3 times a day), dose to be increased at intervals of at least 5 days, reduce total daily dose for patients under 70 kg

**CONTRA-INDICATIONS**

- Atrial conduction defects (unless adequately paced) | Brugada syndrome | bundle branch block (unless adequately paced) | cardiogenic shock (except arrhythmia induced) | distal block (unless adequately paced) | electrolyte disturbances | marked hypotension | myasthenia gravis | myocardial infarction within last 3 months | second degree or greater AV block (unless adequately paced) | severe bradycardia | severe obstructive pulmonary disease (due to weak beta-blocking activity) | sinus node dysfunction (unless adequately paced) | uncontrolled congestive heart failure with left ventricular ejection fraction less than 35%

**CAUTIONS**

- Elderly: great caution in mild to moderate obstructive Airways disease owing to beta-blocking activity | heart failure | pacemaker patients | potential for conversion of paroxysmal atrial fibrillation to atrial flutter with 2:1 or 1:1 conduction block

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**

Manufacturer advises reduce dose by half with concurrent use of amiodarone.

**DOSE EQUIVALENCE AND CONVERSION**

- Patients stabilised on 200 mg daily immediate-release flecainide may be transferred to modified-release medicines.

**UNLICENSED USE**

Capsules, tablets and injection: licensed for AV nodal reciprocating tachycardia, arrhythmias associated with accessory conducting pathways (e.g. Wolff-Parkinson-White syndrome), disabling symptoms of paroxysmal atrial fibrillation in patients without left ventricular dysfunction (arrhythmias of recent onset will respond more readily). Immediate-release tablets only: licensed for symptomatic sustained ventricular tachycardia, disabling symptoms of premature ventricular contractions and/or non-sustained ventricular tachycardia in patients resistant to or intolerant of other therapy. Injection only: licensed for ventricular tachyarrhythmias resistant to other treatment.

**CONTRA-INDICATIONS**

Abnormal left ventricular function | atrial conduction defects (unless pacing rescue available) | bundle branch block (unless pacing rescue available) | control of arrhythmias in acute situations (for modified-release forms only) | distal block (unless pacing rescue available) | haemodynamically significant valvular heart disease | heart failure | history of myocardial infarction and either asymptomatic ventricular ectopics or asymptomatic non-sustained ventricular tachycardia | long-standing atrial fibrillation where conversion to sinus rhythm not attempted | second-degree or greater AV block (unless pacing rescue available) | sinus node dysfunction (unless pacing rescue available)

**CAUTIONS**

Atrial fibrillation following heart surgery | elderly (accumulation may occur) | patients with pacemakers (especially those who may be pacemaker dependent because stimulation threshold may rise appreciably)

**INTERACTIONS**

- **Appendix 1: antiarrhythmics**

**SIDE-EFFECTS**

- **Common or very common** Asthenia | dizziness | dyspnoea | fatigue | fever | oedema | pro-arrhythmic effects | visual disturbances

- **Rare** Anemia | confusion | convulsions | depression | dyskinesia | hallucinations | peripheral neuropathy | pneumonitis

- **Frequency not known** Anaemia | anorexia | anxiety | ataxia | corneal deposits | drowsiness | flushing | gastrointestinal disturbances | headache | hepatic dysfunction | hypersensitivity reactions | increased antinuclear antibodies | increased sweating | insomnia | leukopenia | paraesthesia | photosensitivity | rash | syncope | thrombocytopenia | tinnitus | tremor | urticaria | vertigo

**PREGNANCY**

Used in pregnancy to treat maternal and fetal arrhythmias in specialist centres; toxicity reported in animal studies; infant hyperbilirubinemia also reported.

**BREAST FEEDING**

Significant amount present in milk but not known to be harmful.

**HEPATIC IMPAIRMENT**

Avoid or reduce dose in severe impairment.

**RENAL IMPAIRMENT**

Reduce initial oral dose to max. 100 mg daily or reduce intravenous dose by 50%, if eGFR less than 35 mL/minute/1.73 m².

**MONITORING REQUIREMENTS**

- With intravenous use ECG monitoring and resuscitation facilities must be available.

**DIRECTIONS FOR ADMINISTRATION**

For intravenous infusion (Tambocor®, give continuously or intermittently in concurrent use
Amiodarone hydrochloride

INDICATIONS AND DOSE
Treatment of arrhythmias, particularly when other drugs are ineffective or contra-indicated (including paroxysmal supraventricular, nodal and ventricular tachycardias, atrial fibrillation and flutter, ventricular fibrillation, and tachyarrhythmias associated with Wolf-Parkinson-White syndrome) (initiated in hospital or under specialist supervision)

- **BY MOUTH**
  - Adult: 200 mg 3 times a day for 1 week, then reduced to 200 mg twice daily for a further week, followed by maintenance dose, usually 200 mg daily or the minimum dose required to control arrhythmia

- **BY INTRAVENOUS INFUSION**
  - Adult: Initially 5 mg/kg, to be given over 20–120 minutes with ECG monitoring, subsequent infusions given if necessary according to response; maximum 1.2 g per day

Ventricular fibrillation or pulseless ventricular tachycardia refractory to defibrillation (for cardiopulmonary resuscitation)

- **INITIALLY BY INTRAVENOUS INJECTION**
  - Adult: Initially 300 mg, dose to be considered after administration of adrenaline, dose should be given from a pre-filled syringe or diluted in 20 mL Glucose 5%, then (by intravenous injection) 150 mg if required, followed by (by intravenous infusion) 900 mg/24 hours

**IMPORTANT SAFETY INFORMATION**
MHRA/CHM ADVICE: SOFOSBUVIR WITH DACLATASVIR; SOFOSBUVIR AND LEDIPASVIR (MAY 2015); SIMEPREVIR WITH SOFOSBUVIR (AUGUST 2015); RISK OF SEVERE BRADYCARDIA AND HEART BLOCK WHEN TAKEN WITH AMIODARONE
Avoid concomitant use unless other antiarrhythmics cannot be given.

CONTRA-INDICATIONS
GENERAL CONTRA-INDICATIONS
Avoid in severe conduction disturbances (unless pacemaker fitted) - avoid in sinus node disease (unless pacemaker fitted) - iodine sensitivity - sino-atrial heart block (except in cardiac arrest) - sinus bradycardia (except in cardiac arrest) - thyroid dysfunction

SPECIFIC CONTRA-INDICATIONS
- With intravenous use Avoid bolus injection in cardiomyopathy - avoid bolus injection in congestive heart failure - avoid in circulatory collapse - avoid in severe arterial hypotension - avoid in severe respiratory failure

CAUTIONS
GENERAL CAUTIONS
Acute porphyrias p. 969 - conduction disturbances (in excessive dosage) - elderly - heart failure - hypokalaemia - severe bradycardia (in excessive dosage)

SPECIFIC CAUTIONS
- With intravenous use Moderate and transient fall in blood pressure (circulatory collapse precipitated by rapid administration or overdosage) - severe hepatocellular toxicity

INTERACTIONS
Appendix 1: antiarrhythmics

SIDE-EFFECTS
GENERAL SIDE-EFFECTS
- Common or very common Bradycardia - hypothyroidism - hypothyroidism - jaundice - nausea - persistent slate grey skin discoloration - phototoxicity - pulmonary toxicity (including pneumonitis and fibrosis) - raised serum transaminases (may require dose reduction or withdrawal if accompanied by acute liver disorders) - reversible corneal microdeposits (sometimes with night glare) - sleep disorders - taste disturbance

- Uncommon Conduction disturbances - onset or worsening of arrhythmia - peripheral myopathy (usually reversible on withdrawal) - peripheral neuropathy (usually reversible on withdrawal)

- Very rare Alopecia - aplastic anaemia - ataxia - benign intracranial hypertension - bronchospasm (in patients with severe respiratory failure) - chronic liver disease - cirrhosis - epideridymo-orchitis - exfoliative dermatitis - haemolytic anaemia - headache - hypersensitivity - impaired vision due to optic neuritis or optic neuropathy (including blindness) - impotence - rash - sinus arrest - thrombocytopenia - vasculitis - vertigo

- Frequency not known Hot flushes - hypotension - respiratory distress syndrome - sweating

SPECIFIC SIDE-EFFECTS
- Common or very common
  - With intravenous use Injection-site reactions
  - Very rare
  - With intravenous use Anaphylaxis on rapid injection

SIDE-EFFECTS, FURTHER INFORMATION
- Corneal microdeposits Most patients taking amiodarone develop corneal microdeposits (reversible on withdrawal of treatment); these rarely interfere with vision, but drivers may be dazzled by headlights at night. However, if vision is impaired or if optic neuritis or optic neuropathy occur, amiodarone must be stopped to prevent blindness and expert advice sought.
  - Thyroid function Amiodarone contains iodine and can cause disorders of thyroid function; both hypothyroidism and hyperthyroidism can occur. Thyrotoxicosis may be very
refractory, and amiodarone should usually be withdrawn at least temporarily to help achieve control; treatment with carbimazole may be required. Hypothyroidism can be treated with replacement therapy without withdrawing amiodarone if it is essential; careful supervision is required.

- Hepatotoxicity  Amiodarone is also associated with hepatotoxicity and treatment should be discontinued if severe liver function abnormalities or clinical signs of liver disease develop.
- Pulmonary toxicity  Pneumonitis should always be suspected if new or progressive shortness of breath or cough develops in a patient taking amiodarone.
- Peripheral neuropathy  Fresh neurological symptoms should raise the possibility of peripheral neuropathy.

- **PREGNANCY**  Possible risk of neonatal goitre; use only if no alternative.

- **BREAST FEEDING**  Avoid; present in milk in significant amounts; theoretical risk of neonatal hypothyroidism from release of iodine.

- **MONITORING REQUIREMENTS**
  - Thyroid function tests should be performed before treatment and then every 6 months. Clinical assessment of thyroid function alone is unreliable. Thyroxine (T4) may be raised in the absence of hyperthyroidism; therefore triiodothyronine (T3), T4, and thyroid-stimulating hormone (thyrotrophin, TSH) should all be measured. A raised T3 and T4 with a very low or undetectable TSH concentration suggests the development of thyrotoxicosis.
  - Liver function tests required before treatment and then every 6 months.
  - Serum potassium concentration should be measured before treatment.
  - Chest X-ray required before treatment.
  - If concomitant use of amiodarone with sofosbuvir and daclatasvir, simpeprevir and sofosbuvir, or sofosbuvir and ledipasvir cannot be avoided because other anti-arrhythmics are not tolerated or contra-indicated, patients should be closely monitored, particularly during the first weeks of treatment. Patients at high risk of bradycardia should be monitored continuously for 48 hours in an appropriate clinical setting after starting concomitant treatment. Patients who have stopped amiodarone within the last few months and need to start sofosbuvir and daclatasvir, simpeprevir and sofosbuvir, or sofosbuvir and ledipasvir should be monitored.
  - With intravenous use  ECG monitoring and resuscitation facilities must be available. Monitor liver transaminases closely.

- **DIRECTIONS FOR ADMINISTRATION**
  - With intravenous use  For *intravenous infusion* (*Cordarone X®*), give continuously or intermittently in Glucose 5%. Suggested initial infusion volume 250 mL given over 20–120 minutes; for repeat infusions up to 1.2 g in max. 500 mL; should not be diluted to less than 600 micrograms/mL. See cardio-pulmonary resuscitation for details of infusion in extreme emergency. Incompatible with Sodium Chloride infusion fluids; avoid equipment containing the plasticizer di-2-ethylhexylphthalate (DEHP).
  - With oral use  For administration *by mouth*, tablets may be crushed and dispersed in water; injection solution should not be given orally (irritant).

- **PATIENT AND CARER ADVICE**  Because of the possibility of phototoxic reactions, patients should be advised to shield the skin from light during treatment and for several months after discontinuing amiodarone; a wide-spectrum sunscreen to protect against both long-wave ultraviolet and visible light should be used.
  
  If taking amiodarone with concomitant sofosbuvir and daclatasvir, simpeprevir and sofosbuvir, or sofosbuvir and ledipasvir, patients and their carers should be told how to recognise signs and symptoms of bradycardia and heart block and advised to seek immediate medical attention if symptoms such as shortness of breath, light-headedness, palpitations, fainting, unusual tiredness or chest pain develop.

- **MEDICINAL FORMS**  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

<table>
<thead>
<tr>
<th>Tablet</th>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>11</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amiodarone hydrochloride (Non-proprietary)</td>
<td>Amiodarone hydrochloride 100 mg Amiodarone 100mg tablets</td>
<td>28 tablet (Cost) £4.25 DT price = £1.53</td>
</tr>
<tr>
<td>Amiodarone hydrochloride 200 mg</td>
<td>Amiodarone 200mg tablets</td>
<td>28 tablet (Cost) £7.80 DT price = £1.91</td>
</tr>
<tr>
<td>Cordarone X (Sanofi)</td>
<td>Amiodarone hydrochloride 100 mg Cordarone X 100 tablets</td>
<td>28 tablet (Cost) £4.28 DT price = £1.53</td>
</tr>
<tr>
<td>Amiodarone hydrochloride 200 mg Cordarone X 200 tablets</td>
<td>28 tablet (Cost) £6.69 DT price = £1.91</td>
<td></td>
</tr>
</tbody>
</table>

**Solution for injection**

EXCIPIENTS: May contain Benzyl alcohol

- Amiodarone hydrochloride (Non-proprietary)
  - Amiodarone hydrochloride 30 mg per 1 ml Amiodarone 300mg/10ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (Cost) £13.80 |
  - Amiodarone hydrochloride 50 mg per 1 ml Amiodarone 150mg/3ml concentrate for solution for injection ampoules | 10 ampoule (Cost) £15.00 |
  - Cordarone X (Sanofi)
  - Amiodarone hydrochloride 50 mg per 1 ml Cordarone X 150mg/3ml solution for injection ampoules | 6 ampoule (Cost) £9.60

### Dronedarone

- **DRUG ACTION**  Dronedarone is a multi-channel blocking anti-arrhythmic drug.

### INDICATIONS AND DOSE

**Maintenance of sinus rhythm after cardioversion in clinically stable patients with paroxysmal or persistent atrial fibrillation, when alternative treatments are unsuitable (initiated under specialist supervision)**

- **BY MOUTH**
  - Adult: 400 mg twice daily

- **CONTRA-INDICATIONS**  Atrial conduction defects, bradycardia - complete bundle branch block - distal block - existing or previous heart failure or left ventricular systolic dysfunction - haemodynamically unstable patients - liver toxicity associated with previous amiodarone use - lung toxicity associated with previous amiodarone use - permanent atrial fibrillation - prolonged QT interval - second- or third- degree AV block - sick sinus syndrome (unless pacemaker fitted) - sinus node dysfunction

**CAUTIONS**  Coronary artery disease - correct hypokalaemia and hypomagnesaemia before starting and during treatment

**INTERACTIONS**  → Appendix 1: antiarrhythmics

**SIDE-EFFECTS**

- **Common or very common**  Bradycardia - gastro-intestinal disturbances - heart failure - malaise - pruritis - QT-interval prolongation - raised serum creatinine - rash

- **Uncommon**  Dermatitis - eczema - erythema - interstitial lung disease (investigate if symptoms such as dyspnoea or dry cough develop and discontinue treatment if confirmed) - photosensitivity - pneumonitis (investigate if symptoms such as dyspnoea or dry cough develop and discontinue treatment if confirmed) - pulmonary fibrosis (investigate if symptoms such as dyspnoea or dry cough develop and discontinue treatment if confirmed) - taste disturbance
Rare Liver injury (including life-threatening acute liver failure)

SIDE-EFFECTS, FURTHER INFORMATION

- Liver injury: Liver injury, including life-threatening acute liver failure reported rarely; discontinue treatment if 2 consecutive alanine aminotransferase concentrations exceed 3 times upper limit of normal.
- Heart failure: New onset or worsening heart failure reported. If heart failure or left ventricular systolic dysfunction develops, discontinue treatment.
- Pregnancy: Manufacturer advises avoid—toxicity in animal studies.
- Breastfeeding: Manufacturer advises avoid—present in milk in animal studies.
- Hepatic impairment: Avoid in severe impairment.
- Renal impairment: Avoid if eGFR less than 30 mL/minute/1.73 m².

MONITORING REQUIREMENTS

- Ongoing monitoring should occur under specialist supervision.
- Monitor for heart failure.
- Perform ECG at least every 6 months—consider discontinuation if atrial fibrillation reoccurs.
- Measure serum creatinine before treatment and 7 days after initiation—if raised, measure again after a further 7 days and consider discontinuation if creatinine continues to rise.
- Monitor liver function before treatment, 1 week and 1 month after initiation of treatment, then monthly for 6 months, then every 3 months for 6 months and periodically thereafter.

PATIENT AND CARER ADVICE

Heart failure: Patients or their carers should be told how to recognise signs of heart failure and advised to seek prompt medical attention if symptoms such as weight gain, dependent oedema, or dyspnoea develop or worsen.

Hepatic disorders: Patients or their carers should be told how to recognise signs of liver disorder and advised to seek prompt medical attention if symptoms such as abdominal pain, anorexia, nausea, vomiting, fever, malaise, itching, dark urine, or jaundice develop.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

- Dronedarone for the treatment of non-permanent atrial fibrillation (December 2012) NICE TA197

Dronedarone is an option for the maintenance of sinus rhythm after successful cardioversion in paroxysmal or persistent atrial fibrillation which is not controlled by first-line therapy (usually including beta-blockers), and after alternative options have been considered in patients:

- who have at least 1 of the following cardiovascular risk factors: hypertension requiring drugs of at least 2 different classes, diabetes mellitus, previous transient ischaemic attack, stroke or systemic embolism, left atrial diameter of 50 mm or greater, or age 70 years or older
- who do not have left ventricular systolic dysfunction nor a history of, or current, heart failure

Patients who do not meet the above criteria who are currently receiving dronedarone should have the option to continue treatment until they and their clinicians consider it appropriate to stop.

www.nice.org.uk/TA197

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS

- Dronedarone (Non-proprietary)
- Dronedarone (as Dronedarone hydrochloride) 400 mg Dronedarone 400mg tablets | 60 tablet | no price available
- Multaq (Sanofi)
  - Dronedarone (as Dronedarone hydrochloride) 400 mg Multaq 400mg tablets | 20 tablet | £22.50 GT price = £22.50 | 60 tablet | £61.50

ANTIARRHYTHMICS

Adenosine

INDICATIONS AND DOSE

Rapid reversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory conducting pathways (e.g. Wolff-Parkinson-White syndrome) Used to aid to diagnosis of broad or narrow complex supraventricular tachycardias

- BY RAPID INTRAVENOUS INJECTION
  - Adult: Initially 6 mg, administer into central or large peripheral vein and give over 2 seconds, cardiac monitoring required, followed by 12 mg after 1–2 minutes if required, then 12 mg after 1–2 minutes if required, increments should not be given if high level AV block develops at any particular dose

Rapid reversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory conducting pathways (e.g. Wolff-Parkinson-White syndrome) in patients with a heart transplant Aid to diagnosis of broad or narrow complex supraventricular tachycardias in patients with a heart transplant

- BY RAPID INTRAVENOUS INJECTION
  - Adult: Initially 3 mg, administer into a central or large peripheral vein and give over 2 seconds, followed by 6 mg after 1–2 minutes if required, then 12 mg after 1–2 minutes if required, patients with a heart transplant are very sensitive to the effects of adenosine

Used in conjunction with radionuclide myocardial perfusion imaging in patients who cannot exercise adequately or for whom exercise is inappropriate

- BY INTRAVENOUS INFUSION
  - Adult: (consult product literature)

DOSE ADJUSTMENTS DUE TO INTERACTIONS

If essential to give with dipyridamole reduce adenosine dose to a quarter of the usual dose.

UNLICENSED USE

Adenosine doses in the BNF may differ from those in the product literature.

CONTRA-INDICATIONS

- Asthma · chronic obstructive lung disease · decompensated heart failure · long QT syndrome · second- or third-degree AV block and sick sinus syndrome (unless pacemaker fitted) · severe hypotension

CAUTIONS

- Atrial fibrillation with accessory pathway (conduction down anomalous pathway may increase) · atrial flutter with accessory pathway (conduction down anomalous pathway may increase) · autonomic dysfunction · bundle branch block · first-degree AV block · heart transplant · left main coronary artery stenosis · left to right shunt · pericardial effusion · pericarditis · QT-interval prolongation · recent myocardial infarction · severe heart failure · stenotic carotid artery disease with cerebrovascular insufficiency · stenotic valvular heart disease · uncorrected hypovolaemia

INTERACTIONS

Appendix 1: antiarrhythmics
**SIDE-EFFECTS**

- **Common or very common** Angina (discontinue) - apprehension - arrhythmia (discontinue if asystole or severe bradycardia occur) - AV block - dizziness - dyspnoea - flushing - headache - nausea - sinus pause

- **Uncommon** Blurred vision - hyperventilation - metallic taste - palpitation - sweating - weakness

- **Very rare** Bronchospasm - injection-site reactions - transient worsening of intracranial hypertension

- **Frequency not known** Cardiac arrest - convulsions - hypotension (discontinue if severe) - respiratory failure (discontinue) - syncope - vomiting

**PREGNANCY** Large doses may cause fetal toxicity; manufacturer advises use only if potential benefit outweighs risk.

**BREAST FEEDING** No information available—unlikely to be present in milk owing to short half-life.

**MONITORING REQUIREMENTS** Monitor ECG and have resuscitation facilities available.

**DIRECTIONS FOR ADMINISTRATION** For rapid intravenous injection give over 2 seconds into central or large peripheral vein followed by rapid Sodium Chloride 0.9% flush; injection solution may be diluted with Sodium Chloride 0.9% if required.

**SOLUTIONS FOR INJECTION**

- **Adenosine (Non-proprietary)**
  - Adenosine 3 mg per 1 ml: Adenosine 6mg/2ml solution for injection vials | 6 vial £6.20–£29.24 (Hospital only)
  - Adenoscan (Sanofi)
    - Adenosine 3 mg per 1 ml: Adenocor 6mg/2ml solution for injection vials | 6 vial £29.94 (Hospital only)

- **Solution for infusion**

  ELECTROLYTES: May contain Sodium
  - Adenosine (Non-proprietary)
    - Adenosine 3 mg per 1 ml: Adenosine 30mg/10ml solution for infusion vials | 6 vial £70.00–£85.57 (Hospital only)
  - Adenoscan (Sanofi)
    - Adenosine 3 mg per 1 ml: Adenoscan 30mg/10ml solution for infusion vials | 6 vial £85.57

**BETA-ADRENOCEPTOR BLOCKERS**

**NON-SELECTIVE**

**Sotalol hydrochloride**

**INDICATIONS AND DOSE**

Symptomatic non-sustained ventricular tachyarrhythmias

- Prophylaxis of paroxysmal atrial tachycardia or fibrillation, paroxysmal AV re-entrant tachycardias (both nodal and involving accessory pathways), and paroxysmal supraventricular tachycardia after cardiac surgery

**BY MOUTH**

- Adult: Initially 80 mg daily in 1–2 divided doses, then increased to 160–320 mg daily in 2 divided doses, dose to be increased gradually at intervals of 2–3 days

**Life-threatening arrhythmias including ventricular tachyarrhythmias**

**BY MOUTH**

- Adult: Initially 80 mg daily in 1–2 divided doses, then increased to 160–320 mg daily in 2 divided doses, dose to be increased gradually at intervals of 2–3 days, higher doses of 480–640 mg daily may be required for life-threatening ventricular arrhythmias (under specialist supervision)

**CONTRA-INDICATIONS** Long QT syndrome (congenital or acquired) - torsade de pointes

**CAUTIONS** Diarrhoea (severe or prolonged)

**INTERACTIONS** → Appendix 1: beta blockers (non-selective)

**SIDE-EFFECTS** Arrhythmogenic (pro-arrhythmic) effect (torsade de pointes—increased risk in females)

**BREAST FEEDING** Water soluble beta-blockers such as sotalol are present in breast milk in greater amounts than other beta blockers.

**RENAL IMPAIRMENT** Use half normal dose if eGFR 30–60 mL/minute/1.73 m²; use one-quarter normal dose if eGFR 10–30 mL/minute/1.73 m². Avoid if eGFR less than 10 mL/minute/1.73 m².

**MONITORING REQUIREMENTS** Measurement of corrected QT interval, and monitoring of ECG and electrolytes required; correct hypokalaemia, hypomagnesaemia, or other electrolyte disturbances.

**MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Tablet**

<table>
<thead>
<tr>
<th>Sotalol hydrochloride (Non-proprietary)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sotalol hydrochloride 40 mg</td>
<td>28 tablet</td>
</tr>
<tr>
<td>Sotalol hydrochloride 80 mg</td>
<td>28 tablet</td>
</tr>
<tr>
<td>Sotalol hydrochloride 160 mg</td>
<td>28 tablet</td>
</tr>
<tr>
<td>Beta-Cardone (Focus Pharmaceuticals Ltd)</td>
<td></td>
</tr>
<tr>
<td>Sotalol hydrochloride 200 mg</td>
<td>28 tablet</td>
</tr>
<tr>
<td>Sotacor (Bristol-Myers Squibb Pharmaceuticals Ltd)</td>
<td></td>
</tr>
<tr>
<td>Sotalol hydrochloride 80 mg</td>
<td>30 tablet</td>
</tr>
</tbody>
</table>

**CARDIAC GLYCOSIDES**

**Cardiac glycosides**

**Digoxin**

Digoxin is most useful for controlling ventricular response in persistent and permanent atrial fibrillation and atrial flutter. Digoxin also has a role in heart failure.
For management of atrial fibrillation the maintenance dose of digoxin can usually be determined by the ventricular rate at rest, which should not usually be allowed to fall persistently below 60 beats per minute.

Digoxin is now rarely used for rapid control of heart rate (see management of supraventricular arrhythmias). Even with intravenous administration, response may take many hours; persistence of tachycardia is therefore not an indication for exceeding the recommended dose. The intramuscular route is not recommended.

In patients with heart failure who are in sinus rhythm a loading dose is not required, and a satisfactory plasma-digoxin concentration can be achieved over a period of about a week.

Digoxin has a long half-life and maintenance doses need to be given only once daily (although higher doses may be needed to achieve a therapeutic plasma-digoxin concentration can be achieved over a period of about a week). Persistence of tachycardia is therefore not an indication for exceeding the recommended dose. The intramuscular route is not recommended.

In patients with heart failure who are in sinus rhythm a loading dose is not required, and a satisfactory plasma-digoxin concentration can be achieved over a period of about a week.

Unwanted effects depend both on the concentration of digoxin in the plasma and on the sensitivity of the conducting system or of the myocardium, which is often increased in heart disease. It can sometimes be difficult to distinguish between toxic effects and clinical deterioration because symptoms of both are similar. The plasma concentration alone cannot indicate toxicity reliably, but the likelihood of toxicity increases progressively through the range 1.5 to 3 micrograms/litre for digoxin. Digoxin should be used with special care in the elderly, who may be particularly susceptible to digitalis toxicity.

Regular monitoring of plasma-digoxin concentration during maintenance treatment is not necessary unless problems are suspected. Hypokalaemia predisposes the patient to digitalis toxicity; it is managed by giving a potassium-sparing diuretic or, if necessary, potassium supplementation.

If toxicity occurs, digoxin should be withdrawn; serious manifestations require urgent specialist management. Digoxin-specific antibody fragments are available for reversal of life-threatening overdosage.

**INDICATIONS AND DOSE**

**Rapid digitalisation, for atrial fibrillation or flutter**

- **BY MOUTH**
  - Adult: 0.75–1.5 mg in divided doses, dose to be given over 24 hours, reduce dose in the elderly

**Maintenance, for atrial fibrillation or flutter**

- **BY MOUTH**
  - Adult: Maintenance 125–250 micrograms daily, dose according to renal function and initial loading dose, reduce dose in the elderly

**Heart failure (for patients in sinus rhythm)**

- **BY MOUTH**
  - Adult: 62.5–125 micrograms once daily, reduce dose in the elderly

**Emergency loading dose, for atrial fibrillation or flutter**

- **INITIALLY BY INTRAVENOUS INFUSION**
  - Adult: Loading dose 0.75–1 mg to be given over at least 2 hours, then (by mouth) maintenance, loading dose is rarely necessary, maintenance dose to be started on the day following the loading dose, reduce dose in the elderly

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**

Manufacturer advises reduce dose by half with concurrent use of amiodarone, dronedarone and quinine.

**SIDE-EFFECTS**

- Common or very common Arrhythmias. blurred vision, conduction disturbances, diarrhoea, dizziness, eosinophilia, nausea, rash, vomiting, yellow vision
- Uncommon Depression
- Very rare Anorexia, apathy, confusion, fatigue, gynaecomastia on long-term use, headache, intestinal ischaemia and necrosis, psychosis, thrombocytopenia weakness

**Overdose**

If toxicity occurs, digoxin should be withdrawn; serious manifestations require urgent specialist management.

**PREGNANCY** May need dosage adjustment.

**BREAST FEEDING** Amount too small to be harmful.

**RENUAL IM PAIRMENT** Reduce dose. Monitor plasma-digoxin concentration in renal impairment.

**DIRECTIONS FOR ADMINISTRATION**

- With intravenous use Avoid rapid intravenous administration (risk of hypertension and reduced coronary flow). For intravenous infusion (Lanoxin®), give intermittently in Glucose 5% or Sodium chloride 0.9%; dilute to a concentration of not more than 62.5 micrograms/mL. To be given over at least 2 hours.
- With oral use For oral administration, oral solution must not be diluted.

**PATIENT AND CARER ADVICE** Patient counselling is advised for digoxin elixir (use pipette).

**DOSE EQUIVALENCE AND CONVERSION**

- **Dose may need to be reduced if digoxin (or another cardiac glycoside) has been given in the preceding 2 weeks.**
- **When switching from intravenous to oral route may need to increase dose by 20–33% to maintain the same plasma-digoxin concentration.**

**UNLICENSED USE** Digoxin doses in the BNF may differ from those in product literature.

**CONTRA-INDICATIONS** Constrictive pericarditis (unless to control atrial fibrillation or improve systolic dysfunction— but use with caution) - hypertrrophic cardiomyopathy (unless concomitant atrial fibrillation and heart failure— but use with caution) intermittent complete heart block - myocardiit - second degree AV block - supraventricular arrhythmias associated with accessory conducting pathways e.g. Wolff-Parkinson-White syndrome (although can be used in infancy) - ventricular tachycardia or fibrillation

**CAUTIONS** Hypercalcaemia (risk of digitalis toxicity) - hypokalaemia (risk of digitalis toxicity) - hypomagnesemia (risk of digitalis toxicity) hypoxia (risk of digitalis toxicity) - recent myocardial infarction - severe respiratory disease - sick sinus syndrome - thyroid disease

**INTERACTIONS** → Appendix 1: digoxin

**M EDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, solution for injection

**Tablet**

- **Digoxin (Non-proprietary)**
  - Digoxin 62.5 microgram tablet £9.99 DT price = £1.82
  - Digoxin 125 microgram tablet £4.99 DT price = £1.82

16-Jun-2017
Thrombolytic overdose.

Digoxin 250 microgram

Digoxin 250 microgram tablets | 28 tablet (PO) £4.99 DT price = £1.83 | 500 tablet (PO) no price available

Lanoxin (Aspen Pharma Trading Ltd)

Digoxin 62.5 microgram

Lanoxin PG 62.5 microgram tablets | 500 tablet (PO) £8.09

Digoxin 125 microgram

Lanoxin 125 tablets | 500 tablet (PO) £8.09

Digoxin 250 microgram

Lanoxin 250 microgram tablets | 500 tablet (PO) £8.09

Solution for injection

EXCIPIENTS: May contain Alcohol, propylene glycol

Digoxin (Non-proprietary)

Digoxin 100 microgram per 1 ml

Lanoxin Injection Pediatric 100 micrograms/1ml solution for injection ampoules | 10 ampoule (PO) no price available

Solution for infusion

Digoxin 250 microgram per 1 ml

Digoxin 500 micrograms/2ml solution for infusion ampoules | 10 ampoule (PO) £7.00

Lanoxin (Aspen Pharma Trading Ltd)

Digoxin 250 microgram per 1 ml

Lanoxin 500 micrograms/2ml solution for infusion ampoules | 5 ampoule (PO) £3.30

Oral solution

Lanoxin (Aspen Pharma Trading Ltd)

Digoxin 50 microgram per 1 ml

Lanoxin PG 50 micrograms/ml elixir | 60 ml (PO) £5.35 DT price = £5.35

2 Bleeding disorders

Antifibrinolytic drugs and haematostatics

Overview

Fibrin dissolution can be impaired by the administration of tranexamic acid below, which inhibits fibrinolysis. It can be used to prevent bleeding or to treat bleeding associated with excessive fibrinolysis (e.g. in surgery, dental extraction, obstetric disorders, and traumatic haemhaemorrhage) and in the management of menorrhagia. Tranexamic acid may also be used in hereditary angioedema, epistaxis, and in the management of menorrhagia. Tranexamic acid may also be used in hereditary angioedema, epistaxis, and in the management of menorrhagia. Tranexamic acid may also be used in hereditary angioedema, epistaxis, and in the management of menorrhagia.

Desmopressin p. 628 is used in the management of mild to moderate haemophilia and von Willebrand’s disease. It is also used for fibrinolytic response testing.

Etamsylate p. 108 reduces capillary bleeding in the presence of a normal number of platelets; it does not act by fibrin stabilisation, but probably by correcting abnormal adhesion. Etamsylate is less effective than other treatments in the management of heavy menstrual bleeding and its use is no longer recommended.

ANTHAEMORRHAGICS ▶ ANTIFIBRINOLYTICS

Tranexamic acid

26-Apr-2017

INDICATIONS AND DOSE

Local fibrinolysis

▶ BY MOUTH

Adult: 1–1.5 g 2–3 times a day, alternatively 15–25 mg/kg 2–3 times a day

▶ INITIALLY BY SLOW INTRAVENOUS INJECTION

Adult: 0.5–1 g 2–3 times a day, to be administered at a rate not exceeding 100 mg/minute, followed by (by continuous intravenous infusion) 25–50 mg/kg if required, dose to be given over 24 hours

Menorrhagia

▶ BY MOUTH

Adult: 1 g 3 times a day for up to 4 days, to be initiated when menstruation has started; maximum 4 g per day

Hereditary angioedema

▶ BY MOUTH

Adult: 1–1.5 g 2–3 times a day, for short-term prophylaxis of hereditary angioedema, tranexamic acid is started several days before planned procedures which may trigger an acute attack of hereditary angioedema (e.g. dental work) and continued for 2–5 days afterwards

Epistaxis

▶ BY MOUTH

Adult: 1 g 3 times a day for 7 days

General fibrinolysis

▶ BY SLOW INTRAVENOUS INJECTION

Adult: 1 g every 6–8 hours, alternatively 15 mg/kg every 6–8 hours, dose to be given at a rate not exceeding 100 mg/minute

Prevention and treatment of significant haemorrhage following trauma

▶ INITIALLY BY SLOW INTRAVENOUS INJECTION

Adult: Loading dose 1 g to be given over 10 minutes, treatment should commence within 8 hours of injury, followed by (by intravenous infusion) 1 g to be given over 8 hours

UNLICENSED USE

Use of tranexamic acid by continuous intravenous infusion for treatment of local fibrinolysis is an unlicensed route of administration.

Not licensed for prevention and treatment of significant haemorrhage following trauma.

CONTRA-INDICATIONS

Fibrinolytic conditions following disseminated intravascular coagulation (unless predominant activation of fibrinolytic system with severe bleeding) - history of convulsions - thromboembolic disease

CAUTIONS

Irregular menstrual bleeding (establish cause before initiating therapy) - massive haematuria (avoid if risk of ureteric obstruction) - patients receiving oral contraceptives (increased risk of thrombosis)

INTERACTIONS → Appendix 1: tranexamic acid

SIDE-EFFECTS

Common or very common Diarrhoea (reduce dose) - nausea - vomiting

Uncommon Dermatitis

Rare Impairment of colour vision (discontinue) - thromboembolic events - visual disturbances (discontinue)

Frequency not known Convulsions (usually with high doses) - hypotension (on rapid intravenous injection) - malaise (on rapid intravenous injection)

PREGNANCY

No evidence of teratogenicity in animal studies; manufacturer advises use only if potential benefit outweighs risk—crosses the placenta.

BREAST FEEDING

Small amount present in milk—antifibrinolytic effect in infant unlikely.

RENAI IMPAIRMENT

Reduce dose—consult product literature for details.

MONITORING REQUIREMENTS

Regular liver function tests in long-term treatment of hereditary angioedema.

DIRECTIONS FOR ADMINISTRATION

For intravenous infusion (Cyklokapron®), give continuously in Glucose 5% or Sodium chloride 0.9%.

downloaded from www.medicalbr.com
2.1 Coagulation factor deficiencies

BLOOD AND RELATED PRODUCTS > COAGULATION PROTEINS

Dried prothrombin complex

(Human prothrombin complex)

**INDICATIONS AND DOSE**

Treatment and peri-operative prophylaxis of haemorrhage in patients with congenital deficiency of factors II, VII, IX, or X if purified specific coagulation factors not available/ Treatment and peri-operative prophylaxis of haemorrhage in patients with acquired deficiency of factors II, VII, IX, or X (e.g. during warfarin treatment)

- **BY INTRAVENOUS INFUSION**
- **Adult:** (consult haematologist)

Major bleeding in patients on warfarin following phytomenadione (initiated under specialist supervision)

- **BY INTRAVENOUS INFUSION**
- **Adult:** 25–50 units/kg

**CONTRA-INdications**

Angina - history of hepatic induced thrombocytopenia - recent myocardial infarction (except in life-threatening haemorrhage following overdosage of oral anticoagulants, and before induction of fibrinolytic therapy)

**CAUTIONS** Disseminated intravascular coagulation - history of myocardial infarction or coronary heart disease - postoperative use - risk of thrombosis

**SIDE-EFFECTS**

- **Rare** Headache
- **Very rare** Anaphylaxis - antibody formation - hypersensitivity reactions - pyrexia
- **Frequency not known** Disseminated intravascular coagulation - nephrotic syndrome - thrombotic events

**PRESCRIBING AND DISPENSING INFORMATION**

Dried prothrombin complex is prepared from human plasma by a suitable fractionation technique, and contains factor IX, together with variable amounts of factors II, VII, and X.

Available from CSL Behring (Beriplex® P/N), Octapharma (Octaplex®).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder and solvent for solution for injection**

- **Beriplex P/N** (CSL Behring UK Ltd)
  - Factor II 340 unit, Factor VII 175 unit, Protein S 195 unit, Factor X 410 unit, Protein C 300 unit, Factor IX 255 unit Beriplex P/N 250 powder and solvent for solution for injection vials | 1 vial (£51.20)
  - Factor II 690 unit, Factor VII 350 unit, Protein C 600 unit, Protein S 390 unit, Factor X 820 unit, Factor IX 510 Octaplex P/N 500 powder and solvent for solution for injection vials | 1 vial (£52.50)
  - Factor II 1360 unit, Factor VII 700 unit, Protein C 1200 unit, Protein S 1000 unit, Factor X 1640 unit, Factor IX 1020 Beriplex P/N 1000 powder and solvent for solution for injection vials | 1 vial (£510.00)

- **Octaplex** (Octapharma Ltd)
  - Protein S 390 unit, Factor II 490 unit, Factor VII 330 unit, Factor IX 500 unit, Factor X 480 unit, Protein C 380 unit Octaplex 500unit powder and solvent for solution for injection vials | 1 vial (£208.25)
  - Protein S 880 unit, Factor II 1040 unit, Factor VII 660 unit, Factor IX 1000 unit, Factor X 960 unit, Protein C 880 unit Octaplex 1000unit powder and solvent for solution for injection vials | 1 vial (£416.50)

**Factor IX fraction, dried**

**INDICATIONS AND DOSE**

Treatment and prophylaxis of haemorrhage in congenital factor IX deficiency (haemophilia B)

- **BY INTRAVENOUS INJECTION, OR BY CONTINUOUS INTRAVENOUS INFUSION**
- **Adult:** (consult haematologist)

**CONTRA-INdications**

Disseminated intravascular coagulation

**CAUTIONS** Risk of thrombosis—principally with former low purity products

**SIDE-EFFECTS**

Allergic reactions - chills - dizziness - fever - gastro-intestinal disturbances - headache

**PRESCRIBING AND DISPENSING INFORMATION**

Dried factor IX fraction is prepared from human plasma by a suitable fractionation technique; it may also contain clotting factors II, VII, and X.
Factor VIII fraction (recombinant)  
(Eptacog alfa (activated))

**INDICATIONS AND DOSE**

Treatment and prophylaxis of haemorrhage in patients with haemophilia A or B with inhibitors to factors VIII or IX, acquired haemophilia, factor VII deficiency, or Glanzmann’s thrombasthenia

**INDICATIONS**

- Intravenous injection

**SIDE-EFFECTS**

- Hemodynamic instability
- Hypotension
- Palpitation
- Urticaria

**CAUTIONS**

- Disseminated intravascular coagulation - risk of thrombosis
- Hypersensitivity reactions

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder and solvent for solution for injection**

- **Eptacog alfa activated 50000 unit** NovoSeven 1mg (50,000 units) powder and solvent for solution for injection pre-filled syringes | 1 pre-filled disposable injection (PDS) £255.20 (Hospital only) NovoSeven 1mg (50,000 units) powder and solvent for solution for injection vials | 1 vial (PDS) £105.40 (Hospital only)
- **Eptacog alfa activated 50000 unit** NovoSeven 2mg (100,000 units) powder and solvent for solution for injection vials | 1 vial (PDS) £200.80 (Hospital only) NovoSeven 2mg (100,000 units) powder and solvent for solution for injection pre-filled syringes | 1 pre-filled disposable injection (PDS) £105.40 (Hospital only)

**Factor VIII fraction, dried (Human coagulation factor VIII, dried)**

**INDICATIONS AND DOSE**

Treatment and prophylaxis of haemorrhage in congenital factor VIII deficiency (haemophilia A), acquired factor VIII deficiency | Von Willebrand’s disease

**INDICATIONS**

- Intravenous injection, or by intravenous infusion, or by continuous intravenous infusion

**CAUTIONS**

- Intravascular haemolysis after large or frequently repeated doses in patients with blood groups A, B, or AB—less likely with high potency concentrates

**SIDE-EFFECTS**


**MONITORING REQUIREMENTS**

Monitor for development of factor VIII inhibitors.

**PRESCRIBING AND DISPENSING INFORMATION**

Dried factor VIII fraction is prepared from human plasma by a suitable fractionation technique; it may also contain varying amounts of von Willebrand factor. Optivate®, Fanydi®, and Octanate™ are not indicated for use in von Willebrand’s disease.

Recombinant human coagulation factor VIII including octocog alfa, moroctocog alfa, and simoctocog alfa are not indicated for use in von Willebrand’s disease.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder and solvent for solution for injection**

- **Advate** (Baxalta UK Ltd) Octocog alfa 250 unit Advate 250 unit powder and solvent for solution for injection vials | 1 vial (PDS) no price available Octocog alfa 500 unit Advate 500 unit powder and solvent for solution for injection vials | 1 vial (PDS) no price available Octocog alfa 1000 unit Advate 1000 unit powder and solvent for solution for injection vials | 1 vial (PDS) no price available Octocog alfa 2000 unit Advate 2000 unit powder and solvent for solution for injection vials | 1 vial (PDS) no price available
- **Electa** (Swedish Orphan Biovitrum Ltd)®
  - **Efmorococog alfa 250 unit** Electa 250 unit powder and solvent for solution for injection vials | 1 vial (PDS) no price available (Hospital only) Efmorococog alfa 500 unit Electa 500 unit powder and solvent for solution for injection vials | 1 vial (PDS) no price available (Hospital only)
  - **Efmorococog alfa 1000 unit** Electa 1000 unit powder and solvent for solution for injection vials | 1 vial (PDS) no price available (Hospital only)
  - **Efmorococog alfa 1500 unit** Electa 1500 unit powder and solvent for solution for injection vials | 1 vial (PDS) no price available (Hospital only)
  - **Efmorococog alfa 2000 unit** Electa 2000 unit powder and solvent for solution for injection vials | 1 vial (PDS) no price available (Hospital only)
Cardiovascular system

SIDE-EFFECTS

There can be variation in the licensing of different medicines

Allergic reactions

▶ Powder and solvent for solution for injection vials | 1 vial (POM) £95.00

Helixate NexGen (CSL Behring UK Ltd)

Octocog alfa 250 unit Helixate NexGen 250unit powder and solvent for solution for injection vials | 1 vial (POM) £127.50 (Hospital only)

Octocog alfa 500 unit Helixate NexGen 500unit powder and solvent for solution for injection vials | 1 vial (POM) £330.00 (Hospital only)

Factor VIII high purity 1000 unit Haemostin 1000unit powder and solvent for solution for injection vials | 1 vial (POM) £118.57

▶ Powder and solvent for solution for infusion vials | 1 vial (POM) £118.57

Protein C concentrate

INDICATIONS AND DOSE

Treatment of haemorrhage in congenital hypofibrinogenaeamia or afibrinogenaeamia

› BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION

Adult: (consult haematologist)

CAUTIONS

Risk of thrombosis

SIDE-EFFECTS

› Rare Allergic reactions · fever

› Very rare Myocardial infarction · pulmonary embolism · thromboembolic events

PREGNANCY

Manufacturer advises not known to be harmful—no information available.

BREAST FEEDING

Manufacturer advises avoid—no information available.

PRESCRIBING AND DISPENSING INFORMATION

Fibrinogen is prepared from human plasma.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for infusion

› Riastap (CSL Behring UK Ltd)

Fibrinogen 1 gram Riastap 1g powder for solution for infusion vials | 1 vial (POM) £340.00

Factor XIII fraction, dried

(Human fibrin-stabilising factor, dried)

INDICATIONS AND DOSE

Congenital factor XIII deficiency

› BY INTRAVENOUS INJECTION

Adult: (consult haematologist)

CAUTIONS

Hypersensitivity to heparins

SIDE-EFFECTS

› Very rare Bleeding · dizziness · fever · hypersensitivity reactions

PRESCRIBING AND DISPENSING INFORMATION

Protein C is prepared from human plasma.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Powder and solvent for solution for injection

› Ceprotin (Baxalta UK Ltd)

Protein C 500 unit Ceprotin 500unit powder and solvent for solution for injection vials | 1 vial (POM) no price available

Protein C 1000 unit Ceprotin 1000unit powder and solvent for solution for injection vials | 1 vial (POM) no price available

BLOOD AND RELATED PRODUCTS

HAEMOSTATIC PRODUCTS

Factor VIII inhibitor bypassing fraction

INDICATIONS AND DOSE

Treatment and prophylaxis of haemorrhage in patients with congenital factor VIII deficiency (haemophilia A) and factor VIII inhibitors | Treatment of haemorrhage in non-haemophilic patients with acquired factor VIII inhibitors

› BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION

Adult: (consult haematologist)

CONTRA-INDICATIONS

Disseminated intravascular coagulation

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Powder and solvent for solution for injection

› Fibrogammin P (CSL Behring UK Ltd)

Factor XIII 250 unit Fibrogammin 250unit powder and solvent for solution for injection vials | 1 vial (POM) £90.59

Factor XIII 1250 unit Fibrogammin 1250unit powder and solvent for solution for injection vials | 1 vial (POM) €452.95

Fibrinogen, dried

(Human fibrinogen)

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Powder and solvent for solution for injection vials

› Kogenate Bayer

Factor XIII 250 unit Kogenate Bayer 250unit powder and solvent for solution for injection vials | 1 vial (POM) £118.57

Factor XIII 500 unit Kogenate Bayer 500unit powder and solvent for solution for injection vials | 1 vial (POM) £315.00

Factor XIII 1000 unit Kogenate Bayer 1000unit powder and solvent for solution for injection vials | 1 vial (POM) £630.00

Factor XIII 2000 unit Kogenate Bayer 2000unit powder and solvent for solution for injection vials | 1 vial (POM) £11.260.00

› Nuwiq (Octapharma Ltd)

Simocogal alfa 250 unit Nuwiq 250unit powder and solvent for solution for injection vials | 1 vial (POM) £100.00 (Hospital only)

Simocogal alfa 500 unit Nuwiq 500unit powder and solvent for solution for injection vials | 1 vial (POM) £380.00 (Hospital only)

Simocogal alfa 1000 unit Nuwiq 1000unit powder and solvent for solution for injection vials | 1 vial (POM) £760.00 (Hospital only)

Simocogal alfa 2000 unit Nuwiq 2000unit powder and solvent for solution for injection vials | 1 vial (POM) £1700.00 (Hospital only)

Powder and solvent for solution for infusion

› Advate (Baxalta UK Ltd)

Octocog alfa 1500 unit Advate 1500unit powder and solvent for solution for infusion vials | 1 vial (POM) no price available

Octocog alfa 3000 unit Advate 3000unit powder and solvent for solution for infusion vials | 1 vial (POM) no price available

Kogenate (Bayer Plc)

Octocog alfa 3000 unit Kogenate Bayer 3000unit powder and solvent for solution for injection vials | 1 vial (POM) £11.890.00

DIETARY AND LIFESTYLE ADVICE

For dietary advice, see page 23 of this edition.

INFECTION CONTROL

For infection control advice, see page 13 of this edition.
2.2 Subarachnoid haemorrhage

**CALCIUM-CHANNEL BLOCKERS**

### Nimodipine

**DRUG ACTION** Nimodipine is a dihydropyridine calcium-channel blocker.

**INDICATIONS AND DOSE**

#### Prevention of ischaemic neurological defects following aneurysmal subarachnoid haemorrhage

- **BY MOUTH**
  - Adult: 60 mg every 4 hours, to be started within 4 days of aneurysmal subarachnoid haemorrhage and continued for 21 days

#### Treatment of ischaemic neurological defects following aneurysmal subarachnoid haemorrhage

- **BY INTRAVENOUS INFUSION**
  - Adult (body-weight up to 70 kg): Initially up to 0.5 mg/hour, increased after 2 hours if no severe fall in blood pressure; increased to 2 mg/hour and continue for at least 5 days (max. 14 days); if surgical intervention during treatment, continue for at least 5 days after surgery; max. total duration of nimodipine use 21 days, to be given via central catheter
  - Adult (body-weight 70 kg and above): Initially 1 mg/hour, increased after 2 hours if no severe fall in blood pressure; increased to 2 mg/hour and continue for at least 5 days (max. 14 days); if surgical intervention during treatment, continue for at least 5 days after surgery; max. total duration of nimodipine use 21 days, to be given via central catheter

**TREATMENT OF ISCHAEMIC NEUROLOGICAL DEFECTS FOLLOWING ANEURYSMAL SUBARACHNOID HAEMORRHAGE IN PATIENTS WITH UNSTABLE BLOOD PRESSURE**

- **BY INTRAVENOUS INFUSION**
  - Adult: Initially up to 0.5 mg/hour, increased after 2 hours if no severe fall in blood pressure; increased to 2 mg/hour and continue for at least 5 days (max. 14 days); if surgical intervention during treatment, continue for at least 5 days after surgery; max. total duration of nimodipine use 21 days, to be given via central catheter

### CONTRA-INDICATIONS

- Acute porphyrias (p. 969)
- Unstable angina
- Within 1 month of myocardial infarction
- Cerebral oedema
- Hypotension
- Severely raised intracranial pressure
- Calcium channel blockers

### INTERACTIONS

- Appendix 1: calcium channel blockers

### SIDE-EFFECTS

- Flushing
- Gastro-intestinal disorders
- Headache
- Hypotension
- Ileus
- Nausea
- Sweating
- Feeling of warmth
- Thrombocytopenia
- Variation in heart-rate

### PREGNANCY

- Manufacturer advises use only if potential benefit outweighs risk

### BREAST FEEDING

- Manufacturer advises avoid—present in milk

### HEPATIC IMPAIRMENT

- Elimination reduced in cirrhosis—monitor blood pressure

### RENAL IMPAIRMENT

- With intravenous use—manufacturer advises monitor renal function closely in renal impairment

### DIRECTIONS FOR ADMINISTRATION

- Avoid concomitant administration of nimodipine infusion and tablets
- With oral use: For administration by mouth, tablets may be crushed or halved but are light sensitive—administer immediately
3 Blood clots

3.1 Blocked catheters and lines

Other drugs used for Blocked catheters and lines

Heparin (unfractionated), p. 128 • Urokinase, p. 133

ANTITHROMBOTIC DRUGS PROSTAGLANDINS, CARDIOVASCULAR

Epoprostenol

Prostacyclin

DRUG ACTION
Epoprostenol is a prostaglandin and a potent vasodilator. It is also a powerful inhibitor of platelet aggregation.

INDICATIONS AND DOSE
Inhibition of platelet aggregation during renal dialysis when heparins are unsuitable or contra-indicated. Treatment of primary pulmonary hypertension resistant to other treatments, usually with oral anti-coagulation (initiated by a specialist)

BY CONTINUOUS INTRAVENOUS INFUSION
Adult: (consult product literature)

PHARMACOKINETICS
Short half-life of approximately 3 minutes, therefore it must be administered by continuous intravenous infusion.

CONTRA-INDICATIONS
Severe left ventricular dysfunction

CAUTIONS
Avoid abrupt withdrawal when used for primary pulmonary hypertension (risk of rebound pulmonary hypertension). Extreme caution in coronary artery disease, haemorrhagic diathesis, pulmonary veno-occlusive disease, reconstituted solution highly alkaline—avoid extravasation (irritant to tissues). Risk of pulmonary oedema (dose titration for pulmonary hypertension should be in hospital)

INTERACTIONS
Appendix 1: epoprostenol

SIDE-EFFECTS

Common or very common
Abdominal pain • anxiety • arthralgia • bleeding • bradycardia • chest pain • diarrhoea • flushing • headache • hypotension • jaw pain • nausea • rash • Sepsis • tachycardia • thrombocytopenia • vomiting

Uncommon
Dry mouth • sweating

Very rare
Agitation • hyperthyroidism • malaise • pallor

Frequency not known
Hyperglycaemia • pulmonary oedema (avoid chronic use if occurs during dose titration)

PREGNANCY
Use if potential benefit outweighs risk.

BREAST FEEDING
Manufacturer advises avoid—no information available.

MONITORING REQUIREMENTS
Anticoagulant monitoring required when given with anticoagulants.

TREATMENT CESSATION
Avoid abrupt withdrawal when used for primary pulmonary hypertension (risk of rebound pulmonary hypertension).

DIRECTIONS FOR ADMINISTRATION
For intravenous infusion (Flolan®), give continuously in Sodium chloride 0.9%; reconstitute using the filter and solvent (glycine buffer diluent) provided to make a concentrate; may be diluted further (consult product literature); for pulmonary hypertension dilute further with glycine buffer diluent only and administer via a central venous catheter (can give via peripheral vein until central venous access established); for renal dialysis may be diluted further with sodium chloride 0.9%; protect infusion from light. For intravenous infusion (Veletri®), give continuously in Sodium chloride 0.9%; reconstitute each vial with 5 mL sodium chloride 0.9% then dilute to required concentration with sodium chloride 0.9% (consult product literature); administer through an in-line 0.22 micron filter; for pulmonary hypertension, administer via a central venous catheter (can give via peripheral vein until central venous access established); protect infusion from direct sunlight.

Powder and solvent for solution for infusion

<table>
<thead>
<tr>
<th>Drug</th>
<th>Concentration</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epoprostenol as Epoprostenol sodium</td>
<td>500 microgram</td>
<td>Veletri (Actelion Pharmaceuticals UK Ltd)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>£76.00</td>
</tr>
<tr>
<td>Epoprostenol as Epoprostenol sodium</td>
<td>1.5 mg</td>
<td>Veletri 1.5 mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>£49.24</td>
</tr>
<tr>
<td>Epoprost enol as Epoprostenol sodium</td>
<td>500 microgram</td>
<td>Flolan (GlaxoSmithKline UK Ltd)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>£72.22</td>
</tr>
<tr>
<td></td>
<td></td>
<td>£74.76</td>
</tr>
<tr>
<td></td>
<td></td>
<td>£76.00</td>
</tr>
</tbody>
</table>

3.2 Thromboembolism

Venous thromboembolism

Overview
Venous thromboembolism includes deep-vein thrombosis and pulmonary embolism, and occurs as a result of thrombus formation in a vein.

Prophylaxis of venous thromboembolism

All patients admitted to hospital should undergo a risk assessment for venous thromboembolism on admission. Patients considered to be at high risk include those anticipated to have a substantial reduction in mobility, those with obesity, malignant disease, history of venous thromboembolism, thrombophilic disorder, or patients over 60 years. Patients with risk factors for bleeding (e.g. acute stroke, thrombocytopenia, acquired or untreated inherited bleeding disorders) should only receive pharmacological
prophylaxis when the risk of bleeding does not outweigh the risk of venous thromboembolism. NICE clinical guideline 92 (January 2010) provides a full list of risk factors, and gives recommendations for prophylaxis. A venous thromboembolism risk assessment checklist is also available from the Department of Health (www.gov.uk/dh).

Patients scheduled for surgery should be offered mechanical prophylaxis (e.g. anti-embolism stockings) on admission if appropriate; prophylaxis on admission should continue until the patient is sufficiently mobile. Choice of mechanical prophylaxis will depend on factors such as the type of surgery, suitability for the patient, and their condition. Patients undergoing general or orthopaedic surgery, who are considered to be at high risk of venous thromboembolism, should be offered pharmacological prophylaxis. Choice of prophylaxis will depend on the type of surgery, suitability for the patient, and local policy. A low molecular weight heparin is suitable in all types of general and orthopaedic surgery; heparin (unfractionated) p. 128 is preferred for patients in renal failure. Fondaparinux sodium p. 123 is an option for patients undergoing hip or knee replacement surgery, hip fracture surgery, gastro-intestinal, bariatric, or urgent gynaecological surgery procedures. The oral anticoagulants apixaban p. 121, dabigatran etexilate p. 131, and rivaroxaban p. 123 are indicated for thromboprophylaxis following hip or knee replacement surgery.

Pharmacological prophylaxis in general surgery should usually continue for 5–7 days, or until sufficient mobility has been re-established. Pharmacological prophylaxis should be extended to 28 days after major cancer surgery in the abdomen or pelvis. Hip or knee replacement surgery, and hip fracture surgery, require an extended duration of pharmacological prophylaxis, depending on the preparation used (consult product literature).

General medical patients who are considered to be at high risk of venous thromboembolism should be offered pharmacological prophylaxis on admission. Choice of prophylaxis will depend on the medical condition, suitability for the patient, and local policy. Patients should receive either a low molecular weight heparin, heparin (unfractionated) (if patient in renal failure), or fondaparinux sodium. Prophylaxis should continue until the patient is no longer considered to be at significant risk of venous thromboembolism. Mechanical prophylaxis (e.g. anti-embolism stockings) can be offered to medical patients in whom pharmacological prophylaxis is contra-indicated, and continued until the patient is sufficiently mobile.

Edoxaban
Edoxaban p. 122, an inhibitor of factor Xa, is given orally for the treatment and prophylaxis of venous thromboembolism, although, it should not be used as an alternative to unfractionated heparin in pulmonary embolism in patients with haemodynamic instability, or who may receive thrombolysis or pulmonary embolectomy. Duration of therapy should be determined by balancing the benefit of treatment with the bleeding risk; shorter duration of treatment (at least 3 months) should be based on transient risk factors i.e. recent surgery, trauma, immobilisation, and longer durations should be based on permanent risk factors or idiopathic deep-vein thrombosis or pulmonary embolism. Edoxaban is also licensed for the prophylaxis of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one other risk factor.

Treatment of venous thromboembolism
For the initial treatment of deep-vein thrombosis and pulmonary embolism a low molecular weight heparin is used; alternatively, heparin (unfractionated) is given as an intravenous loading dose, followed by continuous intravenous infusion (using an infusion pump) or (for deep-vein thrombosis only) by intermittent subcutaneous injection. Intermittent intravenous injection of heparin (unfractionated) is no longer recommended. An oral anticoagulant (usually warfarin sodium p. 135 is started at the same time as unfractionated or low molecular weight heparin (the heparin needs to be continued for at least 5 days and until the INR is \geq 2 for at least 24 hours). Laboratory monitoring for heparin (unfractionated), preferably on a daily basis, is essential; determination of the activated partial thromboplastin time (APTT) is the most widely used measure (for heparin (unfractionated). A low molecular weight heparin or, in some circumstances, heparin (unfractionated) is also used in regimens for the management of myocardial infarction and unstable angina.

Management of venous thromboembolism in pregnancy
Heparins are used for the management of venous thromboembolism in pregnancy because they do not cross the placenta. Low molecular weight heparins are preferred because they have a lower risk of osteoporosis and of heparin-induced thrombocytopenia. Low molecular weight heparins are eliminated more rapidly in pregnancy, requiring alteration of the dosage regimen for drugs such as dalteparin sodium p. 126, enoxaparin sodium p. 127, and tinzaparin sodium p. 129. Treatment should be stopped at the onset of labour and advice sought from a specialist on continuing therapy after birth.

Extracorporeal circuits
Heparin (unfractionated) is also used in the maintenance of extracorporeal circuits in cardiopulmonary bypass and haemodialysis.

Haemorrhage
If haemorrhage occurs it is usually sufficient to withdraw unfractionated or low molecular weight heparin, but if rapid reversal of the effects of the heparin is required, protamine sulfate p. 1258 is a specific antidote (but only partially reverses the effects of low molecular weight heparins).

Management of stroke
Overview
Stroke is associated with a significant risk of morbidity and mortality. Patients presenting with acute symptoms should be immediately transferred to hospital for accurate diagnosis of stroke type, and urgent initiation of appropriate treatment; patients should be managed by a specialist multidisciplinary stroke team.

The following notes give an overview of the initial and long-term management of transient ischaemic attack, ischaemic stroke, and intracerebral haemorrhage.

Transient ischaemic attack
Patients suspected of having a transient ischaemic attack should immediately receive aspirin p. 117 (patients with aspirin hypersensitivity, or those intolerant of aspirin despite the addition of a proton pump inhibitor, should receive clopidogrel p. 119 [unlicensed use] as an alternative). Following a confirmed diagnosis, patients should receive treatment for secondary prevention (see Long-term Management, under Ischaemic Stroke).

Ischaemic stroke
Initial management
Alteplase p. 210 is recommended in the treatment of acute ischaemic stroke if it can be administered within 4.5 hours of symptom onset; it should be given by medical staff experienced in the administration of thrombolitics and the treatment of acute stroke, preferably within a specialist...
stroke centre. Treatment with aspirin should be initiated 24 hours after thrombolysis (or as soon as possible within 48 hours of symptom onset in patients not receiving thrombolysis); patients with aspirin hypersensitivity, or those intolerant of aspirin despite the addition of a proton pump inhibitor, should receive clopidogrel [unlicensed use] as an alternative.

Anticoagulants are not recommended as an alternative to antiplatelet drugs in acute ischaemic stroke in patients who are in sinus rhythm. However, parenteral anticoagulants may be indicated in patients who are symptomatic of, or at high risk of developing, deep vein thrombosis or pulmonary embolism; warfarin sodium p. 135 should not be commenced in the acute phase of ischaemic stroke.

Anticoagulants should be considered after cardio-embolic ischaemic stroke in patients with atrial fibrillation, however patients presenting with atrial fibrillation following a disabling ischaemic stroke should receive aspirin before being considered for anticoagulant treatment. Patients already receiving anticoagulation for a prosthetic heart valve who experience a disabling ischaemic stroke and are at significant risk of haemorrhagic transformation, should have their anticoagulant treatment stopped for 7 days and substituted with aspirin.

Treatment of hypertension in the acute phase of ischaemic stroke can result in reduced cerebral perfusion, and should therefore only be instituted in the event of a hypertensive emergency, or in those patients considered for thrombolysis.

Long-term management
Patients should receive long-term treatment following a transient ischaemic attack or an ischaemic stroke to reduce the risk of further cardiovascular events.

Following a transient ischaemic attack or an ischaemic stroke (not associated with atrial fibrillation), long-term treatment with clopidogrel [unlicensed in transient ischaemic attack] is recommended. If clopidogrel is contra-indicated or not tolerated, patients can receive modified-release dipyridamole p. 120 in combination with aspirin; if both aspirin and clopidogrel are contra-indicated or not tolerated, then modified-release dipyridamole alone is recommended; if both modified-release dipyridamole and clopidogrel are contra-indicated or not tolerated, then aspirin alone is recommended.

Patients with stroke associated with atrial fibrillation should be reviewed for long-term treatment with warfarin sodium or an alternative anticoagulant (see Initial Management under Ischaemic Stroke).

Anticoagulants are not routinely recommended in the long-term prevention of recurrent stroke, except in patients with atrial fibrillation.

A statin should be initiated 48 hours after stroke symptom onset, irrespective of the patient’s serum-cholesterol concentration.

Following the acute phase of ischaemic stroke, blood pressure should be measured and treatment initiated to achieve a target blood pressure of <130/80 mmHg. Beta-blockers should not be used in the management of hypertension following a stroke, unless they are indicated for a co-existing condition.

All patients should be advised to make lifestyle modifications that include beneficial changes to diet, exercise, weight, alcohol intake, and smoking.

Intracerebral haemorrhage

Initial Management
Surgical intervention may be required following intracerebral haemorrhage to remove the haematoma and relieve intracranial pressure. Patients taking anticoagulants should have this treatment stopped and reversed; anticoagulant therapy has, however, been used in patients with intracerebral haemorrhage who are symptomatic of deep vein thrombosis or pulmonary embolism; placement of a caval filter is an alternative in this situation.

Long-term management
Aspirin therapy should only be given to patients at a high risk of a cardiac ischaemic event. Anticoagulant therapy is not recommended following an intracerebral haemorrhage, even in those with atrial fibrillation, unless the patient is at very high risk of an ischaemic stroke or cardiac ischaemic events; advice from a specialist should be sought in this situation. Blood pressure should be measured and treatment initiated where appropriate, taking care to avoid hypoperfusion. Statins should be avoided following intracerebral haemorrhage, however they can be used with caution when the risk of a vascular event outweighs the risk of further haemorrhage.

Oral anticoagulants

Overview
The main use of anticoagulants is to prevent thrombus formation or extension of an existing thrombus in the slower-moving venous side of the circulation, where the thrombus consists of a fibrin web enmeshed with platelets and red cells.

Anticoagulants are of less use in preventing thrombus formation in arteries, for in faster-flowing vessels thromb is composed mainly of platelets with little fibrin.

Coumarins and phenindione
The oral anticoagulants warfarin sodium p. 135, acenocoumarol p. 134 and phenindione p. 134, antagonise the effects of vitamin K, and take at least 48 to 72 hours for the anticoagulant effect to develop fully; warfarin sodium is the drug of choice. If an immediate effect is required, unfractionated or low molecular weight heparin must be given concomitantly.

These oral anticoagulants should not be used in cerebral artery thrombosis or peripheral artery occlusion as first-line therapy; aspirin p. 117 is more appropriate for reduction of risk in transient ischaemic attacks. Unfractionated or a low molecular weight heparin (see under Parenteral anticoagulants p. 115) is usually preferred for the prophylaxis of venous thromboembolism in patients undergoing surgery; alternatively, warfarin sodium can be continued in selected patients currently taking long-term warfarin sodium and who are at high risk of thromboembolism (seek expert advice).

Dose
The base-line prothrombin time should be determined but the initial dose should not be delayed whilst awaiting the result.

Target INR
The following indications and target INRs for adults for warfarin take into account recommendations of the British Society for Haematology guidelines on oral anticoagulation with warfarin—fourth edition. Br J Haematol 2011; 154: 311–324:

An INR which is within 0.5 units of the target value is generally satisfactory; larger deviations require dosage adjustment. Target values (rather than ranges) are now recommended.

INR 2.5 for:
• treatment of deep-vein thrombosis or pulmonary embolism (including those associated with antiphospholipid syndrome or for recurrence in patients no longer receiving warfarin sodium)
• atrial fibrillation
• cardioversion—target INR should be achieved at least 3 weeks before cardioversion and anticoagulation should
continue for at least 4 weeks after the procedure (higher target values, such as an INR of 3, can be used for up to 4 weeks before the procedure to avoid cancellations due to low INR)

- mitral stenosis or regurgitation in patients with either atrial fibrillation, a history of systemic embolism, a left atrial thrombus, or an enlarged left atrium
- bioprosthetic heart valves in the mitral position (treat for 3 months), or in patients with a history of systemic embolism (treat for at least 3 months), or with a left atrial thrombus at surgery (treat until clot resolves), or with other risk factors (e.g. atrial fibrillation or a low ventricular ejection fraction)

- acute arterial embolism requiring embolectomy (consider long-term treatment)
- myocardial infarction
- INR 3.5 for:
  - recurrent deep-vein thrombosis or pulmonary embolism in patients currently receiving anticoagulation and with an INR above 2;
  - Mechanical prosthetic heart valves:
    - the recommended target INR depends on the type and location of the valve, and patient-related risk factors
    - consider increasing the INR target or adding an antiplatelet drug, if an embolic event occurs whilst anticoagulated at the target INR.

**Duration**

The risks of thromboembolism recurrence and anticoagulant-related bleeding should be considered when deciding the duration of anticoagulation.


- 6 weeks for isolated calf-vein deep-vein thrombosis
- 3 months for venous thromboembolism provoked by surgery or other transient risk factor (e.g. combined oral contraceptive use, pregnancy, plaster cast)
- at least 3 months for unprovoked proximal deep-vein thrombosis or pulmonary embolism; long-term anticoagulation may be required.

**Haemorrhage**

The main adverse effect of all oral anticoagulants is haemorrhage. Checking the INR and omitting doses when appropriate is essential; if the anticoagulant is stopped but not reversed, the INR should be measured 2–3 days later to ensure that it is falling. The cause of an elevated INR should be considered, and the INR checked before surgery.

**Parenteral anticoagulants**

**Overview**

The main use of anticoagulants is to prevent thrombus formation or extension of an existing thrombus in the slower-moving venous side of the circulation, where the thrombus consists of a fibrin web enmeshed with platelets and red cells.

Anticoagulants are of less use in preventing thrombus formation in arteries, for in faster-flowing vessels thrombi are composed mainly of platelets with little fibrin.
Heparin
Heparin initiates anticoagulation rapidly but has a short duration of action. It is often referred to as ‘standard’ or heparin (unfractionated) p. 128 to distinguish it from the low molecular weight heparins, which have a longer duration of action. Although a low molecular weight heparin is generally preferred for routine use, heparin (unfractionated) can be used in those at high risk of bleeding because its effect can be terminated rapidly by stopping the infusion.

Low molecular weight heparins
Low molecular weight heparins (dalteparin sodium p. 126, enoxaparin sodium p. 127, and tinzaparin sodium p. 129) are usually preferred over heparin (unfractionated) in the prevention of Venous thromboembolism p. 112 because they are as effective and they have a lower risk of heparin-induced thrombocytopenia. The standard prophylactic regimen does not require anticoagulant monitoring. The duration of action of low molecular weight heparins is longer than that of heparin (unfractionated) and once-daily subcutaneous administration is possible for some indications, making them convenient to use.

Low molecular weight heparins are generally preferred over heparin (unfractionated) in the treatment of deep vein thrombosis and pulmonary embolism, and are also used in the treatment of myocardial infarction, unstable coronary artery disease (see under Acute coronary syndromes p. 206) and for the prevention of clotting in extracorporeal circuits.

Dalteparin sodium and tinzaparin sodium (only 20 000 unit/mL syringe) are also licensed for the extended treatment and prophylaxis of venous thromboembolism in patients with solid tumours; treatment is recommended for a duration of 6 months. Treatment should be initiated by healthcare professionals experienced in the treatment of venous thromboembolism.

Heparinoids
Danaparoid sodium p. 125 is a heparinoid used for prophylaxis of deep–vein thrombosis in patients undergoing general or orthopaedic surgery. Providing there is no evidence of cross-reactivity, it also has a role in patients who develop heparin-induced thrombocytopenia.

Argatroban
An oral anticoagulant can be given with argatroban monohydrate p. 130, but it should only be started once thrombocytopenia has substantially resolved.

Hirudins
Bivalirudin, a hirudin analogue, is a thrombin inhibitor which is licensed for unstable angina or non-ST-segment elevation myocardial infarction in patients planned for urgent or early intervention, and as an anticoagulant for patients undergoing percutaneous coronary intervention (including patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention—see also Management of ST-segment elevation myocardial infarction (STEMI) in Acute coronary syndromes p. 206).

Heparin flushes
The use of heparin flushes should be kept to a minimum. For maintaining patency of peripheral venous catheters, sodium chloride injection 0.9% is as effective as heparin flushes. The role of heparin flushes in maintaining patency of arterial and central venous catheters is unclear.

Epoprostenol
Epoprostenol (prostacyclin) can be given to inhibit platelet aggregation during renal dialysis when heparins are unsuitable or contra-indicated. It is also licensed for the treatment of primary pulmonary hypertension resistant to other treatment, usually with oral anticoagulation; it should be initiated by specialists in pulmonary hypertension. Epoprostenol is a potent vasodilator. It has a short half-life of approximately 3 minutes and therefore it must be administered by continuous intravenous infusion.

Fondaparinux
Fondaparinux sodium is a synthetic pentasaccharide that inhibits activated factor X.

Other drugs used for Thromboembolism
Streptokinase, p. 211

ANTIDOTES AND CHELATORS

Idarucizumab

17-Mar-2017

- **DRUG ACTION** Idarucizumab is a humanised monoclonal antibody fragment that binds specifically to dabigatran and its metabolites, thereby reversing the anticoagulant effect.

- **INDICATIONS AND DOSE** Rapid reversal of dabigatran for emergency procedures, or in life-threatening or uncontrolled bleeding (specialist supervision in hospital)
  - BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION
    - Adult: 5 g, followed by 5 g if required

- **CAUTIONS** Risk of thrombosis

- **FURTHER INFORMATION**
  
  Manufacturer advises to consider re-starting anticoagulant therapy as soon as medically appropriate to reduce the risk of thrombosis. Dabigatran can be re-started 24 hours after administration of idarucizumab; other anticoagulant therapy can be started at any time.

- **INTERACTIONS** → Appendix 1: monoclonal antibodies

- **PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk—no information available.

- **DIRECTIONS FOR ADMINISTRATION** Manufacturer advises that one dose of Praxbind® is administered as either two consecutive intravenous infusions, each given over 5–10 minutes, or as a bolus injection.

- **HANDLING AND STORAGE** Manufacturer advises store in a refrigerator at 2–8°C.

- **NATIONAL FUNDING/ACCESS DECISIONS**
  
  Scottish Medicines Consortium (SMC) Decisions
  
  The Scottish Medicines Consortium has advised (September 2016) that idarucizumab (Praxbind®) is accepted for use within NHS Scotland for adult patients treated with dabigatran etexilate when rapid reversal of its anticoagulant effects is required for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding.

- **MEDIcular FORMS** There can be variation in the licensing of different medicines containing the same drug.

- **Solution for infusion**
  
  **EXCIPIENTS:** May contain Polysorbates, sorbitol
  
  **ELECTROLYTES:** May contain Sodium
  
  **Praxbind** (Boehringer Ingelheim Ltd) ▼
  
  Idarucizumab 50 mg per 1 ml Praxbind 2.5g/50ml solution for infusion vials | 2 vial (Pot) £2,400.00 (Hospital only)

downloaded from www.medicalbr.com
ANTITHROMBOTIC DRUGS > ANTIPLATELET DRUGS

Antiplatelet drugs

Overview
Antiplatelet drugs decrease platelet aggregation and inhibit thrombus formation in the arterial circulation, because in faster-flowing vessels, thrombi are composed mainly of platelets with little fibrin.

Use of aspirin below in primary prevention of cardiovascular events, in patients with or without diabetes, is of unproven benefit. Long-term use of aspirin is of benefit in established cardiovascular disease (secondary prevention); unduly high blood pressure must be controlled before aspirin is given. If the patient is at a high risk of gastro-intestinal bleeding, a proton pump inhibitor can be added.

Aspirin is given following coronary bypass surgery. It is also used in atrial fibrillation, for intermittent claudication, for stable angina and acute coronary syndromes, for use following placement of coronary stents and for use in stroke.

Clopidogrel p. 119 is licensed for the prevention of atherothrombotic events in patients with a history of symptomatic ischaemic disease. Clopidogrel, in combination with low-dose aspirin, is also licensed for acute coronary syndrome without ST-segment elevation; in these circumstances the combination is given for up to 12 months (most benefit occurs during the first 3 months; there is no evidence of benefit beyond 12 months). Clopidogrel, in combination with low-dose aspirin, is also licensed for acute myocardial infarction with ST-segment elevation; the combination is licensed for at least 4 weeks, but the optimum treatment duration has not been established. In patients undergoing percutaneous coronary intervention, clopidogrel is used as an adjunct with aspirin. Patients who are not already taking clopidogrel should receive a loading dose prior to procedure.

Clopidogrel is also licensed, in combination with low-dose aspirin, for the prevention of atherothrombotic and thromboembolic events in patients with atrial fibrillation (and at least one risk factor for a vascular event), and for whom warfarin sodium p. 135 is unsuitable.

Use of clopidogrel with aspirin increases the risk of bleeding. Clopidogrel monotherapy may be an alternative when aspirin is contra-indicated, for example in those with aspirin hypersensitivity, or when aspirin is not tolerated despite the addition of a proton pump inhibitor (see also NICE guidance).

Clopidogrel also has uses in stroke. Dipyridamole p. 120 is used by mouth as an adjunct to oral anticoagulation for prophylaxis of thromboembolism associated with prosthetic heart valves. Modified-release preparations are licensed for secondary prevention of ischaemic stroke and transient ischaemic attacks.

Prasugrel p. 208, in combination with aspirin, is licensed for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention; the combination is usually given for up to 12 months.

Ticagrelor p. 209, in combination with aspirin, is licensed for the prevention of atherothrombotic events in patients with acute coronary syndrome; the combination is usually given for up to 12 months.

Cangrelor p. 202, in combination with aspirin, is licensed for the reduction of thrombotic cardiovascular events in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received treatment with oral clopidogrel, prasugrel or ticagrelor prior to the procedure and in whom oral therapy with these drugs is not suitable. Cangrelor is to be used under expert supervision only.

Antiplatelet drugs and coronary stents
Patients selected for percutaneous coronary intervention, with the placement of a coronary stent, will require dual antiplatelet therapy with aspirin and either cangrelor, clopidogrel, prasugrel, or ticagrelor. Aspirin therapy should continue indefinitely. Clopidogrel is recommended for 1 month following elective percutaneous coronary intervention with placement of a bare-metal stent, and for 12 months if percutaneous coronary intervention with placement of a bare-metal stent was for an acute coronary syndrome; clopidogrel should be given for 12 months following placement of a drug-eluting stent. Clopidogrel should not be discontinued prematurely in patients with a drug-eluting stent—there is an increased risk of stent thrombosis as a result of the eluted drug slowing the re-endothelialisation process. Patients considered to be at high risk of developing late stent thrombosis with a drug-eluting stent may require a longer duration of treatment with clopidogrel. Prasugrel or ticagrelor are alternatives to clopidogrel in certain patients undergoing percutaneous coronary intervention.

Glycoprotein IIb/IIIa inhibitors
Glycoprotein IIb/IIIa inhibitors prevent platelet aggregation by blocking the binding of fibrinogen to receptors on platelets. Abciximab p. 203 is a monoclonal antibody which binds to glycoprotein IIb/IIIa receptors and to other related sites; it is licensed as an adjunct to heparin (unfractionated) p. 128 and aspirin for the prevention of ischaemic complications in high-risk patients undergoing percutaneous transluminal coronary intervention. Abciximab should be used once only (to avoid additional risk of thrombocytopenia). Eptifibatide p. 203 (in combination with heparin (unfractionated) and aspirin) and tirofiban p. 204 (in combination with heparin (unfractionated), aspirin, and clopidogrel) also inhibit glycoprotein IIb/IIIa receptors; they are licensed for use to prevent early myocardial infarction in patients with unstable angina or non-ST-segment-elevation myocardial infarction. Tirofiban is also licensed for use in combination with heparin (unfractionated), aspirin, and clopidogrel, for the reduction of major cardiovascular events in patients with ST-segment elevation myocardial infarction intended for primary percutaneous coronary intervention. Abciximab, eptifibatide and tirofiban should be used by specialists only.

Epoprostenol p. 112 is also used to inhibit platelet aggregation during renal dialysis when heparins are unsuitable or contra-indicated.

Aspirin
(Acetylsalicylic Acid)

INDICATIONS AND DOSE
Cardiovascular disease (secondary prevention)

- **Adult:** 75 mg daily

Management of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) / Management of ST-segment elevation myocardial infarction (STEMI)

- **BY MOUTH**
  - **Adult:** 300 mg, chewed or dispersed in water

Suspected transient ischaemic attack

- **BY MOUTH**
  - **Adult:** 300 mg once daily until diagnosis established continued →
Cardiovascular system

Transient ischaemic attack (long-term treatment in combination with dipyridamole) | Ischaemic stroke not associated with atrial fibrillation (in combination with dipyridamole if clopidogrel contra-indicated or not tolerated) | Ischaemic stroke not associated with atrial fibrillation (used alone if clopidogrel and dipyridamole contra-indicated or not tolerated)

- **CONTRA-INDICATIONS** Active peptic ulceration - bleeding disorders (antiplatelet dose) - children under 16 years (risk of Reye’s syndrome) - haemophilia - previous peptic ulceration (analgesic dose) - severe cardiac failure (analgesic dose)

- **CONTRA-INDICATIONS, FURTHER INFORMATION**
  - Reye’s syndrome: Owing to an association with Reye’s syndrome, aspirin-containing preparations should not be given to children under 16 years, unless specifically indicated, e.g. for Kawasaki disease.

- **CAUTIONS** Allergic disease - anaemia - asthma - dehydration - elderly - G6PD deficiency - preferably avoid during fever or viral infection in children (risk of Reye’s syndrome) - previous peptic ulceration (but manufacturers may advise avoidance of low-dose aspirin in history of peptic ulceration) - thyrotoxicosis - uncontrolled hypertension

- **INTERACTIONS** → Appendix 1: aspirin

- **SIDE-EFFECTS** Blood disorders (with analgesic doses) - bronchospasm - confusion (with analgesic doses) - gastrointestinal haemorrhage (occasionally major) - gastrointestinal irritation (with slight asymptomatic blood loss at higher doses) - haemorrhage including subconjunctival haemorrhage (reported with antiplatelet doses) - increased bleeding time - skin reactions in hypersensitive patients - tinnitus (with analgesic doses)

- **Overdose** The main features of salicylate poisoning are hyperventilation, tinnitus, deafness, vasodilatation, and sweating. Coma is uncommon but indicates very severe poisoning. For specific details on the management of poisoning, see *Aspirin*, under Emergency treatment of poisoning p. 1249.

- **ALLERGY AND CROSS-SENSITIVITY** Aspirin is contra-indicated in history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria, or rhinitis have been precipitated by aspirin or any other NSAID.

- **PREGNANCY** Use antiplatelet doses with caution during third trimester; impaired platelet function and risk of haemorrhage; delayed onset and increased duration of labour with increased blood loss; avoid analgesic doses if possible in last few weeks (low doses probably not harmful); high doses may be related to intra-uterine growth restriction, teratogenic effects, closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of newborn; kernicterus may occur in jaundiced neonates.

- **BREAST FEEDING** Avoid—possible risk of Reyee’s syndrome; regular use of high doses could impair platelet function and produce hypoprothrombinaemia in infant if neonatal vitamin K stores low.

- **HEPATIC IMPAIRMENT** Avoid in severe impairment—increased risk of gastro-intestinal bleeding.

- **RENAL IMPAIRMENT** Use with caution; avoid in severe impairment; sodium and water retention; deterioration in renal function; increased risk of gastro-intestinal bleeding.

- **PRESCRIBING AND DISPENSING INFORMATION** BP directs that when no strength is stated the 300 mg strength should be dispensed, and that when soluble aspirin tablets are prescribed, dispersible aspirin tablets shall be dispensed.

- **PROFESSION SPECIFIC INFORMATION** Dental practitioners’ formulary Aspirin Dispersible Tablets 300 mg may be prescribed.

- **EXCEPTIONS TO LEGAL CATEGORY** Can be sold to the public provided packs contain no more than 32 capsules or tablets; pharmacists can sell multiple packs up to a total quantity of 100 capsules or tablets in justifiable circumstances.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule, oral suspension, oral solution

  - **Gastro-resistant tablet** CAUTIONARY AND ADVISORY LABELS 5, 25, 32
    - *Aspirin (Non-proprietary)*
      - Aspirin 75 mg | Aspirin 75 mg gastro-resistant tablets | 56 tablet | £64.00
      - Aspirin 300 mg | Aspirin 300 mg gastro-resistant tablets | 100 tablet | £20.34
    - *Micropirin* (Dexcel-Pharma Ltd)
      - Aspirin 75 mg | Micropirin 75 mg gastro-resistant tablets | 28 tablet | £1.45
      - Aspirin 300 mg | Micropirin 300 mg gastro-resistant tablets | 100 tablet | £2.87
    - *Nu-Seals* (Alliance Pharmaceuticals Ltd)
      - Aspirin 75 mg | Nu-Seals 75 gastro-resistant tablets | 56 tablet | £3.12
    - *Aspirin 300 mg* | Aspirin 300 mg gastro-resistant tablets | 100 tablet | £10.47

  - **Tablet** CAUTIONARY AND ADVISORY LABELS 21, 32
    - *Aspirin (Non-proprietary)*
      - Aspirin 75 mg | Aspirin 75 mg tablets | 28 tablet | £1.13
      - Aspirin 300 mg | Aspirin 300 mg tablets | 100 tablet | £1.13
    - *Aspirin 300 mg* | Aspirin 300 mg suppositories | 10 suppository | £18.67
    - *Dispersible tablet* CAUTIONARY AND ADVISORY LABELS 13, 21, 32
      - *Aspirin (Non-proprietary)*
        - Aspirin 75 mg | Aspirin 75 mg dispersible tablets | 28 tablet | £0.70
Clopidogrel

- **INDICATIONS AND DOSE**
  
  Prevention of atherothrombotic events in percutaneous coronary intervention (adjunct with aspirin) in patients not already on clopidogrel
  
  **BY MOUTH**
  
  **Adult:** Loading dose 300 mg, to be taken prior to the procedure, alternatively loading dose 600 mg, higher dose may produce a greater and more rapid inhibition of platelet aggregation
  
  Transient ischemic attack for patients with aspirin hypersensitivity, or those intolerant of aspirin despite the addition of a proton pump inhibitor or acute ischemic stroke for patients with aspirin hypersensitivity, or those intolerant of aspirin despite the addition of a proton pump inhibitor
  
  **BY MOUTH**
  
  **Adult:** 75 mg once daily
  
  Prevention of atherothrombotic events in peripheral arterial disease or within 35 days of myocardial infarction, or within 6 months of ischemic stroke
  
  **BY MOUTH**
  
  **Adult:** 75 mg once daily
  
  Prevention of atherothrombotic events in acute coronary syndrome without ST-segment elevation (given with aspirin)
  
  **BY MOUTH**
  
  **Adult:** Initially 300 mg, then 75 mg daily for up to 12 months
  
  Prevention of atherothrombotic events in acute myocardial infarction with ST-segment elevation (given with aspirin)
  
  **BY MOUTH**
  
  **Adult:** 75 mg once daily

- **UNLICENSED USE**
  600 mg loading dose prior to percutaneous coronary intervention is an unlicensed dose.

- **CONTRA-INDICATIONS**
  Active bleeding

- **CAUTIONS**
  Discontinue 7 days before elective surgery if antiplatelet effect not desirable; patients at risk of increased bleeding from trauma, surgery, or other pathological conditions

- **INTERACTIONS**
  
  → Appendix 1: clopidogrel

- **SIDE-EFFECTS**
  
  Common or very common
  Abdominal pain • bleeding disorders (including gastro-intestinal and intracranial) • diarrhea • dyspepsia

- **Uncommon**
  Constipation • decreased platelets • dizziness • duodenal ulcers • eosinophilia • flatulence • gastric ulcer • gastritis • headache • leucopenia • nausea • paraesthesia • pruritus • rash • vomiting

- **Rare**
  Vertigo

- **Very rare**
  Acquired haemophilia • acute liver failure • agranulocytosis • arthralgia • blood disorders • bronchospasm • colitis • confusion • eosinophilic pneumonia • fever • glomerulonephritis • hallucinations • hepatitis • hypersensitivity-like reactions • interstitial pneumonitis • lichen planus • pancreatitis • pancytopenia • severe thrombocytopenia • Stevens-Johnson syndrome • stomatitis • taste disturbance • thrombocytopenic purpura • toxic epidermal necrolysis • vasculitis

- **ALLERGY AND CROSS-SENSITIVITY**
  Caution with history of hypersensitivity reactions to thienopyridines (e.g. prasugrel).

- **PREGNANCY**
  Manufacturer advises avoid—no information available.

- **BREAST FEEDING**
  Manufacturer advises avoid.

- **HEPATIC IMPAIRMENT**
  Manufacturer advises caution (risk of bleeding). Avoid in severe impairment.

- **RENAL IMPAIRMENT**
  Manufacturer advises caution.

- **NATIONAL FUNDING/ACCESS DECISIONS**

  NICE technology appraisals (TAs)

  - Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events (December 2010) NICE TA210
  
  The guidance applies to patients who have had an occlusive vascular event, or who have established peripheral arterial disease. The guidance does not apply to patients who have had, or are at risk of, stroke associated with atrial fibrillation, or who need prophylaxis for occlusive events following coronary revascularisation or carotid artery procedures.

  Clopidogrel monotherapy is recommended as an option to prevent occlusive vascular events in patients who have had:

  - an ischemic stroke, or who have peripheral arterial disease or multivascular disease, or
  - a myocardial infarction, only if aspirin is contra-indicated or not tolerated.

  www.nice.org.uk/TA210

  **Scottish Medicines Consortium (SMC) Decisions**

  The **Scottish Medicines Consortium** has advised (February 2004) that clopidogrel be accepted for restricted use for the treatment of confirmed acute coronary syndrome (without ST-segment elevation), in combination with aspirin.

  Clopidogrel should be initiated in hospital inpatients only.

  The **Scottish Medicines Consortium** has also advised (July 2007) that clopidogrel be accepted for restricted use for patients with ST-segment elevation acute myocardial infarction in combination with aspirin; treatment with clopidogrel is restricted to 4 weeks only.

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

  **Tablet**

  - **Clopidogrel (Non-proprietary)**
    
    | Clopidogrel 75 mg | 75mg tablets | 28 tablet | £30.53 DT price = £1.13 | £32.71 |
    | Clopidogrel 75 mg | 75mg tablets | 30 tablet | £32.28 |
    | Gropid (Beacon Pharmaceuticals Ltd) | Clopidogrel 75 mg | 75mg tablets | 30 tablet | £32.28 |
    | Plavix (Sanofi) | Clopidogrel 75 mg | 75mg tablets | 30 tablet | £35.64 |
    | Clopidogrel (as Clopidogrel hydrogen sulfate) 300 mg | Plavix 300mg tablets | 30 tablet | £142.54 DT price = £142.54 |
**Dipyridamole**

**INDICATIONS AND DOSE**
Secondary prevention of ischaemic stroke (not associated with atrial fibrillation) and transient ischaemic attacks (used alone or with aspirin) | Adjunct to oral anticoagulation for prophylaxis of thromboembolism associated with prosthetic heart valves

- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
- **Adult:** 200 mg twice daily, to be taken preferably with food

Adjunct to oral anticoagulation for prophylaxis of thromboembolism associated with prosthetic heart valves

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
- **Adult:** 300–600 mg daily in 3–4 divided doses

**Myocardial imaging—diagnostic use only**
- **BY INTRAVENOUS INJECTION**
- **Adult:** (consult product literature)

**CAUTIONS**
- Aortic stenosis · coagulation disorders · heart failure · hypotension · left ventricular outflow obstruction · may exacerbate migraine · myasthenia gravis (risk of exacerbation) · rapidly worsening angina · recent myocardial infarction

**INTERACTIONS** → Appendix 1: dipyridamole

**SIDE-EFFECTS**
- Angioedema · dizziness · gastro-intestinal effects · hot flushes · hypersensitivity reactions · hypotension · increased bleeding after surgery · increased bleeding during surgery · myalgia · rash · severe bronchospasm · tachycardia · throbbing headache · thrombocytopenia · urticaria · worsening symptoms of coronary heart disease

**PREGNANCY**
Not known to be harmful.

**BREAST FEEDING**
Manufacturers advise use only if essential—small amount present in milk.

**PRESCRIBING AND DISPENSING INFORMATION**
Modified-release capsules should be dispensed in original container (pack contains a desiccant) and any capsules remaining should be discarded 6 weeks after opening.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**
- Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events (December 2010) NICE TA210
  The guidance applies to patients who have had an occlusive vascular event, or who have established peripheral arterial disease. The guidance does not apply to patients who have had, or are at risk of, stroke associated with atrial fibrillation, or who need prophylaxis for occlusive events following coronary revascularisation or carotid artery procedures.
  Modified-release dipyridamole, in combination with aspirin, is recommended as an option to prevent occlusive vascular events in patients who have had:
  - a transient ischaemic attack, or
  - an ischaemic stroke, only if clopidogrel is contra-indicated or not tolerated.
  Modified-release dipyridamole monotherapy is recommended as an option to prevent occlusive vascular events in patients who have had:
  - an ischaemic stroke, only if aspirin and clopidogrel are contra-indicated or not tolerated, or
  - a transient ischaemic attack, only if aspirin is contra-indicated or not tolerated.

www.nice.org.uk/TA210

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Oral suspension**
- **Dipyridamole (Non-proprietary)**
  Dipyridamole 10 mg per 1 ml Dipyridamole 50 mg/ml oral suspension sugar free sugar-free | 150 ml [Pom] £41.06 DT price = £41.06
  Dipyridamole 40 mg per 1 ml Dipyridamole 200 mg/ml oral suspension sugar free sugar-free | 150 ml [Pom] £122.78–£133.53 DT price = £133.53

**Modified-release capsule**

**CAUTIONARY AND ADVISORY LABELS 21, 25**

- **Dipyridamole (Non-proprietary)**
  - **Dipyridamole 200 mg** Dipyridamole 200 mg modified-release capsules | 60 capsule [Pom] £10.06 DT price = £10.06
  - **Attia** (Dr Reddy's Laboratories UK Ltd) Dipyridamole 200 mg Attia 200 mg modified-release capsules | 60 capsule [Pom] £8.55–£10.06 DT price = £10.06
  - **Ofcram PR** (Focus Pharmaceuticals Ltd) Dipyridamole 200 mg Ofcram PR 200 mg capsules | 60 capsule [Pom] £10.06 DT price = £10.06
  - **Persantin Retard** (Boehringer Ingelheim Ltd, Consilient Health Ltd) Dipyridamole 200 mg Persantin Retard 200 mg capsules | 60 capsule [Pom] £8.55–£10.06 DT price = £10.06
  - **Trolactin** (Actavis UK Ltd) Dipyridamole 200 mg Trolactin 200 mg modified-release capsules | 60 capsule [Pom] £10.05 DT price = £10.06

**Tablet**

**CAUTIONARY AND ADVISORY LABELS 22**

- **Dipyridamole (Non-proprietary)**
  - **Dipyridamole 25 mg** Dipyridamole 25 mg tablets | 84 tablet [Pom] £5.40 DT price = £9.40
  - **Dipyridamole 100 mg** Dipyridamole 100 mg tablets | 84 tablet [Pom] £12.50 DT price = £4.07
  - **Persantin** (Boehringer Ingelheim Ltd) Dipyridamole 100 mg Persantin 100 mg tablets | 84 tablet [Pom] £6.30 DT price = £4.07

**Dipyridamole with aspirin**

The properties listed below are those particular to the combination only. For the properties of the components please consider, dipyridamole above, aspirin p. 117.

**INDICATIONS AND DOSE**
Secondary prevention of ischaemic stroke and transient ischaemic attacks

- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
- **Adult:** 25/200 mg twice daily

**INTERACTIONS** → Appendix 1: aspirin, dipyridamole

**PRESCRIBING AND DISPENSING INFORMATION**
Dispense in original container (pack contains a desiccant) and discard any capsules remaining 6 weeks after opening.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Modified-release capsule**

**CAUTIONARY AND ADVISORY LABELS 21, 25, 32**

- **Dipyridamole with aspirin (Non-proprietary)**
  - **Aspirin 25 mg, Dipyridamole 200 mg** Dipyridamole 200 mg modified-release / Aspirin 25 mg capsules | 100 capsule [Pom] £16.40
  - **Molita** (Dr Reddy's Laboratories (UK) Ltd) Aspirin 25 mg, Dipyridamole 200 mg Molita 200 mg/25 mg modified-release capsules | 100 capsule [Pom] £9.35
Apixaban

**DRUG ACTION**  Apixaban is a direct inhibitor of activated factor X (factor Xa).

**INDICATIONS AND DOSE**

- **Prophylaxis of venous thromboembolism following knee replacement surgery**
  - By mouth
  - Adult: 2.5 mg twice daily for 10–14 days, to be started 12–24 hours after surgery

- **Prophylaxis of venous thromboembolism following hip replacement surgery**
  - By mouth
  - Adult: 2.5 mg twice daily for 32–38 days, to be started 12–24 hours after surgery

- **Treatment of deep-vein thrombosis | Treatment of pulmonary embolism**
  - By mouth
  - Adult: Initially 10 mg twice daily for 7 days, then maintenance 5 mg twice daily

- **Prophylaxis of recurrent deep-vein thrombosis | Prophylaxis of recurrent pulmonary embolism**
  - By mouth
  - Adult: 2.5 mg twice daily, following completion of 6 months anticoagulant treatment

- **Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and at least one risk factor (such as previous stroke or transient ischaemic attack, symptomatic heart failure, diabetes mellitus, hypertension, or age 75 years and over)**
  - By mouth
  - Adult: 5 mg twice daily, reduce dose to 2.5 mg twice daily in patients with at least two of the following characteristics: age 80 years and over, body-weight less than 61 kg, or serum creatinine 133 micromol/litre and over

**DOSE EQUIVALENCE AND CONVERSION**

- For information on changing from, or to, other anticoagulants, consult product literature.

**CONTRA-INDICATIONS**  Active, clinically significant bleeding · risk factors for major bleeding

**CONTRA-INDICATIONS, FURTHER INFORMATION**

- Risk factors for major bleeding  Manufacturer advises avoid in conditions with significant risk factors for major bleeding, including current or recent gastrointestinal ulceration, malignant neoplasms at high risk of bleeding, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intrasplanchnic or intracerebral vascular abnormalities.

**CAUTIONS**

- Anaesthesia with postoperative indwelling epidural catheter (risk of paralyis—monitor neurological signs and wait 20–30 hours after apixaban dose before removing catheter and do not give next dose until at least 5 hours after catheter removal) · prosthetic heart valve (efficacy not established) · risk of bleeding

**INTERACTIONS**  → Appendix 1: apixaban

**SIDE-EFFECTS**

- Common or very common  Anaemia · bruising · haemorrhage · nausea
- Uncommon  Hypotension · rash · thrombocytopenia

**PREGNANCY**  Manufacturer advises avoid—no information available.

**BREAST FEEDING**  Manufacturer advises avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT**  Manufacturer advises use with caution in mild-to-moderate impairment; avoid in severe impairment and in hepatic disease associated with coagulopathy and clinically relevant bleeding risk.

**RENAL IMPAIRMENT**

- When used for prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation, reduce dose to 2.5 mg twice daily if serum-creatinine 133 micromol/litre and over is associated with age 80 years and over or body-weight less than 61 kg; reduce dose to 2.5 mg twice daily if creatinine clearance 15–29 mL/minute.

- When used for prophylaxis of venous thromboembolism following knee or hip replacement surgery, prophylaxis of recurrent deep-vein thrombosis or pulmonary embolism, and treatment of deep-vein thrombosis or pulmonary embolism, use with caution if creatinine clearance 15–29 mL/minute. Manufacturer advises avoid if creatinine clearance less than 15 mL/minute—no information available.

**MONITORING REQUIREMENTS**

- Patients should be monitored for signs of bleeding or anaemia; treatment should be stopped if severe bleeding occurs.
- No routine anticoagulant monitoring required (INR tests are unreliable).

**PRESCRIBING AND DISPENSING INFORMATION**

- Duration of treatment should be determined by balancing the benefit of treatment with the bleeding risk; shorter duration of treatment (at least 3 months) should be based on transient risk factors i.e recent surgery, trauma, immobolisation.

- Apixaban should not be used as an alternative to unfractionated heparin in pulmonary embolism in patients with haemodynamic instability, or who may receive thrombolyis or pulmonary embolectomy.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- **Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults (January 2012) NICE TA245**
  
  Apixaban is an option for the prevention of venous thromboembolism in adults after elective hip or knee replacement surgery.
  
  www.nice.org.uk/TA245

- **Apixaban for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation (February 2013) NICE TA275**
  
  Apixaban is an option for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation in accordance with its licensed indication; with one or more of the following risk factors:
  - previous stroke or transient ischaemic attack
  - symptomatic heart failure
  - age ≥ 75 years
  - diabetes mellitus
  - hypertension
  
  The risks and benefits of apixaban compared to warfarin, dabigatran etexilate, and rivaroxaban should be discussed with the patient.
  
  www.nice.org.uk/TA275

- **Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (June 2015) NICE TA341**
  
  Apixaban is an option for the treatment and prevention of recurrent deep vein thrombosis and pulmonary embolism in adults.
  
  www.nice.org.uk/TA341
EDOXaban

EDOXaban is a direct and reversible inhibitor of activated factor X (factor Xa), which prevents conversion of prothrombin to thrombin and prolongs clotting time, thereby reducing the risk of thrombus formation.

INDICATIONS AND DOSE
Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation, in patients with at least one risk factor (such as congestive heart failure, hypertension, aged 75 years and over, diabetes mellitus, previous stroke or transient ischaemic attack)

- BY MOUTH
  - Adult (body-weight up to 61 kg): 30 mg once daily
  - Adult (body-weight 61 kg and above): 60 mg once daily

Treatment of deep-vein thrombosis | Prophylaxis of recurrent deep-vein thrombosis | Treatment of pulmonary embolism | Prophylaxis of recurrent pulmonary embolism

- BY MOUTH
  - Adult (body-weight up to 61 kg): 30 mg once daily, duration of treatment adjusted according to risk factors—consult product literature, treatment should follow initial use of parenteral anticoagulant for at least 5 days
  - Adult (body-weight 61 kg and above): 60 mg once daily, duration of treatment adjusted according to risk factors—consult product literature, treatment should follow initial use of parenteral anticoagulant for at least 5 days

DOSE ADJUSTMENTS DUE TO INTERACTIONS
Manufacturer advises max. dose of 30 mg once daily with concurrent ciclosporin, dronedarone, erythromycin, or ketoconazole.

DOSE EQUIVALENCE AND CONVERSION
- For information on changing from, or to, other anticoagulants, consult product literature.

CONTRA-INDICATIONS
Active bleeding · arteriovenous malformations · current or recent gastrointestinal ulceration · hepatic disease (associated with coagulopathy and clinically relevant bleeding risk) · known or suspected oesophageal varices · major intraspinal or intracerebral vascular abnormalities · presence of malignant neoplasms at high risk of bleeding · recent brain or spinal injury · recent brain, spinal or ophthalmic surgery · recent intracranial haemorrhage · uncontrolled severe hypertension · vascular aneurysms

CONTRA-INDICATIONS, FURTHER INFORMATION
- Risk for major bleeding. Edoxaban treatment is contra-indicated in patients with significant risk factors for major bleeding, these include those listed above.

CAUTIONS
Moderate to severe mitral stenosis (safety and efficacy not established) · prosthetic heart valve (safety and efficacy not established) · risk of bleeding · surgery

CAUTIONS, FURTHER INFORMATION
- Surgery Manufacturer recommends to discontinue treatment at least 24 hours before a surgical procedure;

the risk of bleeding should be weighed against the urgency of the intervention—consult product literature.

INTERACTIONS
- Appendix 1: edoxaban

SIDE-EFFECTS
- Common or very common Anaemia · epistaxis · haemorrhage · nausea · pruritus · rash
- Uncommon Urticaria
- Rare Allergic oedema

SIDE-EFFECTS, FURTHER INFORMATION
- Management of bleeding. Should a bleeding complication arise in a patient receiving edoxaban, the manufacturer recommends to delay the next dose or treatment should be discontinued as appropriate.

PREGNANCY
Manufacturer advises avoid—toxicity in animal studies.

BREAST FEEDING
Manufacturer advises avoid—present in milk in animal studies.

HEPATIC IMPAIRMENT
Manufacturer advises avoid in severe impairment; use with caution in mild to moderate impairment.

RENAL IMPAIRMENT
Manufacturer advises reduce dose to 30 mg once daily in moderate to severe impairment; avoid in end-stage renal disease or in patients undergoing dialysis.

MONITORING REQUIREMENTS
- Manufacturer advises monitor renal function before treatment and when clinically indicated during treatment; monitor hepatic function before treatment and repeat periodically if treatment duration longer than 1 year.
- Manufacturer advises monitor for signs of mucosal bleeding and anaemia in patients at increased risk; treatment should be stopped if severe bleeding occurs.
- No routine anticoagulant monitoring required (INR tests are unreliable).

PATIENT AND CARER ADVICE
Patients should be provided with an alert card and advised to keep it with them at all times.

NATIONAL FUNDING/ACCESS DECISIONS
NICE technology appraisals (TAs)
- Edoxaban for treating and preventing deep vein thrombosis and pulmonary embolism (August 2015) NICE TA354
  Edoxaban (Lixiana®) is recommended as an option for treating and preventing recurrent deep vein thrombosis and pulmonary embolism.
  www.nice.org.uk/guidance/ta354
- Edoxaban for preventing stroke and systemic embolism in non-valvular atrial fibrillation (September 2015) NICE TA355
  Edoxaban (Lixiana®) is an option for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation, with one or more of the following risk factors:
  - previous stroke or transient ischaemic attack
  - congestive heart failure
  - age ≥75 years
  - diabetes mellitus
  - hypertension
  The risks and benefits of edoxaban treatment compared to warfarin, apixaban, dabigatran etexilate, and rivaroxaban should be discussed with the patient.
  www.nice.org.uk/TA355

MEDICINAL FORMS
There will be variation in the licensing of different medicines containing the same drug.

Tablet
- Lixiana (Daiichi Sankyo UK Ltd)
  - Edoxaban (as Edoxaban tosilate) 15 mg Lixiana 15mg tablets | 10 tablet [P] £18.50 DT price = £18.50
  - Edoxaban (as Edoxaban tosilate) 30 mg Lixiana 30mg tablets | 28 tablet [P] £51.80 DT price = £51.80
  - Edoxaban (as Edoxaban tosilate) 60 mg Lixiana 60mg tablets | 28 tablet [P] £51.80 DT price = £51.80
Fondaparinux sodium

**DRUG ACTION** Fondaparinux sodium is a synthetic pentasaccharide that inhibits activated factor X.

**INDICATIONS AND DOSE**

**Prophylaxis of venous thromboembolism in patients after undergoing major orthopaedic surgery of the hip or leg, or abdominal surgery**
- **BY SUBCUTANEOUS INJECTION**
  - Adult: Initially 2.5 mg, dose to be given 6 hours after surgery, then 2.5 mg once daily

**Prophylaxis of venous thromboembolism in medical patients immobilised because of acute illness**
- **BY SUBCUTANEOUS INJECTION**
  - Adult: 2.5 mg once daily

**Treatment of superficial-vein thrombosis**
- **BY SUBCUTANEOUS INJECTION**
  - Adult (body-weight 50 kg and above): 2.5 mg once daily for at least 30 days (max. 45 days if high risk of thromboembolic complications), treatment should be stopped 24 hours before surgery and restarted at least 6 hours post operatively

**Treatment of unstable angina and non-ST-segment elevation myocardial infarction**
- **BY SUBCUTANEOUS INJECTION**
  - Adult: 2.5 mg once daily for up to 8 days (or until hospital discharge if sooner), treatment should be stopped 24 hours before coronary artery bypass graft surgery (where possible) and restarted 48 hours post operatively

**Treatment of ST-segment elevation myocardial infarction**
- **INITIALLY BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
  - Adult: Initially 2.5 mg daily for the first day, then (by subcutaneous injection) 2.5 mg once daily for up to 8 days (or until hospital discharge if sooner), treatment should be stopped 24 hours before coronary artery bypass graft surgery (where possible) and restarted 48 hours post operatively

**Treatment of deep-vein thrombosis and pulmonary embolism**
- **BY SUBCUTANEOUS INJECTION**
  - Adult (body-weight up to 50 kg): 5 mg every 24 hours, an oral anticoagulant (usually warfarin) is started at the same time as fondaparinux (fondaparinux should be discontinued for at least 5 days and until INR ≥ 2 for at least 24 hours)
  - Adult (body-weight 50-100 kg): 7.5 mg every 24 hours, an oral anticoagulant (usually warfarin) is started at the same time as fondaparinux (fondaparinux should be discontinued for at least 5 days and until INR ≥ 2 for at least 24 hours)
  - Adult (body-weight 101 kg and above): 10 mg every 24 hours, an oral anticoagulant (usually warfarin) is started at the same time as fondaparinux (fondaparinux should be discontinued for at least 5 days and until INR ≥ 2 for at least 24 hours)

**CONTRA-INDICATIONS** Active bleeding • bacterial endocarditis

**CAUTIONS** Active gastro-intestinal ulcer disease • bleeding disorders • brain surgery • elderly patients • low body-weight • ophthalmic surgery • recent intracranial haemorrhage • risk of catheter thrombus during percutaneous coronary intervention • spinal or epidural anaesthesia (risk of spinal haematoma—avoid if using treatment doses) • spinal surgery

**INTERACTIONS** ➤ Appendix 1: fondaparinux

**SIDE-EFFECTS**
- Common or very common: Anaemia • bleeding • purpura
- Uncommon: Chest pain • dyspnoea • gastro-intestinal disturbances • hepatic impairment • oedema • pruritus • rash • thrombocythaemia • thrombocytopenia
- Rare: Anxiety • confusion • cough • dizziness • drowsiness • flushing • headache • hyperbilirubinaemia • hypokalaemia • hypotension • injection-site reactions • vertigo

**FREQUENCY NOT KNOWN** Atial fibrillation • pyrexia • tachycardia

**PREGNANCY** Manufacturer advises avoid unless potential benefit outweighs possible risk—no information available.

**BREAST FEEDING** Present in milk in animal studies—manufacturer advises avoid.

**HEPATIC IMPAIRMENT** Caution in severe impairment (increased risk of bleeding).

**RENAL IMPAIRMENT** Increased risk of bleeding in renal impairment.
- When used for prophylaxis of venous thromboembolism and treatment of superficial-vein thrombosis: Reduce dose to 1.5 mg daily if eGFR 20–50 mL/minute/1.73 m².
- When used for treatment of acute coronary syndromes or prophylaxis of venous thromboembolism and treatment of superficial-vein thrombosis: Avoid if eGFR less than 20 mL/minute/1.73 m².
- When used for treatment of venous thromboembolism: Use with caution if eGFR 30–50 mL/minute/1.73 m², avoid if eGFR less than 30 mL/minute/1.73 m².

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Arixtra®), give intermittently in Sodium chloride 0.9%. For ST-segment elevation myocardial infarction, add requisite dose to 25–50 mL infusion fluid and give over 1–2 minutes.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**
- **Fondaparinux sodium (Non-proprietary)**
  - Fondaparinux sodium 5 mg per 1 ml
  - Fondaparinux sodium 5 mg/0.5ml solution for injection pre-filled syringes | 10 pre-filled disposable injection (PSt) £59.65
  - Fondaparinux sodium 12.5 mg per 1 ml
  - Fondaparinux sodium 10mg/0.8ml solution for injection pre-filled syringes | 10 pre-filled disposable injection (PSt) £110.70
  - Fondaparinux sodium 5mg/0.4ml solution for injection pre-filled syringes | 10 pre-filled disposable injection (PSt) £110.70
  - Arixtra (Aspen Pharma Trading Ltd)
  - Arixtra 2.5mg/0.5ml solution for injection pre-filled syringes | 10 pre-filled disposable injection (PSt) £62.79
  - Arixtra 1.5mg/0.3ml solution for injection pre-filled syringes | 10 pre-filled disposable injection (PSt) £62.79 (Hospital only)
  - Fondaparinux sodium 12.5 mg per 1 ml
  - Arixtra 7.5mg/0.6ml solution for injection pre-filled syringes | 10 pre-filled disposable injection (PSt) £116.53
  - Arixtra 5mg/0.4ml solution for injection pre-filled syringes | 10 pre-filled disposable injection (PSt) £116.53
  - Arixtra 10mg/0.8ml solution for injection pre-filled syringes | 10 pre-filled disposable injection (PSt) £116.53

Rivaroxaban

**DRUG ACTION** Rivaroxaban is a direct inhibitor of activated factor X (factor Xa).

**INDICATIONS AND DOSE**

**Prophylaxis of venous thromboembolism following knee replacement surgery**
- **BY MOUTH**
  - Adult: 10 mg once daily for 2 weeks, to be started 6–10 hours after surgery
Prophylaxis of venous thromboembolism following hip replacement surgery
- **BY MOUTH**
- Adult: 10 mg once daily for 5 weeks, to be started 6–10 hours after surgery

Initial treatment of deep-vein thrombosis | Initial treatment of pulmonary embolism
- **BY MOUTH**
- Adult: Initially 15 mg twice daily for 21 days, to be taken with food

Continued treatment of deep-vein thrombosis (following initial treatment) | Continued treatment of pulmonary embolism (following initial treatment) | Prophylaxis of recurrent deep-vein thrombosis | Prophylaxis of recurrent pulmonary embolism
- **BY MOUTH**
- Adult: 20 mg once daily, to be taken with food

Prophylaxis of stroke and systemic embolism in patients with non-valvular atrial fibrillation and with at least one of the following risk factors: congestive heart failure, hypertension, previous stroke or transient ischaemic attack, age ≥ 75 years, or diabetes mellitus
- **BY MOUTH**
- Adult: 20 mg once daily, to be taken with food

Prophylaxis of atherothrombotic events following an acute coronary syndrome with elevated cardiac biomarkers (in combination with aspirin alone or aspirin and clopidogrel)
- **BY MOUTH**
- Adult: 2.5 mg twice daily usual duration 12 months

DOSE EQUIVALENCE AND CONVERSION
- For information on changing from, or to, other DOSE EQUIVALENCE AND CONVERSION

CONTRA-INDICATIONS
- Active bleeding
- In acute coronary syndrome—previous stroke
- In acute coronary syndrome—transient ischaemic attack
- Malignant neoplasms
- Oesophageal varices
- Recent brain surgery
- Recent gastrointestinal ulcer
- Recent intracranial haemorrhage
- Recent ophthalmic surgery
- Recent spine surgery
- Significant risk of major bleeding
- Vascular aneurysm

CAUTIONS
- Anaesthesia with postoperative indwelling epidural catheter (risk of paralysis)
- Monitor neurological signs and wait at least 18 hours after rivaroxaban dose before removing catheter and do not give next dose until at least 6 hours after catheter removal
- Bronchiectasis
- Prosthetic heart valve (efficacy not established)
- Risk of bleeding
- Rivaroxaban should not be used as an alternative to unfractionated heparin in pulmonary embolism in patients with haemodynamic instability, or who may receive thrombolysis or pulmonary embolectomy
- Severe hypertension
- Vascular retinopathy

INTERACTIONS
- Appendix 1: rivaroxaban

SIDE-EFFECTS
- Common or very common
  - Abdominal pain
  - Constipation
  - Diarrhoea
  - Dizziness
  - Dyspepsia
  - Haemorrhage
  - Headache
  - Hypotension
  - Nausea
  - Pain in extremities
  - Pruritus
  - Rash
  - Renal impairment
  - Vomiting
- Uncommon
  - Angioedema
  - Dry mouth
  - Malaise
  - Syncope
  - Tachycardia
  - Thrombocytopenia
- Rare
  - Jaundice
  - Oedema

PREGNANCY
- Manufacturer advises avoid—Toxicity in animal studies.

BREAST FEEDING
- Manufacturer advises avoid—Present in milk in animal studies.

HEPATIC IMPAIRMENT
- Avoid in liver disease with coagulopathy.

RENAL IMPAIRMENT
- When used for treatment of deep-vein thrombosis or pulmonary embolism and prophylaxis of recurrent deep-vein thrombosis and pulmonary embolism, initially 15 mg twice daily for 21 days, then 20 mg once daily (but consider reducing to 15 mg once daily if risk of bleeding outweighs risk of recurrent deep-vein thrombosis or pulmonary embolism) if creatinine clearance 15–49 mL/minute.

For prophylaxis of stroke and systemic embolism in atrial fibrillation, reduce dose to 15 mg once daily if creatinine clearance 15–49 mL/minute.

When used for prophylaxis of venous thromboembolism following knee or hip replacement surgery and prophylaxis of atherothrombotic events in acute coronary syndrome, use with caution if creatinine clearance 15–29 mL/minute.

Use with caution if concomitant use of drugs that increase plasma-rivaroxaban concentration (consult product literature).

Avoid if creatinine clearance less than 15 mL/minute; manufacturer recommends Cockcroft and Gault formula to calculate creatinine clearance.

MONITORING REQUIREMENTS
- Patients should be monitored for signs of bleeding or anaemia; treatment should be stopped if severe bleeding occurs.
- No routine anticoagulant monitoring required (INR tests are unreliable).

DIRECTIONS FOR ADMINISTRATION
- Tablets may be crushed and mixed with water or apple puree just before administration.

PRESCRIBING AND DISPENSING INFORMATION
- Low-dose rivaroxaban, in combination with aspirin alone or aspirin and clopidogrel, is licensed for the prevention of atherothrombotic events following an acute coronary syndrome with elevated cardiac biomarkers. Treatment should be started as soon as possible after the patient has been stabilised following the acute coronary event, at the earliest 24 hours after admission to hospital, and at the time when parenteral anticoagulation therapy would normally be discontinued; the usual duration of treatment is 12 months.

NATIONAL FUNDING/ACCESS DECISIONS
- NICE technology appraisals (TAs)
  - Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (April 2009) NICE TA170
  - Rivaroxaban is an option for the prophylaxis of venous thromboembolism in adults after total hip replacement or total knee replacement surgery.
  - www.nice.org.uk/TA170
  - Rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation (May 2012) NICE TA256
  - Rivaroxaban is an option for the prevention of stroke and systemic embolism (in accordance with its licensed indication) in patients with non-valvular atrial fibrillation and with at least one of the following risk factors:
    - Previous stroke or transient ischaemic attack
    - Congestive heart failure
    - Age ≥75 years
    - Diabetes mellitus
    - Hypertension
  - The risks and benefits of rivaroxaban compared with warfarin should be discussed with the patient.
  - www.nice.org.uk/TA256
  - Rivaroxaban for the treatment of deep-vein thrombosis and prevention of recurrent deep-vein thrombosis and pulmonary embolism (July 2012) NICE TA261
  - Rivaroxaban is an option for the treatment of deep-vein thrombosis and prevention of recurrent deep-vein thrombosis and pulmonary embolism in adults after diagnosis of acute deep-vein thrombosis.
  - www.nice.org.uk/TA261

BNF 74
Blood clots
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (June 2013) NICE TA287
Rivaroxaban is an option for treating pulmonary embolism and preventing recurrent deep-vein thrombosis and pulmonary embolism in adults.
www.nice.org.uk/TA287

Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (March 2015) NICE TA335
Rivaroxaban is an option within its marketing authorisation, in combination with aspirin plus clopidogrel or aspirin alone, for preventing atherothrombotic events in patients who have had an acute coronary syndrome with elevated cardiac biomarkers.

The patient’s risk of bleeding should be carefully assessed before treatment is initiated and the risks and benefits of rivaroxaban in combination with aspirin plus clopidogrel or with aspirin alone, compared with aspirin plus clopidogrel or aspirin alone should be discussed with the patient.

A decision on continuation of treatment should be taken no later than 12 months after starting treatment.

www.nice.org.uk/TA335

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (January 2012) that rivaroxaban (Xarelto®) is accepted for restricted use within NHS Scotland for the prevention of stroke and systemic embolism in accordance with the licensed indication; use is restricted to patients with poor INR control despite compliance with coumarin anticoagulant therapy, or to patients who are allergic to, or unable to tolerate, a coumarin anticoagulant.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet

- Xarelto® (Bayer Plc) ▼

  - Rivaroxaban 2.5 mg Xarelto® 2.5mg tablets | 56 tablet POM £50.40
  - DT price = £50.40
  - Rivaroxaban 10 mg Xarelto® 10mg tablets | 10 tablet POM £18.00
  - 30 tablet POM £54.00 DT price = £54.00 | 100 tablet POM £180.00
  - Rivaroxaban 15 mg Xarelto® 15mg tablets | 14 tablet POM £25.20
  - 28 tablet POM £50.40 DT price = £50.40 | 42 tablet POM £75.60
  - 100 tablet POM £180.00
  - Rivaroxaban 20 mg Xarelto® 20mg tablets | 28 tablet POM £50.40
  - DT price = £50.40 | 100 tablet POM £180.00

ANTITHROMBOTIC DRUGS ▶ HEPARINOIDS

Danaparoid sodium

INDICATIONS AND DOSE
Prevention of deep-vein thrombosis in general or orthopaedic surgery

- BY SUBCUTANEOUS INJECTION
- Adult: 750 units twice daily for 7–10 days, initiate treatment before operation, with last pre-operative dose 1–4 hours before surgery

Thromboembolic disease in patients with history of heparin-induced thrombocytopenia

- INITIALLY BY INTRAVENOUS INJECTION
- Adult (body-weight up to 55 kg): Initially 1250 units, then (by continuous intravenous infusion) 400 units/hour for 2 hours, then (by continuous intravenous infusion) 300 units/hour for 2 hours, then (by continuous intravenous infusion) 200 units/hour for 5 days
- Adult (body-weight > 55–89 kg): Initially 2500 units, then (by continuous intravenous infusion) 400 units/hour for 2 hours, then (by continuous intravenous infusion) 300 units/hour for 2 hours, then (by continuous intravenous infusion) 200 units/hour for 5 days

CONTRA-INDICATIONS

- Active peptic ulcer (unless this is the reason for operation), acute bacterial endocarditis, diabetic retinopathy, epidural anaesthesia (with treatment doses), haemophilia and other haemorrhagic disorders, recent cerebral haemorrhage, severe hypertension, spinal anaesthesia (with treatment doses), thrombocytopenia (unless patient has heparin-induced thrombocytopenia)

CAUTIONS

- Antibodies to heparins (risk of antibody-induced thrombocytopenia), body-weight over 90 kg, recent bleeding, risk of bleeding

INTERACTIONS ▶ Appendix 1: danaparoid

SIDE-EFFECTS

- Bleeding, hypersensitivity reactions, rash

PREGNANCY

- Manufacturer advises avoid—limited information available but not known to be harmful

BREAST FEEDING

- Amount probably too small to be harmful but manufacturer advises avoid

HEPATIC IMPAIRMENT

- Caution in moderate impairment (increased risk of bleeding), avoid in severe impairment unless patient has heparin-induced thrombocytopenia and no alternative available

RENAI IMPAIRMENT

- Use with caution in moderate impairment, avoid in severe impairment unless patient has heparin-induced thrombocytopenia and no alternative available, increased risk of bleeding in renal impairment, monitor anti-Factor Xa activity

MONITORING REQUIREMENTS

- Monitor anti factor Xa activity in patients with body-weight over 90 kg

DIRECTIONS FOR ADMINISTRATION

For intravenous infusion (Orgaran®), give continuously in Glucose 5% or Sodium chloride 0.9%.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

- Danaparoid sodium (Non-proprietary)
  - Danaparoid sodium 1250 unit per 1 ml Danaparoid sodium 750 units/0.6ml solution for injection ampoules | 10 ampoule POM £599.99

ANTITHROMBOTIC DRUGS ▶ HEPARINS

Heparins

- CONTRA-INDICATIONS
  - Acute bacterial endocarditis, major trauma, epidural anaesthesia with treatment doses, haemophilia and other haemorrhagic disorders, peptic ulcer, recent cerebral haemorrhage, recent surgery to eye, recent surgery to nervous system, severe hypertension, spinal anaesthesia with treatment doses, thrombocytopenia (including history of heparin-induced thrombocytopenia)

- CAUTIONS
  - Elderly

- SIDE-EFFECTS
  - Rare: Alopecia (on prolonged use), anaphylaxis, angioedema, hyperkalaemia, hypersensitivity reactions, injection-site reactions, osteoporosis (risk lower with low molecular weight heparins), priapism, rebound hyperlipidaemia (following unfractionated heparin withdrawal), skin necrosis, urticaria
  - Frequency not known: Haemorrhage, thrombocytopenia

SIDE-EFFECTS, FURTHER INFORMATION

- Haemorrhage: If haemorrhage occurs it is usually sufficient to withdraw unfractionated or low molecular weight

downloaded from www.medicalbr.com
heparin, but if rapid reversal of the effects of the heparin is required, protamine sulfate is a specific antidote (but only partially reverses the effects of low molecular weight heparins).

- **Heparin-induced thrombocytopenia** Clinically important heparin-induced thrombocytopenia is immune-mediated and does not usually develop until after 5–10 days; it can be complicated by thrombosis.

  Signs of heparin-induced thrombocytopenia include a 30% reduction of platelet count, thrombosis, or skin allergy. If heparin-induced thrombocytopenia is strongly suspected or confirmed, the heparin should be stopped and an alternative anticoagulant, such as danaparoid, should be given. Ensure platelet counts return to normal range in those who require warfarin.

- **Hyperkalaemia** Inhibition of aldosterone secretion by unfractionated or low molecular weight heparin can result in hyperkalaemia; patients with diabetes mellitus, chronic renal failure, acidosis, raised plasma potassium or those taking potassium-sparing drugs seem to be more susceptible. The risk appears to increase with duration of therapy.

  **ALLERGY AND CROSS-SENSITIVITY** Hypersensitivity to unfractionated or low molecular weight heparin.

- **MONITORING REQUIREMENTS**

  - **Heparin-induced thrombocytopenia** Platelet counts should be measured just before treatment with unfractionated or low molecular weight heparin, and regular monitoring of platelet counts may be required if given for longer than 4 days. See the British Society for Haematology’s Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. Br J Haematol 2012; 159: 528–540.

  - **Hyperkalaemia** Plasma-potassium concentration should be measured in patients at risk of hyperkalaemia before starting the heparin and monitored regularly thereafter, particularly if treatment is to be continued for longer than 7 days.

### Dalteparin sodium

<table>
<thead>
<tr>
<th>INDICATIONS AND DOSE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FRAGMIN ®</strong></td>
</tr>
<tr>
<td><strong>Treatment of deep-vein thrombosis, with oral anticoagulant treatment</strong></td>
</tr>
<tr>
<td>► <strong>BY SUBCUTANEOUS INJECTION</strong></td>
</tr>
<tr>
<td>► Adult: 200 units/kg daily (max. per dose 18 000 units) until adequate oral anticoagulation established</td>
</tr>
</tbody>
</table>

**Treatment of deep-vein thrombosis, with oral anticoagulant treatment (in patients at increased risk of haemorrhage)** | Treatment of pulmonary embolism, with oral anticoagulant treatment (in patients at increased risk of haemorrhage) |
| ► **BY SUBCUTANEOUS INJECTION** |
| ► Adult: 100 units/kg twice daily until adequate oral anticoagulation established |

- **Unstable coronary artery disease** | **BY SUBCUTANEOUS INJECTION** |
| ► Adult: 120 units/kg every 12 hours (max. per dose 10 000 units twice daily) for 5–8 days |

- **Prevention of clotting in extracorporeal circuits** | **TO THE DEVICE AS A FLUSH** |
| ► Adult: (consult product literature) |

### FRAGMIN ® GRADUATED SYRINGES

- **Unstable coronary artery disease (including non-ST-segment-elevation myocardial infarction)** |
  - **BY SUBCUTANEOUS INJECTION** |
  - Adult: 120 units/kg every 12 hours (max. per dose 10 000 units twice daily) for up to 8 days

- **Patients with unstable coronary artery disease (including non-ST-segment-elevation myocardial infarction)** |
  - **BY SUBCUTANEOUS INJECTION** |
  - Adult (body-weight up to 70 kg and male): 5000 units every 12 hours until the day of the procedure (max. 45 days).
  - Adult (body-weight up to 80 kg and female): 5000 units every 12 hours until the day of the procedure (max. 45 days).
  - Adult (body-weight 70 kg and above and male): 7500 units every 12 hours until the day of the procedure (max. 45 days).
  - Adult (body-weight 80 kg and above and female): 7500 units every 12 hours until the day of the procedure (max. 45 days).

### FRAGMIN ® SINGLE-DOSE SYRINGES

- **Prophylaxis of deep-vein thrombosis in surgical patients—moderate risk** |
  - **BY SUBCUTANEOUS INJECTION** |
  - Adult: Initially 2500 units for 1 dose, dose to be given 1–2 hours before surgery, then 2500 units every 24 hours

- **Prophylaxis of deep-vein thrombosis in surgical patients—high risk** |
  - **BY SUBCUTANEOUS INJECTION** |
  - Adult: Initially 2500 units for 1 dose, dose to be administered 1–2 hours before surgery, followed by 2500 units after 8–12 hours, then 5000 units every 24 hours, alternatively initially 5000 units for 1 dose, dose to be given on the evening before surgery, followed by 5000 units after 24 hours, then 5000 units every 24 hours

- **Prophylaxis of deep-vein thrombosis in medical patients** |
  - **BY SUBCUTANEOUS INJECTION** |
  - Adult: 5000 units every 24 hours

- **Treatment of deep-vein thrombosis, with oral anticoagulant treatment** | **TREATMENT OF PULMONARY EMBOLISM, WITH ORAL ANTICOAGULANT TREATMENT** |
  - **BY SUBCUTANEOUS INJECTION** |
  - Adult (body-weight up to 46 kg): 7500 units once daily until adequate oral anticoagulation established
  - Adult (body-weight 46–56 kg): 10 000 units once daily until adequate oral anticoagulation established
  - Adult (body-weight 57–68 kg): 12 500 units once daily until adequate oral anticoagulation established
  - Adult (body-weight 69–82 kg): 15 000 units once daily until adequate oral anticoagulation established
  - Adult (body-weight 83 kg and above): 18 000 units once daily until adequate oral anticoagulation established

- **Extended treatment and prophylaxis of venous thromboembolism in patients with solid tumours** |
  - **BY SUBCUTANEOUS INJECTION** |
  - Adult (body-weight 40–45 kg): 7500 units once daily for 30 days, then 7500 units once daily for a further 5 months, interrupt treatment or reduce dose in chemotherapy-induced thrombocytopenia—consult product literature
  - Adult (body-weight 46–56 kg): 10 000 units once daily for 30 days, then 7500 units once daily for a further 5 months, interrupt treatment or reduce dose in chemotherapy-induced thrombocytopenia—consult product literature
Routine monitoring of anti-Factor Xa activity is not required during treatment of deep-vein thrombosis and of pulmonary embolism; blood should be taken 3–4 hours after a dose (recommended plasma concentration of anti-Factor Xa 0.5–1 unit/mL); monitoring not required for once-daily treatment regimen and not generally necessary for twice-daily regimen.

Routine monitoring of anti-Factor Xa activity is not usually required during treatment with dalteparin, but may be necessary in patients at increased risk of bleeding (e.g. in renal impairment and those who are overweight or obese).

**INDICATIONS AND DOSE**

**Treatment of venous thromboembolism in pregnancy**

- **BY SUBCUTANEOUS INJECTION**
  - Adult (body-weight up to 50 kg): 5000 units twice daily, use body-weight in early pregnancy to calculate the dose
  - Adult (body-weight 50–69 kg): 6000 units twice daily, use body-weight in early pregnancy to calculate the dose
  - Adult (body-weight 70–89 kg): 8000 units twice daily, use body-weight in early pregnancy to calculate the dose
  - Adult (body-weight 90 kg and above): 10 000 units twice daily, use body-weight in early pregnancy to calculate the dose

**Prophylaxis of deep-vein thrombosis, especially in surgical patients—moderate risk**

- **BY SUBCUTANEOUS INJECTION**
  - Adult: 20 mg for 1 dose, dose to be given approximately 2 hours before surgery, then 20 mg every 24 hours

**Prophylaxis of deep-vein thrombosis, especially surgical patients—high risk (e.g. orthopaedic surgery)**

- **BY SUBCUTANEOUS INJECTION**
  - Adult: 40 mg for 1 dose, dose to be given 12 hours before surgery, then 40 mg every 24 hours

**Prophylaxis of deep-vein thrombosis in medical patients**

- **BY SUBCUTANEOUS INJECTION**
  - Adult: 40 mg every 24 hours

**Treatment of deep-vein thrombosis | Treatment of pulmonary embolism**

- **BY SUBCUTANEOUS INJECTION**
  - Adult: 1.5 mg/kg every 24 hours until adequate oral anticoagulation established

**Treatment of acute ST-segment elevation myocardial infarction (patients not undergoing percutaneous coronary intervention)**

- **INITIALLY BY INTRAVENOUS INJECTION**
  - Adult 18–74 years: Initially 30 mg, followed by (by subcutaneous injection) 1 mg/kg for 1 dose, then (by subcutaneous injection) 1 mg/kg every 12 hours (max. per dose 100 mg) for up to 8 days, maximum dose applies for the first two subcutaneous doses only

continued →

**Enoxaparin sodium**

**INDICATIONS AND DOSE**

**Treatment of venous thromboembolism in pregnancy**

- **BY SUBCUTANEOUS INJECTION**
  - Adult (body-weight up to 50 kg): 40 mg twice daily, dose based on early pregnancy body-weight
  - Adult (body-weight 50–69 kg): 60 mg twice daily, dose based on early pregnancy body-weight
  - Adult (body-weight 70–89 kg): 80 mg twice daily, dose based on early pregnancy body-weight
  - Adult (body-weight 90 kg and above): 100 mg twice daily, dose based on early pregnancy body-weight

**Prophylaxis of deep-vein thrombosis, especially in surgical patients—moderate risk**

- **BY SUBCUTANEOUS INJECTION**
  - Adult: 20 mg for 1 dose, dose to be given approximately 2 hours before surgery, then 20 mg every 24 hours

**Prophylaxis of deep-vein thrombosis, especially surgical patients—high risk (e.g. orthopaedic surgery)**

- **BY SUBCUTANEOUS INJECTION**
  - Adult: 40 mg for 1 dose, dose to be given 12 hours before surgery, then 40 mg every 24 hours

**Prophylaxis of deep-vein thrombosis in medical patients**

- **BY SUBCUTANEOUS INJECTION**
  - Adult: 40 mg every 24 hours

**Treatment of deep-vein thrombosis | Treatment of pulmonary embolism**

- **BY SUBCUTANEOUS INJECTION**
  - Adult: 1.5 mg/kg every 24 hours until adequate oral anticoagulation established

**Treatment of acute ST-segment elevation myocardial infarction (patients not undergoing percutaneous coronary intervention)**

- **INITIALLY BY INTRAVENOUS INJECTION**
  - Adult 18–74 years: Initially 30 mg, followed by (by subcutaneous injection) 1 mg/kg for 1 dose, then (by subcutaneous injection) 1 mg/kg every 12 hours (max. per dose 100 mg) for up to 8 days, maximum dose applies for the first two subcutaneous doses only

continued →
Blood clots

128

BY SUBCUTANEOUS INJECTION

Adult 75 years and over: 750 micrograms/kg every 12 hours (max. per dose 75 mg), maximum dose applies for the first two doses only.

Treatment of acute ST-segment elevation myocardial infarction (patients undergoing percutaneous coronary intervention)

INITIALLY BY INTRAVENOUS INJECTION

Adult 18–74 years: Initially 30 mg, followed by (by subcutaneous injection) 1 mg/kg for 1 dose, then (by subcutaneous injection) 1 mg/kg every 12 hours (max. per dose 100 mg) for up to 8 days, maximum dose applies for the first two subcutaneous doses only, then (by intravenous injection) 300 micrograms/kg for 1 dose, to be given at the time of procedure if the last subcutaneous dose was given more than 8 hours previously.

INITIALLY BY SUBCUTANEOUS INJECTION

Adult 75 years and over: 750 micrograms/kg every 12 hours (max. per dose 75 mg), maximum dose applies for the first two doses only, then (by intravenous injection) 300 micrograms/kg for 1 dose, to be given at the time of procedure if the last subcutaneous dose was given more than 8 hours previously.

Prevention of clotting in extracorporeal circuits

TO THE DEVICE AS A FLUSH

Adult: (consult product literature)

DOSE EQUIVALENCE AND CONVERSION

1 mg equivalent to 100 units.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

EXCIPIENTS: May contain Benzyl alcohol

Clexane (Sanofi)

Enoxaparin sodium 100 mg per 1 ml

Clexane 60mg/0.6ml solution for injection pre-filled syringes | 10 pre-filled disposable injection £39.26 DT price = £39.26

Clexane 300mg/3ml solution for injection multidose vials | 1 vial £21.23

Clexane 80mg/0.8ml solution for injection pre-filled syringes | 10 pre-filled disposable injection £55.13 DT price = £55.13

Clexane 40mg/0.4ml solution for injection pre-filled syringes | 10 pre-filled disposable injection £30.27 DT price = £30.27

Clexane 100mg/1ml solution for injection pre-filled syringes | 10 pre-filled disposable injection £72.30 DT price = £72.30

Clexane 20mg/0.2ml solution for injection pre-filled syringes | 10 pre-filled disposable injection £20.86 DT price = £20.86

Enoxaparin sodium 150 mg per 1 ml

Clexane Forte 120mg/0.8ml solution for injection pre-filled syringes | 10 pre-filled disposable injection £87.93 DT price = £87.93

Clexane Forte 150mg/1ml solution for injection pre-filled syringes | 10 pre-filled disposable injection £99.91 DT price = £99.91

Heparin (unfractionated)

INDICATIONS AND DOSE

Treatment of mild to moderate pulmonary embolism

Treatment of unstable angina

Treatment of acute peripheral arterial occlusion

INITIALLY BY INTRAVENOUS INJECTION

Adult: Loading dose 5000 units, alternatively (by intravenous injection) loading dose 75 units/kg, followed by (by continuous intravenous infusion) 18 units/kg/hour, laboratory monitoring essential—preferably on a daily basis, and dose adjusted accordingly.

Treatment of severe pulmonary embolism

INITIALLY BY INTRAVENOUS INJECTION

Adult: Loading dose 10 000 units, followed by (by continuous intravenous infusion) 18 units/kg/hour, laboratory monitoring essential—preferably on a daily basis, and dose adjusted accordingly.

Treatment of deep-vein thrombosis

INITIALLY BY INTRAVENOUS INJECTION

Adult: Loading dose 5000 units, alternatively (by intravenous injection) loading dose 75 units/kg, followed by (by continuous intravenous infusion) 18 units/kg/hour, alternatively (by subcutaneous injection) 15 000 units every 12 hours, laboratory monitoring essential—preferably on a daily basis, and dose adjusted accordingly.

Thromboprophylaxis in medical patients

BY SUBCUTANEOUS INJECTION

Adult: 5000 units every 8–12 hours.

Thromboprophylaxis in surgical patients

BY SUBCUTANEOUS INJECTION

Adult: 5000 units for 1 dose, to be taken 2 hours before surgery, then 5000 units every 8–12 hours.

Thromboprophylaxis during pregnancy

BY SUBCUTANEOUS INJECTION

Adult: 5000–10 000 units every 12 hours, to be administered with monitoring, Important: prevention of prosthetic heart-valve thrombosis in pregnancy calls for specialist management.

Haemodialysis

INITIALLY BY INTRAVENOUS INJECTION

Adult: Initially 1000–5000 units, followed by (by continuous intravenous infusion) 250–1000 units/hour.
Heparin (unfractionated) (Non-proprietary)

Infusion

- Heparin (unfractionated) (Non-proprietary)
  - Heparin sodium 2 unit per 1 ml
    - Heparin sodium 1,000 units/500 ml infusion Viaflex bags | 1 bag (POM) no price available
  - Heparin sodium 2,000 units/1,000 ml infusion Viaflex bags | 1 bag (POM) no price available

- Heparin sodium 5 unit per 1 ml
  - Heparin sodium 5,000 units/1 litre infusion Viaflex bags | 1 bag (POM) no price available

PREPARATIONS

- Solution for injection
  - Heparin (unfractionated) (Non-proprietary)
    - Heparin sodium 1000 unit per 1 ml
      - Heparin sodium 1,000 units/1 ml solution for injection ampoules | 10 ampoule (POM) £14.85
      - Heparin sodium 5,000 units/5 ml solution for injection vials | 10 vial (POM) £16.50–£37.47
      - Heparin sodium 20,000 units/20 ml solution for injection ampoules | 10 ampoule (POM) £70.80–£70.88
      - Heparin sodium 5,000 units/5 ml solution for injection ampoules | 10 ampoule (POM) £37.45–£37.47
      - Heparin sodium 10,000 units/10 ml solution for injection ampoules | 10 ampoule (POM) £64.50–£64.59
  - Heparin sodium 5000 unit per 1 ml
    - Heparin sodium 5,000 units/1 ml solution for injection ampoules | 10 ampoule (POM) £29.04
    - Heparin sodium 25,000 units/5 ml solution for injection vials | 10 vial (POM) £45.00–£84.60
    - Heparin sodium 25,000 units/5 ml solution for injection ampoules | 10 ampoule (POM) £75.78
  - Heparin sodium 25000 unit per 1 ml
    - Heparin calcium 25,000 units/0.2 ml solution for injection ampoules | 10 ampoule (POM) £46.70
  - Heparin sodium 25,000 unit per 1 ml
    - Heparin sodium 25,000 units/1 ml solution for injection ampoules | 10 ampoule (POM) £76.95
    - Heparin sodium 5,000 units/0.2 ml solution for injection ampoules | 10 ampoule (POM) £37.35

- Intravenous flush
  - Heparin (unfractionated) (Non-proprietary)
    - Heparin sodium 10 unit per 1 ml
      - Heparin sodium 50 units/5 ml patency solution ampoules | 10 ampoule (POM) £14.96 DT price = £14.96
      - Heparin sodium 50 units/5 ml I.V. flush solution ampoules | 10 ampoule (POM) £14.96 DT price = £14.96
    - Heparin sodium 100 unit per 1 ml
      - Heparin sodium 200 units/2 ml I.V. flush solution ampoules | 10 ampoule (POM) £15.68 DT price = £15.68
      - Heparin sodium 200 units/2 ml patency solution ampoules | 10 ampoule (POM) £15.68 DT price = £15.68

- Multidose vials
  - Heparin sodium 10,000 units/ml
    - No price available
  - Heparin sodium 20,000 units/ml
    - No price available

REDUCTIONS AND DISPENSING INFORMATION

- Doses listed take into account the guidelines of the British Society for Haematology.

INTERACTIONS

- Appendix 1: heparin (unfractionated)
- Appendix 1: low molecular-weight heparins
- Appendix 1: molecular weight heparins

PREGNANCY

- Does not cross the placenta; maternal osteoporosis reported after prolonged use; multidose vials may contain benzyl alcohol—some manufacturers advise avoid.

BREAST FEEDING

- Not excreted into milk due to high molecular weight.

HEPATIC IMPAIRMENT

- Risk of bleeding increased—reduce dose or avoid in severe impairment (including oesophageal varices).

RENAL IMPAIRMENT

- Risk of bleeding increased in severe impairment—dose may need to be reduced.

DIRECTIONS FOR ADMINISTRATION

- For intravenous infusion, give continuously in Glucose 5% or Sodium chloride 0.9%; administration with a motorised pump is advisable.

PREPARATIONS

- Solution for injection
  - Heparin (unfractionated) (Non-proprietary)
    - Heparin sodium 1000 unit per 1 ml
      - Heparin sodium 1,000 units/1 ml solution for injection ampoules | 10 ampoule (POM) £14.85
      - Heparin sodium 5,000 units/5 ml solution for injection vials | 10 vial (POM) £16.50–£37.47
      - Heparin sodium 20,000 units/20 ml solution for injection ampoules | 10 ampoule (POM) £70.80–£70.88
      - Heparin sodium 5,000 units/5 ml solution for injection ampoules | 10 ampoule (POM) £37.45–£37.47
      - Heparin sodium 10,000 units/10 ml solution for injection ampoules | 10 ampoule (POM) £64.50–£64.59
    - Heparin sodium 5000 unit per 1 ml
      - Heparin sodium 5,000 units/1 ml solution for injection ampoules | 10 ampoule (POM) £29.04
      - Heparin sodium 25,000 units/5 ml solution for injection vials | 10 vial (POM) £45.00–£84.60
      - Heparin sodium 25,000 units/5 ml solution for injection ampoules | 10 ampoule (POM) £75.78
    - Heparin sodium 25000 unit per 1 ml
      - Heparin calcium 25,000 units/0.2 ml solution for injection ampoules | 10 ampoule (POM) £46.70
    - Heparin sodium 25,000 unit per 1 ml
      - Heparin sodium 25,000 units/1 ml solution for injection ampoules | 10 ampoule (POM) £76.95
      - Heparin sodium 5,000 units/0.2 ml solution for injection ampoules | 10 ampoule (POM) £37.35

- Intravenous flush
  - Heparin (unfractionated) (Non-proprietary)
    - Heparin sodium 10 unit per 1 ml
      - Heparin sodium 50 units/5 ml patency solution ampoules | 10 ampoule (POM) £14.96 DT price = £14.96
      - Heparin sodium 50 units/5 ml I.V. flush solution ampoules | 10 ampoule (POM) £14.96 DT price = £14.96
    - Heparin sodium 100 unit per 1 ml
      - Heparin sodium 200 units/2 ml I.V. flush solution ampoules | 10 ampoule (POM) £15.68 DT price = £15.68
      - Heparin sodium 200 units/2 ml patency solution ampoules | 10 ampoule (POM) £15.68 DT price = £15.68

- Multidose vials
  - Heparin sodium 10,000 units/ml
    - No price available
  - Heparin sodium 20,000 units/ml
    - No price available

INDICATIONS AND DOSE

INNOHEP® 10,000 UNITS/ML

- Prophylaxis of deep-vein thrombosis (general surgery)
  - By subcutaneous injection
    - Adult: 3500 units for 1 dose, to be given 2 hours before surgery, then 3500 units every 24 hours

INNOHEP® 20,000 UNITS/ML

- Extended treatment of venous thromboembolism in patients with solid tumours: Prophylaxis of venous thromboembolism in patients with solid tumours
  - By subcutaneous injection
    - Adult: 175 units/kg once daily for up to 6 months

Tinzaparin sodium

- Treatment of deep-vein thrombosis: Treatment of pulmonary embolism
  - By subcutaneous injection
    - Adult: 175 units/kg once daily until adequate oral anticoagulation established, treatment regimens do not require anticoagulation monitoring

- Treatment of venous thromboembolism in pregnancy
  - By subcutaneous injection
    - Adult: 175 units/kg once daily, dose based on early pregnancy body-weight, treatment regimens do not require anticoagulation monitoring

UNLICENCED USE

- Not licensed for the treatment of venous thromboembolism in pregnancy.

- Appendix 1: low molecular-weight heparins

SIDE-EFFECTS

- Uncommon: Headache

PREGNANCY

- Not known to be harmful, low molecular weight heparins do not cross the placenta. Vials contain benzyl alcohol—manufacturer advises avoid.

BREAST FEEDING

- Due to the relatively high molecular weight of tinzaparin and inactivation in the gastrointestinal tract, passage into breast-milk and absorption by the nursing infant are likely to be negligible; however manufacturer advise avoid.

RENAL IMPAIRMENT

- Manufacturer advises caution if eGFR less than 30 ml/minute/1.73 m². Risk of bleeding may be increased. Unfractionated heparin may be preferable. In renal impairment monitoring of anti-Factor Xa may be required if eGFR less than 30 ml/minute/1.73 m².

- Monitoring requirements: Routine monitoring of anti-Factor Xa activity is not usually required during treatment with tinzaparin, but may be necessary in patients at...
increased risk of bleeding (e.g. in renal impairment and those who are underweight or overweight).

**Antithrombotic Drugs > Thrombin inhibitors, Direct**

### Argatroban monohydrate

#### Indications and dose

**Anticoagulation in patients with heparin-induced thrombocytopenia type II who require parenteral antithrombotic treatment**

- **Initially by continuous intravenous infusion**
  - Adult: Initially 2 micrograms/kg/minute, dose to be adjusted according to activated partial thromboplastin time, (by intravenous infusion) increased to up to 10 micrograms/kg/minute maximum duration of treatment 14 days

**Anticoagulation in patients with heparin-induced thrombocytopenia type II who require parenteral antithrombotic treatment (for dose in cardiac surgery, percutaneous coronary intervention, or critically ill patients)**

- **By continuous intravenous infusion**
  - Adult: (consult product literature)

**Anticoagulation in patients with heparin-induced thrombocytopenia type II who require parenteral antithrombotic treatment (when initiating concomitant warfarin treatment)**

- **By continuous intravenous infusion**
  - Adult: Reduced to 2 micrograms/kg/minute, dose should be temporarily reduced and INR measured after 4–6 hours; warfarin should be initiated at intended maintenance dose (do not give loading dose of warfarin); consult product literature for further details

---

**Bivalirudin**

#### Indications and dose

**Uncommon** Alopeza • constipation • deafness • diarrhoea • dizziness • fever • gastritis • headache • hepatic failure • hepatomegaly • hiccup • hyperbilirubinaemia • hypertension • hypoglycaemia • hypoponataemia • hypotension • malaise • muscle weakness • myalgia • rash • renal impairment • sweating • syncope • tachycardia • visual disturbance • vomiting

**Pregnancy** Manufacturer advises avoid unless essential—limited information available.

**Breast feeding** Avoid—no information available.

**Hepatic impairment** Reduce initial dose to 500 nanograms/kg/minute in moderate impairment. Avoid in severe impairment or in patients with hepatic impairment undergoing percutaneous coronary intervention.

**Monitoring requirements** Determine activated partial thromboplastin time 2 hours after start of treatment, then 2 or 4 hours after infusion rate altered (consult product literature), and at least once daily thereafter.

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Exembol®) give continuously in glucose 5% or sodium chloride 0.9%. Dilute each 2.5-ml vial with 250 ml infusion fluid.
1.75 mg/kg/hour during procedure and for up to 4 hours after procedure, then (by intravenous infusion) reduced to 250 micrograms/kg/hour for a further 4–12 hours if necessary

- **CONTRA-INDICATIONS** Active bleeding - bleeding disorders - severe hypertension - subacute bacterial endocarditis
- **CAUTIONS** Brachytherapy procedures - previous exposure to lepirudin (theoretical risk from lepirudin antibodies)
- **INTERACTIONS** ➔ Appendix 1: bivalirudin
- **SIDE-EFFECTS**
  - Common or very common Bleeding (discontinuation) - ecchymosis
  - Uncommon Allergic reactions - anaemia - headache - hypotension - isolated reports of anaphylaxis - nausea - thrombocytopenia
  - Rare Back pain - bradycardia - dyspnoea - tachycardia - thrombosis - vomiting
- **PREGNANCY** Manufacturer advises avoid unless potential benefit outweighs risk—no information available.
- **BREAST FEEDING** Manufacturer advises caution—no information available.
- **RENAL IMPAIRMENT** Avoid if eGFR less than 30 mL/minute/1.73 m².
  - When used for percutaneous coronary intervention  Reduce rate of infusion to 1.4 mg/kg/hour if eGFR 30–60 mL/minute/1.73 m² and monitor blood clotting parameters.
- **DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Angiox®), give continuously in Glucose 5% or Sodium chloride 0.9%. Reconstitute each 250-mg vial with 5 mL water for injections then withdraw 5 mL and dilute to 50 mL with infusion fluid.

- **NATIONAL FUNDING/ACCESS DECISIONS**

  - **BNF 74**

  - **NICE technology appraisals (Tas)**
    - Bivalirudin for the treatment of ST-segment elevation myocardial infarction (July 2011) NICE TA230
      - Bivalirudin in combination with aspirin and clopidogrel is recommended for the treatment of adults with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. [www.nice.org.uk/TA230](http://www.nice.org.uk/TA230)

  - **Scottish Medicines Consortium (SMC) Decisions**
    - The Scottish Medicines Consortium has advised (November 2008) that bivalirudin (Angiox®) is accepted for restricted use within NHS Scotland for patients with acute coronary syndromes planned for urgent or early intervention who would have been considered for treatment with unfractionated heparin in combination with a glycoprotein IIb/IIIa inhibitor; it should not be used as an alternative to heparin alone.
    - The Scottish Medicines Consortium has advised (August 2010) that bivalirudin (Angiox®) is accepted for restricted use within NHS Scotland as an anticoagulant in patients undergoing percutaneous coronary intervention who would have been considered for treatment with unfractionated heparin in combination with a glycoprotein IIb/IIIa inhibitor; it should not be used as an alternative to heparin alone.

- **MEDICINAL FORMS**

  - There can be variation in the licensing of different medicines containing the same drug.

  - **Powder for solution for injection**
    - **Angiox** (The Medicines Company UK Ltd)
      - Bivalirudin 250 mg Angiox 250mg powder for solution for injection vials | 10 vial | Price | no price available

---

### Dabigatran etexilate

- **DRUG ACTION** Dabigatran etexilate is a direct thrombin inhibitor with a rapid onset of action.

- **INDICATIONS AND DOSE**
  - **Prophylaxis of venous thromboembolism following total knee replacement surgery**
    - **BY MOUTH**
      - Adult 18–74 years: 110 mg, to be taken 1–4 hours after surgery, followed by 220 mg once daily for 9 days, to be taken 12–24 hours after initial dose
      - Adult 75 years and over: 75 mg, to be taken 1–4 hours after surgery, followed by 150 mg once daily for 9 days, to be taken 12–24 hours after initial dose
  - **Prophylaxis of venous thromboembolism following total knee replacement surgery in patients receiving concomitant treatment with amiodarone or verapamil**
    - **BY MOUTH**
      - Adult 18–74 years: 110 mg, to be taken 1–4 hours after surgery, followed by 220 mg once daily for 27–34 days, to be taken 12–24 hours after initial dose
      - Adult 75 years and over: 75 mg, to be taken 1–4 hours after surgery, followed by 150 mg once daily for 27–34 days, to be taken 12–24 hours after initial dose
  - **Prophylaxis of venous thromboembolism following total hip replacement surgery**
    - **BY MOUTH**
      - Adult 18–74 years: 110 mg, to be taken 1–4 hours after surgery, followed by 220 mg once daily for 27–34 days, to be taken 12–24 hours after initial dose
      - Adult 75 years and over: 75 mg, to be taken 1–4 hours after surgery, followed by 150 mg once daily for 27–34 days, to be taken 12–24 hours after initial dose
  - **Prophylaxis of venous thromboembolism following total hip replacement surgery in patients receiving concomitant treatment with amiodarone or verapamil**
    - **BY MOUTH**
      - Adult 18–74 years: 110 mg, to be taken 1–4 hours after surgery, followed by 150 mg daily for 27–34 days, to be taken 12–24 hours after initial dose
      - Adult 75 years and over: 75 mg, to be taken 1–4 hours after surgery, followed by 150 mg once daily for 27–34 days, to be taken 12–24 hours after initial dose

- **Prophylaxis of recurrent deep-vein thrombosis**
  - **Treatment of pulmonary embolism**
  - **Prophylaxis of recurrent pulmonary embolism**
    - **Prophylaxis of recurrent deep-vein thrombosis**
      - **BY MOUTH**
        - Adult 18–74 years: 150 mg twice daily, following at least 5 days treatment with a parenteral anticoagulant
        - Adult 75–79 years: 110–150 mg twice daily, following at least 5 days treatment with a parenteral anticoagulant
        - Adult 80 years and over: 110 mg twice daily, following at least 5 days treatment with a parenteral anticoagulant

- **Treatment of deep-vein thrombosis in patients with moderate renal impairment**
  - **Treatment of deep-vein thrombosis in patients at increased risk of bleeding**
  - **Treatment of pulmonary embolism in patients with moderate renal impairment**
  - **Prophylaxis of recurrent deep-vein thrombosis in patients at increased risk of bleeding**
  - **Prophylaxis of recurrent deep-vein thrombosis in patients with moderate renal impairment**
  - **Prophylaxis of recurrent pulmonary embolism in patients at increased risk of bleeding**
    - **BY MOUTH**
      - Adult: 110–150 mg twice daily, following at least 5 days treatment with a parenteral anticoagulant

### Cardiovascular system

---

downloaded from www.medicalbr.com
Treatment of deep-vein thrombosis in patients receiving concomitant treatment with verapamil | Treatment of pulmonary embolism in patients receiving concomitant treatment with verapamil | Prophylaxis of recurrent deep-vein thrombosis in patients receiving concomitant treatment with verapamil | Prophylaxis of recurrent pulmonary embolism in patients receiving concomitant treatment with verapamil

- **BY MOUTH**
  - Adult: 110 mg twice daily, following at least 5 days treatment with a parenteral anticoagulant

**Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and with one or more risk factors such as previous stroke or transient ischaemic attack, symptomatic heart failure, age ≥ 75 years, diabetes mellitus, or hypertension**

- **BY MOUTH**
  - Adult 80 years and over: 75 mg twice daily
  - Adult 18–74 years: 150 mg twice daily
  - Adult 75–79 years: 110–150 mg twice daily
  - Adult 80 years and over: 110 mg twice daily

**Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and with one or more risk factors such as previous stroke or transient ischaemic attack, symptomatic heart failure, age ≥ 75 years, diabetes mellitus, or hypertension in patients receiving concomitant treatment with verapamil**

- **BY MOUTH**
  - Adult: 110 mg twice daily

**Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and with one or more risk factors such as previous stroke or transient ischaemic attack, symptomatic heart failure, age ≥ 75 years, diabetes mellitus, or hypertension in patients with moderate renal impairment**

- **BY MOUTH**
  - Adult: 110–150 mg twice daily

**DOSE EQUIVALENCE AND CONVERSION**

- For information on changing from, or to, other anticoagulants, consult product literature.


- **CAUTIONS** Anaesthesia with postoperative indwelling epidural catheter (risk of paralysis — give initial dose at least 2 hours after catheter removal and monitor neurological signs) – bacterial endocarditis – bleeding disorders – body-weight less than 50 kg – elderly – gastritis – gastro-oesophageal reflux – oesophagitis – recent biopsy – recent major trauma – thrombocytopenia

- **INTERACTIONS** → Appendix 1: dabigatran

- **SIDE-EFFECTS**
  - **Common or very common** Abdominal pain – anaemia – diarrhoea – dyspepsia – haemorrhage – nausea

- **PREGNANCY** Manufacturer advises avoid unless essential — toxicity in animal studies.

- **BREAST FEEDING** Manufacturer advises avoid — no information available.

- **HEPATIC IMPAIRMENT** Avoid in severe liver disease, especially if prothrombin time already prolonged.

- **RENAL IMPAIRMENT**

  When used for prophylaxis of venous thromboembolism following knee or hip replacement surgery, reduce initial dose to 75 mg and subsequent doses to 150 mg once daily if creatinine clearance 30–50 mL/minute; reduce dose to 75 mg once daily if creatinine clearance 30–50 mL/minute and patient receiving concomitant treatment with verapamil.

  When used for treatment of deep-vein thrombosis and pulmonary embolism, prophylaxis of recurrent deep-vein thrombosis and pulmonary embolism, prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation, consider reduced dose of 110 mg twice daily if creatinine clearance 30–50 mL/minute, based on individual assessment of thromboembolic risk and risk of bleeding.

  Avoid if creatinine clearance less than 30 mL/minute. Monitor renal function at least annually (manufacturer recommends Cockcroft and Gault formula to calculate creatinine clearance).

- **MONITORING REQUIREMENTS**

  - Patients should be monitored for signs of bleeding or anaemia; treatment should be stopped if severe bleeding occurs.
  - No routine anticoagulant monitoring required (INR tests are unreliable).
  - Assess renal function (manufacturer recommends Cockcroft and Gault formula to calculate creatinine clearance) before treatment in all patients and at least annually in elderly.

- **DIRECTIONS FOR ADMINISTRATION** When given concomitantly with amiodarone or verapamil, doses should be taken at the same time.

- **PRESCRIBING AND DISPENSING INFORMATION** Dabigatran etexilate, is given orally for prophylaxis of venous thromboembolism in adults after total hip replacement or total knee replacement surgery; it is also licensed for the treatment of deep-vein thrombosis and pulmonary embolism, and prophylaxis of recurrent deep-vein thrombosis and pulmonary embolism in adults. Duration of treatment should be determined by balancing the benefit of treatment with the bleeding risk; shorter duration of treatment (at least 3 months) should be based on transient risk factors i.e recent surgery, trauma, immobilisation, and longer duration of treatment should be based on permanent risk factors, or idiopathic deep-vein thrombosis or pulmonary embolism.

- **NATIONAL FUNDING/ACCESS DECISIONS**

  **NICE technology appraisals (TAs)**

  - Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults (September 2008) NICE TA157
  - Dabigatran etexilate is an option for the prophylaxis of venous thromboembolism in adults after total hip replacement or total knee replacement surgery. www.nice.org.uk/TA157

  - Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (March 2012) NICE TA249
  - Dabigatran etexilate is an option for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and with one or more of the following risk factors:
    - previous stroke, transient ischaemic attack, or systemic embolism
    - left ventricular ejection fraction <40%
    - symptomatic heart failure
    - age ≥ 75 years
    - age ≥ 65 years in patients with diabetes mellitus, coronary artery disease, or hypertension
The risks and benefits of dabigatran compared to warfarin should be discussed with the patient.

www.nice.org.uk/TA249

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and pulmonary embolism (December 2014) NICE TA327

Dabigatran etexilate is recommended, within its marketing authorisation, as an option for treating and for preventing recurrent deep vein thrombosis and pulmonary embolism in adults.

www.nice.org.uk/TA327

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

**CAUTIONARY AND ADVISORY LABELS** 25

- **Pradaxa** (Boehringer Ingelheim Ltd)
  - Dabigatran etexilate (as Dabigatran etexilate mesilate) 75 mg Pradaxa 75mg capsules | 10 capsule (POM) £8.50 | 60 capsule (POM) £51.00 DT price + £51.00
  - Dabigatran etexilate (as Dabigatran etexilate mesilate) 110 mg Pradaixa 110mg capsules | 10 capsule (POM) £8.50 | 60 capsule (POM) £51.00 DT price + £51.00
  - Dabigatran etexilate (as Dabigatran etexilate mesilate) 150 mg Pradaixa 150mg capsules | 60 capsule (POM) £51.00 DT price + £51.00

**ANTITHROMBOTIC DRUGS**

**Tissue plasminogen activators**

---

**Urokinase**

**INDICATIONS AND DOSE**

**Deep-vein thrombosis (thromboembolic occlusive vascular disease)**

- **BY INTRAVENOUS INFUSION**
  - Adult: Initially 4400 units/kg, to be given over 10–20 minutes, followed by 100 000 units/hour for 2–3 days

**Pulmonary embolism (thromboembolic occlusive vascular disease)**

- **BY INTRAVENOUS INFUSION**
  - Adult: Initially 4400 units/kg, to be given over 10–20 minutes, followed by 4400 units/kg/hour for 12 hours

**Occlusive peripheral arterial disease (thromboembolic occlusive vascular disease)**

- **BY INTRA-ARTERIAL INFUSION**
  - Adult: (consult product literature)
  - Occluded central venous catheters (blocked by fibrin clots)
    - **BY INTRAVENOUS INJECTION**
      - Adult: Inject directly into occluded catheter, to be dissolved in sodium chloride 0.9% to a concentration of 5000 units/mL; use a volume sufficient to fill the catheter lumen; leave for 20–60 minutes then aspirate the lysate; repeat if necessary
  - Occluded arteriovenous haemodialysis shunts (blocked by fibrin clots)
    - **BY INTRAVENOUS INFUSION, OR BY INTRA-ARTERIAL INFUSION**
      - Adult: (consult product literature)

**SYNER-KINASE**

**Deep-vein thrombosis (thromboembolic occlusive vascular disease)**

- **BY INTRAVENOUS INFUSION**
  - Adult: Initially 4400 units/kg, to be given over 10 minutes, dose to be made up in 15 mL sodium chloride 0.9%, followed by 4400 units/kg/hour for 12–24 hours

---

**Pulmonary embolism (thromboembolic occlusive vascular disease)**

- **INITIALLY BY INTRAVENOUS INFUSION**
  - Adult: Initially 4400 units/kg, to be given over 10 minutes, dose to be made up in 15 mL sodium chloride 0.9%, followed by (by intravenous infusion) 4400 micrograms/kg/hour for 12 hours, alternatively (by intra-arterial injection) initially 15 000 units/kg, to be injected into pulmonary artery, subsequent doses adjusted according to response; maximum 3 doses per day

**Occlusive peripheral arterial disease**

- **BY INTRA-ARTERIAL INFUSION**
  - Adult: (consult product literature)
  - Occluded intravenous catheters and cannulas (blocked by fibrin clots)
    - **BY INTRA-ARTERIAL INJECTION, OR BY INTRAVENOUS INJECTION**
      - Adult: 5000–25 000 units, to be injected directly into catheter or cannula, dose dissolved in suitable volume of sodium chloride 0.9% to fill the catheter or cannula lumen; leave for 20–60 minutes then aspirate the lysate; repeat if necessary

**INTERACTIONS**

- Appendix 1: urokinase

**BREAST FEEDING**

Manufacturer advises avoid—with no information available.

**HEPATIC IMPAIRMENT**

Dose reduction may be required.

**RENAL IMPAIRMENT**

Dose reduction may be required.

**DIRECTIONS FOR ADMINISTRATION**

For intravenous infusion (Syner-KINASE®), give continuously or intermittently in Sodium chloride 0.9%.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for injection**

- **Urokinase (Non-proprietary)**
  - Urokinase 10000 unit Urokinase 10,000unit powder for solution for injection vials | 1 vial (POM) £33.79
  - Urokinase 50000 unit Urokinase 50,000unit powder for solution for injection vials | 1 vial (POM) £69.70
  - Urokinase 100000 unit Urokinase 100,000unit powder for solution for injection vials | 1 vial (POM) £106.17
  - Urokinase 250000 unit Urokinase 250,000unit powder for solution for injection vials | 1 vial (POM) £185.65
  - Urokinase 500000 unit Urokinase 500,000unit powder for solution for injection vials | 1 vial (POM) £365.00

- **Syner-KINASE** (Syner-Med (Pharmaceutical Products) Ltd)
  - Urokinase 10000 unit Syner-KINASE 10,000unit powder for solution for injection vials | 1 vial (POM) £35.95 (Hospital only)
  - Urokinase 25000 unit Syner-KINASE 25,000unit powder for solution for injection vials | 1 vial (POM) £45.95 (Hospital only)
  - Urokinase 100000 unit Syner-KINASE 100,000unit powder for solution for injection vials | 1 vial (POM) £112.95 (Hospital only)
  - Urokinase 250000 unit Syner-KINASE 250,000unit powder for solution for injection vials | 1 vial (POM) no price available (Hospital only)
  - Urokinase 500000 unit Syner-KINASE 500,000unit powder for solution for injection vials | 1 vial (POM) no price available (Hospital only)
ANTITHROMBOTIC DRUGS > VITAMIN K ANTAGONISTS

Vitamin K antagonists

IMPORTANT SAFETY INFORMATION

A EUROPEAN review has identified that changes in liver function, secondary to hepatitis C treatment with direct-acting antivirals, may affect the efficacy of vitamin K antagonists; the MHRA has advised that INR should be monitored closely in patients receiving concomitant treatment.

- CONTRA-INDICATIONS Avoid use within 48 hours postpartum, haemorrhagic stroke, significant bleeding
- CAUTIONS Bacterial endocarditis (use only if warfarin otherwise indicated), conditions in which risk of bleeding is increased, history of gastrointestinal bleeding, hyperthyroidism, hypothyroidism, peptic ulcer, postpartum (delay warfarin until risk of haemorrhage is low—usually 5–7 days after delivery), recent ischaemic stroke, current surgery, uncontrolled hypertension
- SIDE-EFFECTS Alopecia, diarrhoea, haemorrhage, hepatic dysfunction, jaundice, nausea, pancreatitis, purpura, pyrexia, rash, skin necrosis, increased risk in patients with protein C or protein S deficiency, vomiting, ‘purple toes’
- CONCEPTION AND CONTRACEPTION Women of childbearing age should be warned of the danger of teratogenicity.
- PREGNANCY Should not be given in the first trimester of pregnancy. Warfarin, acenocoumarol, and phenindione cross the placenta with risk of congenital malformations, and placental, fetal, or neonatal haemorrhage, especially during the last few weeks of pregnancy and at delivery. Therefore, if at all possible, they should be avoided in pregnancy, especially in the first trimester of pregnancy (difficult decisions may have to be made, particularly in women with prosthetic heart valves, atrial fibrillation, or with a history of recurrent venous thrombosis or pulmonary embolism). Stopping these drugs before the sixth week of gestation may largely avoid the risk of fetal abnormality.
- MONITORING REQUIREMENTS
  - The base-line prothrombin time should be determined but the initial dose should not be delayed whilst awaiting the result.
  - It is essential that the INR be determined daily or on alternate days in early days of treatment, then at longer intervals (depending on response), then up to every 12 weeks.
  - Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing.

- PATIENT AND CARER ADVICE Anticoagulant treatment booklets should be issued to all patients or their carers; these booklets include advice for patients on anticoagulant treatment, an alert card to be carried by the patient at all times, and a section for recording of INR results and dosage information. In England, Wales, and Northern Ireland, they are available for purchase from: 3M Security Print and Systems Limited Gorse Street, Chadderton Oldham OL9 9OH Tel: 0845 610 1112

GP practices can obtain supplies through their Local Area Team stores. NHS Trusts can order supplies from www.nhsforms.co.uk or by emailing nhsforms@spsl.uk.com.

In Scotland, treatment booklets and starter information packs can be obtained by emailing stockorders.DPPAS@apsgroup.co.uk or by fax on (0131) 6299 967

Electronic copies of the booklets and further advice are also available at www.npsa.nhs.uk/nrls/alerts-and-directives/alerts/anticoagulant.

Acenocoumarol
(Nicoumalone)

- INDICATIONS AND DOSE
  - Prophylaxis of embolisation in rheumatic heart disease and atrial fibrillation
  - Prophylaxis after insertion of prosthetic heart valve
  - Prophylaxis and treatment of venous thrombosis and pulmonary embolism
  - Transient ischaemic attacks

- BY MOUTH
  - Adult: Initially 2–4 mg once daily for 2 days, alternatively initially 6 mg on day 1, then 4 mg on day 2; maintenance 1–8 mg daily, adjusted according to response, dose to be taken at the same time each day, lower doses may be required in patients over 65 years, liver disease, severe heart failure with hepatic congestion, and malnutrition

- CAUTIONS Patients over 65 years
- INTERACTIONS → Appendix 1: coumarins
- SIDE-EFFECTS
  - Rare Anorexia
  - Very rare Vasculitis
- BREAST FEEDING Risk of haemorrhage; increased by vitamin K deficiency—manufacturer recommends prophylactic vitamin K for the infant (consult product literature).
- HEPATIC IMPAIRMENT Use with caution in mild to moderate impairment. Avoid in severe impairment, especially if prothrombin time is already prolonged.
- RENAL IMPAIRMENT Caution in mild to moderate impairment. Avoid in severe impairment.
- PATIENT AND CARER ADVICE Anticoagulant card to be provided.

- MEDICINAL FORMS
  - There can be variation in the licensing of different medicines containing the same drug.

<table>
<thead>
<tr>
<th>Tablet</th>
<th>CAUTIONARY AND ADVISORY LABELS 10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acenocoumarol (Non-proprietary)</td>
<td>Acenocoumarol 1 mg Acenocoumarol 1mg tablets</td>
</tr>
<tr>
<td>Synthrome (Merus Labs Luxco S.a R.L)</td>
<td>Acenocoumarol 1 mg Synthrome 1mg tablets</td>
</tr>
</tbody>
</table>

Phenindione

- INDICATIONS AND DOSE
  - Prophylaxis of embolisation in rheumatic heart disease and atrial fibrillation
  - Prophylaxis after insertion of prosthetic heart valve
  - Prophylaxis and treatment of venous thrombosis and pulmonary embolism

- BY MOUTH
  - Adult: Initially 200 mg on day 1, then 100 mg on day 2, then, adjusted according to response; maintenance 50–150 mg daily
Hypertension

4 Blood pressure conditions

4.1 Hypertension

Overview

Lowering raised blood pressure decreases the risk of stroke, coronary events, heart failure, and renal impairment. Advice on antihypertensive therapy in this section takes into account the recommendations of NICE clinical guidance 127 (August 2011), Hypertension—Clinical management of primary hypertension in adults.

Possible causes of hypertension (e.g. renal disease, endocrine causes), contributory factors, risk factors, and the presence of any complications of hypertension, such as left ventricular hypertrophy, should be established. Patients should be given advice on lifestyle changes to reduce blood pressure or cardiovascular risk; these include smoking cessation, weight reduction, reduction of excessive intake of alcohol and caffeine, reduction of dietary salt, reduction of total and saturated fat, increasing exercise, and increasing fruit and vegetable intake.

Thresholds and targets for treatment

Patients presenting with a blood pressure of 140/90 mmHg or higher when measured in a clinic setting, should be offered ambulatory blood pressure monitoring (or home blood pressure monitoring if ambulatory blood pressure monitoring is unsuitable) to confirm the diagnosis and stage of hypertension.

Stage 1 hypertension:

- Clinic blood pressure 140/90 mmHg or higher, and ambulatory daytime average or home blood pressure average 135/85 mmHg or higher
- Treat patients under 80 years who have stage 1 hypertension and target-organ damage (e.g. left ventricular hypertrophy, chronic kidney disease, hypertensive retinopathy), cardiovascular disease, renal disease, diabetes, or a 10 year cardiovascular risk \( \geq 20\% \); in the absence of these conditions, advise lifestyle changes

---

**INTERACTIONS** → Appendix 1: coumarins

**SIDE-EFFECTS**

- Agranulocytosis
- Eosinophilia
- Exantheme
- Exfoliative dermatitis
- Fever
- Hypersensitivity reactions
- Leucopenia
- Micro-adrenopathy
- Renal damage
- Urine coloured pink or orange

**BREAST FEEDING**

Avoid. Risk of haemorrhage; increased by vitamin K deficiency.

**HEPATIC IMPAIRMENT**

Avoid in severe impairment, especially if prothrombin time is already prolonged.

**RENAL IMPAIRMENT**

Caution in mild to moderate impairment. Avoid in severe impairment.

**PATIENT AND CARER ADVICE**

Anticoagulant card to be provided.

Patient counselling is advised for phenindione tablets (may turn urine pink or orange).

**MEDI CINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS 10, 14</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phenindione (Non-proprietary)</td>
</tr>
<tr>
<td><strong>Phenindione 10 mg</strong> Phenindione 10mg tablets</td>
</tr>
<tr>
<td>£51.98 DT price = £51.98</td>
</tr>
<tr>
<td><strong>Phenindione 25 mg</strong> Phenindione 25mg tablets</td>
</tr>
<tr>
<td>£51.98 DT price = £51.98</td>
</tr>
<tr>
<td><strong>Phenindione 50 mg</strong> Phenindione 50mg tablets</td>
</tr>
<tr>
<td>£51.84</td>
</tr>
</tbody>
</table>

**Warfarin sodium**

10-Oct-2016

- **INDICATIONS AND DOSE**
  - Prophylaxis of embolisation in rheumatic heart disease and atrial fibrillation
  - Prophylaxis after insertion of prosthetic heart valve
  - Prophylaxis and treatment of venous thrombosis and pulmonary embolism
  - Transient ischaemic attacks

- **BY MOUTH**
  - Adult: Initially 5–10 mg, to be taken on day 1; subsequent doses dependent on the prothrombin time, reported as INR (international normalised ratio), a lower induction dose can be given over 3–4 weeks in patients who do not require rapid anticoagulation, elderly patients to be given a lower induction dose; maintenance 3–9 mg daily, to be taken at the same time each day

**IMPORTANT SAFETY INFORMATION**

MHRA/CHM ADVICE: WARFARIN: REPORTS OF CALCIPHYLAXIS (JULY 2016)

An EU-wide review has concluded that on rare occasions, warfarin use may lead to calciphylaxis—patients should be advised to consult their doctor if they develop a painful skin rash; if calciphylaxis is diagnosed, appropriate treatment should be started and consideration should be given to stopping treatment with warfarin. The MHRA has advised that calciphylaxis is most commonly observed in patients with known risk factors such as end-stage renal disease, however cases have also been reported in patients with normal renal function.

- **INTERACTIONS** → Appendix 1: coumarins
- **SIDE-EFFECTS**
- **Pregnancy**
- **Breast Feeding**

**HEPATIC IMPAIRMENT**

Avoid in severe impairment, especially if prothrombin time is already prolonged.

**RENAL IMPAIRMENT**

Use with caution in mild to moderate impairment. In severe renal impairment, monitor INR more frequently.

**PATIENT AND CARER ADVICE**

Anticoagulant card to be provided.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution
and review annually. For patients under 40 years with stage 1 hypertension but no overt target-organ damage, cardiovascular disease, renal disease, or diabetes, consider seeking specialist advice for evaluation of secondary causes of hypertension.

Stage 2 hypertension:
- Clinic blood pressure 160/100 mmHg or higher, and ambulatory daytime average or home blood pressure average 150/95 mmHg or higher
- Treat all patients who have stage 2 hypertension, regardless of age

Severe hypertension:
- Clinic systolic blood pressure ≥ 180 mmHg or clinic diastolic blood pressure ≥ 110 mmHg; treat promptly—see Hypertensive Crises, below.

A target clinic blood pressure below 140/90 mmHg is suggested for patients under 80 years; a target ambulatory or home blood pressure average (during the patient’s waking hours) of below 135/85 mmHg is suggested for patients under 80 years; see also Hypertension in the Elderly, below. A target clinic blood pressure below 130/80 mmHg should be considered for those with established atherosclerotic cardiovascular disease, or diabetes in the presence of kidney, eye, or cerebrovascular disease. In some individuals it may not be possible to reduce blood pressure below the suggested targets despite the use of appropriate therapy.

Drug treatment of hypertension
A single antihypertensive drug is often inadequate in the management of hypertension, and additional antihypertensive drugs are usually added in a step-wise manner until control is achieved. Unless it is necessary to lower the blood pressure urgently (see Hypertensive Crises), an interval of at least 4 weeks should be allowed to determine response; clinicians should ensure antihypertensive drugs are titrated to the optimum or maximum tolerated dose at each step of treatment.

Response to drug treatment may be affected by age and ethnicity.

Patients under 55 years:
- Step 1
  - ACE inhibitor; if not tolerated, offer an angiotensin-II receptor antagonist. If both ACE inhibitors and angiotensin-II receptor antagonists are contra-indicated or not tolerated, consider a beta-blocker; beta-blockers, especially when combined with a thiazide diuretic, should be avoided for the routine treatment of uncomplicated hypertension in patients with diabetes or at high risk of developing diabetes.

Step 2
- ACE inhibitor or angiotensin-II receptor antagonist in combination with a calcium-channel blocker. If a calcium-channel blocker is not tolerated or if there is evidence of, or a high risk of, heart failure, give a thiazide-related diuretic (e.g. chlortalidone or indapamide). If a beta-blocker was given at Step 1, add a calcium channel blocker in preference to a thiazide-related diuretic (see Step 1).

Step 3
- ACE inhibitor or angiotensin-II receptor antagonist in combination with a calcium-channel blocker and a thiazide-related diuretic.

Step 4 (resistant hypertension)
- Consider seeking specialist advice
- Add low-dose spironolactone [unlicensed indication], or use high-dose thiazide related diuretic if plasma-potassium concentration above 4.5 mmol/litre
- Monitor renal function and electrolytes

Patients over 55 years, and patients of any age who are of African or Caribbean family origin:

- Step 1
  - Calcium-channel blocker; if not tolerated or if there is evidence of, or a high risk of, heart failure, give a thiazide-related diuretic (e.g. chlortalidone or indapamide).

Step 2
- Calcium-channel blocker or thiazide-related diuretic in combination with an ACE inhibitor or angiotensin-II receptor antagonist (an angiotensin-II receptor antagonist in combination with a calcium-channel blocker is preferred in patients of African or Caribbean family origin). Steps 3 and 4
- Treat as for patients under 55 years

Other measures to reduce cardiovascular risk

Aspirin p. 117 reduces the risk of cardiovascular events and myocardial infarction. Unduly high blood pressure must be controlled before aspirin is given. Unless contra-indicated, aspirin is recommended for all patients with established cardiovascular disease. Use of aspirin in primary prevention, in those with or without diabetes, is of unproven benefit. For the role of aspirin in the prevention of stroke in patients with atrial fibrillation, see Arrhythmias p. 96.

Statins are also of benefit in cardiovascular disease or in those who are at high risk of developing cardiovascular disease.

Hypertension in the elderly
Benefit from antihypertensive therapy is evident up to at least 80 years of age, but it is probably inappropriate to apply a strict age limit when deciding on drug therapy. Patients who reach 80 years of age while taking antihypertensive drugs should continue treatment, provided that it continues to be of benefit and does not cause significant side-effects. If patients are aged over 80 years when diagnosed with stage 1 hypertension, the decision to treat should be based on the presence of other comorbidities; patients with stage 2 hypertension should be treated as for patients over 55 years. A target clinic blood pressure below 150/90 mmHg is suggested for patients over 80 years; the suggested target ambulatory or home blood pressure average (during the patient’s waking hours) is below 145/85 mmHg.

Isolated systolic hypertension
Isolated systolic hypertension (systolic pressure ≥ 160 mmHg, diastolic pressure < 90 mmHg) is common in patients over 60 years, and is associated with an increased cardiovascular disease risk; it should be treated as for patients with both a raised systolic and diastolic blood pressure. Patients with severe postural hypotension should be referred to a specialist.

Hypertension in diabetes
For patients with diabetes, a target clinic blood pressure below 140/80 mmHg is suggested (below 130/80 mmHg is advised if kidney, eye, or cerebrovascular disease are also present). However, in some individuals, it may not be possible to achieve this level of control despite appropriate therapy. Most patients require a combination of antihypertensive drugs.

Hypertension is common in type 2 diabetes, and antihypertensive treatment prevents macrovascular and microvascular complications. In type 1 diabetes, hypertension usually indicates the presence of diabetic nephropathy. An ACE inhibitor (or an angiotensin-II receptor antagonist) may have a specific role in the management of diabetic nephropathy; in patients with type
2 diabetes, an ACE inhibitor (or an angiotensin-ll receptor antagonist) can delay progression of microalbuminuria to nephropathy.

Hypertension in renal disease
A target clinic blood pressure below 140/90 mmHg is suggested (below 130/80 mmHg is advised in patients with chronic kidney disease and diabetes, or if proteinuria exceeds 1 g in 24 hours). An ACE inhibitor (or an angiotensin-ll receptor antagonist) should be considered for patients with proteinuria; however, ACE inhibitors should be used with caution in renal impairment. Thiazide diuretics may be ineffective and high doses of loop diuretics may be required.

Hypertension in pregnancy
Hypertensive complications in pregnancy can be hazardous for both the mother and the fetus, and are associated with a significant risk of morbidity and mortality; complications can occur in pregnant women with pre-existing chronic hypertension, or in those who develop hypertension in the latter half of pregnancy.

Labetalol hydrochloride p. 143 is widely used for treating hypertension in pregnancy. Methyldopa p. 140 is considered safe for use in pregnancy. Modified-release preparations of nifedipine p. 157 [unlicensed] are also used.

The following advice takes into account the recommendations of NICE Clinical Guideline 107 (August 2010), Hypertension in Pregnancy.

Pregnant women with chronic hypertension who are already receiving antihypertensive treatment should have their drug therapy reviewed. In uncomplicated chronic hypertension, a target blood pressure of <150/100 mmHg is recommended; women with target-organ damage as a result of chronic hypertension, and in women with chronic hypertension who have given birth, a target blood pressure of <140/90 mmHg is advised. Long-term antihypertensive treatment should be reviewed 2 weeks following the birth.

Women managed with methyldopa during pregnancy should discontinue treatment and restart their original antihypertensive medication within 2 days of the birth.

Women are at high risk of developing pre-eclampsia if they have chronic kidney disease, diabetes mellitus, autoimmune disease, chronic hypertension, or if they have had hypertension during a previous pregnancy; these women are advised to take aspirin p. 117 once daily [unlicensed indication] from week 12 of pregnancy until the baby is born. Women with more than one moderate risk factor (first pregnancy, aged ≥40 years, pregnancy interval >10 years, BMI ≥ 35 kg/m² at first visit, multiple pregnancy, or family history of pre-eclampsia) for developing pre-eclampsia are also advised to take aspirin once daily [unlicensed indication] from week 12 of pregnancy until the baby is born.

Women with pre-eclampsia or gestational hypertension who present with a blood pressure over 150/100 mmHg, should receive initial treatment with oral labetalol hydrochloride to achieve a target blood pressure of <150 mmHg systolic, and diastolic 80–100 mmHg. If labetalol hydrochloride is unsuitable, methyldopa or modified-release nifedipine may be considered. Women with gestational hypertension or pre-eclampsia who have been managed with methyldopa during pregnancy should discontinue treatment within 2 days of the birth. Women with a blood pressure of ≥160/110 mmHg who require critical care during pregnancy or after birth should receive immediate treatment with either oral or intravenous labetalol hydrochloride, intravenous hydralazine hydrochloride p. 175, or oral modified-release nifedipine to achieve a target blood pressure of <150 mmHg systolic, and diastolic 80–100 mmHg.

Also see use of magnesium sulfate p. 963 in pre-eclampsia and eclampsia.

Hypertensive crises
If blood pressure is reduced too quickly in the management of hypertensive crises, there is a risk of reduced organ perfusion leading to cerebral infarction, blindness, deterioration in renal function, and myocardial ischaemia.

A hypertensive emergency is defined as severe hypertension with acute damage to the target organs (e.g. signs of papilloedema or retinal haemorrhage, or the presence of clinical conditions such as acute coronary syndromes, acute aortic dissection, acute pulmonary oedema, hypertensive encephalopathy, acute cerebral infarction, intracerebral or subarachnoid haemorrhage, eclampsia, or rapidly progressing renal failure); prompt treatment with intravenous antihypertensive therapy is generally required. Over the first few minutes or within 2 hours, blood pressure should be reduced by 20–25%. When intravenous therapy is indicated, treatment options include sodium nitropusside p. 177 [unlicensed], nicardipine hydrochloride p. 156, labetalol hydrochloride, glyceryl trinitrate p. 212, phenolamine mesilate p. 177, hydralazine hydrochloride, or esmolol hydrochloride p. 149; choice of drug is dependent on concomitant conditions and clinical status of the patient.

Severe hypertension (blood pressure >180/110 mmHg) without acute target-organ damage is defined as a hypertensive urgency; blood pressure should be reduced gradually over 24–48 hours with oral antihypertensive therapy, such as labetalol hydrochloride, or the calcium-channel blockers amloclidine p. 150 or felodipine p. 154. Use of sublingual nifedipine is not recommended.

Also see advice on short-term management of hypertensive episodes in pheochromocytoma.

Phaeochromocytoma
Long-term management of phaeochromocytoma involves surgery. However, surgery should not take place until there is adequate blockade of both alpha- and beta-adrenoceptors; the optimal choice of drug therapy remains unclear. Alpha-blockers are used in the short-term management of hypertensive episodes in pheochromocytoma. Once alpha blockade is established, tachycardia can be controlled by the cautious addition of a beta-blocker; a cardioselective beta-blocker is preferred.

Phenoxybenzamine hydrochloride p. 176, a powerful alpha-blocker, is effective in the management of phaeochromocytoma but it has many side-effects.

Phentolamine mesilate is a short-acting alpha-blocker used mainly during surgery of phaeochromocytoma; its use for the diagnosis of phaeochromocytoma has been superseded by measurement of catecholamines in blood and urine.

Metrosine (available from ‘special-order’ manufacturers or specialist importing companies) inhibits the enzyme tyrosine hydroxylase, and hence the synthesis of catecholamines. It is rarely used in the pre-operative management of phaeochromocytoma, and long term in patients unsuitable for surgery; an alpha-adrenoceptor blocking drug may also be required. Metirosine should not be used to treat essential hypertension.

Antihypertensive drugs
Vasodilator antihypertensive drugs
Vasodilators have a potent hypotensive effect, especially when used in combination with a beta-blocker and a thiazide. Important: see Hypertension (hypertensive crises) for a warning on the hazards of a very rapid fall in blood pressure.

Hydralazine hydrochloride p. 175 is given by mouth as an adjunct to other antihypertensives for the treatment of
resistant hypertension but is rarely used; when used alone it causes tachycardia and fluid retention.

Sodium nitroprusside p. 177 [unlicensed] is given by intravenous infusion to control severe hypertensive emergencies when parenteral treatment is necessary.

Minoxidil p. 176 should be reserved for the treatment of severe hypertension resistant to other drugs. Vasodilatation is accompanied by increased cardiac output and tachycardia and the patients develop fluid retention. For this reason the addition of a beta-blocker and a diuretic (usually furosemide p. 221, in high dosage) are mandatory. Hypertrichosis is troublesome and renders this drug unsuitable for females.

Prazosin p. 739, doxazosin p. 738, and terazosin p. 741 have alpha-blocking and vasodilator properties.

Ambrisentan p. 179, bosentan p. 179, iloprost p. 178, macitentan p. 180, sildenafil p. 766, and tadalafil p. 767 are licensed for the treatment of pulmonary arterial hypertension and should be used under specialist supervision. Epoprostenol p. 112 can be used in patients with primary pulmonary hypertension resistant to other treatments. Bosentan is also licensed to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease. Bosentan p. 180 is licensed for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension; it should be used under specialist supervision.

Sitaxentan has been withdrawn from the market because the benefit of treatment does not outweigh the risk of severe hepatotoxicity.

**Centrally acting antihypertensive drugs**

Methyldopa p. 140 is a centrally acting antihypertensive; it may be used for the management of hypertension in pregnancy.

Clonidine hydrochloride p. 139 has the disadvantage that sudden withdrawal of treatment may cause severe rebound hypertension.

Moxonidine p. 140, a centrally acting drug, is licensed for mild to moderate essential hypertension. It may have a role when thiazides, calcium-channel blockers, ACE inhibitors, and beta-blockers are not appropriate or have failed to control blood pressure.

**Adrenergic neurone blocking drugs**

Adrenergic neurone blocking drugs prevent the release of noradrenaline from postganglionic adrenergic neurones. These drugs do not control supine blood pressure and may cause postural hypotension. For this reason they have largely fallen from use, but may be necessary with other therapy in resistant hypertension.

Guanethidine monosulfate p. 177, which also depletes the nerve endings of noradrenaline, is licensed for rapid control of blood pressure, however alternative treatments are preferred.

**Alpha-adrenoceptor blocking drugs**

Prazosin has post-synaptic alpha-blocking and vasodilator properties and rarely causes tachycardia. It may, however, reduce blood pressure rapidly after the first dose and should be introduced with caution. Doxazosin, indoramin p. 738, and terazosin have properties similar to those of prazosin.

Alpha-blockers can be used with other antihypertensive drugs in the treatment of resistant hypertension.

**Prostatic hyperplasia**

Alfuzosin hydrochloride p. 737, doxazosin, indoramin, prazosin, tamsulosin hydrochloride p. 739, and terazosin are indicated for benign prostatic hyperplasia.

---

**Drugs affecting the renin-angiotensin system**

**Angiotensin-converting enzyme inhibitors**

Angiotensin-converting enzyme inhibitors (ACE inhibitors) inhibit the conversion of angiotensin I to angiotensin II. They have many uses and are generally well tolerated. The main indications of ACE inhibitors are shown below.

**Heart failure**

ACE inhibitors are used in all grades of heart failure, usually combined with a beta-blocker. Potassium supplements and potassium-sparing diuretics should be discontinued before introducing an ACE inhibitor because of the risk of hyperkalaemia. However, a low dose of spironolactone p. 185 may be beneficial in severe heart failure and can be used with an ACE inhibitor provided serum potassium is monitored carefully. Profound first-dose hypotension may occur when ACE inhibitors are introduced to patients with heart failure who are already taking a high dose of a loop diuretic (e.g. furosemide p. 221 80 mg daily or more). Temporary withdrawal of the loop diuretic reduces the risk, but may cause severe rebound pulmonary oedema. Therefore, for patients on high doses of loop diuretics, the ACE inhibitor may need to be initiated under specialist supervision. An ACE inhibitor can be initiated in the community in patients who are receiving a low dose of a diuretic or who are not otherwise at risk of severe hypotension; nevertheless, care is required and a very low dose of the ACE inhibitor is given initially.

**Hypertension**

An ACE inhibitor may be the most appropriate initial drug for hypertension in younger Caucasian patients; Afro-Caribbean patients, those aged over 55 years, and those with primary aldosteronism respond less well. ACE inhibitors are particularly indicated for hypertension in patients with type 1 diabetes with nephropathy. They may reduce blood pressure very rapidly in some patients particularly in those receiving diuretic therapy.

**Diabetic nephropathy**

ACE inhibitors have a role in the management of diabetic nephropathy.

**Prophylaxis of cardiovascular events**

ACE inhibitors are used in the early and long-term management of patients who have had a myocardial infarction. ACE inhibitors may also have a role in preventing cardiovascular events.

**Initiation under specialist supervision**

ACE inhibitors should be initiated under specialist supervision and with careful clinical monitoring in those with severe heart failure or in those:

- receiving multiple or high-dose diuretic therapy (e.g. more than 80 mg of furosemide daily or its equivalent);
- receiving concomitant angiotensin II receptor antagonist or aliskiren;
- with hypovolaemia;
- with hyponatraemia (plasma-sodium concentration below 130 mmol/litre);
- with hypotension (systolic blood pressure below 90 mmHg);
- with unstable heart failure;
- receiving high-dose vasodilator therapy;
- known renovascular disease.

**Renal effects**

Renal function and electrolytes should be checked before starting ACE inhibitors (or increasing the dose) and monitored during treatment (more frequently if features mentioned below present); hyperkalaemia and other side-effects of ACE inhibitors are more common in those with
impaired renal function and the dose may need to be reduced. Although ACE inhibitors now have a specialised role in some forms of renal disease, including chronic kidney disease, they also occasionally cause impairment of renal function which may progress and become severe in other circumstances (at particular risk are the elderly). A specialist should be involved if renal function is significantly reduced as a result of treatment with an ACE inhibitor.

Concomitant treatment with NSAIDs increases the risk of renal damage, and potassium-sparing diuretics (or potassium-containing salt substitutes) increase the risk of hyperkalaemia.

In patients with severe bilateral renal artery stenosis (or severe stenosis of the artery supplying a single functioning kidney), ACE inhibitors reduce or abolish glomerular filtration and are likely to cause severe and progressive renal failure. They are therefore not recommended in patients known to have these forms of critical renovascular disease.

ACE inhibitor treatment is unlikely to have an adverse effect on overall renal function in patients with severe unilateral renal artery stenosis and a normal contralateral kidney, but glomerular filtration is likely to be reduced (or even abolished) in the affected kidney and the long-term consequences are unknown.

ACE inhibitors are therefore best avoided in patients with known or suspected renovascular disease, unless the blood pressure cannot be controlled by other drugs. If ACE inhibitors are used, they should be initiated only under specialist supervision and renal function should be monitored regularly.

ACE inhibitors should also be used with particular caution in patients who may have undiagnosed and clinically silent renovascular disease. This includes patients with peripheral vascular disease or those with severe generalised atherosclerosis.

ACE inhibitors in combination with other drugs

See also, Concomitant use of drugs affecting the renin-angiotensin system, below.

Concomitant diuretics

ACE inhibitors can cause a very rapid fall in blood pressure in volume-depleted patients; treatment should therefore be initiated with very low doses. If the dose of diuretic is greater than 80 mg furosemide or equivalent, the ACE inhibitor should be initiated under close supervision and in some patients the diuretic dose may need to be reduced or the diuretic discontinued at least 24 hours beforehand (may not be possible in heart failure—risk of pulmonary oedema). If high-dose diuretic therapy cannot be stopped, close observation is recommended after administration of the first dose of ACE inhibitor, for at least 2 hours or until the blood pressure has stabilised.

Combination products

Products incorporating an ACE inhibitor with a thiazide diuretic or a calcium-channel blocker are available for the management of hypertension. Use of these combination products should be reserved for patients whose blood pressure has not responded adequately to a single antihypertensive drug and who have been stabilised on the individual components of the combination in the same proportions.

Angiotensin-II receptor antagonists

Azilsartan medoxomil p. 169, candesartan cilexetil p. 170, eprosartan p. 170, irbesartan p. 170, losartan potassium p. 171, olmesartan medoxomil p. 172, telmisartan p. 173, and valsartan p. 174 are angiotensin-II receptor antagonists with many properties similar to those of the ACE inhibitors. However, unlike ACE inhibitors, they do not inhibit the breakdown of bradykinin and other kinins, and thus are less likely to cause the persistent dry cough which can complicate ACE inhibitor therapy. They are therefore a useful alternative for patients who have to discontinue an ACE inhibitor because of persistent cough.

An angiotensin-II receptor antagonist may be used as an alternative to an ACE inhibitor in the management of heart failure or diabetic nephropathy. Candesartan cilexetil and valsartan are also licensed as adjuncts to ACE inhibitors under specialist supervision, in the management of heart failure when other treatments are unsuitable.

Renal effects

Angiotensin-II receptor antagonists should be used with caution in renal artery stenosis (see also Renal effects under Angiotensin-converting enzyme inhibitors, above).

Renin inhibitor

Aliskiren is a renin inhibitor that is licensed for the treatment of hypertension.

Concomitant use of drugs affecting the renin-angiotensin system

Combination therapy with two drugs affecting the renin-angiotensin system (ACE inhibitors, angiotensin-II receptor antagonists, and aliskiren p. 175 is not recommended due to an increased risk of hyperkalaemia, hypotension, and renal impairment, compared to use of a single drug. Patients with diabetic nephropathy are particularly susceptible to developing hyperkalaemia and should not be given an ACE inhibitor with an angiotensin-II receptor antagonist. There is some evidence that the benefits of combination use of an ACE inhibitor with candesartan or valsartan may outweigh the risks in selected patients with heart failure for whom other treatments are unsuitable, however, the concomitant use of this combination, together with an aldosterone antagonist or a potassium-sparing diuretic is not recommended.

For patients currently taking combination therapy, the need for continued combined therapy should be reviewed. If combination therapy is considered essential, it should be carried out under specialist supervision, with close monitoring of blood pressure, renal function, and electrolytes (particularly potassium); monitoring should be considered at the start of treatment, then monthly, and also after any change in dose or during intercurrent illness.
Methyldopa

**INDICATIONS AND DOSE**

**Hypertension**

- **BY MOUTH**
  - Adult: Initially 250 mg 2–3 times a day, dose should be increased gradually at intervals of at least 2 days; maximum 3 g per day
  - Elderly: Initially 125 mg twice daily, dose should be increased gradually; maximum 2 g per day

**CONTRA-INDICATIONS**

- Acute porphyria
- Depression
- Phaeochromocytoma

**CAUTIONS**

- History of depression

**INTERACTIONS**

- Appendix 1: methyldopa

**SIDE-EFFECTS**

- Amenorrhoea
- Arthralgia
- Asthenia
- Bell’s palsy
- Bone-marrow depression
- Bradycardia
- Decreased libido
- Depression
- Dizziness
- Drug fever
- Dry mouth
- Eosinophilia
- Exacerbation of angina
- Failure of ejaculation
- Gastro-intestinal disturbances
- Gynaecomastia
- Haemolytic anaemia
- Headache
- Hepatitis
- Hyperprolactinaemia
- Hypersensitivity reactions
- Impaired mental acuity
- Impotence
- Jaundice
- Leucopenia
- Lupus erythematosus-like syndrome
- Mild psychosis
- Myalgia
- Myocarditis
- Nasal congestion
- Nightmares
- Oedema
- Pancreatitis
- Paraesthesia
- Parkinsonism
- Pericarditis
- Postural hypotension
- Rash
- Sedation
- Sialadenitis
- Stomatitis
- Thrombocytopenia
- Toxic epidermal necrolysis

**SIDE-EFFECTS, FURTHER INFORMATION**

Side-effects are minimised if the daily dose is kept below 1 g.

**PREGNANCY**

- Not known to be harmful.

**BREAST FEEDING**

- Amount too small to be harmful.

**HEPATIC IMPAIRMENT**

- Manufacturer advises caution in history of liver disease. Avoid in active liver disease.

**RENAL IMPAIRMENT**

- Start with small dose. Increased sensitivity to hypotensive and sedative effect.

**MONITORING REQUIREMENTS**

- Monitor blood counts and liver-function before treatment and at intervals during first 6–12 weeks or if unexplained fever occurs.

**EFFECT ON LABORATORY TESTS**

- Interference with laboratory tests. Positive direct Coombs’ test in up to 20% of patients (may affect blood cross-matching).

**PATIENT AND CARER ADVICE**

- Driving and skilled tasks
  - Drowsiness may affect performance of skilled tasks (e.g. driving); effects of alcohol may be enhanced.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Tablet**

| CAUTIONARY AND ADVISORY LABELS | Methyldopa anhydrous 250 mg tablets | £16.26 DT price = £5.37 |
| Methyldopa anhydrous 500 mg tablets | £25.18 DT price = £9.57 |
| Aldomet 500mg tablets | £6.15 |

Moxonidine

**INDICATIONS AND DOSE**

- Mild to moderate essential hypertension
  - **BY MOUTH**
    - Adult: 200 micrograms once daily for 3 weeks, dose to be taken in the morning, then increased if necessary to 400 micrograms daily in 1–2 divided doses (max. per dose 400 micrograms), maximum daily dose to be given in 2 divided doses; maximum 600 micrograms per day

**CONTRA-INDICATIONS**

- Bradycardia
- Conduction disorders
- Second- or third-degree AV block
- Severe heart failure
- Sick sinus syndrome
- Sino-atrial block

**CAUTIONS**

- First-degree AV block
- Moderate heart failure
- Severe coronary artery disease
- Unstable angina

**INTERACTIONS**

- Appendix 1: moxonidine

**SIDE-EFFECTS**

- Back pain
- diarrhoea
- Dizziness
- Dry mouth
- Dyspepsia
- Insomnia
- Nausea
- Pruritus
- Rash
- Somnolence
- Vomiting

- Uncommon
  - Angioedema
  - Bradycardia
  - Neck pain
  - Nervousness
  - Oedema
  - Tinnitus
Pregnancy

Manufacturer advises avoid—no information available.

Breast Feeding

Present in milk—manufacturer advises avoid.

Renal Impairment

Max. single dose 200 micrograms and max. daily dose 400 micrograms if eGFR 30–60 mL/minute/1.73 m². Avoid if eGFR less than 30 mL/minute/1.73 m².

Treatment Cessation

Avoid abrupt withdrawal (if concomitant treatment with beta-blocker has to be stopped, discontinue beta-blocker first, then moxonidine after a few days).

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug.

Tablet

<table>
<thead>
<tr>
<th>Cautionary and Advisory Labels 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moxonidine (Non-proprietary)</td>
</tr>
<tr>
<td>Moxonidine 200 microgram Moxonidine 200microgram tablets</td>
</tr>
<tr>
<td>Moxonidine 300 microgram Moxonidine 300microgram tablets</td>
</tr>
<tr>
<td>Moxonidine 400 microgram Moxonidine 400microgram tablets</td>
</tr>
<tr>
<td>Physiotens (Mylan Ltd)</td>
</tr>
<tr>
<td>Moxonidine 200 microgram Physiotens 200microgram tablets</td>
</tr>
<tr>
<td>Moxonidine 300 microgram Physiotens 300microgram tablets</td>
</tr>
<tr>
<td>Moxonidine 400 microgram Physiotens 400microgram tablets</td>
</tr>
</tbody>
</table>

Beta-Adrenoceptor Blockers

Beta-adrenoceptor blocking drugs

Overview

Beta-adrenoceptor blocking drugs (beta-blockers) block the beta-adrenoceptors in the heart, peripheral vasculature, bronchi, pancreas, and liver.

Many beta-blockers are now available and in general they are all equally effective. There are, however, differences between them, which may affect choice in treating particular diseases or individual patients.

Intrinsic sympathomimetic activity (ISA, partial agonist activity) represents the capacity of beta-blockers to stimulate as well as to block adrenergic receptors.

Oxprenolol hydrochloride p. 144, pindolol p. 145, acebutolol p. 146, and celiprolol hydrochloride p. 148 have intrinsic sympathomimetic activity; they tend to cause less coldness of the extremities (may be less common with those with ISA), and are, therefore, relatively cardioselective, but they are not cardiospecific. They have a lesser effect on airways resistance but are not free of this side-effect.

Beta-blockers are also associated with fatigue, coldness of the extremities (may be less common with those with ISA), and sleep disturbances with nightmares (may be less common with the water-soluble beta-blockers).

Beta-blockers can affect carbohydrate metabolism, causing hypoglycaemia or hyperglycaemia in patients with or without diabetes; they can also interfere with metabolic and autonomic responses to hypoglycaemia, thereby masking symptoms such as tachycardia. However, beta-blockers are not contra-indicated in diabetes, although the cardioselective beta-blockers may be preferred. Beta-blockers should be avoided altogether in those with frequent episodes of hypoglycaemia. Beta-blockers, especially when combined with a thiazide diuretic, should be avoided for the routine treatment of uncomplicated hypertension in patients with diabetes or in those at high risk of developing diabetes.

Hypertension

The mode of action of beta-blockers in hypertension is not understood, but they reduce cardiac output, alter baroceptor reflex sensitivity, and block peripheral adrenoceptors. Some beta-blockers depress plasma renin secretion. It is possible that a central effect may also partly explain their mode of action.

Beta-blockers are effective for reducing blood pressure but other antihypertensives are usually more effective for reducing the incidence of stroke, myocardial infarction, and cardiovascular mortality, especially in the elderly. Other antihypertensives are therefore preferred for routine initial treatment of uncomplicated hypertension.

In general, the dose of a beta-blocker does not have to be high.

Beta-blockers can be used to control the pulse rate in patients with phaeochromocytoma. However, they should never be used alone as beta-blockade without concurrent alpha-blockade may lead to a hypertensive crisis. For this reason phenoxybenzamine hydrochloride p. 176 should always be used together with the beta-blocker.

Angina

By reducing cardiac work beta-blockers improve exercise tolerance and relieve symptoms in patients with angina (see management of stable angina and acute coronary syndromes for further details). As with hypertension there is no good evidence of the superiority of any one drug, although occasionally a patient will respond better to one beta-blocker than to another. There is some evidence that sudden
withdrawal may cause an exacerbation of angina and therefore gradual reduction of dose is preferable when beta-blockers are to be stopped. There is a risk of precipitating heart failure when beta-blockers and verapamil are used together in established ischaemic heart disease.

**Myocardial infarction**

For specific comments see management of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction.

Several studies have shown that some beta-blockers can reduce the recurrence rate of myocardial infarction. However, uncontrolled heart failure, hypotension, bradycardia, and obstructive airways disease render beta-blockers unsuitable in some patients following a myocardial infarction. Atenolol and metoprolol tartrate may reduce early mortality after intravenous and subsequent oral administration in the acute phase, while acebutolol, metoprolol tartrate, propranolol hydrochloride p. 145, and timolol maleate p. 146 have protective value when started in the early convalescent phase. The evidence relating to other beta-blockers is less convincing; some have not been tested in trials of secondary prevention.

**Arrhythmias**

Beta-blockers act as anti-arrhythmic drugs principally by attenuating the effects of the sympathetic system on automaticity and conductivity within the heart. They can be used in conjunction with digoxin to control the ventricular response in atrial fibrillation, especially in patients with thyrotoxicosis. Beta-blockers are also useful in the management of supraventricular tachycardias, and are used to control those following myocardial infarction.

Esmolol hydrochloride p. 149 is a relatively cardioselective beta-blocker with a very short duration of action, used intravenously for the short-term treatment of supraventricular arrhythmias, sinus tachycardia, or hypertension, particularly in the peri-operative period. It may also be used in other situations, such as acute myocardial infarction, when sustained beta-blockade might be hazardous.

Sotalol hydrochloride p. 105, a non-cardioselective beta-blocker with additional class III anti-arrhythmic activity, is used for prophylaxis in paroxysmal supraventricular arrhythmias. It also suppresses ventricular ectopic beats and non-sustained ventricular tachycardia. It has been shown to be more effective than lidocaine in the termination of spontaneous sustained ventricular tachycardia due to coronary disease or cardiomyopathy. However, it may induce torsade de pointes in susceptible patients.

**Heart failure**

Beta-blockers may produce benefit in heart failure by blocking sympathetic activity. Bisoprolol fumarate p. 148 and carvedilol p. 143 reduce mortality in any grade of stable heart failure; nebivolol p. 149 is licensed for stable mild to moderate heart failure in patients over 70 years. Treatment should be initiated by those experienced in the management of heart failure.

**Thyrotoxicosis**

Beta-blockers are used in pre-operative preparation for thyroidectomy. Administration of propranolol hydrochloride p. 145 can reverse clinical symptoms of thyrotoxicosis within 4 days. Routine tests of increased thyroid function remain unaltered. The thyroid gland is rendered less vascular thus making surgery easier.

**Other uses**

Beta-blockers have been used to alleviate some symptoms of anxiety; probably patients with palpitation, tremor, and tachycardia respond best. Beta-blockers are also used in the prophylaxis of migraine. Betaxolol p. 1079, carteolol hydrochloride p. 1078, levobunolol hydrochloride p. 1078, and timolol maleate p. 1079 are used topically in glaucoma.

---

**Beta-adrenoceptor blockers (systemic)**

- **CONTRA-INDICATIONS**  
  Asthma - cardiogenic shock - hypotension - marked bradycardia - metabolic acidosis - phaeochromocytoma (apart from specific use with alpha-blockers) - Prinzmetal’s angina - second-degree AV block - severe peripheral arterial disease - sick sinus syndrome - third-degree AV block - uncontrolled heart failure

- **CONTRA-INDICATIONS, FURTHER INFORMATION**  
  Bronchospasm  
  Beta-blockers, including those considered to be cardioselective, should usually be avoided in patients with a history of asthma, bronchospasm or a history of obstructive airways disease. However, when there is no alternative, a cardioselective beta-blocker can be given to these patients with caution and under specialist supervision. In such cases the risk of inducing bronchospasm should be appreciated and appropriate precautions taken.

- **CAUTIONS**  
  Diabetes - first-degree AV block - history of obstructive airways disease (introduce cautiously) - myasthenia gravis - portal hypertension (risk of deterioration in liver function) - psoriasis - symptoms of hypoglycaemia may be masked - symptoms of thyrotoxicosis may be masked

- **SIDE-EFFECTS**
  - Rare: Dry eyes (reversible on withdrawal) - rashes (reversible on withdrawal)

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Bradycardia  
    With administration by intravenous injection, excessive bradycardia can occur and may be countered with intravenous injection of atropine sulfate.

- **Overdose**  
  Therapeutic overdosages with beta-blockers may cause lightheadedness, dizziness, and possibly syncope as a result of bradycardia and hypotension; heart failure may be precipitated or exacerbated. For details on the management of poisoning, see Beta-blockers, under Emergency treatment of poisoning p. 1253.

- **ALLERGY AND CROSS-SENSITIVITY**
  Caution is advised in patients with a history of hypersensitivity—may increase sensitivity to allergens and result in more serious hypersensitivity response. Furthermore beta-adrenoceptor blockers may reduce response to adrenaline (epinephrine).

- **PREGNANCY**  
  Beta-blockers may cause intra-uterine growth restriction, neonatal hypoglycaemia, and bradycardia; the risk is greater in severe hypertension.

- **BREAST FEEDING**  
  With systemic use in the mother, infants should be monitored as there is a risk of possible toxicity due to beta-blockade. However, the amount of most beta-blockers present in milk is too small to affect infants.

- **MONITORING REQUIREMENTS**  
  Monitor lung function (in patients with a history of obstructive airway disease).

- **TREATMENT CESSATION**  
  Avoid abrupt withdrawal especially in ischaemic heart disease. Sudden cessation of a beta-blocker can cause a rebound worsening of
myocardial ischaemia and therefore gradual reduction of
dose is preferable when beta-blockers are to be stopped.

**BETA-ADRENOCEPTOR BLOCKERS › ALPHA- AND BETA-ADRENOCEPTOR
BLOCKERS**

---

**Carvedilol**

### INDICATIONS AND DOSE

**Hypertension**

- **By mouth**
  - Adult: Initially 12.5 mg once daily for 2 days, then
    increased to 25 mg once daily; increased if necessary
    up to 50 mg daily, dose to be increased at intervals of at
    least 2 weeks and can be given as a single dose or in
    divided doses
  - Elderly: Initially 12.5 mg daily, initial dose may provide
    satisfactory control

**Angina**

- **By mouth**
  - Adult: Initially 12.5 mg twice daily for 2 days, then
    increased to 25 mg twice daily

**Adjunct to diuretics, digoxin, or ACE inhibitors in
symptomatic chronic heart failure**

- **By mouth**
  - Adult: Initially 3.125 mg twice daily, dose to be taken
    with food, then increased to 6.25 mg twice daily, then
    increased to 12.5 mg twice daily, then increased to
    25 mg twice daily, dose should be increased at intervals
    of at least 2 weeks up to the highest tolerated dose,
    max. 25 mg twice daily in patients with severe heart
    failure or body-weight less than 85 kg; max. 50 mg
twice daily in patients over 85 kg

---

**CONTRA-INDICATIONS**

Acute or decompensated heart failure requiring intravenous inotropes

**INTERACTIONS**

- Appendix 1: beta blockers (non-selective)

**SIDE-EFFECTS**

Allergic skin reactions  · angina  · AV block  ·
changes in liver enzymes  · depressed mood  · disturbances
of micturition  · influenza-like symptoms  · leucopenia  ·
nasal stuffiness  · postural hypotension  · thrombocytopenia  ·
wheezing

**PREGNANCY**

Information on the safety of carvedilol during
pregnancy is lacking. If carvedilol is used close to delivery,
infants should be monitored for signs of alpha-blockade
(as well as beta-blockade).

**BREAST FEEDING**

Infants should be monitored as there is a risk
of possible toxicity due to alpha-blockade (in addition
to beta-blockade).

**HEPATIC IMPAIRMENT**

Avoid in hepatic impairment.

**MONITORING REQUIREMENTS**

Monitor renal function during dose titration in patients with heart failure who also have renal impairment, low blood pressure, ischaemic heart disease, or diffuse vascular disease.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines
containing the same drug. Forms available from special-order
manufacturers include: oral suspension

### Tablet

**CAUTIONARY AND ADVISORY LABELS** 8

- **Carvedilol (Non-proprietary)**
  - Carvedilol 3.125 mg Carvedilol 3.125mg tablets  | 28 tablet [POM]
    £8.00 DT price = £0.82
  - Carvedilol 6.25 mg Carvedilol 6.25mg tablets  | 28 tablet [POM]
    £8.99 DT price = £0.31
  - Carvedilol 12.5 mg Carvedilol 12.5mg tablets  | 28 tablet [POM]
    £9.99 DT price = £0.31
  - Carvedilol 25 mg Carvedilol 25mg tablets  | 28 tablet [POM]
    £12.50 DT price = £0.44

---

**Labetalol hydrochloride**

### INDICATIONS AND DOSE

**Controlled hypotension in anaesthesia**

- By intravenous infusion, or by intravenous injection

**Hypertension of pregnancy**

- **By intravenous infusion**
  - Adult: Initially 20 mg/hour, then increased if necessary
to 40 mg/hour after 30 minutes, then increased if
necessary to 80 mg/hour after 30 minutes, then
increased if necessary to 160 mg/hour after 30 minutes,
adjusted according to response; Usual maximum
160 mg/hour

- **By mouth**
  - Adult: Use dose for hypertension

**Hypertension following myocardial infarction**

- **By intravenous infusion**
  - Adult: 15 mg/hour, then increased to up to
    120 mg/hour, dose to be increased gradually

**Hypertensive emergencies**

- **By intravenous injection**
  - Adult: 50 mg, to be given over at least 1 minute, then
    50 mg every 5 minutes if required until a satisfactory
    response occurs; maximum 200 mg per course

- **By intravenous infusion**
  - Adult: Initially 2 mg/minute until a satisfactory
    response is achieved, then discontinue; usual dose
    50–200 mg

**Hypertension**

- **By mouth**
  - Adult: Initially 100 mg twice daily, dose to be increased
    at intervals of 14 days; usual dose 200 mg twice daily,
    increased if necessary up to 800 mg daily in 2 divided
    doses, to be taken with food, higher doses to be given in
    2–3 divided doses; maximum 2.4 g per day

  - Elderly: Initially 50 mg twice daily, dose to be increased
    at intervals of 14 days; usual dose 200 mg twice daily,
    increased if necessary up to 800 mg daily in 2 divided
    doses, to be taken with food, higher doses to be given in
    2–3 divided doses; maximum 2.4 g per day

- **By intravenous injection**
  - Adult: 50 mg, dose to be given over at least 1 minute,
    then 50 mg after 5 minutes if required; maximum
    200 mg per course

- **By intravenous infusion**
  - Adult: Initially 2 mg/minute until a satisfactory
    response is achieved, then discontinue; usual dose
    50–200 mg

---

**CAUTIONS**

Liver damage

**INTERACTIONS**

- Appendix 1: beta blockers (non-selective)

**SIDE-EFFECTS**

- Rare  · Lichenoid rash

**Frequency not known**

Difficulty in micturition  · epigastric pain  · liver damage  · nausea  · postural hypotension  · vomiting  · weakness

**PREGNANCY**

The use of labetalol in maternal hypertension
is not known to be harmful, except possibly in the first trimester. If labetalol is used close to delivery, infants
should be monitored for signs of alpha-blockade (as well as beta-blockade).

**BREAST FEEDING**

Infants should be monitored as there is a
risk of possible toxicity due to alpha-blockade (in addition
to beta-blockade).

**HEPATIC IMPAIRMENT**

Avoid—severe hepatocellular injury reported.

**RENAL IMPAIRMENT**

Dose reduction may be required.
**Liver damage**  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Solution for injection**

- **Labetalol hydrochloride (Non-proprietary)**
  - Labetalol hydrochloride 5 mg per 1 mL  Labetalol 100 mg/20 mL solution for injection ampoules  | 5 ampoule (Pm)  £44.44–£53.33

**Tablet**

**CAUTIONARY AND ADVISORY LABELS**

- Hepatic impairment: Manufacturer advises caution.
- Renal impairment: Increase dosage interval if eGFR less than 50 mL/minute/1.73 m².

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, oral suspension, oral solution

**Tablet**

**CAUTIONARY AND ADVISORY LABELS** 8, 21

- Labetalol hydrochloride (Non-proprietary)
  - Labetalol hydrochloride 100 mg  Labetalol 100 mg tablets  | 56 tablet (Pm)  £72.21 DT price = £5.71
  - Labetalol hydrochloride 200 mg  Labetalol 200 mg tablets  | 56 tablet (Pm)  £9.97 DT price = £8.77
  - Labetalol hydrochloride 400 mg  Labetalol 400 mg tablets  | 56 tablet (Pm)  £23.14 DT price = £23.14
  - Trandate (Focus Pharmaceuticals Ltd)
    - Labetalol hydrochloride 50 mg  Trandate 50 mg tablets  | 56 tablet (Pm)  £3.79 DT price = £3.79
    - Labetalol hydrochloride 100 mg  Trandate 100 mg tablets  | 56 tablet (Pm)  £4.64 DT price = £5.71
      | 250 tablet (Pm)  £15.62
    - Labetalol hydrochloride 200 mg  Trandate 200 mg tablets  | 56 tablet (Pm)  £7.41 DT price = £8.77
      | 250 tablet (Pm)  £24.76
    - Labetalol hydrochloride 400 mg  Trandate 400 mg tablets  | 56 tablet (Pm)  £10.15 DT price = £23.14

**OXPRENOLON hydrochloride**

**INDICATIONS AND DOSE**

**Hypertension | Angina**

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: 80–160 mg daily in 2–3 divided doses, then increased if necessary up to 320 mg daily
  - **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Adult: Initially 160 mg once daily, then increased if necessary up to 320 mg daily

**Arrhythmias**

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: 40–240 mg daily in 2–3 divided doses; maximum 240 mg per day

**Anxiety symptoms (short-term use)**

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: 40–80 mg daily in 1–2 divided doses

**INTERACTIONS**

- **Appendix 1: beta blockers (non-selective)**

**Heparic IMPAIRMENT**

- **Reduce dose.**

**MEDICATIONS**

- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, oral suspension, oral solution

**Tablet**

**CAUTIONARY AND ADVISORY LABELS** 8

- Corgard (Sanofi)
  - Nadolol 80 mg  Corgard 80 mg tablets  | 28 tablet (Pm)  £6.00 DT price = £5.00

**NON-SELECTIVE BETA-ADRENOCEPTOR BLOCKERS**

**Nadolol**

**INDICATIONS AND DOSE**

**Hypertension**

- **BY MOUTH**
  - Adult: Initially 80 mg once daily, then increased in steps of up to 80 mg every week if required, doses higher than the maximum are rarely necessary; maximum 240 mg per day

**Angina**

- **BY MOUTH**
  - Adult: Initially 40 mg once daily, then increased if necessary up to 160 mg daily, doses should be increased at weekly intervals, maximum dose rarely is used; maximum 240 mg per day

**Arrhythmias**

- **BY MOUTH**
  - Adult: Initially 40 mg once daily, then increased if necessary up to 160 mg once daily, doses should be increased at weekly intervals; reduced to 40 mg daily if bradycardia occurs

**Migraine prophylaxis**

- **BY MOUTH**
  - Adult: Initially 40 mg once daily, then increased in steps of 40 mg every week, adjusted according to response; maintenance 80–160 mg once daily

**INTERACTIONS**

- **Appendix 1: beta blockers (non-selective)**

**MEDICATIONS**

- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

**Modified-release tablet**

**CAUTIONARY AND ADVISORY LABELS** 8, 25

- Oxprenolon hydrochloride (Non-proprietary)
  - Oxprenolon hydrochloride 160 mg  Oxprenolon 160 mg modified-release tablets  | 28 tablet (Pm)  no price available
  - Slow-Trasicor (AMCo)
    - Oxprenolon hydrochloride 160 mg  Slow-Trasicor 160 mg tablets  | 28 tablet (Pm)  £7.96

**Tablet**

**CAUTIONARY AND ADVISORY LABELS** 8

- Oxprenolon hydrochloride (Non-proprietary)
  - Oxprenolon hydrochloride 20 mg  Oxprenolon 20 mg tablets  | 56 tablet (Pm)  £5.37 DT price = £5.37
  - Oxprenolon hydrochloride 40 mg  Oxprenolon 40 mg tablets  | 56 tablet (Pm)  £7.22 DT price = £7.22
Pindolol

**INDICATIONS AND DOSE**

**Hypertension**

- **BY MOUTH**
  - Adult: Initially 5 mg 2–3 times a day, alternatively 15 mg once daily, doses to be increased as required at weekly intervals; maintenance 15–30 mg daily; maximum 45 mg per day

**Anxiety**

- **BY MOUTH**
  - Adult: 2.5–5 mg up to 3 times a day

**INTERACTIONS** → Appendix 1: beta blockers (non-selective)

**RENAL IMPAIRMENT**

May adversely affect renal function in severe impairment—manufacturer advises avoid.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>£</th>
<th>DT price</th>
<th>$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pindolol (Non-proprietary)</td>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pindolol 5 mg</td>
<td>Pindolol 5mg tablets</td>
<td>100 tablet</td>
<td>£8.22</td>
</tr>
<tr>
<td>Visken (AMCo)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pindolol 5 mg</td>
<td>Visken 5mg tablets</td>
<td>56 tablet</td>
<td>£5.85</td>
</tr>
<tr>
<td>Pindolol 15 mg</td>
<td>Visken 15mg tablets</td>
<td>28 tablet</td>
<td>£10.55</td>
</tr>
</tbody>
</table>

Pindolol with clopamide

The properties listed below are those particular to the combination only. For the properties of the components please consider, pindolol above.

**INDICATIONS AND DOSE**

**Hypertension**

- **BY MOUTH**
  - Adult: Initially 1 tablet daily for 2–3 weeks, increased if necessary to 2 tablets once daily, dose to be taken in the morning; maximum 3 tablets per day

**INTERACTIONS** → Appendix 1: beta blockers (non-selective), thiazide diuretics

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>£</th>
<th>DT price</th>
<th>$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clopamide 5 mg, Pindolol 10 mg</td>
<td>Viskaldix (AMCo)</td>
<td>28 tablet</td>
<td>£6.70</td>
</tr>
</tbody>
</table>

Propranolol hydrochloride

**INDICATIONS AND DOSE**

**Thyrotoxicosis (adjunct)**

- **BY MOUTH**
  - Adult: 10–40 mg 3–4 times a day

**Thyrotoxic crisis**

- **BY INTRAVENOUS INJECTION**
  - Adult: 1 mg, to be given over 1 minute, dose may be repeated if necessary at intervals of 2 minutes, maximum total dose is 5 mg in anaesthesia; maximum 10 mg per course

**INTERACTIONS** → Appendix 1: beta blockers (non-selective)

**SIDE-EFFECTS**

- Rare: Dry eyes (reversible on withdrawal)

**HEPATIC IMPAIRMENT**

Reduce oral dose.

**RENAL IMPAIRMENT**

Manufacturer advises caution; dose reduction may be required.

**PRESCRIBING AND DISPENSING INFORMATION**

Modified-release preparations can be used for once daily administration.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Oral solution**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>£</th>
<th>DT price</th>
<th>$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propranolol hydrochloride (Non-proprietary)</td>
<td>150 ml</td>
<td>Propranolol 5mg/5ml oral solution sugar free</td>
<td>£18.50 DT price = £15.50</td>
</tr>
</tbody>
</table>

Hypertension

- **BY MOUTH**
  - Adult: Initially 80 mg twice daily, dose should be increased at weekly intervals as required; maintenance 160–320 mg daily

Prophylaxis of variceal bleeding in portal hypertension

- **BY MOUTH**
  - Adult: Initially 40 mg twice daily, then increased to 80 mg twice daily (max. per dose 160 mg twice daily), dose to be adjusted according to heart rate

Phaeochromocytoma (only with an alpha-blocker) in preparation for surgery

- **BY MOUTH**
  - Adult: 60 mg daily for 3 days before surgery

Phaeochromocytoma (only with an alpha-blocker) in patients unsuitable for surgery

- **BY MOUTH**
  - Adult: 30 mg daily

Angina

- **BY MOUTH**
  - Adult: Initially 40 mg 2–3 times a day; maintenance 120–240 mg daily

Hypertrophic cardiomyopathy / Anxiety tachycardia

- **BY MOUTH**
  - Adult: 10–40 mg 3–4 times a day

Anxiety with symptoms such as palpitation, sweating and tremor

- **BY MOUTH**
  - Adult: 40 mg once daily, then increased if necessary to 40 mg 3 times a day

Prophylaxis after myocardial infarction

- **BY MOUTH**
  - Adult: Initially 40 mg 4 times a day for 2–3 days, then 80 mg twice daily, start treatment 5 to 21 days after infarction

Essential tremor

- **BY MOUTH**
  - Adult: 80–240 mg daily in divided doses

Arrhythmias

- **BY MOUTH**
  - Adult: 10–40 mg 3–4 times a day

- **BY INTRAVENOUS INJECTION**
  - Adult: 1 mg, to be given over 1 minute, dose may be repeated if necessary at intervals of 2 minutes, maximum 10 mg per course (5 mg in anaesthesia)
Timolol with amiloride and hydrochlorothiazide

The properties listed below are those particular to the combination only. For the properties of the components please consider, timolol maleate above, amiloride hydrochloride p. 223, hydrochlorothiazide p. 162.

- **INDICATIONS AND DOSE**
  - **Hypertension**
    - BY MOUTH
      - Adult: 1–2 tablets daily
  - **INTERACTIONS** → Appendix 1: beta blockers (non-selective), thiazide diuretics

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

- **Timolol with bendroflumethiazide**

  The properties listed below are those particular to the combination only. For the properties of the components please consider, timolol maleate above, bendroflumethiazide p. 161.

  - **INDICATIONS AND DOSE**
    - **Hypertension**
      - BY MOUTH
        - Adult: 1–2 tablets daily; maximum 4 tablets per day
  - **INTERACTIONS** → Appendix 1: beta blockers (non-selective), thiazide diuretics
  - **MEDICINAL FORMS**
    - There can be variation in the licensing of different medicines containing the same drug.

  - **Timolol with bendroflumethiazide**

    - **BENDROFLUMETHIAZIDE**
      - **INDICATIONS AND DOSE**
        - **Hypertension**
          - BY MOUTH
            - Adult: Initially 400 mg daily for 2 weeks, alternatively initially 200 mg twice daily for 2 weeks, then increased if necessary to 400 mg twice daily; maximum 1.2 g per day

  - **BETA-ADRENOCEPTOR BLOCKERS**
    - **INDICATIONS AND DOSE**
      - **Hypertension**
        - BY MOUTH
          - Adult: 1–2 tablets daily; maximum 4 tablets per day

  - **INTERACTIONS** → Appendix 1: beta blockers (non-selective), thiazide diuretics

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  - **Timolol maleate (Non-proprietary)**
  - **Bendroflumethiazide 2.5 mg, Timolol maleate 10 mg, Hydrochlorothiazide 25 mg Timolol 10mg / Amiloride 2.5mg / Hydrochlorothiazide 25mg tablets | 30 tablet (£23.75–£35.99 DT price = £31.12)**

  - **Timolol with bendroflumethiazide (Non-proprietary)**

  - **BENDROFLUMETHIAZIDE**
    - **INDICATIONS AND DOSE**
      - **Hypertension**
        - BY MOUTH
          - Adult: Initially 400 mg daily for 2 weeks, alternatively initially 200 mg twice daily for 2 weeks, then increased if necessary to 400 mg twice daily; maximum 1.2 g per day

  - **INTERACTIONS** → Appendix 1: beta blockers (non-selective), thiazide diuretics

  - **MEDICINAL FORMS**
    - There can be variation in the licensing of different medicines containing the same drug.

  - **Timolol with bendroflumethiazide**

    - **BENDROFLUMETHIAZIDE**
      - **INDICATIONS AND DOSE**
        - **Hypertension**
          - BY MOUTH
            - Adult: 1–2 tablets daily; maximum 4 tablets per day

  - **INTERACTIONS** → Appendix 1: beta blockers (non-selective), thiazide diuretics

  - **MEDICINAL FORMS**
    - There can be variation in the licensing of different medicines containing the same drug.

  - **Timolol with bendroflumethiazide**

    - **BENDROFLUMETHIAZIDE**
      - **INDICATIONS AND DOSE**
        - **Hypertension**
          - BY MOUTH
            - Adult: Initially 400 mg daily for 2 weeks, alternatively initially 200 mg twice daily for 2 weeks, then increased if necessary to 400 mg twice daily; maximum 1.2 g per day

  - **INTERACTIONS** → Appendix 1: beta blockers (non-selective), thiazide diuretics

  - **MEDICINAL FORMS**
    - There can be variation in the licensing of different medicines containing the same drug.
INTERACTIONS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS

Acebutolol (Non-proprietary)  
Acebutolol (as Acebutolol hydrochloride) 400 mg  
Acebutolol 400mg tablets | 28 tablet | no price available DT price = £18.62

Sectral (Sanofi)  
Acebutolol (as Acebutolol hydrochloride) 400 mg  
Sectral 400mg tablets | 28 tablet | £18.62 DT price = £18.62

Capsule

CAUTIONARY AND ADVISORY LABELS

Acebutolol (as Acebutolol hydrochloride) 100 mg  
Acebutolol 100mg capsules | 84 capsule | no price available DT price = £14.97

Acebutolol (as Acebutolol hydrochloride) 200 mg  
Acebutolol 200mg capsules | 56 capsule | £19.20 DT price = £19.18

Sectral (Sanofi)  
Acebutolol (as Acebutolol hydrochloride) 100 mg  
Sectral 100mg capsules | 84 capsule | £14.97 DT price = £14.97

Acebutolol (as Acebutolol hydrochloride) 200 mg  
Sectral 200mg capsules | 56 capsule | £19.18 DT price = £19.18

BREAST FEEDING

Acebutolol and water soluble beta-blockers are present in breast milk in greater amounts than other beta-blockers.

RENAL IMPAIRMENT

Halve dose if eGFR 25–50 mL/minute/1.73 m²; use quarter dose if eGFR less than 25 mL/minute/1.73 m²; do not administer more than once daily.

MEDIeczAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Atenolol

INDICATIONS AND DOSE

Hypertension

BY MOUTH

Adult: 25–50 mg daily, higher doses are rarely necessary

Angina

BY MOUTH

Adult: 100 mg daily in 1–2 divided doses

Arrhythmias

BY MOUTH

Adult: 50–100 mg daily

BY INTRAVENOUS INJECTION

Adult: 2.5 mg every 5 minutes (max. per dose 10 mg), repeated if necessary, given at a rate of 1 mg/minute

BY INTRAVENOUS INFUSION

Adult: 150 micrograms/kg every 12 hours if required, to be given over 20 minutes

Migraine prophylaxis

BY MOUTH

Adult: 50–200 mg daily in divided doses

DIRECTIONS FOR ADMINISTRATION

For intravenous infusion (Tenormin®), give intermittently in Glucose 5% or Sodium chloride 0.9%. Suggested infusion time 20 minutes.

MEDIeczAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Solution for injection

Tenormin (AstraZeneca UK Ltd)

Atenolol 500 microgram per 1 ml  
Tenormin 5mg/10ml solution for injection ampoules | 10 ampule | £34.45 (Hospital only)

Oral solution

Atenolol (Non-proprietary)

Atenolol 5 mg per 1 ml  
Atenolol 25mg/5ml oral solution sugar free | 300 ml | £6.72 DT price = £5.59

Tablet

CAUTIONARY AND ADVISORY LABELS

Atenolol (Non-proprietary)

Atenolol 25 mg  
Atenolol 25mg tablets | 28 tablet | £1.39 DT price = £0.71

Atenolol 50 mg  
Atenolol 50mg tablets | 28 tablet | £1.44 DT price = £0.73

Atenolol 100 mg  
Atenolol 100mg tablets | 28 tablet | £5.19 DT price = £0.75

Tenormin (AstraZeneca UK Ltd)

Atenolol 50 mg  
Tenormin L5 50mg tablets | 28 tablet | £5.11 DT price = £0.73

Atenolol 100 mg  
Tenormin 100mg tablets | 28 tablet | £6.49 DT price = £0.75

Early intervention within 12 hours of myocardial infarction

INITIALLY BY INTRAVENOUS INJECTION

Adult: Initially 5 mg, to be given over 5 minutes, followed by (by mouth) 50 mg after 15 minutes, then (by mouth) 50 mg after 12 hours, then (by mouth) 100 mg daily

UNLICENSED USE

Use of atenolol for migraine prophylaxis is an unlicensed indication.

INTERACTIONS

Appendix 1: beta blockers (selective)

BREAST FEEDING

Water soluble beta-blockers such as atenolol are present in breast milk in greater amounts than other beta blockers.

RENAl IMPAIRMENT

With oral use Max. 50 mg daily if eGFR 15–35 mL/minute/1.73 m²; max. 25 mg daily or 50 mg on alternate days if eGFR less than 15 mL/minute/1.73 m².

With intravenous use Max. 10 mg on alternate days if eGFR 15–35 mL/minute/1.73 m²; max.10 mg every 4 days if eGFR less than 15 mL/minute/1.73 m².

DIRECTIONS FOR ADMINISTRATION

For intravenous infusion (Tenormin®), give intermittently in Glucose 5% or Sodium chloride 0.9%. Suggested infusion time 20 minutes.

MEDIeczAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Solution for injection

Tenormin (AstraZeneca UK Ltd)

Atenolol 500 microgram per 1 ml  
Tenormin 5mg/10ml solution for injection ampoules | 10 ampule | £34.45 (Hospital only)

Oral solution

Atenolol (Non-proprietary)

Atenolol 5 mg per 1 ml  
Atenolol 25mg/5ml oral solution sugar free | 300 ml | £6.72 DT price = £5.59

Tablet

CAUTIONARY AND ADVISORY LABELS

Atenolol (Non-proprietary)

Atenolol 25 mg  
Atenolol 25mg tablets | 28 tablet | £1.39 DT price = £0.71

Atenolol 50 mg  
Atenolol 50mg tablets | 28 tablet | £1.44 DT price = £0.73

Atenolol 100 mg  
Atenolol 100mg tablets | 28 tablet | £5.19 DT price = £0.75

Tenormin (AstraZeneca UK Ltd)

Atenolol 50 mg  
Tenormin L5 50mg tablets | 28 tablet | £5.11 DT price = £0.73

Atenolol 100 mg  
Tenormin 100mg tablets | 28 tablet | £6.49 DT price = £0.75

Atenolol with nifedipine

The properties listed below are those particular to the combination only. For the properties of the components please consider, atenolol above, nifedipine p. 157.

INDICATIONS AND DOSE

Hypertension

BY MOUTH

Adult: 1 capsule daily, increased if necessary to 1 capsule twice daily

Elderly: 1 capsule daily

Angina

BY MOUTH

Adult: 1 capsule twice daily

INTERACTIONS

Appendix 1: beta blockers (selective), calcium channel blockers

PRESCRIBING AND DISPENSING INFORMATION

Only indicated when calcium-channel blocker or beta-blocker alone proves inadequate.
**Cardiovascular system**

**CONTRA-INDICATIONS**
- Very rare

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Modified-release capsule**

**CAUTIONARY AND ADVISORY LABELS 8, 25**
- Tenil (AstraZeneca UK Ltd)
  - Nifedipine 20 mg, Atenolol 50 mg modified-release capsules | 28 capsule
  - Dose: 10 mg daily in severe renal impairment.

**Bisoprolol fumarate**

**INDICATIONS AND DOSE**

**Hypertension | Angina**
- **BY MOUTH**
  - Adult: 5–10 mg once daily; maximum 20 mg per day

**Adjunct in heart failure**
- **BY MOUTH**
  - Adult: Initially 1.25 mg once daily for 1 week, dose to be taken in the morning, then increased if tolerated to 2.5 mg once daily for 1 week, then increased if tolerated to 3.75 mg once daily for 1 week, then increased if tolerated to 5 mg once daily for 4 weeks, then increased if tolerated to 7.5 mg once daily for 4 weeks, then increased if tolerated to 10 mg once daily; maximum 10 mg per day

**CONTRA-INDICATIONS**
- Acute or decompensated heart failure requiring inotropic support – sino-atrial block

**CAUTIONS**
- Ensure heart failure not worsening before increasing dose

**INTERACTIONS** → Appendix 1: beta blockers (selective)

**SIDE-EFFECTS**
- Uncommon
  - Cramp
  - Depression
  - Muscle weakness
- Rare
  - Hearing impairment
  - Hypertriglyceridaemia
  - Syncope
- Very rare
  - Conjunctivitis

**HEPATIC IMPAIRMENT**
- Max. 10 mg daily in severe impairment.

**RENAL IMPAIRMENT**
- Reduce dose if eGFR less than 20 mL/minute/1.73 m² (max. 10 mg daily).

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Tablet**

**CAUTIONARY AND ADVISORY LABELS 8, 22**
- **Bisoprolol fumarate (Non-proprietary)**
  - Bisoprolol fumarate 1.25 mg Bisoprolol 1.25mg tablets | 28 tablet
  - Dose: 10 mg daily, alternatively increased if necessary to 50 mg daily.

**CONTRACOR (Tillomed Laboratories Ltd)**
- **Bisoprolol fumarate 1.25 mg**
  - Concor 1.25mg tablets | 28 tablet
  - **DT price = £0.87**
- **Bisoprolol fumarate 2.5 mg**
  - Concor 2.5mg tablets | 28 tablet
  - **DT price = £0.78**

**Celiprolol hydrochloride**

**INDICATIONS AND DOSE**
- Mild to moderate hypertension
- **BY MOUTH**
  - Adult: 200 mg once daily, dose to be taken in the morning, then increased if necessary to 400 mg once daily

**INTERACTIONS** → Appendix 1: beta blockers (selective)

**SIDE-EFFECTS**
- Rare
  - Depression
  - Pneumonitis
- Frequency not known
  - Hot flushes

**BREAST FEEDING**
- Manufacturers advise avoidance.

**HEPATIC IMPAIRMENT**
- Consider dose reduction.

**RENAL IMPAIRMENT**
- Reduce dose by half if eGFR 15–40 mL/minute/1.73 m². Avoid if eGFR less than 15 mL/minute/1.73 m².

**MEDITINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Tablet**

**CAUTIONARY AND ADVISORY LABELS 8, 22**
- **Celiprolol hydrochloride (Non-proprietary)**
  - Celiprolol hydrochloride 200 mg Celiprolol 200mg tablets | 28 tablet
  - **DT price = £0.29**
  - Celiprolol hydrochloride 400 mg Celiprolol 400mg tablets | 28 tablet
  - **DT price = £0.38**
- **Celectol (Zeneca)**
  - Celectol hydrochloride 200 mg Celectol 200mg tablets | 28 tablet
  - **DT price = £0.18**
  - Celectol hydrochloride 400 mg Celectol 400mg tablets | 28 tablet
  - **DT price = £0.38**

**Co-tenidone**

**INDICATIONS AND DOSE**
- **Hypertension**
  - **BY MOUTH**
  - Adult: 50/12.5 mg daily, alternatively increased if necessary to 100/25 mg daily, doses higher than 50 mg atenolol rarely necessary

**DOSE EQUIVALENCE AND CONVERSION**
- A mixture of atenolol and chlortalidone in mass proportions corresponding to 4 parts of atenolol and 1 part chlortalidone.

**INTERACTIONS** → Appendix 1: beta blockers (selective), thiazide diuretics

**SIDE-EFFECTS**
- Allergic interstitial nephritis
  - Jaundice

**PREGNANCY**
- Avoid. Diuretics not used to treat hypertension in pregnancy.

**BREAST FEEDING**
- Atenolol present in milk in greater amounts than some other beta-blockers. Possible toxicity due to beta-blockade—monitor infant. Large doses of chlortalidone may suppress lactation.

**RENAL IMPAIRMENT**
- Avoid if eGFR less than 30 mL/minute/1.73 m²—consider alternative treatment.
MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Tablet
CAUTIONARY AND ADVISORY LABELS 8

▶ Co-tenidone (Non-proprietary)
Chlortalidone 12.5 mg, Atenolol 50 mg Co-tenidone 50mg/12.5mg tablets | 28 tablet | £0.40 DT price = £1.65
Chlortalidone 25 mg, Atenolol 100 mg Co-tenidone 100mg/25mg tablets | 28 tablet | £0.40 DT price = £1.68
▶ Tenoret (AstraZeneca UK Ltd)
Chlortalidone 12.5 mg, Atenolol 50 mg Tenoret 50mg/12.5mg tablets | 28 tablet | £0.18 DT price = £1.65
▶ Tenoretic (AstraZeneca UK Ltd)
Chlortalidone 25 mg, Atenolol 100 mg Tenoret 100mg/25mg tablets | 28 tablet | £0.18 DT price = £1.68

SECTION 1: BLOOD VESSELS AND BLOOD PRESSURE INHIBITION

Esmolol hydrochloride

INDICATIONS AND DOSE
Short-term treatment of supraventricular arrhythmias (including atrial fibrillation, atrial flutter, sinus tachycardia). Tachycardia and hypertension in peri-operative period

▶ BY INTRAVENOUS INFUSION
Adult: 50–200 micrograms/kg/minute, consult product literature for details of dose titration and doses during peri-operative period

INTERACTIONS  Appendix 1: beta blockers (selective)
SIDE-EFFECTS Thrombophlebitis - venous irritation
BREAST FEEDING Manufacturer advises avoidance.
RENAL IMPAIRMENT Manufacturer advises caution.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Solution for injection
▶ Brevibloc (Baxter Healthcare Ltd)
Esmolol hydrochloride 10 mg per 1 ml Brevibloc Premixed 100mg/1ml solution for injection vials | 5 vial | no price available

Solution for infusion
▶ Brevibloc (Baxter Healthcare Ltd)
Esmolol hydrochloride 10 mg per 1 ml Brevibloc Premixed 2.5g/250ml infusion bags | 1 bag | £89.69

Metoprolol tartrate

INDICATIONS AND DOSE
Hypertension
▶ BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
Adult: Initially 100 mg daily, increased if necessary to 200 mg daily in 1–2 divided doses, high doses are rarely required; maximum 400 mg per day
▶ BY MOUTH USING MODIFIED-RELEASE MEDICINES
Adult: 200 mg once daily

Angina
▶ BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
Adult: 50–100 mg 2–3 times a day
▶ BY MOUTH USING MODIFIED-RELEASE MEDICINES
Adult: 200–400 mg daily

Arrhythmias
▶ BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
Adult: Usual dose 50 mg 2–3 times a day, then increased if necessary up to 300 mg daily in divided doses
▶ BY INTRAVENOUS INJECTION
Adult: Up to 5 mg, dose to be given at a rate of 1–2 mg/minute, then up to 5 mg after 5 minutes if required, total dose of 10–15 mg

Migraine prophylaxis
▶ BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
Adult: 100–200 mg daily in divided doses
▶ BY MOUTH USING MODIFIED-RELEASE MEDICINES
Adult: 200 mg daily

Early intervention within 12 hours of infarction
▶ INITIALY BY INTRAVENOUS INJECTION
Adult: Initially 5 mg every 2 minutes, to a max. of 15 mg, followed by (by mouth) 50 mg every 6 hours for 48 hours, to be taken 15 minutes after intravenous injection; (by mouth) maintenance 200 mg daily in divided doses

INTERACTIONS  Appendix 1: beta blockers (selective)
Hepatic impairment Reduce dose in severe impairment.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule, oral suspension, oral solution

Modified-release tablet
CAUTIONARY AND ADVISORY LABELS 8, 25
▶ Lopresor SR (Recordati Pharmaceuticals Ltd)
Metoprolol tartrate 200 mg Lopresor SR 200mg tablets | 28 tablet | £9.00

Tablet
CAUTIONARY AND ADVISORY LABELS 8
▶ Metoprolol tartrate (Non-proprietary)
Metoprolol tartrate 50 mg Metoprol 50mg tablets | 28 tablet | £0.30 DT price = £1.05 | 56 tablet | £2.44
Metoprolol tartrate 100 mg Metoprol 100mg tablets | 28 tablet | £0.30 DT price = £1.17 | 56 tablet | £2.74
▶ Lopresor (Recordati Pharmaceuticals Ltd)
Metoprolol tartrate 50 mg Lopresor 50mg tablets | 56 tablet | £2.57
Metoprolol tartrate 100 mg Lopresor 100mg tablets | 56 tablet | £6.68

Solution for injection
▶ Betaloc (AstraZeneca UK Ltd)
Metoprolol tartrate 1 mg per 1 ml Betaloc I.V. 5mg/5ml solution for injection ampoules | 5 ampoule | £0.50 (Hospital only)

Nebivolol

INDICATIONS AND DOSE
Essential hypertension
▶ BY MOUTH
Adult: 5 mg daily
Elderly: Initially 2.5 mg daily, then increased if necessary to 5 mg daily

Hypertension in patient with renal impairment
▶ BY MOUTH
Adult: Initially 2.5 mg once daily, then increased if necessary to 5 mg once daily

Adjunct in stable mild to moderate heart failure
▶ BY MOUTH
Adult: 5 mg once daily; then increased if tolerated to 2.5 mg once daily, then increased if tolerated to 5 mg once daily for 1–2 weeks, then increased if tolerated to 10 mg once daily

Adult: 12.5 mg once daily for 1–2 weeks, then increased if tolerated to 2.5 mg once daily, then increased if tolerated to 5 mg once daily for 1–2 weeks, then increased if tolerated to 10 mg once daily
Calcium-channel blockers

Overview
Calcium-channel blockers differ in their predilection for the various therapeutic sites of action and, therefore, their therapeutic effects are disparate, with much greater variation than those of beta-blockers. There are important differences between verapamil hydrochloride p. 159, diltiazem hydrochloride p. 152, and the dihydropyridine calcium-channel blockers (amlodipine below, felodipine p. 154, lacidipine p. 155, lercanidipine hydrochloride p. 156, nicardipine hydrochloride p. 156, nifedipine p. 157, and nimodipine p. 111). Verapamil hydrochloride and diltiazem hydrochloride should usually be avoided in heart failure because they may further depress cardiac function and cause clinically significant deterioration.

Verapamil hydrochloride is used for the treatment of angina, hypertension, and arrhythmias. It is a highly negatively inotropic calcium-channel blocker and it reduces cardiac output, slows the heart rate, and may impair atrioventricular conduction. It may precipitate heart failure, exacerbate conduction disorders, and cause hypotension at high doses and should not be used with beta-blockers. Constipation is the most common side-effect.

Nifedipine relaxes vascular smooth muscle and dilates coronary and peripheral arteries. It has more influence on vessels and less on the myocardium than does verapamil hydrochloride and unlike verapamil hydrochloride has no anti-arrhythmic activity. It rarely precipitates heart failure because any negative inotropic effect is offset by a reduction in left ventricular work.

Nifedipine hydrochloride has similar effects to those of nifedipine and may produce less reduction of myocardial contractility. Amlodipine and felodipine also resemble nifedipine and nicardipine hydrochloride in their effects and do not reduce myocardial contractility and they do not produce clinical deterioration in heart failure. They have a longer duration of action and can be given once daily. Nifedipine, nicardipine hydrochloride, amlodipine, and felodipine are used for the treatment of angina or hypertension. All are valuable in forms of angina associated with coronary vasospasm. Side-effects associated with vasodilatation such as flushing and headache (which become less obtrusive after a few days), and ankle swelling (which may respond only partially to diuretics) are common.

Intravenous nicardipine hydrochloride is licensed for the treatment of acute life-threatening hypertension, for example in the event of malignant arterial hypertension or hypertensive encephalopathy; aortic dissection, when a short-acting beta-blocker is not suitable, or in combination with a beta-blocker when beta-blockade alone is not effective; severe pre-eclampsia, when other intravenous anti-hypertensives are not recommended or are contra-indicated; and for treatment of postoperative hypertension.

Nimodipine is related to nifedipine but the smooth muscle relaxant effect preferentially acts on cerebral arteries. Its use is confined to prevention and treatment of vascular spasm following aneurysmal subarachnoid haemorrhage.

Diltiazem hydrochloride is effective in most forms of angina; the longer-acting formulation is also used for hypertension. It may be used in patients for whom beta-blockers are contra-indicated or ineffective. It has a less negative inotropic effect than verapamil hydrochloride and significant myocardial depression occurs rarely. Nevertheless because of the risk of bradycardia it should be used with caution in association with beta-blockers.

Unstable angina
Calcium-channel blockers do not reduce the risk of myocardial infarction in unstable angina. The use of diltiazem hydrochloride or verapamil hydrochloride should be reserved for patients resistant to treatment with beta-blockers.

Calcium-channel blockers

Drug action
Calcium-channel blockers (less correctly called ‘calcium-antagonists’) interfere with the inward displacement of calcium ions through the slow channels of active cell membranes. They influence the myocardial cells, the cells within the specialised conducting system of the heart, and the cells of vascular smooth muscle. Thus, myocardial contractility may be reduced, the formation and propagation of electrical impulses within the heart may be depressed, and coronary or systemic vascular tone may be diminished.

Side-effects

Overdose
Features of calcium-channel blocker poisoning include nausea, vomiting, dizziness, agitation, confusion, and coma in severe poisoning. Metabolic acidosis and hyperglycaemia may occur.

For details on the management of poisoning, see Calcium-channel blockers, under Emergency treatment of poisoning p. 1254.

Treatment cessation
There is some evidence that sudden withdrawal of calcium-channel blockers may be associated with an exacerbation of myocardial ischaemia.

Amlodipine

Drug action
Amlodipine is a dihydropyridine calcium-channel blocker.

Indications and dose

Prophylaxis of angina

<table>
<thead>
<tr>
<th>By mouth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adult: Initially 5 mg once daily; maximum 10 mg per day</td>
</tr>
</tbody>
</table>

Medicinal forms

There can be variation in the licensing of different medicines containing the same drug.

Tablet

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nebivolol (Non-proprietary)</td>
</tr>
<tr>
<td>Nebivolol (as Nebivolol hydrochloride) 2.5 mg Nebivolol 2.5mg tablets</td>
</tr>
<tr>
<td>Nebivolol (as Nebivolol hydrochloride) 5 mg Nebivolol 5mg tablets</td>
</tr>
<tr>
<td>Nebivolol (as Nebivolol hydrochloride) 10 mg Nebivolol 10mg tablets</td>
</tr>
<tr>
<td>Nebilet (A. Menarini Farmaceutica Internazionale SRL)</td>
</tr>
<tr>
<td>Nebivolol (as Nebivolol hydrochloride) 5 mg Nebilet 5mg tablets</td>
</tr>
</tbody>
</table>

Calcium-channel blockers

CONTRA-INDICATIONS
Acute or decompensated heart failure requiring intravenous inotropes

INTERACTIONS
Appendix 1: beta blockers (selective)

SIDE-EFFECTS
Depression · oedema

BREAST FEEDING
Manufacturers advise avoidance.

HEPATIC IMPAIRMENT
No information available—manufacturer advises avoid.

RENAL IMPAIRMENT
Manufacturer advises avoid in heart failure if serum creatinine greater than 250 micromol/litre.
Hypertension

BY MOUTH

Adult: Initially 5 mg once daily; maximum 10 mg per day

DOSE EQUVALENE AND CONVERSION

Tables from various suppliers may contain different salts (e.g. amlodipine besilate, amlodipine maleate, and amlodipine mesilate) but the strength is expressed in terms of amlodipine (base); tablets containing different salts are considered interchangeable.

CONTRA-INDICATIONS Cardiogenic shock · significant aortic stenosis · unstable angina

SIDE-EFFECTS

Common or very common Abdominal pain · dizziness · fatigue · flushing · headache · nausea · oedema · palpitation · sleep disturbances

Uncommon Alopecia · arthralgia · asthenia · back pain · chest pain · dry mouth · dyspepsia · gastro-intestinal disturbances · gynaecomastia · hypotension · impotence · mood changes · muscle cramps · myalgia · paraesthesia · pruritus · purpura · rashes · rhinitis · skin discolouration · sweating · syncope · taste disturbances · tinnitus · tremor · urinary disturbances · visual disturbances · weight changes

Very rare Angioedema · arhythmias · cholestasis · coughing · gastritis · gingival hyperplasia · hepatitis · hyperglycaemia · jaundice · myocardial infarction · pancreatitis · peripheral neuropathy · tachycardia · thrombocytopenia · urticaria · vasculitis

Frequency not known Erythema multiforme

Overdose In overdose, the dihydropyridine calcium-channel blockers cause severe hypotension secondary to profound peripheral vasodilatation.

PREGNANCY No information available—manufacturer advises avoid, but risk to fetus should be balanced against risk of uncontrolled maternal hypertension.

BREAST FEEDING Manufacturer advises avoid—no information available.

HEPATIC IMPAIRMENT May need dose reduction—half-life prolonged.

DIRECTIONS FOR ADMINISTRATION Tablets may be dispered in water.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Oral solution

Amlodipine (Non-proprietary)

Amlodipine 1 mg per 1 ml Amlodipine 5mg/5ml oral solution sugar free sugar-free | 150 ml £75.76 DT price = £75.76

Amlodipine 2 mg per 1 ml Amlodipine 10mg/5ml oral solution sugar free sugar-free | 150 ml £115.73 DT price = £115.73

Tablet

Amlodipine (Non-proprietary)

Amlodipine 5 mg Amlodipine 5mg tablets | 28 tablet £9.42 DT price = £0.73

Amlodipine 10 mg Amlodipine 10mg tablets | 28 tablet £14.07 DT price = £0.79

Istin (Pfizer Ltd)

Amlodipine 5 mg Istin 5mg tablets | 28 tablet £11.08 DT price = £0.73

Amlodipine 10 mg Istin 10mg tablets | 28 tablet £16.55 DT price = £0.79

Combinations available: Olmesartan with amlodipine, p. 172 · Olmesartan with amlodipine and hydrochlorothiazide, p. 173

Amlodipine with valsartan

The properties listed below are those particular to the combination only. For the properties of the components please consider, amlodipine p. 150, valsartan p. 174.

INDICATIONS AND DOSE

Hypertension in patients stabilised on the individual components in the same proportions

BY MOUTH

Adult: (consult product literature)

INTERACTIONS → Appendix 1: angiotensin-II receptor antagonists, calcium channel blockers

MEDICINAL FORMS

In the licensing of different medicines containing the same drug.

Tablet

Exforge (Novartis Pharmaceuticals UK Ltd)

Amlodipine (as Amlodipine besilate) 5 mg, Valsartan 80 mg Exforge 5mg/80mg tablets | 28 tablet £20.11 DT price = £20.11

Amlodipine (as Amlodipine besilate) 10 mg, Valsartan 160 mg Exforge 10mg/160mg tablets | 28 tablet £26.51 DT price = £26.51

Amlodipine (as Amlodipine besilate) 5 mg, Valsartan 160 mg Exforge 5mg/160mg tablets | 28 tablet £26.51 DT price = £26.51

Clevadipine

INDICATIONS AND DOSE

Hypertension in the peri-operative setting (specialist use only)

BY INTRAVENOUS INFUSION

Adult: Initially 2 mg/hour, dose may be doubled every 90 seconds as necessary; usual dose 4–6 mg/hour (max. per dose 32 mg/hour); maximum 500 mg per day

CONTRA-INDICATIONS Defective lipid metabolism · uncorrected critical aortic stenosis

CAUTIONS Hypertrophic obstructive cardiomyopathy (risk of reduced oxygen delivery) · lipid load restrictions (injection has a high lipid content) · mitral stenosis (risk of reduced oxygen delivery) · patients who are unable to increase their heart rate adequately to compensate for reduced blood pressure

INTERACTIONS → Appendix 1: calcium channel blockers

SIDE-EFFECTS

Common or very common Acute kidney injury · arrhythmias · chest pain · oedema · tachycardia

Uncommon Bradycardia · congestive heart failure · constipation · dizziness · headache · hypoxia · nausea · pulmonary congestion · vomiting

Rare Ileus

Frequency not known Systemic hypotension

SIDE-EFFECTS, FURTHER INFORMATION

Hypotension and reflex tachycardia Manufacturer advises that systemic hypotension and reflex tachycardia have been reported—consider decreasing the dose by half or stopping the infusion.

ALLERGY AND CROSS-SENSITIVITY Contra—indicated in patients with hypersensitivity to peanut, soy products, or egg products.

PREGNANCY Manufacturer advises avoid unless essential—totoxicity in animal studies (recommendation also supported by specialist sources).

BREAST FEEDING Manufacturer advises avoid—no information available.

MONITORING REQUIREMENTS Manufacturer advises monitor heart rate and blood pressure continuously during...
Diltiazem hydrochloride

**INDICATIONS AND DOSE**

**Prophylaxis and treatment of angina**
- **BY MOUTH**
  - Adult: Initially 60 mg 3 times a day, adjusted according to response; maximum 360 mg per day
  - Elderly: Initially 60 mg twice daily, adjusted according to response; maximum 360 mg per day

**ADIZEM-SR ™ CAPSULES**

**Mild to moderate hypertension**
- **BY MOUTH**
  - Adult: 120 mg twice daily, dose form not appropriate for initial dose titration

**Angina**
- **BY MOUTH**
  - Adult: Initially 90 mg twice daily; increased if necessary to 180 mg twice daily, dose form not appropriate for initial dose titration in the elderly

**ADIZEM-SR ™ TABLETS**

**Mild to moderate hypertension**
- **BY MOUTH**
  - Adult: 120 mg twice daily, dose form not appropriate for initial dose titration

**Angina**
- **BY MOUTH**
  - Adult: Initially 90 mg twice daily; increased if necessary to 180 mg twice daily, dose form not appropriate for initial dose titration in the elderly

**ADIZEM-XL ™**

**Angina | Mild to moderate hypertension**
- **BY MOUTH**
  - Adult: Initially 240 mg once daily, increased if necessary to 300 mg once daily
  - Elderly: Initially 120 mg once daily, increased if necessary up to 300 mg once daily

**ANGITIL ™ SR**

**Angina | Mild to moderate hypertension**
- **BY MOUTH**
  - Adult: Initially 90 mg twice daily; increased if necessary to 120–180 mg twice daily

**ANGITIL ™ XL**

**Angina | Mild to moderate hypertension**
- **BY MOUTH**
  - Adult: Initially 240 mg once daily; increased if necessary to 300 mg once daily, dose form not appropriate for initial dose titration in the elderly

**DILCARDIA ™ SR**

**Angina | Mild to moderate hypertension**
- **BY MOUTH**
  - Adult: Initially 90 mg twice daily; increased if necessary to 180 mg twice daily

**CONTRA-INDICATIONS**

Acute porphyrias p. 969 • left ventricular failure with pulmonary congestion • second- or
Rare ▶ SIDE-EFFECTS

- **SIDE-EFFECTS**
- **Common or very common** Asthenia · AV block · bradycardia · dizziness · gastrointestinal disturbances · headache · hot flushes · hypotension · malaise · oedema (notably of ankles) · palpitation · sino-atrial block
- **Rare** Erythema multiforme · exfoliative dermatitis · photosensitivity · rashes
- **Frequency not known** Depression · extrapyramidal symptoms · gum hyperplasia · gynaecomastia · hepatitis

**OVERDOSE**

In overdose, diltiazem has a profound cardiac depressant effect causing hypotension and arrhythmias, including complete heart block and asystole.

**PREGNANCY** Avoid.

**BREAST FEEDING** Significant amount present in milk—no evidence of harm but avoid unless no safer alternative.

**HEPATIC IMPAIRMENT** Reduce dose.

**TILDIEM RETARD** Dose for mild to moderate hypertension—initially 120 mg once a day; increased if necessary to 120 mg twice a day.

For treatment of angina, dose form not appropriate for initial titration; up to 120 mg twice a day may be required.

**SLOZEM** Dose for angina and mild to moderate hypertension—initially 120 mg once daily.

**DILZEM XL** Dose for angina and mild to moderate hypertension—initially 120 mg once daily.

**ANGITIL XL** Dose form not appropriate for initial dose titration.

**DILCARDIA SR** Dose for angina and mild to moderate hypertension—initially 60 mg twice a day; maximum 90 mg twice a day.

**TILDIEM LA** Dose for angina and mild to moderate hypertension—initially 200 mg daily; increased if necessary to 300 mg daily.

**VIAZEM XL** Dose for angina and mild to moderate hypertension—initially 120 mg once daily, adjusted according to response.

**ADIZEM-XL** Dose for angina and mild to moderate hypertension—initially 120 mg once daily.

**ZEMTARD** Dose for angina and mild to moderate hypertension—initially 120 mg once daily.

**RENAIIMPAIRMENT** Start with smaller dose.

**TILDIEM RETARD** Dose for mild to moderate hypertension—initially 120 mg once a day; increased if necessary to 120 mg twice a day.

For treatment of angina, dose form not appropriate for initial titration; up to 120 mg twice a day may be required.

**SLOZEM** Dose for angina and mild to moderate hypertension—initially 120 mg once daily.

**DILZEM XL** Dose for angina and mild to moderate hypertension—initially 120 mg once daily.

**ANGITIL XL** Dose form not appropriate for initial dose titration.

**DILCARDIA SR** Dose for angina and mild to moderate hypertension—initially 60 mg twice a day; maximum 90 mg twice a day.

**TILDIEM LA** Dose for angina and mild to moderate hypertension—initially 200 mg daily; increased if necessary to 300 mg daily.

**VIAZEM XL** Dose for angina and mild to moderate hypertension—initially 120 mg once daily, adjusted according to response.

**ADIZEM-XL** Dose for angina and mild to moderate hypertension—initially 120 mg once daily.

**ZEMTARD** Dose for angina and mild to moderate hypertension—initially 120 mg once daily.

**PRESCRIBING AND DISPENSING INFORMATION**

The standard formulations containing 60 mg diltiazem hydrochloride are licensed as generics and there is no requirement for brand name dispensing. Although their means of formulation has called for the strict designation ‘modified-release’, their duration of action corresponds to that of tablets requiring administration more frequently.

Different versions of modified-release preparations containing more than 60 mg diltiazem hydrochloride may not have the same clinical effect. To avoid confusion between these different formulations of diltiazem, prescribers should specify the brand to be dispensed.

**PATIENT AND CARER ADVICE**

**TILDIEM RETARD** Tablet membrane may pass through gastro-intestinal tract unchanged, but being porous has no effect on efficacy.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, cream, ointment, gel

**Modified-release tablet**

**CAUTIONARY AND ADVISORY LABELS 25**

**Diltiazem hydrochloride (Non-proprietary)**

| Diltiazem hydrochloride 60 mg | Diltiazem 60mg modified-release tablets | 84 tablet (Pom) £1.59 DT price = £1.59 |
| Diltiazem hydrochloride 90 mg | Diltiazem 90mg modified-release tablets | 56 tablet (Pom) £2.51 DT price = £2.51 |
| Diltiazem hydrochloride 120 mg | Diltiazem 120mg modified-release tablets | 56 tablet (Pom) no price available DT price = £7.27 |

**Retailzem (Kent Pharmaceuticals Ltd)**

| Diltiazem hydrochloride 60 mg | Diltiazem 60 modified-release tablets | 84 tablet (Pom) £1.59 DT price = £1.59 |

**Tildiem (Sanofi)**

| Diltiazem hydrochloride 60 mg | Diltiazem 60 modified-release tablets | 90 tablet (Pom) £7.96 |

**Tildiem Retard (Sanofi)**

| Diltiazem hydrochloride 90 mg | Diltiazem Retard 90mg tablets | 56 tablet (Pom) £7.27 DT price = £7.27 |
| Diltiazem hydrochloride 120 mg | Diltiazem Retard 120mg tablets | 56 tablet (Pom) £7.15 DT price = £7.15 |

**Modified-release capsule**

**CAUTIONARY AND ADVISORY LABELS 25**

**Diltiazem hydrochloride (Non-proprietary)**

| Diltiazem hydrochloride 60 mg | Diltiazem 60mg modified-release capsules | 56 capsule (Pom) £6.04 DT price = £6.04 |
| Diltiazem hydrochloride 90 mg | Diltiazem 90mg modified-release capsules | 56 capsule (Pom) £8.50 DT price = £8.50 |
| Diltiazem hydrochloride 120 mg | Diltiazem 120mg modified-release capsules | 28 capsule (Pom) £11.52 DT price = £11.52 |
| Diltiazem hydrochloride 300 mg | Diltiazem 300mg modified-release capsules | 28 capsule (Pom) £31.01 DT price = £31.01 |
| Diltiazem hydrochloride 360 mg | Diltiazem 360mg modified-release capsules | 28 capsule (Pom) no price available DT price = £13.85 |

**Adizem-SR (Napp Pharmaceuticals Ltd)**

| Diltiazem hydrochloride 90 mg | Adizem-SR 90mg capsules | 56 capsule (Pom) £8.50 DT price = £8.50 |
| Diltiazem hydrochloride 120 mg | Adizem-SR 120mg capsules | 56 capsule (Pom) £9.45 |
| Diltiazem hydrochloride 180 mg | Adizem-SR 180mg capsules | 56 capsule (Pom) £14.15 |

**Adizem-XL (Napp Pharmaceuticals Ltd)**

| Diltiazem hydrochloride 120 mg | Adizem-XL 120mg capsules | 28 capsule (Pom) £9.14 |
Felodipine

**DRUG ACTION** Felodipine is a dihydropyridine calcium-channel blocker.

**INDICATIONS AND DOSE**

**Prophylaxis of angina**
- **BY MOUTH**
  - Adult: Initially 5 mg once daily; increased if necessary to 10 mg once daily, to be taken in the morning
  - Elderly: Initially 2.5 mg once daily; increased if necessary to 10 mg once daily, to be taken in the morning

**Hypertension**
- **BY MOUTH**
  - Adult: Initially 5 mg once daily; usual maintenance 5–10 mg once daily, to be taken in the morning, doses above 20 mg daily rarely needed
  - Elderly: Initially 2.5 mg daily; usual maintenance 5–10 mg once daily, to be taken in the morning, doses above 20 mg daily rarely needed

**CONTRA-INDICATIONS** Cardiac outflow obstruction - significant cardiac valvular obstruction (e.g. aortic stenosis) - uncontrolled heart failure - unstable angina - within 1 month of myocardial infarction

**CAUTIONS** Predisposition to tachycardia - severe left ventricular dysfunction - withhold if cardiogenic shock develops - withhold if existing pain worsens shortly after initiating treatment - withhold if ischaemic pain occurs shortly after initiating treatment

**INTERACTIONS** → Appendix 1: calcium channel blockers

**SIDE-EFFECTS**
- **Common or very common** Flushing, headache, peripheral oedema
- **Uncommon** Abdominal pain, dizziness, malaise, nausea, palpitation, paraesthesia, pruritus, rash, tachycardia
- **Rare** Arthralgia, impotence, myalgia, syncope, vomiting
- **Very rare** Gum hyperplasia, leucocytoclastic vasculitis, photosensitivity, urinary frequency

**PREGNANCY** Avoid; toxicity in animal studies; may inhibit labour.

**BREAST FEEDING** Present in milk but amount probably too small to be harmful.

**HEPATIC IMPAIRMENT** Dose reduction may be required.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Modified-release tablet**

**CAUTIONARY AND ADVISORY LABELS 25**

- **Felodipine (Non-proprietary)**
  - **Felodipine 2.5 mg** Felodipine 2.5mg modified-release tablets | 28 tablet [Pom] no price available DT price = £5.31
  - **Felodipine 5 mg** Felodipine 5mg modified-release tablets | 28 tablet [Pom] £4.21 DT price = £4.21
  - **Felodipine 10 mg** Felodipine 10mg modified-release tablets | 28 tablet [Pom] £5.66 DT price = £5.66
  - **Cardioplen XL (Chiesi Ltd)**
    - **Felodipine 2.5 mg** Cardioplen XL 2.5mg tablets | 28 tablet [Pom] £5.68 DT price = £5.68
    - **Felodipine 5 mg** Cardioplen XL 5mg tablets | 28 tablet [Pom] £3.87 DT price = £3.87
    - **Felodipine 10 mg** Cardioplen XL 10mg tablets | 28 tablet [Pom] £4.21 DT price = £4.21
  - **Folpik XL (Teva UK Ltd)**
    - **Felodipine 2.5 mg** Folpik XL 2.5mg tablets | 28 tablet [Pom] £6.31 DT price = £6.31
    - **Felodipine 5 mg** Folpik XL 5mg tablets | 28 tablet [Pom] £4.21 DT price = £4.21
    - **Felodipine 10 mg** Folpik XL 10mg tablets | 28 tablet [Pom] £7.21 DT price = £7.21
**CONTRA-INDICATIONS**

- Hypotension not severe
- Aortic stenosis
- Chronic heart failure
- Cardiogenic shock
- Depression
- Arthralgia

**INTERACTIONS**

- Common or very common
- Frequency not known

**SIDE-EFFECTS**

- Abdominal discomfort
- Dizziness
- Dyspnoea
- Fatigue
- Flushing
- Headache
- Palpitation
- Peripheral oedema
- Polyuria
- Rash
- Tachycardia
- Hypotension
- Weight gain
- Anaemia
- Anorexia
- Anxiety
- Arrhythmia
- Arterial hypertension
- Blood disorders
- Bradycardia
- Cough
- Depression
- Drowsiness
- Erectile dysfunction
- Gum hyperplasia
- Heart failure
- Hypersensitivity reactions
- Leucopenia
- Nausea
- Paraesthesia
- Thrombocytopenia
- Visual disturbance
- Vomiting
- Gynaecomastia
- Hepatitis

**OVERDOSE**

In overdose, the dihydropyridine calcium-channel blockers cause severe hypotension secondary to profound peripheral vasodilatation.

**PREGNANCY**

May inhibit labour. Risk to fetus should be balanced against risk of uncontrolled maternal hypertension.

**PARENTERAL**

Manufacturer advises avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT**

1.25 mg twice daily, increased if necessary after 3–4 weeks according to response; maintenance dose of 2.5 mg or 5 mg once daily may be sufficient.

**RENA L IMPAIRMENT**

Use with caution.

**MEDICAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. No licensed medicines listed.

## Lacidipine

**DRUG ACTION**

Lacidipine is a dihydropyridine calcium-channel blocker.

### INDICATIONS AND DOSE

**Hypertension**

**BY MOUTH**

- Adult: Initially 2 mg daily; increased if necessary to 4 mg daily; in combination with cimetidine or within 1 month of myocardial infarction, dose increases should occur at intervals of 3–4 weeks, to be taken preferably in the morning.

**SIDE-EFFECTS**

- Common or very common
- Rare
- Aggravation of angina
- Asthenia
- Erythema
- Gastrointestinal disturbances
- Gum hyperplasia
- Mood disturbances
- Muscle cramps
- Polyuria
- Pruritus
- Skin rash

**CONTRA-INDICATIONS**

- Acute porphyrias p. 969
- Aortic stenosis
- Aortic valvular disease
- Cardiogenic shock
- Unstable angina

**CAUTIONS**

Cardiac conduction abnormalities

**INTERACTIONS**

Appendix 1: calcium channel blockers

**MEDICAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- Lacidipine (Non-proprietary)
  - Lacidipine 2 mg: Lacidipine 2 mg tablets | 28 tablet | £6.85 DT price = £2.13
  - Lacidipine 4 mg: Lacidipine 4 mg tablets | 28 tablet | £6.85 DT price = £2.17
  - Molap (Rivopharm UK Ltd)
  - Lacidipine 4 mg: Lacidipine 4 mg tablets | 28 tablet | £2.90 DT price = £2.17
  - Motens (GlaxoSmithKline UK Ltd)
  - Lacidipine 2 mg: Lacidipine 2 mg tablets | 28 tablet | £2.95 DT price = £2.13
  - Lacidipine 4 mg: Lacidipine 4 mg tablets | 28 tablet | £3.10 DT price = £2.17
### Lercanidipine hydrochloride

**DRUG ACTION**  
Lercanidipine is a dihydropyridine calcium-channel blocker.

**INDICATIONS AND DOSE**

**Mild to moderate hypertension**
- **BY MOUTH**
  - Adult: Initially 10 mg once daily; increased if necessary to 20 mg daily, dose can be adjusted after 2 weeks

**CONTRA-INDICATIONS**  
Acute porphyrias p. 969 - aortic stenosis - uncontrolled heart failure - unstable angina - within 1 month of myocardial infarction

**CAUTIONS**  
Left ventricular dysfunction - sick sinus syndrome (if pacemaker not fitted)

**INTERACTIONS**  
Appendix 1: calcium channel blockers

**SIDE-EFFECTS**
- **Uncommon**  
  - Dizziness - flushing - headache - palpitation - peripheral oedema - tachycardia
- **Rare**  
  - Angina - asthenia - drowsiness - gastrointestinal disturbances - myalgia - polyuria - rash
- **Very rare**  
  - Gingival hyperplasia - hypotension - myocardial infarction

**Overdose**

In overdose, the dihydropyridine calcium-channel blockers cause severe hypotension secondary to profound peripheral vasodilatation.

**PREGNANCY**  
Manufacturer advises avoid — no information available.

**BREAST FEEDING**  
Manufacturer advises avoid.

**HEPATIC IMPAIRMENT**  
Avoid in severe disease.

**RENAL IMPAIRMENT**  
Avoid if eGFR less than 30 mL/minute/1.73 m².

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>22</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lercanidipine hydrochloride (Non-proprietary)</td>
<td></td>
</tr>
</tbody>
</table>
  - Lercanidipine hydrochloride 10 mg Lercanidipine 10 mg tablets  
    28 tablet (PO) £12.99 DT price = £4.73  
  - Lercanidipine hydrochloride 20 mg Lercanidipine 20 mg tablets  
    28 tablet (PO) £15.99 DT price = £6.14  
  - Zanidip (Recordati Pharmaceuticals Ltd)  
    - Lercanidipine hydrochloride 10 mg Zanidip 10 mg tablets  
      28 tablet (PO) £5.70 DT price = £4.73  
    - Lercanidipine hydrochloride 20 mg Zanidip 20 mg tablets  
      28 tablet (PO) £10.82 DT price = £6.14 |

---

### Nicardipine hydrochloride

**DRUG ACTION**  
Nicardipine is a dihydropyridine calcium-channel blocker.

**INDICATIONS AND DOSE**

**Prophylaxis of angina**
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: Initially 20 mg 3 times a day, then increased to 30 mg 3 times a day, dose increased after at least 3 days; usual dose 60–120 mg daily

**Mild to moderate hypertension**
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: Initially 20 mg 3 times a day, then increased to 30 mg 3 times a day, dose increased after at least 3 days; usual dose 60–120 mg daily
- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Adult: Initially 30 mg twice daily; increased if necessary up to 45 mg twice daily, usual dose 30–60 mg twice daily

---

### Life-threatening hypertension (specialist use only) | Postoperative hypertension (specialist use only)

**BY CONTINUOUS INTRAVENOUS INFUSION**

- **Adult:** Initially 3–5 mg/hour for 15 minutes, increased in steps of 0.5–1 mg every 15 minutes, adjusted according to response, maximum rate 15 mg/hour, reduce dose gradually when target blood pressure achieved; maintenance 2–4 mg/hour
- **Elderly:** Initially 1–5 mg/hour, then adjusted in steps of 500 micrograms/hour after 30 minutes, adjusted according to response, maximum rate 15 mg/hour

**Life-threatening hypertension in patients with hepatic or renal impairment (specialist use only) | Postoperative hypertension in patients with hepatic or renal impairment (specialist use only)**

**BY CONTINUOUS INTRAVENOUS INFUSION**

- **Adult:** Initially 1–5 mg/hour, then adjusted in steps of 500 micrograms/hour after 30 minutes, adjusted according to response, maximum rate 15 mg/hour

**Acute life-threatening hypertension in pregnancy (specialist use only)**

**BY CONTINUOUS INTRAVENOUS INFUSION**

- **Adult:** Initially 1–5 mg/hour, then adjusted in steps of 500 micrograms/hour after 30 minutes, adjusted according to response, usual maximum rate 4 mg/hour in treatment of pre-eclampsia (maximum rate 15 mg/hour)

**CONTRA-INDICATIONS**

**GENERAL CONTRA-INDICATIONS**

- Acute porphyrias p. 969 - cardiogenic shock - significant or advanced aortic stenosis - unstable or acute attacks of angina

**SPECIFIC CONTRA-INDICATIONS**

- With intravenous use: Avoid within 8 days of myocardial infarction - compensatory hypertension
- With oral use: Avoid within 1 month of myocardial infarction

**CAUTIONS**

**GENERAL CAUTIONS**

Congestive heart failure - elderly - pulmonary oedema - significantly impaired left ventricular function - stroke - withdraw if ischaemic pain occurs or existing pain worsens within 30 minutes of initiating treatment or increasing dose

**SPECIFIC CAUTIONS**

- With intravenous use: Elevated intracranial pressure - portal hypertension

**INTERACTIONS**  
Appendix 1: calcium channel blockers

**SIDE-EFFECTS**


**SIDE-EFFECTS, FURTHER INFORMATION**

- Hypotension and reflex tachycardia: Systemic hypotension and reflex tachycardia with rapid reduction of blood pressure may occur — during intravenous use consider stopping infusion or decreasing dose by half.

**Overdose**

In overdose, the dihydropyridine calcium-channel blockers cause severe hypotension secondary to profound peripheral vasodilatation.

**PREGNANCY**

May inhibit labour. Not to be used in multiple pregnancy (twins or more) unless there is no other acceptable alternative. Toxicity in animal studies. Risk of severe maternal hypotension and fatal foetal hypoxia—
avoid excessive decrease in blood pressure. For treatment of acute life-threatening hypertension only.

**BREAST FEEDING** Manufacturer advises avoid—present in breast milk.

**HEPATIC IMPAIRMENT**

- With oral use Use with caution—consider using lowest initial dose and extending dosing interval according to individual response.
- With intravenous use Use with caution—use lower initial dose.

**RENAL IMPAIRMENT**

- With oral use Consider using lowest initial dose and extending dosing interval according to individual response.
- With intravenous use Use with caution—use lower initial dose.

**MONITORING REQUIREMENTS** Monitor blood pressure and heart rate at least every 5 minutes during intravenous infusion, and then until stable, and continue monitoring for at least 12 hours after end of infusion.

**DIRECTIONS FOR ADMINISTRATION** Intravenous nicardipine should only be administered under the supervision of a specialist and in a hospital or intensive care setting in which patients can be closely monitored.

For intravenous infusion give continuously in Glucose 5%; dilute dose in infusion fluid to a final concentration of 100–200 micrograms/mL (undiluted solution via central venous line only) and give via volumetric infusion pump or syringe driver; protect from light; to minimise peripheral venous irritation, change site of infusion every 12 hours; risk of adsorption on to plastic of infusion set in the presence of saline solutions; incompatible with bicarbonate or alkaline solutions—consult product literature.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Modified-release capsule**

- **Cardene SR (Astellas Pharma Ltd)**
  - Nicardipine hydrochloride 30 mg Cardene SR 30mg capsules  | 56 capsule PoM £7.15 DT price = £7.15
  - Nicardipine hydrochloride 45 mg Cardene SR 45mg capsules  | 56 capsule PoM £10.40 DT price = £10.40

**Solution for infusion**

- **Nicardipine hydrochloride (Non-proprietary)**
  - Nicardipine hydrochloride 1 mg per 1 ml Nicardipine 10mg/10ml solution for injection ampoules  | 5 ampoule PoM £50.00

**Capsule**

- **Nicardipine hydrochloride (Non-proprietary)**
  - Nicardipine hydrochloride 20 mg Nicardipine 20mg capsules  | 56 capsule PoM £8.38 DT price = £6.00
  - Nicardipine hydrochloride 30 mg Nicardipine 30mg capsules  | 56 capsule PoM £9.73 DT price = £6.96
  - **Cardene (Astellas Pharma Ltd)**
  - Nicardipine hydrochloride 20 mg Cardene 20mg capsules  | 56 capsule PoM £6.00 DT price = £6.00
  - Nicardipine hydrochloride 30 mg Cardene 30mg capsules  | 56 capsule PoM £6.96 DT price = £6.96

---

**Nifedipine**

**DRUG ACTION** Nifedipine is a dihydropyridine calcium-channel blocker.

**INDICATIONS AND DOSE**

- **Raynaud’s syndrome**
  - Adult: Initially 5 mg 3 times a day, then adjusted according to response to 20 mg 3 times a day

**Cardene**

- **Hypertension**
  - Adult: 10 mg 3 times a day

**Cardene SR**

- **Hypertension**
  - Adult: 10 mg twice daily, adjusted according to response to 40 mg twice daily

**Adalat Retard**

- **Hypertension | Angina prophyaxis**
  - Adult: 10 mg twice daily, adjusted according to response to 40 mg twice daily

**Adalat LA**

- **Hypertension**
  - Adult: 20–30 mg once daily, increased if necessary up to 90 mg once daily

**Angina prophyaxis**

- Adult: 30 mg once daily, increased if necessary up to 90 mg once daily

**Adalat Retard**

- **Hypertension | Angina prophyaxis**
  - Adult: 10 mg twice daily, adjusted according to response to 40 mg twice daily

**Adalat XL**

- **Hypertension | Angina prophyaxis**
  - Adult: 30 mg daily, increased if necessary up to 90 mg daily

**Coracten SR**

- **Hypertension | Angina prophyaxis**
  - Adult: Initially 10 mg twice daily, increased if necessary up to 40 mg twice daily

**Coracten XL**

- **Hypertension | Angina prophyaxis**
  - Adult: Initially 30 mg daily, increased if necessary up to 90 mg daily

**Fortipine LA 40**

- **Hypertension | Angina prophyaxis**
  - Adult: Initially 40 mg once daily, increased if necessary to 80 mg daily in 1–2 divided doses

**Nifedipress™ MR**

- **Hypertension | Angina prophyaxis**
  - Adult: 10 mg twice daily, adjusted according to response to 40 mg twice daily

Continued →
TENSIPINE MR

Hypertension | Angina prophylaxis

▶ BY MOUTH
▶ Adult: Initially 10 mg twice daily, adjusted according to response to 40 mg twice daily

VALNI XL

Severe hypertension | Prophylaxis of angina

▶ BY MOUTH
▶ Adult: 30 mg once daily, increased if necessary up to 90 mg once daily

● UNLICENSED USE Not licensed for use in postponing premature labour.

● CONTRA-INDICATIONS Acute attacks of angina • cardiogenic shock • significant aortic stenosis • unstable angina • within 1 month of myocardial infarction

● CAUTIONS Diabetes mellitus • elderly • heart failure • poor cardiac reserve • severe hypertension • short-acting formulations are not recommended for angina or long-term management of hypertension; their use may be associated with large variations in blood pressure and reflex tachycardia • significantly impaired left ventricular function (heart failure deterioration observed) • withdrawal if ischaemic pain occurs or existing pain worsens shortly after initiating treatment

ADALAT LA Crohn’s disease • decreased lumen diameter of the gastro-intestinal tract • history of gastro-intestinal obstruction • history of oesophageal obstruction • inflammatory bowel disease

CAUTIONS, FURTHER INFORMATION

Dose form not appropriate for use where there is a history of oesophageal or gastro-intestinal obstruction, decreased lumen diameter of the gastro-intestinal tract, or inflammatory bowel disease (including Crohn’s disease).

VALNI XL Decreased lumen diameter of gastro-intestinal tract • history of gastro-intestinal obstruction • history of oesophageal obstruction • ileostomy after proctocolectomy • inflammatory bowel disease

CAUTIONS, FURTHER INFORMATION

Dose form not appropriate for use where there is a history of oesophageal or gastro-intestinal obstruction, decreased lumen diameter of the gastro-intestinal tract, inflammatory bowel disease, or ileostomy after proctocolectomy.

● INTERACTIONS → Appendix 1: calcium channel blockers

● SIDE-EFFECTS

▶ Common or very common Asthenia • dizziness • gastro-intestinal disturbance • headache • hypotension • lethargy • oedema • palpitation • vasodilatation

▶ Uncommon Angioedema • anxiety • chills • dyspnœa • dysuria • epistaxis • erectile dysfunction • hypersensitivity reactions • jaundice • joint swelling • migraine • myalgia • nasal congestion • nocturia • paraesthesia • polyuria • pruritus • rash • sleep disturbance • sweating • syncope • tachycardia • tremor • urticaria • vertigo • visual disturbance

▶ Rare Anorexia • gum hyperplasia • hyperglycaemia • male infertility • mood disturbances • photosensitivity reactions • purpura

▶ Frequency not known Agranulocytosis • anaphylaxis • bezoar formation (with some modified-release preparations) • dysphagia • gynaecomastia • intestinal obstruction • intestinal ulcer

Overdose

In overdose, the dihydropyridine calcium-channel blockers cause severe hypotension secondary to profound peripheral vasodilatation.

● PREGNANCY May inhibit labour; manufacturer advises avoid before week 20, but risk to fetus should be balanced against risk of uncontrolled maternal hypertension. Use only if other treatment options are not indicated or have failed.

● BREAST FEEDING Amount too small to be harmful but manufacturers advise avoid.

● HEPATIC IMPAIRMENT Dose reduction may be required in severe liver disease.

Some modified-release formulations may not be suitable for dose titration in hepatic disease—consult product literature.

ADALAT LA Dose form not appropriate.

VALNI XL Dose form not appropriate.

● DIRECTIONS FOR ADMINISTRATION

FORTIPINE LA 40 Take with or just after food, or a meal.

● PRESCRIBING AND DISPENSING INFORMATION

Different versions of modified-release preparations may not have the same clinical effect. To avoid confusion between these different formulations of nifedipine, prescribers should specify the brand to be dispensed.

Palliative care

For further information on the use of nifedipine in palliative care, see www.palliativecare.org.uk/formulary/en/nifedipine.html.

● PATIENT AND CARER ADVICE

ADALAT LA Tablet membrane may pass through gastro-intestinal tract unchanged, but being porous has no effect on efficacy.

● MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

Modified-release tablet

CAUTIONARY AND ADVISORY LABELS 25

▶ Nifedipine (Non-proprietary)

Nifedipine 10 mg Nifedipine 10mg modified-release tablets | 56 tablet (Genus Pharmaceuticals Ltd) £8.40 DT price = £7.34

Nifedipine 20 mg Nifedipine 20mg modified-release tablets | 28 tablet (AMCo) £10.06

Nifedipine 30 mg Nifedipine 30mg modified-release tablets | 28 tablet (Bayer Plc) £6.85

Nifedipine 40 mg Nifedipine 40mg modified-release tablets | 30 tablet (Genus Pharmaceuticals Ltd) £14.40

Adalat LA (Bayer Plc)

Nifedipine 20 mg Adalat LA 20 tablets | 28 tablet (AMCo) £5.27

Nifedipine 30 mg Adalat LA 30 tablets | 28 tablet (AMCo) £6.85 DT price = £6.85

Nifedipine 60 mg Adalat LA 60 tablets | 28 tablet (AMCo) £9.03 DT price = £9.03

Adalat retard (Bayer Plc)

Nifedipine 10 mg Adalat retard 10mg tablets | 56 tablet (Genus Pharmaceuticals Ltd) £7.34 DT price = £7.34

Nifedipine 20 mg Adalat retard 20mg tablets | 56 tablet (Genus Pharmaceuticals Ltd) £8.81

Adipine MR (Chiesi Ltd)

Nifedipine 10 mg Adipine MR 10 tablets | 56 tablet (Chiesi Ltd) £3.73 DT price = £3.73

Nifedipine 20 mg Adipine MR 20 tablets | 56 tablet (Chiesi Ltd) £5.21

Adipine XL (Chiesi Ltd)

Nifedipine 30 mg Adipine XL 30mg tablets | 28 tablet (Chiesi Ltd) £6.85

Nifedipine 60 mg Adipine XL 60mg tablets | 28 tablet (Chiesi Ltd) £7.10 DT price = £7.03

Fortipine LA (AMCo)

Nifedipine 40 mg Fortipine LA 40 tablets | 30 tablet (AMCo) £14.40 DT price = £14.40

Nifedipress MR (Dexcel-Pharma Ltd)

Nifedipine 10 mg Nifedipress MR 10 tablets | 56 tablet (Dexcel-Pharma Ltd) £9.23 DT price = £7.34

Tensipine MR (Genus Pharmaceuticals Ltd)

Nifedipine 10 mg Tensipine MR 10 tablets | 56 tablet (Genus Pharmaceuticals Ltd) £3.65 DT price = £7.34

Nifedipine 20 mg Tensipine MR 20 tablets | 56 tablet (Genus Pharmaceuticals Ltd) £4.67

Valni XL (Zentiva)

Nifedipine 30 mg Valni XL 30mg tablets | 28 tablet (Zentiva) £9.14 DT price = £6.85

Downloaded from www.medicalbr.com
Verapamil hydrochloride

**INDICATIONS AND DOSE**

- **Treatment of supraventricular arrhythmias**
  - **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: 40–120 mg 3 times a day
  - **BY SLOW INTRAVENOUS INJECTION**
  - Adult: 5–10 mg, to be given over 2 minutes, preferably with ECG monitoring
  - Elderly: 5–10 mg, to be given over 3 minutes, preferably with ECG monitoring
- **Paroxysmal tachyarrhythmias**
  - **BY SLOW INTRAVENOUS INJECTION**
  - Adult: Initially 5–10 mg, followed by 5 mg after 5–10 minutes if required, to be given over 2 minutes, preferably with ECG monitoring
  - Elderly: Initially 5–10 mg, followed by 5 mg after 5–10 minutes if required, to be given over 3 minutes, preferably with ECG monitoring
- **Angina**
  - **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: 80–120 mg 3 times a day
- **Hypertension**
  - **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: 240–480 mg daily in 2–3 divided doses
- **Prophylaxis of cluster headache (initiated under specialist supervision)**
  - **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: 240–960 mg daily in 3–4 divided doses

**HALF SECURON® SR**

- **Hypertension (in patients new to verapamil)**
  - **BY MOUTH**
  - Adult: Initially 120 mg daily, increased if necessary to 240 mg daily
- **Hypertension**
  - **BY MOUTH**
  - Adult: 240 mg daily, increased if necessary up to 480 mg daily
- **Angina**
  - **BY MOUTH**
  - Adult: 240 mg twice daily, may sometimes be reduced to once daily

**UNLICENSED USE**

- With oral use Prophylaxis of cluster headaches is an unlicensed indication.

**CONTRA-INDICATIONS**

- Acute porphyrias p. 969 - atrial flutter or fibrillation associated with accessory conducting pathways (e.g. Wolff-Parkinson-White-syndrome) - bradycardia - cardiogenic shock - history of heart failure (even if controlled by therapy) - history of significantly impaired left ventricular function (even if controlled by...
therapy · hypotension · second- and third-degree AV block · sick sinus syndrome · sino-atrial block

- **CAUTIONS** Acute phase of myocardial infarction (avoid if bradycardia, hypotension, left ventricular failure) · first-degree AV block

- **INTERACTIONS** → Appendix 1: calcium channel blockers

- **SIDE-EFFECTS**
  - Common or very common Constipation
  - Uncommon Ankle oedema · dizziness · fatigue · flushing · headache · nausea · vomiting
  - Rare Allergic reactions · angioedema · arthralgia · astystole · bradycardia · erythema · erythromelalgia · gingival hyperplasia after long-term treatment · gynaecomastia · hypertension · increased prolactin concentration · myalgia · paraesthesia · pruritus · Stevens-Johnson syndrome · urticaria

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Intravenous administration or high doses · Hypotension, heart failure, bradycardia, heart block, and astystole are side-effects associated with intravenous administration or high doses.

- **OVERDOSE**
  - In overdose, verapamil has a profound cardiac depressant effect causing hypotension and arrhythmias, including complete heart block and asystole.

- **PREGNANCY** May reduce uterine blood flow with fetal hypoxia. Manufacturer advises avoid in first trimester unless absolutely necessary. May inhibit labour.

- **BREAST FEEDING** Amount too small to be harmful.

- **HEPATIC IMPAIRMENT** Oral dose may need to be reduced.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

- **Modified-release tablet**
  - CAUTIONARY AND ADVISORY LABELS 25

  - Half Securon (Mylan Ltd)
    - Verapamil hydrochloride 120 mg · Half Securon SR 120 mg tablets | 28 tablet (POD) £7.71 DT price = £7.71
  - Securon SR (Mylan Ltd)
    - Verapamil hydrochloride 240 mg · Securon SR 240 mg tablets | 28 tablet (POD) £5.55 DT price = £5.55
  - Verapress MR (Dexcel-Pharma Ltd)
    - Verapamil hydrochloride 240 mg · Verapress MR 240 mg tablets | 28 tablet (POD) £9.90 DT price = £5.55
  - Vertab SR (Chiesi Ltd)
    - Verapamil hydrochloride 240 mg · Vertab SR 240 tablets | 28 tablet (POD) £5.45 DT price = £5.55

- **Tablet**

  - Verapamil hydrochloride (Non-proprietary)
    - Verapamil hydrochloride 40 mg · Verapamil 40 mg tablets | 84 tablet (POD) £2.07 DT price = £1.63
    - Verapamil hydrochloride 80 mg · Verapamil 80 mg tablets | 84 tablet (POD) £2.33 DT price = £1.98
    - Verapamil hydrochloride 120 mg · Verapamil 120 mg tablets | 28 tablet (POD) £2.01 DT price = £1.48
    - Verapamil hydrochloride 160 mg · Verapamil 160 mg tablets | 56 tablet (POD) £3.84 DT price = £2.82

- **Solution for injection**
  - Securon (Mylan Ltd)
    - Verapamil hydrochloride 2.5 mg per 1 ml · Securon IV 5mg/2ml solution for injection ampoules | 5 ampoule (POD) £5.41

- **Modified-release capsule**
  - CAUTIONARY AND ADVISORY LABELS 25

  - EXCIPIENTS: May contain Propylene glycol
  - Univer (Teva UK Ltd)
    - Verapamil hydrochloride 120 mg · Univer 120 mg modified-release capsules | 28 capsule (POD) £4.86 DT price = £4.86
    - Verapamil hydrochloride 180 mg · Univer 180 mg modified-release capsules | 56 capsule (POD) £11.38 DT price = £11.38
    - Verapamil hydrochloride 240 mg · Univer 240 mg modified-release capsules | 28 capsule (POD) £7.67 DT price = £7.67

- **Oral solution**
  - Verapamil hydrochloride (Non-proprietary)
    - Verapamil hydrochloride 8 mg per 1 ml · Verapamil 40mg/5ml oral solution sugar free sugar-free | 150 ml (POD) £39.00 DT price = £39.00

- **DIURETICS**

  - **POTASSIUM-SPARING DIURETICS**

  - **Amiloride with cyclopenthiazide**

    - The properties listed below are those particular to the combination only. For the properties of the components please consider, amiloride hydrochloride p. 223, cyclopenthiazide p. 225.

  - **INDICATIONS AND DOSE**

    - **Hypertension**
      - BY MOUTH
      - Adult: 1–2 tablets daily, dose to be taken in the morning

  - **INTERACTIONS** → Appendix 1: potassium-sparing diuretics, thiazide diuretics

  - **MEDICINAL FORMS**

    - There can be variation in the licensing of different medicines containing the same drug.

    - **Tablet**
      - EXCIPIENTS: May contain Gluten
      - Navispare (AMCO)
        - Cyclopenthiazide 250 microgram, Amiloride hydrochloride 2.5 mg · Navispare 2.5mg/250microgram tablets | 28 tablet (POD) £3.24 DT price = £3.24

  - **DIURETICS**

    - **THIAZIDES AND RELATED DIURETICS**

    - **Thiazides and related diuretics**

      - **CONTRA-INDICATIONS** Addison’s disease · hypercalcaemia · hyponatraemia · refractory hypokalaemia · symptomatic hyperuricaemia

      - **CAUTIONS** Diabetes · gout · hyperaldosteronism · malnourishment · nephrotic syndrome · systemic lupus erythematosus

      - **CAUTIONS, FURTHER INFORMATION**

        - **Potassium loss** Hypokalaemia can occur with both thiazide and loop diuretics. The risk of hypokalaemia depends on the duration of action as well as the potency and is thus greater with thiazides than with an equipotent dose of a loop diuretic.

        - Hypokalaemia is dangerous in severe cardiovascular disease and in patients also being treated with cardiac glycosides. Often the use of potassium-sparing diuretics avoids the need to take potassium supplements.

        - Potassium supplements or potassium-sparing diuretics are seldom necessary when thiazides are used in the routine treatment of hypertension.

        - In hepatic failure, hypokalaemia caused by diuretics can precipitate encephalopathy, particularly in alcoholic cirrhosis.

        - Elderly Lower initial doses of diuretics should be used in the elderly because they are particularly susceptible to the side-effects. The dose should then be adjusted according to renal function. Diuretics should not be used continuously on a long-term basis to treat simple gravitational oedema (which will usually respond to increased movement, raising the legs, and support stockings).

        - Existing conditions Thiazides and related diuretics can exacerbate diabetes, gout, and systemic lupus erythematosus.

      - **SIDE-EFFECTS**

        - Common or very common Altered plasma-lipid concentrations · gout · hypercalcaemia · hyperglycaemia ·
hyperuricaemia • hypochloraemic alkalosis • hypokalaemia • hypomagnesaemia • hyponatraemia • metabolic and electrolyte disturbances • mild gastrointestinal disturbances • postural hypotension

- **Uncommon**
  - Agranulocytosis • blood disorders • impotence • leucopenia • thrombocytopenia

- **Frequency not known**
  - Cardiac arrhythmias • dizziness • headache • hypersensitivity reactions • intrahepatic cholestasis • pancreatitis • paraesthesia • photosensitivity • pneumonitis • pulmonary oedema • severe skin reactions • visual disturbances

- **PREGNANCY**
  - Thiazides and related diuretics should not be used to treat gestational hypertension. They may cause neonatal thrombocytopenia, bone marrow suppression, jaundice, electrolyte disturbances, and hypoglycaemia; placental perfusion may also be reduced. Stimulation of labour, uterine inertia, and meconium staining have also been reported.

- **HEPATIC IMPAIRMENT**
  - Caution in mild to moderate impairment. Avoid in severe liver disease. Hypokalaemia may precipitate coma in hepatic impairment, although hypokalaemia can be prevented by using a potassium-sparing diuretic. There is an increased risk of hypomagnesaemia in alcoholic cirrhosis.

- **RENAL IMPAIRMENT**
  - Thiazides and related diuretics are ineffective if eGFR is less than 30 mL/minute/1.73 m² and should be avoided. Metolazone remains effective if eGFR is less than 30 mL/minute/1.73 m² but is associated with a risk of excessive diuresis. Electrolytes should be monitored in renal impairment.

- **MONITORING REQUIREMENTS**
  - Electrolytes should be monitored, particularly with high doses and long-term use.

### Bendroflumethiazide

(Bendrofluazide)

- **INDICATIONS AND DOSE**

  - **Oedema**
    - Adult: Initially 5–10 mg once daily or on alternate days, dose to be taken in the morning, then maintenance 5–10 mg 1–3 times a week

  - **Hypertension**
    - Adult: 2.5 mg daily, dose to be taken in the morning, higher doses are rarely necessary

- **INTERACTIONS** → Appendix 1: thiazide diuretics

- **BREAST FEEDING**
  - The amount present in milk is too small to be harmful. Large doses may suppress lactation.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

  - **Tablet**
    - Bendroflumethiazide (Non-proprietary)
      - Bendroflumethiazide 2.5 mg: Bendroflumethiazide 2.5 mg tablets | 28 tablet [Pres] £3.65 DT price = £0.66 | 500 tablet [Pres] £21.85
      - Bendroflumethiazide 5 mg: Bendroflumethiazide 5 mg tablets | 28 tablet [Pres] £9.80 DT price = £0.86 | 500 tablet [Pres] no price available
      - Aprinox (AMCo)
        - Bendroflumethiazide 2.5 mg: Aprinox 2.5 mg tablets | 500 tablet [Pres] £27.31
      - Neo-Naclex (AMCo)
        - Bendroflumethiazide 2.5 mg: Neo-Naclex 2.5 mg tablets | 28 tablet [Pres] £0.33 DT price = £0.66

    Combinations available: **Timolol with bendroflumethiazide**, p. 146

- **CONTRA-INDICATIONS**
  - Anuria • hyperkalaemia

- **CAUTIONS**
  - Diabetes mellitus • elderly

- **SIDE-EFFECTS**
  - Abdominal pain • agitation • alopecia • angina • anorexia • arrhythmias • arthralgia • confusion • constipation • cough • diarrhoea • dizziness • dry mouth • dyspepsia • dysphoria • encephalopathy • fever • flatulence • flushing • gastro-intestinal bleeding • headache • hyperkalaemia • insomnia • jaundice • malaise • muscle cramp • nasal congestion • nausea • palpitation • paraesthesia • postural hypotension • pruritus • raised intra-ocular pressure • rash • respiratory distress • restlessness • sexual dysfunction • sweating • thirst • tinnitus • tremor • urinary disturbances • visual disturbance • vomiting • weakness

- **BREAST FEEDING**
  - Avoid—no information regarding amiloride component available. Amount of hydrochlorothiazide in milk probably too small to be harmful. Large doses of hydrochlorothiazide may suppress lactation.

- **RENAL IMPAIRMENT**
  - Manufacturers advise avoid in severe impairment. Monitor plasma-potassium concentration (high risk of hyperkalaemia in renal impairment).

- **MONITORING REQUIREMENTS**
  - Monitor electrolytes.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

  - **Tablet**
    - Co-amilozide (Non-proprietary)
      - Amiloride hydrochloride 2.5 mg, Hydrochlorothiazide 25 mg: Amiloride hydrochloride 2.5 mg tablets | 28 tablet [Pres] £6.05 DT price = £6.05
      - Amiloride hydrochloride 5 mg, Hydrochlorothiazide 50 mg: Amiloride hydrochloride 5 mg tablets | 28 tablet [Pres] £1.29 DT price = £1.02
      - Moduretic (Merck Sharp & Dohme Ltd)
        - Amiloride hydrochloride 2.5 mg, Hydrochlorothiazide 25 mg: Moduretic 25 tablets | 28 tablet [Pres] £0.86 DT price = £6.05
        - Amiloride hydrochloride 5 mg, Hydrochlorothiazide 50 mg: Moduretic 50 tablets | 28 tablet [Pres] £1.29 DT price = £1.02
Hydrochlorothiazide

- **INDICATIONS AND DOSE**
  
  Indications listed in combination monographs (available in the UK only in combination with other drugs)

  ▶ BY MOUTH
  
  ▶ Adult: Doses listed in combination monographs

- **INTERACTIONS** → Appendix 1: thiazide diuretics

- **MEDICINAL FORMS**
  
  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, oral suspension, oral solution


Indapamide

- **DRUG ACTION**
  
  Indapamide is a thiazide-like diuretic with antihypertensive effects. At lower doses, vasodilatation is more prominent than diuresis; the diuretic effect becomes more apparent with higher doses.

- **INDICATIONS AND DOSE**
  
  Essential hypertension

  ▶ BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

  ▶ Adult: 2.5 mg daily, dose to be taken in the morning

  ▶ BY MOUTH USING MODIFIED-RELEASE MEDICINES

  ▶ Adult: 1.5 mg daily, dose to be taken preferably in the morning

- **CAUTIONS**
  
  Acute porphyrias p. 969

- **INTERACTIONS** → Appendix 1: thiazide diuretics

- **SIDE-EFFECTS**
  
  Diuresis (with doses above 2.5 mg daily) · palpitation

- **ALLERGY AND CROSS-SENSITIVITY**
  
  Contra-indicated if history of hypersensitivity to sulphonamides.

- **BREAST FEEDING**
  
  Present in milk—manufacturer advises avoid.

- **MEDICINAL FORMS**
  
  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension · modified-release tablet

  **CAUTIONARY AND ADVISORY LABELS** 25

  ▶ Indapamide (Non-proprietary)

  ▶ Indapamide 1.5 mg Indapamide 1.5mg modified-release tablets | 30 tablet POM £3.40 DT price = £3.40

  ▶ Cardide SR (Teva UK Ltd)

  ▶ Indapamide 1.5 mg Cardide SR 1.5mg tablets | 30 tablet POM £4.32 DT price = £3.40

  ▶ Indipam XL (Actavis UK Ltd)

  ▶ Indapamide 1.5 mg Indipam XL 1.5mg tablets | 30 tablet POM £4.32 DT price = £3.40

  ▶ Natrilix SR (Servier Laboratories Ltd)

  ▶ Indapamide 1.5 mg Natrilix SR 1.5mg tablets | 30 tablet POM £3.40 DT price = £3.40

  ▶ Rawel XL (Consilient Health Ltd)

  ▶ Indapamide 1.5 mg Rawel XL 1.5mg tablets | 30 tablet POM £2.89 DT price = £3.40

- **Tensaid XL (Mylan Ltd)**

  ▶ Indapamide 1.5 mg Tensaid XL 1.5mg tablets | 30 tablet POM £3.40 DT price = £3.40

Tablet

- **Indapamide (Non-proprietary)**

  ▶ Indapamide hemihydrate 2.5 mg Indapamide 2.5mg tablets | 28 tablet POM £40.99 DT price = £1.07 | 30 tablet POM £27.99 | 56 tablet POM £12.68

  ▶ Natrilix (Servier Laboratories Ltd)

  ▶ Indapamide hemihydrate 2.5 mg Natrilix 2.5mg tablets | 30 tablet POM £3.40 | 60 tablet POM £6.80

- **Combinations available:** Perindopril arginine with indapamide, p. 167

**DRUGS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM** → ACE INHIBITORS

Angiotensin-converting enzyme inhibitors

- **CONTRA-INDICATIONS**
  
  The combination of an ACE inhibitor with aliskiren is contra-indicated in patients with an eGFR less than 60 mL/minute/1.73 m² · the combination of an ACE inhibitor with aliskiren is contra-indicated in patients with diabetes mellitus

- **CAUTIONS**
  
  Afro-Caribbean patients (may respond less well to ACE inhibitors) · concomitant diuretics · diabetes (may lower blood glucose) · first dose hypotension (especially in patients taking high doses of diuretics, on a low-sodium diet, on dialysis, dehydrated, or with heart failure) · peripheral vascular disease or generalised atherosclerosis (risk of clinically silent renovascular disease) · primary aldosteronism (patients may respond less well to ACE inhibitors) · the risk of agranulocytosis is possibly increased in collagen vascular disease (blood counts recommended) · use with care (or avoid) in those with a history of idiopathic or hereditary angioedema · use with care in patients with hypertrophic cardiomyopathy · use with care in patients with severe or symptomatic aortic stenosis (risk of hypotension)

- **CAUTIONS, FURTHER INFORMATION**
  
  Anaphylactoid reactions To prevent anaphylactoid reactions, ACE inhibitors should be avoided during dialysis with high-flux polycrylicnitrile membranes and during low-density lipoprotein apheresis with dextran sulfate; they should also be withheld before desensitisation with wasp or bee venom.

- **SIDE-EFFECTS**
  
  Pruritus · abdominal pain · altered liver function tests · angioedema (onset may be delayed; higher incidence reported in Afro-Caribbean patients) · arthralgia · blood disorders · bronchospasm · cholestatic jaundice · constipation · diarrhoea · dizziness · dyspepsia · eosinophilia · fatigue · fever · fulminant hepatic necrosis · haemolytic anaemia · headache · hepatic failure · hepatitis · hyperkalaemia · hypoglycaemia · leucocytosis · leucopenia · malaise · myalgia · nausea · neutropenia · pancreatitis · paraesthesia · persistent dry cough · photosensitivity · positive antinuclear antibody · profound hypotension · raised erythrocyte sedimentation rate · rash · renal impairment · rhinitis · serositis · sinusitis · sore throat · taste disturbance · thrombocytopenia · urticaria · vasculitis · vomiting

- **SIDE-EFFECTS, FURTHER INFORMATION**
  
  Hepatic effects In light of reports of cholestatic jaundice, hepatitis, fulminant hepatic necrosis, and hepatic failure, ACE inhibitors should be discontinued if marked elevation of hepatic enzymes or jaundice occur.

- **ALLERGY AND CROSS-SENSITIVITY**
  
  ACE inhibitors are contra-indicated in patients with hypersensitivity to ACE inhibitors (including angioedema).
Captopril

### INDICATIONS AND DOSE

**Hypertension**

- **BY MOUTH**
  - Adult: Initially 12.5–25 mg twice daily, then increased if necessary up to 150 mg daily in 2 divided doses, doses to be increased at intervals of at least 2 weeks, once-daily dosing may be appropriate if other concomitant antihypertensive drugs taken
  - Elderly: Initially 6.25 mg twice daily, then increased if necessary up to 150 mg daily in 2 divided doses, doses to be increased at intervals of at least 2 weeks, once-daily dosing may be appropriate if other concomitant antihypertensive drugs taken

**Essential hypertension if used in volume depletion, cardiac decompensation, or renovascular hypertension**

- **BY MOUTH**
  - Adult: Initially 6.25–12.5 mg for 1 dose (under close medical supervision), then 6.25–12.5 mg twice daily; increased if necessary up to 100 mg daily in 1–2 divided doses, doses to be increased at intervals of at least 2 weeks, once-daily dosing may be appropriate if other concomitant antihypertensive drugs taken

**Heart failure**

- **BY MOUTH**
  - Adult: Initially 6.25–12.5 mg 2–3 times daily, then increased if tolerated to up to 150 mg daily in divided doses, dose to be increased gradually at intervals of at least 2 weeks

**Short-term treatment within 24 hours of onset of myocardial infarction in clinically stable patients**

- **BY MOUTH**
  - Adult: Initially 6.25 mg, then increased to 12.5 mg after 2 hours, followed by 25 mg after 12 hours; increased if tolerated to 50 mg twice daily for 4 weeks

**Prophylaxis of symptomatic heart failure after myocardial infarction in clinically stable patients with asymptomatic left ventricular dysfunction (starting 3–16 days after infarction) (under close medical supervision)**

- **BY MOUTH**
  - Adult: Initially 6.25 mg daily, then increased to 12.5 mg 3 times a day for 2 days, then increased if tolerated to 25 mg 3 times a day, then increased if tolerated to 75–150 mg daily in 2–3 divided doses, doses exceeding 75 mg per day to be increased gradually

**Diabetic nephropathy in type 1 diabetes mellitus**

- **BY MOUTH**
  - Adult: 75–100 mg daily in divided doses

### INTERACTIONS

- Appendix 1: ACE inhibitors

### SIDE-EFFECTS

- **Common or very common**
  - Alopecia · dry mouth · dyspnoea · sleep disorder

- **Uncommon**
  - Angina · arrhythmia · flushing · pallor · palpitation · Raynaud’s syndrome · tachycardia

- **Rare**
  - Anorexia · stomatitis

- **Very rare**
  - Allergic alveolitis · blurred vision · cardiac arrest · cardiogenic shock · cerebrovascular events · confusion · depression · eosinophilic pneumonia · glossitis · gynaeacomastia · hyponatraemia · impotence · peptic ulcer · photosensitivity · Stevens-Johnson syndrome · syncope

### BREAST FEEDING

Avoid in first few weeks after delivery, particularly in preterm infants—risk of profound neonatal hypotension; can be used in mothers breast-feeding older infants if essential but monitor infant’s blood pressure.

### RENAL IMPAIRMENT

Reduce dose; max. initial dose 50 mg if eGFR above 40 ml/minute/1.73 m²; max. initial dose 25 mg daily (do not exceed 100 mg daily) if eGFR 20–40 ml/minute/1.73 m²; max. initial dose 12.5 mg daily (do not exceed 75 mg daily) if eGFR 10–20 ml/minute/1.73 m²; max. initial dose 6.25 mg daily (do not exceed 37.5 mg daily) if eGFR less than 10 ml/minute/1.73 m².

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, capsule, oral suspension, oral solution

#### Tablet

- **Captopril (Non-proprietary)**
  - Captopril 12.5 mg Captopril 12.5mg tablets | 56 tablet [P] £2.80 DT price = £2.44 | 100 tablet [P] £5.00
  - Captopril 25 mg Captopril 25mg tablets | 56 tablet [P] £4.52 DT price = £0.92 | 100 tablet [P] £8.07
  - Captopril 50 mg Captopril 50mg tablets | 56 tablet [P] £5.83 DT price = £2.47 | 100 tablet [P] £10.41
  - Capoten (Bristol-Myers Squibb Pharmaceuticals Ltd)
    - Captopril 25 mg Capoten 25mg tablets | 28 tablet [P] £5.26
  - Ecopace (AMCO)
    - Captopril 12.5 mg Ecopace 12.5mg tablets | 56 tablet [P] £0.48 DT price = £2.44
    - Captopril 25 mg Ecopace 25mg tablets | 56 tablet [P] £0.60 DT price = £0.92
    - Captopril 50 mg Ecopace 50mg tablets | 56 tablet [P] £0.72 DT price = £2.47

#### Oral solution

**ELECTROLYTES:** May contain Sodium

- **Noyada** (Martindale Pharmaceuticals Ltd)
  - Captopril 1 mg per 1 ml Noyada 5mg/5ml oral solution sugar-free | 100 ml [P] £98.21 DT price = £98.21
  - Captopril 5 mg per 1 ml Noyada 25mg/5ml oral solution sugar-free | 100 ml [P] £108.94 DT price = £108.94

### Co-zidocapt

The properties listed below are those particular to the combination only. For the properties of the components please consider, captopril above, hydrochlorothiazide p. 162.

#### INDICATIONS AND DOSE

**Mild to moderate hypertension in patients stabilised on the individual components in the same proportions**

- **BY MOUTH**
  - Adult: (consult product literature)

#### INTERACTIONS

- Appendix 1: ACE inhibitors, thiazide diuretics
Enalapril maleate

**INDICATIONS AND DOSE**

**Hypertension**

- **BY MOUTH**
  - Adult: Initially 5 mg once daily, lower initial doses may be required when used in addition to diuretics or in renal impairment; maintenance 20 mg once daily; maximum 40 mg per day

**Heart failure**

- **BY MOUTH**
  - Adult (under close medical supervision): Initially 2.5 mg once daily, increased if tolerated to 10–20 mg twice daily, dose to be increased gradually over 2–4 weeks

**Prevention of symptomatic heart failure in patients with asymptomatic left ventricular dysfunction**

- **BY MOUTH**
  - Adult (under close medical supervision): Initially 2.5 mg once daily, increased if tolerated to 10–20 mg twice daily, dose to be increased gradually over 2–4 weeks

**SIDE-EFFECTS**

- **Common or very common** Asthenia, blurred vision, depression, dyspepsia
- **Uncommon** Alopecia, anorexia, arrhythmias, confusion, drowsiness, dry mouth, flushing, hyponatraemia, ileus, impotence, insomnia, muscle cramps, nervousness, palpitation, peptic ulcer, sweating, tinnitus, vertigo
- **Rare** Abnormal dreams, allergic alveolitis, exfoliative dermatitis, glossitis, gynaecomastia, pempigus, pulmonary infiltrates, Raynaud's syndrome, Stevens-Johnson syndrome, stomatitis, toxic epidermal necrolysis
- **Very rare** Gastro-intestinal angioedema

**BREAST FEEDING**

Avoid in first few weeks after delivery, particularly in preterm infants—risk of profound neonatal hypotension; can be used in mothers breast-feeding older infants if essential but monitor infant's blood pressure.

**HEPATIC IMPAIRMENT**

Enalapril is a prodrug and requires close monitoring in patients with hepatic impairment.

**RENAL IMPAIRMENT**

Max. initial dose 2.5 mg daily if eGFR less than 30 mL/minute/1.73 m².

**DIRECTIONS FOR ADMINISTRATION**

Tablets may be crushed and suspended in water immediately before use.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Tablet**

- **Enalapril maleate (Non-proprietary)**
  - Enalapril maleate 2.5 mg Enalapril 2.5mg tablets | 28 tablet £5.65 DT price = £3.46
  - Enalapril maleate 5 mg Enalapril 5mg tablets | 28 tablet £9.13 DT price = £0.84
  - Enalapril maleate 10 mg Enalapril 10mg tablets | 28 tablet £18.74 DT price = £0.90
  - Enalapril maleate 20 mg Enalapril 20mg tablets | 28 tablet £35.63 DT price = £0.98

---

**Enalapril with hydrochlorothiazide**

The properties listed below are those particular to the combination only. For the properties of the components please consider, enalapril maleate above, hydrochlorothiazide p. 162.

**INDICATIONS AND DOSE**

Mild to moderate hypertension in patients stabilised on the individual components in the same proportions

- **BY MOUTH**
  - Adult: (consult product literature)

**INTERACTIONS**

Appendix 1: ACE inhibitors, thiazide diuretics

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Enalapril with hydrochlorothiazide (Non-proprietary)**
  - Hydrochlorothiazide 12.5 mg, Enalapril maleate 20 mg Enalapril 20mg / Hydrochlorothiazide 12.5mg tablets | 28 tablet £60.00 DT price = £19.98
- **Innozide** (Merck Sharp & Dohme Ltd)
  - Hydrochlorothiazide 12.5 mg, Enalapril maleate 20 mg Innozide 20mg/12.5mg tablets | 28 tablet £13.90 DT price = £19.98

---

**Fosinopril sodium**

**INDICATIONS AND DOSE**

**Hypertension**

- **BY MOUTH**
  - Adult: Initially 10 mg daily for 4 weeks, then increased if necessary up to 40 mg daily, doses over 40 mg not shown to increase efficacy

**Congestive heart failure (adjunct) (under close medical supervision)**

- **BY MOUTH**
  - Adult: Initially 10 mg once daily, then increased if tolerated to 40 mg once daily, doses to be increased gradually

**INTERACTIONS**

Appendix 1: ACE inhibitors

**SIDE-EFFECTS**

Chest pain, musculoskeletal pain

**BREAST FEEDING**

Not recommended; alternative treatment options, with better established safety information during breast-feeding, are available.

**HEPATIC IMPAIRMENT**

Fosinopril is a prodrug and requires close monitoring in patients with hepatic impairment.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Tablet**

- **Fosinopril sodium (Non-proprietary)**
  - Fosinopril sodium 10 mg Fosinopril 10mg tablets | 28 tablet £28.50 DT price = £7.87
  - Fosinopril sodium 20 mg Fosinopril 20mg tablets | 28 tablet £38.98 DT price = £7.07
**Imidapril hydrochloride**

### INDICATIONS AND DOSE

#### Essential hypertension

- **BY MOUTH**
  - Adult: Initially 5 mg daily, increased if necessary to 10 mg daily, dose to be taken before food, doses to be increased at intervals of at least 3 weeks; maximum 20 mg per day
  - Elderly: Initially 2.5 mg daily, increased if necessary to 10 mg daily, dose to be taken before food, doses to be increased at intervals of at least 3 weeks

#### Renal impairment

- Initial dose 2.5 mg daily if eGFR 30–80 mL/minute/1.73 m². Avoid if eGFR less than 30 mL/minute/1.73 m².

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- **Tanatril** (Mitsubishi Tanabe Pharma Europe Ltd)
  - Imidapril hydrochloride 5 mg Tanatril 5mg tablets | 28 tablet [PO] £6.40 DT price = £6.40
  - Imidapril hydrochloride 10 mg Tanatril 10mg tablets | 28 tablet [PO] £7.22 DT price = £7.22
  - Imidapril hydrochloride 20 mg Tanatril 20mg tablets | 28 tablet [PO] £8.67 DT price = £8.67

**Lisinopril**

### INDICATIONS AND DOSE

#### Hypertension

- **BY MOUTH**
  - Adult: Initially 10 mg once daily; usual maintenance 20 mg once daily; maximum 80 mg per day

#### Hypertension, when used in addition to diuretic, in cardiac decompensation or in volume depletion

- **BY MOUTH**
  - Adult: Initially 2.5–5 mg once daily; usual maintenance 20 mg once daily; maximum 80 mg per day

#### Short-term treatment following myocardial infarction in haemodynamically stable patients—systolic blood pressure over 120 mmHg

- **BY MOUTH**
  - Adult: Initially 5 mg, taken within 24 hours of myocardial infarction, followed by 5 mg, to be taken 24 hours after initial dose, then 10 mg, to be taken 24 hours after second dose, then 10 mg once daily for 6 weeks (or continued if heart failure), temporarily reduce maintenance dose to 5 mg and if necessary 2.5 mg daily if systolic blood pressure 100 mmHg or less during treatment; withdraw if prolonged hypotension occurs during treatment (systolic blood pressure less than 90 mmHg for more than 1 hour)

#### Short-term treatment following myocardial infarction in haemodynamically stable patients—systolic blood pressure 100–120 mmHg

- **BY MOUTH**
  - Adult: Initially 2.5 mg once daily, maintenance 5 mg once daily, increase to maintenance dose only after at least 3 days of the initial dose, should not be started after myocardial infarction if systolic blood pressure less than 100 mmHg, temporarily reduce maintenance dose to 2.5 mg daily if systolic blood pressure 100 mmHg or less during treatment; withdraw if prolonged hypotension occurs (systolic blood pressure less than 90 mmHg for more than 1 hour)

#### Renal complications of diabetes mellitus

- **BY MOUTH**
  - Adult: Initially 2.5–5 mg once daily, adjusted according to response; usual dose 10–20 mg once daily

### SIDE-EFFECTS

- **INTERACTIONS** → Appendix 1: ACE inhibitors
- **SIDE-EFFECTS** Blurred vision · bronchitis · confusion · depression · dry mouth · dyspnoea · glositis · ileus · impotence · sleep disturbances · tinnitus
- **BREAST FEEDING** Not recommended; alternative treatment options, with better established safety information during breast-feeding, are available.
- **HEPATIC IMPAIRMENT** Imidapril is a prodrug and requires close monitoring in patients with hepatic impairment.

### INTERACTIONS

- **INTERACTIONS** → Appendix 1: ACE inhibitors
- **SIDE-EFFECTS** Uncommon Raynaud’s syndrome · vertigo · asthma · cerebrovascular accident · confusion · impotence · mood changes · myocardial infarction · palpitation · sleep disturbances · tachycardia
- **Rare** Alopecia · dry mouth · gynaecostasia · psoriasis
- **Very rare** Allergic alveolitis · pemphigus · profuse sweating · pulmonary infiltrates · Stevens-Johnson syndrome · toxic epidermal necrolysis
- **BREAST FEEDING** Not recommended; alternative treatment options, with better established safety information during breast-feeding, are available.

#### Renal impairment

- Max. initial doses 5–10 mg daily if eGFR 30–80 mL/minute/1.73 m² (max. 40 mg daily); 2.5–5 mg daily if eGFR 10–30 mL/minute/1.73 m² (max. 40 mg daily); 2.5 mg daily if eGFR less than 10 mL/minute/1.73 m².

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

#### Oral solution

- **Lisinopril (Non-proprietary)**
  - Lisinopril 1 mg per 1 ml Lisinopril 5mg/5ml oral solution sugar free sugar-free | 150 ml [PO] £154.11 DT price = £154.11

### Tablet

- **Lisinopril (Non-proprietary)**
  - Lisinopril 2.5 mg Lisinopril 2.5mg tablets | 28 tablet [PO] £1.51 DT price = £0.71
  - Lisinopril 5 mg Lisinopril 5mg tablets | 28 tablet [PO] £7.80 DT price = £0.73
  - Lisinopril 10 mg Lisinopril 10mg tablets | 28 tablet [PO] £9.60 DT price = £0.79
  - Lisinopril 20 mg Lisinopril 20mg tablets | 28 tablet [PO] £10.90 DT price = £0.83
  - Zestril (AstraZeneca UK Ltd)
    - Lisinopril 5 mg Zestril 5mg tablets | 28 tablet [PO] £4.71 DT price = £0.73
    - Lisinopril 10 mg Zestril 10mg tablets | 28 tablet [PO] £7.38 DT price = £0.79
    - Lisinopril 20 mg Zestril 20mg tablets | 28 tablet [PO] £6.51 DT price = £0.83
## Lisinopril with hydrochlorothiazide

The properties listed below are those particular to the combination only. For the properties of the components please consider, lisinopril p. 165, hydrochlorothiazide p. 162.

### INDICATIONS AND DOSE

**Mild to moderate hypertension in patients stabilised on the individual components in the same proportions**

- **BY MOUTH**
- **Adult:** (consult product literature)

### INTERACTIONS

→ Appendix 1: ACE inhibitors, thiazide diuretics

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

#### Tablet

- **Lisinopril with hydrochlorothiazide (Non-proprietary)**
  - Lisinopril 10 mg, Hydrochlorothiazide 12.5 mg
    - Perindopril 2.5 mg, Hydrochlorothiazide 12.5mg tablets: 28 tablet (\textit{Pmd}) £12.99 DT price = £4.99
  - Hydrochlorothiazide 12.5 mg, Lisinopril 20 mg
    - Perindopril 10 mg, Hydrochlorothiazide 12.5mg tablets: 28 tablet (\textit{Pmd}) £14.65 DT price = £1.82
  - Carace Plus (Merk Sharp & Dohme Ltd)
    - Hydrochlorothiazide 12.5 mg, Lisinopril 20 mg, Carace Plus 20 tablets: 28 tablet (\textit{Pmd}) £11.43 DT price = £1.82
  - Zestoretic 10 (AstraZeneca UK Ltd)
    - Lisinopril 10 mg, Hydrochlorothiazide 12.5 mg, Zestoretic 10 tablets: 28 tablet (\textit{Pmd}) £6.81 DT price = £4.99
  - Zestoretic 20 (AstraZeneca UK Ltd)
    - Hydrochlorothiazide 12.5 mg, Lisinopril 20 mg, Zestoretic 20 tablets: 28 tablet (\textit{Pmd}) £11.52 DT price = £1.82

## Moexipril hydrochloride

### INDICATIONS AND DOSE

**Essential hypertension (monotherapy)**

- **BY MOUTH**
  - **Adult:** Initially 7.5 mg once daily, adjusted according to response; maintenance 7.5–15 mg once daily; maximum 30 mg per day
  - **Elderly:** Initially 3.75 mg once daily, adjusted according to response; maintenance 7.5–15 mg once daily; maximum 30 mg per day

**Essential hypertension when used in addition with nifedipine or other antihypertensive drug**

- **BY MOUTH**
  - **Adult:** Initially 3.75 mg once daily, adjusted according to response; maintenance 7.5–15 mg once daily; maximum 30 mg per day

### CAUTIONS

Significant mitral valve stenosis

### INTERACTIONS

→ Appendix 1: ACE inhibitors

### SIDE-EFFECTS

- Very rare: Numbness
- Frequency not known: Alopecia, angina, appetite, arrhythmias, blurred vision, cerebrovascular accident, confusion, depression, drowsiness, dry mouth, dysphonia, flushing, hyperuricaemia, impotence, myocardial infarction, palpitation, pephigus, sleep disturbance, Stevens-Johnson syndrome, sweating, syncope, tachycardia, tinnitus, toxic epidermal necrolysis, weight changes

### BREAST FEEDING

Not recommended; alternative treatment options, with better established safety information during breast-feeding, are available.

### HEPATIC IMPAIRMENT

Initial dose 3.75 mg once daily. Moexipril is a prodrug and requires close monitoring in patients with hepatic impairment.

### RENAL IMPAIRMENT

If eGFR less than 40 mL/minute/1.73 m², initial dose 3.75 mg once daily titrated to max. 15 mg once daily.

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

#### Tablet

CAUTIONARY AND ADVISORY LABELS 22

- **Coversyl Arginine** (Servier Laboratories Ltd)
  - Perindopril arginine 2.5 mg, Hydrochlorothiazide 12.5mg tablets: 28 tablet (\textit{Pmd}) £4.43 DT price = £4.43
  - Perindopril arginine 5 mg, Hydrochlorothiazide 12.5mg tablets: 28 tablet (\textit{Pmd}) £6.28 DT price = £6.28
  - Perindopril arginine 10 mg, Hydrochlorothiazide 12.5mg tablets: 28 tablet (\textit{Pmd}) £10.65 DT price = £10.65

## Perindopril arginine

### INDICATIONS AND DOSE

**Hypertension**

- **BY MOUTH**
  - **Adult:** Initially 2.5 mg once daily for 1 month, dose to be taken in the morning, then, adjusted according to response; maximum 10 mg per day
  - **Elderly:** Initially 2.5 mg once daily for 1 month, dose to be taken in the morning, then, adjusted according to response; maximum 10 mg per day

**Hypertension, if used in addition to diuretic, or in cardiac decompensation or volume depletion**

- **BY MOUTH**
  - **Adult:** Initially 2.5 mg once daily for 1 month, dose to be taken in the morning, then, adjusted according to response; maximum 10 mg per day

**Symptomatic heart failure (adjunct) (under close medical supervision)**

- **BY MOUTH**
  - **Adult:** Initially 2.5 mg once daily for 2 weeks, then increased if tolerated to 5 mg once daily, dose to be taken in the morning

**Prophylaxis of cardiac events following myocardial infarction or revascularisation in stable coronary artery disease**

- **BY MOUTH**
  - **Adult:** Initially 5 mg once daily for 2 weeks, then increased if tolerated to 10 mg once daily, dose to be taken in the morning
  - **Elderly:** Initially 2.5 mg once daily for 1 week, then increased if tolerated to 5 mg once daily for 1 week, then increased if tolerated to 10 mg once daily, dose to be taken in the morning

### INTERACTIONS

→ Appendix 1: ACE inhibitors

### SIDE-EFFECTS

Asthenia, mood disturbances, sleep disturbances

### HEPATIC IMPAIRMENT

Perindopril is a prodrug and requires close monitoring in patients with hepatic impairment.

### RENAL IMPAIRMENT

Max. initial dose 2.5 mg once daily if eGFR 30–60 mL/minute/1.73 m²; 2.5 mg once daily on alternate days if eGFR 15–30 mL/minute/1.73 m².

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

#### Tablet

- **Coversyl Arginine** (Servier Laboratories Ltd)
  - Perindopril arginine 2.5 mg, Hydrochlorothiazide tablets: 28 tablet (\textit{Pmd}) £4.43 DT price = £4.43
  - Perindopril arginine 5 mg, Hydrochlorothiazide tablets: 28 tablet (\textit{Pmd}) £6.28 DT price = £6.28
  - Perindopril arginine 10 mg, Hydrochlorothiazide tablets: 28 tablet (\textit{Pmd}) £10.65 DT price = £10.65
**Perindopril arginine with indapamide**

The properties listed below are those particular to the combination only. For the properties of the components please consider, perindopril arginine p. 166, indapamide p. 162.

#### INDICATIONS AND DOSE

**Hypertension not adequately controlled by perindopril alone**

- **BY MOUTH**
- **Adult:** (consult product literature)

#### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>22</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perindopril erbumine (Non-proprietary)</td>
<td></td>
</tr>
<tr>
<td>Perindopril erbumine 2 mg</td>
<td>Perindopril erbumine 2mg tablets</td>
</tr>
<tr>
<td>Perindopril erbumine 4 mg</td>
<td>Perindopril erbumine 4mg tablets</td>
</tr>
<tr>
<td>Perindopril erbumine 8 mg</td>
<td>Perindopril erbumine 8mg tablets</td>
</tr>
</tbody>
</table>

**INDICATIONS AND DOSE**

**Hypertension**

- **BY MOUTH**
- **Adult:** Initially 4 mg once daily for 1 month, dose to be taken in the morning, then, adjusted according to response; maximum 8 mg per day
- **BY MOUTH**
- **Elderly:** Initially 2 mg once daily for 1 month, dose to be taken in the morning, then, adjusted according to response; maximum 8 mg per day

**Heart failure (adjunct) (under close medical supervision)**

- **BY MOUTH**
- **Adult:** Initially 2 mg once daily for at least 2 weeks, dose to be taken in the morning, then increased if tolerated to 4 mg once daily

**Prophylaxis of cardiac events following myocardial infarction or revascularisation in stable coronary artery disease**

- **BY MOUTH**
- **Adult:** Initially 4 mg once daily for 2 weeks, dose to be taken in the morning, then increased if tolerated to 8 mg once daily
- **Elderly:** Initially 2 mg once daily for 1 week, then increased if tolerated to 4 mg once daily for 1 week, then increased if tolerated to 8 mg once daily

#### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>22</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perindopril erbumine (Non-proprietary)</td>
<td></td>
</tr>
<tr>
<td>Perindopril erbumine 2 mg</td>
<td>Perindopril erbumine 2mg tablets</td>
</tr>
<tr>
<td>Perindopril erbumine 4 mg</td>
<td>Perindopril erbumine 4mg tablets</td>
</tr>
<tr>
<td>Perindopril erbumine 8 mg</td>
<td>Perindopril erbumine 8mg tablets</td>
</tr>
</tbody>
</table>

**INDICATIONS AND DOSE**

**Essential hypertension**

- **BY MOUTH**
- **Adult:** Initially 10 mg once daily; maintenance 20–40 mg daily in up to 2 divided doses; maximum 80 mg per day
- **Elderly:** Initially 2.5 mg once daily; maintenance 20–40 mg daily in up to 2 divided doses; maximum 80 mg per day

**Essential hypertension if used in addition to diuretic**

- **BY MOUTH**
- **Adult:** Initially 2.5 mg once daily; maintenance 20–40 mg daily in up to 2 divided doses; maximum 80 mg per day

**Heart failure (adjunct) (under close medical supervision)**

- **BY MOUTH**
- **Adult:** Initially 2.5 mg daily, increased if tolerated to 10–20 mg daily in 1–2 divided doses, doses to be increased gradually; maximum 40 mg per day

#### INTERACTIONS

- **Appendix 1: ACE inhibitors**

#### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>22</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quinapril (as Quinapril hydrochloride) 5 mg</td>
<td>Quinapril 5mg tablets</td>
</tr>
<tr>
<td>Quinapril (as Quinapril hydrochloride) 10 mg</td>
<td>Quinapril 10mg tablets</td>
</tr>
<tr>
<td>Quinapril (as Quinapril hydrochloride) 20 mg</td>
<td>Quinapril 20mg tablets</td>
</tr>
<tr>
<td>Quinapril (as Quinapril hydrochloride) 40 mg</td>
<td>Quinapril 40mg tablets</td>
</tr>
<tr>
<td>Accupro (Pfizer Ltd)</td>
<td></td>
</tr>
<tr>
<td>Quinapril (as Quinapril hydrochloride) 5 mg</td>
<td>Accupro 5mg tablets</td>
</tr>
<tr>
<td>Quinapril (as Quinapril hydrochloride) 10 mg</td>
<td>Accupro 10mg tablets</td>
</tr>
<tr>
<td>Quinapril (as Quinapril hydrochloride) 20 mg</td>
<td>Accupro 20mg tablets</td>
</tr>
</tbody>
</table>

**INDICATIONS AND DOSE**

**Essential hypertension**

- **BY MOUTH**
- **Adult:** Initially 10 mg once daily; maintenance 20–40 mg daily in up to 2 divided doses; maximum 80 mg per day
- **Elderly:** Initially 2.5 mg once daily; maintenance 20–40 mg daily in up to 2 divided doses; maximum 80 mg per day

**Heart failure (adjunct) (under close medical supervision)**

- **BY MOUTH**
- **Adult:** Initially 2.5 mg daily, increased if tolerated to 10–20 mg daily in 1–2 divided doses, doses to be increased gradually; maximum 40 mg per day

#### INTERACTIONS

- **Appendix 1: ACE inhibitors**

#### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>22</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quinapril (as Quinapril hydrochloride) 5 mg</td>
<td>Quinapril 5mg tablets</td>
</tr>
<tr>
<td>Quinapril (as Quinapril hydrochloride) 10 mg</td>
<td>Quinapril 10mg tablets</td>
</tr>
<tr>
<td>Quinapril (as Quinapril hydrochloride) 20 mg</td>
<td>Quinapril 20mg tablets</td>
</tr>
<tr>
<td>Quinapril (as Quinapril hydrochloride) 40 mg</td>
<td>Quinapril 40mg tablets</td>
</tr>
<tr>
<td>Accupro (Pfizer Ltd)</td>
<td></td>
</tr>
<tr>
<td>Quinapril (as Quinapril hydrochloride) 5 mg</td>
<td>Accupro 5mg tablets</td>
</tr>
<tr>
<td>Quinapril (as Quinapril hydrochloride) 10 mg</td>
<td>Accupro 10mg tablets</td>
</tr>
<tr>
<td>Quinapril (as Quinapril hydrochloride) 20 mg</td>
<td>Accupro 20mg tablets</td>
</tr>
</tbody>
</table>
Quinapril with hydrochlorothiazide

The properties listed below are those particular to the combination only. For the properties of the components please consider, quinapril p. 167, hydrochlorothiazide p. 162.

**INDICATIONS AND DOSE**

Hypertension in patients stabilised on the individual components in the same proportions
- **BY MOUTH**
- Adult: (consult product literature)

**INTERACTIONS** → Appendix 1: ACE inhibitors, thiazide diuretics

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- Quinapril with hydrochlorothiazide (Non-proprietary)
  - Quinapril (as Quinapril hydrochloride) 10 mg, Hydrochlorothiazide 12.5 mg Quinapril 10mg / Hydrochlorothiazide 12.5mg tablets | 28 tablet [Pom] £11.75 DT price = £11.75
  - Accuretic (Pfizer Ltd)
  - Quinapril (as Quinapril hydrochloride) 10 mg, Hydrochlorothiazide 12.5 mg Accuretic 12.5mg/10mg tablets | 28 tablet [Pom] £11.75 DT price = £11.75

Ramipril

**INDICATIONS AND DOSE**

Hypertension
- **BY MOUTH**
- Adult: Initially 1.25–2.5 mg once daily, increased if necessary up to 10 mg once daily, dose to be increased at intervals of 2–4 weeks

Symptomatic heart failure (adjunct) (under close medical supervision)
- **BY MOUTH**
- Adult: Initially 1.25 mg once daily, increased if tolerated to 10 mg daily, preferably taken in 2 divided doses, increase dose gradually at intervals of 1–2 weeks

Prophylaxis after myocardial infarction in patients with clinical evidence of heart failure (started at least 48 hours after infarction)
- **BY MOUTH**
- Adult: Initially 2.5 mg twice daily for 3 days, then increased to 5 mg twice daily

Prophylaxis after myocardial infarction in patients with clinical evidence of heart failure (started at least 48 hours after infarction) when initial dose not tolerated
- **BY MOUTH**
- Adult: 1.25 mg twice daily for 2 days, then increased to 2.5 mg twice daily, then increased to 5 mg twice daily, withdraw treatment if dose cannot be increased to 2.5 mg twice daily

Prevention of cardiovascular events in patients with atherosclerotic cardiovascular disease or with diabetes mellitus and at least one additional risk factor for cardiovascular disease
- **BY MOUTH**
- Adult: Initially 2.5 mg once daily for 1–2 weeks, then increased to 5 mg once daily for a further 2–3 weeks, then increased to 10 mg once daily

Nephropathy (consult product literature)
- **BY MOUTH**
- Adult: Initially 1.25 mg once daily for 2 weeks, then increased to 2.5 mg once daily for a further 2 weeks, then increased if tolerated to 5 mg once daily

**INTERACTIONS** → Appendix 1: ACE inhibitors

**SIDE-EFFECTS**

- Common or very common Bronchitis · dyspnoea · muscle cramps · stomatitis · syncope
- Uncommon Angina · anxiety · arhythmias · chest pain · decreased libido · depression · dry mouth · flushing · impotence · loss of appetite · myocardial infarction · nervousness · palpitations · peripheral oedema · sweating · tachycardia · visual disturbances
- Rare Confusion · conjunctivitis · impaired hearing · onycholysis · tinnitus · tremor
- Frequency not known Alopecia · cerebrovascular accident · erythema multiforme · gynaecomastia · hyponatraemia · pemphigoid exanthema · precipitation or exacerbation of Raynaud’s syndrome · skin reactions · sleep disturbance · Stevens-Johnson syndrome · toxic epidermal necrolysis

**BREAST FEEDING** Not recommended; alternative treatment options, with better established safety information during breast-feeding, are available.

**HEPATIC IMPAIRMENT** Max. daily dose 2.5 mg. Ramipril is a prodrug and requires close monitoring in patients with hepatic impairment.

**RENAL IMPAIRMENT** Max. daily dose 5 mg if eGFR 30–60 mL/minute/1.73 m²; max. initial dose 1.25 mg once daily (do not exceed 5 mg daily) if eGFR less than 30 mL/minute/1.73 m².

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Oral solution**
- **Ramipril (Non-proprietary)**
  - Ramipril 500 microgram per 1 ml Ramipril 2.5mg/5ml oral solution sugar free sugar-free | 150 ml [Pom] £96.00 DT price = £96.00

**Tablet**
- **Ramipril (Non-proprietary)**
  - Ramipril 1.25 mg Ramipril 1.25mg tablets | 28 tablet [Pom] £5.25 DT price = £5.25
  - Ramipril 2.5 mg Ramipril 2.5mg tablets | 28 tablet [Pom] £7.49 DT price = £7.49
  - Ramipril 5 mg Ramipril 5mg tablets | 28 tablet [Pom] £10.40 DT price = £10.40
  - Ramipril 10 mg Ramipril 10mg tablets | 28 tablet [Pom] £14.20 DT price = £14.20
  - **Tritace (Sanofi)**
    - Ramipril 1.25 mg Tritace 1.25mg tablets | 28 tablet [Pom] £5.09 DT price = £5.09
    - Ramipril 2.5 mg Tritace 2.5mg tablets | 7 tablet [Pom] no price available | 10 tablet [Pom] no price available | 28 tablet [Pom] £7.22 DT price = £7.22
    - Ramipril 5 mg Tritace 5mg tablets | 21 tablet [Pom] no price available | 28 tablet [Pom] £10.05 DT price = £10.05
    - Ramipril 10 mg Tritace 10mg tablets | 7 tablet [Pom] no price available | 10 tablet [Pom] no price available | 28 tablet [Pom] £13.68 DT price = £13.68

**Capsule**
- **Ramipril (Non-proprietary)**
  - Ramipril 1.25 mg Ramipril 1.25mg capsules | 28 capsule [Pom] £1.80 DT price = £1.80
  - Ramipril 2.5 mg Ramipril 2.5mg capsules | 28 capsule [Pom] £1.99 DT price = £1.99
  - Ramipril 5 mg Ramipril 5mg capsules | 28 capsule [Pom] £2.05 DT price = £2.05
  - Ramipril 10 mg Ramipril 10mg capsules | 28 capsule [Pom] £2.20 DT price = £2.20
Ramipril with felodipine

The properties listed below are those particular to the combination only. For the properties of the components please consider, ramipril p. 168, felodipine p. 154.

- **INDICATIONS AND DOSE**
  - **Hypertension in patients stabilised on the individual components in the same proportions**
    - BY MOUTH
    - Adult: (consult product literature)

- **INTERACTIONS** → Appendix 1: ACE inhibitors, calcium channel blockers

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Modified-release tablet**
    - CAUTIONARY AND ADVISORY LABELS 25
      - **Triapin** (Sanofi)
        - Felodipine 2.5 mg, Ramipril 2.5 mg Triapin 2.5mg/2.5mg modified-release tablets | 28 tablet | £24.55
        - Felodipine 5 mg, Ramipril 5 mg Triapin 5mg/5mg modified-release tablets | 28 tablet | £16.13 DT price = £16.13

- **Trandolapril**

- **INDICATIONS AND DOSE**
  - **Mild to moderate hypertension**
    - BY MOUTH
    - Adult: Initially 500 micrograms once daily; increased to 1–2 mg once daily, dose to be increased at intervals of 2–4 weeks; maximum 4 mg per day
  - **Prophylaxis after myocardial infarction in patients with left ventricular dysfunction (starting as early as 3 days after infarction)**
    - BY MOUTH
    - Adult: Initially 500 micrograms once daily, then increased to up to 4 mg once daily, doses to be increased gradually

- **INTERACTIONS** → Appendix 1: ACE inhibitors
- **SIDE-EFFECTS**
  - Alopecia, angina, arrhythmias, arthralgia, bronchitis, cerebral haemorrhage, dry mouth, dysphonia, hot flushes, ileus, myocardial infarction, nervousness, palpitation, psoriasis-like efflorescence, skin reactions, sleep disturbances, Stevens-Johnson syndrome, sweating, syncope, tachycardia, toxic epidermal necrolysis, transient ischaemic attacks

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Symptomatic hypotension If symptomatic hypotension develops during titration, do not increase dose further; if possible, reduce dose of any adjunctive treatment and if this is not effective or feasible, reduce dose of trandolapril.

- **BREAST FEEDING**
  - Not recommended; alternative treatment options, with better established safety information during breast-feeding, are available.

- **HEPATIC IMPAIRMENT**
  - Trandolapril is a prodrug and requires close monitoring in patients with hepatic impairment.

- **RENAL IMPAIRMENT**
  - Max. 2 mg daily if eGFR less than 10 mL/minute/1.73 m².

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Capsule**
- **Trandolapril (Non-proprietary)**
  - Trandolapril 500 microgram Trandolapril 500microgram capsules | 14 capsule | £1.66 DT price = £1.66

**DRUGS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM** → ANGIOTENSIN II RECEPTOR ANTAGONISTS

**Angiotensin II receptor antagonists**

- **CONTRA-INDICATIONS**
  - The combination of an angiotensin-II receptor antagonist with aliskiren is contra-indicated in patients with an eGFR less than 60 mL/minute/1.73 m²: the combination of an angiotensin-II receptor antagonist with aliskiren is contra-indicated in patients with diabetes mellitus.

- **CAUTIONS**
  - Afro-Caribbean patients—particularly those with left ventricular hypertrophy (may not benefit from an angiotensin-II receptor antagonist) or aortic or mitral valve stenosis—elderly (lower initial doses may be appropriate).
  - Hypertrophic cardiomyopathy: patients with a history of angioedema: patients with primary aldosteronism (may not benefit from an angiotensin-II receptor antagonist) renal artery stenosis.

- **SIDE-EFFECTS**
  - Hyperkalaemia, angioedema (may be delayed onset) symptomatic hypotension including dizziness (particularly in patients with intravascular volume depletion, e.g. those taking high-dose diuretics).

- **PREGNANCY**
  - Angiotensin-II receptor antagonists should be avoided in pregnancy unless essential. They may adversely affect fetal and neonatal blood pressure control and renal function; neonatal skull defects and oligohydramnios have also been reported.

- **BREAST FEEDING**
  - Information on the use of angiotensin-II receptor antagonists in breast-feeding is limited. They are not recommended in breast-feeding and alternative treatment options, with better established safety information during breast-feeding, are available.

- **RENAL IMPAIRMENT**
  - Use with caution, starting with low dose, and adjust according to response.

- **MONITORING REQUIREMENTS**
  - Monitor plasma-potassium concentration, particularly in the elderly and in patients with renal impairment.

**Azilsartan medoxomil**

- **INDICATIONS AND DOSE**
  - **Hypertension**
    - BY MOUTH
    - Adult 18–74 years: Initially 40 mg once daily, increased if necessary to 80 mg once daily
    - Adult 75 years and over: Initially 20–40 mg once daily, increased if necessary to 80 mg once daily

  - **Hypertension with intravascular volume depletion**
    - BY MOUTH
    - Adult: Initially 20–40 mg daily, increased if necessary to 80 mg daily

- **CAUTIONS**
  - Heart failure

- **INTERACTIONS** → Appendix 1: angiotensin-II receptor antagonists

- **SIDE-EFFECTS**
  - **Common or very common** Diarrhoea, raised creatine kinase
  - **Uncommon** Hyperuricaemia, peripheral oedema, raised creatinine, malaise
Hepatic impairment
Manufacturer advises to consider initial dose of 20 mg in mild to moderate impairment (limited information available). Manufacturer advises avoid in severe impairment (no information available). Manufacturer advises monitor closely in mild to moderate hepatic impairment (limited information available).

Renal impairment
Manufacturer advises caution in severe impairment—no information available.

Medicinal forms
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution.

Candesartan cilexetil

INDICATIONS AND DOSE
Hypertension

BY MOUTH

Adult: Initially 8 mg once daily, increased if necessary up to 32 mg once daily, doses to be increased at intervals of 4 weeks; usual dose 8 mg once daily

Hypertension with intravascular volume depletion

BY MOUTH

Adult: Initially 4 mg once daily, increased if necessary up to 32 mg daily, doses to be increased at intervals of 4 weeks; usual dose 8 mg once daily

Heart failure with impaired left ventricular systolic function when ACE inhibitors are not tolerated
Heart failure with impaired left ventricular systolic function in conjunction with an ACE inhibitor (under expert supervision)

BY MOUTH

Adult: Initially 4 mg once daily, increased at intervals of at least 2 weeks to ‘target’ dose of 32 mg once daily or to maximum tolerated dose

Contra-indications
Cholestatics

Interactions
Appendix 1: angiotensin-II receptor antagonists

Side-effects

Common or very common
Headache • vertigo

Very rare
Arthralgia • back pain • blood disorders • cough • hepatitis • hyponatraemia • myalgia • nausea • pruritus • rash • urticaria

Hepatic impairment
Initially 4 mg once daily in mild or moderate liver impairment. Avoid in severe hepatic impairment.

Renal impairment
Initially 4 mg daily. Use with caution if eGFR less than 15 mL/minute/1.73 m²—limited experience.

Medicinal forms
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution.

Tablet

Candesartan cilexetil (Non-proprietary)

Candesartan cilexetil 2 mg Candesartan 2mg tablets | 7 tablet (POM) £3.40 DT price = £1.92
Candesartan cilexetil 4 mg Candesartan 4mg tablets | 7 tablet (POM) £7.62 DT price = £0.66 | 28 tablet (POM) £9.78
Candesartan cilexetil 8 mg Candesartan 8mg tablets | 28 tablet (POM) £9.89 DT price = £0.98
Candesartan cilexetil 16 mg Candesartan 16mg tablets | 28 tablet (POM) £12.72 DT price = £1.15

Edarbi

Teveten

Eprosartan

INDICATIONS AND DOSE
Hypertension

BY MOUTH

Adult: 600 mg once daily

INTERACTIONS
Appendix 1: angiotensin-II receptor antagonists

SIDE-EFFECTS

Common or very common
Headache • nausea • rhinitis • diarrhoea • malaise • vomiting

Hepatic impairment
Caution in mild or moderate liver disease. Avoid in severe impairment.

Renal impairment
Caution if eGFR less than 30 mL/minute/1.73 m².

Medicinal forms
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution.

Tablet

Candesartan cilexetil 32 mg Candesartan 32mg tablets | 28 tablet (POM) £16.13 DT price = £1.59
Amias (Takeda UK Ltd)

Candesartan cilexetil 2 mg Amias 2mg tablets | 7 tablet (POM) £3.58 DT price = £1.92
Candesartan cilexetil 4 mg Amias 4mg tablets | 7 tablet (POM) £3.88 DT price = £0.66 | 28 tablet (POM) £9.78
Candesartan cilexetil 8 mg Amias 8mg tablets | 28 tablet (POM) £9.89 DT price = £0.98
Candesartan cilexetil 16 mg Amias 16mg tablets | 28 tablet (POM) £12.72 DT price = £1.15
Candesartan cilexetil 32 mg Amias 32mg tablets | 28 tablet (POM) £16.13 DT price = £1.59

Irbesartan

INDICATIONS AND DOSE
Hypertension

BY MOUTH

Adult 18–74 years: Initially 150 mg once daily, increased if necessary to 300 mg once daily

Adult 75 years and over: Initially 75–150 mg once daily, increased if necessary to 300 mg once daily

Hypertension in patients receiving haemodialysis

BY MOUTH

Adult: Initially 75–150 mg once daily, increased if necessary to 300 mg once daily

Renal disease in hypertensive type 2 diabetes mellitus

BY MOUTH

Adult 18–74 years: Initially 150 mg once daily, increased if tolerated to 300 mg once daily

Adult 75 years and over: Initially 75–150 mg once daily, increased if tolerated to 300 mg once daily
Renal disease in hypertensive type 2 diabetes mellitus in patients receiving haemodialysis

- **BY MOUTH**
- Adult: Initially 75–150 mg once daily, increased if tolerated to 300 mg once daily

**INTERACTIONS** → Appendix 1: angiotensin-II receptor antagonists

**SIDE-EFFECTS**
- **Common or very common** Fatigue, musculoskeletal pain, nausea, vomiting
- **Uncommon** Chest pain, cough, diarrhoea, dyspepsia, flushing, sexual dysfunction, tachycardia
- **Rare** Rash, urticaria
- **Very rare** Arthralgia, cutaneous vasculitis, headache, hepatitis, myalgia, renal dysfunction, taste disturbance, tinnitus

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Tablet**

- **Irbesartan (Non-proprietary)**
  - **Irbesartan 75 mg** Irbesartan 75mg tablets | 28 tablet [pos] £9.21 DT price = £0.97
  - **Irbesartan 150 mg** Irbesartan 150mg tablets | 28 tablet [pos] £11.25 DT price = £1.19
  - **Irbesartan 300 mg** Irbesartan 300mg tablets | 28 tablet [pos] £15.13 DT price = £1.63
- **Aprovel (Sanofi)**
  - **Irbesartan 75 mg** Aprovel 75mg tablets | 28 tablet [pos] £9.69 DT price = £0.97
  - **Irbesartan 150 mg** Aprovel 150mg tablets | 28 tablet [pos] £11.84 DT price = £1.19
  - **Irbesartan 300 mg** Aprovel 300mg tablets | 28 tablet [pos] £15.93 DT price = £1.63
- **Ifrimasta (Consilient Health Ltd)**
  - **Irbesartan 75 mg** Ifrimasta 75mg tablets | 28 tablet [pos] £8.23 DT price = £0.97
  - **Irbesartan 150 mg** Ifrimasta 150mg tablets | 28 tablet [pos] £10.06 DT price = £1.19
  - **Irbesartan 300 mg** Ifrimasta 300mg tablets | 28 tablet [pos] £13.54 DT price = £1.63

**Irbesartan with hydrochlorothiazide**

The properties listed below are those particular to the combination only. For the properties of the components please consider, irbesartan p. 170, hydrochlorothiazide p. 162.

**INDICATIONS AND DOSE**

Hypertension not adequately controlled with irbesartan alone

- **BY MOUTH**
- **Adult:** (consult product literature)

**INTERACTIONS** → Appendix 1: angiotensin-II receptor antagonists, thiazide diuretics

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Irbesartan with hydrochlorothiazide (Non-proprietary)**
  - **Hydrochlorothiazide 12.5 mg, Irbesartan 150 mg** Irbesartan 150mg / Hydrochlorothiazide 12.5mg tablets | 28 tablet [pos] £10.06 DT price = £4.65
  - **Hydrochlorothiazide 25 mg, Irbesartan 300 mg** Irbesartan 300mg / Hydrochlorothiazide 25mg tablets | 28 tablet [pos] £13.54 DT price = £6.61
  - **Hydrochlorothiazide 12.5 mg, Irbesartan 300 mg** Irbesartan 300mg / Hydrochlorothiazide 12.5mg tablets | 28 tablet [pos] £13.54 DT price = £2.00

- **CoAprovel (Sanofi)**
  - **Hydrochlorothiazide 12.5 mg, Irbesartan 150 mg** CoAprovel 150mg/12.5mg tablets | 28 tablet [pos] £11.84 DT price = £4.65
  - **Hydrochlorothiazide 25 mg, Irbesartan 300 mg** CoAprovel 300mg/25mg tablets | 28 tablet [pos] £15.93 DT price = £6.61
  - **Hydrochlorothiazide 12.5 mg, Irbesartan 300 mg** CoAprovel 300mg/12.5mg tablets | 28 tablet [pos] £15.93 DT price = £2.00

**Losartan potassium**

**INDICATIONS AND DOSE**

Diabetic nephropathy in type 2 diabetes mellitus

- **BY MOUTH**
- Adult 18–75 years: Initially 50 mg once daily for several weeks, then increased if necessary to 100 mg once daily
- Adult 76 years and over: Initially 25 mg once daily for several weeks, then increased if necessary to 100 mg once daily

**Chronic heart failure when ACE inhibitors are unsuitable or contra-indicated**

- **BY MOUTH**
- Adult: Initially 12.5 mg once daily, increased if tolerated up to 150 mg once daily, doses to be increased at weekly intervals

**Hypertension (including reduction of stroke risk in hypertension with left ventricular hypertrophy)**

- **BY MOUTH**
- Adult 18–75 years: Initially 50 mg once daily for several weeks, then increased if necessary to 100 mg once daily
- Adult 76 years and over: Initially 25 mg once daily for several weeks, then increased if necessary to 100 mg once daily

**Hypertension with intravascular volume depletion**

- **BY MOUTH**
- Adult 18–75 years: Initially 25 mg once daily for several weeks, then increased if necessary up to 100 mg once daily

**CAUTIONS**

Severe heart failure

**INTERACTIONS** → Appendix 1: angiotensin-II receptor antagonists

**SIDE-EFFECTS**
- **Common or very common** Vertigo
- **Uncommon** Angina, dyspnoea, gastro-intestinal disturbances, headache, malaise, oedema, palpitation, pruritus, rash, sleep disorders, urticaria
- **Rare** Atrial fibrillation, cerebrovascular accident, hepatitis, paraesthesia, syncope
- **Frequency not known** Anaemia, anaphylaxis, arthralgia, cough, depression, erectile dysfunction, Henoch–Schönlein purpura, hyponatraemia, myalgia, pancreatitis, photosensitivity, renal impairment, rhabdomyolysis, thrombocytopenia, tinnitus, vasculitis

**HEPATIC IMPAIRMENT**

Consider dose reduction in mild to moderate impairment. Manufacturer advises avoid in severe impairment—no information available.

**PRESCRIBING AND DISPENCING INFORMATION**

Flavours of oral liquid formulations may include berry–citrus.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution and sugar-free oral suspension

- **Cozaar (Merck Sharp & Dohme Ltd)**
  - **Losartan potassium 2.5 mg per 1 ml** Cozaar 2.5mg/ml oral suspension sugar-free | 200 ml [pos] £53.68 DT price = £53.68

**Tablet**

- **Losartan potassium (Non-proprietary)**
  - **Losartan potassium 12.5 mg** Losartan 12.5mg tablets | 28 tablet [pos] £30.00 DT price = £26.66
Losartan with hydrochlorothiazide

The properties listed below are those particular to the combination only. For the properties of the components please consider, losartan potassium p. 171, hydrochlorothiazide p. 162.

- **INDICATIONS AND DOSE**
  - Hypertension not adequately controlled with losartan alone
    - **BY MOUTH**
    - Adult: (consult product literature)

- **INTERACTIONS** → Appendix 1: angiotensin-II receptor antagonists, thiazide diuretics

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  **Tablet**
  - Losartan with hydrochlorothiazide (Non-proprietary)
    - Hydrochlorothiazide 12.5 mg, Losartan potassium 50 mg
    - Tablet (POM) £13.75 DT price = £1.31
    - Hydrochlorothiazide 25 mg, Losartan potassium 100 mg
    - Tablet (POM) £16.18 DT price = £1.55
  - Cozaar-Comp (Merck Sharp & Dohme Ltd)
    - Hydrochlorothiazide 12.5 mg, Losartan potassium 50 mg
    - Cozaar-Comp 50mg/12.5mg tablets | 28 tablet (POM) £12.80 DT price = £1.31
    - Hydrochlorothiazide 25 mg, Losartan potassium 100 mg
    - Cozaar-Comp 100mg/25mg tablets | 28 tablet (POM) £16.18 DT price = £1.55

- **Olmesartan medoxomil**

  - **INDICATIONS AND DOSE**
    - Hypertension in patients stabilised on the individual components in the same proportions
    - **BY MOUTH**
    - Adult: (consult product literature)

  - **INTERACTIONS** → Appendix 1: angiotensin-II receptor antagonists, calcium channel blockers

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  **Tablet**
  - Sevikar (Daiichi Sankyo UK Ltd)
    - Amlodipine (as Amlodipine besilate) 5 mg, Olmesartan medoxomil 20 mg
    - Sevikar 20mg/5mg tablets | 28 tablet (POM) £16.95
    - Amlodipine (as Amlodipine besilate) 10 mg, Olmesartan medoxomil 40 mg
    - Sevikar 40mg/10mg tablets | 28 tablet (POM) £16.95
    - Amlodipine (as Amlodipine besilate) 5 mg, Olmesartan medoxomil 40 mg
    - Sevikar 40mg/5mg tablets | 28 tablet (POM) £16.95

**2 Blood pressure conditions**

- **Losartan potassium 25 mg** Losartan 25mg tablets | 28 tablet (POM) £16.18 DT price = £0.80
- **Losartan potassium 50 mg** Losartan 50mg tablets | 28 tablet (POM) £12.80 DT price = £0.86
- **Losartan potassium 100 mg** Losartan 100mg tablets | 28 tablet (POM) £16.18 DT price = £0.99
  - Cozaar (Merck Sharp & Dohme Ltd)
    - Losartan potassium 12.5 mg | 28 tablet (POM) £9.70 DT price = £26.66
    - Losartan potassium 25 mg | 28 tablet (POM) £16.18 DT price = £0.90
    - Losartan potassium 50 mg | 28 tablet (POM) £12.80 DT price = £0.86
    - Losartan potassium 100 mg | 28 tablet (POM) £16.18 DT price = £0.99
  - Olmesartan medoxomil (Non-proprietary)
    - Olmetec 10 mg
    - Olmetec 20 mg
    - Olmetec 40 mg

- **INDICATIONS AND DOSE**
  - Usually, blood pressure conditions
  - Angina
  - Cough
  - Headache: myalgia, pruritus, thrombocytopenia, urticaria
  - **HEPATIC IMPAIRMENT**
    - Dose should not exceed 20 mg daily in moderate impairment. Manufacturer advises avoid in severe impairment—no information available.
  - **RENAL IMPAIRMENT**
    - Max. 20 mg daily if eGFR 20–60 mL/minute/1.73 m². Avoid if eGFR less than 20 mL/minute/1.73 m².

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

  **Tablet**
  - Olmesartan medoxomil (Non-proprietary)
    - Olmesartan medoxomil 10 mg
    - Olmesartan medoxomil 20 mg
    - Olmesartan medoxomil 40 mg

  **Cozaar-Comp**
  - Losartan with hydrochlorothiazide (Non-proprietary)
    - Losartan with hydrochlorothiazide 12.5mg tablets | 28 tablet (POM) £13.75 DT price = £1.31
    - Losartan with hydrochlorothiazide 25mg tablets | 28 tablet (POM) £16.18 DT price = £1.55

  **Sevikar**
  - Amlodipine (as Amlodipine besilate) 5 mg, Olmesartan medoxomil 20 mg
  - Amlodipine (as Amlodipine besilate) 10 mg, Olmesartan medoxomil 40 mg
  - Amlodipine (as Amlodipine besilate) 5 mg, Olmesartan medoxomil 40 mg

- **Olmesartan with amlodipine**

  The properties listed below are those particular to the combination only. For the properties of the components please consider, olmesartan medoxomil above, amlodipine p. 150.

- **INDICATIONS AND DOSE**
  - Hypertension
  - Given in the same proportions

  **INTERACTIONS** → Appendix 1: angiotensin-II receptor antagonists, calcium channel blockers

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  **Tablet**
  - Sevikar (Daiichi Sankyo UK Ltd)
    - Amlodipine (as Amlodipine besilate) 5 mg, Olmesartan medoxomil 20 mg
    - Sevikar 20mg/5mg tablets | 28 tablet (POM) £16.95
    - Amlodipine (as Amlodipine besilate) 10 mg, Olmesartan medoxomil 40 mg
    - Sevikar 40mg/10mg tablets | 28 tablet (POM) £16.95
    - Amlodipine (as Amlodipine besilate) 5 mg, Olmesartan medoxomil 40 mg
    - Sevikar 40mg/5mg tablets | 28 tablet (POM) £16.95

- **Complaints**
  - Common or very common
  - Uncommon
  - Angina: rash: vertigo

- **CONTRA-INDICATIONS**
  - Biliary obstruction

- **SIDE-EFFECTS**
  - Common or very common
  - Uncommon
  - Angina: rash: vertigo

- **Very rare**
  - Headache: myalgia: pruritus: thrombocytopenia: urticaria

- **Appendix**

  - Appendix 1: angiotensin-II receptor antagonists, calcium channel blockers
Olmesartan with amlodipine and hydrochlorothiazide

The properties listed below are those particular to the combination only. For the properties of the components please consider, olmesartan medoxomil p. 172, amlodipine p. 150, hydrochlorothiazide p. 162.

**INDICATIONS AND DOSE**

Hypertension in patients stabilised on the individual components in the same proportions, or for hypertension not adequately controlled with olmesartan and amlodipine

- **BY MOUTH**
- Adult: (consult product literature)

**INTERACTIONS** → Appendix 1: angiotensin-II receptor antagonists, calcium channel blockers, thiazide diuretics

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Sevikar HCT** (Daiichi Sankyo UK Ltd)
  - Amlodipine besilate 5 mg, Hydrochlorothiazide 12.5 mg, Olmesartan medoxomil 20 mg, Sevikar HCT 20mg/5mg/12.5mg tablets | 28 tablet (PO) £16.95
  - Amlodipine besilate 5 mg, Hydrochlorothiazide 25 mg, Olmesartan medoxomil 40 mg, Sevikar HCT 40mg/5mg/25mg tablets | 28 tablet (PO) £16.95
  - Amlodipine besilate 10 mg, Hydrochlorothiazide 25 mg, Olmesartan medoxomil 40 mg, Sevikar HCT 40mg/10mg/25mg tablets | 28 tablet (PO) £16.95
  - Amlodipine besilate 5 mg, Hydrochlorothiazide 12.5 mg, Olmesartan medoxomil 40 mg, Sevikar HCT 40mg/5mg/12.5mg tablets | 28 tablet (PO) £16.95
  - Amlodipine besilate 10 mg, Hydrochlorothiazide 12.5 mg, Olmesartan medoxomil 40 mg, Sevikar HCT 40mg/10mg/12.5mg tablets | 28 tablet (PO) £16.95

**Olmesartan with hydrochlorothiazide**

The properties listed below are those particular to the combination only. For the properties of the components please consider, olmesartan medoxomil p. 172, hydrochlorothiazide p. 162.

**INDICATIONS AND DOSE**

Hypertension not adequately controlled with olmesartan alone

- **BY MOUTH**
- Adult: (consult product literature)

**INTERACTIONS** → Appendix 1: angiotensin-II receptor antagonists, thiazide diuretics

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Olmetec Plus** (Daiichi Sankyo UK Ltd)
  - Hydrochlorothiazide 12.5 mg, Olmesartan medoxomil 20 mg, Olmetec Plus 20mg/12.5mg tablets | 28 tablet (PO) £12.95 DT price = £12.95
  - Olmesartan medoxomil 20 mg, Hydrochlorothiazide 25 mg, Olmetec Plus 20mg/25mg tablets | 28 tablet (PO) £12.95 DT price = £12.95
  - Hydrochlorothiazide 12.5 mg, Olmesartan medoxomil 40 mg, Olmetec Plus 40mg/12.5mg tablets | 28 tablet (PO) £17.50 DT price = £17.50

**Telmisartan**

**INDICATIONS AND DOSE**

Hypertension

- **BY MOUTH**
- Adult: Initially 20–40 mg once daily for at least 4 weeks, increased if necessary up to 80 mg once daily

Prevention of cardiovascular events in patients with established atherosclerotic cardiovascular disease, or type 2 diabetes mellitus with target-organ damage

- **BY MOUTH**
- Adult: 80 mg once daily

**INTERACTIONS** → Appendix 1: angiotensin-II receptor antagonists

**SIDE-EFFECTS**

- **Common or very common** Arthralgia - back pain - chest pain - eczema - gastro-intestinal disturbances - influenza-like symptoms - leg cramps - myalgia - pharyngitis - sinusitis - urinary-tract infection
- **Uncommon** Abnormal vision - anxiety - dry mouth - flatulence - increased sweating - tendinitis-like symptoms - vertigo
- **Rare** Blood disorders - bradycardia - depression - dyspnoea - eosinophilia - increase in uric acid - insomnia - pruritus - rash - tachycardia
- **Frequency not known** Asthenia - syncope

**HEPATIC IMPAIRMENT**

20–40 mg once daily in mild or moderate impairment. Avoid in severe impairment or biliary obstruction.

**RENAL IMPAIRMENT**

Manufacturer advises initial dose of 20 mg once daily in severe impairment.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Telmisartan (Non-proprietary)**
  - Telmisartan 20 mg Telmisartan 20mg tablets | 28 tablet (PO) £1.01–£1.05 DT price = £1.01
  - Telmisartan 40 mg Telmisartan 40mg tablets | 28 tablet (PO) £1.07–£1.09 DT price = £1.08
  - Telmisartan 80 mg Telmisartan 80mg tablets | 28 tablet (PO) £1.46–£1.56 DT price = £1.46
  - Micardis (Boehringer Ingelheim Ltd)
  - Micardis 20 mg Micardis 20mg tablets | 28 tablet (PO) £1.10 DT price = £1.01
  - Micardis 40 mg Micardis 40mg tablets | 28 tablet (PO) £1.36 DT price = £1.18
  - Micardis 80 mg Micardis 80mg tablets | 28 tablet (PO) £1.70 DT price = £1.46
- **Tolura** (Consilient Health Ltd)
  - Tolura 20 mg Tolura 20mg tablets | 28 tablet (PO) £1.10 DT price = £1.01
  - Tolura 40 mg Tolura 40mg tablets | 28 tablet (PO) £1.36 DT price = £1.18
  - Tolura 80 mg Tolura 80mg tablets | 28 tablet (PO) £1.70 DT price = £1.46

**Telmisartan with hydrochlorothiazide**

The properties listed below are those particular to the combination only. For the properties of the components please consider, telmisartan above, hydrochlorothiazide p. 162.

**INDICATIONS AND DOSE**

Hypertension not adequately controlled by telmisartan alone

- **BY MOUTH**
- Adult: (consult product literature)
INTERACTIONS 

- Appendix 1: angiotensin-II receptor antagonists, thiazide diuretics

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

- Telmisartan with hydrochlorothiazide (Non-proprietary)
  - Hydrochlorothiazide 12.5 mg, Telmisartan 40 mg
  - Telmisartan 80mg / hydrochlorothiazide 12.5mg tablets | 28 tablet (POM) £13.61 DT price = £13.61
  - Hydrochlorothiazide 25 mg, Telmisartan 80 mg
  - Telmisartan 80mg / hydrochlorothiazide 25mg tablets | 28 tablet (POM) £10.99–£17.00 DT price = £17.00
  - Hydrochlorothiazide 12.5 mg, Telmisartan 80 mg
  - Telmisartan 80mg / hydrochlorothiazide 12.5mg tablets | 28 tablet (POM) £9.99–£17.00 DT price = £17.00

- Actelsar HCT (AstraZeneca Ltd)
  - Hydrochlorothiazide 12.5 mg, Telmisartan 40 mg
  - Actelsar HCT 40mg/12.5mg tablets | 28 tablet (POM) £13.61 DT price = £13.61
  - Hydrochlorothiazide 25 mg, Telmisartan 80 mg
  - Actelsar HCT 80mg/25mg tablets | 28 tablet (POM) £17.00 DT price = £17.00
  - Hydrochlorothiazide 12.5 mg, Telmisartan 80 mg
  - Actelsar HCT 80mg/12.5mg tablets | 28 tablet (POM) £17.00 DT price = £17.00

- MicardisPlus (Boehringer Ingelheim Ltd)
  - Hydrochlorothiazide 12.5 mg, Telmisartan 40 mg
  - MicardisPlus 40mg/12.5mg tablets | 28 tablet (POM) £13.61 DT price = £13.61
  - Hydrochlorothiazide 25 mg, Telmisartan 80 mg
  - MicardisPlus 80mg/25mg tablets | 28 tablet (POM) £17.00 DT price = £17.00
  - Hydrochlorothiazide 12.5 mg, Telmisartan 80 mg
  - MicardisPlus 80mg/12.5mg tablets | 28 tablet (POM) £17.00 DT price = £17.00

- Tolucombi (Consolent Health Ltd)
  - Hydrochlorothiazide 12.5 mg, Telmisartan 40 mg
  - Tolucombi 40mg/12.5mg tablets | 28 tablet (POM) £13.61 DT price = £13.61
  - Hydrochlorothiazide 25 mg, Telmisartan 80 mg
  - Tolucombi 80mg/25mg tablets | 28 tablet (POM) £17.00 DT price = £17.00
  - Hydrochlorothiazide 12.5 mg, Telmisartan 80 mg
  - Tolucombi 80mg/12.5mg tablets | 28 tablet (POM) £17.00 DT price = £17.00

INDICATIONS AND DOSE

Blood pressure conditions

- BP SUCCESSION
  - BY MOUTH

Hypertension

- Adult: Initially 80 mg once daily, increased if necessary up to 320 mg daily, doses to be increased at intervals of 4 weeks

Hypertension with intravascular volume depletion

- BY MOUTH

- Adult: Initially 40 mg once daily, increased if necessary up to 320 mg daily, doses to be increased at intervals of 4 weeks

Heart failure when ACE inhibitors cannot be used, or in conjunction with an ACE inhibitor when a beta-blocker cannot be used

- Heart failure, in conjunction with an ACE inhibitor when a beta-blocker cannot be used (under expert supervision)

- BY MOUTH

- Adult: Initially 40 mg twice daily, increased to up to 160 mg twice daily, doses to be increased at intervals of at least 2 weeks

Myocardial infarction with left ventricular failure or left ventricular systolic dysfunction (adjunct)

- BY MOUTH

- Adult: Initially 20 mg twice daily, increased if necessary up to 160 mg twice daily, doses to be increased over several weeks if tolerated

CONTRA-INDICATIONS

- Biliary cirrhosis • cholestasis

INTERACTIONS

- Appendix 1: angiotensin-II receptor antagonists

SIDE-EFFECTS

- Common or very common Renal impairment

- Uncommon Acute renal failure • cough • fatigue • gastrointestinal disturbance • headache • syncope

- Frequency not known Hypersensitivity reactions • myalgia • neutropenia • pruritus • rash • serum sickness • thrombocytopenia • vasculitis

HEPATIC IMPAIRMENT

- Max. dose 80 mg daily in mild to moderate impairment. Avoid in severe hepatic impairment.

RENAL IMPAIRMENT

- Use with caution if eGFR less than 10 mL/minute/1.73 m²—no information available.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Oral solution

- Diovan (Novartis Pharmaceuticals UK Ltd)
  - Valsartan 3 mg per 1 ml Diovan 3mg/1ml oral solution | 160 ml (POM) £7.20

Tablet

- Valsartan (Non-proprietary)
  - Valsartan 40 mg
  - Valsartan 40mg tablets | 7 tablet (POM) £5.00 DT price = £3.11 | 28 tablet (POM) no price available
  - Valsartan 80 mg
  - Valsartan 80mg tablets | 28 tablet (POM) £13.69 DT price = £13.69

- Valsartan 160 mg
  - Valsartan 160mg tablets | 28 tablet (POM) £14.69 DT price = £14.69
  - Valsartan 320 mg
  - Valsartan 320mg tablets | 28 tablet (POM) £20.23 DT price = £13.01

Capsule

- Valsartan (Non-proprietary)
  - Valsartan 40 mg
  - Valsartan 40mg capsules | 28 capsule (POM) £13.97 DT price = £3.31
  - Valsartan 80 mg
  - Valsartan 80mg capsules | 28 capsule (POM) £13.97 DT price = £2.21
  - Valsartan 160 mg
  - Valsartan 160mg capsules | 28 capsule (POM) £18.41 DT price = £4.05

Combinations available: Amlodipine with valsartan, p. 151

Valsartan with hydrochlorothiazide

The properties listed below are those particular to the combination only. For the properties of the components please consider, valsartan above, hydrochlorothiazide p. 162.

INDICATIONS AND DOSE

Hypertension not adequately controlled by valsartan alone

- BY MOUTH

- Adult: (consult product literature)

INTERACTIONS

- Appendix 1: angiotensin-II receptor antagonists, thiazide diuretics

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

- Valsartan with hydrochlorothiazide (Non-proprietary)
  - Hydrochlorothiazide 12.5 mg, Valsartan 80 mg

  - Valsartan 80mg / hydrochlorothiazide 12.5mg tablets | 28 tablet (POM) £13.97 DT price = £7.74

  - Hydrochlorothiazide 25 mg, Valsartan 160 mg

  - Valsartan 160mg / hydrochlorothiazide 25mg tablets | 28 tablet (POM) £18.41 DT price = £10.41

  - Hydrochlorothiazide 12.5 mg, Valsartan 160 mg

  - Valsartan 160mg / hydrochlorothiazide 12.5mg tablets | 28 tablet (POM) £18.41 DT price = £2.19

- Co-Diovan (Novartis Pharmaceuticals UK Ltd)

  - Hydrochlorothiazide 12.5 mg, Valsartan 80 mg

  - Co-Diovan 80mg/12.5mg tablets | 28 tablet (POM) £16.76 DT price = £7.74

  - Hydrochlorothiazide 25 mg, Valsartan 160 mg

  - Co-Diovan 160mg/25mg tablets | 28 tablet (POM) £22.09 DT price = £10.41

  - Hydrochlorothiazide 12.5 mg, Valsartan 160 mg

  - Co-Diovan 160mg/12.5mg tablets | 28 tablet (POM) £22.09 DT price = £2.19
DRUGS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

RENIN INHIBITORS

Aliksiren

- **Drug Action**: Renin inhibitors inhibit renin directly; renin converts angiotensinogen to angiotensin I.

- **Indications and Dose**
  - Essential hypertension either alone or in combination with other antihypertensives
    - By Mouth
    - Adult: 150 mg once daily, increased if necessary to 300 mg once daily

- **Contra-Indications**: Concomitant treatment with an ACE inhibitor or an angiotensin-II receptor antagonist in patients with an eGFR less than 60 mL/minute/1.73 m². Concomitant treatment with an ACE inhibitor or an angiotensin-II receptor antagonist in patients with diabetes mellitus - hereditary angioedema - idiopathic angioedema.

- **Caution**: Combination treatment with an ACE inhibitor - combination treatment with an angiotensin-II receptor antagonist - concomitant use of diuretics (first doses may cause hypotension - initiate with care) - history of angioedema - moderate to severe congestive heart failure - patients at risk of renal impairment - salt depletion (first doses may cause hypotension - initiate with care) - volume depletion (first doses may cause hypotension - initiate with care).

**Caution, Further Information**

- Concomitant use of drugs affecting the renin-angiотensin system
  - Combination therapy with two drugs affecting the renin-angiотensin system (ACE inhibitors, angiotensin-II receptor antagonists, and aliskiren) is not recommended due to an increased risk of hyperkalaemia, hypotension, and renal impairment, compared to use of a single drug.
  - Patients with diabetic nephropathy are particularly susceptible to developing hyperkalaemia and should not be given an ACE inhibitor with an angiotensin-II receptor antagonist. There is some evidence that the benefits of combination use of an ACE inhibitor with candesartan or valsartan may outweigh the risks in selected patients with heart failure for whom other treatments are unsuitable, however, the concomitant use of this combination, together with a aldosterone antagonist or a potassium-sparing diuretic is not recommended. For patients currently taking combination therapy, the need for continued combined therapy should be reviewed. If combination therapy is considered essential, it should be carried out under specialist supervision, with close monitoring of blood pressure, renal function, and electrolytes (particularly potassium); monitoring should be considered at the start of treatment, then monthly, and also after any change in dose or during intercurrent illness.

**Interactions**

- **Appendix 1: aliskiren**

- **Side-Effects**
  - Common or very common: Arthralgia - dizziness - hyperkalaemia - diarrhoea
  - Uncommon: Acute renal failure (reversible on discontinuation of treatment) - hypotension - palpitation - peripheral oedema - cough - pruritus - rash - Stevens-Johnson syndrome - toxic epidermal necrolysis - urticaria
  - Rare: Anaemia - angioedema - erythema
  - Frequency not known: Liver disorders - nausea - vertigo - vomiting

**Side-Effects, Further Information**

- If diarrhoea severe or persistent discontinue treatment.

**Pregnancy**

- Manufacturer advises avoid - no information available; other drugs acting on the renin-angiотensin system have been associated with fetal malformations and neonatal death.

**Breast Feeding**

- Present in milk in animal studies - manufacturer advises avoid.

**Renal Impairment**

- Avoid if eGFR is less than 30 mL/minute/1.73 m² - no information available. Use with caution in renal artery stenosis - no information available. Monitor plasma-potassium concentration in renal impairment.

**Monitoring Requirements**

- Monitor patients with a history of angioedema closely during treatment.

**National Funding/Access Decisions**

- Scottish Medicines Consortium (SMC) Decisions
  - The Scottish Medicines Consortium has advised (January 2010) that aliskiren (Rasilez ®) is not recommended for use within NHS Scotland.

**Medicinal Forms**

- There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Cautionary and Advisory Labels 21**
  - Rasilez (Novartis Pharmaceuticals UK Ltd)
  - Aliskiren (as Aliskiren hemifumarate) 150 mg: Rasilez 150 mg tablets | 28 tablet (P掌柜): £20.51 DT price = £18.51
  - Aliskiren (as Aliskiren hemifumarate) 300 mg: Rasilez 300 mg tablets | 28 tablet (P掌柜): £34.27 DT price = £34.27

**Vasodilators**

Vasodilator Antihypertensives

Hydralazine hydrochloride

- **Indications and Dose**
  - Moderate to severe hypertension (adjunct)
    - By Mouth
    - Adult: Initially 25 mg twice daily, increased if necessary up to 50 mg twice daily
  - Heart failure (with long acting nitrate) (initiated in hospital or under specialist supervision)
    - By Mouth
    - Adult: Initially 25 mg 3–4 times a day, subsequent doses to be increased every 2 days if necessary; usual maintenance 50–75 mg 4 times a day
  - Hypertensive emergencies (including during pregnancy)
    - Hypertension with renal complications
      - By Intravenous Infusion
        - Adult: Initially 200–300 micrograms/minute; usual maintenance 50–150 micrograms/minute
      - By Slow Intravenous Injection
        - Adult: 5–10 mg, to be diluted with 10 mL sodium chloride 0.9%; dose may be repeated after 20–30 minutes

- **Contra-Indications** Acute porphyrias p. 969- cor pulmonale - dissecting aortic aneurysm - high output heart failure - idiopathic systemic lupus erythematosus - myocardial insufficiency due to mechanical obstruction - severe tachycardia

- **Caution**: Cerebrovascular disease - coronary artery disease (may provoke angina, avoid after myocardial infarction until stabilised) - occasionally blood pressure reduction too rapid even with low parenteral doses

**Interactions**

- **Appendix 1: hydralazine**

- **Side-Effects**
  - Rare: Rash
  - Frequency not known: Abnormal liver function - agitation - anorexia - anxiety - arthralgia - blood disorders - dizziness - dysphoria - fever - fluid retention - flushing - gastrointestinal disturbances - haematuria - haemolytic anaemia - headache - hypotension - increased lacrimation - jaundice -
leucopenia • myalgia • nasal congestion • palpitation • paraesthesia • peripheral neuritis • polynuereits • proteinuria • raised plasma creatinine • systemic lupus erythematosus-like syndrome after long-term therapy with over 100 mg daily (or less in women and in slow acetylator individuals) • tachycardia • thrombocytopenia

SIDE-EFFECTS, FURTHER INFORMATION
The incidence of side-effects is lower if the dose is kept below 100 mg daily, but systemic lupus erythematous should be suspected if there is unexplained weight loss, arthritis, or any other unexplained ill health.

PREGNANCY Neonatal thrombocytopenia reported, but risk should be balanced against risk of uncontrolled maternal hypertension. Manufacturer advises avoid before third trimester.

BREAST FEEDING Present in milk but not known to be harmful. Monitor infant in breast-feeding.

HEPATIC IMPAIRMENT Reduce dose.

RENAL IMPAIRMENT Reduce dose if eGFR less than 30 mL/minute/1.73 m².

MONITORING REQUIREMENTS Manufacturer advises test for antinuclear factor and for proteinuria every 6 months and check acetylator status before increasing dose above 100 mg daily, but evidence of clinical value unsatisfactory.

DIRECTIONS FOR ADMINISTRATION For intravenous infusion (Apresoline®) give continuously in Sodium chloride 0.9%. Suggested infusion volume 500 mL.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Tablet

EXCIPIENTS: May contain Gluten, propylene glycol

Hydralazine hydrochloride (Non-proprietary)

| Hydralazine hydrochloride 25 mg | Hydralazine hydrochloride 25mg tablets | 56 tablet [POM] £8.92 DT price = £6.60 | 84 tablet [POM] £14.00 |
| Hydralazine hydrochloride 50 mg | Hydralazine hydrochloride 50mg tablets | 56 tablet [POM] £16.82 DT price = £12.45 |
| Apresoline (AMCo) | Hydralazine hydrochloride 25 mg | Apresoline 25mg tablets | 84 tablet [POM] £3.38 |
| Powder for solution for injection | Hydralazine hydrochloride (Non-proprietary) |
| Hydralazine hydrochloride 20 mg | Hydralazine 20mg powder for concentrate for solution for injection ampoules | 5 ampoule [POM] £64.50 |
| Hydralazine hydrochloride 20 mg | Hydralazine hydrochloride 20 mg powder for solution for injection ampoules | 5 ampoule [POM] £11.09 |

Minoxidil

INDICATIONS AND DOSE
Severe hypertension, in addition to a diuretic and a beta-blocker

BY MOUTH
Adult: Initially 5 mg daily in 1–2 divided doses, then increased in steps of 5–10 mg, increased at intervals of at least 3 days, seldom necessary to exceed 50 mg daily; maximum 100 mg per day

Elderly: Initially 2.5 mg daily in 1–2 divided doses, then increased in steps of 5–10 mg, increased at intervals of at least 3 days, seldom necessary to exceed 50 mg daily; maximum 100 mg per day

CONTRA-INDICATIONS Phaeochromocytoma

CAUTIONS Acute porphyrias p. 969 • after myocardial infarction (until stabilised) • angina

INTERACTIONS ➔ Appendix 1: minoxidil

SIDE-EFFECTS Breast tenderness • gastro-intestinal disturbances • hypertrichosis • peripheral oedema • rashes • reversible rise in creatinine and blood urea nitrogen • sodium retention • tachycardia • water retention • weight gain

PREGNANCY Avoid—possible toxicity including reduced placental perfusion. Neonatal hirsutism reported.

BREAST FEEDING Present in milk but not known to be harmful.

RENAL IMPAIRMENT Use with caution in significant impairment.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet

▷ Loniten (Pfizer Ltd)

| Minoxidil 2.5 mg | Loniten 2.5mg tablets | 60 tablet [POM] £8.88 DT price = £8.88 |
| Minoxidil 5 mg | Loniten 5mg tablets | 60 tablet [POM] £15.83 DT price = £15.83 |
| Minoxidil 10 mg | Loniten 10mg tablets | 60 tablet [POM] £30.68 DT price = £30.68 |

4.1a Hypertension associated with phaeochromocytoma

Other drugs used for Hypertension associated with phaeochromocytoma Propranolol hydrochloride, p. 145

VASODILATORS ➔ PERIPHERAL VASODILATORS

Phenoxybenzamine hydrochloride

INDICATIONS AND DOSE
Hypertension in phaeochromocytoma

BY MOUTH
Adult: Initially 10 mg daily, increased in steps of 10 mg daily until hypertension controlled or treatment not tolerated; maintenance 1–2 mg/kg daily in 2 divided doses

CONTRA-INDICATIONS During recovery period after myocardial infarction (usually 3–4 weeks) • history of cerebrovascular accident

CAUTIONS Avoid contact with skin (risk of contact sensitisation) • avoid in acute porphyrias p. 969 • carcinogenic in animals • cerebrovascular disease • congestive heart failure • elderly • severe ischaemic heart disease

SIDE-EFFECTS Rare Gastro-intestinal disturbances

Frequency not known Inhibition of ejaculation • lassitude • miosis • nasal congestion • postural hypotension (with dizziness and marked compensatory tachycardia)

PREGNANCY Hypotension may occur in newborn.

BREAST FEEDING May be present in milk.

RENAL IMPAIRMENT Use with caution.

HANDLING AND STORAGE Owing to risk of contact sensitisation healthcare professionals should avoid contamination of hands.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Capsule

▷ Phenoxybenzamine hydrochloride (Non-proprietary)

| Phenoxybenzamine hydrochloride 10 mg | Phenoxybenzamine 10mg capsules | 30 capsule [POM] £97.38 DT price = £97.38 |
Phentolamine mesilate

- **INDICATIONS AND DOSE**
  - Hypertensive crises due to phaeochromocytoma e.g. during surgery
    - **BY INTRAVENOUS INJECTION**
    - Adult: 2–5 mg, repeated if necessary

- **Diagnosis of phaeochromocytoma**
  - **BY INTRAVENOUS INJECTION, OR BY INTRAMUSCULAR INJECTION**
  - Adult: (consult product literature)

- **CONTRA-INDICATIONS**
  - Angina - coronary insufficiency
  - evidence of coronary artery disease
  - history of myocardial infarction
  - hypotension

- **CAUTIONS**
  - Elderly - gastritis - peptic ulcer

- **INTERACTIONS**
  - → Appendix 1: phentolamine

- **SIDE-EFFECTS**
  - Acute or prolonged hypotension
  - angina
  - arrhythmias - chest pain - diarrhoea - dizziness - flushing
  - nasal congestion - nausea - postural hypotension
  - tachycardia - vomiting

- **PREGNANCY**
  - Use with caution — may cause marked decrease in maternal blood pressure with resulting fetal anoxia.

- **BREAST FEEDING**
  - Manufacturer advises avoid — no information available.

- **RENAL IMPAIRMENT**
  - Manufacturer advises caution — no information available.

- **MONITORING REQUIREMENTS**
  - Monitor blood pressure and heart rate.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - Forms available from special order manufacturer include: Solution for injection.

### 4.1b Hypertensive crises

- **Other drugs used for Hypertensive crises**
  - Hydralazine hydrochloride, p. 175
  - Labetalol hydrochloride, p. 143

#### ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING

<table>
<thead>
<tr>
<th>Guanethidine monosulfate</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INDICATIONS AND DOSE</strong></td>
</tr>
<tr>
<td>Hypertensive crisis (but no longer recommended)</td>
</tr>
<tr>
<td>→ BY INTRAMUSCULAR INJECTION</td>
</tr>
<tr>
<td>Adult: 10–20 mg, dose may be repeated after 3 hours if necessary</td>
</tr>
</tbody>
</table>

- **CONTRA-INDICATIONS**
  - Heart failure - phaeochromocytoma

- **CAUTIONS**
  - Asthma - cerebral arteriosclerosis - coronary arteriosclerosis - history of peptic ulceration

- **INTERACTIONS**
  - → Appendix 1: guanethidine

- **SIDE-EFFECTS**
  - Diarrhoea - drowsiness - failure of ejaculation - fluid retention - headache - nasal congestion - postural hypotension

- **PREGNANCY**
  - Postural hypotension and reduced uteroplacental perfusion. Should not be used to treat hypertension in pregnancy.

- **RENAL IMPAIRMENT**
  - Reduce dose if eGFR 40–65 mL/minute/1.73 m². Avoid if eGFR less than 40 mL/minute/1.73 m².

- **LESS SUITABLE FOR PRESCRIBING**
  - Guanethidine monosulfate is less suitable for prescribing.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  - **Solution for injection**
    - Guanethidine monosulfate (Non-proprietary)
      - Guanethidine monosulfate 10 mg per 1 ml
      - Guanethidine 10mg/1ml solution for injection ampoules 15 ampoule £224.15

#### Sodium nitroprusside

- **INDICATIONS AND DOSE**
  - Hypertensive emergencies
    - **BY INTRAVENOUS INFUSION**
      - Adult: Initially 0.5–1.5 micrograms/kg/minute, adjusted in steps of 500 nanograms/kg/minute every 5 minutes, usual dose 0.5–8 micrograms/kg/minute, use lower doses if already receiving other antihypertensives, stop if response unsatisfactory with max. dose in 10 minutes, lower initial dose of 300 nanograms/kg/minute has been used

  - **Maintenance of blood pressure at 30–40% lower than pretreatment diastolic blood pressure**
    - **BY INTRAVENOUS INFUSION**
      - Adult: 20–400 micrograms/minute, use lower doses for patients being treated with other antihypertensives

  - **Controlled hypotension in anaesthesia during surgery**
    - **BY INTRAVENOUS INFUSION**
      - Adult: Up to 1.5 micrograms/kg/minute

  - **Acute or chronic heart failure**
    - **BY INTRAVENOUS INFUSION**
      - Adult: Initially 10–15 micrograms/minute, increased every 5–10 minutes as necessary; usual dose 10–200 micrograms/minute normally for max. 3 days

- **UNLICENSED USE**
  - Not licensed for use in the UK.

- **CONTRA-INDICATIONS**
  - Compensatory hypertension - Leber’s optic atrophy - severe vitamin B₁₂ deficiency

- **CAUTIONS**
  - Elderly - hyponatraemia - hypothermia - hypothyroidism - impaired cerebral circulation - ischaemic heart disease

- **INTERACTIONS**
  - → Appendix 1: sodium nitroprusside

- **SIDE-EFFECTS**
  - Abdominal pain - acute transient phlebitis - anxiety - dizziness - headache - nausea - palpitation - perspiration - reduced platelet count - retching - retrosternal discomfort

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Side-effects associated with rapid reduction in blood pressure: Headache, dizziness, nausea, retching, abdominal pain, perspiration, palpitation, anxiety, retrosternal discomfort — reduce infusion rate if any of these side-effects occur.

- **Overdose**
  - Side-effects caused by excessive plasma concentration of the cyanide metabolite include tachycardia, sweating, hyperventilation, arrhythmias, marked metabolic acidosis (discontinue and give antidote, see cyanide in Emergency treatment of poisoning p. 1255).

- **PREGNANCY**
  - Avoid prolonged use — potential for accumulation of cyanide in fetus.

- **BREAST FEEDING**
  - No information available. Caution advised due to thiocyanate metabolite.

- **HEPATIC IMPAIRMENT**
  - Use with caution. Avoid in hepatic failure — cyanide or thiocyanate metabolites may accumulate.
178 Blood pressure conditions

- **RENAL IMPAIRMENT** Avoid prolonged use—cyanide or thiocyanate metabolites may accumulate.
- **MONITORING REQUIREMENTS** Monitor blood pressure (including intra-arterial blood pressure) and blood-cyanide concentration, and if treatment exceeds 3 days, also blood thiocyanate concentration.
- **TREATMENT CESSATION** Avoid sudden withdrawal—terminate infusion over 15–30 minutes.
- **DIRECTIONS FOR ADMINISTRATION** For continuous intravenous infusion in Glucose 5%, infuse via infusion device to allow precise control. For further details, consult product literature. Protect infusion from light.
- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Powder and solvent for solution for infusion**
    - Sodium nitroprusside (Non-proprietary)
    - Sodium nitroprusside dihydrate 50 mg Sodium nitroprusside 50mg powder and solvent for solution for infusion vials | 1 vial | no price available

4.1c Pulmonary hypertension

Other drugs used for Pulmonary hypertension
Epoprostenol, p. 112 - Sildenafil, p. 766 - Tadalafil, p. 767

ANTITHROMBOTIC DRUGS > ANTIPLATELET DRUGS

Selexipag 22-May-2017

- **DRUG ACTION** Selexipag is a selective prostacyclin (IP) receptor agonist.

  - **INDICATIONS AND DOSE** Pulmonary arterial hypertension either as combination therapy (if insufficiently controlled with an endothelin receptor antagonist and/or a phosphodiesterase type-5 inhibitor), or as monotherapy (initiated under specialist supervision)
    - **BY MOUTH**
      - Adult: Initially 200 micrograms twice daily, increased in steps of 200 micrograms twice daily at weekly intervals up to the highest tolerated dose, usual maintenance 200–1600 micrograms twice daily, initial dose and first dose after each dose increase should be taken in the evening; maximum 3200 micrograms per day

- **CONTRA-INDICATIONS** Cerebrovascular event (within the last 3 months) - congenital or acquired valvular defects with myocardial function disorders (not related to pulmonary hypertension) - decompensated cardiac failure (unless under close medical supervision) - myocardial infarction (within last 6 months) - severe arhythmias - severe coronary heart disease - unstable angina
- **CAUTIONS** Elderly (limited information available)
- **INTERACTIONS** → Appendix 1: selexipag
- **SIDE-EFFECTS**
  - **Common or very common** Abdominal pain - anaemia - arthralgia - decreased appetite - diarrhoea - erythema - flushing - headache - hyperthyroidism - hypotension - jaw pain - myalgia - nasal congestion - nasopharyngitis - nausea - pain in extremity - rash - urticaria - vomiting
  - **Uncommon** Sinus tachycardia
- **PREGNANCY** Manufacturer advises avoid—no information available.
- **BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.

- **HEPATIC IMPAIRMENT** Manufacturer advises reduce initial dose to 200 micrograms once daily in moderate impairment and increase in steps of 200 micrograms once daily at weekly intervals, as tolerated. Manufacturer advises avoid in severe impairment.
- **RENAL IMPAIRMENT** Manufacturer advises caution with dose titration in severe impairment.
- **PATIENT AND CARER ADVICE**
  - Missed doses Manufacturer advises if a dose is more than 6 hours late, the missed dose should not be taken and the next dose should be taken at the normal time; if a dose is missed for 3 days or more, treatment should be restarted at a lower dose and then increased—consult product literature.
- **MEDICINAL FORMS**

Table

<table>
<thead>
<tr>
<th>Tablet CAUTIONARY AND ADVISORY LABELS 21, 25</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uptravi (Actelion Pharmaceuticals UK Ltd)</td>
</tr>
<tr>
<td>Selexipag 200 microgram Uptravi 200 microgram tablets</td>
</tr>
<tr>
<td>Selexipag 400 microgram Uptravi 400 microgram tablets</td>
</tr>
<tr>
<td>Selexipag 600 microgram Uptravi 600 microgram tablets</td>
</tr>
<tr>
<td>Selexipag 800 microgram Uptravi 800 microgram tablets</td>
</tr>
<tr>
<td>Selexipag 1 mg Uptravi 1,000 microgram tablets</td>
</tr>
<tr>
<td>Selexipag 1.2 mg Uptravi 1,200 microgram tablets</td>
</tr>
<tr>
<td>Selexipag 1.4 mg Uptravi 1,400 microgram tablets</td>
</tr>
<tr>
<td>Selexipag 1.6 mg Uptravi 1,600 microgram tablets</td>
</tr>
</tbody>
</table>

ANTITHROMBOTIC DRUGS > PROSTAGLANDINS, CARDIOVASCULAR

Iloprost

- **INDICATIONS AND DOSE** Idiopathic or familial pulmonary arterial hypertension (initiated under specialist supervision)
  - **BY INHALATION OF NEBULISED SOLUTION**
  - Adult: Initially 2.5 micrograms for 1 dose, increased to 5 micrograms for 1 dose, increased if tolerated to 5 micrograms 6–9 times a day, adjusted according to response; reduced if not tolerated to 2.5 micrograms 6–9 times a day, reduce to lower maintenance dose if high dose not tolerated

- **CONTRA-INDICATIONS** Conditions which increase risk of haemorrhage - congenital or acquired valvular defects of the myocardium - decompensated cardiac failure (unless under close medical supervision) - pulmonary veno-occlusive disease - severe arhythmias - unstable angina - within 6 months of myocardial infarction
- **CAUTIONS** Acute pulmonary infection - chronic obstructive pulmonary disease - hypotension (do not initiate if systolic blood pressure below 85 mmHg); severe asthma - unstable pulmonary hypertension with advanced right heart failure
- **INTERACTIONS** → Appendix 1: iloprost
- **SIDE-EFFECTS**
  - **Common or very common** Chest pain - cough - diarrhoea - dyspnoea - haemorrhage - headache - hypotension - jaw pain - nausea - oral irritation - rash - throat pain - vomiting
  - **Frequency not known** Bronchospasm - taste disturbance - thrombocytopenia - wheezing

Downloaded from www.medicalbr.com
ENDOTHELIN RECEPTOR ANTAGONISTS

Ambrisentan

**INDICATIONS AND DOSE**
Pulmonary arterial hypertension (initiated under specialist supervision)

- **BY MOUTH**
  - Adult: 5 mg once daily, increased if necessary to 10 mg once daily

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**
Manufacturer advises max. dose 5 mg daily and close monitoring with concurrent use of cyclosporin.

**CONTRA-INDICATIONS**
- Idiopathic pulmonary fibrosis

**CAUTIONS**
- Not to be initiated in significant anaemia

**INTERACTIONS → Appendix 1: ambrisentan**

**SIDE-EFFECTS**
- **Common or very common** Abdominal pain, anaemia, chest pain, constipation, diarrhoea, dizziness, dyspnoea, epistaxis, flushing, headache, heart failure, hypotension, malaise, nausea, palpitation, peripheral oedema, upper respiratory tract disorders, vomiting
- **Uncommon** Autoimmune hepatitis, hepatic injury, syncope

**CONCEPTION AND CONTRACEPTION**
Exclude pregnancy before treatment and ensure effective contraception during treatment. Monthly pregnancy tests advised.

**PREGNANCY**
Avoid (teratogenic in *animal* studies).

**BREAST FEEDING**
Manufacturer advises avoid—no information available.

**HEPATIC IMPAIRMENT**
Avoid in severe impairment.

**RENAL IMPAIRMENT**
Use with caution if eGFR less than 30 mL/minute/1.73 m².

**MONITORING REQUIREMENTS**
- Monitor haemoglobin concentration or haematocrit after 1 month and 3 months of starting treatment, and periodically thereafter (reduce dose or discontinue treatment if significant decrease in haemoglobin concentration or haematocrit observed).
- Monitor liver function before treatment, and monthly thereafter—discontinue if liver enzymes raised significantly or if symptoms of liver impairment develop.

**NATIONAL FUNDING/ACCESS DECISIONS**

**Scottish Medicines Consortium (SMC) Decisions**
The Scottish Medicines Consortium has advised (October 2008) that ambrisentan (*Volibris®*) should be prescribed only by specialists in the Scottish Pulmonary Vascular Unit or other similar specialists.

**MEDIcular system 179**

**Bosentan**

**INDICATIONS AND DOSE**
Pulmonary arterial hypertension (initiated under specialist supervision)

- **BY MOUTH**
  - Adult: Initially 62.5 mg twice daily for 4 weeks, then increased to 125 mg twice daily (max. per dose 250 mg); maximum 500 mg per day

**Systemic scleroderma with ongoing digital ulcer disease (to reduce number of new digital ulcers)**

- **BY MOUTH**
  - Adult: Initially 62.5 mg twice daily for 4 weeks, then increased to 125 mg twice daily

**CONTRA-INDICATIONS**
- Acute porphyrias p. 969
- **CAUTIONS**
  - Not to be initiated if systemic systolic blood pressure is below 85 mmHg
  - **INTERACTIONS → Appendix 1: bosentan**

**SIDE-EFFECTS**
- **Common or very common** Anaemia, diarrhoea, flushing, gastro-oesophageal reflux, headache, hypotension, oedema, palpitation, syncope
- **Uncommon** Leucopenia, neutropenia, thrombocytopenia
- **Rare** Liver cirrhosis, liver failure

**CONCEPTION AND CONTRACEPTION**
Effective contraception required during administration (hormonal contraception not considered effective). Monthly pregnancy tests advised.

**PREGNANCY**
Avoid (teratogenic in *animal* studies).

**BREAST FEEDING**
Manufacturer advises avoid—no information available.

**HEPATIC IMPAIRMENT**
Avoid in moderate and severe impairment.

**MONITORING REQUIREMENTS**
- Monitor haemoglobin before and during treatment (monthly for first 4 months, then 3-monthly).
- Monitor liver function before treatment, at monthly intervals during treatment, and 2 weeks after dose increase (reduce dose or suspend treatment if liver enzymes raised significantly)—discontinue if symptoms of liver impairment.

**TREATMENT CESSATION**
Avoid abrupt withdrawal—withdraw treatment gradually.
**Guanylate Cyclase Stimulators**

**Riociguat**

**INDICATIONS AND DOSE**

Chronic thromboembolic pulmonary hypertension that is recurrent or persistent following surgery, or is inoperable (initiated under specialist supervision) | Monotherapy or in combination with an endothelin receptor antagonist for idiopathic or hereditary pulmonary arterial hypertension, or pulmonary arterial hypertension associated with connective tissue disease (initiated under specialist supervision)

▶ **BY MOUTH**

Adult: Initially 1 mg 3 times a day for 2 weeks, increased in steps of 0.5 mg 3 times a day, dose to be increased every 2 weeks, increased to up to 2.5 mg 3 times a day (max. per dose 2.5 mg 3 times a day), increase up to maximum dose only if systolic blood pressure ≥ 95 mmHg and no signs of hypotension, if treatment interrupted for 3 or more days, restart at 1 mg three times daily for 2 weeks and titrate as before, during titration, reduce dose by 0.5 mg three times daily if systolic blood pressure falls below 95 mmHg and patient shows signs of hypotension

**IMPORTANT SAFETY INFORMATION**

MHRA/CHM ADVICE: PULMONARY HYPERTENSION ASSOCIATED WITH IDIOPATHIC INTERSTITIAL PNEUMONIAS (PH-IIP) (AUGUST 2016)

Interim results from a terminated study to investigate the efficacy and safety of riociguat in patients with symptomatic PH-IIP, showed increased mortality and increased risk of serious adverse events in the riociguat group compared with the placebo group. The MHRA has advised that use of riociguat is contra-indicated in these patients and that existing treatment for this unauthorised indication should be discontinued.

**CONTRA-INDICATIONS**

History of serious haemoptysis - previous bronchial artery embolisation - pulmonary hypertension associated with idiopathic interstitial pneumonias - pulmonary veno-occlusive disease

**CAUTIONS**

Autonomic dysfunction - elderly (risk of hypotension) - hypotension (do not initiate if systolic blood pressure below 95 mmHg) - hypovolaemia - severe left ventricular outflow obstruction

**SIDE-EFFECTS**

Common or very common Anaemia - constipation - diarrhoea - dizziness - dyspepsia - dysphagia - epistaxis - gastritis - gastro-oesophageal reflux - haemoptysis - headache - hypotension - nasal congestion - nausea - palpitation - peripheral oedema - vomiting

Uncommon Pulmonary haemorrhage

**CONCEPTION AND CONTRACEPTION**

Effective contraception required during treatment. Monthly pregnancy tests advised.

**PREGNANCY**

Avoid—toxicity in animal studies.

**BREAST FEEDING**

Manufacturer advises avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT**

Titrated dose cautiously in moderate impairment. Manufacturer advises avoid in severe impairment—no information available.
4.2 Hypotension and shock

Sympathomimetics

Inotropic sympathomimetics

Shock
Shock is a medical emergency associated with a high mortality. The underlying causes of shock such as haemorrhage, sepsis, or myocardial insufficiency should be corrected. The profound hypotension of shock must be treated promptly to prevent tissue hypoxia and organ failure. Volume replacement is essential to correct the hypovolaemia associated with haemorrhage and sepsis but may be detrimental in cardiogenic shock. Depending on haemodynamic status, cardiac output may be improved by the use of sympathomimetic inotropes such as adrenaline/epinephrine p. 216, dobutamine p. 215 or dopamine hydrochloride below. In septic shock, when fluid replacement and inotropic support fail to maintain blood pressure, the vasoconstrictor noradrenaline/norepinephrine p. 183 may be considered. In cardiogenic shock peripheral resistance is frequently high and to raise it further may worsen myocardial performance and exacerbate tissue ischaemia.

The use of sympathomimetic inotropes and vasoconstrictors should preferably be confined to the intensive care setting and undertaken with invasive haemodynamic monitoring.

See also advice on the management of anaphylactic shock in Anti-histamines, allergen immunotherapy and allergic emergencies p. 266.

Vasoconstrictor sympathomimetics
Vasoconstrictor sympathomimetics raise blood pressure transiently by acting on alpha-adrenergic receptors to constrict peripheral vessels. They are sometimes used as an emergency method of elevating blood pressure where other measures have failed.

The danger of vasoconstrictors is that although they raise blood pressure they also reduce perfusion of vital organs such as the kidney.

Spinal and epidural anaesthesia may result in sympathetic block with resultant hypotension. Management may include intravenous fluids (which are usually given prophylactically), oxygen, elevation of the legs, and injection of a pressor drug such as ephedrine hydrochloride p. 261. As well as constricting peripheral vessels ephedrine hydrochloride also accelerates the heart rate (by acting on beta receptors). Use is made of this dual action of ephedrine hydrochloride to manage associated bradycardia (although intravenous injection of atropine sulfate p. 1224 may also be required if bradycardia persists).

**Dopamine hydrochloride**

- **INDICATIONS AND DOSE** Cardiogenic shock in infarction or cardiac surgery
  - BY INTRAVENOUS INFUSION
    - Adult: Initially 2–5 micrograms/kg/minute

- **SIDE-EFFECTS**
  - Common or very common Chest pain - dyspnoea - headache - hypotension - nausea - palpitation - tachycardia - vasoconstriction - vomiting
  - Uncommon Bradycardia - gangrene - hypertension - mydriasis
  - Rare Fatal ventricular arrhythmias

- **PRECAUTIONS** No evidence of harm in animal studies—manufacturer advises use only if potential benefit outweighs risk.

- **DIRECTIONS FOR ADMINISTRATION** Dopamine concentrate for intravenous infusion to be diluted before use.
  For intravenous infusion give continuously in Glucose 5% or Sodium chloride 0.9%. Dilute to max. concentration of 3.2 mg/mL; incompatible with bicarbonate.

- **MEDICATION FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for infusion

**Solution for infusion**

- Dopamine hydrochloride (Non-proprietary)
  - Dopamine hydrochloride 40 mg per 1 ml Dopamine 200mg/5ml solution for infusion ampoules | 5 ampoule £10.80, 10 ampoule £19.04
  - Dopamine 200mg/5ml concentrate for solution for infusion ampoules | 10 ampoule no price available
  - Dopamine hydrochloride 160 mg per 1 ml Dopamine 800mg/5ml solution for infusion ampoules | 10 ampoule £34.00
**Cardiovascular system**

**CONTRA-INDICATIONS**
- Hypertension
- Cirrhosis - coronary vascular thrombosis - diabetes mellitus - elderly - extravasation at injection site may cause necrosis - following myocardial infarction - hypercapnia - hyperthyroidism - hypoxia - mesenteric vascular thrombosis - peripheral vascular thrombosis - Prinzmetal's variant angina - uncorrected hypovolaemia

**INTERACTIONS**
- Hypertensive response - Metaraminol has a longer duration of action than noradrenaline, and an excessive vasopressor response may cause a prolonged rise in blood pressure.

**SIDE-EFFECTS**
- Angle-closure glaucoma - anorexia - anxiety - arrhythmias - bradycardia - confusion - dyspnoea - fatal ventricular arrhythmia reported in Laennec’s cirrhosis - headache - hypotension - hypoxia - insomnia - nausea - palpitation - peripheral ischaemia - psychosis - tachycardia - tremor - urinary retention - vomiting - weakness

**PREGNANCY**
- May reduce placental perfusion - manufacturer advises use only if potential benefit outweighs risk.

**BREAST FEEDING**
- Manufacturer advises caution - no information available.

**MONITORING REQUIREMENTS**
- Monitor blood pressure and rate of flow frequently.

**DIRECTIONS FOR ADMINISTRATION**
- For intravenous infusion (Aramine®), give continuously or via drip tubing in Glucose 5% or Sodium chloride 0.9%. Suggested volume 500 mL.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection

**Solution for injection**
- **Metaraminol** (Non-proprietary)
  - Metaraminol (as Metaraminol tartrate) 10 mg per
  - 1 ml Metaraminol 10mg/2ml solution for injection ampoules: PCT £31.27

---

**PRESSURE INFLATORS**

**INDICATIONS AND DOSE**
- Severe orthostatic hypotension due to autonomic dysfunction when corrective factors have been ruled out and other forms of treatment are inadequate
  - **BY MOUTH**
    - Adult: Initially 2.5 mg 3 times a day, increased if necessary up to 10 mg 3 times a day, dose to be increased at weekly intervals, according to blood pressure measurements; usual maintenance 10 mg 3 times a day, avoid administration at night; the last daily dose should be taken at least 4 hours before bedtime

**CONTRA-INDICATIONS**

**CAUTIONS**
- Atherosclerotic cardiovascular disease (especially with symptoms of intestinal angina or claudication of the legs) - autonomic dysfunction - elderly (manufacturer recommends cautious dose titration) - prostate disorders

**INTERACTIONS**
- Appendix 1: sympathomimetics, vasoconstrictor

**SIDE-EFFECTS**
- Common or very common: Chills - dyspepsia - flushing - headache - nausea - paraesthesia - piloerection - pruritus - rash - stomatitis - supine hypertension (dose dependent) - urinary disorders

- Uncommon: Excitability - irritability - reflex bradycardia - restlessness - sleep disorders

- Rare: Hepatic dysfunction - palpitations - tachycardia

- Frequency not known: Abdominal pain - anxiety - confusion - diarrhea - vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**
- Supine hypertension: Manufacturer advises that treatment must be stopped if supine hypertension is not controlled by reducing the dose.

**CONCEPTION AND CONTRACEPTION**
- Manufacturer recommends effective contraception during treatment in women of childbearing potential.

**PREGNANCY**
- Manufacturer advises avoid - toxicity in animal studies.

**BREAST FEEDING**
- Manufacturer advises avoid - no information available.

**RENAL IMPAIRMENT**
- Manufacturer advises avoid in severe or acute impairment.

**MONITORING REQUIREMENTS**
- Manufacturer advises measure hepatic and renal function before treatment and at regular intervals during treatment.
  - Manufacturer advises regular monitoring of supine and standing blood pressure due to the risk of hypertension in the supine position.

**PATIENT AND CARER ADVICE**
- Manufacturer advises that patients report symptoms of supine hypertension (such as chest pain, palpitations, shortness of breath, headache and blurred vision) immediately. The risk of supine hypertension at night can be reduced by raising the head of the bed.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- **Bramox** (Brancaster Pharma Ltd)
  - Midodrine hydrochloride 2.5 mg: Bramox 2.5mg tablets: 100 tablet: PCT £5.05 DT price = £5.05
  - Midodrine hydrochloride 5 mg: Bramox 5mg tablets: 100 tablet: PCT £7.50 DT price = £7.50
Noradrenaline/norepinephrine

- **INDICATIONS AND DOSE**
  - **Acute hypotension**
    - **BY INTRAVENOUS INFUSION**
      - Adult: Initially 0.16–0.33 mL/minute, adjusted according to response, to be given via central venous catheter, of a solution containing noradrenaline 40 micrograms(base)/mL.

- **DOSE EQUIVALENCE AND CONVERSION**
  - 1 mg of noradrenaline base is equivalent to 2 mg of noradrenaline acid tartrate. **Doses expressed as the base.**

- **CONTRA-INDICATIONS**
  - Hypertension

- **CAUTIONS**
  - Coronary vascular thrombosis • diabetes mellitus • elderly • extravasation at injection site may cause necrosis • following myocardial infarction • hypercapnia • hyperthyroidism • hypoxia • mesenteric vascular thrombosis • peripheral vascular thrombosis • Prinzmetal’s variant angina • uncorrected hypovolaemia

- **INTERACTIONS**
  - Appendix 1: sympathomimetics, vasoconstrictor

- **SIDE-EFFECTS**
  - Angle-closure glaucoma • anorexia • anxiety • arrhythmias • bradycardia • confusion • dyspnoea • headache • hypertension • hypoxia • insomnia • nausea • palpitation • peripheral ischaemia • psychosis • tachycardia • tremor • urinary retention • vomiting • weakness

- **PREGNANCY**
  - Avoid—may reduce placental perfusion.

- **MONITORING REQUIREMENTS**
  - Monitor blood pressure and rate of flow frequently.

- **DIRECTIONS FOR ADMINISTRATION**
  - For treatment of acute hypotension in adults, use a solution containing noradrenaline 40 micrograms (base)/mL. For **intravenous infusion**, give continuously in Glucose 5% or Sodium Chloride and glucose via a controlled infusion device. For administration via syringe pump, dilute 2 mg (2 mL of solution) noradrenaline base with 48 mL infusion fluid. For administration via drip counter dilute 20 mg (20 mL of solution) noradrenaline base with 480 mL infusion fluid; give through a central venous catheter; incompatible with alkalis.

- **PRESCRIBING AND DISPENSING INFORMATION**
  - For a period of time, preparations on the UK market may be described as either noradrenaline base or noradrenaline acid tartrate; doses in the BNF are expressed as the base.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: infusion, solution for infusion

  - **Solution for infusion**
    - Noradrenaline/norepinephrine (Non-proprietary)
      - Noradrenaline (as Noradrenaline acid tartrate) 1 mg per 1 mL Noradrenaline (Norepinephrine) 4mg/4ml concentrate for solution for infusion ampoules | 10 ampoule (£0.59) £4.40
      - Noradrenaline (base) 8mg/8ml concentrate for solution for infusion ampoules | 10 ampoule (£0.59) £11.60
      - Noradrenaline (base) 2mg/2ml solution for infusion ampoules | 5 ampoule (£0.59) £12.00 (Hospital only)
      - Noradrenaline (base) 4mg/4ml solution for infusion ampoules | 5 ampoule (£0.59) £22.00 (Hospital only)
      - Noradrenaline (base) 4mg/4ml concentrate for solution for infusion ampoules | 10 ampoule (£0.59) £58.00
      - Noradrenaline (Norepinephrine) 2mg/2ml concentrate for solution for Infusion ampoules | 5 ampoule (£0.59) £11.00

Phenylephrine hydrochloride

- **INDICATIONS AND DOSE**
  - **Acute hypotension**
    - **BY SUBCUTANEOUS INJECTION, OR BY INTRAMUSCULAR INJECTION**
      - Adult: Initially 2–5 mg, followed by 1–10 mg, after at least 15 minutes if required
    - **BY SLOW INTRAVENOUS INJECTION**
      - Adult: 100–500 micrograms, repeated as necessary after at least 15 minutes
    - **BY INTRAVENOUS INFUSION**
      - Adult: Initially up to 180 micrograms/minute, reduced to 30–60 micrograms/minute, adjusted according to response

- **CONTRA-INDICATIONS**
  - Hypertension • severe hyperthyroidism

- **CAUTIONS**
  - Coronary disease • coronary vascular thrombosis • diabetes • elderly • extravasation at injection site may cause necrosis • following myocardial infarction • hypercapnia • hyperthyroidism • hypoxia • mesenteric vascular thrombosis • peripheral vascular thrombosis • Prinzmetal’s variant angina • susceptibility to angle-closure glaucoma • uncorrected hypovolaemia

- **CAUTIONS, FURTHER INFORMATION**
  - Hypertensive response Phenylephrine has a longer duration of action than noradrenaline (norepinephrine), and an excessive vasopressor response may cause a prolonged rise in blood pressure.

- **INTERACTIONS**
  - Appendix 1: sympathomimetics, vasoconstrictor

- **SIDE-EFFECTS**
  - Angle-closure glaucoma • anorexia • anxiety • arrhythmias • bradycardia (also reflex bradycardia) • confusion • dyspnoea • headache • hypertension • hypoxia • insomnia • nausea • palpitation • tachycardia • peripheral ischaemia • psychosis • tremor • urinary retention • vomiting • weakness

- **PREGNANCY**
  - Avoid if possible; malformations reported following use in first trimester; fetal hypoxia and bradycardia reported in late pregnancy and labour.

- **MONITORING REQUIREMENTS**
  - Contra-indicated in hypertension—monitor blood pressure and rate of flow frequently.

- **DIRECTIONS FOR ADMINISTRATION**
  - For **intravenous infusion** give intermittently in Glucose 5% or Sodium chloride 0.9%. Dilute 10 mg in 500 mL infusion fluid.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection

  - **Solution for injection**
    - Phenylephrine hydrochloride (Non-proprietary)
      - Phenylephrine (as Phenylephrine hydrochloride) 50 microgram per 1 mL Phenylephrine 500micrograms/10ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (£0.50) £15.00
      - 10 pre-filled disposable injection (£0.50) £150.00
    - Phenylephrine hydrochloride 100 microgram per 1 mL Phenylephrine 1mg/10ml solution for injection ampoules | 10 ampoule (£0.50) £4.00
    - Phenylephrine hydrochloride 10 mg per 1 mL Phenylephrine 10mg/1ml solution for injection ampoules | 10 ampoule (£0.50) £99.12
5  Heart failure

Heart failure

Drug treatment

Drug treatment of heart failure associated with a reduced left ventricular ejection fraction (left ventricular systolic dysfunction) is covered below; optimal management of heart failure with a preserved left ventricular ejection fraction has not been established.

The treatment of chronic heart failure aims to relieve symptoms, improve exercise tolerance, reduce the incidence of acute exacerbations, and reduce mortality. An ACE inhibitor, titrated to a 'target dose' (or the maximum tolerated dose if lower), together with a beta-blocker, form the basis of treatment for all patients with heart failure due to left ventricular systolic dysfunction.

An ACE inhibitor is generally advised for patients with asymptomatic left ventricular systolic dysfunction or symptomatic heart failure. An angiotensin-II receptor antagonist may be a useful alternative for patients who, because of side-effects such as cough, cannot tolerate ACE inhibitors; a relatively high dose of the angiotensin-II receptor antagonist may be required to produce benefit. Candesartan cilexetil p. 170 or valsartan p. 174 may be given under specialist supervision as adjuncts to an ACE inhibitor in the treatment of heart failure when other treatments are unsuitable; the concomitant use of this combination, together with an aldosterone antagonist or a potassium-sparing diuretic is not recommended. The combination of valsartan with sacubitril p. 186, an angiotensin-II receptor antagonist with a neprilysin inhibitor, may be a suitable alternative for those patients already stabilised on an ACE inhibitor or angiotensin-II receptor antagonist.

The beta-blockers bisoprolol fumarate p. 148 and carvedilol p. 143 are of value in any grade of stable heart failure due to left ventricular systolic dysfunction; nebivolol p. 149 is licensed for stable mild to moderate heart failure in patients over 70 years. Beta-blocker treatment should be started by those experienced in the management of heart failure, at a very low dose and titrated very slowly over a period of weeks or months. Symptoms may deteriorate initially, calling for adjustment of concomitant therapy.

The aldosterone antagonist spironolactone p. 185 can be added to an ACE inhibitor and a beta-blocker in patients who continue to remain symptomatic (particularly in those with moderate to severe heart failure); low doses of spironolactone reduce symptoms and mortality in these patients. If spironolactone cannot be used, eplerenone p. 185 may be considered for the management of heart failure after an acute myocardial infarction with evidence of left ventricular systolic dysfunction, or for chronic mild heart failure with left ventricular systolic dysfunction. Close monitoring of serum creatinine, eGFR, and potassium is necessary, particularly following any change in treatment or any change in the patient's clinical condition.

Patients who cannot tolerate an ACE inhibitor or an angiotensin-II receptor antagonist, or in whom they are contra-indicated, may be given isosorbide dinitrate p. 214 with hydralazine hydrochloride p. 175 but this combination may be poorly tolerated. The combination of isosorbide dinitrate and hydralazine hydrochloride may be considered in addition to standard therapy with an ACE inhibitor and a beta-blocker in patients who continue to remain symptomatic (particularly in patients of African or Caribbean origin who have moderate to severe heart failure).

Digoxin p. 106 improves symptoms of heart failure and exercise tolerance and reduces hospitalisation due to acute exacerbations but it does not reduce mortality. Digoxin is reserved for patients with worsening or severe heart failure due to left ventricular systolic dysfunction who remain symptomatic despite treatment with an ACE inhibitor and a beta-blocker in combination with either an aldosterone antagonist, candesartan cilexetil, or isosorbide dinitrate with hydralazine hydrochloride.

Patients with fluid overload should also receive either a loop or a thiazide diuretic (with salt or fluid restriction where appropriate). A thiazide diuretic may be of benefit in patients with mild heart failure and good renal function; however, thiazide diuretics are ineffective in patients with poor renal function (eGFR less than 30 mL/minute/1.73 m²) and a loop diuretic is preferred. If diuresis with a single diuretic is insufficient, a combination of a loop diuretic and a thiazide diuretic may be tried; addition of metolazone p. 225 may also be considered but the resulting diuresis may be profound and care is needed to avoid potentially dangerous electrolyte disturbances.

**Other drugs used for Heart failure**

**Bendroflumethiazide**, p. 161 • Captopril, p. 163 • Chlorothalidone, p. 224 • Co-amilozide, p. 161 • Clopenthiazide, p. 225 • Enalapril maleate, p. 164 • Fosinopril sodium, p. 164 • Glyceril trinitrate, p. 212 • Isosorbide mononitrate, p. 214 • Ivabradine, p. 205 • Lisinopril, p. 165 • Losartan potassium, p. 171 • Metoprolol tartrate, p. 149 • Perindopril arginine, p. 166 • Perindopril erbumine, p. 167 • Prasozin, p. 739 • Quinapril, p. 167 • Ramipril, p. 168 • Sodium nitroprusside, p. 177

**DIURETICS > POTASSIUM-SPARRING DIURETICS > ALDOSTERONE ANTAGONISTS**

**Co-Flumactone**

The properties listed below are those particular to the combination only. For the properties of the components please consider, spironolactone p. 185.

- **INDICATIONS AND DOSE**
  - **Congestive heart failure**
    - **BY MOUTH**
      - Adult: Initially 100/100 mg daily; maintenance 25/25–200/200 mg daily, maintenance dose not recommended because spironolactone generally given in lower dose

- **INTERACTIONS** Appendix 1: aldosterone antagonists, thiazide diuretics

- **LESS SUITABLE FOR PRESCRIBING** Co-Flumactone tablets are less suitable for prescribing.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- Aldactide (Pfizer Ltd)
  - Hydroflumethiazide 25 mg, Spironolactone 25 mg Aldactide 25 tablets | 100 tablet (£3.42) £20.23 DT price = £20.23
  - Hydroflumethiazide 50 mg, Spironolactone 50 mg Aldactide 50 tablets | 28 tablet (£3.10) £10.70 | 100 tablet (£3.10) £38.23 DT price = £38.23
Eplerenone

**INDICATIONS AND DOSE**

Adjuvant in stable patients with left ventricular ejection fraction ≤ 40% with evidence of heart failure, following myocardial infarction (start therapy within 3–14 days of event) | Adjunct in chronic mild heart failure with left ventricular ejection fraction ≤ 30% | DOSE ADJUSTMENTS DUE TO INTERACTIONS

- **BY MOUTH**
  - Adult: Initially 25 mg daily, then increased to 50 mg daily, increased within 4 weeks of initial treatment

- **INTERACTIONS** | Appendix 1: aldosterone antagonists

- **SIDE-EFFECTS**
  - Common or very common | Azotaemia • constipation • cough • diarrhoea • dizziness • hyperkalaemia • hypotension • muscle spasm • musculoskeletal pain • nausea • pruritus • rash • renal impairment • syncope
  - Uncommon | Arterial thrombosis • atrial fibrillation • back pain • cholecystitis • dehydration • dyslipidaemia • eosinophilia • epidermal growth factor receptor decreased • flatulence • gynaecomastia • headache • hyperglycaemia • hypoaesthesia • hyponatraemia • hypothyroidism • insomnia • malaise • pharyngitis • postural hypotension • pyelonephritis • sweating • tachycardia • vomiting
  - Frequency not known | Angioedema

- **PREGNANCY** | Manufacturer advises caution — no information available.

- **BREAST FEEDING** | Manufacturer advises use only if potential benefit outweighs risk.

- **HEPATIC IMPAIRMENT** | Avoid in severe impairment.

- **RENAL IMPAIRMENT** | Initially 25 mg on alternate days if eGFR 30–60 mL/minute/1.73 m², adjust dose according to serum-potassium concentration — consult product literature. Avoid if eGFR less than 30 mL/minute/1.73 m². Increased risk of hyperkalaemia in renal impairment — close monitoring required.

- **MONITORING REQUIREMENTS** | Monitor plasma-potassium concentration before treatment, during initiation, and when dose changed.

**COMMON OR VERY COMMON**

- Rash
- Muscle spasm
- Arterial thrombosis

**CONTRA-INDICATIONS**

- Hyperkalaemia
- Elderly

**INTERACTIONS**

- **PRECAUTIONS**
  - Addon’s disease • anuria • hyperkalaemia
- **CAUTIONS**
  - Acute porphyrias p. 969 • elderly • potential metabolic products carcinogenic in rodents

**SIDE-EFFECTS**

- Acute renal failure • agranulocytosis • alopecia • benign breast tumour • breast pain • changes in libido • confusion • dizziness • drowsiness • electrolyte disturbances • gastro-intestinal disturbances • gynaecomastia • hepatotoxicity • hyperkalaemia (discontinue) • hypertrichosis • hyperuricaemia • hyponatraemia • leg cramps • leucopenia • malaise • menstrual disturbances • rash • Stevens-Johnson syndrome • thrombocytopenia

**PREGNANCY**

- Use only if potential benefit outweighs risk — feminisation of male fetus in animal studies.

**BREAST FEEDING**

- Metabolites present in milk, but amount probably too small to be harmful.

**RENAL IMPAIRMENT**

- Avoid in acute renal insufficiency or severe impairment. Monitor plasma-potassium concentration (high risk of hyperkalaemia in renal impairment).

**MONITORING REQUIREMENTS**

- Monitor electrolytes — discontinue if hyperkalaemia occurs (in severe heart failure monitor potassium and creatinine 1 week after initiation and after any dose increase, monthly for first 3 months, then every 3 months for 1 year, and then every 6 months).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Eplerenone (Non-proprietary)**
  - Eplerenone 25 mg | Eplerenone 25 mg tablets | 28 tablet | £42.72 DT price = £4.14
  - Eplerenone 50 mg | Eplerenone 50 mg tablets | 28 tablet | £42.72 DT price = £5.37
  - **Inspira** (Pfizer Ltd)
    - Eplerenone 25 mg | Inspira 25 mg tablets | 28 tablet | £42.72 DT price = £4.14
    - Eplerenone 50 mg | Inspira 50 mg tablets | 28 tablet | £42.72 DT price = £5.37

**Spironolactone**

**INDICATIONS AND DOSE**

Oedema | Ascites in cirrhosis of the liver

- **BY MOUTH**
  - Adult: 100–400 mg daily, adjusted according to response

**Malignant ascites**

- **BY MOUTH**
  - Adult: Initially 100–200 mg daily, then increased if necessary to 400 mg daily, maintenance dose adjusted according to response

**Nephrotic syndrome**

- **BY MOUTH**
  - Adult: 100–200 mg daily

**Oedema in congestive heart failure**

- **BY MOUTH**
  - Adult: Initially 25 mg once daily, then adjusted according to response to 50 mg once daily

**Resistant hypertension (adjunct)**

- **BY MOUTH**
  - Adult: Initially 25 mg once daily

**Primary hyperaldosteronism in patients awaiting surgery**

- **BY MOUTH**
  - Adult: 100–400 mg daily, may be used for long-term maintenance if surgery inappropriate, use lowest effective dose

**UNLICENSED USE**

- Resistant hypertension (adjunct) unlicensed indication.

**CONTRA-INDICATIONS**

- Addison’s disease • anuria • hyperkalaemia

**CAUTIONS**

- Acute porphyrias p. 969 • elderly • potential metabolic products carcinogenic in rodents

**INTERACTIONS**

- **PRECAUTIONS**
  - Addon’s disease • anuria • hyperkalaemia
- **CAUTIONS**
  - Acute porphyrias p. 969 • elderly • potential metabolic products carcinogenic in rodents

**SIDE-EFFECTS**

- Acute renal failure • agranulocytosis • alopecia • benign breast tumour • breast pain • changes in libido • confusion • dizziness • drowsiness • electrolyte disturbances • gastro-intestinal disturbances • gynaecomastia • hepatotoxicity • hyperkalaemia (discontinue) • hypertrichosis • hyperuricaemia • hyponatraemia • leg cramps • leucopenia • malaise • menstrual disturbances • rash • Stevens-Johnson syndrome • thrombocytopenia

**PREGNANCY**

- Use only if potential benefit outweighs risk — feminisation of male fetus in animal studies.

**BREAST FEEDING**

- Metabolites present in milk, but amount probably too small to be harmful.

**RENAL IMPAIRMENT**

- Avoid in acute renal insufficiency or severe impairment. Monitor plasma-potassium concentration (high risk of hyperkalaemia in renal impairment).

**MONITORING REQUIREMENTS**

- Monitor electrolytes — discontinue if hyperkalaemia occurs (in severe heart failure monitor potassium and creatinine 1 week after initiation and after any dose increase, monthly for first 3 months, then every 3 months for 1 year, and then every 6 months).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Tablet**

- **Spironolactone (Non-proprietary)**
  - Spironolactone 25 mg | Spironolactone 25 mg tablets | 28 tablet | £3.50 DT price = £1.30
  - Spironolactone 50 mg | Spironolactone 50 mg tablets | 28 tablet | £6.00 DT price = £1.70
  - Spironolactone 100 mg | Spironolactone 100 mg tablets | 28 tablet | £6.24 DT price = £2.00 | 30 tablet | no price available
Cardiovascular system

DRUGS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

〈 ANGIOTENSIN II RECEPTOR ANTAGONISTS

Valsartan with sacubitril

The properties listed below are those particular to the combination only. For the properties of the components please consider, valsartan p. 174.

DRUG ACTION
Sacubitril (a prodrug) inhibits the breakdown of natriuretic peptides resulting in varied effects including increased diuresis, natriuresis, and vasodilatation.

INDICATIONS AND DOSE
Symptomatic chronic heart failure with reduced ejection fraction (in patients not currently taking an ACE inhibitor or angiotensin II receptor antagonist, or stabilised on low doses of either of these agents)

BY MOUTH
Adult: Initially 26/24 mg twice daily for 3–4 weeks, increased if tolerated to 51/49 mg twice daily for 3–4 weeks, then increased if tolerated to 103/97 mg twice daily.

Symptomatic chronic heart failure with reduced ejection fraction (in patients currently stabilised on an ACE inhibitor or angiotensin II receptor antagonist)

BY MOUTH
Adult: Initially 51/49 mg twice daily for 2–4 weeks, increased if tolerated to 103/97 mg twice daily, consider a starting dose of 26/24 mg if systolic blood pressure less than 100 mmHg.

DOSE EQUIVALENCE AND CONVERSION
Entresto® tablets contain valsartan and sacubitril; the proportions are expressed in the form x/y where x and y are the strength in milligrams of valsartan and sacubitril respectively. Valsartan, in this formulation, is more bioavailable than other tablet formulations—26 mg, 51 mg, and 103 mg valsartan is equivalent to 40 mg, 80 mg and 160 mg, respectively. Furthermore, note that the 26/24 mg, 51/49 mg and 103/97 mg strengths are sometimes referred to as a total of both drug strengths, that is, 50 mg, 100 mg and 200 mg, respectively.

CONTRA-INDICATIONS
Concomitant use of ACE inhibitor (separate administration by 36 hours) • systolic blood pressure less than 100 mmHg

INTERACTIONS
Appendix 1: angiotensin-II receptor antagonists, sacubitril

SIDE-EFFECTS
Common or very common Anaemia • diarrhoea • gastritis • hypoglycaemia • hypokalaemia • nausea • vertigo

PREGNANCY
Manufacturer advises avoid—toxicity with sacubitril in animal studies.

BREAST FEEDING
Manufacturer advises avoid—present in milk in animal studies.

HEPATIC IMPAIRMENT
Manufacturer advises starting dose of 26/24 mg twice daily in moderate impairment. Contra-indicated in severe impairment.

RENAL IMPAIRMENT
Manufacturer recommends a starting dose of 26/24 mg twice daily if eGFR less than 30 mL/minute/1.73m². Also consider this starting dose if eGFR 30 to 60 mL/minute/1.73m².

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)
Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (April 2016) NICE TA388

Sacubitril valsartan is recommended as an option for treating symptomatic chronic heart failure with reduced ejection fraction, only in adults:

• with New York Heart Association class II to IV symptoms and
• a left ventricular ejection fraction of 35% or less and
• who are already taking a stable dose of an ACE inhibitor or angiotensin II receptor antagonist.

www.nice.org.uk/ta388

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet

Entresto® (Novartis Pharmaceuticals UK Ltd)

Sacubitril 24 mg, Valsartan 26 mg
28 tablet POM £45.78 DT price = £45.78
Sacubitril 49 mg, Valsartan 51 mg
28 tablet POM £45.78 56 tablet POM £91.56 DT price = £91.56
Sacubitril 97 mg, Valsartan 103 mg
56 tablet POM £91.56 DT price = £91.56

PHOSPHODIESTERASE TYPE-3 INHIBITORS

Enoximone

DRUG ACTION
Enoximone is a phosphodiesterase-type 3 inhibitor that exerts most effect on the myocardium; it has positive inotropic properties and vasodilator activity.

INDICATIONS AND DOSE
Congestive heart failure where cardiac output reduced and filling pressures increased

BY SLOW INTRAVENOUS INJECTION
Adult: Initially 0.5–1 mg/kg, rate not exceeding 12.5 mg/minute, then 500 micrograms/kg every 30 minutes until satisfactory response or total of 3 mg/kg given; maintenance, initial dose of up to 3 mg/kg may be repeated every 3–6 hours as required.

BY INTRAVENOUS INFUSION
Adult: Initially 90 micrograms/kg/minute, dose to be given over 10–30 minutes, followed by 5–20 micrograms/kg/minute, dose to be given as either a continuous or intermittent infusion; maximum 24 mg/kg per day.

CAUTIONS
Heart failure associated with hypertrophic cardiomyopathy, stenotic or obstructive valvular disease or other outlet obstruction

SIDE-EFFECTS
Chills • diarrhoea • ectopic beats • fever • headache • hypotension • insomnia • nausea • oliguria • supraventricular arrhythmias (more likely in patients with pre-existing arrhythmias) • upper and lower limb pain • urinary retention • ventricular tachycardia (more likely in patients with pre-existing arrhythmias) • vomiting

PREGNANCY
Manufacturer advises use only if potential benefit outweighs risk.

BREAST FEEDING
Manufacturer advises caution—no information available.

HEPATIC IMPAIRMENT
Dose reduction may be required.

RENAL IMPAIRMENT
Consider dose reduction.

MONITORING REQUIREMENTS
Monitor blood pressure, heart rate, ECG, central venous pressure, fluid and electrolyte status, renal function, platelet count and hepatic enzymes.
Milrinone

- **DRUG ACTION** Milrinone is a phosphodiesterase type-3 inhibitor that exerts most effect on the myocardium; it has positive inotropic properties and vasodilator activity.

- **INDICATIONS AND DOSE**
  - **Short-term treatment of severe congestive heart failure unresponsive to conventional maintenance therapy (not immediately after myocardial infarction)**
  - **Acute heart failure**, including low output states following heart surgery
    - **INITIALLY BY INTRAVENOUS INJECTION**
    - **Adult:** Initially 50 micrograms/kg, given over 10 minutes, followed by (by intravenous infusion) 375–750 nanograms/kg/minute usually given following surgery for up to 12 hours or in congestive heart failure for 48–72 hours; maximum 1.13 mg/kg per day

- **CONTRA-INDICATIONS** Severe hypovolaemia

- **CAUTIONS** Correct hypokalaemia · heart failure associated with hypertrophic cardiomyopathy · stenotic or obstructive valvular disease or other outlet obstruction

- **SIDE-EFFECTS**
  - **Common or very common** Ectopic beats · headache · hypotension · supraventricular arrhythmias (more likely in patients with pre-existing arrhythmias) · ventricular tachycardia
  - **Uncommon** Chest pain · hypokalaemia · thrombocytopenia · tremor · ventricular fibrillation
  - **Very rare** Anaphylaxis · bronchospasms · rash

- **PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk.

- **BREAST FEEDING** Manufacturer advises avoid—no information available.

- **RENAL IMPAIRMENT** Reduce dose and monitor response if eGFR less than 50 mL/minute/1.73 m²—consult product literature for details.

- **MONITORING REQUIREMENTS**
  - Monitor blood pressure, heart rate, ECG, central venous pressure, fluid and electrolyte status, renal function, platelet count and hepatic enzymes.

- **DIRECTIONS FOR ADMINISTRATION** Avoid extravasation.

  - For **intravenous injection** (Primacor®) give continuously in Glucose 5% or Sodium chloride 0.9%; dilute to a suggested concentration of 200 micrograms/mL.

- **PRESCRIBING AND DISPENSING INFORMATION** Sustained haemodynamic benefit has been observed after administration of phosphodiesterase type-3 inhibitors, but there is no evidence of any beneficial effect on survival.

### Dopexamine hydrochloride

- **DRUG ACTION** Dopexamine acts on beta receptors in cardiac muscle to produce a positive inotropic effect; and on peripheral dopamine receptors to increase renal perfusion; it is reported not to induce vasoconstriction.

- **INDICATIONS AND DOSE**

  - **Inotropic support and vasodilator in exacerbations of chronic heart failure and in heart failure associated with cardiac surgery**
    - **BY INTRAVENOUS INFUSION**
    - **Adult:** 0.5 microgram/kg/minute, to be administered into central or large peripheral vein, then increased if necessary to 1 microgram/kg/minute, increased if necessary up to 6 micrograms/kg/minute, in increments of 0.5–1 microgram/kg/minute at intervals of not less than 15 minutes

- **CONTRA-INDICATIONS** Aortic stenosis · hypertrophic cardiomyopathy · left ventricular outlet obstruction · phaeochromocytoma · thrombocytopenia

- **CAUTIONS** Correct hypovolaemia before starting and during treatment · hyperglycaemia · hypertension (may raise blood pressure) · hyperthyroidism · hypokalaemia · myocardial infarction · recent angina

- **INTERACTIONS** → Appendix 1: sympathomimetics, inotropic

- **SIDE-EFFECTS**

  - **Common or very common** Angina · arrhythmias · bradycardia · dyspnoea · headache · myocardial infarction · nausea · reversible thrombocytopenia · sweating · tachycardia · tremor · vomiting

- **PREGNANCY** No information available—manufacturer advises avoid.

- **MONITORING REQUIREMENTS** Monitor blood pressure, pulse, plasma potassium, and blood glucose.

- **TREATMENT CESSATION** Avoid abrupt withdrawal.

- **DIRECTIONS FOR ADMINISTRATION** Concentrate for intravenous infusion to be diluted before use. For **continuous intravenous infusion**, dilute to a concentration of 400 or 800 micrograms/mL with Glucose 5% or Sodium Chloride 0.9% · max. concentration via large peripheral vein 1 mg/mL, concentrations up to 4 mg/mL may be infused via central vein; give via infusion pump or other device which provides accurate control of rate; contact with metal in infusion apparatus should be minimised; incompatible with bicarbonate.

### Medicinal forms

- **There can be variation in the licensing of different medicines containing the same drug.**

  - **Solution for infusion**
    - **Dopacard** (Teva UK Ltd)
      - Dopexamine hydrochloride 10 mg per 1 ml
      - Dopacard 50mg/5ml concentrate for solution for infusion ampoules | 10 ampoule £225.00 (Hospital only)
6 Hyperlipidaemia

Lipid-regulating drugs

Primary and secondary prevention of cardiovascular disease
Preventative measures should be taken in individuals with a high risk of developing cardiovascular disease (primary prevention) and to prevent recurrence of events in those with established cardiovascular disease (secondary prevention).

Primary prevention
Individuals at high risk of developing cardiovascular disease include those who have diabetes mellitus, chronic kidney disease (eGFR < 60 mL/minute/1.73 m²) and/or albuminuria, and those with familial hypercholesterolaemia. The risk also increases with age; those aged 85 years and over are at particularly high risk, especially if they smoke or have hypertension. Preventative measures are also required for other individuals who are considered to be at high risk of developing atherosclerotic cardiovascular disease based on risk estimated using risk calculators (see Risk calculators); those with a 10-year risk of cardiovascular disease of 10% or more stand to benefit most from drug treatment. Patients with a 10-year cardiovascular risk of less than 10% may benefit from an assessment of their lifetime risk (using the JBS3 tool—see Risk calculators for more detail), discussion on the impact of lifestyle interventions and, if necessary, drug therapy.

Risk calculators
Risk assessment calculators are recommended by both NICE (clinical guideline 181 (July 2014), Lipid Modification—Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease) and JBS3 (Joint British Societies' consensus recommendations for the prevention of cardiovascular disease 2014). They should not be used in patients at high cardiovascular risk. Both calculators are unsuitable for assessing risk in those aged 85 years and over, and NICE advises against using a risk assessment tool in those with type 1 diabetes mellitus.

The QRISK 2 risk calculator www.qrisk.org/ is recommended by NICE clinical guideline 181, and the JBS3 risk calculator www.jbs3risk.com/pages/risk_calculator.hml is endorsed by JBS3. Both tools assess cardiovascular risk—coronary heart disease (angina and myocardial infarction), stroke, and transient ischaemic attack, on the basis of lipid profile, systolic blood pressure, gender, age, ethnicity, smoking status, BMI, chronic kidney disease, diabetes mellitus, atrial fibrillation, treated hypertension, rheumatoid arthritis, or a family history of premature cardiovascular disease. Risk assessment tools underestimate risk in patients with additional risk due to existing conditions or medication, such as:
- serious mental disorder
- autoimmune disorders such as systemic lupus
- erythematous and other systemic inflammatory disorders
- antiretroviral treatment
- medication causing dyslipidaemia as a side-effect e.g. antipsychotics, corticosteroids, or immunosuppressants
- triglyceride concentration > 4.5 mmol/litre

Cardiovascular disease risk is also underestimated in those who are already taking antihypertensive or lipid-regulating drugs, and in those who have recently stopped smoking. Severe obesity (BMI > 40 kg/m²) also increases cardiovascular risk; the need for further treatment of risk factors in patients below the cardiovascular risk threshold for treatment should be based on clinical judgement.

Preventative measures for primary prevention
All patients at high risk of cardiovascular disease should be advised to make lifestyle modifications that include beneficial changes to diet, exercise, weight management, alcohol consumption, and smoking cessation.

Offer a statin as first-line drug treatment if lifestyle modifications are inappropriate or ineffective (see also Statins for the prevention of cardiovascular disease). Lipid-regulating drug treatment must be combined with advice on diet and lifestyle measures, and where appropriate, treatment of comorbidities and secondary causes of dyslipidaemia.

Secondary prevention
Statins should be offered to all patients, including the elderly, with cardiovascular disease such as those with coronary heart disease (including history of angina or acute myocardial infarction), occlusive arterial disease (including peripheral vascular disease, non-haemorrhagic stroke, or transient ischaemic attacks).

Preventative measures for secondary prevention
Patients should be advised to make lifestyle modifications that include beneficial changes to diet, exercise, weight management, alcohol consumption, and smoking cessation, however, initiation of lipid-regulating drug treatment should not be delayed to manage modifiable risk factors, and must be combined with advice on diet and lifestyle measures, and where appropriate, treatment of co-morbidities and secondary causes of dyslipidaemia.

Statins for the prevention of cardiovascular disease
A statin reduces the risk of cardiovascular disease events, and is the drug of first choice for primary and secondary prevention of cardiovascular disease. Before starting treatment with statins, secondary causes of dyslipidaemia should be addressed; these include uncontrolled diabetes mellitus, hepatic disease, nephrotic syndrome, and excessive alcohol consumption. Patients with hypothyroidism should receive adequate thyroid replacement therapy (before assessing the requirement for lipid-regulating treatment if for primary prevention) because correcting hypothyroidism itself may resolve the lipid abnormality. Untreated hypothyroidism increases the risk of myositis with lipid-regulating drugs.

For the purpose of reducing cardiovascular risk, NICE Clinical Guideline 181 (NICE clinical guideline 181 (July 2014). Lipid Modification—Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease) defines statins by the percentage reduction in LDL-cholesterol they achieve:

For primary prevention, NICE Clinical Guideline 181 recommends that atorvastatin p. 196 a high-intensity statin (when prescribed at a dose of at least 20 mg/day [unlicensed dose]), should be offered to those with a 10-year risk of cardiovascular disease of 10% or more; patients aged 85 years and over may benefit from atorvastatin to reduce the risk of non-fatal myocardial infarction. For secondary prevention, atorvastatin is also recommended [unlicensed indication]. Patients taking a low-intensity statin should discuss the benefits and risks of switching to a high-intensity statin at their next medication review.

A statin should be considered for all adults with type 1 diabetes mellitus, particularly those aged 40 years and over, or who have had diabetes for more than 10 years, or who have established nephropathy, or other risk factors for cardiovascular disease. JBS3 recommendations (Joint British Societies’ consensus recommendations for the prevention of

Total cholesterol, HDL-cholesterol, and non-HDL cholesterol concentrations should be checked 3 months after starting treatment with a high intensity statin. NICE Clinical Guideline 181 recommends aiming for a reduction in non-HDL cholesterol concentration greater than 40%; JBS3 recommends a target non-HDL cholesterol concentration below 2.5 mmol/litre. If these are not achieved, ensure lifestyle modifications are optimised and consider increasing the dose of the statin if started on less than atorvastatin 80 mg and the patient is judged to be at higher risk because of comorbidities, risk score or, using clinical judgement.

Specialist advice should be sought about treatment options for patients at high risk of cardiovascular disease or those with existing cardiovascular disease, who are intolerant of three different statins.

**Fibrates** should not be routinely used for primary or secondary prevention. Nicotinic acid p. 194, **bile acid sequestrants**, and **omega-3 fatty acid compounds** are not recommended for primary or secondary prevention.

### Hypercholesterolaemia, hypertriglyceridaemia, and familial hypercholesterolaemia

A statin is also the drug of first choice for treating hypercholesterolaemia and moderate hypertriglyceridaemia. Severe hyperlipidaemia not adequately controlled with a maximal dose of a statin may require the use of an additional lipid-regulating drug such as ezetimibe p. 191; such treatment should generally be supervised by a specialist.

A number of conditions, some familial, are characterised by very high LDL-cholesterol concentration, high triglyceride concentration, or both. Fenofibrate p. 193 may be added to statin therapy if triglycerides remain high even after the LDL-cholesterol concentration has been reduced adequately; nicotinic acid may also be used to further lower triglyceride or LDL-cholesterol concentration.

Combination of a statin with a fibrate or with nicotinic acid carries an increased risk of side-effects (including rhabdomyolysis) and should be used under specialist supervision; monitoring of liver function and creatine kinase should also be considered. The concomitant administration of gemfibrozil with a statin increases the risk of rhabdomyolysis considerably—this combination should not be used.

A statin is recommended for all patients with familial hypercholesterolaemia. A ‘high-intensity’ statin (as defined in NICE Clinical Guideline 71, August 2008. Identification and management of familial hypercholesterolaemia) e.g. rosuvastatin p. 197 (initiated by a specialist) or atorvastatin p. 196 should be considered in order to achieve the recommended reduction in LDL-cholesterol concentration of greater than 50% from baseline; a ‘high-intensity’ statin is one that produces a greater LDL-cholesterol reduction than simvastatin 40 mg. Patients with heterozygous familial hypercholesterolaemia who have contra-indications to, or are intolerant of, statins should receive ezetimibe. The combination of a statin and ezetimibe can be considered if a statin alone fails to provide adequate control (or if intolerance limits dose titration), and when a switch to an alternative statin is being considered. Patients for whom statins and ezetimibe are inappropriate, should be referred to a specialist for the consideration of treatment with a bile acid sequestrant, nicotinic acid, or a fibrate.

The prescribing of drug therapy in homozygous familial hypercholesterolaemia should be undertaken in a specialist centre.

<table>
<thead>
<tr>
<th>Reduction in low-density lipoprotein cholesterol</th>
<th>Therapy intensity</th>
<th>Drug</th>
<th>Daily dose (reduction in LDL cholesterol)</th>
</tr>
</thead>
<tbody>
<tr>
<td>High-intensity</td>
<td>Atorvastatin</td>
<td>20 mg (43%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>40 mg (49%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>80 mg (55%)</td>
<td></td>
</tr>
<tr>
<td>Rosuvastatin</td>
<td>10 mg (43%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>20 mg (48%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>40 mg (53%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Simvastatin</td>
<td>80 mg (42%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medium-intensity</td>
<td>Atorvastatin</td>
<td>10 mg (37%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fluvastatin</td>
<td>80 mg (33%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rosuvastatin</td>
<td>5 mg (38%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Simvastatin</td>
<td>20 mg (32%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>40 mg (37%)</td>
<td></td>
</tr>
<tr>
<td>Low-intensity</td>
<td>Fluvastatin</td>
<td>20 mg (21%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>40 mg (27%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pravastatin</td>
<td>10 mg (20%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>20 mg (24%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>40 mg (29%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Simvastatin</td>
<td>10 mg (27%)</td>
<td></td>
</tr>
</tbody>
</table>

Advice from the MHRA: there is an increased risk of myopathy associated with high-dose (80 mg) simvastatin. The 80 mg dose should be considered only in patients with severe hypercholesterolaemia and high risk of cardiovascular complications who have not achieved their treatment goals on lower doses, when the benefits are expected to outweigh the potential risks.

### Statins

Statins are more effective than other lipid-regulating drugs at lowering LDL-cholesterol concentration but they are less effective than the fibrates in reducing triglyceride concentration. However, statins reduce cardiovascular disease events and total mortality irrespective of the initial cholesterol concentration.

### Alirocumab and evolocumab

Alirocumab p. 199 and evolocumab p. 200 are licensed for the treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to dietary measures. They can be used in combination with a statin, or with a statin and other lipid-regulating therapies, in patients unable to achieve their LDL-cholesterol treatment goals with the maximum tolerated dose of a statin. They can be used alone or in combination with other lipid-regulating therapies if a statin is contra-indicated or not tolerated. Evolocumab is also licensed for the treatment of homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies.

### Bile acid sequestrants

Bile acid sequestrants effectively reduce LDL-cholesterol but can aggravate hypertriglyceridaemia. Treatment with bile acid sequestrants may be appropriate under specialist supervision if statins and ezetimibe are inappropriate, and when LDL-cholesterol is severely raised, for example in familial hypercholesterolaemia.
Fibrates
Fibrates are mainly used in those whose serum-triglyceride concentration is greater than 10 mmol/litre or in those who cannot tolerate a statin (specialist use).

Lomitapide
Lomitapide p. 201 is licensed as an adjunct to dietary measures and other lipid-regulating drugs for the treatment of homozgyous familial hypercholesterolaemia.

Nicotinic acid group
The value of nicotinic acid is limited by its side-effects, especially vasodilatation.
Nicotinic acid is used by specialists in combination with a statin if the statin alone cannot adequately control dyslipidaemia (raised LDL-cholesterol, triglyceridaemia, and low HDL-cholesterol).
Acipimox p. 194 seems to have fewer side-effects than nicotinic acid but may be less effective in its lipid-regulating capabilities.

Omega-3 fatty acid compounds
There is no evidence that omega-3 fatty acid compounds reduce the risk of cardiovascular disease.

Other drugs used for Hyperlipidaemia

Bile acid sequestrants

- **DRUG ACTION** Bile acid sequestrants act by binding bile acids, preventing their reabsorption; this promotes hepatic conversion of cholesterol into bile acids; the resultant increased LDL-receptor activity of liver cells increases the clearance of LDL-cholesterol from the plasma.
- **CAUTIONS** Interference with the absorption of fat-soluble vitamins (supplements of vitamins A, D, K, and folic acid may be required when treatment is prolonged).
- **SIDE-EFFECTS** Constipation, diarrhoea, gastro-intestinal discomfort, hypertriglyceridaemia (aggravation), hypoprothrombinaemia associated with vitamin K deficiency, increased risk of bleeding, nausea, vomiting.
- **PREGNANCY** Bile acid sequestrants should be used with caution as although the drugs are not absorbed, they may cause fat-soluble vitamin deficiency on prolonged use.
- **BREAST FEEDING** Bile acid sequestrants should be used with caution as although the drugs are not absorbed, they may cause fat-soluble vitamin deficiency on prolonged use.

**CONTRA-INDICATIONS** Biliary obstruction · bowel obstruction.

**CAUTIONS** Gastro-intestinal motility disorders · inflammatory bowel disease · major gastro-intestinal surgery.

**INTERACTIONS** → Appendix 1: colesevelam.

**SIDE-EFFECTS** Headache · myalgia.

**HEPATIC IMPAIRMENT** Manufacturer advises caution.

**MONITORING REQUIREMENTS** Patients receiving ciclosporin should have their blood-ciclosporin concentration monitored before, during, and after treatment with colesevelam.

**DIRECTIONS FOR ADMINISTRATION** Other drugs should be taken at least 4 hours before or after colesevelam to reduce possible interference with absorption.

**PATIENT AND CARER ADVICE** Patient counselling on administration is advised for colesevelam hydrochloride tablets (avoid other drugs at same time).

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS** 21
- **Cholestagel**
  - Cholestagel 625 mg tablets → £6.10
  - Cholestagel 625 mg tablets 30 tablets → £18.30

**Colestipol hydrochloride**

- **INDICATIONS AND DOSE**
Hyperlipidaemias, particularly type IIa, in patients who have not responded adequately to diet and other appropriate measures.

- **BY MOUTH**
  - Adult: Initially 5 g 1–2 times a day, increased in steps of 5 g every month if required, total daily dose may be given in 1–2 divided doses; maximum 30 g per day.

- **INTERACTIONS** → Appendix 1: colestipol.

- **DIRECTIONS FOR ADMINISTRATION** The contents of each sachet should be mixed with at least 100 mL of water or other suitable liquid such as fruit juice or skimmed milk; alternatively it can be mixed with thin soups, cereals, yoghurt, or pulpy fruits ensuring at least 100 mL of liquid is provided.

  Other drugs should be taken at least 1 hour before or 4–6 hours after colestipol to reduce possible interference with absorption.

- **PATIENT AND CARER ADVICE** Patient counselling on administration is advised for colestipol hydrochloride granules (avoid other drugs at same time).

- **MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Granules**

- **CAUTIONARY AND ADVISORY LABELS** 13
  - **Colestid** (Pfizer Ltd)
    - Colestipol hydrochloride 5 gram tablets → £15.05
    - Colestid Orange 5 gram granules sachets sugar-free → £15.05

**Tablet**

- **Colestipol hydrochloride (Non-proprietary)**
  - Colestipol hydrochloride 1 gram tablets → £12.00

Colestyramine

(Cholestyramine)

**INDICATIONS AND DOSE**

Hyperlipidaemias, particularly type IIa, in patients who have not responded adequately to diet and other appropriate measures | Primary prevention of coronary heart disease in men aged 35–59 years with primary hypercholesterolaemia who have not responded to diet and other appropriate measures

- **BY MOUTH**
  - **Adult:** Initially 4 g daily, increased in steps of 4 g every week; increased to 12–24 g daily in 1–4 divided doses, adjusted according to response; maximum 36 g per day

Pruritus associated with partial biliary obstruction and primary biliary cirrhosis

- **BY MOUTH**
  - **Adult:** 4–8 g once daily

Diarrhoea associated with Crohn’s disease, ileal resection, vagotomy, diabetic vagal neuropathy, and radiation

- **BY MOUTH**
  - **Adult:** Initially 4 g daily, increased in steps of 4 g every week; increased to 12–24 g daily in 1–4 divided doses, adjusted according to response, if no response within 3 days an alternative therapy should be initiated; maximum 36 g per day

Accelerated elimination of teriflunomide

- **BY MOUTH**
  - **Adult:** 8 g 3 times a day for 11 days; reduced to 4 g 3 times a day, dose should only be reduced if not tolerated

Accelerated elimination of leflunomide (washout procedure)

- **BY MOUTH**
  - **Adult:** 8 g 3 times a day for 11 days

**CONTRA-INDICATIONS** Complete biliary obstruction (not likely to be effective)

**INTERACTIONS** → Appendix 1: colestyramine

**SIDE-EFFECTS**

- Rare: Intestinal obstruction
- Frequency not known: Hyperchloraemic acidosis (on prolonged use)

**DIRECTIONS FOR ADMINISTRATION** The contents of each sachet should be mixed with at least 150 mL of water or other suitable liquid such as fruit juice, skinned milk, thin soups, and pulpy fruits with a high moisture content.

Other drugs should be taken at least 1 hour before or 4–6 hours after colestyramine to reduce possible interference with absorption.

**PATIENT AND CARER ADVICE** Patient counselling on administration is advised for colestyramine powder (avoid other drugs at same time).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Powder**

**CAUTIONARY AND ADVISORY LABELS** 13

**EXCipients:** May contain Aspartame, sucrose

- **Colestyramine (Non-proprietary)**
  - **Colestyramine anhydrous 4 gram**
    - Colestyramine 4 g oral powder sachets | 50 sachet (Pkt) no price available DT price = £10.76
    - Colestyramine 4g oral powder sachets sugar free sugar-free | 50 sachet (Pkt) £27.68–£30.00 DT price = £27.68
  - **Questran** (Bristol-Myers Squibb Pharmaceuticals Ltd)
    - **Colestyramine anhydrous 4 gram**
      - Questran Light 4 g oral powder sachets | 50 sachet (Pkt) £16.15 DT price = £27.68

**LIPID MODIFYING DRUGS > CHOLESTEROL ABSORPTION INHIBITORS**

**Ezetimibe**

19-May-2016

**DRUG ACTION** Ezetimibe inhibits the intestinal absorption of cholesterol. If used alone, it has a modest effect on lowering LDL-cholesterol, with little effect on other lipoproteins.

**INDICATIONS AND DOSE**

Adjoint to dietary measures and statin treatment in primary hypercholesterolaemia | Adjunct to dietary measures and statin in homozygous familial hypercholesterolaemia | Primary hypercholesterolaemia (if statin inappropriate or not tolerated) | Adjunct to dietary measures in homozygous sitosterolaemia

- **BY MOUTH**
  - **Adult:** 10 mg daily

**INTERACTIONS** → Appendix 1: ezetimibe

**SIDE-EFFECTS**

- Common or very common: Fatigue, gastro-intestinal disturbances, headache, myalgia
- Rare: Anaphylaxis, angioedema, arthralgia, hepatitis, hypersensitivity reactions - rash
- Very rare: Cholelithiasis, myopathy, pancreatitis, raised creatine kinase, rhabdomyolysis, thrombocytopenia

**PREGNANCY** Manufacturer advises use only if potential benefit outweighs risks—no information available.

**BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT** Avoid in moderate and severe impairment—may accumulate.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (February 2016) NICE TA385

This guidance should be used with NICE’s guidelines on cardiovascular disease: risk assessment and reduction, including lipid modification and familial hypercholesterolaemia: identification and management (see Lipid-regulating drugs p. 188).

Ezetimibe, alone, is recommended as an option for the treatment of primary (heterozygous-familial or non-familial) hypercholesterolaemia in adult patients in whom initial statin therapy is contra-indicated, or who are intolerant of initial statin therapy.

Ezetimibe, in combination with initial statin therapy, is also recommended as an option for the treatment of primary (heterozygous-familial or non-familial) hypercholesterolaemia in adult patients when:

- serum total or low-density lipoprotein (LDL) cholesterol concentration is not appropriately controlled either after appropriate dose titration of initial statin therapy or because dose titration is limited by intolerance to the initial statin therapy
- a change from initial statin therapy to an alternative statin is being considered.

When prescribing ezetimibe in combination with statin, ezetimibe should be prescribed on the basis of lowest acquisition cost.

www.nice.org.uk/TA385
Bezafibrate

**DRUG ACTION** Fibrates act by decreasing serum triglycerides; they have variable effect on LDL-cholesterol.

**INDICATIONS AND DOSE** Adjunct to diet and other appropriate measures in mixed hyperlipidaemia if statin contra-indicated or not tolerated

**CONTRA-INDICATIONS** Gall bladder disease · hypoalbuminaemia · nephrotic syndrome · photosensitivity to fibrates

**CAUTIONS** Correct hypothyroidism before initiating treatment

**INTERACTIONS** → Appendix 1: fibrates

**SIDE-EFFECTS**
- **Uncommon** Alopecia · cholestasis · dizziness · erectile dysfunction · headache · myotoxicity (with myasthenia, myalgia, or very rarely rhabdomyolysis) — special risk in renal impairment · photosensitivity reactions · pruritus · rash · renal failure · urticaria
- **Rare** Pancreatitis · peripheral neuropathy
- **Very rare** Anaemia · gallstones · increased platelet count · interstitial lung disease · leucopenia · pancytopenia · Stevens-Johnson syndrome · thrombocytopenic purpura · toxic epidermal necrolysis

**PREGNANCY** Manufacturers advise avoid—no information available.

**BREAST FEEDING** Manufacturer advises avoid—no information available.

**HEPATIC IMPAIRMENT** Avoid in severe liver disease.

**RENAL IMPAIRMENT** Reduce dose to 400 mg daily if eGFR 40–60 mL/minute/1.73 m². Reduce dose to 200 mg every 1–2 days if eGFR 15–40 mL/minute/1.73 m². Avoid immediate-release preparations if eGFR less than 15 mL/minute/1.73 m². Avoid modified-release preparations if eGFR less than 60 mL/minute/1.73 m². Myotoxicity · Special care needed in patients with renal disease, as progressive increases in serum creatinine concentration or failure to follow dosage guidelines may result in myotoxicity (rhabdomyolysis); discontinue if myotoxicity suspected or creatine kinase concentration increases significantly.

**MONITORING REQUIREMENTS** Consider monitoring of liver function and creatine kinase when fibrates used in combination with a statin.

**PRESCRIBING AND DISPENSING INFORMATION** Fibrates are mainly used in those whose serum triglyceride concentration is greater than 10 mmol/litre or in those who cannot tolerate a statin (specialist use).

### MEDICINAL FORMS

- **Bezafibrate (Merck Sharp & Dohme Ltd)**
  - **Ezetimibe 10 mg** Ezetimibe 10 mg tablets | 28 tablet [POM] £26.31 DT price = £26.31
  - **Combinations available:** Simvastatin with ezetimibe, p. 199

**LIPID MODIFYING DRUGS**

**FIBRATES**

### Ciprofibrate

**DRUG ACTION** Fibrates act by decreasing serum triglycerides; they have variable effect on LDL-cholesterol.

**INDICATIONS AND DOSE** Adjunct to diet and other appropriate measures in mixed hyperlipidaemia if statin contra-indicated or not tolerated

**CONTRA-INDICATIONS** Gall bladder disease · hypoalbuminaemia · nephrotic syndrome · photosensitivity to fibrates

**CAUTIONS** Correct hypothyroidism before initiating treatment

**INTERACTIONS** → Appendix 1: fibrates

**SIDE-EFFECTS**
- **Common or very common** Abdominal distension · anorexia · diarrhoea · nausea
- **Uncommon** Alopecia · cholestasis · dizziness · erectile dysfunction · headache · myotoxicity (with myasthenia, myalgia, or very rarely rhabdomyolysis) — special risk in renal impairment · photosensitivity reactions · pruritus · rash · renal failure · urticaria
- **Rare** Pancreatitis · peripheral neuropathy
- **Very rare** Anaemia · gallstones · increased platelet count · interstitial lung disease · leucopenia · pancytopenia · Stevens-Johnson syndrome · thrombocytopenic purpura · toxic epidermal necrolysis
- **Frequency not known** Pneumonitis · pulmonary fibrosis

**PREGNANCY** Manufacturers advise avoid—toxicity in animal studies.

**BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT** Use with caution in mild to moderate impairment. Avoid in severe impairment.

**RENAL IMPAIRMENT** Reduce dose to 100 mg on alternate days in moderate impairment. Avoid in severe impairment. Myotoxicity · Special care needed in patients with renal disease, as progressive increases in serum creatinine concentration or failure to follow dosage guidelines may result in myotoxicity (rhabdomyolysis); discontinue if myotoxicity suspected or creatine kinase concentration increases significantly.

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Modiﬁed-release tablet**

- **Bezafibrate (Non-proprietary)** Bezafibrate 400 mg Bezafibrate 400 mg modified-release tablets | 28 tablet [POM] no price available | 30 tablet [POM] no price available DT price = £7.63
- **Bezalip Mono (Teva UK Ltd)** Bezafibrate 400 mg Bezalip Mono 400 mg modified-release tablets | 30 tablet [POM] £7.63 DT price = £7.63
- **Fibrazate XL (Sandoz Ltd)** Bezafibrate 400 mg Fibrazate XL 400 mg tablets | 30 tablet [POM] £6.87 DT price = £7.63

### Tableau

CAUTIONARY AND ADVISORY LABELS 21

- **Bezafibrate (Non-proprietary)** Bezafibrate 200 mg Bezafibrate 200 mg tablets | 100 tablet [POM] £8.50 DT price = £4.36
- **Bezalip (Teva UK Ltd)** Bezafibrate 200 mg Bezalip 200 mg tablets | 100 tablet [POM] £8.63 DT price = £4.36
**Fenofibrate**

**DRUG ACTION** Fibrates act by decreasing serum triglycerides; they have variable effect on LDL-cholesterol.

**INDICATIONS AND DOSE**

Adjunct to diet and other appropriate measures in mixed hyperlipidaemia if statin contra-indicated or not tolerated | Adjunct to diet and other appropriate measures in severe hypertriglyceridaemia | Adjunct to statin in mixed hyperlipidaemia if triglycerides and HDL-cholesterol inadequately controlled in patients at high cardiovascular risk

- **BY MOUTH USING CAPSULES**
- Adult: Initially 200 mg daily, then increased if necessary to 267 mg daily, maximum 200 mg daily with concomitant statin, 267 mg capsules not appropriate for initial dose titration
- **BY MOUTH USING TABLETS**
- Adult: 160 mg daily

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**

Manufacturer advises max. dose 200 mg daily with concurrent use of a statin.

**CONTRA-INDICATIONS** Gall bladder disease · pancreatitis (unless due to severe hypertriglyceridaemia) · photosensitivity to ketoprofen

**CAUTIONS** Correct hypothyroidism before initiating treatment

**INTERACTIONS** → Appendix 1: fibrates

**SIDE-EFFECTS**

- **Common or very common** Abdominal distension · anorexia · diarrhoea · nausea
- **Uncommon** Alopecia · cholestasis · dizziness · erectile dysfunction · headache · myotoxicity (with myasthenia, myalgia, or very rarely rhabdomyolysis)—special risk in renal impairment · pancreatitis · photosensitivity reactions · pruritus · pulmonary embolism · rash · renal failure · urticaria
- **Rare** Hepatitis · peripheral neuropathy
- **Very rare** Anaemia · gallstones · increased platelet count · interstitial lung disease · leucopenia · pancytopenia · Stevens–Johnson syndrome · thrombocytopenic purpura · toxic epidermal necrolysis
- **Frequency not known** Interstitial pneumopathies

**PREGNANCY** Avoid—embryotoxicity in *animal* studies.

**BREAST FEEDING** Avoid—no information available.

**HEPATIC IMPAIRMENT** Avoid.

**RENAL IMPAIRMENT** Manufacturer advises max. 67 mg daily if eGFR 30–59 mL/minute/1.73 m².

Manufacturer advises use with caution in mild-to-moderate impairment; avoid if eGFR less than 30 mL/minute/1.73 m².

Myotoxicity Special care needed in patients with renal disease, as progressive increases in serum creatinine concentration or failure to follow dosage guidelines may result in myotoxicity (rhabdomyolysis); discontinue if myotoxicity suspected or creatine kinase concentration increases significantly.

**MONITORING REQUIREMENTS** Manufacturer advises monitor hepatic transaminases every 3 months during the first 12 months of treatment and periodically thereafter—discontinue treatment if levels increase to more than 3 times the upper limit of normal; monitor serum creatinine levels during the first 3 months of treatment and periodically thereafter—interrupt treatment if creatinine level is 50% above the upper limit of normal.

**PRESCRIBING AND DISPENSING INFORMATION** Fibrates are mainly used in those whose serum-triglyceride concentration is greater than 10 mmol/litre or in those who cannot tolerate a statin (specialist use).

**Fenofibrate (Non-proprietary)**

- **Ciprofibrate**
  - 100 mg Ciprofibrate 100mg tablets | 28 tablet POM £134.21 DT price = £112.96

**Combination available:** Simvastatin with fenofibrate, p. 199

---

**Gemfibrozil**

**DRUG ACTION** Fibrates act by decreasing serum triglycerides; they have variable effect on LDL-cholesterol.

**INDICATIONS AND DOSE**

Adjunct to diet and other appropriate measures in mixed hyperlipidaemia if statin contra-indicated or not tolerated | Adjunct to diet and other appropriate measures in primary hypercholesterolaemia if statin contra-indicated or not tolerated | Adjunct to diet and other appropriate measures in severe hypertriglyceridaemia | Adjunct to diet and other appropriate measures in primary prevention of cardiovascular disease in men with hyperlipidaemias if statin contra-indicated or not tolerated

- **BY MOUTH**
- Adult: 1.2 g daily in 2 divided doses, maintenance 0.9–1.2 g daily

**CONTRA-INDICATIONS** History of gall-bladder or biliary tract disease including gallstones · photosensitivity to fibrates
**CONTRA-INDICATIONS**
Active peptic ulcer disease · arterial bleeding

**SIDE-EFFECTS**
- **Common or very common** Abdominal pain · dyspepsia · flushing · headache · malaise · urticaria
- **Uncommon** Anaphylactoid reaction · arthralgia · bronchospasm · erythema · myalgia · myositis · nausea · pruritus · rash
- **Frequency not known** Diarrhoea · dry eyes · vasodilatation

**PREGNANCY** Manufacturer advises avoid—no information available.

**BREAST FEEDING** Manufacturer advises avoid—no information available.

**RENAL IMPAIRMENT** Reduce dose to 250 mg 1–2 times daily if eGFR 30–60 mL/minute/1.73 m². Avoid if eGFR less than 30 mL/minute/1.73 m².

**MONITORING REQUIREMENTS** Monitor hepatic and renal function.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS 21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olbetam (Pfizer Ltd)</td>
</tr>
<tr>
<td>Acipimox 250 mg</td>
</tr>
<tr>
<td>Olbetam 250mg capsules</td>
</tr>
<tr>
<td>90 capsule</td>
</tr>
<tr>
<td>DT price = £46.33</td>
</tr>
<tr>
<td>0712 price = £46.33</td>
</tr>
</tbody>
</table>

Nicotinic acid

- **DRUG ACTION** In doses of 1.5 to 3 g daily, it lowers both cholesterol and triglyceride concentrations by inhibiting synthesis; it also increases HDL-cholesterol.

- **INDICATIONS AND DOSE**
  Adjunct to statin in dyslipidaemia or used alone if statin not tolerated
  - **BY MOUTH**
  - Adult: (consult product literature)

- **CONTRA-INDICATIONS** Active peptic ulcer disease · arterial bleeding
- **CAUTIONS** Acute myocardial infarction · diabetes mellitus · gout · history of peptic ulceration · unstable angina
- **INTERACTIONS** → Appendix 1: nicotinic acid

- **SIDE-EFFECTS**
  - **Common or very common** Abdominal pain · diarrhoea · dyspepsia · flushing · headache · malaise · urticaria
  - **Uncommon** Dizziness · headache · hypophosphataemia · increase in uric acid · palpitation · peripheral oedema · prolonged prothrombin time · reduced platelet count · shortness of breath · tachycardia
  - **Rare** Hypotension · insomnia · myalgia · myasthenia · myopathy · reduced glucose tolerance · rhinitis · syncope
  - **Very rare** Anorexia · rhabdomyolysis · visual disturbance
  - **Frequency not known** Jaundice

- **SIDE-EFFECTS, FURTHER INFORMATION**
  Prostaglandin-mediated symptoms. Prostaglandin-mediated symptoms (such as flushing) can be reduced by low initial doses taken with meals or, if patient taking aspirin, aspirin dose should be taken 30 minutes before nicotinic acid.

- **PREGNANCY** No information available—manufacturer advises avoid unless potential benefit outweighs risk.

- **BREAST FEEDING** Present in milk—avoid.

- **HEPATIC IMPAIRMENT** Avoid in severe impairment. Discontinue if severe abnormalities in liver function tests. Manufacturer advises monitor liver function in mild to moderate hepatic impairment.

- **RENAL IMPAIRMENT** Manufacturer advises use with caution—no information available.

---

**LIPID MODIFYING DRUGS**

**NICOTINIC ACID DERIVATIVES**

**Acipimox**

- **INDICATIONS AND DOSE**
  Adjunct or alternative treatment in hyperlipidaemias of types IIb and IV in patients who have not responded adequately to other lipid-regulating drugs such as a statin or fibrate, and lifestyle changes (including diet, exercise, and weight reduction)
  - **BY MOUTH**
  - Adult: 250 mg 2–3 times a day
LIPID MODIFYING DRUGS  STATINS

**Statins**

- **DRUG ACTION** Statins competitively inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, an enzyme involved in cholesterol synthesis, especially in the liver.
- **CAUTIONS** Elderly - high alcohol intake - history of liver disease - hypothyroidism - patients at increased risk of muscle toxicity, including myopathy or rhabdomyolysis (e.g. those with a personal or family history of muscular disorders, previous history of muscular toxicity and a high alcohol intake)

**CAUTIONS, FURTHER INFORMATION**

- **Muscle effects** Muscle toxicity can occur with all statins, however the likelihood increases with higher doses and in certain patients (see below). Statins should be used with caution in patients at increased risk of muscle toxicity, including those with a personal or family history of muscular disorders, previous history of muscular toxicity, a high alcohol intake, renal impairment or hypothyroidism.

In patients at increased risk of muscle effects, a statin should not usually be started if the baseline creatine kinase concentration is more than 5 times the upper limit of normal (some patients may present with an extremely elevated baseline creatine kinase concentration, for example because of a physical occupation or vigorous exercise—specialist advice should be sought regarding consideration of statin therapy in these patients).

- **Hypothyroidism** Hypothyroidism should be managed adequately before starting treatment with a statin.

**SIDE-EFFECTS**

- **Rare** Hepatitis - jaundice
- **Very rare** Hepatic failure - interstitial lung disease - lupus erythematosus-like reactions - pancreatitis

- **Frequency not known** Alopecia - altered liver function tests - amnesia - arthralgia - asthenia - depression - dizziness - fatigue - gastrointestinal disturbances - headache - hyperglycaemia - hypersensitivity reactions - may be associated with the development of diabetes mellitus (particularly in those already at risk of the condition) - myalgia - myopathy - myositis - paraesthesia - peripheral neuropathy - pruritus - rash - rhabdomyolysis - sexual dysfunction - sleep disturbance - thrombocytopenia - urticaria - visual disturbance

**SIDE-EFFECTS, FURTHER INFORMATION**

- **Muscle effects** The risk of myopathy, myositis, and rhabdomyolysis associated with statin use is rare. Although myalgia has been reported commonly in patients receiving statins, muscle toxicity truly attributable to statin use is rare. Muscle toxicity can occur with all statins, however the likelihood increases with higher doses.

If muscular symptoms or raised creatine kinase occur during treatment, other possible causes (e.g. vigorous physical activity, hypothyroidism, infection, recent trauma, and drug or alcohol addiction) should be excluded before statin therapy is implicated, particularly if statin treatment has previously been tolerated for more than 3 months. When a statin is suspected to be the cause of myopathy, and creatine kinase concentration is markedly elevated (more than 5 times upper limit of normal), or if muscular symptoms are severe, treatment should be discontinued. If symptoms resolve and creatine kinase concentrations return to normal, the statin should be reintroduced at a lower dose and the patient monitored closely; an alternative statin should be prescribed if unacceptable side-effects are experienced with a particular statin. Statin therapy should not be discontinued in the event of small, asymptomatic elevations of creatine kinase. Routine monitoring of creatine kinase is unnecessary in asymptomatic patients.

Statins should not be discontinued if there is an increase in the blood-glucose concentration or HbaA1C as the benefits continue to outweigh the risks.

- **Interstitial lung disease** If patients develop symptoms such as dyspnoea, cough, and weight loss, they should seek medical attention.

- **PREGNANCY** Statins should be avoided in pregnancy (discontinue 3 months before attempting to conceive) as congenital anomalies have been reported and the decreased synthesis of cholesterol possibly affects fetal development.

- **HEPATIC IMPAIRMENT** Statins should be used with caution in those with a history of liver disease. Avoid in active liver disease or when there are unexplained persistent elevations in serum transaminases.

- **MONITORING REQUIREMENTS**

  - Before starting treatment with statins, at least one full lipid profile (non-fasting) should be measured, including total cholesterol, HDL-cholesterol, non-HDL-cholesterol (calculated as total cholesterol minus HDL-cholesterol), and triglyceride concentrations, thyroid-stimulating hormone, and renal function should also be assessed.

  - Liver function There is little information available on a rational approach to liver-function monitoring; however, NICE suggests that liver enzymes should be measured before treatment, and repeated within 3 months and at 12 months of starting treatment, unless indicated at other times by signs or symptoms suggestive of hepatotoxicity (NICE clinical guideline 181 (July 2014). Lipid Modification—Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease).

  - Those with serum transaminases that are raised, but less than 3 times the upper limit of the reference range, should not be routinely excluded from statin therapy. Those with serum transaminases of more than 3 times the upper limit of the reference range should discontinue statin therapy.

- **Creatine kinase** Before initiation of statin treatment, creatine kinase concentration should be measured in patients who have had persistent, generalised, unexplained muscle pain (whether associated or not with previous lipid-regulating drugs); if the concentration is more than 5 times the upper limit of normal, a repeat measurement should be taken after 7 days. If the repeat concentration remains above 5 times the upper limit, statin treatment should not be started; if concentrations are still raised but less than 5 times the upper limit, the statin should be started at a lower dose.

- **Diabetes** Patients at high risk of diabetes mellitus should have fasting blood-glucose concentration or HbaA1C checked before starting statin treatment, and then repeated after 3 months.

**PATIENT AND CARER ADVICE** Advise patients to report promptly unexplained muscle pain, tenderness, or weakness.
Atorvastatin

**INDICATIONS AND DOSE**

Primary hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures [Combined (mixed) hyperlipidaemia in patients who have not responded adequately to diet and other appropriate measures]

- **BY MOUTH**
  - Adult: Usual dose 10 mg once daily; increased if necessary up to 80 mg once daily, dose to be increased at intervals of at least 4 weeks

Heterozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures

- **BY MOUTH**
  - Adult: Initially 10 mg once daily, then increased to 40 mg once daily, dose to be increased at intervals of at least 4 weeks; maximum 80 mg per day

Primary prevention of cardiovascular events in patients at high risk of a first cardiovascular event

- **BY MOUTH**
  - Adult: 20 mg once daily, dose can be increased if necessary

Secondary prevention of cardiovascular events

- **BY MOUTH**
  - Adult: 80 mg once daily

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**

Manufacturer advises if concurrent use of ciclosporin is appropriate measures who have not responded adequately to diet and other appropriate measures [Homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures]

- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Combined (mixed) hyperlipidaemia (types IIa and IIb)

**LICENSED USE**

Not licensed for secondary prevention of cardiovascular events. Starting dose of 20 mg once daily is not licensed for the primary prevention of cardiovascular events.

**CAUTIONS**

Haemorrhagic stroke

**INTERACTIONS**  Appendix 1: statins

**SIDE-EFFECTS**

- Common or very common Back pain · epistaxis · hyperglycaemia · nasopharyngitis · pharyngeolaryngeal pain
- Uncommon Anorexia · blurred vision · chest pain · hypoglycaemia · malaise · neck pain · peripheral oedema · pyrexia · tinnitus · weight gain
- Rare Cholestasis · Stevens-Johnson syndrome · toxic epidermal necrolysis
- Very rare Gynaecomastia · hearing loss

**BREAST FEEDING**

Manufacturer advises avoid—no information available.

**RENAI IMPAIRMENT**

In chronic kidney disease, for primary and secondary prevention of cardiovascular events [unlicensed starting dose in primary prevention; unlicensed in secondary prevention], initially 20 mg once daily, increased if necessary (on specialist advice if eGFR < 30 mL/minute/1.73 m²); max. 80 mg once daily.

**PATIENT AND CARER ADVICE**

Patient counselling is advised for atorvastatin tablets (muscle effects).

Fluvastatin

**INDICATIONS AND DOSE**

Adjunct to diet in primary hypercholesterolaemia or combined (mixed) hyperlipidaemia (types IIa and IIb)

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: Initially 20–40 mg daily, dose to be taken in the evening, increased if necessary up to 80 mg daily in 2 divided doses, dose to be adjusted at intervals of at least 4 weeks

**LICENSED USE**

Not licensed for secondary prevention of cardiovascular events.

**CAUTIONS**

Haemorrhagic stroke

**INTERACTIONS**  Appendix 1: statins

**SIDE-EFFECTS**

- Very rare Vasculitis

**BREAST FEEDING**

Manufacturer advises avoid—no information available.
Pravastatin sodium

- **INDICATIONS AND DOSE**
  
  Adjunct to diet for primary hypercholesterolaemia or combined (mixed) hyperlipidaemias in patients who have not responded adequately to dietary control
  
  **BY MOUTH**
  
  Adult: 10–40 mg daily, dose to be taken at night, dose to be adjusted at intervals of at least 4 weeks
  
  Prevention of cardiovascular events in patients with previous myocardial infarction or unstable angina
  
  Adjunct to diet to prevent cardiovascular events in patients with hypercholesterolaemia
  
  **BY MOUTH**
  
  Adult: 40 mg daily, dose to be taken at night
  
  Reduction of hyperlipidaemia in patients receiving immunosuppressive therapy following solid-organ transplantation
  
  **BY MOUTH**
  
  Adult: Initially 20 mg daily, then increased if necessary up to 40 mg daily, dose to be taken at night, close medical supervision is required if dose is increased to maximum dose

### DOSE ADJUSTMENTS DUE TO INTERACTIONS

Manufacturer advises initial dose 20 mg daily with concurrent use of ciclosporin, increasing with caution to 40 mg daily—no specific recommendation made for children.

Manufacturer advises reduce dose by half with concurrent use of ombitasvir with paritaprevir and ritonavir.

- **INTERACTIONS** → Appendix 1: statins
- **SIDE-EFFECTS**
  
  - **Uncommon** Abnormal urination • dysuria • nocturia • urinary frequency
  
  - **Very rare** Fulminant hepatic necrosis
- **BREAST FEEDING**
  
  Manufacturer advises avoid—small amount of drug present in breast milk.
- **RENAIML IMPAIRMENT**
  
  Manufacturer advises initial dose of 10 mg once daily in moderate to severe impairment.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Modified-release tablet**

- **CAUTIONARY AND ADVISORY LABELS**
  
  Fluvastatin (as Fluvastatin sodium) 80 mg Fluvastatin 80mg modified-release tablets | 28 tablet [Pom] no price available DT price = £19.20
  
  Dorisin XL (Aspire Pharma Ltd)
  
  Fluvastatin (as Fluvastatin sodium) 80 mg Dorisin XL 80mg tablets | 28 tablet [Pom] £19.20 DT price = £19.20
  
  Lescol XL (Novartis Pharmaceuticals UK Ltd)
  
  Fluvastatin (as Fluvastatin sodium) 80 mg Lescol XL 80mg tablets | 28 tablet [Pom] £19.20 DT price = £19.20
  
  Luvinsta XL (Actavis UK Ltd)
  
  Fluvastatin (as Fluvastatin sodium) 80 mg Luvinsta XL 80mg tablets | 28 tablet [Pom] £19.20 DT price = £19.20
  
  Nandovar XL (Sandoz Ltd)
  
  Fluvastatin (as Fluvastatin sodium) 80 mg Nandovar XL 80mg tablets | 28 tablet [Pom] £16.32 DT price = £19.20

**Capsule**

- **Fluvastatin (Non-proprietary)**
  
  Fluvastatin (as Fluvastatin sodium) 20 mg Fluvastatin 20mg capsules | 28 capsule [Pom] £6.96 DT price = £2.06
  
  Fluvastatin (as Fluvastatin sodium) 40 mg Fluvastatin 40mg capsules | 28 capsule [Pom] £7.42 DT price = £2.30
  
  Lescol (Novartis Pharmaceuticals UK Ltd)
  
  Fluvastatin (as Fluvastatin sodium) 20 mg Lescol 20mg capsules | 28 capsule [Pom] £15.26 DT price = £2.06
  
  Fluvastatin (as Fluvastatin sodium) 40 mg Lescol 40mg capsules | 28 capsule [Pom] £15.26 DT price = £2.30

**Pravastatin sodium**

- **INDICATIONS AND DOSE**
  
  Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures
  
  **BY MOUTH**
  
  Adult 18–69 years: Initially 5–10 mg once daily, then increased if necessary to 20 mg once daily, dose to be increased at intervals of at least 4 weeks
  
  Adult (patients of Asian origin): Initially 5 mg once daily, then increased if necessary up to 20 mg once daily, dose to be increased at intervals of at least 4 weeks.
  
  Adult 70 years and over: Initially 5 mg once daily, then increased if necessary up to 20 mg once daily, dose to be increased at intervals of at least 4 weeks
  
  Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures and who have risk factors for myopathy or rhabdomyolysis
  
  **BY MOUTH**
  
  Adult: Initially 5 mg once daily, then increased if necessary up to 20 mg once daily, dose to be increased at intervals of at least 4 weeks

**Patient counselling is advised**

Appendix 1: statins

Appendix 1: statins

Manufacturer advises doses above 30 mL/minute/1.73 m².

**PATIENT AND CARER ADVICE**

Patient counselling is advised for fluvastatin tablets/capsules (muscle effects).

**NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (February 2004) that fluvastatin is accepted for restricted use for the secondary prevention of coronary events after percutaneous coronary angioplasty; if the patient has previously been receiving another statin, then there is no need to change the statin.

Downloaded from www.medicalbr.com
Severe primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures, in patients with high cardiovascular risk (under expert supervision)

BY MOUTH

Adult: Initially 5–10 mg once daily, increased if necessary to 20 mg once daily, then increased if necessary to 40 mg once daily, dose to be increased at intervals of at least 4 weeks

Prevention of cardiovascular events in patients at high risk of a first cardiovascular event

BY MOUTH

Adult: Initially 5 mg once daily, then increased if necessary up to 20 mg once daily

Prevention of cardiovascular events in patients at high risk of a first cardiovascular event and with risk factors for myopathy or rhabdomyolysis

BY MOUTH

Adult: Initially 5 mg once daily, then increased if necessary up to 20 mg once daily

DOSE ADJUSTMENTS DUE TO INTERACTIONS

Manufacturer advises initially 5 mg daily with concurrent use of bezafibrate, ciprobate, and fenofibrate—40 mg dose is contra-indicated.

Manufacturer advises initially 5 mg daily with concurrent use of clopidogrel—max. dose 20 mg daily.

Manufacturer advises initially 5 mg daily with concurrent use of simpeprrev—max. dose 10 mg daily.

Manufacturer advises max. dose 5 mg daily with concurrent ombitasvir, paritaprevir, and ritonavir given with dasabuvir, but max. 10 mg daily with concurrent ombitasvir, paritaprevir, and ritonavir given without dasabuvir.

Manufacturer advises max. dose 10 mg daily with concurrent use of sofosbuvir with velpatasvir, or elbasvir with grazoprevir.

Manufacturer advises reduce dose by half with concurrent use of teriflunomide.

CAUTIONS Patients of Asian origin

INTERACTIONS Appendix 1: statins

SIDE-EFFECTS

Common or very common Proteinuria

Very rare Gynaeomastia; haematuria

Frequency not known Oedema; Stevens-Johnson syndrome

BREAST FEEDING Manufacturer advises avoid—no information available.

RENAL IMPAIRMENT Initially 5 mg once daily (do not exceed 20 mg daily) if eGFR 30–60 mL/minute/1.73 m². Avoid if eGFR less than 30 mL/minute/1.73 m².

PATIENT AND CARER ADVICE Patient counselling is advised for rosvustatin tablets (muscle effects).

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

Tablet

Creator (AstraZeneca Ltd)

Rosuvastatin (as Rosuvastatin calcium) 5 mg Creator 5mg tablets | 28 tablet | P&L 18.03 DT price = £18.03 Rosuvastatin (as Rosuvastatin calcium) 10 mg Creator 10mg tablets | 28 tablet | P&L 18.03 DT price = £18.03 Rosuvastatin (as Rosuvastatin calcium) 20 mg Creator 20mg tablets | 28 tablet | P&L 26.02 DT price = £26.02 Rosuvastatin (as Rosuvastatin calcium) 40 mg Creator 40mg tablets | 28 tablet | P&L 25.69 DT price = £25.69

Simvastatin

INDICATIONS AND DOSE

Primary hypercholesterolaemia, or combined (mixed) hyperlipidaemia in patients who have not responded adequately to diet and other appropriate measures

BY MOUTH

Adult: 10–20 mg once daily, then increased if necessary up to 80 mg once daily, adjusted at intervals of at least 4 weeks, dose to be taken at night; 80 mg dose only for those with severe hypercholesterolaemia and at high risk of cardiovascular complications

Homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures

BY MOUTH

Adult: Initially 40 mg once daily, then increased if necessary up to 80 mg once daily, adjusted at intervals of at least 4 weeks, dose to be taken at night; 80 mg dose only for those with severe hypercholesterolaemia and at high risk of cardiovascular complications

Prevention of cardiovascular events in patients with atherosclerotic cardiovascular disease or diabetes mellitus

BY MOUTH

Adult: Initially 20–40 mg once daily, increased if necessary up to 80 mg once daily, adjusted at intervals of at least 4 weeks, dose to be taken at night; 80 mg dose only for those with severe hypercholesterolaemia and at high risk of cardiovascular complications

DOSE ADJUSTMENTS DUE TO INTERACTIONS

Manufacturer advises max. 10 mg daily with concurrent use of bezafibrate or ciprobate.

Manufacturer advises max. 20 mg daily with concurrent use of amiodarone, amiodipine, or ranolazine.

Manufacturer advises reduce dose with concurrent use of some moderate inhibitors of CYP3A4 (max. 20 mg daily with verapamil and diltiazem).

Manufacturer advises max. 40 mg daily with concurrent use of lomitapide or ticagrelor.

Manufacturer advises max. 20 mg daily with concurrent use of elbasvir with grazoprevir.

INTERACTIONS Appendix 1: statins

SIDE-EFFECTS

Rare Anaemia

Frequency not known Tendinopathy

BREAST FEEDING Manufacturer advises avoid—no information available.

RENAL IMPAIRMENT Doses above 10 mg daily should be used with caution if eGFR less than 30 mL/minute/1.73 m².

PATIENT AND CARER ADVICE Patient counselling is advised for simvastatin tablets/oral suspension (muscle effects).

EXCEPTIONS TO LEGAL CATEGORY Simvastatin 10 mg tablets can be sold to the public to reduce risk of first coronary event in individuals at moderate risk of coronary heart disease (approx. 10–15% risk of major event in 10 years), max. daily dose 10 mg and pack size of 28 tablets; treatment should form part of a programme to reduce risk of coronary heart disease.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Oral suspension

EXCIPIENTS May contain Propylene glycol

Simvastatin (Non-proprietary)

Simvastatin 4 mg per 1 ml Simvastatin 20mg/5ml oral suspension sugar free sugar-free | 150 ml P&L £126.87 DT price = £126.41

Simvastatin 8 mg per 1 ml Simvastatin 40mg/5ml oral suspension sugar free sugar-free | 150 ml P&L £193.80 DT price = £193.09
Simvastatin with ezetimibe

The properties listed below are those particular to the combination only. For the properties of the components please consider, simvastatin p. 198, ezetimibe p. 191.

- **INDICATIONS AND DOSE**
  Homozygous familial hypercholesterolaemia, primary hypercholesterolaemia, and mixed hyperlipidaemia in patients over 10 years stabilised on the individual components in the same proportions, or for patients not adequately controlled by statin alone
  - BY MOUTH
  - Adult: (consult product literature)

- **INTERACTIONS** → Appendix 1: ezetimibe, statins

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- **Simvastatin (Non-proprietary)**
  - Simvastatin 10 mg Simvastatin 10mg tablets | 28 tablet | £18.00 DT price = £8.68
  - Simvastatin 20 mg Simvastatin 20mg tablets | 28 tablet | £29.60 DT price = £15.74
  - Simvastatin 40 mg Simvastatin 40mg tablets | 28 tablet | £59.60 DT price = £33.48
  - Simvastatin 80 mg Simvastatin 80mg tablets | 28 tablet | £89.15 DT price = £50.84

- **Simvador (Discovery Pharmaceuticals)**
  - Simvastatin 10 mg Simvador 10mg tablets | 28 tablet | £6.60 DT price = £3.74
  - Simvastatin 20 mg Simvador 20mg tablets | 28 tablet | £13.20 DT price = £7.40
  - Simvastatin 40 mg Simvador 40mg tablets | 28 tablet | £26.40 DT price = £14.90
  - Simvastatin 80 mg Simvador 80mg tablets | 28 tablet | £52.80 DT price = £29.90

- **Zocor** (Merck Sharp & Dohme Ltd)
  - Simvastatin 10 mg Zocor 10mg tablets | 28 tablet | £18.03 DT price = £10.68
  - Simvastatin 20 mg Zocor 20mg tablets | 28 tablet | £29.69 DT price = £18.30
  - Simvastatin 40 mg Zocor 40mg tablets | 28 tablet | £59.38 DT price = £33.62
  - Simvastatin 80 mg Zocor 80mg tablets | 28 tablet | £89.07 DT price = £50.93

Simvastatin with fenofibrate

The properties listed below are those particular to the combination only. For the properties of the components please consider, simvastatin p. 198, fenofibrate p. 193.

- **INDICATIONS AND DOSE**
  Adjunct to diet and exercise in mixed dyslipidaemia, when LDL-cholesterol levels are adequately controlled with the corresponding dose of simvastatin monotherapy (in patients at high cardiovascular risk)
  - BY MOUTH
  - Adult: 20/145 mg once daily, alternatively 40/145 mg once daily, dose should be based on previous simvastatin monotherapy dose

- **CAUTIONS** History of pulmonary embolism

- **INTERACTIONS** → Appendix 1: fibrates, statins

- **SIDE-EFFECTS**
  - Common or very common Gastroenteritis
  - Uncommon Dermatitis - eczema

- **RENAL IMPAIRMENT** Manufacturer advises avoid if eGFR less than 60 mL/minute/1.73 m²; use with caution if eGFR 60–89 mL/minute/1.73 m²

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- **CAUTIONARY AND ADVISORY LABELS** 25
  - **EXCIPIENTS:** May contain Butylated hydroxyanisole, lecithin
  - **Cholib** (Mylan Ltd)
    - Simvastatin 20 mg, Fenofibrate 145 mg Cholib 145mg/20mg tablets | 30 tablet | £7.71 DT price = £4.71
    - Cholib 145mg/40mg tablets | 30 tablet | £8.33 DT price = £5.33

**LIPID MODIFYING DRUGS › OTHER**

**Alirocumab** 24-Oct-2016

- **DRUG ACTION** Alirocumab binds to a pro-protein involved in the regulation of LDL receptors on liver cells; receptor numbers are increased, which results in increased uptake of LDL-cholesterol from the blood.

- **INDICATIONS AND DOSE**
  Primary hypercholesterolaemia or mixed dyslipidaemia in patients who have not responded adequately to other appropriate measures (in combination with a statin, or with a statin and other lipid-lowering therapies, or with other lipid-lowering therapies or alone if a statin contra-indicated or not tolerated)
  - BY SUBCUTANEOUS INJECTION
  - Adult: 75–150 mg every 2 weeks, adjusted according to response, to be administered into the thigh, abdomen or upper arm, dose adjustments should be made at 4-weekly intervals

- **INTERACTIONS** → Appendix 1: monoclonal antibodies

- **SIDE-EFFECTS**
  - Common or very common Oropharyngeal pain · pruritus · rhinorrhea
  - Rare · Eczema (discoid) · urticaria
  - Frequency not known Vascularis

- **PREGNANCY** Manufacturer advises avoid unless clinical condition requires treatment—maternal toxicity in animal studies.

- **BREAST FEEDING** Manufacturer advises avoid—no information available.

- **HEPATIC IMPAIRMENT** Manufacturer advises use with caution in severe impairment—no information available.

- **RENAL IMPAIRMENT** Manufacturer advises use with caution in severe impairment—no information available.

- **HANDLING AND STORAGE** Manufacturer advises store in a refrigerator (2–8 °C)—consult product literature for further information regarding storage outside refrigerator.

- **NATIONAL FUNDING/ACCESS DECISIONS**
  **NICE technology appraisals (Tas)**
  - Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (June 2016) NICE TA393
  Alirocumab is recommended as an option for treating primary hypercholesterolaemia or mixed dyslipidaemia, only if:
  - Low-density lipoprotein cholesterol (LDL-C) concentrations are persistently above the thresholds specified in the NICE documentation and
  - the manufacturer provides alirocumab with the discount agreed in the patient access scheme.
Patients whose treatment was started before this guidance was published should continue treatment until they and their clinician consider it appropriate to stop. www.nice.org.uk/TA393

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (Aug 2016) that alirocumab (Praluent®) is accepted for restricted use within NHS Scotland for treatment of primary hypercholesterolaemia or mixed dyslipidaemia (alone or in combination with other lipid lowering therapies, as specified within it’s license), for specialist use only and only in patients at high cardiovascular risk as follows: ● patients with heterozygous familial hypercholesterolaemia (HeFH) and LDL-C >5.0mmol/L, for primary prevention of cardiovascular events, or ● patients with HeFH and LDL-C >3.5mmol/L, for secondary prevention of cardiovascular events, or ● patients at high risk due to previous cardiovascular events and LDL-C ≥4.0mmol/L, or ● patients with recurrent/polyvascular disease and LDL-C ≥3.5mmol/L
This advice is contingent upon the continuing availability of the Patient Access Scheme (PAS) in NHS Scotland or a list price that is equivalent or lower.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.
Solution for injection
EXCipients: May contain Polysorbates
- Praluent (Sanofi) ▼
  Alirocumab 75 mg per 1 ml Praluent 75mg/1ml solution for injection pre-filled pen | 1 pre-filled disposable injection £168.00 | 2 pre-filled disposable injection £336.00
- Alirocumab 150 mg per 1 ml Praluent 150mg/1ml solution for injection pre-filled pen | 1 pre-filled disposable injection £168.00 | 2 pre-filled disposable injection £336.00

Evolocumab
DRUG ACTION Evolocumab binds to a pro-protein involved in the regulation of LDL receptors on liver cells; receptor numbers are increased, which results in increased uptake of LDL-cholesterol from the blood.

INDICATIONS AND DOSE
Primary hypercholesterolaemia or mixed dyslipidaemia in patients who have not responded adequately to other appropriate measures (in combination with a statin, or with a statin and other lipid-lowering therapies, or with other lipid-lowering therapies or alone if a statin contra-indicated or not tolerated)
- BY SUBCUTANEOUS INJECTION
  - Adult: 140 mg every 2 weeks, alternatively 420 mg every month, to be administered into the thigh, abdomen or upper arm
Homzygous familial hypercholesterolaemia (in combination with other lipid-lowering therapies)
- BY SUBCUTANEOUS INJECTION
  - Adult: Initially 420 mg every month; increased if necessary to 420 mg every 2 weeks, if inadequate response after 12 weeks of treatment, to be administered into the thigh, abdomen or upper arm
Homzygous familial hypercholesterolaemia in patients on apheresis (in combination with other lipid-lowering therapies)
- BY SUBCUTANEOUS INJECTION
  - Adult: 420 mg every 2 weeks, to correspond with apheresis schedule, to be administered into the thigh, abdomen or upper arm

INTERACTIONS ➔ Appendix 1: monoclonal antibodies

SIDE-EFFECTS
- Common or very common Arthralgia · back pain · influenza · nasopharyngitis · nausea · rash · upper respiratory tract infection
- Uncommon Urticaria
- PREGNANCY Manufacturer advises avoid unless essential—limited information available.
- BREAST FEEDING Manufacturer advises avoid—no information available.
- HEPATIC IMPAIRMENT Manufacturer advises monitor in moderate impairment—possible reduced efficacy; use with caution in severe impairment—no information available.
- RENAL IMPAIRMENT Manufacturer advises caution if eGFR less than 30 mL/minute/1.73 m²—no information available.
- HANDLING AND STORAGE Manufacturer advises store in a refrigerator (2–8°C)—consult product literature for further information regarding storage outside refrigerator.
- PATIENT AND CARER ADVICE Patients and their carers should be given training in subcutaneous injection technique.

NATIONAL FUNDING/ACCESS DECISIONS
NICE technology appraisals (TAs)
- Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (June 2016) NICE TA257
  Evolocumab is recommended as an option for treating primary hypercholesterolaemia or mixed dyslipidaemia, only if:
  - it is given at a dose of 140 mg every 2 weeks; and
  - low-density lipoprotein cholesterol (LDL-C) concentrations are persistently above the thresholds specified in the NICE documentation; and
  - the manufacturer provides evolocumab with the discount agreed in the patient access scheme.
Patients whose treatment was started within the NHS before this guidance was published should have the option to continue treatment, without change to their funding arrangements, until they and their clinician consider it appropriate to stop. www.nice.org.uk/TA394

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (February 2017) that evolocumab (Repatha®) is accepted for restricted use within NHS Scotland for the treatment of primary hypercholesterolaemia (heterozygous familial hypercholesterolaemia and non-familial) or mixed dyslipidaemia (alone or in combination with other lipid lowering therapies, as specified within its license), for specialist use only when administered at a dose of 140 mg every 2 weeks and only in patients at high cardiovascular risk as follows:
- patients with heterozygous familial hypercholesterolaemia (HeFH) and LDL-C 5mmol/L or greater for primary prevention of cardiovascular events, or
- patients with HeFH and LDL-C 3.5mmol/L or greater for secondary prevention of cardiovascular event, or
- patients at high risk due to previous cardiovascular events and LDL-C 4mmol/L or greater, or
- patients with recurrent/polyvascular disease and LDL-C 3.5mmol/L or greater
This advice is contingent upon the continuing availability of the Patient Access Scheme in NHS Scotland or a list price that is equivalent or lower.
Lomitapide

**DRUG ACTION** Lomitapide, an inhibitor of microsomal triglyceride transfer protein (MTP), reduces lipoprotein secretion and circulating concentrations of lipoprotein-borne lipids such as cholesterol and triglycerides.

**INDICATIONS AND DOSE**
Adjunct to dietary measures and other lipid-regulating drugs with or without low-density lipoprotein apheresis in homozygous familial hypercholesterolaemia (under expert supervision)

- **BY MOUTH**
  - Adult: Initially 5 mg daily for 2 weeks, dose to be taken at least 2 hours after evening meal, then increased if necessary to 10 mg daily, for at least 4 weeks, then increased to 20 mg daily for at least 4 weeks, then increased in steps of 20 mg daily, adjusted at intervals of at least 4 weeks; maximum 60 mg per day

**CONTRA-INDICATIONS** Significant or chronic bowel disease

**CAUTIONS** Concomitant use of hepatotoxic drugs

**SIDE-EFFECTS**
- Common or very common  
  - Bloating, abdominal pain, appetite changes, constipation, diarrhoea, dizziness, dyspepsia, eechymosis, eructation, erythematous rash, flatulence, gastro-oesophageal reflux disease, gastroenteritis, haemorrhoids, headache, hepatic steatosis, hepatomegaly, hypokalaemia, leucopenia, malaise, migraine, muscle spasms, nausea, neutropenia, raised serum transaminases, tenesmus, vomiting, weight loss
- Uncommon  
  - Abnormal gait, anaemia, arthralgia, chest pain, drowsiness, dry mouth, dry skin, eye swelling, gastrointestinal haemorrhage, haematemesis, haematuria, hyperbilirubinaemia, joint swelling, myalgia, pain in extremities, paraesthesia, proteinuria, pyrexia, sweating, vertigo

**SIDE-EFFECTS, FURTHER INFORMATION**
- Raised transaminases: Reduce dose if serum transaminases raised during treatment (consult product literature).

**CONCEPTION AND CONTRACEPTION** Manufacturer advises exclude pregnancy before treatment and ensure effective contraception used.

**PREGNANCY** Avoid—teratogenicity and embryotoxicity in animal studies.

**BREAST FEEDING** Manufacturer advises avoid—no information available.

**HEPATIC IMPAIRMENT** Reduce dose if serum transaminases raised during treatment (consult product literature). Max. 40 mg daily in mild impairment. Avoid in moderate to severe impairment, or if unexplained persistent abnormal liver function tests.

**MEDICINAL FORMS**
- **Solution for injection**
  - Repatha (Amgen Ltd)  
    - Evolocumab 140 mg per 1ml Repatha 140mg/1ml solution for injection pre-filled syringes | 1 pre-filled disposable injection £170.00
  - Repatha SureClick (Amgen Ltd)  
    - Evolocumab 140 mg per 1ml Repatha SureClick 140mg/1ml solution for injection pre-filled disposable devices | 2 pre-filled disposable injection £340.20

**SIDE-EFFECTS**
- Common or very common
- Rare
- Very rare

**INTERACTIONS**
- **BY MOUTH**
  - Adult: 1 capsule daily, dose to be taken with food

**CAUTIONARY AND ADVISORY LABELS**

**RENA L IMPAIRMENT** Max. 40 mg daily in end-stage renal disease.

**MONITORING REQUIREMENTS**
- Monitor liver function tests before treatment, then at least monthly and before each dose increase for first year, then at least every 3 months and before each dose increase thereafter.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.

**Capsule**
- Lojuxta (Amryt Pharma) ▼
  - Lomitapide 5 mg Lojuxta 5mg capsules | 28 capsule £17,765.00
  - Lomitapide 10 mg Lojuxta 10mg capsules | 28 capsule £17,765.00
  - Lomitapide 20 mg Lojuxta 20mg capsules | 28 capsule £17,765.00

**Omega-3-acid ethyl esters**

**INDICATIONS AND DOSE**
Adjunct to diet and statin in type IIB or III hypertriglyceridaemia | Adjunct to diet in type IV hypertriglyceridaemia

- **BY MOUTH**
  - Adult: Initially 2 capsules daily, dose to be taken with food, increased if necessary to 4 capsules daily

**INTERACTIONS**
- **BY MOUTH**
  - Adult: 1 capsule daily, dose to be taken with food

**CAUTIONS**
- Anticoagulant treatment (bleeding time increased) - haemorrhagic disorders

**SIDE-EFFECTS**
- **BY MOUTH**
  - Common or very common Dyspepsia·nausea
  - Uncommon Abdominal pain·dizziness· gastritis· taste disturbances
  - Rare Acne·headache· hepatic disorders ·hyperglycaemia· rash
  - Very rare Gastro-intestinal haemorrhage· hypotension· increased white cell count· nasal dryness· urticaria

**PREGNANCY** Manufacturers advise use only if potential benefit outweighs risk—no information available.

**BREAST FEEDING** Manufacturers advise avoid—no information available.

**HEPATIC IMPAIRMENT** Monitor liver function in hepatic impairment.

**NATIONAL FUNDING/ACCESS DECISIONS**
Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (November 2002) that omega-3-acid ethyl esters are not recommended for use within NHS Scotland for the treatment of hypertriglyceridaemia.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.

**Capsule**
- **CAUTIONARY AND ADVISORY LABELS**
  - Omega-3-acid ethyl esters (Non-proprietar y)
    - Docosahexaenoic acid 380 mg, Eicosapentaenoic acid 460 mg. Docosahexaenoic acid 380mg capsules | 28 capsule £14.24 DT price = £14.24 | 100 capsule £50.86

- **BY MOUTH**
  - Adult: 1 capsule daily, dose to be taken with food

- **SIDE-EFFECTS**
  - Common or very common
  - Rare
  - Very rare

- **INTERACTIONS**
  - **BY MOUTH**
  - Adult: 1 capsule daily, dose to be taken with food

- **CAUTIONS**
  - Anticoagulant treatment (bleeding time increased) - haemorrhagic disorders

- **SIDE-EFFECTS**
  - **BY MOUTH**
  - Common or very common Dyspepsia·nausea
  - Uncommon Abdominal pain·dizziness· gastritis· taste disturbances
  - Rare Acne·headache· hepatic disorders ·hyperglycaemia· rash
  - Very rare Gastro-intestinal haemorrhage· hypotension· increased white cell count· nasal dryness· urticaria

- **PREGNANCY** Manufacturers advise use only if potential benefit outweighs risk—no information available.

- **BREAST FEEDING** Manufacturers advise avoid—no information available.

- **HEPATIC IMPAIRMENT** Monitor liver function in hepatic impairment.

- **NATIONAL FUNDING/ACCESS DECISIONS**
Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (November 2002) that omega-3-acid ethyl esters are not recommended for use within NHS Scotland for the treatment of hypertriglyceridaemia.
7 Myocardial ischaemia

Stable angina

Overview

It is important to distinguish stable angina from unstable angina. Stable angina usually results from atherosclerotic plaques in the coronary arteries that restrict blood flow and oxygen supply to the heart; it is often precipitated by exertion and relieved by rest. Treatment involves management of acute anginal pain, and long-term management to prevent angina attacks and to reduce the risk of cardiovascular events.

Management

Acute attacks of stable angina should be managed with sublingual glyceryl trinitrate p. 212 which can be taken immediately before performing activities that are known to bring on an attack. If attacks occur more than twice a week, regular drug therapy is required and should be introduced in a step-wise manner according to response.

Patients with stable angina should be given a beta-blocker or a calcium-channel blocker. In those with left-ventricular dysfunction, beta-blocker treatment should be started at a very low dose and titrated very slowly over a period of weeks or months. If a beta-blocker or a calcium-channel blocker alone fails to control symptoms adequately, a combination of a beta-blocker and a dihydropyridine calcium-channel blocker (e.g. amlopidine p. 150, felodipine p. 154, modified-release nifedipine p. 157) should be used; if this combination is not appropriate due to intolerance of, or contra-indication to, either beta-blockers or calcium-channel blockers, addition of a long-acting nitrate, ivabradine p. 205, nicorandil p. 206, or ranolazine p. 205 can be considered.

For those patients in whom both beta-blockers and calcium-channel blockers are not tolerated or are contra-indicated, monotherapy with a long-acting nitrate, ivabradine, nicorandil, or ranolazine should be considered.

Response to treatment should be assessed every 2–4 weeks after initiating or changing drug therapy; the drug should be titrated (according to symptom control) to the maximum tolerated dose. Consider referring the patient to a specialist if a combination of two drugs fails to control symptoms. Addition of a third antianginal drug should only be considered if symptom control is not achieved with two drugs and the patient is either due to undergo a revascularisation procedure, or a revascularisation procedure is considered inappropriate. See the use of antiplatelet drugs in patients undergoing coronary stenting.

For long-term prevention of cardiovascular events, see Prevention of cardiovascular events.

Antianginal drugs

Nitrates, calcium-channel blockers, and potassium channel activators (use in adults only) have a vasodilating and, consequently, blood pressure lowering effect. Vasodilators can act in heart failure by arteriolar dilatation which reduces both peripheral vascular resistance and left ventricular pressure during systole resulting in improved cardiac output. They can also cause venous dilatation which results in dilatation of capacitance vessels, increase of venous pooling, and diminution of venous return to the heart (decreasing left ventricular end-diastolic pressure).

Nicorandil, a potassium-channel activator with a nitrate component, has both arterial and venous vasodilating properties and is licensed for the prevention and long-term treatment of angina. Nicorandil has similar efficacy to other antianginal drugs in controlling symptoms; it may produce additional symptomatic benefit in combination with other antianginal drugs (unlicensed indication).

Ivabradine lowers the heart rate by its action on the sinus node. It is licensed for the treatment of angina in patients who are in normal sinus rhythm in combination with a beta-blocker, or when beta-blockers are contra-indicated or not tolerated. Ivabradine, in combination with standard therapy including a beta-blocker (unless contra-indicated or not tolerated), is also licensed for mild to severe stable chronic heart failure in patients who are in sinus rhythm.

Ranolazine is licensed as adjunctive therapy in patients who are inadequately controlled or intolerant of first-line antianginal drugs.

Other drugs used for Myocardial ischaemia

ACE inhibitors

ACE inhibitors are used to treat hypertension and angina. They improve survival in patients with heart failure in sinus rhythm. They can also cause venous dilatation which results in dilatation of capacitance vessels, increase of venous pooling, and diminution of venous return to the heart (decreasing left ventricular end-diastolic pressure).

Nicorandil, a potassium-channel activator with a nitrate component, has both arterial and venous vasodilating properties and is licensed for the prevention and long-term treatment of angina. Nicorandil has similar efficacy to other antianginal drugs in controlling symptoms; it may produce additional symptomatic benefit in combination with other antianginal drugs (unlicensed indication).

Ivabradine lowers the heart rate by its action on the sinus node. It is licensed for the treatment of angina in patients who are in normal sinus rhythm in combination with a beta-blocker, or when beta-blockers are contra-indicated or not tolerated. Ivabradine, in combination with standard therapy including a beta-blocker (unless contra-indicated or not tolerated), is also licensed for mild to severe stable chronic heart failure in patients who are in sinus rhythm.

Ranolazine is licensed as adjunctive therapy in patients who are inadequately controlled or intolerant of first-line antianginal drugs.

ANTITHROMBOTIC DRUGS

Cangrelor

DRUG ACTION

Cangrelor is a direct P2Y12 platelet receptor antagonist that blocks adenosine diphosphate induced platelet activation and aggregation.

INDICATIONS AND DOSE

In combination with aspirin for the reduction of thrombotic cardiovascular events in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor (e.g. clopidogrel, prasugrel, ticagrelor) prior to the PCI procedure and in whom oral therapy with a P2Y12 inhibitor is not suitable (under expert supervision)

INITIALLY BY INTRAVENOUS INJECTION

Adult: Initially 30 micrograms/kg, to be given as a bolus dose, followed immediately by (by intravenous infusion) 4 micrograms/kg/minute, start treatment before percutaneous coronary intervention and continue infusion for at least 2 hours or for the duration of intervention if longer; maximum duration of infusion 4 hours
CONTRA-INDICATIONS  Active bleeding · history of stroke · history of transient ischaemic attack · patients at increased risk of bleeding (e.g. impaired haemostasis, irreversible coagulation disorders, major surgery or trauma, uncontrolled severe hypertension)

CAUTIONS  Disease states associated with increased bleeding risk

INTERACTIONS  

SIDE-EFFECTS

Dyspnoea · ecchymosis · haematoma · haemorrhage (including gastrointestinal and intracranial)

Uncommon  Acute renal failure · cardiac tamponade · epistaxis · haemyptysis · rash · retropertioneal haemorrhage (fatalities reported) · urticaria

Rare  Anaemia · bruising · thrombocytopenia

Very rare  Menorrhagia

PREGNANCY  Manufacturer advises avoid — toxicity in animal studies.

BREAST FEEDING  Manufacturer advises potential risk to infant — no information available.

RENAL IMPAIRMENT  Manufacturer advises caution in severe renal impairment — increased risk of bleeding.

DIRECTIONS FOR ADMINISTRATION  For intravenous bolus injection and intravenous infusion, reconstitute each 50 mg vial with 5 mL of water for injection and gently swirl, do not shake vigorously. Withdraw 5 mL of reconstituted solution, add to 250 mL of either Sodium Chloride 0.9% or Glucose 5% and mix thoroughly. The bolus injection and infusion should be administered from the infusion solution.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for injection

Kengreal  (Chiesi Ltd) ▼

Cangrelor (as Cangrelor tetrasodium) 50 mg  Kengreal 50 mg powder for concentrate for solution for injection / infusion vials | 10 vial  £2,500.00 (Hospital only)

ANTITHROMBOTIC DRUGS > GLYCOPROTEIN IIb/IIIa INHIBITORS

Abciximab

INDICATIONS AND DOSE

Prevention of ischaemic cardiac complications in patients undergoing percutaneous coronary intervention (specialist use only)

INITIALLY BY INTRAVENOUS INJECTION

Adult: Initially 250 micrograms/kg, to be given over 1 minute, then (by intravenous infusion) 125 nanograms/kg/minute (max. per dose 10 micrograms/minute), to be started up to 24 hours before possible percutaneous coronary intervention and continue infusion for 12 hours after intervention

Short-term prevention of myocardial infarction in patients with unstable angina not responding to conventional treatment and who are scheduled for percutaneous coronary intervention (specialist use only)

INITIALLY BY INTRAVENOUS INJECTION

Adult: Initially 250 micrograms/kg, to be given over 1 minute, then (by intravenous infusion) 125 nanograms/kg/minute (max. per dose 10 micrograms/minute), to be started up to 24 hours before possible percutaneous coronary intervention and continue infusion for 12 hours after intervention

CONTRA-INDICATIONS  Active internal bleeding · arteriovenous malformation or aneurysm · haemorrhagic diathesis · hypertensive retinopathy · intracranial neoplasm · intracranial or intraspinal surgery or trauma within last 2 months · major surgery within last 2 months · severe hypertension · stroke within last 2 years · thrombocytopenia · vasculitis

CAUTIONS  Discontinue if uncontrollable serious bleeding occurs or emergency cardiac surgery needed (consult product literature for details of procedures to minimise bleeding) · elderly

INTERACTIONS  

SIDE-EFFECTS

Common or very common  Back pain · bleeding manifestations · bradycardia · chest pain · fever · headache · hypotension · nausea · puncture site pain · thrombocytopenia · vomiting

Rare  Adult respiratory distress · cardiac tamponade · hypersensitivity reactions

PREGNANCY  Manufacturer advises avoid if potential benefit outweighs risk — no information available.

BREAST FEEDING  Manufacturer advises avoid — no information available.

HEPATIC IMPAIRMENT  Avoid in severe liver disease — increased risk of bleeding.

RENAL IMPAIRMENT  Caution in severe impairment — increased risk of bleeding.

MONITORING REQUIREMENTS

Measure baseline prothrombin time, activated clotting time, activated partial thromboplastin time, platelet count, haemoglobin and haematocrit.

Monitor haemoglobin and haematocrit 12 hours and 24 hours after start of treatment and platelet count 2–4 hours and 24 hours after start of treatment.

DIRECTIONS FOR ADMINISTRATION  For intravenous infusion (Reopro ®), give continuously in Glucose 5% or Sodium Chloride 0.9%. Dilute requisite dose in infusion fluid and give via infusion pump; filter upon dilution through a non-pyrogenic low protein binding 0.2, 0.22, or 5 micron filter or upon administration through an in-line non-progenic low protein-binding 0.2 or 0.22 micron filter.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

Reopro  (Janssen-Cilag Ltd)

Abciximab 2 mg per 1 ml  Reopro 10 mg/5 ml solution for injection vials | 1 vial  £250.24

Eptifibatide

INDICATIONS AND DOSE

In combination with aspirin and unfractionated heparin for the prevention of early myocardial infarction in patients with unstable angina or non-ST-segment-elevation myocardial infarction and with last episode of chest pain within 24 hours (specialist use only)

INITIALLY BY INTRAVENOUS INJECTION

Adult: Initially 180 micrograms/kg, then (by intravenous infusion) 2 micrograms/kg/minute for up to 72 hours (up to 96 hours if percutaneous coronary intervention during treatment)

CONTRA-INDICATIONS  Abnormal bleeding within 30 days · aneurysm · arteriovenous malformation · haemorrhagic diathesis · history of haemorrhagic stroke · increased INR · increased prothrombin time · intracranial disease · major surgery or severe trauma within 6 weeks · neoplasm · severe hypertension · stroke within last 30 days · thrombocytopenia

diabetes · hypertensive retinopathy · intracranial neoplasm · intracranial or intraspinal surgery or trauma within last 2 months · major surgery within last 2 months · severe hypertension · stroke within last 2 years · thrombocytopenia · vasculitis

CAUTIONS  Discontinue if uncontrollable serious bleeding occurs or emergency cardiac surgery needed (consult product literature for details of procedures to minimise bleeding) · elderly

INTERACTIONS  

SIDE-EFFECTS

Common or very common  Back pain · bleeding manifestations · bradycardia · chest pain · fever · headache · hypotension · nausea · puncture site pain · thrombocytopenia · vomiting

Rare  Adult respiratory distress · cardiac tamponade · hypersensitivity reactions

PREGNANCY  Manufacturer advises avoid if potential benefit outweighs risk — no information available.

BREAST FEEDING  Manufacturer advises avoid — no information available.

HEPATIC IMPAIRMENT  Avoid in severe liver disease — increased risk of bleeding.

RENAL IMPAIRMENT  Caution in severe impairment — increased risk of bleeding.

MONITORING REQUIREMENTS

Measure baseline prothrombin time, activated clotting time, activated partial thromboplastin time, platelet count, haemoglobin and haematocrit.

Monitor haemoglobin and haematocrit 12 hours and 24 hours after start of treatment and platelet count 2–4 hours and 24 hours after start of treatment.

DIRECTIONS FOR ADMINISTRATION  For intravenous infusion (Reopro ®), give continuously in Glucose 5% or Sodium Chloride 0.9%. Dilute requisite dose in infusion fluid and give via infusion pump; filter upon dilution through a non-pyrogenic low protein binding 0.2, 0.22, or 5 micron filter or upon administration through an in-line non-progenic low protein-binding 0.2 or 0.22 micron filter.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

Reopro  (Janssen-Cilag Ltd)

Abciximab 2 mg per 1 ml  Reopro 10 mg/5 ml solution for injection vials | 1 vial  £250.24

Eptifibatide

INDICATIONS AND DOSE

In combination with aspirin and unfractionated heparin for the prevention of early myocardial infarction in patients with unstable angina or non-ST-segment-elevation myocardial infarction and with last episode of chest pain within 24 hours (specialist use only)

INITIALLY BY INTRAVENOUS INJECTION

Adult: Initially 180 micrograms/kg, then (by intravenous infusion) 2 micrograms/kg/minute for up to 72 hours (up to 96 hours if percutaneous coronary intervention during treatment)

CONTRA-INDICATIONS  Abnormal bleeding within 30 days · aneurysm · arteriovenous malformation · haemorrhagic diathesis · history of haemorrhagic stroke · increased INR · increased prothrombin time · intracranial disease · major surgery or severe trauma within 6 weeks · neoplasm · severe hypertension · stroke within last 30 days · thrombocytopenia
In combination with unfractionated heparin, aspirin, and clopidogrel for reduction of major cardiovascular events in patients with ST-segment elevation myocardial infarction (STEMI) intended for primary percutaneous coronary intervention (PCI) (initiated under specialist supervision)

- **INITIALLY BY INTRAVENOUS INJECTION**
  - Adult: 25 micrograms/kg, to be given over 3 minutes at start of percutaneous coronary intervention, then (by intravenous infusion) 150 nanograms/kg/minute for 12–24 hours, maximum duration of treatment 48 hours

- **CONTRA-INDICATIONS** Abnormal bleeding within 30 days—history of aneurysm—history of arteriovenous malformation—history of haemorrhagic stroke—history of intracranial disease—history of neoplasm—increased INR—increased prothrombin time—severe hypertension—stroke within 30 days—thrombocytopenia

- **CAUTIONS** Active peptic ulcer (within 3 months)—acute pericarditis—anaemia—aortic dissection—cardiogenic shock—discontinue if intra-aortic balloon pump necessary—discontinue if thrombolytic therapy necessary—discontinue immediately if serious or uncontrollable bleeding occurs—discontinue if emergency cardiac surgery necessary—elderly—faecal occult blood—haematuria—haemorrhagic retinopathy—low body-weight—major surgery within 3 months (avoid if within 6 weeks)—organ biopsy or lithotripsy within last 2 weeks—puncture of non-compressible vessel within 24 hours—risk of bleeding (within 3 months)—severe heart failure—severe trauma within 3 months (avoid if within 6 weeks)—traumatic or protracted cardiopulmonary resuscitation within last 2 weeks—uncontrolled severe hypertension—vasculitis

- **INTERACTIONS** → Appendix 1: tirofiban

- **SIDE-EFFECTS** Bleeding manifestations—fever—headache—nausea—reversible thrombocytopenia

- **PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk—no information available.

- **BREAST FEEDING** Manufacturer advises avoid—no information available.

- **HEPATIC IMPAIRMENT** Avoid in severe liver disease—increased risk of bleeding.

- **RENAL IMPAIRMENT** Reduce infusion to 1 microgram/kg/minute if eGFR 30–50 mL/minute/1.73 m². Avoid if eGFR less than 30 mL/minute/1.73 m².

- **MONITORING REQUIREMENTS**
  - Measure baseline prothrombin time, activated partial thromboplastin time, platelet count, haemoglobin, haematocrit and serum creatinine.
  - Monitor haemoglobin, haematocrit and platelets within 6 hours after start of treatment, then at least once daily.

- **MEDICINAL FORMS**

  - **Solution for injection**
    - **Integrilin (GlaxoSmithKline UK Ltd)**
      - Eptifibatide 2 mg per 1 ml Integrilin 20mg/10ml solution for injection vials | 1 vial (POM) £13.61 (Hospital only)

  - **Solution for infusion**
    - **Integrilin (GlaxoSmithKline UK Ltd)**
      - Eptifibatide 750 microgram per 1 ml Integrilin 75mg/100ml solution for infusion vials | 1 vial (POM) £42.79 (Hospital only)

### Tirofiban

- **INDICATIONS AND DOSE**

  In combination with unfractionated heparin, aspirin, and clopidogrel for prevention of early myocardial infarction in patients with unstable angina or non-ST-segment-elevation myocardial infarction (NSTEMI) and with last episode of chest pain within 12 hours (with angiography planned for 4–48 hours after diagnosis) (initiated under specialist supervision)

  - **BY INTRAVENOUS INFUSION**
    - Adult: Initially 400 nanograms/kg/minute for 30 minutes, then 100 nanograms/kg/minute for at least 48 hours (continue during and for 12–24 hours after percutaneous coronary intervention), maximum duration of treatment 108 hours

  In combination with unfractionated heparin, aspirin, and clopidogrel for prevention of early myocardial infarction in patients with unstable angina or non-ST-segment-elevation myocardial infarction (NSTEMI) and with last episode of chest pain within 12 hours (with angiography within 4 hours of diagnosis) (initiated under specialist supervision)

  - **INITIALLY BY INTRAVENOUS INJECTION**
    - Adult: 25 micrograms/kg, to be given over 3 minutes at start of percutaneous coronary intervention, then (by intravenous infusion) 150 nanograms/kg/minute for 12–24 hours, maximum duration of treatment 48 hours

- **CONTRA-INDICATIONS** Abnormal bleeding within 30 days—history of aneurysm—history of arteriovenous malformation—history of haemorrhagic stroke—history of intracranial disease—history of neoplasm—increased INR—increased prothrombin time—severe hypertension—stroke within 30 days—thrombocytopenia

- **CAUTIONS** Active peptic ulcer (within 3 months)—acute pericarditis—anaemia—arterial dissection—cardiogenic shock—discontinue if intra-aortic balloon pump necessary—discontinue if thrombolytic therapy necessary—discontinue immediately if serious or uncontrollable bleeding occurs—discontinue if emergency cardiac surgery necessary—elderly—faecal occult blood—haematuria—haemorrhagic retinopathy—low body-weight—major surgery within 3 months (avoid if within 6 weeks)—organ biopsy or lithotripsy within last 2 weeks—puncture of non-compressible vessel within 24 hours—risk of bleeding (within 3 months)—severe heart failure—severe trauma within 3 months (avoid if within 6 weeks)—traumatic or protracted cardiopulmonary resuscitation within last 2 weeks—uncontrolled severe hypertension—vasculitis

- **INTERACTIONS** → Appendix 1: tirofiban

- **SIDE-EFFECTS** Bleeding manifestations—fever—headache—nausea—reversible thrombocytopenia

- **PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk—no information available.

- **BREAST FEEDING** Manufacturer advises avoid—no information available.

- **HEPATIC IMPAIRMENT** Avoid in severe liver disease—increased risk of bleeding.

- **RENAL IMPAIRMENT** Use half normal dose if eGFR less than 30 mL/minute/1.73 m². Increased risk of bleeding. Monitor carefully if eGFR less than 60 mL/minute/1.73 m².

- **MONITORING REQUIREMENTS** Monitor platelet count, haemoglobin and haematocrit before treatment, 2–6 hours after start of treatment and then at least once daily.

- **DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Aggrastat®), give continuously in Glucose 5% or Sodium chloride 0.9%. Withdraw 50 mL infusion fluid from 250 mL bag and replace with 50 mL tirofiban concentrate (250 micrograms/mL) to give a final concentration of 50 micrograms/mL.

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug.

  - **Solution for infusion**
    - **Aggrastat (Correvio GmbH)**
      - Tirofiban (as Tirofiban hydrochloride) 250 microgram per 1 ml Aggrastat 12.5mg/50ml concentrate for solution for infusion vials | 1 vial (POM) no price available (Hospital only)

    - **Infusion**
      - **ELECTROLYTES:** May contain Sodium
        - **Tirofiban (Non-proprietary)**
          - Tirofiban (as Tirofiban hydrochloride) 50 microgram per 1 ml Tirofiban 12.5mg/250ml infusion bags | 1 bag (POM) £160.72 (Hospital only)
**Piperazine derivatives**

**Ranolazine**

- **Indications and dose**
  - As adjunctive therapy in the treatment of stable angina in patients inadequately controlled or intolerant of first-line antianginal therapies
  - **By mouth**
    - Adult: Initially 375 mg twice daily for 2–4 weeks, then increased to 500 mg twice daily, then adjusted according to response to 750 mg twice daily; reduced if not tolerated to 375–500 mg twice daily

- **Cautions**
  - Body-weight less than 60 kg: elderly: moderate to severe congestive heart failure: QT interval prolongation

- **Interactions** → Appendix 1: ranolazine

- **Side-effects**
  - Common or very common: Asthenia: constipation: dizziness: headache: nausea: vomiting

- **Rare**

- **Pregnancy**
  - Manufacturer advises avoid unless essential—no information available.

- **Breast Feeding**
  - Manufacturer advises avoid—no information available.

- **Renal impairment**
  - Use with caution if eGFR 30–80 mL/minute/1.73 m²; avoid if eGFR less than 30 mL/minute/1.73 m².

- **Patient and carer advice**
  - Patient alert card to be provided.

- **National funding/access decisions**
  - Scottish Medicines Consortium (SMC) Decisions
    - The Scottish Medicines Consortium has advised (October 2012) that ranolazine (Ranexa®) is not recommended for use within NHS Scotland.

- **Medicinal forms**
  - There can be variation in the licensing of different medicines containing the same drug.

  - **Modified-release tablet**
    - CAUTIONARY AND ADVISORY LABELS 25
    - Ranexa (A. Menarini Farmaceutica Internazionale SRL)
      - Ranolazine 375 mg Ranexa 375 mg modified-release tablets | 60 tablet (PoS) £48.98 DT price = £48.98
      - Ranolazine 500 mg Ranexa 500 mg modified-release tablets | 60 tablet (PoS) £48.98 DT price = £48.98
      - Ranolazine 750 mg Ranexa 750 mg modified-release tablets | 60 tablet (PoS) £48.98 DT price = £48.98

**Selective sinus node If inhibitors**

- **Ivabradine**

  - **Indications and dose**
    - Treatment of angina in patients in normal sinus rhythm
    - **By mouth**
      - Adult: Initially 5 mg twice daily for 3–4 weeks, then increased if necessary to 7.5 mg twice daily; reduced if not tolerated to 2.5–5 mg twice daily, heart rate at rest should not be allowed to fall below 50 beats per minute
      - Elderly: Initially 2.5 mg twice daily, heart rate at rest should not be allowed to fall below 50 beats per minute

  - **Mild to severe chronic heart failure**
    - **By mouth**
      - Adult: Initially 5 mg twice daily for 2 weeks, then increased if necessary to 7.5 mg twice daily; reduced if not tolerated to 2.5 mg twice daily, heart rate at rest should not be allowed to fall below 50 beats per minute

  - **Dose adjustments due to interactions**
    - Manufacturer advises reduce initial dose to 2.5 mg twice daily with concurrent use of moderate CYP3A4 inhibitors (except diltiazem, erythromycin and verapamil where concurrent use is contra-indicated).

  - **Contra-indications**
    - Acute myocardial infarction: cardiogenic shock: congenital QT syndrome: do not initiate for angina if heart rate below 70 beats per minute: do not initiate for chronic heart failure if heart rate below 75 beats per minute: immediately after cerebrovascular accident: patients dependent on pacemaker: second- and third-degree heart block: severe hypotension: sick-sinus syndrome: sino-atrial block: unstable angina: unstable or acute heart failure

  - **Cautions**
    - Atrial fibrillation or other arrhythmias (treatment ineffective): elderly: in angina, consider stopping if there is no or limited symptom improvement after 3 months: intraventricular conduction defects: mild to moderate hypotension (avoid if severe): retinitis pigmentosa

  - **Interactions** → Appendix 1: ivabradine

  - **Side-effects**
    - Common or very common: Atrial fibrillation: blurred vision: bradycardia: dizziness: first-degree heart block: headache: phosphenes: ventricular extrasystoles: visual disturbances
    - Very rare: Second and third-degree heart block: sick sinus syndrome

  - **Pregnancy**
    - Manufacturer advises avoid—toxicity in animal studies.

  - **Breast Feeding**
    - Present in milk in animal studies—manufacturer advises avoid.

  - **Renal impairment**
    - Manufacturer advises caution in moderate impairment. Avoid in severe impairment.

  - **Monitoring requirements**
    - Monitor regularly for atrial fibrillation (consider benefits and risks of continued treatment if atrial fibrillation occurs).
    - Monitor for bradycardia, especially after any dose increase, and discontinue if resting heart rate persistently below 50 beats per minute or continued symptoms of bradycardia despite dose reduction.
NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

- **Ivabradine for the treatment of chronic heart failure (November 2012) NICE TA267**
  - Ivabradine, in combination with standard therapy including a beta-blocker (unless contra-indicated or not tolerated), an ACE inhibitor, and an aldosterone antagonist, is an option for treating mild to severe stable chronic heart failure in patients who:
    - have a left ventricular ejection fraction of < 35%, and
    - are in sinus rhythm with a heart rate of >75 beats per minute
  - Ivabradine should be initiated only by a heart failure specialist after 4 weeks of stable optimal standard therapy; monitoring and dose titration should be carried out by a heart failure specialist, or a GP with special interest in heart failure, or by a heart failure specialist nurse.
  - **www.nice.org.uk/TA267**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (September 2012) that ivabradine (Procoralan®) is accepted for restricted use within NHS Scotland in accordance with its licensed indication for heart failure only if resting heart rate remains >75 beats per minute despite optimal standard therapy.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Procoralan** (Servier Laboratories Ltd)
  - Ivabradine (as ivabradine hydrochloride) 5 mg Procoralan 5 mg tablets | 56 tablet [DT] £40.17 DT price = £40.17
  - Ivabradine (as ivabradine hydrochloride) 7.5 mg Procoralan 7.5 mg tablets | 56 tablet [DT] £40.17 DT price = £40.17

VASODILATORS POTASSIUM-CHANNEL OPENERS

**Nicorandil**

24-Feb-2016

- **INDICATIONS AND DOSE**
  - **Prophylaxis and treatment of stable angina (second-line)**
    - **BY MOUTH**
      - Adult: Initially 5–10 mg twice daily, then increased if tolerated to 40 mg twice daily; usual dose 10–20 mg twice daily, use lower initial dose regimen if patient susceptible to headache

- **CONTRA-INDICATIONS**
  - Acute pulmonary oedema · cardiogenic shock · hypovolaemia · left ventricular failure with low filling pressures · severe hypotension

- **CAUTIONS**
  - Acute myocardial infarction with acute left ventricular failure and low filling pressures · diverticular disease (risk of fistula formation or bowel perforation) · G6PD deficiency · heart failure (class III–IV) · hyperkalaemia · low systolic blood pressure

- **INTERACTIONS**
  - **Appendix 1: nicorandil**

- **SIDE-EFFECTS**
  - **Common or very common** Cutaneous vasodilation with flushing · dizziness · headache (especially on initiation, usually transitory) · increase in heart rate (at high doses) · nausea · rectal bleeding · vomiting · weakness
  - **Uncommon** Angiodyema · hypotension · myalgia · oral ulceration
  - **Rare** Abdominal pain · anal ulceration · cholestasis · gastrointestinal ulceration · hepatitis · jaundice · pruritus · rash · skin ulceration
  - **Very rare** Eye ulceration
  - **Frequency not known** Gastrointestinal haemorrhage

SIDE-EFFECTS, FURTHER INFORMATION

- **Nicorandil-induced ulceration** Nicorandil can cause serious skin, mucosal, and eye ulceration; including gastrointestinal ulcers, which may progress to perforation, haemorrhage, fistula or abscess. Stop treatment if ulceration occurs and consider an alternative.

- **PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk—no information available.

- **BREAST FEEDING** No information available—manufacturer advises avoid.

- **PATIENT AND CARER ADVICE**
  - **Driving and skilled tasks** Patients should be warned not to drive or operate machinery until it is established that their performance is unimpaired.

- **MEDICINAL FORMS**
  - **Tablet**
    - **Nicorandil (Non-proprietary)**
      - Nicorandil 10 mg Nicorandil 10mg tablets | 60 tablet [POM] £7.71 DT price = £2.15
      - Nicorandil 20 mg Nicorandil 20mg tablets | 60 tablet [POM] £14.64 DT price = £4.24
    - **Ikorel (Zentiva)**
      - Nicorandil 10 mg Ikorel 10mg tablets | 60 tablet [POM] £7.71 DT price = £2.15
      - Nicorandil 20 mg Ikorel 20mg tablets | 60 tablet [POM] £14.64 DT price = £4.24

7.1 Acute coronary syndromes

Acute coronary syndromes

**Overview**

Acute coronary syndromes encompass a spectrum of conditions which include unstable angina, and myocardial infarction with or without ST-segment elevation. Patients with different acute coronary syndromes may present similarly; definitive diagnosis is made on the basis of clinical presentation, ECG changes, and measurement of biochemical cardiac markers.

Unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI)

These are related acute coronary syndromes that fall between the classifications of stable angina and ST-segment elevation myocardial infarction (STEMI). They usually occur as a result of atheromatous plaque rupture, and are often characterised by stable angina that suddenly worsens, recurring or prolonged angina at rest, or new onset of severe angina. Patients with unstable angina have no evidence of myocardial necrosis, whereas in NSTEMI, myocardial necrosis (less significant than with STEMI) will be evident. There is a risk of progression to STEMI or sudden death, particularly in patients who experience pain at rest.

Management of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI)

These conditions are managed similarly; the aims of management are to provide supportive care and pain relief during the acute attack and to prevent further cardiac events and death. For advice on the management of patients with acute ST-segment elevation myocardial infarction (STEMI), see below.

**Initial management**

- **Oxygen** should be administered if there is evidence of hypoxia, pulmonary oedema, or continuing myocardial ischaemia; hypoxia should be avoided and particular care
is required in patients with chronic obstructive airways disease. **Nitrates** are used to relieve ischaemic pain. If sublingual glyceryl trinitrate p. 212 is not effective, intravenous or buccal glyceryl trinitrate or intravenous isosorbide dinitrate p. 214 is given. If pain continues, diamorphine hydrochloride p. 433 or morphine p. 439 can be given by slow intravenous injection; an antiemetic such as metoclopramide hydrochloride 411 should also be given.

Aspirin p. 117 (chewed or dispersed in water) is given for its antiplatelet effect. If aspirin is given before arrival at hospital, a note saying that it has been given should be sent with the patient. Clopidogrel p. 119 should also be given. Prasugrel p. 208 is an alternative to clopidogrel in certain patients undergoing percutaneous coronary intervention (see NICE guidance). Ticagrelor p. 209 is also an alternative to clopidogrel (see NICE guidance). Patients should also receive either heparin (unfractionated) p. 128, a **low molecular weight heparin**, or fondaparinux sodium p. 123.

Patients without contra-indications should receive **beta-blockers** which should be continued indefinitely. In patients without left ventricular dysfunction and in whom beta-blockers are inappropriate, diltiazem hydrochloride p. 152 or verapamil hydrochloride p. 159 can be given.

The glycoprotein IIb/IIIa inhibitors eptifibatide p. 203 (in combination with heparin (unfractionated) and aspirin) and tirofiban p. 204 (in combination with heparin (unfractionated), aspirin, and clopidogrel) can be used for unstable angina or for NSTEMI in patients at a high risk of either myocardial infarction or death.

In intermediate- and high-risk patients, abciximab p. 203 or eptifibatide (in combination with heparin (unfractionated) and aspirin), or tirofiban (in combination with heparin (unfractionated), aspirin, and clopidogrel) can also be used in patients undergoing percutaneous coronary intervention, to reduce the immediate risk of vascular occlusion. In intermediate- and high-risk patients in whom early intervention is planned, bivalirudin p. 130 can be considered as an alternative to the combination of a glycoprotein IIb/IIIa inhibitor plus a heparin.

Revascularisation procedures are often appropriate for patients with unstable angina or NSTEMI; see Antiplatelet drugs p. 117 for the use of antiplatelet drugs in patients undergoing coronary stenting.

**Long-term management**

The need for long-term angina treatment or for coronary angiography should be assessed. Most patients will require standard angina treatment to prevent recurrence of symptoms.

**ST-segment elevation myocardial infarction (STEMI)**

This is an acute coronary syndrome where atheromatous plaque rupture leads to thrombosis and myocardial ischaemia, with irreversible necrosis of the heart muscle, often leading to long-term complications. STEMI can also occasionally occur as a result of coronary spasm or embolism, arteritis, spontaneous thrombosis, or sudden severe elevation in blood pressure.

**Management of ST-segment elevation myocardial infarction (STEMI)**

These notes give an overview of the initial and long-term management of myocardial infarction with ST segment elevation (STEMI). For advice on the management of non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina, see above. The aims of management of STEMI are to provide supportive care and pain relief, to promote reperfusion and to reduce mortality. Oxygen, nitrates, and diamorphine hydrochloride or morphine can provide initial support and pain relief; aspirin and percutaneous coronary intervention or thrombolitics promote reperfusion; anticoagulants help to reduce re-occlusion and systemic embolisation; long-term use of aspirin, beta-blockers, ACE inhibitors, and statins help to reduce mortality further.

Local guidelines for the management of myocardial infarction should be followed where they exist.

**Initial management**

**Oxygen** should be administered if there is evidence of hypoxia, pulmonary oedema, or continuing myocardial ischaemia; hyperoxia should be avoided and particular care is required in patients with chronic obstructive airways disease.

The pain (and anxiety) of myocardial infarction is managed with slow intravenous injection of diamorphine hydrochloride or morphine; an antiemetic such as metoclopramide hydrochloride (or, if left ventricular function is not compromised, cyclizine p. 409) by intravenous injection should also be given.

Aspirin (chewed or dispersed in water) is given for its antiplatelet effect. If aspirin is given before arrival at hospital, a note saying that it has been given should be sent with the patient. Clopidogrel, should also be given. Prasugrel, is an alternative to clopidogrel in certain patients undergoing percutaneous coronary intervention (see NICE guidance). Ticagrelor, is also an alternative to clopidogrel (see NICE guidance).

Patency of the occluded artery can be restored by percutaneous coronary intervention or by giving a **thrombolytic drug**, unless contra-indicated. Percutaneous coronary intervention is the preferred method; a **glycoprotein IIb/IIIa inhibitor** can be used to reduce the risk of immediate vascular occlusion in intermediate- and high-risk patients. Patients undergoing percutaneous coronary intervention should also receive either heparin (unfractionated) or a low molecular weight heparin (e.g. enoxaparin sodium p. 127); bivalirudin is an alternative to the combination of a glycoprotein IIb/IIIa inhibitor plus a heparin (see also NICE guidance). In patients who cannot be offered percutaneous coronary intervention within 90 minutes of diagnosis, a thrombolytic drug should be administered along with either heparin (unfractionated) (for maximum 2 days), a low molecular weight heparin (e.g. enoxaparin sodium), or fondaparinux sodium. See use of antiplatelet drugs in patients undergoing coronary stenting in Antiplatelet drugs p. 177.

Patients who do not receive reperfusion therapy (with percutaneous coronary intervention or a thrombolytic) should be treated with either fondaparinux sodium, enoxaparin sodium, or heparin (unfractionated). Prescribers should consult product literature and local protocols (where they exist) for details of anticoagulant dose and duration.

**Nitrates** are used to relieve ischaemic pain. If sublingual glyceryl trinitrate p. 212 is not effective, intravenous glyceryl trinitrate or isosorbide dinitrate p. 214 is given.

Early administration of some **beta-blockers** has been shown to be of benefit and should be given to patients without contra-indications.

**ACE inhibitors**, and angiotensin-II receptor antagonists if an ACE inhibitor cannot be used, are also of benefit to patients who have no contra-indications; in hypertensive and normotensive patients treatment with an ACE inhibitor, or an angiotensin-II receptor antagonist, can be started within 24 hours of the myocardial infarction and continued for at least 5–6 weeks (see below for long-term treatment). All patients should be closely monitored for hyperglycaemia; those with diabetes or raised blood-glucose concentration should receive insulin p. 673.

**Long-term management**

Long-term management following STEMI involves the use of several drugs which should ideally be started before the patient is discharged from hospital.

Aspirin p. 117 should be given to all patients, unless contra-indicated. The addition of clopidogrel p. 119 has been shown to reduce morbidity and mortality. Prasugrel p. 208 or
ticagrelor p. 209 are alternatives to clopidogrel in certain patients. For those intolerant of clopidogrel, and who are at low risk of bleeding, the combination of warfarin sodium p. 135 and aspirin should be considered. In those intolerant of both aspirin and clopidogrel, warfarin sodium alone can be used. Warfarin sodium should be continued for those who are already being treated for another indication, such as atrial fibrillation, with the addition of aspirin if there is a low risk of bleeding. The combination of aspirin with clopidogrel or warfarin sodium increases the risk of bleeding. Low-dose rivaroxaban p. 123, in combination with aspirin alone or aspirin and clopidogrel, is licensed for the prevention of atherothrombotic events following STEMI—see Prevention of cardiovascular events. For details of antiplatelet drug duration following coronary stenting—see also Antiplatelet drugs and coronary stents in Antiplatelet drugs p. 117.

- **Beta-blockers** should be given to all patients in whom they are not contra-indicated. Acetobutolol p. 146, metoprolol tartrate p. 149, propranolol hydrochloride p. 145 and timolol maleate p. 146 are suitable; for patients with left ventricular dysfunction, carvedilol p. 143, bisoprolol fumarate p. 148, or long-acting metoprolol tartrate may be appropriate.

- **Diltiazem hydrochloride** p. 152 (unlicensed) or verapamil hydrochloride p. 159 can be considered if a beta-blocker cannot be used; however, they are contra-indicated in those with left ventricular dysfunction. Other calcium-channel blockers have no place in routine long-term management after a myocardial infarction.

An **ACE inhibitor** should be considered for all patients, especially those with evidence of left ventricular dysfunction. If an ACE inhibitor cannot be used, an angiotensin-II receptor antagonist may be used for patients with heart failure. A relatively high dose of either the ACE inhibitor or angiotensin-II receptor antagonist may be required to produce benefit.

**Nitrates** are used for patients with angina.

Eplerenone p. 185 is licensed for use following a myocardial infarction in those with left ventricular dysfunction and evidence of heart failure.

See also the role of **statins** in preventing recurrent cardiovascular events in Lipid-regulating drugs p. 188.

**Prevention of cardiovascular events**

Patients with stable angina, unstable angina, or NSTEMI should be given advice and treatments to reduce their cardiovascular risk. The importance of life-style changes, especially stopping smoking, should be emphasised. Aspirin should be given indefinitely. Antihypertensive treatment should be initiated if appropriate, and a **statin** should also be given.

In patients with stable angina, addition of an **ACE inhibitor** should be considered for patients with diabetes (and should be continued if indicated for a co-morbidity).

In patients with unstable angina or NSTEMI, clopidogrel is given, in combination with aspirin, for up to 12 months—most benefit occurs during the first 3 months. Prasugrel or ticagrelor are alternatives to clopidogrel in certain patients. An ACE inhibitor should also be given.

Low-dose rivaroxaban, in combination with aspirin alone or aspirin and clopidogrel, is licensed for the prevention of atherothrombotic events following an acute coronary syndrome with elevated cardiac biomarkers.

**Other drugs used for Acute coronary syndromes**

Captopril, p. 163  •  Dalteparin sodium, p. 126  •  Lisinopril, p. 165  •  Perindopril arginine, p. 166  •  Perindopril erbumine, p. 167  •  Ramipril, p. 168  •  Trandolapril, p. 169  •  Valsartan, p. 174

**Antithrombotic Drugs**  •  **Antiplatelet Drugs**

**Prasugrel**

- **INDICATIONS AND DOSE**

  In combination with aspirin for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention

  - **BY MOUTH**
    - Adult 18–74 years (body-weight up to 60 kg): Initially 60 mg for 1 dose, then 5 mg once daily usually for up to 12 months
    - Adult 18–74 years (body-weight 60 kg and above): Initially 60 mg for 1 dose, then 10 mg once daily usually for up to 12 months
    - Adult 75 years and over: Initially 60 mg for 1 dose, then 5 mg once daily usually for up to 12 months

Patients undergoing coronary angiography within 48 hours of admission for unstable angina or NSTEMI

  - **BY MOUTH**
    - Adult: Loading dose 60 mg, not to be administered until the time of percutaneous coronary intervention in order to minimise the risk of bleeding, maintenance dose of 10 mg or 5 mg daily should then be selected as appropriate based on age and weight

Alternative to clopidogrel in certain patients undergoing percutaneous coronary intervention

  - **BY MOUTH**
    - Adult: 60 mg, as a single dose

- **CONTRA-INDICATIONS**
  - Active bleeding · history of stroke or transient ischaemic attack

- **CAUTIONS**
  - Body-weight less than 60 kg · discontinue at least 7 days before elective surgery if antiplatelet effect not desirable · elderly · patients at increased risk of bleeding (e.g. from recent trauma, surgery, gastro-intestinal bleeding, or active peptic ulcer disease)

- **INTERACTIONS**  → Appendix 1: prasugrel

- **SIDE-EFFECTS**
  - Common or very common  
    - Anaemia  
    - Gastro-intestinal haemorrhage  
    - Haematoma  
    - Haematuria  
    - Haemorrhage  
    - Intracranial haemorrhage  
  - Uncommon  
    - Angioedema  
    - Hypersensitivity reactions  
    - Rare  
    - Thrombocytopenia  
    - Frequency not known  
    - Thrombotic thrombocytopenic purpura

- **ALLERGY AND CROSS-SENSITIVITY**
  - Caution in patients with history of hypersensitivity reactions to thienopyridines (e.g. clopidogrel).

- **PREGNANCY**
  - Manufacturer advises use only if potential benefit outweighs risk.

- **BREAST FEEDING**
  - Manufacturer advises avoid—no information available.

- **HEPATIC IMPAIRMENT**
  - Use with caution in moderate impairment—increased risk of bleeding. Avoid in severe impairment.

- **RENAL IMPAIRMENT**
  - Use with caution—increased risk of bleeding.

- **NATIONAL FUNDING/ACCESS DECISIONS**

  **NICE technology appraisals (TAs)**

  - Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (July 2014) NICE TA317

  Prasugrel 10 mg in combination with aspirin is recommended as an option, within its marketing authorisation, for preventing atherothrombotic events in adults with acute coronary syndrome (unstable angina (UA), non-ST segment elevation myocardial infarction
(NSTEMI) or ST segment elevation myocardial infarction (STEMI) having primary or delayed percutaneous coronary intervention.

**Scottish Medicines Consortium (SMC) Decisions**
The Scottish Medicines Consortium has advised (August 2009) that prasugrel (Efient®), in combination with aspirin, be accepted for restricted use within NHS Scotland for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention who are eligible to receive the 10 mg dose of prasugrel.

### Medicinal Forms
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- Efient (Eli Lilly and Company Ltd)
  - Prasugrel (as Prasugrel hydrochloride) 5 mg Efient 5mg tablets | 28 tablet | £47.56 DT price = £47.56
  - Prasugrel (as Prasugrel hydrochloride) 10 mg Efient 10mg tablets | 28 tablet | £47.56 DT price = £47.56

### Ticagrelor

#### Indications and Dose
In combination with aspirin for the prevention of atherothrombotic events in patients with acute coronary syndrome
- **By Mouth**
  - Adult: Initially 180 mg for 1 dose, then 90 mg twice daily usually for up to 12 months
**Alternative to clopidogrel in patients undergoing percutaneous coronary intervention**
- **By Mouth**
  - Adult: 180 mg, as a single dose

#### Contraindications
- Active bleeding - history of intracranial haemorrhage

#### Cautions
- Asthma - bradycardia (unless pacemaker fitted)
  - chronic obstructive pulmonary disease - discontinue 7 days before elective surgery if antiplatelet effect not desirable - history of hyperuricaemia - patients at increased risk of bleeding (e.g. from recent trauma, surgery, gastrointestinal bleeding, or coagulation disorders) - second- or third-degree AV block (unless pacemaker fitted)
  - sick sinus syndrome (unless pacemaker fitted)

#### Interactions
- → Appendix 1: ticagrelor

#### Side-effects
- **Common or very common** Bruising - dyspnoea - haemorrhage
  - Abdominal pain - diarrhoea - dizziness
  - dyspepsia - gastritis - headache - nausea - pruritus - rash - vomiting
  - Rare Confusion - constipation - hyperuricaemia - parasthesia - raised serum creatinine - vertigo

#### Pregnancy
- Manufacturer advises avoid — toxicity in animal studies.

#### Breast Feeding
- Manufacturer advises avoid — present in milk in animal studies.

#### Hepatic Impairment
- Avoid in moderate or severe impairment — no information available.

#### Monitoring Requirements
- Monitor renal function 1 month after initiation.

#### National Funding/Access Decisions

**NICE technology appraisals (TAs)**
- Ticagrelor for the treatment of acute coronary syndromes (October 2011) NICE TA236
  - Ticagrelor, in combination with low-dose aspirin, is recommended for up to 12 months as a treatment option in adults with acute coronary syndromes, that is, people:
    - with ST-segment elevation myocardial infarction—defined as ST elevation or new left bundle branch block on electrocardiogram—that cardiologists intend to treat with primary percutaneous coronary intervention, or
    - with non-ST-segment elevation myocardial infarction (NSTEMI), or
    - admitted to hospital with unstable angina—defined as ST or T wave changes on electrocardiogram suggestive of ischaemia plus one of the characteristics defined below. Before ticagrelor is continued beyond the initial treatment, the diagnosis of unstable angina should first be confirmed, ideally by a cardiologist. Characteristics to be used in defining treatment with ticagrelor for unstable angina are:
      - age 60 years or older,
      - previous myocardial infarction or previous coronary artery bypass grafting,
      - coronary artery disease with stenosis of 50% or more in at least two vessels,
      - previous ischaemic stroke,
      - previous transient ischaemic attack, carotid stenosis of at least 50%, or cerebral revascularisation,
      - diabetes mellitus,
      - peripheral arterial disease, or
      - chronic renal dysfunction (creatinine clearance less than 60 mL/minute/1.73 m²).
  
  www.nice.org.uk/TA236

- Ticagrelor for preventing atherothrombotic events after myocardial infarction (December 2016) NICE TA420
  - Ticagrelor, in combination with aspirin, is recommended within its marketing authorisation as an option for preventing atherothrombotic events in adults who had a myocardial infarction and who are at high risk of a further event. Treatment should be stopped when clinically indicated or at a maximum of 3 years.
  
  www.nice.org.uk/TA420

#### Medicinal Forms
- There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- Brilique (AstraZeneca UK Ltd)
  - Ticagrelor 60 mg Brilique 60mg tablets | 56 tablet | £54.60 DT price = £54.60
  - Ticagrelor 90 mg Brilique 90mg tablets | 56 tablet | £54.60 DT price = £54.60

### Antithrombotic Drugs

**Tissue Plasminogen Activators**

### Fibrinolytic Drugs

**Overview**
The value of thrombolytic drugs for the treatment of myocardial infarction has been established. Streptokinase p. 211 and alteplase p. 210 have been shown to reduce mortality. Reteplase p. 211 and tenecteplase p. 211 are also licensed for acute myocardial infarction. Thrombolytic drugs are indicated for any patient with acute myocardial infarction for whom the benefit is likely to outweigh the risk of treatment. Trials have shown that the benefit is greatest in those with ECG changes that include ST segment elevation (especially in those with anterior infarction) and in patients with bundle branch block. Patients should not be denied thrombolytic treatment on account of age alone because...
mortality in the elderly is high and the reduction in mortality is the same as in younger patients. Alteplase should be given within 6–12 hours of symptom onset, retpalase and streptokinase within 12 hours of symptom onset, but ideally all should be given within 1 hour; use after 12 hours requires specialist advice. Tenecteplase should be given as early as possible and usually within 6 hours of symptom onset. Alteplase, streptokinase and urokinase p. 133 can be used for other thromboembolic disorders such as deep-vein thrombosis and pulmonary embolism. Alteplase is also used for acute ischaemic stroke. Urokinase is also licensed to restore the patency of the placenta in the first 18 weeks of pregnancy. There is also a risk of maternal haemorrhage throughout pregnancy and post-partum, and also a theoretical risk of fetal haemorrhage throughout pregnancy.

**Hepatic Impairment** Avoid in severe hepatic impairment as there is an increased risk of bleeding.

### Fibrinolytics

- **Drug Action** Fibrinolytic drugs act as thrombolytics by activating plasminogen to form plasmin, which degrades fibrin and so breaks up thrombi.
- **Contra-Indications** Active pulmonary disease with cavitation or recent surgery (including dental extraction); recent symptoms of possible peptic ulceration; recent trauma; recent symptoms of possible cerebral bleeding; hypotension can usually be controlled by elevating the patient’s legs, or by reducing the rate of infusion or stopping it temporarily.
- **Caution** Conditions in which thrombolysis might give rise to embolic complications such as enlarged left atrium with atrial fibrillation (risk of dissolution of clot and subsequent embolisation); elderly; external chest compression; hypertension; risk of bleeding (including that from venuepuncture or invasive procedures).
- **Side-Effects** Allergic reactions; anaphylaxis; angina (when used in myocardial infarction); back pain; bleeding (usually limited to the site of injection, but can occur from other sites); cerebral oedema (caused by reperfusion); convulsions; fever; flushing; hypotension; intracerebral haemorrhage; nausea; pulmonary oedema (caused by reperfusion); rash; recurrent ischaemia (when used in myocardial infarction); reperfusion arrhythmias (when used in myocardial infarction); uveitis; vomiting.

**Side-Effects, Further Information**

- **Bleeding** Serious bleeding calls for discontinuation of the thrombolytic and may require administration of coagulation factors and antifibrinolytic drugs (e.g. tranexamic acid). Rarely further embolism may occur (either due to clots that break away from the original thrombus or to cholesterol crystal emboli).
- **Hypotension** Hypotension can usually be controlled by elevating the patient’s legs, or by reducing the rate of infusion or stopping it temporarily.
- **Pregnancy** Thrombolytic drugs can possibly lead to premature separation of the placenta in the first 18 weeks of pregnancy. There is also a risk of maternal haemorrhage throughout pregnancy and post-partum, and also a theoretical risk of fetal haemorrhage throughout pregnancy.

### Alteplase

(rt-PA; Tissue-type plasminogen activator)

- **Indications and Dose**
  - **Acute Myocardial Infarction, Accelerated Regimen**
    - Initially by intravenous injection
    - Adult (body-weight up to 65 kg): Initially 15 mg, to be initiated within 6 hours of symptom onset, followed by (by intravenous infusion) 0.75 mg/kg, to be given over 30 minutes, then (by intravenous infusion) 0.5 mg/kg, to be given over 60 minutes, maximum total dose of 100 mg administered over 90 minutes
    - Adult (body-weight 65 kg and above): Initially 15 mg, to be initiated within 6 hours of symptom onset, followed by (by intravenous infusion) 50 mg, to be given over 60 minutes, then (by intravenous infusion) 35 mg, to be given over 60 minutes, maximum total dose of 100 mg administered over 90 minutes
  - **Acute Myocardial Infarction**
    - Initially by intravenous injection
    - Adult: Initially 10 mg, to be initiated within 6–12 hours of symptom onset, followed by (by intravenous infusion) 50 mg, to be given over 60 minutes, then (by intravenous infusion) 10 mg infusion dose to be given over 30 minutes, total dose of 100 mg over 3 hours; maximum 1.5 mg/kg in patients less than 65 kg
  - **Pulmonary embolism**
    - Initially by intravenous injection
    - Adult: Initially 10 mg, to be given over 1–2 minutes, followed by (by intravenous infusion) 90 mg, to be given over 2 hours, maximum 1.5 mg/kg in patients less than 65 kg
  - **Acute Ischaemic Stroke (Under Specialist Neurology Physician Only)**
    - By intravenous infusion
    - Adult 18–79 years: Initially 900 micrograms/kg (max. per dose 90 mg), treatment must begin within 4.5 hours of symptom onset, to be given over 60 minutes, the initial 10% of dose is to be administered by intravenous injection and the remainder by intravenous infusion

### ACTILYSE CATHFLO®

Thrombolytic treatment of occluded central venous access devices (including those used for haemodialysis)

- **By intravenous injection**
- Adult: (Consult product literature)

- **Contra-Indications**
  - When used for acute ischaemic stroke
  - Convulsion accompanying stroke
  - History of stroke in patients with diabetes
  - Hyperglycaemia
  - Hypoglycaemia
  - Severe stroke
  - Stroke in last 3 months

- **Interactions** → Appendix 1: alteplase

- **Side-Effects** Risk of cerebral bleeding increased in acute stroke

- **Allergy and Cross-Sensitivity** Contra-indicated if history of hypersensitivity to gentamicin (residue from manufacturing process).

- **Monitoring Requirements**
  - When used for acute ischaemic stroke
  - Monitor for intracranial haemorrhage, and monitor blood pressure (antihypertensive recommended if systolic above 180 mmHg or diastolic above 105 mmHg).

- **Directions for Administration** For intravenous infusion (Actilyse®), give intermittently or continuously in Sodium chloride 0.9%; dissolve in water for injections to a concentration of 1 mg/mL or 2 mg/mL and infuse intravenously; alternatively dilute the solution further in...
the infusion fluid to a concentration of not less than 200 micrograms/mL; not to be infused in glucose solution.

- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **NICE technology appraisals (TAs)**
    - Actilyse for the treatment of acute ischaemic stroke (September 2012) NICE TA264
      - Actilyse is recommended for the treatment of acute ischaemic stroke in adults in accordance with its licensed indication if:
        - treatment is started as early as possible within 4.5 hours of onset of stroke symptoms, and
        - intracranial haemorrhage has been excluded by appropriate imaging techniques.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection.
    - **Actilyse** (Boehringer Ingelheim Ltd)
      - Actilyse 10 mg: Actilyse 10mg powder and solvent for solution for injection vials | 1 vial (POM) £172.80
      - Actilyse 20 mg: Actilyse 20mg powder and solvent for solution for injection vials | 1 vial (POM) £259.20
    - **Actilyse Cathflo** (Boehringer Ingelheim Ltd)
      - Actilyse 10 mg: Actilyse Cathflo 2mg powder and solvent for solution for injection vials | 5 vial (Hospital only) £225.00

- **Powder and solvent for solution for infusion**
  - **Actilyse** (Boehringer Ingelheim Ltd)
    - Actilyse 50 mg: Actilyse 50mg powder and solvent for solution for infusion vials | 1 vial (POM) £432.00

- **Tenecteplase**
  - **INDICATIONS AND DOSE**
    - **Acute myocardial infarction**
      - **BY INTRAVENOUS INJECTION**
        - Adult: 30–50 mg (max. per dose 50 mg), dose to be given over 10 seconds and Initiated within 6 hours of symptom onset, dose varies according to body weight—consult product literature
    - **INTERACTIONS** → Appendix 1: tenecteplase
    - **BREAST FEEDING** Manufacturer advises avoid breastfeeding for 24 hours after dose (express and discard milk during this time).

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
    - **Powder and solvent for solution for injection**
      - **Streptokinase (Non-proprietary)**
        - Streptokinase 1.5 mega u: Biofactor Streptokinase 1.5million unit powder for solution for infusion vials | 1 vial (POM) £83.44
        - Streptokinase 250000 unit: Biofactor Streptokinase 250,000unit powder for solution for infusion vials | 1 vial (POM) £15.91
        - Streptokinase 750000 unit: Biofactor Streptokinase 750,000unit powder for solution for infusion vials | 1 vial (POM) £41.72

- **Streptokinase**
  - **INDICATIONS AND DOSE**
    - **Acute myocardial infarction**
      - **BY INTRAVENOUS INJECTION**
        - Adult: 1 500 000 units, to be initiated within 12 hours of symptom onset, dose to be given over 60 minutes
      - **Deep-vein thrombosis | Pulmonary embolism | Acute arterial thromboembolism | Central retinal venous or arterial thrombosis**
        - **BY INTRAVENOUS INJECTION**
          - Adult: 250 000 units, dose to be given over 30 minutes, then 100 000 units every 1 hour for up to 12–72 hours, duration is adjusted according to condition with monitoring of clotting parameters (consult product literature)
    - **INTERACTIONS** → Appendix 1: streptokinase
    - **SIDE-EFFECTS**
      - Rare: Guillain-Barré syndrome

- **ALLERGY AND CROSS-SENSITIVITY**
  - Contra-indicated if previous allergic reaction to either streptokinase or anistreplase (no longer available). Prolonged persistence of antibodies to streptokinase and anistreplase (no longer available) can reduce the effectiveness of subsequent treatment; therefore, streptokinase should not be used again beyond 4 days of first administration of either streptokinase or anistreplase.

- **DIRECTIONS FOR ADMINISTRATION**
  - For intravenous infusion (Streptase®), give continuously or intermittently; reconstitute with sodium chloride 0.9%, then dilute further with Glucose 5% or Sodium Chloride 0.9% after reconstitution.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
    - **Powder for solution for infusion**
      - **Tenecteplase**
        - Tenecteplase 8000 unit: Biofactor Tenecteplase 8000unit powder and solvent for solution for injection vials | 1 vial (POM) £85.61

- **NITRATES**
  - **Overview**
    - Nitrates have a useful role in angina. Although they are potent coronary vasodilators, their principal benefit follows from a reduction in venous return which reduces left ventricular work. Unwanted effects such as flushing, headache, and postural hypotension may limit therapy, especially when angina is severe or when patients are unusually sensitive to the effects of nitrates.

    - **Sublingual glyceryl trinitrate** p. 212 is one of the most effective drugs for providing rapid symptomatic relief of angina, but its effect lasts only for 20 to 30 minutes; the 300-microgram tablet is often appropriate when glyceryl trinitrate is first used. The aerosol spray provides an alternative method of rapid relief of symptoms for those who find difficulty in dissolving sublingual preparations. Duration of action may be prolonged by transdermal preparations (but tolerance may develop).
Isosorbide dinitrate p. 214 is active sublingually and is a more stable preparation for those who only require nitrates infrequently. It is also effective by mouth for prophylaxis; although the effect is slower in onset, it may persist for several hours. Duration of action of up to 12 hours is claimed for modified-release preparations. The activity of isosorbide dinitrate may depend on the production of active metabolites, the most important of which is isosorbide mononitrate p. 214. Isosorbide mononitrate itself is also licensed for angina prophylaxis; modified-release formulations (for once daily administration) are available.

Glyceryl trinitrate or isosorbide dinitrate may be tried by intravenous injection when the sublingual form is ineffective in patients with chest pain due to myocardial infarction or severe ischaemia. Intravenous injections are also useful in the treatment of congestive heart failure.

### Nitrates

**CONTRA-INDICATIONS**
- Aortic stenosis
- Cardiac tamponade
- Constrictive pericarditis
- Hypertrophic cardiomyopathy
- Hypotensive conditions
- Hypovolaemia
- Marked anaemia
- Mitral stenosis
- Raised intracranial pressure due to head trauma
- Toxic pulmonary oedema

**CAUTIONS**
- Heart failure due to obstruction
- Hyperthermia
- Hypothyroidism
- Hypoxaemia
- Malnutrition
- Metal-containing transdermal systems should be removed before magnetic resonance imaging procedures, cardioversion, or diathermy
- Recent history of myocardial infarction
- Susceptibility to angle-closure glaucoma
- Tolerance
- Ventilation and perfusion abnormalities

**CAUTIONS, FURTHER INFORMATION**
- Tolerance: Many patients on long-acting or transdermal nitrates rapidly develop tolerance (with reduced therapeutic effects). Reduction of blood-nitrate concentrations to low levels for 4 to 12 hours each day usually maintains effectiveness in such patients. If tolerance is suspected during the use of transdermal patches they should be left off for 8–12 hours (usually overnight) in each 24 hours; in the case of modified-release tablets of isosorbide dinitrate (and conventional formulations of isosorbide mononitrate), the second of the two daily doses should be given after about 8 hours rather than after 12 hours. Conventional formulations of isosorbide mononitrate should not usually be given more than twice daily unless small doses are used; modified-release formulations of isosorbide mononitrate should only be given once daily, and used in this way do not produce tolerance.

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**
- **Common or very common**: Dizziness, postural hypotension, tachycardia, throbbing headache
- **Uncommon**: Flushing, heartburn, nausea, rash, syncope, temporary hypoxaemia, vomiting
- **Very rare**: Angle-closure glaucoma
- **Frequency not known**: Paradoxical bradycardia

**SPECIFIC SIDE-EFFECTS**
- **Uncommon**: With transdermal use: Application site reactions with transdermal patches
- **Frequency not known**: With intravenous use: Abdominal pain, apprehension, diaphoresis, muscle twitching, palpitation; prolonged administration has been associated with methaemoglobinemia, restlessness, retrosternal discomfort, severe hypotension

### Nitroglycerin

**INDICATIONS AND DOSE**

**Prophylaxis and treatment of angina**
- **By sublingual administration using sublingual tablets**
  - Adult: 0.3–1 mg, dose may be repeated as required

**Control of hypertension and myocardial ischaemia during and after cardiac surgery**
- Induction of controlled hypotension during surgery
- Congestive heart failure
- Unstable angina
  - **By intravenous infusion**
    - Adult: 10–200 micrograms/minute (max. per dose 400 micrograms/minute), adjusted according to response
  - Adult: 1–2 sprays, dose be administered under tongue and then close mouth

**Anal fissure**
- **By rectum using ointment**
  - Adult: Apply 2.5 centimetres every 12 hours until pain stops. Max. duration of use 8 weeks, apply to anal canal, 2.5 cm of ointment contains 1.5 mg of glyceryl trinitrate

**Deponit (R)**

**Prophylaxis of angina**
- **By transdermal application**
  - Adult: One ‘5’ or one ‘10’ patch to be applied to lateral chest wall, upper arm, thigh, abdomen, or shoulder; increase to two ‘10’ patches every 24 hours if necessary, to be replaced every 24 hours, sitting replacement patch on different area

**Minitran (R)**

**Prophylaxis of angina**
- **By transdermal application**
  - Adult: One ‘5’ patch to be applied to chest or upper arm; replace every 24 hours, sitting replacement patch on different area, dose to be altered according to response

**Maintenance of venous patency (‘5’ patch only)**
- **By transdermal application**
  - Adult: (consult product literature)
Prophylaxis of angina
▶ BY TRANSDERMAL APPLICATION
▶ Adult: One 0.2mg/h patch to be applied to chest or outer upper arm and replaced every 24 hours, siting replacement patch on different area, dose adjusted according to response; maximum 15 mg per day

Prophylaxis of angina
▶ TO THE SKIN
▶ Adult: Usual dose 1–2 inches every 3–4 hours as required, to be measured on to Applirule® and applied (usually to chest, arm, or thigh) without rubbing in and secured with surgical tape, approx. 800 micrograms/hour absorbed from 1 inch of ointment.

Prophylaxis of angina (to determine dose)
▶ TO THE SKIN
▶ Adult: ½ inch to be administered on first day then increased by ½ inch/day until headache occurs, then reduced by ½ inch, to be measured on to Applirule® and applied (usually to chest, arm, or thigh) without rubbing in and secured with surgical tape, approx. 800 micrograms/hour absorbed from 1 inch of ointment.

Prophylaxis of phlebitis and extravasation (*5 patch only)
▶ BY TRANSDERMAL APPLICATION
▶ Adult: (consult product literature)

INTERACTIONS
▶ Appendix 1: nitrates

SIDE-EFFECTS
▶ With rectal use Burning • diarrhoea • itching • rectal bleeding

PREGNANCY
Not known to be harmful.

DIRECTIONS FOR ADMINISTRATION
▶ With intravenous use For intravenous infusion (Nitrocine®, Nitronal®), give continuously in Glucose 5% or Sodium Chloride 0.9%. For Nitrocine®, suggested infusion concentration 100 micrograms/ml; incompatible with polyvinyl chloride infusion containers such as Vialflex® or Steriflex®; use glass or polyethylene containers or give via a syringe pump.

▶ With intravenous use Glass or polyethylene apparatus is preferable; loss of potency will occur if PVC is used. Glyceryl trinitrate 1 mg/ml to be diluted before use or given undiluted with syringe pump. Glyceryl trinitrate 5 mg/ml to be diluted before use.

PRESCRIBING AND DISPENSING INFORMATION
▶ With sublingual use Glyceryl trinitrate tablets should be supplied in glass containers of not more than 100 tablets, closed with a foil-lined cap, and containing no cotton wool wadding; they should be discarded after 8 weeks in use.

PATIENT AND CARER ADVICE
Rectal ointment should be discarded 8 weeks after first opening.

PERCUTOL® Patients or carers should be given advice on how to administer glyceryl trinitrate ointment.

NATIONAL FUNDING/ACCESS DECISIONS

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (January 2008) that glyceryl trinitrate 0.4% ointment (Rectogesic®) is not recommended for use within NHS Scotland for the relief of pain associated with chronic anal fissure.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: ointment

Solution for infusion
EXCIPIENTS: May contain Ethanol, propylene glycol
▶ Glyceryl trinitrate (Non-proprietary)
Glyceryl trinitrate 1 mg per 1 ml Glyceryl trinitrate 50mg/50ml solution for infusion vials | 1 vial (PDM) £15.90 | 25 vial (PDM) no price available
Glyceryl trinitrate 5 mg per 1 ml Glyceryl trinitrate 50mg/10ml solution for infusion ampoules | 5 ampoule (PDM) £64.90
Glyceryl trinitrate 25mg/5ml solution for infusion ampoules | 5 ampoule (PDM) £32.45
▶ Nitrocin® (Aspire Pharma Ltd)
Glyceryl trinitrate 1 mg per 1 ml Nitroglycerin 10mg/10ml solution for infusion ampoules | 10 ampoule (PDM) £58.75 (Hospital only)
▶ Nitronal® (Merck Serono Ltd)
Glyceryl trinitrate 1 mg per 1 ml Nitroglycerin 5mg/5ml solution for infusion ampoules | 10 ampoule (PDM) £18.04
Nitroglycerin 50mg/50ml solution for infusion vials | 1 vial (PDM) £14.76

Sublingual tablet
CAUTIONARY AND ADVISORY LABELS
▶ Glyceryl trinitrate (Non-proprietary)
Glyceryl trinitrate 300 microgram GTN 300microgram sublingual tablets | 100 tablet (P) £2.20 DT price = £2.30
Glyceryl trinitrate 300microgram sublingual tablets | 100 tablet (P) no price available DT price = £2.30
Glyceryl trinitrate 500 microgram Glyceryl trinitrate 500microgram sublingual tablets | 100 tablet (P) £5.73 DT price = £5.73
Glyceryl trinitrate 600 microgram Glyceryl trinitrate 600microgram sublingual tablets | 100 tablet (P) no price available

Transdermal patch
▶ DepoNitr® (Aspire Pharma Ltd)
Glyceryl trinitrate 5 mg per 24 hour DepoNitr 5 transdermal patches | 28 patch (P) £12.77
Glyceryl trinitrate 10 mg per 24 hour DepoNitr 10 transdermal patches | 28 patch (P) £14.06
▶ Minitrans (Meira Pharmaceuticals Ltd)
Glyceryl trinitrate 5 mg per 24 hour Minitran 5 transdermal patches | 30 patch (P) £1.62
Glyceryl trinitrate 10 mg per 24 hour Minitran 10 transdermal patches | 30 patch (P) £12.07
Glyceryl trinitrate 15 mg per 24 hour Minitran 15 transdermal patches | 30 patch (P) £14.19
▶ Nitro-Dur® (Merck Sharp & Dohme Ltd)
Glyceryl trinitrate 5 mg per 24 hour Nitro-Dur 0.2mg/hour transdermal patches | 28 patch (P) £10.59
Glyceryl trinitrate 10 mg per 24 hour Nitro-Dur 0.4mg/hour transdermal patches | 28 patch (P) £11.72
Glyceryl trinitrate 15 mg per 24 hour Nitro-Dur 0.6mg/hour transdermal patches | 28 patch (P) £12.90
▶ Transderm-Nitro® (Novartis Pharmaceuticals UK Ltd)
Glyceryl trinitrate 5 mg per 24 hour Transderm-Nitro 5 transdermal patches | 28 patch (P) £10.46
Glyceryl trinitrate 10 mg per 24 hour Transderm-Nitro 10 transdermal patches | 28 patch (P) £22.49

Rectal ointment
EXCIPIENTS: May contain Propylene glycol, wool fat and related substances including lanolin
▶ Rectogesic® (Kyowa Kirin Ltd)
Glyceryl trinitrate 4 mg per 1 gram Rectogesic 0.4% rectal ointment | 30 gram (PDM) £39.30 DT price = £39.30

Ointment
EXCIPIENTS: May contain Wool fat and related substances including lanolin
▶ Percutol® (Aspire Pharma Ltd)
Glyceryl trinitrate 20 mg per 1 gram Percutol 2% ointment | 60 gram (P) £79.00 DT price = £79.00

Sublingual spray
CAUTIONARY AND ADVISORY LABELS
▶ Glyceryl trinitrate (Non-proprietary)
Glyceryl trinitrate 400 microgram per 1 dose Glyceryl trinitrate 400micrograms/dose pump sublingual spray | 180 dose (P) £2.63 DT price = £1.79 | 200 dose (P) £2.71 DT price = £1.83
Glyceryl trinitrate 400micrograms/dose aerosol sublingual spray | 180 dose (P) £3.20 DT price = £2.03 | 200 dose (P) £3.50 DT price = £3.50

Cardiovascular system
Cardiovascular system

Isosorbide dinitrate

**INDICATIONS AND DOSE**

**Prophylaxis of angina** | Adjunct in congestive heart failure

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
- **Adult:** 30–120 mg daily in divided doses
- **BY INTRAVENOUS INFUSION**
- **Adult:** 2–10 mg/hour, increased if necessary up to 20 mg/hour

**Left ventricular failure**

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
- **Adult:** 40–160 mg daily in divided doses, increased if necessary up to 240 mg daily in divided doses
- **BY INTRAVENOUS INFUSION**
- **Adult:** Initially 2–10 mg/hour, increased if necessary up to 20 mg/hour

**Prophylaxis of angina**

- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
- **Adult:** 40 mg daily in 1–2 divided doses, increased if necessary to 60–80 mg daily in 2–3 divided doses

**INTERACTIONS**

- Appendix 1: nitrates

**PREGNANCY**

May cross placenta—manufacturers advise avoid unless potential benefit outweighs risk.

**DIRECTIONS FOR ADMINISTRATION**

For intravenous infusion (Isoket 0.05% ®, Isoket 0.1% ®), give continuously in Glucose 5% or Sodium chloride 0.9%. Adsorbed to some extent by polyvinyl chloride infusion containers; preferably use glass or polyethylene containers or give via a syringe pump; Isoket 0.05% ® can alternatively be administered undiluted using a syringe pump with a glass or rigid plastic syringe. Glass or polyethylene infusion apparatus is preferable; loss of potency if PVC used.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution.

**Modified-release tablet**

**CAUTIONARY AND ADVISORY LABELS**

| Isosorbide dinitrate (Non-proprietary) |
| Isosorbide dinitrate 20 mg |
| Isosorbide dinitrate 40 mg |
| Isoket Retard |
| Isoket Retard 20 mg |
| Isoket Retard 40 mg |

**Tablet**

| Isosorbide dinitrate (Non-proprietary) |
| Isosorbide dinitrate 10 mg |
| Isosorbide dinitrate 20 mg |

**Solution for injection**

| Isosorbide dinitrate (Non-proprietary) |
| Isosorbide dinitrate 1 mg per 1 ml |

**ISOTOARD ®**

**Prophylaxis of angina**

- **BY MOUTH**
- **Adult:** Initially 0.5 tablet once daily, to minimise the occurrence of headache, then 1 tablet once daily, then increased if necessary to 2 tablets daily, dose to be taken in the morning

**ISODUR ®**

**Prophylaxis of angina**

- **BY MOUTH**
- **Adult:** 25–50 mg once daily, then increased if necessary to 50–100 mg once daily, dose to be taken in the morning

**ISOBID ®**

**Prophylaxis of angina**

- **BY MOUTH**
- **Adult:** Initially 0.5 tablet once daily for 2–4 days, to minimise the occurrence of headache, then 1 tablet once daily, then increased if necessary to 2 tablets once daily, dose to be taken in the morning

**ISOMO RETARD ®**

**Prophylaxis of angina**

- **BY MOUTH**
- **Adult:** 1 tablet once daily, dose to be taken in the morning

**ISOTARD ®**

**Prophylaxis of angina**

- **BY MOUTH**
- **Adult:** 25–60 mg once daily, if headaches occur with 60 mg tablet, half a 60 mg tablet may be given for 2–4 days, then increased if necessary to 50–120 mg once daily, dose to be taken in the morning

---

**Isosorbide mononitrate**

**INDICATIONS AND DOSE**

**Prophylaxis of angina | Adjunct in congestive heart failure**

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
- **Adult:** Initially 20 mg 2–3 times a day, alternatively initially 40 mg twice daily, increased if necessary up to 120 mg daily in divided doses

**Prophylaxis of angina (for patients who have not previously had a nitrate) | Adjunct in congestive heart failure (for patients who have not previously had a nitrate)**

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
- **Adult:** Initially 10 mg twice daily, increased if necessary up to 120 mg daily in divided doses

**CHEMYDUR ® 60XL**

**Prophylaxis of angina**

- **BY MOUTH**
- **Adult:** Initially 0.5 tablet daily for 2–4 days, to minimise possibility of headache, then 1 tablet daily, increased if necessary to 2 tablets daily, dose to be taken in the morning

**ELANTAN ® LA**

**Prophylaxis of angina**

- **BY MOUTH**
- **Adult:** 25–50 mg once daily, then increased if necessary to 50–100 mg once daily, dose to be taken in the morning, the lowest effective dose should be used

**IMDUR ®**

**Prophylaxis of angina**

- **BY MOUTH**
- **Adult:** Initially 0.5 tablet once daily, to minimise the occurrence of headache, then 1 tablet once daily, then increased if necessary to 2 tablets once daily, dose to be taken in the morning

**ISIB ® 60XL**

**Prophylaxis of angina**

- **BY MOUTH**
- **Adult:** Initially 0.5 tablet once daily for 2–4 days, to minimise the occurrence of headache, then 1 tablet once daily, then increased if necessary to 2 tablets once daily, dose to be taken in the morning
MODISAL™ XL
Prophylaxis of angina
¬ BY MOUTH
¬ Adult: Initially 0.5 tablet once daily for 2–4 days, to minimise the occurrence of headache, then 1 tablet once daily, increased if necessary to 2 tablets once daily, dose to be taken in the morning

MONOMAX™ SR
Prophylaxis of angina
¬ BY MOUTH
¬ Adult: 40–60 mg daily, increased if necessary to 120 mg daily, dose to be taken in the morning

MONOMAX™ XL
Prophylaxis of angina
¬ BY MOUTH
¬ Adult: Initially 0.5 tablet once daily for 2–4 days, to minimise occurrence of headache, then 1 tablet once daily, increased if necessary to 2 tablets once daily, to be taken in the morning

MONOSORB™
Prophylaxis of angina
¬ Adult: Initially 0.5 tablet daily for 2–4 days, to minimise possibility of headache, then 1 tablet daily, increased if necessary to 2 tablets once daily, to be taken in the morning

MONOSORB™ XL60
Prophylaxis of angina
¬ BY MOUTH
¬ Adult: Initially 0.5 tablet once daily for the first 2–4 days, to minimise the occurrence of headache, then 1 tablet once daily, increased if necessary to 2 tablets once daily, dose to be taken in the morning

ZEMON™
Prophylaxis of angina
¬ BY MOUTH
¬ Adult: Initially 30 mg once daily for 2–4 days, to minimise the occurrence of headache, then 40–60 mg once daily, increased if necessary to 80–120 mg once daily, dose to be taken in the morning

• INTERACTIONS → Appendix 1: nitrates
• PREGNANCY Manufacturers advise avoid unless potential benefit outweighs risk.

• MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Modified-release tablet
CAUTIONARY AND ADVISORY LABELS 25
¬ Chemydur 60XL (AMCo)
  • Isosorbide mononitrate 60 mg Chemydur 60XL tablets | 28 tablet [P] £3.49 DT price = £10.50
  • Imdur (AstraZeneca UK Ltd)
  • Isosorbide mononitrate 60 mg Imdur 60mg modified-release tablets | 28 tablet [P] £10.50 DT price = £10.50
  • Isib XL (Sinclair IS Pharma Plc)
  • Isosorbide mononitrate 60 mg Isib 60XL tablets | 28 tablet [P] £8.15 DT price = £10.50
  • Ismo Retard (Intrapharm Laboratories Ltd)
  • Isosorbide mononitrate 40 mg Ismo Retard 40mg tablets | 30 tablet [P] £10.71
  • Isocard XL (Koowa Kirin Ltd)
  • Isosorbide mononitrate 25 mg Isocard 25XL tablets | 28 tablet [P] £6.75 DT price = £6.75
  • Isosorbide mononitrate 40 mg Isocard 40XL tablets | 28 tablet [P] £6.75 DT price = £6.75
  • Isosorbide mononitrate 50 mg Isocard 50XL tablets | 28 tablet [P] £6.75 DT price = £6.75
  • Isosorbide mononitrate 60 mg Isocard 60XL tablets | 28 tablet [P] £5.75 DT price = £10.50

¬ Monosorb XL (Chiesi Ltd)
  • Isosorbide mononitrate 60 mg Monosorb XL 60mg tablets | 28 tablet [P] £5.25 DT price = £15.50

¬ Monomax SR (Chiesi Ltd)
  • Isosorbide mononitrate 40 mg Monomax SR 40 capsules | 28 capsule [P] £6.52 DT price = £6.52

¬ Monosorb XL (Teva UK Ltd)
  • Isosorbide mononitrate 60 mg Monosorb XL 60mg tablets | 28 tablet [P] £3.49 DT price = £10.50

¬ Monomax XL (Kent Pharmaceuticals Ltd)
  • Isosorbide mononitrate 40 mg Monomax XL 40 tablets | 28 tablet [P] £14.25 DT price = £6.75

¬ BNF 25

CAUTIONARY AND ADVISORY LABELS
¬ Modified-release capsule

CAUTIONARY AND ADVISORY LABELS 25
¬ Elantan LA (Aspire Pharma Ltd)
  • Isosorbide mononitrate 25 mg Elantan LA25 capsules | 28 capsule [P] £3.40 DT price = £3.40
  • Isosorbide mononitrate 50 mg Elantan LA50 capsules | 28 capsule [P] £3.69 DT price = £3.69

¬ Isodur XL (Galen Ltd)
  • Isosorbide mononitrate 25 mg Isodur 25XL capsules | 28 capsule [P] £4.63 DT price = £3.40
  • Isosorbide mononitrate 50 mg Isodur 50XL capsules | 28 capsule [P] £6.45 DT price = £3.69

¬ Monosorb XL (Dexcel Pharma Ltd)
  • Isosorbide mononitrate 60 mg Monosorb XL 60 tablets | 28 tablet [P] £15.53 DT price = £10.50

SYMPATHOMIMETICS ▶ INOTROPIC

Dobutamine

• DRUG ACTION Dobutamine is a cardiac stimulant which acts on beta1 receptors in cardiac muscle, and increases contractility with little effect on rate.

• INDICATIONS AND DOSE

Inotropic support in infusion, cardiac surgery, cardiomyopathies, septic shock, cardiogenic shock, and during positive end expiratory pressure ventilation
¬ BY INTRAVENOUS INFUSION
  • Adult: Usual dose 2.5–10 micrograms/kg/minute, adjusted according to response, alternatively 0.5–40 micrograms/kg/minute

Cardiac stress testing
¬ BY INTRAVENOUS INFUSION
  • Adult: (consult product literature)

• CONTRA-INDICATIONS Phaeochromocytoma
• CAUTIONS Acute heart failure · acute myocardial infarction · arrhythmias · correct hypercapnia before starting and during treatment · correct hypervolaemia before starting and during treatment · correct hypoxia before starting and during treatment · correct metabolic acidosis before starting and during treatment · diabetes mellitus · elderly ·
extravasation may cause tissue necrosis · extreme caution or avoid in marked obstruction of cardiac ejection (such as idiopathic hypertrophic subaortic stenosis) · hyperthyroidism · ischaemic heart disease · occlusive vascular disease · severe hypotension · susceptibility to angle-closure glaucoma · tachycardia · tolerance may develop with continuous infusions longer than 72 hours

- **INTERACTIONS** → Appendix 1: sympathomimetics, inotropic
- **SIDE-EFFECTS**
  - Rare Psychosis
  - Very rare Angle-closure glaucoma · AV block · bradycardia · cardiac arrest · coronary artery spasm · hypokalaemia · myocardial infarction · petechial bleeding
  - Frequency not known Anxiety · arrhythmias · bronchospasm · cerebral haemorrhage · chest pain · dyspnoea · eosinophilia · fever · headache · hypertension (marked increase in systolic blood pressure indicates overdose) · hypotension · increased urinary urgency · myoclonic spasm · nausea · palpitation · paraesthesia · phlebitis · pruritus of scalp · pulmonary oedema · rash · reduced platelet aggregation (on prolonged use) · tachycardia · tremor · vomiting
- **PREGNANCY** No evidence of harm in animal studies — manufacturers advise avoid use only if potential benefit outweighs risk.
- **BREAST FEEDING** Manufacturers advise avoid—no information available.
- **MONITORING REQUIREMENTS** Monitor serum-potassium concentration.
- **DIRECTIONS FOR ADMINISTRATION** Dobutamine injection should be diluted before use or given undiluted with syringe pump. Dobutamine concentrate for intravenous infusion should be diluted before use.
  - For intravenous infusion, give continuously in Glucose 5% or Sodium chloride 0.9%. Dilute to a concentration of 0.5–1 mg/mL and give via an infusion pump; give higher concentration (max. 5 mg/mL) through central venous catheter; incompatible with bicarbonate and other strong alkaline solutions.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.
  - **Solution for infusion** EXCIPIENTS: May contain Sulfites
    - Dobutamine (Non-proprietary)
      - Dobutamine (as Dobutamine hydrochloride) 5 mg per 1 ml Dobutamine 250mg/50ml solution for infusion vials | 1 vial (£7.50)
      - Dobutamine (as Dobutamine hydrochloride) 12.5 mg per 1 ml Dobutamine 250mg/20ml concentrate for solution for infusion ampoules | 5 ampoule (£26.00–£26.25)

### 7.1a Cardiac arrest

#### Cardiopulmonary resuscitation

**Overview**
The algorithm for cardiopulmonary resuscitation (Life support algorithm (image) p. 1533) reflects the most recent recommendations of the Resuscitation Council (UK). These guidelines are available at www.resus.org.uk.

Cardiac arrest can be associated with ventricular fibrillation, pulseless ventricular tachycardia, asystole, and pulseless electrical activity (electromechanical dissociation). Adrenaline/epinephrine below 1 in 10000 (100 micrograms/mL) is recommended by intravenous injection repeated every 3–5 minutes if necessary. Administration through a central line results in a faster response than peripheral administration, however placement of a central line must not interfere with chest compressions; drugs administered peripherally must be followed by a flush of at least 20 mL Sodium Chloride 0.9% injection to aid entry into the central circulation. Intravenous injection of amiodarone hydrochloride p. 102 should be considered after adrenaline/epinephrine to treat ventricular fibrillation or pulseless ventricular tachycardia in cardiac arrest refractory to defibrillation. An additional dose of amiodarone hydrochloride can be given if necessary, followed by an intravenous infusion of amiodarone hydrochloride. Lidocaine hydrochloride p. 1242, is an alternative if amiodarone hydrochloride is not available. Atropine sulfate p. 1064 is no longer recommended in the treatment of asystole or pulseless electrical activity. During cardiopulmonary arrest if intravenous access cannot be obtained, the intrasosseous route can be used instead. Drug administration via the endotracheal route is no longer recommended.

For the management of acute anaphylaxis, see allergic emergencies under Antihistamines, allergen immunotherapy and allergic emergencies p. 265.

**SYMPATHOMIMETICS** → VASOCONSTRICCTOR

#### Adrenaline/epinephrine

- **DRUG ACTION** Acts on both alpha and beta receptors and increases both heart rate and contractility (beta<sub>1</sub> effects); it can cause peripheral vasodilatation (alpha effect); it can cause peripheral vasodilation (beta<sub>2</sub> effect) or vasoconstriction (an alpha effect).

- **INDICATIONS AND DOSE**
  - **Cardiopulmonary resuscitation**
    - BY INTRAVENOUS INJECTION
      - Adult: 1 mg every 3–5 minutes as required, a 1 in 10 000 (100 micrograms/mL) solution is recommended
    - **Acute hypotension**
      - BY CONTINUOUS INTRAVENOUS INFUSION
      - Neonate: Initially 100 nanograms/kg/minute, adjusted according to response, higher doses up to 1.5 micrograms/kg/minute have been used in acute hypotension.
    - **Child**
      - Initially 100 nanograms/kg/minute, adjusted according to response, higher doses up to 1.5 micrograms/kg/minute have been used in acute hypotension
      - BY INTRAMUSCULAR INJECTION
      - Child 1 month–5 years: 150 micrograms, doses may be repeated several times if necessary at 5 minute intervals according to blood pressure, pulse, and respiratory function, suitable syringe to be used for measuring small volume; injected preferably into the anterolateral aspect of the middle third of the thigh
      - Child 6–11 years: 300 micrograms, doses may be repeated several times if necessary at 5 minute intervals according to blood pressure, pulse, and respiratory function, to be injected preferably into the anterolateral aspect of the middle third of the thigh
      - Child 12–17 years: 500 micrograms, to be injected preferably into the anterolateral aspect of the middle third of the thigh, doses may be repeated several times if necessary at 5 minute intervals according to blood pressure, pulse, and respiratory function, 300 micrograms (0.3 mL) to be administered if child small or prepubertal
      - Adult: 500 micrograms, to be injected preferably into the anterolateral aspect of the middle third of the
thigh, doses may be repeated several times if necessary at 5 minute intervals according to blood pressure, pulse, and respiratory function.

**Acute anaphylaxis when there is doubt as to the adequacy of the circulation (specialist use only) / Angioedema (if laryngeal oedema is present) (specialist use only)**

- **BY SLOW INTRAVENOUS INJECTION**
  - Adult: 50 micrograms, using 0.5 mL of the dilute 1 in 10 000 adrenaline injection, dose to be repeated according to response, if multiple doses required, adrenaline should be given as a slow intravenous infusion stopping when a response has been obtained.

**Control of bradycardia in patients with arrhythmias after myocardial infarction, if there is a risk of asystole, or if the patient is unstable and has failed to respond to atropine**

- **BY INTRAVENOUS INFUSION**
  - Adult: 2–10 micrograms/minute, adjusted according to response.

**EMERADE® 150 MICROGRAMS**

**Acute anaphylaxis (for self-administration)**

- **BY INTRAMUSCULAR INJECTION**
  - Child (body-weight up to 15 kg): 150 micrograms, then 150 micrograms after 5–15 minutes as required
  - Child (body-weight 15–30 kg): 150 micrograms, then 150 micrograms after 5–15 minutes as required, on the basis of a dose of 10 micrograms/kg, 300 micrograms may be more appropriate for some children.

**EMERADE® 300 MICROGRAMS**

**Acute anaphylaxis (for self-administration)**

- **BY INTRAMUSCULAR INJECTION**
  - Child (body-weight 30 kg and above): 300 micrograms, then 300 micrograms after 5–15 minutes as required
  - Adult (body-weight 30 kg and above): 300 micrograms, then 300 micrograms after 5–15 minutes as required

**EMERADE® 500 MICROGRAMS**

**Acute anaphylaxis (for self-administration for patients at risk of severe anaphylaxis)**

- **BY INTRAMUSCULAR INJECTION**
  - Child 12-17 years: 500 micrograms, then 500 micrograms after 5–15 minutes as required
  - Adult: 500 micrograms, then 500 micrograms after 5–15 minutes as required

**EPIPEN® AUTO-INJECTOR 0.3MG**

**Acute anaphylaxis (for self-administration)**

- **BY INTRAMUSCULAR INJECTION**
  - Child (body-weight 30 kg and above): 300 micrograms, then 300 micrograms after 5–15 minutes as required
  - Adult (body-weight 30 kg and above): 300 micrograms, then 300 micrograms after 5–15 minutes as required

**EPIPEN® JR AUTO-INJECTOR 0.15MG**

**Acute anaphylaxis (for self-administration)**

- **BY INTRAMUSCULAR INJECTION**
  - Child (body-weight up to 15 kg): 150 micrograms, then 150 micrograms after 5–15 minutes as required
  - Child (body-weight 15–30 kg): 150 micrograms, then 150 micrograms after 5–15 minutes as required, on the basis of a dose of 10 micrograms/kg, 300 micrograms may be more appropriate for some children.

**JEXT® 150 MICROGRAMS**

**Acute anaphylaxis (for self-administration)**

- **BY INTRAMUSCULAR INJECTION**
  - Child (body-weight up to 15 kg): 150 micrograms, then 150 micrograms after 5–15 minutes as required
  - Child (body-weight 15–30 kg): 150 micrograms, then 150 micrograms after 5–15 minutes as required, on the basis of a dose of 10 micrograms/kg, 300 micrograms may be more appropriate for some children.

**JEXT® 300 MICROGRAMS**

**Acute anaphylaxis (for self-administration)**

- **BY INTRAMUSCULAR INJECTION**
  - Child (body-weight 30 kg and above): 300 micrograms, then 300 micrograms after 5–15 minutes as required
  - Adult (body-weight 30 kg and above): 300 micrograms, then 300 micrograms after 5–15 minutes as required

- **UNLICENSED USE**
  - With intramuscular use for acute anaphylaxis in children Auto-injectors delivering 150-microgram dose of adrenaline may not be licensed for use in children with body-weight under 15 kg.
  - With intravenous use for acute hypotension in children Adrenaline 1 in 1000 (1 mg/mL) solution is not licensed for intravenous administration.

### IMPORTANT SAFETY INFORMATION

**SAFE PRACTICE**

Intravenous route should be used with extreme care by specialists only.

**CAUTIONS**

- Arteriosclerosis (in adults) · arrhythmias · cerebrovascular disease · cor pulmonale · diabetes mellitus · elderly · hypercalcaemia · hyperreflexia · hypertension · hyperthyroidism · hypokalaemia · ischaemic heart disease · obstructive cardiomyopathy · occlusive vascular disease · organic brain damage · phaeochromocytoma · prostate disorders · psychoneurosis · severe angina · susceptibility to angle-closure glaucoma

### INTERACTIONS

Appendix 1: sympathomimetics, vasoconstrictor

### SIDE-EFFECTS

- Angina · angle-closure glaucoma · anorexia · anxiety · arrhythmias · cold extremities · confusion · difficulty in micturition · dizziness · dry mouth · dyspnoea · headache · hyperglycaemia · hypersalivation · hypertension (risk of cerebral haemorrhage) · hypokalaemia · insomnia · ketogenic acidosis · mydriasis · myocardial infarction · nausea · pallor · palpitation · psychosis · pulmonary oedema (on excessive dosage or extreme sensitivity) · restless · sweating · tachycardia · tissue necrosis at injection site · tissue necrosis of bowel · tissue necrosis of extremities · tissue necrosis of kidneys · tissue necrosis of liver · tremor · urinary retention · vomiting · weakness

### PREGNANCY

May reduce placental perfusion and cause tachycardia, cardiac irregularities, and extrasystoles in fetus. Can delay second stage of labour. Manufacturers advise use only if benefit outweighs risk.

### BREAST FEEDING

Present in milk but unlikely to be harmful as poor oral bioavailability.

### RENAL IMPAIRMENT

Manufacturers advise use with caution in severe impairment.

### MONITORING REQUIREMENTS

Monitor blood pressure and ECG.

### DIRECTIONS FOR ADMINISTRATION

Acute hypotension

- With intravenous use in children For continuous intravenous infusion, dilute with Glucose 5% or Sodium Chloride 0.9% and give through a central venous catheter. Incompatible with bicarbonate and alkaline solutions. Neonatal intensive care, dilute 3 mg/kg body-weight to a final volume of 50 mL with infusion fluid; an intravenous infusion rate of 0.1 mL/hour provides a dose of 100 nanograms/kg/minute; infuse through a central venous catheter. Incompatible with bicarbonate and alkaline solutions. These infusions are usually made up with adrenaline 1 in 1000 (1 mg/mL) solution.
Cardiopulmonary resuscitation

- With intravenous use in adults Administration through a central line results in a faster response than peripheral administration, however placement of a central line must not interfere with chest compressions; drugs administered peripherally must be followed by a flush of at least 20 mL. Sodium Chloride 0.9% injection to aid entry into the central circulation.

**PRESCRIBING AND DISPENSING INFORMATION** It is important, in acute anaphylaxis where intramuscular injection might still succeed, time should not be wasted seeking intravenous access.

Great vigilance is needed to ensure that the correct strength of adrenaline injection is used; anaphylactic shock kits need to make a very clear distinction between the 1 in 10 000 strength and the 1 in 1000 strength.

Patients with severe allergy should be instructed in the self-administration of adrenaline by intramuscular injection.

Packs for self-administration need to be clearly labelled with instructions on how to administer adrenaline (intramuscularly, preferably at the midpoint of the outer thigh, through light clothing if necessary) so that in the case of rapid collapse someone else is able to give it. It is important to ensure individuals at risk and their carers understand that:

- two injection devices should be carried at all times to treat symptoms until medical assistance is available; if, after the first injection, the individual does not start to feel better, the second injection should be given 5 to 15 minutes after the first;
- an ambulance should be called after every administration, even if symptoms improve;
- the individual should lie down with their legs raised (unless they have breathing difficulties, in which case they should sit up) and should not be left alone. Adrenaline for administration by intramuscular injection is available in 'auto-injectors' (e.g. **Emerade**®, **EpiPen**®, or **Jext**®), pre-assembled syringes fitted with a needle suitable for very rapid administration (if necessary by a bystander or a healthcare provider if it is the only preparation available); injection technique is device specific.

To ensure patients receive the auto-injector device that they have been trained to use, prescribers should specify the brand to be dispensed.

**PATIENT AND CARER ADVICE**

Individuals at considerable risk of anaphylaxis need to carry (or have available) adrenaline at all times and the patient, or their carers, need to be instructed in advance when and how to inject it.

**JEXT® 300 MICROGRAMS** 1.1 mL of the solution remains in the auto-injector device after use.

**JEXT® 150 MICROGRAMS** 1.25 mL of the solution remains in the auto-injector device after use.

**EPIPEN® JR AUTO-INJECTOR 0.15MG** 1.7 mL of the solution remains in the auto-injector device after use.

**EMERADE® 300 MICROGRAMS** 0.2 mL of the solution remains in the auto-injector device after use.

**EPIPEN® AUTO-INJECTOR 0.3MG** 1.7 mL of the solution remains in the auto-injector device after use.

**EMERADE® 500 MICROGRAMS** No solution remains in the auto-injector device after use.

**EMERADE® 150 MICROGRAMS** 0.35 mL of the solution remains in the auto-injector device after use. Medicines for Children leaflet: Adrenaline auto-injector for anaphylaxis www.medicinesforchildren.org.uk/adrenaline-for-anaphylaxis

**EXCEPTIONS TO LEGAL CATEGORY** POM restriction does not apply to the intramuscular administration of up to 1 mg of adrenaline injection 1 in 1000 (1 mg/mL) for the emergency treatment of anaphylaxis.

**MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection

**Solution for injection**

**EXCIPIENTS:** May contain Sulphites

- **Adrenaline/epinephrine (Non-proprietary)**
  - **Adrenaline 100 microgram per 1 mL** Adrenaline (base) 100 micrograms/1mL (1 in 10,000) dilute solution for injection ampoules | 10 ampoule (£93.05)
  - **Adrenaline 100 microgram per 1 mL** Adrenaline (base) 1 mg/10mL (1 in 10,000) dilute solution for injection pre-filled syringes | 1 pre-filled disposable injection (£6.87 | 1 pre-filled disposable injection (£18.00 (Hospital only) | 10 pre-filled disposable injection (£180.00 (Hospital only)
  - **Adrenaline (as Adrenaline acid tartrate) 100 microgram per 1 mL** Adrenaline (base) 1 mg/10mL (1 in 10,000) dilute solution for injection ampoules | 10 ampoule (£43.53) | 10 ampoule (£75.13)
  - **Adrenaline (as Adrenaline acid tartrate) 100 microgram per 1 mL** Adrenaline (base) 1 mg/10mL (1 in 10,000) dilute solution for injection ampoules | 10 ampoule (£67.22)
  - **Adrenaline 1 mg per 1 mL** Adrenaline (base) 10 mg/10mL (1 in 1000) solution for injection ampoules | 10 ampoule (£79.65)
  - **Adrenaline (as Adrenaline acid tartrate) 1 mg per 1 mL** Adrenaline (base) 1 mg/10mL (1 in 1000) solution for injection pre-filled syringes | 1 pre-filled disposable injection (£10.40)
  - **Adrenaline (as Adrenaline acid tartrate) 1 mg per 1 mL** Adrenaline (base) 5 mg/5mL (1 in 1000) solution for injection ampoules | 10 ampoule (£77.34)
  - **Adrenaline (as Adrenaline acid tartrate) 1 mg per 1 mL** Adrenaline (base) 5 mg/5mL (1 in 1000) solution for injection ampoules | 10 ampoule (£59.87-£61.33 DT price = £59.87)
  - **Adrenaline (as Adrenaline acid tartrate) 1 mg per 1 mL** Adrenaline (base) 1 mg/1mL (1 in 1000) solution for injection ampoules | 10 ampoule (£6.01 DT price = £6.01)

- **Emerade** (Bausch & Lomb UK Ltd)
  - **Adrenaline 1 mg per 1 mL** Emerade 300 micrograms/0.3mL (1 in 1000) solution for injection auto-injectors | 1 pre-filled disposable injection (£25.99 DT price = £25.45)
  - **Adrenaline (as Adrenaline acid tartrate) 1 mg per 1 mL** Emerade 150 micrograms/0.15mL (1 in 1000) solution for injection auto-injectors | 1 pre-filled disposable injection (£25.99)
  - **EpiPen** (Meda Pharmaceuticals Ltd)
  - **Adrenaline 500 microgram per 1 mL** EpiPen Jr. 150 micrograms/0.3mL (1 in 2000) solution for injection auto-injectors | 1 pre-filled disposable injection (£26.45 | 2 pre-filled disposable injection (£52.90)
  - **Adrenaline 1 mg per 1 mL** EpiPen 300 micrograms/0.3mL (1 in 1000) solution for injection auto-injectors | 1 pre-filled disposable injection (£26.45 DT price = £26.45 | 2 pre-filled disposable injection (£52.90)

- **Jext** (ALK-Abello Ltd)
  - **Adrenaline 1 mg per 1 mL** Jext 300 micrograms/0.3mL (1 in 1000) solution for injection auto-injectors | 1 pre-filled disposable injection (£23.99 DT price = £26.45)
  - **Adrenaline (as Adrenaline acid tartrate) 1 mg per 1 mL** Jext 150 micrograms/0.15mL (1 in 1000) solution for injection auto-injectors | 1 pre-filled disposable injection (£22.99)

**8 Oedema**

**Diuretics**

**Overview**

Thiazides are used to relieve oedema due to chronic heart failure and, in lower doses, to reduce blood pressure.

Loop diuretics are used in pulmonary oedema due to left ventricular failure and in patients with chronic heart failure.

Combination diuretic therapy may be effective in patients with oedema resistant to treatment with one diuretic. Vigorous diuresis, particularly with loop diuretics, may induce acute hypotension; rapid reduction of plasma volume should be avoided.
Thiazides and related diuretics

Thiazides and related compounds are moderately potent diuretics; they inhibit sodium reabsorption at the beginning of the distal convoluted tubule. They act within 1 to 2 hours of oral administration and most have a duration of action of 12 to 24 hours; they are usually administered early in the day so that the diuresis does not interfere with sleep.

In the management of hypertension a low dose of a thiazide produces a maximal or near-maximal blood pressure lowering effect, with very little biochemical disturbance. Higher doses cause more marked changes in plasma potassium, sodium, uric acid, glucose, and lipids, with little advantage in blood pressure control. Chlortalidone p. 224 and indapamide p. 162 are the preferred diuretics in the management of hypertension. Thiazides also have a role in chronic heart failure.

Bendrofluamide p. 161 can be used for mild or moderate heart failure; it is licensed for the treatment of hypertension but is no longer considered the first-line diuretic for this indication, although patients with stable and controlled blood pressure currently taking bendrofluamide can continue treatment.

Chlortalidone, a thiazide–related compound, has a longer duration of action than the thiazides and may be given on alternate days to control oedema. It is also useful if acute retention is liable to be precipitated by a more rapid diuresis or if patients dislike the altered pattern of micturition caused by other diuretics. Chlortalidone can also be used under close supervision for the treatment of ascites due to cirrhosis in stable patients.

Xipamide p. 225 and indapamide are chemically related to chlortalidone. Indapamide is claimed to lower blood pressure with less metabolic disturbance, particularly less aggravation of diabetes mellitus.

Metolazone p. 225 is particularly effective when combined with a loop diuretic (even in renal failure); profound diuresis can occur and the patient should therefore be monitored carefully.

The thiazide diuretics benztiazide, clopamide, cyclopenthiazide p. 225, hydrochlorothiazide, and hydroflumethiazide do not offer any significant advantage over other thiazides and related diuretics.

Loop diuretics

Loop diuretics are used in pulmonary oedema due to left ventricular failure; intravenous administration produces relief of breathlessness and reduces pre-load sooner than would be expected from the time of onset of diuresis. Loop diuretics are also used in patients with chronic heart failure. Diuretic-resistant oedema (except lymphoedema and oedema due to peripheral venous stasis or calcium–channel blockers) can be treated with a loop diuretic combined with a thiazide or related diuretic (e.g. bendrofluamide or metolazone).

If necessary, a loop diuretic can be added to antihypertensive treatment to achieve better control of blood pressure in those with resistant hypertension, or in patients with impaired renal function or heart failure. Loop diuretics can exacerbate diabetes (but hyperglycaemia is less likely than with thiazides) and gout. If there is an enlarged prostate, urinary retention can occur, although this is less likely if small doses and less potent diuretics are used initially.

Furosemide p. 221 and bumetanide p. 220 are similar in activity; both act within 1 hour of oral administration and diuresis is complete within 6 hours so that, if necessary, they can be given twice in one day without interfering with sleep. Following intravenous administration furosemide has a peak effect within 30 minutes. The diuresis associated with these drugs is dose related.

Torasemide p. 222 has properties similar to those of furosemide and bumetanide, and is indicated for oedema and for hypertension.

Potassium-sparing diuretics and aldosterone antagonists

Amiloride hydrochloride p. 223 and triamterene p. 224 on their own are weak diuretics. They cause retention of potassium and are therefore given with thiazide or loop diuretics as a more effective alternative to potassium supplements. See compound preparations with thiazides or loop diuretics.

Potassium supplements must not be given with potassium-sparing diuretics. Administration of a potassium sparing diuretic to a patient receiving an ACE inhibitor or an angiotensin-II receptor antagonist can also cause severe hyperkalaemia.

Aldosterone antagonists

Spironolactone p. 185 potentiates thiazide or loop diuretics by antagonising aldosterone; it is a potassium-sparing diuretic. Spironolactone is of value in the treatment of oedema and ascites caused by cirrhosis of the liver; furosemide can be used as an adjunct. Low doses of spironolactone are beneficial in moderate to severe heart failure and when used in resistant hypertension [unlicensed indication]. Spironolactone is also used in primary hyperaldosteronism (Conn’s syndrome). It is given before surgery or if surgery is not appropriate, in the lowest effective dose for maintenance.

Eplerenone p. 185 is licensed for use as an adjunct in left ventricular dysfunction with evidence of heart failure after a myocardial infarction; it is also licensed as an adjunct in chronic mild heart failure with left ventricular systolic dysfunction.

Potassium supplements must not be given with aldosterone antagonists

Potassium-sparing diuretics with other diuretics

Although it is preferable to prescribe thiazides and potassium-sparing diuretics separately, the use of fixed combinations may be justified if compliance is a problem. Potassium-sparing diuretics are not usually necessary in the routine treatment of hypertension, unless hypokalaemia develops.

Other diuretics

Mannitol p. 222 is an osmotic diuretic that can be used to treat cerebral oedema and raised intra-ocular pressure.

Mercurial diuretics are effective but are now almost never used because of their nephrotoxicity.

The carbonic anhydrase inhibitor acetazolamide p. 1080 is a weak diuretic and is little used for its diuretic effect. It is used for prophylaxis against mountain sickness [unlicensed indication] but is not a substitute for acclimatisation.

Acetazolamide and eye drops of dorzolamide p. 1081 and brinzolamide p. 1080 inhibit the formation of aqueous humour and are used in glaucoma.

Diuretics with potassium

Many patients on diuretics do not need potassium supplements. For many of those who do, the amount of potassium in combined preparations may not be enough, and for this reason their use is to be discouraged.

Diuretics with potassium and potassium-sparing diuretics should not usually be given together. Diuretics and potassium supplements should be prescribed separately for children.

Other drugs used for Oedema

Diamorphine hydrochloride, p. 433
Loop diuretics

- **DRUG ACTION** Loop diuretics inhibit reabsorption from the ascending limb of the loop of Henle in the renal tubule and are powerful diuretics.
- **CONTRA-INDICATIONS** Anuria - comatose and precomatose states associated with liver cirrhosis - renal failure due to nephrotic or hepatotoxic drugs - severe hypokalaemia - severe hyponatraemia
- **CAUTIONS** Can exacerbate diabetes (but hyperglycaemia less likely than with thiazides) - can exacerbate gout - hypotension should be corrected before initiation of treatment - hypovolaemia should be corrected before initiation of treatment - urinary retention can occur in prostatic hyperplasia

**CAUTIONS, FURTHER INFORMATION**
- **Elderly** Lower initial doses of diuretics should be used in the elderly because they are particularly susceptible to the side-effects. The dose should then be adjusted according to renal function. Diuretics should not be used continuously on a long-term basis to treat simple gravitational oedema (which will usually respond to increased movement, raising the legs, and support stockings).
- **Potassium loss** Hypokalaemia can occur with both thiazide and loop diuretics. The risk of hypokalaemia depends on the duration of action as well as the potency and is thus greater with thiazides than with an equipotent dose of a loop diuretic.
- **Hypokalaemia** is dangerous in severe cardiovascular disease and in patients also being treated with cardiac glycosides. Often the use of potassium-sparing diuretics avoids the need to take potassium supplements.
- In hepatic failure, hypokalaemia caused by diuretics can precipitate encephalopathy, particularly in alcoholic cirrhosis.
- Urinary retention If there is an enlarged prostate, urinary retention can occur, although this is less likely if small doses and less potent diuretics are used initially; an adequate urinary output should be established before initiating treatment.

- **SIDE-EFFECTS**
  - **Very rare** Hyperuricaemia
  - **Frequency not known** Acute urinary retention - blood disorders - bone marrow depression - deafness (usually with high doses and rapid intravenous administration, and in renal impairment) - electrolyte disturbances - hepatic encephalopathy - hyperglycaemia (less common than with thiazides) - hypocalcaemia - hypochloraemia - hypokalaemia - hypomagnesaemia - hyponatraemia - leucopenia - metabolic alkalosis - mild gastrointestinal disturbances - pancreatitis - photosensitization - postural hypotension - pruritus - rash - temporary increase in serum cholesterol and triglyceride concentration - thrombocytopenia - tinnitus (usually with high doses and rapid intravenous administration, and in renal impairment) - visual disturbances

- **HEPATIC IMPAIRMENT** Hypokalaemia induced by loop diuretics may precipitate hepatic encephalopathy and coma — potassium-sparing diuretics can be used to prevent this. Diuretics can increase the risk of hypomagnesaemia in alcoholic cirrhosis, leading to arrhythmias.
- **RENAL IMPAIRMENT** High doses of loop diuretics may occasionally be needed in renal impairment. High doses or rapid intravenous administration can cause tinnitus and deafness.
- **MONITORING REQUIREMENTS** Monitor electrolytes during treatment.

---

Bumetanide

- **INDICATIONS AND DOSE**
  - **Oedema**
    - **BY MOUTH**
      - Adult: 1 mg, dose to be taken in the morning, then 1 mg after 6–8 hours if required
      - Elderly: 500 micrograms daily, this lower dose may be sufficient in elderly patients
  - **Oedema, severe cases**
    - **BY MOUTH**
      - Adult: Initially 5 mg daily, increased in steps of 5 mg every 12–24 hours, adjusted according to response

- **INTERACTIONS** → Appendix 1: loop diuretics
- **SIDE-EFFECTS** Breast pain - gynaecomastia - musculoskeletal pain (associated with high doses in renal failure)
- **PREGNANCY** Bumetanide should not be used to treat gestational hypertension because of the maternal hypovolaemia associated with this condition.
- **BREAST FEEDING** No information available. May inhibit lactation.

- **MEDIATIONAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Oral solution**

- **Bumetanide (Non-proprietary)**
  - Bumetanide 200 microgram per 1 ml Bumetanide 1mg/5ml oral solution sugar free sugar-free | 150 ml [POSM] £198.00 DT price = £198.00

**Tablet**

- **Bumetanide (Non-proprietary)**
  - Bumetanide 1 mg Bumetanide 1mg tablets | 28 tablet [POSM] £7.35 DT price = £6.98
  - Bumetanide 5 mg Bumetanide 5mg tablets | 28 tablet [POSM] £7.00 DT price = £6.98

**Combinations available:** *Amiloride with bumetanide*, p. 224

---

Co-amilofruse

- **INDICATIONS AND DOSE**
  - **Oedema**
    - **BY MOUTH**
      - Adult: 2.5/20–10/80 mg daily, dose to be taken in the morning

**DOSE EQUIVALENCES AND CONVERSION**

  - A mixture of amiloride hydrochloride and furosemide (frusenide) in the mass proportions of 1 part amiloride hydrochloride to 8 parts furosemide (frusenide).

- **CONTRA-INDICATIONS** Addison’s disease - anuria - comatose or precomatose states associated with liver cirrhosis - dehydration - hyperkalaemia - hypovolaemia - renal failure - severe hypokalaemia - severe hyponatraemia

- **CAUTIONS** Correct hypovolaemia before using in oliguria - diabetes mellitus - elderly - gout - hepatorenal syndrome - hypoproteinaemia - hypotension - impaired micturition - prostatic enlargement

- **INTERACTIONS** → Appendix 1: loop diuretics, potassium-sparing diuretics
- **SIDE-EFFECTS** Agranulocytosis - anaphylaxis - aplastic anaemia - blood disorders - bone marrow depression (withdraw treatment) - confusion - deafness (usually in renal impairment or in hypoproteinaemia) - dry mouth - eosinophilia - exfoliative dermatitis - gastrointestinal disturbances - gout - haemolytic anaemia - hepatic encephalopathy - hyperglycaemia - hypersensitivity
Furosemide
(Frusemide)

INDICATIONS AND DOSE

Oedema

- **BY MOUTH**
- Adult: Initially 40 mg daily, dose to be taken in the morning, then maintenance 20–40 mg daily
- Initially by intramuscular injection, or by slow intravenous injection, or by intravenous infusion

Resistant oedema

- **BY MOUTH**
- Adult: 80–120 mg daily
- Initially by intramuscular injection, or by slow intravenous injection, or by intravenous infusion

- Adult: Initially 20–50 mg, then (by intramuscular injection or by intravenous injection or by intravenous infusion) increased in steps of 20 mg every 2 hours if required, doses greater than 50 mg given by intravenous infusion only; maximum 1.5 g per day

CAUTIONS

- Hepatorenal syndrome - hypoproteinaemia may reduce diuretic effect and increase risk of side-effects
- INTERACTIONS - Appendix 1: loop diuretics
- SIDE-EFFECTS - Gout - intrahepatic cholestasis
- PREGNANCY - Furosemide should not be used to treat gestational hypertension because of the maternal hypovolaemia associated with this condition
- BREAST FEEDING - Amount too small to be harmful. May inhibit lactation

DIRECTIONS FOR ADMINISTRATION

- Intravenous administration rate should not usually exceed 4 mg/minute however single doses of up to 80 mg may be administered more rapidly; a lower rate of infusion may be necessary in renal impairment. For intravenous infusion (Lasix®), give continuously in Sodium chloride 0.9%; infusion pH must be above 5.5; glucose solutions are unsuitable.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

- Furosemide (Non-proprietary)
  - Furosemide 20 mg: 28 tablet | 28 tablet | 56 tablet | £1.07
  - Furosemide 40 mg: 28 tablet | 56 tablet | £1.07
  - Furosemide 80 mg: 28 tablet | 56 tablet | £1.52

- Frumil (sanofi)
  - Frumil LS 20mg/2.5mg tablets: 18 tablet | 28 tablet | £4.32
  - Frumil 5mg tablets: 28 tablet | 56 tablet | £1.04

Solution for injection

- Furosemide 10 mg per 1 ml: 250ml/25ml solution for injection ampoules | 10 ampoule | £0.60

- Furosemide 40 mg per 1 ml: 250ml/5ml solution for injection ampoules | 10 ampoule | £2.10

Solution for oral feeding

- Frusol (Sanofi)
  - Frusol 20mg | 50mg | 80mg | 160mg | 180mg | 200mg | 230mg | 260mg | 280mg

- Lasix (Merck)
Furosemide with potassium chloride

The properties listed below are those particular to the combination only. For the properties of the components please consider, furosemide p. 221, potassium chloride p. 968.

- **INDICATIONS AND DOSE**
  - **Oedema**
    - BY MOUTH
    - Adult: 0.5–2 tablets daily, dose to be taken in the morning

- **INTERACTIONS** → Appendix 1: loop diuretics, potassium chloride

- **DIRECTIONS FOR ADMINISTRATION**
  - Furosemide with modified-release potassium chloride tablets should be swallowed whole with plenty of fluid during meals while sitting or standing.

- **PATIENT AND CARER ADVICE**
  - Patients or carers should be given advice on how to administer furosemide with potassium chloride tablets.

- **LESS SUITABLE FOR PRESCRIBING**
  - Furosemide with potassium chloride tablets are less suitable for prescribing.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

- **Modified-release tablet**
  - **CAUTIONARY AND ADVISORY LABELS 25, 27**
  - Diumide-K Continus (Teofarma)
    - Furosemide 40 mg, Potassium chloride 600 mg
      - Diumide-K Continus tablets 30 tablet [POM] £3.00

- **Furosemide with triamterene**

The properties listed below are those particular to the combination only. For the properties of the components please consider, furosemide p. 221, triamterene p. 224.

- **INDICATIONS AND DOSE**
  - **Oedema**
    - BY MOUTH
    - Adult: 0.5–2 tablets daily, dose to be taken in the morning

- **CONTRA-INDICATIONS**
  - Anuria · comatose or precomatose states associated with liver cirrhosis · dehydration · hyperkalaemia · hypovolaemia · renal failure · severe hypokalaemia · severe hyponatraemia

- **CAUTIONS**
  - Diabetes mellitus · elderly · gout · hepatorenal syndrome · hypotension · impaired micturition · may cause blue fluorescence of urine · prostatic enlargement

- **INTERACTIONS** → Appendix 1: loop diuretics, potassium-sparing diuretics

- **SIDE-EFFECTS**
  - **Rare**
    - Agranulocytosis · anaphylaxis · aplastic anaemia · blood disorders · bone marrow depression (withdraw treatment) · deafness (usually in renal impairment or in hypoproteinaemia) · eosinophilia · exfoliative dermatitis · haemolytic anaemia · hypersensitivity reactions · intrahepatic cholestasis · leucopenia · pancreatitis · paraesthesia · photosensitivity · purpura · rash · thrombocytopenia · tinnitus (usually in renal impairment or in hypoproteinaemia)

  - **Frequency not known**
    - Dry mouth · electrolyte disturbances · gastro-intestinal disturbances · gout · hyperglycaemia (less common than with thiazides) · hyperkalaemia · hyperuricaemia · hypocalcaemia · hypokalaemia · hypomagnesaemia · hyponatraemia · hypotension · metabolic alkalosis · temporary increase in plasma cholesterol and triglyceride concentration · triamterene found in kidney stones

  - **BREAST FEEDING**
    - Triamterene present in milk—manufacturer advises avoid. Furosemide may inhibit lactation.

  - **HEPATIC IMPAIRMENT**
    - Increased risk of hypomagnesaemia in alcoholic cirrhosis. Hypokalaemia may precipitate coma.

  - **RENAL IMPAIRMENT**
    - May need high doses. Avoid in severe impairment. Monitor plasma-potassium concentration in renal impairment (high risk of hyperkalaemia).

  - **MONITORING REQUIREMENTS**
    - Monitor electrolytes.

  - **PATIENT AND CARER ADVICE**
    - Urine may look slightly blue in some lights.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

- **Tablet**
  - **CAUTIONARY AND ADVISORY LABELS 14**
  - Frusene (Orion Pharma (UK) Ltd)
    - Furosemide 40 mg, Triamterene 50 mg
      - Frusene 50mg/40mg tablets 56 tablet [POM] £4.34 DT price = £4.34

Torasemide

- **INDICATIONS AND DOSE**
  - **Oedema**
    - BY MOUTH
    - Adult: 5 mg once daily, to be taken preferably in the morning, then increased if necessary to 20 mg once daily; maximum 40 mg per day

- **Hypertension**
  - BY MOUTH
    - Adult: 2.5 mg daily, then increased if necessary to 5 mg once daily

- **INTERACTIONS** → Appendix 1: loop diuretics

- **SIDE-EFFECTS**
  - **Rare**
    - Limb paraesthesia

  - **Frequency not known**
    - Dry mouth

  - **Pregnancy**
    - Manufacturer advises avoid—toxicity in animal studies.

  - **BREAST FEEDING**
    - Manufacturer advises avoid—no information available.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

- **Tablet**
  - **Torasemide (Non-proprietary)**
    - **Torasemide 5 mg**
      - Torasemide 5mg tablets 28 tablet [POM] £14.50 DT price = £5.53
    - **Torasemide 10 mg**
      - Torasemide 10mg tablets 28 tablet [POM] £18.75 DT price = £8.14
    - **Torem (Meda Pharmaceuticals Ltd)**
      - **Torasemide 2.5 mg**
        - Torem 2.5mg tablets 28 tablet [POM] £3.78 DT price = £1.78
      - **Torasemide 5 mg**
        - Torem 5mg tablets 28 tablet [POM] £5.53 DT price = £2.53
      - **Torasemide 10 mg**
        - Torem 10mg tablets 28 tablet [POM] £8.14 DT price = £4.14

**DIURETICS > OSMOTIC DIURETICS**

Mannitol

- **INDICATIONS AND DOSE**
  - **Cerebral oedema**
    - BY INTRAVENOUS INFUSION
    - Adult: 0.25–2 g/kg, repeated if necessary, to be administered over 30–60 minutes, dose may be repeated 1–2 times after 4–8 hours
Raised intra-ocular pressure

▶ By intravenous infusion
Adult: 0.25–2 g/kg, repeated if necessary, to be administered over 30–60 minutes, dose may be repeated 1–2 times after 4–8 hours

● CONTRA-INDICATIONS Anuria · intracranial bleeding (except during craniotomy) · severe cardiac failure · severe dehydration · severe pulmonary oedema

● CAUTIONS Extravasation causes inflammation and thrombophlebitis

● SIDE-EFFECTS
▶ Uncommon Electrolyte imbalance · fluid imbalance · hypotension · thrombophlebitis
▶ Rare Anaphylaxis · arrhythmia · blurred vision · chest pain · chills · convulsions · cramp · dehydration · dizziness · dry mouth · fever · focal osmotic nephrosis · headache · hypersensitivity reactions · hypertension · nausea · oedema · pulmonary oedema · raised intracranial pressure · rhinitis · skin necrosis · thirst · urinary retention · urticaria · vomiting
▶ Very rare Acute renal failure · congestive heart failure

● PREGNANCY Manufacturer advises avoid unless essential—no information available.

● BREAST FEEDING Manufacturer advises avoid unless essential—no information available.

● RENAL IMPAIRMENT Use with caution in severe impairment.

● PRE-TREATMENT SCREENING Assess cardiac function before treatment.

● MONITORING REQUIREMENTS Monitor fluid and electrolyte balance, serum osmolality, and cardiac, pulmonary and renal function.

● DIRECTIONS FOR ADMINISTRATION For mannitol 20%, an in-line filter is recommended (15-micron filters have been used).

● MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: infusion, solution for infusion

Infusion
▶ Mannitol (Non-proprietary)
Mannitol 100 g per 1 ml
Mannitol 50/500 ml (10%) infusion Viaflo bags | 1 bag (POM) no price available | 20 bag (POM) no price available
Mannitol 50/500 ml (10%) infusion Viaflex bags | 1 bag (POM) no price available | 20 bag (POM) no price available
Polyfusor K mannitol 10% infusion 500 ml bottles | 1 bottle (POM) £4.46 | 12 bottle (POM) no price available
Mannitol 150 g per 1 ml
Mannitol 75 g/500 ml (15%) infusion Viaflo bags | 20 bag (POM) no price available
Mannitol 200 g per 1 ml
Mannitol 100 g/500 ml (20%) infusion Viaflo bags | 1 bag (POM) no price available | 20 bag (POM) no price available
Polyfusor M mannitol 20% infusion 500 ml bottles | 1 bottle (POM) £5.86 | 12 bottle (POM) no price available
Mannitol 50/250 ml (20%) infusion Viaflex bags | 1 bag (POM) no price available | 20 bag (POM) no price available
Mannitol 300 g/500 ml (20%) infusion Viaflex bags | 1 bag (POM) no price available | 20 bag (POM) no price available

DIURETICS > POTASSIUM-SPARING DIURETICS > ALDOSTERONE ANTAGONISTS

[Spironolactone with furosemide]

The properties listed below are those particular to the combination only. For the properties of the components please consider, spironolactone p. 185, furosemide p. 221.
Amiloride with bumetanide

The properties listed below are those particular to the combination only. For the properties of the components please consider, amiloride hydrochloride p. 223, bumetanide p. 220.

**INDICATIONS AND DOSE**

**Oedema**

- **BY MOUTH**
  - Adult: 1–2 tablets daily

**INTERACTIONS** → Appendix 1: loop diuretics, potassium-sparing diuretics

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Amiloride with bumetanide (Non-proprietary)**
  - Bumetanide 1 mg, Amiloride hydrochloride 5 mg
  - Amiloride 5 mg tablets | 28 tablet £1.21 DT price = £1.21
  - Combinations available: **Co-amilofruse**, p. 220

**Triamterene with chlortalidone**

The properties listed below are those particular to the combination only. For the properties of the components please consider, triamterene above, chlortalidone below.

**INDICATIONS AND DOSE**

**Hypertension | Oedema**

- **BY MOUTH**
  - Adult: 50/50–100/100 mg once daily, dose to be taken in the morning

**DOSE EQUIVALENCE AND CONVERSION**

- Dose expressed as \( x/y \) mg of triamterene/chlortalidone.

**INTERACTIONS** → Appendix 1: potassium-sparing diuretics, thiazide diuretics

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS 14, 21**
  - **Kalspare** (DHP Healthcare Ltd)
    - Chlortalidone 50 mg, Triamterene 50 mg
    - Kalspare tablets | 28 tablet £9.90

**DIURETICS > THIAZIDES AND RELATED DIURETICS**

**Chlortalidone**

**(Chlorthalidone)**

**INDICATIONS AND DOSE**

**Ascites due to cirrhosis in stable patients (under close supervision) | Oedema due to nephrotic syndrome**

- **BY MOUTH**
  - Adult: Up to 50 mg daily

**Hypertension**

- **BY MOUTH**
  - Adult: 25 mg daily, dose to be taken in the morning, then increased if necessary to 50 mg daily

**Mild to moderate chronic heart failure**

- **BY MOUTH**
  - Adult: 25–50 mg daily, dose to be taken in the morning, then increased if necessary to 100–200 mg daily, reduce to lowest effective dose for maintenance

**Nephrogenic diabetes insipidus | Partial pituitary diabetes insipidus**

- **BY MOUTH**
  - Adult: Initially 100 mg twice daily, then reduced to 50 mg daily

**INTERACTIONS** → Appendix 1: thiazide diuretics

**SIDE-EFFECTS**

- Rare Allergic interstitial nephritis

**BREAST FEEDING** The amount present in milk is too small to be harmful. Large doses may suppress lactation.
Co-triamterzide

The properties listed below are those particular to the combination only. For the properties of the components please consider, triamterene p. 224, hydrochlorothiazide p. 162.

**INDICATIONS AND DOSE**

**Hypertension**
- **BY MOUTH**
  - Adult: 50–25 mg daily, increased if necessary up to 200/100 mg daily, dose to be taken after breakfast

**Oedema**
- **BY MOUTH**
  - Adult: 50–25 mg twice daily, to be taken after breakfast and after midday meal, increased if necessary to 150/75 mg daily, to be taken as 100/50 mg after breakfast and 50/25 mg after midday meal; maintenance 50/25 mg daily, alternatively maintenance 100/50 mg once daily on alternate days; maximum 200/100 mg per day

**DOSE EQUIVALENCE AND CONVERSION**
- Dose expressed as x/y mg of triamterene/hydrochlorothiazide.

**INTERACTIONS** → Appendix 1: potassium-sparing diuretics, thiazide diuretics

**PATIENT AND CARER ADVICE** Urine may look slightly blue in some lights.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- **Chaortalidone (Non-proprietary)**
  - Chlortalidone 25 mg Chlortalidone 25mg tablets 100 tablet [POM] no price available
  - Chlortalidone 50 mg Chlortalidone 50mg tablets 30 tablet [POM] £90.55 DT price = £90.20

**Combinations available:** *Triamterene with chlortalidone*, p. 224

---

**Metolazone**

**INDICATIONS AND DOSE**

**Oedema**
- **BY MOUTH**
  - Adult: 5–10 mg daily, dose to be taken in the morning; increased if necessary to 20 mg daily, dose increased in resistant oedema; maximum 80 mg per day

**Hypertension**
- **BY MOUTH**
  - Adult: Initially 5 mg daily, dose to be taken in the morning; maintenance 5 mg once daily on alternate days

**CAUTIONS** Acute porphyrias p. 969

**INTERACTIONS** → Appendix 1: thiazide diuretics

**SIDE-EFFECTS** CHEST PAIN - CHILLS

**BREAST FEEDING** The amount present in milk is too small to be harmful. Large doses may suppress lactation.

**DIRECTIONs FOR ADMINISTRATION** Tablets may be crushed and mixed with water immediately before use.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, oral suspension, oral solution

**Tablet**
- **Metolazone (Non-proprietary)**
  - Metolazone 2.5 mg Zaroxolyn 2.5mg tablets 100 tablet [POM] no price available
  - Metolazone 5 mg Zaroxolyn 5mg tablets 50 tablet [POM] no price available

---

**Xipamide**

**INDICATIONS AND DOSE**

**Oedema**
- **BY MOUTH**
  - Adult: Initially 40 mg daily, dose to be taken in the morning, increased if necessary to 80 mg daily, higher dose to be used in resistant cases; maintenance 20 mg daily, dose to be taken in the morning

**Hypertension**
- **BY MOUTH**
  - Adult: 20 mg daily, dose to be taken in the morning

**CAUTIONS** Acute porphyrias p. 969

**INTERACTIONS** → Appendix 1: thiazide diuretics

**BREAST FEEDING** No information available.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- **Diurexan** (Meda Pharmaceuticals Ltd)
  - Xipamide 20 mg Diurexan 20mg tablets 140 tablet [POM] £19.46 DT price = £19.46

---
Peripheral vascular disease

Classification and management

Peripheral vascular disease can be either occlusive (e.g. intermittent claudication) in which occlusion of the peripheral arteries is caused by atherosclerosis, or vasospastic (e.g. Raynaud’s syndrome). Peripheral arterial occlusive disease is associated with an increased risk of cardiovascular events; this risk is reduced by measures such as smoking cessation, effective control of blood pressure, regulating blood lipids, optimising glycaemic control in diabetes, taking aspirin p. 117 in a dose of 75 mg daily, and possibly weight reduction in obesity. Exercise training can improve symptoms of intermittent claudication; revascularisation procedures may be appropriate.

Nafldirofuryl oxalate p. 227 can alleviate symptoms of intermittent claudication and improve pain-free walking distance in moderate disease. Patients taking nafldirofuryl oxalate should be assessed for improvement after 3–6 months.

Cilostazol below is licensed for use in intermittent claudication to improve walking distance in patients without peripheral tissue necrosis who do not have pain at rest; use is restricted to second-line treatment where lifestyle modifications and other appropriate interventions have failed to improve symptoms. Cilostazol should be initiated by those experienced in the management of intermittent claudication. Patients receiving cilostazol should be assessed for improvement after 3 months; consider discontinuation of treatment if there is no clinically relevant improvement in walking distance.

Inositol nicotinate p. 227 and pentoxifylline p. 228 are not established as being effective for the treatment of intermittent claudication.

Management of Raynaud’s syndrome includes avoidance of exposure to cold and stopping smoking. More severe symptoms may require vasodilator treatment, which is most often successful in primary Raynaud’s syndrome. Nifedipine p. 157 is useful for reducing the frequency and severity of vasospastic attacks. Alternatively, nafldirofuryl oxalate may produce symptomatic improvement; inositol nicotinate (a nicotinic acid derivative) may also be considered. Pentoxifylline, prazosin p. 739, and moxisylyte p. 227 are not established as being effective for the treatment of Raynaud’s syndrome.

 Vasodilator therapy is not established as being effective for chilblains.

ANTITHROMBOTIC DRUGS > ANTIPLATELET DRUGS

Cilostazol

INDICATIONS AND DOSE

Intermittent claudication in patients without rest pain and no peripheral tissue necrosis

BY MOUTH

Adult: 100 mg twice daily, to be taken 30 minutes before food, cilostazol should be initiated by those experienced in the management of intermittent claudication, patients receiving cilostazol should be assessed for improvement after 3 months; consider discontinuation of treatment if there is no clinically relevant improvement in walking distance

DOSE ADJUSTMENTS DUE TO INTERACTIONS

Manufacturer advises reduce dose to 50 mg twice daily with concurrent use of potent inhibitors of CYP3A4, potent inhibitors of CYP2C19, omeprazole and erythromycin.

CONTRA-INDICATIONS

Active peptic ulcer - congestive heart failure - coronary intervention in previous 6 months - haemorrhagic stroke in previous 6 months - history of severe tachyarrhythmia - myocardial infarction in previous 6 months - poorly controlled hypertension - predisposition to bleeding - proliferative diabetic retinopathy - prolongation of QT interval - severe atrial flutter - unstable angina

CAUTIONS

Atrial fibrillation - atrial or ventricular ectopy - diabetes mellitus (higher risk of intraocular bleeding) - mild to moderate atrial flutter - stable coronary disease - surgery

INTERACTIONS → Appendix I: cilostazol

SIDE-EFFECTS

Common or very common Abdominal pain - angina - anorexia - arrhythmia - diarrhoea - dizziness - dyspepsia - ecchymosis - flatulence - headache - malaise - nausea - oedema - palpitation - pharyngitis - pruritus - rash - rhinitis - tachycardia - vomiting


Rare Bleeding disorders - increased urinary frequency - renal impairment - thrombocytopenia

FREQUENCY NOT KNOWN Agranulocytosis - aplastic anaemia - conjunctivitis - hepatitis - hot flushes - hypertension - leucopenia - pancytopenia - pyrexia - Stevens-Johnson syndrome - thrombocytopenia - tinnitus - toxic epidermal necrosis

SIDE-EFFECTS, FURTHER INFORMATION

Blood Disorders A blood count should be performed and the drug stopped immediately if there is suspicion of a blood dyscrasia.

PREGNANCY

Avoid—toxicity in animal studies.

BREAST FEEDING

Present in milk in animal studies—manufacturer advises avoid.

HEPATIC IMPAIRMENT

Avoid in moderate or severe liver disease.

RENAL IMPAIRMENT

Avoid if eGFR less than 25 mL/minute/1.73 m².

PATIENT AND CARER ADVICE

Blood disorders Patients should be advised to report any unexplained bleeding, bruising, sore throat, or fever.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

Cilostazol, nafldirofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (May 2011) NICE TA223 Cilostazol is not recommended for the treatment of intermittent claudication in patients with peripheral arterial disease; patients currently receiving this treatment should have the option to continue until they and their clinician consider it appropriate to stop.

www.nice.org.uk/TA223

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (October 2005) that cilostazol is not recommended for the treatment of intermittent claudication within NHS Scotland.
MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet
▶ Cilostazol (Non-proprietary)
Cilostazol 50 mg Cilostazol 50mg tablets | 56 tablet £40.05 DT price = £40.05
Cilostazol 100 mg Cilostazol 100mg tablets | 56 tablet £31.70 DT price = £3.33
▶ Pletal (Otsuka Pharmaceuticals (U.K.) Ltd) ▼
Cilostazol 50 mg Pletal 50mg tablets | 56 tablet £35.31 DT price = £40.05
Cilostazol 100 mg Pletal 100mg tablets | 56 tablet DT price = £3.33

LIPID MODIFYING DRUGS ▶ NICOTINIC ACID DERIVATIVES

Inositol nicotinate

INDICATIONS AND DOSE
Peripheral vascular disease
▶ BY MOUTH
Adult: 3 g daily in 2–3 divided doses; maximum 4 g per day

CONTRA-INDICATIONS
Acute phase of a cerebrovascular accident • recent myocardial infarction

CAUTIONS
Cerebrovascular insufficiency • unstable angina

SIDE-EFFECTS
Dizziness • flushing • headache • hypotension • nausea • oedema • paraesthesia • rash • syncope • vomiting

PREGNANCY
No information available—manufacturer advises avoid unless potential benefi ts outweigh risks.

NATIONAL FUNDING/ACCESS DECISIONS
NICE technology appraisals (TAs)
▶ Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (May 2011) NICE TA223
Inositol nicotinate is not recommended for the treatment of intermittent claudication in patients with peripheral arterial disease; patients currently receiving treatment should have the option to continue until they and their clinician consider it appropriate to stop.

www.nice.org.uk/TA223

LESS SUITABLE FOR PRESCRIBING
Less suitable for prescribing.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

Tablet
▶ Hexopal (Genus Pharmaceuticals Ltd)
Inositol nicotinate 500 mg Hexopal 500mg tablets | 100 tablet £26.15 DT price = £26.15
Inositol nicotinate 750 mg Hexopal Forte 750mg tablets | 112 tablet £43.37 DT price = £43.37
Capsule
▶ Inositol nicotinate (Non-proprietary)
Inositol nicotinate 500 mg Solgar No-Flush Niacin 500mg capsules | 50 capsule no price available

VASODILATORS ▶ FLAVONOIDS

Oxerutins

INDICATIONS AND DOSE
Relief of symptoms of oedema associated with chronic venous insufficiency
▶ BY MOUTH
Adult: 500 mg twice daily

SIDE-EFFECTS
Flushing • headache • mild gastro-intestinal disturbances • rash

LESS SUITABLE FOR PRESCRIBING
Oxerutins (rutosides) are not vasodilators and are not generally regarded as effective preparations as capillary sealants or for the treatment of cramps; they are less suitable for prescribing.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Capsule
▶ Paroven (GlaxoSmithKline Consumer Healthcare)
Oxerutins 250 mg Paroven 250mg capsules | 120 capsule £20.34 DT price = £18.49

VASODILATORS ▶ PERIPHERAL VASODILATORS

Moxisylyte
(Thymoxamine)

INDICATIONS AND DOSE
Primary Raynaud’s syndrome (short-term treatment)
▶ BY MOUTH
Adult: Initially 40 mg 4 times a day, increased if necessary to 80 mg 4 times a day, increase dose if poor initial response, discontinue after 2 weeks if no response

CONTRA-INDICATIONS
Active liver disease

CAUTIONS
Diabetes mellitus

INTERACTIONS
Appendix 1: moxisylyte

SIDE-EFFECTS
Cholestatic jaundice • diarrhoea • dizziness • flushing • headache • hepatic reactions • hepatitis • nausea

PREGNANCY
Manufacturer advises avoid.

LESS SUITABLE FOR PRESCRIBING
Less suitable for prescribing.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet
CAUTIONARY AND ADVISORY LABELS 21
▶ Opilon (Kyowa Kirin Ltd)
Moxisylyte (as Moxisylyte hydrochloride) 40 mg Opilon 40mg tablets | 112 tablet £90.22 DT price = £90.22

Naftidrofuryl oxalate

INDICATIONS AND DOSE
Peripheral vascular disease
▶ BY MOUTH
Adult: 100–200 mg 3 times a day, patients taking naftidrofuryl should be assessed for improvement after 3–6 months

Cerebral vascular disease
▶ BY MOUTH
Adult: 100 mg 3 times a day, patients taking naftidrofuryl should be assessed for improvement after 3–6 months

SIDE-EFFECTS
Epigastric pain • hepatic failure • hepatitis • nausea • rash

NATIONAL FUNDING/ACCESS DECISIONS
NICE technology appraisals (TAs)
▶ Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (May 2011) NICE TA223
Naftidrofuryl oxalate is an option for the treatment of intermittent claudication in patients with peripheral arterial disease. In a trial in patients with intermittent claudication, the oxalate formulation was better tolerated than the sodium formulation.
arterial disease in whom vasodilator therapy is considered appropriate.  
www.nice.org.uk/TA223

**MEDICINAL FORMS**  
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

**Capsule**

**CAUTIONARY AND ADVISORY LABELS** 25, 27
- Nafldrofuryl oxalate (Non-proprietary)
  - Nafldrofuryl oxalate 100 mg Nafldrofuryl 100mg capsules | 84 capsule [PoT] £12.75 DT price = £4.41
- Praxilene (Merck Serono Ltd)
  - Nafldrofuryl oxalate 100 mg Praxilene 100mg capsules | 84 capsule [PoT] £8.10 DT price = £4.41

**INTERACTIONS**

**CONTRA-INDICATIONS**

**CAUTIONS**

**NATIONAL FUNDING/ACCESS DECISIONS**

**RENAL IMPAIRMENT**

**HEPATIC IMPAIRMENT**

**CAUTIONARY AND ADVISORY LABELS**

**RARE**

**FREQUENCY NOT KNOWN**

**LESS SUITABLE FOR PRESCRIBING**

Less suitable for prescribing.

---

**Sodium tetracycl decyl sulfate**

**INDICATIONS AND DOSE**

Sclerotherapy of reticular veins and spider veins in legs and varicose veins

> **BY INTRAVENOUS INJECTION**

**ADULT:** Test dose recommended before each treatment (consult product literature)

**CONTRA-INDICATIONS**

Acute infection, asthma, blood disorders, deep vein thrombosis, high risk of thromboembolism, hyperthrombroidism, inability to walk, neoplasm, occlusive arterial disease, phlebitis, pulmonary embolism, recent acute superficial thrombophlebitis, recent surgery, respiratory disease, significant valvular incompetence in deep veins, skin disease, symptomatic patent foramen ovale (if administered as foam), uncontrolled diabetes mellitus, varicose veins caused by tumours (unless tumour removed)

**CAUTIONS**

Arterial disease, asymptomatic patent foramen ovale (use smaller volumes and avoid Valsalva manoeuvre immediately after administration), extravasation may cause necrosis of tissues, history of migraine (use smaller volumes), resuscitation facilities must be available, venous insufficiency with lymphoedema (pain and inflammation may worsen)

**SIDE-EFFECTS**

- **Common or very common** Local burning, local pain
- **Rare** Phlebitis, skin discoloration, superficial thrombophlebitis, telangiectatic matting
- **Uncommon** Deep vein thrombosis, scotoma
- **Very rare** Anaphylaxis, circulatory collapse, diarrhoea, dry mouth, fever, hot flushes, hypersensitivity reactions, nausea, necrosis of skin and tissues, palpitation, pulmonary embolism, sloughing of skin and tissues, stroke, swollen tongue, transient ischaemic attack, vasculitis, vomiting, weakness

**PREGNANCY**

Avoid unless benefit outweighs risk—no information available.

**BREAST FEEDING**

Use with caution—no information available.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

**Modified-release tablet**

**CAUTIONARY AND ADVISORY LABELS** 21, 25
- Trental (Sanofi)
  - Pentoxifylline 400 mg Trental 400 modified-release tablets | 90 tablet [PoM] £19.39 DT price = £19.39

---

**9.1 Vein malformations**

**SCLEROSANTS**

**Indications and use**

Sclerotherapy of reticular veins and spider veins in legs and varicose veins

**Pharmacological action**

- **Anticoagulant**
- **Antithrombin**
- **Venous insufficiency**

**Contraindications**

- Acute myocardial infarction
- Acute pulmonary embolism
- Transient ischaemic attack
- Stroke
- Patent foramen ovale
- valley
- The drug should not be used in the treatment of deep vein thrombosis

**Side effects**

- **Common** Nausea, vomiting
- **Rare** Diaphoresis, skin discoloration, superficial thrombophlebitis, telangiectatic matting

**Pregnancy**

Avoid unless benefit outweighs risk.

**Breast feeding**

Use with caution—no information available.
Chapter 3
Respiratory system

CONTENTS

1 Airways disease, obstructive page 230
2 Allergic conditions 265
2.1 Angioedema 278
3 Conditions affecting sputum viscosity 280
3.1 Cystic fibrosis 280
4 Cough and congestion page 282
5 Idiopathic pulmonary fibrosis 284
6 Respiratory depression, respiratory distress syndrome and apnoea 285

Respiratory system, drug delivery

Inhalation
This route delivers the drug directly to the airways; the dose required is smaller than when given by mouth and side-effects are reduced.

Inhaler devices
These include pressurised metered-dose inhalers, breath-actuated inhalers, and dry powder inhalers. Many patients can be taught to use a pressurised metered-dose inhaler effectively but some patients, particularly the elderly and children, find them difficult to use. Spacer devices can help such patients because they remove the need to co-ordinate actuation with inhalation. Dry powder inhalers may be useful in adults and children over 5 years who are unwilling or unable to use a pressurised metered-dose inhaler. Alternatively, breath-actuated inhalers are suitable for adults and older children provided they can use the device effectively.

Pressurised metered-dose inhalers are an effective and convenient method of drug administration in mild to moderate asthma.

On changing from a pressurised metered-dose inhaler to a dry powder inhaler, patients may notice a lack of sensation in the mouth and throat previously associated with each actuation. Coughing may also occur.

The patient should be instructed carefully on the use of the inhaler and it is important to check that the inhaler continues to be used correctly because inadequate inhalation technique may be mistaken for a lack of response to the drug.

Spacer devices
Spacer devices remove the need for coordination between actuation of a pressurised metered-dose inhaler and inhalation. The spacer device reduces the velocity of the aerosol and subsequent impaction on the oropharynx and allows more time for evaporation of the propellant so that a larger proportion of the particles can be inhaled and deposited in the lungs. Spacer devices are particularly useful for patients with poor inhalation technique, for children, for patients requiring high doses of inhaled corticosteroids, for nocturnal asthma, and for patients prone to candidiasis with inhaled corticosteroids. The size of the spacer is important, the larger spacers with a one-way valve (Volumatic®) being most effective. It is important to prescribe a spacer device that is compatible with the metered-dose inhaler, see devices below. Spacer devices should not be regarded as interchangeable; patients should be advised not to switch between spacer devices.

Use and care of spacer devices
Patients should inhale from the spacer device as soon as possible after actuation because the drug aerosol is very short-lived; single-dose actuation is recommended. Tidal breathing is as effective as single breaths. The device should be cleaned once a month by washing in mild detergent and then allowed to dry in air without rinsing; the mouthpiece should be wiped clean of detergent before use. Some manufacturers recommend more frequent cleaning, but this should be avoided since any electrostatic charge may affect drug delivery. Spacer devices should be replaced every 6–12 months.

Nebulisers
Solutions for nebulisation are available for use in severe acute asthma. They are administered over 5–10 minutes from a nebuliser usually driven by oxygen in hospital.

Patients with a severe attack of asthma should preferably have oxygen during nebulisation since beta₂ agonists can increase arterial hypoxaemia.

A nebuliser converts a solution of a drug into an aerosol for inhalation. It is used to deliver higher doses of drug to the airways than is usual with standard inhalers. The main indications for use of a nebuliser are to deliver:

- a beta₂ agonist or ipratropium bromide p. 239 to a patient with an acute exacerbation of asthma or of chronic obstructive pulmonary disease;
- a beta₂ agonist, corticosteroid, or ipratropium bromide on a regular basis to a patient with severe asthma or reversible airways obstruction when the patient is unable to use other inhalational devices;
- an antibiotic (such as colistimethate sodium p. 525) or a mucolytic to a patient with cystic fibrosis;
- Budesonide p. 251 or adrenaline/epinephrine to a child with severe croup;
- Pentamidine isetionate p. 569 for the prophylaxis and treatment of pneumocystis pneumonia.

The use of nebulisers in chronic persistent asthma and chronic obstructive pulmonary disease should be considered only:

- after a review of the diagnosis;
- after review of therapy (see also Chronic Obstructive Pulmonary Disease) and the patient’s ability to use hand-held devices;
- after increased doses of inhaled therapy from hand-held inhalers (with a spacer if necessary) have been tried for 2 weeks;
- if the patient remains breathless, despite correctly using optimal therapy.

Before prescribing a nebuliser, a home trial should preferably be undertaken to monitor response for up to 2 weeks on standard treatment and up to 2 weeks on nebulised treatment. If prescribed, patients must:
have clear instructions from a doctor, specialist nurse, physiotherapist, or pharmacist on the use of the nebuliser (including maintenance and cleaning) and on peak-flow monitoring;

be instructed not to treat acute attacks at home without also seeking help;

have regular follow-up by a doctor, specialist nurse or physiotherapist after about 1 month and annually thereafter.

The proportion of a nebuliser solution that reaches the lungs depends on the type of nebuliser and although it can be as high as 30%, it is more frequently close to 10% and sometimes below 10%. The remaining solution is left in the nebuliser as residual volume or is deposited in the mouthpiece and tubing. The extent to which the nebulised solution is deposited in the airways or alveoli depends on the droplet size, pattern of breath inhalation, and condition of the lung. Droplets with a mass median diameter of 1–5 microns are deposited in the airways and are therefore appropriate for asthma, whereas a particle size of 1–2 microns is needed for alveolar deposition of pentamidine isetionate to combat pneumocystis infection. The type of nebuliser is therefore chosen according to the deposition required and according to the viscosity of the solution.

Jet nebulisers
Jet nebulisers are more widely used than ultrasonic nebulisers. Most jet nebulisers require an optimum gas flow rate of 6–8 litres/minute and in hospital can be driven by piped air or oxygen; in acute asthma the nebuliser should be driven by oxygen. Domiciliary oxygen cylinders do not provide an adequate flow rate therefore an electrical compressor is required for domiciliary use.

For patients at risk of hypercapnia, such as those with chronic obstructive pulmonary disease, oxygen can be dangerous and the nebuliser should be driven by air. If oxygen is required, it should be given simultaneously by nasal cannula.

Tubing
The Department of Health has reminded users of the need to use the correct grade of tubing when connecting a nebuliser to a medical gas supply or compressor.

Ultrasonic nebulisers
Ultrasonic nebulisers produce an aerosol by ultrasonic vibration of the drug solution and therefore do not require a gas flow; they are not suitable for the nebulisation of some drugs, such as dornase alfa p. 280 and nebulised suspensions.

Nebuliser diluent
Nebulisation may be carried out using an undiluted nebuliser solution or it may require dilution beforehand. The usual diluent is sterile sodium chloride 0.9% (physiological saline).

In England and Wales nebulisers and compressors are not available on the NHS (but they are free of VAT); some nebulisers (but not compressors) are available on form GP10A in Scotland (for details consult Scottish Drug Tariff).

Oral
The oral route is used when administration by inhalation is not possible. Systemic side-effects occur more frequently when a drug is given orally rather than by inhalation. Drugs given by mouth for the treatment of asthma include beta₂ agonists, corticosteroids, theophylline p. 263, and leukotriene receptor antagonists.

Parenteral
Drugs such as beta₂ agonists, corticosteroids, and aminophylline p. 261 can be given by injection in acute severe asthma when administration by nebulisation is inadequate or inappropriate. If the patient is being treated in the community, urgent transfer to hospital should be arranged.

Peak flow meters
When used in addition to symptom-based monitoring, peak flow monitoring has not been proven to improve asthma control in either adults or children, however measurement of peak flow may be of benefit in adult patients who are ‘poor perceivers’ and hence slow to detect deterioration in their asthma, and for those with more severe asthma.

When peak flow meters are used, patients must be given clear guidelines as to the action they should take if their peak flow falls below a certain level. Patients can be encouraged to adjust some of their own treatment (within specified limits) according to changes in peak flow rate.

Peak flow charts should be issued to patients where appropriate, and are available to purchase from:

- 3M Security Print and Systems Limited. Gorse Street, Chadderton, Oldham, OL9 9QH. Tel: 0845 610 1112
- GP practices can obtain supplies through their Area Team stores.
- NHS Hospitals can order supplies from www.nhsforms.co.uk/ or by emailing nhsforms@mmm.com.
- In Scotland, peak flow charts can be obtained by emailing stockorders.dpps@apsgroup.co.uk.

NICE technology appraisals (TAs)
Inhaler devices for children under 5 years with chronic asthma (August 2000) NICE TA10

When selecting inhaler devices for children under 5 years with chronic asthma, a child’s needs and likelihood of good compliance should govern the choice of inhaler and spacer device; only then should cost be considered.

- corticosteroid and bronchodilator therapy should be delivered by pressurised metered-dose inhaler and spacer device, with a facemask if necessary;
- if this is not effective, and depending on the child’s condition, nebulised therapy may be considered and, in children over 3 years, a dry powder inhaler may also be considered.

www.nice.org.uk/TA10

Inhaler devices for children 5–15 years with chronic asthma (March 2002) NICE TA38

When selecting inhaler devices for children between 5–15 years with chronic asthma, a child’s needs, ability to develop and maintain effective technique, and likelihood of good compliance should govern the choice of inhaler and spacer device; only then should cost be considered.

- corticosteroid therapy should be routinely delivered by a pressurised metered-dose inhaler and spacer device;
- for other inhaled drugs, particularly bronchodilators, a wider range of devices should be considered;
- children and their carers should be trained in the use of the chosen device; suitability of the device should be reviewed at least annually. Inhaler technique and compliance should be monitored.

www.nice.org.uk/TA38

1 Airways disease, obstructive

Asthma

Description of condition
Asthma is a common chronic inflammatory condition of the airways characterised by bronchoconstriction. The most frequent symptoms are cough, wheezing, chest tightness,
and shortness of breath. The bronchoconstriction is usually reversible (either spontaneously or with the aid of medication) leading to intermittent symptoms, but in some patients with chronic asthma the inflammation may result in irreversible airway obstruction. Occasionally, asthma symptoms can get gradually or suddenly worse provoking an acute asthma attack that, if severe, may require hospitalisation.

Aims of treatment

In clinical practice, patients may choose to balance the aims of asthma management against the potential side-effects or inconvenience of taking medication necessary to achieve perfect control. Complete control of asthma is defined as no daytime symptoms, no night-time awakening due to asthma, no asthma attacks, no need for rescue medication, no limitations on activity including exercise, and normal lung function (in practical terms FEV1, and/or peak flow > 80% predicted or best).

Lifestyle changes

Weight loss in overweight patients may lead to an improvement in asthma symptoms. Parents with asthma should be advised about the danger to themselves and to their children with asthma, of smoking, and be offered appropriate support to stop smoking. Breathing exercise programmes (including physiotherapist-taught methods) can be offered as an adjuvant to drug treatment in order to improve quality of life and reduce symptoms.

Management of chronic asthma

A stepwise approach aims to stop symptoms quickly and to improve peak flow. Start at the step most appropriate to initial severity of asthma. The aim is to achieve early control and to maintain it by stepping up treatment as necessary and stepping down treatment when control is good. Before initiating a new drug consider whether diagnosis is correct, check compliance and inhaler technique, and eliminate trigger factors for acute attacks.

Adult and child over 5 years

Step 1—Mild intermittent asthma

- Start inhaled short-acting beta2 agonist (such as salbutamol p. 244 or terbutaline sulfate p. 246) as required.
- Patients using more than one short-acting bronchodilator inhaler a month should have their asthma urgently assessed and action taken to improve poorly controlled asthma.
- Inhaled ipratropium bromide p. 259, (or, if over 12 years, short-acting beta2 agonist tablets and syrup, or theophylline p. 263) also act as short-acting bronchodilators but inhaled short-acting beta2 agonists are preferred.
- Move to step 2 if the patient presents with any one of the following features; is using an inhaled beta2 agonist three times a week or more, being symptomatic three times a week or more, experiencing night-time symptoms at least once a week, or has had an asthma attack in the last 2 years.

Step 2—Regular preventive therapy

- Consider adding regular inhaled standard-dose corticosteroid (alternatives to inhaled corticosteroid are leukotriene receptor antagonists, theophylline, inhaled sodium cromoglicate p. 260, or inhaled nedocromil sodium p. 259, but are less effective).

Note, inhaled standard-dose corticosteroid:
- Adult and child over 12 years: 200–800 micrograms/day beclometasone dipropionate p. 249 or equivalent.
- Child 5–12 years: 200–400 micrograms/day beclometasone dipropionate or equivalent.
- Beclometasone dipropionate and budesonide p. 251 are approximately equivalent in clinical practice although there may be variations with different drug delivery devices. Fluticasone p. 253 and mometasone furoate p. 255 provide equal clinical activity to beclometasone dipropionate and budesonide at half the dosage.
- Start the inhaled corticosteroid at a dose appropriate to severity of disease and adjust to the lowest effective dose at which control of asthma is maintained. Inhaled corticosteroids (except ciclesonide p. 253) should be initially taken twice daily, however, the same total daily dose can be considered once a day if good control is established.
- In children, administration of high doses of inhaled corticosteroids may be associated with systemic side-effects, including growth failure, reduced bone mineral density, and adrenal suppression, see individual drug monographs for monitoring information.

If asthma is not adequately controlled, move to step 3.

Step 3—Initial add-on therapy

- Consider adding a regular inhaled long-acting beta2 agonist (LABA) such as formoterol fumarate p. 242 or salmeterol p. 243 (or, in adults only, indacaterol p. 243 or olodaterol p. 243) to be used in conjunction with an inhaled corticosteroid (see also CHM advice for formoterol fumarate and salmeterol).

If the patient is gaining some benefit from addition of a LABA but control is inadequate then continue the LABA and increase dose of inhaled corticosteroid to top end of inhaled standard-dose corticosteroid range. If there is no response to the LABA, discontinue and increase dose of inhaled corticosteroid. If control is still inadequate, start a trial of either a leukotriene receptor antagonist (montelukast p. 258, or zafirlukast p. 259 if over 12 years) or modified-release theophylline.

Step 4—Persistent poor control

Consider the following options:

- Increase dose of inhaled corticosteroid (a spacer should be used).
- Add a leukotriene receptor antagonist, modified-release theophylline, or modified-release oral beta2 agonist (caution in patients already taking a LABA).

Note, increased inhaled corticosteroid dose:
- Adult and child over 12 years: up to 2000 micrograms/day beclometasone dipropionate or equivalent.
- Child 5–12 years: up to 800 micrograms/day beclometasone dipropionate or equivalent.

- Beclometasone dipropionate and budesonide are approximately equivalent in clinical practice although there may be variations with different drug delivery devices. Fluticasone and mometasone furoate provide equal clinical activity to beclometasone dipropionate and budesonide at half the dosage.

Before proceeding to step 5, refer patients with inadequately controlled asthma to specialist care.

Step 5—Continuous or frequent use of oral corticosteroids

- Add a regular oral corticosteroid (prednisolone p. 639, as single daily dose) at lowest dose to provide adequate control; continue high-dose inhaled corticosteroid (in exceptional cases, this may exceed licensed doses).

Child under 5 years

Step 1—Mild intermittent asthma

- Inhaled short-acting beta2 agonist (such as salbutamol or terbutaline sulfate) as required.

Children identified to be using more than one short-acting bronchodilator inhaler a month should have their asthma urgently assessed and action taken to improve poorly controlled asthma.

Move to step 2 if the child presents with any one of the following features; is using an inhaled beta2 agonist three times a week or more, being symptomatic three times a week or more, experiencing night-time symptoms at least once a week.
Step 2—Regular preventer therapy
- Consider adding regular standard-dose inhaled corticosteroid
- If the child is unable to take an inhaled corticosteroid, a leukotriene receptor antagonist (such as montelukast) is an effective first-line preventer.

Note, inhaled standard-dose corticosteroid: *Child under 5 years*: 200–400 micrograms/day beclometasone dipropionate or equivalent
- Beclometasone dipropionate and budesonide are approximately equivalent in clinical practice although there may be variations with different drug delivery devices. Fluticasone p. 253 provides equal activity to beclometasone dipropionate p. 249 and budesonide p. 251 at half the dosage.
- Start inhaled corticosteroid at a dose appropriate to severity of disease and adjust to the lowest effective dose at which control of asthma is maintained.
- Administration of high doses of inhaled corticosteroids in children may be associated with systemic side-effects, including growth failure, reduced bone mineral density and adrenal suppression.
- If asthma is not adequately controlled, move to step 3.

Step 3—Initial add-on therapy
- In children 2–5 years, add a leukotriene receptor antagonist if not added during step 2. If a leukotriene receptor antagonist was added at step 2, reconsider addition of standard-dose inhaled corticosteroid
- In children under 2 years, consider proceeding to step 4.

Step 4—Persistent poor control
- Refer child to respiratory paediatrician.

Stepping down
- Once asthma is controlled, it is recommended to step down therapy and continue to regularly review the patient. When deciding which drug to step down first and at what rate, the severity of asthma, the side-effects of treatment, duration on current dose, the beneficial effect achieved, and the patient’s preference, should be considered.
- Patient should be maintained at the lowest possible dose of inhaled corticosteroid. Reductions should be considered every three months, decreasing the dose by approximately 25–50% each time. Reduce the dose slowly as patients deteriorate at different rates.

Pregnancy and breast-feeding
- Women with asthma should be closely monitored during pregnancy. It is particularly important that asthma should be well controlled during pregnancy; when this is achieved asthma has no important effects on pregnancy, labour, or on the fetus. Women planning to become pregnant should be counselled about the importance of taking their asthma medication regularly to maintain good control. Drugs for asthma should preferably be administered by inhalation to minimise exposure of the fetus. Short-acting beta₂ agonists, long-acting beta₂ agonists, oral and inhaled corticosteroids, sodium cromoglicate p. 260, nedocromil sodium p. 259, and oral and intravenous theophyllines can be used as normal during pregnancy. There is limited information on use of leukotriene receptor antagonists during pregnancy, however they may be used if potential benefit outweighs risk. Drugs for asthma, including corticosteroid tablets, can be used as normal and in-line with manufacturers’ recommendations in breast-feeding.
- Severe acute attacks of asthma can have an adverse effect on pregnancy and should be treated promptly in hospital with conventional therapy, including nebulisation of a beta₂ agonist and oral or parenteral administration of a corticosteroid; prednisolone p. 639 is the preferred corticosteroid for oral administration since very little of the drug reaches the fetus. Oxygen should be given immediately to maintain arterial oxygen saturation of 94–98% and prevent maternal and fetal hypoxia.

Exercise-induced asthma
- For most patients, exercise-induced asthma is an illustration of poorly controlled asthma and regular treatment including inhaled corticosteroids should therefore be reviewed. If exercise is a specific problem in patients already taking inhaled corticosteroids who are otherwise well controlled, consider adding either a leukotriene receptor antagonist, a long-acting beta₂ agonist, an oral beta₂ agonist, sodium cromoglicate or nedocromil sodium, or theophylline.

Management of acute asthma

Adults

Levels of severity
- The nature of treatment required for the management of acute asthma depends on the level of severity, described as follows:
- **Moderate acute asthma**
  - Increasing symptoms
  - Peak flow > 50–75% best or predicted
  - No features of acute severe asthma
- **Severe acute asthma**
  - Any one of the following:
    - Peak flow 33–50% best or predicted
    - Respiratory rate > 25/min
    - Heart rate > 110/min
    - Inability to complete sentences in one breath

Life-threatening acute asthma
- Any one of the following, in a patient with severe asthma:
  - Peak flow < 33% best or predicted
  - Arterial oxygen saturation (SpO₂) < 92%
  - Partial arterial pressure of oxygen (PaO₂) < 8 kPa
  - Normal partial arterial pressure of carbon dioxide (PaCO₂) (4.6–6.0 kPa)
  - Silent chest
  - Cyanosis
  - Poor respiratory effort
  - Arrhythmia
  - Exhaustion
  - Altered conscious level
  - Hypotension

Near-fatal acute asthma
- Raised PaCO₂, requiring mechanical ventilation with raised inflation pressures, or both

Management of acute asthma in adults
- Patients with moderate asthma should be treated at home or in primary care according to response to treatment, while patients with severe or life-threatening acute asthma should start treatment as soon as possible and be admitted to hospital immediately following initial assessment.
- Supplementary oxygen should be given to all hypoxaemic patients with acute severe asthma to maintain a SpO₂ level between 94–98%.
- First-line treatment for acute asthma is a high-dose inhaled short-acting beta₂ agonist (salbutamol p. 244 or terbutaline sulfate p. 246) given as soon as possible. A pressurised metered dose inhaler with spacer device is preferred in patients with non-life-threatening acute asthma. Whereas, in patients with life-threatening acute asthma, a beta₂ agonist administered by an oxygen-driven nebuliser is recommended. If the response to an initial dose of short-acting beta₂ agonist is poor, consider continuous nebulisation with an appropriate nebuliser. Intravenous beta₂ agonists are reserved for those patients in whom inhaled therapy cannot be used reliably.
- In all cases of acute asthma, patients should be prescribed an adequate dose of oral prednisolone once daily for at least...
5 days or until recovery. Parenteral hydrocortisone p. 637 or intramuscular methylprednisolone p. 638 are alternatives in patients who are unable to take oral prednisolone.

Nebulised ipratropium bromide p. 239 may be combined with a nebulised beta₂ agonist in patients with acute severe or life-threatening asthma or in those with a poor initial response to beta₂ agonist therapy to provide greater bronchodilation.

There is some evidence that magnesium sulfate p. 963 has bronchodilator effects. A single intravenous dose of magnesium sulfate may be considered in patients with severe acute asthma (peak flow < 50% best or predicted) who have not had a good initial response to inhaled bronchodilator therapy [unlicensed use]. In an acute asthma attack, intravenous aminophylline p. 261 is not likely to produce any additional bronchodilation compared to standard therapy with inhaled bronchodilators and corticosteroids. However, in some patients with near-fatal or life-threatening acute asthma with a poor response to initial therapy, intravenous aminophylline may provide some benefit. Magnesium sulfate by intravenous infusion or aminophylline should only be used after consultation with, or on the recommendation of, senior medical staff.

**Child over 2 years**

**Levels of severity**

The nature of treatment required for the management of acute asthma depends on the level of severity, described as follows:

**Moderate acute asthma**

- Able to talk in sentences
- Arterial oxygen saturation (SpO₂) ≥ 92%
- Peak flow ≥ 50% best or predicted
- Heart rate ≤ 140/minute in children aged 2–5 years; heart rate ≤ 125/minute in children over 5 years
- Respiratory rate ≤ 40/minute in children aged 2–5 years; respiratory rate ≤ 30/minute in children over 5 years

**Severe acute asthma**

- Can’t complete sentences in one breath or too breathless to talk or feed
- SpO₂ < 92%
- Peak flow 33–50% best or predicted
- Heart rate > 140/minute in children aged 2–5 years; heart rate > 125/minute in children aged over 5 years
- Respiratory rate > 40/minute in children aged 2–5 years; respiratory rate > 30/minute in children over 5 years

**Life-threatening acute asthma**

Any one of the following in a child with severe asthma:

- SpO₂ < 92%
- Peak flow < 33% best or predicted
- Silent chest
- Cyanosis
- Poor respiratory effort
- Hypotension
- Exhaustion
- Confusion

**Management of acute asthma in children over 2 years**

Following initial assessment, supplementary high flow oxygen should be given to all children with life-threatening acute asthma or SpO₂ < 94% to achieve normal saturations of 94–98%.

First-line treatment for acute asthma is an inhaled short-acting beta₂ agonist (salbutamol p. 244 or terbutaline sulfate p. 246) given as soon as possible, ideally via a metered dose inhaler and spacer device in mild to moderate acute asthma. Children with severe or life-threatening acute asthma should be transferred to hospital urgently.

In all cases of acute asthma, children should be prescribed an adequate once daily dose of oral prednisolone p. 639. Treatment for up to 3 days is usually sufficient, but the length of course should be tailored to the number of days necessary to bring about recovery. Intravenous hydrocortisone p. 637 should be reserved for severely affected children who are unable to retain oral medication.

Nebulised ipratropium bromide p. 239 can be combined with beta₂ agonist treatment for children with severe or life-threatening acute asthma or in those with a poor initial response to beta₂ agonist therapy to provide greater bronchodilation. Consider adding magnesium sulfate p. 963 to nebulised salbutamol and ipratropium bromide in the first hour in children with a short duration of acute severe asthma symptoms presenting with an oxygen saturation less than 92%.

Children with continuing severe asthma despite frequent nebulised beta₂ agonists and ipratropium bromide plus oral corticosteroids, and those with life-threatening features, need urgent review by a specialist with a view to transfer to a high dependency unit or paediatric intensive care unit (PICU) to receive second-line intravenous therapies.

In a severe asthma attack where the child has not responded to initial inhaled therapy, early addition of a single bolus dose of intravenous salbutamol may be an option. Continuous intravenous infusion of salbutamol, administered under specialist supervision with continuous ECG and electrolyte monitoring, should be considered in children with unreliable inhalation or severe refractory asthma. Aminophylline p. 261 may be considered in children with severe or life-threatening acute asthma unresponsive to maximal doses of bronchodilators and corticosteroids. Aminophylline is not recommended in children with mild to moderate acute asthma. Intravenous magnesium sulfate has been used for acute asthma [unlicensed use] although its place in management is not yet established.

**Child under 2 years**

Inhaled short-acting beta₂ agonists are the initial treatment of choice for acute asthma in children under 2 years. For mild to moderate acute asthma attacks, a metered-dose inhaler with a spacer and mask is the optimal drug delivery device. In a hospital setting, consider oral prednisolone daily for up to 3 days, early in the management of severe acute asthma attacks. For more severe symptoms, inhaled ipratropium bromide in combination with an inhaled beta₂ agonist is also an option.

**Follow up in all cases**

Episodes of acute asthma may be a failure of preventative therapy, review is required to prevent further episodes. A careful history should be taken to establish the reason for the asthma attack. Inhaler technique should be checked and regular treatment should be reviewed. Patients should be given a written asthma action plan aimed at preventing relapse, optimising treatment, and preventing delay in seeking assistance in future attacks. It is essential that the patient’s GP practice is informed within 24 hours of discharge from the emergency department or hospital following an asthma attack. Patients who have had a near-fatal asthma attack should be kept under specialist supervision indefinitely. A respiratory specialist should follow up all patients admitted with a severe asthma attack for at least one year after the admission.

---

**Bronchodilators**

**Adrenoceptor agonists (sympathomimetics)**

Selective beta₂ agonists produce bronchodilation. A short-acting beta₂ agonist is used for immediate relief of asthma symptoms while some long-acting beta₂ agonists are added to an inhaled corticosteroid in patients requiring prophylactic treatment.

The selective beta₂ agonists (selective beta₂-adrenoceptor agonists, selective beta₂ stimulants) such as salbutamol p. 244 or terbutaline sulfate p. 246 are the safest and most effective short-acting beta₂ agonists for asthma. Less
Respiratory system

Short-acting beta\(_2\) agonists
Mild to moderate symptoms of asthma respond rapidly to the inhalation of a selective short-acting beta\(_2\) agonist, such as salbutamol or terbutaline. If a beta\(_2\) agonist inhalation is needed more often than twice a week, or if night-time symptoms occur at least once a week, or if the patient has suffered an exacerbation in the last 2 years, then prophylactic treatment should be considered using a stepped approach. A short-acting beta\(_2\) agonist inhaled immediately before exercise reduces exercise-induced asthma; however, frequent exercise-induced asthma probably reflects poor overall control and calls for reassessment of asthma treatment.

Long-acting beta\(_2\) agonists
Formoterol fumarate p. 242 (eformoterol) and salmeterol p. 243 are longer-acting beta\(_2\) agonists which are administered by inhalation. They should be used for asthma only in patients who regularly use an inhaled corticosteroid. They have a role in the long-term management of chronic asthma and can be useful in nocturnal asthma. Salmeterol should not be used for the relief of an asthma attack; it has a slower onset of action than salbutamol or terbutaline. Formoterol fumarate is licensed for short-term symptom relief and for the prevention of exercise-induced bronchospasm; its speed of onset of action is similar to that of salbutamol. Combination inhalers that contain a long-acting beta\(_2\) agonist and a corticosteroid ensure that long-acting beta\(_2\) agonists are not used without concomitant corticosteroids, but reduce the flexibility to adjust the dose of each component. Indacaterol p. 243 and olodaterol p. 243 are long-acting beta\(_2\) agonists licensed for chronic obstructive pulmonary disease in adults; they are not indicated for the relief of acute bronchospasm. Vilanterol is a long-acting beta\(_2\) agonist available only in a combination inhaler with fluticasone furoate or with umeclidinium p. 240.

Oral
Oral preparations of beta\(_2\) agonists may be used by patients who cannot manage the inhaled route. They are sometimes used for children and the elderly, but inhaled beta\(_2\) agonists are more effective and have fewer side-effects. The longer-acting oral preparations, including bambuterol hydrochloride p. 241, may be of value in nocturnal asthma but they have a limited role and inhaled long-acting beta\(_2\) agonists are usually preferred.

Parenteral
Salbutamol or terbutaline sulfate can be given intravenously for severe or life-threatening acute asthma; patients should be carefully monitored and the dose adjusted according to response and heart rate. The regular use of beta\(_2\) agonists by the subcutaneous route is not recommended since the evidence of benefit is uncertain and it may be difficult to withdraw such treatment once started. In adults, beta\(_2\) agonists may also be given by intramuscular injection.

Children
Selective beta\(_2\) agonists are useful even in children under the age of 18 months. They are most effective by the inhaled route; a pressurised metered-dose inhaler should be used with a spacer device in children under 5 years. A beta\(_2\) agonist may also be given by mouth but administration by inhalation is preferred; a long-acting inhaled beta\(_2\) agonist may be used where appropriate. In severe attacks nebulisation using a selective beta\(_2\) agonist or ipratropium bromide p. 239 is advisable.

Antimuscarinic bronchodilators
Ipratropium bromide can provide short-term relief in chronic asthma, but short-acting beta\(_2\) agonists act more quickly and are preferred. Ipratropium bromide by nebulisation can be added to other standard treatment in life-threatening asthma or if acute asthma fails to improve with standard therapy. The aerosol inhalation of ipratropium bromide can be used for short-term relief in mild chronic obstructive pulmonary disease in patients who are not using a long-acting antimuscarinic drug. Its maximal effect occurs 30–60 minutes after use; its duration of action is 3 to 6 hours and bronchodilation can usually be maintained with treatment 3 times a day. Aciclividinium bromide p. 238, glycopyrronium bromide p. 238, tiotropium p. 240, and umeclidinium are licensed for the maintenance treatment of adults with chronic obstructive pulmonary disease. They are not suitable for the relief of acute bronchospasm. Tiotropium (via Respimat\textsuperscript{®} device) is also licensed as an adjunct to inhaled corticosteroids and long-acting beta\(_2\) agonists for the maintenance treatment of patients with asthma who have suffered one or more severe exacerbations in the last year.

Theophylline
Theophylline p. 263 is a xanthine used as a bronchodilator in asthma and stable chronic obstructive pulmonary disease; it is not generally effective in exacerbations of chronic obstructive pulmonary disease. Theophylline may have an additive effect when used in conjunction with small doses of beta\(_2\) agonists; the combination may increase the risk of side-effects, including hypokalaemia. Theophylline is given by injection as aminophylline p. 261, a mixture of theophylline with ethylenediamine, which is 20 times more soluble than theophylline alone. Aminophylline injection is needed rarely for severe acute asthma.

Compound bronchodilator preparations
In general, patients are best treated with single-ingredient preparations, such as a selective beta\(_2\) agonist or ipratropium bromide, so that the dose of each drug can be adjusted. This flexibility is lost with compound bronchodilator preparations. However, a combination product may be appropriate for patients stabilised on individual components in the same proportion.

Chronic obstructive pulmonary disease

Management
Smoking cessation reduces the progressive decline in lung function in chronic obstructive pulmonary disease (COPD, chronic bronchitis, or emphysema). Infection can complicate chronic obstructive pulmonary disease and may be prevented by vaccination (pneumococcal polysaccharide conjugate vaccine (adsorbed) p. 1207 and influenza vaccine p. 1212).

A trial of a high-dose inhaled corticosteroid or an oral corticosteroid is recommended for patients with moderate or severe airflow obstruction if the diagnosis is in doubt. Symptoms of chronic obstructive pulmonary disease may be alleviated by an inhaled short-acting beta\(_2\) agonist or a...
short-acting antimuscarinic bronchodilator used as required.

When the airways obstruction is more severe, regular inhaled therapy should be used. It is important to check compliance and inhaler technique before initiating a new drug.

If the Forced Expiratory Volume in 1 second (FEV₁), is 50% of predicted or more, either a long-acting antimuscarinic bronchodilator or a long-acting β₂ agonist should be used. Short-acting antimuscarinic bronchodilators should be discontinued when a long-acting antimuscarinic bronchodilator is started. A long-acting β₂ agonist with a corticosteroid in a combination inhaler can be used for patients who remain symptomatic despite regular treatment with a long-acting β₂ agonist.

If FEV₁ is less than 50% of predicted, either a long-acting antimuscarinic bronchodilator or a long-acting β₂ agonist with a corticosteroid in a combination inhaler should be used.

In any patient who remains breathless or continues to have exacerbations, triple therapy with a long-acting β₂ agonist and a corticosteroid in a combination inhaler plus a long-acting antimuscarinic bronchodilator should be used.

If an inhaled corticosteroid is not appropriate, a long-acting antimuscarinic bronchodilator can be used with a long-acting β₂ agonist, (see Use of inhaled therapies in chronic obstructive pulmonary disease algorithm, below).

If symptoms persist or if the patient is unable to use an inhaler, oral modified-release aminophylline p. 261 or theophylline p. 263 can be used.

Indacaterol p. 243 is a long-acting β₂ agonist licensed for the maintenance treatment of chronic obstructive pulmonary disease.

In patients with severe chronic obstructive pulmonary disease associated with chronic bronchitis and a history of frequent exacerbations, roflumilast p. 260 is licensed as an adjunct to existing bronchodilator treatment.

A mucolytic drug may be considered for a patient with a chronic productive cough.

Long-term oxygen therapy prolongs survival in patients with severe chronic obstructive pulmonary disease and hypoxaemia.

During an exacerbation of chronic obstructive pulmonary disease, bronchodilator therapy can be administered through a nebuliser if necessary and oxygen given if appropriate. Aminophylline can be given intravenously if response to nebulised bronchodilators is poor. A short course of oral corticosteroid, such as prednisolone for 7–14 days, should be given if increased breathlessness interferes with daily activities. Antibacterial treatment is required if sputum becomes more purulent than usual, or if there are other signs of infection.

Patients who have had an episode of hypercapnic respiratory failure should be given a 24% or 28% Venturi mask and an oxygen alert card endorsed with the oxygen saturations required during previous exacerbations. Patients and their carers should be instructed to show the card to emergency healthcare providers in the event of an exacerbation.

### Oxygen alert card based on British Thoracic Society guideline for emergency oxygen use in adult patients (October 2008)

Name: 

I am at risk of type II respiratory failure with a raised CO₂ level.

Please use my ___% Venturi mask to achieve an oxygen saturation of ___% to ___% during exacerbations.

Use compressed air to drive nebulisers (with nasal oxygen at 2 litres/minute). If compressed air not available, limit oxygen-driven nebulisers to 6 minutes.

Oxygen alert card is available at [www.brit-thoracic.org.uk](http://www.brit-thoracic.org.uk).

### Croup

#### Management

Mild croup is largely self-limiting, but treatment with a single dose of a corticosteroid (e.g. dexamethasone p. 635) by mouth may be of benefit.

More severe croup (or mild croup that might cause complications) calls for hospital admission; a single dose of a corticosteroid (e.g. dexamethasone or prednisolone p. 639 by mouth) should be administered before transfer to hospital. In hospital, dexamethasone (by mouth or by injection) or budesonide p. 251 (by nebulisation) will often reduce symptoms; the dose may need to be repeated after 12 hours if necessary.

For severe croup not effectively controlled with corticosteroid treatment, nebulised adrenaline/epinephrine solution 1 in 1000 (1 mg/mL) should be given with close clinical monitoring; the effects of nebulised adrenaline/epinephrine last 2–3 hours and the child needs to be monitored carefully for recurrence of the obstruction.

### Oxygen

#### Overview

Oxygen should be regarded as a drug. It is prescribed for hypoxaemic patients to increase alveolar oxygen tension and decrease the work of breathing. The concentration of oxygen required depends on the condition being treated; the administration of an inappropriate concentration of oxygen can have serious or even fatal consequences.

Oxygen is probably the most common drug used in medical emergencies. It should be prescribed initially to achieve a normal or near-normal oxygen saturation; in most acutely ill patients with a normal or low arterial carbon dioxide (PₐCO₂), oxygen saturation should be 94–98% oxygen saturation. However, in some clinical situations such as cardiac arrest and carbon monoxide poisoning it is more appropriate to aim for the highest possible oxygen saturation until the patient is stable. A lower target of 88–92% oxygen saturation is indicated for patients at risk of hypercapnic respiratory failure.

High concentration oxygen therapy is safe in uncomplicated cases of conditions such as pneumonia, pulmonary thromboembolism, pulmonary fibrosis, shock, severe trauma, sepsis, or anaphylaxis. In such conditions low arterial oxygen (PₐO₂) is usually associated with low or
normal arterial carbon dioxide ($P_{a}CO_2$), and therefore there is little risk of hypoventilation and carbon dioxide retention. In acute severe asthma, the arterial carbon dioxide ($P_{a}CO_2$) is usually subnormal but as asthma deteriorates it may rise steeply (particularly in children). These patients usually require high concentrations of oxygen and if the arterial carbon dioxide ($P_{a}CO_2$) remains high despite other treatment, intermittent positive-pressure ventilation needs to be considered urgently.

Low concentration oxygen therapy (controlled oxygen therapy) is reserved for patients at risk of hypercapnic respiratory failure, which is more likely in those with:
- chronic obstructive pulmonary disease;
- advanced cystic fibrosis;
- severe non-cystic fibrosis bronchiectasis;
- severe kyphoscoliosis or severe ankylosing spondylitis;
- severe lung scarring caused by tuberculosis;
- musculoskeletal disorders with respiratory weakness, especially if on home ventilation;
- an overdose of opioids, benzodiazepines, or other drugs causing respiratory depression.

Until blood gases can be measured, initial oxygen should be given using a controlled concentration of 28% or less, titrated towards a target oxygen saturation of 88–92%. The aim is to provide the patient with enough oxygen to achieve an acceptable arterial oxygen tension without worsening carbon dioxide retention and respiratory acidosis. Patients may carry an oxygen alert card.

Domiciliary oxygen
Oxygen should only be prescribed for use in the home after careful evaluation in hospital by respiratory experts. Patients should be advised of the risks of continuing to smoke when receiving oxygen therapy, including the risk of fire. Smoking cessation therapy should be recommended before home oxygen prescription.

Air travel
Some patients with arterial hypoxaemia require supplementary oxygen for air travel. The patient’s requirement should be discussed with the airline before travel.
Long-term oxygen therapy

Long-term administration of oxygen (usually at least 15 hours daily) prolongs survival in some patients with chronic obstructive pulmonary disease.

Assessment for long-term oxygen therapy requires measurement of arterial blood gas tensions. Measurements should be taken on 2 occasions at least 3 weeks apart to demonstrate clinical stability, and not sooner than 4 weeks after an acute exacerbation of the disease. Long-term oxygen therapy should be considered for patients with:

- chronic obstructive pulmonary disease with \( P_a O_2 < 7.3 \) kPa when breathing air during a period of clinical stability;
- chronic obstructive pulmonary disease with \( P_O_2 \) 7.3–8 kPa in the presence of secondary polycythaemia, nocturnal hypoaxaemia, peripheral oedema, or evidence of pulmonary hypertension;
- severe chronic asthma with \( P_a O_2 < 7.3 \) kPa or persistent disabling breathlessness;
- interstitial lung disease with \( P_a O_2 < 8 \) kPa and in patients with \( P_O_2 < 8 \) kPa with disabling dyspnoea;
- cystic fibrosis when \( P_a O_2 < 7.3 \) kPa or if \( P_O_2 \) 7.3–8 kPa in the presence of secondary polycythaemia, nocturnal hypoaxaemia, pulmonary hypertension, or peripheral oedema;
- pulmonary hypertension, without parenchymal lung involvement when \( P_a O_2 < 8 \) kPa;
- neuromuscular or skeletal disorders, after specialist assessment;
- obstructive sleep apnoea despite continuous positive airways pressure therapy, after specialist assessment;
- pulmonary malignancy or other terminal disease with disabling dyspnoea;
- heart failure with daytime \( P_a O_2 < 7.3 \) kPa when breathing air or with nocturnal hypoaxaemia;
- paediatric respiratory disease, after specialist assessment.

Increased respiratory depression is seldom a problem in patients with stable respiratory failure treated with low concentrations of oxygen although it may occur during exacerbations; patients and relatives should be warned to call for medical help if drowsiness or confusion occur.

Short-burst oxygen therapy

Oxygen is occasionally prescribed for short-burst (intermittent) use for episodes of breathlessness not relieved by other treatment in patients with severe chronic obstructive pulmonary disease, interstitial lung disease, heart failure, and in palliative care. It is important, however, that the patient does not rely on oxygen instead of obtaining medical help or taking more specific treatment. Short-burst oxygen therapy can be used to improve exercise capacity and recovery; it should only be continued if there is proven improvement in breathlessness or exercise tolerance.

Ambulatory oxygen therapy

Ambulatory oxygen is prescribed for patients on long-term oxygen therapy who need to be away from home on a regular basis. Patients who are not on long-term oxygen therapy can be considered for ambulatory oxygen therapy if there is evidence of exercise-induced oxygen desaturation and of improvement in blood oxygen saturation and exercise capacity with oxygen. Ambulatory oxygen therapy is not recommended for patients with heart failure or those who smoke.

Oxygen concentrators are more economical for patients who require oxygen for long periods, and in England and Wales can be ordered on the NHS on a regional tendering basis. A concentrator is recommended for a patient who requires oxygen for more than 8 hours a day (or 21 cylinders per month). Exceptionally, if a higher concentration of oxygen is required the output of 2 oxygen concentrators can be combined using a ‘Y’ connection.

A nasal cannula is usually preferred for long-term oxygen therapy from an oxygen concentrator. It can, however, produce dermatitis and mucosal drying in sensitive individuals.

Giving oxygen by nasal cannula allows the patient to talk, eat, and drink, but the concentration of oxygen is not controlled; this may not be appropriate for acute respiratory failure. When oxygen is given through a nasal cannula at a rate of 1–2 litres/minute the inspiratory oxygen concentration is usually low, but it varies with ventilation and can be high if the patient is underventilating.

Arrangements for supplying oxygen

The following oxygen services may be ordered in England and Wales:

- emergency oxygen;
- short-burst (intermittent) oxygen therapy;
- long-term oxygen therapy;
- ambulatory oxygen.

The type of oxygen service (or combination of services) should be ordered on a Home Oxygen Order Form (HOOF); the amount of oxygen required (hours per day) and flow rate should be specified. The clinician will determine the appropriate equipment to be provided. Special needs or preferences should be specified on the HOOF.

The clinician should obtain the patient or carers consent, to pass on the patient’s details to the supplier, the fire brigade, and other relevant organisations. The supplier will contact the patient to make arrangements for delivery, installation, and maintenance of the equipment. The supplier will also train the patient or carer to use the equipment.

The clinician should send the HOOF to the supplier who will continue to provide the service until a revised HOOF is received, or until notified that the patient no longer requires the home oxygen service.

- East of England, North East: BOC Medical: Tel: 0800 136 603 Fax: 0800 169 9989
- South West: Air Liquide: Tel: 0808 202 2229 Fax: 0191 497 3430
- London, East Midlands, North West: Air Liquide: Tel: 0500 823 773 Fax: 0800 781 4610
- Yorkshire and Humberside, West Midlands, Wales: Air Products: Tel: 0800 373 580 Fax: 0800 214 709
- South East Coast, South Central: Dolby Vivisol: Tel: 08443 814 402 Fax: 0800 781 4610

In Scotland refer the patient for assessment by a respiratory consultant. If the need for a concentrator is confirmed the consultant will arrange for the provision of a concentrator through the Common Services Agency. Prescribers should complete a Scottish Home Oxygen Order Form (SHOOF) and email it to Health Facilities Scotland. Health Facilities Scotland will then liaise with their contractor to arrange the supply of oxygen. Further information can be obtained at: www.dolbyvivisol.com/our-services/healthcare-professionals/home-oxygen-services-sco.aspx

In Northern Ireland oxygen concentrators and cylinders should be prescribed on form HS21; oxygen concentrators are supplied by a local contractor. Prescriptions for oxygen cylinders and accessories can be dispensed by pharmacists contracted to provide domiciliary oxygen services.
Antimuscarinics (inhaled)

09-Feb-2016

- **INDICATIONS AND DOSE**
  - Maintenance treatment of chronic obstructive pulmonary disease
  - Adult: 375 micrograms twice daily

- **DOSE EQUIVALENCE AND CONVERSION**
  - Each 375 microgram inhalation of aclidinium bromide delivers 322 micrograms of aclidinium.

- **CAUTIONS**
  - Arrhythmia (when newly diagnosed within last 3 months) - heart failure (hospitalisation with moderate or severe heart failure within last 12 months) - myocardial infarction within last 6 months - unstable angina

- **INTERACTIONS**
  - Appendix 1: aclidinium

- **SIDE-EFFECTS**
  - Uncommon: Dysphonia - stomatitis

- **PREGNANCY**
  - Manufacturer advises use only if potential benefit outweighs risk.

- **BREAST FEEDING**
  - Manufacturer advises use only if potential benefits outweigh risks.

- **PATIENT AND CARER ADVICE**
  - Patients or carers should be given advice on appropriate inhaler technique.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  - **Inhalation powder**
    - Aclidinium bromide (non-proprietary)
      - Aclidinium bromide 375 microgram per 1 dose: Aclidinium bromide 375 microgram/dose dry powder inhaler | 60 dose | no price available DT price = £28.60
      - Eklira (AstraZeneca UK Ltd)
        - Aclidinium bromide 375 microgram per 1 dose: Eklira 322 micrograms/dose Genuair | 60 dose | £28.60 DT price = £28.60

Aclidinium bromide with formoterol

19-Feb-2016

- **INDICATIONS AND DOSE**
  - Maintenance treatment of chronic obstructive pulmonary disease
  - Adult: 1 inhalation twice daily

Glycopyrronium bromide (Glycopyrrolate)

17-Oct-2016

- **INDICATIONS AND DOSE**
  - Maintenance treatment of chronic obstructive pulmonary disease
  - Adult: 1 capsule once daily

- **DOSE EQUIVALENCE AND CONVERSION**
  - Each capsule delivers 55 micrograms of glycopyrronium bromide (equivalent to 44 micrograms of glycopyrronium).
Glycopyrronium bromide with indacaterol

17-Feb-2016

The properties listed below are those particular to the combination only. For the properties of the components please consider, glycopyrronium bromide p. 238, indacaterol p. 243.

- **INDICATIONS AND DOSE**
  - Maintenance treatment of chronic obstructive pulmonary disease
    - **BY INHALATION OF POWDER**
    - Adult: 1 inhalation daily

- **CAUTIONS**
  - Convulsive disorders

- **INTERACTIONS**
  - Appendix 1: beta₂ agonists, glycopyrronium

- **PATIENT AND CARER ADVICE**
  - Patients or carers should be given advice on appropriate inhaler technique and reminded that the capsules are not for oral administration.

- **MEDICINAL FORMS**
  - Phlebitis can be variation in the licensing of different medicines containing the same drug.
  - **Inhalation powder**
    - **Ultibro Breezhaler** (Novartis Pharmaceuticals UK Ltd)
      - Glycopyrronium bromide 54 microgram per 1 dose, Indacaterol (as Indacaterol maleate) 85 microgram per 1 dose
    - Ultibro Breezhaler 85microgram/4microgram inhalation powder capsules with device | 10 capsule pack | £10.83 | 30 capsule pack | £32.50

Ipratropium bromide

24-Feb-2016

- **INDICATIONS AND DOSE**
  - **Reversible airways obstruction**
    - **BY INHALATION OF AEROSOL**
    - Child 1 month-5 years: 20 micrograms 3 times a day
    - Child 6-11 years: 20–40 micrograms 3 times a day
    - Child 12-17 years: 20–40 micrograms 3–4 times a day
  - **Reversible airways obstruction, particularly in chronic obstructive pulmonary disease**
    - **BY INHALATION OF AEROSOL**
    - Adult: 20–40 micrograms 3–4 times a day
    - **BY INHALATION OF NEBULISED SOLUTION**
    - Adult: 250–500 micrograms 3–4 times a day
  - **Acute bronchospasm**
    - **BY INHALATION OF NEBULISED SOLUTION**
    - Child 1 month-5 years: 125–250 micrograms as required; maximum 1 mg per day
    - Child 6-11 years: 250 micrograms as required; maximum 1 mg per day
    - Child 12-17 years: 500 micrograms as required, doses higher than max. can be given under medical supervision; maximum 2 mg per day
    - Adult: 500 micrograms as required, doses higher than max. can be given under medical supervision; maximum 2 mg per day
  - **Severe or life-threatening acute asthma**
    - **BY INHALATION OF NEBULISED SOLUTION**
    - Child 1 month-11 years: 250 micrograms every 20–30 minutes for the first 2 hours, then 250 micrograms every 4–6 hours as required
    - Child 12-17 years: 500 micrograms every 4–6 hours as required
    - Adult: 500 micrograms every 4–6 hours as required

- **PHARMACOKINETICS**
  - The maximal effect of inhaled ipratropium occurs 30–60 minutes after use; its duration of action is 3 to 6 hours and bronchodilation can usually be maintained with treatment 3 times a day.

- **UNLICENSED USE**
  - The dose of ipratropium for severe or life-threatening acute asthma is unlicensed.

- **CAUTIONS**
  - **Cystic fibrosis**

- **SIDE-EFFECTS**
  - Rare: Ocular accommodation disorder

- **PREGNANCY**
  - Manufacturer advises only use if potential benefit outweighs the risk.

- **PARKING AND DISPENSING INFORMATION**
  - If dilution of ipratropium bromide nebuliser solution is necessary use only sterile sodium chloride 0.9%.

- **PATIENT AND CARER ADVICE**
  - Patients or carers should be given advice on appropriate inhaler technique.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Nebuliser liquid**
    - **Ipratropium bromide (Non-proprietary)**
      - **Ipratropium bromide 250 microgram per 1 ml**
        - Ipratropium bromide 500micrograms/2ml nebuliser liquid unit dose vials | 20 unit dose pack | £2.93 DT price = £2.60
        - Ipratropium bromide 250micrograms/1ml nebuliser liquid unit dose vials | 20 unit dose pack | £4.58 DT price = £4.51
        - Ipratropium bromide 250micrograms/1ml nebuliser liquid Steri-Neb unit dose vials | 20 unit dose pack | £6.99 DT price = £4.51
        - Ipratropium 500micrograms/2ml nebuliser liquid Steri-Neb unit dose vials | 20 unit dose pack | £11.59 DT price = £2.60
    - **Atrovent UDV** (Boehringer Ingelheim Ltd)
      - **Ipratropium bromide 250 microgram per 1 ml**
        - Atrovent 500micrograms/2ml nebuliser liquid UDV | 20 unit dose pack | £4.87 DT price = £2.60 | 60 unit dose pack | £14.59
        - Atrovent 250micrograms/1ml nebuliser liquid UDV | 20 unit dose pack | £4.14 DT price = £4.51 | 60 unit dose pack | £12.44
    - **Respontin** (GlaxoSmithKline UK Ltd)
      - **Ipratropium bromide 250 microgram per 1 ml**
        - Respontin 500micrograms/2ml Nebules | 20 unit dose pack | £5.60 DT price = £2.60

- **Pressurised inhalation**
  - **Ipratropium bromide (Non-proprietary)**
    - **Ipratropium bromide 20 microgram per 1 dose**
      - Ipratropium bromide 20micrograms/dose inhaler CFC free | 200 dose pack | no price available DT price = £5.56
    - **Atrovent** (Boehringer Ingelheim Ltd)
      - **Ipratropium bromide 20 microgram per 1 dose**
        - Atrovent 20micrograms/dose inhaler CFC free | 200 dose pack | £5.56 DT price = £5.56

Ipratropium with salbutamol

17-Feb-2016

The properties listed below are those particular to the combination only. For the properties of the components please consider, ipratropium bromide above, salbutamol p. 244.

- **INDICATIONS AND DOSE**
  - **Bronchospasm in chronic obstructive pulmonary disease**
    - **BY INHALATION OF AEROSOL**
    - Adult: 0.5/2.5 mg 3–4 times a day

- **INTERACTIONS**
  - Appendix 1: beta₂ agonists, ipratropium

- **PRESCRIBING AND DISPENSING INFORMATION**
  - A mixture of ipratropium bromide and salbutamol (as sulphate); the proportions are expressed in the form x/y where x and y
are the strengths in milligrams of ipratropium and salbutamol respectively.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  **Nebuliser liquid**
  - Ipratropium with salbutamol (Non-proprietary)
  - Ipratropium bromide 200 microgram per 1 ml, Salbutamol (as Salbutamol sulfate) 1 mg per 1 ml Salbutamol 2.5mg/2.5ml / Ipratropium bromide 500micrograms/2.5ml nebuliser liquid unit dose vials | 60 unit dose (Pax) no available DT price = £24.10
  - Combivent (Boehringer Ingelheim Ltd)
  - Ipratropium bromide 200 microgram per 1 ml, Salbutamol (as Salbutamol sulfate) 1 mg per 1 ml Combivent nebuliser liquid 2.5ml UDVs | 60 unit dose (Pax) £24.10 DT price = £24.10
  - Ipramol (Teva UK Ltd)
  - Ipratropium bromide 200 microgram per 1 ml, Salbutamol (as Salbutamol sulfate) 1 mg per 1 ml Ipramol nebuliser solution 2.5ml Steri-Neb unit dose vials | 60 unit dose (Pax) £23.83 DT price = £24.10
  - Salipraneb (Actavis UK Ltd)
  - Ipratropium bromide 200 microgram per 1 ml, Salbutamol (as Salbutamol sulfate) 1 mg per 1 ml Salipraneb 0.5mg/2.5mg nebuliser solution 2.5ml ampoules | 60 ampoule (Pax) £17.50 DT price = £17.50

- **SIDE-EFFECTS**
  - Epistaxis
  - Drowsiness
  - Dry mouth
  - Anosmia
  - Diaphoresis
  - Urinary retention
  - Blurred vision
  - Skin rash
  - Acne
  - Acute myoccardial infarction
  - Cardiac disorders (particularly cardiac rhythm disorders)
BETA₂-ADRENOCEPTOR AGONISTS, SELECTIVE

Beta₂-adrenoceptor agonists, selective

12-Feb-2016

- **CONTRA-INDICATIONS** Severe pre-eclampsia
- **CAUTIONS** Arrhythmias, cardiovascular disease, diabetes (risk of hyperglycaemia and ketoacidosis, especially with intravenous use), hypertension, hyperthyroidism, hypokalaemia, susceptibility to QT-interval prolongation

### CAUTIONS, FURTHER INFORMATION
- Hypokalaemia. Potentially serious hypokalaemia may result from beta₂ agonist therapy. Particular caution is required in severe asthma, because this effect may be potentiated by concomitant treatment with theophylline and its derivatives, corticosteroids, diuretics, and by hypoxia.
- **SIDE-EFFECTS** Angioedema, arrhythmias, behavioural disturbances, collapse, fine tremor (particularly in the hands), headache, hyperglycaemia (especially when given intravenously), hypersensitivity reactions, hypokalaemia (with high doses), hypotension, ketoacidosis (especially when given intravenously), muscle cramps, myocardial ischaemia, nervous tension, palpitation, paradoxical bronchospasm (occasionally severe), peripheral vasodilatation, rash, sleep disturbances, tachycardia, urticaria
- **PREGNANCY** Women planning to become pregnant should be counselled about the importance of taking their asthma medication regularly to maintain good control.
- **MONITORING REQUIREMENTS**
  - In severe asthma, plasma-potassium concentration should be monitored (risk of hypokalaemia).
  - In patients with diabetes, monitor blood glucose (risk of hyperglycaemia and ketoacidosis, especially when beta₂ agonist given intravenously).

### PATIENT AND CARER ADVICE
- Patient or carers should be advised to follow manufacturers’ instructions on the care and cleansing of inhaler devices.

### BETA₂-ADRENOCEPTOR AGONISTS, SELECTIVE > LONG-ACTING

### Bambuterol hydrochloride

- **DRUG ACTION** Bambuterol is a pro-drug of terbutaline.

#### INDICATIONS AND DOSE
- **Asthma** (patients who have previously tolerated beta₂-agonists) Other conditions associated with reversible airways obstruction (patients who have previously tolerated beta₂-agonists)
  - **BY MOUTH**
  - Adult: 20 mg once daily, dose to be taken at bedtime
- **Asthma** (patients who have not previously tolerated beta₂-agonists) Other conditions associated with reversible airways obstruction (patients who have not previously tolerated beta₂-agonists)
  - **BY MOUTH**
  - Adult: Initially 10 mg once daily for 1–2 weeks, then increased if necessary to 20 mg once daily, dose to be taken at bedtime
Formoterol fumarate
(Eformoterol fumarate)

INDICATIONS AND DOSE
Reversible airways obstruction in patients requiring long-term regular bronchodilator therapy
• Nocturnal asthma in patients requiring long-term regular bronchodilator therapy
• Prophylaxis of exercise-induced bronchospasm in patients requiring long-term regular bronchodilator therapy
• Chronic asthma in patients who regularly use an inhaled corticosteroid

BY INHALATION OF POWDER
• Child 6–11 years: 12 micrograms twice daily, a daily dose of 24 micrograms of formoterol should be sufficient for the majority of children, particularly for younger age groups; higher doses should be used rarely, and only when control is not maintained on the lower dose
• Child 12–17 years: 12 micrograms twice daily, dose may be increased in more severe airway obstruction; increased to 24 micrograms twice daily, a daily dose of 24 micrograms of formoterol should be sufficient for the majority of children, particularly for younger age groups; higher doses should be used rarely, and only when control is not maintained on the lower dose
• Adult: 12 micrograms twice daily, dose may be increased in more severe airway obstruction; increased to 24 micrograms twice daily

BY INHALATION OF AEROSOL
• Child 12–17 years: 12 micrograms twice daily, dose may be increased in more severe airway obstruction; increased to 24 micrograms twice daily, a daily dose of 24 micrograms of formoterol should be sufficient for the majority of children, particularly for younger age groups; higher doses should be used rarely, and only when control is not maintained on the lower dose
• Adult: 12 micrograms twice daily, dose may be increased in more severe airway obstruction; increased to 24 micrograms twice daily

Chronic obstructive pulmonary disease
• BY INHALATION OF POWDER
• BY INHALATION OF AEROSOL

Special populations
PREGNANCY
• Inhaled drugs for asthma can be taken as normal during pregnancy.
• Inhaled drugs for asthma can be taken as normal during breast-feeding.

INTERACTIONS
• See Appendix 1: beta₂ agonists

SIDE-EFFECTS
• Very rare QT-interval prolongation
• Frequency not known Dizziness, nausea, pruritus, taste disturbances

PREGNANCY
Inhaled drugs for asthma can be taken as normal during pregnancy.

BREAST FEEDING
Inhaled drugs for asthma can be taken as normal during breast-feeding.

PATIENT AND CARER ADVICE
Advise patients that short-acting beta₂ agonists should not be used for the relief of exercise-induced asthma symptoms unless regular inhaled corticosteroids are also used;
• be reviewed as clinically appropriate: stepping down therapy should be considered when good long-term asthma control has been achieved.

CAUTIONS
High doses of beta₂ agonists can be dangerous in some children.

IMPORTANT SAFETY INFORMATION
CHM ADVICE
To ensure safe use, the CHM has advised that for the management of chronic asthma, long-acting beta₂ agonist (formoterol) should:
• be added only if regular use of standard-dose inhaled corticosteroids has failed to control asthma adequately;
• not be initiated in patients with rapidly deteriorating asthma;
• be introduced at a low dose and the effect properly monitored before considering dose increase;
• be discontinued in the absence of benefit;
• not be used for the relief of exercise-induced asthma symptoms unless regular inhaled corticosteroids are also used;
• be reviewed as clinically appropriate: stepping down therapy should be considered when good long-term asthma control has been achieved.

OXYS®

Chronic asthma
• BY INHALATION OF POWDER
• Child 6–17 years: 6–12 micrograms 1–2 times a day (max. per dose 12 micrograms), occasionally doses up to the maximum daily may be needed, reassess treatment if additional doses required on more than 2 days a week; maximum 48 micrograms per day
• Adult: 6–12 micrograms 1–2 times a day, increased if necessary up to 24 micrograms twice daily (max. per dose 36 micrograms), occasionally doses up to the maximum daily may be needed, reassess treatment if additional doses required on more than 2 days a week; maximum 72 micrograms per day

Relief of bronchospasm
• BY INHALATION OF POWDER
• Child 6–17 years: 6–12 micrograms
• Adult: 6–12 micrograms

Prophylaxis of exercise-induced bronchospasm
• BY INHALATION OF POWDER
• Child 6–17 years: 6–12 micrograms, dose to be taken before exercise
• Adult: 12 micrograms, dose to be taken before exercise

PHARMACOKINETICS
At recommended inhaled doses, the duration of action of formoterol is about 12 hours.

Manufacturers
• Bambuterol hydrochloride 20 mg Bambec tablets
• Bambuterol hydrochloride 10 mg Bambec tablets

Importance
There can be variation in the licensing of different medicines containing the same drug.

Tablet
• Bambuc (AstraZeneca UK Ltd)

Bambuterol hydrochloride 10 mg Bambuc 10 mg tablets | 28 tablet p/D $14.46 DT price = $14.46
Bambuterol hydrochloride 20 mg Bambuc 20 mg tablets | 28 tablet p/D $15.77 DT price = $15.77

Appendix

References
of treatment with a long-acting beta₂ agonist. Patient or carer should be given advice on how to administer formoterol fumarate inhalers.

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Inhalation powder**

- Easyhaler (formoterol) (Orion Pharma (UK) Ltd)
  - Formoterol fumarate dihydrate 12 microgram per dose Easyhaler 12micrograms/dose dry powder inhaler 120 dose £23.75 DT price = £23.75
- Foradil (Novartis Pharmaceuticals UK Ltd)
  - Formoterol fumarate dihydrate 12 microgram Foradil 12microgram inhalation powder capsules with device 60 capsule £28.06 DT price = £28.06
- Oxis Turbohaler (AstraZeneca UK Ltd)
  - Formoterol fumarate dihydrate 6 microgram per dose Oxis 6 Turbohaler 60 dose £24.80 DT price = £24.80
  - Formoterol fumarate dihydrate 12 microgram per dose Oxis 12 Turbohaler 60 dose £24.80 DT price = £24.80

**Pressurised inhalation**

- Atimos Modulite (Chiesi Ltd)
  - Formoterol fumarate dihydrate 12 microgram per dose Atimos Modulite 12micrograms/dose inhaler 100 dose £30.06 DT price = £30.06

Combinations available: *Actidinium bromide with formoterol*, p. 238; *Beclometasone with formoterol*, p. 250; *Budesonide with formoterol*, p. 252; *Futicasone with formoterol*, p. 254

---

### Indacaterol

- **INDICATIONS AND DOSE**
  - Maintenance treatment of chronic obstructive pulmonary disease
    - **BY INHALATION OF POWDER**
    - Adult: 150 micrograms once daily, then increased to 300 micrograms once daily

- **CAUTIONS** Convulsive disorders
- **INTERACTIONS** → Appendix 1: beta₂ agonists
- **SIDE-EFFECTS**
  - Common or very common Cough, dizziness, nasopharyngitis, oropharyngeal pain, peripheral oedema, rhinorrhoea, sinusitis
  - Uncommon Atrial fibrillation, chest pain, paraesthesia, pruritus
- **PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk.
- **BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.
- **HEPATIC IMPAIRMENT** Use with caution in severe hepatic impairment—no information available.
- **PATIENT AND CARER ADVICE** Patients or carers should be given advice on how to administer indacaterol inhalation powder.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Inhalation powder**
    - Onbrez Breezhaler (Novartis Pharmaceuticals UK Ltd)
      - Indacaterol (as Indacaterol maleate) 150 microgram Onbrez Breezhaler 150microgram inhalation powder capsules with device 30 capsule £32.19 DT price = £32.19
      - Indacaterol (as Indacaterol maleate) 300 microgram Onbrez Breezhaler 300microgram inhalation powder capsules with device 30 capsule £32.19 DT price = £32.19
  - Combinations available: *Glycopyrronium with indacaterol*, p. 239

---

### Olodaterol

- **INDICATIONS AND DOSE**
  - Maintenance treatment of chronic obstructive pulmonary disease
    - **BY INHALATION**
    - Adult: 5 micrograms once daily
  - **DOSE EQUIVALENCE AND CONVERSION**
    - 2 puffs is equivalent to 5 micrograms.

- **CAUTIONS** Aneurysm, convulsive disorders
- **INTERACTIONS** → Appendix 1: beta₂ agonists
- **SIDE-EFFECTS**
  - Uncommon Dizziness, nasopharyngitis
  - Rare Arthralgia, hypertension
- **PREGNANCY** Manufacturer advises avoid—no information available.
- **BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.
- **HEPATIC IMPAIRMENT** Use with caution in severe hepatic impairment—no information available.
- **PATIENT AND CARER ADVICE** Patients or carers should be given advice on how to administer olodaterol solution for inhalation.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Pressurised inhalation**
    - Striverdi Respimat (Boehringer Ingelheim Ltd)
      - Olodaterol (as Olodaterol hydrochloride) 2.5 microgram per dose Striverdi Respimat 2.5micrograms/dose solution for inhalation cartridge with device 60 dose £26.35 DT price = £26.35
  - Combinations available: *Tiotropium with olodaterol*, p. 240

---

### Salmeterol

- **INDICATIONS AND DOSE**
  - Reversible airways obstruction in patients requiring long-term regular bronchodilator therapy
  - Prevention of exercise-induced bronchospasm in patients requiring long-term regular bronchodilator therapy
  - Chronic asthma only in patients who regularly use an inhaled corticosteroid (not for immediate relief of acute asthma)
    - **BY INHALATION OF AEROSOL, OR BY INHALATION OF POWDER**
      - Child 5-11 years: 50 micrograms twice daily
      - Child 12-17 years: 50 micrograms twice daily, dose may be increased in more severe airway obstruction; increased to 100 micrograms twice daily
      - Adult: 50 micrograms twice daily, dose may be increased in more severe airway obstruction; increased to 100 micrograms twice daily
  - **CHRONIC OBSTRUCTIVE PULMONARY DISEASE**
    - **BY INHALATION OF AEROSOL, OR BY INHALATION OF POWDER**
    - Adult: 50 micrograms twice daily

- **PHARMACOKINETICS**
  - At recommended inhaled doses, the duration of action of salmeterol is about 12 hours.

- **UNLICENSED USE** Neovent® not licensed for use in children under 12 years.
**Salbutamol**

*(Albuterol)*

**INDICATIONS AND DOSE**

**Asthma | Other conditions associated with reversible airways obstruction**

- **By mouth using immediate-release medicines**
  - Adult: 4 mg 3–4 times a day, maximum single dose 8 mg (but unlikely to provide much extra benefit or to be tolerated), inhalation route preferred over oral route, use elderly dose for sensitive patients
  - Elderly: Initially 2 mg 3–4 times a day, maximum single dose 8 mg (but unlikely to provide much extra benefit or to be tolerated), inhalation route preferred over oral route

- **By subcutaneous injection, or by intramuscular injection**
  - Adult: 500 micrograms every 4 hours if required

- **By slow intravenous injection**
  - Adult: 250 micrograms, repeated if necessary, injection to be diluted to a concentration of 50 micrograms/mL, reserve intravenous beta,
  - agonists for those in whom inhalated therapy cannot be used reliably

- **By intravenous infusion**
  - Adult: Initially 5 micrograms/minute, adjusted according to response and heart rate, usual dose 3–20 micrograms/minute, higher doses may be required, reserve intravenous beta,
  - agonists for those in whom inhalated therapy cannot be used reliably

- **By inhalation of aerosol**
  - Adult: 100–200 micrograms, up to 4 times a day for persistent symptoms

- **By inhalation of nebulised solution**
  - Adult: 2.5–5 mg, repeated up to 4 times daily or more frequently in severe cases

**Prophylaxis of allergen- or exercise-induced bronchospasm**

- **By inhalation of aerosol**
  - Adult: 200 micrograms

**Acute asthma**

- **By intravenous injection**
  - Child 1–2 years: 5 micrograms/kg for 1 dose, dose to be administered over 5 minutes, reserve intravenous beta,
  - agonists for those in whom inhalated therapy cannot be used reliably or there is no current effect
  - Child 2–7 years: 15 micrograms/kg (max. per dose
  - 250 micrograms) for 1 dose, dose to be administered over 5 minutes, reserve intravenous beta,
  - agonists for those in whom inhalated therapy cannot be used reliably or there is no current effect

**Moderate, severe, or life-threatening acute asthma**

- **By inhalation of nebulised solution**
  - Child 1 month–4 years: 2.5 mg, repeat every
  - 20–30 minutes or when required, give via oxygen-driven nebuliser if available
  - Child 5–11 years: 2.5–5 mg, repeat every 20–30 minutes or when required, give via oxygen-driven nebuliser if available
  - Child 12–17 years: 5 mg, repeat every 20–30 minutes or when required, give via oxygen-driven nebuliser if available
  - Adult: 5 mg, repeat every 20–30 minutes or when required, give via oxygen-driven nebuliser if available

Combination available: **Fluticasone with salmeterol**, p. 255
Moderate and severe acute asthma
▶ BY INHALATION OF AEROSOL
  ▶ Child: 2–10 puffs, each puff is to be inhaled separately, repeat every 10–20 minutes or when required, give via large volume spacer (and a close-fitting face mask in children under 3 years), each puff is equivalent to 100 micrograms
  ▶ Adult: 2–10 puffs, each puff is to be inhaled separately, repeat every 10–20 minutes or when required, give via large volume spacer, each puff is equivalent to 100 micrograms

Exacerbation of reversible airways obstruction (including nocturnal asthma)
Prophylaxis of allergen- or exercise-induced bronchospasm
▶ BY INHALATION OF AEROSOL
  ▶ Child: 100–200 micrograms, up to 4 times a day for persistent symptoms
  ▶ BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
  ▶ Child 1 month–1 year: 100 micrograms/kg 3–4 times a day (max. per dose 2 mg), inhalation route preferred over oral route
  ▶ Child 2–5 years: 1–2 mg 3–4 times a day, inhalation route preferred over oral route
  ▶ Child 6–11 years: 2 mg 3–4 times a day, inhalation route preferred over oral route
  ▶ Child 12–17 years: 2–4 mg 3–4 times a day, inhalation route preferred over oral route

Chronic asthma
▶ BY MOUTH USING MODIFIED-RELEASE MEDICINES
  ▶ Child 3–11 years: 4 mg twice daily
  ▶ Child 12 years: 8 mg twice daily
  ▶ Adult: 8 mg twice daily

Uncomplicated premature labour (between 22 and 37 weeks of gestation)
(specialist supervision in hospital)
▶ BY INTRAVENOUS INFUSION
  ▶ Adult: Initially 10 micrograms/minute, rate increased gradually according to response at 10-minute intervals until contractions diminish then increase rate slowly until contractions cease (maximum rate 45 micrograms/minute), maintain rate for 1 hour after contractions have stopped, then gradually reduce by 50% every 6 hours, maximum duration 48 hours

ASMASAL CLICKHALER
Acute bronchospasm
▶ BY INHALATION OF POWDER
  ▶ Adult: 1–2 puffs, up to 4 times daily for persistent symptoms

Prophylaxis of allergen- or exercise-induced bronchospasm
▶ BY INHALATION OF POWDER
  ▶ Adult: 1–2 puffs

EASYHALER SALBUTAMOL
Acute bronchospasm
▶ BY INHALATION OF POWDER
  ▶ Adult: Initially 100–200 micrograms, increased if necessary to 400 micrograms; maximum 800 micrograms per day

Prophylaxis of allergen- or exercise-induced bronchospasm
▶ BY INHALATION OF POWDER
  ▶ Adult: 200 micrograms

PULVINAL SALBUTAMOL
Acute bronchospasm
▶ BY INHALATION OF POWDER
  ▶ Child 5–17 years: Initially 200 micrograms, up to 800 micrograms daily for persistent symptoms
  ▶ Adult: Initially 200 micrograms, up to 800 micrograms daily for persistent symptoms

Prophylaxis of allergen- or exercise-induced bronchospasm
▶ BY INHALATION OF POWDER
  ▶ Child 5–17 years: 200 micrograms
  ▶ Adult: 200 micrograms

SALBULIN NOVOLIZER
Acute bronchospasm
▶ BY INHALATION OF POWDER
  ▶ Adult: Initially 100–200 micrograms, up to 800 micrograms daily for persistent symptoms

Prophylaxis of allergen- or exercise-induced bronchospasm
▶ BY INHALATION OF POWDER
  ▶ Adult: 200 micrograms

VENTOLIN ACCUHALER
Acute bronchospasm
▶ BY INHALATION OF POWDER
  ▶ Adult: 200 micrograms

PHARMACOKINETICS
At recommended inhaled doses, the duration of action of salbutamol is about 3 to 5 hours.

● UNLICENSED USE
  Syrup and tablets not licensed for use in children under 2 years. Modified-release tablets not licensed for use in children under 3 years.
  Injection and solution for intravenous infusion not licensed for use in children under 12 years.

● CONTRA-INDICATIONS
  > When used for uncomplicated premature labour Abruptio placentae · antepartum haemorrhage · cord compression · eclampsia · history of cardiac disease · intra-uterine fetal death · intra-uterine infection · placenta praevia · pulmonary hypertension · severe pre-eclampsia · significant risk factors for myocardial ischaemia · threatened miscarriage

● CAUTIONS
GENERAL CAUTIONS
  High doses of beta₂ agonists can be dangerous in some children

SPECIFIC CAUTIONS
  > With intravenous use Mild to moderate pre-eclampsia (when used for uncomplicated premature labour) · suspected cardiovascular disease (should be assessed by a cardiologist before initiating therapy for uncomplicated premature labour)

● INTERACTIONS ➔ Appendix 1: beta₂ agonists

● SIDE-EFFECTS
GENERAL SIDE-EFFECTS
  Lactic acidosis (with high doses) · nausea

SPECIFIC SIDE-EFFECTS
  > When used for uncomplicated premature labour Bronchospasm · muscle tension · pulmonary oedema · vomiting

● BREASTFEEDING
  Inhaled drugs for asthma can be taken as normal during breast-feeding.

● MONITORING REQUIREMENTS
  > In uncomplicated premature labour it is important to monitor blood pressure, pulse rate (should not exceed 120 beats per minute), ECG (discontinue treatment if signs of myocardial ischaemia develop), blood glucose and lactate concentrations, and the patient’s fluid and electrolyte status (avoid over-hydration—discontinue drug immediately and initiate diuretic therapy if pulmonary oedema occurs).
DIRECTIONS FOR ADMINISTRATION

- With intravenous use in children: Dilute to a concentration of 50 micrograms/mL with Glucose 5%, Sodium Chloride 0.9%, or Water for injections.
- When used by inhalation: For nebulisation, dilute nebuliser solution with a suitable volume of sterile Sodium Chloride 0.9% solution according to nebuliser type and duration of administration; salbutamol and ipratropium bromide solutions are compatible and can be mixed for nebulisation.
- With intravenous use in adults: For bronchodilation by continuous intravenous infusion, dilute to a concentration of 200 micrograms/mL with glucose 5% or sodium chloride 0.9%. For premature labour by continuous intravenous infusion, dilute with glucose 5% to a concentration of 200 micrograms/mL for use in a syringe pump or for other infusion methods (preferably via controlled infusion device), dilute to a concentration of 20 micrograms/mL; close attention to patient’s fluid and electrolyte status essential.

PATIENT AND CARER ADVICE

- When used by inhalation: For inhalation by aerosol or dry powder, advise patients and carers not to exceed prescribed dose and to follow manufacturer’s directions; if a previously effective dose of inhaled salbutamol fails to provide at least 3 hours relief, a doctor’s advice should be obtained as soon as possible. For inhalation by nebuliser, the dose given by nebuliser is substantially higher than that given by inhaler. Patients should therefore be warned that it is dangerous to exceed the prescribed dose and they should seek medical advice if they fail to respond to the usual dose of the respirator solution.

Medicines for Children leaflet: Salbutamol inhaler for asthma and wheeze: www.medicinesforchildren.org.uk/salbutamol-inhaler-for-asthma-and-wheeze

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

- Salbutamol (Non-proprietary)
  Salbutamol (as Salbutamol sulfate) 2 mg: Salbutamol 2mg tablets | 28 tablet (Pod) £106.43 DT price = £104.95
  Salbutamol (as Salbutamol sulfate) 4 mg: Salbutamol 4mg tablets | 28 tablet (Pod) £108.95 DT price = £107.43

Inhalation powder

- Easyhaler (salbutamol) (Orion Pharma (UK) Ltd)
  Salbutamol 100 microgram per 1 dose: Easyhaler Salbutamol sulfate 100micrograms/dose dry powder inhaler | 200 dose (Pod) £3.31 DT price = £3.31
  Salbutamol 200 microgram per 1 dose: Easyhaler Salbutamol sulfate 200micrograms/dose dry powder inhaler | 200 dose (Pod) £6.63 DT price = £6.63

- Salbutin Novolizer (Meda Pharmaceuticals Ltd)
  Salbutamol (as Salbutamol sulfate) 100 microgram per 1 dose: Salbutin Novolizer 100micrograms/dose inhalation powder | 200 dose (Pod) £2.75

Solution for injection

- Ventolin (GlaxoSmithKline UK Ltd)
  Salbutamol (as Salbutamol sulfate) 500 microgram per 1 ml: Ventolin 500micrograms/1ml solution for injection ampoules | 5 ampoule (Pod) £1.91

Solution for infusion

- Ventolin (GlaxoSmithKline UK Ltd)
  Salbutamol (as Salbutamol sulfate) 1 mg per 1 ml: Ventolin 5mg/ml solution for infusion ampoules | 10 ampoule (Pod) £24.81

Oral solution

- Salbutamol (Non-proprietary)
  Salbutamol (as Salbutamol sulfate) 400 microgram per 1 ml: Salbutamol 2mg/5ml oral solution sugar free sugar-free | 150 ml (Pod) no price available DT price = £1.15

- Ventolin (GlaxoSmithKline UK Ltd)
  Salbutamol (as Salbutamol sulfate) 400 microgram per 1 ml: Ventolin 2mg/5ml syrup sugar-free | 150 ml (Pod) £1.15 DT price = £1.15

Pressurised inhalation

- Salbutamol (Non-proprietary)
  Salbutamol (as Salbutamol sulfate) 100 microgram per 1 dose: Salbutamol 100micrograms/dose inhaler CFC free | 200 dose (Pod) £1.50 DT price = £1.50

- AirSalb (Sandoz Ltd)
  Salbutamol (as Salbutamol sulfate) 100 microgram per 1 dose: AirSalb 100micrograms/dose inhaler CFC free | 200 dose (Pod) £1.50 DT price = £1.50

- Airomir (Teva UK Ltd)
  Salbutamol (as Salbutamol sulfate) 100 microgram per 1 dose: Airomir 100micrograms/dose inhaler | 200 dose (Pod) £1.97 DT price = £1.50

- Airomir Autohaler (Teva UK Ltd)
  Salbutamol (as Salbutamol sulfate) 100 microgram per 1 dose: Airomir 100micrograms/dose Autohaler | 200 dose (Pod) £6.02 DT price = £6.30

- Salamol (Teva UK Ltd)
  Salbutamol (as Salbutamol sulfate) 100 microgram per 1 dose: Salbutamol 100micrograms/dose inhaler | 200 dose (Pod) £1.50 DT price = £1.20

Nebuliser liquid

- Salbutamol (Non-proprietary)
  Salbutamol (as Salbutamol sulfate) 1 mg per 1 ml: Salbutamol 2.5mg/2.5ml nebuliser liquid unit dose vials | 20 unit dose (Pod) £1.91 DT price = £1.91

  Salbutamol (as Salbutamol sulfate) 2 mg per 1 ml: Salbutamol 5mg/2.5ml nebuliser liquid unit dose vials | 20 unit dose (Pod) £3.82 DT price = £3.82

- Salamol Steri-Neb (Teva UK Ltd)
  Salbutamol (as Salbutamol sulfate) 1 mg per 1 ml: Salamol 2.5mg/2.5ml nebuliser liquid Steri-Neb unit dose vials | 20 unit dose (Pod) £1.91 DT price = £1.91

  Salbutamol (as Salbutamol sulfate) 2 mg per 1 ml: Salamol 5mg/2.5ml nebuliser liquid Steri-Neb unit dose vials | 20 unit dose (Pod) £3.82 DT price = £3.82

- Ventolin Evohaler (GlaxoSmithKline UK Ltd)
  Salbutamol (as Salbutamol sulfate) 100 microgram per 1 dose: Ventolin 100micrograms/dose Evohaler | 200 dose (Pod) £1.50 DT price = £1.20

Combinations available: Ipratropium with salbutamol, p. 239

Terbutaline sulfate

INDICATIONS AND DOSE

- Asthma: Other conditions associated with reversible airways obstruction

  - BY MOUTH
    - Adult: Initially 2.5 mg 3 times a day for 1–2 weeks, then increased to up to 5 mg 3 times a day, use by inhalation preferred over by mouth

  - BY SUBCUTANEOUS INJECTION, OR BY SLOW INTRAVENOUS
    - Adult: 250–500 micrograms up to 4 times a day, reserve intravenous beta₂ agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect
 Airways disease, obstructive 247

**DIRECTIONS FOR ADMINISTRATION**

- With intravenous use in children For *continuous intravenous infusion*, dilute to a concentration of 5 micrograms/mL with Glucose 5% or Sodium Chloride 0.9%; if fluid-restricted, dilute to a concentration of 100 micrograms/mL.
- When used by inhalation For *nebulisation*, dilute nebuliser solution with sterile Sodium Chloride 0.9% solution according to nebuliser type and duration of administration; terbutaline and ipratropium bromide solutions are compatible and may be mixed for nebulisation.
- With intravenous use in adults For *bromodilution* by *continuous intravenous infusion*, dilute 1.5–2.5 mg with 500 mL glucose 5% or sodium chloride 0.9% and give over 8–10 hours. For *premature labour* by *continuous intravenous infusion*, dilute in glucose 5% and give via controlled infusion device preferably a syringe pump; if syringe pump available dilute to a concentration of 100 micrograms/mL; if syringe pump not available dilute to a concentration of 10 micrograms/mL; close attention to patient’s fluid and electrolyte status essential.
- **PATIENT AND CARER ADVICE**
  - For inhalation by dry powder, advise patients and carers not to exceed prescribed dose and to follow manufacturer’s directions; if a previously effective dose of inhaled terbutaline fails to provide at least 3 hours relief, a

---

**SIDE-EFFECTS**

- **GENERAL SIDE-EFFECTS**
  - Nausea

- **SPECIFIC SIDE-EFFECTS**
  - **Electrocardiographic changes** (should be assessed by a cardiologist before initiating therapy for uncomplicated premature labour)
  - **Infantile diarrhoea** (may be relieved by increasing fluid intake and if necessary, give via oxygen-driven nebuliser if available)
  - **Ventricular arrhythmias** (may be relieved by increasing fluid intake and if necessary, give via oxygen-driven nebuliser if available)

---

**MONITORING REQUIREMENTS**

- **In uncomplicated premature labour** it is important to monitor blood pressure, pulse rate (should not exceed 120 beats per minute), ECG (discontinue treatment if signs of myocardial ischaemia develop), blood glucose and lactate concentrations, and the patient’s fluid and electrolyte status (avoid over-hydration—discontinue drug immediately and initiate diuretic therapy if pulmonary oedema occurs).

---

**CONTRA-INDICATIONS**

- **When used for uncomplicated premature labour** Abruptio placenta · antepartum haemorrhage · cord compression · eclampsia · history of cardiac disease · intra-uterine fetal death · intra-uterine infection · placenta praevia · pulmonary hypertension · severe pre-eclampsia · significant risk factors for myocardial ischaemia · threatened miscarriage.

---

**UNLICENSED USE**

- Tablets not licensed for use in children under 7 years. Injection not licensed for use in children under 2 years.

---

**DIRECTIONS FOR ADMINISTRATION**

- With intravenous use in adults For *continuous intravenous infusion*, dilute to a concentration of 3 micrograms/mL, reserve intravenous beta2 agonists for those in whom inhaled therapy cannot be used reliably or there is no current effect
- **MONITORING REQUIREMENTS**
  - **In uncomplicated premature labour** it is important to monitor blood pressure, pulse rate (should not exceed 120 beats per minute), ECG (discontinue treatment if signs of myocardial ischaemia develop), blood glucose and lactate concentrations, and the patient’s fluid and electrolyte status (avoid over-hydration—discontinue drug immediately and initiate diuretic therapy if pulmonary oedema occurs).
doctor’s advice should be obtained as soon as possible. For inhalation by nebuliser, the dose given by nebuliser is substantially higher than that given by inhaler. Patients should therefore be warned that it is dangerous to exceed the prescribed dose and they should seek medical advice if they fail to respond to the usual dose of the respirator solution.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection

**Solution for injection**

- Bricanyl (AstraZeneca UK Ltd)
  - Terbutaline sulfate 500 microgram per 1 ml
  - Bricanyl 2.5mg/5ml solution for injection ampoules | 10 ampoule (POM) £16.74
  - Bricanyl 500micrograms/1ml solution for injection ampoules | 5 ampoule (POM) £2.16

**Inhalation powder**

- Bricanyl Turbohaler (AstraZeneca UK Ltd)
  - Terbutaline sulfate 500 microgram per 1 dose
  - Bricanyl 500micrograms/dose Turbohaler | 100 dose (POM) £6.92

**Nebuliser liquid**

- Bricanyl (Non-proprietary)
  - Terbutaline sulfate 2.5 mg per 1 ml
  - Terbutaline 5mg/2ml nebuliser
  - unit dose vials | 20 unit dose (POM) £4.04

- Bricanyl Respules (AstraZeneca UK Ltd)
  - Terbutaline sulfate 2.5 mg per 1 ml
  - Bricanyl 5mg/2ml Respules | 100 unit dose (POM) £5.82

**Tablet**

- Bricanyl (AstraZeneca UK Ltd)
  - Terbutaline sulfate 5 mg
  - Bricanyl 5mg tablets | 100 tablet (POM) £4.91

**CORTICOSTEROIDS**

Airways disease, use of corticosteroids

**Asthma**

**Inhaled corticosteroids**

An inhaled corticosteroid used for 3–4 weeks may help to distinguish asthma from chronic obstructive pulmonary disease; clear improvement over 3–4 weeks suggests asthma. Corticosteroids are effective in asthma; they reduce airway inflammation (and hence reduce oedema and secretion of mucus into the airway).

An inhaled corticosteroid is used regularly for prophylaxis of asthma when patients require a beta₂ agonist more than twice a week, or if symptoms disturb sleep at least once a week, or if the patient has suffered an exacerbation in the last 2 years requiring systemic corticosteroid. Regular use of inhaled corticosteroids reduces the risk of exacerbation of asthma. Current and previous smoking reduces the effectiveness of inhaled corticosteroids and higher doses may be necessary.

Corticosteroid inhalers must be used regularly for maximum benefit; alleviation of symptoms usually occurs 3 to 7 days after initiation. Beclometasone dipropionate p. 249, budesonide p. 251, fluticasone p. 253, and mometasone furoate p. 255 appear to be equally effective. Preparations that combine a corticosteroid with a long-acting beta₂ agonist may be helpful for patients stabilised on the individual components in the same proportion.

In adults using an inhaled corticosteroid and a long-acting beta₂ agonist for the prophylaxis of asthma, who are poorly controlled, Symbicort® or DuoResp Spirax® (both containing budesonide with formoterol p. 252) can be used as relievers (instead of a short-acting beta₂ agonist), in addition to their regular use for the prophylaxis of asthma. Symbicort® can also be used in this way in adults using an inhaled corticosteroid with a dose greater than beclometasone dipropionate 400 micrograms daily, but who are poorly controlled (standard doses of other inhaled corticosteroids can be used). When starting this treatment, the total regular daily dose of inhaled corticosteroid should not be reduced. Patients must be carefully instructed on the appropriate dose and management of exacerbations before initiating this therapy. Patients using budesonide with formoterol as a reliever once a day or more should have their treatment reviewed regularly. The use of Symbicort® for both reliever and maintenance therapy is also used by some specialists in children 12–18 years [unlicensed]. Fostair® can also be used in adults as a reliever (instead of a short-acting beta₂ agonist) in addition to its regular use for the prophylaxis of asthma. It may be particularly useful for patients with poorly controlled asthma requiring reliever therapy, or for those who have had previous exacerbations of asthma which needed medical intervention. Patients requiring frequent daily use of Fostair® as a reliever should have their maintenance treatment reviewed. This approach has not been investigated with combination inhalers containing other corticosteroids and long-acting beta₂ agonists.

High doses of inhaled corticosteroid can be prescribed for patients who respond only partially to standard doses with a long-acting beta₂ agonist or another long-acting bronchodilator. High doses should be continued only if there is clear benefit over the lower dose. The recommended maximum dose of an inhaled corticosteroid should not generally be exceeded. However, if a higher dose is required, then it should be initiated and supervised by a specialist. The use of high doses of inhaled corticosteroid can minimise the requirement for an oral corticosteroid.

**Oral corticosteroids**

Systemic corticosteroid therapy may be necessary during episodes of stress, such as severe infection, or if the asthma is worsening, when higher doses are needed and access of inhaled drug to small airways may be reduced; patients may need a reserve supply of corticosteroid tablets.

In chronic asthma, when the response to other drugs has been inadequate, longer term administration of an oral corticosteroid may be necessary; in such cases high doses of an inhaled corticosteroid should be continued to minimise oral corticosteroid requirements. Patients taking long-term oral corticosteroids for asthma can often be transferred to an inhaled corticosteroid but the transfer must be slow, with gradual reduction in the dose of the oral corticosteroid, and at a time when the asthma is well controlled.

An acute attack of asthma should be treated with a short course of an oral corticosteroid starting with a high dose. Patients whose asthma has deteriorated rapidly usually respond quickly to corticosteroids. The dose can usually be stopped abruptly; tapering is not needed provided that the patient receives an inhaled corticosteroid in an adequate dose (apart from those on maintenance oral corticosteroid treatment or where oral corticosteroids are required for 3 or more weeks). In patients who have needed several courses of oral corticosteroids and in whom the possibility of a period on maintenance corticosteroids is being considered, it may be useful to taper the corticosteroid dose gradually to identify a threshold dose for asthma control. This should only be done after other standard options for controlling asthma have been tried.

An oral corticosteroid should normally be taken as a single dose in the morning to reduce the disturbance to circadian cortisol secretion. Dosage should always be titrated to the lowest dose that controls symptoms. Regular peak-flow measurements help to optimise the dose.

**Parenteral corticosteroids**

Hydrocortisone injection p. 637 has a role in the emergency treatment of acute severe asthma.
Chronic obstructive pulmonary disease

Inhaled corticosteroids
In chronic obstructive pulmonary disease inhaled corticosteroid therapy may reduce exacerbations when given in combination with an inhaled long-acting beta₂ agonist.

Oral corticosteroids
During an acute exacerbation of chronic obstructive pulmonary disease, prednisolone p. 639 should be given; treatment can be stopped abruptly. Prolonged treatment with oral prednisolone is of no benefit and maintenance treatment is not normally recommended.

Corticosteroids (inhaled)

- SIDE-EFFECTS
  - Very rare  Paradoxical bronchospasm
  - Frequency not known  Adrenal crisis (with prolonged high doses)  - adrenal suppression (with prolonged high doses)  - aggression (particularly in children)  - anxiety  - behavioural changes (particularly in children)  - bruising  - candidiasis of the mouth  - candidiasis of the throat  - cataracts  - coma (with prolonged high doses)  - Cushing’s syndrome (with moon face, striae and acne)  - depression  - dysphonia  - glaucoma (with prolonged high doses)  - hoarseness  - hyperactivity (particularly in children)  - hyperglycaemia (usually only with high doses)  - irritability (particularly in children)  - lower respiratory tract infections in older patients with chronic obstructive pulmonary disease (with high doses)  - pneumonia in older patients with chronic obstructive pulmonary disease (with high doses)  - reduced growth velocity (in children)  - reduced mineral bone density (with long-term treatment of high doses)  - side-effects applicable to systemic corticosteroids may also apply if absorption occurs following inhaled use  - sleep disturbances  - throat irritation

- SIDE-EFFECTS, FURTHER INFORMATION
  - Candidiasis  The risk of oral candidiasis can be reduced by using a spacer device with the corticosteroid inhaler; rinsing the mouth with water after inhalation of a dose may also be helpful. An anti-fungal oral suspension or oral gel can be used to treat oral candidiasis without discontinuing corticosteroid therapy.
  - Paradoxical bronchospasm  The potential for paradoxical bronchospasm (calling for discontinuation and alternative therapy) should be borne in mind—mild bronchospasm may be prevented by inhalation of a short-acting beta₂ agonist beforehand (or by transfer from an aerosol inhalation to a dry powder inhalation).
  - PREGNANCY  Inhaled drugs for asthma can be taken as normal during pregnancy.
  - BREAST FEEDING  Inhaled corticosteroids for asthma can be taken as normal during breast-feeding.
  - MONITORING REQUIREMENTS
    - The height and weight of children receiving prolonged treatment with inhaled corticosteroids should be monitored annually; if growth is slowed, referral to a paediatrician should be considered.
  - NATIONAL FUNDING/ACCESS DECISIONS
    - NICE technology appraisals (TAs)
      - Inhaled corticosteroids for the treatment of chronic asthma in children under 12 years (November 2007) NICE TA131
        - For children under 12 years with chronic asthma in whom treatment with an inhaled corticosteroid is considered appropriate, the least costly product that is suitable for an individual child (taking into consideration NICE TAs 38 and 10), within its marketing authorisation is recommended. For children under 12 years with chronic asthma in whom treatment with an inhaled corticosteroid and a long-acting beta₂ agonist is considered appropriate, the following apply:
          - the use of a combination inhaler within its marketing authorisation is recommended as an option;
          - the decision to use a combination inhaler or two agents in separate inhalers should be made on an individual basis, taking into consideration therapeutic need and the likelihood of treatment adherence;
          - if a combination inhaler is chosen, then the least costly inhaler that is suitable for the individual child is recommended.

Beclometasone dipropionate
(Beclometasone dipropionate)

- INDICATIONS AND DOSE
  - Prophylaxis of asthma
    - BY INHALATION OF POWDER
      - Child 5–11 years: 100–200 micrograms twice daily, dose to be adjusted as necessary
      - Child 12–17 years: 200–400 micrograms twice daily, increased if necessary up to 800 micrograms twice daily, dose to be adjusted as necessary
      - Adult: 200–400 micrograms twice daily; increased if necessary up to 800 micrograms twice daily, dose to be adjusted as necessary
    - BY INHALATION OF POWDER
      - Child 6–11 years: 100–200 micrograms twice daily, dose to be adjusted as necessary
      - Child 12–17 years: 100–400 micrograms twice daily (max. per dose 1 mg twice daily), dose to be adjusted as necessary
      - Adult: 100–400 micrograms twice daily (max. per dose 1 mg twice daily), dose to be adjusted as necessary
    - ASMADEC CLICKHALER
      - Prophylaxis of asthma
        - BY INHALATION OF POWDER
          - Child 6–11 years: 100–200 micrograms twice daily, dose to be adjusted as necessary
          - Child 12–17 years: 100–400 micrograms twice daily (max. per dose 1 mg twice daily), dose to be adjusted as necessary
          - Adult: 100–400 micrograms twice daily (max. per dose 1 mg twice daily), dose to be adjusted as necessary
    - CLENIL MODULITE
      - Prophylaxis of asthma
        - BY INHALATION OF AEROSOL
          - Child 2–11 years: 100–200 micrograms twice daily
          - Child 12–17 years: 200–400 micrograms twice daily, adjusted according to response; increased if necessary up to 1 mg twice daily
          - Adult: 200–400 micrograms twice daily, adjusted according to response; increased if necessary up to 1 mg twice daily

continued →
Respiratory system

### BECLOMETASONE DIPROPIONATE

**Prophylaxis of asthma**
- By inhalation of aerosol
  - Child 12-17 years: 50–200 micrograms twice daily; increased if necessary up to 400 micrograms twice daily
  - Adult: 50–200 micrograms twice daily; increased if necessary up to 400 micrograms twice daily

**Potency**
Qvar® has extra-fine particles, is more potent than traditional beclometasone dipropionate CFC-containing inhalers and is approximately twice as potent as Clenil Modulite®.

**DOSE EQUIVALENCE AND CONVERSION**
- Dose adjustments may be required for some inhaler devices, see under individual preparations.

#### IMPORTANT SAFETY INFORMATION

**MHRA/CHM ADVICE (JULY 2008)**
Beclometasone dipropionate CFC-free pressurised metered-dose inhalers (Qvar® and Clenil Modulite®) are not interchangeable and should be prescribed by brand name; Qvar® has extra-fine particles, is more potent than traditional beclometasone dipropionate CFC-containing inhalers, and is approximately twice as potent as Clenil Modulite®.

#### INTERACTIONS
- Appendix 1: corticosteroids

**INTERACTIONS**
- Beclometasone Dipropionate is not licensed for use in children under 18 years. Clenil Modulite® 200 and 250 are not licensed for use in children under 12 years. Qvar® is not licensed for use in children under 12 years.

**UNLICENSED USE**
- Easyhaler® Beclometasone Dipropionate is not licensed for use in children under 18 years. Clenil Modulite® 200 and 250 are not licensed for use in children under 12 years. Qvar® is not licensed for use in children under 12 years.

**PRESCRIBING AND DISPENSING INFORMATION**
The MHRA has advised (July 2008) that beclometasone dipropionate CFC-free inhalers should be prescribed by brand name. Clenil Modulite® Clenil Modulite® is not interchangeable with other CFC-free beclometasone dipropionate inhalers.

**QVAR® PREPARATIONS**
- When switching a patient with well-controlled asthma from another corticosteroid inhaler, initially a 100-microgram metered dose of Qvar® should be prescribed for 200–250 micrograms of beclometasone dipropionate or budesonide and for 100 micrograms of fluticasone propionate. When switching a patient with poorly controlled asthma from another corticosteroid inhaler, initially a 100-microgram metered dose of Qvar® should be prescribed for 100 micrograms of beclometasone dipropionate, budesonide, or fluticasone propionate; the dose of Qvar® should be adjusted according to response.

**PATIENT AND CARER ADVICE**
- Steroid card should be issued with high doses of inhaled beclometasone dipropionate. Medicines for Children leaflet: Beclometasone for asthma prevention (prophylaxis) www.medicinesforchildren.org.uk/beclometasone-inhaler-asthma-prevention-prophylaxis-0

**PROFESSION SPECIFIC INFORMATION**
- Dental practitioners’ formulary Clenil Modulite® 50 micrograms/ metered inhalation may be prescribed.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.

**Inhalation Powder**
- Asmabec Clickhaler (Focus Pharmaceuticals Ltd)
  - Beclometasone dipropionate 100 microgram per 1 dose Asmabec 100 Clickhaler | 200 dose [POM] £9.81

**INDICATIONS AND DOSE**

**FOSTAIR NEUTHALER® 100/6**
**Asthma maintenance therapy**
- BY INHALATION OF POWDER
  - Adult: 1–2 inhalations twice daily; maximum 4 inhalations per day

**Chronic obstructive pulmonary disease with forced expiratory volume in 1 second < 50% of predicted**
- BY INHALATION OF POWDER
  - Adult: 2 inhalations twice daily

**DOSE EQUIVALENCE AND CONVERSION**
- For inhalation of powder, when switching patients from other beclometasone dipropionate formulations with non-extrafine particle size distribution to Fostair Neuthaler®, the dose should be adjusted according to response.
  - 1 inhalation is equivalent to 100 micrograms beclometasone dipropionate and 6 micrograms formoterol fumarate.

**FOSTAIR NEUTHALER® 200/6**
**Asthma maintenance therapy**
- BY INHALATION OF POWDER
  - Adult: 2 inhalations twice daily; maximum 4 inhalations per day

**DOSE EQUIVALENCE AND CONVERSION**
- For inhalation of powder, when switching patients from other beclometasone dipropionate formulations with non-extrafine particle size distribution to Fostair Neuthaler®, the dose should be adjusted according to response.

#### Easyhaler (beclometasone)
- Beclometasone dipropionate 200 microgram per 1 dose Easyhaler Beclometasone 200 micrograms/dose dry powder inhaler | 200 dose [POM] £14.93

**Pressurised inhalation**
- See under individual preparations.

**Beclometasone with formoterol**

09-Jun-2017

The properties listed below are those particular to the combination only. For the properties of the components please consider, beclometasone dipropionate p. 249, formoterol fumarate p. 242.

- **Qvar® Preparations**
  - Qvar® 50 microgram per 1 dose Qvar 50 inhaler | 200 dose [POM] £7.87
  - Qvar® 100 microgram per 1 dose Qvar 100 inhaler | 200 dose [POM] £17.21
  - Qvar® Autohaler (Teva UK Ltd)
    - Beclometasone dipropionate 50 microgram per 1 dose Qvar 50 Autohaler | 200 dose [POM] £7.87 DT price = £7.87
    - Beclometasone dipropionate 100 microgram per 1 dose Qvar 100 Autohaler | 200 dose [POM] £17.21 DT price = £17.21
  - Qvar Easi-Breathe (Teva UK Ltd)
    - Beclometasone dipropionate 50 microgram per 1 dose Qvar 50 micrograms/dose Easi-Breathe inhaler | 200 dose [POM] £7.47 DT price = £7.47
    - Beclometasone dipropionate 100 microgram per 1 dose Qvar 100 micrograms/dose Easi-Breathe inhaler | 200 dose [POM] £16.95 DT price = £17.21

- **QVAR® Preparations**
  - Beclometasone dipropionate 200 microgram per 1 dose Qvar 200 Autohaler | 200 dose [POM] £7.87 DT price = £7.87
  - Beclometasone dipropionate 400 microgram per 1 dose Qvar 400 Autohaler | 200 dose [POM] £17.21 DT price = £17.21

- **QVAR® Autohaler**
  - Beclometasone dipropionate 50 microgram per 1 dose Qvar 50 Autohaler | 200 dose [POM] £7.87 DT price = £7.87
  - Beclometasone dipropionate 100 microgram per 1 dose Qvar 100 Autohaler | 200 dose [POM] £17.21 DT price = £17.21
  - Beclometasone dipropionate 200 microgram per 1 dose Qvar 200 Autohaler | 200 dose [POM] £21.74 DT price = £21.74
  - Beclometasone dipropionate 400 microgram per 1 dose Qvar 400 Autohaler | 200 dose [POM] £43.48 DT price = £43.48

- **QVAR® Easi-Breathe**
  - Beclometasone dipropionate 50 microgram per 1 dose Qvar 50 micrograms/dose Easi-Breathe inhaler | 200 dose [POM] £7.47 DT price = £7.47
  - Beclometasone dipropionate 100 microgram per 1 dose Qvar 100 micrograms/dose Easi-Breathe inhaler | 200 dose [POM] £16.95 DT price = £17.21

- **QVAR® Autohaler**
  - Beclometasone dipropionate 50 microgram per 1 dose Qvar 50 Autohaler | 200 dose [POM] £7.87 DT price = £7.87
  - Beclometasone dipropionate 100 microgram per 1 dose Qvar 100 Autohaler | 200 dose [POM] £17.21 DT price = £17.21
Chronic obstructive pulmonary disease with forced expiratory volume in 1 second < 50% of predicted

**Fostair® 100/6**

**Asthma maintenance therapy**
- BY INHALATION OF AEROSOL
- Adult: 1–2 inhalations twice daily; maximum 4 inhalations per day

**Asthma, maintenance and reliever therapy**
- BY INHALATION OF AEROSOL
- Adult: Maintenance 1 inhalation twice daily; 1 inhalation as required, for relief of symptoms; maximum 8 inhalations per day

**DOSE EQUIVALENCE AND CONVERSION**
- For inhalation of aerosol, when switching patients from other beclometasone dipropionate and formoterol fumarate inhalers, dose should be adjusted according to response—100 micrograms of beclometasone dipropionate extrafine in Fostair® is equivalent to 250 micrograms of beclometasone dipropionate in a non-extrafine formulation.
- 1 inhalation is equivalent to 100 micrograms beclometasone dipropionate and 6 micrograms formoterol fumarate.

**Fostair® 200/6**

**Asthma maintenance therapy**
- BY INHALATION OF AEROSOL
- Adult: 2 inhalations twice daily; maximum 4 inhalations per day

**DOSE EQUIVALENCE AND CONVERSION**
- For inhalation of aerosol, when switching patients from other beclometasone dipropionate and formoterol fumarate inhalers, dose should be adjusted according to response—100 micrograms of beclometasone dipropionate extrafine in Fostair® is equivalent to 250 micrograms of beclometasone dipropionate in a non-extrafine formulation.
- 1 inhalation is equivalent to 200 micrograms beclometasone dipropionate and 6 micrograms formoterol fumarate.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Inhalation powder**

**CAUTIONARY AND ADVISORY LABELS** 8, 10
- Fostair NEXThaler (Chiesi Ltd)
  - Formoterol fumarate dihydrate 6 microgram per 1 dose, Beclometasone dipropionate 100 microgram per 1 dose Fostair NEXThaler 100micrograms/dose / 6micrograms/dose dry powder inhaler 120 dose £29.32 DT price = £29.32
  - Formoterol fumarate dihydrate 6 microgram per 1 dose, Beclometasone dipropionate 200 microgram per 1 dose Fostair NEXThaler 200micrograms/dose / 6micrograms/dose dry powder inhaler 120 dose £29.32 DT price = £29.32

**Pressurised inhalation**

**CAUTIONARY AND ADVISORY LABELS** 8, 10
- Fostair (Chiesi Ltd)
  - Formoterol fumarate dihydrate 6 microgram, Beclometasone dipropionate 200 microgram Fostair 200micrograms/dose / 6micrograms/dose inhaler 120 dose £29.32 DT price = £29.32
  - Formoterol fumarate dihydrate 6 microgram per 1 dose, Beclometasone dipropionate 100 microgram per 1 dose Fostair 100micrograms/dose / 6micrograms/dose inhaler 120 dose £29.32 DT price = £29.32

**Budesonide**

**INDICATIONS AND DOSE**

**Prophylaxis of mild to moderate asthma (in patients stabilised on twice daily dose)**
- BY INHALATION OF POWDER
  - Child 6–11 years: 200–400 micrograms once daily, dose to be given in the evening
  - Child 12–17 years: 200–400 micrograms once daily (max. per dose 800 micrograms), dose to be given in the evening
  - Adult: 200–400 micrograms once daily (max. per dose 800 micrograms), dose to be given in the evening

**Prophylaxis of asthma**
- BY INHALATION OF POWDER
  - Child 6–11 years: 100–400 micrograms twice daily, dose to be adjusted as necessary
  - Child 12–17 years: 100–400 micrograms twice daily, dose to be adjusted as necessary
  - Adult: 100–400 micrograms twice daily, dose to be adjusted as necessary
- BY INHALATION OF NEBULISED SUSPENSION
  - Child 6 months–11 years: 125–500 micrograms twice daily, adjusted according to response; maximum 2 mg per day
  - Child 12–17 years: Initially 0.25–1 mg twice daily, adjusted according to response, doses higher than recommended max. may be used in severe disease; maximum 2 mg per day
  - Adult: Initially 0.25–1 mg twice daily, adjusted according to response, doses higher than recommended max. may be used in severe disease; maximum 2 mg per day

**BUDELIN NOVALIZER®**

**Prophylaxis of asthma**
- BY INHALATION OF POWDER
  - Adult: 200–800 micrograms twice daily, dose is adjusted as necessary

**Alternative in mild to moderate asthma, for patients previously stabilised on a twice daily dose**
- BY INHALATION OF POWDER
  - Adult: 200–400 micrograms once daily (max. per dose 800 micrograms), to be taken in the evening continued →
**Budesonide with formoterol**

The properties listed below are those particular to the combination only. For the properties of the components please consider, budesonide p. 251, formoterol fumarate p. 242.

### **INDICATIONS AND DOSE**

**DUORESP SPIROMAX** ™ **160MICROGRAMS/4.5MICROGRAMS**

**Asthma maintenance therapy**

- **BY INHALATION OF POWDER**
  - Adult: 1–2 inhalations twice daily, increased if necessary up to 4 inhalations twice daily

**Asthma, maintenance and reliever therapy**

- **BY INHALATION OF POWDER**
  - Adult: 2 inhalations daily in 1–2 divided doses, increased if necessary to 2 inhalations twice daily, 1 inhalation (max. per dose 6 inhalations) as required, for relief of symptoms, a total daily dose of up to 12 inhalations can be used for a limited time but medical assessment is recommended if more than 8 inhalations daily are needed

### **Chronic obstructive pulmonary disease with forced expiratory volume in 1 second < 50% of predicted**

- **BY INHALATION OF POWDER**
  - Adult: 2 inhalations twice daily

**DUORESP SPIROMAX** ™ **320MICROGRAMS/9MICROGRAMS**

**Asthma, maintenance therapy**

- **BY INHALATION OF POWDER**
  - Adult: 1 inhalation twice daily; increased if necessary up to 2 inhalations twice daily

**Chronic obstructive pulmonary disease with forced expiratory volume in 1 second < 50% of predicted**

- **BY INHALATION OF POWDER**
  - Adult: 1 inhalation twice daily

**SYMBICORT 100/6 TURBOHALER** ™

**Asthma, maintenance therapy**

- **BY INHALATION OF POWDER**
  - Child 6–17 years: Initially 1–2 puffs twice daily; reduced to 1 puff daily, dose reduced only if control is maintained
  - Adult: Initially 1–2 puffs twice daily, increased if necessary up to 4 puffs twice daily; reduced to 1 puff daily, dose reduced only if control is maintained

**Asthma, maintenance and reliever therapy**

- **BY INHALATION OF POWDER**
  - Adult: Maintenance 2 puffs daily in 1–2 divided doses; 1 puff as required for relief of symptoms, increased if necessary up to 6 puffs as required, max. 8 puffs per day; up to 12 puffs daily can be used for a limited time but medical assessment should be considered

**SYMBICORT 200/6 TURBOHALER** ™

**Asthma, maintenance therapy**

- **BY INHALATION OF POWDER**
  - Child 12–17 years: Initially 1–2 puffs twice daily; reduced to 1 puff daily, dose reduced only if control is maintained
  - Adult: Initially 1–2 puffs twice daily, increased if necessary up to 4 puffs twice daily; reduced to 1 puff daily, dose reduced only if control is maintained

**Asthma, maintenance and reliever therapy**

- **BY INHALATION OF POWDER**
  - Adult: Maintenance 2 puffs daily in 1–2 divided doses, increased if necessary to 2 puffs twice daily; 1 puff as required for relief of symptoms, increased if necessary up to 6 puffs as required, max. 8 puffs per day; up to 12 puffs daily can be used for a limited time but medical assessment should be considered
Ciclesonide

Chronic obstructive pulmonary disease with forced expiratory volume in 1 second < 50% of predicted

- **BY INHALATION OF POWDER**
- Adult: 2 puffs twice daily

**SYMBOCORT 400/12 TURBOHALER®**

**Asthma, maintenance therapy**

- Child 12-17 years: Initially 1 puff twice daily; reduced to 1 puff daily, dose reduced only if control is maintained
- Adult: Initially 1 puff twice daily, increased if necessary up to 2 puffs twice daily; reduced to 1 puff daily, dose reduced only if control is maintained

Chronic obstructive pulmonary disease with forced expiratory volume in 1 second < 50% of predicted

- **BY INHALATION OF POWDER**
- Adult: 1 puff twice daily

**INTERACTIONS** → Appendix 1: beta₂ agonists, corticosteroids

**PATIENT AND CARER ADVICE** With high doses, a steroid card should be supplied. Patients counselling is advised for budesonide with formoterol dry powder inhaler (administration).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**INHALATION Powder**

**CAUTIONARY AND ADVISORY LABELS** 8, 10 (high doses)

- **DuoResp Spirmax** (Teva UK Ltd)
  - Formoterol fumarate dihydrate 6 microgram per 1 dose, Budesonide 200 microgram per 1 dose: DuoResp Spirmax 160micrograms/dose / 4.5micrograms/dose dry powder inhaler | 120 dose [POT]: £29.97 DT price = £38.00
  - Formoterol fumarate dihydrate 12 microgram per 1 dose, Budesonide 400 microgram per 1 dose: DuoResp Spirmax 320micrograms/dose / 9micrograms/dose dry powder inhaler | 60 dose [POT]: £29.97 DT price = £38.00
- **Symbicort Turbohaler** (AstraZeneca UK Ltd)
  - Formoterol fumarate dihydrate 6 microgram per 1 dose, Budesonide 100 microgram per 1 dose: Symbicort 100/6 Turbohaler | 120 dose [POT]: £33.00 DT price = £33.00
  - Formoterol fumarate dihydrate 6 microgram per 1 dose, Budesonide 200 microgram per 1 dose: Symbicort 200/6 Turbohaler | 120 dose [POT]: £38.00 DT price = £38.00
  - Formoterol fumarate dihydrate 12 microgram per 1 dose, Budesonide 400 microgram per 1 dose: Symbicort 400/12 Turbohaler | 60 dose [POT]: £38.00 DT price = £38.00

**SIDE-EFFECTS**

- In adults: High dose recommended in severe asthma is unlicensed.
- **INTERACTIONS** → Appendix 1: corticosteroids
- **SIDE-EFFECTS** Nausea · taste disturbance
- **PATIENT AND CARER ADVICE** Patients or carers should be given advice on how to administer ciclesonide aerosol inhaler.

**Fluticasone**

**INDICATIONS AND DOSE**

**Prophylaxis of asthma**

- **BY INHALATION OF POWDER**
  - Child 5-15 years: Initially 50–100 micrograms twice daily (max. per dose 200 micrograms twice daily), dose to be adjusted as necessary
  - Child 16-17 years: Initially 100–500 micrograms twice daily (max. per dose 1 mg twice daily), dose may be increased according to severity of asthma. Doses above 500 micrograms twice daily initiated by a specialist
  - Adult: Initially 100–500 micrograms twice daily (max. per dose 1 mg twice daily), dose may be increased according to severity of asthma. Doses above 500 micrograms twice daily initiated by a specialist

**INHALATION of AEROSOL**

- Child 4-15 years: Initially 50–100 micrograms twice daily (max. per dose 200 micrograms twice daily), dose to be adjusted as necessary
  - Child 16-17 years: Initially 100–500 micrograms twice daily (max. per dose 1 mg twice daily), dose may be increased according to severity of asthma. Doses above 500 micrograms twice daily initiated by a specialist
  - Adult: Initially 100–500 micrograms twice daily (max. per dose 1 mg twice daily), dose may be increased according to severity of asthma. Doses above 500 micrograms twice daily initiated by a specialist

**INTERACTIONS** → Appendix 1: corticosteroids

**DIRECTIONS FOR ADMINISTRATION** Fluticasone nebuliser liquid may be diluted with sterile sodium chloride 0.9%. It is not suitable for use in ultrasonic nebulisers.

**PATIENT AND CARER ADVICE** With high doses, a steroid card should be supplied. Patients or carers should be given advice on how to administer all fluticasone inhalation preparations.

Medicines for Children leaflet: Fluticasone inhaler for asthma prevention (prophylaxis) www.medicinesforchildren.org.uk/ fluticasone-inhaler-for-asthma-prevention

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**INHALATION powder**

**CAUTIONARY AND ADVISORY LABELS** 8, 10

- **Flixotide Accuhaler** (GlaxoSmithKline UK Ltd)
  - Fluticasone propionate 50 microgram per 1 dose: Flixotide 50micrograms/dose Accuhaler | 60 dose [POT]: £7.66 DT price = £7.66
  - Fluticasone propionate 100 microgram per 1 dose: Flixotide 100micrograms/dose Accuhaler | 60 dose [POT]: £10.72 DT price = £10.72
  - Fluticasone propionate 250 microgram per 1 dose: Flixotide 250micrograms/dose Accuhaler | 60 dose [POT]: £25.51 DT price = £25.51

**Fluticasone**

**04-Jan-2016**
Fluticasone propionate 500 microgram per 1 dose Flutotide 500 micrograms/dose Accuhaler | 60 dose POM £43.37 DT price = £43.37

Pressurised inhalation
CAUTIONARY AND ADVISORY LABELS 8, 10

- **Flutotide E沃haler** (GlaxoSmithKline UK Ltd)
  - Fluticasone propionate 50 microgram per 1 dose Flutotide 50 micrograms/dose E沃haler | 120 dose POM £5.44 DT price = £5.44
  - Fluticasone propionate 125 microgram per 1 dose Flutotide 125 micrograms/dose E沃haler | 120 dose POM £21.26 DT price = £21.26
  - Fluticasone propionate 250 microgram per 1 dose Flutotide 250 micrograms/dose E沃haler | 120 dose POM £36.14 DT price = £36.14

**Nebuliser liquid**
CAUTIONARY AND ADVISORY LABELS 8, 10

- **Flotinside Nebule** (GlaxoSmithKline UK Ltd)
  - Fluticasone propionate 250 microgram per 1 ml Flutotide 0.5mg/2ml Nebules | 10 unit dose POM £3.34
  - Fluticasone propionate 1 mg per 1 ml Flutotide 2mg/2ml Nebules | 10 unit dose POM £7.35

### Fluticasone furoate with vilanterol

#### INDICATIONS AND DOSE

**RELVAR ELLIPTA® 184 MICROGRAMS/22 MICROGRAMS**

Prophylaxis of asthma
- **BY INHALATION OF POWDER**
  - Child 12-17 years: 1 inhalation once daily
  - Adult: 1 inhalation once daily

**RELVAR ELLIPTA® 92 MICROGRAMS/22 MICROGRAMS**

Prophylaxis of asthma
- **BY INHALATION OF POWDER**
  - Child 12-17 years: 1 inhalation once daily
  - Adult: 1 inhalation once daily

Chronic obstructive pulmonary disease with forced expiratory volume in 1 second < 70% of predicted
- **BY INHALATION OF POWDER**
  - Adult: 1 inhalation once daily

#### INTERACTIONS

→ Appendix 1: beta, agonists, corticosteroids

#### SIDE-EFFECTS

Abdominal pain, back pain

#### PREGNANCY

Manufacturer advises use only if potential benefit outweighs risk.

#### BREAST FEEDING

Manufacturer advises avoid—no information available.

#### HEPATIC IMPAIRMENT

Max. dose fluticasone furoate 92 micrograms, vilanterol 22 micrograms.

**RELVAR ELLIPTA® 184 MICROGRAMS/22 MICROGRAMS**

Avoid in moderate to severe impairment.

#### PATIENT AND CARER ADVICE

A steroid card should be provided. Patients or carers should be given advice on how to administer fluticasone with vilanterol powder for inhalation.

#### NATIONAL FUNDING/ACCESS DECISIONS

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (March 2014) that fluticasone furoate/vilanterol (Relvar Ellipta®) is accepted for restricted use within NHS Scotland in patients with severe chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV₁) less than 50% of the predicted normal value.

#### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Inhalation powder**

CAUTIONARY AND ADVISORY LABELS 8, 10

- Relvar E沃lipa (GlaxoSmithKline UK Ltd) ▲
  - Vilanterol 22 microgram per 1 dose, Fluticasone furoate 92 microgram per 1 dose Relvar E沃lipa 92 micrograms/dose / 22 micrograms/dose dry powder inhaler | 30 dose POM £22.00 DT price = £22.00
  - Vilanterol 22 microgram per 1 dose, Fluticasone furoate 184 microgram per 1 dose Relvar E沃lipa 184 micrograms/dose / 22 micrograms/dose dry powder inhaler | 30 dose POM £29.50 DT price = £29.50

### Fluticasone with formoterol

The properties listed below are those particular to the combination only. For the properties of the components please consider, fluticasone p. 253, formoterol fumarate p. 242.

#### INDICATIONS AND DOSE

**FLUTIFORM® 50**

Prophylaxis of asthma
- **BY INHALATION OF AEROSOL**
  - Child 12-17 years: 2 puffs twice daily
  - Adult: 2 puffs twice daily

**FLUTIFORM® 125**

Prophylaxis of asthma
- **BY INHALATION OF AEROSOL**
  - Child 12-17 years: 2 puffs twice daily
  - Adult: 2 puffs twice daily

**FLUTIFORM® 250**

Prophylaxis of asthma
- **BY INHALATION OF AEROSOL**
  - Adult: 2 puffs twice daily

#### INTERACTIONS

→ Appendix 1: beta, agonists, corticosteroids

#### PATIENT AND CARER ADVICE

With high doses, a steroid card should be provided. Patients or carers should be given advice on how to administer fluticasone with formoterol aerosol inhalation.

#### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Pressurised inhalation**

CAUTIONARY AND ADVISORY LABELS 8, 10 (high doses)

- Flutiform (Napp Pharmaceuticals Ltd)
  - Formoterol fumarate dihydrate 5 microgram per 1 dose, Fluticasone propionate 50 microgram per 1 dose Flutiform 50 micrograms/dose / 5 micrograms/dose inhaler | 120 dose POM £14.40 DT price = £14.40
  - Formoterol fumarate dihydrate 5 microgram per 1 dose, Fluticasone propionate 125 microgram per 1 dose Flutiform 125 micrograms/dose / 5 micrograms/dose inhaler | 120 dose POM £28.00 DT price = £28.00
  - Formoterol fumarate dihydrate 10 microgram per 1 dose, Fluticasone propionate 250 microgram per 1 dose Flutiform 250 micrograms/dose / 10 micrograms/dose inhaler | 120 dose POM £45.56 DT price = £45.56
Fluticasone with salmeterol

The properties listed below are those particular to the combination only. For the properties of the components please consider, fluticasone p. 253, salmeterol p. 243.

**INDICATIONS AND DOSE**

**AIRFLUSAL FORSPIRO ®**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic obstructive pulmonary disease with forced expiratory volume in 1 second &lt;60% of predicted</td>
<td>Fluticasone with salmeterol</td>
</tr>
</tbody>
</table>

**Prophylaxis of asthma**

- **Adult:** 1 inhalation of powder twice daily

**SEREFLO ® 125**

- **Moderate-to-severe asthma**
  - **Adult:** 1 inhalation of powder twice daily

**SEREFLO ® 250**

- **Moderate-to-severe asthma**
  - **Adult:** 2 inhalations of powder twice daily

**PROPHYLAXIS OF AEROSOL**

- **Adult:** 2 inhalations twice daily

**SERETIDE 100 ACCUHALER ®**

**Prophylaxis of asthma**

- **Child 5-17 years:** 1 inhalation twice daily, reduced to 1 inhalation daily, use reduced dose only if control maintained
- **Adult:** 1 inhalation twice daily, reduced to 1 inhalation daily, use reduced dose only if control maintained

**SERETIDE 250 ACCUHALER ®**

**Prophylaxis of asthma**

- **Child 12-17 years:** 1 inhalation twice daily
- **Adult:** 1 inhalation twice daily

**SERETIDE 500 ACCUHALER ®**

**Prophylaxis of asthma**

- **Child 12-17 years:** 1 inhalation twice daily
- **Adult:** 1 inhalation twice daily

**Chronic obstructive pulmonary disease with forced expiratory volume in 1 second <60% of predicted**

- **Adult:** 1 inhalation twice daily

**SERETIDE 125 EVOHALER ®**

**Prophylaxis of asthma**

- **Child 5-17 years:** 2 puffs twice daily, (by inhalation) reduced to 2 puffs once daily, use reduced dose only if control maintained
- **Adult:** 2 puffs twice daily, (by inhalation) reduced to 2 puffs once daily, use reduced dose only if control maintained

**SERETIDE 250 EVOHALER ®**

**Prophylaxis of asthma**

- **Child 12-17 years:** 2 puffs twice daily
- **Adult:** 2 puffs twice daily

**INTERACTIONS** → Appendix 1: beta2 agonists, corticosteroids

**PRESCRIBING AND DISPENSING INFORMATION**

**SEREFLO ® 125** Manufacturer advises spacer devices are not compatible—if spacer device required, switch to alternative fixed-dose combination preparation.

**PATIENT AND CARER ADVICE** With preparations containing greater than 100 micrograms fluticasone, a steroid card should be provided. Patients or carers should be given advice on how to administer fluticasone with salmeterol dry powder inhalation and aerosol inhalation.

**NATIONAL FUNDING/ACCESS DECISIONS**

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (December 2008) that Seretide 500 Accuhaler ® is not recommended for use within NHS Scotland for chronic obstructive pulmonary disease in patients with a forced expiratory volume in 1 second (FEV1) less than 60% and greater than 50% of the predicted normal value, with significant symptoms despite regular bronchodilator therapy, and a history of repeated exacerbations.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Inhalation powder**

**CAUTIONARY AND ADVISORY LABELS** 8, 10 (excluding Seretide 100 Accuhaler ®)

- **AirFlusal Forspiro** (Sandoz Ltd)
  - Salmeterol (as Salmeterol xinafoate) 50 microgram per 1 dose, Fluticasone propionate 500 microgram per 1 dose AirFlusal Forspiro 50micrograms/dose / 500micrograms/dose dry powder inhaler | 60 dose (Pom) £32.74 DT price = £40.92
- **Seretide Accuhaler** (GlaxoSmithKline UK Ltd)
  - Salmeterol (as Salmeterol xinafoate) 50 microgram per 1 dose, Fluticasone propionate 100 microgram per 1 dose Seretide 100 Accuhaler | 60 dose (Pom) £18.00 DT price = £18.00
- **Seretide 250 Accuhaler** Seretide 250 microgram per 1 dose, Fluticasone propionate 250 microgram per 1 dose Seretide 250 Accuhaler | 60 dose (Pom) £35.00 DT price = £35.00
- **Seretide 500 Accuhaler** Seretide 500 microgram per 1 dose, Fluticasone propionate 500 microgram per 1 dose Seretide 500 Accuhaler | 60 dose (Pom) £40.92 DT price = £40.92

**Pressurised inhalation**

**CAUTIONARY AND ADVISORY LABELS** 8, 10 (excluding Seretide 50 Evohaler ®)

- **Serelo** (Kent Pharmaceticals Ltd)
  - Salmeterol (as Salmeterol xinafoate) 25 microgram per 1 dose, Fluticasone propionate 125 microgram per 1 dose Serefl 25micrograms/dose / 125micrograms/dose inhaler | 120 dose (Pom) £23.50 DT price = £35.00
- **Seretide** (GlaxoSmithKline UK Ltd)
  - Salmeterol (as Salmeterol xinafoate) 25 microgram per 1 dose, Fluticasone propionate 250 microgram per 1 dose Seretide 125 micrograms/dose / 250micrograms/dose inhaler | 120 dose (Pom) £39.95 DT price = £59.48
  - Seretide Evohaler Seretide (as Salmeterol xinafoate) 25 microgram per 1 dose, Fluticasone propionate 50 microgram per 1 dose Seretide 25 micrograms/dose / 50micrograms/dose inhaler | 120 dose (Pom) £25.20 DT price = £49.95
  - Salmeterol (as Salmeterol xinafoate) 25 microgram per 1 dose, Fluticasone propionate 125 microgram per 1 dose Seretide 125 Evohaler | 120 dose (Pom) £35.00 DT price = £35.00
  - Salmeterol (as Salmeterol xinafoate) 25 microgram per 1 dose, Fluticasone propionate 250 microgram per 1 dose Seretide 250 Evohaler | 120 dose (Pom) £59.48 DT price = £59.48

**Mometasone furoate**

**INDICATIONS AND DOSE**

**Prophylaxis of asthma**

- **Child 12-17 years:** Initially 400 micrograms daily in 1–2 divided doses, single dose to be inhaled in the evening, reduced to 200 micrograms once daily, if control maintained continued
Respiratory system

MEDICINAL FORMS

PATIENT AND CARER ADVICE

INTERACTIONS → Appendix 1: corticosteroids

SIDE-EFFECTS

Common or very common Headache

Uncommon Dyspepsia • palpitation • weight gain

PATIENT AND CARER ADVICE

Patients or carers should be given advice on how to administer mometasone by inhaler. With high doses, a steroid card should be supplied.

Medicines for Children leaflet: Mometasone furoate inhaler for asthma prevention (prophylaxis)

www.medicinesforchildren.org.uk/mometasone-furoate-inhaler-for-asthma-prevention-prophylaxis

NATIONAL FUNDING/ACCESS DECISIONS

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (November 2003) that Asmanex® is restricted for use following failure of first-line inhaled corticosteroids.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Inhalation powder

CAUTIONARY AND ADVISORY LABELS 8, 10

Asmanex Twisthaler (Merck Sharp & Dohme Ltd)

Mometasone furoate 200 microgram per 1 dose Asmanex 200micrograms/dose Twisthaler | 30 dose [PO] £15.70 DT price = £15.70 | 60 dose [PO] £23.54 DT price = £23.54

Mometasone furoate 400 microgram per 1 dose Asmanex 400micrograms/dose Twisthaler | 30 dose [PO] £21.78 DT price = £21.78 | 60 dose [PO] £36.05 DT price = £36.05

IMMUNOSUPPRESSANTS > MONOCLONAL ANTIBODIES

Mepolizumab

09-Feb-2017

DRUG ACTION

Mepolizumab is a humanised anti-interleukin-5 (anti-IL-5) monoclonal antibody; it reduces the production and survival of eosinophils

INDICATIONS AND DOSE

Add on treatment for severe refractory eosinophilic asthma (under expert supervision)

BY SUBCUTANEOUS INJECTION

Adult: 100 mg every 4 weeks

CAUTIONS

Helminth infection

CAUTIONS, FURTHER INFORMATION

Helminth infections. Manufacturer advises pre-existing helminth infections should be treated before initiation of therapy; if patients become infected during treatment and do not respond to anti-helminth treatment, consider treatment interruption.

INTERACTIONS → Appendix 1: monoclonal antibodies

SIDE-EFFECTS

Common or very common Back pain • eczema • headache • lower respiratory tract infection • nasal congestion • pharyngitis • pyrexia • upper abdominal pain • urinary tract infection

PREGNANCY

Manufacturer advises avoid unless potential benefit outweighs risk—limited data available.

BREAST FEEDING

Manufacturer advises avoid—present in milk in animal studies.

PATIENT AND CARER ADVICE

Asthma Patients and their carers should be advised to seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

Mepolizumab for treating severe refractory eosinophilic asthma (January 2017) NICE TA431

Mepolizumab, as an add-on to optimised standard therapy, is recommended as an option for treating severe refractory eosinophilic asthma in adults, only if:

● the blood eosinophil count is 300 cells/micro litre or more in the previous 12 months and

● the person has agreed to and followed the optimised standard treatment plan and has had 4 or more asthma exacerbations requiring systemic corticosteroids in the previous 12 months or had continuous oral corticosteroids over the previous 6 months and

● the manufacturer provides mepolizumab with the discount agreed in the patient access scheme www.nice.org.uk/TA431

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (June 2016) that mepolizumab (Nucala®) is accepted for restricted use within NHS Scotland as an add-on treatment for severe refractory eosinophilic asthma in adult patients who have eosinophils of at least 150 cells/micro litre (0.15 × 10⁷/L) at initiation of treatment and have had at least four asthma exacerbations in the preceding year or are receiving maintenance treatment with oral corticosteroids.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for injection

Nucala (GlaxoSmithKline UK Ltd)▼

Mepolizumab 100 mg Nucala 100 mg powder for solution for injection vials | 1 vial [PO] £840.00 (Hospital only)

OMALIZUMAB

INDICATIONS AND DOSE

Prophylaxis of severe persistent allergic asthma

BY SUBCUTANEOUS INJECTION

Adult: Dose according to immunoglobulin E concentration and body-weight (consult product literature)

Add-on therapy for chronic spontaneous urticaria in patients who have had an inadequate response to H₁ antihistamine treatment

BY SUBCUTANEOUS INJECTION

Adult: 300 mg every 4 weeks

CAUTIONS

Autoimmune disease • susceptibility to helminth infection—discontinue if infection does not respond to anthelmintic

INTERACTIONS → Appendix 1: monoclonal antibodies

SIDE-EFFECTS

Common or very common Abdominal pain • arthralgia • headache • injection-site reactions • pyrexia • sinusitis • upper respiratory tract infection

Uncommon Bronchospasm • cough • diarrhoea • dizziness • drowsiness • dyspepsia • flushing • influenza-like illness • malaise • nausea • paraesthesia • pharyngitis • photosensitivity • postural hypotension • pruritus • rash • syncope • urticaria • weight gain

Rare Angioedema • antibody formation • laryngoelema • parasitic infection

downloaded from www.medicalbr.com
HEPATIC IMPAIRMENT

Frequency not known

PREGNANCY

Breastfeeding

Previously treated chronic spontaneous urticaria in patients aged 12 years and over, who have had an inadequate response to combination therapy with H1-antihistamines, leukotriene receptor antagonists and H2-antihistamines, used according to current treatment guidelines.

OMALIZUMAB FOR...—

▶ Omalizumab...—

Patients currently receiving omalizumab whose disease does not meet the criteria should be able to continue treatment until they and their clinician consider it appropriate to stop.

www.nice.org.uk/TA339

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (December 2014) that omalizumab (Xolair®) is accepted for restricted use within NHS Scotland for the treatment of chronic spontaneous urticaria in patients aged 12 years and over, who have had an inadequate response to combination therapy with H1-antihistamines, leukotriene receptor antagonists and H2-antihistamines, used according to current treatment guidelines.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

Xolair (Novartis Pharmaceuticals UK Ltd)

Omalizumab 150 mg per 1 ml

Xolair 150mg/1ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (POM) £256.15

Xolair 75mg/0.5ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (POM) £128.07

Reslizumab

18-May-2017

DRUG ACTION

Reslizumab is a humanised monoclonal antibody that interferes with interleukin-5 receptor binding, thereby reducing the survival and activity of eosinophils.

INDICATIONS AND DOSE

Severe eosinophilic asthma (adjunctive therapy when inadequately controlled by high-dose corticosteroids plus another standard treatment) (specialist use only)

BY INTRAVENOUS INFUSION

Adult: (consult product literature)

PHARMACOKINETICS

The half-life of reslizumab is approx. 24 days.

CAUTIONS

Hypersensitivity reactions • pre-existing helminth infection

CAUTIONS, FURTHER INFORMATION

Helminth infection

Manufacturer advises to treat pre-existing helminth infections before starting reslizumab—consider temporarily discontinuing reslizumab if patient becomes infected during therapy and does not respond to anti-helminth treatment.

Hypersensitivity reactions

Serious hypersensitivity reactions, including life-threatening anaphylaxis, can occur and manufacturer advises to monitor closely during treatment and for at least 20 minutes after completion of infusion; in the event of a hypersensitivity reaction, treatment should be permanently discontinued.

INTERACTIONS

→ Appendix 1: monoclonal antibodies

SIDE-EFFECTS

Uncommon

Anaphylaxis • myalgia

PREGNANCY

Manufacturer advises avoid—limited information available.

BREAST FEEDING

Manufacturer advises avoid during first few days after birth—risk of transfer of antibodies to infant cannot be excluded; present in milk in animal studies.

DIRECTIONS FOR ADMINISTRATION

For intravenous infusion, manufacturer advises give intermittently in Sodium chloride 0.9%; administer over 20–50 minutes through an in-line 0.2 micron filter.

HANDLING AND STORAGE

Manufacturer advises store in a refrigerator (2–8°C); consult product literature for storage conditions after preparation of infusion.

PATIENT AND CARER ADVICE

Manufacturer advises patients and their carers should be instructed to seek...
medical advice if their asthma remains uncontrolled or if symptoms worsen after initiation of treatment.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  - **Solution for infusion**
    - **EXCIPIENTS:** May contain Sucrose
    - **Cinqaero** (Teva UK Ltd) ▼
    - Resilizumab 10 mg per 1 ml Cinqaero 100mg/10ml concentrate for solution for infusion vials | 1 vial [POM] £49.99

**LEUKOTRIENE RECEPTOR ANTAGONISTS**

Leodtine receptor antagonists

**Overview**

The leoduine receptor antagonists, montelukast below and zafirlukast p. 259, block the effects of cysteinyl leukotrienes in the airways. They are effective in asthma when used alone or with an inhaled corticosteroid.

Montelukast has not been shown to be more effective than a standard dose of inhaled corticosteroid, but the two drugs appear to have an additive effect. The leoduine receptor antagonists may be of benefit in exercise-induced asthma and in those with concomitant rhinitis, but they are less effective in those with severe asthma who are also receiving high doses of other drugs.

**Montelukast**

- **INDICATIONS AND DOSE**
  - **Prophylaxis of asthma**
    - **BY MOUTH**
      - Child 6 months–5 years: 4 mg once daily, dose to be taken in the evening
      - Child 6–14 years: 5 mg once daily, dose to be taken in the evening
      - Child 15–17 years: 10 mg once daily, dose to be taken in the evening
      - Adult: 10 mg once daily, dose to be taken in the evening
  - **Symptomatic relief of seasonal allergic rhinitis in patients with asthma.**
    - **BY MOUTH**
      - Child 15–17 years: 10 mg once daily, dose to be taken in the evening
      - Adult: 10 mg once daily, dose to be taken in the evening

- **INTERACTIONS** → Appendix 1: montelukast

- **SIDE-EFFECTS**
  - **Common or very common** Abdominal pain · headache · hyperkinesia (in young children) · thirst
  - **Uncommon** Abnormal dreams · aggressive behaviour · agitation · anxiety · arthralgia · bruising · depression · dizziness · drowsiness · dry mouth · dyspepsia · epistaxis · hostility · hypoesthesia · irritability · malaise · muscle cramps · myalgia · oedema · paraesthesia · psychomotor hyperactivity · restlessness · seizures · sleep disturbances · sleep-walking
  - **Rare** Disturbance in attention · increased bleeding tendency · memory impairment · palpitation · tremor
  - **Very rare** Churg–Strauss syndrome · disorientation · erythema multiforme · erythema nodosum · hallucinations · hepatic disorders · hepatic eosinophilic infiltration · suicidal behaviour · suicidal thoughts

**SIDE-EFFECTS, FURTHER INFORMATION**

Churg–Strauss syndrome has occurred very rarely in association with the use of montelukast; in many of the reported cases the reaction followed the reduction or withdrawal of oral corticosteroid therapy. Prescribers should be alert to the development of eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, or peripheral neuropathy.

- **PREGNANCY** Manufacturer advises avoid unless essential.
  - There is limited evidence for the safe use of montelukast during pregnancy; however, it can be taken as normal in women who have shown a significant improvement in asthma not achievable with other drugs before becoming pregnant.

- **BREAST FEEDING** Manufacturer advises avoid unless essential.

- **DIRECTIONS FOR ADMINISTRATION** Granules may be swallowed or mixed with cold, soft food (not liquid) and taken immediately.

- **PRESCRIBING AND DISPENSING INFORMATION** Flavours of chewable tablet formulations may include cherry.

- **PATIENT AND CARER ADVICE** Patients or carers should be given advice on how to administer montelukast granules.
  - Medicines for Children leaflet: Montelukast for asthma
    - www.medicinesforchildren.org.uk/montelukast-for-asthma

- **NATIONAL FUNDING/ACCESS DECISIONS**

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (June 2007) that Singulair® granules are restricted for use as an alternative to low-dose inhaled corticosteroids for children 2–14 years with mild persistent asthma who have not recently had serious asthma attacks that required oral corticosteroid use and who are not capable of using inhaled corticosteroids; Singulair® granules should be initiated by a specialist in paediatric asthma.

**Singulair® Chewable Tablets**

The Scottish Medicines Consortium has advised (June 2007) that Singulair® chewable tablets are restricted for use as an alternative to low-dose inhaled corticosteroids for children 2–14 years with mild persistent asthma who have not recently had serious asthma attacks that required oral corticosteroid use and who are not capable of using inhaled corticosteroids; Singulair® chewable tablets should be initiated by a specialist in paediatric asthma.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  - **Granules**
    - Montelukast (as Montelukast sodium) 4 mg
      - Montelukast 4mg granules sachets sugar free sugar-free | 28 sachet [POM] £4.21–£24.41 DT price = £4.26
    - Singulair (Merck Sharp & Dohme Ltd)
      - Montelukast (as Montelukast sodium) 4 mg
        - Singulair Paediatric 4mg granules sachets sugar-free | 28 sachet [POM] £25.69 DT price = £4.26

  - **Tablet**
    - Montelukast (as Montelukast sodium) 10 mg
      - Montelukast 10mg tablets | 28 tablet [POM] £26.97 DT price = £1.61
    - Singulair (Merck Sharp & Dohme Ltd)
      - Montelukast (as Montelukast sodium) 10 mg
        - Singulair 10mg tablets | 28 tablet [POM] £26.97 DT price = £1.61

  - **Chewable tablet**
    - CAUTIONARY AND ADVISORY LABELS 23, 24
      - **EXCIPIENTS:** May contain Aspartame
    - Montelukast (Non-proprietary)
      - Montelukast (as Montelukast sodium) 4 mg
        - Montelukast 4mg chewable tablets sugar free sugar-free | 28 tablet [POM] £25.69 DT price = £1.34
      - Montelukast (as Montelukast sodium) 5 mg
        - Montelukast 5mg chewable tablets sugar free sugar-free | 28 tablet [POM] £25.69 DT price = £1.50
**PATIENT AND CARER ADVICE**

**Overview**

The mode of action of sodium cromoglicate p. 260 and nedocromil sodium below is not completely understood.

They may be of value in asthma with an allergic basis, but, in practice, it is difficult to predict who will benefit; they could probably be given for 4 to 6 weeks to assess response. Dose frequency is adjusted according to response but is usually 3 to 4 times a day initially; this may subsequently be reduced.

In general, *prophylaxis* with sodium cromoglicate is less effective than prophylaxis with corticosteroid inhalations. There is evidence of efficacy of nedocromil sodium in children aged 5–12 years. Sodium cromoglicate and nedocromil sodium are of no value in the treatment of acute attacks of asthma.

Sodium cromoglicate can prevent exercise-induced asthma. However, exercise-induced asthma may reflect poor overall control and the patient should be reassessed.

Sodium cromoglicate and nedocromil sodium may also have a role in allergic conjunctivitis; sodium cromoglicate is used also in allergic rhinitis and allergy-related diarrhoea.

**MAST-CELL STABILISERS**

### Cromoglicate and related therapy

**Overview**

The mode of action of sodium cromoglicate p. 260 and nedocromil sodium below is not completely understood.
**Sodium cromoglicate**

*(Sodium cromoglycate)*

**INDICATIONS AND DOSE**

Prophylaxis of asthma

- **BY INHALATION OF AEROSOL**
  - Child 5–17 years: Initially 10 mg 4 times a day, additional dose may also be taken before exercise, increased if necessary to 10 mg 6–8 times a day; maintenance 5 mg 4 times a day, 5 mg is equivalent to 1 puff
  - Adult: Initially 10 mg 4 times a day, additional dose may also be taken before exercise, increased if necessary to 10 mg 6–8 times a day; maintenance 5 mg 4 times a day, 5 mg is equivalent to 1 puff

**Food allergy (in conjunction with dietary restriction)**

- **BY MOUTH**
  - Child 2–13 years: Initially 100 mg 4 times a day for 2–3 weeks, then increased if necessary up to 40 mg/kg daily, then reduced according to response, to be taken before meals
  - Child 14–17 years: Initially 200 mg 4 times a day for 2–3 weeks, then increased if necessary up to 40 mg/kg daily, then reduced according to response, to be taken before meals
  - Adult: Initially 200 mg 4 times a day for 2–3 weeks, then increased if necessary up to 40 mg/kg daily, then reduced according to response, to be taken before meals

**SIDE-EFFECTS**

- When used by inhalation: Discontinue if eosinophilic pneumonia occurs
- When used by inhalation: Bronchospasm, cough, eosinophilic pneumonia, headache, paradoxical bronchospasm, rhinitis, throat irritation
- With oral use: Joint pain, occasional nausea, rashes

**CAUTIONS**

- When used by inhalation: Discontinue if eosinophilic pneumonia occurs

**INTERACTIONS** → Appendix 1: roflumilast

**SIDE-EFFECTS**

- Common or very common: Abdominal pain, decreased appetite, diarrhoea, headache, insomnia, nausea, weight loss
- Uncommon: Anxiety, back pain, dizziness, dyspepsia, gastritis, gastro-oesophageal reflux, malaise, muscle spasm, myalgia, palpitation, rash, tremor, vertigo, vomiting

**CONTRA-INDICATIONS**

- Cancer (except basal cell carcinoma)
- Concomitant treatment with immunosuppressive drugs (except short-term systemic corticosteroids)
- History of depression associated with suicidal ideation or behaviour — moderate to severe cardiac failure, severe acute infectious disease — severe immunological disease

**PHOSPHODIESTERASE TYPE-4 INHIBITORS**

**Roflumilast**

**DRUG ACTION**

Roflumilast is a phosphodiesterase type-4 inhibitor with anti-inflammatory properties.

**INDICATIONS AND DOSE**

Adjunct to bronchodilators for the maintenance treatment of patients with severe chronic obstructive pulmonary disease associated with chronic bronchitis and a history of frequent exacerbations

- **BY MOUTH**
  - Adult: 500 micrograms once daily
### Aminophylline

**INDICATIONS AND DOSE**

**Severe acute asthma in patients not previously treated with theophylline**

- **BY SLOW INTRAVENOUS INJECTION**
  - Child: 5 mg/kg (max. per dose 500 mg), to be followed by intravenous infusion
  - Adult: 250–500 mg (max. per dose 5 mg/kg), to be followed by intravenous infusion

**Severe acute asthma**

- **BY INTRAVENOUS INFUSION**
  - Child 1 month–11 years: 1 mg/kg/hour, adjusted according to plasma-theophylline concentration
  - Child 12–17 years: 500–700 micrograms/kg/hour, adjusted according to plasma-theophylline concentration
  - Adult: 500–700 micrograms/kg/hour, adjusted according to plasma-theophylline concentration
  - Elderly: 300 micrograms/kg/hour, adjusted according to plasma-theophylline concentration

**Severe acute exacerbation of chronic obstructive pulmonary disease in patients not previously treated with theophylline**

- **BY SLOW INTRAVENOUS INJECTION**
  - Adult: 250–500 mg (max. per dose 5 mg/kg), to be followed by intravenous infusion

**Severe acute exacerbation of chronic obstructive pulmonary disease**

- **BY INTRAVENOUS INFUSION**
  - Adult: 500–700 micrograms/kg/hour, adjusted according to plasma–theophylline concentration
  - Elderly: 300 micrograms/kg/hour, adjusted according to plasma–theophylline concentration

**Chronic asthma**

- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Child (body-weight 40 kg and above): Initially 225 mg twice daily for 1 week, then increased if necessary to 450 mg twice daily, adjusted according to plasma–theophylline concentration

**Reversible airway obstruction**

- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Adult (body-weight 40 kg and above): Initially 225 mg twice daily for 1 week, then increased if necessary to 450 mg twice daily, adjusted according to plasma–theophylline concentration

---

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Daxas (AstraZeneca UK Ltd)**
  - Roflumilast 500 microgram | 30 tablet (POM) £37.71 DT price = £37.71

**SYMPATHOMIMETICS ➔ VASOCONSTRICTOR**

**Ephedrine hydrochloride**

- **INDICATIONS AND DOSE**
  - **Reversal of hypotension from spinal or epidural anaesthesia**
    - **BY SLOW INTRAVENOUS INJECTION**
    - Adult: 3–6 mg every 3–4 minutes (max. per dose 9 mg), adjusted according to response, injection solution to contain ephedrine hydrochloride 3 mg/ml; maximum 30 mg per course
  - **Reversible airways obstruction**
    - **BY MOUTH**
    - Adult: 15–60 mg 3 times a day
  - **Neuropathic oedema**
    - **BY MOUTH**
    - Adult: 30–60 mg 3 times a day

- **UNLICENSED USE** Not licensed for neuropathic oedema.

**CAUTIONS**

**GENERAL CAUTIONS**

- Diabetes mellitus - elderly - hypertension - hyperthyroidism - ischaemic heart disease - prostatic hypertrophy (risk of acute urinary retention)

**SPECIFIC CAUTIONS**

- With intravenous use Susceptibility to angle-closure glaucoma

**INTERACTIONS** ➔ Appendix 1: sympathomimetics, vasoconstrictor

**SIDE-EFFECTS**

- **Common or very common** Anxiety, arrhythmias, insomnia, restlessness, tachycardia, tremor
- With intravenous use: Anginal pain, anorexia, changes in blood-glucose concentration, confusion, difficulty in micturition, dizziness, dyspnoea, flushing, headache, hypersalivation, nausea, psychoses, sweating, urine retention, vasodilatation with hypertension, vomiting

- **Very rare**
  - With intravenous use: Angle-closure glaucoma
  - **Frequency not known** Increased lacrimation (can have adverse effects on contact lens wear)
- With intravenous use: Bradycardia
- With oral use: Cold extremities, dry mouth

**PREGNANCY**

- With oral use: Manufacturer advises avoid.
- With intravenous use: Increased fetal heart rate reported with parenteral ephedrine.

**BREAST FEEDING**

- Present in milk; manufacturer advises avoid—irritability and disturbed sleep reported.

**RENAI IMPAIRMENT** Use with caution.

**LESS SUITABLE FOR PRESCRIBING**

- Ephedrine tablets are less suitable and less safe for use as a bronchodilator than the selective beta₂ agonists.

**EXCEPTIONS TO LEGAL CATEGORY**


---

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, solution for injection

**Tablet**

- **Ephedrine hydrochloride (Non-proprietary)**
  - Ephedrine hydrochloride 15 mg Ephedrine hydrochloride 15 mg tablets | 28 tablet (POM) £36.25 DT price = £30.22
  - Ephedrine hydrochloride 30 mg Ephedrine hydrochloride 30 mg tablets | 28 tablet (POM) £54.03 DT price = £46.56

**Solution for injection**

- **Ephedrine hydrochloride (Non-proprietary)**
  - Ephedrine hydrochloride 3 mg per 1 ml Ephedrine 30 mg/10 ml solution for injection ampoules | 10 ampoule (POM) £76.87
  - Ephedrine 30 mg/10 ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (POM) £75.99–£9.50 | 12 pre-filled disposable injection (POM) £114.00
  - Ephedrine hydrochloride 30 mg per 1 ml Ephedrine 30 mg/1 ml solution for injection ampoules | 10 ampoule (POM) £4.98–£5.03

**XANTHINES**

**Aminophylline**

- **INDICATIONS AND DOSE**
  - **Severe acute asthma in patients not previously treated with theophylline**
    - **BY SLOW INTRAVENOUS INJECTION**
    - Child: 5 mg/kg (max. per dose 500 mg), to be followed by intravenous infusion
    - Adult: 250–500 mg (max. per dose 5 mg/kg), to be followed by intravenous infusion
  - **Severe acute asthma**
    - **BY INTRAVENOUS INFUSION**
    - Child 1 month–11 years: 1 mg/kg/hour, adjusted according to plasma–theophylline concentration
    - Child 12–17 years: 500–700 micrograms/kg/hour, adjusted according to plasma–theophylline concentration
    - Adult: 500–700 micrograms/kg/hour, adjusted according to plasma–theophylline concentration
    - Elderly: 300 micrograms/kg/hour, adjusted according to plasma–theophylline concentration
  - **Severe acute exacerbation of chronic obstructive pulmonary disease in patients not previously treated with theophylline**
    - **BY SLOW INTRAVENOUS INJECTION**
    - Adult: 250–500 mg (max. per dose 5 mg/kg), to be followed by intravenous infusion
  - **Severe acute exacerbation of chronic obstructive pulmonary disease**
    - **BY INTRAVENOUS INFUSION**
    - Adult: 500–700 micrograms/kg/hour, adjusted according to plasma–theophylline concentration
    - Elderly: 300 micrograms/kg/hour, adjusted according to plasma–theophylline concentration
  - **Chronic asthma**
    - **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
    - Child (body-weight 40 kg and above): Initially 225 mg twice daily for 1 week, then increased if necessary to 450 mg twice daily, adjusted according to plasma–theophylline concentration
  - **Reversible airway obstruction**
    - **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
    - Adult (body-weight 40 kg and above): Initially 225 mg twice daily for 1 week, then increased if necessary to 450 mg twice daily, adjusted according to plasma–theophylline concentration

---

**BNF 74**

Airways disease, obstructive 261

Respiratory system 3
PHYLLOCOTIN CONTINUOUS® FORTE
Reversible airways obstruction

- By mouth using modified-release medicines
- Adult: Initially 350 mg twice daily for 1 week, then increased if necessary to 700 mg twice daily, increase dose according to plasma-theophylline concentration

DOSE ADJUSTMENTS DUE TO INTERACTIONS
Dose adjustment may be necessary if smoking started or stopped during treatment.

DOSES AT EXTREMES OF BODY-WEIGHT
To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal weight for height.

PHARMACOKINETICS
Aminophylline is a stable mixture or combination of theophylline and ethylenediamine; the ethylenediamine confers greater solubility in water. Theophylline is metabolised in the liver. The plasma-theophylline concentration is increased in heart failure, hepatic impairment, and in viral infections. The plasma-theophylline concentration is decreased in smokers, and by alcohol consumption. Differences in the half-life of aminophylline are important because the toxic dose is close to the therapeutic dose.

- UNLICENSED USE Aminophylline injection not licensed for use in children under 6 months.
- CAUTIONS Arrhythmias following rapid intravenous injection - cardiac arrhythmias or other cardiac disease - elderly (increased plasma-theophylline concentration) - epilepsy - fever - hypertension - hyperthyroidism - peptic ulcer - risk of hypokalaemia
- INTERACTIONS → Appendix 1: aminophylline
- SIDE-EFFECTS Arrhythmias (especially if given rapidly by intravenous injection) - CNS stimulation - convulsions (especially if given rapidly by intravenous injection) - diarrhoea - gastric irritation - headache - hypotension (especially if given rapidly by intravenous injection) - insomnia - nausea - palpitation - tachycardia - vomiting
- SIDE-EFFECTS, FURTHER INFORMATION Hypokalaemia Potentially serious hypokalaemia may result from beta, agonist therapy. Particular caution is required in severe asthma, because this effect may be potentiated by concomitant treatment with theophylline and its derivatives, corticosteroids, and diuretics, and by hypoxia. Plasma-potassium concentration should therefore be monitored in severe asthma.

Overdose
Theophylline and related drugs are often prescribed as modified-release formulations and toxicity can therefore be delayed. They cause vomiting (which may be severe and intractable), agitation, restlessness, dilated pupils, sinus tachycardia, and hyperglycaemia. More serious effects are haematemesis, convulsions, and supraventricular and ventricular arrhythmias. Severe hypokalaemia may develop rapidly.

For specific details on the management of poisoning, see Theophylline, under Emergency treatment of poisoning p. 1254.

- ALLERGY AND CROSS-SENSITIVITY Allergy to ethylenediamine can cause urticaria, erythema, and exfoliative dermatitis.
- PREGNANCY Neonatal irritability and apnoea have been reported. Theophylline can be taken as normal during pregnancy as it is particularly important that asthma should be well controlled during pregnancy.
- BREAST FEEDING Present in milk—irritability in infant reported; modified-release preparations preferable. Theophylline can be taken as normal during breastfeeding.
- HEPATIC IMPAIRMENT Reduce dose.

- MONITORING REQUIREMENTS Aminophylline is monitored therapeutically in terms of plasma-theophylline concentrations.
- Measurement of plasma-theophylline concentration may be helpful and is essential if a loading dose of intravenous aminophylline is to be given to patients who are already taking theophylline, because serious side-effects such as convulsions and arrhythmias can occasionally precede other symptoms of toxicity.
- In most individuals, a plasma-theophylline concentration of 10–20 mg/litre (55–110 micromol/litre) is required for satisfactory bronchodilation, although a lower plasma-theophylline concentration of 5–15 mg/litre may be effective. Adverse effects can occur within the range 10–20 mg/litre and both the frequency and severity increase at concentrations above 20 mg/litre.
- If aminophylline is given intravenously, a blood sample should be taken 4–6 hours after starting treatment.
- With oral use Plasma-theophylline concentration is measured 5 days after starting oral treatment and at least 3 days after any dose adjustment. A blood sample should usually be taken 4–6 hours after an oral dose of a modified-release preparation (sampling times may vary consult local guidelines).

- DIRECTIONS FOR ADMINISTRATION With intravenous use For intravenous injection, give very slowly over at least 20 minutes (with close monitoring).
- With intravenous use in children For intravenous infusion, dilute to a concentration of 1 mg/mL with Glucose 5% or Sodium Chloride 0.9%.
- With intravenous use in adults For intravenous infusion, give continuously in Glucose 5% or Sodium Chloride 0.9%.
- With intramuscular use Aminophylline is too irritant for intramuscular use.

- PRESCRIBING AND DISPENSING INFORMATION Patients taking oral theophylline or aminophylline should not normally receive a loading dose of intravenous aminophylline.

Consider intravenous aminophylline for treatment of severe and life-threatening acute asthma only after consultation with senior medical staff.

- Modified release The rate of absorption from modified-release preparations can vary between brands. If a prescription for a modified-release oral aminophylline preparation does not specify a brand name, the pharmacist should contact the prescriber and agree the brand to be dispensed. Additionally, it is essential that a patient discharged from hospital should be maintained on the brand on which that patient was stabilised as an in-patient.

PHYLLOCOTIN CONTINUOUS® FORTE
Phyllocontin Continus® Forte tablets are for smokers and other patients where theophylline half-life is shorter.

- MEDICINAL FORMS There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for infusion

Solution for injection
- Aminophylline (Non-proprietary) Aminophylline 25 mg per 1 ml Aminophylline 250mg/10ml solution for injection ampoules 10 ampoule Pack £6.50 DT price = £6.50

Modified-release tablet

CAUTIONARY AND ADVISORY LABELS 25
- Aminophylline (Non-proprietary) Aminophylline hydrate 225 mg Aminophylline hydrate 225mg modified-release tablets 56 tablet Pack £2.40 DT price = £2.40
- Phyllocontin Continus® (Napp Pharmaceuticals Ltd) Aminophylline hydrate 225 mg Phyllocontin Continus 225mg tablets 56 tablet Pack £2.40 DT price = £2.40

Aminophylline hydrate 350 mg Phyllocontin Forte Continus 350mg tablets 56 tablet Pack £4.22 DT price = £4.22
Theophylline

**INDICATIONS AND DOSE**

**NUELIN SA ® 175MG TABLETS**

**Reversible airways obstruction | Severe acute asthma | Chronic asthma**

- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Adult: 175–350 mg every 12 hours

**Chronic asthma**

- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Child 6–11 years: 175 mg every 12 hours
  - Child 12–17 years: 175–350 mg every 12 hours

**NUELIN SA ® 250 TABLETS**

**Reversible airways obstruction | Severe acute asthma | Chronic asthma**

- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Adult: 250–500 mg every 12 hours

**Chronic asthma**

- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Child 6–11 years: 125–250 mg every 12 hours
  - Child 12–17 years: 250–500 mg every 12 hours

**SLO-PHYLLIN ®**

**Chronic asthma**

- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Child 2–5 years: 60–120 mg every 12 hours
  - Child 6–11 years: 125–250 mg every 12 hours
  - Child 12–17 years: 250–500 mg every 12 hours

**UNIPHYLLIN CONTINUS ®**

**Chronic asthma**

- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Child 2–11 years: 9 mg/kg every 12 hours (max. per dose 200 mg), dose may be increased in some children with chronic asthma; increased to 10–16 mg/kg every 12 hours (max. per dose 400 mg), may be appropriate to give larger evening or morning dose to achieve optimum therapeutic effect when symptoms most severe; in patients whose night or daytime symptoms persist despite other therapy, who are not currently receiving theophylline, total daily requirement may be added as single evening or morning dose
  - Child 12–17 years: 200 mg every 12 hours, adjusted according to response to 400 mg every 12 hours, may be appropriate to give larger evening or morning dose to achieve optimum therapeutic effect when symptoms most severe; in patients whose night or daytime symptoms persist despite other therapy, who are not currently receiving theophylline, total daily requirement may be added as single evening or morning dose

**Reversible airways obstruction | Severe acute asthma | Chronic asthma**

- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Adult: 200 mg every 12 hours, adjusted according to response to 400 mg every 12 hours, may be appropriate to give larger evening or morning dose to achieve optimum therapeutic effect when symptoms most severe; in patients whose night or daytime symptoms persist despite other therapy, who are not currently receiving theophylline, total daily requirement may be added as single evening or morning dose

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**

Dose adjustment may be necessary if smoking started or stopped during treatment.

**PHARMACOKINETICS**

Theophylline is metabolised in the liver. The plasma-theophylline concentration is increased in heart failure, hepatic impairment, and in viral infections. The plasma-theophylline concentration is decreased in smokers, and by alcohol consumption. Differences in the half-life of theophylline are important because the toxic dose is close to the therapeutic dose.

**UNLICENSED USE**

*Slo-phyllin ®* capsules not licensed for use in children under 2 years.

**CAUTIONS**

- Cardiac arrhythmias or other cardiac disease • elderley (increased plasma-theophylline concentration) • epilepsy • fever • hypertension • hyperthyroidism • peptic ulcer • risk of hypokalaemia

**INTERACTIONS**

- Appendix 1: theophylline

**SIDE-EFFECTS**

- Arrhythmias • CNS stimulation • convulsions • diarrhoea • gastric irritation • headache • insomnia • nausea • palpitation • tachycardia • vomiting

**SIDE-EFFECTS. FURTHER INFORMATION**

- Hypokalaemia Potentially serious hypokalaemia may result from beta agonist therapy. Particular caution is required in severe asthma, because this effect may be potentiated by concomitant treatment with theophylline and its derivatives, corticosteroids, and diuretics, and by hypoxia. Plasma-potassium concentration should therefore be monitored in severe asthma.

**Overdose**

Theophylline in overdose can cause vomiting (which may be severe and intractable), agitation, restlessness, dilated pupils, sinus tachycardia, and hyperglycaemia. More serious effects are haematemesis, convulsions, and supraventricular and ventricular arrhythmias. Severe hypokalaemia may develop rapidly.

For details on the management of poisoning, see Theophylline, under Emergency treatment of poisoning p. 1254.

**PREGNANCY**

Neonatal irritability and apnoea have been reported. Theophylline can be taken as normal during pregnancy as it is particularly important that asthma should be well controlled during pregnancy.

**BREAST FEEDING**

Present in milk — irriatbility in infant reported; modified-release preparations preferable. Theophylline can be taken as normal during breast-feeding.

**HEPATIC IMPAIRMENT**

Reduce dose.

**MONITORING REQUIREMENTS**

- In most individuals, a plasma-theophylline concentration of 10–20 mg/litre (55–110 micromol/litre) is required for satisfactory bronchodilatation, although a lower plasma-theophylline concentration of 5–15 mg/litre may be effective. Adverse effects may occur within the range 10–20 mg/litre and both the frequency and severity increase at concentrations above 20 mg/litre.

- Plasma-theophylline concentration is measured 5 days after starting oral treatment and at least 3 days after any dose adjustment. A blood sample should usually be taken 4–6 hours after an oral dose of a modified-release preparation (sampling times may vary — consult local guidelines).

**DIRECTIONS FOR ADMINISTRATION**

**SLO-PHYLLIN ®**

- In adults — Swallow whole with fluid or swallow enclosed granules with soft food (e.g. yoghurt).
- In children — Contents of the capsule (enteric-coated granules) may be sprinkled on to a spoonful of soft food (e.g. yoghurt) and swallowed without chewing.

**PRESCRIBING AND DISPENSING INFORMATION**

The rate of absorption from modified-release preparations can vary between brands. If a prescription for a modified-release
oral theophylline preparation does not specify a brand name, the pharmacist should contact the prescriber and agree the brand to be dispensed. Additionally, it is essential that a patient discharged from hospital should be maintained on the brand on which that patient was stabilised as in-patient.

**PATIENT AND CARER ADVICE**

SLO-PHYLLIN® Patient or carer should be given advice on how to administer theophylline modified release capsules.

**MEDICINAL FORMS**

There can be variation in the licencing of different medicines containing the same drug.

**Modified-release tablet**

CAUTIONARY AND ADVISORY LABELS 21, 25

- **Nuelin SA** (Meda Pharmaceuticals Ltd)
  - Theophylline 175 mg Nuelin SA 175mg tablets | 60 tablet £6.38 DT price = £5.38
  - Theophylline 250 mg Nuelin SA 250 tablets | 60 tablet £8.92 DT price = £8.92
- **Uniphyll Continus** (Napp Pharmaceuticals Ltd)
  - Theophylline 200 mg Uniphyll Continus 200mg tablets | 56 tablet £2.96 DT price = £2.96
  - Theophylline 300 mg Uniphyll Continus 300mg tablets | 56 tablet £4.77 DT price = £4.77
  - Theophylline 400 mg Uniphyll Continus 400mg tablets | 56 tablet £5.65 DT price = £5.65

**Modified-release capsule**

CAUTIONARY AND ADVISORY LABELS 25

- **Slo-Phyllin** (Merck Serono Ltd)
  - Theophylline 60 mg Slo-Phyllin 60mg capsules | 56 capsule £2.76 DT price = £2.76
  - Theophylline 125 mg Slo-Phyllin 125mg capsules | 56 capsule £3.48 DT price = £3.48
  - Theophylline 250 mg Slo-Phyllin 250mg capsules | 56 capsule £4.34 DT price = £4.34

---

**Nebuliser solutions**

**INDICATIONS AND DOSE**

**MUCOCLEAR® 3%**

- **INDICATIONS AND DOSE**
  - **NEBUSAL®**
    - Mobilise lower respiratory tract secretions in mucous consolidation (e.g. cystic fibrosis)
    - **BY INHALATION OF NEBULISED SOLUTION**
    - Adult: 4 mL up to twice daily, temporary irritation, such as coughing, hoarseness, or reversible bronchoconstriction may occur; an inhaled bronchodilator can be used before treatment with hypertonic sodium chloride to reduce the risk of these adverse effects

- **PEAK FLOW METERS**
  - **LOW RANGE PEAK FLOW METERS**
    - **MEDI® LOW RANGE**
    - **MINI-WRIGHT® LOW RANGE**
    - **POCKETPEAK® LOW RANGE**
    - **nSpire Pocket Peak peak flow meter low range** (nSpire Health Ltd)
      - 1 device • NHS indicative price = £6.50 • Drug Tariff (Part Ixa) price = £6.50

- **STANDARD RANGE PEAK FLOW METERS**
  - **AIRZONE®**
  - **MEDI® STANDARD RANGE**
  - **MINI-WRIGHT® STANDARD RANGE**

- **INDICATIONS AND DOSE**

  - **MUCOCLEAR® 6%**
    - Mobilise lower respiratory tract secretions in mucous consolidation (e.g. cystic fibrosis)
      - **BY INHALATION OF NEBULISED SOLUTION**
      - Adult: 4 mL twice daily, temporary irritation, such as coughing, hoarseness, or reversible bronchoconstriction may occur; an inhaled bronchodilator can be used before treatment with hypertonic sodium chloride to reduce the risk of these adverse effects

**INDICATIONS AND DOSE**

**MUCOCLEAR® 6%**

- **INDICATIONS AND DOSE**
  - **NEBUSAL®**
    - Mobilise lower respiratory tract secretions in mucous consolidation (e.g. cystic fibrosis)
    - **BY INHALATION OF NEBULISED SOLUTION**
    - Adult: 4 mL up to twice daily, temporary irritation, such as coughing, hoarseness, or reversible bronchoconstriction may occur; an inhaled bronchodilator can be used before treatment with hypertonic sodium chloride to reduce the risk of these adverse effects

- **PEAK FLOW METERS**
  - **LOW RANGE PEAK FLOW METERS**
    - **MEDI® LOW RANGE**
    - **MINI-WRIGHT® LOW RANGE**
    - **POCKETPEAK® LOW RANGE**
    - **nSpire Pocket Peak peak flow meter low range** (nSpire Health Ltd)
      - 1 device • NHS indicative price = £6.50 • Drug Tariff (Part Ixa) price = £6.50

- **STANDARD RANGE PEAK FLOW METERS**
  - **AIRZONE®**
  - **MEDI® STANDARD RANGE**
  - **MINI-WRIGHT® STANDARD RANGE**
Spacers

- **SPACERS**
  - **AA2 SPACER**
    - For use with all pressurised (aerosol) inhalers.
    - **AA2 Spacer** (Clement Clarke International Ltd) | 1 device - NHS indicative price = £4.15 • Drug Tariff (Part IXa)
    - **AA2 Spacer with medium mask** (Clement Clarke International Ltd) | 1 device - NHS indicative price = £6.68 • Drug Tariff (Part IXa)
    - **AA2 Spacer with small mask** (Clement Clarke International Ltd) | 1 device - NHS indicative price = £4.83 • Drug Tariff (Part IXa)
  - **ABLE SPACER**
    - Small-volume device. For use with all pressurised (aerosol) inhalers.
    - **Able Spacer** (Clement Clarke International Ltd) | 1 device - NHS indicative price = £4.39 • Drug Tariff (Part IXa)
    - **Able Spacer with medium mask** (Clement Clarke International Ltd) | 1 device - NHS indicative price = £7.16 • Drug Tariff (Part IXa)
    - **Able Spacer with small mask** (Clement Clarke International Ltd) | 1 device - NHS indicative price = £7.16 • Drug Tariff (Part IXa)
  - **AEROCHAMBER PLUS**
    - Medium-volume device. For use with all pressurised (aerosol) inhalers.
    - **AeroChamber Plus** (GlaxoSmithKline UK Ltd) | 1 device - NHS indicative price = £4.86 • Drug Tariff (Part IXa)
    - **AeroChamber Plus with adult mask** (GlaxoSmithKline UK Ltd) | 1 device - NHS indicative price = £8.11 • Drug Tariff (Part IXa)
    - **AeroChamber Plus with child mask** (GlaxoSmithKline UK Ltd) | 1 device - NHS indicative price = £8.11 • Drug Tariff (Part IXa)
    - **AeroChamber Plus with infant mask** (GlaxoSmithKline UK Ltd) | 1 device - NHS indicative price = £8.11 • Drug Tariff (Part IXa)
  - **BABYHALER**
    - For paediatric use with Flixotide®, and Ventolin® inhalers.

**PRESCRIBING AND DISPENSING INFORMATION**

Not available for NHS prescription.

- **Babyhaler** (Allen & Hanburys Ltd) | 1 device - No NHS indicative price available • Drug Tariff (Part IXa)

**HALERAI D**

- Device to place over pressurised (aerosol) inhalers to aid when strength in hands is impaired (e.g. in arthritis). For use with Flixotide®, Seretide®, Serevent®, and Ventolin® inhalers.

**PRESCRIBING AND DISPENSING INFORMATION**

Not available for NHS prescription.

- **Haleraid-120** (Allen & Hanburys Ltd) | 1 device - No NHS indicative price available • Drug Tariff (Part IXa)
- **Haleraid-200** (Allen & Hanburys Ltd) | 1 device - No NHS indicative price available • Drug Tariff (Part IXa)

**OPTICHAMBER**

- For use with all pressurised (aerosol) inhalers.
  - **Optichamber** (Respironics (UK) Ltd) | 1 device - NHS indicative price = £4.28 • Drug Tariff (Part IXa)
  - **Optichamber Diamond**
    - For use with all pressurised (aerosol) inhalers.

**2 Allergic conditions**

**Antihistamines, allergen immunotherapy and allergic emergencies**

**Antihistamines**

All antihistamines are of potential value in the treatment of nasal allergies, particularly seasonal allergic rhinitis (hayfever), and they may be of some value in vasomotor rhinitis. They reduce rhinorrhoea and sneezing but are usually less effective for nasal congestion. Antihistamines are used topically in the eye, in the nose, and on the skin.
Oral antihistamines are also of some value in preventing urticaria and are used to treat urticarial rashes, pruritus, and insect bites and stings; they are also used in drug allergies. Injections of chlorphenamine maleate p. 272 or promethazine hydrochloride p. 275 are used as an adjunct to adrenaline/epinephrine p. 216 in the emergency treatment of anaphylaxis and angioedema. Antihistamines (including cinnarizine p. 416, cyclizine p. 409, and promethazine teoclact p. 417) may also have a role in nausea and vomiting. Buclizine is included as an anti-emetic in a preparation for migraine. Antihistamines may also have a role in occasional insomnia.

All older antihistamines cause sedation but alimemazine tartept p. 271 and promethazine may be more sedating whereas chlorphenamine maleate and cyclizine may be less so. This sedating activity is sometimes used to manage the pruritus associated with some allergies. There is little evidence that any one of the older, ‘sedating’ antihistamines is superior to another and patients vary widely in their response.

Non-sedating antihistamines such as acrivastine p. 267, bilastine p. 268, cetirizine hydrochloride p. 268, desloratadine p. 269 (an active metabolite of loratadine p. 270), fexofenadine hydrochloride p. 269 (an active metabolite of terfenadine), levocetirizine hydrochloride p. 270 (an isomer of cetirizine hydrochloride), loratadine, and mizolastine p. 271 cause less sedation and psychomotor impairment than the older antihistamines because they penetrate the blood brain barrier only to a slight extent.

**Allergen immunotherapy**

Immunotherapy using allergen vaccines containing house dust mite, animal dander (cat or dog), or extracts of grass, tree, and dust mite, animal dander (cat or dog), or extracts of grass, tree, dust mite, house dust, etc. can reduce symptoms of asthma and allergic rhinoconjunctivitis. A vaccine containing extracts of wasp and bee venom is used to reduce the risk of severe anaphylaxis and systemic reactions in individuals with hypersensitivity to wasp and bee stings. An oral preparation of grass pollen extract (Grazax®) is also licensed for disease-modifying treatment of grass pollen–induced rhinitis and conjunctivitis. Those requiring immunotherapy must be referred to a hospital specialist for accurate diagnosis, assessment, and treatment.

Omalizumab p. 256 is a monoclonal antibody that binds to immunoglobulin E (IgE). It is used as additional therapy in individuals with proven IgE-mediated sensitization to inhalable allergens, whose severe persistent allergic asthma cannot be controlled adequately with high dose inhaled corticosteroid together with a long-acting beta agonist. Omalizumab should be initiated by physicians in specialist centres experienced in the treatment of severe persistent asthma. Omalizumab is also indicated as add-on therapy for the treatment of chronic spontaneous urticaria in patients who have had an inadequate response to H1 antihistamine treatment.

**Allergic emergencies**

**Anaphylaxis**

Anaphylaxis is a severe, life-threatening, generalised or systemic hypersensitivity reaction. It is characterised by the rapid onset of respiratory and/or circulatory problems and is usually associated with skin and mucosal changes; prompt treatment is required. Patients with pre-existing asthma, especially poorly controlled asthma, have a particular risk of life-threatening reactions. Insect stings are a recognised risk (in particular wasp and bee stings). Latex and certain foods, including eggs, fish, cow’s milk protein, peanuts, sesame, shellfish, soy, and tree nuts may also precipitate anaphylaxis (see Food allergy p. 82). Medicinal products particularly associated with anaphylaxis include blood products, vaccines, hyposensitising (allergen) preparations, antibacterials, aspirin and other NSAIDs, and neuromuscular blocking drugs. In the case of drugs, anaphylaxis is more likely after parenteral administration; resuscitation facilities must always be available for injections associated with special risk. Anaphylactic reactions may also be associated with additives and excipients in foods and medicines. Refined arachis (peanut) oil, which may be present in some medicinal products, is unlikely to cause an allergic reaction—nevertheless it is wise to check the full formula of preparations which may contain allergens.

**Treatment of anaphylaxis**

Adrenaline/epinephrine provides physiological reversal of the immediate symptoms associated with hypersensitivity reactions such as anaphylaxis and angioedema.

First-line treatment includes:

- securing the airway, restoration of blood pressure (laying the patient flat and raising the legs, or in the recovery position if unconscious or nauseous and at risk of vomiting);
- administering adrenaline/epinephrine (by intramuscular injection in a dose of 500 micrograms (a dose of 300 micrograms may be appropriate for immediate self-administration); the dose should be repeated if necessary at 5-minute intervals according to blood pressure, pulse, and respiratory function. Patients receiving beta-blockers require special consideration;
- administering high-flow oxygen and intravenous fluids is also of primary importance;
- administering an antihistamine such as chlorphenamine maleate, by slow intravenous injection or intramuscular injection is a useful adjunctive treatment, given after adrenaline.

- Administering an intravenous corticosteroid such as hydrocortisone p. 637 (preferably as sodium succinate) is of secondary value in the initial management of anaphylaxis because the onset of action is delayed for several hours, but should be given to prevent further deterioration in severely affected patients.

**Continuing respiratory deterioration** requires further treatment with bronchodilators including inhaled or intravenous salbutamol p. 244, inhaled ipratropium bromide p. 239, intravenous aminophylline p. 261, or intravenous magnesium sulfate p. 963 [uncensored indication] (as for acute severe asthma); in addition to oxygen, assisted respiration and possibly emergency tracheotomy may be necessary.

When a patient is so ill that there is doubt about the adequacy of the circulation, the initial injection of adrenaline/epinephrine may need to be given as a dilute solution by the intravenous route.

Cardiopulmonary arrest may follow an anaphylactic reaction; resuscitation should be started immediately. On discharge, patients should be considered for further treatment with an oral antihistamine and an oral corticosteroid for up to 3 days to reduce the risk of further reaction. Patients should be instructed to return to hospital if symptoms recur and to contact their general practitioner for follow-up.

- Patients who are suspected of having had a anaphylactic reaction should be referred to a specialist for specific allergy diagnosis. Avoidance of the allergen is the principal treatment; if appropriate, an adrenaline/epinephrine auto-injector should be given for self-administration or a replacement supplied.

**Intramuscular adrenaline (epinephrine)**

The intramuscular route is the first choice route for the administration of adrenaline/epinephrine in the management of anaphylaxis. Adrenaline/epinephrine is best given as an intramuscular injection into the anterolateral aspect of the middle third of the thigh; it has a rapid onset of action after intramuscular administration and in the shocked patient its absorption from the intramuscular site is faster and more reliable than from the subcutaneous site.
Patients with severe allergy should be instructed in the self-administration of adrenaline/epinephrine p. 216 by intramuscular injection.

Prompt injection of adrenaline/epinephrine is of paramount importance. The adrenaline/epinephrine doses recommended for the emergency treatment of anaphylaxis by appropriately trained healthcare professionals are based on the revised recommendations of the Working Group of the Resuscitation Council (UK).

### Dose of intramuscular injection of adrenaline (epinephrine) for the emergency treatment of anaphylaxis by healthcare professionals

<table>
<thead>
<tr>
<th>Age</th>
<th>Dose</th>
<th>Volume of adrenaline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Child 1 month–5 years</td>
<td>150 micrograms</td>
<td>0.15 mL 1 in 1000 (1 mg/mL) adrenaline¹</td>
</tr>
<tr>
<td>Child 6–11 years</td>
<td>300 micrograms</td>
<td>0.3 mL 1 in 1000 (1 mg/mL) adrenaline</td>
</tr>
<tr>
<td>Child 12–17 years</td>
<td>500 micrograms</td>
<td>0.5 mL 1 in 1000 (1 mg/mL) adrenaline¹</td>
</tr>
<tr>
<td>Adult</td>
<td>500 micrograms</td>
<td>0.5 mL 1 in 1000 (1 mg/mL) adrenaline</td>
</tr>
</tbody>
</table>

These doses may be repeated several times if necessary at 5-minute intervals according to blood pressure, pulse and respiratory function.

1. Use suitable syringe for measuring small volume
2. 300 micrograms (0.3 mL) if child is small or prepubertal

**Intravenous adrenaline (epinephrine)**

Intravenous adrenaline/epinephrine should be given only by appropriately trained healthcare professionals based on the revised recommendations of the Working Group of the Resuscitation Council (UK). When the patient is severely ill and there is real doubt about the adequacy of the circulation and absorption after intramuscular injection, adrenaline/epinephrine can be given by slow intravenous injection repeated according to response; if multiple doses are required, adrenaline/epinephrine should be given as a slow intravenous infusion stopping when a response has been obtained.

It is important that, where intramuscular injection might still succeed, time should not be wasted seeking intravenous access.

The intravenous route is also used for cardiac resuscitation.

**Angioedema**

Angioedema is dangerous if laryngeal oedema is present. In this circumstance adrenaline/epinephrine injection and oxygen should be given as described under Anaphylaxis; antihistamines and corticosteroids should also be given. Tracheal intubation may be necessary.

**Hereditary angioedema**

The treatment of hereditary angioedema should be under specialist supervision. Unlike allergic angioedema, adrenaline/epinephrine, corticosteroids, and antihistamines should not be used for the treatment of acute attacks, including attacks involving laryngeal oedema, as they are ineffective and may delay appropriate treatment—intubation may be necessary. The administration of C1-esterase inhibitor p. 279, an endogenous complement blocker derived from human plasma, (in fresh frozen plasma or in partially purified form) can terminate acute attacks of hereditary angioedema; it can also be used for short-term prophylaxis before dental, medical or surgical procedures. Conestat alfa p. 279 and icatibant p. 279 are licensed for the treatment of acute attacks of hereditary angioedema in adults with C1-esterase inhibitor deficiency.

Tranexamic acid p. 107 and danazol p. 699 [unlicensed indication] are used for short-term and long-term prophylaxis of hereditary angioedema. Short-term prophylaxis with tranexamic acid or danazol is started several days before planned procedures (e.g. dental work) and continued for 2–5 days afterwards. Danazol should be avoided in children because of its androgenic effects.

### ANTIHISTAMINES > NON-SEDATING

#### Acrivastine

**INDICATIONS AND DOSE**

Symptomatic relief of allergy such as hay fever, chronic idiopathic urticaria

- **BY MOUTH**
  - Child 12–17 years: 8 mg 3 times a day
  - Adult: 8 mg 3 times a day

**CONTRA-INDICATIONS**

Avoid in acute porphyrias p. 969 (some antihistamines are thought to be safe) • elderly

**SIDE-EFFECTS**

- **Uncommon** Antimuscarinic effects • gastro-intestinal disturbances • headache • psychomotor impairment
- **Rare** Anaphylaxis • angioedema • angle-closure glaucoma (in adults) • arrhythmias • blood disorders • bronchospasm • confusion • convulsions • depression • dizziness • extrapyramidal effects • hypersensitivity reactions • hypotension • liver dysfunction • palpitation • photosensitivity reactions • rashes • sleep disturbances • tremor
- **Frequency not known** Blurred vision • drowsiness • dry mouth • urinary retention

**SIDE-EFFECTS, FURTHER INFORMATION**

Non-sedating antihistamines such as acrivastine cause less sedation and psychomotor impairment than the older antihistamines because they penetrate the blood brain barrier only to a slight extent. If drowsiness occurs, it may diminish after a few days of treatment.

Children and the elderly are more susceptible to side-effects.

**ALLERGY AND CROSS-SENSITIVITY**

Contra-indicated if history of hypersensitivity to triprolidine.

**PREGNANCY**

Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is no evidence of teratogenicity.

**BREAST FEEDING**

Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

**RENAI IMPAIRMENT**

Avoid in severe impairment.

**PATIENT AND CARER ADVICE**

- Driving and skilled tasks
  - Although drowsiness is rare, nevertheless patients should be advised that it can occur and may affect performance of skilled tasks (e.g. cycling or driving); alcohol should be avoided.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

- **Benadryl Allergy Relief** (McNeil Products Ltd)
  - Acrivastine 8 mg
  - Benadryl Allergy Relief 8 mg capsules | 24 capsule £4.95

---

1. adrenaline/epinephrine p. 216
2. adrenaline/epinephrine p. 216
3. adrenaline/epinephrine p. 216
4. adrenaline/epinephrine p. 216
Bilastine

22-May-2017

**INDICATIONS AND DOSE**
Symptomatic relief of allergic rhinoconjunctivitis and urticaria
- **BY MOUTH**
  - Child 12-17 years: 20 mg once daily
  - Adult: 20 mg once daily

**CONTRA-INDICATIONS**
Avoid in acute porphyrias p. 969 (some antihistamines are thought to be safe)

**SIDE-EFFECTS**
- **Common or very common**
  - Headache
  - Malaise
  - Abdominal pain
  - Nausea
  - Vomiting
  - Diarrhoea
  - Gastro-intestinal disturbances
  - Palpitation
  - Fatigue
  - Dizziness
  - Vertigo
  - Insomnia
  - Thirst
  - Anorexia
  - Appetite
  - Tinnitus
  - Thrombocytopenia
  - Hypersensitivity reactions
  - Other: antihistamines (non-sedating)

**SIDE-EFFECTS, FURTHER INFORMATION**
- Children and the elderly are more susceptible to side-effects.
- Non-sedating antihistamines such as bilastine cause less sedation and psychomotor impairment than the older antihistamines because they penetrate the blood brain barrier only to a slight extent.

**PREGNANCY**
Avoid.—limited information available. Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is no evidence of teratogenicity.

**BREAST FEEDING**
Avoid.—no information available. Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

**DIRECTIONS FOR ADMINISTRATION**
Take tablet 1 hour before or after food or fruit juice.

**PATIENT AND CARER ADVICE**
Patients or carers should be given advice on how to administer bilastine tablets.

Driving and skilled tasks
Although drowsiness is rare, nevertheless patients should be advised that it can occur and may affect performance of skilled tasks (e.g. cycling or driving); alcohol should be avoided.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

Tablet
CAUTIONARY AND ADVISORY LABELS 23
- Ilaxten (A. Menarini Farmaceutica Internazionale SRL)
  - Bilastine 20 mg Ilaxten 20mg tablets | 30 tablet £15.09

Cetirizine hydrochloride

**INDICATIONS AND DOSE**
Symptomatic relief of allergy such as hay fever, chronic idiopathic urticaria, atopic dermatitis
- **BY MOUTH**
  - Child 2-5 years: 2.5 mg twice daily
  - Child 6-11 years: 5 mg twice daily
  - Child 12-17 years: 10 mg once daily
  - Adult: 10 mg once daily

**CONTRA-INDICATIONS**
Avoid in acute porphyrias p. 969 (some antihistamines are thought to be safe)

**CAUTIONS**
- Epilepsy

**INTERACTIONS**
- **Appendix 1: antihistamines (non-sedating)**

**SIDE-EFFECTS**
- **Uncommon**
  - Antimuscarinic effects
  - Blurred vision
  - Dry mouth
  - Gastro-intestinal disturbances
  - Headache
  - Psychomotor impairment
  - Urinary retention
- **Rare**
  - Anaphylaxis
  - Angioedema
  - Hyperkalaemia
  - Hypotension
  - Liver dysfunction
  - Palpitation
  - Photosensitivity reactions
  - Sleep disturbances

**FREQUENCY NOT KNOWN**
- Drowsiness

**SIDE-EFFECTS, FURTHER INFORMATION**
Non-sedating antihistamines such as cetirizine cause less sedation and psychomotor impairment than the older antihistamines because they penetrate the blood brain barrier only to a slight extent.

If drowsiness occurs, it may diminish after a few days of treatment. Children and the elderly are more susceptible to side-effects.

**PREGNANCY**
Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is no evidence of teratogenicity.

**BREAST FEEDING**
Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

**RENAL IMPAIRMENT**
- In adults
  - Use half normal dose if eGFR 30–50 mL/minute/1.73 m². Use half normal dose and reduce dose frequency to alternate days if eGFR 10–30 mL/minute/1.73 m². Avoid if eGFR less than 10 mL/minute/1.73 m².
  - In children
  - Use half normal dose if estimated glomerular filtration rate 30–50 mL/minute/1.73 m². Use half normal dose and reduce dose frequency to alternate days if estimated glomerular filtration rate 10–30 mL/minute/1.73 m². Avoid if estimated glomerular filtration rate less than 10 mL/minute/1.73 m².

**PATIENT AND CARER ADVICE**
Medicines for Children leaflet: Cetirizine hydrochloride for hay fever www.medicinesforchildren.org.uk/cetirizine-hay-fever-0

Driving and skilled tasks
Although drowsiness is rare, nevertheless patients should be advised that it can occur and may affect performance of skilled tasks (e.g. cycling or driving); alcohol should be avoided.

**PROFESSIONAL INFORMATION**
Dental practitioners’ formulary
Cetirizine Tablets 10 mg may be prescribed.
Cetirizine Oral Solution 5 mg/5 mL may be prescribed.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Oral solution**
EXCIPIENTS: May contain Propylene glycol
- Cetirizine hydrochloride (Non-proprietary)
  - Cetirizine hydrochloride 1 mg per 1 ml Cetirizine 1mg/ml oral solution sugar free sugar-free 150 mL £1.38 DT price = £1.55
  - Benadryl Allergy (McNeil Products Ltd)
  - Cetirizine hydrochloride 1 mg per 1 ml Benadryl Allergy Children’s 1mg/ml oral solution sugar-free 100 ml £3.21
  - Zirtek (UCB Pharma Ltd)
  - Cetirizine hydrochloride 1 mg per 1 ml Zirtek Allergy 1mg/ml oral solution sugar-free 150 mL £3.70 sugar-free 200 mL £9.77 DT price = £1.55

Downloaded from www.medicalbr.com
Desloratadine 23-May-2017

● INDICATIONS AND DOSE
Symptomatic relief of allergy such as allergic rhinitis, urticaria, chronic idiopathic urticaria

▶ BY MOUTH
▶ Child 1-5 years: 1.25 mg once daily
▶ Child 6-11 years: 2.5 mg once daily
▶ Child 12-17 years: 5 mg once daily
▶ Adult: 5 mg once daily

PHARMACOKINETICS
Desloratadine is a metabolite of loratadine.

● CAUTIONS
Acute porphyrias p. 969

● INTERACTIONS ➔ Appendix 1: antihistamines (non-sedating)

● SIDE-EFFECTS
Uncommon Antimuscarinic effects • blurred vision • dry mouth • gastro-intestinal disturbances • headache • psychomotor impairment • urinary retention

Rare Anaphylaxis • angioedema • angle-closure glaucoma (in adults) • arrhythmias • blood disorders • bronchospasm • confusion • convulsions • depression • dizziness • extrapyramidal effects • hypersensitivity reactions • hypotension • liver dysfunction • myalgia • palpitation • photosensitivity reactions • rashes • sleep disturbances • tremor

Very rare Hallucinations

Frequency not known Drowsiness

SIDE-EFFECTS, FURTHER INFORMATION
Non-sedating antihistamines such as desloratadine cause less sedation and psychomotor impairment than the older antihistamines because they penetrate the blood brain barrier only to a slight extent.

If drowsiness occurs, it may diminish after a few days of treatment.

Children and the elderly are more susceptible to side-effects.

● ALLERGY AND CROSS-SENSITIVITY
Contra-indicated if history of hypersensitivity to loratadine.

● PREGNANCY
Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is no evidence of teratogenicity.

● BREAST FEEDING
Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

● RENAL IMPAIRMENT
Use with caution in severe impairment.

● PRESCRIBING AND DISPENSING INFORMATION
Flavours of oral liquid formulations may include bubblegum.

Fexofenadine hydrochloride 22-May-2017

● INDICATIONS AND DOSE
Symptomatic relief of seasonal allergic rhinitis

▶ BY MOUTH
▶ Child 6-11 years: 30 mg twice daily
▶ Child 12-17 years: 120 mg once daily
▶ Adult: 120 mg once daily

Symptomatic relief of chronic idiopathic urticaria

▶ BY MOUTH
▶ Child 12-17 years: 180 mg once daily
▶ Adult: 180 mg once daily

PHARMACOKINETICS
Fexofenadine is a metabolite of terfenadine.

● INTERACTIONS ➔ Appendix 1: antihistamines (non-sedating)

● SIDE-EFFECTS
Uncommon Antimuscarinic effects • blurred vision • dry mouth • gastro-intestinal disturbances • headache • psychomotor impairment • urinary retention

Rare Anaphylaxis • angioedema • angle-closure glaucoma (in adults) • arrhythmias • blood disorders • bronchospasm • confusion • convulsions • depression • dizziness • extrapyramidal effects • hypersensitivity reactions • hypotension • liver dysfunction • myalgia • palpitation • photosensitivity reactions • rashes • sleep disturbances • tremor

Frequency not known Drowsiness

SIDE-EFFECTS, FURTHER INFORMATION
Non-sedating antihistamines such as fexofenadine cause less sedation and psychomotor impairment than the older antihistamines because they penetrate the blood brain barrier only to a slight extent.

If drowsiness occurs, it may diminish after a few days of treatment.

Children and the elderly are more susceptible to side-effects.

● PREGNANCY
Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is no evidence of teratogenicity.

● BREAST FEEDING
Most antihistamines are present in breast milk in varying amounts; although not known to be
270 Allergic conditions

Respiratory system

harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

- **PATIENT AND CARER ADVICE**

  **Driving and skilled tasks**

  Although drowsiness is rare, nevertheless patients should be advised that it can occur and may affect performance of skilled tasks (e.g. cycling or driving); alcohol should be avoided.

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, tablet.

  **Tablet**

  QUANITATIVE AND ADVISORY LABELS 5

  - Fexofenadine hydrochloride (Non-proprietary)
    - Fexofenadine hydrochloride 120 mg
      - Tablet
      - £0.36 per pack
    - Fexofenadine hydrochloride 180 mg
      - Tablet
      - £0.38 per pack

  - Telfast (Sanofi)
    - Fexofenadine hydrochloride 30 mg
      - Telfast 30mg tablets
      - 60 tablet pack
      - £5.46 per pack
    - Fexofenadine hydrochloride 120 mg
      - Telfast 120mg tablets
      - 30 tablet pack
      - £1.99 per pack
    - Fexofenadine hydrochloride 180 mg
      - Telfast 180mg tablets
      - 30 tablet pack
      - £2.58 per pack

**Levocetirizine hydrochloride**

**INDICATIONS AND DOSE**

Symptomatic relief of allergy such as hay fever, urticaria

- **BY MOUTH**
  - Child 6–17 years: 5 mg once daily
  - Adult: 5 mg once daily

**PHARMACOKINETICS**

Levocetirizine is an isomer of cetirizine.

- **CONTRA-INDICATIONS** Avoid in acute porphyrias p. 969 (some antihistamines are thought to be safe)
- **INTERACTIONS** → Appendix 1: antihistamines (non-sedating)
- **SIDE-EFFECTS**
  - **Uncommon** Antimuscarinic effects • blurred vision • dry mouth • gastro-intestinal disturbances • headache • psychomotor impairment • urinary retention
  - **Rare** Anaphylaxis • angioedema • angle-closure glaucoma (in adults) • arrhythmias • blood disorders • bronchospasm • confusion • convulsions • depression • dizziness • extrapyramidal effects • hypersensitivity reactions • hypotension • liver dysfunction • palpitation • photosensitivity reactions • rashes • sleep disturbances • tremor
  - **Very rare** Weight gain
  - **Frequency not known** Drowsiness

SIDE-EFFECTS, FURTHER INFORMATION

Non-sedating antihistamines such as levocetirizine cause less sedation and psychomotor impairment than the older antihistamines because they penetrate the blood brain barrier only to a slight extent.

If drowsiness occurs, it may diminish after a few days of treatment.

Children and the elderly are more susceptible to side-effects.

- **PREGNANCY** Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is no evidence of teratogenicity.
- **BREAST FEEDING** Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

- **RENAL IMPAIRMENT**
  - In adults: 5 mg on alternate days if eGFR 30–50 mL/minute/1.73 m². 5 mg every 3 days if eGFR 10–30 mL/minute/1.73 m². Avoid if eGFR less than 10 mL/minute/1.73 m².
  - In children: Reduce dose frequency to alternate days if estimated glomerular filtration rate 30–50 mL/minute/1.73 m². Reduce dose frequency to every 3 days if estimated glomerular filtration rate 10–30 mL/minute/1.73 m². Avoid if estimated glomerular filtration rate less than 10 mL/minute/1.73 m².

- **PATIENT AND CARER ADVICE**

  **Driving and skilled tasks**

  Although drowsiness is rare, nevertheless patients should be advised that it can occur and may affect performance of skilled tasks (e.g. cycling or driving); alcohol should be avoided.

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug.

**Oral solution**

- **Xyzal** (UCB Pharma Ltd)
  - Levocetirizine dihydrochloride 500 microgram per 1 ml
    - Xyzal 0.5mg/ml oral solution sugar-free
      - 200 ml
      - £6.00 per pack
    - £6.00

**Tablet**

- **Xyzal** (UCB Pharma Ltd)
  - Levocetirizine dihydrochloride 5 mg
    - Xyzal 5mg tablets
      - 30 tablet pack
      - £4.39 per pack
      - £4.36

**Loratadine**

**INDICATIONS AND DOSE**

Symptomatic relief of allergy such as hay fever, chronic idiopathic urticaria

- **BY MOUTH**
  - Child 2–11 years (body-weight up to 31 kg): 5 mg once daily
  - Child 2–11 years (body-weight 31 kg and above): 10 mg once daily
  - Child 12–17 years: 10 mg once daily
  - Adult: 10 mg once daily

**CAUTIONS** Acute porphyrias p. 969

**INTERACTIONS** → Appendix 1: antihistamines (non-sedating)

**SIDE-EFFECTS**

- **Uncommon** Antimuscarinic effects • blurred vision • dry mouth • gastro-intestinal disturbances • headache • psychomotor impairment • urinary retention
  - **Rare** Anaphylaxis • angioedema • angle-closure glaucoma (in adults) • arrhythmias • blood disorders • bronchospasm • confusion • convulsions • depression • dizziness • extrapyramidal effects • hypersensitivity reactions • hypotension • liver dysfunction • palpitation • photosensitivity reactions • rashes • sleep disturbances • tremor
  - **Very rare** Weight gain
  - **Frequency not known** Drowsiness

SIDE-EFFECTS, FURTHER INFORMATION

Non-sedating antihistamines such as loratadine cause less sedation and psychomotor impairment than the older antihistamines because they penetrate the blood brain barrier only to a slight extent.

If drowsiness occurs, it may diminish after a few days of treatment.

Children and the elderly are more susceptible to side-effects.
Rare

Uncommon

▶

HEPATIC IMPAIRMENT Reduce dose frequency to alternate days in severe impairment.

PATIENT AND CARER ADVICE

Driving and skilled tasks

Although drowsiness is rare, nevertheless patients and their carers should be advised that it can occur and may affect performance of skilled tasks (e.g. cycling or driving); alcohol should be avoided.

PROFESSION SPECIFIC INFORMATION

Dental practitioners’ formulary

Loratadine 10 mg tablets may be prescribed.

Loratadine 10 mg tablets containing the

Medicinal forms

There can be variation in the licensing of different medicines containing the same drug.

Oral solution

EXCIPIENTS: May contain Propylene glycol

▶ Loratadine (Non-proprietary)

Loratadine 1 mg per 1 ml Loratadine 5mg/5ml oral solution | 100 ml | £2.63 DT price = £1.86

Tablet

▶ Loratadine (Non-proprietary)

Loratadine 10 mg Loratadine 10mg tablets | 30 tablet | £1.44 DT price = £0.84

▶ Claritlyn (Loratadine) (Bayer Plc)

Loratadine 10 mg Claritlyn Allergy 10mg tablets | 60 tablet | £8.85

Oral lyophilisate

▶ Claritlyn (Loratadine) (Bayer Plc)

Loratadine 10 mg Claritlyn Rapide Allergy 10mg tablets sugar-free | 10 tablet | | £3.24

Mizolastine

INDICATIONS AND DOSE

Symptomatic relief of allergy such as hay fever, urticaria

▶ BY MOUTH

Child 12-17 years: 10 mg once daily

Adult: 10 mg once daily

CONTRA-INDICATIONS Avoid in acute porphyrinas p. 969 (some antihistamines are thought to be safe) · cardiac disease · hypokalaemia · susceptibility to QT-interval prolongation

INTERACTIONS ▶ Appendix 1: antihistamines (non-sedating)

SIDE-EFFECTS

Common or very common
Anxiety · asthenia · weight gain

Uncommon
Antimuscarinic effects · arthralgia · blurred vision · dry mouth · gastro-intestinal disturbances · headache · myalgia · psychomotor impairment · urinary retention

Rare
Anaphylaxis · angioedema · angle-closure glaucoma (in adults) · arrhythmias · blood disorders · bronchospasm · confusion · convulsions · depression · dizziness · extrapyramidal effects · hypersensitivity reactions · hypotension · liver dysfunction · palpitation · photosensitivity reactions · rashes · sleep disturbances · tremor

Frequency not known
Drowsiness

SIDE-EFFECTS, FURTHER INFORMATION

Non-sedating antihistamines such as mizolastine cause less sedation and psychomotor impairment than the older antihistamines because they penetrate the blood brain barrier only to a slight extent.

If drowsiness occurs, it may diminish after a few days of treatment.

Children and the elderly are more susceptible to side-effects.

CONTRA-INDICATIONS Children under 2 years except on specialist advice (safety of such use has not been established) · epilepsy · hepatic dysfunction · history of narrow angle glaucoma · hypothyroidism · many antihistamines should be avoided in acute porphyrinas p. 969 but alimemazine is thought to be safe · myasthenia gravis · Parkinson’s disease · phaeochromocytoma · prostatic hypertrophy (in adults) · renal dysfunction

CAUTIONS Cardiovascular diseases (due to tachycardia-inducing and hypertensive effects of phenothiazines) · elderly · exposure to sunlight should be avoided during treatment with high doses · pyloroduodenal obstruction · urinary retention · volume depleted patients who are more susceptible to orthostatic hypotension

INTERACTIONS ▶ Appendix 1: antihistamines (sedating)

SIDE-EFFECTS

Rare
Anaphylaxis · angioedema · bronchospasm · hypersensitivity reactions

Frequency not known
Acute dystonia · agitation · agranulocytosis · akathisia · akinesia · angle-closure glaucoma · anti-muscarinic effects · arrhythmias (may be predisposed by hypokalaemia and cardiac disease) · blurred
Respiratory system

REN AL IMPAIRMENT

HEPATIC IMPAIRMENT

NCY

BR

l

PREG NA

MED ICINAL FORMS

containing the

Driving and skilled tasks

increased risk

Oral solution

NEWER ANTIHISTAMINES.

Tablet

Tablet

CHILD 1-23 MONTHS:

28 mg, repeated if necessary; maximum 4 doses per day

Child 12-17 years: 10 mg, repeated if necessary; maximum 4 doses per day

Adult: 10 mg, repeated if necessary; maximum 4 doses per day

Emergency treatment of anaphylactic reactions

› BY INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INJECTION

Child 1-5 months: 250 micrograms/kg (max. per dose 2.5 mg), repeated if necessary; maximum 4 doses per day

Child 6 months–5 years: 2.5 mg, repeated if necessary; maximum 4 doses per day

Child 6-11 years: 5 mg, repeated if necessary; maximum 4 doses per day

Adult: 10 mg, repeated if necessary; maximum 4 doses per day

UNLICENSED USE

Tablets not licensed for use in children under 6 years. Syrup not licensed for use in children under 1 year.

IMPORTANT SAFETY INFORMATION

MHRA/CHM ADVICE (MARCH 2008 AND FEBRUARY 2009) OVER-THE-COUNTER COUGH AND COLD MEDICINES FOR CHILDREN

Children under 6 years should not be given over-the-counter cough and cold medicines containing chlorphenamine.

CONTRA-INDICATIONS

Many antihistamines should be avoided in acute porphyrias p. 969 but chlorphenamine is thought to be safe

CAUTIONS

Epilepsy - prostatic hypertrophy (in adults) - pyloroduodenal obstruction - susceptibility to angle-closure glaucoma - urinary retention

INTERACTIONS

Appendix 1: antihistamines (sedating)

SIDE-EFFECTS

GENERAL SIDE-EFFECTS

Children and the elderly are more susceptible to side-effects.

Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely, especially with high doses or in children and the elderly. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.

PREGNANCY

Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is no evidence of teratogenicity. Use in the latter part of the third trimester may cause adverse effects in neonates such as irritability, paradoxical excitability, and tremor.

BREAST FEEDING

Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

HEPATIC IMPAIRMENT

Avoid in severe liver disease—increased risk of coma.

RENA L IMPAIRMENT

Avoid.

PATIENT AND CARER ADVICE

Driving and skilled tasks

Drowsiness may affect performance of skilled tasks (e.g. cycling or driving); sedating effects enhanced by alcohol.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

Oral solution

CAUTIONARY AND ADVISORY LABELS

Alimemazine tartrate (Non-proprietary)

Alimemazine tartrate 1.5 mg per 1 ml Alimemazine 7.5mg/5ml oral solution | 100 ml (POD) £179.54 DT price = £179.54

Alimemazine tartrate 6 mg per 1 ml Alimemazine 30mg/5ml oral solution | 100 ml (POD) £243.51 DT price = £243.51

Tablet

CAUTIONARY AND ADVISORY LABELS

Alimemazine tartrate (Non-proprietary)

Alimemazine tartrate 10 mg Alimemazine 10mg tablets | 25 tablet (POD) no price available | 28 tablet (POD) £112.85 DT price = £112.85

Chlorphenamine maleate

(Chlorpheniramine maleate)

INDICATIONS AND DOSE

Symptomatic relief of allergy such as hay fever, urticaria, food allergy, drug reactions | Relief of itch associated with chickenpox

BY MOUTH

Child 1–23 months: 1 mg twice daily

Child 2–5 years: 1 mg every 4–6 hours; maximum 6 mg per day

Child 6–11 years: 2 mg every 4–6 hours; maximum 12 mg per day

Child 12–17 years: 4 mg every 4–6 hours; maximum 24 mg per day

Adult: 4 mg every 4–6 hours; maximum 24 mg per day

Elderly: 4 mg every 4–6 hours; maximum 12 mg per day

BY INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INJECTION

Child 1–5 months: 250 micrograms/kg (max. per dose 2.5 mg), repeated if necessary; maximum 4 doses per day

Child 6 months–5 years: 2.5 mg, repeated if necessary; maximum 4 doses per day

Child 6–11 years: 5 mg, repeated if necessary; maximum 4 doses per day

Child 12–17 years: 10 mg, repeated if necessary; maximum 4 doses per day

Adult: 10 mg, repeated if necessary; maximum 4 doses per day
may occur rarely, especially with high doses or in children and the elderly. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.

- **PREGNANCY** Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is no evidence of teratogenicity. Use in the latter part of the third trimester may cause adverse effects in neonates such as irritability, paradoxical excitability, and tremor.

- **BREAST FEEDING** Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

- **HEPATIC IMPAIRMENT** Avoid in severe liver disease—increased risk of coma.

- **DIRECTIONS FOR ADMINISTRATION** For *intravenous injection*, give over 1 minute; if small dose required, dilute with Sodium Chloride 0.9%.

- **PATIENT AND CARER ADVICE**
  - Medicines for Children leaflet: Chlorphenamine maleate for allergy symptoms www.medicinesforchildren.org.uk/chlorphenamine-maleate-allergy-symptoms-0
  - Driving and skilled tasks: Drowsiness may affect performance of skilled tasks (e.g. cycling or driving); sedating effects enhanced by alcohol.

- **PROFESSIONAL SPECIFIC INFORMATION**
  - Dental practitioners’ formulary: Chlorphenamine tablets may be prescribed. Chlorphenamine oral solution may be prescribed.

- **EXCEPTIONS TO LEGAL CATEGORY**
  - Prescription only medicine restriction does not apply to chlorphenamine injection where administration is for saving life in emergency.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

  - **Solution for injection**
    - Chlorphenamine maleate (Non-proprietary)
      - Chlorphenamine maleate 10 mg per 1 ml
        - Chlorphenamine 10mg/1ml solution for injection ampoules | 5 ampoule ≤ £22.48-£22.50 DT price = £22.50
    - **Oral solution**
      - **CAUTIONARY AND ADVISORY LABELS**
        - 2
      - Chlorphenamine maleate 400 microgram per 1 ml
        - Chlorphenamine 2mg/5ml oral solution sugar-free sugar-free | 150 ml £ £ 2.62 DT price = £2.62
      - **Tablet**
        - **CAUTIONARY AND ADVISORY LABELS**
          - 2
        - Chlorphenamine maleate 4 mg
          - Chlorphenamine 4mg tablets | 28 tablet £ 0.60 DT price = 0.76
        - Hayleve (Genesis Pharmaceuticals Ltd)
          - Chlorphenamine maleate 4 mg
            - Hayleve 4mg tablets | 28 tablet £ 0.76 DT price = 0.76
        - Pirton (GlaxoSmithKline Consumer Healthcare)
          - Chlorphenamine maleate 4 mg
            - Pirton Allergy 4mg tablets | 30 tablet £ 2.06 | 60 tablet £ £ 3.73
          - Pollenase (chlorphenamine) (E M Pharma)
            - Chlorphenamine maleate 4 mg
              - Pollenase Antihistamine 4mg tablets | 30 tablet £ £ 1.00

**Clemastine**

- **INDICATIONS AND DOSE**
  - Symptomatic relief of allergy such as hay fever, urticaria
    - **BY MOUTH**
      - Adult: 1 mg twice daily, increased if necessary up to 6 mg daily

  - **CONTRA-INDICATIONS** Avoid in acute porphyrias p. 969 (some antihistamines are thought to be safe)

- **CAUTIONS**
  - Epilepsy • prostatic hypertrophy • pyloroduodenal obstruction • susceptibility to angle-closure glaucoma • urinary retention

- **INTERACTIONS** Appendix 1: antihistamines (sedating)

- **SIDE-EFFECTS**
  - Rare: Anaphylaxis • angioedema • angle-closure glaucoma • arrhythmias • blood disorders • bronchospasm • confusion • convulsions • depression • dizziness • extrapyramidal effects • hypersensitivity reactions • hypotension • liver dysfunction • palpitation • photosensitivity reactions • rashes • sleep disturbances • tremor

  - **Frequency not known**
    - Antimuscarinic effects • blurred vision • drowsiness • dry mouth • gastro-intestinal disturbances • headache • psychomotor impairment • urinary retention

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Elderly patients are more susceptible to side-effects.

  - Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely, especially with high doses or in the elderly. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.

- **PREGNANCY** Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is no evidence of teratogenicity. Use in the latter part of the third trimester may cause adverse effects in neonates such as irritability, paradoxical excitability, and tremor.

- **BREAST FEEDING** Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

- **HEPATIC IMPAIRMENT** Avoid in severe liver disease—increased risk of coma.

- **PATIENT AND CARER ADVICE**
  - Driving and skilled tasks: Drowsiness may affect performance of skilled tasks (e.g. cycling or driving); sedating effects enhanced by alcohol.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include:

  - **Tablet**
    - **CAUTIONARY AND ADVISORY LABELS**
      - 2
    - Clemastine (as Clemastine Hydrogen fumarate) 1 mg
      - Tavegil (GlaxoSmithKline Consumer Healthcare)
        - Tavegil 1mg tablets | 60 tablet £ £ 6.05 DT price = £5.50

**Cyproheptadine hydrochloride**

- **INDICATIONS AND DOSE**
  - Symptomatic relief of allergy such as hay fever, urticaria | Pruritus
    - **BY MOUTH**
      - Adult: 4 mg 3 times a day, usual dose 4–20 mg daily; maximum 32 mg per day

  - **CONTRA-INDICATIONS** Avoid in acute porphyrias p. 969 (some antihistamines are thought to be safe)
Hydroxyzine is a sedating antihistamine which exerts its actions by antagonising the effects of histamine.

**INDICATIONS AND DOSE**

**Pruritus**

- **By mouth**
  - Child 6 months–5 years: 5–15 mg daily in divided doses, dose adjusted according to weight; maximum 2 mg/kg per day.
  - Child 6–17 years (body-weight up to 40 kg): Initially 15–25 mg daily in divided doses, dose increased as necessary, adjusted according to weight; maximum 2 mg/kg per day.
  - Child 6–17 years (body-weight 40 kg and above): Initially 15–25 mg daily in divided doses, increased if necessary to 50–100 mg daily in divided doses, dose adjusted according to weight.
  - Adult: Initially 25 mg daily, dose to be taken at night; increased if necessary to 25 mg 3–4 times a day.

**SIDE-EFFECTS**

- Elderly: Initially 25 mg daily, dose to be taken at night; increased if necessary to 25 mg twice daily

**CONTRA-INDICATIONS**

- Acquired or congenital QT interval prolongation
- Avoid in acute porphyrias p. 969 (some antihistamines are thought to be safe)
- Predisposition to QT interval prolongation

**UNLICENSED USE**

- **Ucerax** preparations not licensed for use in children under 1 year.

**IMPORTANT SAFETY INFORMATION**

**MAH/CHM ADVICE: RISK OF QT-INTERVAL PROLONGATION AND TORSADE DE POINTES (APRIL 2015)**

Following concerns of heart rhythm abnormalities, the safety and efficacy of hydroxyzine has been reviewed by the European Medicines Agency. The review concludes that hydroxyzine is associated with a small risk of QT-interval prolongation and torsade de pointes; these events are most likely to occur in patients who have risk factors for QT prolongation, e.g. concomitant use of drugs that prolong the QT-interval, cardiovascular disease, family history of sudden cardiac death, significant electrolyte imbalance (low plasma-potassium or plasma-magnesium concentrations), or significant bradycardia. To minimise the risk of such adverse effects, the following dose restrictions have been made and new cautions and contra-indications added:

- Hydroxyzine is contra-indicated in patients with prolonged QT-interval or who have risk factors for QT-interval prolongation;
- Avoid use in the elderly due to increased susceptibility to the side-effects of hydroxyzine;
- Consider the risks of QT-interval prolongation and torsade de pointes before prescribing to patients taking drugs that lower heart rate or plasma-potassium concentration;
- In adults, the maximum daily dose is 100 mg;
- In children with body-weight up to 40 kg, the maximum daily dose is 2 mg/kg;
- In the elderly, the maximum daily dose is 50 mg (if use of hydroxyzine cannot be avoided);
- The lowest effective dose for the shortest period of time should be prescribed.

**CONTRA-INDICATIONS**

- Acquired or congenital QT interval prolongation
- Avoid in acute porphyrias
- Predisposition to QT interval prolongation

**SIDE-EFFECTS**

- Common or very common: Dry mouth, fatigue, headache
- Uncommon: Constipation, dizziness, insomnia, nausea
- Rare: Blood disorders, bronchospasm, liver dysfunction, rashes

**FREQUENCY NOT KNOWN**

- Agitation, alopecia, anorexia, anxiety, blurred vision, coma, confusion, convulsions (with high doses), depression, diarrhoea, drowsiness, dyskinesia (after stopping use), extrapyramidal effects, flushing, hallucinations, hypotension, impotence.
labyrinthitis - menstrual disturbances - myalgia - palpitation - priapism - psychomotor impairment - sleep disturbances - tachycardia - tinnitus - tremor (with high doses) - urinary retention - ventricular arrhythmias - vertigo - vomiting

SIDE-EFFECTS, FURTHER INFORMATION
Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely, especially with high doses or in the elderly. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.

- **ALLERGY AND CROSS-SENSITIVITY** Manufacturer advises hydroxyzine should be avoided in patients with previous hypersensitivity to cetirizine or other piperazine derivatives, and aminophylline.
- **PREGNANCY** Manufacturers advise avoid - toxicity in animal studies with higher doses. Use in the latter part of the third trimester may cause irritability, paradoxical excitability, and tremor in the neonate.
- **BREAST FEEDING** Manufacturer advises avoid—expected to be present in milk but effect unknown.
- **HEPATIC IMPAIRMENT** Manufacturer advises reduce daily dose by one-third. Manufacturer advises avoid in severe liver disease—increased risk of coma.
- **RENAL IMPAIRMENT** Manufacturers advise reduce daily dose by half in moderate to severe renal impairment.

**EFFECT ON LABORATORY TESTS** May interfere with methacholine test—manufacturer advises stop treatment 96 hours prior to test. May interfere with skin testing for allergy—manufacturer advises stop treatment one week prior to test.

**PATIENT AND CARER ADVICE**
Driving and skilled tasks
Drowsiness may affect performance of skilled tasks (e.g. cycling or driving); sedating effects enhanced by alcohol.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Tablet**
CAUTIONARY AND ADVISORY LABELS 2

- **Atarax** (Alliance Pharmaceuticals Ltd)
  - Hydroxyzine hydrochloride 10 mg Atarax 10mg tablets | 84 tablet (Pkt) £1.20 DT price = £1.20
  - Hydroxyzine hydrochloride 25 mg Atarax 25mg tablets | 28 tablet (Pkt) £0.62 DT price = £0.62

**Ketotifen**

**INDICATIONS AND DOSE**

- **Allergic rhinitis**
  - **BY MOUTH**
    - Child 3-17 years: 1 mg twice daily
    - Adult: 1 mg twice daily, increased if necessary to 2 mg twice daily, to be taken with food

- **Allergic rhinitis in readily sedated patients**
  - **BY MOUTH**
    - Adult: Initially 0.5–1 mg once daily, dose to be taken at night

- **CONTRA-INDICATIONS** Avoid in acute porphyrias p. 969
  (some antihistamines are thought to be safe)

- **CAUTIONS** Epilepsy - prostatic hypertrophy (in adults) - pyloroduodenal obstruction - susceptibility to angle-closure glaucoma - urinary retention

- **INTERACTIONS** → Appendix 1: antihistamines (sedating)

- **SIDE-EFFECTS**
  - **Common or very common** Excitation (in adults) - irritability - nervousness
  - **Uncommon** Cystitis
  - **Rare** Weight gain
  - **Very rare** Stevens-Johnson syndrome
  - **Frequency not known** Anaphylaxis - angioedema - angle-closure glaucoma (in adults) - antimuscarinic effects - arrhythmias - blood disorders - blurred vision - bronchospasm - confusion - convulsions - depression - dizziness - dry mouth - extrapyramidal effects - gastro-intestinal disturbances - headache - hypersensitivity reactions - hypotension - liver dysfunction - palpitation - photosensitivity reactions - psychomotor impairment - rashes - sleep disturbances - tremor - urinary retention

**SIDE-EFFECTS, FURTHER INFORMATION**
Elderly are more susceptible to side effects.
Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely, especially with high doses or in children and the elderly. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.

- **PREGNANCY** Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is no evidence of teratogenicity. Use in the latter part of the third trimester may cause adverse effects in neonates such as irritability, paradoxical excitability, and tremor.

- **BREAST FEEDING** Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

- **HEPATIC IMPAIRMENT** Avoid in severe liver disease—increased risk of coma.

- **PATIENT AND CARER ADVICE**
  Driving and skilled tasks
  Drowsiness may affect performance of skilled tasks (e.g. driving or cycling); sedating effects enhanced by alcohol.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Oral solution**
CAUTIONARY AND ADVISORY LABELS 2, 21

- **Zaditen (CD Pharma AB)**
  - Ketotifen (as Ketotifen fumarate) 200 microgram per ml Zaditen 1mg/ml elixir sugar-free | 300 ml (Pkt) £8.91 DT price + £8.91

**Tablet**
CAUTIONARY AND ADVISORY LABELS 2, 21

- **Zaditen (CD Pharma AB)**
  - Ketotifen (as Ketotifen fumarate) 1 mg Zaditen 1mg tablets | 60 tablet (Pkt) £7.53

**Promethazine hydrochloride**

**INDICATIONS AND DOSE**
Symptomatic relief of allergy such as hay fever and urticaria | Insomnia associated with urticaria and pruritus

- **BY MOUTH**
  - Child 2–4 years: 5 mg twice daily, alternatively 5–15 mg once daily, dose to be taken at night
  - Child 5–9 years: 5–10 mg twice daily, alternatively 10–25 mg once daily, dose to be taken at night
  - Child 10–17 years: 10–20 mg 2–3 times a day, alternatively 25 mg once daily, dose to be taken at night, increased if necessary to 25 mg twice daily
  - Adult: 10–20 mg 2–3 times a day

- **BY DEEP INTRAMUSCULAR INJECTION**
  - Adult: 25–50 mg (max. per dose 100 mg)
Emergency treatment of anaphylactic reactions

BY SLOW INTRAVENOUS INJECTION
- Adult: 25–50 mg, to be administered as a solution containing 2.5 mg/mL in water for injections; maximum 100 mg per course

Sedation (short-term use)

BY MOUTH
- Child 2–4 years: 15–20 mg
- Child 5–9 years: 20–25 mg
- Child 10–17 years: 25–50 mg
- Adult: 25–50 mg
- BY DEEP INTRAMUSCULAR INJECTION
- Adult: 25–50 mg

Nausea | Vomiting | Vertigo | Labyrinthine disorders | Motion sickness

BY MOUTH
- Child 2–4 years: 5 mg, to be taken at bedtime on night before travel, repeat following morning if necessary
- Child 5–9 years: 10 mg, to be taken at bedtime on night before travel, repeat following morning if necessary
- Child 10–17 years: 20–25 mg, to be taken at bedtime on night before travel, repeat following morning if necessary
- Adult: 20–25 mg, to be taken at bedtime on night before travel, repeat following morning if necessary

IMPORTANT SAFETY INFORMATION

MHRA/CHM ADVICE (MARCH 2008 AND FEBRUARY 2009) OVER-THE-COUNTER COUGH AND COLD MEDICINES FOR CHILDREN
Children under 6 years should not be given over-the-counter cough and cold medicines containing promethazine.

CONTRA-INDICATIONS
- Many antihistamines should be avoided in acute porphyrias p. 969 but promethazine is thought to be safe - should not be given to children under 2 years, except on specialist advice, because the safety of such use has not been established

CAUTIONS
- Avoid extravasation with intravenous injection
- Epilepsy - prostatic hypertrophy (in adults) - pyloroduodenal obstruction - severe coronary artery disease - susceptibility to angle-closure glaucoma - urinary retention

INTERACTIONS
- Appendix 1: antihistamines (sedating)

SIDE-EFFECTS

GENERAL SIDE-EFFECTS

FREQUENCY not known
- Antimuscarinic effects - blurred vision - drowsiness - dry mouth - gastro-intestinal disturbances - headache - psychomotor impairment - restlessness - urinary retention

SPECIFIC SIDE-EFFECTS
- With intramuscular use

Injection pain

SIDE-EFFECTS, FURTHER INFORMATION
- Children and the elderly are more susceptible to side-effects. Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely, especially with high doses or in children and the elderly. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.

PREGNANCY
- Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is no evidence of teratogenicity. Use in the latter part of the third trimester may cause adverse effects in neonates such as irritability, paradoxical excitability, and tremor.

BREAST FEEDING
- Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

HEPATIC IMPAIRMENT
- Avoid in severe liver disease—increased risk of coma.

RENAL IMPAIRMENT
- Use with caution.

PATIENT AND CARER ADVICE
- Driving and skilled tasks: Drowsiness may affect the performance of skilled tasks (e.g. cycling or driving); sedating effects enhanced by alcohol.

PROFESSION SPECIFIC INFORMATION
- Dental practitioners’ formulary
- Promethazine Hydrochloride Tablets 10 mg or 25 mg may be prescribed.
- Promethazine Hydrochloride Oral Solution (elixir) 5 mg/5 mL may be prescribed.

LESS SUITABLE FOR PRESCRIBING
- Promethazine is less suitable for prescribing for sedation.

EXCEPTIONS TO LEGAL CATEGORY
- Prescription only medicine restriction does not apply to promethazine hydrochloride injection where administration is for saving life in emergency.

MEDICINAL FORMS
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Solution for injection
- EXCIPIENTS: May contain Sulphites
- Phenergan (Sanofi)
  - Promethazine hydrochloride 25 mg per 1 mL Phenergan 25mg/1ml solution for injection ampoules | 10 ampoule POM £6.74

Oral solution
- CAUTIONARY AND ADVISORY LABELS 2
- EXCIPIENTS: May contain Sulphites
- ELECTROLYTES: May contain Sodium
- Phenergan (Sanofi)
  - Promethazine hydrochloride 1 mg per 1 ml Phenergan 5mg/5ml elixir sugar-free | 100 mL P £2.85 DT price + £2.85

Tablet
- CAUTIONARY AND ADVISORY LABELS 2
- Promethazine hydrochloride (Non-proprietary)
  - Promethazine hydrochloride 10 mg Promethazine hydrochloride 10mg tablets | 56 tablet POM £2.96 DT price + £2.96
- Phenergan (Sanofi)
  - Promethazine hydrochloride 25 mg Phenergan 25mg tablets | 56 tablet £4.65 DT price + £4.65
- Sominex (Teva UK Ltd)
  - Promethazine hydrochloride 20 mg Sominex 20mg tablets | 8 tablet P £1.89 | 16 tablet P £2.69

VACCINES

ALLERGEN-TYPE VACCINES

Bee venom extract

INDICATIONS AND DOSE
- Hypersensitivity to bee venom
- BY SUBCUTANEOUS INJECTION
- Adult: (consult product literature)

IMPORTANT SAFETY INFORMATION
- DESENSITISING VACCINES
- In view of concerns about the safety of desensitising vaccines, it is recommended that they are used by specialists and only for the following indications:
seasonal allergic hay fever (caused by pollen) that has not responded to anti-allergic drugs;
- hypersensitivity to wasp and bee venoms.

Desensitising vaccines should generally be avoided or used with particular care in patients with asthma.

**CONTRA-INDICATIONS** Consult product literature

**CAUTIONS** Consult product literature

**INTERACTIONS** → Appendix 1: bee venom extract

**SIDE-EFFECTS** Consult product literature.

Hypersensitivity reactions

Hypersensitivity reactions to immunotherapy (especially to wasp and bee venom extracts) can be life-threatening; bronchospasm usually develops within 1 hour and anaphylaxis within 30 minutes of injection. Therefore, cardiopulmonary resuscitation must be immediately available and patients need to be monitored for at least 1 hour after injection. If symptoms or signs of hypersensitivity develop (e.g. rash, urticaria, bronchospasm, faintness), **even when mild**, the patient should be observed until these have resolved completely.

**PREGNANCY** Avoid.

**PRESCRIBING AND DISPENSING INFORMATION** Each set of allergen extracts usually contains vials for the administration of graded amounts of allergen to patients undergoing hyposensitisation. Maintenance sets containing vials at the highest strength are also available. Product literature must be consulted for details of allergens, vial strengths, and administration.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- **Pharmalgen**® for bee and wasp venom allergy (February 2012) NICE TA246

**Pharmalgen**® is an option for the treatment of IgE-mediated bee and wasp venom allergy in those who have had:

- a severe systemic reaction to bee or wasp venom;
- a moderate systemic reaction to bee or wasp venom and who have a raised baseline serum-tryptase concentration, a high risk of future stings, or anxiety about future stings.

Treatment with **Pharmalgen**® should be initiated and monitored in a specialist centre experienced in venom immunotherapy.

www.nice.org.uk/TA246

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder and solvent for solution for injection**

- **Bee Venom** (ALK-Abello Ltd)
  - **Bee venom 120 nanogram** Pharmalgen Bee Venom 120nanogram powder and solvent for solution for injection vials | 1 vial (Pom) no price available
  - **Bee venom 1.2 microgram** Pharmalgen Bee Venom 1.2microgram powder and solvent for solution for injection vials | 1 vial (Pom) no price available
  - **Bee venom 12 microgram** Pharmalgen Bee Venom 12microgram powder and solvent for solution for injection vials | 1 vial (Pom) no price available
  - **Bee venom 120 microgram** Pharmalgen Bee Venom maintenance set 120microgram powder and solvent for solution for injection vials | 1 vial (Pom) no price available | 4 vial (Pom) £150.00

**Grass pollen extract**

**INDICATIONS AND DOSE**

Treatment of seasonal allergic hay fever due to grass pollen in patients who have failed to respond to anti-allergy drugs

- **BY SUBCUTANEOUS INJECTION**
  - Adult: (consult product literature)

** import-safe information**

**DESENSITISING VACCINES**

In view of concerns about the safety of desensitising vaccines, it is recommended that they are used by specialists and only for the following indications:

- seasonal allergic hay fever (caused by pollen) that has not responded to anti-allergic drugs;
- hypersensitivity to wasp and bee venoms.

Desensitising vaccines should generally be avoided or used with particular care in patients with asthma.

**CONTRA-INDICATIONS** Consult product literature

**CAUTIONS** Consult product literature

**INTERACTIONS** → Appendix 1: grass pollen extract

**SIDE-EFFECTS** Consult product literature.

**SENSITISING VACCINES**

In view of concerns about the safety of desensitising vaccines, it is recommended that they are used by specialists and only for the following indications:

- seasonal allergic hay fever (caused by pollen) that has not responded to anti-allergic drugs;
- hypersensitivity to wasp and bee venoms.

Desensitising vaccines should generally be avoided or used with particular care in patients with asthma.

**CONTRA-INDICATIONS** Consult product literature

**CAUTIONS** Consult product literature

**INTERACTIONS** → Appendix 1: grass pollen extract

**SIDE-EFFECTS** Consult product literature.

**SENSITISING VACCINES**

In view of concerns about the safety of desensitising vaccines, it is recommended that they are used by specialists and only for the following indications:

- seasonal allergic hay fever (caused by pollen) that has not responded to anti-allergic drugs;
- hypersensitivity to wasp and bee venoms.

Desensitising vaccines should generally be avoided or used with particular care in patients with asthma.

**CONTRA-INDICATIONS** Consult product literature

**CAUTIONS** Consult product literature

**INTERACTIONS** → Appendix 1: grass pollen extract

**SIDE-EFFECTS** Consult product literature.

**SENSITISING VACCINES**

In view of concerns about the safety of desensitising vaccines, it is recommended that they are used by specialists and only for the following indications:

- seasonal allergic hay fever (caused by pollen) that has not responded to anti-allergic drugs;
- hypersensitivity to wasp and bee venoms.

Desensitising vaccines should generally be avoided or used with particular care in patients with asthma.

**CONTRA-INDICATIONS** Consult product literature

**CAUTIONS** Consult product literature

**INTERACTIONS** → Appendix 1: grass pollen extract

**SIDE-EFFECTS** Consult product literature.

**SENSITISING VACCINES**

In view of concerns about the safety of desensitising vaccines, it is recommended that they are used by specialists and only for the following indications:

- seasonal allergic hay fever (caused by pollen) that has not responded to anti-allergic drugs;
- hypersensitivity to wasp and bee venoms.

Desensitising vaccines should generally be avoided or used with particular care in patients with asthma.

**CONTRA-INDICATIONS** Consult product literature

**CAUTIONS** Consult product literature

**INTERACTIONS** → Appendix 1: grass pollen extract

**SIDE-EFFECTS** Consult product literature.

**SENSITISING VACCINES**

In view of concerns about the safety of desensitising vaccines, it is recommended that they are used by specialists and only for the following indications:

- seasonal allergic hay fever (caused by pollen) that has not responded to anti-allergic drugs;
- hypersensitivity to wasp and bee venoms.

Desensitising vaccines should generally be avoided or used with particular care in patients with asthma.

**CONTRA-INDICATIONS** Consult product literature

**CAUTIONS** Consult product literature

**INTERACTIONS** → Appendix 1: grass pollen extract

**SIDE-EFFECTS** Consult product literature.

**SENSITISING VACCINES**

In view of concerns about the safety of desensitising vaccines, it is recommended that they are used by specialists and only for the following indications:

- seasonal allergic hay fever (caused by pollen) that has not responded to anti-allergic drugs;
- hypersensitivity to wasp and bee venoms.

Desensitising vaccines should generally be avoided or used with particular care in patients with asthma.

**CONTRA-INDICATIONS** Consult product literature

**CAUTIONS** Consult product literature

**INTERACTIONS** → Appendix 1: grass pollen extract

**SIDE-EFFECTS** Consult product literature.

**SENSITISING VACCINES**

In view of concerns about the safety of desensitising vaccines, it is recommended that they are used by specialists and only for the following indications:

- seasonal allergic hay fever (caused by pollen) that has not responded to anti-allergic drugs;
- hypersensitivity to wasp and bee venoms.

Desensitising vaccines should generally be avoided or used with particular care in patients with asthma.

**CONTRA-INDICATIONS** Consult product literature

**CAUTIONS** Consult product literature

**INTERACTIONS** → Appendix 1: grass pollen extract

**SIDE-EFFECTS** Consult product literature.

**SENSITISING VACCINES**

In view of concerns about the safety of desensitising vaccines, it is recommended that they are used by specialists and only for the following indications:

- seasonal allergic hay fever (caused by pollen) that has not responded to anti-allergic drugs;
- hypersensitivity to wasp and bee venoms.

Desensitising vaccines should generally be avoided or used with particular care in patients with asthma.

**CONTRA-INDICATIONS** Consult product literature

**CAUTIONS** Consult product literature

**INTERACTIONS** → Appendix 1: grass pollen extract

**SIDE-EFFECTS** Consult product literature.

**SENSITISING VACCINES**

In view of concerns about the safety of desensitising vaccines, it is recommended that they are used by specialists and only for the following indications:

- seasonal allergic hay fever (caused by pollen) that has not responded to anti-allergic drugs;
- hypersensitivity to wasp and bee venoms.

Desensitising vaccines should generally be avoided or used with particular care in patients with asthma.

**CONTRA-INDICATIONS** Consult product literature

**CAUTIONS** Consult product literature

**INTERACTIONS** → Appendix 1: grass pollen extract

**SIDE-EFFECTS** Consult product literature.

**SENSITISING VACCINES**

In view of concerns about the safety of desensitising vaccines, it is recommended that they are used by specialists and only for the following indications:

- seasonal allergic hay fever (caused by pollen) that has not responded to anti-allergic drugs;
- hypersensitivity to wasp and bee venoms.

Desensitising vaccines should generally be avoided or used with particular care in patients with asthma.

**CONTRA-INDICATIONS** Consult product literature

**CAUTIONS** Consult product literature

**INTERACTIONS** → Appendix 1: grass pollen extract

**SIDE-EFFECTS** Consult product literature.

**SENSITISING VACCINES**

In view of concerns about the safety of desensitising vaccines, it is recommended that they are used by specialists and only for the following indications:

- seasonal allergic hay fever (caused by pollen) that has not responded to anti-allergic drugs;
- hypersensitivity to wasp and bee venoms.

Desensitising vaccines should generally be avoided or used with particular care in patients with asthma.

**CONTRA-INDICATIONS** Consult product literature

**CAUTIONS** Consult product literature

**INTERACTIONS** → Appendix 1: grass pollen extract

**SIDE-EFFECTS** Consult product literature.

**SENSITISING VACCINES**

In view of concerns about the safety of desensitising vaccines, it is recommended that they are used by specialists and only for the following indications:

- seasonal allergic hay fever (caused by pollen) that has not responded to anti-allergic drugs;
- hypersensitivity to wasp and bee venoms.

Desensitising vaccines should generally be avoided or used with particular care in patients with asthma.

**CONTRA-INDICATIONS** Consult product literature

**CAUTIONS** Consult product literature

**INTERACTIONS** → Appendix 1: grass pollen extract

**SIDE-EFFECTS** Consult product literature.

**SENSITISING VACCINES**

In view of concerns about the safety of desensitising vaccines, it is recommended that they are used by specialists and only for the following indications:

- seasonal allergic hay fever (caused by pollen) that has not responded to anti-allergic drugs;
- hypersensitivity to wasp and bee venoms.

Desensitising vaccines should generally be avoided or used with particular care in patients with asthma.
Tree pollen extract

- **INDICATIONS AND DOSE**
  - Treatment of seasonal allergic hay fever due to tree pollen in patients who have failed to respond to anti-allergy drugs
  - **BY SUBCUTANEOUS INJECTION**
  - Adult: (consult product literature)

- **CONTRA-INDICATIONS** Consult product literature
- **CAUTIONS** Consult product literature
- **INTERACTIONS** → Appendix 1: tree pollen extract
- **SIDE-EFFECTS** Consult product literature.

### IMPORTANT SAFETY INFORMATION

#### DESENSITISING VACCINES

In view of concerns about the safety of desensitising vaccines, it is recommended that they are used by specialists and only for the following indications:

- seasonal allergic hay fever (caused by pollen) that has not responded to anti-allergic drugs;
- hypersensitivity to wasp and bee venoms.

Desensitising vaccines should generally be avoided or used with particular care in patients with asthma.

- **CONTRA-INDICATIONS** Consult product literature
- **CAUTIONS** Consult product literature
- **INTERACTIONS** → Appendix 1: wasp venom extract

### SidE-EFFECTS

Hypersensitivity reactions to allergens, vial strengths, and administration.

### Side-EFFECTS

Consult product literature.

Wasp venom extract

- **INDICATIONS AND DOSE**
  - Hypersensitivity to wasp venom
  - **BY SUBCUTANEOUS INJECTION**
  - Adult: (consult product literature)

### IMPORTANT SAFETY INFORMATION

#### DESENSITISING VACCINES

In view of concerns about the safety of desensitising vaccines, it is recommended that they are used by specialists and only for the following indications:

- seasonal allergic hay fever (caused by pollen) that has not responded to anti-allergic drugs;
- hypersensitivity to wasp and bee venoms.

Desensitising vaccines should generally be avoided or used with particular care in patients with asthma.

- **CONTRA-INDICATIONS** Consult product literature
- **CAUTIONS** Consult product literature
- **INTERACTIONS** → Appendix 1: wasp venom extract

### NATIONAL FUNDING/ACCESS DECISIONS

#### NICE technology appraisals (TAs)

- **Pharmalgen®** for bee and wasp venom allergy (February 2012) NICE TA246

Pharmalgen® is an option for the treatment of IgE-mediated bee and wasp venom allergy in those who have had:

- a severe systemic reaction to bee or wasp venom;
- a moderate systemic reaction to bee or wasp venom and who have a raised baseline serum-tryptase concentration, a high risk of future stings, or anxiety about future stings.

Treatment with Pharmalgen® should be initiated and monitored in a specialist centre experienced in venom immunotherapy.

www.nice.org.uk/TA246

#### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Suspension for injection**

- **Pollinex Trees** (Allergy Therapeutics (UK) Ltd)
  - Pollinex Trees No 3 suspension for injection 1ml vials | 1 vial £450.00
  - Pollinex Trees No 2 suspension for injection 1ml vials | 1 vial £450.00
  - Pollinex Trees No 1 suspension for injection 1ml vials | 1 vial £450.00

**Powder and solvent for solution for injection**

- **Wasp Venom** (ALK-Abello Ltd)
  - Wasp venom 120 microgram Pharmalgen Wasp Venom 120microgram powder and solvent for solution for injection vials | 1 vial £150.00

**2.1 Angioedema**

Other drugs used for Angioedema

Adrenaline/epinephrine, p. 216
DRUGS USED IN HEREDITARY ANGIOEDEMA

C1-esterase inhibitor

INDICATIONS AND DOSE

BERINERT®
Acute attacks of hereditary angioedema (under expert supervision)
- BY SLOW INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION
- Adult: 20 units/kg

Short-term prophylaxis of hereditary angioedema before dental, medical, or surgical procedures (under expert supervision)
- BY SLOW INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION
- Adult: 1000 units for 1 dose, to be administered less than 6 hours before procedure

CINRYZE®
Acute attacks of hereditary angioedema (under expert supervision)
- BY SLOW INTRAVENOUS INJECTION
- Adult: 1000 units, repeated if necessary for 1 dose, dose may be repeated if necessary

Short-term prophylaxis of hereditary angioedema before dental, medical, or surgical procedures (under expert supervision)
- BY SLOW INTRAVENOUS INJECTION
- Adult: 1000 units for 1 dose, to be administered up to 24 hours before procedure

Long-term prophylaxis of severe, recurrent attacks of hereditary angioedema where acute treatment is inadequate, or when oral prophylaxis is inadequate or not tolerated (under expert supervision)
- BY SLOW INTRAVENOUS INJECTION
- Adult: 1000 units every 3–4 days, interval between doses to be adjusted according to response

CAUTIONS
Vaccination against hepatitis A and hepatitis B may be required

SIDE-EFFECTS
Fever, headache, thrombosis (with high doses)

PREGNANCY
Manufacturer advises avoid unless essential.

PRESCRIBING AND DISPENSING INFORMATION
C1-esterase inhibitor is prepared from human plasma.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Powder and solvent for solution for injection

ELECTROLYTES: May contain Sodium
- Berinert P (CSL Behring UK Ltd)
  - C1-esterase inhibitor 500 unit: Berinert 500unit powder and solvent for solution for injection vials | 1 vial | £467.50
  - C1-esterase inhibitor 1500 unit: Berinert 1,500unit powder and solvent for solution for injection vials | 1 vial | £1,402.50
- Cinryze (Shire Pharmaceuticals Ltd)
  - C1-esterase inhibitor 500 unit: Cinryze 500unit powder and solvent for solution for injection vials | 2 vial | £1,336.00

Conestat alfa

INDICATIONS AND DOSE
Acute attacks of hereditary angioedema in patients with C1-esterase inhibitor deficiency
- BY SLOW INTRAVENOUS INJECTION
  - Adult (body-weight up to 84 kg): 50 units/kg for 1 dose, to be administered over 5 minutes, dose may be repeated if necessary; maximum 2 doses per day
  - Adult (body-weight 84 kg and above): 4200 units for 1 dose, to be administered over 5 minutes, dose may be repeated if necessary; maximum 2 doses per day

CONTRA-INDICATIONS
Rabbit allergy

SIDE-EFFECTS
- Common or very common: Headache
- Uncommon: Abdominal discomfort, diarrhoea, nausea, paraesthesia, throat irritation, urticaria, vertigo

PREGNANCY
Use only if potential benefit outweighs risk—toxicity in animal studies.

BREAST FEEDING
Use only if potential benefit outweighs risk—no information available.

PRE-TREATMENT SCREENING
Test for immunoglobulin E (IgE) antibodies against rabbit allergens before starting treatment.

MONITORING REQUIREMENTS
Repeat immunoglobulin E (IgE) antibody testing annually or after 10 treatments—consult product literature.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for injection
- Ruconest (Pharming Group N.V.)
  - Conestat alfa 2100 unit: Ruconest 2,100unit powder for solution for injection vials | 1 vial | £750.00

DRUGS USED IN HEREDITARY ANGIOEDEMA

SELECTIVE BRADYKININ B2 ANTAGONISTS

Icatibant

INDICATIONS AND DOSE
Acute attacks of hereditary angioedema in patients with C1-esterase inhibitor deficiency
- BY SUBCUTANEOUS INJECTION
  - Adult: 30 mg for 1 dose, then 30 mg after 6 hours if required, then 60 mg after 6 hours if required; maximum 3 doses per day

CAUTIONS
Ischaemic heart disease, stroke

INTERACTIONS
Appendix 1: Icatibant

SIDE-EFFECTS
Dizziness, erythema, headache, injection-site reactions, nausea, pruritus, pyrexia, rash

PREGNANCY
Manufacturer advises use only if potential benefit outweighs risk—toxicity in animal studies.

BREAST FEEDING
Manufacturer advises avoid for 12 hours after administration.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Solution for Injection
- Firazyr (Shire Pharmaceuticals Ltd)
  - Icatibant (as Icatibant acetate) 10 mg per 1 ml: Firazyr 30mg/3ml solution for injection pre-filled syringes | 1 pre-filled disposable injection | £1,395.00

Conestat alfa

INDICATIONS AND DOSE
Acute attacks of hereditary angioedema in patients with C1-esterase inhibitor deficiency
- BY SLOW INTRAVENOUS INJECTION
  - Adult (body-weight up to 84 kg): 50 units/kg for 1 dose, to be administered over 5 minutes, dose may be repeated if necessary; maximum 2 doses per day
  - Adult (body-weight 84 kg and above): 4200 units for 1 dose, to be administered over 5 minutes, dose may be repeated if necessary; maximum 2 doses per day

CONTRA-INDICATIONS
Rabbit allergy

SIDE-EFFECTS
- Common or very common: Headache
- Uncommon: Abdominal discomfort, diarrhoea, nausea, paraesthesia, throat irritation, urticaria, vertigo

PREGNANCY
Use only if potential benefit outweighs risk—toxicity in animal studies.

BREAST FEEDING
Use only if potential benefit outweighs risk—no information available.

PRE-TREATMENT SCREENING
Test for immunoglobulin E (IgE) antibodies against rabbit allergens before starting treatment.

MONITORING REQUIREMENTS
Repeat immunoglobulin E (IgE) antibody testing annually or after 10 treatments—consult product literature.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for injection
- Ruconest (Pharming Group N.V.)
  - Conestat alfa 2100 unit: Ruconest 2,100unit powder for solution for injection vials | 1 vial | £750.00

DRUGS USED IN HEREDITARY ANGIOEDEMA

SELECTIVE BRADYKININ B2 ANTAGONISTS

Icatibant

INDICATIONS AND DOSE
Acute attacks of hereditary angioedema in patients with C1-esterase inhibitor deficiency
- BY SUBCUTANEOUS INJECTION
  - Adult: 30 mg for 1 dose, then 30 mg after 6 hours if required, then 60 mg after 6 hours if required; maximum 3 doses per day

CAUTIONS
Ischaemic heart disease, stroke

INTERACTIONS
Appendix 1: Icatibant

SIDE-EFFECTS
Dizziness, erythema, headache, injection-site reactions, nausea, pruritus, pyrexia, rash

PREGNANCY
Manufacturer advises use only if potential benefit outweighs risk—toxicity in animal studies.

BREAST FEEDING
Manufacturer advises avoid for 12 hours after administration.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Solution for Injection
- Firazyr (Shire Pharmaceuticals Ltd)
  - Icatibant (as Icatibant acetate) 10 mg per 1 ml: Firazyr 30mg/3ml solution for injection pre-filled syringes | 1 pre-filled disposable injection | £1,395.00
3 Conditions affecting sputum viscosity

Mucolytics for cystic fibrosis

Overview
Mucolytics are prescribed to facilitate expectoration by reducing sputum viscosity. In some patients with chronic obstructive pulmonary disease and a chronic productive cough, mucolytics can reduce exacerbations; mucolytic therapy should be stopped if there is no benefit after a 4-week trial. Steam inhalation with postural drainage is effective in bronchiectasis and in some cases of chronic bronchitis.

Dornase alfa below is used to reduce sputum viscosity in patients with cystic fibrosis.

Nebulised hypertonic sodium chloride (3–7%) is used to mobilise lower respiratory tract secretions in mucus consolidation (e.g. cystic fibrosis). Nebulised hypertonic sodium chloride solution (3%) is used for mild to moderate acute viral bronchiolitis in infants.

Mannitol p. 282, administered by inhalation, improves mucus clearance and is licensed for the treatment of cystic fibrosis as an add-on therapy to standard care.

MUCOLYTICS

Carbocisteine

- **INDICATIONS AND DOSE**
  - **Reduction of sputum viscosity**
    - **BY MOUTH**
      - Adult: Initially 2.25 g daily in divided doses, then reduced to 1.5 g daily in divided doses, as condition improves

- **CONTRA-INDICATIONS** Active peptic ulceration
- **CAUTIONS** History of peptic ulceration (may disrupt the gastric mucosal barrier)
- **SIDE-EFFECTS**
  - Rare Gastro-intestinal bleeding
  - Frequency not known Erythema multiforme - Stevens-Johnson syndrome
- **PREGNANCY** Manufacturer advises avoid in first trimester.
- **BREAST FEEDING** Manufacturer advises avoid.
- **PRESCRIBING AND DISPENSING INFORMATION** Flavours of oral liquid formulations may include cherry, raspberry, cinnamon, or rum.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Oral solution**
    - Carbocisteine (Non-proprietary)
      - Carbocisteine 75 mg per 1 ml
        - Carbocisteine 750mg/10ml oral solution 10ml sachets sugar free sugar-free | 15 sachet [POM] £3.85 DT price = £3.85
      - Mucodyne (Sanofi)
        - Carbocisteine 50 mg per 1 ml
          - Mucodyne Paediatric 250mg/5ml syrup | 125 ml [POM] £12.60
          - Mucodyne 250mg/5ml syrup | 300 ml [POM] £8.39 DT price = £8.39
    - Mucodyne (Sanofi)
      - Carbocisteine 75 mg per 1 ml
        - Carbocisteine 375mg capsules | 120 capsule [PSt] £18.98 DT price = £9.36
      - Carbocisteine 375 mg
        - Carbocisteine 375mg capsules | 120 capsule [PSt] £18.98 DT price = £9.36

- **EDRONESTEINE**
  - **INDICATIONS AND DOSE**
    - Symptomatic treatment of acute exacerbations of chronic bronchitis
      - **BY MOUTH**
        - Adult: 300 mg twice daily for up to 10 days

- **CAUTIONS** History of peptic ulceration (may disrupt the gastric mucosal barrier)
- **SIDE-EFFECTS**
  - Very rare Abdominal pain - diarrhoea - headache - nausea - rash - taste disturbance - urticaria - vomiting
- **PREGNANCY** Manufacturer advises avoid—no information available.
- **BREAST FEEDING** Manufacturer advises avoid—no information available.
- **HEPATIC IMPAIRMENT** Manufacturer advises max. 300 mg daily in mild to moderate impairment. Avoid in severe impairment.
- **RENAL IMPAIRMENT** Avoid if eGFR less than 25 ml/minute/1.73 m²—no information available.
- **NATIONAL FUNDING/ACCESS DECISIONS**
  - Scottish Medicines Consortium (SMC) Decisions
    - The Scottish Medicines Consortium (October 2007) has advised that erdosteine (Erdotin®) is not recommended for the symptomatic treatment of acute exacerbations of chronic bronchitis.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Capsule**
    - Erdotin (Galen Ltd)
      - Erdosteine 300 mg
        - Erdotin 300mg capsules | 20 capsule [PSt]
        - £4.25 DT price = £4.25

3.1 Cystic fibrosis

MUCOLYTICS

Dornase alfa

(Phosphorylated glycosylated recombinant human deoxyribonuclease 1 (rhDNase))

- **DRUG ACTION** Dornase alfa is a genetically engineered version of a naturally occurring human enzyme which cleaves extracellular deoxyribonucleic acid (DNA).

- **INDICATIONS AND DOSE**
  - Management of cystic fibrosis patients with a forced vital capacity (FVC) of greater than 40% of predicted to improve pulmonary function
    - **BY INHALATION OF NEBULISED SOLUTION**
      - Adult: 2500 units once daily, administered by jet nebuliser, patients over 21 years may benefit from twice daily dosage

- **DOSE EQUIVALENCE AND CONVERSION**
  - Dornase alfa 1000 units is equivalent to 1 mg

- **SIDE-EFFECTS**
  - Rare Chest pain - conjunctivitis - dyspepsia - dysphagia - dyspnoea - laryngitis - pharyngitis - pyrexia - rash - rhinitis - urticaria
  - **PREGNANCY** No evidence of teratogenicity; manufacturer advises use only if potential benefit outweighs risk.
  - **BREAST FEEDING** Amount probably too small to be harmful—manufacturer advises caution.
DIRECTIONS FOR ADMINISTRATION
Dornase alfa is administered by inhalation using a jet nebuliser, usually once daily at least 1 hour before physiotherapy; however, alternate-day therapy may be as effective as daily treatment.
For use undiluted with jet nebulisers only; ultrasonic nebulisers are unsuitable.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.
Nebuliser liquid
- Pulmozyme (Roche Products Ltd)
  Dornase alfa 1 mg per 1 ml Pulmozyme 2.5mg nebuliser liquid 2.5ml ampoules | 30 ampoule ® £496.43 OT price • £496.43

INDICATIONS AND DOSE
Treatment of cystic fibrosis in patients who have a G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (under expert supervision)
- BY MOUTH
  - Adult: 150 mg every 12 hours

DOSE ADJUSTMENTS DUE TO INTERACTIONS
Manufacturer advises reduce dose to 150 mg twice a week with concurrent use of potent inhibitors of CYP3A4.
Manufacturer advises reduce dose to 150 mg once daily with concurrent use of moderate inhibitors of CYP3A4.

CONTRA-INDICATIONS
Organ transplantation (no information available)

INTERACTIONS ➔ Appendix 1: ivacaftor

SIDE-EFFECTS
- Common or very common Abdominal pain • diarrhoea • dizziness • ear discomort • headache • nasal congestion • nasopharyngitis • oropharyngeal pain • pharyngeal erythema • pharyngeal oedema • rash • rhinitis • tinnitus • upper respiratory tract infection
- Uncommon Gynaecomastia • nipple disorders • vestibular disorder

PREGNANCY
Manufacturer advises use only if potential benefit outweighs risk—no information available.

BREAST FEEDING
Manufacturer advises use only if potential benefit outweighs risk—no information available.

HEPATIC IMPAIRMENT
Max. 150 mg once daily in moderate impairment; in severe impairment, manufacturer recommends use only if potential benefit outweighs risk—starting dose 150 mg on alternate days, dosing interval adjusted according to clinical response and tolerability.

RENAL IMPAIRMENT
Caution in severe impairment.

PRE-TREATMENT SCREENING
If the patient's genotype is unknown, a validated genotyping method should be performed to confirm the presence of the G551D mutation in at least one allele of the CFTR gene before starting treatment.

MONITORING REQUIREMENTS
Manufacturer advises monitor liver function before treatment, every 3 months during the first year of treatment, then annually thereafter (more frequent monitoring should be considered in patients with a history of transaminase elevations).

DIRECTIONS FOR ADMINISTRATION
Tablets should be taken with fat-containing food.

PRESCRIBING AND DISPENSING INFORMATION
Ivacaftor should be prescribed by a physician experienced in the treatment of cystic fibrosis.

PATIENT AND CARER ADVICE
Patients or carers should be given advice on how to administer ivacaftor tablets.

Driving and skilled tasks
Manufacturer advises that patients and their carers should be counselled on the effects on driving and skilled tasks—increased risk of dizziness.

NATIONAL FUNDING/ACCESS DECISIONS
Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (December 2016) that ivacaftor (Kalydeco®) is not recommended for use within NHS Scotland for the treatment of patients with cystic fibrosis aged 18 years and above who have an R117H mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, as insufficient clinical and economic evidence was submitted.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.
Tablet
CAUTIONARY AND ADVISORY LABELS
- 25
- Kalydeco (Vertex Pharmaceuticals (UK) Ltd) ▼ Ivacaftor 150 mg Kalydeco 150mg tablets | 56 tablet £14,000.00

Lumacaftor with ivacaftor
The properties listed below are those particular to the combination only. For the properties of the components please consider, ivacaftor above.

INDICATIONS AND DOSE
Treatment of cystic fibrosis in patients who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (under expert supervision)
- BY MOUTH
  - Adult: 400/250 mg every 12 hours

DOSE ADJUSTMENTS DUE TO INTERACTIONS
Manufacturer advises reduce initial dose to 200/125 mg daily for the first week in those also taking a potent inhibitor of CYP3A4.

DOSE EQUIVALENCE AND CONVERSION
- Dose expressed as x/y mg of lumacaftor/ivacaftor.

CAUTIONS
Forced expiratory volume in 1 second (FEV1) less than 40% of the predicted normal value—additional monitoring required at initiation of treatment • pulmonary exacerbation—no information available

INTERACTIONS ➔ Appendix 1: ivacaftor, lumacaftor

SIDE-EFFECTS
- Common or very common Dyspnoea • elevated transaminases (clinically significant) • flatulence • menstrual disturbances • metrorrhagia • nausea • rhinorrhea • vomiting
- Uncommon Cholestatic hepatitis • hepatic encephalopathy • hypertension

BREAST FEEDING
Manufacturer advises avoid—present in milk in animal studies.

HEPATIC IMPAIRMENT
Manufacturer advises reduce dose to 400/250 mg in the morning and 200/125 mg in the evening (600/375 mg total daily dose) in moderate impairment; reduce dose to 200/125 mg every 12 hours (400/250 mg total daily dose) in severe impairment. Manufacturer advises use with caution in severe impairment.

PRE-TREATMENT SCREENING
If the patient's genotype is unknown, a validated genotyping method should be performed to confirm the presence of the F508del mutation on both alleles of the CFTR gene before starting treatment.

MONITORING REQUIREMENTS
Manufacturer advises monitor blood pressure periodically during treatment.
**Mannitol**

**INDICATIONS AND DOSE**
Treatment of cystic fibrosis as an add-on therapy to standard care

- **BY INHALATION OF POWDER**
- **Adult:** Maintenance 400 mg twice daily, an initiation dose assessment must be carried out under medical supervision, for details of the initiation dose regimen, consult product literature

**CONTRA-INDICATIONS**
Bronchial hyperresponsiveness to inhaled mannitol - impaired lung function (forced expiratory volume in 1 second < 30% of predicted) - non-CF bronchiectasis

**CAUTIONS**
Asthma - haemoptysis

**SIDE-EFFECTS**
- **Common or very common** Cough - haemoptysis - headache - pharyngolaryngeal pain - throat irritation - vomiting - wheezing

**PREGNANCY**
Manufacturer advises avoid.

**BREAST FEEDING**
Manufacturer advises avoid.

**PRE-TREATMENT SCREENING**
Patients must be assessed for bronchial hyperresponsiveness to inhaled mannitol before starting the therapeutic dose regimen; an initiation dose assessment must be carried out under medical supervision—for details of the initiation dose regimen, consult product literature.

**DIRECTIONS FOR ADMINISTRATION**
The dose should be administered 5–15 minutes after a bronchodilator and before physiotherapy; the second daily dose should be taken 2–3 hours before bedtime.

**PATIENT AND CARER ADVICE**
Patients or carers should be given advice on how to administer mannitol inhalation powder.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**
- **Orkambi®** (Vertex Pharmaceuticals (UK) Ltd)
  - Ivacaftor 125 mg, Lumacaftor 200 mg to stop.
  - Manufacturer advises if a dose is more than 508 hours late, Missed doses
  - Manufacturer advises avoid.
  - Missed doses
  - Manufacturer advises avoid.

**Scottish Medicine Consortium (SMC) Decisions**
The Scottish Medicine Consortium has advised (May 2016) that lumacaftor with ivacaftor (Orkambi®) is not recommended within NHS Scotland for the treatment of cystic fibrosis in patients who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

**Scottish Medicines Consortium (SMC) Decisions**
The Scottish Medicine Consortium, has advised (November 2013) that mannitol (Bronchitol®) is accepted for restricted use within NHS Scotland for the treatment of cystic fibrosis in adults aged 18 years and over as an add-on therapy to best standard of care. Mannitol is restricted to patients who are not currently using dornase alfa due to lack of response, intolerance, or ineligibility and have rapidly declining lung function and in whom other osmotic agents are considered unsuitable.

**Mannitol**

**INHALATION POWDER**

- **Mannitol (Non-proprietary)**
  - Mannitol 5 mg
    - Osmohale 5mg inhalation powder capsules | 1 capsule £0.00 no price available
  - Mannitol 10 mg
    - Osmohale 10mg inhalation powder capsules | 1 capsule £0.00 no price available
  - Mannitol 20 mg
    - Osmohale 20mg inhalation powder capsules | 1 capsule £0.00 no price available
  - Mannitol 40 mg
    - Osmohale 40mg inhalation powder capsules | 15 capsule £0.00 no price available
  - **Bronchitol®** (Chiesi Ltd)
    - Mannitol 40 mg
      - Bronchitol 40mg inhalation powder capsules with two devices | 280 capsule £231.66
      - Bronchitol 40mg inhalation powder capsules with device | 10 capsule £0.00 no price available

**4 Cough and congestion**

**Aromatic inhalations, cough preparations and systemic nasal decongestants**

**Aromatic inhalations in adults**
Inhalations containing volatile substances such as eucalyptus oil are traditionally used and although the vapour may contain little of the additive it encourages deliberate inspiration of warm moist air which is often comforting in bronchitis; boiling water should not be used owing to the risk of scalding. Inhalations are also used for the relief of
Cough and congestion

nasal obstruction in acute rhinitis or sinusitis. Eucalyptus with menthol inhalation p. 284 is used to relieve sinusitis affecting the maxillary antrum.

Cough preparations in adults

Cough suppressants

Cough may be a symptom of an underlying disorder, such as asthma, gastro-oesophageal reflux disease, or rhinitis, which should be addressed before prescribing cough suppressants. Cough may be a side-effect of another drug, such as an ACE inhibitor, or it can be associated with smoking or environmental pollutants. Cough can also have a significant habit component. When there is no identifiable cause, cough suppressants may be useful, for example if sleep is disturbed. They may cause sputum retention and this may be harmful in patients with chronic bronchitis and bronchiectasis. Codeine phosphate p. 431 may be effective but it is constipating and can cause dependence; dextromethorphan and pholcodine below have fewer side-effects.

Sedating antihistamines are used as the cough suppressant component of many compound cough preparations on sale to the public; all tend to cause drowsiness which may reflect their main mode of action.

Demulcent and expectorant cough preparations

Demulcent cough preparations contain soothing substances such as syrup or glycerol and some patients believe that such preparations relieve a dry irritating cough. Preparations such as simple linctus have the advantage of being harmless and inexpensive; paediatric simple linctus is particularly useful in children.

Expectorants are claimed to promote expulsion of bronchial secretions, but there is no evidence that any drug can specifically facilitate expectoration. Compound preparations are on sale to the public for the treatment of cough and colds but should not be used in children under 6 years; the rationale for some is dubious. Care should be taken to give the correct dose and to not use more than one preparation at a time.

Systemic nasal decongestants

Nasal decongestants for administration by mouth may not be as effective as preparations for local application but they do not give rise to rebound nasal congestion on withdrawal. Pseudoephedrine hydrochloride p. 1100 is available over the counter; it has few sympathomimetic effects.

Aromatic inhalations in children

The use of strong aromatic decongestants (applied as rubs or to pillows) is not advised for infants under the age of 3 months. Carers of young infants in whom nasal obstruction with mucus is a problem can readily be taught appropriate techniques of suction aspiration but sodium chloride 0.9% p. 953 given as nasal drops is preferred; administration before feeds may ease feeding difficulties caused by nasal congestion.

Cough preparations in children

The use of over-the-counter cough suppressants containing codeine phosphate should be avoided in children under 12 years and in children of any age known to be CYP2D6 ultra-rapid metabolisers. Cough suppressants containing similar opioid analgesics such as dextromethorphan and pholcodine are not generally recommended in children and should be avoided in children under 6 years.

MHRA/CHM advice (March 2008 and February 2009)

Children under 6 years should not be given over-the-counter cough and cold medicines containing the following ingredients:

- brompheniramine, chlorphenamine maleate p. 272, diphenhydramine, doxylamine, promethazine, or triprolidine (antihistamines);
- dextromethorphan or pholcodine (cough suppressants);
- guaifenesin or ipecacuanha (expectorants);
- phenylephrine hydrochloride p. 183, pseudoephedrine hydrochloride, ephedrine hydrochloride p. 261, oxymetazoline, or xylometazoline hydrochloride p. 1100 (decongestants).

Over-the-counter cough and cold medicines can be considered for children aged 6–12 years after basic principles of best care have been tried, but treatment should be restricted to five days or less. Children should not be given more than 1 cough or cold preparation at a time because different brands may contain the same active ingredient; care should be taken to give the correct dose.

COUGH AND COLD PREPARATIONS

Pholcodine

INDICATIONS AND DOSE

Dry cough

- BY MOUTH USING LINCTUS
  - Child 6-11 years: 2–5 mg 3–4 times a day
  - Child 12-17 years: 5–10 mg 3–4 times a day
  - Adult: 5–10 mg 3–4 times a day

IMPORTANT SAFETY INFORMATION

MHRA/CHM ADVICE (MARCH 2008 AND FEBRUARY 2009) OVER-THE-COUNTER COUGH AND COLD MEDICINES FOR CHILDREN

Children under 6 years should not be given over-the-counter cough and cold medicines containing pholcodine (cough suppressant).

Over-the-counter cough and cold medicines can be considered for children aged 6–12 years after basic principles of best care have been tried, but treatment should be restricted to 5 days or less. Children should not be given more than 1 cough or cold preparation at a time because different brands may contain the same active ingredient; care should be taken to give the correct dose.

CONTRA-INDICATIONS

Bronchiectasis · bronchiolitis (in children) · chronic bronchitis · chronic obstructive pulmonary disease (in adults) · patients at risk of respiratory failure

CAUTIONS

Asthma · chronic cough · persistent cough · productive cough

INTERACTIONS

Appendix 1: pholcodine

SIDE-EFFECTS

Confusion · constipation · dizziness · drowsiness · excitation · nausea · rash · sputum retention · vomiting

PREGNANCY

Manufacturer advises avoid unless potential benefit outweighs risk.

BREAST FEEDING

Manufacturer advises avoid unless potential benefit outweighs risk—no information available.

HEPATIC IMPAIRMENT

Avoid in hepatic impairment.

RENA! IMPAIRMENT

Use with caution in renal impairment. Avoid in severe renal impairment.
**PR ESCRIBING AND DISPENSING INFORMATION** Pholcodine is not generally recommended for children. Flavours of oral liquid formulations may include orange. When prepared extemporaneously, the BP states Pholcodine Linctus, BP consists of pholcodine 5 mg/5 mL in a suitable flavoured vehicle, containing citric acid monohydrate 1% and Pholcodine Linctus, Strong, BP consists of pholcodine 10 mg/5 mL in a suitable flavoured vehicle, containing citric acid monohydrate 2%.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Oral solution**

- **Pholcodine (Non-proprietary)**
  - Pholcodine 1 mg per 1 ml Pholcodine 5mg/5ml linctus | 200 ml (£1.32 DT price = £1.32)
  - Pholcodine 5mg/5ml linctus sugar free sugar-free | 200 ml (£1.34 DT price = £1.34 sugar-free)  | 2000 ml (£13.40 sugar-free)
  - Pholcodine 2 mg per 1 ml Pholcodine 10mg/5ml linctus strong sugar free sugar-free | 2000 ml (£10.88 DT price = £9.88 sugar-free)
  - Pholcodine 10mg/5ml linctus strong | 200 ml (£1.61 sugar-free)
- **Galenphol** (Thorton & Ross Ltd)
  - Pholcodine 400 microgram per 1 ml Galenphol Paediatric 2mg/5ml linctus sugar-free | 2000 ml (£4.50 DT price = £4.50)
  - Pholcodine 1 mg per 1 ml Galenphol 5mg/5ml linctus sugar-free | 2000 ml (£9.50)
  - Pholcodine 2 mg per 1 ml Galenphol Strong 10mg/5ml linctus sugar-free | 2000 ml (£9.88 DT price = £9.88)
- **Pavacol-D** (Alliance Pharmaceuticals Ltd)
  - Pholcodine 1 mg per 1 ml Pavacol-D 5mg/5ml mixture sugar-free | 150 ml (£1.69 sugar-free)  | 300 ml (£2.55 sugar-free)

**OTHER**

**Cough and Cold Preparations**

**Citric acid**

(Formulated as Simple Linctus)

**INDICATIONS AND DOSE**

- **Cough**
  - **By Mouth**
    - Adult: 5 mL 3–4 times a day, this dose is for Simple Linctus, BP (2.5%).

**PRESCRIBING AND DISPENSING INFORMATION** Flavours of oral liquid formulations may include anise.

When prepared extemporaneously, the BP states Simple Linctus, BP consists of citric acid monohydrate 2.5%, in a suitable vehicle with an anise flavour.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Oral solution**

- **Citric acid (Non-proprietary)**
  - Citric acid monohydrate 6.25 mg per 1 ml Simple linctus paediatric sugar free sugar-free | 2000 ml (£12.50)
  - Care Simple linctus paediatric sugar free sugar-free | 200 ml (£12.50 sugar-free)  | 2000 ml (£12.50 DT price = £1.25 sugar-free)
  - Simple linctus paediatric | 200 ml (£1.05–£1.13 DT price = £1.05 sugar-free)
  - Citric acid monohydrate 25 mg per 1 ml Simple linctus sugar free sugar-free | 200 ml (£0.89 sugar-free)  | 2000 ml (£8.90)
  - Numark Simple linctus | 200 ml (£0.81 DT price = £0.93 sugar-free)
  - Simple linctus | 200 ml (£0.93 DT price = £0.93 sugar-free)
  - Citric acid 100 mg per 1 ml Carebx oral solution 10ml sachets | 10 sachet (£ no price available

**MENTHOL AND DERIVATIVES**

**Eucalyptus with menthol**

**INDICATIONS AND DOSE**

**Aromatic inhalation for relief of nasal congestion**

- **By Inhalation**
  - Child: Add 5 mL to a pint of hot, not boiling, water and inhale the vapour; repeat after 4 hours if necessary
  - Adult: Add 5 mL to a pint of hot, not boiling, water and inhale the vapour; repeat after 4 hours if necessary

**PRESCRIBING AND DISPENSING INFORMATION** When prepared extemporaneously, the BP states Menthol and Eucalyptus Inhalation, BP 1980 consists of racementhon or levomenthon 2 g, eucalyptus oil 10 mL, light magnesium carbonate 7 g, water to 100 mL.

**PROFESSION SPECIFIC INFORMATION**

Dental practitioners’ formulary

Menthol and Eucalyptus Inhalation BP, 1980 may be prescribed.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Inhalation vapour**

- **Eucalyptus with menthol (Non-proprietary)**
  - Menthol 20 mg per 1 ml, Magnesium carbonate light 70 mg per 1 ml, Eucalyptus oil 100 microlitres per 1 ml Menthol and Eucalyptus inhalation | 100 ml (£1.36 DT price = £1.36)

**RESINS**

**Benzoin tincture**

(Friars’ Balsam)

**INDICATIONS AND DOSE**

**Aromatic inhalation for relief of nasal congestion**

- **By Inhalation**
  - Child: Add 5 mL to a pint of hot, not boiling, water and inhale the vapour; repeat after 4 hours if necessary
  - Adult: Add 5 mL to a pint of hot, not boiling, water and inhale the vapour; repeat after 4 hours if necessary

**SIDE-EFFECTS**

Allergic contact dermatitis

**PRESCRIBING AND DISPENSING INFORMATION**

Not recommended (applied as a rub or to pillows) for infants under 3 months.

When prepared extemporaneously, the BP states Benzoin Tincture, Compound, BP consists of balsamic acids approx. 4.5%.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Liquid**

**CAUTIONARY AND ADVISORY LABELS**

- **Benzoin tincture (Non-proprietary)**
  - Balsamic acids 16.5 mg per 1 ml Benzoin tincture | 500 ml (£9.95 DT price = £9.95)

**5 Idiopathic pulmonary fibrosis**

Other drugs used for Idiopathic pulmonary fibrosis

Nintedanib, p. 918
ANTIFIBROTICS

Pirfenidone

- **DRUG ACTION** The exact mechanism of action of pirfenidone is not yet understood, but it is believed to slow down the progression of idiopathic pulmonary fibrosis by exerting both antifibrotic and anti-inflammatory properties.

- **INDICATIONS AND DOSE**
  
  **Treatment of mild to moderate idiopathic pulmonary fibrosis (initiated under specialist supervision)**
  
  - **BY MOUTH**
    - Adult: Initially 267 mg 3 times a day for 7 days, then increased to 534 mg 3 times a day for 7 days, then increased to 801 mg 3 times a day

  **DOSE ADJUSTMENTS DUE TO INTERACTIONS**
  
  Caution with concomitant use with ciprofloxacin—reduce dose of pirfenidone to 534 mg three times daily with high-dose ciprofloxacin (750 mg twice daily). Caution with concomitant use of drugs known to cause photosensitivity—if photosensitivity reaction or rash occurs, dose adjustment or treatment interruption may be required (consult product literature).

- **CONTRA-INDICATIONS** Cigarette smoking

- **CAUTIONS**
  
  Photosensitivity Avoid exposure to direct sunlight—if photosensitivity reaction or rash occurs, dose adjustment or treatment interruption may be required (consult product literature).

  Treatment interruption If treatment is interrupted for 14 consecutive days or more, the initial 1 week titration regimen should be repeated; if treatment is interrupted for less than 14 consecutive days, the dose can be resumed at the previous daily dose without titration.

- **INTERACTIONS**
  
  - **Common or very common** Abdominal discomfort · anorexia · arthralgia · constipation · diarrhoea · dizziness · dry skin · dysgeusia · dyspepsia · erythema · flatulence · gastritis · gastro-oesophageal reflux disease · headache · hot flush · insomnia · malaise · myalgia · nausea · non-cardiac chest pain · photosensitivity reaction · pruritus · raised hepatic enzymes · rash · somnolence · upper respiratory tract infection · urinary tract infection · vomiting · weight loss
  
  - **Rare** Raised bilirubin in combination with raised hepatic transaminases

- **SIDE-EFFECTS, FURTHER INFORMATION**
  
  Gastrointestinal side-effects may require dose reduction or treatment interruption—consult product literature.

- **PREGNANCY** Manufacturer advises avoid—no information available.

- **BREAST FEEDING** Manufacturer advises avoid—no information available.

- **HEPATIC IMPAIRMENT** Use with caution in mild to moderate hepatic impairment, particularly if concomitant use of CYP1A2 inhibitors. Avoid use in severe hepatic impairment.

- **RENAL IMPAIRMENT** Avoid use if eGFR less than 30 mL/minute/1.73 m².

- **MONITORING REQUIREMENTS**
  
  - Monitor for weight loss.
  
  - Test liver function before treatment, then at monthly intervals for the next 6 months, and then every 3 months thereafter; review if abnormal liver function tests—dose reduction, treatment interruption or discontinuation may be required (consult product literature).

- **PATIENT AND CARER ADVICE**
  
  Driving and skilled tasks Dizziness or malaise may affect performance of skilled tasks (e.g. driving).

- **NATIONAL FUNDING/ACCESS DECISIONS**
  
  **NICE technology appraisals (TAs)**
  
  - Pirfenidone for treating idiopathic pulmonary fibrosis (April 2013) NICE TA282

  Pirfenidone is recommended as an option for treating idiopathic pulmonary fibrosis only if:

  - the patient has a forced vital capacity (FVC) between 50% and 80% predicted, and
  
  - the manufacturer provides pirfenidone with the discount agreed in the patient access scheme.

  Treatment should be discontinued if there is evidence of disease progression, defined as a decline in predicted FVC of 10% or more within any 12 month period.

  Patients currently receiving pirfenidone that is not recommended according to the above criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop.

  - www.nice.org.uk/TA282

  **Scottish Medicines Consortium (SMC) Decisions** The Scottish Medicines Consortium has advised (August 2013) that pirfenidone is accepted for restricted use within NHS Scotland for the treatment of mild to moderate idiopathic pulmonary fibrosis. Pirfenidone is restricted for use in patients with a predicted forced vital capacity less than or equal to 80%, and only whilst pirfenidone is available at the price agreed in the patient access scheme.

- **MEDICINAL FORMS**
  
  There can be variation in the licensing of different medicines containing the same drug.

  **Capsule**

  **CAUTIONARY AND ADVISORY LABELS** 21, 25

  - **Esbriet (Roche Products Ltd)**

  Pirfenidone 267 mg

  - Esbriet 267 mg capsules | 63 capsule

  - £501.92 | 252 capsule | £2,007.70 | 270 capsule | £2,151.10

**6 Respiratory depression, respiratory distress syndrome and apnoea**

Respiratory stimulants

**Overview**

Respiratory stimulants (anaesthetic drugs) have a limited place in the treatment of ventilatory failure in patients with chronic obstructive pulmonary disease. They are effective only when given by intravenous injection or infusion and have a short duration of action. Their use has largely been replaced by ventilatory support including nasal intermittent positive pressure ventilation. However, occasionally when ventilatory support is contra-indicated and in patients with hypercapnic respiratory failure who are becoming drowsy or comatose, respiratory stimulants in the short term may arouse patients sufficiently to co-operate and clear their secretions.

Respiratory stimulants can also be harmful in respiratory failure since they stimulate non-respiratory as well as respiratory muscles. They should only be given under expert supervision in hospital and must be combined with active physiotherapy. There is at present no oral respiratory stimulant available for long-term use in chronic respiratory failure.
RESPIRATORY STIMULANTS

### Doxapram hydrochloride

**INDICATIONS AND DOSE**

**Postoperative respiratory depression**
- **INITIALLY BY INTRAVENOUS INJECTION**
  - Adult: Initially 1–1.5 mg/kg, to be administered over at least 30 seconds, repeated if necessary after intervals of one hour, alternatively (by intravenous infusion) 2–3 mg/minute, adjusted according to response

**Acute respiratory failure**
- **BY INTRAVENOUS INFUSION**
  - Adult: 1.5–4 mg/minute, adjusted according to response, to be given concurrently with oxygen and whenever possible monitor with frequent measurement of blood gas tensions

**CONTRA-INDICATIONS**
- Cerebral oedema
- Cerebrovascular accident
- Coronary artery disease
- Epilepsy and other convulsive disorders
- Hyperthyroidism
- Physical obstruction of respiratory tract
- Severe hypertension
- Status asthmaticus

**CAUTIONS**
- Give with beta-agonist in bronchoconstriction
- Give with oxygen in severe irreversible airways obstruction or severely decreased lung compliance (because of increased work load of breathing)
- Hypertension
- Impaired cardiac reserve
- Phaeochromocytoma

**INTERACTIONS** → Appendix 1: doxapram

**SIDE-EFFECTS**
- Arrhythmias
- Bradycardia
- Bronchospasm
- Chest pain
- Confusion
- Convulsions
- Cough
- Dizziness
- Dyspnoea
- Extrasystoles
- Flushing
- Hallucination
- Headache
- Hyperactivity
- Hypertension
- Incontinence
- Laryngospasm
- Muscle spasms
- Nausea
- Perineal warmth
- Pyrexia
- Tachycardia
- Urinary retention
- Vomiting

**PREGNANCY**
- No evidence of harm, but manufacturer advises avoid unless benefit outweighs risk.

**HEPATIC IMPAIRMENT**
- Use with caution.

**MONITORING REQUIREMENTS**
- Frequent arterial blood gas and pH measurements are necessary during treatment to ensure correct dosage.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**
- **Doxapram hydrochloride (Non-proprietary)**
  - Doxapram hydrochloride 20 mg per 1 ml
  - Doxapram hydrochloride 200 mg/5ml solution for injection ampoules | 5 ampoule [PSTM] £110.00

**Infusion**
- **Doxapram hydrochloride (Non-proprietary)**
  - Doxapram hydrochloride 2 mg per 1 ml
  - Doxapram hydrochloride 1g/500ml infusion bags | 1 bag [PSTM] no price available
Chapter 4
Nervous system

CONTENTS

1 Dementia 287
2 Epilepsy and other seizure disorders 292
2.1 Status epilepticus 311
3 Mental health disorders 325
3.1 Anxiety 325
3.2 Attention deficit hyperactivity disorder 330
3.3 Bipolar disorder and mania 336
3.4 Depression 342
3.5 Inappropriate sexual behaviour 363
3.6 Psychoses and schizophrenia 364
4 Movement disorders 385
4.1 Dystonias and other involuntary movements 386
4.2 Parkinson’s disease 389
5 Nausea and labyrinth disorders 408
5.1 Menière’s disease 419
6 Pain 420
6.1 Headache 449
6.1a Migraine 450
6.2 Neuropathic pain 457
7 Sleep disorders 459
7.1 Insomnia 459
7.2 Narcolepsy 466
8 Substance dependence 468
8.1 Alcohol dependence 471
8.2 Nicotine dependence 473
8.3 Opioid dependence 476

1 Dementia

Dementia 27-Sep-2016

Description of condition

Dementia is a progressive and largely irreversible clinical syndrome that is characterised by a widespread impairment of mental function. There are a number of conditions that cause the symptoms of dementia. Alzheimer’s disease accounts for most cases; other common causes include vascular dementia (due to cerebrovascular disease) and dementia with Lewy bodies. The symptoms of dementia include cognitive dysfunction (such as problems with memory, concentration and problem-solving), non-cognitive symptoms (such as psychiatric and behavioural problems) and difficulties with activities of daily living.

Aims of treatment

The aims of treatment are to promote independence, maintain function and treat symptoms.

Non-drug treatment

Patients with all types of mild-to-moderate dementia presenting with cognitive symptoms should be given the opportunity to participate in a structured group cognitive stimulation programme.

Drug treatment

Management of cognitive symptoms

When pharmacological treatments are used, they should be initiated and supervised by a specialist experienced in the management of dementia. The manufacturers of donepezil hydrochloride p. 288, galantamine p. 289, rivastigmine p. 290 and memantine hydrochloride p. 291 recommend that treatment should be reassessed on a regular basis.

Treatment should be continued only when it is considered to be having a worthwhile effect on symptoms. Donepezil hydrochloride, galantamine and rivastigmine (acetylcholinesterase inhibitors) are recommended for the treatment of cognitive symptoms of mild-to-moderate dementia due to Alzheimer’s disease. Memantine hydrochloride is a suitable alternative for patients with moderate Alzheimer’s disease when acetylcholinesterase inhibitors are contra-indicated or are not tolerated. Memantine hydrochloride is the drug of choice for patients with severe Alzheimer’s disease.

Pharmacological treatments are not recommended for the treatment of cognitive symptoms in cases of vascular dementia.

Management of non-cognitive symptoms

Patients with dementia who develop non-cognitive symptoms (such as delusions or anxiety) or ‘behaviour that challenges’ (such as aggression or agitation) should only be offered a pharmacological intervention if they are severely distressed or if there is an immediate risk of harm to the patient or others. Less severe non-cognitive symptoms are treated with non-pharmacological interventions, such as multisensory stimulation or aromatherapy.

Antipsychotic drugs

Patients with mild-to-moderate non-cognitive symptoms due to Alzheimer’s disease, vascular dementia, mixed dementias or dementia with Lewy bodies should not be prescribed antipsychotic drugs.

Patients with severe non-cognitive symptoms due to Alzheimer’s disease, vascular dementia, mixed dementias or dementia with Lewy bodies which are causing significant distress can be offered treatment with an antipsychotic drug (see Antipsychotic drugs under Psychoses and related disorders p. 364). Careful consideration should be given to the patient’s co-morbid conditions and the benefits and risks of treatment. The MHRA has reported (2009) a clear increased risk of stroke and a small increased risk of death when antipsychotic drugs are used in elderly patients with dementia. The balance of risks and benefits should be carefully assessed, including any previous history of stroke or transient ischaemic attack and any risk factors for cerebrovascular disease including hypertension, diabetes, smoking and atrial fibrillation.

Treatment with antipsychotic drugs should be started with a low dose and titrated upwards, with regular review. In patients who have dementia with Lewy bodies, careful monitoring for severe untoward reactions, such as neuroleptic sensitivity reactions, is recommended.
Acetylcholinesterase inhibitors and memantine

An acetylcholinesterase inhibitor may be used to manage non-cognitive symptoms in patients with mild-to-moderate dementia due to Alzheimer’s disease, if a non-pharmacological approach or an antipsychotic drug is inappropriate or ineffective.

Memantine hydrochloride may be considered in patients with severe symptoms, if a non-pharmacological approach or an antipsychotic drug is inappropriate or ineffective. Memantine hydrochloride may also be used in patients with moderate symptoms in whom acetylcholinesterase inhibitors are contra-indicated.

Patients who have dementia with Lewy bodies should be offered an acetylcholinesterase inhibitor for the treatment of non-cognitive symptoms. Acetylcholinesterase inhibitors are not recommended in patients with vascular dementia.

Management of violence, aggression, and extreme agitation

In cases of dementia associated with severe behavioural disturbance that requires urgent treatment (if violence, aggression and extreme agitation threaten the safety of the patient or others), an antipsychotic drug or a benzodiazepine may be given (see Antipsychotic drugs under Psychoses and related disorders p. 364; see Benzodiazepines under Hypnotics and anxiolytics p. 459). High doses or combinations of drugs should be avoided, and the lowest effective dose should be used. Oral treatment should be offered before parenteral administration. If intramuscular administration is needed for behavioural control, lorazepam p. 322, haloperidol p. 368 or olanzapine p. 379 should be used. Diazepam and chlorpromazine hydrochloride are not recommended. Intravenous administration should be used only in exceptional circumstances.

Useful Resources


Other drugs used for Dementia Risperidone, p. 383

ANTICHLORINERGASES  CENTRALLY ACTING

Donepezil hydrochloride

DRUG ACTION

Donepezil is a reversible inhibitor of acetylcholinesterase.

INDICATIONS AND DOSE

Mild to moderate dementia in Alzheimer’s disease

BY MOUTH

Adult: Initially 5 mg once daily for one month, then increased if necessary up to 10 mg daily, doses to be given at bedtime.

CAUTIONS

Asthma - chronic obstructive pulmonary disease - sick sinus syndrome - supraventricular conduction abnormalities - susceptibility to peptic ulcers

INTERACTIONS  Appendix 1: anticholinesterases, centrally acting

SIDE-EFFECTS

Common or very common Abnormal dreams - aggression - agitation - anorexia - diarrhoea - dizziness - fatigue - hallucinations - headache - insomnia - muscle cramps - nausea - pruritus - rash - syncope - urinary incontinence - vomiting

Uncommon Bradycardia - duodenal ulcers - gastric ulcers - gastro-intestinal haemorrhage - seizures

Rare AV block - extrapyramidal symptoms - hepatitis - potential for bladder outflow obstruction - sino-atrial block

Very rare Neuroleptic malignant syndrome

SIDE-EFFECTS, FURTHER INFORMATION

Acetylcholinesterase inhibitors can cause unwanted dose-related cholinergic effects and should be started at a low dose and the dose increased according to response and tolerability.

HEPATIC IMPAIRMENT

Caution in mild to moderate impairment. No information available for severe impairment.

DIRECTIONS FOR ADMINISTRATION

Donepezil orodispersible tablet should be placed on the tongue, allowed to disperse, and swallowed.

PATIENT AND CARER ADVICE

Patient or carers should be given advise on how to administer donepezil hydrochloride orodispersible tablets.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

Donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease—updated May 2016 NICE TA217

Donepezil can be used for the treatment of mild to moderate Alzheimer’s disease. Treatment should only be prescribed under the following conditions:

- treatment should be initiated on the advice of a specialist
- ensure that local arrangements for prescribing, supply and treatment review follow the NICE guideline on medicines optimisation
- treatment should continue only if it is considered to have a worthwhile effect on cognitive, global, functional, or behavioural symptoms.

Healthcare professionals should not rely solely on assessment scales to determine the severity of Alzheimer’s disease when the patient has learning or other disabilities, or other communication difficulties.

www.nice.org.uk/TA217

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

Oral solution

Donepezil hydrochloride (Non-proprietary)

Donepezil hydrochloride 1 mg per 1 ml Donepezil 1mg/ml oral solution sugar free sugar-free 150 ml Cost £48.00 DT price = £48.00

Orodispersible tablet

Donepezil hydrochloride 5 mg Donepezil 5mg orodispersible tablets 28 tablet (Cost) £59.85

Donepezil 5mg orodispersible tablets sugar free sugar-free 28 tablet (Cost) £6.27-£50.87 DT price = £6.60

Donepezil hydrochloride 10 mg Donepezil 10mg orodispersible tablets sugar free sugar-free 28 tablet (Cost) £6.64-£71.31 DT price = £7.99

Aricept Evess (Eisai Ltd)

Donepezil hydrochloride 5 mg Aricept Evess 5mg orodispersible tablets sugar-free 28 tablet (Cost) £59.85 DT price = £6.60

Donepezil hydrochloride 10 mg Aricept Evess 10mg orodispersible tablets sugar-free 28 tablet (Cost) £83.89 DT price = £7.99

Tablet

Donepezil hydrochloride (Non-proprietary)

Donepezil hydrochloride 5 mg Donepezil 5mg tablets 28 tablet (Cost) £59.85 DT price = £0.89

Donepezil hydrochloride 10 mg Donepezil 10mg tablets 28 tablet (Cost) £83.89 DT price = £1.11

Aricept (Eisai Ltd)

Donepezil hydrochloride 5 mg Aricept 5mg tablets 28 tablet (Cost) £59.85 DT price = £0.89

Donepezil hydrochloride 10 mg Aricept 10mg tablets 28 tablet (Cost) £83.89 DT price = £1.11
Galantamine

- **DRUG ACTION** Galantamine is a reversible inhibitor of acetylcholinesterase and it also has nicotinic receptor agonist properties.

- **INDICATIONS AND DOSE**
  - **Mild to moderately severe dementia in Alzheimer's disease**
    - **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
      - Adult: Initially 4 mg twice daily for 4 weeks, increased to 8 mg twice daily for at least 4 weeks; maintenance 8–12 mg twice daily
    - **BY MOUTH USING MODIFIED-RELEASE CAPSULES**
      - Adult: Initially 8 mg once daily for 4 weeks, increased to 16 mg once daily for at least 4 weeks; maintenance 16–24 mg daily

- **CAUTIONS** Avoid in gastro-intestinal obstruction; avoid in urinary outflow obstruction; avoid whilst recovering from bladder surgery; avoid whilst recovering from gastro-intestinal surgery; cardiac disease; chronic obstructive pulmonary disease; congestive heart failure; electrolyte disturbances; history of seizures; history of severe asthma; pulmonary infection; sick sinus syndrome; supraventricular conduction abnormalities; susceptibility to peptic ulcers; unstable angina

- **SIDE-EFFECTS**
  - Common or very common Abdominal pain; bradycardia; decreased appetite; depression; diarrhoea; dizziness; dyspepsia; fatigue; hallucination; headache; hypertension; malaise; muscle spasm; nausea; syncope; tremor; vomiting; weight loss
  - Uncommon Arrhythmias; blurred vision; dehydration; first-degree AV block; flush; hypersomnolence; hypotension; muscular weakness; palpitation; paraesthesia; retching; seizures; sweating; taste disturbance; tinnitus
  - Rare Acute generalized exanthematous pustulosis; erythema multiforme; exacerbation of Parkinson's disease; hepatitis; Stevens-Johnson syndrome

SIDE-EFFECTS, FURTHER INFORMATION
Acetylcholinesterase inhibitors can cause unwanted dose-related cholinergic effects and should be started at a low dose and the dose increased according to response and tolerability.

- Serious skin reactions Serious skin reactions (including Stevens-Johnson syndrome and acute generalized exanthematous pustulosis) have been reported—manufacturer advises discontinue at the first appearance of skin rash.

- **PREGNANCY** Use with caution—toxicity in animal studies.

- **BREAST FEEDING** Avoid—no information available.

- **HEPATIC IMPAIRMENT** For immediate-release preparations in moderate impairment, initially 4 mg once daily (preferably in the morning) for at least 7 days, then 4 mg twice daily for at least 4 weeks; max. 8 mg twice daily; avoid in severe impairment. For modified-release preparations in moderate impairment, initially 8 mg on alternate days (preferably in the morning) for 7 days, then 8 mg once daily for 4 weeks; max. 16 mg daily; avoid in severe impairment.

- **RENAL IMPAIRMENT** Avoid if eGFR less than 9 mL/minute/1.73 m².

- **PATIENT AND CARER ADVICE** Manufacturer recommends that patients are warned of the signs of serious skin reactions; they should be advised to stop taking galantamine immediately and seek medical advice if symptoms occur.

- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **NICE technology appraisals (TAs)**
    - Donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease—updated May 2016 NICE TA217
    - Galantamine can be used for the treatment of mild to moderate Alzheimer’s disease. Treatment should only be prescribed under the following conditions:
      - treatment should be initiated on the advice of a specialist
      - ensure that local arrangements for prescribing, supply and treatment review follow the NICE guideline on medicines optimisation
      - treatment should continue only if it is considered to have a worthwhile effect on cognitive, global, functional, or behavioural symptoms.

Healthcare professionals should not rely solely on assessment scales to determine the severity of Alzheimer’s disease when the patient has learning or other disabilities, or other communication difficulties. www.nice.org.uk/TA217

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet

  **Oral solution**
  **CAUTIONARY AND ADVISORY LABELS** 3, 21
  - **Galantamine (Non-proprietary)**
    - Galantamine (as Galantamine hydrobromide) 4 mg per
      - 1 ml Galantamine 20mg/5ml oral solution sugar free sugar-free | 100 ml | £437.00
    - **Reminyl** (Shire Pharmaceuticals Ltd)
      - Galantamine (as Galantamine hydrobromide) 4 mg per
        - 1 ml Reminyl 4mg/ml oral solution sugar-free | 100 ml | £120.00

  **Modified-release capsule**
  **CAUTIONARY AND ADVISORY LABELS** 3, 21, 25
  - **Acumor XL** (Mylan Ltd)
    - Galantamine (as Galantamine hydrobromide) 8 mg
      - Acumor XL 8 mg capsules | 28 capsule | £49.26 DT price = £51.88
    - **Galantamine (as Galantamine hydrobromide) 16 mg**
      - Acumor XL 16 mg capsules | 28 capsule | £61.65 DT price = £64.90
    - **Galantamine (as Galantamine hydrobromide) 24 mg**
      - Acumor XL 24 mg capsules | 28 capsule | £75.81 DT price = £78.80
    - **Consion XL** (Dr Reddy's Laboratories (UK) Ltd)
      - Galantamine (as Galantamine hydrobromide) 8 mg
        - Consion XL 8 mg capsules | 28 capsule | £25.94 DT price = £31.88
      - **Galantamine (as Galantamine hydrobromide) 16 mg**
        - Consion XL 16 mg capsules | 28 capsule | £32.45 DT price = £36.90
      - **Galantamine (as Galantamine hydrobromide) 24 mg**
        - Consion XL 24 mg capsules | 28 capsule | £39.90 DT price = £79.80
    - **Elmino (Zentiva)**
      - Galantamine (as Galantamine hydrobromide) 8 mg
        - Elmino XL 8 mg capsules | 28 capsule | £51.88 DT price = £53.88
      - **Galantamine (as Galantamine hydrobromide) 16 mg**
        - Elmino XL 16 mg capsules | 28 capsule | £64.90 DT price = £65.90
      - **Galantamine (as Galantamine hydrobromide) 24 mg**
        - Elmino XL 24 mg capsules | 28 capsule | £79.80 DT price = £79.80
    - **Galantex XL** (Creso Pharma Ltd)
      - Galantamine (as Galantamine hydrobromide) 8 mg
        - Galzemic XL 8 mg capsules | 28 capsule | £19.05 DT price = £21.88
      - **Galantamine (as Galantamine hydrobromide) 16 mg**
        - Galzemic XL 16 mg capsules | 28 capsule | £23.84 DT price = £26.90
      - **Galantamine (as Galantamine hydrobromide) 24 mg**
        - Galzemic XL 24 mg capsules | 28 capsule | £29.32 DT price = £79.80
    - **Galsya XL** (Consilient Health Ltd)
      - Galantamine (as Galantamine hydrobromide) 8 mg
        - Galsya XL 8 mg capsules | 28 capsule | £44.09 DT price = £51.88
      - **Galantamine (as Galantamine hydrobromide) 16 mg**
        - Galsya XL 16 mg capsules | 28 capsule | £55.16 DT price = £64.90
      - **Galantamine (as Galantamine hydrobromide) 24 mg**
        - Galsya XL 24 mg capsules | 28 capsule | £67.83 DT price = £79.80
    - **Gatalin XL** (Aspire Pharma Ltd)
      - Galantamine (as Galantamine hydrobromide) 8 mg
        - Gatalin XL 8 mg capsules | 28 capsule | £25.94 DT price = £51.88

---

Dementia 289

4 Nervous System

downloaded from www.medicalbr.com
**Rivastigmine**

**DRUG ACTION** Rivastigmine is a reversible non-competitive inhibitor of acetylcholinesterases.

**INDICATIONS AND DOSE**

**Mild to moderate dementia in Alzheimer’s disease**

- **BY MOUTH**
  - Adult: Initially 1.5 mg twice daily, increased in steps of 1.5 mg twice daily, dose to be increased at intervals of at least 2 weeks according to response and tolerance; usual dose 3–6 mg twice daily (max. per dose 6 mg twice daily), if treatment interrupted for more than several days, titrate from 1.5 mg twice daily

**Dose equivalence and conversion**

- When switching from oral to transdermal therapy, patients taking 3–6 mg by mouth daily should initially switch to 4.6 mg/24 hours patch, then titrate as above. Patients taking 9 mg by mouth daily should switch to 9.5 mg/24 hours patch if oral dose stable and well tolerated; if oral dose not stable or well tolerated, patients should switch to 4.6 mg/24 hours patch, then titrate as above. Patients taking 12 mg by mouth daily should switch to 9.5 mg/24 hours patch. The first patch should be applied on the day following the last oral dose.

- **CAUTIONS** Bladder outflow obstruction, conduction abnormalities, duodenal ulcers, gastric ulcers, history of asthma, history of chronic obstructive pulmonary disease, history of seizures, risk of fatal overdose with patch administration errors, sick sinus syndrome, susceptibility to ulcers

- **SIDE-EFFECTS**
  - Common or very common Abdominal pain, agitation, anorexia, anxiety, bradycardia, confusion, diarrhoea, dizziness, drowsiness, dyspepsia, extrapyramidal symptoms, headache, increased salivation, insomnia, malaise, nausea, sweating, tremor, urinary incontinence, vomiting, weight loss, worsening of Parkinson’s disease
  - Uncommon Atrial fibrillation, AV block, depression, syncope
  - Rare Angina, duodenal ulceration, gastric ulceration, rash, seizures
  - Very rare Gastro-intestinal haemorrhage, hallucinations, hypertension, pancreatitis, tachycardia
  - Frequency not known Aggression, dehydration, hepatitis, restlessness, sick sinus syndrome, skin hypersensitivity reactions

**SIDE-EFFECTS, FURTHER INFORMATION**

Transdermal administration less likely to cause gastro-intestinal disturbance.

Treatment should be interrupted if gastro-intestinal side-effects occur and withheld until their resolution—titrate dose if necessary.

Acetylcholinesterase inhibitors can cause unwanted dose-related cholinergic effects and should be started at a low dose and the dose increased according to response and tolerability.

- **HEPATIC IMPAIRMENT** Titrate according to individual tolerability in mild to moderate impairment. Use with caution in severe impairment—no information available.

- **RENAL IMPAIRMENT** Titrate according to individual tolerability.

**MONITORING REQUIREMENTS** Monitor body-weight.

**DIRECTIONS FOR ADMINISTRATION**

- With transdermal use Apply patches to clean, dry, non-hairy, non-irritated skin on back, upper arm, or chest, removing after 24 hours and siting a replacement patch on a different area (avoid using the same area for 14 days).

**PATIENT AND CARER ADVICE**

EXELON® PATCHES Advise patients and carers of patch administration instructions, particularly to remove the previous day’s patch before applying the new patch—consult product literature.

---

**Galantamine (as Galantamine hydrobromide)**

- 16 mg (Gatalin XL)
  - 16 mg capsule
  - 28 capsule pack £32.45 DT price = £64.90

- 24 mg (Gataline XL)
  - 24 mg capsule
  - 28 capsule pack £39.90 DT price = £79.80

- **Gazylan XL** (Teva UK Ltd)
  - 8 mg (Gazylan XL)
    - 8 mg capsule
    - 28 capsule pack £25.41 DT price = £51.88
  - 16 mg (Gazylan XL)
    - 16 mg capsule
    - 28 capsule pack £31.79 DT price = £64.90

- **Lotroprosin XL** (Actavis UK Ltd)
  - 8 mg (Lotroprosin XL)
    - 8 mg capsule
    - 28 capsule pack £15.88 DT price = £31.76
  - 16 mg (Lotroprosin XL)
    - 16 mg capsule
    - 28 capsule pack £64.90 DT price = £129.80

- **Luventa XL** (Fontus Health Ltd)
  - 12 mg (Luventa XL)
    - 12 mg capsule
    - 28 capsule pack £31.80 DT price = £64.90
  - 16 mg (Luventa XL)
    - 16 mg capsule
    - 28 capsule pack £79.80 DT price = £159.60

- **Reminyl XL** (Shire Pharmaceuticals Ltd)
  - 8 mg (Reminyl XL)
    - 8 mg capsule
    - 28 capsule pack £39.10 DT price = £79.80
  - 12 mg (Reminyl XL)
    - 12 mg capsule
    - 28 capsule pack £90.50 DT price = £181.00

- **Galantamine (as Galantamine hydrobromide)**
  - 8 mg (Galantamine)
    - 8 mg capsule
    - 28 capsule pack £51.88 DT price = £103.76
  - 12 mg (Galantamine)
    - 12 mg capsule
    - 28 capsule pack £80.50 DT price = £161.00
  - 16 mg (Galantamine)
    - 16 mg capsule
    - 28 capsule pack £121.50 DT price = £243.00

- **Lotroprosin XL** (Actavis UK Ltd)
  - 24 mg (Lotroprosin XL)
    - 24 mg capsule
    - 28 capsule pack £79.80 DT price = £159.60

---

**Tablet**

**CAUTIONARY AND ADVISORY LABELS**

**Gazylan XL**

- **Tic IMPAIRMENT**
  - Caution in severe impairment, to ulcers

**Lotroprosin XL**

- **HEPATIC IMPAIRMENT**
  - Titrate according to individual tolerability in mild to moderate impairment. Use with caution in severe impairment—no information available.

**Luventa XL**

- **RENAL IMPAIRMENT**
  - Titrate according to individual tolerability.

**Reminyl XL**

- **MONITORING REQUIREMENTS**
  - Monitor body-weight.

**Directions for Administration**

- With transdermal use Apply patches to clean, dry, non-hairy, non-irritated skin on back, upper arm, or chest, removing after 24 hours and siting a replacement patch on a different area (avoid using the same area for 14 days).

**Patient and Carer Advice**

EXELON® PATCHES Advise patients and carers of patch administration instructions, particularly to remove the previous day’s patch before applying the new patch—consult product literature.

---

**Rivastigmine**

26-Sep-2016
NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

- Donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease—updated May 2016

NICE TA217

Rivastigmine can be used for the treatment of mild to moderate Alzheimer’s disease. Treatment should only be prescribed under the following conditions:

- treatment should be initiated on the advice of a specialist
- ensure that local arrangements for prescribing, supply and treatment review follow the NICE guideline on medicines optimisation
- treatment should continue only if it is considered to have a worthwhile effect on cognitive, global, functional, or behavioural symptoms.

Healthcare professionals should not rely solely on assessment scales to determine the severity of Alzheimer’s disease when the patient has learning or other disabilities, or other communication difficulties.

www.nice.org.uk/TA217

EXELON® PATCHES

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (October 2007) that Exelon® patches should be restricted for use in patients with moderately severe Alzheimer’s disease under the conditions of the NICE guidance (September 2007) and when a transdermal patch is an appropriate choice of formulation.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Oral solution

- Rivastigmine (Non-proprietary)
  - Rivastigmine (as Rivastigmine hydrochloride tartrate) 2 mg per 1 ml
    - Almuriiva 2mg/ml oral solution | 120 ml (PO) £81.75–94.18
    - Rivastigmine 2mg/ml oral solution sugar free sugar-free | 120 ml (PO) £96.82 DT price = £96.82
- Transdermal patch
  - Rivastigmine (Non-proprietary)
    - Rivastigmine 4.6 mg per 24 hour
      - Almuriiva 4.6mg/24hours transdermal patches | 30 patch (PO) £77.97 DT price = £77.97
      - Rivastigmine 4.6mg/24hours transdermal patches | 30 patch (PO) £77.97 DT price = £77.97
    - Rivastigmine 9.5 mg per 24 hour
      - Almuriiva 9.5mg/24hours transdermal patches | 30 patch (PO) £77.97 DT price = £29.97
      - Rivastigmine 9.5mg/24hours transdermal patches | 30 patch (PO) £30.08 DT price = £29.97
    - Rivastigmine 13.3 mg per 24 hour
      - Rivastigmine 13.3mg/24hours transdermal patches | 30 patch (PO) £77.97 DT price = £77.97
      - Aziest (Dr Reddy’s Laboratories (UK) Ltd)
        - Rivastigmine 4.6 mg per 24 hour
          - Alzest 4.6mg/24hours transdermal patches | 30 patch (PO) £35.10 DT price = £77.97
          - Rivastigmine 9.5 mg per 24 hour
            - Alzest 9.5mg/24hours transdermal patches | 30 patch (PO) £19.99 DT price = £29.97
      - Exelon (Novartis Pharmaceuticals UK Ltd)
        - Rivastigmine 4.6 mg per 24 hour
          - Exelon 4.6mg/24hours transdermal patches | 30 patch (PO) £77.97 DT price = £77.97
          - Rivastigmine 9.5 mg per 24 hour
            - Exelon 9.5mg/24hours transdermal patches | 30 patch (PO) £77.97 DT price = £29.97
      - Prometax (Novartis Pharmaceuticals UK Ltd)
        - Rivastigmine 4.6 mg per 24 hour
          - Prometax 4.6mg/24hours transdermal patches | 30 patch (PO) £77.97 DT price = £77.97
          - Rivastigmine 9.5 mg per 24 hour
            - Prometax 9.5mg/24hours transdermal patches | 30 patch (PO) £77.97 DT price = £29.97
      - Rivate (Teva UK Ltd)
        - Rivastigmine 13.3 mg per 24 hour
          - Erastig 13.3mg/24hours transdermal patches | 30 patch (PO) £73.90 DT price = £77.97
        - Rivastigmine 4.6 mg per 24 hour
          - Voleze 4.6mg/24hours transdermal patches | 30 patch (PO) £77.97 DT price = £77.97

DOPAMINERGIC DRUGS

- Memantine hydrochloride

- DRUG ACTION
  - Memantine is a glutamate receptor antagonist.
  - INDICATIONS AND DOSE
    - Moderate to severe dementia in Alzheimer’s disease
      - BY MOUTH
        - Adult: Initially 5 mg once daily, then increased in steps of 5 mg every week; usual maintenance 20 mg daily; maximum 20 mg per day
      - CAUTIONS
        - Epilepsy · history of convulsions · risk factors for epilepsy
      - INTERACTIONS
        - Appendix 1: memantine
      - SIDE-EFFECTS
        - Common or very common Balance disorders · constipation · dizziness · drowsiness · dysphoria · headache · hypertension
        - Uncommon Abnormal gait · confusion · fatigue · hallucinations · heart failure · thrombosis · vomiting
        - Very rare Seizures
        - Frequency not known Depression · hepatitis · pancreatitis · psychosis · suicidal ideation
      - PREGNANCY
        - Manufacturer advises avoid unless essential—no information available.
      - BREAST FEEDING
        - Manufacturer advises avoid—no information available.
      - HEPATIC IMPAIRMENT
        - Avoid in severe impairment—no information available.
      - RENAL IMPAIRMENT
        - Reduce dose to 10 mg daily if eGFR 30–49 ml/minute/1.73 m², if well tolerated after at least 7 days dose can be increased in steps to 20 mg daily; reduce dose to 10 mg daily if eGFR 5–29 ml/minute/1.73 m². Avoid if eGFR less than 5 ml/minute/1.73 m².
      - DIRECTIONS FOR ADMINISTRATION
        - Oral solution should be dosed onto a spoon or into a glass of water.
NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

Donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease—updated May 2016

NICE TA217

Memantine is recommended as an option for managing moderate Alzheimer’s disease in patients who are unable to take acetylcholinesterase inhibitors, and for patients with severe disease; combination treatment with memantine and an acetylcholinesterase inhibitor is not recommended. Treatment should only be prescribed under the following conditions:

- treatment should be initiated on the advice of a specialist
- ensure that local arrangements for prescribing, supply and treatment review follow the NICE guideline on medicines optimisation
- treatment should continue only if it is considered to have a worthwhile effect on cognitive, global, functional, or behavioural symptoms.

Healthcare professionals should not rely solely on assessment scales to determine the severity of Alzheimer’s disease when the patient has learning or other disabilities, or other communication difficulties.

www.nice.org.uk/TA217

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Oral solution

- Memantine hydrochloride (Non-proprietary)
  - Memantine hydrochloride 10 mg per 1 ml Memantine 10mg/ml oral solution sugar free sugar-free | 50 ml [Pom] £61.61 DT price = £55.10 sugar-free | 100 ml [Pom] £123.23
  - Ebixa (Lundbeck Ltd)
    - Memantine hydrochloride 10 mg per 1 ml Ebixa 5mg/0.5ml pump actuation oral solution sugar-free | 50 ml [Pom] £61.61 DT price = £55.10 sugar-free | 100 ml [Pom] £123.23

Orodispersible tablet

EXCIPIENTS: May contain Aspartame

- Valios (Dr Reddy’s Laboratories (UK) Ltd)
  - Memantine hydrochloride 10 mg Valios 10mg oro dispersible tablets sugar free sugar-free | 28 tablet [Pom] £32.78
  - Memantine hydrochloride 20 mg Valios 20mg oro dispersible tablets sugar free sugar-free | 28 tablet [Pom] £65.56

Tablet

- Memantine hydrochloride (Non-proprietary)
  - Memantine hydrochloride 5 mg Memantine 5mg tablets | 7 tablet [Pom] no price available
  - Memantine hydrochloride 10 mg Memantine 10mg tablets | 7 tablet [Pom] no price available | 28 tablet [Pom] £34.50 DT price = £1.28 | 56 tablet [Pom] £69.01
  - Memantine hydrochloride 15 mg Memantine 15mg tablets | 7 tablet [Pom] no price available
  - Memantine hydrochloride 20 mg Memantine 20mg tablets | 7 tablet [Pom] no price available | 28 tablet [Pom] £69.01 DT price = £1.43

  Memantine 5mg/10mg/15mg/20mg 4 week treatment initiation pack | 28 tablet [Pom] £43.13

  - Ebixa (Lundbeck Ltd)
    - Memantine hydrochloride 5 mg Ebixa 5mg tablets | 7 tablet [Pom] no price available
    - Memantine hydrochloride 10 mg Ebixa 10mg tablets | 7 tablet [Pom] no price available | 28 tablet [Pom] £34.50 DT price = £1.28
    - Memantine hydrochloride 15 mg Ebixa 15mg tablets | 7 tablet [Pom] no price available
    - Memantine hydrochloride 20 mg Ebixa 20mg tablets | 7 tablet [Pom] no price available | 28 tablet [Pom] £69.01 DT price = £1.43

  Ebixa tablets treatment initiation pack | 28 tablet [Pom] £43.13

- Maruxa (Consilient Health Ltd)
  - Memantine hydrochloride 10 mg Maruxa 10mg tablets | 28 tablet [Pom] £29.32 DT price = £1.28
  - Memantine hydrochloride 20 mg Maruxa 20mg tablets | 28 tablet [Pom] £58.65 DT price = £1.43

Nemdhatine (Actavis UK Ltd)

- Memantine hydrochloride 5 mg Nemdhatine 5mg tablets | 7 tablet [Pom] no price available
- Memantine hydrochloride 10 mg Nemdhatine 10mg tablets | 7 tablet [Pom] no price available | 28 tablet [Pom] £34.50 DT price = £1.28 | 56 tablet [Pom] £69.01
- Memantine hydrochloride 15 mg Nemdhatine 15mg tablets | 7 tablet [Pom] no price available
- Memantine hydrochloride 20 mg Nemdhatine 20mg tablets | 7 tablet [Pom] no price available | 28 tablet [Pom] £69.01 DT price = £1.43

Nemdhatine tablets treatment initiation pack | 28 tablet [Pom] £43.12

2 Epilepsy and other seizure disorders

Epilepsy

Control of the epilepsies

The object of treatment is to prevent the occurrence of seizures by maintaining an effective dose of one or more antiepileptic drugs. Careful adjustment of doses is necessary, starting with low doses and increasing gradually until seizures are controlled or there are significant adverse effects.

When choosing an antiepileptic drug, the presenting epilepsy syndrome should first be considered. If the syndrome is not clear, the seizure type should determine the choice of treatment. Concomitant medication, co-morbidity, age, and sex should also be taken into account.

The dosage frequency is often determined by the plasma-drug half-life, and should be kept as low as possible to encourage adherence with the prescribed regimen. Most antiepileptics, when used in the usual dosage, can be given twice daily. Lamotrigine p. 303, perampanel p. 307, fosphenytoin p. 308, which have long half-lives, can be given once daily at bedtime. However, with large doses, some antiepileptics may need to be given more frequently to avoid adverse effects associated with high peak plasma-drug concentration.

Management

When monotherapy with a first-line antiepileptic drug has failed, monotherapy with a second drug should be tried; the diagnosis should be checked before starting an alternative drug if the first drug showed lack of efficacy. The change from one antiepileptic drug to another should be cautious, slowly withdrawing the first drug only when the new regimen has been established. Combination therapy with two or more antiepileptic drugs may be necessary, but the concurrent use of antiepileptic drugs increases the risk of adverse effects and drug interactions. If combination therapy does not bring about worthwhile benefits, revert to the regimen (monotherapy or combination therapy) that provided the best balance between tolerability and efficacy. A single antiepileptic drug should be prescribed wherever possible.

MHRA/CHM advice: Antiepileptic drugs: new advice on switching between different manufacturers’ products for a particular drug (November 2013)

The CHM has reviewed spontaneous adverse reactions received by the MHRA and publications that reported potential harm arising from switching of antiepileptic drugs in patients previously stabilised on a branded product to a generic. The CHM concluded that reports of loss of seizure control and/or worsening of side-effects around the time of switching between products could be explained as chance associations, but that a causal role of switching could not be ruled out in all cases. The following guidance has been issued to help minimise risk:
Different antiepileptic drugs vary considerably in their characteristics, which influences the risk of whether switching between different manufacturers’ products of a particular drug may cause adverse effects or loss of seizure control;

Antiepileptic drugs have been divided into three risk-based categories to help healthcare professionals decide whether it is necessary to maintain continuity of supply of a specific manufacturer’s product. These categories are listed below;

- If it is felt desirable for a patient to be maintained on a specific manufacturer’s product this should be prescribed either by specifying a brand name, or by using the generic drug name and name of the manufacturer (otherwise known as the Marketing Authorisation Holder);
- This advice relates only to antiepileptic drug use for treatment of epilepsy; it does not apply to their use in other indications (e.g. mood stabilisation, neuropathic pain);
- Please report on a Yellow Card any suspected adverse reactions to antiepileptic drugs;
- Dispensing pharmacists should ensure the continuity of supply of a particular product when the prescription specifies it. If the prescribed product is unavailable, it may be necessary to dispense a product from a different manufacturer to maintain continuity of treatment of that antiepileptic drug. Such cases should be discussed and agreed with both the prescriber and patient (or carer);
- Usual dispensing practice can be followed when a specific product is not stated.

**Category 1**
Phenytoin, carbamazepine p. 297, phenobarbital, primidone p. 319. For these drugs, doctors are advised to ensure that their patient is maintained on a specific manufacturer’s product.

**Category 2**
Valproate, lamotrigine, perampanel, rufinamide p. 311, clobazam p. 320, clonazepam p. 321, oxcarbazepine p. 306, eslicarbazepine acetate p. 299, zonisamide p. 317, topiramate p. 315. For these drugs, the need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with the patient and/or carer taking into account factors such as seizure frequency and treatment history.

**Category 3**
Levetiracetam p. 305, lamotrigine p. 302, tiagabine p. 314, gabapentin p. 301, pregabalin p. 310, ethosuximide p. 300, vigabatrin p. 316. For these drugs, it is usually unnecessary to ensure that patients are maintained on a specific manufacturer’s product unless there are specific concerns such as patient anxiety, and risk of confusion or dosing errors. Interactions.

**Antiepileptic hypersensitivity syndrome**
Antiepileptic hypersensitivity syndrome is a rare but potentially fatal syndrome associated with some antiepileptic drugs (carbamazepine, lamotrigine, oxcarbazepine, phenobarbital, phenytoin, primidone, and rufinamide); rarely cross-sensitivity occurs between some of these antiepileptic drugs. Some other antiepileptics (eslicarbazepine, stiripentol, and zonisamide) have a theoretical risk. The symptoms usually start between 1 and 8 weeks of exposure; fever, rash, and lymphadenopathy are most commonly seen. Other systemic signs include liver dysfunction, haematological, renal, and pulmonary abnormalities, vasculitis, and multi-organ failure. If signs or symptoms of hypersensitivity syndrome occur, the drug should be withdrawn immediately, the patient must not be re-exposed, and expert advice should be sought.

**Risk of suicidal thoughts and behaviour**
The MHRA has advised (August 2008) that all antiepileptic drugs are associated with a small increased risk of suicidal thoughts and behaviour. Symptoms may occur as early as one week after starting treatment. Patients should be advised to seek medical advice if they develop any mood changes, distressing thoughts, or feelings about suicide or harming themselves, and should be referred for appropriate treatment if necessary.

**Interactions**
Interactions between antiepileptics are complex and may increase toxicity without a corresponding increase in antiepileptic effect. Interactions are usually caused by hepatic enzyme induction or inhibition; displacement from protein binding sites is not usually a problem. These interactions are highly variable and unpredictable.

**Withdrawal**
Antiepileptic drugs should be withdrawn under specialist supervision. Avoid abrupt withdrawal, particularly of barbiturates and benzodiazepines, because this can precipitate severe rebound seizures. Reduction in dosage should be gradual and, in the case of barbiturates, withdrawal of the drug may take months. The decision to withdraw antiepileptic drugs from a seizure-free patient, and its timing, is often difficult and depends on individual circumstances. Even in patients who have been seizure-free for several years, there is a significant risk of seizure recurrence on drug withdrawal. In patients receiving several antiepileptic drugs, only one drug should be withdrawn at a time.

**Driving**
If a driver has a seizure (of any type) they must stop driving immediately and inform the Driver and Vehicle Licensing Agency (DVLA). Patients who have had a first unprovoked epileptic seizure or a single isolated seizure must not drive for 6 months; driving may then be resumed, provided the patient has been assessed by a specialist as fit to drive and investigations do not suggest a risk of further seizures.

Patients with established epilepsy may drive a motor vehicle provided they are not a danger to the public and are compliant with treatment and follow up. To continue driving, these patients must be seizure-free for at least one year (or have a pattern of seizures established for one year where there is no influence on their level of consciousness or the ability to act); also, they must not have a history of unprovoked seizures.

*Note:* additional criteria apply for drivers of large goods or passenger carrying vehicles—consult DVLA guidance.

Patients who have had a `seizure while asleep` are not permitted to drive for one year from the date of each seizure, unless:

- a history or pattern of sleep seizures occurring *only* ever while asleep has been established after the course of at least one year from the date of the first sleep seizure; or
- an established pattern of purely asleep seizures can be demonstrated over the course of three years if the patient has previously had seizures whilst awake (or awake and asleep).

The DVLA recommends that patients should not drive during medication changes or withdrawal of antiepileptic drugs, and for 6 months after their last dose. If a seizure occurs due to a prescribed change or withdrawal of epilepsy treatment, the patient will have their driving license revoked for 1 year; relicensing may be considered earlier if treatment has been reinstated for 6 months and no further seizures have occurred.
Pregnancy
Women of child-bearing potential should discuss with a specialist the impact of both epilepsy, and its treatment, on the outcome of pregnancy.

There is an increased risk of teratogenicity associated with the use of antiepileptic drugs (especially if used during the first trimester and particularly if the patient takes two or more antiepileptic drugs). Valproate is associated with the highest risk of major and minor congenital malformations (in particular neural tube defects), and long-term developmental disorders. There is also an increased risk of teratogenicity with phenytoin, primidone, phenobarbital, lamotrigine, and carbamazepine. Topiramate carries an increased risk of cleft palate if taken in the first trimester of pregnancy. There is not enough evidence to establish the risk of teratogenicity with other antiepileptic drugs.

Prescribers should also consider carefully the choice of antiepileptic therapy in pre-pubescent girls who may later become pregnant. Women of child-bearing potential who take antiepileptic drugs should be given advice about the need for an effective contraception method to avoid unplanned pregnancy. Some antiepileptic drugs can reduce the efficacy of hormonal contraceptives, and the efficacy of some antiepileptics may be affected by hormonal contraceptives.

Women who want to become pregnant should be referred to a specialist for advice in advance of conception. For some women, the severity of seizure or the seizure type may not pose a serious threat, and drug withdrawal may be considered; therapy may be resumed after the first trimester. If treatment with antiepileptic drugs must continue throughout pregnancy, then monotherapy is preferable at the lowest effective dose.

Once an unplanned pregnancy is discovered it is usually too late for changes to be made to the treatment regimen; the risk of harm to the mother and fetus from convulsive seizures outweighs the risk of continued therapy. The likelihood of a woman who is taking antiepileptic drugs having a baby with no malformations is at least 50%, and it is important that women do not stop taking essential drugs abruptly. Therefore, folic acid supplementation is advised before conception and throughout the first trimester. In the case of sodium valproate p. 312 and valproic acid p. 337 an urgent consultation is required to reconsider the benefits and risks of valproate therapy.

The concentration of antiepileptic drugs in the plasma can change during pregnancy. Doses of phenytoin, carbamazepine, and lamotrigine should be adjusted on the basis of plasma-drug concentration monitoring; the dose of other antiepileptic drugs should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis. Plasma-drug concentration monitoring during pregnancy is also useful to check compliance. Additionally, in patients taking topiramate or levetiracetam, it is recommended that fetal growth should be monitored. Women who have seizures in the second half of pregnancy should be assessed for eclampsia before any change is made to antiepileptic treatment. Status epilepticus should be treated according to the standard protocol.

Routine injection of vitamin K at birth minimises the risk of neonatal haemorrhage associated with antiepileptics.

Withdrawal effects in the newborn may occur with some antiepileptic drugs, in particular benzodiazepines and phenobarbital.

Epilepsy and Pregnancy Register
All pregnant women with epilepsy, whether taking medication or not, should be encouraged to notify the UK Epilepsy and Pregnancy Register (Tel: 0800 389 1248).

Breast-feeding
Women taking antiepileptic monotherapy should generally be encouraged to breast-feed; if a woman is on combination therapy or if there are other risk factors, such as premature birth, specialist advice should be sought.

All infants should be monitored for sedation, feeding difficulties, adequate weight gain, and developmental milestones. Infants should also be monitored for adverse effects associated with the antiepileptic drug particularly with newer antiepileptics, if the antiepileptic is readily transferred into breast-milk causing high infant serum-drug concentrations (e.g. ethosuximide, lamotrigine, primidone, and zonisamide), or if slower metabolism in the infant causes drugs to accumulate (e.g. phenobarbital and lamotrigine). Serum-drug concentration monitoring should be undertaken in breast-fed infants if suspected adverse reactions develop; if toxicity develops it may be necessary to introduce formula feeds to limit the infant’s drug exposure, or to wean the infant off breast-milk altogether.

Primidone, phenobarbital, and the benzodiazepines are associated with an established risk of drowsiness in breast-fed babies and caution is required.

Withdrawal effects may occur in infants if a mother suddenly stops breast-feeding, particularly if she is taking phenobarbital, primidone, or lamotrigine.

Focal seizures with or without secondary generalisation
Carbamazepine p. 297 and lamotrigine p. 303 are first-line options for treating newly diagnosed focal seizures; oxcarbazepine p. 306, sodium valproate p. 312 and levetiracetam p. 305 may be used if carbamazepine or lamotrigine are unsuitable or not tolerated. If monotherapy is unsuccessful with two of these first-line antiepileptic drugs, adjunctive treatment may be considered. Options for adjunctive treatment include carbamazepine, clobazam p. 320, gabapentin p. 301, lamotrigine, levetiracetam, oxcarbazepine, sodium valproate, or topiramate p. 315. If adjunctive treatment is ineffective or not tolerated, a tertiary epilepsy specialist should be consulted who may consider eslicarbazepine acetate p. 299, lacosamide p. 302, phenobarbital p. 318, phenytoin p. 308, pregabalin p. 310, tiagabine p. 314, vigabatrin p. 316 and zonisamide p. 317.

Generalised seizures
Tonic-clonic seizures
Sodium valproate is the first-line treatment for newly diagnosed generalised tonic–clonic seizures (except in female patients who are premenopausal, see Valproate below). Lamotrigine is the alternative choice if sodium valproate is not suitable, but may exacerbate myoclonic seizures. In those with established epilepsy with generalised tonic–clonic seizures only, lamotrigine or sodium valproate may be prescribed as the first-line treatment. Carbamazepine and oxcarbazepine may also be considered in newly diagnosed and established tonic–clonic seizures, but may exacerbate myoclonic and absence seizures. Clobazam, lamotrigine, levetiracetam, sodium valproate or topiramate may be used as adjunctive treatment if monotherapy is ineffective or not tolerated.

Absence seizures
Ethosuximide p. 300, or sodium valproate (except in female patients who are premenopausal, see Valproate below), are the drugs of choice in absence seizures and syndromes; lamotrigine is a suitable alternative when ethosuximide and sodium valproate are unsuitable, ineffective or not tolerated. Sodium valproate should be used as the first choice if there is a high risk of generalised tonic–clonic seizures. A combination of any two of these drugs may be used if monotherapy is ineffective. Clobazam, clonazepam p. 321, levetiracetam, topiramate or zonisamide may be considered by a tertiary epilepsy specialist if adjunctive treatment fails.
Carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine and vigabatrin are not recommended in absence seizures or syndromes.

**Myoclonic seizures**

Myoclonic seizures (myoclonic jerks) occur in a variety of syndromes, and response to treatment varies considerably. Sodium valproate is the drug of choice in newly diagnosed myoclonic seizures (except in female patients who are premenopausal, see *Valproate* below); topiramate and levetiracetam are alternative options if sodium valproate is unsuitable but consideration should be given to the less favourable side-effect profile of topiramate. A combination of two of these drugs may be used if monotherapy is ineffective or not tolerated. If adjunctive treatment fails, a tertiary epilepsy specialist should be consulted and may consider clobazam, clonazepam, zonisamide or piracetam p. 386. Carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine and vigabatrin are not recommended for the treatment of myoclonic seizures.

Sodium valproate and levetiracetam are effective in treating the generalised tonic-clonic seizures that coexist with myoclonic seizures in idiopathic generalised epilepsy.

**Atonic and tonic seizures**

Atonic and tonic seizures are usually seen in childhood, in specific epilepsy syndromes, or associated with cerebral damage or mental retardation. They may respond poorly to the traditional drugs. Sodium valproate is the drug of choice (except in female patients who are premenopausal, see *Valproate* below); lamotrigine can also be added as adjunctive treatment. If adjunctive treatment is ineffective or not tolerated, a tertiary epilepsy specialist should be consulted, and may consider rufinamide p. 311 or topiramate.

Carbamazepine, gabapentin, oxcarbazepine, pregabalin, tiagabine or vigabatrin are not recommended in atonic and tonic seizures.

**Epilepsy syndromes**

Some drugs are licensed for use in particular epilepsy syndromes, such as lamotrigine and rufinamide in Lennox-Gastaut syndrome. The epilepsy syndromes are specific types of epilepsy that are characterised according to a number of features including seizure type, age of onset, and EEG characteristics.

**Antiepileptic drugs**

**Carbamazepine and related antiepileptics**

Carbamazepine is a drug of choice for simple and complex focal seizures and is a first-line treatment option for generalised tonic-clonic seizures. It can be used as adjunctive treatment for focal seizures when monotherapy has been ineffective. It is essential to initiate carbamazepine therapy at a low dose and build this up slowly.

Carbamazepine may exacerbate tonic, atonic, myoclonic and absence seizures and is therefore not recommended if these seizures are present.

Oxcarbazepine is licensed as monotherapy or adjunctive therapy for the treatment of focal seizures with or without secondary generalised tonic-clonic seizures. It can also be considered for the treatment of primary generalised tonic-clonic seizures [unlicensed]. Oxcarbazepine is not recommended in tonic, atonic, absence or myoclonic seizures due to the risk of seizure exacerbation.

Eslicarbazepine acetate is licensed for adjunctive treatment in adults with focal seizures with or without secondary generalisation.

**E ethosuximide**

E ethosuximide is a first-line treatment option for absence seizures. It may also be prescribed as adjunctive treatment for absence seizures when monotherapy is ineffective. E ethosuximide is also licensed for myoclonic seizures.

**Gabapentin and pregabalin**

Gabapentin and pregabalin are used for the treatment of focal seizures with or without secondary generalisation. They are not recommended if tonic, atonic, absence or myoclonic seizures are present. Both are also licensed for the treatment of neuropathic pain. Pregabalin is licensed for the treatment of generalised anxiety disorder. Gabapentin is an effective treatment for migraine prophylaxis [unlicensed].

**Lamotrigine**

Lamotrigine is an antiepileptic drug recommended as a first-line treatment for focal seizures and primary and secondary generalised tonic-clonic seizures. It is also licensed for typical absence seizures in children (but efficacy may not be maintained in all children) and is an unlicensed treatment option in adults if first-line treatments have been unsuccessful. Lamotrigine can also be used as adjunctive treatment in atonic or tonic seizures if first-line treatment has failed [unlicensed]. Myoclonic seizures may be exacerbated by lamotrigine and it can cause serious rashes especially in children; dose recommendations should be adhered to closely.

Lamotrigine is used either as sole treatment or as an adjunct to treatment with other antiepileptic drugs. Valproate increases plasma-lamotrigine concentration, whereas the enzyme-inducing antiepileptics reduce it; care is therefore required in choosing the appropriate initial dose and subsequent titration. When the potential for interaction is not known, treatment should be initiated with lower doses, such as those used with valproate.

**Levetiracetam and brivaracetam**

Levetiracetam is used for monotherapy and adjunctive treatment of focal seizures with or without secondary generalisation, and for adjunctive treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy and primary generalised tonic-clonic seizures. Levetiracetam may be prescribed alone and in combination for the treatment of myoclonic seizures, and under specialist supervision for absence seizures [both unlicensed].

Brivaracetam p. 296 is used as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation.

**Phenobarbital and primidone**

Phenobarbital p. 318 is effective for tonic-clonic and focal seizures but may be sedative in adults. It may be tried for atypical absence, atonic, and tonic seizures. Rebound seizures may be a problem on withdrawal.

Primidone p. 319 is largely converted to phenobarbital and this is probably responsible for its antiepileptic action. A low initial dose of primidone is essential.

**Phenytoin**

Phenytoin p. 308 is licensed for tonic-clonic and focal seizures but may exacerbate absence or myoclonic seizures and should be avoided if these seizures are present. It has a narrow therapeutic index and the relationship between dose and plasma-drug concentration is non-linear; small dosage increases in some patients may produce large increases in plasma concentration with acute toxic side-effects. Similarly, a few missed doses or a small change in drug absorption may result in a marked change in plasma-drug concentration. Monitoring of plasma-drug concentration improves dosage adjustment.

When only parenteral administration is possible, fosphenytoin sodium p. 300, a pro-drug of phenytoin, may be convenient to give. Unlike phenytoin (which should only be given intravenously), fosphenytoin sodium may also be given by intramuscular injection.

**Rufinamide**

Rufinamide p. 311 is licensed for the adjunctive treatment of seizures in Lennox-Gastaut syndrome. It may be considered...
by a tertiary specialist for the treatment of refractory tonic or atonic seizures [unlicensed].

**Topiramate**
Topiramate p. 315 can be given alone or as adjunctive treatment in generalised tonic-clonic seizures or focal seizures with or without secondary generalisation. It can be used as adjunctive treatment for seizures associated with Lennox–Gastaut syndrome and for absence, tonic and atonic seizures under specialist supervision [unlicensed]. It can also be considered as an option in myoclonic seizures [unlicensed]. Topiramate is also licensed for prophylaxis of migraine.

**Valproate**
Sodium valproate p. 312 is effective in controlling tonic-clonic seizures, particularly in primary generalised epilepsy. It is a drug of choice in primary generalised tonic-clonic seizures, focal seizures, generalised absences and myoclonic seizures, and can be tried in atypical absence seizures. It is recommended as a first-line option in atonic and tonic seizures. Sodium valproate has widespread metabolic effects and monitoring of liver function tests and full blood count is essential. Valproate should not be used in female children, in females of childbearing potential, and pregnant females, unless alternative treatments are ineffective or not tolerated, because of its high teratogenic potential; the benefits and risks of valproate therapy should be carefully reconsidered at regular treatment reviews, see *Important safety information* in the sodium valproate and valproic acid p. 337 drug monographs.

Valproic acid (as semisodium valproate) is licensed for acute mania associated with bipolar disorder.

**Zonisamide**
Zonisamide p. 317 can be used alone for the treatment of focal seizures with or without secondary generalisation in adults with newly diagnosed epilepsy, and as adjunctive treatment for refractory focal seizures with or without secondary generalisation in adults and children aged 6 years and above. It can also be used under the supervision of a specialist for refractory absence and myoclonic seizures [unlicensed indications].

**Benzodiazepines**
Clobazam p. 320 may be used as adjunctive therapy in the treatment of generalised tonic-clonic and refractory focal seizures. It may be prescribed under the care of a specialist for refractory absence and myoclonic seizures. Clonazepam p. 321 may be prescribed by a specialist for refractory absence and myoclonic seizures, but its sedative side-effects may be prominent.

**Other drugs**
Acetazolamide p. 1080, a carbonic anhydrase inhibitor, has a specific role in treating epilepsy associated with menstruation. Piracetam p. 386 is used as adjunctive treatment for cortical myoclonus.

**Status epilepticus**

**Convulsive status epilepticus**
Immediate measures to manage status epilepticus include positioning the patient to avoid injury, supporting respiration including the provision of oxygen, maintaining blood pressure, and the correction of any hypoglycaemia. Parenteral thiamine p. 989 should be considered if alcohol abuse is suspected; pyridoxine hydrochloride p. 988 should be given if the status epilepticus is caused by pyridoxine hydrochloride deficiency.

Seizures lasting longer than 5 minutes should be treated urgently with intravenous lorazepam p. 322 (repeated once after 10 minutes if seizures recur or fail to respond). Intravenous diazepam p. 327 is effective but it carries a high risk of thrombophlebitis (reduced by using an emulsion formulation). Absorption of diazepam from intramuscular injection or from suppositories is too slow for treatment of status epilepticus. Patients should be monitored for respiratory depression and hypotension.

Where facilities for resuscitation are not immediately available, diazepam can be administered as a rectal solution or midazolam oromucosal solution p. 323 can be given into the buccal cavity.

**Important**
If, after initial treatment with benzodiazepines, seizures recur or fail to respond 25 minutes after onset, phenytoin sodium, fosphenytoin sodium, or phenobarbital sodium should be used; contact intensive care unit if seizures continue. If these measures fail to control seizures 45 minutes after onset, anaesthesia with thiopental sodium p. 322, midazolam, or a non-barbiturate anaesthetic such as propofol p. 1220 [unlicensed indication], should be instituted with full intensive care support.

**Phenytoin sodium** can be given by slow intravenous injection, followed by the maintenance dosage if appropriate.

Alternatively, fosphenytoin sodium (a pro-drug of phenytoin), can be given more rapidly and when given intravenously causes fewer injection-site reactions than phenytoin sodium. Although it can also be given intramuscularly, absorption is too slow by this route for treatment of status epilepticus. Doses of fosphenytoin sodium should be expressed in terms of phenytoin sodium.

**Non-convulsive status epilepticus**
The urgency to treat non-convulsive status epilepticus depends on the severity of the patient’s condition. If there is incomplete loss of awareness, usual oral antiepileptic therapy should be continued or restarted. Patients who fail to respond to oral antiepileptic therapy or have complete lack of awareness can be treated in the same way as for convulsive status epilepticus, although anaesthesia is rarely needed.

**Febrile convulsions**

Brief *febrile convulsions* need no specific treatment; antipyretic medication (e.g. paracetamol p. 422), is commonly used to reduce fever and prevent further convulsions but evidence to support this practice is lacking. *Prolonged febrile convulsions* (those lasting 5 minutes or longer), or recurrent *febrile convulsions* without recovery must be treated actively (as for convulsive status epilepticus). Long-term anticonvulsant prophylaxis for febrile convulsions is rarely indicated.

**Other drugs used for Epilepsy and other seizure disorders** Magnesium sulfate, p. 963

### ANTIEPILEPTICS

**Brivaracetam**

- **INDICATIONS AND DOSE**
  - Adjunctive therapy of partial-onset seizures with or without secondary generalisation
    - By mouth, or by intravenous injection, or by intravenous infusion
      - Child 16–17 years: Initially 25–50 mg twice daily, adjusted according to response; usual maintenance 25–100 mg twice daily
      - Adult: Initially 25–50 mg twice daily, adjusted according to response; usual maintenance 25–100 mg twice daily

- **INTERACTIONS** → Appendix 1: antiepileptics
Epilepsy and other seizure disorders 297

Carbamazepine

- INDICATIONS AND DOSE
  - Focal and secondary generalised tonic-clonic seizures
  - Primary generalised tonic-clonic seizures
    - BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
      - Adult: Initially 100–200 mg 1–2 times a day, increased in steps of 100–200 mg every 2 weeks; usual dose 0.8–1.2 g daily in divided doses; increased if necessary up to 1.6–2 g daily in divided doses
      - Elderly: Reduce initial dose
    - BY RECTUM
      - Adult: Up to 1 g daily in 4 divided doses for up to 7 days, for short-term use when oral therapy temporarily not possible
  - Trigeminal neuralgia
    - BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
      - Adult: Initially 400 mg daily in divided doses, increased until symptoms controlled; usual dose 400–600 mg daily; maximum 1.6 g per day
  - Prophylaxis of bipolar disorder unresponsive to lithium
    - BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
      - Adult: Initially 400 mg daily in divided doses, then reduced to 200 mg daily for usual treatment duration of 7–10 days, dose to be reduced gradually over 5 days
  - Adjunct in acute alcohol withdrawal
    - BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
      - Adult: Initially 800 mg daily in divided doses, then reduced to 200 mg daily for usual treatment duration of 7–10 days, dose to be reduced gradually over 5 days
  - Diabetic neuropathy
    - BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
      - Adult: Initially 100 mg 1–2 times a day, increased gradually according to response; usual dose 200 mg 3–4 times a day, increased if necessary up to 1.6 g daily
  - Focal and generalised tonic-clonic seizures
    - BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
    - Child 1 month–11 years: Initially 5 mg/kg once daily, dose to be taken at night, alternatively initially 2.5 mg/kg twice daily, then increased in steps of 2.5–5 mg/kg every 3–7 days as required; maintenance 5 mg/kg 2–3 times a day, increased if necessary up to 20 mg/kg daily
    - Child 12–17 years: Initially 100–200 mg 1–2 times a day, then increased to 200–400 mg 2–3 times a day, increased if necessary up to 1.8 g daily, dose should be increased slowly

DOSE EQUIVALENCE AND CONVERSION
- Suppositories of 125 mg may be considered to be approximately equivalent in therapeutic

**Oral solution**
- **CAUTIONARY AND ADVISORY LABELS** 2, 8
- **EXCipients:** May contain Sorbitol
- **ELECTROLYTES:** May contain Sodium
  - **Briviact** (UCB Pharma Ltd)
    - **Brivaracetam 10 mg per 1 ml** Briviact 10mg/ml oral solution sugar-free
      - 300 ml [Pos] £115.83
  - **Tablet**
    - **CAUTIONARY AND ADVISORY LABELS** 2, 8, 25
      - **Briviact** (UCB Pharma Ltd)
      - **Brivaracetam 10 mg** Briviact 10mg tablets
        - 14 tablet [Pos] £34.64
      - **Brivaracetam 25 mg** Briviact 25mg tablets
        - 56 tablet [Pos] £129.64
      - **Brivaracetam 50 mg** Briviact 50mg tablets
        - 56 tablet [Pos] £129.64
      - **Brivaracetam 75 mg** Briviact 75mg tablets
        - 56 tablet [Pos] £129.64
      - **Brivaracetam 100 mg** Briviact 100mg tablets
        - 56 tablet [Pos] £129.64

**Nervous system**

- **SIDE-EFFECTS**
  - **Common or very common** Anxiety · constipation · decreased appetite · depression · dizziness · insomnia · irritability · malaise · nausea · somnolence · vertigo · vomiting
  - **Uncommon** Aggression · agitation · neutropenia · psychotic disorder · suicidal ideation
- **PREGNANCY** Manufacturer advises avoid unless potential benefit outweighs risk—limited information available.
- **BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.
- **HEPATIC IMPAIRMENT** Manufacturer advises consider a starting dose of 25 mg twice daily in chronic liver disease; max. maintenance dose 75 mg twice daily in all stages of impairment.
- **TREATMENT CESSATION** Manufacturer advises avoid abrupt withdrawal—reduce daily dose in steps of 50 mg at weekly intervals, then reduce to 20 mg daily for a final week.
- **DIRECTIONS FOR ADMINISTRATION**
  - With intravenous use For intermittent intravenous infusion, manufacturer advises dilute in Glucose 5% or Sodium Chloride 0.9% or Lactated Ringer’s solution; give over 15 minutes.
  - With oral use Manufacturer advises oral solution can be diluted in water or juice shortly before swallowing.
- **PRESCRIBING AND DISPENSING INFORMATION**
  - Manufacturer advises if switching between oral therapy and intravenous therapy (for those temporarily unable to take oral medication), the total daily dose and the frequency of administration should be maintained.
- **PATIENT AND CARER ADVICE**
  - Missed doses Manufacturer advises if one or more doses are missed, a single dose should be taken as soon as possible and the next dose should be taken at the usual time.
  - Driving and skilled tasks Manufacturer advises patients and carers should be cautioned on the effects on driving and performance of skilled tasks—increased risk of dizziness.
- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **Scottish Medicines Consortium (SMC) Decisions**
    - The Scottish Medicines Consortium has advised (July 2016) that brivaracetam (Briviact®) is accepted for restricted use within NHS Scotland as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with refractory epilepsy. Treatment should be initiated by physicians who have appropriate experience in the treatment of epilepsy.
  - **All Wales Medicines Strategy Group (AWMSG) Decisions**
    - The All Wales Medicines Strategy Group has advised (October 2016) that Brivaracetam (Briviact®) is recommended as an option for restricted use within NHS Wales. Brivaracetam (Briviact®) should be restricted to use in the treatment of patients with refractory epilepsy, who remain uncontrolled with, or are intolerant to, other adjunctive anti-epileptic medicines, within its licensed indication as adjunctive therapy in the treatment of partial-onset seizures (POS) with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy. Brivaracetam (Briviact®) is not recommended for use within NHS Wales outside of this subpopulation.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.
- **Solution for injection**
  - **CAUTIONARY AND ADVISORY LABELS** 2
  - **ELECTROLYTES:** May contain Sodium
    - **Briviact** (UCB Pharma Ltd)
      - **Brivaracetam 10 mg per 1 ml** Briviact 50mg/5ml solution for injection vials
        - 10 vial [Pos] £222.75

**BNF 74**

- **Downloaded from www.medicalbr.com**
effect to tablets of 100 mg but final adjustment should always depend on clinical response (plasma concentration monitoring recommended).

**CARBAGEN® SR**

### Focal and secondary generalised tonic-clonic seizures

#### Primary generalised tonic-clonic seizures

- **Adult:** Initially 100–400 mg daily in 1–2 divided doses, increased in steps of 100–200 mg every 2 weeks, dose should be increased slowly; usual dose 0.8–1.2 g daily in 1–2 divided doses, increased if necessary up to 1.6–2 g daily in 1–2 divided doses
- **Elderly:** Reduce initial dose

### Trigeminal neuralgia

- **Adult:** Initially 400 mg daily in 1–2 divided doses, increased until symptoms controlled; usual dose 400–600 mg daily in 1–2 divided doses; maximum 1.6 g per day

### Prophylaxis of bipolar disorder unresponsive to lithium

- **Adult:** Initially 400 mg daily in 2 divided doses, increased until symptoms controlled; usual dose 400–600 mg daily in 2 divided doses; maximum 1.6 g per day

#### By Mouth

- **Child 12 years:** Initially 100–400 mg daily in 1–2 divided doses, increased in steps of 100–200 mg every 2 weeks, dose should be increased slowly; usual dose 0.8–1.2 g daily in 2 divided doses, increased if necessary up to 1.6–2 g daily in 2 divided doses
- **Child 11 years:** Initially 5–10 mg/kg daily in 1–2 divided doses, then increased in steps of 2.5–5 mg/kg every 3–7 days as required, dose should be increased slowly; maintenance 10–15 mg/kg daily in 1–2 divided doses, increased if necessary up to 20 mg/kg daily in 1–2 divided doses
- **Child 10 years:** Initially 100–400 mg daily in 1–2 divided doses, increased in steps of 100–200 mg every 2 weeks, dose should be increased slowly; usual dose 0.8–1.2 g daily in 2 divided doses, increased if necessary up to 1.6–2 g daily in 2 divided doses
- **Elderly:** Reduce initial dose

### Focal and generalised tonic-clonic seizures | Prophylaxis of bipolar disorder

- **Child 5–11 years:** Initially 5 mg/kg daily in 1–2 divided doses, then increased in steps of 2.5–5 mg/kg every 3–7 days as required, dose should be increased slowly; maintenance 10–15 mg/kg daily in 1–2 divided doses, increased if necessary up to 20 mg/kg daily in 1–2 divided doses
- **Child 12–17 years:** Initially 100–400 mg daily in 1–2 divided doses, then increased to 400–1200 mg daily in 2 divided doses, increased if necessary up to 1.8 g daily in 1–2 divided doses; dose should be increased slowly

**TEGRETOL® PROLONGED RELEASE**

### Focal and secondary generalised tonic-clonic seizures

- **Adult:** Initially 100–400 mg daily in 2 divided doses, increased in steps of 100–200 mg every 2 weeks, dose should be increased slowly; usual dose 0.8–1.2 g daily in 2 divided doses, increased if necessary up to 1.6–2 g daily in 2 divided doses
- **Elderly:** Reduce initial dose

### Trigeminal neuralgia

- **Adult:** Initially 100–200 mg daily in 2 divided doses, some patients may require higher initial dose. After initial dose, increase according to response; usual dose 600–800 mg daily in 2 divided doses, increased if necessary up to 1.6 g daily in 2 divided doses, dose should be increased slowly

---

**Prophylaxis of bipolar disorder unresponsive to lithium**

- **BY MOUTH**

- **Child 12 years:** Initially 100–400 mg daily in 1–2 divided doses, increased in steps of 100–200 mg every 2 weeks, dose should be increased slowly; usual dose 0.8–1.2 g daily in 2 divided doses, increased if necessary up to 1.6–2 g daily in 1–2 divided doses

### Trigeminal neuralgia

- **BY MOUTH**

- **Child 12 years:** Initially 100–400 mg daily in 1–2 divided doses, increased in steps of 100–200 mg every 2 weeks, dose should be increased slowly; usual dose 0.8–1.2 g daily in 2 divided doses, increased if necessary up to 1.6–2 g daily in 2 divided doses

---

**SIDE-EFFECTS**

- **Common or very common** Allergic skin reactions • aplastic anaemia • ataxia • blood disorders • blurring of vision • dermatitis • dizziness • drowsiness • dry mouth • eosinophilia • fatigue • haemolytic anaemia • headache • hyponatraemia (leading in rare cases to water intoxication) • leucopenia • nausea • oedema • thrombocytopenia • unsteadiness • urticaria • vomiting

- **Uncommon** Constipation • diarrhoea • involuntary movements (including myasthenia) • visual disturbances

- **Rare** Abdominal pain • aggression • agitation • anorexia • cardiac conduction disorders • confusion • delayed multi-organ hypersensitivity disorder • depression • dysarthria • hallucinations • hepatitis • hypertension • hypotension • jaundice • lymph node enlargement • muscle weakness • paraesthesia • peripheral neuropathy • restlessness • systemic lupus erythematosus • vanishing bile duct syndrome

- **Very rare** Arthralgia • muscle spasm • acne • alopecia • alterations in skin pigmentation • angle-closure glaucoma • aseptic meningitis • AV block with syncope • circulatory collapse • conjunctivitis • dyspnoea • exacerbation of coronary artery disease • galactorrhoea • gynaecomastia • hearing disorders • hepatic failure • hirsutism • hypercholesterolaemia • impaired male fertility • interstitial nephritis • muscle pain • neuroleptic malignant syndrome • osteomalacia • osteoporosis • pancreatitis • photosensitivity • pneumonia • pneumonitis • psychosis • pulmonary hypersensitivity • purpura • renal failure • sexual dysfunction • Stevens–Johnson syndrome • stomatitis • sweating • taste disturbance • thromboembolism • thrombophlebitis • toxic epidermal necrolysis • urinary frequency • urinary retention

- **Frequency not known** Suicidal ideation

**SIDE-EFFECTS, FURTHER INFORMATION**

Some side-effects (such as headache, ataxia, drowsiness, nausea, vomiting, blurring of vision, dizziness, unsteadiness, and allergic skin reactions) are dose-related, and may be dose-limiting. These side-effects are more common at the start of treatment and in the elderly. Patients should be offered a modified-release preparation to reduce the risk of side-effects; altering the timing of medication may also be beneficial.

**SIDE-EFFECTS, FURTHER INFORMATION**

Some side-effects (such as headache, ataxia, drowsiness, nausea, vomiting, blurring of vision, dizziness, unsteadiness, and allergic skin reactions) are dose-related, and may be dose-limiting. These side-effects are more common at the start of treatment and in the elderly. Patients should be offered a modified-release preparation to reduce the risk of side-effects; altering the timing of medication may also be beneficial.
**Overdose**
For details on the management of poisoning, see Active elimination techniques, under Emergency treatment of poisoning p. 1249.

- **ALLERGY AND CROSS-SENSITIVITY** Antiepileptic hypersensitivity syndrome associated with carbamazepine. See under Epilepsy p. 292 for more information. Caution—cross-sensitivity reported with oxcarbazepine and with phenytoin.

- **PREGNANCY** Doses should be adjusted on the basis of plasma-drug concentration monitoring.

- **BREAST FEEDING** Amount probably too small to be harmful. Monitor infant for possible adverse reactions.

- **HEPATIC IMPAIRMENT** Metabolism impaired in advanced liver disease.

- **RENAL IMPAIRMENT** Use with caution.

- **PRE-TREATMENT SCREENING** Test for HLA-B*1502 allele in individuals of Han Chinese or Thai origin (avoid unless no alternative—risk of Stevens-Johnson syndrome in presence of HLA-B*1502 allele).

- **MONITORING REQUIREMENTS**
  - Plasma concentration for optimum response 4–12 mg/litre (20–50 micromol/litre) measured after 1–2 weeks.
  - Manufacturer recommends blood counts and hepatic and renal function tests (but evidence of practical value uncertain).

- **TREATMENT CESSATION** When stopping treatment with carbamazepine for bipolar disorder, reduce the dose gradually over a period of at least 4 weeks.

- **DIRECTIONS FOR ADMINISTRATION**
  - In children Oral liquid has been used rectally—should be retained for at least 2 hours (but may have laxative effect).
  - **Tegretol® PROLONGED RELEASE** Tegretol® Prolonged Release tablets can be halved but should not be chewed.

- **PRESCRIBING AND DISPENSING INFORMATION**
  - Switching between formulations Different formulations of oral preparations may vary in bioavailability. Patients being treated for epilepsy should be maintained on a specific manufacturer’s product.

- **PATIENT AND CARER ADVICE**
  - Blood, hepatic, or skin disorders Patients or their carers should be told how to recognise signs of blood, liver, or skin disorders, and advised to seek immediate medical attention if symptoms such as fever, rash, mouth ulcers, bruising, or bleeding develop.
  - Medicines for Children leaflet: Carbamazepine (oral) for preventing seizures [www.medicinesforchildren.org.uk/carbamazepine-oral-preventing-seizures-0](http://www.medicinesforchildren.org.uk/carbamazepine-oral-preventing-seizures-0)

- **PROFESSION SPECIFIC INFORMATION**
  - Dental practitioners’ formulary Carbamazepine Tablets may be prescribed.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Modified-release tablet**

<table>
<thead>
<tr>
<th>Cautionary and Advisory Labels</th>
<th>3, 8, 25</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Carbagen SR</strong> (Mylan Ltd)</td>
<td></td>
</tr>
<tr>
<td>Carbamazepine 200 mg</td>
<td>Carbagen SR 200mg tablets</td>
</tr>
<tr>
<td>Carbamazepine 400 mg</td>
<td>Carbagen SR 400mg tablets</td>
</tr>
<tr>
<td><strong>Tegretol Retard</strong> (Novartis Pharmaceuticals UK Ltd)</td>
<td></td>
</tr>
<tr>
<td>Carbamazepine 200 mg</td>
<td>Tegretol Prolonged Release 200mg tablets</td>
</tr>
<tr>
<td>Carbamazepine 400 mg</td>
<td>Tegretol Prolonged Release 400mg tablets</td>
</tr>
</tbody>
</table>

---

**Tablet**

<table>
<thead>
<tr>
<th>Cautionary and Advisory Labels</th>
<th>3, 8</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Carbamazepine (Non-proprietary)</strong></td>
<td></td>
</tr>
<tr>
<td>Carbamazepine 100 mg</td>
<td>Carbamazepine 100mg tablets</td>
</tr>
<tr>
<td>Carbamazepine 200 mg</td>
<td>Carbamazepine 200mg tablets</td>
</tr>
<tr>
<td>Carbamazepine 400 mg</td>
<td>Carbamazepine 400mg tablets</td>
</tr>
<tr>
<td><strong>Carbagen</strong> (Mylan Ltd)</td>
<td></td>
</tr>
<tr>
<td>Carbamazepine 100 mg</td>
<td>Carbagen 100mg tablets</td>
</tr>
<tr>
<td>Carbamazepine 200 mg</td>
<td>Carbagen 200mg tablets</td>
</tr>
<tr>
<td>Carbamazepine 400 mg</td>
<td>Carbagen 400mg tablets</td>
</tr>
<tr>
<td><strong>Tegretol</strong> (Novartis Pharmaceuticals UK Ltd)</td>
<td></td>
</tr>
<tr>
<td>Carbamazepine 100 mg</td>
<td>Tegretol 100mg tablets</td>
</tr>
<tr>
<td>Carbamazepine 200 mg</td>
<td>Tegretol 200mg tablets</td>
</tr>
<tr>
<td>Carbamazepine 400 mg</td>
<td>Tegretol 400mg tablets</td>
</tr>
</tbody>
</table>

**Suppository**

<table>
<thead>
<tr>
<th>Cautionary and Advisory Labels</th>
<th>3, 8</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Carbamazepine (Non-proprietary)</strong></td>
<td></td>
</tr>
<tr>
<td>Carbamazepine 125 mg</td>
<td>Carbamazepine 125mg suppositories</td>
</tr>
<tr>
<td>Carbamazepine 250 mg</td>
<td>Carbamazepine 250mg suppositories</td>
</tr>
</tbody>
</table>

**Oral suspension**

<table>
<thead>
<tr>
<th>Cautionary and Advisory Labels</th>
<th>3, 8</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Carbamazepine (Non-proprietary)</strong></td>
<td></td>
</tr>
<tr>
<td>Carbamazepine 20 mg per 1 ml</td>
<td>Carbamazepine 100mg/5ml oral suspension sugar free sugar-free</td>
</tr>
<tr>
<td>Carbamazepine 20 mg per 1 ml</td>
<td>Tegretol 100mg/5ml liquid sugar-free</td>
</tr>
</tbody>
</table>

---

**Elicarbazepine acetate**

- **INDICATIONS AND DOSE**
  - Adjunctive treatment in adults with focal seizures with or without secondary generalisation
  - **BY MOUTH**
    - Adult: Initially 400 mg once daily for 1–2 weeks, then increased to 800 mg once daily (max. per dose 1.2 g)

- **CONTRA-INDICATIONS** Second- or third-degree AV block

- **CAUTIONS**
  - Elderly — hyponatraemia - PR-interval prolongation

- **INTERACTIONS**→ Appendix 1: antiepileptics

- **SIDE-EFFECTS**
  - **Common or very common**
    - Dizziness — drowsiness — fatigue — gastro-intestinal disturbances — headache — impaired coordination — rash — tremor — visual disturbances
  - **Uncommon**

---

Downloaded from www.medicalbr.com
disturbance • tinnitus • urinary tract infection • weight changes

- Very rare Leucopenia • pancreatitis • thrombocytopenia
- Frequency not known PR-interval prolongation • suicidal ideation

- ALLERGY AND CROSS-SENSITIVITY Antiepileptic hypersensitivity syndrome theoretically associated with eslicarbazepine. See under Epilepsy p. 292 for more information.

- PREGNANCY The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.

- HEPATIC IMPAIRMENT Avoid in severe impairment—no information available.

- RENAL IMPAIRMENT Reduce initial dose to 400 mg every other day for 2 weeks then 400 mg once daily if eGFR 30–60 mL/minute/1.73 m², adjusted according to response. Avoid if eGFR less than 30 mL/minute/1.73 m².

- PRE-TREATMENT SCREENING Test for HLA-B*1502 allele in individuals of Han Chinese or Thai origin (avoid unless no alternative—risk of Stevens-Johnson syndrome in presence of HLA-B*1502 allele).

- MONITORING REQUIREMENTS Monitor plasma-sodium concentration in patients at risk of hyponatraemia and discontinue treatment if hyponatraemia occurs.

- PRESCRIBING AND DISPENSING INFORMATION Switching between formulations: Care should be taken when switching between oral formulations. The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with the patient or their carer, taking into account factors such as seizure frequency and treatment history.

- NATIONAL FUNDING/ACCESS DECISIONS

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (October 2010) that eslicarbazepine (Zebinix®) is accepted for restricted use within NHS Scotland as adjunctive therapy in adults with focal seizures with or without secondary generalisation. It is restricted for use in refractory epilepsy.

- MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

CAUTIONARY AND ADVISORY LABELS 8

- Zebinix (Eisai Ltd)
  - Eslicarbazepine acetate 800 mg Zebinix 800 mg tablets | 30 tablet (POM) £136.00

---

**Ethosuximide**

- INDICATIONS AND DOSE

Absence seizures | Atypical absence seizures (adjunct) | Myoclonic seizures

- BY MOUTH
  - Child 1 month–5 years: Initially 5 mg/kg twice daily (max. per dose 125 mg), dose to be increased every 5–7 days; maintenance 10–20 mg/kg twice daily (max. per dose 500 mg), total daily dose may rarely be given in 3 divided doses
  - Child 6–17 years: Initially 250 mg twice daily, then increased in steps of 250 mg every 5–7 days; usual dose 500–750 mg twice daily, increased if necessary up to 1 g twice daily
  - Adult: Initially 500 mg daily in 2 divided doses, then increased in steps of 250 mg every 5–7 days; usual dose 1–1.5 g daily in 2 divided doses, increased if necessary up to 2 g daily

- CAUTIONS Avoid in acute porphyrias p. 969
- INTERACTIONS → Appendix 1: antiepileptics
- SIDE-EFFECTS
  - Common or very common Anorexia • abdominal pain • diarrhoea • gastro-intestinal disturbances • nausea • vomiting • weight loss
  - Uncommon Agitation • ataxia • dizziness • drowsiness • euphoria • fatigue • headache • hiccups • impaired concentration • irritability
  - Rare Depression • dyskinesia • gingival hypertrophy • increased libido • myopia • photophobia • psychosis • rash • sleep disturbances • tongue swelling • vaginal bleeding
  - Frequency not known Agranulocytosis • aplastic anaemia • blood disorders • hyperactivity • increase in seizure frequency • leukopenia • pancytopenia • Stevens-Johnson syndrome • suicidal ideation • systemic lupus erythematosus

SIDE-EFFECTS, FURTHER INFORMATION

- Blood disorders: Blood counts required if features of infection.
- PREGNANCY The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.
- BREAST FEEDING Present in milk. Hyperexcitability and sedation reported.
- HEPATIC IMPAIRMENT Use with caution.
- RENAL IMPAIRMENT Use with caution.
- PATIENT AND CARER ADVICE

Blood disorders: Patients or their carers should be told how to recognise signs of blood disorders, and advised to seek immediate medical attention if symptoms such as fever, mouth ulcers, bruising, or bleeding develop.

Medicines for Children leaflet: Ethosuximide for preventing seizures www.medicinesforchildren.org.uk/ethosuximide-for-preventing-seizures

- MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Oral solution**

CAUTIONARY AND ADVISORY LABELS 8

- Ethosuximide (Non-proprietary)
  - Ethosuximide 50 mg per 1 ml Ethosuximide 250 mg/5 ml syrup | 200 ml (POM) £173.00 DT price + £4.22

**Capsule**

CAUTIONARY AND ADVISORY LABELS 8

- Ethosuximide (Non-proprietary)
  - Ethosuximide 250 mg Ethosuximide 250 mg capsules | 56 capsule (POM) £173.00 DT price + £173.00

---

**Fosphenytoin sodium**

- DRUG ACTION Fosphenytoin is a pro-drug of phenytoin.

**Indications and dose**

Status epilepticus

- BY INTRAVENOUS INFUSION
  - Adult: Initially 20 mg(PE)/kg, dose to be administered at a rate of 100–150 mg(PE)/minute, then 4–5 mg (PE)/kg daily in 1–2 divided doses, dose to be administered at a rate of 50–100 mg(PE)/minute, dose to be adjusted according to response and trough plasma-phenytoin concentration
  - Elderly: Consider 10–25% reduction in dose or infusion rate

Prophylaxis or treatment of seizures associated with neurosurgery or head injury

- BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INFUSION
  - Adult: Initially 10–15 mg(PE)/kg, intravenous infusion to be administered at a rate of 50–100 mg(PE)/minute,
then 4–5 mg(PE)/kg daily in 1–2 divided doses, intravenous infusion to be administered at a rate of 50–100 mg(PE)/minute, dose to be adjusted according to response and trough plasma-phenytoin concentration

> Elderly: Consider 10–25% reduction in dose or infusion rate

**Temporary substitution for oral phenytoin**

> **BY INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INFUSION**
> Adult: Same dose and same dosing frequency as oral phenytoin therapy, intravenous infusion to be administered at a rate of 50–100 mg(PE)/minute
> Elderly: Consider 10–25% reduction in dose or infusion rate

**DOSE EQUIVALENCE AND CONVERSION**

Doses are expressed as phenytoin sodium equivalent (PE); fosphenytoin sodium 1.5 mg = phenytoin sodium 1 mg.

**UNLICENSED USE** Fosphenytoin sodium doses in BNF may differ from those in product literature.

**CONTRA-INDICATIONS** Acute porphyrias p. 969 - second-degree heart block - sino-atrial block - sinus bradycardia - Stokes-Adams syndrome - third-degree heart block

**CAUTIONS** Heart failure - hypotension - injection solutions alkaline (irritant to tissues) - respiratory depression - resuscitation facilities must be available

**INTERACTIONS** > Appendix 1: antiepileptics

**SIDE-EFFECTS**

> Common or very common Alterations in respiratory function - arrhythmias - asthenia - cardiovascular collapse - cardiovascular depression (particularly if injection too rapid) - chills - CNS depression (particularly if injection too rapid) - dry mouth - dysarthria - ecchymosis - euphoria - hypotension - incoordination - pruritus - respiratory arrest - taste disturbance - tinnitus - vasodilatation - visual disturbances
> Uncommon Decreased reflexes - hypoacusis - hypoesthesia - increased reflexes - muscle spasm - muscle weakness - pain - stupor
> Frequency not known Confusion - extrapyramidal disorder - hyperglycaemia - purple glove syndrome - tonic seizures - twitching

**SIDE-EFFECTS, FURTHER INFORMATION**

Cardiovascular reactions Intravenous infusion of fosphenytoin has been associated with severe cardiovascular reactions including asystole, ventricular fibrillation, and cardiac arrest. Hypotension, bradycardia, and heart block have also been reported. The following are recommended:

- monitor heart rate, blood pressure, and respiratory function for duration of infusion;
- observe patient for at least 30 minutes after infusion;
- if hypotension occurs, reduce infusion rate or discontinue;
- reduce dose or infusion rate in elderly, and in renal or hepatic impairment.

**ALLERGY AND CROSS-SENSITIVITY** Cross-sensitivity reported with carbamazepine.

**PREGNANCY** Changes in plasma-protein binding make interpretation of plasma-phenytoin concentrations difficult—monitor unbound fraction. The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.

**BREAST FEEDING** Small amounts present in milk, but not known to be harmful.

**HEPATIC IMPAIRMENT** Consider 10–25% reduction in dose or infusion rate (except initial dose for status epilepticus).

**RENAL IMPAIRMENT** Consider 10–25% reduction in dose or infusion rate (except initial dose for status epilepticus).

**PRE-TREATMENT SCREENING** HLA-B* 1502 allele in individuals of Han Chinese or Thai origin—avoid unless essential (increased risk of Stevens-Johnson syndrome).

**MONITORING REQUIREMENTS**

- Manufacturer recommends blood counts (but evidence of practical value uncertain).
- With intravenous use Monitor heart rate, blood pressure, ECG, and respiratory function for during infusion.

**DIRECTIONS FOR ADMINISTRATION** For intermittent intravenous infusion (Pro-Epanutin®), give in Glucose 5% or Sodium chloride 0.9%; dilute to a concentration of 1.5–25 mg (phenytoin sodium equivalent (PE))/mL.

**PRESCRIBING AND DISPENSING INFORMATION**

Prescriptions for fosphenytoin sodium should state the dose in terms of phenytoin sodium equivalent (PE); fosphenytoin sodium 1.5 mg = phenytoin sodium 1 mg.

**MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

**ELECTROLYTES:** May contain Phosphate

- Pro-Epanutin (Pfizer Ltd)

| Fosphenytoin sodium 75 mg per 1 ml | Pro-Epanutin 750mg/10ml concentrate for solution for injection vials | £400.00 (Hospital only) |

---

**Gabapentin**

**INDICATIONS AND DOSE**

Adjuvant treatment of focal seizures with or without secondary generalisation

**BY MOUTH**

- Child 6–11 years: 10 mg/kg once daily (max. per dose 300 mg) on day 1, then 10 mg/kg twice daily (max. per dose 300 mg) on day 2, then 10 mg/kg 3 times a day (max. per dose 300 mg) on day 3; usual dose 25–35 mg/kg daily in 3 divided doses, some children may not tolerate daily increments; longer intervals (up to weekly) may be more appropriate, daily dose maximum to be given in 3 divided doses; maximum 70 mg/kg per day

- Child 12–17 years: Initially 300 mg once daily on day 1, then 300 mg twice daily on day 2, then 300 mg 3 times a day on day 3, alternatively initially 300 mg 3 times a day on day 1, then increased in steps of 300 mg every 2–3 days in 3 divided doses, adjusted according to response; usual dose 0.9–3.6 g daily in 3 divided doses (max. per dose 1.6 g 3 times a day), some children may not tolerate daily increments; longer intervals (up to weekly) may be more appropriate

- Adult: Initially 300 mg once daily on day 1, then 300 mg twice daily on day 2, then 300 mg 3 times a day on day 3, alternatively initially 300 mg 3 times a day on day 1, then increased in steps of 300 mg every 2–3 days in 3 divided doses, adjusted according to response; usual dose 0.9–3.6 g daily in 3 divided doses (max. per dose 1.6 g 3 times a day)

**Monotherapy for focal seizures with or without secondary generalisation**

**BY MOUTH**

- Child 6–11 years: Initially 300 mg once daily on day 1, then 300 mg twice daily on day 2, then 300 mg 3 times a day on day 3, alternatively initially 300 mg 3 times a day on day 1, then increased in steps of 300 mg every 2–3 days in 3 divided doses, adjusted according to response; usual dose 0.9–3.6 g daily in 3 divided doses (max. per dose 1.6 g 3 times a day), some children may not tolerate daily increments; longer intervals (up to weekly) may be more appropriate

---
# Epilepsy and other seizure disorders

## Nervous system

### Peripheral neuropathic pain

- **BY MOUTH**
  - Adult: Initially 300 mg once daily on day 1, then 300 mg twice daily on day 2, then 300 mg 3 times a day on day 3, alternatively initially 300 mg 3 times a day on day 1, then increased in steps of 300 mg every 2–3 days in 3 divided doses, adjusted according to response; usual dose 0.9–3.6 g daily in 3 divided doses (max. per dose 1.6 g 3 times a day)

### Migraine prophylaxis

- **BY MOUTH**
  - Adult: Initially 300 mg daily, then increased to up to 2.4 g daily in divided doses, adjusted according to response

### Frequency not known

- Uncommon

### PREGNANCY

- Movement disorders during pregnancy and after birth, and adjustments made on a clinical basis.

### INTERACTIONS → Appendix 1: antiepileptics

### SIDE-EFFECTS


- Uncommon Palpitations


### PREGNANCY

- The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.

### BREAST FEEDING

- Present in milk—manufacturer advises use only if potential benefit outweighs risk.

### RENAL IMPAIRMENT

- In adults Reduce dose to 0.6–1.8 g daily in 3 divided doses if eGFR 50–80 mL/minute/1.73 m². Reduce dose to 300–900 mg daily in 3 divided doses if eGFR 30–50 mL/minute/1.73 m². Reduce dose to 300 mg on alternate days (up to max. 600 mg daily) in 3 divided doses if eGFR 15–30 mL/minute/1.73 m². Reduce dose to 300 mg on alternate days (up to max. 300 mg daily) in 3 divided doses if eGFR less than 15 mL/minute/1.73 m²—consult product literature.

- In children Reduce dose if estimated glomerular filtration rate less than 80 mL/minute/1.73 m²; consult product literature.

### EFFECT ON LABORATORY TESTS

- False positive readings with some urinary protein tests.

### DIRECTIONS FOR ADMINISTRATION

- Capsules can be opened but the bitter taste is difficult to mask.

### PATIENT AND CARER ADVICE

- Medicines for Children leaflet: Gabapentin for preventing seizures www.medicinesforchildren.org.uk/gabapentin-for-preventing-seizures

### MEDICINAL FORMS

- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

#### Tablet

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>3, 5, 8</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gabapentin (Non-proprietary)</strong></td>
<td></td>
</tr>
<tr>
<td>Gabapentin 600 mg Gabapentin 600mg tablets</td>
<td>100 tablet</td>
</tr>
<tr>
<td>Gabapentin 800 mg Gabapentin 800mg tablets</td>
<td>100 tablet</td>
</tr>
<tr>
<td><strong>Neurontin (Pfizer Ltd)</strong></td>
<td></td>
</tr>
<tr>
<td>Gabapentin 600 mg Neurontin 600mg tablets</td>
<td>100 tablet</td>
</tr>
<tr>
<td>Gabapentin 800 mg Neurontin 800mg tablets</td>
<td>100 tablet</td>
</tr>
</tbody>
</table>

#### Oral solution

| CAUTIONARY AND ADVISORY LABELS | 3, 5, 8 |
| EXCIPIENTS: | May contain Propylene glycol |
| ELECTROLYTES: | May contain Potassium, sodium |
| **Gabapentin (Non-proprietary)** |        |
| Gabapentin 50 mg per 1 ml Gabapentin 50mg/ml oral solution sugar free sugar-free | 150 ml | £69.00 DT price = £69.00 |

#### Capsule

| CAUTIONARY AND ADVISORY LABELS | 3, 5, 8 |
| **Gabapentin (Non-proprietary)** |        |
| Gabapentin 100 mg Gabapentin 100mg capsules | 100 capsule | £18.29 DT price = £1.19 |
| Gabapentin 300 mg Gabapentin 300mg capsules | 100 capsule | £42.40 DT price = £2.82 |
| Gabapentin 400 mg Gabapentin 400mg capsules | 100 capsule | £49.06 DT price = £3.24 |
| **Neurontin (Pfizer Ltd)** |        |
| Gabapentin 100 mg Neurontin 100mg capsules | 100 capsule | £18.29 DT price = £1.91 |
| Gabapentin 300 mg Neurontin 300mg capsules | 100 capsule | £42.40 DT price = £2.82 |
| Gabapentin 400 mg Neurontin 400mg capsules | 100 capsule | £49.06 DT price = £3.24 |

### Lacosamide

#### INDICATIONS AND DOSE

- **By mouth, or by intravenous infusion**
  - Child 16–17 years: Initially 50 mg twice daily, infusion to be administered over 15–60 minutes (for up to 5 days), then increased, if tolerated, in steps of 50 mg twice daily, adjusted according to response, dose to be increased in weekly intervals; maintenance 100 mg twice daily (max. per dose 200 mg twice daily)
  - Adult: Initially 50 mg twice daily, infusion to be administered over 15–60 minutes (for up to 5 days), then increased, if tolerated, in steps of 50 mg twice daily, adjusted according to response, dose to be increased in weekly intervals; maintenance 100 mg twice daily (max. per dose 200 mg twice daily)
Adjuvent treatment of focal seizures with or without secondary generalisation (alternative loading dose regimen when it is necessary to rapidly attain therapeutic plasma concentrations) (under close medical supervision)

- By mouth
- By intravenous infusion
- Child 16–17 years: Loading dose 200 mg, infusion to be administered over 15–60 minutes (for up to 5 days), followed by maintenance 100 mg twice daily, to be given 12 hours after initial dose, then increased, if tolerated, in steps of 50 mg twice daily (max. per dose 200 mg twice daily), adjusted according to response, dose to be increased in weekly intervals
- Adult: Loading dose 200 mg, infusion to be administered over 15–60 minutes (for up to 5 days), followed by maintenance 100 mg twice daily, to be given 12 hours after initial dose, then increased, if tolerated, in steps of 50 mg twice daily (max. per dose 200 mg twice daily), adjusted according to response, dose to be increased in weekly intervals

## Contra-Indications
- Second- or third-degree AV block

## Cautions
- Conduction problems
- Elderly
- Risk of PR-interval prolongation
- Severe cardiac disease

## Interactions
- Appendix 1: antiepileptics
- Appendix 2: sedative hypnotics
- Patch 1: Second- or third-degree AV block
- Patch 2: Conduction problems

## Side-Effects
- Common or very common: Abnormal gait, blunted vision, cognitive disorder, constipation, depression, dizziness, drowsiness, fatigue, flatulence, headache, impaired coordination, nausea, nystagmus, pruritus, tremor, vomiting
- Rare: Multi-organ hypersensitivity reaction
- Frequency not known: Aggression, agitation, agranulocytosis, atrial fibrillation, atrial flutter, AV block, bradycardia, confusion, dry mouth, dysarthria, dyspepsia, euphoria, hypoesthesia, irritability, muscle spasm, PR-interval prolongation, psychosis, rash, suicidal ideation, tinnitus

## Allergy and Cross-sensitivity
- Antiepileptic hypersensitivity syndrome associated with lacosamide. See under Epilepsy p. 292 for more information.

## Pregnancy
- The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.

## Breast Feeding
- Manufacturer advises avoid—present in milk in animal studies.

## Hepatic Impairment
- Titrate with caution in mild to moderate impairment if co-existing renal impairment. Caution in severe impairment—no information available.

## Renal Impairment
- Loading dose regimen can be considered in mild to moderate impairment—titrate above 200 mg with caution. Titrate with caution in severe impairment, max. 250 mg daily.
- In adults: Consult product literature for loading dose if eGFR less than 30 mL/minute/1.73 m².
- In children: Consult product literature for loading dose if estimated glomerular filtration rate is less than 30 mL/minute/1.73 m².

## Directions for Administration
- With intravenous use in children: For intravenous infusion, give undiluted or dilute with Glucose 5% or Sodium Chloride 0.9%.
- With intravenous use in adults: For intravenous infusion (Vimpat®), give intermittently in Glucose 5% or Sodium Chloride 0.9%. May be administered undiluted.

## Prescribing and Dispensing Information
- Flavours of syrup may include strawberry.

## Patient and Carer Advice
- Medicines for Children leaflet: Lacosamide for preventing seizures www.medicinesforchildren.org.uk/lacosamide-for-preventing-seizures

## National Funding/Access Decisions
- Scottish Medicines Consortium (SMC) Decisions
  The Scottish Medicines Consortium has advised (January 2009) that lacosamide (Vimpat®) is accepted for restricted use within NHS Scotland as adjunctive treatment for focal seizures with or without secondary generalisation in patients from 16 years. It is restricted for specialist use in refractory epilepsy.

## Medicinal Forms
- There can be variation in the licensing of different medicines containing the same drug.

### Solution for Infusion
- ELECTROLYTES: May contain Sodium
  - Vimpat (UCB Pharma Ltd)
    - Lacosamide 10 mg per 1 ml
      - Vimpat 200 mg/20 ml solution for infusion vials | 1 vial £29.70

### Oral Solution
- CAUTIONARY AND ADVISORY LABELS 8
- EXCIPIENTS: May contain Aspartame, propylene glycol
- ELECTROLYTES: May contain Sodium
  - Vimpat (UCB Pharma Ltd)
    - Lacosamide 10 mg per 1 ml
      - Vimpat 10 mg/ml syrup sugar-free | 200 ml £25.74 DT price = £25.74

### Tablet
- CAUTIONARY AND ADVISORY LABELS 8
- Vimpat (UCB Pharma Ltd)
  - Lacosamide 50 mg
    - Vimpat 50 mg tablets | 14 tablet £10.81
    - DT price = £10.81
  - Lacosamide 100 mg
    - Vimpat 100 mg tablets | 14 tablet £21.62
    - DT price = £21.62
  - Lacosamide 150 mg
    - Vimpat 150 mg tablets | 14 tablet £32.44
    - DT price = £32.44
  - Lacosamide 200 mg
    - Vimpat 200 mg tablets | 56 tablet £144.16 DT price = £144.16

### Lamotrigine

## Indications and Dose
- Monotherapy of focal seizures | Monotherapy of primary and secondary generalised tonic-clonic seizures | Monotherapy of seizures associated with Lennox-Gastaut syndrome
  - By mouth
  - Child 12–17 years: Initially 25 mg once daily for 14 days, then increased to 50 mg once daily for further 14 days, then increased in steps of up to 100 mg every 7–14 days; maintenance 100–200 mg daily
  - Adult: Initially 25 mg once daily for 14 days, then increased to 50 mg once daily for further 14 days, then increased in steps of up to 100 mg every 7–14 days; maintenance 100–200 mg daily

## Adjunctive Therapy of Focal Seizures with Valproate
- Monotherapy of primary and secondary generalised tonic-clonic seizures with valproate | Adjunctive therapy of seizures associated with Lennox-Gastaut syndrome with valproate
  - By mouth
  - Child 2–11 years (body-weight up to 13 kg): Initially 2 mg once daily on alternate days for first 14 days, then 300 micrograms/kg once daily for further 14 days, then increased in steps of up to
300 micrograms/kg every 7–14 days; maintenance 1–5 mg/kg daily in 1–2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days; maximum 200 mg per day

- Child 2–11 years (body-weight 13 kg and above): Initially 150 micrograms/kg once daily for 14 days, then 300 micrograms/kg once daily for further 14 days, then increased in steps of up to 300 micrograms/kg every 7–14 days; maintenance 1–5 mg/kg daily in 1–2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days; maximum 200 mg per day

- Child 12–17 years: Initially 25 mg once daily on alternate days for 14 days, then 25 mg once daily for further 14 days, then increased in steps of up to 50 mg every 7–14 days; maintenance 100–200 mg daily in 1–2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days

- Adult: Initially 25 mg once daily for 14 days, then increased in steps of up to 50 mg every 7–14 days; maintenance 100–200 mg daily in 1–2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days

**Adjuvant therapy of focal seizures (with enzyme inducing drugs) without valproate**

**Adjuvant therapy of primary and secondary generalised tonic-clonic seizures (with enzyme inducing drugs) without valproate**

**Adjuvant therapy of seizures associated with Lennox-Gastaut syndromes (with enzyme inducing drugs) without valproate**

- **BY MOUTH**
  - Child 2–11 years: Initially 300 micrograms/kg twice daily for 14 days, then 600 micrograms/kg twice daily for further 14 days, then increased in steps of up to 1.2 mg/kg every 7–14 days; maintenance 5–15 mg/kg daily in 1–2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days; maximum 400 mg per day
  - Child 12–17 years: Initially 50 mg once daily for 14 days, then 50 mg twice daily for further 14 days, then increased in steps of up to 100 mg every 7–14 days; maintenance 200–400 mg daily in 2 divided doses, increased if necessary up to 700 mg daily, dose titration should be repeated if restarting after interval of more than 5 days
  - Adult: Initially 50 mg once daily for 14 days, then 50 mg twice daily for further 14 days, then increased in steps of up to 100 mg every 7–14 days; maintenance 200–400 mg daily in 2 divided doses, increased if necessary up to 700 mg daily, dose titration should be repeated if restarting after interval of more than 5 days

**Adjuvant therapy of focal seizures (without enzyme inducing drugs) without valproate**

**Adjuvant therapy of primary and secondary generalised tonic-clonic seizures (without enzyme inducing drugs) without valproate**

**Adjuvant therapy of seizures associated with Lennox-Gastaut syndromes (without enzyme inducing drugs) without valproate**

- **BY MOUTH**
  - Child 2–11 years: Initially 300 micrograms/kg daily in 1–2 divided doses for 14 days, then 600 micrograms/kg daily in 1–2 divided doses for further 14 days, then increased in steps of up to 600 micrograms/kg every 7–14 days; maintenance 1–10 mg/kg daily in 1–2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days; maximum 200 mg per day
  - Child 12–17 years: Initially 25 mg once daily for 14 days, then increased to 50 mg once daily for further 14 days, then increased in steps of up to 100 mg every 7–14 days; maintenance 100–200 mg daily in 1–2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days

**Monotherapy or adjunctive therapy of bipolar disorder (without enzyme inducing drugs) without valproate**

- **BY MOUTH**
  - Adult: Initially 25 mg once daily for 14 days, then increased to 50 mg once daily for further 14 days, then increased in steps of up to 100 mg every 7–14 days; maintenance 100–200 mg daily in 1–2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days

**Adjuvant therapy of bipolar disorder with valproate**

- **BY MOUTH**
  - Adult: Initially 25 mg once daily for 14 days, then 50 mg daily in 1–2 divided doses for further 14 days, then 100 mg daily in 1–2 divided doses for further 7 days; maintenance 200 mg daily in 1–2 divided doses, patients stabilised on lamotrigine for bipolar disorder may require dose adjustments if other drugs are added to or withdrawn from their treatment regimens—consult product literature, dose titration should be repeated if restarting after interval of more than 5 days; maximum 400 mg per day

**Adjuvant therapy of bipolar disorder (with enzyme inducing drugs) without valproate**

- **BY MOUTH**
  - Adult: Initially 50 mg once daily for 14 days, then 50 mg twice daily for further 14 days, then increased to 100 mg twice daily for further 7 days, then increased to 150 mg twice daily for further 7 days; maintenance 200 mg twice daily, patients stabilised on lamotrigine for bipolar disorder may require dose adjustments if other drugs are added to or withdrawn from their treatment regimens—consult product literature, dose titration should be repeated if restarting after interval of more than 5 days

**IMPORTANT SAFETY INFORMATION**

**SAFE PRACTICE**

Do not confuse the different combinations or indications.

- **CAUTIONS** Myoclonic seizures (may be exacerbated) • Parkinson’s disease (may be exacerbated)
- **INTERACTIONS** → Appendix 1: antiepileptics
- **SIDE-EFFECTS**
  - Common or very common Blurred vision • aggression • agitation • arthralgia • ataxia • back pain • diarrhoea • diplopia • dizziness • drowsiness • dry mouth • headache • insomnia • nausea • nystagmus • rash • tremor • vomiting
  - Rare Conjunctivitis
  - Very rare Anaemia • blood disorders • confusion • exacerbation of Parkinson’s disease • hallucination • hepatic failure • hypersensitivity syndrome • increase in seizure frequency • leucopenia • lupus erythematosus-like reactions • movement disorders • pancytopenia • thrombocytopenia • unsteadiness
  - Frequency not known Aseptic meningitis • suicidal ideation

**BNF 74**

Nervous system

4

304 Epilepsy and other seizure disorders

[downloaded from www.medicalbr.com]
Levetiracetam

INDICATIONS AND DOSE

Monotherapy of focal seizures with or without secondary generalisation

- BY MOUTH, OR BY INTRAVENOUS INFUSION
  - Child 16-17 years: Initially 250 mg once daily for 1 week, then increased to 250 mg twice daily, then increased in steps of 250 mg twice daily (max. per dose 1.5 g twice daily), adjusted according to response, dose to be increased every 2 weeks
  - Adult: Initially 250 mg once daily for 1–2 weeks, then increased to 250 mg twice daily, then increased in steps of 250 mg twice daily (max. per dose 1.5 g twice daily), adjusted according to response, dose to be increased every 2 weeks

Adjunctive therapy of focal seizures with or without secondary generalisation

- BY MOUTH
  - Child 1–5 months: Initially 7 mg/kg once daily, then increased in steps of up to 7 mg/kg twice daily (max. per dose 21 mg/kg twice daily), dose to be increased every 2 weeks
  - Child 6 months–17 years (body-weight up to 50 kg): Initially 10 mg/kg once daily, then increased in steps of up to 10 mg/kg twice daily (max. per dose 30 mg/kg twice daily), dose to be increased every 2 weeks
  - Child 12–17 years (body-weight 50 kg and above): Initially 250 mg twice daily, then increased in steps of 500 mg twice daily (max. per dose 1.5 g twice daily), dose to be increased every 2–4 weeks
  - Adult: Initially 250 mg twice daily, then increased in steps of 500 mg twice daily (max. per dose 1.5 g twice daily), dose to be increased every 2–4 weeks

- BY INTRAVENOUS INFUSION
  - Child 4–17 years (body-weight up to 50 kg): Initially 10 mg/kg once daily, then increased in steps of up to 10 mg/kg twice daily (max. per dose 30 mg/kg twice daily), dose to be increased every 2 weeks
  - Child 12–17 years (body-weight 50 kg and above): Initially 250 mg twice daily, then increased in steps of 500 mg twice daily (max. per dose 1.5 g twice daily), dose to be increased every 2 weeks
  - Adult: Initially 250 mg twice daily, then increased in steps of 500 mg twice daily (max. per dose 1.5 g twice daily), dose to be increased every 2–4 weeks

Adjunctive therapy of myoclonic seizures and tonic-clonic seizures

- BY MOUTH, OR BY INTRAVENOUS INFUSION
  - Child 12–17 years (body-weight up to 50 kg): Initially 10 mg/kg once daily, then increased in
steps of up to 10 mg/kg twice daily (max. per dose 30 mg/kg twice daily), dose to be increased every 2 weeks
- Child 12-17 years (body-weight 50 kg and above): Initially 250 mg/twice daily, then increased in steps of 500 mg twice daily (max. per dose 1.5 g twice daily), dose to be increased every 2 weeks
- Adult: Initially 250 mg twice daily, then increased in steps of 500 mg twice daily (max. per dose 1.5 g twice daily), dose to be increased every 2–4 weeks

- **UNLICENSED USE** Levetiracetam doses in BNF may differ from those in product literature. *Granules* not licensed for use in children under 6 years, for initial treatment in children with body-weight less than 25 kg, or for the administration of doses below 250 mg.
- **INTERACTIONS** → Appendix 1: antiepileptics
- **SIDE-EFFECTS**
  - Common or very common: Abdominal pain, aggression, anorexia, anxiety, ataxia, convulsion, cough, depression, diarrhoea, dizziness, drowsiness, dyspepsia, headache, insomnia, irritability, malaise, nasopharyngitis, nausea, rash, tremor, vertigo, vomiting.
  - Uncommon: Agitation, alopecia, amnesia, blurred vision, confusion, diplopia, eczema, impaired attention, leucopenia, myalgia, paraesthesia, pruritus, psychosis, suicidal ideation, thrombocytopenia, weight changes.
  - Rare: Agranulocytosis, choreoathetosis, drug reaction with eosinophilia and systemic symptoms (DRESS), dyskinesia, erythema multiforme, hepatic failure, hyponatraemia, neutropenia, pancreatitis, pancytopenia, Stevens-Johnson syndrome, toxic epidermal necrolysis.
  - Frequency not known: Completed suicide, pancytopenia.
- **PREGNANCY** The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis. It is recommended that the fetal growth should be monitored.
- **BREAST FEEDING** Present in milk—manufacturer advises avoid.
- **HEPATIC IMPAIRMENT**
  - In adults: Halve dose in severe hepatic impairment if eGFR less than 60 mL/minute/1.73 m².
  - In children: Halve dose in severe hepatic impairment if estimated glomerular filtration rate less than 60 mL/minute/1.73 m².
- **RENAL IMPAIRMENT**
  - In children: Reduce dose if estimated glomerular filtration rate less than 80 mL/minute/1.73 m² (consult product literature).
  - In adults: Maximum 2 g daily if eGFR 50–80 mL/minute/1.73 m². Maximum 1.5 g daily if eGFR 30–50 mL/minute/1.73 m². Maximum 1 g daily if eGFR less than 30 mL/minute/1.73 m².
- **DIRECTIONS FOR ADMINISTRATION**
  - With intravenous use: For *intravenous infusion* (*Keppra*®), dilute requisite dose with at least 100 mL Glucose 5% or Sodium Chloride 0.9%; give over 15 minutes.
  - With oral use: For administration of *oral solution*, requisite dose may be diluted in a glass of water.
- **PRESCRIBING AND DISPENSING INFORMATION** If switching between oral therapy and intravenous therapy (for those temporarily unable to take oral medication), the intravenous dose should be the same as the established oral dose.
- **PATIENT AND CARER ADVICE**
  - Medicines for Children leaflet: *Levetiracetam for preventing seizures* | www.medicinesforchildren.org.uk/levetiracetam-for-preventing-seizures

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution.

**Granules**

- **CAUTIONARY AND ADVISORY LABELS**
- **Desitrend** (Desitin Pharma Ltd)
  - *Levetiracetam 250 mg* *Desitrend 250mg granules sugar-free* | 60 sachet | £22.41
  - *Levetiracetam 500 mg* *Desitrend 500mg granules sugar-free* | 60 sachet | £39.46
  - *Levetiracetam 1 gram* *Desitrend 1000mg granules sugar-free* | 60 sachet | £76.27

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS**
- **Desitrend** (Desitin Pharma Ltd)
  - *Levetiracetam 250 mg* *Desitrend 250 mg tablets* | 60 tablet | £28.01 DT price = £1.98
  - *Levetiracetam 500 mg* *Desitrend 500 mg tablets* | 60 tablet | £49.32 DT price = £2.49
  - *Levetiracetam 750 mg* *Desitrend 750 mg tablets* | 60 tablet | £84.02 DT price = £4.06
  - *Levetiracetam 1 gram* *Desitrend 1 gram tablets* | 60 tablet | £95.34 DT price = £5.50

**Solution for infusion**

**ELECTROLYTES**: May contain Sodium

- **Desitrend** (Desitin Pharma Ltd)
  - *Levetiracetam 250 mg* *Desitrend 250 mg oral solution sugar-free* | 1 vial | £11.45 DT price = £1.57
  - *Levetiracetam 500 mg* *Desitrend 500 mg oral solution sugar-free* | 1 vial | £11.45 DT price = £2.95
  - *Levetiracetam 750 mg* *Desitrend 750 mg oral solution sugar-free* | 1 vial | £19.45 DT price = £2.95

**Oral solution**

- **Desitrend** (Desitin Pharma Ltd)
  - *Levetiracetam 1 mg* *Desitrend 1 ml 1 mg concentrated oral solution sugar-free* | 15 ml | £33.48 sugar-free | 300 ml | £66.95 DT price = £2.49

**Oxcarbazepine**

- **INDICATIONS AND DOSE**
  - Monotherapy for the treatment of focal seizures with or without secondary generalised tonic-clonic seizures
  - **BY MOUTH**
    - Child 6-17 years: Initially 4–5 mg/kg twice daily (max. per dose 300 mg), then increased in steps of up to 5 mg/kg twice daily, adjusted according to response, dose to be adjusted at weekly intervals; maximum 46 mg/kg per day.
    - Adult: Initially 300 mg twice daily, then increased in steps of up to 600 mg daily, adjusted according to response, dose to be adjusted at weekly intervals; usual dose 0.6–2.4 g daily in divided doses
Adjunctive therapy for the treatment of focal seizures with or without secondary generalised tonic-clonic seizures

- BY MOUTH
  - Child 6–17 years: Initially 4–5 mg/kg twice daily (max. per dose 300 mg), then increased in steps of up to 5 mg/kg twice daily, adjusted according to response, dose to be adjusted at weekly intervals; maintenance 15 mg/kg twice daily; maximum 46 mg/kg per day
  - Adult: Initially 300 mg twice daily, then increased in steps of up to 600 mg daily, adjusted according to response, dose to be adjusted at weekly intervals; usual dose 0.6–2.4 g daily in divided doses

Treatment of primary generalised tonic-clonic seizures

- BY MOUTH
  - Adult: Initially 300 mg twice daily, then increased in steps of up to 600 mg daily, adjusted according to response, dose to be adjusted at weekly intervals; usual dose 0.6–2.4 g daily in divided doses

DOSE ADJUSTMENTS DUE TO INTERACTIONS
In adjunctive therapy, the dose of concomitant antiepileptics may need to be reduced when using high doses of oxcarbazepine.

- UNLICENSED USE Not licensed for the treatment of primary generalised tonic-clonic seizures.
- CAUTIONS Avoid in acute porphyrias p. 969; cardiac conduction disorders · heart failure · hyponatraemia
- INTERACTIONS → Appendix 1: antiepileptics
- SIDE-EFFECTS
  - Common or very common Abdominal pain · acne · agitation · alopecia · amnesia · asthma · ataxia · confusion · constipation · depression · diarrhoea · diplopia · dizziness · drowsiness · headache · hyponatraemia · impaired concentration · nausea · nightmares · rash · tremor · visual disorders · vomiting
  - Uncommon Leucopenia · urticaria
  - Very rare Arrhythmias · atrioventricular block · hepatitis · multi-organ hypersensitivity disorders · pancreatitis · Stevens-Johnson syndrome · systemic lupus erythematosus · thrombocytopenia · toxic epidermal necrolysis
  - Frequency not known Aplastic anaemia · bone marrow depression · hypertension · hypothyroidism · neutropenia · osteoporotic bone disorders · pancytopenia · suicidal ideation
- PREGNANCY The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.
- BREAST FEEDING Amount probably too small to be harmful but manufacturer advises avoid.
- HEPATIC IMPAIRMENT Caution in severe impairment—no information available.
- RENAL IMPAIRMENT
  - In adults Halve initial dose if eGFR less than 30 mL/minute/1.73 m²; increase according to response at intervals of at least 1 week.
  - In children Halve initial dose if estimated glomerular filtration rate less than 30 mL/minute/1.73 m², increase according to response at intervals of at least 1 week.
- PRE-TREATMENT SCREENING Test for HLA-B*1502 allele in individuals of Han Chinese or Thai origin (avoid unless no alternative—risk of Stevens-Johnson syndrome in presence of HLA-B*1502 allele).

- MONITORING REQUIREMENTS
  - Monitor plasma-sodium concentration in patients at risk of hyponatraemia.
  - Monitor body-weight in patients with heart failure.
- PRESCRIBING AND DISPENSING INFORMATION Patients may need to be maintained on a specific manufacturer’s branded or generic oxcarbazepine product. Switching between formulations Care should be taken when switching between oral formulations. The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with the patient or their carer, taking into account factors such as seizure frequency and treatment history.
- PATIENT AND CARER ADVICE
  - Blood, hepatic, or skin disorders Patients or their carers should be told how to recognise signs of blood, liver, or skin disorders, and advised to seek immediate medical attention if symptoms such as lethargy, confusion, muscular twitching, fever, rash, blistering, mouth ulcers, bruising, or bleeding develop.
  - Medicines for Children: Oxcarbazepine for preventing seizures www.medicinesforchildren.org.uk/oxcarbazepine-for-preventing-seizures

- MEDICINAL FORMS
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension
  - Oral suspension
  - CAUTIONARY AND ADVISORY LABELS 3, 8
  - EXCIPIENTS: May contain Propylene glycol
  - Trileptal (Novartis Pharmaceuticals UK Ltd)
    - Oxcarbazepine 60 mg per 1 ml Trileptal 60mg/ml oral suspension sugar-free | 250 ml (Pom) £48.96 DT price = £48.96
  - Tablett
  - CAUTIONARY AND ADVISORY LABELS 3, 8
  - Oxcarbazepine (Non-proprietary)
    - Oxcarbazepine 150 mg Oxcarbazepine 150mg tablets | 50 tablet (Pom) £11.14 DT price = £8.42
    - Oxcarbazepine 300 mg Oxcarbazepine 300mg tablets | 50 tablet (Pom) £22.61 DT price = £5.89
    - Oxcarbazepine 600 mg Oxcarbazepine 600mg tablets | 50 tablet (Pom) £45.19 DT price = £38.76
  - Trileptal (Novartis Pharmaceuticals UK Ltd)
    - Oxcarbazepine 150 mg Trileptal 150mg tablets | 50 tablet (Pom) £12.24 DT price = £8.42
    - Oxcarbazepine 300 mg Trileptal 300mg tablets | 50 tablet (Pom) £24.48 DT price = £5.89
    - Oxcarbazepine 600 mg Trileptal 600mg tablets | 50 tablet (Pom) £48.96 DT price = £38.76

Perampanel

- INDICATIONS AND DOSE
  - Adjunctive treatment of focal seizures with or without secondary generalised seizures
  - BY MOUTH
    - Child 12–17 years: Initially 2 mg once daily, dose to be taken before bedtime, then increased, if tolerated, in steps of 2 mg at intervals of at least every 2 weeks, adjusted according to response; maintenance 4–8 mg once daily; maximum 12 mg per day
    - Adult: Initially 2 mg once daily, dose to be taken before bedtime, then increased, if tolerated, in steps of 2 mg at intervals of at least every 2 weeks, adjusted according to response; maintenance 4–8 mg once daily; maximum 12 mg per day
  - DOSE ADJUSTMENTS DUE TO INTERACTIONS
    - Titrate at intervals of at least 1 week with concomitant carbamazepine, fosphenytoin, oxcarbazepine, or phenytoin.
  - INTERACTIONS → Appendix 1: antiepileptics
Phenytoin

INDICATIONS AND DOSE

Tonic-clonic seizures | Focal seizures

- BY MOUTH
  - Child 1 month–11 years: Initially 1.5–2.5 mg/kg twice daily, then adjusted according to response to 2.5–5 mg/kg twice daily (max. per dose 7.5 mg/kg twice daily), dose also adjusted according to plasma-phenytoin concentration; maximum 300 mg per day
  - Child 12–17 years: Initially 75–150 mg twice daily, then adjusted according to response to 150–200 mg twice daily (max. per dose 300 mg twice daily), dose also adjusted according to plasma-phenytoin concentration

Tonic-clonic seizures | Focal seizures | Prevention and treatment of seizures during or following neurosurgery or severe head injury

- BY MOUTH
  - Adult: Initially 3–4 mg/kg daily, alternatively 150–300 mg once daily, alternatively 150–300 mg daily in 2 divided doses; usual maintenance 200–500 mg daily, to be taken preferably with or after food, dose to be increased gradually as necessary (with plasma-phenytoin concentration monitoring), exceptionally, higher doses may be used

Prevention and treatment of seizures during or following neurosurgery or severe head injury

- BY MOUTH
  - Child: Initially 2.5 mg/kg twice daily, then adjusted according to response to 4–8 mg/kg daily, dose also adjusted according to plasma-phenytoin concentration; maximum 300 mg per day

Status epilepticus | Acute symptomatic seizures associated with head trauma or neurosurgery

- INITIAL BY SLOW INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION
  - Child 1 month–11 years: Loading dose 20 mg/kg, then (by slow intravenous injection or by intravenous infusion) 2.5–5 mg/kg twice daily
  - Child 12–17 years: Loading dose 20 mg/kg, then (by intravenous infusion or by slow intravenous injection) up to 100 mg 3–4 times a day
  - Adult: Loading dose 20 mg/kg (max. per dose 2 g), then (by intravenous infusion or by slow intravenous injection or by mouth) maintenance 100 mg every 6–8 hours adjusted according to plasma-concentration monitoring

DOSE EQUIVALENCE AND CONVERSION

Preparations containing phenytoin sodium are not bioequivalent to those containing phenytoin base (such as Epanutin Infatabs® and Epanutin® suspension); 100 mg of phenytoin sodium is approximately equivalent in therapeutic effect to 92 mg phenytoin base. The dose is the same for all phenytoin products when initiating therapy. However, if switching between these products the difference in phenytoin content may be clinically significant. Care is needed when making changes between formulations and plasma-phenytoin concentration monitoring is recommended.

UNLICENSED USE

- With intravenous use Phenytoin doses in BNF publications may differ from those in product literature.

CONTRA-INDICATIONS

GENERAL CONTRA-INDICATIONS

Acute porphyrias p. 969

SPECIFIC CONTRA-INDICATIONS

- With intravenous use Second- and third-degree heart block · sino–atrial block · sinus bradycardia · Stokes–Adams syndrome

CAUTIONS

GENERAL CAUTIONS

Enteral feeding (interrupt feeding for 2 hours before and after dose; more frequent monitoring may be necessary)

SPECIFIC CAUTIONS

- With intravenous use Heart failure · hypotension · injection solutions alkaline (irritant to tissues) · respiratory depression · resuscitation facilities must be available

CAUTIONS, FURTHER INFORMATION

Consider vitamin D supplementation in patients who are immobilised for long periods or who have inadequate sun exposure or dietary intake of calcium.

 Intramuscular phenytoin should not be used (absorption is slow and erratic).

INTERACTIONS

Appendix 1: antiepileptics
SIDE-EFFECTS

GENERAL SIDE-EFFECTS

- **Common or very common** Acne, anorexia, coarsening of facial appearance, constipation, dizziness, drowsiness, gingival hypertrophy and tenderness (maintain good oral hygiene), headache, hirsutism, insomnia, nausea, paraesthesia, rash, transient nervousness, tremor, vomiting

- **Rare** Leucopenia, aplastic anaemia, blood disorders, dyskinesia, hepatotoxicity, lupus erythematosus, lymphadenopathy, megaloblastic anaemia, osteomalacia, peripheral neuropathy, polyarteritis nodosa, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis

- **Frequency not known** Hypersensitivity syndrome, interstitial nephritis, pneumonitis, polyarthropathy, suicidal ideation

SPECIFIC SIDE-EFFECTS

- **Common or very common**
  - With intravenous use Alterations in respiratory function, arrhythmias, cardiovascular collapse, cardiovascular depression (particularly if injection too rapid), CNS depression (particularly if injection too rapid), hypotension, respiratory arrest
  - Frequency not known With intravenous use Purple glove syndrome, tonic seizures

SIDE-EFFECTS, FURTHER INFORMATION

- Hypotoxicity Discontinue immediately and do not re-administer.
- Rash Discontinue; if mild re-introduce cautiously but discontinue immediately if recurrence.
- Use in adolescents Phenytoin may cause coarsening of the facial appearance, acne, hirsutism, and gingival hyperplasia and so may be particularly undesirable in adolescent patients.
- Bradycardia and hypotension
- With intravenous use Reduce rate of administration if bradycardia or hypotension occurs.

Overdose

Symptoms of phenytoin toxicity include nystagmus, diplopia, slurred speech, ataxia, confusion, and hyperglycaemia.

ALLERGY AND CROSS-SENSITIVITY Cross-sensitivity reported with carbamazepine. Antiepileptic hypersensitivity syndrome associated with phenytoin. See under Epilepsy p. 292 for more information.

PREGNANCY

Changes in plasma-protein binding make interpretation of plasma-phenytoin concentrations difficult—monitor unbound fraction. Doses should be adjusted on the basis of plasma-drug concentration monitoring.

Breast feeding

Small amounts present in milk, but not known to be harmful.

Hepatic impairment

Reduce dose to avoid toxicity.

PRE-TREATMENT SCREENING

HLA-B*1502 allele in individuals of Han Chinese or Thai origin—avoid unless essential (increased risk of Stevens-Johnson syndrome).

MONITORING REQUIREMENTS

- In adults The usual total plasma-phenytoin concentration for optimum response is 10–20 mg/litre (or 40–80 micromol/litre). In pregnancy, the elderly, and certain disease states where protein binding may be reduced, careful interpretation of total plasma-phenytoin concentration is necessary; it may be more appropriate to measure free plasma-phenytoin concentration.
  - In children Therapeutic plasma-phenytoin concentrations reduced in first 3 months of life because of reduced protein binding. Trough plasma concentration for optimum response: neonate–3 months, 6–15 mg/litre (25–60 micromol/litre); child 3 months–18 years, 10–20 mg/litre (40–80 micromol/litre).
- With intravenous use Monitor ECG and blood pressure.
- Manufacturer recommends blood counts (but evidence of practical value uncertain).

DIRECTIONS FOR ADMINISTRATION

Manufacturer advises each injection or infusion should be preceded and followed by an injection of Sodium Chloride 0.9% through the same needle or catheter to avoid local venous irritation.

- With intravenous use in children For intravenous injection, give into a large vein at a rate not exceeding 1 mg/kg/minute (max. 50 mg/minute).
- Manufacturer advises for intravenous infusion, dilute to a concentration not exceeding 10 mg/ml with Sodium Chloride 0.9% and give into a large vein through an in-line filter (0.22–0.50 micron). Give at a rate not exceeding 1 mg/kg/minute (max. 50 mg/minute).
- Complete administration within 1 hour of preparation.

- With intravenous use in adults Manufacturer advises for intravenous injection, give into a large vein at a rate not exceeding 50 mg/minute; rate of 25 mg/minute or lower may be more appropriate in some patients (including the elderly and those with heart disease). Manufacturer advises for intravenous infusion, dilute in 50–100 ml Sodium Chloride 0.9% (final concentration not to exceed 10 mg/ml) and give into a large vein through an in-line filter (0.22–0.50 micron) at a rate not exceeding 50 mg/minute; rate of 25 mg/minute or lower may be more appropriate in some patients (including the elderly and those with heart disease). Complete administration within 1 hour of preparation.

PRESCRIBING AND DISPENSING INFORMATION

Switching between formulations Different formulations of oral preparations may vary in bioavailability. Patients being treated for epilepsy should be maintained on a specific manufacturer’s product.

PATIENT AND CARER ADVICE

Blood or skin disorders Patients or their carers should be told how to recognise signs of blood or skin disorders, and advised to seek immediate medical attention if symptoms such as fever, rash, mouth ulcers, bruising, or bleeding develop. Leucopenia that is severe, progressive, or associated with clinical symptoms requires withdrawal (if necessary under cover of a suitable alternative).

Medicines for Children leaflet: Phenytoin for preventing seizures www.medicinesforchildren.org.uk/phenytoin-for-preventing-seizures

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Tablet**

CAUTIONARY AND ADVISORY LABELS

- **Phenytoin (Non-proprietary)**
  - Phenytoin sodium 100 mg Phenytoin sodium 100mg tablets 28 tablet [PO] £32.95 DT price + £23.00 | 100 tablet [PO] no price available

Solution for injection

EXCipients: May contain Alcohol, propylene glycol ELECTROLYTES: May contain Sodium

- **Phenytoin (Non-proprietary)**
  - Phenytoin sodium 50 mg per 1 ml Phenytoin sodium 250mg/5ml solution for injection ampoules 5 ampoule [PO] £15.50–24.40 | 10 ampoule [PO] no price available
  - Epanutin (Phenytoin sodium) (Pfizer Ltd)
    - Phenytoin sodium 50 mg per 1 ml Epanutin Ready-Mixed Parenteral 250mg/5ml solution for injection ampoules 10 ampoule [PO] £48.79

**Oral suspension**

CAUTIONARY AND ADVISORY LABELS

- Epanutin (Phenytoin) (Pfizer Ltd)
  - Phenytoin 6 mg per 1 ml Epanutin 30mg/5ml oral suspension 500 ml [PO] £4.27 DT price = £4.27

BNF 74

4 Nervous System

Epilepsy and other seizure disorders 309

downloaded from www.medicalbr.com
**Pregabalin**

- **INDICATIONS AND DOSE**
  - **Peripheral and central neuropathic pain**
    - **BY MOUTH**
      - Adult: Initially 150 mg daily in 2–3 divided doses, then increased if necessary to 300 mg daily in 2–3 divided doses, dose to be increased after 3–7 days, then increased if necessary up to 600 mg daily in 2–3 divided doses, dose to be increased after 7 days
  - **Adjunctive therapy for focal seizures with or without secondary generalisation**
    - **BY MOUTH**
      - Adult: Initially 25 mg twice daily, then increased in steps of 50 mg daily, dose to be increased at 7 day intervals, increased to 300 mg daily in 2–3 divided doses for 7 days, then increased if necessary up to 600 mg daily in 2–3 divided doses

- **Generalised anxiety disorder**
  - **BY MOUTH**
    - Adult: Initially 150 mg daily in 2–3 divided doses, then increased in steps of 150 mg daily if required, dose to be increased at 7 day intervals, increased if necessary up to 600 mg daily in 2–3 divided doses

- **UNLICENSED USE** Pregabalin doses in BNF may differ from those in product literature.

- **CAUTIONS** Conditions that may precipitate encephalopathy - severe congestive heart failure

- **INTERACTIONS** \(\rightarrow\) Appendix 1: antiepileptics

- **SIDE-EFFECTS**
  - Common or very common
    - Appetite changes - blurred vision - confusion - constipation - diplopia - disturbances in muscle control and movement - dizziness - drowsiness - dry mouth - euphoria - flatulence - impaired attention - impaired memory - insomnia - irritability - malaise - oedema - paraesthesia - sexual dysfunction - speech disorder - visual disturbances - visual field defects - vomiting - weight gain
  - Uncommon
  - Rare

- **Frequency not known**

- **RENAL IMPAIRMENT**
  - Initially 75 mg daily and maximum 300 mg daily if eGFR 30–60 mL/minute/1.73 m². Initially 25–50 mg daily and maximum 150 mg daily in 1–2 divided doses if eGFR 15–30 mL/minute/1.73 m². Initially 25 mg once daily and maximum 75 mg once daily if eGFR less than 15 mL/minute/1.73 m².

- **TREATMENT CESSATION** Avoid abrupt withdrawal ( taper over at least 1 week).

- **PRESCRIBING AND DISPENSING INFORMATION** Flavours of oral liquid formulations may include strawberry.

- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **Scottish Medicines Consortium (SMC) Decisions**
    - The Scottish Medicines Consortium has advised (July 2007) that pregabalin (Lyrica®) is not recommended for the treatment of central neuropathic pain.
    - The Scottish Medicines Consortium has advised (April 2009) that pregabalin (Lyrica®) is accepted for restricted use within NHS Scotland for the treatment of peripheral neuropathic pain in adults who have not achieved adequate pain relief with, or have not tolerated, first- or second-line treatments; discontinue treatment if sufficient benefit is not achieved within 8 weeks of reaching the maximum tolerated dose.

- **MEDIcular FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

### Oral solution

- **CAUTIONARY AND ADVISORY LABELS** 3, 8
  - **Pregabalin (Non-proprietary)**
    - Pregabalin 20 mg per 1 ml Pregabalin 20mg/ml oral solution sugar free (Lyrica®) 473 ml $99.48 DT price $99.48
    - Pregabalin 100 mg Pregabalin 100mg/ml oral solution sugar-free 473 ml $99.48 DT price $99.48
    - Lyrica (Pfizer Ltd)
      - Pregabalin 20 mg per 1 ml Lyrica 20mg/ml oral solution sugar-free 473 ml $99.48 DT price $99.48

---

**Capsule**

- **CAUTIONARY AND ADVISORY LABELS** 3, 8
  - **Pregabalin (Non-proprietary)**
    - Pregabalin 25 mg Pregabalin 25mg capsules 56 capsule $84.40 DT price $96.60
    - Pregabalin 50 mg Pregabalin 50mg capsules 56 capsule $116.40 DT price $128.60
    - Pregabalin 75 mg Pregabalin 75mg capsules 56 capsule $164.40 DT price $176.60
    - Pregabalin 100 mg Pregabalin 100mg capsules 56 capsule $196.60 DT price $208.80
    - Pregabalin 150 mg Pregabalin 150mg capsules 56 capsule $272.00 DT price $284.20
    - Pregabalin 200 mg Pregabalin 200mg capsules 56 capsule $338.40 DT price $350.60
    - Pregabalin 250 mg Pregabalin 250mg capsules 56 capsule $393.60 DT price $405.80
    - Pregabalin 300 mg Pregabalin 300mg capsules 56 capsule $449.00 DT price $461.20

- **Alzain (Dr Reddy’s Laboratories (UK) Ltd)**
  - Pregabalin 25 mg Alzain 25mg capsules 56 capsule $38.64 DT price $40.84
  - Pregabalin 50 mg Alzain 50mg capsules 56 capsule $57.96 DT price $60.16
  - Pregabalin 75 mg Alzain 75mg capsules 56 capsule $79.20 DT price $81.40
  - Pregabalin 100 mg Alzain 100mg capsules 84 capsule $57.96 DT price $60.16
  - Pregabalin 150 mg Alzain 150mg capsules 56 capsule $84.00 DT price $86.20
  - Pregabalin 200 mg Alzain 200mg capsules 84 capsule $57.96 DT price $60.16
  - Pregabalin 250 mg Alzain 250mg capsules 84 capsule $57.96 DT price $60.16
  - Pregabalin 300 mg Alzain 300mg capsules 56 capsule $38.64 DT price $40.84
Pregabalin 300 mg | Alzain 300 mg capsules | 56 capsule PoM £38.64 DT price = £64.40

Axalid (Kent Pharmaceuticals Ltd)

| Pregabalin 25 mg | Axalid 25 mg capsules | 56 capsule PoM | £19.95 DT price = £64.40 |
| Pregabalin 50 mg | Axalid 50 mg capsules | 56 capsule PoM | £19.95 DT price = £64.40 |
| Pregabalin 75 mg | Axalid 75 mg capsules | 56 capsule PoM | £19.95 DT price = £64.40 |

Pregabalin 100 mg | Axalid 100 mg capsules | 56 capsule PoM | £19.95 DT price = £64.40 |

Pregabalin 150 mg | Axalid 150 mg capsules | 56 capsule PoM | £19.95 DT price = £64.40 |

Pregabalin 200 mg | Axalid 200 mg capsules | 56 capsule PoM | £19.95 DT price = £64.40 |

Pregabalin 300 mg | Axalid 300 mg capsules | 56 capsule PoM | £19.95 DT price = £64.40 |

Lecaent (Actavis UK Ltd)

Pregabalin 25 mg | Lecaent 25 mg capsules | 56 capsule PoM | £64.39 DT price = £64.40 |

Pregabalin 50 mg | Lecaent 50 mg capsules | 84 capsule PoM | £96.59 DT price = £96.60 |

Pregabalin 75 mg | Lecaent 75 mg capsules | 56 capsule PoM | £64.39 DT price = £64.40 |

Pregabalin 100 mg | Lecaent 100 mg capsules | 84 capsule PoM | £96.59 DT price = £96.60 |

Pregabalin 150 mg | Lecaent 150 mg capsules | 56 capsule PoM | £64.39 DT price = £64.40 |

Pregabalin 200 mg | Lecaent 200 mg capsules | 84 capsule PoM | £96.59 DT price = £96.60 |

Pregabalin 225 mg | Lecaent 225 mg capsules | 56 capsule PoM | £64.39 DT price = £64.40 |

Pregabalin 300 mg | Lecaent 300 mg capsules | 56 capsule PoM | £64.39 DT price = £64.40 |

∥ Lyrica (Pfizer Ltd)

Pregabalin 25 mg | Lyrica 25 mg capsules | 56 capsule PoM | £64.40 DT price = £64.40 |

Pregabalin 50 mg | Lyrica 50 mg capsules | 84 capsule PoM | £96.60 DT price = £96.60 |

Pregabalin 75 mg | Lyrica 75 mg capsules | 56 capsule PoM | £64.40 DT price = £64.40 |

Pregabalin 100 mg | Lyrica 100 mg capsules | 84 capsule PoM | £96.60 DT price = £96.60 |

Pregabalin 150 mg | Lyrica 150 mg capsules | 56 capsule PoM | £64.40 DT price = £64.40 |

Pregabalin 200 mg | Lyrica 200 mg capsules | 84 capsule PoM | £96.60 DT price = £96.60 |

Pregabalin 225 mg | Lyrica 225 mg capsules | 56 capsule PoM | £64.40 DT price = £64.40 |

Pregabalin 300 mg | Lyrica 300 mg capsules | 56 capsule PoM | £64.40 DT price = £64.40 |

∥ Rewisca (Conslient Health Ltd)

Pregabalin 25 mg | Rewisca 25 mg capsules | 56 capsule PoM | £45.40 DT price = £45.40 |

Pregabalin 50 mg | Rewisca 50 mg capsules | 84 capsule PoM | £68.10 DT price = £96.60 |

Pregabalin 75 mg | Rewisca 75 mg capsules | 56 capsule PoM | £45.40 DT price = £45.40 |

Pregabalin 100 mg | Rewisca 100 mg capsules | 84 capsule PoM | £68.10 DT price = £96.60 |

Pregabalin 150 mg | Rewisca 150 mg capsules | 56 capsule PoM | £45.40 DT price = £45.40 |

Pregabalin 200 mg | Rewisca 200 mg capsules | 84 capsule PoM | £68.10 DT price = £96.60 |

Pregabalin 225 mg | Rewisca 225 mg capsules | 56 capsule PoM | £45.40 DT price = £45.40 |

Pregabalin 300 mg | Rewisca 300 mg capsules | 56 capsule PoM | £45.40 DT price = £64.40

Rufinamide

∥ INDICATIONS AND DOSE

Adjunctive treatment of seizures in Lennox-Gastaut syndrome

∥ BY MOUTH

∥ Child 4–17 years (body-weight up to 30 kg): Initially 100 mg twice daily, then increased in steps of 100 mg twice daily (max. per dose 500 mg twice daily), adjusted according to response, dose to be increased at intervals of not less than 2 days

∥ Child 4–17 years (body-weight 30–49 kg): Initially 200 mg twice daily, then increased in steps of 200 mg twice daily (max. per dose 900 mg twice daily), adjusted according to response, dose to be increased at intervals of not less than 2 days

∥ Child 4–17 years (body-weight 50–69 kg): Initially 200 mg twice daily, then increased in steps of 200 mg twice daily (max. per dose 1.2 g twice daily), adjusted according to response, dose to be increased at intervals of not less than 2 days

∥ Child 4–17 years (body-weight 70 kg and above): Initially 200 mg twice daily, then increased in steps of 200 mg twice daily (max. per dose 1.6 g twice daily), adjusted according to response, dose to be increased at intervals of not less than 2 days

∥ Adult (body-weight 30–49 kg): Initially 200 mg twice daily, then increased in steps of 200 mg twice daily (max. per dose 900 mg twice daily), adjusted according to response, dose to be increased at intervals of not less than 2 days

∥ Adult (body-weight 50–69 kg): Initially 200 mg twice daily, then increased in steps of 200 mg twice daily (max. per dose 1.2 g twice daily), adjusted according to response, dose to be increased at intervals of not less than 2 days

∥ Adult (body-weight 70 kg and above): Initially 200 mg twice daily, then increased in steps of 200 mg twice daily (max. per dose 1.6 g twice daily), adjusted according to response, dose to be increased at intervals of not less than 2 days

Adjunctive treatment of seizures in Lennox-Gastaut syndrome with valproate

∥ BY MOUTH

∥ Child 4–17 years (body-weight up to 30 kg): Initially 100 mg twice daily, then increased in steps of 100 mg twice daily (max. per dose 300 mg twice daily), adjusted according to response, dose to be increased at intervals of not less than 2 days

∥ Adult (body-weight 50–69 kg): Initially 200 mg twice daily, then increased in steps of 200 mg twice daily (max. per dose 1.2 g twice daily), adjusted according to response, dose to be increased at intervals of not less than 2 days

∥ Adult (body-weight 70 kg and above): Initially 200 mg twice daily, then increased in steps of 200 mg twice daily (max. per dose 1.6 g twice daily), adjusted according to response, dose to be increased at intervals of not less than 2 days

∥ INTERACTIONS ∆ Appendix 1: antiepileptics


∥ ALLERGY AND CROSS-SENSITIVITY Antiepileptic hypersensitivity syndrome associated with rufinamide. See under Epilepsy p. 292 for more information.

∥ PREGNANCY The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.

∥ BREAST FEEDING Manufacturer advises avoid—no information available.

∥ HEPATIC IMPAIRMENT Caution and careful dose titration in mild to moderate impairment. Avoid in severe impairment.

———
Sodium valproate

**INDICATIONS AND DOSE**

All forms of epilepsy
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
- Child 1 month–11 years: Initially 10–15 mg/kg daily in 1–2 divided doses (max. per dose 600 mg); maintenance 25–30 mg/kg daily in 2 divided doses, doses up to 60 mg/kg daily in 2 divided doses may be used in infantile spasms; monitor clinical chemistry and haematological parameters if dose exceeds 40 mg/kg daily
- Child 12–17 years: Initially 600 mg daily in 1–2 divided doses, increased in steps of 150–300 mg every 3 days; maintenance 1–2 g daily in 2 divided doses; maximum 2.5 g per day
- Adult: Initially 600 mg daily in 1–2 divided doses, then increased in steps of 150–300 mg every 3 days; maintenance 1–2 g daily, alternatively maintenance 20–30 mg/kg daily; maximum 2.5 g per day

Initiation of valproate treatment
- **INITIALLY BY INTRAVENOUS INJECTION**
- Adult: Initially 10 mg/kg, (usually 400–800 mg), followed by (by intravenous infusion or by intravenous injection) up to 2.5 g daily in 2–4 divided doses, alternatively (by continuous intravenous infusion) up to 2.5 g daily; (by intravenous injection or by

intravenous infusion or by continuous intravenous infusion) usual dose 1–2 g daily, alternatively (by intravenous injection or by intravenous infusion or by continuous intravenous infusion) usual dose 20–30 mg/kg daily, intravenous injection to be administered over 3–5 minutes

Continuation of valproate treatment
- **BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION, OR BY CONTINUOUS INTRAVENOUS INFUSION**
- Adult: If switching from oral therapy to intravenous therapy give the same dose as current oral daily dose, give over 3–5 minutes by intravenous injection or in 2–4 divided doses by intravenous infusion

Migraine prophylaxis
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
- Adult: Initially 200 mg twice daily, then increased if necessary to 1.2–1.5 g daily in divided doses

**EPILIM CHRONOSPHERE**

All forms of epilepsy
- **BY MOUTH**
- Adult: Total daily dose to be given in 1–2 divided doses (consult product literature)

**EPILIM CHRONO**

All forms of epilepsy
- **BY MOUTH**
- Adult: Total daily dose to be given in 1–2 divided doses (consult product literature)

**EPISENTA® CAPSULES**

All forms of epilepsy
- **BY MOUTH**
- Adult: Total daily dose to be given in 1–2 divided doses (consult product literature)

Mania
- **BY MOUTH**
- Adult: Initially 750 mg daily in 1–2 divided doses, adjusted according to response, usual dose 1–2 g daily in 1–2 divided doses, doses greater than 45 mg/kg daily require careful monitoring

**EPISENTA® GRANULES**

All forms of epilepsy
- **BY MOUTH**
- Adult: Total daily dose to be given in 1–2 divided doses (consult product literature)

**EPIVAL®**

All forms of epilepsy
- **BY MOUTH**
- Adult: Total daily dose to be given in 1–2 divided doses (consult product literature)

**UNLICENSED USE** Not licensed for migraine prophylaxis.

**IMPORTANT SAFETY INFORMATION**

**MHRA/CHM ADVICE: VALPROATE AND RISK OF ABNORMAL PREGNANCY OUTCOMES**

Infants exposed to valproate in utero are at a high risk of serious developmental disorders (up to 30–40% risk) and congenital malformations (approx. 11% risk). Valproate should not be used in female children, females of childbearing potential or during pregnancy unless

*312 Epilepsy and other seizure disorders*
CONTRA-INDICATIONS Acute porphyrias p. 969 - known or suspected mitochondrial disorders (higher rate of acute liver failure and liver-related deaths) - personal or family history of severe hepatic dysfunction

CAUTIONS Systemic lupus erythematosus

CAUTIONS, FURTHER INFORMATION Consider vitamin D supplementation in patients that are immobilised for long periods or who have inadequate sun exposure or dietary intake of calcium.

LIVER TOXICITY Liver dysfunction (including fatal hepatic failure) has occurred in association with valproate (especially in children under 3 years and in those with metabolic or degenerative disorders, organic brain disease or severe seizure disorders associated with mental retardation) usually in first 6 months and usually involving multiple antiepileptic therapy. Raised liver enzymes during valproate treatment are usually transient but patients should be reassessed clinically and liver function (including prothrombin time) monitored until return to normal—discontinue if abnormally prolonged prothrombin time (particularly in association with other relevant abnormalities).

SIDE-EFFECTS

Common or very common Agitation - anxiety - ataxia - tremor - weight gain

Uncommon Angioedema - ataxia - coma - encephalopathy - increased alertness - lethargy - leucopenia - pancytopenia - paraesthesia - peripheral oedema - rash - reduced bone mineral density - syndrome of inappropriate secretion of antidiuretic hormone - vasculitis


Very rare Acne - gynaecomastia - hepatic dysfunction - hirsutism - increase in bleeding time - pancreatitis

Frequency not known Hypersensitivity reactions - suicidal ideation

SIDE-EFFECTS, FURTHER INFORMATION

Hepatic dysfunction Withdraw treatment immediately if persistent vomiting and abdominal pain, anorexia, jaundice, oedema, malaise, drowsiness, or loss of seizure control.

Pancreatitis Discontinue treatment if symptoms of pancreatitis develop.

CONCEPTION AND CONTRACEPTION Valproate is associated with teratogenic risks and should not be used in females of child-bearing potential unless there is no safer alternative—this should be fully considered and discussed before prescribing for females of child-bearing age. Exclude pregnancy before treatment—effective contraception advised in females of child-bearing potential. In females planning to become pregnant, all efforts should be made to switch to appropriate alternative treatment prior to conception.

PREGNANCY Valproate is associated with the highest risk of major and minor congenital malformations (in particular neural tube defects), and long-term neurodevelopmental effects. Valproate should not be used during pregnancy unless there is no safer alternative and only after a careful discussion of the risks. If valproate is to be used during pregnancy, the lowest effective dose should be prescribed in divided doses or as modified-release tablets to avoid peaks in plasma-valproate concentrations; doses greater than 1 g daily are associated with an increased risk of teratogenicity. Neonatal bleeding (related to hypofibrininaemia) reported. Neonatal hepatotoxicity also reported.

Special prenatal monitoring should be instigated when valproate has been taken in pregnancy.

The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.

BREAST FEEDING Present in milk—risk of haematological disorders in breast-fed newborns and infants.

HEPATIC IMPAIRMENT Avoid if possible—hepatotoxicity and hepatic failure may occasionally occur (usually in first 6 months). Avoid in active liver disease.

RENAI IMPAIRMENT Reduce dose.

MONITORING REQUIREMENTS

Plasma-valproate concentrations are not a useful index of efficacy, therefore routine monitoring is unhelpful.

Monitor liver function before therapy and during first 6 months especially in patients most at risk.

Measure full blood count and ensure no undue potential for bleeding before starting and before surgery.

EFFECT ON LABORATORY TESTS False-positive urine tests for ketones.

TREATMENT CESSION Avoid abrupt withdrawal; if treatment with valproate is stopped, reduce the dose gradually over at least 4 weeks.

DIRECTIONS FOR ADMINISTRATION For intravenous infusion (Epilim ®, Episenta ®), give continuously or intermittently in Glucose 5% or Sodium Chloride 0.9%. Reconstitute Epilim ® with solvent provided then dilute with infusion fluid.

EPIVAL ® Tablets may be halved but not crushed or chewed.

EPISENTA ® CAPSULES Contents of capsule may be mixed with cold soft food or drink and swallowed immediately without chewing.

EPILIM ® SYRUP May be diluted, preferably in Syrup BP; use within 14 days.

EPISENTA ® GRANULES Granules may be mixed with cold soft food or drink and swallowed immediately without chewing.

EPILIM CHRONOSPHERE ® Granules may be mixed with soft food or drink that is cold or at room temperature, and swallowed immediately without chewing.
**314 Epilepsy and other seizure disorders**

- **PRESCRIBING AND DISPENSING INFORMATION**
  Switching between formulations Care should be taken when switching between oral formulations in the treatment of epilepsy. The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with the patient or their carer, taking into account factors such as seizure frequency and treatment history.

  Patients being treated for epilepsy may need to be maintained on a specific manufacturer’s branded or generic oral sodium valproate product.

**EPILIM CHRONOSPHERE ®** Prescribe dose to the nearest whole 50-mg sachet.

- **PATIENT AND CARER ADVICE**
  Risk of abnormal pregnancy outcomes A patient guide and card should be provided to all female patients. Blood or hepatic disorders Patients or their carers should be told how to recognise signs and symptoms of blood or liver disorders and advised to seek immediate medical attention if symptoms develop.

  Pancreatitis Patients or their carers should be told how to recognise signs and symptoms of pancreatitis and advised to seek immediate medical attention if symptoms such as abdominal pain, nausea, or vomiting develop.

  Medicines for Children leaflet: Sodium valproate for preventing seizures www.medicinesforchildren.org.uk/sodium-valproate-for-preventing-seizures

  MHRA advice: Valproate and the risk of abnormal pregnancy outcomes Female patients and their carers should be counselled on the risk of valproate treatment during pregnancy. Ensure female patients are provided with relevant resources, to support their understanding of the risks. In particular the prescriber must ensure the patient understands:

  - the risks associated with valproate during pregnancy;
  - the need to use effective contraception;
  - the need for regular review of treatment;
  - the need to rapidly consult if she is planning a pregnancy or becomes pregnant

**EPISENTE ® CAPSULES** Patients and carers should be counselled on the administration of capsules.

**EPISENTE ® GRANULES** Patients and carers should be counselled on the administration of granules.

**EPILEN CHRONOSPHERE ®** Patients and carers should be counselled on the administration of granules.

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, suppository

**Modified-release tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>8, 10, 21, 25</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epilim Chrono (Sanofi) ▼</td>
<td>Sodium valproate 200 mg Epilim Chrono 200 tablets</td>
</tr>
<tr>
<td>Sodium valproate 300 mg Epilim Chrono 300 tablets</td>
<td>100 tablet (Pom) £17.47 DT price = £17.47</td>
</tr>
<tr>
<td>Sodium valproate 500 mg Epilim Chrono 500 tablets</td>
<td>100 tablet (Pom) £29.10 DT price = £29.10</td>
</tr>
<tr>
<td>Epival CR (Channel Medical UK Ltd) ▼</td>
<td>Sodium valproate 300 mg Epival CR 300mg tablets</td>
</tr>
<tr>
<td>Sodium valproate 500 mg Epival CR 500mg tablets</td>
<td>100 tablet (Pom) £20.21 DT price = £29.10</td>
</tr>
</tbody>
</table>

**Gastro-resistant tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>5, 8, 10, 25</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium valproate 200 mg Sodium valproate 200mg gastro-resistant tablets</td>
<td>100 tablet (Pom) £7.70 DT price = £8.64</td>
</tr>
<tr>
<td>Sodium valproate 500 mg Sodium valproate 500mg gastro resistant tablets</td>
<td>100 tablet (Pom) £19.25 DT price = £8.80</td>
</tr>
</tbody>
</table>

**Epilim (Sanofi)▼**

| Sodium valproate 200 mg Epilim 200 gastro-resistant tablets | 100 tablet (Pom) £7.70 DT price = £4.64 |
| Sodium valproate 500 mg Epilim 500 gastro-resistant tablets | 100 tablet (Pom) £19.25 DT price = £8.80 |

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>8, 10, 21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epilim (Sanofi) ▼</td>
<td>Sodium valproate 100 mg Epilim 100mg crushable tablets</td>
</tr>
</tbody>
</table>

**Powder and solvent for solution for injection**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>8, 10, 21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium valproate (non-proprietary) ▼</td>
<td>Sodium valproate 400 mg Sodium valproate 400mg powder and solvent for solution for injection vials</td>
</tr>
<tr>
<td>Sodium valproate 400 mg Epilim Intravenous 400mg powder and solvent for solution for injection vials</td>
<td>1 vial (Pom) £13.32</td>
</tr>
</tbody>
</table>

**Solution for injection**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>8, 10, 21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium valproate (non-proprietary) ▼</td>
<td>Sodium valproate 100 mg per 1 ml Sodium valproate 400mg/4ml solution for injection ampoules</td>
</tr>
</tbody>
</table>

| Episenta (Desitin Pharma Ltd) ▼ | Sodium valproate 100 mg per 1 ml Episenta 300mg/3ml solution for injection ampoules | 5 ampoule (Pom) £35.00 |

**Modified-release capsule**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>8, 10, 21, 25</th>
</tr>
</thead>
<tbody>
<tr>
<td>Episenta (Desitin Pharma Ltd) ▼</td>
<td>Sodium valproate 100 mg per 1 ml Episenta 150mg modified-release capsules</td>
</tr>
<tr>
<td>Sodium valproate 300 mg Episenta 300mg modified-release capsules</td>
<td>100 capsule (Pom) £13.00 DT price = £13.00</td>
</tr>
</tbody>
</table>

**Oral solution**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>8, 10, 21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium valproate (non-proprietary) ▼</td>
<td>Sodium valproate 250 mg per 1 ml Sodium valproate 200mg/5ml oral solution sugar-free sugar-free</td>
</tr>
</tbody>
</table>

| Epilim (Sanofi) ▼ | Sodium valproate 40 mg per 1 ml Epilim 200mg/5ml liquid sugar-free | 300 ml (Pom) £7.78 DT price = £5.01 |
| Epilim 200mg/5ml syrup | 300 ml (Pom) £9.33 DT price = £9.33 |

**Modified-release granules**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>8, 10, 21, 25</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epilim Chronosphere MR (Sanofi) ▼</td>
<td>Sodium valproate 50 mg Epilim Chronosphere MR 50mg granules sachets sugar-free</td>
</tr>
<tr>
<td>Sodium valproate 100 mg Epilim Chronosphere MR 100mg granules sachets sugar-free</td>
<td>30 sachet (Pom) £30.00 DT price = £30.00</td>
</tr>
<tr>
<td>Sodium valproate 250 mg Epilim Chronosphere MR 250mg granules sachets sugar-free</td>
<td>30 sachet (Pom) £30.00 DT price = £30.00</td>
</tr>
<tr>
<td>Sodium valproate 500 mg Epilim Chronosphere MR 500mg granules sachets sugar-free</td>
<td>30 sachet (Pom) £30.00 DT price = £30.00</td>
</tr>
<tr>
<td>Sodium valproate 750 mg Epilim Chronosphere MR 750mg granules sachets sugar-free</td>
<td>30 sachet (Pom) £30.00 DT price = £30.00</td>
</tr>
<tr>
<td>Sodium valproate 1 gram Epilim Chronosphere MR 1000mg granules sachets sugar-free</td>
<td>30 sachet (Pom) £30.00 DT price = £30.00</td>
</tr>
</tbody>
</table>

| Episenta (Desitin Pharma Ltd) ▼ | Sodium valproate 500 mg Episenta 500mg modified-release granules sachets sugar-free | 100 sachet (Pom) £21.00 DT price = £21.00 |

| Sodium valproate 1 gram Episenta 1000mg modified-release granules sachets sugar-free | 100 sachet (Pom) £41.00 DT price = £41.00 |

**Tiagabine**

- **INDICATIONS AND DOSE**
  Adjunctive treatment for focal seizures with or without secondary generalisation that are not satisfactorily controlled by other antiepileptics (with enzyme-inducing drugs)

  - **BY MOUTH**
    - Child 12–17 years: Initially 5–10 mg daily in 1–2 divided doses, then increased in steps of 5–10 mg/24 hours
every week; maintenance 30–45 mg daily in 2–3 divided doses

- Adult: Initially 5–10 mg daily in 1–2 divided doses, then increased in steps of 5–10 mg/24 hours every week; maintenance 30–45 mg daily in 2–3 divided doses

**Adjunctive treatment for focal seizures with or without secondary generalisation that are not satisfactorily controlled by other antiepileptics (without enzyme-inducing drugs)**

- **BY MOUTH**
- Child 6–17 years: Initially 5–10 mg daily in 1–2 divided doses, then increased in steps of 5–10 mg/24 hours every week; maintenance 15–30 mg daily in 2–3 divided doses
- Adult: Initially 5–10 mg daily in 1–2 divided doses, then increased in steps of 5–10 mg/24 hours every week; maintenance 15–30 mg daily in 2–3 divided doses

### **CAUTIONS**
Avoid in acute porphyrias p. 969

**CAUTIONS, FURTHER INFORMATION**
Tiagabine should be avoided in absence, myoclonic, tonic and atonic seizures due to risk of seizure exacerbation.

**INTERACTIONS** ➔ Appendix 1: antiepileptics

**SIDE-EFFECTS**

- **Common or very common** Diarrhoea; dizziness; emotional lability; impaired concentration; nervousness; speech impairment; tiredness; tremor
- **Rare** Bruising; confusion; depression; drowsiness; non-convulsive status epilepticus; psychosis; suicidal ideation; visual disturbances
- **Frequency not known** Leucopenia

**PREGNANCY** The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.

**HEPATIC IMPAIRMENT** In mild to moderate impairment reduce dose, prolong the dose interval, or both. Avoid in severe impairment.

**PATIENT AND CARER ADVICE**
Driving and skilled tasks

May impair performance of skilled tasks (e.g. driving). Medicines for Children leaflet: Tiagabine for preventing seizures [www.medicinesforchildren.org.uk/tiagabine-for-preventing-seizures](http://www.medicinesforchildren.org.uk/tiagabine-for-preventing-seizures)

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Tablet**

**CAUTIONARY AND ADVISORY LABELS** 21

- Gabitril (Teva UK Ltd)
  - Tiagabine (as Tiagabine hydrochloride monohydrate) 5 mg Gabitril 5mg tablets | 100 tablet [Pos] £52.04
  - Tiagabine (as Tiagabine hydrochloride monohydrate) 10 mg Gabitril 10mg tablets | 100 tablet [Pos] £104.09
  - Tiagabine (as Tiagabine hydrochloride monohydrate) 15 mg Gabitril 15mg tablets | 100 tablet [Pos] £156.13

**Topiramate**

**INDICATIONS AND DOSE**

**Monotherapy of generalised tonic-clonic seizures or focal seizures with or without secondary generalisation**

- **BY MOUTH**
- Child 6–17 years: Initially 0.5–1 mg/kg once daily (max. per dose 25 mg) for 1 week, dose to be taken at night, then increased in steps of 250–500 micrograms/kg twice daily, dose to be increased by a maximum of 25 mg twice daily at intervals of 1–2 weeks; usual dose 50 mg twice daily (max. per dose 7.5 mg/kg twice daily), if child cannot tolerate titration regimens recommended above then smaller steps or longer interval between steps may be used; maximum 500 mg per day
- Adult: Initially 25 mg once daily for 1 week, dose to be taken at night, then increased in steps of 25–50 mg every 1–2 weeks, dose to be taken in 2 divided doses; usual dose 100–200 mg daily in 2 divided doses, adjusted according to response, doses of 1 g daily have been used in refractory epilepsy; maximum 500 mg per day

**Adjunctive treatment of generalised tonic-clonic seizures or focal seizures with or without secondary generalisation | Adjunctive treatment for seizures associated with Lennox-Gastaut syndrome**

- **BY MOUTH**
- Child 2–17 years: Initially 1–3 mg/kg once daily (max. per dose 25 mg) for 1 week, dose to be taken at night, then increased in steps of 0.5–1.5 mg/kg twice daily, dose to be increased by a maximum of 25 mg twice daily at intervals of 1–2 weeks; usual dose 2.5–4.5 mg/kg twice daily (max. per dose 7.5 mg/kg twice daily), if child cannot tolerate recommended titration regimen then smaller steps or longer interval between steps may be used; maximum 400 mg per day
- Adult: Initially 25–50 mg once daily for 1 week, dose to be taken at night, then increased in steps of 25–50 mg every 1–2 weeks, dose to be taken in 2 divided doses; usual dose 200–400 mg daily in 2 divided doses; maximum 400 mg per day

**Migraine prophylaxis**

- **BY MOUTH**
- Adult: Initially 25 mg once daily for 1 week, dose to be taken at night, then increased in steps of 25 mg every week; usual dose 50–100 mg daily in 2 divided doses; maximum 200 mg per day

**CAUTIONS** Avoid in acute porphyrias p. 969 - risk of metabolic acidosis - risk of nephrolithiasis—ensure adequate hydration (especially in strenuous activity or warm environment)

**INTERACTIONS** ➔ Appendix 1: antiepileptics

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain; aggression; agitation; alopecia; anaemia; anxiety; appetite changes; arthralgia; cognitive impairment; confusion; constipation; depression; diarrhoea; dizziness; drowsiness; dry mouth; dyspepsia; dysphonia; epistaxis; gastritis; impaired attention; impaired coordination; irritability; malaise; mood changes; movement disorders; muscle spasm; muscular weakness; myalgia; nausea; nephrolithiasis; nystagmus; paraesthesia; pruritus; rash; seizures; sleep disturbance; speech disorder; taste disturbance; tinnitus; tremor; urinary disorders; visual disturbances; vomiting
- **Uncommon** Abdominal distension; altered sense of smell; blepharospasm; blood disorders; bradycardia; dry eye; flatulence; flushing; gingival bleeding; glossodynia; haematuria; halitosis; hearing loss; hypokalaemia; hypotension; increased lacrimation; influenza-like symptoms; leucopenia; metabolic acidosis; mydriasis; neutropenia; palpitation; pancreatitis; panic attack; peripheral neuropathy; photophobia; postural hypotension; psychosis; reduced sweating; salivation; sexual dysfunction; skin discoloration; suicidal ideation; thirst; thrombocytopenia; urinary calculus
- **Rare** Abnormal skin odour; calcinosis; hepatic failure; hepatitis; periportal oedema; Raynaud’s syndrome; Stevens-Johnson syndrome; unilateral blindness
- **Very rare** Angle-closure glaucoma
Nervous system

PRESCRIBING AND DISPENSING INFORMATION

DIRECTION FOR ADMINISTRATION

TOPAMAX® CAPSULES Swallow whole or sprinkle contents of capsule on soft food and swallow immediately without chewing.

PRESCRIBING AND DISPENSING INFORMATION

Switching between formulations Care should be taken when switching between oral formulations in the treatment of epilepsy. The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with the patient or their carer, taking into account factors such as seizure frequency and treatment history.

Patients being treated for epilepsy may need to be maintained on a specific manufacturer’s branded or generic topiramate product.

PATIENT AND CARER ADVICE

Medicines for Children leaflet: Topiramate for preventing seizures www.medicinesforchildren.org.uk/topiramate-for-preventing-seizures

TOPAMAX® CAPSULES Patients or carers should be given advice on how to administer Topamax® capsules.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Tablet

CAUTIONARY AND ADVISORY LABELS 3, 8

Topiramate 25 mg Topiramate 25mg tablets | 60 tablet | £7.62
DT price = £1.66
Topiramate 50 mg Topiramate 50mg tablets | 60 tablet | £12.83
DT price = £2.14
Topiramate 100 mg Topiramate 100mg tablets | 60 tablet | £15.20
DT price = £2.52
Topiramate 200 mg Topiramate 200mg tablets | 60 tablet | £19.99
DT price = £3.33
Topamax (Janssen-Cilag Ltd)

Topiramate 25 mg Topamax 25mg tablets | 60 tablet | £19.29
DT price = £1.61
Topiramate 50 mg Topamax 50mg tablets | 60 tablet | £31.69
DT price = £1.87

Topiramate 100 mg Topamax 100mg tablets | 60 tablet | £56.76
DT price = £2.25
Topiramate 200 mg Topamax 200mg tablets | 60 tablet | £110.23
DT price = £14.00

Capsule

CAUTIONARY AND ADVISORY LABELS 3, 8

Topiramate (Non-proprietary)

Topiramate 15 mg Topiramate 15mg capsules | 60 capsule | £8.11
DT price = £0.14
Topiramate 25 mg Topiramate 25mg capsules | 60 capsule | £25.95
DT price = £0.43
Topiramate 50 mg Topiramate 50mg capsules | 60 capsule | £62.81
DT price = £1.05
Topamax (Janssen-Cilag Ltd)

Topiramate 15 mg Topamax 15mg sprinkle capsules | 60 capsule | £14.79
DT price = £0.25
Topiramate 25 mg Topamax 25mg sprinkle capsules | 60 capsule | £22.18
DT price = £0.37
Topiramate 50 mg Topamax 50mg sprinkle capsules | 60 capsule | £36.45
DT price = £0.62

Vigabatrin

INDICATIONS AND DOSE

Adjunctive treatment of focal seizures with or without secondary generalisation not satisfactorily controlled with other antiepileptics (under expert supervision)

BY MOUTH

Child 1-23 months: Initially 15–20 mg/kg twice daily (max. per dose 250 mg), to be increased over 2–3 weeks to usual maintenance dose, usual maintenance 30–40 mg/kg twice daily (max. per dose 75 mg/kg)

Child 2-11 years: Initially 15–20 mg/kg twice daily (max. per dose 250 mg), to be increased over 2–3 weeks to usual maintenance dose, usual maintenance 30–40 mg/kg twice daily (max. per dose 1.5 g)

Child 12-17 years: Initially 250 mg twice daily, to be increased over 2–3 weeks to usual maintenance dose, usual maintenance 1–1.5 g twice daily

Adult: Initially 1 g once daily, alternatively initially 1 g daily in 2 divided doses, then increased in steps of 500 mg every week, adjusted according to response; usual dose 2–3 g daily; maximum 3 g per day

BY RECTUM

Child 1-23 months: Initially 15–20 mg/kg twice daily (max. per dose 250 mg), to be increased over 2–3 weeks to usual maintenance dose, usual maintenance 30–40 mg/kg twice daily (max. per dose 75 mg/kg)

Child 2-11 years: Initially 15–20 mg/kg twice daily (max. per dose 250 mg), to be increased over 2–3 weeks to usual maintenance dose, usual maintenance 30–40 mg/kg twice daily (max. per dose 1.5 g)

Child 12-17 years: Initially 250 mg twice daily, to be increased over 2–3 weeks to usual maintenance dose, usual maintenance 1–1.5 g twice daily

UNLICENSED USE Granules not licensed for rectal use. Tablets not licensed to be crushed and dispersed in liquid. Vigabatrin doses in BNF publications may differ from those in product literature.

CONTRA-INDICATIONS Visual field defects

CAUTIONS Elderly • history of behavioural problems • history of depression • history of psychosis

CAUTIONS, FURTHER INFORMATION Vigabatrin may worsen absence, myoclonic, tonic and atonic seizures.

Visual field defects Vigabatrin is associated with visual field defects. The onset of symptoms varies from 1 month to several years after starting. In most cases, visual field defects have persisted despite discontinuation, and further deterioration after discontinuation cannot be excluded. Product literature advises visual field testing before treatment and at 6-month intervals. Patients and their
carers should be warned to report any new visual symptoms that develop and those with symptoms should be referred for an urgent ophthalmological opinion. Gradual withdrawal of vigabatrin should be considered.

**INTERACTIONS**  
Appendix 1: antiepileptics

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain, agitation, blurred vision, depression, dizziness, drowsiness, excitation (in children), headache, impaired concentration, impatience, irritability, nausea, nervousness, nystagmus, oedema, paraesthesia, paraolfactory, speech disorder, tremor, visual field defects, vomiting, weight gain
- **Uncommon** Ataxia, mania, occasional increase in seizure frequency (especially if myoclonic), psychosis, rash
- **Rare** Peripheral retinal neuropathy, retinial disorders, suicidal ideation
- **Very rare** Hepatitis, optic atrophy, optic neuritis
- **Frequency not known** Movement disorders in infantile spasms

**SIDE-EFFECTS, FURTHER INFORMATION**

- Encephalopathic symptoms. Encephalopathic symptoms including marked sedation, stupor, and confusion with non-specific slow wave EEG can occur rarely—reduce dose or withdraw.
- Visual field defects. About one-third of patients treated with vigabatrin have suffered visual field defects; counselling and careful monitoring for this side-effect are required.
- **PREGNANCY** The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.
- **BREAST FEEDING** Present in milk—manufacturer advises avoid.
- **RENAL IMPAIRMENT**
  - In adults Consider reduced dose or increased dose interval if eGFR less than 60 mL/minute/1.73 m².
  - In children Consider reduced dose or increased dose interval if estimated glomerular filtration rate less than 60 mL/minute/1.73 m².
- **MONITORING REQUIREMENTS** Closely monitor neurological function.
- **DIRECTIONS FOR ADMINISTRATION**
  - With oral use. The contents of a sachet should be dissolved in water or a soft drink immediately before taking. Tablets may be crushed and dispersed in liquid.
  - With rectal use. Dissolve contents of sachet in small amount of water and administer rectally [unlicensed use].
- **PATIENT AND CARER ADVICE**
  - Patients and their carers should be warned to report any new visual symptoms that develop.
  - Medicines for children leaflet: Vigabatrin for preventing seizures
  - www.medicinesforchildren.org.uk/vigabatrin-for-preventing-seizures

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

- **Powder**
  - **CAUTIONARY AND ADVISORY LABELS** 3, 8, 13
  - **Sabril** (Sanofi)
    - Vigabatrin 500 mg Sabril 500mg oral powder sachets sugar-free | 50 sachet [Pack] £24.60 DT price = £24.60

- **Tablet**
  - **CAUTIONARY AND ADVISORY LABELS** 3, 8
  - **Sabril** (Sanofi)
    - Vigabatrin 500 mg Sabril 500mg tablets | 100 tablet [Pack] £44.41 DT price = £44.41

**Zonisamide**

- **INDICATIONS AND DOSE**
  - Monotherapy for treatment of focal seizures with or without secondary generalisation in adults with newly diagnosed epilepsy
    - **BY MOUTH**
    - Adult: Initially 100 mg once daily for 2 weeks, then increased in steps of 100 mg every 2 weeks, usual maintenance dose 300 mg once daily; maximum 500 mg per day
  - **Adjunctive treatment for refractory focal seizures with or without secondary generalisation**
    - **BY MOUTH**
    - Child 6–17 years (body-weight 20–54 kg). Initially 1 mg/kg once daily for 7 days, then increased in steps of 1 mg/kg every 7 days, usual maintenance 6–8 mg/kg once daily (max. per dose 500 mg once daily), dose to be increased at 2-week intervals in patients who are not receiving concomitant carbamazepine, phenytoin, phenobarbital or other potent inducers of cytochrome P450 enzyme CYP3A4
    - Child 6–17 years (body-weight 55 kg and above): Initially 1 mg/kg once daily for 7 days, then increased in steps of 1 mg/kg every 7 days, usual maintenance 300–500 mg once daily, dose to be increased at 2-week intervals in patients who are not receiving concomitant carbamazepine, phenytoin, phenobarbital or other potent inducers of cytochrome P450 enzyme CYP3A4
    - Adult: Initially 50 mg daily in 2 divided doses for 7 days, then increased to 100 mg daily in 2 divided doses, then increased in steps of 100 mg every 7 days, usual maintenance 300–500 mg daily in 1–2 divided doses, dose to be increased at 2-week intervals in patients who are not receiving concomitant carbamazepine, phenytoin, phenobarbital or other potent inducers of cytochrome P450 enzyme CYP3A4

- **CAUTIONS** Elderly: low body-weight or poor appetite—monitor weight throughout treatment (fatal cases of weight loss reported in children)—metabolic acidosis—monitor serum bicarbonate concentration in children and those with other risk factors (consider dose reduction or discontinuation if metabolic acidosis develops)—risk factors for renal stone formation (particularly predisposition to nephro lithiasis)

- **CAUTIONS, FURTHER INFORMATION**
  - Avoid overheating and ensure adequate hydration especially in children, during strenuous activity or if in warm environment (fatal cases of heat stroke reported in children).
  - **INTERACTIONS**  
  - Appendix 1: antiepileptics
  - **SIDE-EFFECTS**
    - **Common or very common** Abdominal pain, agitation, alopecia, anorexia, ataxia, confusion, constipation, depression, diarrhoea, dizziness, drowsiness, ecchymosis, fatigue, impaired attention, impaired memory, insomnia, irritability, nausea, nystagmus, paraesthesia, peripheral oedema, pruritus, psychosis, pyrexia, rash (consider withdrawal)—speech disorder, tremor, weight loss
    - **Uncommon** Aggression, cholecystitis, cholelithiasis, dyspepsia, hypokalaemia, pneumonia, seizures, suicidal ideation, urinary calculi, urinary tract infection, vomiting
    - **Very rare** Amnesia, aspiration, blood disorders, coma, dysphagia, hallucinations, heat stroke, hepatitis, hydronephrosis, impaired sweating, metabolic acidosis, myasthenic syndrome, neuroleptic malignant syndrome, pancreatitis, renal failure, renal tubular acidosis.
rhabdomyolysis • Stevens-Johnson syndrome • toxic epidermal necrolysis

● **ALLERGY AND CROSS-SENSITIVITY** Contra-indicated in sulfonamide hypersensitivity.

Antiepileptic hypersensitivity syndrome theoretically associated with zonisamide. See under Epilepsy p. 292 for more information.

● **CONCEPTION AND CONTRACEPTION** Manufacturer advises women of childbearing potential should use adequate contraception during treatment and for 4 weeks after last dose.

● **PREGNANCY** The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.

● **BREAST FEEDING** Manufacturer advises avoid for 4 weeks after last dose.

● **HEPATIC IMPAIRMENT** Initially increase dose at 2-week intervals if mild or moderate impairment. Avoid in severe impairment.

● **RENAL IMPAIRMENT** Initially increase dose at 2-week intervals; discontinue if renal function deteriorates.

● **TREATMENT CESSATION** Avoid abrupt withdrawal (consult product literature for recommended withdrawal regimens in children).

● **PRESCRIBING AND DISPENSING INFORMATION** Switching between formulations Care should be taken when switching between oral formulations. The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with the patient or their carer, taking into account factors such as seizure frequency and treatment history.

Patients may need to be maintained on a specific manufacturer’s branded or generic zonisamide product.

● **PATIENT AND CARER ADVICE** Children and their carers should be made aware of how to prevent and recognise overheating and dehydration.

Medicines for Children leaflet: Zonisamide for preventing seizures www.medicinesforchildren.org.uk/zonisamide-for-preventing-seizures

● **NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (February 2014) that zonisamide (Zonegran®) is accepted for restricted use within NHS Scotland as adjunctive treatment of focal seizures, with or without secondary generalisation, in adolescents and children aged 6 years and above. It is restricted to use on advice from specialists in paediatric neurology or epilepsy.

● **MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Capsule**

**CAUTIONARY AND ADVISORY LABELS** 3, 8, 10

● Zonisamide (Non-proprietary)

Zonisamide 25 mg Zonisamide 25 mg capsules | 14 capsule POM £7.83–£8.82 DT price = £8.66

Zonisamide 50 mg Zonisamide 50 mg capsules | 56 capsule POM £41.74–£47.04 DT price = £46.16

Zonisamide 100 mg Zonisamide 100 mg capsules | 56 capsule POM £56.07–£62.72 DT price = £62.20

● Zonegran (Esial Ltd)

Zonisamide 25 mg Zonegran 25 mg capsules | 14 capsule POM £8.82 DT price = £8.66

Zonisamide 50 mg Zonegran 50 mg capsules | 56 capsule POM £47.04–£52.72 DT price = £52.20

Zonisamide 100 mg Zonegran 100 mg capsules | 56 capsule POM £52.72 DT price = £52.20

**ANTIEPILEPTICS > BARBITURATES**

**Phenobarbital**

(Phenobarbitone)

● **INDICATIONS AND DOSE**

All forms of epilepsy except typical absence seizures

▶ **BY MOUTH**

• Child 1 month–11 years: Initially 1–1.5 mg/kg twice daily, then increased in steps of 2 mg/kg/daily as required; maintenance 2.5–4 mg/kg 1–2 times a day

• Child 12–17 years: 60–180 mg once daily

• Adult: 60–180 mg once daily, dose to be taken at night

**Status epilepticus**

▶ **BY INTRAVENOUS INJECTION**

• Adult: 10 mg/kg (max. per dose 1 g), dose to be administered at a rate not more than 100 mg/minute, injection to be diluted 1 in 10 with water for injections

▶ **BY SLOW INTRAVENOUS INJECTION**

• Child 1 month–11 years: Initially 20 mg/kg, dose to be administered at a rate no faster than 1 mg/kg/minute, then 2.5–5 mg/kg 1–2 times a day

• Child 12–17 years: Initially 20 mg/kg (max. per dose 1 g), dose to be administered at a rate no faster than 1 mg/kg/minute, then 300 mg twice daily

**DOSE EQUIVALENCE AND CONVERSION**

For therapeutic purposes phenobarbital and phenobarbital sodium may be considered equivalent in effect.

● **CAUTIONS**

Avoid in acute porphyrias p. 969 • children • debilitated • elderly • history of alcohol abuse • history of drug abuse • respiratory depression (avoid if severe)

**CAUTIONS, FURTHER INFORMATION**

Consider vitamin D supplementation in patients who are immobilised for long periods or who have inadequate sun exposure or dietary intake of calcium.

● **INTERACTIONS** → Appendix 1: antiepileptics

● **SIDE-EFFECTS**

▶ **Common or very common**

Agranulocytosis • allergic skin reactions • ataxia • behavioural disturbances • cholestasis • depression • drowsiness • hallucinations • hepatitis • hyperactivity particularly in the elderly and in children • hypotension • impaired cognition • impaired memory • irritability • lethargy • megaloblastic anaemia (may be treated with folic acid) • nystagmus • osteomalacia • paradoxical excitement (in adults) • respiratory depression • thrombocytopenia

▶ **Very rare**

Antiepileptic Hypersensitivity Syndrome • Stevens-Johnson syndrome • suicidal ideation • toxic epidermal necrolysis

▶ **Frequency not known**

Hyperkinesia (in children)

**Overdose**

For details on the management of poisoning, see Active elimination techniques, under Emergency treatment of poisoning p. 1249.

● **ALLERGY AND CROSS-SENSITIVITY** Antiepileptic hypersensitivity syndrome associated with phenobarbital. See under Epilepsy p. 292 for more information.

● **PREGNANCY** The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.

● **BREAST FEEDING** Avoid if possible; drowsiness may occur.

● **HEPATIC IMPAIRMENT** May precipitate coma. Avoid in severe impairment.

● **RENAL IMPAIRMENT** Use with caution.

● **MONITORING REQUIREMENTS**

Plasma-phenobarbital concentration for optimum response is 15–40 mg/litre (60–180 micromol/litre);
however, monitoring the plasma-drug concentration is less useful than with other drugs because tolerance occurs. **TREATMENT CESSATION** Avoid abrupt withdrawal (dependence with prolonged use).

**DIRECTIONS FOR ADMINISTRATION**

- **With intravenous use in children**
- **With intravenous use in adults**

**PRESCRIBING AND DISPENSING INFORMATION** Some hospitals supply alcohol-free formulations of varying phenobarbital strengths.

Switching between formulations Different formulations of oral preparations may vary in bioavailability. Patients should be maintained on a specific manufacturer’s product.

**PATIENT AND CARER ADVICE**

Medicines for Children leaflet: Phenobarbital for preventing seizures www.medicinesforchildren.org.uk/phenobarbital-for-preventing-seizures

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, capsule, oral suspension, oral solution

- **Tablet**
  - **Phenobarbital (Non-proprietary)**
    - Phenobarbital 15 mg Phenobarbital 15mg tablets | 28 tablet | £2.95 DT price = £17.29 CD3
    - Phenobarbital 30 mg Phenobarbital 30mg tablets | 28 tablet | £5.99 DT price = £10.78 CD3
    - Phenobarbital 60 mg Phenobarbital 60mg tablets | 28 tablet | £7.99 DT price = £6.03 CD3

- **Solution for injection**
  - **Phenobarbital sodium 30 mg per 1 ml** Phenobarbital 30mg/1ml solution for injection ampoules | 10 ampoule | £80.71–£81.42 CD3
  - **Phenobarbital sodium 60 mg per 1 ml** Phenobarbital 60mg/1ml solution for injection ampoules | 10 ampoule | £85.82 CD3
  - **Phenobarbital sodium 200 mg per 1 ml** Phenobarbital 200mg/1ml solution for injection ampoules | 10 ampoule | £66.63–£69.96 CD3

- **Oral solution**
  - **Phenobarbital (Non-proprietary)**
    - Phenobarbital 3 mg per 1 ml Phenobarbital 15mg/5ml elixir | 500 ml | £83.00 DT price = £83.00 CD3

---

**INDICATIONS AND DOSE**

**All forms of epilepsy except typical absence seizures**

- **BY MOUTH**
  - Child 1 month–1 year: Initially 125 mg daily, dose to be taken at bedtime, then increased in steps of 125 mg every 3 days, adjusted according to response; maintenance 125–250 mg twice daily
  - Child 2–4 years: Initially 125 mg once daily, dose to be taken at bedtime, then increased in steps of 125 mg every 3 days, adjusted according to response; maintenance 250–375 mg twice daily
  - Child 5–8 years: Initially 125 mg once daily, dose to be taken at bedtime, then increased in steps of 125 mg every 3 days, adjusted according to response; maintenance 375–500 mg twice daily
  - Child 9–17 years: Initially 125 mg once daily, dose to be taken at bedtime, then increased in steps of 125 mg every 3 days, increased to 250 mg twice daily, then increased in steps of 250 mg every 3 days (max. per dose 750 mg twice daily), adjusted according to response
  - Adult: Initially 125 mg once daily, dose to be taken at bedtime, then increased in steps of 125 mg every 3 days, increased to 500 mg daily in 2 divided doses, then increased in steps of 250 mg every 3 days, adjusted according to response; maintenance 0.75–1.5 g daily in 2 divided doses

**Essential tremor**

- **BY MOUTH**
  - Adult: Initially 50 mg daily, then adjusted according to response to up to 750 mg daily, dose to be increased over 2–3 weeks

**CAUTIONS** Avoid in acute porphyria · children · debilitated · elderly · history of alcohol abuse · history of drug abuse · respiratory depression (avoid if severe)

**CAUTIONS, FURTHER INFORMATION**

Consider vitamin D supplementation in patients who are immunomodulated for long periods or who have inadequate sun exposure or dietary intake of calcium.

**INTERACTIONS** → Appendix 1: antiepileptics

**SIDE-EFFECTS**

- **Common or very common**
  - Agranulocytosis · allergic skin reactions · ataxia · behavioural disturbances · cholostasis · depression · drowsiness · hallucinations · hepatitis · hyperactivity (in children) · hyperactivity particularly in the elderly · hypotension · impaired cognition · impaired memory · irritability · lethargy · megaloblastic anaemia (may be treated with folic acid) · nausea · nystagnmus · osteomalacia · paradoxical excitement (in adults) · respiratory depression · thrombocytopenia · visual disturbances
  - **Uncommon**
    - Dizziness · headache · vomiting
  - **Rare**
    - Arthralgia · lupus erythematosus · psychosis
  - **Very rare**
    - Antiepileptic Hypersensitivity Syndrome · Stevens-Johnson syndrome · suicidal ideation · toxic epidermal necrolysis

**FREQUENCY NOT KNOWN**

- **Dupuytren’s contracture**

**ALLERGY AND CROSS-SENSITIVITY**

Antiepileptic hypersensitivity syndrome associated with primidone. See under Epilepsy p. 292 for more information.

**PREGNANCY**

The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.

**HEPATIC IMPAIRMENT** Reduce dose. May precipitate coma.

**RENAL IMPAIRMENT**

Use with caution.

**MONITORING REQUIREMENTS**

Monitor plasma concentrations of derived phenobarbital; plasma concentration for optimum response is 15–40 mg/litre (60–180 micromol/litre).

**TREATMENT CESSATION**

Avoid abrupt withdrawal (dependence with prolonged use).

**PRESCRIBING AND DISPENSING INFORMATION**

Switching between formulations Different formulations of oral preparations may vary in bioavailability. Patients being treated for epilepsy should be maintained on a specific manufacturer’s product.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule, oral suspension

- **Oral suspension**
  - **Primidone (Non-proprietary)**
    - Primidone 25 mg per 1 ml Liskantin Saft 125mg/5ml oral suspension | 250 ml | No price available

---
**Nervous System**

### Table

**Tablet**

<table>
<thead>
<tr>
<th>Common or very common</th>
</tr>
</thead>
<tbody>
<tr>
<td>▶ <strong>Anxiolytics</strong></td>
</tr>
<tr>
<td>▶ <strong>Hypnotics, Sedatives and Anxiolytics</strong></td>
</tr>
<tr>
<td>▶ Benzodiazepines</td>
</tr>
</tbody>
</table>

**Clobazam**

- **INDICATIONS AND DOSE**
  - **Adjunct in epilepsy**
    - **By mouth**
    - Child 6–17 years: Initially 5 mg daily, dose to be increased if necessary at intervals of 5 days, maintenance 0.3–1 mg/kg daily, daily doses of up to 30 mg may be given as a single dose at bedtime, higher doses should be divided; maximum 60 mg per day.
    - Adult: 20–30 mg daily, then increased if necessary up to 60 mg daily.
  - **Anxiety (short-term use)**
    - **By mouth**
    - Adult: 20–30 mg daily in divided doses, alternatively 20–30 mg once daily, dose to be taken at bedtime; increased if necessary up to 60 mg daily in divided doses, dose only increased in severe anxiety (in hospital patients), for debilitated patients, use elderly dose.
    - Elderly: 10–20 mg daily.

- **UNLICENSED USE** Not licensed for use in children under 6 years. Not licensed as monotherapy.

**IMPORTANT SAFETY INFORMATION**

Do not confuse with clonazepam.

- **CONTRA-INDICATIONS** Chronic psychosis (in adults) · hyperkinnesia · not for use alone to treat anxiety associated with depression (in adults) · obsessional states · phobic states · respiratory depression.

- **CAUTIONS** Muscle weakness · organic brain changes · personality disorder (within the fearful group—dependent, avoidant, obsessive-compulsive) may increase risk of dependence.

- **CAUTIONS, FURTHER INFORMATION**

The effectiveness of clobazam may decrease significantly after weeks or months of continuous therapy.

- **INTERACTIONS** → Appendix 1: clobazam.

- **SIDE-EFFECTS**
  - **Common or very common** Amnesia · ataxia (especially in the elderly) · confusion (especially in the elderly) · dependence · drowsiness the next day · lightheadedness · next day · muscle weakness · paradoxical increase in aggression.
  - **Uncommon** Changes in libido (in adults) · dizziness · dysarthria · gastro-intestinal disturbances · gynaecomastia · headache (in adults) · hypotension (in adults) · incontinence · salivation changes · slurred speech (in adults) · tremor · urinary retention (in adults) · vertigo (in adults) · visual disturbances.
  - **Rare** Apnoea · blood disorders · changes in libido (in children) · headache (in children) · hypotension (in children) · jaundice · respiratory depression · skin reactions · urinary retention (in children) · vertigo (in children).
  - **Frequency not known** Delusions (in children) · excitement (in children) · hallucinations (in children) · irritability (in children) · psychosis (in children) · restlessness (in children).

- **BREAST FEEDING** Benzodiazepines are present in milk, and should be avoided if possible during breast-feeding.
  All infants should be monitored for sedation, feeding difficulties, adequate weight gain, and developmental milestones.

- **HEPATIC IMPAIRMENT** Start with smaller initial doses or reduce dose. Can precipitate coma. Avoid in severe impairment.

- **RENAI IMPAIRMENT** Start with small doses in severe impairment.

- **MONITORING REQUIREMENTS**
  - **In children** Routine measurement of plasma concentrations of antiepileptic drugs is not usually justified, because the target concentration ranges are arbitrary and often vary between individuals. However, plasma drug concentrations may be measured in children with worsening seizures, status epilepticus, suspected noncompliance, or suspected toxicity. Similarly, haematological and biochemical monitoring should not be undertaken unless clinically indicated.

- **PRESCRIBING AND DISPENSING INFORMATION**

Switching between formulations Care should be taken when switching between oral formulations in the treatment of epilepsy. The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with the patient or their carer, taking into account factors such as seizure frequency and treatment history.

Patients being treated for epilepsy may need to be maintained on a specific manufacturer’s branded or generic clobazam product.

- **PATIENT AND CARER ADVICE**
  - Medicines for Children leaflet: Clobazam for preventing seizures www.medicinesforchildren.org.uk/clobazam-preventing-seizures-0

- **NATIONAL FUNDING/ACCESS DECISIONS**

NHS restrictions Clobazam is not prescribable under the NHS except for epilepsy and endorsed ‘SLS’.

- **MEDIINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule, oral suspension.

**Oral suspension**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS 2, 19, 8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clobazam (Non-proprietary)</td>
</tr>
<tr>
<td>Clobazam 1 mg per 1 ml Clobazam 5mg/5ml oral suspension sugar free sugar-free</td>
</tr>
<tr>
<td>Clobazam 2 mg per 1 ml Clobazam 10mg/5ml oral suspension sugar free sugar-free</td>
</tr>
<tr>
<td>Perizam (Rosemont Pharmaceuticals Ltd)</td>
</tr>
<tr>
<td>Clobazam 1 mg per 1 ml Perizam 1mg/ml oral suspension sugar-free</td>
</tr>
<tr>
<td>Clobazam 2 mg per 1 ml Perizam 2mg/ml oral suspension sugar-free</td>
</tr>
<tr>
<td>Tapclob (Martindale Pharmaceuticals Ltd)</td>
</tr>
<tr>
<td>Clobazam 1 mg per 1 ml Tapclob 5mg/5ml oral suspension sugar-free</td>
</tr>
<tr>
<td>Clobazam 2 mg per 1 ml Tapclob 10mg/5ml oral suspension sugar-free</td>
</tr>
</tbody>
</table>

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS 2, 19, 8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clobazam (Non-proprietary)</td>
</tr>
<tr>
<td>Clobazam 10 mg Clobazam 10mg tablets</td>
</tr>
<tr>
<td>Frisium (Sanofi)</td>
</tr>
<tr>
<td>Clobazam 10 mg Frisium 10mg tablets</td>
</tr>
</tbody>
</table>
Clonazepam

**INDICATIONS AND DOSE**

**All forms of epilepsy**

- **BY MOUTH**
  - Child 1–11 months: Initially 250 micrograms once daily for 4 nights, dose to be increased over 2–4 weeks, usual dose 0.5–1 mg daily, dose to be taken at night; may be given in 3 divided doses if necessary
  - Child 1–4 years: Initially 250 micrograms once daily for 4 nights, dose to be increased over 2–4 weeks, usual dose 1–2 mg daily, dose to be taken at night; may be given in 3 divided doses if necessary
  - Child 5–11 years: Initially 500 micrograms once daily for 4 nights, dose to be increased over 2–4 weeks, usual dose 3–6 mg daily, dose to be taken at night; may be given in 3 divided doses if necessary
  - Child 12–17 years: Initially 1 mg once daily for 4 nights, dose to be increased over 2–4 weeks, usual dose 4–8 mg daily, dose usually taken at night; may be given in 3–4 divided doses if necessary

**Panic disorders (with or without agoraphobia) resistant to antidepressant therapy**

- **BY MOUTH**
  - Adult: 1–2 mg daily

**ALL FORMS OF EPILEPSY | MYOCLONUS**

- Adult: Initially 1 mg once daily for 4 nights, dose to be increased over 2–4 weeks, usual dose 4–8 mg daily, adjusted according to response, dose usually taken at night; may be given in 3–4 divided doses if necessary

**Elderly**

- Initially 500 micrograms once daily for 4 nights, dose to be increased over 2–4 weeks, usual dose 4–8 mg daily, adjusted according to response, dose usually taken at night; may be given in 3–4 divided doses if necessary

**UNLICENSED USE**

Clonazepam doses in BNF may differ from those in product literature. Use for panic disorders (with or without agoraphobia) resistant to antidepressant therapy is an unlicensed indication.

**IMPORTANT SAFETY INFORMATION**

Do **not** confuse with clonazepam.

**CONTRA-INDICATIONS**

- Coma • current alcohol abuse • current drug abuse • respiratory depression

**CAUTIONS**

- Acute porphyrias p. 969 • airways obstruction • brain damage • cerebellar ataxia • depression • spinal ataxia • suicidal ideation

**CAUTIONS, FURTHER INFORMATION**

The effectiveness of clonazepam may decrease significantly after weeks or months of continuous therapy.

**INTERACTIONS**

- Appendix 1: clonazepam

**SIDE-EFFECTS**

- **Common or very common**
  - Amnesia • bronchial hypersecretion in infants and small children • coordination disturbances • confusion • dependence • dizziness • drowsiness • fatigue • muscle hypotonia • nystagmus • poor concentration • restlessness • salivary hypersecretion in infants and small children • withdrawal symptoms (in children)
  - **Rare**
  - Aggression • anxiety • blood disorders • dysarthria • gastro-intestinal symptoms • headache • paradoxical effects • pruritus • respiratory depression • reversible hair loss • sexual dysfunction • skin pigmentation changes • suicidal ideation (in adults) • urinary incontinence • urticaria • visual disturbances on long-term treatment
  - **Very rare**
  - Increase in seizure frequency

**BREAST FEEDING**

Present in milk, and should be avoided if possible during breast-feeding.

All infants should be monitored for sedation, feeding difficulties, adequate weight gain, and developmental milestones.

**HEPATIC IMPAIRMENT**

Start with smaller initial doses or reduce dose. Can precipitate coma. Avoid in severe impairment.

**RENAL IMPAIRMENT**

Start with small doses in severe impairment.

**MONITORING REQUIREMENTS**

- In children Routine measurement of plasma concentrations of antiepileptic drugs is not usually justified, because the target concentration ranges are arbitrary and often vary between individuals. However, plasma drug concentrations may be measured in children with worsening seizures, status epilepticus, suspected noncompliance, or suspected toxicity. Similarly, haematological and biochemical monitoring should not be undertaken unless clinically indicated.

**PRESCRIBING AND DISPENSING INFORMATION**

Switching between formulations Care should be taken when switching between oral formulations in the treatment of epilepsy. The need for continued supply of a particular manufacturer’s product should be based on clinical judgement and consultation with the patient or their carer, taking into account factors such as seizure frequency and treatment history.

Patients being treated for epilepsy may need to be maintained on a specific manufacturer’s branded or generic oral clonazepam product.

**PATIENT AND CARER ADVICE**

Medicines for Children leaflet: Clonazepam for preventing seizures www.medicinesforchildren.org.uk/clonazepam-preventing-seizures-0

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: orodispersible tablet, oral suspension, oral solution, oral drops

**Tablet**

**CAUTIONARY AND ADVISORY LABELS** 2, 8

- Clonazepam (Non-proprietary)
  - Clonazepam 500 microgram Clonazepam 500 microgram tablets 100 tablet **P** £30.11 DT price = £28.39
  - Clonazepam 2 mg Clonazepam 2 mg tablets 100 tablet **P** £33.41 DT price = £31.11

**Oral drops**

- Clonazepam (Non-proprietary)
  - Clonazepam 2.5 mg/1 ml Rivotril 2.5 mg/1 ml drops sugar-free 10 ml **P** no price available

**Oral solution**

**CAUTIONARY AND ADVISORY LABELS** 2, 8

EXCIPIENTS: May contain Ethanol

- Clonazepam (Non-proprietary)
  - Clonazepam 100 microgram per 1 ml Clonazepam 500 micrograms/5 ml oral solution sugar-free sugar-free 150 ml **P** £83.40 DT price = £69.50
  - Clonazepam 400 microgram per 1 ml Clonazepam 2 mg/5 ml oral solution sugar-free sugar-free 150 ml **P** £108.36 DT price = £108.36

**Oral lyophilisate**

- Clonazepam (Non-proprietary)
  - Clonazepam 500 microgram Klonopin 0.5 mg oral lyophilisates sugar-free 60 tablet **P** no price available

### 2.1 Status epilepticus

**Other drugs used for Status epilepticus**

Diazepam, p. 327 • Fosphenytoin sodium, p. 300 • Phenobarbital, p. 318 • Phenytoin, p. 308
ANTIEPILEPTICS \textgreater{} BARBITURATES

Thiopental sodium

(Thiopentone sodium)

\textbf{INDICATIONS AND DOSE}

\textbf{Status epilepticus (only if other measures fail)}

\textgreater{} BY SLOW INTRAVENOUS INJECTION

Adult: 75–125 mg for 1 dose, to be administered as a 2.5% (25 mg/mL) solution

\textbf{Induction of anaesthesia}

\textgreater{} BY SLOW INTRAVENOUS INJECTION

Adult: Initially 100–150 mg, to be administered over 10–15 seconds usually as a 2.5% (25 mg/mL) solution, followed by 300–450 mg after 5–10 minutes if required, dose to be given in fit and premedicated adults; debilitated patients or adults over 65 years may require a lower dose or increased administration time, alternatively initially up to 4 mg/kg (max. per dose 500 mg)

\textbf{Anaesthesia of short duration}

\textgreater{} BY SLOW INTRAVENOUS INJECTION

Adult: Initially 100–150 mg, to be administered over 10–15 seconds usually as a 2.5% (25 mg/mL) solution, followed by 300–450 mg after 5–10 minutes if required, dose to be given in fit and premedicated adults; debilitated patients or adults over 65 years may require a lower dose or increased administration time, alternatively initially up to 4 mg/kg (max. per dose 500 mg)

\textbf{Reduction of raised intracranial pressure if ventilation controlled}

\textgreater{} BY SLOW INTRAVENOUS INJECTION

Adult: 1.5–3 mg/kg, repeated if necessary

\textbf{IMPORTANT SAFETY INFORMATION}

Thiopental sodium should only be administered by, or under the direct supervision of, personnel experienced in its use, with adequate training in anaesthesia and airway management, and when resuscitation equipment is available.

\textbf{CONTRA-INDICATIONS}

Acute porphyrias p. 969 · myotonic dystrophy

\textbf{CAUTIONS}

Acute circulatory failure (shock) · avoid intravascular injection · cardiovascular disease · elderly · fixed cardiac output · hypovolaemia · reconstituted solution is highly alkaline (extravasation causes tissue necrosis and severe pain)

\textbf{INTERACTIONS} \rightarrow Appendix 1: thiopental

\textbf{SIDE-EFFECTS}

Arrhythmias · cough · headache · hypersensitivity reactions · hypotension · laryngeal spasm · myocardial depression · rash · sneezing

\textbf{PREGNANCY}

May depress neonatal respiration when used during delivery.

\textbf{BREAST FEEDING}

Breast-feeding can be resumed as soon as mother has recovered sufficiently from anaesthesia.

\textbf{HEPATIC IMPAIRMENT}

Use with caution—reduce dose.

\textbf{RENAL IMPAIRMENT}

Caution in severe impairment.

\textbf{PATIENT AND CARER ADVICE}

Driving and skilled tasks

Patients given sedatives and analgesics during minor outpatient procedures should be very carefully warned about the risk of driving or undertaking skilled tasks afterwards. For a short general anaesthetic the risk extends to at least 24 hours after administration. Responsible persons should be available to take patients home. The dangers of taking alcohol should also be emphasised.

\textbf{MEDICINAL FORMS}

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection

\textbf{Powder for solution for injection}

Thiopental sodium (Non-proprietary)

Thiopental sodium 500 mg

Thiopental 500mg powder for solution for injection vials | 25 vial \(\£172.50\)

HYPNOTICS, SEDATIVES AND ANXIOLYTICS \textgreater{} BENZODIAZEPINES

Lorazepam

\textbf{INDICATIONS AND DOSE}

\textbf{Short-term use in anxiety}

\textgreater{} BY MOUTH

Adult: 1–4 mg daily in divided doses, for debilitated patients, use elderly dose

Elderly: 0.5–2 mg daily in divided doses

\textbf{Short-term use in insomnia associated with anxiety}

\textgreater{} BY MOUTH

Adult: 1–2 mg daily, to be taken at bedtime

\textbf{Acute panic attacks}

\textgreater{} BY INTRAMUSCULAR INJECTION, OR BY SLOW INTRAVENOUS INJECTION

Adult: 25–30 micrograms/kg every 6 hours if required; usual dose 1.5–2.5 mg every 6 hours if required, intravenous injection to be administered into a large vein, only use intramuscular route when oral and intravenous routes not possible

\textbf{Conscious sedation for procedures}

\textgreater{} BY MOUTH

Adult: 2–3 mg, to be taken the night before operation; 2–4 mg, to be taken 1–2 hours before operation

\textgreater{} BY SLOW INTRAVENOUS INJECTION

Adult: 50 micrograms/kg, to be administered 30–45 minutes before operation

\textgreater{} BY INTRAMUSCULAR INJECTION

Adult: 50 micrograms/kg, to be administered 60–90 minutes before operation

\textbf{Pre-medication}

\textgreater{} BY MOUTH

Adult: 2–3 mg, to be taken the night before operation; 2–4 mg, to be taken 1–2 hours before operation

\textgreater{} BY SLOW INTRAVENOUS INJECTION

Adult: 50 micrograms/kg, to be administered 30–45 minutes before operation

\textgreater{} BY INTRAMUSCULAR INJECTION

Adult: 50 micrograms/kg, to be administered 60–90 minutes before operation

\textbf{Status epilepticus} \mid \textbf{Febrile convulsions} \mid \textbf{Convulsions caused by poisoning}

\textgreater{} BY SLOW INTRAVENOUS INJECTION

Child 1 month–11 years: 100 micrograms/kg (max. per dose 4 mg) for 1 dose, then 100 micrograms/kg after 10 minutes (max. per dose 4 mg) if required for 1 dose, to be administered into a large vein

Child 12–17 years: 4 mg for 1 dose, then 4 mg after 10 minutes if required for 1 dose, to be administered into a large vein

Adult: 4 mg for 1 dose, then 4 mg after 10 minutes if required for 1 dose, to be administered into a large vein
UNLICENSED USE

IMPORTANT SAFETY INFORMATION
ANAESTHESIA
Benzodiazepines should only be administered for anaesthesia by, or under the direct supervision of, personnel experienced in their use, with adequate training in anaesthesia and airway management.

CONTRA-INDICATIONS
Avoid injections containing benzyl alcohol in neonates • chronic psychosis (in adults) • CNS depression • compromised airway • hyperkinesis • not for use alone to treat depression (or anxiety associated with depression) (in adults) • obsessional states • phobic states • respiratory depression

CAUTIONS
Personality disorder (within the fearful group) • dependent, avoidant, obsessive-compulsive) may increase risk of dependence • muscle weakness • organic brain changes • parenteral administration

CAUTIONS, FURTHER INFORMATION
- Paradoxical effects A paradoxical increase in hostility and aggression may be reported by patients taking benzodiazepines. The effects range from talkativeness and excitement to aggressive and antisocial acts. Adjustment of the dose (up or down) sometimes attenuates the impulses. Increased anxiety and perceptual disorders are other paradoxical effects.
- Special precautions for parenteral administration
  When given parenterally, facilities for managing respiratory depression with mechanical ventilation must be available. Close observation required until full recovery from sedation.

INTERACTIONS
- Appendix 1: lorazepam

SIDE-EFFECTS
- Common or very common Amnesia • ataxia (in children) • ataxia (especially in the elderly) • confusion (in children) • confusion (especially in the elderly) • dependence • drowsiness the next day • lightheadedness the next day • muscle weakness • paradoxical increase in aggression
- Uncommon Changes in libido (in adults) • dizziness • dysarthria • gastro-intestinal disturbances • gynaecomastia • headache (in adults) • hypotension (in adults) • incontinence • salivation changes • slurred speech (in adults) • tremor • urinary retention (in adults) • vertigo (in adults) • visual disturbances
- Rare Apnoea • blood disorders • changes in libido (in children) • headache (in children) • hypotension (in children) • jaundice • respiratory depression • skin reactions • urinary retention (in adults) • vertigo (in children)
- Frequency not known Delusions (in children) • excitement (in children) • hallucinations (in children) • irritability (in children) • marked respiratory depression, particularly with high dose and intravenous use (facilities for its treatment are essential) • pain (on intravenous injection) • psychosis (in children) • restlessness (in children) • thrombophlebitis (on intravenous injection)

BREAST FEEDING
Benzodiazepines are present in milk, and should be avoided if possible during breast-feeding.

HEPATIC IMPAIRMENT
Start with smaller initial doses or reduce dose. Can precipitate coma. Avoid in severe impairment.
- In adults If treatment is necessary, benzodiazepines with shorter half-lives are safer.

RENAL IMPAIRMENT
Start with small doses in severe impairment.

DIRECTIONS FOR ADMINISTRATION
- With intravenous use in children For intravenous injection, dilute with an equal volume of Sodium Chloride 0.9% (for neonates, dilute injection solution to a concentration of 100 micrograms/mL). Give over 3–5 minutes; max. rate 50 micrograms/kg over 3 minutes.
- With intramuscular use in adults For intramuscular injection, solution for injection should be diluted with an equal volume of water for injections or sodium chloride 0.9% (but only use when oral and intravenous routes not possible).
- With intravenous use in adults For slow intravenous injection, solution for injection should preferably be diluted with an equal volume of water for injections or sodium chloride 0.9%.

PATIENT AND CARER ADVICE
Driving and skilled tasks
May impair judgement and increase reaction time, and so affect ability to drive or operate machinery; they increase the effects of alcohol. Moreover the hangover effects of a night dose may impair driving on the following day.

PACIENTS given sedatives and analgesics during minor outpatient procedures should be very carefully warned about the risks of undertaking skilled tasks (e.g. driving) afterwards. For intravenous benzodiazepines the risk extends to at least 24 hours after administration.

RESPONSIBLE persons should be available to take patients home afterwards. The dangers of taking alcohol should be emphasised.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, solution for injection

Solution for injection
- EXCIPIENTS: May contain Benzyl alcohol, propylene glycol
  - Ativan (Pfizer Ltd)
    Lorazepam 4 mg per 1 ml Ativan 4mg/1ml solution for injectionampoules | 10 ampoule [Pom] £3.54 [CD4-1]

Tablet
- CAUTIONARY AND ADVISORY LABELS 2, 19
  - Lorazepam (Non-properitary)
    Lorazepam 1 mg Lorazepam 1mg tablets | 28 tablet [Ptm] £6.90 DT price = £4.41 [CD4-1] | 30 tablet [Pom] no price available [CD4-1]
    Lorazepam 2.5 mg Lorazepam 2.5mg tablets | 28 tablet [Ptm] £12.20 DT price = £12.20 [CD4-1] | 30 tablet [Pom] no price available [CD4-1]

Midazolam

INDICATIONS AND DOSE
Status epilepticus | Febrile convulsions
- BY BUCCAL ADMINISTRATION
  - Child 1–2 months: 300 micrograms/kg (max. per dose 2.5 mg), then 300 micrograms/kg after 10 minutes (max. per dose 2.5 mg) if required
  - Child 3–11 months: 2.5 mg, then 2.5 mg after 10 minutes if required
  - Child 1–4 years: 5 mg, then 5 mg after 10 minutes if required
  - Child 5–9 years: 7.5 mg, then 7.5 mg after 10 minutes if required
  - Child 10–17 years: 10 mg, then 10 mg after 10 minutes if required
  - Adult: 10 mg, then 10 mg after 10 minutes if required

Conscious sedation for procedures
- BY SLOW INTRAVENOUS INJECTION
  - Adult: Initially 2.5 mg, to be administered 5–10 minutes before procedure at a rate of approximately 2 mg/minute, increased in steps of 1 mg if required, usual total dose is 3.5–5 mg; maximum 7.5 mg per course
  - Elderly: Initially 0.5–1 mg, to be administered 5–10 minutes before procedure at a rate of continued
Sedation of patient receiving intensive care

- **INITIALLY BY INTRAVENOUS INJECTION**
  - Adult: 30–100 micrograms/kg, repeated if necessary, alternatively (by continuous intravenous infusion) 30–100 micrograms/kg/hour
  - Elderly: Lower doses needed

**Premedication**

- **BY DEEP INTRAMUSCULAR INJECTION**
  - Adult: 70–100 micrograms/kg, to be administered 20–60 minutes before induction, for debilitated patients, use elderly dose
  - Elderly: 25–50 micrograms/kg, to be administered 20–60 minutes before induction

- **BY INTRAVENOUS INJECTION**
  - Adult: 1–2 mg, repeated if necessary, to be administered 5–30 minutes before procedure, for debilitated patients, use elderly dose
  - Elderly: 0.5 mg, repeated if necessary, initial dose to be administered 5–30 minutes before procedure, repeat dose slowly as required

**Induction of anaesthesia (but rarely used)**

- **BY SLOW INTRAVENOUS INJECTION**
  - Adult: 150–200 micrograms/kg daily in divided doses (max. per dose 5 mg), dose to be given at intervals of 2 minutes, maximum total dose 600 micrograms/kg, for debilitated patients, use elderly dose
  - Elderly: 50–150 micrograms/kg daily in divided doses (max. per dose 5 mg), dose to be given at intervals of 2 minutes, maximum total dose 600 micrograms/kg

**Sedation of patient receiving intensive care**

- **INITIALLY BY SLOW INTRAVENOUS INJECTION**
  - Adult: Initially 30–300 micrograms/kg, dose to be given in steps of 1–2.5 mg every 2 minutes, then (by slow intravenous injection or by continuous intravenous infusion) 30–200 micrograms/kg/hour, reduce dose (or reduce or omit initial dose) in hypovolaemia, vasoconstriction, or hypothermia, lower doses may be adequate if opioid analgesic also used

**Confusion and restlessness in palliative care (adjunct to antipsychotic)**

- **BY SUBCUTANEOUS INFUSION**
  - Adult: Initially 10–20 mg/24 hours, adjusted according to response; usual dose 20–60 mg/24 hours

**Convulsions in palliative care**

- **BY CONTINUOUS SUBCUTANEOUS INFUSION**
  - Adult: Initially 20–40 mg/24 hours

**SIDE-EFFECTS, FURTHER INFORMATION**

- Sedation Midazolam is associated with profound sedation when high doses are given or when it is used with certain other drugs.

**Overdose**

There have been reports of overdose when high strength midazolam has been used for conscious sedation. The use of high-strength midazolam (5 mg/mL in 2 mL and 10 mL ampoules, or 2 mg/mL in 5 mL ampoules) should be restricted to general anaesthesia, intensive care, palliative care, or other situations where the risk has been assessed. It is advised that flumazenil is available when midazolam is used, to reverse the effects if necessary.

**CONTRA-INDICATIONS** CNS depression • compromised airway • severe respiratory depression

**CAUTIONS** Cardiac disease • children (particularly if cardiovascular impairment) • concentration of midazolam in children under 15 kg not to exceed 1 mg/mL • debilitated patients (reduce dose)(in children) • hypothermia • hypovolaemia (risk of severe hypotension) • neonates • risk of airways obstruction and hyperventilation in children under 6 months (monitor respiratory rate and oxygen saturation) • vasoconstriction

**CAUTIONS, FURTHER INFORMATION**

- Recovery when used for sedation Midazolam has a fast onset of action, recovery is faster than for other benzodiazepines such as diazepam, but may be significantly longer in the elderly, in patients with a low cardiac output, or after repeated dosing.

**INTERACTIONS** → Appendix 1: midazolam

- **SIDE-EFFECTS** Amnesia • anaphylaxis • ataxia • blood disorders • bronchospasm • cardiac arrest • changes in libido (in adults) • confusion • convulsions (more common in neonates) • depression of consciousness • dizziness • drowsiness • dry mouth • dysarthria • euphoria • fatigue (in children) • gastro-intestinal disturbances • hallucinations • headache • heart rate changes • hicups • hypotension • incontinence • increased appetite • injection-site reactions • involuntary movements • jaundice • laryngospasm • muscle weakness • paradoxical aggression (especially in children and elderly) • paradoxical excitement (especially in children and elderly) • respiratory arrest (particularly with high doses or on rapid injection) • respiratory depression (may be severe with sedative and peri-operative use—facilities for its treatment are essential) • respiratory depression (particularly with high doses or on rapid injection) • restlessness (with sedative and peri-operative use) (in children) • salivation changes • severe disinhibition (with sedative and peri-operative use) (in children) • skin reactions • thrombosis • urinary retention • vertigo • visual disturbances

**SIDE-EFFECTS, FURTHER INFORMATION**

- Sedation Midazolam is associated with profound sedation when high doses are given or when it is used with certain other drugs.

**UNLICENSED USE** Oromucosal solution not licensed for use in children under 3 months. Oromucosal solution not licensed for use in adults over 18 years. Unlicensed oromucosal formulations are also available and may have different doses—refer to product literature.

**IMPORTANT SAFETY INFORMATION**

**ANAESTHESIA**

Benzodiazepines should only be administered for anaesthesia by, or under the direct supervision of, personnel experienced in their use, with adequate training in anaesthesia and airway management.

**PREScribing of Midazolam In Palliative Care**

The use of high-strength midazolam (5 mg/mL in 2 mL and 10 mL ampoules, or 2 mg/mL in 5 mL ampoules) should be considered in palliative care and other situations where a higher strength may be more appropriate than administering the prescribed dose, and where the risk of overdose has been assessed. It is advised that flumazenil is available when midazolam is used, to reverse the effects if necessary.

**CONTRA-INDICATIONS** CNS depression • compromised airway • severe respiratory depression

**CAUTIONS** Cardiac disease • children (particularly if cardiovascular impairment) • concentration of midazolam in children under 15 kg not to exceed 1 mg/mL • debilitated patients (reduce dose)(in children) • hypothermia • hypovolaemia (risk of severe hypotension) • neonates • risk of airways obstruction and hyperventilation in children under 6 months (monitor respiratory rate and oxygen saturation) • vasoconstriction

**CAUTIONS, FURTHER INFORMATION**

- Recovery when used for sedation Midazolam has a fast onset of action, recovery is faster than for other benzodiazepines such as diazepam, but may be significantly longer in the elderly, in patients with a low cardiac output, or after repeated dosing.

**INTERACTIONS** → Appendix 1: midazolam

- **SIDE-EFFECTS** Amnesia • anaphylaxis • ataxia • blood disorders • bronchospasm • cardiac arrest • changes in libido (in adults) • confusion • convulsions (more common in neonates) • depression of consciousness • dizziness • drowsiness • dry mouth • dysarthria • euphoria • fatigue (in children) • gastro-intestinal disturbances • hallucinations • headache • heart rate changes • hicups • hypotension • incontinence • increased appetite • injection-site reactions • involuntary movements • jaundice • laryngospasm • muscle weakness • paradoxical aggression (especially in children and elderly) • paradoxical excitement (especially in children and elderly) • respiratory arrest (particularly with high doses or on rapid injection) • respiratory depression (may be severe with sedative and peri-operative use—facilities for its treatment are essential) • respiratory depression (particularly with high doses or on rapid injection) • restlessness (with sedative and peri-operative use) (in children) • salivation changes • severe disinhibition (with sedative and peri-operative use) (in children) • skin reactions • thrombosis • urinary retention • vertigo • visual disturbances

**SIDE-EFFECTS, FURTHER INFORMATION**

- Sedation Midazolam is associated with profound sedation when high doses are given or when it is used with certain other drugs.

**Overdose**

There have been reports of overdose when high strength midazolam has been used for conscious sedation. The use of high-strength midazolam (5 mg/mL in 2 mL and 10 mL ampoules, or 2 mg/mL in 5 mL ampoules) should be restricted to general anaesthesia, intensive care, palliative care, or other situations where the risk has been assessed. It is advised that flumazenil is available when midazolam is used, to reverse the effects if necessary.

**BREAST FEEDING** Small amount present in milk—avoid breast-feeding for 24 hours after administration (although amount probably too small to be harmful after single doses).

**HEPATIC IMPAIRMENT** Use with caution particularly in sedative doses; can precipitate coma. For status epilepticus and febrile convulsions: use with caution in mild to moderate impairment; avoid in severe impairment.

**RENAL IMPAIRMENT** Use with caution in chronic renal failure.

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Hypnovel®), give continuously in Glucose 5% or Sodium chloride 0.9%.

**PREscribing and Dispensing Information**

Palliative care

For further information on the use of midazolam in palliative care, see www.palliativedrugs.com/formulary/en/midazolam.html.
PATIENT AND CARER ADVICE
Patients given sedatives and analgesics during minor outpatient procedures should be very carefully warned about the risks of undertaking skilled tasks (e.g. driving) afterwards. For intravenous benzodiazepines the risk extends to at least 24 hours after administration. Responsible persons should be available to take patients home afterwards. The dangers of taking alcohol should be emphasised.
Medicines for Children leaflet: Midazolam for stopping seizures www.medicinesforchildren.org.uk/midazolam-for-stopping-seizures

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oromucosal solution, solution for injection, infusion, solution for infusion

Solution for injection
- Midazolam (Non-proprietary)
  1 mg per 1 ml Midazolam 5mg/5ml solution for injection ampoules
  10 ampoule (Posm) £6.00 (CD)
  2 mg/2ml solution for injection ampoules
  10 ampoule (Posm) £5.00 (CD)

- Midazolam (as Midazolam hydrochloride) 2 mg per 1 ml Midazolam 10mg/5ml solution for injection ampoules
  10 ampoule (Posm) £8.09 (CD) 10 ampoule Posm no price available DT price = £8.09 (Hospital only) (CD)

- Midazolam (as Midazolam hydrochloride) 5 mg per 1 ml Midazolam 50mg/10ml solution for injection ampoules
  10 ampoule (Posm) £78.00 (CD)

- Hypnovel (Roche Products Ltd)
  1 ml Midazolam (as Midazolam hydrochloride) 5 mg per 1 ml Hypnovel 10mg/2ml solution for injection ampoules
  10 ampoule Posm £7.11 DT price = £6.90 (CD)

Solution for infusion
- Midazolam (Non-proprietary)
  1 mg per 1 ml Midazolam 50mg/50ml solution for infusion vials
  1 vial Posm £9.56-£11.00 (CD)

- Midazolam (as Midazolam hydrochloride) 2 mg per 1 ml Midazolam 100mg/50ml solution for infusion vials
  1 vial Posm £9.05-£12.50 (CD)

Oromucosal solution
CAUTIONARY AND ADVISORY LABELS 2
- Buccolam (Shire Pharmaceuticals Ltd)
  Midazolam (as Midazolam hydrochloride) 5 mg per 1 ml Midazolam 7.5mg/1.5ml oromucosal solution pre-filled oral syringes sugar-free
  4 unit dose Posm £89.00 DT price = £89.00 (CD)

- Midazolam 10mg/2ml oromucosal solution pre-filled oral syringes sugar-free
  4 unit dose Posm £91.50 DT price = £91.50 (CD)

- Midazolam 2.5mg/0.5ml oromucosal solution pre-filled oral syringes sugar-free
  4 unit dose Posm £82.00 DT price = £82.00 (CD)

3 Mental health disorders

3.1 Anxiety

Other drugs used for Anxiety Duloxetine, p. 350 • Escitalopram, p. 348 • Lorazepam, p. 322 • Moclobemide, p. 346 • Oxprenolol hydrochloride, p. 144 • Paroxetine, p. 349 • Pericazine, p. 370 • Perphenazine, p. 370 • Pregabaline, p. 310 • Trazodone hydrochloride, p. 352 • Trifluoperazine, p. 372 • Venlafaxine, p. 351

ANTIDEPRESSANTS > SEROTONIN RECEPTOR AGONISTS

Buspirone hydrochloride

INDICATIONS AND DOSE
Anxiety (short-term use)
- BY MOUTH
  - Adult: 5 mg 2–3 times a day, increased if necessary up to 45 mg daily, dose to be increased at intervals of 2–3 days; usual dose 15–30 mg daily in divided doses

DOSE ADJUSTMENTS DUE TO INTERACTIONS
Manufacturer advises reduce dose to 2.5 mg twice daily with concurrent use of potent inhibitors of CYP3A4.

CONTRA-INDICATIONS
Acute porphyrias p. 969 • epilepsy

CAUTIONS
Does not alleviate symptoms of benzodiazepine withdrawal

CAUTIONS, FURTHER INFORMATION
A patient taking a benzodiazepine still needs to have the benzodiazepine withdrawn gradually; it is advisable to do this before starting buspirone.

INTERACTIONS ➔ Appendix 1: buspirone

SIDE-EFFECTS
- Common or very common Dizziness • excitement • headache • nausea • nervousness
- Rare Chest pain • confusion • drowsiness • dry mouth • fatigue • palpitation • seizures • sweating • tachycardia

PREGNANCY
Avoid.

BREAST FEEDING
Avoid.

HEPATIC IMPAIRMENT
Reduce dose in mild to moderate disease. Avoid in severe disease.

RENAL IMPAIRMENT
Reduce dose. Avoid if eGFR less than 20 mL/minute/1.73 m².

PATIENT AND CARER ADVICE
Driving and skilled tasks May affect performance of skilled tasks (e.g. driving); effects of alcohol may be enhanced.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Tablet
- Buspirone hydrochloride (Non-proprietary)
  5 mg Buspirone 5mg tablets 30 tablet (Posm) £28.64 DT price = £3.19

- Buspirone hydrochloride 10 mg Buspirone 10mg tablets 30 tablet Posm £24.00 DT price = £3.85

HYPNOTICS, SEDATIVES AND ANXIOLYTICS > BENZODIAZEPINES

Benzodiazepines

CONTRA-INDICATIONS
Acute pulmonary insufficiency • marked neuromuscular respiratory weakness • sleep apnoea syndrome • unstable myasthenia gravis

CAUTIONS
Avoid prolonged use (and abrupt withdrawal thereafter) • debilitated patients (reduce dose)(in adults) • elderly (reduce dose)(in adults) • history of alcohol dependence or abuse • history of drug dependence or abuse • myasthenia gravis • respiratory disease

CAUTIONS, FURTHER INFORMATION
Paradoxical effects A paradoxical increase in hostility and aggression may be reported by patients taking benzodiazepines. The effects range from talkativeness and excitement to aggressive and antisocial acts. Adjustment of the dose (up or down) sometimes attenuates the...
impulses. Increased anxiety and perceptual disorders are other paradoxical effects.

- **SIDE-EFFECTS**
  - **Overdose**
    Benzodiazepines taken alone cause drowsiness, ataxia, dysarthria, nystagmus, and occasionally respiratory depression, and coma. For details on the management of poisoning, see Benzodiazepines, under Emergency treatment of poisoning p. 1249.
  - **PREGNANCY**
    Risk of neonatal withdrawal symptoms when used during pregnancy. Avoid regular use and use only if there is a clear indication such as seizure control. High doses administered during late pregnancy or labour may cause neonatal hypothermia, hypotonia, and respiratory depression.
  - **RENAL IMPAIRMENT**
    Increased cerebral sensitivity to benzodiazepines.
  - **PATIENT AND CARER ADVICE**
    Driving and skilled tasks
    Drowsiness may persist the next day and affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced.
    For information on 2015 legislation regarding driving whilst taking certain controlled drugs, including benzodiazepines, see Drugs and driving under Guidance on prescribing p. 1.

### Alprazolam

- **INDICATIONS AND DOSE**
  - **Short-term use in anxiety**
    - **BY MOUTH**
      - Adult: 250–500 micrograms 3 times a day, increased if necessary up to 3 mg daily, for debilitated patients, use elderly dose
      - Elderly: 250 micrograms 2–3 times a day, increased if necessary up to 3 mg daily

- **CONTRA-INDICATIONS**
  - Chronic psychosis • hyperkinesia • not for use alone to treat depression (or anxiety associated with depression) • obsessive states • phobic states • respiratory depression

- **CAUTIONS**
  - Muscle weakness • organic brain changes • personality disorder (within the fearful group—dependent, avoidant, obsessive-compulsive) may increase risk of dependence

- **INTERACTIONS** → Appendix 1: alprazolam

- **SIDE-EFFECTS**
  - **Common or very common**
    - Amnesia • ataxia (especially in the elderly) • confusion (especially in the elderly) • dependence • drowsiness the next day • lightheadedness the next day • muscle weakness • paradoxical increase in aggression
  - **Uncommon**
    - Changes in libido • dizziness • dysarthria • gastrointestinal disturbances • gynaecomastia • headache • hypotension • incontinence • salivation changes • slurred speech • tremor • urinary retention • vertigo • visual disturbances
  - **Rare**
    - Apnoea • blood disorders • jaundice • respiratory depression • skin reactions

- **BREAST FEEDING**
  - Benzodiazepines are present in milk, and should be avoided if possible during breast-feeding.

- **HEPATIC IMPAIRMENT**
  - Start with smaller initial doses or reduce dose. Can precipitate coma. If treatment is necessary, benzodiazepines with shorter half-lives (such as temazepam or oxazepam) are safer. Avoid in severe impairment.

- **PATIENT AND CARER ADVICE**
  - **Driving and skilled tasks**
    - May impair judgement and increase reaction time, and so affect ability to drive or operate machinery; they increase the effects of alcohol. Moreover the hangover effects of a night dose may impair driving on the following day.

- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **NHS restrictions**
    - Alprazolam tablets are not prescribable under the NHS.

### Chlordiazepoxide hydrochloride

- **INDICATIONS AND DOSE**
  - **Short-term use in anxiety**
    - **BY MOUTH**
      - Adult: 10 mg 3 times a day, increased if necessary to 60–100 mg daily in divided doses, for debilitated patients, use elderly dose
      - Elderly: 5 mg 3 times a day, increased if necessary to 30–50 mg daily in divided doses

- **TREATMENT OF ALCOHOL WITHDRAWAL IN MODERATE DEPENDENCE**
  - **BY MOUTH**
    - Adult: 10–30 mg 4 times a day, dose to be gradually reduced over 5–7 days, consult local protocols for titration regimens

- **TREATMENT OF ALCOHOL WITHDRAWAL IN SEVERE DEPENDENCE**
  - **BY MOUTH**
    - Adult: 10–50 mg 4 times a day and 10–40 mg as required for the first 2 days, dose to be gradually reduced over 7–10 days, consult local protocols for titration regimens; maximum 250 mg per day

- **CONTRA-INDICATIONS**
  - Chronic psychosis • hyperkinesia • not for use alone to treat depression (or anxiety associated with depression) • obsessive states • phobic states • respiratory depression

- **CAUTIONS**
  - Muscle weakness • organic brain changes • personality disorder (within the fearful group—dependent, avoidant, obsessive-compulsive) may increase risk of dependence

- **INTERACTIONS** → Appendix 1: chlordiazepoxide

- **SIDE-EFFECTS**
  - **Common or very common**
    - Amnesia • ataxia (especially in the elderly) • confusion (especially in the elderly) • dependence • drowsiness the next day • lightheadedness the next day • muscle weakness • paradoxical increase in aggression
  - **Uncommon**
    - Changes in libido • dizziness • dysarthria • gastrointestinal disturbances • gynaecomastia • headache • hypotension • incontinence • salivation changes • slurred speech • tremor • urinary retention • vertigo • visual disturbances
  - **Rare**
    - Apnoea • blood disorders • jaundice • respiratory depression • skin reactions

- **BREAST FEEDING**
  - Benzodiazepines are present in milk, and should be avoided if possible during breast-feeding.

- **HEPATIC IMPAIRMENT**
  - Start with smaller initial doses or reduce dose. Can precipitate coma. If treatment is necessary, benzodiazepines with shorter half-lives (such as temazepam or oxazepam) are safer. Avoid in severe impairment.
**Diazepam**

**INDICATIONS AND DOSE**

**Muscle spasm of varied aetiology**
- **BY MOUTH**
  - Adult: 2–15 mg daily in divided doses, then increased if necessary to 60 mg daily, adjusted according to response, dose only increased in spas tic conditions

**Acute muscle spasm**
- **BY INTRAMUSCULAR INJECTION, OR BY SLOW INTRAVENOUS INJECTION**
  - Adult: 10 mg, then 10 mg after 4 hours if required, intravenous injection to be administered into a large vein at a rate of no more than 5 mg/minute

**Tetanus**
- **BY INTRAVENOUS INJECTION**
  - Child: 100–300 micrograms/kg every 1–4 hours
  - Adult: 100–300 micrograms/kg every 1–4 hours

**BY INTRAVENOUS INFUSION, OR BY NASODUODENAL TUBE**
  - Child: 3–10 mg/kg, adjusted according to response, to be given over 24 hours
  - Adult: 3–10 mg/kg, adjusted according to response, to be given over 24 hours

**Muscle spasm in cerebral spasticity or in postoperative skeletal muscle spasm**
- **BY MOUTH**
  - Child 1-11 months: Initially 250 micrograms/kg twice daily
  - Child 1-4 years: Initially 2.5 mg twice daily
  - Child 5-11 years: Initially 5 mg twice daily
  - Child 12-17 years: Initially 10 mg twice daily; maximum 40 mg per day

**Anxiety**
- **BY MOUTH**
  - Adult: 2 mg 3 times a day, then increased if necessary to 15–30 mg daily in divided doses, for debilitated patients, use elderly dose
  - Elderly: 1 mg 3 times a day, then increased if necessary to 7.5–15 mg daily in divided doses

**Insomnia associated with anxiety**
- **BY MOUTH**
  - Adult: 5–15 mg daily, to be taken at bedtime

**Severe acute anxiety | Control of acute panic attacks | Acute alcohol withdrawal**
- **BY INTRAMUSCULAR INJECTION, OR BY SLOW INTRAVENOUS INJECTION**
  - Adult: 10 mg, then 10 mg after at least 4 hours if required, intravenous injection to be administered into a large vein, at a rate of not more than 5 mg/minute

**Acute drug-induced dystonic reactions**
- **BY INTRAVENOUS INJECTION**
  - Adult: 5–10 mg, then 5–10 mg after at least 10 minutes as required, to be administered into a large vein, at a rate of not more than 5 mg/minute

**Acute anxiety and agitation**
- **BY RECTUM**
  - Adult: 500 micrograms/kg, then 500 micrograms/kg after 12 hours as required
  - Elderly: 250 micrograms/kg, then 250 micrograms/kg after 12 hours as required

**Premedication**
- **BY MOUTH**
  - Adult: 5–10 mg, to be given 1–2 hours before procedure, for debilitated patients, use elderly dose
  - Elderly: 2.5–5 mg, to be given 1–2 hours before procedure

**BY INTRAVENOUS INJECTION**
  - Adult: 100–200 micrograms/kg, to be administered into a large vein at a rate of not more than 5 mg/minute, immediately before procedure

**Sedation in dental procedures carried out in hospital**
- **BY MOUTH**
  - Adult: Up to 20 mg, to be given 1–2 hours before procedure

**Conscious sedation for procedures, and in conjunction with local anaesthesia**
- **BY MOUTH**
  - Adult: 5–10 mg, to be given 1–2 hours before procedure, for debilitated patients, use elderly dose
  - Elderly: 2.5–5 mg, to be given 1–2 hours before procedure

**BY INTRAVENOUS INJECTION**
  - Adult: 10–20 mg, to be administered into a large vein over 2–4 minutes, immediately before procedure

**Status epilepticus | Febrile convulsions | Convulsions due to poisoning**
- **BY INTRAVENOUS INJECTION**
  - Neonate: 300–400 micrograms/kg, then 300–400 micrograms/kg after 10 minutes if required, to be given over 3–5 minutes

  - Child: 1 month-11 years: 300–400 micrograms/kg (max. per dose 10 mg), then 300–400 micrograms/kg after 10 minutes if required, to be given over 3–5 minutes
  - Child 12-17 years: 10 mg, then 10 mg after 10 minutes if required, to be given over 3–5 minutes
  - Adult: 10 mg, then 10 mg after 10 minutes if required, administered at a rate of 1 mL (5 mg) per minute

  **continued**
Nervous system

▶ Common or very common

- headache (in adults)
- hypotension (in adults)
- incontinence
- salivation changes
- slurred speech (in adults)
- tremor
- urinary retention (in adults)
- vertigo (in adults)
- visual disturbances

▶ Rare
- Apnoea
- blood disorders
- changes in Libido (in children)
- headache (in children)
- hypotension (in children)
- jaundice
- respiratory depression
- skin reactions
- urinary retention (in children)
- vertigo (in children)

▶ Frequency not known
- Delusions (in children)
- excitement (in children)
- hallucinations (in children)
- hypotonia (when used for muscle spasm)
- irritability (in children)
- marked respiratory depression, particularly with high dose (facilities for its treatment are essential)
- psychosis (in children)
- restlessness (in children)

SPECIFIC SIDE-EFFECTS

- With intravenous use
  - Pain
  - thrombophlebitis
  - venous thrombosis (in adults)

▶ PREGNANCY
- Women who have seizures in the second half of pregnancy should be assessed for eclampsia before any change is made to antiepileptic treatment. Status epilepticus should be treated according to the standard protocol.

Epilepsy and Pregnancy Register
- All pregnant women with epilepsy, whether taking medication or not, should be encouraged to notify the UK Epilepsy and Pregnancy Register (Tel: 0800 389 1248).

▶ BREAST FEEDING
- Present in milk, and should be avoided if possible during breast-feeding.

▶ HEPATIC IMPAIRMENT
- Start with smaller initial doses or reduce dose. Can precipitate coma. If treatment is necessary, benzodiazepines with shorter half lives are safer, such as temazepam or oxazepam. Avoid in severe impairment.

▶ RENAL IMPAIRMENT
- Start with small doses in severe impairment.

▶ DIRECTIONS FOR ADMINISTRATION

- With intravenous use
  - Diazepam is adsorbed by plastics of infusion bags and giving sets. Emulsion formulation preferred for intravenous injection.

- With intravenous use in children
  - For continuous intravenous infusion of diazepam emulsion, dilute to a concentration of max. 400 micrograms/mL with Glucose 5% or 10%; max. 6 hours between addition and completion of infusion. For continuous intravenous infusion of diazepam solution, dilute to a concentration of max. 50 micrograms/mL with Glucose 5% or Sodium Chloride 0.9%.

- With intravenous use in adults
  - For intravenous infusion (solution) (Diazepam, Wockhardt), give continuously in Glucose 5% or Sodium chloride 0.9%. Dilute to a concentration of not more than 10 mg in 200 mL. For intravenous infusion (emulsion) (Diazemuls®), give continuously in Glucose 5% or 10%. May be diluted to a max. concentration of 200 mg in 500 mL; max. 6 hours between addition and completion of administration. May be given via drip tubing in Glucose 5% or 10% or Sodium chloride 0.9%.

- With intramuscular use or intravenous use in adults
  - Solution for injection should not be diluted, except for intravenous infusion.

- With intramuscular use in adults
  - Only use intramuscular route when oral and intravenous routes not possible.

▶ PRESCRIBING AND DISPENSING INFORMATION

- Palliative care
  - For further information on the use of diazepam in palliative care, see www.palliativedrugs.com/formulary/en/diazepam.html.

▶ PATIENT AND CARER ADVICE

- Driving and skilled tasks
  - May impair judgement and increase reaction time, and so affect ability to drive or perform skilled tasks; they

---

**IMPORTANT SAFETY INFORMATION**

**ANAESTHESIA**

Benzodiazepines should only be administered for anaesthesia by, or under the direct supervision of, personnel experienced in their use, with adequate training in anaesthesia and airway management.

**CONTRA-INDICATIONS**

Avoid injections containing benzyl alcohol in neonates, chronic psychosis (in adults), CNS depression, compromised airway, hyperkinesia, not for use alone to treat depression (or anxiety associated with depression) (in adults), obsessional states, phobic states, respiratory depression

**CAUTIONS**

**GENERAL CAUTIONS**

Muscle weakness, organic brain changes, parenteral administration (close observation required until full recovery from sedation), personality disorder (within the fearful group—dependent, avoidant, obsessive-compulsive) may increase risk of dependence

**SPECIFIC CAUTIONS**

- With intravenous use
  - High risk of venous thrombophlebitis with intravenous use (reduced by using an emulsion formulation)

**CAUTIONS, FURTHER INFORMATION**

- Special precautions for intravenous injection
  - When given intravenously facilities for reversing respiratory depression with mechanical ventilation must be immediately available.

**INTERACTIONS**

- Appendix 1: diazepam

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**

- Amnesia
- ataxia (especially in the elderly)
- confusion (especially in the elderly)
- drowsiness
- dizziness
- slurred speech
- the next day
- lightheadedness
- the next day
- muscle weakness
- paradoxical increase in aggression
- Changes in libido (in adults)
- dizziness
- dysarthria
- gastro-intestinal disturbances
- gynaecomastia

- headache (in adults)
- hypotension (in adults)
- incontinence
- salivation changes
- slurred speech (in adults)
- tremor
- urinary retention (in adults)
- vertigo (in adults)
- visual disturbances

- Apnoea
- blood disorders
- changes in Libido (in children)
- headache (in children)
- hypotension (in children)
- jaundice
- respiratory depression
- skin reactions
- urinary retention (in children)
- vertigo (in children)

- Delusions (in children)
- excitement (in children)
- hallucinations (in children)
- hypotonia (when used for muscle spasm)
- irritability (in children)
- marked respiratory depression, particularly with high dose (facilities for its treatment are essential)
- psychosis (in children)
- restlessness (in children)

**SPECIFIC SIDE-EFFECTS**

- With intravenous use
  - Pain
  - thrombophlebitis
  - venous thrombosis (in adults)

- Women who have seizures in the second half of pregnancy should be assessed for eclampsia before any change is made to antiepileptic treatment. Status epilepticus should be treated according to the standard protocol.

Epilepsy and Pregnancy Register
- All pregnant women with epilepsy, whether taking medication or not, should be encouraged to notify the UK Epilepsy and Pregnancy Register (Tel: 0800 389 1248).

- Present in milk, and should be avoided if possible during breast-feeding.

- Start with smaller initial doses or reduce dose. Can precipitate coma. If treatment is necessary, benzodiazepines with shorter half lives are safer, such as temazepam or oxazepam. Avoid in severe impairment.

- Start with small doses in severe impairment.

- With intravenous use
  - Diazepam is adsorbed by plastics of infusion bags and giving sets. Emulsion formulation preferred for intravenous injection.

- For continuous intravenous infusion of diazepam emulsion, dilute to a concentration of max. 400 micrograms/mL with Glucose 5% or 10%; max. 6 hours between addition and completion of infusion. For continuous intravenous infusion of diazepam solution, dilute to a concentration of max. 50 micrograms/mL with Glucose 5% or Sodium Chloride 0.9%.

- For intravenous infusion (solution) (Diazepam, Wockhardt), give continuously in Glucose 5% or Sodium chloride 0.9%. Dilute to a concentration of not more than 10 mg in 200 mL. For intravenous infusion (emulsion) (Diazemuls®), give continuously in Glucose 5% or 10%. May be diluted to a max. concentration of 200 mg in 500 mL; max. 6 hours between addition and completion of administration. May be given via drip tubing in Glucose 5% or 10% or Sodium chloride 0.9%.

- Solution for injection should not be diluted, except for intravenous infusion.

- Only use intramuscular route when oral and intravenous routes not possible.

- For further information on the use of diazepam in palliative care, see www.palliativedrugs.com/formulary/en/diazepam.html.

- May impair judgement and increase reaction time, and so affect ability to drive or perform skilled tasks; they

---

**UNLICENSED USE**

- Diazepam Desitin®, Diazepam Rectubes®, and Stesolid Rectal Tubes® not licensed for use in children under 1 year.
increase the effects of alcohol. Moreover the hangover effects of a night dose may impair performance on the following day.

Patients given sedatives and analgesics during minor outpatient procedures should be very carefully warned about the risks of undertaking skilled tasks (e.g. driving) afterwards. For intravenous benzodiazepines the risk extends to at least 24 hours after administration. Responsible persons should be available to take patients home afterwards. The dangers of taking alcohol should be emphasised.

Medicines for Children leaflet: Diazepam (rectal) for stopping seizures www.medicinesforchildren.org.uk/diazepam-rectal-stopping-seizures-0

Medicines for Children leaflet: Diazepam for muscle spasm www.medicinesforchildren.org.uk/diazepam-for-muscle-spasm

- PROFESSONAL SPECIFIC INFORMATION
  - Dental practitioners' formulary
  - Diazepam Tablets may be prescribed. Diazepam Oral Solution 2 mg/5 mL may be prescribed.

- MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, suppository

**Tablet**

**CAUTIONARY AND ADVISORY LABELS 2, 19**

- Diazepam 2 mg | Diazepam 2 mg tablets | 28 tablet POM £1.10 DT price = £0.73 (CD4-1) 1000 tablet POM £16.71 (CD4-1)
- Diazepam 5 mg | Diazepam 5 mg tablets | 28 tablet POM £1.12 DT price = £0.76 (CD4-1) 1000 tablet POM £20.71 (CD4-1)
- Diazepam 10 mg | Diazepam 10 mg tablets | 28 tablet POM £4.99 DT price = £0.85 (CD4-1) 500 tablet POM £11.04 (CD4-1)

**Emulsion for injection**

- Diazemuls (Actavis UK Ltd)
- Diazepam 5 mg per 1 ml Diazemuls 10 mg/2 ml emulsion for injection ampoules | 10 ampoule POM £9.05 (CD4-1)

**Solution for injection**

**EXCIPIENTS:** May contain Benzyl alcohol, ethanol, propylene glycol

- Diazepam 5 mg per 1 ml Diazepam 10 mg/2 ml solution for injection ampoules | 10 ampoule POM £5.50 DT price + £5.50 (CD4-1)

**Oral suspension**

- Diazepam 400 microgram per 1 ml Diazepam 2 mg/5 ml oral suspension | 100 ml POM £31.75-£39.00 DT price = £31.75 (CD4-1)
- Diazepam 1 mg per 1 ml Diazepam 5 mg/5 ml oral suspension | 100 ml POM £55.00-£66.00 (CD4-1)

**Oral solution**

- Diazepam 400 microgram per 1 ml Diazepam 2 mg/5 ml oral solution sugar free sugar-free | 100 ml POM £31.75-£38.10 DT price = £31.75 (CD4-1)

**Enema**

- Diazepam 2 mg per 1 ml Diazepam 5 mg RecTubes | 5 tube POM £5.85 DT price = £5.85 (CD4-1)
- Diazepam 2.5 mg/1.25 ml rectal solution tube | 5 tube POM no price available (CD4-1)
- Diazepam 2.5 mg Rectubes | 5 tube POM £5.65 (CD4-1)
- Diazepam 2.5 mg/2.5 ml rectal solution tube | 5 tube POM £5.85 DT price = £5.85 (CD4-1)
- Diazepam 4 mg per 1 ml Diazepam 10 mg RecTubes | 5 tube POM £7.35 DT price = £7.35 (CD4-1)
- Diazepam 10 mg/2.5 ml rectal solution tube | 5 tube POM £7.35 DT price = £7.35 (CD4-1)

- Stesolid (Actavis UK Ltd)
- Diazepam 2 mg per 1 ml Stesolid 5 mg rectal tube | 5 tube POM £6.89 DT price = £6.85 (CD4-1)
- Diazepam 4 mg per 1 ml Stesolid 10 mg rectal tube | 5 tube POM £8.78 DT price = £7.35 (CD4-1)

**Oxazepam**

### INDICATIONS AND DOSE

**Anxiety (short-term use)**

- **BY MOUTH**
  - Adult: 15–30 mg 3–4 times a day, for debilitated patients, use elderly dose
  - Elderly: 10–20 mg 3–4 times a day

**Insomnia associated with anxiety**

- **BY MOUTH**
  - Adult: 15–25 mg once daily (max. per dose 50 mg), dose to be taken at bedtime

- **CONTRA-INDICATIONS** Chronic psychosis · hyperkinesia · not for use alone to treat depression (or anxiety associated with depression) · obsessional states · phobic states · respiratory depression

**CAUTIONS** Muscle weakness · organic brain changes · personality disorder (within the fearful group—dependent, avoidant, obsessive-compulsive) may increase risk of dependence

**CAUTIONS, FURTHER INFORMATION**

- Paradoxical effects A paradoxical increase in hostility and aggression may be reported by patients taking benzodiazepines. The effects range from talkativeness and excitement to aggressive and antisocial acts. Adjustment of the dose (up or down) sometimes attenuates the impulses. Increased anxiety and perceptual disorders are other paradoxical effects.

- **INTERACTIONS** → Appendix 1: oxazepam

- **SIDE-EFFECTS**
  - Common or very common Amnesia · ataxia (especially in the elderly) · confusion (especially in the elderly) · dependence · drowsiness the next day · lightheadedness the next day · muscle weakness · paradoxical increase in aggression
  - Uncommon Changes in libido · dizziness · dysarthria · gastro-intestinal disturbances · gynaecomastia · headache · hypotension · incontinence · salivation changes · slurred speech · tremor · urinary retention · vertigo · visual disturbances
  - Rare Apnoea · blood disorders · jaundice · respiratory depression · skin reactions

- **BREAST FEEDING** Benzodiazepines are present in milk, and should be avoided if possible during breast-feeding.

- **HEPATIC IMPAIRMENT** Start with smaller initial doses or reduce dose. Can precipitate coma. If treatment is necessary, benzodiazepines with shorter half-lives are safer. Avoid in severe impairment.

- **RENAL IMPAIRMENT** Start with small doses in severe impairment.

- **PATIENT AND CARER ADVICE**

Driving and skilled tasks May impair judgement and increase reaction time, and so affect ability to drive or operate machinery; they increase the effects of alcohol. Moreover the hangover effects of a night dose may impair driving on the following day.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Tablet**

**CAUTIONARY AND ADVISORY LABELS 2**

- Oxazepam (Non-proprietary)
  - Oxazepam 10 mg Oxazepam 10 mg tablets | 28 tablet POM £7.97 DT price = £1.37 (CD4-1)
  - Oxazepam 15 mg Oxazepam 15 mg tablets | 28 tablet POM £7.97 DT price = £1.38 (CD4-1)
3.2 Attention deficit hyperactivity disorder

Attention deficit hyperactivity disorder (initiated by a specialist)

Management
Central nervous system stimulants include the amphetamines (dexamfetamine sulfate p. 333 and lisdexamfetamine mesilate p. 334) and related drugs (e.g. methylphenidate hydrochloride p. 331). They have very few indications and in particular, should not be used to treat depression, obesity, senility, debility, or for relief of fatigue.

CNS stimulants should be prescribed for children with severe and persistent symptoms of attention deficit hyperactivity disorder (ADHD), when the diagnosis has been confirmed by a specialist; children with moderate symptoms of ADHD can be treated with CNS stimulants when psychological interventions have been unsuccessful or are unavailable. Prescribing of CNS stimulants may be continued by general practitioners, under a shared-care arrangement. Treatment of ADHD often needs to be continuous into adolescence, and may need to be continued into adulthood.

Drug treatment of ADHD should be part of a comprehensive treatment programme. The choice of medication should take into consideration co-morbid conditions (such as tic disorders, Tourette syndrome, and epilepsy), the adverse effect profile, potential for drug misuse, tolerance and dependence; and preferences of the patient and carers. Methylphenidate hydrochloride and atomoxetine below are used for the management of ADHD; dexamfetamine sulfate and lisdexamfetamine mesilate are an alternative in children who do not respond to these drugs. Guanfacine p. 335, a non-stimulant alpha-2-adrenoceptor agonist, can be used in children for whom stimulants are not suitable, not tolerated, or ineffective. Therapeutic response to guanfacine should be evaluated every 3 months for the first year and then at least yearly, when prescribed for extended periods.

The need to continue drug treatment for ADHD should be reviewed at least annually. This may involve suspending treatment.

CNS STIMULANTS > CENTRALLY ACTING SYMPATHOMIMETICS

Atomoxetine 28-Sep-2016

330 Mental health disorders

HYPNOTICS, SEDATIVES AND ANXIOLYTICS > NON-BENZODIAZEPINE HYPNOTICS AND SEDATIVES

Meprobamate

**INDICATIONS AND DOSE**

Short-term use in anxiety—not recommended

- **BY MOUTH**
  - Adult: 400 mg 3–4 times a day
  - Elderly: Up to 200 mg 3–4 times a day

**IMPORTANT SAFETY INFORMATION**

The European Medicines Agency has recommended (January 2012) the suspension of all marketing authorisations for meprobamate because the risks, particularly of serious CNS side-effects, outweigh the benefits.

**CONTRA-INDICATIONS**

Acute porphyrias p. 969 • acute pulmonary insufficiency • respiratory depression

**CAUTIONS**

Abrupt withdrawal (may precipitate convulsions) • avoid prolonged use • debilitated elderly • epilepsy (may induce seizures) • history of alcohol abuse • history of drug abuse • marked personality disorder • muscle weakness • respiratory disease

**INTERACTIONS**

Appendix 1: meprobamate

**SIDE-EFFECTS**

- Common or very common
  - Amnesia • ataxia (especially in the elderly) • confusion (especially in the elderly) • dependence • drowsiness the next day • lightheadedness the next day • muscle weakness • paradoxical increase in aggression
  - Uncommon
  - Changes in libido • dizziness • dysarthria • gastro-intestinal disturbances • gynaecomastia • headache • hypotension • incontinence • salivation changes • slurred speech • tremor • urinary retention • vertigo • visual disturbances
  - Rare
  - Agranulocytosis • apnoea • blood disorders • jaundice • rashes • respiratory depression • skin reactions
  - Frequency not known
  - CNS effects • paradoxical excitement • paraesthesia • weakness

**PREGNANCY**

Avoid if possible.

**BREAST FEEDING**

Avoid. Concentration in milk may exceed maternal plasma concentrations fourfold and may cause drowsiness in infant.

**HEPATIC IMPAIRMENT**

Can precipitate coma.

**RENAL IMPAIRMENT**

Start with small doses in severe impairment. Increased cerebral sensitivity.

**PATIENT AND CARER ADVICE**

Driving and skilled tasks

Drowsiness may affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced.

**LESS SUITABLE FOR PRESCRIBING**

Meprobamate is less suitable for prescribing.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Tablet**

CAUTIONARY AND ADVISORY LABELS 2

- Meprobamate (Non-proprietary)
  - Meprobamate 400 mg tablets 84 tablet pack £19.763 DT price = £19.763

[BNF 74] Downloaded from www.medicalbr.com
> Adult (body-weight up to 70 kg): Initially 500 micrograms/kg daily for 7 days; dose is increased according to response; maintenance 1.2 mg/kg daily, total daily dose may be given either as a single dose in the morning or in 2 divided doses with last dose no later than early evening, high daily doses to be given under the direction of a specialist; maximum 1.8 mg/kg per day; maximum 120 mg per day.

> Adult (body-weight 70 kg and above): Initially 40 mg daily for 7 days; dose is increased according to response; maintenance 80–100 mg daily, total daily dose may be given either as a single dose in the morning or in 2 divided doses with last dose no later than early evening, high daily doses to be given under the direction of a specialist; maximum 120 mg per day.

**UNLICENSED USE** Atomoxetine doses in BNF may differ from those in product literature.

**IN CHILDREN** Dosages above 100 mg daily not licensed.

**IN ADULTS** Dose maximum of 120 mg not licensed.

**CONTRA-INDICATIONS** Phaeochromocytoma · severe cardiovascular disease · severe cerebrovascular disease

**CAUTIONS** QT-interval prolongation · aggressive behaviour · cardiovascular disease · cerebrovascular disease · emotional lability · history of seizures · hostility · hypertension · mania · psychosis · structural cardiac abnormalities · susceptibility to angle-closure glaucoma · tachycardia

**INTERACTIONS** → Appendix 1: atomoxetine

**SIDE-EFFECTS**

▶ Common or very common Abdominal pain · anorexia · anxiety · agitation · agitation · aggressiveness · aggression · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation · agitation /
Nervous system

DELMOSART®

EQUASYM®

Total daily dose of

DOSE EQUIVALENCE AND CONVERSION

When switching from immediate-release preparations to modified-release preparations—consult product literature.

CONCERTA® XL

Attention deficit hyperactivity disorder

BY MOUTH

Child 6-17 years: Initially 18 mg once daily, dose to be taken in the morning, increased in steps of 18 mg every week, adjusted according to response; increased if necessary up to 2.1 mg/kg daily, licensed max. dose is 54 mg once daily, to be increased to higher dose only under direction of specialist; discontinue if no response after 1 month; maximum 108 mg per day

Adult: Initially 18 mg once daily, dose to be taken in the morning; adjusted at weekly intervals according to response; maximum 108 mg per day

DOSE EQUIVALENCE AND CONVERSION

Total daily dose of 15 mg of standard-release formulation is considered equivalent to Concerta® XL 18 mg once daily.

DELMOSART® PROLONGED-RELEASE TABLET

Attention deficit hyperactivity disorder (under expert supervision)

BY MOUTH

Child 6-17 years: Initially 18 mg once daily, dose to be taken in the morning, then increased in steps of 18 mg every week if required, discontinue if no response after 1 month; maximum 54 mg per day

Adult: Initially 18 mg once daily, dose to be taken in the morning, then increased in steps of 18 mg every week if required, discontinue if no response after 1 month; maximum 54 mg per day

DOSE EQUIVALENCE AND CONVERSION

Total daily dose of 15 mg of standard-release formulation is considered equivalent to Delmosart® 18 mg once daily.

EQUASYM® XL

Attention deficit hyperactivity disorder

BY MOUTH

Child 6-17 years: Initially 10 mg once daily, dose to be taken in the morning before breakfast; increased gradually at weekly intervals if necessary; increased if necessary up to 2.1 mg/kg daily, licensed max. dose is 60 mg daily, to be increased to higher dose only under direction of specialist; discontinue if no response after 1 month; maximum 90 mg per day

Adult: Initially 10 mg once daily, dose to be taken in the morning before breakfast; increased gradually at weekly intervals if necessary; maximum 100 mg per day

MEDIKINET® XL

Attention deficit hyperactivity disorder

BY MOUTH

Child 6-17 years: Initially 10 mg once daily, dose to be taken in the morning with breakfast; adjusted at weekly intervals according to response; increased if necessary up to 2.1 mg/kg daily, licensed max. dose is 60 mg daily, to be increased to higher dose only under direction of specialist; discontinue if no response after 1 month; maximum 90 mg per day

Adult: Initially 10 mg once daily, dose to be taken in the morning with breakfast; adjusted at weekly intervals according to response; maximum 100 mg per day

UNLICENSED USE

Doses over 60 mg daily not licensed; doses of Concerta XL over 54 mg daily not licensed.


CONTRA-INDICATIONS

Anorexia nervosa • arrhythmias • cardiomyopathy • cardiovascular disease • cerebrovascular disorders • heart failure • hyperthyroidism • phaeochromocytoma • psychosis • severe depression • severe hypertension • structural cardiac abnormalities • suicidal ideation • uncontrolled bipolar disorder • vasculitis

CAUTIONS

Agitation • alcohol dependence • anxiety • drug dependence • epilepsy (discontinue if increased seizure frequency) • family history of Tourette syndrome • susceptibility to angle-closure glaucoma • tics

DELmosart®, Concerta® XL: Dysphagia (dose form not appropriate) • restricted gastro-intestinal lumen (dose form not appropriate)

INTERACTIONS → Appendix 1: methylphenidate

SIDE-EFFECTS

Common or very common Abdominal pain • aggression • alopecia • anorexia • arrhythmias • arthralgia • asthenia • changes in blood pressure • cough • depression • diarrhoea • dizziness • drowsiness • dry mouth • dyspepsia • fever • growth restriction • headache • insomnia • irritability • movement disorders • nasopharyngitis • nausea • nervousness • palpitation • pruritus • rash • reduced weight • tachycardia • tics • vomiting

Uncommon Abnormal dreams • confusion • constipation • dysphoria • epistaxis • haematuria • muscle cramps • suicidal ideation • urinary frequency

Rare Angina • sweating • visual disturbances;

Very rare Angle-closure glaucoma • blood disorders • cerebral arteritis • dependence • erythema multiforme • exfoliative dermatitis • hepatic dysfunction • leucopenia • myocardial infarction • neuroleptic malignant syndrome • psychosis • seizures • thrombocytopenia • tolerance • Tourette syndrome

Frequency not known Bradycardia • convulsions • supraventricular tachycardia

PREGNANCY Limited experience—avoid unless potential benefit outweighs risk.

BREAST FEEDING Limited information available—avoid.

MONITORING REQUIREMENTS

Monitor for psychiatric disorders.

Pulse, blood pressure, psychiatric symptoms, appetite, weight and height should be recorded at initiation of therapy, following each dose adjustment, and at least every 6 months thereafter.

TREATMENT CESSATION Avoid abrupt withdrawal.

DIRECTIONS FOR ADMINISTRATION

MEDIKINET® XL: Contents of capsule can be sprinkled on a tablespoon of apple sauce or yoghurt (then swallowed immediately without chewing).

EQUASYM® XL: Contents of capsule can be sprinkled on a tablespoon of apple sauce (then swallowed immediately without chewing).

PRESCRIBING AND DISPENSING INFORMATION

Different versions of modified-release preparations may not have the same clinical effect. To avoid confusion between these different formulations of methylphenidate, prescribers should specify the brand to be dispensed.
CONCERTA® XL Consists of an immediate-release component (22% of the dose) and a modified-release component (78% of the dose).

MEDIKINET® XL Consists of an immediate-release component (50% of the dose) and a modified-release component (50% of the dose).

EQUASYM® XL Consists of an immediate-release component (30% of the dose) and a modified-release component (70% of the dose).

PATIENT AND CARER ADVICE

Drugs and Driving Prescribers and other healthcare professionals should advise patients if treatment is likely to affect their ability to perform skilled tasks (e.g. driving). This applies especially to drugs with sedative effects;

patients should be warned that these effects are increased by alcohol. General information about a patient’s fitness to drive is available from the Driver and Vehicle Licensing Agency at www.dvla.gov.uk.

2015 legislation regarding driving whilst taking certain drugs, may also apply to methylphenidate, see Drugs and driving under Guidance on prescribing p. 1.

DELMOSART® Manufacturer advises tablet membrane may pass through gastro-intestinal tract unchanged.

CONCERTA® XL Tablet membrane may pass through gastro-intestinal tract unchanged.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) (March 2006)

NICE TA98 Methylphenidate is recommended, within its licensed indications, as an option for the management of ADHD in children and adolescents.

www.nice.org.uk/TA98

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Modified-release tablet

CAUTIONARY AND ADVISORY LABELS 25

Methylphenidate hydrochloride 18 mg Concerta XL 18mg tablets | 30 tablet (POT) £31.19 DT price = £31.19 (C02)

Methylphenidate hydrochloride 27 mg Concerta XL 27mg tablets | 30 tablet (POT) £36.81 DT price = £36.81 (C02)

Methylphenidate hydrochloride 36 mg Concerta XL 36mg tablets | 30 tablet (POT) £42.45 DT price = £42.45 (C02)

Methylphenidate hydrochloride 54 mg Concerta XL 54mg tablets | 30 tablet (POT) £73.62 DT price = £60.48 (C02)

Medikinet XL (Shire Pharmaceuticals Ltd)

Methylphenidate hydrochloride 10 mg Medikinet XL 10mg capsules | 30 capsule (POT) £25.00 DT price = £25.00 (C02)

Methylphenidate hydrochloride 20 mg Medikinet XL 20mg capsules | 30 capsule (POT) £30.00 DT price = £30.00 (C02)

Methylphenidate hydrochloride 30 mg Medikinet XL 30mg capsules | 30 capsule (POT) £35.00 DT price = £35.00 (C02)

Methylphenidate hydrochloride 5 mg Medikinet XL 5mg capsules | 30 capsule (POT) £24.04 DT price = £24.04 (C02)

Methylphenidate hydrochloride 10 mg Medikinet XL 10mg capsules | 30 capsule (POT) £24.04 DT price = £25.00 (C02)

Methylphenidate hydrochloride 20 mg Medikinet XL 20mg capsules | 30 capsule (POT) £28.86 DT price = £30.00 (C02)

Methylphenidate hydrochloride 30 mg Medikinet XL 30mg capsules | 30 capsule (POT) £33.66 DT price = £35.00 (C02)

Methylphenidate hydrochloride 40 mg Medikinet XL 40mg capsules | 30 capsule (POT) £57.72 DT price = £57.72 (C02)

Methylphenidate hydrochloride 50 mg Medikinet XL 50mg capsules | 30 capsule (POT) £62.52 (C02)

Methylphenidate hydrochloride 60 mg Medikinet XL 60mg capsules | 30 capsule (POT) £67.32 (C02)

CNS STIMULANTS CENTRALLY ACTING SYMPATHOMIMETICS AMFETAMINES

Dexamfetamine sulfate (Dexamphetamine sulfate)

INDICATIONS AND DOSE

Narcolepsy

BY MOUTH

Adult: Initially 10 mg daily in divided doses, increased in steps of 10 mg every week, maintenance dose to be given in 2–4 divided doses; maximum 60 mg per day.

Elderly: Initially 5 mg daily in divided doses, increased in steps of 5 mg every week, maintenance dose to be given in 2–4 divided doses; maximum 60 mg per day.

Refractory attention deficit hyperactivity disorder (initiated under specialist supervision)

BY MOUTH

Child 6–17 years: Initially 2.5 mg 2–3 times a day, increased in steps of 5 mg once weekly if required, increased if necessary up to 1 mg/kg daily, maintenance dose to be given in 2–4 divided doses, up to 20 mg daily (40 mg daily has been required in some children).

Adult: Initially 5 mg twice daily, dose is increased at weekly intervals according to response, maintenance dose to be given in 2–4 divided doses; maximum 60 mg per day.

UNLICENSED USE

Not licensed for use in adults for refractory attention deficit hyperactivity disorder.

CONTRA-INDICATIONS

Nervous system

MONITORING REQUIREMENTS

- Tics and Tourette syndrome: Discontinue use if tics occur.
- Growth restriction in children: Monitor height and weight as growth restriction may occur during prolonged therapy (drug-free periods may allow catch-up in growth but withdraw slowly to avoid inducing depression or renewed hyperactivity).

INTERACTIONS → Appendix 1: amphetamines

SIDE-EFFECTS

- Common or very common: Abdominal cramps, acidosis, aggression, alopecia, anhedonia, anorexia, ataxia, cardiomyopathy, cardiovascular collapse, cerebral vasculitis, chest pain, confusion, depression, diarrhoea, dizziness, dry mouth, dysphoria, euphoria, growth restriction in children, headache, hyperactivity, hyperypyrexia (in children), hyperreflexia, hypertension, impaired concentration, irritability, ischaemic colitis, malaise, mydriasis, myocardial infarction, nausea, nervousness, neuroleptic malignant syndrome, obsessive-compulsive behaviour, palpitations, panic attack, paranoia, psychosis, pyrexia (in adults), rash, renal impairment, restlessness, rhabdomyolysis, seizures, sexual dysfunction, sleep disturbances, stroke, sweating, tachycardia, taste disturbance, Tourette syndrome (in predisposed individuals), tremor, urticaria, visual disturbances, weight loss

- Very rare: Angle-closure glaucoma
- Frequency not known: Choreaathetoid movements (in predisposed individuals), dyskinesia (in predisposed individuals), increased appetite, tics (in predisposed individuals)

Overdose


PREGNANCY

Avoid (retrospective evidence of uncertain significance suggesting possible embryotoxicity).

BREAST FEEDING

Significant amount in milk—avoid.

RENAL IMPAIRMENT

Use with caution.

MONITORING REQUIREMENTS

- Monitor growth in children.
- Monitor for aggressive behaviour or hostility during initial treatment.
- Pulse, blood pressure, psychiatric symptoms, appetite, weight and height should be recorded at initiation of therapy, following each dose adjustment, and at least every 6 months thereafter.

TREATMENT CESSATION

Avoid abrupt withdrawal.

DIRECTIONS FOR ADMINISTRATION

- In children: Tablets can be halved.

PRESCRIBING AND DISPENSING INFORMATION

Data on safety and efficacy of long-term use not complete.

PATIENT AND CARER ADVICE

Drugs and Driving

Prescribers and other healthcare professionals should advise patients if treatment is likely to affect their ability to perform skilled tasks (e.g. driving). This applies especially to drugs with sedative effects; patients should be warned that these effects are increased by alcohol. General information about a patient’s fitness to drive is available from the Driver and Vehicle Licensing Agency at www.dvla.gov.uk.

For information on 2015 legislation regarding driving whilst taking certain controlled drugs, including amphetamines, see Drugs and driving under Guidance on prescribing p. 1.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

- Methylphenidate, atomoxetine and dexamphetamine for attention deficit hyperactivity disorder (ADHD) (March 2006) NICE TA98

Dexamphetamine is recommended, within its licensed indications, as an option for the management of ADHD in children and adolescents. www.nice.org.uk/TA98

MEDIcular FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: modified-release capsule, oral suspension, oral solution

Oral solution

- Dexamphetamine sulphate (Non-proprietary)

  Dexamphetamine sulphate 1 mg per 1 ml

  Dexamphetamine sulphate 5 mg/5 ml

  Oral solution sugar free sugar-free | 150 ml £29.44-£34.35 (CD)

  Dexamphetamine sulphate 10 mg

  Dexamphetamine sulphate 15 mg

  Dexamphetamine sulphate 20 mg

  Dexamphetamine sulphate 25 mg

  Dexamphetamine sulphate 50 mg

  Dexamphetamine sulphate 100 mg

Tablet

- Dexamphetamine sulphate (Non-proprietary)

  Dexamphetamine sulphate 5 mg

  Dexamphetamine sulphate 10 mg

  Dexamphetamine sulphate 20 mg

  Dexamphetamine sulphate 30 mg

  Dexamphetamine sulphate 40 mg

- Amfexa (Flynn Pharma Ltd)

  Amfexa 15 mg tablets | 30 tablet £11.89 (CD)

  Amfexa 30 mg tablets | 30 tablet £35.78 (CD)

  Amfexa 50 mg tablets | 30 tablet £79.56 (CD)

Lisdexamphetamine mesilate

- DRUG ACTION

  Lisdexamphetamine is a prodrug of dexamphetamine.

INDICATIONS AND DOSE

Attention deficit hyperactivity disorder refractory to methylphenidate (initiated by a specialist)

- BY MOUTH

  - Child: 6-17 years: Initially 30 mg once daily, increased in steps of 20 mg every week if required, dose to be taken in the morning, discontinue if response insufficient after 1 month; maximum 70 mg per day

  - Adult: Initially 30 mg once daily, increased in steps of 20 mg every week if required, dose to be taken in the morning, discontinue if response insufficient after 1 month; maximum 70 mg per day

- UNLICENSED USE

  Not licensed for use in adults for attention deficit hyperactivity disorder.

CONTRA-INDICATIONS

Advanced arteriosclerosis · agitated states · hyperexcitability · hyperthyroidism · moderate hypertension · severe hypertension · symptomatic cardiovascular disease

CAUTIONS

Anorexia · bipolar disorder · history of alcohol abuse · history of cardiac abnormalities · history of cardiovascular disease · history of drug abuse · may lower seizure threshold (discontinue if seizures occur) · psychosis · susceptibility to angle-closure glaucoma · tics · Tourette syndrome

CAUTIONS, FURTHER INFORMATION

- Tics and Tourette syndrome: Discontinue use if tics occur.
- Growth restriction in children: Monitor height and weight as growth restriction may occur during prolonged therapy (drug-free periods may allow catch-up in growth but...
withdraw slowly to avoid inducing depression or renewed hyperactivity).

- INTERACTIONS ➔ Appendix 1: amfetamines
- SIDE-EFFECTS
  - Common or very common Abdominal cramps • aggression • decreased appetite • diarrhoea • dizziness • drowsiness • dry mouth • dysphoria • growth restriction in children • headache • labile mood • malaise • mydriasis • nausea • pyrexia • sleep disturbances • tics • vomiting • weight loss
  - Uncommon Anorexia • anxiety • depression • dermatillomania • dysphoria • hallucination • hypertension • logorrhea • mania • palpitation • paranoia • rash • restlessness • sexual dysfunction • sweating • tachycardia • tremor • visual disturbances
  - Very rare Angle-closure glaucoma
  - Frequency not known Cardiomyopathy • choreoathetoid movements (in predisposed individuals) • dyskinesia (in predisposed individuals) • euphoria • seizures • Tourette syndrome (in predisposed individuals)

Overdose


- PREGNANCY Manufacturer advises use only if potential benefit outweighs risk.
- BREAST FEEDING Manufacturer advises avoid—present in human milk.
- RENAL IMPAIRMENT Max. dose 50 mg daily in severe impairment.
- MONITORING REQUIREMENTS
  - Monitor for aggressive behaviour or hostility during initial treatment.
  - Monitor growth in children.
  - Pulse, blood pressure, psychiatric symptoms, appetite, weight and height should be recorded at initiation of therapy, following each dose adjustment, and at least every 6 months thereafter.

TREATMENT CESSION Avoid abrupt withdrawal.

DIRECTIONS FOR ADMINISTRATION

Swallow whole or mix contents of capsule in yoghurt or a glass of water or orange juice; contents should be dispersed completely and consumed immediately.

- PATIENT AND CARER ADVICE Patients and carers should be counselled on the administration of capsules.
- Drugs and Driving Prescribers and other healthcare professionals should advise patients if treatment is likely to affect their ability to perform skilled tasks (e.g. driving). This applies especially to drugs with sedative effects; patients should be warned that these effects are increased by alcohol. General information about a patient’s fitness to drive is available from the Driver and Vehicle Licensing Agency at www.dvla.gov.uk.

For information on 2015 legislation regarding driving whilst taking certain controlled drugs, including amphetamines, see Drugs and driving under Guidance on prescribing p. 1.

- MEDICINAL FORMS
  - Capsule
    - There can be variation in the licensing of different medicines containing the same drug.
    - Elvanse Capsule (Shire Pharmaceuticals Ltd) ➔ Appendix 1: amfetamines

Lisdexamfetamine dimesylate 40 mg Elvanse 40 mg capsules | 28 capsule (PoM) £52.82 DT price = £56.60 (CD)
Lisdexamfetamine dimesylate 50 mg Elvanse Adult 50 mg capsules | 28 capsule (PoM) £58.60 DT price = £68.60 (CD)
Lisdexamfetamine dimesylate 50 mg Elvanse 50 mg capsules | 28 capsule (PoM) £58.60 DT price = £68.60 (CD)
Lisdexamfetamine dimesylate 60 mg Elvanse 60 mg capsules | 28 capsule (PoM) £75.18 DT price = £75.18 (CD)
Lisdexamfetamine dimesylate 70 mg Elvanse 70 mg capsules | 28 capsule (PoM) £83.16 DT price = £83.16 (CD)

SYMPATHOMIMETICS ➔ ALPH2-ADRENERCEPTOR AGONISTS

Guanfacine 26-May-2016

- INDICATIONS AND DOSE
  - Attention deficit hyperactivity disorder in children for whom stimulants are not suitable, not tolerated or ineffective (initiated under specialist supervision)
    - BY MOUTH
      - Child 6–12 years (body-weight 25 kg and above): Initially 1 mg once daily; adjusted in steps of 1 mg every week if necessary and if tolerated; maintenance 0.05–0.12 mg/kg once daily (max. per dose 4 mg), for optimal weight-adjusted dose titrations, consult product literature
      - Child 13–17 years (body-weight 34–41.4 kg): Initially 1 mg once daily; adjusted in steps of 1 mg every week if necessary and if tolerated; maintenance 0.05–0.12 mg/kg once daily (max. per dose 4 mg), for optimal weight-adjusted dose titrations, consult product literature
      - Child 13–17 years (body-weight 41.5–49.4 kg): Initially 1 mg once daily; adjusted in steps of 1 mg every week if necessary and if tolerated; maintenance 0.05–0.12 mg/kg once daily (max. per dose 5 mg), for optimal weight-adjusted dose titrations, consult product literature
      - Child 13–17 years (body-weight 49.5–58.4 kg): Initially 1 mg once daily; adjusted in steps of 1 mg every week if necessary and if tolerated; maintenance 0.05–0.12 mg/kg once daily (max. per dose 6 mg), for optimal weight-adjusted dose titrations, consult product literature
      - Child 13–17 years (body-weight 58.5 kg and above): Initially 1 mg once daily; adjusted in steps of 1 mg every week if necessary and if tolerated; maintenance 0.05–0.12 mg/kg once daily (max. per dose 7 mg), for optimal weight-adjusted dose titrations, consult product literature
  
DOSE ADJUSTMENTS DUE TO INTERACTIONS

Manufacturer advises reduce dose by half with concurrent use of moderate and potent inhibitors of CYP3A4.

Manufacturer advises increase dose up to max. 7 mg daily with concurrent use of potent inducers of CYP3A4—no specific recommendation made for children.

- CAUTIONS
  - Bradycardia (risk of torsade de pointes) • heart block (risk of torsade de pointes) • history of cardiovascular disease • history of QT-interval prolongation • hypokalaemia (risk of torsade de pointes)
- INTERACTIONS ➔ Appendix 1: guanfacine
- SIDE-EFFECTS
  - Common or very common Abdominal pain • anxiety • bradycardia • constipation • decreased appetite • depression • diarrhoea • dizziness • dry mouth • enuresis • headache • hypotension • irritability • malaise • mood lability • nausea • rash • sleep disturbance • somnolence • vomiting • weight increase
3.3 Bipolar disorder and mania

Drugs for mania and hypomania

Overview
Antimanic drugs are used to control acute attacks and to prevent recurrence of episodes of mania or hypomania. Long-term treatment of bipolar disorder should continue for at least two years from the last manic episode and up to five years if the patient has risk factors for relapse.

An antidepressant drug may also be required for the treatment of co-existing depression, but should be avoided in patients with rapid-cycling bipolar disorder, a recent history of hypomania, or with rapid mood fluctuations.

Benzodiazepines
Use of benzodiazepines (such as lorazepam p. 322) may be helpful in the initial stages of treatment for behavioural disturbance or agitation; they should not be used for long periods because of the risk of dependence.

Antipsychotic drugs
Antipsychotic drugs (normally olanzapine p. 379, quetiapine p. 382, or risperidone p. 383) are useful in acute episodes of mania and hypomania; if the response to antipsychotic drugs is inadequate, lithium or valproate may be added. An antipsychotic drug may be used concomitantly with lithium or valproate in the initial treatment of severe acute mania.

Olanzapine can be used for the long-term management of bipolar disorder in patients whose manic episode responded to olanzapine therapy. It can be given either as monotherapy, or in combination with lithium or valproate if the patient has frequent relapses or continuing functional impairment.

Asenapine p. 338, a second-generation antipsychotic, is licensed for the treatment of moderate to severe manic episodes associated with bipolar disorder.

When discontinuing antipsychotics, the dose should be reduced gradually over at least 4 weeks if the patient is continuing with other antimanic drugs; if the patient is not continuing with other antimanic drugs or if there is a history of manic relapse, a withdrawal period of up to 3 months should be considered.

Carbamazepine
Carbamazepine p. 297 may be used under specialist supervision for the prophylaxis of bipolar disorder (manic-depressive disorder) in patients unresponsive to a combination of other prophylactic drugs; it is used in patients with rapid-cycling manic-depressive illness (4 or more affective episodes per year). The dose of carbamazepine should not normally be increased if an acute episode of mania occurs.

Valproate
Valproate (valproic acid p. 337 (as the semisodium salt) and sodium valproate p. 312) is used for the treatment of manic episodes associated with bipolar disorder. It must be started and supervised by a specialist experienced in managing bipolar disorder. Valproate (valproic acid and sodium valproate) is also used for the prophylaxis of bipolar disorder. Valproic acid and sodium valproate should not be used in female children, in females of childbearing potential and pregnant females, unless alternative treatments are ineffective or not tolerated, because of its high teratogenic potential; the benefit and risk of valproate therapy should be carefully considered at regular treatment reviews. In patients with frequent relapse or continuing functional
impairment, consider switching therapy to lithium or olanzapine, or adding lithium or olanzapine to valproate. If a patient taking valproate experiences an acute episode of mania that is not ameliorated by increasing the valproate dose, consider concomitant therapy with olanzapine,quetiapine, or risperidone.

**Lithium**

Lithium salts are used in the prophylaxis and treatment of mania, hypomania and depression in bipolar disorder (manic-depressive disorder), and in the prophylaxis and treatment of recurrent unipolar depression. Lithium is also used as concomitant therapy with antidepressant medication in patients who have had an incomplete response to treatment for acute bipolar depression and to augment other antidepressants in patients with treatment-resistant depression [unlicensed indication]. It is also licensed for the treatment of aggressive or self-harming behaviour.

The decision to give prophylactic lithium requires specialist advice, and must be based on careful consideration of the likelihood of recurrence in the individual patient, and the benefit of treatment weighed against the risks. The full prophylactic effect of lithium may not occur for six to twelve months after the initiation of therapy. Olanzapine or valproate (given alone or as adjunctive therapy with lithium) are alternative prophylactic treatments in patients who experience frequent relapses or continued functional impairment.

**Other drugs used for Bipolar disorder and mania**

Aripiprazole, p. 376 · Chlorpromazine hydrochloride, p. 367 · Haloperidol, p. 368 · Lamotrigine, p. 303 · Paliperidone, p. 380 · Perphenazine, p. 370 · Prochlorperazine, p. 371 · Zuclopenthixol acetate, p. 373

---

**Unlicensed Use**

Not licensed for migraine prophylaxis.

---

**Indications and Dose**

**Treatment of manic episodes associated with bipolar disorder**

- **BY MOUTH**
- Adult: Initially 750 mg daily in 2–3 divided doses, then increased to 1–2 g daily, adjusted according to response, doses greater than 45 mg/kg daily require careful monitoring

**Migraine prophylaxis**

- **BY MOUTH**
- Adult: Initially 250 mg twice daily, then increased if necessary to 1 g daily in divided doses

**Dose equivalence and conversion**

- Semisodium valproate comprises equimolar amounts of sodium valproate and valproic acid.

**Convulex®**

**Epilepsy**

- **BY MOUTH**
- Adult: Initially 600 mg daily in 2–4 divided doses, increased in steps of 150–300 mg every 3 days; usual maintenance 1–2 g daily in 2–4 divided doses, max. 2.5 g daily in 2–4 divided doses

**Dose equivalence and conversion**

- Convulex® has a 1:1 dose relationship with products containing sodium valproate, but nevertheless care is needed if switching or making changes.

---

**Antiepileptics**

**Valproic acid**

18-Apr-2017

**Contra-indications**

Acute porphyrias p. 969 · known or suspected mitochondrial disorders (higher rate of acute liver failure and liver-related deaths) · personal or family history of severe hepatic dysfunction

**Caution**

Systemic lupus erythematosus

**Caution, further information**

- Liver toxicity
  - Liver dysfunction (including fatal hepatic failure) has occurred in association with valproate (especially in children under 3 years and in those with metabolic or degenerative disorders, organic brain disease or severe seizure disorders associated with mental retardation) usually in first 6 months and usually involving multiple antiepileptic therapy. Raised liver enzymes during valproate treatment are usually transient but patients should be reassessed clinically and liver function (including prothrombin time) monitored until return to normal—discontinue if abnormally prolonged prothrombin time (particularly in association with other relevant abnormalities).

- Consider vitamin D supplementation in patients that are immobilised for long periods or who have inadequate sun exposure or dietary intake of calcium.

**Interactions**

Appendix 1: antiepileptics

**Side-effects**

- Common or very common
  - Diarrhoea · gastric irritation · hyperammonaemia · nausea · thrombocytopenia · transient hair loss (regrowth may be curly) · weight gain
- Uncommon
  - Anger · ataxia · behavioural disturbances · hyperactivity · increased alertness · tremor · vasculitis
- Rare
  - Anaemia · blood disorders · confusion · drowsiness · hallucinations · hearing loss · hepatic dysfunction · lethargy · leucopenia · pancytopenia · rash · stupor
- Very rare
  - Acne · coma · dementia · encephalopathy · enuresis · extrapyramidal symptoms · Fanconi’s syndrome · gynaecomastia · hirsutism · hyponatraemia · increase in bleeding time · pancreatitis · peripheral oedema · reduced bone mineral density · Stevens-Johnson syndrome · suicidal ideation · toxic epidermal necrolysis
- Frequency not known
  - Drug rash with eosinophilia and
systemic symptoms (DRESS) syndrome • hypersensitivity reactions • male infertility • menstrual disturbances • syndrome of inappropriate secretion of antidiuretic hormone

SIDE-EFFECTS, FURTHER INFORMATION

- Hepatic dysfunction Withdraw treatment immediately if persistent vomiting and abdominal pain, anorexia, jaundice, oedema, malaise, drowsiness, or loss of seizure control.
- Pancreatitis Discontinue treatment if symptoms of pancreatitis develop.

CONCEPTION AND CONTRACEPTION Valproate is associated with teratogenic risks and should not be used in females of child-bearing potential unless there is no safer alternative—this should be fully considered and discussed before prescribing for females of child-bearing age. Effective contraception advised in females of child-bearing potential. In females planning to become pregnant, all efforts should be made to switch to appropriate alternative treatment prior to conception.

PREGNANCY Valproate is associated with the highest risk of major and minor congenital malformations (in particular neural tube defects), and long-term neurodevelopmental effects. Valproate should not be used during pregnancy unless there is no safer alternative and only after a careful discussion of the risks. If valproate is to be used during pregnancy, the lowest effective dose should be prescribed in divided doses to avoid peaks in plasma-valproate concentrations; doses greater than 1 g daily are associated with an increased risk of teratogenicity. Neonatal bleeding (related to hypofibrininaemia). Neonatal hepatotoxicity also reported.

Specialist prenatal monitoring should be instigated when valproate has been taken in pregnancy.

The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.

- BREAST FEEDING Present in milk—risk of haematological disorders in breast-fed newborns and infants.
- HEPATIC IMPAIRMENT Avoid if possible—hepatotoxicity and hepatic failure may occasionally occur (usually in first 6 months). Avoid in active liver disease.
- RENAL IMPAIRMENT Reduce dose.

MONITORING REQUIREMENTS

- Monitor closely if dose greater than 45 mg/kg daily.
- Monitor liver function before therapy and during first 6 months especially in patients most at risk.
- Measure full blood count and ensure no undue potential for bleeding before starting and before surgery.

EFFECT ON LABORATORY TESTS False-positive urine tests for ketones.

TREATMENT CESSATION Avoid abrupt withdrawal; if treatment with valproate is stopped, reduce the dose gradually over at least 4 weeks.

PRESCRIBING AND DISPENSING INFORMATION

CONVULEX®. Patients being treated for epilepsy may need to be maintained on a specific manufacturer’s branded or generic oral valproic acid product.

PATIENT AND CARER ADVICE

Risk of abnormal pregnancy outcomes. A patient guide and card should be provided to all female patients. Blood or hepatic disorders. Patients or their carers should be told how to recognise signs and symptoms of blood or liver disorders and advised to seek immediate medical attention if symptoms develop.

Pancreatitis. Patients or their carers should be told how to recognise signs and symptoms of pancreatitis and advised to seek immediate medical attention if symptoms such as abdominal pain, nausea, or vomiting develop.

MHRA advice: Valproate and the risk of abnormal pregnancy outcomes. Female patients and their carers should be counselled on the risk of valproate treatment during pregnancy. Ensure female patients are provided with relevant resources, to support their understanding of the risks. In particular the prescriber must ensure the patient understands:

- the risks associated with valproate during pregnancy;
- the need to use effective contraception;
- the need for regular review of treatment;
- the need to rapidly consult if she is planning a pregnancy or becomes pregnant.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution.

Gastro-resistant capsule

CAUTIONARY AND ADVISORY LABELS 8, 21, 25, 10

- Convulex (Pfizer Ltd) ▼ Valproic acid 150 mg | 100 capsule (POM) £3.68
- Valproic acid 300 mg | 100 capsule (POM) £7.35
- Valproic acid 500 mg | 100 capsule (POM) £12.25

Gastro-resistant tablet

CAUTIONARY AND ADVISORY LABELS 10, 21, 25

- Depakote (Sanofi) ▼ Valproic acid (as Valproate semisodium) 250 mg | 90 tablet (POM) £17.08 DT price = £17.08
- Valproic acid (as Valproate semisodium) 500 mg | 500 gastro-resistant tablets | 90 tablet (POM) £34.11 DT price = £34.11

ANTIPSYCHOTICS > SECOND-GENERATION

Asenapine

INDICATIONS AND DOSE

Monotherapy for the treatment of moderate to severe manic episodes associated with bipolar disorder

- BY MOUTH
  - Adult: Initially 10 mg twice daily, reduced to 5 mg twice daily, adjusted according to response

Combination therapy for the treatment of moderate to severe manic episodes associated with bipolar disorder

- BY MOUTH
  - Adult: Initially 5 mg twice daily, increased if necessary to 10 mg twice daily, adjusted according to response

CAUTIONS Dementia with Lewy Bodies

INTERACTIONS Appendix 1: asenapine

SIDE-EFFECTS Anxiety, dysphagia, glossodynia, hypersalivation, rhabdomyolysis, speech disturbance, taste disturbance, tongue swelling, transient oral hypoaesthesia, transient paraesthesia

PREGNANCY Use only if potential benefit outweighs risk—toxicity in animal studies.

BREAST FEEDING Avoid—no information available.

HEPATIC IMPAIRMENT Use with caution in moderate impairment. Avoid in severe impairment.

RENAL IMPAIRMENT Use with caution if eGFR less than 15 mL/minute/1.73 m²—no information available.

PATIENT AND CARER ADVICE Patient or carer should be given advice on how to administer asenapine sublingual tablet.
**Lithium salts**

- **CONTRA-INDICATIONS** Addison’s disease • cardiac insufficiency • dehydration • family history of Brugada syndrome • low sodium diets • personal history of Brugada syndrome • rhythm disorder • untreated hypothyroidism

- **CAUTIONS** Avoid abrupt withdrawal • cardiac disease • concurrent ECT (may lower seizure threshold) • diuretic treatment (risk of toxicity) • elderly (reduce dose) • epilepsy (may lower seizure threshold) • myasthenia gravis • psoriasis (risk of exacerbation) • QT interval prolongation • review dose as necessary in diarrhoea • review dose as necessary in intercurrent infection (especially if sweating profusely) • review dose as necessary in vomiting • surgery

- **SIDE-EFFECTS**
  - Very rare: Nystagmus
  - Frequency not known: Acneiform eruptions • alopecia • anorexia • arrhythmia • atrialgia • AV block • benign intracranial hypertension • bradycardia • cardiomyopathy • cognitive impairment • dry mouth • dysgeusia • ECG changes • electrolyte imbalance • encaphalopathy • euthyroid goitre • extrapyramidal side effects • fine tremor • gastritis • gastro-intestinal disturbances • hallucinations • hyperparathyroidism • hypersalivation • hyperthyroidism • hypothyroidism • kidney changes • leucocytosis • malaise • memory loss • myalgia • myasthenia gravis • nephrogenic diabetes insipidus • nephrotic syndrome • oedema • other skin disorders • parathyroid adenoma • peripheral neuropathy • polydipsia • psoriasis exacerbation • QT interval prolongation • Raynaud’s phenomenon • renal impairment • sexual dysfunction • sinus node dysfunction • speech disorder • thyroid changes • vertigo • weight changes

- **Overdose** Signs of intoxication require withdrawal of treatment and include increasing gastro-intestinal disturbances (vomiting, diarrhoea), visual disturbances, polyuria, muscle weakness, fine tremor increasing to coarse tremor, CNS disturbances (confusion and drowsiness increasing to lack of coordination, restlessness, stupor); abnormal reflexes, myoclonus, incontinence, hypnothermia. With severe overdoses seizures, cardiac arrhythmias (including sino-atrial block, bradycardia and first-degree heart block), blood pressure changes, circulatory failure, renal failure, coma and sudden death reported.

  For details on the management of poisoning, see Lithium, under Emergency treatment of poisoning p. 1249.

- **CONCEPTION AND CONTRACEPTION** Manufacturer advises effective contraception during treatment for women of child bearing potential.

- **PREGNANCY** Dose requirements increased during the second and third trimesters (but on delivery return abruptly to normal). Avoid if possible, particularly in the first trimester (risk of teratogenicity, including cardiac abnormalities). Close monitoring of serum-lithium concentration advised in pregnancy (risk of toxicity in neonate).

- **BREAST FEEDING** Present in milk and risk of toxicity in infant—avoid.

- **RENAI IMPAIRMENT** Caution in mild to moderate impairment. Avoid in severe impairment. In renal impairment monitor serum-lithium concentration closely and adjust dose accordingly.

- **MONITORING REQUIREMENTS**
  - Serum concentrations: Lithium salts have a narrow therapeutic/toxic ratio and should therefore not be prescribed unless facilities for monitoring serum-lithium concentrations are available.
  - Samples should be taken 12 hours after the dose to achieve a serum-lithium concentration of 0.4–1 mmol/litre (lower end of the range for maintenance therapy and elderly patients). A target serum-lithium concentration of 0.8–1 mmol/litre is recommended for acute episodes of mania, and for patients who have previously relapsed or have sub-syndromal symptoms. It is important to determine the optimum range for each individual patient.
  - Routine serum–lithium monitoring should be performed weekly after initiation and after each dose change until concentrations are stable, then every 3 months thereafter. Additional serum-lithium measurements should be made if a patient develops significant intercurrent disease or if there is a significant change in a patient’s sodium or fluid intake.
  - Renal function should be monitored at baseline and every 6 months thereafter (more often if there is evidence of deterioration or if the patient has other risk factors, such as starting ACE inhibitors, NSAIDs, or diuretics).

- **TREATMENT CESSATION** While there is no clear evidence of withdrawal or rebound psychosis, abrupt discontinuation of lithium increases the risk of relapse. If lithium is to be discontinued, the dose should be reduced gradually over a period of at least 4 weeks (preferably over a period of up to 3 months). Patients and their carers should be warned of the risk of relapse if lithium is discontinued abruptly. If lithium is stopped or is to be discontinued abruptly, consider changing therapy to an atypical antipsychotic or valproate.

- **PATIENT AND CARER ADVICE** Patients should be advised to report signs and symptoms of lithium toxicity, hypothyroidism, renal dysfunction (including polyuria and polydipsia), and benign intracranial hypertension (persistent headache and visual disturbance). Maintain adequate fluid intake and avoid dietary changes which reduce or increase sodium intake.

- **Driving and skilled tasks** May impair performance of skilled tasks (e.g. driving, operating machinery).

- **Lithium treatment packs** A lithium treatment pack should be given to patients on initiation of treatment with lithium. The pack consists of a patient information booklet, lithium alert card, and a record book for tracking serum-lithium concentration. Packs may be purchased from 3M

  0845 610 1112

  nhsforms@mmm.uk.com

---

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Sublingual tablet**

**CAUTIONARY AND ADVISORY LABELS 2, 26**

- Symcrest (Lundbeck Ltd)
  - Asenapine (as Asenapine maleate) 5 mg: Symcrest 5mg sublingual tablets sugar-free | 60 tablet | £102.60 DT price = £102.60
  - Asenapine (as Asenapine maleate) 10 mg: Symcrest 10mg sublingual tablets sugar-free | 60 tablet | £102.60 DT price = £102.60

---

**ANTIPSYCHOTICS > LITHIUM SALTS**

**Bipolar disorder and mania 339**

---

**Nervous system**

---

---
Lithium carbonate

**INDICATIONS AND DOSE**

- **Treatment and prophylaxis of mania**
- **Treatment and prophylaxis of bipolar disorder**
- **Treatment and prophylaxis of recurrent depression**
- **Treatment and prophylaxis of aggressive or self-harming behaviour**

**BY MOUTH**

- **Adult:** Initially 1–1.5 g daily, dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter, doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration stabilised

**CAMCOLIT® IMMEDIATE-RELEASE TABLET**

**Treatment of mania**
- **Treatment of bipolar disorder**
- **Treatment of recurrent depression**
- **Treatment of aggressive or self-harming behaviour**

**BY MOUTH**

- **Adult:** Initially 1–1.5 g daily, dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter, doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration stabilised

- **Elderly:** Reduce initial dose, dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter, doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration stabilised

**Prophylaxis of mania**
- **Prophylaxis of bipolar disorder**
- **Prophylaxis of recurrent depression**
- **Prophylaxis of aggressive or self-harming behaviour**

**BY MOUTH**

- **Adult:** Initially 300–400 mg daily, dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter, doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration stabilised

**LIKSOKUM®**

**Treatment of mania**
- **Treatment of bipolar disorder**
- **Treatment of recurrent depression**
- **Treatment of aggressive or self-harming behaviour**

**BY MOUTH**

- **Adult:** Initially 450–675 mg twice daily, dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter, doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration stabilised

- **Elderly:** Initially 225 mg twice daily, dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter, doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration stabilised

**Prophylaxis of mania**
- **Prophylaxis of bipolar disorder**
- **Prophylaxis of recurrent depression**
- **Prophylaxis of aggressive or self-harming behaviour**

**BY MOUTH**

- **Adult:** Initially 450 mg twice daily, dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter, doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration stabilised

- **Elderly:** Initially 225 mg twice daily, dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter, doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration stabilised

**CAMCOLIT® MODIFIED-RELEASE TABLET**

**Treatment of mania**
- **Treatment of bipolar disorder**
- **Treatment of recurrent depression**
- **Treatment of aggressive or self-harming behaviour**

**BY MOUTH**

- **Adult:** Initially 1–1.5 g daily, dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter, doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration stabilised

- **Elderly:** Reduce initial dose, dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter, doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration stabilised

**PRIADEL® TABLETS**

**Treatment and prophylaxis of mania**
- **Treatment and prophylaxis of bipolar disorder**
- **Treatment and prophylaxis of recurrent depression**
- **Treatment and prophylaxis of aggressive or self-harming behaviour**

**BY MOUTH**

- **Adult (body-weight up to 50 kg):** Initially 200–400 mg daily, dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter, doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration stabilised

- **Adult (body-weight 50 kg and above):** Initially 0.4–1.2 g once daily, alternatively initially 0.4–1.2 g daily in 2 divided doses, dose adjusted to achieve a serum-
lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter, doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration stabilised

- Elderly: Initially 200–400 mg daily, dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter, doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration stabilised

**DOSE EQUIVALENCE AND CONVERSION**

- Preparations vary widely in bioavailability; changing the preparation requires the same precautions as initiation of treatment.

### INTERACTIONS

- Appendix 1: lithium

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Modified-release tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>10, 25</th>
</tr>
</thead>
<tbody>
<tr>
<td>Camcolit (Essential Pharma Ltd)</td>
<td>Lithium carbonate 400 mg Camcolit 400 modified-release tablets</td>
</tr>
<tr>
<td>Liskonum (Teofarma)</td>
<td>Lithium carbonate 450 mg Liskonum 450mg modified-release tablets</td>
</tr>
<tr>
<td>Priadel (lithium carbonate) (Sanofi)</td>
<td>Lithium carbonate 200 mg Priadel 200mg modified-release tablets</td>
</tr>
<tr>
<td></td>
<td>Lithium carbonate 400 mg Priadel 400mg modified-release tablets</td>
</tr>
</tbody>
</table>

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lithium carbonate (Non-proprietary)</td>
<td>Lithium carbonate 250mg tablets</td>
</tr>
</tbody>
</table>

### Lithium citrate

#### INDICATIONS AND DOSE

- Treatment and prophylaxis of mania | Treatment and prophylaxis of bipolar disorder | Treatment and prophylaxis of recurrent depression | Treatment and prophylaxis of aggressive or self-harming behaviour
- BY MOUTH
- Adult: Dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter; doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration stabilised

**DOSE EQUIVALENCE AND CONVERSION**

- Preparations vary widely in bioavailability; changing the preparation requires the same precautions as initiation of treatment.

**LI-LIQUID ®**

- Treatment and prophylaxis of mania | Treatment and prophylaxis of bipolar disorder | Treatment and prophylaxis of recurrent depression | Treatment and prophylaxis of aggressive or self-harming behaviour
- BY MOUTH
- Adult (body-weight up to 50 kg): Initially 509 mg daily in 2 divided doses, dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter
- Adult (body-weight 50 kg and above): Initially 1.018–3.054 g daily in 2 divided doses, dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter
- Elderly: Initially 509 mg daily in 2 divided doses, dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter

**DOSE EQUIVALENCE AND CONVERSION**

- For Li-Liquid ®: Lithium citrate tetrahydrate 509 mg is equivalent to lithium carbonate 200 mg.
- Preparations vary widely in bioavailability; changing the preparation requires the same precautions as initiation of treatment.

**PRIADEL ® LIQUID**

- Treatment and prophylaxis of mania | Treatment and prophylaxis of bipolar disorder | Treatment and prophylaxis of recurrent depression | Treatment and prophylaxis of aggressive or self-harming behaviour
- BY MOUTH
- Adult (body-weight up to 50 kg): Initially 520 mg twice daily, dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter; doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration stabilised
- Adult (body-weight 50 kg and above): Initially 1.04–3.12 g daily in 2 divided doses, dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter, doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration stabilised
- Elderly: Initially 520 mg twice daily, dose adjusted to achieve a serum-lithium concentration of 0.4–1 mmol/litre 12 hours after a dose on days 4–7 of treatment, then every week until dosage has remained constant for 4 weeks and every 3 months thereafter, doses are initially divided throughout the day, but once daily administration is preferred when serum-lithium concentration stabilised

**DOSE EQUIVALENCE AND CONVERSION**

- For Priadel ® liquid: Lithium citrate tetrahydrate 520 mg is equivalent to lithium carbonate 204 mg.
- Preparations vary widely in bioavailability; changing the preparation requires the same precautions as initiation of treatment.

#### INTERACTIONS

- Appendix 1: lithium

#### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Oral solution**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lithium citrate (Non-proprietary)</td>
<td>Lithium citrate 101.8 mg per 1 ml Lithium citrate 509mg/5ml oral solution</td>
</tr>
<tr>
<td></td>
<td>Lithium citrate 104 mg per 1 ml Lithium citrate 520mg/5ml oral solution sugar free sugar-free</td>
</tr>
<tr>
<td></td>
<td>Lithium citrate 203.6 mg per 1 ml Lithium citrate 1.018g/5ml oral solution</td>
</tr>
</tbody>
</table>
3.4 Depression

Antidepressant drugs

Overview
Antidepressant drugs are effective for treating moderate to severe depression associated with psychomotor and physiological changes such as loss of appetite and sleep disturbance; improvement in sleep is usually the first benefit of therapy. Ideally, patients with moderate to severe depression should be treated with psychological therapy in addition to drug therapy. Antidepressant drugs are also effective for dysthymia (lower grade chronic depression typically of at least 2 years duration).

Antidepressant drugs should not be used routinely in mild depression, and psychological therapy should be considered initially; however, a trial of antidepressant therapy may be considered in cases refractory to psychological treatments or in those associated with psychosocial or medical problems.

Drug treatment of mild depression may also be considered in patients with a history of moderate or severe depression.

Choice
The major classes of antidepressant drugs include the tricyclic and related antidepressants, the selective serotonin re-uptake inhibitors (SSRIs), and the monoamine oxidase inhibitors (MAOIs). A number of antidepressant drugs cannot be accommodated easily into this classification.

There is little to choose between the different classes of antidepressant drugs in terms of efficacy, so choice should be based on the individual patient’s requirements, including the presence of concomitant disease, existing therapy, suicide risk, and previous response to antidepressant therapy. Since there may be an interval of 2 weeks before the antidepressant action takes place, electroconvulsive treatment may be required in severe depression when delay is hazardous or intolerable. During the first few weeks of treatment, there is an increased potential for agitation, anxiety, and suicidal ideation.

SSRIs are better tolerated and are safer in overdose than other classes of antidepressants and should be considered first-line for treating depression. In patients with unstable angina or who have had a recent myocardial infarction, sertraline p. 350 has been shown to be safe.

Tricyclic antidepressants have similar efficacy to SSRIs but are more likely to be discontinued because of side-effects; toxicity in overdose is also a problem. SSRIs are less sedating and have fewer antimuscarinic and cardiotoxic effects than tricyclic antidepressants.

MAOIs have dangerous interactions with some foods and drugs, and should be reserved for use by specialists.

Although anxiety is often present in depressive illness (and may be the presenting symptom), the use of an antipsychotic or an anxiolytic may mask the true diagnosis. Anxiolytics or antipsychotic drugs should therefore be used with caution in depression but they are useful adjuncts in agitation. Antidepressants with antipsychotics under specialist supervision may also be necessary in patients who have depression with psychotic symptoms.

St John’s wort (Hypericum perforatum) is a popular herbal remedy on sale to the public for treating mild depression. It should not be prescribed or recommended for depression because St John’s wort can induce drug metabolising enzymes and a number of important interactions with conventional drugs, including conventional antidepressants, have been identified. Furthermore, the amount of active ingredient varies between different preparations of St John’s wort and switching from one to another can change the degree of enzyme induction. If a patient stops taking St John’s wort, the concentration of interacting drugs may increase, leading to toxicity.

Management
Patients should be reviewed every 1–2 weeks at the start of antidepressant treatment. Treatment should be continued for at least 4 weeks (6 weeks in the elderly) before considering whether to switch antidepressant due to lack of efficacy. In cases of partial response, continue for a further 2–4 weeks (elderly patients may take longer to respond). Following remission, antidepressant treatment should be continued at the same dose for at least 6 months (about 12 months in the elderly), or for at least 12 months in patients receiving treatment for generalised anxiety disorder (as the likelihood of relapse is high). Patients with a history of recurrent depression should receive maintenance treatment for at least 2 years.

Hypotension and antidepressant therapy
Hypotension (usually in the elderly and possibly due to inappropriate secretion of antidiuretic hormone) has been associated with all types of antidepressants; however, it has been reported more frequently with SSRIs than with other antidepressants. Hypotension should be considered in all patients who develop drowsiness, confusion, or convulsions while taking an antidepressant.

Suicidal behaviour and antidepressant therapy
The use of antidepressants has been linked with suicidal thoughts and behaviour; children, young adults, and patients with a history of suicidal behaviour are particularly at risk. Where necessary patients should be monitored for suicidal behaviour, self-harm, or hostility, particularly at the beginning of treatment or if the dose is changed.

Serotonin syndrome
Serotonin syndrome or serotonin toxicity is a relatively uncommon adverse drug reaction caused by excessive central and peripheral serotonergic activity. Onset of symptoms, which range from mild to life-threatening, can occur within hours or days following the initiation, dose escalation, or overdose of a serotonergic drug, the addition of a new serotonergic drug, or the replacement of one serotonergic drug by another without allowing a long enough washout period in-between, particularly when the first drug is an irreversible MAOI or a drug with a long half-life. Severe toxicity, which is a medical emergency, usually occurs with a combination of serotonergic drugs, one of which is generally an MAOI.

The characteristic symptoms of serotonin syndrome fall into 3 main areas, although features from each group may not be seen in all patients—neuromuscular hyperactivity (such as tremor, hyperreflexia, clonus, myoclonus, rigidity), autonomic dysfunction (tachycardia, blood pressure changes, hyperthermia, diaphoresis, shivering, diarrhoea), and altered mental state (agitation, confusion, mania).

Treatment consists of withdrawal of the serotonergic medication and supportive care; specialist advice should be sought.

Failure to respond
Failure to respond to initial treatment with an SSRI may require an increase in the dose, or switching to a different SSRI or mirtazapine p. 354. Other second-line choices include lorfenaprine p. 360, moclobemide p. 346, and reboxetine p. 346. Other tricyclic antidepressants and venlafaxine p. 351 should be considered for more severe
forms of depression; irreversible MAOIs should only be prescribed by specialists. Failure to respond to a second antidepressant may require the addition of another antidepressant of a different class, or use of an augmenting agent (such as lithium, aripiprazole p. 376 [unlicensed], olanzapine p. 379 [unlicensed], quetiapine p. 382, or risperidone p. 383 [unlicensed]), but such adjunctive treatment should be initiated only by doctors with special experience of these combinations. Electroconvulsive therapy may be initiated in severe refractory depression.

**Anxiety disorders and obsessive-compulsive disorder**

Management of acute anxiety generally involves the use of a benzodiazepine or buspirone hydrochloride p. 325. For chronic anxiety (of longer than 4 weeks’ duration) it may be appropriate to use an antidepressant. Combined therapy with a benzodiazepine may be required until the antidepressant takes effect. Patients with *generalised anxiety disorder*, a form of chronic anxiety, should be offered psychological treatment before initiating an antidepressant. If drug treatment is needed, an SSRI such as escitalopram p. 348, paroxetine p. 349, or sertraline p. 350 [unlicensed], can be used. Duloxetine p. 350 and venlafaxine p. 351 (serotonin and noradrenaline reuptake inhibitors) are also recommended for the management of generalised anxiety disorder; if the patient cannot tolerate SSRIs or serotonin and noradrenaline reuptake inhibitors (or if treatment has failed to control symptoms), pregabalin p. 310 can be considered.

**Panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder**, and phobic states such as *social anxiety disorder* are treated with SSRIs. Clomipramine hydrochloride p. 356 or imipramine hydrochloride p. 359 can be used second-line in panic disorder [unlicensed]; clomipramine hydrochloride can also be used second-line for obsessive-compulsive disorder. Moclobemide p. 346 is licensed for the treatment of social anxiety disorder.

**Tricyclic and related antidepressant drugs**

**Choice**

Tricyclic and related antidepressants block the re-uptake of both serotonin and noradrenaline, although to different extents. For example, clomipramine hydrochloride is more selective for serotonergic transmission, and imipramine hydrochloride is more selective for noradrenergic transmission. Tricyclic and related antidepressant drugs can be roughly divided into those with additional sedative properties and those that are less sedating. Agitated and anxious patients tend to respond best to the sedative compounds, whereas withdrawn and apathetic patients will often obtain most benefit from the less sedating ones. Those with *sedative* properties include amitriptyline hydrochloride p. 355, clomipramine hydrochloride, dosulepin hydrochloride p. 357, doxepin p. 358, mianserin hydrochloride p. 353, trazodone hydrochloride p. 352, and trimipramine p. 362. Those with *less sedative* properties include imipramine hydrochloride, lofepramine p. 360, and nortriptyline p. 361.

Tricyclic and related antidepressants also have varying degrees of antimuscarinic side-effects and cardio toxicity in overdose, which may be important in individual patients. Lofepramine has a lower incidence of side-effects and is less dangerous in overdose but is infrequently associated with hepatic toxicity. Imipramine hydrochloride is also well established, but has more marked antimuscarinic side-effects than other tricyclic and related antidepressants. Amitriptyline hydrochloride and dosulepin hydrochloride are effective but they are particularly dangerous in overdose and are not recommended for the treatment of depression; dosulepin hydrochloride should be initiated by a specialist.

**Dosage**

About 10 to 20% of patients fail to respond to tricyclic and related antidepressant drugs and inadequate dosage may account for some of these failures. It is important to use doses that are sufficiently high for effective treatment but not so high as to cause toxic effects. Low doses should be used for initial treatment in the elderly. In most patients the long half-life of tricyclic antidepressant drugs allows *once-daily* administration, usually at night; the use of modified-release preparations is therefore unnecessary.

Some tricyclic antidepressants are used in the management of *panic* and other anxiety disorders. Some tricyclic antidepressants may also have a role in some forms of *neuralgia* and in *nocturnal enuresis* in children.

**Children and adolescents**

Studies have shown that tricyclic antidepressants are not effective for treating depression in children.

**Monoamine-oxidase inhibitors**

Monoamine-oxidase inhibitors are used much less frequently than tricyclic and related antidepressants, or SSRIs and related antidepressants because of the dangers of dietary and drug interactions and the fact that it is easier to prescribe MAOIs when tricyclic antidepressants have been unsuccessful than vice versa.

Tranylcypromine p. 345 has a greater stimulant action than phenelzine p. 345 or isocarboxazid p. 345 and is more likely to cause a hypertensive crisis. Isocarboxazid and phenelzine are more likely to cause hepatotoxicity than tranylcypromine.

Moclobemide should be reserved as a second-line treatment.

Phobic patients and depressed patients with atypical, hypochondriacal, or hysterical features are said to respond best to MAOIs. However, MAOIs should be tried in any patients who are refractory to treatment with other antidepressants as there is occasionally a dramatic response. Response to treatment may be delayed for 3 weeks or more and may take an additional 1 or 2 weeks to become maximal.

**Interactions**

Other antidepressants should not be started for 2 weeks after treatment with MAOIs has been stopped (3 weeks if starting clomipramine or imipramine). Conversely, an MAOI should not be started until:

- at least 2 weeks after a previous MAOI has been stopped (then started at a reduced dose)
- at least 7–14 days after a tricyclic or related antidepressant (3 weeks in the case of clomipramine or imipramine) has been stopped
- at least a week after an SSRI or related antidepressant (at least 5 weeks in the case of fluoxetine) has been stopped

**Other antidepressant drugs**

The thioxanthene fluoxetine p. 368 (Fluoxene®) has antidepressant properties when given by mouth in low doses. Fluoxetine is also used for the treatment of psychoses.

Vortioxetine p. 363, an antidepressant thought to directly modulate serotonergic receptor activity and inhibit the re-uptake of serotonin, is recommended in patients whose condition has responded inadequately to 2 antidepressants within the current episode.

**Other drugs used for Depression**

- Lithium carbonate, p. 340
- Lithium citrate, p. 341
ANTIDEPRESSANTS MELATONIN RECEPTOR AGONISTS

Agomelatine

DRUG ACTION A melatonin receptor agonist and a selective serotonin-receptor antagonist; it does not affect the uptake of serotonin, noradrenaline, or dopamine.

INDICATIONS AND DOSE

Major depression

BY MOUTH

Adult: 25 mg daily, dose to be taken at bedtime, dose to be increased if necessary after 2 weeks, increased if necessary to 50 mg daily, dose to be taken at bedtime

DOSE ADJUSTMENTS DUE TO INTERACTIONS

Caution—dose adjustment may be necessary if smoking started or stopped during treatment.

CONTRA-INDICATIONS Dementia patients over 75 years of age

CAUTIONS Alcoholism bipolar disorder diabetes excessive alcohol consumption hypomania mania non-alcoholic fatty liver disease obesity

INTERACTIONS Appendix 1: agomelatine

SIDE-EFFECTS

Common or very common Abdominal pain agitation anxiety back pain constipation diarrhoea dizziness drowsiness fatigue headache increased serum transaminases nausea sleep disturbances sweating vomiting

Uncommon Blurred vision eczema paraesthesia restless legs syndrome tinnitus

Rare Hepatic failure hepatic injury hepatitis rash weight changes

Frequency not known Pruritus suicidal behaviour

SIDE-EFFECTS, FURTHER INFORMATION

Suicidal behaviour The use of antidepressants has been linked with suicidal thoughts and behaviour; children, young adults, and patients with a history of suicidal behaviour are particularly at risk. Where necessary patients should be monitored for suicidal behaviour, self-harm, or hostility, particularly at the beginning of treatment or if the dose is changed.

PREGNANCY Manufacturer advises avoid.

BREAST FEEDING Avoid—present in milk in animal studies.

HEPATIC IMPAIRMENT Manufacturer advises avoid in impairment (or if baseline serum transaminases exceed 3 times the upper limit of reference range).

RENAL IMPAIRMENT Caution in moderate to severe impairment.

MONITORING REQUIREMENTS Test liver function before treatment and after 3, 6, 12 and 24 weeks of treatment, and then regularly thereafter when clinically indicated (restart monitoring schedule if dose increased); discontinue if serum transaminases exceed 3 times the upper limit of reference range or symptoms of liver disorder.

PATIENT AND CARER ADVICE Patients should be given a booklet with more information on the risk of hepatic side-effects.

Hepatotoxicity Patients should be told how to recognise signs of liver disorder, and advised to seek immediate medical attention if symptoms such as dark urine, light coloured stools, jaundice, bruising, fatigue, abdominal pain, or pruritus develop.

ANTIDEPRESSANTS MONOAMINE-OXIDASE INHIBITORS

Monoamine-oxidase inhibitors

DRUG ACTION MAOIs inhibit monoamine oxidase, thereby causing an accumulation of amine neurotransmitters.

CONTRA-INDICATIONS Cerebrovascular disease not indicated in manic phase phaeochromocytoma

CAUTIONS Acute porphyria avoid in agitated patients blood disorders cardiovascular disease concurrent electroconvulsive therapy diabetes mellitus elderly (great caution) epilepsy severe hypertensive reactions to certain drugs and foods surgery

SIDE-EFFECTS

Common or very common Dizziness postural hypotension (especially in elderly)

Uncommon Agitation arrhythmias blurred vision confusion constipation convulsions difficulty in micturition drowsiness dry mouth elevated liver enzymes euphoria fatigue gastro-intestinal disturbances hallucinations headache hyperreflexia insomnia leucopenia myoclonic movement nervousness nystagmus oedema psychotic episodes with hypomanic behaviour purpura rashes sexual disturbances suicidal behaviour sweating tremors weakness weight gain with inappropriate appetite

Rare Fatal progressive hepatocellular necrosis

Frequency not known Jaundice hyponatraemia paraesthesia peripheral neuritis peripheral neuropathy (may be due to pyridoxine deficiency)

SIDE-EFFECTS, FURTHER INFORMATION

Risk of postural hypotension and hypertensive responses Discontinue use if palpitations or frequent headaches occur.

PREGNANCY Increased risk of neonatal malformations manufacturer advises avoid unless there are compelling reasons.

HEPATIC IMPAIRMENT MAOIs may cause idiosyncratic hepatotoxicity if used in patients with hepatic impairment.

MONITORING REQUIREMENTS Monitor blood pressure (risk of postural hypotension and hypertensive responses).

TREATMENT CESSATION Withdrawal If possible avoid abrupt withdrawal. MAOIs are associated with withdrawal symptoms on cessation of therapy. Symptoms include agitation, irritability, ataxia, movement disorders, insomnia, drowsiness, vivid dreams, cognitive impairment, and slowed speech. Withdrawal symptoms occasionally experienced when discontinuing MAOIs include hallucinations and paranoid delusions. If possible MAOIs should be withdrawn slowly.

Withdrawal effects may occur within 5 days of stopping treatment with antidepressant drugs; they are usually mild and self-limiting, but in some cases may be severe. The risk of withdrawal symptoms is increased if the antidepressant is stopped suddenly after regular administration for 8 weeks or more. The dose should preferably be reduced gradually over about 4 weeks, or longer if withdrawal symptoms emerge (6 months in patients who have been on long-term maintenance treatment).
**Isocarboxazid**

**INDICATIONS AND DOSE**

**Depressive illness**
- **By mouth**
  - Adult: Initially 30 mg daily until improvement occurs, initial dose may be given in single or divided doses, dose may be increased if necessary after 4 weeks, increased to 60 mg daily for 4–6 weeks; dose to be increased under close supervision only, then reduced to 10–20 mg daily, usual maintenance dose, but up to 40 mg daily may be required
  - Elderly: 5–10 mg daily

**INTERACTIONS** → Appendix 1: monoamine-oxidase A and B inhibitors, irreversible

**BREAST FEEDING** Avoid.

**HEPATIC IMPAIRMENT** Avoid in hepatic impairment.

**RENAL IMPAIRMENT** Use with caution.

**LESS SUITABLE FOR PRESCRIBING** Less suitable for prescribing.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS 3, 10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isocarboxazid (Non-proprietary)</td>
</tr>
<tr>
<td>Isocarboxazid 10 mg</td>
</tr>
<tr>
<td>10 tablet (Pos)</td>
</tr>
<tr>
<td>£197.95 OT price = £197.95</td>
</tr>
</tbody>
</table>

**Phenelzine**

**INDICATIONS AND DOSE**

**Depressive illness**
- **By mouth**
  - Adult: Initially 15 mg 3 times a day, response is usually seen within first week; dose may be increased if necessary after 2 weeks if response is not evident, increased if necessary to 15 mg 4 times a day, doses up to 30 mg three times a day may be used in hospital patients; response may not become apparent for up to 4 weeks; once satisfactory response has been achieved, reduce dose gradually to lowest suitable maintenance dose (15 mg on alternate days may be adequate)

**INTERACTIONS** → Appendix 1: monoamine-oxidase A and B inhibitors, irreversible

**BREAST FEEDING** Avoid—no information available.

**HEPATIC IMPAIRMENT** Avoid in hepatic impairment or if abnormal liver function tests.
346  Mental health disorders

**Antidepressants**  >  Monoamine-oxidase A inhibitors, reversible

### Moclobemide

- **Drug action**  Moclobemide is reported to act by reversible inhibition of monoamine oxidase type A (it is therefore termed a RIMA).

- **indications and dose**  
  **Depressive illness**
  - **by mouth**
  - Adult: Initially 300 mg daily in divided doses, adjusted according to response; usual dose 150–600 mg daily, dose to be taken after food.

- **Social anxiety disorder**
  - **by mouth**
  - Adult: Initially 300 mg daily for 3 days, then increased to 600 mg daily in 2 divided doses continued for 8–12 weeks to assess efficacy.

- **Dose adjustments due to interactions** Manufacturer advises reduce dose to half or one-third of the usual dose with concurrent use of cinetidine.

- **Contra-indications**  Acute confusional states - phaeochromocytoma.

- **Caution**  Avoid in agitated or excited patients (or give with sedative for up to 2–3 weeks) - may provoke manic episodes in bipolar disorders - thyrotoxicosis.

- **Interactions**  → Appendix 1: moclobemide

- **Side-effects**
  - Rare  Galactorrhoea - hyponatraemia - raised liver enzymes.
  - Frequency not known  Agitation - confusion - dizziness - dry mouth - gastrointestinal disorders - headache - oedema - paraesthesia - restlessness - skin reactions - sleep disturbances - visual disturbances.

- **Pregnancy**  Safety in pregnancy has not been established – manufacturer advises avoid unless there are compelling reasons.

- **Breast feeding**  Amount too small to be harmful, but patient information leaflet advises avoid.

- **Hepatic impairment**  Reduce dose in severe hepatic disease.

- **Treatment cessation**  Withdrawal effects may occur within 5 days of stopping treatment with antidepressant drugs; they are usually mild and self-limiting, but in some cases may be severe. The risk of withdrawal symptoms is increased if the antidepressant is stopped suddenly after regular administration for 8 weeks or more. The dose should preferably be reduced gradually over about 4 weeks, or longer if withdrawal symptoms emerge (6 months in patients who have been on long-term maintenance treatment).

- **Patient and carer advice**  Moclobemide is claimed to cause less potentiation of the pressor effect of tyramine than the traditional (irreversible) MAOIs, but patients should avoid consuming large amounts of tyramine-rich food (such as mature cheese, yeast extracts and fermented soya bean products).

- **Medicinal forms**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension.

### Tablet

- **Cautionary and advisory labels**  10, 21

  - **Moclobemide (non-proprietary)**
    - Moclobemide 150 mg  Moclobemide 150 mg tablets  | 30 tablet  
      £22.12 DT price = £22.09
    - Moclobemide 300 mg  Moclobemide 300 mg tablets  | 30 tablet  
      £15.00 DT price = £13.99

### Antidepressants  >  Noradrenaline reuptake inhibitors

### Reboxetine

- **Drug action**  Reboxetine is a selective inhibitor of noradrenaline re-uptake.

- **Indications and dose**  
  **Major depression**
  - **by mouth**
  - Adult: 4 mg twice daily for 3–4 weeks, then increased if necessary to 10 mg daily in divided doses; maximum 12 mg per day.

- **Caution**  Bipolar disorder - history of cardiovascular disease - history of epilepsy - prostatic hypertrophy - susceptibility to angle-closure glaucoma - urinary retention.

- **Interactions**  → Appendix 1: reboxetine

- **Side-effects**
  - Common or very common  Anorexia - chills - constipation - dizziness - dry mouth - headache - impaired visual accommodation - impotence - insomnia - lowering of plasma-potassium concentration on prolonged administration in the elderly - nausea - palpitation - postural hypotension - sweating - tachycardia - urinary retention - vasodilation.
  - Very rare  Angle-closure glaucoma.

- **Pregnancy**  Use only if potential benefit outweighs risk — limited information available.

- **Breast feeding**  Small amount present in milk — use only if potential benefit outweighs risk.

- **Hepatic impairment**  Initial dose 2 mg twice daily, increased according to tolerance.

- **Renal impairment**  Initial dose 2 mg twice daily, increased according to tolerance.

- **Treatment cessation**  Caution — avoid abrupt withdrawal.

- **Patient and carer advice**  
  Driving and skilled tasks  Counselling advised.

- **Medicinal forms**
  - There can be variation in the licensing of different medicines containing the same drug.

### Tablet

- **Edronax (Pfizer Ltd)**
  - Reboxetine (as Reboxetine mesilate) 4 mg  Edronax 4 mg tablets  | 60 tablet  
    £18.91 DT price = £18.91

### Antidepressants  >  Selective serotonin re-uptake inhibitors

### Selective serotonin re-uptake inhibitors

- **Drug action**  Selectively inhibit the re-uptake of serotonin (5-hydroxytryptamine, 5-HT).

- **Contra-indications**  Poorly controlled epilepsy - SSRIs should not be used if the patient enters a manic phase.
CAUTIONS Cardiac disease; concurrent electroconvulsive therapy; diabetes mellitus; epilepsy (discontinue if convulsions develop); history of bleeding disorders (especially gastro-intestinal bleeding); history of mania; susceptibility to angle-closure glaucoma

SIDE-EFFECTS
- Common or very common Abdominal pain (dose-related) • constipation (dose-related) • diarrhoea (dose-related) • dyspepsia (dose-related) • gastro-intestinal effects (dose-related) • nausea (dose-related) • vomiting (dose-related)
- Uncommon Serotonin syndrome
- Very rare Angle-closure glaucoma
- Frequency not known Anaphylaxis • angioedema • anorexia with weight loss • anxiety • arthralgia • asthma • bleeding disorders • convulsions • dizziness • drowsiness • dry mouth • dyskinesias • eczematoses • galactorrhoea • hallucinations • headache • hypersensitivity reactions • hypomania • hypotension • increased appetite • insomnia • mania • movement disorders • myalgia • nervousness • photosensitivity • pruritus • rash • sexual dysfunction • suicidal behaviour • sweating • tremor • urinary retention • urticaria • visual disturbances • weight gain

SIDE-EFFECTS, FURTHER INFORMATION
- Hypersensitivity reactions If hypersensitivity reactions (including rash) occur, consider discontinuation—may be sign of impending serious systemic reaction, possibly associated with vasculitis.

OVERDOSE Symptoms of poisoning by selective serotonin re-uptake inhibitors include nausea, vomiting, agitation, tremor, mydriasis, drowsiness, and sinus tachycardia; convulsions may occur. Rarely, severe poisoning results in the serotonin syndrome, with marked neuropsychiatric effects, neuromuscular hyperactivity, and autonomic instability; hyperthermia, rhabdomyolysis, renal failure, and coagulopathies may develop.

For details on the management of poisoning, see: Selective serotonin re-uptake inhibitors, under Emergency treatment of poisoning p. 1249.

PREGNANCY Manufacturers advise avoid during pregnancy unless the potential benefit outweighs the risk. There is a small increased risk of congenital heart defects when taken during early pregnancy. If used during the third trimester there is a risk of neonatal withdrawal symptoms, and persistent pulmonary hypertension in the newborn has been reported.

TREATMENT CESSATION Gastro-intestinal disturbances, headache, anxiety, dizziness, paraesthesia, electric shock sensation in the head, neck, and spine, tinnitus, sleep disturbances, fatigue, influenza-like symptoms, and sweating are the most common features of abrupt withdrawal of an SSRI or marked reduction of the dose; palpitation and visual disturbances can occur less commonly. The dose should be tapered over at least a few weeks to avoid these effects. For some patients, it may be necessary to withdraw treatment over a longer period; consider obtaining specialist advice if symptoms persist.

Withdrawal effects may occur within 5 days of stopping treatment with antidepressant drugs; they are usually mild and self-limiting, but in some cases may be severe. The risk of withdrawal symptoms is increased if the antidepressant is stopped suddenly after regular administration for 8 weeks or more. The dose should preferably be reduced gradually over about 4 weeks, or longer if withdrawal symptoms emerge (6 months in patients who have been on long-term maintenance treatment).

PATIENT AND CARER ADVICE
Driving and skilled tasks May also impair performance of skilled tasks (e.g. driving, operating machinery).
Escitalopram

**DRUG ACTION** Escitalopram is the active enantiomer of citalopram.

**INDICATIONS AND DOSE**

**Depressive illness** | **Generalised anxiety disorder** | **Obsessive-compulsive disorder**

- **BY MOUTH**
  - Adult: 10 mg once daily; increased if necessary up to 20 mg daily
  - Elderly: Initially 5 mg once daily; maximum 10 mg per day

**Panic disorder**

- **BY MOUTH**
  - Adult: Initially 5 mg once daily for 7 days, then increased to 10 mg daily; maximum 20 mg per day
  - Elderly: Initially 2.5 mg once daily; maximum 10 mg per day

**Social anxiety disorder**

- **BY MOUTH**
  - Adult: Initially 10 mg once daily for 2–4 weeks, dose to be adjusted after 2–4 weeks of treatment; usual dose 5–20 mg daily

**CONTRA-INDICATIONS** QT-interval prolongation

**CAUTIONS** Susceptibility to QT-interval prolongation

**INTERACTIONS** Appendix 1: SSRIs

**SIDE-EFFECTS**

- **Common or very common** Abnormal dreams, fatigue, paraesthesia, pyrexia, restlessness, sinusitis, yawning

- **Uncommon** Alopeoia, bruxism, confusion, epistaxis, menstrual disturbances, mydriasis, oedema, pruritus, syncope, tachycardia, taste disturbance, tinnitus

- **Rare** Aggression, bradycardia, depersonalisation

- **Frequency not known** Hepatitis, paradoxical increased anxiety during initial treatment of panic disorder (reduce dose), postural hypotension, QT interval prolongation, thrombocytopenia

**BREAST FEEDING** Present in breast milk; avoid.

**HEPATIC IMPAIRMENT** Initial dose 5 mg daily for 2 weeks, thereafter increased to max. 10 mg daily according to response; particular caution in severe impairment.

**RENAL IMPAIRMENT** Caution if eGFR less than 30 mL/minute/1.73m².

**DIRECTIONS FOR ADMINISTRATION** Oral drops can be mixed with water, orange juice, or apple juice before taking.

**PATIENT AND CARER ADVICE** Counselling on administration of oral drops advised.

Driving and skilled tasks

Patients should be counselled about the effects on driving.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Oral drops**

- **Escitalopram (Non-proprietary)**
  - Escitalopram (as Escitalopram oxalate) 20 mg per
  - 1 ml Escitalopram 20 mg oral drops sugar-free sugar-free | 15 ml (POM) no price available
  - **Cipralex** (Lundbeck Ltd)

- **Escitalopram (as Escitalopram oxalate) 20 mg per 1 ml Cipralex**
  - 20 mg/ml oral drops sugar-free | 15 ml (POM) £20.16

**Tablet**

- **Escitalopram (Non-proprietary)**
  - Escitalopram (as Escitalopram oxalate) 5 mg Escitalopram 5 mg tablets | 28 tablet (POM) £8.52 DT price = £1.21
  - Escitalopram (as Escitalopram oxalate) 10 mg Escitalopram 10 mg tablets | 28 tablet (POM) £14.55 DT price = £1.49
  - **Escitalopram (as Escitalopram oxalate) 20 mg Cipralex**
  - Escitalopram 20 mg tablets | 28 tablet (POM) £23.94 DT price = £1.49
  - **Cipralex** (Lundbeck Ltd)

- **Escitalopram (as Escitalopram oxalate) 5 mg** Cipralex 5 mg tablets | 28 tablet (POM) £8.97 DT price = £1.21
  - Escitalopram (as Escitalopram oxalate) 10 mg Cipralex 10 mg tablets | 28 tablet (POM) £14.91 DT price = £1.49
  - Escitalopram (as Escitalopram oxalate) 20 mg Cipralex 20 mg tablets | 28 tablet (POM) £25.20 DT price = £1.49

Fluoxetine

**INDICATIONS AND DOSE**

**Major depression**

- **BY MOUTH**
  - Adult: Initially 20 mg daily, dose is increased after 3–4 weeks if necessary, and at appropriate intervals thereafter, daily dose may be administered as a single or divided dose; maximum 60 mg per day
  - Elderly: Initially 20 mg daily, dose is increased after 3–4 weeks if necessary, and at appropriate intervals thereafter, daily dose may be administered as a single or divided dose, usual maximum dose is 40 mg daily but doses up to 60 mg daily can be used

**Bulimia nervosa**

- **BY MOUTH**
  - Adult: 60 mg daily, daily dose may be administered as a single or divided dose
  - Elderly: Up to 40 mg daily, daily dose may be administered as a single or divided dose, usual maximum dose is 40 mg daily but doses up to 60 mg daily can be used

**Obsessive-compulsive disorder**

- **BY MOUTH**
  - Adult: 20 mg daily, increased if necessary up to 60 mg daily, daily dose may be administered as a single or divided dose, dose to be increased gradually, review treatment if inadequate response after 10 weeks, maximum 60 mg per day
  - Elderly: 20 mg daily, increased if necessary up to 40 mg daily, daily dose may be administered as a single or divided dose, dose to be increased gradually, review treatment if inadequate response after 10 weeks, usual maximum dose is 40 mg daily but doses up to 60 mg daily can be used

**PHARMACOKINETICS**

Consider the long half-life of fluoxetine when adjusting dosage (or in overdosage).

**INTERACTIONS** Appendix 1: SSRIs

**SIDE-EFFECTS** Alopeoia, changes in blood sugar, chills, confusion, diarrhoea, dysphagia, dysphonia, euphoria, flushing, haemorrhage, hepatitis, hypotension, impaired concentration, malaise, neuroleptic malignant syndrome-like event, palpitation, pharyngitis, priapism, pulmonary fibrosis, pulmonary inflammation, sleep disturbances...
taste disturbance • toxic epidermal necrolysis • urinary frequency • vasodilatation • yawning

- **BREAST FEEDING** Present in milk—avoid.
- **HEPATIC IMPAIRMENT** Reduce dose or increase dose interval.
- **DIRECTIONS FOR ADMINISTRATION** Dispersible tablets can be dispersed in water for administration or swallowed whole with plenty of water.
- **PATIENT AND CARER ADVICE** Patients and carers should be counselled on the administration of dispersible tablets.

Driving and skilled tasks
Patients should be counselled about the effects on driving and skilled tasks.

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, oral suspension, oral solution

**Dispersible tablet**

**CAUTIONARY AND ADVISORY LABELS 10**

- **Olena** (AmCo)
  - Fluoxetine (as Fluoxetine hydrochloride) 20 mg: mg tablets sugar-free | 28 tablet [Disp] £3.44 DT price = £3.44

**Oral solution**

- **Fluoxetine (Non-proprietary)**
  - Fluoxetine (as Fluoxetine hydrochloride) 4 mg per 1 ml Fluoxetine 20mg/5ml oral solution | 70 ml [Disp] £2.81 DT price = £2.81
  - Fluoxetine 20mg/5ml oral solution sugar-free | 70 ml [Disp] £12.95 DT price = £12.95

- **Prozac** (Eli Lilly and Company Ltd)
  - Fluoxetine (as Fluoxetine hydrochloride) 4 mg per 1 ml Prozac 20mg/5ml liquid | 70 ml [Disp] £11.12 DT price = £2.81

- **Prozep** (Chemidex Pharma Ltd)
  - Fluoxetine (as Fluoxetine hydrochloride) 4 mg per 1 ml Prozep 20mg/5ml oral solution sugar-free | 70 ml [Disp] £12.95 DT price = £12.95

**Capsule**

- **Fluoxetine (Non-proprietary)**
  - Fluoxetine (as Fluoxetine hydrochloride) 10 mg Fluoxetine 10mg capsules | 30 capsule [Disp] £55.00–£72.00 DT price = £66.16
  - Fluoxetine (as Fluoxetine hydrochloride) 20 mg Fluoxetine 20mg capsules | 30 capsule [Disp] £20.00 DT price = £0.87
  - Fluoxetine (as Fluoxetine hydrochloride) 30 mg Fluoxetine 30mg capsules | 30 capsule [Disp] £1.80–£2.12 DT price = £2.12
  - Fluoxetine (as Fluoxetine hydrochloride) 40 mg Fluoxetine 40mg capsules | 30 capsule [Disp] £1.80–£2.16 DT price = £2.12
  - Fluoxetine (as Fluoxetine hydrochloride) 60 mg Fluoxetine 60mg capsules | 30 capsule [Disp] £54.36 DT price = £6.74

- **Oxactin** (Discovery Pharmaceuticals)
  - Fluoxetine (as Fluoxetine hydrochloride) 20 mg Oxactin 20mg capsules | 30 capsule [Disp] £0.83 DT price = £0.87

- **Prozac** (Eli Lilly and Company Ltd)
  - Fluoxetine (as Fluoxetine hydrochloride) 20 mg Prozac 20mg capsules | 30 capsule [Disp] £1.50 DT price = £0.87

---

**Fluvoxamine maleate**

**INDICATIONS AND DOSE**

**Depressive illness**

- **BY MOUTH**
  - Adult: Initially 50–100 mg daily, dose to be taken in the evening, dose to be increased gradually, increased if necessary up to 300 mg daily, doses over 150 mg daily are given in divided doses; maintenance 100 mg daily

**Obsessive-compulsive disorder**

- **BY MOUTH**
  - Adult: Initially 50 mg daily, dose to be taken in the evening, dose is increased gradually if necessary after several weeks, increased if necessary up to 300 mg daily; maintenance 100–300 mg daily, doses over 150 mg daily are given in divided doses, if no improvement in obsessive-compulsive disorder within 10 weeks, treatment should be reconsidered

**INTERACTIONS** → Appendix 1: SSRIs

**SIDE-EFFECTS**

- **Common or very common** Malaise • palpitation • tachycardia
- **Uncommon** Ataxia • confusion • postural hypotension
- **Rare** Abnormal liver function, usually symptomatic (discontinue treatment)
- **Frequency not known** Neuroleptic malignant syndrome-like event • paraesthesia • taste disturbance

- **BREAST FEEDING** Present in milk—avoid.
- **HEPATIC IMPAIRMENT** Start with low dose.
- **RENAL IMPAIRMENT** Start with low dose.
- **PATIENT AND CARER ADVICE**

Driving and skilled tasks
Patients should be counselled about the effects on driving and skilled tasks.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Tablet**

- **Fluvoxamine maleate (Non-proprietary)**
  - Fluvoxamine maleate 50 mg Fluvoxamine 50mg tablets | 60 tablet [Disp] £25.32 DT price = £20.34
  - Fluvoxamine maleate 100 mg Fluvoxamine 100mg tablets | 30 tablet [Disp] £25.32 DT price = £20.34
  - **Faverin** (BGP Products Ltd)
    - Fluvoxamine maleate 50 mg Faverin 50mg tablets | 60 tablet [Disp] £17.10 DT price = £20.34
    - Fluvoxamine maleate 100 mg Faverin 100mg tablets | 30 tablet [Disp] £17.10 DT price = £20.34

**Paroxetine**

**INDICATIONS AND DOSE**

**Major depression** | **Social anxiety disorder** | **Post-traumatic stress disorder** | **Generalised anxiety disorder**

- **BY MOUTH**
  - Adult: 20 mg daily, dose to be taken in the morning, no evidence of greater efficacy at higher doses; maximum 50 mg per day
  - Elderly: 20 mg daily, dose to be taken in the morning, no evidence of greater efficacy at higher doses; maximum 40 mg per day

**Obsessive-compulsive disorder**

- **BY MOUTH**
  - Adult: Initially 20 mg daily, dose to be taken in the morning, increased in steps of 10 mg, dose to be increased gradually, increased to 40 mg daily, no evidence of greater efficacy at higher doses; maximum 60 mg per day
  - Elderly: Initially 20 mg daily, dose to be taken in the morning, increased in steps of 10 mg, dose to be increased gradually; maximum 40 mg per day

**Panic disorder**

- **BY MOUTH**
  - Adult: Initially 10 mg daily, dose to be taken in the morning, increased in steps of 10 mg, dose to be increased gradually, increased to 40 mg daily, no evidence of greater efficacy at higher doses; maximum 60 mg per day
  - Elderly: Initially 10 mg daily, dose to be taken in the morning, increased in steps of 10 mg, dose to be increased gradually; maximum 40 mg per day

**CAUTIONS**

Achlorhydria • high gastric pH

**CAUTIONS, FURTHER INFORMATION**

Achlorhydria or high gastric pH Causes reduced absorption of the oral suspension.

**INTERACTIONS** → Appendix 1: SSRIs
PREGNANCY

Increased risk of congenital malformations, especially if used in the first trimester.

BREAST FEEDING

Present in milk but amount too small to be harmful.

HEPATIC IMPAIRMENT

Reduce dose.

RENAL IMPAIRMENT

Reduce dose if eGFR less than 30 mL/minute/1.73 m².

SIDE-EFFECTS

Associated with a higher risk of withdrawal reactions.

PATIENT AND CARER ADVICE

Driving and skilled tasks

Patients should be counselled about the effect on driving.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Tablet

CAUTIONARY AND ADVISORY LABELS

Paroxetine (as Paroxetine hydrochloride) 10 mg Paroxetine tablets | 28 tablet £17.03 DT price = £12.98
Paroxetine (as Paroxetine hydrochloride) 20 mg Paroxetine 20 mg tablets | 30 tablet £3.00 DT price = £1.56
Paroxetine (as Paroxetine hydrochloride) 30 mg Paroxetine 30 mg tablets | 30 tablet £4.04 DT price = £1.83
Paroxetine (as Paroxetine hydrochloride) 40 mg Paroxetine 40 mg tablets | 28 tablet £17.03 | 30 tablet £25.07
Sertraline (as Sertraline hydrochloride) 10 mg Sertraline tablets | 28 tablet £14.21 DT price = £12.98
Sertraline (as Sertraline hydrochloride) 50 mg Sertraline tablets | 30 tablet £55.23 DT price = £1.56
Sertraline (as Sertraline hydrochloride) 100 mg Sertraline tablets | 28 tablet £29.16 DT price = £1.26

ANTIDEPRESSANTS

SEROTONIN AND NORADRENALINE RE-UPTAKE INHIBITORS

Duloxetine

DRUG ACTION

Inhibits the re-uptake of serotonin and noradrenaline.

INDICATIONS AND DOSE

Major depressive disorder

BY MOUTH

Adult: 60 mg once daily

Generalised anxiety disorder

BY MOUTH

Adult: Initially 30 mg once daily, increased if necessary to 60 mg once daily; maximum 120 mg per day

Diabetic neuropathy

BY MOUTH

Adult: 60 mg once daily, discontinue if inadequate response after 2 months; review treatment at least every 3 months, maximum dose to be given in divided doses; maximum 120 mg per day

Moderate to severe stress urinary incontinence

BY MOUTH

Adult (female): 40 mg twice daily, patient should be assessed for benefit and tolerability after 2–4 weeks, alternatively initially 20 mg twice daily for 2 weeks, this can minimise side effects, then increased to 40 mg twice daily, the patient should be assessed for benefit and tolerability after 2–4 weeks.

CAUTIONS

Bleeding disorders · cardiac disease · elderly · history of mania · history of seizures · hypertension (avoid

350 Mental health disorders

SIDE-EFFECTS

Common or very common Abnormal dreams · raised cholesterol · yawning

Uncommon Arrhythmias · confusion · urinary incontinence

Rare Depersonalisation · neuroleptic malignant syndrome-like event · panic attacks · paradoxical increased anxiety during initial treatment of panic disorder (reduce dose) · restless legs syndrome

Very rare Acute glaucoma · hepatic disorders · hepatitis · peripheral oedema · priapism

Frequency not known Extrapyramidal reactions · orofacial dystonias · tinnitus · withdrawal reactions

PREGNANCY

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Sertraline (as Sertraline hydrochloride) 50 mg Soluble tablets | 28 tablet £19.25 DT price = £1.13
Sertraline (as Sertraline hydrochloride) 100 mg Sertraline tablets | 28 tablet £29.09 DT price = £1.26
Lustral tablets | 100 tablet £17.82 DT price = £1.13
Lustral tablets | 28 tablet £29.16 DT price = £1.26

INTERACTIONS

Appendix 1: SSRIs

SIDE-EFFECTS

Aggression · amnesia · bronchospasm · hepatitis · hypercholesterolaemia · hyperprolactinaemia · hypertension · hypoglycaemia · hypothyroidism · jaundice · leucopenia · liver failure · menstrual irregularities · palpitation · pancreatitis · paraesthesia · postural hypotension · stomatitis · tachycardia · tinnitus · urinary incontinence

BREAST FEEDING

Not known to be harmful but consider discontinuing breast-feeding.

HEPATIC IMPAIRMENT

Reduce dose or increase dose interval in mild or moderate impairment. Avoid in severe impairment.

RENAL IMPAIRMENT

Use with caution.

PATIENT AND CARER ADVICE

Driving and skilled tasks

Patients should be counselled on the effects on driving and skilled tasks.
Venlafaxine

DRUG ACTION

A serotonin and noradrenaline re-uptake inhibitor.

INDICATIONS AND DOSE

Major depression

BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

Adult: Initially 75 mg daily in 2 divided doses, then increased if necessary up to 375 mg daily, dose to be increased if necessary at intervals of at least 2 weeks, faster dose titration may be necessary in some patients; maximum 375 mg per day

BY MOUTH USING MODIFIED-RELEASE MEDICINES

Adult: Initially 75 mg once daily, increased if necessary up to 375 mg once daily, dose to be increased if necessary at intervals of at least 2 weeks, faster dose titration may be necessary in some patients; maximum 375 mg per day

Generalised anxiety disorder

BY MOUTH USING MODIFIED-RELEASE MEDICINES

Adult: 75 mg once daily, increased if necessary up to 225 mg once daily, dose to be increased at intervals of at least 2 weeks; maximum 225 mg per day

Social anxiety disorder

BY MOUTH USING MODIFIED-RELEASE MEDICINES

Adult: 75 mg once daily, there is no evidence of greater efficacy at higher doses, increased if necessary up to 225 mg once daily, dose to be increased if necessary at intervals of at least 2 weeks; maximum 225 mg per day

CONTRA-INDICATIONS

Conditions associated with high risk of cardiac arrhythmia - uncontrolled hypertension

CAUTIONS

Diabetes - heart disease (monitor blood pressure) - history of bleeding disorders - history of epilepsy - history or family history of mania - susceptibility to angle-closure glaucoma

INTERACTIONS ➔ Appendix 1: venlafaxine

SIDE-EFFECTS

Common or very common


Uncommon


Rare


Very rare

Angle-closure glaucoma

Frequency not known


Duloxetine (as Duloxetine hydrochloride) 20 mg Ventreve 20mg gastro-resistant capsules | 28 capsule [Pom] £18.48 DT price = £2.94

Duloxetine (as Duloxetine hydrochloride) 40 mg Ventreve 40mg gastro-resistant capsules | 56 capsule [Pom] £36.96 DT price = £4.89

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (September 2006) that duloxetine (Cymbalta)® should be restricted for use by specialists when other treatments for diabetic peripheral neuropathic pain are unsuitable or inadequate.
Johnson syndrome • suicidal behaviour • syndrome of inappropriate anti-diuretic hormone secretion • urticaria • vertigo

- **PREGNANCY** Avoid unless potential benefit outweighs risk—toxicity in animal studies. Risk of withdrawal effects in neonate.
- **BREAST FEEDING** Present in milk—avoid.
- **HEPATIC IMPAIRMENT** Consider reducing dose by 50% in mild or moderate impairment; use with caution and reduce dose by at least 50% in severe impairment.
- **RENAL IMPAIRMENT** Use half normal dose (immediate-release tablets may be given once daily) if eGFR less than 30 mL/minute/1.73 m². Use with caution.
- **TREATMENT CESSATION** Associated with a higher risk of withdrawal effects compared with other antidepressants. Gastro-intestinal disturbances, headache, anxiety, dizziness, paraesthesia, tremor, sleep disturbances, and sweating are most common features of withdrawal if treatment stopped abruptly or if dose reduced markedly; dose should be reduced over several weeks.
- **PATIENT AND CARER ADVICE**

Driving and skilled tasks

May affect performance of skilled tasks (e.g. driving).

- **MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Modified-release tablet**

**CAUTIONARY AND ADVISORY LABELS** 3, 21, 25

- **Venlafaxine (as Venlafaxine hydrochloride)** 75 mg Sunveniz XL 75mg tablets | 30 tablet | £11.14 DT price = £11.20 Venlafaxine (as Venlafaxine hydrochloride) 150 mg Sunveniz XL 150mg tablets | 30 tablet | £22.37 DT price = £18.70

- **Venlafex XL** (Dexcel-Pharma Ltd)

Venlafexine (as Venlafaxine hydrochloride) 75 mg Venlafex XL 75mg tablets | 28 tablet | £11.20 Venlafexine (as Venlafaxine hydrochloride) 150 mg Venlafex XL 150mg tablets | 28 tablet | £18.70

- **Venlalic XL** (Ethypharm UK Ltd)

Venlalic (as Venlafaxine hydrochloride) 37.5 mg Venlalic XL 37.5mg tablets | 30 tablet | £6.60 DT price = £6.60 Venlalic (as Venlafaxine hydrochloride) 75 mg Venlalic XL 75mg tablets | 30 tablet | £11.20 DT price = £11.20 Venlalic (as Venlafaxine hydrochloride) 150 mg Venlalic XL 150mg tablets | 30 tablet | £18.70 DT price = £18.70

- **ViePax XL** (Dexcel-Pharma Ltd)

ViePax (as Venlafaxine hydrochloride) 75 mg ViePax XL 75mg tablets | 28 tablet | £10.44 ViePax (as Venlafaxine hydrochloride) 150 mg ViePax XL 150mg tablets | 28 tablet | £17.44

**Tablet**

**CAUTIONARY AND ADVISORY LABELS** 3

- **Venlafaxine (Non-proprietary)**

Venlafaxine (as Venlafaxine hydrochloride) 37.5 mg Venlafaxine 37.5mg tablets | 56 tablet | £4.90 DT price = £1.92 Venlafaxine (as Venlafaxine hydrochloride) 75 mg Venlafaxine 75mg tablets | 56 tablet | £6.44 DT price = £2.19

- **ViePax** (Dexcel-Pharma Ltd)

ViePax (as Venlafaxine hydrochloride) 37.5 mg ViePax 37.5mg tablets | 56 tablet | £21.07 DT price = £1.92 ViePax (as Venlafaxine hydrochloride) 75 mg ViePax 75mg tablets | 56 tablet | £35.13 DT price = £2.19

**Modified-release capsule**

**CAUTIONARY AND ADVISORY LABELS** 3, 21, 25

- **Venlafaxine (Non-proprietary)**

Venlafaxine (as Venlafaxine hydrochloride) 75 mg Venlafaxine 75mg modified-release capsules | 28 capsule | no price available DT price = £22.08 Venlafaxine (as Venlafaxine hydrochloride) 150 mg Venlafaxine 150mg modified-release capsules | 28 capsule | no price available DT price = £36.81

- **Alventa XL** (Consilient Health Ltd)

Venlafaxine (as Venlafaxine hydrochloride) 75 mg Alventa XL 75mg capsules | 28 capsule | £19.12 DT price = £22.08 Venlafaxine (as Venlafaxine hydrochloride) 150 mg Alventa XL 150mg capsules | 28 capsule | £31.08 DT price = £36.81

- **Depefx XL** (Chesi Ltd)

Venlafaxine (as Venlafaxine hydrochloride) 75 mg Depefx XL 75mg capsules | 28 capsule | £10.40 DT price = £22.08 Venlafaxine (as Venlafaxine hydrochloride) 150 mg Depefx XL 150mg capsules | 28 capsule | £36.81 DT price = £36.81

- **Efexor XL** (Pfizer Ltd)

Venlafaxine (as Venlafaxine hydrochloride) 75 mg Efexor XL 75mg capsules | 28 capsule | £22.08 DT price = £22.08 Venlafaxine (as Venlafaxine hydrochloride) 150 mg Efexor XL 150mg capsules | 28 capsule | £36.81 DT price = £36.81

- **Politid XL** (Activis UK Ltd)

Venlafaxine (as Venlafaxine hydrochloride) 75 mg Politid XL 75mg capsules | 28 capsule | £23.41 DT price = £22.08 Venlafaxine (as Venlafaxine hydrochloride) 150 mg Politid XL 150mg capsules | 28 capsule | £39.03 DT price = £36.81

- **Rodomel XL** (Teva UK Ltd)

Venlafaxine (as Venlafaxine hydrochloride) 75 mg Rodomel XL 75mg capsules | 28 capsule | £17.91 DT price = £22.08 Venlafaxine (as Venlafaxine hydrochloride) 150 mg Rodomel XL 150mg capsules | 28 capsule | £29.85 DT price = £36.81

- **Tonpular XL** (Wockhardt UK Ltd)

Venlafaxine (as Venlafaxine hydrochloride) 75 mg Tonpular XL 75mg capsules | 28 capsule | £7.00 DT price = £22.08 Venlafaxine (as Venlafaxine hydrochloride) 150 mg Tonpular XL 150mg capsules | 28 capsule | £12.00 DT price = £36.81

- **Venaxxl** (AMCo)

Venlafaxine (as Venlafaxine hydrochloride) 75 mg Venaxxl 75mg capsules | 28 capsule | £10.40 DT price = £22.08 Venlafaxine (as Venlafaxine hydrochloride) 150 mg Venaxxl 150mg capsules | 28 capsule | £17.40 DT price = £36.81

- **Vencarm XL** (Aspire Pharma Ltd)

Venlafaxine (as Venlafaxine hydrochloride) 37.5 mg Vencarm XL 37.5mg capsules | 28 capsule | £5.25 Venlafaxine (as Venlafaxine hydrochloride) 75 mg Vencarm XL 75mg capsules | 28 capsule | £6.60 DT price = £6.60 Venlafaxine (as Venlafaxine hydrochloride) 150 mg Vencarm XL 150mg capsules | 28 capsule | £33.60 DT price = £33.60

- **ViePax XL** (Dexcel-Pharma Ltd)

ViePax (as Venlafaxine hydrochloride) 75 mg ViePax XL 75mg tablets | 28 tablet | £10.44 ViePax (as Venlafaxine hydrochloride) 150 mg ViePax XL 150mg tablets | 28 tablet | £17.44

**Antidepressants > Serotonin uptake inhibitors**

**Trazodone hydrochloride**

- **INDICATIONS AND DOSE**

Depressive illness (particularly where sedation is required)

- **BY MOUTH**

Adult: Initially 150 mg daily in divided doses, dose to be taken after food, alternatively initially 150 mg once daily, dose to be taken at bedtime, increased if necessary to 300 mg daily; increased if necessary to 600 mg daily in divided doses, higher dose for use in hospital patients only
SIDE-EFFECTS, FURTHER INFORMATION

Treatment should be stopped if the patient enters a manic phase. Elderly patients are particularly susceptible to many of the side-effects of tricyclic antidepressants; low initial doses should be used, with close monitoring, particularly for psychiatric and cardiac side-effects.

CONTRA-INDICATIONS Acute porphyrias p. 969 - arrhythmias - during the manic phase of bipolar disorder - heart block - immediate recovery period after myocardial infarction

CAUTIONS Cardiovascular disease - chronic constipation - diabetes - epilepsy - history of bipolar disorder - history of psychosis - hyperthyroidism (risk of arrhythmias) - increased intra-ocular pressure - patients with a significant risk of suicide - phaeochromocytoma (risk of arrhythmias) - prostatic hypertrophy - susceptibility to angle-closure glaucoma - urinary retention

CAUTIONS, FURTHER INFORMATION

Tricyclic and related antidepressants under Emergency treatment as required

Avoid during first trimester—limited information available. Monitor infant for signs of withdrawal if used until delivery.

PREGNANCY

Avoid during first trimester—limited information available. Monitor infant for signs of withdrawal if used until delivery.

BREAST FEEDING

The amount secreted into breast milk is too small to be harmful.

HEPATIC IMPAIRMENT

Sedative effects are increased in hepatic impairment. Avoid in severe liver disease.

RENA L IMPAIRMENT

Use with caution in severe impairment.

TREATMENT CESSION

Withdrawal effects may occur within 5 days of stopping treatment with antidepressant drugs; they are usually mild and self-limiting, but in some cases may be severe. The risk of withdrawal symptoms is increased if the antidepressant is stopped suddenly after regular administration for 8 weeks or more. The dose should preferably be reduced gradually over about 4 weeks, or longer if withdrawal symptoms emerge (6 months in patients who have been on long-term maintenance treatment). If possible tricyclic and related antidepressants should be withdrawn slowly.

PRESCRIBING AND DISPENSING INFORMATION

Limited quantities of tricyclic antidepressants should be prescribed at any one time because their cardiovascular and epileptogenic effects are dangerous in overdose.

PATIENT AND CARER ADVICE

Effects of alcohol enhanced.

Driving and skilled tasks

Drowsiness may affect the performance of skilled tasks (e.g. driving).

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution.

Oral solution

CAUTIONARY AND ADVISORY LABELS 2, 21

Trazodone hydrochloride (Non-proprietary)

Trazodone hydrochloride 10 mg per 1 ml

Trazodone 50mg/5ml oral solution sugar free sugar-free £205.50 DT price = £151.49

Tablet

CAUTIONARY AND ADVISORY LABELS 2, 21

Trazodone hydrochloride (Non-proprietary)

Trazodone hydrochloride 150 mg

Trazodone 150mg tablets 28 tablet DT price = £36.15 DT price = £23.60

Molipaxin (Zentiva)

Trazodone hydrochloride 150 mg

Molipaxin 150mg tablets 28 tablet DT price = £16.08 DT price = £23.60

Capsule

CAUTIONARY AND ADVISORY LABELS 2, 21

Trazodone hydrochloride (Non-proprietary)

Trazodone hydrochloride 50 mg

Trazodone 50mg capsules 84 capsule DT price = £36.20 DT price = £24.43

Trazodone hydrochloride 100 mg

Trazodone 100mg capsules 56 capsule DT price = £52.10 DT price = £23.89

Molipaxin (Zentiva)

Trazodone hydrochloride 50 mg

Molipaxin 50mg capsules 84 capsule DT price = £23.92 DT price = £24.43

Trazodone hydrochloride 100 mg

Molipaxin 100mg capsules 56 capsule DT price = £28.14 DT price = £23.89

ANTIDEPRESSANTS > TETRACYCLIC ANTIDEPRESSANTS

Mianserin hydrochloride

INDICATIONS AND DOSE

Depressive illness (particularly where sedation is required)

BY MOUTH

Adult: Initially 30–40 mg daily in divided doses, alternatively initially 30–40 mg once daily, continued →
dose to be taken at bedtime, increase dose gradually as necessary; usual dose 30–90 mg

- Elderly: Initially 30 mg daily in divided doses, alternatively initially 30 mg once daily, dose to be taken at bedtime, increase dose gradually as necessary; usual dose 30–90 mg

- **CONTRA-INDICATIONS** Acute porphyrias p. 969 · arrhythmias · during the manic phase of bipolar disorder · heart block · immediate recovery period after myocardial infarction

- **CAUTIONS** Cardiovascular disease · chronic constipation · diabetes · epilepsy · history of bipolar disorder · history of psychosis · hyperthyroidism (risk of arrhythmias) · increased intra-ocular pressure · patients with a significant risk of suicide · phaeochromocytoma (risk of arrhythmias) · prostatic hypertrophy · susceptibility to angle-closure glaucoma · urinary retention

- **SIDE-EFFECTS**

  - Very rare
  - Frequency not known

- **COMMON OR VERY COMMON** Agitation · anxiety · arrhythmia · blurred vision · confusion · dizziness · dry mouth · ECG changes · heart block · irritability · paraesthesia · postural hypotension · sleep disturbances · sudden death of patients with cardiac disease · tachycardia

- **RARE** Dysarthria · extrapyramidal symptoms · paralytic ileus · tremor · urinary retention

- **VERY RARE** Constipation · neuroleptic malignant syndrome · precipitation of angle-closure glaucoma

- **FREQUENCY NOT KNOWN** Alloppecia · anorexia · arthralgia · arthritis · blood dyscrasias · breast enlargement · changes in blood sugar · chills (on withdrawal) · convulsions · delusions · galactorrhea · gynaecomastia · haematological reactions · hallucinations · headache (on withdrawal) · hepatic reactions · hypomania · hypotenraemia · increased appetite · influenza-like symptoms (on withdrawal) · Insomnia (on withdrawal) · jaundice · mania · movement disorders (on withdrawal) · myalgia (on withdrawal) · nausea · nausaea (on withdrawal) · oedema · photosensitivity · pruritus · rash · sexual dysfunction · suicidal behaviour · sweating · sweating (on withdrawal) · taste disturbance · tinnitus · urticaria · vivid dreams (on withdrawal) · vomiting · weight gain · weight loss

- **SIDE-EFFECTS, FURTHER INFORMATION**

  Treatment should be stopped if the patient enters a manic phase.

  Elderly patients are particularly susceptible to many of the side-effects of tricyclic antidepressants; low initial doses should be used, with close monitoring, particularly for psychiatric and cardiac side-effects.

- **INTERACTIONS** → Appendix 1: mianserin

- **SIDE-EFFECTS**

  - Common or very common
  - Rare
  - Frequency not known

- **COMMON OR VERY COMMON** Abnormal dreams · agitation (on withdrawal) · anxiety · anxiety (on withdrawal) · arthralgia · confusion · dizziness · dizziness (on withdrawal) · drowsiness · dry mouth · fatigue · headache (on withdrawal) · increased appetite · insomnia · myalgia · nausea (on withdrawal) · oedema · postural hypotension · tremor · vomiting (on withdrawal) · weight gain

- **CAUTIONS**

  - Contraindications · diabetes mellitus · elderly · history of bipolar disorder · history of seizures · history of urinary retention · hypotension · psychoses (may aggravate psychotic symptoms) · susceptibility to angle-closure glaucoma

- **INTERACTIONS** → Appendix 1: mirtazapine

- **SIDE-EFFECTS**

  - Common or very common

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

- **Tablet**

  **CAUTIONARY AND ADVISORY LABELS 2, 25**

  - Mianserin hydrochloride (Non-proprietary) Mianserin hydrochloride 10 mg Mianserin 10mg tablets | 28 tablet [POT] £8.78 DT price = £8.68
  - Mianserin hydrochloride 30 mg Mianserin 30mg tablets | 28 tablet [POT] £18.34 DT price = £18.34

**Mirtazapine**

- **DRUG ACTION** Mirtazapine is a presynaptic alpha,-adrenoreceptor antagonist which increases central noradrenergic and serotonergic neurotransmission.

- **INDICATIONS AND DOSE**

  - Major depression

    - BY MOUTH

      - Adult: Initially 15–30 mg daily for 2–4 weeks, dose to be taken at bedtime, then adjusted according to response to up to 45 mg once daily, alternatively up to 45 mg daily in 2 divided doses

- **CAUTIONS**

  - Cardiac disorders · diabetes mellitus · elderly · history of bipolar depression · history of seizures · history of urinary retention · hypotension · psychoses (may aggravate psychotic symptoms) · susceptibility to angle-closure glaucoma

- **INTERACTIONS** → Appendix 1: mirtazapine

- **SIDE-EFFECTS**

  - Common or very common

- **PREGNANCY** Avoid.
Antidepressants > Tricyclic antidepressants

Amitriptyline hydrochloride

**Indications and Dose**

- **Abdominal pain or discomfort (in patients who have not responded to laxatives, loperamide, or antispasmodics)**
  - **By mouth**
  - Adult: Initially 5–10 mg daily, to be taken at night; increased in steps of 10 mg at least every 2 weeks as required; maximum 30 mg per day

- **Depressive illness (not recommended—increased risk of fatality in overdose)**
  - **By mouth**
  - Adult: Initially 75 mg daily in divided doses, alternatively initially 75 mg once daily, dose to be taken at bedtime, increased if necessary to 150–200 mg daily, dose to be increased gradually
  - Elderly: Initially 30–75 mg daily in divided doses, alternatively initially 30–75 mg once daily, dose to be taken at bedtime, increased if necessary to 150–200 mg daily, dose to be increased gradually

- **Neuropathic pain**
  - **By mouth**
  - Adult: Initially 10 mg once daily, increased if necessary to 75 mg once daily, dose to be taken at night, dose to be increased gradually, higher doses to be given on specialist advice

- **Migraine prophylaxis**
  - **By mouth**
  - Adult: Initially 10 mg once daily, then increased if necessary to 50–75 mg once daily (max. per dose 150 mg), dose to be taken at night

**Unlicensed use**

Not licensed for use in neuropathic pain. Not licensed for use in migraine prophylaxis. Not licensed for use in abdominal pain or discomfort in patients who have not responded to laxatives, loperamide, or antispasmodics.

**Contra-indications**

Acute porphyrias p. 969-arrhythmias during manic phase of bipolar disorder—heart block—immediate recovery period after myocardial infarction

**Caution**

Cardiovascular disease—chronic constipation—diabetes—epilepsy—history of bipolar disorder—history of psychosis—hyperthyroidism (risk of arrhythmias)—increased intra-ocular pressure—patients with a significant risk of suicide—phaeochromocytoma (risk of arrhythmias)—prostatic hypertrophy—susceptibility to angle-closure glaucoma—urinary retention

**Caution, Further Information**

Treatment should be stopped if the patient enters a manic phase. Elderly patients are particularly susceptible to many of the side-effects of tricyclic antidepressants; low initial doses should be used, with close monitoring, particularly for psychiatric and cardiac side-effects.

**Interactions**

Appendix 1: tricyclic antidepressants

**Side-effects**

- **Common or very common** Abdominal pain—fatigue—hypertension—mydriasis—oedema—palpitation—restlessness—stomatitis
- **Rare** Dysarthria—extrapyramidal symptoms—paralytic ileus—tremor
- **Very rare** Neuroleptic malignant syndrome—precipitation of angle-closure glaucoma
- **Frequency not known** Agitation—alopecia—anorexia—anxiety—arrhythmia—blurred vision—breast enlargement—changes in blood sugar—chills (on withdrawal)—confusion—constipation—convulsions—delusions—dizziness—

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule, oral suspension, oral solution

**Tablet**

**Cautionary and Advisory Labels** 2, 25

- **Mirtazapine (non-proprietary)**
  - Mirtazapine 15 mg Mirtazapine 15 mg tablets | 28 tablet [Pom] £7.14 DT price = £1.19
  - Mirtazapine 30 mg Mirtazapine 30 mg tablets | 28 tablet [Pom] £17.50 DT price = £1.27
  - Mirtazapine 45 mg Mirtazapine 45 mg tablets | 28 tablet [Pom] £7.14 DT price = £1.55

**Oral solution**

**Cautionary and Advisory Labels** 2

- **Mirtazapine (non-proprietary)**
  - Mirtazapine 15 mg per 1 ml Mirtazapine 15 mg/ml oral solution sugar free sugar-free | 66 ml [Pom] £49.89 DT price = £49.89

**Orodispersible tablet**

**Cautionary and Advisory Labels** 2

EXCIPIENTS: May contain Aspartame

- **Mirtazapine (non-proprietary)**
  - Mirtazapine 15 mg Mirtazapine 15 mg orodispersible tablets | 30 tablet [Pom] £19.19 DT price = £1.47
  - Mirtazapine 30 mg Mirtazapine 30 mg orodispersible tablets | 30 tablet [Pom] £19.19 DT price = £1.45
  - Mirtazapine 45 mg Mirtazapine 45 mg orodispersible tablets | 30 tablet [Pom] £19.19 DT price = £1.95

- **Zispin SolTab** (Merck Sharp & Dohme Ltd)
  - Mirtazapine 15 mg Zispin SolTab 15 mg orodispersible tablets | 30 tablet [Pom] £15.06 DT price = £1.47
  - Mirtazapine 30 mg Zispin SolTab 30 mg orodispersible tablets | 30 tablet [Pom] £15.06 DT price = £1.45
  - Mirtazapine 45 mg Zispin SolTab 45 mg orodispersible tablets | 30 tablet [Pom] £15.06 DT price = £1.95
drowsiness • dry mouth • ECG changes • galactorrhoea •
gynaecomastia • haematological reactions • hallucinations •
headache (on withdrawal) • heart block • hepatic reactions •
hypomana • hyponatraemia • increased appetite •
increased intra-ocular pressure • influenza-like symptoms
(on withdrawal) • Insomnia (on withdrawal) • irritability •
mania • movement disorders (on withdrawal) • myalgia (on
withdrawal) • nausea • nausea (on withdrawal) •
paraesthesia • photosensitivity • postural hypotension •
pruritus • rash • sexual dysfunction • sleep disturbances •
sudden death of patients with cardiac disease • suicidal
behaviour • sweating • sweating (on withdrawal) •
tachycardia • taste disturbance • tinnitus • urinary retention •
urticaria • vivid dreams (on withdrawal) • vomiting •
weight gain • weight loss

SIDE-EFFECTS, FURTHER INFORMATION
The patient should be encouraged to persist with
treatment as some tolerance to these side-effects seems to
develop. They are reduced if low doses are given initially
and then gradually increased, but this must be balanced
against the need to obtain a full therapeutic effect as soon
as possible.

Oversed
Overdose with amitriptyline is associated with a
high rate of fatality. Symptoms of overdosage
may include dry mouth, coma of varying degree,
hypotension, hypothermia, hyperreflexia, extensor planter
response, convulsions, respiratory failure, cardiac
conduction defects, and arrhythmias. Dilated pupils and
urinary retention also occur. For details on the
management of poisoning, see Tricyclic and related
antidepressants, under Emergency treatment of poisoning
p. 1249.

PREGNANCY Use only if potential benefit outweighs risk.

BREAST FEEDING The amount secreted into breast milk is
too small to be harmful.

HEPATIC IMPAIRMENT Sedative effects are increased in
hepatic impairment. Avoid in severe liver disease.

TREATMENT CESSATION Withdrawal effects may occur
within 5 days of stopping treatment with antidepressant
drugs; they are usually mild and self-limiting, but in some
cases may be severe. The risk of withdrawal symptoms is
increased if the antidepressant is stopped suddenly after
regular administration for 8 weeks or more. The dose
should preferably be reduced gradually over about 4 weeks,
or longer if withdrawal symptoms emerge (6 months in
patients who have been on long-term maintenance
treatment). If possible tricyclic and related antidepressants
should be withdrawn slowly.

PRESCRIBING AND DISPENSING INFORMATION Limited
quantities of tricyclic antidepressants should be prescribed
at any one time because their cardiovascular and
epileptogenic effects are dangerous in overdosage.

PATIENT AND CARER ADVICE Effects of alcohol enhanced.

Driving and skilled tasks
Drowsiness may affect the performance of skilled tasks
(e.g. driving).

LESS SUITABLE FOR PRESCRIBING Amitriptyline
hydrochloride is less suitable for prescribing, see Tricyclic
and related antidepressant drugs in Antidepressant drugs
p. 342.

MEDICINAL FORMS
There can be variation in the licensing of different medicines
containing the same drug. Forms available from special-order
manufacturers include: oral suspension, oral solution

Oral solution
CAUTIONARY AND ADVISORY LABELS 2

Amitriptyline hydrochloride (Non-proprietary)
Amitriptyline hydrochloride 2 mg per 1 ml Amitriptyline 10mg/5ml
oral solution sugar free sugar-free | 150 ml [PoM] £122.76 DT price =
£114.57

Amitriptyline hydrochloride 5 mg per 1 ml Amitriptyline 25mg/5ml
oral solution sugar free sugar-free | 150 ml [PoM] £18.00 DT price =
£18.00

Amitriptyline hydrochloride 10 mg per 1 ml Amitriptyline
50mg/5ml oral solution sugar free sugar-free | 150 ml [PoM] £19.20 DT
price = £19.20

Tablet

CAUTIONARY AND ADVISORY LABELS 2

Amitriptyline hydrochloride (Non-proprietary)
Amitriptyline hydrochloride 10 mg tablet [PoM] £1.12 DT price = £0.99
Amitriptyline hydrochloride 25 mg Amitriptyline 25mg tablets | 28
tablet [PoM] £1.13 DT price = £0.79
Amitriptyline hydrochloride 50 mg Amitriptyline 50mg tablets | 28
tablet [PoM] £5.99 DT price = £2.77

Amitriptyline with perphenazine
The properties listed below are those particular to the
combination only. For the properties of the components
please consider, amitriptyline hydrochloride p. 355,
perphenazine p. 370.

INDICATIONS AND DOSE
Depression with anxiety

BY MOUTH

Adult: 1 tablet 3 times a day, an additional tablet may
be taken at bedtime when required

INTERACTIONS Appendix 1: phenothiazines, tricyclic
antidepressants

LESS SUITABLE FOR PRESCRIBING Less suitable for
prescribing.

MEDICINAL FORMS
There can be variation in the licensing of different medicines
containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS 2

Triptafen (AMCo)
Perphenazine 2 mg, Amitriptyline hydrochloride 25 mg
Triptafen tablets | 100 tablet [PoM] £33.13

Clomipramine hydrochloride

INDICATIONS AND DOSE
Depressive illness

BY MOUTH

Adult: Initially 10 mg daily, then increased if necessary
to 30–150 mg daily divided doses, dose to be
increased gradually, alternatively increased if
necessary to 30–150 mg once daily, dose to be taken
at bedtime; maximum 250 mg per day

Elderly: Initially 10 mg daily, then increased to
30–75 mg daily, dose to be increased carefully over
approximately 10 days

Phobic and obsessional states

BY MOUTH

Adult: Initially 25 mg daily, then increased to
100–150 mg daily, dose to be increased gradually over
2 weeks; maximum 250 mg per day

Elderly: Initially 10 mg daily, then increased to
100–150 mg daily, dose to be increased gradually over
2 weeks; maximum 250 mg per day

Adjuvance treatment of cataplexy associated with
narcolepsy

BY MOUTH

Adult: Initially 10 mg daily, dose to be gradually
increased until satisfactory response; increased if
necessary to 10–75 mg daily
CONTRA-INDICATIONS Acute porphyrias p. 969 - arrhythmias - during the manic phase of bipolar disorder - heart block - immediate recovery period after myocardial infarction

CAUTIONS Cardiovascular disease - chronic constipation - diabetes - epilepsy - history of bipolar disorder - history of psychosis - hyperthyroidism (risk of arrhythmias) - increased intra-ocular pressure - patients with a significant risk of suicide - phaeochromocytoma (risk of arrhythmias) - prostatic hypertrophy - susceptibility to angle-closure glaucoma - urinary retention

CAUTIONS, FURTHER INFORMATION

Treatment should be stopped if the patient enters a manic phase. Elderly patients are particularly susceptible to many of the side-effects of tricyclic antidepressants; low initial doses should be used, with close monitoring, particularly for psychiatric and cardiac side-effects.

INTERACTIONS → Appendix 1: tricyclic antidepressants

SIDE-EFFECTS

Common or very common Abdominal pain - aggression - diarrhoea - fatigue - flushing - hypertension - impaired memory - muscle hypertonia - muscle weakness - mydriasis - myoclonus - restlessness - yawning

Rare Dysarthria - extrapyramidal symptoms - paralytic ileus - tremor

Very rare Allergic alveolitis - neuroleptic malignant syndrome - precipitation of angle-closure glaucoma

Frequency not known Agitation - alopecia - anorexia - anxiety - arrhythmias - blurred vision - breast enlargement - changes in blood sugar - chills (on withdrawal) - confusion - constipation - convulsions - delusions - dizziness - dry mouth - ECG changes - galactorrhoea - gynaecomastia - haematological reactions - hallucinations - headache (on withdrawal) - heart block - hepatic reactions - hypomania - hyponatraemia - increased appetite - influenza-like symptoms (on withdrawal) - insomnia (on withdrawal) - irritability - mania - movement disorders (on withdrawal) - myalgia (on withdrawal) - nausea - nausea (on withdrawal) - paraesthesia - photosensitivity - postural hypotension - pruritus - rash - sexual dysfunction - sleep disturbances - sudden death of patients with cardiac disease - suicidal behaviour - sweating - sweating (on withdrawal) - tachycardia - taste disturbance - tinnitus - urinary retention - urticaria - vivid dreams (on withdrawal) - vomiting - weight gain - weight loss

SIDE-EFFECTS, FURTHER INFORMATION

The patient should be encouraged to persist with treatment as some tolerance to these side-effects seems to develop. They are reduced if low doses are given initially and then gradually increased, but this must be balanced against the need to obtain a full therapeutic effect as soon as possible.

Overdose Tricyclic and related antidepressants cause dry mouth, coma of varying degree, hypotension, hypothermia, hyperreflexia, extensor plantar responses, convulsions, respiratory failure, cardiac conduction defects, and arrhythmias. Dilated pupils and urinary retention also occur. For details on the management of poisoning see Tricyclic and related antidepressants under Emergency treatment of poisoning p. 1249.

PREGNANCY Neonatal withdrawal symptoms reported if used during third trimester.

BREAST FEEDING The amount secreted into breast milk is too small to be harmful.

HEPATIC IMPAIRMENT Sedative effects are increased in hepatic impairment. Avoid in severe liver disease.

TREATMENT CESSATION Withdrawal effects may occur within 5 days of stopping treatment with antidepressant drugs; they are usually mild and self-limiting, but in some cases may be severe. The risk of withdrawal symptoms is increased if the antidepressant is stopped suddenly after regular administration for 8 weeks or more. The dose should preferably be reduced gradually over about 4 weeks, or longer if withdrawal symptoms emerge (6 months in patients who have been on long-term maintenance treatment). If possible antidepressant treatment should be withdrawn slowly.

PRESCRIBING AND DISPENSING INFORMATION Limited quantities of tricyclic antidepressants should be prescribed at any one time because their cardiovascular and epileptogenic effects are dangerous in overdose.

PATIENT AND CARER ADVICE Effects of alcohol enhanced. Driving and skilled tasks Drowsiness may affect the performance of skilled tasks (e.g. driving).

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Dosulepin hydrochloride

(Dothiepin hydrochloride)

INDICATIONS AND DOSE

Depressive illness, particularly where sedation is required (not recommended—increased risk of fatality in overdose) (initiated by a specialist)

BY MOUTH

Adult: Initially 75 mg daily in divided doses, alternatively initially 75 mg once daily, dose to be taken at bedtime, increased if necessary to 150 mg daily, doses to be increased gradually; up to 225 mg daily in some circumstances (e.g. hospital use)

Elderly: Initially 50–75 mg daily in divided doses, alternatively initially 50–75 mg once daily, dose to be taken at bedtime, increased if necessary to 75–150 mg daily, doses to be increased gradually; up to 225 mg daily in some circumstances (e.g. hospital use)

CONTRA-INDICATIONS Acute porphyrias p. 969 - arrhythmias - during the manic phase of bipolar disorder - heart block - immediate recovery period after myocardial infarction

CAUTIONS Cardiovascular disease - chronic constipation - diabetes - epilepsy - history of bipolar disorder - history of psychosis - hyperthyroidism (risk of arrhythmias) - increased intra-ocular pressure - patients with a significant risk of suicide - phaeochromocytoma (risk of arrhythmias) - prostatic hypertrophy - susceptibility to angle-closure glaucoma - urinary retention

CAUTIONS, FURTHER INFORMATION

Treatment should be stopped if the patient enters a manic phase. Elderly patients are particularly susceptible to many of the side-effects of tricyclic antidepressants; low initial doses should be used, with close monitoring, particularly for psychiatric and cardiac side-effects.

INTERACTIONS → Appendix 1: tricyclic antidepressants

SIDE-EFFECTS

Rare Dysarthria - extrapyramidal symptoms - paralytic ileus - tremor

Dosulepin hydrochloride (Non-proprietary)

Clomipramine hydrochloride 10 mg Clomipramine 10mg capsules

| 28 capsule POM | £6.72 DT price = £1.37

Clomipramine hydrochloride 25 mg Clomipramine 25mg capsules

| 28 capsule POM | £9.36 DT price = £1.62

Clomipramine hydrochloride 50 mg Clomipramine 50mg capsules

| 28 capsule POM | £11.76 DT price = £1.92

BNF 74 Depression 357 Nervous system
TR TREATMENT CESSATION

LESS SUITABLE FOR PRESCRIBING

HEPATIC IMPAIRMENT

PREG NTA

SIDE-EFFECTS, FURTHER INFORMATION

The patient should be encouraged to persist with treatment as some tolerance to these side-effects seems to develop. They are reduced if low doses are given initially and then gradually increased, but this must be balanced against the need to obtain a full therapeutic effect as soon as possible.

Overdose

Overdosage with dosulepin is associated with a relatively high rate of fatality. Tricyclic and related antidepressants cause dry mouth, coma of varying degree, hypotension, hypothermia, hyperreflexia, extensor plantar responses, convulsions, respiratory failure, cardiac conduction defects, and arrhythmias. Dilated pupils and urinary retention also occur. For details on the management of poisoning see Tricyclic and related antidepressants under Emergency treatment of poisoning p. 1249.

PREGNANCY

Use only if potential benefit outweighs risk.

BREAST FEEDING

The amount secreted into breast milk is too small to be harmful.

HEPATIC IMPAIRMENT

Sedative effects are increased in hepatic impairment. Avoid in severe liver disease.

TREATMENT CESSATION

Withdrawal effects may occur within 5 days of stopping treatment with antidepressant drugs; they are usually mild and self-limiting, but in some cases may be severe. The risk of withdrawal symptoms is increased if the antidepressant is stopped suddenly after regular administration for 8 weeks or more. The dose should preferably be reduced gradually over about 4 weeks, or longer if withdrawal symptoms emerge. (6 months in patients who have been on long-term maintenance treatment). If possible tricyclic and related antidepressants should be withdrawn slowly.

PRESCRIBING AND DISPENSING INFORMATION

Limited quantities of tricyclic antidepressants should be prescribed at any one time because their cardiovascular and epileptogenic effects are dangerous in overdosage.

A maximum prescription equivalent to 2 weeks' supply of 75 mg daily should be considered in patients with increased risk factors for suicide at initiation of treatment, during any dose adjustment, and until improvement occurs.

PATIENT AND CARER ADVICE

Driving and skilled tasks

Ef fects of alcohol enhanced.

LESS SUITABLE FOR PRESCRIBING

Dosulepin hydrochloride is less suitable for prescribing, see Tricyclic and related antidepressant drugs in Antidepressant drugs p. 342.

INDICATIONS AND DOSE

Depressive illness (particularly where sedation is required)

BY MOUTH

Adult: Initially 75 mg daily in divided doses, alternatively 75 mg once daily, adjusted according to response, dose to taken at bedtime; maintenance 25–300 mg daily, doses above 100 mg given in 3 divided doses

Elderly: Start with lower doses and adjust according to response

CONTRA-INDICATIONS

Acute porphyrias p. 969 • arrhythmias • during manic phase of bipolar disorder • heart block • immediate recovery period after myocardial infarction

CAUTIONS

Cardiovascular disease • chronic constipation • diabetes • epilepsy • history of bipolar disorder • history of psychosis • hyperthyroidism (risk of arrhythmias) • increased intra-ocular pressure • patients with significant risk of suicide • phaeochromocytoma (risk of arrhythmias) • prostatic hypertrophy • susceptibility to angle-closure glaucoma • urinary retention

CAUTIONS, FURTHER INFORMATION

Treatment should be stopped if the patient enters a manic phase.

Elderly

Elderly patients are particularly susceptible to many of the side-effects of tricyclic antidepressants; low initial doses should be used, with close monitoring, particularly for psychiatric and cardiac side-effects.

INTERACTIONS

Appendix 1: tricyclic antidepressants

SIDE-EFFECTS

Common or very common

Agitation • anxiety • confusion • dizziness • drowsiness • irritability • paraesthesia • sleep disturbances

Rare

Dysarthria • extrapyramidal symptoms • paralytic ileus • tremor

Very rare

Neuroleptic malignant syndrome • precipitation of angle-closure glaucoma

FREQUENCY not known

Abdominal pain • alopecia • anorexia • arrhythmia • blurred vision • breast enlargement • changes in blood sugar • chills (on withdrawal) • constipation • convulsions • delusions • diarrhoea • dry mouth • ECG changes • flushing • galactorrhoea • gynaecomastia • haematological reactions • hallucinations • headache (on withdrawal) • heart block • hepatic reactions • hypomania • hyponatraemia • increased appetite • influenza-like symptoms (on withdrawal) • insomnia (on withdrawal) • mania • movement disorders (on withdrawal) • myalgia (on

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Tablet

CAUTIONARY AND ADVISORY LABELS

Dosulepin hydrochloride 75 mg Dosulepin 75 mg tablets | 28 tablet fl. £1.70 DT price = £1.53

Prothiaden (Teofarma)

Dosulepin hydrochloride 75 mg Prothiaden 75 mg tablets | 28 tablet fl. £2.97 DT price = £1.53

Capsule

CAUTIONARY AND ADVISORY LABELS

Dosulepin hydrochloride 25 mg Dosulepin 25 mg capsules | 28 capsule fl. £3.00 DT price = £1.28

Prothiaden (Teofarma)

Dosulepin hydrochloride 25 mg Prothiaden 25 mg capsules | 28 capsule fl. £1.70 DT price = £1.28

Doxepin

www.medicalbr.com
withdrawal) • nausea • nausea (on withdrawal) • oedema • photosensitivity • postural hypotension • pruritus • rash • sexual dysfunction • stomatitis • sudden death of patients with cardiac disease • suicidal behaviour • sweating • sweating (on withdrawal) • tachycardia • taste disturbance • tinnitus • urinary retention • uralicia • vivid dreams (on withdrawal) • vomiting • weight gain • weight loss

SIDE-EFFECTS, FURTHER INFORMATION
The patient should be encouraged to persist with treatment as some tolerance to these side-effects seems to develop. They are reduced if low doses are given initially and then gradually increased, but this must be balanced against the need to obtain a full therapeutic effect as soon as possible.

Overdose
Tricyclic and related antidepressants cause dry mouth, coma of varying degree, hypotension, hypothermia, hyperreflexia, extensor plantar responses, convulsions, respiratory failure, cardiac conduction defects, and arrhythmias. Dilated pupils and urinary retention also occur. For details on the management of poisoning see Tricyclic and related antidepressants under Emergency treatment of poisoning p. 1249.

PREGNANCY
Use with caution—limited information available.

BREAST FEEDING
The amount secreted into breast milk is too small to be harmful. Accumulation of metabolite may cause sedation and respiratory depression in neonate.

HEPATIC IMPAIRMENT
Sedative effects are increased in hepatic impairment. Avoid in severe liver disease.

RENAL IMPAIRMENT
Use with caution.

TREATMENT CESSION Withdrawal effects may occur within 5 days of stopping treatment with antidepressant drugs; they are usually mild and self-limiting, but in some cases may be severe. The risk of withdrawal symptoms is increased if the antidepressant is stopped suddenly after regular administration for 8 weeks or more. The dose should preferably be reduced gradually over about 4 weeks, or longer if withdrawal symptoms emerge (6 months in patients who have been on long-term maintenance treatment). If possible tricyclic and related antidepressants should be withdrawn slowly.

PRESCRIBING AND DISPENSING INFORMATION
Limited quantities of tricyclic antidepressants should be prescribed at any one time because their cardiovascular and epileptogenic effects are dangerous in overdose.

PATIENT AND CARER ADVICE
Effects of alcohol enhanced. Driving and skilled tasks
Drowsiness may affect performance of skilled tasks (e.g. driving).

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule, oral suspension, oral solution

Capsule

CAUTIONARY AND ADVISORY LABELS

INDICATIONS AND DOSE

Depressive illness

► BY MOUTH
   Adult: Initially up to 75 mg daily in divided doses, then increased to 150–200 mg daily, up to 150 mg may be given as a single dose at bedtime, dose to be increased gradually
   Elderly: Initially 10 mg daily, increased to 30–50 mg daily, dose to be increased gradually

Depressive illness in hospital patients

► BY MOUTH
   Adult: Initially up to 75 mg daily in divided doses, dose to be increased gradually, increased to up to 300 mg daily in divided doses

Nocturnal enuresis

► BY MOUTH
   Child 6–7 years: 25 mg once daily, to be taken at bedtime, initial period of treatment (including gradual withdrawal) 3 months—full physical examination before further course
   Child 8–10 years: 25–50 mg once daily, to be taken at bedtime, initial period of treatment (including gradual withdrawal) 3 months—full physical examination before further course
   Child 11–17 years: 50–75 mg once daily, to be taken at bedtime, initial period of treatment (including gradual withdrawal) 3 months—full physical examination before further course

CONTRA-INDICATIONS
Immediate recovery period after myocardial infarction (in adults) • acute porphyrias p. 969 • arrhythmia • during the manic phase of bipolar disorder • heart block

CAUTIONS
Cardiovascular disease • chronic constipation • diabetes • epilepsy • history of bipolar disorder • history of psychosis • hyperthyroidism (risk of arrhythmias) • increased intraocular pressure (in adults) • patients with a significant risk of suicide • phaeochromocytoma (risk of arrhythmias) • prostatic hypertrophy (in adults) • susceptibility to angle-closure glaucoma • urinary retention

CAUTIONS, FURTHER INFORMATION
Treatment should be stopped if the patient enters a manic phase.

In adults Elderly patients are particularly susceptible to many of the side-effects of tricyclic antidepressants; low initial doses should be used, with close monitoring, particularly for psychiatric and cardiac side-effects.

INTERACTIONS

SIDE-EFFECTS

Common or very common
Fatigue • flushing • headache • palpitation • restlessness

Rare
Extrapyramidal symptoms • paralytic ileus

Very rare
Abdominal pain • aggression • allergic alveolitis • cardiac decompensation • diarrhoea (in children) • hypertension • mydriasis • myoclonus • neuroleptic malignant syndrome • oedema • peripheral vasospasm • precipitation of angle-closure glaucoma • stomatitis

Frequency not known
Agitation • alopecia • anorexia • anxiety • arrhythmia • blurred vision • breast enlargement • changes in blood sugar • chills (on withdrawal) • confusion • constipation • convulsions • delusions • dizziness • drowsiness • dry mouth • dysarthria • ECG changes • galactorrhoea • gynaecomastia • haematological reactions • hallucinations • headache (on withdrawal) • heart block • hepatic reactions • hypomania • hypotension • increased appetite • influenza-like symptoms (on withdrawal) • insomnia (on withdrawal) • irritability • mania • movement disorders (on withdrawal) • myalgia (on withdrawal) •
nerve system

In adults The patient should be encouraged to persist with treatment as some tolerance to these side-effects seems to develop. They are reduced if low doses are given initially and then gradually increased, but this must be balanced against the need to obtain a full therapeutic effect as soon as possible.

Overdose
Tricyclic and related antidepressants cause dry mouth, coma of varying degree, hypotension, hypothermia, hyperreflexia, extensor plantar responses, convulsions, respiratory failure, cardiac conduction defects, and arrhythmias. Dilated pupils and urinary retention also occur. For details on the management of poisoning see Tricyclic and related antidepressants under Emergency treatment of poisoning p. 1249.

Pregnancy Colic, tachycardia, dyspnoea, irritability, muscle spasms, respiratory depression and withdrawal symptoms reported in neonates when used in the third trimester.

Breast feeding The amount secreted into breast milk is too small to be harmful.

Hepatic impairment Sedative effects are increased in hepatic impairment. Avoid in severe liver disease.

Renal impairment Use with caution in severe impairment.

Treatment cessation Withdrawal effects may occur within 5 days of stopping treatment with antidepressant drugs; they are usually mild and self-limiting, but in some cases may be severe. The risk of withdrawal symptoms is increased if the antidepressant is stopped suddenly after regular administration for 8 weeks or more. The dose should preferably be reduced gradually over about 4 weeks, or longer if withdrawal symptoms emerge (6 months in patients who have been on long-term maintenance treatment). If possible tricyclic antidepressants should be withdrawn slowly.

Prescribing and dispensing information Limited quantities of tricyclic antidepressants should be prescribed at any one time because their cardiovascular and epileptogenic effects are dangerous in overdose.

Patient and carer advice Effects of alcohol enhanced. Driving and skilled tasks Drowsiness may affect the performance of skilled tasks (e.g. driving).

Medicines for Children leaflet: Imipramine www.medicinesforchildren.org.uk/imipramine

Medicinal forms

Oral solution

- Imipramine hydrochloride (Non-proprietary)
  - Imipramine hydrochloride 5 mg per 1 ml
  - Imipramine 25mg/5ml
  - Oral solution sugar free sugar-free 150 ml (PZN) £42.00 DT price = £40.38

Tablet

- Imipramine hydrochloride (Non-proprietary)
  - Imipramine hydrochloride 10 mg
  - Imipramine 10mg tablets 28 tablet (PZN) £1.01 DT price = £1.01

lofepramine

- Indications and dose
  - Depressive illness
    - By mouth
      - Adult: 140–210 mg daily in divided doses
      - Elderly: May respond to lower doses
  - Contra-indications
    - Acute porphyrias p. 969
    - Arrhythmias - during the manic phase of bipolar disorder - heart block - immediate recovery period after myocardial infarction
  - Caution
    - Cardiovascular disease - chronic constipation - diabetes - epilepsy - history of bipolar disorder - history of psychosis - hyperthyroidism (risk of arrhythmias)
    - Increased intra-ocular pressure - patients with a significant risk of suicide - phaeochromocytoma (risk of arrhythmias)
    - Prostatic hypertrophy - susceptibility to angle-closure glaucoma - urinary retention
  - Caution, Further information
    - Treatment should be stopped if the patient enters a manic phase. Elderly patients are particularly susceptible to many of the side-effects of tricyclic antidepressants; low initial doses should be used, with close monitoring, particularly for psychiatric and cardiac side-effects.
  - Interactions
    - Appendix 1: tricyclic antidepressants
  - Side-effects
    - Common or very common
      - Agitation - anxiety - confusion - dizziness - irritability - paraesthesia - postural hypotension - sleep disturbances
    - Rare
      - Extrapyramidal symptoms - paralytic ileus
    - Very rare
      - Neuroleptic malignant syndrome - precipitation of angle-closure glaucoma
    - Frequency not known
      - Allopecia - anorexia - arrhythmias - blurred vision - breast enlargement - changes in blood sugar - chills (on withdrawal) - constipation - convulsions - delusions - diarrhoea - drowsiness - dry mouth - dysartria - ECG changes - galactorrhoea - gynaecomastia - haematological reactions - hallucinations - headache - headache (on withdrawal) - heart block - hepatic reactions - hypomania - hyponatraemia - increased appetite - influenza-like symptoms (on withdrawal) - insomnia (on withdrawal) - mania - movement disorders (on withdrawal) - myalgia (on withdrawal) - nausea - nausea (on withdrawal) - oedema - photosensitivity - pruritus - rash - sexual dysfunction - sudden death of patients with cardiac disease - suicidal behaviour - sweating - sweating (on withdrawal) - tachycardia - taste disturbance - tinnitus - tremor - urinary retention - urticaria - vivid dreams (on withdrawal) - vomiting - weight gain - weight loss

Side-effects, further information

The patient should be encouraged to persist with treatment as some tolerance to these side-effects seems to develop. They are reduced if low doses are given initially and then gradually increased, but this must be balanced against the need to obtain a full therapeutic effect as soon as possible.

Overdose
Tricyclic and related antidepressants cause dry mouth, coma of varying degree, hypotension, hypothermia, hyperreflexia, extensor plantar responses, convulsions, respiratory failure, cardiac conduction defects, and arrhythmias. Dilated pupils and urinary retention also occur. Lofepramine is associated with the lowest risk of fatal overdose, in comparison with other tricyclic antidepressant drugs. For details on the management of poisoning see Tricyclic and related antidepressants under Emergency treatment of poisoning p. 1249.
### Nortriptyline

#### INDICATIONS AND DOSE

**Depressive illness**

- **By mouth**
  - Adult: To be initiated at a low dose, then increased if necessary to 75–100 mg daily in divided doses, alternatively increased if necessary to 75–100 mg once daily; maximum 150 mg per day
  - Elderly: To be initiated at a low dose, then increased if necessary to 30–50 mg daily in divided doses

**Neuropathic pain**

- **By mouth**
  - Adult: Initially 10 mg once daily, to be taken at night, increased if necessary to 75 mg daily, dose to be increased gradually; higher doses to be given under specialist supervision

#### UNLICENSED USE

Not licensed for use in neuropathic pain.

#### CONTRA-INDICATIONS

Acute porphyrias p. 969 - arrhythmias - during the manic phase of bipolar disorder - heart block - immediate recovery period after myocardial infarction

#### CAUTIONS

Cardiovascular disease - chronic constipation - diabetes - epilepsy - history of bipolar disorder - history of psychosis - hyperthyroidism (risk of arrhythmias) - increased intra-ocular pressure - patients with a significant risk of suicide - phaeochromocytoma (risk of arrhythmias) - prostatic hypertrophy - susceptibility to angle-closure glaucoma - urinary retention

#### CAUTIONS, FURTHER INFORMATION

Treatment should be stopped if the patient enters a manic phase. Elderly patients are particularly susceptible to many of the side-effects of tricyclic antidepressants; low initial doses should be used, with close monitoring, particularly for psychiatric and cardiac side-effects.

#### SIDE-EFFECTS

- **Common or very common**
  - Fatigue
  - Hypertension
  - Mydriasis
  - Restlessness

- **Rare**
  - Extrapyramidal symptoms
  - Paralytic ileus

- **Very rare**
  - Neuroleptic malignant syndrome

- **Frequency not known**
  - Acute porphyrias

#### INTERACTIONS

→ Appendix 1: tricyclic antidepressants

#### TREATMENT CESSION

Withdrawal effects may occur within 5 days of stopping treatment with antidepressant drugs; they are usually mild and self-limiting, but in some cases may be severe. The risk of withdrawal symptoms is increased if the antidepressant is stopped suddenly after regular administration for 8 weeks or more. The dose should preferably be reduced gradually over about 4 weeks, or longer if withdrawal symptoms emerge (6 months in patients who have been on long-term maintenance treatment). If possible tricyclic and related antidepressants should be withdrawn slowly.

#### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

<table>
<thead>
<tr>
<th><strong>Oral suspension</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CAUTIONARY AND ADVISORY LABELS 2</td>
</tr>
<tr>
<td><strong>Lofepramine (Non-proprietary)</strong></td>
</tr>
<tr>
<td>Lofepramine (as Lofepramine hydrochloride) 14 mg per 1 ml Lofepramine 70mg/5ml oral suspension sugar free sugar-free</td>
</tr>
<tr>
<td>Tablet</td>
</tr>
<tr>
<td>CAUTIONARY AND ADVISORY LABELS 2</td>
</tr>
<tr>
<td><strong>Lofepramine (Non-proprietary)</strong></td>
</tr>
<tr>
<td>Lofepramine (as Lofepramine hydrochloride) 70 mg Lofepramine 70mg tablets</td>
</tr>
</tbody>
</table>

#### PREGNANCY

Neonatal withdrawal symptoms and respiratory depression reported if used during third trimester.

#### BREAST FEEDING

The amount secreted into breast milk is too small to be harmful.

#### HEPATIC IMPAIRMENT

Sedative effects are increased in hepatic impairment. Avoid in severe liver disease.

#### RENAL IMPAIRMENT

Avoid in severe impairment.

<table>
<thead>
<tr>
<th><strong>TREATMENT CESSION</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Withdrawal effects may occur within 5 days of stopping treatment with antidepressant drugs; they are usually mild and self-limiting, but in some cases may be severe. The risk of withdrawal symptoms is increased if the antidepressant is stopped suddenly after regular administration for 8 weeks or more. The dose should preferably be reduced gradually over about 4 weeks, or longer if withdrawal symptoms emerge (6 months in patients who have been on long-term maintenance treatment)</td>
</tr>
</tbody>
</table>
Nervous system

PATIENT AND CARER ADVICE

▶

CONTRA-INDICATIONS

Paralytic ileus

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Tablet

CAUTIONARY AND ADVISORY LABELS

Trimipramine

INDICATIONS AND DOSE

Depressive illness (particularly where sedation required)

BY MOUTH

Adult: Initially 50–75 mg daily in divided doses, alternatively initially 50–75 mg once daily, dose to be taken at bedtime, increased if necessary to 150–300 mg daily

Elderly: Initially 10–25 mg 3 times a day, maintenance 75–150 mg daily

CONTRA-INDICATIONS

Acute porphyrias p. 969 - arrhythmias - during the manic phase of bipolar disorder - heart block - immediate recovery period after myocardial infarction

CAUTIONS

Cardiovascular disease - chronic constipation - diabetes - epilepsy - history of bipolar disorder - history of psychosis - hyperthyroidism (risk of arrhythmias) - increased intra-ocular pressure - patients with a significant risk of suicide - phaeochromocytoma (risk of arrhythmias) - prostatic hypertrophy - susceptibility to angle-closure glaucoma - urinary retention

CAUTIONS, FURTHER INFORMATION

Treatment should be stopped if the patient enters a manic phase. Elderly patients are particularly susceptible to many of the side-effects of tricyclic antidepressants; low initial doses should be used, with close monitoring, particularly for psychiatric and cardiac side-effects.

INTERACTIONS

Appendix 1: tricyclic antidepressants

SIDE-EFFECTS

Rare Paralytic ileus

Very rare Neuroleptic malignant syndrome - precipitation of angle-closure glaucoma

Frequency not known Agitation - alopecia - anorexia - anxiety - arrhythmia - blurred vision - breast enlargement - changes in blood sugar - chills (on withdrawal) - confusion - constipation - convulsions - delusions - dizziness - dry mouth - dysarthria - ECG changes - extrapyramidal symptoms - galactorrhoea - gynaecomastia - haematological reactions - hallucinations - headache (on withdrawal) - heart block - hepatic reactions - hypomania - hypotonia - increased appetite - influenza-like symptoms (on withdrawal) - insomnia (on withdrawal) - irritability - mania - movement disorders (on withdrawal) - myalgia (on withdrawal) - nausea - nausea (on withdrawal) - paraesthesia - photosensitivity - postural hypotension - pruritus - rash - sexual dysfunction - sleep disturbances - sudden death of patients with cardiac disease - suicidal behaviour - sweating - sweating (on withdrawal) - tachycardia - taste disturbance - tinnitus - tremor - urinary retention - urticaria - vivid dreams (on withdrawal) - vomiting - weight gain - weight loss

SIDE-EFFECTS, FURTHER INFORMATION

The patient should be encouraged to persist with treatment as some tolerance to these side-effects seems to develop. They are reduced if low doses are given initially and then gradually increased, but this must be balanced against the need to obtain a full therapeutic effect as soon as possible.

Overdose

Tricyclic and related antidepressants cause dry mouth, coma of varying degree, hypotension, hypothermia, hyperreflexia, extensor plantar responses, convulsions, respiratory failure, cardiac conduction defects, and arrhythmias. Dilated pupils and urinary retention also occur. For details on the management of poisoning see Tricyclic and related antidepressants under Emergency treatment of poisoning p. 1249.

PREGNANCY

Use only if potential benefit outweighs risk.

BREAST FEEDING

The amount secreted into breast milk is too small to be harmful.

HEPATIC IMPAIRMENT

Sedative effects are increased in hepatic impairment. Avoid in severe liver disease.

TREATMENT CESSATION

Withdrawing effects may occur within 5 days of stopping treatment with antidepressant drugs; they are usually mild and self-limiting, but in some cases may be severe. The risk of withdrawal symptoms is increased if the antidepressant is stopped suddenly after regular administration for 8 weeks or more. The dose should preferably be reduced gradually over about 4 weeks, or longer if withdrawal symptoms emerge (6 months in patients who have been on long-term maintenance treatment). If possible tricyclic and related antidepressants should be withdrawn slowly.

PRESCRIBING AND DISPENSING INFORMATION

Limited quantities of tricyclic antidepressants should be prescribed at any one time because their cardiovascular and epileptogenic effects are dangerous in overdose.

PATIENT AND CARER ADVICE

Effects of alcohol enhanced.

Driving and skilled tasks

Drowsiness may affect the performance of skilled tasks (e.g. driving).

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Tablet

CAUTIONARY AND ADVISORY LABELS

Trimipramine (as Trimipramine maleate) 10 mg Trimipramine 10mg tablets | 30 tablet | £1.79

Trimipramine (as Trimipramine maleate) 25 mg Trimipramine 25mg tablets | 30 tablet | £5.72

Trimipramine (as Trimipramine maleate) 50 mg Trimipramine 50mg tablets | 30 tablet | £12.93
OTHER ANTIDEPRESSANTS

Vortioxetine

**DRUG ACTION** Vortioxetine inhibits the re-uptake of serotonin (5-HT) and is an antagonist at 5-HT\(_3\) and an agonist at 5-HT\(_4\) receptors. This multimodal activity appears to be associated with antidepressant and anxiolytic-like effects.

**INDICATIONS AND DOSE**

**Major depression**

- **BY MOUTH**
  - Adult: Initially 10 mg once daily; adjusted according to response to 5–20 mg once daily
  - Elderly: Initially 5 mg once daily; increased if necessary up to 20 mg once daily

**SIDE-EFFECTS**

- **Common or very common** Abnormal dreams, constipation, diarrhea, dizziness, nausea, pruritus, vomiting
- **Rare** Flushing, night sweats
- **Frequency not known** Bleeding disorders

**PREGNANCY**

Manufacturer advises avoid unless potential benefit outweighs risk— toxicity in animal studies. If used during the later stages of pregnancy, there is a risk of neonatal withdrawal symptoms and persistent pulmonary hypertension in the newborn.

**BREAST FEEDING**

Manufacturer advises avoid— present in milk in animal studies.

**INTERACTIONS**

- **CONTRA-INDICATIONS** CNS depression, phaeochromocytoma
- **CAUTIONS** Risk factors for stroke
- **INTERACTIONS** Appendix 1: vortioxetine

**INDICATIONS AND DOSAGE**

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>DOSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major depression</td>
<td>Initially 10 mg once daily; adjusted according to response to 5–20 mg once daily</td>
</tr>
</tbody>
</table>

**INTERACTIONS**

- **CONTRA-INDICATIONS** CNS depression, phaeochromocytoma
- **CAUTIONS** Risk factors for stroke
- **INTERACTIONS** Appendix 1: vortioxetine

**CONTRA-INDICATIONS**

- CNS depression
- Phaeochromocytoma
- Risk factors for stroke

**INTERACTIONS**

- Appendix 1: vortioxetine

**3.5 Inappropriate sexual behaviour**

**ANTIPSYCHOTICS**

### Benperidol

**INDICATIONS AND DOSE**

**Control of deviant antisocial sexual behaviour**

- **BY MOUTH**
  - Adult: 0.25–1.5 mg daily in divided doses, adjusted according to response for debilitated patients, use elderly dose
  - Elderly: Initially 0.125–0.75 mg daily in divided doses, adjusted according to response

**SIDE-EFFECTS**

- **Common or very common** Abnormal dreams, constipation, diarrhea, dizziness, nausea, pruritus, vomiting
- **Rare** Flushing, night sweats
- **Frequency not known** Bleeding disorders

**PREGNANCY**

Manufacturer advises avoid unless absolutely necessary. There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant. Animal studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system. Chronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.

**BREAST FEEDING**

Manufacturer advises avoid— present in milk in animal studies.

**INTERACTIONS**

- **CONTRA-INDICATIONS** CNS depression, phaeochromocytoma
- **CAUTIONS** Risk factors for stroke
- **INTERACTIONS** Appendix 1: benperidol

**CONTRA-INDICATIONS**

- CNS depression
- Phaeochromocytoma
- Risk factors for stroke

**INTERACTIONS**

- Appendix 1: benperidol

**MEDICAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Benperidol (Non-proprietary)**
  - Benperidol 250 microgram tablets
  - 112 tablet | £117.31 DT price = £117.31
  - Anquil (Kyowa Kirin Ltd)
  - Benperidol 250 microgram tablets
  - 112 tablet | £117.31 DT price = £117.31

**Prescribing and dispensing information**

The proprietary name Benquil® has been used for benperidol tablets.
**3.6 Psychoses and schizophrenia**

**Psychoses and related disorders**

06-Mar-2017

**Advice of Royal College of Psychiatrists on doses of antipsychotic drugs above BNF upper limit**

Unless otherwise stated, doses in the BNF are licensed doses—any higher dose is therefore **unlicensed**

- Consider alternative approaches including adjuvant therapy and newer or second-generation antipsychotic drugs such as clozapine.
- Bear in mind risk factors, including obesity; particular caution is indicated in older patients, especially those over 70.
- Consider potential for drug interactions—see interactions: Appendix 1 (antipsychotics).
- Carry out ECG to exclude untoward abnormalities such as prolonged QT interval; repeat ECG periodically and reduce dose if prolonged QT interval or other adverse cardiac abnormality develops.
- Increase dose slowly and not more often than once weekly.
- Carry out regular pulse, blood pressure, and temperature checks; ensure that patient maintains adequate fluid intake.
- Consider high-dose therapy to be for limited period and review regularly; abandon if no improvement after 3 months (return to standard dosage).

**Important:** When prescribing an antipsychotic for administration on an emergency basis, the intramuscular dose should be **lower** than the corresponding oral dose (owing to absence of first-pass effect), particularly if the patient is very active (increased blood flow to muscle considerably increases the rate of absorption). The prescription should specify the dose for each route and should **not** imply that the same dose can be given by mouth or by intramuscular injection. The dose of antipsychotic for emergency use should be reviewed at least **daily**.

**Antipsychotic drugs**

Antipsychotic drugs are also known as 'neuroleptics' and (misleadingly) as 'major tranquillisers'. In the short term they are used to calm disturbed patients whatever the underlying psychopathology, which may be schizophrenia, brain damage, mania, toxic delirium, or agitated depression. Antipsychotic drugs are used to alleviate severe anxiety but this too should be a short-term measure.

**Schizophrenia**

The aim of treatment is to alleviate the suffering of the patient (and carer) and to improve social and cognitive functioning. Many patients require life-long treatment with antipsychotic medication. Antipsychotic drugs relieve positive psychotic symptoms such as thought disorder, hallucinations, and delusions, and prevent relapse; they are usually less effective on negative symptoms such as apathy and social withdrawal. In many patients, negative symptoms persist between episodes of treated positive symptoms, but earlier treatment of psychotic illness may protect against the development of negative symptoms over time. Patients with acute schizophrenia generally respond better than those with chronic symptoms.

Long-term treatment of a patient with a definitive diagnosis of schizophrenia is usually required after the first episode of illness in order to prevent relapses. Doses that are effective in acute episodes should generally be continued as prophylaxis.

First-generation antipsychotic drugs

The first-generation antipsychotic drugs act predominantly by blocking dopamine D₂ receptors in the brain. First-generation antipsychotic drugs are not selective for any of the four dopamine pathways in the brain and so can cause a range of side-effects, particularly extrapyramidal symptoms and elevated prolactin. The phenothiazine derivatives can be divided into 3 main groups:

- **Group 1:** chlorpromazine hydrochloride p. 367, levomepromazine p. 419, and promazine hydrochloride p. 386, generally characterised by pronounced sedative effects and moderate antimuscarinic and extrapyramidal side-effects.
- **Group 2:** pericyazine p. 370, generally characterised by moderate sedative effects, but fewer extrapyramidal side-effects than groups 1 or 3.
- **Group 3:** flufenazine decanoate p. 374, perphenazine p. 370, prochlorperazine p. 371, and trifluoperazine p. 372, generally characterised by fewer sedative and antimuscarinic effects, but more pronounced extrapyramidal side-effects than groups 1 and 2.

**Butyrophenones** (benperidol p. 363 and haloperidol p. 368) resemble the group 3 phenothiazines in their clinical properties. Thioxanthenes (flupentixol p. 368 and zuclopenthixol p. 373) have moderate sedative, antimuscarinic effects, and extrapyramidal effects.

**Diphenylbutyloperidines** (pimozide p. 371) and the substituted benzamides (sulpiride p. 372) have reduced sedative, antimuscarinic, and extrapyramidal effects.

**Second-generation antipsychotic drugs**

The second-generation antipsychotic drugs (sometimes referred to as atypical antipsychotic drugs) act on a range of receptors in comparison to first-generation antipsychotic drugs and have more distinct clinical profiles, particularly with regard to side-effects.

**Prescribing for the elderly**

The balance of risks and benefit should be considered before prescribing antipsychotic drugs for elderly patients. In elderly patients with dementia, antipsychotic drugs are associated with a small increased risk of mortality and an increased risk of stroke or transient ischaemic attack (see *Dementia* p. 287). Furthermore, elderly patients are particularly susceptible to postural hypotension and to hyper- and hypothermia in hot or cold weather. It is recommended that:

- Antipsychotic drugs should not be used in elderly patients to treat mild to moderate psychotic symptoms.
- Initial doses of antipsychotic drugs in elderly patients should be reduced (to half the adult dose or less), taking into account factors such as the patient’s weight, comorbidity, and concomitant medication.
- Treatment should be reviewed regularly.

**Prescribing of antipsychotic drugs in patients with learning disabilities**

When prescribing for patients with learning disabilities who are prescribed antipsychotic drugs and who are not experiencing psychotic symptoms, the following considerations should be taken into account:

- a reduction in dose or the discontinuation of long-term antipsychotic treatment;
- review of the patient’s condition after dose reduction or discontinuation of an antipsychotic drug;
- referral to a psychiatrist experienced in working with patients who have learning disabilities and mental health problems;
- annual documentation of the reasons for continuing a prescription if the antipsychotic is not reduced in dose or discontinued.

---

*BNF 74* Nervous system

---

downloaded from www.medicalbr.com
Side effects of antipsychotic drugs

Side-effects caused by antipsychotic drugs are common and contribute significantly to non-adherence to therapy.

**Extrapyramidal symptoms**

Extrapyramidal symptoms occur most frequently with the piperazine phenothiazines (fluphenazine, perphenazine, prochlorperazine, and trifluoperazine), the butyrophenones (benperidol and haloperidol), and the first-generation depot preparations. They are easy to recognise but cannot be predicted accurately because they depend on the dose, the type of drug, and on individual susceptibility.

Extrapyramidal symptoms consist of:
- **parkinsonian symptoms** (including tremor), which may occur more commonly in adults or the elderly and may appear gradually;
- **dystonia** (abnormal face and body movements) and **dyskinesia**, which occur more commonly in children or young adults and appear after only a few doses;
- **akathisia** (restlessness), which characteristically occurs after large initial doses and may resemble an exacerbation of the condition being treated;
- **tardive dyskinesia** (rhythmic, involuntary movements of tongue, face, and jaw), which usually develops on long-term therapy or with high dosage, but it may develop on short-term treatment with low doses—short-lived tardive dyskinesia may occur after withdrawal of the drug.

**Parkinsonian symptoms** remit if the drug is withdrawn and may be suppressed by the administration of antimuscarinic drugs. However, routine administration of such drugs is not justified because not all patients are affected and they may mask or worsen tardive dyskinesia.

**Tardive dyskinesia** is the most serious manifestation of extrapyramidal symptoms; it is of particular concern because it may be irreversible on withdrawing therapy and treatment is usually ineffective. In children, tardive dyskinesia is more likely to occur when the antipsychotic drug is withdrawn. However, some manufacturers suggest that drug withdrawal at the earliest signs of tardive dyskinesia (fine vermicular movements of the tongue) may halt its full development. Tardive dyskinesia occurs fairly frequently, especially in the elderly, and treatment must be carefully and regularly reviewed.

**Hyperprolactinaemia**

Most antipsychotic drugs, both first- and second-generation, increase prolactin concentration to some extent because dopamine inhibits prolactin release. Aripiprazole reduces prolactin because it is a dopamine-receptor partial agonist. Risperidone, amisulpride, and first-generation antipsychotic drugs are most likely to cause symptomatic hyperprolactinaemia. The clinical symptoms of hyperprolactinaemia include sexual dysfunction, reduced bone mineral density, menstrual disturbances, breast enlargement, and galactorrhea.

**Sexual dysfunction**

Sexual dysfunction is one of the main causes of non-adherence to antipsychotic medication; physical illness, psychiatric illness, and substance misuse are contributing factors. Antipsychotic-induced sexual dysfunction is caused by more than one mechanism. Reduced dopamine transmission and hyperprolactinaemia decrease libido; antimuscarinic effects can cause disorders of arousal; and alpha2-adrenoceptor antagonists are associated with erection and ejaculation problems in men. Risperidone and haloperidol commonly cause sexual dysfunction. If sexual dysfunction is thought to be antipsychotic-induced, dose reduction or switching medication should be considered.

**Cardiovascular side-effects**

Antipsychotic drugs have been associated with cardiovascular side-effects such as tachycardia, arrhythmias, and hypotension. QT-interval prolongation is a particular concern with pimozide and haloperidol. There is also a higher probability of QT-interval prolongation in patients using any intravenous antipsychotic drug, or any antipsychotic drug or combination of antipsychotic drugs with doses exceeding the recommended maximum. Cases of sudden death have occurred.

**Hyperglycaemia and weight gain**

Hyperglycaemia, and sometimes diabetes, can occur with antipsychotic drugs, particularly clozapine, olanzapine, quetiapine, and risperidone. All antipsychotic drugs may cause weight gain, but the risk and extent varies. Clozapine and olanzapine commonly cause weight gain.

**Hypotension and interference with temperature regulation**

Hypotension and interference with temperature regulation are dose-related side-effects that are liable to cause dangerous falls and hypothermia or hyperthermia in the elderly. Clozapine, chlorpromazine, lurasidone, and quetiapine can cause postural hypotension (especially during initial dose titration) which may be associated with syncope or reflex tachycardia in some patients.

**Neuroleptic malignant syndrome**

Neuroleptic malignant syndrome (hyperthermia, fluctuating level of consciousness, muscle rigidity, and autonomic dysfunction with pallor, tachycardia, labile blood pressure, sweating, and urinary incontinence) is a rare but potentially fatal side-effect of all antipsychotic drugs. Discontinuation of the antipsychotic drug is essential because there is no proven effective treatment, but bromocriptine and dantrolene have been used. The syndrome, which usually lasts for 5–7 days after drug discontinuation, may be unduly prolonged if depot preparations have been used.

**Blood dyscrasias**

Perform blood counts if unexplained infection or fever develops.

**Choice**

There is little meaningful difference in efficacy between each of the antipsychotic drugs (other than clozapine p. 377), and response and tolerability to each antipsychotic drug varies. There is no first-line antipsychotic drug which is suitable for all patients. Choice of antipsychotic medication is influenced by the patient’s medication history, the degree of sedation required (although tolerance to this usually develops), and consideration of individual patient factors such as risk of extrapyramidal side-effects, weight gain, impaired glucose tolerance, QT-interval prolongation, or the presence of negative symptoms.

**Negative symptoms**

Second generation antipsychotic drugs may be better at treating the negative symptoms of schizophrenia.

**Extrapyramidal side-effects**

Second-generation antipsychotic drugs should be prescribed if extrapyramidal side-effects are a particular concern. Of these, aripiprazole p. 376, clozapine, olanzapine p. 379, and quetiapine p. 382 are least likely to cause extrapyramidal side-effects. Although amisulpride p. 376 is a dopamine-receptor antagonist, extrapyramidal side-effects are less common than with the first-generation antipsychotic drugs because amisulpride selectively blocks mesolimbic dopamine receptors, and extrapyramidal symptoms are caused by blockade of the striatal dopamine pathway.

**QT interval**

Aripiprazole has negligible effect on the QT interval. Other antipsychotic drugs with a reduced tendency to prolong QT interval include amisulpride, clozapine, flupentixol p. 368, fluphenazine decanoate p. 374, olanzapine, perphenazine p. 370, prochlorperazine p. 371, risperidone p. 383, and sulpiride p. 372.

**Diabetes**

Schizophrenia is associated with insulin resistance and diabetes; the risk of diabetes is increased in patients with schizophrenia who take antipsychotic drugs. First-


### Sexual dysfunction and prolactin

The antipsychotic drugs with the lowest risk of sexual dysfunction are aripiprazole and quetiapine. Olanzapine may be considered if sexual dysfunction is judged to be secondary to hyperprolactinaemia. Hyperprolactinaemia is usually not clinically significant with aripiprazole, clozapine, olanzapine, and quetiapine treatment. When changing from other antipsychotic drugs, a reduction in prolactin concentration may increase fertility.

Patients should receive an antipsychotic drug for 4–6 weeks before it is deemed ineffective. Prescribing more than one antipsychotic drug at a time should be avoided except in exceptional circumstances (e.g. clozapine augmentation or when changing medication during titration) because of the increased risk of adverse effects such as extrapyramidal symptoms, QT-interval prolongation, and sudden cardiac death.

Clozapine is licensed for the treatment of schizophrenia in patients unresponsive to, or intolerant of, other antipsychotic drugs. Clozapine should be introduced if schizophrenia is not controlled despite the sequential use of two or more antipsychotic drugs (one of which should be a second-generation antipsychotic drug), each for at least 6–8 weeks. If symptoms do not respond adequately to an optimised dose of clozapine, plasma-clozapine concentration should be checked before adding a second antipsychotic drug to augment clozapine; allow 8–10 weeks’ treatment to assess response. Patients must be registered with a clozapine patient monitoring service.

### Monitoring

Full blood count, urea and electrolytes, and liver function test monitoring is required at the start of therapy with antipsychotic drugs, and then annually thereafter.

Blood lipids and weight should be measured at baseline, at 3 months (weight should be measured at frequent intervals during the first 3 months), and then yearly.

Fasting blood glucose should be measured at baseline, at 4–6 months, and then yearly.

Before initiating antipsychotic drugs, an ECG may be required, particularly if physical examination identifies cardiovascular risk factors, if there is a personal history of cardiovascular disease, or if the patient is being admitted as an inpatient.

Blood pressure monitoring is advised before starting therapy and frequently during dose titration of antipsychotic drugs.

### Other uses

Some antipsychotic drugs can be used for the treatment of nausea and vomiting, choreas, and motor tics. Chlorpromazine hydrochloride p. 367 and haloperidol p. 368 can be used for intractable hiccup. Benperidol p. 363 is used in deviant antisocial sexual behaviour but its value is not established.

Psychomotor agitation should be investigated for an underlying cause; it can be managed with low doses of chlorpromazine hydrochloride or haloperidol used for short periods. Antipsychotic drugs can be used with caution for the short-term treatment of severe agitation and restlessness in the elderly.

### Equivalent doses of oral antipsychotics

These equivalences are intended only as an approximate guide; individual dosage instructions should also be checked; patients should be carefully monitored after any change in medication. Equivalent daily dose of antipsychotic drug:

- Chlorpromazine 100 mg
- Clozapine 50 mg
- Haloperidol 2–3 mg
- Pimozide 2 mg
- Risperidone 0.5–1 mg
- Sulpiride 200 mg
- Trifluoperazine 5 mg

**Important:** These equivalences must not be extrapolated beyond the maximum dose for the drug. Higher doses require careful titration in specialist units and the equivalences shown here may not be appropriate.

### Dosage

After an initial period of stabilisation, in most patients, the total daily oral dose can be given as a single dose. The Royal College of Psychiatrists has published advice on doses of antipsychotic drugs above BNF upper limit.

### Antipsychotic depot injections

Long-acting depot injections are used for maintenance therapy especially when compliance with oral treatment is unreliable. However, depot injections of conventional antipsychotics may give rise to a higher incidence of extrapyramidal reactions than oral preparations; extrapyramidal reactions occur less frequently with second-generation antipsychotic depot preparations, such as risperidone p. 383 and olanzapine embonate p. 384.

### Choice

There is no clear-cut division in the use of the conventional antipsychotics, but zuclopenthixol p. 373 may be suitable for the treatment of agitated or aggressive patients whereas flupentixol decanoate p. 373 can cause over-excitement in such patients. Zuclopenthixol decanoate p. 375 may be more effective in preventing relapses than other conventional antipsychotic depot preparations. The incidence of extrapyramidal reactions is similar for the conventional antipsychotics.

### Dosage

Individual responses to neuroleptic drugs are variable and to achieve optimum effect, dosage and dosage interval must be titrated according to the patient’s response.

### Equivalent doses of depot antipsychotics

<table>
<thead>
<tr>
<th>Antipsychotic drug/interval</th>
<th>Dosage (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flupentixol decanoate / 2 weeks</td>
<td>40</td>
</tr>
<tr>
<td>Fluphenazine decanoate / 2 weeks</td>
<td>25</td>
</tr>
<tr>
<td>Haloperidol (as decanoate) / 4 weeks</td>
<td>100</td>
</tr>
<tr>
<td>Zuclopenthixol decanoate / 2 weeks</td>
<td>200</td>
</tr>
</tbody>
</table>

**Important:** These equivalences must not be extrapolated beyond the maximum dose for the drug.

These equivalences are intended only as an approximate guide; individual dosage instructions should also be checked; patients should be carefully monitored after any change in medication.

### Antipsychotics

**CAUTIONS** Blood dyscrasias · cardiovascular disease · conditions predisposing to seizures · depression · diabetes (may raise blood glucose) · epilepsy · history of jaundice · myasthenia gravis · Parkinson’s disease (may be exacerbated)(in adults) · photosensitisation (may occur with higher dosages) · prostatic hypertrophy (in adults) ·

---

*BNF 74* Mental health disorders

---

*downloaded from [www.medicalbr.com](http://www.medicalbr.com)*
Patients with schizophrenia should have physical health monitoring at the start of therapy, at 6 months, and then yearly. Patients taking antipsychotic drugs not normally associated with symptomatic hyperprolactinaemia should be considered for prolactin monitoring if they show symptoms of hyperprolactinaemia (such as breast enlargement and galactorrhoea).

Patients with schizophrenia should have physical health monitoring (including cardiovascular disease risk assessment) at least once per year.

In children Regular clinical monitoring of endocrine function should be considered when children are taking an antipsychotic drug known to increase prolactin levels; this includes measuring weight and height, assessing sexual maturation, and monitoring menstrual function.

TREATMENT CESSION There is a high risk of relapse if medication is stopped after 1–2 years. Withdrawal of antipsychotic drugs after long-term therapy should always be gradual and closely monitored to avoid the risk of acute withdrawal syndromes or rapid relapse. Patients should be monitored for 2 years after withdrawal of antipsychotic medication for signs and symptoms of relapse.

PATIENT AND CARER ADVICE As photosensitisation may occur with higher dosages, patients should avoid direct sunlight.

Driving and skilled tasks Drowsiness may affect performance of skilled tasks (e.g. driving or operating machinery), especially at start of treatment; effects of alcohol are enhanced.

Antipsychotics, First-generation

Chlorpromazine hydrochloride

INDICATIONS AND DOSE

Schizophrenia and other psychoses | Mania | Short-term adjunctive management of severe anxiety | Psychomotor agitation, excitement, and violent or dangerously impulsive behaviour

BY MOUTH

Adult: Initially 25 mg 3 times a day, adjusted according to response, alternatively initially 75 mg once daily, adjusted according to response, dose to be taken at night; maintenance 75–300 mg daily, increased if necessary up to 1 g daily, this dose may be required in psychoses; use a third to half adult dose in the elderly or debilitated patients

BY RECTUM

Adult: 100 mg every 6–8 hours, dose expressed as chlorpromazine base

Intractable hiccup

BY MOUTH

Adult: 25–50 mg 3–4 times a day

Relief of acute symptoms of psychoses (under expert supervision)

BY DEEP INTRAMUSCULAR INJECTION

Adult: 25–50 mg every 6–8 hours

Nausea and vomiting of terminal illness (where other drugs have failed or are not available)

BY MOUTH

Child 1–5 years: 500 micrograms/kg every 4–6 hours; maximum 40 mg per day

Child 6–11 years: 500 micrograms/kg every 4–6 hours; maximum 75 mg per day

Child 12–17 years: 10–25 mg every 4–6 hours

Adult: 10–25 mg every 4–6 hours

BY DEEP INTRAMUSCULAR INJECTION

Child 1–5 years: 500 micrograms/kg every 6–8 hours; maximum 40 mg per day

Child 6–11 years: 500 micrograms/kg every 6–8 hours; maximum 75 mg per day

Child 12–17 years: Initially 25 mg, then 25–50 mg every 3–4 hours until vomiting stops

Adult: Initially 25 mg, then 25–50 mg every 3–4 hours until vomiting stops

BY RECTUM

Adult: 100 mg every 6–8 hours

DOSE ADJUSTMENTS DUE TO INTERACTIONS

Dose adjustment may be necessary if smoking started or stopped during treatment.

DOSE EQUIVALENCE AND CONVERSION

For equivalent therapeutic effect 100 mg chlorpromazine base given rectally as a suppository = 20–25 mg chlorpromazine hydrochloride by intramuscular injection = 40–50 mg of chlorpromazine base or hydrochloride given by mouth.
RENAL IMPAIRMENT
Start with small doses in severe renal impairment because of increased cerebral sensitivity.

HANDLING AND STORAGE
Owing to the risk of contact sensitisation, pharmacists, nurses, and other health workers should avoid direct contact with chlorpromazine; tablets should not be crushed and solutions should be handled with care.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, capsule, oral suspension, oral solution, suppository.

Table
CAUTIONARY AND ADVISORY LABELS 2, 11
- Chlorpromazine hydrochloride (Non-proprietary)
  Chlorpromazine hydrochloride 25 mg Chlorpromazine 25 mg tablets | 28 tablet [PO] £4.92 DT price = £1.70
  Chlorpromazine hydrochloride 50 mg Chlorpromazine 50 mg tablets | 28 tablet [PO] £5.28 DT price = £1.74
  Chlorpromazine hydrochloride 100 mg Chlorpromazine 100 mg tablets | 28 tablet [PO] £5.70 DT price = £1.78

Solution for injection
- Largactil (Sanofi)
  Chlorpromazine hydrochloride 25 mg per 1 ml Largactil 50 mg/2 ml solution for injection ampoules | 10 ampoule [PO] £7.51

Oral solution
CAUTIONARY AND ADVISORY LABELS 2, 11
- Chlorpromazine hydrochloride (Non-proprietary)
  Chlorpromazine hydrochloride 5 mg per 1 ml Chlorpromazine 25 mg/5 ml syrup | 150 ml [PO] £2.35 DT price = £2.35
  Chlorpromazine 25 mg/5 ml oral solution sugar free sugar-free | 150 ml [PO] £2.35 DT price = £2.35
  Chlorpromazine 25 mg/5 ml oral solution | 150 ml [PO] £2.35 DT price = £2.35
  Chlorpromazine hydrochloride 20 mg per 1 ml Chlorpromazine 100 mg/5 ml oral solution | 150 ml [PO] £5.50 DT price = £5.50

Flupentixol
(Flupenthixol)

INDICATIONS AND DOSE
Schizophrenia and other psychoses, particularly with apathy and withdrawal but not mania or psychomotor hyperactivity
- BY MOUTH
  - Adult: Initially 3–9 mg twice daily, adjusted according to response, for debilitated patients, use elderly dose; maximum 18 mg per day
  - Elderly: Initially 0.75–4.5 mg twice daily, adjusted according to response

Depressive illness
- BY MOUTH
  - Adult: Initially 1 mg once daily, dose to be taken in the morning, increased if necessary to 2 mg after 1 week, doses above 2 mg to be given in divided doses, last dose to be taken before 4 pm; discontinue if no response after 1 week at maximum dosage; maximum 3 mg per day
  - Elderly: Initially 500 micrograms daily, dose to be taken in the morning, then increased if necessary to 1 mg after 1 week, doses above 1 mg to be given in divided doses, last dose to be taken before 4 pm; discontinue if no response after 1 week at maximum dosage; maximum 1.5 mg per day

CONTRA-INDICATIONS
Circulatory collapse · CNS depression · comatose states · excitable patients · impaired consciousness · overactive patients · phaeochromocytoma

CAUTIONS
Acute porphyrias p. 969 · cardiac disorders · cardiovascular disease · cerebral arteriosclerosis · elderly · parkinsonism · QT-interval prolongation · senile confusional states

INTERACTIONS
Appendix 1: flupentixol

SIDE-EFFECTS
Asthenia · dyspnoea · hypersalivation · myalgia · sudden death · tarsode pointes
SIDE-EFFECTS, FURTHER INFORMATION
Less sedating but extrapyramidal symptoms frequent.

PREGNANCY
Avoid unless potential benefit outweighs risk.

BREAST FEEDING
Present in breast milk—avoid.

HEPATIC IMPAIRMENT
Can precipitate coma. Consider serum-flupentixol concentration monitoring in hepatic impairment.

RENAL IMPAIRMENT
Start with small doses of antipsychotic drugs in severe renal impairment because of increased cerebral sensitivity. Manufacturer advises caution in renal failure.

PATIENT AND CARER ADVICE
Although drowsiness may occur, can also have an alerting effect so should not be taken in the evening.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Table
CAUTIONARY AND ADVISORY LABELS 2
- Depixol (Flupentixol dihydrochloride) (Lundbeck Ltd)
  Flupentixol (as Flupentixol dihydrochloride) 3 mg Depixol 3 mg tablets | 100 tablet [PO] £13.92 DT price = £13.92
  Flupentixol (as Flupentixol dihydrochloride) 500 microgram Fluanxol 500 microgram tablets | 60 tablet [PO] £2.88 DT price = £2.88
  Flupentixol (as Flupentixol dihydrochloride) 1 mg Fluanxol 1 mg tablets | 60 tablet [PO] £4.86 DT price = £4.86

Haloperidol

INDICATIONS AND DOSE
Nausea and vomiting
- BY INTRAMUSCULAR INJECTION
  - Adult: 1–2 mg

Nausea and vomiting in palliative care
- BY MOUTH
  - Adult: Initially 1.5 mg 1–2 times a day, increased if necessary to 5–10 mg daily in divided doses
  - BY CONTINUOUS SUBCUTANEOUS INFUSION
  - Adult: 5–15 mg, to be administered over 24 hours
  - BY SUBCUTANEOUS INFUSION
  - Adult: 2.5–10 mg/24 hours
Schizophrenia | Psychoses | Mania and hypomania | Organic brain damage (depending on symptoms)

- **BY MOUTH**
  - Adult: Initially 2–20 mg once daily, alternatively initially 2–20 mg daily in divided doses; maintenance 1–3 mg 3 times a day, adjusted according to response, daily maximum to be given in divided doses, for debilitated patients, use elderly dose; maximum 20 mg per day
  - Elderly: Initially 1–10 mg once daily, alternatively initially 1–10 mg daily in divided doses; maintenance 1–3 mg 3 times a day, adjusted according to response, daily maximum to be given in divided doses; maximum 20 mg per day
- **BY INTRAMUSCULAR INJECTION**
  - Adult: Initially 2–5 mg, repeated if necessary, repeated dose given according to response and tolerability, for debilitated patients, use elderly dose; maximum 12 mg per day
  - Elderly: Initially 1–2.5 mg, repeated if necessary, repeated dose given according to response and tolerability; maximum 12 mg per day

**Agitation and restlessness in the elderly**

- **BY MOUTH**
  - Elderly: Initially 0.75–1.5 mg 2–3 times a day, adjusted according to response, if necessary

Management of mental or behavioural problems such as aggression, hyperactivity and self-mutilation in patients with intellectual disabilities and in patients with organic brain damage (depending on symptoms) | Gilles de la Tourette syndrome | Severe tics | Intractable hiccup | Adjunct to short-term management of moderate to severe psychomotor agitation, excitement and, violent or dangerously impulsive behaviour

- **BY MOUTH**
  - Adult: Initially 1.5–3 mg 2–3 times a day, alternatively initially 3–5 mg 2–3 times a day, higher dose in severely affected or resistant patients; maintenance 0.5–1 mg 3 times a day, increased if necessary to 2–3 mg 3 times a day, once symptoms are controlled, gradually reduce dose to the lowest effective maintenance dose, for debilitated patients, use elderly dose
  - Elderly: Initially 0.75–1.5 mg 2–3 times a day, alternatively initially 1.5–2.5 mg 2–3 times a day, higher dose in severely affected or resistant patients; maintenance 0.5–1 mg 3 times a day, increased if necessary to 2–3 mg 3 times a day, once symptoms are controlled, gradually reduce dose to the lowest effective maintenance dose

**Restlessness and confusion in palliative care**

- **BY MOUTH**
  - Adult: 2 mg, then 2 mg every 2 hours if required
  - **BY SUBCUTANEOUS INJECTION**
    - Adult: 2.5 mg, then 2.5 mg every 2 hours if required
  - **BY SUBCUTANEOUS INFUSION**
    - Adult: 5–15 mg/24 hours

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**

Dose adjustment may be necessary if smoking started or stopped during treatment.

- **UNLICENSED USE** BNF doses for schizophrenia, psychoses, mania, hypomania, and organic brain damage differ from those in product literature.

**IMPORTANT SAFETY INFORMATION**

When prescribing, dispensing or administering, check that this injection is the correct preparation—this preparation is usually used in hospital for the rapid control of an acute episode and should not be confused with depot preparations which are usually used in the community or clinics for maintenance treatment.

**CONTRA-INDICATIONS** Bradycardia · CNS depression · comatose states · lesions of the basal ganglia · Parkinson’s disease · phaeochromocytoma · QT-interval prolongation

**CAUTIONS** Arteriosclerosis · hypocalcaemia · hypokalaemia · hypomagnesaemia · metabolic disturbances · subarachnoid haemorrhage · thyrotoxicosis

**INTERACTIONS** Appendix 1: haloperidol

**SIDE-EFFECTS**

- Common or very common Depressions · weight loss
- Uncommon Dyspnoea · oedema
- Rare Bronchospasm · hypoglycaemia · inappropriate antidiuretic hormone secretion · photosensitivity reactions · pigmentation

- Frequency not known Hypertension · Stevens-Johnson syndrome · sweating · toxic epidermal necrolysis SIDE-EFFECTS, FURTHER INFORMATION

Less sedating and fewer antimuscarinic or hypotensive symptoms.

**PREGNANCY** Avoid unless benefits outweigh risks.

**HEPATIC IMPAIRMENT** Can precipitate coma.

**RENAL IMPAIRMENT** Start with small doses in severe renal impairment because of increased cerebral sensitivity.

**MONITORING REQUIREMENTS** Baseline ECG required before treatment—assess need for further ECGs during treatment on an individual basis.

**PRESCRIBING AND DISPENSING INFORMATION**

Palliative care

For further information on the use of haloperidol in palliative care, see www.palliativedrugs.com/formulary/en/haloperidol.html.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Tablet**

CAUTIONARY AND ADVISORY LABELS 2

- Haloperidol (Non-proprietary)
  - Haloperidol 500 microgram tablet | 28 tablet | £22.05 DT price = £22.05
  - Haloperidol 1.5 mg tablet | 28 tablet | £5.99 DT price = £1.78
  - Haloperidol 5 mg tablet | 28 tablet | £3.80 DT price = £2.10
  - Haloperidol 10 mg tablet | 28 tablet | £12.99 DT price = £12.96

**Solution for injection**

- Haloperidol (Non-proprietary)
  - Haloperidol 5 mg per 1 ml solution for injection ampoules | 10 ampoule | £35.00 DT price = £35.00

**Oral solution**

CAUTIONARY AND ADVISORY LABELS 2

- Haloperidol (Non-proprietary)
  - Haloperidol 200 microgram per 1 ml | 200 micrograms/ml oral solution sugar free sugar-free | 200 ml | £195.00
  - Haloperidol 1 mg per 1 ml | 100 ml | £35.99 DT price = £6.47 sugar-free | 500 ml | £32.35
  - Haloperidol 2 mg per 1 ml | 100 ml | £46.75 DT price = £7.10 sugar-free | 500 ml | £35.50
  - Haldol (Janssen-Cilag Ltd)
  - Haloperidol 2 mg per 1 ml | 100 ml | £4.45 DT price = £7.10

**Capsule**

CAUTIONARY AND ADVISORY LABELS 2

- Serenace (Teva UK Ltd)
  - Haloperidol 500 microgram capsules | 30 capsule | £1.18 DT price = £1.18
Loxapine

25-Apr-2017

**DRUG ACTION** Loxapine is a dopamine D<sub>2</sub> and serotonin 5-HT<sub>2A</sub> receptor antagonist. It also binds to noradrenergic, histaminergic, and cholinergic receptors.

**INDICATIONS AND DOSE**

Rapid control of mild-to-moderate agitation in patients with schizophrenia or bipolar disorder (specialist supervision in hospital)

- **BY INHALATION**
  - Adult: 9.1 mg as a single dose, followed by 9.1 mg after 2 hours if required, alternatively 4.5 mg as a single dose, followed by 4.5 mg after 2 hours if required, lower dose may be given if more appropriate or if the higher dose not previously tolerated.

**CONTRA-INDICATIONS** Acute respiratory symptoms - asthma - cardiovascular disease - cerebrovascular disease - chronic obstructive pulmonary disease - dehydration - risk of hypotension - elderly patients (especially those with dementia-related psychosis) - hypovolaemia - risk of hypotension

**CAUTIONS** Bronchodilator treatment should be available for treatment of possible severe respiratory side-effects (bronchospasm) - history of extrapyramidal symptoms - risk factors for hyperventilation

**INTERACTIONS** → Appendix 1: loxapine

**SIDE-EFFECTS**

- Common or very common Dysgeusia - malaise - throat irritation
- Uncommon Bronchospasm - oculogyration
- PREGNANCY Manufacturer advises use only if potential benefit outweighs risk.
- BREAST FEEDING Manufacturer advises to avoid for 48 hours after dose (express and discard milk produced during this time) - present in milk in animal studies.
- MONITORING REQUIREMENTS Manufacturer advises to observe patient during the first hour after each dose for signs and symptoms of bronchospasm.
- DIRECTIONS FOR ADMINISTRATION Manufacturer advises remove pull-tab and wait for green light to turn on (product must be used within 15 minutes of pulling tab); instruct patient to inhale through mouthpiece and then hold breath briefly. When green light turns off, this indicates the dose has been delivered.

**PRESCRIBING AND DISPENSING INFORMATION** Educational risk minimisation materials are available for healthcare professionals.

*Adasuve*<sup>®</sup> 4.5 mg inhalation powder may be difficult to obtain.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from specialist-order manufacturers include: oral suspension, oral solution

**Oral solution**

- **CAUTIONARY AND ADVISORY LABELS** 2
  - Pericyazine (Non-proprietary) Pericyazine 2 mg per 1 ml Pericyazine 10mg/5ml oral solution | 100 ml £46.00-£46.01 DT price = £46.01

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS** 2
  - Pericyazine (Non-proprietary) Pericyazine 2.5 mg Pericyazine 2.5mg tablets | 84 tablet £15.87 DT price = £15.87
  - Pericyazine 10 mg Pericyazine 10mg tablets | 84 tablet £40.12 DT price = £40.12

Pericyazine

(Pericazine)

**INDICATIONS AND DOSE**

Schizophrenia | Psychoses

- **BY MOUTH**
  - Adult: Initially 75 mg daily in divided doses, then increased in steps of 25 mg every week, adjusted according to response; maximum 300 mg per day

**INTERACTIONS** → Appendix 1: phenothiazines

**SIDE-EFFECTS**

- Rare Systemic lupus erythematosus
- **FREQUENCY NOT KNOWN** Dystonic reactions

**CONTRA-INDICATIONS** Agitation in the elderly - CNS depression - comatose states - phaeochromocytoma - restlessness in the elderly

**CAUTIONS** Hypothyroidism

**SIDE-EFFECTS, FURTHER INFORMATION**

Less sedating.

Acute dystonic reactions Phenothiazines can all induce acute dystonic reactions such as facial and skeletal muscle spasms and oculogyric crises; children (especially girls,
young women, and those under 10 kg) are particularly susceptible.

- **Hepatic Impairment** Can precipitate coma; phenothiazines are hepatotoxic.
- **Renal Impairment** Start with small doses in severe renal impairment because of increased cerebral sensitivity.

**Medicinal Forms**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, oral suspension

**Pimozide**

- **Indications and Dose**

  **Schizophrenia**
  - **By Mouth**
    - Adult: Initially 4 mg daily, adjusted according to response, then increased in steps of 2–4 mg at intervals of not less than 1 week; maximum 16 mg per day
    - Elderly: Initially 2 mg daily, adjusted according to response, increased in steps of 2–4 mg at intervals of not less than 1 week; usual dose 2–20 mg daily
  
  **Monosymptomatic hypochondriacal psychosis | Paranoid psychoses**
  - **By Mouth**
    - Adult: Initially 4 mg daily, adjusted according to response, then increased in steps of 2–4 mg at intervals of not less than 1 week; maximum 16 mg per day
    - Elderly: Initially 2 mg daily, adjusted according to response, increased in steps of 2–4 mg at intervals of not less than 1 week; maximum 16 mg per day

- **Contra-Indications**

  CNS depression, comatose states, history of arrhythmias, history or family history of congenital QT prolongation, phaeochromocytoma

- **Interactions** → Appendix 1: pimozide

- **Side-Effects**

  - Rare
    - Hyponatraemia
  - Frequency not known
    - Glycosuria, serious arrhythmias

- **Side-Effects, Further Information**

  Less sedating.

- **Hepatic Impairment** Can precipitate coma.
- **Renal Impairment** Start with small doses in severe renal impairment because of increased cerebral sensitivity.

- **Monitoring Requirements**

  ECG monitoring

  Following reports of sudden unexplained death, an ECG is recommended before treatment. It is also recommended that patients taking pimozide should have an annual ECG (if the QT interval is prolonged, treatment should be reviewed and either withdrawn or dose reduced under close supervision) and that pimozide should not be given with other antipsychotic drugs (including depot preparations), tricyclic antidepressants or other drugs which prolong the QT interval, such as certain antimalarials, antiarrhythmic drugs and certain antihistamines and should not be given with drugs which cause electrolyte disturbances (especially diuretics).

- **Medicinal Forms**

  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

  **Tablet**

  **CAUTIONARY AND ADVISORY LABELS** 2

  - **Pimozide (Non-proprietary)**
    - Pimozide 4 mg: Pimozide 4mg tablets: 100 tablet £0.40.31
    - Orap (Eumedica Pharmaceuticals)
      - Pimozide 4 mg Orap 4mg tablets: 100 tablet £0.40.31

**Prochlorperazine**

- **Indications and Dose**

  **Schizophrenia and other psychoses | Mania**
  - **By Mouth**
    - Adult: 12.5 mg twice daily for 7 days, dose to be adjusted at intervals of 4–7 days according to response; usual dose 75–100 mg daily
    - **By Deep Intramuscular Injection**
      - Adult: 12.5–25 mg 2–3 times a day
  
  **Short-term adjunctive management of severe anxiety**
  - **By Mouth**
    - Adult: 15–20 mg daily in divided doses; maximum 40 mg per day
  
  **Nausea and vomiting, acute attack**
  - **By Mouth**
    - Adult: Initially 20 mg, then 10 mg after 2 hours
    - **By Deep Intramuscular Injection**
      - Adult: 12.5 mg as required, to be followed if necessary after 6 hours by an oral dose
  
  **Nausea and vomiting, prevention**
  - **By Mouth**
    - Adult: 5–10 mg 2–3 times a day
    - **By Deep Intramuscular Injection**
      - Adult: 12.5 mg as required, to be followed if necessary after 6 hours by an oral dose
  
  **Prevention and treatment of nausea and vomiting**
  - **By Mouth**
    - Child 1–11 years (body-weight 10 kg and above): 250 micrograms/kg 2–3 times a day
    - Child 12–17 years: 5–10 mg up to 3 times a day if required
    - **By Intramuscular Injection**
      - Child 2–4 years: 1.25–2.5 mg up to 3 times a day if required
      - Child 5–11 years: 5–6.25 mg up to 3 times a day if required
      - Child 12–17 years: 12.5 mg up to 3 times a day if required
  
  **Labyrinthine disorders**
  - **By Mouth**
    - Adult: 5 mg 3 times a day, increased if necessary to 30 mg daily in divided doses, dose to be increased gradually, then reduced to 5–10 mg daily, dose is reduced after several weeks
    - **By Intramuscular Injection**
      - Child 12–17 years: 3–6 mg twice daily, tablets to be placed high between upper lip and gum and left to dissolve
    - Adult: 3–6 mg twice daily, tablets to be placed high between upper lip and gum and left to dissolve
  
  **Dose Equivalence and Conversion**

  - Doses are expressed as prochlorperazine maleate or mesilate; 1 mg prochlorperazine maleate = 1 mg prochlorperazine mesilate.

- **Unlicensed Use**


- **Contra-Indications**

  Avoid oral route in child under 10 kg
  - children (in psychotic disorders) - CNS depression, comatose states, phaeochromocytoma

- **Caution**

  Elderly - hypotension (more likely after intramuscular injection)

- **Interactions** → Appendix 1: phenothiazines

- **Side-Effects**

  Dystonic reactions - respiratory depression may occur in susceptible patients

  **Side-Effects, Further Information**

  Acute dystonic reactions Phenothiazines can all induce acute dystonic reactions such as facial and skeletal muscle

  [downloaded from www.medicalbr.com]
spasms and oculogyric crises; children (especially girls, young women, and those under 10 kg) are particularly susceptible.

- **HEPATIC IMPAIRMENT** Can precipitate coma; phenothiazines are hepatotoxic.
- **RENAL IMPAIRMENT** Start with small doses in severe renal impairment because of increased cerebral sensitivity.
- **DIRECTIONS FOR ADMINISTRATION** Buccal tablets are placed high between upper lip and gum and left to dissolve.
- **PATIENT AND CARER ADVICE** Patients or carers should be given advice on how to administer prochlorperazine buccal tablets.

### MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- **Prochlorperazine (Non-proprietary)**
  - Prochlorperazine maleate 5 mg | 28 tablet | £1.31 DT price = £0.97 | 84 tablet | £3.93
  - Stemetil (Sanofi)
  - Prochlorperazine maleate 5 mg | 28 tablet | £1.98 DT price = £0.97 | 84 tablet | £5.94

**Buccal tablet**
- **Prochlorperazine (Non-proprietary)**
  - Prochlorperazine mesilate 12.5 mg per 1 ml | 10 ampoule | £35.94 DT price = £43.13
  - Stemetil (Sanofi)
  - Prochlorperazine mesilate 12.5 mg per 1 ml | 10 amppoule | £5.23 DT price = £5.23

**Oral solution**
- **Prochlorperazine (Non-proprietary)**
  - Prochlorperazine mesilate 1 mg per 1 ml | 100 ml | £3.34 DT price = £3.34

### Sulpiride
#### INDICATIONS AND DOSE

**Schizophrenia with predominantly negative symptoms**
- **BY MOUTH**
  - Adult: 200–400 mg twice daily; maximum 800 mg per day
  - Elderly: Lower initial dose to be given, increased gradually according to response

**Schizophrenia with mainly positive symptoms**
- **BY MOUTH**
  - Adult: 200–400 mg twice daily; maximum 2.4 g per day
  - Elderly: Lower initial dose to be given, increased gradually according to response

- **CONTRA-INDICATIONS** CNS depression · comatose states · phaeochromocytoma
- **CAUTIONS** Aggressive patients (even low doses may aggravate symptoms) · agitated patients (even low doses may aggravate symptoms) · excited patients (even low doses may aggravate symptoms)
- **INTERACTIONS** → Appendix 1: sulpiride
- **SIDE-EFFECTS** Hepatitis
- **HEPATIC IMPAIRMENT** Can precipitate coma.

### Trifluoperazine
#### INDICATIONS AND DOSE

Schizophrenia and other psychoses · Short-term adjunctive management of psychomotor agitation, excitement, and violent or dangerously impulsive behaviour
- **BY MOUTH**
  - Adult: Initially 5 mg twice daily, increased by 5 mg daily after 1 week, then at intervals of 3 days, according to response
  - Elderly: Initially up to 2.5 mg twice daily, increased by 5 mg daily after 1 week, then at intervals of 3 days, according to response

**Short-term adjunctive management of severe anxiety**
- **BY MOUTH**
  - Adult: 2–4 mg daily in divided doses, increased if necessary to 6 mg daily
  - Elderly: Up to 2 mg daily in divided doses, increased if necessary to 6 mg daily

**Severe nausea and vomiting**
- **BY MOUTH**
  - Adult: 2–4 mg daily in divided doses; maximum 6 mg per day

- **CONTRA-INDICATIONS** CNS depression · comatose states · phaeochromocytoma
- **INTERACTIONS** → Appendix 1: phenothiazines
- **SIDE-EFFECTS** Anorexia · dystonic reactions · muscle weakness

**SIDE-EFFECTS, FURTHER INFORMATION**
Extrapyramidal symptoms are more frequent, especially at doses exceeding 6 mg daily.

Phenothiazines can all induce acute dystonic reactions such as facial and skeletal muscle spasms and oculogyric crises.

- **HEPATIC IMPAIRMENT** Can precipitate coma; phenothiazines are hepatotoxic.
- **RENAL IMPAIRMENT** Start with small doses in severe renal impairment because of increased cerebral sensitivity.
- **MONITORING REQUIREMENTS** Trifluoperazine does not affect blood pressure to the same extent as other
antipsychotic drugs and so blood pressure monitoring is not mandatory for this drug.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Oral solution**

- **Trifluoperazine (Non-proprietary)**
  - Trifluoperazine (as Trifluoperazine hydrochloride) 200 microgram per 1 ml Trifluoperazine 1mg/5ml oral solution sugar free sugar-free | 200 ml Pod | £102.53 DT price = £102.53
  - Trifluoperazine (as Trifluoperazine hydrochloride) 1 mg per 1 ml Trifluoperazine 5mg/5ml oral solution sugar free sugar-free | 150 ml Pod | £25.50 DT price = £25.50

**Tablet**

- **Trifluoperazine (Non-proprietary)**
  - Trifluoperazine (as Trifluoperazine hydrochloride) 1 mg Trifluoperazine 1mg tablets | 112 tablet Pod | £54.00 DT price = £54.00
  - Trifluoperazine (as Trifluoperazine hydrochloride) 5 mg Trifluoperazine 5mg tablets | 112 tablet Pod | £123.20 DT price = £123.20

### Zuclopenthixol

**INDICATIONS AND DOSE**

- **Schizophrenia and other psychoses**
  - **BY MOUTH**
    - Adult: Initially 20–30 mg daily in divided doses, increased if necessary up to 150 mg daily; usual maintenance 20–50 mg daily (max. per dose 40 mg), for debilitated patients, use elderly dose
    - Elderly: Initially 5–15 mg daily in divided doses, increased if necessary up to 150 mg daily; usual maintenance 20–50 mg daily (max. per dose 40 mg)

- **CONTRA-INDICATIONS**
  - Apathetic states
  - CNS depression
  - Comatose states
  - Phaeochromocytoma
  - Withdrawn states

- **CAUTIONS**
  - Avoid in acute porphyrias p. 969

- **INTERACTIONS**
  - Appendix 1: zuclopenthixol

- **SIDE-EFFECTS**
  - Urinary frequency
  - Urinary incontinence
  - Weight loss (less common than weight gain)

- **HEPATIC IMPAIRMENT**

- **RENAL IMPAIRMENT**
  - Halve dose in renal failure; smaller starting doses used in severe renal impairment because of increased cerebral sensitivity.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  **Tablet**
  - **Clopixol (Zuclopenthixol)** (Lundbeck Ltd)
    - Zuclopenthixol (as Zuclopenthixol dihydrochloride) 2 mg Clopixol 2mg tablets | 100 tablet Pod | £3.14 DT price = £3.14
  - Zuclopenthixol (as Zuclopenthixol dihydrochloride) 10 mg Clopixol 10mg tablets | 100 tablet Pod | £8.06 DT price = £8.06
  - Zuclopenthixol (as Zuclopenthixol dihydrochloride) 25 mg Clopixol 25mg tablets | 100 tablet Pod | £16.13 DT price = £16.13

  **Drops**
  - **Zuclopenthixol (Non-proprietary)**
    - Zuclopenthixol (as Zuclopenthixol dihydrochloride) 20 mg per 1 ml Ciatyl-Z 20mg/ml oral drops | 30 ml Pod no price available

### Zuclopenthixol acetate

**INDICATIONS AND DOSE**

- **Short-term management of acute psychosis**
  - **BY DEEP INTRAMUSCULAR INJECTION**
    - Adult: 50–150 mg, then 50–150 mg after 2–3 days if required, (1 additional dose may be needed 1–2 days after the first injection); maximum cumulative dose 400 mg in 2 weeks and maximum 4 injections; maximum duration of treatment 2 weeks—If maintenance treatment necessary change to an oral antipsychotic 2–3 days after last injection, or to a longer acting antipsychotic depot injection given concomitantly with last injection of zuclopenthixol acetate; to be administered into the gluteal muscle or lateral thigh
    - Elderly: 50–100 mg, then 50–100 mg after 2–3 days if required, (1 additional dose may be needed 1–2 days after the first injection); maximum cumulative dose 400 mg in 2 weeks and maximum 4 injections; maximum duration of treatment 2 weeks—if maintenance treatment necessary change to an oral antipsychotic 2–3 days after last injection, or to a longer acting antipsychotic depot injection given concomitantly with last injection of zuclopenthixol acetate; to be administered into the gluteal muscle or lateral thigh

**IMPORTANT SAFETY INFORMATION**

When prescribing, dispensing, or administering, check that this is the correct preparation—this preparation is usually used in hospital for an acute episode and should not be confused with depot preparations which are usually used in the community or clinics for maintenance treatment.

- **CONTRA-INDICATIONS**
  - CNS depression
  - Comatose states
  - Phaeochromocytoma

- **CAUTIONS**
  - Avoid in acute porphyrias p. 969

- **INTERACTIONS**
  - Appendix 1: zuclopenthixol

- **HEPATIC IMPAIRMENT**
  - Can precipitate coma.

- **RENAL IMPAIRMENT**
  - Start with small doses in severe renal impairment because of increased cerebral sensitivity.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Clopixol Acuphase** (Lundbeck Ltd)
  - Zuclopenthixol acetate 50 mg per 1 ml (Clopixol Acuphase) 50mg/1ml solution for injection ampoules | 5 ampoule Pod | £24.21 DT price = £24.21

**ANTIPSYCHOTICS > FIRST-GENERATION (DEPOT INJECTIONS)**

### Flupentixol decanoate

(Flupentixol Decanoate)

**INDICATIONS AND DOSE**

- **Maintenance in schizophrenia and other psychoses**
  - **BY DEEP INTRAMUSCULAR INJECTION**
    - Adult: Test dose 20 mg, dose to be injected into the upper outer buttock or lateral thigh, then 20–40 mg after at least 7 days, then 20–40 mg every 2–4 weeks, adjusted according to response, usual continued →
Fluphenazine decanoate

- **INDICATIONS AND DOSE**
  - **Maintenance in schizophrenia and other psychoses**
    - **BY DEEP INTRAMUSCULAR INJECTION**
      - Adult: Test dose 12.5 mg, dose to be administered into the gluteal muscle, then 12.5–100 mg every 4–7 days, then 12.5–100 mg every 14–35 days, adjusted according to response
      - Elderly: Test dose 6.25 mg, dose to be administered into the gluteal muscle, then 6.25–100 mg after 4–7 days, then 12.5–100 mg every 14–35 days, adjusted according to response
  
- **DOSE ADJUSTMENTS DUE TO INTERACTIONS**
  Dose adjustment may be necessary if smoking started or stopped during treatment.

- **CONTRA-INDICATIONS**
  - Children
  - CNS depression
  - comatose states
  - excitatory states
  - overactive states
  - phaeochromocytoma

- **CAUTIONS**
  - An alternative antipsychotic may be necessary if symptoms such as aggression or agitation appear - avoid in acute porphyrias p. 969 - when transferring from oral to depot therapy, the dose by mouth should be reduced gradually

- **DIRECTIONS FOR ADMINISTRATION**
  - Test dose first be given a small test-dose as undesirable side-effects, the plasma-drug concentration may not fall for some time after reducing the dose, therefore it may be a month or longer before side-effects subside.

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Less sedating but extrapyramidal symptoms frequent.
  - Treatment requires careful monitoring for QT-interval prolongation - when transferring from oral to depot therapy, the dose by mouth should be reduced gradually
  - Antipsychotics, patients should first be given a small test-dose as undesirable side-effects are prolonged.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Solution for injection**
    - **Flupentixol decanoate (Non-proprietary)**
      - **Flupentixol decanoate 20 mg per 1 ml**
        - Flupentixol 40mg/2ml solution for injection ampoules | 10 ampoule (POT) £34.34
      - Flupentixol 20mg/1ml solution for injection ampoules | 10 ampoule (POT) £24.74
    - **Flupentixol decanoate 100 mg per 1 ml**
      - Flupentixol 50mg/0.5ml solution for injection ampoules | 10 ampoule (POT) £38.40
      - Flupentixol 100mg/1ml solution for injection ampoules | 10 ampoule (POT) £76.05
    - **Depixol (Flupentixol decanoate)** (Lundbeck Ltd)
      - **Flupentixol decanoate 20 mg per 1 ml**
        - Depixol 40mg/2ml solution for injection ampoules | 10 ampoule (POT) £25.39
      - Depixol 20mg/1ml solution for injection ampoules | 10 ampoule (POT) £15.17
    - **Flupentixol decanoate 100 mg per 1 ml**
      - Depixol Conc 100mg/1ml solution for injection ampoules | 10 ampoule (POT) £62.51
    - **Flupentixol decanoate 200 mg per 1 ml**
      - Depixol Low Volume 200mg/1ml solution for injection ampoules | 5 ampoule (POT) £97.59
    - **Psytixol (Mylan Ltd)**
      - **Flupentixol decanoate 20 mg per 1 ml**
        - Psytixol 40mg/2ml solution for injection ampoules | 10 ampoule (POT) £25.38
      - Psytixol 20mg/1ml solution for injection ampoules | 10 ampoule (POT) £15.16
    - **Flupentixol decanoate 100 mg per 1 ml**
      - Psytixol 50mg/0.5ml solution for injection ampoules | 10 ampoule (POT) £34.12
      - Psytixol 100mg/1ml solution for injection ampoules | 10 ampoule (POT) £62.50
    - **Flupentixol decanoate 200 mg per 1 ml**
      - Psytixol 200mg/1ml solution for injection ampoules | 5 ampoule (POT) £97.58
  - **Fluphenazine decanoate**
  - **CONTRA-INDICATIONS**
    - Children
    - CNS depression
    - comatose states
    - marked cerebral atherosclerosis
    - phaeochromocytoma
  - **CAUTIONS**
    - QT-interval prolongation - when transferring from oral to depot therapy, the dose by mouth should be reduced gradually
  - **INTERACTIONS**
    - Appendix 1: phenothiazines
  - **SIDE-EFFECTS**
    - Erythema
    - inappropriate antidiuretic hormone secretion
    - nodules
    - oedema
    - pain at injection site
    - swelling
    - systemic lupus erythematosus
  - **SIDE-EFFECTS, FURTHER INFORMATION**
    - Less sedating and fewer antimuscarinic or hypotensive symptoms, but extrapyramidal symptoms, particularly dystonic reactions and akathisia, more frequent.
    - Extrapyramidal symptoms usually appear a few hours after injection and continue for about 2 days but may be delayed.
    - If the dose needs to be reduced to alleviate side-effects, it is important to recognise that the plasma-drug concentration may not fall for some time after reducing the dose, therefore it may be a month or longer before side-effects subside.
  - **MEDICINAL FORMS**
    - There can be variation in the licensing of different medicines containing the same drug.
    - **Solution for injection**
      - **Excipients**: May contain Sesame oil
      - **Modicare (Sanofi)**
        - Fluphenazine decanoate 25 mg per 1 ml | 5 ampoule (POT) £22.22
        - Modicare 25mg/1ml solution for injection ampoules | 10 ampoule (POT) £22.55 DT price = £22.55
      - **Fluphenazine decanoate 100 mg per 1 ml**
        - Modicare Concentrate 100mg/1ml solution for injection ampoules | 5 ampoule (POT) £43.73
        - DT price = £43.73
        - Modicare Concentrate 50mg/0.5ml solution for injection ampoules | 10 ampoule (POT) £44.73
Haloperidol decanoate

INDICATIONS AND DOSE

Maintenance in schizophrenia and other psychoses
- BY DEEP INTRAMUSCULAR INJECTION
  - Adult: Initially 50 mg every 4 weeks, increased in steps of 50 mg if required, increased if necessary up to 300 mg every 4 weeks, higher doses may be needed in some patients, dose to be administered into gluteal muscle, if 2-weekly administration preferred, doses should be halved
  - Elderly: Initially 12.5–25 mg every 4 weeks, if 2-weekly administration preferred, doses should be halved

DOSE ADJUSTMENTS DUE TO INTERACTIONS
Dose adjustment may be necessary if smoking started or stopped during treatment.

IMPORTANT SAFETY INFORMATION
When prescribing, dispensing or administering, check that this is the correct preparation—this preparation is used for maintenance treatment and should not be used for the rapid control of an acute episode.

CONTRA-INDICATIONS
- Bradycardia
- Children
- CNS depression
- Comatose states
- Lesions of the basal ganglia
- Parkinson’s disease
- Phaeochromocytoma
- QT-interval prolongation

CAUTIONS
- Arteriosclerosis
- Hypocalcaemia
- Hypokalaemia
- Hypomagnesaemia
- Metabolic disturbances
- Subarachnoid haemorrhage
- Thyrotoxicosis
- When transferring from oral to depot therapy, the dose by mouth should be reduced gradually

INTERACTIONS
- Appendix 1: haloperidol

SIDE-EFFECTS
- Common or very common: Depression, weight loss
- Uncommon: Dyspnœa, oedema
- Rare: Bronchospasm, hypoglycaemia, inappropriate antidiuretic hormone secretion, photosensitivity reactions, pigmentation
- Frequency not known: Erythema, hypertension, nodules, pain may occur at injection site, Stevens-Johnson syndrome, sweating, swelling, toxic epidermal necrolysis

SIDE-EFFECTS, FURTHER INFORMATION
Less sedating and fewer antimuscarinic or hypotensive symptoms.

PREGNANCY
Avoid unless benefits outweigh risk.

HEPATIC IMPAIRMENT
Can precipitate coma.

RENAL IMPAIRMENT
Start with small doses in severe renal impairment because of increased cerebral sensitivity.

MONITORING REQUIREMENTS
- Treatment requires careful monitoring for optimum effect.
- Baseline ECG required before treatment—assess need for further ECGs during treatment on an individual basis.

DIRECTIONS FOR ADMINISTRATION
In general not more than 2–3 mL of oily injection should be administered at any one site. Correct injection technique (including use of z-track technique) and rotation of injection sites are essential. When initiating therapy with sustained-release preparations of conventional antipsychotics, patients should first be given a small test-dose as undesirable side-effects are prolonged.

Zuclopenthixol decanoate

INDICATIONS AND DOSE

Maintenance in schizophrenia and paranoid psychoses
- BY DEEP INTRAMUSCULAR INJECTION
  - Adult: Test dose 100 mg, dose to be administered into the upper outer buttock or lateral thigh, followed by 200–500 mg after at least 7 days, then 200–500 mg every 1–4 weeks, adjusted according to response, higher doses of more than 500 mg can be used; do not exceed 600 mg weekly
  - Elderly: A quarter to half usual starting dose to be used

IMPORTANT SAFETY INFORMATION
When prescribing, dispensing, or administering, check that this is the correct preparation—this preparation is used for maintenance treatment and should not be used for the short-term management of an acute episode.

CONTRA-INDICATIONS
- Children
- CNS depression
- Comatose states
- Phaeochromocytoma

CAUTIONS
- Avoid in acute porphyrias
- QT interval prolongation
- When transferring from oral to depot therapy, the dose by mouth should be reduced gradually

INTERACTIONS
- Appendix 1: zuclopenthixol

SIDE-EFFECTS
- Erythema, nodules, pain at injection site, swelling

SIDE-EFFECTS, FURTHER INFORMATION
If the dose needs to be reduced to alleviate side-effects, it is important to recognise that the plasma-drug concentration may not fall for some time after reducing the dose, therefore it may be a month or longer before side-effects subside.

HEPATIC IMPAIRMENT
Can precipitate coma.

RENAL IMPAIRMENT
Start with small doses in severe renal impairment because of increased cerebral sensitivity.

MONITORING REQUIREMENTS
Treatment requires careful monitoring for optimum effect.

DIRECTIONS FOR ADMINISTRATION
In general not more than 2–3 mL of oily injection should be administered at any one site. Correct injection technique (including use of z-track technique) and rotation of injection sites are essential. When initiating therapy with sustained-release preparations of conventional antipsychotics, patients should first be given a small test-dose as undesirable side-effects are prolonged.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Solution for injection
- Clopixol (Zuclopenthixol decanoate) (Lundbeck Ltd)
  - Zuclopenthixol decanoate 200 mg per 1 mL Clopixol 200mg/1ml solution for injection ampoules | 10 ampoule £31.51 DT price = £31.51
  - Zuclopenthixol decanoate 500 mg per 1 mL Clopixol Conc 500mg/1ml solution for injection ampoules | 5 ampoule £37.18 DT price = £37.18
**Antipsychotics** > **Second-generation**

**Amisulpride**

- **Drug Action** Amisulpride is a selective dopamine receptor antagonist with high affinity for mesolimbic D₂ and D₃ receptors.

- **Indications and Dose**
  - **Acute psychotic episode in schizophrenia**
    - **By Mouth**
    - Adult: 400–800 mg daily in 2 divided doses, adjusted according to response; maximum 1.2 g per day
  - **Schizophrenia with predominantly negative symptoms**
    - **By Mouth**
    - Adult: 50–300 mg daily

- **Contra-Indications** CNS depression, comatose states, phaeochromocytoma, prolactin-dependent tumours

- **Side-effects**
  - Common or very common
    - Anxiety
  - Uncommon
    - Bradycardia

- **Pregnancy** Avoid.

- **Breast Feeding** Avoid—no information available.

- **Renal Impairment** Halve dose if eGFR 30–60 mL/minute/1.73 m². Use one-third dose if eGFR 10–30 mL/minute/1.73 m². No information available if eGFR less than 10 mL/minute/1.73 m².

- **Monitoring Requirements** Amisulpride does not affect blood pressure to the same extent as other antipsychotic drugs and so blood pressure monitoring is not mandatory for this drug.

- **Prescribing and dispensing information** Flavours of oral liquid formulations may include caramel.

- **Medicinal Forms**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Oral Solution**

- **Cautionary and Advisory Labels** 2
  - **Amisulpride (Non-proprietary)**
  - **Amisulpride 100 mg per 1 mL** Amisulpride 100mg/ml oral solution sugar-free [60 mL PO(T)] £36.00 DT price = £36.00
  - **Solian (Sanofi)**
  - **Amisulpride 100 mg per 1 mL** Solian 100mg/ml oral solution sugar-free [60 mL PO(T)] £33.76 DT price = £36.00

**Tablet**

- **Cautionary and Advisory Labels** 2
  - **Amisulpride (Non-proprietary)**
  - **Amisulpride 50 mg** Amisulpride 50mg tablets [60 tablet PO(T)] £22.76 DT price = £22.06
  - **Amisulpride 100 mg** Amisulpride 100mg tablets [60 tablet PO(T)] £39.48 DT price = £3.59
  - **Amisulpride 200 mg** Amisulpride 200mg tablets [60 tablet PO(T)] £66.00 DT price = £5.44
  - **Amisulpride 400 mg** Amisulpride 400mg tablets [60 tablet PO(T)] £132.00 DT price = £35.21
  - **Solian (Sanofi)**
  - **Amisulpride 50 mg** Solian 50 tablets [60 Tablet PO(T)] £22.76 DT price = £2.06
  - **Amisulpride 100 mg** Solian 100 tablets [60 tablet PO(T)] £35.29 DT price = £5.59
  - **Amisulpride 200 mg** Solian 200 tablets [60 tablet PO(T)] £58.99 DT price = £5.44
  - **Amisulpride 400 mg** Solian 400 tablets [60 tablet PO(T)] £117.97 DT price = £35.21

**Aripiprazole**

- **Drug Action** Aripiprazole is a dopamine D₃ partial agonist with weak 5-HT₁₉ partial agonism and 5-HT₂₆ receptor antagonism.

- **Indications and Dose**
  - **Maintenance in schizophrenia in patients stabilised with oral aripiprazole**
    - **Initially by intramuscular injection**
    - Adult: 400 mg every month, to be injected into the gluteal muscle, minimum of 26 days between injections, for dose adjustment due to side effects—consult product literature and (by mouth) 10–20 mg daily continued for 14 consecutive days after the first injection, for missed depot doses consult product literature
  - **Schizophrenia**
    - **By Mouth**
    - Adult: 10–15 mg once daily; usual dose 15 mg once daily (max. per dose 30 mg once daily)
  - **Treatment and recurrence prevention of mania**
    - **By Mouth**
    - Adult: 15 mg once daily, increased if necessary up to 30 mg once daily
  - **Control of agitation and disturbed behaviour in schizophrenia**
    - **By Intramuscular Injection**
    - Adult: Initially 5.25–15 mg for 1 dose, alternatively usual dose 9.75 mg for 1 dose, followed by 5.25–15 mg after 2 hours if required, maximum 3 injections daily; maximum daily combined oral and parenteral dose 30 mg
  - **Dose Adjustments Due to Interactions**
    - With oral use
      - Manufacturer advises double the dose with concurrent use of potent inducers of CYP3A4. Manufacturer advises reduce dose by half with concurrent use of potent inhibitors of CYP3A4 or CYP2D6.
    - With intramuscular use
      - For dose adjustments due to concurrent use of interacting drugs—consult product literature.

**Important Safety Information**

When prescribing, dispensing, or administering, check that the correct preparation is used—the preparation usually used in hospital for the rapid control of an acute episode (solution for injection containing aripiprazole 7.5 mg/mL) should not be confused with depot preparations (aripiprazole 400–mg vial with solvent), which are usually used in the community or clinics for maintenance treatment.

- **Contra-Indications** CNS depression, comatose state, phaeochromocytoma

- **Cautions**

**General Cautions**

- Cerebrovascular disease: elderly (reduce initial dose)

**Specific Cautions**

- When transferring from oral to depot therapy, the dose by mouth should be reduced gradually

- **Interactions**
  - **By Mouth**
  - Adult: 15 mg once daily, increased if necessary up to 30 mg once daily

- **Side-effects**
  - **Common or very common** Anxiety, hypersalivation, malaise
  - **Uncommon** Depression, dry mouth
  - **Frequency not known** Alopecia, anorexia, bradycardia, hepatitis, hyponatraemia, infection, laryngospasm,
myalgia • oedema • oropharyngeal spasm • pancreatitis • pathological gambling • respiratory disorders • rhabdomyolysis • suicidal ideation • sweating • urinary disorders

SPECIFIC SIDE-EFFECTS
- With intramuscular use: Erythema • nodules • pain at injection site • swelling

SIDE-EFFECTS, FURTHER INFORMATION
- With intramuscular use: If the dose needs to be reduced to alleviate side-effects, it is important to recognise that the plasma–drug concentration may not fall for some time after reducing the dose of the depot injection, therefore it may be a month or longer before side-effects subside.

- PREGNANCY: Use only if potential benefit outweighs risk.
- BREAST FEEDING: Manufacturer advises avoid—present in milk.
- HEPATIC IMPAIRMENT: Use with caution in severe impairment (oral treatment preferred to intramuscular administration).

- MONITORING REQUIREMENTS
- Aripiprazole does not affect blood pressure to the same extent as other antipsychotic drugs and so blood pressure monitoring is not mandatory for this drug.
- With intramuscular use: Treatment requires careful monitoring for optimum effect.

- DIRECTIONS FOR ADMINISTRATION
- With oral use: Orosuspension tablets should be placed on the tongue and allowed to dissolve, or be dispersed in water and swallowed.
- With intramuscular use: Correct injection technique (including the use of z-track technique) and rotation of injection sites are essential.

- PATIENT AND CARER ADVICE: Patients or carers should be given advice on how to administer aripiprazole orosuspension tablets.

- MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

Tablet

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aripiprazole (Non-proprietary)</strong></td>
<td></td>
</tr>
<tr>
<td>Aripiprazole 5 mg Aripiprazole 5mg tablets</td>
<td>28 tablet [POM] £96.04 DT price = £1.60</td>
</tr>
<tr>
<td>Aripiprazole 10 mg Aripiprazole 10mg tablets</td>
<td>28 tablet [POM] £96.04 DT price = £1.76</td>
</tr>
<tr>
<td>Aripiprazole 15 mg Aripiprazole 15mg tablets</td>
<td>28 tablet [POM] £96.04 DT price = £1.86</td>
</tr>
<tr>
<td>Aripiprazole 30 mg Aripiprazole 30mg tablets</td>
<td>28 tablet [POM] £132.08 DT price = £20.65</td>
</tr>
<tr>
<td><strong>Abilify (Otsuka Pharmaceuticals (U.K.) Ltd)</strong></td>
<td></td>
</tr>
<tr>
<td>Aripiprazole 5 mg Abilify 5mg tablets</td>
<td>28 tablet [POM] £96.04 DT price = £1.60</td>
</tr>
<tr>
<td>Aripiprazole 10 mg Abilify 10mg tablets</td>
<td>28 tablet [POM] £96.04 DT price = £1.76</td>
</tr>
<tr>
<td>Aripiprazole 15 mg Abilify 15mg tablets</td>
<td>28 tablet [POM] £96.04 DT price = £1.86</td>
</tr>
<tr>
<td>Aripiprazole 30 mg Abilify 30mg tablets</td>
<td>28 tablet [POM] £132.08 DT price = £20.65</td>
</tr>
</tbody>
</table>

Solution for injection

| **Abilify (Otsuka Pharmaceuticals (U.K.) Ltd)** |
| Aripiprazole 7.5 mg per 1 ml Abilify 7.5mg/1.3ml solution for injection vials | 1 vial [POM] £3.43 |

Oral solution

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aripiprazole (Non-proprietary)</strong></td>
<td></td>
</tr>
<tr>
<td>Aripiprazole 1 mg per 1 ml Aripiprazole 1mg/ml oral solution</td>
<td>150 ml [POM] £102.90 DT price = £102.90</td>
</tr>
<tr>
<td><strong>Abilify (Otsuka Pharmaceuticals (U.K.) Ltd)</strong></td>
<td></td>
</tr>
<tr>
<td>Aripiprazole 1 mg per 1 ml Aripiprazole 1mg/ml oral solution</td>
<td>150 ml [POM] £102.90 DT price = £102.90</td>
</tr>
</tbody>
</table>

Powder and solvent for suspension for injection

| **Abilify Maintena (Otsuka Pharmaceuticals (U.K.) Ltd)** |
| Aripiprazole 400 mg Abilify Maintena 400mg powder and solvent for prolonged-release suspension for injection pre-filled syringes | 1 pre-filled disposable injection [POM] £220.41 |
| Abilify Maintena 400mg powder and solvent for prolonged-release suspension for injection vials | 1 vial [POM] £220.41 |

Orosuspension tablet

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aripiprazole (Non-proprietary)</strong></td>
<td></td>
</tr>
<tr>
<td>Aripiprazole 10 mg Aripiprazole 10mg orosuspension tablets sugar free</td>
<td>28 tablet [POM] £91.24 DT price = £78.89</td>
</tr>
<tr>
<td>Aripiprazole 15 mg Aripiprazole 15mg orosuspension tablets sugar free</td>
<td>28 tablet [POM] £91.24 DT price = £78.89</td>
</tr>
<tr>
<td><strong>Abilify (Otsuka Pharmaceuticals (U.K.) Ltd)</strong></td>
<td></td>
</tr>
<tr>
<td>Aripiprazole 10 mg Abilify 10mg orosuspension tablets sugar-free</td>
<td>28 tablet [POM] £96.04 DT price = £78.89</td>
</tr>
<tr>
<td>Aripiprazole 15 mg Abilify 15mg orosuspension tablets sugar-free</td>
<td>28 tablet [POM] £96.04 DT price = £78.89</td>
</tr>
</tbody>
</table>

Clozapine

- **DRUG ACTION**: Clozapine is a dopamine D2, dopamine D3, 5-HT2A, alpha1, adrenoceptor, and muscarinic-receptor antagonist.

- **INDICATIONS AND DOSE**
Schizophrenia in patients unresponsive to, or intolerant of, conventional antipsychotic drugs

- **BY MOUTH**
- Adult 18–59 years: 12.5 mg 1–2 times a day for day 1, then 25–50 mg for day 2, then increased, if tolerated, in steps of 25–50 mg daily, dose to be increased gradually over 14–21 days, increased to up to 300 mg daily in divided doses, larger dose to be taken at night, up to 200 mg daily may be taken as a single dose at bedtime; increased in steps of 50–100 mg 1–2 times a week if required, it is preferable to increase once a week; usual dose 200–450 mg daily, max. 900 mg per day, if restarting after interval of more than 48 hours, 12.5 mg once or twice on first day (but may be feasible to increase more quickly than on initiation)—extreme caution if previous respiratory or cardiac arrest with initial dosing
- Adult 60 years and over: 12.5 mg once daily for day 1, then increased to 25–37.5 mg for day 2, then increased, if tolerated, in steps of up to 25 mg daily, dose to be increased gradually over 14–21 days, increased to up to 300 mg daily in divided doses, larger dose at to be taken night, up to 200 mg daily may be taken as a single dose at bedtime; increased in steps of 50–100 mg 1–2 times a week if required, it is preferable to increase once a week; usual dose 200–450 mg daily, max. 900 mg per day, if restarting after interval of more than 48 hours, 12.5 mg once or twice on first day (but may be feasible to increase more quickly than on initiation)—extreme caution if previous respiratory or cardiac arrest with initial dosing
- Psychosis in Parkinson’s disease

- **BY MOUTH**
- Adult: 12.5 mg once daily, dose to be taken at bedtime, then increased in steps of 12.5 mg up to twice weekly, adjusted according to response; usual dose 25–37.5 mg once daily, dose to be taken at bedtime; increased in steps of 12.5 mg once weekly, this applies only in exceptional cases, increased if necessary up to 100 mg daily in 1–2 divided doses; usual maximum 50 mg/24 hours

DOSE ADJUSTMENTS DUE TO INTERACTIONS

Dose adjustment may be necessary if smoking started or stopped during treatment.
CONTRA-INDICATIONS Alcoholic and toxic psychoses • bone-marrow disorders • coma • drug intoxication • history of agranulocytosis • history of circulatory collapse • history of neutropenia • paralytic ileus • severe cardiac disorders (e.g. myocarditis) • severe CNS depression • uncontrolled epilepsy

CAUTIONS Age over 60 years • prostatic hypertrophy • susceptibility to angle-closure glaucoma • taper off other antipsychotics before starting

CAUTIONS, FURTHER INFORMATION

Agranulocytosis Neutropenia and potentially fatal agranulocytosis reported. Leucocyte and differential blood counts must be normal before starting; monitor counts every week for 18 weeks then at least every 2 weeks and if clozapine continued and blood count stable after 1 year at least every 4 weeks (and 4 weeks after discontinuation); if leucocyte count below 3000/mm³ or if absolute neutrophil count below 1500/mm³ discontinue permanently and refer to haematologist. Patients who have a low white blood cell count because of benign ethnic neutropenia may be started on clozapine with the agreement of a haematologist. Avoid drugs which depress leucopoiesis; patients should report immediately symptoms of infection, especially influenza-like illness.

Myocarditis and cardiomyopathy Fatal myocarditis (most commonly in first 2 months) and cardiomyopathy reported.

Perform physical examination and take full medical history before starting

Specialist examination required if cardiac abnormalities or history of heart disease found—clozapine initiated only in absence of severe heart disease and if benefit outweighs risk

Persistent tachycardia especially in first 2 months should prompt observation for other indicators for myocarditis or cardiomyopathy

If myocarditis or cardiomyopathy suspected clozapine should be stopped and patient evaluated urgently by cardiologist

Discontinue permanently in clozapine–induced myocarditis or cardiomyopathy

Intestinal obstruction Impairment of intestinal peristalsis, including constipation, intestinal obstruction, faecal impaction, and paralytic ileus, (including fatal cases) reported. Clozapine should be used with caution in patients receiving drugs that may cause constipation (e.g. antimuscarinic drugs) or in those with a history of colonic disease or lower abdominal surgery. It is essential that constipation is recognised and actively treated.

INTERACTIONS → Appendix 1: clozapine

SIDE-EFFECTS

Common or very common Anorexia • constipation • hypersalivation • malaise • speech disorders • urinary incontinence

Uncommon Agranulocytosis

Rare Circulatory collapse • dysphagia • hepatitis • myocarditis • pancreatitis • pericarditis • pneumonia • pulmonary aspiration

Very rare Cardiomyopathy • hypercholesterolaemia • hypertriglyceridaemia • interstitial nephritis • intestinal obstruction (including fatal cases) • myocardial infarction • obsessive compulsive disorder • parotid gland enlargement • respiratory depression

Frequency not known Hepatic disorders • hepatic failure • muscle disorders • renal failure

SIDE-EFFECTS, FURTHER INFORMATION

Hypersalivation Hypersalivation associated with clozapine therapy can be treated with hyoscine hydrobromide [unlicensed indication], provided that the patient is not at particular risk from the additive antimuscarinic side-effects of hyoscine and clozapine.

PREGNANCY Use with caution.

BREAST FEEDING Avoid.


RENAL IMPAIRMENT Avoid in severe impairment.

MONITORING REQUIREMENTS

Monitor leucocyte and differential blood counts. Clozapine requires differential white blood cell monitoring weekly for 18 weeks, then fortnightly for up to one year, and then monthly as part of the clozapine patient monitoring service.

Close medical supervision during initiation (risk of collapse because of hypotension and convulsions).

Blood lipids and weight should be measured at baseline, at 3 months (weight should be measured at frequent intervals during the first 3 months), and then yearly with antipsychotics. Patients taking clozapine require more frequent monitoring of these parameters: every 3 months for the first year, then yearly.

Fasting blood glucose should be measured at baseline, at 4–6 months, and then yearly. Patients taking clozapine should have fasting blood glucose tested at baseline, after one months’ treatment, then every 4–6 months.

Patient, prescriber, and supplying pharmacist must be registered with the appropriate Patient Monitoring Service—it takes several days to do this.

TREATMENT CESSATION On planned withdrawal reduce dose over 1–2 weeks to avoid risk of rebound psychosis. If abrupt withdrawal necessary observe patient carefully.

DIRECTIONS FOR ADMINISTRATION Shake oral suspension well for 90 seconds when dispensing or if visibly settled and stand for 24 hours before use; otherwise shake well for 10 seconds before use. May be diluted with water.

PRESCRIBING AND DISPENSING INFORMATION Clozapine has been used for psychosis in Parkinson’s disease in children aged 16 years and over.

PATIENT AND CARER ADVICE Patients or carers should be given advice on how to administer clozapine oral suspension.

MEDIACL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Oral suspension

CAUTIONARY AND ADVISORY LABELS 2, 10

Denzapine (Britannia Pharmaceuticals Ltd)

Clozapine 50 mg per 1 ml Denzapine 50mg/ml oral suspension sugar-free | 100 ml £39.60

Tablet

CAUTIONARY AND ADVISORY LABELS 2, 10

Clozaril (Mylan Ltd)

Clozapine 25 mg Clozaril 25mg tablets | 28 tablet £2.95 | 84 tablet £6.30 (Hospital only) | 100 tablet (POM) £7.50 (Hospital only)

Clozapine 100 mg Clozaril 100mg tablets | 28 tablet £11.76 | 84 tablet £25.21 (Hospital only) | 100 tablet (POM) £30.01 (Hospital only)

Denzapine (Britannia Pharmaceuticals Ltd)

Clozapine 25 mg Denzapine 25mg tablets | 84 tablet £16.64 | 100 tablet (POM) £18.80

Clozapine 100 mg Denzapine 100mg tablets | 84 tablet £66.53 | 100 tablet (POM) £79.20

Zapone (Leyden Delta B.V.)

Clozapine 25 mg Zapone 25mg tablets | 84 tablet £8.28 | 500 tablet (POM) £48.39

Clozapine 100 mg Zapone 100mg tablets | 84 tablet £33.88 | 500 tablet (POM) £196.43
Lurasidone hydrochloride

**DRUG ACTION** Lurasidone is a dopamine D2, 5-HT2A, 5-HT7, alpha2A- and alpha2C- adrenoceptor antagonist, and is a partial agonist at 5-HT1A receptors.

**INDICATIONS AND DOSE**

**Schizophrenia**
- **BY MOUTH**
  - Adult: Initially 37 mg once daily, increased if necessary up to 148 mg once daily

**Schizophrenia when given with concomitant moderate CYP3A4 inhibitors (e.g. diltiazem, erythromycin, fluconazole, and verapamil)**
- **BY MOUTH**
  - Adult: Initially 18.5 mg once daily (max. per dose 74 mg once daily)

**CAUTIONS** High doses in elderly; susceptibility to QT-interval prolongation

**INTERACTIONS** [Appendix 1: lurasidone]

**SIDE-EFFECTS**
- **Common or very common** Anxiety - musculoskeletal stiffness
- **Uncommon** Catatonia - decreased appetite - dysarthria - dysuria - hot flush - myalgia - nightmares
- **Frequency not known** Angina - AV block - bradycardia - dysphagia - panic attacks - pruritus - suicidal behaviour - vertigo

**PREGNANCY** Use only if potential benefit outweighs risk—limited information available.

**HEPATIC IMPAIRMENT** Initially 18.5 mg once daily, up to max. 74 mg once daily in moderate impairment. Use with caution in severe impairment—initially 18.5 mg once daily, up to max. 37 mg once daily.

**RENAL IMPAIRMENT** Initially 18.5 mg once daily, up to max. 74 mg once daily if eGFR less than 50 mL/minute/1.73 m². Manufacturer advises use only if potential benefit outweighs risk if eGFR less than 15 mL/minute/1.73 m².

**DIRECTIONS FOR ADMINISTRATION** Patients on doses higher than 111 mg once daily whose treatment is interrupted for longer than 3 days should restart on 111 mg once daily and titrate to usual dose; for all other doses, restart on usual dose.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>2, 21, 25</th>
</tr>
</thead>
<tbody>
<tr>
<td>Latuda (Sunovion Pharmaceuticals Europe Ltd)</td>
<td>▼</td>
</tr>
<tr>
<td>Lurasidone (as Lurasidone hydrochloride) 18.5 mg</td>
<td>Latuda 18.5mg tablets</td>
</tr>
<tr>
<td>Lurasidone (as Lurasidone hydrochloride) 37 mg</td>
<td>Latuda 37mg tablets</td>
</tr>
<tr>
<td>Lurasidone (as Lurasidone hydrochloride) 74 mg</td>
<td>Latuda 74mg tablets</td>
</tr>
</tbody>
</table>

Olanzapine

**DRUG ACTION** Olanzapine is a dopamine D1, D2, D4, 5-HT2, histamine-1-, and muscarinic-receptor antagonist.

**INDICATIONS AND DOSE**

**Schizophrenia / Combination therapy for mania**
- **BY MOUTH**
  - Adult: 10 mg daily, adjusted according to response, usual dose 5–20 mg daily, doses greater than 10 mg daily only after reassessment, when one or more factors present that might result in slower metabolism (e.g. female gender, elderly, non-smoker) consider lower initial dose and more gradual dose increase; maximum 20 mg per day

**Preventing recurrence in bipolar disorder**
- **BY MOUTH**
  - Adult: 10 mg daily, adjusted according to response, usual dose 5–20 mg daily, doses greater than 10 mg daily only after reassessment, when one or more factors present that might result in slower metabolism (e.g. female gender, elderly, non-smoker) consider lower initial dose and more gradual dose increase; maximum 20 mg per day

**Monotherapy for mania**
- **BY MOUTH**
  - Adult: 15 mg daily, adjusted according to response, usual dose 5–20 mg daily, doses greater than 15 mg daily only after reassessment, when one or more factors present that might result in slower metabolism (e.g. female gender, elderly, non-smoker) consider lower initial dose and more gradual dose increase; maximum 20 mg per day

**Control of agitation and disturbed behaviour in schizophrenia or mania**
- **BY INTRAMUSCULAR INJECTION**
  - Adult: Initially 5–10 mg for 1 dose; usual dose 10 mg for 1 dose, followed by 5–10 mg after 2 hours if required, maximum 3 injections daily for 3 days; maximum daily combined oral and parenteral dose 20 mg, when one or more factors present that might result in slower metabolism (e.g. female gender, elderly, non-smoker) consider lower initial dose and more gradual dose increase
  - Elderly: Initially 2.5–5 mg, followed by 2.5–5 mg after 2 hours if required, maximum 3 injections daily for 3 days; maximum daily combined oral and parenteral dose 20 mg, when one or more factors present that might result in slower metabolism (e.g. female gender, elderly, non-smoker) consider lower initial dose and more gradual dose increase

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**

Dose adjustment may be necessary if smoking started or stopped during treatment.

**CONTRA-INDICATIONS**
- With intramuscular use
  - Acute myocardial infarction - bradycardia - recent heart surgery - severe hypotension - sick sinus syndrome - unstable angina

**CAUTIONS**
- Bone-marrow depression - diabetes mellitus (risk of exacerbation or ketoacidosis) - hypereosinophilic disorders - low leucocyte count - low neutrophil count - myeloproliferative disease - paralytic ileus

**CAUTIONS, FURTHER INFORMATION**
- CNS and respiratory depression
- With intramuscular use
  - Blood pressure, pulse and respiratory rate should be monitored for at least 4 hours after intramuscular injection, particularly in those also receiving a benzodiazepine or another antipsychotic (leave at least one hour between administration of olanzapine intramuscular injection and parenteral benzodiazepines).

**INTERACTIONS** [Appendix 1: olanzapine]

**SIDE-EFFECTS**
- **General side-effects**
  - **Common or very common** Arthralgia - hypercholesterolaemia - hypertriglyceridaemia - increased appetite - malaise - oedema
  - **Uncommon** Alopecia - anemia - bradycardia - epistaxis
  - **Rare** Hepatitis - pancreatitis - rhabdomyolysis

**SPECIFIC SIDE-EFFECTS**
- With intramuscular use
  - Hypoventilation - sinus pause
Nervous system

PRESCRIBING AND DISPENSING INFORMATION

TREATMENT INFORMATION

▶ Hepatic impairment

▶ Renal impairment

▶ Monitoring requirements

▶ Blood lipids and weight should be measured at baseline, at 3 months (weight should be measured at frequent intervals during the first 3 months), and then yearly with antipsychotic drugs. Patients taking olanzapine require more frequent monitoring of these parameters: every 3 months for the first year, then yearly.

▶ Fasting blood glucose should be measured at baseline, at 4–6 months, and then yearly. Patients taking olanzapine should have fasting blood glucose tested at baseline, after one month’s treatment, then every 4–6 months.

▶ Directions for administration

Olanzapine orodispersible tablet may be placed on the tongue and allowed to dissolve, or dispersed in water, orange juice, apple juice, milk, or coffee.

▶ Prescribing and dispensing information

When prescribing, dispensing, or administering, check that this injection is the correct preparation—this preparation is usually used in the hospital for the rapid control of an acute episode and should not be confused with depot preparations which are usually used in the community or clinics for maintenance treatment.

▶ Patient and carer advice

Patients or carers should be given advice on how to administer orodispersible tablets.

▶ Medicinal forms

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution.

Tablet

CAUTION AND ADVISORY LABELS

▶ Olanzapine (Non-proprietary)

Olanzapine 2.5 mg | 28 tablet 🆕  £21.85 DT price = £0.87
Olanzapine 5 mg | 28 tablet 🆕  £43.70 DT price = £0.95
Olanzapine 7.5 mg | 28 tablet 🆕  £62.27 DT price = £0.92 | 6 tablet 🆕  £113.10
Olanzapine 10 mg | 28 tablet 🆕  £87.40 DT price = £1.05
Olanzapine 15 mg | 28 tablet 🆕  £119.18 DT price = £1.28
Olanzapine 20 mg | 28 tablet 🆕  £158.90 DT price = £1.54

▶ Zalasta (Consilient Health Ltd)

Olanzapine 2.5 mg | 28 tablet 🆕  £18.57 DT price = £0.87
Olanzapine 5 mg | 28 tablet 🆕  £37.14 DT price = £0.95
Olanzapine 7.5 mg | 56 tablet 🆕  £111.43
Olanzapine 10 mg | 28 tablet 🆕  £74.29 DT price = £1.05
Olanzapine 15 mg | 28 tablet 🆕  £101.30 DT price = £1.28
Olanzapine 20 mg | 28 tablet 🆕  £135.06 DT price = £1.54

▶ Zyprexa (Eli Lilly and Company Ltd)

Olanzapine 2.5 mg | 28 tablet 🆕  £21.85 DT price = £0.87
Olanzapine 5 mg | 28 tablet 🆕  £43.70 DT price = £0.95
Olanzapine 7.5 mg | 56 tablet 🆕  £131.10
Olanzapine 10 mg | 28 tablet 🆕  £87.40 DT price = £1.05
Olanzapine 15 mg | 28 tablet 🆕  £119.18 DT price = £1.28
Olanzapine 20 mg | 28 tablet 🆕  £158.90 DT price = £1.54

Oral Lofyphosphate

▶ Zyprexa Velotabs (Eli Lilly and Company Ltd)

Olanzapine 5 mg | 28 tablet 🆕  £48.07 DT price = £1.70
Olanzapine 10 mg | 28 tablet 🆕  £87.40 DT price = £1.70
Olanzapine 15 mg | 28 tablet 🆕  £131.10 DT price = £1.70
Olanzapine 20 mg | 28 tablet 🆕  £174.79 DT price = £1.70

Orodispersible tablet

CAUTION AND ADVISORY LABELS

EXCEPTIONS: May contain Aspartame

▶ Olanzapine (Non-proprietary)

Olanzapine 5 mg | 28 tablet 🆕  £1.72 DT price = £0.07
Olanzapine 10 mg | 28 tablet 🆕  £4.99 DT price = £0.22
Olanzapine 15 mg | 28 tablet 🆕  £1.72 DT price = £0.07
Olanzapine 20 mg | 28 tablet 🆕  £4.99 DT price = £0.22

Zalasta (Consilient Health Ltd)

Olanzapine 5 mg | 28 tablet 🆕  £0.97 DT price = £0.05
Olanzapine 10 mg | 28 tablet 🆕  £3.73 DT price = £0.09
Olanzapine 15 mg | 28 tablet 🆕  £5.24 DT price = £0.09
Olanzapine 20 mg | 28 tablet 🆕  £4.18 DT price = £0.09

Paliperidone

DRUG ACTION

Paliperidone is a metabolite of risperidone.

INDICATIONS AND DOSE

Schizophrenia | Psychotic or manic symptoms of schizoaffective disorder

▶ By mouth

Adult: 6 mg once daily, dose to be taken in the morning, then adjusted in steps of 3 mg if required, dose to be adjusted over at least 5 days; usual dose 3–12 mg daily

TREVICTA® PRE-FILLED SYRINGES

Maintenance of schizophrenia in patients who are clinically stable on once-monthly intramuscular paliperidone

▶ By deep intramuscular injection

Adult: Initially 175–525 mg every 3 months, adjusted according to response, to be administered into the deltoid or gluteal muscle, dose is based on previous once-monthly intramuscular paliperidone and should be initiated in place of the next scheduled dose—consult product literature

XEPLOEN® PRE-FILLED SYRINGES

Maintenance in schizophrenia in patients previously responsive to paliperidone or risperidone

▶ By deep intramuscular injection

Adult: 150 mg for 1 dose on day 1, then 100 mg for 1 dose on day 8, to be injected into the deltoid muscle, dose subsequently adjusted at monthly intervals according to response; maintenance 75 mg once a month, alternatively maintenance 25–150 mg once a month, following the second dose, monthly maintenance doses can be administered into either the deltoid or gluteal muscle

Paliperidone

15-Jun-2017
CAUTIONS

GENERAL CAUTIONS
Cataract surgery (risk of intraoperative floppy iris syndrome) • dementia with Lewy bodies • elderly patients with dementia • elderly patients with risk factors for stroke • predisposition to gastro-intestinal obstruction • prolactin-dependent tumours

SPECIFIC CAUTIONS
When transferring from oral to depot therapy, the dose by mouth should be reduced gradually

INTERACTIONS ➔ Appendix 1: paliperidone

SIDE-EFFECTS

GENERAL SIDE-EFFECTS

Common or very common Anxiety • appetite changes • arthralgia • depression • epistaxis • hypertension • infection • malaise • myalgia • oedema • respiratory disorders • sleep disorders • toothache • urinary disorders

Uncommon Alopecia • elevated plasma-cholesterol concentrations • elevated plasma-triglyceride concentrations • hypoaesthesia • paraesthesia • taste disturbances • tinnitus • visual disorders

Rare Inappropriate antidiuretic hormone secretion • intestinal obstruction • intra-operative floppy iris syndrome • pancreatitis • pulmonary embolism • rhabdomyolysis

SPECIFIC SIDE-EFFECTS
With intramuscular use Erythema • nodules • pain at injection site • swelling

SIDE-EFFECTS, FURTHER INFORMATION
With intramuscular use If the dose needs to be reduced to alleviate side-effects, it is important to recognise that the plasma-drug concentration may not fall for some time after reducing the dose, therefore it may be a month or longer before side-effects subside.

PREGNANCY Use only if potential benefit outweighs risk— toxicity in animal studies; if discontinuation during pregnancy is necessary, withdraw gradually.

TREVICTA ® PRE-FILLED SYRINGES
Manufacturer advises to consider long-acting nature of formulation—paliperidone detected in plasma up to 18 months after single dose.

BREAST FEEDING
Manufacturer advises avoid—present in milk.

TREVICTA ® PRE-FILLED SYRINGES
Manufacturer advises to consider long-acting nature of formulation—paliperidone detected in plasma up to 18 months after single dose.

HEPATIC IMPAIRMENT Caution in severe impairment—no information available.

RENAL IMPAIRMENT
With oral use Manufacturer advises reduce initial dose to 3 mg once daily if creatinine clearance 50–80 mL/minute (max. 6 mg once daily). Manufacturer advises reduce initial dose to 1.5 mg once daily if creatinine clearance 10–50 mL/minute (max. 3 mg once daily). Manufacturer advises avoid if creatinine clearance less than 10 mL/minute.

With intramuscular use Manufacturer advises avoid if creatinine clearance less than 50 mL/minute.

TREVICTA ® PRE-FILLED SYRINGES
Manufacturer advises dose should be adjusted and stabilised using once-monthly injectable paliperidone before switching to three-monthly injectable paliperidone, if creatinine clearance 50–80 mL/minute.

XEPLION ® PRE-FILLED SYRINGES
Manufacturer advises initial dose 100 mg on day 1 and then 75 mg on day 8 if creatinine clearance 50–80 mL/minute; recommended maintenance dose 50 mg (range 25–100 mg) monthly if creatinine clearance 50–80 mL/minute.

MONITORING REQUIREMENTS
With intramuscular use Treatment requires careful monitoring for optimum effect.

DIRECTIONS FOR ADMINISTRATION
With intramuscular use Correct injection technique (including the use of z-track technique) and rotation of injection sites are essential.

With oral use Always take with breakfast or always take on an empty stomach.

PATIENT AND CARER ADVICE
With oral use Patients or carers should be given advice on how to administer paliperidone tablets.

Missed doses
With intramuscular use For missed doses see product literature.

NATIONAL FUNDING/ACCESS DECISIONS

SCOTTISH MEDICINES CONSORTIUM (SMC) DECISIONS

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (September 2016) that paliperidone palmitate (Trevicta ®) is accepted for use within NHS Scotland for the maintenance treatment of schizophrenia in patients who are clinically stable on one-monthly paliperidone palmitate injectable product.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Prolonged-release suspension for injection

Trevicta (Janssen-Cilag Ltd)

Paliperidone (as Paliperidone palmitate) 200 mg per 1 ml Trevicta 175mg/0.875ml prolonged-release suspension for injection pre-filled syringes 1 pre-filled disposable injection POM £55.16

Trevicta 263mg/1.315ml prolonged-release suspension for injection pre-filled syringes 1 pre-filled disposable injection POM £73.40

Trevicta 350mg/1.75ml prolonged-release suspension for injection pre-filled syringes 1 pre-filled disposable injection POM £94.21

Trevicta 525mg/2.625ml prolonged-release suspension for injection pre-filled syringes 1 pre-filled disposable injection POM £117.77

Modified-release tablet

CAUTIONARY AND ADVISORY LABELS 2, 25

Paliperidone (Non-proprietary)

Paliperidone 3 mg Paliperidone 3mg modified-release tablets 28 tablet POM no price available

Paliperidone 6 mg Paliperidone 6mg modified-release tablets 28 tablet POM no price available

Paliperidone 9 mg Paliperidone 9mg modified-release tablets 28 tablet POM no price available

Invega (Janssen-Cilag Ltd)

Paliperidone 3 mg Invega 3mg modified-release tablets 28 tablet POM £92.78

Paliperidone 6 mg Invega 6mg modified-release tablets 28 tablet POM £92.78

Paliperidone 9 mg Invega 9mg modified-release tablets 28 tablet POM £145.92

Suspension for injection

Xeplion (Janssen-Cilag Ltd)

Paliperidone (as Paliperidone palmitate) 100 mg per 1 ml Xeplion 150mg/1.5ml suspension for injection pre-filled syringes 1 pre-filled disposable injection POM £39.59

Xeplion 75mg/0.75ml suspension for injection pre-filled syringes 1 pre-filled disposable injection POM £24.90

Xeplion 100mg/1ml suspension for injection pre-filled syringes 1 pre-filled disposable injection POM £31.07

Xeplion 50mg/0.5ml suspension for injection pre-filled syringes 1 pre-filled disposable injection POM £183.92
Quetiapine

**DRUG ACTION** Quetiapine is a dopamine D₁, dopamine D₂, 5-HT₂, alpha₁-adrenoceptor, and histamine-1 receptor antagonist.

**INDICATIONS AND DOSE**

**Schizophrenia**
- **Adult:** 25 mg twice daily for day 1, then 50 mg twice daily for day 2, then 100 mg twice daily for day 3, then 150 mg twice daily for day 4, then, adjusted according to response, usual dose 300–450 mg daily in 2 divided doses, the rate of dose titration may need to be slower and the daily dose lower in elderly patients; maximum 750 mg per day
- **Elderly:** Initially 50 mg once daily, adjusted according to response. adjusted in steps of 50 mg daily

**Treatment of mania in bipolar disorder**
- **Adult:** 50 mg twice daily for day 1, then 100 mg twice daily for day 2, then 150 mg twice daily for day 3, then 200 mg twice daily for day 4, then adjusted in steps of up to 200 mg daily, adjusted according to response, usual dose 400–800 mg daily in 2 divided doses, the rate of dose titration may need to be slower and the daily dose lower in elderly patients; maximum 800 mg per day
- **Elderly:** Initially 50 mg once daily, adjusted according to response, usual dose 400–800 mg once daily

**Treatment of depression in bipolar disorder**
- **Adult:** 50 mg once daily for day 1, then 100 mg once daily for day 2, then 150 mg once daily for day 3, then 200 mg once daily for day 4, then, adjusted according to response, usual dose 300 mg once daily, the rate of dose titration may need to be slower and the daily dose lower in elderly patients; maximum 600 mg per day
- **Elderly:** Initially 50 mg once daily, adjusted according to response. adjusted in steps of 50 mg daily

**Prevention of mania and depression in bipolar disorder**
- **Adult:** Continue at the dose effective for treatment of bipolar disorder and adjust to lowest effective dose; usual dose 300–800 mg daily in 2 divided doses
- **Elderly:** Continue at the dose effective for treatment of bipolar disorder and adjust to lowest effective dose; usual dose 300–800 mg once daily

**Adjunctive treatment of major depression**
- **Adult:** 50 mg once daily for 2 days, dose to be taken at bedtime, then 150 mg once daily for 2 days, then, adjusted according to response, usual dose 150–300 mg once daily

**DOSE EQUIVALENCE AND CONVERSION**
- Patients can be switched from immediate-release to modified-release tablets at the equivalent daily dose; to maintain clinical response, dose titration may be required.

**CAUTIONS** Cerebrovascular disease · elderly · patients at risk of aspiration pneumonia · treatment of depression in patients under 25 years (increased risk of suicide)

**INTERACTIONS** → Appendix 1: quetiapine

**SIDE-EFFECTS**
- Common or very common
- Angioedema · inappropiate secretion of antidiuretic hormone · rhabdomyolysis · Stevens-Johnson syndrome
- Frequency not known
- Suicidal behaviour (particularly on initiation) · toxic epidermal necrolysis

**PREGNANCY** Use only if potential benefit outweighs risk.

**BREAST FEEDING** Manufacturer advises avoid.

**HEPATIC IMPAIRMENT** For immediate-release tablets, initially 25 mg daily, increased daily in steps of 25–50 mg. For modified-release tablets, initially 50 mg daily, increased daily in steps of 50 mg.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, powder

**Modified-release tablet**

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Dosage Form</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atrolak XL (Accord Healthcare Ltd)</td>
<td>Quetiapine (as Quetiapine fumarate) 50 mg</td>
<td>£67.66</td>
</tr>
<tr>
<td></td>
<td>Atrolak XL 50mg tablets</td>
<td>£67.66</td>
</tr>
<tr>
<td></td>
<td>60 tablet</td>
<td>£67.66</td>
</tr>
<tr>
<td>Quetiapine (as Quetiapine fumarate) 200 mg</td>
<td>£113.10</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Atrolak XL 200mg tablets</td>
<td>£113.10</td>
</tr>
<tr>
<td></td>
<td>60 tablet</td>
<td>£113.10</td>
</tr>
<tr>
<td>Quetiapine (as Quetiapine fumarate) 300 mg</td>
<td>£170.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Atrolak XL 300mg tablets</td>
<td>£170.00</td>
</tr>
<tr>
<td></td>
<td>60 tablet</td>
<td>£170.00</td>
</tr>
<tr>
<td>Quetiapine (as Quetiapine fumarate) 400 mg</td>
<td>£226.20</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Atrolak XL 400mg tablets</td>
<td>£226.20</td>
</tr>
<tr>
<td></td>
<td>60 tablet</td>
<td>£226.20</td>
</tr>
<tr>
<td>Biquelle XL (Aspire Pharma Ltd)</td>
<td>Quetiapine (as Quetiapine fumarate) 50 mg</td>
<td>£67.66</td>
</tr>
<tr>
<td></td>
<td>Biquelle XL 50mg tablets</td>
<td>£67.66</td>
</tr>
<tr>
<td></td>
<td>60 tablet</td>
<td>£67.66</td>
</tr>
<tr>
<td>Quetiapine (as Quetiapine fumarate) 150 mg</td>
<td>£113.10</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Biquelle XL 150mg tablets</td>
<td>£113.10</td>
</tr>
<tr>
<td></td>
<td>60 tablet</td>
<td>£113.10</td>
</tr>
<tr>
<td>Quetiapine (as Quetiapine fumarate) 200 mg</td>
<td>£170.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Biquelle XL 200mg tablets</td>
<td>£170.00</td>
</tr>
<tr>
<td></td>
<td>60 tablet</td>
<td>£170.00</td>
</tr>
<tr>
<td>Quetiapine (as Quetiapine fumarate) 400 mg</td>
<td>£226.20</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Biquelle XL 400mg tablets</td>
<td>£226.20</td>
</tr>
<tr>
<td></td>
<td>60 tablet</td>
<td>£226.20</td>
</tr>
<tr>
<td>Brancico XL (Zentiva)</td>
<td>Quetiapine (as Quetiapine fumarate) 50 mg</td>
<td>£67.66</td>
</tr>
<tr>
<td></td>
<td>Brancico XL 50mg tablets</td>
<td>£67.66</td>
</tr>
<tr>
<td></td>
<td>60 tablet</td>
<td>£67.66</td>
</tr>
<tr>
<td>Quetiapine (as Quetiapine fumarate) 150 mg</td>
<td>£113.10</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Brancico XL 150mg tablets</td>
<td>£113.10</td>
</tr>
<tr>
<td></td>
<td>60 tablet</td>
<td>£113.10</td>
</tr>
<tr>
<td>Quetiapine (as Quetiapine fumarate) 200 mg</td>
<td>£170.00</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Brancico XL 200mg tablets</td>
<td>£170.00</td>
</tr>
<tr>
<td></td>
<td>60 tablet</td>
<td>£170.00</td>
</tr>
<tr>
<td>Quetiapine (as Quetiapine fumarate) 400 mg</td>
<td>£226.20</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Brancico XL 400mg tablets</td>
<td>£226.20</td>
</tr>
<tr>
<td></td>
<td>60 tablet</td>
<td>£226.20</td>
</tr>
<tr>
<td>Drug</td>
<td>Different brands (generic name)</td>
<td>Quetiapine</td>
</tr>
<tr>
<td>------------------------------</td>
<td>---------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td><strong>Psyquet</strong> (as Quetiapine fumarate) 50 mg</td>
<td>Psyquet XL (Sandoz Ltd)</td>
<td>50 mg</td>
</tr>
<tr>
<td><strong>Psyquet</strong> (as Quetiapine fumarate) 150 mg</td>
<td>Psyquet XL (Sandoz Ltd)</td>
<td>150 mg</td>
</tr>
<tr>
<td><strong>Psyquet</strong> (as Quetiapine fumarate) 200 mg</td>
<td>Psyquet XL (Sandoz Ltd)</td>
<td>200 mg</td>
</tr>
<tr>
<td><strong>Psyquet</strong> (as Quetiapine fumarate) 400 mg</td>
<td>Psyquet XL (Sandoz Ltd)</td>
<td>400 mg</td>
</tr>
<tr>
<td><strong>Seroquel</strong> (as Quetiapine fumarate) 50 mg</td>
<td>Seroquel XL (AstraZeneca UK Ltd)</td>
<td>50 mg</td>
</tr>
<tr>
<td><strong>Seroquel</strong> (as Quetiapine fumarate) 150 mg</td>
<td>Seroquel XL (AstraZeneca UK Ltd)</td>
<td>150 mg</td>
</tr>
<tr>
<td><strong>Seroquel</strong> (as Quetiapine fumarate) 200 mg</td>
<td>Seroquel XL (AstraZeneca UK Ltd)</td>
<td>200 mg</td>
</tr>
<tr>
<td><strong>Seroquel</strong> (as Quetiapine fumarate) 400 mg</td>
<td>Seroquel XL (AstraZeneca UK Ltd)</td>
<td>400 mg</td>
</tr>
<tr>
<td><strong>Zaluron</strong> (as Quetiapine fumarate) 50 mg</td>
<td>Zaluron XL (Fontus Health Ltd)</td>
<td>50 mg</td>
</tr>
<tr>
<td><strong>Zaluron</strong> (as Quetiapine fumarate) 150 mg</td>
<td>Zaluron XL (Fontus Health Ltd)</td>
<td>150 mg</td>
</tr>
<tr>
<td><strong>Zaluron</strong> (as Quetiapine fumarate) 200 mg</td>
<td>Zaluron XL (Fontus Health Ltd)</td>
<td>200 mg</td>
</tr>
<tr>
<td><strong>Zaluron</strong> (as Quetiapine fumarate) 400 mg</td>
<td>Zaluron XL (Fontus Health Ltd)</td>
<td>400 mg</td>
</tr>
</tbody>
</table>

**Risperidone**

**Drug action**: Risperidone is a dopamine D2, 5-HT2A, alpha1-adrenoceptor, and histamine-1 receptor antagonist.

**Indications and dose**

**Schizophrenia and other psychoses in patients tolerant to risperidone by mouth and taking oral risperidone up to 4 mg daily**

**By deep intramuscular injection**

- **Adult**: Initially 25 mg every 2 weeks, to be administered into the deltoid or gluteal muscle, adjusted in steps of 12.5 mg (max. per dose 50 mg every 2 weeks) at intervals of at least 4 weeks, during initiation risperidone by mouth may need to be continued for 4–6 weeks; risperidone by mouth may also be used during dose adjustment of depot injection.

**Schizophrenia and other psychoses in patients tolerant to risperidone by mouth and taking oral risperidone over 4 mg daily**

**By deep intramuscular injection**

- **Adult**: Initially 37.5 mg every 2 weeks, adjusted in steps of 12.5 mg (max. per dose 50 mg every 2 weeks) at intervals of at least 4 weeks, during initiation risperidone by mouth may need to be continued for 4–6 weeks; risperidone by mouth may also be used during dose adjustment of depot injection.

**Acute and chronic psychoses**

**By mouth**

- **Adult**: 2 mg daily in 1–2 divided doses for day 1, then 4 mg daily in 1–2 divided doses for day 2, slower titration is appropriate in some patients, usual dose 4–6 mg daily, doses above 10 mg daily only if benefit considered to outweigh risk; maximum 16 mg per day.

- **Elderly**: Initially 500 micrograms twice daily, then increased in steps of 500 micrograms twice daily, increased to 1–2 mg twice daily.

**Mania**

**By mouth**

- **Adult**: Initially 2 mg once daily, then increased in steps of 1 mg daily if required; usual dose 1–6 mg daily.

- **Elderly**: Initially 500 micrograms twice daily, then increased in steps of 500 micrograms twice daily, increased to 1–2 mg twice daily.

**Short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer’s dementia unresponsive to non-pharmacological interventions and when there is a risk of harm to self or others**

**By mouth**

- **Adult**: Initially 250 micrograms twice daily, then increased in steps of 250 micrograms twice a day on alternate days, adjusted according to response; usual dose 500 micrograms twice daily (max. per dose 1 mg twice daily).
Olanzapine embonate
(Olanzapine pamoate)

INDICATIONS AND DOSE
Maintenance in schizophrenia in patients tolerant to olanzapine by mouth (patients taking 10 mg oral olanzapine daily)

BY DEEP INTRAMUSCULAR INJECTION
Adult 18–75 years: Initially 210 mg every 2 weeks, alternatively initially 405 mg every 4 weeks, then maintenance 150 mg every 2 weeks, alternatively maintenance 300 mg every 4 weeks, maintenance dose to be started after 2 months of initial treatment, dose to be administered into the gluteal muscle, consult product literature if supplementation with oral olanzapine required
Maintenance in schizophrenia in patients tolerant to olanzapine by mouth (patients taking 15 mg oral olanzapine daily)

- **BY DEEP INTRAMUSCULAR INJECTION**
- Adult 18-75 years: Initially 300 mg every 2 weeks, then maintenance 210 mg every 2 weeks, alternatively maintenance 405 mg every 4 weeks, maintenance dose to be started after 2 months of initial treatment, dose to be administered into the gluteal muscle, consult product literature if supplementation with oral olanzapine required

**SIDE-EFFECTS**

Dose adjustment may be necessary if smoking started or stopped during treatment.

**IMPORANT SAFETY INFORMATION**

When prescribing, dispensing or administering, check that this is the correct preparation—this preparation is used for maintenance treatment and should not be used for the rapid control of an acute episode.

**CAUTIONS**

- Bone-marrow depression
- Diabetes mellitus (risk of exacerbation or ketoacidosis)
- Hypereosinophilic disorders
- Low leucocyte count
- Low neutrophil count
- Myeloproliferative disease
- Paralytic ileus
- When transferring from oral to depot therapy, the dose by mouth should be reduced gradually

**INTERACTIONS**

- Common or very common
  - Arthralgia
  - Hypercholesterolaemia
  - Hypertriglyceridaemia
  - Increased appetite
  - Malaise

- Uncommon
  - Alopecia
  - Amnesia
  - Bradycardia
  - Epistaxis

- Rare
  - Hepatitis
  - Pancreatitis
  - Rhabdomyolysis

**SIDE-EFFECTS, FURTHER INFORMATION**

If the dose needs to be reduced to alleviate side-effects, it is important to recognise that the plasma-drug concentration may not fall for some time after reducing the dose, therefore it may be a month or longer before side-effects subside.

**OVERDOSE**

Post-injection reactions have been reported leading to signs and symptoms of overdose.

**PREGNANCY**

Use only if potential benefit outweighs risk; neonatal lethargy, tremor, and hypertonopia reported when used in third trimester.

**BREAST FEEDING**

Avoid—present in milk.

**HEPATIC IMPAIRMENT**

Initially 150 mg every 4 weeks; increase with caution in moderate impairment.

**RENAL IMPAIRMENT**

Initially 150 mg every 4 weeks.

**MONITORING REQUIREMENTS**

- Observe patient for at least 3 hours after injection.
- Treatment requires careful monitoring for optimum effect.
- Blood lipids and weight should be measured at baseline, at 3 months (weight should be measured at frequent intervals during the first 3 months), and then yearly with antipsychotic drugs. Patients taking olanzapine require more frequent monitoring of these parameters: every 3 months for the first year, then yearly.
- Fasting blood glucose should be measured at baseline, at 4–6 months, and then yearly. Patients taking olanzapine should have fasting blood glucose tested at baseline, after one month’s treatment, then every 4–6 months.

**DIRECTIONS FOR ADMINISTRATION**

Correct injection technique (including use of z-track technique) and rotation of injection sites are essential.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder and solvent for suspension for injection**

- **Olanzapine (as Olanzapine embonate monohydrate)**
  - 210 mg Zypadhera 210mg powder and solvent for suspension for injection vials | 1 vial (Pow) £142.76 (Hospital only)
  - 300 mg Zypadhera 300mg powder and solvent for suspension for injection vials | 1 vial (Pow) £222.64 (Hospital only)
  - 405 mg Zypadhera 405mg powder and solvent for suspension for injection vials | 1 vial (Pow) £285.52 (Hospital only)

**4 Movement disorders**

**Motor neurone disease**

17-May-2017

**Description of condition**

Motor neurone disease is a neurodegenerative condition affecting the brain and spinal cord. Degeneration of motor neurones leads to progressive muscle weakness; resulting symptoms include muscle cramps, wasting and stiffness, loss of dexterity, reduced respiratory function and cognitive dysfunction. The most common form is amyotrophic lateral sclerosis.

Patients suspected of having developed motor neurone disease should be referred to a neurologist without delay.

**Aims of treatment**

As there is no cure, treatment focuses on maintaining functional ability and managing symptoms.

**Non-drug treatment**

Non-drug treatment includes nutrition, psychosocial support, physiotherapy, exercise programmes and use of special equipment or mobility aids.

**Management of symptoms**

**Muscular symptoms**

- Quinine p. 586 [unlicensed indication] is recommended as first line treatment for muscle cramps. If quinine is ineffective, not tolerated or contra-indicated, baclofen p. 1026 [unlicensed indication] should be considered as second line treatment. Subsequent treatment options include tizanidine p. 1027 [unlicensed indication], dantrolene sodium p. 1236 [unlicensed indication] or gabapentin p. 301 [unlicensed indication].
- Symptoms of muscle stiffness, spasticity or increased tone can be managed with baclofen, tizanidine, dantrolene sodium or gabapentin [unlicensed indication]. Treatment of severe spasticity may require specialist referral.

**Saliva problems**

- A trial of an antimuscarinic drug [unlicensed indication] can be considered for excessive drooling of saliva. Glycopyrronium bromide p. 1225 is recommended in patients who have cognitive impairment as it has fewer central nervous system side-effects. If initial treatment is
386 Movement disorders

ineffective, not tolerated or contra-indicated, referral for specialist administration of botulinum toxin type A p. 387 [unlicensed indication] may be required.

Humidification, nebulisers and carbocisteine p. 280 can be used to treat patients with thick, tenacious saliva. 

Respiratory symptoms
Reversible causes of worsening respiratory impairment (such as respiratory tract infections or secretion problems) should be treated before considering other options.

Patients experiencing breathlessness can be treated with opioids [unlicensed indication], or benzodiazepines [unlicensed indication] if the patient’s symptoms are exacerbated by anxiety. Non-invasive ventilation should be considered in patients with respiratory impairment. 

Amyotrophic lateral sclerosis
Riluzole p. 1023 is licensed for use in patients with amyotrophic lateral sclerosis to extend life or to extend the time to mechanical ventilation—see National funding/access decisions under riluzole.

Useful Resources

4.1 Dystonias and other involuntary movements

Other drugs used for Dystonias and other involuntary movements Chlorpromazine hydrochloride, p. 367 · Clonidine hydrochloride, p. 139 · Clozapine, p. 377 · Diazepam, p. 327 · Haloperidol, p. 368 · Orphenadrine hydrochloride, p. 391 · Pericyazine, p. 370 · Pramipexole, p. 402 · Procyclidine, p. 371 · Promazine hydrochloride, p. 504 · Rotigotine, p. 406 · Trifluoperazine, p. 372 · Trihexyphenidyl hydrochloride, p. 392

ANTIPSYCHOTICS > FIRST-GENERATION

Promazine hydrochloride

● INDICATIONS AND DOSE

Short-term adjunctive management of psychomotor agitation
> BY MOUTH
> Adult: 100–200 mg 4 times a day

Agitation and restlessness in elderly
> BY MOUTH
> Elderly: 25–50 mg 4 times a day

● CONTRA-INDICATIONS

CNS depression · comatose states · phaeochromocytoma

● CAUTIONS

Cerebral arteriosclerosis

● INTERACTIONS

→ Appendix 1: phenothiazines

● SIDE-EFFECTS

Haemolytic anaemia

● HEPATIC IMPAIRMENT

Can precipitate coma; phenothiazines are hepatotoxic.

● RENAL IMPAIRMENT

Start with small doses in severe renal impairment because of increased cerebral sensitivity.

● LESS SUITABLE FOR PRESCRIBING

Promazine hydrochloride is less suitable for prescribing.

● MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Oral solution

CAUTIONARY AND ADVISORY LABELS 2

Promazine hydrochloride (Non-proprietary)

Promazine hydrochloride 5 mg per 1 ml Promazine 25mg/5ml syrup | 150 ml [P] £13.00 DT price = £13.06

Promazine 25mg/5ml oral solution | 150 ml [P] £13.06 DT price = £13.06

Promazine hydrochloride 10 mg per 1 ml Promazine 50mg/5ml syrup | 150 ml [P] £15.00 DT price = £15.06

Promazine 50mg/5ml oral solution | 150 ml [P] £15.06 DT price = £15.06

Tablet

CAUTIONARY AND ADVISORY LABELS 2

Promazine hydrochloride (Non-proprietary)

Promazine hydrochloride 25 mg Promazine 25mg tablets | 100 tablet [P] £4.99 DT price = £43.19

Prazine 25mg tablets | 50 tablet [P] no price available

Promazine hydrochloride 50 mg Promazine 50mg tablets | 100 tablet [P] £76.49 DT price = £76.10

CNS STIMULANTS

Piracetam

● INDICATIONS AND DOSE

Adjuvant treatment of cortical myoclonus
> BY MOUTH
> Adult: Initially 7.2 g daily in 2–3 divided doses, then increased in steps of 4.8 g every 3–4 days, adjusted according to response, subsequently, attempts should be made to reduce dose of concurrent therapy; maximum 24 g per day

● CONTRA-INDICATIONS

Cerebral haemorrhage · Huntington’s chorea

● CAUTIONS

Gastric ulcer · history of haemorrhagic stroke · increased risk of bleeding · major surgery · underlying disorders of haemostasis

● SIDE-EFFECTS

> Common or very common Hyperkinesia · nervousness · weight gain

> Uncommon Abdominal pain · anxiety · asthenia · ataxia · confusion · depression · dermatitis · diarrhoea · drowsiness · haemorrhagic disorder · hallucination · headache · insomnia · nausea · pruritus · urticaria · vertigo · vomiting

● PREGNANCY

Avoid.

● BREAST FEEDING

Avoid.

● HEPATIC IMPAIRMENT

Adjust dose if both hepatic and renal impairment.

● RENAL IMPAIRMENT

Use two-thirds of normal dose if eGFR 50–80 mL/minute/1.73 m²; use one-third of normal dose in 2 divided doses if eGFR 30–50 mL/minute/1.73 m²; use one-sixth of normal dose as a single dose if eGFR 20–30 mL/minute/1.73 m². Avoid if eGFR less than 20 mL/minute/1.73 m².

● TREATMENT CESSATION

Avoid abrupt withdrawal.

● DIRECTIONS FOR ADMINISTRATION

Follow the oral solution with a glass of water (or soft drink) to reduce bitter taste.

● PRESCRIBING AND DISPENSING INFORMATION

Piracetam has been used in children 16 years and over as adjuvant treatment for cortical myoclonus.
Tetrabenazine

**INDICATIONS AND DOSE**
Movement disorders due to Huntington's chorea, hemiballismus, senile chorea, and related neurological conditions
- **BY MOUTH**
  - Adult: Initially 25 mg 3 times a day, then increased, if tolerated, in steps of 25 mg every 3–4 days; maximum 200 mg per day
  - Elderly: Lower initial dose may be necessary
  - **Moderate to severe tardive dyskinesia**
    - **BY MOUTH**
      - Adult: Initially 12.5 mg daily, dose to be gradually increased according to response

**CONTRA-INDICATIONS**
- Depression
- Parkinsonism
- Phaeochromocytoma
- Prolactin-dependent tumours

**CAUTIONS**
- Susceptibility to QT-interval prolongation

**INTERACTIONS**
- Appendix 1: tetrabenazine

**SIDE-EFFECTS**
- Common or very common: Anxiety, confusion, constipation, depression, diarrhoea, drowsiness, dysphagia, hypotension, insomnia, nausea, parkinsonism, vomiting
- Uncommon: Altered consciousness level, extrapyramidal disorders, hyperthermia
- Rare: Neuroleptic malignant syndrome
- Very rare: Rhabdomyolysis
- Frequency not known: Agitation, amnesia, ataxia, bradycardia, disorientation, dizziness, dry mouth, dyspepsia

**PREGNANCY**
- Avoid unless essential—toxicity in animal studies.

**BREAST FEEDING**
- Avoid.

**HEPATIC IMPAIRMENT**
- Use half initial dose and slower dose titration in mild to moderate impairment. Use with caution in severe impairment.

**RENAL IMPAIRMENT**
- Use with caution.

**TREATMENT CESSATION**
- Avoid abrupt withdrawal.

**PATIENT AND CARER ADVICE**
- Driving and skilled tasks
- May affect performance of skilled tasks (e.g. driving).

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Oral solution**
**CAUTIONARY AND ADVISORY LABELS**
- Piracetam (Non-proprietary)
  - Piracetam 333.3 mg per 1 ml: Piracetam 333.3 mg/ml oral solution sugar-free sugar-free 300 ml [PoM] no price available
- Nootropil (UCB Pharma Ltd)
  - Nootropil 333.3 mg per 1 ml: Nootropil 33% oral solution sugar-free 300 ml [PoM] £16.31

**Tablet**
**CAUTIONARY AND ADVISORY LABELS**
- Nootropil (UCB Pharma Ltd)
  - Piracetam 800 mg: Nootropil 800 mg tablets 90 tablet [PoM] £11.75
  - Piracetam 1.2 gram: Nootropil 1200 mg tablets 60 tablet [PoM] £10.97

**MONOAMINE DEPLETING DRUGS**

**Botulinum toxin type A**

**INDICATIONS AND DOSE**
Treatment of focal spasticity (including hand and wrist disability associated with stroke) (specialist use only)
- Blepharospasm (specialist use only)
- Hemifacial spasm (specialist use only)
- Spasmodic torticollis (specialist use only)
- Severe hyperhidrosis of the axillae (specialist use only)
- Prophylaxis of headaches in adults with chronic migraine (specialist use only)
- Temporary improvement of moderate to severe wrinkles between the eyebrows in adults under 65 years (specialist use only)
- Ankle disability due to lower limb spasticity associated with stroke (specialist use only)
- Management of bladder dysfunctions (specialist use only)
- Temporary improvement of moderate to severe crow's feet (specialist use only)
- **BY SUBCUTANEOUS INJECTION, OR BY INTRADERMAL INJECTION, OR BY INTRAMUSCULAR INJECTION**
- Adult: (consult product literature)

**DOSE EQUIVALENCE AND CONVERSION**
- **Important:** information is specific to each individual preparation.

**CONTRA-INDICATIONS**
- Acute urinary retention (specific to use in bladder disorders only)
- Catheterisation difficulties (specific to use in bladder disorders only)
- Generalised disorders of muscle activity: infection at injection site, myasthenia gravis, presence of bladder calculi (specific to use in bladder disorders only)
- Urinary tract infection (specific to use in bladder disorders only)

**CAUTIONS**
- **GENERAL CAUTIONS**
  - Atrophy in target muscle
  - Chronic respiratory disorder
  - Elderly: excessive weakness in target muscle
  - History of aspiration
  - History of dysphagia
  - Inflammation in target muscle
  - Neurological disorders
  - Neuromuscular disorders
  - Off-label use (fatal adverse events reported)

**SPECIFIC CAUTIONS**
- When used for blepharospasm or hemifacial spasm

**CAUTIONS, FURTHER INFORMATION**
Neuromuscular or neurological disorders can lead to increased sensitivity and exaggerated muscle weakness including dysphagia and respiratory compromise.
- Blepharospasm or hemifacial spasm
- Reduced blinking can lead to corneal exposure, persistent epithelial defect and corneal ulceration (especially in those with VFH nerve disorders)—testing of corneal sensation in previously operated eyes, avoidance of injection in lower lid area to avoid ectropion, and vigorous treatment of epithelial defect needed.

**Tetrabenazine**

**INDICATIONS AND DOSE**
Movement disorders due to Huntington's chorea, hemiballismus, senile chorea, and related neurological conditions
- **BY MOUTH**
  - Adult: Initially 25 mg 3 times a day, then increased, if tolerated, in steps of 25 mg every 3–4 days; maximum 200 mg per day
  - Elderly: Lower initial dose may be necessary
  - **Moderate to severe tardive dyskinesia**
    - **BY MOUTH**
      - Adult: Initially 12.5 mg daily, dose to be gradually increased according to response

**CONTRA-INDICATIONS**
- Depression
- Parkinsonism
- Phaeochromocytoma
- Prolactin-dependent tumours

**CAUTIONS**
- Susceptibility to QT-interval prolongation

**INTERACTIONS**
- Appendix 1: tetrabenazine

**SIDE-EFFECTS**
- Common or very common: Anxiety, confusion, constipation, depression, diarrhoea, drowsiness, dysphagia, hypotension, insomnia, nausea, parkinsonism, vomiting
- Uncommon: Altered consciousness level, extrapyramidal disorders, hyperthermia
- Rare: Neuroleptic malignant syndrome
- Very rare: Rhabdomyolysis
- Frequency not known: Agitation, amnesia, ataxia, bradycardia, disorientation, dizziness, dry mouth, dyspepsia

**PREGNANCY**
- Avoid unless essential—toxicity in animal studies.

**BREAST FEEDING**
- Avoid.

**HEPATIC IMPAIRMENT**
- Use half initial dose and slower dose titration in mild to moderate impairment. Use with caution in severe impairment.

**RENAL IMPAIRMENT**
- Use with caution.

**TREATMENT CESSATION**
- Avoid abrupt withdrawal.

**PATIENT AND CARER ADVICE**
- Driving and skilled tasks
- May affect performance of skilled tasks (e.g. driving).

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Tablet**
**CAUTIONARY AND ADVISORY LABELS**
- Tetrabenazine 25 mg: Tetrabenazine 25 mg tablets 112 tablet [PoM] £100.00 DT price = £100.00
- Revocon (Sun Pharmaceuticals UK Ltd)
  - Tetrabenazine 25 mg: Revocon 25 mg tablets 112 tablet [PoM] £100.00 DT price = £100.00
- Xenazine (Alliance Pharmaceuticals Ltd)
  - Tetrabenazine 25 mg: Xenazine 25 mg tablets 112 tablet [PoM] £100.00 DT price = £100.00

**MUSCLE RELAXANTS**

**NEUROTOXINS (BOTULINUM TOXINS)**

**Botulinum toxin type A**

**INDICATIONS AND DOSE**
Treatment of focal spasticity (including hand and wrist disability associated with stroke) (specialist use only)
- Blepharospasm (specialist use only)
- Hemifacial spasm (specialist use only)
- Spasmodic torticollis (specialist use only)
- Severe hyperhidrosis of the axillae (specialist use only)
- Prophylaxis of headaches in adults with chronic migraine (specialist use only)
- Temporary improvement of moderate to severe wrinkles between the eyebrows in adults under 65 years (specialist use only)
- Ankle disability due to lower limb spasticity associated with stroke (specialist use only)
- Management of bladder dysfunctions (specialist use only)
- Temporary improvement of moderate to severe crow's feet (specialist use only)
- **BY SUBCUTANEOUS INJECTION, OR BY INTRADERMAL INJECTION, OR BY INTRAMUSCULAR INJECTION**
- Adult: (consult product literature)

**DOSE EQUIVALENCE AND CONVERSION**
- **Important:** information is specific to each individual preparation.

**CONTRA-INDICATIONS**
- Acute urinary retention (specific to use in bladder disorders only)
- Catheterisation difficulties (specific to use in bladder disorders only)
- Generalised disorders of muscle activity: infection at injection site, myasthenia gravis, presence of bladder calculi (specific to use in bladder disorders only)
- Urinary tract infection (specific to use in bladder disorders only)

**CAUTIONS**
- **GENERAL CAUTIONS**
  - Atrophy in target muscle
  - Chronic respiratory disorder
  - Elderly: excessive weakness in target muscle
  - History of aspiration
  - History of dysphagia
  - Inflammation in target muscle
  - Neurological disorders
  - Neuromuscular disorders
  - Off-label use (fatal adverse events reported)

**SPECIFIC CAUTIONS**
- When used for blepharospasm or hemifacial spasm

**CAUTIONS, FURTHER INFORMATION**
Neuromuscular or neurological disorders can lead to increased sensitivity and exaggerated muscle weakness including dysphagia and respiratory compromise.
- Blepharospasm or hemifacial spasm
- Reduced blinking can lead to corneal exposure, persistent epithelial defect and corneal ulceration (especially in those with VFH nerve disorders)—careful testing of corneal sensation in previously operated eyes, avoidance of injection in lower lid area to avoid ectropion, and vigorous treatment of epithelial defect needed.
INTERACTIONS  → Appendix 1: botulinum toxin type A

SIDE-EFFECTS

GENERAL SIDE-EFFECTS

- **Common or very common** Excessive doses may paralyse distant muscles; increased electrophysiologic jitter in some distant muscles; influenza-like symptoms; misplaced injections may paralyse nearby muscle groups

- **Rare** Antibody formation (substantial deterioration in response), arrhythmias, myocardial infarction, seizures

- **Very rare** Aspiration, dysphagia, dysphonia, exaggerated muscle weakness, respiratory disorders

SPECIFIC SIDE-EFFECTS

- **Common or very common**
  - When used for axillary hyperhidrosis Abnormal skin odour, alopecia, hot flushes, non-axillary sweating, pain in extremities, paraesthesia, pruritus, subcutaneous nodule
  - When used for blepharospasm or hemifacial spasm Dry eye, ecchymosis, facial oedema, irritation, keratitis, lacrimation, lagopthalmos, photophobia, ptosis
  - When used for focal upper-limb spasticity associated with stroke Dysphagia, hypertonia, purpura
  - When used for spasmotic torticollis Back pain, dizziness, drowsiness, dry mouth, dysphagia and pooling of saliva (occurs most frequently after injection into sternomastoid muscle); headache, hypertonia, malaise, nausea, numbness, rhexis, stiffness, weakness
  - When used for temporary improvement of moderate to severe wrinkles between the eyebrows Facial oedema, headache, ptosis

- **Uncommon**
  - When used for axillary hyperhidrosis Joint pain, myalgia
  - When used for blepharospasm or hemifacial spasm Conjunctivitis, dermatitis, diplopia, dizziness, drooping, dry mouth, ectropion, entropion, facial weakness, headache, paraesthesia, tiredness, visual disturbances
  - When used for focal upper-limb spasticity associated with stroke Amnesia, arthralgia, bursitis, cough, depression, dry mouth, dysaesthesia, haematoma, headache, insomnia, malaise, nausea, pain in extremities, paraesthesia, peripheral oedema, vertigo
  - When used for spasmodic torticollis Collitis, diarrhoea, diplopia, dysphoria, eye pain, myalgia, ptosis, skeletal pain, sweating, tremor, voice alteration, vomiting
  - When used for temporary improvement of moderate to severe wrinkles between the eyebrows Anxiety, asthenia, blepharitis, dizziness, dry mouth, dry skin, muscle cramp, nausea, paraesthesia, photosensitivity reactions, tinnitus, visual disturbances

- **Rare**
  - When used for blepharospasm or hemifacial spasm Eyelid bruising and swelling (minimised by applying gentle pressure at injection site immediately after injection)

- **Very rare**
  - When used for blepharospasm or hemifacial spasm Angle-closure glaucoma, corneal epithelial defect, corneal perforation, corneal ulceration

- **Frequency not known**
  - When used for focal lower-limb spasticity associated with stroke Arthralgia, peripheral oedema, rash

CONCEPTION AND CONTRACEPTION  Avoid in women of child-bearing age unless using effective contraception.

PREGNANCY  Avoid unless essential—toxicity in animal studies (manufacturer of Botox® advise avoid).

BREAST FEEDING  Low risk of systemic absorption but avoid unless essential.

PRESCRIBING AND DISPENSING INFORMATION  Preparations are not interchangeable.

PATIENT AND CARER ADVICE  Patients and carers should be warned of the signs and symptoms of toxin spread, such as muscle weakness and breathing difficulties; they should be advised to seek immediate medical attention if swallowing, speech or breathing difficulties occur.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

- Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (June 2012) NICE TA260

Botulinum toxin type A is recommended as an option for the prophylaxis of headaches in adults with chronic migraine, (defined as headaches on at least 15 days per month, of which at least 8 days are with migraine), that has not responded to at least three prior pharmacological prophylaxis therapies and whose condition is appropriately managed for medication overuse.

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised that Azzalure® and Vistabel® (December 2010), and Bocouture® (February 2011) are not recommended for use within NHS Scotland.

The Scottish Medicines Consortium has advised (February 2017) that botulinum toxin type A (Botox®) is accepted for restricted use within NHS Scotland for the prophylaxis of headaches in adults with chronic migraine, (defined as headaches on at least 15 days per month, of which at least 8 days are with migraine), that has not responded to at least three prior oral pharmacological prophylaxis therapies and whose condition is appropriately managed for medication overuse.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for injection

- **Azzalure® (Galdarima (UK) Ltd)**
  - Botulinum toxin type A 125 unit Azzalure 125 unit powder for solution for injection vials | 1 vial (£64.00) | 2 vial (£128.00)

- **Bocouture® (Merz Pharma UK Ltd)**
  - Botulinum toxin type A 50 unit Bocouture 50 unit powder for solution for injection vials | 1 vial (£72.00)
  - Botulinum toxin type A 100 unit Bocouture 100 unit powder for solution for injection vials | 1 vial (£228.90)

- **Botox® (Allergan Ltd)**
  - Botulinum toxin type A 50 unit Botox 50 unit powder for solution for injection vials | 1 vial (£77.50)
  - Botulinum toxin type A 100 unit Botox 100 unit powder for solution for injection vials | 1 vial (£138.20)

- **Dysport® (Ipsen Ltd)**
  - Botulinum toxin type A 300 unit Dysport 300 unit powder for solution for injection vials | 1 vial (£92.40)
  - Botulinum toxin type A 500 unit Dysport 500 unit powder for solution for injection vials | 2 vial (£308.00)

- **Xeomin® (Merz Pharma UK Ltd)**
  - Botulinum toxin type A 50 unit Xeomin 50 unit powder for solution for injection vials | 1 vial (£72.00)

- **Botox® (Allergan Ltd)**
  - Botulinum toxin type A 200 unit Botox 200 unit powder for solution for injection vials | 1 vial (£276.40)

- **Dysport® (Ipsen Ltd)**
  - Botulinum toxin type A 300 unit Dysport 300 unit powder for solution for injection vials | 1 vial (£92.40)
  - Botulinum toxin type A 500 unit Dysport 500 unit powder for solution for injection vials | 2 vial (£308.00)
  - Xeomin® (Merz Pharma UK Ltd)
  - Botulinum toxin type A 50 unit Xeomin 50 unit powder for solution for injection vials | 1 vial (£72.00)
  - Botulinum toxin type A 100 unit Xeomin 100 unit powder for solution for injection vials | 1 vial (£129.90)
  - Botulinum toxin type A 200 unit Xeomin 200 unit powder for solution for injection vials | 1 vial (£259.80) (Hospital only)
### Botulinum toxin type B

**INDICATIONS AND DOSE**

Spasmodic torticollis (cervical dystonia) (specialist use only)

- **BY INTRAMUSCULAR INJECTION**
  - Adult: Initially 5000–10 000 units, adjusted according to response, dose to be divided between 2–4 most affected muscles

**DOSE EQUIVALENCE AND CONVERSION**

- Important: information specific to each individual preparation.

**CONTRA-INDICATIONS**

- Neuromuscular disorders
- Neuromuscular junctional disorders

**CAUTIONS**

- History of dysphagia or aspiration: off-label use (risk of toxin spread) - tolerance may occur

**INTERACTIONS**

- Appendix 1: botulinum toxin type B

**SIDE-EFFECTS**

- Common or very common
  - Dry mouth
  - Dyspepsia
  - Dysphagia
  - Dysphonia
  - Headache
  - Increased electrophysiological jitter in some distant muscles
  - Influenza-like symptoms
  - Malaise
  - Neck pain
  - Nasal irritation
  - Nasal stuffiness
  - Nausea
  - Pharyngitis
  - Pruritus
  - Rhinitis
  - Rash
  - Respiration disorders
  - Respiratory disorders
  - Vertigo
  - Vomiting

**PREGNANCY**

- Low risk of systemic absorption but avoid unless essential.

**BREAST FEEDING**

- Low risk of systemic absorption but avoid unless essential.

**DIRECTIONS FOR ADMINISTRATION**

- Injection may be diluted with sodium chloride 0.9%.

**PRESCRIBING AND DISPENSING INFORMATION**

- Important: not interchangeable with other botulinum toxin preparations.

**PATIENT AND CARER ADVICE**

- Patients should be warned of the signs and symptoms of toxin spread, such as muscle weakness and breathing difficulties; they should be advised to seek immediate medical attention if swallowing, speech or breathing difficulties occur.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **NeuroBloc** (Eisai Ltd)
  - Botulinum toxin type B 5000 unit per 1 ml
  - 5,000 units/1 ml solution for injection vials: 1 vial
  - 10,000 units/2 ml solution for injection vials: 1 vial
  - 20,000 units/4 ml solution for injection vials: 1 vial

**NEUROPROTECTIVE DRUGS**

### Tafamidis

**INDICATIONS AND DOSE**

Treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP) in patients with stage 1 symptomatic polyneuropathy to delay peripheral neurological impairment (initiated under specialist supervision)

- **BY MOUTH**
  - Adult: 20 mg once daily

**SIDE-EFFECTS**

- Abdominal pain
- Diarrhoea
- Urinary tract infection
- Vaginal infection

**CONCEPTION AND CONTRACEPTION**

- Exclude pregnancy before treatment and ensure effective contraception during and for one month after stopping treatment.

**PREGNANCY**

- Avoid (toxicity in animal studies).

**BREAST FEEDING**

- Avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT**

- Caution in severe impairment—no information available.

**PRESCRIBING AND DISPENSING INFORMATION**

- Tafamidis should be prescribed in addition to standard treatment, but before liver transplantation; it should be discontinued in patients who undergo liver transplantation.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

- CAUTIONARY AND ADVISORY LABELS 25
  - **Vyndaqel** (Pfizer Ltd)
  - Tafamidis 20mg

**Appendix**

**4.2 Parkinson’s disease**

### Parkinson’s disease and related disorders

#### Parkinson’s disease

In idiopathic Parkinson’s disease, the progressive degeneration of pigmented neurones in the substantia nigra leads to a deficiency of the neurotransmitter dopamine. The resulting neurochemical imbalance in the basal ganglia causes the characteristic signs and symptoms of the illness. Drug therapy does not prevent disease progression, but it improves most patients’ quality of life.

Patients with suspected Parkinson’s disease should be referred to a specialist to confirm the diagnosis; the diagnosis should be reviewed every 6–12 months.

Features resembling those of Parkinson’s disease can occur in diseases such as progressive supranuclear palsy and multiple system atrophy, but they do not normally show a sustained response to the drugs used in the treatment of idiopathic Parkinson’s disease.

When initiating treatment, patients should be advised about its limitations and possible side-effects. About 5–10% of patients with Parkinson’s disease respond poorly to treatment.

Treatment is usually not started until symptoms cause significant disruption of daily activities. Levodopa, non-ergot-derived dopamine-receptor agonists, or monoamine-oxidase-B inhibitors can be prescribed for initial treatment in early Parkinson’s disease. Therapy with two or more antiparkinsonian drugs may be necessary as the disease progresses. Most patients eventually require levodopa and subsequently develop motor complications.

**Elderly**

Antiparkinsonian drugs can cause confusion in the elderly. It is particularly important to initiate treatment with low doses and to increase the dose gradually.

#### Dopaminergic drugs used in Parkinson’s disease

**Dopamine-receptor agonists**

The dopamine-receptor agonists have a direct action on dopamine receptors. Initial treatment of Parkinson’s disease is often with the dopamine-receptor agonists pramipexole p. 402, ropinirole p. 404, and rotigotine p. 406. The ergot-derived dopamine-receptor agonists bromocriptine p. 399, cabergoline p. 400, and pergolide p. 401 are rarely used because of the risk of fibrotic reactions.
When used alone, dopamine-receptor agonists cause fewer motor complications in long-term treatment compared with levodopa treatment but the overall motor performance improves slightly less. The dopamine-receptor agonists are associated with more psychiatric side-effects than levodopa. 

Dopamine-receptor agonists are also used with levodopa in more advanced disease. If a dopamine-receptor agonist is added to levodopa therapy, the dose of levodopa needs to be reduced.

Apomorphine hydrochloride p. 398 is a potent dopamine-receptor agonist that is sometimes helpful in advanced disease for patients experiencing unpredictable 'off' periods with levodopa treatment. Apomorphine hydrochloride should be initiated in a specialist clinic. After an overnight withdrawal of oral antiparkinsonian medication to induce an 'off' episode, the threshold dose of apomorphine hydrochloride is determined. Oral antiparkinsonian medication is then restarted. The patient must be taught to self-administer apomorphine hydrochloride by subcutaneous injection into the lower abdomen or outer thigh at the first sign of an 'off' episode. Once treatment has been established it may be possible to gradually reduce other antiparkinsonian medications.

**Levodopa**

Levodopa, the amino-acid precursor of dopamine, acts by replenishing depleted striatal dopamine. It is given with an extracerebral dopa-decarboxylase inhibitor, which reduces the peripheral conversion of levodopa to dopamine, thereby limiting side-effects such as nausea, vomiting, and cardiovascular effects; additionally, effective brain-dopamine concentrations are achieved with lower doses of levodopa. The extracerebral dopa-decarboxylase inhibitors used with levodopa are benserazide (in co-beneldopa p. 394) and carbidopa (in co-careldopa p. 396).

Levodopa, in combination with a dopa-decarboxylase inhibitor, is useful in the elderly or frail, in patients with other significant illnesses, and in those with more severe symptoms. It is effective and well tolerated in the majority of patients.

Levodopa therapy should be initiated at a low dose and increased in small steps; the final dose should be as low as possible. Intervals between doses should be chosen to suit the needs of the individual patient.

Nausea and vomiting with co-beneldopa or co-careldopa are rarely dose-limiting and domperidone p. 410 can be useful in controlling these effects.

Levodopa treatment is associated with potentially troublesome motor complications including response fluctuations and dyskinesias. Response fluctuations are characterised by large variations in motor performance, with normal function during the 'on' period, and weakness and restricted mobility during the 'off' period. 'End-of-dose' deterioration with progressively shorter duration of benefit also occurs. Modified-release preparations may help with 'end-of-dose' deterioration or nocturnal immobility and rigidity. Motor complications are particularly problematic in young patients treated with levodopa.

**Monoamine-oxidase-B inhibitors**

Rasagiline p. 406 and selegiline hydrochloride p. 407 are monoamine-oxidase-B inhibitors used in Parkinson's disease. Early treatment with selegiline hydrochloride alone can delay the need for levodopa therapy.

**Antimuscarinic drugs used in parkinsonism**

Antimuscarinic drugs can be useful in drug-induced parkinsonism, but they are generally not used in idiopathic Parkinson’s disease because they are less effective than dopaminergic drugs and they are associated with cognitive impairment.

The antimuscarinic drugs orphenadrine hydrochloride p. 391, procyclidine hydrochloride p. 391, and trihexyphenidyl hydrochloride p. 392 reduce the symptoms of parkinsonism induced by antipsychotic drugs, but there is no justification for giving them routinely in the absence of parkinsonian side-effects. Tardive dyskinesia is not improved by antimuscarinic drugs and may be made worse.

In idiopathic Parkinson’s disease, antimuscarinic drugs reduce tremor and rigidity but they have little effect on Bradykinesia. They may be useful in reducing sialorrhoea. There are no important differences between the antimuscarinic drugs, but some patients tolerate one better than another.

Procyclidine hydrochloride can be given parenterally and is effective emergency treatment for acute drug-induced dystonic reactions.

If treatment with an antimuscarinic is ineffective, intravenous diazepam p. 327 can be given for life-threatening acute drug-induced dystonic reactions.

**Drugs used in essential tremor, chorea, tics, and related disorders**

Tetrabenazine p. 387 is mainly used to control movement disorders in Huntington's chorea and related disorders. Tetrabenazine can also be prescribed for the treatment of tardive dyskinesia if switching or withdrawing the causative antipsychotic drug is not effective. It acts by depleting nerve endings of dopamine. It is effective in only a proportion of patients and its use may be limited by the development of depression.

Haloperidol p. 368 [unlicensed indication], olanzapine p. 379 [unlicensed indication], risperidone p. 383 [unlicensed indication], and quetiapine p. 382 [unlicensed indication], can also be used to suppress chorea in Huntington's disease. Haloperidol can also improve motor tics and symptoms of Tourette syndrome and related choras. Other treatments for Tourette syndrome include pimozide p. 371 [unlicensed indication] (important: ECG monitoring required), clonidine hydrochloride p. 139 [unlicensed indication], and sulpiride p. 372 [unlicensed indication]. Trihexyphenidyl hydrochloride in high dosage can also improve some movement disorders; it is sometimes necessary to build the dose up over many weeks. Chlorpromazine hydrochloride p. 367 and haloperidol are used to relieve intractable hiccup.

Propranolol hydrochloride p. 145 or another beta-adrenoceptor blocking drug may be useful in treating essential tremor or tremors associated with anxiety or thyrotoxicosis. Primidone p. 319 in some cases provides relief from benign essential tremor; the dose is increased slowly to reduce side-effects.

Piracetam p. 386 is used as an adjunctive treatment for myoclonus of cortical origin. After an acute episode, attempts should be made every 6 months to decrease or discontinue treatment.

Riluzole p. 1023 is used to extend life in patients with motor neurone disease who have amyotrophic lateral sclerosis.

**Torsion dystonia and other involuntary movements**

Treatment with botulinum toxin type A p. 387 can be considered after an acquired non-progressive brain injury if rapid-onset spasticity causes postural or functional difficulties.
Orphenadrine hydrochloride

**DRUG ACTION** Orphenadrine exerts its antiparkinsonian action by reducing the effects of the relative central cholinergic excess that occurs as a result of dopamine deficiency.

**INDICATIONS AND DOSE**
- **Parkinsonism | Drug-induced extrapyramidal symptoms (but not tardive dyskinesia)**
  - **BY MOUTH**
    - Adult: Initially 150 mg daily in divided doses, then increased in steps of 50 mg every 2–3 days, adjusted according to response; usual dose 150–300 mg daily in divided doses; maximum 400 mg per day
    - Elderly: Preferably dose at lower end of range

**SIDE-EFFECTS**
- **Common or very common**
  - Hallucinations
  - Restlessness
  - Constipation
  - Seizures
  - Frequency not known
  - Anxiety, blurred vision, confusion, constipation, dizziness, dry mouth, euphoria, hallucinations, impaired memory, nausea, rash, restlessness, tachycardia, vomiting

**PREGNANCY** Caution.

**BREAST FEEDING** Caution.

**HEPATIC IMPAIRMENT** Use with caution.

**RENAI IMPAIRMENT** Use with caution.

**TREATMENT CESSATION** Avoid abrupt withdrawal in patients taking long-term treatment.

**PATIENT AND CARER ADVICE**
- Driving and skilled tasks may affect performance of skills tasks (e.g. driving).

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution
  - **Orphenadrine hydrochloride (Non-proprietary)**
    - Orphenadrine hydrochloride 10 mg per 1 ml Orphenadrine 50mg/5ml oral solution sugar-free
      - 150 ml [POM] £37.50
      - DT price = £35.08
  - **Tablet**
    - **EXCIPIENTS:** May contain Tartrazine
      - Orphenadrine hydrochloride 50 mg
        - Orphenadrine 50mg tablets
          - 100 tablet [POM] £80.00
          - 250 tablet [POM] no price available

Procyclidine hydrochloride

**DRUG ACTION** Procyclidine exerts its antiparkinsonian action by reducing the effects of the relative central cholinergic excess that occurs as a result of dopamine deficiency.

**INDICATIONS AND DOSE**
- **Parkinsonism | Extrapyramidal symptoms (but not tardive dyskinesia)**
  - **BY MOUTH**
    - Adult: 2.5 mg 3 times a day, then increased in steps of 2.5–5 mg daily if required; increased if necessary up to 30 mg daily in 2–4 divided doses, to be increased at 2–3 day intervals. Maximum daily dose only to be used in exceptional circumstances; maximum 60 mg per day
    - Elderly: Lower end of range preferable

  **Acute dystonia**
  - **BY INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INJECTION**
    - Adult: 5–10 mg, occasionally, more than 10 mg, dose usually effective in 5–10 minutes but may need 30 minutes for relief
    - Elderly: Lower end of range preferable

**SIDE-EFFECTS**
- **Common or very common**
  - Urinary retention
  - Uncommon
  - Drowsiness, impaired coordination, insomnia, seizures
  - Very rare
    - Angle-closure glaucoma

**INTERACTIONS**
- **Drug-induced extrapyramidal symptoms**
  - Use only if potential benefit outweighs risk.

**PREGNANCY** Use only if potential benefit outweighs risk.

**BREAST FEEDING** No information available.

**HEPATIC IMPAIRMENT** Use with caution.

**RENAI IMPAIRMENT** Use with caution.

**TREATMENT CESSATION** Avoid abrupt withdrawal in patients taking long-term treatment.

**PATIENT AND CARER ADVICE**
- Driving and skilled tasks may affect performance of skills tasks (e.g. driving).

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

  **Solution for injection**
  - Procyclidine hydrochloride 5 mg per 1 ml
    - Procyclidine 10mg/2ml solution for injection ampoules
      - 5 ampoule [POM] £60.00–£78.75
      - DT price = £72.50

  **Oral solution**
  - Procyclidine hydrochloride 500 microgram per 1 ml
    - Procyclidine 2.5mg/5ml oral solution sugar-free
      - 150 ml [POM] £7.94–£8.22
      - DT price = £7.08
  - Procyclidine hydrochloride 1 mg per 1 ml
    - Procyclidine 5mg/5ml oral solution sugar-free
      - 150 ml [POM] £14.54–£14.72
      - DT price = £13.13

  **Tablet**
  - Procyclidine hydrochloride (Non-proprietary)
    - Procyclidine hydrochloride 5 mg
      - Procyclidine 5mg tablets
        - 28 tablet [POM] £12.24
        - 100 tablet [POM] £43.71
        - 500 tablet [POM] £218.57
      - Kemadrin (Aspen Pharma Trading Ltd)
        - Procyclidine hydrochloride 5 mg
          - Kemadrin 5mg tablets
            - 100 tablet [POM] £4.72
            - 500 tablet [POM] £23.62
Trihexyphenidyl hydrochloride
(Benzhexol hydrochloride)

- **DRUG ACTION** Trihexyphenidyl exerts its effects by reducing the effects of the relative cholinergic excess that occurs as a result of dopamine deficiency.

- **INDICATIONS AND DOSE**
  Parkinson's disease (if used in combination with co-careldopa or co-beneldopa)
  - BY MOUTH
    - Adult: Maintenance 2–6 mg daily in divided doses, use not recommended because of toxicity in the elderly and the risk of aggravating dementia
  Parkinsonism | Drug-induced extrapyramidal symptoms (but not tardive dyskinesia)
  - BY MOUTH
    - Adult: 1 mg daily, then increased in steps of 2 mg every 3–5 days, adjusted according to response; maintenance 5–15 mg daily in 3–4 divided doses, not recommended for use in Parkinson's disease because of toxicity in the elderly and the risk of aggravating dementia; maximum 20 mg per day
    - Elderly: Lower end of range preferable, not recommended for use in Parkinson's disease because of toxicity in the elderly and the risk of aggravating dementia

- **CONTRA-INDICATIONS** Gastro-intestinal obstruction · myasthenia gravis

- **CAUTIONS** Cardiovascular disease · elderly · hypertension · liable to abuse · prostatic hypertrophy · psychotic disorders · pyrexia · those susceptible to angle-closure glaucoma

- **INTERACTIONS** → Appendix 1: trihexyphenidyl

- **SIDE-EFFECTS**
  - Very rare: Angle-closure glaucoma
  - Frequency not known: Anxiety · blurred vision · confusion · constipation · dizziness · dry mouth · dyskinesia · dystonia · fatigue · hallucinations · impaired memory · nausea · rash · restlessness · tachycardia · urinary retention · vomiting

- **PREGNANCY** Use only if potential benefit outweighs risk.

- **BREAST FEEDING** Avoid.

- **HEPATIC IMPAIRMENT** Use with caution.

- **RENAL IMPAIRMENT** Use with caution.

- **TREATMENT CESSATION** Avoid abrupt withdrawal in patients taking long-term treatment.

- **DIRECTIONS FOR ADMINISTRATION** Tablets should be taken with or after food.

- **PATIENT AND CARER ADVICE** Driving and skilled tasks
  May affect performance of skilled tasks (e.g. driving).

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Oral solution**

**EXCIPIENTS:** May contain Propylene glycol

- Trihexyphenidyl hydrochloride (Non-proprietary)
  - Trihexyphenidyl hydrochloride 1 mg per 1 ml: Trihexyphenidyl 5mg/5ml oral solution | 200 ml [Pres] £22.00–£24.00 DT price = £22.00

**Tablet**

- Trihexyphenidyl hydrochloride (Non-proprietary)
  - Trihexyphenidyl hydrochloride 2 mg: Trihexyphenidyl 2mg tablets | 84 tablet [Pres] £5.56 DT price = £4.20
  - Trihexyphenidyl hydrochloride 5 mg: Trihexyphenidyl 5mg tablets | 84 tablet [Pres] £17.91 DT price = £17.51

**DOPAMINERGIC DRUGS > CATECHOL-O-METHYLTRANSFERASE INHIBITORS**

Entacapone

- **DRUG ACTION** Entacapone prevents the peripheral breakdown of levodopa, by inhibiting catechol-O-methyltransferase, allowing more levodopa to reach the brain.

- **INDICATIONS AND DOSE**
  Adjunct to co-beneldopa or co-careldopa in Parkinson's disease with 'end-of-dose' motor fluctuations (under expert supervision)
  - BY MOUTH
    - Adult: 200 mg, dose to be given with each dose of levodopa with dopa-decarboxylase inhibitor; maximum 2 g per day

- **CONTRA-INDICATIONS** History of neuroleptic malignant syndrome · history of non-traumatic rhabdomyolysis · phaeochromocytoma

- **CAUTIONS** Concurrent levodopa dose may need to be reduced by about 10–30% · ischaemic heart disease

- **INTERACTIONS** → Appendix 1: entacapone

- **SIDE-EFFECTS**
  - Common or very common: Abdominal pain · abnormal dreams · confusion · constipation · diarrhea · dizziness · dry mouth · dyskinesia · dystonia · fatigue · hallucinations · insomnia · ischaemic heart disease · nausea · sweating · urine may be coloured reddish-brown · vomiting
  - Uncommon: Myocardial infarction
  - Rare: Rash
  - Very rare: Agitation · anorexia · urticaria · weight loss
  - Frequency not known: Colitis · hepatitis · neuroleptic malignant syndrome · rhabdomyolysis · skin, hair, and nail discoloration

- **PREGNANCY** Avoid—no information available.

- **BREAST FEEDING** Avoid—present in milk in animal studies.

- **HEPATIC IMPAIRMENT** Avoid.

- **TREATMENT CESSATION** Avoid abrupt withdrawal.

- **PATIENT AND CARER ADVICE** Patient counselling is advised (may colour urine reddish-brown, concomitant iron containing products).

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Tablet**

**CAUTIONARY AND ADVISORY LABELS 14**

- Entacapone (Non-proprietary)
  - Entacapone 200 mg: Entacapone 200mg tablets | 30 tablet [Pres] £16.38 DT price = £5.03 | 100 tablet [Pres] £54.58
  - Comtess (Orion Pharma (UK) Ltd)
    - Entacapone 200 mg: Comtess 200mg tablets | 30 tablet [Pres] £17.24 DT price = £5.03 | 100 tablet [Pres] £57.45

**Combinations available:** Carbidopa with entacapone and levodopa, p. 394

downloaded from www.medicalbr.com
Opicapone

**DRUG ACTION** Opicapone prevents the peripheral breakdown of levodopa, by inhibiting catechol-O-methyltransferase, allowing more levodopa to reach the brain.

**INDICATIONS AND DOSE**
Adjunct to co-beneldopa or co-careldopa in Parkinson’s disease with ‘end-of-dose’ motor fluctuations (under expert supervision)
- **BY MOUTH**
  - Adult: 50 mg once daily, dose to be taken at bedtime, at least one hour before or after levodopa combinations

**CONTRA-INDICATIONS**
- Catecholamine-secreting neoplasms
- History of neuroleptic malignant syndrome
- History of non-traumatic rhabdomyolysis
- Paraganglioma
- Phaeochromocytoma

**CAUTIONS**
- Concurrent levodopa dose may need to be reduced - elderly over 85 years (limited information available)

**SIDE-EFFECTS**
- **Common or very common**
  - Abnormal dreams
  - Constipation
  - Dizziness
  - Dry mouth
  - Dyskinesia
  - Hallucination
  - Headache
  - Insomnia
  - Muscle spasms
  - Orthostatic hypotension
  - Raised blood creatine phosphokinase
  - Somnolence
  - Vomiting
- **Uncommon**
  - Abdominal pain
  - Anxiety
  - Blood pressure changes
  - Chromatia
  - Decreased appetite
  - Depression
  - Dry eye
  - Dysgeusia
  - Dyspepsia
  - Dysphonia
  - Hyperkinesia
  - Hypertriglyceridaemia
  - Myalgia
  - Nocturia
  - Pain in extremity
  - Palpitations
  - Sleep disorders
  - Syncope
  - Weight decrease
- **Frequency not known**
  - Raised liver enzymes

**SIDE-EFFECTS, FURTHER INFORMATION**
- Raised liver enzymes
  - Manufacturer advises consider liver function tests in patients who experience progressive anorexia, asthenia and weight decrease within a relatively short period of time.

**PREGNANCY**
- Manufacturer advises avoid - limited information available

**BREAST FEEDING**
- Manufacturer advises avoid - no information available

**HEPATIC IMPAIRMENT**
- Manufacturer advises use with caution in moderate impairment - dose adjustment may be necessary. Manufacturer advises avoid in severe impairment.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.
- **Capsule**
  - Ongentys (BIAL Pharma UK Ltd) ▼
    - Opicapone 50 mg Ongentys 50mg capsules | 30 capsule £93.90

---

Tolcapone

**DRUG ACTION** Tolcapone prevents the peripheral breakdown of levodopa, by inhibiting catechol-O-methyltransferase, allowing more levodopa to reach the brain.

**INDICATIONS AND DOSE**
Adjunct to co-beneldopa or co-careldopa in Parkinson’s disease with ‘end-of-dose’ motor fluctuations if another inhibitor of peripheral catechol-O-methyltransferase inappropriate (under expert supervision)
- **BY MOUTH**
  - Adult: 100 mg 3 times a day (max. per dose 200 mg 3 times a day) continuing beyond 3 weeks only if substantial improvement, leave 6 hours between each dose; first daily dose should be taken at the same time as levodopa with dopa-decarboxylase inhibitor, dose maximum only in exceptional circumstances

**CONTRA-INDICATIONS**
- Phaeochromocytoma
- Previous history of hyperthermia
- Previous history of neuroleptic malignant syndrome
- Previous history of rhabdomyolysis
- Severe dyskinesia

**CAUTIONS**
- Most patients receiving more than 600 mg levodopa daily require reduction of levodopa dose by about 30%

**CAUTIONS, FURTHER INFORMATION**
- Hepatotoxicity
  - Potentially life-threatening hepatotoxicity including fulminant hepatitis reported rarely, usually in women and during the first 6 months, but late-onset liver injury also reported; discontinue if abnormal liver function tests or symptoms of liver disorder; do not re-introduce tolcapone once discontinued.

**INTERACTIONS** → Appendix 1: tolcapone

**SIDE-EFFECTS**
- **Common or very common**
  - Abdominal pain
  - Anorexia
  - Chest pain
  - Confusion
  - Constipation
  - Diarrhoea
  - Dizziness
  - Drowsiness
  - Dyskinesia
  - Dyspepsia
  - Dystonia
  - Excessive dreaming
  - Hallucinations
  - Headache
  - Hepatotoxicity
  - Nausea
  - Sleep disturbances
  - Sweating
  - Syncope
  - Urine discoloration
  - Vomiting
  - Xerostomia
- **Frequency not known**
  - Neuroleptic malignant syndrome
  - Reported on dose reduction or withdrawal - rhabdomyolysis reported on dose reduction or withdrawal

**PREGNANCY**
- Toxicity in animal studies - use only if potential benefit outweighs risk.

**BREAST FEEDING**
- Avoid - present in milk in animal studies.

**HEPATIC IMPAIRMENT**
- Avoid.

**RENAL IMPAIRMENT**
- Caution if eGFR less than 30 mL/minute/1.73 m².

**MONITORING REQUIREMENTS**
- Test liver function before treatment, and monitor every 2 weeks for first year, every 4 weeks for next 6 months and then every 8 weeks thereafter (restart monitoring schedule if dose increased).

**TREATMENT CESSION**
- Avoid abrupt withdrawal.

**PATIENT AND CARER ADVICE**
- Patients should be told how to recognise signs of liver disorder and advised to seek immediate medical attention if symptoms such as anorexia, nausea, vomiting, fatigue, abdominal pain, dark urine, or pruritus develop.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.
- **Tablet**
  - Cautionary and Advisory Labels 14, 25
  - Tasmar (Meda Pharmaceuticals Ltd)
    - Tolcapone 100 mg Tasmar 100mg tablets | 100 tablet £95.20
DOPAMINERGIC DRUGS  →  DOPAMINE PRECURSORS

Carbidopa with entacapone and levodopa

The properties listed below are those particular to the combination only. For the properties of the components please consider, co-careldopa p. 396, entacapone p. 392.

- **INDICATIONS AND DOSE**
  
  **STALEVO® 100/25/200**
  
  Parkinson's disease and end-of-dose motor fluctuations not adequately controlled with levodopa and dopa-carboxylase inhibitor treatment
  
  - **BY MOUTH**
  - Adult: 1 tablet for each dose; maximum 10 tablets per day
  
  **STALEVO® 125/31.25/200**
  
  Parkinson's disease and end-of-dose motor fluctuations not adequately controlled with levodopa and dopa-carboxylase inhibitor treatment
  
  - **BY MOUTH**
  - Adult: 1 tablet for each dose; maximum 10 tablets per day
  
  **STALEVO® 150/37.5/200**
  
  Parkinson's disease and end-of-dose motor fluctuations not adequately controlled with levodopa and dopa-carboxylase inhibitor treatment
  
  - **BY MOUTH**
  - Adult: 1 tablet for each dose; maximum 8 tablets per day
  
  **STALEVO® 175/43.75/200**
  
  Parkinson's disease and end-of-dose motor fluctuations not adequately controlled with levodopa and dopa-carboxylase inhibitor treatment
  
  - **BY MOUTH**
  - Adult: 1 tablet for each dose; maximum 7 tablets per day
  
  **STALEVO® 200/50/200**
  
  Parkinson's disease and end-of-dose motor fluctuations not adequately controlled with levodopa and dopa-carboxylase inhibitor treatment
  
  - **BY MOUTH**
  - Adult: 1 tablet for each dose; maximum 10 tablets per day
  
  **STALEVO® 50/12.5/200**
  
  Parkinson's disease and end-of-dose motor fluctuations not adequately controlled with levodopa and dopa-carboxylase inhibitor treatment
  
  - **BY MOUTH**
  - Adult: 1 tablet for each dose; maximum 10 tablets per day
  
  **STALEVO® 75/18.75/200**
  
  Parkinson's disease and end-of-dose motor fluctuations not adequately controlled with levodopa and dopa-carboxylase inhibitor treatment
  
  - **BY MOUTH**
  - Adult: 1 tablet for each dose; maximum 10 tablets per day

- **INTERACTIONS**  →  Appendix 1: carbidopa, entacapone, levodopa

- **PRESCRIBING AND DISPENSING INFORMATION**
  
  Patients receiving standard-release co-careldopa or co-beneldopa alone, initiate Stalevo® at a dose that provides similar (or slightly lower) amount of levodopa.

Patients with dyskinesia or receiving more than 800 mg levodopa daily, introduce entacapone before transferring to Stalevo® (levodopa dose may need to be reduced by 10–30% initially).

Patients receiving entacapone and standard-release co-careldopa or co-beneldopa, initiate Stalevo® at a dose that provides similar (or slightly higher) amount of levodopa.

- **PATIENT AND CARER ADVICE**
  
  **Sudden onset of sleep**  Excessive daytime sleepiness and sudden onset of sleep can occur with carbidopa with entacapone and levodopa.

  Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.

  Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug.

  **Tablet**

  CAUTIONARY AND ADVISORY LABELS 10, 14((urine reddish-brown)), 25

  - **Stalevo®** (Orion Pharma (UK) Ltd)
    
    Carbidopa 25 mg, Levodopa 100 mg, Entacapone 200 mg  Stalevo 100mg/25mg/200mg tablets  | 30 tablet POM £20.79  | 100 tablet POM £69.31
    
    Carbidopa 18.75 mg, Levodopa 75 mg, Entacapone 200 mg  Stalevo 75mg/18.75mg/200mg tablets  | 30 tablet POM £20.79  | 100 tablet POM £69.31
    
    Carbidopa 37.5 mg, Levodopa 150 mg, Entacapone 200 mg  Stalevo 150mg/37.5mg/200mg tablets  | 30 tablet POM £20.79  | 100 tablet POM £69.31
    
    Carbidopa 25 mg, Levodopa 125 mg, Entacapone 200 mg  Stalevo 125mg/25mg/200mg tablets  | 30 tablet POM £20.79  | 100 tablet POM £69.31
    
    Carbidopa 31.25 mg, Levodopa 125 mg, Entacapone 200 mg  Stalevo 125mg/31.25mg/200mg tablets  | 30 tablet POM £20.79  | 100 tablet POM £69.31
    
    Carbidopa 37.5 mg, Levodopa 150 mg, Entacapone 200 mg  Stalevo 150mg/37.5mg/200mg tablets  | 30 tablet POM £20.79  | 100 tablet POM £69.31
    
    Carbidopa 31.25 mg, Levodopa 50 mg, Entacapone 200 mg  Stalevo 50mg/12.5mg/200mg tablets  | 30 tablet POM £20.79  | 100 tablet POM £69.31
    
    Carbidopa 31.25 mg, Levodopa 20 mg, Entacapone 100 mg  Stalevo 50mg/12.5mg/100mg tablets  | 30 tablet POM £20.79  | 100 tablet POM £69.31

- **Co-beneldopa**

  - **INDICATIONS AND DOSE**
    
    Parkinson's disease
    
    - **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
      
      - Adult: Initially 50 mg 3–4 times a day, then increased in steps of 100 mg daily, dose to be increased once or twice weekly according to response; maintenance 400–800 mg daily in divided doses
      
      - Elderly: Initially 50 mg 1–2 times a day, then increased in steps of 50 mg daily, dose to be increased every 3–4 days according to response

    Parkinson's disease (in advanced disease)
    
    - **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
      
      - Adult: Initially 100 mg 3 times a day, then increased in steps of 100 mg daily, dose to be increased once or twice weekly according to response; maintenance 400–800 mg daily in divided doses

    Parkinson's disease (patients not taking levodopa/dopa-carboxylase inhibitor therapy)
    
    - **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
      
      - Adult: Initially 1 capsule 3 times a day; maximum 6 capsules per day
**Parkinson's disease** (patients transferring from immediate-release levodopa/dopa-decarboxylase inhibitor preparations)

- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Adult: Initially 1 capsule substituted for every 100 mg of levodopa and given at the same dosage frequency, increased every 2–3 days according to response; average increase of 50% needed over previous levodopa dose and titration may take up to 4 weeks, supplementary dose of immediate-release Madopar® may be needed with first morning dose; if response still poor to total daily dose of Madopar® CR plus Madopar® corresponding to 1.2 g levodopa—consider alternative therapy.

**DOSE EQUIVALENCE AND CONVERSION**
- Dose is expressed as levodopa.

---

### IMPORTANT SAFETY INFORMATION

**IMPULSE CONTROL DISORDERS**
Treatment with levodopa is associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. If the patient develops an impulse control disorder, levodopa should be withdrawn or the dose reduced until the symptoms resolve.

- **CAUTIONS**
  - Cushing’s syndrome · diabetes mellitus · endocrine disorders · history of convulsions · history of myocardial infarction with residual arrhythmia · history of peptic ulcer · hyperthyroidism · osteomalacia · phaeochromocytoma · psychiatric illness (avoid if severe and discontinue if deterioration) · severe cardiovascular disease · severe pulmonary disease · susceptibility to angle-closure glaucoma

- **INTERACTIONS**
  - Appendix 1: levodopa

- **SIDE-EFFECTS**
  - Common or very common
    - Abnormal dreams · anorexia · anxiety · arrhythmias · chorea · confusion · dementia · depression · dizziness · drowsiness · dry mouth · dyskinesia · dystonia · euphoria · fatigue · insomnia · nausea · palpitations · postural hypotension · psychosis · syncope · taste disturbances · vomiting
  - Uncommon
    - Ataxia · chest pain · constipation · diarrhoea · dysphagia · flatulence · hand tremor · hoarseness · hypersalivation · hypertension · malaise · muscle cramps · oedema · reddish discolouration of the urine and other body fluids · weakness · weight changes
  - Rare
    - Abdominal pain · activation of Horner’s syndrome · activation of malignant melanoma · agitation · agranulocytosis · alopecia · blepharospasm · blurred vision · bruxism · convulsions · diplopia · disorientation · duodenal ulcer · dyspepsia · dysphonia · exantheme · flushing · gastro-intestinal bleeding · haemolytic anaemia · headache · Henoch–Schönlein purpura · hiccups · leucopenia · neuroleptic malignant syndrome (associated with abrupt withdrawal) · non-haemolytic anaemia · oculogyric crisis · paraesthesia · phlebitis · priapism · pupil dilatation · reduced mental acuity · sweating · thrombocytopenia · trismus · urinary incontinence · urinary retention
  - Very rare
    - Angle-closure glaucoma · suicidal ideation
  - Frequency not known
    - Compulsive behaviour

- **PREGNANCY**
  - Caution in pregnancy—toxicity has occurred in animal studies.

- **BREAST FEEDING**
  - May suppress lactation; present in milk—avoid.

- **HEPATIC IMPAIRMENT**
  - Use with caution.

- **RENAL IMPAIRMENT**
  - Use with caution.

---

### EFFECT ON LABORATORY TESTS
- False positive tests for urinary ketones have been reported.

### TREATMENT CESSION
- Avoid abrupt withdrawal (risk of neuroleptic malignant syndrome and rhabdomyolysis).

### DIRECTIONS FOR ADMINISTRATION
- The dispersible tablets can be dispersed in water or orange squash (not orange juice) or swallowed whole.

### PRESCRIBING AND DISPENSING INFORMATION
- Co-beneldopa is a mixture of benserazide hydrochloride and levodopa in mass proportions corresponding to 1 part of benserazide and 4 parts of levodopa.
- When transferring patients from another levodopa/dopa-decarboxylase inhibitor preparation, the previous preparation should be discontinued 12 hours before (although interval can be shorter).
- When switching from modified-release levodopa to dispersible co-beneldopa, reduce dose by approximately 30%.
- When administered as an adjunct to other antiparkinsonian drugs, once therapeutic effect apparent, the other drugs may be reduced or withdrawn.

### PATIENT AND CARER ADVICE

- **Sudden onset of sleep**
  - Excessive daytime sleepiness and sudden onset of sleep can occur with co-beneldopa.

- **Patients**
  - Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.

- **Management**
  - Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concurrent medication. Patients should be counselled on improving sleep behaviour.

- **Patients or carers**
  - Should be given advice on how to administer co-beneldopa dispersible tablets.

### MEDICINAL FORMS
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution
  - **Dispersible tablet**
    - CAUTIONARY AND ADVISORY LABELS
      - 10, 14, 21
      - Madopar (Roche Products Ltd)
      - Benserazide (as Benserazide hydrochloride) 12.5 mg, Levodopa 50 mg
      - Madopar 50 mg/12.5 mg dispersible tablets sugar-free | 100 tablet (P) £5.90 DT price = £5.90
      - Benserazide (as Benserazide hydrochloride) 25 mg, Levodopa 100 mg
      - Madopar 100 mg/25 mg dispersible tablets sugar-free | 100 tablet (P) £10.45 DT price = £10.45
  - **Modified-release capsule**
    - CAUTIONARY AND ADVISORY LABELS
      - 5, 10, 14, 25
      - Madopar CR (Roche Products Ltd)
      - Benserazide (as Benserazide hydrochloride) 25 mg, Levodopa 100 mg
      - Madopar CR capsules | 100 capsule (P) £12.77 DT price = £12.77
  - **Capsule**
    - CAUTIONARY AND ADVISORY LABELS
      - 10, 14, 21
      - Co-beneldopa (Non-proprietary)
      - Benserazide (as Benserazide hydrochloride) 12.5 mg, Levodopa 50 mg
      - Co-beneldopa 12.5 mg/50 mg capsules | 100 capsule (P) £4.71–£4.96 DT price = £4.96
      - Benserazide (as Benserazide hydrochloride) 25 mg, Levodopa 100 mg
      - Co-beneldopa 25 mg/100 mg capsules | 100 capsule (P) £6.56–£6.91 DT price = £6.91

---

**Costs**

- Cost calculations: 100 capsules = £56.60
- Dose reductions: 100 capsules = £5.90
- DT price: 100 capsules = £5.90

---

**BNF 74 Parkinson’s disease 395**
Benserazide (as Benserazide hydrochloride) 25 mg, Levodopa 100 mg Madopar 100mg/25mg capsules | 100 capsule  
DT price = £6.91
Benserazide (as Benserazide hydrochloride) 50 mg, Levodopa 200 mg Madopar 200mg/50mg capsules | 100 capsule  
DT price = £11.78

### Co-careldopa

#### INDICATIONS AND DOSE

**Parkinson’s disease**

- **BY MOUTH**
  - Adult: Initially 25/100 mg 3 times a day, then increased in steps of 12.5/50 mg once daily or on alternate days, adjusted according to response, do not exceed a total daily dose of 150 mg of levodopa.

**Parkinson’s disease—alternative regimen**

- **BY MOUTH**
  - Adult: Initially 12.5 mg 3–4 times a day, alternatively increased in steps of 12.5 mg once daily or on alternate days, adjusted according to response, do not exceed a total daily dose of 150 mg of levodopa.

**DOSE EQUIVALENT AND CONVERSION**

- The proportions are expressed in the form x/y where x and y are the strengths in milligrams of carbidopa and levodopa respectively.
  - 2 tablets Sinemet® 12.5 mg/50 mg is equivalent to 1 tablet Sinemet® Plus 25 mg/100 mg.

**Caramet® CR**

**Parkinson’s disease (patients not receiving levodopa/dopa-decarboxylase inhibitor preparations, expressed as levodopa)**

- **BY MOUTH USING MODIFIED-RELEASE TABLETS**
  - Adult: Initially 100–200 mg twice daily, dose to be given at least 6 hours apart; dose adjusted according to response at intervals of at least 2 days.

**Parkinson’s disease (patients transferring from immediate-release levodopa/dopa-decarboxylase inhibitor preparations)**

- **BY MOUTH USING MODIFIED-RELEASE TABLETS**
  - Adult: Discontinue previous preparation at least 12 hours before first dose of Caramet® CR; substitute Caramet® CR to provide a similar amount of levodopa daily and extend dosing interval by 30–50%; then adjusted according to response at intervals of at least 2 days.

**Dudodopa®**

**Severe Parkinson’s disease inadequately controlled by other preparations**

- Adult: Administered as intestinal gel, for use with enteral tube (consult product literature).

### IMPORTANT SAFETY INFORMATION

#### IMPULSE CONTROL DISORDERS

Treatment with levodopa is associated with impulse control disorders, including pathological gambling, binge eating, hypersexuality, and hypersexual disorder. Patients and their carers should be informed about the risk of impulse control disorders. If the patient develops an impulse control disorder, levodopa should be withdrawn or the dose reduced until the symptoms resolve.

#### CAUTIONS

- Cushing’s syndrome
- Diabetes mellitus
- Endocrine disorders
- History of convulsions
- History of myocardial infarction with residual arrhythmia
- History of peptic ulcer
- Hyperthyroidism
- Osteomalacia
- Phaeochromocytoma
- Psychiatric illness (avoid if severe depression or anxiety)

#### SIDE-EFFECTS

- Common or very common
  - Abnormal dreams
  - Anorexia
  - Anxiety
  - Arrhythmias
  - Chorea
  - Confusion
  - Depression
  - Dizziness
  - Drowsiness
  - Dry mouth
  - Dyskinesia
  - Dysphagia
  - Fatigue
  - Insomnia
  - Nausea
  - Palpitations
  - Postural hypotension
  - Psychosis
  - Syncope
  - Taste disturbances
  - Vomiting

- Uncommon
  - Ataxia
  - Chest pain
  - Constipation
  - Diarrhoea
  - Dizziness
  - Flatulence
  - Hand tremor
  - Hoarseness
  - Hypersalivation
  - Hypertension
  - Malaise
  - Muscle cramps
  - Oedema
  - Reddish discoloration of the urine and other body fluids

#### INTERACTIONS

- **Appendix 1: carbidopa, levodopa**

#### IMPULSE CONTROL DISORDERS

- **Very rare**
  - Angle-closure glaucoma
  - Suicidal ideation

- **Frequency not known**
  - Compulsive behaviour
PREGNANCY Use with caution—toxicity has occurred in animal studies.

 BREAST FEEDING May suppress lactation; present in milk—avoid.

 HEPATIC IMPAIRMENT Use with caution.

 RENAL IMPAIRMENT Use with caution.

 EFFECT ON LABORATORY TESTS False positive tests for urinary ketones have been reported.

 TREATMENT CESSION Avoid abrupt withdrawal (risk of neuroleptic malignant syndrome and rhabdomyolysis).

 PRESCRIBING AND DISPENSING INFORMATION

 Co-careldopa is a mixture of carbidopa and levodopa; the proportions are expressed in the form x/y where x and y are the strengths in milligrams of carbidopa and levodopa respectively. When transferring patients from another levodopa/dopa-decarboxylase inhibitor preparation, the previous preparation should be discontinued at least 12 hours before.

 Co-careldopa 25/100 provides an adequate dose of carbidopa when low doses of levodopa are needed.

 PATIENT AND CARER ADVICE

 Sudden onset of sleep Excessive daytime sleepiness and sudden onset of sleep can occur with co-careldopa. Patients starting treatment with these drugs should be counselled on improving sleep behaviour.

 NATIONAL FUNDING/ACCESS DECISIONS

 **DUODOPA**

 Scottish Medicines Consortium (SMC) Decisions

 The Scottish Medicines Consortium has advised (June 2016) that Duodopa® intestinal gel is accepted for restricted use within NHS Scotland, within its licensed indication, only in patients not eligible for deep brain stimulation. This advice is contingent upon the continuing availability of the Patient Access Scheme in NHS Scotland or a list price that is equivalent or lower.

 **MEDICINAL FORMS**

 There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

 **Modified-release tablet**

 **CAUTIONARY AND ADVISORY LABELS** 10, 14, 25

 - Caramet CR (Teva UK Ltd) Carbidopa (as Carbidopa monohydrate) 25 mg, Levodopa 100 mg Caramet 25mg/100mg CR tablets | 60 tablet | £11.47 DT price = £11.60
 - Carbidopa (as Carbidopa monohydrate) 50 mg, Levodopa 200 mg Caramet 50mg/200mg CR tablets | 60 tablet | £11.47 DT price = £11.60
 - Half Sinemet CR (Merck Sharp & Dohme Ltd) Carbidopa (as Carbidopa monohydrate) 25 mg, Levodopa 100 mg Half Sinemet CR 25mg/100mg tablets | 60 tablet | £11.60 DT price = £11.60
 - Sinemet CR (Merck Sharp & Dohme Ltd) Carbidopa (as Carbidopa monohydrate) 50 mg, Levodopa 200 mg Sinemet CR 50mg/200mg tablets | 60 tablet | £11.60 DT price = £11.60

 **SCOPA**

 **INDICATIONS AND DOSE**

 Parkinson’s disease

 - Adult: 100 mg daily for 1 week, then increased to 100 mg twice daily, usually administered in conjunction with other treatment. Some patients may require higher doses; maximum 400 mg per day
 - Elderly: 100 mg daily, adjusted according to response

 **Post-herpetic neuralgia**

 - Adult: 100 mg twice daily for 14 days (continued for another 14 days if necessary)

 Treatment of influenza A (but not recommended)

 - Adult: 100 mg twice daily for 14 days

 Prophylaxis of influenza A (but not recommended)

 - Adult: 100 mg daily usually for 6 weeks or with influenza vaccination for 2–3 weeks after vaccination

 **CONTRA-INDICATIONS**

 Epilepsy • history of gastric ulceration

 **CAUTIONS**

 Confused or hallucinatory states • congestive heart disease (may exacerbate oedema) • elderly • tolerance to the effects of amantadine may develop in Parkinson’s disease

 **INTERACTIONS**

 Appendix 1: dopamine receptor agonists

 **SIDE-EFFECTS**

 Common or very common Anorexia • anxiety • dizziness • dry mouth • gastro-intestinal disturbances • hallucinations •
headache · impaired concentration · insomnia · lethargy · livedo reticularis · mood changes · myalgia · palpitation · peripheral oedema · postural hypotension · slurred speech · sweating

- **Uncommon** Confusion · movement disorders · neuroleptic malignant syndrome · psychosis · rash · seizure · tremor · urinary incontinence · urinary retention · visual disturbances

- **Frequency not known** Heart failure · leucopenia · photosensitisation

- **PREGNANCY** Avoid; toxicity in animal studies.
- **BREAST FEEDING** Avoid; present in milk; toxicity in infant reported.
- **HEPATIC IMPAIRMENT** Use with caution.
- **RENA L IMPAIRMENT** Reduce dose. Avoid if eGFR less than 15 mL/minute/1.73 m².
- **TREATMENT CESSATION** Avoid abrupt withdrawal in Parkinson’s disease.

- **PAtIENT AND CARER ADVICE**
- Driving and skilled tasks
  May affect performance of skilled tasks (e.g. driving).

- **NATIONAL FUNDING/ACCESS DECISIONS**

  - **NICE technology appraisals (TAs)**

    - Oseltamivir, zanamivir, and amantadine for prophylaxis of influenza (September 2008) NICE TA158
      Amantadine is **not** recommended for prophylaxis of influenza.
      www.nice.org.uk/TA158

    - Oseltamivir, zanamivir, and amantadine for treatment of influenza (February 2009) NICE TA168
      Amantadine is **not** recommended for treatment of influenza.
      www.nice.org.uk/TA168

- **MEDICINAL FORMS**

  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet

  - **Oral solution**

    - Amantadine hydrochloride (Non-proprietary)
      Amantadine hydrochloride 10 mg per 1 ml
      Amantadine 50mg/5ml oral solution sugar free sugar-free
      150 ml [Pax] £138.99–£140.00
      DT price = £139.25

  - **Capsule**

    - Amantadine hydrochloride (Non-proprietary)
      Amantadine hydrochloride 100 mg
      Amantadine 100mg capsules
      14 capsule [Pax] £10.25–£11.39
      56 capsule [Pax] £41.00–£45.54
      DT price = £44.63

**Apomorphine hydrochloride**

- **INDICATIONS AND DOSE**

  **Refractory motor fluctuations in Parkinson’s disease (‘off’ episodes) inadequately controlled by co-beneldopa or co-careldopa or other dopaminergics (for capable and motivated patients) (under expert supervision)**

    - **BY SUBCUTANEOUS INJECTION**

      - Adult: Initially 1 mg, dose to be administered at the first sign of ‘off’ episode, then 2 mg after 30 minutes, dose to be given if inadequate or no response following initial dose, thereafter increase dose at minimum 40-minute intervals until satisfactory response obtained, this determines threshold dose; usual dose 3–30 mg daily in divided doses (max. per dose 10 mg), subcutaneous infusion may be preferable in those requiring division of injections into more than 10 doses; maximum 100 mg per day

**IMPORTANT SAFETY INFORMATION**

**IMPULSE CONTROL DISORDERS**

Treatment with dopamine-receptor agonists are associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause impulse control disorders, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an impulse control disorder, the dopamine-receptor agonist or levodopa should be withdrawn or the dose reduced until the symptoms resolve.

- **CONTRA-INDICATIONS**
  - Avoid if ‘on’ response to levodopa marred by severe dyskinesia or dystonia · dementia · psychosis · respiratory depression

- **CAUTIONS**

  - Cardiovascular disease · history of postural hypotension (special care on initiation) · neuropsychiatric conditions · pulmonary disease · susceptibility to QT-interval prolongation

- **INTERACTIONS**

  - Appendix 1: dopamine receptor agonists

- **SIDE-EFFECTS**

  - **Common or very common** Confusion · drowsiness · hallucinations · nausea · sudden onset of sleep · vomiting · yawning

  - **Uncommon** Dyskinesia during ‘on’ periods (may require discontinuation) · dyspnœa · haemolytic anaemia (with levodopa) · postural hypotension · rash · thrombocytopenia (with levodopa)

  - **Rare** Eosinophilia

  - **Frequency not known** Compulsive behaviour · dizziness · peripheral oedema

- **ALLERGY AND CROSS-SENSITIVITY**
  - Contra-indicated if history of hypersensitivity to opioids.

- **PREGNANCY**
  - Contra-indicated if history of hypersensitivity to opioids.

- **BREAST FEEDING**
  - No information available; may suppress lactation.

- **HEPATIC IMPAIRMENT**
  - Avoid.

- **RENA L IMPAIRMENT**
  - Use with caution.

- **MONITORING REQUIREMENTS**

  - Monitor hepatic, haemopoietic, renal, and cardiovascular function.

  - With **concomitant levodopa** test initially and every 6 months for haemolytic anaemia and thrombocytopenia (development calls for specialist haematological care with dose reduction and possible discontinuation).
**TREATMENT CESSION** Antiparkinsonian drug therapy should never be stopped abruptly as this carries a small risk of neuroleptic malignant syndrome.

**PATIENT AND CARER ADVICE**

**Sudden onset of sleep** Excessive daytime sleepiness and sudden onset of sleep can occur with dopamine-receptor agonists.

Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.

Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.

**Drugs and driving** Prescribers and other healthcare professionals should advise patients if treatment is likely to affect their ability to perform skilled tasks (e.g. driving). This applies especially to drugs with sedative effects; patients should be warned that these effects are increased by alcohol. General information about a patient’s fitness to drive is available from the Driver and Vehicle Licensing Agency at www.dvla.gov.uk.

2015 legislation regarding driving whilst taking certain drugs, may also apply to apomorphine, see Drugs and driving under Guidance on prescribing p. 1.

**Hypotensive reactions** Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection, solution for infusion

**Solution for injection**

**CAUTIONARY AND ADVISORY LABELS 10**

**EXCIPIENTS:** May contain Sulfites

- **APO-go** (Britannia Pharmaceuticals Ltd)
  - Apomorphine hydrochloride 10 mg per 1 ml
  - solution for injection ampoules | 5 ampoule [Pot] £73.11 DT price = £73.11
- **APO-go Pen** (Britannia Pharmaceuticals Ltd)
  - Apomorphine hydrochloride 10 mg per 1 ml
  - solution for injection pre-filled disposable injection [Pot] £123.91 DT price = £123.91

**Solution for infusion**

**CAUTIONARY AND ADVISORY LABELS 10**

**EXCIPIENTS:** May contain Sulfites

- **APO-go PFS** (Britannia Pharmaceuticals Ltd)
  - Apomorphine hydrochloride 5 mg per 1 ml
  - solution for infusion pre-filled syringes | 5 pre-filled disposable injection [Pot] £73.11 DT price = £73.11

**Bromocriptine**

**DRUG ACTION** Bromocriptine is a stimulant of dopamine receptors in the brain; it also inhibits release of prolactin by the pituitary.

**INDICATIONS AND DOSE**

**Prevention of lactation**

- **BY MOUTH**
  - Adult: Initially 2.5 mg daily for 1 day, then 2.5 mg twice daily for 14 days

**Suppression of lactation**

- **BY MOUTH**
  - Adult: Initially 2.5 mg daily for 2–3 days, then 2.5 mg twice daily for 14 days

**Hypogonadism | Galactorrhoea | Infertility**

- **BY MOUTH**
  - Adult: Initially 1–1.25 mg daily, dose to be taken at bedtime, increase dose gradually; usual dose 7.5 mg daily in divided doses, increased if necessary up to 30 mg daily, usual dose in infertility without hyperprolactinaemia is 2.5 mg twice daily

**Acromegaly**

- **BY MOUTH**
  - Adult: Initially 1–1.25 mg daily, dose to be taken at bedtime, then increased to 5 mg every 6 hours, increase dose gradually

**Prolactinoma**

- **BY MOUTH**
  - Adult: Initially 1–1.25 mg daily for 1 week, dose to be taken at night, then 2–2.5 mg daily for 1 week, dose to be taken at night, then 2.5 mg twice daily for 1 week, then 2.5 mg 3 times a day for 1 week, then increased in steps of 2.5 mg every 3–14 days, adjusted according to response; maintenance 10–30 mg daily

**IMPORTANT SAFETY INFORMATION**

**FIBROTIC REACTIONS**

Bromocriptine has been associated with pulmonary, retroperitoneal, and pericardial fibrotic reactions.

Exclude cardiac valvulopathy with echocardiography before starting treatment with these ergot derivatives for Parkinson’s disease or chronic endocrine disorders (excludes suppression of lactation); it may also be appropriate to measure the erythrocyte sedimentation rate and serum creatinine and to obtain a chest X-ray. Patients should be monitored for dyspnoea, persistent cough, chest pain, cardiac failure, and abdominal pain or tenderness. If long-term treatment is expected, then lung-function tests may also be helpful.

**IMPULSE CONTROL DISORDERS**

Treatment with dopamine-receptor agonists are associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause impulse control disorders, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an impulse control disorder, the dopamine-receptor agonist should be withdrawn or the dose reduced until the symptoms resolve.

**CONTRA-INDICATIONS**

Avoid in pre-eclampsia·cardiac valvulopathy (exclude before treatment)-hypertension in postpartum women or in puerperium

**CONTRA-INDICATIONS, FURTHER INFORMATION**

- Postpartum or puerperium Should not be used postpartum or in puerperium in women with high blood pressure, coronary artery disease, or symptoms (or history) of serious mental disorder; monitor blood pressure carefully (especially during first few days) in postpartum women.

Very rarely hypertension, myocardial infarction, seizures or stroke (both sometimes preceded by severe headache or visual disturbances), and mental disorders have been reported in postpartum women given bromocriptine for lactation suppression—caution with antihypertensive...
therapy and avoid other ergot alkaloids. Discontinue immediately if hypertension, unremitting headache, or signs of CNS toxicity develop.

- **CAUTIONS** Acute porphyrias p. 969 - cardiovascular disease - history of peptic ulcer (particularly in acromegalic patients) - history of serious mental disorders (especially psychotic disorders) - Raynaud’s syndrome

**CAUTIONS, FURTHER INFORMATION**

- Hyperprolactinemic patients In hyperprolactinaemic patients, the source of the hyperprolactinaemia should be established (i.e. exclude pituitary tumour before treatment).

- **INTERACTIONS** Appendix 1: dopamine receptor agonists

- **SIDE-EFFECTS**
  - **Common or very common** Constipation - headache - nasal congestion - nausea
  - **Uncommon** Confusion (particularly with high doses) - dizziness - dry mouth - fatigue - hallucinations (particularly with high doses) - postural hypotension - psychomotor excitation (particularly with high doses) - vomiting
  - **Rare** Abdominal pain - arrhythmia - bradycardia - diarrhea - gastric ulcer - gastro-intestinal bleeding - insomnia - paraesthesia - psychosis - tachycardia - tinnitus - visual disturbances
  - **Very rare** Neuroleptic malignant syndrome on withdrawal - vasospasm of fingers and toes (particularly in patients with Raynaud’s syndrome)
  - **Frequency not known** Allergic skin reactions - alopecia - cardiac valvulopathy - constrictive pericarditis - drowsiness - dyskinesia - hypersexuality - hyponatraemia - hypotension - increased libido - leg cramps - leukopenia - pathological gambling - pericardial effusion - peripheral oedema - pleural effusion - pleural effusion - pleuritis - pulmonary fibrosis - retroperitoneal fibrosis - reversible hearing loss - thrombocytopenia - urinary incontinence

**SIDE-EFFECTS, FURTHER INFORMATION**

- Gastro-intestinal bleeding Treatment should be withdrawn if gastro-intestinal bleeding occurs.

- **ALLERGY AND CROSS-SENSITIVITY** Bromocriptine should not be used in patients with hypersensitivity to ergot alkaloids.

- **CONCEPTION AND CONTRACEPTION** Caution — provide contraceptive advice if appropriate (oral contraceptives may increase prolactin concentration).

- **BREAST FEEDING** Suppresses lactation; avoid breast feeding for about 5 days if lactation prevention fails.

- **HEPATIC IMPAIRMENT** Dose reduction may be necessary.

- **MONITORING REQUIREMENTS**
  - Specialist evaluation — monitor for pituitary enlargement, particularly during pregnancy; monitor visual field to detect secondary field loss in macroprolactinoma.
  - Monitor for fibrotic disease.
  - Monitor blood pressure for a few days after starting treatment and following dosage increase.

- **TREATMENT CESSATION** Antiparkinsonian drug therapy should never be stopped abruptly as this carries a small risk of neuroleptic malignant syndrome.

- **PATIENT AND CARER ADVICE**
  - **Sudden onset of sleep** Excessive daytime sleepiness and sudden onset of sleep can occur with dopamine-receptor agonists.

  Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.

Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.

**Hypotensive reactions** Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Tablet**

**CAUTIONARY AND ADVISORY LABELS 10, 21**

- **Bromocriptine (Non-proprietary)**
  - Bromocriptine (as Bromocriptine mesilate) 1 mg Bromocriptine 1mg tablets | 100 tablet [Pos] £67.62 DT price = £67.62
  - Bromocriptine (as Bromocriptine mesilate) 2.5 mg Bromocriptine 2.5mg tablets | 30 tablet [Pos] £75.00 DT price = £74.54 | 100 tablet [Pos] no price available

**Capsule**

**CAUTIONARY AND ADVISORY LABELS 10, 21**

- **Parlodol** (Meda Pharmaceuticals Ltd)
  - Bromocriptine (as Bromocriptine mesilate) 5 mg Parlodol 5mg capsules | 100 capsule [Pos] £37.57 DT price = £37.57
  - Bromocriptine (as Bromocriptine mesilate) 10 mg Parlodol 10mg capsules | 100 capsule [Pos] £69.50 DT price = £69.50

---

**Cabergoline**

- **DRUG ACTION** Cabergoline is a stimulant of dopamine receptors in the brain and it also inhibits release of prolactin by the pituitary.

- **INDICATIONS AND DOSE**
  - **Prevention of lactation**
    - BY MOUTH
      - Adult: 1 mg, to be taken as a single dose on the first day postpartum
  - **Suppression of established lactation**
    - BY MOUTH
      - Adult: 250 micrograms every 12 hours for 2 days
  - **Hyperprolactinaemic disorders**
    - BY MOUTH
      - Adult: Initially 500 micrograms once weekly, dose may be taken as a single dose or as 2 divided doses on separate days, then increased in steps of 500 micrograms every month until optimal therapeutic response reached, increase dose following monthly monitoring of serum prolactin levels; usual dose 0.25 – 2 mg once weekly, usually 1 mg weekly; reduce initial dose and increase more gradually if patient intolerant, doses over 1 mg weekly to be given as divided dose; maximum 4.5 mg per week

**Alone or as adjunct to co-beneldopa or co-careldopa in Parkinson’s disease where dopamine-receptor agonists other than ergot derivative not appropriate**

- BY MOUTH
  - Adult: Initially 1 mg daily, then increased in steps of 0.5–1 mg every 7–14 days, concurrent dose of levodopa may be decreased gradually while dose of cabergoline is increased; maximum 3 mg per day

---

**Downloaded from www.medicalbr.com**
**FIBROTIC REACTIONS**
Cabergoline has been associated with pulmonary, retroperitoneal, and pericardial fibrotic reactions. Exclude cardiac valvulopathy with echocardiography before starting treatment with these ergot derivatives for Parkinson’s disease or chronic endocrine disorders (excludes suppression of lactation); it may also be appropriate to measure the erythrocyte sedimentation rate and serum creatinine and to obtain a chest X-ray. Patients should be monitored for dyspnoea, persistent cough, chest pain, cardiac failure, and abdominal pain or tenderness. If long-term treatment is expected, then lung-function tests may also be helpful. Patients taking cabergoline should be regularly monitored for cardiac fibrosis by echocardiography (within 3–6 months of initiating treatment and subsequently at 6–12 month intervals).

**IMPULSE CONTROL DISORDERS**
Treatment with dopamine-receptor agonists are associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause impulse control disorders, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an impulse control disorder, the dopamine-receptor agonist should be withdrawn or the dose reduced until the symptoms resolve.

- **CONTRA-INDICATIONS** Avoid in pre-eclampsia · cardiac valvulopathy (exclude before treatment) · history of pericardial fibrotic disorders · history of puerperal psychosis · history of pulmonary fibrotic disorders · history of retroperitoneal fibrotic disorders
- **CAUTIONS** Acute porphrias p. 969 · cardiovascular disease · history of peptic ulcer (particularly in acromegalic patients) · history of serious mental disorders (especially psychotic disorders) · Raynaud’s syndrome

**INTERACTIONS** → Appendix 1: dopamine receptor agonists

**SIDE-EFFECTS**
- **Common or very common** Abdominal pain · angina · breast pain · confusion · constipation · depression · dyspepsia · epigastric pain · gastritis · hallucinations · headache · nausea · syncope
- **Rare** Digital vasospasm · epistaxis · hot flushes · muscle weakness · palpitation · paraesthesia · transient hemianopia · vomiting
- **Frequency not known** Allergic skin reactions · alopecia · cardiac valvulopathy · constrictive pericarditis · drowsiness · dyskinesia · erythromelalgia · hypersexuality · hypotension · increased libido · leg cramps · pathological gambling · pericardial effusion · peripheral oedema · pleural effusion · pleural fibrosis · pleuritis · pulmonary fibrosis · retroperitoneal fibrosis

**SIDE-EFFECTS, FURTHER INFORMATION**
Gastro-intestinal bleeding. Treatment should be withdrawn if gastro-intestinal bleeding occurs.

**ALLERGY AND CROSS-SENSITIVITY** Cabergoline should not be used in patients with hypersensitivity to ergot alkaloids.

**CONCEPTION AND CONTRACEPTION**
Exclude pregnancy before starting and perform monthly pregnancy tests during the amenorrhoeic period. Caution—advise non-hormonal contraception if pregnancy not desired. Discontinue 1 month before intended conception (ovulatory cycles persist for 6 months).

- **PREGNANCY** Discontinue if pregnancy occurs during treatment (specialist advice needed).
- **BREAST FEEDING** Suppresses lactation; avoid breast-feeding if lactation prevention fails.
- **HEPATIC IMPAIRMENT** Reduce dose in severe hepatic impairment.
- **MONITORING REQUIREMENTS**
  - Monitor for fibrotic disease.
  - Monitor blood pressure for a few days after starting treatment and following dosage increase.

**TREATMENT CESSATION** Antiparkinsonian drug therapy should never be stopped abruptly as this carries a small risk of neuroleptic malignant syndrome.

**PRESCRIBING AND DISPENSING INFORMATION** Dispense in original container (contains desiccant).

**PATIENT AND CARER ADVICE**

- **Sudden onset of sleep** Excessive daytime sleepiness and sudden onset of sleep can occur with dopamine-receptor agonists.
  - Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.
  - Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.

**Hypotensive reactions** Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS 10, 21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cabergoline (Non-proprietary)</td>
</tr>
<tr>
<td>Cabergoline 500 microgram</td>
</tr>
<tr>
<td>Cabergoline 1 mg</td>
</tr>
<tr>
<td>Cabergoline 2 mg</td>
</tr>
<tr>
<td>Cabaser (Pfizer Ltd)</td>
</tr>
<tr>
<td>Cabaser 1 mg</td>
</tr>
<tr>
<td>Cabaser 2 mg</td>
</tr>
<tr>
<td>Dostinex (Pfizer Ltd)</td>
</tr>
<tr>
<td>Dostinex 500 microgram</td>
</tr>
</tbody>
</table>

**Pergolide**

- **INDICATIONS AND DOSE**
  - Monotherapy in Parkinson’s disease where dopamine-receptor agonists other than ergot derivative not appropriate
    - **BY MOUTH**
    - Adult: Initially 50 micrograms once daily for day 1, dose to be taken at bedtime, then 50 micrograms twice daily for days 2–4, then increased in steps of 100–250 micrograms daily, dose to be continued →
increased at intervals of 3–4 days, increased to 1.5 mg daily in 3 divided doses at day 28, then increased in steps of up to 250 micrograms every 3–4 days, this increase to be started after day 30; maintenance 2.1–2.5 mg daily; maximum 3 mg per day

Adjuvant therapy with co-beneldopa or co-careldopa in Parkinson’s disease where dopamine-receptor agonists other than ergot derivative not appropriate

- **BY MOUTH**
  - Adult: Initially 50 micrograms daily for 2 days, then increased in steps of 100–150 micrograms every 3 days, dose to be adjusted over next 12 days following initial dose and usually given in 3 divided doses, then increased in steps of 250 micrograms every 3 days, during pergolide titration, levodopa dose may be reduced cautiously; maximum 3 mg per day

**IMPORTANT SAFETY INFORMATION**

**FIBROTIC REACTIONS**
Pergolide has been associated with pulmonary, retroperitoneal, and pericardial fibrotic reactions.

Exclude cardiac valvulopathy with echocardiography before starting treatment with pergolide; it may also be appropriate to measure the erythrocyte sedimentation rate and serum creatinine and to obtain a chest X-ray. Patients should be monitored for dyspnoea, persistent cough, chest pain, cardiac failure, and abdominal pain or tenderness. If long-term treatment is expected, then lung-function tests may also be helpful. Patients taking pergolide should be regularly monitored for cardiac fibrosis by echocardiography (within 3–6 months of initiating treatment and subsequently at 6–12 month intervals).

**IMPELLER CONTROL DISORDERS**
Treatment with dopamine-receptor agonists is associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause impulse control disorders, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an impulse control disorder, the dopamine-receptor agonist or levodopa should be withdrawn or the dose reduced until the symptoms resolve.

- **CONTRA-INDICATIONS** Cardiac valvulopathy (exclude before treatment) - history of fibrotic disorders
- **CAUTIONS** Acute porphyrias p. 969 - arrhythmias - dyskinesia (may exacerbate) - hallucinations - history of confusion - psychosis - underlying cardiac disease
- **INTERACTIONS** → Appendix 1: dopamine receptor agonists
- **PREGNANCY** Use only if potential benefit outweighs risk.
- **BREAST FEEDING** May suppress lactation.
- **TREATMENT CESSATION** Antiparkinsonian drug therapy should never be stopped abruptly as this carries a small risk of neuroleptic malignant syndrome.
- **PATIENT AND CARER ADVICE**
  - Sudden onset of sleep Excessive daytime sleepiness and sudden onset of sleep can occur with dopamine-receptor agonists.

Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.

Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.

**Hypotensive reactions** Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

**CAUTIONARY AND ADVISORY LABELS**

- **Pergolide (Non-proprietary)**
  - Pergolide (as Pergolide mesilate) 50 microgram
    - Pergolide 50microgram tablets | 100 tablet | £32.01 DT price = £32.01
  - Pergolide (as Pergolide mesilate) 250 microgram
    - Pergolide 250microgram tablets | 100 tablet | £56.00–£58.00 DT price = £38.00
  - Pergolide (as Pergolide mesilate) 1 mg
    - Pergolide 1mg tablets | 100 tablet | £125.00–£135.00 DT price = £131.66

**Pramipexole**

**INDICATIONS AND DOSE**
Parkinson’s disease, used alone or as an adjunct to co-beneldopa or co-careldopa

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: Initially 88 micrograms 3 times a day, if tolerated dose to be increased by doubling dose every 5–7 days, increased to 350 micrograms 3 times a day, then increased in steps of 180 micrograms 3 times a day if required, dose to be increased at weekly intervals, during dose titration and maintenance, levodopa dose may be reduced, maximum daily dose to be given in 3 divided doses; maximum 3.3 mg per day

- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Adult: Initially 260 micrograms once daily, dose to be increased by doubling dose every 5–7 days, increased to 1.05 mg once daily, then increased in steps of 520 micrograms every week if required, during dose titration and maintenance, levodopa dose may be reduced according to response; maximum 3.15 mg per day

**Moderate to severe restless legs syndrome**

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: Initially 88 micrograms once daily, dose to be taken 2–3 hours before bedtime, dose to be increased by doubling dose every 4–7 days if necessary, repeat dose titration if restarting treatment after an interval of more than a few days; maximum 540 micrograms per day

**DOSE EQUIVALENCE AND CONVERSION**

- Doses and strengths are stated in terms of pramipexole (base).
- Equivalent strengths of pramipexole (base) in terms of pramipexole dihydrochloride monohydrate (salt) for immediate-release preparations are as follows:
  - 88 micrograms base = 125 micrograms salt;
  - 180 micrograms base = 250 micrograms salt;
  - 350 micrograms base = 500 micrograms salt;
  - 700 micrograms base = 1 mg salt.
**IMPULSE CONTROL DISORDERS**

Treatment with dopamine-receptor agonists is associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause impulse control disorders, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an impulse control disorder, the dopamine-receptor agonist should be withdrawn or the dose reduced until the symptoms resolve.

**CAUTIONS**

- Psychotic disorders - risk of visual disorders (ophthalmological testing recommended) - severe cardiovascular disease

**INTERACTIONS**

- Amnesia - binge eating - cardiac failure - compulsive behaviour - delusion - dysphoria - hiccups - paranoia - pneumonia - pruritus - rash - syncope

**SIDE-EFFECTS**

- Confusion - constipation - decreased appetite - dizziness - drowsiness - dyskinesia - hallucinations - headache - hyperkinesia - hypotension - nausea - peripheral oedema - postural hypotension - restlessness - sudden onset of sleep - visual disturbances - vomiting - weight changes

- Amnesia - binge eating - cardiac failure - compulsive behaviour - delusion - dysphoria - hiccups - paranoia - pneumonia - pruritus - rash - syncope

- Paroxysmal worsening of restless legs syndrome

**PREGNANCY**

Use only if potential benefit outweighs risk—no information available.

**BREAST FEEDING**

May suppress lactation; avoid—present in milk in animal studies.

**RENAI IMPAIRMENT**

For immediate-release tablets in Parkinson’s disease, initially 88 micrograms twice daily (max. 1.57 mg daily in 2 divided doses) if eGFR 20–50 mL/minute/1.73 m²; initially 88 micrograms once daily (max. 1.1 mg once daily) if eGFR less than 20 mL/minute/1.73 m². If renal function declines during treatment, reduce dose by the same percentage as the decline in eGFR. For immediate-release tablets in restless legs syndrome, reduce dose if eGFR less than 20 mL/minute/1.73 m². For modified-release tablets, initially 260 micrograms on alternate days if eGFR 30–50 mL/minute/1.73 m², increased to 260 micrograms once daily after 1 week, further increased if necessary by 260 micrograms daily at weekly intervals to max. 1.57 mg daily. For modified-release tablets, avoid if eGFR less than 30 mL/minute/1.73 m².

**MONITORING REQUIREMENTS**

Risk of postural hypotension (especially on initiation)—monitor blood pressure.

**TREATMENT CESSATION**

Antiparkinsonian drug therapy should never be stopped abruptly as this carries a small risk of neuroleptic malignant syndrome.

**PATIENT AND CARER ADVICE**

**Sudden onset of sleep**

Excessive daytime sleepiness and sudden onset of sleep can occur with dopamine-receptor agonists.

Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.

Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.

**Hypotensive reactions**

Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Modified-release tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>10, 25</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pramipexole (Non-proprietary)</strong></td>
<td></td>
</tr>
<tr>
<td>Pramipexole (as Pramipexole dihydrochloride monohydrate)</td>
<td></td>
</tr>
<tr>
<td>260 microgram Pramipexole 260microgram modified-release tablets</td>
<td>30 tablet (PO) £12.65–£30.87 DT price = £32.49</td>
</tr>
<tr>
<td>Pramipexole (as Pramipexole dihydrochloride monohydrate)</td>
<td></td>
</tr>
<tr>
<td>520 microgram Pramipexole 520microgram modified-release tablets</td>
<td>30 tablet (PO) £25.87–£61.73 DT price = £64.98</td>
</tr>
<tr>
<td>Pramipexole (as Pramipexole dihydrochloride monohydrate)</td>
<td></td>
</tr>
<tr>
<td>1.05 mg Pramipexole 1.05mg modified-release tablets</td>
<td>30 tablet (PO) £45.00–£123.46 DT price = £129.96</td>
</tr>
<tr>
<td>Pramipexole (as Pramipexole dihydrochloride monohydrate)</td>
<td></td>
</tr>
<tr>
<td>1.57 mg Pramipexole 1.57mg modified-release tablets</td>
<td>30 tablet (PO) £154.00–£192.24 DT price = £202.36</td>
</tr>
<tr>
<td>Pramipexole (as Pramipexole dihydrochloride monohydrate)</td>
<td></td>
</tr>
<tr>
<td>2.1 mg Pramipexole 2.1mg modified-release tablets</td>
<td>30 tablet (PO) £118.00–£246.91 DT price = £259.91</td>
</tr>
<tr>
<td>Pramipexole (as Pramipexole dihydrochloride monohydrate)</td>
<td></td>
</tr>
<tr>
<td>2.62 mg Pramipexole 2.62mg modified-release tablets</td>
<td>30 tablet (PO) £260.00–£320.41 DT price = £337.27</td>
</tr>
<tr>
<td>Pramipexole (as Pramipexole dihydrochloride monohydrate)</td>
<td></td>
</tr>
<tr>
<td>3.15 mg Pramipexole 3.15mg modified-release tablets</td>
<td>30 tablet (PO) £333.42–£370.38 DT price = £389.87</td>
</tr>
<tr>
<td>Mirapexin (Boehringer Ingelheim Ltd)</td>
<td></td>
</tr>
<tr>
<td>Pramipexole (as Pramipexole dihydrochloride monohydrate)</td>
<td></td>
</tr>
<tr>
<td>260 microgram Mirapexin 0.26mg modified-release tablets</td>
<td>30 tablet (PO) £32.49 DT price = £32.49</td>
</tr>
<tr>
<td>Pramipexole (as Pramipexole dihydrochloride monohydrate)</td>
<td></td>
</tr>
<tr>
<td>520 microgram Mirapexin 0.52mg modified-release tablets</td>
<td>30 tablet (PO) £64.98 DT price = £64.98</td>
</tr>
<tr>
<td>Pramipexole (as Pramipexole dihydrochloride monohydrate)</td>
<td></td>
</tr>
<tr>
<td>1.05 mg Mirapexin 1.05mg modified-release tablets</td>
<td>30 tablet (PO) £129.96 DT price = £129.96</td>
</tr>
<tr>
<td>Pramipexole (as Pramipexole dihydrochloride monohydrate)</td>
<td></td>
</tr>
<tr>
<td>1.57 mg Mirapexin 1.57mg modified-release tablets</td>
<td>30 tablet (PO) £202.36 DT price = £202.36</td>
</tr>
<tr>
<td>Pramipexole (as Pramipexole dihydrochloride monohydrate)</td>
<td></td>
</tr>
<tr>
<td>2.1 mg Mirapexin 2.1mg modified-release tablets</td>
<td>30 tablet (PO) £259.91 DT price = £259.91</td>
</tr>
<tr>
<td>Pramipexole (as Pramipexole dihydrochloride monohydrate)</td>
<td></td>
</tr>
<tr>
<td>2.62 mg Mirapexin 2.62mg modified-release tablets</td>
<td>30 tablet (PO) £337.27 DT price = £337.27</td>
</tr>
<tr>
<td>Pramipexole (as Pramipexole dihydrochloride monohydrate)</td>
<td></td>
</tr>
<tr>
<td>3.15 mg Mirapexin 3.15mg modified-release tablets</td>
<td>30 tablet (PO) £389.87 DT price = £389.87</td>
</tr>
<tr>
<td>Opryme (Consilient Health Ltd)</td>
<td></td>
</tr>
<tr>
<td>Pramipexole (as Pramipexole dihydrochloride monohydrate)</td>
<td></td>
</tr>
<tr>
<td>260 microgram Opryme 0.26mg modified-release tablets</td>
<td>30 tablet (PO) £25.56 DT price = £32.49</td>
</tr>
<tr>
<td>Pramipexole (as Pramipexole dihydrochloride monohydrate)</td>
<td></td>
</tr>
<tr>
<td>520 microgram Opryme 0.52mg modified-release tablets</td>
<td>30 tablet (PO) £51.14 DT price = £64.98</td>
</tr>
</tbody>
</table>
### Pramipexole

#### INDICATIONS AND DOSE

**Parkinson's disease, either used alone or as adjunct to co-beneldopa or co-careldopa**

- **By Mouth Using Immediate-Release Medicines**
  - **Adult:** Initially 750 micrograms daily in 3 divided doses, then increased in steps of 750 micrograms daily, dose to be increased at weekly intervals, increased to 3 mg daily in 3 divided doses, then increased in steps of 1.5–3 mg daily, adjusted according to response, dose to be increased at weekly intervals; usual dose 9–16 mg daily in 3 divided doses, higher doses may be required if used with levodopa, when administered as adjunct to levodopa, concurrent dose of levodopa may be reduced by approx. 20%, daily maximum dose to be given in 3 divided doses; maximum 24 mg per day

- **By Mouth Using Modified-Release Medicines**
  - **Adult:** Initially 2 mg once daily for 1 week, then 4 mg once daily, increased in steps of 2 mg at intervals of at least 1 week, adjusted according to response, increased to up to 8 mg once daily, dose to be increased further if still no response; increased in steps of 2–4 mg at intervals of at least 2 weeks if required; maximum 24 mg per day

**Parkinson's disease in patients transferring from ropinirole immediate-release tablets**

- **By Mouth Using Modified-Release Medicines**
  - **Adult:** Initially ropinirole modified-release once daily substituted for total daily dose equivalent of ropinirole immediate-release tablets; if control not maintained after switching, titrate dose, consider slower titration in patients over 75 years, when administered as adjunct to levodopa, concurrent dose of levodopa may gradually be reduced by approx. 30%, if treatment interrupted for 1 day or more, consider re-initiation with immediate-release tablets

#### Moderate to Severe Restless Legs Syndrome

- **By Mouth Using Immediate-Release Medicines**
  - **Adult:** Initially 250 micrograms once daily for 2 days, increased if tolerated to 500 micrograms once daily for 5 days, then increased if tolerated to 1 mg once daily for 7 days, then increased in steps of 500 micrograms daily, adjusted according to response, dose to be increased at weekly intervals; usual dose 2 mg once daily, doses to be taken at night, repeat dose titration if restarting after interval of more than a few days; maximum 4 mg per day

#### DOSE ADJUSTMENTS DUE TO INTERACTIONS

Dose adjustment may be necessary if smoking started or stopped during treatment.

#### UNLICENSED USE

Doses in the BNF may differ from those in product literature.

---

**Ropinirole**

**INDICATIONS AND DOSE**

**Parkinson's disease, either used alone or as adjunct to co-beneldopa or co-careldopa**

- **By Mouth Using Immediate-Release Medicines**
  - **Adult:** Initially 750 micrograms daily in 3 divided doses, then increased in steps of 750 micrograms daily, dose to be increased at weekly intervals, increased to 3 mg daily in 3 divided doses, then increased in steps of 1.5–3 mg daily, adjusted according to response, dose to be increased at weekly intervals; usual dose 9–16 mg daily in 3 divided doses, higher doses may be required if used with levodopa, when administered as adjunct to levodopa, concurrent dose of levodopa may be reduced by approx. 20%, daily maximum dose to be given in 3 divided doses; maximum 24 mg per day

- **By Mouth Using Modified-Release Medicines**
  - **Adult:** Initially 2 mg once daily for 1 week, then 4 mg once daily, increased in steps of 2 mg at intervals of at least 1 week, adjusted according to response, increased to up to 8 mg once daily, dose to be increased further if still no response; increased in steps of 2–4 mg at intervals of at least 2 weeks if required; maximum 24 mg per day

**Parkinson's disease in patients transferring from ropinirole immediate-release tablets**

- **By Mouth Using Modified-Release Medicines**
  - **Adult:** Initially ropinirole modified-release once daily substituted for total daily dose equivalent of ropinirole immediate-release tablets; if control not maintained after switching, titrate dose, consider slower titration in patients over 75 years, when administered as adjunct to levodopa, concurrent dose of levodopa may gradually be reduced by approx. 30%, if treatment interrupted for 1 day or more, consider re-initiation with immediate-release tablets

**Moderate to Severe Restless Legs Syndrome**

- **By Mouth Using Immediate-Release Medicines**
  - **Adult:** Initially 250 micrograms once daily for 2 days, increased if tolerated to 500 micrograms once daily for 5 days, then increased if tolerated to 1 mg once daily for 7 days, then increased in steps of 500 micrograms daily, adjusted according to response, dose to be increased at weekly intervals; usual dose 2 mg once daily, doses to be taken at night, repeat dose titration if restarting after interval of more than a few days; maximum 4 mg per day

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**

Dose adjustment may be necessary if smoking started or stopped during treatment.

**UNLICENSED USE**

Doses in the BNF may differ from those in product literature.

---

**IMPORTANT SAFETY INFORMATION**

**IMPULSE CONTROL DISORDERS**

Treatment with dopamine-receptor agonists is associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause impulse control disorders, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an impulse control disorder, the dopamine-receptor agonist should be withdrawn or the dose reduced until the symptoms resolve.
Compulsive behaviour - treatment and care should be exercised when driving or operating machinery. These effects have stopped occurring.

Hypotensive reactions - Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.

National Funding/Access Decisions

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (June 2006) that Adartrel® should be restricted for use in patients with a baseline score of 24 points or more on the International Restless Legs Scale.

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution.

Ropinirole (as Ropinirole hydrochloride) 8 mg tablets | 28 tablet (Pom) £35.79 DT price = £42.11

Rapiner XL (Actavis UK Ltd)

Ropinirole (as Ropinirole hydrochloride) 2 mg tablets | 28 tablet (Pom) £12.54 DT price = £15.24

Ropinirole (as Ropinirole hydrochloride) 4 mg tablets | 28 tablet (Pom) £25.09 DT price = £25.59

Ropinirole (as Ropinirole hydrochloride) 8 mg tablets | 28 tablet (Pom) £42.11 DT price = £42.11

Ropine XL (Aspire Pharma Ltd.)

Ropinirole (as Ropinirole hydrochloride) 2 mg tablets | 28 tablet (Pom) £6.20 DT price = £12.54

Ropinirole (as Ropinirole hydrochloride) 4 mg tablets | 28 tablet (Pom) £12.50 DT price = £25.09

Ropinirole (as Ropinirole hydrochloride) 8 mg tablets | 28 tablet (Pom) £21.00 DT price = £42.11

RopiylNZ X (Lupin (Europe) Ltd)

Ropinirole (as Ropinirole hydrochloride) 2 mg tablets | 28 tablet (Pom) £10.65 DT price = £12.54

Ropinirole (as Ropinirole hydrochloride) 4 mg tablets | 28 tablet (Pom) £21.32 DT price = £25.09

Ropinirole (as Ropinirole hydrochloride) 8 mg tablets | 28 tablet (Pom) £35.79 DT price = £42.11

Spiroco XL (Teva UK Ltd)

Ropinirole (as Ropinirole hydrochloride) 2 mg tablets | 28 tablet (Pom) £5.63 DT price = £12.54

Ropinirole (as Ropinirole hydrochloride) 4 mg tablets | 28 tablet (Pom) £11.28 DT price = £25.09

Ropinirole (as Ropinirole hydrochloride) 8 mg tablets | 28 tablet (Pom) £18.94 DT price = £42.11

Tablet

CAUTIONARY AND ADVISORY LABELS 10, 21

Ropinirole (as Ropinirole hydrochloride) 250 microgram Ropinirole 250 microgram tablets | 12 tablet (Pom) £15.00 DT price = £19.12

Ropinirole (as Ropinirole hydrochloride) 500 microgram Ropinirole 500 microgram tablets | 28 tablet (Pom) £25.00 DT price = £31.63

Ropinirole (as Ropinirole hydrochloride) 1 mg Ropinirole 1 mg tablets | 84 tablet (Pom) £67.50 DT price = £82.07

Ropinirole (as Ropinirole hydrochloride) 2 mg Ropinirole 2 mg tablets | 28 tablet (Pom) £12.50 DT price = £25.09

Ropinirole (as Ropinirole hydrochloride) 5 mg Ropinirole 5 mg tablets | 84 tablet (Pom) £182.37 DT price = £23.91

Adartrel (GlaxoSmithKline UK Ltd)

Ropinirole (as Ropinirole hydrochloride) 250 microgram Adartrel 250 microgram tablets | 12 tablet (Pom) £3.94 DT price = £9.12

Ropinirole (as Ropinirole hydrochloride) 500 microgram Adartrel 500 microgram tablets | 28 tablet (Pom) £15.75 DT price = £21.63

Ropinirole (as Ropinirole hydrochloride) 2 mg Adartrel 2 mg tablets | 28 tablet (Pom) £31.51 DT price = £2.80

Requip (GlaxoSmithKline UK Ltd)

Ropinirole (as Ropinirole hydrochloride) 250 microgram Requip 250 microgram tablets | 21 tablet (Pom) £5.70 | 42 tablet (Pom) no price available

Ropinirole (as Ropinirole hydrochloride) 1 mg Requip 1 mg tablets | 12 tablet (Pom) no price available | 42 tablet (Pom) no price available | 84 tablet (Pom) £56.71 DT price = £2.07

Ropinirole (as Ropinirole hydrochloride) 2 mg Requip 2 mg tablets | 28 tablet (Pom) no price available | 84 tablet (Pom) £11.44

Ropinirole (as Ropinirole hydrochloride) 5 mg Requip 5 mg tablets | 28 tablet (Pom) £195.92 DT price = £3.91
Rotigotine

**INDICATIONS AND DOSE**

**MONIT ORING REQUIREMENTS**

- **BY TRANSDERMAL APPLICATION USING PATCHES**
  - Adult: Initially 2 mg/24 hours, then increased in steps of 2 mg/24 hours every week if required; maximum 8 mg/24 hours per day
  - Adjunctive therapy with co-beneldopa or co-careldopa in Parkinson’s disease
    - **BY TRANSDERMAL APPLICATION USING PATCHES**
      - Adult: Initially 4 mg/24 hours, then increased in steps of 2 mg/24 hours every week if required; maximum 16 mg/24 hours per day

**INTERACTIONS**

- Common or very common
  - confusion
  - hallucinations
  - hypotension
  - sleep disturbances
  - sudden onset of sleep
  - sweating

- Uncommon
  - agitation
  - delusions
  - depression
  - dizziness
  - dyskinesia
  - dyspnea
  - hallucinations
  - headache
  - hiccups
  - hypotension
  - palpitations
  - paresthesia
  - pruritus
  - psychosis
  - rash
  - restlessness
  - sedation
  - syncope
  - vomiting
  - weight changes

**SIDE-EFFECTS**

- Common or very common: Abnormal behaviour - abnormal thinking - aggression - application site reactions - confusion - constipation - dizziness - dry mouth - dyskinesia - dystonia - hallucinations - headache - hiccups - hypotension - malaise - nausea - palpitations - paranoid - peripheral oedema - postural hypotension - pruritus - psychosis - rash - sleep disturbances - sudden onset of sleep - sweating - syncope - vomiting - weight changes

- Uncommon: Abdominal pain - atrial fibrillation - erectile dysfunction - hypotension - impulse control disorders - visual disturbances

- Rare: Irritability - obsessive compulsive disorder - seizures - tachycardia

**INFORMATION AVAILABLE**

- **PATIENT AND CARER ADVICE**
  - Sudden onset of sleep: Excessive daytime sleepiness and sudden onset of sleep can occur with dopamine-receptor agonists.
  - Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.
  - Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.

**Hypotensive reactions**

- Hypotensive reactions can occur in some patients taking dopamine-receptor agonists; these can be particularly problematic during the first few days of treatment and care should be exercised when driving or operating machinery.

**NATIONAL FUNDING/ACCESS DECISIONS**

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised that Neupro® is accepted for restricted use for the treatment of advanced Parkinson’s disease in combination with levodopa where the transdermal route would facilitate treatment (July 2007).

The Scottish Medicines Consortium has advised that Neupro® is accepted as monotherapy for the treatment of early-stage idiopathic Parkinson’s disease (June 2007).

The Scottish Medicines Consortium has advised (April 2009) that rotigotine (Neupro®) is accepted for restricted use within NHS Scotland for the symptomatic treatment of moderate to severe idiopathic restless legs syndrome in adults with a baseline score of 15 points or more on the International Restless Legs Scale.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Transdermal patch**

- Neupro (UCB Pharma Ltd)
  - Rotigotine 1 mg per 24 hour: Neupro 1mg/24hours transdermal patches | 28 patch [Pom] £77.24
  - Rotigotine 2 mg per 24 hour: Neupro 2mg/24hours transdermal patches | 7 patch [Pom] no price available | 28 patch [Pom] £81.10
  - Rotigotine 3 mg per 24 hour: Neupro 3mg/24hours transdermal patches | 28 patch [Pom] £102.35
  - Rotigotine 4 mg per 24 hour: Neupro 4mg/24hours transdermal patches | 7 patch [Pom] no price available | 28 patch [Pom] £123.60
  - Rotigotine 6 mg per 24 hour: Neupro 6mg/24hours transdermal patches | 7 patch [Pom] no price available | 28 patch [Pom] £149.93
  - Rotigotine 8 mg per 24 hour: Neupro 8mg/24hours transdermal patches | 7 patch [Pom] no price available | 28 patch [Pom] £149.93

**DOPAMINERGIC DRUGS** > **monoamine-oxidase B inhibitors**

**Rasagiline**

- **DRUG ACTION**
  - Rasagiline is a monoamine-oxidase B inhibitor.

- **INDICATIONS AND DOSE**
  - Parkinson’s disease, used alone or as adjunct to co-beneldopa or co-careldopa for ‘end-of-dose’ fluctuations
    - **BY MOUTH**
    - Adult: 1 mg daily

- **INTERACTIONS**
  - Appendix 1: monoamine-oxidase B inhibitors

**IMPORTANT SAFETY INFORMATION**

**IMPULSE CONTROL DISORDERS**

Treatment with dopamine-receptor agonists is associated with impulse control disorders, including pathological gambling, binge eating, and hypersexuality. Patients and their carers should be informed about the risk of impulse control disorders. There is no evidence that ergot- and non-ergot-derived dopamine-receptor agonists differ in their propensity to cause impulse control disorders, so switching between dopamine-receptor agonists to control these side-effects is not recommended. If the patient develops an impulse control disorder, the dopamine-receptor agonist should be withdrawn or the dose reduced until the symptoms resolve.

- **CAUTIONS**
  - Avoid exposure of patch to heat - remove patch (aluminium-containing) before magnetic resonance imaging or cardioversion

- **INTERACTIONS**
  - Appendix 1: dopamine receptor agonists

- **SIDE-EFFECTS**
  - Common or very common: Abnormal behaviour - abnormal thinking - aggression - application site reactions - confusion - constipation - dizziness - dry mouth - dyskinesia - dyspnea - hallucinations - headache - hiccups - hypotension - malaise - nausea - palpitations - paranoia - peripheral oedema - postural hypotension - pruritus - psychosis - rash - sleep disturbances - sudden onset of sleep - sweating - syncope - vomiting - weight changes

- **UNCOMMON**
  - Abdominal pain - atrial fibrillation - erectile dysfunction - hypotension - impulse control disorders - visual disturbances

- **RARE**
  - Irritability - obsessive compulsive disorder - seizures - tachycardia

- **PREGNANCY**
  - Avoid—no information available.

- **BREAST FEEDING**
  - May suppress lactation; avoid—present in milk in animal studies.

- **HEPATIC IMPAIRMENT**
  - Caution in severe impairment—no information available.

- **MONITORING REQUIREMENTS**
  - Ophthalmic testing recommended.

- **TREATMENT CESSATION**
  - Antiparkinsonian drug therapy should never be stopped abruptly as this carries a small risk of neuroleptic malignant syndrome.

- **DIRECTIONS FOR ADMINISTRATION**
  - Apply patch to dry, non-irritated skin on torso, thigh, or upper arm, removing after 24 hours and siting replacement patch on a different area (avoid using the same area for 14 days).
Selegiline hydrochloride

**DRUG ACTION** Selegiline is a monoamine-oxidase-B inhibitor.

**INDICATIONS AND DOSE**

- **Parkinson’s disease**, as an adjunct to levodopa alone or in combination with other antiparkinsonian drugs, for mid-to late-stage fluctuations
  - **BY MOUTH**
  - Adult: 50 mg once daily, increased if necessary to 100 mg once daily

**CONTRA-INDICATIONS** Active retinopathy · albinism · family history of hereditary retinal disease · retinal degeneration · uveitis

**CAUTIONS** Hypertension (may raise blood pressure) · may exacerbate pre-existing dyskinesia (requiring levodopa dose reduction)

**INTERACTIONS** → Appendix 1: monoamine-oxidase B inhibitors

**SIDE-EFFECTS**

- **Common or very common** Abnormal dreams · angina · anorexia · arthralgia · conjunctivitis · constipation · depression · dry mouth · dyspepsia · flatulence · hallucinations · headache · influenza-like symptoms · leucopenia · rash · rhinitis · skin carcinoma · urinary urgency · vertigo · weight loss
- **Uncommon** Cerebrovascular accident · myocardial infarction

**PREGNANCY** Use with caution.

**BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT** Manufacturer advises max. daily dose should not exceed 50 mg daily in moderate impairment. Manufacturer advises caution in moderate impairment; avoid in severe impairment.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- Xadago (Profile Pharma Ltd)
  - **Safinamide (as Safinamide methanesulfonate) 50 mg** Xadago 50 mg tablets | 30 tablet (Profile) £69.00 DT price = £69.00
  - **Safinamide (as Safinamide methanesulfonate) 100 mg** Xadago 100 mg tablets | 30 tablet (Profile) £69.00 DT price = £69.00

---

**Safinamide**

31-May-2017

**DRUG ACTION** Safinamide is a monoamine-oxidase-B inhibitor.

**INDICATIONS AND DOSE**

- Parkinson’s disease, used alone or as adjunct to co-beneldopa or co-careldopa to reduce ‘end of dose’ deterioration | Symptomatic parkinsonism
  - **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
    - Adult: Initially 5 mg once daily for 2–4 weeks, then increased if tolerated to 10 mg daily, dose to be taken in the morning
  - **BY MOUTH USING ORAL LYPHILISATE**
    - Adult: 1.25 mg once daily, dose to be taken before breakfast

**DOSE EQUIVALENCE AND CONVERSION**

- 1.25-mg oral lypihilisate is equivalent to 10-mg tablet.
- Patients receiving 10 mg conventional selegeline hydrochloride tablets can be switched to oral lypihilisates (Zelapar®) 1.25 mg.

**CONTRA-INDICATIONS** Active duodenal ulceration · active gastric ulceration · avoid or use with great caution in postural hypotension (when used in combination with levodopa)

**CAUTIONS** Angina · arrhythmias · avoid in acute porphyrias p. 969 · duodenal ulceration · gastric ulceration · history of hepatic dysfunction · patients predisposed to confusion and psychosis · psychosis · uncontrolled hypertension

**INTERACTIONS** → Appendix 1: monoamine-oxidase B inhibitors

**SIDE-EFFECTS**

- **Common or very common** Arthralgia · bradycardia · confusion · constipation · depression · diarrhoea · dizziness · dry mouth · fatigue · hair loss · headache · hypertension · hyponatraemia · impairepd balance · mouth ulcers · movement disorders · muscle cramps · myalgia · myopathy · nasal congestion · nausea · psychosis · sleeping disorders · stomatitis · sweating · tremor
- **Uncommon** Agitation · angina · ankle oedema · anxiety · arrhythmias · blurred vision · dyspnoea · leucocytopenia · loss of appetite · micturition difficulties · palpitation · postural hypotension · skin reactions · supraventricular tachycardia · thrombocytopenia

**Frequency not known** Hypersexuality

**SIDE-EFFECTS, FURTHER INFORMATION**

Side-effects of levodopa may be increased—concurrent levodopa dosage can be reduced by 10–30% in steps of 10% every 3–4 days.

**PREGNANCY** Avoid—no information available.

**BREAST FEEDING** Avoid—no information available.

**HEPATIC IMPAIRMENT** Use with caution in severe impairment.
Nausea and labyrinth disorders

Drug treatment

Antiemetics should be prescribed only when the cause of vomiting is known because otherwise they may delay diagnosis, particularly in children. Antiemetics are unnecessary and sometimes harmful when the cause can be treated, such as in diabetic ketoacidosis, or in digoxin p. 106 or antiepileptic overdose.

If antiemetic drug treatment is indicated, the drug is chosen according to the aetiology of vomiting. Antiemetics are effective against nausea and vomiting resulting from many underlying conditions. There is no evidence that any one antiemetic is superior to another but their duration of action and incidence of adverse effects (drowsiness and antiemetic effects) differ.

The phenothiazines are dopamine antagonists and act centrally by blocking the chemoreceptor trigger zone. They are of considerable value for the prophylaxis and treatment of nausea and vomiting associated with diffuse neoplastic disease, radiation sickness, and the emesis caused by drugs such as opioids, general anaesthetics, and cytotoxics. Prochlorperazine p. 371, perhexazine p. 370, and trimelaurazine p. 372 are less sedating than chlorpromazine hydrochloride p. 367; severe dystonic reactions sometimes occur with phenothiazines, especially in children. Some phenothiazines are available as rectal suppositories, which can be useful in patients with persistent vomiting or with severe nausea; prochlorperazine can also be administered as a buccal tablet which is placed between the upper lip and the gum.

Other antipsychotic drugs including haloperidol p. 368 and levomepromazine p. 419 are used for the relief of nausea and vomiting in terminal illness.

Metoclopramide hydrochloride p. 411 is an effective antiemetic and its activity closely resembles that of the phenothiazines. Metoclopramide hydrochloride also acts directly on the gastrointestinal tract and it may be superior to the phenothiazines for emesis associated with gastroduodenal, hepatic, and biliary disease.

Domperidone p. 410 acts at the chemoreceptor trigger zone; it is licensed only for the relief of nausea and vomiting. It has the advantage over metoclopramide hydrochloride and the phenothiazines of being less likely to cause central effects such as sedation and dystonic reactions because it does not readily cross the blood-brain barrier. In Parkinson’s disease, it can be used to treat nausea caused by dopaminergic drugs.

Granisetron p. 413 and ondansetron p. 414 are of value in the management of nausea and vomiting in patients receiving cytotoxics and in postoperative nausea and vomiting. Palonosetron p. 415 is licensed for prevention of nausea and vomiting associated with moderately or highly emetogenic cytotoxic chemotherapy. Palonosetron is also available in combination with netupitant, a neurokinin 1-receptor antagonist, for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy and highly emetogenic cisplatin-based chemotherapy.

Dexamethasone p. 635 has antiemetic effects and it is used in vomiting associated with cancer chemotherapy. It can be used alone or with metoclopramide hydrochloride, prochlorperazine, lorazepam p. 322, or a 5HT3-receptor antagonist.

Aprepitant p. 412 and fosaprepitant p. 413 are neurokinin 1-receptor antagonists licensed for the prevention of acute and delayed nausea and vomiting associated with cisplatin-based cytotoxic chemotherapy; they are given with dexamethasone and a 5HT3-receptor antagonist.

Nabilone p. 410 is a synthetic cannabinoid with antiemetic properties. It may be used for nausea and vomiting caused by cytotoxic chemotherapy that is unresponsive to conventional antiemetics.

Vomiting during pregnancy

Nausea in the first trimester of pregnancy is generally mild and does not require drug therapy. On rare occasions if vomiting is severe, short-term treatment with an antiemetic, such as promethazine, may be required. Prochlorperazine or metoclopramide hydrochloride are alternatives. If symptoms do not settle in 24 to 48 hours then specialist opinion should be sought. Hyperemesis gravidarum is a more serious condition, which requires regular antiemetic therapy, intravenous fluid and electrolyte replacement and sometimes nutritional support. Supplementation with thiamine p. 989 must be considered in order to reduce the risk of Wernicke’s encephalopathy.

Postoperative nausea and vomiting

The incidence of postoperative nausea and vomiting depends on many factors including the anaesthetic used, and the type and duration of surgery. Other risk factors include female sex, non-smokers, a history of postoperative nausea and vomiting or motion sickness, and intraoperative and postoperative use of opioids. Therapy to prevent postoperative nausea and vomiting should be based on the
assessed risk of postoperative nausea and vomiting in each patient. Drugs used include 5HT3-receptor antagonists, droperidol p. 418, dexamethasone, some phenothiazines (e.g. prochlorperazine), and antihistamines (e.g. cyclizine below). A combination of two or more antiemetic drugs that have different mechanisms of action is often indicated in those at high risk of postoperative nausea and vomiting or where postoperative vomiting presents a particular danger (e.g. in some types of surgery). When a prophylactic antiemetic drug has failed, postoperative nausea and vomiting should be treated with one or more drugs from a different class.

**Motion sickness**
Antiemetics should be given to prevent motion sickness rather than after nausea or vomiting develop. The most effective drug for the prevention of motion sickness is hyoscine hydrobromide p. 417. The sedating antihistamines are slightly less effective against motion sickness, but are generally better tolerated than hyoscine. If a sedative effect is desired promethazine is useful, but generally a slightly less sedating antihistamine such as cyclizine or cinnarizine p. 416 is preferred. Domperidone, metoclopramide hydrochloride, 5HT3-receptor antagonists, and the phenothiazines (except the antihistamine phenothiazine promethazine) are ineffective in motion sickness.

**Other vestibular disorders**
Management of vestibular diseases is aimed at treating the underlying cause as well as treating symptoms of the balance disturbance and associated nausea and vomiting. Vertigo and nausea associated with Ménière’s disease and middle-ear surgery can be difficult to treat. Betahistine dihydrochloride p. 419 is an analogue of histamine and is claimed to reduce endolymphatic pressure by improving the microcirculation. Betahistine dihydrochloride is licensed for vertigo, tinnitus, and hearing loss associated with Ménière’s disease.

A diuretic alone or combined with salt restriction may provide some benefit in vertigo associated with Ménière’s disease; antihistamines (such as cinnarizine), and phenothiazines (such as prochlorperazine) are also used. Where possible, prochlorperazine should be reserved for the treatment of acute symptoms.

**Cytotoxic chemotherapy, palliative care, and migraine**
Antiemetics have a role in the management of nausea and vomiting induced by cytotoxic chemotherapy, in palliative care, and associated with migraine.

### Antiemetics and Antinauseants

#### AntiHistamines

**Cyclizine**

<table>
<thead>
<tr>
<th>INDICATIONS AND DOSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>**Nausea</td>
</tr>
<tr>
<td>By Mouth</td>
</tr>
<tr>
<td>Adult: 50 mg up to 3 times a day, for motion sickness, take 1–2 hours before departure</td>
</tr>
<tr>
<td>By Intravenous Injection, or by Intramuscular Injection</td>
</tr>
<tr>
<td>Adult: 50 mg 3 times a day</td>
</tr>
<tr>
<td>**Nausea and vomiting of known cause</td>
</tr>
<tr>
<td>By Mouth, or by Intravenous Injection</td>
</tr>
<tr>
<td>Child 1 month–5 years: 0.5–1 mg/kg up to 3 times a day (max. per dose 25 mg), intravenous injection to be given over 3–5 minutes, for motion sickness, take 1–2 hours before departure</td>
</tr>
<tr>
<td>Child 6–11 years: 25 mg up to 3 times a day, intravenous injection to be given over 3–5 minutes, for motion sickness, take 1–2 hours before departure</td>
</tr>
<tr>
<td>Child 12–17 years: 50 mg up to 3 times a day, intravenous injection to be given over 3–5 minutes, for motion sickness, take 1–2 hours before departure</td>
</tr>
<tr>
<td>By Rectum</td>
</tr>
<tr>
<td>Child 2–5 years: 12.5 mg up to 3 times a day</td>
</tr>
<tr>
<td>Child 6–11 years: 25 mg up to 3 times a day</td>
</tr>
<tr>
<td>Child 12–17 years: 50 mg up to 3 times a day</td>
</tr>
<tr>
<td>By Continuous Intravenous Infusion, or by Subcutaneous Infusion</td>
</tr>
<tr>
<td>Child 1–23 months: 3 mg/kg, dose to be given over 24 hours</td>
</tr>
<tr>
<td>Child 2–5 years: 50 mg, dose to be given over 24 hours</td>
</tr>
<tr>
<td>Child 6–11 years: 75 mg, dose to be given over 24 hours</td>
</tr>
<tr>
<td>Child 12–17 years: 150 mg, dose to be given over 24 hours</td>
</tr>
</tbody>
</table>

**Nausea and vomiting associated with palliative care**

- **By Subcutaneous Infusion**
  - Adult: 150 mg, dose to be given over 24 hours
  - By Mouth
    - Adult: 50 mg up to 3 times a day

#### UNLICENSED USE


#### CONTRA-INDICATIONS

Avoid in acute porphyrias p. 969 (some antihistamines are thought to be safe)

#### CAUTIONS

Epilepsy · glaucoma (in children) · may counteract haemodynamic benefits of opioids · neuromuscular disorders· increased risk of transient paralysis with intravenous use · prostatic hypertrophy (in adults) · pyloroduodenal obstruction · severe heart failure—may cause fall in cardiac output and associated increase in heart rate, mean arterial pressure and pulmonary wedge pressure · susceptibility to angle-closure glaucoma (in adults) · urinary retention

#### INTERACTIONS

Appendix 1: antihistamines (sedating)

#### SIDE-EFFECTS

**GENERAL SIDE-EFFECTS**

- **Common or very common** Drowsiness
- **Rare** Anaphylaxis · angioedema · angle-closure glaucoma · arrhythmias · blood disorders · bronchospasm · confusion · convulsions · depression · dizziness · extrapyramidal effects · hypersensitivity reactions · hypotension · liver dysfunction · palpitation · paradoxical stimulation (especially with high doses in children) · paradoxical stimulation (especially with high doses in the elderly) ·

---

Other drugs used for Nausea and labyrinth disorders

Paracetamol with metoclopramide, p. 451 · Promethazine hydrochloride, p. 275
photosensitivity reactions • rashes • sleep disturbances • tremor

- **Frequency not known** Antimuscarinic effects • blurred vision • dry mouth • gastro-intestinal disturbances • hallucinations • headache • hypertension • movement disorders • oculargia crisis • paraesthesia • psychomotor impairment • tachycardia • transient speech disorders • twitching • urinaiy retention

**SPECIFIC SIDE-EFFECTS**

- Rare
- With intravenous use Transient paralysis
- With subcutaneous use Local irritation

**SIDE-EFFECTS, FURTHER INFORMATION**

Children and the elderly are more susceptible to side-effects. Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely, especially with high doses or in children and the elderly. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.

- **PREGNANCY** Manufacturer advises avoid; however, there is no evidence of teratogenicity. The use of sedating antihistamines in the latter part of the third trimester may cause adverse effects in neonates such as irritability, paradoxical excitation, and tremor.

- **BREAST FEEDING** No information available. Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

- **HEPATIC IMPAIRMENT** Avoid in severe liver disease—increased risk of coma.

- **DIRECTIONS FOR ADMINISTRATION** For administration by mouth, tablets may be crushed. Mixing and compatibility for the use of syringe drivers in palliative care Cyclizine may precipitate at concentrations above 10 mg/mL or in the presence of sodium chloride 0.9% or as the concentration of diamorphine relative to cyclizine increases; mixtures of diamorphine and cyclizine are also likely to precipitate after 24 hours.

- **PATIENT AND CARER ADVICE**

  Driving and skilled tasks

  Drowsiness may affect performance of skilled tasks (e.g. cycling, driving); effects of alcohol enhanced.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, suppository

**Tablet**

| CAUTIONARY AND ADVISORY LABELS | 2 |
| Cyclizine (Non-proprietary) |
| Cyclizine hydrochloride 50 mg | Cyclizine 50mg tablets | 30 tablet [D] £2.19–5.00 |
| Cyclizine lactate 50 mg per 1 ml | Cyclizine 50mg/1ml solution for injection ampoules | 5 ampoule [POM] £13.54 DT price = £7.29 |

**Solution for injection**

| Cyclizine (Non-proprietary) |
| Cyclizine lactate 50 mg per 1 ml | Cyclizine 50mg/1ml solution for injection ampoules | 5 ampoule [POM] £13.54 DT price = £13.54 |

**ANTIEMETICS AND ANTINAUSEANTS**

**CANNABINIODS**

**Nabilone**

- **INDICATIONS AND DOSE**

  Nausea and vomiting caused by cytotoxic chemotherapy, unresponsive to conventional antiemetics (preferably in hospital setting) (under close medical supervision)

  - **BY MOUTH**

    Adult: Initially 1 mg twice daily, increased if necessary to 2 mg twice daily throughout each cycle of cytotoxic therapy and, if necessary, for 48 hours after the last dose of each cycle, the first dose should be taken the night before initiation of cytotoxic treatment and the second dose 1–3 hours before the first dose of cytotoxic drug, daily dose maximum should be given in 3 divided doses; maximum 6 mg per day.

- **CAUTIONS** Adverse effects on mental state can persist for 48–72 hours after stopping. Elderly, heart disease, history of psychiatric disorder • Hypertension

- **INTERACTIONS** → Appendix 1: nabilone

- **SIDE-EFFECTS**

  - **Common or very common** Ataxia • concentration difficulties • drowsiness • dry mouth • dysphoria • euphoria • headache • hypotension • nausea • sleep disturbance • vertigo • visual disturbance

  - **Frequency not known** Abdominal pain • confusion • decreased appetite • decreased coordination • depression • disorientation • hallucinations • psychosis • tachycardia • tremors

**SIDE-EFFECTS, FURTHER INFORMATION**

Drowsiness and dizziness occur frequently with standard doses.

- **PREGNANCY** Avoid unless essential.

- **BREAST FEEDING** Avoid—no information available.

- **HEPATIC IMPAIRMENT** Avoid in severe impairment.

- **PATIENT AND CARER ADVICE**

  Driving and skilled tasks

  Drowsiness may affect performance of skilled tasks (e.g. driving). Effects of alcohol enhanced.

  For information on 2015 legislation regarding driving whilst taking certain controlled drugs, including nabilone, see Drugs and driving under Guidance on prescribing p. 1. Behavioural effects Patients should be made aware of possible changes of mood and other adverse behavioural effects.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule

**Capsule**

| CAUTIONARY AND ADVISORY LABELS | 2 |
| Nabilone 1 mg | Nabilone 1 mg capsules | 20 capsules [POM] £196.00 |

**ANTIEMETICS AND ANTINAUSEANTS**

**DOPAMINE RECEPTOR ANTAGONISTS**

**Domperidone**

- **INDICATIONS AND DOSE**

  Relief of nausea and vomiting

  - **BY MOUTH**

    Child (body-weight up to 35 kg): 250 micrograms/kg up to 3 times a day; maximum 750 micrograms/kg per day

    Child 12–17 years (body-weight 35 kg and above): 10 mg up to 3 times a day; maximum 30 mg per day
Nausea and labyrinth disorders 411

**DOMPERIDONE** 22

**INDICATIONS AND DOSE** Symptomatic treatment of nausea and vomiting including that associated with acute migraine | Delayed (but not acute) chemotherapy-induced nausea and vomiting | Radiotherapy-induced nausea and vomiting | Prevention of postoperative nausea and vomiting

- **BY MOUTH, OR BY INTRAMUSCULAR INJECTION, OR BY SLOW INTRAVENOUS INJECTION**
- **Adult** (body-weight up to 60 kg): Up to 500 micrograms/kg daily in 3 divided doses, when administered by slow intravenous injection, to be given over at least 3 minutes
- **Adult** (body-weight 60 kg and above): 10 mg up to 3 times a day, when administered by slow intravenous injection, to be given over at least 3 minutes

**Hiccup in palliative care**

- **BY MOUTH, OR BY INTRAMUSCULAR INJECTION, OR BY SUBCUTANEOUS INJECTION**
- **Adult**: 10 mg every 6–8 hours

**Nausea and vomiting in palliative care**

- **BY MOUTH**
- **Adult**: 10 mg 3 times a day
- **BY SUBCUTANEOUS INFUSION**
- **Adult**: 30–100 mg/24 hours

**PATIENT AND CARER ADVICE**

Arrhythmia Patients and their carers should be told how to recognise signs of arrhythmia and advised to seek medical attention if symptoms such as palpitation or syncope develop.

Medicines for Children leaflet: Domperidone for gastro-oesophageal reflux www.medicinesforchildren.org.uk/domperidone-for-gastro-oesophageal-reflux

**IMPORTANT SAFETY INFORMATION**

**MHRA/CHM ADVICE—DOMPERIDONE: RISK OF CARDIAC SIDE-EFFECTS—RESTRICTED INDICATION, NEW CONTRA-INDICATIONS, REDUCED DOSE AND DURATION OF USE**

The benefits and risks of domperidone have been reviewed. As domperidone is associated with a small increased risk of serious cardiac side-effects, the following restrictions to indication, dose and duration of treatment have been made, and new contra-indications added:

- Domperidone should only be used for the relief of the symptoms of nausea and vomiting;
- Domperidone should be used at the lowest effective dose for the shortest possible duration (max. treatment duration should not normally exceed 1 week);
- Domperidone is contra-indicated for use in conditions where cardiac conduction is, or could be, impaired, or where there is underlying cardiac disease, when administered concomitantly with drugs that prolong the QT interval or potent CYP3A4 inhibitors, and in severe hepatic impairment;
- The recommended dose in adults and adolescents over 12 years and over 35 kg is 10 mg up to 3 times daily;
- The recommended dose in children under 35 kg is 250 micrograms/kg up to 3 times daily;
- Oral liquid formulations should be given via an appropriately designed, graduated oral syringe to ensure dose accuracy.

This advice does not apply to unlicensed uses of domperidone (e.g. palliative care).

**CONTRA-INDICATIONS** Cardiac disease - conditions where cardiac conduction is, or could be, impaired (in adults) - gastrointestinal haemorrhage (in children) - if increased gastrointestinal motility harmful (in adults) - mechanical obstruction (in children) - mechanical perforation (in children) - predisposition to cardiac conduction disorders (in children) - prolactinoma

**CAUTIONS** Children - if there are cardiac concerns, obtain ECG before and during treatment (in children) - patients over 60 years—increased risk of ventricular arrhythmias

**INTERACTIONS** → Appendix 1: domperidone

**SIDE-EFFECTS**

- **Common or very common** Drowsiness - dry mouth - malaise
- **Uncommon** Anxiety - breast pain - decreased libido - diarrhoea - galactorrhoea - headache - pruritus - rash
- **Frequency not known** Agitation - amnorrhoea - convulsions - extrapyramidal disorders - gynaecomastia - nervousness - oculogyric crisis - QT-interval prolongation - sudden cardiac death - urinary retention - ventricular arrhythmias

**PREGNANCY** Use only if potential benefit outweighs risk.

**BREAST FEEDING** Amount too small to be harmful.

**HEPATIC IMPAIRMENT** Avoid in moderate or severe impairment.

**RENAL IMPAIRMENT** Reduce frequency.

**PRESCRIBING AND DISPENSING INFORMATION**

**Palliative care** For further information on the use of domperidone in palliative care, see www.palliativefeeds.com/formulary/en/domperidone.html.
vomiting, radiotherapy-induced nausea and vomiting, delayed (but not acute) chemotherapy-induced nausea and vomiting, and symptomatic treatment of nausea and vomiting, including that associated with acute migraine (where it may also be used to improve absorption of oral analgesics);

- Metoclopramide should only be prescribed for short-term use (up to 5 days);
- Usual dose is 10 mg, repeated up to 3 times daily; max. daily dose is 500 micrograms/kg;
- Intravenous doses should be administered as a slow bolus over at least 3 minutes;
- Oral liquid formulations should be given via an appropriately designed, graduated oral syringe to ensure dose accuracy.

This advice does not apply to unlicensed uses of metoclopramide (e.g. palliative care).

- CONTRA-INDICATIONS 3–4 days after gastrointestinal surgery – gastro-intestinal haemorrhage – gastro-intestinal obstruction – gastro-intestinal perforation – phaeochromocytoma
- CAUTIONS Asthma – atopic allergy – bradycardia – cardiac conduction disturbances – children – elderly – epilepsy – may mask underlying disorders such as cerebral irritation – Parkinson’s disease – uncorrected electrolyte imbalance – young adults (15–19 years old)
- INTERACTIONS ➔ Appendix 1: metoclopramide
- SIDE-EFFECTS

GENERAL SIDE-EFFECTS
- Common or very common Extrapyramidal effects (especially in children and young adults (15–19 years old)) – galactorrhoea – gynaecomastia – hyperprolactinaemia – menstrual changes
- Very rare Depression – methaemoglobinaemia (more severe in G6PD deficiency) – neuroleptic malignant syndrome

SPECIFIC SIDE-EFFECTS
- Very rare
  - With intravenous use Cardiac conduction abnormalities

SIDE-EFFECTS, FURTHER INFORMATION
Metoclopramide can induce acute dystonic reactions involving facial and skeletal muscle spasms and oculogyric crises. These dystonic effects are more common in the young (especially girls and young women) and the very old; they usually occur shortly after starting treatment with metoclopramide and subside within 24 hours of stopping it. Injection of an antiparkinsonian drug such as procyclidine will abort dystonic attacks.

- PREGNANCY Not known to be harmful.
- BREAST FEEDING Small amount present in milk; avoid.
- HEPATIC IMPAIRMENT Reduce dose.
- RENAL IMPAIRMENT Avoid or use small dose in severe impairment; increased risk of extrapyramidal reactions.
- DIRECTIONS FOR ADMINISTRATION Oral liquid preparation to be given via a graduated oral dosing syringe.
- PRESCRIBING AND DISPENSING INFORMATION
Palliative care
For further information on the use of metoclopramide hydrochloride in palliative care, see www.palliativedrugs.com/formulary/en/metoclopramide.html.
- PATIENT AND CARER ADVICE Counselling on use of pipette advised with oral solution.

- MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

Solution for injection
- Metoclopramide hydrochloride (Non-proprietary)
  - Metoclopramide hydrochloride 5 mg per 1 ml Metoclopramide 10mg/2ml solution for injection ampoules | 5 ampoule (£) £1.31 | 10 ampoule (£) £3.30
  - Maxolon (AMCo)
  - Metoclopramide hydrochloride 5 mg per 1 ml Maxolon 10mg/2ml solution for injection ampoules | 12 ampoule (£) £3.21 Maxolon High Dose 100mg/20ml solution for injection ampoules | 10 ampoule (£) £26.68

Oral solution
- Metoclopramide hydrochloride (Non-proprietary)
  - Metoclopramide hydrochloride 1 mg per 1 ml Metoclopramide 5mg/5ml oral solution sugar free sugar-free | 150 ml (£) £19.77 DT price = £19.77

Tablet
- Metoclopramide hydrochloride (Non-proprietary)
  - Metoclopramide hydrochloride 10 mg Metoclopramide 10mg tablets | 28 tablet (£) £1.40 DT price = £0.72
  - Maxolon (AMCo)
  - Metoclopramide hydrochloride 10 mg Maxolon 10mg tablets | 84 tablet (£) £5.24

Combinations available: Paracetamol with metoclopramide, p. 451

ANTIEMETICS AND ANTINAUSEANTS ➔ NEUROKININ RECEPTOR ANTAGONISTS

Aprepitant

- INDICATIONS AND DOSE
Adjunct to dexamethasone and a 5HT3-receptor antagonist in preventing nausea and vomiting associated with moderately and highly emetogenic chemotherapy
  ➔ BY MOUTH
  - Adult: Initially 125 mg, dose to be taken 1 hour before chemotherapy, then 80 mg once daily for 2 days, consult product literature for dose of concomitant corticosteroid and 5HT3-antagonist

- CONTRA-INDICATIONS Acute porphyrias p. 969
- INTERACTIONS ➔ Appendix 1: aprepitant
- SIDE-EFFECTS
  - Common or very common Anorexia – asthenia – constipation – diarrhoea – dizziness – dyspepsia – headache – hiccups
  - Frequency not known Dysarthria – dysphonia – insomnia – Stevens-Johnson syndrome – urticaria – visual disturbances

- CONCEPTION AND CONCEPTION
Effectiveness of hormonal contraceptives reduced—effective non-hormonal methods of contraception necessary during treatment and for 2 months after stopping aprepitant.
- PREGNANCY Avoid unless potential benefit outweighs risk—no information available.
- BREAST FEEDING Avoid—present in milk in animal studies.
- HEPATIC IMPAIRMENT Caution in moderate to severe impairment.
**ANTIEMETICS AND ANTINAUSEANTS**

**SEROTONIN (5HT3) RECEPTOR ANTAGONISTS**

**Granisetron**

- **DRUG ACTION** Granisetron is a specific 5HT3-receptor antagonist which blocks 5HT3 receptors in the gastrointestinal tract and in the CNS.

- **INDICATIONS AND DOSE**
  - Nausea and vomiting induced by cytotoxic chemotherapy for planned duration of 3–5 days where oral antiemetics cannot be used
  - **BY TRANSDERMAL APPLICATION USING PATCHES**
    - Adult: Apply 3.1 mg/24 hours, apply patch to clean, dry, non-irritated, non-hairy skin on upper arm (or abdomen if upper arm cannot be used) 24–48 hours before treatment, patch may be worn for up to 7 days; remove at least 24 hours after completing chemotherapy
  - Prevention of postoperative nausea and vomiting
    - **BY INTRAVENOUS INJECTION**
      - Adult: 1 mg, to be administered before induction of anaesthesia, dose to be diluted to 5 mL and given over 30 seconds
    - Treatment of postoperative nausea and vomiting
      - **BY INTRAVENOUS INJECTION**
        - Adult: 1 mg, dose to be diluted to 5 mL and given over 30 seconds; maximum 3 mg per day
    - Management of nausea and vomiting induced by cytotoxic chemotherapy or radiotherapy
      - **BY MOUTH**
        - Adult: 1–2 mg, to be taken within 1 hour before start of treatment, then 2 mg daily in 1–2 divided doses for up to 1 week following treatment, when intravenous route was also used, maximum combined total dose 9 mg in 24 hours
      - **BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
        - Adult: 10–40 micrograms/kg (max. per dose 3 mg), to be given 5 minutes before start of treatment, dose may be repeated if necessary, further maintenance doses must not be given less than 10 minutes apart, for intravenous injection, each 1 mg granisetron diluted to 5 mL and given over not less than 30 seconds, for intravenous infusion, to be given over 5 minutes; maximum 9 mg per day

- **CAUTIONS** Subacute intestinal obstruction - susceptibility to QT-interval prolongation (including electrolyte disturbances)

- **INTERACTIONS**
  - **Appendix 1: granisetron**

- **SIDE-EFFECTS**
  - **GENERAL SIDE-EFFECTS**
    - **Common or very common** Constipation - diarrhoea - headache - insomnia
    - **Uncommon** Extrapyramidal reactions - QT-interval prolongation - rash

- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **Scottish Medicines Consortium (SMC) Decisions**
    - The Scottish Medicines Consortium has advised (January 2011) that fosaprepitant (Ivemend®) is accepted for restricted use within NHS Scotland for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based chemotherapy.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Powder for solution for infusion**
    - **Ivemend** (Merck Sharp & Dohme Ltd)
      - Fosaprepitant (as Fosaprepitant dimeglumine) 150 mg
      - Ivemend 150mg powder for solution for infusion vials | 1 vial [PDM] £47.42

---

**Fosaprepitant**

- **DRUG ACTION** Fosaprepitant is a prodrug of aprepitant.

- **INDICATIONS AND DOSE**
  - Adjunct to dexamethasone and a 5HT3-receptor antagonist in preventing nausea and vomiting associated with moderately and highly emetogenic chemotherapy
  - **BY INTRAVENOUS INFUSION**
    - Adult: 150 mg, dose to be administered over 20–30 minutes and given 30 minutes before chemotherapy on day 1 of cycle only, consult product literature for dose of concomitant corticosteroid and 5HT3-receptor antagonist

- **CONTRA-INDICATIONS** Acute porphyrias p. 969

- **INTERACTIONS**
  - **Appendix 1: fosaprepitant**

- **SIDE-EFFECTS**
  - **Common or very common** Anorexia - asthenia - constipation - diarrhoea - dizziness - dyspepsia - headache - hiccups

- **Frequency not known** Dysarthria - dysphonia - insomnia - Stevens-Johnson syndrome - urticaria - visual disturbances

- **CONCEPTION AND CONCEPTION** Effectiveness of hormonal contraceptives reduced—effective non-hormonal methods of contraception necessary during treatment and for 2 months after stopping fosaprepitant.

- **PREGNANCY** Avoid unless potential benefit outweighs risk—no information available.

- **BREAST FEEDING** Avoid—present in milk in animal studies.

- **HEPATIC IMPAIRMENT** Caution in moderate to severe impairment.

- **DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Ivemend®), give intermittently in Sodium chloride 0.9%; reconstitute each 150-mg vial with 5 mL sodium chloride 0.9% gently without shaking to avoid foaming, then dilute in 145 mL infusion fluid; give over 20–30 minutes.

- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **Scottish Medicines Consortium (SMC) Decisions**
    - The Scottish Medicines Consortium has advised (January 2011) that fosaprepitant (Ivemend®) is accepted for restricted use within NHS Scotland for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based chemotherapy.

---

**Granisetron**

- **DRUG ACTION** Granisetron is a specific 5HT3-receptor antagonist which blocks 5HT3 receptors in the gastrointestinal tract and in the CNS.

- **INDICATIONS AND DOSE**
  - Nausea and vomiting induced by cytotoxic chemotherapy for planned duration of 3–5 days where oral antiemetics cannot be used
  - **BY INTRAVENOUS INJECTION**
    - Adult: 1 mg, to be administered before induction of anaesthesia, dose to be diluted to 5 mL and given over 30 seconds
    - Prevention of postoperative nausea and vomiting
      - **BY INTRAVENOUS INJECTION**
        - Adult: 1 mg, dose to be diluted to 5 mL and given over 30 seconds; maximum 3 mg per day
    - Management of nausea and vomiting induced by cytotoxic chemotherapy or radiotherapy
      - **BY MOUTH**
        - Adult: 1–2 mg, to be taken within 1 hour before start of treatment, then 2 mg daily in 1–2 divided doses for up to 1 week following treatment, when intravenous route was also used, maximum combined total dose 9 mg in 24 hours
      - **BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
        - Adult: 10–40 micrograms/kg (max. per dose 3 mg), to be given 5 minutes before start of treatment, dose may be repeated if necessary, further maintenance doses must not be given less than 10 minutes apart, for intravenous injection, each 1 mg granisetron diluted to 5 mL and given over not less than 30 seconds, for intravenous infusion, to be given over 5 minutes; maximum 9 mg per day

- **CAUTIONS** Subacute intestinal obstruction - susceptibility to QT-interval prolongation (including electrolyte disturbances)

- **INTERACTIONS**
  - **Appendix 1: granisetron**

- **SIDE-EFFECTS**
  - **GENERAL SIDE-EFFECTS**
    - **Common or very common** Constipation - diarrhoea - headache - insomnia
    - **Uncommon** Extrapyramidal reactions - QT-interval prolongation - rash

- **SPECIFIC SIDE-EFFECTS**
  - **Uncommon**
    - With transdermal use Application-site reactions
  - **BREAST FEEDING** Avoid—no information available.
  - **HEPATIC IMPAIRMENT** Manufacturer advises use with caution.

- **DIRECTIONS FOR ADMINISTRATION** For intravenous infusion, give intermittently in Glucose 5% or Sodium Chloride 0.9%; dilute up to 3 mL in 20–50 mL infusion fluid; give over 5 minutes.
**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Granisetron (Non-proprietary)**
  - Granisetron (as Granisetron hydrochloride) 1 mg per 1 ml Granisetron 3mg/3ml concentrate for solution for injection ampoules | 5 ampoule (PO) £24.00
  - Granisetron 1mg/1ml concentrate for solution for injection ampoules | 5 ampoule (PO) £8.00

**Tablet**

- **Granisetron (Non-proprietary)**
  - Granisetron (as Granisetron hydrochloride) 1 mg Granisetron 1mg tablets | 10 tablet (PO) £51.20 DT price = £40.77
  - Granisetron (as Granisetron hydrochloride) 2 mg Granisetron 2mg tablets | 5 tablet (PO) no price available DT price = £52.39
- **Kytril (Roche Products Ltd)**
  - Granisetron (as Granisetron hydrochloride) 1 mg Kytril 1mg tablets | 10 tablet (PO) £52.39 DT price = £40.77
  - Granisetron (as Granisetron hydrochloride) 2 mg Kytril 2mg tablets | 5 tablet (PO) £52.39 DT price = £52.39

**Transdermal patch**

- **Sancuso (Kyowa Kirin Ltd)**
  - Granisetron 3.1 mg per 24 hour Sancuso 3.1mg/24hours transdermal patches | 1 patch (PO) £56.00

---

**Ondansetron**

**DRUG ACTION**

Ondansetron is a specific 5HT3-receptor antagonist which blocks 5HT3 receptors in the gastrointestinal tract and in the CNS.

**INDICATIONS AND DOSE**

- **Moderately emetogenic chemotherapy or radiotherapy**
  - **BY MOUTH**
    - Adult: Initially 8 mg, dose to be taken 1–2 hours before treatment, then 8 mg every 12 hours for up to 5 days
  - **BY RECTUM**
    - Adult: Initially 16 mg, dose to be taken 1–2 hours before treatment, then 16 mg daily for up to 5 days
  - **INITIALLY BY INTRAMUSCULAR INJECTION, OR BY SLOW INTRAVENOUS INJECTION**
    - Adult: Initially 8 mg, dose to be administered immediately before treatment, then (by mouth) 8 mg every 12 hours for up to 5 days, alternatively (by rectum) 16 mg daily for up to 5 days
  - **INITIALLY BY INTRAVENOUS INFUSION**
    - Elderly: Initially 8 mg, dose to be administered immediately before treatment, intravenous infusion to be given over at least 15 minutes, then (by mouth) 8 mg every 12 hours for up to 5 days, alternatively (by rectum) 16 mg daily for up to 5 days
  - **Severely emetogenic chemotherapy (consult product literature for dose of concomitant corticosteroid)**
    - **BY MOUTH**
      - Adult: 24 mg, dose to be taken 1–2 hours before treatment, then 8 mg every 12 hours for up to 5 days
    - **BY RECTUM**
      - Adult: 16 mg, dose to be administered 1–2 hours before treatment, then 16 mg daily for up to 5 days
    - **INITIALLY BY INTRAMUSCULAR INJECTION, OR BY SLOW INTRAVENOUS INJECTION**
      - Adult: Initially 8 mg, dose to be administered immediately before treatment, followed by (by intramuscular injection or by slow intravenous injection) 8 mg every 4 hours if required for 2 doses, alternatively, followed by (by continuous intravenous infusion) 1 mg/hour for up to 24 hours, then (by mouth) 8 mg every 12 hours for up to 5 days, alternatively (by rectum) 16 mg daily for up to 5 days

**CONTRA-INDICATIONS**

- Congenital long QT syndrome

**CAUTIONS**

- Adenotonsillar surgery - subacute intestinal obstruction - susceptibility to QT-interval prolongation (including electrolyte disturbances)

**INTERACTIONS**

- Appendix 1: ondansetron

**SIDE-EFFECTS**

- **GENERAL SIDE-EFFECTS**
  - **Common or very common**
    - Constipation - flushing - headache - injection site-reactions
  - **Uncommon**
    - Arrhythmias - bradycardia - chest pain - hiccups - hypotension - movement disorders - seizures
  - **SPECIFIC SIDE-EFFECTS**
    - Rare
      - With intravenous use
        - Dizziness - transient visual disturbances
      - With intravenous use
        - Transient blindness
      - Frequency not known
        - With rectal use
      - Rectal irritation
  - **PREGNANCY**
    - No information available; avoid unless potential benefit outweighs risk.
  - **BREAST FEEDING**
    - Present in milk in animal studies—avoid.
  - **HEPATIC IMPAIRMENT**
    - Maximum 8 mg daily in moderate or severe impairment.

**DIRECTIONS FOR ADMINISTRATION**

- With intravenous use
  - For intravenous infusion (Zofran®), give continuously or intermittently in glucose 5% or glucose 5% with potassium chloride 0.3% or sodium chloride 0.9% or sodium chloride 0.9% with potassium chloride 0.3% or
With oral use Orodispersible films and lyophilisates should be placed on the tongue, allowed to disperse and swallowed.

- **PRESCRIBING AND DISPENSING INFORMATION** Flavours of oral liquid formulations may include strawberry.

- **PATIENT AND CARER ADVICE** Patients or carers should be given advice on how to administer orodispersible films and lyophilisates.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Tablet**

- **Ondansetron (Non-proprietary)**
  - Ondansetron (as Ondansetron hydrochloride) 4 mg | Ondansetron 4 mg tablets | 10 tablet | £25.46 DT price = £1.04 | 30 tablet | £76.38

- **Ondansetron (as Ondansetron hydrochloride) 8 mg** | Ondansetron 8 mg tablets | 10 tablet | £47.99 DT price = £1.90

- **Ondemet (Alliance Pharmaceuticals Ltd)**
  - Ondansetron (as Ondansetron hydrochloride) 4 mg | Ondemet 4 mg tablets | 30 tablet | £81.15

- **Ondansetron (as Ondansetron hydrochloride) 8 mg** | Ondemet 8 mg tablets | 10 tablet | £54.36 DT price = £1.90 (Hospital only)

- **Zofran (Novartis Pharmaceuticals UK Ltd)**
  - Ondansetron (as Ondansetron hydrochloride) 4 mg | Zofran 4 mg tablets | 30 tablet | £107.91

- **Ondansetron (as Ondansetron hydrochloride) 8 mg** | Zofran 8 mg tablets | 10 tablet | £71.94 DT price = £1.90

**Suppository**

- **Zofran (Novartis Pharmaceuticals UK Ltd)**
  - Ondansetron 16 mg | Zofran 16 mg suppositories | 1 suppository | £14.39

**Solution for injection**

- **Ondansetron (Non-proprietary)**
  - Ondansetron (as Ondansetron hydrochloride) 2 mg per 1 ml | Ondansetron 8 mg/4 ml solution for injection ampoules | 5 ampoule | £58.45
  - Ondansetron 4 mg/2 ml solution for injection ampoules | 5 ampoule | £38.33 | 10 ampoule | £75.00

- **Zofran Flexi-amp (Novartis Pharmaceuticals UK Ltd)**
  - Ondansetron (as Ondansetron hydrochloride) 2 mg per 1 ml | Zofran Flexi-amp 8 mg/4 ml solution for injection | 5 ampoule | £59.95
  - Zofran Flexi-amp 4 mg/2 ml solution for injection | 5 ampoule | £29.97

**Oral solution**

- **Ondansetron (Non-proprietary)**
  - Ondansetron (as Ondansetron hydrochloride) 800 microgram per 1 ml | Ondansetron 4 mg/5 ml oral solution sugar-free sugar-free | 50 ml | £39.00 DT price = £0.78

- **Zofran (Novartis Pharmaceuticals UK Ltd)**
  - Ondansetron (as Ondansetron hydrochloride) 800 microgram per 1 ml | Zofran 4 mg/5 ml syrup sugar-free | 50 ml | £35.97 DT price = £0.78

**Orodispersible film**

- **Setofil (Norgine Pharmaceuticals Ltd)**
  - Ondansetron 4 mg | Setofil 4 mg orodispersible films sugar-free | 10 film | £28.50
  - Ondansetron 8 mg | Setofil 8 mg orodispersible films sugar-free | 10 film | £57.00

**Oral lyophilisate**

- **Ondansetron (as Ondansetron hydrochloride)**

  **EXCIPIENTS:** May contain Aspartame

  - **Zofran Melt (Novartis Pharmaceuticals UK Ltd)**
    - Ondansetron 4 mg | Zofran Melt 4 mg oral lyophilisates sugar-free | 10 tablet | £55.97 DT price = £5.59

  - **Ondansetron 8 mg** | Zofran Melt 8 mg oral lyophilisates sugar-free | 10 tablet | £71.94 DT price = £7.19

**Orodispersible tablet**

- **Ondansetron (Non-proprietary)**
  - Ondansetron 4 mg | Ondansetron 4 mg orodispersible tablets | 10 tablet | £43.46 DT price = £4.34

---

**Palonosetron**

- **DRUG ACTION** Palonosetron is a specific 5HT3-receptor antagonist which blocks 5HT3 receptors in the gastrointestinal tract and in the CNS.

- **INDICATIONS AND DOSE**

  **Moderately emetogenic chemotherapy**
  - **INITIALLY BY MOUTH**
    - Adult: 500 micrograms, dose to be taken 1 hour before treatment, alternatively (by intravenous injection) 250 micrograms for 1 dose, dose to be administered over 30 seconds, 30 minutes before treatment

  **Severely emetogenic chemotherapy**
  - **BY INTRAVENOUS INJECTION**
    - Adult: 250 micrograms for 1 dose, dose to be administered over 30 seconds, 30 minutes before treatment

- **CAUTIONS** History of constipation - intestinal obstruction - susceptibility to QT-interval prolongation (including electrolyte disturbances)

- **INTERACTIONS**

  → Appendix 1: palonosetron

- **SIDE-EFFECTS**

  - **Common or very common**
    - Constipation - diarrhoea - dizziness - headache

  - **Uncommon**

- **PREGNANCY** Avoid—no information available.

- **BREAST FEEDING** Avoid—no information available.

- **PATIENT AND CARER ADVICE**

  Driving and skilled tasks Dizziness or drowsiness may affect performance of skilled tasks (e.g. driving).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Palonosetron (Non-proprietary)**

  - Palonosetron (as Palonosetron hydrochloride) 50 microgram per 1 ml | Palonosetron 250 micrograms/5 ml solution for injection vials | 1 vial | £55.89

  - **Aloxi (Sinclair IS Pharma Plc)**

  Palonosetron (as Palonosetron hydrochloride) 50 microgram per 1 ml | Aloxi 250 micrograms/5 ml solution for injection vials | 1 vial | £55.89

**Capsule**

- **Aloxi (Sinclair IS Pharma Plc)**

  Palonosetron (as Palonosetron hydrochloride) 500 microgram | Aloxi 500 microgram capsules | 1 capsule | £55.89
Palonosetron with netupitant 20-Jun-2016

The properties listed below are those particular to the combination only. For the properties of the components please consider, palonosetron p. 415.

● **INDICATIONS AND DOSE**
  
  Moderately emetogenic chemotherapy | Highly emetogenic cisplatin-based chemotherapy
  
  ▶ By mouth
  
  ▶ Adult: 1 capsule, to be taken approximately 1 hour before the start of each chemotherapy cycle

● **CAUTIONS**
  
  Patients over 75 years

● **INTERACTIONS**
  
  → Appendix 1: netupitant, palonosetron

● **SIDE-EFFECTS**
  
  ▶ Common or very common Fatigue
  
  ▶ Uncommon Alopecia, blood disorders, cardiomyopathy, conduction disorder, decreased appetite, urticaria, vertigo
  
  ▶ Rare Back pain, blurred vision, conjunctivitis, cystitis, dysphagia, hypoaesthesia, hypokalaemia, non-cardiac chest pain, psychosis (acute), sleep disorder

● **CONCEPTION AND CONTRACEPTION**
  
  Manufacturer recommends exclude pregnancy before treatment in females of childbearing age; ensure effective contraception during treatment and for one month after treatment.

● **PREGNANCY**
  
  Manufacturer advises avoid—毒性 in animal studies.

● **BREAST FEEDING**
  
  Manufacturer advises avoid during treatment and for one month after last dose—no information available.

● **HEPATIC IMPAIRMENT**
  
  Manufacturer advises caution in severe impairment.

● **NATIONAL FUNDING/ACCESS DECISIONS**
  
  Scottish Medicines Consortium (SMC) Decisions
  
  The Scottish Medicines Consortium (December 2015) has advised that palonosetron in combination with netupitant (Akynzeo®) is accepted for restricted use within NHS Scotland for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy.

● **MEDICINAL FORMS**
  
  There can be variation in the licensing of different medicines containing the same drug.

  **Capsule**
  
  CAUTIONARY AND ADVISORY LABELS 25
  
  Akynzeo (Chugai Pharma UK Ltd) ▼
  
  Palonosetron (as Palonosetron hydrochloride) 500 microgram, Netupitant 300 mg Akynzeo 300mg/0.5mg capsules | 1 capsule (Pres) £9.00 (Hospital only)

**ANTIHISTAMINES** ➔ **SEDATING ANTIHISTAMINES**

Cinnarizine

● **INDICATIONS AND DOSE**
  
  Relief of symptoms of vestibular disorders, such as vertigo, tinnitus, nausea, and vomiting in Ménière’s disease
  
  ▶ By mouth
  
  ▶ Child 5–11 years: 15 mg 3 times a day
  
  ▶ Child 12–17 years: 30 mg 3 times a day
  
  ▶ Adult: 30 mg 3 times a day

  **Motion sickness**
  
  ▶ By mouth
  
  ▶ Child 5–11 years: Initially 15 mg, dose to be taken 2 hours before travel, then 7.5 mg every 8 hours if required, dose to be taken during journey

  ▶ Child 12–17 years: Initially 30 mg, dose to be taken 2 hours before travel, then 15 mg every 8 hours if required, dose to be taken during journey

  ▶ Adult: Initially 30 mg, dose to be taken 2 hours before travel, then 15 mg every 8 hours if required, dose to be taken during journey

  ▶ **CONTRA-INDICATIONS**
    
    Avoid in acute porphyrias p. 969 (some antihistamines are thought to be safe)

  ▶ **CAUTIONS**
    
    Epilepsy, glaucoma (in children), Parkinson’s disease (in adults), prostatic hypertrophy (in adults), pyloroduodenal obstruction, susceptibility to angle-closure glaucoma (in adults), urinary retention

  ▶ **INTERACTIONS**
    
    → Appendix 1: antihistamines (sedating)

  ▶ **SIDE-EFFECTS**
    
    ▶ Common or very common Drowsiness
    
    ▶ Rare Anaphylaxis, angioedema, angle-closure glaucoma, arrhythmias, blood disorders, bronchospasm, confusion, convulsions, depression, dizziness, extrapyramidal effects, hypersensitivity reactions, hypotension, lichen planus, liver dysfunction, lupus-like skin reactions, palpitation, paradoxic stimulation (especially with high doses in children) in children, paradoxic stimulation (especially with high doses in the elderly) in adults, photosensitivity reactions, rashes, sleep disturbances, sweating, tremor, weight gain

    ▶ **Frequency not known**
      
      Antimuscarinic effects, blurred vision, dry mouth, gastrointestinal disturbances, headache, psychomotor impairment, urinary retention

  **SIDE-EFFECTS, FURTHER INFORMATION**
  
  Children and the elderly are more susceptible to side-effects. Drowsiness is a significant side-effect with most of the older antihistamines although paradoxic stimulation may occur rarely, especially with high doses or in children and the elderly. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.

  ▶ **PREGNANCY**
    
    Manufacturer advises avoid; however, there is no evidence of teratogenicity. The use of sedating antihistamines in the latter part of the third trimester may cause adverse effects in neonates such as irritability, paradoxic excitability, and tremor.

  ▶ **BREAST FEEDING**
    
    Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

  ▶ **HEPATIC IMPAIRMENT**
    
    Avoid in severe liver disease—increased risk of coma.

  ▶ **RENAL IMPAIRMENT**
    
    Use with caution—no information available.

  ▶ **PATIENT AND CARER ADVICE**
    
    Driving and skilled tasks Drowsiness may affect performance of skilled tasks (e.g. cycling, driving); sedating effects enhanced by alcohol.

  **MEDICINAL FORMS**
  
  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

  **Tablet**
  
  CAUTIONARY AND ADVISORY LABELS 2
  
  ▶ Cinnarizine (Non-proprietary)
    
    Cinnarizine 15 mg Cinnarizine 15mg tablets | 84 tablet [P] £15.40
    
    DT price = £4.57
  
  ▶ Stugeron (McNeil Products Ltd, Janssen-Cilag Ltd)
    
    Cinnarizine 15 mg Stugeron 15mg tablets | 15 tablet [P] £1.84 | 100 tablet [P] £4.18
Cinnarizine with dimenhydrinate

The properties listed below are those particular to the combination only. For the properties of the components please consider, cinnarizine p. 416.

- **INDICATIONS AND DOSE**
  - **Vertigo**
    - **BY MOUTH**
    - Adult: 1 tablet 3 times a day

- **INTERACTIONS**
  - Appendix 1: antihistamines (sedating), dimenhydrinate

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Tablet**
    - CAUTIONARY AND ADVISORY LABELS 2, 21
    - Arlevert (Hampton Pharmaceuticals Ltd)
      - Cinnarizine 20 mg, Dimenhydrinate 40 mg Arlevert tablets | 100 tablet [POT] £24.00

Promethazine teoclate

- **INDICATIONS AND DOSE**
  - **Nausea** | **Vomiting** | **Labyrinthine disorders**
    - **BY MOUTH**
      - Child 5–9 years: 12.5–37.5 mg daily
      - Child 10–17 years: 25–75 mg daily; maximum 100 mg per day
      - Adult: 25–75 mg daily; maximum 100 mg per day
  - Motion sickness prevention (acts longer than promethazine hydrochloride)
    - **BY MOUTH**
      - Child 5–9 years: 12.5 mg once daily, dose to be taken at bedtime on night before travel or 1–2 hours before travel
      - Child 10–17 years: 25 mg once daily, dose to be taken at bedtime on night before travel or 1–2 hours before travel
      - Adult: 25 mg once daily, dose to be taken at bedtime on night before travel or 1–2 hours before travel
  - Motion sickness treatment (acts longer than promethazine hydrochloride)
    - **BY MOUTH**
      - Child 5–9 years: 12.5 mg, dose to be taken at onset of motion sickness, then 12.5 mg daily for 2 days, dose to be taken at bedtime
      - Child 10–17 years: 25 mg, dose to be taken at onset of motion sickness, then 25 mg once daily for 2 days, dose to be taken at bedtime
      - Adult: 25 mg, dose to be taken at onset of motion sickness, then 25 mg once daily for 2 days, dose to be taken at bedtime

- **SIDE-EFFECTS**
  - **Rare**
    - Anaphylaxis · angioedema · angle-closure glaucoma · arrhythmias · blood disorders · bronchospasm · confusion · convulsions · depression · dizziness · extrapyramidal effects · hypersensitivity reactions · hypotension · liver dysfunction · palpitation · photosensitivity reactions · rashes · sleep disturbances · tremor
  - **Frequency not known**
    - Antimuscarinic effects · blurred vision · dry mouth · gastro-intestinal disturbances · headache · injection pain · psychomotor impairment · restlessness · urinary retention

SIDE-EFFECTS, FURTHER INFORMATION

Children and the elderly are more susceptible to side-effects.

Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely, especially with high doses or in children and the elderly. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.

- **PREGNANCY**
  - Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is no evidence of teratogenicity. Use in the latter part of the third trimester may cause adverse effects in neonates such as irritability, paradoxical excitability, and tremor.

- **BREAST FEEDING**
  - Most antihistamines are present in breast milk in varying amounts; although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breast-feeding.

- **HEPATIC IMPAIRMENT**
  - Avoid in severe liver disease—increased risk of coma.

- **RENAL IMPAIRMENT**
  - Use with caution.

- **PATIENT AND CARER ADVICE**
  - Driving and skilled tasks
    - Drowsiness may affect performance of skilled tasks (e.g. cycling or driving); sedating effects enhanced by alcohol.

MEDICINAL FORMS

- There can be variation in the licensing of different medicines containing the same drug.
  - **Tablet**
    - CAUTIONARY AND ADVISORY LABELS 2
    - Avomine (Manx Healthcare Ltd)

ANTIMUSCARINICS

Hyoscine hydrobromide

(Scopolamine hydrobromide)

- **INDICATIONS AND DOSE**
  - **Motion sickness**
    - **BY MOUTH**
      - Child 4–9 years: 75–150 micrograms, dose to be taken up to 30 minutes before the start of journey, then 75–150 micrograms every 6 hours if required; maximum 450 micrograms per day
      - Child 10–17 years: 150–300 micrograms, dose to be taken up to 30 minutes before the start of journey, then 150–300 micrograms every 6 hours if required; maximum 900 micrograms per day
      - Adult: 150–300 micrograms, dose to be taken up to 30 minutes before the start of journey, then 150–300 micrograms every 6 hours if required; maximum 900 micrograms per day
    - **BY TRANSDERMAL APPLICATION**
      - Child 10–17 years: Apply 1 patch, apply behind ear 5–6 hours before journey, then apply **continued →**
1 patch after 72 hours if required, remove old patch and site replacement patch behind the other ear
- Adult: Apply 1 patch, apply behind ear 5–6 hours before journey, then apply 1 patch after 72 hours if required, remove old patch and site replacement patch behind the other ear

**Hypersalivation associated with clozapine therapy**
- **BY MOUTH**
- Adult: 300 micrograms up to 3 times a day; maximum 900 micrograms per day

**Excessive respiratory secretion (in palliative care)**
- **BY SUBCUTANEOUS INJECTION**
- Adult: 400 micrograms every 4 hours as required, hourly use is occasionally necessary, particularly in excessive respiratory secretions
- **BY CONTINUOUS SUBCUTANEOUS INFUSION**
- Adult: 1.2–2 mg/24 hours

**Bowel colic in palliative care**
- **BY SUBCUTANEOUS INJECTION**
- Adult: 400 micrograms every 4 hours as required, hourly use is occasionally necessary
- **BY SUBCUTANEOUS INFUSION**
- Adult: 1.2–2 mg/24 hours

**Bowel colic pain in palliative care**
- **BY MOUTH USING SUBLINGUAL TABLETS**
- Adult: 300 micrograms 3 times a day, as Kwells®.

**Premedication**
- **BY SUBCUTANEOUS INJECTION, OR BY INTRAMUSCULAR INJECTION**
- Adult: 200–600 micrograms, to be administered 30–60 minutes before induction of anaesthesia

**Drug Action**
- **Droperidol**
  - **DRUG ACTION** Droperidol is a butyrophenone, structurally related to haloperidol, which blocks dopamine receptors in the chemoreceptor trigger zone.

**Indications and Dose**
- **Prevention and treatment of postoperative nausea and vomiting**
  - **BY INTRAVENOUS INJECTION**
    - Adult: 0.625–1.25 mg, dose to be given 30 minutes before end of surgery, then 0.625–1.25 mg every 6 hours as required
    - Elderly: 625 micrograms, dose to be given 30 minutes before end of surgery, then 625 micrograms every 6 hours as required

**Prevention of nausea and vomiting caused by opioid analgesics in postoperative patient-controlled analgesia (PCA)**
- **BY INTRAVENOUS INJECTION**
  - Adult: 15–50 micrograms of droperidol for every 1 mg of morphine in PCA, reduce dose in elderly; maximum 5 mg per day
## Levomepromazine

*(Methotrimeprazine)*

### INDICATIONS AND DOSE

- **Pain in palliative care (reserved for distressed patients with severe pain unresponsive to other measures)**
  - By continuous subcutaneous infusion, or by intramuscular injection, or by intravenous injection
  - Adult: Seek specialist advice

- **Restlessness and confusion in palliative care**
  - By continuous subcutaneous infusion
  - Child 1-11 years: 0.35–3 mg/kg, to be administered over 24 hours
  - Child 12-17 years: 12.5–200 mg, to be administered over 24 hours
  - By mouth
  - Adult: 6 mg every 2 hours as required
  - By subcutaneous injection
  - Adult: 6.25 mg every 2 hours as required
  - By subcutaneous infusion
  - Adult: Initially 12.5–50 mg/24 hours, titrated according to response (doses greater than 100 mg/24 hours should be given under specialist supervision)

- **Nausea and vomiting in palliative care**
  - By continuous intravenous infusion, or by subcutaneous infusion
  - Child 1 month–11 years: 100–400 micrograms/kg, to be administered over 24 hours
  - Child 12–17 years: 5–25 mg, to be administered over 24 hours
  - By mouth
  - Adult: 6 mg once daily, dose to be taken at bedtime, increased if necessary to 12.5–25 mg twice daily

### Medicinal Forms

| Formulation | Strength | Price
|-------------|----------|--------|
| Xomolix | 10 ampoules | £39.40
| Levomepromazine hydrochloride | 25 mg/ml solution for injection ampoules | £20.13
| Nozinan | 200 mg tablets | £20.26
| Levomepromazine maleate | 25 mg | £20.26

### CONTRA-INDICATIONS

- CNS depression
- Coma
- Hypophysial infarction
- Hypomagnesaemia
- Phaeochromocytoma
- QT-interval prolongation

### CAUTIONS

- Patients receiving large initial doses should remain supine

### PRESCRIBING AND DISPENSING INFORMATION

Pain

Analgesics

Drugs used for pain

The non-opioid drugs, paracetamol p. 422 and aspirin p. 117 (and other NSAIDs), are particularly suitable for pain in musculoskeletal conditions, whereas the opioid analgesics are more suitable for moderate to severe pain, particularly of visceral origin.

Pain in sickle-cell disease

The pain of mild sickle-cell crises is managed with paracetamol, a NSAID, codeine phosphate p. 431, or dihydrocodeine tartrate p. 434. Severe crises may require the use of morphine p. 439 or diamorphine hydrochloride p. 433; concomitant use of a NSAID may potentiate analgesia and allow lower doses of the opioid to be used. Pethidine hydrochloride p. 445 should be avoided if possible because accumulation of a neurotoxic metabolite can precipitate seizures; the relatively short half-life of pethidine hydrochloride necessitates frequent injections.

Dental and orofacial pain

Analgesics should be used judiciously in dental care as a temporary measure until the cause of the pain has been dealt with.

Dental pain of inflammatory origin, such as that associated with pulpitis, apical infection, localised osteitis or pericoronitis is usually best managed by treating the infection, providing drainage, restorative procedures, and other local measures. Analgesics provide temporary relief of pain (usually for about 1 to 7 days) until the causative factors have been brought under control. In the case of pulpitis, intra-osseous infection or abscess, reliance on analgesics alone is usually inappropriate.

Similarly the pain and discomfort associated with acute problems of the oral mucosa (e.g. acute herpetic gingivostomatitis, erythema multiforme) may be relieved by benzylamine hydrochloride mouthwash or spray p. 1112 until the cause of the mucosal disorder has been dealt with. However, where a patient is febrile, the antipyretic action of paracetamol or ibuprofen p. 1041 is often helpful.

The choice of an analgesic for dental purposes should be based on its suitability for the patient. Most dental pain is relieved effectively by non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs that are used for dental pain include ibuprofen, diclofenac sodium p. 1034, and aspirin. Paracetamol has analgesic and antipyretic effects but no anti-inflammatory effect.

Opioid analgesics such as dihydrocodeine tartrate act on the central nervous system and are traditionally used for moderate to severe pain. However, opioid analgesics are relatively ineffective in dental pain and their side-effects can be unpleasant. Paracetamol, ibuprofen, or aspirin are adequate for most cases of dental pain and an opioid is rarely required.

Combining a non-opioid with an opioid analgesic can provide greater relief of pain than either analgesic given alone. However, this applies only when an adequate dose of each analgesic is used. Most combination analgesic preparations have not been shown to provide greater relief of pain than an adequate dose of the non-opioid component given alone. Moreover, combination preparations have the disadvantage of an increased number of side-effects.

Any analgesic given before a dental procedure should have a low risk of increasing postoperative bleeding. In the case of pain after the dental procedure, taking an analgesic before the effect of the local anaesthetic has worn off can improve control. Postoperative analgesia with ibuprofen or aspirin is usually continued for about 24 to 72 hours.

Temporomandibular dysfunction can be related to anxiety in some patients who may clench or grind their teeth (bruxism) during the day or night. The muscle spasm (which appears to be the main source of pain) may be treated empirically with an overlay appliance which provides a free sliding occlusion and may also interfere with grinding. In addition, diazepam p. 327, which has muscle relaxant as well as anxiolytic properties, may be helpful but it should only be prescribed on a short-term basis during the acute phase. Analgesics such as aspirin or ibuprofen may also be required.

Dysmenorrhoea

Use of an oral contraceptive prevents the pain of dysmenorrhoea which is generally associated with ovulatory cycles. If treatment is necessary paracetamol or a NSAID will generally provide adequate relief of pain. The vomiting and severe pain associated with dysmenorrhoea in women with endometriosis may call for an antiemetic (in addition to an analgesic). Antispasmodics (such as alverine citrate p. 84) have been advocated for dysmenorrhoea but the antispasmodic action does not generally provide significant relief.

Non-opioid analgesics and compound analgesic preparations

Aspirin is indicated for headache, transient musculoskeletal pain, dysmenorrhoea, and pyrexia. In inflammatory conditions, most physicians prefer anti-inflammatory treatment with another NSAID which may be better tolerated and more convenient for the patient. Aspirin is used increasingly for its antiplatelet properties. Aspirin tablets or dispersible aspirin tablets are adequate for most purposes as they act rapidly.

Gastric irritation may be a problem; it is minimised by taking the dose after food. Enteric-coated preparations are available, but have a slow onset of action and are therefore unsuitable for single-dose analgesic use (though their prolonged action may be useful for night pain).

Aspirin interacts significantly with a number of other drugs and its interaction with warfarin sodium p. 135 is a special hazard.

Paracetamol is similar in efficacy to aspirin, but has no demonstrable anti-inflammatory activity; it is less irritant to the stomach and for that reason is now generally preferred to aspirin, particularly in the elderly. Overdosage with
paracetamol is particularly dangerous as it may cause hepatic damage which is sometimes not apparent for 4 to 6 days.

Nefopam hydrochloride p. 424 may have a place in the relief of persistent pain unresponsive to other non-opioid analgesics. It causes little or no respiratory depression, but sympathomimetic and antimuscarinic side-effects may be troublesome.

Non-steroidal anti-inflammatory analgesics (NSAIDs) are particularly useful for the treatment of patients with chronic disease accompanied by pain and inflammation. Some of them are also used in the short-term treatment of mild to moderate pain including transient musculoskeletal pain but paracetamol is now often preferred, particularly in the elderly. They are also suitable for the relief of pain in dysmenorrhea and to treat pain caused by secondary bone tumours, many of which produce lysis of bone and release prostaglandins. Selective inhibitors of cyclo-oxygenase-2 may be used in preference to non-selective NSAIDs for patients at high risk of developing serious gastro-intestinal side-effects. Several NSAIDs are also used for postoperative analgesia. A non-opioid analgesic administered by intrathecal infusion (ziconotide (Prialt®), available from Eisai) is licensed for the treatment of chronic severe pain; ziconotide can be used by a hospital specialist as an adjunct to opioid analgesics.

Compound analgesic preparations

Compound analgesic preparations that contain a simple analgesic (such as aspirin or paracetamol) with an opioid component reduce the scope for effective titration of the individual components in the management of pain of varying intensity. Compound analgesic preparations containing paracetamol or aspirin with a low dose of an opioid analgesic (e.g. 8 mg of codeine phosphate per compound tablet) are commonly used, but the advantages have not been substantiated. The low dose of the opioid may be enough to cause opioid side-effects (in particular, constipation) and can complicate the treatment of overdosage yet may not provide significant additional relief of pain. A full dose of the opioid component (e.g. 60 mg codeine phosphate) in compound analgesic preparations effectively augments the analgesic activity but is associated with the full range of opioid side-effects (including nausea, vomiting, severe constipation, drowsiness, respiratory depression, and risk of dependence on long-term administration). Important: the elderly are particularly susceptible to opioid side-effects and should receive lower doses. In general, when assessing pain, it is necessary to weigh up carefully whether there is a need for a non-opioid and an opioid analgesic to be taken simultaneously.

Caffeine is a weak stimulant that is often included, in small doses, in analgesic preparations. It is claimed that the addition of caffeine may enhance the analgesic effect, but the alerting effect, mild habit-forming effect and possible provocation of headache may not always be desirable. Moreover, in excessive dosage or on withdrawal caffeine may itself induce headache.

Co-proxamol tablets (dextropropoxyphene in combination with paracetamol) are no longer licensed because of safety concerns, particularly toxicity in overdose. Co-proxamol tablets [unlicensed] may still be prescribed for patients who find it difficult to change, because alternatives are not effective or suitable.

Opioid analgesics

Opioid analgesics are usually used to relieve moderate to severe pain particularly of visceral origin. Repeated administration may cause dependence and tolerance, but this is no deterrent in the control of pain in terminal illness. Regular use of a potent opioid may be appropriate for certain cases of chronic non-malignant pain; treatment should be supervised by a specialist and the patient should be assessed at regular intervals.

Strong opioids

Morphine p. 439 remains the most valuable opioid analgesic for severe pain although it frequently causes nausea and vomiting. It is the standard against which other opioid analgesics are compared. In addition to relief of pain, morphine also confers a state of euphoria and mental detachment.

Morphine is the opioid of choice for the oral treatment of severe pain in palliative care. It is given regularly every 4 hours (or every 12 or 24 hours as modified-release preparations).

Buprenorphine p. 425 has both opioid agonist and antagonist properties and may precipitate withdrawal symptoms, including pain, in patients dependent on other opioids. It has abuse potential and may itself cause dependence. It has a much longer duration of action than morphine and sublingually is an effective analgesic for 6 to 8 hours. Unlike most opioid analgesics, the effects of buprenorphine are only partially reversed by naloxone hydrochloride p. 1259.

Dipipanone hydrochloride used alone is less sedating than morphine but the only preparation available contains an antiemetic and is therefore not suitable for regular regimens in palliative care.

Diamorphine hydrochloride (heroin) p. 433 is a powerful opioid analgesic. It may cause less nausea and hypotension than morphine. In palliative care the greater solubility of diamorphine hydrochloride allows effective doses to be injected in smaller volumes and this is important in the emaciated patient.

Alfentanil p. 1232, fentanyl p. 434 and remifentanil p. 1233 are used by injection for intra-operative analgesia; fentanyl is available in a transdermal drug delivery system as a self-adhesive patch which is changed every 72 hours. Methadone hydrochloride p. 476 is less sedating than morphine and acts for longer periods. In prolonged use, methadone hydrochloride should not be administered more often than twice daily to avoid the risk of accumulation and opioid overdosage. Methadone hydrochloride may be used instead of morphine in the occasional patient who experiences excitation (or exacerbation of pain) with morphine.

Oxycodone hydrochloride p. 442 has an efficacy and side-effect profile similar to that of morphine. It is used primarily for control of pain in palliative care.

Papaveretum p. 445 is rarely used; morphine is easier to prescribe and less prone to error with regard to the strength and dose.

Pentazocine p. 445 has both agonist and antagonist properties and precipitates withdrawal symptoms, including pain in patients dependent on other opioids. By injection it is more potent than dihydrocodeine tartrate p. 434 or codeine phosphate, but hallucinations and thought disturbances may occur. It is not recommended and, in particular, should be avoided after myocardial infarction as it may increase pulmonary and aortic blood pressure as well as cardiac work.

Pethidine hydrochloride p. 445 produces prompt but short-lasting analgesia; it is less constipating than morphine, but even in high doses is a less potent analgesic. It is not suitable for severe continuing pain. It is used for analgesia in labour; however, other opioids, such as morphine or diamorphine hydrochloride, are often preferred for obstetric pain.

Tapentadol p. 446 produces analgesia by two mechanisms. It is an opioid-receptor agonist and it also inhibits noradrenaline reuptake. Nausea, vomiting, and constipation are less likely to occur with tapentadol than with other strong opioid analgesics.
Tramadol hydrochloride p. 447 produces analgesia by two mechanisms: an opioid effect and an enhancement of serotoninergic and adrenergic pathways. It has fewer of the typical opioid side-effects (notably, less respiratory depression, less constipation and less addiction potential); psychiatric reactions have been reported.

**Weak opioids**

Codeine phosphate can be used for the relief of mild to moderate pain where other painkillers such as paracetamol or ibuprofen p. 1041 have proved ineffective.

Dihydrocodeine tartrate has an analgesic efficacy similar to that of codeine phosphate. Higher doses may provide some additional pain relief but this may be at the cost of more nausea and vomiting.

Meptazinol p. 439 is claimed to have a low incidence of respiratory depression. It has a reported length of action of 2 to 7 hours with onset within 15 minutes.

**Postoperative analgesia**

A combination of opioid and non-opioid analgesics is used to treat postoperative pain. The use of intra-operative opioids affects the prescribing of postoperative analgesics. A postoperative opioid analgesic should be given with care since it may potentiate any residual respiratory depression.

Morphine is used most widely. Tramadol hydrochloride is not as effective in severe pain as other opioid analgesics. Postoperative opioid analgesic should be given with care

**Pain management and opioid dependence**

Although caution is necessary, patients who are dependent on opioids or have a history of drug dependence may be treated with opioid analgesics when there is a clinical need. Treatment with opioid analgesics in this patient group should normally be carried out with the advice of specialists. However, doctors do not require a special licence to prescribe opioid analgesics to patients with opioid dependence for relief of pain due to organic disease or injury.

---

**ANALGESICS › NON-OPIOID**

**Paracetamol (Acetaminophen)**

*INDICATIONS AND DOSE*

**Mild to moderate pain**

- **BY MOUTH**
  - Adult: 0.5–1 g every 4–6 hours; maximum 4 g per day
  - Adult: 1 g up to 4 times a day, dose not to be taken more often than every 4 hours
  - Adult: 0.5–1 g every 4–6 hours; maximum 4 g per day

**Mild to moderate pain**

- **BY INTRAVENOUS INFUSION**
  - Adult (body-weight up to 50 kg): 15 mg/kg every 4–6 hours, dose to be administered over 15 minutes; maximum 60 mg/kg per day
  - Adult (body-weight 50 kg and above): 1 g every 4–6 hours, dose to be administered over 15 minutes; maximum 3 g per day

**PANADOL OA®**

**Mild to moderate pain**

- **BY MOUTH**
  - Adult: 1 g up to 4 times a day, dose not to be taken more often than every 4 hours

**UNLICENSED USE**

Paracetamol oral suspension 500 mg/5 mL not licensed for use in children under 16 years. Not licensed for use as prophylaxis of post-immunisation pyrexia following immunisation with meningococcal group B vaccine.

**CAUTIONS**

Before administering, check when paracetamol last administered and cumulative paracetamol dose over previous 24 hours, body-weight under 50 kg, chronic alcohol consumption, chronic dehydration, chronic
malnutition · hepatocellular insufficiency · long-term use (especially in those who are malnourished)

**CAUTIONS, FURTHER INFORMATION**

Some patients may be at increased risk of experiencing toxicity at therapeutic doses, particularly those with a body-weight under 50 kg and those with risk factors for hepatotoxicity. Clinical judgement should be used to adjust the dose of oral and intravenous paracetamol in these patients.

Co-administration of enzyme-inducing antiepileptic medications may increase toxicity; doses should be reduced.

**INTERACTIONS** → Appendix 1: paracetamol

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**

- **Rare** Acute generalised exanthematous pustulosis · malaise · skin reactions · Stevens-Johnson syndrome · toxic epidermal necrolysis
- **Frequency not known** Blood disorders · leucopenia · neutropenia · thrombocytopenia

**SPECIFIC SIDE-EFFECTS**

- **Rare**
  - With intravenous use Flushing · tachycardia
  - Frequency not known
  - With intravenous use Hypotension

**Overdose**

**Important**: liver damage and less frequently renal damage can occur following overdose. Nausea and vomiting, the only early features of poisoning, usually settle within 24 hours. Persistence beyond this time, often associated with the onset of right subcostal pain and tenderness, usually indicates development of hepatic necrosis.

For specific details on the management of poisoning, see Paracetamol, under Emergency treatment of poisoning p. 1249

**PREGNANCY** Not known to be harmful.

**BREAST FEEDING** Amount too small to be harmful.

**HEPATIC IMPAIRMENT** Dose-related toxicity—avoid large doses.

**RENAL IMPAIRMENT**

- In adults Increase infusion dose interval to every 6 hours if eGFR less than 30 mL/minute/1.73 m².
- In children Increase infusion dose interval to every 6 hours if estimated glomerular filtration rate less than 30 mL/minute/1.73 m².

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Perfalgan®), give in Glucose 5% or Sodium Chloride 0.9%; dilute to a concentration of not less than 1 mg/mL and use within an hour; may also be given undiluted. For children under 33 kg, use 50 mL-vial.

**PRESCRIBING AND DISPENSING INFORMATION** BP directs that when Paediatric Paracetamol Oral Suspension or Paediatric Paracetamol Mixture is prescribed Paracetamol Oral Suspension 120 mg/5 mL should be dispensed.

**PATIENT AND CARER ADVICE**

Medicines for Children leaflet: Paracetamol for mild-to-moderate pain www.medicinesforchildren.org.uk/paracetamol-for-mildtomentorade-pain

**PROFESSION SPECIFIC INFORMATION**

Dental practitioners’ formulary Paracetamol Tablets may be prescribed. Paracetamol Soluble Tablets 500 mg may be prescribed. Paracetamol Oral Suspension may be prescribed.

**EXCEPTIONS TO LEGAL CATEGORY** Paracetamol capsules or tablets can be sold to the public provided packs contain no more than 32 capsules or tablets; pharmacists can sell multiple packs up to a total quantity of 100 capsules or tablets in justifiable circumstances.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, suppository

**Tablet**

**CAUTIONARY AND ADVISORY LABELS** 29 (does not apply to 1 g tablet), 30

- **Paracetamol (Non-proprietary)**
  - Paracetamol 500 mg Paracetamol 500 mg caplets | 32 tablet [P] £0.32 DT price = £0.70 | 100 tablet [Pom] £3.18 DT price = £2.19
  - Paracetamol 500 mg tablets | 32 tablet [P] £1.24 DT price = £0.70 | 100 tablet [Pom] £2.56 DT price = £2.19 | 1000 tablet [Pom] £21.90 | 5000 tablet [Pom] no price available
- **Mandanol (M & A Pharmachem Ltd)**
  - Paracetamol 500 mg Mandanol 500 mg caplets | 32 tablet [P] £0.20 DT price = £0.70
  - Mandanol 500 mg tablets | 32 tablet [P] £0.15 DT price = £0.70
- **Panadol (GlaxoSmithKline Consumer Healthcare)**
  - Paracetamol 500 mg Paranol Advance 500 mg tablets | 32 tablet [P] £1.74 DT price = £0.70
- **Paravict (Ecogen Europe Ltd)**
  - Paracetamol 500 mg Paravict 500 mg tablets | 100 tablet [Pom] £1.62 DT price = £2.19

**Suppository**

**CAUTIONARY AND ADVISORY LABELS** 30

- **Paracetamol (Non-proprietary)**
  - Paracetamol 80 mg Paracetamol 80 mg suppositories | 10 suppository [P] £10.00
  - Paracetamol 120 mg Paracetamol 120 mg suppositories | 10 suppository [P] £11.26 DT price = £11.26
  - Paracetamol 125 mg Paracetamol 125 mg suppositories | 10 suppository [P] £15.00 DT price = £13.80
  - Paracetamol 240 mg Paracetamol 240 mg suppositories | 10 suppository [P] £22.01 DT price = £22.01
  - Paracetamol 250 mg Paracetamol 250 mg suppositories | 10 suppository [P] £24.15 DT price = £27.60
  - Paracetamol 500 mg Paracetamol 500 mg suppositories | 10 suppository [P] £36.50 DT price = £36.50
  - Paracetamol 1 gram Paracetamol 1 g suppositories | 10 suppository [P] £59.50 | 12 suppository [P] no price available
- **Alvedon (Intrapharm Laboratories Ltd)**
  - Paracetamol 60 mg Alvedon 60 mg suppositories | 10 suppository [P] £11.95 DT price = £11.95
  - Paracetamol 125 mg Alvedon 125 mg suppositories | 10 suppository [P] £13.80 DT price = £13.80
  - Paracetamol 250 mg Alvedon 250 mg suppositories | 10 suppository [P] £27.80 DT price = £27.80

**Oral suspension**

**CAUTIONARY AND ADVISORY LABELS** 30

- **Paracetamol (Non-proprietary)**
  - Paracetamol 24 mg per 1 ml Paracetamol 120 mg/5 mL oral suspension paediatric | 100 ml [P] £0.72 | 500 ml [P] £3.11 DT price = £3.11
  - Paracetamol 120 mg/5 mL oral suspension paediatric sugar free sugar-free | 100 ml [P] £1.29 DT price = £1.29 sugar-free | 200 ml [P] £2.58 sugar-free | 500 ml [P] £6.45 sugar-free | 1000 ml [P] £12.90
  - Paracetamol 50 mg per 1 ml Paracetamol 250 mg/5 mL oral suspension | 100 ml [P] £1.12 DT price = £1.12 | 500 ml [P] £5.60
  - Paracetamol 250 mg/5 mL oral suspension sugar free sugar-free | 100 ml [P] £1.10 sugar-free | 200 ml [P] £2.00 DT price = £2.02 sugar-free | 500 ml [P] £5.18 sugar-free | 1000 ml [P] £9.85
  - Paracetamol 100 mg per 1 ml Paracetamol 500 mg/5 mL oral suspension sugar free sugar-free | 150 ml [Pom] £24.00 DT price = £24.00
- **Calpol (McNeil Products Ltd)**
  - Paracetamol 24 mg per 1 ml Calpol Infant 120 mg/5 mL oral suspension | 200 ml [P] £3.35
  - Calpol Infant 120 mg/5 mL oral suspension sugar free-sugar-free | 200 ml [P] £3.35
  - Paracetamol 50 mg per 1 ml Calpol Six Plus 250 mg/5 mL oral suspension | 200 ml [P] £3.88
  - Calpol Six Plus 250 mg/5 mL oral suspension sugar free-sugar-free | 100 ml [P] £2.40 sugar-free | 200 ml [P] £3.88 DT price = £2.02
Paracetamol with tramadol

The properties listed below are those particular to the combination only. For the properties of the components please consider, paracetamol p. 422, tramadol hydrochloride p. 447.

- **INDICATIONS AND DOSE**
  - **Moderate to severe pain**
    - **BY MOUTH**
      - Child 12-17 years: 2 tablets up to every 6 hours; maximum 8 tablets per day
      - Adult: 2 tablets up to every 6 hours; maximum 8 tablets per day
  - **INTERACTIONS** → Appendix 1: opioids, paracetamol
  - **MEDICINAL FORMS**
    - There can be variation in the licensing of different medicines containing the same drug.

Paracetamol with tramadol (Non-proprietary)

- **Tramadol hydrochloride 37.5 mg, Paracetamol 325 mg** Tramacet
- **Tramadol hydrochloride 75 mg, Paracetamol 650 mg** Tramacet

---

Nefopam hydrochloride

- **INDICATIONS AND DOSE**
  - **Moderate pain**
    - **BY MOUTH**
      - Adult: Initially 60 mg 3 times a day, adjusted according to response; usual dose 30–90 mg 3 times a day
      - Elderly: Initially 30 mg 3 times a day, adjusted according to response; usual dose 30–90 mg 3 times a day
  - **SIDE-EFFECTS**
    - Common or very common: Dry mouth, lightheadedness, nausea, nervousness, urinary retention
    - Uncommon: Blurred vision, confusion, drowsiness, hallucinations, headache, insomnia, sweating, tachycardia, vomiting
  - **FREQUENCY NOT KNOWN**
    - May colour urine (pink)
  - **PREGNANCY**
    - No information available—avoid unless no safer treatment.
  - **HEPATIC IMPAIRMENT**
    - Caution.
  - **RENAL IMPAIRMENT**
    - Caution.

---

Aspirin with codeine

- **INDICATIONS AND DOSE**
  - **Mild to moderate pain**
    - **BY MOUTH**
      - Adult: 1–2 tablets every 4–6 hours as required, dose to be dispersed in water; maximum 8 tablets per day
      - **INTERACTIONS** → Appendix 1: aspirin, codeine
      - **PRESCRIBING AND DISPENSING INFORMATION**
        - When codeine phosphate or dispersible tablets are prescribed and no strength is stated, tablets or dispersible tablets, respectfully, containing codeine phosphate 8 mg and aspirin 400 mg should be dispensed.
      - **LESS SUITABLE FOR PRESCRIBING**
        - Aspirin with codeine is less suitable for prescribing.
      - **EXCEPTIONS TO LEGAL CATEGORY**
        - Aspirin with codeine can be sold to the public provided packs contain no more than 32 capsules or tablets; pharmacists can sell multiple packs
up to a total quantity of 100 capsules or tablets in justifiable circumstances.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Dispersible tablet**
*CAUTIONARY AND ADVISORY LABELS 13, 21, 32*

- **Aspirin with codeine (Non-proprietary)**
  - Codeine phosphate 8 mg, Aspirin 400 mg. Co-codaprin 8mg/400mg dispersible tablets | 100 tablet (BNF) £97.55 DT price = £52.19 (GHS)
- **Codis** (Reckitt Benckiser Healthcare (UK) Ltd)
  - Codeine phosphate 8 mg, Aspirin 500 mg. Codis 500 dispersible tablets sugar-free | 32 tablet (P) £3.23 (GHS)

### Tablet

- **Aspirin with codeine (Non-proprietary)**
  - Codeine phosphate 8 mg, Aspirin 400 mg. Aspirin and Codeine tablets | 32 tablet (P) no price available (GHS)

### ANALGESICS > OPIOIDS

**Opioids**

- **CONTRA-INDICATIONS** Acute respiratory depression - comatose patients - head injury (opioid analgesics interfere with pupillary responses vital for neurological assessment) - raised intracranial pressure (opioid analgesics interfere with pupillary responses vital for neurological assessment) - risk of paralytic ileus

- **CAUTIONS** Adrenocortical insufficiency (reduced dose is recommended) - asthma (avoid during an acute attack) - convulsive disorders - debilitated patients (reduced dose is recommended) (in adults) - diseases of the biliary tract - elderly (reduced dose is recommended) - hypotension - hypothryoidism (reduced dose is recommended) - impaired respiratory function (avoid in chronic obstructive pulmonary disease) - inflammatory bowel disorders - myasthenia gravis - obstructive bowel disorders - prostatic hypertrophy (in adults) - shock - urethral stenosis (in adults)

- **CAUTIONS, FURTHER INFORMATION**
  - Dependence Repeated use of opioid analgesics is associated with the development of psychological and physical dependence; although this is rarely a problem with therapeutic use, caution is advised if prescribing for patients with a history of drug dependence.
  - Palliative care In the control of pain in terminal illness, the cautions listed should not necessarily be a deterrent to the use of opioid analgesics.

- **SIDE-EFFECTS**
  - Common or very common Biliary spasm - bradycardia - confusion - constipation - dependence - difficulty with micturition - dizziness - drowsiness - dry mouth - dysphoria - euphoria - flushing - hallucinations - headache - hypotension (larger doses) - miosis - mood changes - muscle rigidity (larger doses) - nausea (particularly in initial stages) - oedema - palpitation - postural hypotension - pruritus - rash - respiratory depression (larger doses) - sexual dysfunction - sleep disturbances - sweating - tachycardia - ureteric spasm - urinary retention - urticaria - vertigo - visual disturbances - vomiting (particularly in initial stages)
  - Frequency not known Adrenal insufficiency (long-term use) - hyperalgesia (long-term use) - hypogonadism (long-term use)

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Hypogonadism and adrenal insufficiency Long-term use of opioid analgesics can cause hypogonadism and adrenal insufficiency in both males and females. This is thought to be dose related and can lead to amenorrhoea, reduced libido, infertility, depression, and erectile dysfunction.

- **Hyperalgesia** Long-term use of opioid analgesics has also been associated with a state of abnormal pain sensitivity (hyperalgesia). Pain associated with hyperalgesia is usually distinct from pain associated with disease progression or breakthrough pain, and is often more diffuse and less defined. Treatment of hyperalgesia involves reducing the dose of opioid medication or switching therapy; cases of suspected hyperalgesia should be referred to a specialist pain team.
  - Respiratory depression Respiratory depression is a major concern with opioid analgesics and it may be treated by artificial ventilation or be reversed by naltroxone.
  - Dependence and withdrawal Psychological dependence rarely occurs when opioids are used therapeutically (e.g. for pain relief) but tolerance can develop during long-term treatment.

**Overdose**
Opioids (narcotic analgesics) cause coma, respiratory depression, and pinpoint pupils. For details on the management of poisoning, see Opioids, under Emergency treatment of poisoning p. 1249 and consider the specific antidote, naltroxone hydrochloride p. 1259.

- **PREGNANCY** Respiratory depression and withdrawal symptoms can occur in the neonate if opioid analgesics are used during delivery; also gastric stasis and inhalation pneumonia has been reported in the mother if opioid analgesics are used during labour.
  - **HEPATIC IMPAIRMENT** Avoid use or reduce dose; may precipitate coma in patients with hepatic impairment.
  - **TREATMENT CESSATION** Avoid abrupt withdrawal after long-term treatment; they should be withdrawn gradually to avoid abstinence symptoms.
  - **PATIENT AND CARER ADVICE**
    - Driving and skilled tasks
      - Drowsiness may affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced. Driving at the start of therapy with opioid analgesics, and following dose changes, should be avoided.
      - For information on 2015 legislation regarding driving whilst taking certain controlled drugs, including opioids, see Drugs and driving under Guidance on prescribing p. 1.

**Buprenorphine**

- **DRUG ACTION** Buprenorphine is an opioid-receptor partial agonist (it has opioid agonist and antagonist properties).

### INDICATIONS AND DOSE

- **Moderate to severe pain**
  - **BY SUBLINGUAL ADMINISTRATION**
    - Child (body-weight 16–25 kg): 100 micrograms every 6–8 hours
    - Child (body-weight 25–37.5 kg): 100–200 micrograms every 6–8 hours
    - Child (body-weight 37.5–50 kg): 200–300 micrograms every 6–8 hours
    - Child (body-weight 50 kg and above): 200–400 micrograms every 6–8 hours
    - Adult: 200–400 micrograms every 6–8 hours
  - **BY INTRAMUSCULAR INJECTION, OR BY SLOW INTRAVENOUS INJECTION**
    - Child 6 months–11 years: 3–6 micrograms/kg every 6–8 hours (max. per dose 9 micrograms/kg)
    - Child 12–17 years: 300–600 micrograms every 6–8 hours
    - Adult: 300–600 micrograms every 6–8 hours

- **Premedication**
  - **BY SUBLINGUAL ADMINISTRATION**
    - Adult: 400 micrograms
  - **BY INTRAMUSCULAR INJECTION**
    - Adult: 300 micrograms

*BNF 74 Pain 425*
BUPEAZE

DOSE EQUIVALENCE AND CONVERSION

▶ Adjunct in the treatment of opioid dependence
▶ BY SUBLINGUAL ADMINISTRATION
▶ Adult: Initially 0.8–4 mg for 1 dose on the first day, adjusted in steps of 2–4 mg daily if required; usual dose 12–24 mg daily; maximum 32 mg per day

DOSE EQUIVALENCE AND CONVERSION

▶ For opioid substitution therapy, in patients taking methadone who want to switch to buprenorphine, the dose of methadone should be reduced to a maximum of 30 mg daily before starting buprenorphine treatment. If the dose of methadone is over 10 mg daily, buprenorphine can be started at a dose of 4 mg daily and titrated according to requirements; if the methadone dose is below 10 mg daily, buprenorphine can be started at a dose of 2 mg daily.

BUTRANS ®

Moderate, non-malignant pain unresponsive to non-opioid analgesics
▶ BY TRANSDERMAL APPLICATION USING PATCHES
▶ Adult: Initially 5 micrograms/hour up to every 7 days, dose adjustments—when starting, analgesic effect should not be evaluated until the system has been worn for 72 hours (to allow for gradual increase in plasma-buprenorphine concentration)—if necessary, dose should be adjusted at intervals of at least 3 days using a patch of the next strength or a combination of 2 patches applied in different places (applied at same time to avoid confusion). Maximum 2 patches can be used at any one time

BUPEAZE ®

Moderate to severe chronic cancer pain in patients who have not previously received strong opioid analgesic | Severe pain unresponsive to non-opioid analgesics in patients who have not previously received strong opioid analgesic
▶ BY TRANSDERMAL APPLICATION USING PATCHES
▶ Adult: Initially 35 micrograms/hour up to every 96 hours, dose adjustment—when starting, analgesic effect should not be evaluated until the system has been worn for 24 hours (to allow for gradual increase in plasma-buprenorphine concentration)—if necessary, dose should be adjusted at intervals of no longer than 96 hours using a patch of the next strength or using 2 patches of the same strength (applied at same time to avoid confusion). Maximum 2 patches can be used at any one time

BUPLAST ®

Moderate to severe chronic cancer pain in patients who have not previously received strong opioid analgesic | Severe pain unresponsive to non-opioid analgesics in patients who have not previously received strong opioid analgesic
▶ BY TRANSDERMAL APPLICATION USING PATCHES
▶ Adult: Initially 35 micrograms/hour up to every 96 hours, dose adjustment—when starting, analgesic effect should not be evaluated until the system has been worn for 24 hours (to allow for gradual increase in plasma-buprenorphine concentration)—if necessary, dose should be adjusted at intervals of no longer than 96 hours using a patch of the next strength or using 2 patches of the same strength (applied at same time to avoid confusion). Maximum 2 patches can be used at any one time

BUPLAST ®

Severe pain unresponsive to non-opioid analgesics in patients who have previously received strong opioid analgesic
▶ BY TRANSDERMAL APPLICATION USING PATCHES
▶ Adult: The initial dose should be based on previous 24-hour opioid requirement, consult product literature, dose adjustment—when starting, analgesic effect should not be evaluated until the system has been worn for 24 hours (to allow for gradual increase in plasma-buprenorphine concentration)—if necessary, dose should be adjusted at intervals of at least 3 days using a patch of the next strength or using 2 patches of the same strength (applied at same time to avoid confusion). Maximum 2 patches can be used at any one time

BUTRANS ®

PHARMACOKINETICS
It may take approximately 30 hours for the plasma-buprenorphine concentration to decrease by 50% after patch is removed.

BUTEC ®

PHARMACOKINETICS
It may take approximately 12 hours for the plasma-buprenorphine concentration to decrease by 50% after patch is removed.

HAPOCTASIN ®

PHARMACOKINETICS
It may take approximately 30 hours for the plasma-buprenorphine concentration to decrease by 50% after patch is removed.

BUPEAZE ®

PHARMACOKINETICS
It may take approximately 30 hours for the plasma-buprenorphine concentration to decrease by 50% after patch is removed.
avoid confusion). Maximum 2 patches can be used at any one time, for breakthrough pain, consider 200–400 micrograms buprenorphine sublingually

**Moderate to severe chronic cancer pain in patients who have previously received strong opioid analgesic | Severe pain unresponsive to non-opioid analgesics in patients who have previously received strong opioid analgesic**

- **BY TRANSDERMAL APPLICATION USING PATCHES**
- **Adult:** The initial dose should be based on previous 24-hour opioid requirement, consult product literature, dose adjustment—when starting, analgesic effect should not be evaluated until the system has been worn for 24 hours (to allow for gradual increase in plasma-buprenorphine concentration)—if necessary, dose should be adjusted at intervals of no longer than 72 hours using a patch of the next strength or using 2 patches of the same strength (applied at *same time* to avoid confusion). Maximum 2 patches can be used at any one time, for breakthrough pain, consider 200–400 micrograms buprenorphine sublingually

**PHARMACOKINETICS**

It may take approximately 25 hours for the plasma-buprenorphine concentration to decrease by 50% after patch is removed.

**PANITAZ®**

**Moderate, non-malignant pain unresponsive to non-opioid analgesics**

- **BY TRANSDERMAL APPLICATION USING PATCHES**
- **Adult:** Initially 5 micrograms/hour up to every 7 days, dose adjustments—when starting, analgesic effect should not be evaluated until the system has been worn for 72 hours (to allow for gradual increase in plasma-buprenorphine concentration)—if necessary, dose should be adjusted at intervals of at least 3 days using a patch of the next strength or a combination of 2 patches applied in different places (applied at *same time* to avoid confusion). Maximum 2 patches can be used at any one time

**PHARMACOKINETICS**

It may take approximately 12 hours for the plasma-buprenorphine concentration to decrease by 50% after patch is removed.

**PRENOTRIX®**

**Moderate to severe chronic cancer pain in patients who have not previously received strong opioid analgesic | Severe pain unresponsive to non-opioid analgesics in patients who have not previously received strong opioid analgesic**

- **BY TRANSDERMAL APPLICATION USING PATCHES**
- **Adult:** Initially 35 micrograms/hour up to every 72 hours, dose adjustment—when starting, analgesic effect should not be evaluated until the system has been worn for 24 hours (to allow for gradual increase in plasma-buprenorphine concentration)—if necessary, dose should be adjusted at intervals of no longer than 72 hours using a patch of the next strength or using 2 patches of the same strength (applied at *same time* to avoid confusion). Maximum 2 patches can be used at any one time

**PHARMACOKINETICS**

It may take approximately 25 hours for the plasma-buprenorphine concentration to decrease by 50% after patch is removed.

**RELETRANS®**

**Moderate, non-malignant pain unresponsive to non-opioid analgesics**

- **BY TRANSDERMAL APPLICATION USING PATCHES**
- **Adult:** Initially 5 micrograms/hour up to every 7 days, dose adjustments—when starting, analgesic effect should not be evaluated until the system has been worn for 72 hours (to allow for gradual increase in plasma-buprenorphine concentration)—if necessary, dose should be adjusted at intervals of at least 3 days using a patch of the next strength or a combination of 2 patches applied in different places (applied at *same time* to avoid confusion). Maximum 2 patches can be used at any one time

**PHARMACOKINETICS**

It may take approximately 12 hours for the plasma-buprenorphine concentration to decrease by 50% after patch is removed.

**RELEVTEC®**

**Moderate to severe chronic cancer pain in patients who have not previously received strong opioid analgesic | Severe pain unresponsive to non-opioid analgesics in patients who have not previously received strong opioid analgesic**

- **BY TRANSDERMAL APPLICATION USING PATCHES**
- **Adult:** Initially 35 micrograms/hour up to every 96 hours, dose adjustment—when starting, analgesic effect should not be evaluated until the system has been worn for 24 hours (to allow for gradual increase in plasma-buprenorphine concentration)—if necessary, dose should be adjusted at intervals of no longer than 96 hours using a patch of the next strength or using 2 patches of the same strength (applied at *same time* to avoid confusion). Maximum 2 patches can be used at any one time

**Moderate to severe chronic cancer pain in patients who have previously received strong opioid analgesic | Severe pain unresponsive to non-opioid analgesics in patients who have previously received strong opioid analgesic**

- **BY TRANSDERMAL APPLICATION USING PATCHES**
- **Adult:** The initial dose should be based on previous 24-hour opioid requirement, consult product literature, dose adjustment—when starting, analgesic effect should not be evaluated until the system has been worn for 24 hours (to allow for gradual increase in plasma-buprenorphine concentration)—if necessary, dose should be adjusted at intervals of no longer than 72 hours using a patch of the next strength or using 2 patches of the same strength (applied at *same time* to avoid confusion). Maximum 2 patches can be used at any one time
SEVODYNE®

Moderate, non-malignant pain unresponsive to non-opioid analgesics
▶ BY TRANSDERMAL APPLICATION USING PATCHES
Adult: Initially 5 micrograms/hour up to every 7 days, dose adjustments—when starting, analgesic effect should not be evaluated until the system has been worn for 72 hours (to allow for gradual increase in plasma-buprenorphine concentration)—if necessary, dose should be adjusted at intervals of at least 3 days using a patch of the next strength or a combination of 2 patches applied in different places (applied at same time to avoid confusion). Maximum 2 patches can be used at any one time.

TRANSTEC®

Moderate to severe chronic cancer pain in patients who have not previously received strong opioid analgesic
Severe pain unresponsive to non-opioid analgesics in patients who have not previously received strong opioid analgesic
▶ BY TRANSDERMAL APPLICATION USING PATCHES
Adult: Initially 35 micrograms/hour up to every 96 hours, dose adjustment—when starting, analgesic effect should not be evaluated until the system has been worn for 24 hours (to allow for gradual increase in plasma-buprenorphine concentration)—if necessary, dose should be adjusted at intervals of no longer than 96 hours using a patch of the next strength or using 2 patches of the same strength (applied at same time to avoid confusion). Maximum 2 patches can be used at any one time, for breakthrough pain, consider 200–400 micrograms buprenorphine sublingually.

Moderate to severe chronic cancer pain in patients who have previously received strong opioid analgesic
Severe pain unresponsive to non-opioid analgesics in patients who have previously received strong opioid analgesic
▶ BY TRANSDERMAL APPLICATION USING PATCHES
Adult: The initial dose should be based on previous 24-hour opioid requirement, consult product literature, dose adjustment—when starting, analgesic effect should not be evaluated until the system has been worn for 24 hours (to allow for gradual increase in plasma-buprenorphine concentration)—if necessary, dose should be adjusted at intervals of no longer than 96 hours using a patch of the next strength or using 2 patches of the same strength (applied at same time to avoid confusion). Maximum 2 patches can be used at any one time, for breakthrough pain, consider 200–400 micrograms buprenorphine sublingually.

PHARMACOKINETICS

It may take approximately 12 hours for the plasma-buprenorphine concentration to decrease by 50% after patch is removed.

TRANSTEC®, SEVODYNE

Unlicensed use Sublingual tablets not licensed for use in children under 6 years. Injection not licensed for use in children under 6 months.

IMPORTANT SAFETY INFORMATION
Do not confuse the formulations of transdermal patches which are available as 72-hourly, 96-hourly and 7-day patches, see Prescribing and dispensing information.

SPECIFIC CAUTIONS
- With transdermal use Other opioids should not be administered within 24 hours of patch removal (long duration of action)
- When used for adjunct in the treatment of opioid dependence
  - Hepatitis B infection
  - Hepatitis C infection
  - Pre-existing liver enzyme abnormalities

INTERACTIONS → Appendix 1: opioids

SIDE-EFFECTS
- Common or very common
  - Abdominal pain
  - Agitation
  - Anorexia
  - Anxiety
  - Asthenia
  - Diarrhoea
  - Dyspepsia
  - Dysphonia
  - Fatigue
  - Mild withdrawal symptoms in patients dependent on opioids
  - Paraesthesia
  - Vasodilatation
- Uncommon
  - Angina (in adults)
  - Cough
  - Depersonalisation
  - Dry eye
  - Dry skin
  - Dysarthria
  - Flatulence
  - Hypertension
  - Hypoaesthesia
  - Hypoxia
  - Impaired memory
  - Influenza-like symptoms
  - Muscle cramp
  - Myalgia
  - Pyrexia
  - Restlessness
  - Rhinitis
  - Rigors
  - Syncope
  - Taste disturbance
  - Tinnitus
  - Tremor
  - Wheezing
- Rare
  - Diverticulitis (in children)
  - Dysphagia
  - Impaired concentration
  - Paralytic ileus
  - Psychosis

VERY RARE
- Hiccups
- Hyperventilation
- Muscle fasciculation
- Retching

FREQUENCY NOT KNOWN
- Hepatic necrosis
- Hepatitis

SIDE-EFFECTS, FURTHER INFORMATION
- Fever or external heat
  - Monitor patients using patches for increased side-effects if fever present (increased absorption possible); avoid exposing application site to external heat (may also increase absorption). In view of the long duration of action, side-effects can persist for many hours after removing patch.
- Overdose
  - The effects of buprenorphine are only partially reversed by naloxone.

BREAST FEEDING
- Present in low levels in breast milk. Neonates should be monitored for drowsiness, adequate weight gain, and developmental milestones.

RENAL IMPAIRMENT
- Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.

PRE-TREATMENT SCREENING
- Documentation of viral hepatitis status is recommended before commencing therapy for opioid dependence.

MONITORING REQUIREMENTS
- Monitor liver function; when used in opioid dependence baseline liver function test is recommended before commencing therapy, and regular liver function tests should be performed throughout treatment.

DIRECTIONS FOR ADMINISTRATION
- With sublingual use in children For administration by mouth, tablets may be halved.

PRENORTIX® HAPOTASIN®
Manufacturer advises apply patch to dry, non-irritated, non-hairy skin on upper torso, removing after no longer than 72 hours and siting replacement patch on a different area (avoid same area for at least 7 days).

TRANSTEC®
Apply patch to dry, non-irritated, non-hairy skin on upper torso, removing after no longer than 96 hours and siting replacement patch on a different area (avoid same area for at least 6 days).

RELETRAN® BUTEC® PANITAZ® SEVODYNE®
Manufacturer advises apply patch to dry, non-irritated, non-hairy skin on upper torso or upper outer arm, removing after 7 days and siting replacement patch on a different area (avoid same area for at least 3 weeks).

BUPEAZ® BUPLAST® RELEVTEC®
Manufacturer advises apply patch to dry, non-irritated, non-hairy skin on upper torso, removing after no longer than 96 hours and siting replacement patch on a different area (avoid same area for at least 7 days).

CAUTIONS

GENERAL CAUTIONS
Impaired consciousness
**BUTEC®** Apply patch to dry, non-irritated, non-hairy skin on upper torso, removing after 7 days and sitting replacement patch on a different area (avoid same area for at least 3 weeks).

- **PRESCRIBING AND DISPENSING INFORMATION**
  Transdermal buprenorphine patches are not suitable for acute pain or in those patients whose analgesic requirements are changing rapidly because the long time to steady state prevents rapid titration of the dose. Transdermal patches are available as 72-hourly, 96-hourly and 7-day formulations; prescribers and dispensers must ensure that the correct preparation is prescribed and dispensed. Preparations that should be applied up to every 72 hours include Naloxodol® and Prenalin®. Preparations that should be applied up to every 96 hours include Bupeaze®, Bupeast®, Relevtec®, and Transept®. Preparations that should be applied up to every 7 days include Butec®, BuTrans®, Panitaz®, Reletrans®, and Sevodine®.

- **PATIENT AND CARER ADVICE**
  Patients or carers should be given advice on how to administer buprenorphine transdermal patches.

- **NATIONAL FUNDING/ACCESS DECISIONS**
  **NICE technology appraisals (TAs)**
  - Methadone and buprenorphine for the management of opioid dependence (January 2007) NICE TA114
  Oral methadone and buprenorphine are recommended for maintenance therapy in the management of opioid dependence. Patients should be committed to a supportive care programme including a flexible dosing regimen administered under supervision for at least 3 months, until compliance is assured. Selection of methadone or buprenorphine should be made on a case-by-case basis, but methadone should be prescribed if both drugs are equally suitable.
  [www.nice.org.uk/TA114](http://www.nice.org.uk/TA114)

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (January 2017) that buprenorphine transdermal patches (Butec®) are accepted for restricted use within NHS Scotland for the treatment of chronic non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia in elderly patients (over 65 years).

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Temgesic® (RB Pharmaceuticals Ltd)**
  Buprenorphine (as Buprenorphine hydrochloride) 100 microgram/1 ml solution for injection ampoules | 5 ampoule [POM] £2.46 [CD]

- **Buprenorphine (as Buprenorphine hydrochloride)**
  - **Sublingual tablet**
    CAUTIONARY AND ADVISORY LABELS 2, 26
    - **Buprenorphine (Non-NProprietary)**
      - 2 mg Buprenorphine 2mg sublingual tablets sugar free | 10 tablet [POM] £6.35 DT price | £1.33 [CD]
      - 8 mg Buprenorphine 8mg sublingual tablets sugar free | 10 tablet [POM] £22.50 DT price | £2.21 [CD]
    - **Natzon® (Morningside Healthcare Ltd)**
      - 0.4mg Natzon 0.4mg sublingual tablets sugar-free | 7 tablet [POM] £1.60 DT price | £1.60 [CD]
      - 1 mg Natzon 1mg sublingual tablets sugar-free | 7 tablet [POM] £6.35 DT price | £1.33 [CD]
    - **Butec® (Qmed Pharmaceuticals Ltd)**
      - 5 mg Butec 5mg sublingual tablets sugar-free | 7 tablet [POM] £6.35 DT price | £1.33 [CD]

**Transdermal patch**

CAUTIONARY AND ADVISORY LABELS 2

- **BuTrans® (Napp Pharmaceuticals Ltd)**
  - Buprenorphine 0.5 microgram per hour BuTrans 5micrograms/hour transdermal patches | 4 patch [POM] £17.60 DT price | £17.60 [CD]
  - Buprenorphine 2.5 microgram per hour BuTrans 10micrograms/hour transdermal patches | 4 patch [POM] £31.55 DT price | £31.55 [CD]
  - Buprenorphine 5 microgram per hour BuTrans 15micrograms/hour transdermal patches | 4 patch [POM] £49.15 DT price | £49.15 [CD]
  - Buprenorphine 10 microgram per hour BuTrans 20micrograms/hour transdermal patches | 4 patch [POM] £57.46 DT price | £57.46 [CD]

- **Buprenorphine 5 microgram per hour Bupeaze® (Dr Reddy’s Laboratories (UK) Ltd)**
  - 5.25micrograms/hour transdermal patches | 4 patch [POM] £15.80 [CD]
  - 10micrograms/hour transdermal patches | 4 patch [POM] £31.60 [CD]
  - Buprenorphine 25 microgram per hour Bupeaze® (Mylan Ltd)
  - 25micrograms/hour transdermal patches | 4 patch [POM] £55.30 [CD]
  - 50micrograms/hour transdermal patches | 4 patch [POM] £88.50 [CD]

- **Buprenorphine 5 microgram per hour Butec® (Qmed Pharmaceuticals Ltd)**
  - 5 microgram/hour transdermal patches | 4 patch [POM] £7.92 DT price | £17.60 [CD]
Buprenorphine 10 microgram per 1 hour Butec 10micrograms/hour transdermal patches | 4 patch £14.20 DT price = £31.55 (D3)

Buprenorphine 15 microgram per 1 hour Butec 15micrograms/hour transdermal patches | 4 patch £22.12 DT price = £49.15 (D3)

Buprenorphine 20 microgram per 1 hour Butec 20micrograms/hour transdermal patches | 4 patch £25.86 DT price = £57.46 (D3)

Hapotasin (Actavis UK Ltd)
Buprenorphine 35 microgram per 1 hour Hapotasin 35micrograms/hour transdermal patches | 4 patch £9.48 DT price = £15.80 (D3)

Buprenorphine 52.5 microgram per 1 hour Hapotasin 52.5micrograms/hour transdermal patches | 4 patch £14.23 DT price = £23.71 (D3)

Buprenorphine 70 microgram per 1 hour Hapotasin 70micrograms/hour transdermal patches | 4 patch £18.96 DT price = £31.60 (D3)

Panitaz (Dr Reddy’s Laboratories (UK) Ltd)
Buprenorphine 5 microgram per 1 hour Panitaz 5micrograms/hour transdermal patches | 4 patch £7.04 DT price = £17.60 (D3)

Buprenorphine 10 microgram per 1 hour Panitaz 10micrograms/hour transdermal patches | 4 patch £12.62 DT price = £31.55 (D3)

Buprenorphine 20 microgram per 1 hour Panitaz 20micrograms/hour transdermal patches | 4 patch £22.98 DT price = £57.46 (D3)

Prenotrix (Genesis Pharmaceuticals Ltd)
Buprenorphine 35 microgram per 1 hour Prenotrix 35micrograms/hour transdermal patches | 4 patch £15.80 DT price = £22.62 (D3)

Buprenorphine 52.5 microgram per 1 hour Prenotrix 52.5micrograms/hour transdermal patches | 4 patch £23.71 DT price = £23.71 (D3)

Buprenorphine 70 microgram per 1 hour Prenotrix 70micrograms/hour transdermal patches | 4 patch £31.60 DT price = £31.60 (D3)

Reletrans (Sandoz Ltd)
Buprenorphine 5 microgram per 1 hour Reletrans 5micrograms/hour transdermal patches | 4 patch £8.80 DT price = £17.60 (D3)

Buprenorphine 10 microgram per 1 hour Reletrans 10micrograms/hour transdermal patches | 4 patch £15.78 DT price = £31.55 (D3)

Buprenorphine 15 microgram per 1 hour Reletrans 15micrograms/hour transdermal patches | 4 patch £24.58 DT price = £49.15 (D3)

Buprenorphine 20 microgram per 1 hour Reletrans 20micrograms/hour transdermal patches | 4 patch £28.73 DT price = £57.46 (D3)

Relevec (Sandoz Ltd)
Buprenorphine 35 microgram per 1 hour Relevec 35micrograms/hour transdermal patches | 4 patch £11.06 DT price = £15.80 (D3)

Buprenorphine 52.5 microgram per 1 hour Relevec 52.5micrograms/hour transdermal patches | 4 patch £16.60 DT price = £31.55 (D3)

Buprenorphine 70 microgram per 1 hour Relevec 70micrograms/hour transdermal patches | 4 patch £22.12 DT price = £31.60 (D3)

Sevodyne (Aspire Pharma Ltd)
Buprenorphine 5 microgram per 1 hour Sevodyne 5micrograms/hour transdermal patches | 4 patch £7.92 DT price = £17.60 (D3)

Buprenorphine 10 microgram per 1 hour Sevodyne 10micrograms/hour transdermal patches | 4 patch £14.20 DT price = £31.55 (D3)

Buprenorphine 20 microgram per 1 hour Sevodyne 20micrograms/hour transdermal patches | 4 patch £25.86 DT price = £57.46 (D3)

Transect (Napp Pharmaceuticals Ltd)
Buprenorphine 35 microgram per 1 hour Transect 35micrograms/hour transdermal patches | 4 patch £15.80 DT price = £31.60 (D3)

Buprenorphine 52.5 microgram per 1 hour Transect 52.5micrograms/hour transdermal patches | 4 patch £23.71 DT price = £49.15 (D3)

Buprenorphine 70 microgram per 1 hour Transect 70micrograms/hour transdermal patches | 4 patch £31.60 DT price = £31.60 (D3)

Co-codamol

- **INDICATIONS AND DOSE**

  **Mild to moderate pain (using co-codamol 8/500 preparations only)**
  - **BY MOUTH**
  - Adult: 8/500–16/1000 mg every 4–6 hours as required; maximum 64/4000 mg per day

  **Mild to moderate pain (using co-codamol 15/500 preparations only)**
  - **BY MOUTH**
  - Adult: 15/500–30/1000 mg every 4–6 hours as required; maximum 120/4000 mg per day

  **Severe pain (using co-codamol 30/500 preparations only)**
  - **BY MOUTH**
  - Adult: 30/500–60/1000 mg every 4–6 hours as required; maximum 240/4000 mg per day

  **KAPAKE® 15/500**
  - **Mild to moderate pain**
  - **BY MOUTH**
  - Adult: 2 tablets every 4–6 hours as required; maximum 8 tablets per day

  **SOLPADOL® CAPLETS**
  - **Severe pain**
  - **BY MOUTH**
  - Adult: 2 capsules every 4–6 hours as required; maximum 8 capsules per day

  **SOLPADOL® CAPSULES**
  - **Severe pain**
  - **BY MOUTH USING EFFERVESCENT TABLETS**
  - Adult: 2 tablets every 4–6 hours as required, tablets to be dispersed in water; maximum 8 tablets per day

- **CONTRA-INDICATIONS**
  - Acute ulcerative colitis - antibiotic-associated colitis - conditions where abdominal distension develops - conditions where inhibition of peristalsis should be avoided - known ultra-rapid codeine metabolisers

- **CAUTIONS**
  - Acute abdomen - alcohol dependence - avoid abrupt withdrawal after long-term treatment - cardiac arrhythmias - chronic alcoholism - chronic dehydration - chronic malnutrition - convulsive disorders - gallstones - hepatocellular insufficiency

  **CAUTIONS, FURTHER INFORMATION**
  - Variation in metabolism The capacity to metabolise codeine to morphine can vary considerably between individuals; there is a marked increase in morphine toxicity in patients who are ultra-rapid codeine metabolisers (CYP2D6 ultra-rapid metabolisers) and a reduced therapeutic effect in poor codeine metabolisers.

- **INTERACTIONS**
  - Appendix 1: opioids, paracetamol

- **SIDE-EFFECTS**
  - Abdominal pain - anorexia - blood disorders - depression (with larger doses) - hypothermia - leucopenia - malaise - muscle fasciculation - neutropenia - pancreatitis - seizures - thrombocytopenia

- **Overdose**
  - Important: liver damage (and less frequently renal damage) following overdosage with paracetamol.

- **BREAST Feeding**
  - Avoid—although amount of codeine usually too small to be harmful, mothers vary considerably...
in their capacity to metabolise codeine—risk of morphine overdose in infant.

- **HEPATIC IMPAIRMENT** Dose-related toxicity with paracetamol—avoid large doses.
- **RENAL IMPAIRMENT** Reduce dose or avoid codeine; increased and prolonged effect; increased cerebral sensitivity.

- **PRESCRIBING AND DISPENSING INFORMATION** Co-codamol is a mixture of codeine phosphate and paracetamol; the proportions are expressed in the form x/y, where x and y are the strengths in milligrams of codeine phosphate and paracetamol respectively.

  When co-codamol tablets, dispersible (or effervescent) tablets, or capsules are prescribed and no strength is stated, tablets, dispersible (or effervescent) tablets, or capsules, respectively, containing codeine phosphate 8 mg and paracetamol 500 mg should be dispensed.

  The Drug Tariff allows tablets of co-codamol labelled ‘dispersible’ to be dispensed against an order for ‘effervescent’ and vice versa.

- **LESS SUITABLE FOR PRESCRIBING** Co-codamol is less suitable for prescribing.

- **EXCEPTIONS TO LEGAL CATEGORY** Co-codamol 8/500 can be sold to the public in certain circumstances; for exemptions see *Medicines, Ethics and Practice*, London, Pharmaceutical Press (always consult latest edition).

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>2(does not apply to the 8/500 tablet), 29, 30</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Co-codamol (Non-proprietary)</strong></td>
<td></td>
</tr>
<tr>
<td>Codeine phosphate 8 mg, Paracetamol 500 mg</td>
<td>Co-codamol 8mg/500mg tablets</td>
</tr>
<tr>
<td>Co-codamol 8mg/500mg caplets</td>
<td>32 tablet (P) £0.95 (COS)</td>
</tr>
<tr>
<td>Codeine phosphate 15 mg, Paracetamol 500 mg</td>
<td>Co-codamol 15mg/500mg tablets</td>
</tr>
<tr>
<td>Codeine phosphate 30 mg, Paracetamol 500 mg</td>
<td>Co-codamol 30mg/500mg tablets</td>
</tr>
<tr>
<td>Co-codamol caplets</td>
<td>30 tablet (P) £1.19 DT price = £1.19 (COS)</td>
</tr>
<tr>
<td><strong>Codipar (AMCo)</strong></td>
<td></td>
</tr>
<tr>
<td>Codeine phosphate 15 mg, Paracetamol 500 mg</td>
<td>Codipar 15mg/500mg capsules</td>
</tr>
<tr>
<td><strong>Kapake (Galen Ltd)</strong></td>
<td></td>
</tr>
<tr>
<td>Codeine phosphate 30 mg, Paracetamol 500 mg</td>
<td>Kapake 30mg/500mg tablets</td>
</tr>
<tr>
<td><strong>Migravie Yellow</strong> (McNeil Products Ltd)</td>
<td></td>
</tr>
<tr>
<td>Codeine phosphate 8 mg, Paracetamol 500 mg</td>
<td>Migravie Yellow tablets</td>
</tr>
<tr>
<td><strong>Panadol Ultra</strong> (GlaxoSmithKline Consumer Healthcare)</td>
<td></td>
</tr>
<tr>
<td>Codeine phosphate 12.8 mg, Paracetamol 500 mg</td>
<td>Panadol Ultra 12.8mg/500mg tablets</td>
</tr>
<tr>
<td><strong>Solpadeine Max</strong> (Omega Pharma Ltd)</td>
<td></td>
</tr>
<tr>
<td>Codeine phosphate 12.8 mg, Paracetamol 500 mg</td>
<td>Solpadeine Max 12.8mg/500mg tablets</td>
</tr>
<tr>
<td><strong>Solpadein (Sanofi)</strong></td>
<td></td>
</tr>
<tr>
<td>Codeine phosphate 30 mg, Paracetamol 500 mg</td>
<td>Solpadein 30mg/500mg capsules</td>
</tr>
<tr>
<td><strong>Zapain (AMCo)</strong></td>
<td></td>
</tr>
<tr>
<td>Codeine phosphate 30 mg, Paracetamol 500 mg</td>
<td>Zapain 30mg/500mg capsules</td>
</tr>
</tbody>
</table>

**Effervescent tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>2(does not apply to the 8/500 tablet), 13, 29, 30</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Co-codamol (Non-proprietary)</strong></td>
<td></td>
</tr>
<tr>
<td>Codeine phosphate 8 mg, Paracetamol 500 mg</td>
<td>Co-codamol 8mg/500mg effervescent tablets</td>
</tr>
<tr>
<td>Codeine phosphate 30 mg, Paracetamol 500 mg</td>
<td>Co-codamol 30mg/500mg effervescent tablets</td>
</tr>
<tr>
<td><strong>Codipar (AMCo)</strong></td>
<td></td>
</tr>
<tr>
<td>Codeine phosphate 15 mg, Paracetamol 500 mg</td>
<td>Codipar 15mg/500mg effervescent tablets sugar-free</td>
</tr>
<tr>
<td><strong>Paracodol</strong> (Bayer Plc)</td>
<td></td>
</tr>
<tr>
<td>Codeine phosphate 8 mg, Paracetamol 500 mg</td>
<td>Paracodol 8mg/500mg effervescent tablets</td>
</tr>
<tr>
<td><strong>Solpadol</strong> (Sanofi)</td>
<td></td>
</tr>
<tr>
<td>Codeine phosphate 30 mg, Paracetamol 500 mg</td>
<td>Solpadol 30mg/500mg effervescent tablets</td>
</tr>
<tr>
<td><strong>Tylex</strong> (UCB Pharma Ltd)</td>
<td></td>
</tr>
<tr>
<td>Codeine phosphate 30 mg, Paracetamol 500 mg</td>
<td>Tylex 30mg/500mg effervescent tablets</td>
</tr>
</tbody>
</table>

**Capsule**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>2(does not apply to the 8/500 capsule), 29, 30</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Co-codamol (Non-proprietary)</strong></td>
<td></td>
</tr>
<tr>
<td>Codeine phosphate 8 mg, Paracetamol 500 mg</td>
<td>Co-codamol 8mg/500mg capsules</td>
</tr>
<tr>
<td>Codeine phosphate 30 mg, Paracetamol 500 mg</td>
<td>Co-codamol 30mg/500mg capsules</td>
</tr>
<tr>
<td><strong>Codipar (AMCo)</strong></td>
<td></td>
</tr>
<tr>
<td>Codeine phosphate 15 mg, Paracetamol 500 mg</td>
<td>Codipar 15mg/500mg capsules</td>
</tr>
<tr>
<td><strong>Kapake</strong> (Galen Ltd)</td>
<td></td>
</tr>
<tr>
<td>Codeine phosphate 30 mg, Paracetamol 500 mg</td>
<td>Kapake 30mg/500mg capsules</td>
</tr>
<tr>
<td><strong>Paracodol</strong> (Bayer Plc)</td>
<td></td>
</tr>
<tr>
<td>Codeine phosphate 8 mg, Paracetamol 500 mg</td>
<td>Paracodol 8mg/500mg capsules</td>
</tr>
<tr>
<td><strong>Solpadol</strong> (Sanofi)</td>
<td></td>
</tr>
<tr>
<td>Codeine phosphate 30 mg, Paracetamol 500 mg</td>
<td>Solpadol 30mg/500mg capsules</td>
</tr>
<tr>
<td><strong>Tylex</strong> (UCB Pharma Ltd)</td>
<td></td>
</tr>
<tr>
<td>Codeine phosphate 30 mg, Paracetamol 500 mg</td>
<td>Tylex 30mg/500mg capsules</td>
</tr>
<tr>
<td><strong>Zapain (AMCo)</strong></td>
<td></td>
</tr>
<tr>
<td>Codeine phosphate 30 mg, Paracetamol 500 mg</td>
<td>Zapain 30mg/500mg capsules</td>
</tr>
</tbody>
</table>

**Codeine phosphate**

- **INDICATIONS AND DOSE**
  - **Acute diarrhoea**
    - **BY MOUTH**
      - Child 12-17 years: 30 mg 3–4 times a day; usual dose 15–60 mg 3–4 times a day
      - Adult: 30 mg 3–4 times a day; usual dose 15–60 mg 3–4 times a day
  - **Mild to moderate pain**
    - **BY MOUTH**
      - Adult: 30–60 mg every 4 hours if required; maximum 240 mg per day

  continued →
**Nervous system**

**CAUTION**

- Contra-indications: Acute ulcerative colitis - antibiotic-associated colitis - children under 18 years who undergo removal of tonsils or adenoids for the treatment of obstructive sleep apnoea - conditions where abdominal distension develops - conditions where inhibition of peristalsis should be avoided - known ultra-rapid codeine metabolisers

- **Cautions** Acute abdomen - cardiac arrhythmias - gallstones - not recommended for adolescents aged 12–18 years with breathing problems

**IMPORTANT SAFETY INFORMATION**

**MHRA/CHM ADVICE (JULY 2013) CODEINE FOR ANALGESIA:**

- **RESTRICTED USE IN CHILDREN DUE TO REPORTS OF MORPHINE TOXICITY**
- Codeine should only be used to relieve acute moderate pain in children older than 12 years and only if it cannot be relieved by other painkillers such as paracetamol or ibuprofen alone. A significant risk of serious and life-threatening adverse reactions has been identified in children with obstructive sleep apnoea who received codeine after tonsillectomy or adenoidectomy:
  - in children aged 12–18 years, the maximum daily dose of codeine should not exceed 240 mg. Doses may be taken up to four times a day at intervals of no less than 6 hours. The lowest effective dose should be used and duration of treatment should be limited to 3 days
  - codeine is contra-indicated in all children (under 18 years) who undergo the removal of tonsils or adenoids for the treatment of obstructive sleep apnoea
  - codeine is not recommended for use in children whose breathing may be compromised, including those with neuromuscular disorders, severe cardiac or respiratory conditions, respiratory infections, multiple trauma or extensive surgical procedures
  - codeine is contra-indicated in patients of any age who are known to be ultra-rapid metabolisers of codeine (CYP2D6 ultra-rapid metabolisers)
  - codeine should not be used in breast-feeding mothers because it can pass to the baby through breast milk
  - parents and carers should be advised on how to recognise signs and symptoms of morphine toxicity, and to stop treatment and seek medical attention if signs or symptoms of toxicity occur (including reduced consciousness, lack of appetite, somnolence, constipation, respiratory depression, ‘pin-point’ pupils, nausea, vomiting)

**MHRA/CHM ADVICE (APRIL 2015) CODEINE FOR COUGH AND COLD: RESTRICTED USE IN CHILDREN**

Do not use codeine in children under 12 years as it is associated with a risk of respiratory side effects. Codeine is not recommended for adolescents (12–18 years) who have problems with breathing. When prescribing or dispensing codeine-containing medicines for cough and cold, consider that codeine is contra-indicated in:

- children younger than 12 years old
- patients of any age known to be CYP2D6 ultra-rapid metabolisers
- breastfeeding mothers

**CAUTIONS, FURTHER INFORMATION**

- Variation in metabolism The capacity to metabolise codeine to morphine can vary considerably between individuals; there is a marked increase in morphine toxicity in patients who are ultra-rapid codeine metabolisers (CYP2D6 ultra-rapid metabolisers) and a reduced therapeutic effect in poor codeine metabolisers.
- **INTERACTIONS** → Appendix 1: opioids
- **SIDE-EFFECTS** Abdominal pain - anorexia - antidiuretic effect - hypothermia - malaise - muscle fasciculation - pancreatitis - seizures

**BREAST FEEDING** Avoid—although amount usually too small to be harmful, mothers vary considerably in their capacity to metabolise codeine—risk of morphine overdose in infant.

**RENAI IMPAIRMENT** Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.

**PRESCRIBING AND DISPENSING INFORMATION** BP directs that when Diabetic Codeine Linctus is prescribed, Codeine Linctus formulated with a vehicle appropriate for administration to diabetics, whether or not labelled 'Diabetic Codeine Linctus', shall be dispensed or supplied.

**PATIENT AND CARER ADVICE**

Medicines for Children leaflet: Codeine phosphate for pain [www.medicinesforchildren.org.uk/codeine-phosphate-pain-0](http://www.medicinesforchildren.org.uk/codeine-phosphate-pain-0)

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, solution for injection

**Tablet**

**CAUTIONARY AND ADVISORY LABELS 2**

**Codeine phosphate (Non-proprietary)**

<table>
<thead>
<tr>
<th>Codeine phosphate 15 mg</th>
<th>Codeine 15mg tablets</th>
<th>28 tablet</th>
<th>£1.40 DT price = £0.95</th>
<th>100 tablet</th>
<th>£3.39 DT price = £3.39</th>
<th>500 tablet</th>
<th>no price available</th>
<th>60 mg</th>
<th>Codeine 60mg tablets</th>
<th>28 tablet</th>
<th>£5.95 DT price = £1.67</th>
</tr>
</thead>
<tbody>
<tr>
<td>Codeine phosphate 30 mg</td>
<td>Codeine 30mg tablets</td>
<td>28 tablet</td>
<td>£1.59 DT price = £1.10</td>
<td>100 tablet</td>
<td>£5.68 DT price = £3.93</td>
<td>500 tablet</td>
<td>£19.65</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Codeine phosphate 60 mg</td>
<td>Codeine 60mg tablets</td>
<td>28 tablet</td>
<td>£5.95 DT price = £1.67</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Solution for injection**

**Codeine phosphate (Non-proprietary)**

<table>
<thead>
<tr>
<th>Codeine phosphate 3 mg per 1 ml</th>
<th>Codeine 15mg/5ml linctus sugar-free</th>
<th>200 ml</th>
<th>£1.90 DT price = £1.62</th>
<th>2000 ml</th>
<th>£16.20</th>
</tr>
</thead>
<tbody>
<tr>
<td>Codeine 15mg/5ml linctus</td>
<td>200 ml</td>
<td>£1.90 DT price = £1.90</td>
<td>2000 ml</td>
<td>no price available</td>
<td></td>
</tr>
<tr>
<td>Codeine phosphate 5 mg per 1 ml</td>
<td>Codeine 25mg/5ml oral solution</td>
<td>500 ml</td>
<td>£6.46 DT price = £6.46</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gal codine (Thornton &amp; Ross Ltd)</td>
<td>Codeine phosphate 3 mg per 1 ml</td>
<td>Codeine 15mg/5ml linctus sugar-free</td>
<td>2000 ml</td>
<td>£9.90</td>
<td></td>
</tr>
</tbody>
</table>

**Combinations available:** *Aspirin with codeine*, p. 424
Co-dydramol

- **INDICATIONS AND DOSE**
  - **Mild to moderate pain (using co-dydramol 10/500 preparations only)**
    - **BY MOUTH**
      - Adult: 10/500–20/1000 mg every 4–6 hours as required; maximum 80/4000 mg per day
  - **Severe pain (using co-dydramol 20/500 preparations only)**
    - **BY MOUTH**
      - Adult: 20/500–40/1000 mg every 4–6 hours as required; maximum 160/4000 mg per day
  - **Severe pain (using co-dydramol 30/500 preparations only)**
    - **BY MOUTH**
      - Adult: 30/500–60/1000 mg every 4–6 hours as required; maximum 240/4000 mg per day
  - **DOSE EQUIVALENCE AND CONVERSION**
    - A mixture of dihydrocodeine tartrate and paracetamol; the proportions are expressed in the form x/y, where x and y are the strengths in milligrams of dihydrocodeine and paracetamol respectively.

- **CAUTIONS**
  - Alcohol dependence: before administering, check when paracetamol last administered and cumulative paracetamol dose over previous 24 hours; chronic alcoholism: chronic dehhydration; chronic malnutrition; hepatocellular insufficiency; pancreatitis; severe cor pulmonale

- **INTERACTIONS**
  - Appendix 1: opioids, paracetamol

- **SIDE-EFFECTS**
  - Abdominal pain; acute generalised exanthematous pustulosis; blood disorders; leucopenia; malaise; neutropenia; pancreatitis; paraesthesia; paralytic ileus; skin reactions; Stevens-Johnson syndrome; thrombocytopenia; toxic epidermal necrolysis

- **Overdose**
  - **Important:** liver damage (and less frequently renal damage) following overdosage with paracetamol.

- **BREAST FEEDING**
  - Amount of dihydrocodeine too small to be harmful but use only if potential benefit outweighs risk.

- **HEPATIC IMPAIRMENT**
  - Dose-related toxicity with paracetamol—avoid large doses.

- **RENAL IMPAIRMENT**
  - Reduce dose or avoid dihydrocodeine; increased and prolonged effect; increased cerebral sensitivity.

- **PRESCRIBING AND DISPENSING INFORMATION**
  - When co-dydramol tablets are prescribed and no strength is stated, tablets containing dihydrocodeine tartrate 10 mg and paracetamol 500 mg should be dispensed.

- **LESS SUITABLE FOR PRESCRIBING**
  - Co-dydramol is less suitable for prescribing.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

  - **Tablet**
    - **CAUTIONARY AND ADVISORY LABELS** 2 (does not apply to the 10/500 tablet), 29, 30
    - **Co-dydramol (Non-proprietary)**
      - Dihydrocodeine tartrate 10 mg, Paracetamol 500 mg
        - Co-dydramol 10mg/500mg tablets: 30 tablet (Pod) £1.14
        - Co-dydramol 10mg/500mg tablets: 100 tablet (Pod) £3.27
        - Co-dydramol 5mg/500mg tablets: 500 tablet (Pod) £11.65

Diamorphine hydrochloride (Heroin hydrochloride)

- **INDICATIONS AND DOSE**
  - **Acute pain**
    - **BY INTRAMUSCULAR INJECTION, OR BY SUBCUTANEOUS INJECTION**
      - Adult: 5 mg every 4 hours if required
    - **BY SLOW INTRAVENOUS INJECTION**
      - Adult: 1.25–2.5 mg every 4 hours if required
  - **Acute pain (heavier, well-muscled patients)**
    - **BY INTRAMUSCULAR INJECTION, OR BY SUBCUTANEOUS INJECTION**
      - Adult: Up to 10 mg every 4 hours if required
    - **BY SLOW INTRAVENOUS INJECTION**
      - Adult: 2.5–5 mg every 4 hours if required
  - **Chronic pain not currently treated with a strong opioid analgesic**
    - **BY SUBCUTANEOUS INJECTION, OR BY INTRAMUSCULAR INJECTION**
      - Adult: Initially 2.5–5 mg every 4 hours, adjusted according to response
    - **BY SUBCUTANEOUS INFUSION**
      - Adult: Initially 5–10 mg, adjusted according to response, dose to be administered over 24 hours
  - **Acute pulmonary oedema**
    - **BY SLOW INTRAVENOUS INJECTION**
      - Adult: 2.5–5 mg, dose to be administered at a rate of 1 mg/minute
  - **Myocardial infarction**
    - **BY SLOW INTRAVENOUS INJECTION**
      - Adult: 5 mg, followed by 2.5–5 mg if required, dose to be administered at a rate of 1–2 mg/minute
      - Elderly: 2.5 mg, followed by 1.25–2.5 mg if required, dose to be administered at a rate of 1–2 mg/minute
  - **Myocardial infarction (frail patients)**
    - **BY SLOW INTRAVENOUS INJECTION**
      - Adult: 2.5 mg, followed by 1.25–2.5 mg if required, dose to be administered at a rate of 1–2 mg/minute

- **CONTRA-INDICATIONS**
  - Delayed gastric emptying; phaeochromocytoma

- **CAUTIONS**
  - CNS depression; severe cor pulmonale; severe diarrhoea; toxic psychosis

- **INTERACTIONS**
  - Appendix 1: opioids

- **SIDE-EFFECTS**
  - Anorexia; asthenia; myocardial infarction; raised intracranial pressure; syncope; taste disturbance

- **BREAST FEEDING**
  - Therapeutic doses unlikely to affect infant; withdrawal symptoms in infants of dependent mothers; breast-feeding not best method of treating dependence in offspring.

- **RENAL IMPAIRMENT**
  - Avoid use or reduce dose; opioid effects increased and prolonged; increased cerebral sensitivity.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule, oral solution, solution for injection, powder for solution for injection

  - **Powder for solution for injection**
    - **Diamorphine hydrochloride (Non-proprietary)**
      - Diamorphine hydrochloride 5 mg: Diamorphine 5mg powder for solution for injection vials | 5 vial (Pom) £15.00
      - Diamorphine 5mg powder for solution for injection ampoules | 5 ampoule (Pom) £11.36
      - Diamorphine hydrochloride 10 mg: Diamorphine 10mg powder for solution for injection ampoules | 5 ampoule (Pom) £15.06-£16.56
      - Diamorphine hydrochloride 10 mg: Diamorphine 10mg powder for solution for injection ampoules | 5 ampoule (Pom) £15.06-£16.56 DT price = £13.56
Dihydrocodeine tartrate

**INDICATIONS AND DOSE**

**Moderate to severe pain**
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Child 4–11 years: 0.5–1 mg/kg every 4–6 hours (max. per dose 30 mg)
  - Child 12–17 years: 30 mg every 4–6 hours
  - Adult: 30 mg every 4–6 hours as required
- **BY DEEP SUBCUTANEOUS INJECTION, OR BY INTRAMUSCULAR INJECTION**
  - Adult: Up to 50 mg every 4–6 hours if required

**Chronic severe pain**
- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Child 12–17 years: 60–120 mg every 12 hours
  - Adult: 60–120 mg every 12 hours

**DF118 FORTE**

**Severe pain**
- **BY MOUTH**
  - Child 12–17 years: 40–80 mg 3 times a day; maximum 240 mg per day
  - Adult: 40–80 mg 3 times a day; maximum 240 mg per day

**UNLICENSED USE**
Most preparations not licensed for use in children under 4 years.

**CAUTIONS**
- Pancreatitis, severe cor pulmonale
- **INTERACTIONS**
  - Appendix 1: opioids
- **SIDE-EFFECTS**
  - Abdominal pain, diarrhoea, paraesthesia, paralytic ileus, seizures
- **BREAST FEEDING**
  - Use only if potential benefit outweighs risk.
- **RENAL IMPAIRMENT**
  - Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.

**PROFESSION SPECIFIC INFORMATION**
Dental practitioners’ formulary

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Modified-release tablet**

<table>
<thead>
<tr>
<th>Tablet</th>
<th>CAUTIONARY AND ADVISORY LABELS 2</th>
</tr>
</thead>
</table>
| Dihydrocodeine tartrate (Non-proprietary) | Dihydrocodeine tartrate 30 mg
- Dihydrocodeine 30mg tablets | 28 tablet (PoM) £1.33 DT price = £1.15 (£55) 30 tablet (PoM) £1.56 (£55) 100 tablet (PoM) £4.11 DT price = £4.11 (£55) 500 tablet (PoM) £20.55 (£55)
| DF 118 (Martindale Pharmaceuticals Ltd) | Dihydrocodeine tartrate 40 mg
- DF 118 Forte 40mg tablets | 100 tablet (PoM) £3.78 DT price = £3.78 (£55)

**Solution for injection**

- **Dihydrocodeine tartrate (Non-proprietary)**
- **Dihydrocodeine tartrate 50 mg per 1 ml**
- **Dihydrocodeine 50mg/1ml solution for injection ampoules**
- **10 ampoule (PoM) £9.70 DT price = £9.70 (£55)

**Oral solution**

- **Dihydrocodeine tartrate (Non-proprietary)**
- **Dihydrocodeine tartrate 2 mg per 1 ml**
- **Dihydrocodeine 10mg/5ml oral solution**
- **150 ml (PoM) £7.92 DT price = £7.61 (£55)

**Dipipanone hydrochloride with cyclizine**

**INDICATIONS AND DOSE**

**Acute pain**
- **BY MOUTH**
  - Adult: Initially 1 tablet every 6 hours, then increased if necessary up to 3 tablets every 6 hours, dose to be increased gradually

**CAUTIONS**
- Diabetes mellitus, palliative care (not recommended), phaechromocytoma
- **INTERACTIONS**
  - Appendix 1: antihistamines (sedating), opioids
- **SIDE-EFFECTS**
  - Psychosis, raised intracranial pressure, restlessness
- **BREAST FEEDING**
  - No information available.
- **RENAL IMPAIRMENT**
  - Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- **Dipipanone hydrochloride with cyclizine (Non-proprietary)**
- **Dipipanone hydrochloride 10 mg, Cyclizine hydrochloride 30 mg**
- **Dipipanone 10mg / Cyclizine 30mg tablets**
- **50 tablet (PoM) £353.06 DT price = £353.06 (£55)

**Fentanyl**

**INDICATIONS AND DOSE**

**Chronic intractable pain not currently treated with a strong opioid analgesic**
- **BY TRANSDERMAL APPLICATION**
  - Child 16–17 years: Initially 12 micrograms/hour every 72 hours, alternatively initially 25 micrograms/hour every 72 hours, when starting, evaluation of the analgesic effect should not be made before the system has been worn for 24 hours (to allow for the gradual increase in plasma-fentanyl concentration)—previous analgesic therapy should be phased out gradually from time of first patch application, dose should be adjusted at 48–72 hour intervals in steps of 12–25 micrograms/hour if necessary, more than one patch may be used at a time (but applied at the same time to avoid confusion)—consider additional or alternative analgesic therapy if dose required exceeds...
300 micrograms/hour (important: it takes 17 hours or more for the plasma-fentanyl concentration to decrease by 50%—replacement opioid therapy should be initiated at a low dose and increased gradually)

- Adult: Initially 12 micrograms/hour every 72 hours, alternatively initially 25 micrograms/hour every 72 hours, when starting, evaluation of the analgesic effect should not be made before the system has been worn for 24 hours (to allow for the gradual increase in plasma-fentanyl concentration)—previous analgesic therapy should be phased out gradually from time of first patch application, dose should be adjusted at 48–72 hour intervals in steps of 12–25 micrograms/hour if necessary, more than one patch may be used at a time (but applied at the same time to avoid confusion)—consider additional or alternative analgesic therapy if dose required exceeds 300 micrograms/hour (important: it takes 17 hours or more for the plasma-fentanyl concentration to decrease by 50%—replacement opioid therapy should be initiated at a low dose and increased gradually)

**Chronic intractable pain currently treated with a strong opioid analgesic**

- **BY TRANSDERMAL APPLICATION**
- Child 2–17 years: Initial dose based on previous 24-hour opioid requirement (consult product literature), for evaluating analgesic efficacy and dose increments, see under Chronic intractable pain not currently treated with a strong opioid analgesic, for conversion from long term oral morphine to transdermal fentanyl, see Pain management with opioids under p. 23.
- Adult: Initial dose based on previous 24-hour opioid requirement (consult product literature), for evaluating analgesic efficacy and dose increments, see under Chronic intractable pain not currently treated with a strong opioid analgesic, for conversion from long term oral morphine to transdermal fentanyl, see Pain management with opioids under p. 23.

**Spontaneous respiration: analgesia and enhancement of anaesthesia, during operation**

- **BY SLOW INTRAVENOUS INJECTION**
- Adult: Initially 50–100 micrograms (max. per dose 200 micrograms), dose maximum on specialist advice, then 25–50 micrograms as required
- **BY INTRAVENOUS INFUSION**
- Adult: 3–4.8 micrograms/kg/hour, adjusted according to response

**Assisted ventilation: analgesia and enhancement of anaesthesia during operation**

- **BY SLOW INTRAVENOUS INJECTION**
- Adult: Initially 300–3500 micrograms, then 100–200 micrograms as required
- **BY INTRAVENOUS INFUSION**
- Adult: Initially 10 micrograms/kg, dose to be given over 10 minutes, then 6 micrograms/kg/hour, adjusted according to response, may require up to 180 micrograms/kg/hour during cardiac surgery

**Assisted ventilation: analgesia and respiratory depression in intensive care**

- **BY SLOW INTRAVENOUS INJECTION**
- Adult: Initially 300–3500 micrograms, then 100–200 micrograms as required
- **BY INTRAVENOUS INFUSION**
- Adult: Initially 10 micrograms/kg, dose to be given over 10 minutes, then 6 micrograms/kg/hour, adjusted according to response, may require up to 180 micrograms/kg/hour during cardiac surgery

**Breakthrough pain in patients receiving opioid therapy for chronic cancer pain**

- **BY BUCAL ADMINISTRATION USING LOZENGES**
- Child 16–17 years: Initially 200 micrograms, dose to be given over 15 minutes, then 200 micrograms after 15 minutes if required, no more than 2 dose units for each pain episode; if adequate pain relief not achieved with 1 dose unit for consecutive breakthrough pain episodes, increase the strength of the dose unit until adequate pain relief achieved with 4 lozenges or less daily, if more than 4 episodes of breakthrough pain each day, adjust background analgesia
- Adult: Initially 200 micrograms, dose to be given over 15 minutes, then 200 micrograms after 15 minutes if required, no more than 2 dose units for each pain episode; if adequate pain relief not achieved with 1 dose unit for consecutive breakthrough pain episodes, increase the strength of the dose unit until adequate pain relief achieved with 4 lozenges or less daily, if more than 4 episodes of breakthrough pain each day, adjust background analgesia

- **BY BUCAL ADMINISTRATION USING BUCAL FILMS**
- Adult: Initially 200 micrograms, adjusted according to response, consult product literature for information on dose adjustments, maximum 1.2 mg per episode of breakthrough pain; leave at least 4 hours between treatment of episodes of breakthrough pain, if more than 4 episodes of breakthrough pain each day occur on more than 4 consecutive days, adjust background analgesia

**DOSE EQUIVALENCE AND CONVERSION**

- Fentanyl films are not bioequivalent to other fentanyl preparations.
- Fentanyl preparations for the treatment of breakthrough pain are not interchangeable; if patients are switched from another fentanyl-containing preparation, a new dose titration is required.

**DOSES AT EXTREMES OF BODY-WEIGHT**

To avoid excessive dosage in obese patients, weight-based doses may need to be calculated on the basis of ideal body weight.

**ABSTRAL®**

**Breakthrough pain in patients receiving opioid therapy for chronic cancer pain**

- **BY MOUTH USING SUBLINGUAL TABLETS**
- Adult: Initially 100 micrograms, then 100 micrograms after 15–30 minutes if required, dose to be adjusted according to response—consult product literature, no more than 2 dose units 15–30 minutes apart, for each pain episode; max. 800 micrograms per episode of breakthrough pain; leave at least 2 hours between treatment of episodes of breakthrough pain, if more than 4 episodes of breakthrough pain each day, adjust background analgesia

**EFFENTORA®**

**Breakthrough pain in patients receiving opioid therapy for chronic cancer pain**

- **BY MOUTH USING SUBLINGUAL TABLETS**
- Adult: Initially 100 micrograms, then 100 micrograms after 30 minutes if required, dose to be adjusted according to response—consult product literature, no more than 2 dose units for each pain episode; max. 800 micrograms per episode of breakthrough pain; leave at least 2 hours between treatment of episodes of breakthrough pain, if more than 4 episodes of breakthrough pain during titration...
INSTANYL®
Breakthrough pain in patients receiving opioid therapy for chronic cancer pain
► BY INTRanasAL ADMINISTRATION
► Adult: Initially 50 micrograms, dose to be administered into one nostril, then 50 micrograms after 10 minutes if required, dose to be adjusted according to response, maximum 2 sprays for each pain episode and minimum 4 hours between treatment of each pain episode, if more than 4 breakthrough pain episodes daily, adjust background analgesia

PECFENT®
Breakthrough pain in patients receiving opioid therapy for chronic cancer pain
► BY INTRanasAL ADMINISTRATION
► Adult: Initially 100 micrograms, adjusted according to response, dose to be administered into one nostril only, maximum 2 sprays for each pain episode and minimum 4 hours between treatment of each pain episode, if more than 4 breakthrough pain episodes daily, adjust background analgesia

RECIVIT® SUBLINGUAL TABLETS
Breakthrough pain in patients receiving opioid therapy for chronic cancer pain
► BY MOUTH
► Adult: Initially 133 micrograms, then 133 micrograms after 15–30 minutes (max. per dose 800 micrograms), dose to be repeated only if necessary. Consult product literature for dose adjustments, no more than 2 dose units, 15–30 minutes apart, for each pain episode, maximum of 800 micrograms per episode of breakthrough pain, if more than 4 episodes of breakthrough pain each day, adjust background analgesia; maximum 4 doses per day

● CAUTIONS
GENERAL CAUTIONS
Cerebral tumour · diabetes mellitus (with Actiq® lozenges) · impaired consciousness

SPECIFIC CAUTIONS
► With buccal use Mucositis—absorption from oral preparations may be increased, caution during dose titration (in adults)
CAUTIONS, FURTHER INFORMATION
► With transdermal use Transdermal fentanyl patches are not suitable for acute pain or in those patients whose analgesic requirements are changing rapidly because the long time to steady state prevents rapid titration of the dose. Risk of fatal respiratory depression, particularly in patients not previously treated with a strong opioid analgesic; manufacturer recommends use only in opioid tolerant patients.
► With intravenous use Repeated intra-operative doses should be given with care since the resulting respiratory depression can persist postoperatively and occasionally it may become apparent for the first time postoperatively when monitoring of the patient might be less intensive.

● INTERACTIONS ➔ Appendix 1: opioids
● SIDE-EFFECTS
GENERAL SIDE-EFFECTS
► Common or very common Abdominal pain · aethesia · anorexia · anxiety · appetite changes · application site reactions · diarrhoea · dyspepsia · dyspnoea · gastro-oesophageal reflux disease · hypertension · myoclonus · paraesthesia · pharyngitis · rhinitis · stomatitis · tremor · vasodilation
► Uncommon · Amnesia · arthralgia · blood disorders · chills · depressed level of consciousness · dysgeusia · flatulence · hyperventilation · ileus · impaired concentration · impaired coordination · loss of consciousness · malaise · parosmia · pyrexia · seizures · speech disorder · thirst · thrombocytopenia
► Rare · Hiccups
► Very rare · Apnoea · arrhythmia · ataxia · bladder pain · delusions · haemoptysis

SPECIFIC SIDE-EFFECTS
► Common or very common
► With intravenous use Myoclonic movements
► Uncommon
► With intravenous use Laryngospasm
► Rare
► With intravenous use Asystole · insomnia

SIDE-EFFECTS, FURTHER INFORMATION
► Fever or external heat Monitor patients using patches for increased side-effects if fever present (increased absorption possible); avoid exposing application site to external heat, for example a hot bath or sauna (may also increase absorption).
► Muscle rigidity Intravenous administration of fentanyl can cause muscle rigidity, particularly of the chest wall or jaw; this can be managed by the use of neuromuscular blocking drugs.

● BREAST FEEDING
Monitor infant for opioid-induced side-effects.

● RENAL IMPAIRMENT
Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.

● DIRECTIONS FOR ADMINISTRATION
► With transdermal use For patches, apply to dry, non-irritated, non-hairy skin on torso or upper arm, removing after 72 hours and siting replacement patch on a different area (avoid using the same area for several days).
► With intravenous use For intravenous infusion (Sublimaze), give continuously or intermittently in Glucose 5% or Sodium Chloride 0.9%.
► With buccal use in adults For buccal films, moisten mouth, place film on inner lining of cheek (pink side to cheek), hold for at least 5 seconds until it sticks, and leave to dissolve (15–30 minutes); if more than 1 film required do not overlap, but use another area of the mouth. Avoid liquids for 5 minutes after application; avoid food until the film has dissolved.
► With buccal use Patients should be advised to place the lozenge in the mouth against the cheek and move it around the mouth using the applicator; each lozenge should be sucked over a 15 minute period. In patients with a dry mouth, water may be used to moisten the buccal mucosa. Patients with diabetes should be advised each lozenge contains approximately 2 g glucose.

INSTANYL®
Patient should sit or stand during administration.

EFFENTORA®
Place tablet between cheek and gum and leave to dissolve; if more than 1 tablet required, place second tablet on the other side of the mouth; tablet may alternatively be placed under the tongue (sublingually).

● PRESCRIBING AND DISPENSING INFORMATION
Prescriptions for fentanyl patches can be written to show the strength in terms of the release rate and it is acceptable to write ‘Fentanyl 25 micrograms per hour’.

● PATIENT AND CARER ADVICE
Medicines for Children leaflet: Fentanyl lozenges for pain
www.medicinesforchildren.org.uk/fentanyl-lozenges-for-pain
Medicines for Children leaflet: Fentanyl patches for pain
www.medicinesforchildren.org.uk/fentanyl-patches-for-pain
With transdermal use Patients and carers should be informed about safe use, including correct administration and disposal, strict adherence to dosage instructions, and the symptoms and signs of opioid overdosage. Patches should be removed immediately in case of breathing difficulties, marked drowsiness, confusion, dizziness, or impaired speech, and patients and carers should seek prompt medical attention.

In adults Patients or carers should be given advice on how to administer fentanyl buccal films or fentanyl lozenges. Patients or carers should be given advice on how to administer fentanyl nasal spray.

**INSTANYL** Avoid concomitant use of other nasal preparations. Patients or carers should be given advice on how to administer Instanyl® spray.

**PECFENT** Avoid concomitant use of other nasal preparations. Patients or carers should be given advice on how to administer PecFent® spray.

**EFFENTORA** Patients or carers should be given advice on how to administer Effentora® buccal tablets.

Patients should be advised not to eat or drink until the tablet is completely dissolved; after 30 minutes, if any remnants remain, they may be swallowed with a glass of water. Patients with a dry mouth should be advised to drink water to moisten the buccal mucosa before administration of the tablets; if appropriate effervescence does not occur, a switch of therapy may be advised.

**ABSTRAL** Patients should be advised not to eat or drink until the tablet is completely dissolved. In patients with a dry mouth, the buccal mucosa may be moistened with water before administration of tablet.

**RECIVIT® SUBLINGUAL TABLETS** Patients should be advised not to eat or drink until the tablet is completely dissolved; after 30 minutes, if any remnants remain, they may be swallowed. In patients with a dry mouth, the buccal mucosa may be moistened with water before administration of tablet.

### NATIONAL FUNDING/ACCESS DECISIONS

#### INSTANYL®

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised that Instanyl® nasal spray should be restricted for use within NHS Scotland for the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain, when other short-acting opioids are unsuitable.

#### PECFENT®

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (September 2008) that PecFent® nasal spray should be restricted for use within NHS Scotland for the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain, when other short-acting opioids are unsuitable.

#### EFFENTORA®

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised that Effentora® buccal tablets should be restricted for the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain, when other short-acting opioids are unsuitable.

#### ABSTRAL®

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (January 2009) that Abstral® sublingual tablets should be restricted for the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain, when other short-acting opioids are unsuitable.

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection, infusion, solution for infusion

#### Solution for injection

- **Fentanyl (Non-proprietary)**
  - Fentanyl (as Fentanyl citrate) 50 microgram per 1 ml Fentanyl 100micrograms/2ml solution for injection ampoules | 10 ampoule (Pt) £13.95 (C02)
  - Fentanyl 500micrograms/10ml solution for injection ampoules | 10 ampoule (Pt) £13.95 (C02)

- **Sublimaze** (Janssen-Cilag Ltd)
  - Fentanyl (as Fentanyl citrate) 50 microgram per 1 ml Sublimaze 500micrograms/10ml solution for injection ampoules | 5 ampoule (Pt) £6.53 (C02)

#### Spray

**CAUTIONARY AND ADVISORY LABELS 2**

- **Instanyl** (Takeda UK Ltd)
  - Fentanyl (as Fentanyl citrate) 50 microgram per 1 dose Instanyl 50micrograms/dose nasal spray | 6 dose (Pt) £35.70 (C02) | 10 dose (Pt) £59.50 (C02) | 20 dose (Pt) £119.00 (C02)
  - Fentanyl (as Fentanyl citrate) 100 microgram per 1 dose Instanyl 100micrograms/dose nasal spray | 6 dose (Pt) £35.70 (C02) | 10 dose (Pt) £59.50 (C02) | 20 dose (Pt) £119.00 (C02)
  - Fentanyl (as Fentanyl citrate) 200 microgram per 1 dose Instanyl 200micrograms/dose nasal spray | 6 dose (Pt) £35.70 (C02) | 10 dose (Pt) £59.50 (C02) | 20 dose (Pt) £119.00 (C02)

- **PecFent** (Kyowa Kirin Ltd)
  - Fentanyl (as Fentanyl citrate) 100 microgram per 1 dose PecFent 100micrograms/dose nasal spray | 8 dose (Pt) £36.48 (C02) | 32 dose (Pt) £145.92 (C02)
  - Fentanyl (as Fentanyl citrate) 400 microgram per 1 dose PecFent 400micrograms/dose nasal spray | 8 dose (Pt) £36.48 (C02) | 32 dose (Pt) £145.92 (C02)

#### Buccal tablet

**CAUTIONARY AND ADVISORY LABELS 2**

- **Effentora** (Teva UK Ltd)
  - Fentanyl (as Fentanyl citrate) 100 microgram Effentora 100microgram buccal tablets sugar-free | 4 tablet (Pt) £19.96 (C02)
  - Fentanyl (as Fentanyl citrate) 200 microgram Effentora 200microgram buccal tablets sugar-free | 4 tablet (Pt) £19.96 (C02)
  - Fentanyl (as Fentanyl citrate) 400 microgram Effentora 400microgram buccal tablets sugar-free | 4 tablet (Pt) £19.96 (C02)
  - Fentanyl (as Fentanyl citrate) 800 microgram Effentora 800microgram buccal tablets sugar-free | 4 tablet (Pt) £19.96 (C02)

#### Solution for infusion

- **Fentanyl (Non-proprietary)**
  - Fentanyl (as Fentanyl citrate) 50 microgram per 1 ml Fentanyl 2.5mg/50ml solution for infusion vials | 1 vial (Pt) £5.00 (C02)

#### Sublingual tablet

**CAUTIONARY AND ADVISORY LABELS 2, 26**

- **Abstral** (Kyowa Kirin Ltd)
  - Fentanyl (as Fentanyl citrate) 100 microgram Abstral 100microgram sublingual tablets sugar-free | 10 tablet (Pt) £49.99 (C02) | sugar-free | 30 tablet (Pt) £149.70 (C02)
  - Fentanyl (as Fentanyl citrate) 200 microgram Abstral 200microgram sublingual tablets sugar-free | 10 tablet (Pt) £49.99 (C02) | sugar-free | 30 tablet (Pt) £149.70 (C02)
  - Fentanyl (as Fentanyl citrate) 300 microgram Abstral 300microgram sublingual tablets sugar-free | 10 tablet (Pt) £49.99 (C02) | sugar-free | 30 tablet (Pt) £149.70 (C02)
  - Fentanyl (as Fentanyl citrate) 400 microgram Abstral 400microgram sublingual tablets sugar-free | 10 tablet (Pt) £49.99 (C02) | sugar-free | 30 tablet (Pt) £149.70 (C02)
  - Fentanyl (as Fentanyl citrate) 600 microgram Abstral 600microgram sublingual tablets sugar-free | 10 tablet (Pt) £149.70 (C02)
  - Fentanyl (as Fentanyl citrate) 800 microgram Abstral 800microgram sublingual tablets sugar-free | 30 tablet (Pt) £149.70 (C02)
Matrifen
Fencino
Fentanyl (Non-proprietary)

Transdermal patch
CAUTIONARY AND ADVISORY LABELS

Fentanyl 12 microgram per 1 hour transdermal patches | 5 patch POM £12.59 (C2)
Fentanyl 25 microgram per 1 hour transdermal patches | 5 patch POM £17.99 (C2)
Fentanyl 50 microgram per 1 hour transdermal patches | 5 patch POM £33.66 (C2)
Fentanyl 75 microgram per 1 hour transdermal patches | 5 patch POM £46.99 (C2)

Fentanyl 100 microgram per 1 hour transdermal patches | 5 patch POM £57.86 (C2)

Fentanyl 100 micrograms per 1 hour transdermal patches | 5 patch POM £57.86 (C2)

Fentanyl 25 microgram per 1 hour transdermal patches | 5 patch POM £12.59 (C2)
Fentanyl 50 microgram per 1 hour transdermal patches | 5 patch POM £33.66 (C2)
Fentanyl 75 microgram per 1 hour transdermal patches | 5 patch POM £46.99 (C2)
Fentanyl 100 microgram per 1 hour transdermal patches | 5 patch POM £57.86 (C2)

Fentanyl 12 microgram per 1 hour transdermal patches | 5 patch POM £12.59 (C2)
Fentanyl 25 microgram per 1 hour transdermal patches | 5 patch POM £17.99 (C2)
Fentanyl 50 microgram per 1 hour transdermal patches | 5 patch POM £33.66 (C2)
Fentanyl 75 microgram per 1 hour transdermal patches | 5 patch POM £46.99 (C2)
Fentanyl 100 microgram per 1 hour transdermal patches | 5 patch POM £57.86 (C2)

Fentanyl 100 micrograms transdermal patches | 5 patch POM £57.86 (C2)

Durogesic DTrans (Janssen-Cigli Ltd)

Fentanyl 12 microgram per 1 hour transdermal patches | 5 patch POM £12.59 (C2)
Fentanyl 25 microgram per 1 hour transdermal patches | 5 patch POM £17.99 (C2)
Fentanyl 50 microgram per 1 hour transdermal patches | 5 patch POM £33.66 (C2)
Fentanyl 75 microgram per 1 hour transdermal patches | 5 patch POM £46.99 (C2)
Fentanyl 100 microgram per 1 hour transdermal patches | 5 patch POM £57.86 (C2)

Fentanyl 12 microgram/hour no price available DT price = £57.86 (C2)

Fentanyl 12 micrograms/hour price = £12.59 (C2)
Fentanyl 25 micrograms/hour price = £17.99 (C2)
Fentanyl 50 micrograms/hour price = £33.66 (C2)
Fentanyl 75 micrograms/hour price = £46.99 (C2)
Fentanyl 100 micrograms/hour price = £57.86 (C2)

Actiq (Teva UK Ltd)

Fentanyl 12 microgram per 1 hour transdermal patches | 5 patch POM £12.59 (C2)
Fentanyl 25 microgram per 1 hour transdermal patches | 5 patch POM £17.99 (C2)
Fentanyl 50 microgram per 1 hour transdermal patches | 5 patch POM £33.66 (C2)
Fentanyl 75 microgram per 1 hour transdermal patches | 5 patch POM £46.99 (C2)
Fentanyl 100 microgram per 1 hour transdermal patches | 5 patch POM £57.86 (C2)

Mylafent (Mylan Ltd)

Fentanyl 12 microgram per 1 hour transdermal patches | 5 patch POM £12.59 (C2)
Fentanyl 25 microgram per 1 hour transdermal patches | 5 patch POM £17.99 (C2)
Fentanyl 50 microgram per 1 hour transdermal patches | 5 patch POM £33.66 (C2)
Fentanyl 75 microgram per 1 hour transdermal patches | 5 patch POM £46.99 (C2)
Fentanyl 100 microgram per 1 hour transdermal patches | 5 patch POM £57.86 (C2)

Osmanil (Zentiva)

Fentanyl 12 microgram per 1 hour transdermal patches | 5 patch POM £12.59 (C2)
Fentanyl 25 microgram per 1 hour transdermal patches | 5 patch POM £17.99 (C2)
Fentanyl 50 microgram per 1 hour transdermal patches | 5 patch POM £33.66 (C2)
Fentanyl 75 microgram per 1 hour transdermal patches | 5 patch POM £46.99 (C2)
Fentanyl 100 microgram per 1 hour transdermal patches | 5 patch POM £57.86 (C2)

Tilofyl (Tillomed Laboratories Ltd)

Fentanyl 25 microgram per 1 hour transdermal patches | 5 patch POM £27.00 (C2)
Fentanyl 50 microgram per 1 hour transdermal patches | 5 patch POM £51.00 (C2)
Fentanyl 75 microgram per 1 hour transdermal patches | 5 patch POM £71.00 (C2)
Fentanyl 100 microgram per 1 hour transdermal patches | 5 patch POM £88.00 (C2)

Victanyl (Actavis UK Ltd)

Fentanyl 12 microgram per 1 hour transdermal patches | 5 patch POM £12.59 (C2)
Fentanyl 25 microgram per 1 hour transdermal patches | 5 patch POM £17.99 (C2)
Fentanyl 50 microgram per 1 hour transdermal patches | 5 patch POM £33.66 (C2)
Fentanyl 75 microgram per 1 hour transdermal patches | 5 patch POM £46.99 (C2)
Fentanyl 100 microgram per 1 hour transdermal patches | 5 patch POM £57.86 (C2)

Yemex (Sandoz Ltd)

Fentanyl 12 microgram per 1 hour transdermal patches | 5 patch POM £12.59 (C2)
Fentanyl 25 microgram per 1 hour transdermal patches | 5 patch POM £17.99 (C2)
Fentanyl 50 microgram per 1 hour transdermal patches | 5 patch POM £33.66 (C2)
Fentanyl 75 microgram per 1 hour transdermal patches | 5 patch POM £46.99 (C2)
Fentanyl 100 microgram per 1 hour transdermal patches | 5 patch POM £57.86 (C2)

Lozenge
CAUTIONARY AND ADVISORY LABELS

Actiq (Teva UK Ltd)

Fentanyl (as Fentanyl citrate) 200 microgram Actiq 200microgram lozenges with integral oromucosal applicator | 3 lozenges POM £21.05 (C2) 30 lozenges POM £210.41 (C2)
Fentanyl (as Fentanyl citrate) 400 microgram Actiq 400 microgram lozenges with integral oromucosal applicator  |  3 lozenge  Price £21.05 CD2 | 30 lozenge  Price £210.41 CD2
Fentanyl (as Fentanyl citrate) 600 microgram Actiq 600 microgram lozenges with integral oromucosal applicator  |  3 lozenge  Price £21.05 CD2 | 30 lozenge  Price £210.41 CD2
Fentanyl (as Fentanyl citrate) 1.2 mg Actiq 1.2mg lozenges with integral oromucosal applicator  |  3 lozenge  Price £21.05 CD2 | 30 lozenge  Price £210.41 CD2
Fentanyl (as Fentanyl citrate) 1.6 mg Actiq 1.6mg lozenges with integral oromucosal applicator  |  3 lozenge  Price £21.05 CD2 | 30 lozenge  Price £210.41 CD2

## Hydromorphone hydrochloride

### INDICATIONS AND DOSE

#### Severe pain in cancer
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Child 12-17 years: 1.3 mg every 4 hours, dose to be increased if necessary according to severity of pain
  - Adult: 1.3 mg every 4 hours, dose to be increased if necessary according to severity of pain
- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Child 12-17 years: 4 mg every 12 hours, dose to be increased if necessary according to severity of pain
  - Adult: 4 mg every 12 hours, dose to be increased if necessary according to severity of pain

#### CONTRA-INDICATIONS
- Acute abdomen
- Pancreatitis - toxic psychosis

#### SIDE-EFFECTS
- Common or very common Abdominal pain - anorexia - anxiety
- Uncommon Agitation - diarrhoea - dysgeusia - dyskinesia - myoclonus - paraesthesia - paralytic ileus - peripheral oedema - seizures - tremor

#### BREAST FEEDING
- Avoid—no information available.

#### RENAL IMPAIRMENT
- Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.

#### DIRECTIONS FOR ADMINISTRATION
- For immediate-release capsules, swallow whole capsule or sprinkle contents on soft food. For modified-release capsules, swallow whole or open capsule and sprinkle contents on soft cold food (swallow the pellets within the capsule whole; do not crush or chew).

#### PATIENT AND CARER ADVICE
- Patients or carers should be given advice on how to administer hydromorphone hydrochloride capsules and modified-release capsules.

#### MEDICINAL FORMS
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

#### Modified-release capsule
- **CAUTIONARY AND ADVISORY LABELS 2**
- **Palladone SR** (Napp Pharmaceuticals Ltd)
  - Hydromorphone hydrochloride 2 mg Palladone SR 2mg capsules | 56 capsule  Price £20.98 CD2
  - Hydromorphone hydrochloride 4 mg Palladone SR 4mg capsules | 56 capsule  Price £28.75 CD2
  - Hydromorphone hydrochloride 8 mg Palladone SR 8mg capsules | 56 capsule  Price £56.08 CD2
  - Hydromorphone hydrochloride 16 mg Palladone SR 16mg capsules | 156 capsule  Price £106.53 CD2
  - Hydromorphone hydrochloride 24 mg Palladone SR 24mg capsules | 56 capsule  Price £159.82 CD2

### Capsule
- **CAUTIONARY AND ADVISORY LABELS 2**
- **Palladone** (Napp Pharmaceuticals Ltd)
  - Hydromorphone hydrochloride 1.3 mg Palladone 1.3mg capsules | 56 capsule  Price £8.82 CD2
  - Hydromorphone hydrochloride 2.6 mg Palladone 2.6mg capsules | 56 capsule  Price £17.64 CD2

### Meptazinol

#### INDICATIONS AND DOSE
- Moderate to severe pain, including post-operative pain and renal colic
  - **BY MOUTH**
    - Adult: 200 mg every 3–6 hours as required
  - **BY INTRAMUSCULAR INJECTION**
    - Adult: 75–100 mg every 2–4 hours if required
  - **BY SLOW INTRAVENOUS INJECTION**
    - Adult: 50–100 mg every 2–4 hours if required
  - **Obstetric analgesia**
    - **BY INTRAMUSCULAR INJECTION**
      - Adult: 2 mg/kg, usual dose 100–150 mg

#### CONTRA-INDICATIONS
- Myocardial infarction - phaeochromocytoma

#### INTERACTIONS
- **Appendix 1: opioids**

#### SIDE-EFFECTS
- Abdominal pain - can induce withdrawal symptoms in patients dependent on opioids - diarrhoea - dyspepsia - hypothermia

#### OVERDOSE
- Effects only partially reversed by naloxone.

#### BREAST FEEDING
- Use only if potential benefit outweighs risk.

#### RENAL IMPAIRMENT
- Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.

#### MEDICINAL FORMS
- There can be variation in the licensing of different medicines containing the same drug.

#### Solution for injection
- **Meptazinol** (as Meptazinol hydrochloride) 100 mg per
- 1 ml Meptazin 100mg/1ml solution for injection ampoules | 10 ampoule  Price £18.21

#### Tablet
- **CAUTIONARY AND ADVISORY LABELS 2**
- **Meptazinol** (Almirall Ltd)
  - Meptazinol (as Meptazinol hydrochloride) 200 mg Meptazin 200mg tablets | 112 tablet  Price £22.11 DT price = £22.11

### Morphine

#### INDICATIONS AND DOSE

#### Pain
- **BY SUBCUTANEOUS INJECTION**
  - Child 1–5 months: Initially 100–200 micrograms/kg every 6 hours, adjusted according to response
  - Child 6 months-1 year: Initially 100–200 micrograms/kg every 4 hours, adjusted according to response
  - Child 2-11 years: Initially 200 micrograms/kg every 4 hours, adjusted according to response
  - Child 12-17 years: Initially 2.5–10 mg every 4 hours, adjusted according to response
- **INITIALLY BY INTRavenous INJECTION**
  - Child 1-5 months: 100 micrograms/kg every 6 hours, adjusted according to response, dose to be administered over at least 5 minutes, alternatively (by intravenous injection) initially 100 micrograms/kg, dose to be administered over at least continued
5 minutes, followed by (by continuous intravenous infusion) 10–30 micrograms/kg/hour, adjusted according to response
- Child 6 months–11 years: 100 micrograms/kg every 4 hours, adjusted according to response, dose to be administered over at least 5 minutes, alternatively (by intravenous injection) initially 100 micrograms/kg, dose to be administered over at least 5 minutes, followed by (by continuous intravenous infusion) 20–30 micrograms/kg/hour, adjusted according to response
- Child 12–17 years: 5 mg every 4 hours, adjusted according to response, dose to be administered over at least 5 minutes, alternatively (by intravenous injection) initially 5 mg, dose to be administered over at least 5 minutes, followed by (by continuous intravenous infusion) 20–30 micrograms/kg/hour, adjusted according to response
- By mouth, or by rectum
- Child 1–2 months: Initially 50–100 micrograms/kg every 4 hours, adjusted according to response
- Child 3–5 months: 100–150 micrograms/kg every 4 hours, adjusted according to response
- Child 6–11 months: 200 micrograms/kg every 4 hours, adjusted according to response
- Child 1 year: Initially 200–300 micrograms/kg every 4 hours, adjusted according to response
- Child 2–11 years: Initially 200–300 micrograms/kg every 4 hours (max. per dose 10 mg), adjusted according to response
- Child 12–17 years: Initially 5–10 mg every 4 hours, adjusted according to response

Acute pain
- By subcutaneous injection, or by intramuscular injection
- Adult: Initially 10 mg every 4 hours, adjusted according to response, subcutaneous injection not suitable for oedematous patients, dose can be given more frequently during titration, use dose for elderly in frail patients
- Elderly: Initially 5 mg every 4 hours, adjusted according to response, subcutaneous injection not suitable for oedematous patients, dose can be given more frequently during titration
- By slow intravenous injection
- Adult: Initially 5 mg every 4 hours, adjusted according to response, dose can be adjusted more frequently during titration, reduced dose recommended in frail and elderly patients

Chronic pain
- By mouth, or by subcutaneous injection, or by intramuscular injection
- Adult: Initially 5–10 mg every 4 hours, adjusted according to response, subcutaneous injection not suitable for oedematous patients
- By rectum
- Adult: Initially 15–30 mg every 4 hours, adjusted according to response

Pain (with modified-release 12-hourly preparations)
- By mouth using modified-release medicines
- Adult: Every 12 hours, dose adjusted according to daily morphine requirements, dosage requirements should be reviewed if the brand is altered

Pain (with modified-release 24-hourly preparations)
- By mouth using modified-release medicines
- Adult: Every 24 hours, dose adjusted according to daily morphine requirements, dosage requirements should be reviewed if the brand is altered

Pain management in palliative care (starting dose for opioid-naïve patients)
- By mouth
- Adult: 20–30 mg daily in divided doses, using immediate-release preparation 4-hourly or a 12-hourly modified-release preparation, for management of breakthrough pain and other general advice, see Pain management with opioids under p. 23.

Pain management in palliative care (starting dose for patients being switched from a regular weak opioid)
- By mouth
- Adult: 40–60 mg daily in divided doses, using immediate-release preparation 4-hourly or 12-hourly modified-release preparation, for management of breakthrough pain and other general advice, see Pain management with opioids under p. 23.

Pain in palliative care (following initial titration)
- By mouth using immediate-release medicines
- Adult: Usual dose 30 mg every 4 hours; up to 200 mg every 4 hours, higher dose may be required for some patients (occasionally more is needed); for management of breakthrough pain and other general advice, see Pain management with opioids under p. 23.

Pain in palliative care
- By intravenous infusion
- Adult: (consult local protocol)

Myocardial infarction
- By slow intravenous injection
- Adult: 5–10 mg, followed by 5–10 mg if required, dose to be administered at a rate of 1–2 mg/minute, use dose for elderly in frail patients
- Elderly: 2.5–5 mg, followed by 2.5–5 mg if required, dose to be administered at a rate of 1–2 mg/minute

Acute pulmonary oedema
- By slow intravenous injection
- Adult: 5–10 mg, dose to be administered at a rate of 2 mg/minute, use dose for elderly in frail patients
- Elderly: 2.5–5 mg, dose to be administered at a rate of 2 mg/minute

Dyspnoea at rest in palliative care
- By mouth
- Adult: Initially 5 mg every 4 hours, to be given in carefully titrated doses

Dose equivalence and conversion
- The doses stated refer equally to morphine hydrochloride and sulfate.

Unlicensed use
IMPORTANT SAFETY INFORMATION
Do not confuse modified-release 12-hourly preparations with 24-hourly preparations, see Prescribing and dispensing information.

- CONTRA-INDICATIONS Acute abdomen • delayed gastric emptying • heart failure secondary to chronic lung disease • phaeochromocytoma
- CAUTIONS Cardiac arrhythmias • pancreatitis • severe cor pulmonale
- INTERACTIONS ▶ Appendix 1: opioids
- SIDE-EFFECTS Abdominal pain • agitation • amenorrhoea • anorexia • asthenia • bronchospasm • delirium • disorientation • dyspepsia • exacerbation of pancreatitis • excitation • hyperventilation • hypothermia • inhibition of cough reflex • malaise • muscle fasciculation • myoclonus • nystagmus • paraesthesia • paralytic ileus • raised intracranial pressure • restlessness • rhabdomyolysis • seizures • syncope • taste disturbance
- BREAST FEEDING Therapeutic doses unlikely to affect infant.
- RENAL IMPAIRMENT Avoid use or reduce dose; opioid effects increased and prolonged; increased cerebral sensitivity.
- DIRECTIONS FOR ADMINISTRATION ▶ With intravenous use in children For continuous intravenous infusion, dilute with Glucose 5% or 10% or Sodium Chloride 0.9%.
▶ With oral use For modified release capsules—swallow whole or open capsule and sprinkle contents on soft food.
- PRESCRIBING AND DISPENSING INFORMATION Modified-release preparations are available as 12-hourly or 24-hourly formulations; prescribers must ensure that the correct preparation is prescribed. Preparations that should be given 12-hourly include Filmarine® SR, MST Continus® Morphgesic® SR and Zomorph®. Preparations that should be given 24-hourly include MXL®. Prescriptions must specify the ‘form’.
▶ With rectal use Both the strength of the suppositories and the morphine salt contained in them must be specified by the prescriber.

Palliative care For further information on the use of morphine in palliative care, see www.palliativedrugs.com/formulary/en/morphine.html.

- PATIENT AND CARER ADVICE Patients or carers should be given advice on how to administer morphine modified-release capsules.

Medicines for Children leaflet: Morphine for pain www.medicinesforchildren.org.uk/morphine-for-pain

- EXCEPTIONS TO LEGAL CATEGORY Morphine Oral Solutions Prescription-only medicines or schedule 2 controlled drug. The proportion of morphine hydrochloride may be altered when specified by the prescriber; if above 13 mg per 5 mL the solution becomes a schedule 2 controlled drug. It is usual to adjust the strength so that the dose volume is 5 or 10 mL.
Oral solutions of morphine can be prescribed by writing the formula:
Morphine hydrochloride 5 mg Chloroform water to 5 mL.

- MEDICINAL FORMS There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule, oral solution, solution for injection, infusion, solution for infusion, suppository

Modified-release tablet

- CAUTIONARY AND ADVISORY LABELS 2, 25
▶ MST Continus (Napp Pharmaceuticals Ltd)
  Morphine sulfate 5 mg MST Continus 5mg tablets | 60 tablet [PbM] £3.29 DT price = £3.29 [CD2]
  Morphine sulfate 10 mg MST Continus 10mg tablets | 60 tablet [PbM] £5.20 DT price = £5.20 [CD2]
  Morphine sulfate 15 mg MST Continus 15mg tablets | 60 tablet [PbM] £9.10 DT price = £9.10 [CD2]
  Morphine sulfate 30 mg MST Continus 30mg tablets | 60 tablet [PbM] £12.47 DT price = £12.47 [CD2]
  Morphine sulfate 60 mg MST Continus 60mg tablets | 60 tablet [PbM] £24.32 DT price = £24.32 [CD2]
  Morphine sulfate 100 mg MST Continus 100mg tablets | 60 tablet [PbM] £38.50 DT price = £38.50 [CD2]
  Morphine sulfate 200 mg MST Continus 200mg tablets | 60 tablet [PbM] £81.34 DT price = £81.34 [CD2]
  Morphgesic SR (AMCo)
  Morphine sulfate 10 mg Morphgesic SR 10mg tablets | 60 tablet [PbM] £3.85 DT price = £3.85 [CD2]
  Morphine sulfate 30 mg Morphgesic SR 30mg tablets | 60 tablet [PbM] £9.24 DT price = £9.24 [CD2]
  Morphine sulfate 60 mg Morphgesic SR 60mg tablets | 60 tablet [PbM] £18.04 DT price = £18.04 [CD2]
  Morphine sulfate 100 mg Morphgesic SR 100mg tablets | 60 tablet [PbM] £28.54 DT price = £28.54 [CD2]

- Suppository

- Sevodol (Napp Pharmaceuticals Ltd)
  Morphine sulfate 10 mg Sevodol 10mg tablets | 56 tablet [PbM] £5.31 DT price = £5.31 [CD2]
  Morphine sulfate 20 mg Sevodol 20mg tablets | 56 tablet [PbM] £10.61 DT price = £10.61 [CD2]
  Morphine sulfate 50 mg Sevodol 50mg tablets | 56 tablet [PbM] £28.02 DT price = £28.02 [CD2]

Solution for injection
- Morphine (Non-proprietary)
  Morphine sulfate 1 mg per 1 ml Morphine sulfate 5mg/5ml solution for injection ampoules | 10 ampoule [PbM] £35.90 [CD2]
  Morphine sulfate 1mg/1ml solution for injection ampoules | 10 ampoule [PbM] £26.10 [CD2]
  Morphine sulfate 10mg/10ml solution for injection ampoules | 10 ampoule [PbM] £15.00-£38.00 [CD2]
  Morphine sulfate 10 mg per 1 ml Morphine sulfate 10mg/1ml solution for injection ampoules | 10 ampoule [PbM] £9.36 [CD2]
  Morphine sulfate 15 mg per 1 ml Morphine sulfate 15mg/1ml solution for injection ampoules | 10 ampoule [PbM] £8.95 [CD2]
  Morphine sulfate 20 mg per 1 ml Morphine sulfate 20mg/1ml solution for injection ampoules | 10 ampoule [PbM] £54.27 [CD2]
  Morphine sulfate 30 mg per 1 ml Morphine sulfate 30mg/1ml solution for injection ampoules | 10 ampoule [PbM] £8.84 [CD2]
  Morphine sulfate 60mg/2ml solution for injection ampoules | 5 ampoule [PbM] £10.07 [CD2]

- Modified-release capsule

- CAUTIONARY AND ADVISORY LABELS 2
▶ MXL (Napp Pharmaceuticals Ltd)
  Morphine sulfate 30 mg MXL 30mg capsules | 28 capsule [PbM] £10.91 [CD2]
  Morphine sulfate 60 mg MXL 60mg capsules | 28 capsule [PbM] £14.95 [CD2]
  Morphine sulfate 90 mg MXL 90mg capsules | 28 capsule [PbM] £22.04 [CD2]
  Morphine sulfate 120 mg MXL 120mg capsules | 28 capsule [PbM] £29.15 [CD2]
  Morphine sulfate 150 mg MXL 150mg capsules | 28 capsule [PbM] £36.43 [CD2]
Morphine with cyclizine

The properties listed below are those particular to the combination only. For the properties of the components please consider, morphine p. 439, cyclizine p. 409.

- **INDICATIONS AND DOSE**
  
  CYCLIMORPH-10®
  
  Moderate to severe pain (short-term use only)
  
  ▶ BY SUBCUTANEOUS INJECTION, OR BY INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INJECTION
  
  Adult: 1 mL, do not repeat dose more often than every 4 hours; maximum 3 doses per day

  CYCLIMORPH-15®
  
  Moderate to severe pain (short-term use only)
  
  ▶ BY SUBCUTANEOUS INJECTION, OR BY INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INJECTION
  
  Adult: 1 mL, do not repeat dose more often than every 4 hours; maximum 3 doses per day

- **CAUTIONS** Myocardial infarction (cyclizine may aggravate severe heart failure and counteract the haemodynamic benefits of opioids) - not recommended in palliative care

- **INTERACTIONS** → Appendix 1: antihistamines (sedating), opioids

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug.

  Solution for injection
  
  ▶ Cyclimorph (AMCo)
    
    Morphine tartrate 15 mg per 1 mL, Cyclizine tartrate 50 mg per 1 mL
    
    Cyclomorph 15 solution for injection 1 mL ampoules | 5 ampoules | £9.12 (C02)
    
    Morphine tartrate 10 mg per 1 mL, Cyclizine tartrate 50 mg per 1 mL
    
    Cyclomorph 10 solution for injection 1 mL ampoules | 5 ampoules | £8.77 (C02)

- **INDICATIONS AND DOSE**

  Postoperative pain | Severe pain | Moderate to severe pain in palliative care

  ▶ BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

  Adult: Initially 5 mg every 4–6 hours, dose to be increased if necessary according to severity of pain, some patients may require higher doses than the maximum daily dose; maximum 400 mg per day

  ▶ BY MOUTH USING MODIFIED-RELEASE MEDICINES

  Adult: Initially 10 mg every 12 hours (max. per dose 200 mg every 12 hours), dose to be increased if necessary according to severity of pain, some patients might require higher doses than the maximum daily dose

  ▶ BY SLOW INTRAVENOUS INJECTION

  Adult: 1–10 mg every 4 hours as required

  ▶ BY INTRAVENOUS INFUSION

  Adult: Initially 2 mg/hour, adjusted according to response

  ▶ BY SUBCUTANEOUS INJECTION

  Adult: Initially 5 mg every 4 hours as required

  Adult: Initially 7.5 mg/24 hours, adjusted according to response

Patient controlled analgesia (PCA)

▶ BY INTRAVENOUS INFUSION

Adult: (consult local protocol)

DOSE EQUIVALENCE AND CONVERSION

2 mg oral oxycodone is approximately equivalent to 1 mg parenteral oxycodone.

**Oxycodone hydrochloride**

19-May-2017

Severe pain

▶ BY MOUTH

Adult: Initially 10 mg every 24 hours, dose to be increased if necessary according to severity of pain, some patients may require higher doses than the maximum daily dose; maximum 400 mg per day

**IMPORTANT SAFETY INFORMATION**

Do not confuse modified-release 12-hourly preparations with 24-hourly preparations, see Prescribing and dispensing information.

**CONTRA-INDICATIONS** Acute abdomen • chronic constipation • cor pulmonale • delayed gastric emptying

**CAUTIONS** Pancreatitis • toxic psychosis

**INTERACTIONS** → Appendix 1: opioids

**SIDE-EFFECTS**

▶ Common or very common

  Abdominal pain • anorexia • anxiety • asthenia • bronchospasm • chills • diarrhoea • dyspepsia • dysphonia • impaired cough reflex

▶ Uncommon

  Agitation • amnorrhea • anemia • belching • cholestasis • dehydration • disorientation • dry skin • dysphagia • flatulence • gastritis • hiccups • hypoesthesia • hypotonia • malaise • muscle fasciculation • paraesthesia • paralytic ileus • pyrexia • restlessnes • seizures • speech
There can be variation in the licensing of different medicines for pain disorders, such as in the treatment of chronic pain. It is important to follow the guidance of the national regulatory bodies, such as the Scottish Medicines Consortium (SMC), which advises on the licensing of different medicines. For example, Oxycodone hydrochloride 80 mg Oxycodone 80mg modified-release tablets are available in the UK, with different presentations and dosages. The pharmacist should be consulted for specific advice on the appropriate dose and regimen.

### Oxycodone hydrochloride 80 mg Oxycodone 80mg modified-release tablets

<table>
<thead>
<tr>
<th>Tablet</th>
<th>Price</th>
<th>BT price</th>
<th>DT price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carexil 20mg modified-release tablets</td>
<td>£5.08</td>
<td>£5.08</td>
<td>£5.08</td>
</tr>
<tr>
<td>Carexil 40mg modified-release tablets</td>
<td>£10.11</td>
<td>£10.11</td>
<td>£10.11</td>
</tr>
<tr>
<td>Carexil 80mg modified-release tablets</td>
<td>£20.00</td>
<td>£20.00</td>
<td>£20.00</td>
</tr>
<tr>
<td>Carexil 100mg modified-release tablets</td>
<td>£30.00</td>
<td>£30.00</td>
<td>£30.00</td>
</tr>
<tr>
<td>Carexil 120mg modified-release tablets</td>
<td>£40.00</td>
<td>£40.00</td>
<td>£40.00</td>
</tr>
<tr>
<td>Carexil 150mg modified-release tablets</td>
<td>£50.00</td>
<td>£50.00</td>
<td>£50.00</td>
</tr>
</tbody>
</table>

Oxycodone hydrochloride 80 mg Oxycodone 80mg modified-release tablets are available in several presentations, including tablets with different strengths and dosages. The pharmacist should be consulted for specific advice on the appropriate dose and regimen. The cost of the tablets can vary depending on the pharmacy and location. It is important to follow the guidance of the national regulatory bodies, such as the Scottish Medicines Consortium (SMC), which advises on the licensing of different medicines. For example, Oxycodone hydrochloride 80 mg Oxycodone 80mg modified-release tablets are available in the UK, with different presentations and dosages. The pharmacist should be consulted for specific advice on the appropriate dose and regimen.

### Conclusion

In summary, Oxycodone hydrochloride 80 mg Oxycodone 80mg modified-release tablets are available in several presentations, including tablets with different strengths and dosages. The pharmacist should be consulted for specific advice on the appropriate dose and regimen. The cost of the tablets can vary depending on the pharmacy and location. It is important to follow the guidance of the national regulatory bodies, such as the Scottish Medicines Consortium (SMC), which advises on the licensing of different medicines. For example, Oxycodone hydrochloride 80 mg Oxycodone 80mg modified-release tablets are available in the UK, with different presentations and dosages. The pharmacist should be consulted for specific advice on the appropriate dose and regimen.
Oxycodone hydrochloride 60 mg Oxycodone hydrochloride 80 mg Oxycodone hydrochloride 120 mg

Oxycodone hydrochloride 5 mg Oxycodone hydrochloride 10 mg Oxycodone hydrochloride 20 mg

Oxycodone hydrochloride 40 mg Oxycodone hydrochloride 60 mg Oxycodone hydrochloride 80 mg

Oxycodone hydrochloride 5 mg Oxycodone hydrochloride 10 mg Oxycodone hydrochloride 20 mg

Oxycodone hydrochloride 40 mg Oxycodone hydrochloride 60 mg Oxycodone hydrochloride 80 mg

Oxycodone hydrochloride 5 mg Oxycodone hydrochloride 10 mg Oxycodone hydrochloride 20 mg

Oxycodone hydrochloride 40 mg Oxycodone hydrochloride 60 mg Oxycodone hydrochloride 80 mg

Oxycodone hydrochloride 5 mg Oxycodone hydrochloride 10 mg Oxycodone hydrochloride 20 mg

Oxycodone hydrochloride 40 mg Oxycodone hydrochloride 60 mg Oxycodone hydrochloride 80 mg

Oxycodone hydrochloride 5 mg Oxycodone hydrochloride 10 mg Oxycodone hydrochloride 20 mg

Oxycodone hydrochloride 40 mg Oxycodone hydrochloride 60 mg Oxycodone hydrochloride 80 mg

Oxycodone with naloxone

The properties listed below are those particular to the combination only. For the properties of the components please consider, oxycodone hydrochloride p. 442, naloxone hydrochloride p. 1259.

**Indications and dose**

Severe pain requiring opioid analgesia in patients not currently treated with opioid analgesics

- **By mouth**
  - Adult: Initially 10/5 mg every 12 hours (max. per dose 40/20 mg every 12 hours), dose to be increased according to response; patients already receiving opioid analgesics can start with a higher dose.

Second-line treatment of symptomatic severe to very severe idiopathic restless legs syndrome after failure of dopaminergic therapy

- **By mouth**
  - Adult: Initially 5/2.5 mg every 12 hours, adjusted weekly according to response, usual dose 10/5 mg every 12 hours; maximum 60/30 mg per day.

Dose equivalence and conversion

Dose quantities are expressed in the form x/y where x and y are the strengths in milligrams of oxycodone and naloxone respectively.

**Interactions**

Appendix 1: naloxone, opioids
**Pentazocine**

### INDICATIONS AND DOSE

**Moderate to severe pain**

- **By mouth**
  - Adult: 50 mg every 3–4 hours, dose to be taken preferably after food, usual dose 25–100 mg every 3–4 hours; maximum 600 mg per day

**Moderate pain**

- **By subcutaneous injection, or by intramuscular injection, or by intravenous injection**
  - Adult: 30 mg every 3–4 hours as required; maximum 360 mg per day

**Severe pain**

- **By subcutaneous injection, or by intramuscular injection, or by intravenous injection**
  - Adult: 45–60 mg every 3–4 hours as required; maximum 360 mg per day

### CONTRA-INDICATIONS

Acute porphyrias p. 969 · heart failure secondary to chronic lung disease · patients dependent on opioids (can precipitate withdrawal)

### CAUTIONS

Arterial hypertension · cardiac arrhythmias · myocardial infarction · pancreatitis · phaeochromocytoma · pulmonary hypertension

### INTERACTIONS

Appendix 1: opioids

### SIDE-EFFECTS

Abdominal pain · blood disorders · chills · disorientation · hypertension · hypothermia · myalgia · paraesthesia · raised intracranial pressure · seizures · syncope · toxic epidermal necrolysis · tremor

### OVERDOSE

Effects only partially reversed by naloxone.

### BREAST FEEDING

Use with caution—limited information available.

### RENAL IMPAIRMENT

Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.

### LESS SUITABLE FOR PRESCRIBING

Pentazocine is less suitable for prescribing.

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

#### Tablet

- **Pentazocine (Non-proprietary)**
  - Pentazocine hydrochloride 25 mg │ 25 mg tablets | 28 tablet [PO] £24.27 DT price = £24.27 [CD]

#### Capsule

- **Pentazocine (Non-proprietary)**
  - Pentazocine hydrochloride 50 mg │ 50 mg capsules | 28 capsule [PO] £28.50 DT price = £28.50 [CD]
### BY SLOW INTRAVENOUS INJECTION
- Adult: 25–50 mg, then 25–50 mg after 4 hours, for debilitated patients use dose described for elderly patients
- Elderly: Initially 25 mg, then 25–50 mg after 4 hours

### Obstetric analgesia
- BY SUBCUTANEOUS INJECTION, OR BY INTRAMUSCULAR INJECTION
- Adult: 50–100 mg, then 50–100 mg after 1–3 hours if required; maximum 400 mg per day

### Premedication
- BY INTRAMUSCULAR INJECTION
- Adult: 25–100 mg, dose to be given 1 hour before operation, for debilitated patients use dose described for elderly patients
- Elderly, 25 mg, dose to be given 1 hour before operation

### Postoperative pain
- BY SUBCUTANEOUS INJECTION, OR BY INTRAMUSCULAR INJECTION
- Adult: 25–100 mg every 2–3 hours if required, for debilitated patients use dose described for elderly patients
- Elderly: Initially 25 mg every 2–3 hours if required

#### CONTRA-INDICATIONS
- Phaeochromocytoma

#### CAUTIONS
- Accumulation of metabolites may result in neurotoxicity • cardiac arrhythmias • not suitable for severe continuing pain • severe cor pulmonale
- **INTERACTIONS** → Appendix 1: opioids
- **SIDE-EFFECTS**
  - Hypothermia • restlessness • tremor
- **OVERDOSE**
  - Convulsions reported in overdosage.

#### BREAST FEEDING
- Present in milk but not known to be harmful.

#### RENAL IMPAIRMENT
- Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.

#### MEDICINAL FORMS
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule, oral solution, solution for injection

#### Tablet
- **CAUTIONARY AND ADVISORY LABELS** 2
  - Pethidine hydrochloride (Non-proprietary)
    
    | Brand name | Concentration | Price (Cost per item) |
    |------------|---------------|-----------------------|
    | Pethidine hydrochloride 10 mg | | |

#### Solution for injection
- **Pethidine hydrochloride (Non-proprietary)**
  
<table>
<thead>
<tr>
<th>Concentration</th>
<th>Price (Cost per item)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pethidine hydrochloride 10 mg per 1 ml</td>
<td></td>
</tr>
<tr>
<td>Pethidine hydrochloride 50 mg per 1 ml</td>
<td></td>
</tr>
</tbody>
</table>

#### Tapentadol
- **INDICATIONS AND DOSE**
  - Moderate to severe acute pain which can be managed only with opioid analgesics
    - **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
      - Adult: Initially 50 mg every 4–6 hours, adjusted according to response, maximum 700 mg in the first 24 hours, during the first 24 hours of treatment, an additional dose of 50 mg may be taken 1 hour after the initial dose, if pain control not achieved; maximum 600 mg per day
  - **Severe chronic pain**
    - **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
      - Adult: Initially 50 mg every 12 hours, adjusted according to response; maximum 500 mg per day

#### INTERACTIONS
- → Appendix 1: opioids

#### SIDE-EFFECTS
- Abdominal discomfort • anxiety • ataxia • decreased appetite • diarrhoea • dystarthis • dyspepsia • hypoaesthesia • malaise • muscle spasms • paraesthesia • seizures • tremor • weight loss

#### BREAST FEEDING
- Avoid—no information available.
**Postoperative pain**

- **BY INTRAVENOUS INJECTION**
  - Adult: Initially 100 mg, then 50 mg every 10–20 minutes if required up to total maximum 250 mg (including initial dose) in first hour, then 50–100 mg every 4–6 hours, intravenous injection to be given over 2–3 minutes; maximum 600 mg per day

**Moderate to severe pain (with modified-release 12-hourly preparations)**

- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Child 12-17 years: 50–100 mg twice daily, increased if necessary to 150–200 mg twice daily, doses exceeding the usual maximum not generally required; Usual maximum 400 mg/24 hours
  - Adult: 50–100 mg twice daily, increased if necessary to 150–200 mg twice daily, doses exceeding the usual maximum not generally required; Usual maximum 400 mg/24 hours

**Moderate to severe pain (with modified-release 24-hourly preparations)**

- **BY MOUTH USING MODIFIED-RELEASE TABLETS**
  - Child 12-17 years: Initially 150 mg once daily; Usual maximum 400 mg/24 hours
  - Adult: Initially 150 mg once daily, increased if necessary up to 400 mg once daily; Usual maximum 400 mg/24 hours

**ZYDOLO XL**

**Moderate to severe pain**

- **BY MOUTH USING MODIFIED-RELEASE TABLETS**
  - Child 12-17 years: Initially 150 mg once daily, increased if necessary up to 400 mg once daily
  - Adult: Initially 150 mg once daily, increased if necessary up to 400 mg once daily

---

**IMPORTANT SAFETY INFORMATION**

Do not confuse modified-release 12-hourly preparations with 24-hourly preparations, see *Prescribing and dispensing information*.

---

**CONTRA-INDICATIONS**

Acute intoxication with alcohol - acute intoxication with analgesics - acute intoxication with hypnotics - acute intoxication with opioids - not suitable for narcotic withdrawal treatment - uncontrolled epilepsy

**CAUTIONS**

Excessive bronchial secretions - history of epilepsy - use tramadol only if compelling reasons - impaired consciousness - not suitable as a substitute in opioid-dependent patients - not suitable in some types of general anaesthesia - susceptibility to seizures - use tramadol only if compelling reasons

**CAUTIONS, FURTHER INFORMATION**

General anaesthesia - Not recommended for analgesia during potentially light planes of general anaesthesia (possibly increased intra-operative recall reported).

**INTERACTIONS**

Appendix 1: opioids

**SIDE-EFFECTS**

Common or very common - Malaise

Uncommon - Diarrhoea - flatulence - gastritis - retching

Rare - Abnormal coordination - anorexia - anxiety - bronchospasm - changes in appetite - delirium - dyspnœa - hypertension - muscle weakness - nightmares - paraesthesia - seizures - syncope - tremor - wheezing

Frequency not known - Blood disorders - hypoglycaemia - speech disorders

**PREGNANCY**

Embryotoxic in animal studies - manufacturers advise avoid.

**BREAST FEEDING**

Amount probably too small to be harmful, but manufacturer advises avoid.

---

**Tramadol hydrochloride**

**INDICATIONS AND DOSE**

**Moderate to severe pain**

- **BY INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
  - Adult: 50–100 mg every 4–6 hours, intravenous injection to be given over 2–3 minutes

**Moderate to severe acute pain**

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Child 12-17 years: Initially 100 mg, then 50–100 mg every 4–6 hours; Usual maximum 400 mg/24 hours
  - Adult: Initially 100 mg, then 50–100 mg every 4–6 hours; Usual maximum 400 mg/24 hours

**Moderate to severe chronic pain**

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Child 12-17 years: Initially 50 mg, then, adjusted according to response; Usual maximum 400 mg/24 hours
  - Adult: Initially 50 mg, then, adjusted according to response; Usual maximum 400 mg/24 hours
**HEPATIC IMPAIRMENT** Caution (avoid for oral drops) in severe impairment.

**RENAL IMPAIRMENT** Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs. Caution (avoid for oral drops) in severe impairment.

**DIRECTIONS FOR ADMINISTRATION** Tramadol hydrochloride orodispersible tablets should be sucked and then swallowed. May also be dispersed in water. Some tramadol hydrochloride modified-release capsule preparations may be opened and the contents swallowed immediately without chewing—check individual preparations.

For intravenous infusion, dilute in Glucose 5% or Sodium Chloride 0.9%.

**PRESCRIBING AND DISPENSING INFORMATION** Modified-release preparations are available as 12-hourly or 24-hourly formulations. Non-proprietary preparations of modified-release tramadol may be available as either 12-hourly or 24-hourly formulations; prescribers and dispensers must ensure that the correct formulation is prescribed and dispensed. Branded preparations that should be given 12-hourly include Invodol SR®, Malron®, Maneo®, Marol®, Maxitram SR®, Oldaram®, Tilodol SR®, Tradorec XL SR®, Tramulief SR®, Zamadol SR®, Zeridame SR® and Zydol SR®. Preparations that should be given 24-hourly include Tradorec XL®, Zamadol® 24 hr, and Zydol XL®.

**PATIENT AND CARER ADVICE** Patients or carers should be given advice on how to administer tramadol hydrochloride orodispersible tablets.

Medicines for Children leaflet: Tramadol for pain

www.medicinesforchildren.org.uk/tramadol-for-pain

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Modified-release tablet**

**CAUTIONARY AND ADVISORY LABELS 2, 25**

- Tramadol hydrochloride (Non-proprietary)
  - Tramadol hydrochloride 50 mg: Tramadol 50 mg modified-release tablets | 60 tablet (Pom) no price available DT price = £6.60 (CD)
  - Tramadol hydrochloride 100 mg: Tramadol 100 mg modified-release tablets | 60 tablet (Pom) £4.80 (CD)
  - Tramadol hydrochloride 150 mg: Tramadol 150 mg modified-release tablets | 60 tablet (Pom) £5.75 (CD)
  - Tramadol hydrochloride 200 mg: Tramadol 200 mg modified-release tablets | 30 tablet (Pom) no price available (CD) | 60 tablet (Pom) £6.90 (CD)
  - Tramadol hydrochloride 300 mg: Tramadol 300 mg modified-release tablets | 30 tablet (Pom) no price available (CD)
  - Invodol SR (Ennogen Healthcare Ltd)
    - Tramadol hydrochloride 100 mg Invodol SR 100 mg tablets | 60 tablet (Pom) £1.61 (CD)
    - Tramadol hydrochloride 150 mg Invodol SR 150 mg tablets | 60 tablet (Pom) £21.91 (CD)
    - Tramadol hydrochloride 200 mg Invodol SR 200 mg tablets | 60 tablet (Pom) £29.22 (CD)
  - Malron (Morningside Healthcare Ltd)
    - Tramadol hydrochloride 100 mg Malron 100 mg modified-release tablets | 60 tablet (Pom) £8.26 (CD)
    - Tramadol hydrochloride 150 mg Malron 150 mg modified-release tablets | 60 tablet (Pom) £27.39 (CD)
    - Tramadol hydrochloride 200 mg Malron 200 mg modified-release tablets | 60 tablet (Pom) £36.52 (CD)
  - Maneo (Mylan Ltd)
    - Tramadol hydrochloride 100 mg Maneo 100 mg modified-release tablets | 60 tablet (Pom) £6.95 (CD)
    - Tramadol hydrochloride 150 mg Maneo 150 mg modified-release tablets | 60 tablet (Pom) £10.40 (CD)
    - Tramadol hydrochloride 200 mg Maneo 200 mg modified-release tablets | 60 tablet (Pom) £14.20 (CD)

- Marol (Teva UK Ltd)
  - Tramadol hydrochloride 100 mg Marol 100mg modified-release tablets | 60 tablet (Pom) £6.94 (CD)
  - Tramadol hydrochloride 150 mg Marol 150mg modified-release tablets | 60 tablet (Pom) £10.39 (CD)
  - Tramadol hydrochloride 200 mg Marol 200mg modified-release tablets | 60 tablet (Pom) £14.19 (CD)
  - Oldaram (Ranbaxy (UK) Ltd)
    - Tramadol hydrochloride 100 mg Oldaram 100mg modified-release tablets | 60 tablet (Pom) £18.80 (CD)
    - Tramadol hydrochloride 150 mg Oldaram 150mg modified-release tablets | 60 tablet (Pom) £28.21 (CD)
    - Tramadol hydrochloride 200 mg Oldaram 200mg modified-release tablets | 60 tablet (Pom) £37.62 (CD)
  - Tilodol SR (Sandoz Ltd)
    - Tramadol hydrochloride 100 mg Tilodol SR 100 mg tablets | 60 tablet (Pom) £15.52 (CD)
    - Tramadol hydrochloride 150 mg Tilodol SR 150 mg tablets | 60 tablet (Pom) £23.28 (CD)
    - Tramadol hydrochloride 200 mg Tilodol SR 200 mg tablets | 60 tablet (Pom) £31.04 (CD)
  - Tradorec XL (Endo Ventures Ltd)
    - Tramadol hydrochloride 100 mg Tradorec XL 100 mg tablets | 30 tablet (Pom) £14.10 (CD)
    - Tramadol hydrochloride 200 mg Tradorec XL 200 mg tablets | 30 tablet (Pom) £14.98 (CD)
    - Tramadol hydrochloride 300 mg Tradorec XL 300 mg tablets | 30 tablet (Pom) £22.47 (CD)
  - Tramulief SR (AMCo)
    - Tramadol hydrochloride 100 mg Tramulief SR 100 mg tablets | 60 tablet (Pom) £6.98 (CD)
    - Tramadol hydrochloride 150 mg Tramulief SR 150 mg tablets | 60 tablet (Pom) £10.48 (CD)
    - Tramadol hydrochloride 200 mg Tramulief SR 200 mg tablets | 60 tablet (Pom) £14.28 (CD)
  - Zamadol 24hr (Meta Pharmaceuticals Ltd)
    - Tramadol hydrochloride 150 mg Zamadol 24hr 150 mg modified-release tablets | 28 tablet (Pom) £10.70 (CD)
    - Tramadol hydrochloride 200 mg Zamadol 24hr 200 mg modified-release tablets | 28 tablet (Pom) £14.26 (CD)
  - Zeridame SR (Actavis UK Ltd)
    - Tramadol hydrochloride 100 mg Zeridame SR 100 mg tablets | 60 tablet (Pom) £11.72 (CD)
    - Tramadol hydrochloride 150 mg Zeridame SR 150 mg tablets | 60 tablet (Pom) £25.82 (CD)
    - Tramadol hydrochloride 200 mg Zeridame SR 200 mg tablets | 60 tablet (Pom) £34.43 (CD)
  - Zydol SR (Grunenthal Ltd)
    - Tramadol hydrochloride 50 mg Zydol SR 50mg tablets | 60 tablet (Pom) £4.60 DT price = £4.60 (CD)
    - Tramadol hydrochloride 100 mg Zydol SR 100 mg tablets | 60 tablet (Pom) £18.26 (CD)
    - Tramadol hydrochloride 150 mg Zydol SR 150 mg tablets | 60 tablet (Pom) £27.39 (CD)
    - Tramadol hydrochloride 200 mg Zydol SR 200 mg tablets | 60 tablet (Pom) £36.52 (CD)
  - Zydol XL (Grunenthal Ltd)
    - Tramadol hydrochloride 150 mg Zydol XL 150 mg tablets | 30 tablet (Pom) £12.18 (CD)
    - Tramadol hydrochloride 200 mg Zydol XL 200 mg tablets | 30 tablet (Pom) £17.98 (CD)
    - Tramadol hydrochloride 300 mg Zydol XL 300 mg tablets | 30 tablet (Pom) £24.94 (CD)
    - Tramadol hydrochloride 400 mg Zydol XL 400 mg tablets | 30 tablet (Pom) £32.47 (CD)

**Soluble tablet**

**CAUTIONARY AND ADVISORY LABELS 2, 13**

- Zydol (Grunenthal Ltd)
  - Tramadol hydrochloride 50 mg Zydol 50mg soluble tablets sugar-free | 20 tablet (Pom) £2.78 Schedule 3 (CD No Register Exempt Safe Custody) sugar-free | 100 tablet (Pom) £13.33 DT price = £13.33 (CD)

**Solution for injection**

- Tramadol hydrochloride (Non-proprietary)
  - Tramadol hydrochloride 50 mg per 1 ml Tramadol 100mg/2ml solution for injection ampoules | 5 ampoule (Pom) £4.90–£5.65 (CD) | 10 ampoule (Pom) £10.00 (CD)
6.1 Headache

Other drugs used for Headache Clonidine hydrochloride, p. 139 • Sumatriptan, p. 455 • Verapamil hydrochloride, p. 159

ANTIHISTAMINES ▶ SEDATING ANTIHISTAMINES

Pizotifen

- INDICATIONS AND DOSE
  - Prevention of vascular headache | Prevention of classical migraine | Prevention of common migraine | Prevention of cluster headache
  - BY MOUTH
    - Adult: Initially 500 micrograms once daily, then increased to 1.5 mg once daily, dose to be increased gradually and taken at night, alternatively increased to 1.5 mg daily in 3 divided doses, doses to be increased gradually; increased if necessary up to 4.5 mg daily (max. per dose 3 mg), this dose is rarely necessary
  - Prophylaxis of migraine
    - BY MOUTH
      - Child 5-17 years: Initially 500 micrograms once daily, dose to be taken at night, then increased to up to 1.5 mg daily in divided doses, dose to be increased gradually, max. single dose (at night) 1 mg

- UNLICENSED USE
  - 1.5 mg tablets not licensed for use in children.
  - CAUTIONS
    - Avoid abrupt withdrawal - history of epilepsy - susceptibility to angle-closure glaucoma - urinary retention
  - INTERACTIONS ▶ Appendix 1: antihistamines (sedating)
  - SIDE-EFFECTS
    - Common or very common: Dizziness - drowsiness - dry mouth - increased appetite - weight gain
    - Uncommon: Constipation
    - Rare: Agitation - anxiety - arthralgia - depression - hallucination - insomnia - myalgia - paraesthesia
    - Very rare: Rash (in adults) - seizures - urticaria (in adults)
    - Frequency not known: Hepatitis - jaundice - muscle cramps
    - PREGNANCY
      - Avoid unless potential benefit outweighs risk.
    - BREAST FEEDING
      - Amount probably too small to be harmful, but manufacturer advises avoid.
    - HEPATIC IMPAIRMENT
      - Use with caution.
    - RENAL IMPAIRMENT
      - Use with caution.

- PATIENT AND CARER ADVICE
  - Driving and skilled tasks
    - Drowsiness may affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced.
  - Medicines for Children leaflet: Pizotifen to prevent migraine headaches www.medicinesforchildren.org.uk/pizotifen-to-prevent-migraine-headaches

- MEDICINAL FORMS
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

Tablet

- CAUTIONARY AND ADVISORY LABELS
  - Pizotifen (Non-proprietary)

  Pizotifen (as Pizotifen hydrochloride)
  - 500 microgram tablets [28 tablet packs] £8.50 DT price = £2.02
  - Pizotifen (as Pizotifen hydrogen malate) 1.5 mg tablets [28 tablet packs] £9.50 DT price = £2.01

- MEDICATION FORMS

  - Zamadol (Meda Pharmaceuticals Ltd)
    - Tramadol hydrochloride 50 mg per 1 ml
    - Zamadol 100mg/2ml solution for injection ampoules | 5 ampoule packs [Pom] £5.49 [CD]
  - Zydol (Grunenthal Ltd)
    - Tramadol hydrochloride 50 mg per 1 ml
    - Zydol 100mg/2ml solution for injection ampoules | 5 ampoule packs [Pom] £4.00 [CD]

Modified-release capsule

- CAUTIONARY AND ADVISORY LABELS
  - Zamadol hydrochloride (Non-proprietary)
    - Tramadol hydrochloride 50 mg
      - Tramadol 50mg modified-release capsules | 60 capsule packs [Pom] £7.24 DT price = £7.24 [CD]
    - Tramadol hydrochloride 100 mg
      - Tramadol 100mg modified-release capsules | 60 capsule packs [Pom] £14.47 DT price = £14.47 [CD]
    - Tramadol hydrochloride 150 mg
      - Tramadol 150mg modified-release capsules | 60 capsule packs [Pom] £21.71 DT price = £21.71 [CD]
    - Tramadol hydrochloride 200 mg
      - Tramadol 200mg modified-release capsules | 60 capsule packs [Pom] £28.93 DT price = £28.93 [CD]
  - Maxitram SR (Chiesi Ltd)
    - Tramadol hydrochloride 50 mg
      - Maxitram SR 50mg capsules | 60 capsule packs [Pom] £4.55 DT price = £7.24 [CD]
    - Tramadol hydrochloride 100 mg
      - Maxitram SR 100mg capsules | 60 capsule packs [Pom] £12.14 DT price = £14.47 [CD]
    - Tramadol hydrochloride 150 mg
      - Maxitram SR 150mg capsules | 60 capsule packs [Pom] £18.21 DT price = £21.71 [CD]
    - Tramadol hydrochloride 200 mg
      - Maxitram SR 200mg capsules | 60 capsule packs [Pom] £24.28 DT price = £28.93 [CD]
  - Tramquel SR (Beechmere Pharmaceuticals Ltd)
    - Tramadol hydrochloride 50 mg
      - Tramquel SR 50mg capsules | 60 capsule packs [Pom] £7.24 DT price = £7.24 [CD]
    - Tramadol hydrochloride 100 mg
      - Tramquel SR 100mg capsules | 60 capsule packs [Pom] £14.47 DT price = £14.47 [CD]
    - Tramadol hydrochloride 150 mg
      - Tramquel SR 150mg capsules | 60 capsule packs [Pom] £21.71 DT price = £21.71 [CD]
    - Tramadol hydrochloride 200 mg
      - Tramquel SR 200mg capsules | 60 capsule packs [Pom] £28.93 DT price = £28.93 [CD]
  - Zamadol SR (Meda Pharmaceuticals Ltd)
    - Tramadol hydrochloride 50 mg
      - Zamadol SR 50mg capsules | 60 capsule packs [Pom] £7.24 DT price = £7.24 [CD]
    - Tramadol hydrochloride 100 mg
      - Zamadol SR 100mg capsules | 60 capsule packs [Pom] £14.47 DT price = £14.47 [CD]
    - Tramadol hydrochloride 150 mg
      - Zamadol SR 150mg capsules | 60 capsule packs [Pom] £21.71 DT price = £21.71 [CD]
    - Tramadol hydrochloride 200 mg
      - Zamadol SR 200mg capsules | 60 capsule packs [Pom] £28.93 DT price = £28.93 [CD]

Oral drops

- CAUTIONARY AND ADVISORY LABELS
  - Tramadol hydrochloride (Non-proprietary)
    - Tramadol (as Tramadol hydrochloride) 100 mg per 1 ml
      - Tramadol 100mg/ml oral drops | 10 ml packs [Pom] £3.50 DT price = £3.50 [CD]

Capsule

- CAUTIONARY AND ADVISORY LABELS
  - Tramadol hydrochloride (Non-proprietary)
    - Tramadol hydrochloride 50 mg
      - Tramadol 50mg capsules | 30 capsule packs [Pom] £4.71 DT price = £0.86 [CD]
    - 100 capsule packs [Pom] £14.40 DT price = £2.87 [CD]
    - Zamadol (Meda Pharmaceuticals Ltd)
      - Tramadol hydrochloride 50 mg
        - Zamadol 50mg capsules | 100 capsule packs [Pom] £8.00 DT price = £2.87 [CD]
    - Zydol (Grunenthal Ltd)
      - Tramadol hydrochloride 50 mg
        - Zydol 50mg capsules | 30 capsule packs [Pom] £2.29 DT price = £0.86 [CD]
        - 100 capsule packs [Pom] £7.63 DT price = £2.87 [CD]

Orodispersible tablet

- CAUTIONARY AND ADVISORY LABELS
  - Tramadol hydrochloride (Non-proprietary)
    - Tramadol hydrochloride 50 mg
      - Tramadol 50mg orodispersible tablets sugar free sugar-free | 60 tablet packs [Pom] no price available [CD]
    - Zamadol Melt (Meda Pharmaceuticals Ltd)
      - Tramadol hydrochloride 50 mg
        - Zamadol Melt 50mg tablets sugar-free | 60 tablet packs [Pom] £7.12 [CD]

Combinations available: Paracetamol with tramadol, p. 424
Migraine

Treatment of acute migraine

Treatment of a migraine attack should be guided by response to previous treatment and the severity of the attacks. A simple analgesic such as aspirin p. 117, paracetamol p. 422 (preferably in a soluble or dispersible form) or a NSAID is often effective; concomitant antiemetic treatment may be required. If treatment with an analgesic is inadequate, an NSAID is often effective; concomitant (preferably in a soluble or dispersible form) or a NSAID is therefore preferred.

Prophylaxis of migraine

Where migraine attacks are frequent, possible provoking factors such as stress, irregular life-style (e.g. lack of sleep), or chemical triggers (e.g. alcohol and nitrates) should be sought; combined oral contraceptives may also provoke migraine.

Preventive treatment for migraine should be considered for patients who:

- suffer at least two attacks a month;
- suffer an increasing frequency of headaches;
- suffer significant disability despite suitable treatment for migraine attacks;
- cannot take suitable treatment for migraine attacks.

Prophylaxis is also necessary in some rare migraine subtypes and those at risk of migrainean infarction.

The beta-blockers propranolol hydrochloride p. 145, atenolol p. 147, metoprolol tartrate p. 149, nadolol p. 144, and timolol maleate p. 146 are all effective. Propranolol hydrochloride is the most commonly used. Tricyclic antidepressants [unlicensed indication], topiramate p. 315, sodium valproate p. 312 [unlicensed indication], valproic acid p. 337 [unlicensed indication], and gabapentin p. 301 [unlicensed indication] are also effective for preventing migraine.

Botulinum toxin type A is licensed for the prophylaxis of headaches in adults with chronic migraine.

Cluster headache and the trigeminal autonomic cephalalgias

Cluster headache rarely responds to standard analgesics. Sumatriptan given by subcutaneous injection is the drug of choice for the treatment of cluster headache. If an injection is unsuitable, sumatriptan nasal spray or zolmitriptan nasal spray [both unlicensed use] may be used. Alternatively, 100% oxygen at a rate of 10–15 litres/minute for 10–20 minutes is useful in aborting an attack.

Prophylaxis of cluster headache is considered if the attacks are frequent, last over 3 weeks, or if they cannot be treated effectively. Verapamil hydrochloride p. 159 or lithium [both unlicensed use] are used for prophylaxis.

Prednisolone p. 639 can be used for short-term prophylaxis of episodic cluster headache [unlicensed use] either as monotherapy, or in combination with verapamil hydrochloride during verapamil titration.

Ergotamine tartrate, used on an intermittent basis is an alternative for patients with short bouts, but it should not be used for prolonged periods.

The other trigeminal autonomic cephalalgias, paroxysmal hemicrania (sensitive to indometacin p. 1043), and short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing, are seen rarely and are best managed by a specialist.

Other drugs used for Migraine

- Amitriptyline hydrochloride, p. 355
- Botulinum toxin type A, p. 387
- Clonidine hydrochloride, p. 139
- Flurphenazine, p. 372
**ANALGESICS > NON-OPIOID**

### Paracetamol with isometheptene

The properties listed below are those particular to the combination only. For the properties of the components please consider, paracetamol p. 422.

#### INDICATIONS AND DOSE

**Treatment of acute attacks of migraine**

- **BY MOUTH**
  - Adult: 2 capsules, dose to be taken at onset of attack, followed by 1 capsule every 1 hour if required, maximum of 5 capsules in 12 hours

#### INTERACTIONS

- **Appendix 1: isometheptene, paracetamol**

#### PATIENT AND CARER ADVICE

Patient counselling is advised (dosage).

#### LESS SUITABLE FOR PRESCRIBING

Isometheptene with paracetamol is less suitable for prescribing (more effective treatments available).

#### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

- **Capsule**
  - CAUTIONARY AND ADVISORY LABELS 30
    - Midrid (DHP Healthcare Ltd)
      - Isometheptene mucate 65 mg, Paracetamol 325 mg
      
  - **Powder**
    - CAUTIONARY AND ADVISORY LABELS 13, 21, 32
      - Migramax (Zentiva)
        - Metoclopramide hydrochloride 10 mg, Aspirin DL-Lysine
        - 900 mg
        
#### IMPORTANT SAFETY INFORMATION

Metoclopramide can cause severe extrapyramidal effects, particularly in children and young adults.

### Paracetamol with metoclopramide

The properties listed below are those particular to the combination only. For the properties of the components please consider, paracetamol p. 422, metoclopramide hydrochloride p. 411.

#### INDICATIONS AND DOSE

**Acute migraine**

- **BY MOUTH USING TABLETS**
  - Adult: 2 tablets, to be taken at the onset of attack, followed by 2 tablets every 4 hours if required; maximum 6 tablets per day

- **BY MOUTH USING EFFERVESCENT POWDER SACHETS**
  - Adult: 2 sachets, to be taken at the onset of attack, followed by 2 sachets every 4 hours if required, sachets to be dissolved in a quarter tumblerful of water; maximum 6 sachets per day

#### IMPORTANT SAFETY INFORMATION

Metoclopramide can cause severe extrapyramidal effects, particularly in young adults.

- **CAUTIONS**
  - Treatment should not exceed 3 months due to risk of tardive dyskinesia

- **INTERACTIONS**
  - **Appendix 1**: metoclopramide, paracetamol

#### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

- **Powder**
  - CAUTIONARY AND ADVISORY LABELS 13, 21, 32
    - Migramax (Zentiva)
      - Metoclopramide hydrochloride 10 mg, Aspirin DL-Lysine
        - 900 mg
        
#### IMPORTANT SAFETY INFORMATION

Metoclopramide can cause severe extrapyramidal effects, particularly in children and young adults.

- **CAUTIONS**
  - Treatment should not exceed 3 months due to risk of tardive dyskinesia

- **INTERACTIONS**
  - **Appendix 1**: aspirin, metoclopramide

- **PRESCRIBING AND DISPENSING INFORMATION**
  - Flavours of oral powder formulations may include lemon.

#### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

- **Powder**
  - CAUTIONARY AND ADVISORY LABELS 13, 21, 32
    - Migramax (Zentiva)
      - Metoclopramide hydrochloride 10 mg, Aspirin DL-Lysine
        - 900 mg
        
#### Tolfenamic acid

#### INDICATIONS AND DOSE

**Treatment of acute migraine**

- **BY MOUTH**
  - Adult: 200 mg, dose to be taken at onset, then 200 mg after 1–2 hours if required

- **CONTRA-INDICATIONS**
  - Active gastro-intestinal bleeding · active gastro-intestinal ulceration · history of gastro-intestinal bleeding related to previous NSAID therapy · history of gastro-intestinal haemorrhage (two or more distinct episodes) · history of gastro-intestinal perforation related to previous NSAID therapy · history of recurrent gastro-intestinal ulceration (two or more distinct episodes) · severe heart failure

- **CAUTIONS**
  - Allergic disorders · cardiac impairment (NSAIDs may impair renal function) · cerebrovascular disease · coagulation defects · connective-tissue disorders · Crohn’s disease (may be exacerbated) · elderly (risk of serious side-effects and fatalities) · heart failure · ischaemic heart disease · peripheral arterial disease · risk factors for cardiovascular events · ulcerative colitis (may be exacerbated) · uncontrolled hypertension

- **INTERACTIONS**
  - **Appendix 1**: NSAIDs

- **SIDE-EFFECTS**
  - Rare: Alveolitis · aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) · hepatic damage · interstitial fibrosis associated with NSAIDs can lead to renal failure · pancreatitis · papillary necrosis associated with NSAIDs can lead to renal failure ·

Downloaded from www.medicalbr.com
pulmonary eosinophilia · Stevens-Johnson syndrome · toxic epidermal necrolysis

- **Frequency not known** Angioedema · blood disorders · bronchospasm · colitis (induction of or exacerbation of) · confusion · Crohn’s disease (induction of or exacerbation of) · depression · diarrhoea · dizziness · drowsiness · dysuria (most commonly in men) · euphoria · fluid retention (rarely precipitating congestive heart failure) · gastro-intestinal bleeding · gastro-intestinal discomfort · gastro-intestinal disturbances · gastro-intestinal ulceration · haematuria · hallucination · headache · hearing disturbances · hypersensitivity reactions · insomnia · malaise · nausea · nervousness · paraesthesia · photosensitivity · raised blood pressure · rashes · renal failure (especially in patients with pre-existing renal impairment) · tinnitus · tremor · vertigo · visual disturbances

**SIDE-EFFECTS, FURTHER INFORMATION**

- Serious side-effects For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 1028.
- **ALLERGY AND CROSS-SENSITIVITY** Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.
- **CONCEPTION AND CONTRACEPTION** Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.
- **PREGNANCY** Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.
- **BREAST FEEDING** Amount too small to be harmful. Use with caution during breast-feeding.
- **HEPATIC IMPAIRMENT** Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.
- **RENAL IMPAIRMENT** The lowest effective dose should be used for the shortest possible duration. Avoid if possible or use with caution. In renal impairment monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS 21**
- **Tolfenamic acid (Non-proprietary)**
  - Tolfenamic acid 200 mg Tolfenamic acid 200mg tablets 10 tablet [PoM] £19.25 DT price = £19.25
  - Clotam Rapid (Galen Ltd)
    - Tolfenamic acid 200 mg Clotam Rapid 200mg tablets 10 tablet [PoM] £12.75 DT price = £12.75

**ANTIHISTAMINES › SEDATING ANTIHISTAMINES**

- **Paracetamol with buclizine hydrochloride and codeine phosphate**

  The properties listed below are those particular to the combination only. For the properties of the components please consider, paracetamol p. 422, codeine phosphate p. 431.

**INDICATIONS AND DOSE**

**MIGRALEVE ®**

**Acute migraine**

- **BY MOUTH**
  - Child 12-14 years: Initially 1 tablet, (pink tablet) to be taken at onset of attack, or if it is imminent, followed by 1 tablet every 4 hours if required, (yellow tablet) to be taken following initial dose; maximum 1 pink and 3 yellow tablets in 24 hours
  - Child 15-17 years: Initially 2 tablets, (pink tablets) to be taken at onset of attack or if it is imminent, followed by 2 tablets every 4 hours if required, (yellow tablets) to be taken following initial dose; maximum 2 pink and 6 yellow tablets in 24 hours
  - Adult: Initially 2 tablets, (pink tablets) to be taken at onset of attack or if it is imminent, followed by 2 tablets every 4 hours if required, (yellow tablets) to be taken following initial dose; maximum 2 pink and 6 yellow tablets in 24 hours

**INTERACTIONS** → Appendix 1: antihistamines (sedating), opioids, paracetamol

**LESS SUITABLE FOR PRESCRIBING**

**MIGRALEVE ®** Migrave ® is less suitable for prescribing.

**ERGOT ALKALOIDS**

**Ergotamine tartrate**

- **INDICATIONS AND DOSE**

  Management of cluster headache

  - **BY MOUTH USING TABLETS**
    - Adult: 1 mg once daily for 6 nights in 7; occasionally given for 1–2 weeks, dose to be taken at night

- **UNLICENSED USE** Not licensed for the management of cluster headache.

- **CONTRA-INDICATIONS** Acute porphyrias p. 969 · coronary heart disease · hyperthyroidism · inadequately controlled hypertension · oblitative vascular disease · peripheral vascular disease · Raynaud’s syndrome · sepsis · severe hypertension · temporal arteritis

- **CAUTIONS** Anaemia · cardiac disease · dependence · elderly · risk of peripheral vasospasm

- **INTERACTIONS** → Appendix 1: ergotamine

- **SIDE-EFFECTS**

  - **Common or very common** Abdominal pain · dizziness · nausea · vomiting
  - **Uncommon** Cyanosis · diarrhoea · hypoaesthesia · pain in extremities · paraesthesia · peripheral vasoconstriction · weakness in extremities
  - **Rare** Arrhythmias · bradycardia · dyspnoea · ergotism (including absence of pulse and numbness in extremities) · increased blood pressure · intestinal ischaemia · myalgia · rash · tachycardia · urticaria
  - **Very rare** Gangrene · heart-valve fibrosis · myocardial infarction · myocardial ischaemia
Ergotamine tartrate with caffeine hydrate and cyclizine hydrochloride

The properties listed below are those particular to the combination only. For the properties of the components please consider, ergotamine tartrate p. 452, cyclizine p. 409.

- **INDICATIONS AND DOSE**
  - **Treatment of acute migraine and migraine variants unresponsive to analgesics**
    - **BY MOUTH**
    - Adult: 1 tablet, to be taken at onset, followed by 0.5–1 tablet after 30 minutes, then 0.5–1 tablet every 30 minutes if required, max. 3 tablets in 24 hours, max. 4 tablets per attack, max. 6 tablets in one week
  - **INTERACTIONS** → Appendix 1: antihistamines (sedating), ergotamine
  - **PATIENT AND CARER ADVICE** Patient counselling is advised for cyclizine hydrochloride with caffeine hydrate and ergotamine tartrate tablets (dosage).
  - **LESS SUITABLE FOR PRESCRIBING** Cyclizine hydrochloride with caffeine hydrate and ergotamine tartrate (Migrel®) is less suitable for prescribing.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. No licensed medicines listed.

**INDICATIONS AND DOSE**

**Treatment of acute migraine and migraine variants unresponsive to analgesics**

**BY MOUTH**

- Adult: 12.5 mg, dose to be taken as soon as possible after onset, followed by 12.5 mg after 2 hours if required, dose to be taken only if migraine recurs (patient not responding to initial dose should not take second dose for same attack); maximum 25 mg per day

**Unlicensed Use**

- Not licensed for use in elderly.

**Contra-Indications**

- Coronary vasospasm - ischaemic heart disease - peripheral vascular disease - previous cerebrovascular accident - previous myocardial infarction - previous transient ischaemic attack - Prinzmetal’s angina - severe hypertension - uncontrolled hypertension

**CAUTIONS**

- Conditions which predispose to coronary artery disease - elderly

**INTERACTIONS** → Appendix 1: almotriptan

**SIDE-EFFECTS**

- Very rare Myocardial infarction - tachycardia

**FURTHER INFORMATION**

- Sensations of tingling, heat, heaviness, pressure, or tightness of any part of the body may occur (including throat and chest — discontinue if intense, may be due to coronary vasocstriction or to anaphylaxis).
Nervous system

UNCOMMON IMPAIRMENT

Common or very common

SIDE-EFFECTS

INTERACTIONS

PREGNANCY

CONTRA-INDICATIONS

LICENSED USE

INTERACTIONS

PREGNANCY

CONTRA-INDICATIONS

LICENSED USE

INTERACTIONS

PREGNANCY

CONTRA-INDICATIONS

LICENSED USE

INTERACTIONS

PREGNANCY

CONTRA-INDICATIONS

LICENSED USE

INTERACTIONS

SIDE-EFFECTS

• CAUTIONS Conditions which predispose to coronary artery disease • elderly

• INTERACTIONS → Appendix 1: eletriptan

• SIDE-EFFECTS

• Common or very common Abdominal pain • drowsiness • dry mouth • dyspepsia • headache • myalgia • myasthenia • palpitation • pharyngitis • rhinitis • sweating • tachycardia

• Uncommon Agitation • anorexia • arthralgia • confusion • depersonalisation • depression • diarrhoea • dysarthria • dysphonia • euphoria • glossitis • hypertonia • insomn

ia • movement disorders • oedema • photophobia • pruritus • rash • shoo • taste disturbance • thirst • tinnitus • tremor • vertigo

• Rare Asthma • bradycardia • constipation • lymphadenopathy • menorrhagia • oesophagitis • syncope

Frovatriptan

• INDICATIONS AND DOSE

Treatment of acute migraine

• BY MOUTH

• Adult: 2.5 mg, dose to be taken as soon as possible after onset, followed by 2.5 mg after 2 hours if required, dose to be taken only if migraine recurs (patient not responding to initial dose should not take second dose for same attack); maximum 5 mg per day

• UNLICENSED USE Not licensed for use in elderly.

• CONTRA-INDICATIONS Coronary vasospasm • ischaemic heart disease • peripheral vascular disease • previous cerebrovascular attack • previous myocardial infarction • previous transient ischaemic attack • Prinzmetal’s angina • severe hypertension • uncontrolled hypertension

• CAUTIONS Conditions which predispose to coronary artery disease • elderly

• INTERACTIONS → Appendix 1: frovatriptan

• SIDE-EFFECTS

• Common or very common Abdominal pain • drowsiness • dry mouth • dyspepsia • headache • paraesthesia • sweating • visual disturbances

• Uncommon Agitation • anxiety • arthralgia • asthenia • confusion • dehydration • depersonalisation • depression • diarrhoea • dysphagia • flatulence • hypertension • impaired concentration • insomnia • laryngitis • micturition disorders • muscle stiffness • nervousness • palpitation • pharyngitis • pruritus • rhinitis • sinusitis • tachycardia • taste disturbances • thirst • tinnitus • tremor • vertigo

• Rare Abnormal dreams • anemia • bilirubinaemia • bradycardia • breast tenderness • constipation • epistaxis • gastro-esophageal reflux • hiccups • hypertension • hyperventilation • hypocalcaemia • hypoglycaemia • hypotonia • irritable bowel syndrome • peptic ulcer • purpura • pyrexia • stomatitis • urticaria

• Frequency not known Dizziness • fatigue • feeling of weakness • flushing • nausea • vomiting

SIDE-EFFECTS, FURTHER INFORMATION

Sensations of tingling, heat, heaviness, pressure, or tightness of any part of the body may occur (including throat and chest—discontinue if intense, may be due to coronary vasoconstriction or to anaphylaxis).

• PREGNANCY There is limited experience of using 5HT1 receptor agonists during pregnancy; manufacturers advise that they should be avoided unless the potential benefit outweighs the risk.

• BREAST FEEDING Present in milk—in avoid breast-feeding for 24 hours.

• HEPATIC IMPAIRMENT Avoid in severe impairment.

• MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Table

CAUTIONARY AND ADVISORY LABELS 3

• Frovatriptan (Non-proprietary)

| Frovatriptan (as Frovatriptan succinate monohydrate) 2.5 mg | Relpar (Pfizer Ltd) | £22.50 DT price = £22.50 |
| Frovatriptan (as Eletriptan hydrobromide) 40 mg | Relpar 20mg tablets | £22.50 DT price = £22.50 |

Naratriptan

• INDICATIONS AND DOSE

Treatment of acute migraine

• BY MOUTH

• Adult: 2.5 mg, followed by 2.5 mg after at least 4 hours if required, to be taken only if migraine recurs (patient not responding to initial dose should not take second dose for same attack); maximum 5 mg per day

• UNLICENSED USE Not licensed for use in elderly.

• CONTRA-INDICATIONS Coronary vasospasm • ischaemic heart disease • moderate or severe hypertension • peripheral vascular disease • previous cerebrovascular accident • previous myocardial infarction • previous transient ischaemic attack • Prinzmetal’s angina • uncontrolled hypertension

• CAUTIONS Conditions which predispose to coronary artery disease • elderly

• INTERACTIONS → Appendix 1: naratriptan

• SIDE-EFFECTS

• Uncommon Bradycardia • palpitation • tachycardia • visual disturbance

• Rare Ischaemic colitis • pruritus • rash
Rizatriptan

INDICATIONS AND DOSE

Treatment of acute migraine

BY MOUTH

Adult: 10 mg, dose to be taken as soon as possible after onset, followed by 10 mg after 2 hours if required, dose to be taken only if migraine recurs (patient not responding to initial dose should not take second dose for same attack); maximum 20 mg per day

DOSE ADJUSTMENTS DUE TO INTERACTIONS

Manufacturer advises reduce dose to 5 mg with concurrent use of propranolol.

UNLICENSED USE

Not licensed for use in elderly.

CONTRA-INDICATIONS

Coronary vasospasm · ischaemic heart disease · peripheral vascular disease · previous cerebrovascular accident · previous myocardial infarction · previous transient ischaemic attack · Prinzmetal’s angina · severe hypertension · uncontrolled hypertension

CAUTIONS

Conditions which predispose to coronary artery disease · elderly

INTERACTIONS → Appendix 1: rizatriptan

SIDE-EFFECTS

Common or very common · Decreased alertness · diarrhoea · drowsiness · dry mouth · dyspepsia · headache · palpitation · paraesthesia · pharyngeal discomfort · sweating · tachycardia · tremor

Uncommon · Arrhythmias · ataxia · blurred vision · confusion · dyspepsia · hypertension · insomnia · muscle weakness · myalgia · nervousness · pruritus · taste disturbances · thirst · urticaria · vertigo

Rare · Bradycardia · syncope

Sumatriptan

INDICATIONS AND DOSE

Treatment of acute migraine

BY MOUTH

Adult: Initially 50–100 mg for 1 dose, followed by 50–100 mg after at least 2 hours if required, to be taken only if migraine recurs (patient not responding to initial dose should not take second dose for same attack); maximum 300 mg per day

SIDE-EFFECTS, FURTHER INFORMATION

Sensations of tingling, heat, heaviness, pressure, or tightness of any part of the body may occur (including throat and chest—discontinue if intense, may be due to coronary vasocostriction or to anaphylaxis).

ALLERGY AND CROSS-SENSITIVITY

Caution in patients with sensitivity to sulphonamides.

PREGNANCY

There is limited experience of using 5HT₁-receptor agonists during pregnancy; manufacturers advise that they should be avoided unless the potential benefit outweighs the risk.

BREAST FEEDING

Withhold breast-feeding for 24 hours.

HEPATIC IMPAIRMENT

Max. 2.5 mg in 24 hours in moderate impairment. Avoid if severe.

RENAL IMPAIRMENT

Max. 2.5 mg in 24 hours. Avoid if eGFR less than 15 mL/minute/1.73 m².

PATIENT AND CARER ADVICE

Driving and skilled tasks

Drowsiness may affect performance of skilled tasks (e.g. driving).

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS 3

Naratriptan (Non-proprietary)

Naratriptan (as Naratriptan hydrochloride) 2.5 mg Naratriptan 2.5mg tablets | 6 tablet [POM] £24.75 DT price = £4.21 | 12 tablet [POM] £46.00

Naramig (GlaxoSmithKline UK Ltd)

Naratriptan (as Naratriptan hydrochloride) 2.5 mg Naramig 2.5mg tablets | 6 tablet [POM] £24.55 DT price = £4.21

Orodispersible tablet

CAUTIONARY AND ADVISORY LABELS 3

EXCIPIENTS: May contain Aspartame

Rizatriptan (Non-proprietary)

Rizatriptan (as Rizatriptan benzoate) 10 mg Rizatriptan 10mg orodispersible tablets sugar free sugar-free | 3 tablet [POM] £2.48 DT price = £2.32 sugar-free | 6 tablet [POM] £4.95

Tablet

CAUTIONARY AND ADVISORY LABELS 3

Rizatriptan (Non-proprietary)

Rizatriptan (as Rizatriptan benzoate) 5 mg Rizatriptan 5mg tablets | 3 tablet [POM] £13.37 | 6 tablet [POM] £26.74 DT price = £26.74

Rizatriptan (as Rizatriptan benzoate) 10 mg Rizatriptan 10mg tablets | 3 tablet [POM] £13.37 DT price = £1.57 | 6 tablet [POM] £26.74

Maxalt (Merck Sharp & Dohme Ltd)

Rizatriptan (as Rizatriptan benzoate) 5 mg Maxalt 5mg tablets | 6 tablet [POM] £26.74 DT price = £26.74

Rizatriptan (as Rizatriptan benzoate) 10 mg Maxalt 10mg tablets | 3 tablet [POM] £13.37 DT price = £1.57 | 6 tablet [POM] £26.74

Oral lyophilisate

CAUTIONARY AND ADVISORY LABELS 3

EXCIPIENTS: May contain Aspartame

Maxalt Melt (Merck Sharp & Dohme Ltd)

Rizatriptan (as Rizatriptan benzoate) 10 mg Maxalt Melt 10mg oral lyophilisates sugar-free | 3 tablet [POM] £13.37 sugar-free | 6 tablet [POM] £26.74 DT price = £26.74 sugar-free | 12 tablet [POM] £53.48

BNF 74

Migraine 455

Nervous system
Nervous system

Contra-indications

With intranasal use

Al lergy and cross-sensitivity

Pregnancy

Cautions

Interactions

By intranasal administration

Adult 18-65 years: Initially 10–20 mg, to be administered into one nostril, followed by 10–20 mg after at least 2 hours if required, to be taken only if migraine recurs (patient not responding to initial dose should not take second dose for same attack); maximum 40 mg per day

Treatment of acute cluster headache

By subcutaneous injection

Adult: Initially 6 mg for 1 dose, followed by 6 mg after at least 1 hour if required, to be taken only if migraine recurs (patient not responding to initial dose should not take second dose for same attack), dose to be administered using an auto-injector; not for intravenous injection which may cause coronary vasospasm and angina; maximum 12 mg per day

By intranasal administration

Adult 18–65 years: Initially 10–20 mg, to be administered into one nostril, followed by 10–20 mg after at least 2 hours if required, to be taken only if migraine recurs (patient not responding to initial dose should not take second dose for same attack); maximum 40 mg per day

Solution for injection

CAUTIONARY AND ADVISORY LABELS 3, 10

Sumatriptan (as Sumatriptan succinate) 12 mg per 1 ml

Sumatriptan (as Sumatriptan succinate) 100 mg per 1 ml

Spray

CAUTIONARY AND ADVISORY LABELS 3, 10

Imigran (GlaxoSmithKline UK Ltd)

Sumatriptan 100 mg per 1 ml Imigran 10mg nas al spray | 2 unit dose PT | 2 pre-filled disposable injection | £48.00 DT price = £39.50

Imigran Subject (GlaxoSmithKline UK Ltd)

Sumatriptan (as Sumatriptan succinate) 12 mg per 1 ml Imigran Subject 6mg/0.5ml solution for injection syringe refill pack | 2 pre-filled disposable injection PT | £40.41 DT price = £40.41

Imigran Subject 6mg/0.5ml solution for injection syringe with device | 2 pre-filled disposable injection PT | £50.96 DT price = £50.96

Tablet

CAUTIONARY AND ADVISORY LABELS 3, 10

Imigran (GlaxoSmithKline UK Ltd, Forest Laboratories UK Ltd)

Sumatriptan (as Sumatriptan succinate) 50 mg

Sumatriptan (as Sumatriptan succinate) 100 mg

Imigran (GlaxoSmithKline UK Ltd, Forest Laboratories UK Ltd)

Imigran (GlaxoSmithKline UK Ltd, Forest Laboratories UK Ltd)

Imigran (GlaxoSmithKline UK Ltd, Forest Laboratories UK Ltd)

Migraitan (Bristol Laboratories Ltd)

Zolmitriptan

INDICATIONS AND DOSE

Treatment of acute migraine

By mouth

Adult: 2.5 mg, followed by 2.5 mg after at least 2 hours if required, dose to be taken only if migraine recurs, then increased if necessary to 5 mg, dose to be taken only for subsequent attacks in patients not achieving satisfactory relief with 2.5 mg dose; maximum 10 mg per day

By intranasal administration

Adult: 5 mg, dose to be administered as soon as possible after onset into one nostril only, followed by 5 mg after at least 2 hours if required, dose to be administered only if migraine recurs; maximum 10 mg per day

Breast feeding

Present in milk but amount probably too small to be harmful; withhold breast-feeding for 12 hours after treatment.

Hepatic impairment

Reduce oral dose to 25–50 mg. Avoid in severe impairment.

Renal impairment

Use with caution.

Patient and carer advice

Driving and skilled tasks

Drowsiness may affect performance of skilled tasks (e.g. driving).

Exceptions to legal category

Sumatriptan 50 mg tablets can be sold to the public to treat previously diagnosed migraine; max. daily dose 100 mg.

Medicinal forms

There can be variation in the licensing of different medicines containing the same drug.

Unlicensed use

Not licensed for use in elderly.

Contra-indications

Coronary vasospasm · ischaemic heart disease · mild uncontrolled hypertension · moderate and severe hypertension · peripheral vascular disease · previous cerebrovascular accident · previous myocardial infarction · previous transient ischaemic attack · Prinzmetal’s angina

Cautions

Conditions which predispose to coronary artery disease · elderly · history of seizures · mild, controlled hypertension · pre-existing cardiac disease · risk factors for seizures

Interactions

Appendix 1: sumatriptan

Side-effects

General side-effects

Common or very common

Dizziness · drowsiness · dyspnoea · fatigue · flushing · myalgia · nausea · sensory disturbances · transient increase in blood pressure · vomiting · weakness

Frequency not known

Arrhythmias · angina · anxiety · arthralgia · Bradycardia · diarrhoea · dystonia · hypersensitivity reactions · hypotension · ischaemic colitis · myocardial infarction · neck stiffness · nystagmus · palpitation · Raynaud’s syndrome · seizures · sweating · tachycardia · transient ischaemic ECG changes · tremor · visual disturbances

Specific side-effects

Common or very common

With intranasal use

Dysgeusia · epistaxis

Side-effects, further information

Sensations of tingling, heat, heaviness, pressure, or tightness of any part of the body may occur (including throat and chest—discontinue if intense, may be due to coronary vasoconstriction or to anaphylaxis).

Allergy and cross-sensitivity

Caution in patients with sensitivity to sulfonamides.

Pregnancy

There is limited experience of using 5HT1 receptor agonists during pregnancy; manufacturers advise that they should be avoided unless the potential benefit outweighs the risk.

By subcutaneous injection

Adult: Initially 6 mg for 1 dose, followed by 6 mg after at least 1 hour if required, to be taken only if migraine recurs (patient not responding to initial dose should not take second dose for same attack), dose to be administered using an auto-injector; not for intravenous injection which may cause coronary vasospasm and angina; maximum 12 mg per day

By intranasal administration

Adult 18–65 years: Initially 10–20 mg, to be administered into one nostril, followed by 10–20 mg after at least 2 hours if required, to be taken only if migraine recurs (patient not responding to initial dose should not take second dose for same attack); maximum 40 mg per day

Medicinal forms

There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

CAUTIONARY AND ADVISORY LABELS 3, 10

Sumatriptan (as Sumatriptan succinate) 12 mg per 1 ml

Imigran Subject 6mg/0.5ml solution for injection | 2 pre-filled disposable injection | £48.00 DT price = £39.50

Imigran Subject (GlaxoSmithKline UK Ltd)

Sumatriptan (as Sumatriptan succinate) 12 mg per 1 ml

Imigran Subject 6mg/0.5ml solution for injection syringe refill pack | 2 pre-filled disposable injection PT | £40.41 DT price = £40.41

Imigran Subject 6mg/0.5ml solution for injection syringe with device | 2 pre-filled disposable injection PT | £50.96 DT price = £50.96

Spray

CAUTIONARY AND ADVISORY LABELS 3, 10

Imigran (GlaxoSmithKline UK Ltd)

Sumatriptan 100 mg per 1 ml

Imigran 10mg nas al spray | 2 unit dose PT | 2 pre-filled disposable injection | £11.80 DT price = £11.80

Imigran 200 mg per 1 ml

Imigran 20mg nas al spray | 2 unit dose PT | £14.16 | 6 unit dose PT | £42.47 DT price = £42.47

Tablet

CAUTIONARY AND ADVISORY LABELS 3, 10

Sumatriptan (as Sumatriptan succinate) 50 mg

Sumatriptan 50mg tablets | 6 tablet PT | £22.56 DT price = £1.25

Sumatriptan (as Sumatriptan succinate) 100 mg

Sumatriptan 100mg tablets | 6 tablet PT | £36.47 DT price = £1.43

Imigran (GlaxoSmithKline UK Ltd, Forest Laboratories UK Ltd)

Sumatriptan (as Sumatriptan succinate) 50 mg

Imigran Radis 50mg tablets | 6 tablet PT | £23.90 DT price = £1.25

Imigran 50mg tablets | 6 tablet PT | £31.85 DT price = £1.25

Imigran Recovery 50mg tablets | 2 tablet PT | £4.76

Possible after onset into one nostril only, followed by 5 mg after at least 2 hours if required, dose to be administered only if migraine recurs; maximum 10 mg per day

Migraitan (Bristol Laboratories Ltd)

Sumatriptan (as Sumatriptan succinate) 50 mg

Migraitan 50mg tablets | 2 tablet PT | £4.24

Zolmitriptan

Indications and dose

Treatment of acute migraine

By mouth

Adult: 2.5 mg, followed by 2.5 mg after at least 2 hours if required, dose to be taken only if migraine recurs, then increased if necessary to 5 mg, dose to be taken only for subsequent attacks in patients not achieving satisfactory relief with 2.5 mg dose; maximum 10 mg per day

By intranasal administration

Adult: 5 mg, dose to be administered as soon as possible after onset into one nostril only, followed by 5 mg after at least 2 hours if required, dose to be administered only if migraine recurs; maximum 10 mg per day
6.2 Neuropathic pain

Neuropathic pain

Overview and management

Neuropathic pain, which occurs as a result of damage to neural tissue, includes phantom limb pain, compression neuropathies, peripheral neuropathies (e.g., due to Diabetic complications p. 648, chronic excessive alcohol intake, HIV infection p. 604, chemotherapy, idiopathic neuropathy), trauma, central pain (e.g., pain following stroke, spinal cord injury, and syringomyelia), and postherpetic neuralgia (peripheral nerve damage following acute herpes zoster infection (shingles)). The pain may occur in an area of sensory deficit and is sometimes accompanied by pain that is evoked by a non-noxious stimulus (allodynia).

Trigeminal neuralgia is also caused by dysfunction of neural tissue, but its management is distinct from other forms of neuropathic pain.

Neuropathic pain is generally managed with a tricyclic antidepressant or with certain antiepileptic drugs.

Amitriptyline hydrochloride p. 355 [unlicensed indication] and pregabalin p. 310 are effective treatments for neuropathic pain. Amitriptyline hydrochloride and pregabalin can be used in combination if the patient has an inadequate response to either drug at the maximum tolerated dose.

Nortriptyline p. 361 [unlicensed indication] may be better tolerated than amitriptyline hydrochloride.

Gabapentin p. 301 is also effective for the treatment of neuropathic pain.

Neuropathic pain may respond to opioid analgesics. There is evidence of efficacy for tramadol hydrochloride p. 447, morphine p. 439, and oxycodone hydrochloride p. 442; however, treatment with morphine or oxycodone hydrochloride should be initiated only under specialist supervision. Tramadol hydrochloride can be prescribed when other treatments have been unsuccessful, while the patient is waiting for assessment by a specialist.

Patients with localised pain who are unable to take oral medicines may benefit from topical local anaesthetic preparations, such as lidocaine hydrochloride medicated plasters p. 1242, while awaiting specialist review.

Capsaicin p. 458 is licensed for neuropathic pain (but the intense burning sensation during initial treatment may limit use). Capsaicin 0.075% cream is licensed for the symptomatic relief of postherpetic neuralgia. A self-adhesive patch containing capsaicin 8% is licensed for the treatment of peripheral neuropathic pain in non-diabetic patients. It should be used under specialist supervision.

### Orodispersible tablet

**EXCIPIENTS:** May contain Aspartame

**Zolmitriptan (Non-proprietary)**

Zolmitriptan 2.5 mg | Zolmitriptan 2.5mg orodispersible tablets sugar free - sugar free | 6 tablet (POM) | £20.35 DT price = £12.70

Zolmitriptan 5 mg | Zolmitriptan 5mg orodispersible tablets sugar free - sugar free | 6 tablet (POM) | £20.35 DT price = £12.70

**Zomig Rapimelt** (AstraZeneca UK Ltd)

Zolmitriptan 2.5 mg | Zomig Rapimelt 2.5mg orodispersible tablets sugar-free - sugar-free | 6 tablet (POM) | £23.99 DT price = £16.99

Zolmitriptan 5 mg | Zomig Rapimelt 5mg orodispersible tablets sugar-free - sugar-free | 6 tablet (POM) | £23.94 DT price = £17.20

**Tablet**

**Zolmitriptan (Non-proprietary)**

Zolmitriptan 2.5 mg | Zolmitriptan 2.5mg tablets | 6 tablet (POM) | £18.36 DT price = £1.48 | 12 tablet (POM) | £30.60

Zolmitriptan 5 mg | Zolmitriptan 5mg tablets | 6 tablet (POM) | £3.60 | 12 tablet (POM) | £7.20

**Zomig** (AstraZeneca UK Ltd)

Zolmitriptan 2.5 mg | Zomig 2.5mg tablets | 6 tablet (POM) | £23.94 DT price = £1.48
A corticosteroid may help to relieve pressure in compression neuropathy and thereby reduce pain.

Neuromodulation by spinal cord stimulation may be of benefit in some patients. Many patients with chronic neuropathic pain require multidisciplinary management, including physiotherapy and psychological support.

**Trigeminal neuralgia**

Surgery may be the treatment of choice in many patients; a neurological assessment will identify those who stand to benefit. Carbamazepine p. 297 taken during the acute stages of trigeminal neuralgia, reduces the frequency and severity of attacks. It is very effective for the severe pain associated with trigeminal neuralgia (and less commonly) glossopharyngeal neuralgia. Blood counts and electrolytes should be monitored when high doses are given. Small doses should be used initially to reduce the incidence of side-effects e.g. dizziness. Some cases respond to phenytoin p. 308; the drug may be given by intravenous infusion (possibly as fosphenytoin sodium p. 300) in a crisis (specialist use only).

**Chronic facial pain**

Chronic oral and facial pain including persistent idiopathic facial pain (also termed ‘atypical facial pain’) and temporomandibular dysfunction (previously termed temporomandibular joint pain dysfunction syndrome) may call for prolonged use of analgesics or for other drugs. **Tricyclic antidepressants** may be useful for facial pain (unlicensed indication), but are not on the Dental Practitioners’ List. Disorders of this type require specialist referral and psychological support to accompany drug treatment. Patients on long-term therapy need to be monitored both for progress and for side-effects.

**Other drugs used for Neuropathic pain**

Amanadine hydrochloride, p. 397

### ANALGESICS > PLANT ALKALOIDS

**Capsaicin**

**INDICATIONS AND DOSE**

**AXSAIN ®**

**Post-herpetic neuralgia**

▶ TO THE SKIN

Adult: Apply 3–4 times a day, dose to be applied sparingly; important; after lesions have healed, not more often than every 4 hours

**Painful diabetic neuropathy (under expert supervision)**

▶ TO THE SKIN

Adult: Apply 3–4 times a day for 8 weeks then review, dose to be applied sparingly, not more often than every 4 hours

**QUTENZA ®**

**Peripheral neuropathic pain in non-diabetic patients (under the supervision of a physician)**

▶ BY TRANSDERMAL APPLICATION USING PATCHES

Adult: (consult product literature)

**ZACIN ®**

**Symptomatic relief in osteoarthritis**

▶ TO THE SKIN

Adult: Apply 4 times a day, dose to be applied sparingly, not more often than every 4 hours

**CAUTIONS**

**GENERAL CAUTIONS**

Avoid contact with broken skin · avoid contact with inflamed skin

**SPECIFIC CAUTIONS**

▶ With topical use Avoid contact with eyes · avoid hot shower or bath just before or after application (burning sensation enhanced) · avoid inhalation of vapours · not to be used under tight bandages

▶ With transdermal use Avoid contact with the face, scalp or in proximity to mucous membranes · avoid holding near eyes or mucous membranes · recent cardiovascular events · uncontrolled hypertension

**SIDE-EFFECTS**

▶ Common or very common

- With topical use Transient burning sensation during initial treatment (particularly if too much used or if administered less than 3–4 times daily)

- With transdermal use Application site reactions · erythema · pruritus · transient burning

▶ Uncommon

- With transdermal use Burning sensation · cough · dysgeusia · eye irritation · first degree AV block · hypertension · hypoaesthesia · muscle spasm · nausea · pain in extremities · palpitations · peripheral oedema · pruritus · tachycardia · throat irritation

▶ Rare

- With topical use Cough · eye irritation · sneezing

- Frequency not known

- With topical use Dyspnoea · exacerbation of asthma

**MONITORING REQUIREMENTS**

- With transdermal use Monitor blood pressure during treatment procedure

**HANDLING AND STORAGE**

- With topical use Wash hands immediately after use (or wash hands 30 minutes after application if hands treated).

- With transdermal use Nitrile gloves to be worn while handling patches and cleaning treatment areas (latex gloves do not provide adequate protection).

**NATIONAL FUNDING/ACCESS DECISIONS**

**QUTENZA ®**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (January 2011) that capsaicin 179 mg (8%) patch (Qutenza®) is accepted for restricted use within NHS Scotland for the treatment of postherpetic neuralgia in patients who have not achieved adequate pain relief from, or who have not tolerated conventional first and second line treatments. Treatment should be under the supervision of a specialist in pain management.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: cream

**Cutaneous patch**

EXCIPIENTS: May contain Butylated hydroxyanisole

▶ Qutenza (Astellas Pharma Ltd)

Capsaicin 179 mg (Qutenza 179mg cutaneous patches) 1 patch £210.00

**Cream**

EXCIPIENTS: May contain Benzyl alcohol, cetylstearyl alcohol (including cetyl and stearyl alcohol)

▶ Axsain (Teva UK Ltd)

Capsaicin 750 microgram per 1 gram Axsain 0.075% cream | 45 gram £14.58 DT price = £14.58

▶ Zacin (Teva UK Ltd)

Capsaicin 250 microgram per 1 gram Zacin 0.025% cream | 45 gram £17.71 DT price = £17.71
7 Sleep disorders

7.1 Insomnia

Hypnotics and anxiolytics

Overview

Most anxiolytics (‘sedatives’) will induce sleep when given at night and most hypnotics will sedate when given during the day. Prescribing of these drugs is widespread but dependence (both physical and psychological) and tolerance occur. This may lead to difficulty in withdrawing the drug after the patient has been taking it regularly for more than a few weeks. Hypnotics and anxiolytics should therefore be reserved for short courses to alleviate acute conditions after causal factors have been established.

Benzodiazepines are the most commonly used anxiolytics and hypnotics; they act at benzodiazepine receptors which are associated with gamma-aminobutyric acid (GABA) receptors. Older drugs such as meprobamate p. 330 and barbiturates are not recommended—they have more side-effects and interactions than benzodiazepines and are much more dangerous in overdosage.

Benzodiazepine indications

- Benzodiazepines are indicated for the short-term relief (two to four weeks only) of anxiety that is severe, disabling, or causing the patient unacceptable distress, occurring alone or in association with insomnia or short-term psychosomatic, organic, or psychotic illness.
- The use of benzodiazepines to treat short-term ‘mild’ anxiety is inappropriate.
- Benzodiazepines should be used to treat insomnia only when it is severe, disabling, or causing the patient extreme distress.

Dependence and withdrawal

Withdrawal of a benzodiazepine should be gradual because abrupt withdrawal may produce confusion, toxic psychosis, convulsions, or a condition resembling delirium tremens. The benzodiazepine withdrawal syndrome may develop at any time up to 3 weeks after stopping a long-acting benzodiazepine, but may occur within a day in the case of a short-acting one. It is characterised by insomnia, anxiety, loss of appetite and of body-weight, tremor, perspiration, tinnitus, and perceptual disturbances. Some symptoms may be similar to the original complaint and encourage further prescribing; some symptoms may continue for weeks or months after stopping benzodiazepines.

Benzodiazepine withdrawal should be flexible and carried out at a reduction rate that is tolerable for the patient. The rate should depend on the initial dose of benzodiazepine, duration of use, and the patient’s clinical response. Short-term users of benzodiazepines (2–4 weeks only) can usually taper off within 2–4 weeks. However, long-term users should be withdrawn over a much longer period of several months or more.

A suggested protocol for withdrawal for prescribed long-term benzodiazepine patients is as follows:

- Transfer patient stepwise, one dose at a time over about a week, to an equivalent daily dose of diazepam preferably taken at night.
- Reduce diazepam dose, usually by 1–2 mg every 2–4 weeks (in patients taking high doses of benzodiazepines, initially it may be appropriate to reduce the dose by up to one-tenth every 1–2 weeks). If uncomfortable withdrawal symptoms occur, maintain this dose until symptoms lessen.

- Reduce diazepam dose further, if necessary in smaller steps; steps of 500 micrograms may be appropriate towards the end of withdrawal. Then stop completely.
- For long-term patients, the period needed for complete withdrawal may vary from several months to a year or more.

Approximate equivalent doses, diazepam 5 mg

- alprazolam 250 micrograms
- clobazam 10 mg
- clonazepam 250 micrograms
- flurazepam 7.5–15 mg
- cloridiazepoxide 12.5 mg
- loprazolam 0.5–1 mg
- lorazepam 500 micrograms
- lormetazepam 0.5–1 mg
- nitrazepam 5 mg
- oxazepam 10 mg
- temazepam 10 mg

Withdrawal symptoms for long-term users usually resolve within 6–18 months of the last dose. Some patients will recover more quickly, others may take longer. The addition of beta-blockers, antidepressants and antipsychotics should be avoided where possible.

Counselling can be of considerable help both during and after the taper.

Hypnotics

Before a hypnotic is prescribed the cause of the insomnia should be established and, where possible, underlying factors should be treated. However, it should be noted that some patients have unrealistic sleep expectations, and others underestimate their alcohol consumption which is often the cause of the insomnia. Short-acting hypnotics are preferable in patients with sleep onset insomnia, when sedation the following day is undesirable, or when prescribing for elderly patients. Long-acting hypnotics are indicated in patients with poor sleep maintenance (e.g. early morning waking) that causes daytime effects, when an anxiolytic effect is needed during the day, or when sedation the following day is acceptable.

Transient insomnia may occur in those who normally sleep well and may be due to extraneous factors such as noise, shift work, and jet lag. If a hypnotic is indicated one that is rapidly eliminated should be chosen, and only one or two doses should be given.

Short-term insomnia is usually related to an emotional problem or serious medical illness. It may last for a few weeks and may recur; a hypnotic can be useful but should not be given for more than three weeks (preferably only one week). Intermittent use is desirable with omission of some doses. A short-acting drug is usually appropriate.

Chronic insomnia is rarely benefited by hypnotics and is sometimes due to mild dependence caused by injudicious prescribing of hypnotics. Psychiatric disorders such as anxiety, depression, and abuse of drugs and alcohol are common causes. Sleep disturbance is very common in depressive illness and early wakening is often a useful pointer. The underlying psychiatric complaint should be treated, adapting the drug regimen to alleviate insomnia. For example, clomipramine hydrochloride p. 356 or mirtazapine p. 354 prescribed for depression will also help to promote sleep if taken at night. Other causes of insomnia include daytime cat-napping and physical causes such as pain, pruritus, and dyspnoea.

Hypnotics should not be prescribed indiscriminately and routine prescribing is undesirable. They should be reserved for short courses in the acutely distressed. Tolerance to their effects develops within 3 to 14 days of continuous use and long-term efficacy cannot be assured. A major drawback of long-term use is that withdrawal can cause rebound insomnia and a withdrawal syndrome.
Where prolonged administration is unavoidable hypnotics should be discontinued as soon as feasible and the patient warned that sleep may be disturbed for a few days before normal rhythm is re-established; broken sleep with vivid dreams may persist for several weeks.

**Elderly**

Benzodiazepines and the Z-drugs should be avoided in the elderly, because the elderly are at greater risk of becoming ataxic and confused, leading to falls and injury.

**Dental patients**

Some anxious patients may benefit from the use of hypnotics during dental procedures such as temazepam p. 463 or diazepam p. 327. Temazepam is preferred when it is important to minimise any residual effect the following day.

**Benzodiazepines**

Benzodiazepines used as hypnotics include nitrazepam p. 462 and flurazepam p. 461 which have a prolonged action and may give rise to residual effects on the following day; repeated doses tend to be cumulative.

Lorazepam p. 461, lormetazepam p. 462, and temazepam act for a shorter time and they have little or no hangover effect. Withdrawal phenomena are more common with the short-acting benzodiazepines.

If insomnia is associated with daytime anxiety then the use of a long-acting benzodiazepine anxiolytic such as diazepam given as a single dose at night may effectively treat both symptoms.

Zaleplon, zolpidem, and zopiclone

Zaleplon p. 465, zolpidem tartrate p. 465 and zopiclone p. 466 are non-benzodiazepine hypnotics (sometimes referred to as Z-drugs), but they act at the benzodiazepine receptor. They are not licensed for long-term use; dependence has been reported in a small number of patients. Zolpidem tartrate and zopiclone have a short duration of action; zaleplon is very short acting.

**Chloral and derivatives**

There is no convincing evidence that they are particularly useful in the elderly and their role as hypnotics is now very limited.

Clomethiazole

Clomethiazole p. 464 may be a useful hypnotic for elderly patients because of its freedom from hangover but, as with all hypnotics, routine administration is undesirable and dependence occurs.

**Antihistamines**

Some antihistamines such as promethazine hydrochloride p. 275 are on sale to the public for occasional insomnia; their prolonged duration of action can often cause drowsiness the following day. The sedative effect of antihistamines may diminish after a few days of continued treatment; antihistamines are associated with headache, psychomotor impairment and antimuscarinic effects.

**Alcohol**

Alcohol is a poor hypnotic because the diuretic action interferes with sleep during the latter part of the night. Alcohol also disturbs sleep patterns, and so can worsen sleep disorders.

**Melatonin**

Melatonin p. 464 is a pineal hormone; it is licensed for the short-term treatment of insomnia in adults over 55 years.

**Anxiolytics**

Benzodiazepine anxiolytics can be effective in alleviating anxiety states. Although these drugs are sometimes prescribed for stress-related symptoms, unhappiness, or minor physical disease, their use in such conditions is inappropriate. Benzodiazepine anxiolytics should not be used as sole treatment for chronic anxiety, and they are not appropriate for treating depression or chronic psychosis. In bereavement, psychological adjustment may be inhibited by benzodiazepines.

Anxiolytic benzodiazepine treatment should be limited to the lowest possible dose for the shortest possible time. Dependence is particularly likely in patients with a history of alcohol or drug abuse and in patients with marked personality disorders.

Some antidepressant drugs are licenced for use in anxiety and related disorders. Some antipsychotic drugs, in low doses, are also sometimes used in severe anxiety for their sedative action, but long-term use should be avoided because of the risk of adverse effects. The use of antihistamines (e.g. hydroxyzine hydrochloride p. 274) for their sedative effect in anxiety is not appropriate.

**Beta-adrenoceptor blocking drugs** do not affect psychological symptoms of anxiety, such as worry, tension, and fear, but they do reduce autonomic symptoms, such as palpitation and tremor; they do not reduce non-autonomic symptoms, such as muscle tension. Beta-blockers are therefore indicated for patients with predominantly somatic symptoms; this, in turn, may prevent the onset of worry and fear.

**Benzodiazepines**

Benzodiazepines are indicated for the short-term relief of severe anxiety; long-term use should be avoided. Diazepam, alprazolam p. 326, chlordiazepoxide hydrochloride p. 326, and clonazepam p. 320 have a sustained action. Shorter-acting compounds such as lorazepam p. 322 and oxazepam p. 329 may be preferred in patients with hepatic impairment but they carry a greater risk of withdrawal symptoms.

In panic disorders (with or without agoraphobia) resistant to antidepressant therapy, a benzodiazepine may be used; alternatively, a benzodiazepine may be used as short-term adjunctive therapy at the start of antidepressant treatment to prevent the initial worsening of symptoms. Diazepam or lorazepam are very occasionally administered intravenously for the control of panic attacks. This route is the most rapid but the procedure is not without risk and should be used only when alternative measures have failed. The intramuscular route has no advantage over the oral route.

**Buspirone**

Buspirone hydrochloride p. 325 is thought to act at specific serotonin (5HT1A) receptors. Response to treatment may take up to 2 weeks. It does not alleviate the symptoms of benzodiazepine withdrawal. Therefore a patient taking a benzodiazepine still needs to have the benzodiazepine withdrawn gradually; it is advisable to do this before starting buspirone hydrochloride. The dependence and abuse potential of buspirone hydrochloride is low; it is, however, licensed for short-term use only (but specialists occasionally use it for several months).

**Meprobamate**

Meprobamate p. 330 is less effective than the benzodiazepines, more hazardous in overdosage, and can also induce dependence. It is not recommended.

**Barbiturates**

The intermediate-acting barbiturates have a place only in the treatment of severe intractable insomnia in patients already taking barbiturates; they should be avoided in the elderly. Intermediate-acting barbiturate preparations containing amobarbital sodium, butobarbital, and secobarbital sodium are available on a named patient basis.

The long-acting barbiturate phenobarbital is still sometimes of value in epilepsy but its use as a sedative is unjustified.

The very short-acting barbiturate thiopental sodium p. 322 is used in anaesthesia.

Increased hostility and aggression after barbiturates and alcohol usually indicates intoxication.
HYPNOTICS, SEDATIVES AND ANXIOLYTICS > BENZODIAZEPINES

Flurazepam

**INDICATIONS AND DOSE**

**Insomnia (short-term use)**

- **BY MOUTH**
  - Adult: 15–30 mg once daily, dose to be taken at bedtime, for debilitated patients, use elderly dose
  - Elderly: 15 mg once daily, dose to be taken at bedtime

**CONTRA-INDICATIONS** Not for use alone to treat chronic psychosis · not for use alone to treat depression (or anxiety associated with depression) · respiratory depression

**CAUTIONS** Acute porphyrias p. 969 · hypoalbuminaemia · marked personality disorder · muscle weakness

**INTERACTIONS** Appendix 1: flurazepam

**SIDE-EFFECTS**

- **Common or very common** Amnesia · ataxia (especially in the elderly) · confusion (especially in the elderly) · dependence · drowsiness the next day · lightheadedness the next day · muscle weakness · paradoxical increase in aggression

- **Uncommon** Changes in libido · dizziness · dysarthria · gastro-intestinal disturbances · gynaecomastia · headache · hypotension · incontinence · salivation changes · slurred speech · tremor · urinary retention · vertigo · visual disturbances

- **Rare** Apnoea · blood disorders · jaundice · respiratory depression · skin reactions

**BREAST FEEDING** Benzodiazepines are present in milk, and should be avoided if possible during breast-feeding.

**HEPATIC IMPAIRMENT** Start with smaller initial doses or reduce dose. Can precipitate coma. If treatment is necessary, benzodiazepines with shorter half-lives (such as temazepam or oxazepam) are safer. Avoid in severe impairment.

**RENAL IMPAIRMENT** Start with small doses in severe impairment.

**PATIENT AND CARER ADVICE**

**Driving and skilled tasks**

May impair judgement and increase reaction time, and so affect ability to drive or operate machinery; they increase the effects of alcohol. Moreover the hangover effects of a night dose may impair driving on the following day.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NHS restrictions** Flurazepam capsules are not prescribable under the NHS.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

**CAUTIONARY AND ADVISORY LABELS**

- **Dalmane (Meda Pharmaceuticals Ltd)**
  - Flurazepam (as Flurazepam hydrochloride) 15 mg Dalmane 15mg capsules | 30 capsule [POM] £6.73 [CD4-I]
  - Flurazepam (as Flurazepam hydrochloride) 30 mg Dalmane 30mg capsules | 30 capsule [POM] £8.63 [CD4-I]

Loprazolam

**INDICATIONS AND DOSE**

**Insomnia (short-term use)**

- **BY MOUTH**
  - Adult: 1 mg once daily, then increased to 1.5–2 mg once daily if required, dose to be taken at bedtime, for debilitated patients, use elderly dose
  - Elderly: 0.5–1 mg once daily, dose to be taken at bedtime

**CONTRA-INDICATIONS** Not for use alone to treat chronic psychosis · not for use alone to treat depression (or anxiety associated with depression) · respiratory depression

**CAUTIONS** Acute porphyrias p. 969 · hypoalbuminaemia · marked personality disorder · muscle weakness

**INTERACTIONS** Appendix 1: loprazolam

**SIDE-EFFECTS**

- **Common or very common** Amnesia · ataxia (especially in the elderly) · confusion (especially in the elderly) · dependence · drowsiness the next day · lightheadedness the next day · muscle weakness · paradoxical increase in aggression

- **Uncommon** Changes in libido · dizziness · dysarthria · gastro-intestinal disturbances · gynaecomastia · headache · hypotension · incontinence · salivation changes · slurred speech · tremor · urinary retention · vertigo · visual disturbances

- **Rare** Apnoea · blood disorders · jaundice · respiratory depression · skin reactions

**BREAST FEEDING** Benzodiazepines are present in milk, and should be avoided if possible during breast-feeding.

**HEPATIC IMPAIRMENT** Start with smaller initial doses or reduce dose. Can precipitate coma. If treatment is necessary, benzodiazepines with shorter half-lives (such as temazepam or oxazepam) are safer. Avoid in severe impairment.

**RENAL IMPAIRMENT** Start with small doses in severe impairment.

**PATIENT AND CARER ADVICE**

Driving and skilled tasks

May impair judgement and increase reaction time, and so affect ability to drive or operate machinery; they increase the effects of alcohol. Moreover the hangover effects of a night dose may impair driving on the following day.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

**CAUTIONARY AND ADVISORY LABELS**

- **Loprazolam (Non-proprietary)**
  - Loprazolam (as Loprazolam mesilate) 1 mg Loprazolam 1mg tablets | 28 tablet [POM] £18.00 DT price = £18.00 [CD4-I]
Lormetazepam

**INDICATIONS AND DOSE**

**Insomnia (short-term use)**

- **BY MOUTH**
  - Adult: 0.5–1.5 mg once daily, dose to be taken at bedtime, for debilitated patients, use elderly dose
  - Elderly: 500 micrograms once daily, dose to be taken at bedtime

**CONTRA-INDICATIONS**

- Not for use alone to treat chronic psychosis, not for use alone to treat depression (or anxiety associated with depression) - respiratory depression

**CAUTIONS**

- Acute porphyrias p. 969 - hypoalbuminaemia - marked personality disorder - muscle weakness

**CAUTIONS, FURTHER INFORMATION**

- **Paradoxical effects**
  - A paradoxical increase in hostility and aggression may be reported by patients taking benzodiazepines. The effects range from talkativeness and excitement to aggressive and antisocial acts. Adjustment of the dose (up or down) sometimes attenuates the impulses. Increased anxiety and perceptual disorders are other paradoxical effects.

**INTERACTIONS** → Appendix 1: lormetazepam

**SIDE-EFFECTS**

- **Common or very common**
  - Amnesia - ataxia (especially in the elderly) - confusion (especially in the elderly) - dependence - drowsiness the next day - lightheadedness - the next day - muscle weakness - paradoxical increase in aggression

- **Uncommon**
  - Changes in libido - dizziness - dysarthria - gastro-intestinal disturbances - gynaecomastia - headache - hypotension - incontinence - salivation changes - slurred speech - tremor - urinary retention - vertigo - visual disturbances

- **Rare**
  - Apnoea - blood disorders - jaundice - respiratory depression - skin reactions

**BREAST FEEDING**

- Benzodiazepines are present in milk, and should be avoided if possible during breast-feeding.

**HEPATIC IMPAIRMENT**

- Start with smaller initial doses or reduce dose. Can precipitate coma. If treatment is necessary, benzodiazepines with shorter half-lives (such as temazepam or oxazepam) are safer. Avoid in severe impairment.

**RENAL IMPAIRMENT**

- Start with small doses in severe impairment.

**PATIENT AND CARER ADVICE**

**Driving and skilled tasks**

- May impair judgement and increase reaction time, and so affect ability to drive or operate machinery; they increase the effects of alcohol. Moreover the hangover effects of a night dose may impair driving on the following day.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

Tablet

- **CAUTIONARY AND ADVISORY LABELS** 19

- **Lormetazepam (Non-proprietary)**
  - Lormetazepam 500 microgram | 30 tablet | £0.64 | 1.17 DT price = £11.66 [CD-1]
  - Lormetazepam 1 mg | 30 tablet | £12.38 | 1.07 DT price = £8.07 [CD-1]

---

Nitrazepam

**INDICATIONS AND DOSE**

**Insomnia (short-term use)**

- **BY MOUTH**
  - Adult: 5–10 mg daily, dose to be taken at bedtime, for debilitated patients, use elderly dose
  - Elderly: 2.5–5 mg daily, dose to be taken at bedtime

**CONTRA-INDICATIONS**

- Not for use alone to treat chronic psychosis, not for use alone to treat depression (or anxiety associated with depression) - respiratory depression

**CAUTIONS**

- Acute porphyrias p. 969 - hypoalbuminaemia - marked personality disorder - muscle weakness

**CAUTIONS, FURTHER INFORMATION**

- **Paradoxical effects**
  - A paradoxical increase in hostility and aggression may be reported by patients taking benzodiazepines. The effects range from talkativeness and excitement to aggressive and antisocial acts. Adjustment of the dose (up or down) sometimes attenuates the impulses. Increased anxiety and perceptual disorders are other paradoxical effects.

**INTERACTIONS** → Appendix 1: nitrazepam

**SIDE-EFFECTS**

- **Common or very common**
  - Amnesia - ataxia (especially in the elderly) - confusion (especially in the elderly) - dependence - drowsiness the next day - lightheadedness the next day - muscle weakness - paradoxical increase in aggression

- **Uncommon**
  - Changes in libido - dizziness - dysarthria - gastro-intestinal disturbances - gynaecomastia - headache - hypotension - incontinence - salivation changes - slurred speech - tremor - urinary retention - vertigo - visual disturbances

- **Rare**
  - Apnoea - blood disorders - jaundice - respiratory depression - skin reactions

**BREAST FEEDING**

- Benzodiazepines are present in milk, and should be avoided if possible during breast-feeding.

**HEPATIC IMPAIRMENT**

- Start with smaller initial doses or reduce dose. Can precipitate coma. If treatment is necessary, benzodiazepines with shorter half-lives (such as temazepam or oxazepam) are safer. Avoid in severe impairment.

**RENAL IMPAIRMENT**

- Start with small doses in severe impairment.

**PATIENT AND CARER ADVICE**

**Driving and skilled tasks**

- May impair judgement and increase reaction time, and so affect ability to drive or operate machinery; they increase the effects of alcohol. Moreover the hangover effects of a night dose may impair driving on the following day.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Oral suspension**

- **CAUTIONARY AND ADVISORY LABELS** 19

- **Nitrazepam (Non-proprietary)**
  - Nitrazepam 500 microgram per 1 ml | 70 ml | £114.00 DT price = £114.00 [CD-1]

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS** 19

- **Nitrazepam (Non-proprietary)**
  - Nitrazepam 5 mg | 28 tablet | £5.00 DT price = £5.00 [CD-1]
  - Mogadon (Meda Pharmaceuticals Ltd) | 500 tablet | £20.00 [CD-1]

- **Mogadon (Meda Pharmaceuticals Ltd)**
  - Nitrazepam 5 mg | 30 tablet | £5.76 [CD-1]
Temazepam

INDICATIONS AND DOSE

Insomnia (short-term use)

- **By mouth**
  - Adult: 10–20 mg once daily, alternatively 30–40 mg once daily, higher dose range only to be administered in exceptional circumstances, dose to be taken at bedtime, for debilitated patients, use elderly doses
  - Elderly: 10 mg once daily, alternatively 20 mg once daily, higher dose only to be administered in exceptional circumstances, dose to be taken at bedtime

Conscious sedation for dental procedures

- **By mouth**
  - Adult: 15–30 mg, to be administered 30–60 minutes before procedure

Premedication before surgery or investigatory procedures

- **By mouth**
  - Adult: 10–20 mg, to be taken 1–2 hours before procedure, alternatively 30 mg, to be taken 1–2 hours before procedure, higher alternate dose only administered in exceptional circumstances
  - Elderly: 10 mg, to be taken 1–2 hours before procedure, alternatively 20 mg, to be taken 1–2 hours before procedure, higher alternate dose only administered in exceptional circumstances

UNLICENSED USE

Temazepam doses in BNF may differ from those in product literature. Not licensed for conscious sedation for dental procedures.

CONTRA-INDICATIONS

CNS depression - compromised airway - hyperkinesia - not for use alone to treat chronic psychosis - not for use alone to treat depression (or anxiety associated with depression) - obsessional state - phobic states - respiratory depression

CAUTIONS

Hypoaalbuminaemia - muscle weakness - organic brain changes - personality disorder (within the fearful group—dependent, avoidant, obsessive-compulsive)—may increase risk of dependence

CAUTIONS, FURTHER INFORMATION

Paradoxical effects A paradoxical increase in hostility and aggression may be reported by patients taking benzodiazepines. The effects range from talkativeness and excitement to aggressive and antisocial acts. Adjustment of the dose (up or down) sometimes attenuates the impulses. Increased anxiety and perceptual disorders are other paradoxical effects.

INTERACTIONS

1. Appendix 1: temazepam

SIDE-EFFECTS

1. Common or very common Amnesia - ataxia (especially in the elderly) - confusion (especially in the elderly) - dependence - drowsiness the next day - lightheadedness the next day - muscle weakness - paradoxical increase in aggression
3. Rare Apnoea - blood disorders - jaundice - skin reactions
4. Frequency not known Respiratory depression (may be marked when used for sedation; facilities for its treatment are essential)

BREAST FEEDING

Benzodiazepines are present in milk, and should be avoided if possible during breast-feeding.

HEPATIC IMPAIRMENT

Start with smaller initial doses or reduce dose. Can precipitate coma. Avoid in severe impairment. If treatment is necessary, benzodiazepines with shorter half-lives are safer.

RENAL IMPAIRMENT

Start with small doses in severe impairment.

PATIENT AND CARER ADVICE

Driving and skilled tasks

May impair judgement and increase reaction time, and so affect ability to drive or operate machinery; they increase the effects of alcohol. Moreover the hangover effects of a night dose may impair driving on the following day.

Patients given sedatives and analgesics during minor outpatient procedures should be very carefully warned about the risks of undertaking skilled tasks (e.g. driving) afterwards. Responsible persons should be available to take patients home afterwards. The dangers of taking alcohol should be emphasised.

PROFESSION SPECIFIC INFORMATION

Dental practitioners’ formulary

Temazepam Tablets and Oral Solution may be prescribed.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Oral solution

- **Cautionary and Advisory labels 19**
  - Temazepam (Non-proprietary)
    - **Tablet**
      - Temazepam 2 mg per 1 ml Temazepam 10 mg/5 ml oral solution sugar free sugar-free | 300 ml [PoM] £121.08 DT price = £121.08 [CD3]
      - **Tablet**
      - Temazepam (Non-proprietary)
        - Temazepam 10 mg Temazepam 10 mg tablets | 28 tablet [PoM] £35.00 DT price = £1.89 [CD3] | 500 tablet [PoM] £524.82 [CD3]
        - Temazepam 20 mg Temazepam 20 mg tablets | 28 tablet [PoM] £35.00 DT price = £1.91 [CD3] | 250 mg tablets [PoM] £307.94 [CD3]

HYPNOTICS, SEDATIVES AND ANXIOLYTICS

NON-BENZODIAZEPINE HYPNOTICS AND SEDATIVES

Chloral hydrate

INDICATIONS AND DOSE

Insomnia (short-term use) using Chloral Mixture, BP 2000

- **By mouth using oral solution**
  - Adult: 0.5–2 g daily, dose to be taken at bedtime

Insomnia (short-term use), using chloral hydrate 143.3 mg/5 ml oral solution

- **By mouth using oral solution**
  - Adult: 15–30 mL, alternatively 430–860 mg once daily, dose to be taken with water or milk at bedtime; maximum 70 mL per day; maximum 2 g per day

Insomnia (short-term use), using chloral betaine 707 mg (= 414 mg chloral hydrate) tablets

- **By mouth using tablets**
  - Adult: 1–2 tablets, alternatively 414–828 mg once daily, dose to be taken with water or milk at bedtime; maximum 4 tablets per day; maximum 2 g per day

CONTRA-INDICATIONS

Acute porphyrias p. 969 - gastritis - severe cardiac disease

CAUTIONS

Avoid contact with mucous membranes - avoid contact with skin - avoid prolonged use (and abrupt withdrawal thereafter) - reduce dose in debilitated - reduce dose in elderly

INTERACTIONS

1. Appendix 1: chloral hydrate

SIDE-EFFECTS

Abdominal distension - delirium (especially on abrupt withdrawal) - dependence - excitement - flatulence - gastric irritation - headache - ketonuria - nausea - rash - tolerance - vomiting

PREGNANCY

Avoid.

BREAST FEEDING

Risk of sedation in infant—avoid.
Nervous system

DIRECTIONS FOR ADMINISTRATION

RENAL IMPAIRMENT

MEDICINAL FORMS

▶ LESS SUITABLE FOR PRESCRIBING

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

Tablet

CAUTIONARY AND ADVISORY LABELS 19, 27

▶ Chloral hydrate (Non-proprietary)

Chloral betaine 707 mg

Oral solution

CAUTIONARY AND ADVISORY LABELS 1 (paediatric solution only), 19

▶ Chloral hydrate (Non-proprietary)

Chloral hydrate 28.66 mg per 1 ml

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

Tablet

CAUTIONARY AND ADVISORY LABELS 19, 27

▶ Chloral hydrate (Non-proprietary)

Cloral betaine 707 mg

Oral solution

CAUTIONARY AND ADVISORY LABELS 1 (paediatric solution only), 19

▶ Chloral hydrate (Non-proprietary)

Cloral hydrate 28.66 mg per 1 ml

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Oral solution

CAUTIONARY AND ADVISORY LABELS 19

Excipients: May contain Alcohol

▶ Clormethiazole (Non-proprietary)

Clormethiazole (as Clormethiazole edisilate) 50 mg per 1 ml Clormethiazole 31.5 mg/ml oral solution sugar free sugar-free

Capsule

CAUTIONARY AND ADVISORY LABELS 19

▶ Clormethiazole (Non-proprietary)

Clormethiazole 192 mg

INDICATIONS AND DOSE

Severe insomnia (short-term use)

BY MOUTH USING CAPSULES

Elderly: 192–384 mg once daily, dose to be taken at bedtime

BY MOUTH USING ORAL SOLUTION

Elderly: 5–10 mL once daily, dose to be taken at bedtime

Restlessness and agitation

BY MOUTH USING CAPSULES

Elderly: 192 mg 3 times a day

BY MOUTH USING ORAL SOLUTION

Elderly: 5 mL 3 times a day

Alcohol withdrawal

BY MOUTH USING CAPSULES

Adult: Initially 2–4 capsules, to be repeated if necessary after some hours. 9–12 capsules daily in 3–4 divided doses on day 1 (first 24 hours), then 6–8 capsules daily in 3–4 divided doses on day 2, then 4–6 capsules daily in 3–4 divided doses on day 3, dose then to be gradually reduced over days 4–6, total duration of treatment for no more than 9 days

BY MOUTH USING ORAL SOLUTION

Adult: Initially 10–20 mL, to be repeated if necessary after some hours, then 45–60 mL daily in 3–4 divided doses on day 1 (first 24 hours), then 30–40 mL daily in 3–4 divided doses on day 2, then 20–30 mL daily in 3–4 divided doses on day 3, dose then to be gradually reduced over days 4–6, total duration of treatment for no more than 9 days

DIVERSIONS FOR ADMINISTRATION

RENAL IMPAIRMENT

Avoid prolonged use (and abrupt withdrawal thereafter) - cardiac disease (confusional state may indicate hypoxia) - chronic pulmonary insufficiency - elderly - excessive sedation may occur (particularly with higher doses); - history of drug abuse - marked personality disorder - respiratory disease (confusional state may indicate hypoxia) - sleep apnoea syndrome

INTERACTIONS

Appendix 1: clormethiazole

SIDE-EFFECTS

▶ Common or very common

Conjunctival irritation - headache - increased bronchial secretions - increased nasopharyngeal secretions - nasal congestion - nasal irritation

▶ Rare

Alterations in liver enzymes - anaphylaxis - bullous eruption - confusion - dependence - gastro-intestinal disturbances - paradoxical excitement - rash - urticaria

PREGNANCY

Avoid if possible—especially during the first and third trimesters.

BREAST FEEDING

Use only if benefit outweighs risk—present in breast milk but effects unknown.

HEPATIC IMPAIRMENT

Reduce dose. Can precipitate coma.

RENAL IMPAIRMENT

Start with small doses in severe impairment. Increased cerebral sensitivity.

PATIENT AND CARER ADVICE

Driving and skilled tasks

Drowsiness may persist the next day and affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced.

Certifine

(Chlormethiazole)

INDICATIONS AND DOSE

Severe insomnia (short-term use)

BY MOUTH USING CAPSULES

Elderly: 192–384 mg once daily, dose to be taken at bedtime

BY MOUTH USING ORAL SOLUTION

Elderly: 5–10 mL once daily, dose to be taken at bedtime

Restlessness and agitation

BY MOUTH USING CAPSULES

Elderly: 192 mg 3 times a day

BY MOUTH USING ORAL SOLUTION

Elderly: 5 mL 3 times a day

Alcohol withdrawal

BY MOUTH USING CAPSULES

Adult: Initially 2–4 capsules, to be repeated if necessary after some hours. 9–12 capsules daily in 3–4 divided doses on day 1 (first 24 hours), then 6–8 capsules daily in 3–4 divided doses on day 2, then 4–6 capsules daily in 3–4 divided doses on day 3, dose then to be gradually reduced over days 4–6, total duration of treatment for no more than 9 days

BY MOUTH USING ORAL SOLUTION

Adult: Initially 10–20 mL, to be repeated if necessary after some hours, then 45–60 mL daily in 3–4 divided doses on day 1 (first 24 hours), then 30–40 mL daily in 3–4 divided doses on day 2, then 20–30 mL daily in 3–4 divided doses on day 3, dose then to be gradually reduced over days 4–6, total duration of treatment for no more than 9 days

CONTRA-INDICATIONS

Acute pulmonary insufficiency - alcohol-dependent patients who continue to drink

CAUTIONS

Avoid prolonged use (and abrupt withdrawal thereafter) - cardiac disease (confusional state may indicate hypoxia) - chronic pulmonary insufficiency - elderly - excessive sedation may occur (particularly with higher doses); - history of drug abuse - marked personality disorder - respiratory disease (confusional state may indicate hypoxia) - sleep apnoea syndrome

INTERACTIONS

Appendix 1: clormethiazole

SIDE-EFFECTS

▶ Common or very common

Conjunctival irritation - headache - increased bronchial secretions - increased nasopharyngeal secretions - nasal congestion - nasal irritation

▶ Rare

Alterations in liver enzymes - anaphylaxis - bullous eruption - confusion - dependence - gastro-intestinal disturbances - paradoxical excitement - rash - urticaria

PREGNANCY

Avoid if possible—especially during the first and third trimesters.

BREAST FEEDING

Use only if benefit outweighs risk—present in breast milk but effects unknown.

HEPATIC IMPAIRMENT

Reduce dose. Can precipitate coma.

RENAL IMPAIRMENT

Start with small doses in severe impairment. Increased cerebral sensitivity.

PATIENT AND CARER ADVICE

Driving and skilled tasks

Drowsiness may persist the next day and affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Oral solution

CAUTIONARY AND ADVISORY LABELS 19

Excipients: May contain Alcohol

▶ Clormethiazole (Non-proprietary)

Clormethiazole (as Clormethiazole edisilate) 50 mg per 1 ml Clormethiazole 31.5 mg/ml oral solution sugar free sugar-free

Capsule

CAUTIONARY AND ADVISORY LABELS 19

▶ Clormethiazole (Non-proprietary)

Clormethiazole 192 mg

INDICATIONS AND DOSE

Severe insomnia (short-term use)

BY MOUTH USING MODIFIED-RELEASE TABLETS

Adult 55 years and over: 2 mg once daily for up to 13 weeks, dose to be taken 1–2 hours before bedtime

CAUTIONS

Autoimmune disease (manufacturer advises avoid—no information available)

INTERACTIONS

Appendix 1: melatonin

SIDE-EFFECTS

▶ Uncommon


▶ Rare

Aggression - angina - arthritis - electrolyte disturbances - flatulence - gastritis - haematuria - halitosis - hot flushes - hypertyglyceridaemia - impaired memory - increased libido - lacrimation - leucopenia - mood changes - muscle spasm - nail disorder - palpititation - paraesthesia - polyuria - priapism - prostatitis - restless legs syndrome -

Melatonin

INDICATIONS AND DOSE

Insomnia (short-term use)

BY MOUTH USING MODIFIED-RELEASE TABLETS

Adult 55 years and over: 2 mg once daily for up to 13 weeks, dose to be taken 1–2 hours before bedtime

CAUTIONS

Autoimmune disease (manufacturer advises avoid—no information available)

INTERACTIONS

Appendix 1: melatonin

SIDE-EFFECTS

▶ Uncommon


▶ Rare

Aggression - angina - arthritis - electrolyte disturbances - flatulence - gastritis - haematuria - halitosis - hot flushes - hypertyglyceridaemia - impaired memory - increased libido - lacrimation - leucopenia - mood changes - muscle spasm - nail disorder - palpititation - paraesthesia - polyuria - priapism - prostatitis - restless legs syndrome -
Zaleplon

**INDICATIONS AND DOSE**

**Insomnia (short-term use)**

- **BY MOUTH**
  - Adult: 10 mg daily for up to 4 weeks, dose to be taken at bedtime, for debilitated patients, use elderly dose
  - Elderly: 5 mg daily for up to 4 weeks, dose to be taken at bedtime

- **Common or very common** Amnesia, drowsiness, dysmenorrhea, paraesthesia
- **Uncommon** Anorexia, asthenia, confusion, depersonalisation, depression, disturbances of hearing, disturbances of smell, disturbances of speech, disturbances of vision, dizziness, hallucinations, impaired concentration, incoordination, nausea, photosensitivity
- **Frequency not known** Paradoxical effects, sleep-walking

**SIDE-EFFECTS, FURTHER INFORMATION**

- Paradoxical effects A paradoxical increase in hostility and aggression may be reported. The effects range from talkativeness and excitement to aggressive and antisocial acts. Adjustment of the dose (up or down) sometimes attenuates the impulses. Increased anxiety and perceptual disorders are other paradoxical effects. Increased hostility and aggression after barbiturates and alcohol usually indicates intoxication.
- **PREGNANCY** Avoid regular use (risk of neonatal withdrawal symptoms); high doses during late pregnancy or labour may cause neonatal hypothermia, hypotonia, and respiratory depression.
- **BREAST FEEDING** Small amounts present in milk—avoid.
- **HEPATIC IMPAIRMENT** Reduce dose to 5 mg. Can precipitate coma. Avoid if severe impairment.
- **RENAL IMPAIRMENT** Use with caution.

**PATIENT AND CARER ADVICE**

Patients should be advised not to take a second dose during a single night.

**NATIONAL FUNDING/ACCESS DECISIONS**

NICE technology appraisals (TAs)

- Zaleplon, zolpidem, and zopiclone for the short-term management of insomnia (April 2004) NICE TA77

Zaleplon is recommended for the short-term management of severe insomnia that interferes with normal daily life, and should be prescribed for short periods of time only. www.nice.org.uk/TA77

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Modified-release tablet**

- **Melatonin (Non-proprietary)**
  - Melatonin 3 mg Melatonin 3mg modified-release tablets | 120 tablet | no price available
  - **Circadin** (Flynn Pharma Ltd)
    - Melatonin 2 mg Circadin 2mg modified-release tablets | 30 tablet | £15.39 B7 price + £15.39

**Zolpidem tartrate**

**INDICATIONS AND DOSE**

**Insomnia (short-term use)**

- **BY MOUTH**
  - Adult: 10 mg daily for up to 4 weeks, dose to be taken at bedtime, for debilitated patients, use elderly dose
  - Elderly: 5 mg daily for up to 4 weeks, dose to be taken at bedtime

- **CONTRA-INDICATIONS** Acute respiratory depression, marked neuromuscular respiratory weakness, obstructive sleep apnoea, psychotic illness, severe respiratory depression, unstable myasthenia gravis
- **CAUTIONS** Avoid prolonged use (and abrupt withdrawal thereafter), depression, elderly, history of alcohol abuse, history of drug abuse, muscle weakness, myasthenia gravis
- **INTERACTIONS** Appendix 1: zolpidem
- **SIDE-EFFECTS** Agitation, amnesia, asthenia, ataxia, changes in libido, confusion, dependence, depression, diarrhoea, diplopia, dizziness, drowsiness, falls, hallucination, headache, memory disturbances, muscular weakness, nausea, nightmares, paradoxical effects, perceptual disturbances, skin reactions, sleep-walking, tremor, vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

- Paradoxical effects A paradoxical increase in hostility and aggression may be reported. The effects range from talkativeness and excitement to aggressive and antisocial acts. Adjustment of the dose (up or down) sometimes attenuates the impulses. Increased anxiety and perceptual disorders are other paradoxical effects. Increased hostility and aggression after barbiturates and alcohol usually indicates intoxication.
- **PREGNANCY** Avoid regular use (risk of neonatal withdrawal symptoms); high doses during late pregnancy or labour may cause neonatal hypothermia, hypotonia, and respiratory depression.
- **BREAST FEEDING** Small amounts present in milk—avoid.
- **HEPATIC IMPAIRMENT** Reduce dose to 5 mg. Can precipitate coma. Avoid if severe impairment.
- **RENAL IMPAIRMENT** Use with caution.

**PATIENT AND CARER ADVICE**

Driving and skilled tasks

Drowsiness may persist the next day—leave at least 8 hours between taking zolpidem and performing skilled tasks (e.g., driving, or operating machinery); effects of alcohol and other CNS depressants enhanced.
Zopiclone

- **INDICATIONS AND DOSE**
  - **Insomnia (short-term use)**
    - **BY MOUTH**
    - Adult: 7.5 mg once daily for up to 4 weeks, dose to be taken at bedtime.
    - Elderly: Initially 3.75 mg once daily for up to 4 weeks, dose to be taken at bedtime, increased if necessary to 7.5 mg daily.
  - **Insomnia (short-term use) in patients with chronic pulmonary insufficiency**
    - **BY MOUTH**
    - Adult: Initially 3.75 mg once daily for up to 4 weeks, dose to be taken at bedtime, increased if necessary to 7.5 mg daily.

- **CONTRA-INDICATIONS**
  - Marked neuromuscular respiratory weakness.
  - Respiratory failure.
  - Severe sleep apnoea syndrome.
  - Unstable myasthenia gravis.

- **CAUTIONS**
  - Avoid prolonged use (risk of tolerance and withdrawal symptoms).
  - Chronic pulmonary insufficiency.
  - Increased risk of respiratory depression.
  - Elderly: history of drug abuse.
  - Muscle weakness.
  - Myasthenia gravis (avoid if unstable).
  - Psychiatric illness.

- **INTERACTIONS**
  - Appendix 1: zopiclone

- **SIDE-EFFECTS**
  - **Common or very common**
    - Taste disturbance.
  - **Uncommon**
    - Dizziness.
    - Dry mouth.
    - Headache.
    - Nausea.
    - Vomiting.
  - **Rare**
    - Amnesia.
    - Confusion.
    - Depression.
    - Hallucinations.
    - Nightmares.
  - **Very rare**
    - Incoordination.
    - Light headedness.
  - **Frequency not known**
    - Paradoxical effects.
    - Sleep-walking.

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Paradoxical effects.
    - A paradoxical increase in hostility and aggression may be reported. The effects range from talkativeness and excitement to aggressive and antisocial acts. Adjustment of the dose (up or down) sometimes attenuates the impulses.
    - Increased anxiety and perceptual disorders are other paradoxical effects.
    - Increased hostility and aggression after barbiturates and alcohol usually indicates intoxication.

- **PREGNANCY**
  - Not recommended (risk of neonatal withdrawal symptoms). Use during late pregnancy or labour may cause neonatal hypothermia, hypotonia, and respiratory depression.

- **BREAST FEEDING**
  - Present in milk—avoid.

- **HEPATIC IMPAIRMENT**
  - Reduce dose to 3.75 mg in mild to moderate impairment, dose can be increased with caution if necessary. Avoid in severe impairment—can precipitate encephalopathy.

- **RENAL IMPAIRMENT**
  - Start with reduced dose of 3.75 mg. Increased cerebral sensitivity.

- **PATIENT AND CARER ADVICE**
  - Driving and skilled tasks.
    - Drowsiness may persist the next day and affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced.

- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **NICE technology appraisals (TAs)**
    - Zaleplon, zolpidem, and zopiclone for the short-term management of insomnia (April 2004) NICE TA77
    - Zolpidem is recommended for the short-term management of severe insomnia that interferes with normal daily life, and should be prescribed for short periods of time only.
    - www.nice.org.uk/TA77

### CENTRAL NERVOUS SYSTEM DEPRESSANTS

#### Sodium oxybate

- **DRUG ACTION**
  - A central nervous system depressant.

- **INDICATIONS AND DOSE**
  - **Narcolepsy with cataplexy (under expert supervision)**
    - **BY MOUTH**
    - Adult: Initially 2.25 g daily, dose to be taken on retiring and 2.25 g after 2.5–4 hours, then increased in steps of 1.5 g daily in 2 divided doses, dose adjusted according to response at intervals of 1–2 weeks; dose titration should be repeated if restarting after interval of more than 14 days, maximum 9 g daily in 2 divided doses.

#### DOSE ADJUSTMENTS DUE TO INTERACTIONS

- Manufacturer advises reduce dose by 20% with concurrent use of sodium valproate or valproic acid.

- **CONTRA-INDICATIONS**
  - Major depression.
  - Succinic semialdehyde dehydrogenase deficiency.

- **CAUTIONS**
  - Body mass index of 40 kg/m² or greater (higher risk of sleep apnoea).
  - Elderly.
  - Epilepsy.
  - Heart failure (high sodium content).
  - History of depression.
  - History of drug dependence.
abuse · hypertension (high sodium content) · respiratory disorders · risk of discontinuation effects including rebound cataplexy and withdrawal symptoms

**INTERACTIONS → Appendix 1: sodium oxybate**

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain · anorexia · anxiety · arthralgia · asthenia · back pain · blurred vision · confusion · depression · diarrhoea · disorientation · dizziness · drowsiness · dyspnoea · headache · hypertension · hypoamasthesia · impaired attention · muscle spasm · nasal congestion · nausea · nocturnal enuresis · palpitation · paraesthesia · peripheral oedema · rash · sleep disorders · sleep paralysis · sleep walking · sweating · taste disturbance · tremor · urinary incontinence · vertigo · vomiting

- **Uncommon** Agitation · amnesia · faecal incontinence · hallucination · myoclonus · paranoia · psychosis · restless legs syndrome · suicidal behaviour

- **Frequency not known** Dependence · euphoria · respiratory depression · seizures · sleep apnoea · suicidal ideation · urticaria

- **PREGNANCY** Avoid.

- **BREAST FEEDING** No information available.

- **HEPATIC IMPAIRMENT** Halve initial dose.

- **RENAL IMPAIRMENT** Caution—contains 3.96 mmol Na⁺ per mL.

- **DIRECTIONS FOR ADMINISTRATION** Dilute each dose with 60 mL water; prepare both doses before retiring. Observe the same time interval (2–3 hours) each night between the last meal and the first dose.

- **PATIENT AND CARER ADVICE**

Driving and skilled tasks
Leave at least 6 hours between taking sodium oxybate and performing skilled tasks (e.g. driving or operating machinery); effects of alcohol and other CNS depressants enhanced.

Patients or carers should be given advice on how to administer sodium oxybate oral solution.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Oral solution**

**CAUTIONARY AND ADVISORY LABELS 13, 19**

**ELECTROLYTES:** May contain Sodium

- **Xyrem** (UCB Pharma Ltd)

Sodium oxybate 500 mg per 1 mL Xyrem 500 mg/mL oral solution sugar-free 380 mL [Pod] £360.00 DT price = £360.00 [62]

**CNS STIMULANTS ▶ CENTRALLY ACTING SYMPATHOMIMETICS**

**Modafinil**

**INDICATIONS AND DOSE**

**Excessive sleepiness associated with narcolepsy with or without cataplexy**

- **BY MOUTH**

  - Adult: Initially 200 mg daily in 2 divided doses, dose to be taken in the morning and at noon, alternatively initially 200 mg once daily, dose to be taken in the morning, adjusted according to response to 200–400 mg daily in 2 divided doses, alternatively adjusted according to response to 200–400 mg once daily

  - Elderly: Initially 100 mg daily

**CONTRA-INDICATIONS**

Arrhythmia · history of clinically significant signs of CNS stimulant-induced mitral valve prolapse (including ischaemic ECG changes, chest pain and arrhythmias) · history of cor pulmonale · history of left ventricular hypertrophy · moderate uncontrolled hypertension · severe uncontrolled hypertension

**CAUTIONS**

History of alcohol abuse · history of depression · history of drug abuse · history of mania · history of psychosis · possibility of dependence

**SIDE-EFFECTS**

- **Common or very common** Anxiety · dizziness · dyspepsia · insomnia · irritability · nausea · tremor · vertigo · vomiting

- **Uncommon** Abdominal pain · appetite changes · blepharospasm · bradycardia · changes in blood pressure · changes in libido · chest pain · constipation · diarrhoea · dry mouth · dysomnia · epilepsy · erythema · extrasystoles · fluid retention · gastritis · gastro-oesophageal reflux disease · hot flush · hyperhidrosis · metorrhagia · migraine · movement disorders · musculoskeletal disorders · paraesthesia · pollakiuria · pruritus · psychiatric disturbances · QT prolongation · rash · restless legs syndrome · restlessness · tinnitus · visual disturbances · weight changes (review treatment if significant)

- **Rare** Dysphagia · enterocolitis · flatulence · photosensitivity · spontaneous abortion · toxic skin eruption

**CONCEPTION AND CONTRACEPTION**

Manufacturer advises effective contraception in women of childbearing potential for at least 21 days after treatment discontinuation—pitolisant may reduce the effectiveness of hormonal contraceptives.

**PREGNANCY**

Manufacturer advises avoid unless potential benefit outweighs risk—toxicity in animal studies.

**BREAST FEEDING**

Manufacturer advises avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT**

Manufacturer advises initial dose may be increased after two weeks in moderate impairment—maximum daily dose should not exceed 18 mg. Manufacturer advises caution in moderate impairment; avoid in severe impairment.

**RENAL IMPAIRMENT** Manufacturer advises use with caution; maximum daily dose should not exceed 18 mg.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Wakix** (Lincoln Medical Ltd) ▷

  - Pitolisant (as Pitolisant hydrochloride) 4.5 mg Wakix 4.5mg tablets 30 tablet [Pod] £310.00

  - Pitolisant (as Pitolisant hydrochloride) 18 mg Wakix 18mg tablets 30 tablet [Pod] £310.00

**Pitolisant (as Pitolisant hydrochloride) 18 mg**

**11-Apr-2017**

**DRUG ACTION**

Pitolisant is a histamine H₃-receptor antagonist which enhances the activity of brain histaminergic neurons.

**INDICATIONS AND DOSE**

**Narcolepsy with or without cataplexy (initiated by a specialist)**

- **BY MOUTH**

  - Adult: Initially 9 mg once daily for 1 week, then increased if necessary to 18 mg once daily for 1 week, then increased if necessary to 36 mg once daily, dose to be taken in the morning with breakfast, dose can be decreased (down to 4.5 mg per day) or increased (up to 36 mg per day) according to response and tolerance

**CAUTIONS**

Acid-related gastric disorders · epilepsy · history of psychiatric disorders · severe anorexia · severe obesity

**INTERACTIONS → Appendix 1: pitolisant**
Substance dependence

Guidance on treatment of drug misuse


Alcohol dependence

Excessive drinking of alcoholic beverages over a prolonged period of time can result in an alcohol withdrawal syndrome on abrupt cessation of, or marked reduction in, drinking. The presence and severity of alcohol dependence can be assessed by The Severity of Alcohol Dependence Questionnaire (SADQ); other assessment questionnaires are also available.

Acute alcohol withdrawal

People with moderate dependence can generally be treated in a community setting unless they are under 18 years of age, or are at high-risk of severe reactions or treatment failure. People with severe dependence should undergo withdrawal in an inpatient setting; withdrawal in severely dependent patients without medical support may lead to seizures, delirium tremens, and death. Long-acting benzodiazepines, usually chloridazepoxide hydrochloride p. 326, are used to attenuate alcohol withdrawal symptoms. In primary care, fixed-dose reducing regimens are usually used, while a symptom-triggered flexible regimen is used in hospital or other settings where continued assessment and monitoring is carried out for 24–48 hours, usually followed by a fixed 5-day reducing dose schedule (sometimes it may be necessary to continue treatment for up to 10 days). Patients with uncomplicated liver disease should be treated under specialist supervision.

Carbamazepine p. 297 [unlicensed indication] is sometimes used as an alternative treatment in acute alcohol withdrawal when benzodiazepines are contra-indicated or not tolerated. Clomethiazole p. 464 is licensed for use in acute alcohol withdrawal, but benzodiazepines are preferred. It should only be used in an inpatient setting and should not be prescribed if the patient is liable to continue drinking alcohol.

Patients with marked agitation or hallucinations and those at risk of delirium tremens (characterised by delirium, hallucinations, tremor, and disorientation) may be prescribed antipsychotic drugs, such as haloperidol p. 368 or olanzapine p. 379 [unlicensed indication], as adjunctive therapy to benzodiazepines; antipsychotics should not be used alone because they do not treat alcohol withdrawal and may lower the seizure threshold. Delirium tremens is a medical emergency that requires specialist inpatient care.

If a patient taking a benzodiazepine as part of a withdrawal regimen develops alcohol withdrawal seizures, a fast-acting benzodiazepine (such as intravenous lorazepam p. 322 [unlicensed indication]) or rectal diazepam p. 327 should be prescribed; thereafter an increase in the dose of oral benzodiazepine should be considered to prevent further seizures from occurring.

Alcohol dependence

Acamprosate calcium p. 471 and naltrexone hydrochloride p. 472 are effective treatments for relapse prevention in patients with alcohol dependence; disulfiram p. 471 is an alternative. Disulfiram should only be used in patients in whom acamprosate calcium and naltrexone hydrochloride are not suitable, or if the patient prefers disulfiram. Nalmefene p. 472 is licensed for the reduction of alcohol consumption in patients with alcohol dependence who have a high drinking risk level, without physical withdrawal symptoms, and who do not require immediate detoxification.

Patients with alcohol dependence are at risk of developing Wernicke’s encephalopathy; patients at high-risk are those who are malnourished, at risk of malnourishment, or have decompensated liver disease. Parenteral thiamine p. 989 (as Pabrinex®) should be prescribed for treatment of suspected or confirmed Wernicke’s encephalopathy, and for prophylaxis in alcohol dependent patients attending hospital for acute treatment (including treatment unrelated to alcohol dependence); parenteral prophylaxis may also be considered for high-risk patients being treated in primary care. High-dose oral thiamine should be prescribed following parenteral treatment until cognitive function is maximised. In primary care, prophylactic high-dose oral thiamine should be prescribed during acute withdrawal of alcohol, before planned withdrawal, and for patients not undergoing
withdrawal but who are at high-risk of developing Wernicke's encephalopathy.

Patients with chronic alcohol-related pancreatitis who have symptoms of steatorrhea or who have poor nutritional status due to exocrine pancreatic insufficiency should be prescribed pancreatic enzyme supplements; supplements are not indicated when pain is the only symptom.

Corticosteroids are used in patients with severe acute alcohol-related hepatitis.

**Drugs used in alcohol dependence**

**Acamprosate**
Acamprosate calcium, in combination with counselling, may be helpful for maintaining abstinence in alcohol-dependent patients. It is useful for patients who are concerned that strong cravings will result in relapse. It should be initiated as soon as possible after abstinence has been achieved and continued for 1 year; treatment should be maintained if the patient has a temporary relapse but stopped if the patient returns to regular or excessive drinking that persists 4–6 weeks after starting treatment. Acamprosate calcium is not effective in all patients, so efficacy should be regularly assessed.

**Disulfiram**
Disulfiram gives rise to an extremely unpleasant systemic reaction after the ingestion of even a small amount of alcohol because it causes accumulation of acetaldehyde in the body; it is only effective if taken daily. Symptoms can occur within 10 minutes of ingesting alcohol and include flushing of the face, throbbing headache, palpitation, tachycardia, nausea, vomiting, and, with large doses of alcohol, arrhythmias, hypotension, and collapse; these reactions can last several hours. Small amounts of alcohol such as those included in many oral medicines may be sufficient to precipitate a reaction—even toiletries and mouthwashes that contain alcohol should be avoided.

**Nalmefene**
Nalmefene should only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption. Nalmefene is not recommended for patients aiming to achieve immediate abstinence.

**Naltrexone**
Naltrexone hydrochloride is an opioid-receptor antagonist, but is useful as an adjunct in the treatment of alcohol dependence after a successful withdrawal. Treatment should be initiated by a specialist and continued under specialist supervision. Naltrexone hydrochloride should be stopped if drinking continues for 4–6 weeks after starting treatment. Naltrexone is only effective if taken daily. Symptoms can cause chest pain. The oral spray can cause increased salivation, and patches can cause minor skin irritation. The nasal spray commonly causes coughing, nasal irritation, epistaxis, sneezing, and watery eyes; the oral spray can cause labile blood pressure and headache.

**Nicotine replacement therapy**
Bupropion hydrochloride has been used as an antidepressant. Its mode of action in smoking cessation is not clear and may involve an effect on noradrenaline and dopamine neurotransmission.

**Nicotine replacement therapy**
Nicotine replacement therapy can be used in place of cigarettes after abrupt cessation of smoking, or alternatively to reduce the amount of cigarettes used in advance of making a quit attempt. Nicotine replacement therapy can also be used to minimise passive smoking, and to treat craving and reduce compensatory smoking after enforced abstinence in smoke-free environments. Smokers who find it difficult to achieve abstinence should consult a healthcare professional for advice.

**Choice**
Nicotine patches p. 473 are a prolonged-release formulation and are applied for 16 hours (with the patch removed overnight) or for 24 hours. If patients experience strong cravings for cigarettes on waking, a 24-hour patch may be more suitable. Immediate-release nicotine preparations (gum, lozenges, sublingual tablets, inhalator, nasal spray, and oral spray) are used whenever the urge to smoke occurs or to prevent cravings.

The choice of nicotine replacement preparation depends largely on patient preference, and should take into account what preparations, if any, have been tried before. Patients with a high level of nicotine dependence, or who have failed with nicotine replacement therapy previously, may benefit from using a combination of an immediate-release preparation and patches to achieve abstinence.

**Side-effects of specific nicotine preparations**
Mild local reactions at the beginning of treatment are common because of the irritant effect of nicotine. Oral preparations and inhalation cartridges can cause irritation of the throat, gum, lozenges, and oral spray can cause increased salivation, and patches can cause minor skin irritation. The nasal spray commonly causes coughing, nasal irritation, epistaxis, sneezing, and watery eyes; the oral spray can cause watery eyes and blurred vision.

Gastro-intestinal disturbances are common and may be caused by swallowed nicotine. Nausea, vomiting, dyspepsia, and hiccup occur most frequently. Ulcerative stomatitis has also been reported. Dry mouth is a common side-effect of lozenges, patches, oral spray, and sublingual tablets. Lozenges cause diaphoresis, constipation, dysphagia, oesophagitis, gastritis, mouth ulcers, bloating, flatulence, and less commonly, taste disturbance, thirst, gingival bleeding, and halitosis. The oral spray may also cause abdominal pain, flatulence, and taste disturbance.

Palpitations may occur with nicotine replacement therapy and rarely patches and oral spray can cause arrhythmia. Patches, lozenges, and oral spray can cause chest pain. The inhalator can very rarely cause reversible atrial fibrillation. Paraesthesia is a common side-effect of oral spray. Abnormal dreams can occur with patches; removal of the patch before bed may help. Lozenges and oral spray may cause rash and hot flushes. Sweating and myalgia can occur with patches and oral spray; the patches can also cause arthralgia.
Opioid dependence
The management of opioid dependence requires medical, social, and psychological treatment; access to a multidisciplinary team is recommended. Treatment for opioid dependence should be initiated under the supervision of an appropriately qualified prescriber.

Untreated heroin dependence shows early withdrawal symptoms within 8 hours, with peak symptoms at 36–72 hours; symptoms subside substantially after 5 days. Methadone hydrochloride p. 476 or buprenorphine p. 425 withdrawal occurs later, with longer-lasting symptoms.

Opioid substitution therapy
Methadone hydrochloride and buprenorphine are used as substitution therapy in opioid dependence. Substitute medication should be commenced with a short period of stabilisation, followed by either a withdrawal regimen or by maintenance treatment. Maintenance treatment enables patients to achieve stability, reduces drug use and crime, and improves health; it should be regularly reviewed to ensure the patient continues to derive benefit. The prescriber should monitor for signs of toxicity, and the patient should be told to be aware of warning signs of toxicity on initiation and during titration.

A withdrawal regimen after stabilisation with methadone hydrochloride or buprenorphine should be attempted only after careful consideration. Enforced withdrawal is ineffective for sustained abstinence, and it increases the risk of patients relapsing and subsequently overdosing because of loss of tolerance. Complete withdrawal from opioids usually takes up to 4 weeks in an inpatient or residential setting, and up to 12 weeks in a community setting. If abstinence is not achieved, illicit drug use is resumed, or the patient cannot tolerate withdrawal, the withdrawal regimen should be stopped and maintenance therapy should be resumed at the optimal dose. Following successful withdrawal treatment, further support and monitoring to maintain abstinence should be provided for a period of at least 6 months.

Missed doses
Patients who miss 3 days or more of their regular prescribed dose of opioid maintenance therapy are at risk of overdose because of loss of tolerance. Consider reducing the dose in these patients.

If the patient misses 5 or more days of treatment, an assessment of illicit drug use is also recommended before restarting substitution therapy; this is particularly important for patients taking buprenorphine because of the risk of precipitated withdrawal.

Buprenorphine
Buprenorphine is preferred by some patients because it is less sedating than methadone hydrochloride; for this reason it may be more suitable for employed patients or those undertaking other skilled tasks such as driving. Buprenorphine is safer than methadone hydrochloride when used in conjunction with other sedating drugs, and has fewer drug interactions. Dose reductions may be easier than with methadone hydrochloride because the withdrawal symptoms are milder, and patients generally require fewer adjunctive medications; there is also a lower risk of overdose. Buprenorphine can be given on alternate days in higher doses and it requires a shorter drug-free period than methadone hydrochloride before induction with naltrexone hydrochloride p. 472 for prevention of relapse.

Patients dependent on high doses of opioids may be at increased risk of precipitated withdrawal. Precipitated withdrawal can occur in any patient if buprenorphine p. 425 is administered when other opioid agonist drugs are in circulation. Precipitated opioid withdrawal, if it occurs, starts within 1–3 hours of the first buprenorphine dose and peaks at around 6 hours. Non-opioid adjunctive therapy, such as lofexidine hydrochloride p. 478, may be required if symptoms are severe.

To reduce the risk of precipitated withdrawal, the first dose of buprenorphine should be given when the patient is exhibiting signs of withdrawal, or 6–12 hours after the last use of heroin (or other short-acting opioid), or 24–48 hours after the last dose of methadone hydrochloride p. 476. It is possible to titrate the dose of buprenorphine within one week—more rapidly than with methadone hydrochloride therapy—but care is still needed to avoid toxicity or precipitated withdrawal; dividing the dose on the first day may be useful.

A combination preparation containing buprenorphine with naloxone (Suboxone®) p. 477 can be prescribed for patients when there is a risk of dose diversion for parenteral administration; the naloxone hydrochloride p. 1259 component precipitates withdrawal if the preparation is injected, but it has little effect when the preparation is taken sublingually.

Methadone
Methadone hydrochloride, a long-acting opioid agonist, is usually administered in a single daily dose as methadone hydrochloride oral solution 1 mg/mL. Patients with a long history of opioid misuse, those who typically abuse a variety of sedative drugs and alcohol, and those who experience increased anxiety during withdrawal of opioids may prefer methadone hydrochloride to buprenorphine because it has a more pronounced sedative effect.

Methadone hydrochloride is initiated at least 8 hours after the last heroin dose, provided that there is objective evidence of withdrawal symptoms. A supplementary dose on the first day may be considered if there is evidence of persistent opioid withdrawal symptoms. Because of the long half-life, plasma concentrations progressively rise during initial treatment even if the patient remains on the same daily dose (it takes 3–10 days for plasma concentrations to reach steady-state in patients on a stable dose); a dose tolerated on the first day of treatment may become a toxic dose on the third day as cumulative toxicity develops. Thus, titration to the optimal dose in methadone hydrochloride maintenance treatment may take several weeks.

Opioid substitution during pregnancy
Acute withdrawal of opioids should be avoided in pregnancy because it can cause fetal death. Opioid substitution therapy is recommended during pregnancy because it carries a lower risk to the fetus than continued use of illicit drugs. If a woman who is stabilised on methadone hydrochloride or buprenorphine for treatment of opioid dependence becomes pregnant, therapy should be continued [buprenorphine is not licensed for use in pregnancy]. Many pregnant patients choose a withdrawal regimen, but withdrawal during the first trimester should be avoided because it is associated with an increased risk of spontaneous miscarriage. Withdrawal of methadone hydrochloride or buprenorphine should be undertaken gradually during the second trimester, with dose reductions made every 3–5 days. If illicit drug use occurs, the patient should be re-stabilised at the optimal maintenance dose and consideration should be given to stopping the withdrawal regimen.

Further withdrawal of methadone hydrochloride or buprenorphine in the third trimester is not recommended because maternal withdrawal, even if mild, is associated with fetal distress, stillbirth, and the risk of neonatal mortality. Drug metabolism can be increased in the third trimester; it may be necessary to either increase the dose of methadone hydrochloride or change to twice-daily consumption (or a combination of both strategies) to prevent withdrawal symptoms from developing.

The neonate should be monitored for respiratory depression and signs of withdrawal if the mother is prescribed high doses of opioid substitute.
Signs of neonatal withdrawal from opioids usually develop 24–72 hours after delivery but symptoms may be delayed for up to 14 days, so monitoring may be required for several weeks. Symptoms include a high-pitched cry, rapid breathing, hungry but ineffective suckling, and excessive wakefulness; severe, but rare symptoms include hypertonicity and convulsions.

Opioid substitution during breastfeeding
Doses of methadone and buprenorphine should be kept as low as possible in breast-feeding mothers. Increased sleepiness, breathing difficulties, or limbness in breast-fed babies of mothers taking opioid substitutes should be reported urgently to a healthcare professional.

Adjunctive therapy and symptomatic treatment
Adjunctive therapy may be required for the management of opioid withdrawal symptoms. Loperamide hydrochloride p. 65 may be used for the control of diarrhoea; mebeverine hydrochloride p. 84 for controlling stomach cramps; paracetamol p. 422 and non-steroidal anti-inflammatory drugs for muscular pains and headaches; metoclopramide hydrochloride p. 411 or prochlorperazine p. 371 may be useful for nausea or vomiting. Topical rubefacients can be helpful for relieving muscle pain associated with methadone hydrochloride withdrawal. If a patient is suffering from insomnia, short-acting benzodiazepines or zopiclone p. 466 may be prescribed, but because of the potential for abuse, prescriptions should be limited to a short course of a few days only. If anxiety or agitation is severe, specialist advice should be sought.

Lofexidine
Lofexidine hydrochloride may alleviate some of the physical symptoms of opioid withdrawal by attenuating the increase in adrenergic neurotransmission that occurs during opioid withdrawal. Lofexidine hydrochloride can be prescribed as an adjuvant to opioid substitution therapy, initiated either at the same time as the opioid substitute or during withdrawal of the opioid substitute. Alternatively, lofexidine hydrochloride may be prescribed instead of an opioid substitute in patients who have mild or uncertain dependence (including young people), and those with a short history of illicit drug use.

Opioid-receptor antagonists
Patients dependent on opioids can be given a supply of naloxone hydrochloride to be used in case of accidental overdose.

Naltrexone hydrochloride p. 472 precipitates withdrawal symptoms in opioid-dependent subjects. Because the effects of opioid-receptor antagonists are blocked by naltrexone hydrochloride, it is prescribed as an aid to prevent relapse in formerly opioid-dependent patients.

Opioid dependence in children
In younger patients (under 18 years), the harmful effects of drug misuse are more often related to acute intoxication than to dependence, so substitution therapy is usually inappropriate. Maintenance treatment with opioid substitution therapy is therefore controversial in young people; however, it may be useful for the older adolescent who has a history of opioid use to undergo a period of stabilisation with buprenorphine or methadone hydrochloride before starting a withdrawal regimen.

ALDEHYDE DEHYDROGENASE INHIBITORS

Disulfiram

- INDICATIONS AND DOSE
  Adjunct in the treatment of alcohol dependence (under expert supervision)
  - BY MOUTH
    - Adult: 200 mg daily, increased if necessary up to 500 mg daily

- UNLICENSED USE
  Disulfiram doses in BNF may differ from those in product literature.

- CONTRA-INDICATIONS
  Cardiac failure - coronary artery disease - history of cerebrovascular accident - hypertension - psychosis - severe personality disorder - suicide risk

- CAUTIONS
  Alcohol challenge not recommended on routine basis (if considered essential—specialist units only with resuscitation facilities) - avoid in acute porphyrias p. 969 - diabetes mellitus - epilepsy - respiratory disease

- INTERACTIONS
  - Appendix 1: disulfiram

- SIDE-EFFECTS
  - Common or very common Drowsiness - fatigue - halitosis - nausea - reduced libido - vomiting
  - Rare Allergic dermatitis - depression - hepatic cell damage - mania - paranoia - peripheral neuritis - psychotic reactions - schizophrenia

- PREGNANCY
  High concentrations of acetaldehyde which occur in presence of alcohol may be teratogenic; avoid in first trimester.

- BREAST FEEDING
  Avoid—no information available.

- HEPATIC IMPAIRMENT
  Use with caution.

- RENAL IMPAIRMENT
  Use with caution.

- PRE-TREATMENT SCREENING
  Before initiating disulfiram, prescribers should evaluate the patient’s suitability for treatment, because some patient factors, for example memory impairment or social circumstances, make compliance to treatment or abstinence from alcohol difficult.

- MONITORING REQUIREMENTS
  During treatment with disulfiram, patients should be monitored at least every 2 weeks for the first 2 months, then each month for the following 4 months, and at least every 6 months thereafter.

- PATIENT AND CARER ADVICE
  Patient counselling is advised (alcohol reaction).

- MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug.

Tablet
  CAUTIONARY AND ADVISORY LABELS 2
  - Disulfiram (Non-proprietary)
    Disulfiram 200 mg
    Disulfiram 200 mg tablets | 50 tablet (POM)
    £91.73 DT price = £91.73

GAMMA-AMINOBUTYRIC ACID ANALOGUES AND DERIVATIVES

Acamprosate calcium

- INDICATIONS AND DOSE
  Maintenance of abstinence in alcohol-dependent patients
  - BY MOUTH
    - Adult 18–65 years (body-weight up to 60 kg): 666 mg once daily at breakfast and 333 mg twice daily at midday and at night
    - Adult 18–65 years (body-weight 60 kg and above): 666 mg 3 times a day

8.1 Alcohol dependence
CAUTIONS Continued alcohol abuse (risk of treatment failure)

INTERACTIONS → Appendix 1: acamprosate

SIDE-EFFECTS
- Common or very common Abdominal pain, diarrhoea, flatulence, frigidity, impotence, maculopapular rash, nausea, pruritus, vomiting
- Very rare Angioedema, hypersensitivity reactions, urticaria
- Frequency not known Fluctuation in libido, vesiculo-bullous skin reactions

PREGNANCY Manufacturer advises avoid unless potential benefit outweighs risk.

BREAST FEEDING Avoid.

HEPATIC IMPAIRMENT Avoid if serum-creatinine greater than 120 micromol/litre.

PRESCRIBING AND DISPENSING INFORMATION
Acamprosate calcium has been used for the maintenance of abstinence in alcohol dependence in children aged 16 years and over.

OPSIIONAL FORMS

Gastro-resistant tablet

ELECTROLYTES: May contain Calcium
- Acamprosate calcium (Non-proprietary) Acamprosate calcium 333 mg gastro-resistant tablets | 168 tablet (PO) £33.68
- Campral EC (Merck Serono Ltd) Acamprosate calcium 333 mg Campral EC 333mg tablets | 168 tablet (PO) £28.80

OPIOID RECEPTOR ANTAGONISTS

Nalmefene

INDICATIONS AND DOSE
Reduction of alcohol consumption in patients with alcohol dependence who have a high drinking risk level without physical withdrawal symptoms, and who do not require immediate detoxification
- BY MOUTH
  - Adult: 18 mg daily if required, taken on each day there is a risk of drinking alcohol, preferably taken 1–2 hours before the anticipated time of drinking, if a dose has not been taken before drinking alcohol, 1 dose should be taken as soon as possible; maximum 18 mg per day

CONTRA-INDICATIONS Recent history of acute alcohol withdrawal syndrome — recent or current opioid use

CAUTIONS Continued treatment for more than 1-year history of seizure disorders (including alcohol withdrawal seizures) — psychiatric illness

INTERACTIONS → Appendix 1: nalmefene

SIDE-EFFECTS
- Common or very common Confusion, decreased appetite, decreased libido, disturbance in attention, dizziness, dry mouth, headache, hyperhidrosis, hypoaesthesia, malaise, muscle spasms, nausea, palpitation, paraesthesia, restlessness, sleep disorders, somnolence, tachycardia, tremor, vomiting, weight loss
- Frequency not known Dissociation, hallucinations

PREGNANCY Manufacturer advises avoid—toxicity in animal studies.

BREAST FEEDING Manufacturer advises avoid—present in milk in animal studies.

HEPATIC IMPAIRMENT Use with caution—avoid in severe impairment.

RENAL IMPAIRMENT Use with caution—avoid in severe impairment.

PRE-TREATMENT SCREENING Before initiating treatment, prescribers should evaluate the patient’s clinical status, alcohol dependence, and level of alcohol consumption. Nalmefene should only be prescribed for patients who continue to have a high drinking risk level two weeks after the initial assessment.

MONITORING REQUIREMENTS During treatment, patients should be monitored regularly and the need for continued treatment assessed.

NATIONAL FUNDING/ACCESS DECISIONS
NICE technology appraisals (TAs)
- Nalmefene for reducing alcohol consumption in people with alcohol dependence (November 2014) NICE TA325

Nalmefene is recommended within its marketing authorisation, as an option for reducing alcohol consumption, for patients with alcohol dependence:
- who have a high drinking risk level (defined as alcohol consumption of more than 60 g per day for men and more than 40 g per day for women, according to the World Health Organization’s drinking risk levels) without physical withdrawal symptoms, and
- who do not require immediate detoxification.

The marketing authorisation states that nalmefene should:
- only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption, and
- be initiated only in patients who continue to have a high drinking risk level 2 weeks after initial assessment.

www.nice.org.uk/TA325

MEDICINAL FORMS

Tablet

CAUTIONARY AND ADVISORY LABELS 25
- Selincro (Lundbeck Ltd) Nalmefene (as Nalmefene hydrochloride) 18 mg Selincro 18 mg tablets | 14 tablet (PO) £42.42 DT price = £42.42 | 28 tablet (PO) £84.84

Naltrexone hydrochloride

INDICATIONS AND DOSE
Adjuvant to prevent relapse in formerly opioid-dependent patients (who have remained opioid-free for at least 7–10 days) (initiated under specialist supervision)
- BY MOUTH
  - Adult: Initially 25 mg daily, then increased to 50 mg daily, total weekly dose may be divided and given on 3 days of the week for improved compliance (e.g. 100 mg on Monday and Wednesday, and 150 mg on Friday); maximum 350 mg per week

Adjunct to prevent relapse in formerly alcohol-dependent patients (initiated under specialist supervision)
- BY MOUTH
  - Adult: 25 mg once daily on the first day, then increased if tolerated to 50 mg daily

UNLICENSED USE 25 mg dose for adjunct to prevent relapse in formerly alcohol-dependent patients is an unlicensed dose.

CONTRA-INDICATIONS Patients currently dependent on opioids

INTERACTIONS → Appendix 1: naltrexone
8.2 Nicotine dependence

ANTIDEPRESSANTS > SEROTONIN AND NORADRENALINE RE-UPTAKE INHIBITORS

Bupropion hydrochloride
(Amfebutamone hydrochloride)

- INDICATIONS AND DOSE
  To aid smoking cessation in combination with motivational support in nicotine-dependent patients
    - BY MOUTH
    - Adult: Initially 150 mg daily for 6 days, then 150 mg twice daily (max. per dose 150 mg), minimum 8 hours between doses; period of treatment 7–9 weeks, start treatment 1–2 weeks before target stop date, discontinue if abstinence not achieved at 7 weeks, consider maximum 150 mg daily in patients with risk factors for seizures; maximum 300 mg per day
    - Elderly: 150 mg daily for 7–9 weeks, start treatment 1–2 weeks before target stop date, discontinue if abstinence not achieved at 7 weeks; maximum 150 mg per day

- CONTRA-INDICATIONS
  Acute alcohol withdrawal • acute benzodiazepine withdrawal • bipolar disorder • CNS tumour • eating disorders • history of seizures • severe hepatic cirrhosis

- CAUTIONS
  Alcohol abuse • diabetes • elderly • history of head trauma • predisposition to seizures (prescribe only if benefit clearly outweighs risk)

- INTERACTIONS
  ▶ Appendix 1: bupropion

- SIDE-EFFECTS
  ▶ Common or very common
    - Agitation • anxiety • depression • dizziness • dry mouth • fever • gastrointestinal disturbances • headache • impaired concentration • insomnia (reduced by avoiding dose at bedtime) • pruritus • rash • sweating • taste disturbance • tremor
  ▶ Uncommon
    - Anorexia • asthenia • chest pain • confusion • flushing • hypertension • tachycardia • tinnitus • visual disturbances
  ▶ Rare
    - Abnormal dreams • ataxia • blood-glucose changes • depersonalisation • dystonia • exacerbation of psoriasis • hallucinations • hepatitis • hostility • impaired memory • incoordination • irritability • jaundice • palpitation • paraesthesia • postural hypotension • seizures • Stevens-Johnson syndrome • twitching • urinary frequency • urinary retention • vasodilatation
  ▶ Very rare
    - Aggression • delusions • paranoid ideation • restlessness
  ▶ Frequency not known
    - Suicidal ideation

- PREGNANCY
  Avoid—no information available.

- BREAST FEEDING
  Present in milk—avoid.

- HEPATIC IMPAIRMENT
  Reduce dose to 150 mg daily. Avoid in severe hepatic cirrhosis.

- RENAL IMPAIRMENT
  Reduce dose to 150 mg daily.

- MONITORING REQUIREMENTS
  Measure blood pressure before and during treatment.

- PATIENT AND CARER ADVICE
  Driving and skilled tasks
  May impair performance of skilled tasks (e.g. driving).

NICOTINIC RECEPTOR AGONISTS

Nicotine

- INDICATIONS AND DOSE
  Nicotine replacement therapy in individuals who smoke fewer than 20 cigarettes each day
    ▶ BY MOUTH USING CHEWING GUM
    ▶ Adult: 2 mg as required, chew 1 piece of gum when the urge to smoke occurs or to prevent cravings, if attempting smoking cessation, treatment should continue for 3 months before reducing the dose
Nervous system

▶ BY TRANSDERMAL APPLICATION USING PATCHES
▶ BY SUBLINGUAL ADMINISTRATION USING SUBLINGUAL TABLETS
▶ BY INHALATION USING INHALATOR

Adult: 4 mg as required, chew 1 piece of gum when the urge to smoke occurs or to prevent cravings.

Cases should not exceed 15 pieces of 4-mg strength gum daily, if attempting smoking cessation, treatment should continue for 3 months before reducing the dose

Nicotine replacement therapy in individuals who smoke more than 20 cigarettes each day or who require more than 15 pieces of 2-mg strength gum each day

▶ BY MOUTH USING CHEWING GUM
▶ BY MOUTH USING LOZENGE
▶ BY MOUTH USING OROMUCOSAL SPRAY
▶ BY INHALATION USING INHALATOR
▶ BY INTRANASAL ADMINISTRATION USING NASAL SPRAY
▶ BY TRANSDERMAL APPLICATION USING PATCHES

Nicotine replacement therapy in individuals who smoke more than 20 cigarettes each day

Adult: 2 tablets every 1 hour, if attempting smoking cessation, treatment should continue for up to 3 months before reducing the dose; maximum 40 tablets per day

Nicotine replacement therapy

▶ BY INHALATION USING INHALATOR
▶ Adult: As required, the cartridges can be used when the urge to smoke occurs or to prevent cravings, individuals should not exceed 12 cartridges of the 10-mg strength daily, or 6 cartridges of the 15-mg strength daily
▶ BY MOUTH USING LOZENGE
▶ Adult: 1 lozenge every 1–2 hours as required, one lozenge should be used when the urge to smoke occurs, individuals who smoke less than 20 cigarettes each day should usually use the lower-strength lozenges; individuals who smoke more than 20 cigarettes each day and those who fail to stop smoking with the lower-strength lozenges should use the higher-strength lozenges; If attempting smoking cessation, treatment should continue for 6–12 weeks before attempting a reduction in dose; maximum 15 lozenges per day
▶ BY MOUTH USING OROMUCOSAL SPRAY
▶ Adult: 1–2 sprays as required, individuals can spray in the mouth when the urge to smoke occurs or to prevent cravings, individuals should not exceed 2 sprays per episode (up to 4 sprays every hour); maximum 64 sprays per day
▶ BY INTRANASAL ADMINISTRATION USING NASAL SPRAY
▶ Adult: 1 spray as required, individuals can spray into each nostril when the urge to smoke occurs, up to twice every hour for 16 hours daily, if attempting smoking cessation, treatment should continue for 8 weeks before reducing the dose; maximum 64 sprays per day
▶ BY TRANSDERMAL APPLICATION USING PATCHES
▶ Adult: Individuals who smoke more than 10 cigarettes daily should apply a high-strength patch daily for 6–8 weeks, followed by the medium-strength patch for 2 weeks, and then the low-strength patch for the final 2 weeks; Individuals who smoke fewer than 10 cigarettes daily can usually start with the medium-strength patch for 6–8 weeks, followed by the low-strength patch for 2–4 weeks; a slower titration schedule can be used in individuals who are not ready to quit but want to reduce cigarette consumption before a quit attempt; if abstinence is not achieved, or if withdrawal symptoms are experienced, the strength of the patch used should be maintained or increased until the patient is stabilised; individuals using the high-strength patch who experience excessive side-effects, that do not resolve within a few days, should change to a medium-strength patch for the remainder of the initial period and then use the low-strength patch for 2–4 weeks

▶ CAUTIONS

GENERAL CAUTIONS
Diabetes mellitus—blood-glucose concentration should be monitored closely when initiating treatment. haemodynamically unstable patients hospitalised with cerebrovascular accident. haemodynamically unstable patients hospitalised with myocardial infarction. haemodynamically unstable patients hospitalised with severe arrhythmias. phaeochromocytoma. uncontrolled hyperthyroidism

SPECIFIC CAUTIONS
- When used by inhalation Bronchospastic disease. chronic throat disease. obstructive lung disease
- With intransal use Bronchial asthma (may exacerbate)
- With oral (topical) use Gum may also stick to and damage dentures
- With oral use Gastritis (can be aggravated by swallowed nicotine). oesophagitis (can be aggravated by swallowed nicotine). peptic ulcers (can be aggravated by swallowed nicotine)
- With transdermal use Patches should not be placed on broken skin. patients with skin disorders

CAUTIONS, FURTHER INFORMATION
Most warnings for nicotine replacement therapy also apply to continued cigarette smoking, but the risk of continued smoking outweighs any risks of using nicotine preparations.

Specific cautions for individual preparations are usually related to the local effect of nicotine.

SIDE-EFFECTS

▶ Common or very common Bloating. blurred vision. constipation. coughing. diarrhoea. dry mouth. dyspepsia. dysphagia. epistaxis. flatulence. gastritis. gastrointestinal disturbances (may be caused by swallowed nicotine). hiccup. increased salivation. irritation of the throat. mild local reactions at the beginning of treatment are common because of the irritant effect of nicotine. minor skin irritation. mouth ulcers. nasal irritation. nausea. oesophagitis. paraesthesia. sneezing. vomiting. watery eyes
▶ Uncommon Gingival bleeding. halitosis. thirst
▶ Rare Arrhythmia
▶ Very rare Reversible atrial fibrillation
▶ Frequency not known Abdominal pain. abnormal dreams (may occur with patches. removal of the patch before bed may help). arthralgia. chest pain. flatulence. hot flushes. myalgia. palpitations. rash. sweating. taste disturbance. ulcerative stomatitis

SIDE-EFFECTS, FURTHER INFORMATION
Side-effects listed have been reported with use of various nicotine replacement therapy preparations. See Nicotine replacement therapy, under Substance dependence p. 468 for further details on individual preparations.

Nicotine withdrawal Some systemic effects occur on initiation of therapy, particularly if the patient is using high-strength preparations; however, the patient may confuse side-effects of the nicotine-replacement preparation with nicotine withdrawal symptoms.

Common symptoms of nicotine withdrawal include malaise, headache, dizziness, sleep disturbance, coughing, influenza—like symptoms. depression. irritability. increased appetite. weight gain. restlessness. anxiety. drowsiness. aphthous ulcers. decreased heart rate. and impaired concentration

PREGNANCY
The use of nicotine replacement therapy in pregnancy is preferable to the continuation of smoking, but should be used only if smoking cessation without nicotine replacement fails. Intermittent therapy is preferable to patches but avoid liquorice-flavoured nicotine products. Patches are useful, however, if the patient is experiencing pregnancy-related nausea and
vomiting. If patches are used, they should be removed before bed.

- **BREAST FEEDING** Nicotine is present in milk; however, the amount to which the infant is exposed is small and less hazardous than second-hand smoke. Intermittent therapy is preferred.

- **HEPATIC IMPAIRMENT** Use with caution in moderate to severe hepatic impairment.

- **RENAL IMPAIRMENT** Use with caution in severe renal impairment.

- **DIRECTIONS FOR ADMINISTRATION** Acids and other beverages, such as coffee or fruit juice, may decrease the absorption of nicotine through the buccal mucosa and should be avoided for 15 minutes before the use of oral nicotine replacement therapy.

Administration by transdermal patch: Patches should be applied on waking to dry, non-hairy skin on the hip, trunk, or upper arm and held in position for 10–20 seconds to ensure adhesion; place next patch on a different area and avoid using the same site for several days.

Administration by nasal spray: Initially 1 spray should be used in both nostrils but when withdrawing from therapy, the dose can be gradually reduced to 1 spray in 1 nostril.

Administration by oral spray: The oral spray should be released into the mouth, holding the spray as close to the mouth as possible and avoiding the lips. The patient should not inhale while spraying and avoid swallowing for a few seconds after use. If using the oral spray for the first time, or if not used for 2 or more days, prime the unit before administration.

Administration by sublingual tablet: Each tablet should be placed under the tongue and allowed to dissolve. Slowly allow each lozenge to dissolve in the mouth, holding the lozenge from one side of the mouth to the other. Lozenges last for 10–30 minutes, depending on their size.

Administration by inhalation: Insert the cartridge into the device and draw in air through the mouthpiece; each session can last for approximately 5 minutes. The amount of nicotine from 1 puff of the cartridge is less than that from a cigarette, therefore it is necessary to inhale more often than when smoking a cigarette. A single 10 mg cartridge lasts for approximately 20 minutes of intense use; a single 15 mg cartridge lasts for approximately 40 minutes of intense use.

Administration by medicated chewing gum: Chew the gum until the taste becomes strong; then rest it between the cheek and gum; when the taste starts to fade, repeat this process. One piece of gum lasts for approximately 30 minutes.

- **PRESCRIBING AND DISPENSING INFORMATION** Flavours of chewing gum and lozenges may include mint, freshfruit, freshmint, icy white, or cherry.

- **PATIENT AND CARER ADVICE** Patient or carers should be given advice on how to administer nicotine chewing gum, inhalators, lozenges, sublingual tablets, oral spray, nasal spray and patches.

- **MEDICINAL FORMS**

**Transdermal patch**

- **Nicotine (Non-proprietary)**

  - Nicotine 7 mg per 24 hour | 7 mg/24 hours transdermal patches | 7 patch [GSL] no price available
  - Nicotine 7 mg/24 hours transdermal patches | 7 patch [GSL] no price available

- **Nicotine 14 mg per 24 hour | 14 mg/24 hours transdermal patches | 7 patch [GSL] no price available

- **Nicotine 10 mg per 16 hour | 10 mg/16 hours patches | 7 patch [GSL] no price available

- **Nicotine 21 mg per 24 hour | 21 mg/24 hours transdermal patches | 7 patch [GSL] no price available

**Medicated chewing-gum**

- **Nicotine (Non-proprietary)**

  - Nicotine 2 mg | 2 mg medicated chewing gum sugar-free | 105 piece [GSL] no price available
  - Nicotine 4 mg | 4 mg medicated chewing gum sugar-free | 105 piece [GSL] no price available

  - Brands may include NiQuitin, NiQuitin Clear, Nicorette invisi, Nicotinell TTS

- **Nicotine (as Nicotine cyclodextrin complex) 2 mg | 2 mg sublingual tablets sugar-free | 100 tablet [GSL] no price available

  - Brands may include Nicorette Microtab

**Varenicline**

- **DRUG ACTION** Varenicline is a selective nicotine-receptor partial agonist.

- **INDICATIONS AND DOSE**

**To aid smoking cessation**

- **BY MOUTH**

  - Adult: Initially 500 micrograms once daily for 3 days, increased to 500 micrograms twice daily for 4 days, then 1 mg twice daily for 11 weeks; reduced if not tolerated to 500 micrograms twice daily, usually to be started 1–2 weeks before target stop date but can be started up to a maximum of 5 weeks before target stop date, 12-week course can be repeated in abstinent individuals to reduce risk of relapse

**IMPORTANT SAFETY INFORMATION**

**MHRA/CHM ADVICE: SUICIDAL BEHAVIOUR AND VARENICLINE**

Patients should be advised to discontinue treatment and seek prompt medical advice if they develop agitation, depressed mood, or suicidal thoughts. Patients with a history of psychiatric illness should be monitored closely while taking varenicline.

- **CAUTIONS**

  - Conditions that may lower seizure threshold: history of cardiovascular disease; history of psychiatric illness (may exacerbate underlying illness including depression); predisposition to seizures

- **SIDE-EFFECTS**

  - Common or very common: Taste disturbance; abnormal dreams; appetite changes; dizziness; drowsiness; dry mouth; gastro-intestinal disturbances; headache; sleep disorders
8.3 Opioid dependence

Other drugs used for Opioid dependence
Naltrexone hydrochloride, p. 472

**Analgesics > Opioids**

**Methadone hydrochloride**

- **INDICATIONS AND DOSE**
  - **Severe pain**
    - **BY MOUTH, OR BY SUBCUTANEOUS INJECTION, OR BY INTRAMUSCULAR INJECTION**
    - Adult: 5–10 mg every 6–8 hours, adjusted according to response, on prolonged use not to be given more frequently than every 12 hours
  - **Adjunct in treatment of opioid dependence**
    - **BY MOUTH USING ORAL SOLUTION**
    - Adult: Initially 10–30 mg daily, increased in steps of 5–10 mg daily if required until no signs of withdrawal

- **ADJUNCT IN TREATMENT CESSATION**
  - Frequency not known
  - Rare

- **PREGNANCY**
  - Methadone hydrochloride doses for opioid dependence in the BNF may differ from those in the product literature.

- **OTHER**
  - Unlicensed use: Methadone hydrochloride doses for opioid dependence in the BNF may differ from those in the product literature.

**Important safety information**

Methadone oral solution 1 mg/mL is 2½ times the strength of Methadone Linctus (2 mg/5 mL). Many preparations of Methadone oral solution are licensed for opioid drug addiction only but some are also licensed for analgesia in severe pain.

- **CONTRA-INDICATIONS**
  - Phaeochromocytoma

- **CAUTIONS**
  - Family history of sudden death (ECG monitoring recommended) - history of cardiac conduction abnormalities

- **FURTHER INFORMATION**
  - QT interval prolongation
  - Patients with the following risk factors for QT interval prolongation should be carefully monitored while taking methadone: heart or liver disease, electrolyte abnormalities, or concomitant treatment with drugs that can prolong QT interval; patients requiring more than 100 mg daily should also be monitored.

- **INTERACTIONS**
  - Appendix 1 - opioids

- **SIDE-EFFECTS**
  - Dry eyes • dysmenorrhoea • hyperprolactinaemia • hypothermia • QT-interval prolongation • raised intracranial pressure • restlessness • torsade de points

**Side-effects, further information**

Methadone is a long-acting opioid therefore effects may be cumulative.

Methadone, even in low doses, is a special hazard for children; non-dependent adults are also at risk of toxicity; dependent adults are at risk if tolerance is incorrectly assessed during induction.

**Overdose**

Methadone has a very long duration of action; patients may need to be monitored for long periods following large overdoses.
Methadone hydrochloride 25 mg per 1 ml Physeptone 50mg/2ml solution for injection ampoules | 10 ampoule (Pha) £15.06 (CD2)
Methadone hydrochloride 50 mg per 1 ml Physeptone 50mg/1ml solution for injection ampoules | 10 ampoule (Pha) £15.06 (CD2)

Opioid receptor antagonists

**Buprenorphine with naloxone**

The properties listed below are those particular to the combination only. For the properties of the components please consider, buprenorphine p. 425, naloxone hydrochloride p. 1259.

**INDICATIONS AND DOSE**

Adjunct in the treatment of opioid dependence (dose expressed as buprenorphine)

- **BY SUBLINGUAL ADMINISTRATION**
  - Adult: Initially 2–4 mg once daily, an additional dose of 2–4 mg may be administered on day 1 depending on the individual patient’s requirement, increased in steps of 2–8 mg, adjusted according to response, total weekly dose may be divided and given on alternate days or 3 times weekly; maximum 24 mg per day

**INTERACTIONS**

Appendix 1: naloxone, opioids

**NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (February 2007) that Suboxone® should be restricted for use in patients in whom methadone is not suitable.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, capsule, oral suspension, oral solution, solution for injection

**Tablet**

CAUTIONARY AND ADVISORY LABELS 2

- Physeptone (Martindale Pharmaceuticals Ltd) Methadone hydrochloride 5 mg Physeptone 5mg tablets | 50 tablet (Pha) £2.41 DT price = £2.41 CD2

Solution for injection

- Methadone hydrochloride (Non-proprietary)
  - Methadone hydrochloride 10 mg per 1 ml Methadone 35mg/3.5ml solution for injection ampoules | 10 ampoule (Pha) £13.92 DT price = £12.87 CD2
  - Methadone hydrochloride 25 mg per 1 ml Methadone 50mg/2ml solution for injection ampoules | 10 ampoule (Pha) no price available CD2
  - Methadone hydrochloride 50 mg per 1 ml Methadone 50mg/1ml solution for injection ampoules | 10 ampoule (Pha) no price available CD2

- Physeptone (Martindale Pharmaceuticals Ltd) Methadone hydrochloride 10 mg per 1 ml Physeptone 35mg/3.5ml solution for injection ampoules | 10 ampoule (Pha) £12.87 DT price = £12.87 CD2
  - Physeptone 50mg/5ml solution for injection ampoules | 10 ampoule (Pha) £13.88 DT price = £13.88 CD2
  - Physeptone 10mg/1ml solution for injection ampoules | 10 ampoule (Pha) £6.49 DT price = £6.49 CD2 | 100 ampoule (Pha) £62.10 CD2
  - Physeptone 20mg/2ml solution for injection ampoules | 10 ampoule (Pha) £11.17 DT price = £11.17 CD2

**OPIOID RECEPTOR ANTAGONISTS**

Buprenorphine with naloxone

- There can be variation in the licensing of different medicines containing the same drug.

Sublingual tablet

CAUTIONARY AND ADVISORY LABELS 2, 26

- Suboxone (Indivior UK Ltd) Naloxone (as Naloxone hydrochloride) 500 microgram, Buprenorphine (as Buprenorphine hydrochloride) 2 mg Suboxone 2mg/500microgram sublingual tablets sugar-free | 28 tablet (Pha) £25.40 DT price = £25.40 CD2
  - Naloxone (as Naloxone hydrochloride) 2 mg, Buprenorphine (as Buprenorphine hydrochloride) 8 mg Suboxone 8mg/2mg sublingual tablets sugar-free | 28 tablet (Pha) £76.19 DT price = £76.19 CD2
  - Naloxone (as Naloxone hydrochloride) 4 mg, Buprenorphine (as Buprenorphine hydrochloride) 16 mg Suboxone 16mg/4mg sublingual tablets sugar-free | 28 tablet (Pha) £152.38 CD3
**Lofexidine hydrochloride**

**DRUG ACTION** Lofexidine is an alpha₂-adrenergic agonist.

**INDICATIONS AND DOSE**

**Management of symptoms of opioid withdrawal**

- **BY MOUTH**
  - **Adult:** Initially 800 micrograms daily in divided doses, increased in steps of 400–800 micrograms daily (max. per dose 800 micrograms) as required recommended duration of treatment 7–10 days if no opioid use (but longer may be required); maximum 2.4 mg per day

**CAUTIONS** Bradycardia, cerebrovascular disease, depression, history of QT prolongation, hypotension (monitor pulse rate and blood pressure), metabolic disturbances, recent myocardial infarction, severe coronary insufficiency

**INTERACTIONS** → Appendix 1: lofexidine

**SIDE-EFFECTS** Bradycardia, dizziness, drowsiness, dry mucous membranes, hypotension, QT-interval prolongation

**PREGNANCY** Use only if benefit outweighs risk—no information available.

**BREAST FEEDING** Use only if benefit outweighs risk—no information available.

**RENAL IMPAIRMENT** Caution in chronic impairment.

**MONITORING REQUIREMENTS** Monitoring of blood pressure and pulse rate is recommended on initiation, for at least 72 hours or until a stable dose is achieved, and on discontinuation.

**TREATMENT CESSATION** Treatment should be withdrawn gradually over 2–4 days (or longer) to reduce the risk of rebound hypertension and associated symptoms.

**PRESCRIBING AND DISPENSING INFORMATION** Lofexidine has been used in children over 12 years in the management of symptoms of opioid withdrawal.

**PATIENT AND CARER ADVICE** The patient should take part of the dose at bedtime to offset insomnia associated with opioid withdrawal.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

CAUTIONARY AND ADVISORY LABELS 2

- BritLofex (Britannia Pharmaceuticals Ltd)
  - Lofexidine hydrochloride 200 microgram BritLofex 200 microgram tablets | 60 tablet [PSt] £61.79
Chapter 5
Infection

CONTENTS

1 Amoebic infection  page 479
2 Bacterial infection  479
  2.1 Anthrax  544
  2.2 Leprosy  544
  2.3 Lyme disease  545
  2.4 Methicillin-resistant staphylococcus aureus  545
  2.5 Tuberculosis  546
  2.6 Urinary tract infections  556
3 Fungal infection  558
  3.1 Pneumocystis pneumonia  568
4 Helminth infection  570
5 Protozoal infection  572
  5.1 Leishmaniasis  573

1 Amoebic infection

Other drugs used for Amoebic infection Metronidazole, p. 512 • Tinidazole, p. 514

ANTIPROTOZOALS

Diloxanide furoate

- INDICATIONS AND DOSE
  Chronic amoebiasis • Acute amoebiasis as adjunct to metronidazole or tinidazole
    ▶ BY MOUTH
    • Child 12-17 years: 500 mg 3 times a day for 10 days
    • Adult: 500 mg 3 times a day for 10 days

- UNLICENSED USE Not licensed for use in children under 25 kg body-weight.
- SIDE-EFFECTS Flatulence • pruritus • urticaria • vomiting
- PREGNANCY Manufacturer advises avoid—no information available.
- BREAST FEEDING Manufacturer advises avoid.

- MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet

Mepacrine hydrochloride

- INDICATIONS AND DOSE
  Giardiasis
    ▶ BY MOUTH
    • Adult: 100 mg every 8 hours for 5–7 days

- UNLICENSED USE Not licensed for use in giardiasis.

- CAUTIONS Avoid in psoriasis • elderly • history of psychosis
- INTERACTIONS ➔ Appendix 1: mepacrine
- SIDE-EFFECTS Yellow discoloration of skin (on prolonged treatment) • aplastic anaemia (on prolonged treatment) • blue/black discoloration of nails • blue/black discoloration of palate • chronic dermatoses (on prolonged treatment) • CNS stimulation (with large doses) • corneal deposits with visual disturbances • dizziness • gastro-intestinal disturbances • headache • hepatitis (on prolonged treatment) • nausea (with large doses) • severe exfoliative dermatitis (on prolonged treatment) • transient acute toxic psychosis (with large doses) • vomiting (with large doses) • yellow discoloration of urine (on prolonged treatment)

- HEPATIC IMPAIRMENT Use with caution.

- MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet

2 Bacterial infection

Antibacterials, principles of therapy

Choice of a suitable drug

Before selecting an antibacterial the clinician must first consider two factors—the patient and the known or likely causative organism. Factors related to the patient which must be considered include history of allergy, renal and hepatic function, susceptibility to infection (i.e. whether immunocompromised), ability to tolerate drugs by mouth, severity of illness, ethnic origin, age, whether taking other medication and, if female, whether pregnant, breast-feeding or taking an oral contraceptive.

The known or likely organism and its antibacterial sensitivity, in association with the above factors, will suggest one or more antibacterials, the final choice depending on the microbiological, pharmacological, and toxicological properties.
An example of a rational approach to the selection of an antibacterial is treatment of a urinary-tract infection in a patient complaining of nausea and symptoms of a urinary-tract infection in early pregnancy. The organism is reported as being resistant to ampicillin p. 520 but sensitive to nitrofurantoin p. 557 (can cause nausea), gentamicin p. 491 (can be given only by injection and best avoided in pregnancy), tetracycline p. 536 (causes dental discoloration) and trimethoprim p. 542 (folate antagonist therefore theoretical teratogenic risk), and cefalexin p. 497. The safest antibiotics in pregnancy are the penicillins and cephalosporins; therefore, cefalexin would be indicated for this patient.

The principles involved in selection of an antibacterial must allow for a number of variables including changing renal and hepatic function, increasing bacterial resistance, and information on side-effects. Duration of therapy, dosage, and route of administration depend on site, type and severity of infection and response.

Antibacterial policies
Local policies often limit the antibacterials that may be used to achieve reasonable economy consistent with adequate cover, and to reduce the development of resistant organisms. A policy may indicate a range of drugs for general use, and permit other drugs only on the advice of the microbiologist or physician responsible for the control of infectious diseases.

Before starting therapy
The following precepts should be considered before starting:

- **Viral infections should not be treated with antibacterials.** However, antibacterials may be used to treat secondary bacterial infection (e.g. bacterial pneumonia secondary to influenza);
- **Samples should be taken for culture and sensitivity testing;** ‘blind’ antibacterial prescribing for unexplained pyrexia usually leads to further difficulty in establishing the diagnosis;
- **Knowledge of prevalent organisms and their current sensitivity is of great help in choosing an antibacterial before bacteriological confirmation is available.** Generally, narrow-spectrum antibacterials are preferred to broad-spectrum antibacterials unless there is a clear clinical indication (e.g. life-threatening sepsis);
- **The dose of an antibacterial varies according to a number of factors including age, weight, hepatic function, renal function, and severity of infection.** The prescribing of the so-called ‘standard’ dose in serious infections may result in failure of treatment or even death of the patient; therefore it is important to prescribe a dose appropriate to the condition. An inadequate dose may also increase the likelihood of antibacterial resistance. On the other hand, for an antibacterial with a narrow margin between the toxic and therapeutic dose (e.g. an aminoglycoside) it is also important to avoid an excessive dose and the concentration of the drug in the plasma may need to be monitored;
- **The route of administration of an antibacterial often depends on the severity of the infection.** Life-threatening infections require intravenous therapy. Antibacterials that are well absorbed may be given by mouth even for some serious infections. Parenteral administration is also appropriate when the oral route cannot be used (e.g. because of vomiting) or if absorption is inadequate. Whenever possible, painful intramuscular injections should be avoided in children;
- **Duration of therapy depends on the nature of the infection and the response to treatment.** Courses should not be unduly prolonged because they encourage resistance, they may lead to side-effects and they are costly. However, in certain infections such as tuberculosis or osteomyelitis it may be necessary to treat for prolonged periods. Conversely a single dose of an antibacterial may cure uncomplicated urinary-tract infections. The prescription for an antibacterial should specify the duration of treatment or the date when treatment is to be reviewed.

Superinfection
In general, broad-spectrum antibacterial drugs such as the cephalosporins are more likely to be associated with adverse reactions related to the selection of resistant organisms e.g. *fungal infections or antibiotic-associated colitis* (pseudomembranous colitis); other problems associated with superinfection include vaginitis and pruritus ani.

**Therapy**
When the pathogen has been isolated treatment may be changed to a more appropriate antibacterial if necessary. If no bacterium is cultured the antibacterial can be continued or stopped on clinical grounds.

Notifiable diseases
Doctors must notify the Proper Officer of the local authority (usually the consultant in communicable disease control) when attending a patient suspected of suffering from any of the diseases listed below; a form is available from the Proper Officer.

**Antibacterial prescribing for unexplained fever**

<table>
<thead>
<tr>
<th>Disease</th>
<th>Antimicrobial</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthrax</td>
<td>Mumps</td>
<td></td>
</tr>
<tr>
<td>Botulism</td>
<td>Paratyphoid fever</td>
<td></td>
</tr>
<tr>
<td>Brucellosis</td>
<td>Plague</td>
<td></td>
</tr>
<tr>
<td>Cholera</td>
<td>Poliomyelitis, acute</td>
<td></td>
</tr>
<tr>
<td>Diarrhoea (infectious bloody)</td>
<td>Rabies</td>
<td></td>
</tr>
<tr>
<td>Diptheria</td>
<td>Rubella</td>
<td></td>
</tr>
<tr>
<td>Encephalitis, acute</td>
<td>SARS</td>
<td></td>
</tr>
<tr>
<td>Food poisoning</td>
<td>Salmonella fever</td>
<td></td>
</tr>
<tr>
<td>Haemolytic uraemic syndrome</td>
<td>Smallpox</td>
<td></td>
</tr>
<tr>
<td>Haemorrhagic fever (viral)</td>
<td>Streptococcal disease (Group A, invasive)</td>
<td></td>
</tr>
<tr>
<td>Hepatitis, viral</td>
<td>Tetanus</td>
<td></td>
</tr>
<tr>
<td>Legionnaires’ disease</td>
<td>Tuberculosis</td>
<td></td>
</tr>
<tr>
<td>Leprosy</td>
<td>Typhoid fever</td>
<td></td>
</tr>
<tr>
<td>Malaria</td>
<td>Typhus</td>
<td></td>
</tr>
<tr>
<td>Measles</td>
<td>Whooping cough</td>
<td></td>
</tr>
<tr>
<td>Meningitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal septicaemia</td>
<td>Yellow fever</td>
<td></td>
</tr>
</tbody>
</table>

**Note** It is good practice for doctors to also inform the consultant in communicable disease control of instances of other infections (e.g. psittacosis) where there could be a public health risk.

**Sepsis, early management**

<table>
<thead>
<tr>
<th>Disease</th>
<th>Antimicrobial</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthrax</td>
<td>Mumps</td>
<td></td>
</tr>
<tr>
<td>Botulism</td>
<td>Paratyphoid fever</td>
<td></td>
</tr>
<tr>
<td>Brucellosis</td>
<td>Plague</td>
<td></td>
</tr>
<tr>
<td>Cholera</td>
<td>Poliomyelitis, acute</td>
<td></td>
</tr>
<tr>
<td>Diarrhoea (infectious bloody)</td>
<td>Rabies</td>
<td></td>
</tr>
<tr>
<td>Diptheria</td>
<td>Rubella</td>
<td></td>
</tr>
<tr>
<td>Encephalitis, acute</td>
<td>SARS</td>
<td></td>
</tr>
<tr>
<td>Food poisoning</td>
<td>Salmonella fever</td>
<td></td>
</tr>
<tr>
<td>Haemolytic uraemic syndrome</td>
<td>Smallpox</td>
<td></td>
</tr>
<tr>
<td>Haemorrhagic fever (viral)</td>
<td>Streptococcal disease (Group A, invasive)</td>
<td></td>
</tr>
<tr>
<td>Hepatitis, viral</td>
<td>Tetanus</td>
<td></td>
</tr>
<tr>
<td>Legionnaires’ disease</td>
<td>Tuberculosis</td>
<td></td>
</tr>
<tr>
<td>Leprosy</td>
<td>Typhoid fever</td>
<td></td>
</tr>
<tr>
<td>Malaria</td>
<td>Typhus</td>
<td></td>
</tr>
<tr>
<td>Measles</td>
<td>Whooping cough</td>
<td></td>
</tr>
<tr>
<td>Meningitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal septicaemia</td>
<td>Yellow fever</td>
<td></td>
</tr>
</tbody>
</table>

**Note** It is good practice for doctors to also inform the consultant in communicable disease control of instances of other infections (e.g. psittacosis) where there could be a public health risk.

**Sepsis, early management**

<table>
<thead>
<tr>
<th>Disease</th>
<th>Antimicrobial</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthrax</td>
<td>Mumps</td>
<td></td>
</tr>
<tr>
<td>Botulism</td>
<td>Paratyphoid fever</td>
<td></td>
</tr>
<tr>
<td>Brucellosis</td>
<td>Plague</td>
<td></td>
</tr>
<tr>
<td>Cholera</td>
<td>Poliomyelitis, acute</td>
<td></td>
</tr>
<tr>
<td>Diarrhoea (infectious bloody)</td>
<td>Rabies</td>
<td></td>
</tr>
<tr>
<td>Diptheria</td>
<td>Rubella</td>
<td></td>
</tr>
<tr>
<td>Encephalitis, acute</td>
<td>SARS</td>
<td></td>
</tr>
<tr>
<td>Food poisoning</td>
<td>Salmonella fever</td>
<td></td>
</tr>
<tr>
<td>Haemolytic uraemic syndrome</td>
<td>Smallpox</td>
<td></td>
</tr>
<tr>
<td>Haemorrhagic fever (viral)</td>
<td>Streptococcal disease (Group A, invasive)</td>
<td></td>
</tr>
<tr>
<td>Hepatitis, viral</td>
<td>Tetanus</td>
<td></td>
</tr>
<tr>
<td>Legionnaires’ disease</td>
<td>Tuberculosis</td>
<td></td>
</tr>
<tr>
<td>Leprosy</td>
<td>Typhoid fever</td>
<td></td>
</tr>
<tr>
<td>Malaria</td>
<td>Typhus</td>
<td></td>
</tr>
<tr>
<td>Measles</td>
<td>Whooping cough</td>
<td></td>
</tr>
<tr>
<td>Meningitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal septicaemia</td>
<td>Yellow fever</td>
<td></td>
</tr>
</tbody>
</table>

**Note** It is good practice for doctors to also inform the consultant in communicable disease control of instances of other infections (e.g. psittacosis) where there could be a public health risk.

**Sepsis, early management**

<table>
<thead>
<tr>
<th>Disease</th>
<th>Antimicrobial</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthrax</td>
<td>Mumps</td>
<td></td>
</tr>
<tr>
<td>Botulism</td>
<td>Paratyphoid fever</td>
<td></td>
</tr>
<tr>
<td>Brucellosis</td>
<td>Plague</td>
<td></td>
</tr>
<tr>
<td>Cholera</td>
<td>Poliomyelitis, acute</td>
<td></td>
</tr>
<tr>
<td>Diarrhoea (infectious bloody)</td>
<td>Rabies</td>
<td></td>
</tr>
<tr>
<td>Diptheria</td>
<td>Rubella</td>
<td></td>
</tr>
<tr>
<td>Encephalitis, acute</td>
<td>SARS</td>
<td></td>
</tr>
<tr>
<td>Food poisoning</td>
<td>Salmonella fever</td>
<td></td>
</tr>
<tr>
<td>Haemolytic uraemic syndrome</td>
<td>Smallpox</td>
<td></td>
</tr>
<tr>
<td>Haemorrhagic fever (viral)</td>
<td>Streptococcal disease (Group A, invasive)</td>
<td></td>
</tr>
<tr>
<td>Hepatitis, viral</td>
<td>Tetanus</td>
<td></td>
</tr>
<tr>
<td>Legionnaires’ disease</td>
<td>Tuberculosis</td>
<td></td>
</tr>
<tr>
<td>Leprosy</td>
<td>Typhoid fever</td>
<td></td>
</tr>
<tr>
<td>Malaria</td>
<td>Typhus</td>
<td></td>
</tr>
<tr>
<td>Measles</td>
<td>Whooping cough</td>
<td></td>
</tr>
<tr>
<td>Meningitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal septicaemia</td>
<td>Yellow fever</td>
<td></td>
</tr>
</tbody>
</table>

**Note** It is good practice for doctors to also inform the consultant in communicable disease control of instances of other infections (e.g. psittacosis) where there could be a public health risk.
death. Patients at high risk should be monitored continuously if possible, and no less than every 30 minutes.

Patients with suspected sepsis who are not immediately deemed to be at high risk of severe illness or death, should be re-assessed regularly for the need for empirical treatment, taking into consideration all risk factors including lactate concentration and evidence of acute kidney injury.

Prevention of recurrence of rheumatic fever
- Phenoxymethylpenicillin p. 518 or sulfadiazine p. 532.

Prevention of secondary case of invasive group A streptococcal infection
- Phenoxymethylpenicillin.

Patients who are penicillin allergic, either erythromycin p. 510 or azithromycin p. 507 [unlicensed indication].

For details of those who should receive chemoprophylaxis contact a consultant in communicable disease control (or a consultant in infectious diseases or the local Public Health England Laboratory).

Prevention of secondary case of meningococcal meningitis
- Ciprofloxacin p. 527 or rifampicin p. 549 or i/m ceftriaxone p. 501 [unlicensed indication].

For details of those who should receive chemoprophylaxis contact a consultant in communicable disease control (or a consultant in infectious diseases or the local Public Health England laboratory). Unless there has been direct exposure of the mouth or nose to infectious droplets from a patient with meningococcal disease who has received less than 24 hours of antibacterial treatment, healthcare workers do not generally require chemoprophylaxis.

Prevention of secondary case of *Haemophilus influenzae* type b disease
- Rifampicin or (if rifampicin cannot be used) i/m or i/v ceftriaxone [unlicensed indication].

For details of those who should receive chemoprophylaxis contact a consultant in communicable disease control (or a consultant in infectious diseases or the local Public Health England laboratory). Unless there has been direct exposure of the mouth or nose to infectious droplets from a patient with meningococcal disease who has received less than 24 hours of antibacterial treatment, healthcare workers do not generally require chemoprophylaxis.

Within 4 weeks of illness onset in an index case with confirmed or suspected invasive *Haemophilus influenzae* type b disease, give antibacterial prophylaxis to all household contacts if there is a vulnerable individual in the household. Also, give antibacterial prophylaxis to the index case if they are in contact with vulnerable household contacts or if they are under 10 years of age. Vulnerable individuals include the immunocompromised, those with asplenia, or children under 10 years of age. If there are 2 or more cases of invasive *Haemophilus influenzae* type b disease within 120 days in a pre-school or primary school, antibacterial prophylaxis should also be given to all room contacts (including staff). Also see immunisation against *Haemophilus influenzae* type b disease.

Prevention of secondary case of diphtheria in non-immune patient
- Erythromycin (or another macrolide e.g. azithromycin or clarithromycin p. 508).

Treat for further 10 days if nasopharyngeal swabs positive after first 7 days’ treatment.

Prevention of pertussis
- Clarithromycin (or azithromycin or erythromycin).

Within 3 weeks of onset of cough in the index case, give antibacterial prophylaxis to all close contacts if amongst them there is at least one unimmunised or partially immunised child under 1 year of age, or if there is at least one individual who has not received a pertussis-containing vaccine more than 1 week and less than 5 years ago (so long as that individual lives or works with children under 4 months of age, is pregnant at over 32 weeks gestation, or is a healthcare worker who works with children under 1 year of age or with pregnant women).

Prevention of pneumococcal infection in asplenia or in patients with sickle-cell disease
- Phenoxymethylpenicillin.

If penicillin-allergic, erythromycin.

Antibacterial prophylaxis is not fully reliable. Antibacterial prophylaxis may be discontinued in children over 5 years of age with sickle-cell disease who have received pneumococcal immunisation and who do not have a history of severe pneumococcal infection.

Prevention of tuberculosis in susceptible close contacts or those who have become tuberculin positive

Prevention of infection from animal and human bites
- Co-amoxiclav p. 521 alone (or doxycycline p. 534 + metronidazole p. 512 if penicillin-allergic).

Cleanse wound thoroughly. For tetanus-prone wound, give human tetanus immunoglobulin p. 1188 (with a tetanus-containing vaccine if necessary, according to immunisation history and risk of infection).

Consider rabies prophylaxis for bites from animals in endemic countries. Assess risk of blood-borne viruses (including HIV, hepatitis B and C) and give appropriate prophylaxis to prevent viral spread.

Antibacterial prophylaxis recommended for wounds less than 48–72 hours old when the risk of infection is high (e.g. bites from humans or cats; bites to the hand, foot, face, or genital area; bites involving oedema, crush or puncture injury, or other moderate to severe injury; wounds that cannot be debrided adequately; patients with diabetes mellitus, cirrhosis, asplenia, prosthetic joints or valves, or those who are immunocompromised). Give antibacterial prophylaxis for up to 5 days.

Prevention of early-onset neonatal infection
- i/v benzylpenicillin sodium p. 517 (or i/v clindamycin p. 506 if history of allergy to penicillins).

Give intrapartum prophylaxis to women with group B streptococcal colonisation, bacteriuria, or infection in the current pregnancy, or to women who had a previous baby with an invasive group B streptococcal infection. Consider prophylaxis for women in preterm labour if there is prelabour rupture of membranes or if intrapartum rupture of membranes lasting more than 18 hours is suspected.
Prevention of infection in gastro-intestinal procedures

Operations on stomach or oesophagus
- Single dose of i/v gentamicin p. 491 or i/v cefuroxime p. 498 or i/v co-amoxiclav (additional intra-operative or postoperative doses may be given for prolonged procedures or if there is major blood loss).

Intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure.

Add i/v teicoplanin p. 504 (or vancomycin p. 505) if high risk of meticillin-resistant Staphylococcus aureus.

Open biliary surgery
- Single dose of i/v cefuroxime + i/v metronidazole or i/v gentamicin + i/v metronidazole or i/v co-amoxiclav alone (additional intra-operative or postoperative doses may be given for prolonged procedures or if there is major blood loss).

Intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure.

Where i/v metronidazole is suggested, it may alternatively be given by suppository but to allow adequate absorption, it should be given 2 hours before surgery.

Add i/v teicoplanin (or vancomycin) if high risk of meticillin-resistant Staphylococcus aureus.

Resections of colon and rectum for carcinoma, and resections in inflammatory bowel disease, and appendicectomy
- Single dose of i/v gentamicin + i/v metronidazole or i/v cefuroxime + i/v metronidazole or i/v co-amoxiclav alone (additional intra-operative or postoperative doses may be given for prolonged procedures or if there is major blood loss).

Intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure.

Where i/v metronidazole is suggested, it may alternatively be given by suppository but to allow adequate absorption, it should be given 2 hours before surgery.

Add i/v teicoplanin p. 504 (or vancomycin p. 505) if high risk of meticillin-resistant Staphylococcus aureus.

Endoscopic retrograde cholangiopancreatography
- Single dose of i/v gentamicin p. 491 or oral or i/v ciprofloxacin p. 527.

Intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure.

Prophylaxis recommended if pancreatic pseudocyst, immunocompromised, history of liver transplantation, or risk of incomplete biliary drainage. For biliary complications following liver transplantation, add i/v amoxicillin p. 518 or i/v teicoplanin (or vancomycin).

Percutaneous endoscopic gastrostomy or jejunostomy
- Single dose of i/v co-amoxiclav p. 521 or i/v cefuroxime p. 498.

Intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure.

Use single dose of i/v teicoplanin (or vancomycin) if history of allergy to penicillins or cephalosporins, or if high risk of meticillin-resistant Staphylococcus aureus.

Prevention of infection in orthopaedic surgery

Joint replacement including hip and knee
- Single dose of i/v cefuroxime alone or i/v flucloxacillin p. 523+ i/v gentamicin (additional intra-operative or postoperative doses may be given for prolonged procedures or if there is major blood loss).

Intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure.

If history of allergy to penicillins or to cephalosporins or if high risk of meticillin-resistant Staphylococcus aureus, use single dose of i/v teicoplanin (or vancomycin) + i/v gentamicin (additional intra-operative or postoperative doses may be given for prolonged procedures or if there is major blood loss).

Closed fractures
- Single dose of i/v cefuroxime or i/v flucloxacillin (additional intra-operative or postoperative doses may be given for prolonged procedures or if there is major blood loss).

Intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure.

If history of allergy to penicillins or to cephalosporins or if high risk of meticillin-resistant Staphylococcus aureus, use single dose of i/v teicoplanin (or vancomycin) (additional intra-operative or postoperative doses may be given for prolonged procedures or if there is major blood loss).

Open fractures
- Use i/v co-amoxiclav alone or i/v cefuroxime + i/v metronidazole p. 512 (or i/v clindamycin p. 506 alone if history of allergy to penicillins or to cephalosporins).

Add i/v teicoplanin (or vancomycin) if high risk of meticillin-resistant Staphylococcus aureus. Start prophylaxis within 3 hours of injury and continue until soft tissue closure (max. 72 hours).

At first debridement also use a single dose of i/v cefuroxime + i/v metronidazole + i/v gentamicin or i/v co-amoxiclav + i/v gentamicin (or i/v clindamycin + i/v gentamicin if history of allergy to penicillins or to cephalosporins).

At time of skeletal stabilisation and definitive soft tissue closure use a single dose of i/v gentamicin + i/v teicoplanin (or vancomycin) (intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure).

High lower-limb amputation
- Use i/v co-amoxiclav alone or i/v cefuroxime + i/v metronidazole.

Intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure.

Continue antibacterial prophylaxis for at least 2 doses after procedure (max. duration of prophylaxis 5 days). If history of allergy to penicillins or to cephalosporins, or if high risk of meticillin-resistant Staphylococcus aureus, use i/v teicoplanin (or vancomycin) + i/v gentamicin + i/v metronidazole.

Where i/v metronidazole is suggested, it may alternatively be given by suppository but to allow adequate absorption, it should be given 2 hours before surgery.

Prevention of infection in urological procedures

Transrectal prostate biopsy
- Single dose of oral ciprofloxacin + oral metronidazole or i/v gentamicin + i/v metronidazole (additional intra-operative or postoperative doses may be given for prolonged procedures or if there is major blood loss).

Intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure.

Use single dose of i/v gentamicin + i/v metronidazole if high risk of meticillin-resistant Staphylococcus aureus (additional intra-operative or postoperative doses of antibacterial may be given for prolonged procedures or if there is major blood loss).

Where i/v metronidazole is suggested, it may alternatively be given by suppository but to allow adequate absorption, it should be given 2 hours before surgery.

Transurethral resection of prostate
- Single dose of oral ciprofloxacin or i/v gentamicin or i/v cefuroxime (additional intra-operative or postoperative doses may be given for prolonged procedures or if there is major blood loss).
Intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure.

Use single dose of i/v gentamicin if high risk of meticillin-resistant *Staphylococcus aureus* (additional intra- or postoperative doses may be given for prolonged procedures or if there is major blood loss).

**Prevention of infection in obstetric and gynaecological surgery**

**Caesarean section**
- Single dose of i/v cefuroxime (additional intra- or postoperative doses may be given for prolonged procedures or if there is major blood loss).

Intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure.

Substitute i/v clindamycin if history of allergy to penicillins or cephalosporins. Add i/v teicoplanin (or vancomycin) if high risk of meticillin-resistant *Staphylococcus aureus*.

**Hysteroscopy**
- Single dose of i/v cefuroxime + i/v metronidazole or i/v gentamicin + i/v metronidazole or i/v co-amoxiclav alone (additional intra- or postoperative doses may be given for prolonged procedures or if there is major blood loss).

Intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure.

Use single dose of i/v gentamicin + i/v metronidazole or add i/v teicoplanin (or vancomycin) to other regimens if high risk of meticillin-resistant *Staphylococcus aureus* (additional intra- or postoperative doses may be given for prolonged procedures or if there is major blood loss).

Where i/v metronidazole is suggested, it may alternatively be given by suppository but to allow adequate absorption, it should be given 2 hours before surgery.

**Termination of pregnancy**
- Single dose of oral metronidazole (additional intra- or postoperative doses may be given for prolonged procedures or if there is major blood loss).

If genital chlamydial infection cannot be ruled out, give doxycycline p. 534 postoperatively.

**Prevention of infection in cardiology procedures**

**Cardiac pacemaker insertion**
- Single dose of i/v cefuroxime alone or i/v flucloxacillin + i/v gentamicin or i/v teicoplanin (or vancomycin) + i/v gentamicin (additional intra- or postoperative doses may be given for prolonged procedures or if there is major blood loss).

Intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure.

Use single dose of i/v teicoplanin (or vancomycin) + i/v cefuroxime or i/v teicoplanin (or vancomycin) + i/v gentamicin if high risk of meticillin-resistant *Staphylococcus aureus* (additional intra- or postoperative doses may be given for prolonged procedures or if there is major blood loss).

**Prevention of infection in vascular surgery**

**Reconstructive arterial surgery of abdomen, pelvis or legs**
- Single dose of i/v cefuroxime p. 498 alone or i/v flucloxacillin p. 523 + i/v gentamicin p. 491 (additional intra- or postoperative doses may be given for prolonged procedures or if there is major blood loss).

Intravenous antibacterial prophylaxis should be given up to 30 minutes before the procedure.

Add i/v metronidazole p. 512 for patients at risk from anaerobic infections including those with diabetes, gangrene, or undergoing amputation. Use single dose of i/v teicoplanin p. 504 (or vancomycin p. 505) + i/v gentamicin if history of allergy to penicillins or cephalosporins, or if high risk of meticillin-resistant *Staphylococcus aureus* (additional intra- or postoperative doses may be given for prolonged procedures or if there is major blood loss).

**Prevention of infective endocarditis**


- Chlorhexidine mouthwash is not recommended for the prevention of infective endocarditis in at risk patients undergoing dental procedures.

Antibacterial prophylaxis is not routinely recommended for the prevention of infective endocarditis in patients undergoing the following procedures:
- dental;
- upper and lower respiratory tract (including ear, nose, and throat procedures and bronchoscopy);
- genito-urinary tract (including urological, gynaecological, and obstetric procedures);
- upper and lower gastro-intestinal tract.

Whilst these procedures can cause bacteraemia, there is no clear association with the development of infective endocarditis. Prophylaxis may expose patients to the adverse effects of antimicrobials when the evidence of benefit has not been proven.

Any infection in patients at risk of endocarditis should be investigated promptly and treated appropriately to reduce the risk of endocarditis.

If patients at risk of endocarditis are undergoing a gastro-intestinal or genito-urinary tract procedure at a site where infection is suspected, they should receive appropriate antibacterial therapy that includes cover against organisms that cause infective endocarditis.

Patients at risk of infective endocarditis should be:
- advised to maintain good oral hygiene;
- told how to recognise signs of infective endocarditis, and advised when to seek expert advice.

Patients at risk of infective endocarditis include those with valve replacement, acquired valvular heart disease with stenosis or regurgitation, structural congenital heart disease (including surgically corrected or palliated structural conditions, but excluding isolated atrial septal defect, fully repaired ventricular septal defect, fully repaired patent ductus arteriosus, and closure devices considered to be endothelialised), hypertrophic cardiomyopathy, or a previous episode of infective endocarditis.

**Dermatological procedures**

- Advice of a Working Party of the British Society for Antimicrobial Chemotherapy is that patients who undergo dermatological procedures do not require antibacterial prophylaxis against endocarditis.

The British Association of Dermatologists Therapy Guidelines and Audit Subcommittee advise that such dermatological procedures include skin biopsies and excision of moles or of malignant lesions.

**Joint prostheses and dental treatment**

Advice of a Working Party of the British Society for Antimicrobial Chemotherapy is that patients with prosthetic joint implants (including total hip replacements) do not require antibiotic prophylaxis for dental treatment. The Working Party considers that it is unacceptable to expose patients to the adverse effects of antibiotics when there is no evidence that such prophylaxis is of any benefit, but that those who develop any intermittent infection require prompt treatment with antibiotics to which the infecting organisms are sensitive.

The Working Party has commented that joint infections have rarely been shown to follow dental procedures and are even more rarely caused by oral streptococci.
Immunosuppression and indwelling intraperitoneal catheters

Advice of a Working Party of the British Society for Antimicrobial Chemotherapy is that patients who are immunosuppressed (including transplant patients) and patients with indwelling intraperitoneal catheters do not require antibiotic prophylaxis for dental treatment provided there is no other indication for prophylaxis. The Working Party has commented that there is little evidence that dental treatment is followed by infection in immunosuppressed and immunodeficient patients nor is there evidence that dental treatment is followed by infection in patients with indwelling intraperitoneal catheters.

Blood infections, bacterial

Antibacterial therapy for septicaemia: community-acquired

- A broad-spectrum antipseudomonal penicillin (e.g. piperacillin with tazobactam p. 516, ticarcillin with clavulanic acid p. 516) or a broad-spectrum cephalosporin (e.g. cefuroxime p. 498)
- If meticillin-resistant Staphylococcus aureus suspected, add vancomycin p. 505 (or teicoplanin p. 504).
- If anaerobic infection suspected, add metronidazole p. 512 to broad-spectrum cephalosporin.
- If other resistant micro-organisms suspected, use a more broad-spectrum beta-lactam antibacterial (e.g. meropenem p. 495).

Antibacterial therapy for septicaemia: hospital-acquired

- A broad-spectrum antipseudomonal beta-lactam antibacterial (e.g. piperacillin with tazobactam, ticarcillin with clavulanic acid, ceftazidime p. 500, imipenem with cilastatin p. 495, or meropenem)
- If meticillin-resistant Staphylococcus aureus suspected, add vancomycin (or teicoplanin).
- If anaerobic infection suspected, add metronidazole to broad-spectrum cephalosporin

Septicaemia related to vascular catheter

- Vancomycin (or teicoplanin)
- If Gram-negative sepsis suspected, especially in the immunocompromised, add a broad-spectrum antipseudomonal beta-lactam.
- Consider removing vascular catheter, particularly if infection caused by Staphylococcus aureus, pseudomonas, or Candida species.

Meningococcal septicaemia

If meningococcal disease suspected, a single dose of benzylpenicillin sodium p. 517 should be given before urgent transfer to hospital, so long as this does not delay the transfer; cefotaxime p. 500 may be an alternative in penicillin allergy; chloramphenicol p. 537 may be used if history of immediate hypersensitivity reaction to penicillin or to cephalosporins.

- Benzylpenicillin sodium or cefotaxime (or ceftriaxone p. 501)
- If history of immediate hypersensitivity reaction to penicillin or to cephalosporins, chloramphenicol

To eliminate nasopharyngeal carriage, ciprofloxacin p. 527, or rifampicin p. 549, or ceftriaxone may be used.

Cardiovascular system infections, bacterial

Antibacterial therapy for endocarditis: initial ‘blind’ therapy

- Native valve endocarditis, amoxicillin p. 518 (or ampicillin p. 520)
- Consider adding low-dose gentamicin p. 491
- If penicillin-allergic, or if meticillin-resistant Staphylococcus aureus suspected, or if severe sepsis, use vancomycin p. 505 + low-dose gentamicin
- If severe sepsis with risk factors for Gram-negative infection, use vancomycin + meropenem p. 495
- If prosthetic valve endocarditis, vancomycin + rifampicin p. 549 + low-dose gentamicin

Antibacterial therapy for native-valve endocarditis caused by staphylococci

- Flucloxacillin p. 523
- Suggested duration of treatment 4 weeks (at least 6 weeks if secondary lung abscess or osteomyelitis also present)
- If penicillin-allergic or if meticillin-resistant Staphylococcus aureus, vancomycin + rifampicin
- Suggested duration of treatment 4 weeks (at least 6 weeks if secondary lung abscess or osteomyelitis also present)

Antibacterial therapy for prosthetic valve endocarditis caused by staphylococci

- Flucloxacillin + rifampicin + low-dose gentamicin
- Suggested duration of treatment at least 6 weeks; review need to continue gentamicin at 2 weeks—seek specialist advice if gentamicin considered necessary beyond 2 weeks
- If penicillin-allergic or if meticillin-resistant Staphylococcus aureus, vancomycin + rifampicin + low-dose gentamicin
- Suggested duration of treatment at least 6 weeks; review need to continue gentamicin at 2 weeks—seek specialist advice if gentamicin considered necessary beyond 2 weeks

Antibacterial therapy for endocarditis caused by fully-sensitive streptococci

- Benzylpenicillin sodium p. 517
- Suggested duration of treatment 4–6 weeks (6 weeks for prosthetic valve endocarditis)
- If penicillin-allergic, vancomycin (or teicoplanin p. 504) + low-dose gentamicin
- Suggested duration of treatment 4–6 weeks (stop gentamicin after 2 weeks)

Antibacterial therapy for endocarditis caused by less-sensitive streptococci

- Benzylpenicillin sodium + low-dose gentamicin
- Suggested duration of treatment 4–6 weeks (6 weeks for prosthetic valve endocarditis); review need to continue gentamicin at 2 weeks—seek specialist advice if gentamicin considered necessary beyond 2 weeks; stop gentamicin at 2 weeks if micro-organisms moderately sensitive to penicillin
- If penicillin-allergic or highly penicillin-resistant, vancomycin (or teicoplanin) + low-dose gentamicin
- Suggested duration of treatment 4–6 weeks (6 weeks for prosthetic valve endocarditis); review need to continue gentamicin at 2 weeks—seek specialist advice if gentamicin considered necessary beyond 2 weeks; stop gentamicin at 2 weeks if micro-organisms moderately sensitive to penicillin
Antibacterial therapy for endocarditis caused by enterococci
- Amoxicillin (or ampicillin) + low dose gentamicin or benzylpenicillin sodium + low-dose gentamicin
  - Suggested duration of treatment: 4–6 weeks (6 weeks for prosthetic valve endocarditis); review need to continue gentamicin at 2 weeks—seek specialist advice if gentamicin considered necessary beyond 2 weeks
- If penicillin-allergic or penicillin-resistant, vancomycin (or teicoplanin) + low-dose gentamicin
  - Suggested duration of treatment: 4–6 weeks (6 weeks for prosthetic valve endocarditis); review need to continue gentamicin at 2 weeks—seek specialist advice if gentamicin considered necessary beyond 2 weeks
- If gentamicin resistant, amoxicillin (or ampicillin)
  - Add streptomycin p.
  - Suggested duration of treatment: at least 6 weeks

Antibacterial therapy for endocarditis caused by Haemophilus, Actinobacillus, Cardiobacterium, Eikenella, and Kingella species (‘HACEK’ micro-organisms)
- Amoxicillin (or ampicillin) + low-dose gentamicin
  - Suggested duration of treatment: 4 weeks (6 weeks for prosthetic valve endocarditis); stop gentamicin after 2 weeks
- If amoxicillin-resistant, ceftriaxone p. 501 (or cefotaxime p. 500) + low-dose gentamicin
  - Suggested duration of treatment: 4 weeks (6 weeks for prosthetic valve endocarditis); stop gentamicin after 2 weeks

Central nervous system infections, bacterial

Antibacterial therapy for meningitis: initial empirical therapy
- Transfer patient to hospital urgently.
- If meningococcal disease (meningitis with non-blanching rash or meningococcal septicaemia) suspected, benzylpenicillin sodium p. 517 should be given before transfer to hospital, so long as this does not delay the transfer. If a patient with suspected bacterial meningitis without non-blanching rash cannot be transferred to hospital urgently, benzylpenicillin sodium should be given before the transfer. Cefotaxime p. 500 may be an alternative in penicillin allergy; chloramphenicol p. 537 may be used if history of immediate hypersensitivity reaction to penicillin or to cephalosporins.
- In hospital, consider adjunctive treatment with dexamethasone p. 635 (particularly if pneumococcal meningitis suspected in adults), preferably starting before or with first dose of antibacterial, but no later than 12 hours after starting antibacterial; avoid dexamethasone in septic shock, meningococcal septicaemia, or if immunocompromised, or in meningitis following surgery. In hospital, if aetiology unknown:
  - Adult and child 3 months–50 years, cefotaxime (or ceftriaxone p. 501)
    - Consider adding vancomycin p. 505 if prolonged or multiple use of other antibacterials in the last 3 months, or if travelled, in the last 3 months, to areas outside the UK with highly penicillin- and cephalosporin-resistant pneumococci.
    - Suggested duration of treatment: at least 10 days
  - Adult over 50 years cefotaxime (or ceftriaxone) + amoxicillin p. 518 (or ampicillin p. 520)
    - Consider adding vancomycin if prolonged or multiple use of other antibacterials in the last 3 months, or if travelled, in the last 3 months, to areas outside the UK with highly penicillin- and cephalosporin-resistant pneumococci.
    - Suggested duration of treatment: at least 10 days

Antibacterial therapy for meningitis caused by meningococci
- Benzylpenicillin sodium or cefotaxime (or ceftriaxone)
  - Suggested duration of treatment: 7 days.
  - If history of immediate hypersensitivity reaction to penicillin or to cephalosporins, chloramphenicol
  - Suggested duration of treatment: 7 days.

Antibacterial therapy for meningitis caused by pneumococci
- Cefotaxime (or ceftriaxone)
  - Consider adjunctive treatment with dexamethasone, preferably starting before or with first dose of antibacterial, but no later than 12 hours after starting antibacterial (may reduce penetration of vancomycin into cerebrospinal fluid).
  - If micro-organism penicillin-sensitive, replace cefotaxime with benzylpenicillin sodium.
  - If micro-organism highly penicillin- and cephalosporin-resistant, add vancomycin and if necessary rifampicin p. 549.
  - Suggested duration of antibacterial treatment: 14 days

Antibacterial therapy for meningitis caused by Haemophilus influenzae
- Cefotaxime (or ceftriaxone)
  - Consider adjunctive treatment with dexamethasone, preferably starting before or with first dose of antibacterial, but no later than 12 hours after starting antibacterial.
  - Suggested duration of antibacterial treatment: 10 days.
  - For H. influenzae type b give rifampicin for 4 days before hospital discharge to those under 10 years of age or to those in contact with vulnerable household contacts
  - If history of immediate hypersensitivity reaction to penicillin or to cephalosporins, or if micro-organism resistant to cefotaxime, chloramphenicol
  - Consider adjunctive treatment with dexamethasone, preferably starting before or with first dose of antibacterial, but no later than 12 hours after starting antibacterial.
  - Suggested duration of antibacterial treatment: 10 days.
  - For H. influenzae type b give rifampicin for 4 days before hospital discharge to those under 10 years of age or to those in contact with vulnerable household contacts

Antibacterial therapy for meningitis caused by Listeria
- Amoxicillin (or ampicillin) + gentamicin p. 491
  - Suggested duration of treatment: 21 days.
  - Consider stopping gentamicin after 7 days.
  - If history of immediate hypersensitivity reaction to penicillin, co-trimoxazole p. 531
  - Suggested duration of treatment: 21 days.

Ear infections, bacterial

Antibacterial therapy for otitis externa
For topical treatments, consider Otitis externa, under Ear p. 1093.
Consider systemic antibacterial if spreading cellulitis or patient systemically unwell.
- Flucloxacillin p. 523
  - If *penicillin-allergic*, clarithromycin p. 508 (or azithromycin p. 507 or erythromycin p. 510)
  - If *pseudomonas suspected*, ciprofloxacin p. 527 (or an aminoglycoside)

**Antibacterial therapy for otitis media**

Many infections are caused by viruses. Most uncomplicated cases resolve without antibacterial treatment. In children without systemic features, antibacterial treatment may be started after 72 hours if no improvement. Consider earlier treatment if deterioration, if systemically unwell, if at high risk of serious complications (e.g. in immunosuppression, cystic fibrosis), if mastoiditis present, or in children under 2 years of age with bilateral otitis media.
- Amoxicillin p. 518 (or ampicillin p. 520)
  - Consider co-amoxiclav p. 521 if no improvement after 48 hours.
  - In severe infection, initial parenteral therapy with co-amoxiclav or cefuroxime p. 498.
  - **Suggested duration of treatment 5 days** (longer if severely ill).
- If *penicillin-allergic*, clarithromycin (or azithromycin or erythromycin)
  - **Suggested duration of treatment 5 days** (longer if severely ill)

**Eye infections, bacterial**

**Antibacterial therapy for purulent conjunctivitis**
- Chloramphenicol eye drops p. 1072.

**Gastro-intestinal system infections, bacterial**

**Antibacterial therapy for gastro-enteritis**

Frequently self-limiting and may not be bacterial.
- Antibacterial not usually indicated

**Antibacterial therapy for campylobacter enteritis**

Frequently self-limiting; treat if immunocompromised or if severe infection.
- Clarithromycin p. 508 (or azithromycin p. 507 or erythromycin p. 510)
- *Alternative*, ciprofloxacin p. 527
- Strains with decreased sensitivity to ciprofloxacin isolated frequently

**Antibacterial therapy for salmonella (non-typhoid)**

Treat invasive or severe infection. Do not treat less severe infection unless there is a risk of developing invasive infection (e.g. immunocompromised patients, those with haemoglobinopathy, or children under 6 months of age).
- Ciprofloxacin or cefotaxime p. 500

**Antibacterial therapy for shigellosis**

Antibacterial not indicated for mild cases.
- Ciprofloxacin or azithromycin
  - *Alternatives if micro-organism sensitive*, amoxicillin p. 518 or trimethoprim p. 542

**Antibacterial therapy for typhoid fever**

Infections from Middle-East, South Asia, and South-East Asia may be multiple-antibacterial-resistant and sensitivity should be tested.
- Cefotaxime (or ceftriaxone p. 501)
  - azithromycin may be an alternative in mild or moderate disease caused by multiple-antibacterial-resistant organisms.
  - *Alternative if micro-organism sensitive*, ciprofloxacin

**Antibacterial therapy for Clostridium difficile infection**

- For first episode of mild to moderate infection, oral metronidazole p. 512
- **Suggested duration of treatment 10–14 days**
- For second or subsequent episode of infection, for severe infection, for infection not responding to metronidazole, or in patients intolerant of metronidazole, oral vancomycin p. 505
- For severe infection in patients with multiple co-morbidities who are receiving treatment with other antibacterials, or for second or subsequent episode of infection, fidaxomicin p. 538 can replace vancomycin
  - **Suggested duration of treatment 10–14 days**
- For infection not responding to vancomycin or fidaxomicin, for life-threatening infection, or in patients with ileus, oral vancomycin + i/v metronidazole
- For infection not responding to vancomycin in patients without life-threatening infection or ileus, fidaxomicin can be used instead of vancomycin + metronidazole
  - **Suggested duration of treatment 10–14 days**

**Antibacterial therapy for biliary-tract infection**
- Ciprofloxacin or gentamicin p. 491 or a cephalosporin

**Antibacterial therapy for peritonitis**
- A cephalosporin + metronidazole or gentamicin + metronidazole or gentamicin + clindamycin p. 506 or piperacillin with tazobactam p. 516 alone

**Antibacterial therapy for peritonitis: peritoneal dialysis-associated**
- Vancomycin (or teicoplanin p. 504) + ceftazidime p. 500 added to dialysis fluid or vancomycin added to dialysis fluid + ciprofloxacin by mouth
  - **Suggested duration of treatment 14 days or longer**

**Genital system infections, bacterial**

**Antibacterial therapy for bacterial vaginosis**
- Oral metronidazole p. 512
  - **Suggested duration of treatment 5–7 days** (or high-dose metronidazole as a single dose)
  - *Alternatively*, topical metronidazole for 5 days or topical clindamycin p. 506 for 7 days

**Antibacterial therapy for uncomplicated genital chlamydial infection, non-gonococcal urethritis, and non-specific genital infection**

Contact tracing recommended.
- Azithromycin p. 507 or doxycycline p. 534
  - **Suggested duration of treatment azithromycin as a single dose or doxycycline for 7 days**
  - **Suggested duration of treatment 14 days**
Antibacterial therapy for gonorrhoea: uncomplicated
Contact tracing recommended. Consider chlamydia co-infection. Choice of alternative antibacterial regimen depends on locality where infection acquired.

- Azithromycin + i/m ceftriaxone p. 501
- **Suggested duration of treatment** is a single-dose of each antibacterial
- Alternatively, when parenteral administration is not possible, cefixime p. 499+ azithromycin
- **Suggested duration of treatment** is a single-dose of each antibacterial
- Alternatively, if micro-organism is sensitive to a quinolone, ciprofloxacin p. 527+ azithromycin
- **Suggested duration of treatment** is a single-dose of each antibacterial
- Pharyngeal infection, azithromycin + i/m ceftriaxone
- **Suggested duration of treatment** is a single-dose of each antibacterial

Antibacterial therapy for pelvic inflammatory disease
Contact tracing recommended.

- Doxycycline + metronidazole + single-dose of i/m ceftriaxone or ofloxacin p. 530 + metronidazole
- **Suggested duration of treatment** 14 days (except i/m ceftriaxone).
- In severely ill patients initial treatment with doxycycline + i/v ceftriaxone + i/v metronidazole, then switch to oral treatment with doxycycline + metronidazole to complete 14 days’ treatment

Antibacterial therapy for early syphilis (infection of less than 2 years)
Contact tracing recommended.

- Benzathine benzylpenicillin [unlicensed]
- **Suggested duration of treatment** single-dose (repeat dose after 7 days for women in the third trimester of pregnancy)
- Alternatively, doxycycline or erythromycin
- **Suggested duration of treatment** 14 days

Antibacterial therapy for late latent syphilis (asymptomatic infection of more than 2 years)
Contact tracing recommended.

- Benzathine benzylpenicillin [unlicensed]
- **Suggested duration of treatment** once weekly for 2 weeks
- Alternatively, doxycycline
- **Suggested duration of treatment** 28 days

Asymptomatic contacts of patients with infectious syphilis
- Doxycycline
- **Suggested duration of treatment** 14 days

Musculoskeletal system infections, bacterial

Antibacterial therapy for osteomyelitis
Seek specialist advice if chronic infection or prostheses present.

- Flucloxacillin p. 523
- Consider adding fusidic acid p. 539 or rifampicin p. 549 for initial 2 weeks.
- **Suggested duration of treatment** 6 weeks for acute infection
- If penicillin-allergic, clindamycin p. 506
- Consider adding fusidic acid or rifampicin for initial 2 weeks.
- **Suggested duration of treatment** 6 weeks for acute infection
- If meticillin-resistant Staphylococcus aureus suspected, vancomycin p. 505 (or teicoplanin p. 504)
- Consider adding fusidic acid or rifampicin for initial 2 weeks.
- **Suggested duration of treatment** 6 weeks for acute infection

Antibacterial therapy for septic arthritis
Seek specialist advice if prostheses present.

- Flucloxacillin
- **Suggested duration of treatment** 4–6 weeks (longer if infection complicated).
- If penicillin-allergic, clindamycin
- **Suggested duration of treatment** 4–6 weeks (longer if infection complicated).
- If meticillin-resistant Staphylococcus aureus suspected, vancomycin (or teicoplanin)
- **Suggested duration of treatment** 4–6 weeks (longer if infection complicated).
- If gonococcal arthritis or Gram-negative infection suspected, cefotaxime p. 500 (or ceftriaxone p. 501)
- **Suggested duration of treatment** 4–6 weeks (longer if infection complicated; treat gonococcal infection for 2 weeks).

Nose infections, bacterial

Antibacterial therapy for sinusitis
Antibacterial therapy should usually be used only for persistent symptoms and purulent discharge lasting at least 7 days or if severe symptoms. Also, consider antibacterial for those at high risk of serious complications (e.g. in immunosuppression, cystic fibrosis).

- Amoxicillin p. 518 (or amoxicillin p. 520) or doxycycline p. 534 or clarithromycin p. 508 (or azithromycin p. 507 or erythromycin p. 510)
- **Suggested duration of treatment** 7 days.
- Consider oral co-amoxiclav p. 521 if no improvement after 48 hours.
- In severe infection, initial parenteral therapy with co-amoxiclav or cefuroxime p. 498 may be required.

Oral bacterial infections

Antibacterial drugs
Antibacterial drugs should only be prescribed for the treatment of oral infections on the basis of defined need. They may be used in conjunction with (but not as an alternative to) other appropriate measures, such as providing drainage or extracting a tooth.

The ‘blind’ prescribing of an antibacterial for unexplained pyrexia, cervical lymphadenopathy, or facial swelling can lead to difficulty in establishing the diagnosis. In severe oral infections, a sample should always be taken for bacteriology.

Oral infections which may require antibacterial treatment include acute periapical or periodontal abscess, cellulitis, acutely created oral-antral communication (and acute sinusitis), severe pericoronitis, localised osteitis, acute necrotising ulcerative gingivitis, and destructive forms of chronic periodontal disease. Most of these infections are readily resolved by the early establishment of drainage and removal of the cause (typically an infected necrotic pulp). Antibacterials may be required if treatment has to be
delayed, in immunocompromised patients, or in those with conditions such as diabetes or Paget’s disease. Certain rarer infections including bacterial sialadenitis, osteomyelitis, actinomycosis, and infections involving fascial spaces such as Ludwig’s angina, require antibiotics and specialist hospital care.

Antibacterial drugs may also be useful after dental surgery in some cases of spreading infection. Infection may spread to involve local lymph nodes, to fascial spaces (where it can cause airway obstruction), or into the bloodstream (where it can lead to cavernous sinus thrombosis and other serious complications). Extension of an infection can also lead to maxillary sinusitis; osteomyelitis is a complication, which usually arises when host resistance is reduced.

If the oral infection fails to respond to antibacterial treatment within 48 hours the antibacterial should be changed, preferably on the basis of bacteriological investigation. Failure to respond may also suggest an incorrect diagnosis, lack of essential additional measures (such as drainage), poor host resistance, or poor patient compliance.

Combination of a penicillin (or a macrolide) with metronidazole p. 512 may sometimes be helpful for the treatment of severe oral infections or oral infections that have not responded to initial antibacterial treatment.

Penicillins
Phenoxyethylpenicillin p. 518 is effective for dentoalveolar abscess.

Broad-spectrum penicillins
Amoxicillin p. 518 is as effective as phenoxyethylpenicillin but is better absorbed; however, it may encourage emergence of resistant organisms.

Like phenoxyethylpenicillin, amoxicillin is ineffective against bacteria that produce beta-lactamases.

Amoxicillin may be useful for short course oral regimens.

Co-amoxiclav p. 521 is active against beta-lactamase-producing bacteria that are resistant to amoxicillin. Co-amoxiclav may be used for severe dental infection with spreading cellulitis or dental infection not responding to first-line antibacterial treatment.

Cephalosporins
The cephalosporins offer little advantage over the penicillins in dental infections, often being less active against anaerobes. Infections due to oral streptococci (often termed viridans streptococci) which become resistant to penicillin are usually also resistant to cephalosporins. This is of importance in the case of patients who have had rheumatic fever and are on long-term penicillin therapy. Cefalexin p. 497 and cefradine p. 497 have been used in the treatment of oral infections.

Tetracyclines
In adults, tetracyclines can be effective against oral anaerobes but the development of resistance (especially by oral streptococci) has reduced their usefulness for the treatment of acute oral infections; they may still have a role in the treatment of destructive (refractory) forms of periodontal disease. Doxycycline p. 534 has a longer duration of action than tetracycline p. 536 or oxytetracycline p. 536 and need only be given once daily; it is reported to be more active against anaerobes than some other tetracyclines.

Doxycycline may have a role in the treatment of recurrent aphthous ulceration, or as an adjunct to gingival scaling and root planing for periodontitis.

Macrolides
The macrolides are an alternative for oral infections in penicillin-allergic patients or where a beta-lactamase producing organism is involved. However, many organisms are now resistant to macrolides or rapidly develop resistance; their use should therefore be limited to short courses.

Clindamycin
Clindamycin p. 506 should not be used routinely for the treatment of oral infections because it may be no more effective than penicillins against anaerobes and there may be cross-resistance with erythromycin-resistant bacteria p. 510. Clindamycin can be used for the treatment of dentoalveolar abscess that has not responded to penicillin or to metronidazole.

Metronidazole and tinidazole
Metronidazole is an alternative to a penicillin for the treatment of many oral infections where the patient is allergic to penicillin or the infection is due to beta-lactamase-producing anaerobes. It is the drug of first choice for the treatment of acute necrotising ulcerative gingivitis (Vincent’s infection) and pericoronitis; amoxicillin is a suitable alternative. For these purposes metronidazole for 3 days is sufficient, but the duration of treatment may need to be longer in pericoronitis. Tinidazole p. 514 is licensed for the treatment of acute ulcerative gingivitis.

Respiratory system infections, bacterial

Antibacterial therapy for Haemophilus influenzae epiglottitis
- Cefotaxime p. 500 (or ceftriaxone p. 501)
- If history of immediate hypersensitivity reaction to penicillin or to cephalosporins, chloramphenicol p. 537

Antibacterial therapy for chronic bronchitis: acute exacerbations
Treat if increase in sputum purulence accompanied by an increase in sputum volume or increase in dyspnoea.

- Amoxicillin p. 518 (or ampicillin p. 520) or a tetracycline p. 536
- Some pneumococci and Haemophilus influenzae strains tetracycline-resistant; approx. 20% H. influenzae strains amoxicillin-resistant
- Suggested duration of treatment 5 days; longer treatment may be necessary in severely ill patients
- Alternative, clarithromycin p. 508 (or azithromycin p. 507 or erythromycin p. 510)
- Suggested duration of treatment 5 days; longer treatment may be necessary in severely ill patients

Antibacterial therapy for pneumonia: low-severity community-acquired
- Amoxicillin (or ampicillin)
- Pneumococci with decreased penicillin sensitivity being isolated, but not yet common in UK.
- If atypical pathogens suspected, add clarithromycin (or azithromycin or erythromycin).
- If staphylococci suspected (e.g. in influenza or measles), add flucloxacillin p. 523.
- Suggested duration of treatment 7 days (14–21 days for infections caused by staphylococci)
- Alternatives, doxycycline p. 534 or clarithromycin (or azithromycin or erythromycin)
- Suggested duration of treatment 7 days (14–21 days for infections caused by staphylococci)
Antibacterial therapy for pneumonia: moderate-severity community-acquired

- Amoxicillin (or ampicillin) + clarithromycin (or azithromycin or erythromycin) or doxycline alone
- Pneumococci with decreased penicillin sensitivity being isolated, but not yet common in UK.
- If meticillin-resistant Staphylococcus aureus suspected, add vancomycin (or teicoplanin).
- Suggested duration of treatment 7–10 days (may extend treatment to 14–21 days in some cases e.g. if staphylococci suspected)
- If life-threatening infection, or if Gram-negative infection suspected, or if co-morbidities present, or if living in long-term residential or nursing home, co-amoxiclav p. 521 + clarithromycin (or azithromycin or erythromycin)
- If meticillin-resistant Staphylococcus aureus suspected, add vancomycin (or teicoplanin).
- Suggested duration of treatment 7–10 days (may extend treatment to 14–21 days in some cases e.g. if staphylococci or Gram-negative enteric bacilli suspected)
- Alternatives if life-threatening infection, or if Gram-negative infection suspected, or if co-morbidities present, or if living in long-term residential or nursing home, cefuroxime p. 498 + clarithromycin (or azithromycin or erythromycin) or cefotaxime (or ceftriaxone) + clarithromycin (or azithromycin or erythromycin)
- If meticillin-resistant Staphylococcus aureus suspected, add vancomycin (or teicoplanin).
- Suggested duration of treatment 7–10 days (may extend treatment to 14–21 days in some cases e.g. if staphylococci or Gram-negative enteric bacilli suspected)

Antibacterial therapy for pneumonia possibly caused by atypical pathogens

- Clarithromycin (or azithromycin or erythromycin)
- If high-severity Legionella infection, add rifampicin p. 549 for the first few days.
- Suggested duration of treatment 14 days (usually 7–10 days for Legionella)
- Alternative if Legionella infection suspected, a quinolone
- If high-severity Legionella infection, add clarithromycin (or azithromycin or erythromycin) or rifampicin for the first few days.
- Suggested duration of treatment usually 7–10 days
- Alternative for chlamydial or mycoplasma infections, doxycline
- Suggested duration of treatment 14 days

Antibacterial therapy for pneumonia: hospital-acquired

- Early-onset infection less than 5 days after admission to hospital, co-amoxiclav or cefuroxime
- If life-threatening infection, or if history of antibacterial treatment in the last 3 months, or if resistant microorganisms suspected, treat as for late-onset hospital-acquired pneumonia.
- Suggested duration of treatment 7 days
- Late-onset infection (more than 5 days after admission to hospital), an antipseudomonal penicillin (e.g. piperacillin with tazobactam p. 516) or a broad-spectrum cephalosporin (e.g. ceftazidime p. 500) or another antipseudomonal beta-lactam or a quinolone (e.g. ciprofloxacin p. 527)
- If meticillin-resistant Staphylococcus aureus suspected, add vancomycin.
- For severe illness caused by Pseudomonas aeruginosa, consider adding an aminoglycoside.
- Suggested duration of treatment 7 days (longer if Pseudomonas aeruginosa confirmed)

Skin infections, bacterial

Antibacterial therapy for impetigo: small areas of skin infected

Seek local microbiology advice before using topical treatment in hospital.

- Topical fusidic acid p. 539
  - Suggested duration of treatment 7 days is usually adequate (max. 10 days).
  - Alternatively, if meticillin-resistant Staphylococcus aureus, topical mupirocin p. 1129
  - Suggested duration of treatment 7 days is usually adequate (max. 10 days).

Impetigo: widespread infection

- Oral flucloxacillin p. 523
  - If streptococci suspected in severe infection, add phenoxymerpenicillin p. 518.
  - Suggested duration of treatment 7 days.
  - If penicillin-allergic, oral clarithromycin p. 508 (or azithromycin p. 507 or erythromycin p. 510)
  - Suggested duration of treatment 7 days.

Antibacterial therapy for erysipelas

- Phenoxymerpenicillin or benzylpenicillin sodium p. 517
  - If severe infection, replace phenoxymerpenicillin or benzylpenicillin sodium with high-dose flucloxacillin
  - Suggested duration of treatment at least 7 days.
  - If penicillin-allergic, clindamycin p. 506 or clarithromycin (or azithromycin or erythromycin)
  - Suggested duration of treatment at least 7 days

Antibacterial therapy for cellulitis

- Flucloxacillin (high-dose)
  - If streptococcal infection confirmed, replace flucloxacillin with phenoxymerpenicillin or benzylpenicillin sodium
  - If Gram-negative bacteria or anaerobes suspected, use broad-spectrum antibiotics.
  - If penicillin-allergic, clindamycin or clarithromycin (or azithromycin or erythromycin) or vancomycin p. 505 (or teicoplanin p. 504)
  - If Gram-negative bacteria suspected, use broad-spectrum antibiotics.

Antibacterial therapy for animal and human bites

Cleanse wound thoroughly. For tetanus-prone wound, give human tetanus immunoglobulin p. 1188 (with a tetanus-containing vaccine if necessary, according to immunisation history and risk of infection). Consider rabies prophylaxis for bites from animals in endemic countries. Assess risk of blood-borne viruses (including HIV, hepatitis B and C) and
give appropriate prophylaxis to prevent viral spread.
- Co-amoxiclav p. 521
- If penicillin-allergic, doxycycline p. 534 + metronidazole p. 512

Antibacterial therapy for mastitis during breast-feeding
Treat if severe, if systemically unwell, if nipple fissure present, if symptoms do not improve after 12–24 hours of effective milk removal, or if culture indicates infection.
- Flucloxacillin, if penicillin-allergic, erythromycin
- Continue breast-feeding or expressing milk during treatment.
- Suggested duration of treatment 10–14 days.

ANTIBACTERIALS>AMINOGLYCOSIDES

Aminoglycosides
Overview
These include amikacin p. 491, gentamicin p. 491, neomycin sulfate p. 492, streptomycin p. 492, and tobramycin p. 493. All are bactericidal and active against many Gram-positive and many Gram-negative organisms. Amikacin, gentamicin, and tobramycin are also active against Pseudomonas aeruginosa; streptomycin is active against Mycobacterium tuberculosis and is now almost entirely reserved for tuberculosis.

The aminoglycosides are not absorbed from the gut (although there is a risk of absorption in inflammatory bowel disease and liver failure) and must therefore be given by injection for systemic infections.

Gentamicin is the aminoglycoside of choice in the UK and is used widely for the treatment of serious infections. It has a broad spectrum but is inactive against anaerobes and has poor activity against haemolytic streptococci and pneumococci. When used for the ‘blind’ therapy of undiagnosed serious infections it is usually given in conjunction with a penicillin or metronidazole p. 512 (or both). Gentamicin is used together with another antibiotic for the treatment of endocarditis. Streptomycin may be used as an alternative in gentamicin-resistant enterococcal endocarditis.

Loading and maintenance doses of gentamicin may be calculated on the basis of the patient’s weight and renal function (e.g. using a nomogram); adjustments are then made according to serum-gentamicin concentrations. High doses are occasionally indicated for serious infections, especially in the neonate, in the patient with cystic fibrosis, or in the immunocompromised patient. Whenever possible treatment should not exceed 7 days.

Amikacin is more stable than gentamicin to enzyme inactivation. Amikacin is used in the treatment of serious infections caused by gentamicin-resistant Gram-negative bacilli.

Tobramycin has similar activity to gentamicin. It is slightly more active against Ps. aeruginosa but shows less activity against certain other Gram-negative bacteria. Tobramycin can be administered by nebuliser or by inhalation of powder on a cyclical basis (28 days of tobramycin followed by a 28-day tobramycin-free interval) for the treatment of chronic pulmonary Ps. aeruginosa infection in cystic fibrosis; however, resistance may develop and some patients do not respond to treatment.

Neomycin sulfate is too toxic for parenteral administration and can only be used for infections of the skin or mucous membranes or to reduce the bacterial population of the colon prior to bowel surgery or in hepatic failure. Oral administration may lead to malabsorption. Small amounts of neomycin sulfate may be absorbed from the gut in patients with hepatic failure and, as these patients may also be uremic, cumulation may occur with resultant ototoxicity.

Once daily dosage
Once daily administration of aminoglycosides is more convenient, provides adequate serum concentrations, and in many cases has largely superseded multiple daily dose regimens (given in 2–3 divided doses during the 24 hours). Local guidelines on dosage and serum concentrations should be consulted. A once-daily, high-dose regimen of an aminoglycoside should be avoided in patients with endocarditis due to Gram-positive bacteria, HACEK endocarditis, burns of more than 20% of the total body surface area, or creatinine clearance less than 20 mL/minute. There is insufficient evidence to recommend a once daily, high-dose regimen of an aminoglycoside in pregnancy.

Serum concentrations
Serum concentration monitoring avoids both excessive and subtherapeutic concentrations thus preventing toxicity and ensuring efficacy. Serum-aminoglycoside concentrations should be monitored in patients receiving parenteral aminoglycosides and must be determined in the elderly, in obesity, and in cystic fibrosis, or if high doses are being given, or if there is renal impairment.

Aminoglycosides (by injection)
- CONTRA-INDICATIONS Myasthenia gravis (aminoglycosides may impair neuromuscular transmission)
- CAUTIONS Care must be taken with dosage (the main side-effects of the aminoglycosides are dose-related) - conditions characterised by muscular weakness (aminoglycosides may impair neuromuscular transmission). If possible, dehydration should be corrected before starting an aminoglycoside - whenever possible, parenteral treatment should not exceed 7 days
- SIDE-EFFECTS
  - Rare Antibiotic-associated colitis - electrolyte disturbances - hypocalcaemia - hypokalaemia - hypomagnesaemia on prolonged therapy - nausea - peripheral neuropathy - stomatitis - vomiting
  - Very rare Blood disorders - CNS effects - convulsions - encephalopathy - headache
  - Frequency not known Auditory damage - impaired neuromuscular transmission - irreversible ototoxicity - nephrotoxicity - transient myasthenic syndrome in patients with normal neuromuscular function with large doses given during surgery - vestibular damage
- SIDE-EFFECTS, FURTHER INFORMATION
  - Nephrotoxicity
    - In adults Occurs most commonly in the elderly; therefore, monitoring is particularly important in these patients, who may require reduced doses.
    - In children Occurs most commonly in children with renal failure.
- PREGNANCY There is a risk of auditory or vestibular nerve damage in the infant when aminoglycosides are used in the second and third trimesters of pregnancy. The risk is greatest with streptomycin. The risk is probably very small with gentamicin and tobramycin, but their use should be avoided unless essential. If given during pregnancy, serum-aminoglycoside concentration monitoring is essential.
- RENAL IMPAIRMENT If there is impairment of renal function, the interval between doses must be increased; if the renal impairment is severe, the dose itself should be reduced as well. Excretion of aminoglycosides is principally via the kidney and accumulation occurs in renal impairment.
In adults  A once-daily, high-dose regimen of an aminoglycoside should be avoided in patients with a creatinine clearance less than 20 mL/minute.

In children  A once-daily, high-dose regimen of an aminoglycoside should be avoided in children over 1 month of age with a creatinine clearance less than 20 mL/minute/1.73 m². Ototoxicity and nephrotoxicity occur commonly in patients with renal failure. Serum-aminoglycoside concentrations must be monitored in patients with renal impairment; earlier and more frequent measurement of aminoglycoside concentration may be required.

**MONITORING REQUIREMENTS**

- Serum concentrations  Serum concentration monitoring avoids both excessive and subtherapeutic concentrations thus preventing toxicity and ensuring efficacy. Serum-aminoglycoside concentrations should be measured in all patients receiving parenteral aminoglycosides and must be determined in obesity, if high doses are being given and in cystic fibrosis.

- In adults  Serum aminoglycoside concentrations must be determined in the elderly. In patients with normal renal function, aminoglycoside concentrations should be measured after 3 or 4 doses of a multiple daily dose regimen and after a dose change. For multiple daily dose regimens, blood samples should be taken approximately 1 hour after intramuscular or intravenous administration (‘peak’ concentration) and also just before the next dose (‘trough’ concentration). If the pre-dose (‘trough’) concentration is high, the interval between doses must be increased. If the post-dose (‘peak’) concentration is high, the dose must be decreased. For once daily dose regimens, consult local guidelines on serum concentration monitoring.

- In children  In children with normal renal function, aminoglycoside concentrations should be measured after 3 or 4 doses of a multiple daily dose regimen. Blood samples should be taken just before the next dose is administered (‘trough’ concentration). If the pre-dose (‘trough’) concentration is high, the interval between doses must be increased. For multiple daily dose regimens, blood samples should also be taken approximately 1 hour after intramuscular or intravenous administration (‘peak’ concentration). If the post-dose (‘peak’) concentration is high, the dose must be decreased.

- Renal function should be assessed before starting an aminoglycoside and during treatment.

- Auditory and vestibular function should also be monitored during treatment.

---

**Amikacin**

**INDICATIONS AND DOSE**

**Serious Gram-negative infections resistant to gentamicin (multiple daily dose regimen)**
- **BY INTRAMUSCULAR INJECTION, OR BY SLOW INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
  - Adult: 15 mg/kg daily in 2 divided doses, increased to 22.5 mg/kg daily in 3 divided doses for up to 10 days, higher dose to be used in severe infections; maximum 1.5 g per day; maximum 15 g per course

**Serious Gram-negative infections resistant to gentamicin (once daily dose regimen)**
- **BY INTRAVENOUS INFUSION**
  - Adult: Initially 15 mg/kg (max. per dose 1.5 g once daily), dose to be adjusted according to serum-amikacin concentration; maximum 15 g per course

**DOSES AT EXTREMES OF BODY-WEIGHT**
To avoid excessive dosage in obese patients, use ideal weight for height to calculate dose and monitor serum-amikacin concentration closely.

---

**INTERACTIONS**  Appendix 1: aminoglycosides

**SIDE-EFFECTS**
- Uncommon  Rash

**MONITORING REQUIREMENTS**

- **Multiple daily dose regimen:** one-hour (‘peak’) serum concentration should not exceed 30 mg/litre; pre-dose (‘trough’) concentration should be less than 10 mg/litre.

- **Once daily dose regimen:** pre-dose (‘trough’) concentration should be less than 5 mg/litre.

**DIRECTIONS FOR ADMINISTRATION**  For intravenous infusion (Amikin®); intermittent in Glucose 5% or Sodium chloride 0.9%. To be given over 30 minutes.

**PRESCRIBING AND DISPENSING INFORMATION**  Once daily dose regime not to be used for endocarditis, febrile neutropenia, or meningitis. Consult local guidelines.

---

**Gentamicin**

**INDICATIONS AND DOSE**

**Gram-positive bacterial endocarditis or HACEK endocarditis (in combination with other antibacterials)**
- **BY INTRAMUSCULAR INJECTION, OR BY SLOW INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
- Adult: 1 mg/kg every 12 hours, intravenous injection to be administered over at least 3 minutes, to be given in a multiple daily dose regimen

**Septicaemia | Meningitis and other CNS infections | Biliary-tract infection | Acute pyelonephritis | Endocarditis | Pneumonia in hospital patients | Adjunct in listerial meningitis | Prostatitis**
- **BY INTRAVENOUS INFUSION, OR BY SLOW INTRAVENOUS INJECTION, OR BY INTRAMUSCULAR INJECTION**
- Adult: 3–5 mg/kg daily in 3 divided doses, to be given in a multiple daily dose regimen, divided doses to be given every 8 hours, intravenous injection to be administered over at least 3 minutes

**Surgical prophylaxis**
- **BY SLOW INTRAVENOUS INJECTION**
- Adult: 1.5 mg/kg, intravenous injection to be administered over at least 3 minutes, administer dose up to 30 minutes before the procedure, dose may be repeated every 8 hours for high-risk procedures; up to 3 further doses may be given

**Surgical prophylaxis (including joint replacement surgery)**
- **BY INTRAVENOUS INFUSION**
- Adult: 5 mg/kg for 1 dose, administer dose up to 30 minutes before the procedure

**DOSES AT EXTREMES OF BODY-WEIGHT**
To avoid excessive dosage in obese patients, use ideal weight for height to calculate parenteral dose and monitor serum-gentamicin concentration closely.
Infection

PRESCRIBING AND DISPENSING INFORMATION

▶ For once-daily dose regimen, consult local guidelines on monitoring serum-gentamicin concentration.

INTERACTIONS

▶ With intravenous use (Cidomycin®; Gentamicin paediatric injection, Beacon; Gentamicin injection Hospira), give intermittently or via drip tubing in Glucose 5% or Sodium Chloride 0.9%. Suggested volume for intermittent infusion 50–100 ml given over 20–30 minutes (given over 60 minutes for once daily dose regimen).

MEDICINAL FORMS

▶ There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

▶ Gentamicin (Non-proprietary)

- Gentamicin (as Gentamicin sulfate) 5 mg per 1 ml Gentamicin Intrathecal 5mg/1ml solution for injection ampoules | 5 ampoule POM £36.28 (Hospital only)
- Gentamicin (as Gentamicin sulfate) 10 mg per 1 ml Gentamicin 20mg/2ml solution for injection ampoules | 5 ampoule POM £11.25 Gentamicin Paediatric 20mg/2ml solution for injection vials | 5 vial POM £11.25 DT price + £11.25
- Gentamicin (as Gentamicin sulfate) 40 mg per 1 ml Gentamicin 80mg/2ml solution for injection vials | 5 vial POM £20.00 Gentamicin 80mg/2ml solution for injection ampoules | 5 ampoule POM £6.88 | 10 ampoule POM £10.00

▶ Cidomycin (Sanofi)

- Gentamicin (as Gentamicin sulfate) 40 mg per 1 ml Cidomycin Adult Injectable 80mg/2ml solution for injection vials | 5 vial POM £6.88
- Cidomycin Adult Injectable 80mg/2ml solution for injection ampoules | 5 ampoule POM £6.88

Infusion

▶ Gentamicin (Non-proprietary)

- Gentamicin (as Gentamicin sulfate) 1 mg per 1 ml Gentamicin 80mg/80ml infusion bags | 20 bag POM £39.00
- Gentamicin (as Gentamicin sulfate) 3 mg per 1 ml Gentamicin 240mg/80ml infusion bags | 20 bag POM £119.00 Gentamicin 360mg/120ml infusion bags | 20 bag POM £169.00

SIDE-EFFECTS

▶ Uncommon Rash

INTERACTIONS

▶ Appendix 1: aminoglycosides

CONTRA-INDICATIONS

⇒ Intestinal obstruction · myasthenia gravis (aminoglycosides may impair neuromuscular transmission)

CAUTIONS

⇒ Avoid prolonged use

INTERACTIONS

⇒ Appendix 1: neomycin

SIDE-EFFECTS

⇒ Common or very common Rash

UNLICENSED USE

⇒ Use in tuberculosis is an unlicensed indication.

Streptomycin

INDICATIONS AND DOSE

Tuberculosis, resistant to other treatment, in combination with other drugs

⇒ BY DEEP INTRAMUSCULAR INJECTION

Adult: 15 mg/kg daily (max. per dose 1 g), reduce dose in those under 50 kg and those over 40 years

Adjuvant to doxycycline in brucellosis (administered on expert advice)

⇒ BY DEEP INTRAMUSCULAR INJECTION

Adult: (consult local protocol)

Enterococcal endocarditis

Adult: (consult local protocol)

Neomycin sulfate

INDICATIONS AND DOSE

Bowel sterilisation before surgery

⇒ BY MOUTH

Adult: 1 g every 1 hour for 4 hours, then 1 g every 4 hours for 2–3 days

Hepatic coma

⇒ BY MOUTH

Adult: Up to 4 g daily in divided doses usually for 5–7 days

CONTRA-INDICATIONS

⇒ Intestinal obstruction · myasthenia gravis (aminoglycosides may impair neuromuscular transmission)

CAUTIONS

⇒ Avoid prolonged use

INTERACTIONS

⇒ Appendix 1: neomycin

SIDE-EFFECTS

⇒ Common or very common Rash

UNLICENSED USE

⇒ Use in tuberculosis is an unlicensed indication.

IMPORTANT SAFETY INFORMATION

Side-effects increase after a cumulative dose of 100 g, which should only be exceeded in exceptional circumstances.
Tobramycin

INDICATIONS AND DOSE

Septicaemia | Meningitis and other CNS infections | Biliary-tract infection | Acute pyelonephritis or prostatis | Pneumonia in hospital patients

- **BY INTRAMUSCULAR INJECTION, OR BY SLOW INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
  - Adult: 3 mg/kg daily in 3 divided doses; increased if necessary up to 5 mg/kg daily in 3–4 divided doses, increased dose used in severe infection; dose to be reduced back to 3 mg/kg daily as soon as clinically indicated

Urinary-tract infection

- **BY INTRAMUSCULAR INJECTION**
  - Adult: 2–3 mg/kg for 1 dose

Chronic *Pseudomonas aeruginosa* infection in patients with cystic fibrosis

- **BY INHALATION OF NEBULISED SOLUTION**
  - Adult: 300 mg every 12 hours for 28 days, subsequent courses repeated after 28-day interval without tobramycin nebuliser solution
  - **BY INHALATION OF POWDER**
  - Adult: 112 mg every 12 hours for 28 days, subsequent courses repeated after 28-day interval without tobramycin inhalation powder

DOSES AT EXTREMES OF BODY-WEIGHT

To avoid excessive dosage in obese patients, use ideal weight for height to calculate parenteral dose and monitor serum tobramycin concentration closely.

VANTOBRA® NEBULISER SOLUTION

Chronic pulmonary *Pseudomonas aeruginosa* infection in patients with cystic fibrosis

- **BY INHALATION OF NEBULISED SOLUTION**
  - Adult: 170 mg every 12 hours for 28 days, subsequent courses repeated after 28-day interval without tobramycin nebuliser solution

CAUTIONS

- When used by inhalation Conditions characterised by muscular weakness—may impair neuromuscular transmission • history of prolonged previous or concomitant intravenous aminoglycosides—increased risk of ototoxicity • renal impairment—limited information available • severe haemoptysis—risk of further haemorrhage

INTERACTIONS

- Appendix 1: aminoglycosides

SIDE-EFFECTS

- Common or very common
  - When used by inhalation Malaise • rhinitis • tinnitus
  - Uncommon
  - With systemic use Rash
  - Rare
  - When used by inhalation Aphony • hearing loss

Rare

- When used by inhalation Bronchospasm • cough (more frequent by inhalation of powder) • dysphonia • epistaxis • haemoptysis • laryngitis • mouth ulcers • pharyngitis • salivary hypersecretion • taste disturbances

SIDE-EFFECTS, FURTHER INFORMATION

- Ear effects
  - When used by inhalation Manufacturer advises monitor serum tobramycin concentration in patients with known or suspected signs of auditory dysfunction; if ototoxicity develops—discontinue treatment until serum concentration falls below 2 mg/litre.

VANTOBRA® NEBULISER SOLUTION

- Uncommon Dyspnoea
  - Rare Anorexia • asthenia • asthma • chest discomfort • dizziness • headache • nausea • pyrexia • vomiting
  - Very rare Abdominal pain • back pain • diarhoea • ear pain • fungal infection • hyperventilation • hypoxia • lymphadenopathy • sinusitis • somnolence

RENAL IMPAIRMENT

- When used by inhalation Manufacturer advises monitor serum tobramycin concentration; if nephrotoxicity develops—discontinue treatment until serum concentration falls below 2 mg/litre.

MONITORING REQUIREMENTS

- With intramuscular use or intravenous use One-hour (‘peak’) serum concentration should not exceed 10 mg/litre; pre-dose (‘trough’) concentration should be less than 2 mg/litre.
  - When used by inhalation Measure lung function before and after initial dose of tobramycin and monitor for bronchospasm; if bronchospasm occurs in a patient not using a bronchodilator, repeat test using bronchodilator. Manufacturer advises monitor renal function before treatment and then annually.

DIRECTIONS FOR ADMINISTRATION

- With intravenous use For intravenous infusion (Nebcin®); intermittent or via drip tubing in Glucose 5% or Sodium chloride 0.9%. For adult intermittent infusion suggested volume 50–100 mL given over 20–60 minutes.
  - When used by inhalation Other inhaled drugs should be administered before tobramycin.

PATIENT AND CARER ADVICE

- When used by inhalation Patient counselling is advised for Tobramycin dry powder for inhalation (administration).

VANTOBRA® NEBULISER SOLUTION

Missed doses

Manufacturer advises if a dose is more than 6 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TaS)

- Tobramycin by dry powder inhalation for pseudomonal lung infection in cystic fibrosis (March 2013) NICE TA276

Tobramycin dry powder for inhalation is recommended for chronic pulmonary infection caused by *Pseudomonas aeruginosa* in patients with cystic fibrosis only if there is an inadequate response to colistimethate sodium, or if colistimethate sodium cannot be used because of contraindications or intolerance. The manufacturer must provide tobramycin dry powder for inhalation at the discount agreed as part of the patient access scheme to primary, secondary and tertiary care in the NHS. Patients currently receiving tobramycin dry powder for inhalation can continue treatment until they and their clinician consider it appropriate to stop.

www.nice.org.uk/TA276

© Crown copyright 2012

BNF 74

Infection

Bacterial infection

493
**Antibacterials**

### Carbapenems

#### Overview

The carbapenems are beta-lactam antibacterials with a broad-spectrum of activity which includes many Gram-positive and Gram-negative bacteria, and anaerobes; *imipenem* (imipenem with cilastatin p. 495) and meropenem p. 495 have good activity against *Pseudomonas aeruginosa*. The carbapenems are not active against metillin-resistant *Staphylococcus aureus* and *Enterococcus faecium*.

*Imipenem* (imipenem with cilastatin) and meropenem are used for the treatment of severe hospital-acquired infections and polymicrobial infections including sepsicaemia, hospital-acquired pneumonia, intra-abdominal infections, skin and soft-tissue infections, and complicated urinary-tract infections.

Ertapenem below is licensed for treating abdominal and gynaecological infections and for community-acquired pneumonias, but it is not active against atypical respiratory pathogens and it has limited activity against penicillin-resistant pneumococci. It is also licensed for treating foot infections of the skin and soft tissue in patients with diabetes. Unlike the other carbapenems, ertapenem is not active against *Pseudomonas* or against *Acinetobacter spp*.

*Imipenem* is partially inactivated in the kidney by enzymatic activity and is therefore administered in combination with *cilastatin* (imipenem with cilastatin), a specific enzyme inhibitor, which blocks its renal metabolism. Meropenem and ertapenem are stable to the renal enzyme which inactivates imipenem and therefore can be given without cilastatin.

Side-effects of imipenem with cilastatin are similar to those of other beta-lactam antibacterials. Meropenem has less seizure-inducing potential and can be used to treat central nervous system infection.

#### Indications and dosage

- **Abdominal infections**
- **Acute gynaecological infections**
- **Community-acquired pneumonia**
- **Diabetic foot infections of the skin and soft-tissue**
- **Surgical prophylaxis, colorectal surgery**

#### Precautions

- **CNS disorders**—risk of seizures.
- **Elderly**

#### Interactions

- **Appendix 1: carbapenems**

#### Side-effects

- **Common or very common** Diarrhoea, headache, injection-site reactions, nausea, pruritus, raised platelet count, rash (also reported with eosinophilia and systemic symptoms), vomiting.
- **Uncommon** Abdominal pain, anorexia, antibiotic-associated colitis, asthma, bradycardia, chest pain, confusion, constipation, dizziness, dry mouth, dyspepsia, dysphonia, hypotension, melaena, oedema, petechiae, pharyngeal discomfort, raised glucose, seizures, sleep disturbances, taste disturbances.
- **Rare** Agitation, anxiety, arrhythmia, blood disorders, cholecystitis, cough, depression, dysphagia, electrolyte disturbances, haemorrhage, hypoglycaemia, increase in blood pressure, jaundice, liver disorder, muscle cramp, nasal congestion, neutropenia, pelvic peritonitis, renal impairment, scleral disorder, syncope, thrombocytopenia, tremor, wheezing.
- **Frequency not known** Dyskinesia, hallucinations.

#### Allergy and cross-sensitivity

Avoid if history of immediate hypersensitivity reaction to beta-lactam antibacterials.

#### Pregnancy

Manufacturer advises avoid unless potential benefit outweighs risk.

#### Breastfeeding

Present in milk—manufacturer advises avoid.

#### Renal impairment

Risk of seizures; max. 500 mg daily if eGFR less than 30 mL/minute/1.73 m².

#### Directions for administration

For intravenous infusion (*Invanz*®), give intermittently in Sodium chloride 0.9%. Reconstitute 1 g with 10 mL. Water for injections or Sodium chloride 0.9%; dilute requisite dose in infusion fluid to a final concentration not exceeding 20 mg/mL; give over 30 minutes; incompatible with glucose solutions.

#### Medicinal forms

There can be variation in the licensing of different medicines containing the same drug.

### Powder for solution for infusion

**Electrolytes:** May contain Sodium

- **Invanz** (Merck Sharp & Dohme Ltd)
  - **Ertapenem (as Ertapenem sodium)** 1 gram Invanz 1g powder for solution for infusion vials | 1 vial (PoM) £31.65
**Indications and Dose**

Aerobic and anaerobic Gram-positive and Gram-negative infections (not indicated for CNS infections) | Hospital-acquired septicaemia

- **By Intravenous infusion**
  - Adult: 500 mg every 6 hours, alternatively 1 g every 8 hours

Infection caused by *Pseudomonas* or other less sensitive organisms | Empirical treatment of infection in febrile patients with neutropenia | Life-threatening infection

- **By Intravenous infusion**
  - Adult: 1 g every 6 hours

**Dose Equivalence and Conversion**

- Dose expressed in terms of imipenem.

**Cautions**

CNS disorders - epilepsy

**Interactions**

Appendix 1: carbapenems

**Side-effects**

Common or very common | Diarrhoea | eosinophilia | nausea (may reduce rate of infusion) | rash | vomiting

Uncommon | Confusion | dizziness | drowsiness | hallucinations | hypotension | leucopenia | myoclonic activity | seizures | thrombocytopenia | thrombocytosis

Rare | Acute renal failure | anaphylactic reactions | antibiotic-associated colitis | encephalopathy | hearing loss | hepatitis | paraesthesia | polyuria | Stevens-Johnson syndrome | taste disturbances | tooth, tongue or urinary discolouration | toxic epidermal necrolysis | tremor

Very rare | Abdominal pain | aggravation of myasthenia gravis | asthenia | cyanosis | dyspnoea | flushing | glossitis | haemolytic anaemia | headache | heartbeat | hyperhidrosis | hypersalivation | hyperventilation | palpitation | polyarthralgia | tachycardia | tinnitus

Frequency not known | Neurotoxicity (at high dose, renal failure, CNS disease)

**Allergy and Cross-sensitivity**

Avoid if history of immediate hypersensitivity reaction to beta-lactam antibacterials.

Use with caution in patients with sensitivity to beta-lactam antibacterials.

**Pregnancy**

Use only if potential benefit outweighs risk — no information available.

**Breast Feeding**

Unlikely to be absorbed (however, manufacturer advises avoid).

**Renal Impairment**

Monitor liver function in hepatic impairment.

**Effect on Laboratory Tests**

Positive Coombs’ test.

**Directions for Administration**

*Intravenous injection* to be administered over 5 minutes.

For *intravenous infusion* (Meronem®), give intermittently in Glucose 5% or Sodium chloride 0.9%.

Dilute dose in infusion fluid to a final concentration of 1–20 mg/mL; give over 15–30 minutes.

**Medicinal Forms**

There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for infusion**

**Electrolytes:** May contain Sodium

- Imipenem with cilastatin (Non-proprietary)
  - Cilastatin (as Cilastatin sodium) 500 mg, Imipenem (as Imipenem monohydrate) 500 mg
  - Imipenem 500mg / Cilastatin 500mg powder for solution for infusion vials | 1 vial (£12.00 (Hospital only)) | 5 vials (£50.00 (Hospital only)) | 10 vials (£75.45)

- Primaxin IV. (Merk Sharp & Dohme Ltd)
  - Cilastatin (as Cilastatin sodium) 500 mg, Imipenem (as Imipenem monohydrate) 500 mg
  - Primaxin IV 500mg powder for solution for infusion vials | 1 vial (£12.00)

**Meropenem**

**Indications and Dose**

Aerobic and anaerobic Gram-positive and Gram-negative infections | Hospital-acquired septicaemia

- **By Intravenous infusion, or by Intravenous injection**
  - Adult: 0.5–1 g every 8 hours

Exacerbations of chronic lower respiratory-tract infection in cystic fibrosis

- **By Intravenous infusion, or by Intravenous injection**
  - Adult: 2 g every 8 hours

Meningitis

- **By Intravenous infusion, or by Intravenous injection**
  - Adult: 2 g every 8 hours

Endocarditis (in combination with another antibacterial)

- **By Intravenous infusion, or by Intravenous injection**
  - Adult: 2 g every 8 hours

**Unlicensed Use**

Not licensed for use in endocarditis.

**Interactions**

Appendix 1: carbapenems

**Side-effects**

Common or very common | Abdominal pain | diarrhoea | disturbances in liver function tests | headache | nausea | pruritus | rash | thrombocytopenia | vomiting

Uncommon | Eosinophilia | leucopenia | paraesthesia | thrombocytopenia

Rare | Convulsions

Frequency not known | Antibiotic-associated colitis | haemolytic anaemia | Stevens-Johnson syndrome | toxic epidermal necrolysis

**Allergy and Cross-Sensitivity**

Avoid if history of immediate hypersensitivity reaction to beta-lactam antibacterials.

Use with caution in patients with sensitivity to beta-lactam antibacterials.

**Pregnancy**

Use only if potential benefit outweighs risk — no information available.

**Breast Feeding**

Unlike to be absorbed (however, manufacturer advises avoid).

**Hepatic Impairment**

Monitor liver function in hepatic impairment.

**Renal Impairment**

Use normal dose every 12 hours if eGFR 26–50 mL/minute/1.73 m². Use half normal dose every 12 hours if eGFR 10–25 mL/minute/1.73 m². Use half normal dose every 24 hours if eGFR less than 10 mL/minute/1.73 m².

**Effect on Laboratory Tests**

Positive Coombs’ test.

**Directions for Administration**

*Intravenous injection* to be administered over 5 minutes.

For *intravenous infusion* (Meronem®), give intermittently in Glucose 5% or Sodium chloride 0.9%.

Dilute dose in infusion fluid to a final concentration of 1–20 mg/mL; give over 15–30 minutes.

**Medicinal Forms**

There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for injection**

**Electrolytes:** May contain Sodium

- **Meropenem (Non-proprietary)**
  - Meropenem (as Meropenem trihydrate) 500 mg | Meropenem 500mg powder for solution for injection vials | 10 vial (£80.75–£103.10 DT price = £80.75)
  - Meropenem (as Meropenem trihydrate) 1 gram | Meropenem 1g powder for solution for injection vials | 10 vial (£161.18–£190.00 DT price = £161.18)
Infection

Cephalosporins

Overview
The cephalosporins are broad-spectrum antibiotics which are used for the treatment of septicaemia, pneumonia, meningitis, biliary-tract infections, peritonitis, and urinary-tract infections. The pharmacology of the cephalosporins is similar to that of the penicillins, excepting in patients with a history of immediate hypersensitivity to penicillin, because a suitable alternative antibacterial is not available, then cefixime p. 499, cefotaxime, cefazidime p. 500, ceftriaxone, or cefuroxime p. 498 can be used with caution; cefaclor p. 498, cefadroxil below, cefalexin p. 497, cefadroxil p. 497, and ceftriaxone p. 503 should be avoided.

The orally active 'first generation' cephalosporins, cefalexin, cefadrine, and cefadroxil and the 'second generation' cephalosporins, cefaclor has a similar duration of action and can be given twice daily; it has poor absorption.

Cefixime is an orally active 'third generation' cephalosporin. It has a longer duration of action than the other cephalosporins that are active by mouth. It is only licensed for acute infections.

Cefuroxime is a 'second generation' cephalosporin that is less susceptible than the earlier cephalosporins to inactivation by beta-lactamases. It is, therefore, active against certain bacteria which are resistant to the other drugs and has greater activity against Haemophilus influenzae. Cefotaxime, cefazidime and ceftriaxone are 'third generation' cephalosporins with greater activity than the 'second generation' cephalosporins against certain Gram-negative bacteria. However, they are less active than cefuroxime against Gram-positive bacteria, most notably Staphylococcus aureus. Their broad antibacterial spectrum may encourage superinfection with resistant bacteria or fungi.

Cefazidime has good activity against pseudomonas. It is also active against other Gram-negative bacteria.

Cefadroxil has a longer half-life and therefore needs to be given once daily. Indications include serious infections such as septicemia, pneumonia, and meningitis. The calcium salt of cefadroxil forms a precipitate in the gall bladder which may rarely cause symptoms but these usually resolve when the antibiotic is stopped.

Cefotaxime, cefuroxime and cefazidime are suitable cephalosporins for infections which do not respond to other drugs or which are resistant to the other cephalosporins. If a cephalosporin is essential in patients with a history of sensitivity and about infections of the CNS (e.g. meningitis).


Side-effects, further information
Antibiotic-associated colitis. Antibiotic-associated colitis may occur more commonly with second- and third-generation cephalosporins.

Allergy and cross-sensitivity
Contra-indicated in patients with cephalosporin hypersensitivity.

Cross-sensitivity with other beta-lactam antibacterials. About 0.5–6.5% of penicillin-sensitive patients will also be allergic to the cephalosporins. Patients with a history of immediate hypersensitivity to penicillin and other beta-lactams should not receive a cephalosporin.

Cephalosporins should be used with caution in patients with sensitivity to penicillin and other beta-lactams.

Effect on laboratory tests
False positive urinary glucose (if tested for reducing substances), false positive Coombs’ test.

Susceptible infections due to sensitive Gram-positive and Gram-negative bacteria
- By mouth
  - Child 6–17 years (body-weight up to 40 kg): 0.5 g twice daily
  - Child 6–17 years (body-weight 40 kg and above): 0.5–1 g twice daily
  - Adult: 0.5–1 g twice daily

Skin infections. Soft-tissue infections. Uncomplicated urinary-tract infections
- By mouth
  - Child 6–17 years (body-weight 40 kg and above): 1 g once daily
  - Adult: 1 g daily

Interactions
Appendix 1: cephalosporins

Pregnancy
Not known to be harmful.
**Breastfeeding** Present in milk in low concentration, but appropriate to use.

**Renal Impairment**
- In adults: 1 g initially, then 500 mg every 12 hours if eGFR 26–50 mL/minute/1.73 m². 1 g initially, then 500 mg every 24 hours if eGFR 11–26 mL/minute/1.73 m². 1 g initially, then 500 mg every 36 hours if eGFR less than 11 mL/minute/1.73 m².
- In children: Reduce dose if estimated glomerular filtration rate less than 50 mL/minute/1.73 m².

**Medicinal Forms**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

- **Cefalexin (Non-proprietary)**
  - Cefadroxil (as Cefadroxil monohydrate) 500 mg Cefadroxil 500mg capsules: 20 capsule £22.38 DT price = £22.38 | 100 capsule £111.90

**Cefalexin**

(Cephalexin)

**Indications and Dose**

Susceptible infections due to sensitive Gram-positive and Gram-negative bacteria

- **By mouth**
  - Child 1-11 months: 12.5 mg/kg twice daily, alternatively 125 mg twice daily
  - Child 1-4 years: 12.5 mg/kg twice daily, alternatively 125 mg 3 times a day
  - Child 5-11 years: 12.5 mg/kg twice daily, alternatively 250 mg 3 times a day
  - Child 12-17 years: 500 mg 2–3 times a day
  - Adult: 250 mg every 6 hours, alternatively 500 mg every 8–12 hours; increased to 1–1.5 g every 6–8 hours, increased dose to be used for severe infections

Serious susceptible infections due to sensitive Gram-positive and Gram-negative bacteria

- **By mouth**
  - Child 1 month-11 years: 25 mg/kg 2–4 times a day (max. per dose 1 g 4 times a day)
  - Child 12-17 years: 1–1.5 g 3–4 times a day

**Prophylaxis of recurrent urinary-tract infection**

- **By mouth**
  - Child: 12.5 mg/kg once daily (max. per dose 125 mg), dose to be taken at night
  - Adult: 125 mg once daily, dose to be taken at night

**Interactions**

- **Appendix 1: cephalexin**

**Pregnancy** Not known to be harmful.

**Breastfeeding** Present in milk in low concentration, but appropriate to use.

**Renal Impairment**
- In adults: Max. 3 g daily if eGFR 40–50 mL/minute/1.73 m². Max. 1.5 g daily if eGFR 10–40 mL/minute/1.73 m². Max. 750 mg daily if eGFR less than 10 mL/minute/1.73 m².
- In children: Reduce dose in moderate impairment.

**Patient and Carer Advice**

Medicines for Children leaflet: Cefalexin for bacterial infections www.medicinesforchildren.org.uk/cefalexin-bacterial-infections-0

**Professional Specific Information**

Dental practitioners’ formulary

Cefalexin Capsules may be prescribed. Cefalexin Tablets may be prescribed. Cefalexin Oral Suspension may be prescribed.
Infection

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Capsule
CAUTIONARY AND ADVISORY LABELS 9
- Cefradine (Non-proprietary)
  - Cefradine 250 mg Cefradine 250 mg capsules | 20 capsule [PoM] £6.00 DT price = £1.81 | 100 capsule [PoM] no price available
  - Cefradine 500 mg Cefradine 500 mg capsules | 20 capsule [PoM] £8.75 DT price = £2.73 | 100 capsule [PoM] no price available
  - Nicel (Strides Shasun (UK) Ltd)
    - Cefradine 250 mg Nicel 250 mg capsules | 20 capsule [PoM] £3.55 DT price = £1.81 | 100 capsule [PoM] £9.39
    - Cefradine 500 mg Nicel 500 mg capsules | 20 capsule [PoM] £5.58 DT price = £2.73 | 100 capsule [PoM] £33.72

ANTIBACTERIALS ➤ CEPHALOSPORINS, SECOND-GENERATION

Cefaclor

INDICATIONS AND DOSE
Susceptible infections due to sensitive Gram-positive and Gram-negative bacteria
- BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
  - Child 1-11 months: 20 mg/kg daily in 3 divided doses, alternatively 62.5 mg 3 times a day
  - Child 1-4 years: 20 mg/kg daily in 3 divided doses, alternatively 125 mg 3 times a day
  - Child 5-11 years: 20 mg/kg daily in 3 divided doses, usual max. 1 g daily, alternatively 250 mg 3 times a day
  - Child 12-17 years: 250 mg 3 times a day; maximum 4 g per day
- Adult: 250 mg 3 times a day; maximum 4 g per day
- BY MOUTH USING MODIFIED-RELEASE MEDICINES
  - Child 12-17 years: 375 mg every 12 hours, dose to be taken with food
- Adult: 375 mg every 12 hours, dose to be taken with food

Severe susceptible infections due to sensitive Gram-positive and Gram-negative bacteria
- BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
  - Child 1-11 months: 40 mg/kg daily in 3 divided doses, usual max. 1 g daily, alternatively 125 mg 3 times a day
  - Child 1-4 years: 40 mg/kg daily in 3 divided doses, usual max. 1 g daily, alternatively 250 mg 3 times a day
  - Child 5-11 years: 40 mg/kg daily in 3 divided doses, usual max. 1 g daily
  - Child 12-17 years: 500 mg 3 times a day; maximum 4 g per day
- Adult: 500 mg 3 times a day; maximum 4 g per day

Pneumonia
- BY MOUTH USING MODIFIED-RELEASE TABLETS
  - Child 12-17 years: 750 mg every 12 hours, dose to be taken with food
  - Adult: 750 mg every 12 hours, dose to be taken with food

Lower urinary-tract infections
- BY MOUTH USING MODIFIED-RELEASE MEDICINES
  - Child 12-17 years: 375 mg every 12 hours, dose to be taken with food
  - Adult: 375 mg every 12 hours, dose to be taken with food

INTERACTIONS ➤ Appendix 1: cephalosporins

SIDE-EFFECTS
SIDE-EFFECTS, FURTHER INFORMATION
- Skin reactions Cefaclor is associated with protracted skin reactions, especially in children.

PREGNANCY
Not known to be harmful.

BREAST FEEDING
Present in milk in low concentration, but appropriate to use.

RENAL IMPAIRMENT
No dose adjustment required. Manufacturer advises caution.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Oral suspension
CAUTIONARY AND ADVISORY LABELS 9
- Cefaclor (Non-proprietary)
  - Cefaclor (as Cefaclor monohydrate) 25 mg per ml Cefaclor 25 mg/ml oral suspension | 100 ml [PoM] no price available
  - Distalcor (Flynn Pharma Ltd)
  - Keftid (Strides Shasun (UK) Ltd)

Modified-release tablet
CAUTIONARY AND ADVISORY LABELS 9
- Cefaclor (as Cefaclor monohydrate) 375 mg Distalcor MR 375 mg tablets | 14 tablet [PoM] £9.10 DT price = £9.10

Capsule
CAUTIONARY AND ADVISORY LABELS 9
- Cefaclor (as Cefaclor monohydrate) 250 mg Cefaclor 250 mg capsules | 21 capsule [PoM] no price available DT price = £6.80
  - Distalcor (Flynn Pharma Ltd)
  - Keftid (Strides Shasun (UK) Ltd)
  - Cefaclor (as Cefaclor monohydrate) 500 mg Distalcor 500 mg capsules | 21 capsule [PoM] £7.50 DT price = £7.50

CEFADROXIL

INDICATIONS AND DOSE
Susceptible infections due to sensitive Gram-positive and Gram-negative bacteria
- BY MOUTH
  - Child 3 months-1 year: 10 mg/kg twice daily (max. per dose 125 mg)
  - Child 2-11 years: 15 mg/kg twice daily (max. per dose 250 mg)

Asymptomatic carriage of Haemophilus influenzae or mild exacerbations in cystic fibrosis
- BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
  - Child 1-11 months: 125 mg every 8 hours
  - Child 1-6 years: 250 mg 3 times a day
  - Child 7-17 years: 500 mg 3 times a day

Asymptomatic carriage of Haemophilus influenzae or mild exacerbations in cystic fibrosis

_downloadged from www.medicalbr.com_
MEDICAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection, infusion

Tablet

CAUTIONARY AND ADVISORY LABELS 9, 21, 25

- **Cefuroxime (Non-proprietary)**
  - Cefuroxime (as Cefuroxime axetil) 250 mg Cefuroxime 250mg tablets | 14 tablet | £17.72 DT price = £17.72
  - Cefuroxime (as Cefuroxime axetil) 125 mg Cefuroxime 125mg tablets | 14 tablet | £4.56 DT price = £4.56
  - Cefuroxime (as Cefuroxime axetil) 250 mg Zinnat 250mg tablets | 14 tablet | £9.11 DT price = £17.72

Powder for injection

ELECTROLYTES: May contain Sodium

- **Cefuroxime (Non-proprietary)**
  - Cefuroxime (as Cefuroxime sodium) 750 mg Cefuroxime 750mg powder for injection vials | 1 vial | £2.52 P | 10 vial | £25.20
  - Cefuroxime (as Cefuroxime sodium) 1.5 gram Cefuroxime 1.5g powder for injection vials | 1 vial | £5.05 P | 10 vial | £50.50
  - Zinacef (GlaxoSmithKline UK Ltd)
    - Cefuroxime (as Cefuroxime sodium) 250 mg Zinacef 250mg powder for injection vials | 5 vial | £4.70
  - Cefuroxime (as Cefuroxime sodium) 750 mg Zinacef 750mg powder for injection vials | 5 vial | £11.72 (Hospital only)
  - Cefuroxime (as Cefuroxime sodium) 1.5 gram Zinacef 1.5g powder for injection vials | 1 vial | £4.70

Oral suspension

CAUTIONARY AND ADVISORY LABELS 9, 21

EXCIPIENTS: May contain Aspartame, sucrose

- Zinacef (GlaxoSmithKline UK Ltd)
  - Cefuroxime (as Cefuroxime axetil) 25 mg per 1 ml Zinnat 25mg/5ml oral suspension | 70 ml P | £5.20

ANTIBACTERIALS > CEPHALOSPORINS, THIRD-GENERATION

**Cefixime**

INDICATIONS AND DOSE

Acute infections due to sensitive Gram-positive and Gram-negative bacteria

- **BY MOUTH**
  - Child 6–11 months: 75 mg daily
  - Child 1–4 years: 100 mg daily
  - Child 5–9 years: 200 mg daily
  - Child 10–17 years: 200–400 mg daily, alternatively 100–200 mg twice daily
  - Adult: 200–400 mg daily in 1–2 divided doses

Uncomplicated gonorrhoea

- **BY MOUTH**
  - Adult: 400 mg for 1 dose

UNLICENSED USE

Use of cefixime for uncomplicated gonorrhoea is an unlicensed indication.

INTERACTIONS

Appendix 1: cephalosporins

PREGNANCY

Not known to be harmful.

BREAST FEEDING

Manufacturer advises avoid unless essential—no information available.

RENAL IMPAIRMENT

- In adults Reduce dose if eGFR less than 20 mL/minute/1.73 m² (max. 200 mg once daily).
  - In children Reduce dose if estimated glomerular filtration rate less than 20 mL/minute/1.73 m².

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS 9

- **Suprax** (Sanofi)
  - Cefixime 200 mg Suprax 200mg tablets | 7 tablet P | £13.23 DT price = £13.23

- Manufacturer advises avoid unless essential—no information available.

- **Renal impairment**
  - In adults Reduce dose if eGFR less than 20 mL/minute/1.73 m² (max. 200 mg once daily).
  - In children Reduce dose if estimated glomerular filtration rate less than 20 mL/minute/1.73 m².
Cefotaxime

- **INDICATIONS AND DOSE**
  - *Uncomplicated gonorrhoea*
    - By intramuscular injection
      - Adult: 500 mg for 1 dose
  - *Infections due to sensitive Gram-positive and Gram-negative bacteria* | Surgical prophylaxis | Haemophilus epiglottitis
    - By intramuscular injection, or by intravenous injection, or by intravenous infusion
      - Adult: 1 g every 12 hours
  - *Severe susceptible infections due to sensitive Gram-positive and Gram-negative bacteria* | Meningitis
    - By intramuscular injection, or by intravenous injection, or by intravenous infusion
      - Adult: 8 g daily in 4 divided doses, increased if necessary to 12 g daily in 3–4 divided doses, intramuscular doses over 1 g should be divided between more than one site
  - *Emergency treatment of suspected bacterial meningitis or meningococcal disease, before urgent transfer to hospital, in patients who cannot be given benzylpenicillin* (e.g. because of an allergy)
    - By intravenous injection, or by intramuscular injection
      - Child 1 month–11 years: 50 mg/kg for 1 dose
      - Child 12–17 years: 1 g for 1 dose
      - Adult: 1 g for 1 dose

- **INTERACTIONS** → Appendix 1: cephalosporins
- **SIDE-EFFECTS**
  - Rare | Arrhythmias (following rapid injection)
  - Pregnancy Not known to be harmful
  - Breast feeding Present in milk in low concentration, but appropriate to use.
- **RENAL IMPAIRMENT**
  - In adults: If eGFR less than 5 mL/minute/1.73 m², initial dose of 1 g then use half normal dose.
  - In children: usual initial dose, then use half normal dose if estimated glomerular filtration rate less than 5 mL/minute/1.73 m².
- **DIRECTIONS FOR ADMINISTRATION**
  - With intravenous use in children: Displacement value may be significant, consult local guidelines. For intermittent intravenous infusion dilute in glucose 5% or sodium chloride 0.9%; administer over 20–60 minutes; incompatible with alkaline solutions.
  - With intravenous use in adults: For intravenous infusion, give intermittently in Glucose 5% or Sodium chloride 0.9%. Suggested volume 40–100 mL given over 20–60 minutes; incompatible with alkaline solutions.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Powder for solution for injection**
    - Cefotaxime (as Cefotaxime sodium) 500 mg
      - Cefotaxime 500mg powder for solution for injection vials | 1 vial (£1.50 | 10 vial (£25.50–£30.00
    - Cefotaxime (as Cefotaxime sodium) 1 gram
      - Cefotaxime 1g powder for solution for injection vials | 1 vial (£3.00 | 10 vial (£35.00
    - Cefotaxime (as Cefotaxime sodium) 2 gram
      - Cefotaxime 2g powder for solution for injection vials | 1 vial (£8.00 | 10 vial (£75.00

Ceftazidime

- **INDICATIONS AND DOSE**
  - *Prophylaxis for transurethral resection of prostate*
    - By intravenous injection, or by intravenous infusion, or by deep intramuscular injection
      - Adult: 1 g, single dose to be administered up to 30 minutes before procedure and may be repeated if necessary when catheter removed
  - *Pseudomonal lung infection in cystic fibrosis*
    - By intravenous injection, or by intravenous infusion, or by deep intramuscular injection
      - Adult: 100–150 mg/kg daily in 3 divided doses; maximum 9 g per day
  - *Complicated urinary-tract infection*
    - By intravenous injection, or by intravenous infusion, or by deep intramuscular injection
      - Adult 18–79 years: 1–2 g every 8–12 hours
      - Adult 80 years and over: 1–2 g every 8–12 hours; maximum 3 g per day
  - *Septicaemia* | Hospital-acquired pneumonia
    - By intravenous infusion, or by intravenous injection, or by deep intramuscular injection
      - Adult 18–79 years: 2 g every 8 hours
      - Adult 80 years and over: 2 g every 8 hours; maximum 3 g per day
  - *Febrile neutropaenia*
    - By intravenous infusion, or by intravenous injection, or by deep intramuscular injection
      - Adult 18–79 years: 2 g every 8 hours
      - Adult 80 years and over: 2 g every 8 hours; maximum 3 g per day
  - *Meningitis*
    - By intravenous infusion, or by intravenous injection, or by deep intramuscular injection
      - Adult 18–79 years: 2 g every 8 hours
      - Adult 80 years and over: 2 g every 8 hours; maximum 3 g per day
  - *Susceptible infections due to sensitive Gram-positive and Gram-negative bacteria*
    - By intravenous infusion, or by intravenous injection, or by deep intramuscular injection
      - Adult 18–79 years: 1–2 g every 8 hours
      - Adult 80 years and over: 1–2 g every 8 hours; maximum 3 g per day

- **INTERACTIONS** → Appendix 1: cephalosporins
- **SIDE-EFFECTS**
  - Paraesthesia • taste disturbances
- **PREGNANCY** Not known to be harmful
- **BREAST FEEDING** Present in milk in low concentration, but appropriate to use.
- **HEPATIC IMPAIRMENT** Manufacturer advises caution in severe impairment.
- **RENAL IMPAIRMENT** Reduce dose if eGFR less than 50 mL/minute/1.73 m²—consult product literature.
- **DIRECTIONS FOR ADMINISTRATION** Intramuscular administration used when intravenous administration not possible; single doses over 1 g by intravenous route only.
  - With intravenous use: For intravenous infusion give intermittently or via drip tubing in Glucose 5% or 10% or Sodium chloride 0.9%. Dissolve 2 g initially in 10 mL (3 g in 15 mL) infusion fluid. For Fortum dilute further to a concentration of 40 mg/mL. For Kefadim dilute further to a concentration of 20 mg/mL. Give over up to 30 minutes.
Bacterial infection 501

Ceftaxone

15-Jun-2016

F 496

INDICATIONS AND DOSE

Community-acquired pneumonia | Hospital-acquired pneumonia | Intra-abdominal infections | Complicated urinary-tract infections | Acute exacerbations of chronic obstructive pulmonary disease

- BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION, OR BY DEEP INTRAMUSCULAR INJECTION
- Adult: 1–2 g once daily, 2 g dose to be used for hospital-acquired pneumonia and severe cases

Complicated skin and soft tissue infections | Infections of bones and joints

- BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION, OR BY DEEP INTRAMUSCULAR INJECTION
- Adult: 2 g once daily

Suspected bacterial infection in neutropenic patients

- BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION, OR BY DEEP INTRAMUSCULAR INJECTION
- Adult: 2–4 g once daily, doses at the higher end of the recommended range used in severe cases

Bacterial meningitis | Bacterial endocarditis

- BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION, OR BY DEEP INTRAMUSCULAR INJECTION
- Adult: 2–4 g once daily, doses at the higher end of the recommended range used in severe cases

- BY INTRAVENOUS INFUSION
- Child 1 month–11 years (body-weight up to 50 kg): 80–100 mg/kg once daily, 100 mg/kg once daily dose should be used for bacterial endocarditis; maximum 4 g per day
- Child 9–11 years (body-weight 50 kg and above): 2–4 g once daily, doses at the higher end of the recommended range used in severe cases
- Child 12–17 years: 2–4 g once daily, doses at the higher end of the recommended range used in severe cases

- BY INTRAVENOUS INJECTION
- Child 9–11 years (body-weight 50 kg and above): 2–4 g once daily, doses at the higher end of the recommended range used in severe cases
- Child 12–17 years: 2–4 g once daily, doses at the higher end of the recommended range used in severe cases

UNLICENSED USE


CAUTIONS

GENERAL CAUTIONS

History of hypercalciuria | history of kidney stones

SPECIFIC CAUTIONS

- With intravenous use Concomitant treatment with intravenous calcium (including total parenteral nutrition containing calcium) (in adults)

INTERACTIONS

- Appendix 1: cephalosporins

SIDE-EFFECTS

- Common or very common Calcium ceftaxone precipitates in gall bladder—consider discontinuation if symptomatic - calcium ceftaxone precipitates in urine (particularly in very young, dehydrated or those who are immobilised)— consider discontinuation if symptomatic

- Uncommon | Gential fungal infection

- Rare

- Bronchospasm | glycosuria | haematuria | prolongation of prothrombin time

- Frequency not known Convulsion | glossitis | oliguria | pancreatitis | stomatitis | toxic epidermal necrolysis | vertigo

PREGNANCY

Manufacturer advises use only if benefit outweighs risk—limited data available but not known to be
502  Bacterial infection

harmful in animal studies. Specialist sources indicate suitable for use in pregnancy. 

- **BREAST FEEDING**  Specialist sources advise ceftriaxone is compatible with breastfeeding—present in milk in low concentration but limited effects to breast-fed infant. 

- **RENA L IMPAIRMENT**  Manufacturer advises reduce dose and monitor efficacy in patients with severe renal impairment in combination with hepatic impairment—no information available.
  - in adults  Manufacturer advises reduce dose if eGFR less than 10 mL/minute/1.73 m² (max. 2 g daily).
  - in children  Manufacturer advises reduce dose if estimated glomerular filtration rate less than 10 mL/minute/1.73 m² max. 50 mg/kg daily or max. 2 g daily.

- **MONITORING REQUIREMENTS**  Manufacturer advises to monitor full blood count regularly during prolonged treatment.

- **DIRECTIONS FOR ADMINISTRATION**
  - With intramuscular use or intravenous use  Twice daily dosing may be considered for doses greater than 2 g daily.
  - With intravenous use in children  For intravenous infusion (preferred route), dilute reconstituted solution with Glucose 5% or Sodium Chloride 0.9%; give over at least 30 minutes. Not to be given simultaneously with parenteral nutrition or infusion fluids containing calcium, even by different infusion lines; in children, may be infused sequentially with infusion fluids containing calcium if flush with sodium chloride 0.9% between infusions or give infusions by different infusion lines at different sites. Displacement value may be significant, consult local guidelines.
  - For intravenous injection, give over 5 minutes; intravenous doses of 50 mg/kg or more in children under 12 years should be given by infusion.
  - With intramuscular use in children  For intramuscular injection, may be mixed with 1% Lidocaine Hydrochloride Injection to reduce pain at intramuscular injection site. Intramuscular injection should only be considered when the intravenous route is not possible or less appropriate. If administered by intramuscular injection, the lower end of the dose range should be used for the shortest time possible; volume depends on the age and size of the child, but doses over 1 g must be divided between more than one site. The maximum intramuscular dose is 2 g, doses greater than 2 g must be given by intravenous infusion or intravenous injection (see above). Displacement value may be significant, consult local guidelines.
  - With intravenous use in adults  For intravenous infusion (preferred route) (Rocephin®; Ceftriaxone Injection, Genus), give intermittently or via drip tubing in Glucose 5% or 10% or Sodium chloride 0.9%. Reconstitute 2-g vial with 40 mL infusion fluid. Give by intermittent infusion over at least 30 minutes. Not to be given simultaneously with total parenteral nutrition or infusion fluids containing calcium, even by different infusion lines. May be infused sequentially with infusion fluids containing calcium if flush with sodium chloride 0.9% between infusions or give infusions by different infusion lines at different sites.
  - For intravenous injection, give over 5 minutes.
  - With intramuscular use in adults  For intramuscular injection, doses over 1 g must be divided between more than one site. The maximum intramuscular dose is 2 g, doses greater than 2 g must be given by intravenous administration. Displacement value may be significant, consult local guidelines.

- **MEDICINAL FORMS**  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: infusion

  - **Powder for solution for injection**
    - **ELECTROLYTES:**  May contain Sodium
      - Ceftriaxone (Non-proprietary)
        - Ceftriaxone (as Ceftriaxone sodium) 250 mg  Ceftriaxone 250mg powder for solution for injection vials | 1 vial (£0.80 DT price = £2.40
        - Ceftriaxone (as Ceftriaxone sodium) 1 gram  Ceftriaxone 1g powder for solution for injection vials | 1 vial (£0 price no available DT price = £9.58 | 10 vial (£95.80
        - Ceftriaxone (as Ceftriaxone sodium) 2 gram  Ceftriaxone 2g powder for solution for injection vials | 1 vial (£19.18 | 10 vial (£191.80
        - Ceftriaxone 2g powder for solution for infusion vials | 1 vial (£17.70 DT price = £19.18
      - Rocephin (Roche Products Ltd)
        - Ceftriaxone (as Ceftriaxone sodium) 250 mg  Rocephin 250mg powder for solution for injection vials | 1 vial (£2.40 DT price = £2.40
        - Ceftriaxone (as Ceftriaxone sodium) 1 gram  Rocephin 1g powder for solution for injection vials | 1 vial (£9.58 DT price = £9.58
        - Ceftriaxone (as Ceftriaxone sodium) 2 gram  Rocephin 2g powder for solution for injection vials | 1 vial (£19.18 DT price = £19.18

  - **ANTIBACTERIALS**  CEPHALOSPORINS, THIRD-GENERATION WITH BETA-LACTAMASE INHIBITOR

I Ceftriaxone with tazobactam

- **INDICATIONS AND DOSE**  Complicated intra-abdominal infection (in combination with metronidazole when anaerobic pathogens suspected)
  - BY INTRAVENOUS INFUSION
    - Adult: 1/0.5 g every 8 hours for 4–14 days
  - Complicated urinary tract infection | Acute pyelonephritis
  - BY INTRAVENOUS INFUSION
    - Adult: 1/0.5 g every 8 hours for 7 days

- **DOSE EQUIVALENCE AND CONVERSION**
  - Dose expressed as x/y g where x and y are ceftriaxone and tazobactam respectively.

- **INTERACTIONS**  → Appendix 1: cephalosporins

- **SIDE-EFFECTS**
  - Common or very common  Anxiety - constipation - hypotension

- **PREGNANCY**  Manufacturer advises use only if potential benefit outweighs risk—toxicity in animal studies with tazobactam.

- **BREAST FEEDING**  Manufacturer advises avoid—no information available.

- **RENA L IMPAIRMENT**  Manufacturer advises reduce dose to 500/250 mg every 8 hours if eGFR 30–50 mL/minute/1.73 m² and 250/125 mg every 8 hours if eGFR 15–29 mL/minute/1.73 m². Manufacturer advises monitor for changes in renal function.

- **DIRECTIONS FOR ADMINISTRATION**  For intravenous infusion (Zerbaxa®), give intermittently in Glucose 5% or Sodium chloride 0.9%; reconstitute initially each vial with 10 mL. Water for Injections or Sodium chloride 0.9% to give a final volume of 11.4 mL; dilute requisite dose in 100 mL of Glucose 5% or Sodium chloride 0.9%; give over 1 hour.
HANDLING AND STORAGE  Manufacturer advises store in a refrigerator at 2°C–8°C.

PATIENT AND CARER ADVICE
Driving and skilled tasks
Manufacturer advises ceftolozane with tazobactam may influence driving and performance of skilled tasks—increased risk of dizziness.

NATIONAL FUNDING/ACCESS DECISIONS
Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (Dec 2012) that ceftolozane with tazobactam (Zerbaxa®) is not recommended for use within NHS Scotland for the treatment of complicated intra-abdominal infections, complicated urinary tract infections, and acute pyelonephritis.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for infusion
- Zinforo (Pfizer Ltd) ▼
- Ceftaroline fosamil (as Ceftaroline fosamil acetic acid solvate monohydrate) 600 mg Zinforo 600mg powder for concentrate for solution for infusion vials | 10 vial (Pom) £375.00

ANTIBACTERIALS  > CECAKOSPORINS, OTHER

Ceftobiprole

INDICATIONS AND DOSE
Hospital-acquired pneumonia (excluding ventilator-associated pneumonia) / Community-acquired pneumonia
- BY INTRAVENOUS INFUSION
- Adult: 500 mg every 8 hours

CAUTIONS
- Pre-existing seizure disorder—increased risk of seizures, supra-normal creatinine clearance

CAUTIONS, FURTHER INFORMATION
- Supra-normal creatinine clearance  Manufacturer advises to measure baseline renal function and increase duration of infusion if creatinine clearance greater than 150 mL/minute.

INTERACTIONS
- Appendix 1: cephalosporins

SIDE-EFFECTS
- Common or very common
  - Dysgeusia, dyspepsia
  - Agitation, asthma, dyspnoea, muscle spasm, pharyngolaryngeal pain, renal failure
- Frequency not known
  - Convulsions
- PREGNANCY  Manufacturer advises avoid unless essential—no information available.
- BREAST FEEDING  Manufacturer advises avoid—present in milk in animal studies.
- RENAL IMPAIRMENT  Reduce dose to 500 mg every 12 hours in moderate impairment and 250 mg every 12 hours in severe impairment. Manufacturer advises use with caution in severe impairment—limited information available.

DIRECTIONS FOR ADMINISTRATION
- Manufacturer advises for intravenous infusion (Zevtera®), give intermittently in Glucose 5%, or Sodium Chloride 0.9%, or Lactated Ringer’s solution; reconstitute each 500 mg with 10 mL. Water for injections or Glucose 5%; dilute in 250 mL infusion fluid and give over 2 hours (increased to 4 hours if creatinine clearance greater than 150 mL/minute). Do not mix with calcium-containing solutions (except Lactated Ringer’s solution) in the same intravenous line—precipitation may occur.

HANDLING AND STORAGE  Manufacturer advises store in a refrigerator (2–8°C)—consult product literature for storage after reconstitution and dilution.

PATIENT AND CARER ADVICE
Driving and skilled tasks
Manufacturer advises patients and carers should be counselled on the effects on driving and performance of skilled tasks—increased risk of dizziness.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for infusion
- Zevtera (Basilea Pharmaceutica International Ltd) ▼
- Ceftobiprole (as Ceftobiprole medocaril sodium) 500 mg Zevtera 500mg powder for concentrate for solution for infusion vials | 10 vial (Pom) £396.30 (Hospital only)
Teicoplanin

**Drug action** The glycopeptide antibiotic teicoplanin has bactericidal activity against aerobic and anaerobic Gram-positive bacteria including multi-resistant staphylococci. However, there are reports of *Staphylococcus aureus* with reduced susceptibility to glycopeptides and increasing reports of glycopeptide-resistant enterococci. Teicoplanin is similar to vancomycin, but has a significantly longer duration of action, allowing once daily administration after the loading dose.

**Indications and dose**

**Clostridium difficile infection**
- **By mouth**
  - Adult: 100–200 mg twice daily for 10–14 days

**Serious infections caused by Gram-positive bacteria (e.g. complicated skin and soft-tissue infections, pneumonia)**
- **By intravenous injection, or by intravenous infusion, or by intramuscular injection**
  - Adult (body-weight up to 70 kg): Initially 400 mg every 12 hours for 3 doses, followed by 400 mg once daily
  - Adult (body-weight 70 kg and above): Initially 6 mg/kg every 12 hours for 3 doses, then 6 mg/kg once daily

**Streptococcal or enterococcal endocarditis (in combination with another antibiotic)**
- **By intravenous injection, or by intravenous infusion**
  - Adult: Initially 10 mg/kg every 12 hours for 3–5 doses, then 10 mg/kg once daily, subsequent doses can be given by intramuscular injection

**Bone and joint infections**
- **By intravenous infusion, or by intravenous injection**
  - Adult: Initially 12 mg/kg every 12 hours for 3–5 doses, then 12 mg/kg once daily subsequent doses can be given by intramuscular injection, increased risk of fever and rash with doses of 12 mg/kg

**Surgical prophylaxis**
- **By intravenous injection**
  - Adult: 400 mg, to be administered up to 30 minutes before the procedure

**Surgical prophylaxis in open fractures**
- **By intravenous infusion**
  - Adult: 800 mg, to be administered up to 30 minutes before skeletal stabilisation and definitive soft-tissue closure

**Peritonitis associated with peritoneal dialysis (added to dialysis fluid)**
- **By intraperitoneal infusion**
  - Adult: (consult local protocol)

**Pharmacokinetics**
Teicoplanin should not be given by mouth for systemic infections because it is not absorbed significantly.

**Unlicensed use** Not licensed for surgical prophylaxis. Teicoplanin doses in BNF may differ from those in product literature.

**Side-effects**
- **Common or very common** Pruritus • rash
- **Uncommon** Bronchospasm • diarrhoea • dizziness • eosinophilia • fever • headache • leucopenia • mild hearing loss • nausea • thrombocytopenia • thrombophlebitis • tinnitus • vestibular disorders • vomiting
- **Frequency not known** Exfoliative dermatitis • nephrotoxicity • renal failure • Stevens-Johnson syndrome • toxic epidermal necrolysis

**Side-effects, further information**
- **Nephrotoxicity** Teicoplanin is associated with a lower incidence of nephrotoxicity than vancomycin.
- **Allergy and cross-sensitivity** Caution if history of vancomycin sensitivity.
- **Pregnancy** Manufacturer advises use only if potential benefit outweighs risk.
- **Breast feeding** No information available.
- **Renal impairment** Use normal dose regimen on days 1–4, then use normal maintenance dose every 48 hours if eGFR 30–80 mL/minute/1.73 m² and use normal maintenance dose every 72 hours if eGFR less than 30 mL/minute/1.73 m². Plasma-teicoplanin concentration should be monitored during parenteral maintenance treatment. Also monitor renal and auditory function during prolonged treatment in renal impairment.

**Monitoring requirements**
- With intramuscular use or intravenous use Plasma-teicoplanin concentration is not measured routinely because a relationship between plasma concentration and toxicity has not been established. However, the plasma-teicoplanin concentration can be used to optimise parenteral treatment in severe sepsis or burns, deep-seated staphylococcal infection (including bone and joint infection), endocarditis and in intravenous drug abusers. Pre-dose (‘trough’) concentrations should be greater than 15 mg/litre (greater than 20 mg/litre in endocarditis or deep-seated infection such as bone and joint infection), but less than 60 mg/litre.

**Plasma-teicoplanin concentration should be measured in elderly patients.**
- **Blood counts and liver and kidney function tests required.**
- **Directions for administration**
  - With intravenous use For intravenous infusion (Targocid®), give intermittently in Glucose 5% or Sodium chloride 0.9%; reconstitute initially with water for injections provided; infuse over 30 minutes. Continuous infusion not usually recommended.
  - With oral use Injection can be used to prepare solution for oral administration.

**Medicinal forms**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection

- **Powder and solvent for solution for injection**
  - **Electrolytes:** May contain Sodium
  - **Targocid** (Sanofi) ▼
    - Teicoplanin 200 mg Targocid 200mg powder and solvent for solution for injection vials | 1 vial £3.93
    - Teicoplanin 400 mg Targocid 400mg powder and solvent for solution for injection vials | 1 vial £7.32

Telavancin

**Drug action** Telavancin is a glycopeptide antibacterial; it has bactericidal activity against aerobic and anaerobic Gram-positive bacteria including multi-resistant staphylococci. However, there are reports of *Staphylococcus aureus* with reduced susceptibility to glycopeptides. There are increasing reports of glycopeptide-resistant enterococci.

**Indications and dose**
- **Hospital-acquired pneumonia, known or suspected to be caused by meticillin-resistant *Staphylococcus aureus* when other antibiotics cannot be used**
  - **By intravenous infusion**
  - Adult: 10 mg/kg once daily for 7–21 days

**Cautions** Conditions that predispose to renal impairment • predisposition to QT interval prolongation (including
electrolyte disturbances, congenital long QT syndrome, uncompensated heart failure, severe left ventricular hypertrophy

- **INTERACTIONS** → Appendix 1: telavancin

- **SIDE-EFFECTS**
  - **Common or very common** Acute renal failure • chills • constipation • diarrhea • dizziness • fungal infection • headache • insomnia • malaise • nausea • pruritus • rash • taste disturbances • vomiting
  - **Uncommon** Abdominal pain • agitation • altered sense of smell • angina • antibiotic-associated colitis • anxiety • arthralgia • atrial fibrillation • back pain • blood disorders • blurred vision • bradycardia • confusion • congestive cardiac failure • decreased appetite • depression • dry mouth • dyspepsia • dysphonia • dysuria • electrolyte disturbances • erythema • eye irritation • flatulence • flushing • haematuria • hepatitis • hiccup • hypokidrosis • hypertension • hypotension • increased INR • microalbuminuria • myalgia • nasal congestion • oedema • oliguria • oral hypoesthesia • palpitation • paraesthesia • pharyngolaryngeal pain • phlebitis • pollikiuria • pyrexia • QT interval prolongation • sinus tachycardia • somnolence • supraventricular extrasystoles • tinnitus • tremor • urinary tract infection • urticaria • ventricular extrasystoles
  - **Rare** Deafness
  - **Frequency not known** Flushing of the upper body (‘red man’ syndrome) • non-cardiac chest pain

- **ALLERGY AND CROSS-SENSITIVITY** Use with caution in patients with vancomycin or teicoplanin sensitivity.

- **CONCEPTION AND CONTRACEPTION** Effective contraception required during treatment.

- **PREGNANCY** Avoid (teratogenic in animal studies).

- **BREAST FEEDING** Manufacturer advises caution unless potential benefit outweighs risk—no information available.

- **HEPATIC IMPAIRMENT** Manufacturer advises caution in severe impairment—no information available.

- **RENAL IMPAIRMENT** In chronic renal failure, use 7.5 mg/kg once daily if eGFR 30–50 mL/minute/1.73 m². Avoid in acute renal failure—risk of mortality increased. In chronic renal failure, avoid if eGFR less than 30 mL/minute/1.73 m².

- **MONITORING REQUIREMENTS** Monitor renal function daily for at least the first 3–5 days, then every 2–3 days thereafter.

- **DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Vibativ®). Avoid rapid infusion (can cause ‘red man’ syndrome). Give intermittently in Glucose 5% or Sodium chloride 0.9%; reconstitute each 750 mg with 45 mL. Glucose 5%, sodium chloride 0.9%, or water for injections to produce a 15 mg/mL solution; for doses of 150–800 mg, dilute requisite dose in 100 to 250 mL infusion fluid; for doses outside this range, dilute to a final concentration of 0.6–8 mg/mL; give over at least 60 minutes.

- **MECHANICAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

  - **Powder for solution for infusion**
    - **Vibativ** (Cilag Corporation Limited) ▼
      - **Telavancin (as Telavancin hydrochloride) 750 mg** *Vibativ* 750mg powder for solution for infusion vials | 1 vial [Pack] £645.00 (Hospital only)

- **Vancocycin**

  - **DRUG ACTION** The glycopeptide antibiotic vancomycin has bactericidal activity against aerobic and anaerobic Gram-positive bacteria including multi-resistant staphylococci. However, there are reports of Staphylococcus aureus with reduced susceptibility to glycopeptides. There are increasing reports of glycopeptide-resistant enterococci. Penetration into cerebrospinal fluid is poor.
  - **With intravenous use** Vancomycin has a long duration of action and can therefore be given every 12 hours.

- **INDICATIONS AND DOSE**
  - **Clostridium difficile infection**
    - **BY MOUTH**
      - Adult: 125 mg 4 times a day for 10–14 days, dose may be increased if infection fails to respond or is life-threatening, increased if necessary up to 500 mg 4 times a day

  - **Infections due to Gram-positive bacteria including endocarditis, osteomyelitis, septicemia and soft-tissue infections**
    - **BY INTRAVENOUS INFUSION**
      - Adult: 1–1.5 g every 12 hours
      - Elderly: 500 mg every 12 hours, alternatively 1 g once daily

- **Surgical prophylaxis (when high risk of MRSA)**
  - **BY INTRAVENOUS INFUSION**
  - Adult: 1 g for 1 dose

- **Peritonitis associated with peritoneal dialysis**
  - **BY INTRAPERITONEAL ADMINISTRATION**
  - Adult: (consult local protocol)

- **PHARMACOKINETICS**
  - Vancomycin should not be given by mouth for systemic infections because it is not absorbed significantly.

- **UNLICENSED USE** Vancomycin doses in BNF publications may differ from those in product literature. Use of vancomycin (added to dialysis fluid) for the treatment of peritonitis associated with peritoneal dialysis is an unlicensed route.

- **CAUTIONS**
  - **GENERAL CAUTIONS**
    - Avoid if history of deafness • elderly
  - **SPECIFIC CAUTIONS**
    - Systemic absorption may follow oral administration especially in inflammatory bowel disorders or following multiple doses

- **INTERACTIONS** → Appendix 1: vancomycin

- **SIDE-EFFECTS**
  - **Common or very common**
    - **With intravenous use** Blood disorders, including neutropenia (usually after 1 week or cumulative dose of 25 g) • interstitial nephritis • nephrotoxicity • ototoxicity (discontinue if tinnitus occurs) • renal failure
  - **Rare**
    - **With intravenous use** Agranulocytosis • thrombocytopenia
  - **Frequency not known**
    - **With intravenous use** Anaphylaxis • cardiac arrest on rapid infusion • chills • dysphonia • eosinophilia • exfoliative dermatitis • fever • flushing of the upper body (‘red man’ syndrome) • nausea • pain and muscle spasm of back and chest • phlebitis (irritant to tissue) • pruritus • rashes • severe hypotension on rapid infusion • shock on rapid infusion • Stevens-Johnson syndrome • toxic epidermal necrolysis • urticaria • vulva • wheezing

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - **Nephrotoxicity** Vancomycin is associated with a higher incidence of nephrotoxicity than teicoplanin.

- **ALLERGY AND CROSS-SENSITIVITY** Caution if teicoplanin sensitivity.

- **PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk.

- **BREAST FEEDING** Present in milk—significant absorption following oral administration unlikely.
• RENAL IMPAIRMENT Reduce dose. In renal impairment monitor plasma–vancomycin concentration and renal function regularly. Also monitor auditory function.

• MONITORING REQUIREMENTS
  ▶ All patients require plasma–vancomycin measurement (after 3 or 4 doses if renal function normal, earlier if renal impairment).
  ▶ All patients require blood counts, urinalysis, and renal function tests.
  ▶ Monitor auditory function in elderly.
  ▶ With intravenous use Pre-dose (‘trough’) concentration should be 10–15 mg/litre (15–20 mg/litre for endocarditis or less sensitive strains of meticillin-resistant Staphylococcus aureus or for complicated infections caused by S. aureus). An initial loading dose, by intravenous infusion, may be considered—consult local guidelines.

• DIRECTIONS FOR ADMINISTRATION
  ▶ With intravenous use Avoid rapid infusion (risk of anaphylactoid reactions) and rotate infusion sites.
  ▶ For intravenous infusion (Vancocin®), give intermittently in Glucose 5% or Sodium chloride 0.9%; reconstitute each 500 mg with 10 mL water for injections and dilute with infusion fluid to a concentration of up to 5 mg/mL (10 mg/mL in fluid restriction but increased risk of infusion-related effects); give over at least 60 minutes (rate not to exceed 10 mg/minute for doses over 500 mg); use continuous infusion only if intermittent not feasible.
  ▶ With oral use Injection can be used to prepare solution for oral administration; flavouring syrups may be added to the solution at the time of administration.

• MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, pastille, powder for solution for infusion vials; reconstitute each dose if necessary to prepare solution for infusion.

Powder for solution for infusion

  ▶ Vancomycin (Non-proprietary)
    Vancomycin (as Vancomycin hydrochloride) 500 mg Vancomycin 500 mg powder for solution for infusion vials | 1 vial (Pom) £7.25 | 10 vial (Pom) £62.50
    Vancomycin 500 mg powder for concentrate for solution for infusion vials | 1 vial (Pom) £8.50 | 10 vial (Pom) £62.50
    Vancomycin (as Vancomycin hydrochloride) 1 gram Vancomycin 1 g powder for solution for infusion vials | 1 vial (Pom) £14.50 | 10 vial (Pom) £125.00
    Vancomycin 1 g powder for concentrate for solution for infusion vials | 1 vial (Pom) £17.25 | 10 vial (Pom) £120.50
    Vancomycin (Flynn Pharma Ltd) Vancomycin (as Vancomycin hydrochloride) 500 mg Vancomycin 500 mg powder for solution for infusion vials | 1 vial (Pom) £6.25
    Vancomycin (as Vancomycin hydrochloride) 1 gram Vancomycin 1 g powder for solution for infusion vials | 1 vial (Pom) £12.50

Capsule
  CAUTIONARY AND ADVISORY LABELS 9
  ▶ Vancomycin (Non-proprietary)
    Vancomycin (as Vancomycin hydrochloride) 125 mg Vancomycin 125 mg capsules | 28 capsule (Pom) £32.47 DT price = £32.47
    Vancomycin (as Vancomycin hydrochloride) 250 mg Vancomycin 250 mg capsules | 28 capsule (Pom) £64.08 DT price = £64.08
    Vancomycin Matrigel (Flynn Pharma Ltd) Vancomycin (as Vancomycin hydrochloride) 125 mg Vancomycin Matrigel 125 mg capsules | 28 capsule (Pom) £88.31 DT price = £132.47

ANTIBACTERIALS > LINCOSAMIDES

Clindamycin

• DRUG ACTION Clindamycin is active against Gram-positive cocci, including streptococci and penicillin-resistant staphylococci, and also against many anaerobes, especially Bacteroides fragilis. It is well concentrated in bone and excreted in bile and urine.

• INDICATIONS AND DOSE
  Staphylococcal bone and joint infections such as osteomyelitis | Peritonitis | Intra-abdominal sepsis | Meticillin-resistant Staphylococcus aureus (MRSA) in bronchiectasis, bone and joint infections, and skin and soft-tissue infections | Erysipelas or cellulitis in penicillin-allergic patients (alternative to macrolides)
  ▶ BY MOUTH
    Child: 3–6 mg/kg 4 times a day (max. per dose 450 mg)
    Adult: 0.5–1 g every 12 hours (max. per dose 450 mg)
  ▶ BY DEEP INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INFUSION
    Adult: 0.6–2.7 g daily in 2–4 divided doses; increased if necessary up to 4.8 g daily, increased dose used in life-threatening infection, single doses above 600 mg to be administered by intravenous infusion only, single doses by intravenous infusion not to exceed 1.2 g

Treatment of mild to moderate pneumocystis pneumonia (in combination with primaquine)
  ▶ BY MOUTH
    Adult: 600 mg every 8 hours

Treatment of falciparum malaria (to be given with or following quinine)
  ▶ BY MOUTH
    Child: 7–13 mg/kg every 8 hours (max. per dose 450 mg) for 7 days
    Adult: 450 mg every 8 hours for 7 days

• UNLICENSED USE Not licensed for treatment of mild to moderate pneumocystis infection. Not licensed for treatment of falciparum malaria.

• CONTRA-INDICATIONS Diarrhoeal states

• CAUTIONS Avoid in acute porphyrias p. 969 · middle-aged and elderly women, especially after an operation (antibiotic-associated colitis more common)

• INTERACTIONS → Appendix 1: clindamycin

SIDE-EFFECTS Abdominal discomfort · anaphylactoid reactions · antibiotic-associated colitis · diarrhoea (discontinue treatment) · eosinophilia · exfoliative dermatitis · jaundice · leucopenia · nausea · oesophageal ulcers · oesophagitis · polyarthritides · pruritus · rash · Stevens-Johnson syndrome · taste disturbances · thrombocytopenia · toxic epidermal necrolysis · urticaria · vesiculobullous dermatitis · vomiting

With intramuscular use Abscess · induration · pain

With intravenous use Thrombophlebitis

SIDE-EFFECTS, FURTHER INFORMATION

Antibiotic-associated colitis Clindamycin has been associated with antibiotic-associated colitis, which may be fatal. Although antibiotic-associated colitis can occur with most antibacterials, it occurs more frequently with clindamycin. Patients should therefore discontinue treatment immediately if diarrhea develops.

PREGNANCY Not known to be harmful.

• BREAST FEEDING Amount probably too small to be harmful but bloody diarrhoea reported in 1 infant.

• MONITORING REQUIREMENTS
  ▶ Monitor liver and renal function if treatment exceeds 10 days.
  ▶ In children Monitor liver and renal function in infants.

• DIRECTIONS FOR ADMINISTRATION Avoid rapid intravenous administration.

  For intravenous infusion (Dalacin® C Phosphate), give continuously or intermittently in Glucose 5% or Sodium Chloride 0.9%; dilute to not more than 18 mg/mL and give over 10–60 minutes at a rate not exceeding 30 mg/minute (1.2 g over at least 60 minutes; higher doses by continuous infusion).
**PATIENT AND CARER ADVICE** Capsules should be swallowed with a glass of water. Patients and their carers should be advised to discontinue immediately and contact doctor if diarrhoea develops.

**PROFESSION SPECIFIC INFORMATION**

**Dental practitioners’ formulary**

Clindamycin capsules may be prescribed.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Capsule**

**CAUTIONARY AND ADVISORY LABELS 9, 27**

- **Clindamycin (Non-proprietary)**
  - Clindamycin (as Clindamycin hydrochloride) 150 mg
  - Clindamycin 150 mg capsules | 24 capsule [POD] £13.72 07 price = £3.81 | 100 capsule [POD] £55.21
  - Clindamycin (as Clindamycin hydrochloride) 300 mg
  - Clindamycin 300 mg capsules | 30 capsule [POD] £46.00 07 price = £39.65
  - Dalacin C (Pfizer Ltd)
  - Clindamycin (as Clindamycin hydrochloride) 75 mg
  - Dalacin C 75 mg capsules | 24 capsule [POD] £7.45 07 price = £7.45
  - Clindamycin (as Clindamycin hydrochloride) 150 mg
  - Dalacin C 150 mg capsules | 24 capsule [POD] £13.72 07 price = £3.81 | 100 capsule [POD] £55.08

**Solution for injection**

**EXCIPIENTS:** May contain Benzyl alcohol

- **Clindamycin (Non-proprietary)**
  - Clindamycin (as Clindamycin phosphate) 150 mg per 1 ml Clindamycin 600 mg/4ml solution for injection ampoules | 5 ampoule [POD] £61.75
  - Clindamycin 300 mg/2ml solution for injection ampoules | 5 ampoule [POD] £28.50-£31.01
  - Dalacin C (Pfizer Ltd)
  - Clindamycin (as Clindamycin phosphate) 150 mg per 1 ml Dalacin C Phosphate 300 mg/2ml solution for injection ampoules | 5 ampoule [POD] £31.01
  - Dalacin C Phosphate 600 mg/4ml solution for injection ampoules | 5 ampoule [POD] £61.75

**ANTIBACTERIALS > MACROLIDES**

**Macrolides**

**Overview**

The macrolides have an antibacterial spectrum that is similar but not identical to that of penicillin; they are thus an alternative in penicillin-allergic patients. They are active against many penicillin-resistant staphylococci, but some are now also resistant to the macrolides.

Indications for the macrolides include campylobacter enteritis, respiratory infections (including pneumonia, whooping cough, Legionella, chlamydia, and mycoplasma infection), and skin infections.

Erythromycin p. 510 is also used in the treatment of early syphilis, uncomplicated genital chlamydial infection, and non-gonococcal urethritis. Erythromycin has poor activity against *Haemophilus influenzae*. Erythromycin causes nausea, vomiting, and diarrhoea in some patients; in mild to moderate infections this can be avoided by giving a lower dose, but if a more serious infection, such as Legionella pneumonia, is suspected higher doses are needed.

Azithromycin below is a macrolide with slightly less activity than erythromycin against Gram-positive bacteria, but enhanced activity against some Gram-negative organisms including *H. influenzae*. Plasma concentrations are very low, but tissue concentrations are much higher. It has a long tissue half-life and once daily dosage is recommended. Azithromycin is also used in the treatment of uncomplicated genital chlamydial infection, non-gonococcal urethritis, uncomplicated gonorrhoea, typhoid [unlicensed indication], and trachoma [unlicensed indication].

Clarithromycin p. 508 is an erythromycin derivative with slightly greater activity than the parent compound. Tissue concentrations are higher than with erythromycin. It is given twice daily. Clarithromycin is also used in regimens for *Helicobacter pylori* eradication.

Erythromycin, azithromycin, and clarithromycin have a role in the treatment of Lyme disease p. 545.

Spiramycin is also a macrolide which is used for the treatment of toxoplasmosis.

**Macrolides**

**CAUTIONS** Electrolyte disturbances (predisposition to QT interval prolongation) - may aggravate myasthenia gravis - predisposition to QT interval prolongation

**SIDE-EFFECTS**

- Common or very common Abdominal discomfort - diarrhoea - nausea - vomiting
- Uncommon Cholestatic jaundice - hepatotoxicity - rash
- Rare Antibiotic-associated colitis - arthralgias - pancreatitis - QT interval prolongation - Stevens-Johnson syndrome - toxic epidermal necrolysis
- Frequency not known Reversible hearing loss (sometimes with tinnitus) can occur after large doses
- With intravenous use Local tenderness - phlebitis

**SIDE-EFFECTS, FURTHER INFORMATION**

Gastro-intestinal side-effects are mild and less frequent with azithromycin and clarithromycin than with erythromycin.

**Azithromycin**

**INDICATIONS AND DOSE**

**Prevention of secondary case of invasive group A streptococcal infection in patients who are allergic to penicillin**

- **BY MOUTH**
  - Child 6 months–11 years: 12 mg/kg once daily (max. per dose 500 mg) for 5 days
  - Child 12-17 years: 500 mg once daily for 5 days
  - Adult: 500 mg once daily for 5 days

**Respiratory-tract infections, otitis media, skin and soft-tissue infections**

- **BY MOUTH**
  - Child 6 months–17 years: 10 mg/kg once daily (max. per dose 500 mg) for 3 days
  - Child 6 months–17 years (body-weight 15–25 kg): 200 mg once daily for 3 days
  - Child 6 months–17 years (body-weight 26–35 kg): 300 mg once daily for 3 days
  - Child 6 months–17 years (body-weight 36–45 kg): 400 mg once daily for 3 days
  - Child 6 months–17 years (body-weight 46 kg and above): 500 mg once daily for 3 days
  - Adult: 500 mg once daily for 3 days, alternatively initially 500 mg once daily for 1 day, then 250 mg once daily for 4 days

**Uncomplicated genital chlamydial infections | Non-gonococcal urethritis**

- **BY MOUTH**
  - Child 12–17 years: 1 g for 1 dose
  - Adult: 1 g for 1 dose

**Uncomplicated gonorrhoea**

- **BY MOUTH**
  - Adult: 1 g for 1 dose

**Lyme disease (under expert supervision)**

- **BY MOUTH**
  - Adult: 500 mg once daily for 7–10 days
508  Bacterial infection

Mild to moderate typhoid due to multiple-antibacterial resistant organisms

▶ BY MOUTH
▶ Adult: 500 mg once daily for 7 days

Community-acquired pneumonia, low to moderate severity

▶ BY MOUTH
▶ Adult: 500 mg once daily for 3 days, alternatively initially 500 mg once daily for 1 day, then 250 mg once daily for 4 days

Community-acquired pneumonia, high severity

▶ INITIALLY BY INTRAVENOUS INFUSION
▶ Adult: Initially 500 mg once daily for at least 2 days, then (by mouth) 500 mg once daily for a total duration of 7–10 days

Antibacterial prophylaxis for insertion of intra-uterine device

▶ BY MOUTH
▶ Adult: 1 g for 1 dose

UNLICENSED USE

In children  Not licensed for typhoid fever, Lyme disease, chronic Pseudomonas aeruginosa infection in cystic fibrosis, or prophylaxis of group A streptococcal infection.

In adults  Oral azithromycin not licensed for trachoma which results from chronic infection with Chlamydia trachomatis. Not licensed for uncomplicated gonorrhoea, mild or moderate typhoid due to multiple-antibacterial-resistant organisms, Lyme disease, or prophylaxis of group A streptococcal infection. Not licensed for community-acquired pneumonia (high severity) when oral treatment continues for more than 3 days.

INTERACTIONS  → Appendix 1: macrolides

SIDE-EFFECTS

▶ Common or very common  Anorexia · arthralgia · disturbances in taste · disturbances in vision · dizziness · dyspepsia · flatulence · headache · malaise · paraesthesia · reversible hearing loss (sometimes with tinnitus) after long-term therapy

▶ Uncommon  Anxiety · chest pain · constipation · gastritis · hypoaesthesia · leucopenia · oedema · photosensitivity · sleep disturbances

▶ Rare  Agitation

▶ Frequency not known  Acute renal failure · convulsions · haemolytic anaemia · interstitial nephritis · smell disturbances · syncope · thrombocytopenia · tongue discoloration

PREGNANCY  Manufacturers advise use only if adequate alternatives not available.

BREAST FEEDING  Present in milk; use only if no suitable alternatives.

HEPATIC IMPAIRMENT  Manufacturers advise avoid in severe liver disease—no information available.

RENAL IMPAIRMENT

▶ In adults  Use with caution if eGFR less than 10 mL/minute/1.73 m².

▶ In children  Use with caution if estimated glomerular filtration rate less than 10 mL/minute/1.73 m².

DIRECTIONS FOR ADMINISTRATION  For intravenous infusion (Zedbac®), give intermittently in Glucose 5% or Sodium Chloride 0.9%. Reconstitute 500 mg with 4.8 mL water for injections to produce a 100 mg/mL solution, then dilute 5 mL of solution with infusion fluid to a final concentration of 1 or 2 mg/mL; give the 1 mg/mL solution over 3 hours or give the 2 mg/mL solution over 1 hour.

PRESCRIBING AND DISPENSING INFORMATION  Flavours of oral liquid formulations may include cherry or banana.

PATIENT AND CARER ADVICE

Medicines for Children leaflet: Azithromycin for bacterial infections  www.medicinesforchildren.org.uk/azithromycin-bacterial-infections-0

PROFESSION SPECIFIC INFORMATION

Dental practitioners’ formulary

Azithromycin Capsules may be prescribed. Azithromycin Tablets may be prescribed. Azithromycin Oral Suspension 200 mg/5 mL may be prescribed.

EXCEPTIONS TO LEGAL CATEGORY  Azithromycin tablets can be sold to the public for the treatment of confirmed, asymptomatic Chlamydia trachomatis genital infection in those over 16 years of age, and for the epidemiological treatment of their sexual partners, subject to maximum single dose of 1 g, maximum daily dose 1 g, and a pack size of 1 g.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

Tablet

CAUTIONARY AND ADVISORY LABELS 5, 9

Azithromycin (Non-proprietary)

Azithromycin 250 mg  Azithromycin 250mg tablets | 4 tablet  POM £10.11 DT price = £1.36 | 6 tablet  POM £14.46

Azithromycin 500 mg  Azithromycin 500mg tablets | 3 tablet  POM £9.80 DT price = £1.25

Oral suspension

CAUTIONARY AND ADVISORY LABELS 5, 9

Azithromycin (Non-proprietary)

Azithromycin 40 mg per 1 ml  Azithromycin 200mg/5ml oral suspension | 15 ml  POM £6.18 DT price = £4.06 | 30 ml  POM £11.04 DT price = £11.04

Zithromax (Pfizer Ltd)

Azithromycin 40 mg per 1 ml  Zithromax 200mg/5ml oral suspension | 15 ml  POM £4.06 DT price = £4.06 | 22.5 ml  POM £6.10 DT price = £6.10 | 30 ml  POM £11.04 DT price = £11.04

Powder for solution for infusion

ELECTROLYTES: May contain Sodium

Zedbac (Aspire Pharma Ltd)

Azithromycin (as Azithromycin dihydrate) 500 mg  Zedbac 500mg powder for solution for infusion vials | 1 vial  POM £9.50 (Hospital only)

Capsule

CAUTIONARY AND ADVISORY LABELS 5, 9, 23

Azithromycin (Non-proprietary)

Azithromycin (as Azithromycin dihydrate) 250 mg  Azithromycin 250mg capsules | 4 capsule  POM £10.10 | 6 capsule  POM £15.15 DT price = £15.15

Zithromax (Pfizer Ltd)

Azithromycin (as Azithromycin dihydrate) 250 mg  Zithromax 250mg capsules | 4 capsule  POM £7.16 | 6 capsule  POM £10.74 DT price = £15.15

Clarithromycin

INDICATIONS AND DOSE

Respiratory-tract infections  Mild to moderate skin and soft-tissue infections  Otitis media

▶ BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

▶ Child 1 month–11 years (body-weight up to 8 kg): 7.5 mg/kg twice daily

▶ Child 1 month–11 years (body-weight 8–11 kg): 62.5 mg/kg twice daily

▶ Child 1 month–11 years (body-weight 12–19 kg): 125 mg/kg twice daily

▶ Child 1 month–11 years (body-weight 20–29 kg): 187.5 mg/kg twice daily

▶ Child 1 month–11 years (body-weight 30–40 kg): 250 mg twice daily

downloaded from www.medicalbr.com
**Bacterial infection** 509

▶ Child 12-17 years: 250 mg twice daily usually for 7–14 days, increased to 500 mg twice daily, if required in severe infections (e.g. pneumonia)
▶ Adult: 250 mg twice daily usually for 7–14 days, increased to 500 mg twice daily, if required in severe infections (e.g. pneumonia)
▶ BY MOUTH USING MODIFIED-RELEASE MEDICINES
▶ Child 12-17 years: 500 mg once daily usually for 7–14 days, increased to 1 g once daily, if required in severe infections (e.g. pneumonia)
▶ Adult: 500 mg once daily usually for 7–14 days, increased to 1 g once daily, if required in severe infections (e.g. pneumonia)
▶ BY INTRAVENOUS INFUSION
▶ Adult: 500 mg every 12 hours maximum duration 5 days, switch to oral route when appropriate, to be administered into a large proximal vein

**Lyme disease**
▶ BY MOUTH
▶ Child 12-17 years: 500 mg twice daily for 14–21 days
▶ Adult: 500 mg twice daily for 14–21 days

**Prevention of pertussis**
▶ BY MOUTH
▶ Child 1 month–11 years (body-weight up to 8 kg): 7.5 mg/kg twice daily for 7 days
▶ Child 1 month–11 years (body-weight 8–11 kg): 62.5 mg twice daily for 7 days
▶ Child 1 month–11 years (body-weight 12–19 kg): 125 mg twice daily for 7 days
▶ Child 1 month–11 years (body-weight 20–29 kg): 187.5 mg twice daily for 7 days
▶ Child 1 month–11 years (body-weight 30–40 kg): 250 mg twice daily for 7 days
▶ Child 12–17 years: 500 mg twice daily for 7 days
▶ Adult: 500 mg twice daily for 7 days

**Helicobacter pylori eradication in combination with a proton pump inhibitor and amoxicillin**
▶ BY MOUTH
▶ Child: 500 mg twice daily

**Helicobacter pylori eradication in combination with a proton pump inhibitor and metronidazole**
▶ BY MOUTH
▶ Adult: 500 mg twice daily

▶ UNLICENSED USE Tablets not licensed for use in children under 12 years; oral suspension not licensed for use in infants under 6 months.
▶ INTERACTIONS → Appendix 1: macrolides
▶ SIDE-EFFECTS
▶ Common or very common Dyspepsia · headache · hyperhidrosis · insomnia · taste disturbances
▶ Uncommon Anorexia · anxiety · blood disorders · chest pain · constipation · dizziness · dry mouth · flatulence · gastritis · glossitis · hepatic dysfunction including jaundice · leucopenia · malaise · myalgia · stomatitis · tinnitus · tremor
▶ Frequency not known Abnormal dreams · confusion · convulsions · depression · hypoglycaemia · interstitial nephritis · myopathy · paraesthesia · psychotic disorders · renal failure · smell disturbances · tongue discoloration · tooth discoloration
▶ PREGNANCY Manufacturer advises avoid, particularly in the first trimester, unless potential benefit outweighs risk.
▶ BREAST FEEDING Manufacturer advises avoid unless potential benefit outweighs risk—present in milk.
▶ HEPATIC IMPAIRMENT Avoid in severe impairment if renal impairment also present.
▶ RENAL IMPAIRMENT
▶ In adults Use half normal dose if eGFR less than 30 mL/minute/1.73 m², max. duration 14 days. Avoid Klaricid XL® or clarithromycin m/r preparations if eGFR less than 30 mL/minute/1.73 m².
▶ In children Use half normal dose if estimated glomerular filtration rate less than 30 mL/minute/1.73 m², max. duration 14 days. Avoid if severe hepatic impairment also present. Avoid Klaricid XL® or clarithromycin m/r preparations if estimated glomerular filtration rate less than 30 mL/minute/1.73 m².
▶ DIRECTIONS FOR ADMINISTRATION For intravenous infusion (Klaricid® I.V.), give intermittently in Glucose 5% or Sodium Chloride 0.9%; dissolve initially in water for injections (500 mg in 10 mL) then dilute to a concentration of 2 mg/mL; give over 60 minutes.
▶ PATIENT AND CARER ADVICE
Medicines for Children leaflet: Clarithromycin for bacterial infections www.medicinesforchildren.org.uk/clarithromycin-bacterial-infections
▶ PROFESSION SPECIFIC INFORMATION
Dental practitioners’ formulary Clarithromycin Tablets may be prescribed. Clarithromycin Oral Suspension may be prescribed.

▶ MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: infusion

**Modified-release tablet**

**CAUTIONARY AND ADVISORY LABELS 9, 21, 25**
▶ Clarie XL (Teva UK Ltd)
Clarithromycin 500 mg Clarie XL 500mg tablets | 7 tablet £6.72 DT price = £6.72 | 14 tablet [POM] £13.23
▶ Klaricid XL (Mylan Ltd)
Clarithromycin 500 mg Klaricid XL 500mg tablets | 7 tablet [POM] £6.72 DT price = £6.72 | 14 tablet [POM] £13.23
▶ Xetinin XL (Morningside Healthcare Ltd)
Clarinifin 500 mg Xetinin XL 500mg tablets | 7 tablet [POM] £6.72 DT price = £6.72 | 14 tablet [POM] £13.23

**Granules**

**CAUTIONARY AND ADVISORY LABELS 9, 13**
▶ Klaricid (Mylan Ltd)
Clarithromycin 250 mg Klaricid Adult 250mg granules sachets | 14 sachet [POM] £11.68

**Tablet**

**CAUTIONARY AND ADVISORY LABELS 9**
▶ Clarithromycin (Non-proprietary)
Clarithromycin 250 mg Clarithromycin 250mg tablets | 14 tablet [POM] £10.50 DT price = £1.36
Clarithromycin 500 mg Clarithromycin 500mg tablets | 14 tablet [POM] £21.50 DT price = £2.21

**Oral suspension**

**CAUTIONARY AND ADVISORY LABELS 9**
▶ Clarithromycin (Non-proprietary)
Clarithromycin 25 mg per 1 ml Clarithromycin 125mg/5ml oral suspension | 70 ml [POM] £4.88 DT price = £4.06
Clarithromycin 50 mg per 1 ml Clarithromycin 250mg/5ml oral suspension | 70 ml [POM] £7.08 DT price = £5.43
▶ Klaricid (Mylan Ltd)
Clarithromycin 25 mg per 1 ml Claricid Paediatric 125mg/5ml oral suspension | 70 ml [POM] £5.26 DT price = £4.06 | 100 ml [POM] £9.04
Clarithromycin 50 mg per 1 ml Claricid Paediatric 250mg/5ml oral suspension | 70 ml [POM] £10.51 DT price = £5.43

**Powder for solution for infusion**

**ELECTROLYTES: May contain Sodium.**
▶ Clarithromycin (Non-proprietary)
Clarithromycin 500 mg Clarithromycin 500mg powder for solution for infusion vials | 1 vial [POM] £11.25 DT price = £9.45
Clarithromycin 500mg powder for concentrate for solution for infusion vials | 1 vial [POM] £9.45 DT price = £9.45
▶ Klaricid (Mylan Ltd)
Clarithromycin 500 mg Klaricid IV 500mg powder for solution for infusion vials | 1 vial [POM] £9.45 DT price = £9.45

Downloaded from www.medicalbr.com
Erythromycin

**INDICATIONS AND DOSE**

Susceptible infections in patients with penicillin hypersensitivity (e.g. respiratory-tract infections (including Legionella infection), skin and oral infections, and campylobacter enteritis)

- **BY MOUTH**
  - Child 1 month–1 year: 125 mg 4 times a day, total daily dose may alternatively be given in two divided doses, increased to 250 mg 4 times a day, dose increase may be used in severe infections
  - Child 2–7 years: 250 mg 4 times a day, total daily dose may alternatively be given in two divided doses, increased to 500 mg 4 times a day, dose increase may be used in severe infections

- **BY INTRAVENOUS INFUSION**
  - Child: 12.5 mg/kg every 6 hours (max. per dose 1 g)
  - Adult: 6.25 mg/kg every 6 hours, for mild infections when oral treatment not possible. Increased to 12.5 mg/kg every 6 hours, dose increase may be used in severe infections

Lyme disease (under expert supervision)

- **BY MOUTH**
  - Adult: 500 mg 4 times a day for 14–21 days

Early syphilis

- **BY MOUTH**
  - Adult: 500 mg 4 times a day for 14 days

Uncomplicated genital chlamydia | Non-gonococcal urethritis

- **BY MOUTH**
  - Adult: 500 mg twice daily for 14 days

Chronic prostatitis

- **BY MOUTH**
  - Adult: 250–500 mg 4 times a day, total daily dose may alternatively be given in two divided doses, increased to 4 g daily in divided doses, dose increase may be used in severe infections

- **BY INTRAVENOUS INFUSION**
  - Adult: 6.25 mg/kg every 6 hours, for mild infections when oral treatment is not possible, increased to 12.5 mg/kg every 6 hours, dose increase may be used in severe infections

Prevention and treatment of pertussis

- **BY MOUTH**
  - Child 1 month–1 year: 125 mg 4 times a day, total daily dose may alternatively be given in two divided doses, increased to 250 mg 4 times a day, dose increase may be used in severe infections
  - Child 2–7 years: 250 mg 4 times a day, total daily dose may alternatively be given in two divided doses, increased to 500 mg 4 times a day, dose increase may be used in severe infections
  - Child 8–17 years: 250–500 mg 4 times a day, total daily dose may alternatively be given in two divided doses, increased to 500–1000 mg 4 times a day, dose increase may be used in severe infections
  - Adult: (consult local protocol)

Prevention of secondary case of diphtheria in non-immune patient

- **BY MOUTH**
  - Child 1 month–1 year: 125 mg every 6 hours for 7 days, treat for further 10 days if nasopharyngeal swabs positive after first 7 days’ treatment
  - Child 2–7 years: 250 mg every 6 hours for 7 days, treat for further 10 days if nasopharyngeal swabs positive after first 7 days’ treatment
  - Child 8–17 years: 500 mg every 6 hours for 7 days, treat for further 10 days if nasopharyngeal swabs positive after first 7 days’ treatment
  - Adult: 500 mg every 6 hours for 7 days, treat for further 10 days if nasopharyngeal swabs positive after first 7 days’ treatment

Prevention of secondary case of invasive group A streptococcal infection in penicillin allergic patients

- **BY MOUTH**
  - Child 1 month–1 year: 125 mg every 6 hours for 10 days
  - Child 2–7 years: 250 mg every 6 hours for 10 days
  - Child 8–17 years: 250–500 mg every 6 hours for 10 days
  - Adult: 250–500 mg every 6 hours for 10 days

Prevention of pneumococcal infection in asplenia or in patients with sickle-cell disease (if penicillin-allergic)

- **BY MOUTH**
  - Child 1 month–1 year: 125 mg twice daily, antibiotic prophylaxis is not fully reliable
  - Child 2–7 years: 250 mg twice daily, antibiotic prophylaxis is not fully reliable. It may be discontinued in those over 5 years of age with sickle-cell disease who have received pneumococcal immunisation and who do not have a history of severe pneumococcal infection
  - Child 8–17 years: 500 mg twice daily, antibiotic prophylaxis is not fully reliable. It may be discontinued in those with sickle-cell disease who have received pneumococcal immunisation and who do not have a history of severe pneumococcal infection
  - Adult: 500 mg twice daily, antibiotic prophylaxis is not fully reliable. It may be discontinued in those with sickle-cell disease who have received pneumococcal immunisation and who do not have a history of severe pneumococcal infection

Prevention of recurrence of rheumatic fever

- **BY MOUTH**
  - Child 1 month–1 year: 125 mg twice daily
  - Child 2–7 years: 250 mg twice daily

Rosacea

- **BY MOUTH**
  - Adult: 500 mg twice daily courses usually last 6–12 weeks and are repeated intermittently

Acne

- **BY MOUTH**
  - Adult: 500 mg twice daily

- **CAUTIONS** Avoid in acute porphyrias p. 969
- **INTERACTIONS** → Appendix 1: macrolides
- **PREGNANCY** Not known to be harmful.
- **BREAST FEEDING** Only small amounts in milk—not known to be harmful.
- **HEPATIC IMPAIRMENT** May cause idiosyncratic hepatotoxicity.
- **RENAL IMPAIRMENT** In adults Max. 1.5 g daily in severe renal impairment (ototoxicity). In children Reduce dose in severe renal impairment (ototoxicity).
- **DIRECTIONS FOR ADMINISTRATION** With intravenous use in children Dilute reconstituted solution further in glucose 5% (neutralised with Sodium bicarbonate) or sodium chloride 0.9% to a concentration of
1–5 mg/mL; give over 20–60 minutes. Concentration of up to 10 mg/mL may be used in fluid-restriction if administered via a central venous catheter.

- With intravenous use For intravenous infusion (as lactobionate), give intermittently in Glucose 5% (neutralised with sodium bicarbonate) or Sodium chloride 0.9%; dissolve initially in water for injections (1 g in 20 mL) then dilute to a concentration of 1–5 mg/mL; give over 20–60 minutes.

**PRESCRIBING AND DISPENSING INFORMATION** Flavours of oral liquid formulations may include banana.

**PATIENT AND CARER ADVICE**

Medicines for Children leaflet: Erythromycin for bacterial infections www.medicinesforchildren.org.uk/erythromycin-for-bacterial-infections

**PROFESSIONAL INFORMATION**

Dental practitioners’ formulary

Erythromycin tablets e/c m may be prescribed. Erythromycin ethyl succinate may be prescribed. Erythromycin stearate tablets may be prescribed. Erythromycin ethyl succinate tablets may be prescribed.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Gastro-resistant capsule**

**CAUTIONARY AND ADVISORY LABELS 5, 9, 25**

- **Erythromycin (Non-proprietary)**
  - Erythromycin 250 mg Erythromycin 250mg gastro-resistant capsules 28 capsule £ no price available DT price = £5.61 | 30 capsule £ no price available
  - Erymax (Teva UK Ltd)
  - Erythromycin 250 mg Erymax 250mg gastro-resistant capsules 28 capsule £5.61 DT price = £5.61 | 112 capsule £22.44
  - Tiloryth (Tilomed Laboratories Ltd)
  - Erythromycin 250 mg Tiloryth 250mg gastro-resistant capsules 30 capsule £5.65 | 100 capsule £18.66

**Gastro-resistant tablet**

**CAUTIONARY AND ADVISORY LABELS 5, 9, 25**

- **Erythromycin (Non-proprietary)**
  - Erythromycin 250 mg Erythromycin 250mg gastro-resistant tablets 28 tablet £2.25 DT price = £1.45 | 500 tablet £27.20

**Tablet**

**CAUTIONARY AND ADVISORY LABELS 9**

- **Erythromycin (Non-proprietary)**
  - Erythromycin (as Erythromycin ethyl succinate) 500 mg Erythromycin ethyl succinate 500mg tablets 28 tablet £11.95 | 500 tablet £10.78
  - Erythromycin (as Erythromycin ethyl succinate) 250 mg Erythromycin ethyl succinate 250mg tablets 100 tablet £18.20 | 500 tablet £36.40
  - Erythromycin (as Erythromycin stearate) 250 mg Erythromycin stearate 250mg tablets 100 tablet £18.20 | 500 tablet £36.40
  - Erythromycin (as Erythromycin stearate) 500 mg Erythromycin stearate 500mg tablets 100 tablet £36.40 | 500 tablet £72.60
  - Erythromycin (as Erythromycin ethyl succinate) 500 mg Erythromycin ethyl succinate 500mg tablets 28 tablet £10.78 DT price = £10.78

**Oral suspension**

**CAUTIONARY AND ADVISORY LABELS 9**

- **Erythromycin (Non-proprietary)**
  - Erythromycin (as Erythromycin ethyl succinate) 25 mg per 1 ml Erythromycin ethyl succinate 25mg/5ml oral suspension 100 ml £4.05 DT price = £4.05 | 200 ml £8.10 DT price = £8.10
  - Erythromycin (as Erythromycin ethyl succinate) 50 mg per 1 ml Erythromycin ethyl succinate 50mg/5ml oral suspension 100 ml £6.38 DT price = £6.38 | 200 ml £12.76 DT price = £12.76

**Erythromycin (as Erythromycin ethyl succinate) 100 mg per 1 ml Erythromycin ethyl succinate 100mg/5ml oral suspension 100 ml £11.24 DT price = £11.24

- Erythromycin (as Erythromycin ethyl succinate) 500 mg/5ml oral suspension sugar free sugar-free 100 ml £0.00 DT price = £0.00

- **Erythromycin (AMCo)**
  - Erythromycin (as Erythromycin ethyl succinate) 25 mg per 1 ml Erythromycin PI SF 125mg/5ml oral suspension sugar-free 140 ml £3.06
  - Erythromycin (as Erythromycin ethyl succinate) 50 mg per 1 ml Erythromycin SF 250mg/5ml oral suspension sugar-free 140 ml £5.95
  - Erythromycin (as Erythromycin ethyl succinate) 100 mg per 1 ml Erythromycin Forte SF 500mg/5ml oral suspension sugar-free 140 ml £10.56 DT price = £10.56

**Powder for solution for infusion**

- **Erythromycin (Non-proprietary)**
  - Erythromycin (as Erythromycin lactobionate) 1 gram Erythromycin 1g powder for solution for infusion vials 1 vial £18.45–£22.92

**ANTIBACTERIALS > MONOBACTAMS**

**Aztreonam**

- **DRUG ACTION** Aztreonam is a monocyclic beta-lactam (‘monobactam’) antibiotic with an antibacterial spectrum limited to Gram-negative aerobic bacteria including Pseudomonas aeruginosa, Neisseria meningitidis, and Haemophilus influenzae; it should not be used alone for ‘blind’ treatment since it is not active against Gram-positive organisms. Aztreonam is also effective against Neisseria gonorrhoeae (but not against concurrent chlamydial infection).

- **INDICATIONS AND DOSE**
  - **Gram-negative infections including Pseudomonas aeruginosa, Haemophilus influenzae, and Neisseria meningitidis**
    - **BY DEEP INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION**
    - Adult: 1 g every 8 hours, alternatively 2 g every 12 hours, single doses over 1 g intravenous route only
  - **Severe gram-negative infections including Pseudomonas aeruginosa, Haemophilus influenzae, Neisseria meningitidis, and lung infections in cystic fibrosis**
    - **BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION**
    - Adult: 2 g every 6–8 hours
  - **Gonorrhoea | Cystitis**
    - **BY INTRAMUSCULAR INJECTION**
    - Adult: 1 g for 1 single dose
  - **Urinary-tract infections**
    - **BY DEEP INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION**
    - Adult: 0.5–1 g every 8–12 hours
  - **Chronic pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis**
    - **BY INHALATION OF NEBULISED SOLUTION**
    - Adult: 75 mg 3 times a day for 28 days, doses to be administered at least 4 hours apart, subsequent courses repeated after 28-day interval without aztreonam nebuliser solution

- **CAUTIONS**
  - When used by inhalation Haemoptysis—risk of further haemorrhage
  - **SIDE-EFFECTS**
    - **GENERAL SIDE-EFFECTS** Bronchospasm • rash
    - **SPECIFIC SIDE-EFFECTS**
      - Rare
      - With systemic use Antibiotic-associated colitis • asthenia • blood disorders • breast tenderness • chest pain • confusion
- diplopia - dizziness - dyspnoea - gastro-intestinal bleeding
- Frequency not known
- When used by inhalation Arthralgia - cough - haemoptysis - pharyngolaryngeal pain - pyrexia - rhinorrhea - wheezing
- With systemic use Abdominal pain - diarrhoea - erythema multiforme - flushing - mouth ulcers - nausea - taste disturbances - toxic epidermal necrolysis - vomiting

ALLERGY AND CROSS-SENSITIVITY Contra-indicated in aztreonam hypersensitivity.

Use with caution in patients with hypersensitivity to other beta-lactam antibiotics (although aztreonam may be less likely than other beta-lactams to cause hypersensitivity in penicillin-sensitive patients).

PREGNANCY
- With systemic use No information available; manufacturer of injection advises avoid.
- When used by inhalation No information available; manufacturer of powder for nebuliser solution advises avoid unless essential.

BREAST FEEDING Amount in milk probably too small to be harmful.

HEPATIC IMPAIRMENT
- With systemic use Use injection with caution. Monitor liver function.

RENAL IMPAIRMENT
- With systemic use If eGFR 10–30 mL/minute/1.73 m², usual initial dose of injection, then half normal dose. If eGFR less than 10 mL/minute/1.73 m², usual initial dose of injection, then one-quarter normal dose.

MONITORING REQUIREMENTS
- When used by inhalation Measure lung function before and after initial dose of aztreonam and monitor for bronchospasm.

DIRECTIONS FOR ADMINISTRATION
- With intravenous use For intravenous infusion (Azactam®), give intermittently in Glucose 5% or Sodium chloride 0.9%. Dissolve initially in water for injections (1 g per 3 mL) then dilute to a concentration of less than 20 mg/mL; to be given over 20–60 minutes. For intravenous injection, give over 3–5 minutes.
- When used by inhalation Other inhaled drugs should be administered before aztreonam; a bronchodilator should be administered before each dose.

NATIONAL FUNDING/ACCESS DECISIONS

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (December 2014) that aztreonam powder for nebuliser solution (Cayston®) is accepted for restricted use within NHS Scotland when inhaled colistimethate sodium and inhaled tobramycin are not tolerated or are not providing satisfactory therapeutic benefit (measured as ≥2% decline in forced expiratory volume in 1 second).

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Powder and solvent for nebuliser solution
- Cayston (Gilead Sciences International Ltd)
  - Aztreonam (as Aztreonam Hycline) 75 mg
  - Cayston 75mg powder and solvent for nebuliser solution vials with Altera Nebuliser Handset | £84 vial (Pod) | £2,181.53

Powder for solution for injection
- Azactam (Bristol-Myers Squibb Pharmaceuticals Ltd)
  - Aztreonam 1 gram
    - Azactam 1g powder for solution for injection vials | 1 vial (Pod) | £94.40 (Hospital only)
  - Aztreonam 2 gram
    - Azactam 2g powder for solution for injection vials | 1 vial (Pod) | £185.82 (Hospital only)

ANTIBACTERIALS > NITROIMIDAZOLE DERIVATIVES

Metronidazole

DRUG ACTION Metronidazole is an antimicrobial drug with high activity against anaerobic bacteria and protozoa.

INDICATIONS AND DOSE

Anaerobic infections
- BY MOUTH
  - Child 1 month: 7.5 mg/kg every 12 hours usually treated for 7 days (for 10–14 days in Clostridium difficile infection)
  - Child 2 months–11 years: 7.5 mg/kg every 8 hours (max. per dose 400 mg) usually treated for 7 days (for 10–14 days in Clostridium difficile infection)
  - Child 12–17 years: 400 mg every 8 hours usually treated for 7 days (for 10–14 days in Clostridium difficile infection)
  - Adult: 400 mg every 8 hours, alternatively 500 mg every 8 hours usually treated for 7 days (for 10–14 days in Clostridium difficile infection)
- BY RECTUM
  - Child 1–11 months: 125 mg 3 times a day for 3 days, then 125 mg twice daily, for usual total treatment duration of 7 days
  - Child 1–4 years: 250 mg 3 times a day for 3 days, then 250 mg twice daily, for usual total treatment duration of 7 days
  - Child 5–9 years: 500 mg 3 times a day for 3 days, then 500 mg twice daily, for usual total treatment duration of 7 days
  - Child 10–17 years: 1 g 3 times a day for 3 days, then 1 g twice daily, for usual total treatment duration of 7 days
- BY INTRAVENOUS INFUSION
  - Adult: 500 mg every 8 hours usually treated for 7 days (for 10–14 days in Clostridium difficile infection), to be given over 20 minutes

Helicobacter pylori eradication; in combination with clarithromycin and esomeprazole; or in combination with clarithromycin and lansoprazole; or in combination with amoxicillin and lansoprazole; or in combination with clarithromycin and omeprazole; or in combination with clarithromycin and pantoprazole; or in combination with clarithromycin and rabeprazole
- BY MOUTH
  - Adult: 400 mg twice daily

Helicobacter pylori eradication; in combination with amoxicillin and omeprazole
- BY MOUTH
  - Adult: 400 mg 3 times a day

Helicobacter pylori eradication failure (two-week regimen comprising a proton pump inhibitor plus tripotassium dicitratobismuthate plus tetracycline)
- BY MOUTH
  - Adult: 400–500 mg 3 times a day for 2 weeks

Fistulating Crohn’s disease
- BY MOUTH
  - Adult: 10–20 mg/kg daily in divided doses, usual dose 400–500 mg 3 times a day usually given for 1 month but no longer than 3 months because of concerns about peripheral neuropathy

Leg ulcers and pressure sores
- BY MOUTH
  - Adult: 400 mg every 8 hours for 7 days

downloaded from www.medicalbr.com
Bacterial vaginosis (notably *Gardnerella vaginalis* infection)
- **BY MOUTH**
  - Adult: 400–500 mg twice daily for 5–7 days, alternatively 2 g for 1 dose

Bacterial vaginosis
- **BY VAGINA USING VAGINAL GEL**
  - Adult: 1 applicatorful daily for 5 days, dose to be administered at night

**DOSE EQUIVALENCE AND CONVERSION**
- 1 applicatorful delivers a 5g dose of metronidazole 0.75%.

Pelvic inflammatory disease
- **BY MOUTH**
  - Adult: 400 mg twice daily for 14 days

**Acute ulcerative gingivitis**
- **BY MOUTH**
  - Child 1-2 years: 50 mg every 8 hours for 3 days
  - Child 3-6 years: 100 mg every 12 hours for 3 days
  - Child 7-9 years: 100 mg every 8 hours for 3 days
  - Child 10-17 years: 200–250 mg every 8 hours for 3 days
  - Adult: 400 mg every 8 hours for 3 days

**Acute oral infections**
- **BY MOUTH**
  - Child 1-2 years: 50 mg every 8 hours for 3–7 days
  - Child 3-6 years: 100 mg every 12 hours for 3–7 days
  - Child 7-9 years: 100 mg every 8 hours for 3–7 days
  - Child 10-17 years: 200–250 mg every 8 hours for 3–7 days
  - Adult: 400 mg every 8 hours for 3–7 days

Surgical prophylaxis
- **BY MOUTH**
  - Adult: 400–500 mg, to be administered 2 hours before surgery, then 400–500 mg every 8 hours if required for up to 3 doses (in high-risk procedures)
  - **BY RECTUM**
  - Adult: 1 g, to be administered 2 hours before surgery, then 1 g every 8 hours if required for up to 3 doses (in high-risk procedures)
  - **BY INTRAVENOUS INFUSION**
  - Adult: 500 mg, to be administered up to 30 minutes before the procedure (if rectal administration inappropriate), then 500 mg every 8 hours if required for up to 3 further doses (in high-risk procedures)

**Invasive intestinal amoebiasis | Extra-intestinal amoebiasis (including liver abscess)**
- **BY MOUTH**
  - Child 1-2 years: 200 mg 3 times a day for 5 days in intestinal infection (for 5–10 days in extra-intestinal infection)
  - Child 3-6 years: 200 mg 4 times a day for 5 days in intestinal infection (for 5–10 days in extra-intestinal infection)
  - Child 7-9 years: 400 mg 3 times a day for 5 days in intestinal infection (for 5–10 days in extra-intestinal infection)
  - Child 10-17 years: 800 mg 3 times a day for 5 days in intestinal infection (for 5–10 days in extra-intestinal infection)
  - Adult: 800 mg 3 times a day for 5 days in intestinal infection (for 5–10 days in extra-intestinal infection)

**Urogenital trichomoniasis**
- **BY MOUTH**
  - Child 1-2 years: 50 mg 3 times a day for 7 days
  - Child 3-6 years: 100 mg twice daily for 7 days
  - Child 7-9 years: 100 mg 3 times a day for 7 days
  - Child 10-17 years: 200 mg 3 times a day for 7 days, alternatively 400–500 mg twice daily for 5–7 days, alternatively 2 g for 1 dose

- **Adult:** 200 mg 3 times a day for 7 days, alternatively 400–500 mg twice daily for 5–7 days, alternatively 2 g for 1 dose

**Giardiasis**
- **BY MOUTH**
  - Child 1-2 years: 500 mg once daily for 3 days
  - Child 3-6 years: 600–800 mg once daily for 3 days
  - Child 7-9 years: 1 g once daily for 3 days
  - Child 10-17 years: 2 g once daily for 3 days, alternatively 400 mg 3 times a day for 5 days, alternatively 500 mg twice daily for 7–10 days
  - Adult: 2 g once daily for 3 days, alternatively 400 mg 3 times a day for 5 days, alternatively 500 mg twice daily for 7–10 days

**Established case of tetanus**
- **BY INTRAVENOUS INFUSION**
  - Adult: (consult product literature)

**Unlicensed use**
- With systemic use in adults Metronidazole doses in the BNF may differ from those in product literature.

**Caution**
- With vaginal use Not recommended during menstruation - some systemic absorption may occur with vaginal gel

**Interactions**
- Appendix 1: metronidazole

**Side-effects**
- Very rare
  - With systemic use Arthralgia - ataxia - darkening of urine - dizziness - drowsiness - erythema multiforme - headache - hepatitis - jaundice - leukopenia (on prolonged or intensive therapy) - myalgia - pancreatitis - pancytopenia - peripheral neuropathy (on prolonged or intensive therapy) - pruritus - psychotic disorders - rash - thrombocytopenia - transient epileptiform seizures (on prolonged or intensive therapy) - visual disturbances
  - Frequency not known
  - With systemic use Anorexia - aseptic meningitis - furred tongue - gastro-intestinal disturbances - nausea - optic neuropathy - oral mucusitis - taste disturbances - vomiting
  - With vaginal use Abnormal vaginal discharge - local irritation - pelvic discomfort - vaginal candidiasis

**Pregnancy**
- With systemic use Manufacturer advises avoidance of high-dose regimens; use only if potential benefit outweighs risk.

**Breast feeding**
- With systemic use Significant amount in milk; manufacturer advises avoid large single doses though otherwise compatible; may give milk a bitter taste.

**Hepatic impairment**
- With systemic use In severe liver disease reduce total daily dose to one-third, and give once daily. Use with caution in hepatic encephalopathy.

**Monitoring requirements**
- With systemic use Clinical and laboratory monitoring advised if treatment exceeds 10 days.

**Directions for administration**
- For intravenous infusion, give over 20–30 minutes.

**Prescribing and dispensing information**
Metronidazole is well absorbed orally and the intravenous route is normally reserved for severe infections. Metronidazole by the rectal route is an effective alternative to the intravenous route when oral administration is not possible.

**Patient and carer advice**
514 Bacterial infection

PROFESSION SPECIFIC INFORMATION

Dental practitioners' formulary

Metronidazole Tablets may be prescribed. Metronidazole Oral suspension may be prescribed.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

Tablet

CAUTIONARY AND ADVISORY LABELS 4, 9, 21, 25, 27

Metronidazole (Non-proprietary)

Metronidazole 200 mg Metronidazole 200mg tablets | 21 tablet [POM] £4.99 DT price = £2.12 | 250 tablet [POM] £13.69

Metronidazole 400 mg Metronidazole 400mg tablets | 21 tablet [POM] £8.10 DT price = £1.47

Metronidazole 500 mg Metronidazole 500mg tablets | 21 tablet [POM] £3.72 DT price = £0.74

Flagyl (Zentiva)

Metronidazole 200 mg Flagyl 200mg tablets | 21 tablet [POM] £4.49 DT price = £2.12

Metronidazole 400 mg Flagyl 400mg tablets | 14 tablet [POM] £6.34

Oral suspension

CAUTIONARY AND ADVISORY LABELS 4, 9

Metronidazole (Non-proprietary)

Metronidazole (as Metronidazole benzoate) 40 mg per 1 ml Metronidazole 200mg/5ml oral suspension | 100 ml [POM] £3.03 DT price = £3.03

Infusion

ELECTROLYTES: May contain Sodium

Metronidazole (Non-proprietary)

Metronidazole 5 mg per 1 ml Metronidazole 500mg/100ml infusion 100ml bags | 20 bag [POM] £62.00

Metronidazole 500mg/100ml infusion 100ml Macoflex bags | 1 bag [POM] no price available | 60 bag [POM] no price available

Suppository

CAUTIONARY AND ADVISORY LABELS 4, 9

Flagyl (Zentiva)

Metronidazole 1 gram Flagyl 1g suppositories | 10 suppository [POM] £3.06

Metronidazole 500 mg Flagyl 500mg suppositories | 10 suppository [POM] £1.58

Vaginal gel

EXCIPIENTS: May contain Disodium edetate, hydroxybenzoates (parabens), propylene glycol

Metronidazole (Non-proprietary)

Metronidazole 7.5 mg per 1 gram Metronidazole 0.75% vaginal gel | 40 gram [POM] no price available DT price = £4.31

Zidoval (Meda Pharmaceuticals Ltd)

Metronidazole 7.5 mg per 1 gram Zidoval 0.75% vaginal gel | 40 gram [POM] £4.31 DT price = £4.31

Tinidazole

DRUG ACTION

Tinidazole is an antimicrobial drug with high activity against anaerobic bacteria and protozoa; it has a longer duration of action than metronidazole.

INDICATIONS AND DOSE

Anaerobic infections

BY MOUTH

Adult: Initially 2 g, followed by 1 g daily usually for 5–6 days, alternatively 500 mg twice daily usually for 5–6 days

Bacterial vaginosis | Acute ulcerative gingivitis

BY MOUTH

Adult: 2 g for 1 single dose

Abdominal surgery prophylaxis

BY MOUTH

Adult: 2 g for 1 single dose, to be administered approximately 12 hours before surgery

Intestinal amoebiasis

BY MOUTH

Child 1 month–11 years: 50–60 mg/kg once daily (max. per dose 2 g) for 3 days

Child 12–17 years: 2 g once daily for 2–3 days

Amebic involvement of liver

BY MOUTH

Child 1 month–11 years: 50–60 mg/kg once daily (max. per dose 2 g) for 5 days

Child 12–17 years: 1.5–2 g once daily for 3–6 days

Urogenital trichomoniasis | Giardiasis

BY MOUTH

Child 1 month–11 years: 50–75 mg/kg (max. per dose 2 g) for 1 single dose, dose may be repeated once if necessary

Child 12–17 years: 2 g for 1 single dose, dose may be repeated once if necessary

Adult: 2 g for 1 single dose

Helicobacter pylori eradication

BY MOUTH

Adult: (consult local protocol)

CAUTIONS

Avoid in acute porphyrias p. 969

INTERACTIONS → Appendix 1: tinidazole

SIDE-EFFECTS

Common or very common

Anorexia · furred tongue · gastrointestinal disturbances · nausea · oral mucositis · taste disturbances · vomiting

Very rare

Arthralgia · ataxia · darkening of urine · dizziness · drowsiness · erythema multiforme · headache · hepatitis · jaundice · leucopenia (on prolonged or intensive therapy) · myalgia · pancreatitis · pancytopenia · peripheral neuropathy (on prolonged or intensive therapy) · pruritus · psychotic disorders · rash · thrombocytopenia · transient epileptiform seizures (on prolonged or intensive therapy) · visual disturbances

Frequency not known

Aseptic meningitis · optic neuropathy

PREGNANCY

Manufacturer advises avoid in first trimester.

BREAST FEEDING

Present in milk—manufacturer advises avoid breast-feeding during and for 3 days after stopping treatment.

MONITORING REQUIREMENTS

Clinical and laboratory monitoring advised if treatment exceeds 10 days.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS 4, 9, 21, 25

Fasigyn (Pfizer Ltd)

Tinidazole 500 mg Fasigyn 500mg tablets | 16 tablet [POM] £11.04 DT price = £11.04

ANTIBACTERIALS → PENICILLINS

Penicillins

Benzylpenicillin and phenoxymethylpenicillin

Benzylpenicillin sodium p. 517 (Penicillin G) remains an important and useful antibiotic but is inactivated by bacterial beta-lactamas. It is effective for many streptococcal (including pneumococcal), gonococcal, and meningococcal infections and also for anthrax, diphtheria, gas-gangrene, leptospirosis, and treatment of Lyme disease. Pneumococci, meningococci, and gonococci which have decreased sensitivity to penicillin have been isolated; benzylpenicillin sodium is no longer the drug of first choice.
for pneumococcal meningitis. Although benzylpenicillin sodium is effective in the treatment of tetanus, metronidazole p. 512 is preferred. Benzylpenicillin is inactivated by gastric acid and absorption from the gastrointestinal tract is low; therefore it must be given by injection.

**Benzathine benzylpenicillin** is used for the treatment of early syphilis and late latent syphilis; broad-spectrum penicillins should not therefore be used for glandular fever; broad-spectrum penicillins should not be used for the treatment of meningococcal meningitis when clinical response has begun. It should not be used for meningococcal or gonococcal infections. Phenoxymethylpenicillin is used for prophylaxis against streptococcal infections following rheumatic fever and against pneumococcal infections following splenectomy or in sickle-cell disease.

### Penicillinase-resistant penicillins

Most staphylococci are now resistant to benzylpenicillin because they produce penicillinases. Flucloxacillin p. 523, however, is not inactivated by these enzymes and is thus effective in infections caused by penicillin-resistant staphylococci, which is the sole indication for its use. Flucloxacillin is acid-stable and can, therefore, be given by mouth as well as by injection. Flucloxacillin is well absorbed from the gut.

Temocillin p. 524 is active against Gram-negative bacteria and is stable against a wide range of beta-lactamases. It should be reserved for the treatment of infections caused by beta-lactamase-producing strains of Gram-negative bacteria, including those resistant to third-generation cephalosporins. Temocillin is not active against *Pseudomonas aeruginosa* or *Acinetobacter* spp.

### Broad-spectrum penicillins

Ampicillin p. 520 is active against certain Gram-positive and Gram-negative organisms but is inactivated by penicillinases including those produced by *Staphylococcus aureus* and by common Gram-negative bacilli such as *Escherichia coli*. Almost all staphylococci, approx. 60% of *E. coli* strains and approx. 20% of *Haemophilus influenzae* strains are now resistant. The likelihood of resistance should therefore be considered before using ampicillin for the 'blind' treatment of infections; in particular, it should not be used for hospital patients without checking sensitivity.

Ampicillin is well excreted in the bile and urine. It is principally indicated for the treatment of exacerbations of chronic bronchitis and middle ear infections, both of which may be due to *Streptococcus pneumoniae* and *H. influenzae*, and for urinary-tract infections. Ampicillin can be given by mouth but less than half the dose is absorbed, and absorption is further decreased by the presence of food in the gut.

Maculopapular rashes commonly occur with ampicillin (and amoxicillin p. 518) but are not usually related to true penicillin allergy. They almost always occur in patients with glandular fever; broad-spectrum penicillins should not therefore be used for 'blind' treatment of a sore throat. The risk of rash is also increased in patients with acute or chronic lymphocytic leukaemia or in cytomegalovirus infection.

Ampicillin is a derivative of amoxicillin and has a similar antibacterial spectrum. It is better absorbed than ampicillin when given by mouth, producing higher plasma and tissue concentrations; unlike amoxicillin, absorption is not affected by the presence of food in the stomach. Amoxicillin may also be used for the treatment of Lyme disease (not licensed).

Co-amoxiclav p. 521 consists of amoxicillin with the beta-lactamase inhibitor clavulanic acid. Clavulanic acid itself has no significant antibacterial activity but, by inactivating beta-lactamases, it makes the combination active against beta-lactamase-producing bacteria that are resistant to amoxicillin. These include resistant strains of *Staph. aureus*, *E. coli*, and *H. influenzae*, as well as many *Bacteroides* and *Klebsiella* spp. Co-amoxiclav should be reserved for infections likely, or known, to be caused by amoxicillin-resistant beta-lactamase-producing strains.

A combination of ampicillin with flucloxacillin (as co-fluampicil p. 520) is available to treat infections involving either streptococci or staphylococci (e.g. cellulitis).

### Antipseudomonal penicillins

**Piperacillin**, a ureidopenicillin, is only available in combination with the beta-lactamase inhibitor tazobactam. **Ticarcillin**, a carboxypenicillin, is only available in combination with the beta-lactamase inhibitor clavulanic acid. Both preparations have a broad spectrum of activity against a range of Gram-positive and Gram-negative bacteria, and anaerobes. Piperacillin with tazobactam p. 516 has activity against a wider range of Gram-negative organisms than ticarcillin with clavulanic acid p. 516 and it is more active against *Pseudomonas aeruginosa*. These antibacterials are not active against MRSA. They are used in the treatment of septicaemia, hospital-acquired pneumonia, and complicated infections involving the urinary tract, skin and soft tissues, or intra-abdomen. For severe pseudomonas infections these antipseudomonal penicillins can be given with an aminoglycoside (e.g. gentamicin p. 491) since they have a synergistic effect.

### Mecillinams

Pivmecillinam hydrochloride p. 523 has significant activity against many Gram-negative bacteria including *Escherichia coli*, *Klebsiella*, enterobacter, and salmonellae. It is not active against *Pseudomonas aeruginosa* or enterococci. Pivmecillinam hydrochloride is hydrolysed to mecillinam, which is the active drug.

### Penicillins

**DRUG ACTION** The penicillins are bactericidal and act by interfering with bacterial cell wall synthesis. They diffuse well into body tissues and fluids, but penetration into the cerebrospinal fluid is poor except when the meninges are inflamed. They are excreted in the urine in therapeutic concentrations.

**CAUTIONS** History of allergy

**SIDE-EFFECTS**

- Common or very common
  - Anaphylaxis
  - angioedema
  - diarrhoea
  - fever
  - hypersensitivity reactions
  - joint pains
  - rashes
  - serum sickness-like reaction
  - urticaria

- Rare
  - Cerebral irritation
  - CNS toxicity (including convulsions)
  - coagulation disorders
  - encephalopathy
  - haemolytic anaemia
  - interstitial nephritis
  - leucopenia
  - thrombocytopenia

- Frequency not known
  - Antibiotic-associated colitis

**SIDE-EFFECTS, FURTHER INFORMATION**

- CNS toxicity A rare but serious toxic effect of the penicillins is encephalopathy due to cerebral irritation. This may result from excessively high doses or in patients with severe renal failure. The penicillins should not be given by intrathecal injection because they can cause encephalopathy which may be fatal.

- Diarrhoea Diarrhoea frequently occurs during oral penicillin therapy. It is most common with broad-spectrum penicillins, which can also cause antibiotic-associated colitis.
**Uncommon**

Allergic reactions to penicillins occur in 1–10% of exposed individuals; anaphylactoid reactions occur in fewer than 0.05% of treated patients. Patients with a history of atopic allergy (e.g. asthma, eczema, hay fever) are at a higher risk of anaphylactoid reactions to penicillins. Individuals with a history of anaphylaxis, urticaria, or rash immediately after penicillin administration are at risk of immediate hypersensitivity to a penicillin; these individuals should not receive a penicillin. Individuals with a history of a minor rash (i.e. non-confluent, non-pruritic rash restricted to a small area of the body) or a rash that occurs more than 72 hours after penicillin administration are probably not allergic to penicillin and in these individuals a penicillin should not be withheld unnecessarily for serious infections; the possibility of an allergic reaction should, however, be borne in mind. Other beta-lactam antibiotics (including cephalosporins) can be used in these patients.

Patients who are allergic to one penicillin will be allergic to all because the hypersensitivity is related to the basic penicillin structure. Patients with a history of immediate hypersensitivity to penicillins may also react to the cephalosporins and other beta-lactam antibiotics, they should not receive these antibiotics. If a penicillin (or another beta-lactam antibiotic) is essential in an individual with immediate hypersensitivity to penicillin then specialist advice should be sought on hypersensitivity testing or using a beta-lactam antibiotic with a different structure to the penicillin that caused the hypersensitivity.

### Antibacterials > Penicillins, Antipseudomonal with Beta-lactamase Inhibitor

**Piperacillin with tazobactam**

**Indications and Dose**

- **Hospital-acquired pneumonia** | **Septicaemia** | **Complicated infections involving the urinary-tract** | **Complicated infections involving the skin** | **Complicated infections involving the soft-tissues**

  - **By intravenous infusion**
  - Adult: 4.5 g every 8 hours; increased if necessary to 4.5 g every 6 hours, increased frequency may be used for severe infections

**Infections in neutropenic patients**

  - **By intravenous infusion**
  - Adult: 4.5 g every 6 hours

**Caution**

High doses may lead to hypernatraemia (owing to sodium content of preparations)

**Interactions**

- Appendix 1: penicillins

**Side-effects**

- Common or very common: Nausea, vomiting
- Uncommon: Constipation, dyspepsia, headache, hypotension, injection-site reactions, insomnia, jaundice, stomatitis
- Rare: Abdominal pain, eosinophilia, hepatitis
- Very rare: Hypoglycaemia, hypokalaemia, pancreatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis

**Pregnancy**

Manufacturers advise use only if potential benefit outweighs risks.

**Breastfeeding**

Trace amount in milk, but appropriate to use.

**Renal impairment**

Max. 4.5 g every 8 hours if eGFR 20–40 mL/minute/1.73 m². Max. 4.5 g every 12 hours if eGFR less than 20 mL/minute/1.73 m².

**Effect on laboratory tests**

False-positive urinary glucose (if tested for reducing substances).

**Directions for administration**

For intravenous infusion, give intermittently in Glucose 5% or Sodium chloride 0.9%. Reconstitute initially (2.25 g in 10 mL, 4.5 g in 20 mL) with water for injections, or glucose 5% (Tazocin® brand only), or sodium chloride 0.9%, then dilute to 50–150 mL with infusion fluid; give over 30 minutes.

**Prescribing and dispensing information**

Dose expressed as a combination of piperacillin and tazobactam (both as sodium salts) in a ratio of 8:1.

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: infusion

- **Piperacillin with tazobactam (non-proprietary)**
  - Tazobactam (as Tazobactam sodium) 250 mg, Piperacillin (as Piperacillin sodium) 2 gram
  - Piperacillin 2g / Tazobactam 250mg powder for solution for injection vials 1 vial (Pom) £19.97 (Hospital only) | 10 vial (Pom) £50.80

- **Tazobactam (as Tazobactam sodium) 500 mg, Piperacillin (as Piperacillin sodium) 4 gram**
  - Piperacillin 4g / Tazobactam 500mg powder for solution for injection vials 1 vial (Pom) £12.90

- **Tazocin (Pfizer Ltd)**
  - Tazobactam (as Tazobactam sodium) 250 mg, Piperacillin (as Piperacillin sodium) 2 gram
  - Tazocin 2.25g powder for solution for injection vials 1 vial (Pom) £7.65 DT price = £8.70
  - Tazobactam (as Tazobactam sodium) 500 mg, Piperacillin (as Piperacillin sodium) 4 gram
  - Tazocin 4.5g powder for solution for injection vials 1 vial (Pom) £15.17 (Hospital only)

**Ticarcillin with clavulanic acid**

**Indications and Dose**

Infections due to Pseudomonas and Proteus spp.

- **By intravenous infusion**
  - Adult: 3.2 g every 6–8 hours; increased if necessary to 3.2 g every 4 hours, increased frequency used for more severe infections

**Caution**

High doses may lead to hypernatraemia (owing to sodium content of preparations)

**Caution, Further Information**

- Cholestatic jaundice: Cholestatic jaundice is possibly associated with clavulanic acid. An epidemiological study has shown that the risk of acute liver toxicity was about 6 times greater with co-amoxiclav (amoxicillin, clavulanic acid) than with amoxicillin. Cholestatic jaundice is more common in patients above the age of 65 years and in men; these reactions have only rarely been reported in children. Jaundice is usually self-limiting and very rarely fatal. The duration of treatment should be appropriate to the indication and should not usually exceed 14 days.

**Interactions**

- Appendix 1: penicillins

**Side-effects**

- Eosinophilia, haemorrhagic cystitis (more frequent in children), hypokalaemia, injection-site reactions, nausea, Stevens-Johnson syndrome, toxic epidermal necrolysis, vomiting

**Pregnancy**

Not known to be harmful.

**Breastfeeding**

Trace amounts in milk, but appropriate to use.

**Hepatic impairment**

Manufacturer advises caution in severe impairment.

**Renal impairment**

Accumulation of electrolytes contained in preparation can occur in patients with renal failure.

---

Note: The information provided is a summary and may not cover all aspects. Always consult a healthcare professional for the latest advice and guidelines.
Benzylpenicillin sodium
(Penicillin G)

**INDICATIONS AND DOSE**

- **Mild to moderate susceptible infections** | **Throat infections** | **Otitis media** | **Cellulitis** | **Pneumonia**
  - By **intramuscular injection**, or by **slow intravenous infusion**
  - Adult: 0.6–1.2 g every 6 hours, dose may be increased if necessary in more serious infections (consult product literature), single doses over 1.2 g to be given by intravenous route only

- **Endocarditis (in combination with other antibacterials if necessary)**
  - By **slow intravenous injection**, or by **intravenous infusion**
  - Adult: 1.2 g every 4 hours, increased if necessary to 2.4 g every 4 hours, dose may be increased in infections such as enterococcal endocarditis

- **Anthrax (in combination with other antibacterials)**
  - By **slow intravenous injection**, or by **intravenous infusion**
  - Adult: 2.4 g every 4 hours

- **Intrapartum prophylaxis against group B streptococcal infection**
  - By **slow intravenous injection**, or by **intravenous infusion**
  - Adult: Initially 3 g for 1 dose, then 1.5 g every 4 hours until delivery

- **Meningitis** | **Meningococcal disease**
  - By **slow intravenous injection**, or by **intravenous infusion**
  - Adult: 2.4 g every 4 hours
  - By **intravenous infusion**
  - Child: 50 mg/kg every 4–6 hours (max. per dose 2.4 g every 4 hours)

**EFFECT ON LABORATORY TESTS**

- False-positive urinary glucose (if tested for reducing substances).

**PRESCRIBING AND DISPENSING INFORMATION**

Dose is expressed as a combination of ticarcillin (as sodium salt) and clavulanic acid (as potassium salt) in a ratio of 15:1.

**MECHANICAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for infusion**

**ELECTROLYTES:** May contain Potassium, sodium

- Timentin (GlaxoSmithKline UK Ltd)
- Clavulanic acid (as Potassium clavulanate) 200 mg, Ticarcillin (as Ticarcillin sodium) 3 gram Timentin 3.2g powder for solution for infusion vials | 4 vial 21.32

**ANTIBACTERIALS | PENICILLINS, BETA-LACTAMASE SENSITIVE**

**Suspected meningococcal disease (meningitis with non-blanching rash or meningococcal septicaemia) prior to urgent transfer to hospital**

- By **intravenous injection**, or by **intramuscular injection**
  - Child 1-11 months: 300 mg, administer as single dose prior to urgent transfer to hospital so long as does not delay transfer
  - Child 1-9 years: 600 mg, administer as single dose prior to urgent transfer to hospital so long as does not delay transfer
  - Child 10-17 years: 1.2 g, administer as single dose prior to urgent transfer to hospital so long as does not delay transfer
  - Adult: 1.2 g, administer as single dose prior to urgent transfer to hospital so long as does not delay transfer

**Suspected bacterial meningitis without non-blanching rash where patient cannot be transferred to hospital urgently**

- By **intravenous injection**, or by **intramuscular injection**
  - Child 1-11 months: 300 mg, administer as single dose prior to transfer to hospital
  - Child 1-9 years: 600 mg, administer as single dose prior to transfer to hospital
  - Child 10-17 years: 1.2 g, administer as single dose prior to transfer to hospital
  - Adult: 1.2 g, administer as single dose prior to transfer to hospital

**UNLICENSED USE**

Benzylpenicillin doses in the BNF may differ from those in product literature.

**IMPORTANT SAFETY INFORMATION**

Intrathecal injection of benzylpenicillin is not recommended.

**CAUTIONS**

- Accumulation of sodium from injection can occur with high doses

**INTERACTIONS**

→ Appendix 1: penicillins

**PREGNANCY**

Not known to be harmful.

**BREAST FEEDING**

Trace amounts in milk, but appropriate to use.

**RENAL IMPAIRMENT**

Accumulation of sodium from injection can occur in renal failure. High doses may cause neurotoxicity, including cerebral irritation, convulsions, or coma.

- In adults Reduce dose—consult product literature.
  - In children Estimated glomerular filtration rate 10–50 mL/minute/1.73 m², use normal dose every 8–12 hours. Estimated glomerular filtration rate less than 10 mL/minute/1.73 m² use normal dose every 12 hours.

**EFFECT ON LABORATORY TESTS**

False-positive urinary glucose (if tested for reducing substances).

**DIRECTIONS FOR ADMINISTRATION**

- With intravenous use in children Intravenous route recommended in infants. For **intravenous infusion**, dilute with Glucose 5% or Sodium Chloride 0.9%; give over 15–30 minutes. Longer administration time is particularly important when using doses of 50 mg/kg (or greater) to avoid CNS toxicity.

  - With intravenous use in adults For **intravenous infusion** (Crystapen®), give intermittently in Glucose 5% or Sodium chloride 0.9%; suggested volume 100 mL given over 30–60 minutes. Continuous infusion not usually recommended.

Reduce dose to 3.2 g every eight hours if eGFR 30–60 mL/minute/1.73 m²; 1.6 g every eight hours if eGFR 10–30 mL/minute/1.73 m²; 1.6 g every twelve hours if eGFR less than 10 mL/minute/1.73 m².
Phenoxymethylpenicillin
(Penicillin V)

**INDICATIONS AND DOSE**

**Oral infections** | Tonsillitis | Otitis media | Erysipelas | Cellulitis

- **BY MOUTH**
  - Child 1–11 months: 62.5 mg 4 times a day; increased if necessary up to 12.5 mg/kg 4 times a day
  - Child 1–5 years: 125 mg 4 times a day; increased if necessary up to 12.5 mg/kg 4 times a day
  - Child 6–11 years: 250 mg 4 times a day; increased if necessary up to 12.5 mg/kg 4 times a day
  - Child 12–17 years: 500 mg 4 times a day; increased if necessary up to 1 g 4 times a day
  - Adult: 500 mg every 6 hours, increased if necessary up to 1 g every 6 hours

**Prevention of recurrence of rheumatic fever**

- **BY MOUTH**
  - Child 1 month–5 years: 125 mg twice daily
  - Child 6–17 years: 250 mg twice daily
  - Adult: 250 mg twice daily

**Prevention of secondary case of invasive group A streptococcal infection**

- **BY MOUTH**
  - Child 1–11 months: 62.5 mg every 6 hours for 10 days
  - Child 1–5 years: 125 mg every 6 hours for 10 days
  - Child 6–11 years: 250 mg every 6 hours for 10 days
  - Child 12–17 years: 500 mg every 6 hours for 10 days
  - Adult: 250–500 mg every 6 hours for 10 days

**Prevention of pneumococcal infection in asplenia or in patients with sickle-cell disease**

- **BY MOUTH**
  - Child 1–11 months: 62.5 mg twice daily
  - Child 1–4 years: 125 mg twice daily
  - Child 5–17 years: 250 mg twice daily
  - Adult: 250 mg twice daily

**UNLICENSED USE**

Phenoxymethylpenicillin doses in the BNF may differ from product literature.

**INTERACTIONS** → Appendix 1: penicillins

**PREGNANCY** Not known to be harmful.

**BREAST FEEDING** Trace amounts in milk, but appropriate to use.

**EFFECT ON LABORATORY TESTS** False-positive urinary glucose (if tested for reducing substances).

**PATIENT AND CARER ADVICE**

- Medicines for Children leaflet: Penicillin V for bacterial infections
  
  www.medicinesforchildren.org.uk/penicillin-v-for-bacterial-infections

- Medicines for Children leaflet: Penicillin V for prevention of pneumococcal infection
  
  www.medicinesforchildren.org.uk/penicillin-v-for-prevention-of-pneumococcal-infection

**PROFESSION SPECIFIC INFORMATION**

- Dental practitioners' formulary
  
  Phenoxymethylpenicillin Tablets may be prescribed. Phenoxymethylpenicillin Oral Solution may be prescribed.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: infusion

**Powder for solution for injection**

- **ELECTROLYTES**: May contain Sodium
  - Benzylpenicillin sodium 600 mg
  - Benzylpenicillin sodium 1.2 gram

**Phenoxymethylpenicillin (Non-proprietary)**

**Phenoxymethylpenicillin (as Phenoxymethylpenicillin potassium)**

- 25 mg per 1 ml
  - 100 ml DT price = £8.72

**Phenoxymethylpenicillin (as Penicillin V)**

- 50 mg per 1 ml
  - 250 mg tablets DT price = £0.14

**Antibacterials > Penicillins, Broad-Spectrum**

**Amoxicillin**

(Amoxyccillin)

**INDICATIONS AND DOSE**

Susceptible infections (including urinary-tract infections, otitis media, sinusitis, uncomplicated community acquired pneumonia, salmonellosis, oral infections)

- **BY MOUTH**
  - Child 1–11 months: 125 mg 3 times a day; increased if necessary up to 30 mg/kg 3 times a day
  - Child 1–4 years: 250 mg 3 times a day; increased if necessary up to 30 mg/kg 3 times a day
  - Child 5–11 years: 500 mg 3 times a day; increased if necessary up to 30 mg/kg 3 times a day (max. per dose 1 g)
  - Child 12–17 years: 500 mg 3 times a day; increased if necessary up to 1 g 3 times a day, use increased dose in severe infections
  - Adult: 500 mg every 8 hours, increased if necessary up to 1 g every 8 hours, increased dose used in severe infections

- **BY INTRAMUSCULAR INJECTION**
  - Adult: 500 mg every 8 hours

- **BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
  - Adult: 500 mg every 8 hours, increased to 1 g every 6 hours, use increased dose in severe infections

**Lyme disease (under expert supervision)**

- **BY MOUTH**
  - Child 5–17 years: 500 mg 3 times a day for 14–21 days (for 28 days in Lyme arthritis)
  - Adult: 500 mg 3 times a day for 14–21 days (for 28 days in Lyme arthritis)

**Anthrax (treatment and post-exposure prophylaxis)**

- **BY MOUTH**
  - Child (body-weight up to 20 kg): 80 mg/kg daily in 3 divided doses
  - Child (body-weight 20 kg and above): 500 mg 3 times a day

- **Dental abscess (short course)**

- **BY MOUTH**
  - Adult: 3 g, then 3 g after 8 hours

**Urinary-tract infections (short course)**

- **BY MOUTH**
  - Adult: 3 g, then 3 g after 10–12 hours
**Listeral meningitis (in combination with another antibiotic)**

- **BY INTRAVENOUS INFUSION**
  - Adult: 2 g every 4 hours

**Endocarditis (in combination with another antibiotic if necessary)**

- **BY INTRAVENOUS INFUSION**
  - Adult: 2 g every 4 hours

**Prevention of pneumococcal infection in asplenia or in patients with sickle-cell disease—if cover also needed for Haemophilus influenzae**

- **BY MOUTH**
  - Child 1 month–4 years: 125 mg twice daily
  - Child 5–11 years: 250 mg twice daily
  - Child 12–17 years: 500 mg twice daily

**Helicobacter pylori eradication in combination with metronidazole and omeprazole**

- **BY MOUTH**
  - Adult: 500 mg 3 times a day

**Helicobacter pylori eradication in combination with clarithromycin and esomeprazole; or in combination with clarithromycin and lansoprazole; or in combination with clarithromycin and pantoprazole; or in combination with clarithromycin and rabeprazole**

- **BY MOUTH**
  - Adult: 1 g twice daily

- **UNLICENSED USE** Amoxicillin doses in BNF Publications may differ from those in product literature.

- **CAUTIONS**

  **GENERAL CAUTIONS**
  Acute lymphocytic leukaemia (increased risk of erythematous rashes) · chronic lymphocytic leukaemia (increased risk of erythematous rashes) · cytomegalovirus infection (increased risk of erythematous rashes) · glandular fever (erythematous rashes common) · maintain adequate hydration with high doses (particularly during parenteral therapy)

  **SPECIFIC CAUTIONS**
  - With intravenous use Accumulation of sodium can occur with high parenteral doses
  - **INTERACTIONS** ▶ Appendix 1: penicillins
  - **SIDE-EFFECTS**
  - **Common or very common** Nausea · vomiting
  - **SIDE-EFFECTS, FURTHER INFORMATION**
  - Rash If rash occurs, discontinue treatment.

- **PREGNANCY** Not known to be harmful.

- **BREAST FEEDING** Trace amount in milk, but appropriate to use.

- **RENAI IMPAIRMENT** Reduce dose in severe impairment; rashes more common. Risk of crystalluria with high doses (particularly during parenteral therapy).
  - With intravenous use Accumulation of sodium from injection can occur in patients with renal failure.

- **DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Amoxil®), give intermittently in Glucose 5% or Sodium chloride 0.9%. Reconstituted solutions diluted and given without delay; suggested volume 100 ml given over 30–60 minutes or give via drip tubing in Glucose 5% or Sodium chloride 0.9%; continuous infusion not usually recommended.

- **PRESCRIBING AND DISPENSING INFORMATION** Flavours of oral liquid formulations and sachets may include peach, strawberry, or lemon.

- **PATIENT AND CARER ADVICE**
  Patient counselling is advised for Amoxicillin (Amoxil®) paediatric suspension (use of pipette).

**Bacterial infection** 519

**Medicines for Children leaflet: Amoxicillin for bacterial infections**

- **PROFESSION SPECIFIC INFORMATION**
  - Dental practitioners’ formulary
  - Amoxicillin capsules may be prescribed. Amoxicillin sachets may be prescribed as Amoxicillin Oral Powder. Amoxicillin Oral Suspension may be prescribed.

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for injection**

**ELECTROLYTES:** May contain Sodium

- **Amoxicillin (Nonproprietary)**
  - Amoxicillin (as Amoxicillin sodium) 250 mg Amoxicillin 250mg powder for solution for injection vials | 10 vial (POM) £6.80
  - Amoxicillin (as Amoxicillin sodium) 500 mg Amoxicillin 500mg powder for solution for injection vials | 10 vial (POM) £9.60 DT price = £5.48
  - Amoxicillin (as Amoxicillin sodium) 1 gram Amoxicillin 1g powder for solution for injection vials | 1 vial (POM) £1.92
  - Amoxil (GlaxoSmithKline UK Ltd) Amoxicillin 500mg powder for solution for injection vials | 10 vial (POM) £5.48 DT price = £5.48
  - Amoxicillin (as Amoxicillin sodium) 1 gram Amoxicillin 1g powder for solution for injection vials | 10 vial (POM) £10.96 DT price = £10.96

**Oral suspension**

**CAUTIONARY AND ADVISORY LABELS 9**

**EXCIPIENTS:** May contain Sucrose

- **Amoxicillin (Nonproprietary)**
  - Amoxicillin (as Amoxicillin trihydrate) 25 mg per 1 ml Amoxicillin 125mg/5ml oral suspension sugar free sugar-free | 100 ml (POM) £25.00 DT price = £1.03
  - Amoxicillin 125mg/5ml oral suspension | 100 ml (POM) £25.00 DT price = £0.96
  - Amoxicillin (as Amoxicillin trihydrate) 50 mg per 1 ml Amoxicillin 250mg/5ml oral suspension sugar free sugar-free | 100 ml (POM) £35.00 DT price = £1.18
  - Amoxicillin 250mg/5ml oral suspension | 100 ml (POM) £35.00 DT price = £1.13
  - Amoxil (GlaxoSmithKline UK Ltd) Amoxicillin 100 mg per 1 ml Amoxil 125mg/1.25ml paediatric oral suspension | 20 ml (POM) £3.18 DT price = £3.18

**Powder**

**CAUTIONARY AND ADVISORY LABELS 9, 13**

- **Amoxicillin (Nonproprietary)**
  - Amoxicillin (as Amoxicillin trihydrate) 3 gram Amoxicillin 3g oral powder sachets sugar free sugar-free | 2 sachet (POM) £15.00 DT price = £9.98

**Capsule**

**CAUTIONARY AND ADVISORY LABELS 9**

- **Amoxicillin (Nonproprietary)**
  - Amoxicillin (as Amoxicillin trihydrate) 250 mg Amoxicillin 250mg capsules | 15 capsule (POM) £8.99 DT price = £0.59 | 21 capsule (POM) £8.99 DT price = £0.59 | 500 capsule (POM) £120.00
  - Amoxicillin (as Amoxicillin trihydrate) 500 mg Amoxicillin 500mg capsules | 15 capsule (POM) £7.50 DT price = £0.91 | 21 capsule (POM) £15.00 DT price = £1.27 | 100 capsule (POM) £75.00
  - Amoxil (GlaxoSmithKline UK Ltd) Amoxicillin (as Amoxicillin trihydrate) 250 mg Amoxicillin 250mg capsules | 21 capsule (POM) £0.92 DT price = £0.92
  - Amoxicillin (as Amoxicillin trihydrate) 500 mg Amoxicillin 500mg capsules | 21 capsule (POM) £0.89 DT price = £1.27

**Combinations available:** Co-amoxiclav, p. 521
Ampicillin

**INDICATIONS AND DOSE**

Susceptible infections (including bronchitis, urinary-tract infections, otitis media, sinusitis, uncomplicated community-acquired pneumonia, salmonellosis)

- **BY MOUTH**
  - Child 1-11 months: 125 mg 4 times a day; increased if necessary up to 30 mg/kg 4 times a day
  - Child 1-4 years: 250 mg 4 times a day; increased if necessary up to 30 mg/kg 4 times a day
  - Child 5-11 years: 500 mg 4 times a day; increased if necessary up to 30 mg/kg 4 times a day (max. per dose 1 g)

- **Child 12-17 years:** 500 mg 4 times a day; increased if necessary to 1 g 4 times a day, use increased dose in severe infection
  - **Adult:** 0.5–1 g every 6 hours
  - **BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
  - Adult: 500 mg every 4–6 hours
  - **BY INTRAMUSCULAR INJECTION**
  - Adult: 500 mg every 4–6 hours

**Endocarditis (in combination with another antibiotic if necessary)**

**Lobar pneumonia (in combination with another antibiotic)**

- **BY INTRAVENOUS INJECTION**
- **Adult:** 2 g every 4 hours

**UNLICENSED USE** Ampicillin doses in BNF may differ from those in product literature.

**CAUTIONS**

**GENERAL CAUTIONS**

Acute lymphocytic leukaemia (increased risk of erythematous rashes) – chronic lymphocytic leukaemia (increased risk of erythematous rashes) – cytomegalovirus infection (increased risk of erythematous rashes) – glandular fever (erythematous rashes common)

**SPECIFIC CAUTIONS**

- With intravenous use Accumulation of electrolytes contained in parenteral preparations can occur with high doses

**INTERACTIONS** → Appendix 1: penicillins

**SIDE-EFFECTS**

- Common or very common Nausea, vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

- Rash If rash occurs, discontinue treatment.

**PREGNANCY** Not known to be harmful.

**BREAST FEEDING** Trace amounts in milk, but appropriate to use.

**RENAL IMPAIRMENT**

- In adults: Reduce dose if eGFR less than 10 mL/minute/1.73 m²; rash more common.
- In children: If estimated glomerular filtration rate less than 10 mL/minute/1.73 m² reduce dose or frequency; rash more common.

- With intravenous use Accumulation of electrolytes contained in parenteral preparations can occur in patients with renal failure.

**DIRECTIONS FOR ADMINISTRATION**

- With oral use: Administer at least 30 minutes before food.

- With intravenous use: For intravenous infusion (Penbritin®), give intermittently in Glucose 5% or Sodium chloride 0.9%. Reconstituted solutions diluted and given without delay; suggested volume 100 mL given over 30–60 minutes via drip tubing in Glucose 5% or Sodium chloride 0.9%. Continuous infusion not usually recommended.

**PATIENT AND CARER ADVICE**

Medicines for Children leaflet: Ampicillin for bacterial infection

www.medicinesforchildren.org.uk/ampicillin-bacterial-infection

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Oral suspension**

**CAUTIONARY AND ADVISORY LABELS 9, 23**

- **Ampicillin (Non-proprietary)**
  - **Ampicillin 25 mg per 1 ml** Ampicillin 125mg/5ml oral suspension | 100 ml [Pt] £29.86 DT price = £29.86
  - **Ampicillin 50 mg per 1 ml** Ampicillin 250mg/5ml oral suspension | 100 ml [Pt] £38.86 DT price = £38.86

**Powder for solution for injection**

- **Ampicillin (Non-proprietary)**
  - **Ampicillin (as Ampicillin sodium) 500 mg** Ampicillin 500mg powder for solution for injection vials | 10 vial [Pt] £78.30 DT price = £78.30

**Capsule**

- **CAUTIONARY AND ADVISORY LABELS 9, 23**
  - **Ampicillin (Non-proprietary)**
  - **Ampicillin 250 mg** Ampicillin 250mg capsules | 28 capsule [Pt] £20.50 DT price = £20.50
  - **Ampicillin 500 mg** Ampicillin 500mg capsules | 28 capsule [Pt] £40.30 DT price = £40.30

**Co-fluampicil**

**INDICATIONS AND DOSE**

Mixed infections involving beta-lactamase-producing staphylococci

- **BY MOUTH**
  - Child 1 month–9 years: 125/125 mg every 6 hours
  - Child 10–17 years: 250/250 mg every 6 hours
  - Adult: 250/250 mg every 6 hours

- **BY INTRAMUSCULAR INJECTION, OR BY SLOW INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
  - Adult: 250/250 mg every 6 hours

**Severe mixed infections involving beta-lactamase-producing staphylococci**

- **BY MOUTH**
  - Child 1 month–9 years: 250/250 mg every 6 hours
  - Adult: 500/500 mg every 6 hours
  - **BY INTRAMUSCULAR INJECTION, OR BY SLOW INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
  - Adult: 500/500 mg every 6 hours

**IMPORTANT SAFETY INFORMATION**

**HEPATIC DISORDERS**

Cholestatic jaundice and hepatitis may occur very rarely, up to two months after treatment with fluclaxacillin has been stopped. Administration for more than 2 weeks and increasing age are risk factors. Healthcare professionals are reminded that:

- fluclaxacillin should not be used in patients with a history of hepatic dysfunction associated with fluclaxacillin;

- fluclaxacillin should be used with caution in patients with hepatic impairment;

- careful enquiry should be made about hypersensitivity reactions to beta-lactam antibacterials.

**CAUTIONS**

**GENERAL CAUTIONS**

Acute lymphocytic leukaemia (increased risk of erythematous rashes) – chronic lymphocytic leukaemia (increased risk of erythematous rashes) – cytomegalovirus infection (increased risk of erythematous rashes) – glandular fever (erythematous rashes common)
**INTERACTIONS** ▶ Appendix 1: penicillins

**SIDE-EFFECTS**
- **Common or very common** Gastro-intestinal disturbances • nausea • vomiting
- **Very rare** Cholestatic jaundice • hepatitis

**SIDE-EFFECTS, FURTHER INFORMATION**
- Rash If rash occurs, discontinue treatment.
- **PREGNANCY** Not known to be harmful.
- **BREAST FEEDING** Trace amount in milk, but appropriate to use.

**HEPATIC IMPAIRMENT** Use with caution.

**RENAL IMPAIRMENT**
- In adults Reduce dose if eGFR less than 10 mL/minute/1.73 m²; rashes more common.
- In children Reduce dose or frequency if estimated glomerular filtration rate less than 10 mL/minute/1.73 m²; rashes more common.
- With intravenous use Accumulation of electrolytes contained in parenteral preparations can occur in patients with renal failure.

**EFFECT ON LABORATORY TESTS** False-positive urinary glucose (if tested for reducing substances).

**DIRECTIONS FOR ADMINISTRATION** For **intravenous infusion** (Magnapen™), give intermittently in Glucose 5% or Sodium Chloride 0.9%. Reconstituted solutions diluted and given without delay; suggested volume 100 mL given over 30–60 minutes. Via drip tubing in Glucose 5% or Sodium Chloride 0.9%.

**PRESCRIBING AND DISPENSING INFORMATION** Dose expressed as a combination of equal parts by mass of flucloxacillin and ampicillin.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Oral suspension**

**CAUTIONARY AND ADVISORY LABELS** 9, 22
- **Co-fluampicil (Non-proprietary)**
  - Ampicillin (as Ampicillin trihydrate) 25 mg per 1 mL, Flucloxacillin (as Flucloxacinil magnesium) 25 mg per 1 mL Co-fluampicil 125mg/125mg/5ml oral suspension | 100 mL £23.93 DT price = £23.93

**Powder for solution for injection**

**ELECTROLYTES:** May contain Sodium
- **Co-fluampicil (Non-proprietary)**
  - Ampicillin (as Ampicillin sodium) 250 mg, Flucloxacillin (as Flucloxacinil sodium) 250 mg Co-fluampicil 250mg/250mg powder for solution for injection vials | 10 vial £13.33

**Capsule**

**CAUTIONARY AND ADVISORY LABELS** 9, 22
- **Co-fluampicil (Non-proprietary)**
  - Ampicillin (as Ampicillin trihydrate) 250 mg, Flucloxacillin (as Flucloxacinil sodium) 250 mg Co-fluampicil 250mg/250mg capsules | 28 capsule £10.31 DT price = £2.18 | 100 capsule £7.79–£42.99

**ANTIBACTERIALS > PENICILLINS, BROAD-SPECTRUM WITH BETA-LACTAMASE INHIBITOR**

**Co-amoxiclav**

- **INDICATIONS AND DOSE**
  - **Infections due to beta-lactamase-producing strains (where amoxicillin alone not appropriate), including respiratory tract infections, bone and joint infections, genito-urinary and abdominal infections, cellulitis and animal bites**
    - **BY MOUTH USING TABLETS**
      - Child 12-17 years: 250/125 mg every 8 hours; increased to 500/125 mg every 8 hours, increased dose used for severe infection
      - Adult: 250/125 mg every 8 hours; increased to 500/125 mg every 8 hours, increased dose used for severe infection
    - **BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
      - Child 1-2 months: 30 mg/kg every 12 hours
      - Child 3 months–17 years: 30 mg/kg every 8 hours (max. per dose 1.2 g every 8 hours)
      - Adult: 1.2 g every 8 hours

  - **Infections due to beta-lactamase-producing strains (where amoxicillin alone not appropriate) including respiratory-tract infections, bone and joint infections, genito-urinary and abdominal infections, cellulitis, animal bites (doses for 125/31 suspension)**
    - **BY MOUTH USING ORAL SUSPENSION**
      - Child 1-11 months: 0.25 mL/kilogram 3 times a day, dose doubled in severe infection
      - Child 1-5 years: 0.25 mL/kilogram 3 times a day, alternatively 5 mL 3 times a day, dose doubled in severe infection

  - **Infections due to beta-lactamase-producing strains (where amoxicillin alone not appropriate) including respiratory-tract infections, bone and joint infections, genito-urinary and abdominal infections, cellulitis, animal bites (doses for 250/62 suspension)**
    - **BY MOUTH USING ORAL SUSPENSION**
      - Child 6-11 years: 0.15 mL/kilogram 3 times a day, alternatively 5 mL 3 times a day, dose doubled in severe infection

  - **Infections due to beta-lactamase-producing strains (where amoxicillin alone not appropriate) including respiratory-tract infections, bone and joint infections, genito-urinary and abdominal infections, cellulitis, animal bites (doses for 400/57 suspension)**
    - **BY MOUTH USING ORAL SUSPENSION**
      - Child 2 months–1 year: 0.15 mL/kilogram twice daily, doubled in severe infection
      - Child 2–6 years (body-weight 13–21 kg): 2.5 mL twice daily, doubled in severe infection
      - Child 7-12 years (body-weight 22–40 kg): 5 mL twice daily, doubled in severe infection
      - Child 12-17 years (body-weight 41 kg and above): 10 mL twice daily; increased if necessary to 10 mL 3 times a day, increased frequency to be used in severe infection
      - Adult: 10 mL twice daily; increased if necessary to 10 mL 3 times a day, increased frequency to be used in severe infection

  - **Severe dental infection with spreading cellulitis** | Dental infection not responding to first-line antibacterial
    - **BY MOUTH USING TABLETS**
      - Child 12-17 years: 250/125 mg every 8 hours for 5 days
      - Adult: 250/125 mg every 8 hours for 5 days

---

**Bacterial infection 521**

---

**BNF 74**

**Infection** 5

---

**downloaded from www.medicalbr.com**
Infection

With intravenous use

▶ Rare

With oral use

▶ Common or very common

SIDE-EFFECTS

GENERAL SIDE-EFFECTS

▶ Common or very common

Cholestatic jaundice. Cholestatic jaundice can occur either during or shortly after the use of co-amoxiclav. An epidemiological study has shown that the risk of acute liver toxicity was about 6 times greater with co-amoxiclav than with amoxicillin. Cholestatic jaundice is more common in patients above the age of 65 years and in men; these reactions have only rarely been reported in children. Jaundice is usually self-limiting and very rarely fatal. The duration of treatment should be appropriate to the indication and should not usually exceed 14 days.

INTERACTIONS

SID-EFFECTS

CONTRA-INDICATIONS

History of co-amoxiclav-associated jaundice or hepatic dysfunction. History of penicillin-associated jaundice or hepatic dysfunction.

CAUTIONS

GENERAL CAUTIONS

Acute lymphocytic leukaemia (increased risk of erythematous rashes). Chronic lymphocytic leukaemia (increased risk of erythematous rashes). Cytomegalovirus infection (increased risk of erythematous rashes). Glandular fever (erythematous rashes common). Infection (increased risk of erythematous rashes). Jaundice is usually self-limiting and very rarely fatal. The epidemiological study has shown that the risk of acute liver toxicity was about 6 times greater with co-amoxiclav than with amoxicillin. Cholestatic jaundice is more common in patients above the age of 65 years and in men; these reactions have only rarely been reported in children. Jaundice is usually self-limiting and very rarely fatal. The duration of treatment should be appropriate to the indication and should not usually exceed 14 days.

INTERACTIONS

Appendix 1: penicillins

SIDE-EFFECTS

GENERAL SIDE-EFFECTS

▶ Common or very common


▶ Rare


SPECIFIC CAUTIONS

With intravenous use

Accumulation of electrolytes contained in parenteral preparations can occur with high doses.

CAUTIONS, FURTHER INFORMATION

With oral use in children

For intravenous infusion, dilute reconstituted solution to a concentration of 10 mg/mL with Sodium Chloride 0.9%; give intermittently over 30–40 minutes. For intravenous injection, administer over 3–4 minutes.

With oral use in adults

For intravenous infusion (Augmentin®), give intermittently in Sodium chloride 0.9%. Reconstitute 600 mg initially with 10 mL water for injections, then dilute with 50 mL infusion fluid; reconstitute 1.2 g initially with 20 mL water for injections, then dilute with 100 mL infusion fluid; give over 30–40 minutes. For intravenous injection, administer over 3–4 minutes. Via drip tubing in Sodium chloride 0.9%.

DIRECTIONS FOR ADMINISTRATION

Prescribing and dispensing information

Doses are expressed as co-amoxiclav: a mixture of amoxicillin (as the trihydrate or as the sodium salt) and clavulanic acid (as potassium clavulanate); the proportions are expressed in the form x/y where x and y are the strengths in milligrams of amoxicillin and clavulanic acid respectively.

Flavours of oral liquid formulations may include raspberry and orange.

Patient and carer advice

Medicines for Children leaflet: Co-amoxiclav for bacterial infections www.medicinesforchildren.org.uk/co-amoxiclav-bacterial-infections-0

Profession specific information

Dental practitioners’ formulary

Co-amoxiclav 250/125 Tablets may be prescribed.

Co-amoxiclav 125/31 Suspension may be prescribed.

Co-amoxiclav 250/62 Suspension may be prescribed.

Medicinal forms

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: infusion

Oral suspension

Cautionary and advisory labels

Excipients: May contain Aspartame.

Co-amoxiclav (Non-proprietary)

Clavulanic acid (as Potassium clavulanate) 6.25 mg per 1 mL

Amoxicillin (as Amoxicillin trihydrate) 25 mg per 1 mL

Co-amoxiclav 125mg/31mg/5ml oral suspension

100 ml (£0.00)

5.00

Co-amoxiclav 125mg/31mg/5ml oral suspension sugar free

100 ml (£0.25)

25.00

£1.94

Clavulanic acid (as Potassium clavulanate) 12.5 mg per 1 mL

Amoxicillin (as Amoxicillin trihydrate) 50 mg per 1 mL
Co-amoxiclav 250mg/62mg/5ml oral suspension | 100 ml | £5.00 DT price = £5.00
Co-amoxiclav 250mg/62mg/5ml oral suspension sugar free | 35 ml | £3.00 DT price = £1.73
Clavulanic acid (as Potassium clavulanate) 11.4 mg per 1 ml, Amoxicillin (as Amoxicillin trihydrate) 80 mg per 1 ml | Co-amoxiclav 400mg/57mg/5ml oral suspension sugar free | 35 ml | £4.13 DT price = £4.13 sugar-free | 70 ml | £6.97 DT price = £5.79
▶ Augmentin (GlaxoSmithKline UK Ltd)
Clavulanic acid (as Potassium clavulanate) 6.25 mg per 1 ml, Amoxicillin (as Amoxicillin trihydrate) 25 mg per 1 ml | Augmentin 125/31 SF oral suspension sugar-free | 100 ml | £3.54 DT price = £1.94
Clavulanic acid (as Potassium clavulanate) 12.5 mg per 1 ml, Amoxicillin (as Amoxicillin trihydrate) 50 mg per 1 ml | Augmentin 250/62 SF oral suspension sugar-free | 100 ml | £3.60 DT price = £1.73
▶ Augmentin-Duo (GlaxoSmithKline UK Ltd)
Clavulanic acid (as Potassium clavulanate) 11.4 mg per 1 ml, Amoxicillin (as Amoxicillin trihydrate) 80 mg per 1 ml | Augmentin-Duo 400/57 oral suspension sugar-free | 35 ml | £4.13 DT price = £4.13 sugar-free | 70 ml | £5.79 DT price = £5.79

Tablet
CAUTIONARY AND ADVISORY LABELS 9
▶ Co-amoxiclav (Non-proprietary)
Clavulanic acid (as Potassium clavulanate) 125 mg, Amoxicillin (as Amoxicillin trihydrate) 250 mg | Co-amoxiclav 250mg/125mg tablets | 21 tablet | £6.00 DT price = £1.66 | 100 tablet | no price available
Clavulanic acid (as Potassium clavulanate) 125 mg, Amoxicillin (as Amoxicillin trihydrate) 500 mg | Co-amoxiclav 500mg/125mg tablets | 21 tablet | £12.00 DT price = £1.88
Clavulanic acid (as Potassium clavulanate) 125 mg, Amoxicillin (as Amoxicillin trihydrate) 875 mg | Co-amoxiclav 875mg/125mg tablets | 14 tablet | £18.00 DT price = £6.50
▶ Augmentin (GlaxoSmithKline UK Ltd)
Clavulanic acid (as Potassium clavulanate) 125 mg, Amoxicillin (as Amoxicillin trihydrate) 250 mg | Augmentin 375mg tablets | 21 tablet | £5.03 DT price = £1.86
Clavulanic acid (as Potassium clavulanate) 125 mg, Amoxicillin (as Amoxicillin trihydrate) 500 mg | Augmentin 625mg tablets | 21 tablet | £9.60 DT price = £1.88
Powder for solution for injection
ELECTROLYTES: May contain Potassium, sodium
▶ Co-amoxiclav (Non-proprietary)
Clavulamic acid (as Potassium clavulanate) 100 mg, Amoxicillin (as Amoxicillin sodium) 500 mg | Co-amoxiclav 500mg/100mg powder for solution for injection vials | 10 vial | £14.90
Clavulamic acid (as Potassium clavulanate) 200 mg, Amoxicillin (as Amoxicillin sodium) 1000 mg | Co-amoxiclav 1000mg/200mg powder for solution for injection vials | 10 vial | £29.70
▶ Augmentin Intravenous (GlaxoSmithKline UK Ltd)
Clavulamic acid (as Potassium clavulanate) 100 mg, Amoxicillin (as Amoxicillin sodium) 500 mg | Augmentin Intravenous 600mg powder for solution for injection vials | 10 vial | £10.60
Clavulamic acid (as Potassium clavulanate) 200 mg, Amoxicillin (as Amoxicillin sodium) 1000 mg | Augmentin Intravenous 1.2g powder for solution for injection vials | 10 vial | £10.60

ANTIBACTERIALS ▶ PENICILLINS, MECILLINAM-TYPE

Pivmecillinam hydrochloride

▶ INDICATIONS AND DOSE
Acute uncomplicated cystitis
▶ BY MOUTH
▶ Child (body-weight 40 kg and above): Initially 400 mg for 1 dose, then 200 mg every 8 hours for 3 days
▶ Adult (body-weight 40 kg and above): Initially 400 mg for 1 dose, then 200 mg every 8 hours for 3 days
Chronic or recurrent bacteriuria
▶ BY MOUTH
▶ Child (body-weight 40 kg and above): 400 mg every 6–8 hours

Adult (body-weight 40 kg and above): 400 mg every 6–8 hours

Urinary-tract infections
▶ BY MOUTH
▶ Child (body-weight up to 40 kg): 5–10 mg/kg every 6 hours, alternatively 20–40 mg/kg daily in 3 divided doses

▶ UNLICENSED USE Not licensed for use in children under 3 months.
▶ CONTRA-INDICATIONS Carnitine deficiency · gastro-intestinal obstruction · infants under 3 months · oesophageal strictures
▶ CAUTIONS Avoid in acute porphyrias p. 969
▶ INTERACTIONS → Appendix 1: penicillins
▶ SIDE-EFFECTS
▶ Common or very common Abdominal pain · dizziness · headache · nausea · vomiting
▶ Frequency not known Mouth ulcers · oesophagitis · reduced serum and total body carnitine (especially with long-term or repeated use)
▶ PREGNANCY Not known to be harmful, but manufacturer advises avoid.
▶ BREAST FEEDING Trace amount in milk, but appropriate to use.
▶ MONITORING REQUIREMENTS Liver and renal function tests required in long-term use.
▶ EFFECT ON LABORATORY TESTS False-positive urinary glucose (if tested for reducing substances).
▶ DIRECTIONS FOR ADMINISTRATION Tablets should be swallowed whole with plenty of fluid during meals while sitting or standing.
▶ PATIENT AND CARER ADVICE Patient counselling is advised on administration of pivmecillinam hydrochloride tablets (posture).

▶ MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.
Tablet
CAUTIONARY AND ADVISORY LABELS 9, 21, 27
▶ Selexid (LEO Pharma)
Pivmecillinam hydrochloride 200 mg | Selexid 200mg tablets | 10 tablet | £5.40 DT price = £5.40 | 18 tablet | £9.72

ANTIBACTERIALS ▶ PENICILLINS, PENICILLINASE-RESISTANT

Flucloxacillin

▶ INDICATIONS AND DOSE
Infections due to beta-lactamase-producing staphylococci including otitis externa | Adjunct in pneumonia | Adjunct in impetigo | Adjunct in cellulitis
▶ BY MOUTH
▶ Child 1 month-1 year: 62.5–125 mg 4 times a day
▶ Child 2–9 years: 125–250 mg 4 times a day
▶ Child 10–17 years: 250–500 mg 4 times a day
▶ Adult: 250–500 mg 4 times a day
▶ BY INTRAMUSCULAR INJECTION
▶ Adult: 250–500 mg every 6 hours
▶ BY SLOW INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION
▶ Adult: 0.25–2 g every 6 hourscontinued
### 524 Bacterial infection

#### Endocarditis (in combination with other antibacterial if necessary)
- By slow intravenous injection, or by intravenous infusion
  - Adult (body-weight up to 85 kg): 8 g daily in 4 divided doses
  - Adult (body-weight 85 kg and above): 12 g daily in 6 divided doses

#### Osteomyelitis
- By slow intravenous injection, or by intravenous infusion
  - Adult: Up to 8 g daily in 3–4 divided doses

#### Surgical prophylaxis
- Initially by slow intravenous injection, or by intravenous infusion
  - Adult: 1–2 g, to be administered up to 30 minutes before the procedure, then (by mouth or by intramuscular injection or by slow intravenous injection or by intravenous infusion) 500 mg every 6 hours if required for up to 4 further doses in high risk procedures

#### Staphylococcal lung infection in cystic fibrosis
- By mouth
  - Child: 25 mg/kg 4 times a day (max. per dose 1 g), alternatively 100 mg/kg daily in 3 divided doses; maximum 4 g per day

#### Prevention of Staphylococcus aureus lung infection in cystic fibrosis—primary prevention
- By mouth
  - Child 1 month–3 years: 125 mg twice daily

#### Prevention of Staphylococcus aureus lung infection in cystic fibrosis—secondary prevention
- By mouth
  - Child: 50 mg/kg twice daily (max. per dose 1 g twice daily)

**UNLICENSED USE** Flucloxacillin doses in the BNF may differ from those in product literature.

---

### IMPORTANT SAFETY INFORMATION

#### HEPATIC DISORDERS

Cholestatic jaundice and hepatitis may occur very rarely, up to two months after treatment with flucloxacillin has been stopped. Administration for more than 2 weeks and increasing age are risk factors. Healthcare professionals are reminded that:
- Flucloxacillin should not be used in patients with a history of hepatic dysfunction associated with flucloxacillin
- Flucloxacillin should be used with caution in patients with hepatic impairment
- Careful enquiry should be made about hypersensitivity reactions to beta-lactam antibacterials

#### CAUTIONS
- With intravenous use Accumulation of electrolytes can occur with high doses
- INTERACTIONS → Appendix 1: penicillins
- SIDE-EFFECTS
  - Common or very common Gastrointestinal disturbances
  - Very rare Cholestatic jaundice · hepatitis
- PREGNANCY Not known to be harmful.
- BREAST FEEDING Trace amounts in milk, but appropriate to use.
- HEPATIC IMPAIRMENT Use with caution.
- RENAL IMPAIRMENT
  - In adults Reduce dose if eGFR less than 10 mL/minute/1.73 m².
  - In children Use normal dose every 8 hours if estimated glomerular filtration rate less than 10 mL/minute/1.73 m².

- With intravenous use Accumulation of electrolytes can occur in patients with renal failure.
- EFFECT ON LABORATORY TESTS False-positive urinary glucose (if tested for reducing substances).
- DIRECTIONS FOR ADMINISTRATION For intravenous infusion (FloxaPen®), give intermittently in Glucose 5% or Sodium chloride 0.9%; suggested volume 100 mL given over 30–60 minutes. ViG drip tubing in Glucose 5% or Sodium chloride 0.9%; continuous infusion not usually recommended.

#### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: infusion

#### Oral solution

CAUTIONARY AND ADVISORY LABELS 9, 23

- **Flucloxacillin (Non-proprietary)**
  - Flucloxacillin (as Flucloxacillin sodium) 25 mg per
    - 1 ml Flucloxacillin 125mg/5ml oral solution | 100 ml | £20.99 DT price + £6.58
    - Flucloxacillin 125mg/5ml oral solution sugar free sugar-free | 100 ml | £31.41 DT price + £22.31
    - Flucloxacillin (as Flucloxacillin sodium) 50 mg per
      - 1 ml Flucloxacillin 250mg/5ml oral solution sugar free sugar-free | 100 ml | £36.27 DT price + £26.91
      - Flucloxacillin 250mg/5ml oral solution | 100 ml | £26.04 DT price + £26.04

#### Powder for solution for injection

- **Flucloxacillin (Non-proprietary)**
  - Flucloxacillin (as Flucloxacillin sodium) 250 mg Flucloxacillin 250mg powder for solution for injection vials | 10 vial | £10.43–£12.25
  - Flucloxacillin (as Flucloxacillin sodium) 500 mg Flucloxacillin 500mg powder for solution for injection vials | 10 vial | £20.85–£24.50

#### Capsule

CAUTIONARY AND ADVISORY LABELS 9, 23

- **Flucloxacillin (Non-proprietary)**
  - Flucloxacillin (as Flucloxacillin sodium) 250 mg Flucloxacillin 250mg capsules | 20 capsule | £3.58 | 28 capsule | £5.00
    - DT price = £1.31 | 100 capsule | £17.80
  - Flucloxacillin (as Flucloxacillin sodium) 500 mg Flucloxacillin 500mg capsules | 20 capsule | £7.50 | 28 capsule | £10.50
    - DT price = £2.17 | 100 capsule | £37.50

Combinations available: **Co-fluampicil**, p. 520

### Temocillin

#### INDICATIONS AND DOSE

- Septicaemia | Urinary-tract infections | Lower respiratory-tract infections caused by susceptible Gram-negative bacteria
  - By intramuscular injection, or by intravenous injection, or by intravenous infusion
  - Adult: 1–2 g every 12 hours, give over 3–4 minutes when administered by intravenous injection

#### CAUTIONS

Accumulation of sodium from injection can occur with high doses

- INTERACTIONS → Appendix 1: penicillins
- PREGNANCY Not known to be harmful.
- BREAST FEEDING Trace amounts in milk.

- RENAL IMPAIRMENT 1 g every 12 hours if eGFR 30–60 mL/minute/1.73 m², 1 g every 24 hours if eGFR 10–30 mL/minute/1.73 m², 1 g every 48 hours or 500 mg every 24 hours if eGFR less than 10 mL/minute/1.73 m².
**ANTIBACTERIALS**

**DIRECTIONS FOR ADMINISTRATION**

**DIRECTIONS FOR ADMINISTRATION**

**Antibacterials, including**

**Gram-negative infections resistant to other antibacterials, including those caused by**

**Pseudomonas aeruginosa, Acinetobacter baumanii, and Klebsiella pneumoniae**

- **BY SLOW INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
  - Adult (body-weight up to 60 kg): 50 000–75 000 units/kg daily in 3 divided doses, to be administered into a totally implantable venous access device when giving via slow intravenous injection
  - Adult (body-weight 60 kg and above): 1–2 million units every 8 hours, to be administered into a totally implantable venous access device when giving via slow intravenous injection; maximum 6 million units per day

Adjunct to standard antibacterial therapy for

**Pseudomonas aeruginosa infection in cystic fibrosis**

- **BY INHALATION OF NEBULISED SOLUTION**
  - Adult: 1–2 million units twice daily, adjusted according to response, increased to 2 million units 3 times daily for subsequent respiratory isolates of **Pseudomonas aeruginosa**

- **BY INHALATION OF POWDER**
  - Adult: 1.66 million units twice daily

**PROMIXIN® INJECTION**

Gram-negative infections resistant to other antibacterials, including those caused by **Pseudomonas aeruginosa, Acinetobacter baumanii, Klebsiella pneumoniae**

- **BY SLOW INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
  - Adult: 9 million units daily in 2–3 divided doses, to be administered into a totally implantable venous access device when giving via slow intravenous injection, an initial loading dose of 9 million units (up to max. 12 million units, if adequate renal function) should be used in those who are critically ill, consult product literature for details

**CONTRA-INDICATIONS**

- **Myasthenia gravis**

**CAUTIONS**

**GENERAL CAUTIONS**

- **Acute porphyrias p. 969**

**SPECIFIC CAUTIONS**

- When used by inhalation: Severe haemoptysis—risk of further haemorrhage

- **INTERACTIONS**
  - Appendix 1: colistimethate sodium

**SIDE-EFFECTS**

- **Dose-related side-effects**
  - The major adverse effects are dose-related neurotoxicity and nephrotoxicity.

- **PREGNANCY**
  - When used by inhalation: Clinical use suggests probably safe.
  - With intravenous use: Use only if potential benefit outweighs risk.

- **BREAST FEEDING**
  - Present in milk but poorly absorbed from gut; manufacturers advise avoid (or use only if potential benefit outweighs risk).

- **RENAL IMPAIRMENT**
  - With intravenous use: Reduce dose.
  - With intravenous use: In renal impairment, monitor plasma colistimethate sodium concentration during parenteral treatment—consult product literature. Recommended ‘peak’ plasma colistimethate sodium concentration (approx. 1 hour after intravenous injection or infusion) 5–15 mg/litre; pre-dose (‘trough’) concentration 2–6 mg/litre.

**MONITORING REQUIREMENTS**

- With intravenous use: Monitor renal function.

- When used by inhalation: Measure lung function before and after initial dose of colistimethate sodium and monitor for bronchospasm; if bronchospasm occurs in a patient not using a bronchodilator, repeat test using a bronchodilator before the dose of colistimethate sodium.

**DIRECTIONS FOR ADMINISTRATION**

- When used by inhalation: Other inhaled drugs should be administered before colistimethate sodium. For **nebulisation** administer required dose in 2–4 mL of sodium chloride 0.9% (or water for injections) or a 1:1 mixture of sodium chloride 0.9% and water for injection.

- With intravenous use: For **intravenous infusion** (Colomycin®, Promixin®), give intermittently in Sodium chloride 0.9%
Colistimethate sodium is included in some preparations for topical application.

**Patient and carer advice**

**Driving and skilled tasks**
Manufacturer advises patients and carers should be counselled on the effects on driving and performance of skilled tasks—increased risk of dizziness, confusion and visual disturbances.

**When used by inhalation**
Patient should be advised to rinse mouth with water after each dose of dry powder inhalation. Patients or carers should be given advice on how to administer colistimethate sodium; first dose should be given under medical supervision.

**National funding/access decisions**

**NICE technology appraisals (TAs)**

- **Colistimethate sodium by dry powder inhalation for pseudomonal lung infection in cystic fibrosis (March 2013)**

  Colistimethate sodium dry powder for inhalation is recommended for chronic pulmonary infection caused by *Pseudomonas aeruginosa* in patients with cystic fibrosis who would benefit from continued treatment, but do not tolerate the drug in its nebulised form. The manufacturer must provide colistimethate sodium dry powder for inhalation at the discount agreed as part of the patient access scheme to primary, secondary and tertiary care in the NHS. Patients currently receiving colistimethate sodium dry powder for inhalation can continue treatment until they and their clinician consider it appropriate to stop.

  www.nice.org.uk/TA276

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- Colomycin (Forest Laboratories UK Ltd)
  - Colistin sulfate 1500000 unit Colomycin 1.5million unit tablets | 50 unit dose | £55.00

**Powder for solution for injection**

**Electrolytes:** May contain Sodium

- **Colistimethate sodium (Non-proprietary)**
  - Colistimethate sodium 1000000 unit Colistimethate 1million unit powder for solution for injection vials | 10 vial (PSt) £19.75 | 10 vial (PSt) £16.79 (hospital only)
  - Colomycin (Teva UK Ltd)
  - Colistimethate sodium 1000000 unit Colistomycin 1million unit powder for solution for injection vials | 10 vial (PSt) £18.00
  - Colistimethate sodium 2000000 unit Colistomycin 2million unit powder for solution for injection vials | 10 vial (PSt) £32.40
  - Promixin (Profile Pharma Ltd)
  - Colistimethate sodium 1000000 unit Promixin 1million unit powder for solution for injection vials | 10 vial (PSt) £30.00 (hospital only)
  - Colambreathe (Pari Medical Ltd)
  - Colistimethate sodium 1000000 unit Colambreathe 1 MIU powder for nebuliser solution unit dose vials | 56 unit dose (PSt) £180.53
  - Colistimethate sodium 2000000 unit Colambreathe 2 MIU powder for nebuliser solution unit dose vials | 56 unit dose (PSt) £261.72
  - Promixin (Profile Pharma Ltd)
  - Colistimethate sodium 1000000 unit Promixin 1million unit powder for nebuliser solution unit dose vials | 30 unit dose (PSt) £168.00 DT price = £168.00

**Powder for nebuliser solution**

- **ColiFin (Pari Medical Ltd)**
  - Colistimethate sodium 1000000 unit ColiFin 1 MIU powder for nebuliser solution unit dose vials | 56 unit dose (PSt) £180.53
  - Colistimethate sodium 2000000 unit ColiFin 2 MIU powder for nebuliser solution unit dose vials | 56 unit dose (PSt) £261.72
  - Promixin (Profile Pharma Ltd)
  - Colistimethate sodium 1000000 unit Promixin 1million unit powder for nebuliser solution unit dose vials | 30 unit dose (PSt) £168.00 DT price = £168.00

**Inhalation powder**

- Colobreathe (Teva UK Ltd)
  - Colistimethate sodium 1662500 unit Colobreathe 1,662,500 unit inhalation powder capsule | 56 capsules (PSt) £968.80

**Antibacterials > Quinolones**

**Quinolones**

**Overview**

Nalidixic acid p. 530 and norfloxacin p. 530 are effective in uncomplicated urinary-tract infections.

Ciprofloxacin p. 527 is active against both Gram-positive and Gram-negative bacteria. It is particularly active against Gram-negative bacteria, including salmonella, shigella, campylobacter, neisseria, and pseudomonas. Ciprofloxacin has only moderate activity against Gram-positive bacteria such as *Streptococcus pneumoniae* and *Enterococcus faecalis*; it should not be used for pneumococcal pneumonia. It is active against chlamydia and some mycobacteria. Most anaerobic organisms are not susceptible. Ciprofloxacin can be used for respiratory tract infections (but not for pneumococcal pneumonia), urinary-tract infections, infections of the gastro-intestinal system (including typhoid fever), bone and joint infections, gonorrhoea and septicemia caused by sensitive organisms.

Ofloxacin p. 530 is used for urinary-tract infections, lower respiratory-tract infections, gonorrhoea, and non-gonococcal urethritis and cervicitis.

Levofloxacin p. 528 is active against Gram-positive and Gram-negative organisms. It has greater activity against pneumococci than ciprofloxacin. Levofloxacin is licensed for the treatment of acute sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumonia, but it should only be considered for these infections when first-line treatment cannot be used or is ineffective. Levofloxacin is also licensed for the treatment of urinary-tract infections.

Although ciprofloxacin, levofloxacin, moxifloxacin p. 529, and ofloxacin are licensed for skin and soft-tissue infections, many staphylococci are resistant to the quinolones and their use should be avoided in MRSA infections.

Moxifloxacin should be reserved for the treatment of sinusitis, community-acquired pneumonia, exacerbations of chronic bronchitis, mild to moderate pelvic inflammatory disease, or complicated skin and soft-tissue infections which have failed to respond to other antibacterials or for patients who cannot be treated with other antibacterials. It has been associated with QT interval prolongation and life-threatening hepatotoxicity. Moxifloxacin is active against Gram-positive and Gram-negative organisms. It has greater activity against Gram-positive organisms, including pneumococci, than ciprofloxacin. Moxifloxacin is not active against *Pseudomonas aeruginosa* or meticillin-resistant *Staphylococcus aureus* (MRSA).

**Quinolones**

**Important safety information**

The CSM has warned that quinolones may induce convulsions in patients with or without a history of convulsions; taking NSAIDs at the same time may also induce them.

**Tendon damage**

Tendon damage (including rupture) has been reported rarely in patients receiving quinolones. Tendon rupture may occur within 48 hours of starting treatment; cases have also been reported several months after stopping a quinolone. Healthcare professionals are reminded that:
Ciprofloxacin

**INDICATIONS AND DOSE**

**Fistulating Crohn's disease**
- **BY MOUTH**
  - Adult: 500 mg twice daily

**Respiratory-tract infections**
- **BY MOUTH**
  - Adult: 500–750 mg twice daily
- **BY INTRAVENOUS INFUSION**
  - Adult: 400 mg every 8–12 hours, to be given over 60 minutes

**Pseudomonal lower respiratory-tract infection in cystic fibrosis**
- **BY MOUTH**
  - Adult: 750 mg twice daily

- **Urinary-tract infections**
  - **BY MOUTH**
    - Adult: 250–750 mg twice daily
  - **BY INTRAVENOUS INFUSION**
    - Adult: 400 mg every 8–12 hours, to be given over 60 minutes

**Acute uncomplicated cystitis in women**
- **BY MOUTH**
  - Adult: 250 mg twice daily for 3 days

**Acute or chronic prostatitis**
- **BY MOUTH**
  - Adult: 500 mg twice daily for 28 days
- **BY INTRAVENOUS INFUSION**
  - Adult: 400 mg every 8–12 hours, to be given over 60 minutes

**Gonorrhoea**
- **BY MOUTH**
  - Adult: 500 mg for 1 dose

**Most other infections**
- **BY MOUTH**
  - Adult: Initially 500 mg twice daily; increased to 750 mg twice daily, in severe or deep-seated infection
- **BY INTRAVENOUS INFUSION**
  - Adult: 400 mg every 8–12 hours, to be given over 60 minutes

**Surgical prophylaxis**
- **BY MOUTH**
  - Adult: 750 mg, to be taken 60 minutes before procedure

**Anthrax (treatment and post-exposure prophylaxis)**
- **BY MOUTH**
  - Adult: 500 mg twice daily
- **BY INTRAVENOUS INFUSION**
  - Adult: 400 mg every 12 hours, to be given over 60 minutes

**Prevention of secondary case of meningococcal meningitis**
- **BY MOUTH**
  - Child 1 month–4 years: 30 mg/kg (max. per dose 125 mg) for 1 dose
  - Child 5–11 years: 250 mg for 1 dose
  - Child 12–17 years: 500 mg for 1 dose
  - Adult: 500 mg for 1 dose

**UNLICENSED USE**

**CAUTIONS**
- Acute myocardial infarction (risk factor for QT interval prolongation) • avoid excessive alkalinity of urine (risk of crystalluria) • bradycardia (risk factor for QT interval prolongation) • congenital long QT syndrome (risk factor for QT interval prolongation) • electrolyte disturbances (risk factor for QT interval prolongation) • ensure adequate fluid intake (risk of crystalluria) • heart failure with reduced left ventricular ejection fraction (risk factor for QT interval prolongation) • history of symptomatic arrhythmias (risk factor for QT interval prolongation)

**INTERACTIONS**
- **Appendix 1: quinolones**

**SIDE-EFFECTS**
- **Common or very common**
  - Flatulence
- **Rare**
  - Abnormal dreams • chest pain • dysphagia • dysphonia • erythema nodosum • hot flushes • hyperglycaemia • hypoglycaemia • oedema • pancreatitis • sweating • syncope • tachycardia

**ALERTS AND INTERACTIONS**
- **Contra-indicated** in patients with a history of tendon disorders related to quinolone use;
- patients over 60 years of age are more prone to tendon damage;
- the risk of tendon damage is increased by the concomitant use of corticosteroids;
- if tendinitis is suspected, the quinolone should be discontinued immediately.

**SIDE-EFFECTS**
- **Common or very common**
  - Diarrhoea • dizziness • headache • nausea • vomiting
- **Uncommon**
  - Abdominal pain • anorexia • anxiety • arthralgia • asthenia • blood disorders • confusion • depression • disturbances in taste • disturbances in vision • dyspepsia • eosinophilia • hallucinations • leucopenia • myalgia • rash • sleep disturbances • thrombocytopenia • tremor
- **Rare**
  - Antibiotic-associated colitis • convulsions • disturbances in hearing • disturbances in smell • dysphonia • hepatic dysfunction • hepatitis • hypotension • interstitial nephritis • jaundice • photosensitivity • psychosis • renal failure • symptoms of peripheral neuropathy (sometimes irreversible) • tendon damage • tendon inflammation • vasculitis
- **Very rare**
  - Stevens-Johnson syndrome • toxic epidermal necrolysis

**ALLERGY AND CROSS-SENSITIVITY**
- Use of quinolones contra-indicated in quinolone hypersensitivity.

**PREGNANCY**
- Avoid in pregnancy—shown to cause arthropathy in animal studies; safer alternatives are available.

**CONTRA-INDICATIONS**
- History of tendon disorders related to quinolone use

**CAUTIONS**
- Can prolong the QT interval - children or adolescents (arthropathy has developed in weight-bearing joints in young animals) - conditions that predispose to seizures - diabetes (may affect blood glucose) - exposure to excessive sunlight should be avoided (discontinue if photosensitivity occurs) • G6PD deficiency • history of epilepsy • myasthenia gravis (risk of exacerbation)

**CAUTIONS, FURTHER INFORMATION**
- In children Quinolones cause arthropathy in the weight-bearing joints of immature animals and are therefore generally not recommended in children and growing adolescents. However, the significance of this effect in humans is uncertain and in some specific circumstances short-term use of either ciprofloxacin or nalidixic acid may be justified in children.

**SIDE-EFFECTS, FURTHER INFORMATION**
- The drug should be discontinued if psychiatric, neurological, or hypersensitivity reactions (including severe rash) occur.

**INTERACTIONS**
- **Appendix 1: quinolones**

**SIDE-EFFECTS**
- **Common or very common**
  - Flatulence
- **Rare**
  - Abnormal dreams • chest pain • dysphagia • dysphonia • erythema nodosum • hot flushes • hyperglycaemia • hypoglycaemia • oedema • pancreatitis • sweating • syncope • tachycardia
- **Very rare**
  - Intracranial hypertension • movement disorders • tenosynovitis • tinnitus • vasculitis (in children)
- **Frequency not known**
  - Peripheral neuropathy • polyneuropathy

**REPRODUCTION**
- **Pregnancy**
  - Avoid in pregnancy—shown to cause arthropathy in animal studies; safer alternatives are available.

**ACKNOWLEDGEMENTS**
- **G6PD deficiency**

**ORGANISATIONS**
- **BNF**
  - 74

**APPENDICES**
- **Appendix 1: quinolones**

**BACTERIAL INFECTION**
- **527**

**INFECTION**
- **5**

**ADULTS**
- **526**

**2005**

**REFERENCES**
- **BNF 74**
528 Bacterial infection

- **PREGNANCY** A single dose of ciprofloxacin may be used for the prevention of a secondary case of meningococcal meningitis.

- **BREAST FEEDING** Amount too small to be harmful but manufacturer advises avoid.

- **RENAL IMPAIRMENT**
  - With oral use in adults
  - With intravenous use in adults
  - With oral use in adults
  - In children
  - Reduce dose if estimated glomerular filtration rate less than 30 mL/minute/1.73 m²—consult product literature.

- **PRESCRIBING AND DISPENSING INFORMATION** Flavours of oral liquid formulations may include strawberry.

- **PATIENT AND CARER ADVICE**
  - Driving and skilled tasks
  - May impair performance of skilled tasks (e.g. driving); effects enhanced by alcohol.
  - Medicines for Children leaflet: Ciprofloxacin for bacterial infections www.medicinesforchildren.org.uk/ciprofloxacin-
bacterial-infections-0

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

- **Tablet**
  - **CAUTIONARY AND ADVISORY LABELS** 7, 9, 25
  - **Ciprofloxacin (Non-proprietary)**
    - Ciprofloxacin (as Ciprofloxacin hydrochloride) 100 mg Ciprofloxacin 100mg tablets | 6 tablet POM £4.50 DT price = £1.90
    - Ciprofloxacin (as Ciprofloxacin hydrochloride) 250 mg Ciprofloxacin 250mg tablets | 10 tablet POM £7.25 DT price = £0.75 | 20 tablet POM £11.20 | 100 tablet POM no price available
    - Ciprofloxacin (as Ciprofloxacin hydrochloride) 500 mg Ciprofloxacin 500mg tablets | 10 tablet POM £14.00 DT price = £0.89 | 20 tablet POM £21.23 | 100 tablet POM no price available
    - Ciprofloxacin (as Ciprofloxacin hydrochloride) 750 mg Ciprofloxacin 750mg tablets | 10 tablet POM £20.00 DT price = £0.80 | 20 tablet POM no price available
  - **Ciproxina** (Bayer Plc)
    - Ciprofloxacin (as Ciprofloxacin hydrochloride) 250 mg Ciproxina 250mg tablets | 10 tablet POM £6.59 DT price = £0.75
    - Ciprofloxacin (as Ciprofloxacin hydrochloride) 500 mg Ciproxina 500mg tablets | 10 tablet POM £12.49 DT price = £0.89
    - Ciprofloxacin (as Ciprofloxacin hydrochloride) 750 mg Ciproxina 750mg tablets | 10 tablet POM £17.78 DT price = £0.80

- **Oral suspension**
  - **CAUTIONARY AND ADVISORY LABELS** 7, 9, 25
  - **Ciproxina** (Bayer Plc)
    - Ciprofloxacin 50 mg per 1 ml Ciproxina 250mg/5ml oral suspension | 100 ml POM £21.29 DT price = £21.29

- **Solution for infusion**
  - **ELECTROLYTES:** May contain Sodium
  - **Ciprofloxacin (Non-proprietary)**
    - Ciprofloxacin (as Ciprofloxacin lactate) 2 mg per 1 ml Ciprofloxacin 400mg/200ml solution for infusion bottles | 5 bottle POM £15.50
    - Ciprofloxacin 400mg/200ml solution for infusion vials | 1 vial POM £19.79 (Hospital only)
    - Ciprofloxacin 200mg/100ml solution for infusion bottles | 10 bottle POM £14.45
  - **Ciproxina** (Bayer Plc)
    - Ciprofloxacin (as Ciprofloxacin lactate) 2 mg per 1 ml Ciproxina Infusion 100mg/50ml solution for infusion bottles | 1 bottle POM £7.61 (Hospital only)
    - Ciprofloxacin Infusion 200mg/100ml solution for infusion bottles | 5 bottle POM £11.43 (Hospital only)
    - Ciprofloxacin Infusion 200mg/100ml solution for infusion bottles | 5 bottle POM £75.06 (Hospital only)

- **Infusion**
  - **Ciprofloxacin (Non-proprietary)**
    - Ciprofloxacin (as Ciprofloxacin lactate) 2 mg per 1 ml Ciprofloxacin 400mg/200ml infusion bags | 10 bag POM £200.00

### Levofoxacin

- **INDICATIONS AND DOSE**
  - **Acute sinusitis**
    - **BY MOUTH**
      - Adult: 500 mg once daily for 10–14 days
  - **Acute exacerbation of chronic bronchitis**
    - **BY MOUTH**
      - Adult: 500 mg once daily for 7–10 days
  - **Community-acquired pneumonia**
    - **BY MOUTH**
      - Adult: 500 mg 1–2 times a day for 7–14 days
      - **BY INTRAVENOUS INJECTION**
        - Adult: 500 mg 1–2 times a day, to be given over at least 60 minutes
  - **Urinary-tract infections**
    - **BY MOUTH**
      - Adult: 500 mg once daily for 7–14 days
    - **Urinary-tract infections (uncomplicated infection)**
      - **BY MOUTH**
        - Adult: 250 mg once daily for 3 days
    - **Complicated urinary-tract infections**
      - **BY INTRAVENOUS INJECTION**
        - Adult: 500 mg once daily, to be given over at least 60 minutes
  - **Chronic prostatitis**
    - **BY MOUTH**
      - Adult: 500 mg once daily for 28 days
      - **BY INTRAVENOUS INJECTION**
        - Adult: 500 mg once daily, to be given over at least 60 minutes
    - **Complicated skin infections | Complicated soft-tissue infections**
      - **BY MOUTH**
        - Adult: 500 mg 1–2 times a day for 7–14 days
      - **BY INTRAVENOUS INJECTION**
        - Adult: 500 mg 1–2 times a day, to be given over at least 60 minutes
    - **Inhalation of anthrax (treatment and post-exposure prophylaxis)**
      - **BY MOUTH**
        - Adult: 500 mg once daily for 8 weeks
      - **BY INTRAVENOUS INJECTION**
        - Adult: 500 mg once daily, to be given over at least 60 minutes

- **CAUTIONS** Acute myocardial infarction (risk factor for QT interval prolongation) · bradycardia (risk factor for QT interval prolongation) · congenital long QT syndrome (risk factor for QT interval prolongation) · electrolyte disturbances (risk factor for QT interval prolongation) · heart failure with reduced left ventricular ejection fraction (risk factor for QT interval prolongation) · history of psychiatric illness · history of symptomatic arrhythmias (risk factor for QT interval prolongation) · risk factors for QT interval prolongation

- **INTERACTIONS** → Appendix 1: quinolones

- **SIDE-EFFECTS**
  - **Common or very common** Constipation · flatulence · hyperhidrosis
  - **Uncommon** Dyspnoea
  - **Rare** Abnormal dreams · hypoglycaemia · palpitation · tachycardia · tinnitus

---

Downloaded from www.medicalbr.com
Frequency not known Benign intracranial hypertension - extrapyramidal symptoms - hyperglycaemia - peripheral neuropathy - pneumonitis - potentially life-threatening hepatic failure - rhabdomyolysis - stomatitis - syncope
With intravenous use Local reactions - transient hypotension

RENAL IMPAIRMENT

With intravenous use

BR EAST FEEDING

Manufacturer advises avoid.

RENAL IMPAIRMENT

Usual initial dose, then use half normal dose if eGFR 20–50 mL/minute/1.73 m²; consult product literature if eGFR less than 20 mL/minute/1.73 m².

PATIENT AND CARER ADVICE

Driving and skilled tasks May impair performance of skilled tasks (e.g. driving).

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS 6, 9, 25

Levofloxacin (Non-proprietary)

Levofloxacin (as Levofloxacin hemihydrate) 250 mg

Levofloxacin 250mg tablets | 5 tablet (Po) £13.23 | 10 tablet (Po) £26.45

Levofloxacin (as Levofloxacin hemihydrate) 500 mg

Levofloxacin 500mg tablets | 5 tablet (Po) £26.45 | 10 tablet (Po) £53.06

Evoxil (Beacon Pharmaceuticals Ltd)

Levofloxacin (as Levofloxacin hemihydrate) 250 mg

Evoxil 250mg tablets | 5 tablet (Po) £7.23 | 10 tablet (Po) £14.45 DT price = £7.03

Levofloxacin (as Levofloxacin hemihydrate) 500 mg

Evoxil 500mg tablets | 5 tablet (Po) £12.93 | 10 tablet (Po) £25.85 DT price = £18.53

Tavanic (Sanofi)

Levofloxacin (as Levofloxacin hemihydrate) 250 mg

Tavanic 250mg tablets | 5 tablet (Po) £7.23 | 10 tablet (Po) £14.45 DT price = £7.03

Levofloxacin (as Levofloxacin hemihydrate) 500 mg

Tavanic 500mg tablets | 5 tablet (Po) £12.93 | 10 tablet (Po) £25.85 DT price = £18.53

Solution for infusion

ELECTROLYTES: May contain Sodium

Levofloxacin (as Levofloxacin hemihydrate) 5 mg per

1 ml Levofloxacin 500mg/100ml solution for infusion bottles | 10 bottle (Po) no price available

Evoxil (Beacon Pharmaceuticals Ltd)

Levofloxacin (as Levofloxacin hemihydrate) 5 mg per 1 ml

Evoxil 500mg/100ml solution for infusion vials | 1 vial (Po) £26.40

Infusion

Levofloxacin (Non-proprietary)

Levofloxacin (as Levofloxacin hemihydrate) 5 mg per

1 ml Levofloxacin 500mg/100ml infusion bags | 20 bag (Po) £52.00

Complicated skin and soft-tissue infections which have failed to respond to other antibacterials or for patients who cannot be treated with other antibacterials

BY MOUTH

Adult: 400 mg once daily for 7–21 days

BY INTRAVENOUS INFUSION

Adult: 400 mg once daily for 7–21 days, to be given over 60 minutes

CONTRA-INDICATIONS

Acute myocardial infarction (risk factor for QT interval prolongation) - bradycardia (risk factor for QT interval prolongation) - congenital long QT syndrome (risk factor for QT interval prolongation) - electrolyte disturbances (risk factor for QT interval prolongation) - heart failure with reduced left ventricular ejection fraction (risk factor for QT interval prolongation) - history of symptomatic arrhythmias (risk factor for QT interval prolongation)

INTERACTIONS

Appendix 1: quinolones

SIDE-EFFECTS

Common or very common Angina - arrhythmias - constipation - flatulence - gastritis - hyperlipidaemia - palpitation - sweating - vasodilatation

Uncommon Dyspnoea

Rare Abnormal dreams - amnesia - dysphagia - hyperglycaemia - hypertension - hyperuricaemia - incoordination - myopathy - oedema - peripheral neuropathy - stomatitis - syncope

Very rare Potentially life-threatening hepatic failure - rhabdomyolysis

Frequency not known

With intravenous use Pain at injection site - phlebitis at injection site

BR EAST FEEDING

Manufacturer advises avoid—present in milk in animal studies.

HEPATIC IMPAIRMENT

Manufacturer advises avoid in severe impairment.

PATIENT AND CARER ADVICE

Driving and skilled tasks May impair performance of skilled tasks (e.g. driving).

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS 6, 9

Moxifloxacin (as Moxifloxacin hydrochloride) 400 mg

Moxifloxacin 400mg tablets | 5 tablet (Po) £13.15 DT price = £10.05

Avelox (Bayer Plc)

Moxifloxacin (as Moxifloxacin hydrochloride) 400 mg

Avelox 400mg tablets | 5 tablet (Po) £12.43 DT price = £10.05

Solution for infusion

ELECTROLYTES: May contain Sodium

Avelox (Bayer Plc)

Moxifloxacin (as Moxifloxacin hydrochloride) 1.6 mg per

1 ml Avelox 400mg/250ml solution for infusion bottles | 1 bottle (Po) £39.95 (Hospital only) | 5 bottle (Po) £199.75 (Hospital only)

Infusion

Moxifloxacin (Non-proprietary)

Moxifloxacin (as Moxifloxacin hydrochloride) 1.6 mg per

1 ml Avelox IV. 400mg/250ml infusion bags | 1 bag (Po) no price available

Moxifloxacin

INDICATIONS AND DOSE

Sinusitis

BY MOUTH

Adult: 400 mg once daily for 7 days

Community-acquired pneumonia

BY MOUTH

Adult: 400 mg once daily for 7–14 days

BY INTRAVENOUS INFUSION

Adult: 400 mg once daily for 7–14 days, to be given over 60 minutes

Exacerbations of chronic bronchitis

BY MOUTH

Adult: 400 mg once daily for 5–10 days

Mild to moderate pelvic inflammatory disease

BY MOUTH

Adult: 400 mg once daily for 14 days
**Nalidixic acid**

**INDICATIONS AND DOSE**

**Urinary-tract infections**
- **BY MOUTH**
  - Adult: 900 mg every 6 hours for 7 days, then reduced to 600 mg every 6 hours for prolonged therapy in chronic infections

**CAUTIONS** Acute myocardial infarction (risk factor for QT interval prolongation) - avoid in acute porphyrias p. 969 - bradycardia (risk factor for QT interval prolongation) - congenital long QT syndrome (risk factor for QT interval prolongation) - electrolyte disturbances (risk factor for QT interval prolongation) - heart failure with reduced left ventricular ejection fraction (risk factor for QT interval prolongation) - history of symptomatic arrhythmias (risk factor for QT interval prolongation)

**INTERACTIONS** → Appendix 1: quinolones

**SIDE-EFFECTS** Cranial nerve palsy - increased intracranial pressure - metabolic acidosis - peripheral neuropathy - toxic psychosis

**BREAST FEEDING** Risk to infant very small but one case of haemolytic anaemia reported.

**HEPATIC IMPAIRMENT** Manufacturer advises caution in liver disease.

**RENAL IMPAIRMENT** Use with caution; avoid if eGFR less than 20 mL/minute/1.73 m².

**MONITORING REQUIREMENTS** Monitor blood counts, renal and liver function if treatment exceeds 2 weeks.

**EFFECT ON LABORATORY TESTS** False positive urinary glucose (if tested for reducing substances).

**PRESCRIBING AND DISPENSING INFORMATION** Flavours of oral liquid formulations may include raspberry and strawberry.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

No licensed medicines listed.

---

**Norfloxacin**

**INDICATIONS AND DOSE**

**Urinary-tract infections**
- **BY MOUTH**
  - Adult: 400 mg twice daily for 7–10 days (for 3 days for uncomplicated infections in women)

**Chronic relapsing lower urinary-tract infections**
- **BY MOUTH**
  - Adult: 400 mg twice daily for up to 12 weeks; reduced to 400 mg once daily, if adequate suppression within first 4 weeks

**Chronic prostatitis**
- **BY MOUTH**
  - Adult: 400 mg twice daily for 28 days

**CAUTIONS** Acute myocardial infarction (risk factor for QT interval prolongation) - bradycardia (risk factor for QT interval prolongation) - congenital long QT syndrome (risk factor for QT interval prolongation) - electrolyte disturbances (risk factor for QT interval prolongation) - heart failure with reduced left ventricular ejection fraction (risk factor for QT interval prolongation) - history of symptomatic arrhythmias (risk factor for QT interval prolongation)

**INTERACTIONS** → Appendix 1: quinolones

---

**Ofloxacin**

**INDICATIONS AND DOSE**

**Urinary-tract infections**
- **BY MOUTH**
  - Adult: 200–400 mg daily, preferably taken in the morning; increased if necessary to 400 mg twice daily, in upper urinary tract infections

**Complicated urinary-tract infection**
- **BY INTRAVENOUS INFUSION**
  - Adult: 400 mg daily, increased if necessary to 400 mg twice daily, dose increased for severe or complicated infections, to be given over at least 30 minutes for each 200 mg

**Acute or chronic prostatitis**
- **BY MOUTH**
  - Adult: 200 mg twice daily for 28 days

**Lower respiratory-tract infections**
- **BY MOUTH**
  - Adult: 400 mg daily, dose preferably taken in the morning, then increased if necessary to 400 mg twice daily

**BY INTRAVENOUS INFUSION**
- Adult: 200 mg twice daily, increased to 400 mg twice daily, dose to be increased for severe or complicated infections, to be given over at least 30 minutes for each 200 mg

**Skin and soft-tissue infections**
- **BY MOUTH**
  - Adult: 400 mg twice daily

**Uncomplicated gonorrhoea**
- **BY MOUTH**
  - Adult: 400 mg as a single dose

**Uncomplicated genital chlamydial infection | Non-gonococcal urethritis**
- **BY MOUTH**
  - Adult: 400 mg daily for 7 days, dose may be taken as a single daily dose or in divided doses

**Pelvic inflammatory disease**
- **BY MOUTH**
  - Adult: 400 mg twice daily for 14 days
Septicaemia

- BY INTRAVENOUS INFUSION
- Adult: 200 mg twice daily, increased if necessary to 400 mg twice daily, dose to be increased for severe or complicated infections, to be given over at least 30 minutes for each 200 mg

- CAUTIONS
  - Acute myocardial infarction (risk factor for QT interval prolongation) - bradycardia (risk factor for QT interval prolongation) - congenital long QT syndrome (risk factor for QT interval prolongation) - electrolyte disturbances (risk factor for QT interval prolongation) - heart failure with reduced left ventricular ejection fraction (risk factor for QT interval prolongation) - history of psychiatric illness - history of symptomatic arrhythmias (risk factor for QT interval prolongation)

- INTERACTIONS
  - Appendix 1: quinolones

- SIDE-EFFECTS
  - Common or very common: Cough - eye irritation - nasopharyngitis
  - Rare: Abnormal dreams - arrhythmias - bronchospasm - dyspnoea - hot flushes - hyperhidrosis
  - Very rare: Extrapyramidal symptoms - neuropathy - tinnitus
  - Frequency not known: Changes in blood sugar - myopathy - pneumonitis - rhabdomyolysis
  - With intravenous use: Hypotension - local reactions - thrombophlebitis

- BREAST FEEDING: Amount probably too small to be harmful but manufacturer advises avoid.

- HEPATIC IMPAIRMENT: Use with caution; elimination may be reduced in severe impairment.

- RENAL IMPAIRMENT: Usual initial dose, then use half normal dose if eGFR 20–50 mL/minute/1.73 m²; 100 mg every 24 hours if eGFR less than 20 mL/minute/1.73 m²

- PATIENT AND CARER ADVICE
  - Driving and skilled tasks: May affect performance of skilled tasks (e.g. driving); effects enhanced by alcohol.

- MEDICINAL FORMS
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

### Tablet

**CAUTIONARY AND ADVISORY LABELS** 6, 9, 11

- **Ofloxacin (Non-proprietary)**
  - Ofloxacin 200 mg: 200 mg tablets | 10 tablet POM £6.75
  - Ofloxacin 400 mg: 400 mg tablets | 5 tablet POM £12.80

- **Tarivid (Sanofi)**
  - Ofloxacin 200 mg: 200 mg tablets | 10 tablet POM £7.53 DT price = £6.71
  - Ofloxacin 400 mg: 400 mg tablets | 5 tablet POM £15.05

- **Solution for infusion**
  - **Tarivid (Sanofi)**
    - Ofloxacin (as Ofloxacin hydrochloride) 2 mg per 1 ml: Tarivid 200mg/100ml solution for infusion bottles | 1 bottle POM £16.16

### ANTIBACTERIALS > SULFONAMIDES

#### Co-trimoxazole

- **DRUG ACTION**: Sulfamethoxazole and trimethoprim are used in combination (as co-trimoxazole) because of their synergistic activity (the importance of the sulfonamides has decreased as a result of increasing bacterial resistance and their replacement by antibacterials which are generally more active and less toxic).

- **INDICATIONS AND DOSE**

  **Treatment of susceptible infections**

  - **BY MOUTH**
    - Child 6 weeks–5 months: 120 mg twice daily, alternatively 24 mg/kg twice daily
    - Child 6 months–5 years: 240 mg twice daily, alternatively 24 mg/kg twice daily
    - Child 6–11 years: 480 mg twice daily, alternatively 24 mg/kg twice daily
    - Child 12–17 years: 960 mg twice daily
    - Adult: 960 mg twice daily

  - **BY INTRAVENOUS INFUSION**
    - Adult: 960 mg every 12 hours, increased to 1.44 g every 12 hours, increased dose used in severe infection

  **Treatment of Pneumocystis jirovecii (Pneumocystis carinii) infections (undertaken where facilities for appropriate monitoring available—consult microbiologist and product literature)**

  - **BY MOUTH, OR BY INTRAVENOUS INFUSION**
    - Child: 120 mg/kg daily in 2–4 divided doses for 14–21 days, oral route preferred for children
    - Adult: 120 mg/kg daily in 2–4 divided doses for 14–21 days

  **Prophylaxis of Pneumocystis jirovecii (Pneumocystis carinii) infections**

  - **BY MOUTH**
    - Child: 450 mg/m² twice daily (max. per dose 960 mg twice daily) for 3 days of the week (either consecutively or on alternate days), dose regimens may vary, consult local guidelines
    - Adult: 960 mg once daily, reduced if not tolerated to 480 mg once daily, alternatively 960 mg once daily on alternate days, alternate day dose to be given 3 times weekly, alternatively 960 mg twice a day on alternate days, alternate day dose to be given 3 times weekly

  **DOSE EQUIVALENCE AND CONVERSION**

  - 480 mg of co-trimoxazole consists of sulfamethoxazole 400 mg and trimethoprim 80 mg.


### IMPORTANT SAFETY INFORMATION

**RESTRICTIONS ON THE USE OF CO-TRIMOXAZOLE**

Co-trimoxazole is the drug of choice in the prophylaxis and treatment of *Pneumocystis jirovecii (Pneumocystis carinii)* pneumonia; it is also indicated for nocardiosis, *Stenotrophomonas maltophilia* infection [unlicensed indication], and toxoplasmosis. It should only be considered for use in acute exacerbations of chronic bronchitis and infections of the urinary tract when there is bacteriological evidence of sensitivity to co-trimoxazole and good reason to prefer this combination to a single antibacterial; similarly it should only be used in acute otitis media in children when there is good reason to prefer it. Co-trimoxazole is also used for the treatment of infections caused by *Burkholderia cepacia* in cystic fibrosis [unlicensed indication].
Sulfadiazine (Septrin)

**CONTRA-INDICATIONS** Acute porphyrias p. 969

**CAUTIONS** Asthma - avoid in blood disorders (unless under specialist supervision) - avoid in infants under 6 weeks (except for treatment or prophylaxis of pneumocystis pneumonia) because of the risk of kernicterus - elderly (increased risk of serious side-effects) - G6PD deficiency (risk of haemolytic anaemia) - maintain adequate fluid intake - predisposition to folate deficiency - predisposition to hyperkalaemia (in adults)

**INTERACTIONS** → Appendix 1: sulfamethoxazole, trimethoprim

**SIDE-EFFECTS**

- **Common or very common** Diarrhoea, headache, hyperkalaemia, nausea, rash
- **Uncommon** Vomiting
- **Rare** Agranulocytosis - bone marrow depression
- **Frequency not known** Rhabdomyolysis reported in HIV-infected patients

**SIDE-EFFECTS, FURTHER INFORMATION**

- Blood disorders or rash
- **Co-trimoxazole** is associated with rare but serious side effects. Discontinue immediately if blood disorders (including leucopenia, thrombocytopenia, megaloblastic anaemia, eosinophilia) or rash (including Stevens-Johnson syndrome, toxic epidermal necrolysis, photosensitivity) develop.

**PREGNANCY** Teratogenic risk in first trimester (trimethoprim a folate antagonist). Neonatal haemolysis and mechaemoglobinemia in third trimester; fear of increased risk of kernicterus in neonates appears to be unfounded.

**BREAST FEEDING** Small risk of kernicterus in jaundiced infants and of haemolysis in G6PD-deficient infants (due to sulfamethoxazole).

**HEPATIC IMPAIRMENT** Manufacturer advises avoid in severe liver disease.

**RENAL IMPAIRMENT**

- In adults Use half normal dose if eGFR 15–30 mL/minute/1.73 m². Avoid if eGFR less than 15 mL/minute/1.73 m² and if plasma-sulfamethoxazole concentration cannot be monitored.
- In children Use half normal dose if estimated glomerular filtration rate 15–30 mL/minute/1.73 m². Avoid if estimated glomerular filtration rate less than 15 mL/minute/1.73 m² and if plasma-sulfamethoxazole concentration cannot be monitored.

**MONITORING REQUIREMENTS**

- In children Plasma concentration monitoring may be required with high doses; seek expert advice.
- Monitor blood counts on prolonged treatment.

**DIRECTIONS FOR ADMINISTRATION**

- With intravenous use in children For intermittent *intravenous infusion*, may be further diluted in glucose 5% and 10% or sodium chloride 0.9%. Dilute contents of 1 ampoule (5 mL) to 125 mL, 2 ampoules (10 mL) to 250 mL or 3 ampoules (15 mL) to 500 mL; suggested duration of infusion 60–90 minutes (but may be adjusted according to fluid requirements); if fluid restriction necessary, 1 ampoule (5 mL) may be diluted with 75 mL glucose 5% and the required dose infused over max. 60 minutes; check container for haze or precipitant during administration. In severe fluid restriction may be given undiluted via a central venous line.
- With intravenous use in adults For *intravenous infusion* (Septrin® for infusion), give intermittently in Glucose 5% or 10% or Sodium chloride 0.9%. Dilute contents of 1 ampoule (5 mL) to 125 mL, 2 ampoules (10 mL) to 250 mL or 3 ampoules (15 mL) to 500 mL; suggested duration of infusion 60–90 minutes (but may be adjusted according to fluid requirements); if fluid restriction necessary, 1 ampoule (5 mL) may be diluted with 75 mL glucose 5% and infused over max. 60 minutes.

**PRESCRIBING AND DISPENSING INFORMATION**

Co-trimoxazole is a mixture of trimethoprim and sulfamethoxazole (sulphamethoxazole) in the proportions of 1 part to 5 parts.

Flavours of oral liquid formulations may include banana, or vanilla.

**MEDICINAL FORMS**

**Solution for infusion**

**EXCIPIENTS:** May contain Alcohol, propylene glycol, sulfates

**ELECTROLYTES:** May contain Sodium

- **Co-trimoxazole (Non-proprietary)**
  - Trimethoprim 16 mg per 1 mL, Sulfamethoxazole 80 mg per 1 mL Co-trimoxazole 80 mg/400 mg/5 ml solution for infusion ampoules | 10 ampoules (PMS) £35.00
  - Septrin (Aspen Pharma Trading Ltd) Trimethoprim 16 mg per 1 mL, Sulfamethoxazole 80 mg per 1 mL Septrin for Infusion 80 mg/400 mg/5 ml solution for infusion ampoules | 10 ampoule (PMS) £11.76

**Oral suspension**

**CAUTIONARY AND ADVISORY LABELS 9**

- **Co-trimoxazole (Non-proprietary)**
  - Trimethoprim 8 mg per 1 mL, Sulfamethoxazole 40 mg per 1 mL Co-trimoxazole 40 mg/200 mg/5 ml oral suspension sugar free sugar-free | 100 ml (PMS) £9.95 DT price + £9.95
  - Trimethoprim 16 mg per 1 mL, Sulfamethoxazole 80 mg per 1 mL Co-trimoxazole 80 mg/400 mg/5 ml oral suspension | 100 ml (PMS) £10.95 DT price + £10.95

**Tablet**

**CAUTIONARY AND ADVISORY LABELS 9**

- **Co-trimoxazole (Non-proprietary)**
  - Trimethoprim 80 mg, Sulfamethoxazole 400 mg Co-trimoxazole 80 mg/400 mg tablets | 28 tablet (PMS) £15.50 DT price + £2.51 | 100 tablet (PMS) £8.96–£10.91
  - Trimethoprim 160 mg, Sulfamethoxazole 800 mg Co-trimoxazole 160 mg/800 mg tablets | 100 tablet (PMS) £23.40–£24.00 DT price = £23.46

**Sulfadiazine**

**DRUG ACTION** Sulfadiazine is a short-acting sulphonamide with bacteriostatic activity against a broad spectrum of organisms. The importance of the sulfonamides has decreased as a result of increasing bacterial resistance and their replacement by antibacterials which are generally more active and less toxic.

**INDICATIONS AND DOSE**

**Prevention of rheumatic fever recurrence**

- **BY MOUTH**
  - Adult (body-weight up to 30 kg): 500 mg daily
  - Adult (body-weight 30 kg and above): 1 g daily

**UNLICENSED USE** Not licensed for use in toxoplasmosis.

**CONTRA-INDICATIONS** Acute porphyrias p. 969

**CAUTIONS** Asthma - avoid in blood disorders (unless under specialist supervision) - avoid in infants under 6 weeks (except for treatment or prophylaxis of pneumocystis pneumonia) because of the risk of kernicterus - elderly (increased risk of serious side effects) - G6PD deficiency (risk of haemolytic anaemia) - maintain adequate fluid intake - predisposition to folate deficiency - predisposition to hyperkalaemia (in adults)
pneumonia) because of the risk of kernicterus, elderly, G6PD deficiency (risk of haemolytic anaemia), maintain adequate fluid intake, predisposition to folate deficiency, predisposition to hyperkalaemia

- **INTERACTIONS** → Appendix 1: sulfonamides

- **SIDE-EFFECTS**
  - **Common or very common** Diarrhoea, headache, hyperkalaemia, nausea, rash
  - **Uncommon** Vomiting
  - **Rare** Agranulocytosis, bone marrow depression
  - **Very rare** Anorexia, antibiotic-associated colitis, arthralgia, septic meningitis, ataxia, blood disorders, convulsions, cough, depression, eosinophilia, glossitis, hallucinations, hepatic necrosis, hypoglycaemia, hypertension (discontinue), interstitial nephritis, jaundice, leucopenia, liver damage, megaloblastic anaemia, myalgia, myocarditis, pancreatitis, peripheral neuropathy, photosensitivity, pulmonary infiltrates, renal disorders, shortness of breath, Stevens-Johnson syndrome, stomatitis, systemic lupus erythematosus, thrombocytopenia, tinnitus, toxic epidermal necrolysis, uveitis, vasculitis, vertigo
  - **Frequency not known** Benign intracranial hypertension, hypothyroidism, optic neuropathy, rhabdomyolysis reported in HIV-infected patients

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Blood disorders or rash Discontinue immediately if blood disorders (including leucopenia, thrombocytopenia, megaloblastic anaemia, eosinophilia) or rash (including Stevens-Johnson syndrome, toxic epidermal necrolysis, photosensitivity, depression) develop.

- **PREGNANCY** Risk of neonatal haemolysis and methaemoglobinemia in third trimester; fear of increased risk of kernicterus in neonates appears to be unfounded.

- **BREAST FEEDING** Small risk of kernicterus in jaundiced infants and of haemolysis in G6PD-deficient infants.

- **HEPATIC IMPAIRMENT** Use with caution in mild to moderate impairment; avoid in severe impairment.

- **RENAL IMPAIRMENT** Use with caution in mild to moderate impairment; avoid in severe impairment; high risk of crystalluria.

- **MONITORING REQUIREMENTS** Monitor blood counts on prolonged treatment.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension
  - **Tablet**
    - Sulfadiazine (Non-proprietary) Sulfadiazine 500 mg | 56 tablet [POM] £139.62 DT price = £114.27

- **ANTIBACTERIALS** → Tetracyclines and related drugs

## Tetracyclines

### Overview
The tetracyclines are broad-spectrum antibiotics whose value has decreased owing to increasing bacterial resistance. They remain, however, the treatment of choice for infections caused by chlamydia (trachoma, psittacosis, salpingitis, urethritis, and lymphogranuloma venereum), rickettsia (including Q-fever), brucella (doxycycline p. 534 with either streptomycin p. 492 or rifampicin p. 549), and the spirochaete, Borrelia burgdorferi (See Lyme disease). They are also used in respiratory and genital mycoplasma infections, in acne, in destructive (refractory) periodontal disease, in exacerbations of chronic bronchitis (because of their activity against Haemophilus influenzae), and for leptospirosis in penicillin hypersensitivity (as an alternative to erythromycin p. 510).

Tetracyclines have a role in the management of meticillin-resistant Staphylococcus aureus (MRSA) infection.

Microbiologically, there is little to choose between the various tetracyclines, the only exception being minocycline p. 535 which has a broader spectrum; it is active against Neisseria meningitidis and has been used for meningococcal prophylaxis but is no longer recommended because of side-effects including dizziness and vertigo. Compared to other tetracyclines, minocycline is associated with a greater risk of lupus-erythematosus-like syndrome. Minocycline sometimes causes irreversible pigmentation.

## Tetracyclines

- **CONTRA-INDICATIONS** Children under 12 years (deposition in growing bone and teeth, by binding to calcium, causes staining and occasionally dental hypoplasia)

- **CAUTIONS** Myasthenia gravis (muscle weakness may be increased) - systemic lupus erythematosus may be exacerbated

- **SIDE-EFFECTS**
  - **Rare** Anaphylaxis, angioedema, blood disorders, exfoliative dermatitis, hepatotoxicity, hypersensitivity reactions, pancreatitis, pericarditis, photosensitivity (particularly with demeclocycline), rash, Stevens-Johnson syndrome, urticaria
  - **Frequency not known** Antibiotic-associated colitis, benign intracranial hypertension, bulging fontanelles (in infants) (in children), diarrhoea, dysphagia, headache, nausea, oesophageal irritation, visual disturbances, vomiting

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Benzodiazepines during pregnancy may cause sedation. The use of benzodiazepines in the second trimester may increase the risk of congenital malformations.
  - Cough may occur with demeclocycline and may also occur with doxycycline in very rare cases. Doxycycline should not be used in children under 6 months of age.
  - Electrolyte disturbances may indicate benign intracranial hypertension.
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension
  - **Tablet CAUTIONARY AND ADVISORY LABELS** 9, 27
    - Sulfadiazine (Non-proprietary) Sulfadiazine 500 mg | 56 tablet [POM] £139.62 DT price = £114.27

## Demeclocycline hydrochloride

- **INDICATIONS AND DOSE**
  - **Susceptible infections (e.g. chlamydia, rickettsia and mycoplasma)**
    - **BY MOUTH**
      - Adult: 150 mg 4 times a day, alternatively 300 mg twice daily

  - **Treatment of hypotension resulting from inappropriate secretion of antidiuretic hormone, if fluid restriction alone does not restore sodium concentration or is not tolerable**
    - **BY MOUTH**
      - Adult: Initially 0.9–1.2 g daily in divided doses, maintenance 600–900 mg daily

- **CAUTIONS** Photosensitivity more common than with other tetracyclines

- **INTERACTIONS** → Appendix 1: tetracyclines
Doxycycline

**INDICATIONS AND DOSE**

Susceptible infections (e.g. chlamydia, rickettsia and mycoplasma)
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Child 12-17 years: Initially 200 mg daily for 1 dose, then maintenance 100 mg once daily
  - Adult: Initially 200 mg daily for 1 dose, then maintenance 100 mg once daily

Severe infections (including refractory urinary-tract infections)
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Child 12-17 years: 200 mg daily
  - Adult: 200 mg once daily

**Acne**
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Child 12-17 years: 100 mg once daily
  - Adult: 100 mg once daily

**Rosacea**
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: 100 mg once daily

**Papulopustular facial rosacea (without ocular involvement)**
- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Adult: 40 mg once daily for 16 weeks, dose to be taken in the morning, consider discontinuing treatment if no response after 6 weeks

**Early syphilis**
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Child 12-17 years: 100 mg twice daily for 14 days
  - Adult: 100 mg twice daily for 14 days

**Late latent syphilis**
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Child 12-17 years: 100 mg twice daily for 28 days
  - Adult: 100 mg twice daily for 28 days

**Neurosyphilis**
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: 200 mg twice daily for 28 days

**Uncomplicated genital chlamydia | Non-gonococcal urethritis**
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Child 12-17 years: 100 mg twice daily for 7 days
  - Adult: 100 mg twice daily for 7 days

**Pelvic inflammatory disease**
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Child 12-17 years: 100 mg twice daily for 14 days

**Prophylaxis of malaria**
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Child 12-17 years: 100 mg once daily, to be started 1–2 days before entering endemic area and continued for 4 weeks after leaving, can be used for up to 2 years
  - Adult: 100 mg once daily, to be started 1–2 days before entering endemic area and continued for 4 weeks after leaving, can be used for up to 2 years

**Adjunct to quinine in treatment of Plasmodium falciparum malaria**
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Child 12-17 years: 200 mg daily for 7 days
  - Adult: 200 mg daily for 7 days

**Periodontitis (as an adjunct to gingival scaling and root planing)**
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Child 12-17 years: 20 mg twice daily for 3 months
  - Adult: 20 mg twice daily for 3 months

**UNLICENSED USE**

**CAUTIONS**
- Alcohol dependence

**INTERACTIONS**
- → Appendix 1: tetracyclines

**SIDE-EFFECTS**
- Alcohol dependence

**PREGNANCY**
- When travel to malarious areas is unavoidable during pregnancy, doxycycline can be used for malaria prophylaxis if other regimens are unsuitable, and if the entire course of doxycycline can be completed before 15 weeks’ gestation.

**RENAL IMPAIRMENT**
- Use with caution (avoid excessive doses).

**MONITORING REQUIREMENTS**
- When used for periodontitis, monitor for superficial fungal infection, particularly if predisposition to oral candidiasis.

**DIRECTIONS FOR ADMINISTRATION**
- Capsules and Tablets should be swallowed whole with plenty of fluid, while sitting or standing. Capsules should be taken during meals.

**PATIENT AND CARER ADVICE**
- Counselling on administration advised (posture). Photosensitivity Patients should be advised to avoid exposure to sunlight or sun lamps.

**PROFESSION SPECIFIC INFORMATION**
- **Dental practitioners’ formulary**
  - Doxycycline Capsules 100 mg may be prescribed. Dispersible tablets may be prescribed as Dispersible Doxycycline Tablets. Tablets may be prescribed as Doxycycline Tablets 20 mg.
### MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

#### Tablet
Cautory and Advisory Labels 6, 11, 27
- **Periostat** (Alliance Pharmaceuticals Ltd)
  - Doxycycline (as Doxycycline hyclate) 20 mg  | 56 tablet [PO][M] £17.30 DT price = £17.30

#### Dispersible tablet
Cautory and Advisory Labels 6, 9, 11, 13
- **Vibramycin-D** (Pfizer Ltd)
  - Doxycycline (as Doxycycline monohydrate) 100 mg  | 8 tablet [PO][M] £4.91 DT price = £4.91

#### Modified-release capsule
Cautory and Advisory Labels 6, 11, 27
- **Efracea** (Galderma (UK) Ltd)
  - Doxycycline (as Doxycycline monohydrate) 40 mg  | 14 capsule [PO][M] £7.99 DT price = £7.99  | 56 capsule [PO][M] £21.71

#### Capsule
Cautory and Advisory Labels 6, 9, 11, 27
- **Doxycycline (Non-proprietary)**
  - Doxycycline (as Doxycycline hyclate) 50 mg  | 28 capsule [PO][M] £2.26 DT price = £1.29
  - Doxycycline (as Doxycycline hyclate) 100 mg  | 8 capsule [PO][M] £1.44 DT price = £0.87  | 50 capsule [PO][M] £5.44

### Lymecycline

#### INDICATIONS AND DOSE
Susceptible infections (e.g. chlamydia, rickettsia and mycoplasma)
- **BY MOUTH**
  - Child 12–17 years: 408 mg twice daily, increased to 1.224–1.632 g daily, (in severe infection)
  - Adult: 408 mg twice daily, increased to 1.224–1.632 g daily, (in severe infection)

#### Acne
- **BY MOUTH**
  - Child 12–17 years: 408 mg daily for at least 8 weeks
  - Adult: 408 mg daily for at least 8 weeks

#### INTERACTIONS
Appendix 1: tetracyclines

#### MEDICATIONS
May exacerbate renal failure and should not be given to patients with renal impairment.

#### MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

#### Capsule
Cautory and Advisory Labels 6, 9
- **Lymecycline (Non-proprietary)**
  - Lymecycline 408 mg  | 28 capsule [PO][M] £6.95 DT price = £5.14  | 56 capsule [PO][M] £11.66
  - Tetralysal (Galderma (UK) Ltd)
  - Lymecycline 408 mg  | 28 capsule [PO][M] £6.95 DT price = £5.14  | 56 capsule [PO][M] £11.53

### Minocycline

#### INDICATIONS AND DOSE
Susceptible infections (e.g. chlamydia, rickettsia and mycoplasma)
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Child 12–17 years: 100 mg once daily, alternatively 50 mg twice daily
  - Adult: 100 mg once daily, alternatively 50 mg twice daily
- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Child 12–17 years: 100 mg daily
  - Adult: 100 mg daily

#### Prophylaxis of asymptomatic meningococcal carrier state (but no longer recommended)
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: 100 mg twice daily for 5 days, minocycline treatment is usually followed by administration of rifampicin

### CAUTIONS
Systemic lupus erythematosus

### SIDE-EFFECTS
- **Rare**
  - Acute renal failure · alopecia · anorexia · hypoaesthesia · impaired hearing · paraesthesia · pigmentation (sometimes irreversible) · tinnitus
  - **Very rare**
    - Discoloration of conjunctiva · discoloration of sweat · discoloration of tears · systemic lupus erythematosus

### FREQUENCY NOT KNOWN
Dizziness (more common in women) · vertigo (more common in women)

### RENAL IMPAIRMENT
Use with caution (avoid excessive doses).

### MONITORING REQUIREMENTS
If treatment continued for longer than 6 months, monitor every 3 months for hepatotoxicity, pigmentation and for systemic lupus erythematosus—discontinue if develop or if pre-existing systemic lupus erythematosus worsens.

### DIRECTIONS FOR ADMINISTRATION
Tablets or capsules should be swallowed whole with plenty of fluid while sitting or standing.

### PATIENT AND CARER ADVICE
Counselling on administration advised (posture).

### LESS SUITABLE FOR PRESCRIBING
Less suitable for prescribing (compared with other tetracyclines, minocycline is associated with a greater risk of lupus-erythematosus-like syndrome; it sometimes causes irreversible pigmentation).

#### MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

#### Tablet
Cautory and Advisory Labels 6, 9
- **Minocycline (Non-proprietary)**
  - Minocycline (as Minocycline hydrochloride) 50 mg  | 28 tablet [PO][M] £8.50 DT price = £6.19
  - Minocycline (as Minocycline hydrochloride) 100 mg  | 28 tablet [PO][M] £14.50 DT price = £14.01

#### Modified-release capsule
Cautory and Advisory Labels 6, 25
- **Minocycline (Non-proprietary)**
  - Minocycline (as Minocycline hydrochloride) 100 mg  | 56 capsule [PO][M] £24.75 DT price = £20.08
  - Acnamino MR (Dexcel-Pharma Ltd)
  - Minocycline (as Minocycline hydrochloride) 100 mg  | 56 capsule [PO][M] £21.14 DT price = £20.08
  - Minocin MR (Meda Pharmaceuticals Ltd)
  - Minocycline (as Minocycline hydrochloride) 100 mg  | 56 capsule [PO][M] £20.08 DT price = £20.08

#### Capsule
Cautory and Advisory Labels 6, 9
- **Aknemin (Almirall Ltd)**
  - Minocycline (as Minocycline hydrochloride) 50 mg  | 56 capsule [PO][M] £15.27 DT price = £15.27
Oxytetracycline

- **INDICATIONS AND DOSE**
  - Susceptible infections (e.g. chlamydia, rickettsia and mycoplasma)
    - **BY MOUTH**
      - Child 12–17 years: 250–500 mg 4 times a day
      - Adult: 250–500 mg 4 times a day
  - Rosacea
    - **BY MOUTH**
      - Adult: 500 mg twice daily usually for 6–12 weeks (course may be repeated intermittently)
  - Acne
    - **BY MOUTH**
      - Child 12–17 years: 500 mg twice daily for at least 3 months, if there is no improvement after the first 3 months another oral antibacterial should be used, maximum improvement usually occurs after 4 to 6 months but in more severe cases treatment may need to be continued for 2 years or longer

- **INTERACTIONS** → Appendix 1: tetracyclines
- **RENAL IMPAIRMENT** May exacerbate renal failure and should not be given to patients with renal impairment.
- **PROFESSION SPECIFIC INFORMATION**
  - **Dental practitioners’ formulary**
    - Oxytetracycline Tablets may be prescribed.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule, oral suspension
  - **Tablet**
    - CAUTIONARY AND ADVISORY LABELS 7, 9, 23
    - **Oxytetracycline (Non-proprietary)**
      - Oxytetracycline (as Oxytetracycline dihydrate) 250 mg Oxytetracycline 250mg tablets | 28 tablet POM £3.45 DT price = £1.07
      - 1000 tablet POM no price available

Tigecycline

- **DRUG ACTION** Tigecycline is a glycylcyclic antibacterial structurally related to the tetracyclines. Tigecycline is active against Gram-positive and Gram-negative bacteria, including tetracycline-resistant organisms, and some anaerobes. It is also active against meticillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci, but *Pseudomonas aeruginosa* and many strains of *Proteus spp* are resistant to tigecycline.

- **INDICATIONS AND DOSE**
  - Treatment of complicated skin and soft-tissue infections and complicated abdominal infections caused by multiple-antibacterial resistant organisms when other antibacterials cannot be used
    - **BY INTRAVENOUS INFUSION**
      - Adult: Initially 100 mg, then 50 mg every 12 hours for 5–14 days, not recommended for the treatment of foot infections in patients with diabetes

- **CAUTIONS** Cholestasis
- **INTERACTIONS** → Appendix 1: tetracyclines
- **SIDE-EFFECTS**
  - Common or very common Abdominal pain · anorexia · bilirubinaemia · diarrhoea · dizziness · dyspepsia · headache · hypoglycaemia · injection-site reactions ·
nausea • prolonged activated partial thromboplastin time • prolonged prothrombin time • pruritus • rash • vomiting

- **Uncommon** Cholestatic jaundice • hypoprothrombinaemia • pancreatitis
- **Frequency not known** Antibiotic-associated colitis • hepatic failure • Stevens-Johnson syndrome • thrombocytopenia

**SIDE-EFFECTS, FURTHER INFORMATION**
Side-effects similar to those of the tetracyclines can potentially occur.

- **ALLERGY AND CROSS-SENSITIVITY** Contra-indicated in patients hypersensitive to tetracyclines.
- **PREGNANCY** Tetracyclines should not be given to pregnant women; effects on skeletal development have been documented in the first trimester in animal studies. Administration during the second or third trimester may cause discoloration of the child’s teeth, and maternal hepatotoxicity has been reported with large parenteral doses.
- **BREAST FEEDING** Manufacturer advises caution—present in milk in animal studies.
- **HEPATIC IMPAIRMENT** Initially 100 mg then 25 mg every 12 hours in severe hepatic impairment.
- **DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Tygacil®), give intermittently in Glucose 5% and Sodium Chloride 0.9%. Reconstitute each vial with 5.3 mL infusion fluid to produce a 10 mg/mL solution; dilute requisite dose in 100 mL infusion fluid; give over 30–60 minutes.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

- **Powder for solution for injection**
  - Tygacil (Pfizer Ltd)
  - Tigecycline 50 mg Tygacil 50mg powder for solution for infusion vials | 10 vial (Pos) £323.10 (Hospital only)

**OTHER**

**ANTIBACTERIALS**

**Chloramphenicol**

- **DRUG ACTION** Chloramphenicol is a potent broad-spectrum antibiotic.

- **INDICATIONS AND DOSE**
  
  Life threatening infections particularly those caused by
  *Haemophilus influenzae* | Typhoid fever
  - By mouth, or by intravenous injection, or by intravenous infusion
  - Adult: 12.5 mg/kg every 6 hours, in exceptional cases dose can be doubled for severe infections such as septicaemia and meningitis, providing high doses reduced as soon as clinically indicated

- **CONTRA-INDICATIONS** Acute porphyrias p. 969
- **CAUTIONS** Avoid repeated courses and prolonged treatment
- **INTERACTIONS** Appendix 1: chloramphenicol
- **SIDE-EFFECTS** Blood disorders • depression • diarrhoea • dry mouth • erythema multiforme • glossitis • headache • nausea • nocturnal haemoglobinuria • optic neuritis • peripheral neuritis • reversible and irreversible aplastic anaemia (with reports of resulting leukaemia) • stomatitis • urticaria • vomiting

  **SIDE-EFFECTS, FURTHER INFORMATION**
  Associated with serious haematological side-effects when given systemically and should therefore be reserved for the treatment of life-threatening infections.

- **PREGNANCY** Manufacturer advises avoid; neonatal ‘grey-baby syndrome’ if used in third trimester.
- **BREAST FEEDING** Manufacturer advises avoid; use another antibiotic; may cause bone-marrow toxicity in infant;

concentration in milk usually insufficient to cause ‘grey syndrome’.

- **HEPATIC IMPAIRMENT** Reduce dose. Avoid if possible—increased risk of bone-marrow depression. Monitor plasma-chloramphenicol concentration in hepatic impairment.

- **RENAL IMPAIRMENT** Avoid in severe renal impairment unless no alternative; dose-related depression of haematopoesis.

- **MONITORING REQUIREMENTS**
  - Plasma concentration monitoring preferred in the elderly.
  - Recommended peak plasma concentration (approx. 2 hours after administration by mouth, intravenous injection or infusion) 10–25 mg/litre; pre-dose (‘trough’) concentration should not exceed 15 mg/litre.
  - Blood counts required before and periodically during treatment.

- **DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Kemicetine®), give intermittently or via drip tubing in Glucose 5% or Sodium chloride 0.9%.

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.

- **Powder for solution for injection**
  - **ELECTROLYTES:** May contain Sodium
  - **Chloramphenicol (Non-proprietary)**
    - Chloramphenicol (as Chloramphenicol sodium succinate)
      - 1 gram Chloramphenicol 1g powder for solution for infusion vials | 1 vial (Pos) £22.00

- **Capsule**
  - **Chloramphenicol (Non-proprietary)**
    - Chloramphenicol 250 mg Chloramphenicol 250mg capsules | 60 capsule (Pos) £377.00 D7 price = £377.00

**Daptomycin**

- **DRUG ACTION** Daptomycin is a lipopeptide antibacterial with a spectrum of activity similar to vancomycin but its efficacy against enterococci has not been established. It needs to be given with other antibacterials for mixed infections involving Gram-negative bacteria and some anaerobes.

- **INDICATIONS AND DOSE**
  Complicated skin and soft-tissue infections caused by Gram-positive bacteria, including meticillin-resistant *Staphylococcus aureus* (MRSA)
  - **BY SLOW INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
    - Adult: 4 mg/kg once daily; increased to 6 mg/kg once daily, increase dose only if associated with *Staphylococcus aureus* bacteraemia

- **Staphylococcal endocarditis caused by organisms resistant to vancomycin or in patients intolerant of vancomycin (in combination with other antibacterials)**
  - **BY SLOW INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
    - Adult: 6 mg/kg once daily

- **UNLICENCED USE** Not licensed for use in left-sided endocarditis.

- **INTERACTIONS** Appendix 1: daptomycin
- **SIDE-EFFECTS**
  - **Common or very common** Abdominal pain • anaemia • anxiety • arthralgia • asthenia • constipation • diarrhoea • dizziness • flatulence • headache • hypertension • hypotension • injection-site reactions • insomnia • nausea • pruritus • rash • vomiting
  - **Uncommon** Anorexia • arrhythmias • dyspepsia • electrolyte disturbances • eosinophilia • flushing • glossitis • hyperglycaemia • muscle effects • muscle weakness •
Fidaxomicin

**DRUG ACTION** Fidaxomicin is a macrocyclic antibacterial that is poorly absorbed from the gastro-intestinal tract, and, therefore, it should not be used to treat systemic infections.

**INDICATIONS AND DOSE**

**Clostridium difficile infection**

- **By mouth**
  - Adult: 200 mg every 12 hours for 10 days. Limited clinical data is available on the use of fidaxomicin in severe or life-threatening *Clostridium difficile* infection

**CAUTIONS** Inflammatory bowel disease · severe or life-threatening *C. difficile* infection

**INTERACTIONS** → Appendix 1: fidaxomicin

**SIDE-EFFECTS**

- **Common or very common** Constipation · nausea · vomiting
- **Uncommon** Abdominal distension · decreased appetite · dizziness · dry mouth · flatulence · headache · taste disturbance

**ALLERGY AND CROSS-SENSITIVITY** Use with caution in macrolide hypersensitivity.

**PREGNANCY** Manufacturer advises avoid—no information available.

**BREAST FEEDING** Manufacturer advises avoid—no information available.

**HEPATIC IMPAIRMENT** Manufacturer advises caution in moderate to severe impairment—no information available.

**RENAL IMPAIRMENT** Manufacturer advises caution in severe impairment—no information available.

**NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (June 2012) that fidaxomicin (*Dificlir®*) is accepted for restricted use within NHS Scotland to treat the first recurrence of *C. difficile* infection, on the advice of a microbiologist or specialist in infectious diseases.

**MEDICINAL FORMS**

Table

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dificlir (Astellas Pharma Ltd)</td>
<td></td>
</tr>
<tr>
<td>Fidaxomicin 200 mg Dificlir 200mg tablets</td>
<td>20 tablet [POM] £1,350.00</td>
</tr>
</tbody>
</table>

Fosfomycin

**DRUG ACTION** Fosfomycin, a phosphonic acid antibacterial, is active against a range of Gram-positive and Gram-negative bacteria including *Staphylococcus aureus* and *Enterobacteriaceae*.

**INDICATIONS AND DOSE**

**Acute uncomplicated lower urinary-tract infections**

- **By mouth using granules**
  - Adult: 3 g for 1 dose

**Prophylaxis of urinary-tract infections in transurethral surgical procedures**

- **By mouth using granules**
  - Adult: 3 g, to be given 3 hours before surgery. Dose may be repeated once, 24 hours after surgery

**Osteomyelitis when first-line treatments are inappropriate or ineffective | Hospital-acquired lower respiratory-tract infections when first-line treatments are inappropriate or ineffective**

- **By intravenous infusion**
  - Adult: 12–24 g daily in 2–3 divided doses (max. per dose 8 g), use the high-dose regimen in severe infection suspected or known to be caused by less sensitive organisms

**Complicated urinary-tract infections when first-line treatment ineffective or inappropriate**

- **By intravenous infusion**
  - Adult: 12–16 g daily in 2–3 divided doses (max. per dose 8 g)

**Bacterial meningitis when first-line treatment ineffective or inappropriate**

- **By intravenous infusion**
  - Adult: 16–24 g daily in 3–4 divided doses (max. per dose 8 g), use the high-dose regimen in severe infection suspected or known to be caused by less sensitive organisms

---

**SIDE-EFFECTS**

- **Common or very common** Constipation · nausea · vomiting
- **Uncommon** Abdominal distension · decreased appetite · dizziness · dry mouth · flatulence · headache · taste disturbance

**ALLERGY AND CROSS-SENSITIVITY** Use with caution in macrolide hypersensitivity.

**PREGNANCY** Manufacturer advises avoid—no information available.

**BREAST FEEDING** Manufacturer advises avoid—no information available.

**HEPATIC IMPAIRMENT** Manufacturer advises caution in moderate to severe impairment—no information available.

**RENAL IMPAIRMENT** Manufacturer advises caution in severe impairment—no information available.

**NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (February 2008) that daptomycin (*Cubicin®*) is accepted for restricted use within NHS Scotland for the treatment of MRSA bacteraemia associated with right-sided endocarditis or with complicated skin and soft-tissue infections.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for infusion**

- **Cubicin** (Merck Sharp & Dohme Ltd)
  - Daptomycin 350 mg Cubicin 350mg powder for concentrate for solution for infusion vials | 1 vial [PPh] £52.00
  - Daptomycin 500 mg Cubicin 500mg powder for concentrate for solution for infusion vials | 1 vial [PPh] £88.57 (Hospital only)

---

**INDICATIONS AND DOSE**

**Acute uncomplicated lower urinary-tract infections**

- **By mouth using granules**
  - Adult: 3 g for 1 dose

**Prophylaxis of urinary-tract infections in transurethral surgical procedures**

- **By mouth using granules**
  - Adult: 3 g, to be given 3 hours before surgery. Dose may be repeated once, 24 hours after surgery

**Osteomyelitis when first-line treatments are inappropriate or ineffective | Hospital-acquired lower respiratory-tract infections when first-line treatments are inappropriate or ineffective**

- **By intravenous infusion**
  - Adult: 12–24 g daily in 2–3 divided doses (max. per dose 8 g), use the high-dose regimen in severe infection suspected or known to be caused by less sensitive organisms

**Complicated urinary-tract infections when first-line treatment ineffective or inappropriate**

- **By intravenous infusion**
  - Adult: 12–16 g daily in 2–3 divided doses (max. per dose 8 g)

**Bacterial meningitis when first-line treatment ineffective or inappropriate**

- **By intravenous infusion**
  - Adult: 16–24 g daily in 3–4 divided doses (max. per dose 8 g), use the high-dose regimen in severe infection suspected or known to be caused by less sensitive organisms
### Fusidic acid

**16-Jun-2017**

**DRUG ACTION** Fusidic acid and its salts are narrow-spectrum antibiotics used for staphylococcal infections.

### Indications and Dose

**Staphylococcal skin infection**
- **By mouth using tablets**
  - Child 12–17 years: 250 mg every 12 hours for 5–10 days, dose expressed as sodium fusidate
  - Adult: 250 mg every 12 hours, dose expressed as sodium fusidate
- **By mouth using oral suspension**
  - Child: Apply 3–4 times a day usually for 7 days
  - Adult: Apply 3–4 times a day

**Penicillin-resistant staphylococcal infection including osteomyelitis**
- **Staphylococcal endocarditis in combination with other antibacterials**
  - **By mouth using oral suspension**
    - Child 1–11 months: 15 mg/kg/3 times a day
    - Child 1–4 years: 250 mg 3 times a day
    - Child 5–11 years: 500 mg 3 times a day
    - Child 12–17 years: 750 mg 3 times a day
    - Adult: 750 mg 3 times a day

**Staphylococcal infections due to susceptible organisms**
- **By intravenous infusion**
  - Child (body-weight up to 50 kg): 6–7 mg/kg 3 times a day, dose expressed as sodium fusidate
  - Child (body-weight 50 kg and above): 500 mg 3 times a day, dose expressed as sodium fusidate
  - Adult (body-weight up to 50 kg): 6–7 mg/kg 3 times a day, dose expressed as sodium fusidate
  - Adult (body-weight 50 kg and above): 500 mg 3 times a day, dose expressed as sodium fusidate

**Dose equivalence and conversion**
- **With oral use**
  - Fusidic acid is incompletely absorbed and doses recommended for suspension are proportionately higher than those for sodium fusidate tablets. 500 mg of sodium fusidate is equivalent to 480 mg fusidic acid.

### Dosage

**With oral use**
- Fusidic acid may be administered as a single daily dose or divided doses every 8 hours. It is usually given for 5–10 days.

**With intravenous use**
- Fusidic acid is given as an intravenous infusion over 1–2 hours followed by 4–6 hours of continuous infusion. Maximum dose is 750 mg/24 hours.

### Contraindications

- **Hypersensitivity to fusidic acid or any component of the formulation.
- Pre-existing hepatic impairment.
- Pregnancy and breastfeeding.

### Warnings

- **Impaired transport and metabolism of bilirubin**
  - Avoid contact of cream or ointment with eyes.

### Medicinal forms

- **Powder for solution for infusion**
  - Fomicyt (Nordic Pharma Ltd)
    - Fosfomycin (as Fosfomycin sodium) 2 gram: Fomicyt 2g powder for solution for infusion vials | 10 vial (POD) £150.00

### Side-effects

- **Common or very common**
  - Gastro-intestinal disturbances (diarrhoea, nausea, rash, vomiting).

### precautions

- **Renal impairment**
  - With oral use: Avoid oral treatment if eGFR less than 10 mL/minute/1.73 m².
  - With intravenous use: Use intravenous treatment with caution if eGFR 40–80 mL/minute/1.73 m² and consult product literature for dose if eGFR less than 40 mL/minute/1.73 m².

### Monitoring requirements

- With intravenous use: Monitor electrolytes and fluid balance.

### Directions for administration

- **With intravenous use**
  - For intravenous infusion (Fomicyt®), give intermittently in Glucose 5% or 10% or Water for Injections; reconstitute each 2-g vial with 50 mL infusion fluid; give 2 g over 15 minutes.
  - With oral use: Manufacturer advises granules should be taken on an empty stomach (about 2–3 hours before or after a meal), preferably before bedtime and after emptying the bladder. The granules should be dissolved into a glass of water and taken immediately.

### Prescribing and dispensing information

- Doses expressed as fosfomycin base.

### National funding/access decisions

- **Scottish Medicines Consortium (SMC) Decisions**
  - The Scottish Medicines Consortium has advised (February 2015) that fosfomycin (Fomicyt®) is accepted for restricted use within NHS Scotland; initiation should be restricted to microbiologists or infectious disease specialists.
  - The Scottish Medicines Consortium has advised (September 2016) that fosfomycin trometamol (Monuril®) is accepted for use within NHS Scotland for the treatment of acute lower uncomplicated urinary tract infections, caused by pathogens sensitive to fosfomycin in adult and adolescent females and for prophylaxis in diagnostic and surgical transurethral procedures.

### Medicinal forms

- There can be variation in the licensing of different medicines containing the same drug.

### Powder for solution for infusion

- **Electrolytes:** May contain Sodium
  - Fomicyt (Nordic Pharma Ltd)
    - Fosfomycin (as Fosfomycin sodium) 2 gram: Fomicyt 2g powder for solution for infusion vials | 10 vial (POD) £150.00

### Granules

- **CAUTIONARY AND ADVISORY LABELS**
  - May contain Sucrose
    - Fosfomycin (Non-proprietary)
      - Fosfomycin (as Fosfomycin trometamol) 3 gram: Fosfomycin 3g granules sachets | 1 sachet (POD): £75.45
      - Monuril (Zambon S.p.A.)
        - Fosfomycin (as Fosfomycin trometamol) 3 gram: Monuril 3g granules sachets | 1 sachet (POD): £4.86

### Interactions

- **Appendix 1: fusidic acid**

---

**BNF 74**

Bacterial infection **539**

---

**Fusidic acid**

16-Jun-2017

**INDICATIONS AND DOSE**

**Staphylococcal skin infection**
- **By mouth using tablets**
  - Child 12–17 years: 250 mg every 12 hours for 5–10 days, dose expressed as sodium fusidate
  - Adult: 250 mg every 12 hours for 5–10 days, dose expressed as sodium fusidate
- **By mouth using oral suspension**
  - Child: Apply 3–4 times a day usually for 7 days
  - Adult: Apply 3–4 times a day

**Penicillin-resistant staphylococcal infection including osteomyelitis**
- **Staphylococcal endocarditis in combination with other antibacterials**
  - **By mouth using oral suspension**
    - Child 1–11 months: 15 mg/kg/3 times a day
    - Child 1–4 years: 250 mg 3 times a day
    - Child 5–11 years: 500 mg 3 times a day
    - Child 12–17 years: 750 mg 3 times a day
    - Adult: 750 mg 3 times a day
  - **By mouth using tablets**
    - Child 12–17 years: 500 mg every 8 hours, increased to 1 g every 8 hours, increased dose can be used for severe infections, dose expressed as sodium fusidate
    - Adult: 500 mg every 8 hours, increased to 1 g every 8 hours, increased dose can be used for severe infections, dose expressed as sodium fusidate

**Staphylococcal infections due to susceptible organisms**
- **By intravenous infusion**
  - Child (body-weight up to 50 kg): 6–7 mg/kg 3 times a day, dose expressed as sodium fusidate
  - Child (body-weight 50 kg and above): 500 mg 3 times a day, dose expressed as sodium fusidate
  - Adult (body-weight up to 50 kg): 6–7 mg/kg 3 times a day, dose expressed as sodium fusidate
  - Adult (body-weight 50 kg and above): 500 mg 3 times a day, dose expressed as sodium fusidate

**Dose equivalence and conversion**
- **With oral use**
  - Fusidic acid is incompletely absorbed and doses recommended for suspension are proportionately higher than those for sodium fusidate tablets. 500 mg of sodium fusidate is equivalent to 480 mg fusidic acid.

**CAUTIONS**

- **With systemic use**
  - Impaired transport and metabolism of bilirubin
- **With topical use**
  - Avoid contact of cream or ointment with eyes

**CAUTIONS, FURTHER INFORMATION**

**Avoiding resistance**
- **With topical use**
  - To avoid the development of resistance, fusidic acid should not be used for longer than 10 days and local microbiology advice should be sought before using it in hospital.

**INTERACTIONS**

- **Appendix 1: fusidic acid**
**SIDE-EFFECTS**
- **Common or very common**
  - With intravenous use: Hepatic disorders - venous intolerance (reduced if given via central vein)
  - With oral use: Abdominal pain - diarrhoea - dyspepsia - nausea - vomiting
  - With systemic use: Dizziness - drowsiness
- **Uncommon**
  - With systemic use: Anorexia - headache - malaise - pruritus - rash - urticaria
- **Rare**
  - With topical use: Hypersensitivity reactions
- **Frequency not known**
  - With intravenous use: Rash

**SIDE-EFFECTS, FURTHER INFORMATION**
- **Hepatic disorders**
  - With systemic use: Elevated liver enzymes, hyperbilirubinaemia and jaundice can occur — these effects are usually reversible following withdrawal of therapy.
- **PREGNANCY**
  - With systemic use: Not known to be harmful; manufacturer advises use only if potential benefit outweighs risk.
- **BREAST FEEDING**
  - With systemic use: Present in milk — manufacturer advises caution.
- **HEPATIC IMPAIRMENT**
  - With systemic use: Manufacturer advises caution — monitor liver function periodically during treatment.
- **MONITORING REQUIREMENTS**
  - With systemic use: Manufacturer advises monitor liver function with high doses or on prolonged therapy; monitoring also advised for patients with biliary tract obstruction, those taking potentially hepatotoxic medication, or those taking concurrent medication with a similar excretion pathway.
- **DIRECTIONS FOR ADMINISTRATION**
  - With intravenous use: Manufacturer advises for intravenous infusion, give intermittently in Sodium chloride 0.9% or Glucose 5%; reconstitute each vial with 10 mL buffer solution, then add contents of vial to 500 mL infusion fluid to give a solution containing approximately 1 mg/mL. Give requisite dose via a central line over 2 hours (give over at least 6 hours if administered via a large peripheral vein).
- **PRESCRIBING AND DISPENSING INFORMATION**
  - Flavours of oral liquid formulations may include banana and orange.
- **PROFESSIONAL SPECIFIC INFORMATION**
  - Dental practitioners’ formulary
  - May be prescribed as Sodium Fusidate ointment.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.
  - **Tablet**
    - CAUTIONARY AND ADVISORY LABELS 9
    - Fusidin (Sodium fusidate) (LEO Pharma)
      - Fusidin (Sodium fusidate) 250 mg: Fusidin 250 mg tablets | 10 tablet
        - Dosage: £0.62 DT price = £0.62 | 100 tablet
        - Price: £54.99
  - **Oral suspension**
    - CAUTIONARY AND ADVISORY LABELS 9, 21
    - Fusidin (Fusidic acid) (LEO Pharma)
      - Fusidic acid 50 mg per 1 ml: Fusidin 250mg/5ml oral suspension | 50 ml
        - Dosage: £0.73 DT price = £0.73
  - **Powder and solvent for solution for infusion**
    - ELECTROLYTES: May contain Sodium
      - Fusidic acid (Non-proprietary)
        - Sodium fusidate 500 mg: Sodium fusidate 500 mg powder and solvent for solution for infusion vials | 1 vial
          - Price: £38.00

**Cream**
- **EXCIPIENTS:** May contain Butylated hydroxyanisole, cetostearyl alcohol (including cetyl and stearyl alcohol)
  - Fusidic acid (Non-proprietary)
    - Fusidic acid 20 mg per 1 gram: Fusidic acid 2% cream | 15 gram
      - Dosage: £1.92 DT price = £1.80 | 30 gram
        - Price: £3.60 DT price = £3.60
  - Fusidin (Fusidic acid) (LEO Pharma)
    - Fusidic acid 20 mg per 1 gram: Fusidin 20mg/g cream | 15 gram
      - Dosage: £1.92 DT price = £1.80 | 30 gram
        - Price: £3.59 DT price = £3.60

**Ointment**
- **EXCIPIENTS:** May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), wool fat and related substances including lanolin
  - Fusidin (Sodium fusidate) (LEO Pharma)
    - Sodium fusidate 20 mg per 1 gram: Fusidin 20mg/g ointment | 15 gram
      - Dosage: £2.68 DT price = £2.68 | 30 gram
        - Price: £4.55 DT price = £4.55

### Linezolid

**DRUG ACTION**
- Linezolid, an oxazolidinone antibacterial, is active against Gram-positive bacteria including meticillin-resistant *Staphylococcus aureus* (MRSA), and glycopeptide-resistant enterococci. Resistance to linezolid can develop with prolonged treatment or if the dose is less than that recommended. Linezolid is **not** active against common Gram-negative organisms; it must be given in combination with other antibacterials for mixed infections that also involve Gram-negative organisms.

**INDICATIONS AND DOSE**
- **Pneumonia (when other antibacterials e.g. a glycopeptide, such as vancomycin, cannot be used) (initiated under specialist supervision) Complicated skin and soft-tissue infections caused by Gram-positive bacteria, when other antibacterials cannot be used (initiated under specialist supervision)**
  - **BY MOUTH**
    - Adult: 600 mg every 12 hours usually for 10–14 days (maximum duration of treatment 28 days)
  - **BY INTRAVENOUS INFUSION**
    - Adult: 600 mg every 12 hours

**IMPORTANT SAFETY INFORMATION**
- **CHM ADVICE (OPTIC NEUROPATHY)**
  - Severe optic neuropathy may occur rarely, particularly if linezolid is used for longer than 28 days. The CHM recommends that:
    - patients should be warned to report symptoms of visual impairment (including blurred vision, visual field defect, changes in visual acuity and colour vision) immediately;
    - patients experiencing new visual symptoms (regardless of treatment duration) should be evaluated promptly, and referred to an ophthalmologist if necessary;
    - visual function should be monitored regularly if treatment is required for longer than 28 days.

**BLOOD DISORDERS**
- Haematopoietic disorders (including thrombocytopenia, anaemia, leucopenia, and pancytopenia) have been reported in patients receiving linezolid. It is recommended that full blood counts are monitored weekly. Close monitoring is recommended in patients who:
  - receive treatment for more than 10–14 days;
  - have pre-existing myelosuppression;
  - are receiving drugs that may have adverse effects on haemoglobin, blood counts, or platelet function;
  - have severe renal impairment.

If significant myelosuppression occurs, treatment should be stopped unless it is considered essential, in which...
case intensive monitoring of blood counts and appropriate management should be implemented.

- **CAUTIONS**
  - Acute confusional states - bipolar depression - carcinoid tumour - elderly (increased risk of blood disorders) - history of seizures - phaeochromocytoma - schizophrenia - thyrotoxicosis - uncontrolled hypertension

  - **FURTHER INFORMATION**
    - Close observation 
      - Unless close observation and blood pressure monitoring possible, linezolid should be avoided in uncontrolled hypertension, phaeochromocytoma, carcinoid tumour, thyrotoxicosis, bipolar depression, schizophrenia, or acute confusional states.

- **INTERACTIONS** ➔ Appendix 1: linezolid

- **SIDE-EFFECTS**
  - **GENERAL SIDE-EFFECTS**
    - **Common or very common** 
      - Diarrhoea - eosinophilia - headache - nausea - taste disturbances - vomiting
    - **Uncommon** 
    - **Rare** 
      - Renal failure - tachycardia - transient ischaemic attacks
    - **Frequency not known** 
      - Anaemia - antibiotic-associated colitis - convulsions - hypotension - lactic acidosis - optic neuropathy reported on prolonged therapy - pancytopenia - peripheral neuropathy reported on prolonged therapy - Stevens-Johnson syndrome - tooth discoloration - toxic epidermal necrolysis

  - **SPECIFIC SIDE-EFFECTS**
    - **Uncommon**
      - With intravenous use 
        - Injection-site reactions
    - **PREGNANCY** 
      - Manufacturer advises use only if potential benefit outweighs risks—no information available.
    - **BREAST FEEDING** 
      - Manufacturer advises avoid—present in milk in animal studies.
    - **HEPATIC IMPAIRMENT** 
      - In severe hepatic impairment manufacturer advises use only if potential benefit outweighs risk.
    - **RENAL IMPAIRMENT** 
      - Manufacturer advises metabolites may accumulate if eGFR less than 30 mL/minute/1.73 m².
    - **MONITORING REQUIREMENTS** 
      - Monitor full blood count (including platelet count) weekly.
    - **DIRECTIONS FOR ADMINISTRATION**
      - With intravenous use 
        - Infusion to be administered over 30–120 minutes.
    - **PRESCRIBING AND DISPENSING INFORMATION** 
      - Flavours of oral liquid formulations may include orange.
    - **PATIENT AND CARER ADVICE** 
      - Patients should be advised to read the patient information leaflet given with linezolid.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Infusion**
    - **EXCIPIENTS:** May contain Asparagine
    - **ELECTROLYTES:** May contain Sodium
    - **Linezolid (Non-proprietary)**
      - Linezolid 2 mg per 1 ml Linezolid 600mg/300ml infusion bags | 10 bag (Pom) £445.00 (Hospital only)
    - **Zyvox (Pfizer Ltd)**
      - Linezolid 2 mg per 1 ml Zyvox 600mg/300ml infusion bags | 10 bag (Pom) £445.00

- **DRUG ACTION**
  - Tedizolid is an oxazolidinone antibacterial, which inhibits bacterial protein synthesis.

- **INDICATIONS AND DOSE**
  - **Treatment of acute bacterial skin and skin structure infections**
    - By intravenous infusion, or by mouth
    - Adult: 200 mg once daily for 6 days, patients should be switched from the intravenous to the oral route when clinically appropriate

- **PRECAUTIONS**
  - Neutropenia—limited clinical experience - patients aged 75 years and over—limited clinical experience

  - **INTERACTIONS** ➔ Appendix 1: tedizolid

- **SIDE-EFFECTS**
  - **Common or very common** 
    - Diarrhoea - dizziness - headache - nausea - pruritis - vomiting
  - **Uncommon**
  - **Frequency not known** 
    - Myelosuppression (reversible on discontinuation of treatment)

- **CONCEPTION AND CONTRACEPTION**
  - Manufacturer recommends effective contraception in women of childbearing potential; an additional method of contraception is advised in women taking hormonal contraceptives—effectiveness may be reduced.

- **PREGNANCY**
  - Manufacturer advises avoid—foetal developmental toxicity in animal studies.

- **BREAST FEEDING**
  - Manufacturer advises avoid—present in milk in animal studies.

- **DIRECTIONS FOR ADMINISTRATION**
  - For intravenous infusion (Sivextro®) give intermittently in Sodium Chloride 0.9%; reconstitute each 200 mg vial with 4 mL Water for Injections, then dilute reconstituted solution in 250 mL sodium chloride 0.9%; give over approx. 1 hour.

- **PATIENT AND CARER ADVICE**
  - Optic neuropathy 
    - Although neuropathy (peripheral and optic) has not been reported in patients treated with tedizolid, manufacturer advises patients and carers are warned to report symptoms of visual impairment (including blurred vision, visual field defect, changes in visual acuity and colour vision) immediately; patients should be evaluated promptly, and referred to an ophthalmologist if necessary.
Missed doses
Manufacturer advises that if a dose is more than 16 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

Driving and skilled tasks
Patients and carers should be counselled on the effects on driving and skilled tasks—increased risk of dizziness and fatigue.

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (August 2015) that tedizolid (Sivextro®) is accepted for restricted use within NHS Scotland as an alternative oxazolidinone antibacterial for the treatment of acute bacterial skin and skin structure infections caused by Gram-positive *Staphylococcus aureus* (specifically methicillin-resistant *Staphylococcus aureus* [MRSA] isolates), on the specific advice of local microbiologists or specialists in infectious disease.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for infusion
- Sivextro (Merck Sharp & Dohme Ltd) ▼
  - Tedizolid phosphate 200 mg Sivextro 200mg powder for concentrate for solution for infusion vials | 6 vial [Link] £862.00

Tablet
- Sivextro (Merck Sharp & Dohme Ltd) ▼
  - Tedizolid phosphate 200 mg Sivextro 200mg tablets | 6 tablet [Link] £862.00

Trimethoprim

INDICATIONS AND DOSE
Urinary-tract infections | Respiratory tract infections
- **BY MOUTH**
  - Child 4–5 weeks: 4 mg/kg twice daily (max. per dose 200 mg)
  - Child 6 weeks–5 months: 4 mg/kg twice daily (max. per dose 200 mg), alternatively 25 mg twice daily
  - Child 6 months–5 years: 4 mg/kg twice daily (max. per dose 200 mg), alternatively 50 mg twice daily
  - Child 6–11 years: 4 mg/kg twice daily (max. per dose 200 mg), alternatively 100 mg twice daily
  - Child 12–17 years: 200 mg twice daily
  - Adult: 200 mg twice daily

Prophylaxis of urinary-tract infection (considered for recurrent infection, significant urinary-tract anomalies, or significant kidney damage)
- **BY MOUTH**
  - Child 4–5 weeks: 2 mg/kg once daily (max. per dose 100 mg), dose to be taken at night
  - Child 6 weeks–5 months: 2 mg/kg once daily (max. per dose 100 mg), dose to be taken at night, alternatively 12.5 mg once daily, dose to be taken at night
  - Child 6 months–5 years: 2 mg/kg once daily (max. per dose 100 mg), dose to be taken at night, alternatively 25 mg once daily, dose to be taken at night
  - Child 6–11 years: 2 mg/kg once daily (max. per dose 100 mg), dose to be taken at night, alternatively 50 mg once daily, dose to be taken at night
  - Child 12–17 years: 100 mg once daily, dose to be taken at night
  - Adult: 100 mg once daily, dose to be taken at night

Treatment of mild to moderate *Pneumocystis jirovecii* (Pneumocystis carinii) pneumonia in patients who cannot tolerate co-trimoxazole (in combination with dapsone)
- **BY MOUTH**
  - Child: 5 mg/kg every 6–8 hours
  - Adult: 5 mg/kg every 6–8 hours

Acne resistant to other antibacterials
- **BY MOUTH**
  - Adult: 300 mg twice daily

Prostatitis
- **BY MOUTH**
  - Adult: (consult product literature)

**SHigellosis** | **Invasive salmonella infection**
- **BY MOUTH**
  - Adult: (consult product literature)


CONTRA-INDICATIONS Blood dyscrasias

CAUTIONS Elderly · acute porphyrias p. 969 · predisposition to folate deficiency

INTERACTIONS → Appendix 1: trimethoprim

SIDE-EFFECTS
- Rare Allergic reactions · anaphylaxis · angioedema · erythema multiforme · photosensitivity · toxic epidermal necrolysis
- Frequency not known Aseptic meningitis · depression of haematopoiesis · gastro-intestinal disturbances · hyperkalaemia · nausea · pruritus · rashes · uveitis (in adults) · vomiting

SIDE-EFFECTS, FURTHER INFORMATION
Trimethoprim has side-effects similar to co-trimoxazole but they are less severe and occur less frequently.

PREGNANCY Teratogenic risk in first trimester (folate antagonist). Manufacturers advise avoid during pregnancy.

BREAST FEEDING Present in milk—short-term use not known to be harmful.

RENAL IMPAIRMENT
- In adults Use half normal dose after 3 days if eGFR 15–30 mL/minute/1.73 m². Use half normal dose if eGFR less than 15 mL/minute/1.73 m².
- In children Use half normal dose after 3 days if estimated glomerular filtration rate 15–30 mL/minute/1.73 m². Use half normal dose if estimated glomerular filtration rate less than 15 mL/minute/1.73 m². Monitor plasma-trimethoprim concentration if eGFR less than 10 mL/minute/1.73 m².

MONITORING REQUIREMENTS Manufacturer recommends blood counts on long-term therapy (but evidence of practical value unsatisfactory).

PATIENT AND CARER ADVICE
Blood disorders On long-term treatment, patients and their carers should be told how to recognise signs of blood disorders and advised to seek immediate medical attention if symptoms such as fever, sore throat, rash, mouth ulcers, purpura, bruising or bleeding develop.

Medicines for Children leaflet: Trimethoprim for bacterial infections www.medicinesforchildren.org.uk/trimethoprim-for-bacterial-infections

MEDICINAL FORMS There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Oral suspension**

CAUTIONARY AND ADVISORY LABELS 9
- **Trimethoprim (Non-proprietary)**
  - Trimethoprim 10 mg per 1 mL Trimethoprim 50mg/5ml oral suspension sugar free sugar-free | 100 mL [Link] £2.69 DT price = £2.12
- **Monotrim** (Chemidex Pharma Ltd)
  - Trimethoprim 10 mg per 1 mL Monotrim 50mg/5ml oral suspension sugar-free | 100 mL [Link] £1.77 DT price = £2.12
Rifabutin

- **INDICATIONS AND DOSE**
  
  **Prophylaxis of Mycobacterium avium complex infections in immunosuppressed patients with low CD4 count**
  
  - **BY MOUTH**
  - Adult: 300 mg once daily, also consult product literature

- **Treatment of non-tuberculous mycobacterial disease, in combination with other drugs**
  
  - **BY MOUTH**
  - Adult: 450–600 mg once daily for up to 6 months after cultures negative

- **Treatment of pulmonary tuberculosis, in combination with other drugs**
  
  - **BY MOUTH**
  - Adult: 150–450 mg once daily for at least 6 months

- **CAUTIONS**
  
  Acute porphyrias p. 969 · discolours soft contact lenses

- **INTERACTIONS** → Appendix 1: rifabutin

- **SIDE-EFFECTS**
  
  - **Common or very common** Anaemia · blood disorders · leucopenia · myalgia · nausea · pyrexia · rash · thrombocytopenia
  
  - **Uncommon** Arthralgia · body secretions coloured orange-red · bronchospasmy · corneal deposits · eosinophilia · hypersensitivity reactions · jaundice · raised liver enzymes · saliva coloured orange-red · skin coloured orange-red · urine coloured orange-red · uveitis · vomiting

- **Rare** Haemolysis · Frequency not known Chest pain · dyspnoea · hepatitis · influenza-like symptoms

- **SIDE-EFFECTS, FURTHER INFORMATION**
  
  Discontinue permanently if serious side-effects develop.

- **ALLERGY AND CROSS-SENSITIVITY**
  
  Contra-indicated in patients with rifamycin hypersensitivity.

- **CONCEPTION AND CONTRACEPTION**
  
  Important Rifabutin induces hepatic enzymes and the effectiveness of hormonal contraceptives is reduced; alternative family planning advice should be offered.

- **PREGNANCY**
  
  Manufacturer advises avoid—no information available.

- **BREAST FEEDING**
  
  Manufacturer advises avoid—no information available.

- **HEPATIC IMPAIRMENT**
  
  Reduce dose in severe impairment. In patients with pre-existing liver disease or hepatic impairment monitor liver function regularly and particularly frequently in the first 2 months; blood counts should also be monitored in these patients.

- **RENAL IMPAIRMENT**
  
  Use half normal dose if eGFR less than 30 mL/minute/1.73 m².

- **MONITORING REQUIREMENTS**
  
  Renal function should be checked before treatment. Hepatic function should be checked before treatment. If there is no evidence of liver disease (and pre-treatment liver function is normal), further checks are only necessary if the patient develops fever, malaise, vomiting, jaundice or unexplained deterioration during treatment. However, hepatic function should be monitored on prolonged therapy.

  - Blood counts should be monitored on prolonged therapy.
  - Those with alcohol dependence should have frequent checks of hepatic function, particularly in the first 2 months. Blood counts should also be monitored in these patients.

- **PRESCRIBING AND DISPENSING INFORMATION**
  
  If treatment interruption occurs, re-introduce with low dosage and increase gradually.

- **PATIENT AND CARER ADVICE**
  
  Soft contact lenses. Patients or their carers should be advised that rifabutin discolours soft contact lenses.

  Hepatic disorders. Patients or their carers should be told how to recognise signs of liver disorder, and advised to discontinue treatment and seek immediate medical attention if symptoms such as persistent nausea, vomiting, malaise or jaundice develop.

- **MEDICINAL FORMS**
  
  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

  **Capsule**
  
  **CAUTIONARY AND ADVISORY LABELS 8, 14**
  
  - **Rifabutin (Pfizer Ltd)**
    - Rifabutin 150 mg Mycobutin 150 mg capsules | 30 capsule £9.08

Rifaximin

- **DRUG ACTION**
  
  Rifaximin is a rifamycin that is poorly absorbed from the gastro-intestinal tract, and, therefore, should not be used to treat systemic infections.

- **INDICATIONS AND DOSE**
  
  **Travellers’ diarrhoea that is not associated with fever, bloody diarrhoea, blood or leucocytes in the stool, or 8 or more unformed stools in the previous 24 hours**
  
  - **BY MOUTH**
    - Adult: 200 mg every 8 hours for 3 days

  - **Reduction in recurrence of hepatic encephalopathy**
    - **BY MOUTH**
      - Adult: 550 mg twice daily

- **CONTRA-INDICATIONS**
  
  Intestinal obstruction

- **INTERACTIONS** → Appendix 1: rifaximin

- **SIDE-EFFECTS**
  
  - **Common or very common** Abdominal pain · depression · diarroea · dizziness · dysphoria · flatulence · headache · muscle spasm · nausea · pruritis · rash · vomiting
  
  - **Uncommon** Anorexia · antibiotic-associated colitis · anxiety · blood disorders · convulsions · dry mouth · dysuria · glcosuria · hyperkalaemia · hypoaesthesia · influenza-like symptoms · memory impairment · paraesthesia · peripheral oedema · polymenorrhoea · polyuria · sleep disturbances · taste disturbances

- **Rare** Blood pressure changes · constipation

- **Frequency not known**
  
  Syncope

- **ALLERGY AND CROSS-SENSITIVITY**
  
  Contra-indicated if history of rifamycin hypersensitivity.

- **PREGNANCY**
  
  Manufacturer advises avoid—toxicity in animal studies.

- **BREAST FEEDING**
  
  Unlikely to be present in milk in significant amounts, but manufacturer advises avoid.

- **HEPATIC IMPAIRMENT**
  
  Manufacturer advises caution when used for hepatic encephalopathy in patients with severe hepatic impairment.
**PRESCRIBING AND DISPENSING INFORMATION** Not recommended for diarrhea associated with invasive organisms such as Campylobacter and Shigella.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Rifaximin for preventing episodes of overt hepatic encephalopathy (March 2015) NICE TA337

Rifaximin is recommended, within its marketing authorisation, as an option for reducing the recurrence of episodes of overt hepatic encephalopathy in adults. www.nice.org.uk/TA337

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

<table>
<thead>
<tr>
<th>Oral suspension</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rifaximin (Non-proprietary)</strong></td>
<td></td>
</tr>
<tr>
<td>Rifaximin 20 mg per 1 ml Normix 100mg/5ml granules for oral suspension</td>
<td>100 ml Pom</td>
</tr>
<tr>
<td><strong>Tablet</strong></td>
<td></td>
</tr>
<tr>
<td>CAUTIONARY AND ADVISORY LABELS</td>
<td></td>
</tr>
<tr>
<td>14 (Targaxan® brand only), 9 (Xifaxan® brand only)</td>
<td></td>
</tr>
<tr>
<td><strong>Targaxan® (Norgine Pharmaceuticals Ltd)</strong></td>
<td></td>
</tr>
<tr>
<td>Rifaximin 550 mg Targaxan 550mg tablets</td>
<td>56 tablet Pom £129.52 DT price = £129.23</td>
</tr>
<tr>
<td><strong>Xifaxant® (Norgine Pharmaceuticals Ltd)</strong></td>
<td></td>
</tr>
<tr>
<td>Rifaximin 200 mg Xifaxanta 200mg tablets</td>
<td>9 tablet Pom £15.15 DT price = £15.15</td>
</tr>
</tbody>
</table>

---

### 2.1 Anthrax

**Anthrax**

**Treatment and post-exposure prophylaxis**

*Inhalation or gastro-intestinal anthrax* should be treated initially with either ciprofloxacin p. 527 or, in patients over 12 years, doxycycline p. 534 [unlicensed indication] combined with one or two other antibacterials (such as amoxicillin p. 518, benzylpenicillin sodium p. 517, chloramphenicol p. 537, clarithromycin p. 508, clindamycin p. 506, imipenem with cilastatin p. 495, rifampicin p. 549 [unlicensed indication], and vancomycin p. 505). When the condition improves and the sensitivity of the *Bacillus anthracis* strain is known, treatment may be switched to a single antibacterial. Treatment should continue for 60 days because germination may be delayed.

*Cutaneous anthrax* should be treated with either ciprofloxacin [unlicensed indication] or doxycycline [unlicensed indication] for 7 days. Treatment may be switched to amoxicillin if the infecting strain is susceptible. Treatment may need to be extended to 60 days if exposure is due to aerosol. A combination of antibacterials for 14 days is recommended for cutaneous anthrax with systemic features, extensive oedema, or lesions of the head or neck.

Ciprofloxacin or doxycycline may be given for *post-exposure prophylaxis*. If exposure is confirmed, antibacterial prophylaxis should continue for 60 days. Antibacterial prophylaxis may be switched to amoxicillin after 10–14 days if the strain of *B. anthracis* is susceptible. Vaccination against anthrax may allow the duration of antibacterial prophylaxis to be shortened.

---

### 2.2 Leprosy

**Leprosy**

**Management**

Advice from a member of the Panel of Leprosy Opinion is essential for the treatment of leprosy (Hansen’s disease).

Details can be obtained from the Hospital for Tropical Diseases, London (telephone (020) 3456 7890).

The World Health Organization has made recommendations to overcome the problem of dapsone p. 545 resistance and to prevent the emergence of resistance to other antileprotic drugs. Drugs recommended are dapsone, rifampicin p. 549, and clofazimine below. Other drugs with significant activity against *Mycobacterium leprae* include doxycycline p. 536, minocycline p. 535 and clarithromycin p. 508, but none of these are as active as rifampicin; at present they should be reserved as second-line drugs for leprosy.

A three-drug regimen is recommended for *multibacillary leprosy* (lepromatous, borderline-lepromatous, and borderline leprosy) and a two-drug regimen for *paucibacillary leprosy* (borderline-tuberculoid, tuberculoid, and indeterminate).

Multibacillary leprosy should be treated with a combination of rifampicin, dapsone and clofazimine for at least 2 years. Treatment should be continued unchanged during both type I (reversal) or type II (erythema nodosum leprosum) reactions. During reversal reactions neuritic pain or weakness can herald the rapid onset of permanent nerve damage. Treatment with prednisolone p. 639 should be instituted at once. Mild type II reactions may respond to aspirin. Severe type II reactions may require corticosteroids; thalidomide p. 887 [unlicensed] is also useful in patients who have become corticosteroid dependent, but it should be used only under *specialist supervision*. Thalidomide is teratogenic and, therefore, contra-indicated in pregnancy; it must not be given to women of child-bearing potential unless they comply with a pregnancy prevention programme. Increased doses of clofazimine are also useful.

Paucibacillary leprosy should be treated with rifampicin and dapsone for 6 months. If treatment is interrupted the regimen should be recommenced where it was left off to complete the full course.

Neither the multibacillary nor the paucibacillary antileprosy regimen is sufficient to treat tuberculosis.

**ANTIMYCOBACTERIALS**

**Clofazimine**

**INDICATIONS AND DOSE**

*Multibacillary leprosy in combination with rifampicin and dapsone (3-drug regimen) (administered on expert advice)*

- **BY MOUTH**
  - Adult: 300 mg once a month, to be administered under supervision and 50 mg daily, to be self-administered, alternatively 300 mg once a month, to be administered under supervision and 100 mg once daily on alternate days, to be self-administered

*Lepromatous lepra reactions (administered on expert advice)*

- **BY MOUTH**
  - Adult: 300 mg daily for max. 3 months

*Severe type II (erythema nodosum leprosum) reactions (administered on expert advice)*

- **BY MOUTH**
  - Adult: 100 mg 3 times a day for one month, subsequent dose reductions are required, may take 4–6 weeks to attain full effect

**CAUTIONS** Avoid if persistent abdominal pain and diarrhea - may discolor soft contact lenses

**INTERACTIONS** → Appendix 1: clofazimine

**SIDE-EFFECTS** Abdominal pain - acne-like eruptions - anorexia - bowel obstruction - brownish-black discoloration of lesions and skin including areas exposed...
to light • dimmed vision • dry eyes • dry skin • elevation of
blood sugar • eosinophilic enteropathy • headache •
lymphadenopathy • macular corneal pigmentation •
nausea • photosensitivity • pruritus • rash • red discoloration of
body fluids • red discoloration of faeces • red
discoloration of urine • reversible hair discoloration •
splenic infarction • subepithelial corneal pigmentation •
tiredness • vomiting (hospitalise if persistent) • weight loss

- PREGNANCY Use with caution.
- BREAST FEEDING May alter colour of milk; skin
discoloration of infant.
- HEPATIC IMPAIRMENT Use with caution.
- RENAL IMPAIRMENT Use with caution.

- MEDICINAL FORMS
There can be variation in the licensing of different medicines
containing the same drug. Forms available from special-order
manufacturers include: capsule

Capsule
CAUTIONARY AND ADVISORY LABELS 8, 14, 21

- Clofazimine (Non-proprietary)
  Clofazimine 50 mg Lamprrene 50mg capsules | 100 capsule POM
  no price available

Dapsone

- INDICATIONS AND DOSE
Multibacillary leprosy in combination with rifampicin and
clofazimine (3-drug regimen) | Paucibacillary leprosy in
combination with rifampicin (2-drug regimen)
  • BY MOUTH
  • Adult (body-weight up to 35 kg): 50 mg daily,
    alternatively 1–2 mg/kg daily, may be self-
    administered
  • Adult (body-weight 35 kg and above): 100 mg daily, may be
    self-administered

Dermatitis herpetiformis
  • BY MOUTH
  • Adult: (consult product literature or local protocols)

Treatment of mild to moderate Pneumocystis jirovecii
(Pneumocystis carinii) pneumonia (in combination with
trimethoprim)
  • BY MOUTH
  • Adult: 100 mg once daily

Prophylaxis of Pneumocystis jirovecii (Pneumocystis
carinii) pneumonia
  • BY MOUTH
  • Adult: 100 mg daily

- UNLICENSED USE Not licensed for treatment of
  pneumocystis (P. jirovecii) pneumonia.
- CAUTIONS Anaemia (treat severe anaemia before starting)
  • Avoid in acute porphyrinas p. 969 • cardiac disease • G6PD
deficiency • pulmonary disease • susceptibility to
  haemolysis
- INTERACTIONS ➔ Appendix 1: dapsone
- SIDE-EFFECTS
  • Rare Stevens-Johnson syndrome • toxic epidermal
    necrolysis
  • Frequency not known Agranulocytosis • allergic dermatitis
    • anorexia • dapsone syndrome • haemolysis • headache •
    hepatitis • insomnia • methaemoglobinaemia • nausea •
    neuropathy • psychosis • tachycardia • vomiting

SIDE-EFFECTS, FURTHER INFORMATION
Side-effects are dose-related and uncommon at doses used
for leprosy.

- Dapsone syndrome If dapsone syndrome occurs (rash with
  fever and eosinophilia)—discontinue immediately (may
  progress to exfoliative dermatitis, hepatitis,
  hypoalbuminaemia, psychosis and death).

- PREGNANCY Folic acid p. 937 (higher dose) should be
given to mother throughout pregnancy; neonatal
  haemolysis and methaemoglobinaemia reported in third
  trimester.
- BREAST FEEDING Haemolytic anaemia; although
  significant amount in milk, risk to infant very small unless
  infant is G6PD deficient.
- PATIENT AND CARER ADVICE
  Blood disorders On long-term treatment, patients and their
  carers should be told how to recognise signs of blood
  disorders and advised to seek immediate medical attention
  if symptoms such as fever, sore throat, rash, mouth ulcers,
  purpura, bruising or bleeding develop.

- MEDICINAL FORMS
There can be variation in the licensing of different medicines
containing the same drug. Forms available from special-order
manufacturers include: oral suspension, oral solution

Tablet
CAUTIONARY AND ADVISORY LABELS 8

- Dapsone (Non-proprietary)
  Dapsone 50 mg Dapsone 50mg tablets | 28 tablet POM £51.00 DT
  price = £40.77
  Dapsone 100 mg Dapsone 100mg tablets | 28 tablet POM £105.07
  DT price = £105.07

2.3 Lyme disease

Lyme disease

Treatment
Doxycycline p. 534, amoxicillin p. 518 [unlicensed
indication] or cefuroxime p. 498 (as cefuroxime axetil) are
the antibacterials of choice for early Lyme disease or Lyme
arthritis. If these antibacterials are contra-indicated, a
macrolide (e.g. clarithromycin p. 508) can be used for early
Lyme disease. Intravenous administration of ceftriaxone
p. 501, cefotaxime p. 500, or benzylpenicillin sodium p. 517
is recommended for Lyme disease associated with cardiac or
neurological complications. The duration of treatment is
usually 2–4 weeks; Lyme arthritis may require further
treatment.

2.4 Methicillin-resistant staphylococcus aureus

MRSA

Management
Infection from Staphylococcus aureus strains resistant to
meticillin [now discontinued] (meticillin-resistant Staph.
aureus, MRSA) and to flucloxacillin p. 523 can be difficult
to manage. Treatment is guided by the sensitivity of the
infecting strain.

Rifampicin p. 549 or fusidic acid p. 539 should not be used
alone because resistance may develop rapidly. A
tetracycline alone or a combination of rifampicin and
fusidic acid can be used for skin and soft-tissue infections
caused by MRSA; clindamycin p. 506 alone is an alternative.
A glycopeptide (e.g. vancomycin p. 505) can be used for
severe skin and soft-tissue infections associated with MRSA;
if a glycopeptide is unsuitable, linezolid p. 540 can be used
on expert advice. As linezolid is not active against Gram-
negative organisms, it can be used for mixed skin and soft-
tissue infections only when other treatments are not
available; linezolid must be given with other antibacterials if
the infection also involves Gram-negative organisms. A
combination of a glycopeptide and fusidic acid or a glycopeptide and rifampicin can be considered for skin and soft-tissue infections that have failed to respond to a single antibacterial. Tigecycline p. 536 and daptomycin p. 537 are licensed for the treatment of complicated skin and soft-tissue infections involving MRSA.

A tetracycline or clindamycin can be used for bronchiectasis caused by MRSA. A glycopeptide can be used for pneumonia associated with MRSA; if a glycopeptide is unsuitable, linezolid can be used on expert advice. Linezolid must be given with other antibacterials if the infection also involves Gram-negative organisms. A tetracycline can be used for urinary-tract infections caused by MRSA; trimethoprim p. 542 or nitrofurantoin p. 557 are alternatives. A glycopeptide can be used for urinary-tract infections that are severe or resistant to other antibacterials.

A glycopeptide can be used for septicaemia associated with MRSA. See the management of endocarditis, osteomyelitis, or septic arthritis associated with MRSA.

Prophylaxis with vancomycin or teicoplanin p. 504 (alone or in combination with another antibacterial active against other pathogens) is appropriate for patients undergoing surgery if:

- there is a history of MRSA colonisation or infection without documented eradication;
- there is a risk that the patient’s MRSA carriage has recurred;
- the patient comes from an area with a high prevalence of MRSA.

See eradication of nasal carriage of MRSA in Nose p. 1098.

## 2.5 Tuberculosis

### Tuberculosis

#### Treatment phases, overview

Active tuberculosis is treated in two phases—an initial phase using four drugs and a continuation phase using two drugs in fully sensitive cases. Treatment requires specialised knowledge and supervision, particularly where the disease involves resistant organisms or non-respiratory organs.

There are two regimens recommended for the treatment of tuberculosis in the UK; variations occur in other countries. Either the unsupervised regimen or the supervised regimen should be used; the two regimens should not be used concurrently. Compliance with therapy is a major determinant of its success.

#### Initial phase

The concurrent use of four drugs during the initial phase is designed to reduce the bacterial population as rapidly as possible and to prevent the emergence of drug-resistant bacteria. The drugs are best given as fixed-dose, combination preparations unless one of the components cannot be given because of resistance or intolerance. The treatment of choice for the initial phase is the daily use of rifampicin p. 549, ethambutol hydrochloride p. 554, pyrazinamide p. 555 and isoniazid p. 556 with pyridoxine hydrochloride p. 988 for prophylaxis of isoniazid-induced neuropathy; modified according to drug susceptibility testing. Treatment should be started without waiting for culture results if clinical features or histology results are consistent with tuberculosis; treatment should be continued even if initial culture results are negative. The initial phase drugs should be continued for two months. Where a positive culture for M. tuberculosis has been obtained, but susceptibility results are not available after two months, treatment with rifampicin, ethambutol hydrochloride, isoniazid and pyrazinamide (with pyridoxine hydrochloride) should be continued until full susceptibility is confirmed, even if this is for longer than two months.

Streptomycin p. 492 is rarely used in the UK but it may be used in the initial phase of treatment if resistance to isoniazid has been established before therapy is commenced, or when patients cannot tolerate standard treatment.

#### Continuation phase

After the initial phase, daily treatment is continued for a further four months with rifampicin and isoniazid (preferably given as a combination preparation) with pyridoxine hydrochloride. Longer treatment is necessary for meningitis, direct spinal cord involvement, and for resistant organisms which may also require modification of the regimen.

#### Unsupervised treatment

The unsupervised treatment regimen should be used for patients who are likely to take antituberculosis drugs reliably without supervision. Patients who are unable or unlikely to comply with daily administration of therapy should be treated with the regimen described under Supervised Treatment.

#### Pregnancy and breast-feeding

The standard unsupervised six month treatment regimen may be used during pregnancy. Streptomycin should not be given in pregnancy. The standard unsupervised six month treatment regimen may be used during breast-feeding.

#### Supervised treatment

Drug administration should be fully supervised (directly observed therapy, DOT) in patients who cannot comply reliably with the treatment regimen. If daily directly observed therapy is not possible, a supervised dosing schedule of three times a week should be considered. Regimens with a dosing schedule of fewer than three times a week should not be used.

Directly observed therapy should be offered to patients who:

- have a history of non-adherence;
- have previously been treated for tuberculosis;
- are in denial of the tuberculosis diagnosis;
- have multidrug-resistant tuberculosis;
- have a major psychiatric or cognitive disorder;
- have a history of homelessness, drug or alcohol misuse;
- are in prison, or have been in the past 5 years;
- are too ill to self-administer treatment;
- request directly observed therapy.

#### Immunocompromised patients

Multi-resistant Mycobacterium tuberculosis may be present in immunocompromised patients. The organism should always be cultured to confirm its type and drug sensitivity. Confirmed M. tuberculosis infection sensitive to first-line drugs should be treated with a standard six month regimen; after completing treatment, patients should be closely monitored. The regimen may need to be modified if infection is caused by resistant organisms, and specialist advice is needed.

Specialist advice should be sought about tuberculosis treatment or chemoprophylaxis for patients who are HIV-positive (see also Latent tuberculosis below); care is required in choosing the regimen and in avoiding potentially serious interactions. Starting antiretroviral treatment in the first two months of antituberculosis treatment increases the risk of immune reconstitution syndrome. Treatment for tuberculosis should not routinely exceed six months in patients who are HIV-positive, unless the tuberculosis has central nervous system involvement (in which case
### Recommended dosage for standard unsupervised 6-month treatment

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Adult:</th>
<th>Child:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rifampicin with isoniazid and pyrazinamide</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body-weight up to 40 kg: 3 tablets daily for 2 months (initial phase), use Rifater&lt;sup&gt;®&lt;/sup&gt; Tablets, preferably taken before breakfast;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body-weight 40–49 kg: 4 tablets daily for 2 months (initial phase), use Rifater&lt;sup&gt;®&lt;/sup&gt; Tablets, preferably taken before breakfast;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body-weight 50–64 kg: 5 tablets daily for 2 months (initial phase), use Rifater&lt;sup&gt;®&lt;/sup&gt; Tablets, preferably taken before breakfast;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body-weight 65 kg and above: 6 tablets daily for 2 months (initial phase), use Rifater&lt;sup&gt;®&lt;/sup&gt; Tablets, preferably taken before breakfast</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethambutol hydrochloride</td>
<td>Adult: 15 mg/kg once daily for 2 months (initial phase)</td>
<td></td>
</tr>
<tr>
<td><strong>Rifampicin with isoniazid</strong></td>
<td>Adult:</td>
<td>Child:</td>
</tr>
<tr>
<td>Body-weight up to 50 kg: 450/300 mg daily for 4 months (continuation phase after 2-month initial phase), use Rifinah&lt;sup&gt;®&lt;/sup&gt;150/100 Tablets, preferably taken before breakfast;</td>
<td></td>
<td>10 mg/kg once daily (max. per dose 300 mg) for 6 months (initial and continuation phases)</td>
</tr>
<tr>
<td>Body-weight 50 kg and above: 600/300 mg daily for 4 months (continuation phase after 2-month initial phase), use Rifinah&lt;sup&gt;®&lt;/sup&gt;300/150 Tablets, preferably taken before breakfast</td>
<td></td>
<td>Adult: 300 mg daily for 6 months (initial and continuation phases)</td>
</tr>
<tr>
<td><strong>Isoniazid</strong></td>
<td>Adult:</td>
<td></td>
</tr>
<tr>
<td>Body-weight up to 50 kg: 15 mg/kg once daily for 6 months (initial and continuation phases); maximum 450 mg per day;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body-weight 50 kg and above: 15 mg/kg once daily for 6 months (initial and continuation phases); maximum 600 mg per day</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pyrazinamide</strong></td>
<td>Adult:</td>
<td>Child:</td>
</tr>
<tr>
<td>Body-weight up to 50 kg: 35 mg/kg once daily for 2 months (initial phase); maximum 1.5 g per day;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body-weight 50 kg and above: 35 mg/kg once daily for 2 months (initial phase); maximum 2 g per day;</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ethambutol hydrochloride</strong></td>
<td>Adult:</td>
<td>Child:</td>
</tr>
<tr>
<td>Body-weight up to 50 kg: 15 g once daily for 2 months (initial phase);</td>
<td></td>
<td>20 mg/kg once daily for 2 months (initial phase)</td>
</tr>
<tr>
<td>Body-weight 50 kg and above: 2 g once daily for 2 months (initial phase)</td>
<td></td>
<td>Adult: 15 mg/kg once daily for 2 months (initial phase)</td>
</tr>
</tbody>
</table>

*or (if combination preparations not appropriate)*

### Recommended dosage for intermittent supervised 6-month treatment

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Adult:</th>
<th>Child:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Isoniazid</strong></td>
<td></td>
<td>Child: 15 mg/kg 3 times a week (max. per dose 900 mg) for 6 months (initial and continuation phases)</td>
</tr>
<tr>
<td><strong>Rifampicin</strong></td>
<td>Adult: 15 mg/kg 3 times a week (max. per dose 900 mg) for 6 months (initial and continuation phases)</td>
<td>Child: 15 mg/kg 3 times a week (max. per dose 900 mg) for 6 months (initial and continuation phases)</td>
</tr>
<tr>
<td><strong>Pyrazinamide</strong></td>
<td>Adult: 600-900 mg 3 times a week for 6 months (initial and continuation phases)</td>
<td>Child: 50 mg/kg 3 times a week (max. per dose 2 g 3 times a week) for 2 months (initial phase);</td>
</tr>
<tr>
<td><strong>Ethambutol hydrochloride</strong></td>
<td>Adult:</td>
<td>Child: 30 mg/kg 3 times a week for 2 months (initial phase)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Adult: 30 mg/kg 3 times a week for 2 months (initial phase)</td>
</tr>
</tbody>
</table>

Downloaded from www.medicalbr.com
treatment should not routinely extend beyond twelve months). Infection may also be caused by other mycobacteria e.g. M. avium complex, in which case specialist advice on management is needed.

**Extrapulmonary tuberculosis**

**Central nervous system tuberculosis**

Patients with active central nervous system tuberculosis should be offered treatment with rifampicin, ethambutol hydrochloride, isoniazid and pyrazinamide (with pyridoxine hydrochloride for prophylaxis of isoniazid-induced neuropathy) for two months. After completion of the initial treatment phase, rifampicin and isoniazid (with pyridoxine hydrochloride) should be continued for a further ten months. Treatment for tuberculosis meningitis should be offered if clinical signs and laboratory findings are consistent with the diagnosis, even if a rapid diagnostic test is negative.

An initial high dose of dexamethasone p. 635 or prednisolone p. 639 should be started at the same time as antituberculosis therapy, and then slowly withdrawn over 4–8 weeks.

Referral for surgery should be considered only in patients who have raised intracranial pressure.

**Pericardial tuberculosis**

An initial high dose of oral prednisolone should be offered to patients with active pericardial tuberculosis at the same time as initiation of antituberculosis therapy; it should then be slowly withdrawn over 2–3 weeks.

**Latent tuberculosis**

Clinicians should be aware that some patients with latent tuberculosis are at increased risk of developing active tuberculosis (such as patients who are HIV-positive, diabetic or receiving treatment with a tumour necrosis factor alpha inhibitor). These patients should be advised of the risks and symptoms of active tuberculosis.

Note: the risk of adverse events to chemoprophylaxis in patients aged over 35 years with a risk of hepatotoxicity is likely to be greater than the potential benefit of treating latent disease. When indicated, drug treatment should only be offered to patients aged 35–65 years if hepatotoxicity is not a concern. Treatment for latent tuberculosis is not usually indicated in patients over 65 years.

**Close contacts**

Anyone aged under 65 years who is a close contact (prolonged, frequent or intense contact, e.g. household contacts or partners) of a person with pulmonary or laryngeal tuberculosis should be tested for latent tuberculosis. Chemoprophylaxis should be offered to all patients aged younger than 65 years, with evidence of latent tuberculosis if the close contact has suspected-infectious or confirmed-active pulmonary or laryngeal drug-sensitive tuberculosis.

**Immunocompromised**

Patients who are immunocompromised, such as those with HIV or who have had a solid organ or allogeneic stem cell transplant, should be tested for latent tuberculosis using an appropriate method. Patients who test positive should then be assessed for active disease, and if negative, offered treatment for latent tuberculosis.

**Healthcare workers**

New NHS employees who are new entrants from a high incidence country should be offered appropriate testing for latent tuberculosis; those who are not new entrants from a high incidence country, but who will be in contact with patients or clinical materials should be offered appropriate testing for latent tuberculosis if prior BCG vaccination cannot be verified (see also BCG vaccine under Vaccines p. 1190). Those who test positive should then be assessed for active disease, and if negative, offered treatment for latent tuberculosis.

For healthcare workers who are immunocompromised, follow standard advice for testing and treatment (see Immunocompromised above).

**Chemoprophylaxis for latent tuberculosis**

Chemoprophylaxis involves use of either isoniazid p. 554 (with pyridoxine hydrochloride p. 988) alone for six months (recommended if interactions with rifamycins are a concern) or rifampicin p. 549 and isoniazid (with pyridoxine hydrochloride) for three months (recommended when hepatotoxicity is a concern).

Choice of regimen is dependent on clinical factors, including age, risk of hepatotoxicity and possible drug interactions. Testing for HIV, hepatitis B and hepatitis C should be offered before starting antituberculosis treatment as this may affect choice of therapy.

Patients with severe liver disease should be treated under the care of a specialist team; careful monitoring of liver function is necessary in patients with non-severe liver disease, abnormal liver function, or who misuse alcohol or drugs.

See advice on immunisation against tuberculosis under Vaccines p. 1190.

**Treatment failure**

Major causes of treatment failure are incorrect prescribing by the physician and inadequate compliance by the patient. Monthly tablet counts and urine examination (rifampicin imparts an orange-red coloration) may be useful indicators of compliance with treatment. Avoid both excessive and inadequate dosage. Treatment should be supervised by a specialist physician.

**Treatment interruptions**

A break in antituberculosis treatment of at least two weeks (during the initial phase) or missing more than 20% of prescribed doses is classified as treatment interruption. Re-establishing treatment appropriately following interruptions is key to ensuring treatment success without relapse, drug resistance or further adverse events. If an adverse reaction recurs upon re-introducing a particular drug, do not give that drug in future regimens and consider extending the total regimen accordingly.

**Treatment interruptions due to drug-induced hepatotoxicity**

Following treatment interruption due to drug-induced hepatotoxicity, all potential causes of hepatotoxicity should be investigated. Once hepatic function has recovered, antituberculosis therapy should be sequentially reintroduced at previous full doses over a period of no more than ten days, initially with ethambutol hydrochloride p. 554 and either isoniazid (with pyridoxine hydrochloride) or rifampicin.

In patients with severe or highly infectious tuberculosis who need to interrupt the standard regimen, consider continuing treatment with at least two drugs with low risk of hepatotoxicity, such as ethambutol hydrochloride and streptomycin p. 492 (with or without a quinolone, such as levofloxacin p. 528 or moxifloxacin p. 529), with ongoing monitoring by a liver specialist.

**Treatment interruptions due to cutaneous reactions**

If a patient with severe or highly infectious tuberculosis has a cutaneous reaction, consider continuing treatment with a combination of at least two drugs with low risk for causing cutaneous reactions, such as ethambutol hydrochloride and streptomycin, with monitoring by a dermatologist.
Antituberculosis drugs
Isoniazid is cheap and highly effective. Like rifampicin it should always be included in any antituberculosis regimen unless there is a specific contra-indication.
Rifampicin, a rifamycin, is a key component of any antituberculosis regimen. Like isoniazid it should always be included unless there is a specific contra-indication.
During the first two months ('initial phase') of rifampicin administration transient disturbance of liver function with elevated serum transaminases is common but generally does not require interruption of treatment. Occasionally more serious liver toxicity requires a change of treatment particularly in those with pre-existing liver disease.
On intermittent treatment six toxicity syndromes have been recognised—influenza-like, abdominal, and respiratory symptoms, shock, renal failure, and thrombocytopenic purpura—and can occur in 20–30% of patients.
Rifabutin p. 543, another rifamycin, is indicated for prophylaxis against M. avium complex infections in patients with a low CD4 count; it is also licensed for the treatment of non-tuberculous mycobacterial disease and pulmonary tuberculosis.
Pyrazinamide p. 555 is a bactericidal drug only active against intracellular dividing forms of Mycobacterium tuberculosis; it exerts its main effect only in the first two or three months. It is particularly useful in tuberculous meningitis because of good meningeal penetration. It is not active against M. bovis.
Ethambutol hydrochloride is included in a treatment regimen if isoniazid resistance is suspected; it can be omitted if the risk of resistance is low.
Streptomycin [unlicensed] is now rarely used in the UK except for resistant organisms.
Drug-resistant tuberculosis
Drug-resistant tuberculosis should be treated by a specialist physician with experience in such cases, and where appropriate facilities for infection-control exist. Multidrug-resistant tuberculosis (resistance to isoniazid and rifampicin, with or without any other resistance) requires treatment with at least six antituberculosis drugs to which the mycobacterium is likely to be sensitive. Testing for resistance to second-line drugs is recommended and treatment should be modified according to susceptibility. The risk of resistance is minimised by ensuring therapy is administered in the correct dose and combination for the prescribed duration.
Second-line drugs available for infections caused by resistant organisms, or when first-line drugs cause unacceptable side-effects, include aminosalicylic acid p. 552, amikacin p. 491, capreomycin p. 553, cycloserine p. 553, newer macrolides (e.g. azithromycin p. 507 and clarithromycin p. 508), moxifloxacin and prothionamide (prothionamide; no longer on UK market). Bedaquiline p. 552 and delamanid p. 553 are licensed for the treatment of multiple-drug resistant pulmonary tuberculosis. Bedaquiline has a long half-life.
Single drug-resistant tuberculosis
For single drug-resistance the following treatment regimens are recommended:

Resistance to isoniazid:
- First two months (initial phase): rifampicin, pyrazinamide and ethambutol hydrochloride
- Continue with (continuation phase): rifampicin and ethambutol hydrochloride for seven months (up to ten months for extensive disease)

Resistance to pyrazinamide:
- First two months (initial phase): rifampicin, ethambutol hydrochloride and isoniazid (with pyridoxine hydrochloride)
- Continue with (continuation phase): rifampicin and isoniazid (with pyridoxine hydrochloride) for seven months

Resistance to ethambutol hydrochloride:
- First two months (initial phase): rifampicin, pyrazinamide and isoniazid (with pyridoxine hydrochloride)
- Continue with (continuation phase): rifampicin and isoniazid (with pyridoxine hydrochloride) for four months

Resistance to rifampicin below:
- Offer treatment with at least six antituberculosis drugs to which the mycobacterium is likely to be sensitive.

Management of tuberculosis in children
Children are given isoniazid p. 554, rifampicin, pyrazinamide p. 555, and ethambutol hydrochloride p. 554 for the first two months followed by isoniazid and rifampicin during the next four months. However, care is needed in young children receiving ethambutol hydrochloride because of the difficulty in testing eyesight and in obtaining reports of visual symptoms.

ANTIMYCOBACTERIALS › RIFAMYCINS

Rifampicin

- INDICATIONS AND DOSE
  - Brucellosis in combination with other antibiotics | Legionnaires disease in combination with other antibiotics | Serious staphylococcal infections in combination with other antibiotics
    - BY MOUTH, OR BY INTRAVENOUS INFUSION
      - Child 1–11 months: 5–10 mg/kg twice daily
      - Child 1–7 years: 10 mg/kg twice daily (max. per dose 600 mg)
      - Adult: 0.6–1.2 g daily in 2–4 divided doses
  - Endocarditis in combination with other drugs
    - BY MOUTH, OR BY INTRAVENOUS INFUSION
      - Adult: 0.6–1.2 g daily in 2–4 divided doses
  - Tuberculosis, in combination with other drugs (intermittent supervised 6-month treatment) (under expert supervision)
    - BY MOUTH
      - Child: 15 mg/kg 3 times a week (max. per dose 900 mg) for 6 months (initial and continuation phases)
      - Adult: 600–900 mg 3 times a week for 6 months (initial and continuation phases)
  - Tuberculosis, in combination with other drugs (standard unsupervised 6-month treatment)
    - BY MOUTH
      - Child (body-weight up to 50 kg): 15 mg/kg once daily for 6 months (initial and continuation phases); maximum 450 mg per day
      - Child (body-weight 50 kg and above): 15 mg/kg once daily for 6 months (initial and continuation phases); maximum 600 mg per day
      - Adult (body-weight up to 50 kg): 450 mg once daily for 6 months (initial and continuation phases)
      - Adult (body-weight 50 kg and above): 600 mg once daily for 6 months (initial and continuation phases)
  - Prevention of tuberculosis in susceptible close contacts or those who have become tuberculin positive, in combination with isoniazid
    - BY MOUTH
      - Child 1 month–11 years (body-weight up to 50 kg): 15 mg/kg daily for 3 months; maximum 450 mg per day
      - Child 1 month–11 years (body-weight 50 kg and above): 15 mg/kg daily for 3 months; maximum 600 mg per day

continued →
 Child 12-17 years (body-weight up to 50 kg): 450 mg daily for 3 months  
 Child 12-17 years (body-weight 50 kg and above): 600 mg daily for 3 months  
 Adult (body-weight up to 50 kg): 450 mg daily for 3 months  
 Adult (body-weight 50 kg and above): 600 mg daily for 3 months

Prevention of tuberculosis in susceptible close contacts or those who have become tuberculin positive, who are isoniazid-resistant

**BY MOUTH**
- Child 1 month-11 years (body-weight up to 50 kg): 15 mg/kg daily for 6 months; maximum 450 mg per day  
- Child 1 month-11 years (body-weight 50 kg and above): 15 mg/kg daily for 6 months; maximum 600 mg per day  
- Child 12-17 years (body-weight up to 50 kg): 450 mg daily for 6 months  
- Child 12-17 years (body-weight 50 kg and above): 600 mg daily for 6 months

Prevention of tuberculosis in susceptible close contacts or those who have become tuberculin positive, who are isoniazid-resistant and under 35 years

**BY MOUTH**
- Adult 18-34 years (body-weight up to 50 kg): 450 mg daily for 6 months  
- Adult 18-34 years (body-weight 50 kg and above): 600 mg daily for 6 months

Prevention of secondary case of Haemophilus influenzae type b disease

**BY MOUTH**
- Child 1-2 months: 10 mg/kg once daily for 4 days  
- Child 3 months-11 years: 20 mg/kg once daily (max. per dose 600 mg) for 4 days  
- Child 12-17 years: 600 mg once daily for 4 days  
- Adult: 600 mg once daily for 4 days

Prevention of secondary case of meningococcal meningitis

**BY MOUTH**
- Child 1-11 months: 5 mg/kg every 12 hours for 2 days  
- Child 1-11 years: 10 mg/kg every 12 hours (max. per dose 600 mg), for 2 days  
- Child 12-17 years: 600 mg every 12 hours for 2 days  
- Adult: 600 mg every 12 hours for 2 days

Multibacillary leprosy in combination with dapsone and clofazimine (3-drug regimen) Paucibacillary leprosy in combination with dapsone (2-drug regimen)

**BY MOUTH**
- Adult (body-weight up to 35 kg): 450 mg once a month, supervised administration  
- Adult (body-weight 35 kg and above): 600 mg once a month, supervised administration

**UNLICENSED USE** Not licensed for use in children for pruritus due to cholestasis.

**CONTRA-INDICATIONS** Acute porphyrias p. 969 · jaundice

**CAUTIONS** Discourages soft contact lenses

**INTERACTIONS** → Appendix 1: rifampicin

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**
- Acute renal failure · adrenal insufficiency · alterations of liver function · anorexia · antibiotic-associated colitis · body secretions coloured orange-red · collapse and shock · diarrhoea · disseminated intravascular coagulation · drowsiness · eosinophilia · exfoliative dermatitis · flushing · gastro-intestinal symptoms · haemolytic anaemia · headache · influenza-like symptoms (with chill, fever, dizziness, bone pain) · jaundice · leucopenia · menstrual disturbances · muscular weakness · myopathy · nausea · oedema · pemphigoid reactions · psychoses · rashes · respiratory symptoms · saliva coloured orange-red · shortness of breath · Stevens-Johnson syndrome · thrombocytopenic purpura · toxic epidermal necrolysis · urine coloured orange-red · urticaria · vomiting

**SPECIFIC SIDE-EFFECTS**
- With intravenous use Thrombophlebitis reported if infusion used for prolonged period

**SIDE-EFFECTS, FURTHER INFORMATION**
- Discontinue permanently if serious side-effects develop.
- Intermittent therapy Side-effects that mainly occur with intermittent therapy include influenza-like symptoms (with chill, fever, dizziness, bone pain), respiratory symptoms (including shortness of breath), collapse and shock, haemolytic anaemia, thrombocytopenic purpura, disseminated intravascular coagulation, and acute renal failure

**ALLERGY AND CROSS-SENSITIVITY** Contra-indicated in patients with rifampicin hypersensitivity.

**CONCEPTION AND CONTRACTION**
- Important Effectiveness of hormonal contraceptives is reduced and alternative family planning advice should be offered.

**PREGNANCY**
- Manufacturers advise very high doses teratogenic in animal studies in first trimester; risk of neonatal bleeding may be increased in third trimester.

** BREAST FEEDING**
- Amount too small to be harmful.

**HEPATIC IMPAIRMENT**
- Avoid or do not exceed 8 mg/kg daily. Impaired elimination. In patients with pre-existing liver disease or hepatic impairment, monitor liver function regularly and particularly frequently in the first 2 months; blood counts should also be monitored in these patients.

**RENAL IMPAIRMENT**
- In children Use with caution if doses above 10 mg/kg daily.  
- In adults Use with caution if dose above 600 mg daily.

**MONITORING REQUIREMENTS**
- Renal function should be checked before treatment.

**HEPATIC FUNCTION**
- Hepatic function should be checked before treatment. If there is no evidence of liver disease (and pre-treatment liver function is normal), further checks are only necessary if the patient develops fever, malaise, vomiting, jaundice or unexplained deterioration during treatment. However, liver function should be monitored on prolonged therapy.
- Blood counts should be monitored in patients on prolonged therapy.
- In adults Those with alcohol dependence should have frequent checks of hepatic function, particularly in the first 2 months. Blood counts should also be monitored in these patients.

**DIRECTIONS FOR ADMINISTRATION**
- With intravenous use in adults For intravenous infusion (Rifadin®), give intermittently in Glucose 5% or Sodium chloride 0.9%; reconstitute with solvent provided then dilute with 500 mL infusion fluid; give over 2–3 hours.
- With intravenous use in children Displacement value may be significant, consult local reconstitution guidelines; reconstitute with solvent provided. May be further diluted with Glucose 5% or Sodium chloride 0.9% to a final concentration of 1.2 mg/mL. Infuse over 2–3 hours.

**PRESCRIBING AND DISPENSING INFORMATION**
- If treatment interruption occurs, re-introduce with low dosage and increase gradually. Flavours of syrup may include raspberry.
- With oral use in children In general, doses should be rounded up to facilitate administration of suitable volumes of liquid or an appropriate strength of tablet. Doses may also need to be recalculated to allow for weight gain in younger children.

**PATIENT AND CARER ADVICE**
- Soft contact lenses Patients or their carers should be advised that rifampicin discourages soft contact lenses.
Hepatic disorders Patients or their carers should be told how to recognise signs of liver disorder, and advised to discontinue treatment and seek immediate medical attention if symptoms such as persistent nausea, vomiting, malaise or jaundice develop.

Medicines for Children leaflet: Rifampicin for meningococcal prophylaxis www.medicinesforchildren.org.uk/ rifampicin-for-meningococcal-prophylaxis


**CAUTIONS**

There can be variation in the licensing of different medicines containing the same drug. Please consider rifampicin p. 549, isoniazid p. 554, ethambutol hydrochloride p. 554, pyrazinamide p. 555.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

- **Oral suspension**
  - rifampicin-for-treatment-of-tuberculosis

**CAUTIONARY AND ADVISORY LABELS**

- **Oral suspension**
  - rifampicin-for-treatment-of-tuberculosis

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS**
  - rifampicin-for-treatment-of-tuberculosis

**INDICATIONS AND DOSE**

**Treatment of tuberculosis (continuation phase)**

- **BY MOUTH**
  - Adult (body-weight up to 50 kg): 450/300 mg daily for 4 months (continuation phase after 2-month initial phase), use Rifater® 150/100 Tablets, preferably taken before breakfast.
  - Adult (body-weight 50 kg and above): 600/300 mg daily for 4 months (continuation phase after 2-month initial phase), use Rifater® 300/150 Tablets, preferably taken before breakfast.

**DOSE EQUIVALENCE AND CONVERSION**

- Each Rifater® 150/100 Tablet contains rifampicin 150 mg and isoniazid 100 mg.
  - Each Rifater® 300/150 Tablet contains rifampicin 300 mg and isoniazid 150 mg.

**INTERACTIONS**

- Appendix 1: ethambutol, isoniazid, pyrazinamide, rifampicin

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS**
  - rifampicin-for-treatment-of-tuberculosis

**Rifampicin with isoniazid**

The properties listed below are those particular to the combination only. For the properties of the components please consider, rifampicin p. 549, isoniazid p. 554.

**INDICATIONS AND DOSE**

**Treatment of tuberculosis (continuation phase)**

- **BY MOUTH**
  - Adult (body-weight up to 50 kg): 450/300 mg daily for 4 months (continuation phase after 2-month initial phase), use Rifater® 150/100 Tablets, preferably taken before breakfast.
  - Adult (body-weight 50 kg and above): 600/300 mg daily for 4 months (continuation phase after 2-month initial phase), use Rifater® 300/150 Tablets, preferably taken before breakfast.

**DOSE EQUIVALENCE AND CONVERSION**

- Each Rifater® 150/100 Tablet contains rifampicin 150 mg and isoniazid 100 mg.
  - Each Rifater® 300/150 Tablet contains rifampicin 300 mg and isoniazid 150 mg.

**INTERACTIONS**

- Appendix 1: isoniazid, rifampicin

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS**
  - rifampicin-for-treatment-of-tuberculosis

**Rifampicin with isoniazid and pyrazinamide**

The properties listed below are those particular to the combination only. For the properties of the components please consider, rifampicin p. 549, ethambutol hydrochloride p. 554, isoniazid p. 554, pyrazinamide p. 555.

**INDICATIONS AND DOSE**

**Initial treatment of tuberculosis**

- **BY MOUTH**
  - Adult (body-weight 30–39 kg): 2 tablets daily for 2 months (initial phase)
  - Adult (body-weight 40–54 kg): 3 tablets daily for 2 months (initial phase)
  - Adult (body-weight 55–69 kg): 4 tablets daily for 2 months (initial phase)
  - Adult (body-weight 70 kg and above): 5 tablets daily for 2 months (initial phase)

**DOSE EQUIVALENCE AND CONVERSION**

- Tablet quantities refer to the number of Voractiv® Tablets which should be taken. Each Voractiv® Tablet contains ethambutol hydrochloride 275 mg, isoniazid 75 mg, pyrazinamide 400 mg and rifampicin 150 mg.

**INTERACTIONS**

- Appendix 1: ethambutol, isoniazid, pyrazinamide, rifampicin

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS**
  - rifampicin-for-treatment-of-tuberculosis

**Rifampicin with isoniazid and pyrazinamide**

The properties listed below are those particular to the combination only. For the properties of the components please consider, rifampicin p. 549, isoniazid p. 554, pyrazinamide p. 555.

**INDICATIONS AND DOSE**

**Initial unsupervised treatment of tuberculosis (in combination with ethambutol)**

- **BY MOUTH**
  - Adult (body-weight up to 40 kg): 3 tablets daily for 2 months (initial phase), use Rifater® Tablets, preferably taken before breakfast.
  - Adult (body-weight 40–49 kg): 4 tablets daily for 2 months (initial phase), use Rifater® Tablets, preferably taken before breakfast.

**INTERACTIONS**

- Appendix 1: isoniazid, rifampicin

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS**
  - rifampicin-for-treatment-of-tuberculosis

**Rifampicin with ethambutol, isoniazid and pyrazinamide**

The properties listed below are those particular to the combination only. For the properties of the components please consider, rifampicin p. 549, ethambutol hydrochloride p. 554, isoniazid p. 554, pyrazinamide p. 555.

**INDICATIONS AND DOSE**

**Initial treatment of tuberculosis**

- **BY MOUTH**
  - Adult (body-weight 30–39 kg): 2 tablets daily for 2 months (initial phase)
  - Adult (body-weight 40–54 kg): 3 tablets daily for 2 months (initial phase)
  - Adult (body-weight 55–69 kg): 4 tablets daily for 2 months (initial phase)
  - Adult (body-weight 70 kg and above): 5 tablets daily for 2 months (initial phase)

**DOSE EQUIVALENCE AND CONVERSION**

- Tablet quantities refer to the number of Voractiv® Tablets which should be taken. Each Voractiv® Tablet contains ethambutol hydrochloride 275 mg, isoniazid 75 mg, pyrazinamide 400 mg and rifampicin 150 mg.

**CAUTIONS**

**CAUTIONS, FURTHER INFORMATION**

- Peripheral neuropathy The risk of peripheral neuropathy may be increased by high doses of isoniazid; pyridoxine should, therefore, be considered for those receiving Voractiv® 5 tablets daily.

**INTERACTIONS**

- Appendix 1: ethambutol, isoniazid, pyrazinamide, rifampicin

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS**
  - rifampicin-for-treatment-of-tuberculosis

**Rifampicin with isoniazid and pyrazinamide**

The properties listed below are those particular to the combination only. For the properties of the components please consider, rifampicin p. 549, isoniazid p. 554, pyrazinamide p. 555.

**INDICATIONS AND DOSE**

**Initial unsupervised treatment of tuberculosis (in combination with ethambutol)**

- **BY MOUTH**
  - Adult (body-weight up to 40 kg): 3 tablets daily for 2 months (initial phase), use Rifater® Tablets, preferably taken before breakfast.
  - Adult (body-weight 40–49 kg): 4 tablets daily for 2 months (initial phase), use Rifater® Tablets, preferably taken before breakfast.
**Aminosalicylic acid**

**INDICATIONS AND DOSE**

**Multiple-drug resistant tuberculosis, in combination with other drugs**

- **BY MOUTH**
  - Adult: 4 g every 8 hours for a usual treatment duration of 24 months; maximum 12 g per day

**Desensitisation regimen**

- **BY MOUTH**
  - Adult: (consult product literature)

**CAUTIONS**

- Peptic ulcer

**INTERACTIONS**

- Appendix 1: aminosalicylic acid

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain, bloating, diarrhea, nausea, rash, vestibular syndrome, vomiting

- **Uncommon** Anorexia

- **Rare** Gastrointestinal bleeding, hypothyroidism, jaundice, malabsorption syndrome, metallic taste, peptic ulcer, uryctaria

- **Very rare** Agranulocytosis, anemia, crystalluria, dizziness, headache, hypoglycaemia, leucopenia, methemoglobinemia, peripheral neuropathy, purpura, tendon pain, thrombocytopenia, visual abnormalities, weight loss

- **Frequency not known** Hepatitis, hypersensitivity

**PREGNANCY**

- Manufacturer advises avoid unless essential—toxicity in animal studies (highest risk during first trimester).

**BREAST FEEDING**

- Present in milk—manufacturer advises avoid.

**HEPATIC IMPAIRMENT**

- Use with caution.

**RENAL IMPAIRMENT**

- Use with caution in mild to moderate impairment. Avoid in severe impairment due to accumulation of inactive metabolites.

**MONITORING REQUIREMENTS**

- Monitor for hypersensitivity reaction during the first 3 months of treatment—for desensitisation dosing regimen consult product literature.

- Monitor liver function—discontinue immediately if signs or symptoms of hepatic toxicity (including rash, fever and gastrointestinal disturbance).

**DIRECTIONS FOR ADMINISTRATION**

- Disperse granules in orange or tomato juice and take immediately (granules will not dissolve, ensure all granules are swallowed). Granules can be sprinkled on apple sauce or yoghurt for administration.

**MEDICAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- Cautionary and Advisory Labels 8, 14, 22
- rifater® tablets: 100 tablet (POM) £26.34

**ANTIMYCOBACTERIALS**

**Bedaquiline**

**INDICATIONS AND DOSE**

**Multiple-drug resistant pulmonary tuberculosis, in combination with other drugs**

- **BY MOUTH**
  - Adult: Initially 400 mg once daily for 2 weeks, then 200 mg 3 times a week for 22 weeks, intervals of at least 48 hours between each dose, continue appropriate combination therapy after bedaquiline

**CONTRA-INDICATIONS**

- QTc interval more than 500 milliseconds (derived using Fridericia’s formula) • ventricular arrhythmia

**CAUTIONS**

- Hypothyroidism • QTc interval (derived using Fridericia’s formula) 450–500 milliseconds—discontinue if QTc interval more than 500 milliseconds • risk factors for QT interval prolongation (e.g. electrolyte disturbances, heart failure with reduced left ventricular ejection fraction, history of symptomatic arrhythmias (avoid if ventricular arrhythmia present), bradycardia, congenital long QT syndrome)

**INTERACTIONS**

- Appendix 1: bedaquiline

**SIDE-EFFECTS**

- Arthralgia, diarrhea, dizziness, headache, myalgia, nausea, QT interval prolongation • vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

- Syncope If syncope occurs, obtain ECG.

- PREGNANCY

- Manufacturer advises avoid unless potential benefit outweighs risk.

- BREAST FEEDING

- Manufacturer advises avoid—present in milk in animal studies.

- HEPATIC IMPAIRMENT

- Manufacturer advises caution in moderate impairment; avoid in severe impairment—no information available. Avoid concomitant use of hepatotoxic drugs unless essential.

- RENAL IMPAIRMENT

- Manufacturer advises caution if eGFR less than 30 mL/minute/1.73 m².

**MONITORING REQUIREMENTS**

- Determine serum potassium, calcium, and magnesium before starting treatment (correct if abnormal)—remeasure if QT prolongation occurs during treatment.

- Obtain ECG before starting treatment, and then at least monthly during treatment or more frequently if concomitant use with other drugs known to prolong the QT interval.

- Monitor liver function before starting treatment and then at least monthly during treatment—discontinue treatment if severe abnormalities in liver function tests.

**PATIENT AND CARER ADVICE**

**Missed doses**

- If a dose is missed during the first two weeks of treatment, the missed dose should not be taken and the next dose should be taken at the usual time; if a dose is missed during weeks 3–24 of treatment, the missed dose should...
be taken as soon as possible and then the usual regimen resumed.

Driving and skilled tasks
Dizziness may affect performance of skilled tasks (e.g. driving)

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

*CAUTIONARY AND ADVISORY LABELS* 4, 8, 21
- Sirturo (Janssen-Cilag Ltd) ▼
  Bedaquiline (as Bedaquiline fumarate) 100 mg  Sirturo 100mg tablets  ▶ £18,700.00

---

**Capreomycin**

**INDICATIONS AND DOSE**
Tuberculosis resistant to first-line drugs, in combination with other drugs

- **BY DEEP INTRAMUSCULAR INJECTION**
- Adult: 1 g daily (max. per dose 20 mg/kg) for 2–4 months, then reduced to 1 g 2–3 times a week

**CAUTIONS** Auditory impairment

**INTERACTIONS** ▶ Appendix 1: capreomycin

**SIDE-EFFECTS** Induration at injection site - changes in liver function tests - electrolyte disturbances - hearing loss with tinnitus and vertigo - hypersensitivity reactions - leucocytosis - leucopenia - nephrotoxicity - neuromuscular block after large doses - pain at injection site - rashes - thrombocytopenia - urticaria

**PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk - teratogenic in animal studies.

**BREAST FEEDING** Manufacturer advises caution - no information available.

**HEPATIC IMPAIRMENT** Use with caution.


**MONITORING REQUIREMENTS** Monitor renal, hepatic, auditory, and vestibular function and electrolytes.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for injection**

- Capreomycin (Non-proprietary)
  Capreomycin (as Capreomycin sulfate) 1 gram  Capreomycin 1g powder for solution for injection vials  ▶ 1 vial  £28.61

---

**Cycloserine**

**INDICATIONS AND DOSE**
Tuberculosis resistant to first-line drugs, in combination with other drugs

- **BY MOUTH**
  - Adult: Initially 250 mg every 12 hours for 2 weeks, then increased if necessary up to 500 mg every 12 hours, dose to be increased according to blood concentration and response

**PHARMACOKINETICS**
Cycloserine penetrates the CNS.

**CONTRA-INDICATIONS** Alcohol dependence - depression - epilepsy - psychotic states - severe anxiety

**INTERACTIONS** ▶ Appendix 1: cycloserine

**SIDE-EFFECTS** Allergic dermatitis - changes in liver function tests - confusion - convulsions - depression - dizziness - drowsiness - headache - heart failure at high doses - megaloblastic anaemia - psychosis - rashes - tremor - vertigo

**SIDE-EFFECTS, FURTHER INFORMATION**
- CNS toxicity Discontinue or reduce dose if symptoms of CNS toxicity occur.
- Rashes or allergic dermatitis Discontinue or reduce dose if rashes or allergic dermatitis develops.
- **PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk - crosses the placenta.
- **BREAST FEEDING** Present in milk - amount too small to be harmful.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

*CAUTIONARY AND ADVISORY LABELS* 2, 8
- Cycloserine (Non-proprietary)
  Cycloserine 250 mg  Cycloserine 250mg capsules  ▶ 100 capsule (BNF) £402.63 DT price  £402.63

---

**Delamanid**

**INDICATIONS AND DOSE**
Multiple-drug resistant pulmonary tuberculosis, in combination with other drugs

- **BY MOUTH**
- Adult: 100 mg twice daily for 24 weeks, continue appropriate combination therapy after delamanid

**CONTRA-INDICATIONS** QTc interval more than 500 milliseconds (derived using Fridericia’s formula) - serum albumin less than 28 g/litre

**CAUTIONS** Risk factors for QT interval prolongation (e.g. electrolyte disturbances, acute myocardial infarction, heart failure with reduced left ventricular ejection fraction, severe hypertension, left ventricular hypertrophy, bradycardia, congenital long QT syndrome, history of symptomatic arrhythmias)

**INTERACTIONS** ▶ Appendix 1: delamanid

**SIDE-EFFECTS**
- Uncommon Arrhythmias - balance disorder - dehydration - dysphagia - herpes zoster - hypocalcaemia - leucopenia - nocturia - rash - thrombocytopenia - urinary retention

**CONCEPTION AND CONTRACEPTION** Effective contraception required during treatment.

**PREGNANCY** Manufacturer advises avoid - toxicity in animal studies.

**BREAST FEEDING** Manufacturer advises avoid - present in milk in animal studies.
Infection

RENAL IMPAIRMENT

Manufacturer advises avoid in severe impairment.

Rifampicin with ethambutol, isoniazid and pyrazinamide, p. 551

Hepatic Impairment

Manufacturer advises avoid in moderate to severe impairment.

RENAL IMPAIRMENT

Manufacturer advises avoid in severe impairment—no information available.

MONITORING REQUIREMENTS

- Monitor serum albumin and electrolytes before starting treatment and then during treatment—discontinue treatment if serum albumin less than 28 g/litre.
- Obtain ECG before starting treatment and then monthly during treatment (more frequently if serum albumin 28–34 g/litre, or if concomitant use of potent CYP3A4 inhibitors, or if risk factors for QT interval prolongation, or if QTc interval 450–500 milliseconds in men or 470–500 milliseconds in women)—discontinue treatment if QTc interval more than 500 milliseconds (derived using Fridericia’s formula).

HANDLING AND STORAGE

Dispense in original container (contains desiccant).

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS 8, 21

- Deltyba (Otsuka Novel Products GmbH)
- Delamanid 50 mg Deltyba 50 mg tablets | 48 tablet

Dispense in original container

€1,250.00

Ethambutol hydrochloride

INDICATIONS AND DOSE

Tuberculosis, in combination with other drugs (standard unsupervised 6-month treatment)

- BY MOUTH
  - Child: 20 mg/kg once daily for 2 months (initial phase)
  - Adult: 15 mg/kg once daily for 2 months (initial phase)

Tuberculosis, in combination with other drugs (intermittent supervised 6-month treatment) (under expert supervision)

- BY MOUTH
  - Child: 30 mg/kg 3 times a week for 2 months (initial phase)
  - Adult: 30 mg/kg 3 times a week for 2 months (initial phase)

CONTRA-INDICATIONS

Optic neuritis · poor vision

CAUTIONS

Elderly · young children

CAUTIONS, FURTHER INFORMATION

Understanding warnings. Patients who cannot understand warnings about visual side-effects should, if possible, be given an alternative drug. In particular, ethambutol should be used with caution in children until they are at least 5 years old and capable of reporting symptomatic visual changes accurately.

INTERACTIONS

Appendix 1: ethambutol

SIDE-EFFECTS

- Rare
  - Pruritus · rash · thrombocytopenia · urticaria
- Frequency not known
  - Colour blindness · loss of visual acuity · optic neuritis · peripheral neuritis · red/green colour blindness · restriction of visual fields · visual disturbances

SIDE-EFFECTS, FURTHER INFORMATION

Ocular toxicity. Ocular toxicity is more common where excessive dosage is used or if the patient’s renal function is impaired. Early discontinuation of the drug is almost always followed by recovery of eyesight.

PREGNANCY

Not known to be harmful.

BREAST FEEDING

Amount too small to be harmful.

RENAL IMPAIRMENT

Risk of optic nerve damage. Should preferably be avoided in patients with renal impairment. If creatinine clearance less than 30 mL/minute, monitor plasma-ethambutol concentration.

- In adults If creatinine clearance less than 30 mL/minute, use 15–25 mg/kg (max. 2.5 g) 3 times a week.
- In children If creatinine clearance less than 30 mL/minute/1.73 m², use 15–25 mg/kg (max. 2.5 g) 3 times a week.

MONITORING REQUIREMENTS

- ‘Peak’ concentration (2–2.5 hours after dose) should be 2–6 mg/litre (7–22 micromol/litre); ‘trough’ (pre-dose) concentration should be less than 1 mg/litre (4 micromol/litre).
- Renal function should be checked before treatment.
- Visual acuity should be tested by Snellen chart before treatment with ethambutol.
- In children In young children, routine ophthalmological monitoring recommended.

PATIENT AND CARER ADVICE

Ocular toxicity. The earliest features of ocular toxicity are subjective and patients should be advised to discontinue therapy immediately if they develop deterioration in vision and promptly seek further advice.


MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Tablet

CAUTIONARY AND ADVISORY LABELS 8

- Ethambutol hydrochloride (Nonproprietary)
  - Ethambutol hydrochloride 100 mg Ethambutol 100 mg tablets | 56 tablet
    - £11.51 DT price = £11.51
  - Ethambutol hydrochloride 400 mg Ethambutol 400 mg tablets | 56 tablet
    - £42.74 DT price = £42.74

Combinations available: Rifampicin with ethambutol, isoniazid and pyrazinamide, p. 551

Isoniazid

INDICATIONS AND DOSE

Tuberculosis, in combination with other drugs (standard unsupervised 6-month treatment)

- BY MOUTH, OR BY INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INJECTION
  - Child: 10 mg/kg once daily (max. per dose 300 mg) for 6 months (initial and continuation phases)
  - Adult: 300 mg daily for 6 months (initial and continuation phases)

Tuberculosis, in combination with other drugs (intermittent supervised 6-month treatment) (under expert supervision)

- BY MOUTH, OR BY INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INJECTION
  - Child: 15 mg/kg 3 times a week (max. per dose 900 mg) for 6 months (initial and continuation phases)
  - Adult: 15 mg/kg 3 times a week (max. per dose 900 mg) for 6 months (initial and continuation phases)

Prevention of tuberculosis in susceptible close contacts or those who have become tuberculin positive

- BY MOUTH, OR BY INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INJECTION
  - Child 1 month–11 years: 10 mg/kg daily (max. per dose 300 mg) for 6 months, alternatively 10 mg/kg daily (max. per dose 300 mg) for 3 months, to be taken in combination with rifampicin
  - Child 12–17 years: 300 mg daily for 6 months, alternatively 300 mg daily for 3 months, to be taken in combination with rifampicin
Pyrazinamide

**INDICATIONS AND DOSE**

Tuberculosis, in combination with other drugs (standard unsupervised 6-month treatment)

- **BY MOUTH**
  - Child (body-weight up to 50 kg): 35 mg/kg once daily for 2 months (initial phase); maximum 1.5 g per day
  - Child (body-weight 50 kg and above): 35 mg/kg once daily for 2 months (initial phase); maximum 2 g per day
  - Adult (body-weight up to 50 kg): 1.5 g once daily for 2 months (initial phase)
  - Adult (body-weight 50 kg and above): 2 g once daily for 2 months (initial phase)

Tuberculosis, in combination with other drugs (intermittent supervised 6-month treatment) (under expert supervision)

- **BY MOUTH**
  - Child (body-weight up to 50 kg): 50 mg/kg 3 times a week (max. per dose 2 g 3 times a week) for 2 months (initial phase)
  - Child (body-weight 50 kg and above): 50 mg/kg 3 times a week (max. per dose 2.5 g 3 times a week) for 2 months (initial phase)
  - Adult (body-weight up to 50 kg): 2 g 3 times a week for 2 months (initial phase)
  - Adult (body-weight 50 kg and above): 2.5 g 3 times a week for 2 months (initial phase)

**CONTRA-INDICATIONS**

- Acute attack of gout (in adults)
- Diabetes · gout (in adults)
- **INTERACTIONS**
  - Appendix 1: pyrazinamide

**SIDE-EFFECTS**

- Anorexia · arthralgia · dysuria · fever · flushing (in adults) · hepatomegaly · hepatotoxicity · jaundice · liver failure · nausea · photosensitivity · rash · sideroblastic anaemia · splenomegaly · thrombocytopenia · vomiting
- **PREGNANCY**
  - Manufacturer advises use only if potential benefit outweighs risk.
- **BREAST FEEDING**
  - Amount too small to be harmful.
- **HEPATIC IMPAIRMENT**
  - Idiosyncratic hepatotoxicity more common; avoid in severe hepatic impairment. In patients with pre-existing liver disease or
2.6 Urinary tract infections

Urinary-tract infections

Overview
Urinary-tract infection is more common in women than in men; when it occurs in men there is frequently an underlying abnormality of the renal tract. Recurrent episodes of infection are an indication for radiological investigation especially in children in whom untreated pyelonephritis may lead to permanent kidney damage.

Escherichia coli is the most common cause of urinary-tract infection; Staphylococcus saprophyticus is also common in sexually active young women. Less common causes include Proteus and Klebsiella spp. Pseudomonas aeruginosa infections usually occur in the hospital setting and may be associated with functional or anatomical abnormalities of the renal tract. Staphylococcus epidermidis and Enterococcus faecalis infection may complicate catheterisation or instrumentation.

A specimen of urine should be collected for culture and sensitivity testing before starting antibacterial therapy;
- in men;
- in pregnant women;
- in children under 3 years of age;
- in patients with suspected upper urinary-tract infection;
- complicated infection, or recurrent infection;
- if resistant organisms are suspected;
- if urine dipstick testing gives a single positive result for leucocyte esterase or nitrite;
- if clinical symptoms are not consistent with results of dipstick testing.

Treatment should not be delayed while waiting for results. The antibacterial chosen should reflect current local bacterial sensitivity to antibiotics.

Antibacterial therapy for lower urinary-tract infections

Uncomplicated lower urinary-tract infections often respond to trimethoprim p. 542 or nitrofurantoin p. 557, or alternatively, amoxicillin p. 518, ampicillin p. 520 or oral cefalosporin.

Suggested duration of treatment is 7 days, but a short course (e.g. 3 days) is usually adequate for uncomplicated urinary-tract infections in women.

Infections caused by fully sensitive bacteria respond to amoxicillin.

Widespread bacterial resistance to ampicillin, amoxicillin, and trimethoprim has been reported. Alternatives for resistant organisms include co-amoxiclav p. 521 (amoxicillin with clavulanic acid), an oral cefalosporin, nitrofurantoin, pivmecillinam hydrochloride p. 523, or a quinolone.

Fosfomycin p. 538 can be used, on the advice of a microbiologist, for the treatment of acute uncomplicated lower urinary-tract infections caused by organisms sensitive to fosfomycin.

Long-term low dose therapy may be required in selected patients to prevent recurrence of infection; indications include frequent relapses and significant kidney damage. Trimethoprim, nitrofurantoin and cefalexin p. 497 have been recommended for long-term therapy.

Methenamine hippurate p. 557 (hexamine hippurate) should not generally be used because it requires an acidic urine for its antimicrobial activity and it is ineffective for upper urinary-tract infections; it may, however, have a role in the prophylaxis and treatment of chronic or recurrent uncomplicated lower urinary-tract infections.

Antibacterial therapy for upper urinary-tract infections

Acute pyelonephritis can lead to sepsicaemia and is treated initially by injection of a broad-spectrum antibacterial such as a cefalosporin (e.g. cefuroxime p. 498) or a quinolone if the patient is severely ill; gentamicin p. 491 can also be used.

Suggested duration of treatment is 10–14 days (longer treatment may be necessary in complicated pyelonephritis).

Prostatitis can be difficult to cure and requires treatment for several weeks with an antibacterial which penetrates prostatic tissue such as some of the quinolones (ciprofloxacin p. 527 or ofloxacin p. 530), or alternatively, trimethoprim.

Suggested duration of treatment is 28 days. Where infection is localised and associated with an indwelling catheter, a bladder instillation is often effective.

Pregnancy
Urinary-tract infection in pregnancy may be asymptomatic and requires prompt treatment to prevent progression to acute pyelonephritis. Penicillins and cefalosporins are suitable for treating urinary-tract infection during pregnancy. Nitrofurantoin may also be used but it should be avoided at term. Sulfonamides and quinolones should be
avoided during pregnancy; trimethoprim should also preferably be avoided particularly in the first trimester.

**Renal impairment**

In renal failure antibacterial agents normally excreted by the kidney accumulate with resultant toxicity unless the dose is reduced. This applies especially to the aminoglycosides which should be used with great caution; tetracyclines, methenamine hippurate, and nitrofurantoin should be avoided altogether.

**Urinary-tract infections in children**

Urinary-tract infections in children require prompt antibacterial treatment to minimise the risk of renal scarring. Uncomplicated 'lower' urinary-tract infections in children over 3 months of age can be treated with trimethoprim, nitrofurantoin, a first generation cephalosporin (e.g. cefalexin), or amoxicillin for recurrent episodes of infection, significant urinary-tract anomalies, or significant kidney damage.

**ANTIBACTERIALS**

### Methenamine hippurate

*(Hexamine hippurate)*

- **INDICATIONS AND DOSE**
  - **Prophylaxis and long-term treatment of chronic or recurrent uncomplicated lower urinary-tract infections**
    - **BY MOUTH**
      - Adult: 1 g every 12 hours
    - **Prophylaxis and long-term treatment of chronic or recurrent uncomplicated lower urinary-tract infections in patients with catheters**
      - **BY MOUTH**
      - Adult: 1 g every 8–12 hours

- **CONTRA-INDICATIONS**
  - Acute porphyrias
  - Severe chronic recurrent urinary-tract infections

- **INTERACTIONS**
  - Appendix 1: methenamine

- **SIDE-EFFECTS**
  - Bladder irritation
  - Gastro-intestinal disturbances
  - Rash

- **PREGNANCY**
  - Use with caution.

- **BREAST FEEDING**
  - Amount too small to be harmful.

- **HEPATIC IMPAIRMENT**
  - Avoid.

- **RENAL IMPAIRMENT**
  - Avoid if eGFR less than 10 mL/minute/1.73 m²—risk of hippurate crystalluria.

- **LESS SUITABLE FOR PRESCRIBING**
  - Methenamine (hexamine) hippurate should not generally be used because it requires an acidic urine for its antimicrobial activity and it is ineffective for upper urinary-tract infections; it may, however, have a role in the prophylaxis and treatment of chronic or recurrent uncomplicated lower urinary-tract infections. It is considered less suitable for prescribing.

### Nitrofurantoin

- **INDICATIONS AND DOSE**
  - **Acute uncomplicated urinary-tract infections**
    - **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
      - Child 3 months–11 years: 750 micrograms/kg 4 times a day for 3–7 days
      - Child 12–17 years: 50 mg 4 times a day for 3–7 days
      - Adult: 50 mg 4 times a day for 3–7 days, dose to be taken with food
    - **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
      - Child 12–17 years: 100 mg twice daily, dose to be taken with food
      - Adult: 100 mg twice daily, dose to be taken with food

  - **Severe chronic recurrent urinary-tract infections**
    - **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
      - Child 3 months–11 years: 100 mg 4 times a day for 3–7 days
      - Child 12–17 years: 100 mg 4 times a day for 7 days, dose to be taken with food, reduce dose or discontinue treatment if severe nausea occurs

  - **Prophylaxis of urinary-tract infection (considered for recurrent infection, significant urinary-tract anomalies, or significant kidney damage)**
    - **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
      - Child 3 months–11 years: 1 mg/kg once daily, dose to be taken at night
      - Child 12–17 years: 50–100 mg once daily, dose to be taken at night
    - **Adult: 50–100 mg once daily, dose to be taken at night**

  - **Genito-urinary surgical prophylaxis**
    - **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
      - Adult: 100 mg twice daily on day of procedure and for 3 days after

- **CONTRA-INDICATIONS**
  - Acute porphyrias p. 969 • G6PD deficiency • infants less than 3 months old

- **CAUTIONS**
  - Anaemia • diabetes mellitus • electrolyte imbalance • folate deficiency • pulmonary disease • susceptibility to peripheral neuropathy • urine may be coloured yellow or brown • vitamin B deficiency

- **INTERACTIONS**
  - Appendix 1: nitrofurantoin

- **SIDE-EFFECTS**
  - Rare: Agranulocytosis • aplastic anaemia • arthralgia • benign intracranial hypertension • blood disorders • cholestatic jaundice • erythema multiforme • exfoliative dermatitis • hepatitis • pancreatitis • thrombocytopenia • transient alopecia

  - Frequency not known: Acute pulmonary reactions • anaphylaxis • angioedema • anorexia • chronic pulmonary reactions (pulmonary fibrosis reported; possible association with lupus erythematosus-like syndrome) • diarrhoea • hypersensitivity reactions • nausea • peripheral neuropathy • pruritus • rash • sialadenitis • urticaria • vomiting

- **PREGNANCY**
  - Avoid at term—may produce neonatal haemolysis.

- **BREAST FEEDING**
  - Avoid; only small amounts in milk but enough to produce haemolysis in G6PD-deficient infants.
Hepatic Impairment

Use with caution; cholestatic jaundice and chronic active hepatitis reported.

Renal Impairment

Risk of peripheral neuropathy; antibacterial efficacy depends on renal secretion of the drug into urinary tract.

In adults

Avoid if eGFR less than 45 mL/minute/1.73 m²; may be used with caution if eGFR 30–44 mL/minute/1.73 m² as a short-course only (3 to 7 days), to treat uncomplicated lower urinary-tract infection caused by suspected or proven multidrug resistant bacteria and only if potential benefit outweighs risk.

In children

Avoid if estimated glomerular filtration rate less than 45 mL/minute/1.73 m²; may be used with caution if estimated glomerular filtration rate 30–44 mL/minute/1.73 m² as a short-course only (3 to 7 days), to treat uncomplicated lower urinary-tract infection caused by suspected or proven multidrug resistant bacteria and only if potential benefit outweighs risk.

Monitoring Requirements

On long-term therapy, monitor liver function and monitor for pulmonary symptoms, especially in the elderly (discontinue if deterioration in lung function).

Effect on Laboratory Tests

False positive urinary glucose (if tested for reducing substances).

Patient and Carer Advice

Medicines for Children leaflet: Nitrofurantoin for urinary tract infections www.medicinesforchildren.org.uk/nitrofurantoin-for-urinary-tract-infections

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Tablet

CAUTIONARY AND ADVISORY LABELS 9, 14, 21

- Nitrofurantoin (Non-proprietary)
  - Nitrofurantoin 50 mg Nitrofurantoin 50mg tablets | 28 tablet £35.00 DT price = £11.66 | 100 tablet £111.89
  - Nitrofurantoin 100 mg Nitrofurantoin 100mg tablets | 28 tablet £16.80 DT price = £7.03 | 100 tablet £60.00
- Genfura (Genesis Pharmaceuticals Ltd)
  - Nitrofurantoin 50 mg Genfura 50mg tablets | 28 tablet £23.57 DT price = £11.66
  - Nitrofurantoin 100 mg Genfura 100mg tablets | 28 tablet £18.76 DT price = £7.03 | 100 tablet £67.02

Oral Suspension

CAUTIONARY AND ADVISORY LABELS 9, 14, 21

- Nitrofurantoin (Non-proprietary)
  - Nitrofurantoin 5 mg per 1 ml Nitrofurantoin 25mg/5ml oral suspension sugar free sugar-free | 300 ml £446.95 DT price = £446.95

Modified-release capsule

CAUTIONARY AND ADVISORY LABELS 9, 14, 21, 25

- Macrobid (AMCo)
  - Nitrofurantoin 100 mg Macrobid 100mg modified-release capsules | 14 capsule £9.50 DT price = £9.50

Capsule

CAUTIONARY AND ADVISORY LABELS 9, 14, 21

- Nitrofurantoin (Non-proprietary)
  - Nitrofurantoin 50 mg Nitrofurantoin 50mg capsules | 30 capsule £15.42 DT price = £15.42
  - Nitrofurantoin 100 mg Nitrofurantoin 100mg capsules | 30 capsule £10.42 DT price = £10.42

Fungal infection

Antifungals, systemic use

Common fungal infections

The systemic treatment of common fungal infections is outlined below; specialist treatment is required in most forms of systemic or disseminated fungal infections. Local treatment is suitable for a number of fungal infections (genital, bladder, eye, ear, oropharynx, and skin).

Aspergillosis

Aspergillosis most commonly affects the respiratory tract but in severely immunocompromised patients, invasive forms can affect the heart, brain, and skin. Voriconazole p. 566 is the treatment of choice for aspergillosis; liposomal amphotericin p. 561 is an alternative first-line treatment when voriconazole cannot be used. Caspofungin p. 560, itraconazole p. 564, or posaconazole p. 565 can be used in patients who are refractory to, or intolerant of voriconazole and liposomal amphotericin. Itraconazole is also used for the treatment of chronic pulmonary aspergillosis or as an adjunct in the treatment of allergic bronchopulmonary aspergillosis [unlicensed indication].

Candidiasis

Many superficial candidal infections including infections of the skin are treated locally; widespread or intractable infection requires systemic antifungal treatment. Vaginal candidiasis may be treated with locally acting antifungals or with fluconazole p. 562 given by mouth; for resistant organisms in adults, itraconazole can be given by mouth.

Oropharyngeal candidiasis generally responds to topical therapy; fluconazole is given by mouth for unresponsive infections; it is effective and is reliably absorbed. Itraconazole may be used for infections that do not respond to fluconazole. Topical therapy may not be adequate in immunocompromised patients and an oral triazole antifungal is preferred.

For invasive or disseminated candidiasis, an echinocandin can be used. Fluconazole is an alternative for Candida albicans infection in clinically stable patients who have not received an azole antifungal recently. Amphotericin is an alternative when an echinocandin or fluconazole cannot be used, however, amphotericin should be considered for the initial treatment of CNS candidiasis. Voriconazole can be used for infections caused by fluconazole-resistant Candida spp. when oral therapy is required, or in patients intolerant of amphotericin or an echinocandin. In refractory cases, flucytosine p. 567 can be used with intravenous amphotericin.

Cryptococcosis

Cryptococcosis is uncommon but infection in the immunocompromised, especially in HIV-positive patients, can be life-threatening; cryptococcal meningitis is the most common form of fungal meningitis. The treatment of choice in cryptococcal meningitis is amphotericin by intravenous infusion and flucytosine by intravenous infusion for 2 weeks, followed by fluconazole by mouth for 8 weeks or until cultures are negative. In cryptococcosis, fluconazole is sometimes given alone as an alternative in HIV-positive patients with mild, localised infections or in those who cannot tolerate amphotericin. Following successful treatment, fluconazole can be used for prophylaxis against relapse until immunity recovers.

Histoplasmosis

Histoplasmosis is rare in temperate climates; it can be life-threatening, particularly in HIV-infected persons. Itraconazole can be used for the treatment of immunocompetent patients with indolent non-meningeal...
infection, including chronic pulmonary histoplasmosis. Amphotericin by intravenous infusion is used for the initial treatment of fulminant or severe infections, followed by a course of itraconazole by mouth. Following successful treatment, itraconazole can be used for prophylaxis against relapse until immunity recovers.

**Skin and nail infections**

Mild localised fungal infections of the skin (including tinea corporis, tinea cruris, and tinea pedis) respond to topical therapy. Systemic therapy is appropriate if topical therapy fails, if many areas are affected, or if the site of infection is difficult to treat such as in infections of the nails (onychomycosis) and of the scalp (tinea capitis). Oral imidazole or triazole antifungals (particularly itraconazole) and terbinafine p. 1132 are used more frequently than griseofulvin p. 568 because they have a broader spectrum of activity and require a shorter duration of treatment.

*Tinea capitis* is treated systemically; additional topical application of an antifungal may reduce transmission. Griseofulvin is used for tinea capitis in adults and children; it is effective against infections caused by *Trichophyton tonsurans* and *Microsporum* spp. Terbinafine is used for tinea capitis caused by *T. tonsurans* [unlicensed indication]. The role of terbinafine in the management of *Microsporum* infections is uncertain. *Pityriasis versicolor* may be treated with itraconazole by mouth if topical therapy is ineffective; fluconazole by mouth is an alternative. Oral terbinafine is not effective for pityriasis versicolor.

Antifungal treatment may not be necessary in asymptomatic patients with tinea infection of the nails. If treatment is necessary, a systemic antifungal is more effective than topical therapy. Terbinafine and itraconazole have largely replaced griseofulvin for the systemic treatment of *onychomycosis*, particularly of the toenail; terbinafine is considered to be the drug of choice. Itraconazole can be administered as intermittent ‘pulse’ therapy. Topical antifungals also have a role in the treatment of onychomycosis.

**Immunocompromised patients**

Immunocompromised patients are at particular risk of fungal infections and may receive antifungal drugs prophylactically; oral triazole antifungals are the drugs of choice for prophylaxis. Fluconazole is more reliably absorbed than itraconazole, but fluconazole is not effective against *Aspergillus* spp. Itraconazole is preferred in patients at risk of invasive aspergillosis. Posaconazole can be used for prophylaxis in patients who are undergoing haematopoietic stem cell transplantation or receiving chemotherapy for acute myeloid leukaemia and myelodysplastic syndrome, if they are intolerant of fluconazole or itraconazole. Micafungin p. 560 can be used for prophylaxis of candidiasis in patients undergoing haematopoietic stem cell transplantation when fluconazole, itraconazole or posaconazole cannot be used.

Amphotericin by intravenous infusion or caspofungin is used for the empirical treatment of serious fungal infections; caspofungin is not effective against fungal infections of the CNS.

**Triazole antifungals**

Triazole antifungal drugs have a role in the prevention and systemic treatment of fungal infections.

Fluconazole is very well absorbed after oral administration. It also achieves good penetration into the cerebrospinal fluid to treat fungal meningitis. Fluconazole is excreted largely unchanged in the urine and can be used to treat candiduria.

Itraconazole is active against a wide range of dermatophytes. Itraconazole capsules require an acid environment in the stomach for optimal absorption. Itraconazole has been associated with liver damage and should be avoided or used with caution in patients with liver disease; fluconazole is less frequently associated with hepatotoxicity.

Posaconazole is licensed for the treatment of invasive fungal infections unresponsive to conventional treatment. Voriconazole is a broad-spectrum antifungal drug which is licensed for use in life-threatening infections.

**Imidazole antifungals**

The imidazole antifungals include clotrimazole p. 781, econazole nitrte p. 781, ketoconazole p. 641, and itraconazole p. 1131. They are used for the local treatment of vaginal candidiasis and for dermatophyte infections. Miconazole p. 782 can be used locally for oral infections; it is also effective in intestinal infections. Systemic absorption may follow use of miconazole oral gel and may result in significant drug interactions.

**Polyene antifungals**

The polyene antifungals include amphotericin p. 561 and nystatin p. 1116; neither drug is absorbed when given by mouth. Nystatin is used for oral, oropharyngeal, and perioral infections by local application in the mouth. Nystatin is also used for *Candida albicans* infection of the skin.

Amphotericin by intravenous infusion is used for the treatment of systemic fungal infections and is active against most fungi and yeasts. It is highly protein bound and penetrates poorly into body fluids and tissues. When given parenterally amphotericin is toxic and side-effects are common. Lipid formulations of amphotericin (Abelcet® and AmBisome®) are significantly less toxic and are recommended when the conventional formulation of amphotericin is contra-indicated because of toxicity, especially nephrotoxicity or when response to conventional amphotericin is inadequate; lipid formulations are more expensive.

**Echinocandin antifungals**

The echinocandin antifungals include anidulafungin p. 560, caspofungin p. 560 and micafungin p. 560. They are only active against *Aspergillus* spp. and *Candida* spp.; however, anidulafungin and micafungin are not used for the treatment of aspergillosis. Echinocandins are not effective against fungal infections of the CNS.

**Other antifungals**

Flucytosine p. 567 is used with amphotericin in a synergistic combination. Bone marrow depression can occur which limits its use, particularly in HIV-positive patients; weekly blood counts are necessary during prolonged therapy.

Resistance to flucytosine can develop during therapy and sensitivity testing is essential before and during treatment. Flucytosine has a role in the treatment of systemic candidiasis and cryptococcal meningitis.

Griseofulvin p. 568 is effective for widespread or intractable dermatophyte infections but has been superseded by newer antifungals, particularly for nail infections. It is the drug of choice for trichophytion infections in children. Duration of therapy is dependent on the site of the infection and may extend to a number of months.

Terbinafine p. 1132 is the drug of choice for fungal nail infections and is also used for ringworm infections where oral treatment is considered appropriate.
**Antifungals**

**Anidulafungin**

- **INDICATIONS AND DOSE**
  - **Invasive candidiasis**
    - BY INTRAVENOUS INFUSION
    - Adult: Initially 200 mg once daily for 1 day, then 100 mg once daily.

- **SIDE-EFFECTS**
  - Common or very common: Coagulopathy, convulsion, diarrhoea, flushing, headache, hypokalaemia, nausea, pruritus, raised serum creatinine, rash, vomiting
  - Uncommon: Abdominal pain, cholestasis, hyperglycaemia, hypertension, injection-site pain, urticaria
  - Frequency not known: Bronchospasm, dyspnoea, hepatitis, hypotension

- **PREGNANCY**
  - Manufacturer advises avoid—no information available.

- **BREAST FEEDING**
  - Manufacturer advises avoid unless potential benefit outweighs risk—present in milk in animal studies.

- **DIRECTIONS FOR ADMINISTRATION**
  - For intravenous infusion (Ecalta®), give intermittently in glucose 5% or sodium chloride 0.9%. Reconstitute each 100 mg with 30 mL water for injections and allow up to 5 minutes for reconstitution; dilute dose in infusion fluid to a concentration of 770 micrograms/mL; give at a rate not exceeding 1.1 mg/minute. Follow product information if using stock supplied with ethanol solvent.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for infusion**

- Ecalta (Pfizer Ltd)
  - Anidulafungin 100 mg: Ecalta 100mg powder for concentrate for solution for infusion vials | 1 vial (PO) £299.99 (Hospital only)

**Caspofungin**

- **INDICATIONS AND DOSE**
  - **Invasive aspergillosis | Invasive candidiasis | Empirical treatment of systemic fungal infections in patients with neutropenia**
    - BY INTRAVENOUS INFUSION
    - Adult (body-weight up to 81 kg): 70 mg once daily for 1 day, then 50 mg once daily
    - Adult (body-weight 81 kg and above): 70 mg once daily

- **DOSE ADJUSTMENTS DUE TO INTERACTIONS**
  - Manufacturer advises increase dose to 70 mg daily with concurrent use of some enzyme inducers (such as carbamazepine, dexamethasone, phenytoin, and rifampicin); no dose adjustment required for patients already on 70 mg daily.

- **INTERACTIONS** → Appendix 1: caspofungin

- **SIDE-EFFECTS**
  - Common or very common: Arthralgia, diarrhoea, dyspnoea, headache, hypokalaemia, injection-site reactions, nausea, pruritus, rash, sweating, vomiting
  - Uncommon: Abdominal pain, anaemia, anorexia, anxiety, arrhythmia, ascites, blurred vision, bronchospasm, chest pain, cholestasis, constipation, cough, disorientation, dizziness, dry mouth, dyspepsia, dysphagia, erythema multiforme, fatigue, flatulence, flushing, heart failure, hepatic dysfunction, hyperglycaemia, hypertension, hypoaesthesia, hypocalcaemia, hypomagnesaemia, hypotension, leucopenia, metabolic acidosis, muscular weakness, myalgia, palpitation, paraesthesia, renal failure, sleep disturbances, taste disturbances, thrombocytopenia, thrombophlebitis, tremor
  - Frequency not known: Adult respiratory distress syndrome—anaphylaxis

- **PREGNANCY**
  - Adult respiratory distress syndrome—anaphylaxis

- **BREAST FEEDING**
  - Present in milk in animal studies—manufacturer advises avoid.

- **HEPATIC IMPAIRMENT**
  - 70 mg on first day then 35 mg once daily in moderate impairment. No information available for severe impairment.

- **DIRECTIONS FOR ADMINISTRATION**
  - For intravenous infusion (Cancidas®), give intermittently in sodium chloride 0.9%. Allow vial to reach room temperature; initially reconstitute each vial with 10.5 mL water for injections, mixing gently to dissolve then dilute requisite dose in 250 mL infusion fluid (35- or 50-mg doses may be diluted in 100 mL infusion fluid if necessary); give over 60 minutes; incompatible with glucose solutions.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for infusion**

- Cancidas (Merck Sharp & Dohme Ltd)
  - Caspofungin (as Caspofungin acetate) 50 mg: Cancidas 50mg powder for solution for infusion vials | 1 vial (PO) £372.67
  - Caspofungin (as Caspofungin acetate) 70 mg: Cancidas 70mg powder for solution for infusion vials | 1 vial (PO) £416.78

**Micafungin**

- **INDICATIONS AND DOSE**
  - **Invasive candidiasis**
    - BY INTRAVENOUS INFUSION
    - Adult (body-weight up to 40 kg): 2 mg/kg once daily for at least 14 days; increased if necessary to 4 mg/kg once daily, increase dose if response inadequate
    - Adult (body-weight 40 kg and above): 100 mg once daily for at least 14 days; increased if necessary to 200 mg once daily, increase dose if response inadequate

- **Oesophageal candidiasis**
  - BY INTRAVENOUS INFUSION
  - Adult (body-weight up to 40 kg): 3 mg/kg once daily
  - Adult (body-weight 40 kg and above): 150 mg once daily

- **Prophylaxis of candidiasis in patients undergoing bone-marrow transplantation or who are expected to become neutropenic for over 10 days**
  - BY INTRAVENOUS INFUSION
  - Adult (body-weight up to 40 kg): 1 mg/kg once daily continue for at least 7 days after neutrophil count is in desirable range
  - Adult (body-weight 40 kg and above): 50 mg once daily continue for at least 7 days after neutrophil count is in desirable range

- **INTERACTIONS** → Appendix 1: micafungin

- **SIDE-EFFECTS**
  - Common or very common: Abdominal pain, anaemia, diarrhoea, fever, headache, hypocalcaemia, hypokalaemia, hypomagnesaemia, leucopenia, nausea, phlebitis, rash, vomiting
  - Uncommon: Anorexia, anxiety, blood pressure changes, bradycardia, cholestasis, confusion, constipation, dizziness, dyspepsia, dysphagia, hyperglycaemia, hyperhidrosis, hyperkalaemia, hyponatraemia, hypophosphataemia, palpitation, pancytopenia, pruritus, sleep disturbances, tachycardia, taste disturbances, thrombocytopenia, tremor
  - Rare: Haemolytic anaemia
ANTIFUNGALS

Amphotericin (Amphotericin B)

INDICATIONS AND DOSE

ABELCET®, AMBISOME®, FUNGIZONE®

Severe invasive candidiasis
Severe systemic fungal infections in patients not responding to conventional amphotericin or to other antifungal drugs or where toxicity or renal impairment precludes conventional amphotericin, including invasive aspergillosis, cryptococcal meningitis and disseminated cryptococcosis in HIV patients

BY INTRAVENOUS INFUSION

Adult: Test dose 1 mg, to be given over 15 minutes, then 5 mg/kg once daily for at least 14 days

AMBISOME®

Severe systemic or deep mycoses where toxicity (particularly nephrotoxicity) precludes use of conventional amphotericin | Suspected or proven infection in febrile neutropenic patients unresponsive to broad-spectrum antibacterials

BY INTRAVENOUS INFUSION

Adult: Test dose 1 mg, to be given over 10 minutes, then 3 mg/kg once daily; maximum 5 mg/kg per day

Aspergillosis

BY INTRAVENOUS INFUSION

Adult: Test dose 1 mg, to be given over 10 minutes, then 3 mg/kg once daily; maximum 5 mg/kg per day

Visceral leishmaniasis (unresponsive to the antimonial alone)

BY INTRAVENOUS INFUSION

Adult: 1–3 mg/kg daily for 10–21 days to a cumulative dose of 21–30 mg/kg, alternatively 3 mg/kg for 5 consecutive days, followed by 3 mg/kg after 6 days for 1 dose

FUNGIZONE®

Systemic fungal infections

BY INTRAVENOUS INFUSION

Adult: Test dose 1 mg, to be given over 20–30 minutes, then 250 micrograms/kg daily, gradually increased over 2–4 days, increased if tolerated to 1 mg/kg daily, max. (severe infection) 1.5 mg/kg daily or on alternate days. Prolonged treatment usually necessary; if interrupted for longer than 7 days recommence at 250 micrograms/kg daily and increase gradually

UNLICENSED USE

AMBISOME® Use at the maximum dose of 5 mg/kg once daily is an unlicensed dose.

CAUTIONS

Avoid rapid infusion (risk of arrhythmias) - when given parenterally, toxicity common (close supervision necessary and close observation required for at least 30 minutes after test dose)

CAUTIONS, FURTHER INFORMATION

Anaphylaxis: Anaphylaxis can occur with any intravenous amphotericin product and a test dose is advisable before the first infusion; the patient should be carefully observed for at least 30 minutes after the test dose. Prophylactic antipyretics or hydrocortisone should only be used in patients who have previously experienced acute adverse reactions (in whom continued treatment with amphotericin is essential).

INTERACTIONS

Appendix 1: amphotericin

SIDE-EFFECTS

Common or very common: Abdominal pain - abnormal liver function (discontinue treatment) - anaemia - arrhythmias - blood disorders - blood pressure changes - cardiovascular effects - chest pain - diarrhoea - disturbances in renal function - dyspnoea - electrolyte disturbances - febrile reactions - headache - hypokalaemia - hypomagnesaemia - nausea - rash - renal tubular acidosis - thrombocytopenia - vomiting


PREGNANCY

Not known to be harmful but manufacturers advise avoid unless potential benefit outweighs risk.

BREAST FEEDING

No information available.

RENAL IMPAIRMENT

Use only if no alternative; nephrotoxicity may be reduced with use of lipid formulation.

MONITORING REQUIREMENTS

Hepatic and renal function tests, blood counts, and plasma electrolyte (including plasma-potassium and magnesium concentration) monitoring required.

DIRECTIONS FOR ADMINISTRATION

ABELCET® Amphotericin (lipid complex)

For intravenous infusion, give intermittently in Glucose 5%. Allow suspension to reach room temperature, shake gently to ensure no yellow settlement, withdraw requisite dose (using 17-19 gauge needle) into one or more 20-mL syringes; replace needle on syringe with a 5-micron filter needle provided (fresh needle for each syringe) and dilute to a concentration of 1 mg/mL (2 mg/mL can be used in fluid restriction and in children); preferably give via an infusion pump at a rate of 2.5 mg/kg/hour (initial test dose of 1 mg over 15 minutes); an in-line filter (pore size no less than 15 micron) may be used; do not use sodium chloride or other electrolyte solutions, flush existing intravenous line with glucose 5% or use separate line.
AMBSOME® Amphotericin (liposomal)
For intravenous infusion (AmBisome®), give intermittently in Glucose 5% or 10%. Reconstitute each vial with 12 mL water for injections and shake vigorously to produce a preparation containing 4 mg/mL; withdraw requisite dose from vial and introduce into infusion fluid through the 5 micron filter provided to produce a final concentration of 0.2–2 mg/mL; Infuse over 30–60 minutes, or if non-anaphylactic infusion-related reactions occur Infuse over 2 hours (initial test dose of 1 mg over 10 minutes); an in-line filter (pore size no less than 1 micron) may be used; incompatible with sodium chloride solutions, flush existing intravenous line with glucose 5% or 10%, or use separate line.

FUNGIZONE® Amphotericin (as sodium deoxycollate complex)
For intravenous infusion (Fungizone®), give intermittently in Glucose 5%. Reconstitute each vial with 10 mL water of injections and shake immediately to produce a 5 mg/mL colloidal solution; dilute further in infusion fluid to a concentration of 100 micrograms/mL; pH of the glucose must not be below 4.2 (check each container—consult product literature for details of the buffer); infuse over 2–4 hours, or longer if not tolerated (initial test dose of 1 mg over 20–30 minutes); begin infusion immediately after dilution; protect from light; incompatible with sodium chloride solutions, flush existing intravenous line with glucose 5% or use separate line; an in-line filter (pore size no less than 1 micron) may be used.

**PRESCRIBING AND DISPENSING INFORMATION** Different preparations of intravenous amphotericin vary in their pharmacodynamics, pharmacokinetics, dosage, and administration; these preparations should not be considered interchangeable. To avoid confusion, prescribers should specify the brand to be dispensed.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

Suspension for infusion

**ELECTROLYTES:** May contain Sodium
- Abelcet (Teva UK Ltd)
  - Amphotericin B (as Amphotericin B phospholipid complex) 5 mg per 1 ml Abelcet 100mg/20ml concentrate for suspension for infusion vials 1 x 10 vial (Rx) £775.04 (Hospital only)
- Powder for solution for infusion
  - EXCIPIENTS: May contain Sucrose ELECTROLYTES: May contain Sodium
  - AmBisome (Gilead Sciences International Ltd)
    - Amphotericin B liposomal 50 mg AmBisome 50mg powder for solution for infusion vials 1 x 10 vial (Rx) £821.87
  - Fungizone (Bristol-Myers Squibb Pharmaceuticals Ltd)
    - Amphotericin B 50 mg Fungizone Intravenous 50mg powder for solution for infusion vials 1 x 1 vial (POM) £3.88

**ANTIFUNGALS > TRIAZOLE ANTIFUNGALS**

Fluconazole

**INDICATIONS AND DOSE**

**Candidal balanitis**
- **BY MOUTH**
  - Child 16–17 years: 150 mg for 1 dose
  - Adult: 150 mg for 1 dose

**Vaginal candidiasis**
- **BY MOUTH**
  - Child 16–17 years: 150 mg for 1 dose
  - Adult: 150 mg for 1 dose

**Vulvovaginal candidiasis (recurrent)**
- **BY MOUTH**
  - Adult: Initially 150 mg every 72 hours for 3 doses, then 150 mg once weekly for 6 months

**Mucosal candidiasis (except genital)**
- **BY MOUTH, OR BY INTRAVENOUS INFUSION**
  - Child 1 month–11 years: 3–6 mg/kg, dose to be given on first day, then 3 mg/kg daily (max. per dose 100 mg) for 7–14 days in oropharyngeal candidiasis (max. 14 days except in severely immunocompromised patients); for 14–30 days in other mucosal infections (e.g. oesophagitis, candiduria, non-invasive bronchopulmonary infections)
  - Child 12–17 years: 50 mg daily for 7–14 days in oropharyngeal candidiasis (max. 14 days except in severely immunocompromised patients); for 14–30 days in other mucosal infections (e.g. oesophagitis, candiduria, non-invasive bronchopulmonary infections); increased to 100 mg daily, increased dose only for unusually difficult infections
  - **BY MOUTH**
    - Adult: 50 mg daily given for 7–14 days in oropharyngeal candidiasis (max. 14 days except in severely immunocompromised patients); for 14 days in atrophic oral candidiasis associated with dentures; for 14–30 days in other mucosal infections (e.g. oesophagitis, candiduria, non-invasive bronchopulmonary infections); increased to 100 mg daily, increased dose only for unusually difficult infections

Tinea pedis, corporis, cruris, pityriasis versicolor | Dermal candidiasis
- **BY MOUTH**
  - Adult: 50 mg daily for 2–4 weeks (for up to 6 weeks in tinea pedis); max. duration of treatment 6 weeks

Invasive candidal infections (including candidaemia and disseminated candidiasis) and cryptococcal infections (including meningitis)
- **BY MOUTH, OR BY INTRAVENOUS INFUSION**
  - Child: 6–12 mg/kg daily (max. per dose 800 mg), treatment continued according to response (at least 8 weeks for cryptococcal meningitis)
  - Adult: 400 mg, dose to be given on first day, then 200–400 mg daily (max. per dose 800 mg once daily), treatment continued according to response (at least 8 weeks for cryptococcal meningitis), maximum dose for use in severe infections

Prevention of fungal infections in immunocompromised patients
- **BY MOUTH, OR BY INTRAVENOUS INFUSION**
  - Child: 3–12 mg/kg daily (max. per dose 400 mg), commence treatment before anticipated onset of neutropenia and continue for 7 days after neutrophil count in desirable range, dose given according to extent and duration of neutropenia
  - Adult: 50–400 mg daily, commence treatment before anticipated onset of neutropenia and continue for 7 days after neutrophil count in desirable range, dose adjusted according to risk

Prevention of fungal infections in immunocompromised patients (for patients with high risk of systemic infections e.g. following bone-marrow transplantation)
- **BY MOUTH, OR BY INTRAVENOUS INFUSION**
  - Adult: 400 mg daily, commence treatment before anticipated onset of neutropenia and continue for 7 days after neutrophil count in desirable range

Prevention of relapse of cryptococcal meningitis in HIV-infected patients after completion of primary therapy
- **BY MOUTH, OR BY INTRAVENOUS INFUSION**
  - Adult: 200 mg daily

**CONTRA-INDICATIONS** Acute porphyrias p. 969
**CAUTIONS** Susceptibility to QT interval prolongation
**INTERACTIONS** → Appendix 1: antifungals, azoles
**SIDE-EFFECTS**

- **Common or very common** Abdominal discomfort - diarrhoea - flatulence - headache - nausea - rash
- **Uncommon** Alopecia - anaphylaxis - angioedema (in children) - dizziness - dyspepsia - hepatic disorders - hyperlipidaemia - hypersensitivity reactions (in adults) - pruritus - seizures - Stevens-Johnson syndrome - taste disturbance - toxic epidermal necrolysis - vomiting
- **Frequency not known** Hypokalaemia - leucopenia - thrombocytopenia

**SIDE-EFFECTS, FURTHER INFORMATION**

If rash occurs, discontinue treatment (or monitor closely if infection invasive or systemic); severe cutaneous reactions are more likely in patients with AIDS.

**PREGNANCY**

Manufacturer advises avoid—multiple congenital abnormalities reported with long-term high doses.

**BREAST FEEDING**

Present in milk but amount probably too small to be harmful.

**HEPATIC IMPAIRMENT** Toxicity with related drugs.

**RENAL IMPAIRMENT**

- In adults Usual initial dose then halve subsequent doses if eGFR less than 50 ml/minute/1.73 m².
- In children Usual initial dose then halve subsequent doses if estimated glomerular filtration rate less than 50 ml/minute/1.73 m².

**MONITORING REQUIREMENTS** Monitor liver function with high doses or extended courses—discontinue if signs or symptoms of hepatic disease (risk of hepatic necrosis).

**DIRECTIONS FOR ADMINISTRATION**

- With intravenous use in children For intravenous infusion, give over 10–30 minutes; do not exceed an infusion rate of 5–10 ml/minute.

**PRESCRIBING AND DISPENSING INFORMATION**

- Flavours of oral liquid formulations may include orange.

**PROFESSION SPECIFIC INFORMATION**

Dental practitioners’ formulary

Fluconazole Capsules 50 mg may be prescribed. Fluconazole Oral Suspension 50 mg/5 ml may be prescribed.

**EXCEPTIONS TO LEGAL CATEGORY**

Fluconazole capsules can be sold to the public for vaginal candidiasis and associated candidal balanitis in those aged 16–60 years, in a container or packaging containing not more than 150 mg and labelled to show a max. dose of 150 mg.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for infusion**

**ELECTROLYTES:** May contain Sodium

- **Fluconazole (Non-proprietary)**
  - Fluconazole 2 mg per 1 ml Fluconazole 100 mg/50 ml solution for infusion bottles | 5 bottle | £12.60
  - Fluconazole 200 mg/100 ml solution for infusion vials | 1 vial | £29.28
  - Fluconazole 50 mg/25 ml solution for infusion vials | 1 vial | £7.31–£7.32
  - Fluconazole 200 mg/100 ml solution for infusion bottles | 5 bottle | £247.50
  - **Diffucan** (Pfizer Ltd)
  - Fluconazole 2 mg per 1 ml Diffucan 200 mg/100 ml solution for infusion vials | 1 vial | £29.28

**Oral suspension**

**CAUTIONARY AND ADVISORY LABELS**

- **Fluconazole (Non-proprietary)**
  - Fluconazole 10 mg per 1 ml Fluconazole 50 mg/5 ml oral suspension | 35 ml | £20.51 DT price = £20.51
  - **Diffucan** (Pfizer Ltd)
  - Fluconazole 10 mg per 1 ml Diffucan 50 mg/5 ml oral suspension | 35 ml | £16.61 DT price = £16.61
  - Fluconazole 40 mg per 1 ml Diffucan 200 mg/5 ml oral suspension | 35 ml | £66.42 DT price = £66.42

**Capsule**

**CAUTIONARY AND ADVISORY LABELS**

- **Fluconazole (Non-proprietary)**
  - Fluconazole 50 mg Fluconazole 50 mg capsules | 7 capsule | £5.00 DT price = £5.91
  - Fluconazole 150 mg Fluconazole 150 mg capsules | 1 capsule | £8.50 DT price = £8.41
  - Fluconazole 200 mg Fluconazole 200 mg capsules | 7 capsule | £6.92 DT price = £6.62

**Isavuconazole**

**DRUG ACTION** Isavuconazole is a triazole antifungal that blocks the synthesis of ergosterol, a key component of the fungal cell membrane.

**INDICATIONS AND DOSE**

Invasive aspergillosis | Mucormycosis in patients for whom amphotericin B is inappropriate

- **BY MOUTH, OR BY INTRAVENOUS INFUSION**
  - Adult: Loading dose 200 mg every 8 hours for 48 hours (6 administrations in total), then maintenance 200 mg once daily, maintenance dose to be started at least 12 hours after the last loading dose; long-term treatment should be reviewed after 6–months

**CONTRA-INDICATIONS** Short QT syndrome

**CAUTIONS** Elderly—limited information

**INTERACTIONS** Appendix 1: antifungals, azoles

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain - chest pain - decreased appetite - delirium - diarrhoea - dysphoria - electrolyte disturbances - headache - nausea - pruritus - rash - renal failure - somnolence - thrombophlebitis - vomiting

**Frequency not known**

- Infusion-related reactions - Stevens-Johnson syndrome

**SIDE-EFFECTS, FURTHER INFORMATION**

- Infusion-related reactions Infusion-related reactions have been reported, including hypotension, dyspnoea, dizziness, paraesthesia, nausea, and headache—manufacturer advises discontinue treatment if these reactions occur.

**PREGNANCY**

Manufacturer advises avoid unless severe or life-threatening infection—toxicity in animal studies.

**HEPATIC IMPAIRMENT** Manufacturer advises use with caution and monitor for toxicity in severe impairment—no information available.

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion, reconstitute each 200 mg with 5 ml Water for Injection; dilute dose to concentration of 0.8 mg/ml with
Glucose 5% or Sodium Chloride 0.9% and give via a
0.2–1.2 micron filter over at least 1 hour.

● HANDLING AND STORAGE
- With intravenous use Manufacturer advises store in a
refrigerator (2–8°C)—consult product literature for storage
after reconstitution or dilution.

● PATIENT AND CARER ADVICE
Driving and skilled tasks
Manufacturer advises patients and carers should be
cautioned on the effects on driving and performance of
skilled tasks—increased risk of confusion, syncope and
dizziness.

● NATIONAL FUNDING/ACCESS DECISIONS
All Wales Medicines Strategy Group (AWMSG) Decisions
The All Wales Medicines Strategy Group has advised
(January 2017) that isavuconazole (Cresemba) is
recommended as an option for use in adults within NHS
Wales for the treatment of invasive aspergillosis, and the
treatment of mucormycosis in patients for whom
amphotericin B is inappropriate, only if the approved
Wales Patient Access Scheme (WPAS) is used or where the
list/contract price is equivalent or lower.

● MEDICINAL FORMS
There can be variation in the licensing of different medicines
containing the same drug.

Powder for solution for infusion
CAUTIONARY AND ADVISORY LABELS 3
- Cresemba (Basilea Pharmaceutica International Ltd) ☑
Isavuconazole (as isavuconazolum sulfate) 200 mg Cresemba
200mg powder for concentrate for solution for infusion vials | 1 vial [PO] £297.84 (Hospital only)

Capsule
CAUTIONARY AND ADVISORY LABELS 25, 3
- Cresemba (Basilea Pharmaceutica International Ltd) ☑
Isavuconazole (as isavuconazolum sulfate) 100 mg Cresemba
100mg capsules | 14 capsule [PO] £599.28 (Hospital only)

Itraconazole

● INDICATIONS AND DOSE

Vulvovaginal candidiasis
- BY MOUTH
- Adult: 200 mg twice daily for 1 day

Vulvovaginal candidiasis (recurrent)
- BY MOUTH
- Adult: 50–100 mg daily for 6 months

Oral or oesophageal candidiasis that has not responded to
fluconazole
- BY MOUTH USING ORAL SOLUTION
- Adult: 100–200 mg twice daily for 2 weeks (continue
for another 2 weeks if no response; the higher dose
should not be used for longer than 2 weeks if no signs
of improvement)

Oral or oesophageal candidiasis in HIV-positive or other
immunocompromised patients
- BY MOUTH USING ORAL SOLUTION
- Adult: 200 mg daily in 1–2 divided doses for 1 week
(continue for another week if no response)

Systemic candidiasis where other antifungal drugs
inappropriate or ineffective
- BY MOUTH
- Adult: 100–200 mg once daily
- BY INTRAVENOUS INFUSION
- Adult: 200 mg every 12 hours for 2 days, then 200 mg
once daily for max. 12 days

Systemic candidiasis (invasive or disseminated) where
other antifungal drugs inappropriate or ineffective
- BY MOUTH
- Adult: 200 mg twice daily

Pityriasis versicolor
- BY MOUTH
- Adult: 200 mg once daily for 7 days

Tinea pedis | Tinea manuum
- BY MOUTH
- Adult: 100 mg once daily for 30 days, alternatively
200 mg twice daily for 7 days

Tinea corporis | Tinea cruris
- BY MOUTH
- Adult: 100 mg once daily for 15 days, alternatively
200 mg once daily for 7 days

Onychomycosis
- BY MOUTH
- Adult: 200 mg twice daily

Systemic aspergillosis where other antifungal drugs
inappropriate or ineffective
- BY INTRAVENOUS INFUSION
- Adult: 200 mg every 12 hours for 2 days, then 200 mg
once daily for max. 12 days

Histoplasmosis
- BY MOUTH
- Adult: 200 mg 3 times a day for 3 days, then 200 mg
1–2 times a day
- BY INTRAVENOUS INFUSION
- Adult: 200 mg every 12 hours for 2 days, then 200 mg
once daily for max. 12 days

Systemic cryptococcosis including cryptococcal meningitis
where other antifungal drugs inappropriate or ineffective
- BY MOUTH
- Adult: 200 mg once daily, dose increased in invasive or
disseminated disease and in cryptococcal meningitis,
increased to 200 mg twice daily
- BY INTRAVENOUS INFUSION
- Adult: 200 mg every 12 hours for 2 days, then 200 mg
once daily for max. 12 days

Maintenance in HIV-infected patients to prevent relapse
of underlying fungal infection and prophylaxis in
neutropenia when standard therapy inappropriate
- BY MOUTH
- Adult: 200 mg once daily, then increased to 200 mg
twice daily, dose increased only if low plasma-
itraconazole concentration

Prophylaxis of deep fungal infections (when standard
therapy inappropriate) in patients with haematological
malignancy or undergoing bone-marrow transplantation
who are expected to become neutropenic
- BY MOUTH USING ORAL SOLUTION
- Adult: 5 mg/kg daily in 2 divided doses, to be started
before transplantation or before chemotherapy (taking
care to avoid interaction with cytotoxic drugs) and
continued until neutrophil count recovers, safety and
efficacy not established in elderly patients

DOSE ADJUSTMENTS DUE TO INTERACTIONS
Manufacturer advises max. dose 200 mg daily with
concurrent use of cobicistat.
Itraconazole doses in BNF may differ from those in product literature.

**UNLICENSED USE**

**IMPORTANT SAFETY INFORMATION**

**HEART FAILURE**
Following reports of heart failure, caution is advised when prescribing itraconazole to patients at high risk of heart failure. Those at risk include:
- patients receiving high doses and longer treatment courses;
- older adults and those with cardiac disease;
- patients with chronic lung disease (including chronic obstructive pulmonary disease) associated with pulmonary hypertension;
- patients receiving treatment with negative inotropic drugs, e.g. calcium channel blockers.

Itraconazole should be avoided in patients with ventricular dysfunction or a history of heart failure unless the infection is serious.

**CONTRA-INDICATIONS**
Acute porphyrias p. 969

**CAUTIONS**
Active liver disease - history of hepatotoxicity with other drugs - susceptibility to congestive heart failure

**INTERACTIONS**
- Appendix 1: antifungals, azoles

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**
- Common or very common Abdominal pain - diarrhoea - dyspepsia - headache - hepatitis - hypokalaemia - nausea - rash - taste disturbances - vomiting
- Uncommon Constipation - dizziness - dyspepsia - flatulence - menstrual disorder - myalgia - oedema - peripheral neuropathy (discontinue treatment)
- Rare Alopecia - deafness - electrolyte dysfunction - heart failure - hypertriglyceridaemia - leucopenia - pancreatitis - photosensitivity - Stevens-Johnson syndrome - tinnitus - toxic epidermal necrolysis - urinalysis - visual disturbances
- Frequency not known Arthralgia - blood pressure changes - confusion - drowsiness - hepatotoxicity - renal impairment - thrombocytopenia - tremor

**SPECIFIC SIDE-EFFECTS**
- With intravenous use Hyperglycaemia

**SIDE-EFFECTS, FURTHER INFORMATION**
- Hepatotoxicity Potentially life-threatening hepatotoxicity reported very rarely — discontinue if signs of hepatitis develop.

**CONCEPTION AND CONTRACEPTION**
Ensure effective contraception during treatment and until the next menstrual period following end of treatment.

**PREGNANCY**
Manufacturer advises use only in life-threatening situations (toxicity at high doses in animal studies).

**BREAST FEEDING**
Small amounts present in milk — may accumulate; manufacturer advises avoid.

**HEPATIC IMPAIRMENT**
Dose reduction may be necessary. Use only if potential benefit outweighs risk of hepatotoxicity.

**RENAL IMPAIRMENT**
Risk of congestive heart failure.
- With oral use Bioavailability of oral formulations possibly reduced.
- With intravenous use Use intravenous infusion with caution if eGFR 30–80 mL/minute/1.73 m²; avoid intravenous infusion if eGFR less than 30 mL/minute/1.73 m².

**MONITORING REQUIREMENTS**
- Absorption reduced in AIDS and neutropenia (monitor plasma-itraconazole concentration and increase dose if necessary).
- Monitor liver function if treatment continues for longer than one month, if receiving other hepatotoxic drugs, if history of hepatotoxicity with other drugs, or in hepatic impairment.

**DIRECTIONS FOR ADMINISTRATION**
- With intravenous use For intravenous infusion (Sporanox®), give intermittently in Sodium Chloride 0.9%; dilute 250 mg in 50 mL infusion fluid and infuse only 60 mL through an in-line filter (0.2 micron) over 60 minutes.
- With oral use For oral liquid, do not take with food; swish around mouth and swallow, do not rinse afterwards.

**PRESCRIBING AND DISPENSING INFORMATION**
Flavours of oral liquid formulations may include cherry.

**PATIENT AND CARER ADVICE**
Patients should be told how to recognise signs of liver disorder and advised to seek prompt medical attention if symptoms such as anorexia, nausea, vomiting, fatigue, abdominal pain or dark urine develop.

Patients or carers should be given advice on how to administer itraconazole oral liquid.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Solution for infusion**
EXCIPIENTS: May contain Propylene glycol
- **Sporanox** (Janssen-Cilag Ltd)
  - Itraconazole 10 mg per 1 mL Sporanox i.v. 250 mg/25 mL solution for infusion amphotericin and diluent | 1 ampoule (POM) £79.71

**Oral solution**

**CAUTIONARY AND ADVISORY LABELS**
9, 23

**Itraconazole (Non-proprietary)**
- Itraconazole 10 mg per 1 mL Itraconazole 50 mg/mL oral solution sugar free sugar-free | 150 mL (POM) £58.34 DT price + £58.34
- **Sporanox** (Janssen-Cilag Ltd)
  - Itraconazole 10 mg per 1 mL Itraconazole 50 mg/mL oral solution sugar free sugar-free | 150 mL (POM) £58.34 DT price + £58.34

**Capsule**

**CAUTIONARY AND ADVISORY LABELS**
5, 9, 21, 25

**Itraconazole (Non-proprietary)**
- Itraconazole 100 mg Itraconazole 100 mg capsules | 15 capsule (POM) £13.77 DT price + £3.19 | 60 capsule (POM) £56.21
- **Sporanox** (Janssen-Cilag Ltd)
  - Itraconazole 100 mg Sporanox-Pulse 100 mg capsules | 28 capsule (POM) £25.72
  - Sporanox 100 mg capsules | 4 capsule (POM) £3.67 | 15 capsule (POM) £13.77 DT price + £3.19 | 60 capsule (POM) £55.10

**Posaconazole**

**INDICATIONS AND DOSE**
Invasive aspergillosis in patients who are refractory to, or intolerant of voriconazole and liposomal amphotericin | Fusariosis either unresponsive to, or in patients intolerant of, amphotericin | Chromoblastomycosis and mycetoma either unresponsive to, or in patients intolerant of, itraconazole | Coccidioidomycosis either unresponsive to, or in patients intolerant of, amphotericin, itraconazole, or fluconazole
- **BY MOUTH USING ORAL SUSPENSION**
  - Adult: 400 mg twice daily, to be taken with food, alternatively 200 mg 4 times a day, dose if food not tolerated
- **BY MOUTH USING TABLETS**
  - Adult: 300 mg twice daily on first day, then 300 mg once daily

**Oropharyngeal candidiasis (severe infection or in immunocompromised patients only)**
- **BY MOUTH USING ORAL SUSPENSION**
  - Adult: 200 mg on first day, then 100 mg once daily for 13 days, dose to be taken with food

**Posaconazole**

**Indications and Dose**
- Invasive aspergillosis in patients who are refractory to, or intolerant of voriconazole and liposomal amphotericin
- Fusariosis either unresponsive to, or in patients intolerant of, amphotericin
- Chromoblastomycosis and mycetoma either unresponsive to, or in patients intolerant of, itraconazole
- Coccidioidomycosis either unresponsive to, or in patients intolerant of, amphotericin, itraconazole, or fluconazole

**Dosage Forms**
- Oral Suspension
  - Posaconazole 250 mg/5 mL Oral Suspension sugar free sugar-free [250 mg/5 mL]; 280 mg/5 mL Oral Suspension sugar free sugar-free [280 mg/5 mL]; 420 mg/5 mL Oral Suspension sugar free sugar-free [420 mg/5 mL]

**Administration**
- Adult: 200 mg twice daily
- Pediatric: 200 mg twice daily in three divided doses

**Contraindications**
- Hypersensitivity to posaconazole or any component of the formulation
- Severe liver impairment

**Warnings**
- False positive reactions with sugars, alcohol, and glucose oxidase-based immunoassays for blood and urine glucose tests
- Pregnancy: Category B. Use only if potential benefit outweighs any potential risk to the fetus
- Breastfeeding: Use only if potential benefit outweighs any potential risk to the neonate

**Interactions**
- Posaconazole may inhibit the metabolism of other drugs that rely on the CYP3A4 isoenzyme
- Drug interactions may alter the pharmacodynamics and/or pharmacokinetics of co-administered drugs

**Pharmacology**
- Posaconazole is a triazole antifungal agent
- Inhibits fungal RNA polymerase
- Has broad-spectrum activity against a variety of fungi

**Pharmacokinetics**
- Posaconazole is well absorbed after oral administration
- Bioavailability is increased with food
- Distribution is extensive, with high concentrations in lung, liver, and spleen
- Metabolism is primarily via the cytochrome P450 3A4 system
- Elimination is mainly via the bile and粪便

**Adverse Effects**
- Common: Headache, nausea, diarrhea, abdominal pain, vomiting, anorexia, and rash
- Serious: Hepatotoxicity, bone marrow suppression, and skin reactions

**Dosage and Administration**
- Oral Suspension: Administer on a full stomach
- Tablets: Take with food

**Monitoring**
- Liver function tests
- Complete blood count

**Special Considerations**
- Use with caution in patients with liver or bone marrow toxicity
- Discontinue if signs of hepatotoxicity or rash develop

**Precautions**
- Use with caution in patients with renal impairment
- Use with caution in patients with hypersensitivity to other triazole antifungals

**Manufacturers**
- Pfizer

**References**
- FDA approval
- Summary of Product Characteristics

**Downloaded from www.medicalbr.com**
Prophylaxis of invasive fungal infections in patients undergoing bone-marrow transplantation or receiving chemotherapy for acute myeloid leukaemia and myelodysplastic syndrome who are expected to become neutropenic, and who are intolerant of fluconazole or itraconazole

▶ BY MOUTH USING ORAL SUSPENSION
  Adult: 200 mg 3 times a day start before transplantation or before chemotherapy and continued until neutrophil count recovers, dose to be taken with food

▶ BY MOUTH USING TABLETS
  Adult: 300 mg twice daily on first day, then 300 mg once daily start before transplantation or before chemotherapy and continued until neutrophil count recovers

DOSE EQUIVALENCE AND CONVERSION
Posaconazole oral suspension is not interchangeable with tablets on a milligram-for-milligram basis.

PHARMACOKINETICS
Posaconazole oral suspension should be taken with food (preferably a high fat meal) or nutritional supplement to ensure adequate exposure for systemic effects. Where possible, tablets should be used in preference to suspension because tablets have a higher bioavailability.

UNLICENSED USE Tablets not licensed for oophoronygael candidiasis.

CONTRA-INDICATIONS Acute porphyrias p. 969

CAUTIONS Body-weight over 120 kg—risk of treatment failure possibly increased.
Body-weight under 60 kg—risk of side effects increased.
Bradycardia, cardiomyopathy, history of QT interval prolongation, symptomatic arrhythmias

INTERACTIONS ▶ Appendix 1: antifungals, azoles

SIDE-EFFECTS
▶ Common or very common Abdominal pain, anaemia, anorexia, blood disorders, constipation, diarrhoea, dizziness, drowsiness, dry mouth, dyspepsia, electrolyte disturbances, fatigue, fever, flatulence, gastro-intestinal disturbances, headache, nausea, neutropenia, paraesthesia, pruritus, rash, thrombocytopenia, vomiting
▶ Uncommon Alopecia, aphasia, arthralgias, bradyarrhythmia, changes in blood pressure, convulsions, cough, gastro-oesophageal reflux, hepatic disorders, hiccups, hyperglycaemia, insomnia, menstrual disorders, mouth ulcers, musculoskeletal pain, neuropathy, oedema, palpitation, pancreatitis, renal failure, tachycardia, tremor, vasculitis, visual disturbances
▶ Rare Adrenal insufficiency, breast pain, cardiac failure, depression, encephalopathy, hearing impairment, ileus, myocardial infarction, pneumonitis, psychosis, Stevens-Johnson syndrome, stroke, syncope, thrombosis

CONCEPTION AND CONTRAINDICATIONS Manufacturer recommends effective contraception during treatment.

PREGNANCY Manufacturer advises avoid unless potential benefit outweighs risk; toxicity in animal studies.

BREAST FEEDING Manufacturer advises avoid—present in milk in animal studies.

HEPATIC IMPAIRMENT Manufacturer advises caution. Monitor liver function in hepatic impairment.

MONITORING REQUIREMENTS
Monitor electrolytes (including potassium, magnesium, and calcium) before and during therapy.
Monitor liver function before and during therapy.

PRESCRIBING AND DISPENSING INFORMATION Flavours of oral liquid formulations may include cherry.

MEDICATION FORMS
There can be variation in the licensing of different medicines containing the same drug.

Oral suspension
CAUTIONARY AND ADVISORY LABELS 3, 9, 21
▶ Noxafil (Merck Sharp & Dohme Ltd)
  Posaconazole 40 mg per 1 ml Noxafil 40mg/ml oral suspension ▶ 105 ml £491.20 (Hospital only)

Gastro-resistant tablet
CAUTIONARY AND ADVISORY LABELS 3, 9, 25
▶ Noxafil (Merck Sharp & Dohme Ltd)
  Posaconazole 100 mg Noxafil 100mg gastro-resistant tablets ▶ 24 tablet £596.96 ▶ 96 tablet £2,387.85

Voriconazole

INDICATIONS AND DOSE
Invasive aspergillosis ▶ Serious infections caused by Scedosporium spp., Fusarium spp., or invasive fluconazole-resistant Candida spp. (including C. krusei)
▶ BY MOUTH
  Adult (body-weight up to 40 kg): Initially 200 mg every 12 hours for 2 doses, then 100 mg every 12 hours, increased if necessary to 150 mg every 12 hours
  Adult (body-weight 40 kg and above): Initially 400 mg every 12 hours for 2 doses, then 200 mg every 12 hours, increased if necessary to 300 mg every 12 hours

▶ BY INTRAVENOUS INFUSION
  Adult: Initially 6 mg/kg every 12 hours for 2 doses, then 4 mg/kg every 12 hours; reduced if not tolerated to 3 mg/kg every 12 hours; for max. 6 months

DOSE ADJUSTMENTS DUE TO INTERACTIONS
With intravenous use Manufacturer advises increase maintenance dose to 5 mg/kg every 12 hours with concurrent use of fosphenytoin, phenytoin or rifabutin.

With oral use Manufacturer advises increase maintenance dose with concurrent use of fosphenytoin or phenytoin; 400 mg every 12 hours for patients of body-weight 40 kg and above; 200 mg every 12 hours for patients of body-weight less than 40 kg. Manufacturer advises if concurrent use of rifabutin is unavoidable, increase maintenance dose to 350 mg every 12 hours for patients of body-weight 40 kg and above; 200 mg every 12 hours for patients of body-weight less than 40 kg.

CONTRA-INDICATIONS Acute porphyrias p. 969

CAUTIONS Avoid exposure to sunlight, bradycardia, cardiomyopathy, electrolyte disturbances, history of QT interval prolongation, patients at risk of pancreatitis, symptomatic arrhythmias

INTERACTIONS ▶ Appendix 1: antifungals, azoles

SIDE-EFFECTS
GENERAL SIDE-EFFECTS

Abdominal pain, acute renal failure, agitation, alopecia, altered perception, anaemia, anxiety, asthenia, blood disorders, blurred vision, cheilitis, chest pain, confusion, depression, diarrhoea, dizziness, haematuria, hallucinations, headache, hypoglycaemia, hypokalaemia, hypotension, influenza-like symptoms, jaundice, leucopenia, nausea, oedema, pancreatopathy, paraesthesia, photophobia, photosensitivity, pruritus, rash, respiratory distress syndrome, sinuses, thrombocytopenia, tremor, visual disturbances, vomiting

Uncommon Adrenocortical insufficiency, arrhythmias, arthritis, ataxia, blepharitis, cholecytitis, constipation, duodenitis, dyspepsia, flushing, fulminant hepatic failure, gingivitis, glossitis, hepatitis, hypersensitivity reactions, hypoaesthesia, hyponatraemia, nystagmus

Uncommon Gotaitan and seizures, headache, hypothermia, intercurrent infection, joint pain, myalgia, myoperoneal weakness, myopathy, parasthesia, pancytopenia, pericarditis, petechiae, peritonitis, photosensitivity, postural hypotension, pruritus, rash, respiratory distress syndrome, sepsis, shivering, sinusitis, thrombocytopenia, tremor, visual disturbances, vomiting

Uncommon Drowsiness, fatigue, fever, flu-like symptoms, headache, myalgia, nervousness, pancytopenia, paraesthesia, photophobia, photosensitivity, pruritus, rash, respiratory distress syndrome, sinusitis, thrombocytopenia, tremor, visual disturbances, vomiting

Uncommon Adrenocortical insufficiency, arrhythmias, arthritis, ataxia, blepharitis, cholecytitis, constipation, duodenitis, dyspepsia, flushing, fulminant hepatic failure, gingivitis, glossitis, hepatitis, hypersensitivity reactions, hypoaesthesia, hyponatraemia, nystagmus
optic neuritis · pancreatitis · psoasitis · QT interval prolongation · raised serum cholesterol · scleritis · Stevens-Johnson syndrome · syncope

- Rare · Convulsions · discoid lupus erythematosus · extrapyramidal effects · hearing disturbances · hypertension · hypotension · hypothyroidism · insomnia · optic atrophy · pseudomembranous colitis · pseudoporphyria · retinal haemorrhage · taste disturbances (more common with oral suspension) · tinnitus · toxic epidermal necrolysis

- Frequency not known · On long term treatment, squamous cell carcinoma of skin (particularly in presence of phototoxicity) · peristitis (particularly in transplant patients)

SPECIFIC SIDE-EFFECTS

- Common or very common

- With intravenous use · Injection-site reactions

SIDE-EFFECTS, FURTHER INFORMATION

- Hepatotoxicity · Hepatitis, cholestasis, and fulminant hepatic failure usually occur in the first 10 days; risk of hepatotoxicity increased in patients with haematological malignancy. Consider treatment discontinuation if severe abnormalities in liver function tests.

- Phototoxicity · Phototoxicity occurs commonly. If phototoxicity occurs, consider treatment discontinuation; if treatment is continued, monitor for pre-malignant skin lesions and squamous cell carcinoma, and discontinue treatment if they occur.

- CONCEPTION AND CONTRACEPTION · Effective contraception required during treatment.

- PREGNANCY · Toxicity in animal studies—manufacturer advises avoid unless potential benefit outweighs risk.

- BREAST FEEDING · Manufacturer advises avoid—no information available.

- HEPATIC IMPAIRMENT · In mild to moderate hepatic cirrhosis use usual initial dose then halve maintenance dose. No information available for severe hepatic cirrhosis—manufacturer advises use only if potential benefit outweighs risk.

- RENAL IMPAIRMENT · Intravenous vehicle may accumulate if eGFR less than 50 mL/minute/1.73 m²—use intravenous infusion only if potential benefit outweighs risks, and monitor renal function; alternatively, use tablets or oral suspension (no dose adjustment required).

- MONITORING REQUIREMENTS

- Monitor renal function.

- Monitor liver function before starting treatment, then at least weekly for 1 month, and then monthly during treatment.

- DIRECTIONS FOR ADMINISTRATION · For intravenous infusion, reconstitute each 200 mg with 19 mL. Water for Injections or Sodium Chloride 0.9% to produce a 10 mg/mL solution; dilute dose to concentration of 0.5–5 mg/mL with Glucose 5% or Sodium Chloride 0.9% and give intermittently at a rate not exceeding 3 mg/kg/hour.

- PRESCRIBING AND DISPENSING INFORMATION · Flavours of oral liquid formulations may include orange.

- PATIENT AND CARER ADVICE · Patients and their carers should be advised to keep the alert card with them at all times.

- Patients and their carers should be told how to recognise symptoms of liver disorder, and advised to seek immediate medical attention if symptoms such as persistent nausea, vomitining, malaise or jaundice develop.

- Patients and their carers should be advised that patients should avoid intense or prolonged exposure to direct sunlight, and to avoid the use of sunbeds. In sunlight, patients should cover sun-exposed areas of skin and use a sunscreen with a high sun protection factor. Patients should seek medical attention if they experience sunburn or a severe skin reaction following exposure to light or sun.

MEDICINAL FORMS

- There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS 9, 11, 23

- Voriconazole (Non-proprietary)

Voriconazole 50 mg · Voriconazole 50 mg tablets · 28 tablet $54.43–$273.68 DT price = $118.99

Voriconazole 200 mg · Voriconazole 200 mg tablets · 28 tablet $157.49–$1,102.74 DT price = $460.32

- VFEND (Pfizer Ltd)

Voriconazole 50 mg · VFEND 50 mg tablets · 28 tablet $275.68 DT price = $118.99

Voriconazole 200 mg · VFEND 200 mg tablets · 28 tablet $1,102.74 DT price = $460.32

Oral suspension

CAUTIONARY AND ADVISORY LABELS 9, 11, 23

- VFEND (Pfizer Ltd)

Voriconazole 40 mg per 1 ml · VFEND 40 mg/ml oral suspension · 75 ml $551.37

Powder for solution for infusion

EXCIPIENTS: · May contain Sulfobutylether beta cyclodextrin sodium

ELECTROLYTES: · May contain Sodium

- Voriconazole (Non-proprietary)

Voriconazole 200 mg · Voriconazole 200 mg powder for solution for infusion vials · 1 vial $51.43–$77.14 (Hospital only)

- VFEND (Pfizer Ltd)

Voriconazole 200 mg · VFEND 200 mg powder for solution for infusion vials · 1 vial $77.14 (Hospital only)

Powder and solvent for solution for infusion

EXCIPIENTS: · May contain Sulfobutylether beta cyclodextrin sodium

ELECTROLYTES: · May contain Sodium

- VFEND (Pfizer Ltd)

Voriconazole 200 mg · VFEND 200 mg powder and solvent for solution for infusion vials · 1 vial $77.14 (Hospital only)

OTHER

Flucytosine

INDICATIONS AND DOSE

- Systemic yeast and fungal infections · Adjunct to amphotericin in severe systemic candidiasis and in other severe or long-standing infections

B Y INTRAVENOUS INFUSION

- Adult: Usual dose 200 mg/kg daily in 4 divided doses usually for not more than 7 days, alternatively 100–150 mg/kg daily in 4 divided doses, lower dose may be sufficient for extremely sensitive organisms

Cytococcal meningitis (adjunct to amphotericin)

B Y INTRAVENOUS INFUSION

- Adult: 100 mg/kg daily in 4 divided doses for 2 weeks

UNLICENSED USE

Use in cryptococcal meningitis for 2 weeks is an unlicensed duration.

CAUTIONS · Blood disorders · elderly

INTERACTIONS · Appendix 1: flucytosine

SIDE-EFFECTS

Common or very common · Diarrhoea · nausea · rashes · vomitining

Uncommon · Alterations in liver function tests · cardiotoxicity · confusion · convulsions · hallucinations · headache · sedation · toxic epidermal necrolysis · vertigo

Frequency not known · Aplastic anaemia · blood disorders · hepatic necrosis · hepatitis · leucopenia · thrombocytopenia

PREGNANCY · Teratogenic in animal studies; manufacturer advises use only if potential benefit outweighs risk.

BREAST FEEDING · Manufacturer advises avoid.

RENAL IMPAIRMENT · Use 50 mg/kg every 12 hours if creatinine clearance 20–40 mL/minute; use 50 mg/kg every
24 hours if creatinine clearance 10–20 mL/minute; use initial dose of 50 mg/kg if creatinine clearance less than 10 mL/minute and then adjust dose according to plasma-flucytosine concentration. In renal impairment liver- and kidney-function tests and blood counts required weekly.

**MONITORING REQUIREMENTS**
- For plasma concentration monitoring, blood should be taken shortly before starting the next infusion; plasma concentration for optimum response 25–50 mg/litre (200–400 micromol/litre)—should not be allowed to exceed 80 mg/litre (620 micromol/litre).
- Liver- and kidney-function tests and blood counts required (weekly in Wilson diseases).

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion, give over 20–40 minutes.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Solution for infusion**
- **ELECTROLYTES:** May contain Sodium
  - Ancotil (Meda Pharmaceuticals Ltd)
  - Flucytosine 10 mg per 1 ml Ancotil 2.5g/250ml solution for infusion bottles | 5 bottle [PoM] £151.67 (Hospital only)

**Griseofulvin**

- **INDICATIONS AND DOSE**
  - **Dermatophyte infections of the skin, scalp, hair and nails where topical therapy has failed or is inappropriate**
    - **BY MOUTH**
    - Adult: 500 mg daily, increased if necessary to 1 g daily, for severe infections; reduce dose when response occurs, daily dose may be taken once daily or in divided doses
  - **Tinea capitis caused by Trichophyton tonsurans**
    - **BY MOUTH**
    - Adult: 1 g once daily, alternatively 1 g daily in divided doses

- **UNLICENSED USE** Griseofulvin doses in BNF may differ from those in product literature.

- **CONTRA-INDICATIONS** Acute porphyrias p. 969; systemic lupus erythematosus (risk of exacerbation)

- **INTERACTIONS** → Appendix 1: griseofulvin

- **SIDE-EFFECTS**
  - **Rare** Erythema multiforme; toxic epidermal necrolysis
  - **Very rare** Headache
  - **Frequency not known** Abdominal pain; agitation; confusion; depression; diarrhoea; dizziness; dyspepsia; fatigue; glossitis; hepatotoxicity; impaired coordination; impaired hearing; leucopenia; menstrual disturbances; nauscea; peripheral neuropathy; photosensitivity; rash; renal failure; sleep disturbances; systemic lupus erythematosus; taste disturbances; vomiting

- **CONCEPTION AND CONTRACEPTION** Effective contraception required during and for at least 1 month after administration to women (important: effectiveness of oral contraceptives may be reduced, additional contraceptive precautions e.g. barrier method, required). Men should avoid fathering a child during and for at least 6 months after administration

- **PREGNANCY** Avoid (fetotoxicity and teratogenicity in animals).

- **BREAST FEEDING** Avoid—no information available.

- **HEPATIC IMPAIRMENT** Avoid in severe liver disease.

- **PATIENT AND CARER ADVICE**
  - Driving and skilled tasks
    - May impair performance of skilled tasks (e.g. driving); effects of alcohol enhanced.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension
  - **Tablet**
    - **CAUTIONARY AND ADVISORY LABELS** 9, 21
    - **Griseofulvin (Non-proprietary)**
      - **Griseofulvin 125 mg** Griseofulvin 125mg tablets | 100 tablet [PoM] £96.67 DT price = £96.67
      - **Griseofulvin 500 mg** Griseofulvin 500mg tablets | 90 tablet [PoM] £99.00 | 100 tablet [PoM] £100.17

### 3.1 Pneumocystis pneumonia

**Pneumocystis pneumonia**

**Overview**
Pneumonia caused by *Pneumocystis jirovecii* (*Pneumocystis carinii*) occurs in immunosuppressed patients; it is a common cause of pneumonia in AIDS. Pneumocystis pneumonia should generally be treated by those experienced in its management. Blood gas measurement is used to assess disease severity.

**Treatment**

**Mild to moderate disease**
Co-trimoxazole p. 531 in high dosage is the drug of choice for the treatment of mild to moderate pneumocystis pneumonia.

Atovaquone p. 569 is licensed for the treatment of mild to moderate pneumocystis infection in patients who cannot tolerate co-trimoxazole. A combination of dapsone p. 545 with trimethoprim p. 542 is given by mouth for the treatment of mild to moderate disease [unlicensed indication].

A combination of clindamycin p. 506 and primaquine p. 585 by mouth is used in the treatment of mild to moderate disease [unlicensed indication]; this combination is associated with considerable toxicity.

**Severe disease**
Co-trimoxazole in high dosage, given by mouth or by intravenous infusion, is the drug of choice for the treatment of severe pneumocystis pneumonia. Pentamidine isetionate p. 569 given by intravenous infusion is an alternative for patients who cannot tolerate co-trimoxazole, or who have not responded to it. Pentamidine isetionate is a potentially toxic drug that can cause severe hypotension during or immediately after infusion.

Corticosteroid treatment can be lifesaving in those with severe pneumocystis pneumonia.

**Adjunctive therapy**
In moderate to severe infections associated with HIV infection, prednisolone p. 639 is given by mouth for 5 days (alternatively, hydrocortisone p. 637 may be given parenterally); the dose is then reduced to complete 21 days of treatment. Corticosteroid treatment should ideally be started at the same time as the anti-pneumocystis therapy and certainly no later than 24–72 hours afterwards. The corticosteroid should be withdrawn before anti-pneumocystis treatment is complete.

**Prophylaxis**
Prophylaxis against pneumocystis pneumonia should be given to all patients with a history of the infection. Prophylaxis against pneumocystis pneumonia should also be considered for severely immunocompromised patients. Prophylaxis should continue until immunity recovers sufficiently. It should not be discontinued if the patient has oral candidiasis, continues to lose weight, or is receiving cytotoxic therapy or long-term immunosuppressant therapy.
Co-trimoxazole by mouth is the drug of choice for prophylaxis against pneumocystis pneumonia. It is given daily or on alternate days (3 times a week); the dose may be reduced to improve tolerance.

Inhaled pentamidine isetionate is better tolerated than parenteral pentamidine isetionate. Intermittent inhalation of pentamidine isetionate is used for prophylaxis against pneumocystis pneumonia in patients unable to tolerate co-trimoxazole. It is effective but patients may be prone to extrapulmonary infection. Alternatively, dapsone can be used. Atovaquone has also been used for prophylaxis [unlicensed indication].

**INTERACTIONS**

Co-trimoxazole by mouth is the drug of choice for antiprotozoals [unlicensed indication].

Atovaquone has also been used for prophylaxis against pneumocystis pneumonia. It is effective but patients may be prone to pneumocystis pneumonia in patients unable to tolerate pentamidine isetionate is used for prophylaxis against pneumocystis pneumonia in patients unable to tolerate co-trimoxazole. It is effective but patients may be prone to extrapulmonary infection. Alternatively, dapsone can be used. Atovaquone has also been used for prophylaxis [unlicensed indication].

**ANTIPROTOZOALS**

### Atovaquone

<table>
<thead>
<tr>
<th>INDICATIONS AND DOSE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment of mild to moderate Pneumocystis jirovecii (Pneumocystis carinii) pneumonia in patients intolerant of co-trimoxazole</strong></td>
</tr>
<tr>
<td>▶ BY MOUTH</td>
</tr>
<tr>
<td>Adult: 750 mg twice daily for 21 days, dose to be taken with food, particularly high fat food</td>
</tr>
</tbody>
</table>

**Prophylaxis against pneumocystis pneumonia**

- **BY MOUTH**
  - Adult: 750 mg twice daily

<table>
<thead>
<tr>
<th>UNLICENSED USE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not licensed for prophylaxis against pneumocystis pneumonia.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CAUTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other causes of pulmonary disease should be sought and treated—elderly—initial diaphoresis and difficulty in taking with food may reduce absorption (and require alternative therapy)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INTERACTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>▶ Appendix 1: antimalarials</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SIDE-EFFECTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anaemia—diarrhoea—fever—headache—hyponatraemia—insomnia—nausea—neutropenia—pruritus—rash—Stevens-Johnson syndrome—vomiting</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PREGNANCY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manufacturer advises avoid unless potential benefit outweighs risk—no information available.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BREAST FEEDING</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manufacturer advises avoid.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HEPATIC IMPAIRMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manufacturer advises caution. Monitor more closely in hepatic impairment.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RENAL IMPAIRMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manufacturer advises caution. Monitor more closely in renal impairment.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PRESCRIBING AND DISPENSING INFORMATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flavours of oral liquid formulations may include tutti-frutti.</td>
</tr>
</tbody>
</table>

**MATIC MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Oral suspension**

- **Wellvone** (GliaoxsmithKline Ltd)
  - Atovaquone 150 mg per 1 ml Wellvone 750mg/5ml oral suspension sugar-free | 226 ml | £48.37

### Pentamidine isetionate

<table>
<thead>
<tr>
<th>INDICATIONS AND DOSE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment of Pneumocystis jirovecii (Pneumocystis carinii) pneumonia (specialist use only)</strong></td>
</tr>
<tr>
<td>▶ BY INTRAVENOUS INFUSION</td>
</tr>
<tr>
<td>Adult: 4 mg/kg once daily for at least 14 days</td>
</tr>
</tbody>
</table>

**Prophylaxis of Pneumocystis jirovecii (Pneumocystis carinii) pneumonia (specialist use only)**

- **BY INHALATION OF NEBULISED SOLUTION**
  - Adult: 300 mg every 4 weeks, alternatively 150 mg every 2 weeks, using suitable equipment—consult product literature

**Visceral leishmaniasis (specialist use only)**

- **BY DEEP INTRAMUSCULAR INJECTION**
  - Adult: 3–4 mg/kg once daily on alternate days, maximum total of 10 injections, course may be repeated if necessary

**Cutaneous leishmaniasis (specialist use only)**

- **BY DEEP INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INFUSION**
  - Adult: 4 mg/kg once daily or on alternate days for a total of 7–10 injections

**UNLICENSED USE**

- Not licensed for primary prevention of Pneumocystis jirovecii (Pneumocystis carinii) pneumonia by inhalation of nebulised solution.

**CAUTIONS**

- Anemia—bradycardia—coronary heart disease—history of ventricular arrhythmias—hyperglycaemia—hypertension—hypoglycaemia—hypokalaemia—hypomagnesaemia—hypotension—leucopenia—risk of severe hypotension following administration—thrombocytopenia

**INTERACTIONS**

- ▶ Appendix 1: antimalarials

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**

- Abnormal liver function tests—acute renal failure—anaemia—arrhythmias (can be severe and sometimes fatal)—azotaemia—dizziness—flushing—hyperglycaemia—hyperkalaemia—hypocalcaemia—hypoglycaemia (can be severe and sometimes fatal)—hypotension (can be severe and sometimes fatal)—leucopenia—nausea—pancreatitis (can be severe and sometimes fatal)—rash—Stevens-Johnson syndrome—syncope—taste disturbances—thrombocytopenia—vomiting

**SPECIFIC SIDE-EFFECTS**

- When used by inhalation—Bronchoconstriction (may be prevented by prior use of bronchodilators)—cough—shortness of breath

- With intramuscular use or intravenous use. Injection site reactions (muscle necrosis, discomfort, pain, induration, abscess formation)

**PREGNANCY**

- Manufacturer advises avoid unless essential.

**BREAST FEEDING**

- Manufacturer advises avoid unless essential—no information available.

**HEPATIC IMPAIRMENT**

- Manufacturer advises caution.

**RENAL IMPAIRMENT**

- Manufacturer advises caution. Monitor more closely in renal impairment.

**PRESCRIBING AND DISPENSING INFORMATION**

- Flavours of oral liquid formulations may include tutti-frutti.
Infection
Niclosamide [unlicensed] (available from Taenicide well tolerated.
side-effects are limited to occasional gastrointestinal upset, light-headedness, and pruritus; it is not effective against
Powder for injection (dissolved in water for injection) may be used for nebulisation.

**HANDLING AND STORAGE** Pentamidine isetionate is toxic and personnel should be adequately protected during handling and administration—consult product literature.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for injection**
- Pentamidine isetionate 300 mg
  - Pentamidine isetionate 300 mg powder for solution for injection vials | 5 vial (Poz) £158.86

**4 Helminth infection**

**Helminth infections**

**Specialist centres**
Advice on prophylaxis and treatment of helminth infections is available from the following specialist centres:

<table>
<thead>
<tr>
<th>Location</th>
<th>Contact Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birmingham</td>
<td>(0121) 424 0357</td>
</tr>
<tr>
<td>Scotland</td>
<td>Contact local Infectious Diseases Unit</td>
</tr>
<tr>
<td>Liverpool</td>
<td>(0151) 705 3100</td>
</tr>
<tr>
<td>London</td>
<td>0845 155 5000 (treatment)</td>
</tr>
</tbody>
</table>

**Drugs for threadworms**
Anthelmintics are effective in threadworm (pinworms, *Enterobius vermicularis*) infections, but their use needs to be combined with hygiene measures to break the cycle of auto-infection. All members of the family require treatment.

Adult threadworms do not live for longer than 6 weeks and for development of fresh worms, ova must be swallowed and exposed to the action of digestive juices in the upper intestinal tract. Direct multiplication of worms does not take place in the large bowel. Adult female worms lay ova on the perianal skin which causes pruritus; scratching the area then leads to ova being transmitted on fingers to the mouth, often via food eaten with unwashed hands. Washing hands and scrubbing nails before each meal and after each visit to the toilet is essential. A bath taken immediately after rising will remove ova laid during the night.

Mebendazole is effective against *Ascaris lumbricoides* and is generally considered to be the drug of choice.

Levamisole p. 571 [unlicensed] (available from ‘special-order’ manufacturers or specialist importing companies) is an alternative when mebendazole cannot be used. It is very well tolerated.

**Drugs for tapeworm infections**

**Taenicides**

Niclosamide [unlicensed] (available from ‘special-order’ manufacturers or specialist importing companies) is the most widely used drug for tapeworm infections and side-effects are limited to occasional gastro-intestinal upset, light-headedness, and pruritus; it is not effective against larval worms. Fears of developing cysticercosis in *Taenia solium* infections have proved unfounded. All the same, an antiemetic can be given before treatment and a laxative can be given 2 hours after niclosamide.

Praziquantel p. 572 [unlicensed] (available from ‘special-order’ manufacturers or specialist importing companies) is as effective as niclosamide.

**Hydatid disease**

Cysts caused by *Echinococcus granulosus* grow slowly and asymptomatic patients do not always require treatment. Surgical treatment remains the method of choice in many situations. Albendazole p. 571 [unlicensed] (available from ‘special-order’ manufacturers or specialist importing companies) is used in conjunction with surgery to reduce the risk of recurrence or as primary treatment in inoperable cases. Alveolar echinococcosis due to *E. multilocularis* is usually fatal if untreated. Surgical removal with albendazole cover is the treatment of choice, but where effective surgery is impossible, repeated cycles of albendazole (for a year or more) may help. Careful monitoring of liver function is particularly important during drug treatment.

**Drugs for hookworms**

Hookworms (anctlostomiasis, necatoriasis) live in the upper small intestine and draw blood from the point of their attachment to their host. An iron-deficiency anaemia may occur and, if present, effective treatment of the infection requires not only expulsion of the worms but treatment of the anaemia.

Mebendazole has a useful broad-spectrum activity, and is effective against hookworms. Albendazole [unlicensed] (available from ‘special-order’ manufacturers or specialist importing companies) is an alternative. Levamisole is also is effective in children.

**Schistosomicides (bilharziasis)**

Adult *Schistosoma haematobium* worms live in the genito-urinary veins and adult *S. mansoni* in those of the colon and mesentery. *S. japonicum* is more widely distributed in veins of the alimentary tract and portal system.

Praziquantel [unlicensed] is available from Merck Serono (Cysticide *) and is effective against all human schistosomes. No serious adverse effects have been reported. Of all the available schistosomicides, it has the most attractive combination of effectiveness, broad-spectrum activity, and low toxicity.

**Filaricides**

Diethylcarbamazine [unlicensed] (available from ‘special-order’ manufacturers or specialist importing companies) is effective against microfilariae and adults of *Loa loa*, *Wuchereria bancrofti*, and *Brugia malayi*. To minimise reactions, treatment in adults and children over 1 month, is commenced with a dose of diethylcarbamazine citrate on the first day and increased gradually over 3 days. Length of treatment varies according to infection type, and usually gives a radical cure for these infections. Close medical supervision is necessary particularly in the early phase of treatment.

In heavy infections there may be a febrile reaction, and in heavy *Loa loa* infection there is a small risk of encephalopathy. In such cases specialist advice should be sought, and treatment must be given under careful in-patient supervision and stopped at the first sign of cerebral involvement.

Ivermectin p. 571 [unlicensed] (available from ‘special-order’ manufacturers or specialist importing companies) is very effective in onchocerciasis and it is now the drug of choice; reactions are usually slight. Diethylcarbamazine or suramin should no longer be used for onchocerciasis because of their toxicity.
Drugs for cutaneous larva migrans (creeping eruption)

Dog and cat hookworm larvae may enter human skin where they produce slowly extending itching tracks usually on the foot. Single tracks can be treated with topical tiabendazole (no commercial preparation available). Multiple infections respond to ivermectin, albendazole or tiabendazole (tiabendazole) by mouth [all unlicensed] (available from ‘special-order’ manufacturers or specialist importing companies).

Drugs for strongyloidiasis

Adult Strongyloides stercoralis live in the gut and produce larvae which penetrate the gut wall and invade the tissues, setting up a cycle of auto-infection. Ivermectin [unlicensed] (available from ‘special-order’ manufacturers or specialist importing companies) is the treatment of choice for chronic Strongyloides infection in adults and children over 5 years. Albendazole [unlicensed] (available from ‘special order’ manufacturers or specialist importing companies) is an alternative given to adults and children over 2 years.

ANTHELMINTICS

Albendazole

- **INDICATIONS AND DOSE**
  - Chronic Strongyloides infection
    - **BY MOUTH**
      - Adult: 400 mg twice daily for 3 days, dose may be repeated after 3 weeks if necessary
  - Hydatid disease, in conjunction with surgery to reduce the risk of recurrence or as primary treatment in inoperable cases
    - **BY MOUTH**
      - Adult: (consult product literature)
  - Hookworm infections
    - **BY MOUTH**
      - Adult: 400 mg for 1 dose
- **UNLICENSED USE** Albendazole is an unlicensed drug.
- **INTERACTIONS** → Appendix 1: albendazole

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, chewable tablet, oral suspension
  - **Tablet**
    - CAUTIONARY AND ADVISORY LABELS 9
      - Albendazole (Non-proprietary)
        - Albendazole 400 mg Eskazole 400mg tablets | 60 tablet | no price available
  - **Chewable tablet**
    - CAUTIONARY AND ADVISORY LABELS 9
      - Albendazole (Non-proprietary)
        - Albendazole 200 mg Zentel 200mg chewable tablets | 6 tablet | no price available
        - Albendazole 400 mg Zentel 400mg chewable tablets | 1 tablet | no price available | 3 tablet | no price available

Diethylcarbamazine

- **INDICATIONS AND DOSE**
  - Wuchereria bancrofti infections | Brugia malayi infections
    - **BY MOUTH**
      - Adult: Initially 1 mg/kg daily on the first day, then increased to 6 mg/kg daily in divided doses, dose to be increased gradually over 3 days
- **UNLICENSED USE** Diethylcarbamazine is an unlicensed drug.
- **INTERACTIONS** → Appendix 1: diethylcarbamazine

Ivermectin

**INDICATIONS AND DOSE**

- Chronic Strongyloides infection
  - **BY MOUTH**
    - Adult: 200 micrograms/kg for 2 days
- Onchocerciasis
  - **BY MOUTH**
    - Adult: 150 micrograms/kg for 1 dose, retreatment at intervals of 6 to 12 months, depending on symptoms, must be given until the adult worms die out
- Scabies, in combination with topical drugs, for the treatment of hyperkeratotic (crusted or ‘Norwegian’) scabies that does not respond to topical treatment alone
  - **BY MOUTH**
    - Adult: 200 micrograms/kg for 1 dose, further doses of 200 micrograms/kg may be required

- **UNLICENSED USE** Ivermectin is unlicensed.
- **SIDE-EFFECTS** Aggravation of itching - aggravation of rash
- **NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (December 2015) that ivermectin (Soolantra®) is accepted for restricted use within NHS Scotland for the treatment of moderate-to-severe inflammatory lesions of rosacea (papulopustular) where a topical treatment is considered appropriate.

All Wales Medicines Strategy Group (AWMSG) Decisions

The All Wales Medicines Strategy Group has advised (April 2016) that ivermectin (Soolantra®) is recommended as an option for use within NHS Wales for the topical treatment of inflammatory lesions of rosacea (papulopustular) in adult patients.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet
  - **Tablet**
    - Ivermectin (Non-proprietary)
      - Ivermectin 3 mg Stromectol 3mg tablets | 4 tablet | no price available | 20 tablet | no price available

Levamisole

- **INDICATIONS AND DOSE**
  - Roundworm infections
    - **BY MOUTH**
      - Adult: 120–150 mg for 1 dose
- **UNLICENSED USE** Not licensed.
- **CONTRA-INDICATIONS** Blood disorders
- **CAUTIONS** Epilepsy · Sjögren’s syndrome
572 Protozoal infection

Mebendazole

**INDICATIONS AND DOSE**

**Threadworm infections**

- **BY MOUTH**
  - Child 6 months–17 years: 100 mg for 1 dose, if reinfection occurs, second dose may be needed after 2 weeks
  - Adult: 100 mg for 1 dose, if reinfection occurs, second dose may be needed after 2 weeks

** Whipworm infections** | **Hookworm infections**

- **BY MOUTH**
  - Child 1–17 years: 100 mg twice daily for 3 days
  - Adult: 100 mg twice daily for 3 days

**Roundworm infections**

- **BY MOUTH**
  - Child 1 year: 100 mg twice daily for 3 days
  - Child 2–17 years: 100 mg twice daily for 3 days, alternatively 500 mg for 1 dose
  - Adult: 100 mg twice daily for 3 days, alternatively 500 mg for 1 dose

**UNLICENSED USE** Not licensed for use as a single dose of 500 mg in roundworm infections. Not licensed for use in children under 2 years.

**INTERACTIONS** → Appendix 1: mebendazole

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain
- **Uncommon** Diarrhoea • flatulence
- **Rare** Alopecia • convulsions • dizziness • hepatitis • neutropenia • rash • Stevens-Johnson syndrome • toxic epidermal necrolysis • urticaria

**PREGNANCY** Manufacturer advises avoid—tendency in animal studies.

**BREAST FEEDING** Amount present in milk too small to be harmful but manufacturer advises avoid.

**PRESCRIBING AND DISPENSING INFORMATION** Flavours of oral liquid formulations may include banana.

**PATIENT AND CARER ADVICE**

Medicines for Children leaflet: Mebendazole for worm infections www.medicinesforchildren.org.uk/mebendazole-for-worm-infections

**EXCEPTIONS TO LEGAL CATEGORY** Mebendazole tablets can be sold to the public if supplied for oral use in the treatment of enterobiasis in adults and children over 2 years provided its container or package is labelled to show a max. single dose of 100 mg and it is supplied in a container or package containing not more than 800 mg.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Oral suspension**

- **Ovex (McNeil Products Ltd)**
  - Mebendazole 20 mg per 1 ml Ovex 100mg/5ml oral suspension | 30 ml £6.03 DT price = £1.55
  - Vermox (Janssen-Cilag Ltd)
  - Mebendazole 20 mg per 1 ml Vermox 100mg/5ml oral suspension | 30 ml £1.55 DT price = £1.55

**Chewable tablet**

- **Ovex (McNeil Products Ltd)**
  - Mebendazole 100 mg Ovex 100mg chewable tablets sugar-free | 1 tablet £2.03 sugar-free | 4 tablet £4.74
  - Vermox (Janssen-Cilag Ltd)
  - Mebendazole 100 mg Vermox 100mg chewable tablets sugar-free | 6 tablet £1.34 DT price = £1.34

Praziquantel

**INDICATIONS AND DOSE**

**Tapeworm infections (Taenia solium)**

- **BY MOUTH**
  - Adult: 5–10 mg/kg for 1 dose, to be taken after a light breakfast

**Tapeworm infections (Hymenolepis nana)**

- **BY MOUTH**
  - Adult: 25 mg/kg for 1 dose, to be taken after a light breakfast

**Schistosoma haematobium worm infections | Schistosoma mansoni worm infections**

- **BY MOUTH**
  - Adult: 20 mg/kg, followed by 20 mg/kg after 4–6 hours

**Schistosoma japonicum worm infections**

- **BY MOUTH**
  - Adult: 20 mg/kg 3 times a day for 1 day

**UNLICENSED USE** Praziquantel is an unlicensed drug.

**INTERACTIONS** → Appendix 1: praziquantel

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet

**Tablet**

- **Cysticide (Imported (Germany))**
  - Praziquantel 500 mg tablets | 90 tablet no price available

### 5 Protozoal infection

#### Antiprotozoal drugs

**Amebicicides**

Metronidazole p. 512 is the drug of choice for acute invasive amoebic dysentery since it is very effective against vegetative forms of Entamoeba histolytica in ulcers. Tindazole p. 514 is also effective. Metronidazole and tindazole are also active against amoebae which may have migrated to the liver.

Treatment with metronidazole (or tinidazole) is followed by a 10-day course of diloxanide furoate p. 479.

Diloxanide furoate is the drug of choice for asymptomatic patients with E. histolytica cysts in the faeces; metronidazole and tindazole are relatively ineffective. Diloxanide furoate is relatively free from toxic effects and the usual course is of...
10 days, given alone for chronic infections or following metronidazole or tinidazole treatment.

For amoebic abscesses of the liver metronidazole is effective; tinidazole is an alternative. Aspiration of the abscess is indicated where it is suspected that it may rupture or where there is no improvement after 72 hours of metronidazole; the aspiration may need to be repeated. Aspiration aids penetration of metronidazole and, for abscesses with more than 100 mL of pus, if carried out in conjunction with drug therapy, may reduce the period of disability.

Diloxanide furoate is not effective against hepatic amoebiasis, but a 10-day course should be given at the completion of metronidazole or tinidazole treatment to destroy any amoebae in the gut.

**Trichomonacides**

Metronidazole is the treatment of choice for *Trichomonas vaginalis* infection. Contact tracing is recommended and sexual contacts should be treated simultaneously. If metronidazole is ineffective, tinidazole may be tried.

**Antigiardial drugs**

Metronidazole is the treatment of choice for *Giardia lamblia* infections. Alternative treatments are tinidazole or mepacrine hydrochloride p. 479.

**Leishmaniaces**

Cutaneous leishmaniasis frequently heals spontaneously but if skin lesions are extensive or unsightly, treatment is indicated, as it is in visceral leishmaniasis (kala-azar). Leishmaniasis should be treated under specialist supervision.

Sodium stibogluconate below, an organic pentavalent antimony compound, is used for visceral leishmaniasis. The dosage varies with different geographical regions and expert advice should be obtained. Some early non-inflamed lesions of cutaneous leishmaniasis can be treated with intralesional injections of sodium stibogluconate under specialist supervision.

Amphotericin p. 561 is used with or after an antimony compound for visceral leishmaniasis unresponsive to the antimonial alone; side-effects may be reduced by using liposomal amphotericin (*AmBisome*®). *Abelcet®*, a lipid formulation of amphotericin is also likely to be effective but less information is available.

Pentamidine isetionate p. 569 has been used in antimony-resistant visceral leishmaniasis, but although the initial response is often good, the relapse rate is high; it is associated with serious side-effects. Other treatments include paromomycin [unlicensed] (available from ‘special-order’ manufacturers or specialist importing companies).

**Trypanocides**

The prophylaxis and treatment of trypanosomiasis is difficult and differs according to the strain of organism. Expert advice should therefore be obtained.

**Drugs for toxoplasmosis**

Most infections caused by *Toxoplasma gondii* are self-limiting, and treatment is not necessary. Exceptions are patients with eye involvement (toxoplasma chorioretinitis), and those who are immunosuppressed. Toxoplasminic encephalitis is a common complication of AIDS. The treatment of choice is a combination of pyrimethamine p. 586 and sulfadiazine p. 532, given for several weeks (expert advice essential). Pyrimethamine is a folate antagonist, and adverse reactions to this combination are relatively common (folinic acid supplements and weekly blood counts needed). Alternative regimens use combinations of pyrimethamine with clindamycin p. 506 or clarithromycin p. 508 or azithromycin p. 507. Long-term secondary prophylaxis is required after treatment of toxoplasmosis in immunocompromised patients; prophylaxis should continue until immunity recovers.

If toxoplasmosis is acquired in pregnancy, transplacental infection may lead to severe disease in the fetus; specialist advice should be sought on management. Spiramycin [unlicensed] (available from ‘special-order’ manufacturers or specialist importing companies) may reduce the risk of transmission of maternal infection to the fetus.

### 5.1 Leishmaniasis

Other drugs used for Leishmaniasis

*Amphotericin, p. 561 - Pentamidine isetionate, p. 569*

**ANTIPROTOZOALS**

### Sodium stibogluconate

<table>
<thead>
<tr>
<th>INDICATIONS AND DOSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visceral leishmaniasis (specialist use only)</td>
</tr>
<tr>
<td>By intravenous injection, or by intramuscular injection</td>
</tr>
<tr>
<td>Adult: 20 mg/kg daily for 28 days</td>
</tr>
</tbody>
</table>

| Cutaneous leishmaniasis (specialist use only) |
| By intravenous injection, or by intramuscular injection |
| Adult: 20 mg/kg daily for 20 days |

| CAUTIONS |
| Heart disease (withdraw if conduction disturbances occur) • mucocutaneous disease • predisposition to QT interval prolongation • treat intercurrent infection (e.g. pneumonia) |

| CAUTIONS, FURTHER INFORMATION |
| Mucocutaneous disease Successful treatment of mucocutaneous leishmaniasis may induce severe inflammation around the lesions (may be life-threatening if pharyngeal or tracheal involvement) — may require corticosteroid. |

| INTERACTIONS |
| Appendix 1: sodium stibogluconate |

| SIDE-EFFECTS |
| Rare |
| Bleeding from gums • bleeding from nose • fever • flushing • jaundice • rash • substernal pain • sweating • vertigo |

| Frequency not known |
| Abdominal pain • anaphylaxis • anorexia • arthralgia • coughing • diarrhea • ECG changes • headache • lethargy • myalgia • nausea • pain on intramuscular injection • pain on intravenous administration • pancreatitis • thrombosis on intravenous administration • vomiting |

| PREGNANCY |
| Manufacturer advises use only if potential benefit outweighs risk. |

| BREAST FEEDING |
| Amount probably too small to be harmful. |

| HEPATIC IMPAIRMENT |
| Use with caution. |

| RENAL IMPAIRMENT |
| Avoid in significant impairment. |

| MONITORING REQUIREMENTS |
| Monitor ECG before and during treatment. |

| DIRECTIONS FOR ADMINISTRATION |
| Intravenous injections must be given slowly over 5 minutes (to reduce risk of local thrombosis) and stopped if coughing or substernal pain occur. Injection should be filtered immediately before administration using a filter of 5 microns or less. |
### 5.2 Malaria

#### Antimalarials

**Artemether with lumefantrine**
Artemether with lumefantrine p. 581 is licensed for the treatment of acute non-complicated falciparum malaria.

**Chloroquine**
Chloroquine p. 582 is used for the prophylaxis of malaria in areas of the world where the risk of chloroquine-resistant falciparum malaria is still low. It is also used with proguanil hydrochloride p. 585 when chloroquine-resistant falciparum malaria is present but this regimen may not give optimal protection (see recommended regimens for prophylaxis against malaria in Malaria, prophylaxis p. 574). Chloroquine is no longer recommended for the treatment of falciparum malaria owing to widespread resistance, nor is it recommended if the infective species is not known or if the infection is mixed; in these cases treatment should be with quinine p. 586, Malarone®, or Riamet®. It is still recommended for the treatment of non-falciparum malaria.

**Mefloquine**
Mefloquine p. 584 is used for the prophylaxis of malaria in areas of the world where there is a high risk of chloroquine-resistant falciparum malaria (for details, see recommended regimens for prophylaxis against malaria in Malaria, prophylaxis below). Mefloquine is now rarely used for the treatment of falciparum malaria because of increased resistance. It is rarely used for the treatment of non-falciparum malaria because better tolerated alternatives are available. Mefloquine should not be used for treatment if it has been used for prophylaxis.

**Piperaquine with artenimol**
Artenimol with piperaquine phosphate p. 581 is not recommended for the first-line treatment of acute uncomplicated falciparum malaria because there is limited experience of its use in travellers who usually reside in areas where malaria is not endemic. Piperaquine has a long half-life.

**Primaquine**
Primaquine p. 585 is used to eliminate the liver stages of P. vivax or P. ovale following chloroquine treatment.

**Proguanil**
Proguanil hydrochloride is used (usually with chloroquine, but occasionally alone) for the prophylaxis of malaria, (for details, see Recommended regimens for prophylaxis against malaria p. 575). Proguanil hydrochloride used alone is not suitable for the treatment of malaria; however, Malarone® (a combination of atovaquone with proguanil hydrochloride p. 582) is licensed for the treatment of acute uncomplicated falciparum malaria. Malarone® is also used for the prophylaxis of falciparum malaria in areas of widespread mefloquine or chloroquine resistance. Malarone® is also used as an alternative to mefloquine or doxycycline p. 534. Malarone® is particularly suitable for short trips to highly chloroquine-resistant areas because it needs to be taken only for 7 days after leaving an endemic area.

**Pyrimethamine**
Pyrimethamine p. 586 should not be used alone, but is used with sulfadoxine.

Pyrimethamine with sulfadoxine p. 586 is not recommended for the prophylaxis of malaria, but can be used in the treatment of falciparum malaria with (or following) quinine.

**Quinine**
Quinine is not suitable for the prophylaxis of malaria. Quinine is used for the treatment of falciparum malaria or if the infective species is not known or if the infection is mixed (for details see Malaria, treatment p. 580).

**Tetracyclines**
Doxycycline is used in adults and children over 12 years for the prophylaxis of malaria in areas of widespread mefloquine or chloroquine resistance. Doxycycline is also used as an alternative to mefloquine or Malarone® (for details, see Recommended regimens for prophylaxis against malaria p. 575).

#### Malaria, prophylaxis

**Prophylaxis**
The recommendations on prophylaxis reflect guidelines agreed by UK malaria specialists; the advice is aimed at residents of the UK who travel to endemic areas. The choice of drug for a particular individual should take into account:

- risk of exposure to malaria
- extent of drug resistance
- efficacy of the recommended drugs
- side-effects of the drugs
- patient-related factors (e.g. age, pregnancy, renal or hepatic impairment, compliance with prophylactic regimen)

**Protection against bites**
Prophylaxis is not absolute, and breakthrough infection can occur with any of the drugs recommended. Personal protection against being bitten is very important. Mosquito nets impregnated with permethrin p. 1135 provide the most effective barrier protection against insects; mats and vaporised insecticides are also useful. Diethyltoluamide (DEET) 20–50% in lotions, sprays, or roll-on formulations is safe and effective when applied to the skin of adults and children over 2 months of age. It can also be used during pregnancy and breast-feeding. The duration of protection varies according to the concentration of DEET and is longest for DEET 50%. When sunscreen is also required, DEET should be applied after the sunscreen. DEET reduces the SPF of sunscreen, so a sunscreen of SPF 30–50 should be applied. Long sleeves and trousers worn after dusk also provide protection against bites.

**Length of prophylaxis**
In order to determine tolerance and to establish habit, prophylaxis should generally be started one week (2–3 weeks in the case of mefloquine p. 584) before travel into an endemic area; Malarone® or doxycycline p. 534 prophylaxis should be started 1–2 days before travel. Prophylaxis should be continued for 4 weeks after leaving (except for Malarone® prophylaxis which should be stopped 1 week after leaving). For extensive journeys across different regions, the traveller must be protected in all areas of risk.

In those requiring long-term prophylaxis, chloroquine p. 582 and proguanil hydrochloride p. 585 may be used for periods of over 5 years. Mefloquine is licensed for up to...
<table>
<thead>
<tr>
<th>Country</th>
<th>Comments on risk of malaria and regional or seasonal variation</th>
<th>Codes for regimens</th>
</tr>
</thead>
<tbody>
<tr>
<td>Afghanistan</td>
<td>Risk below 2000 m from May–November</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Low risk below 2000 m from December–April</td>
<td>1</td>
</tr>
<tr>
<td>Algeria</td>
<td>Very low risk in Illizi department only</td>
<td>1</td>
</tr>
<tr>
<td>Andaman and Nicobar Islands (India)</td>
<td>Risk present</td>
<td>1</td>
</tr>
<tr>
<td>Angola</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Argentina</td>
<td>Low risk in low altitude areas of Salta provinces bordering Bolivia and in Chaco, Corrientes, and Misiones provinces close to border with Paraguay and Brazil</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>No risk in Iguazu Falls and areas other than those above</td>
<td>1</td>
</tr>
<tr>
<td>Armenia</td>
<td>No risk</td>
<td>1</td>
</tr>
<tr>
<td>Azerbaijan</td>
<td>Low to no risk</td>
<td>1</td>
</tr>
<tr>
<td>Bangladesh</td>
<td>High risk in Chittagong Hill Tract districts (but not Chittagong city)</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Low to no risk in Chittagong city and other areas, except Chittagong Hill Tract districts</td>
<td>1</td>
</tr>
<tr>
<td>Belize</td>
<td>Low risk in rural areas</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>No risk in Belize district (including Belize city and islands)</td>
<td>1</td>
</tr>
<tr>
<td>Benin</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Bhutan</td>
<td>Risk in southern belt districts, along border with India: Chukha, Geyleg-phug, Samchi, Samdrup Jonkhar, and Shemgang</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Low to no risk in areas other than those above</td>
<td>1</td>
</tr>
<tr>
<td>Bolivia</td>
<td>High risk in Amazon basin</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Risk in rural areas below 2500 m (other than above)</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>No risk above 2500 m</td>
<td>1</td>
</tr>
<tr>
<td>Botswana</td>
<td>High risk from November–June in northern half, including Okavango Delta area</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Low risk from July–October in northern half; low to no risk all year in southern half</td>
<td>1</td>
</tr>
<tr>
<td>Brazil</td>
<td>Risk in Amazon basin, including city of Manaus</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Very low risk in areas other than those above, and no risk in Iguazu Falls</td>
<td>1</td>
</tr>
<tr>
<td>Brunei Darussalam</td>
<td>Very low risk</td>
<td>1</td>
</tr>
<tr>
<td>Burkina Faso</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Burundi</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Cambodia</td>
<td>High risk, with widespread chloroquine and mefloquine resistance, in western provinces bordering Thailand</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>High risk in areas other than those above and below</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Very low risk in Angkor Wat and Lake Tonle Sap, including Siem Reap; no risk in Phnom Penh</td>
<td>1</td>
</tr>
<tr>
<td>Cameroon</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Cape Verde</td>
<td>Very low risk on island of Santiago (Sao Tiago) and Boa Vista</td>
<td>1</td>
</tr>
<tr>
<td>Central African Republic</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Chad</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>China</td>
<td>High risk in Yunnan and Hainan provinces</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Very low risk in areas other than those above and below</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>No risk in Hong Kong</td>
<td>-</td>
</tr>
<tr>
<td>Colombia</td>
<td>High risk in rural areas below 1600 m</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Low to no risk above 1600 m and in Cartagena</td>
<td>1</td>
</tr>
<tr>
<td>Country</td>
<td>Comments on risk of malaria and regional or seasonal variation</td>
<td>Codes for regimens</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Comoros</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Congo</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Costa Rica</td>
<td>Risk in Limon province (but not city of Limon)</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Very low risk in areas other than those above</td>
<td>1</td>
</tr>
<tr>
<td>Cote d’Ivoire (Ivory Coast)</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Democratic Republic of the Congo</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Djibouti</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Dominican Republic</td>
<td>Risk in all areas except cities of Santiago and Santo Domingo</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Cities of Santiago and Santo Domingo</td>
<td>1</td>
</tr>
<tr>
<td>East Timor (Timor-Leste)</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Ecuador</td>
<td>Risk in areas below 1500 m including coastal provinces and Amazon basin (no risk in Galapagos islands or city of Guayaquil)</td>
<td>4</td>
</tr>
<tr>
<td>Egypt</td>
<td>No risk</td>
<td>1</td>
</tr>
<tr>
<td>El Salvador</td>
<td>Low risk in rural areas of Santa Ana, Ahuachapán, and La Unión provinces in western part of country; low to no risk in other areas</td>
<td>1</td>
</tr>
<tr>
<td>Equatorial Guinea</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Eritrea</td>
<td>High risk below 2200 m</td>
<td>4</td>
</tr>
<tr>
<td>Ethiopia</td>
<td>High risk below 2000 m</td>
<td>4</td>
</tr>
<tr>
<td>French Guiana</td>
<td>High risk (particularly in border areas) except city of Cayenne or Devil’s Island (Ile du Diable)</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>No risk in city of Cayenne or Devil’s Island (Ile du Diable)</td>
<td>1</td>
</tr>
<tr>
<td>Gabon</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Gambia</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Georgia</td>
<td>Very low risk in rural south east from June–October</td>
<td>1</td>
</tr>
<tr>
<td>Ghana</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Guatemala</td>
<td>Low risk below 1500 m</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>No risk in Guatemala City, Antigua, or Lake Atitlan</td>
<td>-</td>
</tr>
<tr>
<td>Guinea</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Guinea-Bissau</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Guyana</td>
<td>High risk in all interior regions</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Very low risk in Georgetown and coastal region</td>
<td>1</td>
</tr>
<tr>
<td>Haiti</td>
<td>Risk present</td>
<td>2</td>
</tr>
<tr>
<td>Honduras</td>
<td>Risk below 1000 m and in Roatán and other Bay Islands (no risk in San Pedro Sula or Tegucigalpa)</td>
<td>2</td>
</tr>
<tr>
<td>India</td>
<td>High risk in states of Assam and Orissa, districts of East Godavari, Srikakulam, Vishakhapatnam, and Vizianagaram in the state of Andhra Pradesh, and districts of Balaghat, Dindori, Manlia, and Seoni in the state of Madhya Pradesh</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Risk in areas other than those above or below (including Goa, Andaman and Nicobar islands)</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>No risk in Lakshadweep islands</td>
<td>-</td>
</tr>
<tr>
<td>Indonesia</td>
<td>High risk in Lombok and Irian Jaya (Papua)</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Risk in areas other than those above or below</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Very low risk in Bali, and cities on islands of Java and Sumatra</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>No risk in city of Jakarta</td>
<td>-</td>
</tr>
<tr>
<td>Indonesia (Borneo)</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Iran</td>
<td>Risk from March–November in rural south eastern provinces and in north, along Azerbaijan border in Ardabil, and near Turkmenistan border in North Khorasan</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Low to no risk in areas other than those above</td>
<td>1</td>
</tr>
<tr>
<td>Iraq</td>
<td>Very low risk from May–November in rural northern area below 1500 m</td>
<td>1</td>
</tr>
<tr>
<td>Kenya</td>
<td>High risk below 2500 m (except city of Nairobi)</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Very low risk in the highlands above 2500 m and in city of Nairobi</td>
<td>1</td>
</tr>
<tr>
<td>Kyrgyzstan</td>
<td>Very low risk from June–October in southwest areas bordering Tajikistan and Uzbekistan</td>
<td>1</td>
</tr>
</tbody>
</table>
### Key to recommended regimens for prophylaxis against malaria

<table>
<thead>
<tr>
<th>Codes for regimens</th>
<th>Details of regimens for prophylaxis against malaria</th>
</tr>
</thead>
<tbody>
<tr>
<td>-</td>
<td>No risk</td>
</tr>
<tr>
<td>1</td>
<td>Chemoprophylaxis not recommended, but avoid mosquito bites and consider malaria if fever presents</td>
</tr>
<tr>
<td>2</td>
<td>Chloroquine only</td>
</tr>
<tr>
<td>3</td>
<td>Chloroquine with proguanil</td>
</tr>
<tr>
<td>4</td>
<td>Atovaquone with proguanil hydrochloride or doxycycline or mefloquine</td>
</tr>
<tr>
<td>5</td>
<td>Atovaquone with proguanil hydrochloride or doxycycline</td>
</tr>
</tbody>
</table>

### Specific recommendations

<table>
<thead>
<tr>
<th>Country</th>
<th>Comments on risk of malaria and regional or seasonal variation</th>
<th>Codes for regimens</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laos</td>
<td>High risk along the border with Myanmar in the provinces of Bokeo and Louang Namtha, and along the border with Thailand in the province of Champasak and Saravan High risk in areas other than those above or below Low to no risk in city of Vientiane</td>
<td>5</td>
</tr>
<tr>
<td>Liberia</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Libya</td>
<td>No risk</td>
<td>1</td>
</tr>
<tr>
<td>Madagascar</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Malawi</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Malaysia</td>
<td>Risk in inland forested areas of peninsular Malaysia Very low risk in rest of peninsular Malaysia, including Cameron Highlands and city of Kuala Lumpur</td>
<td>4</td>
</tr>
<tr>
<td>Malaysia (Borneo)</td>
<td>High risk in inland areas of eastern Sabah and in inland, forested areas of Sarawak Very low risk in areas other than those above, including coastal areas of Sabah and Sarawak</td>
<td>4</td>
</tr>
<tr>
<td>Mali</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Mauritania</td>
<td>High risk all year in southern provinces, and from July–October in the northern provinces Low risk from November–June in the northern provinces</td>
<td>4</td>
</tr>
<tr>
<td>Mauritius</td>
<td>No risk</td>
<td>1</td>
</tr>
<tr>
<td>Mayotte</td>
<td>Risk present</td>
<td>4</td>
</tr>
<tr>
<td>Mexico</td>
<td>Low risk in Oaxaca and Chiapas Very low risk in areas other than those above</td>
<td>1</td>
</tr>
<tr>
<td>Mozambique</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Myanmar</td>
<td>High risk (but not in cities of Mandalay and Yangon) No risk in cities of Mandalay and Yangon</td>
<td>5</td>
</tr>
<tr>
<td>Namibia</td>
<td>High risk all year in regions of Caprivi Strip, Kavango, and Kunene river, and from November–June in northern third of country Low to no risk in areas other than those above; low risk from July–October in northern third of country</td>
<td>4</td>
</tr>
<tr>
<td>Nepal</td>
<td>Risk below 1500 m, particularly in Terai district No risk in city of Kathmandu and on typical Himalayan treks</td>
<td>3</td>
</tr>
<tr>
<td>Nicaragua</td>
<td>Low risk (except Managua) Very low risk in Managua</td>
<td>2</td>
</tr>
<tr>
<td>Niger</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Nigeria</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>North Korea</td>
<td>Very low risk in some southern areas</td>
<td>1</td>
</tr>
<tr>
<td>Pakistan</td>
<td>Risk below 2000 m Low to no risk above 2000 m</td>
<td>3</td>
</tr>
<tr>
<td>Panama</td>
<td>Risk east of Canal Zone Low risk west of Canal Zone No risk in Panama City or Canal Zone itself</td>
<td>3</td>
</tr>
<tr>
<td>Papua New Guinea</td>
<td>High risk below 1800 m Low to no risk above 1800 m</td>
<td>4</td>
</tr>
<tr>
<td>Country</td>
<td>Comments on risk of malaria and regional or seasonal variation</td>
<td>Codes for regimens</td>
</tr>
<tr>
<td>-------------------------</td>
<td>---------------------------------------------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>Paraguay</td>
<td>Low risk in departments of Alto Paraná and Caaguazú</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Very low risk in areas other than those above</td>
<td>1</td>
</tr>
<tr>
<td>Peru</td>
<td>High risk in Amazon basin along border with Brazil, particularly in Loreto province</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Risk in rural areas below 2000 m (other than those above and below) including in Amazon basin along border with Bolivia</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>No risk in city of Lima and coastal region south of Chiclayo</td>
<td>1</td>
</tr>
<tr>
<td>Philippines</td>
<td>Risk in rural areas below 600 m and on islands of Luzon, Mindanao, Mindoro, and Palawan</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>No risk in cities or on islands of Boracay, Bohol, Catanduanes, Cebu, or Leyte</td>
<td>1</td>
</tr>
<tr>
<td>Rwanda</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>São Tomé and Principe</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Saudi Arabia</td>
<td>Risk in south-western provinces along border with Yemen, including below 2000 m in Asir province</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>No risk in cities of Jeddah, Makkah (Mecca), Medina, Riyadh, or Ta’i, or above 2000 m in Asir province</td>
<td>1</td>
</tr>
<tr>
<td>Senegal</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Sierra Leone</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Solomon Islands</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Somalia</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>South Africa</td>
<td>Moderate risk from September–May in low altitude areas of Mpumalanga and Limpopo, which border Mozambique and Zimbabwe (including Kruger National Park)</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Low risk in north-east KwaZulu-Natal</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Low risk in areas bordering those above</td>
<td>1</td>
</tr>
<tr>
<td>South Korea</td>
<td>Very low risk in northern areas, in Gangwon-do and Gyeonggi-do provinces, and Incheon city (towards Demilitarized Zone)</td>
<td>1</td>
</tr>
<tr>
<td>South Sudan</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Sri Lanka</td>
<td>Low risk north of Vavuniya</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Very low risk in areas other than those above and below</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>No risk in Colombo or Kandy</td>
<td>-</td>
</tr>
<tr>
<td>Sudan</td>
<td>High risk in central and southern areas; risk also present in rest of country (except Khartoum)</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Very low risk in Khartoum</td>
<td>1</td>
</tr>
<tr>
<td>Suriname</td>
<td>High risk (except coastal districts or city of Paramaribo)</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Very low risk in coastal districts; no risk in city of Paramaribo</td>
<td>1</td>
</tr>
<tr>
<td>Swaziland</td>
<td>High risk in northern and eastern regions bordering Mozambique and South Africa, including all of Lubombo district and Big Bend, Mhlume, Simunye, and Tshaneni regions</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Very low risk in the areas other than those above</td>
<td>1</td>
</tr>
<tr>
<td>Syria</td>
<td>Very low risk in small, remote foci of El Hasakah</td>
<td>1</td>
</tr>
<tr>
<td>Tajikistan</td>
<td>Risk below 2000 m from June–October</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Low risk below 2000 m from November–May</td>
<td>1</td>
</tr>
<tr>
<td>Tanzania</td>
<td>High risk below 1800 m; risk also in Zanzibar</td>
<td>4</td>
</tr>
<tr>
<td>Thailand</td>
<td>High risk, with chloroquine and mefloquine resistance, in rural forested borders with Cambodia, Laos, and Myanmar</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Very low risk in areas other than those above, including Kanchanaburi (Kwai Bridge); no risk in cities of Bangkok, Chiang Mai, Chiang Rai, Koh Phangan, Koh Samui, and Pattaya</td>
<td>1</td>
</tr>
<tr>
<td>Togo</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Turkey</td>
<td>Low risk from May–October along the border plain with Syria, around Adana and east of Adana</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Very low risk from November–April along the border plain with Syria, around Adana and east of Adana; very low risk all year in rest of country</td>
<td>1</td>
</tr>
<tr>
<td>Uganda</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Uzbekistan</td>
<td>Very low risk in extreme south-east</td>
<td>1</td>
</tr>
<tr>
<td>Vanuatu</td>
<td>Risk present</td>
<td>4</td>
</tr>
</tbody>
</table>
Key to recommended regimens for prophylaxis against malaria

<table>
<thead>
<tr>
<th>Codes for regimens</th>
<th>Details of regimens for prophylaxis against malaria</th>
</tr>
</thead>
<tbody>
<tr>
<td>-</td>
<td>No risk</td>
</tr>
<tr>
<td>1</td>
<td>Chemoprophylaxis not recommended, but avoid mosquito bites and consider malaria if fever presents</td>
</tr>
<tr>
<td>2</td>
<td>Chloroquine only</td>
</tr>
<tr>
<td>3</td>
<td>Chloroquine with proguanil</td>
</tr>
<tr>
<td>4</td>
<td>Atovaquone with proguanil hydrochloride or doxycycline or mefloquine</td>
</tr>
<tr>
<td>5</td>
<td>Atovaquone with proguanil hydrochloride or doxycycline</td>
</tr>
</tbody>
</table>

Specific recommendations

<table>
<thead>
<tr>
<th>Country</th>
<th>Comments on risk of malaria and regional or seasonal variation</th>
<th>Codes for regimens</th>
</tr>
</thead>
<tbody>
<tr>
<td>Venezuela</td>
<td>High risk in all areas south of, and including, the Orinoco river and Angel Falls; Risk in rural areas of Apure, Monagas, Sucre, and Zulia states; No risk in city of Caracas or on Margarita Island</td>
<td>4</td>
</tr>
<tr>
<td>Western Sahara</td>
<td>No risk</td>
<td>1</td>
</tr>
<tr>
<td>Yemen</td>
<td>Risk below 2000 m; Very low risk on Socrota Island; no risk above 2000 m, including Sana’a city</td>
<td>3, 1</td>
</tr>
<tr>
<td>Zambia</td>
<td>High risk</td>
<td>4</td>
</tr>
<tr>
<td>Zimbabwe</td>
<td>High risk all year in Zambezi valley, and from November–June in areas below 1200 m; Low risk from July–October in areas below 1200 m; very low risk all year in Harare and Bulawayo</td>
<td>4, 1</td>
</tr>
</tbody>
</table>

Return from malarial region

It is important to be aware that any illness that occurs within 1 year and especially within 3 months of return might be malaria even if all recommended precautions against malaria were taken. Travellers should be warned of this and told that if they develop any illness particularly within 3 months of their return they should go immediately to a doctor and specifically mention their exposure to malaria.

Epilepsy

Both chloroquine and mefloquine are unsuitable for malaria prophylaxis in individuals with a history of epilepsy. In areas without chloroquine resistance proguanil alone is recommended; in areas with chloroquine resistance, doxycycline or Malarone® may be considered.

Asplenia

Asplenic individuals (or those with severe splenic dysfunction) are at particular risk of severe malaria. If travel to malarious areas is unavoidable, rigorous precautions are required against contracting the disease.

Renal impairment

Avoidance (or dosage reduction) of proguanil hydrochloride is recommended since it is excreted by the kidneys. Malarone® should not be used for prophylaxis in patients with estimated glomerular filtration rate less than 30 mL/minute/1.73m². Chloroquine is only partially excreted by the kidneys and reduction of the dose for prophylaxis is not required except in severe impairment. Mefloquine is considered to be appropriate to use in renal impairment and does not require dosage reduction. Doxycycline is also considered to be appropriate.

Pregnancy

Travel to malarious areas should be avoided during pregnancy; if travel is unavoidable, effective prophylaxis must be used. Chloroquine and proguanil hydrochloride can be given in the usual doses during pregnancy, but these drugs are not appropriate for most areas because their effectiveness has declined, particularly in Sub-Saharan Africa; in the case of proguanil hydrochloride, folic acid (dosed as a pregnancy at ‘high-risk’ of neural tube defects) should be given for at least the first trimester. The centres listed (see Malaria, treatment p. 580) should be consulted for advice on prophylaxis in chloroquine-resistant areas. Although the manufacturer advises that mefloquine should not be used during pregnancy, particularly in the first trimester, unless the potential benefit outweighs the risk, studies of mefloquine in pregnancy (including use in the first trimester) indicate that it can be considered for travel to chloroquine-resistant areas. Doxycycline is contra-indicated during pregnancy; however, it can be used for malaria prophylaxis if other regimens are unsuitable, and if the entire course of doxycycline can be completed before 15 weeks’ gestation [unlicensed]. Malarone® should be avoided during pregnancy, however, it can be considered during the second and third trimesters if there is no suitable alternative.

Breast-feeding

Prophylaxis is required in breast-fed infants; although antimalarials are present in milk, the amounts are too variable to give reliable protection.
Anticoagulants
Travellers taking warfarin sodium p. 135 should begin chemoprophylaxis 2–3 weeks before departure. The INR should be stable before departure. It should be measured before starting chemoprophylaxis, 7 days after starting, and after completing the course. For prolonged stays, the INR should be checked at regular intervals.

Standby treatment
Travellers visiting remote, malarious areas for prolonged periods should carry standby treatment if they are likely to be more than 24 hours away from medical care. Self-medication should be avoided if medical help is accessible.

In order to avoid excessive self-medication, the traveller should be provided with written instructions that urgent medical attention should be sought if fever (38°C or more) develops 7 days (or more) after arriving in a malarious area and that self-treatment is indicated if medical help is not available within 24 hours of fever onset.

In view of the continuing emergence of resistant strains and of the different regimens required for different areas expert advice should be sought on the best treatment course available for an individual traveller. A drug used for chemoprophylaxis should not be considered for standby treatment for the same traveller.

Specific recommendations
Where a journey requires two regimens, the regimen for the higher risk area should be used for the whole journey. Those travelling to remote or little-visited areas may require expert advice. See Recommended regimens for prophylaxis against malaria.

Important
Settled immigrants (or long-term visitors) to the UK may be unaware that any immunity they may have acquired while living in malarious areas is lost rapidly after migration to the UK, or that any non-malarious areas where they lived previously may now be malarious.

Malaria, treatment
Advice for healthcare professionals
A number of specialist centres are able to provide advice on specific problems.

PHE (Public Health England) Malaria Reference Laboratory (020) 7637 0248 (fax) (prophylaxis only) www.malaria-reference.co.uk

National Travel Health Network and Centre 0845 602 6712

Travel Medicine Team, Health Protection Scotland (registered users of Travax only) www.travax.nhs.uk (for registered users of the NHS Travax website only) (0141) 300 1100 (weekdays 2–4 p.m. only)

Birmingham (0121) 424 2358

Liverpool (0151) 705 3100

London 0845 155 5000 (treatment)

Oxford (01865) 225 430

Advice for travellers
Hospital for Tropical Diseases Travel Healthline (020) 7950 7799 www.fitfortravel.nhs.uk

WHO advice on international travel and health www.who.int/ith

National Travel Health Network and Centre (NaTHNaC) nathnac.net

Treatment of malaria
Recommendations on the treatment of malaria reflect guidelines agreed by UK malaria specialists.

If the infective species is not known, or if the infection is mixed, initial treatment should be as for falciparum malaria with quinine p. 586, Malarone® (atovaquone with proguaulin hydrochloride p. 582), or Riamet® (artemether with lumefantrine p. 581). Falciparum malaria can progress rapidly in unprotected individuals and antimalarial treatment should be considered in those with features of severe malaria and possible exposure, even if the initial blood tests for the organism are negative.

Falciparum malaria (treatment)
Falciparum malaria (malignant malaria) is caused by Plasmodium falciparum. In most parts of the world P. falciparum is now resistant to chloroquine p. 582 which should not therefore be given for treatment.

Quinine, Malarone® (atovaquone with proguaulin hydrochloride), or Riamet® (artemether with lumefantrine) can be given by mouth if the patient can swallow and retain tablets and there are no serious manifestations (e.g. impaired consciousness); quinine should be given by intravenous infusion if the patient is seriously ill or unable to take tablets. Mefloquine p. 584 is now rarely used for treatment because of concerns about resistance.

Oral quinine is given by mouth for 5–7 days, together with or followed by either doxycycline p. 534 for 7 days or clindamycin p. 506 for 7 days [unlicensed].

If the parasite is likely to be sensitive, pyrimethamine with sulfadoxine p. 586 as a single dose [unlicensed] may be given (instead of either clindamycin or doxycycline) together with, or after, a course of quinine.

Alternatively, Malarone®, or Riamet® may be given instead of quinine. It is not necessary to give clindamycin, doxycycline, or pyrimethamine with sulfadoxine after Malarone® or Riamet® treatment.

If the patient is seriously ill or unable to take tablets, or if more than 2% of red blood cell are parasitized, quinine should be given by intravenous infusion [unlicensed] (until patient can swallow tablets to complete the 7-day course together with or followed by either doxycycline or clindamycin).

Specialist advice should be sought in difficult cases (e.g. very high parasite count, deterioration on optimal doses of quinine, infection acquired in quinine-resistant areas of south east Asia) because intravenous artesunate may be available for ’named-patient’ use.

Pregnancy
Falciparum malaria is particularly dangerous in pregnancy, especially in the last trimester. The adult treatment doses or oral and intravenous quinine (including the loading dose) can safely be given to pregnant women. Chloramycin should be given after quinine [unlicensed indication]. Doxycycline should be avoided in pregnancy (affects teeth and skeletal development); pyrimethamine with sulfadoxine, Malarone®, and Riamet® are also best avoided until more information is available. Specialist advice should be sought in difficult cases (e.g. very high parasite count, deterioration on optimal doses of quinine, infection acquired in quinine-resistant areas of south east Asia) because intravenous artesunate may be available for ’named patient’ use.

Non-falciparum malaria (treatment)
Non-falciparum malaria is usually caused by Plasmodium vivax and less commonly by P. ovale and P. malariae. P. knowlesi is also present in the Asia-Pacific region.

Chloroquine is the drug of choice for the treatment of non-falciparum malaria (but chloroquine-resistant P. vivax has been reported in the Indonesian archipelago, the Malay Peninsula, including Myanmar, and eastward to Southern Vietnam).

For the treatment of chloroquine-resistant non-falciparum malaria, Malarone®[unlicensed indication], quinine, or Riamet®[unlicensed indication] can be used; as with
chloroquine, primaquine p. 585 should be given for radical cure.

Chloroquine alone is adequate for *P. malarias* and *P. knowlesi* infections but in the case of *P. vivax* and *P. ovale*, a radical cure (to destroy parasites in the liver and thus prevent relapses) is required. This is achieved with primaquine [unlicensed] given after chloroquine, with the dose dependent on the infecting organism. For a radical cure, primaquine [unlicensed] is then given for 14 days, with the dose also dependent on the infecting organism.

**Parenteral**

Parenteral If the patient is unable to take oral therapy, quinine can be given by intravenous infusion [unlicensed], changed to oral chloroquine as soon as the patient’s condition permits.

**Pregnancy**
The adult treatment doses of chloroquine can be given for non-falciparum malaria. In the case of *P. vivax* or *P. ovale*, however, the radical cure with primaquine should be postponed until the pregnancy is over; instead chloroquine should be continued, given weekly during the pregnancy.

### ARTENIMOL WITH PIPERAQUINE PHOSPHATE

**(Piperaquine tetraphosphate with dihydroartemisinin)**

<table>
<thead>
<tr>
<th>INDICATIONS AND DOSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of uncomplicated falciparum malaria</td>
</tr>
<tr>
<td><strong>BY MOUTH</strong></td>
</tr>
<tr>
<td>Child 6 months-17 years (body-weight 7-12 kg): 0.5 tablet once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after first course</td>
</tr>
<tr>
<td>Child 6 months-17 years (body-weight 13-23 kg): 1 tablet once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after first course</td>
</tr>
<tr>
<td>Child 6 months-17 years (body-weight 24-35 kg): 2 tablets once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after first course</td>
</tr>
<tr>
<td>Child 6 months-17 years (body-weight 36-74 kg): 3 tablets once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after first course</td>
</tr>
<tr>
<td>Child 6 months-17 years (body-weight 75-99 kg): 4 tablets once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after first course</td>
</tr>
<tr>
<td>Adult (body-weight 75-99 kg): 4 tablets once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after first course</td>
</tr>
<tr>
<td>Adult (body-weight ≥100 kg): 5 tablets once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after first course</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CONTRA-INDICATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute myocardial infarction</td>
</tr>
<tr>
<td>Bradycardia</td>
</tr>
<tr>
<td>Congenital QT syndrome</td>
</tr>
<tr>
<td>Electrolyte disturbances</td>
</tr>
<tr>
<td>Family history of symptomatic arrhythmias</td>
</tr>
<tr>
<td>Left ventricular hypertrophy</td>
</tr>
<tr>
<td>Risk factors for QT interval prolongation</td>
</tr>
<tr>
<td>Severe hypertension</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INTERACTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breastfeeding</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SIDE-EFFECTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdominal pain</td>
</tr>
<tr>
<td>Anorexia</td>
</tr>
<tr>
<td>Arthralgia</td>
</tr>
<tr>
<td>Asthenia</td>
</tr>
<tr>
<td>Cough</td>
</tr>
<tr>
<td>Diarrhoea</td>
</tr>
<tr>
<td>Dizziness</td>
</tr>
<tr>
<td>Headache</td>
</tr>
<tr>
<td>Myalgia</td>
</tr>
<tr>
<td>Nausea</td>
</tr>
<tr>
<td>Palpitation</td>
</tr>
<tr>
<td>Paraesthesia</td>
</tr>
<tr>
<td>Rash</td>
</tr>
<tr>
<td>Tachycardia</td>
</tr>
<tr>
<td>Vomiting</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PREGNANCY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toxicity in animal studies with artemether. Manufacturer advises use only if potential benefit outweighs risk.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PARENTERAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>If the patient is unable to take oral therapy, quinine can be given by intravenous infusion [unlicensed], changed to oral chloroquine as soon as the patient’s condition permits.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PREPARATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tablet</td>
</tr>
</tbody>
</table>

**Medicinal Forms**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

**CAUTIONARY AND ADVISORY LABELS**

**Artenimol with piperaquine phosphate**

**(Piperaquine tetraphosphate with dihydroartemisinin)**

<table>
<thead>
<tr>
<th>INDICATIONS AND DOSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of uncomplicated falciparum malaria</td>
</tr>
<tr>
<td><strong>BY MOUTH</strong></td>
</tr>
<tr>
<td>Adult (body-weight 35 kg and above): Initially 4 tablets, followed by 4 tablets for 5 doses each given at 8, 24, 36, 48 and 60 hours (total 24 tablets over 60 hours)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>UNLICENSED USE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use in treatment of non-falciparum malaria is an unlicensed indication.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CONTRA-INDICATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Family history of congenital QT interval prolongation</td>
</tr>
<tr>
<td>Family history of sudden death</td>
</tr>
<tr>
<td>Family history of arrhythmias</td>
</tr>
<tr>
<td>History of clinically relevant bradycardia</td>
</tr>
<tr>
<td>History of congestive heart failure accompanied by reduced left ventricular ejection fraction</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CAUTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avoid in acute porphyrias p. 969</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INTERACTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exceptional</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SIDE-EFFECTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abnormal paraesthesia</td>
</tr>
<tr>
<td>Abnormal sweating</td>
</tr>
<tr>
<td>Anorexia</td>
</tr>
<tr>
<td>Anosmia</td>
</tr>
<tr>
<td>Arthralgia</td>
</tr>
<tr>
<td>Asthenia</td>
</tr>
<tr>
<td>Cough</td>
</tr>
<tr>
<td>Daunorubicin</td>
</tr>
<tr>
<td>Diarrhoea</td>
</tr>
<tr>
<td>Dizziness</td>
</tr>
<tr>
<td>Headache</td>
</tr>
<tr>
<td>Malarial fever</td>
</tr>
<tr>
<td>Malaria</td>
</tr>
<tr>
<td>Malaria fever</td>
</tr>
<tr>
<td>Malaise</td>
</tr>
<tr>
<td>Myalgia</td>
</tr>
<tr>
<td>Nausea</td>
</tr>
<tr>
<td>Palpitation</td>
</tr>
<tr>
<td>Paraesthesia</td>
</tr>
<tr>
<td>Rash</td>
</tr>
<tr>
<td>Tachycardia</td>
</tr>
<tr>
<td>Vomiting</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PREGNANCY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toxicity in animal studies with artemether. Manufacturer advises use only if potential benefit outweighs risk.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PARENTERAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parenteral If the patient is unable to take oral therapy, quinine can be given by intravenous infusion [unlicensed], changed to oral chloroquine as soon as the patient’s condition permits.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PREPARATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tablet</td>
</tr>
</tbody>
</table>

**Patient and Carer Advice**

**Driving and skilled tasks**

Dizziness may affect performance of skilled tasks (e.g. driving).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

**CAUTIONARY AND ADVISORY LABELS**

**Artenimol with piperaquine phosphate**

**(Piperaquine tetraphosphate with dihydroartemisinin)**

<table>
<thead>
<tr>
<th>INDICATIONS AND DOSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment of uncomplicated falciparum malaria</td>
</tr>
<tr>
<td><strong>BY MOUTH</strong></td>
</tr>
<tr>
<td>Child 6 months-17 years (body-weight 7-12 kg): 0.5 tablet once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after first course</td>
</tr>
<tr>
<td>Child 6 months-17 years (body-weight 13-23 kg): 1 tablet once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after first course</td>
</tr>
<tr>
<td>Child 6 months-17 years (body-weight 24-35 kg): 2 tablets once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after first course</td>
</tr>
<tr>
<td>Child 6 months-17 years (body-weight 36-74 kg): 3 tablets once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after first course</td>
</tr>
<tr>
<td>Child 6 months-17 years (body-weight 75-99 kg): 4 tablets once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after first course</td>
</tr>
<tr>
<td>Adult (body-weight ≥100 kg): 5 tablets once daily for 3 days, max. 2 courses in 12 months; second course given at least 2 months after first course</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CONTRA-INDICATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute myocardial infarction</td>
</tr>
<tr>
<td>Bradycardia</td>
</tr>
<tr>
<td>Congenital QT syndrome</td>
</tr>
<tr>
<td>Electrolyte disturbances</td>
</tr>
<tr>
<td>Family history of symptomatic arrhythmias</td>
</tr>
<tr>
<td>Left ventricular hypertrophy</td>
</tr>
<tr>
<td>Risk factors for QT interval prolongation</td>
</tr>
<tr>
<td>Severe hypertension</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INTERACTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breastfeeding</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SIDE-EFFECTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdominal pain</td>
</tr>
<tr>
<td>Anemia</td>
</tr>
<tr>
<td>Blood disorders (in children)</td>
</tr>
<tr>
<td>Conjunctivitis (in children)</td>
</tr>
<tr>
<td>Cough (in children)</td>
</tr>
<tr>
<td>Diarrhoea (in children)</td>
</tr>
<tr>
<td>Headache (in adults)</td>
</tr>
<tr>
<td>Irregular heart rate (in children)</td>
</tr>
<tr>
<td>Leucopenia (in children)</td>
</tr>
<tr>
<td>Malaise (in children)</td>
</tr>
<tr>
<td>QT interval prolonged (in children)</td>
</tr>
<tr>
<td>Rash (in children)</td>
</tr>
<tr>
<td>Tachycardia (in adults)</td>
</tr>
<tr>
<td>Thrombocytopenia (in children)</td>
</tr>
<tr>
<td>Vomiting (in children)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PREGNANCY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Teratogenic in animal studies—manufacturer advises use only if other antimalarials cannot be used.</td>
</tr>
</tbody>
</table>
Infection

**HEPATIC IMPAIRMENT** No information available in moderate to severe impairment. Manufacturer advises monitor ECG and plasma-potassium concentration in moderate to severe hepatic impairment.

**RENAL IMPAIRMENT** No information available in moderate to severe impairment. Manufacturer advises monitor ECG and plasma-potassium concentration in moderate to severe renal impairment.

**MONITORING REQUIREMENTS**
- Consider obtaining ECG in all patients before third dose and 4–6 hours after third dose. If QTc interval more than 500 milliseconds, discontinue treatment and monitor ECG for a further 24–48 hours.
- In adults Obtain ECG as soon as possible after starting treatment then continue monitoring in those taking medicines that increase plasma-piperazine concentration, in females, or in the elderly.
- In children Obtain ECG as soon as possible after starting treatment then continue monitoring in those taking medicines that increase plasma-piperazine concentration, in children who are vomiting or in females.

**DIRECTIONS FOR ADMINISTRATION** Tablets to be taken at least 3 hours before and at least 3 hours after food. Tablets may be crushed and mixed with water immediately before administration.

**PATIENT AND CARER ADVICE** Patients or carers should be given advice on how to administer tablets containing piperaquine phosphate with arteminol.

**MEDICINAL FORMS**

**Tablet**
- Eurartesim (Logixx Pharma Solutions Ltd)
  - Artenimol 40 mg, Piperaquine phosphate 320 mg
  - Eurartesim 320mg/40mg tablets | 12 tablet [PPh] £40.00

**Atovaquone with proguanil hydrochloride**

**INDICATIONS AND DOSE**

**MALARONE**

Prophylaxis of falciparum malaria, particularly where resistance to other antimalarial drugs suspected
- **BY MOUTH**
  - Adult (body-weight 41 kg and above): 1 tablet daily, to be started 1–2 days before entering endemic area and continued for 1 week after leaving

Treatment of acute uncomplicated falciparum malaria
- **BY MOUTH**
  - Adult: 4 tablets once daily for 3 days

**UNLICENSED USE** Not licensed for treatment of non-falciparum malaria.

**CAUTIONS** Diarrhoea or vomiting (reduced absorption of atovaquone) - efficacy not evaluated in cerebral or complicated malaria (including hyperparasitaemia, pulmonary oedema or renal failure)

**INTERACTIONS** → Appendix 1: antimalarials

**SIDE-EFFECTS**
- **Common or very common** Abdominal pain - abnormal dreams - anorexia - cough - depression - diarrhoea - dizziness - fever - headache - insomnia - nausea - pruritus - rash - vomiting
- **Uncommon** Anxiety - blood disorders - hair loss - hyponatraemia - palpitation - stomatitis

**Chloroquine**

**INDICATIONS AND DOSE**

Active rheumatoid arthritis (administered on expert advice) | Systemic and discoid lupus erythematosus (administered on expert advice)
- **BY MOUTH**
  - Adult: 150 mg daily; maximum 2.5 mg/kg per day

Prophylaxis of malaria
- **INITIALLY BY MOUTH USING SYRUP**
  - Child 4-5 weeks (body-weight up to 4.5 kg): 25 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
  - Child 6 weeks–5 months (body-weight 4.5–7 kg): 50 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
  - Child 6–11 months (body-weight 8–10 kg): 75 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
  - Child 1–2 years (body-weight 11–14 kg): 100 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
  - Child 3–4 years (body-weight 15–16.4 kg): 125 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
  - Child 5–7 years (body-weight 16.5–24 kg): 150 mg once weekly, alternatively (by mouth using syrup) 155 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
  - Child 8–13 years (body-weight 25–44 kg): 225 mg once weekly, alternatively (by mouth using syrup) 232.5 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
  - Child 14–17 years (body-weight 45 kg and above): 310 mg once weekly, alternatively (by mouth using syrup) 300 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving

- **INITIALLY BY MOUTH USING TABLETS**
  - Child 4–5 weeks (body-weight up to 4.5 kg): 25 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
  - Child 6 weeks–5 months (body-weight 4.5–7 kg): 50 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
  - Child 6–11 months (body-weight 8–10 kg): 75 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
  - Child 1–2 years (body-weight 11–14 kg): 100 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
  - Child 3–4 years (body-weight 15–16.4 kg): 125 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
  - Child 5–7 years (body-weight 16.5–24 kg): 150 mg once weekly, alternatively (by mouth using syrup) 155 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
  - Child 8–13 years (body-weight 25–44 kg): 225 mg once weekly, alternatively (by mouth using syrup) 232.5 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
  - Child 14–17 years (body-weight 45 kg and above): 310 mg once weekly, alternatively (by mouth using syrup) 300 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving

**FREQUENCY NOT KNOWN** Cholestasis - hallucinations - hepatitis - mouth ulcers - photosensitivity - seizures - Stevens-Johnson syndrome - tachycardia - vasculitis

**PREGNANCY** Manufacturer advises avoid unless essential.

**RENAL IMPAIRMENT** Avoid for malaria prophylaxis (and if possible for malaria treatment) if eGFR less than 30 mL/minute/1.73m².

**PATIENT AND CARER ADVICE** Warn travellers about importance of avoiding mosquito bites, importance of taking prophylaxis regularly, and importance of immediate visit to doctor if ill within 1 year and especially within 3 months of return.

**NATIONAL FUNDING/ACCESS DECISIONS**

NHS restrictions Drugs for malaria prophylaxis not prescribable on the NHS; health authorities may investigate circumstances under which antimalarials prescribed.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- **CAUTIONARY AND ADVISORY LABELS** 21
  - Malarone (GlaxoSmithKline UK Ltd)
    - Proguanil hydrochloride 25 mg, Atovaquone 62.5 mg
    - Malarone Paediatric tablets | 12 tablet [PPh] £6.26
    - Proguanil hydrochloride 100 mg, Atovaquone 250 mg
    - Malarone tablets | 12 tablet [PPh] £25.21 DT price = £25.21

**Chloroquine**

**INDICATIONS AND DOSE**

Active rheumatoid arthritis (administered on expert advice) | Systemic and discoid lupus erythematosus (administered on expert advice)
- **BY MOUTH**
  - Adult: 150 mg daily; maximum 2.5 mg/kg per day

Prophylaxis of malaria
- **INITIALLY BY MOUTH USING SYRUP**
  - Child 4-5 weeks (body-weight up to 4.5 kg): 25 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
  - Child 6 weeks–5 months (body-weight 4.5–7 kg): 50 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
  - Child 6–11 months (body-weight 8–10 kg): 75 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
  - Child 1-2 years (body-weight 11–14 kg): 100 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
  - Child 3–4 years (body-weight 15–16.4 kg): 125 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
  - Child 5-7 years (body-weight 16.5–24 kg): 150 mg once weekly, alternatively (by mouth using syrup) 155 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
  - Child 8–13 years (body-weight 25–44 kg): 225 mg once weekly, alternatively (by mouth using syrup) 232.5 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
  - Child 14–17 years (body-weight 45 kg and above): 310 mg once weekly, alternatively (by mouth using syrup) 300 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving

- **INITIALLY BY MOUTH USING TABLETS**
  - Child 4–5 weeks (body-weight up to 4.5 kg): 25 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
  - Child 6 weeks–5 months (body-weight 4.5–7 kg): 50 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
  - Child 6–11 months (body-weight 8–10 kg): 75 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
  - Child 1–2 years (body-weight 11–14 kg): 100 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
  - Child 3–4 years (body-weight 15–16.4 kg): 125 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
  - Child 5–7 years (body-weight 16.5–24 kg): 150 mg once weekly, alternatively (by mouth using tablets) 155 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
  - Child 8–13 years (body-weight 25–44 kg): 225 mg once weekly, alternatively (by mouth using tablets) 232.5 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
  - Child 14–17 years (body-weight 45 kg and above): 310 mg once weekly, alternatively (by mouth using syrup) 300 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving
Treatment of non-falciparum malaria

**BY MOUTH**
- **Child:** Initially 10 mg/kg (max. per dose 620 mg), then 5 mg/kg after 6–8 hours (max. per dose 310 mg), then 5 mg/kg daily (max. per dose 310 mg) for 2 days
- **Adult:** Initially 620 mg, then 310 mg after 6–8 hours, then 310 mg daily for 2 days, approximate total cumulative dose of 25 mg/kg of base

**P. vivax or P. ovale infection during pregnancy while radical cure is postponed**

**BY MOUTH**
- **Adult:** 310 mg once weekly

**DOSE EQUIVALENCE AND CONVERSION**
- Doses expressed as chloroquine base. Chloroquine base 150 mg = chloroquine sulfate 200 mg = chloroquine phosphate 250 mg (approx.).

**DOSES AT EXTREMES OF BODY-WEIGHT**
- With oral use in adults In active rheumatoid arthritis and systemic and discoid lupus erythematosus, to avoid excessive dosage in obese patients, the daily maximum dose should be calculated on the basis of ideal body weight.

**INTERACTIONS**
- Appendix 1: antimalarials

**SIDE-EFFECTS**
- **Common or very common** Gastro-intestinal disturbances - headache - pruritus - rashes - skin reactions
- **Uncommon** Convulsions - discoloration of mucous membranes - discolouration of nails - discoloration of skin - ECG changes - hair depigmentation - hair loss - keratopathy - otoxicity - retinal damage - visual changes
- **Rare** Acute generalised exanthematous pustulosis - agranulocytosis - angioedema - aplastic anaemia - blood disorders - bone marrow suppression - cardiomyopathy - emotional disturbances - exfoliative dermatitis - hepatic damage - hypersensitivity reactions - mental changes - myopathy - neutropenia - photosensitivity - psychosis - Stevens-Johnson syndrome - thrombocytopenia - urticaria

**WARNING**
- Frequency not known Bronchospasm (in children) - diffuse parenchymal lung disease - drug rash with eosinophilia and systemic symptoms - extrapyramidal symptoms (associated with use in malaria) - hypotension - visual disturbances

**SIDE-EFFECTS, FURTHER INFORMATION**
- **Malaria prophylaxis and treatment** Serious skin reactions, ECG changes, visual effects, ototoxicity, blood disorders, mental changes, myopathies and hepatic damage are not usually associated with malaria prophylaxis or treatment.

**Overdose**
- Chloroquine is very toxic in overdosage; overdosage is extremely hazardous and difficult to treat. Urgent advice from the National Poisons Information Service is essential. Life-threatening features include arrhythmias (which can have a very rapid onset) and convulsions (which can be intractable).
- **PREGNANCY** Benefit of use in prophylaxis and treatment in malaria outweighs risk. For rheumatoid disease, it is not necessary to withdraw an antimalarial drug during pregnancy if the disease is well controlled.
- **BREAST FEEDING** Present in breast milk and breast-feeding should be avoided when used to treat rheumatic disease. Amount in milk probably too small to be harmful when used for malaria.
- **HEPATIC IMPAIRMENT** Use with caution in moderate to severe impairment.
- **RENAI IMPAIRMENT** Only partially excreted by the kidneys and reduction of the dose is not required for prophylaxis of malaria except in severe impairment. For rheumatoid arthritis and lupus erythematosus, reduce dose. Manufacturers advise caution.

**MONITORING REQUIREMENTS**
- In adults Manufacturers recommend regular ophthalmological examination but the evidence of practical value is unsatisfactory.
- In children Ophthalmic examination with long-term therapy.

**PATIENT AND CARER ADVICE**
- Warnings travellers going to malarious areas about importance of avoiding mosquito bites, importance of taking prophylaxis regularly, and importance of immediate visit to doctor if ill within 1 year and especially within 3 months of return.

**NATIONAL FUNDING/ACCESS DECISIONS**
- **NHS restrictions** Drugs for malaria prophylaxis not prescribable on the NHS; health authorities may investigate circumstances under which antimalarials are prescribed.

**EXCEPTIONS TO LEGAL CATEGORY**
- Can be sold to the public provided it is licensed and labelled for the prophylaxis of malaria.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

**Oral solution**
- **CAUTIONARY AND ADVISORY LABELS 5**
- **Malarivon** (Wallace Manufacturing Chemists Ltd)
- Chloroquine phosphate 16 mg per 1 ml
- Malarivon 80mg/5ml syrup
- 75 ml [POM] £30.00

**Tablet**
- **CAUTIONARY AND ADVISORY LABELS 5**
- **Avloclor** (Alliance Pharmaceuticals Ltd)
- Chloroquine phosphate 250 mg
- Avloclor 250mg tablets 20 tablet [POM] £7.95 DT price = £7.95
Chloroquine with proguanil

The properties listed below are those particular to the combination only. For the properties of the components please consider, chloroquine p. 582, proguanil hydrochloride p. 585.

- **INDICATIONS AND DOSE**
  - **Prophylaxis of malaria**
    - By mouth
    - Adult: (consult product literature)

- INTERACTIONS → Appendix 1: antimalarials
- EXCEPTIONS TO LEGAL CATEGORY Can be sold to the public provided it is licensed and labelled for the prophylaxis of malaria.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Tablet**
    - Paludrine/Avloclor (Alliance Pharmaceuticals Ltd)
      - Paludrine/Avloclor tablets anti-malarial travel pack | 112 tablet | £13.50

Mefloquine

- **INDICATIONS AND DOSE**
  - **Treatment of malaria**
    - By mouth
    - Adult: (consult product literature)
  - **Prophylaxis of malaria**
    - By mouth
      - Child (body-weight 5–15 kg): 62.5 mg once weekly, dose to be started 2–3 weeks before entering endemic area and continued for 4 weeks after leaving
      - Child (body-weight 16–24 kg): 125 mg once weekly, dose to be started 2–3 weeks before entering endemic area and continued for 4 weeks after leaving
      - Child (body-weight 25–44 kg): 187.5 mg once weekly, dose to be started 2–3 weeks before entering endemic area and continued for 4 weeks after leaving
      - Child (body-weight 45 kg and above): 250 mg once weekly, dose to be started 2–3 weeks before entering endemic area and continued for 4 weeks after leaving
      - Adult (body-weight 45 kg and above): 250 mg once weekly, dose to be started 2–3 weeks before entering endemic area and continued for 4 weeks after leaving
  - **LICENSED USE** Mefloquine doses in BNF Publications may differ from those in product literature.
  - In children Not licensed for use in children under 5 kg body-weight and under 3 months.
  - **CONTRA-INDICATIONS** Avoid for prophylaxis if history of psychiatric disorders (including depression) or convulsions
  - Avoid for standby treatment if history of convulsions
  - History of blackwater fever
  - **CAUTIONS** Cardiac conduction disorders, epilepsy (avoid for prophylaxis), not recommended in infants under 3 months (5 kg), traumatic brain injury
  - **CAUTIONS, FURTHER INFORMATION**
    - Neuropsychiatric reactions Mefloquine is associated with potentially serious neuropsychiatric reactions. Abnormal dreams, insomnia, anxiety, and depression occur commonly. Psychosis, suicidal ideation, and suicide have also been reported. Psychiatric symptoms such as nightmares, acute anxiety, depression, restlessness, or confusion should be regarded as potentially prodromal for a more serious event. Adverse reactions may occur and persist up to several months after discontinuation because mefloquine has a long half-life. For a prescribing checklist, and further information on side-effects, particularly neuropsychiatric side-effects, which may be associated with the use of mefloquine for malaria prophylaxis, see the Guide for Healthcare Professionals provided by the manufacturer.
  - **INTERACTIONS** → Appendix 1: antimalarials
  - **SIDE-EFFECTS**
    - Common or very common Abdominal pain, diarrhoea, dizziness, headache, nausea, neuropsychiatric reactions, pruritis, visual disturbances, vomiting
    - Very rare Optic neuropathy
  - **Frequency not known** Alopecia, anemia, anorexia, arrhythmias, arthralgia, ataxia, blood disorders, bradycardia, cataract, chest pain, confusion, drowsiness, dyspepsia, dyspnoea, encephalopathy, fever, flushing, hepatic failure, hyperhidrosis, hypertension, hypotension, leucocytosis, leucopenia, malaise, motor neuropathies, muscle weakness, myalgia, oedema, palpitation, panic attacks, pneumonitis, rash, seizures, senory neuropathies, speech disturbances, Stevens-Johnson syndrome, syncope, tachycardia, thrombocytopenia, tremor, vestibular disorders
  - **ALLERGY AND CROSS-SENSITIVITY** Contra-indicated in patients with hypersensitivity to quinine.
  - **CONCEPTION AND CONTRACEPTION** Manufacturer advises adequate contraception during prophylaxis and for 3 months after stopping (teratogenicity in animal studies).
  - **PREGNANCY** Manufacturer advises avoid (particularly in the first trimester) unless the potential benefit outweighs the risk; however, studies of mefloquine in pregnancy (including use in the first trimester) indicate that it can be considered for travel to chloroquine-resistant areas.
  - **BREAST FEEDING** Present in milk but risk to infant minimal.
  - **HEPATIC IMPAIRMENT** Elimination may be prolonged; avoid in severe impairment.
  - **RENAL IMPAIRMENT** Manufacturer advises caution.
  - **DIRECTIONS FOR ADMINISTRATION** Tablet may be crushed and mixed with food such as jam or honey just before administration.
  - **PATIENT AND CARER ADVICE** A patient alert card should be provided. Manufacturer advises that patients receiving mefloquine for malaria prophylaxis should be informed to discontinue its use if neuropsychiatric symptoms occur and seek immediate medical advice so that mefloquine can be replaced with an alternative antimalarial. Travellers should also be warned about importance of avoiding mosquito bites. importance of taking prophylaxis regularly, and importance of immediate visit to doctor if ill within 1 year and especially within 3 months of return.
  - **Driving and skilled tasks** Dizziness or a disturbed sense of balance may affect performance of skilled tasks (e.g. driving); effects may occur and persist up to several months after stopping mefloquine.
  - **NATIONAL FUNDING/ACCESS DECISIONS** NHS restrictions Drugs for malaria prophylaxis not prescribable on the NHS; health authorities may investigate circumstances under which antimalarials prescribed.
  - **MEDICINAL FORMS**
    - There can be variation in the licensing of different medicines containing the same drug.
    - **Tablet**
      - CAUTIONARY AND ADVISORY LABELS 10, 21, 27
        - Lariam (Rochef Products Ltd)
          - Mefloquine (as Mefloquine hydrochloride) 250 mg | Lariam 250mg tablets | 8 tablet | £14.53
Primaquine

- **INDICATIONS AND DOSE**
  - Adjunct in the treatment of non-falciparum malaria caused by *P. vivax* infection
    - **BY MOUTH**
    - Adult: 30 mg daily for 14 days
  - Adjunct in the treatment of non-falciparum malaria caused by *P. ovale* infection
    - **BY MOUTH**
    - Adult: 15 mg daily for 14 days
  - Adjunct in the treatment of non-falciparum malaria caused by *P. vivax* infection in patients with mild G6PD deficiency (administered on expert advice)
    - **BY MOUTH**
    - Adult: 600 mg once daily, dose to be started 1 week before entering endemic area and continued for 4 weeks after leaving
  - Treatment of mild to moderate pneumocystis infection (in combination with clindamycin)
    - **BY MOUTH**
    - Adult: 30 mg daily, this combination is associated with considerable toxicity

- **UNLICENSED USE**
  Not licensed.

- **CAUTIONS**
  G6PD deficiency · systemic diseases associated with granulocytopenia (e.g. juvenile idiopathic arthritis, rheumatoid arthritis, lupus erythematosus)

- **INTERACTIONS** → Appendix 1: antimalarials

- **SIDE-EFFECTS**
  - Common or very common Abdominal pain · anorexia · nausea · vomiting
  - Uncommon Haemolytic anaemia especially in G6PD deficiency · leucopenia · methaemoglobinemia

- **PREGNANCY**
  Risk of neonatal haemolysis and methaemoglobinemia in third trimester.

- **BREAST FEEDING**
  No information available; theoretical risk of haemolysis in G6PD-deficient infants.

- **PRE-TREATMENT SCREENING**
  Before starting primaquine, blood should be tested for glucose-6-phosphate dehydrogenase (G6PD) activity since the drug can cause haemolysis in G6PD-deficient patients. Specialist advice should be obtained in G6PD deficiency.

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

  **Tablet**
  - Primaquine (Non-proprietary)
    - Primaquine (as Primaquine phosphate) 15 mg

  **Primaquine tablets** | 100 tablet [Pack] no price available

---

Proguanil hydrochloride

- **INDICATIONS AND DOSE**
  - Prophylaxis of malaria
    - **BY MOUTH**
    - Child 4–7 years (body-weight 16–24 kg): 100 mg once daily, dose to be started 1 week before entering endemic area and continued for 4 weeks after leaving
    - Child 8–12 years (body-weight 25–44 kg): 150 mg once daily, dose to be started 1 week before entering endemic area and continued for 4 weeks after leaving
    - Child 13–17 years (body-weight 45 kg and above): 200 mg once daily, dose to be started 1 week before entering endemic area and continued for 4 weeks after leaving
    - Adult: 200 mg once daily, dose to be started 1 week before entering endemic area and continued for 4 weeks after leaving

- **UNLICENSED USE**
  Proguanil doses in BNF Publications may differ from those in product literature.

- **INTERACTIONS** → Appendix 1: antimalarials

- **SIDE-EFFECTS**
  - Very rare Cholestasis · hair loss · skin reactions · vasculitis
  - Frequency not known Mouth ulcers · stomatitis
  - Pregnancy Benefit of prophylaxis in malaria outweighs risk. Adequate folate supplements should be given to mother.

- **BREAST FEEDING**
  Amount in milk probably too small to be harmful when used for malaria prophylaxis.

- **RENAL IMPAIRMENT**
  - In children Use half normal dose if estimated glomerular filtration rate 20–60 mL/minute/1.73m². Use one-quarter normal dose on alternate days if estimated glomerular filtration rate 10–20 mL/minute/1.73m². Use one-quarter normal dose once weekly if estimated glomerular filtration rate less than 10 mL/minute/1.73m²; increased risk of haematological toxicity in severe impairment.
  - In adults 100 mg once daily if eGFR 20–60 mL/minute/1.73m². 50 mg on alternate days if eGFR 10–20 mL/minute/1.73m². 50 mg once weekly if eGFR less than 10 mL/minute/1.73m²; increased risk of haematological toxicity in severe impairment.

- **DIRECTIONS FOR ADMINISTRATION**
  Tablet may be crushed and mixed with food such as milk, jam, or honey just before administration.

- **PATIENT AND CARER ADVICE**
  Warn travellers about importance of avoiding mosquito bites, importance of taking prophylaxis regularly, and importance of immediate visit to doctor if ill within 1 year and especially within 3 months of return.

- **NATIONAL FUNDING/ACCESS DECISIONS**
  **NHS restrictions** Drugs for malaria prophylaxis not prescribable on the NHS; health authorities may investigate circumstances under which antimalarials are prescribed.

- **EXCEPTIONS TO LEGAL CATEGORY**
  Can be sold to the public provided it is licensed and labelled for the prophylaxis of malaria.

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

  **Tablet**
  - **CAUTIONARY AND ADVISORY LABELS** 21
    - Paludrine (Alliance Pharmaceuticals Ltd)
      - Proguanil hydrochloride 100 mg
      - Paludrine 100mg tablets | 98 tablet [Pack] £11.95 DT price = £11.95
**Pyrimethamine**

- **INDICATIONS AND DOSE**
  - Toxoplasmosis in pregnancy (in combination with sulfadiazine and folic acid)
    - **BY MOUTH**
    - Adult: 50 mg once daily until delivery
  - Malaria
    - **BY MOUTH**
    - Adult: No dose stated because not recommended alone

- **CAUTIONS** History of seizures—avoid large loading doses
- **INTERACTIONS** → Appendix 1: antimalarials
- **SIDE-EFFECTS**
  - Common or very common Anaemia (with high doses)
  - Blood disorders (with high doses)
  - Diarrhoea
  - Dizziness
  - Headache
  - Leucopenia
  - Nausea
  - Rash
  - Thrombocytopenia
  - Vomiting
  - Uncommon Abnormal skin pigmentation
  - Very rare Buccal ulceration
  - Other: Convulsions

- **PREGNANCY** Theoretical teratogenic risk in first trimester (folate antagonist). Adequate folate supplements should be given to the mother.

- **BREAST FEEDING** Significant amount in milk—avoid administration of other folate antagonists to infant. Avoid breast-feeding during toxoplasmosis treatment.

- **HEPATIC IMPAIRMENT** Manufacturer advises caution.

- **RENAL IMPAIRMENT** Manufacturer advises caution.

- **MONITORING REQUIREMENTS** Blood counts required with prolonged treatment.

- **LESS SUITABLE FOR PRESCRIBING** Pyrimethamine should not be used alone for malaria, but is used with sulfadoxine.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

  - **Tablet**
    - Daraprim (GlaxoSmithKline UK Ltd)
      - Pyrimethamine 25 mg Daraprim 25mg tablets | 30 tablet Pack £13.00

**Pyrimethamine with sulfadoxine**

- **INDICATIONS AND DOSE**
  - Adjunct to quinine in treatment of Plasmodium falciparum malaria
    - **BY MOUTH**
    - Child 1 month–4 years (body-weight 5 kg and above): 12.5/250 mg for 1 dose
    - Child 5–6 years: 25/500 mg for 1 dose
    - Child 7–9 years: 37.5/750 mg for 1 dose
    - Child 10–13 years: 50/1000 mg for 1 dose
    - Child 14–17 years: 75/1500 mg for 1 dose
    - Adult: 75/1500 mg for 1 dose
  - Malaria prophylaxis
    - **BY MOUTH**
    - Adult: Not recommended by UK malaria experts

- **DOSE EQUIVALENCE AND CONVERSION**
  - Dose quantities are expressed in the form x/y where x and y are the strengths in milligrams of pyrimethamine and sulfadoxine respectively.

- **UNLICENSED USE** Not licensed for use in children of body-weight under 5 kg.

- **CONTRA-INDICATIONS** Acute porphyrias p. 969

- **CAUTIONS** Asthma—avoid in blood disorders (unless under specialist supervision)
  - Avoid in infants under 6 weeks
  - Elderly
  - G6PD deficiency
  - History of seizures—avoid large loading doses
  - Not recommended for prophylaxis (severe side-effects on long-term use)
  - Predisposition to folate deficiency
  - Predisposition to hyperkalaemia (in adults)

- **INTERACTIONS** → Appendix 1: antimalarials

- **SIDE-EFFECTS**
  - Common or very common Diarrhoea, headache, hyperkalaemia, nausea, rash
  - Uncommon Vomiting
  - Very rare Anorexia, antibiotic-associated colitis, arthralgia, aseptic meningitis, ataxia, blood disorders, convulsions, cough, depression, eosinophilia, glossitis, hallucinations, hepatic necrosis, hypoglycaemia, hyponatraemia, interstitial nephritis, jaundice, leucopenia, liver damage, megaloblastic anaemia, myalgia, myocarditis, pancreatitis, peripheral neuropathy, photosensitivity, renal disorders, rhabdomyolysis reported in HIV-infected patients, shortness of breath, Stevens-Johnson syndrome, stomatitis, systemic lupus erythematosus, thrombocytopenia, tinnitus, toxic epidermal necrolysis, uveitis, vasculitis, vertigo

- **FREQUENCY NOT KNOWN** Allergic alveolitis, eosinophilic alveolitis, pulmonary infiltrates

**SIDE-EFFECTS, FURTHER INFORMATION**
- Discontinue immediately if blood disorders or rash occur. Discontinue if cough or shortness of breath occur.

- **ALLERGY AND CROSS-SENSITIVITY** Contra-indicated in patients with sulfonamide allergy.

- **PREGNANCY** Possible teratogenic risk in first trimester (pyrimethamine a folate antagonist); in third trimester—risk of neonatal haemolysis and methaemoglobinæmia. Fear of increased risk of kernicterus in neonates appears to be unfounded.

- **BREAST FEEDING** Small risk of kernicterus in jaundiced infants; risk of haemolysis in G6PD-deficient infants (due to sulfadoxine).

- **MONITORING REQUIREMENTS** Monitor blood counts on prolonged treatment.

- **PATIENT AND CARER ADVICE** Patients should be advised to maintain adequate fluid intake.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug. No licensed medicines listed.

**Quinine**

- **INDICATIONS AND DOSE**
  - Nocturnal leg cramps
    - **BY MOUTH**
    - Adult: 200–300 mg once daily, to be taken at bedtime
  - Non-falciparum malaria
    - **BY INTRAVENOUS INFUSION**
    - Adult: 10 mg/kg every 8 hours (max. per dose 700 mg), infused over 4 hours, given if patient is unable to take oral therapy. Changed to oral chloroquine as soon as the patient’s condition permits
  - Falciparum malaria
    - **BY MOUTH**
    - Child: 10 mg/kg every 8 hours (max. per dose 600 mg) for 7 days, together with or followed by either doxycycline (in children over 12 years), or clindamycin
    - Adult: 600 mg every 8 hours for 5–7 days, the quinine should be given together with or followed by either doxycycline or clindamycin
## Hepatitis

### 6 Viral infection

#### 6.1 Hepatitis

**Hepatitis**

**Overview**

Treatment for viral hepatitis should be initiated by a specialist. The management of uncomplicated acute viral hepatitis is largely symptomatic. Early treatment of acute hepatitis C with interferon alfa p. 882 [unlicensed indication] may reduce the risk of chronic infection. Hepatitis B and hepatitis C viruses are major causes of chronic hepatitis. Active or passive immunisation against hepatitis A and B infections can be given.

**Chronic hepatitis B**

Peginterferon alfa p. 590 is an option for the initial treatment of chronic hepatitis B and may be preferable to interferon alfa. The use of peginterferon alfa and interferon alfa is limited by a response rate of 30–40% and relapse is frequent. Treatment should be discontinued if no improvement occurs after 4 months. The manufacturers of peginterferon alfa-2a and interferon alfa contraindicate use in decompensated liver disease, but low doses can be used with great caution in these patients. Although interferon alfa is contra-indicated in patients receiving immunosuppressant treatment (or who have received it recently), cautious use of peginterferon alfa-2a may be justified in some cases.

Entecavir p. 588 or tenofovir disoproxil p. 616 are options for the initial treatment of chronic hepatitis B. If the response is inadequate after 6–9 months of treatment, a change in treatment should be considered. Other drugs that are licensed for the treatment of chronic hepatitis B include adefovir dipivoxil p. 589, lamivudine p. 615, or telbivudine p. 589.

Entecavir alone, tenofovir disoproxil alone, or a combination of lamivudine with either adefovir dipivoxil or tenofovir disoproxil can be used in patients with decompensated liver disease.

If drug-resistant hepatitis B virus emerges during treatment, another antiviral drug to which the virus is not resistant may be added.
sensitive should be added. Hepatitis B viruses with reduced susceptibility to lamivudine have emerged following extended therapy. Adefovir dipivoxil or tenofovir disoproxil can be given with lamivudine in lamivudine-resistant chronic hepatitis B; telbivudine or entecavir should not be used because cross-resistance can occur.

If there is no toxicity or loss in efficacy, treatment with adefovir dipivoxil, entecavir, lamivudine, telbivudine, or tenofovir disoproxil is usually continued until adequate seroconversion has occurred. Treatment is usually continued long-term in patients with decompensated liver disease.

Tenofovir disoproxil, or a combination of tenofovir disoproxil with either emtricitabine p. 613 or lamivudine may be used with other antiretrovirals, as part of “highly active antiretroviral therapy” in patients who require treatment for both HIV and chronic hepatitis B. If patients infected with both HIV and chronic hepatitis B only require treatment for chronic hepatitis B, they should receive antivirals that are not active against HIV, such as peginterferon alfa or adefovir dipivoxil. Treatment may be continued long-term, even if adequate seroconversion occurs. Management of these patients should be coordinated between HIV and hepatology specialists.

### Chronic hepatitis C

Before starting treatment, the genotype of the infecting hepatitis C virus should be determined and the viral load measured as this may affect the choice and duration of treatment. A combination of ribavirin p. 593 and peginterferon alfa is used for the treatment of chronic hepatitis C. The combination of ribavirin and interferon alfa is less effective than the combination of peginterferon alfa and ribavirin. Peginterferon alfa alone should be used if ribavirin is contra-indicated or not tolerated. Ribavirin monotherapy is ineffective.

Daclatasvir p. 591 is licensed for use in combination with sofosbuvir p. 595 for the treatment of chronic hepatitis C infection of genotypes 1 or 4, with or without compensated cirrhosis; the addition of ribavirin should be considered for patients with advanced liver disease or with other negative prognostic factors, such as prior treatment experience. It is also licensed in combination with sofosbuvir and ribavirin for the treatment of chronic hepatitis C infection of genotype 3 in patients who are treatment experienced, with or without compensated cirrhosis, and in combination with peginterferon alfa and ribavirin for the treatment of chronic hepatitis C infection of genotype 4. Daclatasvir must not be given as monotherapy.

Ombitasvir with paritaprevir and ritonavir p. 592 (Viekirax®,) is licensed for use in combination with dasabuvir p. 598, with or without ribavirin, for the treatment of chronic hepatitis C infection of genotype 1 in patients with or without compensated cirrhosis; it is also licensed for use in combination with ribavirin for the treatment of chronic hepatitis C infection of genotype 4 with or without compensated cirrhosis.

Ribavirin inhibits a wide range of DNA and RNA viruses. It is given by mouth for the treatment of chronic hepatitis C infection, in double therapy with peginterferon alfa, interferon alfa, or sofosbuvir, or in triple therapy with peginterferon alfa and one protease inhibitor (i.e. sipimprev p. 597) or sofosbuvir. Ribavirin is also effective in Lassa fever [unlicensed indication].

Sofosbuvir is a pro-drug of a nucleoside inhibitor that is effective against hepatitis C virus polymerase NS5B. It is licensed for use in combination with ribavirin, with or without peginterferon alfa, for the treatment of chronic hepatitis C infection of genotypes 1, 2, 3, 4, 5, or 6 in patients with compensated liver disease. Sofosbuvir monotherapy is not recommended because it is less effective than combination therapy.

Ledipasvir is licensed for use in combination with sofosbuvir (sofosbuvir with ledipasvir p. 596), with or without ribavirin, for the treatment of chronic hepatitis C infections of genotypes 1, 3, 4, 5, or 6.

Simeprevir is licensed for use in combination with ribavirin and peginterferon alfa for the treatment of chronic hepatitis C infection of genotype 1 or 4; regimens containing peginterferon alfa-2a are less effective than those containing peginterferon alfa-2b. Simeprevir may also be used in combination with sofosbuvir, with or without ribavirin, for the urgent treatment of chronic hepatitis C infection of genotypes 1 or 4 only when peginterferon alfa cannot be used because of intolerance or contra-indications. Simeprevir monotherapy is not recommended.

### 6.2 Hepatitis infections

#### 6.2a Chronic hepatitis B

Other drugs used for Chronic hepatitis B Interferon alfa, p. 882 · Lamivudine, p. 615 · Tenofovir disoproxil, p. 616

#### ANTIVIRALS > NUCLEOSIDE ANALOGUES

### Entecavir

- **INDICATIONS AND DOSE**

  **Chronic hepatitis B in patients with compensated liver disease (with evidence of viral replication, and histologically documented active liver inflammation or fibrosis) not previously treated with nucleoside analogues**

  - **BY MOUTH**
  - Adult: 500 micrograms once daily

  **Chronic hepatitis B in patients with compensated liver disease (with evidence of viral replication, and histologically documented active liver inflammation or fibrosis) and lamivudine-resistance**

  - **BY MOUTH**
  - Adult: 1 mg once daily, consider other treatment if inadequate response after 6 months

  **Chronic hepatitis B in patients with decompensated liver disease**

  - **BY MOUTH**
  - Adult: 1 mg once daily

- **CAUTIONS**

  - HIV infection—risk of HIV resistance in patients not receiving “highly active antiretroviral therapy” lamivudine-resistant chronic hepatitis B—risk of entecavir resistance

- **CAUTIONS, FURTHER INFORMATION**

  Discontinue if deterioration in liver function, hepatic steatosis, progressive hepatomegaly or unexplained lactic acidosis.

- **SIDE-EFFECTS**

  - **Common or very common** Diarrhoea · dizziness · dyspepsia · fatigue · headache · nausea · raised serum amylase · raised serum lipase · sleep disturbances · vomiting
  - **Uncommon** Alopecia · rash · thrombocytopenia

- **CONCEPTION AND CONTRACEPTION**

  Effective contraception required during treatment.

- **PREGNANCY**

  - Toxicity in animal studies—manufacturer advises use only if potential benefit outweighs risk.

- **BREAST FEEDING**

  Manufacturer advises avoid—present in milk in animal studies.

- **RENAL IMPAIRMENT**

  - Reduce dose if eGFR less than 50 mL/minute/1.73 m². Consult product literature.
● **MONITORING REQUIREMENTS** Monitor liver function tests every 3 months, and viral markers for hepatitis B every 3–6 months during treatment (continue monitoring for at least 1 year after discontinuation—recurrent hepatitis may occur on discontinuation).

- **DIRECTIONS FOR ADMINISTRATION** To be taken at least 2 hours before or 2 hours after food.

- **PRESCRIBING AND DISPENSING INFORMATION** Flavours of oral liquid formulations may include orange.

- **PATIENT AND CARER ADVICE** Patients or carers should be counselled on the administration of entecavir tablets and oral solution.

- **NATIONAL FUNDING/ACCESS DECISIONS**

  - **NICE technology appraisals (TAs)**
    - Entecavir for chronic hepatitis B (August 2008) NICE TA153
    - Entecavir is an option for the treatment of chronic hepatitis B.
    - www.nice.org.uk/TA153

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.

  - **Oral solution**
    - **Baraclude** (Bristol-Myers Squibb Pharmaceuticals Ltd)
      - Entecavir (as Entecavir monohydrate) 50 microgram per 1 ml
      - Entecavir (as Entecavir monohydrate) 500 microgram per 1 ml
    - **Tablet**
      - **Baraclude** (Bristol-Myers Squibb Pharmaceuticals Ltd)
        - Entecavir (as Entecavir monohydrate) 1 mg
        - Entecavir (as Entecavir monohydrate) 500 microgram
        - Entecavir (as Entecavir monohydrate) 50 microgram
        - Entecavir (as Entecavir monohydrate) 100 microgram
      - **Baraclude** (Bristol-Myers Squibb Pharmaceuticals Ltd)
        - Tablet containing the same drug.

**Telbivudine**

- **INDICATIONS AND DOSE**
  Chronic hepatitis B infection with compensated liver disease, evidence of viral replication, and histologically documented active liver inflammation or fibrosis, when other treatment is not appropriate.

  - **BY MOUTH**
    - Adult: 600 mg once daily

- **CAUTIONS**
  - Lamivudine-resistant chronic hepatitis B—risk of telbivudine resistance.
  - CAUTIONS, FURTHER INFORMATION
    - Discontinue if deterioration in liver function, hepatic steatosis, progressive hepatomegaly or unexplained lactic acidosis.

- **INTERACTIONS**
  - Appendix 1: telbivudine

- **SIDE-EFFECTS**
  - Common or very common: Abdominal pain, cough, diarrhoea, dizziness, fatigue, headache, nausea, raised serum amylase, raised serum lipase, rash.
  - Uncommon: Arthralgia, myalgia, myopathy (discontinue treatment), peripheral neuroopathy, taste disturbance.
  - Rare: Lactic acidosis, rhabdomyolysis.

- **PREGNANCY**
  - Manufacturer advises use only if potential benefit outweighs risk.

- **BREAST FEEDING**
  - Manufacturer advises avoid—present in milk in animal studies.

- **RENAL IMPAIRMENT**
  - 600 mg every 48 hours if eGFR 30–49 mL/minute/1.73 m²; 600 mg every 72 hours if eGFR less than 30 mL/minute/1.73 m².

- **MONITORING REQUIREMENTS**
  - Monitor liver function tests every 3 months and viral markers of hepatitis B every 3–6 months during treatment (continue monitoring for at least 1 year after discontinuation—recurrent hepatitis may occur on discontinuation).

- **PATIENT AND CARER ADVICE**
  - Muscle effects and peripheral neuropathy: Patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, or numbness, tingling or burning sensations.

- **NATIONAL FUNDING/ACCESS DECISIONS**

  - **NICE technology appraisals (TAs)**
    - Telbivudine for chronic hepatitis B (August 2008) NICE TA154
    - Telbivudine is not recommended for the treatment of chronic hepatitis B. Patients currently receiving telbivudine can continue treatment until they and their clinician consider it appropriate to stop.
    - www.nice.org.uk/TA154

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.

  - **Tablet**
    - Sebivo (Novartis Pharmaceuticals UK Ltd)
      - Telbivudine 600 mg Sebivo 600mg tablets | 28 tablet pack
      - £290.33

**ANTIVIRALS > NUCLEOTIDE ANALOGUES**

Adefovir dipivoxil

- **INDICATIONS AND DOSE**
  Chronic hepatitis B infection with either compensated liver disease with evidence of viral replication, and histologically documented active liver inflammation and fibrosis, when other treatment not appropriate or decompensated liver disease in combination with another antiviral for chronic hepatitis B that has no cross-resistance to adefovir.

  - **BY MOUTH**
    - Adult: 10 mg once daily

- **CAUTIONS**
  - Elderly
  - CAUTIONS, FURTHER INFORMATION
    - Discontinue if deterioration in liver function, hepatic steatosis, progressive hepatomegaly or unexplained lactic acidosis.

- **INTERACTIONS**
  - Appendix 1: adefovir

- **SIDE-EFFECTS**
  - Abdominal pain, asthenia, diarrhoea, dyspepsia, flatulence, headache, hypophosphataemia, nausea, pancreatitis, pruritus, rash, renal failure, vomiting.

- **PREGNANCY**
  - Toxicity in animal studies—manufacturer advises use only if potential benefit outweighs risk.

- **BREAST FEEDING**
  - Manufacturer advises avoid—no information available.

- **RENAL IMPAIRMENT**
  - 10 mg every 48 hours if eGFR 30–50 mL/minute/1.73 m²; 10 mg every 72 hours if eGFR 10–30 mL/minute/1.73 m². No information available if eGFR less than 10 mL/minute/1.73 m². Monitor renal function more frequently in patients with renal impairment.

- **MONITORING REQUIREMENTS**
  - Monitor liver function tests every 3 months, and viral markers for hepatitis B every 3–6 months during treatment (continue monitoring for at least 1 year after discontinuation—recurrent hepatitis may occur on discontinuation).

  - Monitor renal function before treatment then every 3 months, more frequently in patients receiving nephrotoxic drugs.
Peginterferon alfa

**DRUG ACTION** Polyethylene glycol-conjugated (‘pegylated’) derivatives of interferon alfa (peginterferon alfa-2a and peginterferon alfa-2b) are available; pegylation increases the persistence of the interferon in the blood.

**INDICATIONS AND DOSE**

PEGASYS®

Combined with ribavirin for chronic hepatitis C | Monotherapy for chronic hepatitis C if ribavirin not tolerated or contra-indicated | Monotherapy for chronic hepatitis B

- BY SUBCUTANEOUS INJECTION
- Adult: consult product literature

VIRAFERONPEG®

Combined with ribavirin for chronic hepatitis C | Combined with ribavirin and boceprevir for chronic hepatitis C infection of genotype 1 in patients with compensated liver disease | Monotherapy for chronic hepatitis C if ribavirin not tolerated or contra-indicated

- BY SUBCUTANEOUS INJECTION
- Adult: consult product literature

**CONTRA-INDICATIONS** For contra-indications consult product literature.

**CAUTIONS** For cautions consult product literature.

**INTERACTIONS** Appendix 1: interferons

**SIDE-EFFECTS**

- Common or very common: Anorexia • diarrhoea • influenza-like symptoms • lethargy • nausea
- Frequency not known: Alopecia • arrhythmias • cardiovascular problems • coma (usually with high doses in the elderly) • confusion • depression • hepatotoxicity • hyperglycaemia • hypersensitivity reactions • hypertension • hypertriglyceridaemia (sometimes severe) • hypotension • myelosuppression (particularly affecting granulocyte counts) • nephrotoxicity • ocular side-effects • palpitation • psoriasisform rash • seizures (usually with high doses in the elderly) • suicidal behaviour • thyroid abnormalities

SIDE-EFFECTS, FURTHER INFORMATION

For information on side effects consult product literature.

**CONCEPTION AND CONTRACEPTION** Effective contraception required during treatment—consult product literature.

**PREGNANCY** Manufacturers recommend avoid unless potential benefit outweighs risk (toxicity in animal studies).

**BREAST FEEDING** Manufacturers advise avoid—no information available.

**HEPATIC IMPAIRMENT** Avoid in severe impairment. Close monitoring required in mild to moderate hepatic impairment.

**RENAL IMPAIRMENT** Reduce dose in moderate to severe impairment. For information on peginterferon alfa use in renal impairment consult product literature. Close monitoring required in renal impairment.

**MONITORING REQUIREMENTS** Monitoring of lipid concentration is recommended.
6.2b Chronic hepatitis C

Other drugs used for Chronic hepatitis C interferon alfa, p. 882 • Peginterferon alfa, p. 590

ANTIVIRALS ▶ HCV INHIBITORS

Elbasvir with grazoprevir 24-Apr-2017

▶ DRUG ACTION Elbasvir is an HCV NS5A inhibitor and grazoprevir is an HCV NS3/4A protease inhibitor; they reduce viral load by inhibiting hepatitis C virus RNA replication.

▶ INDICATIONS AND DOSE Chronic hepatitis C infection of genotypes 1 or 4 (with or without ribavirin) (initiated by a specialist)
  ▶ BY MOUTH
  ▶ Adult: 50/100 mg once daily for 12 weeks (may extend to 16 weeks in some circumstances—consult product literature)

DOSE EQUIVALENCE AND CONVERSION
▶ Dose expressed as x/y mg elbasvir/grazoprevir.

IMPORTANT SAFETY INFORMATION

MHRA/CHM ADVICE: DIRECT-ACTING ANTIVIRALS TO TREAT CHRONIC HEPATITIS C: RISK OF INTERACTION WITH VITAMIN K ANTAGONISTS AND CHANGES IN INR (JANUARY 2017)

An EU-wide review has identified that changes in liver function, secondary to hepatitis C treatment with direct-acting antivirals, may affect the efficacy of vitamin K antagonists; the MHRA has advised that INR should be monitored closely in patients receiving concomitant treatment.

MHRA/CHM ADVICE: DIRECT-ACTING ANTIVIRAL INTERFERON-FREE REGIMENS TO TREAT CHRONIC HEPATITIS C: RISK OF HEPATITIS B REACTIVATION (JANUARY 2017)

An EU-wide review has concluded that direct-acting antiviral interferon-free regimens for chronic hepatitis C can cause hepatitis B reactivation in patients co-infected with hepatitis B and C viruses; the MHRA recommends to screen patients for hepatitis B before starting treatment—patients infected with both hepatitis B and C viruses must be monitored and managed according to current clinical guidelines.

▶ CAUTIONS Hepatitis B co-infection - re-treatment following treatment failure—efficacy not established
▶ INTERACTIONS ▶ Appendix 1: elbasvir, grazoprevir
▶ SIDE-EFFECTS
  ▶ Common or very common Abdominal pain · alopecia · anxiety · arthralgia · constipation · decreased appetite · depression · diarrhea · dizziness · dry mouth · headache · insomnia · irritability · malaise · myalgia · nausea · pruritus · vomiting
  ▶ Frequency not known Elevated liver enzymes
▶ PREGNANCY Manufacturer advises use only if potential benefit outweighs risk.
▶ BREAST FEEDING Manufacturer advises avoid—present in milk in animal studies.
▶ HEPATIC IMPAIRMENT Manufacturer advises avoid in moderate-to-severe impairment.
▶ MONITORING REQUIREMENTS Manufacturer advises monitor liver function before treatment, at week 8 in all patients, at week 12 in patients receiving 16 weeks of treatment, and then as clinically indicated—consider discontinuing treatment if alanine aminotransferase (ALT) is greater than 10 times the upper limit of normal; discontinue treatment if ALT elevation is accompanied by signs or symptoms of hepatic impairment or inflammation.

PATIENT AND CARER ADVICE
Hepatic effects Manufacturer advises that patients and their carers should consult a healthcare professional if signs and symptoms of hepatic dysfunction occur (including fatigue, weakness, lack of appetite, nausea and vomiting, jaundice or discoloured faeces).

Vomiting Manufacturer advises if vomiting occurs within 4 hours of a dose, an additional dose should be taken.

Missed doses Manufacturer advises if a dose is more than 16 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)
▶ Elbasvir–grazoprevir for treating chronic hepatitis C (October 2016) NICE TA413

Elbasvir with grazoprevir is recommended, within its marketing authorisation, as an option for treating genotype 1 or 4 chronic hepatitis C infection:
  ▶ of genotype 1a—12 weeks’ treatment (consider use in combination with ribavirin for 16 weeks in patients with a baseline hepatitis C virus RNA level of more than 800 000 IU/mL or specific NSSA polymorphisms causing at least a 5-fold reduction in activity of elbasvir);
  ▶ of genotype 1b—12 weeks’ treatment;
  ▶ of genotype 4—12 weeks’ treatment (consider use in combination with ribavirin for 16 weeks in patients with a baseline hepatitis C virus RNA level of more than 800 000 IU/mL).

This is contingent on the manufacturer providing the drug at the same price or lower than that agreed with the Commercial Medicines Unit.

www.nice.org.uk/guidance/ta413

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium advises (December 2016) that Zepatier® (elbasvir with grazoprevir) is accepted for use within NHS Scotland for the treatment of chronic hepatitis C in adults with genotype 1a, 1b or 4; this advice is contingent upon the continuing availability of the Patient Access Scheme in NHS Scotland or a list price that is equivalent or lower.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS

Electrolytes: May contain Sodium
▶ Zepatier (Merck Sharp & Dohme Ltd)
  ▶ Elbasvir 50 mg, Grazoprevir 100 mg
  ▶ 28 tablet (Po) £12,166.67

ANTIVIRALS ▶ NON-STRUCTURAL PROTEIN 5A INHIBITORS

Daclatasvir 11-May-2017

▶ DRUG ACTION Daclatasvir is an inhibitor of the multifunctional protein NSSA, which is an essential component of the hepatitis C virus replication process.

▶ INDICATIONS AND DOSE
In combination with sofosbuvir for the treatment of chronic hepatitis C infection of genotypes 1 or 4, with or without compensated cirrhosis; in combination with sofosbuvir and ribavirin for the treatment of chronic hepatitis C infection of genotype 3 in patients who are treatment experienced, with or without compensated cirrhosis; in combination with peginterferon alfa and ribavirin for the treatment of chronic hepatitis C infection of genotype 4
▶ BY MOUTH
  ▶ Adult: Usual dose 60 mg once daily (for duration of treatment consult product literature)
DOSE ADJUSTMENTS DUE TO INTERACTIONS
Manufacturer advises reduce dose to 30 mg once daily with concurrent use of some of the potent CYP3A4 inhibitors—consult product literature. Manufacturer advises increase dose to 90 mg once daily with bosentan.

IMPORTANT SAFETY INFORMATION

MHRA/CHM ADVICE: DIRECT-ACTING ANTIVIRALS TO TREAT CHRONIC HEPATITIS C: RISK OF INTERACTION WITH VITAMIN K ANTAGONISTS AND CHANGES IN INR (JANUARY 2017)

An EU-wide review has identified that changes in liver function, secondary to hepatitis C treatment with direct-acting antivirals, may affect the efficacy of vitamin K antagonists; the MHRA has advised that INR should be monitored closely in patients receiving concomitant treatment.

MHRA/CHM ADVICE: DIRECT-ACTING ANTIVIRAL INTERFERON-FREE REGIMENS TO TREAT CHRONIC HEPATITIS C: RISK OF HEPATITIS B REACTIVATION (JANUARY 2017)

An EU-wide review has concluded that direct-acting antiviral interferon-free regimens for chronic hepatitis C can cause hepatitis B reactivation in patients co-infected with hepatitis B and C viruses; the MHRA recommends to screen patients for hepatitis B before starting treatment—patients infected with both hepatitis B and C viruses must be monitored and managed according to current clinical guidelines.

- CAUTIONS
  - Decompensated liver disease • hepatitis B virus co-infection • human immunodeficiency virus co-infection • organ transplant patients • retreatment • efficacy not established in patients with prior exposure to a NS5A inhibitor
- INTERACTIONS → Appendix 1: daclatasvir
- SIDE-EFFECTS
  - Common or very common Abdominal pain • alopecia • anaemia • anxiety • arthralgia • blurred vision • constipation • cough • decreased appetite • depression • diarrhoea • disturbance in attention • dizziness • dry mouth • dry skin • dyspnoea • flatulence • gastro-oesophageal reflux • headache • hot flush • insomnia • irritability • lymphopenia • malaise • migraine • myalgia • nasal congestion • nausea • neutropenia • pruritus • pyrexia • rash • reduced visual acuity • vomiting
  - Frequency not known Hyperbilirubinaemia
- SIDE-EFFECTS, FURTHER INFORMATION
  Side-effects listed are reported when daclatasvir is used in combination with sofosbuvir with or without ribavirin or with ribavirin and peginterferon alfa.
- CONCEPTION AND CONTRACEPTION
  Highly effective contraception required during and for 5 weeks after treatment.
- PREGNANCY
  Manufacturer advises avoid (toxicity in animal studies).
- BREAST FEEDING
  Manufacturer advises avoid—present in milk in animal studies.
- PATIENT AND CARER ADVICE
  Missed doses
  If a dose is more than 20 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.
- Driving and skilled tasks
  May affect performance of skilled tasks (e.g. driving)
- NATIONAL FUNDING/ACCESS DECISIONS
- NICE technology appraisals (TAs)
  - Daclatasvir for treating chronic hepatitis C (November 2015)
    NICE TA364
    Daclatasvir in combination with sofosbuvir or peginterferon alfa, and with/without ribavirin, is recommended as an option for the treatment of chronic hepatitis C infection of genotypes 1, 3 or 4 in adults, depending on the level of fibrosis and only if the manufacturer provides daclatasvir at the same price or lower than agreed with the Commercial Medicines Unit. www.nice.org.uk/TA364

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (November 2014) that daclatasvir (Daklinza®) is accepted for restricted use within NHS Scotland for the treatment of chronic hepatitis C virus infection in patients with significant fibrosis (Metavir score F3–F4) or compensated cirrhosis.

- MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug.

Table

<table>
<thead>
<tr>
<th>CAU TIONS</th>
<th>DAKLINZA</th>
<th>SCOTTISH MEDICINES CONSORTIUM DECISIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Daklinza (Bristol-Myers Squib Pharmaceuticals Ltd)</td>
<td>NICE TA364</td>
</tr>
<tr>
<td></td>
<td>Daclatasvir (as Daclatasvir dihydrochloride) 30 mg</td>
<td>Daklinza</td>
</tr>
<tr>
<td></td>
<td>30mg tablets</td>
<td>£8,172.61</td>
</tr>
<tr>
<td></td>
<td>Daclatasvir (as Daclatasvir dihydrochloride) 60 mg</td>
<td>Daklinza</td>
</tr>
<tr>
<td></td>
<td>60mg tablets</td>
<td>£8,172.61</td>
</tr>
<tr>
<td></td>
<td>Daclatasvir (as Daclatasvir dihydrochloride) 90 mg</td>
<td>Daklinza</td>
</tr>
<tr>
<td></td>
<td>90mg tablets</td>
<td>£8,172.61</td>
</tr>
</tbody>
</table>

Ombitasvir with paritaprevir and ritonavir

Ombitasvir with paritaprevir and ritonavir

The properties listed below are those particular to the combination only. For the properties of the components please consider, ritonavir p. 621.

- INDICATIONS AND DOSE
  Chronic hepatitis C of genotype 1 (in combination with dasabuvir, with or without ribavirin) • Chronic hepatitis C of genotype 4 (in combination with ribavirin)
  - BY MOUTH
  - Adult: 2 tablets once daily for duration of treatment consult product literature, to be taken with food

IMPORTANT SAFETY INFORMATION

MHRA/CHM ADVICE: DIRECT-ACTING ANTIVIRALS TO TREAT CHRONIC HEPATITIS C: RISK OF INTERACTION WITH VITAMIN K ANTAGONISTS AND CHANGES IN INR (JANUARY 2017)

An EU-wide review has identified that changes in liver function, secondary to hepatitis C treatment with direct-acting antivirals, may affect the efficacy of vitamin K antagonists; the MHRA has advised that INR should be monitored closely in patients receiving concomitant treatment.

MHRA/CHM ADVICE: DIRECT-ACTING ANTIVIRAL INTERFERON-FREE REGIMENS TO TREAT CHRONIC HEPATITIS C: RISK OF HEPATITIS B REACTIVATION (JANUARY 2017)

An EU-wide review has concluded that direct-acting antiviral interferon-free regimens for chronic hepatitis C can cause hepatitis B reactivation in patients co-infected with hepatitis B and C viruses; the MHRA recommends to screen patients for hepatitis B before starting treatment—patients infected with both hepatitis B and C viruses must be monitored and managed according to current clinical guidelines.

- CONTRA-INDICATIONS
  - HIV co-infection without suppressive antiretroviral therapy
- CAUTIONS
  - Retreatment—efficacy not established
- INTERACTIONS → Appendix 1: HIV-protease inhibitors, ombitasvir, paritaprevir
- SIDE-EFFECTS
  - Common or very common Anaemia • asthenia • fatigue • insomnia • nausea
  - Frequency not known Elevated liver enzymes • transient hyperbilirubinemia
Chronic hepatitis C

**SIDE-EFFECTS, FURTHER INFORMATION**

Side-effects listed are reported when ombitasvir with paritaprevir and ritonavir is used in combination with dasabuvir, or with or without ribavirin.

- **CONCEPTION AND CONTRACEPTION** For women of child-bearing potential, exclude pregnancy before initiation of treatment; effective contraception should be used during treatment.

- **PREGNANCY** Manufacturer advises avoid—toxicity in animal studies.

- **BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.

- **HEPATIC IMPAIRMENT** Manufacturer advises avoid in moderate or severe impairment.

- **PATIENT AND CARER ADVICE**
  - **Missed doses**
    - If a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **NICE technology appraisals (TAs)**
    - Ombitasvir with paritaprevir and ritonavir with or without dasabuvir for treating chronic hepatitis C NICE TA365
    - Ombitasvir with paritaprevir and ritonavir with or without dasabuvir is recommended, within its marketing authorisation, as an option for treating genotype 1 or 4 chronic hepatitis C in adults, only if the manufacturer provides it with the discount agreed in the patient access scheme.
    - [www.nice.org.uk/guidance/ta365](http://www.nice.org.uk/guidance/ta365)

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Tablet**
    - **CAUTIONARY AND ADVISORY LABELS** 21, 25
    - **EXCIPIENTS:** May contain Propylene glycol
    - **Viekirax** (AbbVie Ltd) ▼
      - Ombitasvir 12.5 mg, Ritonavir 50 mg, Paritaprevir 75 mg
    - **Viekirax ED**
    - **CAPSULES**
    - **INHALATION OF AEROSOL, OR BY INHALATION OF NEBULISED SOLUTION**
    - **Life-threatening RSV, parainfluenza virus, and adenovirus infection in immunocompromised children (administered on expert advice)**
    - **BY INTRAVENOUS INFUSION**
    - **Child:** 33 mg/kg for 1 dose, to be administered over 15 minutes, then 16 mg/kg every 6 hours for 4 days, then 8 mg/kg every 8 hours for 3 days

- **ANTIVIRALS ▶ NUCLEOSIDE ANALOGUES**

**Ribavirin** (Tribavirin)

- **INDICATIONS AND DOSE**
  - **Bronchiolitis**
    - **BY INHALATION OF AEROSOL, OR BY INHALATION OF NEBULISED SOLUTION**
    - **Child 1–23 months:** Inhale a solution containing 20 mg/mL for 12–18 hours for at least 3 days, maximum of 7 days, to be administered via small particle aerosol generator
  - **Life-threatening RSV, parainfluenza virus, and adenovirus infection in immunocompromised children**
    - **administered on expert advice**
  - **BY INTRAVENOUS INFUSION**
  - **Child:** 33 mg/kg for 1 dose, to be administered over 15 minutes, then 16 mg/kg every 6 hours for 4 days, then 8 mg/kg every 8 hours for 3 days

**COPEGUS ▶ TABLETS**

- **Chronic hepatitis C** (in combination with direct acting antivirals, or interferon alfa 2a, or peginterferon alfa 2a with or without direct acting antivirals)
  - **BY MOUTH**
  - **Adult** (body-weight up to 75 kg): 400 mg, dose to be taken in the morning and 600 mg, dose to be taken in the evening
  - **Adult** (body-weight 75 kg and above): 600 mg twice daily

**Chronic hepatitis C (in combination with peginterferon alfa 2b with or without direct acting antivirals)**

- **BY MOUTH**
  - **Adult** (body-weight up to 65 kg): 400 mg twice daily
  - **Adult** (body-weight 65–80 kg): 400 mg, to be taken in the morning and 600 mg, to be taken in the evening
  - **Adult** (body-weight 81–105 kg): 600 mg twice daily
  - **Adult** (body-weight 106 kg and above): 600 mg, to be taken in the morning and 800 mg, to be taken in the evening

**Chronic hepatitis C genotype 2 or 3 (not previously treated), or patients infected with HIV and hepatitis C (in combination with peginterferon alfa)**

- **BY MOUTH**
  - **Adult:** Usual dose 400 mg twice daily

**REBETOL ▶ CAPSULES**

- **Chronic hepatitis C (in combination with interferon alfa 2b, or peginterferon alfa 2b with or without boceprevir)**
  - **BY MOUTH**
  - **Adult** (body-weight up to 65 kg): 400 mg twice daily
  - **Adult** (body-weight 65–80 kg): 400 mg, dose to be taken in the morning and 600 mg, dose to be taken in the evening
  - **Adult** (body-weight 81–104 kg): 600 mg twice daily
  - **Adult** (body-weight 105 kg and above): 600 mg, dose to be taken in the morning and 800 mg, dose to be taken in the evening

**REBETOL ▶ ORAL SOLUTION**

- **Chronic hepatitis C (in combination with interferon alfa 2b, or peginterferon alfa 2b with or without boceprevir)**
  - **BY MOUTH**
  - **Adult** (body-weight up to 65 kg): 400 mg twice daily
  - **Adult** (body-weight 65–80 kg): 400 mg daily, dose to be taken in the morning and 600 mg daily, dose to be taken in the evening
  - **Adult** (body-weight 81–104 kg): 600 mg twice daily
  - **Adult** (body-weight 105 kg and above): 600 mg daily, dose to be taken in the morning and 800 mg daily, dose to be taken in the evening

- **UNLICENSED USE** Inhalation licensed for use in children (age range not specified by manufacturer). Intravenous preparation not licensed.

- **CONTRA-INDICATIONS**
  - With systemic use Active severe psychiatric condition (in children) - autoimmune disease (in children) - autoimmune hepatitis (in children) - consult product literature for specific contra-indications when ribavirin above used in combination with other medicinal products - haemoglobinopathies - history of severe psychiatric condition (in children) - severe cardiac disease (in adults) - severe debilitating medical conditions - severe, uncontrolled cardiac disease in children with chronic hepatitis C - unstable or uncontrolled cardiac disease in previous 6 months (in adults)

- **CAUTIONS**
  - When used by inhalation Maintain standard supportive respiratory and fluid management therapy
  - With systemic use Anaemia (haemoglobin concentration should be monitored during the treatment and corrective action taken) (in adults) - cardiac disease (assessment including ECG recommended before and during treatment—discontinue if deterioration) - consult product literature for specific cautions when ribavirin above used in combination with other medicinal products - gout (in adults) - haemolysis (haemoglobin concentration should be monitored during the treatment and corrective action taken) (in adults) - patients with a transplant—risk of rejection - risk of growth retardation in children, the reversibility of which is uncertain—if possible, consider starting treatment after pubertal growth spurt - severe
dental disorders (in adults) • severe ocular disorders (in adults) • severe periodontal disorders (in adults) • severe psychiatric effects (in adults)

- **INTERACTIONS** → Appendix 1: ribavirin
- **SIDE-EFFECTS**
  - When used by inhalation Bacterial pneumonia • haemolysis • non-specific anaemia • pneumothorax • worsening respiration
  - With oral use Abdominal pain • abnormal dreams • acne • alopecia • angina • anorexia • anxiety • aplastic anaemia • arrhythmias • arthralgia • ataxia • bipolar disorders • breast pain • cardiomyopathy • cerebral haemorrhage • cerebral ischaemia • changes in blood pressure • cholecystitis • chest pain • colitis • constipation • cough • dehydration • depression • diabetes • diarrhoea • dizziness • dry eyes • dry mouth • dry skin • dyspepsia • dysphagia • dyspnoea • earache • endocarditis • eye pain • flatulence • flushing • gastrointestinal bleeding • gingival bleeding • gingivitis • glossitis • haemolytic anaemia (anaemia may be improved by epoetin) • headache • hearing impairment • hearing loss • hyperaesthesia • hyperglycaemia • hypertonia • hypertensive glomerulonephritis • impotence • injury • inflammation • influenza-like symptoms • interstitial pneumonitis • leucopenia • lymphadenopathy • malaise • mania • menstrual disturbance • micturition disorders • mouth ulcers • musculoskeletal pain • myalgia • myocardial infarction • myositis • nasal congestion • nausea • neutropenia • optic neureopathy • oral candidiasis • palpitation • pancreatitis • paraesthesia • peptic ulcer • pericarditis • peripheral neuropathy • peripheral oedema • photosensitivity • prostatitis • pruritus • psoriasis • psychotic disorders • pulmonary embolism • rash • renal failure • respiratory infections • retinal detachment • retinal haemorrhage • rhabdomyolysis • rheumatoid arthritis • sarcoidosis • seizures • sexual dysfunction • sinus congestion • skin discoloration • sleep disturbances • sore throat • Stevens–Johnson syndrome • stomatitis • suicidal ideation • syncope • systemic lupus erythematosus • tachycardia • taste disturbance • thrombocytopenia • thrombocytopenia purpura • thyroid disorders • tinnitus • tongue pigmentation • toxic epidermal necrolysis • tremor • urinary tract infections • vacuolitis • vision loss • visual disturbances • vomiting • weight loss • wheezing

**SIDE-EFFECTS, FURTHER INFORMATION**
Side effects listed are reported when oral ribavirin is used in combination with peginterferon alfa or interferon alfa, consult product literature for details.

- **CONCEPTION AND CONTRACEPTION**
  - With systemic use Exclude pregnancy before treatment in females of childbearing age. Effective contraception essential during treatment and for 4 months after treatment in females and for 7 months after treatment in males of childbearing age. Routine monthly pregnancy tests recommended. Condoms must be used if partner of male patient is pregnant (ribavirin excreted in semen).
  - When used by inhalation Women planning pregnancy should avoid exposure to aerosol.
- **PREGNANCY** Avoid; teratogenicity in animal studies.
- **BREAST FEEDING** Avoid—no information available.
- **HEPATIC IMPAIRMENT** No dosage adjustment required. Avoid oral ribavirin in severe hepatic dysfunction or decompensated cirrhosis.
- **RENAL IMPAIRMENT** Plasma-ribavirin concentration increased.
  - In adults Manufacturer advises avoid oral ribavirin unless essential if eGFR less than 50 mL/minute/1.73 m²—monitor haemoglobin concentration closely.
  - In children Manufacturer advises avoid oral ribavirin if estimated glomerular filtration rate less than 30 mL/minute/1.73 m²—monitor haemoglobin concentration closely. Manufacturer advises use intravenous preparation with caution if estimated glomerular filtration rate less than 30 mL/minute/1.73 m².
- **MONITORING REQUIREMENTS**
  - When used by inhalation Monitor electrolytes closely. Monitor equipment for precipitation.
  - With systemic use Determine full blood count, platelets, electrolytes, glucose, serum creatinine, liver function tests and uric acid before starting treatment and then on weeks 2 and 4 of treatment, then as indicated clinically—adjust dose if adverse reactions or laboratory abnormalities develop (consult product literature).
- **PRESCRIBING AND DISPENSING INFORMATION** Flavours of oral liquid formulations may include bubble-gum.
- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **NICE technology appraisals (TAs)**
    - Peginterferon alfa and ribavirin for mild chronic hepatitis C (August 2006 and September 2010) NICE TA200
      The combination of peginterferon alfa and ribavirin can be used for treating mild chronic hepatitis C in patients over 18 years. Alternatively, treatment can be delayed until the disease has reached a moderate stage (‘watchful waiting’). www.nice.org.uk/TA200
    - Peginterferon alfa, interferon alfa, and ribavirin for moderate to severe chronic hepatitis C (January 2004 and September 2010) NICE TA200
      The combination of peginterferon alfa and ribavirin should be used for treating moderate to severe chronic hepatitis C in patients aged over 18 years:
      - not previously treated with interferon alfa or peginterferon alfa;
      - treated previously with interferon alfa alone or in combination with ribavirin;
      - whose condition did not respond to peginterferon alfa alone or to a combination of peginterferon alfa and ribavirin, or responded but subsequently relapsed;
      - co-infected with HIV.
      Peginterferon alfa alone should be used if ribavirin is contra-indicated or not tolerated. Interferon alfa for either monotherapy or combined therapy should be used only if neutropenia and thrombocytopenia are a particular risk. Patients receiving interferon alfa may be switched to peginterferon alfa. www.nice.org.uk/TA200
  - **LESS SUITABLE FOR PRESCRIBING** Ribavirin inhalation is less suitable for prescribing.
- **MEDITICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Solution for Injection**
    - **Virazole** (Meda Pharmaceuticals Ltd)
      - Ribavirin 100 mg per 1 ml Virazole 12ml solution for injection vials | 5 vials (Pom) £360.00
  - **Oral solution**
    - **CAUTIONARY AND ADVISORY LABELS** 21
      - **Rebetol** (Merck Sharp & Dohme Ltd)
        - Ribavirin 40 mg per 1 ml Rebetol 40mg/ml oral solution | 100 ml (Pom) £67.08
  - **Tablet**
    - **CAUTIONARY AND ADVISORY LABELS** 21
      - **Copegus** (Roche Products Ltd)
        - Ribavirin 200 mg Copegus 200mg tablets | 112 tablet (Pom) £233.58 | 168 tablet (Pom) £350.37
        - Ribavirin 400 mg Copegus 400mg tablets | 56 tablet (Pom) £233.58
**Capsule**

CAUTIONARY AND ADVISORY LABELS  21

▶ Rebetol (Merck Sharp & Dohme Ltd)

Ribavirin 200 mg Rebetol 200mg capsules | 84 capsule (POM) £160.69 | 140 capsule (POM) £267.81 | 168 capsule (POM) £221.38

**ANTIVIRALS** ▶ NUCLEOTIDE ANALOGUES

**Sofosbuvir** 07-Mar-2017

**INDICATIONS AND DOSE**

In combination with ribavirin (Copegus®, with or without peginterferon alfa, for chronic hepatitis C infection of genotypes 1, 3, 4, 5, or 6 in patients with compensated liver disease | In combination with ribavirin (Copegus®) for chronic hepatitis C infection of genotype 2 in patients with compensated liver disease | In combination with daclatasvir for chronic hepatitis C infection of genotype 1, 3, or 4

▶ BY MOUTH

▶ Adult: 400 mg once daily, for duration of treatment consult product literature

**IMPORTANT SAFETY INFORMATION**

MHRA/CHM ADVICE: DIRECT-ACTING ANTIVIRALS TO TREAT CHRONIC HEPATITIS C: RISK OF INTERACTION WITH VITAMIN K ANTAGONISTS AND CHANGES IN INR (JANUARY 2017)

An EU-wide review has identified that changes in liver function, secondary to hepatitis C treatment with direct-acting antivirals, may affect the efficacy of vitamin K antagonists; the MHRA has advised that INR should be monitored closely in patients receiving concomitant treatment.

MHRA/CHM ADVICE: DIRECT-ACTING ANTIVIRAL INTERFERON-FREE REGIMENS TO TREAT CHRONIC HEPATITIS C: RISK OF HEPATITIS B REACTIVATION (JANUARY 2017)

An EU-wide review has concluded that direct-acting antiviral interferon-free regimens for chronic hepatitis C can cause hepatitis B reactivation in patients co-infected with hepatitis B and C viruses; the MHRA recommends to screen patients for hepatitis B before starting treatment—patients infected with both hepatitis B and C viruses must be monitored and managed according to current clinical guidelines.

**CAUTIONS**

CAUTIONS, FURTHER INFORMATION

In chronic hepatitis C of genotype 1, 4, 5, or 6, only use sofosbuvir with ribavirin in those with intolerance or contra-indications to peginterferon alfa who require urgent treatment.

**INTERACTIONS** ▶ Appendix 1: sofosbuvir

**SIDE-EFFECTS**

▶ Common or very common Hyperbilirubinaemia


SIDE-EFFECTS, FURTHER INFORMATION

Side-effects listed are reported when sofosbuvir is used in combination with ribavirin or with ribavirin and peginterferon alfa.

▶ PREGNANCY Manufacturer advises avoid.

▶ BREAST FEEDING Manufacturer advises avoid—present in milk in animal studies.

**RENAL IMPAIRMENT** Safety and efficacy not established if eGFR less than 30 mL/minute/1.73 m²—accumulation may occur.

**PRESCRIBING AND DISPENSING INFORMATION** Dispense in original container (contains desiccant).

**PATIENT AND CARER ADVICE**

Missed doses

If a dose is more than 18 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

**NATIONAL FUNDING/ACCESS DECISIONS**

NICE technology appraisals (TAs)

▶ Sofosbuvir for treating chronic hepatitis C (February 2015) NICE TA330

Sofosbuvir in combination with peginterferon alfa and ribavirin is an option for treating adults with chronic hepatitis C infection:

- of genotype 1
- of genotype 3 with cirrhosis (treatment naive patients)
- of genotype 3 that has not adequately responded to interferon-based treatment
- of genotype 4, 5, or 6 with cirrhosis

Sofosbuvir in combination with ribavirin is an option for treating adults with chronic hepatitis C infection:

- of genotype 2 who are intolerant to or ineligible for interferon (treatment naive patients)
- of genotype 2 that has not adequately responded to interferon-based treatment
- of genotype 3 with cirrhosis who are intolerant to or ineligible for interferon (treatment naive patients)
- of genotype 3 with cirrhosis that has not adequately responded to interferon-based treatment

www.nice.org.uk/TA330

▶ Sofosbuvir for treating chronic hepatitis C (February 2015) NICE TA330

Sofosbuvir in combination with ribavirin is not recommended for the treatment of adults with chronic hepatitis C infection of genotypes 1, 4, 5, or 6.

www.nice.org.uk/TA330

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (June 2014) that sofosbuvir (Sovaldi®) is accepted for use within NHS Scotland for the treatment of chronic hepatitis C infection of genotypes 1 to 6; its use in combination with ribavirin as dual therapy for chronic hepatitis C infection of either genotype 2 (in treatment naive patients) or genotype 3 is restricted to those who cannot use peginterferon alfa because of intolerance or contra-indications.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

CAUTIONARY AND ADVISORY LABELS  21, 25

▶ Sovaldi (Gilead Sciences International Ltd) ▼

Sofosbuvir 400 mg | Sovaldi 400mg tablets | 28 tablet (POM) £11,660.98
Sofosbuvir with ledipasvir 12-Apr-2017

The properties listed below are those particular to the combination only. For the properties of the components please consider, sofosbuvir p. 595.

- **DRUG ACTION** Sofosbuvir is a nucleotide analogue inhibitor and ledipasvir is an HCV inhibitor; they reduce viral load by inhibiting hepatitis C virus RNA replication.

- **INDICATIONS AND DOSE**
  - Chronic hepatitis C of genotypes 1, 4, 5 or 6 in patients with or without compensated cirrhosis (with or without ribavirin) | Chronic hepatitis C of genotypes 1, 4, 5 or 6 in patients with or without compensated cirrhosis (with or without ribavirin) | Chronic hepatitis C of genotypes 1, 4, 5 or 6 in patients with or without compensated cirrhosis, irrespective of transplant status (with or without ribavirin) | Chronic hepatitis C of genotype 3 in patients with compensated cirrhosis or prior treatment failure

- **SIDE-EFFECTS**
  - Common or very common: Headache, malaise

- **DOSE ADJUSTMENTS DUE TO INTERACTIONS**
  - Manufacturer advises reduce dose of concurrent proton pump inhibitor if above a dose comparable to omeprazole 20 mg; take at the same time as sofosbuvir with ledipasvir.

| CAUTIONS | Retreatment following treatment failure—efficacy not established |
| INTERACTIONS | Appendix 1: ledipasvir, sofosbuvir |
| PRESCRIBING AND DISPENSING INFORMATION | Dispense in original container (contains desiccant). |
| PATIENT AND CARER ADVICE | Vomiting | Mismeasured doses |
  - If vomiting occurs within 5 hours of administration, an additional dose should be taken. |
  - If a dose is more than 18 hours late, the missed dose should not be taken and the next dose should be taken at the normal time. |

- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **NICE technology appraisals (TAs)**
    - Ledipasvir with sofosbuvir for the treatment of chronic hepatitis C (November 2015) NICE TA363
      - Ledipasvir with sofosbuvir is recommended as an option for treating adults with chronic hepatitis C infection: |
      - of genotype 1 without cirrhosis (treatment naive patients)—8 weeks’ treatment |
      - of genotype 1 or 4 with cirrhosis (treatment naive patients)—12 weeks’ treatment |
      - of genotype 1 or 4 without cirrhosis (or with cirrhosis but only if the person has a low risk of the disease getting worse) that has not responded adequately to previous treatment—12 weeks’ treatment |
    - In addition, ledipasvir with sofosbuvir is only recommended in patients with cirrhosis for the durations mentioned above if the following criteria are met:
      - Child-Pugh class A |
      - platelet count of 75 000/mm³ or more |
      - no features of portal hypertension |
      - no history of an HCV-associated decompensation episode |
      - not previously treated with an NS5A inhibitor

Patients whose treatment with ledipasvir with sofosbuvir is not recommended in this NICE guidance, but was started within the NHS before this guidance was published, should be able to continue treatment until they and their clinician consider it appropriate to stop.

- **Scottish Medicines Consortium (SMC) Decisions**
  - The Scottish Medicines Consortium has advised (March and September 2015) that Harvoni® (ledipasvir with sofosbuvir) is accepted for restricted use within NHS Scotland for the treatment of chronic hepatitis C infection of genotypes 1, 3 and 4 only, in patients who are ineligible for, or unable to tolerate, interferon.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

<table>
<thead>
<tr>
<th>Tablet</th>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>25</th>
</tr>
</thead>
<tbody>
<tr>
<td>Harvoni (Gilead Sciences International Ltd)</td>
<td>28 tablet</td>
<td>£12,993.33</td>
</tr>
</tbody>
</table>

Sofosbuvir with velpatasvir 24-Apr-2017

The properties listed below are those particular to the combination only. For the properties of the components please consider, sofosbuvir p. 595.

- **DRUG ACTION** Sofosbuvir is a nucleotide analogue inhibitor and velpatasvir is an HCV inhibitor; they reduce viral load by inhibiting hepatitis C virus RNA replication.

- **INDICATIONS AND DOSE**
  - Chronic hepatitis C infection, with or without ribavirin (initiated by a specialist)
    - BY MOUTH |
    - Adult: 400/100 mg once daily for 12 weeks (may extend to 24 weeks in some circumstances—consult product literature) |

- **DOSE ADJUSTMENTS DUE TO INTERACTIONS**
  - Manufacturer advises reduce dose of concurrent H₂-receptor antagonist if above a dose comparable to famotidine 40 mg twice daily. |
  - Manufacturer advises reduce dose of concurrent proton pump inhibitor if above a dose comparable to omeprazole 20 mg; take at the same time as sofosbuvir with ledipasvir.

- **DOSE EQUIVALENCE AND CONVERSION**
  - Dose expressed as x/y mg sofosbuvir/velpatasvir.

- **CAUTIONS**
  - Hepatitis B co-infection |

- **INTERACTIONS**
  - Appendix 1: sofosbuvir, velpatasvir |

- **PATIENT AND CARER ADVICE**
  - Vomiting | Manufacturer advises if vomiting occurs within 5 hours of administration, an additional dose should be taken. |
  - Missed doses | If a dose is more than 18 hours late, the missed dose should not be taken and the next dose should be taken at the normal time. |

- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **NICE technology appraisals (TAs)**
    - Sofosbuvir–velpatasvir for treating chronic hepatitis C (January 2017) NICE TA430
      - Sofosbuvir with velpatasvir is recommended as an option for treating chronic hepatitis C infection, if the following criteria are met:
        - of genotype 1, 3, 4, 5 or 6 with or without cirrhosis (previously treated or treatment naive patients); |
        - of genotype 2 with cirrhosis (previously treated or treatment naive patients); |
        - of genotype 2 without cirrhosis (treatment naive patients), only if interferon not suitable or not tolerated, or without cirrhosis (previously treated patients); |

- **Scottish Medicines Consortium (SMC) Decisions**
  - The Scottish Medicines Consortium has advised (March and September 2015) that Harvoni® (ledipasvir with sofosbuvir) is accepted for restricted use within NHS Scotland for the treatment of chronic hepatitis C infection of genotypes 1, 3 and 4 only, in patients who are ineligible for, or unable to tolerate, interferon.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

<table>
<thead>
<tr>
<th>Tablet</th>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>25</th>
</tr>
</thead>
<tbody>
<tr>
<td>Harvoni (Gilead Sciences International Ltd)</td>
<td>28 tablet</td>
<td>£12,993.33</td>
</tr>
</tbody>
</table>

- **INTERACTIONS**
  - Appendix 1: sofosbuvir, velpatasvir |

- **PATIENT AND CARER ADVICE**
  - Vomiting | Manufacturer advises if vomiting occurs within 3 hours of administration, an additional dose should be taken. |

- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **NICE technology appraisals (TAs)**
    - Sofosbuvir–velpatasvir for treating chronic hepatitis C (January 2017) NICE TA430
      - Sofosbuvir with velpatasvir is recommended as an option for treating chronic hepatitis C infection, if the following criteria are met:
        - of genotype 1, 3, 4, 5 or 6 with or without cirrhosis (previously treated or treatment naive patients); |
        - of genotype 2 with cirrhosis (previously treated or treatment naive patients); |
        - of genotype 2 without cirrhosis (treatment naive patients), only if interferon not suitable or not tolerated, or without cirrhosis (previously treated patients); |
This is contingent on the manufacturer providing the drug with the discount agreed in the simple discount agreement.

Patients whose treatment was started within the NHS before this guidance was published, should continue treatment until they and their clinician consider it appropriate to stop.

www.nice.org.uk/guidance/ta430

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium (SMC) has advised (October 2016) that Epclusa® (sofosbuvir with velpatasvir) is accepted for restricted use within NHS Scotland for the treatment of chronic hepatitis C infection of genotype 3 only.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

CAUTIONARY AND ADVISORY LABELS 25

- **Epclusa** (Gilead Sciences International Ltd) ▼
  - Velpatasvir 100 mg, Sofosbuvir 400 mg
  - *Epclusa* 400mg/100mg tablets | 28 tablet [POM] £12,993.33

**ANTIVIRALS › PROTEASE INHIBITORS**

**Simeprevir**

**INDICATIONS AND DOSE**

In combination with ribavirin and peginterferon alfa for chronic hepatitis C infection of genotype 1 or 4

In combination with sofosbuvir (with or without ribavirin) for urgent treatment of chronic hepatitis C infection of genotype 1 or 4 when peginterferon alfa cannot be used because of intolerance or contra-indications

- **BY MOUTH**
- **Adult**: 150 mg once daily (for duration of treatment consult product literature)

**IMPORTANT SAFETY INFORMATION**

**MHRA/CHM ADVICE: DIRECT-ACTING ANTI-VIRALS TO TREAT CHRONIC HEPATITIS C: RISK OF INTERACTION WITH VITAMIN K ANTAGONISTS AND CHANGES IN INR (JANUARY 2017)**

An EU-wide review has identified that changes in liver function, secondary to hepatitis C treatment with direct-acting antivirals, may affect the efficacy of vitamin K antagonists; the MHRA has advised that INR should be monitored closely in patients receiving concomitant treatment.

**MHRA/CHM ADVICE: DIRECT-ACTING ANTIVIRAL INTERFERON-FREE REGIMENS TO TREAT CHRONIC HEPATITIS C: RISK OF HEPATITIS B REACTIVATION (JANUARY 2017)**

An EU-wide review has concluded that direct-acting antiviral interferon-free regimens for chronic hepatitis C can cause hepatitis B reactivation in patients co-infected with hepatitis B and C viruses; the MHRA recommends to screen patients for hepatitis B before starting treatment—patients infected with both hepatitis B and C viruses must be monitored and managed according to current clinical guidelines.

**CAUTIONS**

Consider alternative treatment in presence of NS3 Q80K polymorphism—efficacy of simeprevir is reduced—patients of East Asian origin

**INTERACTIONS** → Appendix 1: simeprevir

**SIDE-EFFECTS**

Constipation • dyspepsia • fatigue (in combination with sofosbuvir) • headache (in combination with sofosbuvir) • hepatic decompensation • hepatic failure • insomnia (in combination with sofosbuvir) • nausea • photosensitivity • pruritus • raised bilirubin concentration • rash

**SIDE-EFFECTS, FURTHER INFORMATION**

- Rash  Monitor for deterioration if mild or moderate; discontinue if severe.
- **CONCEPTION AND CONTRACEPTION**  Effective contraception essential during treatment.
- **PREGNANCY**  Manufacturer advises use only if potential benefit outweighs risk—toxicity in animal studies.
- **BREAST FEEDING**  Manufacturer advises avoid—present in plasma of breast-fed animals.
- **HEPATIC IMPAIRMENT**  Manufacturer advises caution in moderate to severe impairment—elimination reduced in severe impairment. Manufacturer advises caution in decompensated cirrhosis—elimination reduced in severe impairment.
- **RENAL IMPAIRMENT**  Manufacturer advises caution if eGFR less than 30 ml/minute/1.73 m²—elimination may be reduced.
- **PRE-TREATMENT SCREENING**  Test for NS3 Q80K polymorphism before combination treatment with ribavirin and peginterferon alfa in patients with chronic hepatitis C infection of genotype 1a. Consider testing for NS3 Q80K polymorphism before combination treatment with sofosbuvir (with or without ribavirin) in patients with chronic hepatitis C infection of genotype 1a.

**PREGNANCY**

- **MATERNAL**
- **FETAL**
- **NEONATE**

**BREAST FEEDING**

- **FETAL**
- **NEONATE**

**SIDE-EFFECTS, FURTHER INFORMATION**

**CAPSULES**

**SIDE-EFFECTS, FURTHER INFORMATION**

**SIDE-EFFECTS, FURTHER INFORMATION**

**SIDE-EFFECTS, FURTHER INFORMATION**
Dasabuvir

**DRUG ACTION** Dasabuvir is a non-nucleoside inhibitor of hepatitis C virus polymerase NS5B, which is an essential component of the hepatitis C virus replication process.

**INDICATIONS AND DOSE**

**Chronic hepatitis C infection of genotype 1, in combination with other antiviral drugs (ombitasvir with paritaprevir and ritonavir, with or without ribavirin)**

- **BY MOUTH**
  - Adult: 250 mg twice daily for details of duration of treatment, consult product literature, dose to be taken in the morning and evening

**IMPORTANT SAFETY INFORMATION**

MHRA/CHM ADVICE: DIRECT-ACTING ANTIVIRALS TO TREAT CHRONIC HEPATITIS C: RISK OF INTERACTION WITH VITAMIN K ANTAGONISTS AND CHANGES IN INR (JANUARY 2017)

A EU-wide review has identified that changes in liver function, secondary to hepatitis C treatment with direct-acting antivirals, may affect the efficacy of vitamin K antagonists; the MHRA has advised that INR should be monitored closely in patients receiving concomitant treatment.

MHRA/CHM ADVICE: DIRECT-ACTING ANTIVIRAL INTERFERON-FREE REGIMENS TO TREAT CHRONIC HEPATITIS C: RISK OF HEPATITIS B REACTIVATION (JANUARY 2017)

An EU-wide review has concluded that direct-acting antiviral interferon-free regimens for chronic hepatitis C can cause hepatitis B reactivation in patients co-infected with hepatitis B and C viruses; the MHRA recommends to screen patients for hepatitis B before starting treatment—patients infected with both hepatitis B and C viruses must be monitored and managed according to current clinical guidelines.

**CONTRA-INDICATIONS** HIV co-infection without suppressive antiretroviral therapy

**CAUTIONS** Retreatment—efficacy not established

**INTERACTIONS**

- **APPENDIX 1: dasabuvir**
  - **SIDE-EFFECTS**
    - **Common or very common** Anaemia · asthenia · fatigue · insomnia · nausea
    - **Frequency not known** Elevated liver enzymes
  - **SIDE-EFFECTS, FURTHER INFORMATION**
    - Side-effects listed are reported when dasabuvir is used in combination with Viekirax® (ombitasvir with paritaprevir and ritonavir), with or without ribavirin.
  - **PREGNANCY** Manufacturer advises avoid—no information available.
  - **BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.
  - **HEPATIC IMPAIRMENT** Manufacturer advises avoid in moderate to severe impairment.
  - **PATIENT AND CARER ADVICE**
    - **Missed doses** If a dose is more than 6 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.
  - **NATIONAL FUNDING/ACCESS DECISIONS**
    - **NICE technology appraisals (TAs)**
      - Ombitasvir with paritaprevir and ritonavir with or without dasabuvir for treating chronic hepatitis C (November 2015) NICE TA365
        - Dasabuvir, in combination with ombitasvir with paritaprevir and ritonavir p. 592, is recommended, within its marketing authorisation, as an option for treating genotype 1 or 4 chronic hepatitis C in adults only if the manufacturer provides it with the discount agreed in the patient access scheme. [www.nice.org.uk/guidance/ta365](http://www.nice.org.uk/guidance/ta365)

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS 3, 21, 25**
  - **Exviera (AbbVie Ltd)**
    - Dasabuvir (as Dasabuvir sodium monohydrate) 250 mg Exviera 25mg tablets | 56 tablet [Podi] £933.33

6.3 Herpesvirus infections

**Herpesvirus infections**

**Herpes simplex and varicella–zoster infection**

The two most important herpesvirus pathogens are herpes simplex virus (herpesvirus hominis) and varicella–zoster virus.

**Herpes simplex infections**

Herpes infection of the mouth and lips and in the eye is generally associated with herpes simplex virus serotype 1 (HSV–1); other areas of the skin may also be infected, especially in immunodeficiency. Genital infection is most often associated with HSV-2 and also HSV–1. Treatment of herpes simplex infection should start as early as possible and usually within 5 days of the appearance of the infection.

In individuals with good immune function, mild infection of the eye (ocular herpes) and of the lips (herpes labialis or cold sores) is treated with a topical antiviral drug. Primary herpetic gingivostomatitis is managed by changes to diet and with analgesics. Severe infection, neonatal herpes infection or infection in immunocompromised individuals requires treatment with a systemic antiviral drug. Primary or recurrent genital herpes simplex infection is treated with an antiviral drug given by mouth. Persistence of a lesion or recurrence in an immunocompromised patient may signal the development of resistance.

Specialist advice should be sought for systemic treatment of herpes simplex infection in pregnancy.

**Varicella-zoster infections**

Regardless of immune function and the use of any immunoglobulins, neonates with chickenpox should be treated with a parenteral antiviral to reduce the risk of severe disease. Oral therapy in children is not recommended as absorption is variable. Chickenpox in otherwise healthy children between 1 month and 12 years is usually mild and antiviral treatment is not usually required.

Chickenpox is more severe in adolescents and adults than in children; antiviral treatment started within 24 hours of the onset of rash may reduce the duration and severity of symptoms in otherwise healthy adults and adolescents.

Antiviral treatment is generally recommended in immunocompromised patients and those at special risk (e.g. because of severe cardiovascular or respiratory disease or chronic skin disorder); in such cases, an antiviral is given for 10 days with at least 7 days of parenteral treatment.

Pregnant women who develop severe chickenpox may be at risk of complications, especially varicella pneumonia. Specialist advice should be sought for the treatment of chickenpox during pregnancy.

Those who have been exposed to chickenpox and are at special risk of complications may require prophylaxis with varicella–zoster immunoglobulin (see under Disease Specific Immunoglobulins).

In herpes zoster (shingles) systemic antiviral treatment can reduce the severity and duration of pain, reduce
complications, and reduce viral shedding. Treatment with the antiviral should be started within 72 hours of the onset of rash and is usually continued for 7–10 days. Immunocompromised patients at high risk of disseminated or severe infection should be treated with a parenteral antiviral drug.

Chronic pain which persists after the rash has healed (postherpetic neuralgia) requires specific management.

**Choice**

Aciclovir below is active against herpesviruses but does not eradicate them. Uses of aciclovir include systemic treatment of varicella–zoster and the systemic and topical treatment of herpes simplex infections of the skin and mucous membranes. It is used by mouth for severe herpetic stomatitis. Aciclovir eye ointment is used for herpes simplex infections of the eye; it is combined with systemic treatment for ophthalmic zoster.

Famciclovir p. 601, a prodrug of penciclovir, is similar to aciclovir and is licensed for use in herpes zoster and genital herpes.

Valaciclovir p. 602 is an ester of aciclovir, licensed for herpes zoster and herpes simplex infections of the skin and mucous membranes (including genital herpes); it is also licensed for preventing cytomegalovirus disease following solid organ transplantation. Famciclovir or valaciclovir are suitable alternatives to aciclovir for oral lesions associated with herpes zoster. Valaciclovir once daily may reduce the risk of transmitting genital herpes to heterosexual partners—specialist advice should be sought.

Foscarnet sodium p. 604 is used for mucocutaneous herpes simplex virus infection unresponsive to aciclovir in immunocompromised patients; it is toxic and can cause renal impairment.

Inosine pranobex below has been used by mouth for herpes simplex infections; its effectiveness remains unproven.

**Cytomegalovirus infection**

Ganciclovir p. 603 is related to aciclovir but it is more active against cytomegalovirus (CMV); it is also much more toxic than aciclovir and should therefore be prescribed only when the potential benefit outweighs the risks. Ganciclovir is administered by intravenous infusion for the initial treatment of CMV infection. Ganciclovir causes profound myelosuppression when given with zidovudine p. 617; the two should not normally be given together particularly during initial ganciclovir therapy. The likelihood of ganciclovir resistance increases in patients with a high viral load or in those who receive the drug over a long duration.

Valaciclovir is licensed for prevention of cytomegalovirus disease following renal transplantation.

Valganciclovir p. 603 is an ester of ganciclovir which is licensed for the initial treatment and maintenance treatment of CMV retinitis in AIDS patients. Valganciclovir is also licensed for preventing CMV disease following solid organ transplantation from a cytomegalovirus-positive donor.

Foscarnet sodium is also active against cytomegalovirus; it is toxic and can cause renal impairment.

See local treatment of CMV retinitis.

**ANTIVIRALS > INOSINE COMPLEXES**

**Inosine pranobex**

(Inosine acedoben dimepranol)

**INDICATIONS AND DOSE**

**Muco-cutaneous herpes simplex**

► **BY MOUTH**

► Adult: 1 g 4 times a day for 7–14 days

**Adjunctive treatment of genital warts**

► **BY MOUTH**

► Adult: 1 g 3 times a day for 14–28 days

**Subacute sclerosing panencephalitis**

► **BY MOUTH**

► Adult: 50–100 mg/kg daily in 6 divided doses

**CAUTIONS** History of gout; history of hyperuricaemia

**SIDE-EFFECTS**

► Common or very common Reversible increase in serum uric acid; reversible increase in urinary uric acid

► Uncommon Arthralgia; epigastric discomfort; fatigue; headache; itching; nausea; rashes; vertigo; vomiting

► Rare Anxiety; constipation; diarrhoea; polyuria; sleep disturbances

**PREGNANCY** Manufacturer advises avoid.

**RENAL IMPAIRMENT** Manufacturer advises caution; metabolised to uric acid.

**LESS SUITABLE FOR PRESCRIBING** Inosine pranobex is less suitable for prescribing.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

CAUTIONARY AND ADVISORY LABELS 9

► Imunovir (KoRa Healthcare)

Inosine acedoben dimepranol 500 mg Imunovir 500mg tablets | 100 tablet £39.50

**ANTIVIRALS > NUCLEOSIDE ANALOGUES**

**Aciclovir**

(Acyclovir)

**INDICATIONS AND DOSE**

**Herpes simplex, suppression**

► **BY MOUTH**

► Child 12–17 years: 400 mg twice daily, alternatively 200 mg 4 times a day; increased to 400 mg 3 times a day, dose may be increased if recurrences occur on standard suppressive therapy or for suppression of genital herpes during late pregnancy (from 36 weeks gestation), therapy interrupted every 6–12 months to reassess recurrence frequency—consider restarting after two or more recurrences

► Adult: 400 mg twice daily, alternatively 200 mg 4 times a day; increased to 400 mg 3 times a day, dose may be increased if recurrences occur on standard suppressive therapy or for suppression of genital herpes during late pregnancy (from 36 weeks gestation), therapy interrupted every 6–12 months to reassess recurrence frequency—consider restarting after two or more recurrences

**Herpes simplex, prophylaxis in the immunocompromised**

► **BY MOUTH**

► Child 1–23 months: 100–200 mg 4 times a day

► Child 2–17 years: 200–400 mg 4 times a day

► Adult: 200–400 mg 4 times a day

► **BY INTRAVENOUS INFUSION**

► Adult: 5 mg/kg every 8 hours

**Herpes simplex, treatment (non-genital)**

► **BY MOUTH**

► Adult: 200 mg 5 times a day usually for 5 days (longer if new lesions appear during treatment or if healing incomplete)

continued →
Infection

▶ BY MOUTH
- Adult: 400 mg 5 times a day usually for 5 days (longer if new lesions appear during treatment or if healing incomplete)

Herpes simplex, treatment of recurrent infection in immunocompromised or if absorption impaired
▶ BY MOUTH
- Adult: 400 mg 5 times a day usually for 5 days (longer if new lesions appear during treatment or if healing incomplete)
- Child 1-2 years: 200 mg 5 times a day usually for 5 days (longer if new lesions appear during treatment or if healing incomplete)

Herpes simplex, treatment, in immunocompromised or if absorption impaired
▶ BY MOUTH
- Adult: 200 mg 5 times a day, alternatively 400 mg 3 times a day both courses usually for 5 days (longer if new lesions appear during treatment or if healing incomplete)

Severe genital herpes simplex, treatment, initial infection
▶ INTRAVENOUS INFUSION
- Adult: Initially 5 mg/kg every 8 hours usually for 5 days, alternatively 10 mg/kg every 8 hours for at least 14 days in encephalitis (at least 21 days if also immunocompromised)—confirm cerebrospinal fluid negative for herpes simplex virus before stopping treatment, higher dose to be used only if resistant organisms suspected or in simplex encephalitis

Genital herpes simplex, treatment of recurrent infection in immunocompromised or HIV-positive patients
▶ BY MOUTH
- Adult: 800 mg 3 times a day for 2 days, alternatively 200 mg 5 times a day for 5 days, alternatively 400 mg 3 times a day for 3–5 days

Varicella zoster (chickenpox), treatment | Herpes zoster (shingles), treatment
▶ BY MOUTH
- Child 1-2 years: 200 mg 4 times a day for 5 days
- Child 2-5 years: 400 mg 4 times a day for 5 days
- Child 6-11 years: 800 mg 4 times a day for 5 days
- Child 12-17 years: 800 mg 5 times a day for 7 days
▶ INTRAVENOUS INFUSION
- Adult: 5 mg/kg every 8 hours usually for 5 days

Varicella zoster (chickenpox), treatment in immunocompromised | Herpes zoster (shingles), treatment in immunocompromised
▶ INTRAVENOUS INFUSION
- Adult: 10 mg/kg every 8 hours usually for 5 days

Herpes zoster (shingles), treatment in immunocompromised
▶ BY MOUTH
- Child 1-2 years: 200 mg 4 times a day continued for 2 days after crusting of lesions
- Child 2-5 years: 400 mg 4 times a day continued for 2 days after crusting of lesions
- Child 6-11 years: 800 mg 4 times a day continued for 2 days after crusting of lesions
- Child 12-17 years: 800 mg 5 times a day continued for 2 days after crusting of lesions
- Adult: 800 mg 5 times a day continued for 2 days after crusting of lesions

Herpes zoster, treatment in encephalitis | Varicella zoster, treatment in encephalitis
▶ INTRAVENOUS INFUSION
- Adult: 10 mg/kg every 8 hours given for 10–14 days in encephalitis, possibly longer if also immunocompromised or if severe infection

Varicella zoster (chickenpox), attenuation of infection if varicella-zoster immunoglobulin not indicated
▶ BY MOUTH
- Child: 10 mg/kg 4 times a day for 7 days, to be started 1 week after exposure
- Adult: 10 mg/kg 4 times a day for 7 days, to be started 1 week after exposure

DOSES AT EXTREMES OF BODY-WEIGHT
To avoid excessive dosage in obese patients parenteral dose should be calculated on the basis of ideal weight for height.

- UNLICENSED USE Tablets and suspension not licensed for suppression of herpes simplex or for treatment of herpes zoster in children. Aciclovir doses in BNF may differ from those in product literature. Attenuation of chickenpox is an unlicensed indication.

- CAUTIONS Elderly (risk of neurological reactions) · maintain adequate hydration (especially with infusion or high doses)

- INTERACTIONS → Appendix 1: aciclovir

- SIDE-EFFECTS
  - Common or very common Abdominal pain · diarrhoea · fatigue · headache · nausea · photosensitivity · pruritus · rash · urticaria · vomiting
  - Very rare Acute renal failure · anaemia · ataxia · confusion · convulsions · dizziness · drowsiness · dysarthria · dyspnoea · hallucinations · hepatitis · jaundice · leucopenia · neurological reactions · thrombocytopenia
  - With intravenous use Agitation · fever · psychosis · severe local inflammation (sometimes leading to ulceration) · tremors

- PREGNANCY Not known to be harmful—manufacturers advise use only when potential benefit outweighs risk.

- BREAST FEEDING Significant amount in milk after systemic administration—not known to be harmful but manufacturer advises caution.

- RENAL IMPAIRMENT Risk of neurological reactions increased. Maintain adequate hydration (especially during renal impairment).

- With intravenous use Use normal intravenous dose every 12 hours if eGFR 25–50 mL/minute/1.73 m² (every 24 hours if eGFR 10–25 mL/minute/1.73 m²). Consult product literature for intravenous dose if eGFR less than 10 mL/minute/1.73 m².

- With oral use in adults For herpes zoster, use normal oral dose every 8 hours if eGFR 10–25 mL/minute/1.73 m² (every 12 hours if eGFR less than 10 mL/minute/1.73 m²). For herpes simplex, use normal oral dose every 12 hours if eGFR less than 10 mL/minute/1.73 m².
With oral use in children For herpes zoster, use normal oral dose every 8 hours if estimated glomerular filtration rate 10 – 25 ml/minute/1.73 m² (every 12 hours if estimated glomerular filtration rate less than 10 ml/minute/1.73 m²). For herpes simplex, use normal dose every 12 hours if estimated glomerular filtration rate less than 10 ml/minute/1.73 m².

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion Zovirax IV®, Aciclovir IV (Genus), give intermittently in Sodium chloride 0.9% or Sodium chloride and glucose; initially reconstitute to 25 mg/ml in water for injection or Sodium chloride 0.9% then dilute to not more than 5 mg/ml with the infusion fluid; to be given over 1 hour; alternatively, may be administered in a concentration of 25 mg/ml using a suitable infusion pump and given over 1 hour; for Aciclovir IV (Hospira) dilute to not more than 5 mg/ml with infusion fluid; give over 1 hour.

**PRESCRIBING AND DISPENSING INFORMATION** Flavours of oral liquid preparations may include banana, or orange.

**PATIENT AND CARER ADVICE**
Medicines for Children leaflet: Aciclovir (oral) for viral infections www.medicinesforchildren.org.uk/aciclovir-for-viral-infections

**PROFESSION SPECIFIC INFORMATION**
Dental practitioners’ formulary
Aciclovir Tablets 200 mg or 800 mg may be prescribed. Aciclovir Oral Suspension 200 mg/5ml may be prescribed.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

<table>
<thead>
<tr>
<th>Aciclovir (Non-proprietary)</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Aciclovir 200 mg</td>
<td>Aciclovir 200mg tablets</td>
<td>25 tablet [Pos] £10.00 DT price = £1.36</td>
</tr>
<tr>
<td>Aciclovir 400 mg</td>
<td>Aciclovir 400mg tablets</td>
<td>56 tablet [Pos] £15.00 DT price = £2.96</td>
</tr>
<tr>
<td>Aciclovir 800 mg</td>
<td>Aciclovir 800mg tablets</td>
<td>35 tablet [Pos] £20.00 DT price = £3.36</td>
</tr>
</tbody>
</table>

**Dispersible tablet**

<table>
<thead>
<tr>
<th>Aciclovir (Non-proprietary)</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Aciclovir 200 mg</td>
<td>Aciclovir 200mg dispersible tablets</td>
<td>25 tablet [Pos] £17.50 DT price = £1.47</td>
</tr>
<tr>
<td>Aciclovir 400 mg</td>
<td>Aciclovir 400mg dispersible tablets</td>
<td>56 tablet [Pos] £20.00 DT price = £11.98</td>
</tr>
<tr>
<td>Aciclovir 800 mg</td>
<td>Aciclovir 800mg dispersible tablets</td>
<td>35 tablet [Pos] £35.00 DT price = £10.98</td>
</tr>
<tr>
<td>Zovirax (GlaxoSmithKline UK Ltd)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aciclovir 200 mg</td>
<td>Zovirax 200mg dispersible tablets</td>
<td>25 tablet [Pos] £2.85 DT price = £1.47</td>
</tr>
<tr>
<td>Aciclovir 800 mg</td>
<td>Zovirax 800mg dispersible tablets</td>
<td>35 tablet [Pos] £10.50 DT price = £10.98</td>
</tr>
</tbody>
</table>

**Oral suspension**

<table>
<thead>
<tr>
<th>Aciclovir (Non-proprietary)</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Aciclovir 40 mg per 1 ml</td>
<td>Aciclovir 200mg/5ml oral suspension sugar-free sugar-free</td>
<td>125 ml [Pos] £35.76 DT price = £35.76</td>
</tr>
<tr>
<td>Aciclovir 80 mg per 1 ml</td>
<td>Aciclovir 400mg/5ml oral suspension sugar-free sugar-free</td>
<td>100 ml [Pos] £39.47 DT price = £39.47</td>
</tr>
<tr>
<td>Zovirax (GlaxoSmithKline UK Ltd)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aciclovir 40 mg per 1 ml</td>
<td>Zovirax 200mg/5ml oral suspension sugar-free</td>
<td>125 ml [Pos] £29.56 DT price = £35.76</td>
</tr>
<tr>
<td>Zovirax (GlaxoSmithKline UK Ltd)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aciclovir 80 mg per 1 ml</td>
<td>Zovirax Double Strength 400mg/5ml oral suspension sugar-free</td>
<td>100 ml [Pos] £33.02 DT price = £39.47</td>
</tr>
</tbody>
</table>

**Solution for infusion**

<table>
<thead>
<tr>
<th>Aciclovir (Non-proprietary)</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Aciclovir (as Aciclovir sodium) 25 mg per 1 ml</td>
<td>Aciclovir 1g/40ml solution for infusion vials</td>
<td>1 vial [Pos] £4.00</td>
</tr>
<tr>
<td>Aciclovir 500mg/200ml solution for infusion vials</td>
<td>5 vial [Pos] £7.15–£100.00</td>
<td></td>
</tr>
<tr>
<td>Aciclovir 250mg/10ml solution for infusion vials</td>
<td>5 vial [Pos] £16.25–£50.00</td>
<td></td>
</tr>
</tbody>
</table>

Aciclovir 500mg/20ml concentrate for solution for infusion vials | 5 vial (Pos) no price available (Hospital only)

**Powder for solution for infusion**

**ELECTROLYTES:** May contain Sodium

| Aciclovir (as Aciclovir sodium) 250 mg | Aciclovir 250mg powder for solution for infusion vials | 5 vial [Pos] £49.30 |
| Zovirax (GlaxoSmithKline UK Ltd) | | |
| Aciclovir (as Aciclovir sodium) 250 mg | Zovirax I.V. 250mg powder for solution for infusion vials | 5 vial [Pos] £16.70 |
| Aciclovir (as Aciclovir sodium) 500 mg | Zovirax I.V. 500mg powder for solution for infusion vials | 5 vial [Pos] £17.00 |

**Famciclovir**

**INDICATIONS AND DOSE**

<table>
<thead>
<tr>
<th>Herpes zoster infection, treatment</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Aciclovir (Non-proprietary)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aciclovir (as Aciclovir sodium) 25 mg</td>
<td>Adult: 500 mg 3 times a day for 7 days, alternatively 750 mg 1–2 times a day for 7 days</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Herpes zoster infection, treatment in immunocompromised patients</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Aciclovir (as Aciclovir sodium)</td>
<td>Adult: 500 mg 3 times a day for 10 days, continue for 2 days after crusting of lesions</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Genital herpes, suppression</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Aciclovir (as Aciclovir sodium)</td>
<td>Adult: 250 mg twice daily, therapy to be interrupted every 6–12 months to reassess recurrence frequency—consider restarting after two or more recurrences</td>
<td></td>
</tr>
</tbody>
</table>

**Genital herpes, suppression in immunocompromised or HIV-positive patients**

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Aciclovir (as Aciclovir sodium)</td>
<td>Adult: 500 mg twice daily for 10 days</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Herpes zoster infection, treatment of recurrent infection</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Aciclovir (as Aciclovir sodium)</td>
<td>Adult: 125 mg twice daily for 5 days, alternatively 1 g twice daily for 1 day</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Herpes infection, treatment of recurrent infections in immunocompromised or HIV-positive patients</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Aciclovir (as Aciclovir sodium)</td>
<td>Adult: 500 mg twice daily for 5–10 days</td>
</tr>
</tbody>
</table>

**Herpes simplex infection (non-genital), treatment in immunocompromised patients**

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Aciclovir (as Aciclovir sodium)</td>
<td>Adult: 250 mg twice daily for 7 days</td>
</tr>
</tbody>
</table>

**UNLICENSED USE**
Famciclovir doses in BNF may differ from those in product literature.

**SIDE-EFFECTS**

| Common or very common | Headache, nausea, vomiting |
| Rare | Confusion |
| Very rare | Dizziness, drowsiness, hallucinations, jaundice, rash, Stevens-Johnson syndrome, thrombocytopenia |
| Frequency not known | Constipation, abdominal pain, diarrhoea, fatigue, fever, pruritus, sweating |

**PREGNANCY**
Manufacturers advise avoid unless potential benefit outweighs risk.
Valaciclovir

**INDICATIONS AND DOSE**

**Herpes zoster infection, treatment**

- **BY MOUTH**
- Adult: 1 g 3 times a day for 7 days

**Herpes zoster infection, treatment in immunocompromised patients**

- **BY MOUTH**
- Adult: 1 g 3 times a day for at least 7 days and continued for 2 days after crusting of lesions

**Herpes simplex, treatment of first infective episode**

- **BY MOUTH**
- Adult: 500 mg twice daily for 5 days (longer if new lesions appear during treatment or healing is incomplete)

**Herpes simplex infections treatment of first episode in immunocompromised or HIV-positive patients**

- **BY MOUTH**
- Adult: 1 g twice daily for 10 days

**Herpes simplex, treatment of recurrent infections**

- **BY MOUTH**
- Adult: 500 mg twice daily for 3–5 days

**Treatment of recurrent herpes simplex infections in immunocompromised or HIV-positive patients**

- **BY MOUTH**
- Adult: 1 g twice daily for 5–10 days

**Herpes labialis treatment**

- **BY MOUTH**
- Child 12–17 years: Initially 2 g, then 2 g after 12 hours
- Adult: Initially 2 g, then 2 g after 12 hours

**Herpes simplex, suppression of infections**

- **BY MOUTH**
- Adult: 500 mg daily in 1–2 divided doses, therapy to be interrupted every 6–12 months to reassess recurrence frequency—consider restarting after two or more recurrences

---

**Herpes simplex, suppression of infections in immunocompromised or HIV-positive patients**

- **BY MOUTH**
  - Adult: 500 mg twice daily, therapy to be interrupted every 6–12 months to reassess recurrence frequency—consider restarting after two or more recurrences

**Genital herpes, reduction of transmission (administered on expert advice)**

- **BY MOUTH**
  - Adult: 500 mg once daily, to be taken by the infected partner

**Prevention of cytomegalovirus disease following solid organ transplantation when valganciclovir or ganciclovir cannot be used**

- **BY MOUTH**
  - Adult: 2 g 4 times a day usually for 90 days, preferably starting within 72 hours of transplantation

---

**CAUTIONS**

- Elderly (risk of neurological reactions) • maintain adequate hydration (especially with high doses)

**INTERACTIONS**

- Appendix 1: valaciclovir

**SIDE-EFFECTS**

- Very rare: Acute renal failure • anaemia • ataxia • confusion • convulsions • dizziness • drowsiness • dysarthria • dysphoria • hallucinations • hepatitis • jaundice • leucopenia • neurological reactions • thrombocytopenia

- Frequency not known: Abdominal pain • diarrhoea • fatigue • headache • nausea • photosensitivity • pruritus • rash • urticaria • vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

- Neurological reactions: Neurological reactions (including dizziness, confusion, hallucinations, convulsions, ataxia, dysarthria, and drowsiness) more frequent with higher doses

**PREGNANCY**

- Not known to be harmful—manufacturers advise use only when potential benefit outweighs risk

**BREAST FEEDING**

- Significant amount in milk after systemic administration—not known to be harmful but manufacturer advises caution

**HEPATIC IMPAIRMENT**

- Manufacturer advises caution with high doses used for herpes labialis and prevention of cytomegalovirus disease—no information available

**RENAL IMPAIRMENT**

- Maintain adequate hydration.
  - In adults: For herpes zoster: 1 g every 12 hours if eGFR 30–50mL/minute/1.73 m² (1 g every 24 hours if eGFR 10–30 mL/minute/1.73 m²; 500 mg every 24 hours if eGFR less than 10 mL/minute/1.73 m²). For treatment of herpes simplex, 500 mg (1 g in immunocompromised or HIV-positive patients) every 24 hours if eGFR less than 30 mL/minute/1.73 m². For treatment of herpes labialis, if eGFR 30–50 mL/minute/1.73 m², initially 1 g, then 1 g 12 hours after initial dose (if eGFR 10–30 mL/minute/1.73 m², initially 500 mg, then 500 mg 12 hours after initial dose; if eGFR less than 10 mL/minute/1.73 m², 500 mg as a single dose). For suppression of herpes simplex, 250 mg (500 mg in immunocompromised or HIV-positive patients) every 24 hours if eGFR less than 30 mL/minute/1.73 m². For reduction of genital herpes transmission, 250 mg every 24 hours if eGFR less than 15 mL/minute/1.73 m². Reduce dose according to eGFR for cytomegalovirus prophylaxis following solid organ transplantation (consult product literature).
  - In children: For treatment of herpes labialis, if estimated glomerular filtration rate 30–50 mL/minute/1.73 m², initially 1 g, then 1 g 12 hours after initial dose (if estimated glomerular filtration rate 10–30 mL/minute/1.73 m², initially 500 mg, then 500 mg 12 hours after initial dose; if estimated glomerular filtration rate
f he filtration rate is less than $10 \text{mL/minute}/1.73 \text{m}^2$, 500 mg as a single dose).

**PRESCRIBING AND DISPENSING INFORMATION** Valaciclovir is a pro-drug of aciclovir.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Tablet**

- Valaciclovir (Non-proprietary)
  - Valaciclovir (as Valaciclovir hydrochloride) 500 mg  Valaciclovir 500mg tablets | 10 tablet  £20.59 07 price | £2.80 | 42 tablet  £86.30
- Valtrex (GlaxoSmithKline UK Ltd)
  - Valaciclovir (as Valaciclovir hydrochloride) 250 mg  Valtrex 250mg tablets | 60 tablet  £123.28 07 price = £123.28
  - Valaciclovir (as Valaciclovir hydrochloride) 500 mg  Valtrex 500mg tablets | 10 tablet  £20.59 07 price = £2.80 | 42 tablet  £86.30

---

6.3a Cytomegalovirus infections

**ANTIVIRALS**

### Ganciclovir

**INDICATIONS AND DOSE**

**Prevention of cytomegalovirus disease during immunosuppressive therapy following organ transplantation**

- **BY INTRAVENOUS INFUSION**
  - Adult: 5 mg/kg every 12 hours for 7–14 days

**Treatment of life-threatening or sight-threatening cytomegalovirus infections in immunocompromised patients only**

- **BY INTRAVENOUS INFUSION**
  - Adult: Initially 5 mg/kg every 12 hours for 14–21 days, followed by maintenance 6 mg/kg daily on 5 days of the week, alternatively 5 mg/kg daily until adequate recovery of immunity, maintenance only for patients at risk of relapse of retinitis, if retinitis progresses initial induction treatment may be repeated

**CONTRA-INDICATIONS** Abnormally low haemoglobin count (consult product literature) • abnormally low neutrophil count (consult product literature) • abnormally low platelet count (consult product literature)

**CAUTIONS** Children (possible risk of long-term carcinogenic or reproductive toxicity) • ensure adequate hydration • history of cytopenia • potential carcinogen • potential teratogen • radiotherapy • vesicant

**INTERACTIONS** → Appendix 1: ganciclovir

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain • abnormal thinking • anaemia • anorexia • anxiety • arthralgia • chest pain • confusion • constipation • convulsions • cough • depression • dermatitis • diarrhoea • dizziness • dyspepsia • dysphagia • dyspnoea • ear pain • eye pain • fatigue • flattulence • headache • hepatic dysfunction • infection • injection-site reactions • insomnia • leucopenia • macular oedema • myalgia • nausea • night sweats • pancytopenia • peripheral neuropathy • pruritus • pyrexia • renal impairment • retinal detachment • taste disturbance • thrombocytopenia • vitreous floaters • vomiting • weight loss

- **Uncommon** Alopecia • anaphylactic reactions • arrhythmias • disturbances in hearing and vision • haematuria • hypotension • male infertility • mouth ulcers • pancreatitis • psychosis • tremor

**ALLERGY AND CROSS-SENSITIVITY** Contra-indicated in patients hypersensitive to ganciclovir, aciclovir, or valaciclovir.

**CONCEPTION AND CONTRACEPTION** Ensure effective contraception during treatment and barrier contraception for men during and for at least 90 days after treatment.

**PREGNANCY** Avoid—teratogenic risk.

**BREAST FEEDING** Avoid—no information available.

**RENAL IMPAIRMENT** Reduce dose if eGFR less than 70 mL/minute/1.73 m²; consult product literature.

**MONITORING REQUIREMENTS** Monitor full blood count closely (severe deterioration may require correction and possibly treatment interruption).

**DIRECTIONS FOR ADMINISTRATION** Infuse into vein with adequate flow preferably using plastic cannula. For intravenous infusion (Cymevene®) give intermittently in Glucose 5% or Sodium chloride 0.9%. Reconstitute initially in water for injections (500 mg/10 mL) then dilute to not more than 10 mg/mL with infusion fluid (usually 100 mL); give over 1 hour.

**HANDLING AND STORAGE**

Caution in handling Ganciclovir is toxic and personnel should be adequately protected during handling and administration; if solution comes into contact with skin or mucosa, wash off immediately with soap and water.

---

### Valganciclovir

**INDICATIONS AND DOSE**

**Cytomegalovirus retinitis, induction and maintenance treatment in patients with AIDS**

- **BY MOUTH**
  - Adult: Initially 900 mg twice daily for 21 days, then 900 mg daily, induction regimen may be repeated if retinitis progresses

**Prevention of cytomegalovirus disease following solid organ transplantation from a cytomegalovirus positive donor**

- **BY MOUTH**
  - Adult: 900 mg daily for 100 days (for 100–200 days following kidney transplantation), to be started within 10 days of transplantation

**DOSE EQUIVALENCE AND CONVERSION**

- Oral valganciclovir 900 mg twice daily is equivalent to intravenous ganciclovir 5 mg/kg twice daily.

**CONTRA-INDICATIONS** Abnormally low haemoglobin count (consult product literature) • abnormally low neutrophil count (consult product literature) • abnormally low platelet count (consult product literature)

**CAUTIONS** Children (possible risk of long-term carcinogenic or reproductive toxicity) • history of cytopenia • potential carcinogen • potential teratogen • radiotherapy

**INTERACTIONS** → Appendix 1: valganciclovir

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain • abnormal thinking • anaemia • anorexia • anxiety • arthralgia • chest pain • confusion • constipation • convulsions • cough • depression • dermatitis • diarrhoea • dizziness • dyspepsia • dysphagia • dyspnoea • ear pain • eye pain • fatigue •...
Foscarnet sodium

**Indications and dose**

**Cytomegalovirus disease**
- **By intravenous infusion**
  - Adult: Initially 60 mg/kg every 8 hours for 2–3 weeks, alternatively initially 90 mg/kg every 12 hours for 2–3 weeks, then maintenance 60 mg/kg daily, then increased if tolerated to 90–120 mg/kg daily, if disease progresses on maintenance dose, repeat induction regimen

**Mucocutaneous herpes simplex virus infections unresponsive to aciclovir in immunocompromised patients**
- **By intravenous infusion**
  - Adult: 40 mg/kg every 8 hours for 2–3 weeks or until lesions heal

**Antivirals**

**Unlicensed use**
Licensed for CMV retinitis in AIDS patients only. Foscarnet doses in BNF may differ from those in product literature.

**Cautions**
Ensure adequate hydration

**Interactions**
Appendix 1: foscarnet

**Side-effects**
- **Common or very common** Abdominal pain · acute renal failure · aggression · agitation · anaemia · anorexia · anxiety · changes in blood pressure · changes in ECG · confusion · constipation · convulsions · depression · diarrhoea · dizziness · dyspepsia · dysuria · electrolyte disturbances · genital irritation and ulceration (due to high concentrations excreted in urine) · granulocytopenia · headache · hepatic dysfunction · hypocalcaemia · hypokalaemia · hypomagnesaemia · leucopenia · malaise · myalgia · nausea · renal impairment · retinal detachment · taste disturbance · thrombocytopenia · vitreous floaters · vomiting · weight loss
- **Uncommon** Alopecia · anaphylactic reactions · arrhythmias · disturbances in hearing · disturbances in vision · haematuria · hypotension · male infertility · mouth ulcers · pancreatitis · psychosis · tremor

**Allergy and cross-sensitivity**
Contra-indicated in patients hypersensitive to ganciclovir, aciclovir, or valaciclovir.

**Conception and contraception**
Ensure effective contraception during treatment and barrier contraception for men during and for at least 90 days after treatment.

**Pregnancy**
Avoid—teratogenic risk.

**Breast feeding**
Avoid—no information available.

**Renal impairment**
Reduce dose, consult product literature.

**Monitoring requirements**
Monitor full blood count closely (severe deterioration may require correction and possibly treatment interruption).

**Prescribing and dispensing information**
Valganciclovir is a pro-drug of ganciclovir.
  - Flavours of oral liquid formulations may include tutti-frutti.

**Handling and storage**
Caution in handling Valganciclovir is a potential teratogen and carcinogen and caution is advised when handling the powder, reconstituted solution, or broken tablets; if these come into contact with skin or mucosa, wash off immediately with water; avoid inhalation of powder.

**Medicinal forms**

**Oral solution**

<table>
<thead>
<tr>
<th>Cautionary and advisory labels</th>
<th>21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valcyte (Roche Products Ltd)</td>
<td></td>
</tr>
<tr>
<td>Valganciclovir (as Valganciclovir hydrochloride) 50 mg per 1 ml Valgcyte 50mg/ml oral solution sugar-free</td>
<td>100 ml (PoS) £29.32</td>
</tr>
</tbody>
</table>

**Tablet**

<table>
<thead>
<tr>
<th>Cautionary and advisory labels</th>
<th>21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valganciclovir (non-proprietary)</td>
<td></td>
</tr>
<tr>
<td>Valganciclovir (as Valganciclovir hydrochloride)</td>
<td></td>
</tr>
<tr>
<td>450 mg Valganciclovir 450mg tablets</td>
<td>60 tablet (PoS) £1,027.39</td>
</tr>
<tr>
<td>Valgcyte (Roche Products Ltd)</td>
<td></td>
</tr>
<tr>
<td>Valganciclovir (as Valganciclovir hydrochloride) 450 mg Valgcyte 450mg tablets</td>
<td>60 tablet (PoS) £1,081.46</td>
</tr>
</tbody>
</table>

**6.4 HIV infection**

**Overview**

There is no cure for infection caused by the human immunodeficiency virus (HIV) but a number of drugs slow or halt disease progression. Drugs for HIV infection (antiretrovirals) may be associated with serious side-effects. Although antiretrovirals increase life expectancy considerably and decrease the risk of complications associated with premature ageing, mortality and morbidity remain slightly higher than in uninfected individuals. Treatment should be undertaken only by those experienced in their use.
Principles of treatment
Treatment aims to prevent the mortality and morbidity associated with chronic HIV infection whilst minimising drug toxicity. Although it should be started before the immune system is irreversibly damaged, the need for early drug treatment should be balanced against the risk of toxicity. Commitment to treatment and strict adherence over many years are required; the regimen chosen should take into account convenience and patient tolerance. The development of drug resistance is reduced by using a combination of drugs; such combinations should have synergistic or additive activity while ensuring that their toxicity is not additive. It is recommended that viral sensitivity to antiretroviral drugs is established before starting treatment or before switching drugs if the infection is not responding.

Treatment also reduces the risk of HIV transmission to sexual partners, but the risk is not eliminated completely; this risk and strategies to reduce HIV transmission should be discussed with patients and their sexual partners.

Initiation of treatment
The optimum time for initiating antiretroviral treatment depends primarily on the CD4 cell count. The timing and choice of treatment should also take account of clinical symptoms, comorbidities, and the possible effect of antiretroviral drugs on factors such as the risk of cardiovascular events. Treatment includes a combination of drugs known as 'highly active antiretroviral therapy'. Treatment of HIV-1 infection is initiated with 2 nucleoside reverse transcriptase inhibitors and either a non-nucleoside reverse transcriptase inhibitor, or a boosted protease inhibitor, or an integrase inhibitor; the regimen of choice contain tenofovir disoproxil p. 616 and emtricitabine p. 613 with either efavirenz p. 608 or ritonavir p. 621-boosted atazanavir p. 618, or ritonavir-boosted darunavir p. 619, or raltegravir p. 607. Alternative regimens contain abacavir p. 610 and lamivudine p. 615 with either lopinavir with ritonavir p. 620, or ritonavir-boosted fosamprenavir p. 620, or nevirapine p. 609, or rilpivirine p. 610. Patients who require treatment for both HIV and chronic hepatitis B should be treated with antivirals active against both diseases.

Switching therapy
Deterioration of the condition (including clinical and virological changes) may require a change in therapy. The choice of an alternative regimen depends on factors such as the response to previous treatment, tolerance and the possibility of cross-resistance.

Pregnancy
Treatment of HIV infection in pregnancy aims to reduce the risk of toxicity to the fetus (although information on the teratogenic potential of most antiretroviral drugs is limited), to minimise the viral load and disease progression in the mother, and to prevent transmission of infection to the neonate. All treatment options require careful assessment by a specialist. Combination antiretroviral therapy maximises the chance of preventing transmission and represents optimal therapy for the mother. However, it may be associated with a greater risk of preterm delivery. Pregnancies in HIV-positive women and babies born to them should be reported prospectively to the National Study of HIV in Pregnancy and Childhood at www.ucl.ac.uk/nshpc/ and to the Antiretroviral Pregnancy Registry at www.apregistry.com.

Breast-feeding
Breast-feeding by HIV-positive mothers may cause HIV infection in the infant and should be avoided.

Pre-exposure prophylaxis
The risk of acquiring HIV is increased in:
- men or transgendered individuals who have unprotected intercourse with men;
- partners of people who are HIV-positive and have a detectable viral load; and
- heterosexual men and women who have unprotected intercourse with a partner who is HIV positive.

Emtricitabine with tenofovir disoproxil p. 615 may be appropriate for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in combination with safer sex practices in adults at high risk; recommendations developed by the British Association for Sexual Health and HIV are available at: www.bashh.org. Note: there is currently no publicly funded HIV pre-exposure prophylaxis programme in the UK.

Post-exposure prophylaxis
Prophylaxis with antiretroviral drugs [unlicensed indication] may be appropriate following exposure to HIV-contaminated material. Immediate expert advice should be sought in such cases; national guidelines on post-exposure prophylaxis for healthcare workers have been developed (by the Chief Medical Officer’s Expert Advisory Group on AIDS), www.gov.uk/dh and local ones may also be available. Antiretrovirals for prophylaxis are chosen on the basis of efficacy and potential for toxicity. Prompt prophylaxis with antiretroviral drugs [unlicensed indication] is also appropriate following potential sexual exposure to HIV; recommendations have been developed by the British Association for Sexual Health and HIV, www.bashh.org.

Drugs for HIV infection
Zidovudine p. 617, a nucleoside reverse transcriptase inhibitor (or ‘nucleoside analogue’), was the first anti-HIV drug to be introduced. Other nucleoside reverse transcriptase inhibitors include abacavir, didanosine p. 612, emtricitabine, lamivudine, stavudine p. 616, and tenofovir disoproxil.

The protease inhibitors include atazanavir, darunavir, fosamprenavir (a pro-drug of amprenavir), indinavir p. 620, lopinavir (available as lopinavir with ritonavir), ritonavir, saquinavir p. 621, and tipranavir p. 622. Indinavir is rarely used in the treatment of HIV-infection because it is associated with nephrolithiasis. Ritonavir in low doses boosts the activity of atazanavir, darunavir, fosamprenavir, indinavir, lopinavir (available as lopinavir with ritonavir), saquinavir, and tipranavir increasing the persistence of plasma concentrations of these drugs; at such a low dose, ritonavir has no intrinsic antiviral activity. The protease inhibitors are metabolised by cytochrome P450 enzyme systems and therefore have a significant potential for drug interactions. Protease inhibitors are associated with lipodystrophy and metabolic effects.

The non-nucleoside reverse transcriptase inhibitors efavirenz, etravirine p. 608, nevirapine, and rilpivirine are used in the treatment of HIV-1 infection, but not against the subtype HIV-2, a subtype that is rare in the UK. Nevirapine is associated with a high incidence of rash (including Stevens-Johnson syndrome) and occasionally fatal hepatitis. Rash is also associated with efavirenz and etravirine but it is usually milder. Psychiatric or CNS disturbances are common with efavirenz; CNS disturbances are often self-limiting and can be reduced by taking the dose at bedtime (especially in the first 2–4 weeks of treatment). Efavirenz has also been associated with an increased plasma-cholesterol concentration. Etravirine is used in regimens containing a boosted protease inhibitor for HIV infection resistant to other non-nucleoside reverse transcriptase inhibitors and protease inhibitors.
Enfuvirtide below, which inhibits the fusion of HIV to the host cell, is licensed for managing infection that has failed to respond to a regimen of other antiretroviral drugs; enfuvirtide should be combined with other potentially active antiretroviral drugs.

Maraviroc p. 622 is an antagonist of the CCR5 chemokine receptor. It is licensed for patients exclusively infected with CCR5-tropic HIV.

Dolutegravir below, elvitegravir p. 607 and raltegravir p. 607 are inhibitors of HIV integrase. They are licensed for the treatment of HIV infection in combination with other antiretroviral drugs.

Cobicistat p. 622 is a pharmacokinetic enhancer that boosts the concentrations of other antiretrovirals, but it has no antiretroviral activity itself.

**Immune reconstitution syndrome**

Improvement in immune function as a result of antiretroviral treatment may provoke a marked inflammatory reaction against residual opportunistic organisms; these reactions may occur within the first few weeks or months of initiating treatment. Autoimmune disorders (such as Graves’ disease) have also been reported many months after initiation of treatment.

**Osteonecrosis**

Osteonecrosis has been reported in patients with advanced HIV disease or following long-term exposure to combination antiretroviral therapy.

**HIV infection in children**

HIV disease in children has a different natural progression to HIV disease in adults. Children infected with HIV should be managed within a formal paediatric HIV clinical network by specialists with expertise in HIV infection in children. Differences in the natural progression of HIV disease or following long-term exposure to combination antiretroviral treatment may provoke a marked inflammatory reaction against residual opportunistic organisms; these reactions may occur within the first few weeks or months of initiating treatment. Autoimmune disorders (such as Graves’ disease) have also been reported many months after initiation of treatment.

**SIDE-EFFECTS, FURTHER INFORMATION**

Hypersensitivity reactions Hypersensitivity reactions including rash, fever, nausea, vomiting, chills, rigors, low blood pressure, respiratory distress, glomerulonephritis, and raised liver enzymes reported; discontinue immediately if any signs or symptoms of systemic hypersensitivity develop and do not rechallenge.

Osteonecrosis For further information see HIV infection p. 604.
HIV infection

Elvitegravir

**DRUG ACTION** Elvitegravir is an inhibitor of HIV integrase, which is an enzyme required for viral replication.

**INDICATIONS AND DOSE**

**HIV infection without resistance to other inhibitors of HIV integrase, in combination with low-dose ritonavir and atazanavir or lopinavir**

**BY MOUTH**

- Adult: 85 mg once daily, take at the same time as a once daily ritonavir-boosted regimen or with the first dose of a twice daily ritonavir-boosted regimen

**HIV infection without resistance to other inhibitors of HIV integrase, in combination with low-dose ritonavir and darunavir or fosamprenavir**

**BY MOUTH**

- Adult: 150 mg once daily, take with the first dose of a twice daily ritonavir-boosted regimen

**CAUTIONS**

- Elderly—limited information available

**INTERACTIONS**

- Appendix 1: elvitegravir

**SIDE-EFFECTS**

- Common or very common Diarrhoea, fatigue, headache, nausea, rash, vomiting

- Uncommon Abdominal distension, depression, dizziness, dysgeusia, dyspepsia, flatulence, insomnia, paraesthesia, somnolence, suicidal ideation (in patients with history of depression or psychiatric illness)

- Frequency not known Hyperglycaemia, increased blood lipids, osteonecrosis, weight gain

**SIDE-EFFECTS, FURTHER INFORMATION**

- Osteonecrosis For further information see HIV infection p. 604.

**CONCEPTION AND CONTRACEPTION**

- Manufacturer advises women of child-bearing potential should use effective contraception during treatment (if using a hormonal contraceptive, it must contain norgestimate as the progestogen and at least 30 micrograms ethinylestradiol)

**PREGNANCY**

- Manufacturer advises avoid unless essential—limited data available

**HEPATIC IMPAIRMENT**

- Manufacturer advises use with caution in severe impairment—no information available. Use with caution in patients with chronic hepatitis B or C (greater risk of hepatic side-effects).

**PATIENT AND CARER ADVICE**

- Missed doses

  Manufacturer advises if a dose is more than 18 hours late, the missed dose should not be taken and the next dose should be taken at the normal time. If vomiting occurs within 1 hour of taking a dose, a replacement dose should be taken.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Elvitegravir 150 mg**
  - Tivicay 150mg tablets | 30 tablet (PO) £523.79

**Combinations available:** Elvitegravir with cobicistat, emtricitabine and tenofovir alafenamide, p. 613 - Elvitegravir with cobicistat, emtricitabine and tenofovir disoproxil, p. 613

**RALTEGRAVIR**

**DRUG ACTION** Raltegravir is an inhibitor of HIV integrase.

**INDICATIONS AND DOSE**

**HIV infection in combination with other antiretroviral drugs**

- **BY MOUTH USING TABLETS**
  - Adult: 400 mg twice daily

**DOSE EQUIVALENCE AND CONVERSION**

- The bioavailability of Isentress® chewable tablets is higher than that of the ‘standard’ 400 mg tablets; the chewable tablets are not interchangeable with the ‘standard’ tablets on a milligram-for-milligram basis.

**CAUTIONS**

- Psychiatric illness (may exacerbate underlying illness including depression) - risk factors for myopathy - risk factors for rhabdomyolysis

**INTERACTIONS**

- Appendix 1: raltegravir

**SIDE-EFFECTS**

- Common or very common Abdominal pain, abnormal dreams, asthenia, depression, diarrhoea, dizziness, dyspepsia, flatulence, headache, hyperactivity, hypertriglyceridaemia, insomnia, nausea, rash, vomiting

- Uncommon Acne, alopecia, anaemia, anxiety, appetite changes, arthralgia, bradycardia, carpal tunnel syndrome, chest pain, chills, confusion, constipation, drowsiness, dry mouth, dry skin, dysphonia, epistaxis, erectile dysfunction, flushing, gastritis, gingivitis, glossitis, gynaecomastia, hepatitis, hyperhidrosis, hypertension, impaired memory and attention, lipodystrophy, Lipodystrophy Syndrome, menopausal symptoms, myalgia, nasal congestion, neutropenia, nocturia, oedema, osteopenia, pain on swallowing, palpitation, pancreatitis, peptic ulcer, peripheral neuropathy, polydipsia, pruritus, pyrexia, rash with eosinophilia and systemic symptoms, rectal bleeding, renal failure, rhabdomyolysis, skin papilloma, Stevens-Johnson syndrome, suicidal ideation, taste disturbances, thrombocytopenia, tinnitus, tremor, ventricular extrasystoles, visual disturbances

- Frequency not known Osteonecrosis

**SIDE-EFFECTS, FURTHER INFORMATION**

- Rash Rash occurs commonly. Discontinue if severe rash or rash accompanied by fever, malaise, arthralgia, myalgia, blistering, mouth ulceration, conjunctivitis, angioedema, hepatitis, or eosinophilia.

- Osteonecrosis For further information see HIV infection p. 604.

**PHARMACOKINETICS**

- Absorption Rapid, complete absorption following oral dosing

- Metabolism Mainly liver; no active metabolites

- Excretion Renal, mainly via faeces

- **Half-life**
  - Raltegravir: 5.3 hours
  - Raltegravir-phosphate: 6.7 hours

**DRUG INTERACTIONS**

- Rifampicin: Raltegravir concentration reduced, rifampicin concentration increased

**CONTRAINDICATIONS**

- Hypersensitivity to any component of the formulation

**CAUTIONS**

- Pregnancy
  - Category B
  - Use only if benefit to the mother clearly outweighs potential risk to the fetus

- Lactation
  - Use with caution, advise against breastfeeding

- Elderly
  - Use with caution

**SIDE-EFFECTS, FURTHER INFORMATION**

- Rash Rash occurs commonly. Discontinue if severe rash or rash accompanied by fever, malaise, arthralgia, myalgia, blistering, mouth ulceration, conjunctivitis, angioedema, hepatitis, or eosinophilia.

- Osteonecrosis For further information see HIV infection p. 604.

**PATIENT AND CARER ADVICE**

- Missed doses

  Manufacturer advises if a dose is more than 18 hours late, the missed dose should not be taken and the next dose should be taken at the normal time. If vomiting occurs within 1 hour of taking a dose, a replacement dose should be taken.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- CAUTIONARY AND ADVISORY LABELS 21
  - **Vitekta** (Gilead Sciences International Ltd)
    - Elvitegravir 85 mg Vitekta 85mg tablets | 30 tablet (PO) £249.38
    - Elvitegravir 150 mg Vitekta 150mg tablets | 30 tablet (PO) £253.79

**Combinations available:** Elvitegravir with cobicistat, emtricitabine and tenofovir alafenamide, p. 613 - Elvitegravir with cobicistat, emtricitabine and tenofovir disoproxil, p. 613

**CONTRAINDICATIONS**

- Hypersensitivity to any component of the formulation

**CAUTIONS**

- Pregnancy
  - Category B
  - Use only if benefit to the mother clearly outweighs potential risk to the fetus

- Lactation
  - Use with caution, advise against breastfeeding

- Elderly
  - Use with caution

**SIDE-EFFECTS, FURTHER INFORMATION**

- Rash Rash occurs commonly. Discontinue if severe rash or rash accompanied by fever, malaise, arthralgia, myalgia, blistering, mouth ulceration, conjunctivitis, angioedema, hepatitis, or eosinophilia.

- Osteonecrosis For further information see HIV infection p. 604.

**PREGNANCY**

- Manufacturer advises avoid unless essential—limited data available

**HEPATIC IMPAIRMENT**

- Manufacturer advises use with caution in severe impairment—no information available. Use with caution in patients with chronic hepatitis B or C (greater risk of hepatic side-effects).

**PHEMIPAR IMPAIRMENT**

- Manufacturer advises caution in severe impairment—no information available.
PREGNANCY  Manufacturer advises avoid—toxicity in animal studies.

HEPATIC IMPAIRMENT  Manufacturer advises caution in severe impairment—no information available. Use with caution in patients with chronic hepatitis B or C (at greater risk of hepatic side-effects).

PRESCRIBING AND DISPENSING INFORMATION  Dispense raltegravir chewable tablets in original container (contains desiccant).

NATIONAL FUNDING/ACCESS DECISIONS  Scottish Medicines Consortium (SMC) Decisions The Scottish Medicines Consortium has advised (April 2010) that raltegravir (Isentress®) is accepted for restricted use within NHS Scotland for the treatment of HIV infection when non-nucleoside reverse transcriptase inhibitors or protease inhibitors cannot be used because of intolerance, drug interactions, or resistance.

MEDICINAL FORMS  There can be variation in the licensing of different medicines containing the same drug.

Tablet  CAUTIONARY AND ADVISORY LABELS  25
   • Isentress (Merck Sharp & Dohme Ltd)
   • Raltegravir 400 mg Isentress 400mg tablets | 60 tablet  £471.41

ANTIVIRALS  >  NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS  Efavirenz

INDICATIONS AND DOSE  HIV infection in combination with other antiretroviral drugs
   •一件事情 USING CAPSULES
   • Adult: 600 mg once daily
   •事情 USING TABLETS
   •成人: 600 mg once daily
   •事情 USING ORAL SOLUTION
   •成人: 720 mg once daily

DOSE EQUIVALENCE AND CONVERSION  The bioavailability of Sustiva® oral solution is lower than that of the capsules and tablets; the oral solution is not interchangeable with either capsules or tablets on a milligram-for-milligram basis.

UNLICENSED USE  Opening capsules and adding contents to food is an unlicensed method of administration.

CAUTIONS  Acute porphyrias p. 969  • elderly  • history of psychiatric disorders  • history of seizures

INTERACTIONS  >  Appendix 1: efavirenz

SIDE-EFFECTS  Common or very common Abdominal pain  • abnormal dreams  • anxiety  • depression  • diarrhoea  • dizziness  • fatigue  • headache  • impairead concentration  • nausea  • pruritus  • rash  • sleep disturbances  • Stevens-Johnson syndrome  • vomiting
   • Uncommon Amnesia  • ataxia  • blurred vision  • convulsions  • flushing  • gynaecomastia  • hepatitis  • hypersensitivity  • mania  • pancreatitis  • psychosis  • suicidal ideation  • tinnitus  • tremor  • vertigo
   • Rare Hepatic failure  • photosensitivity  • suicide
   • Frequency not known Lipodystrophy syndrome  • osteonecrosis  • raised serum cholesterol SIDE-EFFECTS, FURTHER INFORMATION

 Rash  Rash, usually in the first 2 weeks, is the most common side-effect; discontinue if severe rash with blistering, desquamation, mucosal involvement or fever; if rash mild or moderate, may continue without interruption—usually resolves within 1 month.

CNS effects  Administration at bedtime especially in first 2-4 weeks reduces CNS effects.

Osteonecrosis  For further information see HIV infection p. 604.

Immune Reconstitution Syndrome  For further information see HIV infection p. 604.

PREGNANCY  Reports of neural tube defects when used in first trimester.

HEPATIC IMPAIRMENT  Greater risk of hepatic side-effects in chronic hepatitis B or C. Avoid in moderate to severe impairment. In mild liver disease, monitor for dose related side-effects (e.g. CNS effects) and monitor liver function.

RENAL IMPAIRMENT  Manufacturer advises caution in severe renal failure—no information available.

MONITORING REQUIREMENTS  Monitor liver function if receiving other hepatotoxic drugs.

DIRECTIONS FOR ADMINISTRATION  Capsules may be opened and contents added to food (contents have a peppery taste).

PRESCRIBING AND DISPENSING INFORMATION  Flavours of oral liquid formulations may include strawberry and mint.

PATIENT AND CARER ADVICE  Psychiatric disorders  Patients or their carers should be advised to seek immediate medical attention if symptoms such as severe depression, psychosis or suicidal ideation occur.

MEDICINAL FORMS  There can be variation in the licensing of different medicines containing the same drug.

Tablet  CAUTIONARY AND ADVISORY LABELS  23
   • Efavirenz (Non-proprietary)
   • Efavirenz 600 mg Efavirenz 600mg tablets | 30 tablet  £200.27–£452.94  | 30 tablet  £18.33 (Hospital only)
   • Sustiva (Bristol-Myers Squibb Pharmaceuticals Ltd)
   • Efavirenz 600 mg Sustiva 600mg tablets | 30 tablet  £200.27 (Hospital only)

Capsule  CAUTIONARY AND ADVISORY LABELS  23
   • Sustiva (Bristol-Myers Squibb Pharmaceuticals Ltd)
   • Efavirenz 50 mg Sustiva 50mg capsules | 30 capsule  £16.73 (Hospital only)
   • Efavirenz 100 mg Sustiva 100mg capsules | 30 capsule  £33.41 (Hospital only)
   • Efavirenz 200 mg Sustiva 200mg capsules | 90 capsule  £200.27 (Hospital only)

Combinations available: Efavirenz with emtricitabine and tenofovir disoproxil, p. 612

Etravirine

INDICATIONS AND DOSE  HIV infection resistant to other non-nucleoside reverse transcriptase inhibitor and protease inhibitors in combination with other antiretroviral drugs (including a boosted protease inhibitor)

   • BY MOUTH
   • Adult: 200 mg twice daily, to be taken after food

CONTRA-INDICATIONS  Acute porphyrias p. 969

INTERACTIONS  >  Appendix 1: etravirine

SIDE-EFFECTS  Common or very common Abdominal pain  • anaemia  • diabetes  • flatulence  • gastritis  • gastro-oesophageal reflux  • hyperlipidaemia  • hypertension  • Lipodystrophy Syndrome  • myocardial infarction  • nausea  • peripheral neuropathy  • rash  • renal failure
   • Uncommon Angina  • blurred vision  • bronchospasm  • drowsiness  • dry mouth  • gynaecomastia  • haematemesis  • hepatitis  • malaise  • pancreatitis  • sweating
HIV infection in combination with other antiretroviral drugs (maintenance dose following initial dose titration if no rash present)

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: 200 mg twice daily
  - BY MOUTH USING MODIFIED-RELEASE MEDICINES
  - Adult: 400 mg once daily

**CONTRA-INDICATIONS**
Acute porphyrias p. 969 · post-exposure prophylaxis

**CAUTIONS**
Females (at greater risk of hepatic side effects) · high CD4 cell count (at greater risk of hepatic side effects)

**CAUTIONS, FURTHER INFORMATION**
- Hepatic effects
  - Patients with chronic hepatitis B or C, high CD4 cell count, and women are at increased risk of hepatic side effects— if plasma HIV-1 RNA detectable, manufacturer advises avoid in women with CD4 cell count greater than 250 cells/mm³ or in men with CD4 cell count greater than 400 cells/mm³ unless potential benefit outweighs risk.

**INTERACTIONS** 
Appendix 1: nevirapine

**SIDE-EFFECTS**
- Common or very common
  - Abdominal pain · diarrhoea · fatigue · fever · granulocytopenia · headache · hepatitis · hypersensitivity reactions (may involve hepatic reactions and rash) · nausea · rash · Stevens-Johnson syndrome · toxic epidermal necrolysis · vomiting

- Uncommon
  - Anaemia · arthralgia · myalgia

- Frequency not known
  - Osteonecrosis

**SIDE-EFFECTS, FURTHER INFORMATION**
- Hepatic effects
  - Potentially life-threatening hepatotoxicity including fatal fulminant hepatitis reported usually in first 6 weeks; discontinue permanently if abnormalities in liver function tests accompanied by hypersensitivity reaction (rash, fever, arthralgia, myalgia, lymphadenopathy, hepatitis, renal impairment, eosinophilia, granulocytopenia); suspend if severe abnormalities in liver function tests but no hypersensitivity reaction—discontinue permanently if significant liver function abnormalities recur; monitor patient closely if mild to moderate abnormalities in liver function tests with no hypersensitivity reaction.

- Rash
  - Rash, usually in first 6 weeks, is most common side-effect; incidence reduced if introduced at low dose and dose increased gradually (after 14 days); Discontinue permanently if severe rash or if rash accompanied by blistering, oral lesions, conjunctivitis, facial oedema, general malaise or hypersensitivity reactions; if rash mild or moderate may continue without interruption but dose should not be increased until rash resolves.

- Osteonecrosis
  - For more information see HIV infection p. 604.

**Hepatic impairment**
Manufacturer advises avoid modified-release preparation—no information available; use ‘immediate-release’ preparation with caution in moderate impairment and avoid in severe impairment. Use with caution in patients with chronic hepatitis B or C (at greater risk of hepatic side effects).

**Renal impairment**
Manufacturer advises avoid modified-release preparation—no information available.

**Monitoring requirements**
- Hepatic disease
  - Close monitoring of liver function required during first 18 weeks; monitor liver function before treatment then every 2 weeks for 2 months then after 1 month and then regularly.
  - Rash
  - Monitor closely for skin reactions during first 18 weeks.

**Patient and carer advice**
Hypersensitivity reactions
Patients or carers should be told how to recognise hypersensitivity reactions and advised to discontinue treatment and seek immediate medical attention.

---

**Rare**
- Stevens-Johnson syndrome

**Very rare**
- Toxic epidermal necrolysis

**Frequency not known**
- Haemorrhagic stroke · hypersensitivity reactions · osteonecrosis

**Side-effects, further information**
- Hypersensitivity reactions
  - Rash, usually in the second week, is the most common side-effect and appears more frequently in females. Life-threatening hypersensitivity reactions reported usually during week 3–6 of treatment and characterised by rash, eosinophilia, and systemic symptoms (including fever, general malaise, myalgia, arthralgia, blistering, oral lesions, conjunctivitis, and hepatitis). Discontinue permanently if hypersensitivity reaction or severe rash develop. If rash mild or moderate (without signs of hypersensitivity reaction), may continue without interruption—usually resolves within 2 weeks.

- Osteonecrosis
  - For further information see HIV infection p. 604.

**Hepatic impairment**
- Manufacturer advises caution in moderate impairment; avoid in severe impairment—no information available; greater risk of hepatic side-effects in chronic hepatitis B or C.

**Directions for administration**
- Patients with swallowing difficulties may disperse tablets in a glass of water just before administration.

**Prescribing and dispensing information**
- Dispense in original container (contains desiccant).

**Patient and carer advice**
- Hypersensitivity reactions
  - Patients or carers should be told how to recognise hypersensitivity reactions and advised to seek immediate medical attention if hypersensitivity reaction or severe rash develop.

- Missed doses
  - If a dose is more than 6 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

**Medicinal forms**
- There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- CAUTIONARY AND ADVISORY LABELS
  - **IntenCe** (Janssen-Cilag Ltd)
    - **Etravirine 25 mg** IntenCe 25mg tablets | 120 tablet £75.32
    - **Etravirine 100 mg** IntenCe 100mg tablets | 120 tablet £301.27
    - **Etravirine 200 mg** IntenCe 200mg tablets | 60 tablet £301.27

---

**Nevirapine**

**Indications and dose**

**HIV infection in combination with other antiretroviral drugs (initial dose)**

- **By mouth using immediate-release medicines**
  - Adult: Initially 200 mg once daily for first 14 days, initial dose titration using ‘immediate-release’ preparation should not exceed 28 days; if rash occurs and is not resolved within 28 days, alternative treatment should be sought. If treatment interrupted for more than 7 days, restart using the lower dose of the ‘immediate-release’ preparation for the first 14 days as for new treatment
attention if severe skin reaction, hypersensitivity reactions, or symptoms of hepatitis develop.

Missed doses
If a dose is more than 8 hours late with the ‘immediate-release’ preparation (or more than 12 hours late with the modified-release preparation), the missed dose should not be taken and the next dose should be taken at the usual time.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Oral suspension
- Viramune (Boehringer Ingelheim Ltd)
- Nevirapine (as Nevirapine hemihydrate) 10 mg per 1 ml Viramune 50mg/5ml oral suspension | 240 ml $50.40

Modified-release tablet
CAUTIONARY AND ADVISORY LABELS 25
- Nevirapine (Non-proprietary)
  - Nevirapine 400 mg Nevirapine 400mg modified-release tablets | 30 tablet POM £52.13–£161.50
  - Nevirapine 100 mg Nevirapine 100mg modified-release tablets | 90 tablet POM £17.50 (Hospital only)
  - Nevirapine 400 mg Nevirapine 400mg modified-release tablets | 30 tablet POM £170.00 (Hospital only)

Tablet
- Nevirapine (Non-proprietary)
  - Nevirapine 200 mg Nevirapine 200mg tablets | 14 tablet POM £33.69 | 60 tablet POM £21.45–£170.00
  - Viramune (Boehringer Ingelheim Ltd)
  - Nevirapine 200 mg Viramune 200mg tablets | 14 tablet POM £39.67 | 60 tablet POM £170.00

Rilpivirine 28-Sep-2016

INDICATIONS AND DOSE
HIV infection in combination with other antiretroviral drugs in patients not previously treated with antiretroviral therapy and if plasma HIV-1 RNA concentration less than or equal to 100 000 copies/mL
- BY MOUTH
- Adult: 25 mg once daily

INTERACTIONS  Appendix 1: rilpivirine
SIDE-EFFECTS
Abdominal pain  anorexia  arthralgia  blood disorders  cough  diarrhea  dizziness  dyspnoea  fatigue  fever  flatulence  gastrointestinal disturbances  headache  insomnia  liver damage  metabolic effects  myalgia  nausea  neutropenia  osteonecrosis  pancreatitis  rash  thrombocytopenia  urticaria  vomiting
SIDE-EFFECTS, FURTHER INFORMATION
- Osteonecrosis  For further information see HIV infection p. 604.
- PREGNANCY  Mitochondrial dysfunction has been reported in infants exposed to nucleoside reverse transcriptase inhibitors in utero; the main effects include haematological, metabolic, and neurological disorders; all infants whose mothers received nucleoside reverse transcriptase inhibitors during pregnancy should be monitored for relevant signs or symptoms.
- HEPATIC IMPAIRMENT  Use with caution in patients with chronic hepatitis B or C (greater risk of hepatic side-effects).

Abacavir

INDICATIONS AND DOSE
HIV infection in combination with other antiretroviral drugs
- BY MOUTH
- Adult: 600 mg daily in 1–2 divided doses

CAUTIONS
HIV load greater than 100 000 copies/mL  patients at high risk of cardiovascular disease (especially if 10-year cardiovascular risk greater than 20%)

INTERACTIONS  Appendix 1: abacavir
SIDE-EFFECTS
- Very rare  Stevens-Johnson syndrome  toxic epidermal necrolysis
- Frequency not known  Hypersensitivity reactions

SIDE-EFFECTS, FURTHER INFORMATION
- Hypersensitivity reactions  Life-threatening hypersensitivity reactions reported—characterised by fever or rash and possibly nausea, vomiting, diarrhea, abdominal pain, dyspnoea, cough, lethargy, malaise, headache, and myalgia; less frequently mouth ulceration, oedema, hypotension, sore throat, acute respiratory distress syndrome, anaphylaxis, paraesthesia, arthralgia, conjunctivitis, lymphadenopathy, lymphocytopenia and renal failure; rarely myolysis; laboratory abnormalities may include raised liver function tests and creatine kinase; symptoms usually appear in the first 6 weeks, but may occur at any time.
Discontinue immediately if any symptom of hypersensitivity develops and do not rechallenge (risk of more severe hypersensitivity reaction); discontinue if hypersensitivity cannot be ruled out, even when other diagnoses possible—if rechallenge necessary it must be carried out in hospital setting; if abacavir is stopped for any reason other than hypersensitivity, exclude hypersensitivity reaction as the cause and rechallenge only if medical assistance is readily available; care needed with concomitant use of drugs which cause skin toxicity.

- Rash More common in children.

**ALLERGY AND CROSS-SENSITIVITY** Caution—increased risk of hypersensitivity reaction in presence of HLA-B*5701 allele.

**HEPATIC IMPAIRMENT** Monitor closely in mild impairment (combination preparations not recommended as reduced abacavir dose may be required). Avoid in moderate impairment unless essential—close monitoring recommended. Avoid in severe impairment.

**RENAL IMPAIRMENT** Manufacturer advises avoid in end-stage renal disease.

**PRE-TREATMENT SCREENING** Test for HLA-B*5701 allele before treatment or if restarting treatment and HLA-B*5701 status not known.

**MONITORING REQUIREMENTS** Monitor for symptoms of hypersensitivity reaction every 2 weeks for 2 months.

**PRESCRIBING AND DISPENSING INFORMATION** Flavours of oral liquid formulations may include banana, or strawberry.

**PATIENT AND CARER ADVICE** Patients should be provided with an alert card and advised to keep it with them at all times.

Patients and their carers should be told the importance of regular dosing (intermittent therapy may increase the risk of sensitisation), how to recognise signs of hypersensitivity, and advised to seek immediate medical attention if symptoms develop or before re-starting treatment.

**INDICATIONS AND DOSE**

**HIV infection**

**BY MOUTH**

Adult (body-weight 40 kg and above): 1 tablet once daily

**PATIENT AND CARER ADVICE**

Missed doses

If a dose is more than 20 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- *Triumeq* (ViiV Healthcare UK Ltd)
  - Dolutegravir (as Dolutegravir sodium) 50 mg, Lamivudine 300 mg, Abacavir (as Abacavir sulfate) 600 mg
  - Triumeq 50mg/600mg/300mg tablets | 30 tablet pack £79.816

**Abacavir with lamivudine**

The properties listed below are those particular to the combination only. For the properties of the components please consider, abacavir p. 610, lamivudine p. 615.

**INDICATIONS AND DOSE**

**HIV infection in combination with other antiretrovirals**

**BY MOUTH**

Adult (body-weight 40 kg and above): 1 tablet once daily

**INTERACTIONS**

- Appendix 1: abacavir, lamivudine

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- *Abacavir with lamivudine (Non-proprietary)*
  - Lamivudine 300 mg, Abacavir 600 mg
  - Lamivudine 300mg tablets | 30 tablet pack £150.83-£299.41 | 30 tablet pack £224.56 (Hospital only)
  - *Kivexa* (ViiV Healthcare UK Ltd)
  - Lamivudine 300 mg, Abacavir 600 mg
  - Kivexa 600mg/300mg tablets | 30 tablet pack £299.41

**Abacavir with lamivudine and zidovudine**

The properties listed below are those particular to the combination only. For the properties of the components please consider, abacavir p. 610, lamivudine p. 615, zidovudine p. 617.

**INDICATIONS AND DOSE**

**HIV infection (use only if patient is stabilised for 6–8 weeks on the individual components in the same proportions)**

**BY MOUTH**

- Adult: 1 tablet twice daily

**INTERACTIONS**

- Appendix 1: abacavir, lamivudine, zidovudine

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- *Trizivir* (ViiV Healthcare UK Ltd)
  - Lamivudine 150 mg, Abacavir (as Abacavir sulfate) 300 mg, Zidovudine 300 mg
  - Trizivir tablets | 60 tablet pack £432.70

**Abacavir with dolutegravir and lamivudine**

The properties listed below are those particular to the combination only. For the properties of the components please consider, abacavir p. 610, lamivudine p. 615, dolutegravir p. 606.

**INDICATIONS AND DOSE**

**HIV infection**

**BY MOUTH**

- Adult (body-weight 40 kg and above): 1 tablet once daily

**INTERACTIONS**

- Appendix 1: abacavir, dolutegravir, lamivudine

**RENAI IMPAIRMENT**

- Avoid *Triumeq* if eGFR less than 50 mL/minute/1.73 m² (consult product literature).
Didanosine (ddI; DDI)

**INDICATIONS AND DOSE**

HIV infection in combination with other antiretroviral drugs

- **BY MOUTH**
  - Adult (body-weight up to 60 kg): 250 mg daily in 1–2 divided doses
  - Adult (body-weight 60 kg and above): 400 mg daily in 1–2 divided doses

**CAUTIONS**  History of pancreatitis (preferably avoid, otherwise extreme caution) · hyperuricaemia · lactic acidosis · peripheral neuropathy

**CAUTIONS, FURTHER INFORMATION**

- Lactic acidosis  Lactic acidosis associated with hepatomegaly and hepatic steatosis has been reported with didanosine. Use with caution in patients with hepatomegaly, hepatitis, or other risk factors for liver disease and hepatic steatosis (including obesity and alcohol abuse). Discontinue treatment if symptoms of hyperlactataemia, lactic acidosis, progressive hepatomegaly or rapid deterioration of liver function become apparent.

**INTERACTIONS**  → Appendix 1: didanosine

**SIDE-EFFECTS**

- Acute renal failure · alopecia · anaphylactic reactions · diabetes mellitus · dry eyes · dry mouth · hyperuricaemia (suspend if raised significantly) · hypoglycaemia · lactic acidosis · lipodystrophy · liver failure · non-cirrhotic portal hypertension · optic nerve changes · pancreatitis (less common in children) · parotid gland enlargement · peripheral neuropathy (switch to another antiretroviral if peripheral neuropathy develops) · retinal changes · rhabdomyolysis · sialadenitis

**SIDE-EFFECTS, FURTHER INFORMATION**

- Pancreatitis  Suspend treatment if serum lipase raised (even if asymptomatic) or if symptoms of pancreatitis develop; discontinue if pancreatitis confirmed. Whenever possible avoid concomitant treatment with other drugs known to cause pancreatic toxicity (e.g. intravenous pentamidine isetionate); monitor closely if concomitant therapy unavoidable. Since significant elevations of triglycerides cause pancreatitis monitor closely if elevated.

- Lipodystrophy syndrome  Metabolic effects may occur with antiretroviral regimens containing didanosine; these include fat redistribution, insulin resistance, and dyslipidaemia—collectively termed lipodystrophy syndrome. The usual risk factors for cardiovascular disease should be taken into account before starting therapy and patients should be advised about lifestyle changes to reduce their cardiovascular risk. Plasma lipids and blood glucose should be measured before starting treatment, after 3–6 months of treatment, and then annually.

- PREGNANCY  Manufacturer advises use only if potential benefit outweighs risk.

- HEPATIC IMPAIRMENT  Insufficient information. In hepatic impairment, monitor for toxicity.

- RENAL IMPAIRMENT  Reduce dose if eGFR less than 60 mL/minute/1.73 m²; consult product literature.

- MONITORING REQUIREMENTS  Ophthalmological examination (including visual acuity, colour vision, and dilated fundus examination) recommended annually or if visual changes occur.

- DIRECTIONS FOR ADMINISTRATION  Capsules should be swallowed whole and taken at least 2 hours before or 2 hours after food.

  With chewable tablets, to ensure sufficient antacid, each dose to be taken as at least 2 tablets chewed thoroughly, crushed or dispersed in water; clear apple juice may be added for flavouring; tablets to be taken 2 hours after lopinavir with ritonavir capsules and oral solution or atazanavir with ritonavir.

**PATIENT AND CARER ADVICE**  Patients or carers should be given advice on how to administer didanosine capsules and chewable tablets.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Gastro-resistant capsule**

**CAUTIONARY AND ADVISORY LABELS** 25

- Videx EC  (Bristol-Myers Squibb Pharmaceuticals Ltd)
  - Didanosine 125 mg Videx EC 125mg capsules | 30 capsule £48.18 (Hospital only)
  - Didanosine 200 mg Videx EC 200mg capsules | 30 capsule £77.09 (Hospital only)
  - Didanosine 250 mg Videx EC 250mg capsules | 30 capsule £96.37 (Hospital only)
  - Didanosine 400 mg Videx EC 400mg capsules | 30 capsule £154.19 (Hospital only)

**Chewable tablet**

**CAUTIONARY AND ADVISORY LABELS** 23

**EXCIPIENTS:** May contain Aspartame

- Videx  (Bristol-Myers Squibb Pharmaceuticals Ltd)
  - Didanosine 25 mg Videx 25mg chewable dispersible tablets sugar-free | 60 tablet £25.06 (Hospital only)

Efavirenz with emtricitabine and tenofovir disoproxil

The properties listed below are those particular to the combination only. For the properties of the components please consider, tenofovir disoproxil p. 616, efavirenz p. 608, emtricitabine p. 613.

**INDICATIONS AND DOSE**

HIV infection stabilised on antiretroviral therapy for more than 3 months

- **BY MOUTH**
  - Adult: 1 tablet once daily

**INTERACTIONS**  → Appendix 1: efavirenz, tenofovir

**HEPATIC IMPAIRMENT**  Manufacturer of Atripla® advises caution in mild impairment; avoid Atripla® in moderate to severe impairment.

**RENAI IMPAIRMENT**  Avoid Atripla® if eGFR less than 50 mL/minute/1.73 m².

**PATIENT AND CARER ADVICE**

Missed doses

If a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

**CAUTIONARY AND ADVISORY LABELS** 23, 25

- Atripla  (Gilead Sciences International Ltd)
  - Emtricitabine 200 mg, Tenofovir disoproxil (as Tenofovir disoproxil fumarate) 245 mg, Efavirenz 600 mg Atripla 600mg/200mg/245mg tablets | 30 tablet £53.87
Elvitegravir with cobicistat, emtricitabine and tenofovir alafenamide

The properties listed below are those particular to the combination only. For the properties of the components please consider, tenofovir disoproxil p. 616, emtricitabine below, cobicistat p. 622.

- **INDICATIONS AND DOSE**
  - **HIV infection (specialist use only)**
    - By mouth
    - Adult: 1 tablet once daily

- **INTERACTIONS**
  - Appendix 1: cobicistat, elvitegravir, tenofovir

- **SIDE-EFFECTS**
  - Uncommon Angioedema

- **CONCEPTION AND CONTRACEPTION**
  - Manufacturer advises effective contraception in women of childbearing potential; if using a hormonal contraceptive, it must contain norgestimate as the progestogen and at least 30 micrograms ethinylestradiol—no information available on progestogens other than norgestimate.

- **HEPATIC IMPAIRMENT**
  - Manufacturer advises use with caution in mild-to-moderate impairment (greater risk of hepatic side-effects); avoid in severe impairment—no information available.

- **RENAL IMPAIRMENT**
  - Manufacturer advises avoid if creatinine clearance less than 30 mL/minute—limited information available.

- **PRESCRIBING AND DISPENSING INFORMATION**
  - Dispense in original container—contains desiccant.

- **PATIENT AND CARER ADVICE**
  - Driving and skilled tasks
    - Manufacturer advises patients and carers should be counselled on the effects on driving and performance of skilled tasks—increased risk of dizziness.

- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **Scottish Medicines Consortium (SMC) Decisions**
    - The Scottish Medicines Consortium has advised (June 2016) that elvitegravir with cobicistat, emtricitabine and tenofovir alafenamide (Genvoya) is accepted for use within NHS Scotland for the treatment of human immunodeficiency virus type 1 (HIV-1), without known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir. This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.

  - **All Wales Medicines Strategy Group (AWMSG) Decisions**
    - The All Wales Medicines Strategy Group has advised (July 2016) that elvitegravir with cobicistat, emtricitabine and tenofovir alafenamide (Genvoya) is recommended as an option for use within NHS Wales for the treatment of human immunodeficiency virus type 1 (HIV-1), without known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir. The recommendation applies only if the approved Wales Patient Access Scheme (WPAS) is used or where the list price is equivalent or lower.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  - **Tablet**
    - CAUTIONARY AND ADVISORY LABELS 21
      - Genvoya (Gilead Sciences International Ltd)
        - Tenofovir alafenamide 10 mg, Cobicistat 150 mg, Elvitegravir 150 mg, Emtricitabine 200 mg
        - Genovaya 150mg/150mg/200mg/10mg tablets | 30 tablet

Elvitegravir with cobicistat, emtricitabine and tenofovir disoproxil

The properties listed below are those particular to the combination only. For the properties of the components please consider, tenofovir disoproxil p. 616, emtricitabine below, cobicistat p. 622.

- **INDICATIONS AND DOSE**
  - **HIV infection**
    - By mouth
    - Adult: 1 tablet once daily

- **INTERACTIONS**
  - Appendix 1: cobicistat, elvitegravir, tenofovir

- **SIDE-EFFECTS**
  - Uncommon Depression and suicidal ideation (in patients with a history of psychiatric illness)

- **CONCEPTION AND CONTRACEPTION**
  - Women of childbearing potential should use effective contraception during treatment (if using a hormonal contraceptive, it must contain norgestimate as the progestogen and at least 30 micrograms ethinylestradiol).

- **PREGNANCY**
  - Manufacturer advises use only if potential benefit outweighs risk.

- **HEPATIC IMPAIRMENT**
  - Avoid Stribild in severe impairment.

- **RENAL IMPAIRMENT**
  - If eGFR less than 90 mL/minute/1.73 m², only initiate Stribild if other treatments cannot be used (avoid initiating Stribild if eGFR less than 70 mL/minute/1.73 m²); if eGFR less than 70 mL/minute/1.73 m², only continue Stribild if potential benefit outweighs risk (discontinue Stribild if eGFR less than 50 mL/minute/1.73 m²).

- **MONITORING REQUIREMENTS**
  - Test urine glucose before treatment, then every 4 weeks for 1 year and then every 3 months.

- **DIRECTIONS FOR ADMINISTRATION**
  - Avoid antacids 4 hours before or 4 hours after taking Stribild.

- **PRESCRIBING AND DISPENSING INFORMATION**
  - Dispense in original container (contains desiccant).

- **PATIENT AND CARER ADVICE**
  - Patients or carers should be given advice on how to administer Stribild.

- **Missed doses**
  - If a dose is more than 18 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  - **Tablet**
    - CAUTIONARY AND ADVISORY LABELS 21
      - Stribild (Gilead Sciences International Ltd)
        - Cobicistat 150 mg, Elvitegravir 150 mg, Emtricitabine 200 mg, Tenofovir disoproxil (as Tenofovir disoproxil fumarate) 245 mg
        - Stribild 150mg/150mg/200mg/245mg tablets | 30 tablet
        - £879.51

Emtricitabine (FTC)

- **INDICATIONS AND DOSE**
  - **HIV infection in combination with other antiretroviral drugs**
    - By mouth using capsules
    - Adult: 200 mg once daily
    - By mouth using oral solution
    - Adult: 240 mg once daily
Emtricitabine with rilpivirine and tenofovir alafenamide

The properties listed below are those particular to the combination only. For the properties of the components please consider, emtricitabine p. 613, rilpivirine p. 610.

**INDICATIONS AND DOSE**

HIV infection in patients with plasma HIV-1 RNA concentration of 100 000 copies/mL or less (specialist use only)

- **BY MOUTH**
  - Adult: 1 tablet once daily

**INTERACTIONS** → Appendix 1: rilpivirine, tenofovir

**SIDE-EFFECTS**

- **Common or very common** Raised bilirubin
- **Uncommon** Angioedema, dyspepsia, severe skin reactions (with systemic symptoms)

**SIDE-EFFECTS, FURTHER INFORMATION**

- Severe skin reactions Systemic symptoms reported with severe skin reactions include fever, blisters, conjunctivitis, angioedema, elevated liver function tests, and eosinophilia.

**HEPATIC IMPAIRMENT**

Manufacturer advises use with caution in moderate impairment (greater risk of hepatic side-effects); avoid in severe impairment—no information available.

**RENAL IMPAIRMENT**

Manufacturer advises avoid if creatinine clearance less than 30 mL/minute—no information available.

**PATIENT AND CARER ADVICE**

Vomiting Manufacturer advises if vomiting occurs within 4 hours of taking a dose, a replacement dose should be taken.

Driving and skilled tasks

Manufacturer advises patients and carers should be counselled on the effects on driving and performance of skilled tasks—increased risk of dizziness.

**INDICATIONS AND DOSE**

HIV infection in patients with plasma HIV-1 RNA concentration less than 100 000 copies/mL

- **BY MOUTH**
  - Adult: 1 tablet once daily

**INTERACTIONS** → Appendix 1: rilpivirine, tenofovir

**HEPATIC IMPAIRMENT**

Manufacturer of Eviplera® advises caution in moderate impairment; avoid Eviplera® in severe impairment.

**RENAL IMPAIRMENT**

Avoid Eviplera® if eGFR less than 50 mL/minute/1.73 m².

**DIRECTIONS FOR ADMINISTRATION**

Avoid antacids 2 hours before or 4 hours after taking Eviplera®.

**PATIENT AND CARER ADVICE**

Patients or carers should be given advice on how to administer Eviplera®.

**Missed doses**

If a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

**DOSE EQUIVALENCE AND CONVERSION**

- 240 mg oral solution = 200 mg capsule; where appropriate the capsule may be used instead of the oral solution.

**SIDE-EFFECTS**

Abnormal dreams, hyperpigmentation, pruritus

**HEPATIC IMPAIRMENT**

On discontinuation, monitor patients with hepatitis B (risk of exacerbation of hepatitis).

**RENAL IMPAIRMENT**

Reduce dose if eGFR less than 50 mL/minute/1.73 m²; consult product literature.

**PRESCRIBING AND DISPENSING INFORMATION**

Flavours of oral liquid formulations may include candy.

**PATIENT AND CARER ADVICE**

- **Missed doses**
  - If a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Oral solution**

**ELECTROLYTES:** May contain Sodium

- **Emtriva** (Gilead Sciences International Ltd)
  - Emtricitabine 10 mg per 1 ml Emtriva 10mg/ml oral solution sugar-free 170 ml [POM] £39.53

**Capsule**

- **Emtriva** (Gilead Sciences International Ltd)
  - Emtricitabine 200 mg Emtriva 200mg capsules 30 capsule [POM] £138.98

**Emtricitabine with rilpivirine and tenofovir alafenamide**

The properties listed below are those particular to the combination only. For the properties of the components please consider, tenofovir disoproxil p. 610.

**INDICATIONS AND DOSE**

HIV infection in patients with plasma HIV-1 RNA concentration of 100 000 copies/mL or less (specialist use only)

- **BY MOUTH**
  - Adult: 1 tablet once daily

**INTERACTIONS** → Appendix 1: rilpivirine, tenofovir

**SIDE-EFFECTS**

- **Common or very common** Raised bilirubin
- **Uncommon** Angioedema, dyspepsia, severe skin reactions (with systemic symptoms)

**SIDE-EFFECTS, FURTHER INFORMATION**

- Severe skin reactions Systemic symptoms reported with severe skin reactions include fever, blisters, conjunctivitis, angioedema, elevated liver function tests, and eosinophilia.

**HEPATIC IMPAIRMENT**

Manufacturer advises use with caution in moderate impairment (greater risk of hepatic side-effects); avoid in severe impairment—no information available.

**RENAL IMPAIRMENT**

Manufacturer advises avoid if creatinine clearance less than 30 mL/minute—no information available.

**PATIENT AND CARER ADVICE**

Vomiting Manufacturer advises if vomiting occurs within 4 hours of taking a dose, a replacement dose should be taken.

Driving and skilled tasks

Manufacturer advises patients and carers should be counselled on the effects on driving and performance of skilled tasks—increased risk of dizziness.

**NATIONAL FUNDING/ACCESS DECISIONS**

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (October 2016) that emtricitabine with rilpivirine and tenofovir alafenamide (Odefsey®) is accepted for use within NHS Scotland for the treatment of human immunodeficiency virus type 1 (HIV-1), without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with viral load HIV-1 RNA of 100 000 copies/mL or less.

**All Wales Medicines Strategy Group (AWMSG) Decisions**

The All Wales Medicines Strategy Group has advised (November 2016) that emtricitabine with rilpivirine and tenofovir alafenamide (Odefsey®) is recommended as an option for use within NHS Wales for the treatment of human immunodeficiency virus type 1, without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with viral load HIV-1 RNA of 100 000 copies/mL or less.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

**CAUTIONARY AND ADVISORY LABELS**

- **Odefsey** (Gilead Sciences International Ltd) → Eviplera®
  - Rilpivirine (as Rilpivirine hydrochloride) 25 mg, Tenofovir alafenamide (as Tenofovir alafenamide fumarate) 25 mg, Emtricitabine 200 mg Odefsey 200mg/25mg/25mg tablets 30 tablet [POM] £525.95

**Emtricitabine with rilpivirine and tenofovir disoproxil**

The properties listed below are those particular to the combination only. For the properties of the components please consider, tenofovir disoproxil p. 610, emtricitabine p. 613, rilpivirine p. 610.

**INDICATIONS AND DOSE**

HIV infection in patients with plasma HIV-1 RNA concentration less than 100 000 copies/mL

- **BY MOUTH**
  - Adult: 1 tablet once daily

**INTERACTIONS** → Appendix 1: rilpivirine, tenofovir

**HEPATIC IMPAIRMENT**

Manufacturer of Eviplera® advises caution in moderate impairment; avoid Eviplera® in severe impairment.

**RENAL IMPAIRMENT**

Avoid Eviplera® if eGFR less than 50 mL/minute/1.73 m².

**DIRECTIONS FOR ADMINISTRATION**

Avoid antacids 2 hours before or 4 hours after taking Eviplera®.

**PATIENT AND CARER ADVICE**

Patients or carers should be given advice on how to administer Eviplera®.

**Missed doses**

If a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.
**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- Eviplera (Gilead Sciences International Ltd)
  - 25 mg, Emtricitabine 200 mg
  - Tenofovir disoproxil (as Tenofovir disoproxil fumarate)
  - 245 mg
  - Eviplera 200mg/25mg/245mg tablets | 30 tablet [Pom] £525.95

---

**Emtricitabine with tenofovir disoproxil**

The properties listed below are those particular to the combination only. For the properties of the components please consider, tenofovir disoproxil p. 616, emtricitabine p. 613.

### INDICATIONS AND DOSE

**HIV infection in combination with other antiretroviral drugs**

- **BY MOUTH**
- **Adult:** 1 tablet once daily

### INTERACTIONS

Appendix 1: tenofovir

### SIDE-EFFECTS

- **Uncommon**
  - Angioedema, dyspepsia

### HEPATIC IMPAIRMENT

Manufacturer advises use with caution (greater risk of hepatic side-effects).

### RENAL IMPAIRMENT

Manufacturer advises avoid if creatinine clearance less than 30 mL/minute—limited information available.

### PATIENT AND CARER ADVICE

Vomiting

Manufacturer advises if vomiting occurs within 1 hour of taking a dose, a replacement dose should be taken.

Missed doses

Manufacturer advises if a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

Driving and skilled tasks

Manufacturer advises patients and carers should be counselled on the effects on driving and performance of skilled tasks—increased risk of dizziness.

### NATIONAL FUNDING/ACCESS DECISIONS

Scottish Medicines Consortium (SMC) Decisions

The **Scottish Medicines Consortium** has advised (April 2017) that emtricitabine with tenofovir disoproxil (Truvada®) is accepted for use within NHS Scotland in combination with safer sex practices for pre-exposure prophylaxis of sexually acquired HIV-1 infection in adults at high risk.

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- Truvada (Gilead Sciences International Ltd)
  - Emtricitabine 200 mg, Tenofovir disoproxil (as Tenofovir disoproxil fumarate) 245 mg
  - Truvada tablets | 30 tablet [Pom] £355.73

---

**Lamivudine**

(3TC)

### INDICATIONS AND DOSE

**EPIVIR® ORAL SOLUTION**

**HIV infection in combination with other antiretroviral drugs**

- **BY MOUTH**
- **Adult:** 150 mg every 12 hours, alternatively 300 mg once daily

### EPIVIR® TABLETS

**HIV infection in combination with other antiretroviral drugs**

- **BY MOUTH**
- **Adult:** 150 mg every 12 hours, alternatively 300 mg once daily
**ZEFFIX ®**

Chronic hepatitis B infection either with compensated liver disease (with evidence of viral replication and histology of active liver inflammation or fibrosis) when first-line treatments cannot be used, or (in combination with another antiviral drug without cross-resistance to lamivudine) with decompensated liver disease

- **BY MOUTH**
  - Adult: 100 mg once daily, patients receiving lamivudine for concomitant HIV infection should continue to receive lamivudine in a dose appropriate for HIV infection

**CAUTIONS** Recurrent hepatitis in patients with chronic hepatitis B may occur on discontinuation of lamivudine

**INTERACTIONS** → Appendix 1: lamivudine

**SIDE-EFFECTS** Alopecia · muscle disorders · nasolabial symptoms · peripheral neuropathy · rhabdomyolysis

**BREAST FEEDING** Can be used with caution in women infected with chronic hepatitis B alone, providing that adequate measures are taken to prevent hepatitis B infection in infants.

**RENAL IMPAIRMENT** Reduce dose if eGFR less than 50 mL/minute/1.73 m²; consult product literature.

**MONITORING REQUIREMENTS** When treating chronic hepatitis B with lamivudine, monitor liver function tests every 3 months, and viral markers of hepatitis B every 3–6 months, more frequently in patients with advanced liver disease or following transplantation (monitoring to continue for at least 1 year after discontinuation— recurrent hepatitis may occur on discontinuation).

**PRESCRIBING AND DISPENSING INFORMATION** Flavours of oral liquid formulations may include banana and strawberry.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Oral solution**

EXCIPIENTS: May contain Sucrose

- **Epivir** (ViiV Healthcare UK Ltd)
  - Lamivudine 10 mg per 1 ml Epivir 50mg/5ml oral solution | 240 ml [POM] £33.16

**Tablet**

- **Epivir** (ViiV Healthcare UK Ltd)
  - Lamivudine 150 mg Epivir 150mg tablets | 60 tablet [POM] £121.82
  - Lamivudine 300 mg Epivir 300mg tablets | 30 tablet [POM] £133.89

- **Zeffix** (GliaSmithKline UK Ltd)
  - Lamivudine 100 mg Zeffix 100mg tablets | 28 tablet [POM] £78.09
  - Lamivudine 200 mg Zeffix 200mg tablets | 14 tablet [POM] £120.10

**Stavudine**

(d4T)

**INTERACTIONS AND DOSE**

HIV infection in combination with other antiretroviral drugs when no suitable alternative available and when prescribed for shortest period possible

- **BY MOUTH**
  - Adult (body-weight up to 60 kg): 30 mg every 12 hours, to be taken preferably at least 1 hour before food
  - Adult (body-weight 60 kg and above): 40 mg every 12 hours, to be taken preferably at least 1 hour before food

**CAUTIONS** Excessive alcohol intake · history of pancreatitis · history of peripheral neuropathy · lactic acidosis (especially when used in combination with didanosine)—use only if alternative regimens are not suitable

**SIDE-EFFECTS**

- Lactic acidosis Lactic acidosis associated with hepatomegaly and hepatic steatosis has been reported with stavudine. Use with caution in patients with hepatomegaly, hepatitis, or other risk factors for liver disease and hepatic steatosis (including obesity and alcohol abuse). Discontinue treatment if symptoms of hyperlactataemia, lactic acidosis, progressive hepatomegaly or rapid deterioration of liver function become apparent.

**INTERACTIONS** → Appendix 1: stavudine

**SIDE-EFFECTS**

- Common or very common Abnormal dreams · cognitive dysfunction · depression · drowsiness · peripheral neuropathy (switch to another antiretroviral if peripheral neuropathy develops) · pruritus

**INTERACTIONS**

- ** Frequencies of stavudine interactions:**
  - **Very common** Lipodystrophy syndrome · Metabolic effects may occur with antiretroviral regimens containing stavudine; these include fat redistribution, insulin resistance, and dyslipidaemia—collectively termed lipodystrophy syndrome. The usual risk factors for cardiovascular disease should be taken into account before starting therapy and patients should be advised about lifestyle changes to reduce their cardiovascular risk. Plasma lipids and blood glucose should be measured before starting treatment, after 3–6 months of treatment, and then annually.

**PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk.

**CAUTIONS, FURTHER INFORMATION**

- **RENAL IMPAIRMENT** Use half normal dose every 12 hours if eGFR 25–50 mL/minute/1.73 m². Use half normal dose every 24 hours if eGFR less than 25 mL/minute/1.73 m².

**PRESCRIBING AND DISPENSING INFORMATION**

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Oral solution**
    - **EXCIPIENTS:** May contain Sucrose
    - **Epivir** (ViiV Healthcare UK Ltd)
      - Lamivudine 10 mg per 1 ml Epivir 50mg/5ml oral solution | 240 ml [POM] £33.16
    - **Zeffix** (GliaSmithKline UK Ltd)
      - Lamivudine 100 mg Zeffix 100mg tablets | 28 tablet [POM] £78.09
      - Lamivudine 200 mg Zeffix 200mg tablets | 14 tablet [POM] £120.10
  - **Tablet**
    - **Epivir** (ViiV Healthcare UK Ltd)
      - Lamivudine 150 mg Epivir 150mg tablets | 60 tablet [POM] £121.82
      - Lamivudine 300 mg Epivir 300mg tablets | 30 tablet [POM] £133.89
    - **Zeffix** (GliaSmithKline UK Ltd)
      - Lamivudine 100 mg Zeffix 100mg tablets | 28 tablet [POM] £78.09
      - Lamivudine 200 mg Zeffix 200mg tablets | 14 tablet [POM] £120.10

**Stavudine**

**d4T**

01-Sep-2016

**Tenofovir disoproxil**

**INDICATIONS AND DOSE**

HIV infection in combination with other antiretroviral drugs | Chronic hepatitis B infection with compensated liver disease (with evidence of viral replication, and histologically documented active liver inflammation or fibrosis) | Chronic hepatitis B infection with decompensated liver disease

- **BY MOUTH**
  - Adult: 245 mg once daily

**DOSE EQUIVALENCE AND CONVERSION**

- 7.5 scoops of granules contains approx. 245 mg tenofovir disoproxil (as fumarate).
Zidovudine
(Azidothymidine; AZT)

**INDICATIONS AND DOSE**

**HIV infection in combination with other antiretroviral drugs**
- **BY MOUTH**
- Adult: 250–300 mg twice daily

**Prevention of maternal-fetal HIV transmission**
- **BY MOUTH, OR BY INTRAVENOUS INFUSION**
- Adult: Seek specialist advice (combination therapy preferred) (consult local protocol)

**HIV infection in combination with other antiretroviral drugs in patients temporarily unable to take zidovudine by mouth**
- **BY INTRAVENOUS INFUSION**
- Adult: 0.8–1 mg/kg every 4 hours usually for not more than 2 weeks, dose approximating to 1.2–1.5 mg/kg every 4 hours by mouth

**CONTRA-INDICATIONS**
Abnormally low haemoglobin concentration (consult product literature) • Abnormally low neutrophil counts (consult product literature) • acute porphyrias p. 969

**CAUTIONS**
Elderly • lactic acidosis • risk of haematological toxicity particularly with high dose and advanced disease • vitamin B12 deficiency (increased risk of neutropenia)

**CAUTIONS, FURTHER INFORMATION**
Lactic acidosis • Lactic acidosis associated with hepatomegaly and hepatic steatosis has been reported with zidovudine.

Use with caution in patients with hepatomegaly, hepatitis, or other risk factors for liver disease and hepatic steatosis (including obesity and alcohol abuse). Discontinue treatment if symptoms of hyperlactataemia, lactic acidosis, progressive hepatomegaly or rapid deterioration of liver function become apparent.

**INTERACTIONS**
-> Appendix 1: zidovudine

**SIDE-EFFECTS**
Anaemia (may require transfusion) • anxiety • chest pain • convulsions • depression • dizziness • drowsiness • gynaecomastia • influenza-like symptoms • lactic acidosis • lipodystrophy • loss of mental acuity • myopathy • neuropathy • paraesthesia • pigmentation of nails • pigmentation of oral mucosa • pigmentation of skin • pruritus • sweating • taste disturbance • urinary frequency

**SIDE-EFFECTS, FURTHER INFORMATION**
Anaemia and myelosuppression If anaemia or myelosuppression occur, reduce dose or interrupt treatment according to product literature, or consider other treatment.

Lipodystrophy syndrome Metabolic effects may occur with antiretroviral regimens containing zidovudine; these include fat redistribution, insulin resistance, and dyslipidaemia—collectively termed lipodystrophy syndrome. The usual risk factors for cardiovascular disease should be taken into account before starting therapy and patients should be advised about lifestyle changes to reduce their cardiovascular risk. Plasma lipids and blood glucose should be measured before starting treatment, after 3–6 months of treatment, and then annually.

**HEPATIC IMPAIRMENT**
Accumulation may occur.

**RENAL IMPAIRMENT**
Reduce oral dose to 300–400 mg daily in divided doses or intravenous dose to 1 mg/kg 3–4 times daily if eGFR is less than 10 mL/minute/1.73 m².

**MONITORING REQUIREMENTS**
Monitor full blood count after 4 weeks of treatment, then every 3 months.

**DIRECTIONS FOR ADMINISTRATION**
For intermittent intravenous infusion, dilute to a concentration of 2 mg/mL or 4 mg/mL with Glucose 5% and give over 1 hour.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Granules**

**CAUTIONARY AND ADVISORY LABELS. 21**
- **Viread** (Gilead Sciences International Ltd)
  - Tenofovir disoproxil (as Tenofovir disoproxil fumarate) 33 mg per 1 gram Viread 33mg/g granules | 60 gram (Pom) £54.50

**Tablet**

**CAUTIONARY AND ADVISORY LABELS. 21**
- **Viread** (Gilead Sciences International Ltd)
  - Tenofovir disoproxil (as Tenofovir disoproxil fumarate) 123 mg Viread 123mg tablets | 30 tablet (Pom) £102.60
  - Tenofovir disoproxil (as Tenofovir disoproxil fumarate) 163 mg Viread 163mg tablets | 30 tablet (Pom) £135.98
  - Tenofovir disoproxil (as Tenofovir disoproxil fumarate) 204 mg Viread 204mg tablets | 30 tablet (Pom) £170.19
  - Tenofovir disoproxil (as Tenofovir disoproxil fumarate) 245 mg Viread 245mg tablets | 30 tablet (Pom) £204.39
SYNOPSIS

**Zidovudine with lamivudine**

The properties listed below are those particular to the combination only. For the properties of the components please consider, zidovudine p. 617, lamivudine p. 615.

**INDICATIONS AND DOSE**

**HIV infection in combination with other antiretroviral drugs**—with low-dose ritonavir

- **BY MOUTH**
  - Adult: 300 mg once daily

**HIV infection in combination with other antiretroviral drugs**—with cobicistat

- **BY MOUTH**
  - Adult: 300 mg daily

**CAUTIONS** Cardiac conduction disorders—electrolyte disturbances—predisposition to QT interval prolongation

**INTERACTIONS** → Appendix 1: HIV—protease inhibitors

**SIDE-EFFECTS, FURTHER INFORMATION**

- Uncommon Abnormal dreams—alopecia—amnesia—anxiety—arthralgia—chest pain—cholelithiasis—depression—disorientation—dry mouth—dysphagia—gynaecomastia—haematuria—hypertension—increased appetite—mouth ulcers—nephrolithiasis—peripheral neuropathy—proteinuria—syncope—tenderness—urinary frequency—weight changes

- Rare Abnormal gait—cholecystitis—hepatosplenomegaly—oedema—palpitation

**ANTIVIRALS** > **PROTEASE INHIBITORS**

**Protease inhibitors**

- **CONTRA-INDICATIONS** Acute porphyrias p. 969

- **CAUTIONS** Haemophilia (increased risk of bleeding)


**SIDE-EFFECTS, FURTHER INFORMATION**

- Osteonecrosis For further information see HIV infection p. 604.

**HEPATIC IMPAIRMENT** Use with caution in patients with chronic hepatitis B or C (increased risk of hepatic side-effects).

**Atazanavir**

**INDICATIONS AND DOSE**

**HIV infection in combination with other antiretroviral drugs**—with low-dose ritonavir

- **BY MOUTH**
  - Adult: 300 mg once daily

**HIV infection in combination with other antiretroviral drugs**—with cobicistat

- **BY MOUTH**
  - Adult: 300 mg daily

**CAUTIONS** Cardiac conduction disorders—electrolyte disturbances—predisposition to QT interval prolongation

**INTERACTIONS** → Appendix 1: HIV—protease inhibitors

**SIDE-EFFECTS, FURTHER INFORMATION**

- Uncommon Abnormal dreams—alopecia—amnesia—anxiety—arthralgia—chest pain—cholelithiasis—depression—disorientation—dry mouth—dysphagia—gynaecomastia—haematuria—hypertension—increased appetite—mouth ulcers—nephrolithiasis—peripheral neuropathy—proteinuria—syncope—tenderness—urinary frequency—weight changes

- Rare Abnormal gait—cholecystitis—hepatosplenomegaly—oedema—palpitation

**ANTIVIRALS** > **PROTEASE INHIBITORS**

**Protease inhibitors**

- **CONTRA-INDICATIONS** Acute porphyrias p. 969

- **CAUTIONS** Haemophilia (increased risk of bleeding)


**SIDE-EFFECTS, FURTHER INFORMATION**

- Osteonecrosis For further information see HIV infection p. 604.

**HEPATIC IMPAIRMENT** Use with caution in patients with chronic hepatitis B or C (increased risk of hepatic side-effects).

**Atazanavir with cobicistat**

**INDICATIONS AND DOSE**

**HIV infection, in combination with other antiretroviral drugs** (initiated by a specialist)

- **BY MOUTH**
  - Adult: 300/150 mg once daily

**DOSE EQUIVALENCE AND CONVERSION**

- Dose expressed as x/y mg of atazanavir/cobicistat.
**CONTRA-INDICATIONS**  
Haemodialysis

**INTERACTIONS**  
Appendix 1: cobicistat, HIV-protease inhibitors

**SIDE-EFFECTS**

- **Common or very common**  
  Abdominal distension · dysgeusia · dyspepsia · hyperbilirubinemia · insomnia · jaundice · ocular icterus · somnolence
- **Uncommon**  
  Angioedema · asthma · cholestasis · erythema multiforme · gastritis · hepatitis · interstitial nephritis · malaise · muscle atrophy · pollakiuria · pyrexia · stomatitis · urticaria
- **Rare**  
  Eczema · myopathy · QTc prolongation · vasodilatation

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

<table>
<thead>
<tr>
<th>Table</th>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>21</th>
</tr>
</thead>
</table>
| Evotaz (Bristol-Myers Squibb Pharmaceuticals Ltd) | Cobicistat 150 mg, Atazanavir (as Atazanavir sulfate) 300 mg Evotaz 300mg/150mg tablets | 30 tablet  
  £323.38 |

### Darunavir

#### INDICATIONS AND DOSE

**HIV infection in combination with other antiretroviral drugs in patients previously treated with antiretroviral therapy—with low-dose ritonavir**

- **BY MOUTH**
  - Adult: 600 mg twice daily, alternatively 800 mg once daily, once daily dose only to be used if no resistance to darunavir, if plasma HIV-RNA concentration less than 100 000 copies/mL, and if CD4 cell count greater than 100 cells × 10⁶/litre

**HIV infection in combination with other antiretroviral drugs in patients previously treated with antiretroviral therapy—with cobicistat**

- **BY MOUTH**
  - Adult: 800 mg once daily, dose appropriate if no resistance to darunavir, if plasma HIV-RNA concentration less than 100 000 copies/mL, and if CD4 cell count greater than 100 cells × 10⁶/litre

**HIV infection in combination with other antiretroviral drugs in patients not previously treated with antiretroviral therapy—with low-dose ritonavir**

- **BY MOUTH**
  - Adult: 800 mg once daily

**HIV infection in combination with other antiretroviral drugs in patients not previously treated with antiretroviral therapy—with cobicistat**

- **BY MOUTH**
  - Adult: 800 mg once daily

**INTERACTIONS**  
Appendix 1: HIV-protease inhibitors

**SIDE-EFFECTS**

- **Common or very common**  
  Peripheral neuropathy · rash
- **Uncommon**  
  Abnormal dreams · acne · alopecia · angina · anxiety · arthralgia · conjunctival hyperaemia · cough · depression · dry eyes · dry mouth · dyspnoea · dysuria · eczema · erectile dysfunction · flushing · gynaecomastia · hypertension · hypothyroidism · increased appetite · increased sweating · memory impairment · myocardial infarction · nail discoloration · nephrolithiasis · osteoporosis · peripheral oedema · polyuria · pyrexia · QT interval prolongation · reduced libido · renal failure · severe skin rash · Stevens-Johnson syndrome · stomatitis · tachycardia · throat irritation · toxic epidermal necrolysis · weight changes

**Rare**  
Bradycardia · confusion · convulsions · haematemesis · palpitation · rhinorrhea · seborrhoeic dermatitis · syncope · visual disturbances

**SIDE-EFFECTS, FURTHER INFORMATION**

- **Rash**  
  Mild to moderate rash occurs commonly, usually within the first 4 weeks of therapy and resolves without stopping treatment. Severe skin rash (including Stevens-Johnson syndrome and toxic epidermal necrolysis) occurs less frequently and may be accompanied by fever, malaise, arthralgia, myalgia, oral lesions, conjunctivitis, hepatitis, or eosinophilia; treatment should be stopped if severe rash develops.

**ALLERGY AND CROSS-SENSITIVITY**  
Use with caution in patients with sulfonamide sensitivity.

**PREGNANCY**  
Manufacturer advises use only if potential benefit outweighs risk; if required, use the twice daily dose regimen.

**HEPATIC IMPAIRMENT**  
Manufacturer advises caution in mild to moderate impairment; avoid in severe impairment—no information available.

**MONITORING REQUIREMENTS**  
Monitor liver function before and during treatment.

**PRESCRIBING AND DISPENSING INFORMATION**  
Flavours of oral liquid formulations may include strawberry.

**PATIENT AND CARER ADVICE**

**Missed doses**

If a dose is more than 6 hours late on the twice daily regimen (or more than 12 hours late on the once daily regimen), the missed dose should not be taken and the next dose should be taken at the normal time.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Oral suspension**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>21</th>
</tr>
</thead>
</table>
| Prezista (Janssen-Cilag Ltd) | Darunavir (as Darunavir ethanolate) 100 mg per 1 ml Prezista 100mg/ml oral suspension sugar-free | 200 ml  
  £248.17 |

<table>
<thead>
<tr>
<th>Table</th>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>21</th>
</tr>
</thead>
</table>
| Prezista (Janssen-Cilag Ltd) | Darunavir (as Darunavir ethanolate) 75 mg Prezista 75mg tablets | 480 tablet  
  £446.70 |
| | Darunavir (as Darunavir ethanolate) 150 mg Prezista 150mg tablets | 240 tablet  
  £446.70 |
| | Darunavir (as Darunavir ethanolate) 400 mg Prezista 400mg tablets | 60 tablet  
  £297.80 |
| | Darunavir (as Darunavir ethanolate) 600 mg Prezista 600mg tablets | 60 tablet  
  £446.70 |
| | Darunavir (as Darunavir ethanolate) 800 mg Prezista 800mg tablets | 30 tablet  
  £297.80 |

### Darunavir with cobicistat

19-Apr-2017

The properties listed below are those particular to the combination only. For the properties of the components please consider, cobicistat p. 622, darunavir above.

#### INDICATIONS AND DOSE

**HIV infection, in combination with other antiretroviral drugs (initiated by a specialist)**

- **BY MOUTH**
  - Adult: 800/150 mg once daily, dosage should not be altered or therapy discontinued without instruction from the healthcare provider

#### DOSE EQUIVALENCE AND CONVERSION

- Dose expressed as x/y mg of darunavir/cobicistat.

#### CONTRA-INDICATIONS

Treatment-experienced patients with 1 or more darunavir resistance-associated mutations,
plasma HIV-RNA concentration of 100,000 copies/mL or greater, or CD4 count less than 100 cells × 10⁹/litre

- **CAUTIONS** Elderly
- **INTERACTIONS** → Appendix 1: cobicistat, HIV-protease inhibitors

- **SIDE-EFFECTS**
  - **Common or very common** Abdominal distension · angioedema · diabetes mellitus · dyspepsia · hypercholesterolaemia · hyperlipidaemia · hypertriglyceridaemia · pruritus · urticaria
  - **Uncommon** Asthenia · hepatitis

- **PREGNANCY**
  - **Manufacturer advises use only if potential benefit outweighs risk.**

### MEDICINAL FORMS

**Tablet**

<table>
<thead>
<tr>
<th>Cautionary and Advisory Labels 21</th>
</tr>
</thead>
</table>
| Cobicistat 150 mg, Darunavir (as Darunavir ethanolate) 800 mg Rezolsta 800mg/150mg tablets | 30 tablet [Base] £317.24

**Drug Action**

Fosamprenavir is a pro-drug of amprenavir.

#### INDICATIONS AND DOSE

**HIV infection in combination with other antiretroviral drugs—with low-dose ritonavir**

- **BY MOUTH**
  - **Adult:** 700 mg twice daily

**DOSE EQUIVALENT AND CONVERSION**

700 mg fosamprenavir is equivalent to approximately 600 mg amprenavir.

- **INTERACTIONS** → Appendix 1: HIV-protease inhibitors
- **SIDE-EFFECTS**
  - **Rare** Stevens-Johnson syndrome
  - **Frequency not known** Rash

**SIDE-EFFECTS, FURTHER INFORMATION**

- **Rash** Rash may occur, usually in the second week of therapy; discontinue permanently if severe rash with systemic or allergic symptoms or, mucosal involvement; if rash mild or moderate, may continue without interruption—usually resolves within 2 weeks and may respond to antihistamines.

- **PREGNANCY**
  - **Toxicity in animal studies; manufacturer advises use only if potential benefit outweighs risk; theoretical risk of hyperbilirubinaemia and renal stones in neonate if used at term.**
  - **Hepatic Impairment** Reduce dose in mild to moderate impairment. Not studied in severe impairment. Increased risk of nephrolithiasis.
  - **Renal Impairment** Use with caution. In patients with renal impairment, monitor for nephrolithiasis.

- **DIRECTIONS FOR ADMINISTRATION**
  - **Administer 1 hour before or 2 hours after a meal; may be administered with a low-fat light meal; in combination with didanosine tablets, allow 1 hour between each drug (antacids in didanosine tablets reduce absorption of indinavir); in combination with low-dose ritonavir, give with food.**

- **Prescribing and Dispensing Information**
  - Dispense in original container (contains desiccant).
  - **Patient and Carer Advice** Patients or carers should be given advice on how to administer fosamprenavir oral suspension.

- **Medicinal Forms**
  - **Tablet**
    - **Telzir (ViiV Healthcare UK Ltd)**
      - Fosamprenavir (as Fosamprenavir calcium) 50 mg per 1 ml Telzir 50mg/ml oral suspension | 225 ml [Plast] £58.70

---

### Indinavir

#### INDICATIONS AND DOSE

**HIV infection in combination with nucleoside reverse transcriptase inhibitors**

- **BY MOUTH**
  - **Adult:** Seek specialist advice

- **CAUTIONS** Ensure adequate hydration (risk of nephrolithiasis) · patients at high risk of cardiovascular disease (especially if 10-year cardiovascular risk greater than 20%) · patients at risk of nephrolithiasis (monitor for nephrolithiasis)

- **INTERACTIONS** → Appendix 1: HIV-protease inhibitors

- **SIDE-EFFECTS**
  - **Alopecia · crystalluria · dry mouth · dry skin · dysuria · haematuria · haemolytic anaemia · hyperpigmentation · hypoaesthesia · interstitial nephritis (with medullary calcification and cortical atrophy in asymptomatic severe leucocyturia) · nephrolithiasis (may require interruption or discontinuation) · paronychia · proteinuria · pyelonephritis**

- **PREGNANCY**
  - **Toxicity in animal studies; manufacturer advises use only if potential benefit outweighs risk; theoretical risk of hyperbilirubinaemia and renal stones in neonate if used at term.**

- **Hepatic Impairment** Reduce dose in mild to moderate impairment. Not studied in severe impairment. Increased risk of nephrolithiasis.

- **Renal Impairment** Use with caution. In patients with renal impairment, monitor for nephrolithiasis.

- **DIRECTIONS FOR ADMINISTRATION**
  - **Administer 1 hour before or 2 hours after a meal; may be administered with a low-fat light meal; in combination with didanosine tablets, allow 1 hour between each drug (antacids in didanosine tablets reduce absorption of indinavir); in combination with low-dose ritonavir, give with food.**

- **Prescribing and Dispensing Information**
  - Dispense in original container (contains desiccant).

- **Patient and Carer Advice**
  - Patients or carers should be given advice on how to administer indinavir capsules.

- **Less Suitable for Prescribing**
  - Indinavir is rarely used in the treatment of HIV-infection because it is associated with nephrolithiasis; it is considered to be less suitable for prescribing.

- **Medicinal Forms**
  - **Capsule**

---

### Lopinavir with ritonavir

#### INDICATIONS AND DOSE

**HIV infection in combination with other antiretroviral drugs**

- **BY MOUTH USING TABLETS**
  - **Adult:** 400/100 mg twice daily, alternatively 800/200 mg once daily, once daily dose to be used only in adults with a HIV strain that has less than 3 mutations to protease inhibitors.
MEDICINAL FORMS

BY MOUTH USING ORAL SOLUTION
Adult: 5 mL twice daily, to be taken with food, oral solution contains 400 mg lopinavir, 100 mg ritonavir/5 mL.

CAUTIONS Cardiac conduction disorders · pancreatitis · patients at high risk of cardiovascular disease (especially if 10-year cardiovascular risk greater than 20%) · structural heart disease

INTERACTIONS → Appendix 1: HIV-protease inhibitors

SIDE-EFFECTS

Common or very common Amenorrhoea · anxiety · arthralgia · colitis · hypertension · menorrhagia · neuropathy · night sweats · sexual dysfunction · weight change

Uncommon Abnormal dreams · alopecia · AV block · cerebrovascular accident · convulsions · deep vein thrombosis · dry mouth · gastrointestinal ulcer · haematuria · myocardial infarction · nephritis · rectal bleeding · stomatitis · tinnitus · tremor · visual disturbances

CAUTIONARY AND ADVISORY LABELS

Pregnancy Avoid oral solution due to high propylene glycol content; use tablets only if potential benefit outweighs risk (toxicity in animal studies).

Hepatic Impairment Avoid oral solution due to propylene glycol content; manufacturer advises avoid tablets in severe impairment.

Renal Impairment Avoid oral solution due to high propylene glycol content. Use tablets with caution in severe impairment.

Monitoring Requirements Monitor liver function before and during treatment.

Patient and Carer Advice Oral solution tastes bitter.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Oral solution

CAUTIONARY AND ADVISORY LABELS 21

EXCipients: May contain Alcohol, propylene glycol

Kaletra (AbbVie Ltd)
Ritonavir 20 mg per 1 mL, Lopinavir 80 mg per 1 mL Kaletra 80mg/20mg/1mL oral solution 300 mL

Tablet

CAUTIONARY AND ADVISORY LABELS 25

Kaletra (AbbVie Ltd)
Ritonavir 25 mg, Lopinavir 100 mg Kaletra 100mg/25mg tablets 60 tablet
Ritonavir 50 mg, Lopinavir 200 mg Kaletra 200mg/50mg tablets 120 tablet

Saquinavir

INDICATIONS AND DOSE

HIV infection in combination with other antiretrovirals in patients previously treated with antiretroviral therapy— with low-dose ritonavir

BY MOUTH
Adult: 1 g every 12 hours

HIV infection in combination with other antiretrovirals in patients not previously treated with antiretroviral therapy— with low-dose ritonavir

BY MOUTH
Adult: 500 mg every 12 hours for 7 days, then increased to 1 g every 12 hours

CONTRA-INDICATIONS Bradycardia · congenital QT prolongation · electrolyte disturbances · heart failure with reduced left ventricular ejection fraction · history of symptomatic arrhythmias · predisposition to cardiac arrhythmias

INTERACTIONS → Appendix 1: HIV-protease inhibitors

SIDE-EFFECTS

Common or very common Alopecia · changes in libido · dry mouth · dysphonia · increased appetite · peripheral neuropathy

Uncommon Convulsions · mucosal ulceration · renal impairment · visual impairment

Hepatic Impairment Manufacturer advises caution in moderate impairment; avoid in decompensated liver disease.

Renal Impairment Use with caution if eGFR less than 30 mL/minute/1.73 m².

Monitoring Requirements Monitor ECG before starting treatment (do not initiate treatment if QT interval over 450 milliseconds); if baseline QT interval less than 450 milliseconds, monitor ECG during treatment.
HEPATIC IMPAIRMENT

▶ Hepatotoxicity
▶ Rare

PREGNANCY

PATIENT AND CARER ADVICE

Arrhythmias Patients should be told how to recognise signs of arrhythmia and advised to seek medical attention if symptoms such as palpitation or syncope develop.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS 21

▶ Invirase (Roche Products Ltd)

Saquinavir (as Saquinavir mesilate) 500 mg Invirase 500mg tablets | 120 tablet [PSt] £251.26

INDICATIONS AND DOSE

HIV infection resistant to other protease inhibitors, in combination with other antiretroviral drugs in patients previously treated with antiretrovirals—with low-dose ritonavir

▶ BY MOUTH USING CAPSULES
▶ Adult: 500 mg twice daily

DOSE EQUIVALENCE AND CONVERSION

▶ The bioavailability of tipranavir oral solution is higher than that of the capsules; the oral solution is not interchangeable with the capsules on a milligram-for-milligram basis.

SAFETY AND PHARMACOTHERAPEUTIC CONSIDERATIONS

SAFETY AND PHARMACOTHERAPEUTIC CONSIDERATIONS

SIDE-EFFECTS

▶ Rare
▶ Frequency not known

Anorexia · dyspnoea · influenza-like symptoms · peripheral neuropathy · photosensitivity · renal impairment

SIDE-EFFECTS, FURTHER INFORMATION

Hepatotoxicity Potentially life-threatening hepatotoxicity reported. Discontinue if signs or symptoms of hepatitis develop or if liver-function abnormality develops (consult product literature).

PREGNANCY

Manufacturer advises use only if potential benefit outweighs risk—toxicity in animal studies.

HEPATIC IMPAIRMENT

Manufacturer advises caution in mild impairment; avoid in moderate or severe impairment—no information available.

MONITORING REQUIREMENTS

Monitor liver function before treatment then every 2 weeks for 1 month, then every 3 months.

PRESCRIBING AND DISPENSING INFORMATION

Flavours of oral liquid formulations may include toffee and mint.

PATIENT AND CARER ADVICE

Patients or carers should be told to observe the oral solution for crystallisation; the bottle should be replaced if more than a thin layer of crystals form (doses should continue to be taken at the normal time until the bottle is replaced).

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Oral solution

CAUTIONARY AND ADVISORY LABELS 5, 21

EXCIPIENTS: May contain Vitamin e

▶ Aptivus (Boehringer Ingelheim Ltd)

Tipranavir 100 mg per 1 ml Aptivus 100mg/ml oral solution sugar-free | 95 ml [PSt] £129.65

ANTIVIRALS > OTHER

Maraviroc

DRUG ACTION

Maraviroc is an antagonist of the CCR5 chemokine receptor.

INDICATIONS AND DOSE

CCR5-tropic HIV infection in combination with other antiretroviral drugs in patients previously treated with antiretrovirals

▶ BY MOUTH
▶ Adult: 300 mg twice daily

CAUTIONS

Cardiovascular disease

INTERACTIONS ➔ Appendix 1: maraviroc

SIDE-EFFECTS

▶ Common or very common

Abdominal pain · anaemia · anorexia · depression · diarrhoea · flatulence · headache · insomnia · malaise · nausea · rash

▶ Uncommon

Myositis · proteinuria · renal failure · seizures

▶ Rare

Angina · granulocytopenia · hepatitis · pancytopenia · Stevens-Johnson syndrome · toxic epidermal necrolysis

Frequency not known

Eosinophilia · fever · hepatic reactions · hypersensitivity reactions · osteonecrosis · rash

SIDE-EFFECTS, FURTHER INFORMATION

Osteonecrosis For further information see HIV infection p. 604.

PREGNANCY

Manufacturer advises use only if potential benefit outweighs risk—toxicity in animal studies.

HEPATIC IMPAIRMENT

Manufacturer advises caution in hepatic impairment, including patients with chronic hepatitis B or C.

RENAL IMPAIRMENT

If eGFR less than 80 mL/minute/1.73 m², consult product literature.

NATIONAL FUNDING/ACCESS DECISIONS

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (March 2008) that maraviroc (Celsentri®) is not recommended for use within NHS Scotland.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

▶ Celsentri (ViiV Healthcare UK Ltd)

Maraviroc 150 mg Celsentri 150mg tablets | 60 tablet [PSt] £441.27

Maraviroc 300 mg Celsentri 300mg tablets | 60 tablet [PSt] £441.27

PHARMACOKINETIC ENHANCERS

Cobicistat

INDICATIONS AND DOSE

Pharmacokinetic enhancer used to increase the effect of atazanavir or darunavir

▶ BY MOUTH
▶ Adult: 150 mg once daily

INTERACTIONS ➔ Appendix 1: cobicistat

PREGNANCY

Manufacturer advises avoid unless essential.

downloaded from www.medicalbr.com
**6.5 Influenza**

**Influenza**

**Management**

Oseltamivir below and zanamivir p. 625 are most effective for the treatment of influenza if started within a few hours of the onset of symptoms; they are licensed for use within 48 hours of the first symptoms. In otherwise healthy individuals they reduce the duration of symptoms by about 1–1.5 days. Oseltamivir or zanamivir can reduce the risk of complications from influenza in the elderly and in patients with chronic disease.

Oseltamivir and zanamivir are licensed for post-exposure prophylaxis of influenza when influenza is circulating in the community. Oseltamivir should be given within 48 hours of exposure to influenza while zanamivir should be given within 36 hours of exposure to influenza. However, in patients with severe influenza or in those who are immunocompromised, antivirals may still be effective after this time if viral shedding continues [unlicensed use]. Oseltamivir and zanamivir are also licensed for use in exceptional circumstances (e.g. when vaccination does not cover the infecting strain) to prevent influenza in an epidemic.

There is evidence that some strains of influenza A virus have reduced susceptibility to oseltamivir, but may retain susceptibility to zanamivir. Resistance to oseltamivir may be greater in severely immunocompromised patients.

Zanamivir should be reserved for patients who are severely immunocompromised, or when oseltamivir cannot be used, or when resistance to oseltamivir is suspected. For those unable to use the dry powder for inhalation, zanamivir is available as a solution that can be administered by nebuliser or intravenously [unlicensed].

Information on pandemic influenza, avian influenza, and swine influenza may be found at www.gov.uk/phe.

Immunisation against influenza is recommended for persons at high risk, and to reduce transmission of infection.

**Oseltamivir in children under 1 year of age**

Data on the use of oseltamivir in children under 1 year of age is limited. Furthermore, oseltamivir may be ineffective in neonates because they may not be able to metabolise oseltamivir to its active form. However, oseltamivir can be used (under specialist supervision) for the treatment or post-exposure prophylaxis of influenza in children under 1 year of age. The Department of Health has advised (May 2009) that during a pandemic, treatment with oseltamivir can be overseen by healthcare professionals experienced in assessing children.

**ANTIVIRALS > NEURAMINIDASE INHIBITORS**

**Oseltamivir**

**Drug action** Reduces replication of influenza A and B viruses by inhibiting viral neuraminidase.

**Indications and dose**

**Prevention of influenza**

- **By mouth**
  - Child 1–11 months: 3 mg/kg once daily for 10 days for post-exposure prophylaxis
  - Child 1–12 years (body-weight 10–15 kg): 30 mg once daily for 10 days for post-exposure prophylaxis; for up to 6 weeks during an epidemic
  - Child 1–12 years (body-weight 15–23 kg): 60 mg once daily for 10 days for post-exposure prophylaxis; for up to 6 weeks during an epidemic
  - Child 1–12 years (body-weight 23–40 kg): 90 mg once daily for 10 days for post-exposure prophylaxis; for up to 6 weeks during an epidemic
  - Child 1–12 years (body-weight 40 kg and above): 120 mg once daily for 10 days for post-exposure prophylaxis; for up to 6 weeks during an epidemic
  - Child 13–17 years: 75 mg once daily for 10 days for post-exposure prophylaxis; for up to 6 weeks during an epidemic
  - Adult: 75 mg once daily for 10 days for post-exposure prophylaxis; for up to 6 weeks during an epidemic

**Treatment of influenza**

- **By mouth**
  - Child 1–11 months: 3 mg/kg twice daily for 5 days
  - Child 1–12 years (body-weight 10–15 kg): 30 mg twice daily for 5 days
  - Child 1–12 years (body-weight 15–23 kg): 45 mg twice daily for 5 days
  - Child 1–12 years (body-weight 23–40 kg): 60 mg twice daily for 5 days
  - Child 1–12 years (body-weight 40 kg and above): 75 mg twice daily for 5 days
  - Child 13–17 years: 75 mg twice daily for 5 days
  - Adult: 75 mg twice daily for 5 days

**Unlicensed use** Not licensed for use in premature infants.

**Side-effects**

- **Common or very common** Abdominal pain · dyspepsia · headache · nausea · vomiting
- **Uncommon** Altered consciousness (in children) · altered consciousness (usually in children and adolescents) (in adults) · arrhythmias · convulsions · eczema · rash
- **Rare** Gastro-intestinal bleeding · hepatitis · neuropsychiatric disorders (in children) · neuropsychiatric disorders (usually in children and adolescents) (in adults) · Stevens-Johnson syndrome · thrombocytopenia · toxic epidermal necrolysis · visual disturbances
- **Pregnancy** Although safety data are limited, oseltamivir can be used in women who are pregnant when the potential benefit outweighs the risk (e.g. during a...
pandemic). Use only if potential benefit outweighs risk (e.g. during a pandemic).

**BREAST FEEDING** Although safety data are limited, oseltamivir can be used in women who are breast-feeding when the potential benefit outweighs the risk (e.g. during a pandemic). Oseltamivir is the preferred drug in women who are breast-feeding. Amount probably too small to be harmful; use only if potential benefit outweighs risk (e.g. during a pandemic).

**RENAL IMPAIRMENT**
- In adults For treatment, use 30 mg twice daily if eGFR 30–60 mL/minute/1.73 m² (30 mg once daily if eGFR 10–30 mL/minute/1.73 m²). For prevention, use 30 mg once daily if eGFR 30–60 mL/minute/1.73 m² (30 mg every 48 hours if eGFR 10–30 mL/minute/1.73 m²). Avoid for treatment and prevention if eGFR less than 10 mL/minute/1.73 m².
- In children For treatment, use 40% of normal dose twice daily if estimated glomerular filtration rate 30–60 mL/minute/1.73 m² (40% of normal dose once daily if estimated glomerular filtration rate 10–30 mL/minute/1.73 m²). For prevention, use 40% of normal dose once daily if estimated glomerular filtration rate 30–60 mL/minute/1.73 m² (40% of normal dose every 48 hours if estimated glomerular filtration rate 10–30 mL/minute/1.73 m²). Avoid for treatment and prevention if estimated glomerular filtration rate less than 10 mL/minute/1.73 m².

**DIRECTIONS FOR ADMINISTRATION** If suspension not available, capsules can be opened and the contents mixed with a small amount of sweetened food, such as sugar water or chocolate syrup, just before administration.

**PRESCRIBING AND DISPENSING INFORMATION** Flavours of oral liquid formulations may include tutti-frutti.

**PATIENT AND CARER ADVICE**
- Medicines for Children leaflet: Oseltamivir for influenza (flu)
  www.medicinesforchildren.org.uk/oseltamivir-for-influenza

**NATIONAL FUNDING/ACCESS DECISIONS**

### NICE technology appraisals (TAs)
- Oseltamivir, zanamivir, and amantadine for prophylaxis of influenza (September 2008) NICE TA158
  Oseltamivir is not a substitute for vaccination, which remains the most effective way of preventing illness from influenza.
- Oseltamivir is not recommended for seasonal prophylaxis against influenza.
- When influenza is circulating in the community, oseltamivirs an option recommended (in accordance with UK licensing) for post-exposure prophylaxis in at-risk patients who can start treatment within 48 hours of the onset of symptoms. (National surveillance schemes, including those run by Public Health England, should be used to indicate when influenza is circulating in the community.)
- During local outbreaks of influenza-like illness, when there is a high level of certainty that influenza is present, oseltamivir may be used for treatment in at-risk patients living in long-term residential or nursing homes.
- At risk patients include those aged over 65 years or those who have one or more of the following conditions:
  - chronic respiratory disease (including asthma and chronic obstructive pulmonary disease);
  - chronic heart disease;
  - chronic renal disease;
  - chronic liver disease;
  - chronic neurological disease;
  - immunosuppression;
  - diabetes mellitus.
  The Department of Health in England has advised (November 2010 and April 2011) that ‘at risk patients’ also includes patients under 65 years of age who are at risk of developing medical complications from influenza (treatment only) or women who are pregnant.
  This guidance does not cover the circumstances of a pandemic, an impending pandemic, or a widespread epidemic of a new strain of influenza to which there is little or no immunity in the community.
  www.nice.org.uk/TA158
- Oseltamivir, zanamivir, and amantadine for treatment of influenza (February 2009) NICE TA168
  Oseltamivir is not a substitute for vaccination, which remains the most effective way of preventing illness from influenza.
- When influenza is circulating in the community, oseltamivirs an option recommended (in accordance with UK licensing) for the treatment of influenza in at-risk patients who can start treatment within 48 hours of the onset of symptoms. (National surveillance schemes, including those run by Public Health England, should be used to indicate when influenza is circulating in the community.)
  - Local outbreaks of influenza-like illness, when there is a high level of certainty that influenza is present, oseltamivir may be used for treatment in at-risk patients living in long-term residential or nursing homes.
  - At risk patients include those aged over 65 years or those who have one or more of the following conditions:
  - chronic respiratory disease (including asthma and chronic obstructive pulmonary disease);
  - chronic heart disease;
  - chronic renal disease;
  - chronic liver disease;
  - chronic neurological disease;
  - immunosuppression;
  - diabetes mellitus.
  The Department of Health in England has advised (November 2010 and April 2011) that ‘at risk patients’ also includes patients under 65 years of age who are at risk of developing medical complications from influenza (treatment only) or women who are pregnant.
  This guidance does not cover the circumstances of a pandemic, an impending pandemic, or a widespread epidemic of a new strain of influenza to which there is little or no immunity in the community.
  www.nice.org.uk/TA168

**BNF 74**

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

### Oral solution

#### CAUTIONARY AND ADVISORY LABELS 9
- Oseltamivir (Non-proprietary)
  Oseltamivir (as Oseltamivir phosphate) 15 mg per
  1 ml Oseltamivir 15mg/ml oral solution sugar free sugar-free | 20 ml £0.10

#### Oral suspension

#### CAUTIONARY AND ADVISORY LABELS 9
EXCIPIENTS: May contain Sorbitol
- Tamiflu (Roche Products Ltd)
  Oseltamivir (as Oseltamivir phosphate) 6 mg per 1 ml
  Tamiflu 6mg/ml oral suspension sugar-free | 65 ml £10.27

*downloaded from www.medicalbr.com*
Zanamivir

**DRUG ACTION** Reduces replication of influenza A and B viruses by inhibiting viral neuraminidase.

**INDICATIONS AND DOSE**

**Post-exposure prophylaxis of influenza**
- **BY INHALATION OF POWDER**
  - Child 5-17 years: 10 mg once daily for 10 days
  - Adult: 10 mg once daily for 10 days

**Prevention of influenza during an epidemic**
- **BY INHALATION OF POWDER**
  - Child 5-17 years: 10 mg once daily for up to 28 days
  - Adult: 10 mg once daily for up to 28 days

**Treatment of influenza**
- **BY INHALATION OF POWDER**
  - Child 5-17 years: 10 mg twice daily for 5 days (for up to 10 days if resistance to oseltamivir suspected)
  - Adult: 10 mg twice daily for 5 days (for up to 10 days if resistance to oseltamivir suspected)

**UNLICENSED USE** Use of zanamivir for up to 10 days if resistance to oseltamivir suspected is an unlicensed duration.

**CAUTIONS** Asthma · chronic pulmonary disease · uncontrolled chronic illness

**CAUTIONS, FURTHER INFORMATION**
- Asthma and chronic pulmonary disease  Risk of bronchospasm—short-acting bronchodilator should be available.
- Avoid in severe asthma unless close monitoring possible and appropriate facilities available to treat bronchospasm.

**SIDE-EFFECTS**
- **Common or very common** Rash
- **Uncommon** Angioedema · bronchospasm · dyspnoea · urticaria
- **Rare** Neuropsychiatric disorders (in children) · neuropsychiatric disorders (especially in children and adolescents) (in adults) · Stevens-Johnson syndrome · toxic epidermal necrolysis

**PREGNANCY** Although safety data are limited, zanamivir can be used in women who are pregnant when the potential benefit outweighs the risk (e.g. during a pandemic). Use only if potential benefit outweighs risk (e.g. during a pandemic).

**BREAST FEEDING** Although safety data are limited, zanamivir can be used in women who are breast-feeding when the potential benefit outweighs the risk (e.g. during a pandemic). Amount probably too small to be harmful; use only if potential benefit outweighs risk (e.g. during a pandemic).

**DIRECTIONS FOR ADMINISTRATION** Other inhaled drugs should be administered before zanamivir.

**PRESCRIBING AND DISPENSING INFORMATION** Except for the treatment and prophylaxis of influenza as indicated in the NICE guidance; endorse prescription ‘SLS’.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**
- Oseltamivir, zanamivir, and amantadine for prophylaxis of influenza (September 2008) NICE TA158
  - Zanamivir is not a substitute for vaccination, which remains the most effective way of preventing illness from influenza.
  - Zanamivir is not recommended for seasonal prophylaxis against influenza.
  - When influenza is circulating in the community, zanamivir is an option recommended (in accordance with UK licensing) for post-exposure prophylaxis in at-risk patients who are not effectively protected by influenza vaccine, and who have been in close contact with someone suffering from influenza-like illness in the same household or residential setting. Zanamivir should be given within 36 hours of exposure to influenza.
    - (National surveillance schemes, including those run by Public Health England, should be used to indicate when influenza is circulating in the community).
  - During local outbreaks of influenza-like illness, when there is a high level of certainty that influenza is present, zanamivir may be used for post-exposure prophylaxis in at-risk patients (regardless of influenza vaccination) living in long-term residential or nursing homes.
  - At risk patients include those aged over 65 years or those who have one or more of the following conditions:
    - chronic respiratory disease (including asthma and chronic obstructive pulmonary disease);
    - chronic heart disease;
    - chronic renal disease;
    - chronic liver disease;
    - chronic neurological disease;
    - immunosuppression;
    - diabetes mellitus.

The Department of Health in England has advised (November 2010 and April 2011) that ‘at risk patients’ also includes patients under 65 years of age who are at risk of developing medical complications from influenza (treatment only) or women who are pregnant.

This guidance does not cover the circumstances of a pandemic, an impending pandemic, or a widespread epidemic of a new strain of influenza to which there is little or no immunity in the community.

www.nice.org.uk/TA158

- Oseltamivir, zanamivir, and amantadine for treatment of influenza (February 2009) NICE TA168
  - Zanamivir is not a substitute for vaccination, which remains the most effective way of preventing illness from influenza.
  - When influenza is circulating in the community, zanamivir is an option recommended (in accordance with UK licensing) for the treatment of influenza in at-risk patients who can start treatment within 48 hours (within 36 hours for zanamivir in children) of the onset of symptoms. (National surveillance schemes, including those run by Public Health England, should be used to indicate when influenza is circulating in the community.)
  - During local outbreaks of influenza-like illness, when there is a high level of certainty that influenza is present, zanamivir may be used for treatment in at-risk patients living in long-term residential or nursing homes.

At risk patients include those aged over 65 years or those who have one or more of the following conditions:
- chronic respiratory disease (including asthma and chronic obstructive pulmonary disease);
- chronic heart disease;
- chronic renal disease;
- chronic liver disease;
chronic neurological disease;
• immunosuppression;
• diabetes mellitus.
The Department of Health in England has advised (November 2010 and April 2011) that 'at risk patients' also includes patients under 65 years of age who are at risk of developing medical complications from influenza (treatment only) or women who are pregnant.

This guidance does not cover the circumstances of a pandemic, an impending pandemic, or a widespread epidemic of a new strain of influenza to which there is little or no immunity in the community.

www.nice.org.uk/TA168

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Inhalation powder
• Relenza (GlaxoSmithKline UK Ltd)
  Zanamivir 5 mg Relenza 5mg inhalation powder blisters with Diskhaler | 20 blister £16.36

6.6 Respiratory syncytial virus

Respiratory syncytial virus

Management in children
Ribavirin p. 593 is licensed for administration by inhalation for the treatment of severe bronchiolitis caused by the respiratory syncytial virus (RSV) in infants, especially when they have other serious diseases. However, there is no evidence that ribavirin produces clinically relevant benefit in RSV bronchiolitis.

Palivizumab is a monoclonal antibody licensed for preventing serious lower respiratory-tract disease caused by respiratory syncytial virus in children at high risk of the disease; it should be prescribed under specialist supervision and on the basis of the likelihood of hospitalisation.

Palivizumab is recommended for:
• children under 9 months of age with chronic lung disease (defined as requiring oxygen for at least 28 days from birth) and who were born preterm;
• children under 6 months of age with haemodynamically significant, acyanotic congenital heart disease who were born preterm.

Palivizumab should be considered for:
• children under 2 years of age with severe combined immunodeficiency syndrome;
• children under 1 year of age who require long-term ventilation;
• children 1–2 years of age who require long-term ventilation and have an additional co-morbidity (including cardiac disease or pulmonary hypertension).

For details of the preterm age groups included in the recommendations, see Immunisation against Infectious Disease (2006), available at www.gov.uk/dh.
Chapter 6
Endocrine system

1 Antidiuretic hormone disorders

Posterior pituitary hormones and antagonists

Posterior pituitary hormones

Diabetes insipidus

Vasopressin p. 630 (antiuretic hormone, ADH) is used in the treatment of pituitary ('cranial') diabetes insipidus as is its analogue desmopressin p. 628. Dosage is tailored to produce a slight diuresis every 24 hours to avoid water intoxication. Treatment may be required for a limited period only in diabetes insipidus following trauma or pituitary surgery.

Desmopressin is more potent and has a longer duration of action than vasopressin; unlike vasopressin it has no vasoconstrictor effect. It is given by mouth or intranasally for maintenance therapy, and by injection in the postoperative period or in unconscious patients. Desmopressin is also used in the differential diagnosis of diabetes insipidus. Following a dose intramuscularly or intranasally, restoration of the ability to concentrate urine after water deprivation confirms a diagnosis of cranial diabetes insipidus. Failure to respond occurs in nephrogenic diabetes insipidus. In nephrogenic and partial pituitary diabetes insipidus benefit may be gained from the paradoxical antidiuretic effect of thiazides.

Carbamazepine p. 297 is sometimes useful in partial pituitary diabetes insipidus [unlicensed]; it may act by sensitising the renal tubules to the action of remaining endogenous vasopressin.

Other uses

Desmopressin is also used to boost factor VIII concentration in mild to moderate haemophilia and in von Willebrand's disease; it is also used to test fibrinolytic response. Desmopressin may also have a role in nocturnal enuresis.

Vasopressin infusion is used to control variceal bleeding in portal hypertension, prior to more definitive treatment and with variable results. Terlipressin acetate, a derivative of vasopressin with reportedly less pressor and antidiuretic activity, is used similarly.

Oxytocin p. 775, another posterior pituitary hormone, is indicated in obstetrics.

Antidiuretic hormone antagonists

Demeclocycline hydrochloride p. 533 can be used in the treatment of hyponatraemia resulting from inappropriate secretion of antidiuretic hormone, if fluid restriction alone does not restore sodium concentration or is not tolerable. Demeclocycline hydrochloride is thought to act by directly blocking the renal tubular effect of antidiuretic hormone.

Tolvaptan p. 630 is a vasopressin V1-receptor antagonist licensed for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion; treatment duration with tolvaptan is determined by the underlying disease and its treatment.

Rapid correction of hyponatraemia during tolvaptan therapy can cause osmotic demyelination, leading to serious neurological events; close monitoring of serum sodium concentration and fluid balance is essential.

1.1 Diabetes insipidus

Other drugs used for Diabetes insipidus Chlortalidone, p. 224
Endocrine system

ANALOGUES
AND PITUITARY AND HYPOTHALAMIC HORMONES

PITUITARY AND HYPOTHALAMIC HORMONES
AND ANALOGUES

Desmopressin

09-Jun-2017

Desmopressin is an analogue of vasopressin.

**INDICATIONS AND DOSE**

**Diabetes insipidus, treatment**

- **BY MOUTH**
  - Child 1–23 months: Initially 10 micrograms 2–3 times a day, adjusted according to response; usual dose 30–150 micrograms daily
  - Child 2–11 years: Initially 50 micrograms 2–3 times a day, adjusted according to response; usual dose 100–800 micrograms daily
  - Child 12–17 years: Initially 100 micrograms 2–3 times a day, adjusted according to response; usual dose 0.2–1.2 mg daily
  - Adult: Initially 100 micrograms 3 times a day; maintenance 100–200 micrograms 3 times a day; usual dose 0.2–1.2 mg daily

- **BY SUBLINGUAL ADMINISTRATION**
  - Child 2–17 years: Initially 60 micrograms 3 times a day, adjusted according to response; usual dose 40–240 micrograms 3 times a day
  - Adult: Initially 60 micrograms 3 times a day, adjusted according to response; usual dose 40–240 micrograms 3 times a day

- **BY INTRANASAL ADMINISTRATION**
  - Child 1–23 months: Initially 2.5–5 micrograms 1–2 times a day, adjusted according to response
  - Child 2–11 years: Initially 5–20 micrograms 1–2 times a day, adjusted according to response
  - Child 12–17 years: Initially 10–20 micrograms 1–2 times a day, adjusted according to response
  - Adult: 10–40 micrograms daily in 1–2 divided doses

- **BY SUBCUTANEOUS INJECTION, OR BY INTRAVENTEVEN INJECTION, OR BY INTRAMUSCULAR INJECTION**
  - Adult: 1–4 micrograms daily

**Primary nocturnal enuresis**

- **BY MOUTH**
  - Child 5–17 years: 200 micrograms once daily, only increased to 400 micrograms if lower dose not effective; withdraw for at least 1 week for reassessment after 3 months, dose to be taken at bedtime, limit fluid intake from 1 hour before to 8 hours after administration
  - Adult 18–65 years: 200 micrograms once daily, only increased to 400 micrograms if lower dose not effective; withdraw for at least 1 week for reassessment after 3 months, dose to be taken at bedtime, limit fluid intake from 1 hour before to 8 hours after administration

- **BY SUBLINGUAL ADMINISTRATION**
  - Child 5–17 years: 120 micrograms once daily, increased if necessary to 240 micrograms once daily, dose to be taken at bedtime, limit fluid intake from 1 hour before to 8 hours after administration, dose to be increased only if lower dose not effective, reassess after 3 months by withdrawing treatment for at least 1 week
  - Adult 18–65 years: 120 micrograms once daily, increased if necessary to 240 micrograms once daily, dose to be taken at bedtime, limit fluid intake from 1 hour before to 8 hours after administration, dose to be increased only if lower dose not effective, reassess after 3 months by withdrawing treatment for at least 1 week

**Postoperative polyuria or polydipsia**

- **BY MOUTH**
  - Adult: Dose to be adjusted according to urine osmolality

**Polyuria or polydipsia after hypophysectomy**

- **BY SUBLINGUAL ADMINISTRATION**
  - Adult: Dose to be adjusted according to urine osmolality

**Idiopathic nocturnal polyuria in females**

- **BY SUBLINGUAL ADMINISTRATION**
  - Adult: 50 micrograms daily, to be taken 1 hour before bedtime

**Idiopathic nocturnal polyuria in males**

- **BY SUBLINGUAL ADMINISTRATION**
  - Adult: 50 micrograms daily, to be taken 1 hour before bedtime

**Diabetes insipidus, diagnosis (water deprivation test)**

- **BY INTRANASAL ADMINISTRATION**
  - Adult: 20 micrograms, limit fluid intake to 500 mL from 1 hour before to 8 hours after administration
  - **BY INTRAMUSCULAR INJECTION, OR BY SUBCUTANEOUS INJECTION**
  - Adult: 2 micrograms for 1 dose, limit fluid intake to 500 mL from 1 hour before to 8 hours after administration

**Nocturia associated with multiple sclerosis (when other treatments have failed)**

- **BY INTRANASAL ADMINISTRATION**
  - Adult 18–65 years: 10–20 micrograms once daily, to be taken at bedtime, dose not to be repeated within 24 hours, limit fluid intake from 1 hour before to 8 hours after administration

**Renal function testing**

- **BY INTRANASAL ADMINISTRATION**
  - Adult: 40 micrograms, empty bladder at time of administration and limit fluid intake to 500 mL from 1 hour before until 8 hours after administration to avoid fluid overload
  - **BY SUBCUTANEOUS INJECTION, OR BY INTRAMUSCULAR INJECTION**
  - Adult: 2 micrograms, empty bladder at time of administration and restrict fluid intake to 500 mL from 1 hour before until 8 hours after administration to avoid fluid overload

**Mild to moderate haemophilia and von Willebrand’s disease**

- **BY INTRANASAL ADMINISTRATION**
  - Adult: 300 micrograms every 12 hours if required, one 150 microgram spray into each nostril, 30 minutes before surgery or when bleeding, dose may alternatively be repeated at intervals of at least 3 days, if self-administered
  - **BY INTRAVENOUS INFUSION, OR BY SUBCUTANEOUS INJECTION**
  - Adult: 300 nanograms/kg for 1 dose, to be administered immediately before surgery or after trauma; may be repeated at intervals of 12 hours

**Fibrinolytic response testing**

- **BY INTRANASAL ADMINISTRATION**
  - Adult: 300 micrograms, blood to be sampled after 1 hour for fibrinolytic activity, one 150 microgram spray to be administered into each nostril

- **BY SUBCUTANEOUS INJECTION, OR BY INTRAVENOUS INJECTION**
  - Adult: 300 nanograms/kg for 1 dose, blood to be sampled after 20 minutes for fibrinolytic activity

**Lumbar-puncture-associated headache**

- **BY INTRAMUSCULAR INJECTION, OR BY SUBCUTANEOUS INJECTION**
  - Adult: (consult product literature)
**UNLICENSED USE** Consult product literature for individual preparations. Oral use of DDAVP intravenous injection is not licensed.

**CONTRA-INDICATIONS** Cardiac insufficiency· conditions treated with diuretics· history of hyponatraemia· polydipsia in alcohol dependence· psychogenic polydipsia· syndrome of inappropriate ADH secretion (in adults)

**CAUTIONS**

**GENERAL CAUTIONS**
Asthma· avoid fluid overload· cardiovascular disease (not indicated for nocturnal enuresis or nocturia)· conditions which might be aggravated by water retention· cystic fibrosis· elderly (avoid for primary nocturnal enuresis and nocturia associated with multiple sclerosis in those over 65 years)· epilepsy· heart failure· hypertension (not indicated for nocturnal enuresis or nocturia)· migraine· nocturia—limit fluid intake to minimum from 1 hour before dose until 8 hours afterwards· nocturnal enuresis—limit fluid intake to minimum from 1 hour before dose until 8 hours afterwards

**SPECIFIC CAUTIONS**
With intranasal use Should not be given intranasally for nocturnal enuresis due to an increased incidence of side-effects

**SIDE-EFFECTS, FURTHER INFORMATION**
Elderly patients are at increased risk of hyponatraemia and renal impairment—manufacturer advises measure baseline serum sodium concentration, then monitor regularly during treatment; discontinue treatment if levels fall below the normal range. Review treatment if no therapeutic benefit after 3 months.

**INTERACTIONS** → Appendix 1: desmopressin

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**

**Common or very common** Hyponatraemia (in more serious cases with convulsions) on administration without restricting fluid intake· nausea

**Frequency not known** Allergic reactions· emotional disturbance in children· epistaxis· fluid retention· headache· nasal congestion· stomach pain· vomiting

**SPECIFIC SIDE-EFFECTS**

**With intranasal use** Rhinitis

**SIDE-EFFECTS, FURTHER INFORMATION**
Hyponatraemic convulsions The risk of hyponatraemic convulsions can be minimised by keeping to the recommended starting doses and by avoiding concomitant use of drugs which increase secretion of vasopressin (e.g. tricyclic antidepressants).

**PREGNANCY** Small oxytocic effect in third trimester; increased risk of pre-eclampsia.

**BREAST FEEDING** Amount too small to be harmful.

**RENAL IMPAIRMENT** Use with caution; antidiuretic effect may be reduced.

**MONITORING REQUIREMENTS** In nocturia, periodic blood pressure and weight checks are needed to monitor for fluid overload.

**DIRECTIONS FOR ADMINISTRATION** DDAVP® and Desmotabs® tablets may be crushed. DDAVP® intranasal solution may be diluted with Sodium Chloride 0.9% to a concentration of 10 micrograms/mL. DDAVP® injection may be administered orally. Desmopressin oral lozenges are for sublingual administration.

For intravenous infusion (DDAVP®, Octim®), give intermittently in Sodium chloride 0.9%; dilute with 50 mL and give over 20 minutes.

**PRESCRIBING AND DISPENSING INFORMATION** Oral, intranasal, intravenous, subcutaneous and intramuscular doses are expressed as desmopressin acetate; sublingual doses are expressed as desmopressin base.

Children requiring an intranasal dose of less than 10 micrograms should be given DDAVP® intranasal solution.

**PATIENT AND CARER ADVICE**

Hyponatraemic convulsions Patients being treated for primary nocturnal enuresis should be warned to avoid fluid overload (including during swimming) and to stop taking desmopressin during an episode of vomiting or diarrhoea (until fluid balance normal).

Medicines for Children leaflet: Desmopressin for bedwetting www.medicinesforchildren.org.uk/desmopressin-bedwetting-0

**NATIONAL FUNDING/ACCESS DECISIONS**
Scottish Medicines Consortium (SMC) Decisions

In adults The Scottish Medicines Consortium has advised (February 2017) that desmopressin (Noqdirna®) is not recommended for use within NHS Scotland for the symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults as the economic case was not demonstrated.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule, oral suspension, oral solution, spray, nasal drops

**Tablet**

- Desmopressin (Non-proprietary)
  - Desmopressin acetate 100 microgram Desmopressin 100microgram tablets | 90 tablet (POM) £76.62 DT price = £63.08
  - Desmopressin acetate 200 microgram Desmopressin 200microgram tablets | 30 tablet (POM) £35.23 DT price = £7.25 | 90 tablet (POM) no price available

- DDAVP (Ferring Pharmaceuticals Ltd)
  - Desmopressin acetate 100 microgram DDAVP 0.1mg tablets | 90 tablet (POM) £44.12 DT price = £63.08
  - Desmopressin acetate 200 microgram DDAVP 0.2mg tablets | 90 tablet (POM) £88.23

- Desmotabs (Ferring Pharmaceuticals Ltd)
  - Desmopressin acetate 200 microgram Desmotabs 0.2mg tablets | 30 tablet (POM) £29.43 DT price = £7.25

**Solution for injection**

- DDAVP (Ferring Pharmaceuticals Ltd)
  - Desmopressin acetate 4 microgram per 1 ml DDAVP 4micrograms/1ml solution for injection ampoules | 10 ampoule (POM) £13.16

- Octim (Ferring Pharmaceuticals Ltd)
  - Desmopressin acetate 15 microgram per 1 ml Octim 15micrograms/1ml solution for injection ampoules | 10 ampoule (POM) £192.20

**Spray**

- Desmopressin (Non-proprietary)
  - Desmopressin acetate 2.5 microgram per 1 dose Desmopressin 2.5 microgram/spray | 10 dose (POM) £31.50 DT price = £23.25

- Desmospray (Ferring Pharmaceuticals Ltd)
  - Desmopressin acetate 2.5 microgram per 1 dose Desmospray 2.5micrograms/spray | 50 dose no price available

- Desmopressin acetate 10 microgram per 1 dose Desmospray 10micrograms/spray | 60 dose (POM) £25.02 DT price = £23.25

- Octim (Ferring Pharmaceuticals Ltd)
  - Desmopressin acetate 150 microgram per 1 dose Octim 150micrograms/spray | 25 dose (POM) £576.60

**Oral solution**

- Desmopressin (Non-proprietary)
  - Desmopressin (as Desmopressin acetate) 360 microgram per 1 ml Desmopressin 360micrograms/ml oral solution | 15 ml (POM) £30.00 DT price = £30.00
**Oral lyophilisate**

**CAUTIONARY AND ADVISORY LABELS 26**

- **Desmopressin (Non-proprietary)**
  - **Desmopressin (as Desmopressin acetate)**
    - 120 microgram Desmopressin 120 microgram oral lyophilisates sugar-free sugar-free | 30 tablet (Pot) no price available DT price = £30.34
  - **Desmopressin (as Desmopressin acetate)**
    - 240 microgram Desmopressin 240 microgram oral lyophilisates sugar-free sugar-free | 30 tablet (Pot) no price available DT price = £60.68
  - **DDAVP (Ferring Pharmaceuticals Ltd)**
    - **Desmopressin (as Desmopressin acetate) 60 microgram**
      - DDAVP Melt 60 microgram oral lyophilisates sugar-free | 100 tablet (Pot) £50.53 DT price = £50.53
    - **Desmopressin (as Desmopressin acetate) 120 microgram**
      - DDAVP Melt 120 microgram oral lyophilisates sugar-free | 100 tablet (Pot) £101.07 DT price = £101.07
    - **Desmopressin (as Desmopressin acetate) 240 microgram**
      - DDAVP Melt 240 microgram oral lyophilisates sugar-free | 100 tablet (Pot) £202.14
  - **Desmopressin acetate (non-proprietary)**
    - 25 microgram Desmopressin acetate 25 microgram oral lyophilisates sugar-free | 30 tablet (Pot) £15.16 DT price = £15.16
  - **Desmopressin acetate (as Desmopressin acetate) 50 microgram**
    - Noqdirna 50microgram oral lyophilisates sugar-free | 30 tablet (Pot) £15.16 DT price = £15.16

- **Nasal drops**
  - **DDAVP (Ferring Pharmaceuticals Ltd)**
    - Desmopressin acetate 100 microgram per 1 ml DDAVP 100 micrograms/ml intranasal solution | 2.5 ml (Pot) £9.72 DT price = £9.72

**Vasopressin**

- **INDICATIONS AND DOSE**
  - **Pituitary diabetes insipidus**
    - **BY INTRAMUSCULAR INJECTION, OR BY SUBCUTANEOUS INJECTION**
    - Adult: 5–20 units every 4 hours
  - **Initial control of oesophageal variceal bleeding**
    - **BY INTRAVENOUS INFUSION**
    - Adult: 20 units, dose to be administered over 15 minutes

- **CONTRA-INDICATIONS**
  - Chronic nephritis (until reasonable blood nitrogen concentrations attained) - vascular disease (especially disease of coronary arteries) unless extreme caution
  - **CAUTIONS**
    - Asthma - avoid fluid overload - conditions which might be aggravated by water retention - epilepsy - heart failure - hypertension - migraine
  - **SIDE-EFFECTS**
    - Rare
    - Frequent not known
      - Abdominal cramps - anaphylaxis - anginal attacks - belching - constriction of coronary arteries - desire to defaecate - fluid retention - headache - hypersensitivity reactions - myocardial ischaemia - nausea - pallor - peripheral ischaemia - sweating - tremor - vertigo - vomiting
  - **PREGNANCY**
    - Oxytocic effect in third trimester.
  - **BREAST FEEDING**
    - Not known to be harmful.
  - **DIRECTIONS FOR ADMINISTRATION**
    - For intravenous infusion (argipressin), give intermittently in Glucose 5%; suggested concentration 20 units/100 ml given over 15 minutes.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Vasopressin (Non-proprietary)**
  - **Argipressin 20 unit per 1 ml**
    - Argipressin 20 units/ml solution for injection ampoules | 10 ampoule (Pot) £800.00 (Hospital only)

**1.2 Syndrome of inappropriate antidiuretic hormone secretion**

**Other drugs used for Syndrome of inappropriate antidiuretic hormone secretion**

- Demeclocycline hydrochloride, p. 533

**DIURETICS >> SELECTIVE VASOPRESSIN V2-RECEPTOR ANTAGONISTS**

<table>
<thead>
<tr>
<th>Tolvaptan</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DRUG ACTION</strong></td>
</tr>
<tr>
<td>Tolvaptan is a vasopressin V2-receptor antagonist.</td>
</tr>
</tbody>
</table>

**INDICATIONS AND DOSE**

- **JINARC ®**
  - **Autosomal dominant polycystic kidney disease in adults with CKD stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease (initiated by a specialist)**
    - **BY MOUTH**
    - Adult: Initially 60 mg daily in 2 divided doses for at least a week, 45 mg in the morning before breakfast, and then 15 mg taken 8 hours later; increased to 90 mg daily in 2 divided doses for at least a week, 60 mg in the morning before breakfast, and then 30 mg taken 8 hours later, then increased if tolerated to 120 mg daily in 2 divided doses, 90 mg in the morning before breakfast, and then 30 mg taken 8 hours later, dose titration should be performed cautiously; patients may down-titrate to lower doses based on tolerability

**SAMSCA ®**

- **Treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion**
  - **BY MOUTH**
  - Adult: 15 mg once daily, increased if necessary up to 60 mg daily; treatment duration is determined by the underlying disease and its treatment

- **CONTRA-INDICATIONS**
  - Anuria - hyporeninaemic hypoaldosteronism - impaired perception of thirst - volume depletion

- **CAUTIONS**
  - Alcoholism (increased risk of demyelination syndrome if rapid correction of hyponatraemia) - diabetes mellitus - ensure adequate fluid intake - hypovolaemia (increased risk of demyelination syndrome if rapid correction of hyponatraemia) - malnutrition (increased risk of demyelination syndrome if rapid correction of hyponatraemia) - pseudohyponatraemia associated with diabetes mellitus (exclude before treatment)

- **INTERACTIONS**
  - Appendix 1: tolvaptan

- **SIDE-EFFECTS**
  - Common or very common
    - Constipation - decreased appetite - dehydration - dry mouth - ecchymosis - fever - hyperglycaemia - hyperkalaemia - increased blood creatinine - malaise - nausea - neurological disturbance (following rapid correction of hyponatraemia) - postural hypotension - pruritus - thirst - urinary frequency

Downloaded from www.medicalbr.com
Corticosteroid responsive conditions

2 Corticosteroid responsive conditions

Corticosteroids, general use

Overview

Dosages of corticosteroids vary widely in different diseases and in different patients. If the use of a corticosteroid can save or prolong life, as in exfoliative dermatitis, pemphigus, acute leukaemia or acute transplant rejection, high doses may need to be given, because the complications of therapy are likely to be less serious than the effects of the disease itself.

When long-term corticosteroid therapy is used in some chronic diseases, the adverse effects of treatment may become greater than the disabilities caused by the disease. To minimise side-effects the maintenance dose should be kept as low as possible.

When potentially less harmful measures are ineffective corticosteroids are used topically for the treatment of inflammatory conditions of the skin. Corticosteroids should be avoided or used only under specialist supervision in psoriasis.

Corticosteroids are used both topically (by rectum) and systemically (by mouth or intravenously) in the management of ulcerative colitis and Crohn’s disease. They are also included in locally applied creams for haemorrhoids.

Use can be made of the mineralocorticoid activity of fludrocortisone acetate p. 637 to treat postural hypotension in autonomic neuropathy.

High-dose corticosteroids should be avoided for the management of septic shock. However, there is evidence that administration of lower doses of hydrocortisone p. 637 and fludrocortisone acetate is of benefit in adrenocortical insufficiency resulting from septic shock.

Dexamethasone p. 635 and betamethasone p. 635 have little if any mineralocorticoid action and their long duration of action makes them particularly suitable for suppressing corticotropin secretion in congenital adrenal hyperplasia where the dose should be tailored to clinical response and by measurement of adrenal androgens and 17-hydroxypregosterone.

In common with all glucocorticoids their suppressive action on the hypothalamic-pituitary-adrenal axis is greatest and most prolonged when they are given at night. In most individuals a single dose of dexamethasone at night, is sufficient to inhibit corticotropin secretion for 24 hours. This is the basis of the ‘overnight dexamethasone suppression test’ for diagnosing Cushing’s syndrome.

Betamethasone and dexamethasone are also appropriate for conditions where water retention would be a disadvantage.

A corticosteroid may be used in the management of raised intracranial pressure or cerebral oedema that occurs as a result of malignancy (see Prescribing in palliative care p. 23); high doses of betamethasone or dexamethasone are generally used. However, a corticosteroid should not be used for the management of head injury or stroke because it is unlikely to be of benefit and may even be harmful.

In acute hypersensitivity reactions, such as angioedema of the upper respiratory tract and anaphylaxis, corticosteroids are indicated as an adjunct to emergency treatment with adrenaline/epinephrine p. 216. In such cases hydrocortisone (as sodium succinate) by intravenous injection may be required.

Corticosteroids are preferably used by inhalation in the management of asthma but systemic therapy in association

MEDICINAL FORMS

There are several corticosteroids available in different strengths and in different dosage forms. They may be obtained over the counter from pharmacies or by prescription from a doctor.

Available for oral administration are tablets, liquid, intramuscular (IM) and intravenous (IV) injections.

INFORMATION

Corticosteroids are available in different strengths and in different dosage forms. They may be obtained over the counter from pharmacies or by prescription from a doctor.

Available for oral administration are tablets, liquid, intramuscular (IM) and intravenous (IV) injections.

PRODUCT INFORMATION

Tablet: Jinarc (Otsuka Pharmaceuticals (U.K.) Ltd) ▼

<table>
<thead>
<tr>
<th>Dose</th>
<th>Form</th>
<th>Pack Size</th>
<th>Unit Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>15 mg</td>
<td>Tablet</td>
<td>7 tablet</td>
<td>£302.05</td>
</tr>
<tr>
<td>30 mg</td>
<td>Tablet</td>
<td>7 tablet</td>
<td>£302.05</td>
</tr>
<tr>
<td>45 mg</td>
<td>Tablet</td>
<td>7 tablet</td>
<td>no price</td>
</tr>
<tr>
<td>60 mg</td>
<td>Tablet</td>
<td>7 tablet</td>
<td>no price</td>
</tr>
<tr>
<td>90 mg</td>
<td>Tablet</td>
<td>7 tablet</td>
<td>no price</td>
</tr>
</tbody>
</table>

A tablet of fludrocortisone is available in the same form.

SIDE-EFFECTS

Corticosteroids may cause side-effects such as weakness, joint pain, muscle weakness, dizziness, abnormal blood pressure, infection, acne, heartburn or a feeling of fullness.

Monitor for dehydration in patients who are fluid-restricted.

Prescribe tablets of corticosteroids to be taken 30 minutes before food to avoid irritation to the stomach.

The corticosteroids are easily absorbed from the gastrointestinal tract and are used to treat a wide range of medical conditions, including inflammatory conditions such as rheumatoid arthritis and Crohn’s disease.

Corticosteroids are used both topically (by rectum) and systemically (by mouth or intravenously) in the management of ulcerative colitis and Crohn’s disease. They are also included in locally applied creams for haemorrhoids.

Use can be made of the mineralocorticoid activity of fludrocortisone acetate p. 637 to treat postural hypotension in autonomic neuropathy.

High-dose corticosteroids should be avoided for the management of septic shock. However, there is evidence that administration of lower doses of hydrocortisone p. 637 and fludrocortisone acetate is of benefit in adrenocortical insufficiency resulting from septic shock.

Dexamethasone p. 635 and betamethasone p. 635 have little if any mineralocorticoid action and their long duration of action makes them particularly suitable for suppressing corticotropin secretion in congenital adrenal hyperplasia where the dose should be tailored to clinical response and by measurement of adrenal androgens and 17-hydroxypregosterone. In common with all glucocorticoids their suppressive action on the hypothalamic-pituitary-adrenal axis is greatest and most prolonged when they are given at night. In most individuals a single dose of dexamethasone at night, is sufficient to inhibit corticotropin secretion for 24 hours. This is the basis of the ‘overnight dexamethasone suppression test’ for diagnosing Cushing’s syndrome.

Betamethasone and dexamethasone are also appropriate for conditions where water retention would be a disadvantage.

A corticosteroid may be used in the management of raised intracranial pressure or cerebral oedema that occurs as a result of malignancy (see Prescribing in palliative care p. 23); high doses of betamethasone or dexamethasone are generally used. However, a corticosteroid should not be used for the management of head injury or stroke because it is unlikely to be of benefit and may even be harmful.

In acute hypersensitivity reactions, such as angioedema of the upper respiratory tract and anaphylaxis, corticosteroids are indicated as an adjunct to emergency treatment with adrenaline/epinephrine p. 216. In such cases hydrocortisone (as sodium succinate) by intravenous injection may be required.

Corticosteroids are preferably used by inhalation in the management of asthma but systemic therapy in association
with bronchodilators is required for the emergency treatment of severe acute asthma.

Corticosteroids may also be useful in conditions such as autoimmune hepatitis, rheumatoid arthritis and sarcoidosis; they may also lead to remissions of acquired haemolytic anaemia, and some cases of the nephrotic syndrome (particularly in children) and thrombocytopenic purpura.

Corticosteroids can improve the prognosis of serious conditions such as systemic lupus erythematosus, temporal arteritis, and polyarteritis nodosa; the effects of the disease process may be suppressed and symptoms relieved, but the underlying condition is not cured, although it may ultimately remit. It is usual to begin therapy in these conditions at fairly high dose, and then to reduce the dose to the lowest commensurate with disease control.

For other references to the use of corticosteroids see: Prescribing in Palliative Care, immunosuppression, rheumatic diseases, eye, otis externa allergic rhinitis, and aphthous ulcers.

**Side-effects**

Overdosage or prolonged use can exaggerate some of the normal physiological actions of corticosteroids leading to mineralocorticoid and glucocorticoid side-effects.

**Mineralocorticoid side effects**

- hypertension
- sodium retention
- water retention
- potassium loss
- calcium loss

Mineralocorticoid side effects are most marked with fludrocortisone, but are significant with hydrocortisone, corticosterone, and tetracosactide. Mineralocorticoid actions are negligible with the high potency glucocorticoids, betamethasone and dexamethasone, and occur only slightly with methylprednisolone, prednisolone, and triamcinolone.

**Glucocorticoid side effects**

- diabetes
- osteoporosis, which is a danger, particularly in the elderly, as it can result in osteoporotic fractures for example of the hip or vertebrae;
- in addition high doses are associated with avascular necrosis of the femoral head.
- Muscle wasting (proximal myopathy) can also occur.
- Corticosteroid therapy is also weakly linked with peptic ulceration and perforation.
- Psychiatric reactions may also occur.

**Managing side-effects**

Side-effects can be minimised by using lowest effective dose for minimum period possible. The suppressive action of a corticosteroid on cortisol secretion is least when it is given as a single dose in the morning. In an attempt to reduce pituitary-adrenal suppression further, the total dose for two days can sometimes be taken as a single dose on alternate days; alternate-day administration has not been very successful in the management of asthma. Pituitary-adrenal suppression can also be reduced by means of intermittent therapy with short courses. In some conditions it may be possible to reduce the dose of corticosteroid by adding a small dose of an immunosuppressive drug.

Whenever possible local treatment with creams, intra-articular injections, inhalations, eye-drops, or enemas should be used in preference to systemic treatment.

Inhaled corticosteroids have considerably fewer systemic effects than oral corticosteroids, but adverse effects including adrenal suppression have been reported. Use of other corticosteroid therapy (including topical) or concurrent use of drugs which inhibit corticosteroid metabolism should be taken into account when assessing systemic risk. In children, growth restriction associated with systemic corticosteroid therapy does not seem to occur with recommended doses of inhaled therapy; although initial growth velocity may be reduced, there appears to be no effect on achieving normal adult height. Large-volume spacer devices should be used for administering inhaled corticosteroids in children under 15 years; they are also useful in older children and adults, particularly if high doses are required. Spacer devices increase airway deposition and reduce oropharyngeal deposition.

**Corticosteroids, replacement therapy**

**Overview**

The adrenal cortex normally secretes hydrocortisone p. 637 (cortisol) which has glucocorticoid activity and weak mineralocorticoid activity. It also secretes the mineralocorticoid aldosterone.

In deficiency states, physiological replacement is best achieved with a combination of hydrocortisone and the mineralocorticoid fludrocortisone acetate p. 637; hydrocortisone alone does not usually provide sufficient mineralocorticoid activity for complete replacement.

In Addison’s disease or following adrenalectomy, hydrocortisone by mouth is usually required. This is given in 2 doses, the larger in the morning and the smaller in the evening, mimicking the normal diurnal rhythm of cortisol secretion. The optimum daily dose is determined on the basis of clinical response. Glucocorticoid therapy is supplemented by fludrocortisone acetate.

In acute adrenocortical insufficiency, hydrocortisone is given intravenously (preferably as sodium succinate) every 6 to 8 hours in sodium chloride intravenous infusion 0.9% p. 955.

In hypopituitarism, glucocorticoids should be given as in adrenocortical insufficiency, but since production of aldosterone is also regulated by the renin-angiotensin system a mineralocorticoid is not usually required. Additional replacement therapy with levethyroxine sodium p. 729 and sex hormones should be given as indicated by the pattern of hormone deficiency.

**Glucocorticoid therapy**

**Glucocorticoid and mineralocorticoid activity**

In comparing the relative potencies of corticosteroids in terms of their anti-inflammatory (glucocorticoid) effects it should be borne in mind that high glucocorticoid activity in itself is of no advantage unless it is accompanied by relatively low mineralocorticoid activity (see Disadvantages of Corticosteroids). The mineralocorticoid activity of fludrocortisone acetate p. 637 is so high that its anti-inflammatory activity is of no clinical relevance.

<table>
<thead>
<tr>
<th>Equivalent anti-inflammatory doses of corticosteroids</th>
</tr>
</thead>
<tbody>
<tr>
<td>This table takes no account of mineralocorticoid effects, nor does it take account of variations in duration of action</td>
</tr>
<tr>
<td>Prednisolone 5 mg</td>
</tr>
<tr>
<td>➢ Betamethasone 750 micrograms</td>
</tr>
<tr>
<td>➢ Deflazacort 6 mg</td>
</tr>
<tr>
<td>➢ Dexamethasone 750 micrograms</td>
</tr>
<tr>
<td>➢ Hydrocortisone 20 mg</td>
</tr>
<tr>
<td>➢ Methylprednisolone 4 mg</td>
</tr>
<tr>
<td>➢ Prednisone 5 mg</td>
</tr>
<tr>
<td>➢ Triamcinolone 4 mg</td>
</tr>
</tbody>
</table>
Corticosteroids (systemic)

- **CONTRA-INDICATIONS** Avoid injections containing benzyl alcohol in neonates - avoid live virus vaccines in those receiving immunosuppressive doses (serum antibody response diminished) - systemic infection (unless specific therapy given)

**CONTRA-INDICATIONS, FURTHER INFORMATION**

For further information on contra-indications associated with intra-articular, intradermal and intraleisional preparations, consult product literature.

- **CAUTIONS** Congestive heart failure - diabetes mellitus (including a family history of) - diverticulitis - epilepsy - glaucoma (including a family history of or susceptibility to) - history of steroid myopathy - history of tuberculosis or X-ray changes (frequent monitoring required) - hypertension - hypothyroidism - infection (particularly untreated) - myasthenia gravis - ocular herpes simplex (risk of corneal perforation) - osteoporosis (in children) - osteoporosis (post-menopausal women and the elderly at special risk) - peptic ulcer - psychiatric reactions - recent intestinal anastomoses - recent myocardial infarction (rupture reported) - severe affective disorders (particularly if history of steroid-induced psychosis) - should not be used long-term - thromboembolic disorders - ulcerative colitis

**CAUTIONS, FURTHER INFORMATION**

For further information on cautions associated with intra-articular, intradermal and intraleisional preparations, consult product literature.

- **SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**


**SPECIFIC SIDE-EFFECTS**

- With intra-articular use Flushing - may affect the hyaline cartilage

**SIDE-EFFECTS, FURTHER INFORMATION**

For further information on side-effects associated with intra-articular, intradermal and intraleisional preparations, consult product literature.

Side-effects can be managed by choice of route and duration of course. For further detail see Corticosteroids, general use p. 631

- Adrenal suppression During prolonged therapy with corticosteroids, particularly with systemic use, adrenal atrophy develops and can persist for years after stopping. Abrupt withdrawal after a prolonged period can lead to acute adrenal insufficiency, hypotension, or death.

  To compensate for a diminished adrenocortical response caused by prolonged corticosteroid treatment, any significant intercurrent illness, trauma, or surgical procedure requires a temporary increase in corticosteroid dose, or if already stopped, a temporary reintroduction of corticosteroid treatment. To avoid a precipitous fall in blood pressure during anaesthesia or in the immediate postoperative period, anaesthetists must know whether a patient is taking or has been taking a corticosteroid. A suitable regimen for corticosteroid replacement, in patients who have taken more than 10 mg prednisolone daily (or equivalent) within 3 months of surgery, is:

  - Minor surgery under general anaesthesia—usual oral corticosteroid dose on the morning of surgery or hydrocortisone (usually the sodium succinate) intravenously at induction; the usual oral corticosteroid dose is recommenced after surgery.

  - Moderate or major surgery—usual oral corticosteroid dose on the morning of surgery and hydrocortisone intravenously at induction, followed by hydrocortisone 3 times a day by intravenous injection for 24 hours after moderate surgery or for 48–72 hours after major surgery; the usual pre-operative oral corticosteroid dose is recommenced on stopping hydrocortisone injections. Patients on long-term corticosteroid treatment should carry a steroid treatment card which gives guidance on minimising risk and provides details of prescriber, drug, dosage and duration of treatment.

- Infections Prolonged courses of corticosteroids increase susceptibility to infections and severity of infections; clinical presentation of infections may also be atypical. Serious infections e.g. septicaemia and tuberculosis may reach an advanced stage before being recognised, and amoebiasis or strongyloidiasis may be activated or
exacerbated (exclude before initiating a corticosteroid in those at risk or with suggestive symptoms). Fungal or viral ocular infections may also be exacerbated.

- **Chickenpox** Unless they have had chickenpox, patients receiving oral or parenteral corticosteroids for purposes other than replacement should be regarded as being at risk of severe chickenpox (see Steroid Treatment Card). Manifestations of fulminant illness include pneumonia, hepatitis and disseminated intravascular coagulation; rash is not necessarily a prominent feature.

  Passive immunisation with varicella–zoster immunoglobulin is needed for exposed non–immune patients receiving systemic corticosteroids or for those who have used them within the previous 3 months. Confirmed chickenpox warrants specialist care and urgent treatment. Corticosteroids should not be stopped and dosage may need to be increased.

  Topical, inhaled or rectal corticosteroids are less likely to be associated with an increased risk of severe chickenpox.

- **Measles** Patients taking corticosteroids should be advised to take particular care to avoid exposure to measles and to seek immediate medical advice if exposure occurs. Prophylaxis with intramuscular normal immunoglobulin may be needed.

- **Psychiatric reactions** Systemic corticosteroids, particularly in high doses, are linked to psychiatric reactions including euphoria, nightmares, insomnia, irritability, mood lability, suicidal thoughts, psychotic reactions, and behavioural disturbances. A serious paranoid state or depression with risk of suicide can be induced, particularly in patients with a history of mental disorder. These reactions frequently subside on reducing the dose or discontinuing the corticosteroid but they may also require specific management. Patients should be advised to seek medical advice if psychiatric symptoms (especially depression and suicidal thoughts) occur and they should also be alert to the rare possibility of such reactions during withdrawal of corticosteroid treatment.

  Systemic corticosteroids should be prescribed with care in those predisposed to psychiatric reactions, including those who have previously suffered corticosteroid–induced psychosis, or who have a personal or family history of psychiatric disorders.

- **PREGNANCY** The benefit of treatment with corticosteroids during pregnancy outweighs the risk. Corticosteroid cover is required during labour. Following a review of the data on the safety of systemic corticosteroids used in pregnancy and breast–feeding the CSM (May 1998) concluded that corticosteroids vary in their ability to cross the placenta but there is no convincing evidence that systemic corticosteroids increase the incidence of congenital abnormalities such as cleft palate or lip. When administration is prolonged or repeated during pregnancy, systemic corticosteroids increase the risk of intra–uterine growth restriction; there is no evidence of intra–uterine growth restriction following short–term treatment (e.g. prophylactic treatment for neonatal respiratory distress syndrome). Any adrenal suppression in the neonate following prenatal exposure usually resolves spontaneously after birth and is rarely clinically important.

  Pregnant women with fluid retention should be monitored closely when given systemic corticosteroids.

- **BREAST FEEDING** The benefit of treatment with corticosteroids during breast–feeding outweighs the risk.

- **HEPATIC IMPAIRMENT** The plasma–drug concentration may be increased (particularly on systemic use). Oral and parenteral use should be undertaken with caution.

- **RENAL IMPAIRMENT** Use by oral and injectable routes should be undertaken with caution.

- **MONITORING REQUIREMENTS**
  - In children The height and weight of children receiving prolonged treatment with corticosteroids should be monitored annually; if growth is slowed, referral to a paediatrician should be considered.
  - **EFFECT ON LABORATORY TESTS** Suppression of skin test reactions.
  - **TREATMENT CESSATION** In adults Abrupt withdrawal after a prolonged period can lead to acute adrenal insufficiency, hypotension or death. Withdrawal can also be associated with fever, myalgia, arthralgia, rhinitis, conjunctivitis, painful itchy skin nodules and weight loss. The magnitude and speed of dose reduction in corticosteroid withdrawal should be determined on a case–by–case basis, taking into consideration the underlying condition that is being treated, and individual patient factors such as the likelihood of relapse and the duration of corticosteroid treatment. **Gradual withdrawal of systemic corticosteroids should be considered in those whose disease is unlikely to relapse and have:**
    - received more than 40 mg prednisolone (or equivalent) daily for more than 1 week;
    - been given repeat doses in the evening;
    - received more than 3 weeks’ treatment;
    - recently received repeated courses (particularly if taken for longer than 3 weeks);
    - taken a short course within 1 year of stopping long–term therapy;
    - other possible causes of adrenal suppression.
  
  Systemic corticosteroids may be stopped abruptly in those whose disease is unlikely to relapse and who have received treatment for 3 weeks or less and who are not included in the patient groups described above.

  During corticosteroid withdrawal the dose may be reduced rapidly down to physiological doses (equivalent to prednisolone 7.5 mg daily) and then reduced more slowly. Assessment of the disease may be needed during withdrawal to ensure that relapse does not occur.

  - In children The magnitude and speed of dose reduction in corticosteroid withdrawal should be determined on a case–by–case basis, taking into consideration the underlying condition that is being treated, and individual patient factors such as the likelihood of relapse and the duration of corticosteroid treatment. **Gradual withdrawal of systemic corticosteroids should be considered in those whose disease is unlikely to relapse and have:**
    - received more than 40 mg prednisolone (or equivalent) daily for more than 1 week or 2 mg/kg daily for 1 week or 1 mg/kg daily for 1 month;
    - been given repeat doses in the evening;
    - received more than 3 weeks’ treatment;
    - recently received repeated courses (particularly if taken for longer than 3 weeks);
    - taken a short course within 1 year of stopping long–term therapy;
    - other possible causes of adrenal suppression.

  Systemic corticosteroids may be stopped abruptly in those whose disease is unlikely to relapse and who have received treatment for 3 weeks or less and who are not included in the patient groups described above.

  During corticosteroid withdrawal the dose may be reduced rapidly down to physiological doses (equivalent to prednisolone 2–2.5 mg/m² daily) and then reduced more slowly. Assessment of the disease may be needed during withdrawal to ensure that relapse does not occur.

- **PATIENT AND CARER ADVICE**
  - **Advice for patients** Patients on long–term corticosteroid treatment should carry a Steroid Treatment Card which gives guidance on minimising risk and provides details of prescriber, drug, dosage and duration of treatment.
A patient information leaflet should be supplied to every patient when a systemic corticosteroid is prescribed. Patients should especially be advised of the following:

- **Immunosuppression** Prolonged courses of corticosteroids can increase susceptibility to infection and serious infections can go unrecognized. Unless already immune, patients are at risk of severe chickenpox and should avoid close contact with people who have chickenpox or shingles. Similarly, precautions should also be taken against contracting measles;

- **Adrenal suppression** If the corticosteroid is given for longer than 3 weeks, treatment must not be stopped abruptly. Adrenal suppression can last for a year or more after stopping treatment and the patient must mention the course of corticosteroid when receiving treatment for any illness or injury;

- **Mood and behaviour changes** Corticosteroid treatment, especially with high doses, can alter mood and behaviour early in treatment—the patient can become confused, irritable and suffer from delusion and suicidal thoughts. These effects can also occur when corticosteroid treatment is being withdrawn. Medical advice should be sought if worrying psychological changes occur;

- **Other serious effects** Serious gastro-intestinal, musculoskeletal, and ophthalmic effects which require medical help can also occur.

Steroid treatment cards Steroid treatment cards should be issued where appropriate. Consider giving a ‘steroid card’ to support communication of the risks associated with treatment, and specific written advice to consider corticosteroid replacement during an episode of stress, such as severe intercurrent illness or an operation, to patients using greater than maximum licensed doses of inhaled corticosteroids. Steroid treatment cards are available for purchase from the NHS Print online ordering portal www.nhsforms.co.uk

GP practices can obtain supplies through Primary Care Support England. NHS Trusts can order supplies via the online ordering portal www.stockorders.dppas@apsgroup.co.uk or by fax on 0131 629 9967.

### Betamethasone

#### INDICATIONS AND DOSE

**Suppression of inflammatory and allergic disorders**

- **Congenital adrenal hyperplasia**
  - **BY MOUTH**
  - Adult: Usual dose 0.5–5 mg daily
  - **BY INTRAMUSCULAR INJECTION, OR BY SLOW INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
  - Adult: 4–20 mg, repeated up to 4 times in 24 hours

#### INTERACTIONS

- **Appendix 1: corticosteroids**
- **PREGNANCY** Readily crosses the placenta. Transient effect on fetal movements and heart rate.
- **DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (as sodium phosphate) (Betnesol®), give continuously or intermittently or via drip tubing in Glucose 5% or Sodium chloride 0.9%
- **PATIENT AND CARER ADVICE** Patient counselling is advised for betamethasone soluble tablets (steroid card).

### Deflazacort

#### INDICATIONS AND DOSE

**Suppression of inflammatory and allergic disorders**

- **BY MOUTH**
- Adult: Maintenance 3–18 mg daily

**Suppression of inflammatory and allergic disorders (acute disorders)**

- **BY MOUTH**
- Adult: Initially up to 120 mg daily

**Inflammatory and allergic disorders**

- **BY MOUTH**
  - Child 1 month-11 years: 0.25–1.5 mg/kg once daily or on alternate days; increased if necessary up to 2.4 mg/kg daily (max. per dose 120 mg), in emergency situations
  - Child 12-17 years: 3–18 mg once daily or on alternate days; increased if necessary up to 2.4 mg/kg daily (max. per dose 120 mg), in emergency situations

#### INTERACTIONS

- **Appendix 1: deflazacort**

#### PATIENT AND CARER ADVICE

Patient counselling is advised for deflazacort tablets (steroid card).

### Dexamethasone

#### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Soluble tablet**

- **CAUTIONARY AND ADVISORY LABELS** 10, 13, 21 (not for use as mouthwash for oral ulceration)
  - Betamethasone (Non-proprietary)
  - Betamethasone (as Betamethasone sodium phosphate) 500 microgram Betamethasone 500 microgram soluble tablets sugar free sugar-free
  - 100 tablet [POM] £42.60 DT price = £42.60

**Solution for injection**

- **CAUTIONARY AND ADVISORY LABELS** 10
  - Betamethasone (Non-proprietary)
  - Betamethasone (as Betamethasone sodium phosphate) 4 mg per
  - 1 ml Betamethasone 4 mg/mL solution for injection ampoules | 5 ampoules [POM] £13.06–15.68

#### INDICATIONS AND DOSE

**Suppression of inflammatory and allergic disorders**

- **BY MOUTH**
- Adult: 0.5–10 mg daily

**Mild croup**

- **BY MOUTH**
- Child: 150 micrograms/kg for 1 dose

**Severe croup (or mild croup that might cause complications)**

- **INITIALLY BY MOUTH**
- Child: Initially 150 micrograms/kg for 1 dose, to be given before transfer to hospital, then (by mouth or by intravenous injection) 150 micrograms/kg, then (by mouth or by intravenous injection) 150 micrograms/kg after 12 hours if required continued →
Congenital adrenal hyperplasia (under expert supervision)

- **BY MOUTH**
  - Adult: Consult specialist for advice on dosing
- **BY INTRAMUSCULAR INJECTION, OR BY SLOW INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
  - Adult: Consult specialist for advice on dosing

**Overnight dexamethasone suppression test**

- **BY MOUTH**
  - Adult: 1 mg for 1 dose, to be given at night

**Adjuvant treatment of bacterial meningitis (starting before or with first dose of antibacterial)**

- **BY INTRAVENOUS INJECTION**
  - Adult: 8.3 mg every 6 hours for 4 days

**Symptom control of anorexia (in palliative care)**

- Adult: 2–4 mg daily

**Obstruction due to tumour (dysphagia in palliative care)**

- Adult: 8 mg daily

**Bronchospasm or partial obstruction (dyspnoea in palliative care)**

- Adult: 4–8 mg daily

**Nausea and vomiting (adjunct in palliative care)**

- **BY MOUTH**
  - Adult: 8–16 mg daily

**Headaches due to raised intracranial pressure (in palliative care)**

- Adult: 16 mg daily for 4–5 days, then reduced to 4–6 mg daily, reduce dose if possible. To be given before 6pm to reduce the risk of insomnia

**Pain due to nerve compression (in palliative care)**

- Adult: 8 mg daily

**Cerebral oedema associated with malignancy**

- **BY MOUTH**
  - Adult: 0.5–10 mg daily

**Cerebral oedema**

- **INITIALLY BY INTRAVENOUS INJECTION**
  - Adult: Initially 8–16 mg for 1 dose, then (by intramuscular injection or by intravenous injection)

5 mg every 6 hours until adequate response achieved then taper-off gradually, use the 3.8 mg/mL injection preparation for this dose

**Cerebral oedema associated with malignancy**

- **INITIALLY BY INTRAVENOUS INJECTION**
  - Adult: Initially 8.3 mg for 1 dose, then (by intramuscular injection) 3.3 mg every 6 hours as required for 2–4 days, subsequently, reduce dose gradually and stop over 5–7 days, use the 3.3 mg/mL injection preparation for this dose

---

**UNLICENSED USE** Consult product literature; not licensed for use in bacterial meningitis.

**INTERACTIONS** → Appendix 1: corticosteroids

**SIDE-EFFECTS**

With intravenous use Perineal irritation may follow intravenous administration of the phosphate ester

**PREGNANCY** Dexamethasone readily crosses the placenta.

**DIRECTIONS FOR ADMINISTRATION**

- With oral use in children For administration by mouth tablets may be dispersed in water or injection solution given by mouth.
- With intravenous use in adults For intravenous infusion (Dexamethasone, Hospira) give continuously or intermittently or via drip tubing in Glucose 5% or Sodium Chloride 0.9%.

**PRESCRIBING AND DISPENSING INFORMATION**

Dexamethasone 3.8 mg/mL Injection has replaced Dexamethasone 4 mg/mL Injection. All dosage recommendations for intravenous, intramuscular, intrarticular use or local infiltration; are given in units of dexamethasone base.

**PATIENT AND CARER ADVICE** Patient counselling is advised for dexamethasone tablet, oral solution and injection (steroid card).

Medicines for Children leaflet: Dexamethasone for croup www.medicinesforchildren.org.uk/dexamethasone-croup-0

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule, oral suspension, oral solution

**Soluble tablet**

- **Dexamethasone (Non-proprietary)**
  - Dexamethasone (as Dexamethasone sodium phosphate)
    - 2 mg Dexamethasone 2mg soluble tablets sugar free sugar-free | 50 tablet £30.00–£31.03 DT price = £31.03
    - Dexamethasone (as Dexamethasone sodium phosphate)
    - 4 mg Dexamethasone 4mg soluble tablets sugar free sugar-free | 50 tablet £60.00–£62.06 DT price = £62.06
    - Dexamethasone (as Dexamethasone sodium phosphate)
    - 8 mg Dexamethasone 8mg soluble tablets sugar free sugar-free | 50 tablet £120.00–£123.70 DT price = £123.70

**Tablet**

**CAUTIONARY AND ADVISORY LABELS. 10, 21**

- **Dexamethasone (Non-proprietary)**
  - Dexamethasone 500 microgram Dexamethasone 500microgram tablets | 28 tablet £54.25 DT price = £54.25 | 30 tablet £64.82
  - Dexamethasone 2 mg Dexamethasone 2mg tablets | 50 tablet £49.00 DT price = £42.85 | 100 tablet £98.00 | 500 tablet £490.00
  - Dexamethasone 4 mg Dexamethasone 4mg tablets | 50 tablet £85.00–£96.00

**Solution for injection**

**CAUTIONARY AND ADVISORY LABELS. 10, 21**

- **Dexamethasone (Non-proprietary)**
  - Dexamethasone (as Dexamethasone sodium phosphate) 3.3 mg per 1 ml Dexamethasone 6.6mg/2ml solution for injection vials | 5 vial £24.00 DT price = £24.00
  - Dexamethasone (as Dexamethasone sodium phosphate) 6.6mg/2ml solution for injection ampoules | 5 ampoule £11.00 DT price = £11.00 | 10 ampoule £22.00
  - Dexamethasone 3.3mg/1ml solution for injection ampoules | 5 ampoule £12.00 | 10 ampoule £12.00 DT price = £12.00
  - Dexamethasone (as Dexamethasone sodium phosphate) 3.8 mg per 1 ml Dexamethasone 3.8mg/1ml solution for injection vials | 10 vial £19.99 DT price = £19.99

**Oral solution**

**CAUTIONARY AND ADVISORY LABELS. 10, 21**

- **Dexamethasone (Non-proprietary)**
  - Dexamethasone (as Dexamethasone sodium phosphate)
    - 400 microgram per 1 ml Dexamethasone 2mg/5ml oral solution sugar free sugar-free | 75 ml £42.30 DT price = £42.30
    - Dexamethasone (as Dexamethasone sodium phosphate) 2 mg per 1 ml Dexamethasone 10mg/5ml oral solution sugar free sugar-free | 50 ml £24.50–£24.95 sugar-free | 150 ml £101.40 DT price = £94.44
  - Dexsol (Rosemont Pharmaceuticals Ltd)
    - Dexamethasone (as Dexamethasone sodium phosphate) 4 mg per 1 ml Dexamethasone 20mg/5ml oral solution sugar free sugar-free | 50 ml £49.50 DT price = £49.50
  - Martapan (Martindale Pharmaceuticals Ltd)
    - Dexamethasone (as Dexamethasone sodium phosphate) 400 microgram per 1 ml Martapan 2mg/5ml oral solution sugar-free | 75 ml £21.15 sugar-free | 150 ml £42.30 DT price = £42.30
    - Dexamethasone (as Dexamethasone sodium phosphate) 400 microgram per 1 ml Martapan 2mg/5ml oral solution sugar-free | 150 ml £42.30 DT price = £42.30

---

636 Corticosteroid responsive conditions

BNF 74

6

Endocrine system

downloaded from www.medicalbr.com
**Fludrocortisone acetate**

**INDICATIONS AND DOSE**

- **Neuropathic postural hypotension**
  - Adult: 100–400 micrograms daily

- **Mineralocorticoid replacement in adrenocortical insufficiency**
  - Adult: 50–300 micrograms once daily

- **Adrenocortical insufficiency resulting from septic shock**
  - Adult: 50 micrograms daily

**UNLICENSED USE** Not licensed for use in neuropathic postural hypotension.

**INTERACTIONS** → Appendix 1: corticosteroids

**HEPATIC IMPAIRMENT** Monitor patient closely in hepatic impairment.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule, oral suspension.

**Tablet**

- **Fludrocortisone acetate (Non-proprietary)**
  - Fludrocortisone acetate 100 microgram Fludrocortisone 100 microgram tablets: 30 tablet £30.00 DT price = £26.77
  - 100 tablet £55.00

**Hydrocortisone**

**INDICATIONS AND DOSE**

- **Thyrotoxic crisis (thyroid storm)**
  - Adult: 100 mg every 6 hours, to be administered as sodium succinate

- **Adrenocortical insufficiency resulting from septic shock**
  - Adult: 50 mg every 6 hours, given in combination with fludrocortisone

- **Acute hypersensitivity reactions such as angioedema of the upper respiratory tract and anaphylaxis (adjunct to adrenaline)**
  - Adult: 100–300 mg, to be administered as sodium succinate

- **Corticosteroid replacement, in patients who have taken more than 10 mg prednisolone daily (or equivalent) within 3 months of minor surgery under general anaesthesia**
  - Adult: Initially 25–50 mg, to be administered at induction of surgery, the patient’s usual oral corticosteroid dose is recommenced after surgery

- **Corticosteroid replacement, in patients who have taken more than 10 mg prednisolone daily (or equivalent) within 3 months of moderate or major surgery**
  - Adult: Initially 25–50 mg, to be administered at induction of surgery (following usual oral corticosteroid dose on the morning of surgery), followed by 25–50 mg 3 times a day for 24 hours after moderate surgery and for 48–72 hours after major surgery

**DOSE EQUIVALENCE AND CONVERSION**

When switching from immediate-release hydrocortisone tablets to modified release Plenadren® use same total daily dose. Bioavailability of Plenadren® lower than immediate release tablets—monitor clinical response.

**CONTRA-INDICATIONS**

- With rectal use Bowel perforation • extensive fistulas • intestinal obstruction • recent intestinal anastomoses

**Adrenocortical insufficiency in Addison’s disease or following adrenalectomy**

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: 20–30 mg daily in 2 divided doses, the larger dose to be given in the morning and the smaller in the evening, mimicking the normal diurnal rhythm of cortisol secretion, the optimum daily dose is determined on the basis of clinical response

**Adrenocortical insufficiency**

- **BY INTRAMUSCULAR INJECTION, OR BY SLOW INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
  - Adult: 100–500 mg 3–4 times a day or when required

**Severe inflammatory bowel disease**

- **BY SLOW INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
  - Adult: 100–500 mg 3–4 times a day or when required

**Replacement in adrenocortical insufficiency**

- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Adult: 20–30 mg once daily, adjusted according to response, dose to be taken in the morning

**Ulcerative colitis | Proctitis | Proctosigmoiditis**

- **BY RECTUM USING RECTAL FOAM**
  - Adult: Initially 1 metered application 1–2 times a day for 2–3 weeks, then reduced to 1 metered application once daily on alternate days, to be inserted into the rectum

**Acute hypersensitivity reactions | Angioedema**

- **BY INTRAMUSCULAR INJECTION**
  - Adult: 20–30 mg once daily, adjusted according to response

- **Child 1–5 months: Initially 25 mg 3 times a day, adjusted according to response**

- **Child 6–11 months: Initially 100 mg 3 times a day, adjusted according to response**

- **Child 12–17 years: Initially 200 mg 3 times a day, adjusted according to response**

**Severe acute asthma | Life-threatening acute asthma**

- **BY INTRAVENOUS INJECTION**
  - Child 1 month–1 year: 4 mg/kg every 6 hours (max. per dose 100 mg), alternatively 25 mg every 6 hours until conversion to oral prednisolone is possible, dose given, preferably, as sodium succinate

  - Child 2–4 years: 4 mg/kg every 6 hours (max. per dose 100 mg), alternatively 50 mg every 6 hours until conversion to oral prednisolone is possible, dose given, preferably, as sodium succinate

  - Child 5–11 years: 4 mg/kg every 6 hours (max. per dose 100 mg), alternatively 100 mg every 6 hours until conversion to oral prednisolone is possible, dose given, preferably, as sodium succinate

  - Child 12–17 years: 4 mg/kg every 6 hours (max. per dose 100 mg), alternatively 100 mg every 6 hours until conversion to oral prednisolone is possible, dose given, preferably, as sodium succinate

  - Adult: 100 mg every 6 hours until conversion to oral prednisolone is possible, dose given, preferably, as sodium succinate

**DOSE EQUIVALENCE AND CONVERSION**

- When switching from immediate-release hydrocortisone tablets to modified release Plenadren® use same total daily dose. Bioavailability of Plenadren® lower than immediate release tablets—monitor clinical response.
Methylprednisolone

**INDICATIONS AND DOSE**

**Suppression of inflammatory and allergic disorders**
- Cerebral oedema associated with malignancy
  - By mouth
  - Adult: Initially 2–40 mg daily
  - By intramuscular injection, or by slow intravenous injection, or by intravenous infusion
  - Adult: Initially 10–500 mg

**Treatment of graft rejection reactions**
- By intravenous infusion
- Adult: Up to 1 g daily for up to 3 days

**Treatment of relapse in multiple sclerosis**
- By mouth
- Adult: 500 mg once daily for 5 days

**Treatment of relapse in multiple sclerosis (when oral steroids have failed or have not been tolerated, or in those who require hospital admission)**
- By intravenous infusion
- Adult: 1 g once daily for 3–5 days

**DEPO-MEDRONE**

**Suppression of inflammatory and allergic disorders**
- By deep intramuscular injection
- Adult: 40–120 mg, then 40–120 mg after 2–3 weeks if required, to be injected into the gluteal muscle

**LICENSED USE**
- Methylprednisolone doses in the BNF may differ from those in product literature.

**CAUTIONS**
- With intravenous use Rapid intravenous administration of large doses associated with cardiovascular collapse
- INTERACTIONS → Appendix 1: corticosteroids

**DIRECTIONS FOR ADMINISTRATION**

For intravenous infusion
- Propylene glycol or Sodium Chloride
- Rapid intravenous administration
- For small doses, give over at least 30 minutes.
- For large doses associated with cardiovascular collapse, give over at least 30 minutes.

**SIDE-EFFECTS**

- Systemic absorption may occur
- Phosphate ester associated with pain and paraesthesia (particularly in the perineal region)
- Local irritation

**DIRECTIONS FOR ADMINISTRATION**

- With intravenous use in children For intravenous administration, dilute with Glucose 5% or Sodium Chloride 0.9%. For intermittent infusion give over 20–30 minutes.
- With intravenous use in adults For intravenous infusion (SoluCortef® or Efocortesol®), give continuously or intermittently or via drip tubing in Glucose 5% or Sodium Chloride 0.9%

**INTERACTIONS**

- Systemic use Patient counselling is advised for hydrocortisone tablets and injections (steroid card).
- Systemic use Where administration is for saving life in emergency.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule, oral suspension, oral solution

**Modified-release tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>10, 22, 25</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plenadren (Shire Pharmaceuticals Ltd)</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone 5 mg</td>
<td>Plenadren 5mg modified-release tablets</td>
</tr>
<tr>
<td>Hydrocortisone 20 mg</td>
<td>Plenadren 20mg modified-release tablets</td>
</tr>
</tbody>
</table>

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>10, 21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydrocortisone (Non-proprietary)</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone 10 mg</td>
<td>Hydrocortisone 10mg tablets</td>
</tr>
<tr>
<td>Hydrocortisone 20 mg</td>
<td>Hydrocortisone 20mg tablets</td>
</tr>
</tbody>
</table>

**Powder for solution for injection**

- Plenadren [Plifer Ltd]
- Hydrocortisone (as Hydrocortisone sodium succinate)
- 100 mg | Solu-Cortef powder for solution for injection vials | 10 vial | £9.17 |

**Suspension for injection**

- Hydrocortisone acetate 25 mg per 1 ml | Hydrocortisone sodium succinate 500mg solution for injection ampoules | 5 ampoule | £36.45 |

**Foam**

- EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), disodium edetate, hydroxybenzoates (parabens), propylene glycol
- Colifoam (Medd Pharmaceuticals Ltd)
- Hydrocortisone acetate 100 mg per 1 gram | Colifoam 10% aerosol | 14 dose | £3.39 |

**Medicinal System**

**CAUTIONS**

- With rectal use Systemic absorption may occur
- With intravenous use Phosphate ester associated with pain and paraesthesia (particularly in the perineal region)
- With rectal use Local irritation

**DIRECTIONS FOR ADMINISTRATION**

- With intravenous use in children For intravenous administration, dilute with Glucose 5% or Sodium Chloride 0.9%. For intermittent infusion give over 20–30 minutes.
- With intravenous use in adults For intravenous infusion (SoluCortef® or Efocortesol®), give continuously or intermittently or via drip tubing in Glucose 5% or Sodium Chloride 0.9%.
**Prednisolone**

**INDICATIONS AND DOSE**

**Acute exacerbation of chronic obstructive pulmonary disease (if increased breathlessness interferes with daily activities)**

- **BY MOUTH**
  - Adult: 30 mg daily for 7–14 days

**Severe croup (before transfer to hospital) / Mild croup that might cause complications (before transfer to hospital)**

- **BY MOUTH**
  - Child: 1–2 mg/kg

**Mild to moderate acute asthma (when oral corticosteroid taken for more than a few days) / Severe or life-threatening acute asthma (when oral corticosteroid taken for more than a few days)**

- **BY MOUTH**
  - Child 1 month-11 years: 2 mg/kg once daily (max. per dose 60 mg) for up to 3 days, longer if necessary
  - Child 12-17 years: 40–50 mg daily for at least 5 days
  - Adult: 40–50 mg daily for at least 5 days

**Mild to moderate acute asthma / Severe or life-threatening acute asthma**

- **BY MOUTH**
  - Child 1 month-11 years: 2 mg/kg once daily (max. per dose 40 mg) for up to 3 days, longer if necessary
  - Child 12-17 years: 40–50 mg daily for at least 5 days
  - Adult: Initially 10–20 mg daily, dose preferably taken in the morning after breakfast, can often be reduced within a few days but may need to be continued for several weeks or months

**Suppression of inflammatory and allergic disorders**

- **BY MOUTH**
  - Adult: Initially 10–20 mg daily, dose preferably taken in the morning after breakfast, can often be reduced within a few days but may need to be continued for several weeks or months
may be necessary to continue long term low-dose corticosteroid treatment

Polyarteritis nodosa | Polymyositis | Systemic lupus erythematosus
▶ By mouth
- Adult: Initially 60 mg daily, to be reduced gradually; maintenance 10–15 mg daily

Anorexia (symptom control in palliative care)
▶ By mouth
- Adult: 15–30 mg daily

Pneumocystis pneumonia in moderate to severe infections associated with HIV infection
▶ By mouth
- Adult: 50–80 mg daily for 5 days, the dose is then reduced to complete 21 days of treatment; corticosteroid treatment should ideally be started at the same time as the anti-pneumocystis therapy and certainly no later than 24–72 hours afterwards. The corticosteroid should be withdrawn before anti-pneumocystis treatment is complete

Short-term prophylaxis of episodic cluster headache as monotherapy or in combination with verapamil during verapamil titration
▶ By mouth
- Adult: 60–100 mg once daily for 2–5 days, then reduced in steps of 10 mg every 2–3 days until prednisolone is discontinued

Proctitis
▶ By rectum using rectal foam
- Adult: 1 metered application 1–2 times a day for 2 weeks, continued for further 2 weeks if good response, to be inserted into the rectum, 1 metered application contains 20 mg prednisolone
▶ By rectum using suppositories
- Adult: 5 mg twice daily, to be inserted into the rectum morning and night, after a bowel movement

Distal ulcerative colitis
▶ By rectum using rectal foam
- Adult: 1 metered application 1–2 times a day for 2 weeks, continued for further 2 weeks if good response, to be inserted into the rectum, 1 metered application contains 20 mg prednisolone

Rectal complications of Crohn's disease
▶ By rectum using suppositories
- Adult: 5 mg twice daily, to be inserted in to the rectum morning and night, after a bowel movement

Rectal and rectosigmoidal ulcerative colitis | Rectal and rectosigmoidal Crohn’s disease
▶ By rectum using enema
- Adult: 20 mg daily for 2–4 weeks, continued if response good, to be used at bedtime

With systemic use Infant should be monitored for adrenal suppression if mother is taking a dose higher than 40 mg.

- **PATIENT AND CARER ADVICE** Patient counselling is advised for prednisolone tablets (steroid card). Medicines for Children leaflet: Prednisolone for asthma www.medicinesforchildren.org.uk/prednisolone-for-asthma

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, enema

**Foam**
- **Prednisolone (Non-proprietary)**
  - Prednisolone (as Prednisolone sodium metasulfobenzoate) 20 mg per 1 application Prednisolone 20mg/application foam enema | 14 dose | £187.00

**Gastro-resistant tablet**
- **CAUTIONARY AND ADVISORY LABELS** 5, 10, 25
  - **Prednisolone (Non-proprietary)**
    - Prednisolone 1 mg Prednisolone 1mg gastro-resistant tablets | 30 tablet | £1.60–£1.92 DT price = £1.84
    - Prednisolone 2.5 mg Prednisolone 2.5mg gastro-resistant tablets | 28 tablet | £1.20 DT price = £1.17 | 30 tablet | £6.15 | 100 tablet | £4.29
    - Prednisolone 5 mg Prednisolone 5mg gastro-resistant tablets | 28 tablet | £1.21 DT price = £1.20 | 30 tablet | £6.29
  - **Deltacortril Enteric** (Alliance Pharmaceuticals Ltd)
    - Prednisolone 2.5 mg Deltacortril 2.5mg gastro-resistant tablets | 30 tablet | £1.16
    - Prednisolone 5 mg Deltacortril 5mg gastro-resistant tablets | 30 tablet | £1.19
  - **Dilacort** (Crescent Pharma Ltd, Teva UK Ltd)
    - Prednisolone 2.5 mg Dilacort 2.5mg gastro-resistant tablets | 28 tablet | £1.14–£1.85 DT price = £1.71
    - Prednisolone 5 mg Dilacort 5mg gastro-resistant tablets | 28 tablet | £1.45–£1.95 DT price = £1.20

**Soluble tablet**
- **CAUTIONARY AND ADVISORY LABELS** 10, 13, 21
  - **Prednisolone (Non-proprietary)**
    - Prednisolone (as Prednisolone sodium phosphate) 5 mg Prednisolone 5mg soluble tablets | 30 tablet | £60.00 DT price = £53.48

**Tablet**
- **CAUTIONARY AND ADVISORY LABELS** 10, 21
  - **Prednisolone (Non-proprietary)**
    - Prednisolone 1 mg Prednisolone 1mg tablets | 28 tablet | £0.78
    - Prednisolone 2.5 mg Prednisolone 2.5mg tablets | 28 tablet | £1.33
    - Prednisolone 5 mg Prednisolone 5mg tablets | 28 tablet | £0.86 DT price = £0.87
    - Prednisolone 10 mg Prednisolone 10mg tablets | 28 tablet | £0.72
    - Prednisolone 20 mg Prednisolone 20mg tablets | 28 tablet | £0.53
    - Prednisolone 25 mg Prednisolone 25mg tablets | 56 tablet | £0.00 DT price = £0.00
    - Prednisolone 30 mg Prednisolone 30mg tablets | 28 tablet | £0.15
  - **Pevanti (AMCo)**
    - Prednisolone 2.5 mg Pevanti 2.5mg tablets | 30 tablet | £1.42 DT price = £1.42
    - Prednisolone 5 mg Pevanti 5mg tablets | 30 tablet | £0.95
    - Prednisolone 10 mg Pevanti 10mg tablets | 30 tablet | £1.90 DT price = £1.90
    - Prednisolone 20 mg Pevanti 20mg tablets | 30 tablet | £3.80 DT price = £3.80
    - Prednisolone 25 mg Pevanti 25mg tablets | 56 tablet | £4.00 DT price = £4.00
  - **Suppository**
    - **Prednisolone (Non-proprietary)**
      - Prednisolone (as Prednisolone sodium phosphate) 5 mg Prednisolone sodium phosphate 5mg suppositories | 10 suppository | £38.63 DT price = £38.63
  - **Suspension for injection**
    - **Deltastab (AMCo)**
      - Prednisolone acetate 25 mg per 1 ml Deltastab 25mg/1ml suspension for injection ampoules | 10 ampoule | £68.72
### Cushing’s syndrome and disease

**Management**

Most types of Cushing’s syndrome are treated surgically, that which occasionally accompanies carcinoma of the bronchus is not usually amenable to surgery. Metyrapone p. 642 has been found helpful in controlling the symptoms of the disease; it is also used in other forms of Cushing’s syndrome to prepare the patient for surgery.

The dosages of metyrapone used are either low, and tailored to cortisol production, or high, in which case corticosteroid replacement therapy is also needed.

Ketoconazole below may have a direct effect on corticotropin tumour cells in patients with Cushing’s disease. It is used under specialist supervision for treatment of endogenous Cushing’s syndrome.

### Enzyme inhibitors

#### Ketoconazole

**Drug action**
An imidazole derivative which acts as a potent inhibitor of cortisol and aldosterone synthesis by inhibiting the activity of 17α-hydroxylase, 11-hydroxylase steps and at higher doses the cholesterol side-chain cleavage enzyme. It also inhibits the activity of adrenal C17–20 lyase enzymes resulting in androgen synthesis inhibition, and may have a direct effect on corticotropin tumour cells in patients with Cushing’s disease.

### Other drugs used for Cushing’s syndrome and disease
Pasireotide, p. 878

---

**Prednisone**

### INDICATIONS AND DOSE

**Moderate to severe rheumatoid arthritis**

- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
- **Adult:** 10–20 mg daily, adjusted according to response, dose to be take at bedtime

### INTERACTIONS
- Appendix 1: corticosteroids

### HEPATIC IMPAIRMENT
- Monitor patient closely in hepatic impairment.

### PATIENT AND CARER ADVICE
- Patient counselling is advised for prednisone tablets (steroid card).

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

#### Modified-release tablet

**CAUTIONARY AND ADVISORY LABELS 10, 21, 25**

- **Lodotra** (Napp Pharmaceuticals Ltd)
  - Prednisone 1 mg Lodotra 1mg modified-release tablets: 30 tablet {pom} £26.70
  - Prednisone 2 mg Lodotra 2mg modified-release tablets: 30 tablet {pom} £26.70 | 100 tablet {pom} £89.00
  - Prednisone 5 mg Lodotra 5mg modified-release tablets: 30 tablet {pom} £26.70 | 100 tablet {pom} £89.00

---

**Triamcinolone acetonide**

### INDICATIONS AND DOSE

**Suppression of inflammatory and allergic disorders**

- **BY DEEP INTRAMUSCULAR INJECTION**
  - Adult: 40 mg (max. per dose 100 mg), repeated if necessary, dose given for depot effect, to be administered into gluteal muscle; repeated at intervals according to patient’s response

### CAUTIONS
- High dosage (may cause proximal myopathy), avoid in chronic treatment

### INTERACTIONS
- Appendix 1: corticosteroids

### PATIENT AND CARER ADVICE
- Patient counselling is advised for triamcinolone acetonide injection (steroid card).

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

#### Suspension for injection

**CAUTIONARY AND ADVISORY LABELS 10**

- **EXCipients:** May contain Benzyl alcohol
  - **Kenalog** (Bristol-Myers Squibb Pharmaceuticals Ltd)
  - Triamcinolone acetonide 40 mg per 1 ml Kenalog Intra-articular / Intramuscular 40mg/1ml suspension for injection vials: 5 vial {pom} £7.45 DT price = £7.45
increased appetite · insomnia · menstrual disorder · myalgia · nervousness · paraesthesia · peripheral oedema · photophobia · photosensitivity · raised intracranial pressure · reduced testosterone concentrations · tongue discoloration · xeroderma

SIDE-EFFECTS, FURTHER INFORMATION

- Hepatotoxicity Potentially life-threatening hepatotoxicity reported rarely.
- CONCEPTION AND CONTRACEPTION Effective contraception must be used in women of child-bearing potential.
- PREGNANCY Manufacturer advises avoid—teratogenic in animal studies.
- BREAST FEEDING Manufacturer advises avoid—present in breast milk.
- HEPATIC IMPAIRMENT Avoid in acute or chronic impairment. Do not initiate treatment if liver enzymes greater than 2 times the normal upper limit.
- MONITORING REQUIREMENTS
  - Monitor ECG before and one week after initiation, and then as clinically indicated thereafter.
  - Adrenal insufficiency Monitor adrenal function within one week of initiation, then regularly thereafter. When cortisol levels are normalised or close to target and effective dose established, monitor every 3–6 months as there is a risk of autoimmune disease development or exacerbation after normalisation of cortisol levels. If symptoms suggestive of adrenal insufficiency such as fatigue, anorexia, nausea, vomiting, hypotension, hyponatraemia, hyperkalaemia, and/or hypoglycaemia occur, measure cortisol levels and discontinue treatment temporarily (can be resumed thereafter at lower dose) or reduce dose and if necessary, initiate corticosteroid substitution.
- Hepatotoxicity Monitor liver function before initiation of treatment, then weekly for 1 month after initiation, then monthly for 6 months—more frequently if dose adjusted or abnormal liver function detected. Reduce dose if liver enzymes increase less than 3 times the normal upper limit—consult product literature; if liver enzymes are raised to 3 times or greater the normal upper limit, discontinue treatment permanently.
- PATIENT AND CARER ADVICE Patients or their carers should be told how to recognise signs of liver disorder, and advised to discontinue treatment and seek prompt medical attention if symptoms such as anorexia, nausea, vomiting, fatigue, jaundice, abdominal pain, or dark urine develop.
  - Patients or their carers should also be told how to recognise signs of adrenal insufficiency.

Driving and skilled tasks

Dizziness and somnolence may affect the performance of skilled tasks (e.g. driving).

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

Tablet

CAUTIONARY AND ADVISORY LABELS 2, 5, 21

- Ketoconazole (non-proprietary) ▼
  - Ketoconazole 200 mg Ketoconazole 200mg tablets | 60 tablet [Pom] £460.00

Metyrapone

- DRUG ACTION Metyrapone is a competitive inhibitor of 11β-hydroxylation in the adrenal cortex; the resulting inhibition of cortisol (and to a lesser extent aldosterone) production leads to an increase in ACTH production which, in turn, leads to increased synthesis and release of cortisol precursors. Metyrapone may be used as a test of anterior pituitary function.

INDICATIONS AND DOSE

Differential diagnosis of ACTH-dependent Cushing’s syndrome (specialist supervision in hospital)

- BY MOUTH
  - Adult: 750 mg every 4 hours for 6 doses

Management of Cushing’s syndrome (specialist supervision in hospital)

- BY MOUTH
  - Adult: Usual dose 0.25–6 g daily, dose to be tailored to cortisol production, dose is either low, and tailored to cortisol production, or high, in which case corticosteroid replacement therapy is also needed

Resistant oedema due to increased aldosterone secretion in cirrhosis, nephrotic syndrome, and congestive heart failure (with glucocorticoid replacement therapy) (specialist supervision in hospital)

- BY MOUTH
  - Adult: 3 g daily in divided doses

CONTRA-INDICATIONS Adrenocortical insufficiency

- CAUTIONS Avoid in acute porphyrias p. 969 · gross hypopituitarism (risk of precipitating acute adrenal failure) · hypertension on long-term administration · hypothyroidism (delayed response)

INTERACTIONS → Appendix 1: metyrapone

- SIDE-EFFECTS
  - Rare Abdominal pain · allergic skin reactions · hirsutism · hypoadrenalism
  - Frequency not known Dizziness · headache · hypotension · nausab · sedation · vomiting

- PREGNANCY Avoid (may impair biosynthesis of fetal-placental steroids).

- BREAST FEEDING Avoid—no information available.

- HEPATIC IMPAIRMENT Use with caution in hepatic impairment (delayed response).

PATIENT AND CARER ADVICE

Driving and skilled tasks

Drowsiness may affect the performance of skilled tasks (e.g. driving).

MEDITICL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Capsule

CAUTIONARY AND ADVISORY LABELS 21

- Metopirone (HRA Pharma UK Ltd)
  - Metyrapone 250 mg Metopirone 250mg capsules | 100 capsule [Pom] £363.66
Diabetes mellitus and hypoglycaemia

3.1 Diabetes mellitus

Diabetes

05-Jun-2017

Description of condition

Diabetes mellitus is a group of metabolic disorders in which persistent hyperglycaemia is caused by deficient insulin secretion or by resistance to the action of insulin. This leads to the abnormalities of carbohydrate, fat and protein metabolism that are characteristic of diabetes mellitus.

Type 1 diabetes mellitus p. 644 and Type 2 diabetes mellitus p. 646 are the two most common classifications of diabetes. Other common types of diabetes are gestational diabetes (develops during pregnancy and resolves after delivery) and secondary diabetes (may be caused by pancreatic damage, hepatic cirrhosis, or endocrine disease). Treatment with endocrine, antiviral, or antipsychotic drugs may also cause secondary diabetes.

Driving

Drivers with diabetes may be required to notify the Driver and Vehicle Licensing Agency (DVLA) of their condition depending on their treatment, the type of licence they hold, and whether they have diabetic complications (including episodes of hypoglycaemia). All drivers who are treated with insulin must inform the DVLA, with some exceptions for temporary treatment. Detailed guidance on notification requirements, eligibility to drive, and precautions required, is available from the DVLA at www.gov.uk/guidance/diabetes-mellitus-assessing-fitness-to-drive

Advice from the DVLA

The DVLA recommends (2016) that drivers with diabetes need to be particularly careful to avoid hypoglycaemia and should be informed of the warning signs and actions to take. Drivers treated with insulin should always carry a glucose meter and blood glucose strips when driving, and check their blood-glucose concentration no more than 2 hours before driving and every 2 hours while driving. More frequent self-monitoring may be required if, for any reason, there is a greater risk of hypoglycaemia, such as after physical activity or altered meal routine.

Blood glucose should always be above 5 mmol/litre while driving. If blood glucose falls to 5 mmol/litre or below, a snack should be taken. Drivers treated with insulin should ensure that a supply of fast-acting carbohydrate is always available in the vehicle. If blood glucose is less than 4 mmol/Litre, or warning signs of hypoglycaemia develop, the driver should not drive. If already driving, the driver should:

- stop the vehicle in a safe place;
- switch off the engine, remove keys from the ignition, and move from the driver’s seat;
- eat or drink a suitable source of sugar;
- wait until 45 minutes after blood glucose has returned to normal, before continuing journey.

Drivers must not drive if hypoglycaemia awareness has been lost and the DVLA must be notified; driving may resume if a medical report confirms that awareness has been regained.

Depending on the type of licence, notification and monitoring may also be necessary for drivers taking oral antidiabetic drugs, particularly those which carry a risk of hypoglycaemia (e.g. sulfonylureas, nateglinide p. 660, repaglinide p. 660).

Note: additional criteria apply for drivers of large goods or passenger carrying vehicles—consult DVLA guidance.

Alcohol

Alcohol can make the signs of hypoglycaemia less clear, and can cause delayed hypoglycaemia; specialist sources recommend that patients with diabetes should drink alcohol only in moderation, and when accompanied by food.

Oral glucose tolerance tests

The oral glucose tolerance test is used mainly for diagnosis of impaired glucose tolerance; it is not recommended or necessary for routine diagnostic use when severe symptoms of hyperglycaemia are present. In patients who have less severe symptoms and a blood-glucose concentration that does not establish or exclude diabetes (e.g. impaired fasting glycaemia), an oral glucose tolerance test may be required. It is also used to establish the presence of gestational diabetes.

An oral glucose tolerance test involves measuring the blood-glucose concentration after fasting, and then 2 hours after drinking a standard anhydrous glucose drink. Anhydrous glucose may alternatively be given as the appropriate amount of Polycal® or as Rapilose® OGTT oral solution.

HbA1c measurement

Glycated haemoglobin (HbA1c) forms when red blood cells are exposed to glucose in the plasma. The HbA1c test reflects average plasma glucose over the previous 2 to 3 months and provides a good indicator of glycaemic control. Unlike the oral glucose tolerance test, an HbA1c test can be performed at any time of the day and does not require any special preparation such as fasting.

HbA1c values are expressed in mmol of glycated haemoglobin per mol of haemoglobin (mmol/mol), a standardised unit specific for HbA1c created by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). HbA1c values were previously aligned to the assay used in the Diabetes Control and Complications Trial (DCCT) and expressed as a percentage.

Equivalent values

<table>
<thead>
<tr>
<th>Equivalent values</th>
<th>IFCC-HbA1c (mmol/mol)</th>
<th>DCCT-HbA1c (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>42</td>
<td>6.0</td>
<td></td>
</tr>
<tr>
<td>48</td>
<td>6.5</td>
<td></td>
</tr>
<tr>
<td>53</td>
<td>7.0</td>
<td></td>
</tr>
<tr>
<td>59</td>
<td>7.5</td>
<td></td>
</tr>
<tr>
<td>64</td>
<td>8.0</td>
<td></td>
</tr>
<tr>
<td>69</td>
<td>8.5</td>
<td></td>
</tr>
<tr>
<td>75</td>
<td>9.0</td>
<td></td>
</tr>
</tbody>
</table>

Diagnosis

The HbA1c test is used for monitoring glycaemic control in both Type 1 diabetes p. 644 and Type 2 diabetes p. 646 and is now also used for diagnosis of type 2 diabetes. HbA1c should not be used for diagnosis in those with suspected type 1 diabetes, in children, during pregnancy, or in women who are up to two months postpartum. It should also not be used for patients who have:

- had symptoms of diabetes for less than 2 months;
- a high diabetes risk and are acutely ill;
- treatment with medication that may cause hyperglycaemia;
- Acute pancreatic damage;
- end-stage chronic kidney disease;
- HIV infection.

HbA1c used for diagnosis of diabetes should be interpreted with caution in patients with abnormal haemoglobin, anaemia, altered red cell lifespan, or who have had a recent blood transfusion.
Endocrine system

Diabetes mellitus and hypoglycaemia

Monitoring
HbA1c is also a reliable predictor of microvascular and macrovascular complications and mortality. Lower HbA1c is associated with a lower risk of long-term vascular complications and patients should be supported to aim for an individualised HbA1c target (see Type 1 diabetes p. 644 and Type 2 diabetes p. 646).

HbA1c should usually be measured in patients with type 1 diabetes every 3 to 6 months, and more frequently if blood glucose control is thought to be changing rapidly. Patients with type 2 diabetes should be monitored every 3 to 6 months until HbA1c and medication are stable when monitoring can be reduced to every 6 months.

HbA1c monitoring is invalid for patients with disturbed erythrocyte turnover or for patients with a lack of, or abnormal haemoglobin. In these cases, quality-controlled plasma glucose profiles, total glycated haemoglobin estimation (if there is abnormal haemoglobin), or fructosamine estimation can be used.

Laboratory measurement of fructosamine concentration measures the glycated fraction of all plasma proteins over the previous 14 to 21 days but is a less accurate measure of glycaemic control than HbA1c.

Type 1 diabetes

Description of condition
Type 1 diabetes describes an absolute insulin deficiency in which there is little or no endogenous insulin secretory capacity due to destruction of insulin-producing beta-cells in the pancreatic islets of Langerhans. This form of the disease has an auto-immune basis in most cases, and it can occur at any age, but most commonly before adulthood.

Loss of insulin secretion results in hyperglycaemia and other metabolic abnormalities. If poorly managed, the resulting tissue damage has both short-term and long-term adverse effects on health; this can result in retinopathy, nephropathy, neuropathy, premature cardiovascular disease, and peripheral arterial disease.

Typical features in adult patients presenting with type 1 diabetes are hyperglycaemia (random plasma-glucose concentration above 11 mmol/litre), ketosis, rapid weight loss, a body mass index below 25 kg/m², age younger than 50 years, and a personal/family history of autoimmune disease (though not all features may be present).

Aims of treatment
Treatment is aimed at using insulin regimens to achieve as optimal a level of blood-glucose control as is feasible, while avoiding or reducing the frequency of hypoglycaemic episodes, in order to minimise the risk of long-term microvascular and macrovascular complications.

Disability from complications can often be prevented by early detection and active management of the disease (see Diabetic complications p. 648). The target for glycaemic control should be individualised for each patient, considering factors such as daily activities, aspirations, likelihood of complications, adherence to treatment, comorbidities, occupation and history of hypoglycaemia.

A target HbA1c concentration of 48 mmol/mol (6.5 %) or lower is recommended in patients with type 1 diabetes.

Blood-glucose concentration should be monitored at least four times a day, including before each meal and before bed. Patients should aim for:

- a fasting blood-glucose concentration of 5–7 mmol/litre on waking;
- a blood-glucose concentration of 4–7 mmol/litre before meals at other times of the day;
- a blood-glucose concentration of 5–9 mmol/litre at least 90 minutes after eating;
- a blood-glucose concentration of at least 5 mmol/litre when driving.

Overview
Type 1 diabetes requires insulin replacement, supported by active management of other cardiovascular risk factors, such as hypertension and high circulating lipids (see Diabetic complications p. 648). Insulin replacement therapy aims to recreate normal fluctuations in circulating insulin concentrations while supporting a flexible lifestyle with minimal restrictions. Flexible insulin therapy usually involves self-injecting multiple daily doses of insulin, with doses adjusted according to planned exercise, intended food intake and other factors, including current blood-glucose, which the patient needs to test on a regular basis.

Patients who have a BMI of 25 kg/m² or above (23 kg/m² or above for patients of South Asian or related ethnicity) who wish to improve their blood-glucose control while minimising their effective insulin dose, may benefit from metformin hydrochloride p. 652 [unlicensed indication] as an addition to insulin therapy.

Dietary control is important in both type 1 and type 2 diabetes and patients should receive advice from a dietitian. Dietary advice should include information on weight control, cardiovascular risk, hyperglycaemic effects of different foods and appropriate changes in insulin doses according to food intake. Healthy eating can reduce cardiovascular risk and dietary modifications may be recommended to account for various associated features of diabetes such as excess weight and obesity, low body-weight, eating disorders, hypertension and renal failure. Patients with type 1 diabetes should be offered carbohydrate-counting training as part of a structured education programme.

Management of type 1 diabetes with insulin
All patients with type 1 diabetes require insulin therapy (see also Insulin p. 645). Treatment should be initiated and managed by clinicians with relevant expertise; there are several different types of regimens.

Multiple daily injection basal-bolus insulin regimens
One or more separate daily injections of intermediate-acting insulin or long-acting insulin analogue as the basal insulin; alongside multiple bolus injections of short-acting insulin before meals. This regimen offers flexibility to tailor insulin therapy with the carbohydrate load of each meal.

Mixed (biphasic) regimen
One, two, or three insulin injections per day of short-acting insulin mixed with intermediate-acting insulin. The insulin preparations may be mixed by the patient at the time of injection, or a premixed product can be used.

Continuous subcutaneous insulin infusion (insulin pump)
A regular or continuous amount of insulin (usually in the form of a rapid-acting insulin analogue or soluble insulin), delivered by a programmable pump and insulin storage reservoir via a subcutaneous needle or cannula.

Recommended insulin regimens
Patients with type 1 diabetes should be offered multiple daily injection basal-bolus insulin regimens as the first-line choice. Twice-daily insulin detemir p. 671 should be offered as the long-acting basal insulin therapy. Once-daily insulin glargine p. 672 may be prescribed if insulin detemir is not tolerated, or if a twice-daily regimen is not acceptable to the patient. Insulin detemir may also be offered as an alternative once-daily regimen.

Patients who are using alternative basal regimens may continue if agreed targets are being achieved; other basal insulin regimens should be considered only if the recommended regimens do not deliver agreed targets. Non-basal-bolus insulin regimens (e.g. twice-daily mixed [biphasic], basal-only, or bolus-only regimens) are not
recommended for adults with newly diagnosed type 1 diabetes.

A rapid-acting insulin analogue is recommended as the bolus or mealtime insulin replacement, rather than soluble human insulin or animal insulin (rarely used). The rapid-acting insulin analogue should be injected before meals—routine use after meals should be discouraged. Patients who have a strong preference for an alternative mealtime insulin should be offered their preferred insulin.

Alternatively, if a multiple daily injection basal–bolus regimen is not possible, a twice-daily mixed insulin regimen should be considered if it is preferred.

In patients who are using a twice-daily human insulin mixed regimen and have hypoglycaemia that affects their quality of life, a trial of a twice-daily analogue mixed insulin regimen should be considered.

Continuous subcutaneous insulin infusion (insulin pump) therapy, should only be offered to adults who suffer disabling hypoglycaemia, or, who have high HbA1c concentrations (69 mmol/mol [8.5%] or above) with multiple daily injection therapy (including, if appropriate, the use of long-acting insulin analogues) despite a high level of care. Insulin pump therapy should be initiated by a specialist team.

Insulin requirements

The dosage of insulin must be determined individually for each patient and should be adjusted as necessary according to the results of regular monitoring of blood-glucose concentrations.

Persistent poor glucose control, leading to erratic insulin requirements or episodes of hypoglycaemia, may be due to many factors, including adherence, injection technique, injection site problems, blood-glucose monitoring skills, lifestyle issues (including diet, exercise and alcohol intake), psychological issues, and organic causes such as renal disease, thyroid disorders, coeliac disease, Addison’s disease or gastroparesis.

Infection, stress, accidental or surgical trauma can all increase the required insulin dose. Insulin requirements may be decreased (and therefore susceptibility to hypoglycaemia increased) by physical activity, intercurrent illness, reduced food intake, impaired renal function, and in certain endocrine disorders.

Risks of hypoglycaemia with insulin

Hypoglycaemia is an inevitable adverse effect of insulin treatment, and patients should be advised of the warning signs and actions to take (for guidance on management, see Hypoglycaemia p. 680).

Impaired awareness of hypoglycaemia can occur when the ability to recognise usual symptoms is lost, or when the symptoms are blunted or no longer present. Patients’ awareness of hypoglycaemia should be assessed annually using the Gold score or the Clarke score.

An increase in the frequency of hypoglycaemic episodes may reduce the warning symptoms experienced by the patient. Impaired awareness of symptoms below 3 mmol/litre is associated with a significantly increased risk of severe hypoglycaemia. Beta-blockers can also blunt hypoglycaemic awareness, by reducing warning signs such as tremor.

Loss of warning of hypoglycaemia among insulin-treated patients can be a serious hazard, especially for drivers and those in dangerous occupations. Advice should be given in line with the Driver and Vehicle Licensing Agency (DVLA) guidance (see Driving under Diabetes p. 643).

To restore the warning signs, episodes of hypoglycaemia must be minimised. Insulin regimens, doses and blood-glucose targets should be reviewed and continuous subcutaneous insulin infusion therapy and real-time continuous blood-glucose monitoring should be considered. Patients should receive structured education to ensure they are following the principles of a flexible insulin regimen correctly, with additional education regarding avoiding and treating hypoglycaemia for those who continue to have impaired awareness. Relaxation of individualised blood-glucose targets should be avoided as a strategy to improve impaired awareness of symptoms. If recurrent severe episodes of hypoglycaemia continue despite appropriate interventions, the patient should be referred to a specialist centre.

There is conflicting evidence regarding reports that some patients may experience loss of awareness of hypoglycaemia after transfer from animal to human insulin; clinical studies do not confirm that human insulin decreases hypoglycaemia awareness.

Manufacturers advise any switch between brands or formulation of insulin (including switching from animal to human insulin) should be done under strict supervision; a change in dose may be required.

Hypodermic equipment

Patients should be advised on the safe disposal of lancets, single-use syringes, and needles, and should be provided with suitable disposal containers. Arrangements should be made for the suitable disposal of these containers.

Lancets, needles, syringes, and accessories are listed under Hypodermic Equipment in Part IXA of the Drug Tariff (Part III of the Northern Ireland Drug Tariff, Part 3 of the Scottish Drug Tariff). The drug Tariffs can be access online at:

- Health and Personal Social Services for Northern Ireland Drug Tariff: www.hsbcusiness.hscni.net/services/2034.htm
- Scottish Drug Tariff: www.isdscotland.org/Health-Topics/Prescribing-and-Medicines/Scottish-Drug-Tariff

Useful Resources

Type 1 diabetes in adults: diagnosis and management.

Insulin

Overview

For recommended insulin regimens see Type 1 diabetes p. 644 and Type 2 diabetes p. 646.

Insulin is a polypeptide hormone secreted by pancreatic beta-cells. Insulin increases glucose uptake by adipose tissue and muscles, and suppresses hepatic glucose release. The role of insulin is to lower blood-glucose concentrations in order to prevent hyperglycaemia and its associated microvascular, macrovascular and metabolic complications.

The natural profile of insulin secretion in the body consists of basal insulin (a low and steady secretion of background insulin that controls the glucose continuously released from the liver) and meal-time bolus insulin (secreted in response to glucose absorbed from food and drink).

Sources of insulin

Three types of insulin are available in the UK: human insulin, human insulin analogues, and animal insulin. Animal insulins are extracted and purified from animal sources (bovine or porcine insulin). Although widely used in the past, animal insulins are no longer initiated in people with diabetes but may still be used by some adult patients who cannot, or do not wish to, change to human insulins.

Human insulins are produced by recombinant DNA technology and have the same amino acid sequence as...
endogenous human insulin. Human insulin analogues are produced in the same way as human insulins, but the insulin is modified to produce a desired kinetic characteristic, such as an extended duration of action or faster absorption and onset of action.

Immunological resistance to insulin is uncommon and true insulin allergy is rare. Human insulin and insulin analogues are less immunogenic than animal insulins.

Administration of insulin

Insulin is inactivated by gastro-intestinal enzymes and must therefore be given by injection; the subcutaneous route is ideal in most circumstances. Insulin should be injected into a body area with plenty of subcutaneous fat—usually the abdomen (fastest absorption rate) or outer thighs/buttocks (slower absorption compared with the abdomen or inner thighs).

Absorption from a limb site can vary considerably (by as much as 20–40%) day-to-day, particularly in children. Local tissue reactions, changes in insulin sensitivity, injection site, blood flow, depth of injection, and the amount of insulin injected can all affect the rate of absorption. Increased blood flow around the injection site due to exercise can also increase insulin absorption. Lipohypertrophy can occur due to repeatedly injecting into the same small area, and can cause erratic absorption of insulin, and contribute to poor glycaemic control. Patients should be advised not to use affected areas for further injection until the skin has recovered. Lipohypertrophy can be minimised by using different injection sites in rotation. Injection sites should be checked for signs of infection, swelling, bruising, and lipohypertrophy before administration.

Insulin preparations

Insulin preparations can be broadly categorised into three groups based on their time-action profiles: short-acting insulins (including soluble insulin and rapid-acting insulins), intermediate-acting insulins and long-acting insulins. The duration of action of each particular type of insulin varies considerably from one patient to another, and needs to be assessed individually.

Short-acting insulins

Short-acting insulins have a short duration and a relatively rapid onset of action, to replicate the insulin normally produced by the body in response to glucose absorbed from a meal. These are available as soluble insulin (human and, bovine or porcine—both rarely used), and the rapid-acting insulin analogues (insulin aspart p. 673, insulin glulisine p. 674 and insulin lispro p. 675).

Soluble insulin

Soluble insulin is usually given subcutaneously but some preparations can be given intravenously and intramuscularly. For maintenance regimes, it is usual to inject the insulin 15 to 30 minutes before meals, depending on the insulin preparation used.

When injected subcutaneously, soluble insulin has a rapid onset of action (30 to 60 minutes), a peak action between 1 and 4 hours, and a duration of action of up to 9 hours.

When injected intravenously, soluble insulin has a short half-life of only a few minutes and its onset of action is instantaneous.

Soluble insulin administered intravenously is the most appropriate form of insulin for use in diabetic emergencies e.g. Diabetic ketoacidosis p. 651 and peri-operatively.

Rapid-acting insulin

Insulin aspart, insulin glulisine, and insulin lispro have a faster onset of action (within 15 minutes) and shorter duration of action (approximately 2–5 hours) than soluble insulin, and are usually given by subcutaneous injection. For maintenance regimes, these insulins should ideally be injected immediately before meals. Rapid-acting insulin, administered before meals, has an advantage over short-acting soluble insulin in terms of improved glucose control, reduction of HbA1c, and reduction in the incidence of severe hypoglycaemia, including nocturnal hypoglycaemia.

The routine use of post-meal injections of rapid-acting insulin should be avoided—when given during or after meals, they are associated with poorer glucose control, an increased risk of high postprandial-glucose concentration, and subsequent hypoglycaemia.

Intermediate-acting insulin

Intermediate-acting insulins (isophane insulin p. 670) have an intermediate duration of action, designed to mimic the effect of endogenous basal insulin. When given by subcutaneous injection, they have an onset of action of approximately 1–2 hours, a maximal effect at 3–12 hours, and a duration of action of 11–24 hours.

Insuline glargine and insulin glargine are given once daily and insulin detemir is given once or twice daily according to individual requirements. The older long-acting insulins, insulin glargine and insulin detemir are now rarely prescribed.

Type 2 diabetes

Description of condition

Type 2 diabetes is a chronic metabolic condition characterised by insulin resistance. Insufficient pancreatic insulin production also occurs progressively over time, resulting in hyperglycaemia.

It is commonly associated with obesity, physical inactivity, raised blood pressure, dyslipidaemia and a tendency to develop thrombosis; therefore it increases cardiovascular risk. It is associated with long-term microvascular and macrovascular complications, together with reduced quality of life and life expectancy.

Type 2 diabetes typically develops later in life but is increasingly diagnosed in children, despite previously being considered a disease of adulthood.

Aims of treatment

Treatment is aimed at minimising the risk of long-term microvascular and macrovascular complications by effective treatment.
Overview

Weight loss, smoking cessation and regular exercise can help to reduce hyperglycaemia and reduce cardiovascular risk, and should be encouraged (with input from a dietitian where appropriate). Antidiabetic drugs should be prescribed to augment lifestyle interventions, when these changes are not adequate to control blood-glucose alone.

Antidiabetic drugs

There are several classes of non-insulin antidiabetic drugs available for the treatment of type 2 diabetes. The choice of drug should be based on effectiveness, safety, tolerability and should also take into consideration the patient’s comorbidities and concomitant medication. For recommended treatment regimens and the place in therapy of each drug, see Drug treatment, antidiabetic drugs (below).

Metformin hydrochloride p. 652 has an anti-hyperglycaemic effect, lowering both basal and postprandial blood-glucose concentrations. It does not stimulate insulin secretion and therefore, when given alone, does not cause hypoglycaemia. The dose of standard-release metformin hydrochloride should be increased gradually to minimise the risk of gastro-intestinal side effects. Modified-release metformin hydrochloride should be offered if standard treatment is not tolerated.

The sulfonylureas (glibenclamide p. 665, gliclazide p. 666, glimepiride p. 666, glipizide p. 667, tolbutamide p. 667) may cause hypoglycaemia; it is more likely with long-acting sulfonylureas such as glibenclamide, which have been associated with severe, prolonged and sometimes fatal cases of hypoglycaemia. Sulfonylureas are also associated with modest weight gain, probably due to increased plasma-insulin concentrations.

Acarbose p. 651 has a poorer anti-hyperglycaemic effect than many other antidiabetic drugs, including the sulfonylureas, metformin hydrochloride, and pioglitazone p. 667.

The meglitinides, nateglinide p. 660 and repaglinide p. 660, have a rapid onset of action and short duration of activity. These drugs can be used flexibly around mealtimes and adjusted to fit around individual eating habits which may be beneficial for some patients, but generally are a less preferred option than the sulfonylureas.

The thiazolidinedione, pioglitazone, is associated with several long-term risks and its ongoing benefit to the patient should be reviewed regularly and treatment stopped if response is insufficient (see Important safety information under pioglitazone).

The dipeptidylpeptidase-4 inhibitors (glitins), alogliptin p. 653, linagliptin p. 654, sitagliptin p. 655, saxagliptin p. 654, and vildagliptin p. 656, do not appear to be associated with weight gain and have less incidence of hypoglycaemia than the sulfonylureas.

The sodium glucose co-transporter 2 inhibitors, canagliflozin p. 661, dapagliflozin p. 662, and empagliflozin p. 664, may be suitable for some patients when first-line options are not appropriate; they are associated with a risk of diabetic ketoacidosis.

The glucagon-like peptide-1 receptor agonists, albiglutide p. 657, dulaglutide p. 657, exenatide p. 658, liraglutide p. 659 and lixisenatide p. 659, should be reserved for combination therapy when other treatment options have failed.

Polycystic ovary syndrome

Metformin hydrochloride (initiated by a specialist) is prescribed as an insulin sensitising drug in women with polycystic ovary syndrome who are not planning pregnancy [unlicensed indication]. Long-term benefit or superiority over other treatment options has not been confirmed by good quality evidence. Metformin hydrochloride may improve short-term insulin sensitivity and reduce androgen concentrations, but there is insufficient supporting evidence that metformin improves weight gain, hirsutism, acne or regulation of the menstrual cycle. Treatment should only be initiated by a specialist. Metformin hydrochloride does not exert a hypoglycaemic action in non-diabetic patients except in overdose.

Drug treatment, antidiabetic drugs

Type 2 diabetes should initially be treated with a single oral antidiabetic drug. A target HbA1c concentration of 48 mmol/mol (6.5 %) is generally recommended when type 2 diabetes is managed by diet and lifestyle alone or when combined with a single antidiabetic drug not associated with hypoglycaemia (such as metformin hydrochloride). Adults prescribed a single drug associated with hypoglycaemia (such as a sulphonylurea), or two or more antidiabetic drugs in combination, should usually aim for an HbA1c concentration of 53 mmol/mol (7.0 %). Targets may differ and should be individualised and agreed with each patient.

Note: Consider relaxing the target HbA1c level on a case-by-case basis, with particular consideration for people who are older, frail, or where tight blood-glucose control is not appropriate or poses a high risk of the consequences of hypoglycaemia.

If HbA1c concentrations are poorly controlled despite treatment with a single drug (usually considered to be a rise of HbA1c to 58 mmol/mol (7.5 %) or higher), the drug treatment should be intensified, alongside reinforcement of advice regarding diet, lifestyle, and adherence to drug treatment.

When two or more antidiabetic drugs are prescribed, an HbA1c concentration target of 53 mmol/mol (7.0 %) is recommended for patients in which it is appropriate, but a relaxation of the target may be more appropriate in some individual cases (for example, those at high risk of the consequences of hypoglycaemia, poor life expectancy, or significant comorbidities).

Initial treatment

Metformin hydrochloride is recommended as the first choice for initial treatment for all patients, due to its positive effect on weight loss, reduced risk of hypoglycaemic events and the additional long-term cardiovascular benefits associated with its use.

If metformin is contra-indicated or not tolerated, see Alternative non-metformin regimens below.

First intensification of treatment

If metformin hydrochloride (alongside modification to diet) does not control HbA1c to below the agreed threshold, treatment should be intensified, and metformin hydrochloride combined with one of the following:

- a sulfonylurea (glibenclamide, gliclazide, glimepiride, glipizide, tolbutamide);
- pioglitazone;
- a dipeptidylpeptidase-4 inhibitor (linagliptin, saxagliptin, sitagliptin, or vildagliptin);
- a sodium glucose co-transporter 2 inhibitor (canagliflozin, dapagliflozin or empagliflozin) only when sulfonylureas are contra-indicated or not tolerated, or if the patient is at significant risk of hypoglycaemia or its consequences.

Elderly patients or those with renal impairment are at particular risk of hypoglycaemia; if a sulfonylurea is indicated, a shorter-acting sulfonylurea, such as gliclazide or tolbutamide should be prescribed.

The place in therapy of alogliptin (a dipeptidylpeptidase-4 inhibitor) is not yet known.
Second intensification of treatment

If dual therapy is unsuccessful, treatment should be intensified again, and one of the following triple therapy regimens prescribed:

- metformin hydrochloride p. 652 and a dipeptidylpeptidase-4 inhibitor and a sulfonylurea;
- metformin hydrochloride and pioglitazone p. 667 and a sulfonylurea;
- metformin hydrochloride and a sulfonylurea and one of the sodium glucose co-transporter 2 inhibitors;
- metformin hydrochloride and pioglitazone and a sodium glucose co-transporter 2 inhibitor (canagliflozin p. 661 or empagliflozin p. 664; note that dapagliflozin is not recommended in a triple therapy regimen with pioglitazone).

Alternatively, it may be appropriate to start insulin-based treatment at this stage—see Drug treatment, insulin.

Glucagon-like peptide-1 receptor agonists

If triple therapy with metformin hydrochloride and two other oral drugs is tried and is not effective, not tolerated or contra-indicated, a glucagon-like peptide-1 receptor agonist (exenatide p. 658, liraglutide p. 659 or lixisenatide p. 659) may be prescribed as part of a triple combination regimen with metformin hydrochloride and a sulfonylurea. These should only be prescribed for patients who have a BMI of 35 kg/m² or above (adjusted for ethnicity) and who also have specific psychological or medical problems associated with obesity; or for those who have a BMI lower than 35 kg/m² but for whom insulin therapy would have significant occupational implications or if the weight loss associated with glucagon-like peptide-1 receptor agonists would benefit other significant obesity-related comorbidities.

After 6 months, the drug should be reviewed and only continued if there has been a beneficial metabolic response (a reduction of at least 11 mmol/mol [1.0%] in HbA1c and a weight loss of at least 3% of initial body-weight).

The place in therapy of the newer glucagon-like peptide-1 receptor agonists, albiglutide p. 657 and dulaglutide p. 657, is not yet known.

Insulin should only be prescribed in combination with a glucagon-like peptide-1 receptor agonist under specialist care advice and with ongoing support from a consultant-led multidisciplinary team.

Alternative non-metformin regimens

If metformin is contra-indicated or not tolerated, initial treatment should be single therapy with:

- a dipeptidylpeptidase-4 inhibitor (linagliptin p. 654, saxagliptin p. 654, sitagliptin p. 655, or vildagliptin p. 656), or
- pioglitazone, or

The sodium glucose co-transporter 2 inhibitors canagliflozin, dapagliflozin p. 662, or empagliflozin are also options for monotherapy when metformin is contra-indicated or not tolerated, only if a dipeptidylpeptidase-4 inhibitor would otherwise be prescribed and neither a sulfonylurea nor pioglitazone is appropriate.

Repaglinide p. 660 is also an effective alternative option for single therapy, but it has a limited role in treatment because, should an intensification of treatment be required, it is not licensed to be used in any combination other than with metformin hydrochloride; it would therefore require a complete change of treatment in those patients who have started it due to intolerance or contra-indication to metformin.

Intensification

If the initial single drug does not control HbA1c to below the agreed threshold, treatment should be intensified and one of the following dual combinations prescribed:

- a dipeptidylpeptidase-4 inhibitor and pioglitazone;
- a dipeptidylpeptidase-4 inhibitor and a sulfonylurea; or
- pioglitazone and a sulfonylurea.

If dual therapy does not provide adequate glucose control, insulin-based treatment should be considered—see Drug treatment, insulin.

Drug treatment, insulin

When indicated for intensification, insulin (see also, Insulin p. 645) should be started with a structured support programme covering insulin dose titration, injection technique, self-monitoring, and knowledge of dietary effects and glucose control. Metformin hydrochloride should be continued unless it is contra-indicated or not tolerated. Other antidiabetic drugs should be reviewed and stopped if necessary.

Recommended insulin regimens include:

- human isophane insulin p. 670 injected once or twice daily, according to requirements;
- a human isophane insulin in combination with a short-acting insulin, administered either separately or as a pre-mixed (biphasic) human insulin preparation (this may be particularly appropriate if HbA1c is 75 mmol/mol (9.0%) or higher);
- Insulin detemir p. 671 or insulin glargine p. 672 as an alternative to human isophane insulin. This can be preferable if a once daily injection would be beneficial (for example if assistance is required to inject insulin), or if recurrent symptomatic hypoglycaemic episodes are problematic, or if the patient would otherwise need twice-daily human isophane insulin injections in combination with oral glucose-lowering drugs. Also consider switching to insulin detemir or insulin glargine from human isophane insulin if significant hypoglycaemia is problematic, or in patients who cannot use the device needed to inject human isophane insulin;
- biphasic preparations (pre-mixed) that include a short-acting human analogue insulin (rather than short-acting human soluble insulin) can be preferable for patients who prefer injecting insulin immediately before a meal, or if hypoglycaemia is a problem, or if blood-glucose concentrations rise markedly after meals.

Patients who are prescribed a basal insulin regimen (human isophane insulin, insulin detemir or insulin glargine) should be monitored for the need for short-acting insulin before meals (or a biphasic insulin preparation).

Patients who are prescribed a biphasic insulin should be monitored for the need for a further injection of short-acting insulin before meals or for a change to a basal-bolus regimen with human isophane insulin or insulin detemir or insulin glargine if blood-glucose control remains inadequate.

Useful Resources


Diabetic complications

Cardiovascular disease

Diabetes is a strong risk factor for cardiovascular disease. Other risk factors for cardiovascular disease such as smoking, hypertension, obesity, and hyperlipidaemia should be addressed. Cardiovascular risk in patients with diabetes
can be further reduced by the use of an ACE inhibitor, low-dose aspirin p. 117 and a lipid-regulating drug.

**Diabetic nephropathy**

Regular review of diabetic patients should include an annual test for urinary protein (using Albustix®) and serum creatinine measurement. If the urinary protein test is negative, the urine should be tested for microalbuminuria (the earliest sign of nephropathy). If reagent strip tests (Micral-Test II® or Microbumintest®) are used and prove positive, the result should be confirmed by laboratory analysis of a urine sample. Provided there are no contraindications, all diabetic patients with nephropathy causing proteinuria or with established microalbuminuria (at least 3 positive tests) should be treated with an ACE inhibitor or an angiotensin-II receptor antagonist even if the blood pressure is normal; in any case, to minimise the risk of renal deterioration, blood pressure should be carefully controlled. Patients with diabetic nephropathy are particularly susceptible to developing hyperkalaemia and should not be given an ACE inhibitor together with an angiotensin-II receptor antagonist. ACE inhibitors can potentiate the hypoglycaemic effect of insulin and oral antidiabetic drugs; this effect is more likely during the first weeks of combined treatment and in patients with renal impairment.

See also treatment of hypertension in diabetes.

**Diabetic neuropathy**

Optimal diabetic control is beneficial for the management of painful neuropathy in patients with type 1 diabetes. Paracetamol p. 422 or a non-steroidal anti-inflammatory drug such as ibuprofen p. 1041 may relieve mild to moderate pain.

Duloxetine p. 350 is effective for the treatment of painful diabetic neuropathy; amitriptyline hydrochloride p. 355 [unlicensed use] can be used if duloxetine is ineffective or unsuitable. Nortriptyline p. 361 [unlicensed use] may be better tolerated than amitriptyline hydrochloride. If treatment with amitriptyline hydrochloride or duloxetine is inadequate, treatment with pregabalin p. 310 should be tried. Combination therapy of duloxetine or amitriptyline hydrochloride with pregabalin can be used if monotherapy at the maximum tolerated dose does not control symptoms.

Neuropathic pain may respond to opioid analgesics. There is evidence of efficacy for tramadol hydrochloride p. 447, morphine p. 439, and oxycodone hydrochloride p. 442; however treatment with morphine or oxycodone hydrochloride should be initiated only under specialist supervision. Tramadol hydrochloride can be prescribed while the patient is waiting for assessment by a specialist if other treatments have been unsuccessful.

Gabapentin p. 301 and carbamazepine p. 297 are sometimes used for the treatment of neuropathic pain. Capsaicin cream 0.075% p. 458 is licensed for painful diabetic neuropathy and may have some effect, but it produces an intense burning sensation during the initial treatment period.

In autonomic neuropathy diabetic diarrhoea can often be managed by tetracycline [unlicensed use], otherwise codeine phosphate p. 431 is the best drug, but other antidiarrhoeal preparations can be tried. Erythromycin p. 510 (especially when given intravenously) may be beneficial for gastroparesis [unlicensed use] but this needs confirmation.

In neuropathic postural hypotension increased salt intake and the use of the mineralcorticoid fludrocortisone acetate p. 637 [unlicensed use] may help by increasing plasma volume, but uncomfortable oedema is a common side-effect. Fludrocortisone can also be combined with flurbiprofen p. 1040 and ephedrine hydrochloride p. 261 [both unlicensed]. Midodrine [unlicensed], an alpha agonist, may also be useful in postural hypotension.

Gustatory sweating can be treated with an antimuscarinic such as propantheline bromide p. 84; side-effects are common. See also, the management of hyperhidrosis (Hyperhidrosis p. 1159).

In some patients with neuropathic oedema, ephedrine hydrochloride [unlicensed use] offers effective relief.

See also the management of Erectile dysfunction p. 765.

**Diabetes, pregnancy and breast-feeding**

**Pregnancy and breast-feeding**

During pregnancy, women with pre-existing diabetes can be treated with metformin hydrochloride p. 652 [unlicensed use], either alone or in combination with insulin. Metformin hydrochloride can be continued, or glibenclamide p. 665 resumed, during breast-feeding for those with pre-existing diabetes. Women with gestational diabetes may be treated, with or without concomitant insulin, with glibenclamide from 11 weeks gestation (after organogenesis) [unlicensed use] or with metformin [unlicensed use]. Women with gestational diabetes should discontinue hypoglycaemic treatment after giving birth.

**Diabetes, surgery and medical illness**

Peri-operative management of blood-glucose concentrations depends on factors including the required duration of fasting, timing of surgery (morning or afternoon), usual treatment regimen (insulin, antidiabetic drugs or diet), prior glycaemic control, other co-morbidities, and the likelihood that the patient will be capable of self-managing their diabetes in the immediate post-operative period. All patients should have emergency treatment for hypoglycaemia written on their drug chart on admission.

**Use of insulin during surgery**

**Elective surgery—minor procedures in patients with good glycaemic control**

Patients usually treated with insulin who have good glycaemic control (HbA1c less than 69 mmol/mol or 8.5 %) and are undergoing minor procedures, can be managed during the operative period by adjustment of their usual insulin regimen, which should be adjusted depending on the type of insulin usually prescribed, following detailed local protocols (which should also include intravenous fluid management, monitoring and control of electrolytes and avoidance of hyperchloreaemic metabolic acidosis). On the day before the surgery, the patient’s usual insulin should be given as normal, other than once daily long-acting insulin analogues, which should be given at a dose reduced by 20%.

**Elective surgery—major procedures or poor glycaemic control**

Patients usually treated with insulin, who are either undergoing major procedures (surgery requiring a long fasting period of more than one missed meal) or whose diabetes is poorly controlled, will usually require a variable insulin infusion, with or without concomitant insulin, with glibenclamide from 11 weeks gestation (after organogenesis) [unlicensed use] or with metformin [unlicensed use]. Women with gestational diabetes should discontinue hypoglycaemic treatment after giving birth.
insulin at a variable rate. Detailed local protocols should be consulted. In general, the following steps should be followed:

- on the day before surgery, once daily long-acting insulin analogues should be given at 80 % of the usual dose; otherwise the patient’s usual insulin should be given as normal;
- on the day of surgery and throughout the intra-operative period, once daily long-acting insulin analogues should be continued at 80 % of the usual dose; all other insulin should be stopped until the patient is eating and drinking again after surgery;
- on the day of surgery, start an intravenous substrate infusion of potassium chloride with glucose and sodium chloride p. 952 (based on serum electrolytes which must be measured frequently), and infuse at a rate appropriate to the patient’s fluid requirements. To prevent hypoglycaemia, this infusion must not be stopped while the insulin infusion is running;
- a variable rate intravenous insulin infusion of soluble human insulin p. 673 in sodium chloride 0.9 % p. 953 (made either according to locally agreed protocols or using prefilled syringes) should be given via a syringe pump at an initial infusion rate determined by bedside capillary blood glucose measurement. Hourly blood glucose measurement should be taken to ensure that the intravenous insulin infusion rate is correct for at least the first 12 hours; the insulin infusion rate should be adjusted according to local protocol to maintain blood glucose concentrations within the usual target range (6–10 mmol/litre; up to 12 mmol/litre is acceptable);
- intravenous glucose 20 % p. 955 should be given if blood glucose drops below 6 mmol/litre, and blood glucose checked every hour, to prevent a drop below 4 mmol/litre. If blood glucose drops below 4 mmol/litre, intravenous glucose 20 % should be adjusted and blood glucose checked every 15 minutes, until blood glucose is above 6 mmol/litre (testing can then revert to hourly). If blood glucose rises above 12 mmol/litre, check ketones and consider other signs of diabetic ketoacidosis (see Diabetic ketoacidosis p. 651).

Conversion back to a subcutaneous insulin should not begin until the patient can eat and drink without nausea or vomiting. Once the patient’s previous insulin regimen is re-started, the usual insulin dose may require adjustment, as insulin requirements can change due to post-operative stress, infection or altered food intake.

Previous subcutaneous basal-bolus regimens, should be restarted when the first postoperative meal-time insulin dose is due (e.g. with breakfast or lunch); doses may need adjustment due to postoperative stress, infection or altered food intake. The variable rate intravenous insulin infusion and intravenous fluids should be continued until 30–60 minutes after the first meal-time short-acting insulin dose. If the patient was previously on a long-acting insulin analogue, this should have been continued throughout the operative period at 80 % of the normal dose, and should now just continue at that same dose until the patient leaves hospital—only the short-acting insulin needs to be restarted as above.

Previous subcutaneous twice-daily mixed insulin regimens, should be restarted before breakfast or an evening meal (not at any other time). The variable rate intravenous insulin infusion should be maintained for 30–60 minutes after the first subcutaneous insulin dose has been given.

Patients who were previously managed with a continuous subcutaneous insulin infusion should be referred to a specialist team. The subcutaneous infusion should be restarted at the normal basal rate, not at bedtime, and the insulin infusion continued until the next meal bolus has been given.

Patients not previously prescribed insulin, who are to start a subcutaneous insulin regimen post-surgery, should have an insulin dose calculated with advice from a specialist diabetes team, considering the patient’s sensitivity to insulin, degree of glycaemic control, weight, age, and the average hourly insulin dose used in the peri-operative period.

Emergency surgery

Patients with diabetes (type 1 and 2) requiring emergency surgery, should always have their blood glucose, blood or urinary ketone concentration, serum electrolytes and serum bicarbonate checked before surgery. If ketones are high or bicarbonate is low, blood gases should also be checked. If ketoacidosis is present, recommendations for Diabetic ketoacidosis p. 651 should be followed immediately, and surgery delayed if possible. If there is no acidosis, intravenous fluids and an insulin infusion should be started and managed as for major elective surgery (above).

Use of antidiabetic drugs during surgery

Manipulation of antidiabetic drug may not be appropriate for all surgery or for all patients; particularly when fasting time is more than one missed meal, in patients with poor glycaemic control, and when there is risk of renal injury. In these cases, a variable rate intravenous insulin p. 673 infusion should be used as for major elective surgery (above), and usual antidiabetic medication adjusted in the peri-operative period. Insulin is almost always required in medical and surgical emergencies.

When insulin is required and given during surgery, acarbose p. 651, miglitolines, sulfonylureas, pioglitazone p. 667, dipeptidyl peptidase-4 inhibitors (gliptins) and sodium glucose co-transporter 2 inhibitors should be stopped once the insulin infusion is commenced and not restarted until the patient is eating and drinking normally. Glucagon-like peptide-1 receptor agonists can be continued as normal during the insulin infusion.

If elective minor surgical procedures only require a short-fasting period (just one missed meal), it may be possible to adjust antidiabetic drugs to avoid a switch to a variable rate intravenous insulin infusion; normal drug treatment can continue.

In suitable cases, acarbose, nateglinide p. 660 and repaglinide p. 660 can be continued with just the dose omitted on the morning of surgery if fasting (the morning dose may be given if the patient is not fasting and surgery is in the afternoon).

Pioglitazone, dipeptidylpeptidase-4 inhibitors (gliptins) and glucagon-like peptide-1 receptor agonists can be taken as normal during the whole peri-operative period.

Sodium glucose co-transporter 2 inhibitors should be omitted on the day of surgery and not restarted until the patient is stable; their use during periods of dehydration and acute illness is associated with an increased risk of developing diabetic ketoacidosis.

Sulfonylureas are associated with hypoglycaemia in the fasted state and therefore should always be omitted on the day of surgery until the patient is eating and drinking again. Capillary blood glucose should be checked hourly. If hyperglycaemia occurs, an appropriate dose of subcutaneous rapid-acting insulin may be given. A second dose may be given 2 hours later, and a variable rate intravenous insulin infusion considered if hyperglycaemia persists.

Metformin hydrochloride p. 652 is renally excreted; renal impairment may lead to accumulation and lactic acidosis during surgery. If only one meal will be missed during surgery, and the patient has an eGFR greater than 60 mL/minute/1.73m² and a low risk of acute kidney injury (and the procedure does not involve administration of contrast media), it may be possible to continue metformin...
hydrochloride throughout the peri-operative period—just the lunchtime dose should be omitted if the usual dose is prescribed three times a day.

If the patient will miss more than one meal or there is significant risk of the patient developing acute kidney injury, metformin hydrochloride should be stopped when the pre-operative fast begins. A variable rate intravenous insulin infusion should be started if the metformin hydrochloride dose is more than once daily. Otherwise insulin should only be started if blood glucose concentration is greater than 12 mmol/litre on two consecutive occasions. Metformin should not be recommenced until the patient is eating and drinking again, and normal renal function has been assured.

There is no need to stop metformin hydrochloride after contrast medium in patients missing only one meal or who have an eGFR greater than 60 mL/minute/1.73m². If contrast medium is to be used, and eGFR is less than 60 mL/minute/1.73m², metformin should be omitted on the day of the procedure and for the following 48 hours.

Use of antidiabetic drugs during medical illness
Manufacturers of some antidiabetic drugs recommend that they may need to be replaced temporarily with insulin during undercurrent illness when the drug is unlikely to control hyperglycaemia (such as myocardial infarction, coma, severe infection, trauma and other medical emergencies). Consult individual product literature.

Sodium glucose co-transporter 2 inhibitors are associated with increased risk of developing diabetic ketoacidosis during periods of dehydration, stress, surgery, trauma, acute medical illness or any other catabolic state, and should be used with caution during these times. The MHRA has advised (2016) that these drugs should be temporarily stopped in patients who are hospitalised for acute serious illness until the patient is medically stable.

Diabetic ketoacidosis
Management

- To restore circulating volume if systolic blood pressure is below 90 mmHg (adjusted for age, sex, and medication as appropriate), give 500 mL sodium chloride 0.9% by intravenous infusion over 10–15 minutes; repeat if blood pressure remains below 90 mmHg and seek senior medical advice.
- When blood pressure is over 90 mmHg, sodium chloride 0.9% should be given by intravenous infusion at a rate that replaces deficit and provides maintenance; see guideline or suggested regimen.
- Include potassium chloride in the fluids unless anauria is suspected; adjust according to plasma-potassium concentration (measure at 60 minutes, 2 hours, and 2 hourly thereafter; measure hourly if outside the normal range).
- Start an intravenous insulin infusion: soluble insulin should be diluted (and mixed thoroughly) with sodium chloride 0.9% intravenous infusion to a concentration of 1 unit/mL; infuse at a fixed rate of 0.1 units/kg/hour.
- Established subcutaneous therapy with long-acting insulin analogues (insulin detemir p. 671 or insulin glargine p. 672) should be continued during treatment of diabetic ketoacidosis.
- Monitor blood-ketone and blood-glucose concentrations hourly and adjust the insulin infusion rate accordingly. Blood-ketone concentration should fall by at least 0.5 mmol/litre/hour and blood-glucose concentration should fall by at least 3 mmol/litre/hour.
- Once blood-glucose concentration falls below 14 mmol/litre, glucose 10% should be given by intravenous infusion (into a large vein through a large-gauge needle) at a rate of 125 mL/hour, in addition to the sodium chloride 0.9% infusion.
- Continue insulin infusion until blood-ketone concentration is below 0.3 mmol/litre, blood pH is above 7.3 and the patient is able to eat and drink; ideally give subcutaneous fast-acting insulin and a meal, and stop the insulin infusion 1 hour later.

The management of hyperosmolar hyperglycaemic state or hyperosmolar hyperglycaemic nonketotic coma is similar to that of diabetic ketoacidosis, although lower rates of insulin infusion are usually necessary and slower rehydration may be required.

BLOOD GLUCOSE LOWERING DRUGS > ALPHA GLUCOSIDASE INHIBITORS

Acarbose
- **DRUG ACTION** Acarbose, an inhibitor of intestinal alpha glucosidases, delays the digestion and absorption of starch and sucrose; it has a small but significant effect in lowering blood glucose.

- **INDICATIONS AND DOSE**
  - **Diabetes mellitus inadequately controlled by diet or by diet with oral antidiabetic drugs**
    - **BY MOUTH**
    - **Adult:** Initially 50 mg daily, then increased to 50 mg 3 times a day for 6–8 weeks, then increased if necessary to 100 mg 3 times a day (max. per dose 200 mg 3 times a day).
  - **SIDE-EFFECTS**
    - Common or very common: Abdominal distention and pain, diarrhoea (may need to reduce dose or withdraw), flatulence, soiled stools.
    - Rare: Abnormal liver function tests, nausea, skin reactions.
    - Very rare: Hepatitis, ileus, jaundice, oedema.

- **CONTRA-INDICATIONS**
  - Hernia, inflammatory bowel disease.
  - Hypersensitivity to acarbose.
  - Predisposition to partial intestinal obstruction.
  - Previous abdominal surgery.
  - **CAUTIONS** May enhance hypoglycaemic effects of insulin and sulfonylureas (hypoglycaemic episodes may be treated with oral glucose but not with sucrose).
  - **INTERACTIONS**
    - **Appendix 1:** acarbose.

- **PREGNANCY**
  - **Avoid.**

- **BREAST FEEDING**
  - **Avoid.**

- **HEPATIC IMPAIRMENT**
  - **Avoid.**

- **RENAL IMPAIRMENT**
  - **Avoid.** eGFR less than 25 mL/minute/1.73 m².

- **MONITORING REQUIREMENTS**
  - Monitor liver function.

- **DIRECTIONS FOR ADMINISTRATION**
  - Tablets should be chewed with first mouthful of food or swallowed whole with a little liquid immediately before food.

- **PATIENT AND CARER ADVICE**
  - Antacids unlikely to be beneficial for treating side effects. To counteract possible hypoglycaemia, patients receiving insulin or a sulfonylurea as well as acarbose need to carry glucose (not...
sucrose—acarbose interferes with sucrose absorption). Patients should be given advice on how to administer acarbose tablets.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Acarbose (Non-proprietary)**
  - Acarbose 50 mg Acarbose 50mg tablets | 90 tablet [Pax] £11.51 DT price = £11.51
  - Acarbose 100 mg Acarbose 100mg tablets | 90 tablet [Pax] £19.03 DT price = £13.03
  - **Glucobay (Bayer Plc)**
    - Acarbose 50 mg Glucobay 50mg tablets | 90 tablet [Pax] £7.35 DT price = £11.51
    - Acarbose 100 mg Glucobay 100mg tablets | 90 tablet [Pax] £13.50 DT price = £13.03

**BLOOD GLUCOSE LOWERING DRUGS**

**BIGUANIDES**

**Metformin hydrochloride**

**DRUG ACTION** Metformin exerts its effect mainly by decreasing gluconeogenesis and by increasing peripheral utilisation of glucose; since it acts only in the presence of endogenous insulin it is effective only if there are some residual functioning pancreatic islet cells.

**INDICATIONS AND DOSE**

- **Diabetes mellitus**
  - **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
    - Child 10–17 years (special use only): Initially 500 mg once daily, dose to be adjusted according to response at intervals of at least 1 week, maximum daily dose to be given in 2–3 divided doses; maximum 2 g per day
  - **Adult:** Initially 500 mg once daily for at least 1 week, dose to be taken with breakfast, then 500 mg twice daily for at least 1 week, dose to be taken with breakfast and evening meal, then 500 mg 3 times a day, dose to be taken with breakfast, lunch and evening meal; maximum 2 g per day
  - **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
    - **Adult:** Initially 500 mg once daily, then increased if necessary up to 2 g once daily, dose increased gradually, every 10–15 days, dose to be taken with evening meal, alternatively increased to 1 g twice daily, dose to be taken with meals, alternative dose only to be used if control not achieved with once daily dose regimen. If control still not achieved then change to standard release tablets
  - **Polycystic ovary syndrome**
    - **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
      - **Adult:** Initially 500 mg once daily for 1 week, dose to be taken with breakfast, then 500 mg twice daily for 1 week, dose to be taken with breakfast and evening meal, then 1.5–1.7 g daily in 2–3 divided doses

**UNLICENSED USE**

- In adults Doses in the BNF may differ from those in the product literature. Not licensed for polycystic ovary syndrome.
- In children Not licensed for use in children under 10 years.

**CONTRA-INDICATIONS** Acute metabolic acidosis (including lactic acidosis and diabetic ketoacidosis)

**CAUTIONS** Risk factors for lactic acidosis

**CAUTIONS, FURTHER INFORMATION**

- Risk factors for lactic acidosis Manufacturer advises caution in chronic stable heart failure (monitor cardiac function), and concomitant use of drugs that can acutely impair renal function; interrupt treatment if dehydration occurs, and avoid in conditions that can acutely worsen renal function, or cause tissue hypoxia.

**INTERACTIONS** → Appendix 1: metformin

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain, anorexia, diarrhoea (usually transient), nausea, taste disturbance, vomiting
- **Rare** Decreased vitamin-B₁₂, absorption, erythema, lactic acidosis (withdraw treatment), pruritus, urticaria
- **Frequency not known** Hepatitis

**SIDE-EFFECTS, FURTHER INFORMATION**

- Gastro-intestinal effects Gastro-intestinal side-effects are initially common with metformin, and may persist in some patients, particularly when very high doses are given. A slow increase in dose may improve tolerability.

**PREGNANCY** Can be used in pregnancy for both pre-existing and gestational diabetes. Women with gestational diabetes should discontinue treatment after giving birth.

**BREAST FEEDING** May be used during breast-feeding in women with pre-existing diabetes.

**HEPATIC IMPAIRMENT** Withdraw if tissue hypoxia likely.

**RENAL IMPAIRMENT**

- In children Manufacturer advises consider dose reduction in moderate impairment. Manufacturer advises avoid if estimated glomerular filtration rate is less than 30 mL/minute/1.73 m².
- In adults Manufacturer advises reduce dose in moderate impairment—consult product literature. Manufacturer advises avoid if eGFR is less than 30 mL/minute/1.73 m².

**MONITORING REQUIREMENTS** Determine renal function before treatment and at least annually (at least twice a year in patients with additional risk factors for renal impairment, or if deterioration suspected).

**PRESCRIBING AND DISPENSING INFORMATION**

- In adults Patients taking up to 2 g daily of the standard-release metformin may start with the same daily dose of metformin modified release; not suitable if dose of standard-release tablets more than 2 g daily.
- **PATIENT AND CARER ADVICE** Manufacturer advises that patients and their carers should be informed of the risk of lactic acidosis and told to seek immediate medical attention if symptoms such as dyspnoea, muscle cramps, abdominal pain, hypothermia, or asthenia occur. Medicines for Children leaflet: Metformin for diabetes www.medicinesforchildren.org.uk/metformin-diabetes

**NATIONAL FUNDING/ACCESS DECISIONS**

**GLUCOPHAGE® SR**

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (September 2009) that Glucophage® SR is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes mellitus in adult patients who are intolerant of standard-release metformin, and in whom the prolonged-release tablet allows the use of a dose of metformin not previously tolerated, or in patients for whom a once daily preparation offers a clinically significant benefit.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule, oral suspension, oral solution

**Modified-release tablet**

**CAUTIONARY AND ADVISORY LABELS** 21, 25

- **Metformin hydrochloride (Non-proprietary)**
  - **Metformin hydrochloride 500 mg** Metformin 500mg modified-release tablets | 28 tablet [Pax] £6.26 | 56 tablet [Pax] £5.32 DT price = £5.32
  - **Metformin hydrochloride 1 gram** Metformin 1g modified-release tablets | 28 tablet [Pax] no price available | 56 tablet [Pax] no price available DT price = £8.52
Bolamyn SR (Teva UK Ltd)  
Metformin hydrochloride 500 mg tablet (PO) £3.20 | 56 tablet (PO) £5.32  
Metformin hydrochloride 1 gram tablet (PO) £5.06 | 56 tablet (PO) £10.13 DT price = £5.52  
Diagmet XL (Genus Pharmaceuticals Ltd)  
Metformin hydrochloride 500 mg tablet (PO) £1.49 | 56 tablet (PO) £2.97 DT price = £5.32  
Glucient SR (Consilient Health Ltd)  
Metformin hydrochloride 500 mg tablet (PO) £2.51 | 56 tablet (PO) £5.03 DT price = £5.32  
Metformin hydrochloride 750 mg tablet (PO) £3.20  
Metformin hydrochloride 1 gram tablet (PO) £4.26 | 56 tablet (PO) £5.82 DT price = £5.32  
Glucophage SR (Merck Serono Ltd)  
Metformin hydrochloride 500 mg tablet (PO) £2.66 | 56 tablet (PO) £5.32 DT price = £5.32  
Metformin hydrochloride 750 mg tablet (PO) £3.30 | 56 tablet (PO) £6.40 DT price = £6.40  
Metformin hydrochloride 1 gram tablet (PO) £4.26 | 56 tablet (PO) £8.52 DT price = £5.32  
Metabet SR (Morningside Healthcare Ltd)  
Metformin hydrochloride 500 mg tablet (PO) £3.07 | 56 tablet (PO) £6.14 DT price = £5.32  
Metformin hydrochloride 1 gram tablet (PO) £5.33 | 56 tablet (PO) £10.66 DT price = £8.52  
Sukkarto SR (Morningside Healthcare Ltd)  
Metformin hydrochloride 500 mg tablet (PO) £3.46 DT price = £5.32  
Metformin hydrochloride 1 gram tablet (PO) £5.54 DT price = £8.52

**Tablet**  
**CAUTIONARY AND ADVISORY LABELS**  
Metformin hydrochloride (Non-proprietary)  
Metformin hydrochloride 500 mg tablet (PO) £1.55 DT price = £0.86 | 64 tablet (PO) £2.58 | 500 tablet (PO) £15.36  
Metformin hydrochloride 850 mg tablet (PO) £2.48 DT price = £1.23 | 60 tablet (PO) no price available | 300 tablet (PO) £6.59  
Glucophage (Merck Serono Ltd)  
Metformin hydrochloride 500 mg tablet (PO) £2.68  
Metformin hydrochloride 850 mg tablet (PO) £3.20 DT price = £1.23

**Oral solution**  
**CAUTIONARY AND ADVISORY LABELS**  
Metformin hydrochloride (Non-proprietary)  
Metformin hydrochloride 100 mg per 1 ml (PO) £1.55 DT price = £0.86 | 100 ml (PO) £2.58 | 500 ml (PO) £15.36  
Metformin hydrochloride 170 mg per 1 ml (PO) £2.48 DT price = £1.23 | 150 ml (PO) £19.95  
Metformin hydrochloride 200 mg per 1 ml (PO) £2.48-£24.00

**Powder**  
Metformin hydrochloride (Non-proprietary)  
Metformin hydrochloride 1 gram Metformin 1g oral powder sachets sugar free sugar-free | 30 sachet (PO) no price available

Combinations available:  
- Alogliptin with metformin, p. 654 - Canagliflozin with metformin, p. 662 - Dapagliflozin with metformin, p. 663 - Empagliflozin with metformin, p. 665 - Linagliptin with metformin, p. 656 - Pioglitazone with metformin, p. 668 - Saxagliptin with metformin, p. 655 - Sitagliptin with metformin, p. 656 - Vildagliptin with metformin, p. 656

**BLOOD GLUCOSE LOWERING DRUGS**  
**DIPEPTIDYLPEPTIDASE-4 INHIBITORS (GLIPTINS)**

**Alogliptin**  
**DRUG ACTION**  
Inhibits dipeptidylpeptidase-4 to increase insulin secretion and lower glucagon secretion.

**INDICATIONS AND DOSE**  
Type 2 diabetes mellitus as dual therapy in combination with either metformin, pioglitazone, a sulfonylurea, or insulin (when treatment with these drugs alone fails to achieve adequate glycaemic control), or as triple therapy in combination with metformin and either pioglitazone or insulin

- **BY MOUTH**  
  - Adult: 25 mg once daily

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**  
Dose of concomitant sulfonylurea or insulin may need to be reduced. Caution with use in combination with both metformin and pioglitazone—risk of hypoglycaemia (dose of metformin or pioglitazone may need to be reduced).

**CONTRA-INDICATIONS**  
Ketoacidosis

**CAUTIONS**  
History of pancreatitis not recommended in moderate to severe heart failure (limited experience)

**INTERACTIONS**  
Appendix 1: alogliptin

**SIDE-EFFECTS**  
- Common or very common  
  - Abdominal pain, gastrointestinal reflux, headache, nasopharyngitis, pruritus, rash, upper respiratory-tract infection

**Frequency not known**  
Angioma, hepatic impairment, pancreatitis, Stevens-Johnson syndrome, urticaria

**SIDE-EFFECTS, FURTHER INFORMATION**  
Pancreatitis Discontinue if symptoms of acute pancreatitis (persistent, severe abdominal pain).

**ALLERGY AND CROSS-SENSITIVITY**  
Contra—indicated if history of serious hypersensitivity to dipeptidylpeptidase-4 inhibitors.

**PREGNANCY**  
Manufacturer advises avoid—no information available.

**BREAST FEEDING**  
Avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT**  
Manufacturer advises avoid in severe impairment—no information available.

**RENAL IMPAIRMENT**  
Reduce dose to 12.5 mg once daily if eGFR 30–50 mL/minute/1.73 m². Reduce dose to 6.25 mg once daily if eGFR less than 30 mL/minute/1.73 m². Use with caution if eGFR less than 30 mL/minute/1.73 m².

**MONITORING REQUIREMENTS**  
Determine renal function before treatment and periodically thereafter.

**MEDICINAL FORMS**  
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**  
- Alogliptin (non-proprietary)  
  - Alogliptin (as Alogliptin benzoate) 6.25 mg Alogliptin 6.25mg tablets | 28 tablet (PO) no price available DT price = £26.60  
  - Alogliptin (as Alogliptin benzoate) 12.5 mg Alogliptin 12.5mg tablets | 28 tablet (PO) no price available DT price = £26.60  
  - Alogliptin (as Alogliptin benzoate) 25 mg Alogliptin 25mg tablets | 28 tablet (PO) no price available DT price = £26.60  
  - Vipidia (Takeda UK Ltd)  
    - Alogliptin (as Alogliptin benzoate) 6.25 mg Vipidia 6.25mg tablets | 28 tablet (PO) £26.60 DT price = £26.60  
    - Alogliptin (as Alogliptin benzoate) 12.5 mg Vipidia 12.5mg tablets | 28 tablet (PO) £26.60 DT price = £26.60  
    - Alogliptin (as Alogliptin benzoate) 25 mg Vipidia 25mg tablets | 28 tablet (PO) £26.60 DT price = £26.60
Alogliptin with metformin

The properties listed below are those particular to the combination only. For the properties of the components please consider, alogliptin p. 653, metformin hydrochloride p. 652.

**INDICATIONS AND DOSE**

Type 2 diabetes mellitus not controlled by metformin alone or by metformin in combination with either pioglitazone or insulin

- **BY MOUTH**
- **Adult:** 1 tablet twice daily, based on patient’s current metformin dose

**INTERACTIONS** → Appendix 1: alogliptin, metformin

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

CAUTIONARY AND ADVISORY LABELS 21

- Alogliptin with metformin (non-proprietary)

  - Alogliptin (as Alogliptin benzoate) 12.5 mg, Metformin hydrochloride 1 gram  Alogliptin 12.5mg / Metformin 1g tablets | 56 tablet [POf] no price available DT price = £26.60
  - Vipdomet (Takeda UK Ltd)

    - Alogliptin (as Alogliptin benzoate) 12.5 mg, Metformin hydrochloride 1 gram  Vipdomet 12.5mg/1000mg tablets | 56 tablet [POf] £26.60 DT price = £26.60

Linagliptin

**DRUG ACTION**

Inhibits dipeptidylpeptidase-4 to increase insulin secretion and lower glucagon secretion.

**INDICATIONS AND DOSE**

Type 2 diabetes mellitus as monotherapy (if metformin inappropriate), or in combination with metformin (when treatment with metformin alone fails to achieve adequate glycaemic control), or both metformin and a sulfonylurea (when dual therapy with these drugs fails to achieve adequate glycaemic control) | Type 2 diabetes mellitus in combination with insulin (with or without metformin) when a stable dose of insulin has not provided adequate glycaemic control

- **BY MOUTH**
- **Adult:** 5 mg once daily

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**

Dose of concomitant sulfonylurea or insulin may need to be reduced.

**INTERACTIONS** → Appendix 1: linagliptin

**SIDE-EFFECTS**

- Uncommon  Cough - nasopharyngitis
- Frequency not known  Pancreatitis

**SIDE-EFFECTS, FURTHER INFORMATION**

- Pancreatitis  Discontinue if symptoms of acute pancreatitis (persistent, severe abdominal pain).
- PREGNANCY  Avoid—no information available.
- BREAST FEEDING  Avoid—present in milk in animal studies.
- NATIONAL FUNDING/ACCESS DECISIONS

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised that linagliptin (Trajenta®) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes mellitus as monotherapy when both metformin and sulfonylurea are inappropriate (January 2013), and in combination with metformin when addition of a sulfonylurea is inappropriate (December 2011).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- Trajenta (Boehringer Ingelheim Ltd) Linagliptin 5 mg  Trajenta 5mg tablets | 28 tablet [POf] £33.26 DT price = £33.26

Linagliptin with metformin

The properties listed below are those particular to the combination only. For the properties of the components please consider, linagliptin above, metformin hydrochloride p. 652.

**INDICATIONS AND DOSE**

Type 2 diabetes mellitus not controlled by metformin alone or by metformin in combination with either a sulfonylurea or insulin

- **BY MOUTH**
- **Adult:** 1 tablet twice daily, based on patient’s current metformin dose

**INTERACTIONS** → Appendix 1: linagliptin, metformin

**NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (May 2015) that linagliptin plus metformin combination tablets (Jentadueto®) are accepted for restricted use within NHS Scotland for the treatment of adult patients with type 2 diabetes mellitus in combination with insulin, as an adjunct to diet and exercise to improve glycaemic control when a combination of insulin and metformin alone is inadequate. It is restricted to use in the treatment of patients for whom a combination of linagliptin and metformin is an appropriate choice of therapy and the fixed doses are considered appropriate.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

CAUTIONARY AND ADVISORY LABELS 21

- Jentadueto (Boehringer Ingelheim Ltd)

  - Linagliptin 2.5 mg, Metformin hydrochloride 850 mg  Jentadueto 2.5mg/850mg tablets | 56 tablet [POf] £33.26
  - Linagliptin 2.5 mg, Metformin hydrochloride 1000 mg  Jentadueto 2.5mg/1000mg tablets | 56 tablet [POf] £33.26

Saxagliptin

**DRUG ACTION**

Inhibits dipeptidylpeptidase-4 to increase insulin secretion and lower glucagon secretion.

**INDICATIONS AND DOSE**

Type 2 diabetes mellitus as monotherapy (if metformin inappropriate), or in combination with metformin or a sulfonylurea (if metformin inappropriate), or pioglitazone (when treatment with either metformin or a sulfonylurea or pioglitazone fails to achieve adequate glycaemic control), and also in combination with both metformin and a sulfonylurea (when dual therapy with these drugs fails to achieve adequate glycaemic control) | Type 2 diabetes mellitus in combination with insulin (with or without metformin) when a stable dose of insulin has not provided adequate glycaemic control

- **BY MOUTH**
- **Adult:** 5 mg once daily

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**

Dose of concomitant sulfonylurea or insulin may need to be reduced.

**CAUTIONS**

Elderly
● **INTERACTIONS** → Appendix 1: saxagliptin

**SIDE-EFFECTS**

- **Common or very common** Dizziness, dyspepsia, fatigue, gastritis, gastroenteritis, headache, hypoglycaemia, myalgia, nasopharyngitis, peripheral oedema, sinusitis, upper respiratory tract infection, urinary tract infection, vomiting
- **Uncommon** Anaphylaxis, arthralgia, dyslipidaemia, erectile dysfunction, hypersensitivity reactions, hypertriglyceridaemia, pancreatitis
- **Frequency not known** Rash

**SIDE-EFFECTS, FURTHER INFORMATION**

- Pancreatitis: Discontinue if symptoms of acute pancreatitis (persistent, severe abdominal pain).
- **ALLERGY AND CROSS-SENSITIVITY** Contra-indicated if patient has a history of severe hypersensitivity to dipeptidylpeptidase-4 inhibitors.
- **PREGNANCY** Avoid unless essential—toxicity in animal studies.
- **LACTATION** Not recommended.
- **BREAST FEEDING** Avoid—present in milk in animal studies.
- **HEPATIC IMPAIRMENT** Use with caution in moderate impairment. Avoid in severe impairment.
- **RENAL IMPAIRMENT** Reduce dose to 2.5 mg once daily in moderate to severe impairment. Use with caution in severe impairment.
- **MONITORING REQUIREMENTS** Determine renal function before treatment and periodically thereafter.
- **NATIONAL FUNDING/ACCESS DECISIONS**

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised that saxagliptin (Onglyza®) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes mellitus as triple therapy in combination with metformin and a sulfonylurea, as an alternative to existing dipeptidyl peptidase-4 inhibitors, when treatment with metformin and a sulfonylurea is inadequate (November 2013).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- Onglyza (AstraZeneca UK Ltd)
  - Saxagliptin (as Saxagliptin hydrochloride) 2.5 mg: Onglyza 2.5 mg tablets | 28 tablet | £31.60 DT price = £31.60
  - Saxagliptin (as Saxagliptin hydrochloride) 5 mg: Onglyza 5 mg tablets | 28 tablet | £31.60 DT price = £31.60

**MEDICINAL USES**

Type 2 diabetes mellitus as monotherapy (if metformin inappropriate), or in combination with metformin or a sulfonylurea (if metformin inappropriate), or pioglitazone when treatment with either metformin or a sulfonylurea or pioglitazone fails to achieve adequate glycaemic control, and also in combination with both metformin and a sulfonylurea (when dual therapy with these drugs fails to achieve adequate glycaemic control)

**INDICATIONS AND DOSE**

Type 2 diabetes mellitus not controlled by metformin alone or by metformin in combination with either a sulfonylurea or insulin

- **BY MOUTH**
  - Adult: 1 tablet twice daily, based on patient’s current metformin dose

**INTERACTIONS** → Appendix 1: metformin, saxagliptin

**SIDE-EFFECTS**

- **Common or very common** Gastro-intestinal disturbances, nasopharyngitis, pain, peripheral oedema, upper respiratory tract infection
- **Uncommon** Anorexia, dizziness, drowsiness, dry mouth, headache, hypoglycaemia, osteoarthritis
- **Frequency not known** Cutaneous vasculitis, pancreatitis, rash, Stevens-Johnson syndrome

**SIDE-EFFECTS, FURTHER INFORMATION**

- Pancreatitis: Discontinue if symptoms of acute pancreatitis (persistent, severe abdominal pain).
- **PREGNANCY** Avoid—toxicity in animal studies.
- **LACTATION** Not recommended.
- **BREAST FEEDING** Avoid—present in milk in animal studies.
- **RENAL IMPAIRMENT** Reduce dose to 2.5 mg once daily if eGFR 30–50 mL/min/1.73 m². Reduce dose to 25 mg once daily if eGFR less than 30 mL/min/1.73 m².

**NATIONAL FUNDING/ACCESS DECISIONS**

The Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (June 2010) that Januvia® is accepted for restricted use within NHS Scotland as monotherapy, to improve glycaemic control in patients with type 2 diabetes mellitus, for whom both metformin and sulfonylureas are not appropriate.

**CONTRA-INDICATIONS**

Ketoacidosis

**INDICATIONS AND DOSE**

Type 2 diabetes mellitus not controlled by metformin alone or by metformin in combination with either a sulfonylurea or insulin

- **BY MOUTH**
  - Adult: 1 tablet twice daily, based on patient’s current metformin dose

**INTERACTIONS** → Appendix 1: metformin, saxagliptin

**SIDE-EFFECTS**

- **Common or very common** Gastro-intestinal disturbances, nasopharyngitis, pain, peripheral oedema, upper respiratory tract infection
- **Uncommon** Anorexia, dizziness, drowsiness, dry mouth, headache, hypoglycaemia, osteoarthritis
- **Frequency not known** Cutaneous vasculitis, pancreatitis, rash, Stevens-Johnson syndrome

**SIDE-EFFECTS, FURTHER INFORMATION**

- Pancreatitis: Discontinue if symptoms of acute pancreatitis (persistent, severe abdominal pain).
- **PREGNANCY** Avoid—toxicity in animal studies.
- **LACTATION** Not recommended.
- **BREAST FEEDING** Avoid—present in milk in animal studies.
- **RENAL IMPAIRMENT** Reduce dose to 2.5 mg once daily if eGFR 30–50 mL/min/1.73 m². Reduce dose to 25 mg once daily if eGFR less than 30 mL/min/1.73 m².

**NATIONAL FUNDING/ACCESS DECISIONS**

The Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (May 2013) that Komboglyze® is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes mellitus in patients unable to achieve adequate glycaemic control with metformin alone and when the addition of a sulfonylurea is inappropriate.
Sitagliptin with metformin

The properties listed below are those particular to the combination only. For the properties of the components please consider, sitagliptin p. 655, metformin hydrochloride p. 652.

- **INDICATIONS AND DOSE**
  Type 2 diabetes mellitus not controlled by metformin alone or by metformin in combination with either a sulfonylurea or pioglitazone or insulin
  - **BY MOUTH**
  - Adult: 1 tablet twice daily

- **INTERACTIONS** → Appendix 1: metformin, sitagliptin

- **NATIONAL FUNDING/ACCESS DECISIONS**
  **Scottish Medicines Consortium (SMC) Decisions**
  The Scottish Medicines Consortium has advised (July 2008) that Janumet® is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes mellitus when the addition of a sulfonylurea to metformin is not appropriate; it is also accepted for use in NHS Scotland in combination with a sulfonylurea in patients inadequately controlled on maximum tolerated doses of metformin and a sulfonylurea.

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.
  **Tablet**
  CAUTIONARY AND ADVISORY LABELS 21
  - Janumet (Merck Sharp & Dohme Ltd)
  - Sitagliptin (as Sitagliptin phosphate) 50 mg, Metformin hydrochloride 1 gram | 56 tablet | **£33.26 DT price = £33.26**

Vildagliptin

- **DRUG ACTION**
  Inhibits dipeptidylpeptidase-4 to increase insulin secretion and lower glucagon secretion.

- **INDICATIONS AND DOSE**
  Type 2 diabetes mellitus as monotherapy (if metformin inappropriate) | Type 2 diabetes mellitus in combination with metformin or pioglitazone (when treatment with either metformin or pioglitazone fails to achieve adequate glycaemic control) | Type 2 diabetes mellitus in combination with both metformin and a sulfonylurea (when dual therapy with these drugs fails to achieve adequate glycaemic control) | Type 2 diabetes mellitus in combination with insulin (with or without metformin) when a stable dose of insulin has not provided adequate glycaemic control
  - **BY MOUTH**
  - Adult: 50 mg twice daily

  **Type 2 diabetes mellitus in combination with sulfonylurea (if metformin inappropriate)**
  - **BY MOUTH**
  - Adult: 50 mg daily, dose to be taken in the morning

  **DOSE ADJUSTMENTS DUE TO INTERACTIONS**
  Dose of concomitant sulfonylurea or insulin may need to be reduced.

- **CONTRA-INDICATIONS**
  Ketoacidosis

- **CAUTIONS**
  Manufacturer advises avoid in severe heart failure—no information available

- **INTERACTIONS** → Appendix 1: vildagliptin

- **SIDE-EFFECTS**
  - Common or very common Asthenia · dizziness · headache · nausea · peripheral oedema · tremor
  - Uncommon Arthralgia · constipation · hypoglycaemia
  - Rare Hepatic dysfunction
  - Very rare Nasopharyngitis · upper respiratory tract infection

- **FREQUENCY NOT KNOWN**
  Bullous skin reactions · exfoliative skin reactions · pancreatitis

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Pancreatitis Discontinue if symptoms of acute pancreatitis (persistent, severe abdominal pain)
  - Liver toxicity Rare reports of liver dysfunction; discontinue if jaundice or other signs of liver dysfunction occur.
  - **PREGNANCY**
    Avoid— toxicity in animal studies.
  - **BREAST FEEDING**
    Avoid— present in milk in animal studies.
  - **HEPATIC IMPAIRMENT**
    Avoid.
  - **RENAL IMPAIRMENT**
    Reduce dose to 50 mg once daily if eGFR less than 50 mL/minute/1.73 m².
  - **MONITORING REQUIREMENTS**
    Monitor liver function before treatment and every 3 months for first year and periodically thereafter.
  - **PATIENT AND CARER ADVISE**
    Liver toxicity Patients should be advised to seek prompt medical attention if symptoms such as nausea, abdominal pain, fatigue, and dark urine develop.

- **NATIONAL FUNDING/ACCESS DECISIONS**
  **Scottish Medicines Consortium (SMC) Decisions**
  The Scottish Medicines Consortium has advised that vildagliptin (Galvus®) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes mellitus as monotherapy when treatment with metformin or a sulfonylurea is inappropriate (December 2012), and in combination with metformin when addition of a sulfonylurea is inappropriate (March 2008), and in combination with a sulfonylurea if metformin is inappropriate (September 2009), and also as triple therapy in combination with metformin and a sulfonylurea, as an alternative to existing dipeptidyl peptidase-4 inhibitors, when treatment with metformin and a sulfonylurea is inadequate (November 2013).

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.
  **Tablet**
  - Galvus (Novartis Pharmaceuticals UK Ltd)
  - Vildagliptin 50 mg | 56 tablet | **£33.35 DT price = £33.35**

Vildagliptin with metformin

The properties listed below are those particular to the combination only. For the properties of the components please consider, vildagliptin above, metformin hydrochloride p. 652.

- **INDICATIONS AND DOSE**
  Type 2 diabetes mellitus not controlled by metformin alone or by metformin in combination with either a sulfonylurea or insulin
  - **BY MOUTH**
  - Adult: 1 tablet twice daily, based on patient’s current metformin dose

- **INTERACTIONS** → Appendix 1: metformin, vildagliptin

- **NATIONAL FUNDING/ACCESS DECISIONS**
  **Scottish Medicines Consortium (SMC) Decisions**
  The Scottish Medicines Consortium has advised (June 2008) that Euceran® is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes mellitus in
patients unable to achieve adequate glycaemic control with metformin alone or those already treated with vildagliptin and metformin as separate tablets.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

**CAUTIONARY AND ADVISORY LABELS**

- **Euceran** (Novartis Pharmaceuticals UK Ltd)
  - Vildagliptin 50 mg, Metformin hydrochloride 850 mg Euceran 50mg/850mg tablets | 60 tablet [PDT] £35.68 DT price = £35.68
  - Vildagliptin 50 mg, Metformin hydrochloride 1 gram Euceran 50mg/1000mg tablets | 60 tablet [PDT] £35.68 DT price = £35.68

**CONTRA-INDICATIONS**

- **BLOOD GLUCOSE LOWERING DRUGS**
  - **GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS**

---

### Albiglutide 01-Jun-2016

**DRUG ACTION**

Albiglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist that augments glucose-dependent insulin secretion, and slows gastric emptying.

**INDICATIONS AND DOSE**

**Type 2 diabetes mellitus as monotherapy when treatment with metformin is considered inappropriate** | **Type 2 diabetes mellitus in combination with basal insulin and other oral glucose lowering agents**

- **BY SUBCUTANEOUS INJECTION**
  - Adult: 30 mg once weekly, increased if necessary up to 50 mg once weekly, to be administered on the same day each week

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**

Dose of concomitant insulin or drugs that stimulate insulin secretion may need to be reduced.

**CONTRA-INDICATIONS**

- Severe gastrointestinal disease—no information available

**CAUTIONS**

- History of pancreatitis - moderate to severe heart failure—no information available

**INTERACTIONS**

- Appendix 1: albiglutide

**SIDE-EFFECTS**

- **Common or very common** Atrial fibrillation - constipation - diarrhoea - dyspepsia - gastro-oesophageal reflux disease - hypoglycaemia - injection site reactions - nausea - vomiting

- **Uncommon** Intestinal obstruction - pancreatitis (discontinue treatment)

**CONCEPTION AND CONTRACEPTION**

Manufacturer recommends effective contraception in women of childbearing potential. Discontinue treatment at least one month before a planned pregnancy.

**PREGNANCY**

Manufacturer advises avoid—xicity in animal studies.

**BREAST FEEDING**

Manufacturer advises avoid—no information available.

**RENAL IMPAIRMENT**

Manufacturer advises avoid if eGFR less than 30 mL/minute/1.73 m².

**HANDLING AND STORAGE**

Store at 2–8°C. May be stored at temperatures up to 30°C for up to 4 weeks.

**PATIENT AND CARER ADVICE**

Patients or carers should be given advice on how to administer albiglutide injection. Acute pancreatitis Patients should be told how to recognise signs and symptoms of acute pancreatitis and advised to seek medical attention if symptoms such as persistent, severe abdominal pain develop.

**Missed doses**

If a dose is missed it should be administered as soon as possible within 3 days; if more than 3 days have passed, the missed dose should not be taken and the next dose should be taken at the normal time.

---

### Dulaglutide 14-Jun-2016

**DRUG ACTION**

Dulaglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist that augments glucose-dependent insulin secretion, and slows gastric emptying.

**INDICATIONS AND DOSE**

**Type 2 diabetes mellitus as monotherapy if metformin inappropriate**

- **BY SUBCUTANEOUS INJECTION**
  - Adult: 0.75 mg once weekly

**Type 2 diabetes mellitus in combination with insulin or other antidiabetic drugs (if existing treatment fails to achieve adequate glycaemic control)**

- **BY SUBCUTANEOUS INJECTION**
  - Adult: 1.5 mg once weekly

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**

Dose of concomitant insulin or drugs that stimulate insulin secretion may need to be reduced.

**CONTRA-INDICATIONS**

- Severe gastro-intestinal disease—no information available

**CAUTIONS**

- Congestive heart failure—no information available

**INTERACTIONS**

- Appendix 1: dulaglutide

**SIDE-EFFECTS**

- **Common or very common** Abdominal distention, - abdominal pain - atrioventricular block - constipation - decreased appetite - diarrhoea - dyspepsia - fatigue - flatulence - gastro-oesophageal reflux disease - nausea - sinus tachycardia - vomiting

- **Rare** Acute pancreatitis (discontinue treatment)

**PREGNANCY**

Manufacturer advises avoid—xicity in animal studies.

**BREAST FEEDING**

Manufacturer advises avoid—no information available.

**RENAL IMPAIRMENT**

Manufacturer advises avoid in severe impairment and end stage renal disease—no information available.

**HANDLING AND STORAGE**

Refrigerated storage is usually necessary (2°C – 8°C). Once in use, may be stored unrefrigerated for up to 14 days at a temperature not above 30°C.

**PATIENT AND CARER ADVICE**

Patients or carers should be given advice on how to administer dulaglutide injection. Acute pancreatitis Patients should be told how to recognise signs and symptoms of acute pancreatitis and advised to seek medical attention if symptoms such as persistent, severe abdominal pain develop.
Missed doses
If a dose is missed, it should be administered as soon as possible only if there are at least 3 days until the next scheduled dose; if less than 3 days remain before the next scheduled dose, the missed dose should not be taken and the next dose should be taken at the normal time.

**NATIONAL FUNDING/ACCESS DECISIONS**

**Scottish Medicines Consortium (SMC) Decisions**
The Scottish Medicines Consortium has advised (January 2016) that dulaglutide (Trulicity®) is accepted for restricted use for treating adults with type 2 diabetes to improve glycaemic control as add-on therapy in combination with other glucose-lowering medicines, when these, together with diet and exercise, do not provide adequate glycaemic control. It is restricted to use as part of a triple therapy in people with inadequate glycaemic control on control. It is restricted to use as part of a triple therapy in combination with basal insulin in patients where treatment with metformin or sulfonylurea (or both) at maximally tolerated doses has been inadequate, and treatment with insulin would be the next option.

**INTERACTIONS**

- people with inadequate glycaemic control on control. It is restricted to use as part of a triple therapy in combination with basal insulin in patients where treatment with metformin or sulfonylurea (or both) at maximally tolerated doses has been inadequate, and treatment with insulin would be the next option.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Trulicity** (Eli Lilly and Company Ltd)
  - Dulaglutide 1.5 mg per 1 ml Trulicity 0.75mg/0.5ml solution for injection prefilled pen 4 prefilled disposable injection £73.25
  - Dulaglutide 3 mg per 1 ml Trulicity 1.5mg/0.5ml solution for injection prefilled pen 4 prefilled disposable injection £73.25

**Exenatide**

**DRUG ACTION**

Binds to, and activates, the GLP-1 (glucagon-like peptide-1) receptor to increase insulin secretion, suppresses glucagon secretion, and slows gastric emptying.

**INDICATIONS AND DOSE**

Type 2 diabetes mellitus in combination with metformin or a sulfonylurea, or both, or with pioglitazone, or with both metformin and pioglitazone, in patients who have not achieved adequate glycaemic control with these drugs alone or in combination

- **By subcutaneous injection using immediate-release medicines**
  - Adult: Initially 5 micrograms twice daily for at least 1 month, then increased if necessary up to 10 micrograms twice daily, dose to be taken within 1 hour before 2 main meals (at least 6 hours apart)

**By subcutaneous injection using modified-release medicines**

- Adult: 2 mg once weekly

Type 2 diabetes mellitus in combination with basal insulin alone or with metformin or pioglitazone (or both)

- **By subcutaneous injection using immediate-release medicines**
  - Adult: Initially 5 micrograms twice daily for at least 1 month, then increased if necessary up to 10 micrograms twice daily, dose to be taken within 1 hour before 2 main meals (at least 6 hours apart)

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**

Dose of concomitant sulfonylurea may need to be reduced.

**Pharmacokinetics**

Effect of modified-release exenatide injection (Bydureon®) may persist for 10 weeks after discontinuation.

**CONTRA-INDICATIONS**

- Ketoacidosis · severe gastrointestinal disease

**CAUTIONS**

- Elderly · may cause weight loss greater than 1.5 kg weekly · pancreatitis

**INTERACTIONS**

- Appendix 1: exenatide

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain and distension · agitation · antibody formation · asthenia · decreased appetite · diarrhoea · dizziness · dyspepsia · gastrointestinal disturbances · gastro-oesophageal reflux disease · headache · hypoglycaemia · increased sweating · injection-site reactions · nausea · vomiting · weight loss

- **Uncommon** Pancreatitis

- **Rare** Alopecia

- **Very rare** Anaphylactic reactions

- **Frequency not known** Angioedema · constipation · dehydration · drowsiness · eructation · flatulence · pruritus · rash · renal impairment · taste disturbance · urticaria

**SIDE-EFFECTS, FURTHER INFORMATION**

- Pancreatitis · Severe pancreatitis (sometimes fatal), including haemorrhagic or necrotising pancreatitis, has been reported rarely; discontinue permanently if pancreatitis is diagnosed.

**CONCEPTION AND CONTRACEPTION**

Women of child-bearing age should use effective contraception during treatment with modified-release exenatide and for 12 weeks after discontinuation.

**PREGNANCY**

Avoid—toxicity in animal studies.

**BREAST FEEDING**

Avoid—no information available.

**RENAL IMPAIRMENT**

- **Standard-release injection**, use with caution if eGFR less than 30 mL/minute/1.73 m². For standard-release injection, avoid if eGFR less than 30 mL/minute/1.73 m². For modified-release injection, avoid if eGFR less than 50 mL/minute/1.73 m².

**PATIENT AND CARER ADVICE**

Patients changing from standard-release to modified-release exenatide formulation may experience initial transient increase in blood glucose.

Some oral medications should be taken at least 1 hour before or 4 hours after exenatide injection—consult product literature for details.

Patients or their carers should be told how to recognise signs and symptoms of pancreatitis and advised to seek prompt medical attention if symptoms such as abdominal pain, nausea, and vomiting develop.

**Missed doses**

If a dose of the immediate-release medicine is missed, continue with the next scheduled dose—do not administer after a meal.

**NATIONAL FUNDING/ACCESS DECISIONS**

**Scottish Medicines Consortium (SMC) Decisions**
The Scottish Medicines Consortium has advised (June 2007) that standard-release exenatide (Byetta®) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes in combination with metformin or sulfonylurea (or both), as an alternative to treatment with insulin in patients where treatment with metformin or sulfonylurea (or both) at maximally tolerated doses has been inadequate, and treatment with insulin would be the next option.

The Scottish Medicines Consortium has also advised (February 2011) that standard-release exenatide (Byetta®) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes in combination with metformin and pioglitazone as a third-line pre-insulin treatment option.

The Scottish Medicines Consortium has advised (December 2011) that modified-release exenatide (Bydureon®) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes as a third-line treatment option.
Liraglutide

01-Jun-2016

DRUG ACTION Liraglutide binds to, and activates, the GLP-1 (glucagon-like peptide-1) receptor to increase insulin secretion, suppresses glucagon secretion, and slows gastric emptying.

INDICATIONS AND DOSE Type 2 diabetes mellitus in combination with metformin or a sulfonylurea, or both, in patients who have not achieved adequate glycaemic control with these drugs alone or in combination | Type 2 diabetes mellitus in combination with basal insulin or both metformin and pioglitazone when dual therapy with these drugs fails to achieve adequate glycaemic control

BY SUBCUTANEOUS INJECTION

Adult: Initially 0.6 mg once daily for at least 1 week, then increased to 1.2 mg once daily for at least 1 week, then increased if necessary up to 1.8 mg once daily

DOSE ADJUSTMENTS DUE TO INTERACTIONS Dose of concomitant insulin or sulfonylurea may need to be reduced.

CONTRA-INDICATIONS Diabetic gastroparesis; inflammatory bowel disease; ketoacidosis; moderate to severe congestive heart failure—no information available

CAUTIONS History of pancreatitis; mild congestive heart failure—limited experience; thyroid disease

INTERACTIONS → Appendix 1: liraglutide

SIDE-EFFECTS

Common or very common Abdominal pain and distension; bronchitis; constipation; decreased appetite; diarrhoea; dizziness; dyspepsia; flatulence; gastritis; gastrointestinal disturbances; gastro-oesophageal reflux disease; headache; hypoglycaemia; injection site reactions; malaise; nasopharyngitis; nausea; tachycardia; vomiting

Uncommon Acute renal failure; dehydration; renal impairment

Very rare Acute pancreatitis

Frequent or not known Goitre; increased blood calcitonin; thyroid neoplasm

SIDE-EFFECTS, FURTHER INFORMATION

Pancreatitis Discontinue if symptoms of acute pancreatitis (persistent, severe abdominal pain).

PREGNANCY Manufacturer advises avoid—toxicity in animal studies (recommendation also supported by primary literature).

BREAST FEEDING Avoid—no information available.

HEPATIC IMPAIRMENT Manufacturer advises avoid—limited experience.

RENAL IMPAIRMENT Manufacturer advises avoid if eGFR less than 30 mL/minute/1.73 m²—limited experience.

HANDLING AND STORAGE Store in a refrigerator (2°C–8°C); after first use can be stored below 30°C, discard 1 month after first use.

PATIENT AND CARER ADVICE Patients or carers should be given advice on how to administer liraglutide injection. Acute pancreatitis Patients should be told how to recognise signs and symptoms of acute pancreatitis and advised to seek immediate medical attention if symptoms such as persistent, severe abdominal pain develop.

Lixisenatide

DRUG ACTION Binds to, and activates, the GLP-1 (glucagon-like peptide-1) receptor to increase insulin secretion, suppresses glucagon secretion, and slows gastric emptying.

INDICATIONS AND DOSE Type 2 diabetes mellitus in combination with oral antidiabetic drugs (e.g. metformin, pioglitazone, or a sulfonylurea) or basal insulin, or both, when adequate glycaemic control has not been achieved with these drugs

BY SUBCUTANEOUS INJECTION

Adult: Initially 10 micrograms once daily for 14 days, then increased to 20 micrograms once daily, dose to be taken within 1 hour before the first meal of the day or the evening meal

DOSE ADJUSTMENTS DUE TO INTERACTIONS Dose of concomitant sulfonylurea or insulin may need to be reduced.

CONTRA-INDICATIONS Ketoacidosis; severe gastrointestinal disease

INTERACTIONS → Appendix 1: lixisenatide

SIDE-EFFECTS

Common or very common Diarrhoea; dizziness; drowsiness; dyspepsia; headache; hypoglycaemia; injection site reactions; nausea; palpititation; vomiting

Uncommon Tachycardia; urticaria

SIDE-EFFECTS, FURTHER INFORMATION

Pancreatitis Discontinue if symptoms of acute pancreatitis (persistent, severe abdominal pain).

CONCEPTION AND CONTRACEPTION Women of child-bearing age should use effective contraception.

PREGNANCY Avoid—toxicity in animal studies.

BREAST FEEDING Avoid—no information available.

RENAL IMPAIRMENT Use with caution if eGFR 30–50 mL/minute/1.73 m². Avoid if eGFR less than 30 mL/minute/1.73 m²—no information available.
PATIENT AND CARER ADVICE
Some oral medications should be taken at least 1 hour before or 4 hours after lixisenatide injection—consult product literature for details.

MISSED DOSES
If a dose is missed, inject within 1 hour before the next meal—do not administer after a meal.

NATIONAL FUNDING/ACCESS DECISIONS
Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (August 2013) that lixisenatide (Lyxumia®) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes in combination with oral antidiabetic drugs or basal insulin (or both), when adequate glycaemic control has not been achieved with these drugs; use is restricted to patients in whom a GLP-1 agonist is appropriate, as an alternative to an existing GLP-1 agonist (exenatide or liraglutide).

MEDICAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Solution for injection
CAUTIONARY AND ADVISORY LABELS
Nateglinide

DRUG ACTION
Nateglinide stimulates insulin secretion.

INDICATIONS AND DOSE
Type 2 diabetes mellitus (as monotherapy or in combination with metformin when metformin alone inadequate)

BY MOUTH
Initial 50 micrograms (max. per dose 150 micrograms)

Type 2 diabetes mellitus (as monotherapy or in combination with metformin when metformin alone inadequate), if transferring from another oral antidiabetic drug

BY MOUTH
Initial 1 mg (max. per dose 3 mg), adjusted according to response, dose to be taken within 30 minutes before main meals and adjusted at intervals of 1–2 weeks; maximum 16 mg per day

Type 2 diabetes mellitus (as monotherapy or in combination with metformin when metformin alone inadequate), if transferring from another oral antidiabetic drug

BY MOUTH
Initial 1 mg (max. per dose 3 mg), adjusted according to response, dose to be taken within 30 minutes before main meals and adjusted at intervals of 1–2 weeks; maximum 16 mg per day

CONTRA-INDICATIONS
Ketoacidosis

CAUTIONS
Debilitated patients · malnourished patients

CAUTIONS, FURTHER INFORMATION
Substitute insulin during intercurrent illness (such as myocardial infarction, coma, infection, and trauma) and during surgery (omit nateglinide on morning of surgery and recommence when eating and drinking normally).

INTERACTIONS
Appendix 1: nateglinide

SIDE-EFFECTS
Hypersensitivity reactions · hypoglycaemia · pruritus · rash · urticaria · vasculitis · visual disturbances

PREGNANCY
Avoid.

BREAST FEEDING
Avoid—present in milk in animal studies.

HEPATIC IMPAIRMENT
Avoid in severe liver disease.

PATIENT AND CARER ADVICE
Driving and skilled tasks
Drivers need to be particularly careful to avoid hypoglycaemia and should be warned of the problems.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet

Starlix (Novartis Pharmaceuticals UK Ltd)
Nateglinide 60 mg Starlix 60 mg tablets | 84 tablet pack £26.12 DT price = £26.12
Nateglinide 120 mg Starlix 120 mg tablets | 84 tablet pack £29.76 DT price = £29.76
Nateglinide 180 mg Starlix 180 mg tablets | 84 tablet pack £29.76 DT price = £29.76

Repaglinide

DRUG ACTION
Repaglinide stimulates insulin secretion.

INDICATIONS AND DOSE
Type 2 diabetes mellitus (as monotherapy or in combination with metformin when metformin alone inadequate)

BY MOUTH
Adult 18–74 years: Initially 50 micrograms (max. per dose 4 mg), adjusted according to response, dose to be taken within 30 minutes before main meals and adjusted at intervals of 1–2 weeks; maximum 16 mg per day

Type 2 diabetes mellitus (as monotherapy or in combination with metformin when metformin alone inadequate), if transferring from another oral antidiabetic drug

BY MOUTH
Adult 18–74 years: Initially 1 mg (max. per dose 4 mg), adjusted according to response, dose to be taken within 30 minutes before main meals and adjusted at intervals of 1–2 weeks; maximum 16 mg per day

CONTRA-INDICATIONS
Ketoacidosis

CAUTIONS
Debilitated patients · malnourished patients

CAUTIONS, FURTHER INFORMATION
Substitute insulin during intercurrent illness (such as myocardial infarction, coma, infection, and trauma) and during surgery.

INTERACTIONS
Appendix 1: repaglinide

SIDE-EFFECTS
Common or very common Abdominal pain · constipation · diarrhoea · nausea · vomiting

Rare Hypersensitivity reactions · hypoglycaemia · pruritus · rash · urticaria · vasculitis · visual disturbances

PREGNANCY
Avoid.

BREAST FEEDING
Avoid—present in milk in animal studies.

HEPATIC IMPAIRMENT
Avoid in severe liver disease.

PATIENT AND CARER ADVICE
Driving and skilled tasks
Drivers need to be particularly careful to avoid hypoglycaemia and should be warned of the problems.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet

Repaglinide (Non-proprietary)
Repaglinide 500 microgram Repaglinide 500 microgram tablets | 30 tablet pack £3.92 | 90 tablet pack £11.76 DT price = £10.48
Repaglinide 1 mg Repaglinide 1 mg tablets | 30 tablet pack £3.92 | 90 tablet pack £11.76 DT price = £10.48
Repaglinide 2 mg Repaglinide 2 mg tablets | 90 tablet pack £28.00 DT price = £5.88
GLUCOSE CO-TRANSPORTER 2 INHIBITORS

BLOOD GLUCOSE LOWERING DRUGS

Canagliflozin

**DRUG ACTION**
Reversibly inhibits sodium-glucose co-transporter 2 (SGLT2) in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary glucose excretion.

**INDICATIONS AND DOSE**
Type 2 diabetes mellitus as monotherapy (if metformin inappropriate) | Type 2 diabetes mellitus in combination with insulin or other antidiabetic drugs (if existing treatment fails to achieve adequate glycaemic control)
- **BY MOUTH**
  - **Adult:** 100 mg once daily; increased if tolerated to 300 mg once daily if required, dose to be taken preferably before breakfast

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**
Manufacturer advises increase dose if tolerated to 300 mg once daily with concurrent use of rifampicin.

**IMPORTANCE SAFETY INFORMATION**

**CONTRA-INDICATIONS**
Ketoacidosis

**CAUTIONS**
Cardiovascular disease (risk of hypotension) | elderly (risk of hypotension) | elevated haematocrit | history of hypotension

**CAUTIONS, FURTHER INFORMATION**
Volume depletion | Correct hypovolaemia before starting treatment.

**INTERACTIONS**
Appendix 1: canagliflozin

**SIDE-EFFECTS**
Common or very common
- Constipation | dyslipidaemia | genital infection | hypoglycaemia (in combination with insulin or sulfonylurea) | nausea | polyuria | raised haematocrit | thirst | urinary frequency | urinary-tract infection

Uncommon
- Dehydration | dizziness | hypovolaemia | lower-limb amputation | postural hypotension | raised serum creatinine | raised serum urea | rash | syncope

**SIDE-EFFECTS, FURTHER INFORMATION**
Volume depletion | Consider interrupting treatment if volume depletion occurs.

**PREGNANCY**
Avoid—toxicity in animal studies.

**BREAST FEEDING**
Avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT**
Manufacturer advises avoid in severe impairment—no information available.

**RENAL IMPAIRMENT**
Reduce dose to 100 mg once daily if eGFR falls persistently below 60 mL/minute/1.73 m² and existing canagliflozin treatment tolerated. Avoid initiation if eGFR less than 60 mL/minute/1.73 m². Avoid if eGFR less than 45 mL/minute/1.73 m². Monitor renal function at least twice a year in moderate impairment.

**MONITORING REQUIREMENTS**
Determine renal function before treatment and at least annually thereafter, and before initiation of concomitant drugs that reduce renal function and periodically thereafter.

**PATIENT AND CARER ADVICE**
Patients should be advised to report symptoms of volume depletion including postural hypotension and dizziness. Patients should be informed of having only moderately elevated blood glucose levels, and some of them occurred during off-label use.

To minimise the risk of such effects when treating patients with a SGLT2 inhibitor, the European Medicines Agency has issued the following advice:
- inform patients of the signs and symptoms of DKA, (including rapid weight loss, nausea or vomiting, abdominal pain, fast and deep breathing, sleepiness, a sweet smell to the breath, a sweet or metallic taste in the mouth, or a different odour to urine or sweat), and advise them to seek immediate medical advice if they develop any of these
- test for raised ketones in patients with signs and symptoms of DKA, even if plasma glucose levels are near-normal
- use canagliflozin with caution in patients with risk factors for DKA, (including a low beta cell reserve, conditions leading to restricted food intake or severe dehydration, sudden reduction in insulin, increased insulin requirements due to acute illness, surgery or alcohol abuse), and discuss these risk factors with patients
- discontinue treatment if DKA is suspected or diagnosed
- do not restart treatment with any SGLT2 inhibitor in patients who experienced DKA during use, unless another cause for DKA was identified and resolved
- interrupt SGLT2 treatment in patients who are hospitalised for major surgery or acute serious illnesses; treatment may be restarted once the patient’s condition has stabilised

Canagliflozin (Consilent Health Ltd)

Repaglinide 500 microgram | Prandin 0.5mg tablets | 30 tablet | £3.92
- Repaglinide 1 mg | Enyglid 2mg tablets | 90 tablet | £11.76 DT price = £5.88

**BNF 74**

Diabetes mellitus 661

Endocrine system
the signs and symptoms of diabetic ketoacidosis, see MHRA advice.

- **NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (May 2016) NICE TA390

Canagliflozin as monotherapy is recommended as an option for treating type 2 diabetes in adults for whom metformin is contra-indicated or not tolerated, only if a dipeptidyl peptidase-4 (DPP-4) inhibitor would otherwise be prescribed and a sulfonylurea or pioglitazone is not appropriate.

Patients currently receiving canagliflozin whose disease does not meet the above criteria should be able to continue treatment until they and their clinician consider it appropriate to stop.

www.nice.org.uk/TA390

- Canagliflozin in combination therapy for treating type 2 diabetes (June 2014) NICE TA315

Canagliflozin in a dual therapy regimen in combination with metformin is recommended for the treatment of type 2 diabetes, only if a sulfonylurea is contra-indicated or not tolerated or the patient has a significant risk of hypoglycaemia.

Canagliflozin in a triple therapy regimen is an option for the treatment of type 2 diabetes in combination with metformin and a sulfonylurea or metformin and a thiazolidinedione.

Canagliflozin in combination with insulin (alone or with other antidiabetic drugs) is an option for the treatment of type 2 diabetes.

Patients currently receiving canagliflozin in a dual or triple therapy regimen that is not recommended according to the above criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop.

www.nice.org.uk/TA315

- **MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- Canagliflozin (Non-proprietary)
  - Canagliflozin (as Canagliflozin hemihydrate) 100 mg Canagliflozin 100mg tablets | 30 tablet | no price available DT price = £39.20
  - Canagliflozin (as Canagliflozin hemihydrate) 300 mg Canagliflozin 300mg tablets | 30 tablet | no price available DT price = £39.20
  - Invokana (Janssen-Cilag Ltd) ▼
    - Canagliflozin (as Canagliflozin hemihydrate) 100 mg Invokana 100mg tablets | 30 tablet | £39.20 DT price = £39.20
    - Canagliflozin (as Canagliflozin hemihydrate) 300 mg Invokana 300mg tablets | 30 tablet | £39.20 DT price = £39.20

- **Canagliflozin with metformin**

The properties listed below are those particular to the combination only. For the properties of the components please consider, canagliflozin p. 661, metformin hydrochloride p. 652.

- **INDICATIONS AND DOSE**

  **Type 2 diabetes mellitus not controlled by metformin alone or by metformin in combination with insulin or other antidiabetic drugs**

  - **BY MOUTH**
  - Adult: 1 tablet twice daily, dose based on patient’s current metformin dose, daily dose of metformin should not exceed 2 g

- **DOSE ADJUSTMENTS DUE TO INTERACTIONS**

  Dose of concomitant insulin or drugs that stimulate insulin secretion may need to be reduced.

- **INTERACTIONS** → Appendix 1: canagliflozin, metformin

- **RENAL IMPAIRMENT**

  Avoid if eGFR less than 60 mL/minute/1.73 m².

- **NATIONAL FUNDING/ACCESS DECISIONS**

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (December 2014) that Vokanamet® is accepted for restricted use within NHS Scotland in patients with type 2 diabetes mellitus for whom a combination of canagliflozin and metformin is an appropriate choice of therapy.

- **MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

CAUTIONARY AND ADVISORY LABELS 21

- Vokanamet (Janssen-Cilag Ltd) ▼
  - Canagliflozin (as Canagliflozin hemihydrate) 50 mg, Metformin hydrochloride 850 mg Vokanamet 50mg/850mg tablets | 60 tablet | £39.20 DT price = £39.20
  - Canagliflozin (as Canagliflozin hemihydrate) 50 mg, Metformin hydrochloride 1 gram Vokanamet 50mg/1000mg tablets | 60 tablet | £39.20 DT price = £39.20

**Dapagliflozin**

- **DRUG ACTION**

  Reversibly inhibits sodium-glucose co-transporter 2 (SGLT2) in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary glucose excretion.

- **INDICATIONS AND DOSE**

  **Type 2 diabetes mellitus as monotherapy (if metformin inappropriate)**

  Type 2 diabetes mellitus in combination with insulin or other antidiabetic drugs (if existing treatment fails to achieve adequate glycaemic control)

  - **BY MOUTH**
  - Adult 18–74 years: 10 mg once daily
  - Adult 75 years and over: Initiation not recommended

- **DOSE ADJUSTMENTS DUE TO INTERACTIONS**

  Dose of concomitant insulin or drugs that stimulate insulin secretion may need to be reduced.

**IMPORTANT SAFETY INFORMATION**

MHRA/CHM ADVICE (UPDATED APRIL 2016): RISK OF DIABETIC KETOACIDOSIS WITH SODIUM–GLUCOSE CO-TRANSPORTER 2 (SGLT2) INHIBITORS (CANAGLIFLOZIN, DAPAGLIFLOZIN OR EMPAGLIFLOZIN)

A review by the European Medicines Agency has concluded that serious, life-threatening, and fatal cases of diabetic ketoacidosis (DKA) have been reported rarely in patients taking an SGLT2 inhibitor. In several cases, the presentation of DKA was atypical with patients having only moderately elevated blood glucose levels, and some of them occurred during off-label use.

To minimise the risk of such effects when treating patients with a SGLT2 inhibitor, the European Medicines Agency has issued the following advice:

- inform patients of the signs and symptoms of DKA, (including rapid weight loss, nausea or vomiting, abdominal pain, fast and deep breathing, sleepiness, a sweet smell to the breath, a sweet or metallic taste in the mouth, or a different odour to urine or sweat), and advise them to seek immediate medical advice if they develop any of these

- test for raised ketones in patients with signs and symptoms of DKA, even if plasma glucose levels are near-normal

- use dapagliflozin with caution in patients with risk factors for DKA, (including a low beta cell reserve, conditions leading to restricted food intake or severe dehydration, sudden reduction in insulin, increased
insulin requirements due to acute illness, surgery or alcohol abuse), and discuss these risk factors with patients
- discontinue treatment if DKA is suspected or diagnosed
- do not restart treatment with any SGLT2 inhibitor in patients who experienced DKA during use, unless another cause for DKA was identified and resolved
- interrupt SGLT2 treatment in patients who are hospitalised for major surgery or acute serious illnesses; treatment may be restarted once the patient’s condition has stabilised

- **CONTRA-INDICATIONS** Ketoadiabetes
- **CAUTIONS** Cardiovascular disease (risk of hypotension) • elderly (risk of hypotension) • electrolyte disturbances • hypotension • raised haematocrit

**CAUTIONS, FURTHER INFORMATION**
- Volume depletion Correct hypovolaemia before starting treatment.

**INTERACTIONS** → Appendix 1: dapagliflozin

**SIDE-EFFECTS**
- Common or very common Back pain • constipation • dyslipidaemia • dysuria • genital infection • hypoglycaemia (in combination with insulin or sulfonylurea) • polyuria • sweating • thirst • urinary-tract infection
- Uncommon Dehydration • dizziness • hypotension • hypovolaemia • nausea • nocturia • raised serum creatinine • raised serum urea • rash

**SIDE-EFFECTS, FURTHER INFORMATION**
- Volume depletion Consider interrupting treatment if volume depletion occurs.

**PREGNANCY** Avoid—toxicity in animal studies.

**BREAST FEEDING** Avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT** Initial dose 5 mg daily in severe impairment, increased according to response.

**RENAL IMPAIRMENT** Avoid if eGFR less than 60 mL/minute/1.73 m² (ineffective).

**MONITORING REQUIREMENTS** Determine renal function before treatment and at least annually thereafter.

**PATIENT AND CARER ADVICE** Patients should be informed of the signs and symptoms of diabetic ketoacidosis, see MHRA advice.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**
- **Dapagliflozin in combination therapy for treating type 2 diabetes (updated November 2016)** NICE TA288 Dapagliflozin in a dual therapy regimen in combination with metformin is recommended for the treatment of type 2 diabetes, only if the patient is at significant risk of hypoglycaemia or its consequences, or if a sulfonylurea is contra-indicated or not tolerated. Dapagliflozin in combination with insulin (alone or with other antidiabetic drugs) is an option for the treatment of type 2 diabetes. Patients currently receiving dapagliflozin in a dual therapy regimen that is not recommended according to the above criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop. www.nice.org.uk/TA288
- **Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (May 2016)** NICE TA390 Dapagliflozin as monotherapy is recommended as an option for treating type 2 diabetes in adults for whom metformin is contra-indicated or not tolerated, only if a dipeptidyl peptidase-4 (DPP-4) inhibitor would otherwise be prescribed and a sulfonylurea or pioglitazone is not appropriate.

Patients currently receiving dapagliflozin whose disease does not meet the above criteria should be able to continue treatment until they and their clinician consider it appropriate to stop. www.nice.org.uk/TA390

**Dapagliflozin in triple therapy for treating type 2 diabetes (November 2016) NICE TA418** Dapagliflozin in a triple therapy regimen is recommended as an option for treating type 2 diabetes in adults, only in combination with metformin and a sulfonylurea. Patients currently receiving dapagliflozin in other triple therapy regimens, whose treatment was started within the NHS before this guidance was published should have the option to continue treatment, without change to their funding arrangements, until they and their clinician consider it appropriate to stop. www.nice.org.uk/TA418

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium (SMC) has advised that dapagliflozin (Forxiga®) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes in combination with metformin, when treatment with metformin alone is inadequate and a sulfonylurea is inappropriate (December 2012), or in combination with insulin when treatment with insulin alone is inadequate (February 2014).

**MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- **Forxiga (AstraZeneca UK Ltd)**
  - Dapagliflozin 5 mg Forxiga 5mg tablets | 28 tablet | £36.59 DT price = £36.59
  - Dapagliflozin 10 mg Forxiga 10mg tablets | 28 tablet | £36.59 DT price = £36.59

**Dapagliflozin with metformin**

The properties listed below are those particular to the combination only. For the properties of the components please consider, dapagliflozin p. 662, metformin hydrochloride p. 652.

**INDICATIONS AND DOSE**

**Type 2 diabetes mellitus not controlled by metformin alone or by metformin in combination with insulin or other antidiabetic drugs**
- **BY MOUTH**
  - Adult 18–74 years: 1 tablet twice daily, based on patient’s current metformin dose
  - Adult 75 years and over: Initiation not recommended

**INTERACTIONS** → Appendix 1: dapagliflozin, metformin

**HEPATIC IMPAIRMENT** Avoid.

**NATIONAL FUNDING/ACCESS DECISIONS**

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (July 2014) that dapagliflozin plus metformin (Xigduo®) is accepted for restricted use within NHS Scotland in patients for whom a combination of dapagliflozin and metformin is an appropriate choice of therapy i.e when metformin alone does not provide adequate glycaemic control and a sulfonylurea is inappropriate, or in combination with insulin, when insulin and metformin does not provide adequate control, or in combination with a sulfonylurea, when a sulfonylurea and metformin does not provide adequate control.
Empagliflozin

18-May-2017

DRUG ACTION
Reversibly inhibits sodium-glucose co-transporter 2 (SGLT2) in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary glucose excretion.

INDICATIONS AND DOSE
Type 2 diabetes mellitus as monotherapy (if metformin inappropriate) | Type 2 diabetes mellitus in combination with insulin or other antidiabetic drugs (if existing treatment fails to achieve adequate glycaemic control)

BY MOUTH
Adult 18-84 years: 10 mg once daily, increased to 25 mg once daily if necessary and if tolerated
Adult 85 years and over: Initiation not recommended

DOSE ADJUSTMENTS DUE TO INTERACTIONS
Dose of concomitant insulin or drugs that stimulate insulin secretion may need to be reduced.

CONTRA-INDICATIONS
Diabetic ketoacidosis

CAUTIONS
Cardiovascular disease (increased risk of volume depletion) - complicated urinary tract infections - consider temporarily interrupting treatment - concomitant antihypertensive therapy (increased risk of volume depletion) - elderly patients aged over 75 years (increased risk of volume depletion) - heart failure - history of hypotension (increased risk of volume depletion) - patients at increased risk of volume depletion - predisposition to fluid disturbances e.g. gastro-intestinal illness, concomitant use of diuretics (increased risk of volume depletion)

CAUTIONS, FURTHER INFORMATION
Volume depletion Correct hypovolaemia before starting treatment. Consider interrupting treatment if volume depletion occurs.

INTERACTIONS
Appendix 1: empagliflozin

SIDE-EFFECTS
Common or very common
Genital infection, hypoglycaemia (in combination with insulin or sulfonylurea), polyuria, pruritus, urinary tract infection
Uncommon
Dysuria, volume depletion

PREGNANCY
Manufacturer advises avoid — toxicity in animal studies.

BREAST FEEDING
Manufacturer advises avoid — present in milk in animal studies.

HEPATIC IMPAIRMENT
Manufacturer advises avoid in severe impairment—no information available.

RENAL IMPAIRMENT
Reduce dose to 10 mg once daily if eGFR falls persistently below 60 mL/minute/1.73 m². Avoid initiation if eGFR below 60 mL/minute/1.73 m². Avoid if eGFR is persistently below 45 mL/minute/1.73 m².

MONITORING REQUIREMENTS
Determine renal function before treatment and before initiation of concomitant drugs that may reduce renal function, then at least annually thereafter.

PATIENT AND CARER ADVICE
Patients should be informed of the signs and symptoms of diabetic ketoacidosis, see MHRA advice.

NATIONAL FUNDING/ACCESS DECISIONS
NICE technology appraisals (TAs)

Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (May 2016) NICE TA390
Empagliflozin as monotherapy is recommended as an option for treating type 2 diabetes in adults for whom metformin is contra-indicated or not tolerated, only if a dipeptidyl peptidase-4 (DPP-4) inhibitor would otherwise be prescribed and a sulfonylurea or pioglitazone is not appropriate.

Canagliflozin, dapagliflozin and empagliflozin in combination therapy for treating type 2 diabetes (March 2015) NICE TA336
Empagliflozin in a dual therapy regimen in combination with metformin is an option for the treatment of type 2 diabetes, only if:
- a sulfonylurea is contra-indicated or not tolerated, or
- the patient is at significant risk of hypoglycaemia or its consequences.

Empagliflozin in a triple therapy regimen is an option for the treatment of type 2 diabetes in combination with:
- metformin and a sulfonylurea or
- metformin and a thiazolidinedione.

IMPORTANT SAFETY INFORMATION
MHRA/CHM ADVICE (UPDATED APRIL 2016): RISK OF DIABETIC KETOACIDOSIS WITH SODIUM-GLUCOSE CO-TRANSPORTER 2 (SGLT2) INHIBITORS (CANAGLIFLOZIN, DAPAGLIFLOZIN OR EMPAGLIFLOZIN)
A review by the European Medicines Agency has concluded that serious, life-threatening, and fatal cases of diabetic ketoacidosis (DKA) have been reported rarely in patients taking an SGLT2 inhibitor. In several cases, the presentation of DKA was atypical with patients having only moderately elevated blood glucose levels, and some of them occurred during off-label use.

To minimise the risk of such effects when treating patients with an SGLT2 inhibitor, the European Medicines Agency has issued the following advice:

- inform patients of the signs and symptoms of DKA, (including rapid weight loss, nausea or vomiting, abdominal pain, fast and deep breathing, sleepiness, a sweet smell to the breath, a sweet or metallic taste in the mouth, or a different odour to urine or sweat), and advise them to seek immediate medical advice if they develop any of these
- test for raised ketones in patients with signs and symptoms of DKA, even if plasma glucose levels are near-normal
- use empagliflozin with caution in patients with risk factors for DKA, (including a low beta cell reserve, conditions leading to restricted food intake or severe dehydration, sudden reduction in insulin, increased insulin requirements due to acute illness, surgery or alcohol abuse), and discuss these risk factors with patients
- discontinue treatment if DKA is suspected or diagnosed
- do not restart treatment with any SGLT2 inhibitor in patients who experienced DKA during use, unless another cause for DKA was identified and resolved
- interrupt SGLT2 treatment in patients who are hospitalised for major surgery or acute serious illnesses; treatment may be restarted once the patient’s condition has stabilised
Empagliflozin in combination with insulin with or without other antidiabetic drugs is an option for the treatment of type 2 diabetes.

Patients currently receiving empagliflozin whose disease does not meet the above criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop.

www.nice.org.uk/TA336

**Medicinal Forms**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Jardiance** (Boehringer Ingelheim Ltd) ▼
  - Empagliflozin 10 mg Jardiance 10mg tablets | 28 tablet [POM] £36.59 DT price = £36.59
  - Empagliflozin 25 mg Jardiance 25mg tablets | 28 tablet [POM] £36.59 DT price = £36.59

**Empagliflozin with metformin**

The properties listed below are those particular to the combination only. For the properties of the components please consider, empagliflozin p. 664, metformin hydrochloride p. 652.

**Indications and Dose**

Type 2 diabetes mellitus not controlled by metformin alone or by metformin in combination with other antidiabetic drugs or insulin

- **By Mouth**
  - Adult 18–84 years: 5/850–5/1000 mg twice daily, based on patient’s current metformin dose, increased if necessary to 12.5/850–12.5/1000 mg twice daily
  - **By Mouth**
  - Adult 85 years and over: Initiation not recommended

**Dose Adjustments Due to Interactions**

Dose of concomitant insulin or drugs that stimulate insulin secretion may need to be reduced.

**Dose Equivalence and Conversion**

The proportions are expressed in the form “x”/“y” where “x” and “y” are the strengths in milligrams of empagliflozin and metformin respectively.

**Interactions** → Appendix 1: empagliflozin, metformin

**National Funding/Access Decisions**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (October 2015) that Synjardy® (empagliflozin with metformin) is accepted for restricted use within NHS Scotland in patients for whom a fixed dose combination of empagliflozin and metformin is an appropriate choice of therapy or when use of a sulfonylurea is considered inappropriate.

**Medicinal Forms**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

CAUTIONARY AND ADVISORY LABELS 21

- **Synjardy** (Boehringer Ingelheim Ltd) ▼
  - Empagliflozin 12.5 mg, Metformin hydrochloride 850 mg Synjardy 12.5mg/850mg tablets | 56 tablet [POM] £36.59 DT price = £36.59
  - Empagliflozin 12.5 mg, Metformin hydrochloride 1500 mg Synjardy 12.5mg/1500mg tablets | 56 tablet [POM] £36.59 DT price = £36.59
  - Empagliflozin 25 mg, Metformin hydrochloride 1500 mg Synjardy 25mg/1500mg tablets | 56 tablet [POM] £36.59 DT price = £36.59

**Sulfonylureas**

**Drug Action**

The sulfonylureas act mainly by augmenting insulin secretion and consequently are effective only when some residual pancreatic beta-cell activity is present; during long-term administration they also have an extrapancreatic action.

**Contra-Indications**

Presence of ketoacidosis

**Cautions**

Can encourage weight gain (should be prescribed only if poor control and symptoms persist despite adequate attempts at dieting) · elderly · G6PD deficiency

**Side-Effects**

- **Uncommon**
  - Hypoglycaemia
  - **Rare**
  - Agranulocytosis · aplastic anaemia · blood disorders · cholestatic jaundice · haemolytic anaemia · hepatic failure · hepatitis · leucopenia · pancytopenia · thrombocytopenia

**Frequency Not Known**

Allergic skin reactions (usually in the first 6–8 weeks of therapy) · constipation · diarrhoea · disturbance in liver function · erythema multiforme (usually in the first 6–8 weeks of therapy) · exfoliative dermatitis (usually in the first 6–8 weeks of therapy) · fever (usually in the first 6–8 weeks of therapy) · gastrointestinal disturbances · hypersensitivity reactions (usually in the first 6–8 weeks of therapy) · jaundice (usually in the first 6–8 weeks of therapy) · nausea · vomiting

SIDE-EFFECTS, FURTHER INFORMATION

Hypoglycaemia: This is uncommon and usually indicates excessive dosage. Sulfonylurea-induced hypoglycaemia may persist for many hours and must always be treated in hospital.

**Hepatic Impairment**

Sulfonylureas should be avoided or a reduced dose should be used in severe hepatic impairment, because there is an increased risk of hypoglycaemia. Jaundice may occur.

**Renal Impairment**

Sulfonylureas should be used with care in those with mild to moderate renal impairment, because of the hazard of hypoglycaemia. Care is required to use the lowest dose that adequately controls blood glucose. Avoid where possible in severe renal impairment.

**Patient and Carer Advice**

The risk of hypoglycaemia associated with sulfonylureas should be discussed with the patient, especially when concomitant glucose-lowering drugs are prescribed.

**Driving and skilled tasks**

Drivers need to be particularly careful to avoid hypoglycaemia and should be warned of the problems.

**Glibenclamide**

**Indications and Dose**

Type 2 diabetes mellitus

- **By Mouth**
  - Adult: Initially 5 mg daily, adjusted according to response, dose to be taken with or immediately after breakfast; maximum 15 mg per day

**Unlicensed Use**


**Contra-Indications**

Avoid where possible in acute porphyrias p. 969

**Interactions** → Appendix 1: sulfonylureas

**Pregnancy**

The use of sulfonylureas in pregnancy should generally be avoided because of the risk of neonatal hypoglycaemia; however, glibenclamide can be used
during the second and third trimesters of pregnancy in women with gestational diabetes.

- **BREAST FEEDING** Glibenclamide can be used during breast-feeding in women with pre-existing diabetes.

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

### Tablet
- **Glibenclamide (Non-proprietary)**
  - Glibenclamide 2.5 mg Glibenclamide 2.5 mg tablets | 28 tablet (Prop) £11.46 DT price = £8.91
  - Glibenclamide 5 mg Glibenclamide 5 mg tablets | 28 tablet (Prop) £14.72 DT price = £11.39

### Gliclazide

- **INDICATIONS AND DOSE**
  - **Type 2 diabetes mellitus**
    - **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
      - Adult: Initially 40–80 mg daily, adjusted according to response, increased if necessary up to 160 mg once daily, dose to be taken with breakfast, doses higher than 160 mg to be given in divided doses; maximum 320 mg per day
    - **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
      - Adult: Initially 30 mg daily, dose to be taken with breakfast, adjust dose according to response every 4 weeks (after 2 weeks if no decrease in blood glucose); maximum 120 mg per day
  - **DOSE EQUIVALENT AND CONVERSION**
    - Gliclazide modified release 30 mg may be considered to be approximately equivalent in therapeutic effect to standard formulation gliclazide 80 mg.

- **CONTRA-INDICATIONS** Avoid where possible in acute porphyrias p. 969
- **INTERACTIONS** Appendix 1: sulfonylureas
- **PREGNANCY** The use of sulfonylureas in pregnancy should generally be avoided because of the risk of neonatal hypoglycaemia.
- **BREAST FEEDING** Avoid—there is theoretical possibility of hypoglycaemia in the infant.
- **RENAL IMPAIRMENT** If necessary, gliclazide which is mainly metabolised in the liver, can be used in renal impairment but careful monitoring of blood-glucose concentration is essential.

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

#### Modified-release tablet
**CAUTIONARY AND ADVISORY LABELS 25**

- **Gliclazide (Non-proprietary)**
  - Gliclazide 30 mg Gliclazide 30 mg modified-release tablets | 28 tablet (Prop) £2.81 DT price = £2.81 | 56 tablet (Prop) £5.62
  - Bilbona (Actavis UK Ltd)
    - Gliclazide 30 mg Bilbona 30 mg modified-release tablets | 28 tablet (Prop) £1.63 DT price = £2.81 | 56 tablet (Prop) £3.27
    - Gliclazide 60 mg Bilbona 60 mg modified-release tablets | 28 tablet (Prop) £3.27 DT price = £4.77 | 56 tablet (Prop) £6.55
  - Dacasis MR (Mylan Ltd)
    - Gliclazide 30 mg Dacasis MR 30 mg tablets | 28 tablet (Prop) £2.81 DT price = £2.81
  - Diamicron MR (Servier Laboratories Ltd)
    - Gliclazide 30 mg Diamicron 30 mg MR tablets | 28 tablet (Prop) £2.81 DT price = £2.81 | 56 tablet (Prop) £5.62
  - Edeil MR (Teva UK Ltd)
    - Gliclazide 30 mg Edeil MR 30 mg tablets | 28 tablet (Prop) £2.62 DT price = £2.81 | 56 tablet (Prop) £5.24

#### Glimepiride

- **INDICATIONS AND DOSE**
  - **Type 2 diabetes mellitus**
    - **BY MOUTH**
      - Adult: Initially 1 mg daily, adjusted according to response, then increased in steps of 1 mg every 1–2 weeks, increased to 4 mg daily, dose to be taken shortly before or with first main meal, the daily dose may be increased further, in exceptional circumstances; maximum 6 mg per day

- **CAUTIONS, FURTHER INFORMATION**
  - **Porphyria** Sulfonylureas should be avoided where possible in acute porphyrias p. 969 but glimepiride is thought to be safe.
  - **INTERACTIONS** Appendix 1: sulfonylureas
  - **SIDE-EFFECTS** Hyponatraemia
  - **PREGNANCY** The use of sulfonylureas in pregnancy should generally be avoided because of the risk of neonatal hypoglycaemia.
  - **BREAST FEEDING** Avoid—there is theoretical possibility of hypoglycaemia in the infant.

- **MONITORING REQUIREMENTS** Manufacturer recommends regular hepatic and haematological monitoring but limited evidence of clinical value.

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

#### Tablet
- **Glimepiride (Non-proprietary)**
  - Glimepiride 1 mg Glimepiride 1 mg tablets | 30 tablet (Prop) £3.33 DT price = £2.80
  - Glimepiride 2 mg Glimepiride 2 mg tablets | 30 tablet (Prop) £7.13 DT price = £6.80
  - Glimepiride 3 mg Glimepiride 3 mg tablets | 30 tablet (Prop) £10.75 DT price = £9.87
  - Glimepiride 4 mg Glimepiride 4 mg tablets | 30 tablet (Prop) £14.24 DT price = £13.07
  - Amaryl (Zeneca)
    - Glimepiride 3 mg Amaryl 3 mg tablets | 30 tablet (Prop) £10.75 DT price = £9.87

- **Laaglyda MR** (Consilient Health Ltd)
  - Gliclazide 60 mg Laaglyda MR 60 mg tablets | 28 tablet (Prop) £4.77 DT price = £4.77

- **Nadolol MR** (Consilient Health Ltd)
  - Gliclazide 30 mg Nadolol MR 30 mg tablets | 28 tablet (Prop) £2.35 DT price = £2.81 | 56 tablet (Prop) £4.92

- **Vamju** (AMCo)
  - Gliclazide 30 mg Vamju 30 mg modified-release tablets | 28 tablet (Prop) £1.64 DT price = £2.81 | 56 tablet (Prop) £3.28
  - Gliclazide 60 mg Vamju 60 mg modified-release tablets | 28 tablet (Prop) £3.28 DT price = £4.77

- **Zilasseg** (Lupin (Europe) Ltd)
  - Gliclazide 30 mg Zilasseg 30 mg modified-release tablets | 28 tablet (Prop) £2.38 DT price = £2.81 | 56 tablet (Prop) £4.77

- **Zicron PR** (Bristol Laboratories Ltd)
  - Gliclazide 30 mg Zicron PR 30 mg tablets | 28 tablet (Prop) £1.95 DT price = £2.81 | 56 tablet (Prop) £3.90

### Price

- **DT price** = £
  - 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 0
  - £

- **Glimepiride**
  - Glimepiride 1 mg Glimepiride 1 mg tablets | 30 tablet (Prop) £3.33 DT price = £2.80
  - Glimepiride 2 mg Glimepiride 2 mg tablets | 30 tablet (Prop) £7.13 DT price = £6.80
  - Glimepiride 3 mg Glimepiride 3 mg tablets | 30 tablet (Prop) £10.75 DT price = £9.87
  - Glimepiride 4 mg Glimepiride 4 mg tablets | 30 tablet (Prop) £14.24 DT price = £13.07
Glipizide

- **INDICATIONS AND DOSE**
  - **Type 2 diabetes mellitus**
    - **BY MOUTH**
    - **Adult**: Initially 2.5–5 mg daily, adjusted according to response, dose to be taken shortly before breakfast or lunch, doses up to 15 mg may be given as a single dose, higher doses to be given in divided doses; maximum 20 mg per day

- **CAUTIONS**
  - **SIDE-EFFECTS**
  - **INTERACTIONS** → Appendix 1: sulfonylureas
  - **SIDE-EFFECTS**
  - **PREGNANCY** The use of sulfonylureas in pregnancy should generally be avoided because of the risk of neonatal hypoglycaemia.
  - **BREAST FEEDING** Avoid—there is theoretical possibility of hypoglycaemia in the infant.
  - **HEPATIC IMPAIRMENT** Avoid if the patient has both renal and hepatic impairment.
  - **RENAL IMPAIRMENT** Avoid if the patient has both renal and hepatic impairment.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension
  - **Tablet**
    - **Glipizide (Non-proprietary)**
      - Glipizide 5 mg Glipizide 5mg tablets | 28 tablet P (REF) £2.69
      - Minodiab (Pfizer Ltd)
        - Glipizide 5 mg Minodiab 5mg tablets | 28 tablet P (REF) £2.60

**BLOOD GLUCOSE LOWERING DRUGS**

Pioglitazone

- **DRUG ACTION** The thiazolidinedione, pioglitazone, reduces peripheral insulin resistance, leading to a reduction of blood-glucose concentration.

- **INDICATIONS AND DOSE**
  - **Type 2 diabetes mellitus** (alone or combined with metformin or a sulfonylurea, or with both, or with insulin)
    - **BY MOUTH**
    - **Adult**: Initially 15–30 mg once daily, adjusted according to response to 45 mg once daily, in elderly patients, initiate with lowest possible dose and increase gradually; review treatment after 3–6 months and regularly thereafter

- **DOSE ADJUSTMENTS DUE TO INTERACTIONS**
  - Dose of concomitant sulfonylurea or insulin may need to be reduced.

**Tolbutamide**

- **INDICATIONS AND DOSE**
  - **Type 2 diabetes mellitus**
    - **BY MOUTH**
    - **Adult**: 0.5–1.5 g daily in divided doses, dose to be taken with or immediately after meals, alternatively 0.5–1.5 g once daily, dose to be taken with or immediately after breakfast; maximum 2 g per day

- **CONTRA-INDICATIONS** Avoid where possible in acute porphyrias p. 969
- **INTERACTIONS** → Appendix 1: sulfonylureas
- **SIDE-EFFECTS** Headache · tinnitus
- **PREGNANCY** The use of sulfonylureas in pregnancy should generally be avoided because of the risk of neonatal hypoglycaemia.
- **BREAST FEEDING** The use of sulfonylureas in breast-feeding should be avoided because there is a theoretical possibility of hypoglycaemia in the infant.
- **RENAL IMPAIRMENT** If necessary, the short-acting drug tolbutamide can be used in renal impairment but careful monitoring of blood-glucose concentration is essential.

**IMPORTANT SAFETY INFORMATION**

**PIOGLITAZONE: RISK OF BLADDER CANCER (JULY 2011)**

The European Medicines Agency has advised that there is a small increased risk of bladder cancer associated with pioglitazone use. However, in patients who respond adequately to treatment, the benefits of pioglitazone continue to outweigh the risks.

Pioglitazone should not be used in patients with active bladder cancer or a past history of bladder cancer, or in those who have uninvestigated macroscopic haematuria. Pioglitazone should be used with caution in elderly patients as the risk of bladder cancer increases with age.

Before initiating treatment with pioglitazone, patients should be assessed for risk factors of bladder cancer (including age, smoking status, exposure to certain occupational or chemotherapy agents, or previous radiation therapy to the pelvic region) and any macroscopic haematuria should be investigated. The safety and efficacy of pioglitazone should be reviewed after 3–6 months and pioglitazone should be stopped in patients who do not respond adequately to treatment.

Patients already receiving treatment with pioglitazone should be assessed for risk factors of bladder cancer and treatment should be reviewed after 3–6 months, as above.

Patients should be advised to report promptly any haematuria, dysuria, or urinary urgency during treatment.
**Rare national pregnancy contraindications**

**CAUTIONS, FURTHER INFORMATION**

Substitute insulin during peri-operative period.

**INTERACTIONS → Appendix 1: pioglitazone**

**SIDE-EFFECTS**

- **Common or very common** Anaemia; arthralgia; dizziness; gastro-intestinal disturbances; haematuria; headache; hypoaesthesia; impotence; oedema; vertigo; visual disturbances; weight gain

- **Uncommon** Altered blood lipids; bladder cancer; fatigue; hypoglycaemia; insomnia; proteinuria; sweating

- **Rare** Liver dysfunction

**SIDE-EFFECTS, FURTHER INFORMATION**

- Liver toxicity. Rare reports of liver dysfunction; discontinue if jaundice occurs.

**PREGNANCY** Avoid—toxicity in animal studies.

**BREAST FEEDING** Avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT** Avoid.

**MONITORING REQUIREMENTS** Monitor liver function before treatment and periodically thereafter.

**PATIENT AND CARER ADVICE**

Lever toxicity. Patients should be advised to seek immediate medical attention if symptoms such as nausea, vomiting, abdominal pain, fatigue and dark urine develop.

**NATIONAL FUNDING/ACCESS DECISIONS**

The Scottish Medicines Consortium accepts use of pioglitazone (February 2007) with metformin and a sulfonylurea, for patients (especially if overweight) whose glycaemic control is inadequate despite the use of 2 oral hypoglycaemic drugs and who are unable or unwilling to take insulin; treatment should be initiated and monitored by an experienced diabetes physician.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Tablet**

- **Pioglitazone (Non-proprietary)**
  - Pioglitazone (as Pioglitazone hydrochloride) 15 mg, Metformin 1000 mg tablets | 28 tablet pack £55.00 DT price = £2.22
  - Pioglitazone (as Pioglitazone hydrochloride) 15 mg, Metformin 500 mg tablets | 28 tablet pack £40.00 DT price = £1.63

- **Actos** (Takeda UK Ltd)
  - Pioglitazone (as Pioglitazone hydrochloride) 15 mg, Metformin 1000 mg tablets | 28 tablet pack £50.89 DT price = £1.79

- **Diabimol** (Tillomed Laboratories Ltd)
  - Pioglitazone (as Pioglitazone hydrochloride) 15 mg, Metformin 500 mg tablets | 28 tablet pack £45.89 DT price = £1.71

- **Gildipion** (Actavis UK Ltd)
  - Pioglitazone (as Pioglitazone hydrochloride) 15 mg, Metformin 1000 mg tablets | 28 tablet pack £52.89 DT price = £1.90

**INSULINS**

**Insulins**

**IMPORTANT SAFETY INFORMATION**

**NHS IMPROVEMENT PATIENT SAFETY ALERT: RISK OF SEVERE HARM AND DEATH DUE TO WITHDRAWING INSULIN FROM PEN DEVICES (NOVEMBER 2016)**

Insulin should not be extracted from insulin pen devices. The strength of insulin in pen devices can vary by multiples of 100 units/mL. Insulin syringes have graduations only suitable for calculating doses of standard 100 units/mL. If insulin extracted from a pen or cartridge is of a higher strength, and that is not considered in determining the volume required, it can lead to a significant and potentially fatal overdose.

**SIDE-EFFECTS**

- **Common or very common** Fat hypertrophy at injection site - local reactions at injection site - transient oedema

- **Rare** Hypersensitivity reactions - rash - urticaria

**ACTIONS**

- **Overdose**
  - Overdose causes hypoglycaemia.

- **PREGNANCY** During pregnancy, insulin requirements may alter and doses should be assessed frequently by an experienced diabetes physician. The dose of insulin generally needs to be increased in the second and third trimesters of pregnancy.

- **BREAST FEEDING**
  - During breast-feeding, insulin requirements may alter and doses should be assessed frequently by an experienced diabetes physician. The dose of insulin generally needs to be increased in the second and third trimesters of pregnancy.

- **HEPATIC IMPAIRMENT**
  - Insulin requirements may be decreased in patients with hepatic impairment.

- **RENAL IMPAIRMENT**
  - Insulin requirements may decrease in patients with renal impairment and therefore dose reduction may be necessary. The compensatory response to hypoglycaemia is impaired in renal impairment.

**MONITORING REQUIREMENTS**

- Many patients now monitor their own blood-glucose concentrations; all carers and children need to be trained to do this.
Since blood-glucose concentration varies substantially throughout the day, ‘normoglycaemia’ cannot always be achieved throughout a 24-hour period without causing damaging hypoglycaemia.

In adults It is therefore best to recommend that patients should maintain a blood-glucose concentration of between 4 and 9 mmol/litre for most of the time (4–7 mmol/litre before meals and less than 9 mmol/litre after meals).

In children It is therefore best to recommend that children should maintain a blood-glucose concentration of between 4 and 10 mmol/litre for most of the time (4–8 mmol/litre before meals and less than 10 mmol/litre after meals).

While accepting that on occasions, for brief periods, the blood-glucose concentration will be above these values; strenuous efforts should be made to prevent it from falling below 4 mmol/litre. Patients using multiple injection regimens should understand how to adjust their insulin dose according to their carbohydrate intake. With fixed-dose insulin regimens, the carbohydrate intake needs to be regulated, and should be distributed throughout the day to match the insulin regimen. The intake of energy and of simple and complex carbohydrates should be adequate to allow normal growth and development but obesity must be avoided.

**DIRECTIONS FOR ADMINISTRATION** Insulin is generally given by subcutaneous injection; the injection site should be rotated to prevent lipodystrophy. Injection devices (‘pens’), which hold the insulin in a cartridge and meter the required dose, are convenient to use. Insulin syringes (for use with needles) are required for insulins not available in cartridge form, but are less popular with children and carers. For intensive insulin regimens multiple subcutaneous injections (3 or more times daily) are usually recommended.

**PRESCRIBING AND DISPENSING INFORMATION** Show container to patient or carer and confirm the expected version is dispensed.

Units The word ‘unit’ should not be abbreviated.

**PATIENT AND CARER ADVICE**

**Driving and skilled tasks**

Drivers need to be particularly careful to avoid hypoglycaemia and should be warned of the problems. Insulin Passport Insulin Passports and patient information booklets should be offered to patients receiving insulin. The Insulin Passport provides a record of the patient’s current insulin preparations and contains a section for emergency information. The patient information booklet provides advice on the safe use of insulin. They are available for purchase from:

3M Security Print and Systems Limited
Gorse Street, Chadderton
Oldham
OL9 9QH
Tel: 0845 610 1112
GP practices can obtain supplies through their Local Area Team stores.

NHS Trusts can order supplies from www.nhsforms.co.uk/ or by emailing nhsforms@mnim.com. Further information is available at www.npsa.nhs.uk.

Hypoglycaemia Hypoglycaemia is a potential problem with insulin therapy. All patients must be carefully instructed on how to avoid it; this involves appropriate adjustment of insulin type, dose and frequency together with suitable timing and quantity of meals and snacks.

**INSULINS**

**INTERMEDIATE-ACTING**

**Biphasic isophane insulin**

(Biphasic Isophane Insulin Injection— intermediate acting)

- **INDICATIONS AND DOSE**

<table>
<thead>
<tr>
<th>Diabetes mellitus</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BY SUBCUTANEOUS INJECTION</strong></td>
</tr>
<tr>
<td><strong>Child:</strong> According to requirements</td>
</tr>
<tr>
<td><strong>Adult:</strong> According to requirements</td>
</tr>
</tbody>
</table>

- **INTERACTIONS** Appendix 1: Insulins

- **SIDE-EFFECTS**

Proamine may cause allergic reactions

- **PRESCRIBING AND DISPENSING INFORMATION**

A sterile buffered suspension of either porcine or human insulin complexed with proamine sulfate (or another suitable proamine) in a solution of insulin of the same species. Check product container—the proportions of the two components should be checked carefully (the order in which the proportions are stated may not be the same in other countries).

- **MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Suspension for injection**

- Humulin M3 (Eli Lilly and Company Ltd)
  - Insulin human (as Insulin soluble human) 30 unit per 1 ml, Insulin human (as Insulin isophane human) 70 unit per 1 ml Humulin M3 100units/ml suspension for injection 3ml cartridges | 5 cartridge (£19.08 DT price + £19.08)
  - Humulin M3 100units/ml suspension for injection 10ml vials | 1 vial (£15.68)

- Humulin M3 KwikPen (Eli Lilly and Company Ltd)
  - Insulin human (as Insulin soluble human) 30 unit per 1 ml, Insulin human (as Insulin isophane human) 70 unit per 1 ml Humulin M3 KwikPen 100units/ml suspension for injection 3ml pre-filled pen | 5 pre-filled disposable injection (£21.70 DT price + £21.70)

- Hypurin Porcine 30/70 Mix (Wockhardt UK Ltd)
  - Insulin porcine (as Insulin soluble porcine) 30 unit per 1 ml, Insulin porcine (as Insulin isophane porcine) 70 unit per 1 ml Hypurin Porcine 30/70 Mix 100units/ml suspension for injection 3ml cartridges | 5 cartridge (£37.80)
  - Hypurin Porcine 30/70 Mix 100units/ml suspension for injection 10ml vials | 1 vial (£25.20)

- Insumin Comb 15 (Sanofi)
  - Insulin human (as Insulin soluble human) 15 unit per 1 ml, Insulin human (as Insulin isophane human) 85 unit per 1 ml Insumin Comb 15 100units/ml suspension for injection 3ml cartridges | 5 cartridge (£17.50)

- Insumin Comb 25 (Sanofi)
  - Insulin human (as Insulin soluble human) 25 unit per 1 ml, Insulin human (as Insulin isophane human) 75 unit per 1 ml Insumin Comb 25 100units/ml suspension for injection 5ml vials | 1 vial (£17.50)
  - Insumin Comb 25 100units/ml suspension for injection 3ml cartridges | 5 cartridge (£17.50)

- Insumin Comb 25 SoloStar (Sanofi)
  - Insulin human (as Insulin soluble human) 25 unit per 1 ml, Insulin human (as Insulin isophane human) 75 unit per 1 ml Insumin Comb 25 100units/ml suspension for injection 3ml pre-filled SoloStar (£19.60)

- Insumin Comb 50 (Sanofi)
  - Insulin human (as Insulin soluble human) 50 unit per 1 ml, Insulin human (as Insulin isophane human) 50 unit per 1 ml Insumin Comb 50 100units/ml suspension for injection 3ml cartridges | 5 cartridge (£17.50)
Isophane insulin

(ISophane Insulin Injection; Isophane Protamine Insulin Injection; Isophane insulin (NPH)—intermediate acting)

- **INDICATIONS AND DOSE**
  - **Diabetes mellitus**
    - **By subcutaneous injection**
    - **Child:** According to requirements
    - **Adult:** According to requirements
  - **INTERACTIONS** → Appendix 1: insulins
  - **SIDE-EFFECTS**
  - **PREGNANCY** Recommended where longer-acting insulins are needed.
  - **PRESCRIBING AND DISPENSING INFORMATION** A sterile suspension of bovine or porcine insulin or of human insulin in the form of a complex obtained by the addition of protamine sulfate or another suitable protamine.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Suspension for injection**
    - **Humulin I** (Eli Lilly and Company Ltd)
      - Insulin human (as insulin isophane human) 100 unit per 1 ml Humulin I 100units/ml suspension for injection 10ml vials | 1 vial (Po) £15.68
      - Humulin I 100units/ml suspension for injection 3ml cartridges | 5 cartridge (Po) £13.08 DT price = £13.08
    - **Humulin I KwikPen** (Eli Lilly and Company Ltd)
      - Insulin human (as insulin isophane human) 100 unit per 1 ml Humulin I KwikPen 100units/ml suspension for injection 3ml pre-filled pen | 5 pre-filled disposable injection (Po) £21.70 DT price = £21.70
    - **Hypurin Bovine Isophane** (Wockhardt UK Ltd)
      - Insulin bovine (as insulin isophane bovine) 100 unit per 1 ml Hypurin Bovine Isophane 100units/ml suspension for injection 10ml vials | 1 vial (Po) £27.72
      - Hypurin Bovine Isophane 100units/ml suspension for injection 3ml cartridges | 5 cartridge (Po) £41.58
    - **Hypurin Porcine Isophane (Wockhardt UK Ltd)**
      - Insulin porcine (as insulin isophane porcine) 100 unit per 1 ml Hypurin Porcine Isophane 100units/ml suspension for injection 3ml cartridges | 5 cartridge (Po) £37.80
      - Hypurin Porcine Isophane 100units/ml suspension for injection 10ml vials | 1 vial (Po) £25.20
    - **Insulatard** (Novo Nordisk Ltd)
      - Insulin human (as insulin isophane human) 100 unit per 1 ml Insulatard 100units/ml suspension for injection 10ml vials | 1 vial (Po) £7.48
    - **Insulatard InnoLet** (Novo Nordisk Ltd)
      - Insulin human (as insulin isophane human) 100 unit per 1 ml Insulatard InnoLet 100units/ml suspension for injection 3ml pre-filled pen | 5 pre-filled disposable injection (Po) £20.40 DT price = £21.70
    - **Insulatard Penfill** (Novo Nordisk Ltd)
      - Insulin human (as insulin isophane human) 100 unit per 1 ml Insulatard Penfill 100units/ml suspension for injection 3ml cartridges | 5 cartridge (Po) £22.90 DT price = £19.08
    - **Insman Basal** (Sanofi)
      - Insulin human (as insulin isophane human) 100 unit per 1 ml Insulman Basal 100units/ml suspension for injection 5ml vials | 1 vial (Po) £5.61
      - Insulman Basal 100units/ml suspension for injection 3ml cartridges | 5 cartridge (Po) £17.50 DT price = £19.08
    - **Insuman Basal SoloStar** (Sanofi)
      - Insulin human (as insulin isophane human) 100 unit per 1 ml Insuman Basal SoloStar 100units/ml suspension for injection 3ml pre-filled SoloStar pen | 5 pre-filled disposable injection (Po) £19.80 DT price = £21.70

Biphasic insulin aspart

(Intermediate-acting insulin)

- **INDICATIONS AND DOSE**
  - **Diabetes mellitus**
    - **By subcutaneous injection**
    - **Child:** Administer up to 10 minutes before or soon after a meal, according to requirements
    - **Adult:** Administer up to 10 minutes before or soon after a meal, according to requirements
  - **INTERACTIONS** → Appendix 1: insulins
  - **SIDE-EFFECTS** Protamine may cause allergic reactions.
  - **PRESCRIBING AND DISPENSING INFORMATION** Check product container—the proportions of the two components should be checked carefully (the order in which the proportions are stated may not be the same in other countries).

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Suspension for injection**
    - **NovoMix 30 FlexPen** (Novo Nordisk Ltd)
      - Insulin aspart 30 unit per 1 ml, Insulin aspart (as insulin aspart protamine) 70 unit per 1 ml NovoMix 30 FlexPen 100units/ml suspension for injection 3ml pre-filled pen | 5 pre-filled disposable injection (Po) £29.89 DT price = £29.89
    - **NovoMix 30 Penfill** (Novo Nordisk Ltd)
      - Insulin aspart 30 unit per 1 ml, Insulin aspart (as insulin aspart protamine) 70 unit per 1 ml NovoMix 30 Penfill 100units/ml suspension for injection 3ml cartridges | 5 cartridge (Po) £28.79 DT price = £28.79

Biphasic insulin lispro

(Intermediate-acting insulin)

- **INDICATIONS AND DOSE**
  - **Diabetes mellitus**
    - **By subcutaneous injection**
    - **Child:** Administer up to 15 minutes before or soon after a meal, according to requirements
    - **Adult:** Administer up to 15 minutes before or soon after a meal, according to requirements
  - **CAUTIONS** Children under 12 years (use only if benefit likely compared to soluble insulin)
  - **INTERACTIONS** → Appendix 1: insulins
  - **SIDE-EFFECTS** Protamine may cause allergic reactions.
  - **PRESCRIBING AND DISPENSING INFORMATION** Check product container—the proportions of the two components should be checked carefully (the order in which the proportions are stated may not be the same in other countries).

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Suspension for injection**
    - **Humalog Mix25** (Eli Lilly and Company Ltd)
      - Insulin lispro 25 unit per 1 ml, Insulin lispro (as insulin lispro protamine) 75 unit per 1 ml Humalog Mix25 100units/ml suspension for injection 10ml vials | 1 vial (Po) £16.61
      - Humalog Mix25 100units/ml suspension for injection 3ml cartridges | 5 cartridge (Po) £22.46 DT price = £22.46
    - **Humalog Mix25 KwikPen** (Eli Lilly and Company Ltd)
      - Insulin lispro 25 unit per 1 ml, Insulin lispro (as insulin lispro protamine) 75 unit per 1 ml Humalog Mix25 KwikPen 100units/ml
Insulin degludec with liraglutide

02-Jun-2016

The properties listed below are those particular to the combination only. For the properties of the components please consider, insulin degludec above, liraglutide p. 659.

**INDICATIONS AND DOSE**

As add-on to oral antidiabetics in type 2 diabetes mellitus not controlled by oral antidiabetics alone

- **BY SUBCUTANEOUS INJECTION**
  - Adult: Initially 10 dose-steps once daily, adjusted according to response; maximum 50 dose-steps per day

When transferring from basal insulin in type 2 diabetes mellitus not controlled by oral antidiabetics in combination with basal insulin

- **BY SUBCUTANEOUS INJECTION**
  - Adult: Initially 16 dose-steps once daily, adjusted according to response; maximum 50 dose-steps per day

**INTERACTIONS**  ➔ Appendix 1: insulins, liraglutide

**PATIENT AND CARER ADVICE**

Counselling advised on administration. Show container to patient and confirm that patient is expecting the version dispensed.

**NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (October 2015) that insulin degludec with liraglutide (Xultophy®) is accepted for restricted use within NHS Scotland for the treatment of type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with a GLP-1 receptor agonist or with basal insulin do not provide adequate glycaemic control.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Xultophy (Novo Nordisk Ltd)**
  - Liraglutide 3.6 mg per 1 ml, Insulin human (as Insulin degludec) 100 unit per 1 ml / Xultophy 100units/ml / 3.6mg/ml solution for injection 3ml pre-filled pen | 3 pre-filled disposable injection £95.53

**Insulin detemir**

(Recombinant human insulin analogue—long acting)

**INDICATIONS AND DOSE**

Diabetes mellitus

- **BY SUBCUTANEOUS INJECTION**
  - Child 2-17 years: According to requirements
  - Adult: According to requirements

**INTERACTIONS**  ➔ Appendix 1: insulins

**PREGNANCY**

Evidence of the safety of long-acting insulin analogues in pregnancy is limited, therefore isophane insulin p. 670 is recommended where longer-acting insulins are needed; insulin detemir may also be considered where longer-acting insulins are needed.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Levemir FlexPen (Novo Nordisk Ltd)**
  - Insulin human (as Insulin detemir) 100 unit per 1 ml / Levemir FlexPen 100units/ml solution for injection 3ml pre-filled pen | 5 pre-filled disposable injection £42.00 DT price = £42.00
Insulin glargine
(Recombinant human insulin analogue—long acting)

- **INDICATIONS AND DOSE**
  - **Diabetes mellitus**
    - By subcutaneous injection
    - Child: 2–17 years: According to requirements
    - Adult: According to requirements
  - **TOUJEO®**
    - **Diabetes mellitus**
      - By subcutaneous injection
      - Adult: According to requirements

- **INTERACTIONS** → Appendix 1: insulins
- **PREGNANCY** Evidence of the safety of long-acting insulin analogues in pregnancy is limited, therefore isophane insulin is recommended where longer-acting insulins are needed; insulin detemir may also be considered.
- **PRESCRIBING AND DISPENSING INFORMATION** Insulin glargine is a biological medicine. Biological medicines must be prescribed and dispensed by brand name, see Biological medicines and Biosimilar medicines, under Guidance on prescribing p. 1. Dose adjustments and close metabolic monitoring is recommended if switching between insulin glargine preparations.
- **NATIONAL FUNDING/ACCESS DECISIONS**
  - Scottish Medicines Consortium (SMC) Decisions
    - The Scottish Medicines Consortium has advised that Lantus® preparations (April 2013) and Toujeo® (August 2015) are accepted for restricted use within NHS Scotland for the treatment of type 1 diabetes:
      - in those who are at risk of or experience unacceptable frequency or severity of nocturnal hypoglycaemia on attempting to achieve better hypoglycaemic control during treatment with other insulin
      - as a once daily insulin therapy for patients who require a carer to administer their insulin
    - It is **not** recommended for routine use in patients with type 2 diabetes unless they suffer from recurrent episodes of hypoglycaemia or require assistance with their insulin injections.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Solution for injection**
    - **Abasaglar (Eli Lilly and Company Ltd)**
      - Insulin human (as Insulin glargine) 100 unit per 1 ml Abasaglar 100 units/ml solution for injection 3ml cartridges | 5 cartridge POM £42.00 DT price = £42.00
    - **Abasaglar KwikPen (Eli Lilly and Company Ltd)**
      - Insulin human (as Insulin glargine) 100 unit per 1 ml Abasaglar KwikPen 100 units/ml solution for injection 3ml cartridges | 5 cartridge POM £42.00 DT price = £42.00
    - **Lantus (Sanofi)**
      - Insulin human (as Insulin glargine) 100 unit per 1 ml Lantus 100 units/ml solution for injection 3ml cartridges | 5 cartridge POM £41.50 DT price = £41.50
      - Lantus 100 units/ml solution for injection 10ml vials | 1 vial POM £30.68
  - **Toujeo® (Sanofi)**
      - Insulin human (as Insulin glargine) 100 unit per 1 ml Toujeo 100 units/ml solution for injection 3ml pre-filled SoloStar pen | 5 pre-filled disposable injection (POM) £44.85 DT price = £44.85
      - Insulin human (as Insulin glargine) 300 unit per 1 ml Toujeo 300 units/ml solution for injection 1.5ml pre-filled SoloStar pen | 3 pre-filled disposable injection (POM) £33.13

Insulin zinc suspension
(Insulin zinc suspension (mixed)—long acting)

- **INDICATIONS AND DOSE**
  - **Diabetes mellitus**
    - By subcutaneous injection
    - Child: According to requirements
    - Adult: According to requirements
  - **INTERACTIONS** → Appendix 1: insulins
  - **PREGNANCY** Evidence of the safety of long-acting insulin analogues in pregnancy is limited, therefore isophane insulin p. 670 is recommended where longer-acting insulins are needed; insulin detemir p. 671 may also be considered.
  - **PRESCRIBING AND DISPENSING INFORMATION**
    - A sterile neutral suspension of bovine and/or porcine insulin or of human insulin in the form of a complex obtained by the addition of a suitable zinc salt; consists of rhombohedral crystals (10–40 microns) and of particles of no uniform shape (not exceeding 2 microns).

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  - **Suspension for injection**
    - **Hypurin Bovine Lente** (Wockhardt UK Ltd)
      - Insulin bovine (as Insulin zinc suspension mixed bovine) 100 unit per 1 ml
      - Hypurin Bovine Lente 100 units/ml suspension for injection 10ml vials | 1 vial POM £27.72

Protamine zinc insulin
(Protamine zinc insulin injection—long acting)

- **INDICATIONS AND DOSE**
  - **Diabetes mellitus**
    - By subcutaneous injection
    - Child: According to requirements
    - Adult: According to requirements
  - **INTERACTIONS** → Appendix 1: insulins
  - **SIDE-EFFECTS** Protamine may cause allergic reactions
  - **PREGNANCY** Evidence of the safety of long-acting insulin analogues in pregnancy is limited, therefore isophane insulin p. 670 is recommended where longer-acting insulins are needed; insulin detemir p. 671 may also be considered.

- **PRESCRIBING AND DISPENSING INFORMATION**
  - A sterile suspension of insulin in the form of a complex obtained by the addition of a suitable protamine and zinc chloride; this preparation was included in BP 1980 but is not included in BP 1988.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  - **Suspension for injection**
    - **Hypurin Bovine Protamine Zinc** (Wockhardt UK Ltd)
      - Insulin bovine (as Insulin protamine zinc bovine) 100 unit per 1 ml
      - Hypurin Bovine Protamine Zinc 100 units/ml suspension for injection 10ml vials | 1 vial POM £27.72
**INSULINS › RAPID-ACTING**

**Insulin**
*(Insulin Injection; Neutral Insulin; Soluble Insulin—short acting)*

**INDICATIONS AND DOSE**

**Diabetes mellitus**
- BY SUBCUTANEOUS INJECTION, OR BY INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INJECTION
  - Adult: According to requirements

**Diabetic ketoacidosis › Diabetes during surgery**
- BY INTRAVENOUS INJECTION
  - Adult: (consult local protocol)

**INTERACTIONS › Appendix 1: insulins**

**DIRECTIONS FOR ADMINISTRATION**

Short-acting injectable insulins can be given by continuous subcutaneous infusion using a portable infusion pump. This device delivers a continuous basal insulin infusion and patient-activated bolus doses at meal times. This technique can be useful for patients who suffer recurrent hypoglycaemia or marked morning rise in blood-glucose concentration despite optimised multiple-injection regimens. Patients on subcutaneous insulin infusion must be highly motivated, able to monitor their blood-glucose concentration, and have expert training, advice and supervision from an experienced healthcare team. Some insulin preparations are not recommended for use in subcutaneous insulin infusion pumps—may precipitate in catheter or needle—consult product literature.

With intravenous use For intravenous infusion give continuously in Sodium chloride 0.9%. Adsorbed to some extent by plastic infusion set; ensure insulin is not injected into ‘dead space’ of injection port of the infusion bag.

**PRESCRIBING AND DISPENSING INFORMATION**

A sterile solution of insulin (i.e. bovine or porcine) or of human insulin; pH 6.6–8.0.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**
- Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (type 1) (July 2008) NICE TA151
  - Continuous subcutaneous insulin infusion is recommended as an option in adults and children over 12 years with type 1 diabetes:
    - who suffer repeated or unpredictable hypoglycaemia, whilst attempting to achieve optimal glycaemic control with multiple-injection regimens, or
    - whose glycaemic control remains inadequate (HbA1c over 8.5% [69 mmol/mol]) despite optimised multiple-injection regimens (including the use of long-acting insulin analogues where appropriate).
  - Continuous subcutaneous insulin infusion is also recommended as an option for children under 12 years with type 1 diabetes for whom multiple-injection regimens are considered impractical or inappropriate. Children on insulin pumps should undergo a trial of multiple-injection therapy between the ages of 12 and 18 years.
  - www.nice.org.uk/TA151

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection, solution for infusion

**Solution for injection**
- Actrapid (Novo Nordisk Ltd)
  - Insulin human (as Insulin soluble human) 100 unit per 1 ml Actrapid 100units/ml solution for injection 10ml vials | 1 vial (Cost) £7.48
- Humulin S (Eli Lilly and Company Ltd)
  - Insulin human (as Insulin soluble human) 100 unit per 1 ml Humulin S 100units/ml solution for injection 10ml vials | 1 vial (Cost) £15.68
  - Humulin S 100units/ml solution for injection 3ml cartridges | 5 cartridge (Cost) £19.08
- Hypurin Bovine Neutral (Wockhardt UK Ltd)
  - Insulin bovine (as Insulin soluble bovine) 100 unit per 1 ml Hypurin Bovine Neutral 100units/ml solution for injection 10ml vials | 1 vial (Cost) £27.72
  - Hypurin Bovine Neutral 100units/ml solution for injection 3ml cartridges | 5 cartridge (Cost) £41.58
- Hypurin Porcine Neutral (Wockhardt UK Ltd)
  - Insulin porcine (as Insulin soluble porcine) 100 unit per 1 ml Hypurin Porcine Neutral 100units/ml solution for injection 10ml vials | 1 vial (Cost) £25.20
  - Hypurin Porcine Neutral 100units/ml solution for injection 3ml cartridges | 5 cartridge (Cost) £37.80
- Insumin Insufast (Sanofi)
  - Insulin human 100 unit per 1 ml Insumin Insufast 100units/ml solution for injection 3.15ml cartridges | 5 cartridge (Cost) £250.00
- Insumin Insufast 100units/ml solution for injection 10ml vials | 3 vial (Cost) £250.00
- Insumin Rapid (Sanofi)
  - Insulin human (as Insulin soluble human) 100 unit per 1 ml Insumin Rapid 100units/ml solution for injection 3ml cartridges | 5 cartridge (Cost) £17.50

**Insulin aspart**
*(Recombinant human insulin analogue—short acting)*

**INDICATIONS AND DOSE**

**Diabetes mellitus**
- BY SUBCUTANEOUS INJECTION
  - Child 2–17 years: Administer immediately before meals or when necessary shortly after meals, according to requirements
  - Adult: Administer immediately before meals or when necessary shortly after meals, according to requirements
- BY SUBCUTANEOUS INFUSION, OR BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION
  - Child 2–17 years: According to requirements
  - Adult: According to requirements

**FIASP ®**

**Diabetes mellitus**
- BY SUBCUTANEOUS INJECTION, OR BY INTRAVENOUS INFUSION, OR BY CONTINUOUS SUBCUTANEOUS INFUSION
  - Adult: According to requirements

**UNLICENSED USE**

Not licensed for use in children under 2 years.

**INTERACTIONS › Appendix 1: insulins**

**PREGNANCY**

Not known to be harmful—may be used during pregnancy.

**BREAST FEEDING**

Not known to be harmful—may be used during lactation.

**DIRECTIONS FOR ADMINISTRATION**

Short-acting injectable insulins can be given by continuous subcutaneous infusion using a portable infusion pump. This device delivers a continuous basal insulin infusion and patient-activated bolus doses at meal times. This technique can be useful for
patients who suffer recurrent hypoglycaemia or marked morning rise in blood-glucose concentration despite optimised multiple-injection regimens. Patients on subcutaneous insulin infusion must be highly motivated, able to monitor their blood-glucose concentration, and have expert training, advice and supervision from an experienced healthcare team.

- With intravenous use in adults. For intravenous infusion, give continuously in Glucose 5% or Sodium chloride 0.9%; dilute to 0.05–1 unit/mL with infusion fluid; adsorbed to some extent by plastics of infusion set.
- With intravenous use in children. For intravenous infusion, dilute to a concentration of 0.05–1 unit/mL with Glucose 5% or Sodium Chloride 0.9% and mix thoroughly; insulin may be adsorbed by plastics, flush giving set with 5 mL of infusion fluid containing insulin.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (type 1) (July 2008) NICE TA151

Continuous subcutaneous insulin infusion is recommended as an option in adults and children over 12 years with type 1 diabetes:

- who suffer repeated or unpredictable hypoglycaemia, whilst attempting to achieve optimal glycaemic control with multiple-injection regimens, or

- whose glycaemic control remains inadequate (HbA1c over 8.5% [69 mmol/mol]) despite optimised multiple-injection regimens (including the use of long-acting insulin analogues where appropriate).

Continuous subcutaneous insulin infusion is also recommended as an option for children under 12 years with type 1 diabetes for whom multiple-injection regimens are considered impractical or inappropriate. Children on insulin pumps should undergo a trial of multiple-injection therapy between the ages of 12 and 18 years.

www.nice.org.uk/TA151

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (April 2017) that insulin aspart (Fiasp®) is accepted for use within NHS Scotland for the treatment of diabetes mellitus in adults.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Fiasp** (Novo Nordisk Ltd) ▼
  - Insulin aspart 100 unit per 1 ml Flasp 100units/ml solution for injection 10ml vials | 1 vial £0.80 DT price = £14.08
  - **Fiasp FlexTouch** (Novo Nordisk Ltd)▼
  - Insulin aspart 100 unit per 1 ml Fiasp FlexTouch 100units/ml solution for injection 3ml pre-filled pen | 5 pre-filled disposable injection (Psp) £30.60 DT price = £30.60
  - **Fiasp Penfill** (Novo Nordisk Ltd)▼
  - Insulin aspart 100 unit per 1 ml Fiasp Penfill 100units/ml solution for injection 3ml cartridge | 5 cartridge (Psp) £28.31 DT price = £28.31
  - **NovoRapid** (Novo Nordisk Ltd)
    - Insulin aspart 100 unit per 1 ml NovoRapid 100units/ml solution for injection 10ml vials | 1 vial (Psp) £14.08 DT price = £14.08
  - **NovoRapid FlexPen** (Novo Nordisk Ltd)
    - Insulin aspart 100 unit per 1 ml NovoRapid FlexPen 100units/ml solution for injection 3ml pre-filled pen | 5 pre-filled disposable injection (Psp) £30.60 DT price = £30.60
  - **NovoRapid FlexTouch** (Novo Nordisk Ltd)
    - Insulin aspart 100 unit per 1 ml NovoRapid FlexTouch 100units/ml solution for injection 3ml pre-filled pen | 5 pre-filled disposable injection (Psp) £32.13 DT price = £32.13
  - **NovoRapid Penfill** (Novo Nordisk Ltd)
    - Insulin aspart 100 unit per 1 ml NovoRapid Penfill 100units/ml solution for injection 3ml cartridges | 5 cartridge (Psp) £28.31 DT price = £28.31
  - **NovoRapid PumpCart** (Novo Nordisk Ltd)
    - Insulin aspart 100 unit per 1 ml NovoRapid PumpCart 100units/ml solution for injection 1.6ml cartridges | 5 cartridge (Psp) £15.10

**Insulin glulisine**

*(Recombinant human insulin analogue—short acting)*

**INDICATIONS AND DOSE**

**Diabetes mellitus**

- BY SUBCUTANEOUS INJECTION
  - **Child:** Administer immediately before meals or when necessary shortly after meals, according to requirements
  - **Adult:** Administer immediately before meals or when necessary shortly after meals, according to requirements

**BY SUBCUTANEOUS INFUSION, OR BY INTRAVENOUS INFUSION**

- Child: According to requirements
- Adult: According to requirements

**UNLICENSED USE**

Not licensed for children under 6 years.

**INTERACTIONS**

→ Appendix 1: insulin

**DIRECTIONS FOR ADMINISTRATION**

Short-acting injectable insulins can be given by continuous subcutaneous infusion using a portable infusion pump. This device delivers a continuous basal insulin infusion and patient-activated bolus doses at meal times. This technique can be useful for patients who suffer recurrent hypoglycaemia or marked morning rise in blood-glucose concentration despite optimised multiple-injection regimens. Patients on subcutaneous insulin infusion must be highly motivated, able to monitor their blood-glucose concentration, and have expert training, advice and supervision from an experienced healthcare team.

- With intravenous use in adults. For intravenous infusion (Apidra®), give continuously in Sodium chloride 0.9%; dilute to 1 unit/mL with infusion fluid; use a co-extruded polyolefin/polyamide plastic infusion bag with a dedicated infusion line.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (type 1) (July 2008) NICE TA151

Continuous subcutaneous insulin infusion is recommended as an option in adults and children over 12 years with type 1 diabetes:

- who suffer repeated or unpredictable hypoglycaemia, whilst attempting to achieve optimal glycaemic control with multiple-injection regimens, or

- whose glycaemic control remains inadequate (HbA1c over 8.5% [69 mmol/mol]) despite optimised multiple-injection regimens (including the use of long-acting insulin analogues where appropriate).

Continuous subcutaneous insulin infusion is also recommended as an option for children under 12 years with type 1 diabetes for whom multiple-injection regimens are considered impractical or inappropriate. Children on insulin pumps should undergo a trial of multiple-injection therapy between the ages of 12 and 18 years.

www.nice.org.uk/TA151

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (October 2008) that Apidra® is accepted for restricted use within NHS Scotland for the treatment of adults and children over 6 years with diabetes mellitus in whom the use of a short-acting insulin analogue is appropriate.
Insulin lispro
(Recombinant human insulin analogue—short acting)

**INDICATIONS AND DOSE**

**Diabetes mellitus**

- **BY SUBCUTANEOUS INJECTION**
  - Child 2-17 years: Administer shortly before meals or when necessary shortly after meals, according to requirements
  - Adult: Administer shortly before meals or when necessary shortly after meals, according to requirements
  - **BY SUBCUTANEOUS INFUSION, OR BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION**
  - Child 2-17 years: According to requirements
  - Adult: According to requirements

**UNLICENSED USE**

Not licensed for use in children under 2 years.

**CAUTIONS**

Children under 12 years (use only if benefit likely compared to soluble insulin)

**INTERACTIONS** → Appendix 1: insulins

**PREGNANCY**

Not known to be harmful—may be used during pregnancy.

**BREAST FEEDING**

Not known to be harmful—may be used during lactation.

**DIRECTIONS FOR ADMINISTRATION**

Short-acting injectable insulins can be given by continuous subcutaneous infusion using a portable infusion pump. This device delivers a continuous basal insulin infusion and patient-activated bolus doses at meal times. This technique can be useful for patients who suffer recurrent hypoglycaemia or marked morning rise in blood-glucose concentration despite optimised multiple-injection regimens (see also NICE guidance, below). Patients on subcutaneous insulin infusion must be highly motivated, able to monitor their blood-glucose concentration, and have expert training, advice and supervision from an experienced healthcare team.

- With intravenous use in adults For intravenous infusion give continuously in Glucose 5% or Sodium chloride 0.9%. Adsorbed to some extent by plastics of infusion set.
- With intravenous use in children For intravenous infusion, dilute to a concentration of 0.1–1 unit/mL with Glucose 5% or Sodium Chloride 0.9% and mix thoroughly; insulin may be adsorbed by plastics, flush giving set with 5 mL of infusion fluid containing insulin.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (type 1) (July 2008) NICE TA151

Continuous subcutaneous insulin infusion is recommended as an option in adults and children over 12 years with type 1 diabetes:

- who suffer repeated or unpredictable hypoglycaemia, whilst attempting to achieve optimal glycaemic control with multiple-injection regimens, or
- whose glycaemic control remains inadequate (HbA\textsubscript{c} over 8.5% [69 mmol/mol]) despite optimised multiple-injection regimens (including the use of long-acting insulin analogues where appropriate).

Continuous subcutaneous insulin infusion is also recommended as an option for children under 12 years with type 1 diabetes for whom multiple-injection regimens are considered impractical or inappropriate. Children on insulin pumps should undergo a trial of multiple-injection therapy between the ages of 12 and 18 years.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Apidra** (Sanofi)
  - Insulin glulisine 100 unit per 1 ml Apidra® 100 units/ml solution for injection 10 ml vials | 1 vial | £16.00
  - Apidra 100 units/ml solution for injection 3ml cartridges | 5 cartridge | £28.30
- **Apidra SoloStar** (Sanofi)
  - Insulin glulisine 100 unit per 1 ml Apidra® 100 units/ml solution for injection 3ml pre-filled SoloStar pen | 5 pre-filled disposable injection | £28.30 DT price + £28.30

- **Humalog** (Eli Lilly and Company Ltd)
  - Humalog insulin lispro 100 unit per 1 ml Humalog® 100 units/ml solution for injection 10 ml vials | 1 vial | £16.61 DT price + £16.61
  - Humalog 100 units/ml solution for injection 3ml cartridges | 5 cartridge | £28.31 DT price + £28.31
- **Humalog KwikPen** (Eli Lilly and Company Ltd)
  - Humalog insulin lispro 100 unit per 1 ml Humalog® 100 units/ml solution for injection 3ml pre-filled pen | 5 pre-filled disposable injection | £29.46 DT price + £29.46
  - Humalog KwikPen insulin lispro 200 unit per 1 ml Humalog® 200 units/ml solution for injection 3ml pre-filled pen | 5 pre-filled disposable injection | £58.92

**Diabetes mellitus, diagnostic and monitoring devices**

**Urinalysis**

Reagent strips are available for measuring for glucose in the urine. Tests for ketones by patients are rarely required unless they become unwell—see Blood Monitoring.

Microalbuminuria can be detected with Micral-Test II® but this should be followed by confirmation in the laboratory, since false positive results are common.

**Blood monitoring**

Blood glucose monitoring using a meter gives a direct measure of the glucose concentration at the time of the test and can detect hypoglycaemia as well as hyperglycaemia. Patients should be properly trained in the use of blood glucose monitoring systems and to take appropriate action on the results obtained. Inadequate understanding of the normal fluctuations in blood glucose can lead to confusion and inappropriate action.

Patients using multiple injection regimens should understand how to adjust their insulin dose according to their carbohydrate intake. With fixed-dose insulin regimens, the carbohydrate intake needs to be regulated, and should be distributed throughout the day to match the insulin regimen. Self-monitoring of blood-glucose concentration is appropriate for patients with type 2 diabetes:

- who are treated with insulin;
- who are treated with oral hypoglycaemic drugs e.g. sulfonylureas, to provide information on hypoglycaemia;
- to monitor changes in blood-glucose concentration resulting from changes in lifestyle or medication, and during intercurrent illness;
- to ensure safe blood-glucose concentration during activities, including driving.
In the UK blood-glucose concentration is expressed in mmol/litre and Diabetes UK advises that these units should be used for self-monitoring of blood glucose. In other European countries units of mg/100 mL (or mg/dL) are commonly used.

It is advisable to check that the meter is pre-set in the correct units. If the patient is unwell and diabetic ketoacidosis is suspected, blood ketones should be measured according to local guidelines. Patients and their carers should be trained in the use of blood ketone monitoring systems and to take appropriate action on the results obtained, including when to seek medical attention.

Other drugs used for Diabetes, diagnosis and monitoring Glucose, p. 955

**Blood monitoring test strips**

- **BLOOD GLUCOSE TESTING STRIPS**
  - Accu-Chek Inform II testing strips (Roche Diagnostics Ltd) 50strip - NHS indicative price £9.95 - Drug Tariff (Part IXr)
  - Active testing strips (Roche Diabetes Care Ltd) 50strip - NHS indicative price £14.73 - Drug Tariff (Part IXr)
  - Advocate Redi-Code+ testing strips (Diabetes Care Technology Ltd) 50strip - NHS indicative price £9.95 - Drug Tariff (Part IXr)
  - AutoSense testing strips (Advance Diagnostic Products (NI) Ltd) 25strip - NHS indicative price £4.50 - Drug Tariff (Part IXr)
  - Aviva testing strips (Roche Diabetes Care Ltd) 50strip - NHS indicative price £15.96 - Drug Tariff (Part IXr)
  - BGStar testing strips (Sanofi) 50strip - NHS indicative price £14.73 - Drug Tariff (Part IXr)
  - Betachek C50 cassette (National Diagnostic Products) 100device - NHS indicative price £29.98 - Drug Tariff (Part IXr)
  - Betachek G5 testing strips (National Diagnostic Products) 50strip - NHS indicative price £14.19 - Drug Tariff (Part IXr)
  - Betachek Visual testing strips (National Diagnostic Products) 50strip - NHS indicative price £6.80 - Drug Tariff (Part IXr)
  - Breeze 2 testing discs (Bayer Plc) 50strip - NHS indicative price £15.00 - Drug Tariff (Part IXr)
  - CareSens N testing strips (Spirit Healthcare Ltd) 50strip - NHS indicative price £12.75 - Drug Tariff (Part IXr)
  - CareSens PRO testing strips (Spirit Healthcare Ltd) 50strip - NHS indicative price £9.95 - Drug Tariff (Part IXr)
  - Compact testing strips (Roche Diabetes Care Ltd) 51strip - NHS indicative price £16.39 - Drug Tariff (Part IXr)
  - Contour Next testing strips (Bayer Diagnostics Manufacturing Ltd) 50strip - NHS indicative price £13.04 - Drug Tariff (Part IXr)
  - Contour TS testing strips (Bayer Diagnostics Manufacturing Ltd) 50strip - NHS indicative price £9.50 - Drug Tariff (Part IXr)
  - Contour testing strips (Bayer Diagnostics Manufacturing Ltd) 50strip - NHS indicative price £9.50 - Drug Tariff (Part IXr)
  - Dario Lite testing strips (LabStyle Innovations Ltd) 50strip - NHS indicative price £9.95 - Drug Tariff (Part IXr)
  - Dario testing strips (LabStyle Innovations Ltd) 50strip - NHS indicative price £14.95 - Drug Tariff (Part IXr)
  - Diastix testing strips (Bayer Diagnostics Manufacturing Ltd) 50strip - NHS indicative price £2.89 - Drug Tariff (Part IXr)
  - Element testing strips (Neon Diagnostics Ltd) 50strip - NHS indicative price £9.89 - Drug Tariff (Part IXr)
  - Finetest Lite testing strips (Neon Diagnostics Ltd) 50strip - NHS indicative price £5.95 - Drug Tariff (Part IXr)
  - FreeStyle Lite testing strips (Abbott Laboratories Ltd) 50strip - NHS indicative price £15.97 - Drug Tariff (Part IXr)
  - FreeStyle Optimum testing strips (Abbott Laboratories Ltd) 50strip - NHS indicative price £15.87 - Drug Tariff (Part IXr)
  - FreeStyle testing strips (Abbott Laboratories Ltd) 50strip - NHS indicative price £15.97 - Drug Tariff (Part IXr)
  - GluNEO testing strips (Neon Diagnostics Ltd) 50strip - NHS indicative price £9.89 - Drug Tariff (Part IXr)
  - GlucoDock testing strips (Medisana Healthcare (UK) Ltd) 50strip - NHS indicative price £14.90 - Drug Tariff (Part IXr)
  - GlucoLab testing strips (Neon Diagnostics Ltd) 50strip - NHS indicative price £9.89 - Drug Tariff (Part IXr)
  - GlucoMen GM testing strips (A Menarini Diagnostics Ltd) 50strip - NHS indicative price £9.95 - Drug Tariff (Part IXr)
  - GlucoMen LX Sensor testing strips (A Menarini Diagnostics Ltd) 50strip - NHS indicative price £15.76 - Drug Tariff (Part IXr)
  - GlucoMen Visio testing strips (A Menarini Diagnostics Ltd) 50strip - NHS indicative price £15.75 - Drug Tariff (Part IXr)
  - GlucoMen areo Sensor testing strips (A Menarini Diagnostics Ltd) 50strip - NHS indicative price £9.95 - Drug Tariff (Part IXr)
  - GlucoNavii testing strips (Neon Diagnostics Ltd) 50strip - NHS indicative price £8.95 - Drug Tariff (Part IXr)
  - GlucoRx GO testing strips (GlucoRx Ltd) 50strip - NHS indicative price £9.95 - Drug Tariff (Part IXr)
  - GlucoRx HCT Glucose testing strips (GlucoRx Ltd) 50strip - NHS indicative price £9.95 - Drug Tariff (Part IXr)
  - GlucoRx Nexus testing strips (GlucoRx Ltd) 50strip - NHS indicative price £9.95 - Drug Tariff (Part IXr)
  - GlucoRx Q testing strips (GlucoRx Ltd) 50strip - NHS indicative price £6.95 - Drug Tariff (Part IXr)
  - GlucoZen.auto testing strips (GlucoZen Ltd) 50strip - NHS indicative price £7.64 - Drug Tariff (Part IXr)
  - Glucoflex-R testing strips (Bio-Diagnostics Ltd) 50strip - NHS indicative price £6.75 - Drug Tariff (Part IXr)
  - IME-DC testing strips (Arctic Medical Ltd) 50strip - NHS indicative price £14.10 - Drug Tariff (Part IXr)
  - MODZ testing strips (Modz Dy) 50strip - NHS indicative price £14.00 - Drug Tariff (Part IXr)
  - Medi-Test Glucose testing strips (BHR Pharmaceuticals Ltd) 50strip - NHS indicative price £2.33 - Drug Tariff (Part IXr)
  - Medisense SoftSense testing strips (Abbott Laboratories Ltd) 50strip - NHS indicative price £15.95 - Drug Tariff (Part IXr)
  - MediTouch 2 testing strips (Medisana Healthcare (UK) Ltd) 50strip - NHS indicative price £12.43 - Drug Tariff (Part IXr)
  - MediTouch testing strips (Medisana Healthcare (UK) Ltd) 50strip - NHS indicative price £14.90 - Drug Tariff (Part IXr)
  - Mendor Discreet testing strips (SpringMed Solutions Ltd) 50strip - NHS indicative price £14.75 - Drug Tariff (Part IXr)
  - Microdot+ testing strips (Cambridge Sensors Ltd) 50strip - NHS indicative price £9.49 - Drug Tariff (Part IXr)
  - Mission Glucose testing strips (Spirit Healthcare Ltd) 50strip - NHS indicative price £2.29 - Drug Tariff (Part IXr)
  - Mobile cassette (Roche Diabetes Care Ltd) 50device - NHS indicative price £16.24 - Drug Tariff (Part IXr)
  - Myglucohealth testing strips (Entra Health Systems Ltd) 50strip - NHS indicative price £15.50 - Drug Tariff (Part IXr)
  - Mylefe Pura testing strips (Yposmed Ltd) 50strip - NHS indicative price £9.50 - Drug Tariff (Part IXr)
  - Mylefe Unio testing strips (Yposmed Ltd) 50strip - NHS indicative price £9.50 - Drug Tariff (Part IXr)
  - Omnitest 3 testing strips (B.Braun Medical Ltd) 50strip - NHS indicative price £9.89 - Drug Tariff (Part IXr)
  - Omnitest 5 testing strips (B.Braun Medical Ltd) 50strip - NHS indicative price £9.89 - Drug Tariff (Part IXr)
  - On-Call Advanced testing strips (Point Of Care Testing Ltd) 50strip - NHS indicative price £13.65 - Drug Tariff (Part IXr)
  - OneTouch Select Plus testing strips (LifeScan) 50strip - NHS indicative price £9.99 - Drug Tariff (Part IXr)
  - OneTouch Ultra testing strips (LifeScan) 50strip - NHS indicative price £9.99 - Drug Tariff (Part IXr)
  - OneTouch Verio testing strips (LifeScan) 50strip - NHS indicative price £15.12 - Drug Tariff (Part IXr)
  - OneTouch Vita testing strips (LifeScan) 50strip - NHS indicative price £15.07 - Drug Tariff (Part IXr)
  - Performax testing strips (Roche Diabetes Care Ltd) 50strip - NHS indicative price £9.95 - Drug Tariff (Part IXr)
## Meters and test strips

<table>
<thead>
<tr>
<th>Meter (all)</th>
<th>Type of monitoring</th>
<th>Compatible test strips</th>
<th>Test strip net price</th>
<th>Sensitivity range (mmol/litre)</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accu-Chek® Active</td>
<td>Blood glucose</td>
<td>Active®</td>
<td>50 strip = £9.95</td>
<td>0.6-33.3 mmol/litre</td>
<td>Roche Diabetes Care Ltd</td>
</tr>
<tr>
<td>Accu-Chek® Advantage Meter no longer available</td>
<td>Blood glucose</td>
<td>Advantage Plus®</td>
<td>50 strip = £0.00</td>
<td>0.6-33.3 mmol/litre</td>
<td>Roche Diabetes Care Ltd</td>
</tr>
<tr>
<td>Accu-Chek® Aviva</td>
<td>Blood glucose</td>
<td>Aviva®</td>
<td>50 strip = £15.96</td>
<td>0.6-33.3 mmol/litre</td>
<td>Roche Diabetes Care Ltd</td>
</tr>
<tr>
<td>Accu-Chek® Aviva Expert</td>
<td>Blood glucose</td>
<td>Aviva®</td>
<td>50 strip = £15.96</td>
<td>0.6-33.3 mmol/litre</td>
<td>Roche Diabetes Care Ltd</td>
</tr>
<tr>
<td>Accu-Chek® Compact Plus Meter no longer available</td>
<td>Blood glucose</td>
<td>Compact®</td>
<td>3 × 17 strips = £16.39</td>
<td>0.6-33.3 mmol/litre</td>
<td>Roche Diabetes Care Ltd</td>
</tr>
<tr>
<td>Accu-Chek® Mobile</td>
<td>Blood glucose</td>
<td>Mobile®</td>
<td>100 device = £0.00</td>
<td>0.3-33.3 mmol/litre</td>
<td>Roche Diabetes Care Ltd</td>
</tr>
<tr>
<td>Accu-Chek® Aviva Nano</td>
<td>Blood glucose</td>
<td>Aviva®</td>
<td>50 strip = £15.96</td>
<td>0.6-33.3 mmol/litre</td>
<td>Roche Diabetes Care Ltd</td>
</tr>
<tr>
<td>BGStar® Free of charge from diabetes healthcare professionals</td>
<td>Blood glucose</td>
<td>BGStar®</td>
<td>50 strip = £14.73</td>
<td>1.1-33.3 mmol/litre</td>
<td>Sanofi</td>
</tr>
<tr>
<td>Breeze 2®</td>
<td>Blood glucose</td>
<td>Breeze 2®</td>
<td>50 strip = £15.00</td>
<td>0.6-33.3 mmol/litre</td>
<td>Bayer Plc</td>
</tr>
<tr>
<td>CareSens N® Free of charge from diabetes healthcare professionals</td>
<td>Blood glucose</td>
<td>CareSens N®</td>
<td>50 strip = £12.75</td>
<td>1.1-33.3 mmol/litre</td>
<td>Spirit Healthcare Ltd</td>
</tr>
<tr>
<td>Contour®</td>
<td>Blood glucose</td>
<td>Contour®</td>
<td>50 strip = £9.95</td>
<td>0.6-33.3 mmol/litre</td>
<td>Bayer Diagnostics Manufacturing Ltd</td>
</tr>
<tr>
<td>Contour® XT</td>
<td>Blood glucose</td>
<td>Contour® Next</td>
<td>50 strip = £15.04</td>
<td>0.6-33.3 mmol/litre</td>
<td>Bayer Diagnostics Manufacturing Ltd</td>
</tr>
<tr>
<td>Element®</td>
<td>Blood glucose</td>
<td>Element®</td>
<td>50 strip = £9.89</td>
<td>0.55-33.3 mmol/litre</td>
<td>Neon Diagnostics Ltd</td>
</tr>
<tr>
<td>FreeStyle® Meter no longer available</td>
<td>Blood glucose</td>
<td>FreeStyle®</td>
<td>50 strip = £15.97</td>
<td>1.1-27.8 mmol/litre</td>
<td>Abbott Laboratories Ltd</td>
</tr>
<tr>
<td>FreeStyle Freedom® Meter no longer available</td>
<td>Blood glucose</td>
<td>FreeStyle®</td>
<td>50 strip = £15.97</td>
<td>1.1-27.8 mmol/litre</td>
<td>Abbott Laboratories Ltd</td>
</tr>
<tr>
<td>FreeStyle Freedom Lite®</td>
<td>Blood glucose</td>
<td>FreeStyle Lite®</td>
<td>50 strip = £15.97</td>
<td>1.1-27.8 mmol/litre</td>
<td>Abbott Laboratories Ltd</td>
</tr>
<tr>
<td>FreeStyle InsuLinx®</td>
<td>Blood glucose</td>
<td>FreeStyle Lite®</td>
<td>50 strip = £15.97</td>
<td>1.1-27.8 mmol/litre</td>
<td>Abbott Laboratories Ltd</td>
</tr>
<tr>
<td>FreeStyle Lite®</td>
<td>Blood glucose</td>
<td>FreeStyle Lite®</td>
<td>50 strip = £15.97</td>
<td>1.1-27.8 mmol/litre</td>
<td>Abbott Laboratories Ltd</td>
</tr>
<tr>
<td>FreeStyle Mini® Meter no longer available</td>
<td>Blood glucose</td>
<td>FreeStyle®</td>
<td>50 strip = £15.97</td>
<td>1.1-27.8 mmol/litre</td>
<td>Abbott Laboratories Ltd</td>
</tr>
<tr>
<td>FreeStyle Optium®</td>
<td>Blood glucose</td>
<td>FreeStyle Optium®</td>
<td>50 strip = £15.87</td>
<td>1.1-27.8 mmol/litre</td>
<td>Abbott Laboratories Ltd</td>
</tr>
<tr>
<td>FreeStyle Optium®</td>
<td>Blood ketones</td>
<td>FreeStyle Optium®/β-ketone</td>
<td>10 strip = £21.36</td>
<td>0-8.0 mmol/litre</td>
<td>Abbott Laboratories Ltd</td>
</tr>
<tr>
<td>FreeStyle Optium Neo®</td>
<td>Blood glucose</td>
<td>FreeStyle Optium®</td>
<td>50 strip = £15.87</td>
<td>1.1-27.8 mmol/litre</td>
<td>Abbott Laboratories Ltd</td>
</tr>
<tr>
<td>FreeStyle Optium Neo®</td>
<td>Blood ketones</td>
<td>FreeStyle Optium®/β-ketone</td>
<td>10 strip = £21.36</td>
<td>0-8.0 mmol/litre</td>
<td>Abbott Laboratories Ltd</td>
</tr>
<tr>
<td>GlucoDock® module</td>
<td>Blood glucose</td>
<td>GlucoDock®</td>
<td>50 strip = £14.90</td>
<td>1.1-33.3 mmol/litre</td>
<td>Medisana Healthcare (UK) Ltd</td>
</tr>
<tr>
<td>GlucoLab®</td>
<td>Blood glucose</td>
<td>GlucoLab®</td>
<td>50 strip = £9.89</td>
<td>0.55-33.3 mmol/litre</td>
<td>Neon Diagnostics Ltd</td>
</tr>
<tr>
<td>GlucoMen® GM</td>
<td>Blood glucose</td>
<td>GlucoMen® GM</td>
<td>50 strip = £9.95</td>
<td>0.6-33.3 mmol/litre</td>
<td>Neon Diagnostics Ltd</td>
</tr>
</tbody>
</table>
## Endocrine system

### Diabetes mellitus and hypoglycaemia

<table>
<thead>
<tr>
<th>Meter (all NHS)</th>
<th>Type of monitoring</th>
<th>Compatible test strips</th>
<th>Test strip net price</th>
<th>Sensitivity range (mmol/litre)</th>
<th>Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>GlucoMen® LX</td>
<td>Blood glucose</td>
<td>GlucoMen® LX Sensor</td>
<td>50 strip = £15.76</td>
<td>1.1-33.3 mmol/litre</td>
<td>A Menarini Diagnostics Ltd</td>
</tr>
<tr>
<td>GlucoMen® LX Plus</td>
<td>Blood glucose</td>
<td>GlucoMen® LX Sensor</td>
<td>50 strip = £15.76</td>
<td>1.1-33.3 mmol/litre</td>
<td>A Menarini Diagnostics Ltd</td>
</tr>
<tr>
<td>GlucoMen® LX Plus</td>
<td>Blood ketones</td>
<td>GlucoMen® LX Ketone</td>
<td>10 strip = £21.06</td>
<td>0-0.8 mmol/litre</td>
<td>A Menarini Diagnostics Ltd</td>
</tr>
<tr>
<td>GlucoMen® Visio</td>
<td>Blood glucose</td>
<td>GlucoMen® Visio Sensor</td>
<td>50 strip = £15.75</td>
<td>1.1-33.3 mmol/litre</td>
<td>A Menarini Diagnostics Ltd</td>
</tr>
<tr>
<td>GlucoRx®</td>
<td>Free of charge from diabetes healthcare professionals</td>
<td>Blood glucose</td>
<td>GlucoRx®</td>
<td>50 strip = £6.95</td>
<td>1.1-33.3 mmol/litre</td>
</tr>
<tr>
<td>GlucoRx Nexus®</td>
<td>Free of charge from diabetes healthcare professionals</td>
<td>Blood glucose</td>
<td>GlucoRx Nexus®</td>
<td>50 strip = £9.95</td>
<td>1.1-33.3 mmol/litre</td>
</tr>
<tr>
<td>Glucotrend®</td>
<td>Meter no longer available</td>
<td>Blood glucose</td>
<td>Active®</td>
<td>50 strip = £9.95</td>
<td>0.6-33.3 mmol/litre</td>
</tr>
<tr>
<td>iBGStar®</td>
<td>Blood glucose</td>
<td>BGStar®</td>
<td>50 strip = £14.73</td>
<td>1.1-33.3 mmol/litre</td>
<td>Sanofi</td>
</tr>
<tr>
<td>IME-DC®</td>
<td>Blood glucose</td>
<td>IME-DC®</td>
<td>50 strip = £14.10</td>
<td>1.1-33.3 mmol/litre</td>
<td>Arctic Medical Ltd</td>
</tr>
<tr>
<td>Mendor Discreet®</td>
<td>Blood glucose</td>
<td>Mendor Discreet®</td>
<td>50 strip = £14.75</td>
<td>1.1-33.3 mmol/litre</td>
<td>SpringMed Solutions Ltd</td>
</tr>
<tr>
<td>Microdot®+</td>
<td>Free of charge from diabetes healthcare professionals</td>
<td>Blood glucose</td>
<td>Microdot®+</td>
<td>50 strip = £9.49</td>
<td>1.1-29.2 mmol/litre</td>
</tr>
<tr>
<td>MyGlucoHealth®</td>
<td>Blood glucose</td>
<td>MyGlucoHealth®</td>
<td>50 strip = £15.50</td>
<td>0.6-33.3 mmol/litre</td>
<td>Entra Health Systems Ltd</td>
</tr>
<tr>
<td>Omnitest® 3</td>
<td>Blood glucose</td>
<td>Omnitest® 3</td>
<td>50 strip = £9.89</td>
<td>0.6-33.3 mmol/litre</td>
<td>B. Braun Medical Ltd</td>
</tr>
<tr>
<td>One Touch Ultra®</td>
<td>Blood glucose</td>
<td>One Touch Ultra®</td>
<td>50 strip = £9.99</td>
<td>1.1-33.3 mmol/litre</td>
<td>LifeScan</td>
</tr>
<tr>
<td>One Touch Ultra® 2®</td>
<td>Blood glucose</td>
<td>One Touch Ultra® 2®</td>
<td>50 strip = £9.99</td>
<td>1.1-33.3 mmol/litre</td>
<td>LifeScan</td>
</tr>
<tr>
<td>One Touch UltraEasy®</td>
<td>Blood glucose</td>
<td>One Touch UltraEasy®</td>
<td>50 strip = £9.99</td>
<td>1.1-33.3 mmol/litre</td>
<td>LifeScan</td>
</tr>
<tr>
<td>One Touch UltraSmart®</td>
<td>Blood glucose</td>
<td>One Touch UltraSmart®</td>
<td>50 strip = £9.99</td>
<td>1.1-33.3 mmol/litre</td>
<td>LifeScan</td>
</tr>
<tr>
<td>One Touch® Verio</td>
<td>Blood glucose</td>
<td>One Touch® Verio</td>
<td>50 strip = £15.12</td>
<td>1.1-33.3 mmol/litre</td>
<td>LifeScan</td>
</tr>
<tr>
<td>One Touch® Vita</td>
<td>Blood glucose</td>
<td>One Touch® Vita</td>
<td>50 strip = £15.07</td>
<td>1.1-33.3 mmol/litre</td>
<td>LifeScan</td>
</tr>
<tr>
<td>SD CodeFree®</td>
<td>Blood glucose</td>
<td>SD CodeFree®</td>
<td>50 strip = £6.99</td>
<td>0.6-33.3 mmol/litre</td>
<td>SD Biosensor Inc</td>
</tr>
<tr>
<td>Sensocard Plus®</td>
<td>Meter no longer available</td>
<td>Blood glucose</td>
<td>Sensocard®</td>
<td>50 strip = £16.30</td>
<td>1.1-33.3 mmol/litre</td>
</tr>
<tr>
<td>Meter (all NHS)</td>
<td>Type of monitoring</td>
<td>Compatible test strips</td>
<td>Test strip net price</td>
<td>Sensitivity range (mmol/litre)</td>
<td>Manufacturer</td>
</tr>
<tr>
<td>----------------</td>
<td>--------------------</td>
<td>------------------------</td>
<td>----------------------</td>
<td>-----------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>SuperCheck2® Free of charge from diabetes healthcare professionals</td>
<td>Blood glucose</td>
<td>SuperCheck2®</td>
<td>50 strip = £8.49</td>
<td>1.1-33.3 mmol/litre</td>
<td>Apollo Medical Technologies Ltd</td>
</tr>
<tr>
<td>TRUEone® All-in-one test strips and meter</td>
<td>Blood glucose</td>
<td>TRUEone®</td>
<td>50 strip = £0.00</td>
<td>1.1-33.3 mmol/litre</td>
<td>Nipro Diagnostics (UK) Ltd</td>
</tr>
<tr>
<td>TRUEresult® Free of charge from diabetes healthcare professionals</td>
<td>Blood glucose</td>
<td>TRUEresult®</td>
<td>50 strip = £14.99</td>
<td>1.1-33.3 mmol/litre</td>
<td>Nipro Diagnostics (UK) Ltd</td>
</tr>
<tr>
<td>TRUEresult twist® Free of charge from diabetes healthcare professionals</td>
<td>Blood glucose</td>
<td>TRUEresult®</td>
<td>50 strip = £14.99</td>
<td>1.1-33.3 mmol/litre</td>
<td>Nipro Diagnostics (UK) Ltd</td>
</tr>
<tr>
<td>TRUEtrack® Free of charge from diabetes healthcare professionals</td>
<td>Blood glucose</td>
<td>TRUEtrack®</td>
<td>50 strip = £14.99</td>
<td>1.1-33.3 mmol/litre</td>
<td>Nipro Diagnostics (UK) Ltd</td>
</tr>
<tr>
<td>TRUEyou mini®</td>
<td>Blood glucose</td>
<td>TRUEyou®</td>
<td>50 strip = £9.92</td>
<td>1.1-33.3 mmol/litre</td>
<td>Nipro Diagnostics (UK) Ltd</td>
</tr>
<tr>
<td>WaveSense JAZZ® Free of charge from diabetes healthcare professionals</td>
<td>Blood glucose</td>
<td>WaveSense JAZZ®</td>
<td>50 strip = £9.87</td>
<td>1.1-33.3 mmol/litre</td>
<td>AgaMatrix Europe Ltd</td>
</tr>
</tbody>
</table>

### BLOOD KETONES TESTING STRIPS

- **FreeStyle Optium beta-ketone testing strips** (Abbott Laboratories Ltd) | 10strip - NHS indicative price = £21.36 - Drug Tariff (Part IXr)
- **GlucoMen LX beta-ketone testing strips** (A Menarini Diagnostics Ltd) | 10strip - NHS indicative price = £21.06 - Drug Tariff (Part IXr)
- **GlucoMen areo Ketone Sensor testing strips** (A Menarini Diagnostics Ltd) | 10strip - NHS indicative price = £9.95 - Drug Tariff (Part IXr)
- **GlucoRx HCT Ketone testing strips** (GlucoRx Ltd) | 10strip - NHS indicative price = £9.95 - Drug Tariff (Part IXr)
- **KetoSens testing strips** (Spirit Healthcare Ltd) | 10strip - NHS indicative price = £9.95 - Drug Tariff (Part IXr)

### Hypodermic insulin injection pens

- **AUTOOPEN® 24**
  - **Autopen® 24** (for use with Sanofi- Aventis 3-mL insulin cartridges), allowing 1-unit dosage adjustment, max. 21 units (single-unit version) or 2-unit dosage adjustment, max. 42 units (2-unit version).
- **Autopen 24 hypodermic insulin injection pen reusable for 3ml cartridge 1 unit dial up / range 1-21 units** (Owen Mumford Ltd)
  - 1device - NHS indicative price = £16.47 - Drug Tariff (Part IXa)
- **Autopen 24 hypodermic insulin injection pen reusable for 3ml cartridge 2 unit dial up / range 2-42 units** (Owen Mumford Ltd)
  - 1device - NHS indicative price = £16.47 - Drug Tariff (Part IXa)

- **AUTOOPEN® CLASSIC**
  - **Autoopen® Classic** (for use with Lilly and Wockhardt 3-mL insulin cartridges), allowing 1-unit dosage adjustment, max. 21 units (single-unit version) or 2-unit dosage adjustment, max. 42 units (2-unit version).
- **Autoopen Classic hypodermic insulin injection pen reusable for 3ml cartridge 1 unit dial up / range 1-21 units** (Owen Mumford Ltd)
  - 1device - NHS indicative price = £16.72 - Drug Tariff (Part IXa)
- **Autoopen Classic hypodermic insulin injection pen reusable for 3ml cartridge 2 unit dial up / range 2-42 units** (Owen Mumford Ltd)
  - 1device - NHS indicative price = £16.72 - Drug Tariff (Part IXa)
3.2 Hypoglycaemia

Hypoglycaemia

Treatment of hypoglycaemia

Initially glucose 10–20 g is given by mouth either in liquid form or as granulated sugar or sugar lumps. If necessary this may be repeated after 10–15 minutes. After initial treatment, a snack providing sustained availability of carbohydrate (e.g. a sandwich, fruit, milk, or biscuits) or the next meal (if it is due) can prevent blood-glucose concentration from falling again.

Proprietary products of quick-acting carbohydrate (e.g. GlucoGel®, DextroGel®, GSF-Syrup®, Rapilose® gel) are available on prescription for patients to keep on hand in case of hypoglycaemia.

Alternatively, approximately 10 g of glucose is available from 2 teaspoons of sugar, or from 3 sugar lumps, and also from non-diet versions of the following soft drinks: 110 mL of Lucozade® Energy Original® (also, see note below), 100 mL of Coca-Cola®, 19 mL of Ribena® Blackcurrant (to be diluted). Note: the carbohydrate content of some commercially available glucose-containing drinks is currently subject to change—individual product labels should be checked. Patients should be aware that for a time, both old and new bottles and cans may be available—individual product labels should be checked.

Hypoglycaemia which causes unconsciousness is an emergency. Glucagon p. 681, a polypeptide hormone produced by the alpha cells of the islets of Langerhans, increases plasma-glucose concentration by mobilising glycogen stored in the liver. In hypoglycaemia, if sugar cannot be given by mouth, glucagon can be given by injection. Carbohydrates should be given as soon as possible to restore liver glycogen; glucagon is not appropriate for chronic hypoglycaemia. Glucagon may be issued to close relatives of insulin-treated patients for emergency use in hypoglycaemic attacks. It is often advisable to prescribe on an “if necessary” basis to hospitalised insulin-treated patients, so that it may be given rapidly by the nurses during an hypoglycaemic emergency. If not effective in 10 minutes intravenous glucose should be given.

Alternatively, glucose intravenous infusion 20% may be given intravenously into a large vein through a large-gauge needle; care is required since this concentration is irritating especially if extravasation occurs. Glucose intravenous infusion 10% may also be used but larger volumes are needed. Glucose intravenous infusion 50% is not recommended because of the higher risk of extravasation injury and because administration is difficult. Close monitoring is necessary in the case of an overdose with a long-acting insulin because further administration of glucose may be required. Patients whose hypoglycaemia is caused by an oral antidiabetic drug should be transferred to hospital because the hypoglycaemic effects of these drugs may persist for many hours.

See also, emergency management of hypoglycaemia in dental practice for further advice.

Chronic hypoglycaemia

Diazoxxe p. 681, administered by mouth, is useful in the management of patients with chronic hypoglycaemia from
excess endogenous insulin secretion, either from an islet cell tumour or islet cell hyperplasia. It has no place in the management of acute hypoglycaemia.

**GLYCOGENOLYTIC HORMONES**

**Glucagon**

- **INDICATIONS AND DOSE**
  - **Insulin-induced hypoglycaemia**
    - By subcutaneous injection, or by intramuscular injection
  - **Child 1 month–1 year**: 500 micrograms
  - **Child 2–7 years (body weight up to 25 kg)**: 500 micrograms, if no response within 10 minutes intravenous glucose must be given
  - **Child 2–7 years (body weight 25 kg and above)**: 1 mg, if no response within 10 minutes intravenous glucose must be given
  - **Adult**: 1 mg, if no response within 10 minutes intravenous glucose must be given

- **Beta-blocker poisoning (cardiogenic shock unresponsive to atropine)**
  - Initially by intravenous injection
  - **Child**: 50–150 micrograms/kg (max. per dose 10 mg), to be administered in glucose 5% (with precautions to protect the airway in case of vomiting), followed by (by intravenous infusion) 50 micrograms/kg/hour
  - **Adult**: 2–10 mg, to be administered in glucose 5% (with precautions to protect the airway in case of vomiting), followed by (by intravenous infusion) 50 micrograms/kg/hour

- **Diagnostic aid**
  - By intravenous injection, or by intramuscular injection
  - **Adult**: (consult product literature)

- **DOSE EQUIVALENCE AND CONVERSION**
  - 1 unit of glucagon = 1 mg of glucagon.

- **UNLICENSED USE** Dose and indication for cardiogenic shock unresponsive to atropine in beta-blocker overdose not licensed.

- **CONTRA-INDICATIONS** Phaeochromocytoma

- **CAUTIONS** Glucagonoma - ineffective in chronic hypoglycaemia, starvation, and adrenal insufficiency - insulinoma

- **INTERACTIONS** → Appendix 1: glucagon

- **SIDE-EFFECTS**
  - Rare
  - Hypersensitivity reactions
  - Frequency not known
  - Abdominal pain (in adults) - diarrhoea (in children) - hypokalaemia - hypotension (in adults) - nausea - vomiting

- **DIRECTIONS FOR ADMINISTRATION**
  - With intravenous use in children. When administered by continuous intravenous infusion, do not add to infusion fluids containing calcium—precipitation may occur.

- **PATIENT AND CARER ADVICE**
  - Medicines for Children leaflet: Glucagon for hypoglycaemia
  - www.medicinesforchildren.org.uk/glucagon-for-hypoglycaemia

- **EXCEPTIONS TO LEGAL CATEGORY** Prescription-only medicine restriction does not apply where administration is for saving life in emergency.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

**THIAZIDE DERIVATIVES**

**Diazoxide**

- **INDICATIONS AND DOSE**
  - **Chronic intractable hypoglycaemia**
    - By mouth
  - **Adult**: Initially 5 mg/kg daily in 2–3 divided doses, adjusted according to response; maintenance 3–8 mg/kg daily in 2–3 divided doses

- **CAUTIONS** Aortic coarctation - aortic stenosis - arteriovenous shunt - heart failure - hyperuricaemia - impaired cardiac circulation - impaired cerebral circulation

- **INTERACTIONS** → Appendix 1: diazoxide


- **PREGNANCY** Use only if essential; alopecia and hypertrichosis reported in neonates with prolonged use; may inhibit uterine activity during labour.

- **BREAST FEEDING** Manufacturer advises avoid—no information available.

- **RENAI IMPAIRMENT** Dose reduction may be required.

- **MONITORING REQUIREMENTS**
  - Monitor blood pressure.
  - Monitor white cell and platelet count during prolonged use.

**Disorders of bone metabolism**

**Bone metabolism**

**Osteoporosis**

Osteoporosis occurs most commonly in postmenopausal women and in those taking long-term oral corticosteroids (glucocorticosteroids). Other risk factors for osteoporosis include low body weight, cigarette smoking, excess alcohol intake, lack of physical activity, family history of osteoporosis, and early menopause.
Those at risk of osteoporosis should maintain an adequate intake of **calcium and vitamin D** and any deficiency should be corrected by increasing dietary intake or taking supplements.

Elderly patients, especially those who are housebound or live in residential or nursing homes, are at increased risk of calcium and vitamin D deficiency and may benefit from supplements. Reversible secondary causes of osteoporosis such as hyperthyroidism, hyperparathyroidism, osteomalacia or hypogonadism should be excluded, in both men and women, before treatment for osteoporosis is initiated.

Also see: calcium, phosphorus, vitamin D and oestrogens in postmenopausal osteoporosis.

**Postmenopausal osteoporosis**
The **bisphosphonates** (alendronic acid and risedronate) are effective for preventing postmenopausal osteoporosis.

**Hormone replacement therapy (HRT)** is an option where other therapies are contra-indicated, cannot be tolerated, or if there is a lack of response. The CSM has advised that HRT should not be considered first-line therapy for long-term prevention of osteoporosis in women over 50 years of age. HRT is of most benefit for the prophylaxis of postmenopausal osteoporosis if started early in menopause and continued for up to 5 years, but bone loss resumes (possibly at an accelerated rate) on stopping HRT. Women of Afro-Caribbean origin appear to be less susceptible to osteoporosis than those who are white or of Asian origin.

Postmenopausal osteoporosis may be treated with a **bisphosphonate**. The bisphosphonates (such as alendronate and risedronate) decrease the risk of vertebral fracture; alendronate and risedronate have also been shown to reduce non-vertebral fractures. If bisphosphonates are unsuitable calcitriol p. 992 or **strontium ranelate** may be considered.

Calcitonin (salmon) p. 689 is no longer recommended for the treatment of postmenopausal osteoporosis as the benefits are outweighed by the risk of malignancy associated with long-term use. Calcitonin (salmon) [unlicensed indication] has been used for pain relief for up to 3 months after a vertebral fracture when other analgesics were ineffective, but the benefits of treatment should be balanced against the risks. **Teriparatide** has been introduced for the treatment of postmenopausal osteoporosis.

**Corticosteroid-induced osteoporosis**
To reduce the risk of osteoporosis doses of oral corticosteroids should be as low as possible and courses of treatment as short as possible. The risk of osteoporosis may be related to cumulative dose of corticosteroids; even intermittent courses can therefore increase the risk. The greatest rate of bone loss occurs during the first 6–12 months of corticosteroid use and so early steps to prevent the development of osteoporosis are important.

Long-term use of high-dose inhaled corticosteroids may also contribute to corticosteroid-induced osteoporosis.

Patients taking (or who are likely to take) an oral corticosteroid for 3 months or longer should be assessed and where necessary given prophylactic treatment; those aged over 55 years are at greater risk. Patients taking oral corticosteroids who have sustained a low trauma fracture should receive treatment for osteoporosis. The therapeutic options for **prophylaxis and treatment** of corticosteroid-induced osteoporosis are the same:

- a bisphosphonate;
- calcitriol [unlicensed indication];
- hormone replacement (HRT in women, testosterone in men [unlicensed indication]).

**Calcitonin and parathyroid hormone**
Calcitonin is involved with parathyroid hormone in the regulation of bone turnover and hence in the maintenance of calcium balance and homeostasis. Calcitonin (salmon) (synthetic or recombinant salmon calcitonin) is used to lower the plasma-calcium concentration in patients with hypercalcaemia associated with malignancy.

Calcitonin (salmon) is also licensed for treatment of Paget’s disease of bone when other treatments are ineffective or inappropriate; it is also licensed for the prevention of acute bone loss due to sudden immobility.

Calcitonin (salmon) is no longer recommended for the prevention or treatment of postmenopausal osteoporosis because the benefits are outweighed by the risk of malignancy associated with long-term use.

Teriparatide p. 690 (a recombinant fragment of parathyroid hormone) is used for the treatment of postmenopausal osteoporosis, osteoporosis in men at increased risk of fracture, and corticosteroid-induced osteoporosis.

Cinacalcet p. 957 is licensed for the treatment of hypercalcaemia in parathyroid carcinoma.

**Bisphosphonates**
Bisphosphonates have an important role in the prophylaxis and treatment of osteoporosis and corticosteroid-induced osteoporosis; alendronic acid p. 683 or risedronate sodium p. 686 are considered the drugs of choice for these conditions. There is no consistent evidence of any further benefit from continuing treatment with a bisphosphonate beyond 3 years in patients with osteoporosis.

**Strontium ranelate**
Strontium ranelate treatment has been associated with an increased risk of serious cardiovascular disease, including myocardial infarction, and the risk should be assessed before treatment and regularly during treatment.

**ANABOLIC STEROID**

---

**Nandrolone**

- **INDICATIONS AND DOSE**
  - **Osteoporosis in postmenopausal women (but not recommended)**
    - **BY DEEP INTRAMUSCULAR INJECTION**
      - Adult (female): 50 mg every 3 weeks.
  - **CONTRA-INDICATIONS**
    - Acute porphyrias p. 969 - male breast cancer - prostate cancer
  - **CAUTIONS**
    - Cardiac impairment - diabetes mellitus - epilepsy - hypertension - migraine - skeletal metastases (risk of hypercalcaemia)
  - **INTERACTIONS**
    - **SIDE-EFFECTS** Abnormal liver-function tests (with high doses) - acne - amenorrhoea - inhibition of spermatogenesis - liver tumours (with prolonged treatment with anabolic steroids) - premature epiphyseal closure - sodium retention with oedema - virilisation (with high doses including voice changes—sometimes irreversible)
Bisphosphonates

**DRUG ACTION** Bisphosphonates are adsorbed onto hydroxyapatite crystals in bone, slowing both their rate of growth and dissolution, and therefore reducing the rate of bone turnover.

**IMPORTANT SAFETY INFORMATION**

**MHRA/CHM ADVICE: BISPHOSPHONATES: ATYPICAL FEMORAL FRACTURES (JUNE 2011)**

Atypical femoral fractures have been reported rarely with bisphosphonate treatment, mainly in patients receiving long-term treatment for osteoporosis.

The need to continue bisphosphonate treatment for osteoporosis should be re-evaluated periodically based on an assessment of the benefits and risks of treatment for individual patients, particularly after 5 or more years of use.

Patients should be advised to report any thigh, hip, or groin pain during treatment with a bisphosphonate.

Discontinuation of bisphosphonate treatment in patients suspected to have an atypical femoral fracture should be considered after an assessment of the benefits and risks of continued treatment.


The risk of osteonecrosis of the jaw is substantially greater for patients receiving intravenous bisphosphonates in the treatment of cancer than for patients receiving oral bisphosphonates for osteoporosis or Paget’s disease.

Risk factors for developing osteonecrosis of the jaw that should be considered are: potency of bisphosphonate (highest for zoledronate), route of administration, cumulative dose, duration and type of malignant disease, concomitant treatment, smoking, comorbid conditions, and history of osteoporosis.

All patients should have a dental check-up (and any necessary remedial work should be performed) before bisphosphonate treatment, or as soon as possible after starting treatment. Patients should also maintain good oral hygiene, receive routine dental check-ups, and report any oral symptoms such as dental mobility, pain, or swelling, non-healing sores or discharge to a doctor and dentist during treatment.

Before prescribing an intravenous bisphosphonate, patients should be given a patient reminder card and informed of the risk of osteonecrosis of the jaw. Advise patients to tell their doctor if they have any problems with their mouth or teeth before starting treatment, and if the patient wears dentures, they should make sure their dentures fit properly. Patients should tell their doctor and dentist that they are receiving an intravenous bisphosphonate if they need dental treatment or dental surgery.


**MHRA/CHM ADVICE: BISPHOSPHONATES: OSTEONECROSIS OF THE EXTERNAL AUDITORY CANAL (DECEMBER 2015)**

Benign idiopathic osteonecrosis of the external auditory canal has been reported rarely with bisphosphonate treatment, mainly in patients receiving long-term therapy (2 years or longer).

The possibility of osteonecrosis of the external auditory canal should be considered in patients receiving bisphosphonates who present with ear symptoms, including chronic ear infections, or suspected cholesteatoma.

Risk factors for developing osteonecrosis of the external auditory canal include: steroid use, chemotherapy, infection, an ear operation, or cotton-bud use.

Patients should be advised to report any ear pain, discharge from the ear, or an ear infection during treatment with a bisphosphonate.

**Alendronic acid** (Alendronate)

### INDICATIONS AND DOSE

**Treatment of postmenopausal osteoporosis**

- **BY MOUTH**
  - Adult (female): 10 mg daily, alternatively 70 mg once weekly.

**Treatment of osteoporosis in men**

- **BY MOUTH**
  - Adult (male): 10 mg daily.

**Prevention and treatment of corticosteroid-induced osteoporosis in postmenopausal women not receiving hormone replacement therapy**

- **BY MOUTH**
  - Adult (female): 10 mg daily.

### CONTRA-INDICATIONS

Abnormalities of oesophagus - hypocalcaemia - other factors which delay emptying (e.g. stricture or achalasia)

### CAUTIONS

Active gastro-intestinal bleeding - atypical femoral fractures - duodenitis - dysphagia - exclude other causes of osteoporosis - gastritis - history (within 1 year) of ulcers - surgery of the upper gastro-intestinal tract - symptomatic oesophageal disease - ulcers - upper gastro-intestinal disorders

### INTERACTIONS

Appendix 1: bisphosphonates

### SIDE-EFFECTS

- Common or very common - Abdominal distension - abdominal pain - constipation - diarrhoea - dyspepsia -
684 Disorders of bone metabolism

Endocrine system

flatulence · headache · oesophageal reactions · regurgitation

- **Uncommon** Episcleritis · erythema · gastritis · nausea · rash · scleritis · uveitis · vomiting
- **Rare** Atypical femoral fractures with long-term use · hypocalcaemia · osteonecrosis of the jaw · photosensitivity · severe skin reactions · Stevens-Johnson syndrome · toxic epidermal necrolysis · upper gastro-intestinal ulcers
- **Very rare** Osteonecrosis of the external auditory canal
- **Frequency not known** Musculoskeletal pain

**SIDE-EFFECTS, FURTHER INFORMATION**

- Oesophageal reactions  Severe oesophageal reactions (oesophagitis, oesophageal ulcers, oesophageal stricture and oesophageal erosions) have been reported; patients should be advised to stop taking the tablets and to seek medical attention if they develop symptoms of oesophageal irritation such as dysphagia, new or worsening heartburn, pain on swallowing or retrosternal pain.

- **PREGNANCY** Avoid.
- **BREAST FEEDING** Manufacturer advises avoid—no information available.
- **RENAL IMPAIRMENT** Avoid if eGFR less than 35 mL/minute/1.73 m².

**MONITORING REQUIREMENTS** Correct disturbances of calcium and mineral metabolism (e.g. vitamin-D deficiency, hypocalcaemia) before starting treatment. Monitor serum-calcium concentration during treatment.

**DIRECTIONS FOR ADMINISTRATION** Tablets should be swallowed whole and oral solution should be swallowed as a single 100 mL dose. Doses should be taken with plenty of water while sitting or standing, on an empty stomach at least 30 minutes before breakfast (or another oral medicine); patient should stand or sit upright for at least 30 minutes after administration.

- **PATIENT AND CARER ADVICE** Patients or their carers should be given advice on how to administer alendronic acid tablets and oral solution. Oesophageal reactions Patients (or their carers) should be advised to stop taking alendronic acid and to seek medical attention if they develop symptoms of oesophageal irritation such as dysphagia, new or worsening heartburn, pain on swallowing or retrosternal pain.

- **NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008) NICE TA160

**Alendronate** is recommended as a treatment option for the primary prevention of osteoporotic fractures in the following susceptible postmenopausal women:

- Women over 70 years who have an independent risk factor for fracture (parental history of hip fracture, alcohol intake of 4 or more units per day, or rheumatoid arthritis) or an indicator of low bone mineral density (body mass index under 22 kg/m², ankylosing spondylitis, Crohn’s disease, prolonged immobility, untreated premature menopause, or rheumatoid arthritis) and confirmed osteoporosis.
- Women aged 65–69 years who have an independent risk factor for fracture and confirmed osteoporosis.
- Women under 65 years who have an independent risk factor for fracture and at least one additional indicator of low bone mineral density and confirmed osteoporosis.

www.nice.org.uk/TA160

- Alendronate, etidronate, risedronate, raloxifene, strontium ranelate, and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008) NICE TA161

This guideline recommends treatment options for the secondary prevention of osteoporotic fractures in postmenopausal women with confirmed osteoporosis who have also sustained a clinically apparent osteoporotic fracture.

**Alendronate** is recommended as a treatment option for the secondary prevention of osteoporotic fractures in susceptible postmenopausal women.

www.nice.org.uk/TA161

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (April 2016) that alendronic acid (*Binosto®*) is accepted for restricted use within NHS Scotland for the treatment of postmenopausal osteoporosis where alendronic acid is the appropriate treatment choice, but the patient is unable to swallow tablets.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

**Oral solution**

- **Alendronic acid (Non-proprietary)**
  - Alendronic acid 700 microgram per 1 mL  Alendronic acid 70mg/100ml oral solution unit dose sugar free sugar-free | 4 unit dose (PoP) £27.36 DT price + £27.36

**Effervescent tablet**

- **Binosto** (Internis Pharmaceuticals Ltd)
  - Alendronic acid (as Alendronate sodium) 70 mg Binosto 70mg effervescent tablets sugar-free | 4 tablet (PoP) £22.80 DT price + £22.80

**Tablet**

- **Alendronic acid (Non-proprietary)**
  - Alendronic acid (as Alendronate sodium) 10 mg Alendronic acid 10mg tablets | 28 tablet (PoP) £3.25 DT price + £1.83
  - Alendronic acid (as Alendronate sodium) 70 mg Alendronic acid 70mg tablets | 4 tablet (PoP) £22.80 DT price + £0.74

- **Fosamax** (Merck Sharp & Dohme Ltd)
  - Alendronic acid (as Alendronate sodium) 10 mg Fosamax 10mg tablets | 28 tablet (PoP) £23.12 DT price + £1.83
  - Alendronic acid (as Alendronate sodium) 70 mg Fosamax Once Weekly 70mg tablets | 4 tablet (PoP) £22.80 DT price + £0.74

**Alendronic acid with colecalciferol**

The properties listed below are those particular to the combination only. For the properties of the components please consider, alendronic acid p. 683, colecalciferol p. 992.

**INDICATIONS AND DOSE**

**Treatment of postmenopausal osteoporosis in women at risk of vitamin D deficiency**

- **BY MOUTH**
  - Adult (female): 1 tablet once weekly.

**INTERACTIONS**

- **Appendix 1:** bisphosphonates, vitamin D substances

**DIRECTIONS FOR ADMINISTRATION**

Tablets should be swallowed whole with plenty of water while sitting or standing; to be taken on an empty stomach at least 30 minutes before breakfast (or another oral medicine); patient should stand or sit upright for at least 30 minutes after taking tablet.

**PATIENT AND CARER ADVICE**

Patients or carers should be given advice on how to administer alendronic acid with colecalciferol tablets.
Ibodranic acid

### INDICATIONS AND DOSE

**Reduction of bone damage in bone metastases in breast cancer**
- **INITIALLY BY MOUTH**
- Adult: 50 mg daily, alternatively (by intravenous infusion) 6 mg every 3–4 weeks

**Hypercalcaemia of malignancy**
- **BY INTRAVENOUS INFUSION**
- Adult: 2–4 mg as a single infusion, dose to be adjusted according to serum calcium concentration

**Treatment of postmenopausal osteoporosis**
- **INITIALLY BY MOUTH**
- Adult (female): 150 mg once a month, alternatively (by intravenous injection) 3 mg every 3 months, to be administered over 15–30 seconds.

### CONTRA-INDICATIONS

**GENERAL CONTRA-INDICATIONS**

Hypocalcaemia

**SPECIFIC CONTRA-INDICATIONS**

- With oral use Abnormalities of the oesophagus - other factors which delay emptying (e.g. stricture or achalasia)
- **CAUTIONS** Atypical femoral fractures - cardiac disease (avoid fluid overload)

**INTERACTIONS**

- Appendix 1: bisphosphonates

**SIDE-EFFECTS**

- **RARE** Anaemia - angioedema - atypical femoral fractures - bronchospasm - hypersensitivity reactions - injection-site reactions - pruritus - urticaria
- **VERY RARE** Osteonecrosis of the external auditory canal - osteonecrosis of the jaw

**SPECIFIC SIDE-EFFECTS**

- With oral use Severe oesophageal reactions (discontinue)
- **PREGNANCY** Avoid.
- **BREAST FEEDING** Avoid—present in milk in animal studies.
- **RENAL IMPAIRMENT**
  - With intravenous use When used for bone metastases, if eGFR 30–50 mL/minute/1.73 m² reduce dose to 4 mg and infuse over 1 hour; if eGFR less than 30 mL/minute/1.73 m² reduce dose to 2 mg and infuse over 1 hour.
  - With oral use When used for bone metastases, if eGFR 30–50 mL/minute/1.73 m² reduce dose to 50 mg on alternate days; if eGFR less than 30 mL/minute/1.73 m² reduce dose to 50 mg once weekly. When used for postmenopausal osteoporosis, avoid if eGFR less than 30 mL/minute/1.73 m².
- **MONITORING REQUIREMENTS** Monitor renal function and serum calcium, phosphate and magnesium.

**DIRECTIONS FOR ADMINISTRATION** Tablets should be swallowed whole with plenty of water while sitting or standing; to be taken on an empty stomach at least 30 minutes (for most ibandronic acid tablets, 50 mg) or 1 hour (for Boniva™ tablets, 150 mg) before first food or drink (other than water) of the day, or another oral medicine; patient should stand or sit upright for at least 1 hour after taking tablet.

For **intravenous infusion (Bondronat®)**, give intermittently in Glucose 5% or Sodium chloride 0.9%; dilute requisite dose in 500 mL infusion fluid and give over 1–2 hours.

### PATIENT AND CARER ADVICE

A patient reminder card should be provided to patients receiving intravenous ibandronic acid (risk of osteonecrosis of the jaw).

Patients or carers should be given advice on how to administer ibandronic acid tablets.

**Oesophageal reactions** Patients and carers should be advised to stop tablets and seek medical attention for symptoms of oesophageal irritation such as dysphagia, pain on swallowing, retrosternal pain, or heartburn.

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**
- **Ibandronic acid (Non-proprietary)**
  - Ibandronic acid (as ibandronic sodium monohydrate) 1 mg per 1 mL Ibandronic acid 3mg/3ml solution for injection pre-filled syringes
    | 1 pre-filled disposable injection
  - Bondronat (Roche Products Ltd)
  - Ibandronic acid (as ibandronic sodium monohydrate) 1 mg per 1 mL Bonviva 3mg/3ml solution for injection pre-filled syringes
    | 1 pre-filled disposable injection

**Solution for infusion**
- **Ibandronic acid (Non-proprietary)**
  - Ibandronic acid (as ibandronic sodium monohydrate) 1 mg per 1 mL Ibandronic acid 2mg/2ml solution for infusion vials
    | 1 vial
  - Bondronat (Roche Products Ltd)
  - Ibandronic acid (as ibandronic sodium monohydrate) 1 mg per 1 mL Bondronat 2mg/2ml concentrate for solution for infusion vials
    | 1 vial

**Tablet**
- **Ibandronic acid (Non-proprietary)**
  - Ibandronic acid (as ibandronic sodium monohydrate) 50 mg
    | 28 tablet

  | Price
  | £17.51

  | 150 mg
  | 28 tablet

  | Price
  | £14.80

  | 50 mg
  | 28 tablet

  | Price
  | £18.40

  | 150 mg
  | 28 tablet

  | Price
  | £18.00

**Bondronat (Roche Products Ltd)**
- Ibandronic acid (as ibandronic sodium monohydrate) 150 mg
    | 1 tablet

  | Price
  | £17.48

  | 150 mg
  | 1 tablet

  | Price
  | £18.40

**Iasibon (Aspire Pharma Ltd)**
- Ibandronic acid (as ibandronic sodium monohydrate) 50 mg
    | 28 tablet

  | Price
  | £17.50

**Quodixor (Aspire Pharma Ltd)**
- Ibandronic acid (as ibandronic sodium monohydrate) 150 mg
    | 1 tablet

  | Price
  | £18.40
Pamidronate disodium
(Formerly called aminohydroxypropylidenediphosphonate disodium (APD))

- **INDICATIONS AND DOSE**
  - **Hypercalcaemia of malignancy**
    - **BY INTRAVENOUS INFUSION**
      - Adult: 15–60 mg, to be given (via cannula in a relatively large vein) as a single infusion or in divided doses over 2–4 days, dose adjusted according to serum calcium concentration; maximum 90 mg per course
  - **OSTEOLYTIC LESIONS AND BONE PAIN IN BONE METASTASES ASSOCIATED WITH BREAST CANCER OR MULTIPLE MYELOMA**
    - **BY INTRAVENOUS INFUSION**
      - Adult: 90 mg every 4 weeks, to be administered via cannula in a relatively large vein, dose may alternatively be administered every 3 weeks, to coincide with chemotherapy in breast cancer
  - **Paget’s disease of bone**
    - **BY INTRAVENOUS INFUSION**
      - Adult: 30 mg every week for a 6 week course (total dose 180 mg), alternatively initially 30 mg once weekly for 1 week, then increased to 60 mg every 2 weeks (max. per dose 60 mg) for a 6 week course (total dose 210 mg), to be administered via cannula in a relatively large vein, course may be repeated every 6 months; maximum 360 mg per course

- **CAUTIONS**
  - Atypical femoral fractures - cardiac disease (especially in elderly) - ensure adequate hydration - previous thyroid surgery (risk of hypocalcaemia)
  - **INTERACTIONS**
    - Appendix 1: bisphosphonates

- **SIDE-EFFECTS**
  - Common or very common Abdominal pain - anaemia - anorexia - arthralgia - bone pain - constipation - diarrhoea - drowsiness - fever - headache - hypertension - hypomagnesaemia - hypophosphataemia - influenza - like symptoms (sometimes accompanied by malaise, rigor, fatigue and flushest) - insomnia - lymphocytopenia - myalgia - nausea - paraesthesia - rash - symptomatic hypocalcaemia - tetany - thrombocytopenia - vomiting
  - Rare Acute renal failure - agitation - atypical femoral fractures - confusion - conjunctivitis - deterioration of renal disease - dizziness - dyspepsia - haematuria - hallucinations - hyperkalaemia - hypernatraemia - hypokalaemia - hypotension - isolated cases of seizures - lethargy - leucopenia - muscle cramps - osteonecrosis of the jaw - other ocular symptoms - pruritus
  - Very rare Osteonecrosis of the external auditory canal
  - Frequency not known Atrial fibrillation - injection-site reactions - reactivation of herpes simplex - reactivation of herpes zoster

**SIDE-EFFECTS, FURTHER INFORMATION**

- Calcium and vitamin D supplements Oral supplements are advised to minimise potential risk of hypocalcaemia for those with mainly lytic bone metastases or multiple myeloma at risk of calcium or vitamin D deficiency (e.g. through malabsorption or lack of exposure to sunlight) and in those with Paget’s disease.
- **PREGNANCY** Avoid — toxicity in animal studies.
- **BREAST FEEDING** Avoid.
- **HEPATIC IMPAIRMENT** Caution in severe hepatic impairment — no information available.
- **RENA L IMPAIRMENT** Max. infusion rate 20 mg/hour. Avoid if eGFR less than 30 mL/minute/1.73 m², except in life-threatening hypercalcaemia if benefit outweighs risk. If renal function deteriorates in patients with bone metastases, withhold dose until serum creatinine returns to within 10% of baseline value.

- **MONITORING REQUIREMENTS**
  - Monitor serum electrolytes, calcium and phosphate — possibility of convulsions due to electrolyte changes.
  - Assess renal function before each dose.

- **DIRECTIONS FOR ADMINISTRATION** For slow intravenous infusion (Aredia®, Pamidronate disodium, Hospira, Medac, Wockhardt), give intermittently in Glucose 5% or Sodium chloride 0.9%; give at a rate not exceeding 1 mg/minute; not to be given with infusion fluids containing calcium. For Aredia®, reconstitute initially with water for injections (15 mg in 5 mL, 30 mg or 90 mg in 10 mL), then dilute with infusion fluid to a concentration of not more than 90 mg in 250 mL. For Pamidronate disodium (Medac, Hospira, Wockhardt) dilute with infusion fluid to a concentration of not more than 90 mg in 250 mL.

- **PATIENT AND CARER ADVICE** A patient reminder card should be provided (risk of osteonecrosis of the jaw).

- **DRIVING AND SKILLED TASKS**
  - Patients should be warned against performing skilled tasks (e.g. cycling, driving or operating machinery) immediately after treatment (somnolence or dizziness can occur).

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

**Solution for infusion**

- **Pamidronate disodium (Non-proprietary)**
  - Pamidronate disodium 3 mg per 1 mL Pamidronate disodium 15mg/5mL solution for infusion vials | 1 vial (£0.75 (Hospital only) | 5 vial (£14.95)
  - Pamidronate disodium 30mg/10mL solution for infusion vials | 1 vial (£1.65 (Hospital only) | 1 vial (£0.55)
  - Pamidronate disodium 60mg/20mL solution for infusion vials | 1 vial (£1.00 (Hospital only) | 1 vial (£11.00)
  - Pamidronate disodium 90mg/30mL solution for infusion vials | 1 vial (£1.00 (Hospital only) | 1 vial (£1.10)
  - Pamidronate disodium 9 mg per 1 mL Pamidronate disodium 90mg/10mL solution for infusion vials | 1 vial (£0.75 (Hospital only) | 1 vial (£17.05)
  - Pamidronate disodium 15 mg per 1 mL Pamidronate disodium 60mg/4ml solution for infusion ampoules | 1 ampoule (£0.32 (Hospital only) | 1 ampoule (£11.99)
  - Pamidronate disodium 15mg/1ml solution for infusion ampoules | 4 ampoules (£0.06 (Hospital only) | 0.06 (Hospital only)
  - Pamidronate disodium 90mg/6ml solution for infusion ampoules | 1 ampoule (£17.00 (Hospital only) | 1 ampoule (£0.66)
  - Pamidronate disodium 30mg/2ml solution for infusion ampoules | 2 ampoules (£11.32)

Risedronate sodium

- **INDICATIONS AND DOSE**
  - **Paget’s disease of bone**
    - **BY MOUTH**
    - Adult: 30 mg daily for 2 months, course may be repeated if necessary after at least 2 months

- **TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS TO REDUCE RISK OF VERTEBRAL OR HIP FRACTURES**
  - **BY MOUTH**
    - Adult (female): 5 mg daily, alternatively 35 mg once weekly.

- **PREVENTION OF OSTEOPOROSIS (INCLUDING CORTICOSTEROID-INDUCED OSTEOPOROSIS) IN POSTMENOPAUSAL WOMEN**
  - **BY MOUTH**
    - Adult (female): 5 mg daily.

- **TREATMENT OF OSTEOPOROSIS IN MEN AT HIGH RISK OF FRACTURES**
  - **BY MOUTH**
    - Adult (male): 35 mg once weekly.

- **CONTRA-INDICATIONS**
  - Hypocalcaemia

- **CAUTIONS**
  - Atypical femoral fractures - oesophageal abnormalities - other factors which delay transit or emptying (e.g. stricture or achalasia)
Risedronate with calcium carbonate and colecalciferol

The properties listed below are those particular to the combination only. For the properties of the components please consider, risedronate sodium p. 686, calcium carbonate p. 958, colecalciferol p. 992.

INDICATIONS AND DOSE

Treatment of postmenopausal osteoporosis to reduce risk of vertebral or hip fractures

BY MOUTH

Adult: 1 tablet once weekly on day 1 of the weekly cycle, followed by 1 sachet daily on days 2–6 of the weekly cycle

INTERACTIONS → Appendix 1: bisphosphonates, calcium salts, vitamin D substances

DIRECTIONS FOR ADMINISTRATION

Tablets should be swallowed whole with plenty of water while sitting or standing; to be taken on an empty stomach at least 30 minutes before breakfast (or another oral medicine); patient should stand or sit upright for at least 30 minutes after taking tablet. Granules should be stirred into a glass of water and after dissolution complete taken immediately.

PRESCRIBING AND DISPENSING INFORMATION

Actonel Combi® effervescent granules contain calcium carbonate 2.5 g (calcium 1 g or Ca²⁺ 25 mmol) and colecalciferol 22 micrograms (880 units)/sachet.

PATIENT AND CARER ADVICE

Patients or carers should be given advice on how to administer calcium carbonate with colecalciferol and risedronate tablets and granules.

INTERACTIONS → Appendix 1: bisphosphonates, calcium salts, vitamin D substances

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Tablet

Risedronate sodium (Non-proprietary)

Risedronate sodium 5 mg Risedronate sodium 5mg tablets | 28 tablet | £24.78 DT price = £18.85

Risedronate sodium 30 mg Risedronate sodium 30mg tablets | 28 tablet | £143.95 DT price = £143.83

Risedronate sodium 35 mg Risedronate sodium 35mg tablets | 4 tablet | £19.12 DT price = £0.85

Actonel (Warner Chilcott UK Ltd, Teva UK Ltd)

Risedronate sodium 5 mg Actonel 5mg tablets | 28 tablet | £17.99 DT price = £18.85

Risedronate sodium 30 mg Actonel 30mg tablets | 28 tablet | £143.95 DT price = £143.83

Risedronate sodium 35 mg Actonel Once a Week 35mg tablets | 4 tablet | £19.12 DT price = £0.85

Actonel 35mg tablets | 4 tablet no price available DT price = £0.85

Risedronate with calcium carbonate and colecalciferol

The properties listed below are those particular to the combination only. For the properties of the components please consider, risedronate sodium p. 686, calcium carbonate p. 958, colecalciferol p. 992.

INDICATIONS AND DOSE

Treatment of postmenopausal osteoporosis to reduce risk of vertebral or hip fractures

BY MOUTH

Adult: 1 tablet once weekly on day 1 of the weekly cycle, followed by 1 sachet daily on days 2–6 of the weekly cycle

INTERACTIONS → Appendix 1: bisphosphonates, calcium salts, vitamin D substances

DIRECTIONS FOR ADMINISTRATION

Tablets should be swallowed whole with plenty of water while sitting or standing; to be taken on an empty stomach at least 30 minutes before breakfast (or another oral medicine); patient should stand or sit upright for at least 30 minutes after taking tablet. Granules should be stirred into a glass of water and after dissolution complete taken immediately.

PRESCRIBING AND DISPENSING INFORMATION

Actonel Combi® effervescent granules contain calcium carbonate 2.5 g (calcium 1 g or Ca²⁺ 25 mmol) and colecalciferol 22 micrograms (880 units)/sachet.

PATIENT AND CARER ADVICE

Patients or carers should be given advice on how to administer calcium carbonate with colecalciferol and risedronate tablets and granules.

INTERACTIONS → Appendix 1: bisphosphonates, calcium salts, vitamin D substances

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet/Granules

Actonel Combi (Teva UK Ltd)

Actonel Combi 35mg tablets and 1000mg/880unit effervescent granules sachets | 4 week supply | £19.12

Risedronate with calcium carbonate and colecalciferol

The properties listed below are those particular to the combination only. For the properties of the components please consider, risedronate sodium p. 686, calcium carbonate p. 958, colecalciferol p. 992.

INDICATIONS AND DOSE

Treatment of postmenopausal osteoporosis to reduce risk of vertebral or hip fractures

BY MOUTH

Adult: 1 tablet once weekly on day 1 of the weekly cycle, followed by 1 sachet daily on days 2–6 of the weekly cycle

INTERACTIONS → Appendix 1: bisphosphonates, calcium salts, vitamin D substances

DIRECTIONS FOR ADMINISTRATION

Tablets should be swallowed whole with plenty of water while sitting or standing; to be taken on an empty stomach at least 30 minutes before breakfast (or another oral medicine); patient should stand or sit upright for at least 30 minutes after taking tablet. Granules should be stirred into a glass of water and after dissolution complete taken immediately.

PRESCRIBING AND DISPENSING INFORMATION

Actonel Combi® effervescent granules contain calcium carbonate 2.5 g (calcium 1 g or Ca²⁺ 25 mmol) and colecalciferol 22 micrograms (880 units)/sachet.

PATIENT AND CARER ADVICE

Patients or carers should be given advice on how to administer calcium carbonate with colecalciferol and risedronate tablets and granules.

INTERACTIONS → Appendix 1: bisphosphonates, calcium salts, vitamin D substances

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet/Granules

Actonel Combi (Teva UK Ltd)

Actonel Combi 35mg tablets and 1000mg/880unit effervescent granules sachets | 4 week supply | £19.12

Risedronate with calcium carbonate and colecalciferol

The properties listed below are those particular to the combination only. For the properties of the components please consider, risedronate sodium p. 686, calcium carbonate p. 958, colecalciferol p. 992.

INDICATIONS AND DOSE

Treatment of postmenopausal osteoporosis to reduce risk of vertebral or hip fractures

BY MOUTH

Adult: 1 tablet once weekly on day 1 of the weekly cycle, followed by 1 sachet daily on days 2–6 of the weekly cycle

INTERACTIONS → Appendix 1: bisphosphonates, calcium salts, vitamin D substances

DIRECTIONS FOR ADMINISTRATION

Tablets should be swallowed whole with plenty of water while sitting or standing; to be taken on an empty stomach at least 30 minutes before breakfast (or another oral medicine); patient should stand or sit upright for at least 30 minutes after taking tablet. Granules should be stirred into a glass of water and after dissolution complete taken immediately.

PRESCRIBING AND DISPENSING INFORMATION

Actonel Combi® effervescent granules contain calcium carbonate 2.5 g (calcium 1 g or Ca²⁺ 25 mmol) and colecalciferol 22 micrograms (880 units)/sachet.

PATIENT AND CARER ADVICE

Patients or carers should be given advice on how to administer calcium carbonate with colecalciferol and risedronate tablets and granules.

INTERACTIONS → Appendix 1: bisphosphonates, calcium salts, vitamin D substances

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet/Granules

Actonel Combi (Teva UK Ltd)

Actonel Combi 35mg tablets and 1000mg/880unit effervescent granules sachets | 4 week supply | £19.12

Risedronate with calcium carbonate and colecalciferol

The properties listed below are those particular to the combination only. For the properties of the components please consider, risedronate sodium p. 686, calcium carbonate p. 958, colecalciferol p. 992.
Sodium clodronate

**INDICATIONS AND DOSE**

**Osteolytic lesions, hypercalcaemia and bone pain associated with skeletal metastases in patients with breast cancer or multiple myeloma**

- **BY MOUTH**
  - **Adult:** 1.6 g daily in 1–2 divided doses, then increased if necessary up to 3.2 g daily in 2 divided doses

**SIDE-EFFECTS**

**PRECAUTIONS**

**CAUTIONS**
- Atypical femoral fractures - maintain adequate fluid intake during treatment
- **INTERACTIONS** → Appendix 1: bisphosphonates
- **SIDE-EFFECTS**
  - **Common or very common** Bronchospasm - diarrhoea - nausea - skin reactions - vomiting
  - **Rare** Atypical femoral fractures
  - **Very rare** Osteonecrosis of the external auditory canal - osteonecrosis of the jaw
  - **Frequency not known** Renal impairment - uveitis
- **PREGNANCY** Avoid.
- **BREAST FEEDING** Manufacturer advises avoid—no information available.
- **RENAL IMPAIRMENT** Max. initial dose 1200 mg daily if eGFR 30–50 mL/minute/1.73 m². Use half normal dose if eGFR 10–30 mL/minute/1.73 m². Avoid if eGFR less than 10 mL/minute/1.73 m².
- **MONITORING REQUIREMENTS** Monitor renal function, serum calcium and serum phosphate before and during treatment.
- **DIRECTIONS FOR ADMINISTRATION** Avoid food for 2 hours before and 1 hour after treatment, particularly calcium-containing products e.g. milk; also avoid iron and mineral supplements and antacids; maintain adequate fluid intake.
- **PATIENT AND CARER ADVICE** Patients or carers should be given advice on how to administer sodium clodronate capsules and tablets.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS**
  - **Sodium clodronate 800 mg** Sodium clodronate 800mg tablets | 60 tablet [PoT]: £116.72 DT price = £146.43
  - **Bonefos** (Bayer Plc) Sodium clodronate 800 mg Bonefos 800mg tablets | 60 tablet [PoT]: £146.43 DT price = £146.43
  - **Clasteon** (Beacon Pharmaceuticals Ltd) Sodium clodronate 800 mg Clasteon 800mg tablets | 60 tablet [PoT]: £146.43 DT price = £146.43
  - **Loron** (Intrapharm Laboratories Ltd) Sodium clodronate 520 mg Loron 520mg tablets | 60 tablet [PoT]: £152.50 DT price = £152.50
  - **Sodium clodronate (Non-proprietary)** Sodium clodronate 400 mg Sodium clodronate 400mg capsules | 30 capsule [PoT]: £40.49 | 120 capsule [PoT]: £161.97 DT price = £139.83

**Capsule**

- **Sodium clodronate (Non-proprietary)**
  - **Sodium clodronate 400 mg** Sodium clodronate 400mg capsules | 30 capsule [PoT]: £40.49 | 120 capsule [PoT]: £161.97 DT price = £139.83

Zoledronic acid

**INDICATIONS AND DOSE**

**ACLASTA®**

Treatment of Paget's disease of bone

- **BY INTRAVENOUS INFUSION**
  - **Adult:** 5 mg as a single dose, to be administered over at least 15 minutes, at least 500 mg elemental calcium twice daily (with vitamin D) for at least 10 days is recommended following infusion

Treatment of postmenopausal osteoporosis and osteoporosis in men (including corticosteroid-induced osteoporosis)

- **BY INTRAVENOUS INFUSION**
  - **Adult:** 5 mg once yearly as a single dose, to be administered over at least 15 minutes, in patients with a recent low-trauma hip fracture, the dose should be given 2 or more weeks following hip fracture repair; before first infusion give 50000–125000 units of vitamin D

**ZOMETA®**

Reduction of bone damage in advanced malignancies involving bone

- **BY INTRAVENOUS INFUSION**
  - **Adult:** 4 mg every 3–4 weeks, to be administered over at least 15 minutes, calcium 500 mg daily and vitamin D 400 units daily should also be taken

**Hypercalcaemia of malignancy**

- **BY INTRAVENOUS INFUSION**
  - **Adult:** 4 mg for 1 dose, to be administered over at least 15 minutes

**CAUTIONS**
- Atypical femoral fractures - cardiac disease (avoid fluid overload) - concomitant medicines that affect renal function
- **INTERACTIONS** → Appendix 1: bisphosphonates
- **SIDE-EFFECTS**
  - **Common or very common** Anaemia - arthralgia - atrial fibrillation - bone pain - conjunctivitis - dizziness - fever - gastro-intestinal disturbances - headache - hypophosphataemia - influenza - like symptoms - myalgia - renal impairment - rigors
  - **Rare** Acute renal failure - atypical femoral fractures - bradycardia - confusion - hyperkalaemia - hypernatraemia - osteonecrosis of the jaw - pancyclopenia
  - **Very rare** Episcleritis - osteonecrosis of the external auditory canal - uveitis

**SIDE-EFFECTS, FURTHER INFORMATION**

- **Renal function** Renal impairment and renal failure have been reported; ensure patient is hydrated before each dose and assess renal function.
- **CONCEPTION AND CONTRACEPTION** Contra-indicated in women of child-bearing potential.
- **PREGNANCY** Avoid—toxicity in animal studies.
CALCIUM REGULATING DRUGS > BONE RESORPTION INHIBITORS

Calcitonin (salmon)
(Salcatonin)

- INDICATIONS AND DOSE

Hypercalcaemia of malignancy
- BY SUBCUTANEOUS INJECTION, OR BY INTRAMUSCULAR INJECTION
- Adult: 100 units every 6–8 hours (max. per dose 400 units every 6–8 hours), adjusted according to response
- BY INTRAVENOUS INFUSION
- Adult: Up to 10 units/kg, in severe or emergency cases, to be administered by slow intravenous infusion over at least 6 hours

Paget’s disease of bone
- BY SUBCUTANEOUS INJECTION, OR BY INTRAMUSCULAR INJECTION
- Adult: 100 units daily, adjusted according to response for maximum 3 months (6 months in exceptional circumstances), a minimum dosage regimen of 50 units three times a week has been shown to achieve clinical and biochemical improvement

Prevention of acute bone loss due to sudden immobility
- BY SUBCUTANEOUS INJECTION, OR BY INTRAMUSCULAR INJECTION
- Adult: Initially 100 units daily in 1–2 divided doses, then reduced to 50 units daily at the start of mobilisation, usual duration of treatment is 2 weeks; maximum 4 weeks

- CONTRA-INDICATIONS
Hypocalcaemia

- CAUTIONS
Heart failure • history of allergy (skin test advised) • risk of malignancy—avoid prolonged use (use lowest effective dose for shortest possible time)

- INTERACTIONS
Appendix 1: calcitonin (salmon)

- SIDE-EFFECTS
Common or very common
Abdominal pain • diarrhoea • dizziness • fatigue • flushing • headache • malignancy (with long-term use) • musculoskeletal pain • nausea • taste disturbances • vomiting

Uncommon
Cough • hypersensitivity reactions • hypotension • injection-site reactions • oedema • polyuria • pruritus • rash • visual disturbances

Frequency not known
Tremor

- PREGNANCY
Avoid unless potential benefit outweighs risk (toxicity in animal studies).

- BREAST FEEDING
Avoid; inhibits lactation in animals.

- RENAL IMPAIRMENT
Use with caution.

- DIRECTIONS FOR ADMINISTRATION
For intravenous infusion (Micalef®), give intermittently in Sodium chloride 0.9%; dilute requisite dose according to product literature; infuse over at least 15 minutes; administer as a single intravenous solution in a separate infusion line.

- MEDICAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Solution for infusion
- Zometa (Novartis Pharmaceuticals UK Ltd)
  - 800 microgram per 1 ml Zometa 4mg/5ml solution for infusion vials | 1 vial (POM) £174.14

Infusion
- Aclasta (Novartis Pharmaceuticals UK Ltd)
  - Zoledronic acid (as Zoledronic acid monohydrate) 50 microgram per 1 ml Aclasta 5mg/100ml infusion bottles | 1 bottle (POM) £253.38

- Zometa (Novartis Pharmaceuticals UK Ltd)
  - Zoledronic acid (as Zoledronic acid monohydrate) 40 microgram per 1 ml Zometa 4mg/100ml infusion bottles | 1 bottle (POM) £174.14

- CALCITONIN (salmon) (Non-proprietary)
  - Calcitonin (salmon) 50 unit per 1 ml Calcitonin (salmon) 50units/1ml solution for injection ampoules | 5 ampoule (POM) £167.50
  - Calcitonin (salmon) 100 unit per 1 ml Calcitonin (salmon) 100units/1ml solution for injection ampoules | 5 ampoule (POM) £220.00
  - Calcitonin (salmon) 200 unit per 1 ml Calcitonin (salmon) 400units/2mlm solution for injection vials | 1 vial (POM) £352.00

- MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Solution for injection
- Zoledronic acid (Novartis Pharmaceuticals UK Ltd)
  - Zoledronic (40 microgram per 1 ml Zoledronic 40microgram/1ml solution for infusion vials | 1 bottle (POM) £174.14

- MONITORING REQUIREMENTS

  - Correct disturbances of calcium metabolism (e.g. vitamin D deficiency, hypocalcaemia) before starting. Monitor serum electrolytes, calcium, phosphate and magnesium.
  - Monitor renal function in patients at risk, such as those with pre-existing renal impairment, those of advanced age, those taking concomitant nephrotoxic drugs or diuretics, or those who are dehydrated.

- DIRECTIONS FOR ADMINISTRATION
For intravenous infusion (Zometa®), give intermittently in Glucose 5% or Sodium chloride 0.9%; dilute requisite dose according to product literature; infuse over at least 15 minutes; administer as a single intravenous solution in a separate infusion line.

- PATIENT AND CARER ADVICE
A patient reminder card should be provided (risk of osteonecrosis of the jaw).

- NATIONAL FUNDING/ACCESS DECISIONS
ZOMETA® INFUSION

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (May 2003) that for the prevention of skeletal related events Zometa® is accepted for restricted use within NHS Scotland for the treatment of patients with breast cancer and multiple myeloma if prescribed by an oncologist.

ACLAStA®

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (February 2008) that in postmenopausal women Aclasta® is accepted for restricted use within the NHS Scotland for the treatment of osteoporosis in those for whom oral treatment options for osteoporosis are inappropriate and when initiated by a specialist.

- BREAST FEEDING
Avoid—no information available.

- HEPATIC IMPAIRMENT
Caution in severe hepatic impairment—limited information available.

- RENAL IMPAIRMENT
In advanced malignancies involving bone, if eGFR 50–60 mL/minute/1.73 m² reduce dose to 3.5 mg every 3–4 weeks; if eGFR 40–50 mL/minute/1.73 m² reduce dose to 3.3 mg every 3–4 weeks; if eGFR 30–40 mL/minute/1.73 m² reduce dose to 3 mg every 3–4 weeks; if renal function deteriorates in patients with bone metastases, withhold dose until serum creatinine returns to within 10% of baseline value. Avoid in tumour-induced hypercalcaemia if serum creatinine above 400 micromol/litre. Avoid in advanced malignancies involving bone if eGFR less than 30 mL/minute/1.73 m² (or if serum creatinine greater than 265 micromol/litre).

Avoid in Paget’s disease, treatment of postmenopausal osteoporosis and osteoporosis in men if eGFR less than 35 mL/minute/1.73 m².

- MONITORING REQUIREMENTS

  - There can be variation in the licensing of different medicines returns to within 130% of baseline value. Avoid in tumour-induced hypercalcaemia if serum creatinine above 400 micromol/litre. Avoid in advanced malignancies involving bone if eGFR less than 30 mL/minute/1.73 m² (or if serum creatinine greater than 265 micromol/litre).

  - Scottish Medicines Consortium (SMC) Decisions
  - Scottish Medicines Consortium (SMC) Decisions

  - Calcitonin (salmon)

  - Zolendronic acid (as Zoledronic acid monohydrate) 40 microgram per 1 ml Zometa 4mg/100ml infusion bottles | 1 bottle (POM) £174.14
Strontium ranelate

**DRUG ACTION** Stimulates bone formation and reduces bone resorption.

**INDICATIONS AND DOSE**

Treatment of severe osteoporosis in postmenopausal women or men at high risk of fracture for whom other treatments are contra-indicated or not tolerated (initiated under specialist supervision)

- **BY MOUTH**
  - Adult: 2 g once daily, dose to be taken in water, preferably at bedtime

**CONTRA-INDICATIONS**
Cerebrovascular disease · current or previous venous thromboembolic event · ischaemic heart disease · peripheral arterial disease · temporary or prolonged immobilisation · uncontrolled hypertension

**CAUTIONS**
Predisposition to cardiovascular disease—assess risk before and every 6–12 months during treatment

**INTERACTIONS** → Appendix 1: strontium ranelate

**SIDE-EFFECTS**

- **Common or very common** Dermatitis · diarrhoea · eczema · headache · myocardial infarction · nausea · venous thromboembolism
- **Very rare** Angioedema · hypersensitivity reactions · pruritus · rash · urticaria

**SIDE-EFFECTS, FURTHER INFORMATION**
Severe allergic reactions
Severe allergic reactions, including drug rash with eosinophilia and systemic symptoms (DRESS), have been reported in patients taking strontium ranelate. DRESS starts with rash, fever, swollen glands, and increased white cell count, and it can affect the liver, kidneys and lungs; DRESS can also be fatal. Treatment with strontium ranelate should not be restarted.

**RENA L IMPAIRMENT**
Avoid if eGFR less than 30 mL/minute/1.73 m².

**EFFECT ON LABORATORY TESTS**
Interferes with colorimetric measurements of calcium in blood and urine.

**DIRECTIONS FOR ADMINISTRATION**
Avoid food for 2 hours before and after taking granules, particularly calcium-containing products e.g. milk; also preferably avoid concomitant antacids containing aluminium and magnesium hydroxides for 2 hours after taking granules.

**PATIENT AND CARER ADVICE**
Patients or carers should be given advice on how to administer strontium ranelate granules.
Severe allergic reactions
Patients should be advised to stop taking strontium ranelate and consult their doctor immediately if skin rash develops.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Alendronate, etidronate, risedronate, raloxifene and strontium ranelate, and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008) NICE TA161

This guideline recommends treatment options for the secondary prevention of osteoporotic fractures in postmenopausal women with confirmed osteoporosis who have also sustained a clinically apparent osteoporotic fracture.

- Strontium ranelate is recommended as an alternative for women:
  - in whom alendronate and risedronate are contra-indicated or not tolerated and
  - who comply with particular combinations of bone mineral density measurement, age, and independent risk factors for fracture, as indicated in the full NICE guidance.

www.nice.org.uk/TA160

**CALCIUM REGULATING DRUGS**

**TERIPARATIDE**

**INDICATIONS AND DOSE**

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures | Treatment of corticosteroid-induced osteoporosis

- **BY SUBCUTANEOUS INJECTION**
  - Adult: 20 micrograms daily for maximum duration of treatment 24 months (course not to be repeated)

**CONTRA-INDICATIONS**
Bone metastases · hyperparathyroidism · metabolic bone diseases · Paget’s disease · pre-existing hypercalcaemia · previous radiation therapy to the skeleton · skeletal malignancies · unexplained raised alkaline phosphatase

**SIDE-EFFECTS**

- **Common or very common** Anaemia · arthralgia · asthenia · depression · dizziness · dyspepsia · fatigue · gastrointestinal disorders · haemorrhoids · headache · increased sweating · muscle cramps · myalgia · nausea · palpitation · reflux · sciatica · vertigo
- **Uncommon** Hypercalcaemia · injection-site reactions · urinary disorders
- **Rare** Hypersensitivity reactions

**PREGNANCY**
Avoid.

**BREAST FEEDING**
Avoid.

**RENA L IMPAIRMENT**
Caution in moderate impairment; avoid if severe.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Alendronate, etidronate, risedronate, raloxifene, strontium ranelate, and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (October 2008) NICE TA161

This guideline recommends treatment options for the secondary prevention of osteoporotic fractures in postmenopausal women with confirmed osteoporosis who have also sustained a clinically apparent osteoporotic fracture.
Teriparatide is recommended as an alternative for women:
- in whom alendronate or risedronate, or strontium ranelate are contra-indicated or not tolerated, or where treatment with alendronate or risedronate has been unsatisfactory (indicated by another fragility fracture and a decline in bone mineral density despite treatment for 1 year) and
- who comply with particular combinations of bone mineral density measurement, age, and number of fractures, as indicated in the full NICE guidance.

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (December 2003) that the use of teriparatide (Forsteo®) in postmenopausal women should be restricted to the treatment of established (severe) osteoporosis and should be initiated by specialists experienced in the treatment of osteoporosis.

Medicinal Forms
There can be variation in the licensing of different medicines containing the same drug.

Solution for injection
- Forsteo (Eli Lilly and Company Ltd)
  - Teriparatide 250 microgram per 1 ml Forsteo
  - 20micrograms/80microlitres solution for injection 2.4ml pre-filled disposable devices | 1 pre-filled disposable injection (BNF 74) £271.88

Drugs Affecting Bone Structure and Mineralisation > Monoclonal Antibodies

Denosumab
- Drug Action Denosumab is a human monoclonal antibody that inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption.

Indications and Dose

Prolia®
Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures | Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures
- By Subcutaneous Injection
- Adult: 60 mg every 6 months, supplement with calcium and vitamin D

Xgeva®
Prevention of skeletal related events in patients with bone metastases from solid tumours
- By Subcutaneous Injection
- Adult: 120 mg every 4 weeks, supplementation of at least Calcium 500 mg and vitamin D 400 units daily should also be taken unless hypercalcaemia is present

Treatment of giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity in adults and skeletally mature adolescents
- By Subcutaneous Injection
- Adult: 120 mg every 4 weeks, give additional dose on days 8 and 15 of the first month of treatment only, supplementation of at least Calcium 500 mg and vitamin D 400 units daily should also be taken unless hypercalcaemia is present

Important Safety Information
MHRA/CHM Advice: Denosumab: Atypical Femoral Fractures (February 2013)
Atypical femoral fractures have been reported rarely in patients receiving denosumab for the long-term treatment (2.5 or more years) of postmenopausal osteoporosis.

Patients should be advised to report any new or unusual thigh, hip, or groin pain during treatment with denosumab.
Discontinuation of denosumab in patients suspected to have an atypical femoral fracture should be considered after an assessment of the benefits and risks of continued treatment.

MHRA/CHM Advice: Denosumab: Minimising the Risk of Osteonecrosis of the Jaw; Monitoring for Hypocalcaemia—Updated Recommendations (September 2014) and Denosumab: Osteonecrosis of the Jaw—Further Measures to Minimise Risk (July 2015)
Denosumab is associated with a risk of osteonecrosis of the jaw (ONJ) and with a risk of hypocalcaemia.

Osteonecrosis of the Jaw
Osteonecrosis of the jaw is a well-known and common side-effect in patients receiving denosumab 120 mg for cancer. Risk factors include smoking, old age, poor oral hygiene, invasive dental procedures (including tooth extractions, dental implants, oral surgery), comorbidity (including dental disease, anaemia, coagulopathy, infection), advanced cancer, previous treatment with bisphosphonates, and concomitant treatments (including chemotherapy, anti-angiogenic biologics, corticosteroids, and radiotherapy to head and neck). The following precautions are now recommended to reduce the risk of ONJ:
- Denosumab 120 mg (cancer indication)
  - A dental examination and appropriate preventative dentistry before starting treatment are now recommended for all patients
  - Do not start denosumab in patients with a dental or jaw condition requiring surgery, or in patients who have unhealed lesions from dental or oral surgery
- Denosumab 60 mg (osteoporosis indication)
  - Check for ONJ risk factors before starting treatment. A dental examination and appropriate preventative dentistry are now recommended for patients with risk factors

All patients should be given a patient reminder card and informed of the risk of ONJ. Advise patients to tell their doctor if they have any problems with their mouth or teeth before starting treatment, if they wear dentures they should make sure their dentures fit properly before starting treatment, to maintain good oral hygiene, receive routine dental check-ups during treatment, and immediately report any oral symptoms such as dental mobility, pain, swelling, non-healing sores or discharge to a doctor and dentist. Patients should tell their doctor and dentist that they are receiving denosumab if they need dental treatment or dental surgery.

Hypocalcaemia
Denosumab is associated with a risk of hypocalcaemia. This risk increases with the degree of renal impairment. Hypocalcaemia usually occurs in the first weeks of denosumab treatment, but it can also occur later in treatment.

Plasma-calcium concentration monitoring is recommended for denosumab 120 mg (cancer indication):
- before the first dose
- within two weeks after the initial dose
- if suspected symptoms of hypocalcaemia occur
- consider monitoring more frequently in patients with risk factors for hypocalcaemia (e.g. severe renal impairment, creatinine clearance less than 30 mL/minute)

Plasma-calcium concentration monitoring is recommended for denosumab 60 mg (osteoporosis indication):
- before each dose
- within two weeks after the initial dose in patients with risk factors for hypocalcaemia (e.g. severe renal impairment, creatinine clearance less than 30 mL/minute)
impaired, creatinine clearance less than 30 mL/minute)
- if suspected symptoms of hypocalcaemia occur
  All patients should be advised to report symptoms of hypocalcaemia to their doctor (e.g. muscle spasms, twitches, cramps, numbness or tingling in the fingers, toes, or around the mouth).

- **CONTRA-INDICATIONS** Hypocalcaemia
- **SIDE-EFFECTS**
  - **Common or very common** Abdominal discomfort, constipation, diarrhoea, dyspepsia, eczema, hypocalcaemia, fatigue cases reported, hypophosphataemia, musculoskeletal pain, pain in extremity, rash, scatica, sweating, upper respiratory tract infection, urinary tract infection
  - **Uncommon** Cellulitis, diverticulitis, ear infection, skin infections (seek prompt medical attention)
  - **Rare** Atypical femoral fractures, osteonecrosis of the jaw
- **CONCEPTION AND CONTRACEPTION** Ensure effective contraception in women of child-bearing potential, during treatment and for at least 5 months after stopping treatment.
- **PREGNANCY** Avoid—in toxicity in animal studies; risk of toxicity increases with each trimester—advise women who become pregnant during treatment to enrol in the manufacturer’s Pregnancy Surveillance Programme (consult product literature).
- **BREAST FEEDING** Avoid (if women do decide to breast-feed during treatment, they should enrol in the manufacturer’s Lactation Surveillance Programme—consult product literature.
- **RENAI IMPAIRMENT** Increased risk of hypocalcaemia if eGFR less than 30 mL/minute/1.73 m².
- **MONITORING REQUIREMENTS** Correct hypocalcaemia and vitamin D deficiency before starting. Monitor plasma-calcium concentration during therapy.
- **PATIENT AND CARER ADVICE** A patient reminder card should be provided (risk of osteonecrosis of the jaw). Atypical femoral fractures Patients should be advised to report any new or unusual thigh, hip, or groin pain during treatment with denosumab. Osteonecrosis of the jaw All patients should be informed to maintain good oral hygiene, receive routine dental check-ups, and immediately report any oral symptoms such as dental mobility, pain, or swelling to a doctor and dentist. Hypocalcaemia. All patients should be advised to report symptoms of hypocalcaemia to their doctor (e.g. muscle spasms, twitches, cramps, numbness or tingling in the fingers, toes, or around the mouth).
- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **NICE technology appraisals (TAs)**
    - Denosumab for the prevention of osteoporotic fractures in postmenopausal women (October 2010) NICE TA204
    - Denosumab is recommended as a treatment option for the primary prevention of osteoporotic fragility fractures in postmenopausal women at increased risk of fractures:
      - who are unable to comply with the special instructions for administering alendronate and risedronate, or have an intolerance of, or a contra-indication to, those treatments and
      - who comply with particular combinations of bone mineral density measurement, age, and independent risk factors for fracture, as indicated in the full NICE guidance.

Denosumab is recommended as a treatment option for the secondary prevention of osteoporotic fragility fractures only in postmenopausal women at increased risk of fractures who are unable to comply with the special instructions for administering alendronate and risedronate, or have an intolerance of, or a contra-indication to, those treatments.

- **SIDE-EFFECTS**
  - Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (October 2012) NICE TA265
    - Denosumab is recommended for the prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate if:
      - bisphosphonates would otherwise be prescribed, and
      - the manufacturer provides denosumab with the discount agreed in the patient access scheme.
    - Patients with bone metastases from solid tumours currently receiving denosumab whose disease does not meet the above criteria can continue treatment until they and their clinician consider it appropriate to stop.
    - www.nice.org.uk/TA265
- **PROLIA**
  - **Scottish Medicines Consortium (SMC) Decisions**
  - *The Scottish Medicines Consortium has advised (November 2010) that denosumab (Prolia®) is accepted for restricted use within NHS Scotland for the treatment of osteoporosis in postmenopausal women at increased risk of fractures who have a bone mineral density T-score < −2.5 and ≥−4.0 and for whom bisphosphonates are unsuitable.*

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

- **Solution for injection**
  - **Prolia** (Amgen Ltd)
    - Denosumab 60 mg per 1 ml Prolia 60mg/1ml solution for injection pre-filled syringes 1 pre-filled disposable injection (PHV) £183.00 DT price = £183.00
    - Xgeva (Amgen Ltd)
  - **Xgeva** 70 mg per 1 ml Xgeva 120mg/1.7ml solution for injection vials 1 vial (PHV) £309.86

## 5 Dopamine responsive conditions

### DOPAMINERGIC DRUGS > DOPAMINE RECEPTOR AGONISTS

**Dopamine-receptor agonists**

**Overview**

Bromocriptine p. 399 is used for the treatment of galactorrhoea, and for the treatment of prolactinomas (when it reduces both plasma prolactin concentration and tumour size). Bromocriptine also inhibits the release of growth hormone and is sometimes used in the treatment of acromegaly, but somatostatin analogues (such as octreotide p. 877) are more effective.

Cabergoline p. 400 has similar side-effects to bromocriptine, however patients intolerant of bromocriptine may be able to tolerate cabergoline (and vice versa).
Quinagolide below has actions and uses similar to those of ergot-derived dopamine agonists, but its side-effects differ slightly.

### Suppression of lactation

Although bromocriptine and cabergoline are licensed to suppress lactation, they are not recommended for routine suppression (or for the relief of symptoms of postpartum pain and engorgement) that can be adequately treated with simple analgesics and breast support. If a dopamine-receptor agonist is required, cabergoline is preferred. Quinagolide is not licensed for the suppression of lactation.

### Quinagolide

**Drug action** Quinagolide is a non-ergot dopamine D₂ agonist.

#### Indications and dose

**Hyperprolactinaemia**

- **By mouth**
  - Adult: Initially 25 micrograms once daily for 3 days, dose to be taken at bedtime, increased in steps of 25 micrograms every 3 days; usual dose 75–150 micrograms daily, for doses higher than 300 micrograms daily increase in steps of 75–150 micrograms at intervals of not less than 4 weeks

**Unlicensed use** Not licensed for the suppression of lactation.

**Caution**

- Acute porphyrias p. 969
- History of psychotic illness
- History of serious mental disorders

**Caution, Further information**

Hyperprolactinaemic patients In hyperprolactinaemic patients, the source of the hyperprolactinaemia should be established (i.e. exclude pituitary tumour before treatment).

**Interactions**

- Common or very common
  - Abdominal pain
  - Anorexia
  - Constipation or diarrhoea
  - Dizziness
  - Fatigue
  - Flushing
  - Headache
  - Hypotension
  - Insomnia
  - Nasal congestion
  - Nausea
  - Oedema
  - Syncope
  - Vomiting

- Very rare
  - Psychosis

**Side-effects**

- Gastro-intestinal bleeding
  - Treatment should be withdrawn if gastro-intestinal bleeding occurs.

**Allergy and cross-sensitivity**

Quinagolide should not be used in patients with hypersensitivity to quinagolide (does not apply to hypersensitivity to ergot alkaloids).

**Conception and contraception**

Advise non-hormonal contraception if pregnant not desired.

**Pregnancy**

Discontinue when pregnancy confirmed unless medical reason for continuing (specialist advice needed).

**Breast feeding**

Suppresses lactation.

**Hepatic impairment**

Avoid—no information available.

**Renal impairment**

Avoid—no information available.

**Monitoring requirements**

Monitor blood pressure for a few days after starting treatment and following dosage increase.

**Patient and carer advice**

- **Sudden onset of sleep**
  - Excessive daytime sleepiness and sudden onset of sleep can occur with dopamine-receptor agonists.

  Patients starting treatment with these drugs should be warned of the risk and of the need to exercise caution when driving or operating machinery. Those who have experienced excessive sedation or sudden onset of sleep should refrain from driving or operating machines until these effects have stopped occurring.

  Management of excessive daytime sleepiness should focus on the identification of an underlying cause, such as depression or concomitant medication. Patients should be counselled on improving sleep behaviour.

**Hypotensive reactions**

Hypotensive reactions can be disturbing in some patients during the first few days of treatment with dopamine-receptor agonists, particular care should be exercised when driving or operating machinery.

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

<table>
<thead>
<tr>
<th>Cautionary and advisory labels 10, 21</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Quinagolide (Non-proprietary)</strong></td>
</tr>
<tr>
<td>25 microgram Quinagolide 25 microgram tablets</td>
</tr>
<tr>
<td>50 microgram Quinagolide 50 microgram tablets</td>
</tr>
<tr>
<td>75 microgram Quinagolide 75 microgram tablets</td>
</tr>
<tr>
<td>582.50 DT price = £55.00</td>
</tr>
<tr>
<td>Quinagolide 50 microgram tablets and Quinagolide 25 microgram tablets</td>
</tr>
<tr>
<td><strong>Norprolac (Ferring Pharmaceuticals Ltd)</strong></td>
</tr>
<tr>
<td>Quinagolide (as Quinagolide hydrochloride) 25 microgram Norprolac 25 microgram tablets</td>
</tr>
<tr>
<td>Quinagolide (as Quinagolide hydrochloride) 50 microgram Norprolac 50 microgram tablets</td>
</tr>
</tbody>
</table>

---

### 6 Gonadotrophin responsive conditions

#### Gonadotrophins

**Drugs affecting gonadotrophins**

Danazol p. 699 is licensed for the treatment of endometriosis and for the relief of severe pain and tenderness in benign fibrocystic breast disease where other measures have proved unsatisfactory. It may also be effective in the long-term management of hereditary angioedema [unlicensed indication].

Cetrorelix p. 694 and ganirelix p. 694 are luteinising hormone releasing hormone antagonists, which inhibit the release of gonadotrophins (luteinising hormone and follicle stimulating hormone). They are used in the treatment of infertility by assisted reproductive techniques.

**Gonadorelin analogues**

Gonadorelin analogues are used in the treatment of endometriosis, precocious puberty, infertility, male hypersexuality with severe sexual deviation, anaemia due to uterine fibroids (together with iron supplementation), breast cancer, prostate cancer and before in-uterine surgery. Use of leuprolrelin acetate and triptorelin for 3 to 4 months before surgery reduces the uterine volume, fibroid size and associated bleeding. For women undergoing hysterecomy or myomectomy, a vaginal procedure is made more feasible following the use of a gonadorelin analogue.

**Breast pain (mastalgia)**

Once any serious underlying cause for breast pain has been ruled out, most women will respond to reassurance and reduction in dietary fat; withdrawal of an oral contraceptive
Endocrine system

694 Gonadotropin responsive conditions

BNF 74

or of hormone replacement therapy may help to resolve the pain.
Mild, non-cyclical breast pain is treated with simple analgesics; moderate to severe pain, cyclical pain or symptoms that persist for longer than 6 months may require specific drug treatment.
Danazol is licensed for the relief of severe pain and tenderness in benign fibrocystic breast disease which has not responded to other treatment.
Tamoxifen p. 879 may be a useful adjunct in the treatment of mastalgia [unlicensed indication] especially when symptoms can definitely be related to cyclic oestrogen production; it may be given on the days of the cycle when symptoms are predicted.
Treatment for breast pain should be reviewed after 6 months and continued if necessary. Symptoms recur in about 50% of women within 2 years of withdrawal of therapy but may be less severe.

PITUITARY AND HYPOTHALAMIC HORMONES

AND ANALOGUES  >  ANTI-GONADOTROPHIN-RELEASING HORMONES

Cetrorelix

● INDICATIONS AND DOSE

Adjunct in the treatment of female infertility (initiated under specialist supervision)

> BY SUBCUTANEOUS INJECTION

> Adult (female): 250 micrograms once daily, dose to be administered in the morning, starting on day 5 or 6 of ovarian stimulation with gonadotrophins (or each evening starting on day 5 of ovarian stimulation), continue throughout administration of gonadotrophin including day of ovulation induction (or evening before ovulation induction), dose to be injected into the lower abdominal wall.

> BY INTRanasal ADMINISTRATION

> Adult: 150 microgram spray into each nostril 1–2 times a day maximum duration of treatment 6 months then maintained during gonadotrophin administration (stopping gonadotrophin and buserelin on day 21) and continued until down-regulation achieved (usually 1–3 weeks) then maintained during gonadotrophin administration (stopping gonadotrophin and buserelin on administration of choriionic gonadotrophin at appropriate stage of follicular development)

> BY INTRanasAL ADMINISTRATION

> Adult: 200–500 micrograms once daily, increased if necessary up to 500 micrograms twice daily, starting in early follicular phase (day 1) or, after exclusion of pregnancy, in midluteal phase (day 21) and continued until down-regulation achieved (usually 1–3 weeks) then maintained during gonadotrophin administration (stopping gonadotrophin and buserelin on administration of choriionic gonadotrophin at appropriate stage of follicular development)

● SIDE-EFFECTS

> Very rare  Facial oedema  hypersensitivity reactions  rash

> Frequency not known  Dyspnoea  headache  injection-site reactions  malaise  nausea

> PREGNANCY  Avoid in confirmed pregnancy—toxicity in animal studies.

> BREAST FEEDING  Avoid—no information available.

> HEPATIC IMPAIRMENT  Avoid in moderate or severe hepatic impairment.

> RENAL IMPAIRMENT  Avoid in moderate to severe renal impairment.

● MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Powder and solvent for solution for injection

> Cetrotide  (Merck Serono Ltd)

Cetrorelix (as Cetrorelix acetate) 250 microgram  Cetrotide  250 microgram powder and solvent for solution for injection vials  1 vial (PODS) £22.61

Ganirelix

● INDICATIONS AND DOSE

Adjunct in the treatment of female infertility (initiated under specialist supervision)

> BY SUBCUTANEOUS INJECTION

> Adult: 250 micrograms once daily, dose to be administered in the morning (or each afternoon) starting on day 5 or day 6 of ovarian stimulation with gonadotrophins, continue throughout administration of gonadotrophins including day of ovulation induction (if administering in afternoon, give last dose in afternoon before ovulation induction), dose to be injected preferably into the upper leg (rotate injection sites to prevent lipoatrophy)

> BY INTRANASAL ADMINISTRATION

> Adult: 300 micrograms 3 times a day maximum duration of treatment 6 months then maintained during gonadotrophin administration (stopping gonadotrophin and buserelin on administration of choriionic gonadotrophin at appropriate stage of follicular development)

● INDICATIONS AND DOSE

Endometriosis

> BY INTRanasAL ADMINISTRATION

> Adult: 300 micrograms 3 times a day maximum duration of treatment 6 months then maintained during gonadotrophin administration (stopping gonadotrophin and buserelin on administration of choriionic gonadotrophin at appropriate stage of follicular development)

> BY SUBCUTANEOUS INJECTION

> Adult: 200–500 micrograms once daily, increased if necessary up to 500 micrograms twice daily, starting in early follicular phase (day 1) or, after exclusion of pregnancy, in midluteal phase (day 21) and continued until down-regulation achieved (usually 1–3 weeks) then maintained during gonadotrophin administration (stopping gonadotrophin and buserelin on administration of choriionic gonadotrophin at appropriate stage of follicular development)

> BY INTRanasAL ADMINISTRATION

> Adult: 200–500 micrograms once daily, increased if necessary up to 500 micrograms twice daily, starting in early follicular phase (day 1) or, after exclusion of pregnancy, in midluteal phase (day 21) and continued until down-regulation achieved (usually 1–3 weeks) then maintained during gonadotrophin administration (stopping gonadotrophin and buserelin on administration of
chorionic gonadotrophin at appropriate stage of follicular development

Advanced prostate cancer

- **INITIALLY BY SUBCUTANEOUS INJECTION**
  - Adult: 500 micrograms every 8 hours for 7 days, then (by intranasal administration) 200 micrograms 6 times a day, (a single 100 microgram spray to be administered into each nostril)

**SIDE-EFFECTS**

- **GENERAL SIDE-EFFECTS**
  - Abdominal pain, acne, altered blood lipids, anaphylaxis, anxiety, arthralgia, asthma, bleeding associated with fibroid degeneration (when treating uterine fibroids), breakthrough bleeding, breast tenderness, changes in appetite, changes in breast size, changes in scalp and body hair, concentration disturbances, constipation, decrease in trabecular bone density, depression, diarrhoea, dizziness, drowsiness, dry eyes, dry skin, dyspareunia, fatigue, gynaecomastia, hair loss, headache, hearing disturbances, hot flushes, hypersensitivity reactions, hypertension, increased sweating, increased thirst, initially withdrawal bleeding, lactation, leucopenia, leucorrhoea, local reactions at injection site, loss of libido, memory disturbances, menopausal-like symptoms, migraine, mood changes, musculoskeletal pain, musculoskeletal weakness, myalgia, nausea, nervousness, oedema of the face and extremities, ovarian cysts (may require withdrawal), palpitation, paraesthesia, pruritus, rash, reduced glucose tolerance, sexual dysfunction, sleep disturbances, splitting nails, thrombocytopenia, urticaria, vaginal dryness, visual disturbances, vomiting, weight changes

**SPECIFIC SIDE-EFFECTS**

- With intranasal use: Altered sense of taste and smell, nasal irritation, nose bleeds

**SIDE-EFFECTS, FURTHER INFORMATION**

- Tumour flare (when used for advanced prostate cancer) During the initial stage (1–2 weeks) increased production of testosterone may be associated with progression of prostate cancer. In susceptible patients this tumour ‘flare’ may cause spinal cord compression, ureteric obstruction or increased bone pain.

**CONCEPTION AND CONTRACEPTION**

- Non-hormonal, barrier methods of contraception should be used during entire treatment period. Pregnancy should be excluded before treatment, the first injection should be given during menstruation or shortly afterwards or use barrier contraception for 1 month beforehand.

**PREGNANCY**

- Avoid.

**BREAST FEEDING**

- Avoid.

**DIRECTIONS FOR ADMINISTRATION**

- With intranasal use: Avoid use of nasal decongestants before treatment and for at least 30 minutes after treatment.
- With subcutaneous use: Rotate injection site to prevent atrophy and nodule formation.

**PATIENT AND CARER ADVICE**

- Patients or carers should be given advice on how to administer buserelin nasal spray.

**CAUTIONS**

- Depression, diabetes, hypertension, patients with metabolic bone disease (decrease in bone mineral density can occur), polycystic ovarian disease

**PATIENT AND CARER ADVICE**

- When used for endometriosis: Hormone dependent tumours, undiagnosed vaginal bleeding, use longer than 6 months (do not repeat)
- When used for pituitary desensitisation: Hormone dependent tumours, undiagnosed vaginal bleeding

**INDICATIONS AND DOSE**

**Goseralin**

- **DRUG ACTION**
  - Administration of gonadorelin analogues produces an initial phase of stimulation; continued administration is followed by down-regulation of gonadotrophin-releasing hormone receptors, thereby reducing the release of gonadotrophins (follicle stimulating hormone and luteinising hormone) which in turn leads to inhibition of androgen and oestrogen production.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Suprecur** (Sanofi)
  - Buserelin (as Buserelin acetate) 1 mg per 1 ml Suprecur
    - 5.5mg/5.5ml solution for injection vials | 2 vial [Pom] £33.02
  - **Suprecur** (Sanofi)
  - Buserelin (as Buserelin acetate) 1 mg per 1 ml Suprecur
    - 5.5mg/5.5ml solution for injection vials | 2 vial [Pom] £34.37

**Spray**

- **Suprecur** (Sanofi)
  - Buserelin (as Buserelin acetate) 150 microgram per 1 dose Suprecur
    - 150micrograms/dose nasal spray | 168 dose [Pom] £105.16
  - **Suprecur** (Sanofi)
  - Buserelin (as Buserelin acetate) 100 microgram per 1 dose Suprecur
    - 100micrograms/dose nasal spray | 336 dose [Pom] £122.24

**ZOLADEX LA®**

- Locally advanced prostate cancer as an alternative to surgical castration | Adjuvant treatment to radiotherapy or radical prostatectomy in patients with high-risk localised or locally advanced prostate cancer | Neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer | Metastatic prostate cancer
  - **BY SUBCUTANEOUS INJECTION**
  - Adult: 10.8 mg every 12 weeks, to be administered into the anterior abdominal wall

**ZOLADEX®**

- Locally advanced prostate cancer as an alternative to surgical castration | Adjuvant treatment to radiotherapy or radical prostatectomy in patients with high-risk localised or locally advanced prostate cancer | Neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer | Metastatic prostate cancer | Advanced breast cancer | Oestrogen-receptor-positive early breast cancer
  - **BY SUBCUTANEOUS INJECTION**
  - Adult: 3.6 mg every 28 days, to be administered into the anterior abdominal wall

**Endometriosis**

- **BY SUBCUTANEOUS INJECTION**
  - Adult: 3.6 mg every 28 days maximum duration of treatment 6 months (do not repeat), to be administered into the anterior abdominal wall

**Endometrial thinning before intra-uterine surgery**

- **BY SUBCUTANEOUS INJECTION**
  - Adult: 3.6 mg, dose may be repeated after 28 days if uterus is large or to allow flexible surgical timing, to be administered into the anterior abdominal wall

**Before surgery in women who have anaemia due to uterine fibroids**

- **BY SUBCUTANEOUS INJECTION**
  - Adult: 3.6 mg every 28 days maximum duration of treatment 3 months, to be given with
supplementary iron, to be administered into the anterior abdominal wall

Pituitary desensitisation before induction of ovulation by gonadotrophins for in vitro fertilisation (after exclusion of pregnancy) (under expert supervision)

- By subcutaneous injection
  - Adult: 3.6 mg, dose given to achieve pituitary down-regulation (usually 1–3 weeks) then gonadotrophin is administered (stopping gonadotrophin on administration of chorionic gonadotrophin at appropriate stage of follicular development), to be administered into the anterior abdominal wall

- Contra-indications
  - Undiagnosed vaginal bleeding: use longer than 6 months in endometriosis (do not repeat)
  - Rare: Hypercalcaemia (in women)
  - Frequency not known
    - Anaphylaxis - arthralgia - asthma - breast tenderness - changes in blood pressure - changes in breast size - changes in scalp and body hair - decrease in trabecular bone density - depression - dizziness - dyspareunia (when used for gynaecological conditions) - gastro-intestinal disturbances - gynaecomastia - headache - heart failure (when used for prostate or breast cancer) - hot flushes - hypersensitivity reactions - increased sweating - local reactions at injection site - loss of libido - menopausal-like symptoms - migraine - mood changes - musculoskeletal pain - musculoskeletal weak (when used for gynaecological conditions) - myalgia - myocardial infarction (when used for prostate or breast cancer) - oedema of the face and extremities (when used for gynaecological conditions) - ovarian cysts (may require withdrawal) - palpitation (when used for gynaecological conditions) - paraesthesia - parasthesia - pruritus - rash - sexual dysfunction - sleep disorders - urticaria - vaginal bleeding - vaginal dryness - visual disturbances - weight change - withdrawal bleeding

- Side-effects, further information
  - Tumour flare (when used for advanced prostate cancer) During the initial stage (1–2 weeks) increased production of testosterone may be associated with progression of prostate cancer. In susceptible patients this tumour ‘flare’ may cause spinal cord compression, ureretic obstruction or increased bone pain.

- Contra-indications
  - Non-hormonal, barrier methods of contraception should be used during entire treatment period. Pregnancy should be excluded before treatment, the first injection should be given during menstruation or shortly afterwards or use barrier contraception for 1 month beforehand.

- Pregnancy
  - Avoid.

- Breast feeding
  - Avoid.

- Monitoring requirements
  - Men at risk of tumour ‘flare’ should be monitored closely during the first month of therapy for prostate cancer.

- Directions for administration
  - Rotate injection site to prevent atrophy and nodule formation.

Leuprolrelin acetate

- Drug action
  - Administration of gonadorelin analogues produces an initial phase of stimulation; continued administration is followed by down-regulation of gonadotrophin-releasing hormone receptors, thereby reducing the release of gonadotrophins ( follicle stimulating hormone and lutening hormone) which in turn leads to inhibition of androgen and oestrogen production.

- Indications and dose

  **Prostap 3 Dcs**
  - Locally advanced prostate cancer as an alternative to surgical castration | Adjuvant treatment to radiotherapy or radical prostatectomy in patients with high-risk localised or locally advanced prostate cancer | Metastatic prostate cancer
  - By subcutaneous injection
  - Adult: 11.25 mg every 3 months

  **Endometriosis**
  - By intramuscular injection
  - Adult: Initially 11.25 mg for single dose to be given as a single dose in first 5 days of menstrual cycle, then 11.25 mg every 3 months for maximum 6 months (course not to be repeated)

  **Prostap Sr Dcs**
  - Locally advanced prostate cancer as an alternative to surgical castration | Adjuvant treatment to radiotherapy or radical prostatectomy in patients with high-risk localised or locally advanced prostate cancer | Metastatic prostate cancer
  - By subcutaneous injection, or by intramuscular injection
  - Adult: 3.75 mg every month

  **Endometriosis**
  - By subcutaneous injection, or by intramuscular injection
  - Adult: Initially 3.75 mg for single dose, dose to be given as a single dose in first 5 days of menstrual cycle, then 3.75 mg every month for maximum 6 months (course not to be repeated)

  **Endometrial thinning before intra-uterine surgery**
  - By subcutaneous injection, or by intramuscular injection
  - Adult: Initially 3.75 mg for single dose, dose to be given as a single dose between day 3 and 5 of menstrual cycle, 5–6 weeks before surgery

  **Reduction of size of uterine fibroids and of associated bleeding before surgery**
  - By subcutaneous injection, or by intramuscular injection
  - Adult: Initially 3.75 mg every month usually for 3–4 months (maximum 6 months)

- Contra-indications
  - General contra-indications
  - Undiagnosed vaginal bleeding
SPECIFIC CONTRA-INDICATIONS

- When used for endometriosis Use longer than 6 months (do not repeat)

- **CAUTIONS**
  - Diabetes · family history of osteoporosis · patients with metabolic bone disease (decrease in bone mineral density can occur) · risk of spinal cord compression in men with prostate cancer · risk of ureteric obstruction in men with prostate cancer

- **INTERACTIONS**
  - Appendix 1: leuprolin

- **SIDE-EFFECTS**
  - Alteration of glucose tolerance · altered blood lipids · anaphylaxis · anorexia · asthma · breast tenderness (males and females) · changes in blood pressure · changes in breast size · changes in scalp and body hair · chills · decrease in trabecular bone density · depression · diarrhoea · diziness · dyspareunia · fatigue · fever · gastrointestinal disturbances · headache · hot flushes · hypersensitivity reactions · increased sweating · jaundice · leucopenia · local reactions at injection site · loss of libido · menopausal-like symptoms · migraine · mood changes · musculoskeletal pain · musculoskeletal weakness · nausea · palpitation · paraesthesia · paraesthesia · pruritus · pulmonary embolism · rash · sexual dysfunction · sleep disturbances · spinal fracture · thrombocytopenia · urticaria · vaginal bleeding · vaginal dryness · visual disturbances · vomiting · weight changes

SIDE-EFFECTS, FURTHER INFORMATION

- Tumour flare (when used for advanced prostate cancer) During the initial stage (1–2 weeks) increased production of testosterone may be associated with progression of prostate cancer. In susceptible patients this tumour ‘flare’ may cause spinal cord compression, ureteric obstruction or increased bone pain.

- **CONCEPTION AND CONTRACEPTION**
  - Non-hormonal, barrier methods of contraception should be used during entire treatment period. Pregnancy should be excluded before treatment, the first injection should be given during menstruation or shortly afterwards or use barrier contraception for 1 month beforehand.

- **PREGNANCY**
  - Avoid—teratogenic in animal studies.

- **BREAST FEEDING**
  - Avoid.

- **MONITORING REQUIREMENTS**
  - Monitor liver function.
  - Men at risk of tumour ‘flare’ should be monitored closely during the first month of therapy.

- **DIRECTIONS FOR ADMINISTRATION**
  - Rotate injection site to prevent atrophy and nodule formation.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

 **Powder and solvent for suspension for injection**

- **Prostap 3 DCS (Takeda UK Ltd)**
  - Leuprorelin acetate 11.25 mg Prostap 3 DCS 11.25mg powder and solvent for suspension for injection pre-filled syringes | 1 pre-filled disposable injection [Pack] £225.72 DT price = £225.72

- **Prostap SR DCS (Takeda UK Ltd)**
  - Leuprorelin acetate 3.75 mg Prostap SR DCS 3.75mg powder and solvent for suspension for injection pre-filled syringes | 1 pre-filled disposable injection [Pack] £75.24 DT price = £75.24

- **DRUG ACTION**
  - Administration of gonadorelin analogues produces an initial phase of stimulation; continued administration is followed by down-regulation of gonadotrophin-releasing hormone receptors, thereby reducing the release of gonadotrophins (follicle stimulating hormone and luteinising hormone) which in turn leads to inhibition of androgen and oestrogen production.

- **INDICATIONS AND DOSE**

  **Endometriosis**
  - **BY INTRANASAL ADMINISTRATION**
    - Adult (female): 200 micrograms twice daily for maximum 6 months (do not repeat), one spray in one nostril in the morning, and one spray in the other nostril in the evening (starting on days 2–4 of menstruation)

  **Pituitary desensitisation before induction of ovulation by gonadotrophins for in vitro fertilisation (under expert supervision)**
  - **BY INTRANASAL ADMINISTRATION**
    - Adult: 400 micrograms twice daily, one spray in each nostril, to be started in early follicular phase (day 2) or, after exclusion of pregnancy, in midluteal phase (day 21) and continued until down regulation achieved (usually within 4 weeks) then maintained (usually for 8–12 days) during gonadotrophin administration (stopping gonadotrophin and nafarelin on administration of chorionic gonadotrophin at follicular maturity), discontinue if down-regulation not achieved within 12 weeks

- **CONTRA-INDICATIONS**
  - Undiagnosed vaginal bleeding · use longer than 6 months in the treatment of endometriosis (do not repeat)

- **CAUTIONS**
  - Patients with metabolic bone disease (decrease in bone mineral density can occur)

- **SIDE-EFFECTS**
  - Acne · anaphylaxis · asthma · changes in breast size · changes in scalp and body hair · decrease in trabecular bone density · depression · dyspareunia · headache · hot flushes · hypersensitivity reactions · hypertension · increased sweating · irritation of the nasal mucosa · loss of libido · menopausal-like symptoms · migraine · mood changes · musculoskeletal pain · musculoskeletal weakness · oedema of the face and extremities · ovarian cysts (may require withdrawal) · palpitation · paraesthesia · pruritus · rash · urticaria · vaginal dryness · visual disturbances · weight changes

SIDE-EFFECTS, FURTHER INFORMATION

- Menopausal-like symptoms These effects can be reduced by hormone replacement (e.g. with an oestrogen and a progestogen or with tibolone).

- **CONCEPTION AND CONTRACEPTION**
  - Non-hormonal, barrier methods of contraception should be used during entire treatment period. Pregnancy should be excluded before treatment, the first dose should be given during menstruation or shortly afterwards or use barrier contraception for 1 month beforehand.

- **PREGNANCY**
  - Avoid.

- **BREAST FEEDING**
  - Avoid.

- **DIRECTIONS FOR ADMINISTRATION**
  - Avoid use of nasal decongestants before and for at least 30 minutes after treatment; repeat dose if sneezing occurs during or immediately after administration.

- **PATIENT AND CARER ADVICE**
  - Patients or carers should be given advice on how to administer nafarelin nasal spray.
MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Spray
CAUTORY AND ADVISORY LABELS 10
- Synarel (Pfizer Ltd) Nafarelin (as Nafarelin acetate) 200 microgram per
  1 dose Synarel 200micrograms/dose nasal spray | 60 dose POM
  £52.43

DRUG ACTION
Administration of gonadorelin analogues produces an initial phase of stimulation; continued administration is followed by down-regulation of gonadotrophin-releasing hormone receptors, thereby reducing the release of gonadotrophins (follicle stimulating hormone and luteinising hormone) which in turn leads to inhibition of androgen and oestrogen production.

INDICATIONS AND DOSE
DECAPEPTYL® SR 11.25MG
Locally advanced non-metastatic prostate cancer as an alternative to surgical castration | Metastatic prostate cancer | Adjuvant treatment to radiotherapy in high-risk localised or locally advanced prostate cancer | Neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer | Adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression
- BY INTRAMUSCULAR INJECTION
  Adult: 11.25 mg every 3 months
Endometriosis
- BY INTRAMUSCULAR INJECTION
  Adult: 11.25 mg every 3 months for maximum
  6 months (not to be repeated), to be started during first
  5 days of menstrual cycle
DECAPEPTYL® SR 22.5MG
Locally advanced non-metastatic prostate cancer as an alternative to surgical castration | Metastatic prostate cancer | Adjuvant treatment to radiotherapy in high-risk localised or locally advanced prostate cancer | Neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer | Adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression
- BY INTRAMUSCULAR INJECTION
  Adult: 22.5 mg every 6 months
DECAPEPTYL® SR 3MG
Locally advanced non-metastatic prostate cancer as an alternative to surgical castration | Metastatic prostate cancer | Adjuvant treatment to radiotherapy in high-risk localised or locally advanced prostate cancer | Neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer | Adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression
- BY INTRAMUSCULAR INJECTION
  Adult: 3 mg every 4 weeks
Endometriosis
- BY INTRAMUSCULAR INJECTION
  Adult: 3 mg every 4 weeks maximum duration of
  6 months (not to be repeated), to be started during first
  5 days of menstrual cycle

Reduction in size of uterine fibroids
- BY INTRAMUSCULAR INJECTION
  Adult: 3 mg every 4 weeks for at least 3 months, maximum duration of treatment 6 months (not to be repeated), to be started during first 5 days of menstrual cycle

GONAPEPTYL DEPOT®
Advanced prostate cancer
- BY SUBCUTANEOUS INJECTION, OR BY DEEP INTRAMUSCULAR INJECTION
  Adult: 3.75 mg every 4 weeks
Endometriosis | Reduction in size of uterine fibroids
- BY SUBCUTANEOUS INJECTION, OR BY DEEP INTRAMUSCULAR INJECTION
  Adult: 3.75 mg every 4 weeks maximum duration of
  6 months (not to be repeated), to be started during first
  5 days of menstrual cycle
SALVACYL®
Male hypersexuality with severe sexual deviation
- BY INTRAMUSCULAR INJECTION
  Adult: 11.25 mg every 12 weeks

CONTRA-INDICATIONS
In endometriosis do not use for longer than 6 months (do not repeat) - undiagnosed vaginal bleeding
SALVACYL® Severe osteoporosis

CAUTIONS
GENERAL CAUTIONS
Patients with metabolic bone disease (decrease in bone mineral density can occur)

SPECIFIC CAUTIONS
- When used for prostate cancer Risk factors for osteoporosis - risk of spinal cord compression in men - risk of ureteric obstruction in men
SALVACYL® Increased risk of sensitivity to restored testosterone if treatment interrupted—consider administration of an antiandrogen before stopping treatment - transient increase in serum testosterone occurs on initiation—consider administration of an anti-androgen

SIDE-EFFECTS
GENERAL SIDE-EFFECTS
Anaphylaxis | arthralgia | asthenia | asthma | breast tenderness (males and females) - changes in blood pressure | changes in breast size - changes in scalp and body hair - depression - gastro-intestinal disturbances - headache - hot flushes - hypersensitivity reactions - increased sweating - local reactions at injection site - mood changes - ovarian cysts (may require withdrawal) - paraesthesia - pruritus - rash - urticaria - visual disturbances - weight changes

SPECIFIC SIDE-EFFECTS
- When used for endometriosis Decrease in trabecular bone density - dyspareunia - loss of libido - menopausal-like symptoms - migraine - musculoskeletal pain - musculoskeletal weakness - oedema of the face and extremities - palpitation - vaginal dryness - withdrawal bleeding (may occur in the first month of treatment)
- When used for male hypersexuality with severe sexual deviation Decrease in trabecular bone density - dyspareunia - loss of libido - migraine - musculoskeletal pain - musculoskeletal weakness - oedema of the face and extremities - palpitation
- When used for prostate cancer Dizziness - dry mouth - hair loss - increased dysuria - myalgia - peripheral oedema - sexual dysfunction - sleep disorders
- When used for reduction in size of uterine fibroids Bleeding associated with fibroid degeneration - decrease in trabecular bone density - dyspareunia - loss of libido - menopausal-like symptoms - migraine - musculoskeletal density.
pain • musculoskeletal weakness • oedema of the face and extremities • palpitation • vaginal dryness • withdrawal bleeding (may occur in the first month of treatment)

SIDE-EFFECTS, FURTHER INFORMATION

- Tumour flare (when used for advanced prostate cancer) During the initial stage (1–2 weeks) increased production of testosterone may be associated with progression of prostate cancer. In susceptible patients this tumour ‘flare’ may cause spinal cord compression, ureteric obstruction or increased bone pain.

- CONCEPTION AND CONTRACEPTION Non-hormonal, barrier methods of contraception should be used during entire treatment period. Pregnancy should be excluded before treatment, the first injection should be given during menstruation or shortly afterwards or use barrier contraception for 1 month beforehand.

- PREGNANCY Avoid.

- BREAST FEEDING Avoid.

- MONITORING REQUIREMENTS

- When used for Prostate cancer Men at risk of tumour ‘flare’ should be monitored closely during the first month of therapy.

- DIRECTIONS FOR ADMINISTRATION Rotate injection site to prevent atrophy and nodule formation.

- PRESCRIBING AND DISPENSING INFORMATION

  DECAPEPTYL® SR 11.25MG Each vial includes an overage to allow accurate administration of an 11.25 mg dose.

  DECAPEPTYL® SR 22.5MG Each vial includes an overage to allow accurate administration of a 22.5 mg dose.

  DECAPEPTYL® SR 3MG Each vial includes an overage to allow accurate administration of 3 mg dose.

- NATIONAL FUNDING/ACCESS DECISIONS

All Wales Medicines Strategy Group (AWMSG) Decisions The All Wales Medicines Strategy Group (AWMSG) has advised (March 2017) that triptorelin (Decapeptyl® SR) is recommended as an option for use within NHS Wales as an adjuvant treatment to radiotherapy and as a neoadjuvant treatment prior to radiotherapy, in patients with high-risk localised or locally advanced prostate cancer.

- MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Powder and solvent for suspension for injection

- Decapeptyl® SR (Ipsen Ltd) Triptorelin (as Triptorelin acetate) 3 mg Decapeptyl® SR 3mg powder and solvent for suspension for injection vials | 1 vial | £65.00

- Decapeptyl® SR (Ipsen Ltd) Triptorelin (as Triptorelin acetate) 11.25 mg Decapeptyl® SR 11.25mg powder and solvent for suspension for injection vials | 1 vial | £200.00

- Decapeptyl® SR (Ipsen Ltd) Triptorelin (as Triptorelin embonate) 22.5 mg Decapeptyl® SR 22.5mg powder and solvent for suspension for injection vials | 1 vial | £414.00

- Gonapexyl Depot® (Ferring Pharmaceuticals Ltd) Triptorelin (as Triptorelin acetate) 3.75 mg Gonapexyl Depot 3.75mg powder and solvent for suspension for injection pre-filled disposable devices | 1 pre-filled disposable injection | £81.69

- Salvacyl® (Ipsen Ltd) Triptorelin (as Triptorelin embonate) 11.25 mg Salvacyl 11.25mg powder and solvent for suspension for injection vials | 1 vial | £248.00

6.1 Hereditary angioedema

PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES > ANTI-GONADOTROPHIN-RELEASING HORMONES

Danazol

- DRUG ACTION Danazol inhibits pituitary gonadotrophins; it combines androgenic activity with antioestrogenic and antiprogestogenic activity.

- INDICATIONS AND DOSE

  Endometriosis

  - BY MOUTH

  Adult: 200–800 mg daily in up to 4 divided doses usually for 3–6 months, dose to be adjusted to achieve amenorrhoea, in women of child-bearing potential, treatment should start during menstruation, preferably on day 1

  Severe pain and tenderness in benign fibrocystic breast disease not responding to other treatment

  - BY MOUTH

  Adult: 300 mg daily in divided doses usually for 3–6 months, in women of child-bearing potential, treatment should start during menstruation, preferably on day 1

- HEREDITARY ANGIOEDEMA

  - BY MOUTH

  Adult: Initially 100–200 mg daily, dose to be reduced according to response, in women of child-bearing potential, treatment should start during menstruation, preferably on day 1

- UNLICENSED USE Not licensed for use in hereditary angioedema.

- CONTRA-INDICATIONS Acute porphyrias p. 969 • androgen-dependent tumours • thromboembolic disease • undiagnosed genital bleeding

- CAUTIONS Cardiac impairment (avoid if severe) • diabetes mellitus • elderly • epilepsy • history of thrombosis or thromboembolic disease • hypertension • lipoprotein disorder • migraine • polycythaemia

- INTERACTIONS Appendix 1: danazol

- SIDE-EFFECTS

  Rare • Benign hepatic adenomata • cholestatic jaundice • clitoral hypertrophy • pancreatitis • peliosis hepatitis

  Frequency not known Acne • androgenic effects • anxiety • backache • changes in libido • dizziness • eosinophilia • epigastric pain • exfoliative dermatitis • fatigue • fever • flushing and reduction in breast size • hair loss • headache • headache (may indicate benign intracranial hypertension) • hirsutism • insulin resistance • joint pain • joint swelling • leucopenia • menstrual disturbances • mood changes • musculo-skeletal spasm • nausea • nervousness • oedema • oily skin • pleuritic pain • rashes • reversible erythrocytosis • reversible polycythaemia • skin reactions • temporary alteration in lipoproteins and other metabolic changes • thrombocytopoenia • thrombotic events • vaginal dryness • vaginal irritation • vertigo • visual disturbances (may indicate benign intracranial hypertension) • voice changes • weight gain

SIDE-EFFECTS, FURTHER INFORMATION

- Virilisation Withdraw if virilisation effects occur—may be irreversible on continued use.

- CONCEPTION AND CONTRACEPTION Ensure patients with amenorrhoea are not pregnant. Non-hormonal contraceptive methods should be used, if appropriate.
700 Hypothalamic and anterior pituitary hormone related disorders

7 Hypothalamic and anterior pituitary hormone related disorders

Hypothalamic and anterior pituitary hormones

Anterior pituitary hormones

Corticotrophins

Tetracosactide (tetracosactrin), an analogue of corticotropin (ACTH), is used to test adrenocortical function; failure of the plasma cortisol concentration to rise after administration of tetracosactide indicates adrenocortical insufficiency.

Both corticotropin and tetracosactide were formerly used as alternatives to corticosteroids in conditions such as Crohn's disease or rheumatoid arthritis; their value was limited by the variable and unpredictable therapeutic response and by the waning of their effect with time.

Gonadotrophins

Follicle-stimulating hormone (FSH) and luteinising hormone (LH) together, follicle-stimulating hormone alone (as in follitropin), or chionic gonadotrophin p. 702, are used in the treatment of infertility in women with proven hypopituitarism or who have not responded to clomifene citrate p. 723, or in superovulation treatment for assisted conception (such as in vitro fertilisation).

The gonadotrophins are also occasionally used in the treatment of hypergonadotrophic hypogonadism and associated oligosperma. There is no justification for their use in primary gonadal failure.

Chorionic gonadotrophin has also been used in delayed puberty in the male to stimulate endogenous testosterone production, but has little advantage over testosterone.

Growth hormone

Growth hormone is used to treat deficiency of the hormone in children and in adults. In children it is used in Prader-Willi syndrome, Turner syndrome, chronic renal insufficiency, short children considered small for gestational age at birth, and short stature homeobox-containing gene (SHOX) deficiency.

Growth hormone of human origin (HGH; somatotrophin) has been replaced by a growth hormone of human sequence, somatropin p. 705, produced using recombinant DNA technology.

Mecasermin, a human insulin-like growth factor-I (rhIGF-I), is licensed to treat growth failure in children and adolescents with severe primary insulin-like growth factor-I deficiency.

Hypothalamic hormones

Gonadorelin p. 701 when injected intravenously in normal subjects leads to a rapid rise in plasma concentrations of both luteinising hormone (LH) and follicle-stimulating hormone (FSH). It has not proved to be very helpful, however, in distinguishing hypothalamic from pituitary lesions. Gonadorelin analogues are indicated in endometriosis and infertility and in breast and prostate cancer.

7.1 Adrenocortical function testing

PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES > CORTICOTROPHINS

Tetracosactide

(Tetracosactrin)

CONTRA-INDICATIONS

Acute psychosis - adenogenital syndrome - allergic disorders - asthma - avoid injections containing benzyl alcohol in neonates - Cushing's syndrome - infectious diseases - peptic ulcer - primary adrenocortical insufficiency - refractory heart failure

CAUTIONS

Active infectious diseases (should not be used unless adequate disease-specific therapy is being given) - active systemic diseases (should not be used unless adequate disease-specific therapy is being given) - diabetes mellitus - diverticulitis - history of asthma - history of atopic allergy - history of eczema - history of hayfever - history of hypersensitivity - hypertension - latent amoebiasis (may become activated) - latent tuberculosis (may become activated) - myasthenia gravis - ocular herpes simplex - osteoporosis - predisposition to thromboembolic - psychological disturbances may be triggered - recent intestinal anastomosis - reduced immune response (should not be used unless adequate disease-specific therapy is being given) - ulcerative colitis
7.2 Assessment of pituitary function

PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES \( \supset \) GONADOTROPIN-RELEASING HORMONES

**Gonadorelin**

**(Gonadotrophin-releasing hormone; GnRH; LH-RH)**

- **INDICATIONS AND DOSE**
  - **Assessment of pituitary function**
    - **By subcutaneous injection, or by intravenous injection**
    - Adult: 100 micrograms for 1 dose
  - **CAUTIONS**
    - Pituitary adenoma
  - **SIDE-EFFECTS**
    - Abdominal pain
    - Headache
    - Hypersensitivity reaction on repeated administration of large doses
    - Increased menstrual bleeding
    - Irritation at injection site
    - Nausea
  - **PREGNANCY**
    - Avoid
  - **BREAST FEEDING**
    - Avoid

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Powder and solvent for solution for injection**
    - **Gonadorelin (Non-proprietary)**
      - 100 microgram Gonadorelin 100 microgram powder and solvent for solution for injection vials | 1 vial (POD) £75.00 (Hospital only)

7.3 Gonadotrophin replacement therapy

**GONADOTROPHINS**

**Choriogonadotropin alfa**

**(Human chorionic gonadotropin)**

- **INDICATIONS AND DOSE**
  - Treatment of infertility in women with proven hypopituitarism or who have not responded to clomifene.
  - Superovulation treatment for assisted conception (such as in vitro fertilisation)
  - **By subcutaneous injection**
    - Adult (female): Adjusted according to response.

- **CONTRA-INDICATIONS**
  - Active thromboembolic disorders
  - Ectopic pregnancy in previous 3 months
  - Hypothalamic malignancy
  - Mammary malignancy
  - Ovarian enlargement or cyst (unless caused by polycystic ovarian disease)
  - Ovarian malignancy
  - Pituitary malignancy
  - Uterine malignancy

- **CAUTIONS**
  - Acute porphyrias p. 969

- **SIDE-EFFECTS**
  - Abdominal pain
  - Depression
  - Diarrhoea
  - Ecopic pregnancy
  - Headache
  - Injection-site
reactions · irritability · nausea · ovarian hyperstimulation syndrome · ovarian torsion · tiredness · vomiting

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**
- Ovitrelle (Merck Serono Ltd)
  - Chorionic gonadotrophin alfa 500 microgram per 1 ml
  - Ovitrelle 250micrograms/0.5ml solution for injection pre-filled syringes | 1 pre-filled disposable injection [Pom] £31.38 (C04-2)
  - Ovitrelle 250micrograms/0.5ml solution for injection pre-filled pen | 1 pre-filled disposable injection [Pom] £31.38 (C04-2)

**Chorionic gonadotrophin**
(Human chorionic gonadotrophin; HCG)

**DRUG ACTION** A preparation of a glycoprotein fraction secreted by the placenta and obtained from the urine of pregnant women having the action of the pituitary luteinising hormone.

**INDICATIONS AND DOSE**
Treatment of infertility in women with proven hypopituitarism or who have not responded to clomifene | Superovulation treatment for assisted conception (such as in vitro fertilisation)
- BY INTRAMUSCULAR INJECTION, OR BY SUBCUTANEOUS INJECTION
- Adult (female): Adjusted according to response.

**CONTRA-INDICATIONS** Androgen-dependent tumours
**CAUTIONS** Asthma · cardiac impairment · epilepsy · migraine · prepubertal boys (risk of premature epiphysseal closure or precocious puberty)
**SIDE-EFFECTS** Gynaecomastia · headache · local reactions · may aggravate ovarian hyperstimulation · mood changes · multiple pregnancy · oedema (particularly in males—reduce dose) · tiredness
**RENAL IMPAIRMENT** Use with caution.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Powder and solvent for solution for injection**
- Choragon (Ferring Pharmaceuticals Ltd)
  - Chorionic gonadotrophin human 5000 unit | Choragon 5,000unit powder and solvent for solution for injection ampoules | 3 ampoules [Pom] £9.77 (C04-Z)
- Pregnyl (Merck Sharp & Dohme Ltd)
  - Chorionic gonadotrophin human 1500 unit | Pregnyl 1,500unit powder and solvent for solution for injection ampoules | 1 ampoule [Pom] £2.12 (C04-Z)
  - Chorionic gonadotrophin human 5000 unit | Pregnyl 5,000unit powder and solvent for solution for injection ampoules | 1 ampoule [Pom] £3.15 (C04-Z)

**Corifollitropin alfa**

**INDICATIONS AND DOSE**
Controlled ovarian stimulation in combination with a gonadotrophin-releasing hormone antagonist
- BY SUBCUTANEOUS INJECTION
  - Adult (body-weight up to 60 kg): 100 micrograms
  - Adult (body-weight 60 kg and above): 150 micrograms

**CONTRA-INDICATIONS** History of ovarian hyperstimulation syndrome · ovarian enlargement or cyst · polycystic ovarian syndrome · tumours of breast · tumours of hypothalamus · tumours of ovaries · tumours of pituitary · tumours of uterus · vaginal bleeding of unknown cause

**CAUTIONS** Acute porphyrias p. 969 · risk factors for thromboembolism · risk of ovarian hyperstimulation syndrome

**SIDE-EFFECTS**
- Common or very common Breast pain · fatigue · headache · nausea · ovarian hyperstimulation · pelvic pain
- Uncommon Abdominal distension and pain · constipation · diarrhoea · dizziness · ovarian torsion · vomiting
- Frequency not known Ectopic pregnancy · miscarriage · multiple pregnancies
**BREAST FEEDING** Avoid.
**RENAL IMPAIRMENT** Avoid.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**
- Elonva (Merck Sharp & Dohme Ltd)
  - Corifollitropin alfa 200 microgram per 1 ml
  - Elonva 100micrograms/0.5ml solution for injection pre-filled syringes | 1 pre-filled disposable injection [Pom] £838.00
  - Corifollitropin alfa 300 microgram per 1 ml
  - Elonva 150micrograms/0.5ml solution for injection pre-filled syringes | 1 pre-filled disposable injection [Pom] £638.00

**Follitropin alfa**
(Recombinant human follicle stimulating hormone)

**INDICATIONS AND DOSE**
Infertility in women with proven hypopituitarism or who have not responded to clomifene | Superovulation treatment for assisted conception (such as in vitro fertilisation)
- BY SUBCUTANEOUS INJECTION
- Adult (female): Adjusted according to response.

**Hypogonadotrophic hypogonadism**
- BY SUBCUTANEOUS INJECTION
- Adult (male): (consult product literature).

**CONTRA-INDICATIONS** Ovarian cysts (not caused by polycystic ovarian syndrome) · ovarian enlargement (not caused by polycystic ovarian syndrome) · tumours of breast · tumours of hypothalamus · tumours of ovaries · tumours of pituitary · tumours of prostate · tumours of testes · tumours of uterus · vaginal bleeding of unknown cause

**CAUTIONS** Acute porphyrias p. 969 · history of tubal disease

**SIDE-EFFECTS**
- Common or very common Fever · gastro-intestinal disturbances · headache · hypersensitivity reactions · injection site reactions · joint pain · ovarian hyperstimulation · varicocele
- Very rare Exacerbation or aggravation of asthma · thromboembolism
- Frequency not known Acne · gynaecomastia · increased risk of miscarriage · increased risk of multiple pregnancy · weight gain

**PREGNANCY** Avoid.
**BREAST FEEDING** Avoid.

**PRESCRIBING AND DISPENSING INFORMATION** Follitropin alfa is a biological medicine. Biological medicines must be prescribed and dispensed by brand name, see Biological medicines and Biosimilar medicines, under Guidance on prescribing p. 1.

**PATIENT AND CARER ADVICE**
Patient advice required around conception and contraception
Patients planning to conceive should be warned that there is a risk of multiple pregnancy.
Follitropin beta
(Recombinant human follicle stimulating hormone)

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

INDICATIONS AND DOSE
Infertility in women with proven hypopituitarism or who have not responded to clomifene | Superoovulation treatment for assisted conception (such as in vitro fertilisation)
▶ BY INTRAMUSCULAR INJECTION, OR BY SUBCUTANEOUS INJECTION
▶ Adult (female): Adjusted according to response.

CONTRA-INDICATIONS
Ovarian cysts (not caused by polycystic ovarian syndrome) | ovarian enlargement (not caused by polycystic ovarian syndrome) | tumours of breast | tumours of hypothalamus | tumours of ovaries | tumours of pituitary | tumours of prostate | tumours of testes | tumours of uterus | vaginal bleeding of unknown cause

CAUTIONS
Acute porphyrias p. 969 | history of tubal disease

SIDE-EFFECTS
▶ Common or very common
- Fever | gastro-intestinal disturbances | headache | hypersensitivity reactions | injection site reactions | joint pain | ovarian hyperstimulation
- Very rare
- Thromboembolism
- Frequency not known
- Acne | gynaecomastia | increased risk of miscarriage | increased risk of multiple pregnancy | weight gain

PREGNANCY
Avoid.

BREAST FEEDING
Avoid.

DIRECTIONS FOR ADMINISTRATION
Cartridges and vials are used for subcutaneous administration; vials are used for intramuscular injection.

PATIENT AND CARER ADVICE
Patient advice required around conception and contraception
Patients planning to conceive should be warned that there is a risk of multiple pregnancy.

MEDICAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

SOLUTION FOR INJECTION
EXCIPIENTS: May contain Neomycin, streptomycin
- Puregon (Merck Sharp & Dohme Ltd)
  Follitropin beta 100 unit per 1 ml Puregon 50units/0.5ml solution for injection vials | 1 vial (POM) £18.03
  Follitropin beta 200 unit per 1 ml Puregon 100units/0.5ml solution for injection vials | 1 vial (POM) £36.06
  Follitropin beta 833 unit per 1 ml Puregon 900units/1.08ml solution for injection vials | 1 vial (POM) £292.23
- Puregon 600units/0.72ml solution for injection cartridges | 1 cartridge (POM) £194.82
- Puregon 300units/0.36ml solution for injection cartridges | 1 cartridge (POM) £57.41
Lutropin alfa
(Recombinant human luteinising hormone)

- **INDICATIONS AND DOSE**
  Treatment of infertility in women with proven hypopituitarism or who have not responded to clomifene (in conjunction with follicle-stimulating hormone)
  - Superovulation treatment for assisted conception (such as in vitro fertilisation) (in conjunction with follicle-stimulating hormone)
  - **BY SUBCUTANEOUS INJECTION**
  - Adult (female): Adjusted according to response.

- **CONTRA-INDICATIONS** Mammary carcinoma - ovarian carcinoma - ovarian enlargement or cyst (unless caused by polycystic ovarian disease) - tumours of hypothalamus - tumours of pituitary - undiagnosed vaginal bleeding - uterine carcinoma

- **CAUTIONS** Acute porphyrias p. 969

- **SIDE-EFFECTS** Abdominal pain - adnexal torsion - breast pain - ectopic pregnancy - haemoperitoneum - headache - injection-site reactions - nausea - ovarian cyst - ovarian hyperstimulation syndrome - pelvic pain - somnolence - thromboembolism - vomiting

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.

  **Powder and solvent for solution for injection**
  - **Lutropin alfa 75 unit** Luveris 75 unit powder and solvent for solution for injection vials | 1 vial £16.38 | 10 vial £163.80
  - **Menotrophin 75 unit** Menopur 75 unit powder and solvent for solution for injection vials | 1 vial £16.38 | 10 vial £163.80
  - **Menotrophin 150 unit** Menopur 150 unit powder and solvent for solution for injection vials | 5 vial £163.80 | 10 vial £227.60
  - **Menotrophin 600 unit** Menopur 600 unit powder and solvent for solution for injection vials | 1 vial £131.04
  - **Menotrophin 1200 unit** Menopur 1200 unit powder and solvent for solution for injection vials | 1 vial £262.08
  - **Merional** (IBSA Farmaceutici Italia Srl)
    - **Menotrophin 75 unit** Merional 75 unit powder and solvent for solution for injection vials | 10 vial £279.00
    - **Menotrophin 150 unit** Merional 150 unit powder and solvent for solution for injection vials | 10 vial £558.00

Menotrophin

- **INDICATIONS AND DOSE**
  Infertility in women with proven hypopituitarism or who have not responded to clomifene | Superovulation treatment for assisted conception (such as in vitro fertilisation)
  - **BY SUBCUTANEOUS INJECTION, OR BY DEEP INTRAMUSCULAR INJECTION**
  - Adult (female): Adjusted according to response.

- **CONTRA-INDICATIONS** Ovarian cysts (not caused by polycystic ovarian syndrome) - tumours of breast - tumours of hypothalamus - tumours of ovaries - tumours of pituitary - tumours of prostate - tumours of testes - tumours of uterus - vaginal bleeding of unknown cause

- **CAUTIONS** Acute porphyrias p. 969

- **SIDE-EFFECTS**
  - Very rare Thromboembolism
  - Frequency not known Fever - gastro-intestinal disturbances - headache - hypersensitivity reactions - increased risk of miscarriage - increased risk of multiple pregnancy - injection site reactions - joint pain - ovarian hyperstimulation

- **PREGNANCY** Avoid.

- **BREAST FEEDING** Avoid.

- **PRESCRIBING AND DISPENSING INFORMATION**
  Menotrophin is purified extract of human post-menopausal urine containing follicle-stimulating hormone (FSH) and luteinising hormone (LH) in a ratio of 1:1

- **PATIENT AND CARER ADVICE**
  Patient advice required around conception and contraception
  Patients planning to conceive should be warned that there is a risk of multiple pregnancy.

Urofollitropin

- **INDICATIONS AND DOSE**
  Infertility in women with proven hypopituitarism or who have not responded to clomifene
  - Superovulation treatment for assisted conception (such as in vitro fertilisation)

  - **BY SUBCUTANEOUS INJECTION, OR BY DEEP INTRAMUSCULAR INJECTION**
  - Adult (female): Adjusted according to response.

- **CONTRA-INDICATIONS** Ovarian cysts - tumours of breast - tumours of hypothalamus - tumours of ovaries - tumours of pituitary - tumours of prostate - tumours of testes - tumours of uterus - vaginal bleeding of unknown cause

- **CAUTIONS** Acute porphyrias p. 969

- **SIDE-EFFECTS**
  - Very rare Thromboembolism
  - Frequency not known Fever - gastro-intestinal disturbances - headache - hypersensitivity reactions - increased risk of miscarriage - increased risk of multiple pregnancy - injection site reactions - joint pain - ovarian hyperstimulation

- **PREGNANCY** Avoid.

- **BREAST FEEDING** Avoid.

- **PRESCRIBING AND DISPENSING INFORMATION**
  Urofollitropin is purified extract of human post-menopausal urine containing follicle-stimulating hormone (FSH).

- **PATIENT AND CARER ADVICE**
  Patient advice required around conception and contraception
  Patients planning to conceive should be warned that there is a risk of multiple pregnancy.

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.

  **Powder and solvent for solution for injection**
  - **Bravelle** (Ferring Pharmaceuticals Ltd)
    - **Follicle stimulating hormone human (as Urofollitropin)**
      - **75 unit** Bravelle 75 unit powder and solvent for solution for injection vials | 10 vial £270.00
      - **Fostimon** (IBSA Farmaceutici Italia Srl)
        - **Follicle stimulating hormone human (as Urofollitropin)**
          - **75 unit** Fostimon 75 unit powder and solvent for solution for injection vials | 10 vial £279.00
7.4 Growth hormone disorders

PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES

RECEPTOR ANTAGONISTS

Somatropin

(Recombinant Human Growth Hormone)

- INDICATIONS AND DOSE
  Gonadal dysgenesis (Turner syndrome)
  → BY SUBCUTANEOUS INJECTION
    - Adult: 1.4 mg/m² daily, alternatively 45–50 micrograms/kg daily
  Deficiency of growth hormone
  → BY SUBCUTANEOUS INJECTION
    - Adult: Initially 150–300 micrograms daily, then increased if necessary up to 1 mg daily, dose to be increased gradually, use minimum effective dose (requirements may decrease with age)

- DOSE EQUIVALENCE AND CONVERSION
  - Dose formerly expressed in units; somatropin 1 mg = 3 units.

- CONTRA-INDICATIONS
  - Evidence of tumour activity (complete antitumour therapy and ensure intracranial lesions inactive before starting) - not to be used after renal transplantation - severe obesity in Prader-Willi syndrome - severe respiratory impairment in Prader-Willi syndrome

- CAUTIONS
  - Diabetes mellitus (adjustment of antidiabetic therapy may be necessary) - liver disease

- SIDE-EFFECTS
  - Uncommon
    - Bleeding tendency
    - Leucocytosis
    - Leucopenia
    - Thrombocytopenia
  - Frequency not known
    - Abdominal distension
    - Arthritis
    - Asthenia
    - Constipation
    - Diarrhoea
    - Dizziness
    - Drowsiness
    - Dyspepsia
    - Elevated enzyme levels
    - Fatigue
    - Flatulence
    - Headache
    - Hypercholesterolaemia
    - Hyperglycaemia
    - Hypertension
    - Hypoglycaemia
    - Influenza-like syndrome
    - Injection-site reactions
    - Myalgia
    - Nausea
    - Pruritus
    - Rash
    - Sleep disturbances
    - Sweating
    - Tremor
    - Vomiting
    - Weight gain

SIDE-EFFECTS, FURTHER INFORMATION
- Injection-site reactions
  - Rotate injection sites to avoid lipoatrophy.

- CONCEPTION AND CONTRACEPTION
  - Possible increase in female fertility.

- PREGNANCY
  - Avoid.

- BREAST FEEDING
  - Avoid.

- MONITORING REQUIREMENTS
  - Monitor liver enzymes every 4–6 weeks for 6 months or if symptoms of hepatitis develop.

- MEDICINAL FORMS
  - There can be variation in the licensing of different medicines containing the same drug.

Powder and solvent for solution for injection
- Somavert (Pfizer Ltd)
  - Pegvisomant 10 mg Somavert 10 mg powder and solvent for solution for injection vials | 30 vial £1,500.00 (Hospital only)
  - Pegvisomant 15 mg Somavert 15 mg powder and solvent for solution for injection vials | 30 vial £2,250.00 (Hospital only)
  - Pegvisomant 20 mg Somavert 20 mg powder and solvent for solution for injection vials | 1 vial £100.00 (Hospital only) | 30 vial £3,000.00 (Hospital only)
  - Pegvisomant 25 mg Somavert 25 mg powder and solvent for solution for injection vials | 30 vial £3,750.00 (Hospital only)
  - Pegvisomant 30 mg Somavert 30 mg powder and solvent for solution for injection vials | 30 vial £4,500.00 (Hospital only)

Papilloedema
- Funduscop}'y for papilloedema recommended if severe or recurrent headache, visual problems, nausea and vomiting occur—if papilloedema confirmed consider benign intracranial hypertension (rare cases reported).

- PREGNANCY
  - Discontinue if pregnancy occurs—no information available.

- BREAST FEEDING
  - No information available. Absorption from milk unlikely.

- DIRECTIONS FOR ADMINISTRATION
  - Rotate subcutaneous injection sites to prevent lipoatrophy.

SAIZEN® SOLUTION FOR INJECTION
- For use by subcutaneous injection.

NUTROPINAQ®
- For use by subcutaneous injection.

OMNITROPE®
- For use by subcutaneous injection.

NORDITROPIN® PREPARATIONS
- For use by subcutaneous injection.

ZOMACTON®
- For use by subcutaneous injection.

GENOTROPIN® PREPARATIONS
- For use by subcutaneous injection.
SAIZEN® POWDER AND SOLVENT FOR SOLUTION FOR INJECTION For use by subcutaneous injection.
HUMATROPE® Cartridges for use by subcutaneous injection. Powder for reconstitution for use by subcutaneous or intramuscular injection.

● PRESCRIBING AND DISPENSING INFORMATION Somatropin is a biological medicine. Biological medicines must be prescribed and dispensed by brand name, see Biological medicines and Biosimilar medicines, under Guidance on prescribing p. 1.
SAIZEN® SOLUTION FOR INJECTION For use with cool.click® needle-free autoinjector device or easypod® autoinjector device (non-NHS but available free of charge from clinics).
NUTROPIN® For use with NutropinAq® Pen device (non-NHS but available free of charge from clinics).
OMNITROPE® For use with Omnitrope Pen® and Omnitrope Pen 10® devices (non-NHS but available free of charge from clinics).
NORDITROPIN® PREPARATIONS Cartridges are for use with appropriate NordiPen® device (non-NHS but available free of charge from clinics). Multidose disposable prefilled pens for use with NovoFine® or NovoTwist® needles.
ZOMACRON® 4 mg vial for use with Zomact 2® Vision needle-free device (non-NHS but available free of charge from clinics) or with needles and syringes.
10 mg vial for use with Zomact 2® Vision needle-free device (non-NHS but available free of charge from clinics) or with needles and syringes.
GENOTROPIN® PREPARATIONS Cartridges are for use with Genotropin® Pen device (non-NHS but available free of charge from clinics).
SAIZEN® POWDER AND SOLVENT FOR SOLUTION FOR INJECTION For use with one. click® autoinjector device or cool.click® needle-free autoinjector device or easypod® autoinjector device (non-NHS but available free of charge from clinics).

● NATIONAL FUNDING/ACCESS DECISIONS NICE technology appraisals (TAs)
Somatropin for the treatment of growth failure in children (May 2010) NICE TA188 Somatropin is recommended for children with growth failure who:
- have growth-hormone deficiency
- have Turner syndrome
- have Prader-Willi syndrome
- have chronic renal insufficiency
- are born small for gestational age with subsequent growth failure at 4 years of age or later
- have short stature homeobox-containing gene (SHOX) deficiency.
Treatment should be discontinued if growth velocity increases by less than 50% from baseline in the first year of treatment.

www.nice.org.uk/TA188 Somatropin for adults with growth hormone deficiency (August 2003) NICE TA64 Somatropin is recommended in adults only if the following 3 criteria are fulfilled:
- Severe growth hormone deficiency, established by an appropriate method,
- Impaired quality of life, measured by means of a specific questionnaire,
- Already receiving treatment for another pituitary hormone deficiency.
Somatropin treatment should be discontinued if the quality of life has not improved sufficiently by 9 months.
Severe growth hormone deficiency developing after linear growth is complete but before the age of 25 years should be treated with growth hormone; treatment should continue until adult peak bone mass has been achieved. Treatment for adult–onset growth hormone deficiency should be stopped only when the patient and the patient’s physician consider it appropriate.
Treatment with somatropin should be initiated and managed by a physician with expertise in growth hormone disorders; maintenance treatment can be prescribed in the community under a shared-care protocol.

www.nice.org.uk/TA64

● MEDICINAL FORMS There can be variation in the prescribing of different medicines containing the same drug.

Solution for injection EXCIPIENTS: May contain Benzyl alcohol

Norditropin NordiFlex (Novo Nordisk Ltd)
- Somatropin (epr) 3.3 mg per 1 ml Norditropin NordiFlex 5 mg/1.5 ml solution for injection pre-filled pen | 1 pre-filled disposable injection (Pom) £115.90 (CD4-2)
- Somatropin (epr) 6.7 mg per 1 ml Norditropin NordiFlex 10 mg/1.5 ml solution for injection pre-filled pen | 1 pre-filled disposable injection (Pom) £231.80 (CD4-2)
- Somatropin (epr) 10 mg per 1 ml Norditropin NordiFlex 15 mg/1.5 ml solution for injection pre-filled pen | 1 pre-filled disposable injection (Pom) £347.70 (CD4-2)
- Norditropin Simplexx (Novo Nordisk Ltd)
- Somatropin (epr) 5.3 mg per 1 ml Norditropin Simplexx 5 mg/1.5 ml solution for injection cartridges | 1 cartridge (Pom) £106.35 (CD4-2)
- Somatropin (epr) 6.7 mg per 1 ml Norditropin Simplexx 10 mg/1.5 ml solution for injection cartridges | 1 cartridge (Pom) £212.70 (CD4-2)
- Somatropin (epr) 10 mg per 1 ml Norditropin Simplexx 15 mg/1.5 ml solution for injection cartridges | 1 cartridge (Pom) £319.05 (CD4-2)
- NutropinAq (Opex Ltd)
- Somatropin (rbe) 5 mg per 1 ml NutropinAq 10 mg/2 ml solution for injection cartridges | 1 cartridge (Pom) £203.00 (CD4-2) | 3 cartridge (Pom) £609.00 (CD4-2)
- Omnitrope Pen (Sandoz Ltd)
- Somatropin (rbe) 3.33 mg per 1 ml Omnitrope Pen 5 mg/1.5 ml solution for injection cartridges | 5 cartridge (Pom) £368.74 (CD4-2)
- Somatropin (rbe) 6.667 mg per 1 ml Omnitrope Pen 10 mg/1.5 ml solution for injection cartridges | 5 cartridge (Pom) £737.49 (CD4-2)
- Omnitrope SurePal (Sandoz Ltd)
- Somatropin (rbe) 3.33 mg per 1 ml Omnitrope SurePal 5 mg/1.5 ml solution for injection cartridges | 5 cartridge (Pom) £368.74 (CD4-2)
- Somatropin (rbe) 6.667 mg per 1 ml Omnitrope SurePal 10 mg/1.5 ml solution for injection cartridges | 5 cartridge (Pom) £737.49 (CD4-2)
- Somatropin (rbe) 10 mg per 1 ml Omnitrope SurePal 15 mg/1.5 ml solution for injection cartridges | 5 cartridge (Pom) £1,106.22 (CD4-2)
- Genotropin (Merck Serono Ltd)
- Somatropin (rmc) 5.825 mg per 1 ml Genotropin 6 mg/1.03 ml solution for injection cartridges | 1 cartridge (Pom) £139.08 (CD4-2)
- Somatropin (rmc) 8 mg per 1 ml Genotropin 12 mg/1.5 ml solution for injection cartridges | 1 cartridge (Pom) £278.16 (CD4-2)
- Somatropin (rmc) 20 mg/2.5 ml solution for injection cartridges | 1 cartridge (Pom) £463.60 (CD4-2)

Powder and solvent for solution for injection EXCIPIENTS: May contain Benzyl alcohol

Genotropin (Pfizer Ltd)
- Somatropin (rbe) 5.3 mg Genotropin 5.3 mg powder and solvent for solution for injection cartridges | 1 cartridge (Pom) £92.15 (CD4-2)
- Somatropin (rbe) 12 mg Genotropin 12 mg powder and solvent for solution for injection cartridges | 1 cartridge (Pom) £208.65 (CD4-2)
- Genotropin GoQuick (Pfizer Ltd)
- Somatropin (rbe) 5.3 mg Genotropin GoQuick 5.3 mg powder and solvent for solution for injection pre-filled disposable devices | 1 pre-filled disposable injection (Pom) £92.15 (CD4-2)
- Somatropin (rbe) 12 mg Genotropin GoQuick 12 mg powder and solvent for solution for injection pre-filled disposable devices | 1 pre-filled disposable injection (Pom) £208.65 (CD4-2)
- Genotropin MiniQuick (Pfizer Ltd)
- Somatropin (rbe) 200 microgram Genotropin MiniQuick 200 microgram powder and solvent for solution for injection pre-filled disposable devices | 7 pre-filled disposable injection (Pom) £24.35 (CD4-2)
Sex hormone responsive conditions 707

Hormone replacement therapy

Hormone replacement therapy (HRT) with small doses of an oestrogen (together with a progestogen in women with a uterus) is appropriate for alleviating menopausal symptoms such as vaginal atrophy or vasomotor instability. Oestrogen given systemically in the perimenopausal and postmenopausal period or tibolone given in the postmenopausal period also diminish postmenopausal osteoporosis but other drugs are preferred. Menopausal atrophic vaginitis may respond to a short course of a topical vaginal oestrogen preparation used for a few weeks and repeated if necessary.

Systemic therapy with an oestrogen or drugs with oestrogenic properties alleviates the symptoms of oestrogen deficiency such as vasomotor symptoms. Tibolone combines oestrogenic and progestogenic activity with weak androgenic activity; it is given continuously, without cyclical progestogen.

HRT may be used in women with early natural or surgical menopause (before age 45 years), since they are at high risk of osteoporosis. For early menopause, HRT can be given until the approximate age of natural menopause (i.e. until age 50 years). Alternatives to HRT should be considered if osteoporosis is the main concern. Clonidine hydrochloride p. 139 may be used to reduce vasomotor symptoms in women who cannot take an oestrogen, but clonidine hydrochloride may cause unacceptable side-effects.

HRT increases the risk of venous thromboembolism, stroke, endometrial cancer (reduced by a progestogen), breast cancer, and ovarian cancer; there is an increased risk of coronary heart disease in women who start combined HRT more than 10 years after menopause. For details of these risks see HRT Risk table.

The minimum effective dose of HRT should be used for the shortest duration. Treatment should be reviewed at least annually and for osteoporosis alternative treatments considered. HRT does not prevent coronary heart disease or protect against a decline in cognitive function and it should not be prescribed for these purposes. Experience of treating women over 65 years with HRT is limited.

For the treatment of menopausal symptoms the benefits of short-term HRT outweigh the risks in the majority of women, especially in those aged under 60 years.

Risk of breast cancer

It is estimated that using all types of HRT, including tibolone, increases the risk of breast cancer within 1–2 years of initiating treatment. The increased risk is related to the duration of HRT use (but not to the age at which HRT is started) and this excess risk disappears within 5 years of stopping. Radiological detection of breast cancer can be made more difficult as mammographic density can increase with HRT use; tibolone has only a limited effect on mammographic density.

Risk of endometrial cancer

The increased risk of endometrial cancer depends on the dose and duration of oestrogen–only HRT. In women with a uterus, the addition of a progestogen cyclically (for at least 10 days per 28-day cycle) reduces the additional risk of endometrial cancer; this additional risk is eliminated if a progestogen is given continuously. However, this should be weighed against the increased risk of breast cancer.

Risk of ovarian cancer

Long-term use of combined HRT or oestrogen–only HRT is associated with a small increased risk of ovarian cancer; this excess risk disappears within a few years of stopping.

Risk of venous thromboembolism

Women using combined or oestrogen–only HRT are at an increased risk of deep vein thrombosis and of pulmonary embolism especially in the first year of use. In women who
### HRT Risks

<table>
<thead>
<tr>
<th>Risk</th>
<th>Age range (years)</th>
<th>Background incidence per 1000 women in Europe not using HRT</th>
<th>Additional cases per 1000 women using oestrogen only HRT (estimated)</th>
<th>Additional cases per 1000 women using combined (oestrogen-progesterone) HRT (estimated)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Over 5 years</td>
<td>Over 10 years</td>
<td>For 5 years’ use</td>
<td>For 10 years’ use</td>
</tr>
<tr>
<td>Breast cancer(^1)</td>
<td>50-59</td>
<td>10</td>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td>Endometrial cancer(^2,3)</td>
<td>60-69</td>
<td>15</td>
<td>30</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>50-59</td>
<td>2</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Ovarian cancer</td>
<td>60-69</td>
<td>3</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Venous thromboembolism(^4,5)</td>
<td>50-59</td>
<td>5</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>60-69</td>
<td>8</td>
<td>–</td>
<td>2</td>
</tr>
<tr>
<td>Stroke(^6)</td>
<td>50-59</td>
<td>4</td>
<td>–</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>60-69</td>
<td>9</td>
<td>–</td>
<td>3</td>
</tr>
<tr>
<td>Coronary heart disease(^7,8)</td>
<td>70-79</td>
<td>29-44</td>
<td>–</td>
<td>NS</td>
</tr>
</tbody>
</table>

Where background incidence or additional cases have not been included in the table, this indicates a lack of available data. NS indicates a non-significant difference. Taken from MHRA/CHM (Drug Safety 2007; 1 (2): 2-6) available at [www.gov.uk/drug-safety-update](http://www.gov.uk/drug-safety-update)

1. Tibolone increases the risk of breast cancer but to a lesser extent than with combined HRT.
2. Evidence suggests an increased risk of endometrial cancer with tibolone. After 2.7 years of use (in women of average age 68 years), 1 extra case of endometrial hyperplasia and 4 extra cases of endometrial cancer were diagnosed compared with placebo users.
3. The risk of endometrial cancer cannot be reliably estimated in those using combined HRT because the addition of progestogen for at least 10 days per 28-day cycle greatly reduces the additional risk, and addition of a daily progestogen eliminates the additional risk. The risk of endometrial cancer in women who have not used HRT increases with body mass index (BMI); the increased risk of endometrial cancer in users of oestrogen-only HRT or tibolone is more apparent in women who are not overweight.
4. Limited data does not suggest an increased risk of thromboembolism with tibolone compared with combined HRT or women not taking HRT.
5. Although the level of risk of thromboembolism associated with non-oral routes of administration of HRT has not been established, it may be lower for the transdermal route.
6. Tibolone increases the risk of stroke about 2.2 times from the first year of treatment; risk of stroke is age-dependent and therefore the absolute risk of stroke with tibolone increases with age.
7. Increased risk of coronary heart disease in women who start combined HRT more than 10 years after menopause.
8. There is insufficient data to draw a conclusion on the risk of coronary heart disease with tibolone.

- Tibolone increases the risk of breast cancer but to a lesser extent than with combined HRT.
- Evidence suggests an increased risk of endometrial cancer with tibolone.
- The risk of endometrial cancer cannot be reliably estimated in those using combined HRT.
- Limited data does not suggest an increased risk of thromboembolism with tibolone.
- Tibolone increases the risk of stroke about 2.2 times from the first year of treatment.
- Increased risk of coronary heart disease in women who start combined HRT more than 10 years after menopause.

In younger women who start HRT close to the menopause, studies suggest a lower relative risk compared with older women.

**Risk of stroke**

Risk of stroke increases with age; therefore older women have a greater absolute risk of stroke. Combined HRT or oestrogen-only HRT slightly increases the risk of stroke. Tibolone increases the risk of stroke about 2.2 times from the first year of treatment.

**Risk of coronary heart disease**

HRT does not prevent coronary heart disease and should not be prescribed for this purpose. There is an increased risk of coronary heart disease in women who start combined HRT more than 10 years after menopause. Although very little information is available on the risk of coronary heart disease in younger women who start HRT close to the menopause, studies suggest a lower relative risk compared with older women.

**Choice**

The choice of HRT for an individual depends on an overall balance of indication, risk, and convenience. A woman with a uterus normally requires oestrogen with cyclical progestogen for the last 12 to 14 days of the cycle or a preparation which involves continuous administration of an oestrogen and a progestogen (or one which provides both oestrogenic and progestogenic activity in a single preparation). Continuous combined preparations or tibolone are not suitable for use in the perimenopause or within 12 months of the last menstrual period; women who use such preparations may bleed irregularly in the early stages of treatment—if bleeding continues endometrial abnormality should be ruled out and consideration given to changing to cyclical HRT.

An oestrogen alone is suitable for continuous use in women without a uterus. However, in endometriosis, endometrial foci may remain despite hysterectomy and the addition of a progestogen should be considered in these circumstances.

An oestrogen may be given by mouth or by transdermal administration, which avoids first-pass metabolism.

**Surgery**

Major surgery under general anaesthesia, including orthopaedic and vascular leg surgery, is a predisposing factor for venous thromboembolism and it may be prudent to stop HRT 4–6 weeks before surgery; it should be restarted only after full mobilisation. If HRT is continued or if discontinuation is not possible (e.g. in non-elective surgery), prophylaxis with unfractionated or low molecular weight heparin and graduated compression hosiery is advised.

**Reasons to stop HRT**

Hormone replacement therapy should be stopped (pending investigation and treatment), if any of the following occur:

- sudden severe chest pain (even if not radiating to left arm);
- sudden breathlessness (or cough with blood-stained sputum);
- unexplained swelling or severe pain in calf of one leg;
Female sex hormone responsive conditions 709

- severe stomach pain;
- serious neurological effects including unusual severe, prolonged headache especially if first time or getting progressively worse or sudden partial or complete loss of vision or sudden disturbance of hearing or other perceptual disorders or dysphasia or bad fainting attack or collapse or first unexplained epileptic seizure or weakness, motor disturbances, very marked numbness suddenly affecting one side or one part of body;
- hepatitis, jaundice, liver enlargement;
- blood pressure above systolic 160 mmHg or diastolic 95 mmHg;
- prolonged immobility after surgery or leg injury;
- detection of a risk factor which contra-indicates treatment.

**Ethinylestradiol**

Ethinylestradiol p. 715 (ethinylestradiol) is licensed for short-term treatment of symptoms of oestrogen deficiency, for osteoporosis prophylaxis if other drugs cannot be used and for the treatment of female hypogonadism and menstrual disorders.

Ethinylestradiol is occasionally used under specialist supervision for the management of hereditary haemorrhagic telangiectasia (but evidence of benefit is limited). It is also used licensed for the palliative treatment of prostate cancer.

**Raloxifene**

Raloxifene hydrochloride is licensed for the treatment and prevention of postmenopausal osteoporosis; unlike hormone replacement therapy, raloxifene hydrochloride does not reduce menopausal vasomotor symptoms.

**Progestogens and progesterone receptor modulators**

There are two main groups of progestogen, progesterone and its analogues (dydrogesterone and medroxyprogesterone acetate p. 763) and testosterone analogues (norethisterone p. 720 and norgestrel). The newer progestogens (desogestrel p. 758, norgestimate, and gestodene) are all derivatives of norgestrel; levonorgestrel p. 759 is the active isomer of norgestrel and has twice its potency. Progesterone p. 721 and its analogues are less androgenic than the testosterone derivatives and neither progesterone nor dydrogesterone causes virilisation.

Where endometriosis requires drug treatment, it may respond to a progestogen, e.g. norethisterone, administered on a continuous basis. Danazol p. 699 and gonadorelin analogues are also available.

Although oral progestogens have been used widely for menorrhagia they are relatively ineffective compared with tranexamic acid p. 107 or, particularly where dysmenorrhoea is also a factor, mefenamic acid p. 1046; the levonorgestrel-releasing intra-uterine system may be particularly useful for women also requiring contraception. Oral progestogens have also been used for severe dysmenorrhoea, but where contraception is also required in younger women the best choice is a combined oral contraceptive.

Progestogens have also been advocated for the alleviation of premenstrual symptoms, but no convincing physiological basis for such treatment has been shown.

Progestogens have been used for the prevention of miscarriage in women with a history of recurrent miscarriage but there is no evidence of benefit and they are not recommended for this purpose. In pregnant women with antiphospholipid antibody syndrome who have suffered recurrent miscarriage, administration of low-dose aspirin p. 117 and a prophylactic dose of a low molecular weight heparin may decrease the risk of fetal loss (use under specialist supervision only).

**Hormone replacement therapy**

In women with a uterus a progestogen needs to be added to long-term oestrogen therapy for hormone replacement, to prevent cystic hyperplasia of the endometrium and possible transformation to cancer; it can be added on a cyclical or a continuous basis. Combined packs incorporating suitable progestogen tablets are available.

**Oral contraception**

Desogestrel, gestodene, levonorgestrel, norethisterone, and norgestimate are used in combined oral contraceptives and in progestogen-only contraceptives.

**Cancer**

Progestogens also have a role in neoplastic disease.

**Progestosterone receptor modulators**

Ulipristal acetate p. 757 is a progestosterone receptor modulator with a partial progesterone antagonist effect. Ulipristal acetate is used in the pre-operative treatment of moderate to severe symptoms of uterine fibroids; it is also used as an hormonal emergency contraceptive.

**Heavy menstrual bleeding**

Ulipristal acetate (up to four courses) is recommended in patients with heavy menstrual bleeding associated with uterine fibroids of a diameter of 3 cm or more, and a haemoglobin level of 102 g/litre or below; ulipristal acetate may also be considered if the haemoglobin level is greater than 102 g/litre.

### 8.1 Female sex hormone responsive conditions

**Calcium regulating drugs**

**Bone resorption inhibitors**

**Raloxifene hydrochloride**

- **indications and dose**
  - Treatment and prevention of postmenopausal osteoporosis
  - By mouth
  - Adult: 60 mg once daily

- **Adverse effects**

  - **Contra-indications**
    - Cholestasis - endometrial cancer - history of venous thromboembolism - undiagnosed uterine bleeding
  - **Caution**
    - Avoid in acute porphyrias
    - Hypertriglyceridaemia (monitor serum triglycerides)
    - Risk factors for stroke - risk factors for venous thromboembolism (discontinue if prolonged immobilisation)
  - **Interactions**
    - ![Appendix 1: raloxifene](downloaded from www.medicalbr.com)
  - **Side-effects**
    - **Common or very common**
      - Hot flushes - influenza-like symptoms - leg cramps - peripheral oedema
    - **Uncommon**
      - Thrombophlebitis - venous thromboembolism
    - **Rare**
      - Arterial thromboembolism - breast discomfort - gastro-intestinal disturbances - headache - hypertension - migraine - rashes - thrombocytopenia
  - **Hepatic Impairment**
    - Avoid.
  - **Renal Impairment**
    - Caution in mild to moderate impairment. Avoid in severe impairment.
  - **National funding/access decisions**

**Nice technology appraisals (TAs)**

- Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic
Endocrine system

OESTROGENS

Conjugated oestrogens (equine)

**INDICATIONS AND DOSE**

**PREMARIN® TABLETS**

**Menopausal symptoms**

- **BY MOUTH**
  - Adult: 0.3–1.25 mg daily continuously; with cyclical progestogen for 12–14 days of each cycle in women with a uterus

**Osteoporosis prophylaxis**

- **BY MOUTH**
  - Adult: 0.625–1.25 mg daily continuously; with cyclical progestogen for 12–14 days of each cycle in women with a uterus

**CONTRA-INDICATIONS**

- Active arterial thromboembolic disease (e.g. angina or myocardial infarction) - active thrombophlebitis - Dubin–Johnson syndromes (or monitor closely) - history of breast cancer - history of recurrent venous thromboembolism (unless already on anticoagulant treatment) - liver disease (where liver function tests have failed to return to normal) - oestrogen-dependent cancer - recent arterial thromboembolic disease (e.g. angina or myocardial infarction) - Rotor syndromes (or monitor closely) - thrombophilic disorder - undiagnosed vaginal bleeding - untreated endometrial hyperplasia - venous thromboembolism

**CAUTIONS**

- Acute porphyrias p. 969 - diabetes (increased risk of heart disease) - factors predisposing to thromboembolism - history of breast nodules (closely monitor breast status — risk of breast cancer) - history of endometrial hyperplasia - history of fibrocystic disease (closely monitor breast status — risk of breast cancer) - hypophyseal tumours - increased risk of gall-bladder disease reported - migraine - migraine-like headaches - presence of antiphospholipid antibodies (increased risk of thrombotic events) - risk factors for oestrogen-dependent tumours (e.g. breast cancer in first-degree relative) - risk of breast cancer

**CAUTIONS, FURTHER INFORMATION**

- Risk of breast cancer It is estimated that using all types of HRT, including tibolone, increases the risk of breast cancer in women who start combined HRT more than 1–2 years of initiating treatment. The increased risk is related to the duration of HRT use (but not to the age at which HRT is started) and this excess risk disappears within 5 years of stopping.

- Risk of endometrial cancer The increased risk of endometrial cancer depends on the dose and duration of oestrogen-only HRT.

- Risk of ovarian cancer Long-term use of combined HRT or oestrogen-only HRT is associated with a small increased risk of ovarian cancer. This excess risk disappears within a few years of stopping.

- Risk of venous thromboembolism Women using combined or oestrogen-only HRT are at an increased risk of deep vein thrombosis and of pulmonary embolism especially in the first year of use.

- In women who have predisposing factors (such as a personal or family history of deep vein thrombosis or pulmonary embolism, severe varicose veins, obesity, trauma, or prolonged bed-rest) it is prudent to review the need for HRT, as in some cases the risks of HRT may exceed the benefits.

**Travel** involving prolonged immobility further increases the risk of deep vein thrombosis.

- Risk of stroke Risk of stroke increases with age, therefore older women have a greater absolute risk of stroke. Combined HRT or oestrogen-only HRT slightly increases the risk of stroke.

- Risk of coronary heart disease HRT does not prevent coronary heart disease and should not be prescribed for this purpose. There is an increased risk of coronary heart disease in women who start combined HRT more than 10 years after menopause. Although very little information is available on the risk of coronary heart disease in younger women who start HRT close to the menopause, studies suggest a lower relative risk compared with older women.

- Other conditions The product literature advises caution in other conditions including hypertension, renal disease, asthma, epilepsy, sickle-cell disease, melanoma, otosclerosis, multiple sclerosis, and systemic lupus erythematosus (but care required if antiphospholipid antibodies present). Evidence for caution in these conditions is unsatisfactory and many women with these conditions may stand to benefit from HRT.

**INTERACTIONS** → Appendix 1: hormone replacement therapy
CONCEPTION AND CONTRACEPTION  HRT does not provide contraception and a woman is considered potentially fertile for 2 years after her last menstrual period if she is under 50 years, and for 1 year if she is over 50 years. A woman who is under 50 years and free of all risk factors for venous and arterial disease can use a low-oestrogen combined oral contraceptive pill to provide both relief of menopausal symptoms and contraception; it is recommended that the oral contraceptive be stopped at 50 years of age since there are more suitable alternatives. If any potentially fertile woman needs HRT, non-hormonal contraceptive measures (such as condoms) are necessary. Measurement of follicle-stimulating hormone can help to determine fertility, but high measurements alone (particularly in women aged under 50 years) do not necessarily preclude the possibility of becoming pregnant.

PREGNANCY  Not known to be harmful.

BREAST FEEDING  Avoid until weaning or for 6 months after birth (adverse effects on lactation).

HEPATIC IMPAIRMENT  Avoid in active liver disease including disorders of hepatic excretion (e.g. Dubin-Johnson or Rotor syndromes), infective hepatitis (until safe), cholestasis.

MEDICINAL FORMS  There can be variation in the licensing of different medicines containing the same drug.

Tablet
- Premarin (Pfizer Ltd)  Conjugated oestrogens 300 microgram  Premarin 0.3mg tablets | 84 tablet  £6.07 DT price + £6.07
- Conjugated oestrogens 625 microgram  Premarin 0.625mg tablets | 84 tablet  £4.02 DT price + £4.02
- Conjugated oestrogens 1.25 mg  Premarin 1.25mg tablets | 84 tablet  £3.58 DT price + £3.58

Combinations available: Conjugated oestrogens with medroxyprogesterone, p. 717

Conjugated oestrogens with bazedoxifene acetate  28-Mar-2017
The properties listed below are those particular to the combination only. For the properties of the components please consider, conjugated oestrogens (equine) p. 710.

INDICATIONS AND DOSE  Menopausal symptoms (in women with at least 12 months since last menses for whom treatment with progestogen-containing therapy is not appropriate)
- By mouth
  - Adult: 0.45/20 mg daily continuously

DOSE EQUIVALENCE AND CONVERSION  Dose expressed as x/y mg conjugated oestrogens/bazedoxifene.

INTERACTIONS  → Appendix 1: hormone replacement therapy

SIDE-EFFECTS  Common or very common
- Common or very common  Dry mouth • muscle spasms • somnolence
- Uncommon  Cholecytitis
- Frequency not known  Visual disturbances

MEDICINAL FORMS  There can be variation in the licensing of different medicines containing the same drug.

Modified-release tablet
CAUTIONARY AND ADVISORY LABELS  3, 25
- Duavive (Merck Sharp & Dohme Ltd)  Conjugated oestrogens 450 microgram, Bazedoxifene (as Bazedoxifene acetate) 20 mg  Duavive 0.45mg/20mg modified-release tablets | 28 tablet  £15.00

Estradiol  28-Mar-2017

INDICATIONS AND DOSE  BEDOL ®
Menopausal symptoms | Osteoporosis prophylaxis
- By mouth
  - Adult: 2 mg daily, started on day 1–5 of menstruation (or at any time if cycles have ceased or are infrequent), to be taken with cyclical progestogen for 12–14 days of each cycle in women with a uterus

CLIMAVAL ®
Menopausal symptoms (if patient has had a hysterectomy)
- By mouth
  - Adult: 1–2 mg daily

ELLESTE SOLO ® MX
Menopausal symptoms
- By transdermal application
  - Adult: Apply 1 patch twice weekly continuously, started within 5 days of onset of menstruation (or at any time if cycles have ceased or are infrequent), to be used with cyclical progestogen for 12–14 days of each cycle in women with a uterus, initiate therapy with MX 40, subsequently adjust according to response

Osteoporosis prophylaxis
- By transdermal application
  - Adult: Apply 1 patch twice weekly continuously, started within 5 days of onset of menstruation (or at any time if cycles have ceased or are infrequent), to be used with cyclical progestogen for 12–14 days of each cycle in women with a uterus, initiate therapy with MX 80, subsequently adjust according to response
**ELLESTESOLO® 1-MG**

**Menopausal symptoms**
- **By mouth**
  - Adult: 1 mg daily, starting on day 1 of menstruation (or at any time if cycles have ceased or are infrequent), to be taken with cyclical progestogen for 12–14 days of each cycle in women with a uterus

**ELLESTESOLO® 2-MG**

**Menopausal symptoms not controlled with lower strength**
- **Osteoporosis prophylaxis**
  - **By mouth**
  - Adult: 2 mg daily, started on day 1 of menstruation (or at any time if cycles have ceased or are infrequent), to be given with cyclical progestogen for 12–14 days of each cycle in women with a uterus

**ESTRADERM MX®**

**Menopausal symptoms**
- **By transdermal application**
  - Adult: Apply 1 patch twice weekly continuously, started within 5 days of onset of menstruation (or at any time if cycles have ceased or are infrequent), to be used with cyclical progestogen for at least 12 days of each cycle in women with a uterus, initiate therapy with MX25 for first 3 months; subsequently adjust according to response

**Osteoporosis prophylaxis**
- **By transdermal application**
  - Adult: Apply 1 patch twice weekly continuously, started within 5 days of onset of menstruation (or at any time if cycles have ceased or are infrequent), to be used with cyclical progestogen for at least 12 days of each cycle in women with a uterus, initiate therapy with MX50; subsequently adjust according to response

**ESTRADO®**

**Menopausal symptoms**
- **By transdermal application**
  - Adult: Apply 1 patch twice weekly continuously, to be used with cyclical progestogen for 12–14 days of each cycle in women with a uterus, initiate therapy with 25 patch for 3 months; subsequently adjust according to response

**Osteoporosis prophylaxis**
- **By transdermal application**
  - Adult: Apply 1 patch twice weekly continuously, to be used with cyclical progestogen for 12–14 days of each cycle in women with a uterus, initiate therapy with 50 patch; subsequently adjust according to response

**EVOREL®**

**Menopausal symptoms | Osteoporosis prophylaxis**
- **By transdermal application**
  - Adult: Apply 1 patch twice weekly continuously, started within 5 days of onset of menstruation (or at any time if cycles have ceased or are infrequent), to be used with cyclical progestogen for 12–14 days of each cycle in women with a uterus, therapy should be initiated with Evarel 50 patch; subsequently adjust according to response; dose may be reduced to Evarel 25 patch after first month if necessary for menopausal symptoms only

**FEMSEVEN®**

**Menopausal symptoms | Osteoporosis prophylaxis**
- **By transdermal application**
  - Adult: Apply 1 patch once weekly continuously, to be used with cyclical progestogen for 12–14 days of each cycle in women with a uterus, initiate therapy with FemSeven 50 patches for the first few months, subsequently adjust according to response

**OESTROGEL®**

**Menopausal symptoms**
- **To the skin**
  - Adult: Apply 1.5 mg once daily continuously, increased if necessary up to 3 mg after 1 month continuously, to be applied over an area twice that of the template provided, starting within 5 days of menstruation (or anytime if cycles have ceased or are infrequent), to be used with cyclical progestogen for at least 12 days of each cycle in women with a uterus

**Osteoporosis prophylaxis**
- **To the skin**
  - Adult: Apply 1.5 mg once daily continuously, to be applied over an area twice that of the template provided, starting within 5 days of menstruation (or anytime if cycles have ceased or are infrequent), to be used with cyclical progestogen for at least 12 days of each cycle in women with a uterus

**Dose equivalence and conversion**
- For Oestrogel®: 2 measures is equivalent to estradiol 1.5 mg.

**PROGYNOVA®**

**Menopausal symptoms**
- **By mouth**
  - Adult: 1–2 mg daily continuously, to be started on day 1 of menstruation (or at any time if cycles have ceased or are infrequent), to be taken with cyclical progestogen for 12–14 days of each cycle in women with a uterus

**Osteoporosis prophylaxis**
- **By mouth**
  - Adult: 2 mg daily continuously, to be taken with cyclical progestogen for 12–14 days of each cycle in women with a uterus

**PROGYNOVA® TS**

**Menopausal symptoms | Osteoporosis prophylaxis**
- **By transdermal application**
  - Adult: Apply 1 patch once weekly continuously, alternatively apply 1 patch once weekly for 3 weeks, followed by a 7-day patch-free interval (cyclical), to be used with cyclical progestogen for 12–14 days of each cycle in women with a uterus, initiate therapy with Progynova TS 50, subsequently adjust according to response, women receiving Progynova TS 100 patches for menopausal symptoms may continue with this strength for osteoporosis prophylaxis

**SANDRENA®**

**Menopausal symptoms**
- **To the skin**
  - Adult: Apply 1 mg once daily, to be applied over area 1–2 times size of hand; with cyclical progestogen for 12–14 days of each cycle in women with a uterus, dose may be adjusted after 2–3 cycles to lowest effective dose; usual dose 0.5–1.5 mg daily

**ZUMENON®**

**Menopausal symptoms**
- **By mouth**
  - Adult: Initially 1 mg daily, to be started within 5 days of onset of menstruation (or any time if cycles have ceased or are infrequent), increased if necessary to 2 mg daily, to be taken with a cyclical progestogen for 12–14 days of each cycle in women with a uterus

**Osteoporosis prophylaxis**
- **By mouth**
  - Adult: 2 mg daily, to be taken with a cyclical progestogen for 12–14 days of each cycle in women with a uterus
CONTRA-INDICATIONS Active arterial thromboembolic disease (e.g. angina or myocardial infarction) • active thrombophlebitis • Dubin–Johnson syndrome (or monitor closely) • history of breast cancer • history of recurrent venous thromboembolism (unless already on anticoagulant treatment) • oestrogen-dependent cancer • recent arterial thromboembolic disease (e.g. angina or myocardial infarction) • Rotor syndrome (or monitor closely) • thrombopathic disorder • undiagnosed vaginal bleeding • untreated endometrial hyperplasia • venous thromboembolism

CAUTIONS Acute porphyrias p. 969 • diabetes (increased risk of heart disease) • history of breast nodules—closely monitor breast status (risk of breast cancer) • history of endometrial hyperplasia; factors predisposing to thromboembolism • history of fibrocystic disease—closely monitor breast status (risk of breast cancer) • hypophyseal tumours • increased risk of gall-bladder disease • migraine (or migraine-like headaches) • presence of antiphospholipid antibodies (increased risk of thrombotic events) • prolonged exposure to unopposed oestrogens may increase risk of developing endometrial cancer • risk factors for oestrogen-dependent tumours (e.g. breast cancer in first-degree relative) • symptoms of endometriosis may be exacerbated • uterine fibroids may increase in size

CAUTIONS, FURTHER INFORMATION
- Risk of breast cancer It is estimated that using all types of HRT increases the risk of breast cancer within 1–2 years of initiating treatment. The increased risk is related to the duration of HRT use (but not to the age at which HRT is started) and this excess risk disappears within 5 years of stopping.

Radioiodine detection of breast cancer can be made more difficult as mammographic density can increase with HRT use.

- Risk of endometrial cancer The increased risk of endometrial cancer depends on the dose and duration of oestrogen-only HRT.

In women with a uterus, the addition of a progestogen cyclically (for at least 10 days per 28-day cycle) reduces the additional risk of endometrial cancer; this additional risk is eliminated if a progestogen is given continuously. However, this should be weighed against the increased risk of breast cancer.

- Risk of ovarian cancer Long-term use of combined HRT or oestrogen-only HRT is associated with a small increased risk of ovarian cancer. This excess risk disappears within a few years of stopping.

- Risk of venous thromboembolism Women using combined or oestrogen-only HRT are at an increased risk of deep vein thrombosis and of pulmonary embolism especially in the first year of use.

In women who have predisposing factors (such as a personal or family history of deep vein thrombosis or pulmonary embolism, severe varicose veins, obesity, trauma, or prolonged bed-rest) it is prudent to review the need for HRT, as in some cases the risks of HRT may exceed the benefits.

Travel involving prolonged immobility further increases the risk of deep vein thrombosis.

- Risk of stroke Risk of stroke increases with age, therefore older women have a greater absolute risk of stroke. Combined HRT or oestrogen-only HRT slightly increases the risk of stroke.

- Risk of coronary heart disease HRT does not prevent coronary heart disease and should not be prescribed for this purpose. There is an increased risk of coronary heart disease in women who start combined HRT more than 10 years after menopause. Although very little information is available on the risk of coronary heart disease in younger women who start HRT close to the menopause, studies suggest a lower relative risk compared with older women.

Other conditions The product literature advises caution in other conditions including hypertension, renal disease, asthma, epilepsy, sickle-cell disease, meloma, otosclerosis, multiple sclerosis, and systemic lupus erythematosus (but care required if antiphospholipid antibodies present). Evidence for caution in these conditions is unsatisfactory and many women with these conditions may stand to benefit from HRT.

INTERACTIONS Appendix 1: hormone replacement therapy

SIDE-EFFECTS
GENERAL SIDE-EFFECTS Abdominal bloating • abdominal cramps • altered blood lipids (may lead to pancreatitis, rashes and chloasma) • breast enlargement • breast tenderness • changes in libido • cholestatic jaundice • contact lenses may irritate • depression • dizziness • fluid retention • glucose intolerance • headache • headache (on vigorous exercise) • leg cramps (rule out venous thrombosis) • migraine • mood changes • nausea • premenstrual-like syndrome • sodium retention • vaginal candidiasis • vomiting • weight changes

SPECIFIC SIDE-EFFECTS
- With transdermal use Cause contact sensitisation (possible severe hypersensitivity reaction on continued exposure)

SIDE-EFFECTS, FURTHER INFORMATION
- Withdrawal bleeding Cyclical HRT (where a progestogen is taken for 12–14 days of each 28-day oestrogen treatment cycle) usually results in regular withdrawal bleeding towards the end of the progestogen. The aim of continuous combined HRT (where a combination of oestrogen and progestogen is taken, usually in a single tablet, throughout each 28-day treatment cycle) is to avoid bleeding, but irregular bleeding may occur during the early treatment stages (if it continues endometrial abnormality should be excluded and consideration given to cyclical HRT instead).

CONCEPTION AND CONTRACEPTION HRT does not provide contraception and a woman is considered potentially fertile for 2 years after her last menstrual period if she is under 50 years, and for 1 year if she is over 50 years. A woman who is under 50 years and free of all risk factors for venous and arterial disease can use a low-oestrogen combined oral contraceptive pill to provide both relief of menopausal symptoms and contraception; it is recommended that the oral contraceptive be stopped at 50 years of age since there are more suitable alternatives. If any potentially fertile woman needs HRT, non-hormonal contraceptive measures (such as condoms) are necessary. Measurement of follicle-stimulating hormone can help to determine fertility, but high measurements alone (particularly in women aged under 50 years) do not necessarily preclude the possibility of becoming pregnant.

PREGNANCY Not known to be harmful.

BREAST FEEDING Avoid; adverse effects on lactation.

HEPATIC IMPAIRMENT Avoid in active liver disease including disorders of hepatic excretion (e.g. Dubin–Johnson or Rotor syndromes), infective hepatitis (until liver function returns to normal), and liver tumours.

MONITORING REQUIREMENTS
- Close diagnosis of breast nodules or fibrocystic disease—closely monitor breast status (risk of breast cancer).

The endometrial safety of long-term or repeated use of topical vaginal oestrogens is uncertain; treatment should be reviewed at least annually, with special consideration given to any symptoms of endometrial hyperplasia or carcinoma.
### Endocrine system

#### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Bedol** *(ReSource Medical UK Ltd)*
  - Estradiol 2 mg Bedol 2mg tablets | 84 tablet *PsM* | £5.07 DT price = £5.06
- **Elleste Solo** *(Meda Pharmaceuticals Ltd)*
  - Estradiol 1 mg Elleste Solo 1mg tablets | 84 tablet *PsM* | £5.06 DT price = £5.06
  - Estradiol 2 mg Elleste Solo 2mg tablets | 84 tablet *PsM* | £5.06 DT price = £5.06
- **Progynova** *(Bayer Plc)*
  - Estradiol valerate 1 mg Progynova 1mg tablets | 84 tablet *PsM* | £7.30 DT price = £7.30
  - Estradiol valerate 2 mg Progynova 2mg tablets | 84 tablet *PsM* | £7.30 DT price = £7.30
- **Zumenon** *(Mylan Ltd)*
  - Estradiol 1 mg Zumenon 1mg tablets | 84 tablet *PsM* | £6.89 DT price = £6.89
  - Estradiol 2 mg Zumenon 2mg tablets | 84 tablet *PsM* | £6.89 DT price = £6.89

**Transdermal patch**

- **Elleste Solo MX** *(Meda Pharmaceuticals Ltd)*
  - Estradiol 40 microgram per 24 hour Elleste Solo MX 40 transdermal patches | 8 patch *PsM* | £5.99
  - Estradiol 80 microgram per 24 hour Elleste Solo MX 80 transdermal patches | 8 patch *PsM* | £5.99
- **Estraderm MX** *(Merus Labs Luxco S.A.R.L.)*
  - Estradiol 25 microgram per 24 hour Estraderm MX 25 patches | 8 patch *PsM* | £5.50 | 24 patch *PsM* | £16.46
  - Estradiol 50 microgram per 24 hour Estraderm MX 50 patches | 8 patch *PsM* | £5.51 | 20 patch *PsM* | no price available (Hospital only)
  - Estradiol 75 microgram per 24 hour Estraderm MX 75 patches | 8 patch *PsM* | £6.42 | 24 patch *PsM* | £19.27
  - Estradiol 100 microgram per 24 hour Estraderm MX 100 patches | 8 patch *PsM* | £6.66 | 24 patch *PsM* | £19.99
- **Estradot** *(Novartis Pharmaceuticals UK Ltd)*
  - Estradiol 25 microgram per 24 hour Estradot 25micrograms/24hours patches | 8 patch *PsM* | £5.99
  - Estradiol 37.5 microgram per 24 hour Estradot 37.5micrograms/24hours patches | 8 patch *PsM* | £6.00
  - Estradiol 50 microgram per 24 hour Estradot 50micrograms/24hours patches | 8 patch *PsM* | £6.02
  - Estradiol 75 microgram per 24 hour Estradot 75micrograms/24hours patches | 8 patch *PsM* | £7.00
  - Estradiol 100 microgram per 24 hour Estradot 100micrograms/24hours patches | 8 patch *PsM* | £7.27

**Gel**

- **Oestrogel** *(Besins Healthcare (UK) Ltd)*
  - Estradiol 100 microgram per 24 hour Oestrogel Pump-Pack 7.06% gel | 80 gram *PsM* | £4.80 DT price = £4.80
  - Estradiol (as Estradiol hemihydrate) 500 microgram Sandrena 500microgram gel sachets | 28 sachet *PsM* | £5.08 DT price = £5.08
  - Estradiol (as Estradiol hemihydrate) 1 mg Sandrena 1mg gel sachets | 28 sachet *PsM* | £5.85 DT price = £5.85 | 91 sachet *PsM* | £17.57


### Estradiol with estriol and estrone

The properties listed below are those particular to the combination only. For the properties of the components please consider, estradiol p. 711, estriol p. 783.

#### INDICATIONS AND DOSE

**Menopausal symptoms**

- **BY MOUTH**
  - Adult: 1–2 tablets daily continuously or cyclically (21 days out of 28), started within 5 days of onset of menstruation (or at any time if cycles have ceased or are infrequent), to be taken with cyclical progestogen for 12–14 days of each cycle in women with a uterus

**INTERACTIONS**

→ Appendix 1: hormone replacement therapy

#### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Hormonin** *(AMCo)*
  - Estradiol 270 microgram, Estradiol 600 microgram, Estrone 1.4 mg Hormonin tablets | 84 tablet *PsM* | £7.93
Ethinylestradiol
(Ethinyleoestradiol)

**INDICATIONS AND DOSE**

**Short-term treatment of symptoms of oestrogen deficiency**

- **Osteoporosis prophylaxis if other drugs cannot be used**
  - **BY MOUTH**
    - Adult (male): 10–50 micrograms daily for 21 days, repeated after 7-day tablet-free period, to be given with progestogen for 12–14 days per cycle in women with intact uterus.

**Female hypogonadism**

- **BY MOUTH**
  - Adult (female): 10–50 micrograms daily usually on cyclical basis, initial oestrogen therapy should be followed by combined oestrogen and progestogen therapy.

**Menstrual disorders**

- **BY MOUTH**
  - Adult (female): 20–50 micrograms daily from day 5 to day 25 of each cycle, to be given with progestogen, added either throughout the cycle or from day 15 to 25.

**Palliative treatment of prostate cancer**

- **BY MOUTH**
  - Adult (male): 0.15–1.5 mg daily.

**CONTRA-INDICATIONS** Active or recent arterial thromboembolic disease (e.g. angina or myocardial infarction) • active thrombophlebitis • acute porphyrias p. 969 • Dubin–Johnson and Rotor syndromes (or monitor closely) • gallstones • heart disease associated with pulmonary hypertension • heart disease associated with risk of embolus • history during pregnancy of cholestatic jaundice • history during pregnancy of chorea • history during pregnancy of pemphigoid gestationis • history during pregnancy of pruritus • history of breast cancer • history of haemolytic uraemic syndrome • liver disease (where liver function tests have failed to return to normal) • migraine with aura • oestrogen-dependent cancer • sclerosing treatment for varicose veins • severe or multiple risk factors for arterial disease • severe or multiple risk factors for venous thromboembolism • systemic lupus erythematosus with (or unknown) antiphospholipid antibodies • thrombophilic disorder • transient cerebral ischaemic attacks without headaches • undiagnosed vaginal bleeding • untreated endometrial hyperplasia • venous thromboembolism, or history of recurrent venous thromboembolism (unless already on antiocoagulant treatment)

**CAUTIONS** Active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration)—seek specialist advice • cardiovascular disease (sodium retention with oedema, thromboembolism) • Crohn’s disease • diabetes (increased risk of heart disease) • gene mutations associated with breast cancer (e.g. BRCA 1) • history of breast nodules or fibrocystic disease—closely monitor breast status (risk of breast cancer) • history of endometrial hyperplasia • history of severe depression (especially if induced by hormonal contraceptive) • hyperprolactinaemia (seek specialist advice) • hypophysial tumours • increased risk of gall-bladder disease • inflammatory bowel disease • migraine (migraine-like headaches) • personal or family history of hypertrophiccardiama (increased risk of pancreatitis) • presence of antiphospholipid antibodies (increased risk of thrombotic events) • prolonged exposure to unopposed oestrogens may increase risk of developing endometrial cancer • risk factors for arterial disease • risk factors for migraine • risk factors for oestrogen-dependent tumours (e.g. breast cancer in first-degree relative) • risk factors for venous thromboembolism • sickle-cell disease • undiagnosed breast mass

**CAUTIONS, FURTHER INFORMATION**

- **Other conditions** The product literature advises caution in other conditions including hypertension, renal disease, asthma, epilepsy, sickle-cell disease, melanoma, otosclerosis, multiple sclerosis, and systemic lupus erythematosus (but care required if antiphospholipid antibodies present, see above). Evidence for caution in these conditions is unsatisfactory and many women with these conditions may stand to benefit from HRT.

- **Risk of venous thromboembolism** Use with caution if any of the following factors present but avoid if two or more factors present:
  - family history of venous thromboembolism in first-degree relative aged under 45 years (avoid if known prothrombotic coagulation abnormality e.g. factor V Leiden or antiphospholipid antibodies (including lupus anticoagulant));
  - obesity—body mass index ≥30 kg/m² (avoid body mass index ≥35 kg/m² unless no suitable alternative); (In adolescents, caution if obese according to BMI (adjusted for age and gender); in those who are markedly obese, avoid unless no suitable alternative);
  - long-term immobilisation e.g. in a wheelchair (avoid if confined to bed or leg in plaster cast);
  - history of superficial thrombophlebitis;
  - age over 35 years (avoid if over 50 years);
  - smoking.

- **Risk factors for arterial disease** Use with caution if any one of the following factors present but avoid if two or more factors present:
  - family history of arterial disease in first degree relative aged under 45 years (avoid if atherogenic lipid profile);
  - diabetes mellitus (avoid if diabetes complications present);
  - hypertension—blood pressure above systolic 140 mmHg or diastolic 90 mmHg (avoid if blood pressure above systolic 160 mmHg or diastolic 95 mmHg); (In adolescents, avoid if blood pressure very high);
  - smoking (avoid if smoking 40 or more cigarettes daily);
  - age over 35 years (avoid if over 50 years);
  - obesity (avoid if body mass index ≥35 kg/m² unless no suitable alternative); (In adolescents, caution if obese according to BMI (adjusted for age and gender); in those who are markedly obese, avoid unless no suitable alternative);
  - migraine without aura (avoid if migraine with aura (focal symptoms), or severe migraine frequently lasting over 72 hours despite treatment, or migraine treated with ergot derivatives).

- **Migraine** Women should report any increase in headache frequency or onset of focal symptoms (discontinue immediately and refer urgently to neurology expert if focal neurological symptoms not typical of aura persist for more than 1 hour).

**INTERACTIONS** → Appendix 1: hormone replacement therapy

**SIDE-EFFECTS**

- **Rare** Gallstones • systemic lupus erythematosus

- **Frequency not known** Abdominal bloating • abdominal cramps • absence of withdrawal bleeding • altered blood lipids (may lead to pancreatitis) • amenorrhoea after discontinuation • breast enlargement • breast secretion • breast tenderness • cervical erosion • changes in libido • changes in lipid metabolism • changes in vaginal discharge • chloasma • cholestatic jaundice • chorea • contact lenses may irritate • depression • dizziness • feminising effects • fluid retention • glucose intolerance • headache • hepatic tumours • hypertension • irritability • leg cramps (rule out venous thrombosis) • liver impairment • migraine • mood changes • nausea • nervousness • photosensitivity

---

*downloaded from www.medicalbr.com*
premenstrual-like syndrome • rash • reduced menstrual loss • skin reactions • sodium retention • symptoms of endometriosis may be exacerbated • thrombosis (more common when factor V Leiden present or in blood groups A, B, and AB) • uterine fibroids may increase in size • vaginal candidiasis • visual disturbances • vomiting • weight changes • ‘spotting’ in early cycles

**SIDE-EFFECTS, FURTHER INFORMATION**

- Withdrawal bleeding  
  Cyclical HRT (where a progestogen is taken for 12–14 days of each 28-day oestrogen treatment cycle) usually results in regular withdrawal bleeding towards the end of the progestogen. The aim of continuous combined HRT (where a combination of oestrogen and progestogen is taken, usually in a single tablet, throughout each 28-day treatment cycle) is to avoid bleeding, but irregular bleeding may occur during the early treatment stages (if it continues endometrial abnormality should be excluded and consideration given to cyclical HRT instead).

**PREGNANCY**  
Not known to be harmful.

**BREAST FEEDING**  
Avoid until weaning or for 6 months after birth (adverse effects on lactation).

**HEPATIC IMPAIRMENT**  
Avoid.

**MEDICINAL FORMS**

<table>
<thead>
<tr>
<th>Tablet</th>
<th>Ethinylestradiol (Non-proprietary)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethinylestradiol 10 microgram</td>
<td>£200.00 DT price = £200.00</td>
</tr>
<tr>
<td>Ethinylestradiol 50 microgram</td>
<td>£200.00 DT price = £200.00</td>
</tr>
<tr>
<td>Ethinylestradiol 1 mg</td>
<td>£200.00 DT price = £200.00</td>
</tr>
</tbody>
</table>

**Tibolone**

**INDICATIONS AND DOSE**

Short-term treatment of symptoms of oestrogen deficiency (including women being treated with gonadotrophin releasing hormone analogues)  
Osteoporosis prophylaxis in women at high risk of fractures when other prophylaxis contra-indicated or not tolerated

- **BY MOUTH**
- Adult: 2.5 mg daily

**CONTRA-INDICATIONS**

- Active or recent arterial thromboembolic disease (e.g. angina or myocardial infarction) • active thrombophlebitis • acute porphyrias p. 969 • Dubin–Johnson and Rotor syndrome (or monitor closely) • history of breast cancer • history of cardiovascular disease • history of cerebrovascular disease • history of recurrent venous thromboembolism (unless already on anticoagulant treatment) • history of thrombolysis • history of thrombophlebitis • hormone-dependent tumours • liver disease (where liver function tests have failed to return to normal) • oestrogen-dependent cancer • thrombophilic disorder • uninvestigated or undiagnosed vaginal bleeding • untreated endometrial hyperplasia • venous thromboembolism

**CAUTIONS**

- Acute porphyrias p. 969 • diabetes (increased risk of heart disease) • epilepsy • factors predisposing to thromboembolism • history of breast nodules—closely monitor breast status (risk of breast cancer) • history of endometrial hyperplasia • history of fibrocystic disease—closely monitor breast status (risk of breast cancer) • history of liver disease • hypertriglyceridaemia • hypophysial tumours • migraine (or migraine-like headaches) • presence of antiphospholipid antibodies (increased risk of thrombotic events) • prolonged exposure to unopposed oestrogens may increase risk of developing endometrial cancer • risk factors for oestrogen-dependent tumours (e.g. breast cancer in first-degree relative) • risk of stroke

**INTERACTIONS**

- Other conditions  
  The product literature advises caution in other conditions including hypertension, renal disease, asthma, epilepsy, sickle-cell disease, melanoma, otosclerosis, multiple sclerosis, and systemic lupus erythematosus (but care required if antiphospholipid antibodies present). Evidence for caution in these conditions is unsatisfactory and many women with these conditions may stand to benefit from HRT.

**SIDE-EFFECTS**

- Common or very common  
  Abdominal pain • facial hair • leucorrhoea • vaginal bleeding • weight changes

- Rare  
  Amnesia

- Frequency not known  
  Arthralgia • breast cancer • depression • dizziness • gastro-intestinal disturbances • headache • increased risk of gall-bladder disease • migraine • myalgia • oedema • pruritus • rash • seborrhoeic dermatitis • symptoms of endometriosis may be exacerbated • uterine fibroids may increase in size • visual disturbances

**SIDE-EFFECTS, FURTHER INFORMATION**

- Vaginal bleeding  
  Investigate for endometrial cancer if bleeding continues beyond 6 months or after stopping treatment.

- Reasons to withdraw treatment  
  Withdraw treatment if signs of thromboembolic disease, abnormal liver function tests, or signs of cholestatic jaundice.

- **PREGNANCY**  
  Avoid; toxicity in animal studies.

- **BREAST FEEDING**  
  Avoid.

- **HEPATIC IMPAIRMENT**  
  Avoid in acute liver disease or if history of liver disease and liver function tests not returned to normal.

- **RENAI IMPAIRMENT**  
  Patients with renal impairment should be closely monitored (risk of fluid retention).

**PRESCRIBING AND DISPENSING INFORMATION**

- Unsuitable for use in the premenopause (unless being treated with gonadotrophin-releasing hormone analogue) and as (or with) an oral contraceptive.

- Also unsuitable for use within 12 months of last menstrual period (may cause irregular bleeding).

- If transferring from cyclical HRT, start at end of regimen; if transferring from continuous–combined HRT, start at any time.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

<table>
<thead>
<tr>
<th>Tablet</th>
<th>Tibolone (Non-proprietary)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tibolone 2.5 mg</td>
<td>£10.36–£10.43 DT price = £10.36</td>
</tr>
<tr>
<td>Livial (Merck Sharp &amp; Dohme Ltd)</td>
<td>£10.36 DT price = £10.36</td>
</tr>
</tbody>
</table>

**716 Sex hormone responsive conditions**

BNF 74

Endocrine system
OESTROGENS COMBINED WITH PROGESTOGENS

Conjugated oestrogens with medroxyprogesterone

The properties listed below are those particular to the combination only. For the properties of the components please consider, conjugated oestrogens (equine) p. 710, medroxyprogesterone acetate p. 763.

- **INDICATIONS AND DOSE**
  - **PREMIQUE® LOW DOSE TABLETS**
    - Menopausal symptoms in women with a uterus
      - BY MOUTH
        - Adult: 1 tablet daily continuously

- **INTERACTIONS** → Appendix 1: hormone replacement therapy

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Modified-release tablet**
    - **Premique** (Pfizer Ltd)
      - Conjugated oestrogens 300 microgram, Medroxyprogesterone acetate 1.5 mg
  - **Premique Low Dose**

Estradiol with drospirenone

The properties listed below are those particular to the combination only. For the properties of the components please consider, estradiol p. 711.

- **INDICATIONS AND DOSE**
  - **Menopausal symptoms in women with a uterus whose last menstrual period occurred over 12 months previously**
    - BY MOUTH
      - Adult: 1 tablet daily continuously, if changing from cyclical HRT begin treatment the day after finishing oestrogen plus progestogen phase

- **CAUTIONS** Use with care if an increased concentration of potassium might be hazardous
- **INTERACTIONS** → Appendix 1: hormone replacement therapy
- **RENAL IMPAIRMENT** Avoid if eGFR less than 30 mL/minute/1.73 m².

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Tablet**
    - **Angeliq** (Bayer Plc)
      - Estradiol (as Estradiol hemihydrate) 1 mg, Drospirenone 2 mg

Estradiol with dydrogesterone

The properties listed below are those particular to the combination only. For the properties of the components please consider, estradiol p. 711.

- **INDICATIONS AND DOSE**
  - **FEMOSTON® 1 MG/10 MG**
    - Menopausal symptoms in women with a uterus
      - BY MOUTH
        - Adult: 1 tablet daily for 14 days, white tablet to be taken and started within 5 days of onset of menstruation (or any time if cycles have ceased or are infrequent), then 1 tablet daily for 14 days, grey tablet to be taken, subsequent courses repeated without interval, **Femoston® 1 mg/10 mg** substituted if symptoms not controlled

  - **Osteoporosis prophylaxis in women with a uterus**
    - BY MOUTH
      - Adult: 1 tablet daily for 14 days, white tablet to be taken and started within 5 days of onset of menstruation (or any time if cycles have ceased or are infrequent), then 1 tablet daily for 14 days, grey tablet to be taken, subsequent courses repeated without interval

  - **FEMOSTON® 2 MG/10 MG**
    - Menopausal symptoms in women with a uterus whose last menstrual period occurred over 12 months previously
      - BY MOUTH
        - Adult: 1 tablet daily for 14 days, red tablet to be taken and started within 5 days of onset of menstruation (or any time if cycles have ceased or are infrequent), then 1 tablet daily for 14 days, yellow tablet to be taken, subsequent courses repeated without interval

  - **Osteoporosis prophylaxis in women with a uterus**
    - BY MOUTH
      - Adult: 1 tablet daily for 14 days, red tablet to be taken and started within 5 days of onset of menstruation (or any time if cycles have ceased or are infrequent), then 1 tablet daily for 14 days, yellow tablet to be taken, subsequent courses repeated without interval

  - **FEMOSTON®-CONTI 0.5 MG/2.5MG**
    - Menopausal symptoms in women with a uterus whose last menstrual period occurred over 12 months previously
      - BY MOUTH
        - Adult: 1 tablet daily continuously, if changing from cyclical HRT begin treatment the day after finishing oestrogen plus progestogen phase

  - **Osteoporosis prophylaxis in women with a uterus**
    - BY MOUTH
      - Adult: 1 tablet daily continuously, if changing from cyclical HRT begin treatment the day after finishing oestrogen plus progestogen phase

- **CONTRA-INDICATIONS**
  - Acute porphyrias p. 969 • genital or breast cancer • history during pregnancy of idiopathic jaundice, severe pruritus, or pempigoid gestationis • history of liver tumours • severe arterial disease • undiagnosed vaginal bleeding

- **CAUTIONS** Conditions that may worsen with fluid retention e.g. epilepsy, hypertension, migraine, asthma, or cardiac dysfunction • diabetes (progestogens can decrease glucose tolerance) • history of depression • in those
susceptible to thromboembolism (particular caution with high dose)

- INTERACTIONS → Appendix 1: hormone replacement therapy
- SIDE-EFFECTS Acne · alopecia · anaphylactoid reactions · bloating · breast tenderness · change in libido · depression · dizziness · drowsiness · fluid retention · headache · hirsutism · insomnia · jaundice · menstrual disturbances · nausea · premenstrual-like syndrome · pruritus · rash · skin reactions · urticaria · weight change
- HEPATIC IMPAIRMENT Avoid.
- RENAL IMPAIRMENT Use with caution.

- MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug.
  **Tablet**
  - Femoston 1/10 (Mylan Ltd)
    Femoston 1/10mg tablets | 84 tablet (POM) £16.16
  - Femoston 2/10 (Mylan Ltd)
    Femoston 2/10mg tablets | 84 tablet (POM) £16.16
  - Femoston-conti (Mylan Ltd)
    Estradiol 500 microgram, Dydrogesterone 2.5 mg Femoston-conti 0.5mg/2.5mg tablets | 84 tablet (POM) £24.43
    Estradiol 1 mg, Dydrogesterone 5 mg Femoston-conti 1mg/5mg tablets | 84 tablet (POM) £24.43 DT price = £24.43

**Estradiol with levonorgestrel**

The properties listed below are those particular to the combination only. For the properties of the components please consider, estradiol p. 711, levonorgestrel p. 759.

- INDICATIONS AND DOSE

  **FEMSEVEN SEQUI®**
  *Menopausal symptoms in women with a uterus*  
  → BY TRANSDERMAL APPLICATION  
  *Adult:* Apply 1 patch once weekly continuously

  **FEMSEVEN CONTI®**
  *Menopausal symptoms in women with a uterus*  
  → BY TRANSDERMAL APPLICATION  
  *Adult:* Apply 1 patch once weekly for 2 weeks, phase 1 patches to be applied, then apply 1 patch once weekly for 2 weeks, phase 2 patches to be applied, subsequent courses are repeated without interval

- INTERACTIONS → Appendix 1: hormone replacement therapy
- PATIENT AND CARER ADVICE Patient counselling is advised for estradiol with levonorgestrel patches (application).

- MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug.
  **Transdermal patch**
  - FemSeven Conti (Teva UK Ltd)
    Levonorgestrel 7 microgram per 24 hour, Estradiol 50 microgram per 24 hour FemSeven Conti patches | 4 patch (POM) £15.48 | 12 patch (POM) £44.12
  - FemSeven Sequi (Teva UK Ltd)
    FemSeven Sequi patches | 4 patch (POM) £13.18 | 12 patch (POM) £37.54

**Estradiol with medroxyprogesterone**

The properties listed below are those particular to the combination only. For the properties of the components please consider, estradiol p. 711, medroxyprogesterone acetate p. 763.

- INDICATIONS AND DOSE

  **INDIVINA® TABLETS**
  *Menopausal symptoms in women with a uterus whose last menstrual period occurred over 3 years previously*  
  → BY MOUTH  
  *Adult:* Initially 1/2.5 mg daily taken continuously, adjust according to response, to be started at end of scheduled bleed if changing from cyclical HRT

  **TRIDESTRA®**
  *Menopausal symptoms in women with a uterus*  
  → BY MOUTH  
  *Adult:* 1 tablet daily for 70 days, white tablet to be taken, then 1 tablet daily for 14 days, blue tablet to be taken, then 1 tablet daily for 7 days, yellow tablet to be taken, subsequent courses are repeated without interval

- INTERACTIONS → Appendix 1: hormone replacement therapy

**Estradiol with norethisterone**

The properties listed below are those particular to the combination only. For the properties of the components please consider, estradiol p. 711, norethisterone p. 720.

- INDICATIONS AND DOSE

  **CLIMAGET® 1-MG**
  *Menopausal symptoms*  
  → BY MOUTH  
  *Adult:* 1 tablet daily for 16 days, grey tablet to be taken and started on day 1 of menstruation (or at any time if cycles have ceased or are infrequent), then 1 tablet daily for 12 days, white tablet to be taken, subsequent courses are repeated without interval

  **CLIMAGET® 2-MG**
  *Menopausal symptoms (if symptoms not controlled with lower strength)*  
  → BY MOUTH  
  *Adult:* 1 tablet daily for 16 days, blue tablet to be taken and started on day 1 of menstruation (or at any time if cycles have ceased or are infrequent), then 1 tablet daily for 12 days, white tablet to be taken, subsequent courses are repeated without interval
Menopausal symptoms in women with a uterus whose last menstrual period occurred over 12 months previously | Osteoporosis prophylaxis in women with a uterus whose last menstrual period occurred over 12 months previously

- **BY MOUTH**
  - Adult: 1 tablet daily continuously

**KLIOFEM**

Menopausal symptoms in women with a uterus whose last menstrual period occurred over 12 months previously | Osteoporosis prophylaxis in women with a uterus whose last menstrual period occurred over 12 months previously

- **BY MOUTH**
  - Adult: 1 tablet daily continuously, to be started at end of scheduled bleed if changing from cyclical HRT

**EVOREL**

Menopausal symptoms in women with a uterus | Osteoporosis prophylaxis in women with a uterus

- **BY TRANSDERMAL APPLICATION**
  - Adult: 1 tablet daily for 16 days, white tablets to be taken, started on day 5 of menstruation (or at any time if cycles have ceased or are infrequent), then 1 tablet daily for 12 days, pink tablets to be taken, subsequent courses repeated without interval

**ELLESTE-DUET**

Menopausal symptoms in women with a uterus | Osteoporosis prophylaxis in women with a uterus

- **BY MOUTH**
  - Adult: 1 tablet daily for 16 days, white tablets to be taken, started on day 1 of menstruation (or at any time if cycles have ceased or are infrequent), then 1 tablet daily for 12 days, green tablets to be taken, subsequent courses repeated without interval

**EVOREL CONTI**

Menopausal symptoms in women with a uterus | Osteoporosis prophylaxis in women with a uterus

- **BY TRANSDERMAL APPLICATION**
  - Adult: 1 patch twice weekly for 1 week, Evorel® patch to be applied, subsequent courses repeated without interval

**KLIOVANCE**

Menopausal symptoms in women with a uterus whose last menstrual period occurred over 12 months previously | Osteoporosis prophylaxis in women with a uterus whose last menstrual period occurred over 12 months previously

- **BY MOUTH**
  - Adult: 1 tablet daily continuously, to be started at end of scheduled bleed if changing from cyclical HRT

**NOVFEM**

Menopausal symptoms in women with a uterus | Osteoporosis prophylaxis in women with a uterus

- **BY MOUTH**
  - Adult: 1 tablet daily for 16 days, red tablets to be taken, then 1 tablet daily for 12 days, white tablets to be taken, subsequent courses repeated without interval; start treatment with red tablet at any time or if changing from cyclical HRT, start treatment the day after finishing oestrogen plus progestogen phase

**NUVELLE CONTINUOUS**

Menopausal symptoms in women with a uterus whose last menstrual period occurred over 12 months previously | Osteoporosis prophylaxis in women with a uterus whose last menstrual period occurred over 12 months previously

- **BY MOUTH**
  - Adult: 1 tablet daily continuously, if changing from cyclical HRT, start treatment the day after finishing oestrogen plus progestogen phase

**TRISEQUENS**

Menopausal symptoms in women with a uterus | Osteoporosis prophylaxis in women with a uterus

- **BY MOUTH**
  - Adult: 1 tablet daily for 12 days, blue tablets to be taken, followed by 1 tablet daily for 10 days, white tablets to be taken, then 1 tablet daily for 6 days, red tablet to be taken, subsequent courses repeated without interval

**INTERACTIONS** Appendix 1: hormone replacement therapy

**PATIENT AND CARER ADVICE**

Evorel® Sequi Patients and carers should be advised on the application of Evorel® Sequi patches.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Clinorette** (Resource Medical UK Ltd)
  - Clinorette tablets | 84 tablet [POM] £9.23
- **Elleste Duet (Meda Pharmaceuticals Ltd)**
  - Elleste Duet 1 mg tablets | 84 tablet [POM] £9.20
  - Elleste Duet 2 mg tablets | 84 tablet [POM] £9.20
- **Elleste Duet Conti** (Meda Pharmaceuticals Ltd)
  - Norethisterone acetate 1 mg, Estradiol 2 mg Elleste Duet Conti tablets | 84 tablet [POM] £17.02 DT price = £17.02
- **Kliofem** (Novo Nordisk Ltd)
  - Norethisterone acetate 1 mg, Estradiol 2 mg Kliofem tablets | 84 tablet [POM] £11.43 DT price = £17.02
- **Kliovance** (Novo Nordisk Ltd)
  - Norethisterone acetate 500 microgram, Estradiol 1 mg Kliovance tablets | 84 tablet [POM] £13.20 DT price = £13.20
- **Novofem** (Novo Nordisk Ltd)
  - Novofem tablets | 84 tablet [POM] £11.43
- **Nuvelle Continuous** (Bayer Plc)
  - Norethisterone acetate 1 mg, Estradiol 2 mg Nuvelle Continuous tablets | 84 tablet [POM] £19.00 DT price = £17.02
- **Trisequens** (Novo Nordisk Ltd)
  - Trisequens tablets | 84 tablet [POM] £11.10
Estradiol with norgestrel

The properties listed below are those particular to the combination only. For the properties of the components please consider, estradiol p. 711.

**INDICATIONS AND DOSE**

**CYCLO-PROGYNOVA® 2MG TABLETS**

Menopausal symptoms in women with a uterus | Osteoporosis prophylaxis in women with a uterus

- **BY MOUTH**
  - Adult: 1 tablet daily for 11 days, white tablet to be taken; start on day 5 of menstruation (or at any time if cycles have ceased or are infrequent), then 1 tablet daily for 10 days, brown tablet to be taken, followed by a 7-day tablet free interval

**INTERACTIONS**

Appendix 1: hormone replacement therapy

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

Tablets

- Cyclo-Progynova (Meda Pharmaceuticals Ltd)
  - Cyclo-Progynova 2mg tablets | 21 tablet (PO) £3.11

PROGESTOGENS

Norethisterone

**INDICATIONS AND DOSE**

**Endometriosis**

- **BY MOUTH**
  - Adult: 10–15 mg daily for 4–6 months or longer, to be started on day 5 of cycle; increased to 20–25 mg daily if required, dose only increased if spotting occurs and reduced once bleeding has stopped

**Dysfunctional uterine bleeding (to arrest bleeding) | Menorrhagia (to arrest bleeding)**

- **BY MOUTH**
  - Adult: 5 mg 3 times a day for 10 days

**Dysfunctional uterine bleeding (to prevent bleeding) | Menorrhagia (to prevent bleeding)**

- **BY MOUTH**
  - Adult: 5 mg twice daily, to be taken from day 19 to day 26 of cycle

**Dysmenorrhoea**

- **BY MOUTH**
  - Adult: 5 mg 3 times a day for 3–4 cycles, to be taken from day 5–24 of cycle

**Premenstrual syndrome (but not recommended)**

- **BY MOUTH**
  - Adult: 5 mg 2–3 times a day for several cycles, to be taken from day 19–26 of cycle

**Postponement of menstruation**

- **BY MOUTH**
  - Females of childbearing potential: 5 mg 3 times a day, to be started 3 days before expected onset (menstruation occurs 2–3 days after stopping)

**CONTRA-INDICATIONS**

**GENERAL CONTRA-INDICATIONS**

Avoid in patients with a history of liver tumours, breast cancer (unless progestogens are being used in the management of this condition), genital cancer (unless progestogens are being used in the management of this condition), history during pregnancy of idiopathic jaundice, history during pregnancy of pemphigoid gestationis (non-contraceptive indications), history during pregnancy of severe pruritus (non-contraceptive indications) when used as a contraceptive, history of breast cancer (can be used after 5 years if no evidence of disease and non-hormonal contraceptive methods unacceptable)

**SPECIFIC CONTRA-INDICATIONS**

- With oral use: Acute porphyrias, severe arterial disease, undiagnosed vaginal bleeding

**CAUTIONS**

**GENERAL CAUTIONS**

Asthma, cardiac dysfunction, conditions that may worsen with fluid retention, diabetes (progestogens can decrease glucose tolerance—monitor patient closely), epilepsy, history of depression, hypertensive migraine, susceptibility to thromboembolism (particular caution with high dose)

**SPECIFIC CAUTIONS**

- When used for contraception: Active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration)—seek specialist advice. arterial disease, functional ovarian cysts, history of jaundice in pregnancy, malabsorption syndromes, past ectopic pregnancy, sex-stereoid dependent cancer, systemic lupus erythematosus with positive (or unknown) anti-phospholipid antibodies
- With intramuscular use: Disturbances of lipid metabolism, history during pregnancy of deterioration of otosclerosis, history during pregnancy of pruritus, possible risk of breast cancer

**CAUTIONS, FURTHER INFORMATION**

- Use as a contraceptive in co-morbidities. The product literature advises caution in patients with history of thromboembolism, hypertension, diabetes mellitus and migraine; evidence for caution in these conditions is unsatisfactory.
- Breast cancer risk with contraceptive use. There is a small increase in the risk of having breast cancer diagnosed in women using, or who have recently used, a progestogen-only contraceptive pill; this relative risk may be due to an earlier diagnosis. The most important risk factor appears to be the age at which the contraceptive is stopped rather than the duration of use; the risk disappears gradually during the 10 years after stopping and there is no excess...
risk by 10 years. A possible small increase in the risk of breast cancer should be weighed against the benefits.

- **INTERACTIONS** → Appendix 1: norethisterone

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**

Acne · alopecia · anaphylactoid reactions · breast tenderness · change in libido · depression · disturbance of appetite · dizziness · fluid retention · headache · hirsutism · insomnia (non-contraceptive indications) · jaundice · menstrual disturbances · nausea · premenstrual-like syndrome · pruritus · rash · skin reactions · urticaria · vomiting · weight change

**SPECIFIC SIDE-EFFECTS**

- With intramuscular use Injection-site reactions
- Cervical cancer Use of injectable progestogen-only contraceptives may be associated with a small increased risk of cervical cancer, similar to that seen with combined oral contraceptives (use of combined oral contraceptives for 5 years or longer is associated with a small increased risk of cervical cancer; the risk diminishes after stopping and disappears by about 10 years). The risk of cervical cancer with other progestogen-only contraceptives is not yet known.

- **PREGNANCY**

  - With oral use Masculinisation of female fetuses and other defects reported with non-contraceptive use.

- **BREAST FEEDING** Progestogen-only contraceptives do not affect lactation. Higher doses (used in malignant conditions) may suppress lactation and alter milk composition—use lowest effective dose.

  - With intramuscular use Withhold breast-feeding for neonates with severe or persistent jaundice requiring medical treatment.

- **HEPATIC IMPAIRMENT** When used as a contraceptive; caution in severe liver disease and recurrent cholestatic jaundice, avoid in liver tumour. Avoid in non-contraceptive indications.

- **RENAL IMPAIRMENT** Use with caution in non-contraceptive indications.

- **PATIENT AND CARER ADVICE**

  **Missed oral contraceptive pill** The following advice is recommended: ‘If you forget a pill, take it as soon as you remember and carry on with the next pill at the right time. If the pill was more than 3 hours overdue you are not protected. Continue normal pill-taking but you must also use another method, such as the condom, for the next 2 days.’

  The Faculty of Sexual and Reproductive Healthcare recommends emergency contraception if one or more progestogen-only contraceptive tablets are missed or taken more than 3 hours late and unprotected intercourse has occurred before 2 further tablets have been correctly taken.

  Diarrhoea and vomiting with oral contraceptives Vomiting and persistent, severe diarrhoea can interfere with the absorption of oral progestogen-only contraceptives. If vomiting occurs within 2 hours of taking an oral progestogen-only contraceptive, another pill should be taken as soon as possible. If a replacement pill is not taken within 3 hours of the normal time for taking the progestogen-only pill, or in cases of persistent vomiting or very severe diarrhoea, additional precautions should be used during illness and for 2 days after recovery.

  Starting routine for oral contraceptives One tablet daily, on a continuous basis, starting on day 1 of cycle and taken at the same time each day (if delayed by longer than 3 hours contraceptive protection may be lost). Additional contraceptive precautions are not required if norethisterone is started up to and including day 5 of the menstrual cycle; if started after this time, additional contraceptive precautions are required for 2 days.

  Changing from a combined oral contraceptive Start on the day following completion of the combined oral contraceptive course without a break (or in the case of ED tablets omitting the inactive ones).

  After childbirth Oral progestogen-only contraceptives can be started up to and including day 21 postpartum without the need for additional contraceptive precautions. If started more than 21 days postpartum, additional contraceptive precautions are required for 2 days. Contraceptives by injection Full counselling backed by patient information leaflet required before administration—likelihood of menstrual disturbance and the potential for a delay in return to full fertility. Delayed return of fertility and irregular cycles may occur after discontinuation of treatment but there is no evidence of permanent infertility.

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

  **Solution for injection**

  - Noristerat (Bayer Plc)
    - Norethisterone enantate 200 mg per 1 ml Noristerat 200mg/1ml solution for injection ampoules | 1 ampoule (POD) £4.05
  - Noristerate (Non-proprietary)
    - Norethisterone 5 mg Norethisterone 5mg tablets | 30 tablet (POD) £2.48 DT price = £2.18
    - Noriday (Pfizer Ltd)
      - Norethisterone 350 microgram Noriday 350mcg tablets | 84 tablet (POD) £2.10 DT price = £1.80
      - Primolut N (Bayer Plc)
        - Norethisterone 5 mg Primolut N 5mg tablets | 30 tablet (POD) £2.26 DT price = £2.18
        - Utovlan (Pfizer Ltd)
          - Norethisterone 5 mg Utovlan 5mg tablets | 30 tablet (POD) £1.40 DT price = £2.18 | 90 tablet (POD) £4.21

  Combinations available: Estradiol with norethisterone, p. 718

**Progesterone 06-Jun-2017**

**INDICATIONS AND DOSE**

**CRINONE® VAGINAL GEL**

Infertility due to inadequate luteal phase

- **BY VAGINA**
  - Adult: 1 applicatorful daily, to be started either after documented ovulation or on day 18–21 of cycle, in vitro fertilisation, daily application continued for 30 days after laboratory evidence of pregnancy

**CYCLOGEST® PESSARIES**

Premenstrual syndrome | Post-natal depression

- **BY VAGINA, OR BY RECTUM**
  - Adult: 200–800 mg daily, doses above 200 mg to be given in 2 divided doses, for premenstrual syndrome start on day 12–14 and continue until onset of menstruation (but not recommended); rectally if barrier methods of contraception are used, in patients who have recently given birth or in those who suffer from vaginal infection or recurrent cystitis

**GESTONE® SOLUTION FOR INJECTION**

Dysfunctional uterine bleeding

- **BY DEEP INTRAMUSCULAR INJECTION**
  - Adult: 5–10 mg daily for 5–10 days until 2 days before expected onset of menstruation, to be administered into buttocks continued →
722  Sex hormone responsive conditions

**Recurrent miscarriage due to inadequate luteal phase** (but not recommended) or following in vitro fertilisation or gamete intra-fallopian transfer

- **BY DEEP INTRAMUSCULAR INJECTION**
- Adult: 25–100 mg 2–7 times a week from day 15, or day of embryo or gamete transfer, until 8–16 weeks of pregnancy, to be administered into buttocks; maximum 200 mg per day

**LUBION**

Supplementation of luteal phase during assisted reproductive technology (ART) treatment in women for whom vaginal preparations are inappropriate

- **BY SUBCUTANEOUS INJECTION, OR BY INTRAMUSCULAR INJECTION**
- Adult: 25 mg once daily from day of oocyte retrieval up to week 12 of pregnancy

**LUTIGEST**

Luteal support as part of an Assisted Reproductive Technology (ART) treatment programme

- **BY VAGINA**
- Adult: 100 mg 3 times a day, to be started the day after oocyte retrieval, and continued for 30 days once pregnancy is confirmed

**UTROGESTAN**

Progestogenic opposition of oestrogen HRT

- **BY MOUTH**
- Adult: 200 mg once daily on days 15–26 of each 28-day oestrogen HRT cycle, alternatively 100 mg once daily on days 1–25 of each 28-day oestrogen HRT cycle

**UTROGESTAN**

Supplementation of luteal phase during assisted reproductive technology (ART) cycles

- **BY VAGINA**
- Adult: 1 capsule 3 times a day from day of embryo transfer until at least week 7 of pregnancy up to week 12 of pregnancy

**CONTRA-INDICATIONS** Acute porphyrias p. 969 - avoid in patients with a history of liver tumours - breast cancer (unless progestogens are being used in the management of this condition) - genital cancer (unless progestogens are being used in the management of this condition) - history during pregnancy of idiopathic jaundice - history during pregnancy of pempigoid gestationis - history during pregnancy of severe pruritus - history of thromboembolism - incomplete miscarriage - missed miscarriage - severe arterial disease - thrombophlebitis - undiagnosed vaginal bleeding

**CAUTIONS** Asthma - cardiac dysfunction - conditions that may worsen with fluid retention - diabetes (progestogens can decrease glucose tolerance—monitor patient closely) - epilepsy - history of depression - hypertension - migraine - susceptibility to thromboembolism (particular caution with high dose)

**INTERACTIONS** → Appendix 1: progesterone

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**


**SPECIFIC SIDE-EFFECTS**

- With intramuscular use or subcutaneous use Injection-site reactions
- With rectal use Diarrhoea - flatulence - pain
- With vaginal use Local irritation

**PREGNANCY** Not known to be harmful.

**BREAST FEEDING** Avoid—present in milk.

**HEPATIC IMPAIRMENT** Avoid in hepatic impairment. Avoid in active liver disease including disorders of hepatic excretion (e.g. Dublin-Johnson or Rotor Syndromes), infective hepatitis (until liver function returns to normal) and liver tumours.

**RENAL IMPAIRMENT** Use with caution.

**DIRECTIONS FOR ADMINISTRATION**

- With oral use Capsules should be taken at bedtime on an empty stomach.

**PATIENT AND CARER ADVICE**

- With oral use Patient counselling is advised for progesterone capsules (administration).

**NATIONAL FUNDING/ACCESS DECISIONS**

**LUTIGEST**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (October 2016) that progesterone (Lutigest®) is accepted for use within NHS Scotland for luteal support as part of an assisted reproductive technology (ART) treatment program for infertile women. This advice is contingent upon the continuing availability of the Patient Access Scheme (PAS) in NHS Scotland or a list price that is equivalent or lower.

**UTROGESTAN**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (May 2017) that micronised progesterone (Utrogestan Vaginal)® is accepted for use within NHS Scotland for supplementation of the luteal phase during Assisted Reproductive Technology cycles in women. This advice is contingent upon the continuing availability of the Patient Access Scheme in Scotland or a list price that is equivalent or lower.

**LESS SUITABLE FOR PRESCRIBING** Progesterone pessaries are less suitable for prescribing.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Pessary**

- **Cyclogest** (Actavis UK Ltd)
  - Progesterone 200 mg Cyclogest 200mg pessaries | 15 pessary £6.95 DT price = £8.95
  - Progesterone 400 mg Cyclogest 400mg pessaries | 15 pessary £12.96 DT price = £12.96
- **Lutigest** (Ferring Pharmaceuticals Ltd)
  - Progesterone 100 mg Lutigest 100mg vaginal tablets | 21 pessary £19.50 DT price = £19.50

**Solution for injection**

- **Gestone** (Nordic Pharma Ltd)
  - Progesterone 50 mg per 1 ml Gestone 50mg/1ml solution for injection ampoules | 10 ampoule £45.00
  - Gestone 100mg/2ml solution for injection ampoules | 10 ampoule £45.00
- **Lubion** (Pharmasure Ltd)
  - Progesterone 22.35 mg per 1 ml Lubion 25mg/1.119ml solution for injection vials | 7 vial £56.00

**Vaginal gel**

- **Crinone** (Merck Serono Ltd)
  - Progesterone 80 mg per 1 gram Crinone 8% progesterone vaginal gel | 15 unit dose £30.83

**Capsule**

**EXCIPIENTS:** May contain Arachis (peanut) oil

- **Utrogestan** (Besins Healthcare (UK) Ltd)
  - Progesterone 100 mg Utrogestan 100mg capsules | 30 capsule £5.13
  - Progesterone 200 mg Utrogestan 200mg vaginal capsules with applicators | 21 capsule £21.00

**BNF 74**
8.1a Anti-oestrogens

**OVULATION STIMULANTS**

### Clomifene citrate

*Clomiphene citrate*

#### Drug Action
Anti-oestrogen which induces gonadotrophin release by occupying oestrogen receptors in the hypothalamus, thereby interfering with feedback mechanisms; chorionic gonadotrophin is sometimes used as an adjunct.

#### Indications and Dose
Treatment of female infertility due to oligomenorrhoea or secondary amenorrhoea (e.g. associated with polycystic ovarian disease)

- **By Mouth**
  - Adult (female): 50 mg daily for 5 days, to be started within about 5 days of onset of menstruation (preferably on 2nd day) or at any time (normally preceded by a progestogen induced withdrawal bleed) if cycles have ceased, followed by 100 mg daily if required for a further 5 days, this second course may be given in absence of ovulation; most patients who are going to respond will do so to first course, 3 courses should constitute adequate therapeutic trial; long-term cyclical therapy not recommended.

<table>
<thead>
<tr>
<th>Important Safety Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>The CSM has recommended that clomifene should not normally be used for longer than 6 cycles (possibly increased risk of ovarian cancer).</td>
</tr>
</tbody>
</table>

#### Contra-Indications
Abnormal uterine bleeding of undetermined cause - hormone-dependent tumours - ovarian cysts

#### Cautions
Ectopic pregnancy - incidence of multiple births increased (consider ultrasound monitoring) - ovarian hyperstimulation syndrome - polycystic ovary syndrome (cysts may enlarge during treatment, also risk of exaggerated response to usual doses) - uterine fibroids

#### Interactions
- **Appendix 1: clomifene**
- **Side-effects** Abdominal discomfort - breast tenderness - convulsions - depression - dizziness - endometriosis - hair loss - headache - hot flushes - insomnia - intermenstrual spotting - menorrhagia - nausea - ovarian hyperstimulation (withdraw) - rash - visual disturbances (withdraw and initiate ophthalmological examination) - vomiting - weight gain

#### Conception and Contraception
Exclude pregnancy before treatment.

#### Pregnancy
Possible effects on fetal development.

#### Breast Feeding
May inhibit lactation.

#### Hepatic Impairment
Avoid in severe liver disease.

#### Patient and Carer Advice
Patient advice required around conception and contraception. Patients planning to conceive should be warned that there is a risk of multiple pregnancy (rarely) more than twins.

### Medicinal Forms
There can be variation in the licensing of different medicines containing the same drug.

#### Tablet
- **Clomifene citrate (Non-proprietary)**
  - Clomifene citrate 50 mg Clomifene 50mg tablets | 30 tablet £9.15 DT price = £10.15

---

## 8.2 Male sex hormone responsive conditions

### Androgens, anti-androgens and anabolic steroids

#### Androgens
Androgens cause masculinisation; they may be used as replacement therapy in castrated adults and in those who are hypogonadal due to either pituitary or testicular disease. In the normal male they inhibit pituitary gonadotrophin secretion and depress spermatogenesis. Androgens also have an anabolic action which led to the development of anabolic steroids.

Androgens are useless as a treatment of impotence and impaired spermatogenisis unless there is associated hypogonadism; they should not be given until the hypogonadism has been properly investigated. Treatment should be under expert supervision.

When given to patients with hypopituitarism they can lead to normal sexual development and potency but not to fertility. If fertility is desired, the usual treatment is with gonadotrophins or pulsatile gonadotrophin-releasing hormone which will stimulate spermatogenesis as well as androgen production.

Intramuscular depot preparations of testosterone esters are preferred for replacement therapy. Testosterone enantate, propionate or undecanoate, or alternatively Sustanon®, which consists of a mixture of testosterone esters and has a longer duration of action, may be used.

#### Anti-androgens

**Cyproterone acetate**

Cyproterone acetate p. 725 is an anti-androgen used in the treatment of severe hypersexuality and sexual deviation in the male. It inhibits spermatogenesis and produces reversible infertility (but is not a male contraceptive); abnormal sperm forms are produced. Fully informed consent is recommended and an initial spermogram. As hepatic tumours have been produced in animal studies, careful consideration should be given to the risk/benefit ratio before treatment. Cyproterone acetate is also licensed for use alone in patients with metastatic prostate cancer refractory to gonadorelin analogue therapy and has been used as an adjunct in prostatic cancer and in the treatment of acne and hirsutism in women.

**Dutasteride and finasteride**

Dutasteride p. 741 and finasteride p. 742 are alternatives to alpha-blockers particularly in men with a significantly enlarged prostate. Finasteride is also licensed for use with doxazosin p. 738 in the management of benign prostatic hyperplasia.

A low strength of finasteride is licensed for treating male-pattern baldness in men.

#### Anabolic steroids

Anabolic steroids have some androgenic activity but they cause less virilisation than androgens in women. They are used in the treatment of some aplastic anaemias. Anabolic steroids have been given for osteoporosis in women but they are no longer advocated for this purpose.

The protein-building properties of anabolic steroids have not proved beneficial in the clinical setting. Their use as
ENDOCRINE SYSTEM

and they abuse

ANDROGENS

Androgens

- CONTRA-INDICATIONS Breast cancer in males • history of liver tumours • hypercalcaemia • prostate cancer
- CAUTIONS Cardiac impairment • diabetes mellitus • elderly • epilepsy • hypertension • ischaemic heart disease • migraine • pre-pubertal boys (fetus of epiphyses is hardened and may result in short stature) – statural growth and sexual development should be monitored • skeletal metastases – risk of hypercalcaemia or hypercalciuria (if this occurs, treat appropriately and restart treatment once normal serum calcium concentration restored) • sleep apnoea • stop treatment or reduce dose if severe polycythaemia occurs • tumours – risk of hypercalcaemia or hypercalciuria (if this occurs, treat appropriately and restart treatment once normal serum calcium concentration restored)
- SIDE-EFFECTS
  - Common or very common Acne • androgenic effects (to be assessed regularly in women) • anxiety • arthralgia • asthenia • changes in libido • cholestatic jaundice • depression • electrolyte disturbances • excessive duration of penile erection • excessive frequency of penile erection • gastro-intestinal bleeding • gynaecomastia • headache • hirsutism • hypercalcaemia • hypertension • increased bone growth • irritability • male-pattern baldness • muscle cramps • nausea • nervousness • oedema • paraesthesia • polycythaemia • precocious sexual development in pre-pubertal males • premature closure of epiphyses in pre-pubertal males • prostate abnormalities • prostate cancer • pruritus • seborrhoea • sodium retention • suppression of virilism in women • vomiting • weight gain
  - Rare Liver tumours
  - Frequency not known Sleep apnoea

SIDE-EFFECTS, FURTHER INFORMATION

- Polycythaemia Stop treatment or reduce dose if severe polycythaemia occurs.
- PREGNANCY Avoid – causes masculinisation of female fetus.
- BREAST FEEDING Avoid.
- HEPATIC IMPAIRMENT Avoid if possible – fluid retention and dose-related toxicity.
- RENAL IMPAIRMENT Caution – potential for fluid retention.
- MONITORING REQUIREMENTS
  - Monitor haematocrit and haemoglobin before treatment, every three months for the first year, and yearly thereafter.
  - Monitor prostate and PSA in men over 45 years.
- PATIENT AND CARER ADVICE
  - Androgenic effects in women • Women should be advised to report any signs of virilisation e.g. deepening of the voice or hirsutism.

Mesterolone

- INDICATIONS AND DOSE
  - Androgen deficiency • Male infertility associated with hypogonadism
  - BY MOUTH
  - Adult: 25 mg 3–4 times a day for several months, then maintenance 50–75 mg daily in divided doses

TESTIM®

Hypogonadism due to testosterone deficiency in men

- BY TRANSDERMAL APPLICATION
  - Adult: Apply 50 mg once daily, subsequent application adjusted according to response; maximum 100 mg per day

DOSE EQUIVALENCE AND CONVERSION

- One tube of 5 g contains 50 mg testosterone.

TESTOGEL®

Hypogonadism due to androgen deficiency in men

- BY TRANSDERMAL APPLICATION
  - Adult: Apply 50 mg once daily; increased in steps of 25 mg, adjusted according to response; maximum 100 mg per day

DOSE EQUIVALENCE AND CONVERSION

- One sachet of 5 g contains 50 mg of testosterone.

TOSTRAN®

Hypogonadism due to testosterone deficiency in men

- BY TRANSDERMAL APPLICATION
  - Adult: Apply 60 mg once daily, subsequent application adjusted according to response; maximum 80 mg per day

DOSE EQUIVALENCE AND CONVERSION

- 1 g of gel contains 20 mg testosterone.

- SIDE-EFFECTS
  - Allergic reactions • local irritation • suppression of spermatogenesis
- DIRECTIONS FOR ADMINISTRATION
  - Avoid skin contact with gel application sites to prevent testosterone transfer to other people, especially pregnant women and children – consult product literature.

TESTOGEL®

Apply thin layer of gel on clean, dry, healthy skin such as shoulders, arms or abdomen, immediately after sachet is opened. Not to be applied on genital area as high alcohol content may cause local irritation. Allow to dry for 3–5 minutes before dressing. Wash hands with soap and water after applying gel, avoid shower or bath for at least 6 hours.

TESTIM®

Squeeze entire content of tube on to one palm and apply as a thin layer on clean, dry, healthy skin of shoulder or upper arm, preferably in the morning after washing or bathing (if 2 tubes required use 1 per shoulder or upper arm); rub in and allow to dry before putting on clothing to cover site; wash hands with soap after application; avoid washing application site for at least 2 hours.

TOSTRAN®

Apply gel on clean, dry, intact skin of abdomen or both inner thighs, preferably in the morning. Gently rub in with a finger until dry before dressing. Wash hands with soap and water after applying gel; avoid washing application site for at least 2 hours. Not to be applied on genital area.

- PATIENT AND CARER ADVICE
  - Patient or carer should be given advice on how to administer testosterone gel.
Testosterone decanoate, isocaproate, phenylpropionate and propionate

The properties listed below are those particular to the combination only. For the properties of the components please consider, testosterone propionate below.

**INDICATIONS AND DOSE**
- **Androgen deficiency**
  - Adult: 1 mL every 3 weeks

**MEDICAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**
- **Sustanon** (Aspen Pharma Trading Ltd)
  - Testosterone propionate 30 mg per 1 mL, Testosterone isocaproate 60 mg per 1 mL, Testosterone phenylpropionate 60 mg per 1 mL, Testosterone decanoate 100 mg per 1 mL
  - Solution for injection ampoules | 1 ampoule (£2.45 C04-2)

Testosterone enantate

**INDICATIONS AND DOSE**
- **Hypogonadism**
  - Adult: Initially 250 mg every 2–3 weeks; maintenance 250 mg every 3–6 weeks
- **Breast cancer**
  - Adult: 250 mg every 2–3 weeks

**UNLICENSED USE**
- Not licensed for use in breast cancer.

**SIDE-EFFECTS**
- Suppression of spermatogenesis

**MEDICAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**
- **Testosterone enantate (Non-proprietary)**
  - Testosterone enantate 250 mg per 1 mL
  - Solution for injection ampoules | 3 ampoules (£79.75 C04-2)

Testosterone propionate

**INDICATIONS AND DOSE**
- **Androgen deficiency**
  - Adult: 50 mg 2–3 times a week
Thyroid disorders

9 Thyroid disorders

PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES

Thyrotropin alfa
(Recombinant human thyroid stimulating hormone; rhTSH)

- **DRUG ACTION** Thyrotropin alfa is a recombinant form of thyrotrophin (thyroid stimulating hormone).

- **INDICATIONS AND DOSE**
  Detection of thyroid remnants and thyroid cancer in post-thyroidectomy patients, together with serum thyroglobulin testing (with or without radiodine imaging)
  To increase radio-iodine uptake for the ablation of thyroid remnant tissue in suitable post-thyroidectomy patients

  - **BY INTRAMUSCULAR INJECTION**
  - Adult: 900 micrograms every 24 hours for 2 doses, dose to be administered into the gluteal muscle, consult product literature for further information on indications and dose

- **CAUTIONS**
  Presence of thyroglobulin autoantibodies may give false negative results

- **SIDE-EFFECTS**
  - **Common or very common** Dizziness, fatigue, headache, nausea, vomiting
  - **Uncommon** Asthenia, back pain, influenza-like symptoms, paraesthesia, rash, urticaria
  - **Rare** Diarrhoea, very rare Arthralgia, dyspnoea, flushing, hyperhidrosis, injection-site pain, injection-site pruritus, injection-site rash, injection-site reactions, myalgia, pain at site of metastases, palpitation, tremor

- **ALLERGY AND CROSS-SENSITIVITY**
  Contra-indicated if previous hypersensitivity to bovine or human thyrotropin.

- **PREGNANCY**
  Avoid.

- **BREAST FEEDING**
  Avoid.

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for injection

- Thyrogen (Genzyme Therapeutics Ltd)
  Thyrotropin alfa 900 microgram Thyrogen 900 microgram powder for solution for injection vials

9.1 Hyperthyroidism

Antithyroid drugs

**Overview**

Antithyroid drugs are used for hyperthyroidism either to prepare patients for thyroidectomy or for long-term management. In the UK carbimazole p. 727 is the most commonly used drug. Propylthiouracil p. 728 should be reserved for patients who are intolerant of carbimazole or for those who experience sensitivity reactions to carbimazole (sensitivity is not necessarily displayed to both drugs), and for whom other treatments are inappropriate. Both drugs act primarily by interfering with the synthesis of thyroid hormones.
Over-treatment with antithyroid drugs can result in the rapid development of hypothyroidism and should be avoided particularly during pregnancy because it can cause fetal goitre.

A combination of carbimazole with levotyroxine sodium p. 729 daily, may be used in a blocking-replacement regimen; therapy is usually given for 18 months. The blocking-replacement regimen is not suitable during pregnancy.

Iodine has been used as an adjunct to antithyroid drugs for 10 to 14 days before partial thyroidectomy; however, there is little evidence of a beneficial effect. Iodine should not be used for long-term treatment because its antithyroid action tends to diminish.

Radioactive sodium iodide (\(^{131}\)I) solution is used increasingly for the treatment of thyrotoxicosis at all ages, particularly where medical therapy or compliance is a problem, in patients with cardiac disease, and in patients who relapse after thyroidectomy.

Propranolol hydrochloride p. 145 is useful for rapid relief of thyrotoxic symptoms and may be used in conjunction with antithyroid drugs or as an adjunct to radioactive iodine. Beta-blockers are also useful in neonatal thyrotoxicosis and in supraventricular arrhythmias due to hyperthyroidism. Propranolol hydrochloride has been used in conjunction with iodine to prepare mildly thyrotoxic patients for surgery but it is preferable to make the patient euthyroid with carbimazole. Laboratory tests of thyroid function are not altered by beta-blockers. Most experience in treating thyrotoxicosis has been gained with propranolol hydrochloride but nadolol p. 144 is also used.

Thyrotoxic crisis (‘thyroid storm’) requires emergency treatment with intravenous administration of fluids, propranolol hydrochloride and hydrocortisone p. 637 (as sodium succinate), as well as oral iodine solution and carbimazole or propylthiouracil which may need to be administered by nasogastric tube.

Pregnancy
Radioactive iodine therapy is contra-indicated during pregnancy. Propylthiouracil and carbimazole can be given but the blocking-replacement regimen is not suitable. Rarely, carbimazole has been associated with congenital defects, including aplasia cutis of the neonate, therefore propylthiouracil remains the drug of choice during the first trimester of pregnancy. In the second trimester, consider switching to carbimazole because of the potential risk of hepatotoxicity with propylthiouracil. Both propylthiouracil and carbimazole cross the placenta and in high doses may cause fetal goitre and hyperthyroidism—the lowest dose that will control the hyperthyroid state should be used (requirements in Graves’ disease tend to fall during pregnancy).

Other drugs used for Hyperthyroidism Metoprolol tartrate, p. 149

ANTITHYROID DRUGS SULFUR-CONTAINING IMIDAZOLES

Carbimazole

INDICATIONS AND DOSE

Hyperthyroidism

› By mouth

› Adult: 15–40 mg daily continue until the patient becomes euthyroid, usually after 4 to 8 weeks, higher doses should be prescribed under specialist supervision only, then reduced to 5–15 mg daily, reduce dose gradually, therapy usually given for 12 to 18 months

DOSE EQUIVALENCE AND CONVERSION

› When substituting, carbimazole 1 mg is considered equivalent to propylthiouracil 10 mg but the dose may need adjusting according to response.

Hyperthyroidism (blocking-replacement regimen) in combination with levothyroxine

› By mouth

› Adult: 40–60 mg daily, therapy usually given for 18 months

IMPORTANT SAFETY INFORMATION

NEUTROPENIA AND AGRANULOCYTOSIS

Doctors are reminded of the importance of recognising bone marrow suppression induced by carbimazole and the need to stop treatment promptly.

› Patient should be asked to report symptoms and signs suggestive of infection, especially sore throat.

› A white blood cell count should be performed if there is any clinical evidence of infection.

› Carbimazole should be stopped promptly if there is clinical or laboratory evidence of neutropenia.

› CONTRA-INDICATIONS Severe blood disorders

› INTERACTIONS Appendix 1: carbimazole

› SIDE-EFFECTS

› Common or very common Arthralgia · fever · headache · jaundice · malaise · mild gastro-intestinal disturbances · nausea · pruritus · rash · taste disturbance

› Rare Agranulocytosis · alopecia · bone marrow suppression · jaundice · myopathy · pancytopenia

SIDE-EFFECTS, FURTHER INFORMATION

Rashes and pruritus are common with carbimazole but they can be treated with antihistamines without discontinuing therapy; alternatively propylthiouracil can be substituted.

› PREGNANCY Carbimazole can be given but the blocking-replacement regimen is not suitable. Rarely, carbimazole has been associated with congenital defects, including aplasia cutis of the neonate. Carbimazole cross the placenta and in high doses may cause fetal goitre and hyperthyroidism—the lowest dose that will control the hyperthyroid state should be used (requirements in Graves’ disease tend to fall during pregnancy).

› BREAST FEEDING Present in breast milk but this does not preclude breast-feeding as long as neonatal development is closely monitored and the lowest effective dose is used. Amount in milk may be sufficient to affect neonatal thyroid function therefore lowest effective dose should be used.

› HEPATIC IMPAIRMENT Use with caution in mild to moderate impairment. Avoid in severe impairment.

› PATIENT AND CARER ADVICE Warn patient or carers to tell doctor immediately if sore throat, mouth ulcers, bruising, fever, malaise, or non-specific illness develops.

› MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule, oral suspension, oral solution

Tablet

› Carbimazole (Non-proprietary)

<table>
<thead>
<tr>
<th>Dosage</th>
<th>Pack Size</th>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 mg</td>
<td>100 tablet</td>
<td>Carbimazole 5mg tablets</td>
<td>£84.80 DT price = £62.37</td>
</tr>
<tr>
<td>20 mg</td>
<td>100 tablet</td>
<td>Carbimazole 20mg tablets</td>
<td>£216.00 DT price = £166.71</td>
</tr>
</tbody>
</table>
ANTITHYROID DRUGS  THIOUARCILS

Propylthiouracil

**INDICATIONS AND DOSE**

Hyperthyroidism

- By mouth
- Adult: Initially 200–400 mg daily in divided doses until the patient becomes euthyroid, then reduced to 50–150 mg daily in divided doses, initial dose should be gradually reduced to the maintenance dose.

**DOSE EQUIVALENCE AND CONVERSION**

- When substituting, carbimazole 1 mg is considered equivalent to propylthiouracil 10 mg but the dose may need adjusting according to response.

**INTERACTIONS**  Appendix 1: propylthiouracil

**SIDE-EFFECTS**

- Common or very common  Arthralgia, fever, headache, jaundice, leucopenia, malaise, mild gastrointestinal disturbances, nausea, pruritus, rash, taste disturbance
- Rare  Agranulocytosis, alopecia, aplastic anaemia, bone marrow suppression, cutaneous vasculitis, encephalopathy, hepatic disorders, hepatic failure, hepatic necrosis, hepatitis, hypoprophosphorobinaemia, jaundice, lupus erythematosus-like syndromes, myopathy, nephritis, pancreatopathy, thrombocytopenia

**SIDE-EFFECTS, FURTHER INFORMATION**

- Hepatotoxicity  Severe hepatic reactions have been reported, including fatal cases and cases requiring liver transplant—discontinue if significant liver-enzyme abnormalities develop.

**PREGNANCY**

- Propylthiouracil can be given but the blocking-replacement regimen is not suitable.
- Propylthiouracil crosses the placenta and in high doses may cause fetal goitre and hypothyroidism—the lowest dose that will control the hyperthyroid state should be used (requirements in Graves’ disease tend to fall during pregnancy).

**BREAST FEEDING**

- Present in breast milk but this does not preclude breast-feeding as long as neonatal development is closely monitored and the lowest effective dose is used. Amount in milk probably too small to affect infant; high doses may affect neonatal thyroid function.
- Monitor infant’s thyroid status.

**HEPATIC IMPAIRMENT**

- Reduce dose.

**RENAL IMPAIRMENT**

- Use three-quarters normal dose if eGFR 10–50 mL/minute/1.73 m². Use half normal dose if eGFR less than 10 mL/minute/1.73 m².

**MONITORING REQUIREMENTS**

- Monitor for hepatotoxicity.

**PATIENT AND CARER ADVICE**

- Patients should be told how to recognise signs of liver disorder and advised to seek prompt medical attention if symptoms such as anorexia, nausea, vomiting, fatigue, abdominal pain, jaundice, dark urine, or pruritus develop.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution.

**Tablet**

- Propylthiouracil (Non-proprietary)
  - Propylthiouracil 50 mg  Propylthiouracil 50 mg tablets  56 tablet  £71.14 DT price  £59.47  100 tablet  £127.57

VITAMINS AND TRACE ELEMENTS

Iodide with iodine elements

**INDICATIONS AND DOSE**

Thyrotoxicosis (pre-operative)

- By mouth using oral solution
- Adult: 0.1–0.3 mL 3 times a day

**CAUTIONS**

- Children: not for long-term treatment

**SIDE-EFFECTS**

- Bronchitis, conjunctivitis, coryza-like symptoms, depression (on prolonged treatment), goitre in infants of mothers taking iodides, headache, hypersensitivity reactions, impotence (on prolonged treatment), insomnia (on prolonged treatment), lachrymation, laryngitis, pain in salivary glands, rashes

**PREGNANCY**

- Neonatal goitre and hypothyroidism.

**BREAST FEEDING**

- Stop breast-feeding. Danger of neonatal hypothyroidism or goitre. Appears to be concentrated in milk.

**DIRECTIONS FOR ADMINISTRATION**

- For oral solution, dilute well with milk or water.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

**Oral solution**

- CAUTIONARY AND ADVISORY LABELS  27
- Iodide with iodine (Non-proprietary)
  - Iodine 50 mg per 1 mL, Potassium iodide 100 mg per 1 mL  Iodine aqueous oral solution  500 mL  £9.58

9.2 Hypothyroidism

Thyroid hormones

**Overview**

Thyroid hormones are used in hypothyroidism (myxoedema), and also in diffuse non-toxic goitre, Hashimoto’s thyroiditis (lymphadenoid goitre), and thyroid carcinoma. Neonatal hypothyroidism requires prompt treatment for normal development. Levothyroxine sodium p. 729 (thyroxine sodium) is the treatment of choice for maintenance therapy.

- In infants and children with congenital hypothyroidism and juvenile myxoedema, the dose of levothyroxine sodium should be titrated according to clinical response, growth assessment, and measurements of plasma thyroxine and thyroid-stimulating hormone.
- Lithotryonine sodium p. 729 has a similar action to levothyroxine sodium but is more rapidly metabolised and has a more rapid effect. Its effects develop after a few hours and disappear within 24 to 48 hours of discontinuing treatment. It may be used in severe hypothyroid states when a rapid response is desired.
- Lithotryonine sodium by intravenous injection is the treatment of choice in hypothyroid coma. Adjunctive therapy includes intravenous fluids, hydrocortisone p. 637, and treatment of infection; assisted ventilation is often required.

728 Thyroid disorders
thyroid hormones

Levothyroxine sodium
(Thyroxine sodium)

indications and dose

Hypothyroidism

▶ BY MOUTH
- Adult 18-49 years: Initially 50–100 micrograms once daily; adjusted in steps of 25–50 micrograms every 3–4 weeks, adjusted according to response; maintenance 100–200 micrograms once daily, dose to be taken preferably at least 30 minutes before breakfast, caffeine-containing liquids (e.g. coffee, tea), or other medication
- Adult 50 years and over: Initially 25 micrograms once daily; adjusted in steps of 25 micrograms every 4 weeks, adjusted according to response; maintenance 50–200 micrograms once daily, dose to be taken preferably at least 30 minutes before breakfast, caffeine-containing liquids (e.g. coffee, tea), or other medication

Hypothyroidism in patients with cardiac disease | Severe hypothyroidism

▶ BY MOUTH
- Adult: Initially 25 micrograms once daily; adjusted in steps of 25 micrograms every 4 weeks, adjusted according to response; maintenance 50–200 micrograms once daily, dose to be taken preferably at least 30 minutes before breakfast, caffeine-containing liquids (e.g. coffee, tea), or other medication

Hyperthyroidism (blocking-replacement regimen) in combination with carbimazole

▶ BY MOUTH
- Adult: 50–150 micrograms daily therapy usually given for 18 months

contraindications

Thyrotoxicosis

cautions

Cardiovascular disorders - diabetes insipidus - diabetes mellitus (dose of antidiabetic drugs including insulin may need to be increased) - elderly - hypertension - long-standing hypothyroidism - myocardial infarction - myoccardial insufficiency - panhypopituitarism (initiate corticosteroid therapy before starting levothyroxine) - predisposition to adrenal insufficiency (initiate corticosteroid therapy before starting levothyroxine)

cautions, further information

Cardiovascular disorders Baseline ECG is valuable because changes induced by hypothyroidism can be confused with ischaemia.

interactions

▶ Appendix 1: levothyroxine

side-effects

Anginal pain (usually at excessive dosage) - arrhythmias (usually at excessive dosage) - diarrhoea (usually at excessive dosage) - excitability (usually at excessive dosage) - fever - flushing - headache - heat intolerance - hypersensitivity reactions - insomnia (usually at excessive dosage) - muscle cramp - muscular weakness - oedema - palpitation (usually at excessive dosage) - pruritus - rash - restlessness (usually at excessive dosage) - sweating - tachycardia (usually at excessive dosage) - transient hair loss in children - tremor (usually at excessive dosage) - vomiting (usually at excessive dosage) - weight-loss

side-effects, further information

Initial dosage in patients with cardiovascular disorders If metabolism increases too rapidly (causing diarrhoea, nervousness, rapid pulse, insomnia, tremors and sometimes anginal pain where there is latent myocardial ischaemia), reduce dose or withhold for 1–2 days and start again at a lower dose.

Pregnancy

Levothyroxine requirement may increase during pregnancy. Levothyroxine may cross the placenta. Excessive or insufficient maternal thyroid hormones can be detrimental to fetus.

Assess maternal thyroid function before conception (if possible), at diagnosis of pregnancy, at antenatal booking, during both the second and third trimesters, and after delivery (more frequent monitoring required on initiation or adjustment of levothyroxine).

Breast Feeding

Amount too small to affect tests for neonatal hypothyroidism.

medicinal forms

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule, oral suspension, oral solution

Tablet

- Levothyroxine sodium (Non-proprietary)
  - Levothyroxine sodium anhydrous 12.5 microgram Levothyroxine sodium 12.5microgram tablets | 28 tablet (PO) £12.75–£15.00 DT price = £14.10
  - Levothyroxine sodium anhydrous 25 microgram Levothyroxine sodium 25microgram tablets | 28 tablet (PO) £4.00 DT price = £2.91 | 500 tablet (PO) £56.26
- Levothyroxine sodium 25microgram tablets lactose free | 100 tablet (PO) no price available
  - Levothyroxine sodium anhydrous 50 microgram Levothyroxine sodium 50microgram tablets lactose free | 100 tablet (PO) no price available
  - Levothyroxine sodium 50microgram tablets lactose free | 100 tablet (PO) no price available
  - Levothyroxine sodium 50microgram tablets | 100 tablet (PO) £4.98 DT price = £1.66 | 1000 tablet (PO) £68.21
  - Levothyroxine sodium anhydrous 75 microgram Levothyroxine sodium 75microgram tablets | 28 tablet (PO) £2.82–£4.00 DT price = £3.34
  - Levothyroxine sodium anhydrous 100 microgram Levothyroxine sodium 100microgram tablets lactose free | 100 tablet (PO) no price available
  - Levothyroxine sodium 100microgram tablets lactose free | 100 tablet (PO) no price available
  - Levothyroxine sodium 100microgram tablets | 100 tablet (PO) £4.75 DT price = £1.66 | 1000 tablet (PO) £68.57
  - Eltroxin (AMCo)
    - Levothyroxine sodium anhydrous 25 microgram Eltroxin 25microgram tablets | 28 tablet (PO) £2.33 DT price = £2.91
    - Levothyroxine sodium anhydrous 50 microgram Eltroxin 50microgram tablets | 28 tablet (PO) £1.33 DT price = £1.66
    - Levothyroxine sodium anhydrous 100 microgram Eltroxin 100microgram tablets | 28 tablet (PO) £1.33 DT price = £1.66

oral solution

- Levothyroxine sodium (Non-proprietary)
  - Levothyroxine sodium anhydrous 5 microgram per
    - 1 ml Levothyroxine sodium 5microgram/5ml oral solution sugar free sugar-free | 100 ml (PO) £95.00 DT price = £94.59
  - Levothyroxine sodium anhydrous 10 microgram per
    - 1 ml Levothyroxine sodium 10microgram/5ml oral solution sugar free sugar-free | 100 ml (PO) £94.44 DT price = £93.02
  - Levothyroxine sodium anhydrous 20 microgram per
    - 1 ml Levothyroxine sodium 100micrograms/5ml oral solution sugar free sugar-free | 100 ml (PO) £165.00 DT price = £164.14

liothyronine sodium
(L-Tri-iodothyronine sodium)

indications and dose

Hypothyroidism

▶ BY MOUTH
- Adult: Initially 10–20 micrograms daily; increased to 60 micrograms daily in 2–3 divided doses, dose should be increased gradually, smaller initial doses given for the elderly

Hypothyroid coma

▶ BY SLOW INTRAVENOUS INJECTION
- Adult: 5–20 micrograms every 12 hours, increased to 5–20 micrograms every 4 hours if required, continued
alternatively initially 50 micrograms for 1 dose, then 25 micrograms every 8 hours, reduced to 25 micrograms twice daily

**DOSE EQUIVALENCE AND CONVERSION**
- 20–25 micrograms of liothyronine sodium is equivalent to approximately 100 micrograms of levothyroxine sodium.
- Brands without a UK licence may not be bioequivalent and dose adjustment may be necessary.

**CONTRA-INDICATIONS** Thyrotoxicosis

**CAUTIONS** Cardiovascular disorders - diabetes insipidus - diabetes mellitus (dose of antidiabetic drugs including insulin may need to be increased) - elderly - hypertension - long-standing hypothyroidism - myocardial infarction - myocardial insufficiency - panhypopituitarism (initiate corticosteroid therapy before starting liothyronine) - predisposition to adrenal insufficiency (initiate corticosteroid therapy before starting liothyronine)

**INTERACTIONS** → Appendix 1: liothyronine

**SIDE-EFFECTS**
- Anginal pain (usually at excessive dosage)
- arrhythmias (usually at excessive dosage)
- diarrhoea (usually at excessive dosage)
- excitation (usually at excessive dosage)
- fever
- flushing
- headache
- heat intolerance
- hypersensitivity reactions
- insomnia (usually at excessive dosage)
- muscle cramp
- muscular weakness
- oedema
- palpitation (usually at excessive dosage)
- pruritus
- rash
- restlessness (usually at excessive dosage)
- sweating
- tachycardia (usually at excessive dosage)
- tremor
- vomiting (usually at excessive dosage)
- weight-loss

**SIDE-EFFECTS, FURTHER INFORMATION**
- Initial dosage in patients with cardiovascular disorders. If metabolism increases too rapidly (causing diarrhoea, nervousness, rapid pulse, insomnia, tremors and sometimes anginal pain where there is latent myocardial ischaemia), reduce dose or withhold for 1–2 days and start again at a lower dose.

**PREGNANCY** Liothyronine requirement may increase during pregnancy. Does not cross the placenta in significant amounts. Excessive or insufficient maternal thyroid hormones can be detrimental to fetus.

Assess maternal thyroid function before conception (if possible), at diagnosis of pregnancy, at antenatal booking, during both the second and third trimesters, and after delivery (more frequent monitoring required on initiation or adjustment of liothyronine).

**BREAST FEEDING** Amount too small to affect tests for neonatal hypothyroidism.

**PRESCRIBING AND DISPENSING INFORMATION**

Switching to a different brand. Patients switched to a different brand should be monitored (particularly if pregnant or if heart disease present) as brands without a UK licence may not be bioequivalent. Pregnant women or those with heart disease should undergo an early review of thyroid status, and other patients should have thyroid function assessed if experiencing a significant change in symptoms. If liothyronine is continued long-term, thyroid function tests should be repeated 1–2 months after any change in brand.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, capsule, oral suspension, oral solution, solution for injection

**Tablet**
- Liothyronine sodium (Non-proprietary)
  - Liothyronine sodium 20 microgram tablets | 28 tablet £258.20 DT price = £258.20

**Powder for solution for injection**
- Liothyronine sodium (Non-proprietary)
  - Liothyronine sodium 20 microgram powder for solution for injection vials | 5 vial £1,425.00
Chapter 7
Genito-urinary system

CONTENTS

1 Bladder and urinary disorders  
1.1 Urinary frequency, enuresis, and incontinence 731
1.2 Urinary retention 736
1.3 Urological pain 742
2 Bladder instillations and urological surgery 743
3 Contraception 745
3.1 Contraception, combined 749
3.2 Contraception, devices 756
3.3 Contraception, emergency 757
3.4 Contraception, oral progesterone-only 758
3.5 Contraception, parenteral progesterone-only 762
3.6 Contraception, spermicidal 764
4 Erectile and ejaculatory conditions 765
4.1 Erectile dysfunction 765

1 Bladder and urinary disorders

1.1 Urinary frequency, enuresis, and incontinence

Urinary frequency, enuresis and incontinence

Urinary frequency and incontinence

Incontinence in adults which arises from detrusor instability is managed by combining drug therapy with conservative methods for managing urge incontinence such as pelvic floor exercises and bladder training; stress incontinence is generally managed by non-drug methods. Duloxetine p. 350 can be added and is licensed for the treatment of moderate to severe stress incontinence in women; it may be more effective when used as an adjunct to pelvic floor exercises.

Antimuscarinic drugs reduce symptoms of urgency and urge incontinence and increase bladder capacity. Oxybutynin hydrochloride p. 733 also has a direct relaxant effect on urinary smooth muscle. Side-effects limit the use of oxybutynin hydrochloride, but they may be reduced by starting at a lower dose. A modified-release preparation of oxybutynin hydrochloride is effective and has fewer side-effects; a transdermal patch is also available. The efficacy and side-effects of tolterodine tartrate p. 735 are comparable to those of modified-release oxybutynin hydrochloride. Flavoxate hydrochloride p. 733 has less marked side-effects but it is also less effective. Darifenacin p. 732, fesoterodine fumarate p. 732, propiverine hydrochloride p. 735, solifenacin succinate p. 734, and trospium chloride p. 734 are newer antimuscarinic drugs licensed for urinary frequency, urgency, and incontinence. The need for continuing antimuscarinic drug therapy should be reviewed every 4–6 weeks until symptoms stabilise, and then every 6–12 months.

Propantheline bromide p. 84 and tricyclic antidepressants were used for urge incontinence but they are little used now because of their side-effects. The use of imipramine hydrochloride p. 359 is limited by its potential to cause cardiac side-effects.

Mirabegron p. 736, a selective beta_3 agonist, is licensed for the treatment of urinary frequency, urgency, and urge incontinence associated with overactive bladder syndrome. Purified bovine collagen implant (Contigen®, Bard) is indicated for urinary incontinence caused by intrinsic sphincter deficiency (poor or non-functioning bladder outlet mechanism). The implant should be inserted only by surgeons or physicians trained in the technique for injection of the implant.

See also Nocturnal enuresis in children, below.

Nocturnal enuresis in children

23-May-2017

Description of condition

Nocturnal enuresis is the involuntary discharge of urine during sleep, which is common in young children. Children are generally expected to be dry by a developmental age of 5 years, and historically it has been common practice to consider children for treatment only when they reach 7 years; however, symptoms may still persist in a small proportion by the age of 10 years.

Treatment

Children under 5 years

For children under 5 years, treatment is usually unnecessary as the condition is likely to resolve spontaneously. Reassurance and advice can be useful for some families.

Non Drug Treatment

Initially, advice should be given on fluid intake, diet, toileting behaviour, and use of reward systems. For children who do not respond to this advice (more than 1–2 wet beds per week), an enuresis alarm should be the recommended treatment for motivated, well-supported children. Alarms in
children under 7 years should be considered depending on the child’s maturity, motivation and understanding of the alarm. Alarms have a lower relapse rate than drug treatment when discontinued.

Treatment using an alarm should be reviewed after 4 weeks and continued until a minimum of 2 weeks’ uninterrupted dry nights have been achieved. If complete dryness is not achieved after 3 months but the condition is still improving and the child remains motivated to use the alarm, it is recommended to continue the treatment.

Combined treatment with desmopressin p. 628, or the use of desmopressin alone, is recommended if the initial alarm treatment is unsuccessful or it is no longer appropriate or desirable. ▲

Drug Treatment

Treatment with oral or sublingual desmopressin is recommended for children over 5 years of age when alarm use is inappropriate or undesirable, or when rapid or short-term results are the priority (for example, to cover periods away from home). Desmopressin alone can also be used if there has been a partial response to a combination of desmopressin and an alarm alone. Treatment should be assessed after 4 weeks and continued for 3 months if there are signs of response. Repeated courses of desmopressin can be used in responsive children who experience repeated recurrences of bedwetting, but should be withdrawn gradually at regular intervals (for 1 week every 3 months) for full reassessment.

Under specialist supervision, nocturnal enuresis associated with daytime symptoms (overflowing bladder) can be managed with desmopressin alone or in combination with an antimuscarinic drug (such as oxybutynin hydrochloride p. 733 or tolterodine tartrate p. 735 [unlicensed indication]). Treatment should be continued for 3 months; the course can be repeated if necessary.

The tricyclic antidepressant imipramine hydrochloride p. 359 can be considered for children who have not responded to all other treatments and have undergone specialist assessment, however relapse is common after withdrawal and children and their carers should be aware of the dangers of overdose. Initial treatment should continue for 3 months; further courses can be considered following a medical review every 3 months. Tricyclic antidepressants should be withdrawn gradually. ▲

Useful Resources


ANTIMUSCARINICS

Antimuscarinics (systemic)

● CONTRA-INDICATIONS Gastro-intestinal obstruction • intestinal atony • myasthenia gravis (but some antimuscarinics may be used to decrease muscarinic side-effects of anticholinesterases) • paralytic ileus • prostatic enlargement (in adults) • pyloric stenosis • severe ulcerative colitis • significant bladder outflow obstruction • toxic megacolon • urinary retention

● CAUTIONS Acute myocardial infarction (in adults) • arrhythmias (may be worsened) • autonomic neuropathy • cardiac insufficiency (due to association with tachycardia) • cardiac surgery (due to association with tachycardia) • children (increased risk of side-effects) • conditions characterised by tachycardia • congestive heart failure (may be worsened) • coronary artery disease (may be worsened) • diarrhoea • elderly (especially if frail) • gastro-oesophageal reflux disease • hiatus hernia with reflux oesophagitis • hypertension • hyperthyroidism (due to association with tachycardia) • individuals susceptible to angle-closure glaucoma • prostatic hyperplasia (in adults) • pyrexia • ulcerative colitis

● SIDE-EFFECTS

▶ Common or very common Constipation • dilation of pupils with loss of accommodation • dry mouth • photophobia • reduced bronchial secretions • skin dryness • skin flushing • transient bradycardia (followed by tachycardia, palpitation and arrhythmias) • urinary retention • urinary urgency

▶ Uncommon Confusion (in children) • confusion (particularly in the elderly) • giddiness • nausea • vomiting

▶ Very rare Angle-closure glaucoma

● FREQUENCY NOT KNOWN Angioedema • blurred vision • blurred vision • central nervous system stimulation • convulsion • diarrhoea • difficulty in micturition • disorientation • dizziness • drowsiness • dry eyes • euphoria • fatigue • flatulence • hallucinations • headache • impaired memory • palpitation • photosensitivity • rash • reduced sweating (may lead to heat sensations and fainting in hot environments or patients with fever) • restlessness • taste disturbances

● PATIENT AND CARER ADVICE

Driving and skilled tasks Antimuscarinics can affect the performance of skilled tasks (e.g. driving).

ANTIMUSCARINICS > URINARY

Darifenacin

● INDICATIONS AND DOSE

Urinary frequency | Urinary urgency | Incontinence

▶ BY MOUTH

Adult: Initially 7.5 mg once daily, increased if necessary to 15 mg after 2 weeks

● INTERACTIONS ➔ Appendix 1: darifenacin

● SIDE-EFFECTS

▶ Uncommon Cough • dyspnoea • hypertension • impotence • insomnia • oedema • rhinitis • ulcerative stomatitis • vaginitis • weakness

● PREGNANCY Manufacturer advises avoid—toxicity in animal studies.

● BREAST FEEDING Present in milk in animal studies—manufacturer advises caution.

● HEPATIC IMPAIRMENT Max. 7.5 mg daily in moderate impairment. Avoid in severe impairment.

● PRESCRIBING AND DISPENSING INFORMATION The need for continuing therapy for urinary incontinence should be reviewed every 4–6 weeks until symptoms stabilise, and then every 6–12 months.

● MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Modified-release tablet

CAUTIONARY AND ADVISORY LABELS 3, 25

▶ Emselex (Merus Labs Luxco S.A R.L.)

Darifenacin (as Darifenacin hydrobromide) 7.5 mg Emselex 7.5mg modified-release tablets ▲ 28 tablet £25.48 DT price = £25.48

Darifenacin (as Darifenacin hydrobromide) 15 mg Emselex 15mg modified-release tablets ▲ 28 tablet £25.48 DT price = £25.48

Fesoterodine fumarate

● INDICATIONS AND DOSE

Urinary frequency | Urinary urgency | Urge incontinence

▶ BY MOUTH

Adult: 4 mg once daily, increased if necessary up to 8 mg once daily

08-May-2017
DOSE ADJUSTMENTS DUE TO INTERACTIONS
Manufacturer advises max. 4 mg daily with concurrent use of potent inhibitors of CYP3A4; avoid concurrent use in patients who also have hepatic or renal impairment. For dose adjustments with concurrent use of moderate inhibitors of CYP3A4 in patients with hepatic or renal impairment, consult product literature.

INTERACTIONS → Appendix 1: fesoterodine

SIDE-EFFECTS
- Common or very common: Insomnia
- Uncommon: Cough, nasal dryness, pharyngolaryngeal pain, vertigo

PREGNANCY Manufacturer advises avoid—toxicity in animal studies.

BREAST FEEDING Manufacturer advises avoid—no information available.

HEPATIC IMPAIRMENT Manufacturer advises increase dose cautiously in mild impairment; max. 4 mg daily in moderate impairment. Manufacturer advises avoid in severe impairment.

RENAL IMPAIRMENT Increase dose cautiously if eGFR 30–80 mL/minute/1.73 m²; max. 4 mg daily if eGFR less than 30 mL/minute/1.73 m².

PRESCRIBING AND DISPENSING INFORMATION The need for continuing therapy for urinary incontinence should be reviewed every 4–6 weeks until symptoms stabilise, and then every 6–12 months.

NATIONAL FUNDING/ACCESS DECISIONS
Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (June 2008) that fesoterodine (Toviaz®) is accepted for restricted use within NHS Scotland as a second-line treatment for overactive bladder syndrome.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Tablet

CAUTIONARY AND ADVISORY LABELS 3
- Flavoxate hydrochloride 200 mg Flurisul (Recordati Pharmaceuticals Ltd) Flavoxate hydrochloride 200 mg Flurisul 200 tablets |

INTERACTIONS → Appendix 1: fesoterodine

Oxybutynin hydrochloride

INDICATIONS AND DOSE
Urinary frequency | Urinary urgency | Urinary incontinence | Neurogenic bladder instability
- By mouth using immediate-release medicines
- Child 5–11 years: Initially 2.5–3 mg twice daily, increased to 5 mg 2–3 times a day
- Child 12–17 years: Initially 5 mg 2–3 times a day, increased if necessary up to 5 mg 4 times a day
- Adult: Initially 5 mg 2–3 times a day, increased if necessary up to 5 mg 4 times a day
- Elderly: Initially 2.5–3 mg twice daily, increased if tolerated to 5 mg twice daily, adjusted according to response

By mouth using modified-release tablets
- Child 5–11 years: Initially 5 mg once daily, adjusted in steps of 5 mg every week, adjusted according to response; maximum 15 mg per day
- Adult: Initially 5 mg once daily, increased in steps of 5 mg every week, adjusted according to response; maximum 20 mg per day

Urinary frequency | Urinary urgency | Urinary incontinence
- By transdermal application using patches
- Adult: Apply 1 patch twice weekly, patch is to be applied to clean, dry unbroken skin on abdomen, hip or buttock. Patch should be removed every 3–4 days and site replacement patch on a different area. The same area should be avoided for 7 days

Nocturnal enuresis associated with overactive bladder
- By mouth using immediate-release medicines
- Child 5–11 years: 2.5–3 mg twice daily, increased to 5 mg 2–3 times a day, last dose to be taken before bedtime

By mouth using modified-release tablets
- Child 5–11 years: Initially 5 mg once daily, adjusted in steps of 5 mg every week, adjusted according to response; maximum 15 mg per day

DOSE EQUIVALENCE AND CONVERSION
- Patients taking immediate-release oxybutynin may be transferred to the nearest equivalent daily dose of Lyrinel® XL

INTERACTIONS → Appendix 1: oxybutynin

SIDE-EFFECTS

GENERAL SIDE-EFFECTS
- Common: Anorexia, facial flushing
- Rare: Night terrors
- Frequency not known: Cognitive impairment (in adults)

SPECIFIC SIDE-EFFECTS
- Rare
- With transdermal use: Application site reactions with patches

PREGNANCY
- Manufacturers advise avoid—present in milk in animal studies.

BREAST FEEDING
- Manufacturers advise avoid—present in milk in animal studies.

HEPATIC IMPAIRMENT
- Manufacturer advises caution.

RENAL IMPAIRMENT
- Manufacturer advises caution.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Tablet

CAUTIONARY AND ADVISORY LABELS 3
- Flavoxate hydrochloride 200 mg Flurisul (Recordati Pharmaceuticals Ltd)

INTERACTIONS → Appendix 1: fesoterodine

Oxybutynin hydrochloride

INDICATIONS AND DOSE
Urinary frequency | Urinary urgency | Urinary incontinence | Neurogenic bladder instability
- By mouth using immediate-release medicines
- Child 5–11 years: Initially 2.5–3 mg twice daily, increased to 5 mg 2–3 times a day
- Child 12–17 years: Initially 5 mg 2–3 times a day, increased if necessary up to 5 mg 4 times a day
- Adult: Initially 5 mg 2–3 times a day, increased if necessary up to 5 mg 4 times a day
- Elderly: Initially 2.5–3 mg twice daily, increased if tolerated to 5 mg twice daily, adjusted according to response

By mouth using modified-release tablets
- Child 5–11 years: Initially 5 mg once daily, adjusted in steps of 5 mg every week, adjusted according to response; maximum 15 mg per day
- Adult: Initially 5 mg once daily, increased in steps of 5 mg every week, adjusted according to response; maximum 20 mg per day

Urinary frequency | Urinary urgency | Urinary incontinence
- By transdermal application using patches
- Adult: Apply 1 patch twice weekly, patch is to be applied to clean, dry unbroken skin on abdomen, hip or buttock. Patch should be removed every 3–4 days and site replacement patch on a different area. The same area should be avoided for 7 days

Nocturnal enuresis associated with overactive bladder
- By mouth using immediate-release medicines
- Child 5–11 years: 2.5–3 mg twice daily, increased to 5 mg 2–3 times a day, last dose to be taken before bedtime

By mouth using modified-release tablets
- Child 5–11 years: Initially 5 mg once daily, adjusted in steps of 5 mg every week, adjusted according to response; maximum 15 mg per day

DOSE EQUIVALENCE AND CONVERSION
- Patients taking immediate-release oxybutynin may be transferred to the nearest equivalent daily dose of Lyrinel® XL

INTERACTIONS → Appendix 1: oxybutynin

SIDE-EFFECTS

GENERAL SIDE-EFFECTS
- Common: Anorexia, facial flushing
- Rare: Night terrors
- Frequency not known: Cognitive impairment (in adults)

SPECIFIC SIDE-EFFECTS
- Rare
- With transdermal use: Application site reactions with patches

PREGNANCY
- Manufacturers advise avoid—present in milk in animal studies.

BREAST FEEDING
- Manufacturers advise avoid—present in milk in animal studies.

HEPATIC IMPAIRMENT
- Manufacturer advises caution.

RENAL IMPAIRMENT
- Manufacturer advises caution.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Tablet

CAUTIONARY AND ADVISORY LABELS 3
- Flavoxate hydrochloride 200 mg Flurisul (Recordati Pharmaceuticals Ltd) Flavoxate hydrochloride 200 mg Flurisul 200 tablets |

INTERACTIONS → Appendix 1: fesoterodine

Oxybutynin hydrochloride

INDICATIONS AND DOSE
Urinary frequency | Urinary urgency | Urinary incontinence | Neurogenic bladder instability
- By mouth using immediate-release medicines
- Child 5–11 years: Initially 2.5–3 mg twice daily, increased to 5 mg 2–3 times a day
- Child 12–17 years: Initially 5 mg 2–3 times a day, increased if necessary up to 5 mg 4 times a day
- Adult: Initially 5 mg 2–3 times a day, increased if necessary up to 5 mg 4 times a day
- Elderly: Initially 2.5–3 mg twice daily, increased if tolerated to 5 mg twice daily, adjusted according to response

By mouth using modified-release tablets
- Child 5–11 years: Initially 5 mg once daily, adjusted in steps of 5 mg every week, adjusted according to response; maximum 15 mg per day
- Adult: Initially 5 mg once daily, increased in steps of 5 mg every week, adjusted according to response; maximum 20 mg per day

Urinary frequency | Urinary urgency | Urinary incontinence
- By transdermal application using patches
- Adult: Apply 1 patch twice weekly, patch is to be applied to clean, dry unbroken skin on abdomen, hip or buttock. Patch should be removed every 3–4 days and site replacement patch on a different area. The same area should be avoided for 7 days

Nocturnal enuresis associated with overactive bladder
- By mouth using immediate-release medicines
- Child 5–11 years: 2.5–3 mg twice daily, increased to 5 mg 2–3 times a day, last dose to be taken before bedtime

By mouth using modified-release tablets
- Child 5–11 years: Initially 5 mg once daily, adjusted in steps of 5 mg every week, adjusted according to response; maximum 15 mg per day

DOSE EQUIVALENCE AND CONVERSION
- Patients taking immediate-release oxybutynin may be transferred to the nearest equivalent daily dose of Lyrinel® XL

INTERACTIONS → Appendix 1: oxybutynin

SIDE-EFFECTS

GENERAL SIDE-EFFECTS
- Common: Anorexia, facial flushing
- Rare: Night terrors
- Frequency not known: Cognitive impairment (in adults)

SPECIFIC SIDE-EFFECTS
- Rare
- With transdermal use: Application site reactions with patches

PREGNANCY
- Manufacturers advise avoid—present in milk in animal studies.

BREAST FEEDING
- Manufacturers advise avoid—present in milk in animal studies.

HEPATIC IMPAIRMENT
- Manufacturer advises caution.

RENAL IMPAIRMENT
- Manufacturer advises caution.
Oxybutynin hydrochloride

**INDICATIONS AND DOSE**

Urinary frequency | Urinary urgency | Urinary incontinence

▶ BY MOUTH

Adult: 5 mg once daily, increased if necessary to 10 mg once daily

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**

Manufacturer advises max. dose 5 mg daily with concurrent use of potent inhibitors of CYP3A4; avoid concurrent use in patients who also have moderate hepatic impairment or severe renal impairment.

**CONTRA-INDICATIONS**

Narrow-angle glaucoma

**CAUTIONS**

Neurogenic bladder disorder - susceptibility to QT-interval prolongation

**INTERACTIONS** → Appendix 1: solifenacin

**SIDE-EFFECTS**

- Uncommon Gastro-oesophageal reflux - oedema
- Frequency not known Dysphonia - hepatic impairment - hyperkalaemia - muscle weakness - reduced appetite - torsade de pointes
- **PREGNANCY**
  - Manufacturer advises caution—no information available.
- **BREAST FEEDING**
  - Manufacturer advises avoid—present in milk in animal studies.
- **HEPATIC IMPAIRMENT**
  - Max. 5 mg daily in moderate impairment.
  - Avoid in severe impairment.
- **RENAL IMPAIRMENT**
  - Max. 5 mg daily if eGFR less than 30 mL/minute/1.73 m².

**PREScribing AND DISPENSING INFORMATION**

The need for continuing therapy for urinary incontinence should be reviewed every 4–6 weeks until symptoms stabilise, and then every 6–12 months.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Modified-release tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>3, 25</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lyriilen XL (Janssen-Cilag Ltd)</td>
<td></td>
</tr>
<tr>
<td>Oxybutynin hydrochloride 5 mg</td>
<td>30 tablet (Pom) £13.77 DT price = £13.77</td>
</tr>
<tr>
<td>Oxybutynin hydrochloride 10 mg</td>
<td>30 tablet (Pom) £27.54 DT price = £27.54</td>
</tr>
</tbody>
</table>

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxybutynin hydrochloride (Non-proprietary)</td>
<td></td>
</tr>
<tr>
<td>Oxybutynin hydrochloride 2.5 mg</td>
<td>56 tablet (Pom) £6.58 DT price = £1.15</td>
</tr>
<tr>
<td>Oxybutynin hydrochloride 5 mg</td>
<td>56 tablet (Pom) £16.80 DT price = £16.80</td>
</tr>
<tr>
<td>Oxybutynin hydrochloride 10 mg</td>
<td>56 tablet (Pom) £34.65 DT price = £1.49</td>
</tr>
<tr>
<td>Cystrin (Zentiva)</td>
<td></td>
</tr>
<tr>
<td>Oxybutynin hydrochloride 5 mg</td>
<td>84 tablet (Pom) £23.99</td>
</tr>
<tr>
<td>Ditropan (Sanofi)</td>
<td></td>
</tr>
<tr>
<td>Oxybutynin hydrochloride 2.5 mg</td>
<td>84 tablet (Pom) £1.60</td>
</tr>
<tr>
<td>Oxybutynin hydrochloride 5 mg</td>
<td>84 tablet (Pom) £2.90</td>
</tr>
</tbody>
</table>

**Oral solution**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxybutynin hydrochloride (Non-proprietary)</td>
<td></td>
</tr>
<tr>
<td>Oxybutynin hydrochloride 0.5 mg/5ml oral solution</td>
<td>150 ml (Pom) £144.50–£173.40 DT price = £144.50</td>
</tr>
<tr>
<td>Oxybutynin hydrochloride 0.6 mg/5ml oral solution</td>
<td>150 ml (Pom) £199.20–£239.04 DT price = £199.20</td>
</tr>
</tbody>
</table>

**Transdermal patch**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kentera (Orion Pharma (UK) Ltd)</td>
<td></td>
</tr>
<tr>
<td>Oxybutynin 3.9 mg per 24 hour</td>
<td>Kentera 3.9mg/24hours patches</td>
</tr>
</tbody>
</table>

**Solifenacin succinate**

**INDICATIONS AND DOSE**

Urinary frequency | Urinary urgency | Urinary incontinence

▶ BY MOUTH

Adult: 5 mg once daily, increased if necessary to 10 mg once daily

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**

Manufacturer advises max. dose 5 mg daily with concurrent use of potent inhibitors of CYP3A4; avoid concurrent use in patients who also have moderate hepatic impairment or severe renal impairment.

**CONTRA-INDICATIONS**

Narrow-angle glaucoma

**CAUTIONS**

Neurogenic bladder disorder - susceptibility to QT-interval prolongation

**INTERACTIONS** → Appendix 1: solifenacin

**SIDE-EFFECTS**

- Uncommon Gastro-oesophageal reflux - oedema
- Frequency not known Dysphonia - hepatic impairment - hyperkalaemia - muscle weakness - reduced appetite - torsade de pointes
- **PREGNANCY**
  - Manufacturer advises caution—no information available.
- **BREAST FEEDING**
  - Manufacturer advises avoid—present in milk in animal studies.
- **HEPATIC IMPAIRMENT**
  - Max. 5 mg daily in moderate impairment.
  - Avoid in severe impairment.
- **RENAL IMPAIRMENT**
  - Max. 5 mg daily if eGFR less than 30 mL/minute/1.73 m².

**PREScribing AND DISPENSING INFORMATION**

The need for continuing therapy for urinary incontinence should be reviewed every 4–6 weeks until symptoms stabilise, and then every 6–12 months.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solifenacin succinate 5 mg</td>
<td>30 tablet (Pom) £27.62 DT price = £27.62</td>
</tr>
<tr>
<td>Solifenacin succinate 10 mg</td>
<td>30 tablet (Pom) £35.91 DT price = £35.91</td>
</tr>
</tbody>
</table>

**Tropism chloride**

**INDICATIONS AND DOSE**

Urinary frequency | Urinary urgency | Urinary incontinence

▶ BY MOUTH USING IMMEDIATE-RELEASE MEDICINES

Adult: 20 mg twice daily, to be taken before food

▶ BY MOUTH USING MODIFIED-RELEASE MEDICINES

Adult: 60 mg once daily

**INTERACTIONS** → Appendix 1: tropism

**SIDE-EFFECTS**

- Rare Asthenia - chest pain - dyspnoea
- Very rare Arthralgia - myalgia
- **PREGNANCY**
  - Manufacturer advises caution.
- **BREAST FEEDING**
  - Manufacturer advises caution.
- **HEPATIC IMPAIRMENT**
  - Manufacturer advises caution.
- **RENAL IMPAIRMENT**
  - Reduce dose to 20 mg once daily or 20 mg on alternate days if eGFR 10–30 mL/minute/1.73m². Use with caution. Avoid Regurin® XL.
● PRESCRIBING AND DISPENSING INFORMATION  The need for continuing therapy for urinary incontinence should be reviewed every 4–6 weeks until symptoms stabilise, and then every 6–12 months.

● MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

Modified-release capsule
CAUTIONARY AND ADVISORY LABELS 23, 25
> Tolterodine tartrate (Non-proprietary)
  Tolterodine 2 mg Tolterodine 1 mg modified-release capsules  | 28 capsule  POM  no price available DT price = £29.03 | 30 capsule  POM  no price available
> Regurin XL (Speciality European Pharma Ltd)
  Tolterodine chloride 60 mg Regurin XL 60mg capsules  | 28 capsule  POM  £23.05 | 30 capsule  POM  no price available

Tablet
CAUTIONARY AND ADVISORY LABELS 23
> Tolterodine chloride (Non-proprietary)
  Tolterodine 2 mg Tolterodine chloride 20 mg tablets  | 60 tablet  POM  £26.00 DT price = £13.01
> Flotros (Galen Ltd)
  Tolterodine 2 mg Flotros 20mg tablets  | 60 tablet  POM  £15.47 DT price = £13.01
> Regurin (Speciality European Pharma Ltd)
  Tolterodine 2 mg Regurin 20mg tablets  | 60 tablet  POM  £26.00 DT price = £13.01
> Uraplex (Speciality European Pharma Ltd)
  Tolterodine 2 mg Uraplex 20mg tablets  | 60 tablet  POM  £26.00 DT price = £13.01

Antimuscarinics ▶ Other

Propiverine hydrochloride
● INDICATIONS AND DOSE
Urinary frequency, urgency and incontinence associated with overactive bladder
  ▶ BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
  ▶ Adult: 15 mg 1–2 times a day, increased if necessary up to 15 mg 3 times a day
  ▶ BY MOUTH USING MODIFIED-RELEASE CAPSULES
  ▶ Adult: 30 mg once daily

Urinary frequency, urgency and incontinence associated with neurogenic bladder instability
  ▶ BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
  ▶ Adult: 15 mg 3 times a day

● INTERACTIONS  → Appendix 1: propiverine
● PREGNANCY  Manufacturer advises avoid—toxicity in animal studies.
● BREAST FEEDING  Manufacturer advises avoid—no information available.
● HEPATIC IMPAIRMENT  Reduce dose to 1 mg twice daily. Avoid modified-release preparations.
● RENAL IMPAIRMENT  Reduce dose to 1 mg twice daily if eGFR less than 30 mL/minute/1.73m². Avoid modified-release preparations if eGFR less than 30 mL/minute/1.73m².

● MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Modified-release capsule
CAUTIONARY AND ADVISORY LABELS 3, 25
> Tolterodine tartrate (Non-proprietary)
  Tolterodine tartrate 1 mg Tolterodine 1mg tablets  | 56 tablet  POM  £29.03 DT price = £1.85
  Tolterodine tartrate 2 mg Tolterodine 2mg tablets  | 56 tablet  POM  £30.56 DT price = £1.81
> Detruristol (Pfizer Ltd)
  Tolterodine tartrate 1 mg Detruristol 1mg tablets  | 56 tablet  POM  £29.03 DT price = £1.85
  Tolterodine tartrate 2 mg Detruristol 2mg tablets  | 56 tablet  POM  £30.56 DT price = £1.81

Tablet
CAUTIONARY AND ADVISORY LABELS 3
> Tolterodine tartrate (Non-proprietary)
  Tolterodine tartrate 2 mg Tolterodine 2mg modified-release capsules  | 28 capsule  POM  no price available DT price = £11.60
> Blerone XL (Zentiva)
  Tolterodine tartrate 4 mg Blerone XL 4mg capsules  | 28 capsule  POM  £25.78 DT price = £25.78
> Detruristol XL (Pfizer Ltd)
  Tolterodine tartrate 4 mg Detruristol XL 4mg capsules  | 28 capsule  POM  £25.78 DT price = £25.78

Tolterodine tartrate

● INDICATIONS AND DOSE
Urinary frequency | Urinary urgency | Urinary incontinence
  ▶ BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
  ▶ Adult: 2 mg twice daily, reduced if not tolerated to 1 mg twice daily
  ▶ BY MOUTH USING MODIFIED-RELEASE CAPSULES
  ▶ Adult: 4 mg once daily

DOSE EQUIVALENCE AND CONVERSION
Children stabilised on immediate-release tolterodine tartrate 2 mg twice daily may be transferred to modified-release tolterodine tartrate 4 mg once daily.

● CAUTIONS  History of QT-interval prolongation
● INTERACTIONS  → Appendix 1: tolterodine
● SIDE-EFFECTS
  ▶ Common or very common Bronchitis, chest pain, fatigue, paraesthesia, peripheral oedema, sinusitis, vertigo, weight gain
  ▶ Uncommon Memory impairment
  ▶ Frequency not known  Flushing

● PREGNANCY  Manufacturer advises avoid—no information available.

● MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Modified-release capsule
CAUTIONARY AND ADVISORY LABELS 3, 25
> Tolterodine tartrate (Non-proprietary)
  Tolterodine tartrate 2 mg Tolterodine 2mg modified-release capsules  | 28 capsule  POM  no price available DT price = £11.60
> Blerone XL (Zentiva)
  Tolterodine tartrate 4 mg Blerone XL 4mg capsules  | 28 capsule  POM  £25.78 DT price = £25.78
> Detruristol XL (Pfizer Ltd)
  Tolterodine tartrate 4 mg Detruristol XL 4mg capsules  | 28 capsule  POM  £25.78 DT price = £25.78

Propiverine hydrochloride 45 mg Detrunorm XL 45mg capsules  | 28 capsule  POM  £27.00 DT price = £27.00

Tablet
CAUTIONARY AND ADVISORY LABELS 3
> Detrunorm (AMCo)
  Propiverine hydrochloride 15 mg Detrunorm 15mg tablets  | 56 tablet  POM  £18.00 DT price = £18.00
BETA\(_3\)-ADRENOCEPTOR AGONISTS

Mirabegron

- **INDICATIONS AND DOSE**
  - Urinary frequency, urgency, and urge incontinence
    - **BY MOUTH**
    - Adult: 50 mg once daily

- **DOSE ADJUSTMENTS DUE TO INTERACTIONS**
  - Manufacturer advises reduce dose to 25 mg once daily in patients with mild hepatic impairment with concurrent use of potent inhibitors of CYP3A4; avoid in moderate impairment.
  - Manufacturer advises reduce dose to 25 mg once daily if eGFR 30–89 mL/minute/1.73 m\(^2\) with concurrent use of potent inhibitors of CYP3A4; avoid if eGFR less than 30 mL/minute/1.73 m\(^2\).

- **CONTRA-INDICATIONS**
  - Severe uncontrolled hypertension (systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg)

- **CAUTIONS**
  - History of QT-interval prolongation - stage 2 hypertension

- **INTERACTIONS**
  - Appendix 1: mirabegron

- **SIDE-EFFECTS**
  - Common or very common
    - Tachycardia - urinary-tract infection
  - Uncommon
    - Atrial fibrillation - dyspepsia - gastritis - hypertension - joint swelling - palpitation - pruritus - rash - vulvovaginal infection - vulvovaginal pruritus

- **CONCEPTION AND CONTRACEPTION**
  - Contraception advised in women of child-bearing potential.

- **PREGNANCY**
  - Avoid — toxicity in animal studies.

- **BREAST FEEDING**
  - Avoid — present in milk in animal studies.

- **HEPATIC IMPAIRMENT**
  - Reduce dose to 25 mg once daily in moderate impairment. Avoid in severe impairment — no information available.

- **RENAL IMPAIRMENT**
  - Reduce dose to 25 mg once daily if eGFR 15–29 mL/minute/1.73 m\(^2\). Avoid if eGFR less than 15 mL/minute/1.73 m\(^2\) — no information available.

- **MONITORING REQUIREMENTS**
  - Blood pressure should be monitored before starting treatment and regularly during treatment, especially in patients with pre-existing hypertension.

- **NATIONAL FUNDING/ACCESS DECISIONS**
  - NICE technology appraisals (TAs)
  - Mirabegron for treating symptoms of overactive bladder (June 2013) NICE TA290
  - Mirabegron is recommended as an option only for patients in whom antimuscarinic drugs are ineffective, contra-indicated, or not tolerated; patients currently receiving mirabegron who do not meet these criteria should have the option to continue until they and their clinician consider it appropriate to stop.
  - [www.nice.org.uk/TA290](http://www.nice.org.uk/TA290)

1.2 Urinary retention

**Urinary retention**

31-May-2017

**Description of condition**

Urinary retention is the inability to voluntarily urinate. It may be secondary to urethral blockage, drug treatment (such as use of antimuscarinic drugs, sympathomimetics, tricyclic antidepressants), conditions that reduce detrusor contractions or interfere with relaxation of the urethra, neurogenic causes, or it may occur postpartum or postoperatively.

Acute urinary retention is a medical emergency characterised by the abrupt development of the inability to pass urine (over a period of hours).

Chronic urinary retention is the gradual (over months or years) development of the inability to empty the bladder completely, characterised by a residual volume greater than one litre or associated with the presence of a distended or palpable bladder.

**Urinary retention due to benign prostatic hyperplasia**

The most common cause of urinary retention in men is benign prostatic hyperplasia. Men with an enlarged prostate can have lower urinary tract symptoms associated with obstruction, such as urinary retention (acute or chronic), frequency, urgency or nocturia.

**Treatment**

Treatment of urinary retention depends on the underlying condition. Catheterisation is used to relieve acute painful urinary retention or when no cause can be found. Surgical procedures or dilatation are often used to correct mechanical outflow obstructions.

**Acute urinary retention**

Acute retention is painful and requires immediate treatment by catheterisation. Before the catheter is removed an alpha-adrenoceptor blocker (such as alfuzosin hydrochloride p. 737, doxazosin p. 738, tamsulosin hydrochloride p. 739, prazosin p. 739, indoramin p. 738 or terazosin p. 741) should be given for at least two days to manage acute urinary retention.

**Chronic urinary retention**

In patients with chronic urinary retention, intermittent bladder catheterisation should be offered before an indwelling catheter. Catheters may be used as a long-term solution where persistent urinary retention is causing...
incontinence, infection, or renal dysfunction and a surgical solution is not feasible. A Their use is associated with an increased risk of adverse events including recurrent urinary infections, trauma to the urethra, pain, and stone formation. ESGR In men who have symptoms that are bothersome, drug treatment should only be offered when other conservative management options have failed. Men with moderate-to-severe symptoms should be offered an alpha-adrenoceptor blocker (alfuzosin hydrochloride, doxazosin, tamsulosin hydrochloride or terazosin). Treatment should initially be reviewed after 4–6 weeks and then every 6–12 months. A

The parasympathetic bethanechol chloride p. 741 increases detrusor muscle contraction. It is licensed for acute postoperative, postpartum and neurogenic urinary retention but its use has largely been superseded by catheterisation.

**Urinary retention due to benign prostatic hyperplasia**

In patients with benign prostatic hyperplasia, treatment is influenced by the severity of symptoms and their effect on the patient’s quality of life. ESGR Watchful waiting is suitable for men with symptoms that are not troublesome and in those who have not yet developed complications of benign prostatic hyperplasia such as renal impairment, urinary retention or recurrent infection.

The recommended treatment of benign prostatic hyperplasia is usually an alpha-adrenoceptor blocker. The alpha₁-selective adrenoceptor blockers relax smooth muscle in benign prostatic hyperplasia producing an increase in urinary flow-rate and an improvement in obstructive symptoms.

In patients with an enlarged prostate, a raised prostate specific antigen concentration, and who are considered to be at high risk of progression (such as the elderly), a 5α-reductase inhibitor (such as finasteride p. 742 or dutasteride p. 741) should be used. A combination of an alpha-adrenoceptor blocker and a 5α-reductase inhibitor can be offered if symptoms remain a problem.

Surgery is recommended for men with more severe symptoms that do not respond to drug therapy, or who have complications such as acute urinary retention, haematuria, renal failure, bladder calculi or recurrent urinary-tract infection. A

**Useful Resources**


[www.nice.org.uk/guidance/cg97](http://www.nice.org.uk/guidance/cg97)

Other drugs used for Urinary retention Tadalafil, p. 767

### ALPHA-ADRENOCEPTOR BLOCKERS

**Alfuzosin hydrochloride**

**INDICATIONS AND DOSE**

**Benign prostatic hyperplasia**

- **Adult:** 2.5 mg 3 times a day; maximum 10 mg per day
- **Elderly:** Initially 2.5 mg twice daily, adjusted according to response; maximum 10 mg per day
- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
- **Adult:** 10 mg once daily

**Acute urinary retention associated with benign prostatic hyperplasia**

- **BY MOUTH USING MODIFIED-RELEASE TABLETS**
- **Elderly:** 10 mg once daily for 2–3 days during catheterisation and for one day after removal; max. 4 days

- **CONTRA-INDICATIONS** Avoid if history of micturition syncope - avoid if history of postural hypotension

- **CAUTIONS** Acute heart failure - concomitant antihypertensives (reduced dosage and specialist supervision may be required) - discontinue if angina worsens - elderly - history of QT-interval prolongation - patients undergoing cataract surgery (risk of intra-operative floppy iris syndrome)

- **INTERACTIONS** → Appendix 1: alpha blockers

- **SIDE-EFFECTS**
  - **Uncommon** Chest pain - flushes
  - **Frequency not known** Angioedema - asthenia - blurred vision - cholestasis - depression - dizziness - drowsiness - dry mouth - erectile disorders (including priapism) - gastrointestinal disturbances - headache - hypersensitivity - hypotension (notably postural hypotension) - intra-operative floppy iris syndrome - liver damage - oedema - palpitations - pruritus - rash - rhinitis - syncope - tachycardia

**SIDE-EFFECTS, FURTHER INFORMATION**

- **First dose effect** First dose may cause collapse due to hypotensive effect (therefore should be taken on retiring to bed). Patient should be warned to lie down if symptoms such as dizziness, fatigue or sweating develop, and to remain lying down until they abate completely.

- **HEPATIC IMPAIRMENT** Initial dose 2.5 mg once daily, adjusted according to response to 2.5 mg twice daily in mild to moderate impairment—avoid if severe. Avoid modified-release preparations.

- **RENAL IMPAIRMENT** Initial dose 2.5 mg twice daily and adjust according to response. Manufacturers advise avoid use of modified-release preparations if eGFR less than 30 ml/minute/1.73 m² as limited experience.

- **PATIENT AND CARER ADVICE** Patient should be counselled on the first dose effect.

**Driving and skilled tasks**

May affect performance of skilled tasks e.g. driving.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

**Modified-release tablet**

**CAUTIONARY AND ADVISORY LABELS** 21, 25

- **Alfuzosin hydrochloride (Non-proprietary)**
  - Alfuzosin hydrochloride 10 mg
  - Alfuzosin 10 mg modified-release tablets | 30 tablet pack no price available DT price = £12.51
  - Besavar XL (Zentiva)
  - Alfuzosin hydrochloride 10 mg
  - Besavar XL 10 mg tablets | 30 tablet pack | £12.51 DT price = £12.51
  - Fuzatal XL (Teva UK Ltd)
  - Alfuzosin hydrochloride 10 mg
  - Fuzatal XL 10 mg tablets | 30 tablet pack | £12.76 DT price = £12.51
  - Vasran XL (Ranbaxy (UK) Ltd)
  - Alfuzosin hydrochloride 10 mg
  - Vasran XL 10 mg tablets | 30 tablet pack | £11.48 DT price = £12.51
  - Xatral XL (Sanofi)
  - Alfuzosin hydrochloride 10 mg
  - Xatral XL 10 mg tablets | 10 tablet pack | £4.17 | 30 tablet pack | £12.51 DT price = £12.51

**Tablet**

- **Alfuzosin hydrochloride (Non-proprietary)**
  - Alfuzosin hydrochloride 2.5 mg
  - Alfuzosin 2.5 mg tablets | 60 tablet pack | £21.20 DT price = £2.10
  - Xatral (Sanofi)
  - Alfuzosin hydrochloride 2.5 mg
  - Xatral 2.5 mg tablets | 60 tablet pack | £20.37 DT price = £2.10
Doxazosin

**INDICATIONS AND DOSE**

**Hypertension**

- **By mouth using immediate-release medicines**
  - Adult: Initially 1 mg once daily for 1–2 weeks, then increased to 2 mg once daily, then increased if necessary to 4 mg once daily; maximum 16 mg per day

- **By mouth using modified-release medicines**
  - Adult: Initially 4 mg once daily, dose can be adjusted after 4 weeks, then increased if necessary to 8 mg once daily

**Benign prostatic hyperplasia**

- **By mouth using immediate-release medicines**
  - Adult: Initially 1 mg daily, dose may be doubled at intervals of 1–2 weeks according to response; usual maintenance 2–4 mg daily; maximum 8 mg per day

- **By mouth using modified-release medicines**
  - Adult: Initially 4 mg once daily, dose can be adjusted after 4 weeks, then increased if necessary to 8 mg once daily

**DOSE EQUIVALENCE AND CONVERSION**

- Patients stabilised on immediate-release doxazosin can be transferred to the equivalent dose of modified-release doxazosin.

**CONTRA-INDICATIONS**

History of micturition syncope (in patients with benign prostatic hypertrophy) - history of postural hypotension - monotherapy in patients with overflow bladder or anuria

**CAUTIONS**

Care with initial dose (postural hypotension) - cataract surgery (risk of intra-operative floppy iris syndrome) - elderly - heart failure - pulmonary oedema due to aortic or mitral stenosis

**INTERACTIONS** → Appendix 1: alpha blockers

**SIDE-EFFECTS**

- Common or very common
  - Anxiety - back pain - coughing - dyspnoea - fatigue - influenza-like symptoms - myalgia - paraesthesia - sleep disturbance - vertigo

- Uncommon
  - Agitation - angina - arthralgia - epistaxis - gout - hypoesthesia - micturition disturbance - myocardial infarction - tinnitus - tremor - weight changes

- Very rare
  - Abnormal ejaculation - alopecia - arrhythmias - bradycardia - bronchospasm - cholostasis - gynaecomastia - hepatitis - hot flushes - jaundice - leucopenia - thrombocytopenia

- Frequency not known

**PREGNANCY**

No evidence of teratogenicity; manufacturers advise use only when potential benefit outweighs risk

**BREAST FEEDING**

Accumulates in milk in animal studies—manufacturer advises avoid.

**HEPATIC IMPAIRMENT**

Use with caution. Manufacturer advises avoid in severe impairment—no information available.

**PATIENT AND CARER ADVICE**

Patient counselling is advised for doxazosin tablets (initial dose).

**Driving and skilled tasks**

May affect performance of skilled tasks e.g. driving.

**MEDICINAL FORMS**

There may be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule, oral suspension, oral solution

**Modified-release tablet**

**CAUTIONARY AND ADVISORY LABELS 25**

- **Cardura XL** (Pfizer Ltd)
  - Doxazosin (as Doxazosin mesilate) 4 mg Cardura XL 4 mg tablets | 28 tablet £5.00 DT price = £5.00
  - Doxazosin (as Doxazosin mesilate) 8 mg Cardura XL 8 mg tablets | 28 tablet £9.98 DT price = £9.98

- **Doxadura XL** (Discovery Pharmaceuticals)
  - Doxazosin (as Doxazosin mesilate) 4 mg Doxadura XL 4 mg tablets | 28 tablet £4.75 DT price = £4.75

- **Larbx XL** (Teva UK Ltd)
  - Doxazosin (as Doxazosin mesilate) 4 mg Larbx XL 4 mg tablets | 28 tablet £6.08 DT price = £6.08

- **Raporsin XL** (Actavis UK Ltd)
  - Doxazosin (as Doxazosin mesilate) 4 mg Raporsin XL 4 mg tablets | 28 tablet £5.70 DT price = £5.70

- **Slocinx XL** (Zenitiva)
  - Doxazosin (as Doxazosin mesilate) 4 mg Slocinx XL 4 mg tablets | 28 tablet £5.96 DT price = £5.96

**Tablet**

- **Doxazosin (Non-proprietary)**
  - Doxazosin (as Doxazosin mesilate) 1 mg Doxazosin 1 mg tablets | 28 tablet £10.56 DT price = £10.56
  - Doxazosin (as Doxazosin mesilate) 2 mg Doxazosin 2 mg tablets | 28 tablet £14.08 DT price = £14.08
  - Doxazosin (as Doxazosin mesilate) 4 mg Doxazosin 4 mg tablets | 28 tablet £14.08 DT price = £14.08

- **Cardura** (Pfizer Ltd)
  - Doxazosin (as Doxazosin mesilate) 1 mg Cardura 1 mg tablets | 28 tablet £10.56 DT price = £10.56
  - Doxazosin (as Doxazosin mesilate) 2 mg Cardura 2 mg tablets | 28 tablet £14.08 DT price = £14.08

- **Doxadura** (Discovery Pharmaceuticals)
  - Doxazosin (as Doxazosin mesilate) 1 mg Doxadura 1 mg tablets | 28 tablet £0.64 DT price = £0.64
  - Doxazosin (as Doxazosin mesilate) 2 mg Doxadura 2 mg tablets | 28 tablet £0.66 DT price = £0.66
  - Doxazosin (as Doxazosin mesilate) 4 mg Doxadura 4 mg tablets | 28 tablet £0.73 DT price = £0.73

**Indoramin**

**INDICATIONS AND DOSE**

**Hypertension**

- **By mouth**
  - Adult: Initially 25 mg twice daily, increased in steps of 25–50 mg every 2 weeks, maximum daily dose should be given in divided doses; maximum 200 mg per day

**Benign prostatic hyperplasia**

- **By mouth**
  - Adult: 20 mg twice daily, increased in steps of 20 mg every 2 weeks if required, increased if necessary up to 100 mg daily in divided doses
  - Elderly: 20 mg daily may be adequate, dose to be taken at night

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**

Caution with concomitant antihypertensives in benign prostatic hyperplasia—reduced dosage and specialist supervision may be required.

**CONTRA-INDICATIONS**

Established heart failure - history micturition syncope (when used for benign prostatic hyperplasia) - history of postural hypotension (when used for benign prostatic hyperplasia)

**CAUTIONS**

Cataract surgery (risk of intra-operative floppy iris syndrome) - control incipient heart failure before initiating indoramin - elderly - epilepsy (convulsions in animal studies) - history of depression - Parkinson’s disease (extrapyramidal disorders reported)

**INTERACTIONS** → Appendix 1: alpha blockers
Side-effects

- Common or very common: Sedation
- Uncommon: Failure of ejaculation, fatigue, weight gain
- Frequency not known: Angioedema, asthenia, blurred vision, depression, dizziness, drowsiness, dry mouth, erectile disorders, extrapyramidal disorders, gastrointestinal disturbances, headache, hypersensitivity reactions, hypotension, incontinence, intra-operative floppy iris syndrome, oedema, palpitations, postural hypotension, priapism, pruritus, rash, rhinitis, syncope, tachycardia, urinary frequency

Pregnancy

- No evidence of teratogenicity; manufacturers advise use only when potential benefit outweighs risk.

Breast Feeding

- No information available.

Hepatic Impairment

- Manufacturer advises caution.

Renal Impairment

- Manufacturer advises caution.

Patient and Carer Advice

- Driving and skilled tasks: Drowsiness may affect performance of skilled tasks (e.g. driving); effects of alcohol may be enhanced.

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug.

Tablet

- Cautionary and Advisory Labels: 2

  - Indoramin (Non-proprietary)
    - Indoramin hydrochloride 20 mg: Indoramin 20mg tablets | 60 tablet (PF) £61.00 DT price = £8.21
    - Indoramin (as Indoramin hydrochloride) 25 mg: Indoramin 25mg tablets | 84 tablet (PF) £60.26 DT price = £60.26
  - Doralese Tiltab (Chemidex Pharma Ltd)
    - Indoramin hydrochloride 20 mg: Doralese Tiltab 20mg tablets | 60 tablet (PF) £11.44 DT price = £8.21

Prazosin

- Indications and Dose

  - Hypertension
    - By Mouth
      - Adult: Initially 500 micrograms 2–3 times a day for 3–7 days, the initial dose should be taken on retiring to bed at night to avoid collapse, increased to 1 mg 2–3 times a day for a further 3–7 days, then increased if necessary up to 20 mg daily in divided doses
  - Congestive heart failure (rarely used)
    - By Mouth
      - Adult: 500 micrograms 2–4 times a day, initial dose to be taken at bedtime, then increased to 4 mg daily in divided doses; maintenance 4–20 mg daily in divided doses
  - Raynaud’s syndrome (but efficacy not established)
    - By Mouth
      - Adult: Initially 500 micrograms twice daily, initial dose to be taken at bedtime, dose may be increased after 3–7 days, then increased if necessary to 1–2 mg twice daily
  - Benign prostatic hyperplasia
    - By Mouth
      - Adult: Initially 500 micrograms twice daily for 3–7 days, subsequent doses should be adjusted according to response, maintenance 2 mg twice daily, initiate with lowest possible dose in elderly patients

Dose Adjustments due to Interactions

Caution with concomitant antihypertensives in benign prostatic hyperplasia—reduced dosage and specialist supervision may be required.

Contra-Indications

- History of micturition syncope, history of postural hypotension, not recommended for congestive heart failure due to mechanical obstruction (e.g. aortic stenosis)

Caution

- Cataract surgery (risk of intra-operative floppy iris syndrome) - elderly, first dose hypotension

Interactions

- Appendix 1: alpha blockers

Side-Effects

- Angioedema, asthenia, blurred vision, depression, dizziness, drowsiness, dry mouth, erectile disorders, extrapyramidal disorders, gastrointestinal disturbances, headache, hypersensitivity reactions, hypotension, incontinence, intra-operative floppy iris syndrome, oedema, palpitations, postural hypotension, priapism, pruritus, rash, rhinitis, syncope, tachycardia, urinary frequency

Renal Impairment

- No information available.

Hepatic Impairment

- Manufacturer advises caution.

Patient and Carer Advice

- Driving and skilled tasks: Drowsiness may affect performance of skilled tasks (e.g. driving); effects of alcohol may be enhanced.

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug.

Tablet

- Cautionary and Advisory Labels: 2

  - Prazosin (Non-proprietary)
    - Prazosin (as Prazosin hydrochloride) 1 mg: Prazosin hydrochloride 1 mg tablets | 100 tablet (PF) no price available
    - Prazosin (as Prazosin hydrochloride) 5 mg: Prazosin hydrochloride 5 mg tablets | 100 tablet (PF) no price available
    - Hypovase (Pflizer Ltd)
      - Prazosin (as Prazosin hydrochloride) 500 microgram: Hypovase 500microgram tablets | 60 tablet (PF) £2.69 DT price = £2.69
      - Prazosin (as Prazosin hydrochloride) 1 mg: Prazosin hydrochloride 1 mg tablets | 60 tablet (PF) £3.46 DT price = £3.46

Tamsulosin Hydrochloride

- Indications and Dose

  - Benign prostatic hyperplasia
    - By Mouth Using Modified-Release Medicines
      - Adult: 400 micrograms once daily

Contra-Indications

- History of micturition syncope, history of postural hypotension

Caution

- Cataract surgery (risk of intra-operative floppy iris syndrome) - concomitant antihypertensives (reduced dosage and specialist supervision may be required) - elderly

Interactions

- Appendix 1: alpha blockers

Side-Effects

- Angioedema, asthenia, blurred vision, depression, dizziness, drowsiness, dry mouth, erectile disorders, extrapyramidal disorders, gastrointestinal disturbances, headache, hypersensitivity reactions, hypotension, incontinence, intra-operative floppy iris syndrome, oedema, palpitations, postural hypotension, priapism, pruritus, rash, rhinitis, syncope, tachycardia, urinary frequency

Downloaded from www.medicalbr.com
disorders · gastro-intestinal disturbances · headache · hypersensitivity reactions · hypotension (notably postural hypotension) · intra-operative floppy iris syndrome · oedema · palpitations · priapism · pruritus · rash · rhinitis · syncope · tachycardia

- **HEPATIC IMPAIRMENT** Avoid in severe impairment.
- **RENAL IMPAIRMENT** Use with caution if eGFR less than 10 mL/minute/1.73 m².
- **PATIENT AND CARER ADVICE**
  - Driving and skilled tasks
  - May affect performance of skilled tasks e.g. driving.
- **EXCEPTIONS TO LEGAL CATEGORY**
  - Tamsulosin hydrochloride 400 microgram capsules can be sold to the public for the treatment of functional symptoms of benign prostatic hyperplasia in men aged 45–75 years to be taken for up to 6 weeks before clinical assessment by a doctor.
- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
- **Modified-release tablet**
  - **Tamsulosin hydrochloride (Non-proprietary)**
    - Tamsulosin hydrochloride 400 microgram Tamsulosin 400 microgram modified-release tablets | 30 tablet (Pom) £10.47 DT price = £10.47
    - Cositam XL (Consilient Health Ltd)
    - Tamsulosin hydrochloride 400 microgram Cositam XL 400 microgram tablets | 30 tablet (Pom) £8.89 DT price = £10.47
    - Faramsil (Sandoz Ltd)
    - Tamsulosin hydrochloride 400 microgram Faramsil 400 microgram modified-release tablets | 30 tablet (Pom) £8.89 DT price = £10.47
    - Flectone XL (Teva UK Ltd)
    - Tamsulosin hydrochloride 400 microgram Flectone XL 400 microgram tablets | 30 tablet (Pom) £9.95 DT price = £10.47
    - Flomaxtra XL (Astellas Pharma Ltd)
    - Tamsulosin hydrochloride 400 microgram Flomaxtra XL 400 microgram modified-release tablets | 30 tablet (Pom) £10.47 DT price = £10.47
  - **Modified-release capsule**
    - **Tamsulosin hydrochloride (Non-proprietary)**
      - Tamsulosin hydrochloride 400 microgram Tamsulosin hydrochloride 400 microgram modified-release capsules | 30 capsule (Pom) £5.08 DT price = £3.89
    - Contiflo XL (Ranbaxy (UK) Ltd)
      - Tamsulosin hydrochloride 400 microgram Contiflo XL 400 microgram capsules | 30 capsule (Pom) £7.44 DT price = £3.89
    - Diffundox XL (Zentiva)
      - Tamsulosin hydrochloride 400 microgram Diffundox XL 400 microgram capsules | 30 capsule (Pom) £9.55 DT price = £3.89
    - Flomax MR (Boehringer Ingelheim Self-Medication Division)
      - Tamsulosin hydrochloride 400 microgram Flomax Relief MR 400 microgram capsules | 14 capsule (P) £5.58 | 28 capsule (P) £10.55
    - Galebon (Consilient Health Ltd)
      - Tamsulosin hydrochloride 400 microgram Galebon 400 microgram modified-release capsules | 30 capsule (Pom) £3.78 DT price = £3.89
    - Losinate MR (Aspire Pharma Ltd)
      - Tamsulosin hydrochloride 400 microgram Losinate MR 400 microgram capsules | 30 capsule (Pom) £10.14 DT price = £3.89
    - Pamsvax XL (Almus Pharmaceuticals Ltd, Actavis UK Ltd)
      - Tamsulosin hydrochloride 400 microgram Pamsvax XL 400 microgram capsules | 30 capsule (Pom) £1.31 DT price = £3.89
    - Petyme XL (Teva UK Ltd)
      - Tamsulosin hydrochloride 400 microgram Petyme 400 microgram MR capsules | 30 capsule (Pom) £4.06 DT price = £3.89
    - PineXel PR (Wockhardt UK Ltd)
      - Tamsulosin hydrochloride 400 microgram PineXel PR 400 microgram capsules | 30 capsule (Pom) £2.50 DT price = £3.89
    - Prosurin XL (Mylan Ltd)
      - Tamsulosin hydrochloride 400 microgram Prosurin XL 400 microgram capsules | 30 capsule (Pom) £4.28 DT price = £3.89
    - Tabphyn MR (Genus Pharmaceuticals Ltd)
      - Tamsulosin hydrochloride 400 microgram Tabphyn MR 400 microgram capsules | 30 capsule (Pom) £4.45 DT price = £3.89

- **Tamsulosin with dutasteride**
  - The properties listed below are those particular to the combination only. For the properties of the components please consider, tamsulosin hydrochloride p. 739, dutasteride p. 741.

  - **INDICATIONS AND DOSE**
    - **Benign prostatic hyperplasia**
      - **BY MOUTH**
      - Adult (male): 1 capsule daily.

  - **INTERACTIONS**
    - Appendix 1: alpha blockers, dutasteride

  - **PATIENT AND CARER ADVICE**
    - Driving and skilled tasks
    - May affect performance of skilled tasks e.g. driving.

  - **MEDICINAL FORMS**
    - There can be variation in the licensing of different medicines containing the same drug.
    - **Capsule**
      - **CAUTIONARY AND ADVISORY LABELS 25**
      - Combadot (GlaxoSmithKline UK Ltd)
        - Tamsulosin hydrochloride 400 microgram, Dutasteride 500 microgram Combadot 0.5mg/0.4mg capsules | 30 capsule (Pom) £23.76 DT price = £23.76

- **Tamsulosin with solifenacin**
  - The properties listed below are those particular to the combination only. For the properties of the components please consider, tamsulosin hydrochloride p. 739, solifenacin succinate p. 734.

  - **INDICATIONS AND DOSE**
    - Moderate to severe urinary frequency, urgency, and obstructive symptoms associated with benign prostatic hyperplasia when monotherapy ineffective
      - **BY MOUTH**
      - Adult (male): 1 tablet daily.

  - **DOSE ADJUSTMENTS DUE TO INTERACTIONS**
    - Manufacturer advises max. 1 Vesomni® tablet daily with concurrent use of potent inhibitors of CYP3A4; avoid concurrent use in patients who also have moderate hepatic impairment, severe renal impairment, are poor metabolisers of CYP2D6, or in patients also taking a potent inhibitor of CYP2D6.

  - **INTERACTIONS**
    - Appendix 1: alpha blockers, solifenacin

  - **HEPATIC IMPAIRMENT**
    - Max. 1 Vesomni® tablet daily in moderate impairment.

  - **RENAL IMPAIRMENT**
    - Max. 1 Vesomni® tablet daily if eGFR less than 30 mL/minute/1.73 m².

  - **MEDICINAL FORMS**
    - There can be variation in the licensing of different medicines containing the same drug.
    - **Modified-release tablet**
      - **CAUTIONARY AND ADVISORY LABELS 3, 25**
      - Vesomni (Astellas Pharma Ltd)
        - Tamsulosin hydrochloride 400 microgram, Solifenacin succinate 6 mg Vesomni 6mg/0.4mg modified-release tablets | 30 tablet (Pom) £27.62 DT price = £27.62
Terazosin

● INDICATIONS AND DOSE

Mild to moderate hypertension

BY MOUTH

Adult: 1 mg daily for 7 days, then increased if necessary to 2 mg daily, dose should be taken at bedtime; maintenance 2–10 mg once daily, doses above 20 mg rarely improve efficacy

Benign prostatic hyperplasia

BY MOUTH

Adult: Initially 1 mg daily, dose should be taken at bedtime, if necessary dose may be doubled at intervals of 1–2 weeks according to response; maintenance 5–10 mg daily; maximum 10 mg per day

● CONTRA-INDICATIONS

History of micturition syncope (in benign prostatic hyperplasia) - history of postural hypotension (in benign prostatic hyperplasia)

● CAUTIONS

Cataract surgery (risk of intra-operative floppy iris syndrome) - elderly - first dose

CAUTIONS, FURTHER INFORMATION

First dose may cause collapse due to hypotension within 30–90 minutes, therefore should be taken on retiring to bed; may also occur with rapid dose increase.

● INTERACTIONS → Appendix 1: alpha blockers

● SIDE-EFFECTS


● PREGNANCY

No evidence of teratogenicity; manufacturers advise use only when potential benefit outweighs risk.

● BREAST FEEDING

No information available.

● PATIENT AND CARER ADVICE

Patient counselling is advised for terazosin tablets (initial dose).

First dose effect First dose may cause collapse due to hypotensive effect (therefore should be taken on retiring to bed). Patient should be warned to lie down if symptoms such as dizziness, fatigue or sweating develop, and to remain lying down until they abate completely.

Driving and skilled tasks

May affect performance of skilled tasks e.g. driving.

● MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

Terazosin (Non-proprietary)

Terazosin (as Terazosin hydrochloride) 2 mg Terazosin 2mg tablets | 28 tablet (PO) £2.70 DT price = £1.92

Terazosin (as Terazosin hydrochloride) 5 mg Terazosin 5mg tablets | 28 tablet (PO) £3.34 DT price = £2.10

Terazosin (as Terazosin hydrochloride) 10 mg Terazosin 10mg tablets | 28 tablet (PO) £8.11 DT price = £7.87

Benph (Mylan Ltd)

Terazosin (as Terazosin hydrochloride) 2 mg Benph 2mg tablets | 28 tablet (PO) £1.87 DT price = £1.92

Terazosin (as Terazosin hydrochloride) 5 mg Benph 5mg tablets | 28 tablet (PO) £2.12 DT price = £2.10

Hytrin (AMCo)

Terazosin (as Terazosin hydrochloride) 1 mg Hytrin 1mg tablets | 7 tablet (PO) no price available

Terazosin (as Terazosin hydrochloride) 2 mg Hytrin 2mg tablets | 14 tablet (PO) no price available | 21 tablet (PO) no price available | 28 tablet (PO) £2.20 DT price = £1.92

Terazosin (as Terazosin hydrochloride) 5 mg Hytrin 5mg tablets | 7 tablet (PO) no price available | 28 tablet (PO) £4.13 DT price = £2.10

Terazosin (as Terazosin hydrochloride) 10 mg Hytrin 10mg tablets | 28 tablet (PO) £7.87 DT price = £7.87

Hytrin BPH tablets starter pack | 28 tablet (PO) £10.97

Hytrin tablets starter pack | 28 tablet (PO) £13.00

CHOLINE ESTERS

Bethanechol chloride

● INDICATIONS AND DOSE

Urinary retention

BY MOUTH

Adult: 10–25 mg 3–4 times a day, to be taken within 30 minutes before food

● CONTRA-INDICATIONS

Bradycardia - cardiovascular disorders - conditions where increased motility of the gastro-intestinal tract could be harmful - conditions where increased motility of the urinary tract could be harmful - epilepsy - heart block - hypothyroidism - hypotension - intestinal obstruction - obstructive airways disease - parkinsonism - peptic ulcer - recent myocardial infarction - urinary obstruction

● CAUTIONS

Autonomic neuropathy (use lower initial dose)

● SIDE-EFFECTS

Abdominal pain - bradycardia - bronchoconstriction - diarrhoea - eructation - flushing - headache - hypotension - increased lacrimation - increased salivation - increased sweating - nausea - rhinorrhoea - vomiting

● PREGNANCY

Manufacturer advises avoid — no information available.

● BREAST FEEDING

Manufacturer advises avoid; gastrointestinal disturbances in infant reported.

● LESS SUITABLE FOR PRESCRIBING

Less suitable for prescribing.

● MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Tablet

CAUTIONARY AND ADVISORY LABELS

Myotonine (Glenwood GmbH)

Bethanechol chloride 10 mg Myotonine 10mg tablets | 100 tablet (PO) £18.51

Bethanechol chloride 25 mg Myotonine 25mg tablets | 100 tablet (PO) £27.26

5α-REDUCTASE INHIBITORS

Dutasteride

● DRUG ACTION

A specific inhibitor of the enzyme 5α-reductase, which metabolises testosterone into the more potent androgen, dihydrotestosterone.

● INDICATIONS AND DOSE

Benign prostatic hyperplasia

BY MOUTH

Adult: 500 micrograms daily, review treatment at 3–6 months and then every 6–12 months (may require several months treatment before benefit is obtained)

● INTERACTIONS → Appendix 1: dutasteride

● SIDE-EFFECTS

Breast enlargement - breast tenderness - decreased libido - ejaculation disorders - impotence

● CONCEPTION AND CONTRACEPTION

Dutasteride is excreted in semen and use of a condom is recommended if sexual partner is pregnant or likely to become pregnant.

● HEPATIC IMPAIRMENT

Avoid in severe impairment — no information available.
**Finasteride**

**DRUG ACTION** A specific inhibitor of the enzyme 5α-reductase, which metabolises testosterone into the more potent androgen, dihydrotestosterone.

**INDICATIONS AND DOSE**

**Benign prostatic hyperplasia**
- **BY MOUTH**
  - Adult: 5 mg daily, review treatment at 3–6 months and then every 6–12 months (may require several months treatment before benefit is obtained)

**Androgenetic alopecia in men**
- **BY MOUTH**
  - Adult: 1 mg daily

**IMPORTANT SAFETY INFORMATION**

MHRA/CHM ADVICE: RARE REPORTS OF DEPRESSION AND SUICIDAL THOUGHTS (MAY 2017)

The MHRA has received reports of depression and, in rare cases, suicidal thoughts in men taking finasteride (*Proppecia*®) for male pattern hair loss; depression is also associated with *Proscar*® for benign prostatic hyperplasia. Patients should be advised to stop finasteride immediately and inform a healthcare professional if they develop depression.

**CAUTIONS**
- Obstructive uropathy

**SIDE-EFFECTS**
- Rare: Depression - suicidal ideation
- Frequency not known: Breast enlargement - breast tenderness - decreased libido - ejaculation disorders - face swelling - hypersensitivity reactions - impotence - lip swelling - male breast cancer - pruritus - rash - testicular pain

**CONCEPTION AND CONTRACEPTION** Finasteride is excreted in semen and use of a condom is recommended if sexual partner is pregnant or likely to become pregnant.

**EFFECT ON LABORATORY TESTS** Decreases serum concentration of prostate cancer markers such as prostate-specific antigen; reference values may need adjustment.

**HANDLING AND STORAGE** Women of childbearing potential should avoid handling crushed or broken tablets of finasteride.

**PATIENT AND CARER ADVICE** Cases of male breast cancer have been reported. Patients or their carers should be told to promptly report to their doctor any changes in breast tissue such as lumps, pain, or nipple discharge.

**NATIONAL FUNDING/ACCESS DECISIONS**

NHS restrictions Finasteride is not prescribable under the NHS for the treatment of androgenetic alopecia in men.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

**Capsule**

**CAUTIONARY AND ADVISORY LABELS**

**SIDE-EFFECTS**

- **Finasteride (Non-proprietary)**
  - Finasteride 1 mg: Finasteride 1mg tablets | 28 tablet [PoM] no price available
  - Finasteride 5 mg: Finasteride 5mg tablets | 28 tablet [PoM] £11.85 DT price = £1.12
  - Aindeem (Actavis UK Ltd)
    - Finasteride 1 mg: Aindeem 1mg tablet | 28 tablet [PoM] £33.68 | 84 tablet [PoM] £88.40
  - Propecia (Merck Sharp & Dohme Ltd)
    - Finasteride 1 mg: Propecia 1mg tablets | 28 tablet [PoM] £33.68 | 84 tablet [PoM] £88.40
  - Proscar (Merck Sharp & Dohme Ltd)
    - Finasteride 5 mg: Proscar 5mg tablets | 28 tablet [PoM] £13.94 DT price = £1.12

**1.3 Urological pain**

**Urological pain**

**Treatment**

The acute pain of *ureteric colic* may be relieved with pethidine hydrochloride p. 445. *Diclofenac* by injection or as suppositories is also effective and compares favourably with pethidine hydrochloride; other non-steroidal anti-inflammatory drugs are occasionally given by injection.

Lidocaine hydrochloride gel is a useful topical application in *urethral pain* or to relieve the discomfort of catheterisation.

**Alkalisation of urine**

*Alkalisation* of urine can be undertaken with potassium citrate. The alkalising action may relieve the discomfort of *cystitis* caused by lower urinary tract infections. Sodium bicarbonate p. 950 is used as a urinary alkalising agent in some metabolic and renal disorders.

**ALKALISING DRUGS**

**Citric acid with potassium citrate**

**INDICATIONS AND DOSE**

**Relief of discomfort in mild urinary-tract infections**

**Alkalisation of urine**

- **BY MOUTH USING ORAL SOLUTION**
  - Adult: 10 mL 3 times a day, diluted well with water

**CAUTIONS**
- Cardiac disease - elderly

**INTERACTIONS** → Appendix 1: potassium citrate

**SIDE-EFFECTS**
- Hyperkalaemia on prolonged high dosage - mild diuresis

**RENAL IMPAIRMENT** Avoid in severe impairment. Close monitoring required in renal impairment—high risk of hyperkalaemia.

**PRESCRIBING AND DISPENSING INFORMATION**

When prepared extemporaneously, the BP states Potassium Citrate Mixture BP consists of potassium citrate 30%, citric acid monohydrate 5% in a suitable vehicle with a lemon flavour. Extemporaneous preparations should be recently prepared according to the following formula: potassium citrate 3 g, citric acid monohydrate 500 mg, syrup 2.5 mL, quillia tincture 0.1 mL, lemon spirit 0.05 mL, double-
Sodium citrate

**INDICATIONS AND DOSE**

**Bladder washouts**
- Adult: (consult product literature)

**Relief of discomfort in mild urinary-tract infections**
- **BY MOUTH**
- **Adult:** (consult product literature)

**MICOLETTE®**

**Constipation**
- **BY RECTUM**
  - Child 3-17 years: 5–10 mL for 1 dose
  - Adult: 5–10 mL for 1 dose

**MICRALAX®**

**Constipation**
- **BY RECTUM**
  - Child 3-17 years: 5 mL for 1 dose
  - Adult: 5 mL for 1 dose

**RELAXIT®**

**Constipation**
- **BY RECTUM**
  - Child 1 month-2 years: 5 mL for 1 dose, insert only half the nozzle length
  - Child 3-17 years: 5 mL for 1 dose
  - Adult: 5 mL for 1 dose

**CONTRA-INDICATIONS**
- With rectal use Acute gastro-intestinal conditions

**CAUTIONS**
- With oral use Cardiac disease · elderly · hypertension · patients on a sodium-restricted diet
- With rectal use Debilitated patients (in adults) · sodium and water retention in susceptible individuals

**INTERACTIONS**
- Appendix 1: sodium citrate

**SIDE-EFFECTS**
- With oral use Mild diuresis

**PREGNANCY**
- With oral use Use with caution.

**RENAL IMPAIRMENT**
- With oral use In patients with fluid retention, avoid antacids containing large amounts of sodium.

**PRESCRIBING AND DISPENSING INFORMATION**
- Sodium citrate 300 mmol/litre (88.2 mg/mL) oral solution is licensed for use before general anaesthesia for caesarean section (available from Viridian).

**EXCEPTIONS TO LEGAL CATEGORY**
- Proprietary brands of sodium citrate are on sale to the public for the relief of discomfort in mild urinary-tract infections.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

**Granules**
- **Sodium citrate (Non-proprietary)**
  - Sodium citrate 4 gram Cystitis Relief 4g oral granules sachets | 6 sachets (£) £2.38
  - Brands may include Cymal (sodium citrate), Cystocalm

**Oral solution**
- **Sodium citrate (Non-proprietary)**
  - Sodium citrate 88.23 mg per 1 mL Sodium citrate 0.3M oral solution | 30 mL (Box) £4.50
  - Sodium citrate 441.17mg/5ml oral solution | 30 mL (Box) no price available

**Powder**
- **Sodium citrate (Non-proprietary)**
  - Sodium citrate 1 mg per 1 mg Sodium citrate powder | 500 gram (£) £6.86 DT price = £6.86

**Irrigation solution**
- **Sodium citrate (Non-proprietary)**
  - Sodium citrate 3% irrigation solution 1litre bags | 1 bag no price available

**Enema**
- **Micolette Micro-enema** (Pinewood Healthcare)
  - Sodium citrate 90 mg per 1 mL Micolette Micro-enema 5ml | 12 enema (£) £4.26
  - Micralax Micro-enema (Focus Pharmaceuticals Ltd)
  - Sodium citrate 90 mg per 1 mL Micralax Micro-enema 5ml | 12 enema (£) £4.87
  - Relaxit (Supra Enterprises Ltd)
  - Sodium citrate 90 mg per 1 mL Relaxit Micro-enema 5ml | 12 enema £5.21

**TERPENES**

Anethol with borneol, camphene, cineole, fenchone and pinene

**INDICATIONS AND DOSE**

**Urolithiasis for the expulsion of calculi**
- **BY MOUTH**
- **Adult:** 1–2 capsules 3–4 times a day, to be taken before food

**LESS SUITABLE FOR PRESCRIBING**
- Preparation is less suitable for prescribing.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.

**Capsule**
- **CAUTIONARY AND ADVISORY LABELS**
- **Rowatinex** (Meadow Laboratories Ltd)
  - Cineole 3 mg, Anethol 4 mg, Fenchone 4 mg, Borneol 10 mg, Camphene 15 mg, Pinene 31 mg Rowatinex capsules | 50 capsule (Pom) £7.35

2 Bladder instillations and urological surgery

Bladder instillations and urological surgery

Bladder infection

Various solutions are available as irrigations or washouts. Aqueous chlorhexidine p. 1108 can be used in the management of common infections of the bladder but it is ineffective against most *Pseudomonas spp.* Solutions containing chlorhexidine 1 in 5000 (0.02%) are used but they...
may irritate the mucosa and cause burning and haematuria (in which case they should be discontinued); sterile sodium chloride solution 0.9% (physiological saline) is usually adequate and is preferred as a mechanical irrigant.

Continuous bladder irrigation with amphotericin p. 561 50 micrograms/mL may be of value in mycotic infections in adults.

**Dissolution of blood clots**

Clot retention is usually treated by irrigation with sterile sodium chloride solution 0.9% but sterile sodium citrate solution for bladder irrigation 3% p. 743 may also be helpful.

**Bladder cancer**

Bladder instillations of doxorubicin hydrochloride p. 835 and mitomycin p. 850 are used for recurrent superficial bladder tumours. Such instillations reduce systemic side-effects; adverse effects on the bladder (e.g. micturition disorders and reduction in bladder capacity) may occur.

Instillation of epirubicin hydrochloride p. 836 is used for treatment and prophylaxis of certain forms of superficial bladder cancer; instillation of doxorubicin hydrochloride is also used for some papillary tumours.

Instillation of BCG (Bacillus Calmette-Guérin p. 884), a live attenuated strain derived from Mycobacterium bovis is licensed for the treatment of primary or recurrent bladder carcinoma in-situ and for the prevention of recurrence following transurethral resection.

**Urological surgery**

Glycine below irrigation solution 1.5% is the irrigant of choice for transurethral resection of the prostate gland and bladder tumours; sterile sodium chloride solution 0.9% (physiological saline) is used for percutaneous renal surgery.

**Maintenance of indwelling urinary catheters**

The deposition which occurs in catheterised patients is usually chiefly composed of phosphate and to minimise this the catheter (if latex) should be changed at least as often as every 6 weeks. If the catheter is to be left for longer periods a silicone catheter should be used together with the appropriate use of catheter maintenance solutions. Repeated blockage usually indicates that the catheter needs to be changed.

**ANTISEPTICS AND DISINFECTANTS**

### Chlorhexidine with lidocaine

The properties listed below are those particular to the combination only. For the properties of the components please consider, chlorhexidine p. 1108, lidocaine hydrochloride p. 1242.

#### INDICATIONS AND DOSE

**Urethral sounding and catheterisation**

- **Adult:** 6–11 mL

**Cystoscopy**

- **Adult:** 11 mL, then 6–11 mL if required

#### INTERACTIONS

→ Appendix 1: antiarrhythmics

#### MEDICINAL FORMS

- **Excipients:** May contain hydroxybenzoates (parabens)
- **Instillagel (Clinimed Ltd)**

Chlorhexidine gluconate 500 microgram per 1 ml, Lidocaine hydrochloride 20 mg per 1 ml Instillagel gel 60 mL £14.05 DT price = £11.00 110 mL  

<table>
<thead>
<tr>
<th>Price</th>
<th>Price DT</th>
</tr>
</thead>
<tbody>
<tr>
<td>£15.76</td>
<td>£15.76</td>
</tr>
</tbody>
</table>

### IRRIGATING SOLUTIONS

#### Glycine

- **INDICATIONS AND DOSE**

Bladder irrigation during urological surgery | Irrigation for transurethral resection of the prostate gland and bladder tumours

- **Adult:** (consult product literature)

- **CAUTIONS**

FURTHER INFORMATION

- **Urological surgery** There is a high risk of fluid absorption from the irrigant used in endoscopic surgery within the urinary tract.

- **SIDE-EFFECTS** Haemolysis • Hypervolaemia • Renal failure

#### MEDICINAL FORMS

- There can be variation in the licensing of different medicines containing the same drug.

### IRRIGATING SOLUTIONS

#### Glycine

- **INDICATIONS AND DOSE**

Bladder irrigation during urological surgery | Irrigation for transurethral resection of the prostate gland and bladder tumours

- **Adult:** (consult product literature)

#### CAUTIONS

- **Urological surgery** There is a high risk of fluid absorption from the irrigant used in endoscopic surgery within the urinary tract.

#### SIDE-EFFECTS

- Haemolysis • Hypervolaemia • Renal failure

### MEDICINAL FORMS

- There can be variation in the licensing of different medicines containing the same drug.

#### INTRAVESICAL INSTALLATION

- **Glycine (Non-proprietary)**

Glycine 1.5% irrigation solution 3 litre Easyflow bags | 1 bottle no price available

Glycine 1.5% irrigation solution 1 litre Flowfusor bottles | 1 bottle no price available

Glycine 1.5% irrigation solution 1 litre Easyflow bags | 1 bottle no price available

Glycine 1.5% irrigation solution 2 litre Flowfusor bottles | 1 bottle no price available

### UROLOGICAL ANTI-INFLAMMATORY DRUGS

#### Dimethyl sulfoxide

- **INDICATIONS AND DOSE**

Symptomatic relief in interstitial cystitis (Hunner’s ulcer)

- **BY INTRAVESICAL INSTALLATION**

- **Adult:** 50 mL every 2 weeks retained for 15 minutes then voided by the patient, 50% solution is used and instilled into the bladder

- **SIDE-EFFECTS** Bladder spasm • Hypersensitivity

- **MONITORING REQUIREMENTS** Ophthalmic, renal and hepatic assessments at intervals of 6 months are required in long-term treatment.

#### MEDICINAL FORMS

- There can be variation in the licensing of different medicines containing the same drug.

#### Liquid

- **RIMSO-50 (Thornton & Ross Ltd)**

Dimethyl sulfoxide 500 mg per 1 ml RIMSO-50 solution for installation | 50 ml | Poun £324.00

### Catheter maintenance solutions

#### CATHETER MAINTENANCE SOLUTIONS

OptiFlo R citric acid 6% catheter maintenance solution (Bard Ltd) 50 mL • NHS indicative price = £3.60 • Drug Tariff (Part IXa) 100 mL • NHS indicative price = £3.60 • Drug Tariff (Part IXa)

Uro-Tainer Twin Solution R citric acid 6% catheter maintenance solution (B. Braun Medical Ltd) 60 mL • NHS indicative price = £4.81 • Drug Tariff (Part IXa)

OptiFlo S saline 0.9% catheter maintenance solution (Bard Ltd) Sodium chloride 9 mg per 1 mL 50 mL • NHS indicative price = £3.39 • Drug Tariff (Part IXa) 100 mL • NHS indicative price = £3.39 • Drug Tariff (Part IXa)

Uro-Tainer M sodium chloride 0.9% catheter maintenance solution (B. Braun Medical Ltd) Sodium chloride 9 mg per 1 mL 50 mL • No NHS indicative price available • Drug Tariff (Part IXa) 100 mL • No NHS indicative price available • Drug Tariff (Part IXa)
3 Contraception

Contraceptives, hormonal

Overview
The Fraser Guidelines (Department of Health Guidance (July 2004): Best practice guidance for doctors and other health professionals on the provision of advice and treatment to young people under 16 on contraception, sexual and reproductive health, available at www.tinyurl.com/bpg16) should be followed when prescribing contraception for women under 16 years. The UK Medical Eligibility Criteria for Contraceptive Use (available at www.fsrh.org) is published by the Faculty of Sexual and Reproductive Healthcare; it categorises the risks of using contraceptive methods with pre-existing medical conditions.

Hormonal contraception is the most effective method of fertility control, but can have major and minor side-effects, especially for certain groups of women. Hormonal contraception should only be used by adolescents after menarche.

Intra-uterine devices are a highly effective method of contraception but may produce undesirable local side-effects. They may be used in women of all ages irrespective of parity, but are less appropriate for those with an increased risk of pelvic inflammatory disease.

Barrier methods alone (condoms, diaphragms, and caps) are less effective but can be reliable for well-motivated couples if used in conjunction with a spermicide. Occasionally sensitivity reactions occur. A female condom (Femidom®) is also available; it is pre-lubricated but does not contain a spermicide.

Combined hormonal contraceptives

Oral contraceptives containing an oestrogen and a progestogen (‘combined oral contraceptives’) are effective preparations for general use. Advantages of combined oral contraceptives include:

- reliable and reversible;
- reduced dysmenorrhoea and menorrhagia;
- reduced incidence of premenstrual tension;
- less symptomatic fibroids and functional ovarian cysts;
- less benign breast disease;
- reduced risk of ovarian and endometrial cancer;
- reduced risk of pelvic inflammatory disease.

Combined oral contraceptives containing a fixed amount of an oestrogen and a progestogen in each active tablet are termed ‘monophasic’; those with varying amounts of the two hormones are termed ‘phasic’. A transdermal patch and a vaginal ring, both containing an oestrogen with a progestogen, are also available.
Combined Oral Contraceptives Phasic 21-day preparations

<table>
<thead>
<tr>
<th>Oestrogen content</th>
<th>Progestogen content</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethinylestradiol 30 micrograms</td>
<td>Gestodene</td>
<td>Triadene®</td>
</tr>
<tr>
<td>Ethinylestradiol 40 micrograms</td>
<td>Gestodene</td>
<td>Logyron®</td>
</tr>
<tr>
<td>Ethinylestradiol 30 micrograms</td>
<td>Levonorgestrel</td>
<td>TriRegol®</td>
</tr>
<tr>
<td>Ethinylestradiol 35 micrograms</td>
<td>Norethisterone</td>
<td>Synphase®</td>
</tr>
<tr>
<td>Ethinylestradiol 35 micrograms</td>
<td>Norethisterone 1 mg</td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol 35 micrograms</td>
<td>Norethisterone 500 micrograms</td>
<td></td>
</tr>
</tbody>
</table>

Combined Oral Contraceptives Phasic 28-day preparations

<table>
<thead>
<tr>
<th>Oestrogen content</th>
<th>Progestogen content</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethinylestradiol 30 micrograms</td>
<td>Levonorgestrel</td>
<td>Logynon ED®</td>
</tr>
<tr>
<td>Ethinylestradiol 40 micrograms</td>
<td>Levonorgestrel</td>
<td></td>
</tr>
<tr>
<td>Ethinylestradiol 30 micrograms</td>
<td>Levonorgestrel</td>
<td></td>
</tr>
<tr>
<td>Estradiol valerate 3 mg</td>
<td>Dienogest 2 mg</td>
<td>Qlaira®</td>
</tr>
<tr>
<td>Estradiol valerate 2 mg</td>
<td>Dienogest 3 mg</td>
<td></td>
</tr>
<tr>
<td>Estradiol valerate 1 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Choice

The majority of combined oral contraceptives contain ethinylestradiol p. 715 as the oestrogen component; mestranol and estradiol are also used. The ethinylestradiol content of combined oral contraceptives ranges from 20 to 40 micrograms. Generally a preparation with the lowest oestrogen and progestogen content which gives good cycle control and minimal side-effects in the individual woman is chosen. It is recommended that combined hormonal contraceptives are not continued beyond 50 years of age since more suitable alternatives exist.

- **Low strength preparations** (containing ethinylestradiol 20 micrograms) are particularly appropriate for women with risk factors for circulatory disease, provided a combined oral contraceptive is otherwise suitable.
- **Standard strength preparations** (containing ethinylestradiol 30 or 35 micrograms or in 30–40 microgram phased preparations) are appropriate for standard use. Phased preparations are generally reserved for women who either do not have withdrawal bleeding or who have breakthrough bleeding with monophasic products.

The progestogens ethinylestradiol with desogestrel p. 751, ethinylestradiol with drospirenone p. 752, and ethinylestradiol with gestodene p. 753 may be considered for women who have side-effects (such as acne, headache, depression, breast symptoms, and breakthrough bleeding) with other progestogens. Drospirenone, a derivative of spironolactone, has anti-androgenic and anti-mineralocorticoid activity; it should be used with care if an increased plasma-potassium concentration might be hazardous.

Dienogest with estradiol valerate p. 751 is in the combined oral contraceptive Qlaira®. Nomegestrol is the progestogen contained in the combined oral contraceptive Zoely®, in combination with estradiol.

The progestogen norelgestromin is combined with ethinylestradiol in a transdermal patch (Evra®). The vaginal contraceptive ring contains the progestogen etonogestrel combined with ethinylestradiol (NuvaRing®).

Surgery

Oestrogen-containing contraceptives should preferably be discontinued (and adequate alternative contraceptive arrangements made) 4 weeks before major elective surgery and all surgery to the legs or surgery which involves prolonged immobilisation of a lower limb; they should normally be recommenced at the first menses occurring at least 2 weeks after full mobilisation. A progestogen-only contraceptive may be offered as an alternative and the oestrogen-containing contraceptive restarted after mobilisation. When discontinuation of an oestrogen-containing contraceptive is not possible, e.g. after trauma or if a patient admitted for an elective procedure is still on an oestrogen-containing contraceptive, thromboprophylaxis (with unfractionated or low molecular weight heparin and graduated compression hosiery) is advised. These recommendations do not apply to minor surgery with short duration of anaesthesia, e.g. laparoscopic sterilisation or tooth extraction, or to women using oestrogen-free hormonal contraceptives.

Reason to stop immediately

Combined hormonal contraceptives or hormone replacement therapy (HRT) should be stopped (pending investigation and treatment), if any of the following occur:

- sudden severe chest pain (even if not radiating to left arm);
- sudden breathlessness (or cough with blood-stained sputum);
- unexplained swelling or severe pain in calf of one leg;
- severe stomach pain;
- serious neurological effects including unusual severe, prolonged headache especially if first time or getting progressively worse or sudden partial or complete loss of vision or sudden disturbance of hearing or other perceptual disorders or dysphasia or bad fainting attack or collapse or first unexplained epileptic seizure or weakness, motor disturbances, very marked numbness suddenly affecting one side or one part of body;
- hepatitis, jaundice, liver enlargement;
- blood pressure above systolic 160 mmHg or diastolic 95 mmHg; (in adolescents stop if blood pressure very high);
- prolonged immobility after surgery or leg injury;
- detection of a risk factor which contra-indicates treatment.
Progestogen-only contraceptives

Oral progestogen-only contraceptives

Oral progestogen-only preparations after cervical mucus to prevent sperm penetration and may inhibit ovulation in some women; oral desogestrel-only preparations consistently inhibit ovulation and this is their primary mechanism of action. There is insufficient clinical trial evidence to compare the efficacy of oral progestogen-only contraceptives with each other or with combined hormonal contraceptives. Progestogen-only contraceptives offer a suitable alternative to combined hormonal contraceptives when oestrogens are contra-indicated (including those with venous thrombosis or a past history or predisposition to venous thrombosis, heavy smokers, those with hypertension above systolic 160 mmHg or diastolic 95 mmHg, valvular heart disease, diabetes mellitus with complications, and migraine with aura).

Parenteral progestogen-only contraceptives

Medroxyprogesterone acetate p. 763 (Depo-Provera®, SAYANA PRESS®) is a long-acting progestogen given by injection; it is at least as effective as the combined oral preparations but because of its prolonged action it should never be given without full counselling backed by the patient information leaflet. It may be used as a short-term or long-term contraceptive for women who have been counselled about the likelihood of menstrual disturbance and the potential for a delay in return to full fertility. Delayed return of fertility and irregular cycles may occur after discontinuation of treatment but there is no evidence of permanent infertility. Troublesome bleeding has been reported in patients given medroxyprogesterone acetate in the immediate puerperium; delaying the first injection until 6 weeks after birth may minimise bleeding problems. If the woman is not breast-feeding, the first injection may be given within 5 days postpartum (she should be warned that the risk of troublesome bleeding may be increased).

- In adolescents, medroxyprogesterone acetate (Depo-Provera®, SAYANA PRESS®) should be used only when other methods of contraception are inappropriate;
- in all women, the benefits of using medroxyprogesterone acetate beyond 2 years should be evaluated against the risks;
- in women with risk factors for osteoporosis, a method of contraception other than medroxyprogesterone acetate should be considered.

Norethisterone enantate (Noristerat®) is a long-acting progestogen given as an oily injection which provides contraception for 8 weeks; it is used as short-term interim contraception e.g. before vasectomy becomes effective.

An etonogestrel-releasing implant (Nexplanon®) is also available. It is a highly effective long-acting contraceptive, consisting of a single flexible rod that is inserted subdermally into the lower surface of the upper arm and provides contraception for up to 3 years. The manufacturer advises that in heavier women, blood-etonogestrel concentrations are lower and therefore the implant may not provide effective contraception during the third year; they advise that earlier replacement may be considered in such patients—however, evidence to support this recommendation is lacking. Local reactions such as bruising and itching can occur at the insertion site. The contraceptive effect of etonogestrel is rapidly reversed on removal of the implant.

Intra-uterine progestogen-only device

The progestogen-only intra-uterine systems Mirena®, Jaydess® and Levosert® release levonorgestrel p. 759 directly into the uterine cavity. Mirena® is licensed for use as a contraceptive, for the treatment of primary menorrhagia and for the prevention of endometrial hyperplasia during oestrogen replacement therapy. Jaydess® and Levosert® are licensed for contraception, and Levosert® is additionally licensed for the treatment of menorrhagia. These may therefore be a contraceptive method of choice for women who have excessively heavy menses.

The effects of the progestogen-only intra-uterine system are mainly local and hormonal including prevention of endometrial proliferation, thickening of cervical mucus, and suppression of ovulation in some women (in some cycles). In addition to the progestogenic activity, the intra-uterine system itself may contribute slightly to the contraceptive effect. Return of fertility after removal is rapid and appears to be complete.

Advantages of the progestogen-only intra-uterine system over copper intra-uterine devices are that there may be an improvement in any dysmenorrhea and a reduction in blood loss; there is also evidence that the frequency of pelvic inflammatory disease may be reduced (particularly in the youngest age groups who are most at risk).

In primary menorrhagia, menstrual bleeding is reduced significantly within 3–6 months of inserting the progestogen-only intra-uterine system, probably because it prevents endometrial proliferation. Another treatment should be considered if menorrhagia does not improve within this time.

Surgery

All progestogen-only contraceptives (including those given by injection) are suitable for use as an alternative to combined hormonal contraceptives before major elective surgery, before all surgery to the legs, or before surgery which involves prolonged immobilisation of a lower limb.

Emergency contraception

Hormonal methods

Hormonal emergency contraceptives include levonorgestrel and ulipristal acetate p. 757; either drug should be taken as soon as possible after unprotected intercourse to increase efficacy.

Levonorgestrel is effective if taken within 72 hours (3 days) of unprotected intercourse and may also be used between 72 and 96 hours after unprotected intercourse (unlicensed use), but efficacy decreases with time. Ulipristal acetate, a progestosterone receptor modulator, is effective if taken within 120 hours (5 days) of unprotected intercourse.

Levonorgestrel is less effective than insertion of an intra-uterine device. Ulipristal acetate is as effective as levonorgestrel, but its efficacy compared to an intra-uterine device is not yet known.

Intra-uterine device

Insertion of an intra-uterine device is more effective than oral levonorgestrel for emergency contraception. A copper intra-uterine contraceptive device can be inserted up to 120 hours (5 days) after unprotected intercourse; sexually transmitted infections should be tested for and insertion of the device should usually be covered by antibacterial prophylaxis (e.g. azithromycin p. 507). If intercourse has occurred more than 5 days previously, the device can still be inserted up to 5 days after the earliest likely calculated ovulation (i.e. within the minimum period before implantation), regardless of the number of episodes of unprotected intercourse earlier in the cycle.

Contraceptives, interactions

Overview

The effectiveness of combined oral contraceptives, progestagen-only oral contraceptives, contraceptive patches, vaginal rings, and emergency hormonal contraception can be considerably reduced by interaction with drugs that induce hepatic enzyme activity (e.g. carbamazepine p. 297, eslicarbazepine acetate p. 299, nevirapine p. 609, oxcarbazepine p. 306, phenytoin p. 308, phenobarbital p. 318,
Combined hormonal contraceptives interactions

Women using combined hormonal contraceptive patches, vaginal rings or oral tablets who require enzyme-inducing drugs or griseofulvin should be advised to change to a reliable contraceptive method that is unaffected by enzyme-inducers, such as some parenteral progesteron-only contraceptives (medroxyprogesterone acetate p. 763 and norethisterone p. 720) or intra-uterine devices (levonorgestrel p. 759; see also Contraceptives, non-hormonal p. 749). This should be continued for the duration of treatment and for four weeks after stopping. If a change in contraceptive method is undesirable or inappropriate the following options should be discussed: 

Short course (2 months or less) of an enzyme-inducing drug

Continuing the combined hormonal contraceptive method may be appropriate if used in combination with consistent and careful use of condoms for the duration of treatment and for four weeks after stopping the enzyme-inducing drug. 

Long-term course (over 2 months) of an enzyme-inducing drug (except rifampicin or rifabutin) or a course of griseofulvin

Use a monophasic combined oral contraceptive at a dose of ethinylestradiol 50 micrograms or more daily [unlicensed use] and use either an extended or a ‘tricycling’ regimen (i.e. taking three packets of monophasic tablets without a break followed by a shortened tablet-free interval of four days [unlicensed use]); continue for the duration of treatment with the interacting drug and for four weeks after stopping. 

If breakthrough bleeding occurs (and all other causes are ruled out) it is recommended that the dose of ethinylestradiol is increased by increments of 10 micrograms up to a maximum of 70 micrograms daily [unlicensed use] on specialist advice, or to use additional precautions, or to change to a method unaffected by the interacting drugs. 

Use of contraceptive patches and vaginal rings (including concurrent use of two patches or two vaginal rings) is not recommended for women taking enzyme-inducing drugs over a long period. 

Long-term course (over 2 months) of rifampicin or rifabutin

An alternative method of contraception (such as an IUD) is always recommended because they are such potent enzyme-inducing drugs; the alternative method of contraception should be continued for four weeks after stopping the enzyme-inducing drug. 

Antibacterials that do not induce liver enzymes

It is recommended that no additional contraceptive precautions are required when combined oral contraceptives, contraceptive patches or vaginal rings are used with antibacterials that do not induce liver enzymes, unless diarrhoea or vomiting occur. These recommendations should be discussed with the woman. 

There had been concerns that some antibacterials that do not induce liver enzymes (e.g. ampicillin p. 520, doxycycline p. 534) reduce the efficacy of combined oral contraceptives by impairing the bacterial flora responsible for recycling ethinylestradiol from the large bowel. However, there is a lack of evidence to support this interaction. 

Oral progestogen-only contraceptives interactions

Effectiveness of oral progestogen-only preparations is not affected by antibacterials that do not induce liver enzymes. 

The efficacy of oral progestogen-only preparations is, however, reduced by enzyme-inducing drugs or griseofulvin and an alternative contraceptive method, unaffected by the interacting drug, is recommended during treatment with an interacting drug and for at least 4 weeks afterwards. 

For a short course of an enzyme-inducing drug (less than two months), continuing the progestogen-only oral method may be appropriate if used in combination with consistent and careful use of condoms for the duration of treatment and for four weeks after stopping the enzyme-inducing drug. 

Parenteral progestogen-only contraceptives interactions

Effectiveness of parenteral progestogen-only contraceptives is not affected by antibacterials that do not induce liver enzymes. 

The effectiveness of intramuscular norethisterone injection and intramuscular and subcutaneous medroxyprogesterone acetate injections is not affected by enzyme-inducing drugs and they may be continued as normal during courses of these drugs. 

Effectiveness of the etonogestrel-releasing implant p. 762 may be reduced by enzyme-inducing drugs or griseofulvin and an alternative contraceptive method, unaffected by the interacting drug, is recommended during treatment with the interacting drug and for at least 4 weeks after stopping. 

For a short course of an enzyme-inducing drug, if a change in contraceptive method is undesirable or inappropriate, continued contraception with the implant may be appropriate if used in combination with consistent and careful use of condoms for the duration of treatment and for 4 weeks after stopping the enzyme-inducing drug. 

Hormonal emergency contraception interactions

The effectiveness of levonorgestrel and ulipristal acetate p. 757 is reduced in women taking enzyme-inducing drugs or griseofulvin (and for at least 4 weeks after stopping). 

A copper intra-uterine device can be offered instead. If the copper intra-uterine device is declined or unsuitable, the dose of levonorgestrel should be increased (See Dose adjustments due to interactions under levonorgestrel). There is no need to increase the dose for emergency contraception if the patient is taking antibacterials that are not enzyme inducers. 

The effectiveness of ulipristal acetate for emergency contraception may be reduced by drugs that increase gastric pH (such as regular use of antacids, H₂ receptor antagonists and proton pump inhibitors). 

Levonorgestrel or a copper intra-uterine device should be considered as alternatives. 

Hormonal contraception should not be newly initiated in a patient until five days after administration of ulipristal acetate as emergency hormonal contraception— the contraceptive effect of ulipristal acetate will be reduced. Consistent and careful use of condoms is recommended. Ulipristal acetate can be used as emergency hormonal contraception more than once in the same cycle. 

Conversely, manufacturer advises that use of levonorgestrel as emergency contraception more than once in the same cycle is not advisable due to increased risk of side-effects (such as menstrual irregularities). 

Levonorgestrel should not be used (as emergency hormonal contraception) within 5 days of administration of ulipristal acetate (as emergency hormonal contraception), as the contraceptive effect of ulipristal acetate may be reduced by progestogens. 

Ulipristal acetate is not recommended for use in women who have severe asthma treated by oral corticosteroids, due to the antiglucocorticoid effect of ulipristal acetate. 

Useful Resources


Contraceptives, non-hormonal

Spermicidal contraceptives

Spermicidal contraceptives are useful additional safeguards but do not give adequate protection if used alone unless fertility is already significantly diminished. They have two components: a spermicide and a vehicle which itself may have some inhibiting effect on sperm activity. They are suitable for use with barrier methods, such as diaphragms or caps; however, spermicidal contraceptives are not generally recommended for use with condoms, as there is no evidence of any additional protection compared with non-spermicidal lubricants.

Spermicidal contraceptives are not suitable for use in those with or at high risk of sexually transmitted infections (including HIV); high frequency use of the spermicide nonoxinol-9 p. 764 has been associated with genital lesions, which may increase the risk of acquiring these infections.

Contraceptive devices

Intra-uterine devices

The intra-uterine device (IUD) is a suitable contraceptive for women of all ages irrespective of parity; however, it is less appropriate for those with an increased risk of pelvic inflammatory disease e.g. women under 25 years.

The most effective intra-uterine devices have at least 380 mm² of copper and have banded copper on the arms. Smaller devices have been introduced to minimise side-effects; these consist of a plastic carrier wound with copper wire or fitted with copper bands; some also have a central core of silver to prevent fragmentation of the copper.

Fertility declines with age and therefore a copper intra-uterine device which is fitted in a woman over the age of 40, may remain in the uterus until menopause.

A frameless, copper-bearing intra-uterine device (GyneFix™) is also available. It consists of a knotted, polypropylene thread with 6 copper sleeves; the device is anchored in the uterus by inserting the knot into the uterine fundus.

Caution with oil-based lubricants

Products such as petroleum jelly (Vaseline®), baby oil and oil-based vaginal and rectal preparations are likely to damage condoms and contraceptive diaphragms made from latex rubber, and may render them less effective as a barrier method of contraception and as a protection from sexually transmitted infections (including HIV).

3.1 Contraception, combined

OESTROGENS COMBINED WITH PROGESTOGENS

Combined hormonal contraceptives

- CONTRA-INDICATIONS Acute porphyrias p. 969 • gallstones • heart disease associated with pulmonary hypertension or risk of embolus • history during pregnancy of cholestatic jaundice • history during pregnancy of choorea • history during pregnancy of pempigoid gestationis • history during pregnancy of pruritus • history of breast cancer (but can be used after 5 years if no evidence of disease and non-hormonal methods unacceptable) • history of haemolytic uraemic syndrome • migraine with aura • personal history of venous or arterial thrombosis • sclerosing treatment for varicose veins • severe or multiple risk factors for arterial disease • severe or multiple risk factors for venous thromboembolism • systemic lupus erythematosus with (or unknown) antiphospholipid antibodies • transient ischaemic attacks without headaches • undiagnosed vaginal bleeding

- CAUTIONS Active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration)—seek specialist advice • Crohn’s disease • gene mutations associated with breast cancer (e.g. BRCA 1) • history of severe depression especially if induced by hormonal contraceptive • hyperprolactinaemia (seek specialist advice) • inflammatory bowel disease • migraine • personal or family history of hypertriglyceridaemia (increased risk of pancreatitis) • risk factors for arterial disease • risk factors for venous thromboembolism • sickle-cell disease • undiagnosed breast mass

- Risk of venous thromboembolism There is an increased risk of venous thromboembolic disease in users of combined hormonal contraceptives particularly during the first year and possibly after restarting combined hormonal contraceptives following a break of four weeks or more. This risk is considerably smaller than that associated with pregnancy (about 60 cases of venous thromboembolic disease per 100 000 pregnancies). In all cases the risk of venous thromboembolism increases with age and in the presence of other risk factors, such as obesity. The risk also varies depending on the type of progestogen.

Provided that women are informed of the relative risks of venous thromboembolism and accept them, the choice of oral contraceptive is for the woman together with the prescriber jointly to make in light of her individual medical history and any contra-indications.

Combined hormonal contraceptives also slightly increase the risk of arterial thromboembolism; however, there is no evidence to suggest that this risk varies between different preparations.

- Risk factors for venous thromboembolism Use with caution if any of following factors present but avoid if two or more factors present:
  - family history of venous thromboembolism in first-degree relative aged under 45 years (avoid contraceptive containing desogestrel or gestodene, or avoid if known prothrombotic coagulation abnormality e.g. factor V Leiden or antiphospholipid antibodies (including lupus anticoagulant));
  - obesity; body mass index ≥ 30 kg/m² (avoid if body mass index ≥ 35 kg/m² unless no suitable alternative); (in adolescents, caution if obese according to BMI (adjusted for age and gender); in those who are markedly obese, avoid unless no suitable alternative);
  - long-term immobilisation e.g. in a wheelchair (avoid if confined to bed or leg in plaster cast);
  - history of superficial thrombophlebitis;
  - age over 35 years (avoid if over 50 years);
  - smoking.
**Combined Hormonal Contraception and Risk of Venous Thromboembolism**

<table>
<thead>
<tr>
<th>Progestogen in Combined Hormonal Contraceptive</th>
<th>Estimated incidence per 10 000 women per year of use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-pregnant, not using combined hormonal contraception</td>
<td>2</td>
</tr>
<tr>
<td>Levonorgestrel</td>
<td>5-7</td>
</tr>
<tr>
<td>Norgestimate</td>
<td>5-7</td>
</tr>
<tr>
<td>Norethisterone</td>
<td>5-7</td>
</tr>
<tr>
<td>Etonorgestrel</td>
<td>6-12</td>
</tr>
<tr>
<td>Norelgestromin</td>
<td>6-12</td>
</tr>
<tr>
<td>Gestodene</td>
<td>9-12</td>
</tr>
<tr>
<td>Desogestrel</td>
<td>9-12</td>
</tr>
<tr>
<td>Drospirenone</td>
<td>Not known–insufficient data</td>
</tr>
<tr>
<td>Dienogest</td>
<td>Not known–insufficient data</td>
</tr>
<tr>
<td>Nomestrogel</td>
<td>Combined with ethinylestradiol</td>
</tr>
<tr>
<td>1Combined with ethinylestradiol</td>
<td>*Combined with estradiol</td>
</tr>
</tbody>
</table>

- **Risk factors for arterial disease** Use with caution if any one of following factors present but avoid if two or more factors present:
  - family history of arterial disease in first degree relative aged under 45 years (avoid if atherogenic lipid profile);
  - diabetes mellitus (avoid if diabetes complications present);
  - hypertension; blood pressure above systolic 140 mmHg or diastolic 90 mmHg (avoid if blood pressure above systolic 160 mmHg or diastolic 95 mmHg); (in adolescents, avoid if blood pressure very high);
  - smoking (avoid if smoking 40 or more cigarettes daily);
  - age over 35 years (avoid if over 50 years);
  - obesity (avoid if body mass index ≥ 35 kg/m² unless no suitable alternative); (in adolescents, caution if obese according to BMI (adjusted for age and gender); in those who are markedly obese, avoid unless no suitable alternative);
  - migraine without aura (avoid if migraine with aura (focal symptoms), or severe migraine frequently lasting over 72 hours despite treatment, or migraine treated with ergot derivatives).

- **Migraine** Women should report any increase in headache frequency or onset of focal symptoms (discontinue immediately and refer urgently to neurology expert if focal neurological symptoms not typical of aura persist for more than 1 hour).

  Combined hormonal contraceptives should be stopped (pending investigation and treatment), if serious neurological effects occur, including unusual severe, prolonged headache especially if first time or getting progressively worse or sudden partial or complete loss of vision or sudden disturbance of hearing or other perceptual disorders or dysphasia or bad fainting attack or collapse or first unexplained epileptic seizure or weakness, motor disturbances, very marked numbness suddenly affecting one side or one part of body.

- **INTERACTIONS** → Appendix 1: combined hormonal contraceptives

- **SIDE-EFFECTS**
  - **Rare** Gallstones, systemic lupus erythematosus
  - **Frequency not known** Abdominal cramps, absence of withdrawal bleeding, amenorrhoea after discontinuation, breast enlargement, breast secretion, breast tenderness, cervical erosion, changes in libido, changes in lipid metabolism, changes in vaginal discharge, chloasma, chorea, contact lenses may irritate, depression, fluid retention, headache, hepatic tumours, hypertension, irritability, leg cramps, liver impairment, nausia, nervousness, photosensitivity, reduced menstrual loss, skin reactions, thrombosis (more common when factor V Leiden present or in blood groups A, B, and AB), visual disturbances, vomiting, spotting, in early cycles

### SIDE-EFFECTS, FURTHER INFORMATION

- **Breast cancer** There is a small increase in the risk of having breast cancer diagnosed in women taking the combined oral contraceptive pill; this relative risk may be due to an earlier diagnosis. In users of combined oral contraceptive pills the cancers are more likely to be localised to the breast. The most important factor for diagnosing breast cancer appears to be the age at which the contraceptive is stopped rather than the duration of use; any increase in the rate of diagnosis diminishes gradually during the 10 years after stopping and disappears by 10 years.

- **Cervical cancer** Use of combined oral contraceptives for 5 years or longer is associated with a small increased risk of cervical cancer; the risk diminishes after stopping and disappears by about 10 years.

  The possible small increase in the risk of breast cancer and cervical cancer should be weighed against the protective effect against cancers of the ovary and endometrium.

- **PREGNANCY** Not known to be harmful.

- **BREAST FEEDING** Avoid until weaning or for 6 months after birth (adverse effects on lactation).

- **HEPATIC IMPAIRMENT** Avoid in active liver disease including disorders of hepatic excretion (e.g. Dubin-Johnson or Rotor syndromes), infective hepatitis (until liver function returns to normal), liver tumours.

### DIRECTIONS FOR ADMINISTRATION

- **With oral use** Each tablet should be taken at approximately same time each day; if delayed, contraceptive protection may be lost. 21-day combined preparations, 1 tablet daily for 21 days; subsequent courses repeated after a 7-day interval (during which withdrawal bleeding occurs); if reasonably certain woman is not pregnant, first course can be started on any day of cycle—if starting on day 6 of cycle or later, additional precautions (barrier methods) necessary during first 7 days. **Every day (ED) combined preparations**, 1 active tablet daily for 21 days, followed by 1 inactive tablet daily for 7 days; subsequent courses repeated without interval (withdrawal bleeding occurs when inactive tablets are being taken); if reasonably certain woman is not pregnant, first course can be started on any day of cycle—if starting on day 6 of cycle or later, additional precautions (barrier methods) necessary during first 7 days.

  Changing to combined preparation containing different progestogen If previous contraceptive used correctly, or pregnancy can reasonably be excluded, start the first active tablet of new brand immediately. See individual monographs for requirements of specific preparations.

  Changing from progestogen-only tablet If previous contraceptive used correctly, or pregnancy can reasonably be excluded, start new brand immediately, additional precautions (barrier methods) necessary for first 7 days. Secondary amenorrhoea (exclude pregnancy) Start any day, additional precautions (barrier methods) necessary during first 7 days (9 days for Qlaira®).

- **After childbirth (not breast-feeding)** Start 3 weeks after birth (increased risk of thrombosis if started earlier); later than 3 weeks postpartum additional precautions (barrier methods) necessary for first 7 days (9 days for Qlaira®).

- **After abortion or miscarriage** Start same day.

- **PATIENT AND CARER ADVICE**

  **Missed pill** The critical time for loss of contraceptive protection is when a pill is omitted at the beginning or end of a cycle (which lengthens the pill-free interval).
If a woman forgets to take a pill, it should be taken as soon as she remembers, and the next one taken at the normal time (even if this means taking 2 pills together). A missed pill is one that is 24 or more hours late. If a woman misses only one pill, she should take an active pill as soon as she remembers and then resume normal pill-taking. No additional precautions are necessary. If a woman misses 2 or more pills (especially from the first 7 in a packet), she may not be protected. She should take an active pill as soon as she remembers and then resume normal pill-taking. In addition, she must either abstain from sex or use an additional method of contraception such as a condom for the next 7 days. If these 7 days run beyond the end of the packet, the next packet should be started at once, omitting the pill-free interval (or, in the case of ordinary (ED) pills, omitting the 7 inactive tablets).

Emergency contraception is recommended if 2 or more combined oral contraceptive tablets are missed from the first 7 tablets in a packet and unprotected intercourse has occurred since finishing the last packet. Travel. Women taking oral contraceptives are at an increased risk of deep vein thrombosis during travel involving long periods of immobility (over 3 hours). The risk may be reduced by appropriate exercise during the journey and possibly by wearing graduated compression hosiery. Diarrhoea and vomiting. Vomiting and persistent, severe diarrhoea can interfere with the absorption of combined oral contraceptives. If vomiting occurs within 2 hours of taking a combined oral contraceptive another pill should be taken as soon as possible. In cases of persistent vomiting or severe diarrhoea lasting more than 24 hours, additional precautions should be used during and for 7 days after recovery. If the vomiting and diarrhoea occurs during the last 7 tablets, the next pill-free interval should be omitted (in the case of ED tablets the inactive ones should be omitted).

**Dienogest with estradiol valerate**

**INDICATIONS AND DOSE**

Contraception with 28-day combined preparations

| Menstrual symptoms with 28-day combined preparations |
|BY MOUTH |
| Females of childbearing potential: 1 active tablet once daily for 26 days, followed by 1 inactive tablet daily for 2 days, withdrawal bleeding may occur during the 2-day interval of inactive tablets, should be taken at approximately the same time each day

**DIRECTIONS FOR ADMINISTRATION** Changing to *Qlaira®*: start the first active *Qlaira®* tablet on the day after taking the last active tablet of the previous brand

**PATIENT AND CARER ADVICE**

Missed doses

A missed pill for a patient taking *Qlaira®* is one that is 12 hours or more late; for information on how to manage missed pills in women taking *Qlaira®, refer to product literature.

Diarrhoea and vomiting In cases of persistent vomiting or severe diarrhoea lasting more than 12 hours in women taking *Qlaira®, refer to product literature.

**Estradiol with nomegestrol**

**INDICATIONS AND DOSE**

Contraception

| BY MOUTH |
| Females of childbearing potential: 1 active tablet daily for 24 days, followed by 1 inactive tablet daily for 4 days, to be started on day 1 of cycle with first active tablet (withdrawal bleeding occurs when inactive tablets being taken); subsequent courses repeated without interval

**PREGNANCY** Toxicity in animal studies.

**DIRECTIONS FOR ADMINISTRATION** Changing to *Zoely®*: start the first active *Zoely®* tablet on the day after taking the last active tablet of the previous brand or, at the latest, the day after the tablet-free or inactive tablet interval of the previous brand

**PATIENT AND CARER ADVICE**

Missed doses

A missed pill for a patient taking *Zoely®* is one that is 12 hours or more late; for information on how to manage missed pills in women taking *Zoely®, refer to product literature.

Diarrhoea and vomiting In cases of persistent vomiting or severe diarrhoea lasting more than 12 hours in women taking *Zoely®, refer to product literature.

**Ethinylestradiol with desogestrel**

**INDICATIONS AND DOSE**

Contraception with 21-day combined preparations

| Menstrual symptoms with 21-day combined preparations |
|BY MOUTH |
| Females of childbearing potential: 1 tablet once daily for 21 days; subsequent courses repeated after 7-day interval, withdrawal bleeding occurs during the 7-day interval, if reasonably certain woman is not pregnant, first course can be started on any day of cycle—if starting on day 6 of cycle or later, additional precautions (barrier methods) necessary during first 7 days, tablets should be taken at approximately the same time each day

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Tablet**
  - Dienogest with estradiol valerate (Non-proprietary)
  - Dienogest 2 mg, Estradiol valerate 2 mg
  - Estradiol valerate 2mg / Dienogest 2mg tablets | 15 tablet | no price available
  - Estradiol valerate 2 mg, Dienogest 3 mg
  - Estradiol valerate 2mg / Dienogest 3mg tablets | 28 tablet | no price available

- **Qlaira® (Bayer Plc)**
  - Qlaira tablets | 84 tablet | £25.18
There can be variation in the licensing of different medicines containing the same drug.

### Table

- **Ethinylestradiol with desogestrel (Non-proprietary)**
  - Ethinylestradiol 20 microgram, Desogestrel
  - 150 microgram Ethinylestradiol 20 microgram / Desogestrel 150 microgram tablets | £63 tablet | no price available

- **Ethinylestradiol 30 microgram, Desogestrel**
  - 150 microgram Ethinylestradiol 30 microgram / Desogestrel 150 microgram tablets | £63 tablet | no price available

- **Alenini (Actavis UK Ltd)**
  - Ethinylestradiol 20 microgram, Desogestrel 150 microgram ALENINI 150 microgram/20 microgram tablets | £8.44

- **Alenona (Teva UK Ltd)**
  - Ethinylestradiol 30 microgram, Desogestrel 150 microgram ALENOVA 150 microgram/30 microgram tablets | £6.13

- **Bimizza (Morningside Healthcare Ltd)**
  - Ethinylestradiol 20 microgram, Desogestrel 150 microgram BIMIZZA 150 microgram/20 microgram tablets | £5.04

- **Cimizt (Morningside Healthcare Ltd)**
  - Ethinylestradiol 30 microgram, Desogestrel 150 microgram CIMIZT 30 microgram/150 microgram tablets | £3.80

- **Gedarel (Consilient Health Ltd)**
  - Ethinylestradiol 20 microgram, Desogestrel 150 microgram Gedarel 20 microgram/150 microgram tablets | £5.08

- **Lestranyl (Mylan Ltd)**
  - Ethinylestradiol 20 microgram, Desogestrel 150 microgram LESTRANYL 20 microgram/150 microgram tablets | £4.49

- **Marvelon (Merck Sharp & Dohme Ltd)**
  - Ethinylestradiol 30 microgram, Desogestrel 150 microgram MARVELON 150 microgram/30 microgram tablets | £7.10

- **Mercilon (Merck Sharp & Dohme Ltd)**
  - Ethinylestradiol 20 microgram, Desogestrel 150 microgram MERCILON 150 microgram/20 microgram tablets | £8.44

- **Munalea (Lupin (Europe) Ltd)**
  - Ethinylestradiol 20 microgram, Desogestrel 150 microgram MUNALEA 150 microgram/20 microgram tablets | £5.07

- **Acondro (Mylan Ltd)**
  - Ethinylestradiol 30 microgram, Drospirenone 3 mg ACNDRRO 0.03 mg/3 mg tablets | £8.35 DT price = £14.70

- **Cleossensa (Actavis UK Ltd)**
  - Ethinylestradiol 30 microgram, Drospirenone 3 mg CLEOSENSA 0.03 mg/3 mg tablets | £14.70 DT price = £14.70

- **Daylette (Consilient Health Ltd)**
  - Ethinylestradiol 20 microgram, Drospirenone 3 mg DAYLETTE 0.02 mg/3 mg tablets | £10.50 DT price = £14.70

- **Drette (Teva UK Ltd)**
  - Ethinylestradiol 30 microgram, Drospirenone 3 mg Drette 0.03 mg/3 mg tablets | £8.30 DT price = £14.70

- **ELOINE (Bayer Plc)**
  - Ethinylestradiol 20 microgram, Drospirenone 3 mg ELOINE 0.02 mg/3 mg tablets | £14.70 DT price = £14.70

- **Ellanite (Stragen UK Ltd)**
  - Ethinylestradiol 30 microgram, Drospirenone 3 mg ELLANITE 0.03 mg/3 mg tablets | £14.70 DT price = £14.70

- **Lucette (Consilient Health Ltd)**
  - Ethinylestradiol 30 microgram, Drospirenone 3 mg LUCETTE 0.03 mg/3 mg tablets | £9.35 DT price = £14.70

- **Yacella (Morningside Healthcare Ltd)**
  - Ethinylestradiol 30 microgram, Drospirenone 3 mg YACELLA 0.03 mg/3 mg tablets | £8.30 DT price = £14.70

- **Yasmin (Bayer Plc)**
  - Ethinylestradiol 30 microgram, Drospirenone 3 mg YASMIN 0.03 mg/3 mg tablets | £14.70 DT price = £14.70

- **Yiznell (Lupin (Europe) Ltd)**
  - Ethinylestradiol 30 microgram, Drospirenone 3 mg YIZNELL 0.03 mg/3 mg tablets | £8.30 DT price = £14.70

---

**Ethinylestradiol with etonogestrel**

### Indications and Dose

**Contraception | Menstrual symptoms**

- **By Vagina**
  - Females of childbearing potential: 1 unit, insert the ring into the vagina on day 1 of cycle and leave in for 3 weeks; remove ring on day 22; subsequent courses repeated after 7-day ring free interval (during which withdrawal bleeding occurs)

### Directions for Administration

Changing method of contraception to vaginal ring

Changing from combined hormonal contraception Insert ring at the latest on the day after the usual tablet-free, patch-free, or inactive-tablet interval. If previous contraceptive used correctly, or pregnancy can reasonably be excluded, can switch to ring on any day of cycle.

Changing from progestogen-only method From an implant or intra-uterine progestogen-only device, insert ring on the day implant or intra-uterine progestogen-only device removed; from an injection, inject ring when next injection due; from oral preparation, given advice removed; from an injection, insert ring when next

### Patient and Carer Advice

Patients or carers should be given advice on how to administer vaginal ring.

Counselling The presence of the ring should be checked regularly.

Missed doses

Expulsion, delayed insertion or removal, or broken vaginal ring If the vaginal ring is expelled for less than 3 hours, rinse the ring with cool water and reinsert immediately; no additional contraception is needed.

If the ring remains outside the vagina for more than 3 hours or if the user does not know when the ring was expelled, contraceptive protection may be reduced:

- If ring expelled during week 1 or 2 of cycle, rinse ring with cool water and reinsert; use additional precautions (barrier methods) for next 7 days;

---

**Ethinylestradiol with drospirenone**

### Indications and Dose

**Contraception with 21-day combined preparations | Menstrual symptoms with 21-day combined preparations**

- **By Mouth**
  - Females of childbearing potential: 1 tablet once daily for 21 days; subsequent courses repeated after 7-day interval, withdrawal bleeding occurs during the 7-day interval

### Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Ethinylestradiol with drospirenone (Non-proprietary)**
  - Ethinylestradiol 30 microgram, Drospirenone 3 mg Ethinylestradiol 30 microgram / Drospirenone 3 mg tablets | £63 tablet | no price available DT price = £14.70

---

**Ethinylestradiol with etonogestrel**

**Indications and Dose**

Contraception | Menstrual symptoms

- **By Vagina**
  - Females of childbearing potential: 1 unit, insert the ring into the vagina on day 1 of cycle and leave in for 3 weeks; remove ring on day 22; subsequent courses repeated after 7-day ring free interval (during which withdrawal bleeding occurs)

**Directions for Administration**

Changing method of contraception to vaginal ring Changing from combined hormonal contraception Insert ring at the latest on the day after the usual tablet-free, patch-free, or inactive-tablet interval. If previous contraceptive used correctly, or pregnancy can reasonably be excluded, can switch to ring on any day of cycle. Changing from progestogen-only method From an implant or intra-uterine progestogen-only device, insert ring on the day implant or intra-uterine progestogen-only device removed; from an injection, inject ring when next injection due; from oral preparation, first ring may be inserted on any day after stopping pill. For all methods additional precautions (barrier methods) should be used concurrently for first 7 days.

**Patient and Carer Advice**

Patients or carers should be given advice on how to administer vaginal ring. Counselling The presence of the ring should be checked regularly. Missed doses Expulsion, delayed insertion or removal, or broken vaginal ring If the vaginal ring is expelled for less than 3 hours, rinse the ring with cool water and reinsert immediately; no additional contraception is needed. If the ring remains outside the vagina for more than 3 hours or if the user does not know when the ring was expelled, contraceptive protection may be reduced: If ring expelled during week 1 or 2 of cycle, rinse ring with cool water and reinsert; use additional precautions (barrier methods) for next 7 days;
If insertion of a new ring at the start of a new cycle is delayed, contraceptive protection is lost. A new ring should be inserted as soon as possible; additional precautions (barrier methods) should be used for the first 7 days of the new cycle. If intercourse occurred during the extended ring-free interval, pregnancy should be considered. No additional contraception is required if removal of the ring is delayed by up to 1 week (4 weeks of continuous use). The 7-day ring-free interval should be observed and subsequently a new ring should be inserted. Contraceptive protection may be reduced with continuous use of the ring for more than 4 weeks—pregnancy should be ruled out before inserting a new ring.

If the ring breaks during use, remove it and insert a new ring immediately; additional precautions (barrier methods) should be used for the first 7 days of the new cycle.

### MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

#### Tablet
- **Ethinylestradiol with gestodene (Non-proprietary)**
  - Ethinylestradiol 30 microgram, Gestodene 75 microgram tablets | 18 tablet [PO] no price available
  - Ethinylestradiol 30 microgram, Gestodene 75 microgram tablets | 15 tablet [PO] no price available

- **Ethinylestradiol 40 microgram, Gestodene**
  - 70 microgram Ethinylestradiol 40 microgram / Gestodene 70 microgram tablets | 15 tablet [PO] no price available

- **Ethinylestradiol 30 microgram, Gestodene**
  - 75 microgram Ethinylestradiol 30 microgram / Gestodene 75 microgram tablets | 63 tablet [PO] no price available DT price = £8.85
  - 75 microgram Ethinylestradiol 30 microgram / Gestodene 75 microgram tablets | 57 tablet [PO] no price available DT price = £8.85

- **Ethinylestradiol 20 microgram, Gestodene**
  - 100 microgram Ethinylestradiol 20 microgram / Gestodene 100 microgram tablets | 30 tablet [PO] no price available

#### Aidulan (Lupin (Europe) Ltd)
- **Ethinylestradiol 30 microgram, Gestodene**
  - 75 microgram Ethinylestradiol 30 microgram / Gestodene 75 microgram tablets | 63 tablet [PO] £4.11 DT price = £6.73

- **Femodene (Bayer Plc)**
  - **Ethinylestradiol 30 microgram, Gestodene**
    - 75 microgram Femodene tablets | 63 tablet [PO] £6.73 DT price = £6.73

- **Femodette (Bayer Plc)**
  - **Ethinylestradiol 20 microgram, Gestodene**
    - 75 microgram Femodette tablets | 63 tablet [PO] £8.85 DT price = £8.85

- **Juliperla (Actavis UK Ltd)**
  - **Ethinylestradiol 20 microgram, Gestodene**
    - 75 microgram Juliperla 75 microgram tablets | 63 tablet [PO] £8.85 DT price = £8.85

- **Katya (Stragen UK Ltd)**
  - **Ethinylestradiol 30 microgram, Gestodene**
    - 75 microgram Katya tablets | 63 tablet [PO] £5.04 DT price = £6.73

- **Millinette (Consign Health Ltd)**
  - **Ethinylestradiol 30 microgram, Gestodene**
    - 75 microgram Millinette tablets | 63 tablet [PO] £4.11 DT price = £6.73

- **Sofiperla (Actavis UK Ltd)**
  - **Ethinylestradiol 30 microgram, Gestodene**
    - 75 microgram Sofiperla 75 microgram tablets | 63 tablet [PO] £4.12 DT price = £6.73

- **Sunya (Stragen UK Ltd)**
  - **Ethinylestradiol 20 microgram, Gestodene**
    - 75 microgram Sunya tablets | 63 tablet [PO] £6.82 DT price = £8.85

### Ethinylestradiol with levonorgestrel

#### INDICATIONS AND DOSE
**Contraception with 21-day combined preparations**

- **Menstrual symptoms with 21-day combined preparations**
  - **BY MOUTH**
    - Females of childbearing potential: 1 tablet once daily for 21 days; subsequent courses repeated after 7-day interval, withdrawal bleeding occurs during the 7-day interval, if reasonably certain woman is not pregnant, first course can be started on any day of cycle—if starting on day 6 of cycle or later, additional precautions (barrier methods) necessary during first 7 days, tablets should be taken at approximately the same time each day.

**Contraception with 28-day combined preparations**

- **Menstrual symptoms with 28-day combined preparations**
  - **BY MOUTH**
    - Females of childbearing potential: 1 active tablet once daily for 21 days, followed by 1 inactive tablet daily for 7 days; subsequent courses repeated without interval, withdrawal bleeding occurs during the 7-day interval of inactive tablets being taken, if reasonably certain woman is not pregnant, first course can be started on any day of cycle—if starting on day 6 of cycle or later, additional precautions (barrier methods) necessary during first 7 days, tablets should be taken at approximately the same time each day.

---

**Ethinylestradiol with etonogestrel**

- **BY MOUTH**
  - Females of childbearing potential: 1 tablet once daily for 21 days; subsequent courses repeated after 7-day interval, withdrawal bleeding occurs during the 7-day interval of inactive tablets being taken, if reasonably certain woman is not pregnant, first course can be started on any day of cycle—if starting on day 6 of cycle or later, additional precautions (barrier methods) necessary during first 7 days, tablets should be taken at approximately the same time each day.
Contraception with 28-day combined preparations | Menstrual symptoms with 28-day combined preparations

- **BY MOUTH**
  - Females of childbearing potential: 1 active tablet once daily for 21 days, followed by 1 inactive tablet once daily for 7 days. Withdrawal bleeding occurs during the 7-day interval of inactive tablets being taken, if reasonably certain a woman is not pregnant, first course can be started on any day of cycle—if starting on day 6 of cycle or later, additional precautions (barrier methods) necessary during first 7 days. Tablets should be taken at approximately the same time each day. Subsequent courses repeated without interval

### MEDICINAL FORMS
- There can be variation in the licensing of different medicines containing the same drug.

#### Tablet
- **Ethinylestradiol with levonorgestrel (Non-proprietary)**
  - **Ethinylestradiol 30 microgram, Levonorgestrel**
    - 50 microgram Ethinylestradiol 30 microgram / Levonorgestrel 50 microgram tablets | 6 tablet POM no price available | 18 tablet POM no price available
    - **Ethinylestradiol 40 microgram, Levonorgestrel**
      - 75 microgram Ethinylestradiol 40 microgram / Levonorgestrel 75 microgram tablets | 5 tablet POM no price available | 15 tablet POM no price available
    - **Ethinylestradiol 30 microgram, Levonorgestrel**
      - 125 microgram Ethinylestradiol 30 microgram / Levonorgestrel 125 microgram tablets | 10 tablet POM no price available | 30 tablet POM no price available
  - **Elevin** (MedRx Licences Ltd)
    - **Ethinylestradiol 30 microgram, Levonorgestrel**
      - 150 microgram Elevin 150 microgram tablets | 63 tablet POM £23.25 DT price = £2.82
  - **Erlibelle** (Actavis UK Ltd)
    - **Ethinylestradiol 30 microgram, Levonorgestrel**
      - 150 microgram Erlibelle 30 microgram tablets | 63 tablet POM £2.82 DT price = £2.82
  - **Leandra** (Genesis Pharmaceuticals Ltd)
    - **Ethinylestradiol 30 microgram, Levonorgestrel**
      - 150 microgram Leandra 30 microgram tablets | 63 tablet POM £2.82 DT price = £2.82
  - **Levest** (Morningside Healthcare Ltd)
    - **Ethinylestradiol 30 microgram, Levonorgestrel**
      - 150 microgram Levest 150 microgram tablets | 21 tablet POM £0.85
  - **Maxenix** (Lupin (Europe) Ltd)
    - **Ethinylestradiol 30 microgram, Levonorgestrel**
      - 150 microgram Maxenix 150 microgram tablets | 63 tablet POM £1.80 DT price = £2.82
  - **Microgynon 30** (Bayer Plc)
    - **Ethinylestradiol 30 microgram, Levonorgestrel**
      - 150 microgram Microgynon 30 tablets | 63 tablet POM £2.82 DT price = £2.82
  - **Ovranette** (Pfizer Ltd)
    - **Ethinylestradiol 30 microgram, Levonorgestrel**
      - 150 microgram Ovranette 150 microgram tablets | 63 tablet POM £2.20 DT price = £2.82
  - **Rigevidon** (Consilient Health Ltd)
    - **Ethinylestradiol 30 microgram, Levonorgestrel**
      - 150 microgram Rigevidon tablets | 63 tablet POM £1.89 DT price = £2.82

### Ethinylestradiol with norelgestromin

#### INDICATIONS AND DOSE

**Contraception | Menstrual symptoms**

- **BY TRANSDERMAL APPLICATION**
  - Females of childbearing potential: Apply 1 patch once weekly for 3 weeks, apply first patch on day 1 of cycle, change patch on days 8 and 15; remove third patch on day 22 and apply new patch after 7-day patch-free interval to start subsequent contraceptive cycle, subsequent courses repeated after a 7-day patch free interval (during which withdrawal bleeding occurs)

- **DIRECTIONS FOR ADMINISTRATION**
  - Adhesives or bandages should not be used to hold patch in place. If no longer sticky do not reapply but use a new patch.
  - Changing to a transdermal combined hormonal contraceptive Changing from combined oral contraception Apply patch on the first day of withdrawal bleeding; if no withdrawal bleeding within 5 days of taking last active tablet, rule out pregnancy before applying first patch. Unless patch is applied on first day of withdrawal bleeding, additional precautions (barrier methods) should be used concurrently for first 7 days.
  - **Changing from progestogen-only method**
    - from an implant, apply first patch on the day implant removed
    - from an injection, apply first patch when next injection due
    - from an oral progestogen, first patch may be applied on any day after stopping pill.
  - **After childbirth (not breast-feeding)**
    - Start 4 weeks after birth; if started later than 4 weeks after birth additional precautions (barrier methods) should be used for first 7 days.
  - **After abortion or miscarriage**
    - Before 20 weeks’ gestation start immediately; no additional contraception required if started immediately. After 20 weeks’ gestation start on day 21 after abortion or on the first day of first spontaneous menstruation; additional precautions (barrier methods) should be used for first 7 days after applying the patch.

- **PATIENT AND CARER ADVICE**
  - Patients and carers should be given advice on how to administer patches.
  - **Travel**
    - Women using patches are at an increased risk of deep vein thrombosis during travel involving long periods of immobility (over 3 hours). The risk may be reduced by appropriate exercise during the journey and possibly by wearing graduated compression hosiery.

- **Missed doses**
  - **Delayed application or detached patch**
    - If a patch is partly detached for less than 24 hours, reapply to the same site or replace with a new patch immediately; no additional contraception is needed and the next patch should be applied on the usual ‘change day’. If a patch remains detached for more than 24 hours or if the user is not aware when the patch became detached, then stop the current contraceptive cycle and start a new cycle by applying a new patch, giving a new ‘Day 1’; an additional non-hormonal contraceptive must be used concurrently for the first 7 days of the new cycle.
  - If application of a new patch at the start of a new cycle is delayed, contraceptive protection is lost. A new patch should be applied as soon as remembered giving a new ‘Day 1’; additional non-hormonal methods of contraception should be used for the first 7 days of the new cycle. If application of a patch in the middle of the cycle is delayed (i.e. the patch is not changed on day 8 or day 15):
    - for up to 48 hours, apply a new patch immediately; next patch ‘change day’ remains the same and no additional contraception is required;
    - for more than 48 hours, contraceptive protection may have been lost. Stop the current cycle and start a new 4-week cycle immediately by applying a new patch giving a new ‘Day 1’; additional non-hormonal contraception should be used for the first 7 days of the new cycle. If the patch is not removed at the end of the cycle (day 22), remove it as soon as possible and start the next cycle on...
the usual ‘change day’, the day after day 28; no additional contraception is required.

**NATIONAL FUNDING/ACCESS DECISIONS**

**Scottish Medicines Consortium (SMC) Decisions**
The Scottish Medicines Consortium has advised (September 2003) that Evra® patches should be restricted for use in women who are likely to comply poorly with combined oral contraceptives.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Transdermal patch**

▶ Evra (Janssen-Cilag Ltd)

Ethinylestradiol 33.9 microgram per 24 hour, Norelgestromin 203 microgram per 24 hour Evra transdermal patches | 9 patch (P&Q) £19.51 DT price = £19.51

---

**Ethinylestradiol with norethisterone**

**INDICATIONS AND DOSE**

Contraception with 21-day combined preparations | Menstrual symptoms with 21-day combined preparations

▶ BY MOUTH

▶ Females of childbearing potential: 1 tablet once daily for 21 days; subsequent courses repeated after 7-day interval, withdrawal bleeding occurs during the 7-day interval, if reasonably certain woman is not pregnant, first course can be started on any day of cycle—if starting on day 6 of cycle or later, additional precautions (barrier methods) necessary during first 7 days, tablets should be taken at approximately the same time each day

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

▶ Ethinylestradiol with norethisterone (Non-proprietary)

Ethinylestradiol 35 microgram, Norethisterone 200 microgram tablets | 5 tablet (P&Q) no price available | 7 tablet (P&Q) no price available | 21 tablet (P&Q) no price available

Ethinylestradiol 35 microgram, Norethisterone 350 microgram tablets | 21 tablet (P&Q) no price available

Ethinylestradiol 35 microgram, Norethisterone 350 microgram / Norelgestromin 250 microgram tablets | 63 tablet (P&Q) no price available DT price = £7.16

▶ Cilest (Janssen-Cilag Ltd)

Ethinylestradiol 35 microgram, Norethisterone 750 microgram tablets | 21 tablet (P&Q) no price available

Ethinylestradiol 35 microgram, Norethisterone 750 microgram / Norelgestromin 250 microgram tablets | 63 tablet (P&Q) no price available

Ethinylestradiol 35 microgram, Norethisterone 1 mg tablets | 9 tablet (P&Q) no price available | 21 tablet (P&Q) no price available | 42 tablet (P&Q) no price available

▶ Brevinor (Pfizer Ltd)

Ethinylestradiol 35 microgram, Norethisterone 500 microgram tablets | 63 tablet (P&Q) DT price = £1.99

▶ Loestrin 20 (Galen Ltd)

Ethinylestradiol 20 microgram, Norethisterone acetate 1 mg tablets | 63 tablet (P&Q) £2.28 DT price = £2.28

▶ Loestrin 30 (Galen Ltd)

Ethinylestradiol 30 microgram, Norethisterone acetate 1.5 mg tablets | 63 tablet (P&Q) £3.32 DT price = £3.32

▶ Norimin (Pfizer Ltd)

Ethinylestradiol 35 microgram, Norethisterone 1 mg tablets | 63 tablet (P&Q) £2.28 DT price = £2.28

---

**Norethisterone with mestranol**

**INDICATIONS AND DOSE**

Contraception | Menstrual symptoms

▶ BY MOUTH

▶ Females of childbearing potential: 1 tablet once daily for 21 days; subsequent courses repeated after 7-day interval, withdrawal bleeding can occur during the 7-day interval, if reasonably certain woman is not pregnant, first course can be started on any day of cycle—if starting on day 6 of cycle or later, additional precautions (barrier methods) necessary during first 7 days, tablets should be taken at the same time each day

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

▶ Norinyl-1 (Pfizer Ltd)

Mestranol 50 microgram, Norethisterone 1 mg tablets | 63 tablet (P&Q) £2.19 DT price = £2.19
3.2 Contraception, devices

**CONTRACEPTIVE DEVICES**

**Intra-uterine contraceptive devices (copper)**

- **INDICATIONS AND DOSE**
  - **Contraception**
  - **Females of childbearing potential**: (consult product literature)

- **INDICATIONS**
  - Active trophoblastic disease (until return to normal of urine and plasma-gonadotrophin concentration)
  - Distorted uterine cavity
  - Established or marked immunosuppression
  - Genital malignancy
  - Medical diathermy
  - Pelvic inflammatory disease
  - Recent sexually transmitted infection
  - Severe anaemia
  - Small uterine cavity
  - Unexplained uterine bleeding
  - Wilson’s disease

- **CAUTIONS**
  - Anaemia
  - Anticoagulant therapy
  - Diabetes
  - Disease-induced immunosuppression
  - Drug-induced immunosuppression
  - Epilepsy
  - Endometriosis
  - Fertility problems
  - History of pelvic inflammatory disease
  - Increased risk of expulsion if inserted before uterine involution
  - Menorrhagia (progestogen intra-uterine system might be preferable)
  - Nulliparity
  - Severe cervical stenosis
  - Severe primary dysmenorrhoea
  - Severely scarred uterus

- **CONTRA-INDICATIONS**
  - Active trophoblastic disease (until return to normal of urine and plasma-gonadotrophin concentration)
  - Distorted uterine cavity
  - Established or marked immunosuppression
  - Genital malignancy
  - Medical diathermy
  - Pelvic inflammatory disease
  - Recent sexually transmitted infection (if not fully investigated and treated)
  - Severe anaemia
  - Small uterine cavity
  - Unexplained uterine bleeding
  - Wilson’s disease

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Allergy
  - Bleeding (on insertion)
  - Cervical perforation
  - Displacement
  - Dysmenorrhoea
  - Menorrhagia
  - Occasional epileptic seizure
  - Pain (on insertion, alleviated by NSAID such as ibuprofen 30 minutes before insertion)
  - Pelvic infection

- **UTERINE PERFORATION**
  - Uterine perforation most often occurs during insertion.
  - Consider this if there is severe pain following insertion.
  - Uterine perforation may occur even if the threads can be seen.

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Presence of significant symptoms (especially pain). Advise the patient to seek medical attention promptly in case of significant symptoms.

- **ALLERGY AND CROSS-SENSITIVITY**
  - Contra-indicated if the patient has a copper allergy.

- **PREGNANCY**
  - If an intra-uterine device fails the woman wishes to continue to full-term the device should be removed in the first trimester if possible. Remove device if pregnancy occurs, increased likelihood that it may be ectopic.

- **BREAST FEEDING**
  - Not known to be harmful.

- **MONITORING REQUIREMENTS**
  - Gynaecological examination before insertion, 6–8 weeks after insertion, then annually.

- **DIRECTIONS FOR ADMINISTRATION**
  - The timing and technique of fitting an intra-uterine device are critical for its subsequent performance.

- **PRESCRIBING AND DISPENSING INFORMATION**
  - **UT380 STANDARD**
    - For uterine length 6.5–9 cm; replacement every 5 years.
  - **NOVAPLUS T 380 A G**
    - ‘Mini’ size for minimum uterine length 5 cm; ‘Normal’ size for uterine length 6.5–9 cm; replacement every 5 years.
  - **GYNEFIX**
    - Suitable for all uterine sizes; replacement every 5 years.
  - **UT380 SHORT**
    - For uterine length 5–7 cm; replacement every 5 years.
  - **NOVA-T 380**
    - For uterine length 6.5–9 cm; replacement every 5 years.
  - **FLEXI-T 380**
    - For uterine length over 6 cm; replacement every 5 years.
  - **NOVAPLUS T 380 CU**
    - ‘Mini’ size for minimum uterine length 5 cm; ‘Normal’ size for uterine length 6.5–9 cm; replacement every 5 years.
  - **LOAD 375**
    - For uterine length over 7 cm; replacement every 5 years.
  - **ANCORA 375 CU**
    - For uterine length over 6.5 cm; replacement every 5 years.
  - **T-SAFE 380A QL**
    - For uterine length 6.5–9 cm; replacement every 10 years.
MULTILOAD® CU375 For uterine length 6–9 cm; replacement every 5 years.
MINI TT380® SLIMLINE For minimum uterine length 5 cm; replacement every 5 years.
COPPER T380 A® For uterine length 6.5–9 cm; replacement every 10 years.
TT380® SLIMLINE For uterine length 6.5–9 cm; replacement every 10 years.
NEO-SAFE® T380 For uterine length 6.5–9 cm; replacement every 5 years.
MULTI-SAFE® 375 For uterine length 6–9 cm; replacement every 5 years.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Intra-uterine device
- Intra-uterine contraceptive devices (R.F. Medical Supplies Ltd, Farla Medical Ltd, Durbin Plc, Williams Medical Supplies Ltd, Bayer Plc, Organon Laboratories Ltd)
  - Copper T380 A intra-uterine contraceptive device 1 device £8.95
  - Steriload intra-uterine contraceptive device 1 device £9.65
  - Load 375 intra-uterine contraceptive device 1 device £8.52
  - Novaplus T380 Ag intra-uterine contraceptive device mini 1 device £12.50
  - T-Safe 380A QL intra-uterine contraceptive device 1 device £10.55
  - UT380 Standard intra-uterine contraceptive device 1 device £11.22
  - Nova-T 380 intra-uterine contraceptive device 1 device £15.20
  - Flexi-T® 380 intra-uterine contraceptive device 1 device £10.06
  - Mini TT380 Slimline intra-uterine contraceptive device 1 device £12.46
  - Flexi-T® 300 intra-uterine contraceptive device 1 device £9.47
  - Multi-Safe 375 intra-uterine contraceptive device 1 device £8.96
  - Multiload Cu375 intra-uterine contraceptive device 1 device £9.24
  - Optima Tcu 380A intra-uterine contraceptive device 1 device £9.65
  - Novaplus T 380 Ag intra-uterine contraceptive device normal 1 device £12.50
  - Gymeflex intra-uterine contraceptive device 1 device £27.11
  - Novaplus T 380 Cu intra-uterine contraceptive device mini 1 device £10.95
  - TT380 Slimline intra-uterine contraceptive device 1 device £12.46
  - Ancora 375 Cu intra-uterine contraceptive device 1 device £7.95
  - Novaplus T 380 Cu intra-uterine contraceptive device normal 1 device £10.95
  - Neo-Safe T380 intra-uterine contraceptive device 1 device £13.40
  - UT380 Short intra-uterine contraceptive device 1 device £11.22

3.3 Contraception, emergency

Other drugs used for Contraception, emergency Intra-uterine contraceptive devices (copper), p. 756 • Levonorgestrel, p. 759

PROGESTERONE RECEPTOR MODULATORS

Ulipristone acetate
- DRUG ACTION Ulipristone acetate is a progesterone receptor modulator with a partial progesterone antagonist effect.

INDICATIONS AND DOSE
Pre-operative and intermittent treatment of moderate to severe symptoms of uterine fibroids
- BY MOUTH
  - Adult: 5 mg once daily for up to 3 months starting during the first week of menstruation, courses may be repeated if necessary, re-treatment should start no sooner than during the first week of the second menstruation following completion of the first course; max. 4 courses

Emergency contraception
- BY MOUTH
  - Females of childbearing potential: 30 mg for 1 dose, to be taken as soon as possible after coitus, but no later than after 120 hours

CONTRA-INDICATIONS
GENERAL CONTRA-INDICATIONS
Repeated use as an emergency contraceptive within a menstrual cycle
SPECIFIC CONTRA-INDICATIONS
- When used for uterine fibroids Breast cancer - cervical cancer - ovarian cancer - undiagnosed vaginal bleeding - uterine cancer - vaginal bleeding not caused by uterine fibroids
- CAUTIONS Uncontrolled severe asthma
- INTERACTIONS → Appendix 1: ulipristal
Genito-urinary system

SIDE-EFFECTS
- Common or very common
  - When used for emergency contraception: Abdominal pain, back pain, diarrhoea, dizziness, fatigue, gastro-intestinal disturbances, headache, menstrual irregularities, muscle spasms, nausea, vomiting.
  - When used for uterine fibroids: Abdominal pain, acne, breast pain, dizziness, endometrial thickening, headache, hot flushes, hyperhidrosis, malaise, menstrual disturbances, myalgia, nausea, oedema, ovarian cyst (including rupture), pelvic pain, uterine haemorrhage.
- Uncommon
  - When used for emergency contraception: Blurred vision, breast tenderness, dry mouth, hot flushes, pruritus, rash, tremor, uterine spasm.
  - When used for uterine fibroids: Anxiety, constipation, dry mouth, dyspepsia, epistaxis, flatulence, urinary incontinence.

CONCEPTION AND CONTRACEPTION
When ulipristal is given as an emergency contraceptive the effectiveness of combined hormonal and progestogen-only contraceptives may be reduced—additional precautions (barrier methods) required for 14 days for combined and parenteral progestogen-only hormonal contraceptives (16 days for Qlaira®) and 9 days for oral progestogen-only contraceptives. When ulipristal is given for uterine fibroids non-hormonal contraceptive methods (barrier methods or intra-uterine device) should be used both during treatment and for 12 days after stopping, if required.

PREGNANCY
Limited information available when used as an emergency contraceptive. Manufacturer advises avoid for uterine fibroids—no information available.

BREAST FEEDING
In emergency contraception manufacturer advises avoid for 1 week after administration—present in milk. When used for uterine fibroids, manufacturer advises avoid—no information available.

HEPATIC IMPAIRMENT
- When used for Emergency contraception: Manufacturer advises avoid in severe impairment—no information available.
- When used for Uterine fibroids: Manufacturer advises avoid in moderate to severe impairment unless patient is closely monitored—no information available.

RENAL IMPAIRMENT
- When used for Uterine fibroids: Manufacturer advises avoid in severe impairment unless patient is closely monitored—no information available.

MONITORING REQUIREMENTS
- When used for Uterine fibroids: Periodic monitoring of the endometrium is recommended following repeated intermittent treatment.

PATIENT AND CARER ADVICE
- When used for Emergency contraception: If vomiting occurs within 3 hours of taking a dose, a replacement dose should be given. When prescribing or supplying hormonal emergency contraception, women should be advised:
  - that their next period may be early or late;
  - that a barrier method of contraception needs to be used until the next period;
  - to seek medical attention promptly if any lower abdominal pain occurs because this could signify an ectopic pregnancy;
  - to return in 3 to 4 weeks if the subsequent menstrual bleed is abnormally light, heavy or brief, or is absent, or if she is otherwise concerned (if there is any doubt as to whether menstruation has occurred, a pregnancy test should be performed at least 3 weeks after unprotected intercourse).
- Treatment free intervals
- When used for Uterine fibroids: The prescriber should explain the requirement for treatment free intervals.

Missed doses
- When used for Uterine fibroids: If a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet
- EllaOne (HRA Pharma UK Ltd) Ulipristal acetate 30 mg EllaOne 30mg tablets | 1 tablet £14.05
- Esmya (Gedeon Richter (UK) Ltd) Ulipristal acetate 5 mg Esmya 5mg tablets | 28 tablet £13.14

3.4 Contraception, oral progestogen-only

Other drugs used for Contraception, oral progestogen-only Norethisterone, p. 720

PROGESTOGENS

Desogestrel

INDICATIONS AND DOSE
Contraception
- BY MOUTH
- Females of childbearing potential: 75 micrograms daily, dose to be taken at same time each day, starting on day 1 of cycle then continuously, if administration delayed for 12 hours or more it should be regarded as a ‘missed pill’.

CONTRA-INDICATIONS
Acute porphyrias p. 969 · history of breast cancer but can be used after 5 years if no evidence of disease and non-hormonal contraceptive methods unacceptable · severe arterial disease · undiagnosed vaginal bleeding.

CAUTIONS
Active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration)—seek specialist advice · arterial disease · functional ovarian cysts · history of jaundice in pregnancy · malabsorption syndromes · past ectopic pregnancy · sex-steroid dependent cancer · systemic lupus erythematosus with positive (or unknown) antiphospholipid antibodies.

CAUTIONS, FURTHER INFORMATION
- Other conditions: The product literature advises caution in patients with history of thromboembolism, hypertension, diabetes mellitus and migraine; evidence for caution in these conditions is unsatisfactory.

INTERACTIONS
- Appendix 1: desogestrel

SIDE-EFFECTS
Breast discomfort · changes in libido · depression · disturbance of appetite · dizziness · headache · menstrual irregularities · nausea · skin disorders · vomiting.

SIDE-EFFECTS, FURTHER INFORMATION
Breast cancer: There is a small increase in the risk of having breast cancer diagnosed in women using, or who have recently used, a progestogen-only contraceptive pill; this relative risk may be due to an earlier diagnosis. The most important risk factor appears to be the age at which the contraceptive is stopped rather than the duration of use; the risk disappears gradually during the 10 years after stopping and there is no excess risk by 10 years. A possible small increase in the risk of breast cancer should be weighed against the benefits.

PREGNANCY
Not known to be harmful.

BREAST FEEDING
Progestogen-only contraceptives do not affect lactation.
Hepatic impairment

Caution in severe liver disease and recurrent cholestatic jaundice. Avoid in liver tumour.

Patient and carer advice

Missed pill The following advice is recommended: 'If you forget a pill, take it as soon as you remember and carry on with the next pill at the right time. If the pill was more than 12 hours overdue you are not protected. Continue normal pill-taking but you must also use another method, such as the condom, for the next 2 days'. The Faculty of Sexual and Reproductive Healthcare recommends emergency contraception if one or more tablets are missed or taken more than 12 hours late and unprotected intercourse has occurred before 2 further tablets have been correctly taken.

Surgery All progestogen-only contraceptives are suitable for use as an alternative to combined hormonal contraceptives before major elective surgery, before all surgery to the legs, or before surgery which involves prolonged immobilisation of a lower limb.

Starting routine One tablet daily, on a continuous basis, starting on day 1 of cycle and taken at the same time each day (if delayed by longer than 12 hours contraceptive protection may be lost). Additional contraceptive precautions are not required if desogestrel is started up to 7 days postpartum, additional contraceptive precautions are required for 2 days.

Changing from a combined oral contraceptive Start on the day following completion of the combined oral contraceptive course without a break (or in the case of ED tablets omitting the inactive ones).

After childbirth Oral progestogen-only contraceptives can be started up to and including day 21 postpartum without the need for additional contraceptive precautions. If started more than 21 days postpartum, additional contraceptive precautions are required for 2 days. Diarrhoea and vomiting Vomiting and persistent, severe diarrhoea can interfere with the absorption of oral progestogen-only contraceptives. If vomiting occurs within 2 hours of taking desogestrel, another pill should be taken as soon as possible. If a replacement pill is not taken within 12 hours of the normal time for taking desogestrel, or in cases of persistent vomiting or very severe diarrhoea, additional precautions should be used during illness and for 2 days after recovery.

National funding/access decisions

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (September 2003) that Cerazette® should be restricted for use in women who cannot tolerate oestrogen-containing contraceptives or in whom such preparations are contra-indicated.

Medicinal forms

There can be variation in the licensing of different medicines containing the same drug.

Tablet

Desogestrel (Non-proprietary)

Desogestrel 75 microgram Desogestrel 75 microgram tablets | 84 tablet £9.55 DT price = £2.17
Aizea (Besins Healthcare (UK) Ltd)
Desogestrel 75 microgram Aizea 75 microgram tablets | 84 tablet £5.21 DT price = £2.17
Cerazette (Merck Sharp & Dohme Ltd)
Desogestrel 75 microgram Cerazette 75 microgram tablets | 84 tablet £9.55 DT price = £2.17
Cerelle (Conscient Health Ltd)
Desogestrel 75 microgram Cerelle 75 microgram tablets | 84 tablet £5.80 DT price = £2.17
Desomeno (MedRx Licences Ltd)
Desogestrel 75 microgram Desomeno 75 microgram tablets | 84 tablet £7.49 DT price = £2.17

Desorex (Somex Pharma)

Desogestrel 75 microgram Desorex 75 microgram tablets | 84 tablet £6.70 DT price = £2.17

Feanolla (Lupin (Europe) Ltd)

Desogestrel 75 microgram Feanolla 75 microgram tablets | 84 tablet £3.49 DT price = £2.17

Nacrez (Teva UK Ltd)

Desogestrel 75 microgram Nacrez 75 microgram tablets | 84 tablet £3.50 DT price = £2.17

Zelleta (Morningside Healthcare Ltd)

Desogestrel 75 microgram Zelleta 75 microgram tablets | 84 tablet £3.35 DT price = £2.17

Levonorgestrel

Indications and dose

Emergency contraception

By mouth

Females of childbearing potential: 1.5 mg for 1 dose, taken as soon as possible after coitus, preferably within 12 hours but no later than after 72 hours

Contraception

By mouth

Females of childbearing potential: 1 tablet daily starting on day 1 of the cycle then continuously, dose is to be taken at the same time each day, if administration delayed for 3 hours or more it should be regarded as a ‘missed pill’

Jaydess® 13.5mg Intra-uterine device

Contraception

By vagina

Females of childbearing potential: Insert into uterine cavity within 7 days of onset of menstruation, or any time if replacement, or immediately after first-trimester termination; postpartum insertions should be delayed until at least 6 weeks after delivery (12 weeks if uterus involution is substantially delayed); effective for 3 years

Levosert® 20micrograms/24hours Intra-uterine device

Contraception | Menorrhagia

By intra-uterine administration

Females of childbearing potential: Insert into uterine cavity within 7 days of onset of menstruation, or any time if replacement, or immediately after first-trimester abortion; postpartum insertions should be delayed until at least 6 weeks after delivery; effective for 3 years

Mirena® 20micrograms/24hours Intra-uterine device

Contraception | Menorrhagia

By intra-uterine administration

Females of childbearing potential: Insert into uterine cavity within 7 days of onset of menstruation, or any time if replacement, or any time if reasonably certain woman is not pregnant and there is no risk of conception (additional precautions (e.g. barrier methods) necessary for next 7 days), or immediately after first-trimester termination by curettage; postpartum insertions should be delayed until at least 4 weeks after delivery; effective for 5 years

Prevention of endometrial hyperplasia during oestrogen replacement therapy

By intra-uterine administration

Females of childbearing potential: Insert during last days of menstruation or withdrawal bleeding or at any time if amenorrhoeic; effective for 4 years continued →
DOSE ADJUSTMENTS DUE TO INTERACTIONS
When used orally as an emergency contraceptive, the effectiveness of levonorgestrel is reduced in women taking enzyme-inducing drugs (and for up to 4 weeks after stopping); a copper intra-uterine device should preferably be used instead. If the copper intra-uterine device is undesirable or inappropriate, the dose of levonorgestrel should be increased to a total of 3 mg taken as a single dose [unlicensed dose—advise women accordingly]; pregnancy should be excluded following use, and medical advice sought if pregnancy occurs. There is no need to increase the dose for emergency contraception if the patient is taking antibiotics that are not enzyme inducers. With the progestogen-only intra-uterine device, levonorgestrel is released close to the site of the main contraceptive action (on cervical mucus and endometrium) and therefore progestogenic side-effects and interactions are less likely; in particular, enzyme-inducing drugs are unlikely to significantly reduce the contraceptive effect of the progestogen-only intra-uterine system and additional contraceptive precautions are not required.

■ UNLICENSED USE
  ■ With oral use in children Consult product literature for licensing status of individual preparations.
  ■ With vaginal use in children Not licensed for use in women under 18 years.

IMPORTANT SAFETY INFORMATION
MHRA/CHM ADVICE (JUNE 2015) INTRA-UTERINE CONTRACEPTION: UTERINE PERFORATION—UPDATED INFORMATION ON RISK FACTORS
Uterine perforation most often occurs during insertion, but might not be detected until sometime later. The risk of uterine perforation is increased when the device is inserted up to 36 weeks postpartum or in patients who are breastfeeding. Before inserting an intra-uterine contraceptive device, inform patients that perforation occurs in approximately 1 in every 1000 insertions and signs and symptoms include:
  ■ severe pelvic pain after insertion (worse than period cramps);
  ■ pain or increased bleeding after insertion which continues for more than a few weeks;
  ■ sudden changes in periods;
  ■ pain during intercourse;
  ■ unable to feel the threads.
Patients should be informed on how to check their threads and to arrange a check-up if threads cannot be felt, especially if they also have significant pain. Partial perforation may occur even if the threads can be seen; consider this if there is severe pain following insertion and perform an ultrasound.

■ CONTRA-INDICATIONS
  ■ With intra-uterine use Active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration—acute cervicitis; acute vaginitis—distorted uterine cavity—established immunosuppression—genital malignancies—history of breast cancer but can be considered for a woman in long-term remission who has menorrhagia and requires effective contraception—infected abortion during the previous three months—marked immunosuppression—not suitable for emergency contraception—pelvic inflammatory disease—postpartum endometritis—recent sexually transmitted infection (if not fully investigated and treated)—severe anaemia—small uterine cavity—unexplained uterine bleeding
  ■ With oral use Acute porphyrias p. 969
  ■ With oral use for contraception History of breast cancer but can be used after 5 years if no evidence of disease and non-hormonal contraceptive methods unacceptable · severe arterial disease · undiagnosed vaginal bleeding

■ CAUTIONS
  ■ With intra-uterine use Disease-induced immunosuppression (risk of infection—avoid if marked immunosuppression) · anaemia · anticoagulant therapy (avoid if possible) · diabetes · drug-induced immunosuppression (risk of infection—avoid if marked immunosuppression) · endometriosis · epilepsy (risk of seizure at time of insertion) · fertility problems · history of pelvic inflammatory disease · increased risk of expulsion if inserted before uterine involution · menorrhagia (progestogen intra-uterine system might be preferable) · nulliparity · severe cervical stenosis · severe primary dysmenorrhoea · severely scarred uterus (including after endometrial resection) · young age
  ■ With oral use for contraception Active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration)—seek specialist advice · arterial disease · functional ovarian cysts · history of jaundice in pregnancy · malabsorption syndromes · past ectopic pregnancy · sex-steroid dependent cancer · systemic lupus erythematosus with positive (or unknown) antiphospholipid antibodies
  ■ When used for emergency contraception Active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration)—seek specialist advice · past ectopic pregnancy · severe malabsorption syndromes

CAUTIONS, FURTHER INFORMATION
An intra-uterine device should not be removed in mid-cycle unless an additional contraceptive was used for the previous 7 days. If removal is essential post-coital contraception should be considered.
Risk of infection with intra-uterine devices The main excess risk of infection occurs in the first 20 days after insertion and is believed to be related to existing carriage of a sexually transmitted infection. Women are considered to be at a higher risk of sexually transmitted infections if:
  ■ they are under 25 years old or
  ■ they are over 25 years old and
  ■ have a new partner or
  ■ have had more than one partner in the past year or
  ■ their regular partner has other partners.
In these women, pre-insertion screening (for chlamydia and, depending on sexual history and local prevalence of disease, Neisseria gonorrhoeae) should be performed. If results are unavailable at the time of fitting an intra-uterine device for emergency contraception, appropriate prophylactic antibacterial cover should be given. The woman should be advised to attend as an emergency if she experiences sustained pain during the next 20 days.
Use as a contraceptive in co-morbidities
With oral use The product literature advises caution in patients with history of thromboembolism, hypertension, diabetes mellitus and migraine; evidence for caution in these conditions is unsatisfactory.
MIRENA® 20MICROGRAMS/24HOURS INTRA-UTERINE DEVICE Advanced uterine atrophy
■ INTERACTIONS → Appendix 1: levonorgestrel

■ SIDE-EFFECTS
GENERAL SIDE-EFFECTS
  ■ Common or very common Depression (sometimes severe) · headache · nausea
  ■ Frequency not known Vomiting
SPECIFIC SIDE-EFFECTS
  ■ Common or very common
  ■ With intra-uterine use Changes in the pattern and duration of menstrual bleeding (spotting or prolonged bleeding) · abdominal pain · acne · alopecia · back pain · breast pain · expulsion · hirsutism · migraine · nervousness · pelvic pain · peripheral oedema · salpingitis
With intra-uterine use Abdominal distension · cervicitis · eczema · pelvic inflammatory disease · pruritus · skin hyperpigmentation

Rare

With intra-uterine use Rash · uterine perforation

Frequency not known

With intra-uterine use Functional ovarian cysts (usually asymptomatic and usually resolve spontaneously—ultrasound monitoring recommended) · allergy · bleeding (on insertion) · cervical perforation · displacement · dysmenorrhoea · epileptic seizures (on insertion) · menorrhagia · pain (on insertion, alleviated by NSAID such as ibuprofen 30 minutes before insertion) · pelvic infection may be exacerbated · vasovagal attack (on insertion)

With oral use Breast discomfort · breast tenderness · changes in libido · disturbances of appetite · dizziness · fatigue · menstrual irregularities · skin disorders

Rare

With intra-uterine use

**SIDE-EFFECTS, FURTHER INFORMATION**

Breast cancer There is a small increase in the risk of having breast cancer diagnosed in women using, or who have recently used, a progestogen-only contraceptive pill; this relative risk may be due to an earlier diagnosis. The most important risk factor appears to be the age at which the contraceptive is stopped rather than the duration of use; the risk disappears gradually during the 10 years after stopping and there is no excess risk by 10 years. A possible small increase in the risk of breast cancer should be weighed against the benefits.

Although the progestogen-only intra-uterine system produces little systemic progestogenic activity, it is usually avoided for 5 years after any evidence of breast cancer. However, the system can be considered for a woman in long-term remission from breast cancer who has menorrhagia and requires effective contraception.

With intra-uterine use Endometrial disorders should be ruled out before insertion and the patient should be fully counselled (and provided with a patient information leaflet). Improvement in progestogenic side-effects, such as mastalgia and in the bleeding pattern may often become very light or absent. Removal of the intra-uterine system should be considered if the patient experiences migraine or severe headache, jaundice, marked increase of blood pressure, or severe arterial disease.

**PREGNANCY**

With oral use Not known to be harmful.

With vaginal use If an intra-uterine device fails and the woman wishes to continue to full-term the device should be removed in the first trimester if possible. Avoid; if pregnancy occurs remove intra-uterine system.

**BREAST FEEDING** Progestogen-only contraceptives do not affect lactation.

**HEPATIC IMPAIRMENT** Caution in severe liver disease and recurrent cholestatic jaundice. Avoid in liver tumour.

**MONITORING REQUIREMENTS**

With intra-uterine use Gynaecological examination before insertion, 4–6 weeks after insertion, then annually.

**DIRECTIONS FOR ADMINISTRATION**

With intra-uterine use The doctor or nurse administering (or removing) the system should be fully trained in the technique and should provide full counselling reinforced by the patient information leaflet.

**PRESCRIBING AND DISPENSING INFORMATION**

With intra-uterine use Levonorgestrel-releasing intra-uterine devices vary in licensed indication, duration of use and insertion technique—the MHRA recommends to prescribe and dispense by brand name to avoid inadvertent switching.

**MIRENA® 20MICROGRAMS/24HOURS INTRA-UTERINE DEVICE** When system is removed (and not immediately replaced) and pregnancy is not desired, remove during the first few days of menstruation, otherwise additional precautions (e.g. barrier methods) should be used for at least 7 days before removal.

**JAYDESS® 13.5MG INTRA-UTERINE DEVICE** When system is removed (and not immediately replaced) and pregnancy is not desired, remove within 7 days of the onset of menstruation; additional precautions (e.g. barrier methods) should be used if the system is removed at some other time during the cycle and there is intercourse within 7 days.

**LEVONELLE® ONE STEP** Can be sold to women over 16 years; when supplying emergency contraception to the public, pharmacists should refer to guidance issued by the Royal Pharmaceutical Society.

**PATIENT AND CARER ADVICE**

Diarrhoea and vomiting with use as an oral contraceptive Vomiting and persistent, severe diarrhoea can interfere with the absorption of oral progestogen-only contraceptives. If vomiting occurs within 2 hours of taking an oral progestogen-only contraceptive, another pill should be taken as soon as possible. If a replacement pill is not taken within 3 hours of the normal time for taking the progestogen-only pill, or in cases of persistent vomiting or very severe diarrhoea, additional precautions should be used during illness and for 2 days after recovery.

Starting routine

With oral use for contraception One tablet daily, on a continuous basis, starting on day 1 of cycle and taken at the same time each day (if delayed by longer than 3 hours contraceptive protection may be lost). Additional contraceptive precautions are not required if levonorgestrel is started up to and including day 5 of the menstrual cycle; if started after this time, additional contraceptive precautions are required for 2 days.

Changing from a combined oral contraceptive Start on the day following completion of the combined oral contraceptive course without a break (or in the case of ED tablets omitting the inactive ones). After childbirth Oral progestogen-only contraceptives can be started up to and including day 21 postpartum without the need for additional contraceptive precautions. If started more than 21 days postpartum, additional contraceptive precautions are required for 2 days.

With intra-uterine use Counsel women to seek medical attention promptly in case of significant symptoms, especially pain. Patient counselling advised. Patient information leaflet to be provided.

With oral use for emergency contraception If vomiting occurs within 2 hours of taking levonorgestrel, a replacement dose should be given.

When prescribing or supplying hormonal emergency contraception, women should be advised:

- that their next period may be early or late;
- that a barrier method of contraception needs to be used until the next period;
- to seek medical attention promptly if any lower abdominal pain occurs because this could signify an ectopic pregnancy;
- to return in 3 to 4 weeks if the subsequent menstrual bleed is abnormally light, heavy or brief, or is absent, or if she is otherwise concerned (if there is any doubt as to whether menstruation has occurred, a pregnancy test should be performed at least 3 weeks after unprotected intercourse).

**Missed doses**

When used as an oral contraceptive, the following advice is recommended ‘If you forget a pill, take it as soon as you remember and carry on with the next pill at the right time. If the pill was more than 3 hours overdue you are not
protected. Continue normal pill-taking but you must also use another method, such as the condom, for the next 2 days’.

The Faculty of Sexual and Reproductive Healthcare recommends emergency contraception if one or more progestogen-only contraceptive tablets are missed or taken more than 3 hours late and unprotected intercourse has occurred before 2 further tablets have been correctly taken.

● EXCEPTIONS TO LEGAL CATEGORY Levonelle® One Step can be sold to women over 16 years; when supplying emergency contraception to the public, pharmacists should refer to guidance issued by the Royal Pharmaceutical Society.

● MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

### Intra-uterine device

- **Jaydess** (Bayer Plc)
  - Levonorgestrel 13.5 mg Jaydess 13.5mg intra-uterine device | 1 device [PoM] £69.22
- **Levosert** (Allergan Ltd)
  - Levonorgestrel 20 microgram per 24 hour Levosert 20micrograms/24hours intra-uterine device | 1 device [PoM] £66.00 DT price = £88.00
- **Mirena** (Bayer Plc)
  - Levonorgestrel 20 microgram per 24 hour Mirena 20micrograms/24hours intra-uterine device | 1 device [PoM] £88.00 DT price = £88.00

### Tablet

- **Levonorgestrel (Non-proprietary)**
  - Levonorgestrel 1.5 mg Levonorgestrel 1.5mg tablets | 1 tablet [P] £13.83 DT price = £5.20 | 1 tablet [PoM] £3.74-£5.20 DT price = £5.20
- **Emerges** (Morningside Healthcare Ltd)
  - Emerges 1.5mg tablets | 1 tablet [P] £13.83 DT price = £5.20
  - Emerges Una 1.5mg tablets | 1 tablet [P] £3.65 DT price = £5.20
- **Ezilinelle** (Mylan Ltd)
  - Ezilinelle 1.5mg tablets | 1 tablet [P] £9.64 DT price = £5.20
- **Levonelle** (Bayer Plc)
  - Levonorgestrel 1.5 mg Levonelle 1500microgram tablets | 1 tablet [PoM] £5.20 DT price = £5.20
  - Levonelle One Step 1.5mg tablets | 1 tablet [P] £13.83 DT price = £5.20
- **Norgeston** (Bayer Plc)
  - Norgeston 30 microgram Norgeston 30microgram tablets | 35 tablet [PoM] £0.92 DT price = £0.92
- **Upostelle** (Consilient Health Ltd)
  - Upostelle 1.5 mg Upostelle 1500microgram tablets | 1 tablet [PoM] £3.75 DT price = £5.20

### Contraception (postpartum)

- **BY SUBDERMAL IMPLANTATION**
  - Females of childbearing potential: 1 implant to be inserted 21–28 days after delivery (delay until 28 days postpartum if breast-feeding), implant should be removed within 3 years of insertion

### Contraception following abortion or miscarriage in the second trimester

- **BY SUBDERMAL IMPLANTATION**
  - Females of childbearing potential: 1 implant to be inserted 21–28 days after abortion or miscarriage, implant should be removed within 3 years of insertion

### Contraception following abortion or miscarriage in the first trimester

- **BY SUBDERMAL IMPLANTATION**
  - Females of childbearing potential: 1 implant to be inserted within 5 days after abortion or miscarriage, implant should be removed within 3 years of insertion

### Contraception (changing from other hormonal contraceptive)

- **BY SUBDERMAL IMPLANTATION**
  - Females of childbearing potential: Implant should be removed within 3 years of insertion (consult product literature)

### UNLICENSED USE

Nexplanon® not licensed for use in females outside of the age range 18–40 years.

**IMPORTANT SAFETY INFORMATION**

**MRHA/CHM ADVICE (JUNE 2016): NEXPLANON® (ETONOGESTREL) CONTRACEPTIVE IMPLANTS: REPORTS OF DEVICE IN VASCULATURE AND LUNG**

There have been rare reports of Nexplanon® implants reaching the lung via the pulmonary artery. An implant that cannot be palpated at its insertion site should be located and removed as soon as possible; if unable to locate implant within the arm, the MRHA recommends using chest imaging. Correct subdermal insertion reduces the risk of these events.

### CONTRA-INDICATIONS

Acute porphyria - history of breast cancer but can be used after 5 years if no evidence of disease and non-hormonal contraceptive methods unacceptable - severe arterial disease - undiagnosed vaginal bleeding

### CAUTIONS

Active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration)—seek specialist advice - arterial disease - disturbances of lipid metabolism - history during pregnancy of deterioration of otosclerosis - history during pregnancy of pruritus - history of jaundice in pregnancy - malabsorption syndromes - possible risk of breast cancer - sex-steroid dependent cancer - systemic lupus erythematosus with positive (or unknown) antiphospholipid antibodies

### INTERACTIONS

Appendix 1: etonogestrel

### SIDE-EFFECTS

Breast discomfort - changes in libido - depression - disturbance of appetite - dizziness - headache - injection - site reactions - menstrual irregularities - nausea - vomiting

### SIDE-EFFECTS, FURTHER INFORMATION

Cervical cancer - Use of injectable progestogen-only contraceptives may be associated with a small increased risk of cervical cancer, similar to that seen with combined oral contraceptives. The risk of cervical cancer with other progestogen-only contraceptives is not yet known.

Breast cancer - There is a small increase in the risk of having breast cancer diagnosed in women using, or who have recently used, a progestogen-only contraceptive pill; this relative risk may be due to an earlier diagnosis. The most important risk factor appears to be the age at which the

### PROGESTOGENS

#### Etonogestrel

- **INDICATIONS AND DOSE**

  - **Contraception (no hormonal contraceptive use in previous month)**
    - **BY SUBDERMAL IMPLANTATION**
    - Females of childbearing potential: 1 implant inserted during first 5 days of cycle, implant should be removed within 3 years of insertion

Other drugs used for Contraception, parenteral progestogen-only: Norethisterone, p. 720
contraceptive is stopped gradually rather than the duration of use; the risk disappears gradually during the 10 years after stopping and there is no excess risk by 10 years. A possible small increase in the risk of breast cancer should be weighed against the benefits.

- **Pregnancy** Not known to be harmful, remove implant if pregnancy occurs.
- **Breast Feeding** Progestogen-only contraceptives do not affect lactation.
- **Directions for Administration** The doctor or nurse administering (or removing) the system should be fully trained in the technique and should provide full counselling reinforced by the patient information leaflet.
- **Patient and Carer Advice** Full counselling backed by patient information leaflet required before administration.

**Medroxyprogesterone Acetate**

- **INDICATIONS AND DOSE**
  - Dysfunctional uterine bleeding
    - **By Mouth**
    - Adult: 2.5–10 mg daily for 5–10 days, repeated for 2 cycles, begin treatment on day 16–21 of cycle
  - Secondary amenorrhoea
    - **By Mouth**
    - Adult: 2.5–10 mg daily for 5–10 days, repeated for 3 cycles, begin treatment on day 16–21 of cycle
  - Mild to moderate endometriosis
    - **By Mouth**
    - Adult: 10 mg 3 times a day for 90 consecutive days, begin treatment on day 1 of cycle
  - Progestogenic opposition of oestrogen HRT
    - **By Mouth**
    - Adult: 10 mg daily for the last 14 days of each 28-day oestrogen HRT cycle
  - Endometrial cancer | Renal cell cancer
    - **By Mouth**
    - Adult: 200–600 mg daily
  - Breast cancer
    - **By Mouth**
    - Adult: 0.4–1.5 g daily
  - Contraception
    - **By Deep Intramuscular Injection**
    - Females of childbearing potential: 150 mg, to be administered within the first 5 days of cycle or within first 5 days after parturition (delay until 6 weeks after parturition if breast-feeding)
    - **By Subcutaneous Injection**
    - Females of childbearing potential: 104 mg, to be administered within the first 5 days of cycle or within 5 days postpartum (delay until 6 weeks postpartum if breast-feeding), injected into anterior thigh or abdomen, dose only suitable if no hormonal contraceptive use in previous month
  - Long-term contraception
    - **By Deep Intramuscular Injection**
    - Females of childbearing potential: 150 mg every 12 weeks, first dose to be administered within the first 5 days of cycle or within first 5 days after parturition (delay until 6 weeks after parturition if breast-feeding)
    - **By Subcutaneous Injection**
    - Females of childbearing potential: 104 mg, to be administered within the first 5 days of cycle or within 5 days postpartum (delay until 6 weeks postpartum if breast-feeding), injected into anterior thigh or abdomen, dose only suitable if no hormonal contraceptive use in previous month

**Contraception (When Patient Changing from Other Hormonal Contraceptive)**

- **By Subcutaneous Injection**
  - Females of childbearing potential: 104 mg every 13 weeks, first dose to be administered within first 5 days of cycle or within 5 days postpartum (delay until 6 weeks postpartum if breast-feeding), injected into anterior thigh or abdomen, dose only suitable if no hormonal contraceptive use in previous month

**Side-Effects**

- **General Side-Effects**
  - Breast discomfort
  - Changes in libido
  - Depression
  - Dizziness
  - Headache
  - Indigestion
  - Loss of vision during treatment (discontinue treatment if papilloedema or retinal vascular lesions)
  - Menstrual irregularities
  - Nausea
  - Pruritus
  - Vomiting
  - Weight gain

**Specific Side-Effects**

- **Rare**
  - With intramuscular use or subcutaneous use
  - Osteoporosis
  - Osteoporotic fractures
  - Frequency not known
  - With intramuscular use or subcutaneous use
  - Disturbance of appetite
  - Injection site-reactions
  - Reduced bone mineral density
  - Skin disorders
  - With oral use
    - Acne
    - Adrenergic-like effects (when used for malignant disease)
    - Alopecia
    - Anaphylactoid reactions
    - Bloating
    - Breast tenderness
    - Cervical erosions
    - Confusion (when used for malignant disease)
Genito-urinary system

RENAL IMPAIRMENT
- When used for mild to moderate endometriosis or Progestogen
  opposition of oestrogen HRT or dysfunctional uterine bleeding or
  secondary amenorrhoea. Use with caution.

PATIENT AND CARER ADVICE
- With intramuscular use or subcutaneous use. Full counselling
  backed by patient information leaflet required before
  administration—likelihood of menstrual disturbance and
  the potential for a delay in return to full fertility. Delayed
  return of fertility and irregular cycles may occur after
  discontinuation of treatment but there is no evidence of
  permanent infertility.

Gel
- Excipients: May contain hydroxybenzoates (parabens), propylene
  glycol, sorbic acid.
- Gygel (Marlborough Pharmaceuticals Ltd)
  Nonoxinol-9 20 mg per 1 ml Gygel 2% contraceptive jelly | 30
  gram | £4.25 | 81 gram | £11.00

■ MEDICINAL FORMS
- There can be variation in the licensing of different medicines
  containing the same drug. Forms available from special-order
  manufacturers include: oral suspension, oral solution.

Tablet
- Climanor (Resourcing Medical Ltd)
  Medroxyprogesterone acetate 5 mg Climanor 5 mg tablets | 28
  tablet | £3.27
- Provera (Pfizer Ltd)
  Medroxyprogesterone acetate 5 mg Provera 5 mg tablets | 10
  tablet | £1.23 DT price = £1.84
  Medroxyprogesterone acetate 5 mg Provera 5 mg tablets | 10
  tablet | £1.23 DT price = £1.23 | 100 tablet | £12.32
  Provera 10 mg tablets | 10
  tablet | £2.47 | 90 tablet | £22.16 DT price = £22.16 | 100
  tablet | £24.73
  Provera 20 mg tablets | 10
  tablet | £29.59 | 100 tablet | £49.94 DT price = £49.94
  Medroxyprogesterone acetate 200 mg Provera 200 mg tablets | 30
  tablet | £29.65 DT price = £29.65
  Provera 400 mg tablets | 30
  tablet | £58.67 DT price = £58.67

Suspension for injection
- Depo-Provera (Pfizer Ltd)
  Medroxyprogesterone acetate 150 mg per 1 ml Depo-Provera
  150 mg/mL suspension for injection pre-filled syringes | 1 pre-filled
  disposable injection | £6.01 DT price = £6.01
- Sayana Press (Pfizer Ltd)
  Medroxyprogesterone acetate 160 mg per 1 ml Sayana Press
  104 mg/0.65 ml suspension for injection pre-filled disposable devices
  | 1 pre-filled disposable injection | £6.90

SIDES-EFFECTS, FURTHER INFORMATION
- With intramuscular use or subcutaneous use. Use of injectable
  progesterone-only contraceptives may be associated with
  a small increased risk of cervical cancer, similar to that seen
  with combined oral contraceptives. The risk of cervical cancer
  with other progesterone-only contraceptives is not yet
  known.
- With intramuscular use or subcutaneous use. Reduction in bone
  mineral density occurs in the first 2–3 years of use then
  stabilises.

CONCEPTION AND CONTRACEPTION
- With intramuscular use. If interval between dose is greater
  than 12 weeks and 5 days (long-term contraception),
  rule out pregnancy before next injection, and advise
  patient to use additional contraceptive measures (e.g.
  barrier) for 14 days after the injection.
- With subcutaneous use. If interval between dose is greater
  than 13 weeks and 7 days (long-term contraception),
  rule out pregnancy before next injection.

PREGNANCY
- With oral use. Avoid—genital malformations and cardiac
defects reported.
- With intramuscular use or subcutaneous use. Not known to be
  harmful.

BREAST FEEDING
- Present in milk—no adverse effects reported. Progestogen-only
  contraceptives do not affect lactation.
- With intramuscular use or subcutaneous use. The
  manufacturers advise that in women who are breast-
  feeding, the first dose should be delayed until 6 weeks after
  birth; however, evidence suggests no harmful effect to
  infant if given earlier. The benefits of using
  medroxyprogesterone acetate in breast-feeding women
  outweigh any risks.

HEPATIC IMPAIRMENT
- Avoid in liver tumour.
- With oral use. Avoid in hepatic impairment.
- With intramuscular use or subcutaneous use. Caution in severe
  liver disease and recurrent cholestatic jaundice.

RENAL IMPAIRMENT
- When used for mild to moderate endometriosis or Progestogen
  opposition of oestrogen HRT or dysfunctional uterine bleeding or
  secondary amenorrhoea. Use with caution.

PATIENT AND CARER ADVICE
- With intramuscular use or subcutaneous use. Full counselling
  backed by patient information leaflet required before
  administration—likelihood of menstrual disturbance and
  the potential for a delay in return to full fertility. Delayed
  return of fertility and irregular cycles may occur after
  discontinuation of treatment but there is no evidence of
  permanent infertility.

3.6 Contraception, spermicidal SPERMICIDALS

Nonoxinol

INDICATIONS AND DOSE
Spermicidal contraceptive in conjunction with barrier
methods of contraception such as diaphragms or caps
- By Vagina
- Females of childbearing potential: (consult product
  literature)

SIDE-EFFECTS
Genital lesions

SIDE-EFFECTS, FURTHER INFORMATION
High frequency use of the spermicide nonoxinol 9 has
been associated with genital lesions, which may increase the
risk of acquiring these infections.

CONCEPTION AND CONTRACEPTION
No evidence of harm to latex condoms and diaphragms.

PREGNANCY
Toxicity in animal studies.

BREAST FEEDING
Present in milk in animal studies.

MEDICINAL FORMS
There can be variation in the licensing of different medicines
containing the same drug. Forms available from special-order
manufacturers include: oral suspension, oral solution.
4 Erectile and ejaculatory conditions

4.1 Erectile dysfunction

Erectile dysfunction

06-Mar-2017

Description of condition

Erectile dysfunction (impotence) is the persistent inability to attain and maintain an erection that is sufficient to permit satisfactory sexual performance. It can have physical or psychological causes. Erectile dysfunction can also be a side-effect of drugs such as antihypertensives, antidepressants, antipsychotics, cytotoxic drugs and recreational drugs (including alcohol).

Risk factors for erectile dysfunction include sedentary lifestyle, obesity, smoking, hypercholesterolaemia and metabolic syndrome. Erectile dysfunction increases the risk of cardiovascular disease. All men with unexplained erectile dysfunction should be evaluated for the presence of cardiovascular disease. All men with erectile dysfunction should be evaluated for the presence of cardiovascular risk factors and any identified risk should be addressed.

Drug treatment

The recommended approach for the management of erectile dysfunction is a combination of drug treatment and lifestyle changes (including regular exercise, reduction in body mass index, smoking cessation, and reduced alcohol consumption).

An oral phosphodiesterase type-5 inhibitor is the first-line drug treatment for erectile dysfunction, regardless of the cause. These drugs act by increasing the blood flow to the penis. They do not initiate an erection—sexual stimulation is required.

The choice of oral phosphodiesterase type-5 inhibitor depends on the frequency of intercourse and response to treatment. Avanafil below, sildenafil p. 766 and vardenafil p. 768 are short-acting drugs and are suitable for occasional use as required. Tadalafil p. 767 is a longer-acting drug. It can be used as required, but can also be used as a regular lower daily dose to allow for spontaneous (rather than scheduled) sexual activity or in those who have frequent sexual activity. A patient with erectile dysfunction should receive six doses of an individual phosphodiesterase type-5 inhibitor at the maximum dose (with sexual stimulation) before being classified as a non-responder. Patients who fail to respond to the maximum dose of at least two different phosphodiesterase type-5 inhibitors should be referred to a specialist.

Intracavernosal, intraurethral or topical application of alprostadil p. 769 (prostaglandin E1) is recommended as second-line therapy under careful medical supervision. Intracavernosal or intraurethral preparations can also be used to aid diagnosis.

Priapism associated with alprostadil

Manufacturers advise that patients should seek medical help if a prolonged erection lasting four hours or more occurs; application of an ice pack to the upper-inner thigh (alternating between the left and right thighs every two minutes for up to ten minutes) may result in reflex opening of the venous valves.

If priapism has lasted more than six hours, treatment should not be delayed; manufacturer advises management as follows:

- Initial therapy by penile aspiration: using aseptic technique, 20–50mL of blood should be aspirated using a 19–21 gauge butterfly needle inserted into the corpus cavernosum; if necessary the procedure may be repeated on the opposite side;
- Lavage: if initial aspiration is unsuccessful, a second 19–21 gauge butterfly needle can be inserted into the opposite corpus cavernosum; sterile physiological saline can be injected through the first needle and drained through the second;
- If aspiration and lavage of are unsuccessful, intracavernosal injection of a sympathomimetic with action on alpha-adrenergic receptors can be given, with continuous monitoring of blood pressure and pulse—see phenylephrine hydrochloride p. 772 [unlicensed indication], adrenaline/epinephrine p. 771 [unlicensed indication], and metaraminol p. 772 [unlicensed indication]. Extreme caution is required in patients with coronary heart disease, hypertension, cerebral ischaemia and in patients taking a monoamine-oxidase inhibitor (facilities for managing hypertensive crisis should be available when administered to patients taking MAOIs);
- If necessary the sympathomimetic injections can be followed by further aspiration of blood through the same butterfly needle;
- If administration of a sympathomimetic drug is unsuccessful, urgent referral for surgical management is required.

Prescribing on the NHS


PHOSPHODIESTERASE TYPE-5 INHIBITORS

Avanafil

- INDICATIONS AND DOSE

Erectile dysfunction

- BY MOUTH

- Adult: Initially 100 mg, to be taken approximately 15–30 minutes before sexual activity, then adjusted according to response to 50–200 mg (max. per dose 200 mg), to be taken as a single dose as needed; maximum 1 dose per day

Erectile dysfunction in patients on alpha-blocker therapy

- BY MOUTH

- Adult: Initially 50 mg, to be taken approximately 15–30 minutes before sexual activity, then adjusted according to response to 50–200 mg (max. per dose 200 mg), to be taken as a single dose as needed; maximum 1 dose per day

DOSE ADJUSTMENTS DUE TO INTERACTIONS

Manufacturer advises max. 100 mg once every 48 hours with concurrent use of moderate inhibitors of CYP3A4.

- CONTRA-INDICATIONS Avoid if systolic blood pressure below 90 mmHg (no information available) • blood pressure >170/100 mmHg • hereditary degenerative retinal disorders • history of non-arteritic anterior ischaemic optic neuropathy • life-threatening arrhythmia in previous 6 months • mild to severe heart failure • patients in whom vasodilation or sexual activity are inadvisable • recent history of myocardial infarction • recent history of stroke • recent unstable angina
Erectile and ejaculatory conditions

**Genito-urinary system**

**Genito-urinary system**

### NATIONAL FUNDING/ACCESS DECISIONS

**PATIENT AND CARER ADVICE**

**INTERACTIONS** → Appendix 1: phosphodiesterase type-5 inhibitors

**SIDE-EFFECTS**

- **Common or very common** Back pain, dizziness, dyspepsia, flushing, headache, migraine, myalgia, nasal congestion, nausea, visual disturbances, vomiting
- **Uncommon** Drowsiness, epistaxis, hypertension, hypotension, malaïse, painful red eyes, palpitation, tachycardia
- **Rare** Abdominal pain, diarrhoea, dry mouth, facial oedema, gastritis, genital irritation, gout, haematuria, hyperactivity, hyperbilirubinaemia, hypersensitivity reactions, increased serum creatinine, insomnia, muscle spasms, peripheral oedema, polliakiuria, priapism, rash, Stevens-Johnson syndrome, syncope, weight gain
- **Frequency not known** Arrhythmia, myocardial infarction, non-artertiar anterior ischaemic optic neuropathy (stop drug if sudden visual impairment occurs), retinal vascular occlusion, seizures, serious cardiovascular events, sudden hearing loss (discontinue drug and seek medical advice), unstable angina

**HEPATIC IMPAIRMENT** Use lowest effective initial dose in mild to moderate impairment, adjusted according to response. Manufacturer advises avoid in severe impairment—no information available.

**RENAL IMPAIRMENT** Avoid if eGFR less than 30 mL/minute/1.73 m².

**NATIONAL FUNDING/ACCESS DECISIONS**

**NHS restrictions** Spedra® is not prescribable under the NHS for treatment of erectile dysfunction except in men who meet the criteria listed in part XVIII B of the Drug Tariff (Part XI b of the Northern Ireland Drug Tariff, Part 12 of the Scottish Drug Tariff). The prescription must be endorsed ‘SLS’.

The Drug Tariffs can be accessed online at: National Health Service Drug Tariff for England and Wales: www.ppa.org.uk/ppa/edt_intro.htm; Health and Personal Social Services for Northern Ireland Drug Tariff: www.hscbusiness.hscni.net/services/2034.htm; Scottish Drug Tariff: www.isdscotland.org/Health-Topics/Prescribing-and-Medicines/Scottish-Drug-Tariff/

**MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- Spedra® (A. Menarini Farmaceutica Internazionale SRL) ▼
  - **Avanafil 50 mg** Spedra® 50mg tablets | 4 tablet | £10.94 DT price = £10.94 | 8 tablet | £19.70 DT price = £19.70
  - **Avanafil 100 mg** Spedra® 100mg tablets | 4 tablet | £14.08 DT price = £14.08 | 8 tablet | £26.26 DT price = £26.26
  - **Avanafil 200 mg** Spedra® 200mg tablets | 4 tablet | £21.90 DT price = £21.90 | 8 tablet | £39.40 DT price = £39.40

**Sildenafil**

**INDICATIONS AND DOSE**

**Pulmonary arterial hypertension (initiated under specialist supervision)**

- **BY MOUTH**
  - Adult: 20 mg 3 times a day

- **BY INTRAVENOUS INJECTION**
  - Adult: 10 mg 3 times a day, use intravenous route when the oral route is not appropriate

**Erectile dysfunction**

- **BY MOUTH**
  - Adult: Initially 50 mg, to be taken approximately 1 hour before sexual activity, adjusted according to response to 25–100 mg (max. per dose 100 mg) as required, to be taken as a single dose; maximum 1 dose per day

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**

- When used for Erectile dysfunction Manufacturer advises a starting dose of 25 mg with concurrent use of moderate and potent inhibitors of CYP3A4. Manufacturer advises if concurrent use of ritonavir is unavoidable, the max. dose should not exceed 25 mg within 48 hours.
- With oral use for Pulmonary arterial hypertension Manufacturer advises reduce dose to 20 mg twice daily with concurrent use of moderate inhibitors of CYP3A4. Manufacturer advises reduce dose to 20 mg once daily with concurrent use of some potent inhibitors of CYP3A4 (avoid with ketoconazole, itraconazole and ritonavir).
- With intravenous use for Pulmonary arterial hypertension Manufacturer advises reduce dose to 10 mg twice daily with concurrent use of moderate inhibitors of CYP3A4. Manufacturer advises reduce dose to 10 mg once daily with concurrent use of some potent inhibitors of CYP3A4 (avoid with ketoconazole, itraconazole and ritonavir).

**CONTRA-INDICATIONS**

**GENERAL CONTRA-INDICATIONS**

Hereditary degenerative retinal disorders - history of non-arterior anterior ischaemic optic neuropathy - recent history of myocardial infarction - recent history of stroke

**SPECIFIC CONTRA-INDICATIONS**

- When used for erectile dysfunction Avoid if systolic blood pressure below 90 mmHg (no information available) • patients in whom vasodilation or sexual activity are inadvisable - recent unstable angina
- When used for pulmonary arterial hypertension Sickle-cell anaemia

**CAUTIONS**

**GENERAL CAUTIONS**

Active peptic ulceration - bleeding disorders - cardiovascular disease - left ventricular outflow obstruction

**SPECIFIC CAUTIONS**

- When used for erectile dysfunction Anatomical deformation of the penis (e.g. angulation, cavernosal fibrosis, Peyronie’s disease) - predisposition to priapism (e.g. in sickle-cell disease, multiple myeloma, or leukaemia)
- When used for pulmonary arterial hypertension Anatomical deformation of the penis - autonomic dysfuncin - hypotension (avoid if systolic blood pressure below 90 mmHg) - intravascular volume depletion - predisposition to priapism - pulmonary veno-occlusive disease

**INTERACTIONS** → Appendix 1: phosphodiesterase type-5 inhibitors

**SIDE-EFFECTS** → Appendix 1: phosphodiesterase type-5 inhibitors

- **Common or very common** Back pain, dyspepsia, flushing, migraine, myalgia, nasal congestion, visual disturbances
- **Frequency not known** Non-arterior anterior ischaemic optic neuropathy (discontinue if sudden visual impairment occurs) • sudden hearing loss (advise patient to seek medical help)
Tadalafil

- **INDICATIONS AND DOSE**

  - **Pulmonary arterial hypertension (initiated under specialist supervision)**
    - **BY MOUTH**
    - Adult: 40 mg once daily

  - **Erectile dysfunction**
    - **BY MOUTH**
    - Adult: Initially 10 mg once daily (max. per dose 20 mg), to be taken at least 30 minutes before sexual activity, subsequent doses adjusted according to response, the effect of intermittent dosing may persist for longer than 24 hours, daily dose of 10–20 mg not recommended; maximum 1 dose per day

  - **Erectile dysfunction; for patients who anticipate sexual activity at least twice a week**
    - **BY MOUTH**
    - Adult: 5 mg once daily, reduced to 2.5 mg once daily, adjusted according to response, the effect continued

---

**SPECIFIC SIDE-EFFECTS**
- **Common or very common**
  - When used for erectile dysfunction Nausea, dizziness, vomiting
  - When used for pulmonary arterial hypertension Abdominal distension, alopecia, anaemia, anxiety, bronchitis, cellulitis, cough, diarrhoea, dry mouth, epistaxis, fever, gastritis, gastro-oesophageal reflux, haemorrhoids, headache, influenza-like symptoms, insomnia, limb pain, night sweats, oedema, painful red eyes, parasthesia, photophobia, retinal haemorrhage, tremor, vertigo
- **Uncommon**
  - When used for erectile dysfunction Chest pain, drowsiness, dry mouth, epistaxis, fatigue, hypertension, hypoaesthesia, hypotension, painful red eyes, palpitation, tachycardia, tinnitus, vertigo
  - When used for pulmonary arterial hypertension Gynaecomastia, haematuria, penile haemorrhage, priapism
- **Rare**
  - When used for erectile dysfunction Atrial fibrillation, cerebrovascular accident, facial oedema, hypersensitivity reactions, priapism, rash, Stevens-Johnson syndrome, syncope
- **Frequency not known**
  - When used for erectile dysfunction Arrhythmia, myocardial infarction, seizures, unstable angina
  - When used for pulmonary arterial hypertension Rash, retinal vascular occlusion

**PREGNANCY**
Use only if potential benefit outweighs risk—no evidence of harm in animal studies.

**BREAST FEEDING**
Manufacturer advises avoid—no information available.

**HEPATIC IMPAIRMENT**
In pulmonary arterial hypertension, if usual dose not tolerated, reduce oral dose to 20 mg daily and intravenous dose to 10 mg twice daily. For erectile dysfunction, use initial dose of 25 mg. Manufacturer advises avoid in severe impairment.

**RENAL IMPAIRMENT**
Use initial dose of 25 mg in erectile dysfunction if eGFR less than 30 mL/minute/1.73 m².

In pulmonary hypertension, if usual dose not tolerated, reduce oral dose to 20 mg twice daily and intravenous dose to 10 mg twice daily.

**TREATMENT CESSATION**
- When used for Pulmonary arterial hypertension Consider gradual withdrawal.

**PATIENT AND CARER ADVICE**
- When used for erectile dysfunction Onset of effect may be delayed if taken with food.

**NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (January 2010 and February 2011) that sildenafil tablets (Revatio®) should be initiated for patients with pulmonary arterial hypertension only by specialists in the Scottish Pulmonary Vascular Unit or other similar specialists and that sildenafil injection (Revatio®) should be prescribed only on the advice of specialists in the Scottish Pulmonary Vascular Unit or the Scottish Adult Congenital Cardiac Service.

NHS restrictions Viagra® is not prescribable under NHS for treatment of erectile dysfunction except in men who meet the criteria listed in part XVIIIb of the Drug Tariff (Part Xib of the Northern Ireland Drug Tariff, Part 12 of the Scottish Drug Tariff). The prescription must be endorsed ‘SL’S’. For more information see Prices in the BNF, under How to use the BNF.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Tablet**

- **Sildenafil (Non-proprietary)**
  - Sildenafil (as Sildenafil citrate) 20 mg Sildenafil 20mg tablets 90 tablet [Pkt] £37.38—£424.01
  - Sildenafil (as Sildenafil citrate) 25 mg Sildenafil 25mg tablets 4 tablet [Pkt] £16.59 DT price = £0.78 | 8 tablet [Pkt] £33.19
  - Sildenafil (as Sildenafil citrate) 50 mg Sildenafil 50mg tablets 4 tablet [Pkt] £21.27 DT price = £0.86 | 8 tablet [Pkt] £42.54
  - Sildenafil (as Sildenafil citrate) 100 mg Sildenafil 100mg tablets 4 tablet [Pkt] £23.50 DT price = £0.94 | 8 tablet [Pkt] £46.99 | 12 tablet [Pkt] £6.69
  - **Revatio® (Pfizer Ltd)**
    - Sildenafil (as Sildenafil citrate) 20 mg Revatio 20mg tablets 90 tablet [Pkt] £446.33
    - **Viagra® (Pfizer Ltd)**
      - Sildenafil (as Sildenafil citrate) 25 mg Viagra 25mg tablets 4 tablet [Pkt] £16.59 DT price = £0.78 | 8 tablet [Pkt] £33.19
      - Sildenafil (as Sildenafil citrate) 50 mg Viagra 50mg tablets 4 tablet [Pkt] £21.27 DT price = £0.86 | 8 tablet [Pkt] £42.54
      - Sildenafil (as Sildenafil citrate) 100 mg Viagra 100mg tablets 4 tablet [Pkt] £23.50 DT price = £0.94 | 8 tablet [Pkt] £46.09
  - **Vizarsin® (Consilient Health Ltd)**
    - Sildenafil (as Sildenafil citrate) 25 mg Vizarsin 25mg tablets 4 tablet [Pkt] £14.10 DT price = £0.78
    - Sildenafil (as Sildenafil citrate) 50 mg Vizarsin 50mg tablets 4 tablet [Pkt] £18.07 DT price = £0.86
    - Sildenafil (as Sildenafil citrate) 100 mg Vizarsin 100mg tablets 4 tablet [Pkt] £19.97 DT price = £0.94

**Solution for injection**

- **Revatio® (Pfizer Ltd)**
  - Sildenafil (as Sildenafil citrate) 8 mg per 1 ml Revatio 10mg/12.5ml solution for injection vials | 1 vial [Pkt] £45.28

**Oral suspension**

- **Revatio® (Pfizer Ltd)**
  - Sildenafil (as Sildenafil citrate) 10 mg per 1 ml Revatio 10mg/ml oral suspension sugar-free | 112 ml [Pkt] £186.75

**Chewable tablet**

CAUTIONARY AND ADVISORY LABELS 24
EXCIPIENTS: May contain: Aspartame

- **Nipatran® (AMCo)**
  - Sildenafil (as Sildenafil citrate) 25 mg Nipatra 25mg chewable tablets sugar-free | 4 tablet [Pkt] £1.05 sugar-free | 8 tablet [Pkt] £2.10
  - Sildenafil (as Sildenafil citrate) 50 mg Nipatra 50mg chewable tablets sugar-free | 4 tablet [Pkt] £1.03 sugar-free | 8 tablet [Pkt] £2.06
  - Sildenafil (as Sildenafil citrate) 100 mg Nipatra 100mg chewable tablets sugar-free | 4 tablet [Pkt] £1.11 sugar-free | 8 tablet [Pkt] £2.22
CONTRA-INDICATIONS

General Contra-Indications

History of non-arteritic anterior ischaemic optic neuropathy

Specific Contra-Indications

- When used for benign prostatic hyperplasia or erectile dysfunction: Hypotension (avoid if systolic blood pressure below 90 mmHg) - mild to severe heart failure - myocardial infarction - patients in whom vasodilatation or sexual activity are inadvisable - recent stroke - uncontrolled arhythmias - uncontrolled hypertension - unstable angina

- When used for pulmonary arterial hypertension: Acute myocardial infarction in past 90 days

Cautions

- When used for benign prostatic hyperplasia or erectile dysfunction: Anatomical deformation of the penis (e.g. angulation, cavernosal fibrosis, Peyronie’s disease) - cardiovascular disease - left ventricular outflow obstruction - predisposition to priapism (e.g. in sickle-cell disease, multiple myeloma, or leukaemia)

- When used for pulmonary arterial hypertension: Anatomical deformation of the penis - aortic and mitral valve disease - congestive cardiomyopathy - coronary artery disease - hereditary degenerative retinal disorders - hypertension (avoid if systolic blood pressure below 90 mmHg) - left ventricular dysfunction - life-threatening arhythmias - pericardial constriction - predisposition to priapism - pulmonary veno-occlusive disease - uncontrolled hypertension

Interactions

Appendix 1: Phosphodiesterase type-5 inhibitors

Side Effects

General Side-Effects

- Common or very common: Back pain - dyspepsia - flushing - headache - myalgia - nausea - vomiting

- Uncommon: Hypertension - tachycardia

- Frequency not known: Arrhythmia - myocardial infarction - non-arteritic anterior ischaemic optic neuropathy (stop drug if sudden visual impairment occurs) - retinal vascular occlusion - sudden hearing loss (discontinue drug and seek medical advice) - unstable angina

Specific Side-Effects

- Common or very common

- When used for benign prostatic hyperplasia or erectile dysfunction: Dizziness - migraine - nasal congestion - visual disturbances

- When used for pulmonary arterial hypertension: Blurred vision - chest pain - epistaxis - facial oedema - gastro-oesophageal reflux - hypotension - increased uterine bleeding - limb pain - nasopharyngitis - palpitation - rash

- Uncommon

- When used for benign prostatic hyperplasia or erectile dysfunction: Epistaxis - hypotension - painful red eyes - palpitation

- When used for pulmonary arterial hypertension: Amnesia - hyperhidrosis - priapism - seizures

- Rare

- When used for benign prostatic hyperplasia or erectile dysfunction: Facial oedema - hypersensitivity reactions - priapism - rash - Stevens-Johnson syndrome - syncope

- Frequency not known

- When used for benign prostatic hyperplasia or erectile dysfunction: Abdominal pain - increased sweating - seizures - serious cardiovascular events - transient amnesia

- When used for pulmonary arterial hypertension: Stevens-Johnson syndrome - stroke - visual field defect

Pregnancy

Manufacturer advises avoid.

Breast Feeding

Manufacturer advises avoid—present in milk in animal studies.

Hepatic Impairment

For pulmonary arterial hypertension use initial dose of 20 mg once daily in mild to moderate impairment. Use maximum dose of 10 mg in erectile dysfunction and benign prostatic hyperplasia. When used for pulmonary arterial hypertension, avoid in severe impairment. Manufacturer advises caution in severe impairment and for regular once–daily dosing in erectile dysfunction and benign prostatic hyperplasia—no information available.

Renal Impairment

In pulmonary arterial hypertension for patients with mild to moderate impairment, initially use 20 mg once daily, increased to 40 mg once daily if tolerated. For erectile dysfunction and benign prostatic hyperplasia, maximum dose 10 mg if eGFR less than 30 mL/minute/1.73 m² (avoid regular once–daily dosing). In pulmonary arterial hypertension, avoid in severe impairment.

National Funding/Access Decisions

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (June 2012) that tadalafil (Adcirca®) should be initiated only by specialists in the Scottish Pulmonary Vascular Unit or other similar specialists.

NHS restrictions

Cialis® is not prescribable under the NHS for treatment of erectile dysfunction except in men who meet the criteria listed in part XVIIIB of the Drug Tariff (Part XIB of the Northern Ireland Drug Tariff, Part 12 of the Scottish Drug Tariff). The prescription must be endorsed ‘SLS’. For more information see Prices in the BNF, under How to use the BNF.

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug.

Tablet

- Adcirca (Eli Lilly and Company Ltd)
  - Tadalafil 20 mg
  - Price: £49.12
- Cialis (Eli Lilly and Company Ltd)
  - Tadalafil 2.5 mg
  - Price: £54.99
  - Tadalafil 5 mg
  - Price: £54.99
  - Tadalafil 10 mg
  - Price: £28.88
  - Tadalafil 20 mg
  - Price: £28.88

Vardenafil

Indications and Dose

Erectile dysfunction

- By mouth using tablets

  - Adult: Initially 10 mg (max. per dose 20 mg), to be taken approximately 25–60 minutes before sexual activity, subsequent doses adjusted according to response, onset of effect may be delayed if taken with high-fat meal; maximum 1 dose per day

  - By mouth using orodispersible tablet

  - Adult: 10 mg, to be taken approximately 25–60 minutes before sexual activity; maximum 10 mg per day

Erectile dysfunction (patients on alpha-blocker therapy)

- By mouth using tablets

  - Adult: Initially 5 mg (max. per dose 20 mg), to be taken approximately 25–60 minutes before sexual activity, subsequent doses adjusted according to response,
Erectile dysfunction

for whom an orodispersible tablet is an appropriate formulation.

● MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Orodispersible tablet
EXCIPIENTS: May contain Aspartame

Vardenafil (as Vardenafil hydrochloride trihydrate) 10 mg Levitra 10mg orodispersible tablets sugar-free | 4 tablet (Pom) £19.67 DT price = £19.67

Tablet

Levitra (Bayer Plc)

Vardenafil (as Vardenafil hydrochloride trihydrate) 5 mg Levitra 5mg tablets | 4 tablet (Pom) £8.32 DT price = £8.32 | 8 tablet (Pom) £16.63

Vardenafil (as Vardenafil hydrochloride trihydrate) 10 mg Levitra 10mg tablets | 4 tablet (Pom) £14.78 DT price = £14.78 | 8 tablet (Pom) £29.57

Vardenafil (as Vardenafil hydrochloride trihydrate) 20 mg Levitra 20mg tablets | 4 tablet (Pom) £24.30 DT price = £24.30 | 8 tablet (Pom) £48.60

PROSTAGLANDIN ANALOGUES AND PROSTAMIDES » PROSTAGLANDINS

Alprostadil

● INDICATIONS AND DOSE
Erectile dysfunction (initiated under specialist supervision)

BY URETHRAL APPLICATION

Adult: Initially 250 micrograms, adjusted according to response; usual dose 0.125–1 mg; maximum 2 doses per day; maximum 7 doses per week

Aid to diagnosis of erectile dysfunction

BY URETHRAL APPLICATION

Adult: 500 micrograms for 1 dose

Erectile dysfunction

TO THE SKIN

Adult: Apply 300 micrograms, to the tip of the penis, 5–30 minutes before sexual activity; max 1 dose in 24 hours not more than 2–3 times per week

Cavrject®

Erectile dysfunction

BY INTRACAVERNOSAL INJECTION

Adult: Initially 2.5 micrograms for 1 dose (first dose), followed by 5 micrograms for 1 dose (second dose), to be given if some response to first dose, alternatively 7.5 micrograms for 1 dose (second dose), to be given if no response to first dose, then increased in steps of 5–10 micrograms, to obtain a dose suitable for producing erection lasting not more than 1 hour; if no response to dose then next higher dose can be given within 1 hour, if there is a response the next dose should not be given for at least 24 hours; usual dose 5–20 micrograms (max. per dose 60 micrograms), maximum frequency of injection not more than 3 times per week with at least 24 hour interval between injections

Erectile dysfunction associated with neurological dysfunction

BY INTRACAVERNOSAL INJECTION

Adult: Initially 1.25 micrograms for 1 dose (first dose), then 2.5 micrograms for 1 dose (second dose), then 5 micrograms for 1 dose (third dose), increased in steps of 5–10 micrograms, to obtain a dose suitable for producing erection lasting not more than 1 hour; if no response to dose then next higher dose can be given within 1 hour, if there is a response the next dose should not be given for at least 24 hours; continued →

● CONTRA-INDICATIONS Avoid if systolic blood pressure below 90 mmHg; hereditary degenerative retinal disorders - myocardial infarction - patients in whom vasodilatation or sexual activity are inadvisable - previous history of non-arteritic anterior ischaemic optic neuropathy - recent stroke - unstable angina

● CAUTIONS Active peptic ulceration - anatomical deformation of the penis (e.g. angulation, cavernosal fibrosis, Peyronie’s disease) - bleeding disorders - cardiovascular disease - elderly - left ventricular outflow obstruction - predisposition to priapism (e.g. in sickle-cell disease, multiple myeloma, or leukaemia) - susceptibility to prolongation of QT interval

● INTERACTIONS → Appendix 1: phosphodiesterase type-5 inhibitors

● SIDE-EFFECTS

Common or very common Back pain - dizziness - dyspepsia - flushing - headache - migraine - myalgia - nasal congestion - nausea - visual disturbances - vomiting

Uncommon Drowsiness - dyspnoea - epistaxis - hypertension - hypotension - increased lacrimation - painful red eyes - palpitation - photosensitivity - tachycardia

Rare Anxiety - facial oedema - hypersensitivity reactions - hypotonia - priapism - raised intra-ocular pressure - rash - Stevens-Johnson syndrome - syncope - transient amnesia

Frequency not known Arrhythmia - myocardial infarction - non-arteritic anterior ischaemic optic neuropathy (stop drug if sudden visual impairment occurs) - retinal vascular occlusion - seizures - serious cardiovascular events - sudden hearing loss (discontinue drug and seek medical advice) - unstable angina

● HEPATIC IMPAIRMENT Initial dose 5 mg in mild to moderate impairment, increased subsequently according to response (max. 10 mg in moderate impairment). Manufacturer advises avoid in severe impairment. Orodispensible tablets not suitable for patients with moderate hepatic impairment.

● RENAL IMPAIRMENT Initial dose 5 mg if eGFR less than 30 mL/minute/1.73 m². Orodispensible tablets not suitable if eGFR less than 30 mL/minute/1.73 m².

● PRESCRIBING AND DISPENSING INFORMATION
Orodispisable tablets not suitable for initiation of therapy in patients taking alpha-blockers.

● NATIONAL FUNDING/ACCESS DECISIONS
Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (September 2011) that vardenafil orodispersible tablets (Levitra®) are accepted for restricted use within NHS Scotland for men for whom an orodispersible tablet is an appropriate formulation.

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (September 2011) that vardenafil orodispersible tablets (Levitra®) are accepted for restricted use within NHS Scotland for men who meet the criteria listed in part XVIIIB of the Drug Tariff (Part XIb of the Northern Ireland Drug Tariff, Part 12 of the Scottish Drug Tariff). The prescription must be endorsed ‘SLS’. For more information see Prices in the BNF, under How to use the BNF.

Levitra® Orodispensible Tablets

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (September 2011) that vardenafil orodispersible tablets (Levitra®) are accepted for restricted use within NHS Scotland for men who meet the criteria listed in part XVIIIB of the Drug Tariff (Part XIb of the Northern Ireland Drug Tariff, Part 12 of the Scottish Drug Tariff). The prescription must be endorsed ‘SLS’. For more information see Prices in the BNF, under How to use the BNF.

Levitra® Orodispensible Tablets

Orodispensible tablets are not bioequivalent.

Dose equivalence and conversion

● Levitra® 10 mg orodispersible tablets and Levitra® 10 mg film coated tablets are not bioequivalent.

Onset of effect may be delayed if taken with high-fat meal; maximum 1 dose per day

Downloaded from www.medicalbr.com | 769

Genito-urinary system
usual dose 5–20 micrograms (max. per dose 60 micrograms), maximum frequency of injection not more than 3 times per week with at least 24 hour interval between injections

Aid to diagnosis
- BY INTRACAVERNOSAL INJECTION
- Adult: 10–20 micrograms for 1 dose (consult product literature)

Aid to diagnosis where evidence of neurological dysfunction
- BY INTRACAVERNOSAL INJECTION
- Adult: Initially 5 micrograms (max. per dose 10 micrograms) for 1 dose, (consult product literature)

CAVERJET® DUAL CHAMBER

Erectile dysfunction
- BY INTRACAVERNOSAL INJECTION
- Adult: Initially 2.5 micrograms for 1 dose (first dose), followed by 5 micrograms for 1 dose (second dose), to be given if same response to first dose, alternatively 7.5 micrograms for 1 dose (second dose), to be given if no response to first dose, then increased in steps of 5–10 micrograms, to obtain a dose suitable for producing erection lasting not more than 1 hour; if no response to dose then next higher dose can be given within 1 hour, if there is a response the next dose should not be given for at least 24 hours; usual dose 5–20 micrograms (max. per dose 60 micrograms), maximum frequency of injection not more than 3 times per week with at least 24 hour interval between injections

Erectile dysfunction associated with neurological dysfunction
- BY INTRACAVERNOSAL INJECTION
- Adult: Initially 1.25 micrograms for 1 dose (first dose), then 2.5 micrograms for 1 dose (second dose), then 5 micrograms for 1 dose (third dose), increased in steps of 5–10 micrograms, to obtain a dose suitable for producing erection lasting not more than 1 hour; if no response to dose then next higher dose can be given within 1 hour, if there is a response the next dose should not be given for at least 24 hours; usual dose 5–20 micrograms (max. per dose 60 micrograms), maximum frequency of injection not more than 3 times per week with at least 24 hour interval between injections

Aid to diagnosis
- BY INTRACAVERNOSAL INJECTION
- Adult: 10–20 micrograms for 1 dose (consult product literature)

Aid to diagnosis where evidence of neurological dysfunction
- BY INTRACAVERNOSAL INJECTION
- Adult: Initially 5 micrograms (max. per dose 10 micrograms) for 1 dose, (consult product literature)

VIRIDAL® DUO CONTINUATION PACK

Erectile dysfunction
- BY INTRACAVERNOSAL INJECTION
- Adult: Initially 5 micrograms, increased in steps of 2.5–5 micrograms, to obtain dose suitable for producing erection not lasting more than 1 hour; usual dose 10–20 micrograms (max. per dose 40 micrograms), maximum frequency of injection not more than 2–3 times per week with at least 24 hour interval between injections; reduce dose if erection lasts longer than 2 hours

Neurogenic erectile dysfunction
- BY INTRACAVERNOSAL INJECTION
- Adult: Initially 2.5 micrograms, increased in steps of 2.5–5 micrograms, to obtain dose suitable for producing erection not lasting more than 1 hour; usual dose 10–20 micrograms (max. per dose 40 micrograms), maximum frequency of injection not more than 2–3 times per week with at least 24 hour interval between injections; reduce dose if erection lasts longer than 2 hours

VIRIDAL® DUO STARTER PACK

Neurogenic erectile dysfunction
- BY INTRACAVERNOSAL INJECTION
- Adult: Initially 2.5 micrograms, increased in steps of 2.5–5 micrograms, to obtain dose suitable for producing erection not lasting more than 1 hour; usual dose 10–20 micrograms (max. per dose 40 micrograms), maximum frequency of injection not more than 2–3 times per week with at least 24 hour interval between injections; reduce dose if erection lasts longer than 2 hours

CONTRA-INDICATIONS

GENERAL CONTRA-INDICATIONS
Not for use in patients with penile implants or when sexual activity medically inadvisable (e.g. orthostatic hypotension, myocardial infarction, and syncope) • not for use with other agents for erectile dysfunction • predisposition to prolonged erection (as in thrombocytopenia, polycythemia, sickle cell anaemia, multiple myeloma or leukaemia) • urethral application contra-indicated in balanitis • urethral application contra-indicated in severe curvature • urethral application contra-indicated in severe hypospadia • urethral application contra-indicated in urethral stricture • urethral application contra-indicated in urethritis

SPECIFIC CONTRA-INDICATIONS
- With topical use Balanitis • severe curvature • severe hypospadia • urethral stricture • urethritis

CAUTIONS
Anatomical deformations of penis (painful erection more likely) — follow up regularly to detect signs of penile fibrosis (consider discontinuation if angulation, cavernosal fibrosis or Peyronie’s disease develop) • priapism (patients should be instructed to report any erection lasting 4 hours or longer)

INTERACTIONS
- Appendix 1: alprostadil

SIDE-EFFECTS
- Common or very common Dizziness • haematoma • haemosiderin deposits • headache • hypertension • hypotension • influenza-like syndrome • injection site reactions • other localised pain (buttoks, leg, testicular, abdominal) • penile fibrosis • penile oedema • penile pain • penile rash • urethral bleeding • urethral burning
- Uncommon Abnormal ejaculation • asthenia • balanitis • dry mouth • haematuria • irritation • leg cramps • local reactions • micturation difficulties • mydriasis • nausea • pelvic pain • penile numbness or sensitivity • penile warmth • phimosis • priapism • pruritus • rapid pulse • scrotal erythema • scrotal oedema • scrotal pain • supraventricular extrasystole • sweating • syncope • testicular oedema • testicular thickening • urethral stenosis • vasodilatation
- Rare Anaphylaxis • erythema • hypersensitivity reactions • rash • urinary-tract infection • urticaria • vertigo
Erectile dysfunction

**CONCEPTION AND CONTRACEPTION**
- With urethral use: If partner is pregnant, barrier contraception should be used. No evidence of harm to latex condoms and diaphragms.
- With topical use: Condoms should be used to avoid exposure to women of child-bearing age, pregnant or lactating women. No evidence of harm to latex condoms.

**DIRECTIONS FOR ADMINISTRATION**
- With intracavernosal use: The first dose of the intracavernosal injection must be given by medically trained personnel; self-administration may only be undertaken after proper training.
- With urethral use: During initiation of treatment the urethral application should be used under medical supervision; self-administration may only be undertaken after proper training.

**PATIENT AND CARER ADVICE**
Patients should be instructed to report any erection lasting 4 hours or longer.
With topical use: Counsel patients that condoms should be used to avoid local reactions and exposure of alprostadil to women. No evidence of harm to latex condoms. Condoms should be used to avoid exposure and angle-closure glaucoma.

**NATIONAL FUNDING/ACCESS DECISIONS**
- **NHS restrictions**: Caverject®, Viridal® Duo, Vitaros® and MUSE® are not prescribable under the NHS for treatment of erectile dysfunction except in men who meet the criteria listed in part XVIIIIB of the Drug Tariff (Part XII of the Northern Ireland Drug Tariff, Part 12 of the Scottish Drug Tariff). The prescription must be endorsed ‘SLS’. For more information see Prices in the BNF, under How to use BNF publications.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

- **Stick**
  - Muse (Meda Pharmaceuticals Ltd)
    - Alprostadil 250 microgram: Muse 250 microgram urethral sticks | 1 applicator (POM) £11.30 DT price = £11.30 | 6 applicator (POM) £67.79
    - Alprostadil 500 microgram: Muse 500 microgram urethral sticks | 1 applicator (POM) £11.30 DT price = £11.30 | 6 applicator (POM) £67.79
    - Alprostadil 1 mg: Muse 1000 microgram urethral sticks | 1 applicator (POM) £11.56 DT price = £11.56 | 6 applicator (POM) £65.67

- **Cream**
  - Vitaros (Ferring Pharmaceuticals Ltd)
    - Alprostadil 3 mg per 1 gram: Vitaros 3 mg/g cream | 4 applicator (POM) £40.00

- **Powder and solvent for solution for injection**
  - Caverject (Pfizer Ltd)
    - Alprostadil 10 microgram: Caverject 10 microgram powder and solvent for solution for injection vials | 1 vial (POM) £9.24 DT price = £9.24
    - Alprostadil 20 microgram: Caverject 20 microgram powder and solvent for solution for injection vials | 1 vial (POM) £11.94 DT price = £11.94
    - Alprostadil 40 microgram: Caverject 40 microgram powder and solvent for solution for injection vials | 1 vial (POM) £21.58 DT price = £21.58
  - Caverject Dual Chamber (Pfizer Ltd)
    - Alprostadil 10 microgram: Caverject Dual Chamber 10 microgram powder and solvent for solution for injection | 2 pre-filled disposable injection (POM) £14.70
    - Alprostadil 20 microgram: Caverject Dual Chamber 20 microgram powder and solvent for solution for injection | 2 pre-filled disposable injection (POM) £19.00

- **Viridal** (UCB Pharma Ltd)
  - Alprostadil 10 microgram: Viridal Duo Starter Pack 10 microgram powder and solvent for solution for injection cartridges | 2 cartridge (POM) £20.13 (Hospital only)
  - Viridal Duo Continuation Pack 10 microgram powder and solvent for solution for injection cartridges | 2 cartridge (POM) £16.55
  - Alprostadil 20 microgram: Viridal Duo Starter Pack 20 microgram powder and solvent for solution for injection cartridges | 2 cartridge (POM) £24.54 (Hospital only)
  - Viridal Duo Continuation Pack 20 microgram powder and solvent for solution for injection cartridges | 2 cartridge (POM) £21.39

- **Alprostadil 40 microgram**: Viridal Duo Starter Pack 40 microgram powder and solvent for solution for injection cartridges with device | 2 cartridge (POM) £29.83 (Hospital only)
- Viridal Duo Continuation Pack 40 microgram powder and solvent for solution for injection cartridges | 2 cartridge (POM) £27.22

**SYMPTOMIMETICS → VASOCONSTRICTOR**

**Adrenaline/epinephrine**

- **DRUG ACTION**: Acts on both alpha and beta receptors and increases both heart rate and contractility (beta1 effects); it can cause peripheral vasodilation (a beta2 effect) or vasoconstriction (an alpha effect).

- **INDICATIONS AND DOSE**
  - Priapism associated with alprostadil, if aspiration and lavage of corpora are unsuccessful (alternative to phenylephrine or metaraminol)
  - By intracavernosal injection
    - Adult: 10–20 micrograms every 5–10 minutes, using a 20 microgram/mL solution, Important: if suitable strength of adrenaline not available may be specially prepared by diluting 0.1 mL of the adrenaline 1 in 1000 (1 mg/mL) injection to 5 mL with sodium chloride 0.9%, continuously monitor blood pressure and pulse; maximum 100 micrograms per course

- **UNLICENSED USE**: The use of adrenaline for the treatment of priapism is an unlicensed indication.

- **CAUTIONS**

- **INTERACTIONS**: Appendix 1: sympathomimetics, vasoconstrictor

- **SIDE-EFFECTS**

- **RENAI IMPAIRMENT**
  - Manufacturers advise use with caution in severe impairment.

- **MONITORING REQUIREMENTS**
  - Monitor blood pressure and ECG.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection

**Solution for injection**

- Excipients: May contain Sulfites
  - Adrenaline/epinephrine (Non-proprietary)
    - Adrenaline (as Adrenaline acid tartrate) 1 mg per 1 mL Adrenaline (base) 5mg/Snl (1 in 1000) solution for injection ampoules | 10 ampoule (POM) £77.34
    - Adrenaline (base) 50 micrograms/0.5 mL (1 in 1000) solution for injection ampoules | 10 ampoule (POM) £59.87–£61.33 DT price = £59.87
    - Adrenaline (base) 1 mg/L (1 in 1000) solution for injection ampoules | 10 ampoule (POM) £66.01 DT price = £66.01
### Metaraminol

**INDICATIONS AND DOSE**

- **Priapism (alternative to intracavernosal injections of phenylephrine and adrenaline)**
  - **BY INTRACAVERNOSAL INJECTION**
  - Adult: 1 mg every 15 minutes

**UNLICENSED USE** Use for priapism is an unlicensed indication.

**CONTRA-INDICATIONS** Hypertension

**CAUTIONS** Associated with fatal hypertensive crises - cirrhosis - coronary vascular thrombosis - diabetes mellitus - elderly - extravasation at injection site may cause necrosis - following myocardial infarction - hypercapnia - hyperthyroidism - hypoxia - mesenteric vascular thrombosis - peripheral vascular thrombosis - Prinzmetal’s variant angina - uncorrected hypovolaemia

**INTERACTIONS** → Appendix 1: sympathomimetics, vasoconstrictor

**SIDE-EFFECTS** Angle-closure glaucoma - anorexia - anxiety - arrhythmias - bradycardia - confusion - dyspnoea - fatal ventricular arrhythmia reported in Laennec’s cirrhosis - headache - hypertension - hypoxia - insomnia - nausea - palpitation - peripheral ischaemia - psychosis - tachycardia - tremor - urinary retention - vomiting - weakness

**MONITORING REQUIREMENTS** Monitor blood pressure and rate of flow frequently.

**DIRECTIONS FOR ADMINISTRATION** For intracavernosal injection, dilute 1 mg (0.1 mL of 10 mg/mL metaraminol injection to 50 mL with Sodium chloride injection 0.9% and give carefully by slow injection into the corpora in 5 mL injections.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection

**Solution for injection**

- **Metaraminol (Non-proprietary)**
  - Metaraminol (as Metaraminol tartrate) 10 mg per 1 mL Metaraminol 10mg/1ml solution for injection ampoules | 10 ampoule (POM) £31.97

### Phenylephrine hydrochloride

**INDICATIONS AND DOSE**

- **Priapism associated with alprostadil, if aspiration and lavage of the corpora are unsuccessful (alternative to adrenaline or metaraminol)**
  - **BY INTRACAVERNOSAL INJECTION**
  - Adult: 100–200 micrograms every 5–10 minutes, dose to be administered using a 200 micrograms/mL solution; maximum 1 mg per course

**UNLICENSED USE** Use of phenylephrine hydrochloride injection in priapism is an unlicensed indication.

**CONTRA-INDICATIONS** Hypertension

**INTERACTIONS** → Appendix 1: sympathomimetics, vasoconstrictor

**SIDE-EFFECTS** Arrhythmias - hypertension - palpitation - tachycardia

**DIRECTIONS FOR ADMINISTRATION** For intracavernosal injection, if suitable strength of phenylephrine injection is not available, it may be specially prepared by diluting 0.1 mL of the phenylephrine 1% (10 mg/mL) injection to 5 mL with sodium chloride 0.9%.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection

**Solution for injection**

- **Phenylephrine hydrochloride (Non-proprietary)**
  - Phenylephrine (as Phenylephrine hydrochloride) 50 microgram per 1 mL Phenylephrine 500micrograms/10ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (POM) £15.00 | 10 pre-filled disposable injection (POM) £150.00
  - Phenylephrine hydrochloride 100 microgram per 1 mL Phenylephrine 1mg/10ml solution for injection ampoules | 10 ampoule (POM) £40.00
  - Phenylephrine hydrochloride 10mg per 1 mL Phenylephrine 10mg/1ml solution for injection ampoules | 10 ampoule (POM) £99.12

### Aviptadil with phentolamine mesilate

09-Feb-2017

**DRUG ACTION** Phentolamine is a short-acting α-adrenoceptor antagonist that acts directly on vascular smooth muscle, resulting in vasodilatation; aviptadil is a vasoactive intestinal polypeptide that acts as a smooth muscle relaxant.

**INDICATIONS AND DOSE**

- **Erectile dysfunction**
  - **BY INTRACAVERNOSAL INJECTION**
  - Adult: 25/2000 micrograms, frequency of injection should not exceed once daily or three times weekly, duration of erection should not exceed 1 hour

**DOSE EQUIVALENCE AND CONVERSION**

- Dose expressed as x/y micrograms of aviptadil/phentolamine.

**CONTRA-INDICATIONS** Anatomical deformation of the penis (e.g. angulation, cavernosal fibrosis, Peyronie’s disease) - not for use with other agents for erectile dysfunction - patients for whom sexual activity is inadvisable - penile implants - predisposition to priapism (e.g. in sickle cell anaemia or trait, multiple myeloma, or leukaemia)

**CAUTIONS** Concomitant treatment with anticoagulants (potential increased risk of bleeding) - history of psychiatric disorder or addiction (potential for abuse) - severe cardiovascular disease - severe cerebrovascular disease

**SIDE-EFFECTS**

- **Common or very common** Flushing
  - **Uncommon** Dizziness - headache - palpitation - tachycardia
  - **Rare** Penile fibrosis (following multiple injections) - priapism
  - **Very rare** Angina - myocardial infarction

**MONITORING REQUIREMENTS** Manufacturer advises monitor regularly (e.g. every 3 months), particularly in the initial stages of self-injection therapy; careful examination of the penis is recommended to detect signs of penile fibrosis or Peyronie’s disease—discontinue treatment in patients who develop penile angulation, cavernosal fibrosis, or Peyronie’s disease.

**DIRECTIONS FOR ADMINISTRATION** Manufacturer advises that the initial injections of Invicorp® must be administered by medically trained personnel; self-administration may only be undertaken after proper training.

**HANDLING AND STORAGE** Manufacturer advises store in a refrigerator (2–8°C).

**PATIENT AND CARER ADVICE** Manufacturer advises that patients should be instructed to report any erection lasting 4 hours or longer.
4.2 Premature ejaculation

**SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS**

**Dapoxetine**

- **DRUG ACTION** Dapoxetine is a short-acting selective serotonin re-uptake inhibitor.

- **INDICATIONS AND DOSE**
  Premature ejaculation in men who meet all the following criteria:
  - poor control over ejaculation, a history of premature ejaculation over the past 6 months, marked distress or interpersonal difficulty as a consequence of premature ejaculation, and an intravaginal ejaculatory latency time of less than two minutes

  - **BY MOUTH**
    - Adult: Initially 30 mg, to be taken approximately 1–3 hours before sexual activity, subsequent doses adjusted according to response; review treatment after 4 weeks (or 6 doses) and at least every 6 months thereafter, not recommended for adults 65 years and over; maximum 1 dose per day; maximum 60 mg per day

- **DOSE ADJUSTMENTS DUE TO INTERACTIONS**
  Manufacturer advises max. dose 30 mg with concurrent use of moderate inhibitors of CYP3A4 except in patients verified to be extensive CYP2D6 metabolisers where manufacturer recommends max. dose 60 mg. Manufacturer advises avoid with concurrent use of potent inhibitors of CYP3A4 except in patients verified to be extensive CYP2D6 metabolisers where manufacturer recommends max. dose 30 mg.

- **CONTRA-INDICATIONS** History of bipolar disorder · history of mania · history of severe depression · history of syncope · significant cardiac disease · uncontrolled epilepsy

- **CAUTIONS** Bleeding disorders · epilepsy (discontinue if convulsions develop) · susceptibility to angle-closure glaucoma

- **INTERACTIONS** → Appendix 1: SSRIs

- **SIDE-EFFECTS**
  - **Common or very common** Abdominal distension · abdominal pain · abnormal dreams · agitation · anxiety · constipation · diarrhoea · dizziness · drowsiness · dry mouth · dyspepsia · flushing · headache · hypertension · impaired attention · irritability · malaise · nausea · paraesthesia · sexual dysfunction · sleep disturbances · sweating · tinnitus · tremor · visual disturbances · vomiting
  - **Uncommon** Abnormal thoughts · bradycardia · bruxism · confusion · depression · eye pain · hypotension · mood disturbances · mydriasis · postural hypotension · pruritus · restlessness · sinus arrest · syncope · tachycardia · taste disturbances · vertigo
  - **Rare** Defaecation urgency · sudden onset of sleep

**SIDE-EFFECTS, FURTHER INFORMATION**
Discontinue if psychiatric disorder develops. Avoid if postural hypotension occurs during test dose.

**HEPATIC IMPAIRMENT** Avoid in moderate to severe impairment.

**RENAL IMPAIRMENT** Use with caution if eGFR 30–80 mL/minute/1.73 m²; avoid if eGFR less than 30 mL/minute/1.73 m².

**PRE-TREATMENT SCREENING** Test for postural hypotension before starting treatment.

**PATIENT AND CARER ADVICE**
Postural hypotension and syncope Patients should be advised to maintain hydration and to sit or lie down until prodromal symptoms such as nausea, dizziness, and sweating abate.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>2, 25</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dapoxetine (Non-proprietary)</td>
<td></td>
</tr>
<tr>
<td>Dapoxetine 30 mg</td>
<td>6 tablet PrN no price available DT price = £26.48</td>
</tr>
<tr>
<td>Dapoxetine 60 mg</td>
<td>6 tablet PrN £14.71 DT price = £26.48</td>
</tr>
<tr>
<td>Priligy (A. Menarini Farmaceutica Internazionale SRL)</td>
<td></td>
</tr>
<tr>
<td>Dapoxetine 30 mg</td>
<td>3 tablet PrN £14.71 DT price = £26.48</td>
</tr>
<tr>
<td>Dapoxetine 60 mg</td>
<td>3 tablet PrN £19.12 DT price = £34.42</td>
</tr>
</tbody>
</table>

5 **Obstetrics**

**Prostaglandins and oxytocics**

Prostaglandins and oxytocics are used to induce abortion or induce or augment labour and to minimise blood loss from the placental site. They include oxytocin p. 775, carbocetin p. 776, ergometrine maleate p. 776, and the prostaglandins. All induce uterine contractions with varying degrees of pain according to the strength of contractions induced.

**Induction of abortion**

Gemeupro p. 778, a prostaglandin administered vaginally as pessaries, is suitable for the medical induction of late therapeutic abortion; gemeupro is also used to ripen the cervix before surgical abortion, particularly in primigravids. The prostaglandin misoprostol p. 778 is given by mouth, buccally, sublingually, or vaginally, to induce medical abortion or to augment labour and to minimise blood loss from the placental site. They include oxytocin p. 775, carbocetin p. 776, ergometrine maleate p. 776, and the prostaglandins.

**Induction and augmentation of labour**

Dinoprostone is available as vaginal tablets, pessaries and vaginal gels for the induction of labour. The intravenous solution is rarely used; it is associated with more side-effects.

- **Oxytocin** (Syntocinon®) is administered by slow intravenous infusion, using an infusion pump, to induce or augment labour, usually in conjunction with amniotomy. Uterine activity must be monitored carefully and hyperstimulation avoided. Large doses of oxytocin may result in excessive fluid retention.
- Misoprostol is given orally or vaginally for the induction of labour [unlicensed indication].

**NICE Guidance, Induction of labour (updated July 2008), available at www.nice.org.uk/guidance/CG70.**
Prevention and treatment of haemorrhage
Bleeding due to incomplete miscarriage or abortion can be controlled with ergometrine maleate and oxytocin (Syntometrine®) given intramuscularly, the dose is adjusted according to the patient’s condition and blood loss. This is commonly used before surgical evacuation of the uterus, particularly when surgery is delayed. Oxytocin and ergometrine maleate combined are more effective in early pregnancy than either drug alone.

Active management of the third stage of labour reduces the risk of postpartum haemorrhage; oxytocin is given by intramuscular injection [unlicensed] on delivery of the anterior shoulder or, at the latest, immediately after the baby is delivered. Alternatively, ergometrine maleate with oxytocin (Syntometrine®) can be given by intramuscular injection in the absence of hypertension; oxytocin alone causes less nausea, vomiting, and hypertension than when given with ergometrine maleate.

In excessive uterine bleeding, any placental products remaining in the uterus should be removed. Oxytocic drugs are used to treat postpartum haemorrhage caused by uterine atony; treatment options are as follows:
- oxytocin by slow intravenous injection, followed in severe cases by intravenous infusion of oxytocin at a rate that controls uterine atony or
- ergometrine by intramuscular injection or
- ergometrine by slow intravenous injection (use with caution—risk of hypertension) or
- ergometrine with oxytocin (Syntometrine®) by intramuscular injection

Carboprost p. 776 has an important role in severe postpartum haemorrhage unresponsive to ergometrine maleate and oxytocin.

Misoprostol [unlicensed] can be used in postpartum haemorrhage when oxytocin, ergometrine maleate, and carboprost are not available or are inappropriate.

Mifepristone
For termination of pregnancy, a single dose of mifepristone is followed by administration of a prostaglandin (gemeprost or misoprostol [unlicensed]). Guidelines of the Royal College of Obstetricians and Gynaecologists (November 2011) include [unlicensed] regimens for inducing medical abortion.

Myometrial relaxants
Tocolytic drugs postpone premature labour and they are used with the aim of reducing harm to the child. However, there is no satisfactory evidence that the use of these drugs reduces mortality. The greatest benefit is gained by using the delay to administer corticosteroid therapy or to implement other measures which improve perinatal health (including transfer to a unit with neonatal intensive care facility).

The oxytocin receptor antagonist, atosiban p. 777, is licensed for the inhibition of uncomplicated premature labour between 24 and 33 weeks of gestation. Atosiban may be preferable to a beta, agonist because it has fewer side effects. The dihydroyproline calcium-channel blocker nifedipine p. 157 also has fewer side-effects than a beta₂ agonist.

The beta, agonists salbutamol p. 244 and terbutaline sulfate p. 246 are licensed for inhibiting uncomplicated premature labour between 22 and 37 weeks of gestation to permit a delay in delivery of up to 48 hours. Use of high-dose short acting beta, agonists in obstetric indications has been associated with serious, sometimes fatal cardiovascular events in the mother and fetus, particularly when used for a prolonged period of time. Oral therapy is no longer recommended and parenteral therapy should be restricted to a maximum duration of 48 hours, given under the supervision of a specialist, and with close monitoring.

Indometacin p. 1043, a cyclo-oxygenase inhibitor, also inhibits labour [unlicensed indication] and it can be useful in situations where a beta, agonist is not appropriate; however, there are concerns about neonatal complications such as transient impairment of renal function and premature closure of ductus arteriosus.

5.1 Induction of labour

PROSTAGLANDINS AND OXYTOCICS

Dinoprostone

- **INDICATIONS AND DOSE**

  **PROPESS®**
  - **Cervical ripening and induction of labour at term**
    - **BY VAGINA**
      - Adult: 1 pessary, insert pessary (in retrieval device) high into posterior fornix and remove when cervical ripening adequate; if oxytocin necessary, remove 30 minutes before oxytocin infusion; remove if cervical ripening inadequate after 24 hours (dose not to be repeated)

  **PROSTIN E2® VAGINAL GEL**
  - **Induction of labour**
    - **BY VAGINA**
      - Adult: 1 mg, inserted high into the posterior fornix (avoid administration into the cervical canal), followed by 1–2 mg after 6 hours if required; maximum 3 mg per course

  **Induction of labour (unfavourable primigravida)**
    - **BY VAGINA**
      - Adult: 2 mg, inserted high into the posterior fornix (avoid administration into the cervical canal), followed by 1–2 mg if required, after 6 hours; maximum 4 mg per course

  **PROSTIN E2® VAGINAL TABLETS**
  - **Induction of labour**
    - **BY VAGINA**
      - Adult: 3 mg, inserted high into the posterior fornix, followed by 3 mg after 6–8 hours, to be given if labour not established; maximum 6 mg per course

  **DOSE EQUIVALENCE AND CONVERSION**
  - Prostin E2 Vaginal tablets and Vaginal Gel are not bioequivalent.

- **CONTRA-INDICATIONS**
  - Active cardiac disease • active pulmonary disease • avoid extra-amniotic route in cervicitis or vaginitis • fetal distress • fetal malpresentation • grand multiparas • history of caesarean section • history of difficult or traumatic delivery • history of major uterine surgery • major cephalopelvic disproportion • multiple pregnancy • placenta praevia or unexplained vaginal bleeding during pregnancy • ruptured membranes • untreated pelvic infection

- **CAUTIONS**
  - Effect of oxytocin enhanced • history of asthma • history of epilepsy • history of glaucoma and raised intraocular pressure • hypertension • risk factors for disseminated intravascular coagulation • uterine rupture • uterine scarring

- **SIDE-EFFECTS**
  - Abruptio placenta • amniotic fluid embolism • backache • bronchospasm • cardiac arrest • diarrhoea • disseminated intravascular coagulation • fetal distress • fever • low Apgar scores • maternal hypertension • nausea • pulmonary embolism • rapid cervical dilatation • severe uterine contractions • stillbirth or neonatal death • uterine hypercontractility with or without fetal bradycardia • uterine hypertonus • uterine rupture • vaginal symptoms (warmth, irritation, pain) • vomiting
HEPATIC IMPAIRMENT  Manufacturers advise avoid.
RENAL IMPAIRMENT  Manufacturers advise avoid.

MONITORING REQUIREMENTS
- Monitor for disseminated intravascular coagulation after parturition.
- Monitor uterine activity and fetal status (particular care if history of uterine hypertony)
- Care needed in monitoring uterine activity when used in sequence following oxytocin.

PRESCRIBING AND DISPENSING INFORMATION
Important: Do not confuse dose of Prostin E2® vaginal gel with that of Prostin E2® vaginal tablets—no bioequivalent.

LESS SUITABLE FOR PRESCRIBING
Intravenous solution rarely used and is considered less suitable for prescribing. Extra-amniotic solution less commonly used and is considered less suitable for prescribing.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Pessary
- Prostin E2® (Pfizer Ltd)
  - Dinoprostone 3 mg Prostin E2 3mg vaginal tablets | 8 pessary (Pack) £110.23 (Hospital only)

Vaginal gel
- Prostin E2® (Pfizer Ltd)
  - Dinoprostone 400 microgram per 1 ml Prostin E2 1mg vaginal gel | 2.5 ml (Pack) £13.28 (Hospital only)
  - Dinoprostone 800 microgram per 1 ml Prostin E2 2mg vaginal gel | 2.5 ml (Pack) £13.28 (Hospital only)

Vaginal device
- Propess (Ferring Pharmaceutical Ltd)
  - Dinoprostone 10 mg Propess 10mg vaginal delivery system | 5 device (Pack) £150.00

Induction of labour | Stimulate of labour in hypotonic uterine inertia

INDICATIONS AND DOSE

- BY INTRAVENOUS INFUSION
  - Adult: Initially 0.001–0.004 unit/minute, not to be started for at least 6 hours after administration of vaginal prostaglandin, dose increased at intervals of at least 30 minutes until a maximum of 3–4 contractions occur every 10 minutes (0.01 unit/minute is often adequate) up to max. 0.02 units/minute, if regular contractions not established after a total 5 units, stop induction attempt (may be repeated next day starting again at 0.001–0.004 units/minute).

CAESAREAN SECTION
- BY SLOW INTRAVENOUS INJECTION
  - Adult: 5 units immediately after delivery

PREVENTION OF POSTPARTUM HAEMORRHAGE AFTER DELIVERY OF PLACENTA
- BY SLOW INTRAVENOUS INJECTION
  - Adult: 5 units, if infusion previously used for induction or enhancement of labour, increase rate during third stage and for next few hours

- BY INTRAMUSCULAR INJECTION
  - Adult: 10 units, can be used instead of oxytocin with ergometrine (Syntometrine®).

TREATMENT OF POSTPARTUM HAEMORRHAGE
- BY SLOW INTRAVENOUS INJECTION
  - Adult: 5 units, repeated if necessary

TREATMENT OF SEVERE CASES OF POSTPARTUM HAEMORRHAGE (FOLLOWING INTRAVENOUS INJECTION)
- BY INTRAVENOUS INFUSION
  - Adult: 40 units, given in 500 mL infusion fluid given at a rate sufficient to control uterine atony

Incomplete, inevitable, or missed miscarriage
- INITIALLY BY SLOW INTRAVENOUS INJECTION
  - Adult: 5 units, followed by (by intravenous infusion) 0.02–0.04 unit/minute if required, the rate of infusion can be faster if necessary

UNLICENSED USE
Oxytocin doses in the BNF may differ from those in the product literature. Administration by Intramuscular injection is an unlicensed use.

IMPORTANT SAFETY INFORMATION
Prolonged intravenous administration at high doses with large volume of fluid (which is possible in inevitable or missed miscarriage or postpartum haemorrhage) may cause water intoxication with hyponatraemia. To avoid: use electrolyte-containing diluent (i.e. not glucose), increase oxytocin concentration to reduce fluid, restrict fluid intake by mouth; monitor fluid and electrolytes.

CONTRA-INDICATIONS
Any condition where spontaneous labour inadvisable—any condition where vaginal delivery inadvisable—avoid intravenous injection during labour—avoid prolonged administration in oxytocin-resistant uterine inertia—avoid rapid intravenous injection (may transiently reduce blood pressure)—fetal distress (discontinue immediately if this occurs)—hypertonic uterine contractions (discontinue immediately if this occurs)—severe cardiovascular disease—severe pre-eclamptic toxaemia

CAUTIONS
Avoid large infusion volumes and restrict fluid intake by mouth (risk of hyponatraemia and water-intoxication) - enhancement of labour—presence of borderline cephalopelvic disproportion (avoid if significant)—history of lower-uterine segment caesarean section—induction of labour—presence of borderline cephalopelvic disproportion (avoid if significant)—mild pregnancy-induced cardiac disease—mild pregnancy-induced hypertension—moderate pregnancy-induced cardiac disease—moderate pregnancy-induced hypertension—risk factors for disseminated intravascular coagulation—secondary uterine inertia—women over 35 years

SIDE-EFFECTS
- Common or very common  Arrhythmia • headache • nausea • vomiting
- Rare  Anaphylactoid reactions (with dyspnoea, hypotension, or shock) • disseminated intravascular coagulation • hyponatraemia associated with high doses with large infusion volumes of electrolyte-free fluid • rash • uterine hyperstimulation (usually with excessive doses—may cause fetal distress, asphyxia, and death, or may lead to hypertonicity, tetanic contractions, soft-tissue damage or uterine rupture) • uterine spasm (may occur at low doses) • water intoxication associated with high doses with large infusion volumes of electrolyte-free fluid

SIDE-EFFECTS, FURTHER INFORMATION
Avoid rapid intravenous injection (may transiently reduce blood pressure).

OVERDOSE
Placental abruption and amniotic fluid embolism reported on overdose.

MONITORING REQUIREMENTS
- Careful monitoring of fetal heart rate and uterine motility essential for dose titration.
- Monitor for disseminated intravascular coagulation after parturition.

DIRECTIONS FOR ADMINISTRATION
- For intravenous infusion (Syntocinon®), give continuously in Glucose 5% or Sodium chloride 0.9%. Preferably given via a variable-speed infusion pump in a concentration appropriate to the pump; if given by drip infusion for induction or
enforcement of labour, dilute 5 units in 500 mL infusion fluid or for higher doses, 10 units in 500 mL; for treatment of postpartum uterine haemorrhage dilute 40 units in 500 mL; if high doses given for prolonged period (e.g. for inevitable or missed abortion or for postpartum haemorrhage), use low volume of an electrolyte-containing infusion fluid (not Glucose 5%) given at higher concentration than for induction or enhancement of labour; close attention to patient’s fluid and electrolyte status essential.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: infusion, solution for infusion

  **Solution for injection**
  - Pabal (Ferring Pharmaceuticals Ltd)
    - Carbetocin 100 microgram per 1 ml Pabal 100micrograms/1ml solution for injection ampoules | 5 ampoule £88.20 (Hospital only)

- **SIDE-EFFECTS**
  - There can be variation in the licensing of different medicines containing the same drug.

  **Solution for injection**
  - Hemabate (Pfizer Ltd)
    - Carboprost (as Carboprost trometamol) 250 microgram per 1 ml Hemabate 250micrograms/1ml solution for injection ampoules | 10 ampoule £162.01 (Hospital only)

### 5.2 Postpartum haemorrhage

**Other drugs used for Postpartum haemorrhage** Oxytocin, p. 775

#### PROSTAGLANDINS AND OXYTOCICS

### Carbetocin

- **INDICATIONS AND DOSE**
  - Prevention of uterine atony after caesarean section
    - **BY SLOW INTRAVENOUS INJECTION**
    - Adult: 100 micrograms for 1 dose, to be given over 1 minute, administer as soon as possible after delivery, preferably before removal of placenta

- **CONTRA-INDICATIONS**
  - Eclampsia · epilepsy · pre-eclampsia

- **CAUTIONS**
  - Asthma · cardiovascular disease (avoid if severe) · hyponatraemia · migraine

- **SIDE-EFFECTS**
  - Abdominal pain · anaemia · back pain · chest pain · chills · diarrhoea · dizziness · dyspnoea · feeling of warmth · flushing · headache · hypotension · metallic taste · nausea · pruritus · sweating · tachycardia · tremor · vomiting

- **HEPATIC IMPAIRMENT**
  - Manufacturer advises avoid.

- **RENAL IMPAIRMENT**
  - Manufacturer advises avoid.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  **Solution for injection**
  - Pabal (Ferring Pharmaceuticals Ltd)
    - Carbetocin 100 microgram per 1 ml Pabal 100micrograms/1ml solution for injection ampoules | 5 ampoule £88.20 (Hospital only)

### Carboprost

- **INDICATIONS AND DOSE**
  - Postpartum haemorrhage due to uterine atony in patients unresponsive to ergometrine and oxytocin
    - **BY DEEP INTRAMUSCULAR INJECTION**
    - Adult: 250 micrograms, repeated if necessary, to be given at intervals of not less than 15 minutes. Total dose should not exceed 2 mg (8 doses)

- **CONTRA-INDICATIONS**
  - Cardiac disease · pulmonary disease · untreated pelvic infection

- **CAUTIONS**
  - Excessive dosage may cause uterine rupture · history of anaemia · history of asthma · history of diabetes · history of epilepsy · history of glaucoma · history of hypertension · history of hypotension · history of jaundice · history of raised intra-ocular pressure · uterine scars

- **SIDE-EFFECTS**
  - Bronchospasm · cardiovascular collapse · chill · diarrhoea · dizziness · dyspnoea · erythema at injection site · flushing · headache · hyperthermia · nausea · pain at injection site · pulmonary oedema · raised blood pressure · vomiting

- **HEPATIC IMPAIRMENT**
  - Manufacturer advises avoid.

- **RENAL IMPAIRMENT**
  - Manufacturer advises avoid.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  **Solution for injection**
  - Ergometrine maleate (Non-proprietary)
    - Ergometrine maleate 500 microgram per 1 ml Ergometrine 500micrograms/1ml solution for injection ampoules | 10 ampoule £12.00–£15.00
Ergometrine with oxytocin

The properties listed below are those particular to the combination only. For the properties of the components please consider, ergometrine maleate p. 776, oxytocin p. 775.

**INDICATIONS AND DOSE**

Active management of the third stage of labour

Postpartum haemorrhage caused by uterine atony

- **BY INTRAMUSCULAR INJECTION**
  - Adult: 1 mL for one dose
  - Adult: No longer recommended

Bleeding due to incomplete miscarriage or abortion

- **BY INTRAMUSCULAR INJECTION**
  - Adult: Adjusted according to response to, the patient’s condition and blood loss

**INTERACTIONS** → Appendix 1: ergometrine

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Syntometrine (Alliance Pharmaceuticals Ltd)**
  - Ergometrine maleate 500 microgram per 1 mL, Oxytocin 5 unit per 1 mL Syntometrine 500micrograms/1ml solution for injection ampoules | 5 ampoule £7.87

**BY INTRAMUSCULAR INJECTION**

Atosiban (as Atosiban acetate) 7.5 mg per 1 mL Atosiban 6.75mg/0.9ml solution for injection vials | 1 vial £18.41 (Hospital only)

Tractocile (Ferring Pharmaceuticals Ltd)

Atosiban (as Atosiban acetate) 7.5 mg per 1 mL Tractocile 6.75mg/0.9ml solution for injection vials | 1 vial £18.41 (Hospital only)

**Solution for infusion**

- **Atosiban (Non-proprietary)**
  - Atosiban (as Atosiban acetate) 7.5 mg per 1 mL Atosiban 37.5mg/5ml concentrate for solution for infusion vials | 1 vial £52.82 (Hospital only)
  - Atosiban 37.5mg/5ml solution for infusion vials | 1 vial £51.09 (Hospital only)

**BY MOUTH**

Atosiban (as Atosiban acetate) 7.5 mg per 1 mL Tractocile 37.5mg/5ml solution for infusion vials | 1 vial £52.82 (Hospital only)

**5.3 Premature labour**

Other drugs used for Premature labour Nifedipine, p. 157
- Salbutamol, p. 244 - Terbutaline sulfate, p. 246

**OXYTOCIN RECEPTOR ANTAGONISTS**

**Atosiban**

**INDICATIONS AND DOSE**

Uncomplicated premature labour between 24 and 33 weeks of gestation

- **INITIALLY BY INTRAVENOUS INJECTION**
  - Adult: Initially 6.75 mg over 1 minute, then (by intravenous infusion) 18 mg/hour for 3 hours, then (by intravenous infusion) reduced to 6 mg/hour for up to 45 hours. Maximum duration of treatment is 48 hours

**CONTRA-INDICATIONS** Abruptio placentae - antepartum haemorrhage (requiring immediate delivery) - eclampsia - intra-uterine fetal death - intra-uterine infection - intra-uterine growth restriction with abnormal fetal heart rate - placenta praevia - premature rupture of membranes after 50 weeks’ gestation - severe pre-eclampsia

**CAUTIONS** Abnormal placental site - intra-uterine growth restriction

**SIDE-EFFECTS**

- Common or very common Dizziness - headache - hot flushes - hyperglycaemia - hypotension - injection-site reaction - nausea - tachycardia - vomiting
- Uncommon Fever - insomnia - pruritus - rash
- **HEPATIC IMPAIRMENT** No information available.
- **RENAL IMPAIRMENT** No information available.
- **MONITORING REQUIREMENTS** Monitor blood loss after delivery.

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Tractocile® concentrate for intravenous infusion), give continuously in Glucose 5% or Sodium chloride 0.9%. Withdraw 10 mL infusion fluid from 100-mL bag and replace with 10 mL atosiban concentrate (7.5 mg/mL) to produce a final concentration of 750 micrograms/mL.

**5.4 Termination of pregnancy**

**PROGESTERONE RECEPTOR MODULATORS**

**Mifepristone**

**INDICATIONS AND DOSE**

Cervical ripening before mechanical cervical dilatation for termination of pregnancy of up to 84 days gestation (under close medical supervision)

- **BY MOUTH**
  - Adult: 200 mg for 1 dose, to be taken 36–48 hours before procedure

Labour induction in fetal death in utero where prostaglandin or oxytocin inappropriate (under close medical supervision)

- **BY MOUTH**
  - Adult: 600 mg once daily for 2 days, if labour not started within 72 hours of first dose, another method should be used

Medical termination of intra-uterine pregnancy of up to 49 days gestation (under close medical supervision)

- **BY MOUTH**
  - Adult: 600 mg for 1 dose, dose followed 36–48 hours later (unless abortion already complete) by gemeprost 1 mg by vagina or misoprostol 400 micrograms by mouth, alternatively 200 mg for 1 dose, dose followed 36–48 hours later (unless abortion already complete) by gemeprost 1 mg by vagina; observe for at least 3 hours (or until bleeding or pain at acceptable level); follow-up visit within 2 weeks to verify complete expulsion and to assess vaginal bleeding

Medical termination of intra-uterine pregnancy of 50–63 days gestation (under close medical supervision)

- **BY MOUTH**
  - Adult: 600 mg for 1 dose, alternatively 200 mg for 1 dose, dose followed 36–48 hours later (unless abortion already complete) by gemeprost 1 mg by vagina; observe for at least 3 hours (or until bleeding or pain at acceptable level); follow-up visit within 2 weeks to verify complete expulsion and to assess vaginal bleeding continued →
Termination of pregnancy of 13–24 weeks gestation (in combination with a prostaglandin) (under close medical supervision)

- **BY MOUTH**
  - Adult: 600 mg for 1 dose, alternatively 200 mg for 1 dose, dose followed 36–48 hours later by gemeprost 1 mg by vagina every 3 hours up to max. 5 mg or misoprostol; if abortion does not occur, 24 hours after start of treatment repeat course of gemeprost 1 mg by vagina up to max. 5 mg; follow-up visit after appropriate interval to assess vaginal bleeding recommended.

- **CONTRA-INDICATIONS**
  - Acute porphyrias p. 969 · chronic adrenal failure · suspected ectopic pregnancy (use other specific means of termination) · uncontrolled severe asthma

- **CAUTIONS**
  - Adrenal suppression (may require corticosteroid) · anticoagulant therapy · asthma (avoid if severe and uncontrolled) · existing cardiovascular disease · haemorrhagic disorders · history of endocarditis · prostatic heart valve · risk factors for cardiovascular disease

- **SIDE-EFFECTS**
  - Common or very common: Gastro-intestinal cramps · uterine contractions · vaginal bleeding (sometimes severe) may occur between administration of mifepristone and surgery (and rarely abortion may occur before surgery)
  - Uncommon: Hypersensitivity reactions · rash · urticaria
  - Rare: Chills · dizziness · fever · headache · hot flushes · hypotension · malaise
  - Frequency not known: Infections · toxic shock syndrome

- **HEPATIC IMPAIRMENT**
  - Manufacturer advises avoid.

- **Renal Impairment**
  - Manufacturer advises avoid.

- **MONITORING REQUIREMENTS**
  - Careful monitoring of blood pressure and pulse essential for 3 hours after administration of gemeprost pessary (risk of profound hypotension).

- **PRESCRIBING AND DISPENSING INFORMATION**
  - Supplied to NHS hospitals and premises approved under Abortion Act 1967.

- **PATIENT AND CARER ADVICE**
  - Patient information leaflet to be provided.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  **Tablet**

  - **CAUTIONARY AND ADVISORY LABELS**
    - 10
  - Mifepristone (Non-proprietary)
    - Mifepristone 200 mg Mifepristone 200mg tablets | 1 tablet [PBCM]
    - no price available (Hospital only)
  - Mifegyne (Nordic Pharma Ltd)
    - Mifepristone 200 mg Mifepristone 200mg tablets | 3 tablet [PBCM]
    - £52.66 (Hospital only)

**PROSTAGLANDINS AND OXYTOCICS**

**Gemeprost**

- **INDICATIONS AND DOSE**
  - **Cervical ripening prior to first trimester surgical abortion**
    - **BY VAGINA**
    - Adult: 1 mg, dose to be inserted into posterior fornix 3 hours before surgery
  - **Second trimester abortion**
    - **BY VAGINA**
    - Adult: 1 mg every 3 hours for maximum 5 administrations, to be inserted into posterior fornix,

  - Second course may begin 24 hours after start of treatment (if treatment fails, pregnancy should be terminated by another method)

- **SECOND TRIMESTER INTRA-UTERINE DEATH**
  - **BY VAGINA**
  - Adult: 1 mg every 3 hours for maximum 5 administrations only, to be inserted into posterior fornix

- **MEDICAL TERMINATION OF INTRA-UTERINE PREGNANCY OF UP TO 49 DAYS GESTATION FOLLOWING MIFEPRISTONE**
  - **BY VAGINA**
  - Adult: 1 mg every 3 hours, if abortion does not occur, 24 hours after start of treatment repeat course of gemeprost 1 mg by vagina up to max. 5 mg; follow-up visit after appropriate interval to assess vaginal bleeding recommended, careful monitoring of blood pressure and pulse essential for 3 hours after administration of gemeprost pessary (risk of profound hypotension); maximum 5 mg per course

- **CONTRA-INDICATIONS**
  - Placenta praevia · unexplained vaginal bleeding · uterine scarring

- **CAUTIONS**
  - Cardiovascular insufficiency · cervicitis · obstructive airways disease · raised intra-ocular pressure · vaginitis

- **SIDE-EFFECTS**
  - Backache · chest pain · chills · coronary artery spasm · diarrhoea · dizziness · dyspnoea · flushing · headache · mild pyrexia · muscle weakness · myocardial infarction · nausea · palpitation · severe hypotension · uterine pain · uterine rupture (most commonly in multiparas or if history of uterine surgery or if given with intravenous oxytocics) · vaginal bleeding · vomiting

- **RENAL IMPAIRMENT**
  - Manufacturer advises avoid.

- **MONITORING REQUIREMENTS**
  - If used in combination with mifepristone, carefully monitor blood pressure and pulse for 3 hours.
  - When used for second trimester intra-uterine death, monitor for coagulopathy during treatment.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  **Pessary**

  - Gemeprost (Non-proprietary)
    - Gemeprost 1 mg Gemeprost 1mg pessaries | 5 pessary [PBCM] no price available

**Misoprostol**

- **INDICATIONS AND DOSE**
  - **Termination of pregnancy following mifepristone (gestation up to 49 days)**
    - **BY MOUTH**
    - Adult: 400 micrograms for 1 dose, dose to be given 24–48 hours after mifepristone

- **DRUG ACTION**
  - Misoprostol acts as a potent uterine stimulant.
6 Vaginal and vulval conditions

Vaginal and vulval conditions

Management

Symptoms are often restricted to the vulva, but infections almost invariably involve the vagina which should also be treated. Applications to the vulva alone are likely to give only symptomatic relief without cure. Aqueous medicated douches may disturb normal vaginal acidity and bacterial flora.

Topical anaesthetic agents give only symptomatic relief and may cause sensitivity reactions. They are indicated only in cases of pruritus where specific local causes have been excluded.

Systemic drugs are required in the treatment of infections such as gonorrhoea and syphilis.

Preparations for vaginal and vulval changes

Topical HRT for vaginal atrophy

A cream containing an oestrogen may be applied on a short-term basis to improve the vaginal epithelium in menopausal atrophic vaginitis. It is important to bear in mind that topical oestrogens should be used in the smallest effective amount to minimise systemic effects. Modified-release vaginal tablets and an impregnated vaginal ring are now also available.

The risk of endometrial hyperplasia and carcinoma is increased when systemic oestrogens are administered alone for prolonged periods. The endometrial safety of long-term or repeated use of topical vaginal oestrogens is uncertain; treatment should be reviewed at least annually, with special consideration given to any symptoms of endometrial hyperplasia or carcinoma.

Topical oestrogens are also used in postmenopausal women before vaginal surgery for prolapse when there is epithelial atrophy.

Non-hormonal preparations for vaginal atrophy

Several non-hormonal vaginal moisturisers are available and some are prescribable on the NHS (consult Drug Tariff).

Vaginal and vulval infections

Effective specific treatments are available for the common vaginal infections.

Fungal infections

Candidal vaginitis can be treated locally with cream, but is almost invariably associated with vaginal infection which should also be treated. Vaginal candidiasis is treated primarily with antifungal pessaries or cream inserted high into the vagina (including during menstruation). Single-dose preparations offer an advantage when compliance is a problem. Local irritation may occur on application of vaginal antifungal products.

Imidazole drugs ( clotrimazole p. 781, econazole nitrate p. 781, fenticonazole nitrate p. 782, and miconazole p. 782) are effective against candida in short courses of 1 to 14 days according to the preparation used; treatment can be repeated if initial course fails to control symptoms or if symptoms recur. Vaginal applications may be supplemented with antifungal cream for vulvitis and to treat other superficial sites of infection.

Oral treatment of vaginal infection with fluconazole p. 562 or itraconazole p. 564 is also effective.

Vulvovaginal candidiasis in pregnancy

Vulvovaginal candidiasis is common during pregnancy and can be treated with vaginal application of an imidazole (such as clotrimazole), and a topical imidazole cream for vulvitis. Pregnant women need a longer duration of treatment, usually about 7 days, to clear the infection. Oral antifungal treatment should be avoided during pregnancy.

Recurrent vulvovaginal candidiasis

Recurrence of vulvovaginal candidiasis is particularly likely if there are predisposing factors, such as antibacterial therapy, pregnancy, diabetes mellitus, or possibly oral contraceptive use. Reservoirs of infection may also lead to recontamination and should be treated; these include other skin sites such as the digits, nail beds, and umbilicus as well as the gastro-intestinal tract and the bladder. The partner may also be the source of reinfection and, if symptomatic, should be treated with a topical imidazole cream at the same time.
Treatment against candida may need to be extended for 6 months in recurrent vulvovaginal candidiasis.

### Other infections

**Trichomonal infections** commonly involve the lower urinary tract as well as the genital system and need systemic treatment with metronidazole p. 512 or tinidazole p. 514. **Bacterial infections** with Gram-negative organisms are particularly common in association with gynaecological operations and trauma. Metronidazole is effective against certain Gram-negative organisms, especially *Bacteroides* spp. and can be used prophylactically in gynaecological surgery.

Clindamycin below cream and metronidazole gel are indicated for bacterial vaginosis.

Vaginal preparations intended to restore normal acidity may prevent recurrence of vaginal infections and permit the re-establishment of the normal vaginal flora.

The antiviral drugs aciclovir p. 599, famciclovir p. 601, and valaciclovir p. 602 can be used in the treatment of genital infection due to *herpes simplex virus*, the HSV type 2 being a major cause of genital ulceration; they have a beneficial effect on virus shedding and healing, generally giving relief from pain and other symptoms.

#### 6.1 Vaginal and vulval infections

##### 6.1a Vaginal and vulval bacterial infections

Other drugs used for Vaginal and vulval bacterial infections Metronidazole, p. 512

### ANTIBACTERIALS

#### Clindamycin

<table>
<thead>
<tr>
<th>INDICATIONS AND DOSE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DALACIN® 2% CREAM</strong></td>
</tr>
<tr>
<td><strong>Bacterial vaginosis</strong></td>
</tr>
<tr>
<td>➤ BY VAGINA</td>
</tr>
<tr>
<td>Adult: 1 applicatorful daily for 3–7 nights, dose to be administered at night</td>
</tr>
</tbody>
</table>

**DOSE EQUIVALENCE AND CONVERSION**

1 applicatorful delivers a 5 g dose of clindamycin 2%.

- **SIDE-EFFECTS**
  - Cervicitis - irritation - vaginitis

**SIDE-EFFECTS**

**FURTHER INFORMATION**

Clindamycin 2% cream is poorly absorbed into the blood—low risk of systemic effects.

- **CONCEPTION AND CONTRACEPTION**
  - Damages latex condoms and diaphragms.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

**Cream**

**EXCIPIENTS:** May contain Benzyl alcohol, cetostearyl alcohol (including cetyl and stearyl alcohol), polysorbates, propylene glycol

- Dalacin (Pfizer Ltd)
  - Clindamycin (as Clindamycin phosphate) 20 mg per 1 gram Dalacin 2% cream | 40 gram | POM | £10.86 DT price = £10.86

### ANTISEPTICS AND DISINFECTANTS

#### Dequalinium chloride

**DRUG ACTION** Dequalinium chloride is a bactericidal anti-infective which causes bacterial cell death by increasing cell permeability and reducing enzyme activity.

<table>
<thead>
<tr>
<th>INDICATIONS AND DOSE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bacterial vaginosis</strong></td>
</tr>
<tr>
<td>➤ BY VAGINA</td>
</tr>
<tr>
<td>Adult 18–55 years: 10 mg once daily for 6 days, inserted at night</td>
</tr>
</tbody>
</table>

- **CONTRA-INDICATIONS**
  - Vaginal ulceration

- **SIDE-EFFECTS**
  - Common or very common: Vaginal candidiasis - vulvovaginal burning sensation - vulvovaginal pruritus
  - Uncommon: Headache - nausea - vaginal haemorrhage - vaginal pain
  - Frequency not known: Cystitis - fever - uterine bleeding - vaginal dryness - vaginal ulceration

- **CONCEPTION AND CONTRACEPTION**
  - Does not affect efficacy of latex condoms; however, manufacturer advises avoid use of non-latex condoms and intravaginal devices—no information available

- **PREGNANCY**
  - Manufacturer advises avoid unless essential—limited information available.

### NATIONAL FUNDING/ACCESS DECISIONS

#### Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (November 2016) that dequalinium chloride (*Fluomizin®*) is accepted for restricted use within NHS Scotland for treatment of bacterial vaginosis in patients for whom the initial treatment is not effective or well tolerated.

#### All Wales Medicines Strategy Group (AWMSG) Decisions

The All Wales Medicines Strategy Group has advised (November 2016) that dequalinium chloride (*Fluomizin®*) is recommended as an option for restricted use within NHS Wales for the treatment of bacterial vaginosis only after initial treatment is ineffective or not tolerated, as an alternative option to clindamycin vaginal cream.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- Fluomizin (KoRa Healthcare)
  - Dequalinium chloride 10 mg | Fluomizin 10mg vaginal tablets | 6 tablet | POM | £6.95

### CARBOXYLIC ACIDS

#### Lactic acid

<table>
<thead>
<tr>
<th>INDICATIONS AND DOSE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BALANCE ACTIV RX® GEL</strong></td>
</tr>
<tr>
<td><strong>Prevention of bacterial vaginosis</strong></td>
</tr>
<tr>
<td>➤ BY VAGINA</td>
</tr>
<tr>
<td>Adult: 5 mL 1–2 times a week, insert the content of 1 tube (5 mL)</td>
</tr>
</tbody>
</table>

**RELACTAGEL® GEL**

<table>
<thead>
<tr>
<th>INDICATIONS AND DOSE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prevention of bacterial vaginosis</strong></td>
</tr>
<tr>
<td>➤ BY VAGINA</td>
</tr>
<tr>
<td>Adult: 5 mL daily for 2–3 nights after menstruation, insert the contents of one tube</td>
</tr>
</tbody>
</table>
6.1b Vaginal and vulval fungal infections

Other drugs used for Vaginal and vulval fungal infections
Fluconazole, p. 562. Itraconazole, p. 564

ANTIFUNGALS > IMIDAZOLE ANTIFUNGALS

Clotrimazole

● INDICATIONS AND DOSE
Superficial sites of infection in vaginal and vulval candidiasis (dose for 1% or 2% cream)
▷ BY VAGINA USING CREAM
▷ Adult: Apply 2–3 times a day, to be applied to anogenital area
Vaginal candidiasis (dose for 10% intravaginal cream)
▷ BY VAGINA USING VAGINAL CREAM
▷ Adult: 5 g for 1 dose, one applicatorful to be inserted into the vagina at night, dose can be repeated once if necessary
Vaginal candidiasis
▷ BY VAGINA USING VAGINAL CREAM
▷ Adult: 200 mg for 3 nights, course can be repeated once if necessary, alternatively 100 mg for 6 nights, course can be repeated once if necessary, alternatively 500 mg for 1 night, dose can be repeated once if necessary
Recurrent vulvovaginal candidiasis
▷ BY VAGINA USING VAGINAL CREAM
▷ Adult: 500 mg every week for 6 months, dose to be administered following topical imidazole for 10–14 days

● INTERACTIONS → Appendix 1: antifungals, imidazole

● SIDE-EFFECTS Local irritation

● CONCEPTION AND CONTRACEPTION

CONCEPTION AND CONTRACEPTION
Cream and pessaries may damage latex condoms and diaphragms.

PREGNANCY
Pregnant women need a longer duration of treatment, usually about 7 days, to clear the infection.

● MEDICINAL FORMS

CONCEPTION AND CONTRACEPTION

There can be variation in the licensing of different medicines containing the same drug.

Pessary
EXCIPIENTS: May contain Benzyl alcohol, cetostearyl alcohol (including cetyl and stearyl alcohol), polysorbates
Clotrimazole (Non-proprietary)
Clotrimazole 500 mg
3 pessaries | £3.75 DT price = £2.88
782 Vaginal and vulval conditions

Fenticonazole nitrate

- **INDICATIONS AND DOSE**
  - **Vaginal and vulval candidiasis**
    - **BY VAGINA USING CAPSULES**
    - Adult: 200 mg daily for 3 days, alternatively 600 mg daily for 1 dose, to be inserted at night
    - **BY VAGINA USING CREAM**
    - Adult: 1 applicatorful twice daily for 3 days

- **DOSE EQUIVALENCE AND CONVERSION**
  - With topical use
  - 1 applicatorful delivers a 5 g dose of fenticonazole 2%.

- **SIDE-EFFECTS**
  - Local irritation

- **CONCEPTION AND CONTRACEPTION**
  - Intravaginal cream and vaginal capsules damage latex condoms and diaphragms.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  - **Cream**
    - **EXCIPIENTS:** May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), propylene glycol, wool fat and related substances including lanolin
    - **Gyno-Daktarin®** (Janssen-Cilag Ltd)
      - Fenticonazole nitrate 20 mg per 1 gram
      - Gyno-Daktarin® 2% vaginal cream 30 gram
      - **Price:** £3.74

  - **Capsule**
    - **EXCIPIENTS:** May contain Hydroxybenzoates (parabens)
    - **Gyno-Daktarin®** (Janssen-Cilag Ltd)
      - Fenticonazole nitrate 200 mg
      - Gyno-Daktarin® 2% vaginal capsules 3 capsule
      - **Price:** £2.42
    - **Fenticonazole nitrate 600 mg**
      - Gyno-Daktarin® 2% vaginal capsules 1 capsule
      - **Price:** £2.62

Ketoconazole

- **INDICATIONS AND DOSE**
  - **Vaginal and vulval candidiasis**
    - **BY VAGINA USING CREAM**
    - Adult: Apply 1–2 times a day, to be applied to the anogenital area

- **SIDE-EFFECTS**
  - Occasional local irritation

- **CONCEPTION AND CONTRACEPTION**
  - Effects on latex condoms and diaphragms not yet known.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  - **Cream**
    - **EXCIPIENTS:** May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), propylene glycol, wool fat and related substances including lanolin
    - **Nizoral®** (Janssen-Cilag Ltd)
      - Ketoconazole 20 mg per 1 gram
      - Nizoral® 2% cream 30 gram
      - **Price:** £4.24

Miconazole

- **INDICATIONS AND DOSE**
  - **Vaginal and vulval candidiasis**
    - **BY VAGINA USING CAPSULES**
      - Child: 1 capsule daily, ovule to be inserted at night as a single dose, dose can be repeated once if necessary
      - Adult: 1 capsule daily, ovule to be inserted at night as a single dose, dose can be repeated once if necessary
    - **BY VAGINA USING CREAM**
      - Adult: Apply 1 applicatorful daily for 10 to 14 days, alternatively apply 1 applicatorful twice daily for 7 days, course can be repeated once if necessary

- **SIDE-EFFECTS**
  - Common or very common
    - Nausea, rash, vomiting
  - Frequency not known
    - Occasional local irritation
  - **CONCEPTION AND CONTRACEPTION**
    - **Gyno-Daktarin®**
      - Damages latex condoms and diaphragms.
  - **PREGNANCY**
    - Pregnant women need a longer duration of treatment, usually about 7 days, to clear the infection.
  - **BREAST FEEDING**
    - Manufacturer advises caution—no information available.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  - **Capsule**
    - **EXCIPIENTS:** May contain Hydroxybenzoates (parabens)
    - **Gyno-Daktarin®** (Janssen-Cilag Ltd)
      - Miconazole nitrate 12 gram
      - Gyno-Daktarin® 1200 mg vaginal capsules 1 capsule
      - **Price:** £2.94
    - **Cream**
      - **EXCIPIENTS:** May contain Butylated hydroxyanisole
      - **Gyno-Daktarin®** (Janssen-Cilag Ltd)
      - Miconazole nitrate 20 mg per 1 gram
      - Gyno-Daktarin® 2% vaginal cream 78 gram
      - **Price:** £4.33

6.2 Vaginal atrophy

OESTROGENS

Estradiol

- **INDICATIONS AND DOSE**
  - **ESTRING®**
    - Postmenopausal urogenital conditions (not suitable for vasomotor symptoms or osteoporosis prophylaxis)
    - **BY VAGINA**
    - Adult: To be inserted into upper third of vagina and worn continuously; replace after 3 months; max. duration of continuous treatment 2 years

  - **VAGIFEM®**
    - Improve the vaginal epithelium in menopausal atrophic vaginitis
    - **BY VAGINA**
    - Adult: 1 tablet daily for 2 weeks, then reduced to 1 tablet twice weekly

- **CONTRA-INDICATIONS**
  - Active arterial thromboembolic disease (e.g. angina or myocardial infarction) – active thrombophlebitis – Dubin-Johnson syndrome (or monitor closely) – history of breast cancer – history of recurrent venous thromboembolism (unless already on anticoagulant treatment) – oestrogen-dependent cancer – recent arterial thromboembolic disease (e.g. angina or myocardial infarction) – Rotor syndrome (or monitor closely) – thrombophilic disorder – undiagnosed vaginal bleeding – untreated endometrial hyperplasia – venous thromboembolism

- **CAUTIONS**
  - Acute porphyrias p. 969 – diabetes (increased risk of heart disease) – history of breast nodules—closely monitor breast status (risk of breast cancer) – history of endometrial hyperplasia; factors predisposing to thromboembolism – history of fibrocystic disease—closely monitor breast status (risk of breast cancer) – hypophysel tumours – increased risk of gall–bladder disease – interrupt treatment periodically to assess need for continued treatment - migraine (or migraine-like headaches) –...
presence of antiphospholipid antibodies (increased risk of thrombotic events) - prolonged exposure to unopposed oestrogens may increase risk of developing endometrial cancer - risk factors for oestrogen-dependent tumours (e.g. breast cancer in first-degree relative) - symptoms of endometriosis may be exacerbated - uterine fibroids may increase in size

CAUTIONS, FURTHER INFORMATION

- **Risk of breast cancer** It is estimated that using all types of HRT increases the risk of breast cancer within 1–2 years of initiating treatment. The increased risk is related to the duration of HRT use (but not to the age at which HRT is started) and this excess risk disappears within 5 years of stopping. Radiological detection of breast cancer can be made more difficult as mammographic density can increase with HRT use.

- **Risk of endometrial cancer** The increased risk of endometrial cancer depends on the dose and duration of oestrogen-only HRT.

  In women with a uterus, the addition of a progestogen cyclically (for at least 10 days per 28-day cycle) reduces the additional risk of endometrial cancer; this additional risk is eliminated if a progestogen is given continuously. However, this should be weighed against the increased risk of breast cancer.

- **Risk of ovarian cancer** Long-term use of combined HRT or oestrogen-only HRT is associated with a small increased risk of ovarian cancer. This excess risk disappears within a few years of stopping.

- **Risk of venous thromboembolism** Women using combined or oestrogen-only HRT are at an increased risk of deep vein thrombosis and of pulmonary embolism especially in the first year of use.

  In **women who have predisposing factors** (such as a personal or family history of deep vein thrombosis or pulmonary embolism, severe varicose veins, obesity, trauma, or prolonged bed-rest) it is prudent to review the need for HRT, as in some cases the risks of HRT may exceed the benefits. **Travel** involving prolonged immobility further increases the risk of deep vein thrombosis.

- **Risk of stroke** Risk of stroke increases with age, therefore older women have a greater absolute risk of stroke. Combined HRT or oestrogen-only HRT slightly increases the risk of stroke.

- **Risk of coronary heart disease** HRT does not prevent coronary heart disease and should not be prescribed for this purpose. There is an increased risk of coronary heart disease in women who start combined HRT more than 10 years after menopause. Although very little information is available on the risk of coronary heart disease in younger women who start HRT close to the menopause, studies suggest a lower relative risk compared with older women.

  Other conditions The product literature advises caution in other conditions including hypertension, renal disease, asthma, epilepsy, sickle-cell disease, melanoma, otosclerosis, multiple sclerosis, and systemic lupus erythematosus (but care required if antiphospholipid antibodies present). Evidence for caution in these conditions is unsatisfactory and many women with these conditions may stand to benefit from HRT.

- **SIDE-EFFECTS** Abdominal bloating - abdominal cramps - altered blood lipids (may lead to pancreatitis, rashes and chloasma) - breast enlargement - breast tenderness - changes in libido - cholesterol jaundice - contact lenses may irritate - depression - dizzyiness - fluid retention - glucose intolerance - headache - headache (on vigorous exercise) - leg cramps (rule out venous thrombosis) - local irritation - migraine - mood changes - nausea - premenstrual-like syndrome - sodium retention - vaginal candidiasis - vomiting - weight changes

SIDE-EFFECTS, FURTHER INFORMATION

- **Withdrawal bleeding** Cyclical HRT (where a progestogen is taken for 12–14 days of each 28-day oestrogen treatment cycle) usually results in **regular withdrawal bleeding** towards the end of the progestogen. The aim of continuous combined HRT (where a combination of oestrogen and progestogen is taken, usually in a single tablet, throughout each 28-day treatment cycle) is to avoid bleeding; but **irregular bleeding** may occur during the early treatment stages (if it continues endometrial abnormality should be excluded and consideration given to cyclical HRT instead).

- **CONCEPTION AND CONTRACEPTION** HRT does **not** provide contraception and a woman is considered potentially fertile for 2 years after her last menstrual period if she is under 50 years, and for 1 year if she is over 50 years. A woman who is under 50 years and free of all risk factors for venous and arterial disease can use a low-oestrogen combined oral contraceptive pill to provide both relief of menopausal symptoms and contraception; it is recommended that the oral contraceptive be stopped at 50 years of age since there are more suitable alternatives. If any potentially fertile woman needs HRT, non-hormonal contraceptive measures (such as condoms) are necessary. Measurement of follicle-stimulating hormone can help to determine fertility, but high measurements alone (particularly in women aged under 50 years) do not necessarily preclude the possibility of becoming pregnant.

VAGIFEM ® No evidence of damage to latex condoms and diaphragms.

- **PREGNANCY** Not known to be harmful.

- **BREAST FEEDING** Avoid; adverse effects on lactation.

- **HEPATIC IMPAIRMENT** Avoid in active liver disease including disorders of hepatic excretion (e.g. Dubin-Johnson or Rotor syndromes), infective hepatitis (until liver function returns to normal), and liver tumours.

- **MONITORING REQUIREMENTS**

  - History of breast nodules or fibrocystic disease—closely monitor breast status (risk of breast cancer).
  - The endometrial safety of long-term or repeated use of topical vaginal oestrogens is uncertain; treatment should be reviewed at least annually, with special consideration given to any symptoms of endometrial hyperplasia or carcinoma.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Pessary**

| Vagifem® (Novo Nordisk Ltd) | Estradiol 10 microgram Vagifem®10microgram vaginal tablets | 24 pessary | £16.72 DT price = £16.72 |

**Vaginal delivery system**

| CAUTIONARY AND ADVISORY LABELS | 10 |

| Estrin® (Pfizer Ltd) | Estradiol (as Estradiol hemihydrate) 7.5 microgram per 24 hour Estrin® 7.5micrograms/24hours vaginal delivery system | 1 device | £31.42 |

**Estriol**

- **INDICATIONS AND DOSE**

OVESTIN ®

Improve the vaginal epithelium in menopausal atrophic vaginitis (short-term use)

- **BY VAGINA**

  - Adult: Apply 1 applicatorful daily for 2–3 weeks, then reduced to 1 applicatorful twice weekly, continued →
discontinue every 2–3 months for 4 weeks to assess need for further treatment

**Vaginal surgery for prolapse when there is epithelial atrophy in postmenopausal women (before surgery)**

**BY VAGINA**
- Adult: Apply 1 applicatorful daily for 2 weeks before surgery, resume 2 weeks after surgery

**CONTRA-INDICATIONS** Active arterial thromboembolic disease (e.g. angina or myocardial infarction) - active thrombophlebitis - Dubin-Johnson syndrome (or monitor closely) - history of breast cancer - history of recurrent venous thromboembolism (unless already on anticoagulant treatment) - oestrogen-dependent cancer - recent arterial thromboembolic disease (e.g. angina or myocardial infarction) - Rotor syndrome (or monitor closely) - thrombophilic disorder - undiagnosed vaginal bleeding - untreated endometrial hyperplasia - venous thromboembolism

**CAUTIONS** Acute porphyrrias p. 969 - diabetes (increased risk of heart disease) - factors predisposing to thromboembolism - history of breast nodules - closely monitor breast status (risk of breast cancer) - history of endometrial hyperplasia - history of fibrocystic disease - closely monitor breast status (risk of breast cancer) - hypophyseal tumours - increased risk of gall-bladder disease - interrupt treatment periodically to assess need for continued treatment - migraine (or migraine-like headaches) - presence of antiphospholipid antibodies (increased risk of thrombotic events) - prolonged exposure to unopposed oestrogens may increase risk of developing endometrial cancer - risk factors for oestrogen-dependent tumours (e.g. breast cancer in first-degree relative) - symptoms of endometriosis may be exacerbated - uterine fibroids may increase in size

**CAUTIONS, FURTHER INFORMATION**
- Risk of breast cancer It is estimated that using all types of HRT increases the risk of breast cancer within 1–2 years of initiating treatment. The increased risk is related to the duration of HRT use (but not to the age at which HRT is started) and this excess risk disappears within 5 years of stopping.
  - Radiological detection of breast cancer can be made more difficult as mammographic density can increase with HRT use.

- Risk of endometrial cancer The increased risk of endometrial cancer depends on the dose and duration of oestrogen-only HRT.
  - In women with a uterus, the addition of a progestogen cyclically (for at least 10 days per 28-day cycle) reduces the additional risk of endometrial cancer; this additional risk is eliminated if a progestogen is given continuously. However, this should be weighed against the increased risk of breast cancer.

- Risk of ovarian cancer Long-term use of combined HRT or oestrogen-only HRT is associated with a small increased risk of ovarian cancer. This excess risk disappears within a few years of stopping.

- Risk of venous thromboembolism Women using combined or oestrogen-only HRT are at an increased risk of deep vein thrombosis and of pulmonary embolism especially in the first year of use.
  - In women who have predisposing factors (such as a personal or family history of deep vein thrombosis or pulmonary embolism, severe varicose veins, obesity, trauma, or prolonged bed-rest) it is prudent to review the need for HRT, as in some cases the risks of HRT may exceed the benefits.
  - Travel involving prolonged immobility further increases the risk of deep vein thrombosis.

- Risk of stroke Risk of stroke increases with age, therefore older women have a greater absolute risk of stroke.

Combined HRT or oestrogen-only HRT slightly increases the risk of stroke.
- Risk of coronary heart disease HRT does not prevent coronary heart disease and should not be prescribed for this purpose. There is an increased risk of coronary heart disease in women who start combined HRT more than 10 years after menopause. Although very little information is available on the risk of coronary heart disease in younger women who start HRT close to the menopause, studies suggest a lower relative risk compared with older women.

- Other conditions The product literature advises caution in other conditions including hypertension, renal disease, asthma, epilepsy, sickle-cell disease, melanoma, otosclerosis, multiple sclerosis, and systemic lupus erythematosus (but care required if antiphospholipid antibodies present). Evidence for caution in these conditions is unsatisfactory and many women with these conditions may stand to benefit from HRT.

**SIDE-EFFECTS** Abdominal bloating - abdominal cramps - altered blood lipids (may lead to pancreatitis, rashes and chloasma) - breast enlargement - breast tenderness - changes in libido - cholestatic jaundice - contact lenses may irritate - depression - dizziness - fluid retention - glucose intolerance - headache - leg cramps - local irritation - migraine - mood changes - nausea - premenstrual-like syndrome - sodium retention - vaginal candidiasis - vomiting - weight changes

**SIDE-EFFECTS, FURTHER INFORMATION**
- Leg Cramps Venous thrombosis should be ruled out.
- Withdrawal Bleeding Cyclical HRT (where a progestogen is taken for 12–14 days of each 28-day oestrogen treatment cycle) usually results in regular withdrawal bleeding towards the end of the progestogen. The aim of continuous combined HRT (where a combination of oestrogen and progestogen is taken, usually in a single tablet, throughout each 28-day treatment cycle) is to avoid bleeding, but irregular bleeding may occur during the early treatment stages (if it continues endometrial abnormality should be excluded and consideration given to cyclical HRT instead).

**CONCEPTION AND CONTRACEPTION** Effect on latex condoms and diaphragms not yet known.

**PREGNANCY** Not known to be harmful.

**BREAST FEEDING** Avoid; adverse effects on lactation.

**HEPATIC IMPAIRMENT** Avoid in active liver disease including disorders of hepatic excretion (e.g. Dubin-Johnson or Rotor syndromes), infective hepatitis (until liver function returns to normal), and liver tumours.

**RENAL IMPAIRMENT** Manufacturer advises caution in renal disease. Evidence for caution is unsatisfactory and many women with these conditions may stand to benefit from HRT.

**MONITORING REQUIREMENTS**
- Closely monitor breast status if history of breast nodules or fibrocystic disease (risk of breast cancer).
- The endometrial safety of long-term or repeated use of topical vaginal oestrogens is uncertain; treatment should be reviewed at least annually, with special consideration given to any symptoms of endometrial hyperplasia or carcinoma.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Cream**
- EXCIPIENTS: May contain Arachis (peanut) oil, cetostearyl alcohol (including cetyl and stearyl alcohol), polysorbates
- **Ovestin** (Aspen Pharma Trading Ltd)
  - **Estriol 1 mg per 1 gram** Ovestin 1mg cream | 15 gram **POM** £4.45
  - DT price = £4.45
Chapter 8
Immune system and malignant disease

Contents

1 Immune system disorders and transplantation

1.1 Multiple sclerosis

Malignant disease

1 Antibody responsive malignancy

2 Cytotoxic responsive malignancy

2.1 Cytotoxic drug-induced side effects

2.1a Hyperuricaemia associated with cytotoxic drugs

3 Hormone responsive malignancy

3.1 Hormone responsive breast cancer

4 Immunotherapy responsive malignancy

5 Photodynamic therapy responsive malignancy

6 Targeted therapy responsive malignancy

Immune system

1 Immune system disorders and transplantation

Immune response

Inflammatory bowel disease
Azathioprine p. 787, ciclosporin p. 788, mercaptopurine p. 844, and methotrexate p. 844 have a role in the treatment of inflammatory bowel disease.

Folic acid p. 937 should be given to reduce the possibility of methotrexate toxicity [unlicensed indication]. Folic acid is usually given weekly on a different day to the methotrexate; alternative regimens may be used in some settings.

Immunosuppressant therapy

Immunosuppressants are used to suppress rejection in organ transplant recipients and to treat a variety of chronic inflammatory and autoimmune diseases. Solid organ transplant patients are maintained on drug regimens, which may include antiproliferative drugs (azathioprine or mercaptopurine), calcineurin inhibitors (ciclosporin or tacrolimus), corticosteroids, or sirolimus. Choice is dependent on the type of organ, time after transplantation, and clinical condition of the patient. Specialist management is required and other immunomodulators may be used to initiate treatment or to treat rejection.

Impaired immune responsiveness

Modification of tissue reactions caused by corticosteroids and other immunosuppressants may result in the rapid spread of infection. Corticosteroids may suppress clinical signs of infection and allow diseases such as septicaemia or tuberculosis to reach an advanced stage before being recognised—important: normal immunoglobulin administration should be considered as soon as possible after measles exposure, and varicella—zoster immunoglobulin (VZIG) is recommended for individuals who have significant chickenpox (varicella) exposure. Specialist advice should be sought on the use of live vaccines for those being treated with immunosuppressive drugs.

Antiproliferative immunosuppressants
Azathioprine is widely used for transplant recipients and it is also used to treat a number of auto-immune conditions, usually when corticosteroid therapy alone provides inadequate control. It is metabolised to mercaptopurine, and doses should be reduced when allopurinol p. 1021 is given concurrently.

Mycophenolate mofetil is metabolised to mycophenolic acid which has a more selective mode of action than azathioprine.

There is evidence that compared with similar regimens incorporating azathioprine, mycophenolate mofetil reduces the risk of acute rejection episodes; the risk of opportunistic infections (particularly due to tissue-invasive cytomegalovirus) and the occurrence of blood disorders such as leucopenia may be higher.

Cyclophosphamide p. 830 is less commonly prescribed as an immunosuppressant.

Corticosteroids and other immunosuppressants
Prednisolone p. 639 is widely used in oncology. It has a marked antitumour effect in acute lymphoblastic leukaemia, Hodgkin’s disease, and the non-Hodgkin lymphomas. It has a role in the palliation of symptomatic end-stage malignant disease when it may enhance appetite and produce a sense of well-being.

The corticosteroids are also powerful immunosuppressants. They are used to prevent organ transplant rejection, and in high dose to treat rejection episodes.

Ciclosporin a calcineurin inhibitor, is a potent immunosuppressant which is virtually non-myelotoxic but markedly nephrotoxic. It has an important role in organ and tissue transplantation, for prevention of graft rejection following bone marrow, kidney, liver, pancreas, heart, lung, and heart—lung transplantation, and for prophylaxis and treatment of graft—versus—host disease.

Sirolimus is also a calcineurin inhibitor. Although not chemically related to ciclosporin it has a similar mode of action and side-effects, but the incidence of neurotoxicity appears to be greater; cardiomyopathy has also been reported. Disturbance of glucose metabolism also appears to be significant.

Sirolimus is a non—calcineurin inhibiting immunosuppressant licensed for renal transplantation. Basiliximab p. 795 is used for prophylaxis of acute rejection in allogeneic renal transplantation. It is given with ciclosporin and corticosteroid immunosuppression regimens; its use should be confined to specialist centres.

Belatacept p. 797 is a fusion protein and co-stimulation blocker that prevents T-cell activation; it is licensed for prophylaxis of graft rejection in adults undergoing renal transplantation who are seropositive for the Epstein—Barr virus. It is used with interleukin—2 receptor antagonist.
Induction, in combination with corticosteroids and a mycophenolic acid.

Antithymocyte immunoglobulin (rabbit) below is licensed for the prophylaxis of organ rejection in renal and heart allograft recipients and for the treatment of corticosteroid-resistant allograft rejection in renal transplantation. Tolerability is increased by pretreatment with an intravenous corticosteroid and antihistamine; an antipyretic drug such as paracetamol may also be beneficial.

**NICE technology appraisals (TAs)**

Immunosuppressive therapy for renal transplantation in adults (September 2004) NICE TAs5

When selecting immunosuppressive therapy for induction therapy in the prophylaxis of organ rejection following renal transplantation in adults, either basiliximab or daclizumab [discontinued] are options for combining with a calcineurin inhibitor. For each individual, ciclosporin or tacrolimus is chosen as the calcineurin inhibitor on the basis of side-effects.

Mycophenolate mofetil [mycophenolic acid also available but not licensed for use in children] is recommended as part of an immunosuppressive regimen only if:

- the calcineurin inhibitor is not tolerated, particularly if nephrotoxicity endangers the transplanted kidney; or
- there is very high risk of nephrotoxicity from the calcineurin inhibitor, requiring a reduction in the dose of the calcineurin inhibitor or its avoidance.

Sirolimus is recommended as a component of immunosuppressive regimen only if intolerance necessitates the withdrawal of a calcineurin inhibitor. These recommendations may not be consistent with the marketing authorisation of some of the products.

www.nice.org.uk/TAs5


When selecting immunosuppressive therapy for renal transplantation in children and adolescents, NICE has recommended that for induction therapy in the prophylaxis of organ rejection, either basiliximab or daclizumab [discontinued] are options for combining with a calcineurin inhibitor. For each individual, ciclosporin or tacrolimus is chosen as the calcineurin inhibitor on the basis of side-effects. Mycophenolate mofetil is recommended as part of an immunosuppressive regimen only if:

- the calcineurin inhibitor is not tolerated, particularly if nephrotoxicity endangers the transplanted kidney; or
- there is very high risk of nephrotoxicity from the calcineurin inhibitor, requiring a reduction in the dose of the calcineurin inhibitor or its avoidance.

Mycophenolic acid is not recommended as part of an immunosuppressive regimen for renal transplantation in children or adolescents.

Sirolimus [not licensed for use in children] is recommended as a component of immunosuppressive regimen only if intolerance necessitates the withdrawal of a calcineurin inhibitor.

These recommendations may not be consistent with the marketing authorisation of some of the products.

www.nice.org.uk/TAs99

---

**Antithymocyte immunoglobulin (rabbit)**

- **INDICATIONS AND DOSE**
  - Prophylaxis of organ rejection in heart allograft recipients
    - **BY INTRAVENOUS INFUSION**
      - Adult: 1–2.5 mg/kg daily for 3–5 days, to be given over at least 6 hours
  - Prophylaxis of organ rejection in renal allograft recipients
    - **BY INTRAVENOUS INFUSION**
      - Adult: 1–1.5 mg/kg daily for 3–9 days, to be given over at least 6 hours
  - Treatment of corticosteroid-resistant allograft rejection in renal transplantation
    - **BY INTRAVENOUS INFUSION**
      - Adult: 1.5 mg/kg daily for 7–14 days, to be given over at least 6 hours

- **DOSES AT EXTREMS OF BODY-WEIGHT**
  - To avoid excessive dosage in obese patients, calculate dose on the basis of ideal body weight.

- **CONTRA-INDICATIONS**
  - Infection

- **SIDE-EFFECTS**
  - Anaphylaxis - cytokine release syndrome - diarrhoea - dysphagia - fever - hypotension - increased susceptibility to infection - increased susceptibility to malignancy - infusion-related reactions - lymphopenia - myalgia - nausea - neutropenia - pruritus - rash - serum sickness - shivering - thrombocytopenia - vomiting

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Tolerability is increased by pretreatment with an antipyretic drug such as paracetamol may also be beneficial.

- **PREGNANCY**
  - Manufacturer advises use only if potential benefit outweighs risk—no information available.

- **BREAST FEEDING**
  - Manufacturer advises avoid—no information available.

- **MONITORING REQUIREMENTS**
  - Monitor blood count.

- **DIRECTIONS FOR ADMINISTRATION**
  - For **continuous intravenous infusion** (Thymoglobuline®) in Glucose 5% or Sodium chloride 0.9%; reconstitute each vial with 5 mL water for injections to produce a solution of 5 mg/mL; gently rotate to dissolve. Dilute requisite dose with infusion fluid to a total volume of 50–500 mL (usually 50 mL/vial); begin infusion immediately after dilution; give through an in-line filter (pore size 0.22 micron); not to be given with unfractionated heparin and hydrocortisone in glucose infusion—precipitation reported.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

- **Solution for infusion**
  - **Antithymocyte immunoglobulin (rabbit) (Non-proprietary)**
    - **Antithymocyte immunoglobulin (rabbit) 20 mg per 1 ml** Grafalon
      - 100mg/5ml concentrate for solution for infusion vials | 1 vial [POM] no price available

- **Powder and solvent for solution for infusion**
  - **Thymoglobuline (Sanofi)**
    - **Antithymocyte immunoglobulin (rabbit) 25 mg** Thymoglobuline
      - 25mg powder and solvent for solution for infusion vials | 1 vial [POM] £158.77 (Hospital only)

---

Other drugs used for Immune system disorders and transplantation

Chloroquine, p. 582·Ereverolimus, p. 900·Hydroxychloroquine sulfate, p. 1001·Rituximab, p. 820

---

**Immune system and malignant disease**
Azathioprine

- **DRUG ACTION** Azathioprine is metabolised to mercaptopurine.

- **INDICATIONS AND DOSE**
  - **Severe acute Crohn’s disease | Maintenance of remission of Crohn’s disease | Maintenance of remission of acute ulcerative colitis**
    - **BY MOUTH**
    - **Adult:** 2–2.5 mg/kg daily, some patients may respond to lower doses
  - **Rheumatoid arthritis that has not responded to other disease-modifying drugs | Severe systemic lupus erythematosus and other connective tissue disorders | Polymyositis in cases of corticosteroid resistance**
    - **BY MOUTH**
    - **Adult:** Initially up to 2.5 mg/kg daily in divided doses, adjusted according to response, rarely more than 3 mg/kg daily; maintenance 1–3 mg/kg daily, consider withdrawal if no improvement within 3 months
  - **Autoimmune conditions**
    - **BY MOUTH, OR BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
    - **Adult:** 1–3 mg/kg daily, adjusted according to response, consider withdrawal if no improvement within 3 months, oral administration preferable, if not possible then can be given by intravenous injection (intravenous solution very irritant) or by intravenous infusion
  - **Suppression of transplant rejection**
    - **BY MOUTH, OR BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
    - **Adult:** 1–2.5 mg/kg daily, adjusted according to response, oral administration preferable, if not possible then can be given by intravenous injection (intravenous solution very irritant) or by intravenous infusion
  - **Severe refractory eczema, normal or high TPMT activity**
    - **BY MOUTH**
    - **Adult:** 1–3 mg/kg daily
  - **Severe refractory eczema, intermediate TPMT activity**
    - **BY MOUTH**
    - **Adult:** 0.5–1.5 mg/kg daily
  - **Generalised myasthenia gravis**
    - **BY MOUTH, OR BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
    - **Adult:** Initially 0.5–1 mg/kg daily, then increased to 2–2.5 mg/kg daily, dose is increased over 3–4 weeks, azathioprine is usually started at the same time as the corticosteroid and allows a lower maintenance dose of the corticosteroid to be used, oral administration preferable, if not possible then can be given by intravenous injection (intravenous solution very irritant) or by intravenous infusion

- **DOSE ADJUSTMENTS DUE TO INTERACTIONS**
  - Manufacturer advises reduce dose to one-quarter of the usual dose with concurrent use of allopurinol.

- **UNLICENSED USE** Azathioprine doses given in BNF for suppression of transplant rejection and autoimmune conditions may differ from those in product literature. Use for severe refractory eczema is unlicensed.

- **CONTRA-INDICATIONS**
  - When used for severe refractory eczema: absent thiopurine methyltransferase (TPMT) activity | very low thiopurine methyltransferase (TPMT) activity
  - **CAUTIONS** Reduce dose in elderly | reduced thiopurine methyltransferase activity

- **INTERACTIONS** → Appendix 1: azathioprine

- **SIDE-EFFECTS**
  - **Rare** Hepatic veno-occlusive disease | lymphoma | pancreatitis | pneumonitis | red cell aplasia
  - **Frequency not known** Arthralgia | cholestatic jaundice | colitis in patients also receiving corticosteroids | diarrhoea | dizziness | dose-related bone marrow suppression | fever | hair loss | herpes zoster infection | hypersensitivity reactions | hypotension | increased susceptibility to infections in patients also receiving corticosteroids | interstitial nephritis | liver impairment | malaise | myalgia | neutropenia | rash | rigors | thrombocytopenia | vomiting

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - **Red cell aplasia** Cases of pure red cell aplasia have been reported with azathioprine; dose reduction or discontinuation should be considered under specialist supervision.
  - **Neutropenia and thrombocytopenia** Usually resolved by reducing the dose.
  - **Hypersensitivity reactions** Hypersensitivity reactions (including malaise, dizziness, vomiting, diarrhoea, fever, rigors, myalgia, arthralgia, rash, hypotension and interstitial nephritis) call for immediate withdrawal.
  - **Nausea, vomiting and diarrhea** Nausea, vomiting and diarrhoea may occur, usually starting early during the course of treatment, and in rheumatoid arthritis it may be appropriate to withdraw the drug.

- **ALLERGY AND CROSS-SENSITIVITY** Contra-indicated in hypersensitivity to mercaptopurine.

- **PREGNANCY** Transplant patients immunosuppressed with azathioprine should not discontinue it on becoming pregnant. However, there have been reports of premature birth and low birth-weight following exposure to azathioprine, particularly in combination with corticosteroids. Spontaneous abortion has been reported following maternal or paternal exposure. Azathioprine is teratogenic in animal studies. The use of azathioprine during pregnancy needs to be supervised in specialist units. Treatment should not generally be initiated during pregnancy.

- **BREAST FEEDING** Present in milk in low concentration. No evidence of harm in small studies—use if potential benefit outweighs risk.

- **HEPATIC IMPAIRMENT** Reduce dose. Monitor liver function.

- **RENAL IMPAIRMENT** Reduce dose.

- **PRE-TREATMENT SCREENING** Thiopurine methyltransferase The enzyme thiopurine methyltransferase (TPMT) metabolises thiopurine drugs (azathioprine, mercaptopurine, tioguanine); the risk of myelosuppression is increased in patients with reduced activity of the enzyme, particularly for the few individuals in whom TPMT activity is undetectable. Consider measuring TPMT activity before starting azathioprine, mercaptopurine, or tioguanine therapy. Patients with absent TPMT activity should not receive thiopurine drugs; those with reduced TPMT activity may be treated under specialist supervision.

- **MONITORING REQUIREMENTS**
  - Monitor for toxicity throughout treatment.
  - Monitor full blood count weekly (more frequently with higher doses or if severe hepatic or renal impairment) for first 4 weeks (manufacturer advises weekly monitoring for 8 weeks but evidence of practical value unsatisfactory), thereafter reduce frequency of monitoring to at least every 3 months.
  - Blood tests and monitoring for signs of myelosuppression are essential in long-term treatment.
Immune system and malignant disease

DIRECTIONS FOR ADMINISTRATION

With intravenous use  For intravenous injection, give over at least 1 minute (followed by 50 mL sodium chloride intravenous infusion). For intravenous infusion (Imuran®), give intermittently in glucose 5% or sodium chloride 0.9%. Reconstitute 50 mg with 5–15 mL water for injections; dilute requisite dose to a volume of 20–200 mL with infusion fluid. Intravenous injection is alkaline and very irritant, intravenous route should therefore be used only if oral route not feasible.

PATIENT AND CARER ADVICE
Bone marrow suppression  Patients and their carers should be warned to report immediately any signs or symptoms of bone marrow suppression e.g. inexplicable bruising or bleeding, infection.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule, oral suspension, oral solution

Tablet

CAUTIONARY AND ADVISORY LABELS  21

Azathioprine (Non-proprietary)

Azathioprine 25 mg  Azathioprine 25mg tablets  28 tablet  £8.41 DT price = £1.66  100 tablet  £33.26
Azathioprine 50 mg  Azathioprine 50mg tablets  56 tablet  £7.28 DT price = £2.21  100 tablet  £16.55
Azapress (Ennogen Pharma Ltd)
Azathioprine 50 mg  Azapress 50mg tablets  56 tablet  £2.83 DT price = £2.21
Imuran (Aspen Pharma Trading Ltd)
Azathioprine 25 mg  Imuran 25mg tablets  100 tablet  £10.99
Azathioprine 50 mg  Imuran 50mg tablets  100 tablet  £7.99
Powder for solution for injection
Imuran (Aspen Pharma Trading Ltd)
Azathioprine 50 mg  Imuran 50mg powder for solution for injection vials  1 vial  £15.38

IMMUNOSUPPRESSANTS  CALCINEURIN INHIBITORS AND RELATED DRUGS

Ciclosporin  (Cyclosporin)

DRUG ACTION  Ciclosporin inhibits production and release of lymphokines, thereby suppressing cell-mediated immune response.

INDICATIONS AND DOSE

Severe acute ulcerative colitis refractory to corticosteroid treatment

BY CONTINUOUS INTRAVENOUS INFUSION
Adult: 2 mg/kg, to be given over 24 hours, dose adjusted according to blood-ciclosporin concentration and response

Severe active rheumatoid arthritis when conventional second-line therapy inappropriate or ineffective (administered on expert advice)

BY MOUTH
Adult: Initially 2.5 mg/kg daily in 2 divided doses, increased if necessary up to 4 mg/kg daily after 6 weeks, if dose increases are necessary they should be made gradually, discontinue if response insufficient after 3 months, dose adjusted according to response for maintenance and treatment reviewed after 6 months (continue only if benefits outweigh risks)

Short-term treatment of severe atopic dermatitis where conventional therapy ineffective or inappropriate (administered on expert advice)

BY MOUTH
Adult: Initially 1.25 mg/kg twice daily (max. per dose 2.5 mg/kg twice daily) usual maximum duration of 8 weeks but may be used for longer under specialist supervision

Short-term treatment of very severe atopic dermatitis where conventional therapy ineffective or inappropriate (administered on expert advice)

BY MOUTH
Adult: 2.5 mg/kg twice daily usual maximum duration of 8 weeks but may be used for longer under specialist supervision

Severe psoriasis where conventional therapy ineffective or inappropriate (administered on expert advice)

BY MOUTH
Adult: Initially 1.25 mg/kg twice daily (max. per dose 2.5 mg/kg twice daily), increased gradually to maximum if no improvement within 1 month, initial dose of 2.5 mg/kg twice daily justified if condition requires rapid improvement; discontinue if inadequate response after 3 months at the optimum dose; maximum duration of treatment usually 1 year unless other treatments cannot be used

Organ transplantation (used alone)

BY MOUTH
Adult: 10–15 mg/kg, to be administered 4–12 hours before transplantation, followed by 10–15 mg/kg daily for 1–2 weeks postoperatively, then maintenance 2–6 mg/kg daily, reduce dose gradually to maintenance. Dose should be adjusted according to blood-ciclosporin concentration and renal function; dose is lower if given concomitantly with other immunosuppressant therapy (e.g. corticosteroids); if necessary one-third corresponding oral dose can be given by intravenous infusion over 2–6 hours

Bone-marrow transplantation | Prevention and treatment of graft-versus-host disease

INITIALLY BY INTRAVENOUS INFUSION
Adult: 3–5 mg/kg daily, to be administered over 2–6 hours from day before transplantation to 2 weeks postoperatively, alternatively (by mouth) initially 12.5–15 mg/kg daily, then (by mouth) 12.5 mg/kg daily for 3–6 months and then tailed off (may take up to a year after transplantation)

Nephrotic syndrome

BY MOUTH
Adult: 5 mg/kg daily in 2 divided doses, for maintenance reduce to lowest effective dose according to proteinuria and serum creatinine measurements; discontinue after 3 months if no improvement in glomerulonephritis or glomerulosclerosis (after 6 months in membranous glomerulonephritis)

DOSE ADJUSTMENTS DUE TO INTERACTIONS

With oral use  Manufacturer advises increase dose by 50% or switch to intravenous administration with concurrent use of octreotide.

UNLICENSED USE  Not licensed for use in severe acute ulcerative colitis refractory to corticosteroid treatment

IMPORTANT SAFETY INFORMATION
MHRA/CHM ADVICE: CICLOSPORIN MUST BE PRESCRIBED AND DISPENSED BY BRAND NAME (DECEMBER 2009)

Patients should be stabilised on a particular brand of oral ciclosporin because switching between formulations without close monitoring may lead to clinically important changes in blood-ciclosporin concentration.

CONTRA-INDICATIONS  Abnormal baseline renal function (in non-transplant indications) - malignancy (in non-transplant indications) - uncontrolled hypertension (in non-transplant indications) - uncontrolled infections (in non-transplant indications)
CAUTIONS  Elderly—monitor renal function - hyperuricaemia - in atopic dermatitis, active herpes simplex infections—allow infection to clear before starting (if they occur during treatment withdraw if severe) - in atopic dermatitis, Staphylococcus aureus skin infections— not absolute contra-indication providing controlled (but avoid erythromycin unless no other alternative) - in psoriasis treat, patients with malignant or pre-malignant conditions of skin only after appropriate treatment (and if no other option) - in uveitis, Behcet’s syndrome (monitor neurological status) - lymphoproliferative disorders (discontinue treatment) - malignancy

CAUTIONS, FURTHER INFORMATION

Malignancy
In psoriasis, exclude malignancies (including those of skin and cervix) before starting (biopsy any lesions not typical of psoriasis) and treat patients with malignant or pre-malignant conditions of skin only after appropriate treatment (and if no other option); discontinue if lymphoproliferative disorder develops.

INTERACTIONS  ▶ Appendix 1: ciclosporin

SIDE-EFFECTS

Common or very common
Abdominal pain  ·  acne  ·  anorexia  ·  convulsion  ·  diarrhoea  ·  fatigue  ·  flushing  ·  gingival hyperplasia  ·  headache  ·  hepatic dysfunction  ·  hirsutism  ·  hyperglycaemia  ·  hyperkalaemia  ·  hyperlipidaemia  ·  hypertension  ·  hypertrichosis  ·  hyperuricaemia  ·  hyperglycaemia  ·  hypomagnesaemia  ·  leucopenia  ·  muscle cramps  ·  myalgia  ·  nausea  ·  paraesthesia  ·  peptic ulcer  ·  pyrexia  ·  renal dysfunction (renal structural changes on long-term administration)  ·  tremor  ·  vomiting

Uncommon
Anaemia  ·  oedema  ·  signs of encephalopathy  ·  thrombocytopenia  ·  weight gain

Rare
Gynaecomastia  ·  haemolytic uraemic syndrome  ·  menstrual disturbances  ·  micro-angiopathic haemolytic anaemia  ·  motor polyneuropathy  ·  muscle weakness  ·  myopathy  ·  pancreatitis

Very rare
Visual disturbances secondary to benign intracranial hypertension

Frequency not known
With intravenous use  ·  Anaphylaxis
With systemic use  ·  Migraine  ·  pain in lower extremities

PREGNANCY
Crosses placenta; manufacturer advises avoid unless potential benefit outweighs risk—toxicity in animal studies.

NURSING AND MIDWIFE

Breast feeding
Manufacturer advises avoid—present in milk.

HEPATIC IMPAIRMENT
Extensively metabolised by the liver—manufacturer advises consider dose adjustment based on bilirubin and liver enzyme levels.

RENAL IMPAIRMENT
In non-transplant indications, manufacturer advises establishing baseline renal function before initiation of treatment; if baseline function is impaired in non-transplant indications, except nephrotic syndrome—avoid. In nephrotic syndrome, manufacturer advises initial dose should not exceed 2.5 mg/kg daily in patients with baseline renal impairment. During treatment for non-transplant indications, manufacturer recommends if eGFR decreases by more than 25% below baseline on more than one measurement, reduce dose by 25–50%. If the eGFR decrease from baseline exceeds 35%, further dose reduction should be considered (even if within normal range); discontinue if reduction not successful within 1 month.

MONITORING REQUIREMENTS
Monitor whole blood ciclosporin concentration (trough level dependent on indication—consult local treatment protocol for details).

Dermatological and physical examination, including blood pressure and renal function measurements required at least twice before starting treatment for psoriasis or atopic dermatitis.

Monitor liver function.

Monitor serum potassium, especially in renal dysfunction (risk of hyperkalaemia).

Monitor serum magnesium.

Measure blood lipids before treatment and after the first month of treatment.

In psoriasis and atopic dermatitis monitor serum creatinine every 2 weeks for first 3 months then every month.

Investigate lymphadenopathy that persists despite improvement in atopic dermatitis.

Monitor kidney function—dose dependent increase in serum creatinine and urea during first few weeks may necessitate dose reduction in transplant patients (exclude rejection if kidney transplant) or discontinuation in non-transplant patients.

Monitor blood pressure—discontinue if hypertension develops that cannot be controlled by antihypertensives.

In long-term management of nephrotic syndrome, perform renal biopsies at yearly intervals.

In rheumatoid arthritis measure serum creatinine at least twice before treatment. During treatment, monitor serum creatinine every 2 weeks for first 3 months, then every month for a further 3 months, then every 4–8 weeks depending on the stability of the disease, concomitant medication, and concomitant diseases (or more frequently if dose increased or concomitant NSAIDs introduced or increased).

Monitor hepatic function if concomitant NSAIDs given.

DIRECTIONS FOR ADMINISTRATION

With oral use  Mix solution with orange or apple juice, or other soft drink (to improve taste) immediately before taking (and rinse with more to ensure total dose). Do not mix with grapefruit juice. Total daily dose should be taken in 2 divided doses.

With intravenous use  For intravenous infusion (Sandimmun ®), give intermittently or continuously in Glucose 5% or Sodium Chloride 0.9%; dilute to a concentration of 50 mg in 20–100 mL; give intermittent infusion over 2–6 hours; not to be used with PVC equipment. Observe patient for signs of anaphylaxis for at least 30 minutes after starting infusion and at frequent intervals thereafter.

PRESCRIBING AND DISPENSING INFORMATION
Brand name prescribing  Prescribing and dispensing of ciclosporin should be by brand name to avoid inadvertent switching. If it is necessary to switch a patient to a different brand of ciclosporin, the patient should be monitored closely for changes in blood-ciclosporin concentration, serum creatinine, blood pressure, and transplant function (for transplant indications).

Sandimmun ® capsules and oral solution are available direct from Novartis for patients who cannot be transferred to a different oral preparation.

PATIENT AND CARER ADVICE
Patients and carers should be counselled on the administration of different formulations of ciclosporin. Manufacturer advises avoid excessive exposure to UV light, including sunlight. In psoriasis and atopic dermatitis, avoid use of UVB or PUVA.
Sirolimus

**DRUG ACTION** Sirolimus is a non-calcineurin inhibiting immunosuppressant.

**INDICATIONS AND DOSE**

Prophylaxis of organ rejection in kidney allograft recipients

- **BY MOUTH**
  - Adult: Initially 6 mg for 1 dose, to be given after surgery once wound has healed, then 2 mg once daily; to be given in combination with ciclosporin and corticosteroid for 2–3 months (sirolimus doses should be given 4 hours after ciclosporin). Ciclosporin should then be withdrawn over 4–8 weeks (if not possible, sirolimus should be discontinued and an alternate immunosuppressive regimen used), dose to be adjusted according to whole blood-sirolimus trough concentration.

**DOSE EQUIVALENCE AND CONVERSION**

- The 500 microgram tablet is not bioequivalent to the 1 mg and 2 mg tablets. Multiples of 500 microgram tablets should not be used as a substitute for other tablet strengths.

**CAUTIONS** Hyperlipidaemia, increased susceptibility to infection (especially urinary-tract infection), increased susceptibility to lymphoma and other malignancies, particularly of the skin (limit exposure to UV light).

**SIDE-EFFECTS**

- Common or very common Abdominal pain • acne • anaemia • arthralgia • ascites • constipation • diarrhoea • epistaxis • haemolytic uraemic syndrome • headache • hypercholesterolaemia • hyperglycaemia • hypertension • hypertriglyceridaemia • hypokalaemia • hypophosphataemia • impaired healing • leucopenia • lymphocoele • nausea • neutropenia • oedema • osteonecrosis • pleural effusion • pneumonitis • proteinuria • pyrexia • rash • stomatitis • tachycardia • thrombocytopenia • thrombotic thrombocytopenic purpura • venous thromboembolism

- Uncommon Nephrotic syndrome • pancreatitis • pancytopenia • pericardial effusion • pulmonary embolism • pulmonary haemorrhage

- Rare Alveolar proteinosis • anaphylactic reactions • angioedema • exfoliative dermatitis • hepatic necrosis • hypersensitivity reactions • hypersensitivity vasculitis • interstitial lung disease • lymphoedema

- Frequency not known Focal segmental glomerulosclerosis • reversible impairment of male fertility

**CONCEPTION AND CONTRACEPTION** Effective contraception must be used during treatment and for 12 weeks after stopping.

**PREGNANCY** Avoid unless essential—toxicity in animal studies.

**BREAST FEEDING** Discontinue breast-feeding.

**HEPATIC IMPAIRMENT** In severe impairment decrease dose by 50% and monitor whole blood-sirolimus trough concentration every 5–7 days until 3 consecutive measurements have shown stable blood-sirolimus concentration. Clearance reduced in mild to moderate impairment. Monitor whole blood-sirolimus level closely and consult local treatment protocol in hepatic impairment.

**MONITORING REQUIREMENTS**

- Monitor whole blood-sirolimus trough concentration (Afro–Caribbean patients may require higher doses).
- Manufacturer advises pre-dose (‘trough’) whole blood-sirolimus concentration (using chromatographic assay) when used with ciclosporin should be 4–12 micrograms/litre (local treatment protocols may differ); after withdrawal of ciclosporin pre-dose whole blood-sirolimus concentration should be 12–20 micrograms/litre (local treatment protocols may differ).
- Close monitoring of whole blood-sirolimus concentration required if concomitant treatment with potent inducers or inhibitors of metabolism and after discontinuing them, or if ciclosporin dose reduced significantly or stopped.
- When changing between oral solution and tablets, measurement of whole blood ‘trough’ sirolimus concentration after 1–2 weeks is recommended.
- Therapeutic drug monitoring assays Sirolimus whole-blood concentration is measured using either high performance
Tacrolimus is a calcineurin inhibitor.

**INDICATIONS AND DOSE**

**ADOPORT®**

*Prophylaxis of graft rejection following liver transplantation, starting 12 hours after transplantation*
- **BY MOUTH**
  - Adult: Initially 100–200 micrograms/kg daily in 2 divided doses

*Prophylaxis of graft rejection following kidney transplantation, starting within 24 hours of transplantation*
- **BY MOUTH**
  - Adult: Initially 200–300 micrograms/kg daily in 2 divided doses

*Prophylaxis of graft rejection following heart transplantation following antibody induction, starting within 5 days of transplantation*
- **BY MOUTH**
  - Adult: Initially 75 micrograms/kg daily in 2 divided doses

*Prophylaxis of graft rejection following heart transplantation without antibody induction, starting within 12 hours of transplantation*
- **BY MOUTH**
  - Adult: Initially 75 micrograms/kg daily in 2 divided doses

**Allograft rejection resistant to conventional immunosuppressive therapy**
- **BY MOUTH**
  - Adult: Seek specialist advice

**ENVARSUS® MODIFIED-RELEASE TABLETS**

*Prophylaxis of graft rejection following liver transplantation, starting within 24 hours of transplantation*
- **BY MOUTH**
  - Adult: Initially 110–130 micrograms/kg once daily, to be taken in the morning

*Prophylaxis of graft rejection following renal transplantation, starting within 24 hours of transplantation*
- **BY MOUTH**
  - Adult: Initially 170 micrograms/kg once daily, to be taken in the morning

**Rejection therapy**
- **BY MOUTH**
  - Adult: Seek specialist advice

**MODIGRAF®**

*Prophylaxis of graft rejection following liver transplantation, starting 12 hours after transplantation*
- **BY MOUTH**
  - Adult: Initially 100–200 micrograms/kg daily in 2 divided doses
Immune system and malignant disease

Prophylaxis of graft rejection following kidney transplantation, starting within 24 hours of transplantation
▶ BY MOUTH
Adult: Initially 200–300 micrograms/kg daily in 2 divided doses

Prophylaxis of graft rejection following heart transplantation following antibody induction, starting within 5 days of transplantation
▶ BY MOUTH
Adult: Initially 75 micrograms/kg daily in 2 divided doses

Prophylaxis of graft rejection following heart transplantation without antibody induction, starting within 12 hours of transplantation
▶ BY MOUTH
Adult: Initially 75 micrograms/kg daily in 2 divided doses

Rejection therapy
▶ BY MOUTH
Adult: Seek specialist advice

PROGRAF ® CAPSULES
Prophylaxis of graft rejection following liver transplantation, starting 12 hours after transplantation
▶ BY MOUTH
Adult: Initially 100–200 micrograms/kg daily in 2 divided doses

Prophylaxis of graft rejection following kidney transplantation, starting within 24 hours of transplantation
▶ BY MOUTH
Adult: Initially 200–300 micrograms/kg daily in 2 divided doses

Prophylaxis of graft rejection following heart transplantation following antibody induction, starting within 5 days of transplantation
▶ BY MOUTH
Adult: Initially 75 micrograms/kg daily in 2 divided doses

Prophylaxis of graft rejection following heart transplantation without antibody induction, starting within 12 hours of transplantation
▶ BY MOUTH
Adult: Initially 75 micrograms/kg daily in 2 divided doses

Allograft rejection resistant to conventional immunosuppressive therapy
▶ BY MOUTH
Adult: Seek specialist advice

PROGRAF ® INFUSION
Prophylaxis of graft rejection following liver transplantation, starting 12 hours after transplantation when oral route not appropriate
▶ BY INTRAVENOUS INFUSION
Adult: Initially 10–50 micrograms/kg daily for up to 7 days (then transfer to oral therapy), dose to be administered over 24 hours

Prophylaxis of graft rejection following kidney transplantation, starting within 24 hours of transplantation when oral route not appropriate
▶ BY INTRAVENOUS INFUSION
Adult: Initially 50–100 micrograms/kg daily for up to 7 days (then transfer to oral therapy), dose to be administered over 24 hours

Prophylaxis of graft rejection following heart transplantation following antibody induction, starting within 5 days of transplantation
▶ BY INTRAVENOUS INFUSION
Adult: Initially 10–20 micrograms/kg daily for up to 7 days (then transfer to oral therapy), dose to be administered over 24 hours

Prophylaxis of graft rejection following heart transplantation without antibody induction, starting within 12 hours of transplantation
▶ BY INTRAVENOUS INFUSION
Adult: Initially 10–20 micrograms/kg daily for up to 7 days (then transfer to oral therapy), dose to be administered over 24 hours

Allograft rejection resistant to conventional immunosuppressive therapy
▶ BY CONTINUOUS INTRAVENOUS INFUSION
Adult: Seek specialist advice (consult local protocol)

TACNI ®
Prophylaxis of graft rejection following liver transplantation, starting 12 hours after transplantation
▶ BY MOUTH
Adult: Initially 100–200 micrograms/kg daily in 2 divided doses

Prophylaxis of graft rejection following kidney transplantation, starting within 24 hours of transplantation
▶ BY MOUTH
Adult: Initially 200–300 micrograms/kg daily in 2 divided doses

Prophylaxis of graft rejection following heart transplantation following antibody induction, starting within 5 days of transplantation
▶ BY MOUTH
Adult: Initially 75 micrograms/kg daily in 2 divided doses

Prophylaxis of graft rejection following heart transplantation without antibody induction, starting within 12 hours of transplantation
▶ BY MOUTH
Adult: Initially 75 micrograms/kg daily in 2 divided doses

Allograft rejection resistant to conventional immunosuppressive therapy
▶ BY MOUTH
Adult: Seek specialist advice

VIVADEX ®
Prophylaxis of graft rejection following liver transplantation, starting 12 hours after transplantation
▶ BY MOUTH
Adult: Initially 100–200 micrograms/kg daily in 2 divided doses

Prophylaxis of graft rejection following kidney transplantation, starting within 24 hours of transplantation
▶ BY MOUTH
Adult: Initially 200–300 micrograms/kg daily in 2 divided doses

Prophylaxis of graft rejection following heart transplantation following antibody induction, starting within 5 days of transplantation
▶ BY MOUTH
Adult: Initially 75 micrograms/kg daily in 2 divided doses
Prophylaxis of graft rejection following heart transplantation without antibody induction, starting within 12 hours of transplantation

- BY MOUTH
- Adult: Initially 75 micrograms/kg daily in 2 divided doses

Allograft rejection resistant to conventional immunosuppressive therapy

- BY MOUTH
- Adult: Seek specialist advice

IMPORTANT SAFETY INFORMATION

MHRA/CHM ADVICE: ORAL TACROLIMUS PRODUCTS: PRESCRIBE AND DISPENSE BY BRAND NAME ONLY. TO MINIMISE THE RISK OF INADVERTENT SWITCHING BETWEEN PRODUCTS, WHICH HAS BEEN ASSOCIATED WITH REPORTS OF TOXICITY AND GRAFT REJECTION (JUNE 2012)

Inadvertent switching between oral tacrolimus products has been associated with reports of toxicity and graft rejection. To ensure maintenance of therapeutic response when a patient is stabilised on a particular brand, oral tacrolimus products should be prescribed and dispensed by brand name only.

- Adoport®, Prograf®, Capexion®, Tacni®, and Vivadex® are immediate-release capsules that are taken twice daily, once in the morning and once in the evening;
- Modgraf® granules are used to prepare an immediate-release oral suspension which is taken twice daily, once in the morning and once in the evening;
- Advagraf® is a prolonged-release capsule that is taken once daily in the morning.

Switching between tacrolimus brands requires careful supervision and therapeutic monitoring by an appropriate specialist.

Important: Envarsus® is not interchangeable with other oral tacrolimus containing products; the MHRA has advised (June 2012) that oral tacrolimus products should be prescribed and dispensed by brand only.

- CAUTIONS Increased risk of infections.
  lymphoproliferative disorders, malignancies, neurotoxicity, QT-interval prolongation, UV light (avoid excessive exposure to sunlight and sunlamps)
- INTERACTIONS ➔ Appendix 1: tacrolimus
- SIDE-EFFECTS

  - Common or very common Acne, alopecia, anaemia, anorexia, anxiety, arthralgia, ascites, bile-duct abnormalities, bloating, blood disorders, cholestasis, confusion, constipation, depression, diarrhoea, dizziness, dyspepsia, dysphonia, electrolyte disturbances, flatulence, gastro-intestinal inflammation, gastro-intestinal perforation, gastro-intestinal ulceration, haemorrhage, headache, hepatic dysfunction, hyperglycaemia, hyperkalaemia, hypertension, hyperuricaemia, hypokalaemia, impaired hearing, ischaemic events, jaundice, leucopenia, mood changes, muscle cramp, nausea, oedema, pancytopenia, paraesthesia, parenchymal lung disorders, peripheral neuropathy, photophobia, pleural effusion, psychosis, renal failure, renal impairment, renal tubular necrosis, seizures, sleep disturbances, sweating, tachycardia, thrombocytopenia, thromboembolic events, tinnitus, tremor, urinary abnormalities, visual disturbances, vomiting, weight changes

  - Uncommon Anaemia, arrhythmia, cardiac arrest, cardiomyopathy, cataract, cerebrovascular accident, coagulation disorders, coma, dermatitis, dysmenorrhoea, encephalopathy, gastro-intestinal reflux disease, heart failure, hypotonia, hypoglycaemia, influenza-like symptoms, palpitation, pancreatitis, paralysis, paralytic ileus, peritonitis, photosensitivity, respiratory failure, speech disorder

  - Rare Blindness, dehydration, hirsutism, pericardial effusion, posterior reversible encephalopathy syndrome, respiratory distress syndrome, thrombotic thrombocytopenic purpura, toxic epidermal necrolysis

  - Very rare Haemorrhagic cystitis, myasthenia, Stevens-Johnson syndrome

  - Frequency not known Agranulocytosis, haemolytic anaemia, pure red cell aplasia

SIDE-EFFECTS, FURTHER INFORMATION

- Cardiomyopathy Cardiomyopathy has been reported in children. Patients should be monitored by echocardiography for hypertrophic changes—consider dose reduction or discontinuation if these occur.
- ALLERGY AND CROSS-SENSITIVITY Contra-indicated if history of hypersensitivity to macrolides.

- CONCEPTION AND CONTRACEPTION Exclude pregnancy before treatment.
- PREGNANCY Avoid unless potential benefit outweighs risk—crosses the placenta and risk of premature delivery, intra-uterine growth restriction, and hyperkalaemia.

- BREAST FEEDING Avoid—present in breast milk (following systemic administration).

- HEPATIC IMPAIRMENT Dose reduction may be necessary in severe impairment.

- MONITORING REQUIREMENTS

  - After initial dosing, and for maintenance treatment, tacrolimus doses should be adjusted according to whole-blood concentration. Monitor whole blood-tacrolimus trough concentration (especially during episodes of diarrhoea)—consult local treatment protocol for details.
  - Monitor blood pressure, ECG (for hypertrophic changes—risk of cardiomyopathy), fasting blood-glucose concentration, haematological and neurological (including visual) and coagulation parameters, electrolytes, hepatic and renal function.

- DIRECTIONS FOR ADMINISTRATION

  - For intravenous infusion (Prograf®); give continuously in Glucose 5% or Sodium Chloride 0.9%. Dilute concentrate in infusion fluid to a final concentration of 4–100 micrograms/mL; give over 24 hours. Tacrolimus is incompatible with PVC.

- PATIENT AND CARER ADVICE

  - Avoid excessive exposure to UV light including sunlight.
  - Driving and skilled tasks

    - May affect performance of skilled tasks (e.g. driving).

- NATIONAL FUNDING/ACCESS DECISIONS

  - Scottish Medicines Consortium (SMC) Decisions

    - With oral use The Scottish Medicines Consortium has advised (November 2010) that tacrolimus granules for oral suspension (Modgraf®) are accepted for restricted use within NHS Scotland in patients for whom tacrolimus is an appropriate choice of immunosuppressive therapy and where small changes (less than 500 micrograms) in dosing increments are required (such as, in paediatric patients) or in seriously ill patients who are unable to swallow tacrolimus capsules.

- MEDICINAL FORMS

  - There can be variation in the licensing of different medicines containing the same drug.

  - Modified-release tablet

    - Envarsus (Chiesi Ltd)
    - Tacrolimus (as Tacrolimus monohydrate)
    - 750 microgram Envarsus 750 microgram modified-release tablets | 30 tablet | £44.33
    - Tacrolimus (as Tacrolimus monohydrate) 1 mg Envarsus 1 mg modified-release tablets | 30 tablet | £59.10
    - Tacrolimus (as Tacrolimus monohydrate) 4 mg Envarsus 4 mg modified-release tablets | 30 tablet | £236.40
Canakinumab

**Drug action** Canakinumab is a recombinant human monoclonal antibody that selectively inhibits interleukin-1 beta receptor binding.

**Indications and dose**

Acute gout in patients whose condition has not responded adequately to treatment with NSAIDs or colchicine, or who are intolerant of them

- **By subcutaneous injection**
  - **Adult:** 150 mg for 1 dose, dose may be repeated at least 12 weeks after initial response if symptoms recur, patients who do not respond to initial dose should not be retreated.

**Treatment of cryopyrin-associated periodic syndromes, including severe forms of familial cold auto-inflammatory syndrome (or familial cold urticaria), Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory syndrome (also known as chronic infantile neurological cutaneous and articular syndrome)**

- **By subcutaneous injection**
- **Adult:** (consult product literature)

**Contra-indications**

- Active infection - leucopenia - neutropenia

**Cautions**

- History of recurrent infection - latent and active tuberculosis - predisposition to infection

**Cautions, further information**

- Vaccinations Patients should receive all recommended vaccinations (including pneumococcal and inactivated influenza vaccine) before starting treatment; avoid live vaccines unless potential benefit outweighs risk—consult product literature for further information.

**Interactions**

- Appendix 1: monoclonal antibodies

**Side-effects**

- Common or very common Back pain - increased susceptibility to infection (including serious infection) - injection-site reactions - malaise - neutropenia - vertigo

- Uncommon Gastro-oesophageal reflux

- Frequency not known Malignancy - vomiting

**Conception and contraception**

- Effective contraception required during treatment and for up to 3 months after last dose.

**Pregnancy**

- Manufacturer advises avoid unless potential benefit outweighs risk.

**Breast feeding**

- Consider if benefit outweighs risk—not known if present in human milk.

**Hepatic impairment**

- No information available.

**Renal impairment**

- Limited information available but manufacturer advises no dose adjustment required.

**Pre-treatment screening**

- Patients should be evaluated for latent and active tuberculosis before starting treatment.

**Monitoring requirements**

- Monitor full blood count including neutrophil count for latent and active tuberculosis before starting treatment, and periodically thereafter.
- Monitor for signs and symptoms of tuberculosis during and after treatment.

**Medicinal forms**

- There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for injection**

- **Ilaris (Novartis Pharmaceuticals UK Ltd)**
  - Canakinumab 150 mg Ilaris 150mg powder for solution for injection vials | 1 vial (Pom) £9,927.80
**Basiliximab**

- **Drug Action** Basiliximab is a monoclonal antibody that acts as an interleukin-2 receptor antagonist and prevents T-lymphocyte proliferation.

- **Indications and Dose** Prophylaxis of acute rejection in allogeneic renal transplantation used in combination with cyclosporin and corticosteroid-containing immunosuppression regimens (specialist use only)
  - By intravenous injection, or by intravenous infusion
  - Adult: Initially 20 mg, administered within 2 hours before transplant surgery, followed by 20 mg after 4 days, dose to be administered after surgery, withhold second dose if severe hypersensitivity or graft loss occurs.

- **Caution** Off-label use in cardiac transplantation—increased risk of serious cardiac side-effects.

- **Interactions** → Appendix 1: monoclonal antibodies.

- **Side-effects** Atrial flutter · cardiac arrest · cytokine release syndrome · palpitations · severe hypersensitivity reactions.

- **Conception and contraception** Adequate contraception must be used during treatment and for 16 weeks after last dose.

- **Pregnancy** Manufacturer advises avoid—no information available.

- **Breast feeding** Manufacturer advises avoid—no information available.

- **Directions for administration** For intravenous infusion (Simulect®), give intermittently in Glucose 5% or Sodium chloride 0.9%; reconstitute 10 mg with 2.5 mL water for injections then dilute to at least 25 mL with infusion fluid; reconstitute 20 mg with 5 mL water for injections then dilute to at least 50 mL with infusion fluid; give over 20-30 minutes.

- **Medicinal forms** There can be variation in the licensing of different medicines containing the same drug.

- **Powder and solvent for solution for injection**
  - Simulect (Novartis Pharmaceuticals UK Ltd)
    - Basiliximab 10 mg Simulect 10mg powder and solvent for solution for injection vials | 1 vial (£24.92) (Hospital only)
    - Basiliximab 20 mg Simulect 20mg powder and solvent for solution for injection vials | 1 vial (£42.38) (Hospital only)

---

**Belimumab**

24-Oct-2016

- **Indications and Dose** Adjunctive therapy in patients with active, autoantibody-positive systemic lupus erythematosus with a high degree of disease activity despite standard therapy
  - By intravenous infusion
  - Adult: 10 mg/kg every 2 weeks for 3 doses, then 10 mg/kg every 4 weeks, review treatment if no response within 6 months.

- **Caution** Do not initiate until active infections controlled · history or development of malignancy · predisposition to infection.

- **Interactions** → Appendix 1: monoclonal antibodies.

- **Side-effects** Common or very common: Infusion-related reactions · Frequency not known: Depressions · diarrhoea · hypersensitivity reactions · infections · insomnia · leucopenia · migraine · nausea · pain in extremities · pyrexia · vomiting.

**Side-effects, further information** Infusion-related side-effects are reported commonly, including severe or life-threatening hypersensitivity and infusion reactions. Premedication with an antihistamine, with or without an antipyretic may be considered.

- **Conception and contraception** Manufacturer advises adequate contraception during treatment and for at least 4 months after last dose.

- **Pregnancy** Avoid unless essential.

- **Breast feeding** Avoid—present in milk in animal studies.

- **Renal impairment** Caution in severe impairment—no information available.

- **Monitoring requirements** Delay in the onset of acute hypersensitivity reactions has been observed; patients should remain under clinical supervision for several hours following at least the first 2 infusions.

- **Directions for administration** For intravenous infusion (Benlysta®), give intermittently in Sodium chloride 0.9%; reconstitute with water for injections (120 mg in 1.5 mL, 400 mg in 4.8 mL) to produce a solution containing 80 mg/mL; gently swirl vial for 60 seconds, then allow to stand; swirl vial (without shaking) for 60 seconds every 5 minutes until dissolved; dilute requisite dose with infusion fluid to a final volume of 250 mL and give over 1 hour.

- **National funding/access decisions**

**NICE technology appraisals (TAs)**

- Belimumab for treating active autoantibody-positive systemic lupus erythematosus (June 2016) NICE TA397

  Belimumab is recommended as an add-on treatment option in adults with active autoantibody-positive systemic lupus erythematosus, only if all of the following criteria are met:
  - There is evidence for serological disease activity (defined as positive anti-double-stranded DNA and low complement) and a Safety of Estrogen in Lupus National Assessment – Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score of greater than or equal to 10 despite standard therapy;
  - Treatment with belimumab is continued after 24 weeks only if the SELENA-SLEDAI score has improved by 4 points or more;
  - The manufacturer provides belimumab with the discount agreed in the patient access scheme; and
  - Under the conditions specified in the NICE managed access agreement documentation.

Patients whose treatment was started before this guidance was published should continue treatment until they and their clinician consider it appropriate to stop.

www.nice.org.uk/TA397

**Scottish medicines consortium (SMC) decisions**

The Scottish Medicines Consortium (SMC) has advised (May 2017) that belimumab (Benlysta®) is accepted for restricted use within NHS Scotland as adjunctive therapy in patients with active, autoantibody-positive systemic lupus erythematosus with a high degree of disease activity despite standard therapy, and who have evidence of serological disease activity and a Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score of 10 or greater. This advice is contingent upon the continuing availability of the Patient Access Scheme in NHS Scotland or a list price that is equivalent or lower.
Immune system disorders and transplantation

796

Mycophenolate mofetil

**INDICATIONS AND DOSE**

**Prophylaxis of acute rejection in renal transplantation (in combination with a corticosteroid and ciclosporin) (under expert supervision)**

- **By mouth**
  - Adult: 1 g twice daily, to be started within 72 hours of transplantation
  - By intravenous infusion
  - Adult: 1 g twice daily for maximum 14 days, then transfer to oral therapy, to be started within 24 hours of transplantation

**Prophylaxis of acute rejection in cardiac transplantation (in combination with ciclosporin and corticosteroids) (under expert supervision)**

- **By mouth**
  - Adult: 1.5 g twice daily, to be started within 5 days of transplantation

**Prophylaxis of acute rejection in hepatic transplantation (in combination with ciclosporin and corticosteroids) (under expert supervision)**

- **Initially by intravenous infusion**
  - Adult: 1 g twice daily for 4 days, up to a maximum of 14 days, to be started within 24 hours of transplantation, then (by mouth) 1.5 g twice daily; the dose route should be changed as soon as is tolerated

**MYFORTIC®**

Renal transplantation

- **By mouth**
  - Adult: 720 mg twice daily, to be started within 72 hours of transplantation

**DOSE EQUIVALENCE AND CONVERSION**

- For Myfortic®: Mycophenolic acid 720 mg is approximately equivalent to mycophenolate mofetil 1 g but avoid unnecessary switching because of pharmacokinetic differences.

**CAUTIONS**

Active serious gastrointestinal disease (risk of haemorrhage, ulceration and perforation) - children (higher incidence of side-effects may call for temporary reduction of dose or interruption) - delayed graft function - elderly (increased risk of infection, gastro-intestinal haemorrhage and pulmonary oedema) - increased susceptibility to skin cancer (avoid exposure to strong sunlight) - risk of hypogammaglobulinaemia or bronchiectasis when used in combination with other immunosuppressants

**CAUTIONS, FURTHER INFORMATION**

- Hypogammaglobulinaemia or bronchiectasis
  - Measure serum immunoglobulin levels if recurrent infections develop, and consider bronchiectasis or pulmonary fibrosis if persistent respiratory symptoms such as cough and dyspnoea develop.

**INTERACTIONS** → Appendix 1: mycophenolate

**SIDE-EFFECTS**


- Frequency not known Interstitial lung disease - intestinal villous atrophy - progressive multifocal leucoencephalopathy - pulmonary fibrosis

**SIDE-EFFECTS, FURTHER INFORMATION**

Cases of pure red cell aplasia have been reported with mycophenolate mofetil; dose reduction or discontinuation should be considered under specialist supervision.

**CONCEPTION AND CONTRACEPTION**

Pregnancy prevention In females of child-bearing potential, exclude pregnancy immediately before and during treatment.

- Women should use 2 methods of effective contraception during treatment, and for 6 weeks after discontinuation. Men should use condoms during treatment and for at least 90 days after discontinuation of treatment; female partners of male patients should also use effective contraception during treatment and for 90 days after discontinuation.

**MYFORTIC®**

Manufacturer advises that men should use condoms during treatment and for 13 weeks after last dose.

**PREGNANCY**

Avoid unless no suitable alternative—congenital malformations and spontaneous abortions reported.

**BREAST FEEDING**

Manufacturer advises avoid—present in milk in animal studies.

**RENAI IMPAIRMENT**

No data available in cardiac or hepatic transplant patients with renal impairment.

**MONITORING REQUIREMENTS**

Monitor full blood count every week for 4 weeks then twice a month for 2 months then every month in the first year (consider interrupting treatment if neutropenia develops).

**DIRECTIONS FOR ADMINISTRATION**

- With intravenous use For intravenous infusion (CellCept®), give intermittently in Glucose 5%; reconstitute each 500 mg vial with 14 mL glucose 5% and dilute the contents of 2 vials in 140 mL infusion fluid; give over 2 hours.

**PATIENT AND CARER ADVICE**

Bone marrow suppression Patients should be warned to report immediately any signs or symptoms of bone marrow suppression e.g. infection or inexplicable bruising or bleeding.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Gastro-resistant tablet**

CAUTIONARY AND ADVISORY LABELS 25

- Myfortic (Novartis Pharmaceuticals UK Ltd) Mycophenolic acid (as Mycophenolate sodium) 180 mg Myfortic 180 mg gastro-resistant tablets | 120 tablet | £96.72
  - Mycophenolic acid (as Mycophenolate sodium) 360 mg Myfortic 360 mg gastro-resistant tablets | 120 tablet | £193.43

**Tablet**

- Mycophenolate mofetil (Non-proprietary)
  - Mycophenolate mofetil 500 mg Mycophenolate mofetil 500 mg tablets | 50 tablet | £42.50 DT price | £6.17

---

Medicines, vaccines and treatments can change. Always check the product information leaflet (PIL) or consult with a healthcare professional before using any medicine. Information from: www.medicinescomplete.com

Downloaded from www.medicalbr.com
Belatacept

INDICATIONS AND DOSE
Prophylaxis of graft rejection in adults undergoing renal transplantation who are seropositive for the Epstein-Barr virus

BY INTRAVENOUS INFUSION

Adult: (consult product literature)

CAUTIONS
Increased risk of acute graft rejection—with tapering of corticosteroid, particularly in patients with high immunologic risk—increased risk of infection—latent and active tuberculosis—risk factors for post-transplant lymphoproliferative disorder

INTERACTIONS → Appendix 1: belatacept

SIDE-EFFECTS

Common or very common Anaemia·constipation·cough·dehydration·diarrhoea·headache·hypertension·hypophosphataemia·infection·leucopenia·malignancy·nausea·peripheral oedema·pyrexia·vomiting

Uncommon Infusion related reactions—progressive multifocal leucoencephalopathy

SIDE-EFFECTS, FURTHER INFORMATION
Side effects are reported when used in combination with basiliximab, mycophenolate motefil and corticosteroids.

CONCEPTION AND CONTRACEPTION

Adequate contraception must be used during treatment and for up to 8 weeks after last dose.

PREGNANCY
Use only if essential.

BREAST FEEDING
Avoid—no information available.

PRE-TREATMENT SCREENING
Patients should be evaluated for latent and active tuberculosis before starting treatment.

MONITORING REQUIREMENTS
Patients should be monitored for signs and symptoms of tuberculosis during and after treatment.

PATIENT AND CARER ADVICE

Patients should be advised to avoid excessive exposure to UV light including sunlight.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for infusion

Belatacept 250 mg

Belatacept 250 mg Nulojix 250 mg powder for concentrate for solution for infusion vials | 1 vial POM £354.52 (Hospital only) | 2 vial POM £709.04 (Hospital only)

1.1 Multiple sclerosis

Description of condition

Multiple sclerosis is a chronic, immune-mediated, demyelinating inflammatory condition of the central nervous system, which affects the brain, optic nerves and spinal cord, and leads to progressive severe disability.

Relapsing-remitting multiple sclerosis is the most common pattern of the disease. It is characterised by periods of exacerbation of symptoms (relapses) followed by unpredictable periods of stability (remission). The severity and frequency of relapses varies greatly between patients, but on average occur once or twice per year. This clinical pattern often develops into secondary-progressive multiple sclerosis, with progressive disability unrelated to relapses. Most patients develop secondary progressive disease 6–10 years after onset.

Primary-progressive multiple sclerosis follows a gradual course, with the development of symptoms that worsen over time, without relapses and remissions.

Progressive-relapsing multiple sclerosis follows a course of steadily worsening neurological function from onset, in addition to acute relapses.

Disease activity in relapsing-remitting multiple sclerosis

Active disease is defined as at least two clinically significant relapses occurring within the last 2 years. Highly active disease is characterised by an unchanged/increased relapse rate or by ongoing severe relapses compared with the previous year, despite treatment with interferon beta p. 799. Rapidly-evolving severe relapsing–remitting multiple sclerosis is defined by two or more disabling relapses in 1 year, and one or more gadolinium–enhancing lesions on brain magnetic resonance imaging (MRI) or a significant increase in T2 lesion load compared with a previous MRI.

Aims of treatment

There is no cure for multiple sclerosis. The overall aims of treatment are to modify the course of the disease and manage symptoms, in order to improve quality of life. Treatment is aimed at reducing the frequency and duration of relapses and at preventing or slowing disability.

Drug treatment

Shared decision-making between the patient and their clinicians is particularly important in the treatment of multiple sclerosis, due to the unpredictability of the condition and the lack of evidence of long-term benefit of treatments. A discussion about treatment options, disease activity, risk, and benefit should take place to ensure that treatment choices are right for the patient and their circumstances. The choice of drug also depends on the patient’s disability status, individual tolerance, disease severity and disease activity (see Disease activity in relapsing-remitting multiple sclerosis above). ECG Treatment should be initiated as early as possible, under the supervision of a specialist.
Note: NHS England (May 2014) has provided guidance on the use of interferon beta, glatiramer acetate p. 801, fingolimod p. 802 and natalizumab p. 805 for the treatment of multiple sclerosis in England, see Useful resources below. This Clinical Commissioning Policy outlines the funding arrangements and the criteria for initiating and discontinuing these treatment options. See also National funding/access decisions, under individual monographs for teriflunomide p. 806, dimethyl fumarate p. 801 and alemtuzumab p. 804.

Low levels of vitamin D are believed to be a risk factor for developing multiple sclerosis. Patients with diagnosed multiple sclerosis are usually given regular vitamin D after assessment of their serum levels of vitamin D, but there is insufficient evidence to support its use as a treatment for multiple sclerosis. Patients should not be offered vitamin D solely for the purpose of treating multiple sclerosis.

Relapsing-remitting multiple sclerosis

Disease-modifying drugs are the recommended treatment for patients presenting with active relapsing-remitting multiple sclerosis. Interferon beta and glatiramer acetate may be the preferred choice for some patients, due to their established safety profile, and the long term clinical experience associated with their use. Peginterferon beta-1a p. 800 requires less frequent administration and is available as an alternative to the non-pegylated interferon beta therapies.

Teriflunomide and dimethyl fumarate are treatment options for patients with active disease. They may be preferred due to their oral route of administration. There is insufficient evidence for the use of either drug to treat highly active or rapidly-evolving severe relapsing-remitting multiple sclerosis.

More active disease may be treated with natalizumab or alemtuzumab. Natalizumab may be preferred due to the complex safety profile associated with alemtuzumab. Natalizumab is only recommended for the treatment of rapidly-evolving severe relapsing-remitting multiple sclerosis. Although licensed as a treatment option in all patients with active disease, alemtuzumab may be used more frequently in patients for whom other disease-modifying treatments have not been effective, due to the risk of serious side effects associated with its use.

Fingolimod is also taken by the oral route and is the recommended treatment for patients with highly active disease. The NHS England Clinical Commissioning Policy advises that fingolimod is a suitable alternative for patients receiving natalizumab who are at high risk of developing progressive multifocal leuкоencephalopathy (defined as patients previously exposed to the JC virus or who are receiving immunosuppressants or who have been receiving treatment with natalizumab for more than 2 years).

Secondary progressive multiple sclerosis

Currently, only interferon beta 1b is licensed for use in secondary progressive multiple sclerosis. Interferon beta 1b reduces the risk of relapse and of short-term relapse-related disability, but does not prevent the development of permanent physical disability or retard progression once it is established. Therefore its role in secondary progressive disease is limited.

Primary progressive multiple sclerosis

Currently there are no effective disease-modifying treatments licensed for primary progressive multiple sclerosis. Interferon beta [unlicensed indication] has been used, but there is limited evidence to support its use due to the lack of a significant reduction in disability progression.

Progressive-relapsing multiple sclerosis

There are no specific treatment options for this type of multiple sclerosis. None of the currently licensed disease-modifying drugs are recommended in non-relapsing progressive disease.

Management of symptoms

Other than episodes of neurological dysfunction, chronic symptoms (such as fatigue, spasticity, visual problems, and emotional lability) produce much of the disability in multiple sclerosis. Smoking may increase the progression of disability in multiple sclerosis, and cessation should be encouraged.

Relapses

Suspected relapses should be referred to a specialist for diagnosis and treatment. Corticosteroids are recommended for reducing inflammation and accelerating recovery in acute relapses of relapsing-remitting multiple sclerosis. Oral methylprednisolone p. 638 is recommended as the first-line option. Intravenous methylprednisolone should be considered as an alternative if oral methylprednisolone has failed or is not tolerated or if hospitalisation is required.

Fatigue and impaired mobility

Regular exercise may have beneficial effects on mobility and fatigue in patients with multiple sclerosis, and should be encouraged. Cognitive behavioural techniques for fatigue should also be considered in combination with exercise. Amantadine hydrochloride p. 397 [unlicensed indication] may be used to treat fatigue related to multiple sclerosis. Vitamin B12 injections are not recommended as a treatment for fatigue in patients with multiple sclerosis.

Fampridine p. 799 is licensed for the improvement of walking in patients with multiple sclerosis who have a walking disability. NICE do not consider it to be a cost-effective treatment and do not recommend its use.

Spasticity

Many factors may aggravate spasticity in multiple sclerosis, including constipation, infection, poor mobility aids, pressure ulcers, posture and pain. These causes should be managed appropriately. The first-line options for managing spasticity in multiple sclerosis are baclofen p. 1026 or gabapentin p. 301 [unlicensed indication]. They may be used cautiously in combination if the individual drugs are ineffective or if side effects prevent an increase in the dose of either drug. Tizanidine p. 1027 or dantrolene sodium p. 1236 are second-line options; benzodiazepines may be used as third-line therapy and may also be effective in treating nocturnal spasms. A cannabis extract p. 1026 containing dronabinol and cannabidiol is licensed as an adjunct treatment for moderate-to-severe spasticity associated with multiple sclerosis in patients who have not responded adequately to other skeletal muscle relaxants. NICE do not consider it to be a cost-effective treatment and do not recommend its use.

Oscillopsia

Gabapentin [unlicensed indication] is the first-line treatment for oscillopsia; memantine hydrochloride p. 291 [unlicensed indication] is the second-line option.

Emotional lability

Amitriptyline hydrochloride p. 355 [unlicensed indication] may be used to treat emotional lability in patients with multiple sclerosis.

Useful Resources


CHOLINERGIC RECEPTOR STIMULATING DRUGS

Fampyra

INDICATIONS AND DOSE

Improvement of walking disability in multiple sclerosis (specialist use only)

- By mouth
  - Adult: 10 mg every 12 hours, discontinue treatment if no improvement within 2 weeks

CONTRA-INDICATIONS

History of seizures (discontinue treatment if seizures occur)

CAUTIONS

- Atrioventricular conduction disorders - predisposition to seizures - sinoatrial conduction disorders - symptomatic cardiac rhythm disorders

SIDE-EFFECTS

- Common or very common: Anxiety, back pain, constipation, dizziness, dyspepsia, dyspnoea, headache, insomnia, malaise, nausea, paraesthesia, pharyngolaryngeal pain, tremor, urinary tract infection, vomiting

- Uncommon: Seizures

PREGNANCY

Avoid – toxicity in animal studies.

BREAST FEEDING

Avoid – no information available.

RENAI IMPAIRMENT

Avoid if eGFR less than 80 ml/minute/1.73 m².

PRESCRIBING AND DISPENSING INFORMATION

Dispense in original container (pack contains a desiccant) and discard any tablets remaining 7 days after opening.

NATIONAL FUNDING/ACCESS DECISIONS

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium (November 2016) that fampyra (Fampyra®) is not recommended for use within NHS Scotland for the improvement of walking in adult patients with multiple sclerosis (MS) with walking disability (EDSS [expanded disability status scale] 4 to 7) as the economic case was not demonstrated.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule

Modified-release tablet

CAUTIONARY AND ADVISORY LABELS 23, 25

- Fampyra (Biogen Idec Ltd)

  Fampyra 10 mg Fampyra 10mg modified-release tablets | 28 tablet [PO] £181.00 | 56 tablet [PO] £362.00

IMMUNOSTIMULANTS

Interferon beta

INDICATIONS AND DOSE

AVONEX® INJECTION

For relapsing, remitting multiple sclerosis (characterised by at least two attacks of neurological dysfunction over the previous 2 or 3 years, followed by complete or incomplete recovery) who are able to walk unaided | For a single demyelinating event with an active inflammatory process (if severe enough to require intravenous corticosteroid and patient at high risk of developing multiple sclerosis)

- By intramuscular injection

  - Adult: (consult product literature)

CONTRA-INDICATIONS

Decompensated liver disease · severe depressive illness

CONTRA-INDICATIONS, FURTHER INFORMATION

Consult product literature for further information on contra-indications.

CAUTIONS

History of cardiac disorders · history of depressive disorders (avoid in severe depression or in those with suicidal ideation) · history of seizures · history of severe myelosuppression
Interferon beta

INTERACTIONS ▶ Appendix 1: interferons

SIDE-EFFECTS
Alopecia  anaphylaxis  blood disorders  chills  confusion  convulsions  fever  hepatitis  hypersensitivity reactions  influenza-like symptoms  (decreasing over time) — irritation at injection site (including inflammation, hypersensitivity, necrosis)— malaise— menstrual disorders — mood and personality changes— myalgia— nausea— nephrotic syndrome — suicide attempts— thrombotic microangiopathy — thyroid dysfunction — urticaria — vomiting

SIDE-EFFECTS, FURTHER INFORMATION
Also consult product literature for all side effects.

CONCEPTION AND CONTRACEPTION
Effective contraception required during treatment—consult product literature.

PREGNANCY
Avoid unless potential benefit outweighs risks (toxicity in animal studies).

BREAST FEEDING
Avoid—no information available.

HEPATIC IMPAIRMENT
Caution in severe hepatic impairment.

RENAL IMPAIRMENT
Caution in severe renal impairment.

MONITORING REQUIREMENTS
▷ Monitor for signs of hepatic injury—hepatic failure has been reported rarely.

Patients should be monitored for clinical features of thrombotic microangiopathy (TMA), including thrombocytopenia, new onset hypertension, fever, central nervous system symptoms (e.g. confusion and paresis), and impaired renal function. Any signs of TMA should be investigated fully and, if diagnosed, interferon beta should be stopped immediately and treatment for TMA promptly initiated (consult product literature for details).

Patients should also be monitored for signs and symptoms of nephrotic syndrome, including oedema, proteinuria, and impaired renal function—monitor renal function periodically. If nephrotic syndrome develops, treat promptly and consider stopping interferon beta treatment.

PRESCRIBING AND DISPENSING INFORMATION
REBIF ® CARTRIDGE
Cartridges for use with RebiSmart ® auto-injector device.

BETAFERON ® INJECTION
An auto-injector device (Betaject ® Light) is available from Bayer Schering.

EXTAVIA ®
An auto-injector device (ExtaviPro ® 30G) is supplied as part of the ExtaviPro ® 30G kit.

NATIONAL FUNDING/ACCESS DECISIONS
NICE technology appraisals (TAs)
▷ Interferon beta and glatiramer acetate for multiple sclerosis (January 2002) NICE TA32

Interferon beta and glatiramer acetate are not recommended for the treatment of multiple sclerosis in the NHS in England and Wales.

Patients who are currently receiving interferon beta or glatiramer acetate for multiple sclerosis, whether as routine therapy or as part of a clinical trial, should have the option to continue treatment until they and their consultant consider it appropriate to stop, having regard to the established criteria for withdrawal from treatment. www.nice.org.uk/TA32

NHSE restrictions

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

EXCIPIENTS: May contain Benzyl alcohol

Avonex (Biogen Idec Ltd)
Interferon beta-1a 12 mega u per 1 ml Avonex 30micrograms/0.5ml (6million units) solution for injection pre-filled syringes ▶ 4 pre-filled disposable injection (Ps) £654.00 ▶ 12 pre-filled disposable injection (Ps) £1,962.00
Avonex 30micrograms/0.5ml (6million units) solution for injection pre-filled pen ▶ 4 pre-filled disposable injection (Ps) £654.00 ▶ 12 pre-filled disposable injection (Ps) £1,962.00

Rebif (Merck Serono Ltd)
Interferon beta-1a 12 mega u per 1 ml Rebif 22micrograms/0.5ml (6million units) solution for injection 1.5ml cartridges ▶ 4 cartridge (Ps) £613.52
Rebif 8.8micrograms/0.2ml (2.4million units) solution for injection pre-filled syringes ▶ 6 pre-filled disposable injection (Ps) no price available
Rebif 8.8micrograms/0.2ml (2.4million units) solution for injection pre-filled pen ▶ 6 pre-filled disposable injection (Ps) no price available
Rebif 22micrograms/0.5ml (6million units) solution for injection pre-filled pen ▶ 6 pre-filled disposable injection (Ps) no price available ▶ 12 pre-filled disposable injection (Ps) £613.52
Rebif 22micrograms/0.5ml (6million units) solution for injection pre-filled syringes ▶ 6 pre-filled disposable injection (Ps) no price available ▶ 12 pre-filled disposable injection (Ps) £613.52

Interferon beta-1a 24 mega u per 1 ml Rebif 44micrograms/0.5ml (12million units) solution for injection pre-filled pen ▶ 12 pre-filled disposable injection (Ps) £813.21
Rebif 44micrograms/0.5ml (12million units) solution for injection pre-filled syringes ▶ 12 pre-filled disposable injection (Ps) £813.21
Rebif 44micrograms/0.5ml (12million units) solution for injection 1.5ml cartridges ▶ 4 cartridge (Ps) £813.21

Powder and solvent for solution for injection

Betaseron (Bayer Plc)
Interferon beta-1b 300 microgram Betaseron 300micrograms powder and solvent for solution for injection vials ▶ 15 vial (Ps) £596.63 (Hospital only)

Extavia (Novartis Pharmaceuticals UK Ltd)
Interferon beta-1b 300 microgram Extavia 300micrograms powder and solvent for solution for injection vials ▶ 15 vial (Ps) £596.63

Peginterferon beta-1a

DRUG ACTION
Peginterferon beta-1a is a polyethylene glycol-conjugated (‘pegylated’) derivative of interferon beta; pegylation increases the persistence of interferon in the blood.

INDICATIONS AND DOSE
Treatment of relapsing, remitting multiple sclerosis
▷ BY SUBCUTANEOUS INJECTION
▷ Adult: (consult product literature)

CONTRA-INDICATIONS
Severe depression — suicidal ideation

CAUTIONS
History of cardiac disorders — history of depressive disorders (avoid in severe depression or in those with suicidal ideation) — history of seizures — history of severe myelosuppression

FURTHER INFORMATION
Consult product literature for further information about cautions.

INTERACTIONS ▶ Appendix 1: peginterferon beta-1a

SIDE-EFFECTS
SIDE-EFFECTS, FURTHER INFORMATION
Consult product literature for information about side effects.

CONCEPTION AND CONTRACEPTION
Effective contraception required during treatment—consult product literature.

PREGNANCY
Do not initiate during pregnancy. Avoid unless potential benefit outweighs risks.

BREAST FEEDING
Avoid—no information available.
**Hepatic Impairment**  Caution in severe hepatic impairment.

**Renal Impairment**  Caution in severe renal impairment.

**Monitoring Requirements**
- Monitor for signs of hepatic injury—hepatic failure has been reported rarely.
- Thrombotic microangiopathy  Patients should be monitored for clinical features of thrombotic microangiopathy (TMA), including thrombocytopenia, new onset hypertension, fever, central nervous system symptoms (e.g. confusion and paresis), and impaired renal function. Any signs of TMA should be investigated fully and, if diagnosed, interferon beta should be stopped immediately and treatment for TMA promptly initiated (consult product literature for details).
- Nephrotic syndrome  Patients should also be monitored for signs and symptoms of nephrotic syndrome, including oedema, proteinuria, and impaired renal function—monitor renal function periodically. If nephrotic syndrome develops, treat promptly and consider stopping interferon beta treatment.

**Medicinal Forms**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for Injection**
- **Plergyd (Biogen Idec Ltd)**
  - Peginterferon beta-1a 126 microgram per 1 ml  Peginterferon beta-1a 126 microgram per 1 ml solution for injection (Pfsi) £654.00
  - Peginterferon beta-1a 188 microgram per 1 ml  Peginterferon beta-1a 188 microgram per 1 ml solution for injection (Pfsi) £654.00
  - Peginterferon beta-1a 250 microgram per 1 ml  Peginterferon beta-1a 250 microgram per 1 ml solution for injection (Pfsi) £654.00

**IMMUNOSTIMULANTS**

**Glaltiramer Acetate**

**Drug Action**  Glaltiramer is an immunomodulating drug comprising synthetic polypeptides.

**Indications and Dose**

Treatment of initial symptoms in patients at high risk of developing multiple sclerosis (initiated under specialist supervision). Reducing frequency of relapses in ambulatory patients with relapsing remitting multiple sclerosis who have had at least 2 clinical relapses in the past 2 years (initiated under specialist supervision).

**By Subcutaneous Injection**
- Adult: 20 mg daily

**Caution**  Cardiac disorders

**Interactions**  + Appendix 1: glatiramer

**Side-Effects**
- Common or very common  Anxiety, arthralgia, asthenia, back pain, chest pain, constipation, depression, dyspepsia, dyspnœa (may occur within minutes of injection), flushing, headache, hypersensitivity reactions, hypertonía, influenza-like symptoms, injection-site reactions, lymphenadonopathy, nausea, oedema, palpitatio, rash, sweating, syncope, tachycardia, tremor
- Rare  Seizures

**Pregnancy**  Manufacturer advises avoid—no information available.

**Breast Feeding**  Manufacturer advises caution—no information available.

**Renal Impairment**  No information available—manufacturer advises caution.

**National Funding/Access Decisions**

**NICE Technology Appraisals (TAs)**
- Interferon beta and glatiramer acetate for multiple sclerosis (January 2002)  NICE TA32
  - Interferon beta and glatiramer acetate are not recommended for the treatment of multiple sclerosis in the NHS in England and Wales.
  - Patients who are currently receiving interferon beta or glatiramer acetate for multiple sclerosis, whether as routine therapy or as part of a clinical trial, should have the option to continue treatment until they and their consultant consider it appropriate to stop, having regard to the established criteria for withdrawal from treatment. [www.nice.org.uk/TA32](http://www.nice.org.uk/TA32)

**NHS Restrictions**

**IMMUNOSUPPRESSANTS**

**IMMUNOMODULATING DRUGS**

**Dimethyl Fumarate**

**Drug Action**  Dimethyl fumarate has immunomodulatory and anti-inflammatory properties.

**Indications and Dose**

Treatment of adults with relapsing remitting multiple sclerosis (initiated by a specialist).

**By Mouth**
- Adult: 120 mg twice daily for 7 days, then increased to 240 mg twice daily, for dose adjustment due to side effects—consult product literature.

**Caution**  Reduced lymphocyte count, risk of serious infections (do not start treatment until resolved and consider suspending treatment if infection develops during treatment), severe active gastro-intestinal disease

**Interactions**  + Appendix 1: dimethyl fumarate

**Side-Effects**
- Abdominal pain, burning sensation, diarrhoea, dyspepsia, erythema, flushing (may be severe and indicate hypersensitivity), gastritis, gastroenteritis, leucopenia, lymphopenia, nausea, proteinuria, pruritus, rash, vomiting

**Side-Effects, Further Information**
- Progressive multifocal leukoencephalopathy (PML)  Severe prolonged lymphopenia reported, and patients are exposed to a potential risk of PML. Treatment should be stopped immediately if PML is suspected.
- Conception and Contraception  Contraception required in women of child-bearing potential (consider non-hormonal methods).
- Pregnancy  Manufacturer advises avoid unless essential and potential benefit outweighs risk—toxicity in animal studies.
Immune system and malignant disease

- **BREAST FEEDING** Manufacturer advises avoid.
- **HEPATIC IMPAIRMENT** Manufacturer advises caution in severe impairment.
- **RENAL IMPAIRMENT** Manufacturer advises caution in severe impairment.
- **MONITORING REQUIREMENTS**
  - Monitor full blood count (including lymphocytes) before treatment (within 6 months before initiation), then every 6 to 12 months thereafter, and as clinically indicated.
  - Monitor patient closely for features of progressive multifocal leukoencephalopathy (PML) (e.g. signs and symptoms of neurological dysfunction) and other opportunistic infections.
  - Monitor renal and hepatic function before treatment, after 3 and 6 months of treatment, then every 6 to 12 months thereafter, and as clinically indicated.
- **PATIENT AND CARER ADVICE** Patient information leaflet should be provided.
- Counselling is advised on progressive multifocal leukoencephalopathy.
- **NATIONAL FUNDING/ACCESS DECISIONS**
  - NICE technology appraisals (TAs)
    - Dimethyl fumarate for treating relapsing-remitting multiple sclerosis (August 2014) NICE TA320
      - Dimethyl fumarate is recommended for the treatment of active relapsing-remitting multiple sclerosis, only if:
        1. the patient does not have highly active or rapidly evolving severe relapsing-remitting multiple sclerosis and
        2. the manufacturer provides dimethyl fumarate with the discount agreed in the patient access scheme
- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Gastro-resistant capsule**
    - CAUTIONARY AND ADVISORY LABELS 21, 25
      - **Tecfidera** (Biogen Idec Ltd)
        - Dimethyl fumarate 120 mg Tecfidera 120mg gastro-resistant capsules | 14 capsule (PO) £343.00
        - Dimethyl fumarate 240 mg Tecfidera 240mg gastro-resistant capsules | 66 capsule (PO) £1,373.00

Fingolimod

- **DRUG ACTION** Fingolimod is an immunomodulating drug.
- **INDICATIONS AND DOSE**
  - Treatment of highly active relapsing-remitting multiple sclerosis in patients who have high disease activity despite treatment with at least one disease modifying therapy or in those with rapidly evolving severe relapsing-remitting multiple sclerosis (initiated under specialist supervision)
    - **BY MOUTH**
    - Adult: 500 micrograms once daily

- **ADVERSE EFFECTS**
  - Heart rate
    - Patients with the following medical conditions:
      - 2nd degree Mobitz Type II or higher degree atrioventricular block, sick sinus syndrome, or sino-atrial heart block
      - Significant QT prolongation (QT-interval greater than 470 milliseconds in women, or greater than 450 milliseconds in men)
      - History of symptomatic bradycardia or recurrent syncope, known ischaemic heart disease, cerebrovascular disease, history of myocardial infarction, congestive heart failure, history of cardiac arrest, uncontrolled hypertension, or severe sleep apnoea.
    - Patients receiving the following antiarrhythmic or heart-rate lowering drugs:
      - Class la or class III antiarrhythmics
      - Beta blockers
      - Heart rate-lowering calcium channel blockers
      - Other substances which may decrease heart rate (e.g. digoxin, anticholinesteratic drugs or pilocarpine).
    - All patients receiving fingolimod should be monitored at treatment initiation, (first dose monitoring), and after treatment interruption (see note below); monitoring should include:
      - **Pre-treatment**
        - A 12-lead ECG and blood pressure measurement before starting
      - **During the first 6 hours of treatment**
        - Continuous ECG monitoring for 6 hours
        - Blood pressure and heart rate measurement every hour
      - **After 6 hours of treatment**
        - A further 12-lead ECG and blood pressure measurement
        - If heart rate at the end of the 6 hour period is at its lowest since fingolimod was first administered, monitoring should be extended by at least 2 hours and until heart rate increases.
        - Extended monitoring, (at least overnight), should be performed in patients with evidence of clinically important cardiac effects during first dose monitoring. Monitoring in patients requiring pharmacological intervention for bradycardia-related symptoms during first dose monitoring should be extended at least overnight, and first dose monitoring should be repeated after the second dose.
      - **Note**
        - First dose monitoring as above should be repeated in all patients whose treatment is interrupted for:
          - 1 day or more during the first 2 weeks of treatment
          - More than 7 days during weeks 3 and 4 of treatment
          - More than 2 weeks after one month of treatment
        - If the treatment interruption is of shorter duration than the above, repeated monitoring is not required and treatment should be continued with the next dose as planned.

- **CONTRA-INDICATIONS** Active malignancies • immunosuppression • severe active infection

---

**IMPORTANT SAFETY INFORMATION**

- **MHRA/CHM ADVICE: MULTIPLE SCLEROSIS THERAPIES: SIGNAL OF REBOUND EFFECT AFTER STOPPING OR SWITCHING THERAPY (APRIL 2017)**
  - A signal of rebound syndrome in multiple sclerosis patients whose treatment with fingolimod was stopped or switched to other treatments has been reported in two recently published articles. The MHRA advise to be vigilant for such events and report any suspected adverse effects relating to fingolimod, or other treatments for multiple sclerosis, via the Yellow Card Scheme, while this report is under investigation.

- **MHRA/CHM ADVICE: FINGOLIMOD—NOT RECOMMENDED FOR PATIENTS AT KNOWN RISK OF CARDIOVASCULAR EVENTS, ADVICE FOR EXTENDED MONITORING FOR THOSE WITH SIGNIFICANT BRADYCARDIA OR HEART BLOCK AFTER THE FIRST DOSE AND FOLLOWING TREATMENT INTERRUPTION (JANUARY 2013)**
  - Fingolimod is known to cause transient bradycardias and heart block after the first dose. Fingolimod is not recommended in the following patient groups who are at high risk of cardiovascular events unless the anticipated benefits outweigh the potential risks, and advice from a cardiologist is sought before initiation:
    - Patients with the following medical conditions:
      - 2nd degree Mobitz Type II or higher degree atrioventricular block, sick sinus syndrome, or sino-atrial heart block
      - Significant QT prolongation (QT-interval greater than 470 milliseconds in women, or greater than 450 milliseconds in men)
      - History of symptomatic bradycardia or recurrent syncope, known ischaemic heart disease, cerebrovascular disease, history of myocardial infarction, congestive heart failure, history of cardiac arrest, uncontrolled hypertension, or severe sleep apnoea.
    - Patients receiving the following antiarrhythmic or heart-rate lowering drugs:
      - Class ia or class III antiarrhythmics
      - Beta blockers
      - Heart rate-lowering calcium channel blockers
      - Other substances which may decrease heart rate (e.g. digoxin, anticholinesteratic drugs or pilocarpine).
    - All patients receiving fingolimod should be monitored at treatment initiation, (first dose monitoring), and after treatment interruption (see note below); monitoring should include:
      - **Pre-treatment**
        - A 12-lead ECG and blood pressure measurement before starting
      - **During the first 6 hours of treatment**
        - Continuous ECG monitoring for 6 hours
        - Blood pressure and heart rate measurement every hour
      - **After 6 hours of treatment**
        - A further 12-lead ECG and blood pressure measurement
        - If heart rate at the end of the 6 hour period is at its lowest since fingolimod was first administered, monitoring should be extended by at least 2 hours and until heart rate increases.
        - Extended monitoring, (at least overnight), should be performed in patients with evidence of clinically important cardiac effects during first dose monitoring. Monitoring in patients requiring pharmacological intervention for bradycardia-related symptoms during first dose monitoring should be extended at least overnight, and first dose monitoring should be repeated after the second dose.
      - **Note**
        - First dose monitoring as above should be repeated in all patients whose treatment is interrupted for:
          - 1 day or more during the first 2 weeks of treatment
          - More than 7 days during weeks 3 and 4 of treatment
          - More than 2 weeks after one month of treatment
        - If the treatment interruption is of shorter duration than the above, repeated monitoring is not required and treatment should be continued with the next dose as planned.

- **CONTRA-INDICATIONS** Active malignancies • immunosuppression • severe active infection

**CAUTIONS, FURTHER INFORMATION**

- **PREGNANCY**
  - **CONCEPTION MONITORING REQUIREMENTS**
    - Manufacturer advises eye examination recommended
  - **HEPATIC IMPAIRMENT AND CONTRACEPTION**
    - Progressive multifocal leukoencephalopathy (PML) and other basal-cell carcinoma. Progressive multifocal leukoencephalopathy (PML) and other opportunistic infections. Suspension of treatment should be considered if a patient develops a severe infection, taking into consideration the risk-benefit.
  - **UNCOMMON**
    - Maculopapular rash, pruritus
  - **RARE**
    - Lymphoma
  - **FREQUENCY NOT KNOWN**
    - Haemophagocytic syndrome.
    - Lymphoma.
    - Progressive multifocal leukoencephalopathy.

**SIDE-EFFECTS, FURTHER INFORMATION**

- **BASAL-CELL CARCINOMA**
  - Patients should be advised to seek medical advice if they have any signs of basal-cell carcinoma including skin nodules, patches or open sores that do not heal within weeks.
  - Progressive multifocal leukoencephalopathy (PML) and other opportunistic infections. Suspension of treatment should be considered if a patient develops a severe infection, taking into consideration the risk-benefit.

**CONCESSION AND CONTRACEPTION**

Exclude pregnancy before treatment. Ensure effective contraception during and for at least 2 months after treatment.

**PREGNANCY**

Avoid (toxicity in animal studies).

**BREAST FEEDING**

Avoid.

**HEPATIC IMPAIRMENT**

Use with caution in mild to moderate impairment. Avoid in severe impairment.

**MONITORING REQUIREMENTS**

- Manufacturer advises eye examination recommended 3–4 months after initiation of treatment (and before initiation of treatment in patients with diabetes or history of uveitis).
- Manufacturer advises skin examination for signs of basal-cell carcinoma before starting treatment and then at least yearly thereafter.
- Monitor hepatic transaminases before treatment, then every 3 months for 1 year, then periodically thereafter.
- Monitor full blood count before treatment, at 3 months, then at least yearly thereafter and if signs of infection—interrupt treatment if lymphocyte count reduced—consult product literature.
- Monitor for signs and symptoms of haemophagocytic syndrome (including pyrexia, asthenia, hepato—splenomegaly and adenopathy)—may be associated with hepatic failure and respiratory distress; also progressive cytopenia, elevated serum ferritin concentrations, hypertriglyceridaemia, hypofibrinogenaeemia, coagulopathy, hepatic cytolysis, hyponatraemia)—initiate treatment immediately.
- Manufacturer advises to monitor routine MRI for lesions suggestive of progressive multifocal leukoencephalopathy (PML), particularly in patients considered at increased risk.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- **Fingolimod for the treatment of highly active relapsing-remitting multiple sclerosis (April 2012) NICE TA254**
  - Fingolimod is recommended as an option for the treatment of highly active relapsing-remitting multiple sclerosis in adults, only if:
    - they have an unchanged or increased relapse rate or ongoing severe relapses compared with the previous year despite treatment with interferon beta, and
    - the manufacturer provides fingolimod with the discount agreed as part of the patient access scheme.
  - Patients currently receiving fingolimod whose disease does not meet the above criteria should be able to continue treatment until they and their clinician consider it appropriate to stop.
  - www.nice.org.uk/TA254

**Scottish Medicines Consortium (SMC) Decisions**

The **Scottish Medicines Consortium** (SMC) has advised (August 2012) that fingolimod (Gilenya®) is accepted for restricted use within NHS Scotland as single disease modifying therapy in highly active relapsing-remitting multiple sclerosis despite treatment with interferon beta, with an unchanged or increased relapse rate or ongoing severe relapses, as compared to the previous year.

- All Wales Medicines Strategy Group (AWMSG) Decisions
  - The **All Wales Medicines Strategy Group** (AWMSG) has advised (January 2017) that fingolimod (Gilenya®) is recommended as an option for use within NHS Wales as a single disease modifying therapy in highly active relapsing-remitting multiple sclerosis only in patients with rapidly evolving severe relapsing-remitting multiple sclerosis defined by 2 or more disabling relapses in 1 year and with 1 or more gadolinium-enhancing lesions on brain magnetic resonance imaging (MRI) or a significant increase in T2 lesion load compared with a previous recent MRI, only if the manufacturer provides fingolimod with the discount agreed as part of the patient access scheme or where the list price is equivalent or lower.

**NHS restrictions**

- **NHS England Clinical Commissioning Policy**

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

- **Gilenya®** (Novartis Pharmaceuticals UK Ltd)
  - Fingolimod (as Fingolimod hydrochloride)
  - 500 microgram
  - Gilenya 0.5mg capsules | 7 capsule [PoM] £367.50
  - 28 capsule [PoM] £1,470.00

**IMMUNOSUPPRESSANTS > INTERLEUKIN INHIBITORS**

**Daclizumab**

25-Apr-2017

**DRUG ACTION**

Daclizumab is a humanised monoclonal antibody that inhibits interleukin-2 receptor binding.

**INDICATIONS AND DOSE**

Relapsing multiple sclerosis (initiated by a specialist)

- **BY SUBCUTANEOUS INJECTION**
  - Adult: 150 mg once a month, to be administered into the thigh, abdomen or upper arm.
**CAUTIONS** History of depressive disorders, patients over 55 years—limited information available, severe active infection (consider delaying treatment initiation)

**INTERACTIONS** → Appendix 1: monoclonal antibodies

**SIDE-EFFECTS**
- **Common or very common** Abnormal liver function tests, acne, anaemia, decreased lymphocyte count, depression, dermatitis, diarrhoea, eczema, erythema, folliculitis, hepatitis, influenza, lymphadenopathy, nasopharyngitis, oropharyngeal pain, pruritus, psoriasis, pyrexia, rash, respiratory tract infection, rhinitis
- **Uncommon** Collitis, serious skin reactions

**SIDE-EFFECTS, FURTHER INFORMATION**
- Serious skin reactions. Serious skin reactions (including exfoliative rash or dermatitis, and toxic skin eruption) have been reported; if a diffuse or highly inflammatory rash develops—manufacturer advises referral to a dermatologist and discontinuation may be required.

**PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk.

**BREAST FEEDING** Manufacturer advises use only if potential benefit outweighs risk—present in milk in animal studies.

**HEPATIC IMPAIRMENT** Manufacturer advises avoid in severe impairment or when serum transaminases are greater than 2 times the upper limit of normal range.

**MONITORING REQUIREMENTS**
- Manufacturer advises monitor liver function before treatment, monthly during treatment and for up to 4 months after the last dose—treatment interruption or discontinuation may be required if serum transaminases are greater than 3 times the upper limit of normal range (consult product literature).
- Manufacturer advises monitor full blood count every 3 months.

**HANDLING AND STORAGE** Manufacturer advises store in a refrigerator (2–8°C). May be stored at room temperature up to 30°C for up to 30 days.

**PATIENT AND CARER ADVICE**
- Patients should be provided with a patient card.
- Manufacturer advises patients and their carers should be advised to report any signs of hepatic injury, or symptoms of new or worsening depression and/or suicidal ideation. Patients or carers should also be given advice on how to administer daclizumab injection.

**MEDICINAL FORMS**
- Daclizumab 150 mg per 1 ml Zinbryta (Biogen Idec Ltd) ▼
- Daclizumab 150 mg/1 ml solution for injection pre-filled pen 1 pre-filled disposable injection £1,596.67

**IMMUNOSUPPRESSANTS > MONOClonAL ANTIBodies > ANTI-LYMPHOCYTE**

**Anti-lymphocyte monoclonal antibodies**

**DRUG ACTION** The anti-lymphocyte monoclonal antibodies cause lysis of B lymphocytes.

**IMPORTANT SAFETY INFORMATION**
- All anti-lymphocyte monoclonal antibodies should be given under the supervision of an experienced specialist, in an environment where full resuscitation facilities are immediately available.

**SIDE-EFFECTS**
- **Common or very common** Allergic reactions, angioedema, bronchospasm, chills, cytokine release syndrome, dyspnoea, fever, flushing, nausea, pruritus, rash, tumour pain, vomiting
- **Frequency not known** Cardiac events

**SIDE-EFFECTS, FURTHER INFORMATION**
- Infusion-related side-effects In rare cases infusion reactions may be fatal.
- Infusion-related side-effects occur predominantly during the first infusion. Patients should receive premedication before administration of anti-lymphocyte monoclonal antibodies to reduce these effects—consult product literature for details of individual regimens.
- The infusion may have to be stopped temporarily and the infusion-related effects treated—consult product literature for appropriate management.
- Evidence of pulmonary infiltration and features of tumour lysis syndrome should be sought if infusion-related effects occur.
- Cytokine release syndrome. Fatalities following severe cytokine release syndrome (characterised by severe dyspnoea) and associated with features of tumour lysis syndrome have occurred after infusions of anti-lymphocyte monoclonal antibodies. Patients with a high tumour burden as well as those with pulmonary insufficiency or infiltration are at increased risk and should be monitored very closely (and a slower rate of infusion considered).

**PRE-TREATMENT SCREENING** All patients should be screened for hepatitis B before treatment.

**MONITORING REQUIREMENTS** Patients should also be monitored for cytopenias—consult product literature for specific recommendations.

**Alemtuzumab**

**INDICATIONS AND DOSE**
- Treatment of adults with relapsing-remitting multiple sclerosis with active disease defined by clinical or imaging features
- **BY INTRAVENOUS INFUSION**
- **Adult:** (consult product literature)

**UNLICENSED USE** Although no longer licensed for oncological and transplant indications, alemtuzumab is
also available through a patient access programme for these indications.

**IMPORTANT SAFETY INFORMATION**
Alemtuzumab should be given under the care of a specialist with facilities for the management of hypersensitivity and anaphylactic reactions.

### CONTRA-INDICATIONS
- Human immunodeficiency virus
- Hepatitis B carriers
- Hepatitis C carriers
- in patients with active infection

### CAUTIONS
- Hepatitis B carriers
- Hepatitis C carriers
- in patients with active infection
- A delay in initiation of alemtuzumab treatment should be considered until the infection is fully controlled
- not recommended for inactive disease
- not recommended for stable disease
- patients should receive oral prophylaxis for herpes infection starting on the first day of treatment and continuing for at least a month following each treatment course
- patients with previous autoimmune conditions other than multiple sclerosis
- pretreatment before administration is required (consult product literature)

### PRE-TREATMENT SCREENING
For full details of cautions, consult product literature.
- Autoimmune mediated conditions
- Patients with active infection
- A delay in initiation of treatment should be considered until the infection is fully controlled
- Patients with previous autoimmune conditions other than multiple sclerosis
- Pretreatment before administration is required (consult product literature).

### INTERACTIONS
- Appendix 1: monoclonal antibodies

### SIDE-EFFECTS

**SIDE-EFFECTS, FURTHER INFORMATION**
For full side effects details (including monitoring and management) consult product literature

### CONCEPTION AND CONTRACEPTION
- Women of childbearing potential should use effective contraception

### PREGNANCY
- Manufacturer advises avoid unless potential benefit outweighs risk—tocicity in animal studies
- Autoimmune thyroid disease during treatment may affect fetus (consult product literature)

### BREAST FEEDING
- Manufacturer advises avoid during and for 4 months after each treatment course unless potential benefit outweighs risk.

### PRE-TREATMENT SCREENING
- Screening patients at high risk of hepatitis B or C is recommended before treatment
- All patients should be evaluated for active or latent tuberculosis before starting treatment.

### MONITORING REQUIREMENTS
- HPV screening should be carried out annually in female patients.

### PRESCRIBING AND DISPENSING INFORMATION
- All patients should receive oral prophylaxis for herpes infection starting on the first day of treatment and continuing for at least a month following each treatment course.

### PATIENT AND CARER ADVICE
- Patients should be provided with a patient alert card and patient guide.

### NATIONAL FUNDING/ACCESS DECISIONS

**NICE technology appraisals (TAs)**
- Alemtuzumab for treating relapsing-remitting multiple sclerosis (May 2014) NICE TA312
- Alemtuzumab is recommended as an option, within its marketing authorisation, for treating adults with active relapsing-remitting multiple sclerosis.
  - www.nice.org.uk/TA312

### MEDICINAL FORMS
- There can be variation in the licensing of different medicines containing the same drug.
- **Solution for infusion**
  - **Lemtrada** (Genzyme Therapeutics Ltd) ▼
  - Alemtuzumab 10 mg per 1 ml
  - Lemtrada 12mg/1.2ml concentrate for solution for infusion vials
  - 1 vial (£7,045.00) (Hospital only)

### NATALIZUMAB

#### DRUG ACTION
- Natalizumab is a monoclonal antibody that inhibits the migration of leucocytes into the central nervous system, hence reducing inflammation and demyelination.

#### INDICATIONS AND DOSE
- **Highly active relapsing-remitting multiple sclerosis**
  - despite treatment with interferon beta or glatiramer acetate, or those patients with rapidly evolving severe relapsing-remitting multiple sclerosis (initiated under specialist supervision)
  - **BY INTRAVENOUS INFUSION**
    - Adult 18–65 years: 300 mg every 4 weeks, treatment should be discontinued if no response after 6 months

#### CONTRA-INDICATIONS
- Active infection
- Active malignancies
- Immunosuppression
- Progressive multifocal leucoencephalopathy

#### CAUTIONS

**CAUTIONS, FURTHER INFORMATION**
For information on cautions consult product literature.
- Progressive Multifocal Leucoencephalopathy
- Natalizumab is associated with an increased risk of opportunistic infection and progressive multifocal leucoencephalopathy (PML) caused by JC virus.
- The risk of developing PML increases with the presence of anti-JCV antibodies, previous use of immunosuppressant therapy, and treatment duration (especially beyond 2 years of treatment); the risk beyond 4 years of treatment is not known.
- Patients with all three risk factors should only be treated with natalizumab if the benefits of treatment outweigh the risks.

### SIDE-EFFECTS

- **Common or very common**
  - Arthralgia
  - Arthralgia (during infusion)
  - Autoantibodies
  - Dizziness (during infusion)
  - Fatigue (during infusion)
  - Headache (during infusion)
  - Nasopharyngitis
  - Nausea (during infusion)
  - Pyrexia
  - Rigors (during infusion)
  - Urinary-tract infection
  - Urticaria (during infusion)
  - Vomiting

- **Uncommon**
  - Hypersensitivity reactions (discontinue permanently)
  - Progressive Multifocal Leukoencephalopathy (PML)

- **Frequency not known**
  - Flushing (during infusion)
  - Increased risk of opportunistic infection
  - Liver toxicity

### SIDE-EFFECTS, FURTHER INFORMATION
- Progressive Multifocal Leukoencephalopathy
  - If Progressive Multifocal Leukoencephalopathy (PML) is suspected, treatment should be suspended until PML has been excluded.
  - If a patient develops an opportunistic infection or PML, natalizumab should be permanently discontinued.

### INTERACTIONS
- Appendix 1: monoclonal antibodies

### BREAST FEEDING
- Present in milk in animal studies—avoid.
**PRE-TREATMENT SCREENING**
Progressive Multifocal Leucoencephalopathy A magnetic resonance image (MRI) scan is recommended before starting treatment with natalizumab.

Testing for serum anti-JCV antibodies before starting treatment or in those with unknown antibody status already receiving natalizumab is recommended and should be repeated every 6 months (consult product literature for full details).

**MONITORING REQUIREMENTS**
- Progressive Multifocal Leucoencephalopathy A magnetic resonance image (MRI) scan is recommended annually. Patients should be monitored for new or worsening neurological symptoms, and for cognitive and psychiatric signs of PML.
- All patients should continue to be monitored for signs and symptoms that may be suggestive of PML for approximately 6 months following discontinuation of treatment.

**DIRECTIONS FOR ADMINISTRATION**
For intravenous infusion (Tysabri®), give intermittently in Sodium chloride 0.9%; dilute 300 mg in 100 mL infusion fluid; gently invert to mix, do not shake. Use within 8 hours of dilution and give over 1 hour.

**PATIENT AND CARER ADVICE**
A patient alert card should be provided.

**NATIONAL FUNDING/ACCESS DECISIONS**
NICE technology appraisals (TAs)
- Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis (August 2007) NICE TAI27

Natalizumab is an option for the treatment only of rapidly evolving severe relapsing-remitting multiple sclerosis (RES). RES is defined by 2 or more disabling relapses in 1 year, and 1 or more gadolinium-enhancing lesions on brain magnetic resonance imaging (MRI) or a significant increase in T2 lesion load compared with a previous MRI.

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (August 2007) that natalizumab is accepted for restricted use as single disease-modifying therapy in highly active relapsing-remitting multiple sclerosis only in patients with rapidly evolving severe relapsing-remitting multiple sclerosis defined by 2 or more disabling relapses in 1 year and with 1 or more gadolinium-enhancing lesions on brain magnetic resonance imaging (MRI) or a significant increase in T2 lesion load compared with a previous MRI.

NHS England Clinical Commissioning Policy

**MEDIINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Solution for infusion**
- Tysabri (Biogen Idec Ltd)

Natalizumab 20 mg per 1 ml Tysabri 300mg/15ml concentrate for solution for infusion vials 1 vial £1,130.00 (Hospital only)

**IMMUNOSUPPRESSANTS**

**Teriflunomide**

**DRUG ACTION**
Teriflunomide is a metabolite of leflunomide which has immunomodulating and anti-inflammatory properties.

**INDICATIONS AND DOSE**
Treatment of relapsing-remitting multiple sclerosis (initiated under specialist supervision)
- **BY MOUTH**
  - Adult: 14 mg once daily

**CONTRA-INDICATIONS**
Anaemia • leucopenia • neutropenia • serious infection • severe hypoprothaeinaemia • severe immunodeficiency • significantly impaired bone-marrow function • thrombocytopenia

**CAUTIONS**
Adult over 65 years • anaemia • dyspnoea— assess for interstitial lung disease and consider suspending treatment • hypoprothaeinaemia (avoid if severe) • impaired bone-marrow function (avoid if severe) • latent tuberculosis • leucopenia • persistent cough—assess for interstitial lung disease and consider suspending treatment • severe infection—delay or suspend treatment until resolved • significant alcohol consumption • signs or symptoms of serious skin reactions (including ulcerative stomatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis)—discontinue treatment • switching between other immunomodulating drugs • thrombocytopenia

**INTERACTIONS**
Appendix 1: teriflunomide

**SIDE-EFFECTS**
- **Common or very common** Acne • alopecia • anxiety • carpal tunnel syndrome • cystitis • diarrhoea • elevated liver enzymes • gastroenteritis • hyperaesthesia • hypertension • laryngitis • leucopenia • menorrhagia • musculoskeletal pain • myalgia • nausea • neuralgia • neutropenia • oral infection • paraesthesia • peripheral neuropathy • poliakuria • rash • respiratory tract infection • sciatica • tinea pedis • urinary tract infection • vomiting • weight loss
- **Uncommon** Anaemia • thrombocytopenia
- **Very rare** Interstitial lung disease • pancreatitis

**SIDE-EFFECTS, FURTHER INFORMATION**
- Accelerated elimination procedure Important: accelerated elimination procedure recommended following discontinuation due to serious adverse effects (consult product literature).
- Hepatic injury Discontinue treatment if signs or symptoms of hepatic injury, or if liver enzymes exceed 3 times the upper limit of reference range.

**CONCEPTION AND CONTRACEPTION**
Effective contraception essential for women of child-bearing potential during treatment and for up to 2 years after treatment. In patients undergoing treatment with teriflunomide that are planning to conceive, the accelerated elimination procedure should be used prior to conception. Use of non-oral contraception is
Malignant disease

1 Antibody responsive malignancy

ANTINEOPLASTIC DRUGS > MONOCLONAL ANTIBODIES

Bevacizumab

- **DRUG ACTION** Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor.

- **INDICATIONS AND DOSE**
  - Treatment of metastatic colorectal cancer in combination with fluoropyrimidine-based chemotherapy
  - First-line treatment of metastatic breast cancer in combination with paclitaxel when treatment with other chemotherapy, including taxanes or anthracyclines is not appropriate
  - First-line treatment of metastatic breast cancer in combination with capcitabine when treatment with other chemotherapy, including taxanes or anthracyclines is not appropriate (patients who have received adjuvant taxane or anthracycline-containing regimens in the previous 12 months should not be treated with bevacizumab in combination with capcitabine)
  - Advanced or metastatic renal cell carcinoma in combination with interferon alfa-2a
  - First-line treatment of unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology (in combination with platinum-based chemotherapy)
  - First-line treatment of advanced (FIGO stages IIIB, IIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (in combination with carboplatin and paclitaxel)
  - First recurrence of platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who have not been treated previously with bevacizumab or other drugs that target vascular endothelial growth factor (in combination with carboplatin and gemcitabine)

- **BY INTRAVENOUS INFUSION**
- **Adult:** (consult local protocol)

**IMPORTANT SAFETY INFORMATION**

MHRA/CHM ADVICE: BEVACIZUMAB AND SUNITINIB: RISK OF OSTEOONECROSIS OF THE JAW (JANUARY 2011)

Treatment with bevacizumab or sunitinib may be a risk factor for the development of osteonecrosis of the jaw. Patients treated with bevacizumab or sunitinib, who have previously received bisphosphonates, or are treated concurrently with bisphosphonates, may be particularly at risk.

- Dental examination and appropriate preventive dentistry should be considered before treatment with bevacizumab or sunitinib.
- If possible, invasive dental procedures should be avoided in patients treated with bevacizumab or sunitinib who have previously received, or who are currently receiving, intravenous bisphosphonates.

- **CAUTIONS** Elective surgery (withhold treatment and avoid for at least 28 days after major surgery or until wound fully healed) - history of arterial thromboembolism - history of cardiovascular disease (increased risk of cardiovascular events, especially in the elderly) - history of hypertension (increased risk of proteinuria—discontinue if nephrotic syndrome) - increased risk of fistulas (discontinue...
permanently if tracheo-oesophageal or grade 4 fistula develops). Increased risk of haemorrhage. Increased risk of tumour-associated haemorrhage. Intra-abdominal inflammation (risk of gastro-intestinal perforation and gall bladder perforation) uncontrolled hypertension. Ununtreated CNS metastases.

Interactions → Appendix 1: monoclonal antibodies.

Side-effects Abdominal pain, alopecia, anaemia, anorexia, arterial thromboembolism, asthma, bone marrow suppression, chest pain, congestive heart failure, constipation, dehydration, diarrhoea, drowsiness, dry skin, dysarthria, dyspnoea, exfoliative dermatitis, extravasation, eye disorders, fistulas, flushing, gall bladder perforation, gastro-intestinal perforation, haemorrhage, hand-foot syndrome, headache, hypersensitivity reactions, hypertension, hyperuricaemia, hypotension, hypoxia, impaired wound healing, infection, intestinal obstruction, lethargy, mucocutaneous bleeding, nausea, necrotising fascitis (discontinue and initiate treatment promptly). Neutropenia, oral mucositis, osteonecrosis of the jaw, peripheral neuropathy, posterior reversible encephalopathy syndrome, proteinuria, pulmonary hypertension, pyrexia, rash, rhinitis, rigors, skin discoloration, supraventricular tachycardia, syncope, taste disturbances, thrombocytopenia, thromboembolism, tumour lysis syndrome, vomiting.

Conception and Contraception Effective contraception required during and for at least 6 months after treatment in women.

Pregnancy Avoid toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

Breast Feeding Manufacturer advises avoid breast-feeding and for at least 6 months after treatment.

Monitoring requirements
- Monitor for necrotising fascitis (usually secondary to wound healing complications, gastrointestinal perforation or fistula formation)—discontinue and initiate treatment promptly.
- Monitor blood pressure.
- Monitor for congestive heart failure.
- Monitor for posterior reversible encephalopathy syndrome (presenting as seizures, headache, altered mental status, visual disturbance or cortical blindness, with or without hypertension).
- Consider dental check-up before initiating treatment (risk of osteonecrosis of the jaw).

National funding/access decisions

NICE technology appraisals (TAs)
- Bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer (May 2013) NICE TA285
- Bevacizumab in combination with paclitaxel and carboplatin is not recommended within its marketing authorisation, that is, for the first recurrence of platinum-sensitive advanced ovarian cancer (including fallopian tube and primary peritoneal cancer) that has not been previously treated with bevacizumab or other vascular endothelial growth factor (VEGF) inhibitors or VEGF receptor-targeted agents.
- Bevacizumab in combination with capcitabine for the first-line treatment of metastatic breast cancer (August 2012) NICE TA263
- Bevacizumab in combinations with capcitabine is not recommended within its marketing authorisation for the first-line treatment of metastatic breast cancer, that is, when treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate, or when taxanes or anthracyclines have been used as part of adjuvant treatment in the previous 12 months.
- Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (February 2011) NICE TA214
- Bevacizumab in combination with a taxane is not recommended for the first-line treatment of metastatic breast cancer.
- Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capcitabine for the treatment of metastatic colorectal cancer (December 2010) NICE TA212
- Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capcitabine is not recommended for the treatment of metastatic colorectal cancer.
- Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (January 2007) NICE TA118
- Bevacizumab in combination with fluorouracil plus folinic acid, with or without irinotecan, is not recommended for the first-line treatment of metastatic colorectal cancer; see also NICE guidance Bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy.
- Bevacizumab (first-line), sorafenib (first and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced or metastatic renal cell carcinoma (August 2009) NICE TA178
- Bevacizumab, sorafenib, and temsirolimus are not recommended as first-line treatments for people with advanced or metastatic renal cell carcinoma. Sorafenib and sunitinib are not recommended as second-line treatments for people with advanced or metastatic renal cell carcinoma.

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (April 2012) that bevacizumab (Avastin®) is not recommended for use within NHS Scotland for the first line treatment of patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate.

The Scottish Medicines Consortium has advised (August 2015) that bevacizumab (Avastin®) is accepted for restricted use within NHS Scotland in combination with paclitaxel for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian
tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (VEGF) inhibitors or VEGF receptor-targeted agents.

The Scottish Medicines Consortium has advised (October 2015) that bevacizumab (Avastin®) is accepted for restricted use within NHS Scotland in combination with carboplatin and paclitaxel for the first-line treatment of advanced FIGO stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection

**Solution for infusion**

- **Avastin** (Roche Products Ltd)
  - Bevacizumab 25 mg per 1 ml Avastin 400mg/16ml solution for infusion vials | 1 vial £924.40 (Hospital only)
  - Avastin 100mg/4ml solution for infusion vials | 1 vial £242.66 (Hospital only)

<table>
<thead>
<tr>
<th>Blinatumomab</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>01-Feb-2017</strong></td>
</tr>
</tbody>
</table>

**INDICATIONS AND DOSE**

**Relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukaemia**

- **BY CONTINUOUS INTRAVENOUS INFUSION**
  - Adult (body-weight 45 kg and above): Initially 9 micrograms/24 hours on days 1–7 of first cycle, followed by 28 micrograms/24 hours on days 8–28, first cycle is followed by a 2 week treatment-free interval, then 28 micrograms/24 hours for days 1–28 of second and subsequent cycles—patients who achieve complete remission after 2 treatment cycles may receive up to 3 additional cycles of consolidation treatment, for dose adjustments due to side-effects and infusion-related reactions or patients with high tumour burden—consult product literature

**CAUTIONS**

- Aphasia · brain injuries (severe) · cerebellar disease · dementia · elderly—limited information available · epilepsy · paresis · Parkinson’s disease · patients may need pre-medication to minimise adverse reactions · psychosis · seizure · severe hepatic impairment · severe renal impairment · stroke

**CAUTIONS, FURTHER INFORMATION**

- Pre-medication Manufacturer advises pre-medication with intravenous dexmethylazone and an anti-pyretic—consult product literature.
- Neurological events There is potentially a higher risk of neurological events in patients with clinically relevant CNS pathology—manufacturer advises caution.

**INTERACTIONS**

- **Appendix 1: monoclonal antibodies**

**SIDE-EFFECTS**

- **Common or very common** Anaemia · aphasia · arthralgia · chills · cognitive disorder · confusion · constipation · convulsion · cough · cytokine release syndrome · decreased appetite · diarrhoea · disorientation · dizziness · electrolyte disturbances · encephalopathy · fatigue · headache · hypoalbuminemia · hypotension · infusion-related reactions · insomnia · leukocytosis · leucopenia · lymphopenia · memory impairment · nausea · neutropenia · oedema · pain (including abdominal, bone and back) · paraesthesia · peripheral oedema · pneumonia · pyrexia · rash · sepsis · tachycardia · thrombocytopenia · tremor · tumour lysis syndrome · vomiting
- **Uncommon** Pancreatitis

- **Frequency not known** Bone marrow suppression · leukoencephalopathy (including progressive multifocal leukoencephalopathy)

**SIDE-EFFECTS, FURTHER INFORMATION**

- **Pancreatitis** Life-threatening or fatal cases of pancreatitis have been reported; manufacturer advises monitor for signs and symptoms of pancreatitis during treatment—temporary interruption or discontinuation may be required (consult product literature).
- **Cytokine release syndrome, infusion-reactions and tumour lysis syndrome** Life-threatening (including fatal) cases of cytokine release syndrome and tumour lysis syndrome have been reported in patients taking blinatumomab. Manufacturer advises monitor signs and symptoms of cytokine release syndrome and infusion reactions during treatment; temporary interruption or discontinuation may be required—consult product literature.

**CONCEPTION AND CONTRACEPTION**

- Manufacturer advises effective contraception during treatment and for at least 48 hours after treatment in women of child-bearing potential. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**PREGNANCY**

- Manufacturer advises avoid unless potential benefit outweighs risk—no information available; if exposed during pregnancy, monitor infant for B-cell depletion. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**BREAST FEEDING**

- Manufacturer advises avoid during and for at least 48 hours after treatment—no information available.

**HEPATIC IMPAIRMENT**

- Manufacturer advises caution in severe impairment—no information available.

**RENAL IMPAIRMENT**

- Manufacturer advises caution in severe impairment—no information available.

**MONITORING REQUIREMENTS**

- Manufacturer advises neurological examination prior to the initiation of treatment and continued monitoring during treatment—consult product literature.

**HANDLING AND STORAGE**

- Manufacturer advises store in a refrigerator (2–8°C); consult product literature for storage conditions after reconstitution and dilution.

**PATIENT AND CARER ADVICE**

- A patient alert card should be provided.

- Educational materials should be provided to patients, carers and healthcare professionals to ensure blinatumomab is used in a safe and effective way, and to prevent the risk of medication errors and neurological events—consult product information.

**Driving and skilled tasks**

- Manufacturer advises patients and carers should be counselled about the effects on driving and performance of skilled tasks—increased risk of confusion, disorientation, co-ordination and balance disorders, seizures and disturbances in consciousness.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for infusion**

- **Blinicyto** (Amgen Ltd)

<table>
<thead>
<tr>
<th>Blinatumomab 38.5 microgram</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinicyto 38.5 micrograms powder for concentrate and solution for solution for infusion vials</td>
</tr>
</tbody>
</table>
Brentuximab vedotin

- **INDICATIONS AND DOSE**
  Treatment of relapsed or refractory CD-30 positive Hodgkin’s disease following autologous stem cell transplant or following at least two prior therapies, when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option. Relapsed or refractory systemic anaplastic large cell lymphoma
  - **BY INTRAVENOUS INFUSION**
  - Adult: (consult product literature)

- **CAUTIONS** Elevated BMI—risk of hyperglycaemia, high tumour burden—risk of tumour lysis syndrome, rapidly proliferating tumours—risk of tumour lysis syndrome

- **INTERACTIONS** 
  - Appendix 1: monoclonal antibodies

- **SIDE-EFFECTS**
  - Common or very common: Anaphylaxis, arthralgia, back pain, constipation, cough, demyelinating polyneuropathy, diarrhoea, dizziness, dysphonia, fatigue, hyperglycaemia, infusion-related reactions, myalgia, peripheral neuropathy, pruritus, rash
  - Uncommon: Stevens-Johnson syndrome
  - Frequency not known: Alopecia, bone-marrow suppression, extravasation, hyperuricaemia, infusion related side-effects, nausia, oral mucositis, progressive multifocal leuкоencephalopathy, thromboembolism, tumour lysis syndrome, vomiting

- **CONCEPTION AND CONTRACEPTION** Effective contraception required during treatment and for 6 months after treatment in men and women.

- **PREGNANCY** Avoid unless potential benefit outweighs risk (toxicity in animal studies).

- **BREAST FEEDING** Avoid—no information available.

- **MONITORING REQUIREMENTS**
  - Monitor for symptoms of progressive multifocal leuкоencephalopathy (presenting as new or worsening neurological, cognitive or behavioural signs or symptoms).
  - Monitor for new or worsening abdominal pain—investigate and withhold treatment if acute pancreatitis suspected and discontinue if confirmed (fatal cases reported).
  - Monitor for pulmonary toxicity—treat symptoms promptly.
  - Routinely monitor hepatic function.
  - Monitor for infusion-related (including anaphylactic) reactions.
  - Monitor for signs of peripheral neuropathy—consult product literature for treatment adjustment.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - Powder for solution for infusion
    - Electrolytes: May contain Sodium
    - Adcetris (Takeda UK Ltd)
      - Brentuximab vedotin 50 mg: Adcetris 50mg powder for concentrate for solution for infusion vials | 1 vial (£2,500.00)

Cetuximab

- **INDICATIONS AND DOSE**
  Treatment of wild-type RAS metastatic colorectal cancer in patients with tumours expressing epidermal growth factor receptor, as combination therapy, or as monotherapy if oxaliplatin- and irinotecan-based therapy has failed or if irinotecan is not tolerated. Treatment of locally advanced squamous cell cancer of the head and neck (in combination with radiotherapy). Treatment of recurrent or metastatic squamous cell cancer of the head and neck (in combination with platinum-based chemotherapy)
  - **BY INTRAVENOUS INFUSION**
  - Adult (initiated by a specialist): (consult product literature or local protocols)

- **SIDE-EFFECTS**
  - Common or very common: Abdominal pain, anorexia, anxiety, arthralgia, cholangitis, constipation, cough, dehydration, diarrhoea, dizziness, dyspepsia, dysphonia, electrolyte disturbances, flatulence, flushing, haematuria, headache, hyperglycaemia, hypertension, hypotension, hypoxia, ileus, infection, insomnia, leucocyturia, myalgia, pleural effusion, proteinuria, rash, skin reactions, sweating, tachycardia, vertigo
  - Uncommon: Acute renal failure, gastro-intestinal haemorrhage, intestinal obstruction, seizures

- **FREQUENCY NOT KNOWN**
  - Alopecia, bone-marrow suppression, extravasation, hyperuricaemia, infusion related side-effects, nausia, oral mucositis, thromboembolism, tumour lysis syndrome, vomiting

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Infusion-related side-effects: Infusion-related side-effects have been reported with catumaxomab; premedication with analgesics, antipyretics, or NSAIDs is recommended by the manufacturer.

- **CONCEPTION AND CONTRACEPTION**
  - Contraceptive advice required, see *Pregnancy and reproductive function* in Cytotoxic drugs p. 825.

- **PREGNANCY**
  - Avoid—limited information available.

- **BREAST FEEDING**
  - Avoid—limited information available.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  **Solution for infusion**
  - **Removab** (Neovii Biotech GmbH)
    - Catumaxomab 100 microgram per 1 ml: Removab 50micrograms/0.5ml concentrate for solution for infusion pre-filled syringes | 1 pre-filled disposable injection (£550.00) (Hospital only)
    - Removab 10micrograms/0.1ml concentrate for solution for infusion pre-filled syringes | 1 pre-filled disposable injection (£10.00) (Hospital only)

Catumaxomab

- **INDICATIONS AND DOSE**
  Treatment of malignant ascites in patients with epithelial cell adhesion molecule (EpCAM) positive carcinomas, where standard therapy is not available or no longer feasible
  - **BY INTRAPERITONEAL INFUSION**
  - Adult: (consult product literature)

- **CAUTIONS** Haemodynamic insufficiency, hypoproteinaemia, oedema

- **INTERACTIONS** 
  - Appendix 1: monoclonal antibodies

- **MEDICAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Powder for solution for infusion**
    - Electrolytes: May contain Sodium
    - **Adcetris** (Takeda UK Ltd)
      - Brentuximab vedotin 50 mg: Adcetris 50mg powder for concentrate for solution for infusion vials | 1 vial (£2,500.00)

- **IMPORTANT SAFETY INFORMATION**
  - MHRA/CHM ADVICE: EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS: SERIOUS CASES OF KERATITIS AND ULCERATIVE KERATITIS (MAY 2012)
    - Keratitis and ulcerative keratitis have been reported following treatment with epidermal growth factor receptor (EGFR) inhibitors for cancer (cetuximab, erlotinib, gefitinib and panitumumab). In rare cases, this has resulted in corneal perforation and blindness. Patients undergoing treatment with EGFR inhibitors who present with acute or worsening signs and symptoms suggestive of keratitis should be referred promptly to an ophthalmology specialist. Treatment should be interrupted or discontinued if ulcerative
Cetuximab for metastatic colorectal cancer

**CONTRA-INDICATIONS** Combination of cetuximab with oxaliplatin-containing chemotherapy is contra-indicated in patients with metastatic colorectal cancer who have mutant or unknown RAS status. RAS mutated colorectal tumours (or if RAS tumour status unknown)

**CAUTIONS** Cardiopulmonary disease, cardiovascular disease, history of keratitis, pulmonary disease—discontinue if interstitial lung disease, risk factors for keratitis, severe dry eye, ulcerative keratitis (including contact lens use)

**INTERACTIONS** → Appendix 1: monoclonal antibodies

**SIDE-EFFECTS**

- Common or very common: Acne, aseptic meningitis, blepharitis, bronchospasm, chill, conjunctivitis, desquamation, diarrhoea, dizziness, dry skin, dyspnoea, fever, headache, hypertension, hypertrichosis, hypocalcaemia, hypomagnesaemia, hypotension, infusion-related reactions, keratitis, nail disorders, nausea, pruritus, rash, severe (sometimes fatal) hypersensitivity reactions (possibly delayed onset), shock, skin reactions, urticaria, vomiting

- Very rare: Stevens-Johnson syndrome, toxic epidermal necrolysis

**CONCEPTION AND CONTRACEPTION** Contraceptive advice required, see Pregnancy and reproductive function in Cytoxic drugs p 825

**PREGNANCY** Use only if potential benefit outweighs risk—no information available. See also Pregnancy and reproductive function in Cytoxic drugs p 825

**BREAST FEEDING** Avoid breast-feeding during and for 2 months after treatment—no information available.

**PRE-TREATMENT SCREENING** Evidence of non-mutated (wild-type) RAS status (at exons 2, 3 and 4 of KRAS and NRAS) is required before cetuximab is initiated for the treatment of metastatic colorectal cancer, and should be determined by an experienced laboratory using a validated test method.

**DIRECTIONS FOR ADMINISTRATION** Resuscitation facilities should be available.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (June 2008) NICE TA145
  Cetuximab in combination with radiotherapy is an option for the treatment of locally advanced squamous cell cancer of the head and neck in patients who have a Karnofsky performance status of 90% or greater and when all forms of platinum-based chemoradiotherapy treatment are contra-indicated.
  www.nice.org.uk/TA145

- Cetuximab for the treatment of recurrent or metastatic squamous cell cancer of the head and neck (June 2009) NICE TA172
  Cetuximab in combination with platinum-based chemotherapy is not recommended for the treatment of recurrent or metastatic squamous cell cancer of the head and neck.
  www.nice.org.uk/TA172

- Cetuximab for the first-line treatment of metastatic colorectal cancer (August 2009) NICE TA176
  Cetuximab in combination with fluorouracil, folinic acid and oxaliplatin is an option for the first-line treatment of metastatic colorectal cancer under the following circumstances:
  - the primary tumour has been resected or is potentially resectable;
  - the metastatic disease is confined to the liver and is unresectable; and
  - the patient is fit to undergo surgery to resect the primary colorectal tumour and to undergo liver surgery if the metastases become resectable after treatment with cetuximab.

In patients unable to tolerate oxaliplatin, or in whom oxaliplatin is contra-indicated, cetuximab in combination with fluorouracil, folinic acid and irinotecan can be used as an alternative.

In addition, the manufacturer is required to rebate 16% of the amount of cetuximab used per patient when used in combination with fluorouracil, folinic acid, and oxaliplatin.

Patients who meet the above criteria should receive cetuximab for no more than 16 weeks. At 16 weeks, cetuximab should be stopped and the patient should be assessed for resection of liver metastases.

www.nice.org.uk/TA176

- Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (January 2012) NICE TA242
  Cetuximab monotherapy or combination chemotherapy is not recommended for the treatment of patients with metastatic colorectal cancer that has progressed after first-line chemotherapy.
  www.nice.org.uk/TA242

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium (SMC) has advised (December 2014) that cetuximab (Erbitux®) is accepted for restricted use within NHS Scotland, in combination with irinotecan or oxaliplatin-based chemotherapy, for the treatment of RAS wild-type metastatic colorectal cancer in patients who have not previously received chemotherapy for their metastatic disease (first-line treatment).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for infusion**

- Erbitux (Merck Serono Ltd)
  Cetuximab 5 mg per 1 ml Erbitux 100mg/20ml solution for infusion vials | 1 vial (PoMr £178.10 (Hospital only))
  Erbitux 500mg/100ml solution for infusion vials | 1 vial (PoMr £890.50 (Hospital only))

**Daratumumab**

12-Apr-2017

- **DRUG ACTION** Daratumumab is a monoclonal antibody that binds to CD38, a cell-surface protein, resulting in tumour cell death by immune-mediated actions and apoptosis.

- **INDICATIONS AND DOSE**
  **Treatment of relapsed and refractory multiple myeloma**
  (as monotherapy after failure of a proteasome inhibitor and an immunomodulatory agent) (specialist use only)
  - **BY INTRAVENOUS INFUSION**
    - Adult: 16 mg/kg once weekly for weeks 1 to 8, then 16 mg/kg every 2 weeks for weeks 9 to 24, then 16 mg/kg every 4 weeks for week 25 onwards until disease progression, for dose adjustments due to side-effects and infusion-related reactions—consult product literature

- **CAUTIONS** History of obstructive pulmonary disorder (consider additional post-medication—consult product literature); patients may need pre-medication to minimise adverse reactions; risk of herpes zoster reactivation (consider antiviral prophylaxis)
Elotuzumab

07-Apr-2017

**DRUG ACTION** Elotuzumab is a monoclonal antibody that targets the signalling lymphocytic activation molecule family member 7 (SLAMF7) protein, thereby activating natural killer cells and mediating myeloma cell death.

**INDICATIONS AND DOSE**

Multiple myeloma in patients who have received at least one prior therapy (in combination with lenalidomide and dexamethasone) (specialist use only)

- **BY INTRAVENOUS INFUSION**
  - Adult: 10 mg/kg every week, on days 1, 8, 15 and 22 of cycles 1 and 2, then 10 mg/kg every 2 weeks, on days 1 and 15 of subsequent cycles

**CAUTIONS**

Pre-medication must be administered to minimise the development of infusion-related reactions—consult product literature; secondary primary malignancies

**CAUTIONS, FURTHER INFORMATION**

Secondary primary malignancies. Manufacturer advises to monitor for the development of secondary primary malignancy before and during treatment with elotuzumab.

**INTERACTIONS** → Appendix 1: monoclonal antibodies

**SIDE-EFFECTS**

- Common or very common Chest pain, cough, deep vein thrombosis, diarrhoea, fatigue, headache, herpes zoster, hypoaesthesia, infusion-related reactions, lymphopenia, mood changes, nasopharyngitis, night sweats, oropharyngeal pain, pneumonia, pyrexia, upper respiratory tract infection, weight loss

**SIDE-EFFECTS, FURTHER INFORMATION**

Side-effects reported when used in combination with lenalidomide and dexamethasone.

Infusion-related reactions. Manufacturer advises for mild-to-moderate infusion reactions interrupt treatment or reduce infusion rate, and monitor closely (consult product literature); permanently discontinue therapy in severe infusion reactions.

**CONCEPTION AND CONTRACEPTION** Manufacturer advises effective contraception in men and women of childbearing potential; male patients should continue effective contraceptive measures for 180 days after stopping treatment if their partner is pregnant or of childbearing potential. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**PREGNANCY** Manufacturer advises avoid unless essential—no information available. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**BREAST FEEDING** Manufacturer advises avoid—no information available.

**EFFECT ON LABORATORY TESTS** Possible positive indirect Coombs test (may affect antibody screening).

**HANDLING AND STORAGE** Manufacturer advises store in a refrigerator (2–8°C); consult product literature for storage advice following dilution.

**NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (January 2017) that daratumumab (Darzalex) is not recommended for use within NHS Scotland as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy, as insufficient clinical analysis was submitted and the economic case was not demonstrated. This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for infusion**

**EXCIPIENTS:** May contain Polysorbates, sucrose  
**ELECTROLYTES:** May contain Sodium  
**Darzalex (Janssen-Cilag Ltd)**  
Darzatumab 20mg per 1ml Darzalex 100mg/5ml concentrate for solution for infusion vials | 1 vial (£360.00)  
Darzalex 400mg/20ml concentrate for solution for infusion vials | 1 vial (£1440.00)

**Elotuzumab 300 mg** Empliciti 300mg powder for concentrate for solution for infusion vials | 1 vial (£1,085.00)  
Elotuzumab 400 mg Empliciti 400mg powder for concentrate for solution for infusion vials | 1 vial (£1,446.00)

**MEDICATIONS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for infusion**

**EXCIPIENTS:** May contain Polysorbates, sucrose

- **Empliciti (Bristol-Myers Squibb Pharmaceuticals Ltd)**
  - Empliciti 300mg powder for concentrate for solution for infusion vials | 1 vial (£1,085.00)
  - Empliciti 400mg powder for concentrate for solution for infusion vials | 1 vial (£1,446.00)
**Ipilimumab**

- **DRUG ACTION** Ipilimumab causes T-cell activation.

- **INDICATIONS AND DOSE**
  - Treatment of unresectable or metastatic advanced melanoma
    - **BY INTRAVENOUS INFUSION**
    - **Adult:** (consult product literature)

- **CAUTIONS, FURTHER INFORMATION**
  - For full details consult product literature.

- **INTERACTIONS** → Appendix 1: monoclonal antibodies

- **SIDE-EFFECTS** Infusion-related side-effects

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - For further information on side-effects, (including monitoring and management of side effects) consult product literature.
  - Immune-related reactions: A corticosteroid can be used after starting ipilimumab, to treat immune-related reactions.

- **CONCEPTION AND CONTRACEPTION** Use effective contraception.

- **PREGNANCY** Avoid unless potential benefit outweighs risk (toxicity in animal studies).

- **BREAST FEEDING** Discontinue breast-feeding—no information available.

- **HEPATIC IMPAIRMENT** Use with caution if plasma-bilirubin concentration greater than 3 times upper limit of normal range or if plasma-transaminase concentration 5 times or greater than the upper limit of normal range.

- **MONITORING REQUIREMENTS** For information on monitoring of side effects, consult product literature.

- **PRESCRIBING AND DISPENSING INFORMATION** Infusion-related side-effects have been reported; premedication with paracetamol and an antihistamine is recommended.

- **NATIONAL FUNDING/ACCESS DECISIONS**

  NICE technology appraisals (TAs)
  - Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (July 2014) NICE TA319
    - Ipilimumab is recommended, within its marketing authorisation, as an option for treating adults with previously untreated advanced (unresectable or metastatic) melanoma, only if the manufacturer provides ipilimumab with the discount agreed in the patient access scheme.
    - [www.nice.org.uk/TA319](http://www.nice.org.uk/TA319)
  - Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (December 2012) NICE TA268
    - Ipilimumab is recommended as an option for the treatment of advanced (unresectable or metastatic) melanoma in patients who have received prior therapy, only if the manufacturer provides ipilimumab with the discount agreed in the patient access scheme.
    - [www.nice.org.uk/TA268](http://www.nice.org.uk/TA268)
  - Nivolumab in combination with ipilimumab for treating advanced melanoma (July 2016) NICE TA400
    - Nivolumab in combination with ipilimumab is recommended, within its marketing authorisation, as a treatment option for advanced (unresectable or metastatic) melanoma in adults, only if the manufacturer provides ipilimumab with the discount agreed in the patient access scheme.
    - [www.nice.org.uk/TA400](http://www.nice.org.uk/TA400)

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (March 2013) that ipilimumab (Yervoy®) is accepted for restricted use within NHS Scotland for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy, only whilst ipilimumab is available at the price agreed in the patient access scheme.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  **Solution for infusion**

  **ELECTROLYTES:** May contain Sodium

  ▶ Yervoy (Bristol-Myers Squibb Pharmaceuticals Ltd)
    - Ipilimumab 5 mg per 1 ml Yervoy 50mg/10ml concentrate for solution for infusion vials | 1 vial (£150.00 (Hospital only))
    - Yervoy 200mg/40ml concentrate for solution for infusion vials | 1 vial (£15,000.00 (Hospital only))

---

**Necitumumab**

21-Feb-2017

- **DRUG ACTION** Necitumumab is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR).

- **INDICATIONS AND DOSE**
  - Locally advanced or metastatic epidermal growth factor receptor expressing squamous non-small-cell lung cancer, in patients who have not received previous chemotherapy (in combination with gemcitabine and cisplatin) (specialist use only)
    - **BY INTRAVENOUS INFUSION**
      - Adult: 800 mg once daily on days 1 and 8 of a 3-week cycle, for up to 6 cycles, patients whose disease has not progressed after combination therapy may continue with necitumumab monotherapy, for dose adjustments due to infusion-related reactions or skin reactions—consult product literature

- **CAUTIONS, FURTHER INFORMATION**
  - Cardiorespiratory disorders (no information available) - history of thromboembolic events - patients may need pre-medication to minimise the development of infusion-related and skin reactions (consult product literature) - risk factors for thromboembolic events

  **CAUTIONS, FURTHER INFORMATION**
  - Thromboembolic events
    - Manufacturer advises that necitumumab should not be administered to patients with multiple risk factors for thromboembolic events unless the benefits outweigh the risks. Thromboprophylaxis should be considered after assessment of a patient’s risk factors.

- **INTERACTIONS** → Appendix 1: monoclonal antibodies

- **SIDE-EFFECTS**
  - Common or very common: Conjunctivitis - dysphagia - dysuria - electrolyte disturbances - epistaxis - haemoptysis - headache - hypomagnesaemia (severe) - infusion-related reactions - mouth ulceration - muscle spasms - oropharyngeal pain - phlebitis - pyrexia - skin reactions - stomatitis - taste disturbance - thromboembolic events - urinary tract infection - vomiting - weight loss
  - Frequency not known: Cardiorespiratory arrest - eyelash growth

- **CONCEPTION AND CONTRACEPTION**
  - Manufacturer advises women of child-bearing potential should use effective contraception during and for 3 months after treatment.

- **PREGNANCY**
  - Manufacturer advises avoid unless potential benefit outweighs risk—limited information available. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

- **BREAST FEEDING**
  - Manufacturer advises avoid during treatment and for at least 4 months after the last dose—no information available.

- **MONITORING REQUIREMENTS**
  - Manufacturer advises monitor patients during and following each infusion for signs of hypersensitivity and infusion-related reactions; monitor electrolytes (including magnesium, potassium and calcium) prior to each infusion and after completion of treatment, until within normal limits—correct any electrolyte disturbance promptly.
Nivolumab is a human immunoglobulin G monoclonal antibody, which binds to the programmed death-1 (PD-1) receptor thereby potentiating an immune response to tumour cells.

**INDICATIONS AND DOSE**

**Treatment of unresectable or metastatic advanced melanoma in combination with ipilimumab**

- **BY INTRAVENOUS INFUSION**
  - Adult: (consult product literature)

**Treatment of unresectable or metastatic advanced melanoma (as monotherapy)**

- **TREATMENT OF LOCAL ADVANCED OR METASTATIC NON- small-cell lung cancer after prior chemotherapy**

- **TREATMENT OF ADVANCED RENAL CELL CARCINOMA AFTER PRIOR THERAPY (AS MONOTHERAPY)**

- **BY INTRAVENOUS INFUSION**
  - Adult: 3 mg/kg every 2 weeks, consult product literature for information on dose adjustments based on individual patient safety and tolerability

**CAUTIONS**

Patients may need pre-medications to minimise the development of infusion-related reactions

**INTERACTIONS**

- Appendix 1: monoclonal antibodies

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain, alopecia, arthralgia, blurred vision, constipation, cough, decreased appetite, diarrhoea, dizziness, dry eyes, dry mouth, dry skin, dyspnoea, erythema, headache, hyperglycaemia, hypertension, infusion-related reactions

- **Common or very common** Malaise, musculoskeletal pain, nausée, oedema, peripheral neuropathy, pneumonitis, pruritus, pyrexia, rash, stomatitis, thyroid disorders, upper respiratory tract infection, vitiligo, vomiting

- **Uncommon** Adrenal insufficiency, anaphylactic reaction, arthritis, chest pain, dehydration, diabetic ketoacidosis, eosinophilia, erythema multiforme, hepatitis, hyperbilirubinaemia, hypophysitis, hypopituitarism, metabolic acidosis, pancreatitis, pleural effusion, polymyalgia rheumatica, polyneuropathy, psoriasis, renal failure, rosacea, tachycardia, tubulointerstitial nephritis, urticaria, uraemia, vasculitis

- **Rare** Arrhythmias, autoimmune neuropathy, cholestasis, demyelination, diabetes mellitus, duodenal ulcer, gastritis, Guillain-Barré syndrome, histiocytic necrotising lymphadenitis, lung infiltration, myasthenic syndrome, myopathy, toxic epidermal necrolysis

- **Frequency not known** Cardiac adverse events

**SIDE-EFFECTS, FURTHER INFORMATION**

Side effects listed are reported when nivolumab is used as monotherapy; if combination therapy used, consult product literature for further information.

**Immune-related reactions**

Manufacturer advises that most immune-related adverse reactions improved or resolved with appropriate management, including initiation of corticosteroids and treatment modiftings—consult product literature for further information.

**Infusion-related reactions**

Manufacturer advises that patients with mild or moderate infusion reactions may continue treatment with close monitoring and use of premedication according to local guidelines; discontinue treatment if severe infusion reactions occur.

**CONCEPTION AND CONTRACEPTION**

Manufacturer advises effective contraception required during treatment and for at least 5 months after treatment in women of childbearing potential.

**PREGNANCY**

Manufacturer advises avoid unless potential benefit outweighs risk—toxicity in animal studies.

**BREAST FEEDING**

Manufacturer advises avoid—no information available.

**HEPATIC IMPAIRMENT**

Manufacturer advises use with caution in moderate to severe impairment—limited information available.

**MONITORING REQUIREMENTS**

Manufacturer advises monitor for signs and symptoms of infusion- and immune-related reactions, cardiac and pulmonary reactions, and electrolyte disturbances before and periodically during treatment. Patients should be monitored for adverse reactions for at least 5 months after the last dose.

**DIRECTIONS FOR ADMINISTRATION**

Manufacturer advises for intermittent intravenous infusion, give undiluted or dilute to a concentration of not less than 1 mg/mL with Glucose 5% or Sodium Chloride 0.9%; give over 60 minutes through an in-line filter (pore size 0.2–1.2 micron).

**HANDLING AND STORAGE**

Manufacturer advises store in a refrigerator (2–8 °C)—consult product literature for storage conditions after preparation of the infusion.

**PATIENT AND CARER ADVICE**

Patients should be provided with a patient alert card with each prescription.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Nivolumab for treating advanced (unresectable or metastatic) melanoma (February 2016) NICE T384

  Nivolumab as monotherapy is recommended, within its marketing authorisation, as a treatment option for advanced (unresectable or metastatic) melanoma in adults.

  www.nice.org.uk/T384

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for infusion**

**ELECTROLYTES:** May contain Sodium

- **Portrazza (Eli Lilly and Company Ltd)**
  - Nivolumab 16 mg per 1 ml Portrazza 800mg/50ml concentrate for solution for infusion vials | 1 vial (Polv) £1,450.00 (Hospital only)

**Nivolumab 23-Mar-2017**
Nivolumab in combination with ipilimumab for treating advanced melanoma (July 2016) NICE TA400

Nivolumab in combination with ipilimumab is recommended, within its marketing authorisation, as a treatment option for advanced (unresectable or metastatic) melanoma in adults, only if the manufacturer provides ipilimumab with the discount agreed in the patient access scheme.

http://www.nice.org.uk/TA400

Nivolumab for previously treated advanced renal cell carcinoma (November 2016) NICE TA417

Nivolumab is recommended, within its marketing authorisation, as a treatment option for previously treated advanced renal cell carcinoma in adults, only if the manufacturer provides nivolumab with the discount agreed in the patient access scheme.

http://www.nice.org.uk/TA417

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (July 2016) that nivolumab (Opdivo®) is accepted for use within NHS Scotland for the treatment of locally advanced or metastatic squamous non-small cell lung cancer after prior chemotherapy in adults; it has also advised (August 2016) that nivolumab (Opdivo®) is accepted for restricted use within NHS Scotland as monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults previously untreated with ipilimumab and (October 2016) for restricted use for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer after prior chemotherapy in adults, subject to a 2-year clinical stopping rule. It has also advised (November 2016) that nivolumab (Opdivo®) is accepted for restricted use within NHS Scotland in combination with ipilimumab for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults. This advice is contingent upon the continuing availability of the Patient Access Scheme (PAS) in NHS Scotland or a list price that is equivalent or lower.

The Scottish Medicines Consortium has advised (November 2016) that nivolumab (Opdivo®) is not recommended within NHS Scotland as monotherapy for the treatment of advanced renal cell carcinoma after prior therapy in adults as the economic case was not demonstrated.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
- **Solution for infusion**
  - CAUTIONARY AND ADVISORY LABELS 3
  - ELECTROLYTES: May contain Sodium
  - Opdivo (Bristol-Myers Squibb Pharmaceuticals Ltd) ▼
  - Nivolumab 10 mg per 1 ml Opdivo 40mg/4ml concentrate for solution for infusion vials | 1 vial [POW] £439.00 (Hospital only)
  - Opdivo 100mg/10ml concentrate for solution for infusion vials | 1 vial [POW] £1,097.00 (Hospital only)

Obinutuzumab

21-Apr-2017

- **INDICATIONS AND DOSE**
  - Treatment of previously untreated chronic lymphocytic leukaemia in patients for whom full-dose fludarabine-based therapy is unsuitable due to co-morbidities
  - By INTRavenous INFUSION
  - Adult: (consult product literature or local protocols)

- **CONTRA-INDICATIONS**
  - For obinutuzumab contra-indications, consult product literature.

- **CAUTIONS**
  - CAUTIONS, FURTHER INFORMATION
  - For full details on the cautions of obinutuzumab, consult product literature.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - Hepatitis B infection and reactivation
  - Hepatitis B infection and reactivation (including fatal cases) have been reported in patients taking obinutuzumab. Patients with positive hepatitis B serology should be referred to a liver specialist for monitoring and initiation of antiviral therapy before treatment initiation; treatment should not be initiated in patients with evidence of current hepatitis B infection until the infection has been adequately treated. Patients should be closely monitored for clinical and laboratory signs of active hepatitis B infection during treatment and for up to a year following the last infusion (consult product literature).
  - INTERACTIONS ▶ Appendix 1: monoclonal antibodies
  - SIDE-EFFECTS For full side effect details for obinutuzumab (including monitoring and management), consult product literature.
  - CONCEPTION AND CONTRACEPTION Use effective contraception during and for 18 months after treatment.
  - PREGNANCY Avoid unless potential benefit outweighs risk of B-lymphocyte depletion in fetus.
  - BREAST FEEDING Avoid breast-feeding during and for 18 months after treatment—present in milk in animal studies.
  - MONITORING REQUIREMENTS Patients should be closely monitored for clinical and laboratory signs of active hepatitis B infection during treatment and for up to a year following the last infusion (consult product literature).
  - PRESCRIBING AND DISPENSING INFORMATION Infusion related side-effects have been reported; Patients should receive premedication with paracetamol, an antihistamine, and a corticosteroid before each dose—consult product literature for details.

Scottish Medicines Consortium (SMC) Decisions

NICE technology appraisals (TAs)

- Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (June 2015) NICE TA343
  - Obinutuzumab, in combination with chlorambucil, is an option for untreated chronic lymphocytic leukaemia in patients who have comorbidities that make full-dose fludarabine-based therapy unsuitable for them, only if: bendamustine-based therapy is not suitable and the manufacturer provides obinutuzumab with the discount agreed in the patient access scheme.
  - Patients currently receiving obinutuzumab that is not recommended according to the above criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop.
  - http://www.nice.org.uk/TA343

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (March 2017) that obinutuzumab (Gazyvaro®) is accepted for use within NHS Scotland in combination with bendamustine followed by obinutuzumab maintenance for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to six months after treatment with rituximab or a rituximab-containing regimen. This advice is contingent upon the continuing availability of the Patient Access Scheme in NHS Scotland or a list price that is equivalent or lower.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - Gazyvaro (Roche Products Ltd) ▼
  - Obinutuzumab 25 mg per 1 ml Gazyvaro 1000mg/40ml concentrate for solution for infusion vials | 1 vial [POW] £3,312.00 (Hospital only)
**Ofatumumab**

**INDICATIONS AND DOSE**
Treatment of chronic lymphocytic leukaemia (CLL) in patients refractory to fludarabine and alemtuzumab | Treatment of CLL in patients who have not received prior therapy and who are not eligible for fludarabine based therapy (in combination with chlorambucil or bendamustine)

- BY INTRAVENOUS INFUSION
- Adult: Premedication must be given 30 minutes to 2 hours before each dose—consult product literature for details

**CONTRA-INDICATIONS** For full details on the contra-indications for ofatumumab, consult product literature.

**CAUTIONS** History of cardiac disease—monitor closely and discontinue treatment if cardiac arrhythmias occur

**CAUTIONS, FURTHER INFORMATION** For full details about the cautions for ofatumumab, consult product literature

- Hepatitis B infection and reactivation: Hepatitis B infection and reactivation (including fatal cases) have been reported in patients taking ofatumumab. Patients with positive hepatitis B serology should be referred to a liver specialist for monitoring and initiation of antiviral therapy before treatment initiation; treatment should not be initiated in patients with evidence of current hepatitis B infection until the infection has been adequately treated. Patients should be closely monitored for clinical and laboratory signs of active hepatitis B infection during treatment and for up to a year following the last infusion (consult product literature).

**INTERACTIONS** → Appendix 1: monoclonal antibodies

**SIDE-EFFECTS**

**SIDE-EFFECTS, FURTHER INFORMATION** Infusion-related side-effects (including cytokine release syndrome) have been reported with ofatumumab; premedication with paracetamol, an antihistamine, and a corticosteroid must be given—consult product literature.

For full details (including monitoring and management of side-effects) consult product literature.

**CONCEPTION AND CONTRACEPTION** Use effective contraception during and for 12 months after treatment.

**PREGNANCY** Avoid unless potential benefit outweighs risk.

**BREAST FEEDING** Discontinue breast-feeding during and for 12 months after treatment—no information available.

**RENAL IMPAIRMENT** No information available for creatinine clearance less than 30 mL/minute.

**MONITORING REQUIREMENTS**
- Monitor electrolytes (including potassium and magnesium) before and during administration and correct if abnormal.
- Patients must be monitored closely during each infusion for the onset of infusion reactions.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**
- Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab (October 2010) NICE TA202

Ofatumumab is not recommended for the treatment of chronic lymphocytic leukaemia that is refractory to fludarabine and alemtuzumab.

Patients currently receiving ofatumumab for this condition should have the option to continue treatment until they and their clinician consider it appropriate to stop.

www.nice.org.uk/TA202

- Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia (June 2015) NICE TA344

Ofatumumab in combination with chlorambucil is an option for untreated chronic lymphocytic leukaemia only if:
- the person is ineligible for fludarabine-based therapy and
- bendamustine is not suitable and
- the manufacturer provides ofatumumab with the discount agreed in the patient access scheme.

Patients currently receiving ofatumumab that is not recommended according to the above criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop.

www.nice.org.uk/TA344

**Scottish Medicines Consortium (SMC) Decisions**
The Scottish Medicines Consortium has advised (April 2015) that ofatumumab (Arzerra®) is accepted for restricted use within NHS Scotland for the treatment of chronic lymphocytic leukaemia in patients who have not received prior therapy and who are not eligible for fludarabine-based therapy. It is restricted to use in patients who would not be considered for bendamustine therapy and who would receive chlorambucil-based therapy.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Solution for infusion**

**ELECTROLYTES:** May contain Sodium
- Arzerra (Novartis Pharmaceuticals UK Ltd)
  - Ofatumumab 20 mg per 1 ml Arzerra 100mg/5ml concentrate for solution for infusion vials | 3 vial(s) £54.00 (Hospital only)
  - Arzerra 1000mg/50ml concentrate for solution for infusion vials | 1 vial(s) £1,820.00 (Hospital only)
- Panitumumab
  - BY INTRAVENOUS INFUSION
  - Adult: (consult product literature)

**Panitumumab**

**DRUG ACTION** Panitumumab is a monoclonal antibody that binds to the epidermal growth factor receptor (EGFR).

**INDICATIONS AND DOSE**
Treatment of non-mutated RAS metastatic colorectal cancer (combination therapy) | Treatment of non-mutated RAS metastatic colorectal cancer (monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens)

- BY INTRAVENOUS INFUSION
- Adult: (consult product literature)

**IMPORTANT SAFETY INFORMATION**

**MHRA/CHM ADVICE: SEVERE SKIN REACTIONS**
Severe skin reactions have been reported very commonly in patients treated with panitumumab. Patients receiving panitumumab who have severe skin reactions or develop worsening skin reactions should be monitored for the development of inflammatory or infectious sequelae (including cellulitis, sepsis, and necrotising fasciitis). Appropriate treatment should be promptly initiated and panitumumab withheld or discontinued.

**MHRA/CHM ADVICE: EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS: SERIOUS CASES OF KERATITIS AND ULCERATIVE KERATITIS**

Keratitis and ulcerative keratitis have been reported following treatment with epidermal growth factor receptor (EGFR) inhibitors for cancer (cetuximab, erlotinib, gefitinib and panitumumab). In rare cases, this has resulted in corneal perforation and blindness. Patients undergoing treatment with EGFR inhibitors who present with acute or worsening signs and
symptoms suggestive of keratitis should be referred promptly to an ophthalmology specialist. Treatment should be interrupted or discontinued if ulcerative keratitis is diagnosed.

**CONTRA-INDICATIONS** Interstitial pulmonary disease - the combination of panitumumab with oxaliplatin-containing chemotherapy is contra-indicated in patients with mutant RAS metastatic colorectal cancer or for whom RAS status is unknown.

**CAUTIONS** History of keratitis - history of severe dry eye - history of ulcerative keratitis - pulmonary disease—discontinue if interstitial lung disease develops - risk factors for keratitis - risk factors for severe dry eye - risk factors for ulcerative keratitis (including contact lens use)

**INTERACTIONS** → Appendix 1: monoclonal antibodies

**SIDE-EFFECTS**
- **Common or very common** Anorexia - anxiety - back pain - biochemical disturbances - cellulitis - chills - cough - deep vein thrombosis - dyspepsia - dysphagia - electrolyte disturbances - epistaxis - eyelash growth - flushing - folliculitis - gastro-oesophageal reflux disease - hyperhydrosis - insulinoma - malaise - pain in extremities - peripheral oedema - pulmonary embolism - pyrexia - rectal haemorrhage - severe hypersensitivity reactions (possibly delayed) - urinary tract infection - weight loss
- **Uncommon** Bronchospasm - cyanosis - hirsutism - infusion-related reactions - nasal dryness
- **Rare** Keratitis - skin necrosis - Stevens-Johnson syndrome - toxic epidermal necrolysis

**CONCEPTION AND CONTRACEPTION** Manufacturer advises effective contraception during and for 6 months after treatment.

**PREGNANCY** Avoid (toxicity in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

** BREAST FEEDING** Manufacturer advises avoid breastfeeding during and for 2 months after treatment.

**PRE-TREATMENT SCREENING** Evidence of non-mutated RAS status (at exons 2, 3 and 4 of KRAS and NRAS) is required before panitumumab treatment is initiated, and should be determined by an experienced laboratory using a validated test method.

**MONITORING REQUIREMENTS**
- Monitor for hypomagnesaemia.
- Monitor for hypocalcaemia.
- Monitor for dermatological reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis (consult product literature).

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (Tas)**
- Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (January 2012) NICE TA242
Panitumumab monotherapy is not recommended for the treatment of patients with metastatic colorectal cancer that has progressed after first-line chemotherapy. www.nice.org.uk/TA242

**MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Solution for infusion**
- ELECTROLYTES: May contain Sodium
  - Vectibix (Amgen Ltd)
  - Panitumumab 20 mg per 1 ml
    - Vectibix 400mg/20ml concentrate for solution for infusion vials | 1 vial (PST) £1,517.16 (Hospital only)
  - Vectibix 100mg/5ml concentrate for solution for infusion vials | 1 vial (PST) £379.29 (Hospital only)

**Pembrolizumab**

**DRUG ACTION** Pembrolizumab is a monoclonal antibody, which binds to the programmed death-1 (PD-1) receptor, thereby potentiating an immune response to tumour cells.

**INDICATIONS AND DOSE**
- **Treatment of unresectable or metastatic advanced melanoma**
  - **BY INTRAVENOUS INFUSION**
  - **Adult:** 2 mg/kg every 3 weeks

**CAUTIONS** Patients may need pretreatment to minimise the development of adverse reactions (consult product literature)

**INTERACTIONS** → Appendix 1: monoclonal antibodies

**SIDE-EFFECTS**
- **Common or very common** Abdominal pain - alopecia - arthritis - blood dyscrasia - changes in hair colour - chills - colitis - constipation - cough - decreased appetite - depigmentation - diarrhoea - dizziness - dry eye - dry mouth - dry skin - eczema - erythema - headache - hepatitis - influenza-like symptoms - infusion-related reactions - insomnia - malaise - musculoskeletal pain - myositis - nausea - oedema - peripheral neuropathy - pneumonitis - pruritus - pyrexia - rash - shortness of breath - taste disturbances - thyroid dysfunction - vomiting
- **Rare** Guillain–Barré syndrome - myasthenic syndrome - small intestinal perforation

**SIDE-EFFECTS, FURTHER INFORMATION**
- Immune-related reactions: Most immune-related adverse reactions are reversible and managed by temporarily stopping treatment and administration of a corticosteroid—consult product literature for further information.
- Infusion-related reactions: Manufacturer advises to permanently discontinue treatment in patients with severe infusion reactions.

**CONCEPTION AND CONTRACEPTION** Manufacturer recommends effective contraception during treatment and for at least 4 months after treatment in women of childbearing potential.

**PREGNANCY** Manufacturer advises avoid unless potential benefit outweighs risk—no information available

** BREAST FEEDING** Manufacturer advises avoid—no information available.

**MONITORING REQUIREMENTS** Manufacturer advises monitor for signs and symptoms of infusion- and immune-related reactions.

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Keytruda®), give intermittently in Sodium chloride 0.9% or Glucose 5%. Reconstitute each 50 mg vial with 2.3 mL water for injection, to produce a 25 mg/mL solution. Gently swirl without shaking to dissolve, and allow up to 5 minutes for the bubbles to clear. Withdraw the required
818 Antibody responsive malignancy

handling and storage
Manufacturer advises store in a refrigerator at 2–8°C.

patient and carer advice
Patients should be provided with an alert card and advised to keep it with them at all times.

national funding/access decisions

NICe technology appraisals (TAs)

Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (October 2015) NICe TA357

Pembrolizumab is recommended as an option for treating advanced (unresectable or metastatic) melanoma only if:
- the disease has progressed with ipilimumab and, for BRAF V600 mutation-positive disease, a BRAF or MEK inhibitor and
- the manufacturer provides pembrolizumab with the discount agreed in the patient access scheme.

NICe.org.uk/guidance/TA357

Pembrolizumab for advanced melanoma not previously treated with ipilimumab (November 2015) NICe TA366

Pembrolizumab is recommended as an option for treating advanced (unresectable or metastatic) melanoma that has not been previously treated with ipilimumab, only if the manufacturer provides pembrolizumab with the discount agreed in the patient access scheme.

NICe.org.uk/guidance/TA366

Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (January 2017) NICe TA428

Pembrolizumab is recommended as an option for treating locally advanced or metastatic PD-L1-positive non-small-cell lung cancer in adults who have had at least one chemotherapy (and targeted treatment) if they have an epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive tumour, only if:
- pembrolizumab is stopped at 2 years of uninterrupted treatment and no documented disease progression, and
- the manufacturer provides pembrolizumab with the discount agreed in the patient access scheme, which has been revised in the context of this appraisal. Patients whose treatment was started within the NHS before this guidance was published should have the option to continue treatment, without change to their funding arrangements, until they or their clinician consider it appropriate to stop.

NICe.org.uk/guidance/TA428

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (November 2015) that pembrolizumab (Keytruda®) is accepted for use within NHS Scotland as monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults previously untreated with ipilimumab. The advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.

The Scottish Medicines Consortium has advised (December 2016) that pembrolizumab (Keytruda®) is not recommended for use within NHS Scotland as monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults previously treated with ipilimumab as the economic case was not demonstrated.

The Scottish Medicines Consortium has advised (January 2017) that pembrolizumab (Keytruda®) is accepted for restricted use within NHS Scotland for the treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express programmed death ligand 1 (PD-L1) and who have received at least one prior chemotherapy regimen, subject to a two-year clinical stopping rule. The advice is contingent upon the continuing availability of pembrolizumab at the price agreed in the patient access scheme in NHS Scotland or a list price that is equivalent or lower.

medicinal forms
There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for infusion

NICe.org.uk/guidance/TA428

Pembrolizumab 50 mg Keytruda 50mg powder for concentrate for solution for infusion vials | 1 vial (£815.00 (Hospital only)

Pertuzumab

Drug action
Pertuzumab is a recombinant humanised monoclonal antibody, and acts by inhibiting human epidermal growth factor receptor 2 protein (HER2) dimerisation.

indications and dose
Treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer in combination with trastuzumab and docetaxel, in patients who have not received previous anti-HER2 therapy or chemotherapy (initiated by a specialist)

By intravenous infusion

Adult: (consult product literature)

Caution
Conditions that could impair left ventricular function - history of congestive heart failure - impaired left ventricular function - prior anthracycline exposure - radiotherapy to the chest area - recent myocardial infarction - serious cardiac arrhythmia - uncontrolled hypertension

Interactions
Appendix 1: monoclonal antibodies

Side-effects
Common or very common

Uncommon
- Interstitial lung disease
- Frequency not known
- Alopecia - bone-marrow suppression • extravasation • hyperuricaemia • nausea • oral mucositis • thromboembolism • tumour lysis syndrome • vomiting

Side-effects, further information
Side effects mostly described for pertuzumab in combination with trastuzumab and docetaxel.

Conception and contraception
Ensure effective contraception during and for six months after treatment in women of childbearing potential.

Pregnancy
Avoid (toxicity in animal studies). Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester. Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.

Breast feeding
Avoid—no information available.

Hepatic impairment
Caution—no information available.

Renal impairment
Caution in severe impairment—no information available.

Monitoring requirements
Assess for signs and symptoms of congestive heart failure (including left ventricular ejection fraction) before and

818 Antibody responsive malignancy BNF 74

Immune system and malignant disease

downloaded from www.medicalbr.com
Monitor for febrile neutropenia.
- **DIRECTIONS FOR ADMINISTRATION** Resuscitation facilities should be available.
- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **NICE technology appraisals (TAs)**
    - Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (December 2016) NICE TA424
      Pertuzumab, in combination with trastuzumab and chemotherapy, is recommended, within its marketing authorisation, as an option for neoadjuvant treatment in adults with human epidermal growth factor receptor 2 (HER2-positive), locally advanced, inflammatory or early-stage breast cancer at high risk of recurrence, only if the manufacturer provides it with the discount agreed in the patient access scheme.
    - **Scottish Medicines Consortium (SMC) Decisions**
      - The Scottish Medicines Consortium (SMC) has advised (December 2016) that pertuzumab (Perjeta®) is not recommended for use within NHS Scotland in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence, as the economic case was not demonstrated.
- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
- **Solution for infusion**
  - **Perjeta** (Roche Products Ltd)
    - Pertuzumab 30 mg per 1 ml
  - **NICE TA424**
    - Adult: 8 mg/kg every 2 weeks, dose to be administered prior to FOLFIRI administration, consult product literature for dose adjustments due to side-effects and infusion-related reactions
    - Adult: 10 mg/kg on day 1 of a 21 day cycle, dose to be administered prior to docetaxel infusion, consult product literature for dose adjustments due to side-effects and infusion-related reactions

---

**Treatment of metastatic colorectal cancer, in combination with FOLFIRI (irinotecan, fluorouracil and folinic acid), in patients with disease progression on, or after, prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine**
- **BY INTRAVENOUS INFUSION**
  - Adult: 8 mg/kg every 2 weeks, dose to be administered prior to FOLFIRI administration, consult product literature for dose adjustments due to side-effects and infusion-related reactions

**Treatment of locally advanced or metastatic non-small cell lung cancer, in combination with docetaxel, in patients with disease progression after platinum-based chemotherapy**
- **BY INTRAVENOUS INFUSION**
  - Adult: 10 mg/kg on day 1 of a 21 day cycle, dose to be administered prior to docetaxel infusion, consult product literature for dose adjustments due to side-effects and infusion-related reactions

- **CAUTIONS** Elective surgery—discontinue treatment for at least 4 weeks prior to surgery; hypertension—must be controlled before initiation; impaired wound healing—discontinue treatment until wound fully healed; pre-treatment is recommended to minimise the development of adverse reactions (consult product literature) risk of bleeding
- **INTERACTIONS** → Appendix 1: monoclonal antibodies
- **SIDE-EFFECTS**
  - **Common or very common** Abdominal pain; diarrhoea; epistaxis; gastro-intestinal haemorrhage; headache; hypertension; hypoalbuminaemia; hypokalaemia; hyponatraemia; leucopenia; malaise; mucosal inflammation; neutropenia; palmar-plantar erythrodysoaesthesia syndrome; peripheral oedema; proteinuria; stomatitis; thrombocytopenia
  - **Frequency not known** Arterial thromboembolic events (permanently discontinue if severe); fistula (permanently discontinue); gastro-intestinal perforation (permanently discontinue); infusion-related reactions; intestinal obstruction; rash; sepsis (in combination with paclitaxel)
- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Infusion-related reactions Infusion-related hypersensitivity reactions have been reported with ramucirumab, particularly during or following the first or second infusion; if the patient experiences a grade 1 or 2 infusion-related reaction, the manufacturer advises to reduce rate of infusion by 50% and give premedication for all subsequent infusions—consult product literature. Manufacturer advises to permanently discontinue treatment in the event of a grade 3 or 4 infusion-related reaction.
  - **CONCEPTION AND CONTRACEPTION** Manufacturer advises effective contraception during treatment and for up to 3 months after treatment in women of childbearing potential.
  - **PREGNANCY** Manufacturer advises avoid unless potential benefit outweighs risk—no information available.
  - **BREAST FEEDING** Manufacturer advises discontinue breast-feeding during treatment and for at least 3 months after treatment—no information available.
  - **HEPATIC IMPAIRMENT** Manufacturer advises caution in severe cirrhosis, cirrhosis with hepatic encephalopathy, cirrhosis with clinically significant ascites, or hepatorenal syndrome—use only if potential benefit outweighs risk of progressive hepatic failure.
  - **MONITORING REQUIREMENTS** Manufacturer advises monitor for signs of infusion-related hypersensitivity reactions; monitor blood pressure prior to each infusion; monitor for development or worsening of proteinuria
during treatment—consult product literature; monitor blood counts and coagulation parameters in patients at risk of bleeding.

- **DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Cyramza®), give intermittently in Sodium chloride 0.9%; dilute requisite dose with infusion fluid to final volume of 250 mL and invert gently to mix. Do not exceed a rate of 25 mg/minute, and give over approximately 60 minutes via an infusion pump using a separate infusion line with a protein sparing 0.22 micron filter.

- **PRESCRIBING AND DISPENSING INFORMATION** For Cyramza®, each 10 mL vial contains sodium 17 mg (equivalent to Na⁺ 0.74 mmol).

- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **NICE technology appraisals (TAs)**
    - Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy (January 2016) NICE TA378
    - Ramucirumab alone or in combination with paclitaxel is not recommended for the treatment of advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy.
    - Patients whose treatment was started within the NHS before this guidance was published should have the option to continue treatment until they and their clinicians consider it appropriate to stop.
    - www.nice.org.uk/TA378

  - **Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (August 2016)** NICE TA403
    - Ramucirumab, in combination with docetaxel, is not recommended for treating locally advanced or metastatic non-small-cell lung cancer in patients whose disease has progressed after platinum-based chemotherapy.
    - Patients whose treatment was started within the NHS before this guidance was published should have the option to continue treatment, without change to their funding arrangements, until they and their clinicians consider it appropriate to stop.
    - www.nice.org.uk/TA403

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Solution for infusion**
    - **ELECTROLYTES:** May contain Sodium
      - **Cyramza** (Eli Lilly and Company Ltd)
        - Ramucirumab 10 mg per 1 ml: Cyramza 100 mg/10 ml concentrate for solution for infusion vials | 1 vial (£10.50) / £50.00 (Hospital only)
        - Cyramza 500 mg/50 ml concentrate for solution for infusion vials | 1 vial (£50.00) / £250.00 (Hospital only)

- **Rituximab**

  - **INDICATIONS AND DOSE**
    - Treatment of previously untreated stage III–IV follicular lymphoma (in combination with other chemotherapy) | Maintenance therapy in patients with follicular non-Hodgkin’s lymphoma that has responded to induction therapy (in combination with other chemotherapy) | Treatment of diffuse large B-cell non-Hodgkin’s lymphoma (in combination with other chemotherapy) | Treatment of chemotherapy-resistant or relapsed stage III–IV follicular non-Hodgkin’s lymphoma | Previously untreated or relapsed chronic lymphocytic leukaemia | Induction of remission in patients with severe, active granulomatosis with polyangiitis (Wegener’s) and microscopic polyangiitis (in combination with glucocorticoids)
    - **BY INTRAVENOUS INFUSION**
      - Adult: Patients should receive premedication before each dose (consult product literature for details)

  - **SIDE-EFFECTS, FURTHER INFORMATION**
    - Associated with infections, sometimes severe, including tuberculosis, sepsis, and hepatitis B reactivation.
For full details, including management of side-effects, consult product literature.

- **Progressive multifocal leucoencephalopathy**
  - Progressive multifocal leucoencephalopathy (which is usually fatal or causes severe disability) has been reported in association with rituximab; patients should be monitored for cognitive, neurological, or psychiatric signs and symptoms. If progressive multifocal leucoencephalopathy is suspected, suspend treatment until it has been excluded.

- **CONCEPTION AND CONTRACEPTION**
  - Effective contraception (in both sexes) required during and for 12 months after treatment.

- **PREGNANCY**
  - Avoid unless potential benefit to mother outweighs risk of B-lymphocyte depletion in fetus.

- **BREAST FEEDING**
  - Avoid breast-feeding during and for 12 months after treatment.

- **MONITORING REQUIREMENTS**
  - For full details on monitoring requirements consult product literature.

- **DIRECTIONS FOR ADMINISTRATION**
  - For intravenous infusion (MabThera®), give intermittently in Glucose 5% or Sodium chloride 0.9%; dilute to 1–4 mg/mL and gently invert bag to avoid foaming.

- **PATIENT AND CARER ADVICE**
  - Alert card: Patients treated for granulomatosis with polyangiitis and microscopic polyangiitis or rheumatoid arthritis should be provided with a patient alert card with each infusion.

- **NATIONAL FUNDING/ACCESS DECISIONS**

  - **NICE technology appraisals (TAs)**
    - **Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (March 2014)** NICE TA308
      - This NICE guidance was issued for rituximab by intravenous infusion. Rituximab, in combination with glucocorticoids, is recommended as an option for inducing remission in adults with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (severely active granulomatosis with polyangiitis [Wegener’s] and microscopic polyangiitis), only if:
        - further cyclophosphamide treatment would exceed the maximum cumulative cyclophosphamide dose, or
        - cyclophosphamide is contra-indicated or not tolerated, or
        - the patient has not completed their family, and
        - treatment with cyclophosphamide may materially affect their fertility, or
        - the disease has remained active or progressed despite a course of cyclophosphamide lasting 3–6 months or
        - the patient has had uroepithelial malignancy.
      - [www.nice.org.uk/TA308](http://www.nice.org.uk/TA308)

    - **Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (August 2010)** NICE TA195
      - Rituximab, in combination with methotrexate, is an option for the treatment of severe active rheumatoid arthritis in adults who have had an inadequate response to, or are intolerant of, other disease-modifying antirheumatic drugs (DMARDs), including at least 1 tumour necrosis factor (TNF) inhibitor. Repeat courses of rituximab should be given no more frequently than every 6 months, and should only be continued if an adequate response is achieved and maintained.
      - [www.nice.org.uk/TA195](http://www.nice.org.uk/TA195)

    - **Rituximab for the first-line treatment of stage III-IV follicular lymphoma (January 2012)** NICE TA243
      - This NICE guidance was issued for rituximab by intravenous infusion. Rituximab, in combination with:
        - cyclophosphamide, vincristine and prednisolone (CVP); or
        - cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP); or
        - mitoxantrone, chlorambucil and prednisolone (MCP); or
        - cyclophosphamide, doxorubicin, etoposide, prednisolone and interferon-alpha (CHVP); or
        - chlorambucil is recommended as an option for the treatment of symptomatic stage III and IV follicular lymphoma in previously untreated patients.
      - [www.nice.org.uk/TA243](http://www.nice.org.uk/TA243)

- **Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma (February 2008)** NICE TA137

  - This NICE guidance was issued for rituximab by intravenous infusion. Rituximab, in combination with chemotherapy, is an option for the induction of remission in patients with relapsed stage III or IV follicular non-Hodgkin’s lymphoma.

  - Rituximab monotherapy as maintenance therapy is an option for the treatment of patients with relapsed stage III or IV follicular non-Hodgkin’s lymphoma in remission induced with chemotherapy (with or without rituximab).

  - Rituximab monotherapy is an option for the treatment of patients with relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma, when all alternative treatment options have been exhausted (that is, if there is resistance to or intolerance of chemotherapy).

  - [www.nice.org.uk/TA137](http://www.nice.org.uk/TA137)

- **Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (July 2010)** NICE TA193

  - This NICE guidance was issued for rituximab by intravenous infusion. Rituximab in combination with fludarabine and cyclophosphamide is recommended as a treatment option for people with relapsed or refractory chronic lymphocytic leukaemia except when the condition:
    - is refractory to fludarabine (that is, it has not responded to fludarabine, or has relapsed within 6 months of treatment), or
    - has previously been treated with rituximab, unless it was in the context of a clinical trial, at a dose lower than the dose currently licensed for chronic lymphocytic leukaemia or with chemotherapy other than fludarabine and cyclophosphamide.

  - Rituximab in combination with fludarabine and cyclophosphamide is recommended only in the context of research for patients with relapsed or refractory chronic lymphocytic leukaemia that has previously been treated with rituximab, unless rituximab has been given as specified above.

  - [www.nice.org.uk/TA193](http://www.nice.org.uk/TA193)

- **Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma (June 2011)** NICE TA226

  - This NICE guidance was issued for rituximab by intravenous infusion. Rituximab maintenance therapy is recommended as an option for the treatment of people with follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab in combination with chemotherapy.

  - [www.nice.org.uk/TA226](http://www.nice.org.uk/TA226)

- **Rituximab for the first-line treatment of chronic lymphocytic leukaemia (July 2009)** NICE TA174

  - This NICE guidance was issued for rituximab by intravenous infusion. Rituximab, in combination with fludarabine and cyclophosphamide, is recommended as an option for the first-line treatment of chronic lymphocytic leukaemia.

  - [www.nice.org.uk/TA174](http://www.nice.org.uk/TA174)

- **Idelalisib for treating chronic lymphocytic leukaemia (October 2015)** NICE TA359

  - Rituximab, in combination with idelalisib, is recommended as an option for treatment in adults:
    - who have untreated chronic lymphocytic leukaemia or
822 Antibody responsive malignancy

- who have chronic lymphocytic leukaemia when the disease has been treated but has relapsed within 24 months and
- if the manufacturer provides idelalisib with the discount agreed in the simple discount agreement.

Patients who are already receiving idelalisib should continue treatment until they or their clinician consider it appropriate to stop.

www.nice.org.uk/guidance/TA359

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (August 2013) that Rituximab (MabThera®) is accepted for restricted use within NHS Scotland, in combination with glucocorticoids for the induction of remission in adult patients with severe, active granulomatosis with polyangitis (Wegener's) and microscopic polyangiitis. It is restricted to use in patients who have relapsed following treatment with cyclophosphamide or who are intolerant to or unable to receive cyclophosphamide.

The Scottish Medicines Consortium has advised (June 2014) that subcutaneous rituximab (MabThera®) is accepted for restricted use within NHS Scotland, in accordance with UK licensing, except in the maintenance setting, where use is restricted to patients who have responded to induction therapy with rituximab plus chemotherapy.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for infusion**

- MabThera (Roche Products Ltd)
  - Rituximab 10 mg per 1 ml MabThera 100mg/10ml concentrate for solution for infusion vials | 2 vial (Pom) £349.25
  - MabThera 500mg/50ml concentrate for solution for infusion vials | 1 vial (Pom) £873.15

**Siltuximab**

**DRUG ACTION**

Siltuximab is a monoclonal antibody that inhibits interleukin-6 receptor binding.

**INDICATIONS AND DOSE**

Treatment of multicentric Castleman’s disease (MCD) in patients who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative

- BY INTRAVENOUS INFUSION

- Adult: 11 mg/kg every 3 weeks

**CAUTIONS**

Patients at increased risk of gastrointestinal perforation—promptly investigate those presenting with symptoms suggestive of gastrointestinal perforation • severe infection— withhold treatment until resolved • treatment prior to treatment

**CAUTIONS, FURTHER INFORMATION**

- Hypersensitivity reactions Infusion-related side-effects are reported commonly with siltuximab; resuscitation facilities should be available during treatment.
  - Consult product literature for further information about siltuximab cautions.

**INTERACTIONS**

→ Appendix 1: monoclonal antibodies

**SIDE-EFFECTS**

- Common or very common Infusion related side effects
  - Frequency not known Abdominal pain • anaphylaxis • hepatitis B reactivation • hypersensitivity reactions • hypertension • hypertriglyceridaemia • hypoglycaemia • increased haemoglobin levels • infections • localised oedema • maculopapular rash • nasopharyngitis • neutropenia • pruritus • renal impairment • thrombocytopenia • upper respiratory tract infection • weight gain

**SIDE-EFFECTS, FURTHER INFORMATION**

Infusion-related side effects Siltuximab therapy should be discontinued permanently in the event of a severe infusion-related reaction, anaphylaxis, a severe allergic reaction, or the occurrence of cytokine-release syndrome. Mild to moderate infusion-related reactions may improve by temporarily reducing the rate or stopping the infusion. When restarting treatment, a reduced infusion rate and the administration of antihistamines, paracetamol, and corticosteroids should be considered. Consider discontinuation of siltuximab if more than 2 doses are delayed due to treatment-related toxicities during the first 48 weeks—for full details consult product literature.

**CONCEPTION AND CONTRACEPTION**

Women of childbearing potential should use effective contraception during and for 3 months after treatment.

**PREGNANCY**

Manufacturer advises avoid unless potential benefit outweighs risk.

**BREAST FEEDING**

Manufacturer advises avoid—no information available.

**HEPATIC IMPAIRMENT**

Use with caution in hepatic impairment.

**MONITORING REQUIREMENTS**

- Monitor neutrophil and platelet count, and haemoglobin levels prior to each dose of siltuximab treatment for the first 12 months and thereafter prior to every third dosing cycle. Consider delaying treatment if required neutrophil, platelet, and haemoglobin levels not achieved—consult product literature for details.

- Monitor for infection during treatment.

**DIRECTIONS FOR ADMINISTRATION**

For intravenous infusion (Sylvant®), give intermittently in Glucose 5%. Allow vials to reach room temperature over approximately 30 minutes, then reconstitute each 100 mg vial with 5.2 mL of water for injection, and each 400 mg vial with 20 mL of water for injection, to produce a 20 mg/mL solution. Gently swirl without shaking to dissolve. Further dilute to 250 mL with glucose 5% and gently mix. Use within 6 hours of dilution and give over 60 minutes using an administration set lined with polyvinyl chloride or polyurethane, through a low-protein binding in-line 0.2 micron filter.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for infusion**

- Sylvant (Janssen-Cilag Ltd)
  - Siltuximab 100 mg Sylvant 100mg powder for concentrate for solution for infusion vials | 1 vial (Pom) £415.00 (Hospital only)
  - Siltuximab 400 mg Sylvant 400mg powder for concentrate for solution for infusion vials | 1 vial (Pom) £1,661.00 (Hospital only)
Trastuzumab

**INDICATIONS AND DOSE**

Treatment of early breast cancer which overexpresses human epidermal growth factor receptor-2 (HER2) (initiated by a specialist) | Treatment of metastatic breast cancer in patients with HER2-positive tumours who have not received chemotherapy for metastatic breast cancer and in whom anthracycline treatment is inappropriate (in combination with paclitaxel or docetaxel) (initiated by a specialist) | Treatment of metastatic breast cancer in postmenopausal patients with hormone-receptor positive HER2-positive tumours not previously treated with trastuzumab (in combination with an aromatase inhibitor)  

**CONTRA-INDICATIONS** Severe dyspnoea at rest

**CAUTIONS** Coronary artery disease | history of hypertension | symptomatic heart failure | uncontrolled arrhythmias

**SIDE-EFFECTS** Acne | alopecia | anaphylaxis | angioedema | anxiety | arthralgia | arthritis | asthenia | bone pain | bone marrow suppression | cardiotoxicity | chest pain | chills | depression | dizziness | drowsiness | dry eye | dry skin | ecchymosis | extravasation | fever | gastrointestinal symptoms | headache | hepatitis | hypersensitivity reactions | hypertension | hyperthermia | hyperuricaemia | hypotension | increased lacrimation | infection | infusion-related side-effects (possibly delayed onset) | insomnia | leg cramps | malaise | mastitis | myalgia | nail disorders | nausea | oedema | oral mucositis | paraesthesia | paresis | peripheral neuropathy | pruritus | pulmonary events (possibly delayed onset) | rash | sweating | taste disturbance | thromboembolism | tremor | tumour lysis syndrome | urticaria | vomiting | weight loss

**CONCEPTION AND CONTRACEPTION** Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**PREGNANCY** Manufacturer advises avoid—oligohydramnios reported. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**BREAST FEEDING** Avoid breast-feeding during treatment and for 7 months afterwards.

**MONITORING REQUIREMENTS** Cardiotoxicity | Monitor cardiac function before and during treatment—for details of monitoring and managing cardiotoxicity, consult product literature.

**DIRECTIONS FOR ADMINISTRATION** Resuscitation facilities should be available during administration of trastuzumab.

**PRESCRIBING AND DISPENSING INFORMATION** When prescribing, dispensing or administering, check that this is the correct preparation—trastuzumab is not interchangeable with trastuzumab emtansine.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (June 2012) NICE TA257
  
- Lapatinib or trastuzumab in combination with an aromatase inhibitor is not recommended for first-line treatment in postmenopausal women of metastatic hormone-receptor-positive breast cancer that overexpresses human epidermal growth factor receptor 2 (HER2).

  Postmenopausal women currently receiving lapatinib or trastuzumab in combination with an aromatase inhibitor for this indication should have the option to continue treatment until they and their clinician consider it appropriate to stop. www.nice.org.uk/TA257

- Guidance on the use of trastuzumab for the treatment of advanced breast cancer (March 2002) NICE TA34

  Trastuzumab in combination with paclitaxel is recommended as an option for patients with tumours expressing human epidermal growth factor receptor 2 (HER2) scored at levels of 3+ who have not received chemotherapy for metastatic breast cancer, and in whom anthracycline treatment is inappropriate.

  Trastuzumab monotherapy is recommended as an option for patients with tumours expressing HER2 scored at levels of 3+ who have received at least two chemotherapy regimens for metastatic breast cancer. Prior chemotherapy must have included at least an anthracycline and a taxane where these treatments are appropriate. It should also have included hormonal therapy in suitable oestrogen-receptor-positive patients. www.nice.org.uk/TA34

- Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (August 2006) NICE TA107

  Trastuzumab, given at 3-week intervals for 1 year or until disease recurrence (whichever is the shorter period), is recommended as an option for women with early-stage HER2-positive breast cancer following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable). www.nice.org.uk/TA107

- Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (November 2010) NICE TA208

  Trastuzumab in combination with cisplatin and capecitabine or fluorouracil is recommended for human epidermal growth factor receptor-2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction in patients who:

  - have not received treatment for metastatic disease and
  - have tumours expressing high levels of HER2 as defined by a positive immunohistochemistry score of 3. www.nice.org.uk/TA208

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (December 2013) that subcutaneous trastuzumab injection (Herceptin®) is accepted for restricted use within NHS Scotland for the treatment of adults with HER2 positive metastatic breast cancer and early breast cancer, when used within licensed indications excluding use in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive metastatic breast cancer, not previously treated with trastuzumab.

The Scottish Medicines Consortium has advised (September 2015) that trastuzumab solution for infusion
**824 Antibody responsive malignancy**

(Herceptin®) is accepted for restricted use within NHS Scotland in combination with capecitabine or fluorouracil and cisplatin for the treatment of patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction, who have not received prior anti-cancer treatment for their metastatic disease. It is restricted to patients with metastatic gastric cancer whose tumours have HER2 over-expression, as determined by an accurate and validated assay.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Solution for injection**
    - Herceptin (Roche Products Ltd)
      - Trastuzumab 120 mg per 1 ml Herceptin 600mg/5ml solution for injection vials | 1 vial (PoS) £1222.20 (Hospital only)
  - **Powder for solution for infusion**
    - Herceptin (Roche Products Ltd)
      - Trastuzumab 150 mg Herceptin 150mg powder for solution for infusion vials | 1 vial (PoS) £407.40

- **Trastuzumab emtansine 15-Apr-2016**

- **DRUG ACTION**
  - Trastuzumab emtansine is an antibody-drug conjugate that contains trastuzumab covalently linked to DM1, a cytotoxic microtubule inhibitor.

- **INDICATIONS AND DOSE**
  - Monotherapy for the treatment of HER2-positive, unresectable, locally advanced or metastatic breast cancer, in adult patients who have previously received trastuzumab and a taxane separately or in combination (initiated by a specialist)
  - Monotherapy for the treatment of HER2-positive, unresectable, locally advanced or metastatic breast cancer, in adult patients who have developed disease recurrence during or within 6 months of completing adjuvant therapy (initiated by a specialist)

- **BY INTRAVENOUS INFUSION**
  - Adult: (consult product literature or local protocols)

- **CAUTIONS**
  - Dyspnoea at rest—increased risk of pulmonary events: history of congestive heart failure, patients over 75 years, peripheral neuropathy (temporarily discontinue treatment—consult product literature: recent history of myocardial infarction: recent history of unstable angina: risk of left ventricular dysfunction—consult product literature for specific risks with trastuzumab treatment: serious arrhythmias

- **INTERACTIONS**
  - Appendix 1: monoclonal antibodies

- **SIDE-EFFECTS**
  - **Common or very common**
    - Abdominal pain
    - Arthralgia
    - Blurred vision
    - Chills
    - Conjunctivitis
    - Constipation
    - Cough
    - Diarrhoea
    - Dizziness
    - Dry eye
    - Dry mouth
    - Dysgeusia
    - Dyspepsia
    - Dyspnoea
    - Epistaxis
    - Gingival bleeding
    - Haemorrhage
    - Hand-foot syndrome
    - Headache
    - Hypersensitivity
    - Hypokalaemia
    - Increased lactic acidosis
    - Infusion-related reactions
    - Insomnia
    - Left ventricular dysfunction
    - Malaise
    - Memory impairment
    - Myalgia: nail disorder
    - Peripheral neuropathy
    - Peripheral oedema
    - Pruritus
    - Pyrexia
    - Rash
    - Thrombocytopenia
    - Urinary tract infection
    - Urticaria
  - **Uncommon**
  - **Frequency not known**
    - Alopecia
    - Bone-marrow suppression
    - Extravasation
    - Hyperuricaemia
    - Nausea: oral mucositis: thromboembolism: tumour lysis syndrome: vomiting

- **CONCEPTION AND CONTRACEPTION**
  - Effective contraception must be used during and for 6 months after stopping treatment in women and men.

- **PREGNANCY**
  - Manufacturer advises avoid—oligohydranmios reported with trastuzumab. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

- **BREAST FEEDING**
  - Manufacturer advises avoid—feeding during and for 6 months after treatment.

- **HEPATIC IMPAIRMENT**
  - Consult product literature for dose modification in cases of abnormal liver function tests.

- **RENAL IMPAIRMENT**
  - No information available—manufacturer advises caution in severe impairment.

- **MONITORING REQUIREMENTS**
  - Monitor hepatic function before each dose.
  - Monitor for signs and symptoms of neurotoxicity.
  - Monitor closely for infusion-related and hypersensitivity reactions.
  - Monitor platelet count before each dose and as clinically indicated (consult product literature for treatment modification in thrombocytopenia).
  - Test cardiac function before treatment and regularly during treatment—delay or discontinue treatment in cases of left ventricular dysfunction.
  - Monitor for dyspnoea, cough: fatigue and pulmonary infiltrates—discontinue if interstitial lung disease or pneumonitis confirmed (fatal cases reported).

- **DIRECTIONS FOR ADMINISTRATION**
  - Resuscitation facilities should be available during administration of trastuzumab emtansine.

- **PRESCRIBING AND DISPENSING INFORMATION**
  - When prescribing, dispensing or administering, check that this is the correct preparation—trastuzumab emtansine and trastuzumab are not interchangeable.

- **NATIONAL FUNDING/ACCESS DECISIONS**
  - NICE technology appraisals (TAs)
    - Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane (December 2015) NICE TA371
    - Trastuzumab emtansine is not recommended for treating adults with human epidermal growth factor 2 (HER2) positive, unresectable locally advanced or metastatic breast cancer previously treated with trastuzumab and a taxane.
    - www.nice.org.uk/TA371

- **Scottish Medicines Consortium (SMC) Decisions**
  - The Scottish Medicines Consortium has advised (April 2017) that trastuzumab emtansine (Kadcyla®) is accepted for use within NHS Scotland as monotherapy for the treatment of patients with human epidermal growth factor type 2 (HER2)-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination, and have either received prior therapy for locally advanced or metastatic disease or developed disease recurrence during or within six months of completing adjuvant therapy. This advice is contingent on the continuing availability of the Patient Access Scheme in NHS Scotland or a list price that is equivalent or lower.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Powder for solution for infusion**
    - Kadcyla (Roche Products Ltd)
      - Trastuzumab emtansine 100 mg Kadcyla 100mg powder for concentrate for solution for infusion vials | 1 vial (PoS) £1,641.01
      - Trastuzumab emtansine 160 mg Kadcyla 160mg powder for concentrate for solution for infusion vials | 1 vial (PoS) £2,625.62
2 Cytotoxic responsive malignancy

Cytotoxic drugs

Overview
The chemotherapy of cancer is complex and should be confined to specialists in oncology. Cytotoxic drugs have both anti-cancer activity and the potential to damage normal tissue; most cytotoxic drugs are teratogenic. Chemotherapy may be given with a curative intent or it may aim to prolong life or to palliate symptoms. In an increasing number of cases chemotherapy may be combined with radiotherapy or surgery or both as either neoadjuvant treatment (initial chemotherapy aimed at shrinking the primary tumour, thereby rendering local therapy less destructive or more effective) or as adjuvant treatment (which follows definitive treatment of the primary disease, when the risk of subclinical metastatic disease is known to be high). All cytotoxic drugs cause side-effects and a balance has to be struck between likely benefit and acceptable toxicity.

Combinations of cytotoxic drugs, as continuous or pulsed cycles of treatment, are frequently more toxic than single drugs but have the advantage in certain tumours of enhanced response, reduced development of drug resistance and increased survival. However for some tumours, single-agent chemotherapy remains the treatment of choice.

Cytotoxic drugs fall into a number of classes, each with characteristic antitumour activity, sites of action, and toxicity. A knowledge of sites of metabolism and excretion is important because impaired drug handling as a result of disease is not uncommon and may result in enhanced toxicity.

Guidelines for handling cytotoxic drugs
- Trained personnel should reconstitute cytotoxics
- Reconstitution should be carried out in designated pharmacy areas
- Protective clothing (including gloves, gowns, and masks) should be worn
- The eyes should be protected and means of first aid should be specified
- Pregnant staff should avoid exposure to cytotoxic drugs (all females of child-bearing age should be informed of the reproductive hazard)
- Use local procedures for dealing with spillages and safe disposal of waste material, including syringes, containers, and absorbent material
- Staff exposure to cytotoxic drugs should be monitored

Intrathecal chemotherapy
A Health Service Circular (HSC 2008/001) provides guidance on the introduction of safe practice in NHS Trusts where intrathecal chemotherapy is administered; written local guidance covering all aspects of national guidance should be available. Support for training programmes is also available. Copies, and further information may be obtained from: Department of Health PO Box 777 London SE1 6XH Fax: 01623 724524 It is also available from the Department of Health website (www.dh.gov.uk).

Safe systems for cytotoxic medicines
NHS cancer networks have been established across the UK to bring together all stakeholders in all sectors of care, to work collaboratively to plan and deliver high quality cancer services for a given population. NHS cancer networks have websites containing information on local chemotherapy services and treatment.

Safe system requirements:
- cytotoxic drugs for the treatment of cancer should be given as part of a wider pathway of care coordinated by a multidisciplinary team
- cytotoxic drugs should be prescribed, dispensed, and administered only in the context of a written protocol or treatment plan
- injectable cytotoxic drugs should only be dispensed if they are prepared for administration
- oral cytotoxic medicines should be dispensed with clear directions for use

IMPORTANT SAFETY INFORMATION
RISK OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES
The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.
- non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;
- staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.

Doses
Doses of cytotoxic drugs are determined using a variety of different methods including body-surface area or body-weight. Alternatively, doses may be fixed. Doses may be further adjusted following consideration of a patient’s neutrophil count, renal and hepatic function, and history of previous adverse effects to the cytotoxic drug. Doses may also differ depending on whether a drug is used alone or in combination.

Because of the complexity of dosage regimens in the treatment of malignant disease, dose statements have been omitted from some of the drug entries in this chapter. However, even where dose statements have been provided, detailed specialist literature, individual hospital chemotherapy protocols, or local cancer networks should be consulted before prescribing, dispensing, or administering cytotoxic drugs.

Prescriptions should not be repeated except on the instructions of a specialist.

Side-effects of cytotoxic drugs
Side-effects common to most cytotoxic drugs are discussed below whilst side-effects characteristic of a particular drug or class of drugs (e.g. neurotoxicity with vinca alkaloids) are mentioned in the appropriate sections. Manufacturers’ product literature, hospital-trust protocols, and cancer-network protocols should be consulted for full details of side-effects associated with individual drugs and specific chemotherapy regimes.

Many side-effects of cytotoxic drugs often do not occur at the time of administration, but days or weeks later. It is therefore important that patients and healthcare professionals can identify symptoms that cause concern and can contact an expert for advice. Toxicities should be
accurately recorded using a recognised scoring system such as the Common Toxicity Criteria for Adverse Events (CTCAE) developed by the National Cancer Institute.

Extravasation of intravenous drugs
A number of cytotoxic drugs will cause severe local tissue necrosis if leakage into the extravascular compartment occurs. To reduce the risk of extravasation injury it is recommended that cytotoxic drugs are administered by appropriately trained staff. See information on the prevention and management of extravasation injury.

Oral mucositis
A sore mouth is a common complication of cancer chemotherapy; it is most often associated with fluorouracil p. 842, methotrexate p. 844, and the anthracyclines. It is best to prevent the complication. Good oral hygiene (rinsing the mouth frequently and effective brushing of the teeth with a soft brush 2–3 times daily) is probably beneficial. For fluorouracil p. 842, sucking ice chips during short infusions of the drug is also helpful.

Once a sore mouth has developed, treatment is much less effective. Saline mouthwashes should be used but there is no good evidence to support the use of antiseptic or anti-inflammatory mouthwashes. In general, mucositis is self-limiting but with poor oral hygiene it can be a focus for blood-borne infection.

Tumour lysis syndrome
Tumour lysis syndrome occurs secondary to spontaneous or treatment-related rapid destruction of malignant cells. Patients at risk of tumour lysis syndrome include those with non-Hodgkin’s lymphoma (especially if high grade and bulky disease), Burkitt’s lymphoma, acute lymphoblastic leukaemia and acute myeloid leukaemia (particularly if high white blood cell counts or bulky disease), and occasionally those with solid tumours. Pre-existing hyperuricaemia, dehydration, and renal impairment are also predisposing factors. Features include hyperkalaemia, hyperuricaemia (see below), and hyperphosphataemia with hypocalcaemia; renal damage and arrhythmias can follow. Early identification of patients at risk, and initiation of prophylaxis or therapy for tumour lysis syndrome, is essential.

Hyperuricaemia
Hyperuricaemia, which may be present in high-grade lymphoma and leukaemia, can be markedly worsened by chemotherapy and is associated with acute renal failure. Allopurinol p. 1021 should be started 24 hours before treating such tumours and patients should be adequately hydrated. The dose of mercaptopurine p. 844 or azathioprine p. 787 should be reduced if allopurinol needs to be given concomitantly. Febuxostat p. 1021 may also be used and should be started 2 days before cytotoxic therapy is initiated.

Rasburicase p. 870, a recombinant urate oxidase, is licensed for hyperuricaemia in patients with haematological malignancy. It rapidly reduces plasma-uric acid concentration and may be of particular value in preventing complications following treatment of leukaemias or bulky lymphomas.

Bone-marrow suppression
All cytotoxic drugs except vincristine sulfate p. 858 and bleomycin p. 849 cause bone-marrow suppression. This commonly occurs 7 to 10 days after administration, but is delayed for certain drugs, such as carmustine p. 529, lomustine p. 832, and melphalan p. 833. Peripheral blood counts must be checked before each treatment, and doses should be reduced or therapy delayed if bone-marrow has not recovered.

Cytotoxic drugs may be contra-indicated in patients with acute infection; any infection should be treated before, or when starting, cytotoxic drugs.

Fever in a neutropenic patient (neutrophil count less than 1.06 × 10^9/litre) requires immediate broad-spectrum antibacterial therapy. Appropriate bacteriological investigations should be conducted as soon as possible. Patients taking cytotoxic drugs who have signs or symptoms of infection should be advised to seek prompt medical attention. All patients should initially be investigated and treated under the supervision of the appropriate oncology or haematology specialist.

In selected patients, the duration and the severity of neutropenia can be reduced by the use of recombinant human granulocyte-colony stimulating factors. Symptomatic anaemia is usually treated with red blood cell transfusions. For guidance on the use of erythropoietins in patients with cancer, see MHRA/CHM advice and NICE guidance.

See advice on the use of live vaccines in individuals with impaired immune response, see Vaccines.

Alopecia
Reversible hair loss is a common complication, although it varies in degree between drugs and individual patients. No pharmacological methods of preventing this are available.

Thromboembolism
Venous thromboembolism can be a complication of cancer itself, but chemotherapy increases the risk.

Pregnancy and reproductive function
Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester. Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.

Exclude pregnancy before treatment with cytotoxic drugs. Contraceptive advice should be given before cytotoxic therapy begins—women of childbearing age should use effective contraception during and after treatment.

Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.

Nausea and vomiting
Nausea and vomiting cause considerable distress to many patients who receive chemotherapy and to a lesser extent abdominal radiotherapy, and may lead to refusal of further treatment; prophylaxis of nausea and vomiting is therefore extremely important. Symptoms may be acute (occurring within 24 hours of treatment), delayed (first occurring more than 24 hours after treatment), or anticipatory (occurring occurring prior to subsequent doses). Delayed and anticipatory symptoms are more difficult to control than acute symptoms and require different management.

Patients vary in their susceptibility to drug-induced nausea and vomiting; those affected more often include women, patients under 50 years of age, anxious patients, and those who experience motion sickness. Susceptibility also increases with repeated exposure to the cytotoxic drug. Drugs may be divided according to their emetogenic potential and some examples are given below, but the symptoms vary according to the dose, to other drugs administered and to the individual’s susceptibility to emetogenic stimuli.

Mildly emetogenic treatment—fluorouracil, etoposide p. 853, methotrexate p. 844 (less than 100 mg/m^2, low dose
in children), the vinca alkaloids, and abdominal radiotherapy.

**Moderately emetogenic treatment**—the taxanes, doxorubicin hydrochloride p. 835, intermediate and low doses of cyclophosphamide p. 830, mitoxantrone p. 837, and high doses of methotrexate (0.1 – 1.2 g/m²).

**Highly emetogenic treatment**—cisplatin p. 852, dacarbazine p. 831, and high doses of cyclophosphamide.

**Prevention of acute symptoms**
For patients at low risk of emesis, pretreatment with dexamethasone p. 635 or lorazepam p. 322 may be used.
For patients at high risk of emesis, a SHT3-receptor antagonist, usually given by mouth in combination with dexamethasone and the neurokinin receptor antagonist aprepitant p. 412 is effective.

**Prevention of delayed symptoms**
For delayed symptoms associated with moderately emetogenic chemotherapy, a combination of dexamethasone and SHT3-receptor antagonist is effective; for highly emetogenic chemotherapy, a combination of dexamethasone and aprepitant is effective. Metoclopramide hydrochloride p. 411 is also licensed for delayed chemotherapy-induced nausea and vomiting.

**Prevention of anticipatory symptoms**
Good symptom control is the best way to prevent anticipatory symptoms. Lorazepam can be helpful for its amnesic, sedative, and anxiolytic effects.

**Treatment for cytotoxic-induced side effects**

** Anthracycline side-effects**

**Anthracycline-induced cardiotoxicity**
The anthracycline cytotoxic drugs are associated with dose-related, cumulative, and potentially life-threatening cardiotoxic side-effects.

**Anthracycline extravasation**
Local guidelines for the management of extravasation should be followed or specialist advice sought.

See further information on the prevention and management of extravasation injury.

**Chemotherapy-induced mucositis and myelosuppression**
Folinic acid p. 869 (given as calcium folinate) is used to counteract the folate-antagonist action of methotrexate p. 844 and thus speed recovery from methotrexate-induced mucositis or myelosuppression (‘folinic acid rescue’).

Folinic acid is also used in the management of methotrexate overdose, together with other measures to maintain fluid and electrolyte balance, and to manage possible renal failure.

Folinic acid does not counteract the antibacterial activity of folate antagonists such as trimethoprim p. 542.

When folinic acid and fluorouracil p. 842 are used together in metastatic colorectal cancer the response-rate improves compared to that with fluorouracil alone.

The calcium salt of levofoolic acid p. 870, a single isomer of folinic acid, is also used for rescue therapy following methotrexate administration, for cases of methotrexate overdose, and for use with fluorouracil for colorectal cancer. The dose of calcium levofoilate is generally half that of calcium folinate.

The disodium salts of folinic acid and levofoolic acid are also used for rescue therapy following methotrexate therapy, and for use with fluorouracil for colorectal cancer.

**Urothelial toxicity**
Haemorrhagic cystitis is a common manifestation of urothelial toxicity which occurs with the oxazaphosphorines, cyclophosphamide p. 830 and ifosfamide p. 832; it is caused by the metabolite acrolein. Mesna p. 869 reacts specifically with this metabolite in the urinary tract, preventing toxicity. Mesna is used routinely (preferably by mouth) in patients receiving ifosfamide, and in patients receiving cyclophosphamide by the intravenous route at a high dose (e.g. more than 2 g) or in those who experienced urothelial toxicity when given cyclophosphamide previously.

**Antimetrabolics**
Antimetabolites are incorporated into new nuclear material or combine irreversibly with cellular enzymes, preventing normal cellular division.

**Alkylating drugs**
Extensive experience is available with these drugs, which are among the most widely used in cancer chemotherapy. They act by damaging DNA, thus interfering with cell replication. Cyclophosphamide is used mainly in combination with other agents for treating a wide range of malignancies, including some leukaemias, lymphomas, and solid tumours.
It is given by mouth or intravenously; it is inactive until metabolised by the liver.
Ifosfamide is related to cyclophosphamide and is given intravenously.
Melphalan p. 833 is licensed for the treatment of multiple myeloma, polycythaemia vera, childhood neuroblastoma, advanced ovarian adenocarcinoma, and advanced breast cancer. However, in practice, melphalan is rarely used for ovarian adenocarcinoma; it is no longer used for advanced breast cancer. Melphalan is also licensed for regional arterial perfusion in localised malignant melanoma of the extremities and localised soft-tissue sarcoma of the extremities.

Lomustine p. 832 is a lipid-soluble nitrosourea and the drug is given at intervals of 4 to 6 weeks.

Carmustine implants are also licensed for high-grade recurrent glioblastoma multiforme as an adjunct to surgery. Carmustine implants are also given to patients with multiple myeloma, non-Hodgkin’s lymphomas, and brain tumours. Carmustine implants are licensed for intralesional use in adults for the treatment of recurrent glioblastoma multiforme as an adjunct to surgery. Carmustine implants are also licensed for high-grade malignant glioma as adjunctive treatment to surgery and radiotherapy.

Estramustine phosphate p. 831 is a combination of an oestrogen and chlormethine used predominantly in prostate cancer. It is given by mouth and has both an antimitotic effect and (by reducing testosterone concentration) a hormonal effect.

Mitobronitol is occasionally used to treat chronic myeloid leukaemia; it is available on a named-patient basis from specialist importing companies.

**ANTINEOPLASTIC DRUGS > ALKYLATED AGENTS**

### Bendamustine hydrochloride

- **INDICATIONS AND DOSE**
  - Treatment of chronic lymphocytic leukaemia | Treatment of non-Hodgkin's lymphoma | Treatment of multiple myeloma
  - **BY INTRAVENOUS INFUSION**
    - **Adult:** (consult local protocol)

- **CONTRA-INDICATIONS**
  - Jaundice • low leucocyte count • low platelet count • major surgery less than 30 days before start of treatment • severe bone marrow suppression

- **CAUTIONS**
  - Avoid in Acute porphyrias p. 969 • cardiac disorders—monitor serum potassium and ECG

- **INTERACTIONS**
  - **Appendix 1:** alkylating agents

- **SIDE-EFFECTS**
  - Common or very common
    - Amenorrhea • angina • anorexia • arthralgias • chills • constipation • dehydration • diarrhoea • electrolyte disturbances • haemorrhage • hypertension • hypokalaemia • hypotension • infection • insomnia • malaise • pain • palpitation • pyrexia • respiratory dysfunction
  - Uncommon
    - Pericardial effusion
  - Rare
    - Acute circulatory failure • drowsiness • sweating • voice changes
  - Very rare
    - Anticholinergic syndrome • ataxia • cardiac failure • encephalitis • haemolysis • multiple organ failure • myocardial infarction • neurological disorders • paraesthesia • peripheral neuropathy • phlebitis • pulmonary fibrosis • tachycardia • taste disturbance
  - Frequency not known
    - Alopecia • bone-marrow suppression • extravasation • hyperuricaemia • male sterility • nausea • oral mucositis • premature menopause • secondary malignancy • Stevens-Johnson syndrome • thromboembolism • toxic epidermal necrolysis • tumour lysis syndrome • vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

- Secondary malignancy
  - Prolonged use of alkylating drugs, particularly when combined with extensive irradiation, is associated with a marked increase in the incidence of acute non-lymphocytic leukaemia.

- **CONCEPTION AND CONTRACEPTION**
  - Effective contraception is required during treatment in men or women, and for 6 months after treatment in men. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

- **PREGNANCY**
  - Avoid (teratogenic and mutagenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

- **BREAST FEEDING**
  - Discontinue breast-feeding.

- **HEPATIC IMPAIRMENT**
  - Consider a 30% dose reduction in moderate impairment. Avoid in severe impairment.

- **RENAL IMPAIRMENT**
  - No information available on use in patients with creatinine clearance less than 10 mL/minute.

- **NATIONAL FUNDING/ACCESS DECISIONS**

  **NICE technology appraisals (TAs)**
  - Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (February 2011) NICE TA216
  - Bendamustine is recommended as an option for the treatment of chronic lymphocytic leukaemia in patients for whom fludarabine combination chemotherapy is not appropriate.
  - [www.nice.org.uk/TA216](http://www.nice.org.uk/TA216)

  **Scottish Medicines Consortium (SMC) Decisions**
  - The Scottish Medicines Consortium has advised (March 2011) that bendamustine (Levact®) is accepted for restricted use within NHS Scotland for the treatment of chronic lymphocytic leukaemia in patients for whom fludarabine combination chemotherapy is not appropriate.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  **Powder for solution for infusion**
  - **Bendamustine hydrochloride (Non-proprietary)**
    - Bendamustine hydrochloride 25 mg
      - Bendamustine 25mg powder for concentrate for solution for infusion vials | 1 vial (Pom) £6.85–£65.98 | 5 vial (Pom) £312.53–£347.26 (Hospital only) | 20 vial (Pom) £1,241.14 (Hospital only)
    - Bendamustine hydrochloride 100 mg
      - Bendamustine 100mg powder for concentrate for solution for infusion vials | 1 vial (Pom) £27.77–£262.02 | 5 vial (Pom) £1,241.14–£1,379.04 (Hospital only)
    - **Levact** (Napp Pharmaceuticals Ltd)
      - Bendamustine hydrochloride 25 mg
        - Levact 25mg powder for concentrate for solution for infusion vials | 5 vial (Pom) £347.26 (Hospital only)
      - Bendamustine hydrochloride 100 mg
        - Levact 100mg powder for concentrate for solution for infusion vials | 5 vial (Pom) £1,379.04 (Hospital only)

### Busulfan

**Busulphan**

- **INDICATIONS AND DOSE**
  - Chronic myeloid leukaemia, induction of remission
    - **BY MOUTH**
      - Adult: 60 micrograms/kg daily (max. per dose 4 mg); maintenance 0.5–2 mg daily
  - Conditioning treatment before haematopoietic progenitor cell transplantation
    - **BY MOUTH, OR BY INTRAVENOUS INFUSION**
      - Adult: (consult local protocol)
  - Conditioning treatment before haematopoietic progenitor cell transplantation in patients who are candidates for a reduced-intensity conditioning (RIC) regimen
    - **BY INTRAVENOUS INFUSION**
      - Adult: (consult local protocol)
DOSES AT EXTREMES OF BODY-WEIGHT
Dose may need to be calculated based on body surface area or adjusted ideal body weight in obese patients—consult product literature.

IMPORTANT SAFETY INFORMATION
RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES
See Cytotoxic drugs p. 825.

● CAUTIONS Avoid in Acute porphyrias p. 969 · high dose (anti-epileptic prophylaxis required) · history of seizures (anti-epileptic prophylaxis required) · ineffective once in blast crisis phase · previous progenitor cell transplant (increased risk of hepatic veno-occlusive disease) · previous radiation therapy (increased risk of hepatic veno-occlusive disease) · risk of second malignancy · three or more cycles of chemotherapy (increased risk of hepatic veno-occlusive disease)

● INTERACTIONS Appendix 1: alkylating agents

● SIDE-EFFECTS

GENERAL SIDE-EFFECTS

● Common or very common Cardiac tamponade in thalassaemia · hepatic fibrosis · hepatic veno-occlusive disease · hepatotoxicity · hyperbilirubinaemia · jaundice · pneumonia · skin hyperpigmentation
● Rare Aplastic anaemia · seizures · visual disturbances
● Very rare Gynaecomastia · myasthenia gravis

● Frequency not known Alopecia · bone-marrow suppression · hyperuricaemia · irreversible bone-marrow aplasia · lung toxicity · male sterility · nausea · oral mucositis · premature menopause · secondary malignancy · thromboembolism · tumour lysis syndrome · vomiting

SPECIFIC SIDE-EFFECTS

● With intravenous use Extravasation

SIDE-EFFECTS, FURTHER INFORMATION

● Lung toxicity Discontinue if lung toxicity develops.
● Secondary malignancy Prolonged use of alkylating drugs, particularly when combined with extensive irradiation, is associated with a marked increase in the incidence of acute non-lymphocytic leukaemia.

● CONCEPTION AND CONTRACEPTION Manufacturers advise effective contraception during treatment in men or women. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

● PREGNANCY Avoid (teratogenic and embryotoxic in animals). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

● BREAST FEEDING Discontinue breast-feeding.

● NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

● Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (June 2007) NICE TA121 Carmustine implants are an option for the treatment of newly diagnosed high-grade (Grade 3 or 4) glioma only for patients in whom at least 90% of the tumour has been resected. Carmustine implants should only be used within specialist centres.

www.nice.org.uk/TA121

● MEDICIAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

● Busulfan (Non-proprietary)
  Busulfan 2 mg Busulfan 2mg tablets | 25 tablet £69.02

Solution for infusion

● BusilveX (Pierre Fabre Ltd)
  Busulfan 6 mg per 1 ml BusilveX 60mg/10ml concentrate for solution for infusion ampoules | 8 ampoule £1,610.00 (Hospital only)
Chlorambucil

- **INDICATIONS AND DOSE**
  - Some lymphomas and chronic leukaemias (used either alone or in combination therapy)
    - **BY MOUTH**
    - Adult: (consult local protocol)

**IMPORTANT SAFETY INFORMATION**

**RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES**

See Cytotoxic drugs p. 825.

- **CAUTIONS**
  - Avoid in Acute porphyrias p. 969· children with nephrotic syndrome (increased seizure risk)· history of epilepsy (increased seizure risk)
- **INTERACTIONS** → Appendix 1: alkylating agents
- **SIDE-EFFECTS**
  - Uncommon Skin rash
  - Very rare Male sterility (in prepubertal and pubertal males)
  - Frequency not known Alopecia· bone-marrow suppression· hyperuricaemia· nausea· oral mucositis· premature menopause· secondary malignancy· Stevens-Johnson syndrome· thromboembolism· toxic epidermal necrolysis· tumour lysis syndrome· vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

- Secondary malignancy Prolonged use of alkylating drugs, particularly when combined with extensive irradiation, is associated with a marked increase in the incidence of acute non-lymphocytic leukaemia.
- Skin reactions If a rash occurs further chlorambucil is contra-indicated and cyclophosphamide is substituted.
- **CONCEPTION AND CONTRACEPTION**
  - Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 825.
- **PREGNANCY**
  - Avoid. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.
- **BREAST FEEDING**
  - Discontinue breast-feeding.
- **HEPATIC IMPAIRMENT**
  - Manufacturer advises consider dose reduction in severe impairment—limited information available.
- **NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Otinubuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (June 2015) NICE TA343
  - Otinubuzumab, in combination with chlorambucil, is an option for untreated chronic lymphocytic leukaemia in patients who have comorbidities that make full-dose fludarabine-based therapy unsuitable for them, only if:
    - bendamustine-based therapy is not suitable and
    - the manufacturer provides otinubuzumab with the discount agreed in the patient access scheme.
  - Patients currently receiving obinutuzumab that is not recommended according to the above criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop. www.nice.org.uk/TA344

- Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia (June 2015) NICE TA344
  - Ofatumumab in combination with chlorambucil is an option for untreated chronic lymphocytic leukaemia only if:
    - the person is ineligible for fludarabine-based therapy and
    - bendamustine is not suitable and
    - the manufacturer provides ofatumumab with the discount agreed in the patient access scheme.

**Cyclophosphamide**

- **INDICATIONS AND DOSE**
  - Rheumatoid arthritis with severe systemic manifestations
    - **BY MOUTH**
    - Adult: 1–1.5 mg/kg daily
  - Severe systemic rheumatoid arthritis / Other connective tissue diseases (especially with active vasculitis)
    - **BY INTRAVENOUS INJECTION**
    - Adult: 0.5–1 g every 2 weeks, then reduced to 0.5–1 g every month, frequency adjusted according to clinical response and haematological monitoring. To be given with prophylactic mesna
  - Used, mainly in combination with other agents for treating a wide range of malignancies, including some leukaemias, lymphomas, and solid tumours
    - **BY MOUTH, OR BY INTRAVENOUS INFUSION**
    - Adult: (consult local protocol)

- **UNLICENSED USE**
  - Not licensed for rheumatoid arthritis with severe systemic manifestations.

**IMPORTANT SAFETY INFORMATION**

**RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES**

See Cytotoxic drugs p. 825.

- **CONTRA-INDICATIONS**
  - Haemorrhagic cystitis
- **CAUTIONS**
  - Avoid in Acute porphyrias p. 969· diabetes mellitus· previous or concurrent mediastinal irradiation—risk of cardiotoxicity
- **INTERACTIONS** → Appendix 1: alkylating agents
- **SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**

- Common or very common Anorexia· cardiotoxicity at high doses· disturbances of carbohydrate metabolism· inappropriate secretion of anti-diuretic hormone· interstitial pulmonary fibrosis· pancreatitis· pigmentation of nails· pigmentation of palms· pigmentation of soles· urothelial toxicity
- Rare Hepatotoxicity· renal dysfunction
- Frequency not known Alopecia· bone-marrow suppression· haemorrhagic cystitis· hyperuricaemia· male sterility· nausea· oral mucositis· premature menopause· secondary malignancy· thromboembolism· tumour lysis syndrome· vomiting

**SPECIFIC SIDE-EFFECTS**

- With intravenous use Extravasation

**SIDE-EFFECTS, FURTHER INFORMATION**

- Haemorrhagic cystitis A urinary metabolite of cyclophosphamide, acrolein, can cause haemorrhagic cystitis; this is a rare but serious complication; increased fluid intake for 24–48 hours after intravenous injection, can prevent this complication. When high-dose therapy (e.g. more than 2 g intravenously) is used or when the patient is considered to be at high risk of cystitis (e.g. because of pelvic irradiation), mesna (given initially

Patients currently receiving ofatumumab that is not recommended according to the above criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop. www.nice.org.uk/TA344
intravenously then by mouth) can also help prevent cystitis.

- Secondary malignancy  Prolonged use of alkylating drugs, particularly when combined with extensive irradiation, is associated with a marked increase in the incidence of acute non-lymphocytic leukaemia.

**CONCEPTION AND CONTRACEPTION**  Manufacturer advises effective contraception during and for at least 3 months after treatment in men or women. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

- **PREGNANCY**  Avoid. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.
- **BREAST FEEDING**  Discontinue breast-feeding.
- **HEPATIC IMPAIRMENT**  Dose reduction may be required in combined renal and hepatic impairment. Avoid in severe impairment.
- **RENAI IMPAIRMENT**  Dose reduction may be required in combined renal and hepatic impairment. Avoid in severe impairment.

**INDICATIONS AND DOSE**

**Prostate cancer**

- **BY MOUTH**
  - Adult: Initially 560–840 mg daily in divided doses; maintenance 140–1400 mg daily in divided doses

**IMPORTANT SAFETY INFORMATION**

**RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES**

See Cytotoxic drugs p. 825.

- **CONTRA-INDICATIONS**  Peptic ulceration - severe cardiovascular disease  - thromboembolic disorders
- **CAUTIONS**  Avoid in Acute porphyrias p. 969  - cardiovascular disease  - cerebrovascular disease - conditions which might be aggravated by fluid retention (such as epilepsy or migraine)  - congestive heart failure  - diabetes  - hypercalcaemia  - hypertension
- **INTERACTIONS**  → Appendix 1: alkylating agents
- **SIDE-EFFECTS**
  - Rare  Angioedema
  - **Frequency not known**  Alopecia  - bone-marrow suppression  - extravasation  - hyperuricaemia  - myelosuppression  - oral mucositis  - severe nausea  - severe vomiting  - tumour lysis syndrome  - vomiting

**Dacarbazine**

- **INDICATIONS AND DOSE**
  - **Metastatic melanoma**  |  **Soft-tissue sarcomas (combination therapy)**  |  **Hodgkin’s disease (combination therapy)**
  - **BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION**
  - **Adult:** (consult local protocol)

- **CAUTIONS**  Caution in handling—irritant to tissues
- **INTERACTIONS**  → Appendix 1: alkylating agents
- **SIDE-EFFECTS**
  - Rare  Irritant to skin  - irritant to tissues  - liver necrosis due to hepatic vein thrombosis
  - **Frequency not known**  Alopecia  - bone-marrow suppression  - extravasation  - hyperuricaemia  - myelosuppression  - oral mucositis  - severe nausea  - severe vomiting  - tumour lysis syndrome  - vomiting

**CONCEPTION AND CONTRACEPTION**  Ensure effective contraception during and for at least 6 months after treatment in men or women. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**PRECAUTIONS**  → Appendix 1: alkylating agents

**DIRECTIONS FOR ADMINISTRATION**

- For **intravenous infusion**  (cyclophosphamide injection; **Baxter**)
  - **Give via drip tubing in Glucose 5% or Sodium chloride 0.9%**; reconstitute 1 g with 50 mL sodium chloride 0.9%.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, oral suspension, oral solution, solution for injection, solution for infusion

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS 25, 27**
  - **Cyclophosphamide (Non-proprietary)**
    - Cyclophosphamide (as Cyclophosphamide monohydrate) 50 mg: Cyclophosphamide 50mg tablets  |  100 tablet  [POM] £139.00
  - **Cytoxan** (Imported (United States))
    - **Cyclophosphamide 25 mg**  |  Cytoxan 25mg tablets  |  100 tablet  [POM] no price available

**Powder for solution for injection**

- **Cyclophosphamide (Non-proprietary)**
  - **Cyclophosphamide (as Cyclophosphamide monohydrate)**
    - 500 mg: Cyclophosphamide 500mg powder for solution for injection vials  |  1 vial  [POM] £9.66
    - 1 gram: Cyclophosphamide 1g powder for solution for injection vials  |  1 vial  [POM] £17.91
  - **Cyclophosphamide (as Cyclophosphamide monohydrate)**
    - 2 gram: Cyclophosphamide 2g powder for solution for injection vials  |  1 vial  [POM] £34.12

**Powder for solution for infusion**

- **Cyclophosphamide (Non-proprietary)**
  - **Cyclophosphamide (as Cyclophosphamide monohydrate)**
    - 500 mg: Cyclophosphamide 500mg powder for solution for infusion vials  |  1 vial  [POM] £9.66
    - 100 mg: Cyclophosphamide 100mg powder for solution for infusion vials  |  1 vial  [POM] £9.66

**Powder for solution for infusion (cytoxan)**

- **Cytoxan** (Imported): Cyclophosphamide 25 mg: Cyclophosphamide 25mg vials  |  500 mg  [POM] £19.95

**Estramustine phosphate**

- **INDICATIONS AND DOSE**
  - **Prostate cancer**
    - **BY MOUTH**
      - Adult: Initially 560–840 mg daily in divided doses; maintenance 140–1400 mg daily in divided doses
### Ifosfamide

#### INDICATIONS AND DOSE

**Malignant disease**
- BY INTRAVENOUS INFUSION
- Adult: (consult local protocol)

#### CONTRA-INDICATIONS

- Acute infection · urinary-tract infection · urinary-tract obstruction · urothelial damage

#### CAUTIONS

- Avoid in Acute porphyrias p. 969 · diabetes mellitus

#### INTERACTIONS

- Appendix 1: alkylating agents

#### SIDE-EFFECTS

- Common or very common: Confusion · disorientation · drowsiness · psychosis · renal toxicity (may lead to tubular dysfunction, Fanconi’s syndrome, or diabetes insipidus) · restlessness · urothelial toxicity
- Uncommon: Severe encephalopathy
- Rare: Anorexia · constipation · convulsions · diarrhoea
- Very rare: Jaundice · syndrome of inappropriate antidiuretic hormone secretion · thrombophlebitis

#### Frequency not known

- Acute pancreatitis · alopecia · arrhythmias · bone-marrow suppression · extravasation · heart failure · hyperuricaemia · male sterility · nausea · oral mucositis · premature menopause · secondary malignancy · thromboembolism · tumour lysis syndrome · vomiting

#### SIDE-EFFECTS, FURTHER INFORMATION

- Urothelial toxicity: Mesna is routinely given with ifosfamide to reduce urothelial toxicity.
- Secondary malignancy: Prolonged use of alkylating drugs, particularly when combined with extensive irradiation, is associated with a marked increase in the incidence of acute non-lymphocytic leukaemia.

#### CONCESSION AND CONTRACEPTION

- Manufacturer advises adequate contraception during and for at least 6 months after treatment in men or women. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

#### PREGNANCY

- Avoid (teratogenic and carcinogenic in animals). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

#### BREAST FEEDING

- Discontinue breast-feeding.

#### MEDICINAL FORMS

- There can be variation in the licensing of different medicines containing the same drug.

#### Powder for solution for injection

- **Ifosfamide (Non-proprietary)**
  - **Ifosfamide 1 gram** Ifosfamide 1g powder for concentrate for solution for injection vials | 1 vial [POSM] £19.32
  - **Ifosfamide 2 gram** Ifosfamide 2g powder for concentrate for solution for injection vials | 1 vial [POSM] £17.88

### Lomustine

#### DRUG ACTION

Lomustine is a lipid-soluble nitrosourea.

#### INDICATIONS AND DOSE

- **Hodgkin’s disease resistant to conventional therapy**
- **Malignant melanoma**
- **Certain solid tumours**

- BY MOUTH
  - Adult: 120–130 mg/m² every 6–8 weeks, dose is for when lomustine is used alone

#### IMPORTANT SAFETY INFORMATION

**RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES**

See Cytotoxic drugs p. 825.

#### CONTRA-INDICATIONS

- Coeliac disease

#### CAUTIONS

- Avoid in Acute porphyrias p. 969

#### INTERACTIONS

- Appendix 1: alkylating agents

#### SIDE-EFFECTS

- Alopecia · bone-marrow suppression (delayed) · hyperuricaemia · male sterility · nausea · oral mucositis · permanent bone marrow damage (with prolonged use) · premature menopause · secondary malignancy · thromboembolism · tumour lysis syndrome · vomiting

#### SIDE-EFFECTS, FURTHER INFORMATION

- Secondary malignancy: Prolonged use of alkylating drugs, particularly when combined with extensive irradiation, is associated with a marked increase in the incidence of acute non-lymphocytic leukaemia.

#### CONCEPTION AND CONTRACEPTION

- Manufacturer advises effective contraception during and for at least 6 months after treatment in men or women. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

#### PREGNANCY

- Avoid. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

#### BREAST FEEDING

- Discontinue breast-feeding.

#### MEDICATIONS

- Avoid in severe impairment. In hepatic impairment, manufacturer advises regular liver function tests.

#### HEPATIC IMPAIRMENT

- Manufacturer advises caution.

#### RENAL IMPAIRMENT

- Manufacturer advises caution.

#### DIRECTIONS FOR ADMINISTRATION

- Each dose should be taken not less than 1 hour before or 2 hours after meals and should not be taken with products containing calcium, magnesium or aluminium, including dairy products and antacid medication.

#### PATIENT AND CARER ADVICE

- Patients should be given advice on how to administer estramustine capsules.

#### MEDICINAL FORMS

- There can be variation in the licensing of different medicines containing the same drug.

#### Capsule

- **CAUTIONARY AND ADVISORY LABELS 5, 23**
  - Estracyt (Pfizer Ltd)
    - Estramustine phosphate (as Estramustine sodium phosphate)
      - 140 mg Estracyt 140mg capsules | 100 capsule [POSM] £171.28

### Appendix 1

The brand name CCNU® has been used for lomustine capsules.
Melphalan

**INDICATIONS AND DOSE**

Multiple myeloma
- **BY MOUTH**
  - Adult: 150 micrograms/kg daily for 4 days, dose to be repeated every 6 weeks, dose may vary according to regimen
- **BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
  - Adult: (consult product literature)

Polycythaemia vera
- **BY MOUTH**
  - Adult: Initially 6–10 mg daily for 5–7 days, then reduced to 2–4 mg daily until satisfactory response, then reduced to 2–6 mg once weekly

Localised malignant melanoma of the extremities
- **BY REGIONAL ARTERIAL PERFUSION**
  - Adult: (consult local protocol)

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**
- Rare
  - Intestinal pneumatosis
  - Life threatening pulmonary fibrosis
- Frequency not known
  - Alopecia
  - Bone-marrow suppression (delayed)
  - Hyperuricaemia
  - Male sterilisation
  - Nausea
  - Oral mucositis
  - Premature menopause
  - Secondary malignancy
  - Thromboembolism
  - Tumour lysis syndrome
  - Vomiting

**SPECIFIC SIDE-EFFECTS**
- With intravenous use
  - Extravasation

**INTERACTIONS**
- Monitor liver function before treatment initiation, after each treatment cycle and midway through treatment cycles
- Monitor bone-marrow suppression

**CONCESSION AND CONTRACEPTION**
- Manufacturer advises adequate contraception during treatment. Men should avoid fathering a child during and for at least 6 months after treatment. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**PRECAUTIONS**
- Avoid. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**CAUTIONS**
- Avoid in Acute porphyrias p. 969
- **INTERACTIONS**
  - Appendix 1: alkylating agents

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder and solvent for solution for injection**
- **Melphalan (Non-proprietary)**
  - Melphalan (as Melphalan hydrochloride) 50 mg
  - Melphalan 50 mg powder and solvent for solution for injection vials
  - 1 vial
  - **£137.37**

**Tablet**
- **Melphalan (Non-proprietary)**
  - Melphalan 2 mg
  - Melphalan 2 mg tablets
  - 25 tablet
  - **£45.38 DT**
  - price = £45.38

Temozolomide

**DRUG ACTION**
- Temozolomide is structurally related to dacarbazine.

**INDICATIONS AND DOSE**
- Newly diagnosed glioblastoma multiforme in adults (in combination with radiotherapy) and subsequently as monotherapy
- Second-line treatment of malignant glioma in adults
  - **BY MOUTH**
  - Adult: (consult product literature)

**IMPORTANT SAFETY INFORMATION**

**RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES**
- See Cytotoxic drugs p. 825.

**CAUTIONS**
- Pneumocystis jirovecii pneumonia—consult product literature for monitoring and prophylaxis requirements

**INTERACTIONS**
- Appendix 1: alkylating agents

**SIDE-EFFECTS**
- Alopecia
- Bone-marrow suppression
- Hyperuricaemia
- Nausea
- Oral mucositis
- Thromboembolism
- Tumour lysis syndrome
- Vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**
- For further information on side-effects consult product literature.

**CONCESSION AND CONTRACEPTION**
- Manufacturer advises adequate contraception during treatment. Men should avoid fathering a child during and for at least 6 months after treatment. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**PRECAUTIONS**
- Avoid (teratogenic and embryotoxic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**CAUTIONS**
- Discontinue breast-feeding.

**HEPATIC IMPAIRMENT**
- Use with caution in severe impairment—no information available.

**RENAI IMPAIRMENT**
- Manufacturer advises caution—no information available.

**MONITORING REQUIREMENTS**
- Monitor liver function before treatment initiation, after each treatment cycle and midway through 42-day treatment cycles—consider the balance of benefits and risks of treatment if results are abnormal at any point (fateful liver injury reported).
- Monitor for myelodysplastic syndrome.
- Monitor for secondary malignancies.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**
  - Temozolomide may be considered for the treatment of recurrent malignant glioma, which has not responded to first-line chemotherapy.
  - www.nice.org.uk/TA23

- Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (June 2007) NICE TA121
  - Temozolomide is an option for the treatment of newly diagnosed glioblastoma multiforme in patients with a WHO performance status of 0 or 1.
  - www.nice.org.uk/TA121

downloaded from www.medicalbr.com
**Immune system and malignant disease**

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Capsule**

CAUTIONARY AND ADVISORY LABELS 23, 25

▶ **Temozolomide (Non-proprietary)**
  - Temozolomide 5 mg Temozolomide 5mg capsules | 5 capsule 
    
  | POM £16.00
  - Temozolomide 20 mg Temozolomide 20mg capsules | 5 capsule 
    
  | POM £65.00
  - Temozolomide 100 mg Temozolomide 100mg capsules | 5 capsule 
    
  | POM £225.00
  - Temozolomide 140 mg Temozolomide 140mg capsules | 5 capsule 
    
  | POM £465.00
  - Temozolomide 180 mg Temozolomide 180mg capsules | 5 capsule 
    
  | POM £580.00
  - Temozolomide 250 mg Temozolomide 250mg capsules | 5 capsule 
    
  | POM £821.75

▶ **Temodal (Merck Sharp & Dohme Ltd)**
  - Temozolomide 5 mg Temozol 5mg capsules | 5 capsule 
    
  | POM £10.59 (Hospital only)
  - Temozolomide 20 mg Temozal 20mg capsules | 5 capsule 
    
  | POM £42.35 (Hospital only)
  - Temozolomide 100 mg Temozol 100mg capsules | 5 capsule 
    
  | POM £211.77 (Hospital only)
  - Temozolomide 140 mg Temozal 140mg capsules | 5 capsule 
    
  | POM £451.40
  - Temozolomide 180 mg Temozal 180mg capsules | 5 capsule 
    
  | POM £590.37
  - Temozolomide 250 mg Temozal 250mg capsules | 5 capsule 
    
  | POM £860.08

▶ **Temomedac (medac UK)**
  - Temozolomide 5 mg Temodal 5mg capsules | 5 capsule 
    
  | POM £16.12
  - Temozolomide 20 mg Temodal 20mg capsules | 5 capsule 
    
  | POM £64.49
  - Temozolomide 100 mg Temodal 100mg capsules | 5 capsule 
    
  | POM £322.43
  - Temozolomide 140 mg Temodal 140mg capsules | 5 capsule 
    
  | POM £451.40
  - Temozolomide 180 mg Temodal 180mg capsules | 5 capsule 
    
  | POM £590.37
  - Temozolomide 250 mg Temodal 250mg capsules | 5 capsule 
    
  | POM £860.08

**Breastfeeding** Discontinue breast-feeding.

**National funding/access decisions**

The **Scottish Medicines Consortium (SMC) Decisions**

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (June 2012) that thiopeta (Tepadina®) is not recommended for use within NHS Scotland in combination with other chemotherapy as conditioning treatment in adults or children with haematological diseases, or solid tumours prior to haematopoietic stem cell transplantation.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for infusion**

▶ **Tepadina (Adieenne Pharma & Biotech)**
  - Thiopeta 15 mg Tepadina 15mg powder for concentrate for solution for infusion vials | 1 vial 
    
  | no price available
  - Thiopeta 100 mg Tepadina 100mg powder for concentrate for solution for infusion vials | 1 vial 
    
  | no price available

**Temozolomide (Non-proprietary)**

▶ **Thiotepa**

**INDICATIONS AND DOSE**

Ovarian cancer

▶ BY MOUTH, OR BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION, OR BY INTRAPERITONEAL INSTALLATION

▶ Adult: (consult product literature)

**INTERACTIONS**

▶ Appendix 1: alkylating agents

**SIDE-EFFECTS**

▶ Common or very common Skin pigmentation

▶ Rare Allergic alveolitis · haemorrhagic cystitis · pulmonary fibrosis

▶ Frequency not known Alopecia · bone-marrow suppression · extravasation of intravenous drugs · hyperuricaemia · nausea · oral mucositis · premature menopause · secondary malignancy · thromboembolism · tumour lysis syndrome · vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

▶ Secondary malignancy Prolonged use of alkylyating drugs, particularly when combined with extensive irradiation, is associated with a marked increase in the incidence of acute non-lymphocytic leukaemia.

**Conception and contraception** Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**Pregnancy** Avoid. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**Breastfeeding** Discontinue breast-feeding.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

CAUTIONARY AND ADVISORY LABELS 25

▶ **Treosulfan (Non-proprietary)**
  - Treosulfan 250 mg Treosulfan 250mg capsules | 100 capsule 
    
  | POM £622.10–£653.20

**Powder for solution for injection**

▶ **Treosulfan (Non-proprietary)**
  - Treosulfan 1 gram Treosulfan 1g powder for solution for injection vials | 5 vial 
    
  | POM £269.17
  - Treosulfan 5 gram Treosulfan 5g powder for solution for injection vials | 5 vial 
    
  | POM £1,040.17

**Thiotepa**

**INDICATIONS AND DOSE**

Conditioning treatment before haematopoietic stem cell transplantation in the treatment of haematological disease or solid tumours, in combination with other chemotherapy

▶ BY INTRAVENOUS INFUSION

▶ Adult: (consult local protocol)

**CAUTIONS**

Avoid in Acute porphyrias p. 969

**INTERACTIONS**

▶ Appendix 1: alkylating agents

**SIDE-EFFECTS**

▶ Alopecia · bone-marrow suppression · extravasation of intravenous drugs · hyperuricaemia · male sterility · nausea · oral mucositis · premature menopause · secondary malignancy · thromboembolism · tumour lysis syndrome · vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

▶ Secondary malignancy Prolonged use of alkylyating drugs, particularly when combined with extensive irradiation, is associated with a marked increase in the incidence of acute non-lymphocytic leukaemia.

**Conception and contraception** Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**Pregnancy** Avoid. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**Breastfeeding** Discontinue breast-feeding.
ANTINEOPLASTIC DRUGS › ANTHRACYCLINES AND RELATED DRUGS

Daunorubicin

**INDICATIONS AND DOSE**

Acute myelogenous leukaemia | Acute lymphocytic leukaemia

- **BY INTRAVENOUS INFUSION**
  - Adult: (consult local protocol)

Advanced AIDS-related Kaposi’s sarcoma (liposomal formulation only)

- **BY INTRAVENOUS INFUSION**
  - Adult: (consult product literature)

**CONTRA-INDICATIONS** Myocardial insufficiency - previous treatment with maximum cumulative doses of daunorubicin or other anthracycline - recent myocardial infarction - severe arhythmia

**CAUTIONS** Caution in handling—irritant to tissues

**INTERACTIONS** → Appendix 1: anthracyclines

**SIDE-EFFECTS** Alopecia - bone-marrow suppression - extravasation - hyperuricaemia - nausea - oral mucositis - thromboembolism - tumour lysis syndrome - vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

Cardiotoxicity All anthracycline antibiotics have been associated with varying degrees of cardiac toxicity—this may be idiosyncratic and reversible, but is commonly related to total cumulative dose and is irreversible

**CONCEPTION AND CONTRACEPTION** Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**PREGNANCY** Avoid (teratogenic and carcinogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**BREAST FEEDING** Discontinue breast-feeding.

**HEPATIC IMPAIRMENT** Reduce dose according to serum bilirubin concentration—consult local protocol for details. Avoid in severe impairment.

**RENAL IMPAIRMENT** Reduce dose by 25% if serum creatinine 105–265 micromol/litre. Reduce dose by 50% if serum creatinine greater than 265 micromol/litre. Avoid in severe impairment.

**MONITORING REQUIREMENTS** Cardiac monitoring essential.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Emulsion for infusion**

- DaunoXome (Galen Ltd)
  - Daunorubicin (as Daunorubicin hydrochloride citrate) 50 mg DaunoXome 50mg emulsion for infusion vials | 1 vial £250.00

**Powder for solution for infusion**

- Daunorubicin (Non-proprietary)
  - Daunorubicin hydrochloride 20 mg Daunorubicin 20mg powder for solution for infusion vials | 10 vial £550.00 (Hospital only)

Doxorubicin hydrochloride

**INDICATIONS AND DOSE**

Acute leukaemias | Hodgkin’s lymphoma | Non-Hodgkin’s lymphoma | Some solid tumours including breast cancer

- **BY INTRAVENOUS INJECTION**
  - Adult: (consult product literature)

Some papillary bladder tumours (bladder instillation) | Recurrent superficial bladder tumours (bladder instillation) | Transitional cell carcinoma (bladder instillation) | Carcinoma in situ (bladder instillation)

- **BY INTRAVERSICAL INSTALLATION**
  - Adult: (consult product literature)

**CAELYX®**

For AIDS-related Kaposis’s sarcoma in patients with low CD4 count and extensive mucocutaneous or visceral disease | Advanced ovarian cancer when platinum-based chemotherapy has failed | Progressive multiple myeloma (in combination with bortezomib) in patients who have received at least one prior therapy and who have undergone or are unsuitable for bone-marrow transplantation | Monotherapy for metastatic breast cancer in patients with increased cardiac risk

- **BY INTRAVENOUS INFUSION**
  - Adult: (consult product literature)

**MYOCET®**

For use with cyclophosphamide for metastatic breast cancer

- **BY INTRAVENOUS INFUSION**
  - Adult: (consult product literature)

**CONTRA-INDICATIONS** Consult product literature

**CAUTIONS** Cardiac disease - caution in handling—irritant to tissues - consult product literature - elderly - hypertension - previous myocardial irradiation

**INTERACTIONS** → Appendix 1: anthracyclines

**SIDE-EFFECTS**

- **Common or very common** Dehydration - diarrhoea - red colouration of the urine

- **Uncommon** Supraventricular tachycardia (related to drug administration)

- **Frequency not known** Alopecia - bone-marrow suppression - cardiomyopathy (with higher cumulative doses) - consult product literature - extravasation - heart failure (potentially fatal) - hyperuricaemia - nausea - oral mucositis - renal damage - thromboembolism - tumour lysis syndrome - vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

Extravasation Extravasation can cause severe tissue necrosis.

- Cardiomyopathy Higher cumulative doses are associated with cardiomyopathy and it is usual to limit total cumulative doses to 450 mg/m² because symptomatic and potentially fatal heart failure is common above this dose.

- Cardiotoxic Some evidence suggests that weekly low-dose administration may be less cardiotoxic.

- Liposomal formulations Liposomal formulations of doxorubicin may reduce the incidence of cardiotoxicity and lower the potential for local necrosis, but infusion reactions, sometimes severe, may occur. Hand-foot syndrome (painful, macular reddening skin eruptions) occurs commonly with liposomal doxorubicin and may be dose limiting. It can occur after 2–3 treatment cycles and may be prevented by cooling hands and feet and avoiding socks, gloves, or tight-fitting footwear for 4–7 days after treatment.

- Elevated bilirubin concentration Doxorubicin is largely excreted in the bile and an elevated bilirubin concentration is an indication for reducing the dose.

**CONCEPTION AND CONTRACEPTION** Manufacturer advises effective contraception during and for at least 6 months after treatment in men or women.

**PREGNANCY** Avoid (teratogenic and toxic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**BREAST FEEDING** Discontinue breast-feeding.
Hepatic Impairment
Reduce dose according to bilirubin concentration—consult product literature or local treatment protocol for details. Avoid in severe impairment.

Renal Impairment
Consult product literature in severe impairment.

Monitoring Requirements
Patients should be assessed before treatment, by echocardiography. Cardiac monitoring during treatment may assist in determining safe dosage.

Directions for Administration
Conventional doxorubicin is given by injection into a fast-running infusion, commonly at 21-day intervals.

Prescribing and Dispensing Information
Doxorubicin is available as both conventional and liposomal formulations. The different formulations vary in their licensed indications, pharmacokinetics, dosage and administration, and are not interchangeable.

National Funding/Access Decisions
NICE Technology Appraisals (TAs)
- Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (April 2016) NICE TA389
Pegylated liposomal doxorubicin hydrochloride (PLDH) monotherapy or in combination with platinum, is recommended as an option for treating recurrent ovarian cancer.
PLDH, in combination with trabectedin, is not recommended for treating the first recurrence of platinum-sensitive ovarian cancer.
Patients currently receiving PLDH in combination with trabectedin should have the option to continue their treatment until they and their clinician consider it appropriate to stop.
www.nice.org.uk/TA389

Medicinal Forms
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for infusion

Solution for Injection
- Doxorubicin hydrochloride (Non-proprietary)
  - Doxorubicin hydrochloride 2 mg per 1 ml
  Doxorubicin 10mg/5ml solution for injection vials 1 vial £18.84 (Hospital only)
  Doxorubicin 50mg/25ml solution for injection Cytosafe vials 1 vial £103.00
  Doxorubicin 50mg/25ml solution for infusion vials 1 vial £103.00 (Hospital only)
  Doxorubicin 10mg/5ml solution for injection Cytosafe vials 1 vial £20.60
  Doxorubicin 10mg/5ml solution for infusion vials 1 vial £20.60 (Hospital only)
  Doxorubicin 10mg/5ml solution for infusion vials 1 vial no price available
  Doxorubicin 50mg/25ml solution for infusion vials 1 vial £92.70 (Hospital only)
  Doxorubicin 50mg/25ml solution for infusion vials 1 vial no price available

Solution for Infusion
- Doxorubicin hydrochloride (Non-proprietary)
  - Doxorubicin hydrochloride 0.5 mg per 1 ml
  Doxorubicin 200mg/100ml solution for injection Cytosafe vials 1 vial £412.00
  Doxorubicin 200mg/100ml solution for infusion vials 1 vial £370.80/£412.00 (Hospital only)
  Doxorubicin 200mg/100ml solution for infusion vials 1 vial no price available
  - Caelyx (Janssen-Cilag Ltd)
  Doxorubicin hydrochloride (as Doxorubicin hydrochloride liposomal pegylated) 2 mg per 1 ml
  Caelyx 50mg/25ml concentrate for solution for infusion vials 1 vial £712.40
  Caelyx 20mg/10ml concentrate for solution for infusion vials 1 vial £360.23

Powder for solution for injection
- Doxorubicin (medac UK)
  - Doxorubicin hydrochloride 10 mg
    Doxorubicin 10mg powder for solution for infusion vials 1 vial £182.00
  - Doxorubicin hydrochloride 50 mg
    Doxorubicin 50mg powder for solution for infusion vials 1 vial £914.00

Powder and solvent for suspension for infusion
ELECTROLYTES: May contain Sodium
- Myocet (Teva UK Ltd)
  - Doxorubicin hydrochloride 50 mg
    Myocet 50mg powder and solvent for suspension for infusion vials 2 vial £912.26 (Hospital only)

Epirubicin hydrochloride

Indications and Dose
Treatment of breast cancer | Treatment and prophylaxis of certain forms of superficial bladder cancer
- By Intravenous infusion, or by Intravesical Instillation
- Adult: consult product literature or local protocols

Contra-Indications
Bladder inflammation or contraction (when used as a bladder instillation) - catheterisation difficulties (when used as a bladder instillation) - haematuria (when used as a bladder instillation) - invasive tumours penetrating the bladder (when used as a bladder instillation) - myocardopathy - previous treatment with maximum cumulative doses of epirubicin or other anthracycline - recent myocardial infarction - severe arrhythmia - severe myocardial insufficiency - unstable angina - urinary tract infections (when used as a bladder instillation)

Caution
Caution in handling—irritant to tissues

Interactions
Appendix 1: anthracyclines

Side-Effects
Alopecia - bone-marrow suppression - cardiotoxicity - extravasation - hyperpigmentation of nails - hyperpigmentation of oral mucosa - hyperpigmentation of skin - hyperuricaemia - nausea - oral mucositis - red colouration of the urine - thromboembolism - tumour lysis syndrome - vomiting

Side-Effects, Further Information
Cardiotoxicity A maximum cumulative dose of 0.9–1 g/m² is recommended to help avoid cardiotoxicity.

Conception and Contraception
Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 825.

Pregnancy
Avoid (carcinogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

Breast Feeding
Discontinue breast-feeding.

Hepatic Impairment
Reduce dose according to bilirubin concentration—consult local treatment protocol for details. Avoid in severe impairment.

Renal Impairment
Dose reduction may be necessary in severe impairment.

Medicinal Forms
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection, solution for infusion

Solution for Injection
- Epirubicin hydrochloride (Non-proprietary)
  Epirubicin hydrochloride 2 mg per 1 ml
  Epirubicin 50mg/25ml solution for injection vials 1 vial £100.88
  Epirubicin 10mg/5ml solution for injection vials 1 vial £17.38
  - Pharmorubicin (Pfizer Ltd)
  Epirubicin hydrochloride 2 mg per 1 ml
  Pharmorubicin 50mg/25ml solution for injection Cytosafe vials 1 vial £106.19
  Pharmorubicin 10mg/5ml solution for injection Cytosafe vials 1 vial £21.24

Downloaded from www.medicalbr.com
Idarubicin hydrochloride

**INDICATIONS AND DOSE**

- **Acute non-lymphocytic leukaemias monotherapy**
  - **BY MOUTH**
  - Adult: 30 mg/m² daily for 3 days; maximum 400 mg/m² per course

- **Acute non-lymphocytic leukaemias in combination therapy**
  - **BY MOUTH**
  - Adult: 15–30 mg/m² daily for 3 days; maximum 400 mg/m² per course

- **Advanced breast cancer after failure of first-line chemotherapy (not including anthracyclines)—monotherapy**
  - **BY MOUTH**
  - Adult: 45 mg/m² for 1 dose, repeat treatment every 3–4 weeks, alternatively 15 mg/m² daily for 3 consecutive days, repeat treatment every 3–4 weeks; maximum 400 mg/m² per course

- **Acute leukaemias/Advanced breast cancer after failure of first-line chemotherapy (not including anthracyclines)**
  - **BY INTRAVENOUS INJECTION**
  - Adult: (consult product literature)

**IMPORTANT SAFETY INFORMATION**

**RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES**

See Cytotoxic drugs p. 825.

- **CONTRA-INDICATIONS** Previous treatment with maximum cumulative dose of idarubicin or other anthracycline · recent myocardial infarction · severe arrhythmias · severe myocardial insufficiency
- **CAUTIONS** Caution in handling—irritant to tissues
- **INTERACTIONS** → Appendix 1: anthracyclines
- **SIDE-EFFECTS**
  - **GENERAL SIDE-EFFECTS**
    - **Common or very common** Abdominal pain · cardiac disorders · diarrhoea · haemorrhage · rash · red pigmentation of the urine
    - **Uncommon** Nail hyperpigmentation · skin hyperpigmentation
    - **Frequency not known** Alopecia · bone-marrow suppression · hyperuricaemia · nausea · oral mucositis · thromboembolism · tumour lysis syndrome · vomiting
  - **SPECIFIC SIDE-EFFECTS**
    - With intravenous use Extravasation
    - **CONCEPTION AND CONTRACEPTION** Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 825.
    - **PREGNANCY** Avoid (teratogenic and toxic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.
    - **BREAST FEEDING** Discontinue breast-feeding.
    - **HEPATIC IMPAIRMENT** Reduce dose according to serum bilirubin concentration. Avoid in severe impairment.
    - **RENAL IMPAIRMENT** Reduce dose. Avoid in severe impairment.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

- **CAUTIONARY AND ADVISORY LABELS** 25
  - **Zavedos** (Pfizer Ltd)
    - Idarubicin hydrochloride 5 mg Zavedos 5mg capsules | 1 vial £91.47
    - Idarubicin hydrochloride 10 mg Zavedos 10mg capsules | 1 capsule £69.12

**Powder for solution for injection**

- **Zavedos** (Pfizer Ltd)
  - Idarubicin hydrochloride 5 mg Zavedos 5mg powder for solution for injection vials | 1 vial £97.36
  - Idarubicin hydrochloride 10 mg Zavedos 10mg powder for solution for injection vials | 1 vial £174.72

**Mitoxantrone**

(Mitozantrone)

**INDICATIONS AND DOSE**

- **Metastatic breast cancer** · Non-Hodgkin’s lymphoma · Adult acute non-lymphocytic leukaemia · Non-resectable primary hepatocellular carcinoma
  - **BY INTRAVENOUS INFUSION**
  - Adult: (consult local protocol)

- **CAUTIONS** Intrathecal administration not recommended
- **INTERACTIONS** → Appendix 1: anthracyclines
- **SIDE-EFFECTS** Abdominal pain · alopoeia · amenorrhoea · anorexia · anxiety · blue discoloration of nails · blue discoloration of skin · bone-marrow suppression · confusion · constipation · diarrhoea · dose-related cardiotoxicity · drowsiness · dyspnoea · extravasation · gastro-intestinal bleeding · hyperuricaemia · myelosuppression · nausea · oral mucositis · paraesthesia · thromboembolism · transient blue-green discoloration of urine · tumour lysis syndrome · vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

Cardiotoxicity Cardiac examinations are recommended after a cumulative dose of 160 mg/m².

- **CONCEPTION AND CONTRACEPTION** Manufacturer advises effective contraception during and for at least 6 months after treatment in men or women.
- **PREGNANCY** Avoid. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.
- **BREAST FEEDING** Discontinue breast-feeding.
- **HEPATIC IMPAIRMENT** Use with caution—consult local treatment protocol.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for infusion**

- **Mitoxantrone (Non-proprietary)**
  - Mitoxantrone (as Mitoxantrone hydrochloride) 2 mg per 1 ml Mitoxantrone 20mg/10ml concentrate for solution for infusion vials | 1 vial £121.85
  - **Onkotrone** (Baxter Healthcare Ltd)
    - Mitoxantrone (as Mitoxantrone hydrochloride) 2 mg per 1 ml Onkotrone 20mg/10ml solution for infusion vials | 1 vial no price available
    - Onkotrone 25mg/12.5ml solution for infusion vials | 1 vial no price available

- **Onkotrone (Non-proprietary)**
  - Mitoxantrone 2 mg per 1 ml Mitoxantrone 20mg/10ml concentrate for solution for infusion vials | 1 vial £121.85
  - **Pharmorubicin** (Pfizer Ltd)
    - Mitoxantrone hydrochloride 2 mg per 1 ml Pharmorubicin 200mg/100ml solution for infusion Cytosafe vials | 1 vial £386.16
Pixantrone

**INDICATIONS AND DOSE**
Treatment of refractory or multiply relapsed aggressive non-Hodgkin B-cell lymphomas (monotherapy)

- BY INTRAVENOUS INFUSION
  - Adult: (consult product literature)

**CONTRA-INDICATIONS**
Active severe infection - risk factors for severe infection

**CAUTIONS**
Active cardiovascular disease - cardiac risk factors - caution in handling - irritant to tissues - concurrent radiotherapy to the mediastinal area - history of cardiovascular disease - previous radiotherapy to the mediastinal area - previous therapy with anthrancenides - previous therapy with anthracyclines

**INTERACTIONS**
Appendix 1: anthracyclines

**SIDE-EFFECTS**

- **Common or very common**
  - Abdominal pain
  - Abnormal liver function tests
  - Biochemical disturbances
  - Bone pain
  - Cardiac disorders (dysrhythmia, congestive heart failure, pericardial effusion)
  - Cardiac toxicity (dysrhythmia, congestive heart failure, pericardial effusion)
  - Cough
  - Diarrhoea
  - Drowsiness
  - Dry mouth
  - Dyspepsia
  - Dysphagia
  - Electrolyte disturbances (transient)
  - Fatigue
  - Headache
  - Hypertension
  - Infection
  - Loss of appetite
  - Malaise
  - Nail disorder
  - Oedema
  - Pallor
  - Paraesthesia
  - Photo sensitivity
  - Pruritus
  - Pyrexia
  - Severe myelosuppression
  - Skin discoloration
  - Tachycardia
  - Taste disturbances
  - Venin discoloration
  - Weight loss

- **Uncommon**
  - Anxiety
  - Arrhythmia
  - Arthralgia
  - Arthritis
  - Dizziness
  - Dry eye
  - Keratitis
  - Musculoskeletal pain
  - Musculoskeletal weakness
  - Night sweats
  - Oesophagitis
  - Oliguria
  - Petechiae
  - Pleural effusion
  - Pneumonitis
  - Rash
  - Rectal haemorrhage
  - Rhinorhoea
  - Skin ulcer
  - Sleep disorder
  - Spontaneous erection
  - Tumour progression
  - Vein disorder
  - Vertigo

- **Frequency not known**
  - Alopecia
  - Bone-marrow suppression
  - Extravasation
  - Hyperuricaemia
  - Nausea
  - Oral mucositis
  - Photosensitivity (thromboembolism, tumour lysis syndrome, vomiting

**CONCEPTION AND CONTRACEPTION**
Ensure effective contraception during and for at least 6 months after treatment in men or women.

**PREGNANCY**
Manufacturer advises avoid — toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**BREAST FEEDING**
Manufacturer advises avoid — no information available.

**HEPATIC IMPAIRMENT**
No information available — manufacturer advises caution in mild to moderate impairment. Avoid in severe impairment.

**RENAL IMPAIRMENT**
No information available — manufacturer advises caution.

**MONITORING REQUIREMENTS**
Baseline investigations should include a full blood count, assessment of cardiac function measured by left ventricular ejection fraction, and measurement of serum concentrations of total bilirubin and total creatinine.

- Full blood count and cardiac function should be monitored throughout treatment.

**PATIENT AND CARER ADVICE**
Photosensitivity. Photosensitivity is a theoretical risk and patients should be advised to follow sun protection strategies.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**
- Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma (February 2014) NICE TA306
  - Pixantrone monotherapy is recommended as an option for treating adults with multiply relapsed or refractory aggressive non-Hodgkin’s B-cell lymphoma in patients:

  - who have previously been treated with rituximab and
  - who are receiving third- or fourth-line treatment and
  - if the manufacturer provides pixantrone with the discount agreed in the patient access scheme.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for infusion**

ELECTROLYTES: May contain Sodium
- Pixuvri (CTI Life Sciences Ltd) ▼
- Pixantrone (as Pixantrone dimaleate) 29 mg
  - 29 mg powder for concentrate for solution for infusion via 1 vial (POD) no price available

**ANTINEOPLASTIC DRUGS > ANTIMETABOLITES**

Azacitidine

**DRUG ACTION**
Azacitidine is a pyrimidine analogue.

**INDICATIONS AND DOSE**
Treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocytic leukaemia, and acute myeloid leukaemia, in adults who are not eligible for haematopoietic stem cell transplantation

- BY SUBCUTANEOUS INJECTION
  - Adult: (consult local protocol)
Monitor full blood count before initiation of treatment, before each treatment cycle, and as clinically indicated. Monitor for bleeding.

### NATIONAL FUNDING/ACCESS DECISIONS

**NICE technology appraisals (TAs)**

- **Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts** (July 2016) NICE TA399
  - Azacitidine is not recommended, within its marketing authorisation, for treating acute myeloid leukaemia with greater than 30% bone marrow blasts in patients aged 65 years or above who are not eligible for haematopoietic stem cell transplant.
  - Patients whose treatment was started before this guidance was published should continue treatment until they and their clinician consider it appropriate to stop. [www.nice.org.uk/TA399](http://www.nice.org.uk/TA399)

- **Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia** (March 2011) NICE TA218
  - Azacitidine is recommended in adults who are not eligible for haematopoietic stem cell transplantation as an option for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocytic leukaemia, or acute myeloid leukaemia. [www.nice.org.uk/TA218](http://www.nice.org.uk/TA218)

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Powder for suspension for injection**

- Vidaza (Celsogen Ltd)
  - **Azacitidine 100 mg** Vidaza 100 mg powder for suspension for injection vials | 1 vial [£321.00](https://www.nice.org.uk/TA399)

### Capecitabine

**DRUG ACTION**

Capecitabine is metabolised to fluorouracil.

**INDICATIONS AND DOSE**

**Stage III colon cancer, adjuvant following surgery (monotherapy)**

- **BY MOUTH**
  - Adult: 1.25 g/m² twice daily for 14 days, subsequent courses repeated after a 7-day interval, recommended duration of treatment is 6 months, adjust dose according to tolerability—consult product literature

**Stage III colon cancer, adjuvant following surgery (combination therapy)**

- **BY MOUTH**
  - Adult: 0.8–1 g/m² twice daily for 14 days, subsequent courses repeated after a 7-day interval, recommended duration of treatment is 6 months, adjust dose according to tolerability—consult product literature

**Metastatic colorectal cancer (monotherapy)**

- **BY MOUTH**
  - Adult: 1.25 g/m² twice daily for 14 days, subsequent courses repeated after a 7-day interval, adjust dose according to tolerability—consult product literature

**Metastatic colorectal cancer (combination therapy)**

- **BY MOUTH**
  - Adult: 0.8–1 g/m² twice daily for 14 days, subsequent courses repeated after a 7-day interval, adjust dose according to tolerability—consult product literature

**Advanced gastric cancer (first-line treatment in combination with a platinum based regimen)**

- **BY MOUTH**
  - Adult: 0.8–1 g/m² twice daily for 14 days, subsequent courses repeated after a 7-day interval, alternatively 625 mg/m² twice daily given continuously, adjust dose according to tolerability—consult product literature

**IN DICATIONS AND DOSE**

Capecitabine is metabolised to fluorouracil.

**SIDE-EFFECTS**

- Alopecia—bone-marrow suppression—hyperuricaemia—nausea—oral mucositis—thromboembolism—tumour lysis syndrome—vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

For further information on side-effects, consult product literature.

**CONCEPTION AND CONTRACEPTION**

Contraceptive advice required, see [Pregnancy and reproductive function](#) in Cytotoxic drugs p. 825.

**PREGNANCY**

Avoid (teratogenic in animal studies). See also [Pregnancy and reproductive function](#) in Cytotoxic drugs p. 825.

**BREAST FEEDING**

Discontinue breast-feeding.

**HEPATIC IMPAIRMENT**

Manufacturer advises monitor liver function in mild to moderate impairment—consult product literature for guidance on treatment interruption; avoid in severe impairment.

**RENAL IMPAIRMENT**

Reduce starting dose of 1.25 g/m² to 75% if creatinine clearance 30–50 mL/minute. Avoid if creatinine clearance less than 30 mL/minute.

**MONITORING REQUIREMENTS**

- Monitor plasma—calcium concentration.
- Monitor for eye disorders (including keratitis and corneal disorders).
- Monitor for symptoms of hand-foot syndrome. Monitor for symptoms of severe skin reactions (including Stevens-Johnson syndrome and toxic epidermal necrolys)—permanently discontinue treatment immediately if symptoms occur.
- Monitor for symptoms of hand-foot syndrome—interrupt treatment if significant syndrome occurs and refer to product literature.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- **Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer** (August 2012) NICE TA263
  - Bevacizumab in combinations with capcitabine is not recommended within its marketing authorisation for the first-line treatment of metastatic breast cancer, that is, when treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate, or when taxanes or anthracyclines have been used as part of adjuvant treatment in the previous 12 months. [www.nice.org.uk/TA263](http://www.nice.org.uk/TA263)

**CONTRA-INDICATIONS**

- Dihydropyrimidine dehydrogenase deficiency

**CAUTIONS**

- Diabetes mellitus—diarrhoea or dehydration—consult product literature for guidance on dose modification and treatment interruption—electrolyte disturbances—history of angina pectoris—history of arrhythmias—history of significant cardiovascular disease—nervous system disease

**INTERACTIONS**

- Appendix 1: capecitabine

**IMPORTANT SAFETY INFORMATION**

**RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES**

See Cytotoxic drugs p. 825.

- **CONTRA-INDICATIONS**
  - Dihydropyrimidine dehydrogenase deficiency

- **CAUTIONS**
  - Diabetes mellitus—diarrhoea or dehydration—consult product literature for guidance on dose modification and treatment interruption—electrolyte disturbances—history of angina pectoris—history of arrhythmias—history of significant cardiovascular disease—nervous system disease

- **INTERACTIONS**
  - Appendix 1: capecitabine

- **SIDE-EFFECTS**
  - Alopecia—bone-marrow suppression—hyperuricaemia—nausea—oral mucositis—thromboembolism—tumour lysis syndrome—vomiting

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - For further information on side-effects, consult product literature.

- **CONCEPTION AND CONTRACEPTION**
  - Contraceptive advice required, see [Pregnancy and reproductive function](#) in Cytotoxic drugs p. 825.

- **PREGNANCY**
  - Avoid (teratogenic in animal studies). See also [Pregnancy and reproductive function](#) in Cytotoxic drugs p. 825.

- **BREAST FEEDING**
  - Discontinue breast-feeding.

- **HEPATIC IMPAIRMENT**
  - Manufacturer advises monitor liver function in mild to moderate impairment—consult product literature for guidance on treatment interruption; avoid in severe impairment.

- **RENAL IMPAIRMENT**
  - Reduce starting dose of 1.25 g/m² to 75% if creatinine clearance 30–50 mL/minute. Avoid if creatinine clearance less than 30 mL/minute.

- **MONITORING REQUIREMENTS**
  - Monitor plasma—calcium concentration.
  - Monitor for eye disorders (including keratitis and corneal disorders).
  - Monitor for symptoms of severe skin reactions (including Stevens-Johnson syndrome and toxic epidermal necrolys)—permanently discontinue treatment immediately if symptoms occur.
  - Monitor for symptoms of hand-foot syndrome—interrupt treatment if significant syndrome occurs and refer to product literature.

- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **NICE technology appraisals (TAs)**
    - **Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer** (August 2012) NICE TA263
      - Bevacizumab in combinations with capcitabine is not recommended within its marketing authorisation for the first-line treatment of metastatic breast cancer, that is, when treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate, or when taxanes or anthracyclines have been used as part of adjuvant treatment in the previous 12 months. [www.nice.org.uk/TA263](http://www.nice.org.uk/TA263)
**Cladribine**

**INDICATIONS AND DOSE**

**LEUSTAT®**

B-cell chronic lymphocytic leukaemia in patients who have failed to respond to standard regimens containing an alkylating agent | **Hairy cell leukaemia**

- **BY INTRAVENOUS INFUSION**
  - Adult: (consult product literature or local protocols)

**LITAK®**

Hairy cell leukaemia | **BY SUBCUTANEOUS INJECTION**

- Adult: (consult product literature or local protocols)

**CAUTIONS** Use irradiated blood only

**FURTHER INFORMATION**

Immunosuppressive effect of cladribine. Cladribine has a potent and prolonged immunosuppressive effect. Patients treated with cladribine are more prone to serious bacterial, opportunistic fungal, and viral infections, and prophylactic therapy is recommended in those at risk. To prevent potentially fatal transfusion-related graft-versus-host reaction, only irradiated blood products should be administered. Prescribers should consult specialist literature when using highly immunosuppressive drugs.

**INTERACTIONS** → Appendix 1: cladribine

**SIDE-EFFECTS** Abdominal pain - acute renal failure (with high doses) - alopecia - anxiety - arthralgia - asthenia - bone-marrow suppression - chills - constipation - cough - diarrhoea - dizziness - dysphoea - extravasation - flatulence - haemolytic anaemia - headache - hyperuricaemia - insomnia - malaise - myalgia - nausea - oedema - oral mucositis - pruritus - purpura - rash - severe myelosuppression (with neutropenia, anaemia and thrombocytopenia) - severe neurotoxicity (with high doses) - sweating - tachycardia - thromboembolism - tumour lysis syndrome - vomiting

**CONCEPTION AND CONTRACEPTION** Contraceptive advice required, see *Pregnancy and reproductive function* in Cytotoxic drugs p. 825.

**PREGNANCY** Manufacturer advises avoid (teratogenic in animal studies). See also *Pregnancy and reproductive function* in Cytotoxic drugs p. 825.

**BREAST FEEDING** Discontinue breast-feeding.

**HEPATIC IMPAIRMENT** Regular monitoring recommended in hepatic impairment.

**RENAL IMPAIRMENT** Regular monitoring recommended in renal impairment.

**DIRECTIONS FOR ADMINISTRATION** Litak® for subcutaneous use only — no dilution required.

**MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Litak (Lipomed GmbH)** Cladribine 2 mg per 1 ml Litak 10mg/5ml solution for injection vials | 1 vial POM £165.00 (Hospital only) | 5 vial POM £320.00 (Hospital only)

**Solution for infusion**

- **Leustat (Janssen-Cilag Ltd)** Cladribine 1 mg per 1 ml Leustat 10mg/10ml solution for infusion vials | 1 vial POM £159.70

---

**Clofarabine**

**INDICATIONS AND DOSE** Relapsed or refractory acute lymphoblastic leukaemia in patients who have received at least two previous regimens

- **BY INTRAVENOUS INFUSION**
  - Adult 18-20 years: (consult local protocol)

**CAUTIONS** Cardiac disease

**INTERACTIONS** → Appendix 1: clofarabine


**CONCEPTION AND CONTRACEPTION** Contraceptive advice required, see *Pregnancy and reproductive function* in Cytotoxic drugs p. 825.

**PREGNANCY** Manufacturer advises avoid (teratogenic in animal studies). See also *Pregnancy and reproductive function* in Cytotoxic drugs p. 825.

**BREAST FEEDING** Discontinue breast-feeding.

**HEPATIC IMPAIRMENT** Manufacturer advises caution in mild to moderate impairment. Avoid in severe impairment.
**RENAL IMPAIRMENT** Manufacturer advises caution in mild to moderate impairment. Avoid in severe impairment.

**MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Solution for infusion**
- **Electrolytes:** May contain Sodium
- **Evotra** (Sanofi) 
  Clofarabine 1 mg per 1 ml Evotra 20 mg/20 ml concentrate for solution for infusion vials | 1 vial [Pom] £1.326.18 (Hospital only)

### Cytarabine

**DRUG ACTION** Cytarabine acts by interfering with pyrimidine synthesis.

**INDICATIONS AND DOSE**

**Induction of remission of acute myeloblastic leukaemia**
- By intravenous infusion, or by intravenous injection, or by subcutaneous injection
- Adult: (consult local protocol)

**Lymphomatous meningitis**
- By intrathecal injection
- Adult: (consult local protocol)

---

**IMPORTANT SAFETY INFORMATION** Not all cytarabine preparations can be given by intrathecal injection—consult product literature.

**INTERACTIONS** → Appendix 1: cytarabine

**SIDE-EFFECTS** Alopecia, bone-marrow suppression, extravasation, hyperuricaemia, nausea, oral mucositis, thromboembolism, tumour lysis syndrome, vomiting

**CONCEPTION AND CONTRACEPTION** Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**PREGNANCY** Avoid (teratogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**BREAST FEEDING** Discontinue breast-feeding.

**HEPATIC IMPAIRMENT** Reduce dose—consult product literature.

**MONITORING REQUIREMENTS** Haematological monitoring, Cytarabine is a potent myelosuppressant and requires careful haematological monitoring.

**NATIONAL FUNDING/ACCESS DECISIONS**

**DEPOCYTE**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium (SMC) has advised (July 2007) that liposomal cytarabine suspension (DepoCyte®) is not recommended for use within NHS Scotland for the intrathecal treatment of lymphomatous meningitis.

**MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection

**Solution for injection**
- **Cytarabine (Non-proprietary)**
  - Cytarabine 20 mg per 1 ml Cytarabine 500 mg/25 ml solution for injection vials | 1 vial [Pom] £19.50
  - Cytarabine 100 mg/5 ml solution for injection vials | 5 vial [Pom] £20.98-£30.00
  - Cytarabine 100 mg per 1 ml Cytarabine 1 g/10 ml solution for injection vials | 1 vial [Pom] £40.00
  - Cytarabine 500 mg/5 ml solution for injection vials | 5 vial [Pom] £100.00
  - Cytarabine 4 g/40 ml solution for injection vials | 1 vial [Pom] no price available

---

### Fludarabine phosphate

**INDICATIONS AND DOSE**

Initial treatment of advanced B-cell chronic lymphocytic leukaemia (CLL) or after first line treatment in patients with sufficient bone-marrow reserves
- By mouth
- Adult: 40 mg/m² for 5 days every 28 days, usually given for 6 cycles
- By intravenous injection, or by intravenous infusion
- Adult: (consult product literature)

**IMPORTANT SAFETY INFORMATION**

**RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES**

See Cytotoxic drugs p. 825.

**CONTRA-INDICATIONS** Haemolytic anaemia

**CAUTIONS** Increased susceptibility to skin cancer—worsening of existing skin cancer

**CAUTIONS, FURTHER INFORMATION** Co-trimoxazole is used to prevent pneumocystis infection.
Cytotoxic responsive malignancy

- Immunosuppression Fludarabine has a potent and prolonged immunosuppressive effect. Patients treated with fludarabine are more prone to serious bacterial, opportunistic fungal, and viral infections, and prophylactic therapy is recommended in those at risk. To prevent potentially fatal transfusion-related graft-versus-host reaction, only irradiated blood products should be administered. Prescribers should consult specialist literature when using highly immunosuppressive drugs.

- **INTERACTIONS** → Appendix 1: fludarabine

- **SIDE-EFFECTS**
  - Common or very common Acute myeloid leukaemia - anorexia - chills - cough - diarrhoea - fever - immunosuppression - malaise - myelodysplastic syndrome - myelosuppression (may be cumulative) - oedema - peripheral neuropathy - pneumonia - rash - visual disturbances - weakness
  - Uncommon Autoimmune disorder - confusion - fibrosis - haemorrhage - immune-mediated haemolytic anaemia - neutropenia - pneumonitis - pulmonary toxicity - thrombocytopenia
  - Rare Agitation - arrhythmia - blindness - coma - heart failure - optic neuropathy - seizures - skin cancer - Stevens-Johnson syndrome - toxic epidermal necrolysis
  - Frequency not known Alopecia - bone marrow suppression - extravasation - haemorrhagic cystitis - hyperuricaemia - nausea - oral mucositis - thromboembolism - tumour lysis syndrome - vomiting

- **CONCEPTION AND CONTRACEPTION** Manufacturer advises effective contraception during and for at least 6 months after treatment in men or women.

- **PREGNANCY** Avoid (embryotoxic and teratogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

- **BREAST FEEDING** Discontinue breast-feeding.

- **RENAL IMPAIRMENT** Reduce dose by up to 50% if creatinine clearance 30–70 mL/minute. Avoid if creatinine clearance less than 30 mL/minute.

- **MONITORING REQUIREMENTS**
  - Monitor for signs of haemolysis.
  - Monitor for neurological toxicity.
  - Assess creatinine clearance in patients over 65 years before treatment initiation.

- **DIRECTIONS FOR ADMINISTRATION** Concentrate for intravenous injection or infusion must be diluted before administration (consult product literature).

- **NATIONAL FUNDING/ACCESS DECISIONS**

  **NICE technology appraisals (TAs)**
  - Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia (February 2007) NICE TA119
    Fludarabine monotherapy is not recommended for the first-line treatment of chronic lymphocytic leukaemia.
    [www.nice.org.uk/TA119](http://www.nice.org.uk/TA119)
  - Fludarabine for the treatment of B-cell chronic lymphocytic leukaemia (September 2001) NICE TA29
    Oral fludarabine is recommended for the second-line treatment of B-cell chronic lymphocytic leukaemia in patients who have either failed, or are intolerant of, first line chemotherapy, and who would otherwise have received combination chemotherapy of either:
    - cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP)
    - cyclophosphamide, doxorubicin and prednisolone (CAP)
    or
    - cyclophosphamide, vincristine and prednisolone (CVP)
    Intra-venous fludarabine should only be used when oral fludarabine is contra-indicated.
    [www.nice.org.uk/TA29](http://www.nice.org.uk/TA29)

- **Scottish Medicines Consortium (SMC) Decisions**
  - The Scottish Medicines Consortium has advised (October 2006) that fludarabine is accepted for restricted use for the treatment of B-cell chronic lymphocytic leukaemia (CLL) in patients with sufficient bone marrow reserves. First-line treatment should only be initiated in patients with advanced disease, Rai stages III/IV (Binet stage C), or Rai stages I/II (Binet stage A/B) where the patient has disease-related symptoms or evidence of progressive disease.

  **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  **Solution for injection**
  - Fludarabine phosphate (Non proprietary)
    Fludarabine phosphate 25 mg per 1 ml Fludarabine phosphate 50mg/2ml concentrate for solution for injection vials | 1 vial [POM] £156.00 (Hospital only) | 1 vial [POM] £155.00

  **Tablet**
  - Fludara (Sanofi)
    Fludarabine phosphate 10 mg Fludara 10mg tablets | 15 tablet [POM] £302.48 (Hospital only) | 20 tablet [POM] £403.31 (Hospital only)

  **Powder for solution for injection**
  - Fludarabine phosphate (Non proprietary)
    Fludarabine phosphate 50 mg Fludarabine phosphate 50mg powder for solution for injection vials | 1 vial [POM] £155.00 (Hospital only)
  - Fludara (Sanofi)
    Fludarabine phosphate 50 mg Fludara 50mg powder for solution for injection vials | 5 vial [POM] £735.34 (Hospital only)

Fluorouracil

- **INDICATIONS AND DOSE**
  - Treatment of some solid tumours including gastro-intestinal tract cancers and breast cancer in combination with folinic acid in advanced colorectal cancer
    - By intravenous injection, or by intravenous infusion.
    - Or by intra-arterial infusion
    - Adult: (consult product literature)

  **INTERACTIONS** → Appendix 1: fluorouracil

  **SIDE-EFFECTS**
  - Rare Cerebellar syndrome
  - Frequency not known Alopecia - bone marrow suppression - desquamative hand-foot syndrome (on prolonged infusion) - extravasation - hyperuricaemia - mucositis - myelosuppression - nausea - oral mucositis - thromboembolism - tumour lysis syndrome - vomiting

  **CONCEPTION AND CONTRACEPTION** Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 825.

- **PREGNANCY** Avoid (teratogenic). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

- **BREAST FEEDING** Discontinue breast-feeding.

- **HEPATIC IMPAIRMENT** Manufacturer advises caution.

- **HANDLING AND STORAGE** Caution in handling—irritant to tissues.

  **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection

  **Solution for injection**
  - Fluorouracil (Non proprietary)
    Fluorouracil (as Fluorouracil sodium) 25 mg per 1 ml Fluorouracil 500mg/20ml solution for injection vials | 10 vial [POM] £64.00
    Fluorouracil 250mg/10ml solution for injection vials | 5 vial [POM] £24.00
  - Fluorouracil (as Fluorouracil sodium) 50 mg per 1 ml Fluorouracil 1g/20ml solution for injection vials | 1 vial [POM] £12.80
    Fluorouracil 500mg/10ml solution for injection vials | 1 vial [POM] £6.40 | 5 vial [POM] £32.00
Gemcitabine

INDICATIONS AND DOSE
First-line treatment for locally advanced or metastatic non-small cell lung cancer (as monotherapy in elderly patients and in palliative treatment; otherwise in combination with cisplatin) | Treatment of locally advanced or metastatic pancreatic cancer | Treatment of advanced or metastatic bladder cancer (in combination with cisplatin) | Treatment of locally advanced or metastatic epithelial ovarian cancer which has relapsed after a recurrence-free interval of at least 6 months following previous platinum-based therapy (in combination with carboplatin) | Treatment of metastatic breast cancer which has relapsed after previous chemotherapy including an anthracycline (in combination with paclitaxel)

BY INTRAVENOUS INFUSION
Adult: (consult local protocol)

INTERACTIONS
Appendix 1: gemcitabine

SIDE-EFFECTS
Rare: Haemolytic uraemic syndrome
Frequency not known: Alopecia, bone-marrow suppression, extravasation, hyperuricaemia, influenza-like symptoms, microangiopathic haemolytic anaemia, mild gastrointestinal side-effects, musculoskeletal pain, nausea, oral mucositis, pulmonary toxicity, rash, renal impairment, thromboembolism, tumour lysis syndrome, vomiting

SIDE-EFFECTS, FURTHER INFORMATION
Microangiopathic haemolytic anaemia. Gemcitabine should be discontinued if signs of microangiopathic haemolytic anaemia occur.

CONCEPTION AND CONTRACEPTION
Manufacturer advises effective contraception during treatment. Men must avoid fathering a child during and for 6 months after treatment.

PREGNANCY
Avoid (teratogenic in animal studies). See Pregnancy and reproductive function in Cytotoxic drugs p. 825.

BREAST FEEDING
Discontinue breast-feeding.

HEPATIC IMPAIRMENT
Manufacturer advises caution.

RENAL IMPAIRMENT
Manufacturer advises caution.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)
Gemcitabine is an option for first-line chemotherapy for patients with advanced or metastatic adenocarcinoma of the pancreas and a Karnofsky score of at least 50 [Karnofsky score is a measure of the ability to perform ordinary tasks].

Gemcitabine is not recommended for patients who can have potentially curative surgery. There is insufficient evidence about its use for second-line treatment of pancreatic adenocarcinoma.

www.nice.org.uk/TA25

Gemcitabine, in combination with paclitaxel, is an option for the treatment of metastatic breast cancer only when docetaxel monotherapy or docetaxel plus capcitabine are also considered appropriate.

www.nice.org.uk/TA116

Solution for infusion

Gemcitabine (as Gemcitabine hydrochloride) 200 mg

Gemcitabine 200mg/5.3ml concentrate for solution for infusion vials | 1 vial (£2.00) £32.00

Gemcitabine 200mg/5ml concentrate for solution for infusion vials | 1 vial (£2.00) £6.40

Gemcitabine 200mg/2ml concentrate for solution for infusion vials | 1 vial (£2.00) no price available

Gemcitabine (as Gemcitabine hydrochloride) 1 gram

Gemcitabine 1g/26.3ml concentrate for solution for infusion vials | 1 vial (£2.00) £162.00 (Hospital only)

Gemcitabine 1g/25ml concentrate for solution for infusion vials | 1 vial (£2.00) £13.09

Gemcitabine 1g/10ml concentrate for solution for infusion vials | 1 vial (£2.00) no price available

Gemcitabine (as Gemcitabine hydrochloride) 2 gram

Gemcitabine 2g/50ml concentrate for solution for infusion vials | 1 vial (£2.00) £26.86

Gemcitabine 2g/20ml concentrate for solution for infusion vials | 1 vial (£2.00) no price available

Gemcitabine 2g/52.6ml concentrate for solution for infusion vials | 1 vial (£2.00) £32.40 (Hospital only)

Gemcitabine (as Gemcitabine hydrochloride) 10 mg per 1 ml

Gemcitabine 1.6g/160ml infusion bags | 1 bag (£2.00) £140.00

Gemcitabine 2.2g/220ml infusion bags | 1 bag (£2.00) £200.00

Gemcitabine 2g/200ml infusion bags | 1 bag (£2.00) £180.00

Gemcitabine 1.2g/120ml infusion bags | 1 bag (£2.00) £120.00

Gemcitabine 1.8g/180ml infusion bags | 1 bag (£2.00) £160.00

Bevacizumab in combination with gemcitabine and carboplatin for the treatment of the first recurrence of platinum-sensitive advanced ovarian cancer (May 2013) NICE TA285

Bevacizumab in combination with gemcitabine and carboplatin is not recommended within its marketing authorisation, that is, for the treatment of the first recurrence of platinum-sensitive advanced ovarian cancer (including fallopian tube and primary peritoneal cancer) that has not been previously treated with bevacizumab or other vascular endothelial growth factor (VEGF) inhibitors or VEGF receptor–targeted agents.

www.nice.org.uk/TA285

Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer (October 2015) NICE TA360

Gemcitabine in combination with albumin-bound paclitaxel (nab–paclitaxel, Abraxane®) is not recommended for the treatment of previously untreated metastatic adenocarcinoma of the pancreas.

Patients whose treatment was started before this guidance was published should continue treatment until they and their clinician consider it appropriate to stop.

www.nice.org.uk/TA360

Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (April 2016) NICE TA389

Gemcitabine, in combination with carboplatin, is not recommended for treating the first recurrence of platinum-sensitive ovarian cancer.

Patient currently receiving gemcitabine in combination with carboplatin should have the option to continue their treatment until they and their clinician consider it appropriate to stop.

www.nice.org.uk/TA389

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (November 2006) that gemcitabine is accepted for restricted use for the treatment of metastatic breast cancer, which has relapsed following previous chemotherapy including an anthracycline (unless contra-indicated).

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Solution for infusion

Gemcitabine (as Gemcitabine hydrochloride) 200 mg

Gemcitabine 200mg/5.3ml concentrate for solution for infusion vials | 1 vial (£2.00) £32.00 (Hospital only)

Gemcitabine 200mg/5ml concentrate for solution for infusion vials | 1 vial (£2.00) £6.40

Gemcitabine 200mg/2ml concentrate for solution for infusion vials | 1 vial (£2.00) no price available

Gemcitabine (as Gemcitabine hydrochloride) 1 gram

 Gemcitabine 1g/26.3ml concentrate for solution for infusion vials | 1 vial (£2.00) £162.00 (Hospital only)

 Gemcitabine 1g/25ml concentrate for solution for infusion vials | 1 vial (£2.00) £13.09

 Gemcitabine 1g/10ml concentrate for solution for infusion vials | 1 vial (£2.00) no price available

Gemcitabine (as Gemcitabine hydrochloride) 2 gram

 Gemcitabine 2g/50ml concentrate for solution for infusion vials | 1 vial (£2.00) £26.86

 Gemcitabine 2g/20ml concentrate for solution for infusion vials | 1 vial (£2.00) no price available

 Gemcitabine 2g/52.6ml concentrate for solution for infusion vials | 1 vial (£2.00) £32.40 (Hospital only)

Gemcitabine (as Gemcitabine hydrochloride) 10 mg per 1 ml

 Gemcitabine 1.6g/160ml infusion bags | 1 bag (£2.00) £140.00

 Gemcitabine 2.2g/220ml infusion bags | 1 bag (£2.00) £200.00

 Gemcitabine 2g/200ml infusion bags | 1 bag (£2.00) £180.00

 Gemcitabine 1.2g/120ml infusion bags | 1 bag (£2.00) £120.00

 Gemcitabine 1.8g/180ml infusion bags | 1 bag (£2.00) £160.00
Mercaptopurine (6-Mercaptopurine)

**INDICATIONS AND DOSE**
- **Severe acute Crohn's disease** | **Maintenance of remission of Crohn's disease** | **Ulcerative colitis**
  - **BY MOUTH**
    - Adult: 1 – 1.5 mg/kg daily, some patients may respond to lower doses

- **Acute leukaemias** | **Chronic myeloid leukaemia**
  - **BY MOUTH USING TABLETS**
    - Adult: Initially 2.5 mg/kg daily, adjusted according to response, alternatively initially 50 – 75 mg/m² daily, adjusted according to response
  - **BY MOUTH USING ORAL SUSPENSION**
    - Adult: Initially 25 – 75 mg/m² daily, adjusted according to response

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**
Manufacturer advises reduce dose to one-quarter of the usual dose with concurrent use of allopurinol.

**DOSE EQUIVALENCE AND CONVERSION**
- Mercaptopurine tablets and Xaluprine® oral suspension are not bioequivalent, haematological monitoring is advised when switching formulations.

**UNLICENSED USE**
Not licensed for use in severe ulcerative colitis and Crohn’s disease.

**IMPORTANT SAFETY INFORMATION**
**RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES**
See Cytotoxic drugs p. 825.

**CONTRA-INDICATIONS**
- Absent thiopurine methyltransferase activity

**CAUTIONS**
- Reduced thiopurine methyltransferase activity

**CAUTIONS, FURTHER INFORMATION**
- Thiopurine methyltransferase
  - The enzyme thiopurine methyltransferase (TPMT) metabolises thiopurine drugs (azathioprine, mercaptopurine, tioguanine); the risk of myelosuppression is increased in patients with reduced activity of the enzyme, particularly for the few individuals in whom TPMT activity is undetectable. Patients with absent TPMT activity should not receive thiopurine drugs; those with reduced TPMT activity may be treated under specialist supervision.

**INTERACTIONS**
- Appendix 1: mercaptopurine

**SIDE-EFFECTS**
- **Rare** Pancreatitis, transient oligospermia
- **Very rare** Intestinal ulceration, lymphoma

**FREQUENCY NOT KNOWN**
- Alopecia, anorexia, bone-marrow suppression, hepatotoxicity, hyperuricaemia, nausea, oral mucositis, thromboembolism, tumour lysis syndrome, vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**
- Gastro-intestinal side-effects
  - Tioguanine has a lower incidence of gastrointestinal side-effects than mercaptopurine.

**CONCEPTION AND CONTRACEPTION**
Contraceptive advice required, see *Pregnancy and reproductive function* in Cytotoxic drugs p. 825.

**PREGNANCY**
- Avoid (teratogenic). See also *Pregnancy and reproductive function* in Cytotoxic drugs p. 825.

**BREAST FEEDING**
- Discontinue breast-feeding.

**HEPATIC IMPAIRMENT**
- May need dose reduction.

**RENAL IMPAIRMENT**
- Reduce dose.

**PRE-TREATMENT SCREENING**
- Consider measuring thiopurine methyltransferase (TPMT) activity before starting mercaptopurine therapy.

**MONITORING REQUIREMENTS**
- Monitor liver function.

**PRESCRIBING AND DISPENSING INFORMATION**
- Flavours of oral liquid formulations may include raspberry.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, capsule, oral suspension

**Oral suspension**
- **EXCIPIENTS:** May contain Aspartame
  - **Xaluprine** (Nova Laboratories Ltd)
    - Mercaptopurine 20 mg per 1 ml
    - Xaluprine 20mg/ml oral suspension
      - 100 ml [POD] £170.00
  - **Mercaptopurine (Non-proprietary)**
    - Mercaptopurine 50 mg
    - Mercaptopurine 50mg tablets | 25 tablet [POD] £49.15 DT price = £49.15

**Methotrexate**

**DRUG ACTION**
Methotrexate inhibits the enzyme dihydrofolate reductase, essential for the synthesis of purines and pyrimidines.

**INDICATIONS AND DOSE**
- **Severe Crohn's disease**
  - **BY INTRAMUSCULAR INJECTION**
    - Adult: Initially 25 mg once weekly until remission induced; maintenance 15 mg once weekly

**Maintenance of remission of severe Crohn's disease**
- **BY MOUTH**
  - Adult: 10 – 25 mg once weekly

**Moderate to severe active rheumatoid arthritis**
- **BY INTRAMUSCULAR INJECTION, OR BY SUBCUTANEOUS INJECTION**
  - Adult: 7.5 mg once weekly, adjusted according to response; maximum 20 mg per week

**Severe active rheumatoid arthritis**
- **BY INTRAVENOUS INJECTION, OR BY INTRACHEAL INJECTION, OR BY INTRA-ARTERIAL INFUSION, OR BY INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INFUSION, OR BY MOUTH**
  - Adult: (consult product literature)
Severe psoriasis unresponsive to conventional therapy (specialist use only)

- By mouth, or by intramuscular injection, or by intravenous injection, or by subcutaneous injection
- Adult: Initially 2.5–10 mg once weekly, then increased in steps of 2.5–5 mg, adjusted according to response, dose to be adjusted at intervals of at least 1 week; usual dose 7.5–15 mg once weekly, stop treatment if inadequate response after 3 months at the optimum dose; maximum 30 mg per week

**Unlicensed use** Not licensed for use in severe Crohn’s disease.

**Important Safety Information**

Note that the dose is a weekly dose. To avoid error with low-dose methotrexate, it is recommended that:

- the patient is carefully advised of the dose and frequency and the reason for taking methotrexate and any other prescribed medicine (e.g. folic acid);
- only one strength of methotrexate tablet (usually 2.5 mg) is prescribed and dispensed;
- the prescription and the dispensing label clearly show the dose and frequency of methotrexate administration;
- the patient is warned to report immediately the onset of any feature of blood disorders (e.g. sore throat, bruising, and mouth ulcers), liver toxicity (e.g. nausea, vomiting, abdominal discomfort, and dark urine), and respiratory effects (e.g. shortness of breath).

**Contraindications** Active infection (in non-malignant conditions) · ascites · immunodeficiency syndromes (in non-malignant conditions) · significant pleural effusion

**Caution** Acute porphyrias p. 969 · photosensitivity—psoriasis lesions aggravated by UV radiation (skin ulceration reported) · diarrhoea · extreme caution in blood disorders (avoid if severe) · peptic ulceration · risk of accumulation in pleural effusion or ascites—drain before treatment · ulcerative colitis · ulcerative stomatitis

**CAUTIONS, FURTHER INFORMATION**

- Blood count Bone marrow suppression can occur abruptly; factors likely to increase toxicity include advanced age, renal impairment, and concomitant use with another anti-folate drug (e.g. trimethoprim). A clinically significant drop in white cell count or platelet count calls for immediate withdrawal of methotrexate and introduction of supportive therapy.
- Gastro-intestinal toxicity Withdraw treatment if stomatitis develops—may be first sign of gastro-intestinal toxicity.
- Liver toxicity Liver cirrhosis reported. Treatment should not be started or should be discontinued if any abnormality of liver function tests or liver biopsy is present or develops during therapy. Abnormalities can return to normal within 2 weeks after which treatment may be recommenced if judged appropriate.
- Pulmonary toxicity Pulmonary toxicity may be a special problem in rheumatoid arthritis (patient to seek medical attention if dyspnoea, cough or fever); monitor for symptoms at each visit—discontinue if pneumonitis suspected.

**INTERACTIONS** 

- Appendix 1: methotrexate
- Rare Pneumonitis
- Frequency not known Abdominal discomfort · acne · alopecia · anaphylactic reactions · anorexia · arthralgia · blood disorders · changes in nail pigmentation · changes in skin pigmentation · chills · chronic pulmonary fibrosis · confusion · conjunctivitis · cystitis · diarrhoea · dizziness · drowsiness · dyspepsia · dysuria · ecchymosis · fever · furunculosis · gastro-intestinal bleeding · gastro-intestinal ulceration · haematuria · headache · hepatotoxicity · hypotension · impotence · injection-site reactions · insomnia · interstitial pneumonitis · malaise · menstrual disturbances · mood changes · mucositis · myalgia · myelosuppression · nausea · neurotoxicity · osteoporosis · paraesthesia · pericardial tamponade · pericarditis · photosensitivity · pleuritic pain · precipitation of diabetes · pruritus · pulmonary fibrosis · pulmonary oedema · rash · reduced libido · renal failure · Stevens-Johnson syndrome · telangiectasia · thrombosis · toxic epidermal necrolysis · toxic megacolon · urticaria · vaginitis · vasculitis · visual disturbance · vomiting

**Side-effects, Further Information**

In patients taking methotrexate for non-malignant conditions who experience side-effects, folic acid given on a different day from the methotrexate, may help to reduce the frequency of such side-effects.

Withdraw treatment if stomatitis develops—may be first sign of gastro-intestinal toxicity.

Treatment with folic acid (as calcium folinate) may be required in acute toxicity.

**Conception and Contraception** Effective contraception required during and for at least 3 months after treatment in men or women.

**Pregnancy** Avoid (teratogenic; fertility may be reduced during therapy but this may be reversible).

**Breast Feeding** Discontinue breast-feeding—present in milk.

**Hepatic Impairment** When used for malignancy, avoid in severe hepatic impairment—consult local treatment protocol for details. Avoid with hepatic impairment in non-malignant conditions—dose-related toxicity.

**Renal Impairment** Reduce dose. Risk of nephrotoxicity at high doses. Avoid in severe impairment.

**Pre-Treatment Screening** Exclude pregnancy before treatment. Patients should have full blood count and renal and liver function tests before starting treatment.

**Monitoring Requirements**

- In view of reports of blood dyscrasias (including fatalities) and liver cirrhosis with low-dose methotrexate patients should:
  - have full blood count and renal and liver function tests repeated every 1–2 weeks until therapy stabilised, thereafter patients should be monitored every 2–3 months.
  - be advised to report all symptoms and signs suggestive of infection, especially sore throat
- Local protocols for frequency of monitoring may vary.
- Treatment with folic acid (as calcium folinate) may be required in acute toxicity.

**Prescribing and Dispensing Information**

Folinic acid following methotrexate administration helps to prevent methotrexate-induced mucositis and myelosuppression.

The licensed routes of administration for parenteral preparations vary—further information can be found in the product literature for the individual preparations.

**Patient and Carer Advice**

Patients and their carers should be warned to report immediately the onset of any feature of blood disorders (e.g. sore throat, bruising, and mouth ulcers), liver toxicity (e.g. nausea, vomiting, abdominal discomfort and dark urine), and respiratory effects (e.g. shortness of breath).

Patients should be advised to avoid self-medication with over-the-counter aspirin or ibuprofen.

Patients should be counselled on the dose, treatment booklet, and the use of NSAIDs.

**Methotrexate treatment booklets** Methotrexate treatment booklets should be issued where appropriate.
In England, Wales, and Northern Ireland, they are available for purchase from:
Gorse Street, Chadderton
Oldham
OL3 9QH
Tel: 0845 610 1112
GP practices can obtain supplies through their Local Area Team stores.
NHS Hospitals can order supplies from www.nhsforms.co.uk or by emailing nhsforms@mmm.com.

In Scotland, treatment books can be obtained by emailing stockorders.dppas@theapsgroup.com or by fax on 0131 629 9967.
These books include advice for adults taking oral methotrexate for inflammatory conditions, and a section for recording results of blood tests and dosage information.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, solution for injection

**Table**

- **Methotrexate (Non-proprietary)**
  - Methotrexate 2.5 mg: Methotrexate 2.5mg tablets | 24 tablet | £3.75 | 28 tablet | £3.82 DT price | £1.77 | 100 tablet | £14.19
  - Methotrexate 10 mg: Methotrexate 10mg tablets | 100 tablet | £57.21 DT price | £33.97

- **Maxtrex** (Pfizer Ltd)
  - Methotrexate 2.5 mg: Maxtrex 2.5mg tablets | 24 tablet | £2.39 | 100 tablet | £9.96
  - Methotrexate 10 mg: Maxtrex 10mg tablets | 100 tablet | £45.16 DT price | £37.97

**Solution for injection**

- **Methotrexate (as Methotrexate sodium)** 2.5 mg per 1 ml
  - Methotrexate 5mg/2ml solution for injection vials | 5 vial | £35.00
  - Methotrexate (as Methotrexate sodium) 25 mg per 1 ml
    - Methotrexate 5g/200ml solution for infusion vials | 1 vial | £100.57
  - Methotrexate (as Methotrexate sodium) 100 mg per 1 ml
    - Methotrexate 5g/50ml solution for infusion vials | 1 vial | £400.00

**Oral solution**

- **Methotrexate (as Methotrexate sodium)** 2 mg per 1 ml
  - Methotrexate 2mg/ml oral solution sugar free sugar-free | 35 ml | £95.00–£114.00 DT price | £95.00 sugar-free | 65 ml | £125.00–£145.00 DT price | £125.00

**Nelarabine**

- **INDICATIONS AND DOSE**

  **T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma in patients who have relapsed or who are refractory after receiving at least two previous regimens**

  - **BY INTRAVENOUS INFUSION**
  - **Adult:** (consult local protocol)

  - **CAUTIONS**
  - Previous or concurrent craniospinal irradiation (increased risk of neurotoxicity)
  - Previous or concurrent intrathecal chemotherapy (increased risk of neurotoxicity)

- **INTERACTIONS** → Appendix 1: nelarabine

- **SIDE-EFFECTS**

  - **Common or very common**
  - Neurotoxicity (discontinue)
  - Frequency not known Abdominal pain, alopecia, amnesia, anorexia, arthralgia, asthenia, ataxia, benign and malignant tumours, blurred vision, bone-marrow suppression, confusion, constipation, cough, demyelination, diarrhoea, dizziness, drowsiness, dryness, electrolyte disturbances, extravasation, fatigue, headache, hyperuricaemia, hypoesthesia, hypotension, muscle weakness, myalgia, nausea, oedema, oral mucositis, paraesthesia, peripheral neurological disorders, pleural effusion, pyrexia, seizures, taste disturbance, thromboembolism, tremor, tumour lysis syndrome, vomiting, wheezing

- **CONCEPTION AND CONTRACEPTION**

  Manufacturer advises effective contraception during and for at least 3 months after treatment in men and women.
Pregnancy
Avoid (toxicity in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

Breastfeeding
Discontinue breast-feeding.

Monitoring requirements
- Neurotoxicity: Close monitoring for neurological events is strongly recommended—discontinue if neurotoxicity occurs.

Patient and carer advice
Driving and skilled tasks
Drowsiness may affect performance of skilled tasks (e.g., cycling or driving).

National funding/access decisions
Scottish Medicines Consortium (SMC) decisions
The Scottish Medicines Consortium has advised (March 2008) that the use of nelarabine (Atriance®) within NHS Scotland is restricted to bridging treatment before stem cell transplantation.

Medicinal forms
There can be variation in the licensing of different medicines containing the same drug.

Solution for infusion
Electrolytes: May contain Sodium
- Atriance (Novartis Pharmaceuticals UK Ltd) ▼
  Nelarabine 5 mg per 1 ml
  Atriance 250mg/50ml solution for infusion
  vials | 6 vial (Path) £1,332.00

Pemetrexed

Drug action
Pemetrexed inhibits thymidylate transferase and other folate-dependent enzymes.

Indications and dose
Treatment of unresectable malignant pleural mesothelioma which has not previously been treated with chemotherapy (in combination with cisplatin) | First-line treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (in combination with cisplatin) | Second-line treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (monotherapy) | Maintenance treatment in locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology that has not progressed immediately following platinum-based chemotherapy (monotherapy)
- By intravenous infusion
- Adult: (consult local protocol)

Cautions
Diabetes • history of cardiovascular disease • prophylactic folic acid supplementation required (consult product literature) • prophylactic vitamin B12 supplementation required (consult product literature)

Interactions ➔ Appendix 1: pemetrexed

Side-effects
- Common or very common
  Conjunctivitis • dehydration • gastro-intestinal disturbances • increased lacrimation • neuropathy • oedema • skin disorders
- Uncommon
  Arrhythmias • colitis • interstitial pneumonitis
- Rare
  Acute renal failure • hepatitis • peripheral ischaemia
- Frequency not known
  Alopecia • bone-marrow suppression • extravasation • hyperuricaemia • nausea • oral mucositis • Stevens–Johnson syndrome • thromboembolism • toxic epidermal necrolysis • tumour lysis syndrome • vomiting

Conception and contraception
Manufacturer advises effective contraception during treatment. Men must avoid fathering a child during and for 6 months after treatment.

Pregnancy
Avoid (toxicity in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

Breastfeeding
Discontinue breast-feeding.

Renal impairment
Manufacturer advises avoid if creatinine clearance less than 45 mL/minute—no information available.

National funding/access decisions
NICE technology appraisals (TAs)
- Pemetrexed for the treatment of non-small cell lung cancer (June 2010) NICE TA190
  Pemetrexed is an option for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology that has not progressed immediately following combination therapy of a platinum compound with either gemcitabine, paclitaxel, or docetaxel.
  www.nice.org.uk/TA190
- Pemetrexed for the treatment of non-small cell lung cancer (August 2007) NICE TA124
  Pemetrexed is not recommended for the treatment of locally advanced or metastatic non-small cell lung cancer which has previously been treated with chemotherapy.
  www.nice.org.uk/TA124
- Pemetrexed for the first-line treatment of non-small cell lung cancer (September 2009) NICE TA181
  Pemetrexed, in combination with cisplatin, is an option for the first-line treatment of locally advanced or metastatic non-small cell lung cancer only if the histology of the tumour has been confirmed as adenocarcinoma or large-cell carcinoma.
  www.nice.org.uk/TA181
- Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (August 2016) NICE TA402
  Pemetrexed is recommended as an option for the maintenance treatment of locally advanced or metastatic non-squamous non-small-cell lung cancer when: a patient’s disease has not progressed immediately after 4 cycles of pemetrexed and cisplatin induction therapy; their Eastern Cooperative Oncology Group (ECOG) performance status is 0 or 1 at the start of maintenance treatment; the company provides the drug according to the terms of the commercial access agreement as agreed with NHS England.
  Patients whose treatment was started within the NHS before this guidance was published should have the option to continue treatment, without change to their funding arrangements, until they and their clinicians consider it appropriate to stop.
  www.nice.org.uk/TA402
- Pemetrexed for the treatment of malignant pleural mesothelioma (January 2008) NICE TA135
  Pemetrexed is an option for the treatment of malignant pleural mesothelioma only in patients who have a WHO performance status of 0 or 1 [WHO performance status is a measure of the ability to perform ordinary tasks], who are considered to have advanced disease and for whom surgical resection is considered inappropriate.
  www.nice.org.uk/TA135

Scottish Medicines Consortium (SMC) decisions
The Scottish Medicines Consortium has advised (August 2008) that pemetrexed (Alimta®) is accepted for restricted use within NHS Scotland as monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer without predominantly squamous cell histology; it is restricted for use in patients with good performance status who would otherwise be eligible for docetaxel treatment.

The Scottish Medicines Consortium has advised (January 2010) that pemetrexed (Alimta®) is accepted for restricted use within NHS Scotland in combination with cisplatin for the first-line treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology; it is restricted to patients in...
whom the histology of the tumour has been confirmed as adenocarcinoma or large cell carcinoma.

The Scottish Medicines Consortium has advised (July 2005) that pemetrexed (Alimta®) in combination with cisplatin is accepted for restricted use within NHS Scotland for previously untreated patients with stage III/IV unresectable malignant pleural mesothelioma.

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

<table>
<thead>
<tr>
<th>Solution for infusion</th>
<th>BY MOUTH</th>
<th>Combination with cisplatin (Thiopurine methyltransferase status)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pemetrexed (Non-proprietary)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pemetrexed (as Pemetrexed ditrometanol) 25 mg per 1 ml</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pemetrexed 100mg/4ml concentrate for solution for infusion vials</td>
<td>1 vial (POD) £140.00</td>
<td></td>
</tr>
<tr>
<td>Pemetrexed 500mg/20ml concentrate for solution for infusion vials</td>
<td>1 vial (POD) £700.00</td>
<td></td>
</tr>
<tr>
<td>Pemetrexed 1000mg/40ml concentrate for solution for infusion vials</td>
<td>1 vial (POD) £1,400.00</td>
<td></td>
</tr>
<tr>
<td>Powder for solution for infusion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Electrolytes: May contain Sodium</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pemetrexed (Non-proprietary)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pemetrexed (as Pemetrexed disodium) 100 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pemetrexed 100mg powder for concentrate for solution for infusion vials</td>
<td>1 vial (POD) £150.00 (Hospital only)</td>
<td></td>
</tr>
<tr>
<td>Pemetrexed (as Pemetrexed disodium) 500 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pemetrexed 500mg powder for concentrate for solution for infusion vials</td>
<td>1 vial (POD) £800.00 (Hospital only)</td>
<td></td>
</tr>
<tr>
<td>Alimta (Eli Lilly and Company Ltd)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pemetrexed (as Pemetrexed disodium) 100 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alimta 100mg powder for concentrate for solution for infusion vials</td>
<td>1 vial (POD) £200.00 (Hospital only)</td>
<td></td>
</tr>
<tr>
<td>Pemetrexed (as Pemetrexed disodium) 500 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alimta 500mg powder for concentrate for solution for infusion vials</td>
<td>1 vial (POD) £800.00 (Hospital only)</td>
<td></td>
</tr>
</tbody>
</table>

### RENAL IMPAIRMENT

Reduced dose if creatinine clearance 30–50 ml/minute—consult product literature. Manufacturer advises avoid if creatinine clearance less than 30 ml/minute.

### NATIONAL FUNDING/ACCESS DECISIONS

#### Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (August 2012) that tegafur with gimeracil and oteracil (Teysono®) is accepted for restricted use within NHS Scotland for the treatment of advanced gastric cancer, when given in combination with cisplatin, in patients who are unsuitable for an anthracycline, fluorouracil and platinum triplet first-line regimen.

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

<table>
<thead>
<tr>
<th>Capsule</th>
<th>CAUTIONARY AND ADVISORY LABELS 23</th>
</tr>
</thead>
<tbody>
<tr>
<td>Teysono (Nordic Pharma Ltd)</td>
<td></td>
</tr>
<tr>
<td>Gimeracil 4.35 mg, Oteracil (as Oteracil potassium) 11.8 mg, Tegafur 15 mg</td>
<td>Teysono 15mg/4.35mg/11.8mg capsules</td>
</tr>
<tr>
<td>Gimeracil 5.8 mg, Oteracil (as Oteracil potassium) 15.8 mg, Tegafur 20 mg</td>
<td>Teysono 20mg/5.8mg/15.8mg capsules</td>
</tr>
</tbody>
</table>

---

### Tioguanine (Thioguanine)

#### INDICATIONS AND DOSE

Acute leukaemia | Chronic myeloid leukaemia

- **BY MOUTH**
- Adult: 100–200 mg/m² daily, can be given at various stages of treatment in short-term cycles

#### IMPORTANT SAFETY INFORMATION

**RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES**

See Cytotoxic drugs p. 825.

- **CONTRA-INDICATIONS** Absent thiopurine methyltransferase activity
- **CAUTIONS** Thiopurine methyltransferase status

**CAUTIONS, FURTHER INFORMATION**

- Thiopurine methyltransferase The enzyme thiopurine methyltransferase (TPMT) metabolises thiopurine drugs (azathioprine, mercaptopurine, tioguanine); the risk of myelosuppression is increased in patients with reduced activity of the enzyme, particularly for the few individuals in whom TPMT activity is undetectable. Patients with absent TPMT activity should not receive thiopurine drugs; those with reduced TPMT activity may be treated under specialist supervision.
- Long-term therapy Long-term therapy is no longer recommended because of the high risk of liver toxicity.

#### INTERACTIONS

- Appendix 1: tioguanine
- **SIDE-EFFECTS**
  - Rare Intestinal necrosis | intestinal perforation
  - Frequency not known Allopecia | bone-marrow suppression | hyperuricaemia | nausea | neuropathy | ocular toxicity | oral mucositis | thromboembolism | tumour lysis syndrome | vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

- Gastro-intestinal side-effects Tioguanine has a lower incidence of gastrointestinal side-effects than mercaptopurine.
- **CONCEPTION AND CONTRACEPTION** Ensure effective contraception during treatment in men or women.
- **PREGNANCY** Avoid (teratogenicity reported when men receiving tioguanine have fathered children). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.
- **BREAST FEEDING** Discontinue breast-feeding.
Trifluridine with tipiracil 24-Apr-2017

**INDICATIONS AND DOSE**
Metastatic colorectal cancer, in patients previously treated with (or unsuitable for treatment with) available therapies including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, or anti-vascular endothelial growth factor (VEGF) agents, or anti-epidermal growth factor receptor (EGFR) agents (specialist use only)

▶ **BY MOUTH**
Adult: Initially 35 mg/m² twice daily (max. per dose 80 mg), given on days 1 to 5 and days 8 to 12 of each 28-day cycle, consult product literature for further information on dose adjustment.

**IMPORTANT SAFETY INFORMATION**
**RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES**
See Cytotoxic drugs p. 825.

**SIDE-EFFECTS**
▶ Common or very common Abdominal pain, bone-marrow suppression, constipation, cough, diarrhoea, dizziness, dysgeusia, dysphonia, flushing, headache, hypoalbuminaemia, nausea, palmar-plantar erythrodysaesthesia, peripheral neuropathy, proteinuria, pruritus, rash, stomatitis, vomiting.
▶ Uncommon Acute pancreatitis, angina, arthralgia, blood pressure changes, blood-electrolyte concentration changes, blurred vision, buccal polyp, cataract, dehydration, diplopia, dry eye, dyspepsia, dysphonia, embolism, epistaxis, erythema, gastritis, gastro-oesophageal reflux disease, gout, haematuria, haemorrhage, hepatotoxicity, hyperglycaemia, lethargy, leukocyturia, muscle spasm, neurotoxicity, oesophagitis, palpitations, paraesthesia, photosensitivity reaction, pulmonary embolism, renal failure, septic shock (fatal cases have been reported), syncope, urticaria, vertigo.

**CONCEPTION AND CONTRAINDICATION**
Manufacturer advises effective contraception in women of child-bearing potential and in men as a partner of child-bearing potential, during treatment and for 6 months after stopping treatment. Manufacturer also advises use of an additional barrier method in women using hormonal contraceptives—effect of trifluridine with tipiracil on hormonal contraception unknown.

**PREGNANCY**
Manufacturer advises avoid unless essential—reproductive toxicity in animal studies.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule
- **Tablet**
  - Tioguanine (Non-proprietary)
    - Tioguanine 40 mg Tioguanine 40mg tablets | 25 tablet

**Milk**
Manufacturer advises avoid in breast feeding.

**BREAST FEEDING**
Manufacturer advises avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT**
Manufacturer advises avoid in moderate-to-severe impairment—no information available.

**RENAI IMPAIRMENT**
Manufacturer advises caution if eGFR 30–59 mL/minute/1.73 m²—monitor for haematological toxicities; manufacturer advises avoid if eGFR less than 30 mL/minute/1.73 m²—no information available.

**MONITORING REQUIREMENTS**
Manufacturer advises obtain baseline blood cell counts before and during treatment; monitor closely for myelosuppression.

**NATIONAL FUNDING/ACCESS DECISIONS**
NICE technology appraisals (TAs)
- Trifluridine with tipiracil for previously treated metastatic colorectal cancer (August 2016) NICE TA405
  Trifluridine with tipiracil is recommended, within its marketing authorisation, as an option for treating metastatic colorectal cancer in adults, only when provided by the manufacturer with the discount agreed in the patient access scheme.
  www.nice.org.uk/guidance/TA405

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (February 2017) that trifluridine with tipiracil (Lonsurf™) is accepted for use within NHS Scotland for the treatment of adults with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vascular endothelial growth factor agents, and anti-epidermal growth factor receptor agents.

This advice is contingent upon the continuing availability of the Patient Access Scheme in NHS Scotland or a list price that is equivalent or lower.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.
- **Tablet**
  - CAUTIONARY AND ADVISORY LABELS, 21
  - Lonsurf (Servier Laboratories Ltd) ▼
    - Tipiracil (as Tipiracil hydrochloride) 6.14 mg, Trifluridine
      - 15 mg Lonsurf 15mg/6.14mg tablets | 20 tablet | £500.00 | £1,500.00
      - Tipiracil (as Tipiracil hydrochloride) 8.19 mg, Trifluridine
        - 20 mg Lonsurf 20mg/8.19mg tablets | 20 tablet | £666.67 | £2,000.00

**ANTINEOPLASTIC DRUGS**
**CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES**

**Bleomycin**

**INDICATIONS AND DOSE**
Squamous cell carcinoma | Metastatic germ cell cancer | Non-Hodgkin’s lymphoma

▶ **BY INTRAVENOUS INJECTION, OR BY LOCAL INFILTRATION, OR BY INTRA-ARTERIAL INFUSION, OR BY INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INFUSION**
Adult: (consult product literature or local protocols)

**CAUTIONS**
Caution in handling—irritant to tissues

**INTERACTIONS**
Appendix 1: bleomycin

**SIDE-EFFECTS**
Common or very common Dermatological toxicity, mucositis

**CONCEPTION AND CONTRAINDICATION**
Manufacturer advises effective contraception in women of child-bearing potential and in men as a partner of child-bearing potential, during treatment and for 6 months after stopping treatment. Manufacturer also advises use of an additional barrier method in women using hormonal contraceptives—effect of trifluridine with tipiracil on hormonal contraception unknown.

**PREGNANCY**
Manufacturer advises avoid unless essential—reproductive toxicity in animal studies.

**Milk**
Manufacturer advises avoid in breast feeding.
Mitomycin 10 mg powder for solution for injection | 1 vial (Pom) £75.98

Mitomycin 20 mg powder for solution for injection | 1 vial (Pom) £39.94

Mitomycin 40 mg powder for solution for injection | 1 vial (Pom) £79.88

As containing the same drug.

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops

**Medicinal forms**

**INDICATIONS AND DOSE**

Hairy cell leukaemia (initiated in specialist centres)

- By intravenous injection, or by intravenous infusion

Adult: To be given on alternate weeks (consult product literature)

**INTERACTIONS** → Appendix 1: pentostatin

**SIDE-EFFECTS**

Alopecia · bone-marrow suppression · extravasation · hyperuricaemia · lung fibrosis · nausea · oral mucositis · renal damage · thromboembolism · tumour lysis syndrome · vomiting

**SPECIFIC SIDE-EFFECTS**

- With intravenous use Extravasation

**SIDE-EFFECTS, FURTHER INFORMATION**

- Bone-marrow toxicity. Mitomycin is usually administered at 6-weekly intervals because it causes delayed bone-marrow toxicity. Prolonged use may result in a permanent effect.

**CONCEPTION AND CONTRACEPTION**

Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**PREGNANCY**

Avoid (teratogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**BREAST FEEDING**

Discontinue breast-feeding.

**MEDICINAL FORMS**

Theoretically, there can be variation in the licensing of different medicines containing the same drug. Manufacturers include: eye drops

**Pentostatin**

**INDICATIONS AND DOSE**

Hairy cell leukaemia (initiated in specialist centres)

- By intravenous injection, or by intravenous infusion

Adult: To be given on alternate weeks (consult product literature)

**INTERACTIONS** → Appendix 1: pentostatin

**SIDE-EFFECTS**

Alopecia · bone-marrow suppression · extravasation · hyperuricaemia · immunosuppression · myelosuppression · nausea · neurotoxicity (withhold or discontinue) · oral mucositis · severe rash (withhold treatment) · thromboembolism · tumour lysis syndrome · vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

Pentostatin can cause myelosuppression, immunosuppression, and a number of other side-effects that may be severe. Treatment should be withheld in patients who develop a severe rash, and withheld or discontinued in patients showing signs of neurotoxicity.

**CONCEPTION AND CONTRACEPTION**

Manufacturer advises that men should not father children during and for 6 months after treatment.

**PREGNANCY**

Avoid (teratogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**BREAST FEEDING**

Discontinue breast-feeding.

**HEPATIC IMPAIRMENT**

Manufacturer advises caution—limited information available.

**RENAL IMPAIRMENT**

Avoid if creatinine clearance less than 60 ml/minute.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for injection**

Pentostatin 10 mg Nipent 10mg powder for solution for injection vials | 1 vial (Pom) £75.21 (Hospital only)
Trabectedin

10-Jun-2016

> INDICATIONS AND DOSE

Treatment of advanced soft-tissue sarcoma when treatment with anthracyclines and ifosfamide has failed or is contra-indicated. Treatment of relapsed platinum-sensitive ovarian cancer (in combination with pegylated liposomal doxorubicin)

- By Intravenous infusion
- Adult: (consult product literature or local protocols)

- CONTRA-INDICATIONS - Elevated creatine phosphokinase (consult product literature)
- INTERACTIONS - Appendix 1: trabectedin
- SIDE-EFFECTS - Rare Rhabdomyolysis (with raised creatine phosphokinase)

SIDE-EFFECTS, FURTHER INFORMATION
A corticosteroid, such as dexamethasone by intravenous infusion, must be given 30 minutes before therapy for its antiemetic and hepatoprotective effects (consult product literature).

- CONCEPTION AND CONTRACEPTION - Effective contraception recommended during and for at least 3 months after treatment in women and during and for at least 5 months after treatment in men.
- PREGNANCY - See Pregnancy and reproductive function in Cytotoxic drugs p. 825.
- BREAST FEEDING - Manufacturer advises avoid breast-feeding during and for 3 months after treatment.
- RENAL IMPAIRMENT - Avoid monotherapy if creatinine clearance less than 60 mL/minute. Avoid combination regimens if creatinine clearance less than 60 mL/minute.
- MONITORING REQUIREMENTS - Specific haematological, renal and hepatic parameters must be monitored and within certain ranges prior to starting treatment and repeated weekly during the first 2 cycles and at least once between treatments in subsequent cycles—consult product literature for full details.
- Monitor for signs and symptoms of rhabdomyolysis (including myelotoxicity, severe liver function disorder, renal failure, muscle weakness or pain)—monitor creatine phosphokinase closely and discontinue treatment (consult product literature).

- NATIONAL FUNDING / ACCESS DECISIONS

NICE technology appraisals (TAs)
- Trabectedin for the treatment of advanced soft tissue sarcoma (February 2010) NICE TA185

Trabectedin is an option for advanced soft tissue sarcoma when treatment with anthracyclines and ifosfamide has failed, is inappropriate or is not tolerated. The cost of trabectedin for treatment after the fifth cycle is met by the manufacturer.

www.nice.org.uk/TA185

- MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for infusion

- Yondelis (Pharma Mar, S.A.)
  - Trabectedin 250 microgram Yondelis 0.25mg powder for concentrate for solution for infusion vials | 1 vial (£63.00 (Hospital only)
  - Trabectedin 1 mg Yondelis 1mg powder for concentrate for solution for infusion vials | 1 vial (£1.366.00 (Hospital only)

Carboplatin

10-Jun-2016

> INDICATIONS AND DOSE

Treatment of advanced ovarian cancer and lung cancer (particularly the small cell type)

- By Intravenous infusion
- Adult: The dose of carboplatin is determined according to renal function rather than body surface area (consult product literature)

INTERACTIONS - Appendix 1: platinum compounds


SIDE-EFFECTS, FURTHER INFORMATION
Carboplatin is better tolerated than cisplatin; nausea and vomiting are reduced in severity and nephrotoxicity, neurotoxicity, and ototoxicity are much less of a problem than with cisplatin. It is, however, more myelosuppressive than cisplatin.

CONCEPTION AND CONTRACEPTION - Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 825.

PREGNANCY - Avoid (teratogenic and embryotoxic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

BREAST FEEDING - Discontinue breast-feeding.

RENAI IMPAIRMENT - Reduce dose. Avoid if creatinine clearance less than 20 mL/minute. Monitor haematological parameters in renal impairment. Monitor renal function in renal impairment.

PRESCRIBING AND DISPENSING INFORMATION - Carboplatin can be given in an outpatient setting.

NATIONAL FUNDING / ACCESS DECISIONS

NICE technology appraisals (TAs)
- Bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer (May 2013) NICE TA284

Bevacizumab in combination with paclitaxel and carboplatin is not recommended for the first-line treatment of advanced ovarian cancer (including fallopian tube and primary peritoneal cancer).
Bevacizumab in combination with gemcitabine and carboplatin for the treatment of the first recurrence of platinum-sensitive advanced ovarian cancer (May 2013) NICE TA285

Bevacizumab in combination with gemcitabine and carboplatin is not recommended within its marketing authorisation, that is, for the treatment of the first recurrence of platinum-sensitive advanced ovarian cancer (including fallopian tube and primary peritoneal cancer) that has not been previously treated with bevacizumab or other vascular endothelial growth factor (VEGF) inhibitors or VEGF receptor-targeted agents. www.nice.org.uk/TA285

Medicinal forms

There can be variation in the licensing of different medicines containing the same drug.

Solution for infusion

- **Carboplatin (Non-proprietary)**
  - **Carboplatin 10 mg per 1 ml** Carboplatin 50mg/5ml concentrate for solution for infusion vials | 1 vial POM £22.04 (Hospital only) | 1 vial POM £20.00
  - Carboplatin 150mg/15ml concentrate for solution for infusion vials | 1 vial POM £56.92 (Hospital only) | 1 vial POM £50.00
  - Carboplatin 600mg/60ml concentrate for solution for infusion vials | 1 vial POM £260.00
  - Carboplatin 600mg/60ml concentrate for solution for infusion vials | 1 vial POM £260.00
  - Carboplatin 450mg/45ml concentrate for solution for infusion vials | 1 vial POM £168.85 (Hospital only) | 1 vial POM £160.00
  - Carboplatin 450mg/45ml concentrate for solution for infusion vials | 1 vial POM £197.48
  - Carboplatin 150mg/15ml concentrate for solution for infusion vials | 1 vial POM £65.83
  - Carboplatin 50mg/5ml solution for infusion vials | 1 vial POM £22.86

Cisplatin

- **INDICATIONS AND DOSE**
  - Treatment of testicular, lung, cervical, bladder, head and neck, and ovarian cancer (alone or in combination)
  - **BY INTRAVENOUS INFUSION**
  - Adult: (consult product literature)

- **CAUTIONS**
  - **CAUTIONS, FURTHER INFORMATION**
  - Hydration Cisplatin requires intensive intravenous hydration and treatment may be complicated by severe nausea and vomiting.

- **INTERACTIONS** → Appendix 1: platinum compounds

- **SIDE-EFFECTS**
  - Alopecia - bone-marrow suppression - extravasation - hyperuricaemia - hypomagnesaemia - myelosuppression - nephrotoxicity - oral mucositis - ototoxicity - peripheral neuropathy - severe nausea - severe vomiting - thromboembolism - tumour lysis syndrome

- **CONCEPTION AND CONTRACEPTION**
  - Manufacturer advises effective contraception during and for at least 6 months after treatment in men or women.

- **PREGNANCY**
  - Avoid (teratogenic and toxic in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

- **BREAST FEEDING**
  - Discontinue breast-feeding.

- **RENAL IMPAIRMENT**
  - Avoid if possible — nephrotoxic.

- **MONITORING REQUIREMENTS**
  - Monitor full blood count.
  - Monitor audiometry.
  - Monitor plasma electrolytes.
  - Nephrotoxicity Monitoring of renal function is essential.

- **DIRECTIONS FOR ADMINISTRATION**
  - Cisplatin is increasingly given in a day care setting.

Oxaliplatin

- **INDICATIONS AND DOSE**
  - Treatment of metastatic colorectal cancer (in combination with fluorouracil and folinic acid) - Treatment of colon cancer after resection of the primary tumour (adjuvant treatment)
  - **BY INTRAVENOUS INFUSION**
  - Adult: (consult product literature)

- **CONTRA-INDICATIONS**
  - Peripheral neuropathy with functional impairment

- **INTERACTIONS** → Appendix 1: platinum compounds

- **SIDE-EFFECTS**
  - Alopecia - bone-marrow suppression - extravasation - gastro-intestinal disturbances - hyperuricaemia - myelosuppression - nausea - neurotoxicity (dose limiting) - ototoxicity - posterior reversible encephalopathy syndrome (associated with oxaliplatin combination chemotherapy) - sensory peripheral neuropathy (dose limiting) - thromboembolism - transient vision loss (reversible on discontinuation) - tumour lysis syndrome - vomiting

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Respiratory symptoms - If unexplained respiratory symptoms occur, oxaliplatin should be discontinued until investigations exclude interstitial lung disease and pulmonary fibrosis.

- **CONCEPTION AND CONTRACEPTION**
  - Effective contraception required during and for 4 months after treatment in women and 6 months after treatment in men.

- **PREGNANCY**
  - Manufacturer advises avoid — toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

- **BREAST FEEDING**
  - Discontinue breast-feeding.

- **RENAL IMPAIRMENT**
  - Reduce dose in mild to moderate impairment (consult product literature). Avoid if creatinine clearance less than 30 ml/minute.

- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **NICE technology appraisals (TAs)**
    - Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer (April 2006) NICE TA100
    - Capecitabine alone or oxaliplatin combined with fluorouracil and folinic acid are options for adjuvant treatment following surgery for stage III (Dukes’ C) colon cancer.
    - www.nice.org.uk/TA100
  - Irinotecan, oxaliplatin, and raltitrexed for advanced colorectal cancer (August 2005) NICE TA93
    - A combination of fluorouracil and folinic acid with either irinotecan or oxaliplatin are options for first-line treatment for advanced colorectal cancer.
Irinotecan alone or fluorouracil and folinic acid with oxaliplatin are options for patients who require further treatment subsequently.

www.nice.org.uk/T943

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Solution for infusion**

- **Oxaliplatin (Non-proprietary)**
  - Oxaliplatin 5 mg per 1 ml Oxaliplatin 100mg/20ml concentrate for solution for infusion vials | 1 vial (POM) £283.32-£330.00 (Hospital only) | 1 vial (POM) £131.50
  - Oxaliplatin 50mg/10ml concentrate for solution for infusion vials | 1 vial (POM) £141.48-£156.00 (Hospital only) | 1 vial (POM) £156.75
  - Oxaliplatin 200mg/40ml concentrate for solution for infusion vials | 1 vial (POM) £595.65 (Hospital only) | 1 vial (POM) £627.00

**Powder for solution for infusion**

- **Oxaliplatin (Non-proprietary)**
  - Oxaliplatin 50 mg Oxaliplatin 50mg powder for solution for infusion vials | 1 vial (POM) £156.75
  - Oxaliplatin 100 mg Oxaliplatin 100mg powder for solution for infusion vials | 1 vial (POM) £313.50

**ANCINEOPLASTIC DRUGS ＞ PODOPHYLLOTOXIN DERIVATIVES**

**Etoposide**

- **INDICATIONS AND DOSE**
  - Small cell carcinoma of the bronchus, the lymphomas and testicular cancer
  - BY MOUTH
  - Adult: 120–240 mg/m² daily for 5 days
  - BY INTRAVENOUS INFUSION
  - Adult: (consult product literature)

**IMPORTANT SAFETY INFORMATION**

**RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES**
See Cytotoxic drugs p. 825.

- **INTERACTIONS**
  - Appendix 1: etoposide
- **SIDE-EFFECTS**
  - Alopecia - bone-marrow suppression - hyperuricaemia - irritant to tissues - nausea - oral mucositis (more common if given with doxorubicin) - thromboembolism - tumour lymph syndrome - vomiting
- **CONCEPTION AND CONTRACEPTION**
  - Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 825.
- **PREGNANCY**
  - Avoid (teratogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.
- **BREAST FEEDING**
  - Discontinue breast-feeding.
- **HEPATIC IMPAIRMENT**
  - Avoid in severe impairment.
- **RENAL IMPAIRMENT**
  - Consider dose reduction—consult local treatment protocol for details.
- **DIRECTIONS FOR ADMINISTRATION**
  - Etoposide may be given orally or by slow intravenous infusion, the oral dose being double the intravenous dose. A preparation containing etoposide phosphate can be given by intravenous injection or infusion. Etoposide is usually given daily for 3–5 days and courses should not be repeated more frequently than at intervals of 21 days.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  **Solution for infusion**

  - **Etoposide (Non-proprietary)**
    - Etoposide 20 mg per 1 ml Etoposide 100mg/5ml concentrate for solution for infusion vials | 1 vial (POM) no price available (Hospital only) | 1 vial (POM) £11.50 | 10 vial (POM) £115.00

**ANTINEOPLASTIC DRUGS ＞ TAXANES**

**Cabazitaxel**

- **INDICATIONS AND DOSE**
  - Treatment of hormone refractory metastatic prostate cancer in patients who have previously been treated with a docetaxel-containing regimen (in combination with prednisone or prednisolone)
  - BY INTRAVENOUS INFUSION
  - Adult: (consult product literature or local protocols)
- **CAUTIONS**
  - Avoid in acute porphyrias p. 969
- **INTERACTIONS**
  - Appendix 1: taxanes
- **SIDE-EFFECTS**
  - Common or very common
    - Hypersensitivity reactions
    - Frequency not known
- **SIDE-EFFECTS, FURTHER INFORMATION**
  - For further information on side-effects, consult product literature.
  - Hypersensitivity reactions
    - Routine premedication with a corticosteroid, an antihistamine, and a histamine H₂-receptor antagonist is recommended to prevent severe hypersensitivity reactions.
  - CONCEPTION AND CONTRACEPTION
    - Ensure effective contraception during treatment (women) and for up to 6 months after treatment (men).
- **PREGNANCY**
  - See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.
- **BREAST FEEDING**
  - Discontinue breast-feeding.
- **HEPATIC IMPAIRMENT**
  - Avoid.
- **RENAL IMPAIRMENT**
  - Use with caution if creatinine clearance less than 50 mL/minute.
- **MONITORING REQUIREMENTS**
  - Monitor electrolytes—correct dehydration.
- **DIRECTIONS FOR ADMINISTRATION**
  - Intravenous infusion incompatible with PVC.

**Powder for solution for injection**

- **Etopophos** (Bristol-Myers Squibb Pharmaceuticals Ltd)
  - Etoposide (as Etoposide phosphate) 100 mg Etopophos 100mg powder for solution for injection vials | 10 vial (POM) £201.58 (Hospital only)

**Capsule**

- **CAUTIONARY AND ADVISORY LABELS**
  - 23

- **Vepsid** (Bristol-Myers Squibb Pharmaceuticals Ltd)
  - Etoposide 50 mg Vepsid 50mg capsules | 20 capsule (POM) £99.82 (Hospital only)

- **Etoposide 100 mg** Vepsid 100mg capsules | 10 capsule (POM) £87.23 (Hospital only)
NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)
- Cabazitaxel for hormone-related metastatic prostate cancer treated with docetaxel (updated August 2016) NICE TA391
  - Cabazitaxel in combination with prednisone or prednisolone is recommended as an option for treating metastatic hormone-related prostate cancer in patients whose disease has progressed during or after docetaxel chemotherapy, only if the following criteria are met:
    - the patient has an eastern cooperative oncology group (ECOG) performance status of 0 or 1
    - the patient has had 225 mg/m² or more of docetaxel
    - treatment with cabazitaxel is stopped when the disease progresses or after a maximum of 10 cycles
    - the manufacturer provides cabazitaxel with the discount agreed in the patient access scheme
    - NHS trusts purchase cabazitaxel in accordance with the commercial access agreement, either in vials (at a reduced price to reflect the average cost of waste per patient), or in pre-prepared intravenous infusion bags.
  - Patients currently receiving cabazitaxel that is not recommended according to the above criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop.
  - www.nice.org.uk/TA391

Scottish Medicines Consortium (SMC) Decisions
- The Scottish Medicines Consortium (SMC) has advised (December 2016) that cabazitaxel (Jevtana®) in combination with prednisone or prednisolone is accepted for restricted use within NHS Scotland for the treatment of adult patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen (patients who have received at least 225 mg/m² (three cycles) of docetaxel and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1). This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.

MEDICINAL FORMS
- There can be variation in the licensing of different medicines containing the same drug.

Solution for infusion
- EXCIPIENTS: May contain Ethanol
  - Jevtana (Sanofi)
    - Cabazitaxel 40 mg per 1 ml JEVITANA 60mg/1.5ml concentrate and solvent for solution for infusion vials | 1 vial (£75) £3,696.00
      (Hospital only)

Docetaxel

INDICATIONS AND DOSE
- Adjuvant treatment of operable node-positive and operable node-negative breast cancer (in combination with doxorubicin and cyclophosphamide) | Initial chemotherapy of locally advanced or metastatic breast cancer (with doxorubicin) | Locally advanced or metastatic breast cancer where cytotoxic chemotherapy with an anthracycline or an alkylating drug has failed (monotherapy) | Locally advanced or metastatic breast cancer where cytotoxic chemotherapy with an anthracycline has failed (with capcetabine) | Initial chemotherapy of metastatic breast cancer which overexpresses human epidermal growth factor-2 (with trastuzumab) | Locally advanced or metastatic non-small cell lung cancer where previous chemotherapy has failed | Initial chemotherapy of unresetable, locally advanced or metastatic non-small cell lung cancer (with cisplatin) | Hormone-resistant metastatic prostate cancer (in combination with prednisone or prednisolone) | Initial treatment of metastatic gastric adenocarcinoma, including adenocarcinoma of the gastro-oesophageal junction (with cisplatin and fluorouracil) | Induction treatment of locally advanced squamous cell carcinoma of the head and neck (with cisplatin and fluorouracil)
- BY INTRAVENOUS INFUSION
- Adult: (consult product literature or local protocols)

CAUTIONS
- Avoid in acute porphyrias p. 969 - consult product literature

SIDE-EFFECTS
- Alopecia | bone-marrow suppression | cytoid maculae oedema | extravasation | fatal respiratory disorders | gastro-intestinal toxicity | heart failure | hypersensitivity reactions | hyperuricaemia | nausea | oral mucositis | peripheral neurotoxicity | persistent fluid retention (commonly as leg oedema that worsens during treatment) can be resistant to treatment | severe skin reactions | thromboembolism | tumour lysis syndrome | vomiting

SIDE-EFFECTS, FURTHER INFORMATION
- Consult product literature for monitoring and management of side effects.
- Hypersensitivity reactions and fluid retention | Pretreatment with dexamethasone by mouth is recommended for reducing fluid retention and hypersensitivity reactions (consult product literature).

CONCEPTION AND CONTRACEPTION
- Manufacturer advises effective contraception for men and women during treatment, and for at least 6 months after stopping treatment in men.

PREGNANCY
- Avoid (toxicity in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

BREAST FEEDING
- Discontinue breast-feeding.

HEPATIC IMPAIRMENT
- Reduce dose according to liver enzymes (consult product literature). Avoid in severe impairment. Monitor liver function in hepatic impairment.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)
- Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (June 2006) NICE TA101
  - Docetaxel is an option for hormone-refractory metastatic prostate cancer and a Karnofsky score of at least 60% [Karnofsky score is a measure of the ability to perform ordinary tasks].
  - www.nice.org.uk/TA101
- Docetaxel for the adjuvant treatment of early node-positive breast cancer (September 2006) NICE TA109
  - Docetaxel, when given concurrently with doxorubicin and cyclophosphamide (TAC regimen), is recommended as an option for the adjuvant treatment of women with early node-positive breast cancer.
  - www.nice.org.uk/TA109

Scottish Medicines Consortium (SMC) Decisions
- The Scottish Medicines Consortium has advised that docetaxel (Taxotere®) in combination with cisplatin and fluorouracil is accepted for restricted use within NHS Scotland for the induction treatment of patients with unresectable (May 2007) and resectable (June 2008) locally advanced squamous cell carcinoma of the head and neck.

MEDICINAL FORMS
- There can be variation in the licensing of different medicines containing the same drug.

Solution for infusion
- EXCIPIENTS: May contain Ethanol
  - Docetaxel (Non-proprietary)
    - Docetaxel 10 mg per 1 ml Docetaxel 80mg/8ml concentrate for solution for infusion vials | 1 vial (£43.75) £534.75 (Hospital only)
    - Docetaxel 160mg/16ml concentrate for solution for infusion vials | 1 vial (£75) £1,069.50 (Hospital only)
Docetaxel 20mg/2ml concentrate for solution for infusion vials | 1 vial (medic) £162.75 (Hospital only)
Docetaxel 20 mg per 1 ml Docetaxel 80mg/4ml concentrate for solution for infusion vials | 1 vial (medic) £590.00
Docetaxel 160mg/8ml concentrate for solution for infusion vials | 1 vial (medic) no price available
Docetaxel 140mg/7ml concentrate for solution for infusion vials | 1 vial (medic) £900.00
Docetaxel 20mg/1ml concentrate for solution for infusion vials | 1 vial (medic) £160.00

Taxotere (medac UK)
Docetaxel 20 mg per 1 ml Taxotere 80mg/4ml concentrate for solution for infusion vials | 1 vial (product) £508.01
Taxotere 140mg/7ml concentrate for solution for infusion vials | 1 vial (product) £720.10
Taxotere 20mg/1ml concentrate for solution for infusion vials | 1 vial (product) £154.61

Taxotere (Sanofi)
Docetaxel 20 mg per 1 ml Taxotere 20mg/1ml concentrate for solution for infusion vials | 1 vial (product) £53.47 (Hospital only)
Taxotere 160mg/8ml concentrate for solution for infusion vials | 1 vial (product) £1,008.54 (Hospital only)
Taxotere 80mg/4ml concentrate for solution for infusion vials | 1 vial (product) £504.27 (Hospital only)

Paclitaxel

**DRUG ACTION** Paclitaxel is a member of the taxane group of drugs.

**INDICATIONS AND DOSE**

- Treatment of ovarian cancer (advanced or residual disease following laparotomy) in combination with cisplatin (conventional paclitaxel only)
- Treatment of metastatic ovarian cancer where platinum-containing therapy has failed (conventional paclitaxel only)
- Treatment of locally advanced or metastatic breast cancer (in combination with other cytotoxics or alone if other cytotoxics have failed or are inappropriate) (conventional paclitaxel only)
- Adjuvant treatment of node-positive breast cancer following treatment with anthracycline and cyclophosphamide (conventional paclitaxel only)
- Treatment of non-small cell lung cancer (in combination with cisplatin) when surgery or radiotherapy not appropriate (conventional paclitaxel only)
- Treatment of advanced AIDS-related Kaposis sarcoma where liposomal anthracycline therapy has failed (conventional paclitaxel only)
- First-line treatment of metastatic adenocarcinoma of the pancreas (in combination with gemcitabine) (conventional paclitaxel only)
- Monotherapy of metastatic breast cancer when first-line treatment has failed and standard, anthracycline-containing therapy is not indicated (albumin-bound paclitaxel only)
- In combination with gemcitabine for the first-line treatment of metastatic adenocarcinoma of the pancreas (albumin-bound paclitaxel only)

**BY INTRAVENOUS INFUSION**

- Adult: (consult product literature or local protocols)

**CAUTIONS**

- Avoid in acute porphyrias p. 969 - consult product literature - patients aged over 75 years with metastatic adenocarcinoma of the pancreas

**INTERACTIONS**

- Common or very common: Arrhythmia, arthralgia, febrile neutropenia, gastro-intestinal disorders, myalgia, peripheral neuropathy, sensory neuropathy, tachycardia
- Rare: Bradycardia, cardiac arrest, congestive heart failure, left ventricular dysfunction
- Frequency not known: Alopecia, arrhythmias (nearly always asymptomatic), asymptomatic hypotension, bone-marrow suppression, bradycardia, cardiac conduction defects, extravasation, hypersensitivity reactions

- hyperuricaemia, muscle pain, myelosuppression, nausea, neutropenia, oral mucositis, pneumonitis, Stevens-Johnson syndrome, thromboembolism, toxic epidermal necrolysis, tumour lysis syndrome, vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

- Hypersensitivity reactions: Routine premedication with a corticosteroid, an antihistamine and a histamine H2-receptor antagonist is recommended to prevent severe hypersensitivity reactions; hypersensitivity reactions may occur rarely despite premedication.

**CONCEPTION AND CONTRACEPTION**

- Ensure effective contraception during and for at least 6 months after treatment in men or women.

**PREGNANCY**

- Avoid (toxicity in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**BREAST FEEDING**

- Discontinue breast-feeding.

**HEPATIC IMPAIRMENT**

- Avoid in severe impairment.

**MONITORING REQUIREMENTS**

- Cardiac monitoring should be undertaken, particularly if patients have underlying cardiac disease or previous exposure to antracyclines.
- Patients should be monitored for signs and symptoms of pneumonitis and sepsis.

**PRESCRIBING AND DISPENSING INFORMATION**

- Paclitaxel is available as both conventional and albumin-bound formulations. The different formulations vary in their licensed indications, pharmacokinetics, dosage and administration, and are not interchangeable.
- Prescribers should specify the brand to be dispensed.

**NATIONAL FUNDING/ACCESS DECISIONS**

- NICE technology appraisals (TAs)
  - Paclitaxel for ovarian cancer (January 2003) NICE TA55
    - Either paclitaxel in combination with a platinum compound (cisplatin or carboplatin) or a platinum compound alone are alternatives for the first-line treatment of ovarian cancer (usually following surgery). www.nice.org.uk/TA55
  - Paclitaxel for the adjuvant treatment of early node-positive breast cancer (September 2006) NICE TA108
    - Paclitaxel, within its licensed indication, is not recommended for the adjuvant treatment of women with early node-positive breast cancer. www.nice.org.uk/TA108
  - Bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer (May 2013) NICE TA284
    - Bevacizumab in combination with paclitaxel and carboplatin is not recommended for the first-line treatment of advanced ovarian cancer (including fallopian tube and primary peritoneal cancer). www.nice.org.uk/TA284
  - Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer (October 2015) NICE TA360
    - Albumin-bound paclitaxel (Abraxane®) with gemcitabine, within its licensed indication, is not recommended for the treatment of previously untreated metastatic adenocarcinoma of the pancreas.

- Patients whose treatment was started before this guidance was published should continue treatment until they and their clinician consider it appropriate to stop. www.nice.org.uk/TA360
- Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (April 2016) NICE TA389
  - Paclitaxel, in combination with platinum or as monotherapy, is recommended as an option for treating recurrent ovarian cancer. www.nice.org.uk/TA389
Drugs: irinotecan hydrochloride

**Indications and Dose**
Metastatic colorectal cancer in combination with fluorouracil and folinic acid or as monotherapy when treatment containing fluorouracil has failed. Treatment of epidermal growth factor receptor-expressing metastatic colorectal cancer after failure of chemotherapy that has included irinotecan (in combination with cetuximab). First-line treatment of metastatic carcinoma of the colon or rectum (in combination with fluorouracil, folinic acid and bevacizumab). First-line treatment of metastatic colorectal carcinoma in combination with capcitabine with or without bevacizumab.

- **By Intravenous Infusion**
- **Adult:** (consult product literature or local protocols)

Metastatic adenocarcinoma of the pancreas in patients who have progressed following gemcitabine based therapy (in combination with fluorouracil and leucovorin) (specialist use only).

- **By Intravenous Infusion Using Lipid Formulation**
- **Adult:** (consult product literature or local protocols)

**Contra-Indications**
Bowel obstruction, chronic inflammatory bowel disease.

**Caution**
Raised plasma-bilirubin concentration, risk factors for cardiac disease, risk factors for pulmonary toxicity, underweight patients—increased risk of adverse events.

**Interactions**
Appendix 1: irinotecan

**Side-effects**
- Uncommon: Intestinal obstruction
- Frequency not known: Acute cholinergic syndrome (with early diarrhoea) and delayed diarrhoea (consult product literature), alopecia, anorexia, asthenia, bone-marrow suppression, extravasation, gastrointestinal effects (delayed diarrhoea requiring prompt treatment may follow irinotecan treatment), hyperuricaemia, myelosuppression (dose limiting), nausea, oral mucositis, thromboembolism, tumour lysis syndrome, vomiting.

**Concept and Contraception**
For conventional formulations, manufacturer advises effective contraception during treatment and for up to 1 month after treatment in women of child-bearing potential, and up to 3 months after treatment in men. For liposomal formulations, manufacturer advises effective contraception during treatment and for up to 1 month after treatment in women of child-bearing potential, and up to 4 months after treatment in men.

**Pregnancy**
Manufacturer advises avoid unless essential—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**Breast Feeding**
For conventional formulations, manufacturer advises avoid. For liposomal formulations, manufacturer advises avoid until one month after the last dose—no information available.

**Hepatic Impairment**
For conventional formulations, manufacturer advises dose adjustment—consult product literature. Manufacturer advises monitor liver function at baseline and before each cycle; also monitor complete blood counts weekly if plasma-bilirubin concentration 1.5–3 times the upper limit of normal; avoid if plasma-bilirubin concentration greater than 3 times the upper limit of normal.

For liposomal formulations, manufacturer advises use with caution; avoid if bilirubin greater than 2 mg/dL or if plasma-transaminase greater than 2.5 times the upper limit of normal (greater than 5 times the upper limit of normal if liver metastasis present)—limited information available.

**Renal Impairment**
For conventional formulations, manufacturer advises avoid—no information available. For liposomal formulations, manufacturer advises avoid in severe impairment—no information available.

**Monitoring Requirements**
Monitor respiratory function.

**Prescribing and Dispensing Information**
Irinotecan is available as both conventional and liposomal formulations. Manufacturers advise that the different formulations vary in their licensed indications, pharmacokinetics, dosage and administration, and are not interchangeable.

**National Funding/Access Decisions**
NICE technology appraisals (TAs)
- Irinotecan, oxaliplatin, and raltitrexed for advanced colorectal cancer (August 2005) NICE TA93
  A combination of fluorouracil and folinic acid with either irinotecan or oxaliplatin are options for first-line treatment for advanced colorectal cancer. Irinotecan alone or fluorouracil and folinic acid with oxaliplatin are options for patients who require further treatment subsequently.
  www.nice.org.uk/TA93
- Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (April 2017) NICE TA440
  Pegylated liposomal irinotecan, in combination with fluorouracil and leucovorin, is not recommended for treating metastatic adenocarcinoma of the pancreas in adults whose disease has progressed following gemcitabine-based therapy.
  Patients whose treatment was started within the NHS before this guidance was published should have the option to continue treatment, without change to their funding arrangements, until they and their clinician consider it appropriate to stop.
  www.nice.org.uk/guidance/TA440

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (March 2017) that liposomal irinotecan (Onivyde®) is not recommended for use within NHS Scotland for the treatment of metastatic adenocarcinoma of the pancreas, in combination with fluorouracil and leucovorin (folinic acid), in patients who have progressed following gemcitabine based therapy as there was insufficient evidence submitted.
Topotecan

**DRUG ACTION**
Topotecan inhibits topoisomerase I, an enzyme involved in DNA replication.

**INDICATIONS AND DOSE**
- Metastatic ovarian cancer when first-line or subsequent treatment has failed
- Treatment of recurrent carcinoma of the cervix, after radiotherapy, and for patients with stage IVB disease (in combination with cisplatin)
  - **BY INTRAVENOUS INFUSION**
  - **Adult:** (consult product literature or local protocols)
- Relapsed small-cell lung cancer when retreatment with the first-line regimen is considered inappropriate
  - **BY INTRAVENOUS INFUSION, OR BY MOUTH**
  - **Adult:** (consult product literature or local protocols)

**NATIONAL FUNDING/ACCESS DECISIONS**
**NICE technology appraisals (TAs)**
- Topotecan for the treatment of recurrent and stage IVB cervical cancer (October 2009) NICE TA183
  Topotecan in combination with cisplatin is recommended as a treatment option for recurrent or stage IVB cervical cancer in patients who have not previously received cisplatin.
  [www.nice.org.uk/TA183](http://www.nice.org.uk/TA183)
- Topotecan for the treatment of relapsed small-cell lung cancer (November 2009) NICE TA184
  Oral topotecan is recommended as an option for treatment in patients with relapsed small-cell lung cancer only if retreatment with the first-line regimen is not considered appropriate, and the combination of cyclophosphamide, doxorubicin and vincristine is contra-indicated.
  Intravenous topotecan is not recommended for people with relapsed small-cell lung cancer.
  [www.nice.org.uk/TA184](http://www.nice.org.uk/TA184)
- Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (April 2016) NICE TA389
  Topotecan is **not** recommended for treating first recurrence of platinum-sensitive ovarian cancer, recurrent platinum-resistant ovarian cancer, or platinum-refractory ovarian cancer.
  Patients currently receiving topotecan should have the option to continue their treatment until they or their clinician consider it appropriate to stop.
  [www.nice.org.uk/TA389](http://www.nice.org.uk/TA389)

**Scottish Medicines Consortium (SMC) Decisions**
The Scottish Medicines Consortium has advised (November 2007) that topotecan (Hyacintin®) is accepted for restricted use in combination with cisplatin for treatment of recurrent carcinoma of the cervix after radiotherapy and for stage IVB disease; it is restricted to patients who have not previously received cisplatin treatment.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Solution for infusion**
- **ELECTROLYTES:** May contain Sodium
- **Irinotecan hydrochloride (Non-proprietary)**
  - Irinotecan hydrochloride trihydrate 20 mg per 1 ml
  - Irinotecan 500mg/25ml concentration for solution for infusion vials | 1 vial (Pom) £601.25–650.00 (Hospital only)
  - Irinotecan 40mg/2ml concentration for solution for infusion vials | 1 vial (Pom) £40.03–53.00 (Hospital only) | 1 vial (Pom) £47.37–50.35
  - Irinotecan 300mg/15ml concentration for solution for infusion vials | 1 vial (Pom) £390.00 (Hospital only) | 1 vial (Pom) £345.42–390.00
  - Irinotecan 100mg/5ml concentration for solution for infusion vials | 1 vial (Pom) £120.25–130.00 (Hospital only) | 1 vial (Pom) £116.15–£123.50
- **Campto (Pfizer Ltd)**
  - Irinotecan hydrochloride trihydrate 20 mg per 1 ml
  - Campto 100mg/5ml concentration for solution for infusion vials | 1 vial (Pom) £130.00 (Hospital only)
  - Campto 40mg/2ml concentration for solution for infusion vials | 1 vial (Pom) £53.00 (Hospital only)
  - Campto 300mg/15ml concentration for solution for infusion vials | 1 vial (Pom) £390.00 (Hospital only)
- **Onivyde (Baxalta UK Ltd)**
  - Irinotecan hydrochloride trihydrate 5 mg per 1 ml
  - Onivyde 50mg/10ml concentration for solution for infusion vials | 1 vial (Pom) £615.35 (Hospital only)

**Topotecan**
10-Jun-2016

- **Indications and Dose**
  - Metastatic ovarian cancer when first-line or subsequent treatment has failed
  - Treatment of recurrent carcinoma of the cervix, after radiotherapy, and for patients with stage IVB disease (in combination with cisplatin)
    - **By Intravenous Infusion**
    - **Adult:** (consult product literature or local protocols)
  - Relapsed small-cell lung cancer when retreatment with the first-line regimen is considered inappropriate
    - **By Intravenous Infusion, or by Mouth**
    - **Adult:** (consult product literature or local protocols)

**Important Safety Information**
**Risks of incorrect dosing of oral anti-cancer medicines**
See Cytotoxic drugs p. 825.

**Interactions**
- Appendices 1: topotecan

**Side-effects**
- Alopecia · anorexia · asthenia · bone-marrow suppression · extravasation · gastro-intestinal effects · hyperuricaemia · myelosuppression (dose-limiting) · nausea · oral mucositis · thromboembolism · tumour lysis syndrome · vomiting

**Conception and Contraception**
Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**Pregnancy**
Avoid (teratogenicity and fetal loss in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**Breast Feeding**
Discontinue breast-feeding.

**Hepatic Impairment**
Avoid in severe impairment.

**Renal Impairment**
Reduce dose. Avoid infusion if creatinine clearance less than 20 mL/minute. Avoid oral route if creatinine clearance less than 60 mL/minute.

**Powder for solution for infusion**
- **Topotecan (as Topotecan hydrochloride) 1 mg per 1 ml**
  - **Topotecan 4mg/4ml concentration for solution for infusion vials | 1 vial (Pom) £226.55 (Hospital only) | 1 vial (Pom) no price available | 5 vial (Pom) £1,453.10 (Hospital only)
  - **Topotecan 1mg/1ml concentration for solution for infusion vials | 1 vial (Pom) £87.88 (Hospital only) | 1 vial (Pom) no price available | 5 vial (Pom) £488.25 (Hospital only)

**Capsule**
**Cautionary and Advisory Labels**
- **Hycamitn (Novartis Pharmaceuticals UK Ltd)**
  - **Topotecan (as Topotecan hydrochloride) 1 mg**
    - **Hycamitn 1mg powder for concentrate for solution for infusion vials | 1 vial (Pom) £97.65
    - **Topotecan (as Topotecan hydrochloride) 4 mg**
      - **Hycamitn 4mg powder for concentrate for solution for infusion vials | 1 vial (Pom) £348.76
    - **Potactasol (Actavis UK Ltd)**
      - **Topotecan (as Topotecan hydrochloride) 1 mg**
        - **Potactasol 1mg powder for concentrate for solution for infusion vials | 1 vial (Pom) £97.00 (Hospital only)
      - **Topotecan (as Topotecan hydrochloride) 4 mg**
        - **Potactasol 4mg powder for concentrate for solution for infusion vials | 1 vial (Pom) £290.00 (Hospital only)

- **Topotecan (as Topotecan hydrochloride) 1 mg**
  - **Hycamitn 1mg capsules | 10 capsule (Pom) £75.00
  - **Topotecan (as Topotecan hydrochloride) 1 mg**
    - **Hycamitn 1mg capsules | 10 capsule (Pom) £360.00
downloaded from www.medicalbr.com
Vinblastine sulfate

**INDICATIONS AND DOSE**
Variety of cancers including leukaemias, lymphomas, and some solid tumours (e.g. breast and lung cancer)
- Adult: (consult product literature)

**SIDE-EFFECTS, FURTHER INFORMATION**
- Neurotoxicity: Neurotoxicity, usually as peripheral or autonomic neuropathy, occurs with all vinca alkaloids; it occurs less often with vinblastine than with vincristine. Patients with neurotoxicity commonly have peripheral paraesthesia, loss of deep tendon reflexes, abdominal pain, and constipation; ototoxicity has been reported. If symptoms of neurotoxicity are severe, doses should be reduced.
- Motor weakness can also occur and dose reduction or discontinuation of therapy may be appropriate if motor weakness increases. Recovery from neurotoxic effects is usually slow but complete.

**CONTRA-INDICATIONS**
- Contra-indications, further information
- Intrathecal injection contra-indicated.

**CAUTIONS**
- Caution in handling—irritant to tissues

**INTERACTIONS**
- Appendix 1: vinca alkaloids

**CONCEPTION AND CONTRACEPTION**
- Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**PREGNANCY**
- Avoid (limited experience suggests fetal harm; teratogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**BREAST FEEDING**
- Discontinue breast-feeding.

**HEPATIC IMPAIRMENT**
- Dose reduction may be necessary—consult local treatment protocol for details.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.
- Solution for injection
  - Vinblastine sulfate (non-proprietary)
    - Vinblastine sulfate 1 mg per 1 ml Vinblastine 10mg/10ml solution for injection vials | 5 vial | £58.00

**IMPORTANT SAFETY INFORMATION**
- Vinblastine is for intravenous administration only. Inadvertent intrathecal administration can cause severe neurotoxicity, which is usually fatal.

- The National Patient Safety Agency has advised (August 2008) that adult and teenage patients treated in an adult or adolescent unit should receive their vinca alkaloid dose in a 50 mL minibag. Teenagers and children treated in a child unit may receive their vinca alkaloid dose in a syringe.

**Vincristine sulfate**

**INDICATIONS AND DOSE**
Variety of cancers including leukaemias, lymphomas, and some solid tumours (e.g. breast and lung cancer)
- Adult: (consult product literature)

**SIDE-EFFECTS, FURTHER INFORMATION**
- Neurotoxicity: Neurotoxicity, usually as peripheral or autonomic neuropathy, occurs with all vinca alkaloids and is a limiting side-effect of vincristine. Patients with neurotoxicity commonly have peripheral paraesthesia, loss of deep tendon reflexes, abdominal pain, and constipation; ototoxicity has been reported. If symptoms of neurotoxicity are severe, doses should be reduced.
- Motor weakness can also occur and dose reduction or discontinuation of therapy may be appropriate if motor weakness increases. Recovery from neurotoxic effects is usually slow but complete.

**CONTRA-INDICATIONS**
- Contra-indications, further information
- Intrathecal injection contra-indicated.

**CAUTIONS**
- Caution in handling—irritant to tissues

**INTERACTIONS**
- Appendix 1: vinca alkaloids

**CONCEPTION AND CONTRACEPTION**
- Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**PREGNANCY**
- Avoid (teratogenicity and fetal loss in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**BREAST FEEDING**
- Discontinue breast-feeding.

**HEPATIC IMPAIRMENT**
- Dose reduction may be necessary—consult local treatment protocol for details.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.
- Solution for injection
  - Vincristine sulfate (non-proprietary)
    - Vincristine sulfate 1 mg per 1 ml Vincristine 1mg/1ml solution for injection vials | 1 vial | £13.47 (Hospital only) | 5 vial | £67.35
Vindesine sulfate

**INDICATIONS AND DOSE**
Variety of cancers including leukaemias, lymphomas, and some solid tumours (e.g. breast and lung cancer)
- Adult: (consult local protocol)

**IMPORTANT SAFETY INFORMATION**
Vindesine injections are for intravenous administration only. Inadvertent intrathecal administration can cause severe neurotoxicity, which is usually fatal.

The National Patient Safety Agency has advised (August 2008) that adult and teenage patients treated in an adult or adolescent unit should receive their vinca alkaloid dose in a 50 mL minibag. Teenagers and children treated in a child unit may receive their vinca alkaloid dose in a syringe.

**CONTRA-INDICATIONS**
CONTRA-INDICATIONS, FURTHER INFORMATION
Intrathecal injection contra-indicated.

**CAUTIONS**
Caution in handling—irritant to tissues • neuromuscular disease

**INTERACTIONS**
→ Appendix 1: vinca alkaloids

**SIDE-EFFECTS, FURTHER INFORMATION**
- Neurotoxicity Neurotoxicity, usually as peripheral or autonomic neuropathy; it occurs less often with vindesine than with vincristine. Patients with neurotoxicity commonly have peripheral paraesthesia, loss of deep tendon reflexes, abdominal pain, and constipation; ototoxicity has been reported. If symptoms of neurotoxicity are severe, doses should be reduced. Motor weakness can also occur, and increasing motor weakness calls for dose reduction or discontinuation. Recovery from neurotoxic effects is usually slow but complete.

- CONCEPTION AND CONTRACEPTION
  Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 825.

- PREGNANCY
  Avoid (teratogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

- BREAST FEEDING
  Discontinue breast-feeding.

- HEPATIC IMPAIRMENT
  Dose reduction may be necessary.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for injection**
- Eldisine (Genus Pharmaceuticals Ltd)
  Vindesine sulfate 5 mg Eldisine 5mg powder for solution for injection vials | 1 vial £66.55 (Hospital only)

**CONTRA-INDICATIONS, FURTHER INFORMATION**
Intrathecal injection contra-indicated.

**CAUTIONS**
Cardiovascular disease • QT-interval prolongation (avoid hypokalaemia)

**INTERACTIONS**
- Common or very common
  Anorexia • cutaneous reactions • dehydration • diarrhoea • dyspepsia • fatigue • hypertension • hypotension • insomnia • oedema • sweating • tachycardia • thrombosis

- Uncommon
  Increased weight • myocardial infarction • renal failure

- Frequency not known
  Alopecia • autonomic neuropathy • blurred vision • extravasation • hyperuricaemia • inappropriate anti-diuretic hormone secretion • myelosuppression (dose-limiting) • nausea • neurotoxicity • oral mucositis • peripheral neuropathy • QT-interval prolongation • severe bronchospasm following administration (more commonly when used in combination with mitomycin-C) • severe local irritation (if extravasated) • thromboembolism • tumour lysis syndrome • vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**
- Neurotoxicity Neurotoxicity, usually as peripheral or autonomic neuropathy, occurs with all vinca alkaloids and is a limiting side-effect of vindesine. Patients with neurotoxicity commonly have peripheral paraesthesia, loss of deep tendon reflexes, abdominal pain, and constipation; ototoxicity has been reported. If symptoms of neurotoxicity are severe, doses should be reduced. Motor weakness can also occur and increasing motor weakness calls for dose reduction or discontinuation. Recovery from neurotoxic effects is usually slow but complete.

- CONCEPTION AND CONTRACEPTION
  Manufacturer advises effective contraception during and for up to 3 months after treatment.

- PREGNANCY
  Avoid unless essential—teratogenicity and embryotoxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

- BREAST FEEDING
  Discontinue breast-feeding.

- HEPATIC IMPAIRMENT
  Reduce dose—consult product literature.

- RENAL IMPAIRMENT
  Reduce dose if creatinine clearance less than 60 mL/minute—consult product literature.
Vinorelbine

**Indications and Dose**

Vinorelbine is a semi-synthetic vinca alkaloid.

**Advanced breast cancer | Advanced non-small cell lung cancer**

- **By mouth**
  - Adult: 60 mg/m² once weekly for 3 weeks, then increased if tolerated to 80 mg/m² once weekly (max. per dose 160 mg once weekly)
  - **By intravenous injection, or by intravenous infusion**
  - Adult: (consult product literature)

**Important Safety Information**

Vinorelbine injections are for intravenous administration only. Inadvertent intrathecal administration can cause severe neurotoxicity, which is usually fatal.

The National Patient Safety Agency has advised (August 2008) that adult and teenage patients treated in an adult or adolescent unit should receive their vinca alkaloid dose in a 50 mL minibag. Teenagers and children treated in a child unit may receive their vinca alkaloid dose in a syringe.

**Risks of Incorrect Dosing of Oral Anti-Cancer Medicines**

See Cytotoxic drugs p. 825.

**Contra-Indications**

- With oral use concurrent radiotherapy if treating the liver - long-term oxygen therapy - previous significant surgical resection of small bowel - previous significant surgical resection of stomach

**Contra-Indications, Further Information**

Intrathecal injection contra-indicated.

**Caution**

- Caution in handling — irritant to tissues - ischaemic heart disease

**Interactions**

- Appendix 1: vinca alkaloids

**Side-Effects**

- Rare: Pancreatitis
- Frequency not known: Alopecia - autonomic neuropathy - extravasation - hyperuricaemia - hypoaetraemia - inappropriate secretion of antidiuretic hormone - irritant to tissues - motor weakness - myelosuppression (dose-limiting) - nausea - neurotoxicity - oral mucositis - peripheral neuropathy - severe bronchospasm following administration of the vinca alkaloids (more commonly when used in combination with mitomycin-C) - severe local irritation (if extravasated) - thromboembolism - tumour lysis syndrome - vomiting

**SIDE-EFFECTS, Further Information**

- Neurotoxicity: Neurotoxicity, usually as peripheral or autonomic neuropathy, occurs with all vinca alkaloids; it occurs less often with vinorelbine. Patients with neurotoxicity commonly have peripheral paraesthesia, loss of deep tendon reflexes, abdominal pain, and constipation; ototoxicity has been reported. If symptoms of neurotoxicity are severe, doses should be reduced.

- Motor weakness can also occur, and increasing motor weakness calls for dose reduction or discontinuation of these drugs. Recovery from neurotoxic effects is usually slow but complete.

**Conception and Contraception**

Manufacturer advises effective contraception during and for 3 months after treatment; men must avoid fathering a child during and for at least 3 months after treatment.

**Pregnancy**

Avoid unless essential (teratogenicity, and fetal loss in animal studies). See also Pregnancy and Reproductive function in Cytotoxic drugs p. 825.

**Breast Feeding**

Discontinue breast-feeding.

**Hepatic Impairment**

- With oral use: Reduce oral dose in moderate impairment. Avoid oral use in severe impairment.

- With injectable use: Reduce intravenous dose in severe impairment. Consult product literature.

**Medicinal Forms**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for Infusion**

- [Javelor (Pierre Fabre Ltd)](https://www.medicines.org.uk/emc/medicine/16062) (Non-proprietary) Vinorelbine (as Vinorelbine tartrate) 80 mg/2ml concentrate for solution for infusion | 1 vial £1,221.50

- Javelor (Pierre Fabre Ltd) Vinorelbine (as Vinorelbine tartrate) 30 mg/1ml concentrate for solution for infusion | 1 vial £100.50

- Javelor (Pierre Fabre Ltd) Vinorelbine (as Vinorelbine tartrate) 20 mg/1ml concentrate for solution for infusion | 1 vial £100.50

**Capsule**

- [Navelbine](https://www.medicines.org.uk/emc/medicine/16079) (Pierre Fabre Ltd)
  - Navelbine (as Vinorelbine tartrate) 30 mg Navelbine 30mg capsules | 1 capsule £65.98 (Hospital only)
  - Navelbine (as Vinorelbine tartrate) 10 mg Navelbine 10mg capsules | 1 capsule £43.98 (Hospital only)

**Antineoplastic Drugs > Other**

**Amsacrine**

**Indications and Dose**

Acute leukaemia (refractory to anthracycline chemotherapy used alone or in combination with other chemotherapy agents) (specialist use only)

- **By Intravenous Infusion**
  - Adult: (consult product literature)

**Caution**

- Hypokalaemia — increased risk of ventricular fibrillation (correct hypokalaemia before initiating treatment)

**Interactions**

- Appendix 1: amsacrine

**Side-Effects**

- Common or very common: Abdominal pain - alopecia - arrhythmias - bone marrow suppression - cardiotoxicity - congestive heart failure - diarrhoea - dyspnoea - emotional
lability • Grand mal seizure • haematuria • haemorrhage • hepatic insufficiency • hepatitis • hypokalaemia • hypotension • infection • jaundice • nausea • pancytopenia • purpura • raised hepatic enzymes • rash • stomatitis • thrombocytopenia • urticaria • vomiting

- Rare Acute renal insufficiency • anaemia • anuria • confusion • dizziness • granulocytopenia • headache • hypoaesthesia • lethargy • leucopenia • peripheral neuropathy • proteinuria • reduced ejection fraction • visual disturbances • weight changes

- Frequency not known Cardiac arrest • hyperuricaemia

- CONCEPTION AND CONTRACEPTION Manufacturer advises effective contraception during and for 3 months after treatment in women of child-bearing potential, and during and for 6 months after treatment in men.

- PREGNANCY Manufacturer advises avoid—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

- BREAST FEEDING Discontinue breast-feeding.

- HEPATIC IMPAIRMENT Manufacturer advises caution—limited information available.

- RENAL IMPAIRMENT Manufacturer advises caution—limited information available.

- MONITORING REQUIREMENTS
  - Manufacturer advises monitor full blood count, liver function and renal function regularly; electrolytes should be re-evaluated prior to each treatment.
  - Manufacturer advises monitor for cardiotoxicity during treatment.

- MEDICINAL FORMS
  - There can be variation in the licensing of different medicines containing the same drug.

  Solution for infusion
  - Amsidine (Eurocept International bv)
    - Amsacrine 50 mg per 1 ml Amsidine 75mg/1.5ml solution for infusion ampoules and diluent | 6 ampoule (£1,200.00 (Hospital only))

Arsenic trioxide

- INDICATIONS AND DOSE
  - Acute promyelocytic leukaemia in patients who have relapsed or failed to respond to previous treatment with a retinoid and chemotherapy
    - BY INTRAVENOUS INFUSION
      - Adult: (consult local protocol)

- CAUTIONS
  - Hypokalaemia (correct before treatment) • hypomagnesaemia (correct before treatment) • previous treatment with anthracyclines (increased risk of QT interval prolongation)

- INTERACTIONS
  - Common or very common • Atrial fibrillation • atrial flutter • diarrhoea • fatigue • haemorrhage • hyperglycaemia • hypokalaemia • leucocyte activation syndrome • musculoskeletal pain • paraesthesia • pleuritic pain • QT interval prolongation
  - Uncommon • Abdominal pain • blurred vision • hypotension • oedema • pneumonitis • rash • renal failure • seizures • tachycardia • vasculitis
  - Frequency not known • Alopecia • bone-marrow suppression • extravasation • hyperuricaemia • nausea • oral mucositis • thromboembolism • tumour lysis syndrome • vomiting

- SIDE-EFFECTS, FURTHER INFORMATION
  - Leucocyte activation syndrome • Signs and symptoms of leucocyte activation syndrome include unexplained fever, dyspnoea, weight gain, pulmonary infiltrates, pleural or pericardial effusions, with or without leucocytosis—treat with high dose corticosteroids, consult product literature.

- CONCEPTION AND CONTRACEPTION
  - Manufacturer advises effective contraception during treatment in men and women.

- PREGNANCY
  - Avoid (teratogenic and embryotoxic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

- BREAST FEEDING
  - Discontinue breast-feeding.

- HEPATIC IMPAIRMENT
  - Manufacturer advises caution—limited information available.

- RENAL IMPAIRMENT
  - Manufacturer advises caution—limited information available.

- MONITORING REQUIREMENTS
  - ECG required before and during treatment—consult product literature.

Asparaginase

- DRUG ACTION
  - Asparaginase is an enzyme which acts by breaking down L-asparagine to aspartic acid and ammonia, this disrupts protein synthesis of tumour cells.

- INDICATIONS AND DOSE
  - Acute lymphoblastic leukaemia (in combination with other antineoplastic drugs) (specialist use only)
    - BY INTRAVENOUS INFUSION
      - Adult: 5000 units/m² every 3 days

- CONTRA-INDICATIONS
  - History of pancreatitis related to asparaginase therapy • history of serious haemorrhage related to asparaginase therapy • history of serious thrombosis related to asparaginase therapy • pancreatitis • pre-existing known coagulopathy

- CAUTIONS
  - Diabetes (may raise blood glucose) • hypersensitivity reactions • hypertriglyceridaemia (severe)—increased risk of acute pancreatitis

- CAUTIONS, FURTHER INFORMATION
  - Hypersensitivity reactions
    - Serious hypersensitivity reactions, including life-threatening anaphylaxis, can occur—asparaginase should only be administered when appropriately trained staff and resuscitation facilities are immediately available; in the event of a hypersensitivity reaction, treatment should be stopped immediately and appropriate management initiated. Manufacturer advises an intracutaneous or small intravenous test dose can be used but is of limited value for predicting which patients will experience an allergic reaction.

- INTERACTIONS
  - Appendix 1: asparaginase

- SIDE-EFFECTS
  - Common or very common • Abdominal pain • acute pancreatitis—discontinue if suspected and do not re-start if confirmed • agitation • anaemia • confusion • decreased appetite • decreased clotting factors • decreased fibrinogen • depression • diarrhoea • dizziness • elevated blood lipids • haemorrhage • hallucination • hyperglycaemia • hypersensitivity reactions • hypoalbuminaemia • hypoglycaemia • myelosuppression • nausea • oedema • pain • somnolence • thrombosis • vomiting • weight loss
Cytotoxic responsive malignancy

- **Uncommon** Headache • hyperammonaemia • hyperuricaemia
- **Rare** Convulsion • diabetic ketoacidosis • disturbances in consciousness (including coma) • hepatotoxicity • ischaemic stroke • parotitis • reversible posterior leucoencephalopathy syndrome
- **Very rare** Hypoparathyroidism • hypothyroidism (secondary) • tremor

**SIDE-EFFECTS, FURTHER INFORMATION**
- Hepatotoxicity. There have been rare reports of cholestasis, icterus, hepatic cell necrosis and hepatic failure with fatal outcome; manufacturer advises interrupt treatment if these symptoms develop.
- **CONCEPTION AND CONTRACEPTION** Manufacturer advises monitor trough serum asparaginase and contraception during treatment; in addition, monitor plasma and urinary levels containing the same drug.
- **INTERACTIONS** Cytotoxic drugs p. 825.
- **CONCEPTION AND CONTRACEPTION** Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 825.
- **PREGNANCY** Avoid. See also, Pregnancy and reproductive function in Cytotoxic drugs p. 825.
- **BREAST FEEDING** Discontinue breast-feeding.
- **DIRECTIONS FOR ADMINISTRATION** Facilities for the management of anaphylaxis should be available.

**SIDE-EFFECTS**
- **Common or very common** Coagulation disorders • confusion • convulsions • diarrhoea • dizziness • drowsiness • headache • lethargy • liver dysfunction • neurotoxicity • pancreatitis
- **Uncommon** Anaphylaxis • changes in blood lipids • hyperglycaemia
- **Rare** CNS depression
- **Very rare** Abdominal pain • hypertension • myalgia
- Frequency not known Alopecia • bone-marrow suppression • extravasation • hyperuricaemia • nausea • oral mucositis • thromboembolism • tumour lysis syndrome • vomiting

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for injection**
- **Eribulin** (EUSA Pharma Ltd)
  - **Crisantaspase 10000 unit** Erwinase 10,000 unit powder for solution for injection vials | 5 vial | £3,065.00

---

**Crisantaspase**

**DRUG ACTION** Crisantaspase is the enzyme asparaginase produced by Erwinia chrysanthemi.

**INDICATIONS AND DOSE**
- **Acute lymphoblastic leukaemia**
  - **BY INTRAMUSCULAR INJECTION, OR BY SUBCUTANEOUS INJECTION, OR BY INTRAVENOUS INJECTION**
  - Adult: (consult product literature)

**CONTRA-INDICATIONS** History of pancreatitis related to asparaginase therapy
- **CAUTIONS** Diabetes (may raise blood glucose)
- **INTERACTIONS** → Appendix 1: crisantaspase

---

**Eribulin**

**INDICATIONS AND DOSE**
- Treatment of locally advanced or metastatic breast cancer when the disease has progressed after treatment with at least 1 chemotherapy regimen for advanced disease
- **BY INTRAVENOUS INJECTION**
  - Adult: Give on day 1 and day 8 of a 21-day cycle, previous therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless the patient is unsuitable for these treatments (consult local protocol)

**CONTRA-INDICATIONS** Congenital long QT syndrome
- **CAUTIONS** Bradycardias (increased susceptibility to QT-interval prolongation) • congestive heart failure (increased susceptibility to QT-interval prolongation) • electrolyte disturbances (increased susceptibility to QT-interval prolongation) • susceptibility to QT-interval prolongation
- **INTERACTIONS** → Appendix 1: eribulin
- **SIDE-EFFECTS** Alopecia • bone-marrow suppression • extravasation • hyperuricaemia • myelosuppression • nausea • oral mucositis • peripheral neuropathy • QT-interval prolongation • thromboembolism • tumour lysis syndrome • vomiting

---

**Cytotoxic responsive malignancy**

**Takeout**

- Uncommon Headache • hyperammonaemia • hyperuricaemia
- Rare Convulsion • diabetic ketoacidosis • disturbances in consciousness (including coma) • hepatotoxicity • ischaemic stroke • parotitis • reversible posterior leucoencephalopathy syndrome
- Very rare Hypoparathyroidism • hypothyroidism (secondary) • tremor

**SIDE-EFFECTS, FURTHER INFORMATION**
- Hepatotoxicity. There have been rare reports of cholestasis, icterus, hepatic cell necrosis and hepatic failure with fatal outcome; manufacturer advises interrupt treatment if these symptoms develop.
- **CONCEPTION AND CONTRACEPTION** Manufacturer advises monitor trough serum asparaginase and contraception during treatment; in addition, monitor plasma and urinary levels containing the same drug.
- **INTERACTIONS** Cytotoxic drugs p. 825.
- **CONCEPTION AND CONTRACEPTION** Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 825.
- **PREGNANCY** Avoid. See also, Pregnancy and reproductive function in Cytotoxic drugs p. 825.
- **BREAST FEEDING** Discontinue breast-feeding.
- **DIRECTIONS FOR ADMINISTRATION** Facilities for the management of anaphylaxis should be available.

**SIDE-EFFECTS**
- Common or very common Coagulation disorders • confusion • convulsions • diarrhoea • dizziness • drowsiness • headache • lethargy • liver dysfunction • neurotoxicity • pancreatitis
- Uncommon Anaphylaxis • changes in blood lipids • hyperglycaemia
- Rare CNS depression
- Very rare Abdominal pain • hypertension • myalgia
- Frequency not known Alopecia • bone-marrow suppression • extravasation • hyperuricaemia • nausea • oral mucositis • thromboembolism • tumour lysis syndrome • vomiting

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for injection**
- **Eribulin** (EUSA Pharma Ltd)
  - **Crisantaspase 10000 unit** Erwinase 10,000 unit powder for solution for injection vials | 5 vial | £3,065.00

---

**Crisantaspase**

**DRUG ACTION** Crisantaspase is the enzyme asparaginase produced by Erwinia chrysanthemi.

**INDICATIONS AND DOSE**
- **Acute lymphoblastic leukaemia**
  - **BY INTRAMUSCULAR INJECTION, OR BY SUBCUTANEOUS INJECTION, OR BY INTRAVENOUS INJECTION**
  - Adult: (consult product literature)

**CONTRA-INDICATIONS** History of pancreatitis related to asparaginase therapy
- **CAUTIONS** Diabetes (may raise blood glucose)
- **INTERACTIONS** → Appendix 1: crisantaspase

---

**Eribulin**

**INDICATIONS AND DOSE**
- Treatment of locally advanced or metastatic breast cancer when the disease has progressed after treatment with at least 1 chemotherapy regimen for advanced disease
- **BY INTRAVENOUS INJECTION**
  - Adult: Give on day 1 and day 8 of a 21-day cycle, previous therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless the patient is unsuitable for these treatments (consult local protocol)

**CONTRA-INDICATIONS** Congenital long QT syndrome
- **CAUTIONS** Bradycardias (increased susceptibility to QT-interval prolongation) • congestive heart failure (increased susceptibility to QT-interval prolongation) • electrolyte disturbances (increased susceptibility to QT-interval prolongation) • susceptibility to QT-interval prolongation
- **INTERACTIONS** → Appendix 1: eribulin
- **SIDE-EFFECTS** Alopecia • bone-marrow suppression • extravasation • hyperuricaemia • myelosuppression • nausea • oral mucositis • peripheral neuropathy • QT-interval prolongation • thromboembolism • tumour lysis syndrome • vomiting

---
Monitor electrolytes periodically.

ECG monitoring recommended in patients prescribed Halaven.

Monitor for signs of peripheral neuropathy—severe peripheral neuropathy requires treatment delay or dose reduction (consult product literature).

Monitor electrolytes periodically.

NICE technology appraisals (TAs)

Eribulin is recommended for the treatment of locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (December 2016) NICE TA423.

Eribulin is recommended for the treatment of locally advanced or metastatic breast cancer, only if:

- the condition has progressed after at least 2 chemotherapy regimens (which may include an anthracycline or a taxane, and capecitabine), and
- the manufacturer provides eribulin with the discount agreed in the patient access scheme.

Patients whose treatment was started within the NHS before this guidance was published should continue treatment, without change to their funding arrangements, until they and their clinician consider it appropriate to stop.

www.nice.org.uk/TA423

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (March 2016) that eribulin (Halaven®) is accepted for restricted use within NHS Scotland for the treatment of patients with locally advanced or metastatic breast cancer that has progressed after at least two prior chemotherapy regimens for advanced disease, which includes capetitabine if indicated.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

EXCIPIENTS: May contain Ethanol

- Halaven (Eisai Ltd)

  Eribulin 4.4 mg per 1 ml Halaven 0.88mg/2ml solution for injection vials | 1 vial (PPh) £361.00 (Hospital only)

  Halaven 1.32mg/3ml solution for injection vials | 1 vial (PPh) £541.50 (Hospital only)

Hydroxyurea (Hydroxyurea)

INDICATIONS AND DOSE

Treatment of chronic myeloid leukaemia | Treatment of cancer of the cervix in conjunction with radiotherapy | Polycythaemia

- BY MOUTH

  Adult: 20–30 mg/kg daily, alternatively 80 mg/kg every 3 days

Sickle-cell disease — consult with a specialist centre

- BY MOUTH

  Adult: Initially 15 mg/kg daily, increased in steps of 2.5–5 mg/kg daily, dose to be increased every 12 weeks according to response; usual dose 15–30 mg/kg daily; maximum 35 mg/kg per day

IMPORTANT SAFETY INFORMATION

RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES

See Cytotoxic drugs p. 825.

CAUTIONS

Leg ulcers (review treatment if cutaneous vasculitic ulcerations develop).

INTERACTIONS

- Appendix 1: hydroxyurea

SIDE-EFFECTS

- Common or very common Headache · myelosuppression · skin reactions

- Rare Amenorrhoea (in sickle-cell disease) · fever (in sickle-cell disease)

- Frequency not known Alopecia · bleeding (in sickle-cell disease) · bone–marrow suppression · dizziness · hyperuricaemia · hypomagnesaemia (in sickle-cell disease) · nausea · oral mucositis · rash · reduced sperm count and activity · skin cancers (particularly in elderly patients) · thromboembolism · tumour lysis syndrome · vomiting

CONCEPTION AND CONTRACEPTION

Manufacturer advises effective contraception before and during treatment.

PREGNANCY

Avoid (teratogenic in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

BREAST FEEDING

Discontinue breast-feeding.

HEPATIC IMPAIRMENT

Manufacturer advises caution in mild to moderate impairment. Avoid in severe impairment, unless used for malignant conditions.

RENAL IMPAIRMENT

In sickle-cell disease, reduce initial dose by 50% if eGFR less than 60 mL/minute/1.73 m². In sickle-cell disease, avoid if eGFR less than 30 mL/minute/1.73 m². Use with caution in malignant disease.

MONITORING REQUIREMENTS

- Monitor renal and hepatic function before and during treatment.

- Monitor full blood count before treatment, and repeatedly throughout use; in sickle-cell disease monitor every 2 weeks for the first 2 months and then every 2 months thereafter (or every 2 weeks if on maximum dose).

- Patients receiving long-term therapy for malignant disease should be monitored for secondary malignancies.

PATIENT AND CARER ADVICE

Patients receiving long-term therapy with hydroxyurea should be advised to protect skin from sun exposure.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule, oral suspension, oral solution

Tablet

- Siklos (Nordic Pharma Ltd)

  Hydroxyureamide 100 mg Siklos 100mg tablets | 60 tablet (PPh) £100.00 DT price = £100.00

  Hydroxyureamide 1 gram Siklos 1000mg tablets | 30 tablet (PPh) £500.00

Capsule

- Hydroxyureamide (Non-proprietary)

  Hydroxyureamide 500 mg Hydroxyureamide 500mg capsules | 100 capsule (PPh) £86.00 DT price = £12.12

  Dragia (Imported (United States))

  Hydroxyureamide 300 mg Dragia 300mg capsules | 60 capsule (PPh) no price available

- Hydrea (Bristol-Myers Squibb Pharmaceuticals Ltd)

  Hydroxyureamide 500 mg Hydrea 500mg capsules | 100 capsule (PPh) £10.47 DT price = £12.12

Mitotane

DRUG ACTION

Mitotane selectively inhibits the activity of the adrenal cortex, necessitating corticosteroid replacement therapy.

INDICATIONS AND DOSE

Symptomatic treatment of advanced or inoperable adrenocortical carcinoma

- BY MOUTH

  Adult: Initially 2–3 g daily in 2–3 divided doses adjusted according to plasma-concentration monitoring, in severe illness initial dose continued →

downloaded from www.medicalbr.com
Panobinostat

DRUG ACTION Panobinostat is a histone deacetylase inhibitor, which promotes cell-cycle arrest and apoptosis of tumour cells via multiple pathways.

INDICATIONS AND DOSE
Treatment of relapsed or refractory multiple myeloma (in combination with bortezomib and dexamethasone), in patients who have received at least two prior regimens, including bortezomib and an immunomodulatory agent

BY MOUTH
Adult 18–74 years: 20 mg once daily, on days 1, 3, 5, 8, and 10 of a 21-day cycle for 8 cycles. Patients with clinical benefit should continue treatment for 8 additional cycles; total duration 16 cycles (48 weeks), for doses of dexamethasone and bortezomib, or dose adjustment due to side-effects—consult product literature

Adult 75 years and over: 20 mg once daily, on days 1, 3, 5, 8, 10, and 12 of a 21-day cycle for 8 cycles. Patients with clinical benefit should continue treatment for 8 additional cycles; total duration 16 cycles (48 weeks), alternatively initially 15 mg once daily, on days 1, 3, 5, 8, 10, and 12 of a 21-day cycle for 1 cycle, increased if tolerated to 20 mg once daily, on days 1, 3, 5, 8, 10, and 12 of a 21-day cycle for 7 subsequent cycles, patients with clinical benefit should continue treatment for 8 additional cycles; total duration 16 cycles (48 weeks), lower dose may be used for the first cycle depending on patient’s condition and co-morbidities, for doses of dexamethasone and bortezomib, or dose adjustment due to side-effects—consult product literature

DOSE ADJUSTMENTS DUE TO INTERACTIONS
Manufacturer advises reduce dose to 10 mg with concurrent use of potent inhibitors of CYP3A4; if the potent inhibitor of CYP3A4 is to be continued, consider increasing the dose to 15 mg if tolerated.
Manufacturer advises avoid potent inhibitors of CYP3A4 if possible in patients taking a reduced panobinostat dose due to side-effects, or in those with hepatic impairment.
Cytotoxic responsive malignancy

**SIDE-EFFECTS, FURTHER INFORMATION**

Side-effects are reported when used in combination with bortezomib and dexamethasone.

- Gastro-intestinal disorders  Manufacturer advises that patients are treated with anti-diarrhoeals, or any additional treatment, in accordance with local treatment guidelines at the first sign of abdominal cramping or onset of diarrhoea.

**CONCEPTION AND CONTRACEPTION**  Manufacturer advises monitor full blood count before emergency and contraception used during treatment and for 3 months after last dose.

**PREGNANCY**  Manufacturer advises avoid unless potential benefit outweighs risk—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**BREAST FEEDING**  Manufacturer advises avoid—no information available.

**HEPATIC IMPAIRMENT**  Manufacturer advises reduce initial dose to 15 mg during the first treatment cycle in mild impairment—dose may be increased to 20 mg based on patient tolerability; reduce initial dose to 10 mg during the first treatment cycle in moderate impairment—dose may be increased to 15 mg based on patient tolerability. Manufacturer advises frequent monitoring of hepatic function in mild and moderate impairment, particularly during the dose escalation phase; avoid in severe impairment—no information available.

**MONITORING REQUIREMENTS**

- Manufacturer advises monitor full blood count before treatment, then frequently during treatment; reduce dose or interrupt treatment if thrombocytopenia or neutropenia occur—consult product literature.
- Manufacturer advises monitor ECG before treatment and repeat periodically before each treatment cycle; QTcF should be <480 milliseconds before treatment initiation—consult product literature.
- Manufacturer advises monitor electrolytes before treatment and periodically as clinically indicated, especially in patients with diarrhoea; monitor thyroid and pituitary function (free T4 and TSH) as clinically indicated; monitor hepatic function before treatment and regularly during treatment as clinically indicated.
- Manufacturer advises monitor patients over 65 years more frequently, especially for thrombocytopenia and gastrointestinal toxicity.

**PATIENT AND CARER ADVICE**

Manufacturer advises that patients and their carers should be told to seek medical advice if severe gastro-intestinal toxicity occurs.

**Missed doses**

Manufacturer advises if a dose is missed, it can be taken up to 12 hours after the specified dose time.

**Driving and skilled tasks**

Dizziness may affect performance of skilled tasks (e.g. driving).

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Panobinostat for treating multiple myeloma after at least 2 previous treatments (January 2016) NICE TA380

Panobinostat, in combination with bortezomib and dexamethasone, is recommended as an option for treating relapsed or refractory multiple myeloma in patients who have received at least 2 prior regimens including bortezomib and an immunomodulatory agent when the manufacturer provides panobinostat with the discount agreed in the patient access scheme.

[www.nice.org.uk/TA380](http://www.nice.org.uk/TA380)

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

**CAUTIONARY AND ADVISORY LABELS**

- Farydak (Novartis Pharmaceuticals UK Ltd) ▼
- Panobinostat (as Panobinostat lactate anhydrous)
  - 10 mg  Farydak 10mg capsules 6 capsule £3,492.00
  - Panobinostat (as Panobinostat lactate anhydrous) 15 mg  Farydak 15mg capsules 6 capsule £3,492.00
- Panobinostat (as Panobinostat lactate anhydrous)
  - 20 mg  Farydak 20mg capsules 6 capsule £4,656.00

**Pegasparagase**

**DRUG ACTION**

Pegasparagase breaks down the amino acid L-asparagine, thereby interfering with the growth of malignant cells, which are unable to synthesise L-asparagine.

**INDICATIONS AND DOSE**

**Acute lymphoblastic leukaemia (in combination with other antineoplastic drugs) (specialist use only)**

- **BY INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INFUSION**
  - Adult 18–21 years: 2500 units/m² every 14 days
  - Adult 22 years and over: 2000 units/m² every 14 days

**CONTRA-INDICATIONS**

History of pancreatitis • History of serious haemorrhagic event with previous L-asparaginase therapy • History of serious thrombosis with previous L-asparaginase therapy

**CAUTIONS**

Concomitant use of other hepatotoxic drugs (particularly in pre-existing hepatic impairment)—monitor hepatic function • Diabetes (may raise blood glucose) • Hypersensitivity reactions—marked decrease of leukocyte count at start of treatment is possible—may be associated with significant rise in serum uric acid and development of uric acid nephropathy

**CAUTIONS, FURTHER INFORMATION**

- Hypersensitivity reactions  Serious hypersensitivity reactions, including life-threatening anaphylaxis, can occur—pegasparagase should only be administered when appropriately trained staff and resuscitation facilities are immediately available; manufacturer advises patients should be closely monitored for signs of hypersensitivity during treatment and for an hour after administration. In the event of a hypersensitivity reaction, treatment should be stopped immediately and appropriate management initiated.

**INTERACTIONS**

▶ Appendix 1: pegasparagase

**SIDE-EFFECTS**

- **Common or very common**
  - Abdominal pain • convulsion • diarrhoea • elevated blood lipids • hyperglycaemia • hypersensitivity reactions • hypoxia • myelosuppression • pain in extremities • pancreatitis—discontinue if suspected and do not re-start if confirmed • peripheral motor neuropathy • rash • stomatitis • syncope • thrombosis—dissociate treatment • vomiting

- **Rare**
  - Acute renal failure • reversible posterior leukoencephalopathy syndrome

- **Very rare**
  - Tremor

- **Frequency not known**
  - Confusion • decreased clotting factors • decreased fibrinogen • diabetic ketoacidosis • hepatobiliary disorders • hyperammonaemia—monitor if symptoms present • somnolence • toxic epidermal necrolysis
SIDE-EFFECTS, FURTHER INFORMATION

- Hepatobiliary disorders There have been rare reports of cholestasis, icterus, hepatic cell necrosis and hepatic failure with fatal outcome.

CONCEPT AND CONCEPTION Manufacturer advises effective contraception in men and women of childbearing potential during treatment and for at least 6 months after discontinuing treatment; pegaspargase may reduce effectiveness of oral contraceptives—additional precautions (e.g. barrier method) are required, see also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

PREGNANCY Manufacturer advises avoid unless essential. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

BREAST FEEDING Manufacturer advises avoid—no information available.

HEPATIC IMPAIRMENT Manufacturer advises avoid in severe impairment.

MONITORING REQUIREMENTS
- Manufacturer advises trough serum asparaginase activity levels may be measured before the next administration of pegaspargase; consider switching to a different asparaginase preparation if target levels not reached—seek expert advice.
- Manufacturer advises monitor plasma and urine glucose levels during treatment; monitor coagulation profile at baseline and periodically during and after treatment (particularly with concomitant use of other drugs that inhibit coagulation); monitor serum amylase.

DIRECTIONS FOR ADMINISTRATION Manufacturer advises for intramuscular injection, volumes over 3 mL must be divided between more than one site.

HANDLING AND STORAGE Manufacturer advises store in a refrigerator between 2–8°C.

PATIENT AND CARER ADVICE
Pancreatitis Manufacturer advises patients and carers should be told how to recognise signs and symptoms of pancreatitis and advised to seek medical attention if symptoms such as persistent, severe abdominal pain develop.

Driving and skilled tasks
Manufacturer advises patients and carers should be counselled on the effects on driving and performance of skilled tasks—increased risk of confusion and somnolence.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)
- Pegaspargase for treating acute lymphoblastic leukaemia (September 2016) NICE TA408

Pegaspargase, as part of antineoplastic combination therapy, is recommended as an option for treating acute lymphoblastic leukaemia only in patients with untreated newly diagnosed disease.

Patients whose treatment was started within the NHS before this guidance was published may continue treatment until they and their clinician consider it appropriate to stop.

www.nice.org.uk/guidance/ta408

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (October 2016) that pegaspargase (Onasca®) is accepted for use within NHS Scotland as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for injection
- Pegaspargase (non-proprietary) Pegaspargase 750 unit per 1 ml

Solution for injection vials | 1 vial £373.95

Procarbazine

- DRUG ACTION Procarbazine is a mild monoamine-oxidase inhibitor.

- INDICATIONS AND DOSE

- Hodgkin’s lymphoma
  - BY MOUTH
  - Adult: (consult local protocol)

IMPORTANT SAFETY INFORMATION

Risks of incorrect dosing of oral anti-cancer medicines

CONCEPT AND CONCEPTION

Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 825.

CONTRA-INDICATIONS

- Pre-existing severe leucopenia
- pre-existing severe thrombocytopenia

CAUTIONS

- Cardiovascular disease
- cerebrovascular disease
- epilepsy
- phaeochromocytoma
- procarbazine is a mild monoamineoxidase inhibitor (dietary restriction is rarely considered necessary)

INTERACTIONS → Appendix 1: procarbazine

SIDE-EFFECTS

- Common or very common Loss of appetite
- Frequency not known Alopecia
- bone-marrow suppression
- hypersensitivity rash (discontinue treatment)
- hyperuricaemia
- jaundice
- myelosuppression
- nausea
- oral mucositis
- thromboembolism
- tumour lysis syndrome
- vomiting

CONCEPT AND CONCEPTION

Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 825.

PREGNANCY

- Avoid (teratogenic in animal studies and isolated reports in humans). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

BREAST FEEDING

Discontinue breast-feeding.

HEPATIC IMPAIRMENT

Caution in mild to moderate impairment. Avoid in severe impairment.

RENAL IMPAIRMENT

Caution in mild to moderate impairment. Avoid in severe impairment.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Capsule

CAUTIONARY AND ADVISORY LABELS 4

- Procarbazine (Non-proprietary)

Procarbazine (as Procarbazine hydrochloride)

50 mg

Procarbazine 50mg capsules | 50 capsule £373.95

Raltitrexed

- DRUG ACTION Raltitrexed is a thymidylate synthase inhibitor.

- INDICATIONS AND DOSE

Palliation of advanced colorectal cancer when fluorouracil and folinic acid cannot be used

- BY INTRAVENOUS INFUSION

- Adult: (consult local protocol)

INTERACTIONS → Appendix 1: raltitrexed

SIDE-EFFECTS

Alopecia
- bone-marrow suppression
- extravasation
- gastro-intestinal effects
- hyperuricaemia
- myelosuppression
- nausea
- oral mucositis
- thromboembolism
- tumour lysis syndrome
- vomiting

CONCEPT AND CONCEPTION

Ensure effective contraception during and for at least 6 months after treatment in men or women.

PREGNANCY

See Pregnancy and reproductive function in Cytotoxic drugs p. 825.
BREAST FEEDING  Discontinue breast-feeding.

HEPATIC IMPAIRMENT  Caution in mild to moderate impairment. Avoid in severe impairment.

RENAL IMPAIRMENT  Reduce dose and increase dosing interval if creatinine clearance less than 65 mL/minute (consult product literature). Avoid if creatinine clearance less than 25 mL/minute.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)
- Irinotecan, oxaliplatin, and raltitrexed for advanced colorectal cancer (August 2005) NICE TA93
- Raltitrexed is not recommended for the treatment of advanced colorectal cancer. Its use should be confined to clinical studies.
  
  www.nice.org.uk/TA93

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for infusion
- Tomudex (Hospira UK Ltd)
  - Raltitrexed 2 mg  Tomudex 2mg powder for solution for infusion vials
  | 1 vial (£93)  £148.75

RETINOID AND RELATED DRUGS

Bexarotene

DRUG ACTION  Bexarotene is an agonist at the retinoid X receptor, which is involved in the regulation of cell differentiation and proliferation. Bexarotene can cause regression of cutaneous T-cell lymphoma.

INDICATIONS AND DOSE
Skin manifestations of cutaneous T-cell lymphoma refractory to previous systemic treatment

BY MOUTH
- Adult: Initially 300 mg/m² once daily, adjusted according to response, to be taken with a meal

IMPORTANT SAFETY INFORMATION

RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES
See Cytotoxic drugs p. 825.

CONTRA-INDICATIONS  History of pancreatitis · hypervitaminosis A · uncontrolled hyperlipidaemia · uncontrolled hypothyroidism

CAUTIONS  Avoid in acute porphyrias p. 969 · hyperlipidaemia · hypothyroidism

INTERACTIONS  ▶ Appendix 1: retinoids

SIDE-EFFECTS  Alopecia · anxiety · arrhythmias · benign intracranial hypertension (children particularly susceptible—consider dose reduction if intractable headache in children) · bone pain · chelitis · chest pain · confusion · depression · dizziness · dry mucous membranes · dry skin · erythema · flushing · gastro-intestinal disturbances · genital ulceration · headache · hearing disturbances · hypercalcemia · insomnia · oedema · pancreatitis · paraesthesia · pruritus · raised lipids · raised liver enzymes · raised serum creatinine · rash · retinoic acid syndrome · shivering · sweating · thromboembolism · visual disturbances

SIDE-EFFECTS, FURTHER INFORMATION  Retinoic acid syndrome Fever, dyspnoea, acute respiratory distress, pulmonary infiltrates, pleural effusion, hyperleucocytosis, hypotension, oedema, weight gain, hepatic, renal and multi-organ failure requires immediate treatment—consult product literature.

CONCEPTION AND CONTRACEPTION  Effective contraception must be used for at least 1 month before oral treatment, during treatment and for at least 1 month after stopping (oral progestogen—only contraceptives not considered effective).

PREGNANCY  Teratogenic. See Pregnancy and reproductive function in Cytotoxic drugs p. 825.

BREAST FEEDING  Avoid (discontinue breast-feeding).

HEPATIC IMPAIRMENT  Reduce dose to 25 mg/m².

RENAL IMPAIRMENT  Reduce dose to 25 mg/m².

MONITORING REQUIREMENTS  Monitor haematological and coagulation profile, liver function, serum calcium and plasma lipids before and during treatment.

PRESCRIBING AND DISPENSING INFORMATION  Tretinoin is the acid form of vitamin A.

MEDICINAL FORMS  There can be variation in the licensing of different medicines containing the same drug.

Capsule
- Targretin (Eisai Ltd)
  - Bexarotene 75 mg  Targretin 75mg capsules  | 100 capsule (£93) £937.50

Tretinoin

INDICATIONS AND DOSE
Induction of remission in acute promyelocytic leukaemia (used in previously untreated patients as well as in those who have relapsed after standard chemotherapy or who are refractory to it)

BY MOUTH
- Adult: 45 mg/m² daily in 2 divided doses maximum duration of treatment is 90 days, consult product literature for details of concomitant chemotherapy

CAUTIONS  Increased risk of thromboembolism during first month of treatment

INTERACTIONS  ▶ Appendix 1: retinoids

SIDE-EFFECTS  Alopecia · anxiety · arrhythmias · benign intracranial hypertension (children particularly susceptible—consider dose reduction if intractable headache in children) · bone pain · chelitis · chest pain · confusion · depression · dizziness · dry mucous membranes · dry skin · erythema · flushing · gastro-intestinal disturbances · genital ulceration · headache · hearing disturbances · hypercalcemia · insomnia · oedema · pancreatitis · paraesthesia · pruritus · raised lipids · raised liver enzymes · raised serum creatinine · rash · retinoic acid syndrome · shivering · sweating · thromboembolism · visual disturbances

SIDE-EFFECTS, FURTHER INFORMATION  Retinoic acid syndrome Fever, dyspnoea, acute respiratory distress, pulmonary infiltrates, pleural effusion, hyperleucocytosis, hypotension, oedema, weight gain, hepatic, renal and multi-organ failure requires immediate treatment—consult product literature.

CONCEPTION AND CONTRACEPTION  Effective contraception must be used for at least 1 month before oral treatment, during treatment and for at least 1 month after stopping (oral progestogen—only contraceptives not considered effective).

PREGNANCY  Teratogenic. See Pregnancy and reproductive function in Cytotoxic drugs p. 825.

BREAST FEEDING  Avoid (discontinue breast-feeding).

HEPATIC IMPAIRMENT  Reduce dose to 25 mg/m².

RENAL IMPAIRMENT  Reduce dose to 25 mg/m².

MONITORING REQUIREMENTS  Monitor haematological and coagulation profile, liver function, serum calcium and plasma lipids before and during treatment.

PRESCRIBING AND DISPENSING INFORMATION  Tretinoin is the acid form of vitamin A.

MEDICINAL FORMS  There can be variation in the licensing of different medicines containing the same drug.

Capsule
- Targretin (Eisai Ltd)
  - Bexarotene 75 mg  Targretin 75mg capsules  | 100 capsule (£93) £937.50

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (November 2002) that bexarotene is recommended for restricted use as a second-line treatment for patients with advanced cutaneous T-cell lymphoma.
2.1 Cytotoxic drug-induced side effects

ANTIDOTES AND CHELATORS > IRON CHELATORS

Dexrazoxane

- **DRUG ACTION**: Dexrazoxane is an iron chelator.

- **INDICATIONS AND DOSE**

  **CARDIOXANE®**: Prevention of chronic cumulative cardiotoxicity caused by doxorubicin or epirubicin treatment in advanced or metastatic breast cancer patients who have received a prior cumulative dose of 300 mg/m² of doxorubicin or a prior cumulative dose of 540 mg/m² of epirubicin when further anthracycline treatment is required.
  - **BY INTRAVENOUS INFUSION**
    - Adult: Administer 10 times the doxorubicin-equivalent dose or 10 times the epirubicin-equivalent dose, dose to be given 30 minutes before anthracyline administration.

  **SAVENE®**: Anthracycline extravasation.
  - **BY INTRAVENOUS INFUSION**
    - Adult: Initially 1 g/m² daily (max. per dose 2 g) for 2 days, then 500 mg/m² for 1 day, first dose to be given as soon as possible and within 6 hours after injury.

- **CONTRA-INDICATIONS**: Children

- **CAUTIONS**: Myelosuppression (effects may be additive to those of chemotherapy).

  **CARDIOXANE®**: Manufacturer advises caution in patients with heart failure—no information available. Manufacturer advises caution in patients with myocardial infarction in previous 12 months—no information available. Manufacturer advises caution in patients with symptomatic valvular heart disease—no information available. Manufacturer advises caution in patients with uncontrolled angina—no information available.

- **SIDE-EFFECTS**

  **CARDIOXANE®**:  
  - Common or very common: Anorexia, asthenia, diarrhoea, dizziness, dry mouth, dyspnoea, erythema, infection, malaise, nausea, oedema, paraesthesia, peripheral neuropathy, stomatitis, syncope, vomiting.
  - Uncommon: Abdominal pain, acute myeloid leukaemia, constipation, cough, dyspepsia, headache, lymphoedema, nail disorder, reduced ejection fraction, tachycardia, thromboembolism when given with cytotoxic drugs.
  - Frequency not known: Alopecia, anaemia, blood disorders, fatigue, injection-site reactions, leucopenia, phlebitis, pruritus, pyrexia, thrombocytopenia.

  **SAVENE®**:  
  - Common or very common: Alopecia, anaemia, anorexia, blood disorders, diarrhoea, dizziness, drowsiness, dry mouth, dyspnoea, erythema, fatigue, injection-site reactions, leucopenia, malaise, nausea, oedema, peripheral neuropathy, peripheral oedema, phlebitis, pruritus, pyrexia, stomatitis, syncope, thrombocytopenia, tremor, vaginal haemorrhage, vomiting.
  - Uncommon: Drowsiness, myalgia, thromboembolism (when given with cytotoxic drugs), weight loss.

- **CONCEPTION AND CONTRACEPTION**: Ensure effective contraception during and for at least 3 months after treatment in men and women.
**PREGNANCY** Manufacturer advises avoid unless potential benefit outweighs risk—toxicity in animal studies.

**BREAST FEEDING** Manufacturer advises avoid—no information available.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. No licensed medicines listed.

**DETOXIFYING DRUGS | UROPROTECTIVE DRUGS**

**Mesna**

**INDICATIONS AND DOSE**

Cytotoxic induced urethral toxicity

- **BY MOUTH, OR BY INTRAVENOUS INJECTION**
- **Adult:** Dose to be calculated according to oxazaphosphorine (cyclophosphamide or ifosfamide) treatment (consult product literature)

**SIDE-EFFECTS**

Common or very common

- Colic
- Depression
- Diarrhoea
- Fatigue
- Headache
- Hypotension
- Irritability
- Joint pains
- Limb pains
- Nausea
- Rash
- Tachycardia
- Vomiting

Rare

- Hypersensitivity reactions (more common in patients with auto-immune disorders)

**ALLERGY AND CROSS-SENSITIVITY** Contra-indicated if history of hypersensitivity to thiol-containing compounds.

**PREGNANCY** Not known to be harmful. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**EFFECT ON LABORATORY TESTS** False positive urinary ketones. False positive or false negative urinary erythrocytes.

**DIRECTIONS FOR ADMINISTRATION** For oral administration of the injection, contents of ampoule are taken in a flavoured drink such as orange juice or cola which may be stored in a refrigerator for up to 24 hours in a sealed container.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

**Solution for injection**

- **Mesna (Non-proprietary)**
  - Mesna 100 mg per 1 ml Mesna 1g/10ml solution for injection ampoules | 15 ampoule Pdm £441.15
  - Mesna 400mg/4ml solution for injection ampoules | 5 ampoule Pdm no price available

- **Tablet**
  - **Mesna (Non-proprietary)**
    - Mesna 400 mg Mesna 400mg tablets | 10 tablet Pdm £134.30
    - Mesna 600 mg Mesna 600mg tablets | 10 tablet Pdm £190.60

**VITAMINS AND TRACE ELEMENTS | FOLATES**

**Folinic acid**

**INDICATIONS AND DOSE**

Prevention of methotrexate-induced adverse effects

- **BY INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
- **Adult:** 15 mg every 6 hours for 24 hours, to be started usually 12–24 hours after start of methotrexate infusion, dose may be continued by mouth, consult local treatment protocol for further information

Suspected methotrexate overdosage

- **BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
- **Adult:** Initial dose equal to or exceeding dose of methotrexate, to be given at a maximum rate of 160 mg/minute, consult poisons information centres for advice on continuing management

**CONTRA-INDICATIONS** Intrathecal injection

**CAUTIONS** Avoid simultaneous administration of methotrexate - not indicated for pernicious anaemia or other megaloblastic anaemias caused by vitamin B_{12} deficiency

**INTERACTIONS** → Appendix 1: folates

**SIDE-EFFECTS**

- **Rare** Agitation (after high doses) - depression (after high doses) - insomnia (after high doses) - pyrexia (after parenteral use)

- **PREGNANCY** Not known to be harmful; benefit outweighs risk.

- **BREAST FEEDING** Presence in milk unknown but benefit outweighs risk.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capcitabine for the treatment of metastatic colorectal cancer (December 2010) NICE TA212

Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capcitabine is not recommended for the treatment of metastatic colorectal cancer.

[www.nice.org.uk/TA212](http://www.nice.org.uk/TA212)

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Solution for injection**

- **Folinic acid (Non-proprietary)**
  - Folinic acid (as Calcium folinate) 7.5 mg per 1 ml Calcium folinate 15mg/2ml solution for injection ampoules | 5 ampoule Pdm £39.00
  - DT price = £39.00
  - Folinic acid (as Calcium folinate) 10 mg per 1 ml Calcium folinate 50mg/5ml solution for injection vials | 1 vial Pdm £20.00 (Hospital only) | 1 vial Pdm £37.50 (Hospital only)
  - Folinic acid (as Disodium folinate) 50 mg per 1 ml Disodium folinate 50mg/1ml solution for injection vials | 1 vial Pdm £24.70
  - Disodium folinate 200mg/4ml solution for injection vials | 1 vial Pdm £80.40

- **Refolinon** (Pfizer Ltd)
  - Folinic acid (as Calcium folinate) 3 mg per 1 ml Refolinon 30mg/10ml solution for injection ampoules | 5 ampoule Pdm £23.12
  - **Sodionfolin** (medac UK)
  - Folinic acid (as Disodium folinate) 50 mg per 1 ml Sodionfolin 400mg/8ml solution for injection vials | 1 vial Pdm £126.25 (Hospital only)
  - Sodionfolin 100mg/2ml solution for injection vials | 1 vial Pdm £35.09 (Hospital only)

- **Tablet**
  - **Folinic acid (Non-proprietary)**
    - Folinic acid (as Calcium folinate) 15 mg Folinic acid 15mg tablets | 10 tablet Pdm £49.06 DT price = £49.05
  - **Refolinon** (Pfizer Ltd)
    - Folinic acid (as Calcium folinate) 15 mg Refolinon 15mg tablets | 30 tablet Pdm £85.74
Levofolinic acid

**DRUG ACTION**  Levofolinic acid is an isomer of folinic acid.

**INDICATIONS AND DOSE**

- Prevention of methotrexate-induced adverse effects
  - By intramuscular injection, or by intravenous injection, or by intravenous infusion
  - Adult: Usual dose 7.5 mg every 6 hours for 10 doses, usually started 12–24 hours after beginning of methotrexate infusion

**Suspected methotrexate overdosage**

- By intravenous infusion, or by intravenous injection
  - Adult: Initial dose at least 50% of the dose of methotrexate, intravenous infusion to be administered at a maximum rate of 160 mg/minute, consult poisons information centres for advice on continuing management

**Adjunct to fluorouracil in colorectal cancer**

- By slow intravenous injection
  - Adult: (consult product literature)

**CONTRA-INDICATIONS**  Intrathecal injection

**CAUTIONS**  Avoid simultaneous administration of methotrexate - not indicated for pernicious anaemia or other megaloblastic anaemias caused by vitamin B12 deficiency

**INTERACTIONS**  → Appendix 1: folates

**SIDE-EFFECTS**

- Rare: Agitation (after high doses) - depression (after high doses) - insomnia (after high doses) - pyrexia (after parenteral use)

**PREGNANCY**  Not known to be harmful; benefit outweighs risk.

**BREAST FEEDING**  Presence in milk unknown but benefit outweighs risk.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Solution for injection**
  - Isovorin (Pfizer Ltd)
    - Levofolinic acid (as Calcium levofolinate) 10 mg per 1 ml Isovorin 175mg/17.5ml solution for injection vials  | 1 vial £1.13
      (Hospital only)
    - Isovorin 25mg/2.5ml solution for injection vials  | 1 vial £11.62
      (Hospital only)

**SIDE-EFFECTS**

- Common or very common: Fever
- Uncommon: Anaphylaxis - bronchospasm - diarrhoea - haemolytic anaemia - headache - hypersensitivity reactions - methaemoglobinemia - nausea - rash - vomiting

**PREGNANCY**  Manufacturer advises avoid — no information available.

**BREAST FEEDING**  Manufacturer advises avoid — no information available.

**MONITORING REQUIREMENTS**  Monitor closely for hypersensitivity.

**EFFECT ON LABORATORY TESTS**  May interfere with test for uric acid—consult product literature.

**DIRECTIONS FOR ADMINISTRATION**  For intravenous infusion (Fasturtec®), give intermittently in Sodium chloride 0.9%; reconstitute with solvent provided; gently swirl vial without shaking to dissolve; dilute requisite dose to 50 mL with infusion fluid and give over 30 minutes.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Powder and solvent for solution for infusion**
  - Fasturtec (Sanofi)
    - Rasburicase 1.5 mg  Fasturtec 1.5mg powder and solvent for solution for infusion vials  | 3 vial £20.83 (Hospital only)
      (Hospital only)
    - Rasburicase 7.5 mg  Fasturtec 7.5mg powder and solvent for solution for infusion vials  | 1 vial £347.32 (Hospital only)

3  **Hormone responsive malignancy**

**Breast cancer**  01-Jun-2016

**Description of condition**

Breast cancer is the most common form of malignancy in women. The causes of breast cancer are complex and there are several risk factors. Established risk factors include age, early onset of menstruation, late menopause, greater age at first completed pregnancy, and a family history. The use of oral contraceptives and postmenopausal HRT are also associated with a small excess risk.

Non-invasive breast cancer, also known as ductal carcinoma in situ, is when the cancer remains localised in the ducts. However, in most cases, the cancer is invasive at the time of diagnosis, which means that malignant cells are liable to spread beyond the immediate area of the tumour. Invasive breast cancer, where malignant cells spread beyond the ducts, can be defined as early breast cancer (operable, primary, stage I/II), locally advanced disease (inoperable local, stage III) and advanced disease (metastatic, stage IV).

**Aims of treatment**

Reducing mortality, increasing progression-free and disease-free survival and improving quality of life are the main aims of the available treatments for breast cancer and are dependant on the stage of the disease.

Surgery and radiotherapy aim to remove the tumour mass, while adjuvant drug therapy aims to reduce the risk of recurrence and the risk of developing invasive disease. Advanced breast cancer is not curable and treatment aims to achieve remission, to prolong the disease free survival, to relieve symptoms and improve quality of life.

**Treatment**

The course of the disease and the therapeutic approach vary depending on the characteristics of the cancer; factors such as patient age and menopausal status, tumour size and...
grade, involvement of axillary lymph nodes or skin, and presence of hormone receptors within the tumour may inform the extent and aggressiveness of the disease. The management of patients with breast cancer involves surgery, radiotherapy, drug therapy, or a combination of these.

**Early and locally advanced breast cancer**

For operable breast cancer, primary treatment is surgical using breast-conserving surgery or mastectomy, followed by adjuvant therapy to eradicate the micro-metastases that cause relapses. Radiotherapy is recommended after breast conserving surgery, as it reduces local recurrence rates. It is also used after mastectomy if there is a high risk of recurrence.

Drug therapy can be used after surgery (adjuvant therapy) or may be offered before surgery (neoadjuvant therapy) to achieve local tumour downsizing in order to make breast-conserving surgery possible. The choice of adjuvant therapy is determined by the safety and efficacy of the drugs, the oestrogen-receptor status, and the human epidermal growth factor 2 (HER2) status of the primary tumour.

Adjuvant chemotherapy or radiotherapy should be considered for all patients, irrespective of age, and it should be started as soon as clinically possible within 31 days of surgery.

A high-dose anthracycline-based chemotherapy regimen is usually preferred to a low-dose anthracycline-based regimen or to a non-anthracycline-based regimen. Choice of chemotherapy regimen is usually guided by local policy, Clinical Cancer Networks, and funding arrangements.

Adjuvant anthracycline-taxane combination chemotherapy should be considered in patients where the additional benefit outweighs risk. For patients with lymph node-positive breast cancer, docetaxel p. 854 can be added as part of an adjuvant chemotherapy regimen; paclitaxel p. 855 is not recommended.

Following surgery, tamoxifen p. 879, alone or in combination with chemotherapy, can be given to premenopausal women with oestrogen-receptor-positive early invasive breast cancer. If chemotherapy has not been selected, tamoxifen can be used in combination with ovarian ablation or suppression. Tamoxifen is not recommended for non-invasive (ductal carcinoma in situ) early breast cancer.

Premenopausal women with oestrogen-receptor-positive breast cancer who decline chemotherapy may benefit from treatment with goserelin p. 695 or ovarian ablation.

For postmenopausal women with oestrogen-receptor-positive early invasive breast cancer, not considered to be low risk, an aromatase inhibitor, such as anastrozole p. 880 or letrozole p. 881, is first-line therapy. Tamoxifen is an alternative if an aromatase inhibitor is not tolerated or is contra-indicated. An aromatase inhibitor should be given as initial adjuvant therapy for 5 years, or by switching to an aromatase inhibitor after 2–3 years of tamoxifen for a total of 5 years. Postmenopausal women who have already received tamoxifen for 5 years may be considered for extended therapy (5 years) with letrozole.

Adjuvant trastuzumab p. 823 is recommended as an option in patients with HER2 positive breast cancer following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy. Trastuzumab should not be given concurrently with anthracycline-containing regimens (because of the risk of congestive heart failure) but it may be given either concurrently with taxane-based regimens or sequentially.

**Advanced breast cancer**

Treatment of advanced breast cancer depends on the patient’s drug history, disease severity, and oestrogen receptor and HER2 status.

For the majority of patients with oestrogen-receptor-positive advanced breast cancer, endocrine therapy is first-line treatment. Aromatase inhibitors, such as anastrozole, letrozole and exemestane p. 880, may be offered to patients with no previous history of endocrine treatment or in those previously treated with tamoxifen.

Tamoxifen should be considered as first-line treatment for pre- and perimenopausal women with oestrogen-receptor-positive breast cancer not previously treated with tamoxifen. Ovarian suppression is used in pre- and perimenopausal women who have had disease progression despite treatment with tamoxifen.

In patients with advanced breast cancer that is imminently life-threatening or with visceral organ involvement, which requires early relief of symptoms, an anthracycline-based chemotherapy regimen is the preferred treatment. If anthracyclines are not suitable, the alternative is docetaxel monotherapy as first-line treatment, vinorelbine p. 860 or capecitabine p. 839 as second-line treatment or, for third-line treatment, whichever of the two drugs was not used second line. Gemcitabine p. 843 in combination with paclitaxel is recommended for the treatment of metastatic breast cancer only when docetaxel monotherapy or docetaxel with capecitabine are also considered appropriate.

Trastuzumab is recommended for the treatment of HER2-positive advanced breast cancer. It is used in combination with paclitaxel in those who have not received chemotherapy for metastatic breast cancer and as monotherapy for patients who have received at least two chemotherapy regimens for metastatic breast cancer (see trastuzumab National funding/access decisions).

Lapatinib p. 905 in combination with an aromatase inhibitor, fulvestrant p. 878, trastuzumab emtansine p. 824, and toremifene p. 879 are all licensed for use in patients with metastatic breast cancer, however their use is not recommended (see drug monographs for Indications and National funding/access decisions).

The gonadorelin analogue, goserelin is licensed for advanced breast cancer in pre- and perimenopausal women suitable for hormone manipulation. Some progesterone preparations, such as medroxyprogesterone acetate p. 763, norethisterone p. 720, megestrol acetate p. 878 are also licensed for the treatment of breast cancer (see drug monographs).

The use of bisphosphonates in patients with metastatic breast cancer may reduce pain and prevent skeletal complications of bone metastases.

**Familial breast cancer**

Chemoprevention should be offered to all women who have been identified as high-risk of developing breast cancer. For women at moderate-risk, chemoprevention should only be considered. Other strategies should also be considered to reduce the risk.

Chemoprevention should not be given to patients at high-risk of developing breast cancer who have had a risk-reducing bilateral mastectomy.

**Treatment options for chemoprevention**

Chemoprevention should only be continued for 5 years.

Tamoxifen p. 879 [unlicensed indication] is recommended for premenopausal women who do not have a history or increased risk of thromboembolic disease or endometrial cancer.

In post-menopausal women (who do not have severe osteoarthritis), anastrozole p. 880 [unlicensed indication] is recommended. Women who have severe osteoarthritis, or who do not wish to take anastrozole, can be treated with tamoxifen provided there is no history or risk of thromboembolic disease or endometrial cancer. Alternatively, raloxifene hydrochloride p. 709 is an option [unlicensed indication] in post-menopausal women with a uterus who do not wish to take tamoxifen, unless there is a history or increased risk of thromboembolic disease.

**Breast cancer in men**

Breast cancer in men is rare. Although, not fully understood, risk factors may be associated with sex hormone metabolism,
Prostate Cancer

31-May-2016

Description of condition
Prostate cancer is the most common form of cancer affecting men. The main risk factors are age (most cases being diagnosed in men over 65 years of age), ethnicity (more common in black African–Caribbean men), and a familial component. Prostate cancer is usually slow-growing and asymptomatic at diagnosis, however, the presenting symptoms of advanced disease are usually urinary outflow obstruction, or, pelvic or back pain due to bone metastases. Treatment decisions are guided by baseline prostate specific antigen (PSA) levels, tumour grade (Gleason score), the stage of the tumour, the patient’s life expectancy (based on age and comorbid conditions), treatment morbidity, and patient preference.

Aims of treatment
In early or locally advanced prostate cancer, radical treatment aims to eliminate the malignancy. In metastatic disease, drug therapy is aimed at prolonging survival and reducing symptoms.

Drug treatment
Treatment options for patients with prostate cancer include active monitoring, radical prostatectomy, external beam radiotherapy, and brachytherapy. Hormone therapy (androgen deprivation or anti-androgens) is the primary treatment for metastatic prostate cancer, but is also increasingly being used for patients with locally advanced, non-metastatic disease.

In patients with localised prostate cancer, the choice of treatment is guided by whether the disease is considered low, intermediate, or high risk according to the Gleason score, the serum PSA level, and the tumour stage.

Localised or locally advanced prostate cancer

In patients with low-risk localised prostate cancer, and those at intermediate risk who decline radical treatments (prostatectomy or radiotherapy), active monitoring is a suitable option. This involves close monitoring to avoid unnecessary treatment until disease progression occurs (or until the patient requests treatment).

In patients with intermediate-risk or high-risk localised prostate cancer (when there is a realistic prospect of long-term disease control) and in those with locally advanced disease, radical prostatectomy or radical radiotherapy should be offered. Other treatment options include a combination of radical radiotherapy and androgen deprivation therapy, consisting of 6 months of androgen deprivation therapy before, during or after radiotherapy. Pelvic radiotherapy should be considered in those with locally advanced prostate cancer who have a higher than 15% risk of pelvic lymph node involvement and are to receive neoadjuvant hormonal therapy.

Androgen deprivation therapy involves the use of a luteinising hormone-releasing hormone (LHRH) agonist (buserelin p. 694, goserelin p. 695, leuprorelin acetate p. 696, or triptorelin p. 698), or bilateral orchidectomy, which removes the supply of endogenous hormone. Androgen deprivation therapy may be continued for up to 3 years in patients with high-risk localised prostate cancer.

Patients should be informed about the side-effects of treatment, particularly urinary and sexual dysfunction, loss of fertility, radiation-induced enteropathy, and hot flushes. Although there is limited evidence, intermittent therapy may be considered for patients who are having long-term androgen deprivation therapy, to reduce drug toxicity. Tumour flare, due to an initial surge in testosterone concentrations, has been reported in the initial stages of treatment with androgen deprivation therapy and prophylactic anti-androgen therapy (such as cyproterone acetate p. 725) may be added.

Medroxyprogesterone acetate p. 763 [unlicensed indication] can be used, initially for up to 10 weeks, to manage troublesome hot flushes caused by long-term androgen suppression; cyproterone acetate is an alternative if medroxyprogesterone acetate is not effective or not tolerated.

Patients who experience a reduction in libido and loss of sexual function should have access to specialist erectile dysfunction services and be considered for treatment with a phosphodiesterase type 5 inhibitor.

Osteoporosis and fatigue may also be a problem with androgen deprivation therapy. A biphosphonate can be offered to men who have osteoporosis; denosumab p. 691 is an alternative if biphosphonates are not appropriate. Gynaecomastia can occur with long-term (longer than 6 months) bicalutamide p. 874 treatment. Prophylactic radiotherapy (within the first month of treatment), or weekly tamoxifen p. 879 [unlicensed indication], if radiotherapy is unsuccessful, can be considered.

Metastatic prostate cancer

Bilateral orchidectomy should be offered to all patients with metastatic prostate cancer as an alternative to continuous LHRH agonist treatment. Anti-androgen monotherapy with bicalutamide [unlicensed indication] can be offered to those who are willing to accept the adverse impact on overall survival and gynaecomastia in the hope of retaining sexual function. However, if satisfactory sexual function is not maintained, stop bicalutamide and start androgen deprivation therapy.

Abiraterone acetate p. 873 (in combination with prednisone p. 641 or prednisolone p. 639) and enzalutamide p. 874 are both recommended as options for the treatment of castration-resistant metastatic prostate cancer in patients whose disease has progressed during or after treatment with a docetaxel-containing p. 854 chemotherapy regimen.

In patients who develop hormone-relapsed metastatic tumour, chemotherapy with docetaxel can be used. It is recommended to stop the treatment with docetaxel after 10 cycles, or if severe adverse events occurred, or if there is evidence of disease progression.

Abiraterone acetate (in combination with prednisone or prednisolone) is also recommended as an option for treating...
metastatic hormone-relapsed prostate cancer in patients who have no or mild symptoms after androgen deprivation therapy has failed, and before chemotherapy is indicated.

In patients with hormone-relapsed prostate cancer, a corticosteroid, such as dexamethasone p. 635, can be offered as third line therapy, after androgen deprivation therapy and anti-androgen therapy. (A)

Useful Resources
www.nice.org.uk/guidance/cg175

Other drugs used for Hormone responsive malignancy
Ethinylestradiol, p. 715

ANTINEOPLASTIC DRUGS › ANTI-ANDROGENS

Abiraterone acetate
31-May-2016

- INDICATIONS AND DOSE
Metastatic castration-resistant prostate cancer in patients whose disease has progressed during or after treatment with a docetaxel-containing chemotherapy regimen (in combination with prednisone or prednisolone) | Metastatic castration-resistant prostate cancer in patients who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (in combination with prednisone or prednisolone)
- BY MOUTH
- Adult: 1 g once daily, for dose of concurrent prednisone or prednisolone—consult product literature

- CAUTIONS
Diabetes (increased risk of hyperglycaemia—monitor blood sugar frequently) | history of cardiovascular disease

CAUTIONS, FURTHER INFORMATION
- Cardiovascular disease | Correct hypertension and hypokalaemia before treatment (if significant risk of congestive heart failure, such as history of cardiac failure, uncontrolled hypertension or cardiac events, consult product literature for management and increased monitoring).

- INTERACTIONS ➔ Appendix 1: abiraterone
- SIDE-EFFECTS
- Common or very common
  - Angina | arrhythmia | atrial fibrillation | diarrhoea | dyspepsia | fractures | haematuria | heart failure | hepatotoxicity | hypertension | hypertriglyceridaemia | hypokalaemia | peripheral oedema | rash | sepsis | tachycardia | urinary tract infection
- Uncommon
  - Adrenal insufficiency | myopathy | rhabdomyolysis
- Rare
  - Allergic alveolitis

- CONCEPTION AND CONTRACEPTION
  - Men should use condoms if their partner is pregnant, and use condoms in combination with another effective contraceptive method if their partner is of child-bearing potential—toxicity in animal studies.

- HEPATIC IMPAIRMENT
  - Use with caution in moderate impairment and only if benefit clearly outweighs risk.
  - Avoid in severe impairment.

- RENAL IMPAIRMENT
  - Use with caution in severe impairment—no information available.

- MONITORING REQUIREMENTS
  - Monitor blood pressure, serum potassium concentration, and fluid balance before treatment, and at least monthly during treatment—consult product literature for management of hypertension, hypokalaemia and oedema.
  - Monitor liver function before treatment, then every 2 weeks for the first 3 months of treatment, then monthly thereafter—interrupt treatment if serum alanine aminotransferase or aspartate aminotransferase greater than 5 times the upper limit (consult product literature for details of restarting treatment at a lower dose) and discontinue permanently if 20 times the upper limit.

NICE technology appraisals (TAs)
- Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (June 2012) NICE TA259
  - Abiraterone in combination with prednisone or prednisolone is recommended as an option for the treatment of castration-resistant metastatic prostate cancer only if:
    - their disease has progressed on or after one docetaxel-containing chemotherapy regimen, and
    - the manufacturer provides abiraterone with the discount agreed in the patient access scheme.

  - Patients currently receiving abiraterone in combination with prednisone or prednisolone whose disease does not meet the first criteria should be able to continue therapy until they and their clinician consider it appropriate to stop.
  - www.nice.org.uk/TA259

- Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (April 2016) NICE TA387
  - Abiraterone, in combination with prednisone or prednisolone, is recommended as an option for treating metastatic hormone-relapsed prostate cancer in patients who have mild or no symptoms after androgen deprivation therapy has failed, and before chemotherapy is indicated. In addition, the manufacturer is required to rebate the cost of abiraterone from the 11th month until the end of treatment for patients who remain on treatment for more than 10 months.
  - www.nice.org.uk/TA387

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (July 2012) that abiraterone (Zytiga®), in combination with prednisone or prednisolone, is accepted for restricted use within NHS Scotland for the treatment of metastatic castration-resistant prostate cancer in patients whose disease has progressed during or after treatment with docetaxel-containing chemotherapy regimen, and have received only one prior chemotherapy regimen.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.
Tablet
CAUTIONARY AND ADVISORY LABELS 23
- Zytiga (Janssen-Cilag Ltd)
  - Abiraterone acetate 250 mg Zytiga 250mg tablets | 120 tablet pack £2,930.00
  - Abiraterone acetate 500 mg Zytiga 500mg tablets | 56 tablet pack £2,735.00
Immune system and malignant disease

### Bicalutamide

**INDICATIONS AND DOSE**

Locally advanced prostate cancer at high risk of disease progression either alone or as adjuvant treatment to prostatectomy or radiotherapy | Locally advanced, non-metastatic prostate cancer when surgical castration or other medical intervention inappropriate

- **BY MOUTH**
- Adult: 150 mg once daily

Advanced prostate cancer, in combination with gonadorelin analogue or surgical castration

- **BY MOUTH**
- Adult: 50 mg once daily, to be started at the same time as surgical castration or at least 3 days before gonadorelin therapy

Prostate cancer (metastatic) with the aim of retaining sexual function.

- **BY MOUTH**
- Adult: 150 mg once daily

**UNLICENSED USE**

Not licensed for use in prostate cancer (metastatic), with the aim of retaining sexual function. 

**CAUTIONS**

Risk of photosensitivity—avoid excessive exposure to UV light and sunlight

**INTERACTIONS** → Appendix 1: bicalutamide

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain · alopecia · anaemia · asthenia · breast tenderness · chest pain · cholestasis · constipation · decreased appetite · decreased libido · depression · dizziness · dry skin · dyspepsia · flatulence · gynaecomastia · haematuria · hepatotoxicity · hirsutism · hot flushes · impotence · jaundice · nausea · oedema · pruritus · rash · somnolence · weight gain

- **Uncommon** Angioedema · hypersensitivity reactions · interstitial lung disease · urticaria

- **Rare** Hepatic failure · photosensitivity reactions

- **HEPATIC IMPAIRMENT** Increased accumulation possible in moderate to severe impairment—manufacturer advises caution.

- **MONITORING REQUIREMENTS** Consider periodic liver function tests.

- **PATIENT AND CARER ADVICE**

Risk of photosensitivity. Patients should be advised to consider the use of sunscreen.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Tablet**

- **Bicalutamide (Non-proprietary)**
  - Bicalutamide 50 mg (Bicalutamide 50mg tablets | 28 tablet | POM)
    - £128.00 DT price = £1.79
  - Bicalutamide 150 mg (Bicalutamide 150mg tablets | 28 tablet | POM)
    - £240.00 DT price = £4.48
  - Casodex (AstraZeneca UK Ltd)
    - Bicalutamide 50 mg (Casodex 50mg tablets | 28 tablet | POM)
      - £115.79 DT price = £1.79
    - Bicalutamide 150 mg (Casodex 150mg tablets | 28 tablet | POM)
      - £240.00 DT price = £4.48

---

### Enzalutamide

**INDICATIONS AND DOSE**

Metastatic castration-resistant prostate cancer in patients whose disease has progressed during or after docetaxel therapy

- **BY MOUTH**
- Adult: 160 mg once daily, for dose adjustments due to side-effects, consult product literature

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**

Manufacturer advises if concurrent use of potent inhibitors of CYP2C8 is unavoidable, reduce dose to 80 mg daily.

**CAUTIONS**

- Alcoholism · bradycardia · brain injury · brain metastases · brain tumours · history of QT-interval prolongation · history or risk of seizure · recent cardiovascular disease · risk factors for QT-interval prolongation · stroke · uncontrolled hypertension

**INTERACTIONS** → Appendix 1: enzalutamide

**SIDE-EFFECTS**

- **Common or very common** Anxiety · cognitive disorder · dry skin · falls · fractures · headache · hot flush · hypertension · memory impairment · neutropenia · pruritus · visual hallucinations

- **Uncommon** Leucopenia · seizure

- **CONCEPTION AND CONTRACEPTION**

Men should use condoms during treatment and for 3 months after stopping treatment if their partner is pregnant, and use condoms in combination with another effective contraceptive method if their partner is of child-bearing potential—toxicity in animal studies.

- **HEPATIC IMPAIRMENT**

Manufacturer advises caution in moderate impairment. Avoid in severe impairment.

- **RENAL IMPAIRMENT**

Caution in severe impairment—no information available.

**NATIONAL FUNDING/ACCESS DECISIONS**

NICE technology appraisals (TAs)

- Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (January 2016) NICE TA377

Enzalutamide is recommended as an option for treating metastatic hormone-relapsed prostate cancer in patients who have mild or no symptoms after androgen deprivation therapy has failed, and before chemotherapy is indicated, and only if the manufacturer provides enzalutamide with the discount agreed in the patient access scheme.

[wwww.nice.org.uk/TA377](www.nice.org.uk/TA377)

- Enzalutamide for metastatic hormone relapsed prostate cancer previously treated with a docetaxel containing regimen (July 2014) NICE TA316

Enzalutamide is recommended, within its marketing authorisation, as an option for treating metastatic hormone-relapsed prostate cancer in adults only if, their disease has progressed during or after docetaxel-containing chemotherapy, and the manufacturer provides enzalutamide with the discount agreed in the patient access scheme. This guidance does not cover the use of enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with abiraterone.

[wwww.nice.org.uk/TA316](www.nice.org.uk/TA316)

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

- **Xtandi** (Astellas Pharma Ltd)
  - Enzalutamide 40 mg (Xtandi 40mg capsules | 112 capsule | POM)
    - £2,734.67
**Flutamide**

- **INDICATIONS AND DOSE**
  - Advanced prostate cancer | Metastatic prostate cancer refractory to gonadorelin analogue therapy (monotherapy)
    - **BY MOUTH**
      - Adult: 250 mg 3 times a day

- **CAUTIONS**
  - Avoid excessive alcohol consumption - avoid in acute porphyrias p. 969 - cardiac disease (oedema reported)
  - **SIDE-EFFECTS**
  - **HEPATIC IMPAIRMENT**
    - Use with caution (hepatoxic).
  - **MONITORING REQUIREMENTS**
    - Liver function tests, monthly for first 4 months, periodically thereafter and at the first sign or symptom of liver disorder (e.g. pruritus, dark urine, persistent anorexia, jaundice, abdominal pain, unexplained influenza-like symptoms).

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Tablet**
    - **Flutamide (Non-proprietary)**
      - Flutamide 250 mg tablets | £0.106.24 DT price = £106.24

**OESTROGENS**

**Diethylstilbestrol**

- **(Stilboestrol)**

- **INDICATIONS AND DOSE**
  - Breast cancer in postmenopausal women
    - **BY MOUTH**
      - Adult: 10–20 mg daily
  - Prostate cancer
    - **BY MOUTH**
      - Adult: 1–3 mg daily

- **CAUTIONS**
  - Cardiovascular disease
  - **SIDE-EFFECTS**
  - **PREGNANCY**
    - In first trimester, high doses associated with vaginal carcinoma, urogenital abnormalities, and reduced fertility in female offspring. Increased risk of hypospadias in male offspring.
  - **HEPATIC IMPAIRMENT**
    - Avoid. Avoid in active liver disease including disorders of hepatic excretion (e.g. Dubin-Johnson or Rotor syndromes), infective hepatitis (until liver function returns to normal), and liver tumours.

**Flutamide**

- **MEDICATION FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Tablet**
    - **Diethylstilbestrol (Non-proprietary)**
      - Diethylstilbestrol 1 mg tablets | 28 tablet [Pom] £123.00 DT price = £120.34
      - Diethylstilbestrol 5 mg tablets | 28 tablet [Pom] £185.00–£208.00 DT price = £208.00

**PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES > ANTI-GONADOTROPHIN-RELEASING HORMONES**

**Degarelix**

- **INDICATIONS AND DOSE**
  - Advanced hormone-dependent prostate cancer
    - **BY SUBCUTANEOUS INJECTION**
      - Adult: Initially 240 mg, to be administered as 2 injections of 120 mg, then 80 mg every 28 days, dose to be administered into the abdominal region

- **CAUTIONS**
  - Diabetes - susceptibility to QT-interval prolongation
  - **SIDE-EFFECTS**
    - Common or very common: Asthenia - dizziness - drowsiness - headache - hot flushes - influenza-like symptoms - injection-site reactions - insomnia - nausea - night sweats - sweating - weight gain
  - **HEPATIC IMPAIRMENT**
    - Manufacturer advises caution in severe impairment — no information available.
  - **RENAL IMPAIRMENT**
    - Manufacturer advises caution in severe impairment — no information available.
  - **MONITORING REQUIREMENTS**
    - Monitor bone density.
  - **NATIONAL FUNDING/ACCESS DECISIONS**
    - NICE technology appraisals (TAs)
      - Degarelix for treating advanced hormone-dependent prostate cancer (August 2016) NICE TA404
      - Degarelix is recommended as an option for treating advanced hormone-dependent prostate cancer in patients with spinal metastases, only if at least the same discounted drug cost which was available to the NHS in June 2016 is achieved by the commissioner.
      - Patients whose treatment was started within the NHS before this guidance was published should have the option to continue treatment, without change to their funding arrangements, until they and their clinician consider it appropriate to stop.
      - [www.nice.org.uk/guidance/TA404](http://www.nice.org.uk/guidance/TA404)

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Powder and solvent for solution for injection**
    - **Firmagon (Ferring Pharmaceuticals Ltd)**
      - Degarelix (as Degarelix acetate) 80 mg | Firmagon 80mg powder and solvent for solution for injection vials | 1 vial [Pom] £129.37
      - Degarelix (as Degarelix acetate) 120 mg | Firmagon 120mg powder and solvent for solution for injection vials | 2 vial [Pom] £260.00

---

**Immune system and malignant disease**

---

**downloaded from www.medicalbr.com**
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES  > SOMATOSTATIN ANALOGUES

Somatostatin analogues, malignant disease

Overview
Lanreotide below, octreotide p. 877 and pasireotide p. 878 are analogues of the hypothalamic release-inhibiting hormone somatostatin. Lanreotide and octreotide are indicated for the relief of symptoms associated with neuroendocrine (particularly carcinoid) tumours and acromegaly. Additionally, lanreotide is licensed for the treatment of thyroid tumours and octreotide is also licensed for the prevention of complications following pancreatic treatment of thyroid tumours and octreotide is also licensed for acromegaly. Additionally, lanreotide is licensed for the treatment of unresectable locally advanced or metastatic gastroenteropancreatic neuroendocrine tumours of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded. Octreotide long-acting depot injection is licensed for treatment of advanced neuroendocrine tumours of the midgut, or treatment where primary origin is not known but non-midgut sites of origin have been excluded. Octreotide long-acting depot injection may be valuable in reducing vomiting in palliative care and in stopping variceal bleeding [unlicensed indication]—see also vasopressin p. 630 and terlipressin acetate p. 87. Pasireotide is licensed for the treatment of Cushing’s disease when surgery has failed or is inappropriate.

Somatostatin analogues

● CAUTIONS Diabetes mellitus (antidiabetic requirements may be reduced) • insulinoma (increased depth and duration of hypoglycaemia may occur) • observe patients and monitor blood glucose levels when initiating treatment and changing doses) • may cause growth hormone-secreting pituitary tumour expansion during treatment (causing serious complications)

● SIDE-EFFECTS
  ▶ Rare Pancreatitis (shortly after administration)
  ▶ Frequency not known Abdominal pain • anorexia • bloating • diarrhoea • flatulence • gallstones (after long-term treatment) • gastro-intestinal disturbances • hyperglycaemia (with chronic administration) • hypoglycaemia • impaired postprandial glucose tolerance (with chronic administration) • irritation at the injection site • nausea • pain at the injection site • steatorrhoea • vomiting

● MONITORING REQUIREMENTS
  ▶ Monitor for signs of tumour expansion (e.g. visual field defects).
  ▶ Ultrasound examination of the gallbladder is recommended before treatment and at intervals of 6–12 months during treatment.

● DIRECTIONS FOR ADMINISTRATION Injection sites should be rotated.

Lanreotide

● INDICATIONS AND DOSE

SOMATULINE AUTOGEL ®

Acromegaly (if somatostatin analogue not given previously)
▶ BY DEEP SUBCUTANEOUS INJECTION
  ▶ Adult: Initially 60 mg every 28 days, adjusted according to response, (consult product literature), for patients treated previously with somatostatin analogue, consult product literature for initial dose, dose to be given in the gluteal region

Neuroendocrine (particularly carcinoid) tumours
▶ BY DEEP SUBCUTANEOUS INJECTION
  ▶ Adult: Initially 60–120 mg every 28 days, adjusted according to response, dose to be given in the gluteal region

Unresectable locally advanced or metastatic gastroenteropancreatic neuroendocrine tumours of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded
▶ BY DEEP SUBCUTANEOUS INJECTION
  ▶ Adult: 120 mg every 28 days

SOMATULINE LA ®

Acromegaly and neuroendocrine (particularly carcinoid) tumours
▶ BY INTRAMUSCULAR INJECTION
  ▶ Adult: Initially 30 mg every 14 days, increased to 30 mg every 7–10 days, adjusted according to response

Thyroid tumours
▶ BY INTRAMUSCULAR INJECTION
  ▶ Adult: Initially 30 mg every 14 days, increased to 30 mg every 10 days, adjusted according to response

● CAUTIONS Cardiac disorders (including bradycardia) • patients with carcinoid tumours—exclude the presence of an obstructive intestinal tumour before treatment

● INTERACTIONS  ▶ Appendix 1: lanreotide

● SIDE-EFFECTS
  ▶ Common or very common Alopecia • biliary dilatation • bradycardia • constipation • dizziness • dyspepsia • headache • lethargy • malaise • musculoskeletal pain • myalgia • raised bilirubin
  ▶ Uncommon Hot flushes • insomnia
  ▶ Rare Hypothyroidism

● PREGNANCY Manufacturer advises use only if potential benefit outweighs risk.

● BREAST FEEDING Manufacturer advises caution—no information available.

● MONITORING REQUIREMENTS Monitor for hypothyroidism when clinically indicated.

● MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for injection
▶ Somatuline Autogel (Ipsen Ltd)
  Lanreotide (as Lanreotide acetate) 120 mg per 1 ml
  Somatuline Autogel 60mg/0.5ml solution for injection pre-filled syringes with safety system  ▶ £551.00
  Lanreotide (as Lanreotide acetate) 180 mg per 1 ml
  Somatuline Autogel 90mg/0.5ml solution for injection pre-filled syringes with safety system  ▶ £736.00
  Lanreotide (as Lanreotide acetate) 240 mg per 1 ml
  Somatuline Autogel 120mg/0.5ml solution for injection pre-filled syringes with safety system  ▶ £937.00
  Powder and solvent for suspension for injection
▶ Somatuline LA (Ipsen Ltd)
  Lanreotide (as Lanreotide acetate) 30 mg Somatuline LA 30mg powder and solvent for suspension for injection vials  ▶ £323.00
Octreotide

**INDICATIONS AND DOSE**

Symptoms associated with carcinoid tumours with features of carcinoid syndrome, VIPomas, glucagonomas

- **BY SUBCUTANEOUS INJECTION**
  - Adult: Initially 50 micrograms 1–2 times a day, adjusted according to response; increased to 200 micrograms 3 times a day, higher doses may be required exceptionally; maintenance doses are variable; in carcinoid tumours, discontinue after 1 week if no effect, if rapid response required, initial dose may be given by intravenous injection (with ECG monitoring and after dilation)

Acromegaly, short-term treatment before pituitary surgery or long-term treatment in those inadequately controlled by other treatment or until radiotherapy becomes fully effective

- **BY SUBCUTANEOUS INJECTION**
  - Adult: 100–200 micrograms 3 times a day, discontinue if no improvement within 3 months

Prevention of complications following pancreatic surgery

- **BY SUBCUTANEOUS INJECTION**
  - Adult: (consult product literature)

Test dose before use of depot preparation

- **BY SUBCUTANEOUS INJECTION**
  - Adult: Test dose 50–100 micrograms for 1 dose, test dose should be given if subcutaneous octreotide not previously given

Acromegaly / Neuroendocrine (particularly carcinoid) tumour adequately controlled by subcutaneous octreotide

- **BY DEEP INTRAMUSCULAR INJECTION USING DEPOT INJECTION**
  - Adult: Initially 20 microg every 4 weeks for 3 months then adjusted according to response, increased if necessary up to 30 mg every 4 weeks, to be administered into the gluteal muscle, for acromegaly, start depot 1 day after the last dose of subcutaneous octreotide, for neuroendocrine tumours, continue subcutaneous octreotide for 2 weeks after first dose of depot octreotide

Advanced neuroendocrine tumours of the midgut, or tumours of unknown primary origin where non-midgut sites of origin have been excluded

- **BY DEEP INTRAMUSCULAR INJECTION USING DEPOT INJECTION**
  - Adult: 30 mg every 4 weeks

Reduce intestinal secretions in palliative care | Reduce vomiting due to bowel obstruction in palliative care

- **BY CONTINUOUS SUBCUTANEOUS INFUSION**
  - Adult: 0.25–0.5 mg/24 hours (max. per dose 0.75 mg/24 hours), occasionally doses higher than the maximum are sometimes required

**INTERACTIONS**

- Appendix 1: octreotide

**SIDE-EFFECTS**

- Alopecia  |  arrhythmias  |  biliary colic (associated with abrupt withdrawal of subcutaneous octreotide)  |  bradycardia  |  dehydration  |  dizziness  |  dyspnoea  |  headache  |  hepatitis  |  pancreatitis (associated with abrupt withdrawal of subcutaneous octreotide)  |  rash

**SIDE-EFFECTS, FURTHER INFORMATION**

- Gastro-intestinal side-effects  |  Administering non-depot injections of octreotide between meals and at bedtime may reduce gastro-intestinal side-effects.

**CONCEPTION AND CONTRACEPTION**

Effective contraception required during treatment.

**PREGNANCY**

Possible effect on fetal growth; manufacturer advises use only if potential benefit outweighs risk.

**BREAST FEEDING**

Manufacturer advises avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT**

Adjustment of maintenance dose of non-depot preparations may be necessary in patients with liver cirrhosis.

**MONITORING REQUIREMENTS**

- Monitor thyroid function on long-term therapy.
- Monitor liver function.
- With intravenous use  |  ECG monitoring required with intravenous administration.

**TREATMENT CESSATION**

Avoid abrupt withdrawal of short-acting subcutaneous octreotide (associated with biliary colic and pancreatitis).

**DIRECTIONS FOR ADMINISTRATION**

For intravenous injection or intravenous infusion, dilute with Sodium Chloride 0.9% to a concentration of 10–50%.

**PRESCRIBING AND DISPensing INFORMATION**

Palliative care

For further information on the use of octreotide in palliative care, see www.palliativecare.org.uk/oc/centre-strategy.html.

**MEdICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Octreotide (Non-proprietary)**
  - Octreotide (as Octreotide acetate) 50 microgram per 1 ml
    - Octreotide 50 micrograms/1ml solution for injection pre-filled syringes  |  5 pre-filled disposable injection (PDP)  |  £18.35 DT price = £18.85
    - Octreotide 50 micrograms/1ml solution for injection ampoules  |  5 ampoule (PMP)  |  £14.85–£18.60
    - Octreotide 50 micrograms/1ml solution for injection vials  |  5 vial (PVP)  |  £14.97–£19.00 DT price = £18.00
  - Octreotide (as Octreotide acetate) 100 microgram per 1 ml
    - Octreotide 100 micrograms/1ml solution for injection ampoules  |  5 ampoule (PMP)  |  £32.65 DT price = £37.97
    - Octreotide 100 micrograms/1ml solution for injection pre-filled syringes  |  5 pre-filled disposable injection (PDP)  |  £28.90–£32.90
    - Octreotide 100 micrograms/1ml solution for injection vials  |  5 vial (PVP)  |  £37.97–£43.60
  - Octreotide (as Octreotide acetate) 200 microgram per 1 ml
    - Octreotide 1 mg/5 ml solution for injection vials  |  1 vial (PMP)  |  £65.00–£69.66
  - Octreotide (as Octreotide acetate) 500 microgram per 1 ml
    - Octreotide 500 micrograms/1ml solution for injection vials  |  5 vial (PVP)  |  £135.47–£158.25
    - Octreotide 500 micrograms/1ml solution for injection ampoules  |  5 ampoule (PMP)  |  £169.35 DT price = £175.47
    - Octreotide 500 micrograms/1ml solution for injection pre-filled syringes  |  5 pre-filled disposable injection (PDP)  |  £139.43–£169.00
  - Sandostatin (Novartis Pharmaceuticals UK Ltd)
    - Octreotide (as Octreotide acetate) 50 microgram per 1 ml
      - Sandostatin 50 micrograms/1ml solution for injection ampoules  |  5 ampoule (PMP)  |  £14.87
    - Octreotide (as Octreotide acetate) 100 microgram per 1 ml
      - Sandostatin 100 micrograms/1ml solution for injection ampoules  |  5 ampoule (PMP)  |  £27.97 DT price = £27.97
    - Octreotide (as Octreotide acetate) 200 microgram per 1 ml
      - Sandostatin 1 mg/5 ml solution for injection vials  |  1 vial (PMP)  |  £55.73
  - Octreotide (as Octreotide acetate) 500 microgram per 1 ml
    - Sandostatin 500 micrograms/1ml solution for injection ampoules  |  1 ampoule (PMP)  |  £135.47
  - Powder and solvent for suspension for injection
    - **Sandostatin LAR** (Novartis Pharmaceuticals UK Ltd)
      - Octreotide (as Octreotide acetate) 10 mg
        - Sandostatin LAR 10mg powder and solvent for suspension for injection vials  |  1 vial (PDP)  |  £549.71
      - Octreotide (as Octreotide acetate) 20 mg
        - Sandostatin LAR 20mg powder and solvent for suspension for injection vials  |  1 vial (PDP)  |  £799.33
      - Octreotide (as Octreotide acetate) 30 mg
        - Sandostatin LAR 30mg powder and solvent for suspension for injection vials  |  1 vial (PDP)  |  £998.41
## Hormone responsive breast cancer

### Fulvestrant

**INDICATIONS AND DOSE**

Treatment of oestrogen-receptor-positive metastatic or locally advanced breast cancer in postmenopausal women in whom disease progresses or relapses while on, or after, other anti-oestrogen therapy

- **BY DEEP INTRAMUSCULAR INJECTION**
- **Adult:** 500 mg every 2 weeks for the first 3 doses, then 500 mg every month, to be administered into the buttock

**INTERACTIONS**

- Appendix 1: fulvestrant
Tamoxifen

**DRUG ACTION** An anti-oestrogen which induces gonadotrophin release by occupying oestrogen receptors in the hypothalamus, thereby interfering with feedback mechanisms; chorionic gonadotrophin is sometimes used in the hypothalamus, thereby interfering with feedback mechanisms; chorionic gonadotrophin release in the hypothalamus, thereby interfering with feedback mechanisms.

**INDICATIONS AND DOSE**

**Pre- and perimenopausal women with oestrogen-receptor-positive breast cancer not previously treated with tamoxifen**

- **BY MOUTH**
  - Adult: 20 mg daily

**Anovulatory infertility**

- **BY MOUTH**
  - Adult: Initially 20 mg daily on days 2, 3, 4 and 5 of cycle, if necessary the daily dose may be increased to 40 mg then 80 mg for subsequent courses; if cycles irregular, start initial course on any day, with subsequent course starting 45 days later or on day 2 of cycle if menstruation occurs

**CONTRA-INDICATIONS** Treatment of infertility contra-indicated if personal or family history of idiopathic venous thromboembolism or genetic predisposition to thromboembolism

**CAUTIONS** Porphyria

**INTERACTIONS** → Appendix 1: tamoxifen

**SIDE-EFFECTS**

- **Rare** Anorexia · bullous pemphigoid · cholestasis · fatty liver · hepatitis · hypersensitivity reactions · hypertriglyceridaemia · interstitial pneumonitis · neutropenia · Stevens-Johnson syndrome

- **Frequency not known** Alopecia · anaemia · cataracts · corneal changes · decreased platelet counts · endometrial changes · gastrointestinal disturbances · headache · hot flushes · hypercalcaemia if bony metastases · increased risk of thromboembolic events, especially when used with cytotoxics · leucopenia · light-headedness · liver enzyme changes · occasional cystic ovarian swellings in premenopausal women · occasionally oedema · pancreatitis · pruritus vulvae · rashes · retinopathy · suppression of menstruation in some premenopausal women · thrombocytopenia · thromboembolic events · tumour flare · uterine fibroids · vaginal bleeding · vaginal discharge · visual disturbances

**SIDE-EFFECTS, FURTHER INFORMATION**

- **Endometrial changes** Increased endometrial changes, including hyperplasia, polyps, cancer, and uterine sarcoma reported; prompt investigation required if abnormal vaginal bleeding including menstrual irregularities, vaginal discharge, and pelvic pain or pressure in those receiving (or who have received) tamoxifen.

- **Risk of thromboembolism** Tamoxifen can increase the risk of thromboembolism particularly during and immediately after major surgery or periods of immobility (consider interrupting treatment to initiate anticoagulant measures).

- **CONCEPTION AND CONTRACEPTION** Unless being used in the treatment of female infertility, effective contraception must be used during treatment and for 2 months after stopping. Patients being treated for infertility should be warned that there is a risk of multiple pregnancy (rarely more than twins).

- **PREGNANCY** Avoid—possible effects on fetal development.

- **BREAST FEEDING** Suppresses lactation. Avoid unless potential benefit outweighs risk.

- **PATIENT AND CARER ADVICE** Endometrial changes Patients should be informed of the risk of endometrial cancer and told to report relevant symptoms promptly. Thromboembolism Patients should be made aware of the symptoms of thromboembolism and advised to report sudden breathlessness and any pain in the calf of one leg.

**MEDICAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Faslodex** (AstraZeneca UK Ltd)
  - Fulvestrant 50 mg per 1 ml Faslodex 250mg/5ml solution for injection pre-filled syringes | 2 pre-filled disposable injection £522.41

---

**Toremifene**

**INDICATIONS AND DOSE**

Hormone-dependent metastatic breast cancer in postmenopausal women

- **BY MOUTH**
  - Adult: 60 mg daily

**CONTRA-INDICATIONS** Bradycardia · electrolyte disturbances (particularly uncorrected hypokalaemia) · endometrial hyperplasia · heart failure with reduced
left-ventricular ejection fraction • history of arrhythmias • QT prolongation

**CAUTIONS** Avoid in acute porphyrrias p. 969 • history of severe thromboembolic disease

**INTERACTIONS** → Appendix 1: toremifene

**SIDE-EFFECTS**
- **Common or very common** Depressions • dizziness • fatigue • hot flushes • nausea • oedema • rash • sweating • vaginal bleeding • vaginal discharge • vomiting
- **Uncommon** Anorexia • constipation • dyspnoea • endometrial hypertrophy • headache • increased weight • insomnia • thromboembolic events
- **Very rare** Alopecia • jaundice • transient corneal opacity
- **Frequency not known** Hypercalcaemia (especially if bone metastases and usually at beginning of treatment)

**SIDE-EFFECTS, FURTHER INFORMATION**
- Endometrial changes • Increased endometrial changes, including hyperplasia, polyps and cancer reported. Abnormal vaginal bleeding including menstrual irregularities, vaginal discharge and symptoms such as pelvic pain or pressure should be promptly investigated.

**PREGNANCY** Avoid.

**BREAST FEEDING** Avoid.

**HEPATIC IMPAIRMENT** Elimination decreased in hepatic impairment—avoid if severe.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- **Fareston** (Orion Pharma (UK) Ltd) 
  Toremifene (as Toremifene citrate) 60 mg  |  30 tablet *PO* £23.00

**HORMONE ANTAGONISTS AND RELATED AGENTS**  >  **AROMATASE INHIBITORS**

### **Anastrozole**

**INDICATIONS AND DOSE**
Adjuvant treatment of oestrogen-receptor-positive early invasive breast cancer in postmenopausal women | Adjuvant treatment of oestrogen-receptor-positive early breast cancer in postmenopausal women following 2–3 years of tamoxifen therapy | Advanced breast cancer in postmenopausal women which is oestrogen-receptor-positive or responsive to tamoxifen

**BY MOUTH**
- Adult: 1 mg daily

**CONTRA-INDICATIONS** Not indicated for premenopausal women

**CAUTIONS** Susceptibility to osteoporosis

**SIDE-EFFECTS**
- **Very rare** Allergic reactions • anaphylaxis • angioedema
- **Frequency not known** Anorexia • arthralgia • arthritis • asthenia • bone fractures • bone pain • cutaneous vasculitis • diarrhoea • drowsiness • hair thinning • headache • hot flushes • nausea • rash • slight increases in total cholesterol levels • Stevens-Johnson syndrome • vaginal bleeding • vaginal dryness • vomiting
- **PREGNANCY** Avoid.
- **BREAST FEEDING** Avoid.
- **HEPATIC IMPAIRMENT** Avoid in moderate to severe impairment.
- **RENAL IMPAIRMENT** Avoid if creatinine clearance less than 20 mL/minute.
- **PRE-TREATMENT SCREENING** Laboratory test for menopause if doubt.

**MONITORING REQUIREMENTS**
- Osteoporosis Assess bone mineral density before treatment and at regular intervals.

**PATIENT AND CARER ADVICE**
- Driving and skilled tasks
  - Asthenia and drowsiness may initially affect ability to drive or operate machinery.

**NATIONAL FUNDING/ACCESS DECISIONS**

**ARIMIDEX®**

**Scottish Medicines Consortium (SMC) Decisions**
The Scottish Medicines Consortium has advised (August 2005 and October 2006) that anastrozole (Arimidex®) is accepted for restricted use within NHS Scotland, within the licensed indications, for early breast cancer and early invasive breast cancer.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- **Anastrozole (Non-proprietary)**
  Anastrozole 1 mg  |  28 tablet *PO* £65.13 DT price = £1.08
- **Arimidex** (AstraZeneca Uk Ltd)
  Anastrozole 1 mg  |  28 tablet *PO* £68.56 DT price = £1.08

### **Exemestane**

**INDICATIONS AND DOSE**
Adjuvant treatment of oestrogen-receptor-positive early breast cancer in postmenopausal women following 2–3 years of tamoxifen therapy | Advanced breast cancer in postmenopausal women in whom anti-oestrogen therapy has failed

**BY MOUTH**
- Adult: 25 mg daily

**CONTRA-INDICATIONS**
- Not indicated for premenopausal women

**INTERACTIONS** → Appendix 1: exemestane

**SIDE-EFFECTS**
- **Common or very common** Abdominal pain • alopecia • anorexia • constipation • depression • dizziness • dyspepsia • fatigue • headache • hot flushes • insomnia • nausea • rash • sweating • vomiting
- **Uncommon** Asthenia • drowsiness • peripheral oedema
- **Rare** Leucopenia • thrombocytopenia
- **PREGNANCY** Avoid.
- **BREAST FEEDING** Avoid.
- **HEPATIC IMPAIRMENT** Manufacturer advises caution.
- **RENAL IMPAIRMENT** Manufacturer advises caution.

**NATIONAL FUNDING/ACCESS DECISIONS**

**Scottish Medicines Consortium (SMC) Decisions**
The Scottish Medicines Consortium has advised (October 2005) that exemestane (Aromasin®) is accepted for restricted use within NHS Scotland as an adjuvant treatment in postmenopausal women with oestrogen-receptor-positive invasive early breast cancer, following 2–3 years of initial adjuvant tamoxifen therapy.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- **CAUTIONARY AND ADVISORY LABELS 21**
  - Exemestane (Non-proprietary)
  - Exemestane 25 mg  |  30 tablet *PO* £88.80 DT price = £5.71 |  90 tablet *PO* no price available
Letrozole

**INDICATIONS AND DOSE**
First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer | Adjunct treatment of oestrogen-receptor-positive invasive early breast cancer in postmenopausal women | Advanced breast cancer in postmenopausal women (naturally or artificially induced menopause) in whom another oestrogen therapy has failed | Extended adjuvant treatment of hormone-dependent invasive breast cancer in postmenopausal women who have received standard adjuvant tamoxifen therapy for 5 years | Neo-adjuvant treatment in postmenopausal women with localised hormone-receptor-positive, human epidermal growth factor-2 negative breast cancer where chemotherapy is not suitable and surgery not yet indicated

- **BY MOUTH**
  - Adult: 2.5 mg daily

- **CONTRA-INDICATIONS** Not indicated for premenopausal women
- **CAUTIONS** Susceptibility to osteoporosis
- **SIDE-EFFECTS**
  - **Common or very common** Abdominal pain · alopecia · anorexia · appetite increase · arthralgia · bone fracture · constipation · depression · diarrhea · dizziness · dry skin · dyspepsia · fatigue · headache · hot flushes · hypercholesterolaemia · hypertension · increased sweating · musculoskeletal pain · nausea · osteoporosis · peripheral oedema · rash · vaginal bleeding · vomiting · weight changes
  - **Uncommon** Anxiety · arthritis · blurred vision · breast pain · cardiac events · cataract · cerebrovascular events · cough · dysaesthesia · dyspnoea · eye irritation · general oedema · insomnia · leucopenia · memory impairment · mucosal dryness · palpitation · pruritus · pyrexia · stomatitis · tachycardia · taste disturbance · thrombophlebitis · tumour pain · urinary frequency · urinary-tract infection · urticaria · vaginal discharge
  - **Frequency not known** Hepatitis · toxic epidermal necrolysis
  - **CONCEPTION AND CONTRACEPTION** Manufacturer advises effective contraception required until postmenopausal status fully established (return of ovarian function reported in postmenopausal women)
- **PREGNANCY** Avoid (isolated cases of birth defects reported)
- **BREAST FEEDING** Manufacturer advises avoid.
- **HEPATIC IMPAIRMENT** Manufacturer advises caution in severe impairment.
- **RENAL IMPAIRMENT** Manufacturer advises caution if creatinine clearance less than 10 mL/minute.
- **MONITORING REQUIREMENTS**
  - Osteoporosis Assess bone mineral density before treatment and at regular intervals.
- **MEDICINAL FORMS**
  - **Tablet**
    - Letrozole (Non-proprietary)
      - Letrozole 2.5 mg Letrozole 2.5mg tablets | 14 tablet | £49.90
      - DT price = £1.26 | 28 tablet | £73.24
    - Femara (Novartis Pharmaceuticals UK Ltd)
      - Letrozole 2.5 mg Femara 2.5mg tablets | 30 tablet | £90.92

**DRUG ACTION**
Talimogene laherparevvec is an oncolytic immunotherapy derived from herpes simplex virus type-1 which causes tumour lysis and the release of tumour-derived antigens.

**INDICATIONS AND DOSE**
Unresectable metastatic melanoma with no bone, brain, or visceral disease
  - **BY INTRALESIONAL INJECTION**
  - Adult: (consult product literature)

**CONTRA-INDICATIONS**
Severely immunocompromised patients

**CONTRA-INDICATIONS, FURTHER INFORMATION**
Manufacturer advises avoid in patients who are severely immunocompromised, for example, those with severe congenital or acquired cellular and/or humoral immune deficiency—may be at increased risk of disseminated herpetic infection.

**CAUTIONS**
Administration of antivirals (may interfere with effectiveness of Imlygic® · autoimmune disease · immunocompromised patients · multiple myeloma (risk of plasmacytoma at injection site)

**CAUTIONS, FURTHER INFORMATION**
Immunocompromised patients Manufacturer advises caution in patients who are immunocompromised, for example, those with HIV/AIDS, leukaemia, lymphoma, common variable immunodeficiency, or in those who require chronic high-dose steroids or other immunosuppressive agents—risk of disseminated herpetic infection.

**SIDE-EFFECTS**
- **Common or very common** Abdominal pain · anaemia · anxiety · arthralgia · cellulitis · confusion · constipation · cough · deep vein thrombosis · dehydration · depression · dermatitis · diarrhea · dizziness · dyspnoea · flushing · glomerulonephritis · headache · hypertension · injection-site reactions · insomnia · malaise · myalgia · nausea · oral herpes infection · oropharyngeal pain · pain in extremity · peripheral oedema · pneumonitis · pyrexia · rash · tachycardia · tumour pain · upper respiratory tract infection · vasculitis · vitiligo · vomiting · worsening psoriasis
- **Uncommon** Herpetic keratitis · plasmacytoma at injection site

**SIDE-EFFECTS, FURTHER INFORMATION**
Injection-site reactions Necrosis or ulceration of tumour tissue may occur, and impaired healing at the injection site has been reported. Manufacturer advises careful wound care and injection precautions; if persistent infection or delayed healing develops, the risks and benefits of continuing treatment should be considered.

**CONCEPTION AND CONTRACEPTION** Manufacturer advises use of latex condoms.

**PREGNANCY** Manufacturer advises avoid—no information available.

**BREAST FEEDING** Manufacturer advises avoid—no information available.

**DIRECTIONS FOR ADMINISTRATION** Consult product literature for information on injection technique.

**HANDLING AND STORAGE** Manufacturer advises caution in handling—risk of accidental exposure; avoid preparation.
or administration if immunocompromised or pregnant. For further information, see the Physician's Brochure provided by the manufacturer. Store and transport frozen at -90°C to -70°C—consult product literature for further information on thawing and storage after thawing.

**PATIENT AND CARER ADVICE**

Provide patient alert card—record batch number for each administration of Imlygic®.

Manufacturer advises that patients and carers should be informed about the risks of treatment, advised to avoid touching or scratching injection sites, and to keep these sites covered with occlusive dressings. Close contacts should avoid direct contact with injected lesions or body fluids of treated patients during treatment and for up to 30 days after last treatment—if exposed, clean the affected area and seek medical attention if symptoms of herpetic infection develop; close contacts who are immunocompromised or pregnant should not be exposed to potentially contaminated materials. For further information, see the Information for Patients and Close Contacts provided by the manufacturer.

**Driving and skilled tasks**

Manufacturer advises that patients and their carers should be counselled on the effects on driving and performance of skilled tasks—risk of dizziness and confusion.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

† Talimogene laherparepvec for treating unresectable metastatic melanoma (September 2016)

Talimogene laherparepvec is recommended as an option for treating unresectable, regionally or distantly metastatic (Stage III B, IIIC or IVM1a) melanoma that has not spread to bone, brain or other internal organs, only if:

- treatment with systemically administered immunotherapies is not suitable and,
- the manufacturer provides talimogene laherparepvec with the discount agreed in the patient access scheme. Patients whose treatment was started within the NHS before this guidance was published should have the option to continue treatment, without change to their funding arrangements, until they and their clinician consider it appropriate to stop. [www.nice.org.uk/TA410](http://www.nice.org.uk/TA410)

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

**EXCIPIENTS:** May contain Sorbitol

**ELECTROLYTES:** May contain Sodium

† Imlygic (Amgen Ltd) ▼

Talimogene laherparepvec 1 mega u per 1 ml Imlygic 1 million plaque forming units/1ml solution for injection vials | 1 vial £1,670.00

Talimogene laherparepvec 100 mega u per 1 ml Imlygic 100 million plaque forming units/1ml solution for injection vials | 1 vial £1,670.00

**IMMUNOSTIMULANTS † INTERFERONS**

**Interferon alfa**

**DRUG ACTION** Interferon alfa has shown some antitumour effect in certain lymphomas and solid tumours.

**INDICATIONS AND DOSE**

**INTRONA® PEN**

Chronic myelogenous leukaemia (as monotherapy or in combination with cytarabine) | Hairy cell leukaemia | Follicular lymphoma | Lymph or liver metastases of carcinoid tumour | Chronic hepatitis B | Chronic hepatitis C | Adjunct to surgery in malignant melanoma | Maintenance of remission in multiple myeloma

‡ BY SUBCUTANEOUS INJECTION

‡ Adult: (consult local protocol)

**INTRONA® VIALS**

Chronic myelogenous leukaemia (as monotherapy or in combination with cytarabine) | Hairy cell leukaemia | Follicular lymphoma | Lymph or liver metastases of carcinoid tumour | Chronic hepatitis B | Chronic hepatitis C | Adjunct to surgery in malignant melanoma | Maintenance of remission in multiple myeloma

‡ BY SUBCUTANEOUS INJECTION, OR BY INTRAVENOUS INFUSION

‡ Adult: (consult local protocol)

**ROFERON-A®**

Chronic myelogenous leukaemia | Hairy cell leukaemia | Chronic hepatitis B | Chronic hepatitis C | Adjunct to surgery in malignant melanoma | AIDS-related Kaposi’s sarcoma | Advanced renal cell carcinoma | Progressive cutaneous T-cell lymphoma | Follicular non-Hodgkin’s lymphoma

‡ BY SUBCUTANEOUS INJECTION

‡ Adult: (consult local protocol)

**CONTRA-INDICATIONS** For contra-indications consult product literature and local treatment protocol.

**CAUTIONS** For cautions consult product literature and local treatment protocol.

**INTERACTIONS** Appendix 1: interferons

**SIDE-EFFECTS**

† Common or very common

Anorexia | diarrhoea | influenza-like symptoms | lethargy | nausea

† Frequency not known

Alopecia | arrhythmias | cardiovascular problems | coma (usually with high doses in the elderly) | confusion | depression | hepatotoxicity | hyperglycaemia | hypersensitivity reactions | hypertension | hypertriglyceridaemia | (sometimes severe) | hypotension | myelosuppression (particularly affecting granulocyte counts) | nephrotoxicity | ocular side-effects | palpitation | psoriasiform rash | seizures (usually with high doses in the elderly) | suicidal behaviour | thyroid abnormalities

**SIDE-EFFECTS, FURTHER INFORMATION**

Consult product literature and local treatment protocols for information on side-effects

**CONCEPTION AND CONTRACEPTION** Effective contraception required during treatment—consult product literature.

**PREGNANCY** Avoid unless potential benefit outweighs risk (toxicity in animal studies).

**BREAST FEEDING** Unlikely to be harmful.

**HEPATIC IMPAIRMENT** Avoid in severe hepatic impairment. Close monitoring required in mild to moderate hepatic impairment.

**RENAL IMPAIRMENT** Avoid in severe renal impairment. Close monitoring required in mild to moderate renal impairment.

**MONITORING REQUIREMENTS** Monitoring of lipid concentration is recommended.
**INDICATIONS AND DOSE**

To reduce the frequency of serious infection in chronic granulomatous disease

- **BY SUBCUTANEOUS INJECTION**
  - Adult: 50 micrograms/m² 3 times a week

To reduce the frequency of serious infection in severe malignant osteopetrosis

- **BY SUBCUTANEOUS INJECTION**
  - Adult: 50 micrograms/m² 3 times a week

**CONTRA-INDICATIONS** Simultaneous administration of foreign proteins including immunological products (such as vaccines)—risk of exaggerated immune response

**CAUTIONS** Arrhythmias, cardiac disease, congestive heart failure, ischaemia, seizure disorders (including seizures associated with fever)

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain, arthralgia, chills, depression, diarrhoea, fatigue, fever, headache, injection-site reactions, myalgia, nausea, rash, vomiting
  - Rare: Confusion, systemic lupus erythematosus

- **Frequency not known** Neutropenia, proteinuria, raised liver enzymes, thrombocytopenia

**CONCEPTION AND CONTRACEPTION** Effective contraception required during treatment—consult product literature.

**PREGNANCY** Manufacturers recommend avoid unless potential benefit outweighs risk (toxicity in animal studies).

**BREAST FEEDING** Manufacturers advise avoid—no information available.

**HEPATIC IMPAIRMENT** Manufacturer advises caution in severe impairment—risk of accumulation.

**RENAL IMPAIRMENT** Manufacturer advises caution in severe impairment—risk of accumulation.

**MONITORING REQUIREMENTS** Monitor before and during treatment: haematological tests (including full blood count, differential white cell count, and platelet count), blood chemistry tests (including renal and liver function tests) and urinalysis.

**IMMUNOSTIMULANTS >/ INTERLEUKINS**

**Aldesleukin**

**DRUG ACTION** Aldesleukin produces tumour shrinkage in a small proportion of patients, but it has not been shown to increase survival.

**INDICATIONS AND DOSE**

Metastatic renal cell carcinoma (specialist use only)

- **BY SUBCUTANEOUS INJECTION, OR BY INTRAVENOUS INFUSION**
  - Adult: (consult product literature)

**UNLICENSED USE** Aldesleukin is not licensed for use in patients in whom all three of the following prognostic factors are present: performance status of Eastern Cooperative Oncology Group of 1 or greater, more than one organ with metastatic disease sites, and a period of less than 24 months between initial diagnosis of primary tumour and date of evaluation of treatment.

**CONTRA-INDICATIONS** Consult product literature for information about aldesleukin contra-indications.

**CAUTIONS** Consult product literature for information about aldesleukin cautions.

**SIDE-EFFECTS**

- **Common or very common** Bone-marrow toxicity, CNS toxicity, hepatic toxicity, renal toxicity, thyroid toxicity
  - **Frequency not known** Alopecia, bone-marrow suppression, extravasation, hyperuricaemia, nausea, oral mucositis, thromboembolism, tumour lysis syndrome, vomiting
  - **SIDE-EFFECTS, FURTHER INFORMATION** Also consult product literature.

**CONCEPTION AND CONTRACEPTION** Ensure effective contraception during treatment in men and women.

**PREGNANCY** Use only if potential benefit outweighs risk (toxicity in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**BREAST FEEDING** Discontinue breast-feeding.

**DIRECTIONS FOR ADMINISTRATION** Aldesleukin is now rarely given by intravenous infusion because of an increased risk of capillary leak syndrome, which can cause pulmonary oedema and hypotension.
Immunotherapy responsive malignancy

**Bacillus Calmette-Guérin**

**INDICATIONS AND DOSE**
Bladder instillation for the treatment of primary or recurrent bladder carcinoma and for the prevention of recurrence following transurethral resection
- **BY INTRAVESICAL INSTILLATION**
- Adult: (consult product literature)

**SIDE-EFFECTS**
- Rare Arthralgia - bladder contracture - hypersensitivity reactions - orchitis - rash - renal abscess - transient urethral obstruction
- Frequency not known Cystitis - dysuria - fever - haematuria - influenza-like syndrome - malaise - ocular symptoms - systemic BCG infection (with fatalities) - consult product literature - urinary frequency

**PREPARATIONS**
- Immucyst (Alliance Pharmaceuticals Ltd)
  - Connaught strain Bacillus Calmette-Guérin 81 mg Immucyst 81mg powder for reconstitution for instillation vials | 1 vial (£18.73) (Hospital only)
  - OncoTICE (Merck Sharp & Dohme Ltd)
  - TICE strain Bacillus of Calmette-Guérin 12.5 mg OncoTICE 12.5mg powder for reconstitution for instillation vials | 1 vial (£71.61) (Hospital only)

**Mifamurtide**

**INDICATIONS AND DOSE**
Treatment of high-grade, resectable, non-metastatic osteosarcoma after complete surgical resection (in combination with chemotherapy)
- **BY INTRAVENOUS INFUSION**
- Adult: Infusion to be given over 1 hour (consult product literature or local protocols)

**SIDE-EFFECTS**

**CONCEPTION AND CONTRACEPTION**
Effective contraception required.

**PREPARATIONS**
- Ceplene
  - No licensed medicines listed.

**Histamine dihydrochloride**

**INDICATIONS AND DOSE**
Maintenance therapy, in combination with aldesleukin, in patients with acute myeloid leukaemia in first remission
- **BY SUBCUTANEOUS INJECTION**
- Adult: (consult local protocol)

**CONTRA-INDICATIONS**
Consult product literature for information about histamine dihydrochloride contra-indications.

**CAUTIONS**
Consult product literature for information about histamine dihydrochloride cautions.

**INTERACTIONS**
- Appendix 1: histamine

**SIDE-EFFECTS**
Consult product literature for side effects.

**CONCEPTION AND CONTRACEPTION**
Ensure effective contraception during treatment in men and women.
DRUG ACTION
Mifamurtide for CAUTIONS— Lenalidomide syndrome.

IMMUNOSUPPRESSANTS ▶ THALIDOMIDE AND RELATED ANALOGUES

Lenalidomide

DRUG ACTION Lenalidomide is an immunomodulating drug with anti-neoplastic, anti-angiogenic, and pro-erythropoietic properties.

INDICATIONS AND DOSE
Multiple myeloma (newly diagnosed) in patients not eligible for transplant, given in combination with dexamethasone until disease progression
▶ BY MOUTH
Adult: 25 mg once daily for 21 consecutive days of repeated 28-day cycles, for doses of dexamethasone, and dose adjustments due to side-effects, consult product literature

Multiple myeloma (newly diagnosed) in patients not eligible for transplant, given in combination with melphalan and prednisone followed by maintenance monotherapy
▶ BY MOUTH
Adult: 10 mg once daily for 21 consecutive days of repeated 28-day cycles for up to 9 cycles, for doses of melphalan and prednisone, and dose adjustments due to side-effects, consult product literature

Multiple myeloma in patients who have received at least one prior therapy, given in combination with dexamethasone
▶ BY MOUTH
Adult: 25 mg once daily for 21 consecutive days of repeated 28-day cycles, for doses of dexamethasone, and dose adjustments due to side-effects, consult product literature

Treatment of transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality when other treatment options are insufficient or inadequate
▶ BY MOUTH
Adult: 10 mg once daily for 21 consecutive days of repeated 28-day cycles, for dose adjustments due to side-effects, consult product literature

CAUTIONS  High tumour burden—risk of tumour lysis syndrome • patients with risk factors for myocardial infarction

CAUTIONS, FURTHER INFORMATION
▶ Thromboembolism Risk factors for thromboembolism (such as smoking, hypertension, hyperlipidaemia) should be minimised and thromboprophylaxis should be considered in patients with multiple risk factors.

Second primary malignancy Patients should be carefully evaluated before and during treatment with lenalidomide using routine cancer screening for occurrence of second primary malignancy and treatment should be instituted as indicated.

INTERACTIONS ▶ Appendix 1: lenalidomide

SIDE-EFFECTS
▶ Common or very common Abdominal pain, anaemia, arthralgia, asthenia, ataxia, atrial fibrillation, bacterial infection, bradycardia, cardiac failure, cataract, cerebrovascular events, chest pain, cholestasis, constipation, decreased appetite, deep vein thrombosis, dehydration, depression, diarrhoea, dizziness, dry mouth, dyspepsia, dysphagia, dyspnoea, electrolyte disturbances, falls, flu-like illness, fungal infections, haematoma, haematuria, haemorrhagic disorders, headache, hearing disturbances, hyperglycaemia, hyperhidrosis, hypertension, hypotension, hypothyroidism, insomnia, iron-overload, lethargy, leucopenia, malaise, mood changes, musculoskeletal disorders, myalgia, myocardial infarction, nausea, oedema, peripheral neuropathy, pneumonia, pruritus, pulmonary embolism, pyrexia, rash, renal failure, respiratory distress, respiratory tract infections, sepsis, severe neutropenia, sexual dysfunction, sinusitis, skin disorders, stomatitis, syncope, tachycardia, taste disturbance, thrombocytopenia, tremor, urinary incontinence, urinary retention, vasculitis, viral infections, visual disturbances, vomiting

▶ Uncommon Acquired Fanconi syndrome, angiodema, blindness, caecitis, clotting disorders, colitis, haemolysis, hepatic failure, ischaemia, secondary malignancies

▶ Rare Stevens-Johnson syndrome, toxic epidermal necrolysis, tumour lysis syndrome

▶ Frequency not known Cholestatic hepatitis, cytolytic hepatitis, interstitial pneumonitis, leukocytoclastic vasculitis, pancreatitis, toxic hepatitis

SIDE-EFFECTS, FURTHER INFORMATION
For information on side effects consult product literature.

▶ Rash If rash occurs, treatment should be discontinued and only restarted following appropriate clinical evaluation. Discontinue permanently if angioedema, exfoliative or bullous rash, or if Stevens-Johnson syndrome or toxic epidermal necrolysis is suspected.

CONCEPTION AND CONTRACEPTION For women of child-bearing potential, pregnancy must be excluded before starting treatment with lenalidomide (perform pregnancy test on initiation or within 3 days prior to initiation). Women must practise effective contraception at least 1 month before, during, and for at least 1 month after treatment, including during dose interruptions (oral combined hormonal contraceptives and copper-releasing intra-uterine devices not recommended) and men should use condoms during treatment, during dose interruption, and for at least 1 week after stopping if their partner is pregnant or is of childbearing potential and not using effective contraception. Patients, prescribers and pharmacists must comply with pregnancy prevention measures as specified in the manufacturer’s Pregnancy Prevention Programme.

PREGNANCY Important: teratogenic risk. Lenalidomide is structurally related to thalidomide and there is a risk of teratogenesis.

▶ BREAST FEEDING Discontinue breast-feeding—no information available.
Immune system and malignant disease

▪ RENAL IMPAIRMENT Reduce dose in moderate to severe impairment—consult product literature.

▪ MONITORING REQUIREMENTS
  ▪ Monitor full blood count (including differential white cell count, platelet count, haemoglobin, and haematocrit) and liver function before treatment, then every week for the first 8 weeks, then monthly thereafter (reduce dose or interrupt treatment if neutropenia, thrombocytopenia or impaired liver function develop—consult product literature).
  ▪ Monitor for arterial or venous thromboembolism (if thromboembolic event occurs, discontinue lenalidomide and treat with standard anticoagulation therapy; lenalidomide may be restarted with continued anticoagulation therapy once thromboembolic event resolved—consult product literature).
  ▪ Monitor thyroid function.
  ▪ Monitor visual ability regularly (risk of cataract).
  ▪ Monitor for signs and symptoms of peripheral neuropathy.

▪ PRESCRIBING AND DISPENSING INFORMATION
  ▪ Patient, prescriber, and supplying pharmacy must comply with a pregnancy prevention programme. Every prescription must be accompanied by a completed Prescription Authorisation Form.
  ▪ Patient advice required around conception and contraception

▪ PATIENT AND CARER ADVICE
  ▪ Thromboembolism Patients and their carers should be made aware of the symptoms of thromboembolism and advised to report sudden breathlessness, chest pain, or swelling of a limb.
  ▪ Neutropenia and thrombocytopenia Patients and their carers should be made aware of the symptoms of neutropenia and advised to seek medical advice if symptoms suggestive of neutropenia (such as fever, sore throat) or of thrombocytopenia (such as bleeding) develop.
  ▪ Patient advice required around conception and contraception

▪ NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)
▪ Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (September 2014) NICE TA322
  ▪ Lenalidomide is recommended as an option, within its marketing authorisation, for treating transfusion-dependent anaemia caused by low or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate, with the following condition:
    ▪ the drug cost of lenalidomide (excluding any related costs) for people who remain on treatment for more than 26 cycles (each of 28 days; normally a period of 2 years) will be met by the company. 
    www.nice.org.uk/TA322

▪ Lenalidomide for the treatment of multiple myeloma (June 2009) NICE TA171
  ▪ Lenalidomide in combination with dexamethasone is an option for the treatment of multiple myeloma in patients who have received two or more prior therapies. The drug cost of lenalidomide will be met by the manufacturer for patients who remain on treatment for more than 26 cycles. 
  www.nice.org.uk/TA171

Scottish Medicines Consortium (SMC) Decisions
  The Scottish Medicines Consortium has advised (April 2010) that lenalidomide, in combination with dexamethasone, is accepted for restricted use within NHS Scotland for patients with multiple myeloma who have received at least two prior therapies and (March 2014) for those who have received prior treatment with bortezomib and for whom thalidomide has not been tolerated or is contra-indicated.
  The Scottish Medicines Consortium has advised (December 2015) that lenalidomide is accepted for restricted use within NHS Scotland for patients with previously untreated multiple myeloma who are not eligible for transplant and when thalidomide-containing regimens are unsuitable.

▪ MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug.

Capsule

CAUTIONARY AND ADVISORY LABELS 25
  ▪ Revlimid
    ▪ Lenalidomide 2.5 mg Revlimid 2.5mg capsules | 21 capsule £3,426.00
    ▪ Lenalidomide 5 mg Revlimid 5mg capsules | 21 capsule £3,570.00
    ▪ Lenalidomide 7.5 mg Revlimid 7.5mg capsules | 21 capsule £3,675.00
    ▪ Lenalidomide 10 mg Revlimid 10mg capsules | 21 capsule £3,780.00
    ▪ Lenalidomide 15 mg Revlimid 15mg capsules | 21 capsule £3,969.00
    ▪ Lenalidomide 20 mg Revlimid 20mg capsules | 21 capsule £4,168.50
    ▪ Lenalidomide 25 mg Revlimid 25mg capsules | 21 capsule £4,368.00

Pomalidomide

02-Jun-2017

▪ DRUG ACTION Pomalidomide is structurally related to thalidomide and has immunomodulatory properties and direct anti-myeloma tumoricidal activity.

▪ INDICATIONS AND DOSE
  Treatment of relapsed and refractory multiple myeloma in patients who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and who have had disease progression during the last treatment (in combination with dexamethasone)
  ▪ BY MOUTH
    ▪ Adult: 4 mg once daily for 21 consecutive days of repeated 28—day cycles, for doses of dexamethasone and dose adjustment due to side effects—consult product literature

DOSE ADJUSTMENTS DUE TO INTERACTIONS
  Manufacturer advises halve dose with concurrent use of potent inhibitors of CYP1A2 and ciprofloxacin.

IMPORANT SAFETY INFORMATION

MHRA/CHM ADVICE (MAY 2016): RISK OF HEPATITIS B REACTIVATION
  An EU wide review has concluded that pomalidomide can cause hepatitis B reactivation; the MHRA recommends to establish hepatitis B virus status in all patients before initiation of treatment.

▪ CAUTIONS
  ▪ Cardiac disease - cardiac risk factors - hepatitis B infection - high tumour burden—risk of tumour lysis syndrome - interstitial lung disease—discontinue if suspected - peripheral neuropathy

CAUTIONS, FURTHER INFORMATION
  ▪ Thromboembolism Risk factors for thromboembolism (such as smoking, hypertension, hyperlipidaemia) should be minimised. Thromboprophylaxis should be considered, particularly in patients with additional risk factors.
  ▪ Second primary malignancy Patients should be carefully evaluated before and during treatment with pomalidomide

downloaded from www.medicalbr.com
using routine cancer screening for occurrence of second primary malignancy and treatment should be instituted as indicated.

- Hepatitis B infection  The MHRA advises that those with a history of hepatitis B infection should be closely monitored for signs and symptoms of active infection throughout treatment; expert advice should be sought for patients who test positive for active infection.

- INTERACTIONS  → Appendix 1: pomalidomide

- SIDE-EFFECTS

- Common or very common  Anaemia  bone pain  cardiac failure  confusion  constipation  cough  decreased appetite  diarrhoea  dizziness  dysphonia  febrile neutropenia  hyperkalaemia  hyponatraemia  impaired consciousness  interstitial lung disease  leucopenia  malaise  muscle spasms  nasopharyngitis  nausea  neutropenia  neutropenic sepsis  pelvic pain  peripheral neuropathy  peripheral oedema  pneumonia  pruritus  pyrexia  rash  renal failure  respiratory tract infection  thrombocytopenia  thromboembolic events  tremor  urinary retention  vertigo  vomiting

- Uncommon

- Frequency not known  Atrial fibrillation  hepatitis B reactivation  pulmonary oedema

- CONCEPTION AND CONTRACEPTION  For women of childbearing potential, pregnancy must be excluded before starting treatment with pomalidomide (perform pregnancy test on initiation or within 3 days prior to initiation). Women must practise effective contraception at least 1 month before, during, and for at least 1 month after treatment, including during dose interruptions (oral combined hormonal contraceptives and copper-releasing intra-uterine devices not recommended) and men should use condoms during treatment, during dose interruption, and for at least 1 week after stopping if their partner is pregnant or is of childbearing potential and not using effective contraception. Patients, prescribers and pharmacists must comply with pregnancy prevention measures as specified in the manufacturer’s Pregnancy Prevention Programme.

- PREGNANCY  Important: teratogenic risk.

- BREAST FEEDING  Avoid—present in milk in animal studies.

- HEPATIC IMPAIRMENT  Manufacturer advises caution—no information available.

- RENAL IMPAIRMENT  Manufacturer advises caution—no information available.

- MONITORING REQUIREMENTS

- Manufacturer advises monitor full blood count before treatment, then every week for the first 8 weeks, then monthly thereafter (reduce dose or interrupt treatment if neutropenia or thrombocytopenia develop—consult product literature).

- Manufacturer advises monitor for arterial or venous thromboembolism.

- Manufacturer advises monitor for signs and symptoms of cardiac failure.

- Manufacturer advises monitor for acute onset or unexplained worsening of respiratory symptoms.

- Manufacturer advises monitor liver function for 6 months after initiation, then as clinically indicated.

- PRESCRIBING AND DISPENSING INFORMATION  Patient, prescriber, and supplying pharmacy must comply with a pregnancy prevention programme. Every prescription must be accompanied by a completed Prescription Authorisation Form.

- PATIENT AND CARER ADVICE  Patients and their carers should be made aware of the symptoms of thromboembolism and advised to report sudden breathlessness, chest pain, or swelling of a limb. Patients and their carers should be made aware of the symptoms of neutropenia and advised to seek medical advice if symptoms suggestive of neutropenia (such as fever, sore throat) or of thrombocytopenia (such as bleeding) develop.

- NATIONAL FUNDING/ACCESS DECISIONS

- NICE technology appraisals (TAs)

- Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (January 2017) NICE TA427 Pomalidomide, in combination with low-dose dexamethasone, is recommended as an option for treating multiple myeloma in adults at third or subsequent relapse (that is, after three previous treatments including both lenalidomide and bortezomib), only when the manufacturer provides pomalidomide with the discount agreed in the patient access scheme. Patients whose treatment was started within the NHS before this guidance was published should have the option to continue treatment, without change to their funding arrangements, until they and their clinician consider it appropriate to stop.

www.nice.org.uk/TA427

- MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Capsule

CAUTIONARY AND ADVISORY LABELS  3, 25

EXCIPIENTS: May contain Propylene glycol

- Imnovid (Celgene Ltd)  ▼

- Pomalidomide 1 mg  Imnovid 1mg capsules  |  21 capsule  POM

- Pomalidomide 2 mg  Imnovid 2mg capsules  |  21 capsule  POM

- Pomalidomide 3 mg  Imnovid 3mg capsules  |  21 capsule  POM

- Pomalidomide 4 mg  Imnovid 4mg capsules  |  21 capsule  POM

- £8,884.00

- £8,884.00

- £8,884.00

- £8,884.00

Thalidomide

- DRUG ACTION  Thalidomide has immunomodulatory and anti-inflammatory activity.

- INDICATIONS AND DOSE

First-line treatment for untreated multiple myeloma, in patients aged 65 years and over, for those not eligible for high-dose chemotherapy (for example, patients with significant co-morbidity such as cardiac risk factors) in combination with melphalan and prednisolone

- BY MOUTH

- Adult 18–75 years: 200 mg once daily for 6–week cycle for a maximum of 12 cycles, dose to be taken at bedtime

- Adult 76 years and over: 100 mg once daily for 6–week cycle for a maximum of 12 cycles, dose to be taken at bedtime

- CAUTIONS  High tumour burden—risk of tumour lysis syndrome  patients aged 76 years and over—increased risk of serious side-effects

- CAUTIONS, FURTHER INFORMATION

- Thromboembolism  Risk factors for thromboembolism (such as smoking, hypertension, hyperlipidaemia) should be minimised. Thrombophrophylaxis is recommended for at least the first 5 months of treatment, especially in patients with additional thrombotic risk factors.

- Second primary malignancy  Patients should be carefully evaluated before and during treatment with thalidomide using routine cancer screening for occurrence of second
primary malignancy and treatment should be instituted as indicated.

- Peripheral neuropathy Patients with pre-existing peripheral neuropathy should not be treated with thalidomide unless the potential clinical benefits outweigh the risk.

- INTERACTIONS → Appendix 1: thalidomide

- SIDE-EFFECTS
- Common or very common Anaemia · asthenia · bradycardia · cardiac failure · confusion · constipation · deep vein thrombosis · depression · dizziness · drowsiness · dry mouth · dysaesthesis · dyspepsia · dyspnoea · interstitial lung disease · leucopenia · lymphopenia · neutropenia · paraesthesia · peripheral neuropathy · peripheral oedema · pneumonia · pulmonary embolism · pyrexia · skin reactions · Stevens-Johnson syndrome · syndrome · thrombocytopenia · tremor · vomiting
- Frequency not known Atrial fibrillation · atrioventricular block · cerebrovascular events · convulsions · gastro-intestinal haemorrhage · gastro-intestinal perforation · hearing loss · hepatic disorders · hypothyroidism · intestinal obstruction · menstrual disorders · myocardial infarction · renal failure · second primary malignancy · sexual dysfunction · toxic epidermal necrolysis · worsening of Parkinson’s disease symptoms

- MONITORING REQUIREMENTS
- Monitor patients for signs and symptoms of peripheral neuropathy such as paraesthesia, abnormal coordination, or weakness develop. Patients and their carers should be advised to seek medical advice if symptoms of peripheral neuropathy such as paraesthesia, abnormal coordination, or weakness develop.

- PATIENT AND CARER ADVICE
- Avoid in severe impairment.

- CONCEPTION AND CONTRACEPTION
- For women of child-bearing potential, pregnancy must be excluded before starting treatment with thalidomide (perform pregnancy test on initiation or within 3 days prior to initiation). Women must practise effective contraception at least 1 month before, during, and for at least 1 month after treatment, including during dose interruptions (oral combined hormonal contraceptives and copper-releasing intra-uterine devices not recommended) and men should use condoms during treatment, during dose interruption, and for at least 1 week after stopping if their partner is pregnant or is of childbearing potential and not using effective contraception. Patients, prescribers and pharmacists must comply with pregnancy prevention measures as specified in the manufacturer’s Pregnancy Prevention Programme.

- PREGNANCY
- Important: teratogenic risk.

- BREAST FEEDING
- Avoid—present in milk in animal studies.

- HEPATIC IMPAIRMENT
- Caution in severe impairment—no information available.

- RENAL IMPAIRMENT
- Caution in severe impairment—no information available.

- MONITORING REQUIREMENTS
- Monitor white blood cell count (including differential count) and platelet count (reduce dose or interrupt treatment if neutropenia or thrombocytopenia develop—consult product literature).
- Monitor for arterial or venous thromboembolism.
- Monitor patients for signs and symptoms of peripheral neuropathy.
- Hepatic disorder Liver function should be monitored, particularly when there is history of, or concurrent viral liver infection, or when thalidomide is combined with drugs known to be associated with liver dysfunction (e.g. paracetamol).

- PRESCRIBING AND DISPENSING INFORMATION
- Patient, prescriber, and supplying pharmacy must comply with a pregnancy prevention programme. Every prescription must be accompanied by a complete Prescription Authorisation Form.

- PATIENT AND CARER ADVICE
- Patients and their carers should be made aware of the symptoms of thromboembolism and advised to report sudden breathlessness, chest pain, or swelling of a limb.

- NATIONAL FUNDING/ACCESS DECISIONS
- NICE technology appraisals (TAs)
- Bortezomib and thalidomide for the first-line treatment of multiple myeloma (July 2011) NICE TA228 Thalidomide in combination with an alkylating drug and a corticosteroid is recommended as an option for the first-line treatment of multiple myeloma in people for whom high-dose chemotherapy with stem cell transplantation is considered inappropriate.

- MEDIcular FORMS
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, oral suspension, oral solution

- Capsule

- Porfimer sodium

- PHOTOSENSITISERS

- Photodynamic therapy responsive malignancy

- Photodynamic therapy responsive malignancy

- Porfimer sodium

- DRUG ACTION
- Photofrin accumulates in malignant tissue and is activated by laser light to produce a cytotoxic effect.

- INDICATIONS AND DOSE
- Photodynamic therapy of non-small cell lung cancer and obstructing oesophageal cancer
- By slow intravenous injection
- Adult: (consult product literature)

- CONTRA-INDICATIONS
- Acute porphyrias p. 969 · broncho-oesophageal fistula · tracheo-oesophageal fistula

- SIDE-EFFECTS
- Alopecia · bone-marrow suppression · constipation · extravasation · hyperuricaemia · nausea · oral mucositis · photosensitivity (sunscreens offer no protection) · thromboembolism · tumour lysis syndrome · vomiting

- PREGNANCY
- Manufacturer advises avoid unless essential.

- BREAST FEEDING
- No information available—manufacturer advises avoid.

- HEPATIC IMPAIRMENT
- Avoid in severe impairment.
6  Targeted therapy responsive malignancy

ANTINEOPLASTIC DRUGS  PROTEASOME INHIBITORS

Bortezomib

- **DRUG ACTION** Bortezomib is a proteasome inhibitor.

- **INDICATIONS AND DOSE**
  Treatment of multiple myeloma that has progressed despite the use of at least one therapy, and where the patient has already had, or is unable to have, haematopoietic stem cell transplantation (either as monotherapy, or in combination with pegylated liposomal doxorubicin or dexamethasone) | Treatment of previously untreated multiple myeloma in patients who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation (in combination with melphalan and prednisolone) | Induction treatment of previously untreated multiple myeloma in patients who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation (in combination with dexamethasone, or with dexamethasone and thalidomide)
  - **BY INTRAVENOUS INJECTION, OR BY SUBCUTANEOUS INJECTION**
  - **Adult:** (consult local protocol)

**IMPORTANT SAFETY INFORMATION**
Bortezomib injection is for intravenous or subcutaneous administration only. Inadvertent intrathecal administration with fatal outcome has been reported.

- **CONTRA-INDICATIONS** Acute diffuse infiltrative pulmonary disease | pericardial disease
- **CAUTIONS** Amyloidosis | cardiovascular disease | consider antiviral prophylaxis for herpes zoster infection | dehydration | diabetes (may affect blood glucose) | history of syncope | pulmonary disease (discontinue if interstitial lung disease develops) | risk factors for seizures | risk of neuropathy—consult product literature
- **INTERACTIONS** Appendix 1: bortezomib
- **SIDE-EFFECTS**
  - **Common or very common** Constipation (cases of ileus reported) | decreased appetite | diarrhoea | dyspnoea | fatigue | headache | herpes zoster | hypotension | myalgia | paraesthesia | peripheral neuropathy | pyrexia | rash | reactivation of herpes zoster | sensory neuropathy
  - **Uncommon** Acute diffuse infiltrative pulmonary disorders | heart failure | posterior reversible encephalopathy syndrome (discontinue treatment) | pulmonary hypertension | seizures
  - **Rare** Autonomic neuropathy
  - **Very rare** Progressive multifocal leucoencephalopathy
- **FREQUENCY NOT KNOWN** Alopecia | bone-marrow suppression | extravasation | hyperuricaemia | nausea | oral mucositis | thromboembolism | tumour lysis syndrome | vomiting

**FURTHER INFORMATION**
For further information on side-effects, consult product literature.

- **CONCEPTION AND CONTRACEPTION** Manufacturer advises effective contraception during and for 3 months after treatment in men or women.
- **PREGNANCY** Toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.
- **BREAST FEEDING** Discontinue breast-feeding.

---

**Temoporfin**

- **DRUG ACTION** Temoporfin accumulates in malignant tissue and is activated by laser light to produce a cytotoxic effect.

- **INDICATIONS AND DOSE** Photodynamic therapy of advanced head and neck squamous cell carcinoma refractory to, or unsuitable for, other treatments
  - **BY SLOW INTRAVENOUS INJECTION**
  - **Adult:** (consult product literature)

- **CONTRA-INDICATIONS** Acute porphyrias p. 969 | concomitant photosensitising treatment | diseases exacerbated by light | elective surgery | ophthalmic slit-lamp examination for 30 days after administration

- **SIDE-EFFECTS**
  - Alopecia | blistering | bone-marrow suppression | constriction | dysphagia | erythema | extravasation | facial pain | giddiness | haemorrhage | hyperpigmentation | hyperuricaemia | injection site pain | nausea | oedema | oral mucositis | photosensitivity (sunscreens ineffective) | scarring | skin necrosis | thromboembolism | trismus | tumour lysis syndrome | vomiting

- **CONCEPTION AND CONTRACEPTION** Manufacturer advises avoid pregnancy for at least 3 months after treatment.

- **PREGNANCY** Toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

- **BREAST FEEDING** Manufacturer advises avoid breastfeeding for at least 1 month after treatment—no information available.

- **PATIENT AND CARER ADVICE** Photosensitivity | Avoid exposure of skin and eyes to direct sunlight or bright indoor light for at least 30 days.

**Solution for Injection**

- **Foscan** (Biolitec Pharma Ltd)
  - **Temoporfin 1 mg per 1 ml** Foscan 3mg/3ml solution for injection vials | 1 vial (POM) £1,800.00 (Hospital only)
  - Foscan 6mg/6ml solution for injection vials | 1 vial (POM) £3,400.00 (Hospital only)

**CONTRA-INDICATIONS**

- Acute porphyrias p. 969
- Pregnancy and reproductive function in Cytotoxic drugs p. 969

**SIDE-EFFECTS**

- Alopecia
- Photosensitivity
- Dysphagia
- Erythema
- Facial pain
- Giddiness
- Haemorrhage
- Hyperpigmentation
- Hyperuricaemia
- Injection site pain
- Nausea
- Oedema
- Oral mucositis
- Photosensitivity (sunscreens ineffective)
- Scarring
- Skin necrosis
- Thromboembolism
- Trismus
- Tumour lysis syndrome
- Vomiting

**CONCEPTION AND CONTRACEPTION**

- Manufacturer advises avoid pregnancy for at least 3 months after treatment.

**PREGNANCY**

- Toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**BREAST FEEDING**

- Discontinue breast-feeding.

---

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

**Solution for Injection**

- **Foscan** (Biolitec Pharma Ltd)
  - **Temoporfin 1 mg per 1 ml** Foscan 3mg/3ml solution for injection vials | 1 vial (POM) £1,800.00 (Hospital only)
  - Foscan 6mg/6ml solution for injection vials | 1 vial (POM) £3,400.00 (Hospital only)

**CONTRA-INDICATIONS**

- Acute porphyrias p. 969
- Pregnancy and reproductive function in Cytotoxic drugs p. 969

**SIDE-EFFECTS**

- Alopecia
- Photosensitivity
- Dysphagia
- Erythema
- Facial pain
- Giddiness
- Haemorrhage
- Hyperpigmentation
- Hyperuricaemia
- Injection site pain
- Nausea
- Oedema
- Oral mucositis
- Photosensitivity (sunscreens ineffective)
- Scarring
- Skin necrosis
- Thromboembolism
- Trismus
- Tumour lysis syndrome
- Vomiting

**CONCEPTION AND CONTRACEPTION**

- Manufacturer advises avoid pregnancy for at least 3 months after treatment.

**PREGNANCY**

- Toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**BREAST FEEDING**

- Discontinue breast-feeding.
**HEPATIC IMPAIRMENT** Reduce dose in moderate to severe impairment—consult product literature.

**RENAL IMPAIRMENT** No information available for creatinine clearance less than 20 mL/minute/1.73 m².

**MONITORING REQUIREMENTS**
- Monitor blood-glucose concentration in patients on oral antidiabetics.
- Monitor for symptoms of progressive multifocal leuкоencephalopathy (presenting as new or worsening neurological signs or symptoms)—discontinue treatment if diagnosed.
- Chest x-ray recommended before treatment to monitor for pulmonary disease—discontinue if interstitial lung disease develops.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**
- Bortezomib for previously untreated mantle cell lymphoma (December 2015) NICE TA370
Bortezomib is recommended as an option for the treatment of previously untreated mantle cell lymphoma in adults for whom haematopoietic stem cell transplantation is unsuitable.

www.nice.org.uk/TA370

- Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation (April 2014) NICE TA311
Bortezomib is recommended as an option within its marketing authorisation, in combination with dexamethasone, or with dexamethasone and thalidomide, for the induction treatment of adults with previously untreated multiple myeloma, who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.

www.nice.org.uk/TA311

- Bortezomib and thalidomide for the first-line treatment of multiple myeloma (July 2011) NICE TA228
Bortezomib in combination with an alkylating drug and a corticosteroid is recommended as an option for the first-line treatment of multiple myeloma if:
  - high-dose chemotherapy with stem cell transplantation is considered inappropriate and
  - the person is unable to tolerate or has contraindications to thalidomide.

www.nice.org.uk/TA228

- Bortezomib monotherapy for relapsed multiple myeloma (October 2007) NICE TA129
Bortezomib monotherapy is an option for the treatment of progressive multiple myeloma in patients who are at first relapse having received one prior therapy and who have undergone, or are unsuitable for, bone-marrow transplantation, under the following circumstances:
  - the response to bortezomib is measured using serum M protein after a maximum of four cycles of treatment, and treatment is continued only in patients who have a reduction in serum M protein of 50% or more (where serum M protein is not measurable, an appropriate alternative biochemical measure of response should be used) and
  - the manufacturer rebates the full cost of bortezomib if there is an inadequate response (as defined above) after four cycles of treatment.

www.nice.org.uk/TA129

**Scottish Medicines Consortium (SMC) Decisions**
The Scottish Medicines Consortium, has advised (December 2013) that bortezomib (Velcade®) is accepted for restricted use within NHS Scotland in combination with dexamethasone and thalidomide for the induction treatment of adults with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for injection**
- **Velcade** (Janssen-Cilag Ltd)
  - Bortezomib 3.5 mg Velcade 3.5mg powder for solution for injection vials | 1 vial (Pow) | £762.38 (Hospital only)

**Carfilzomib**

17-Mar-2017

**DRUG ACTION** Carfilzomib is an irreversible selective proteasome inhibitor that disrupts tumour cell turnover and induces apoptosis.

**INDICATIONS AND DOSE**
Treatment of multiple myeloma in patients who have received at least one prior therapy (in combination with dexamethasone, or with dexamethasone and lenalidomide) (specialist use only)

- **BY INTRAVENOUS INFUSION**
  - Adult: (consult product literature or local protocols)

**CAUTIONS**
- Elderly (over 75 years)—higher incidence of adverse effects—ensure adequate hydration—infusion-related reactions—recent history of myocardial infarction—risk of cardiac failure—risk of herpes zoster reactivation—uncontrolled angina—uncontrolled arrhythmias

**CAUTIONS, FURTHER INFORMATION**
- Infusion-related reactions Manufacturer advises premedication with dexamethasone to reduce incidence and severity of infusion-related reactions.
- Risk of herpes zoster reactivation Manufacturer advises consider antiviral prophylaxis for herpes zoster infection.

**INTERACTIONS** → Appendix 1: carfilzomib

**SIDE-EFFECTS**
- **Common or very common** Abdominal pain, anxiety, atrial fibrillation, blood disorders, blurred vision, cardiac failure, cataract, constipation, decreased appetite, deep vein thrombosis, dehydration, diarrhoea, dizziness, dyspepsia, dysphonia, electrolyte disturbances, epistaxis, erythema, flushing, headache, hyperbilirubinaemia, hyperglycaemia, hyperhidrosis, hypertension, hypoaesthesia, hypoalbuminaemia, hypotension, infection, infusion-related reactions, insomnia, muscle spasm, muscular weakness, musculoskeletal pain, nausea, ophthalmalgia, pain, palpitations, paraesthesia, peripheral neuropathy, pruritus, pulmonary embolism, pulmonary hypertension, pulmonary oedema, renal failure, sepsis, tachycardia, vomiting
- **Uncommon** Acute respiratory distress syndrome, cardiac arrest, cerebrovascular accident, cholestasis, ejection fraction decreased, gastrointestinal perforation, haemolytic uraemic syndrome, haemorrhage, hepatic failure, hypertensive crisis, interstitial lung disease, myocardial infarction, myocardial ischaemia, pericardial effusion, pericarditis, pneumonitis, tumour lysis syndrome
- **Rare** Posterior reversible encephalopathy syndrome, thrombotic microangiopathy
- **Frequency not known** QT-interval prolongation

**SIDE-EFFECTS, FURTHER INFORMATION**
For further information on side-effects, including management of specific side-effects, consult product literature.

**CONCEPTION AND CONTRACEPTION** Manufacturer recommends effective contraception during and for 1 month after treatment in women of childbearing potential; efficacy of oral contraceptives may be reduced, and hormonal contraceptives associated with a risk of thrombosis should be avoided. Male patients should use effective contraception during and for 3 months after
Ixazomib

- **DRUG ACTION** Ixazomib is a proteasome inhibitor.

- **INDICATIONS AND DOSE**

  - **Multiple myeloma in patients who have received at least one prior therapy, in combination with lenalidomide and dexamethasone (specialist use only)**
    - **BY MOUTH**
    - **Adult:** 4 mg once weekly on days 1, 8, and 15 of a 28-day treatment cycle, for dose adjustments due to side-effects, consult product literature

- **CAUTIONS** Risk of herpes zoster reactivation

- **CAUTIONS, FURTHER INFORMATION**

  - **Herpes zoster reactivation** Manufacturer advises consider concomitant antiviral prophylaxis to decrease the risk of herpes zoster reactivation.
  - **INTERACTIONS** → Appendix 1: ixazomib
  - **SIDE-EFFECTS**
    - **Common or very common** Back pain, constipation, diarrhoea, nausea, neutropenia, peripheral neuropathy (monitor for symptoms), peripheral oedema, rash, thrombocytopenia, vomiting
    - **Uncommon** Hepatotoxicity
    - **Rare** Acute febrile neutrophilic dermatosis (Sweet’s syndrome), pneumonia (including fatal cases), posterior reversible encephalopathy syndrome (PRES)—discontinue treatment, Stevens-Johnson syndrome, thrombotic thrombocytopenic purpura, transverse myelitis, tumour lysis syndrome
    - **Frequency not known** Blurred vision, dry eye
  - **CONCEPTION AND CONTRACEPTION** Manufacturer advises effective contraception in women of child-bearing potential and in men with a partner of child-bearing potential, during treatment and for at least 90 days after stopping treatment; additional barrier method recommended in women using hormonal contraceptives.
  - **PREGNANCY** Manufacturer advises avoid—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.
  - **BREAST FEEDING** Manufacturer advises avoid—no information available.
  - **HEPATIC IMPAIRMENT** Manufacturer advises reduce dose to 3 mg in moderate-to-severe impairment.
  - **RENAL IMPAIRMENT** Manufacturer advises reduce dose to 3 mg in severe impairment (creatinine clearance less than 30 mL/min).
  - **MONITORING REQUIREMENTS** Manufacturer advises to monitor hepatic function regularly and adjust dose accordingly—consult product literature.
  - **PATIENT AND CARER ADVICE**
    - **Missed doses**
      - Manufacturer advises if less than 72 hours remain before the next scheduled dose, the missed dose should not be taken and the next dose should be taken at the normal time.

- **MEDICINAL FORMS**

  - **Powder for solution for infusion**
    - **ELECTROLYTES:** May contain Sodium
    - **Kryprolis** (Amgen Ltd) ▼
    - Carfilzomib 60 mg Kryprolis 60mg powder for solution for infusion vials | 1 vial [POM] £1,056.00

- **MEDICINAL FORMS**

  - **Capsule**
    - **CAUTIONARY AND ADVISORY LABELS 23, 25**
    - **Ninlaro** (Takeda UK Ltd) ▼
    - Ixazomib (as ixazomib citrate) 2.3 mg Ninlaro 2.3mg capsules | 3 capsule [POM] £6,336.00

---

**TARGETED THERAPY RESPONSIVE MALIGNANCY**

---

**HEPATIC IMPAIRMENT**

**NATIONAL FUNDING/ACCESS DECISIONS**

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (January 2017) that carfilzomib (Kryprolis®) in combination with lenalidomide and dexamethasone is **not** recommended for use within NHS Scotland for the treatment of adult patients with multiple myeloma who have received at least one prior therapy as the economic case was not demonstrated.

**MEDICAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for infusion**

**ELECTROLYTES:** May contain Sodium

- **Kryprolis** (Amgen Ltd) ▼
  - Carfilzomib 60 mg Kryprolis 60mg powder for solution for infusion vials | 1 vial [POM] £1,056.00

**MEDICAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

**CAUTIONARY AND ADVISORY LABELS 23, 25**

- **Ninlaro** (Takeda UK Ltd) ▼
  - Ixazomib (as ixazomib citrate) 2.3 mg Ninlaro 2.3mg capsules | 3 capsule [POM] £6,336.00

---

**CONCEPTION AND CONTRACEPTION**

Manufacturer advises effective contraception in women of child-bearing potential and in men with a partner of child-bearing potential, during treatment and for at least 90 days after stopping treatment; additional barrier method recommended in women using hormonal contraceptives.

**PREGNANCY**

Manufacturer advises avoid—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**BREAST FEEDING**

Manufacturer advises avoid—no information available.

**HEPATIC IMPAIRMENT**

Manufacturer advises reduce dose to 3 mg in moderate-to-severe impairment.

**RENAL IMPAIRMENT**

Manufacturer advises reduce dose to 3 mg in severe impairment (creatinine clearance less than 30 mL/min).

**MONITORING REQUIREMENTS**

Manufacturer advises to monitor hepatic function regularly and adjust dose accordingly—consult product literature.

**PATIENT AND CARER ADVICE**

**Missed doses**

Manufacturer advises if less than 72 hours remain before the next scheduled dose, the missed dose should not be taken and the next dose should be taken at the normal time.
Afatinib

**DRUG ACTION** Afatinib is a protein kinase inhibitor.

**INDICATIONS AND DOSE**

Treatment of locally advanced or metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations, in patients who have not previously been treated with EGFR tyrosine kinase inhibitor

- **BY MOUTH**
  - Adult: 40 mg once daily; increased if tolerated to up to 50 mg once daily, dose increase may be considered after 3 weeks at initial dose; consult product literature for details on dosing and dose adjustment due to side effects

**SIDE-EFFECTS**

- Common or very common: Acne · conjunctivitis · cystitis · decreased appetite · dehydration · diarrhoea · dry eyes · dry skin · dysgeusia · dyspnea · epistaxis · hand-foot syndrome · hypokalaemia · muscle spasms · paronychia · pruritus · pyrexia · rash (see Cautions) · renal failure · rhinorrhoea · weight loss
- Uncommon: Interstitial lung disease · keratitis
- Frequency not known: Alopecia · bone-marrow suppression · hyperuricaemia · nausea · oral mucositis · thromboembolism · tumour lysis syndrome · vomiting

**CONCEPTION AND CONTRACEPTION** Ensure effective contraception during and for at least one month after treatment in women of childbearing potential.

**PREGNANCY** Manufacturer advises avoid. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT** Monitor hepatic function regularly and consult product literature for dose adjustment in worsening liver function. Manufacturer advises avoid in severe hepatic impairment.

**RENAL IMPAIRMENT** Manufacturer advises avoid in severe renal impairment.

**IMPORTANT SAFETY INFORMATION**

**RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES** See Cytotoxic drugs p. 825.

- **CAUTIONS** Cardiac risk factors · conditions which may affect left ventricular ejection fraction—consider cardiac monitoring, including assessment of left ventricular ejection fraction, at baseline and during treatment · diarrhoea—proactive management recommended (consult product literature) · exposure to sun (protect skin from exposure to sun) · history of keratitis · new pulmonary symptoms (including dyspnoea, cough, fever)—interrupt treatment if severe or if Stevens-Johnson syndrome suspected (consult product literature) · ulcerative keratitis · use of contact lenses · worsening pulmonary symptoms (including dyspnoea, cough, fever)—interrupt treatment until interstitial lung disease is excluded
- **INTERACTIONS** → Appendix 1: afatinib

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS** 25
  - Giotrif® (Boehringer Ingelheim Ltd) ▼
  - Afatinib 20 mg Giotrif® 20mg tablets  28 tablet £2,023.28
  - Afatinib 30 mg Giotrif® 30mg tablets  28 tablet £2,023.28
  - Afatinib 40 mg Giotrif® 40mg tablets  28 tablet £2,023.28
  - Afatinib 50 mg Giotrif® 50mg tablets  28 tablet £2,023.28

Axitinib

**DRUG ACTION** Axitinib is a tyrosine kinase inhibitor.

**INDICATIONS AND DOSE**

Treatment of advanced renal cell carcinoma following failure of previous treatment with sunitinib or a cytokine (aldesleukin or interferon alfa)

- **BY MOUTH**
  - Adult: (consult product literature)

**SIDE-EFFECTS**

- Common or very common: Abdominal pain · anal fistula · arthralgia · asthenia · cerebral haemorrhage · constipation · cough · decreased appetite · dehydration · diarrhoea · dizziness · dry skin · dysgeusia · dyspepsia · dysphonia · dyspnoea · erythema · fatigue · flatulence · gastro-intestinal haemorrhage · gastro-intestinal perforation ·
haemoptysis • haemorrhage • haemorrhoids • hand-foot syndrome • headache • hypercalcaemia • hyperkalaemia • hypertension • hyperthyroidism • hypothyroidism • myalgia • proteinuria • pruritus • rash • renal failure • tinnitus • weight loss

- Uncommon Hypertensive crisis • polycythaemia • posterior reversible encephalopathy syndrome
- Frequency not known Alopecia • bone-marrow suppression • hyperuricaemia • nausea • oral mucositis • thromboembolism • tumour lysis syndrome • vomiting

CONCEPTION AND CONTRACEPTION Effective contraception required during and for up to 1 week after treatment.

- PREGNANCY Manufacturer advises avoid unless potential benefit outweighs risk (toxicity in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.
- HEPATIC IMPAIRMENT Reduce starting dose in moderate impairment. Avoid in severe impairment—no information available.

MONITORING REQUIREMENTS
- Monitor for thyroid dysfunction.
- Monitor haemoglobin or haematocrit before and during treatment.
- Monitor for symptoms of gastro-intestinal perforation.
- Monitor for symptoms of fistula.
- Monitor for proteinuria before and during treatment.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)
- Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (February 2015) NICE TA333

Axitinib is recommended as an option for treating adults with advanced renal cell carcinoma after failure of treatment with a first-line tyrosine kinase inhibitor or a cytokine, only if the company provides axitinib with the discount agreed in the patient access scheme. www.nice.org.uk/TA333

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Table

CAUTIONARY AND ADVISORY LABELS 25
- Inlyta (Pfizer Ltd) 
  - Axitinib 1 mg Inlyta 1mg tablets | 56 tablet £703.40 (Hospital only)
  - Axitinib 3 mg Inlyta 3mg tablets | 56 tablet £2,110.20 (Hospital only)
  - Axitinib 5 mg Inlyta 5mg tablets | 56 tablet £3,517.00 (Hospital only)
  - Axitinib 7 mg Inlyta 7mg tablets | 56 tablet £4,923.80 (Hospital only)

Targeted therapy responsive malignancy 893

MHRA/CHM ADVICE (MAY 2016): RISK OF HEPATITIS B VIRUS REACTIVATION WITH BCR-ABL TYROSINE KINASE INHIBITORS

An EU wide review has concluded that bosutinib can cause hepatitis B reactivation; the MHRA recommends establishing hepatitis B virus status in all patients before initiation of treatment.

- CAUTIONS Cardiac disease • hepatitis B infection • history of pancreatitis—hold treatment if lipase elevated and abdominal symptoms occur • history of QT prolongation—monitor ECG and correct hypokalaemia and hypomagnesaemia before and during treatment • recent cardiac event—monitor ECG and correct hypokalaemia and hypomagnesaemia before and during treatment • risk factors for QT prolongation—monitor ECG and correct hypokalaemia and hypomagnesaemia before and during treatment • significant gastrointestinal disorder

CAUTIONS, FURTHER INFORMATION
- Hepatitis B infection The MHRA advises that patients who are carriers of hepatitis B virus should be closely monitored for signs and symptoms of active infection throughout treatment and for several months after stopping treatment; expert advice should be sought for patients who test positive for hepatitis B virus and in those with active infection.

INTERACTIONS Appendix 1: bosutinib

SIDE-EFFECTS
- Common very common Abdominal pain • abnormal liver function • acne • arthralgia • biochemical disturbances • cough • decreased appetite • dehydration • diarrhoea • dizziness • dysgeusia • dysphonia • electrolyte disturbances • gastritis • headache • hepatotoxicity • infection • malaise • myalgia • oedema • pericardial effusion • pleural effusion • pruritus • pyrexia • QT prolongation • rash • renal failure • renal impairment • urticaria
- Uncommon Gastric haemorrhage • pancreatitis • pericarditis • pulmonary hypertension • pulmonary oedema • respiratory failure • tinnitus
- Frequency not known Alopecia • bone-marrow suppression • hepatic failure (fatal cases reported) • hepatitis • hepatitis B reactivation • hyperuricaemia • nausea • oral mucositis • thromboembolism • tumour lysis syndrome • vomiting

CONCEPTION AND CONTRACEPTION Effective contraception required during treatment in women.

PREGNANCY Avoid—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 826.

BREAST FEEDING Manufacturer advises avoid—no information available.

HEPATIC IMPAIRMENT Caution—no information available.

MONITORING REQUIREMENTS
- Manufacturer advises monitor liver function before treatment initiation, then monthly for the first 3 months and thereafter as clinically indicated—consult product literature for management of raised transaminases.
- Manufacturer advises monitor full blood count weekly for the first month and then monthly thereafter or as clinically indicated.
- Manufacturer advises monitor for signs and symptoms of fluid retention (including pericardial effusion, pleural effusion and pulmonary oedema).

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)
- Bosutinib for previously treated chronic myeloid leukaemia (August 2016) NICE TA401

Bosutinib is recommended as a treatment option, within its marketing authorisation, for chronic, accelerated and blast phase Philadelphia-chromosome-positive CML in adults, when:

- they have previously been treated with 1 or more tyrosine kinase inhibitor, and

Bosutinib

INDICATIONS AND DOSE

Treatment of chronic, accelerated and blast phase Philadelphia chromosome-positive chronic myeloid leukaemia, in those previously treated with one or more tyrosine kinase inhibitors, and for whom imatinib, nilotinib and dasatinib are not clinically appropriate

BY MOUTH
- Adult: 500 mg once daily, consult product literature for dose adjustment due to side effects, or incomplete haematologic response by week 8, or incomplete cytogenetic response by week 12

IMPORTANT SAFETY INFORMATION
RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES
See Cytotoxic drugs p. 825.
Cabozantinib

**DRUG ACTION** Cabozantinib is an inhibitor of several protein kinases.

**INDICATIONS AND DOSE**
Treatment of progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma

- **BY MOUTH**
- **Adult:** 140 mg once daily, for dose adjustment or treatment interruption due to side effects, consult product literature (closely monitor for first 8 weeks of therapy)

**IMPORTANT SAFETY INFORMATION**
Risks of incorrect dosing of oral anti-cancer medicines

See Cytotoxic drugs p. 825.

**CONTRA-INDICATIONS** Reversible Posterior Leuкоencephalopathy Syndrome

**CAUTIONS** Hypertension—discontinue treatment if uncontrolled despite medical intervention — palmar-plantar erythrodysesthesia syndrome — consider treatment interruption if severe and restart at a lower dose when resolved to grade 1 • patients at increased risk of fistulas — consult product literature • patients at increased risk of gastro-intestinal perforation — consult product literature • patients at increased risk of intra-abdominal abscess — consult product literature • patients at risk of haemorrhage (including tumour involvement of the trachea or bronchi) — discontinue if symptoms develop • patients at risk of thromboembolic events including myocardial infarction — discontinue if symptoms develop • risk of osteonecrosis of the jaw — susceptibility to QT-interval prolongation (e.g. cardiac disease, electrolyte disturbances, bradycardia, concomitant use of drugs that prolong the QT interval) — monitor ECG and electrolytes periodically

**CAUTIONS, FURTHER INFORMATION**
- Elective surgery Withhold treatment for at least 28 days before elective surgery and restart only if adequate wound healing — discontinue in patients with wound healing complications requiring medical intervention.
- Risk of osteonecrosis of the jaw Discontinue treatment at least 28 days before elective invasive dental procedures — monitor for symptoms before and during treatment and discontinue if osteonecrosis develops.

**SIDE-EFFECTS**
- Common or very common Abdominal pain • abnormal hair growth • abscess • acne • alopecia • anal fissure • anxiety • arthralgia • aspiration • atrial fibrillation • blurred vision • chelitis • chills • cholelithiasis • constipation • decreased appetite • dehydration • depression • diaphoresis • dizziness • dry skin • dysgeusia • dyspepsia • dysphagia • dysphonia • dysuria • erythema • face oedema • folliculitis • fungal infection • gastro-intestinal perforation • gastrointestinal haemorrhage • glossodynia • haematuria • haemorrhoids • hair colour changes • headache • hyperbilirubinaemia • hyperkeratosis • hypertension • hypoalbuninaemia • hypocalcaemia • hypokalaemia • hypophosphataemia • hypotension • hypothyroidism • impaired wound healing • lymphopenia • mucosal inflammation • muscle spasms • musculoskeletal chest pain • nausea • neutropenia • non-gastro-intestinal fistula • oropharyngeal pain • osteonecrosis of jaw • pallor • palmar-plantar erythrodysesthesia syndrome • pancreatitis • paraesthesia • peripheral coldness • peripheral neuropathy • platelet disorders • pneumonia • proteinuria • pulmonary embolism • rash • respiratory tract haemorrhage • skin exfoliation • skin hypopigmentation • stomatitis • tinnitus • tremor • venous thrombosis • vomiting
- Uncommon Hypoacusis • acute renal failure • amenorrhoea • angina • arterial thrombosis • aspergillosis • ataxia • atelectasis • catarract • conjunctivitis • cyst • delirium • facial pain • gastrointestinal fistula • hepatic encephalopathy • loss of consciousness • oesophagitis • pharyngeal oedema • pneumonitis • posterior reversible encephalopathy syndrome • rhabdomyolysis • skin ulcer • speech disorder • supraventricular tachycardia • telangiectasia • transient ischaemic attack • vaginal haemorrhage
- Frequency not known Bone-marrow suppression • hyperuricaemia • oral mucositis • thromboembolism • tumour lysis syndrome
- Conception and Contraception Patients and their sexual partners must use effective contraception (in addition to barrier method) during treatment and for at least 4 months after the last dose.
- Pregnancy Manufacturer advises avoid unless potential benefit outweighs risk — toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.
- Breast Feeding Manufacturer advises discontinue breast-feeding during treatment and for at least 4 months after the last dose.
- Hepatic Impairment Manufacturer advises avoid.
- Renal Impairment Manufacturer advises caution in renal impairment. Avoid in severe impairment.
- Monitoring Requirements Monitor urine protein regularly and discontinue if nephrotic syndrome develops.
- Patient and Carer Advice
Food should not be consumed for at least 2 hours before and at least 1 hour after each dose.

Driving and skilled tasks
Fatigue and weakness may affect performance of skilled tasks e.g. driving.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

**CAUTIONARY AND ADVISORY LABELS**

- **Cometriq** (Ipsen Ltd) ▼
  - Cabozantinib (as Cabozantinib s-malate) 20 mg Cometriq 20mg capsules | 7 capsule PSt £ no price available | 21 capsule PSt no price available | 84 capsule PSt £4,800.00
  - Cabozantinib (as Cabozantinib s-malate) 80 mg Cometriq 80mg capsules | 7 capsule PSt no price available
Ceritinib

**DRUG ACTION** Ceritinib is a tyrosine kinase inhibitor, with particular activity against anaplastic lymphoma kinase (ALK).

**INDICATIONS AND DOSE**

Treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer previously treated with crizotinib

- **BY MOUTH**
- Adult: 750 mg once daily, dose should be taken at the same time every day, temporary dose interruption or dose reduction may be required based on tolerability—consult product literature; discontinue treatment if patient unable to tolerate at least 300 mg daily

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**

Manufacturer advises if concurrent use of potent inhibitors of CYP3A4 is unavoidable, reduce the dose by one-third (rounded to the nearest multiple of the 150 mg dosage form).

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain, anaemia, bradycardia, constipation, decreased appetite, diarrhoea, dyspepsia, dysphagia, fatigue, gastro-oesophageal reflux disease, hyperglycaemia, hypophosphataemia, nausea, pericarditis, pneumonitis, QT-interval prolongation, rash, renal failure, renal impairment, visual disorders, vomiting
- **Uncommon** Hepatotoxicity, pancreatitis

**INTERACTIONS**

- **CONTRA-INDICATIONS** Congenital long QT syndrome
- **CAUTIONS** Diabetes mellitus, history or susceptibility to QT-interval prolongation
- **CAUTIONS, FURTHER INFORMATION** QT-interval prolongation—QT-interval prolongation has been observed in clinical studies, which may lead to an increased risk for ventricular tachyarrhythmias (e.g. torsade de pointes) or sudden death. Risk factors include pre-existing bradycardia, other relevant pre-existing cardiac disease or electrolyte disturbances; manufacturer advises to monitor ECG and electrolytes periodically.

**MONITORING REQUIREMENTS**

- Manufacturer advises to monitor fasting blood glucose concentration prior to initiation of treatment and periodically thereafter. Also monitor for amylase and lipase elevations periodically during treatment. Consider dose reduction, interruption or discontinuation of treatment if outside of normal range.
- In addition, manufacturer advises measure baseline liver function, then monitor every 2 weeks for the first month and monthly thereafter; consider discontinuation if severe changes in liver function occur—increased risk of hepatotoxicity. Monitor heart rate and blood pressure regularly; consider dose reduction or discontinuation if bradycardia is reported—consult product literature.

**DIRECTIONS FOR ADMINISTRATION**

Capsules should be taken on an empty stomach—no food should be eaten for 2 hours before or after dose.

**PATIENT AND CARER ADVICE**

Patients and carers should be counselled on the effects on driving and skilled tasks—increased risk of fatigue and vision disorders.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (Tas)**

- **Ceritinib for previously treated anaplastic lymphoma kinase-positive non small cell lung cancer (June 2016) NICE TA395**
- Ceritinib is recommended, within its marketing authorisation, as an option for treating advanced anaplastic lymphoma kinase-positive non-small cell lung cancer in adults previously treated with crizotinib; only if the manufacturer provides the discount agreed in the patient access scheme.

- www.nice.org.uk/guidance/ta395

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Capsule**
  - **CAUTIONARY AND ADVISORY LABELS** 25
  - **EXCIPIENTS**: May contain Gelatin, propylene glycol
  - **Zykadia** (Novartis Pharmaceuticals UK Ltd)
    - Ceritinib 150 mg Zykadia 150mg capsules | 150 capsule pack £4,923.45

Cobimetinib

**DRUG ACTION** Cobimetinib is a mitogen-activated protein kinase (MAPK) inhibitor.

**INDICATIONS AND DOSE**

Treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma (in combination with vemurafenib) (specialist use only)

- **BY MOUTH**
- Adult: 60 mg once daily for 21 days; subsequent cycles repeated after a 7-day interval, for dose adjustment due to side-effects—consult product literature

**INTERACTIONS**

- **CONCEPTION AND CONTRACEPTION** Manufacturer recommends effective contraception in women of childbearing potential during treatment and for up to 3 months after discontinuation of treatment.
- **PREGNANCY** Manufacturer advises avoid unless essential—no information available. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.
- **BREAST FEEDING** Manufacturer advises avoid—no information available.
- **HEPATIC IMPAIRMENT** Manufacturer advises avoid in moderate to severe impairment—no information available but extensively metabolised by the liver.
- **RENAL IMPAIRMENT** Manufacturer advises caution in severe impairment—no information available.

**CAUTIONS**

- Left ventricular dysfunction—risk factors for bleeding

**IMPORTANT SAFETY INFORMATION**

**RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES**

See Cytotoxic drugs p. 825.
### Crizotinib

**Drug Action** Crizotinib is a tyrosine kinase inhibitor.

### Indications and Dose

**Treatment of previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer**

First-line treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer

- **By Mouth**
  - Adult: 250 mg twice daily, consult product literature for dose adjustments based on individual patient safety and tolerability

### Important Safety Information

**Risks of Incorrect Dosing of Oral Anti-Cancer Medicines**

See Cytotoxic drugs p. 825.

**MHRA/CHM Advice (November 2015): Risk of Cardiac Failure**

Severe, sometimes fatal cases of cardiac failure have been reported in patients treated with crizotinib.

The MHRA has issued the following advice:

- Monitor all patients for signs and symptoms of heart failure (including dyspnoea, oedema, or rapid weight gain from fluid retention)
- Consider reducing the dose, or interrupting or stopping treatment if symptoms of heart failure occur

### Caution

**History of diverticulitis** (risk of gastrointestinal perforation—discontinue treatment if gastrointestinal perforation occurs) - metastases of gastrointestinal tract (risk of gastro-intestinal perforation—discontinue treatment if gastrointestinal perforation occurs) - patients with susceptibility to QT-prolongation (including bradycardia, history of cardiac disease, concomitant use of drugs that prolong QT interval, and electrolyte disturbances)—periodic renal monitoring required - risk of gastro-intestinal perforation—discontinue treatment if gastrointestinal perforation occurs - vision disorders reported—consider full ophthalmological evaluation if vision disorder worsens or persists

### Caution, Further Information

- Fatal interstitial lung disease and pneumonitis
- Fatal interstitial lung disease and pneumonitis reported (monitor patients with pulmonary symptoms, withdraw treatment if suspected, and permanently discontinue treatment if diagnosed)

### Interactions

- Appendix 1: crizotinib

### Side-Effects

**Common or very common** Bone-marrow suppression - bradycardia - cardiac failure - constipation - decreased appetite - diarrhoea - dizziness - dyspepsia - fatigue - hypophosphataemia - interstitial lung disease - nausea - neuropathy - oedema - pneumonitis - pneumonitis - QT-interval prolongation - rash - renal cyst - syncope - taste disturbance - vision disorder - vomiting

**Uncommon** Gastrointestinal perforation (fatality reported) - hepatotoxicity (including fatal hepatic failure)

**Frequency not known** Alopecia - hyperuricaemia - oral mucositis - thromboembolism - tumour lysis syndrome

### Side-Effects, Further Information

- Cardiac failure
- Consider reducing the dose, or interrupting or stopping treatment if symptoms of cardiac failure occur

### Conception and Contraception

Ensure effective contraception during and for at least 90 days after treatment

**Pregnancy** Avoid (toxicity in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

---

**Targeted therapy responsive malignancy**

**NICE Technology Appraisals (TAs)**

- **Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (October 2016)** NICE TA414 Cobimetinib in combination with vemurafenib is **not** recommended within its marketing authorisation for treating unresectable or metastatic melanoma with a BRAF V600 mutation.

  - Patients currently receiving cobimetinib may continue without change to prior funding arrangements, until they and their clinician consider it appropriate to stop.

  [www.nice.org.uk/TA414](http://www.nice.org.uk/TA414)

**Medicinal Forms**

**Tablet**

- **Cotellic** (Roche Products Ltd) ▼
  - **Cobimetinib (as Cobimetinib hemifumarate) 20 mg** Cotellic 20mg tablets  63 tablet  £427.57

---

**Side-Effects**

**Common or very common** Anaemia - basal cell carcinoma - blurred vision - chills - cutaneous squamous cell carcinoma - decreased ejection fraction - dermatitis acniform - diarrhoea - haemorrhage - hyperkeratosis - hypertension - keratoacanthoma - nausea - photosensitivity - pneumonitis - pyrexia - raised liver enzymes - rash - serious retinopathy - visual impairment - vomiting

**Uncommon** Rhabdomyolysis

**Conception and Contraception** Manufacturer advises use of two effective contraceptive methods during treatment and for at least 3 months after stopping treatment.

**Pregnancy** Manufacturer advises avoid unless essential—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**Breast Feeding** Manufacturer advises caution.

**Hepatic Impairment** Manufacturer advises avoid—no information available.

**Renal Impairment** Manufacturer advises caution in severe impairment—limited information available.

**Monitoring Requirements**

- **Creatine kinase elevation** Manufacturer advises baseline creatine kinase and creatinine levels should be measured before starting treatment, and then at monthly intervals during treatment or as clinically indicated—consult product literature if elevated.

- **Left ventricular function** Manufacturer advises ejection fraction should be evaluated before initiation of treatment, then after the first month of treatment and at least every 3 months thereafter (or as clinically indicated) until treatment discontinuation.

- **Liver function** Manufacturer advises liver function should be evaluated before initiation of treatment and monthly thereafter (or more frequently as clinically indicated).

- **Visual disturbances** Manufacturer advises assess for new or worsening visual disturbances at each visit; if symptoms of new or worsening visual disturbances are identified, an ophthalmologic examination is recommended.

**Patient and Carer Advice**

**Vomiting** Manufacturer advises if vomiting occurs after taking tablets, no additional dose should be taken on that day and the next dose should be taken at the usual time.

**Missed doses**

Manufacturer advises if a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

**Driving and skilled tasks**

Manufacturer advises patients should be counselled on the effects on driving and performance of skilled tasks—increased risk of visual disturbances.

**National Funding/Access Decisions**

**NICE Technology Appraisals (TAs)**

- **Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma** (October 2016) NICE TA414

Cobimetinib in combination with vemurafenib is **not** recommended within its marketing authorisation for treating unresectable or metastatic melanoma with a BRAF V600 mutation.

Patients currently receiving cobimetinib may continue without change to prior funding arrangements, until they and their clinician consider it appropriate to stop.

[www.nice.org.uk/TA414](http://www.nice.org.uk/TA414)

**Medicinal Forms**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Cotellic** (Roche Products Ltd) ▼
  - Cobimetinib (as Cobimetinib hemifumarate) 20 mg Cotellic 20mg tablets  63 tablet  £427.57

---

896 Targeted therapy responsive malignancy

BNF 74

Immune system and malignant disease
Monitor for signs and symptoms of treatment emergent toxicity.

ECG and electrolytes (correct if abnormal) in all patients before starting treatment, then periodically and as clinically indicated.

For signs and symptoms of treatment emergent emergent bradycardia (including syncope, dizziness and hypotension)—monitor blood pressure and heart rate regularly.

Counsel all patients on the early signs and symptoms of side-effects, consult product literature.

Driving and skilled tasks
Symptomatic bradycardia (including syncope, dizziness and hypotension), vision disorder and fatigue may affect performance of skilled tasks (e.g. driving or operating machinery).

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (September 2016)
NICE TA406
Crizotinib is recommended, within its marketing authorisation, as an option for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults, only if the manufacturer provides it with the discount agreed in the patient access scheme.

www.nice.org.uk/TA406

Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (December 2016)
NICE TA422
Crizotinib is recommended, within its marketing authorisation, as an option for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults, only if the manufacturer provides it with the discount agreed in the patient access scheme.

www.nice.org.uk/TA422

MÉDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Capsule

CAUTIONARY AND ADVISORY LABELS 25

Xalkori (Pfizer Ltd)

Crisotinib 200 mg: Xalkori 200mg capsules | 60 capsule £4,689.00 (Hospital only)
Crisotinib 250 mg: Xalkori 250mg capsules | 60 capsule £4,689.00 (Hospital only)

Dabrafenib

DRUG ACTION
Dabrafenib is a BRAF kinase inhibitor, which inhibits BRAF V600 mutation-positive melanoma cell growth.

INDICATIONS AND DOSE
Unresectable or metastatic melanoma with a BRAF V600 mutation (as monotherapy or in combination with trametinib)

BY MOUTH
Adult: 150 mg every 12 hours, for dose adjustments due to side-effects, consult product literature.

CONTRA-INDICATIONS
BRAF wild-type melanoma

CAUTIONS
Elderly (more frequent dose adjustments may be required) - prior or concurrent cancer associated with RAS mutations—risk of secondary or recurrent malignancy

INTERACTIONS → Appendix 1: dabrafenib

SIDE-EFFECTS

Common or very common
Actinic keratosis · alopecia · arthralgia · basal cell carcinoma · constipation · cough · cutaneous squamous cell carcinoma · decreased appetite · decreased left ventricular ejection fraction · diarrhea · dry skin · erythema · hand-foot syndrome · headache · hyperglycaemia · hyperkeratosis · hypophosphataemia · influenza-like symptoms · malaise · myalgia · nausea · papilloma · pruritus · pyrexia · rash · seborrhoeic keratosis · skin lesions · skin tags · vomiting

Uncommon
Nephritis · new primary melanoma · pancreatitis · panniculitis · QT-interval prolongation · renal failure · uveitis

Frequency not known
Thromboembolism

SIDE-EFFECTS, FURTHER INFORMATION

Additional side-effects reported when used in combination with trametinib include dizziness, hyperhidrosis, hyponatraemia, hypotension, leucopenia, muscle spasms, myocardiitis, neutropenia, night sweats, and thrombocytopenia.

CONCEPTION AND CONTRACEPTION
Manufacturer advises avoid unless potential benefit outweighs risk— toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

PREGNANCY
Manufacturer advises avoid unless potential benefit outweighs risk— toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

BREAST FEEDING
Manufacturer advises avoid—no information available.

HEPATIC IMPAIRMENT
Manufacturer advises caution in moderate to severe impairment.

RENAL IMPAIRMENT
Manufacturer advises caution in severe impairment—no information available.

MONITORING REQUIREMENTS

Manufacturer advises assess for cutaneous squamous cell carcinoma and new primary melanoma before treatment, monthly during treatment, and for 6 months after discontinuation or until initiation of alternative treatment; assess and monitor for non-cutaneous secondary or recurrent malignancy before, during, and for 6 months after discontinuation or until initiation of alternative treatment—consult product literature.

Monitor full blood count as clinically indicated.

Monitor for ophthalmologic reactions including uveitis, iridocyclitis and iritis.

Monitor serum creatinine.

IMPORTANT SAFETY INFORMATION
RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES
See Cytotoxic drugs p. 825.
DRUG ACTION

Dasatinib is a tyrosine kinase inhibitor.

INDICATIONS AND DOSE

BY MOUTH

Adult: 100 mg once daily, then increased if necessary up to 140 mg once daily

Accelerated and blast phase chronic myeloid leukaemia (consult product literature for details) · Acute lymphoblastic leukaemia (consult product literature for details)

BY MOUTH

Adult: 140 mg once daily, then increased if necessary up to 180 mg once daily

INDICATIONS AND DOSE

Chronic phase chronic myeloid leukaemia (consult product literature for details)

BY MOUTH

Adult: 100 mg once daily, then increased if necessary up to 140 mg once daily

CAUTIONS

Hepatitis B infection · risk of cardiac dysfunction (monitor closely) · susceptibility to QT-interval prolongation (correct hypokalaemia or hypomagnesaemia before starting treatment)

CAUTIONS, FURTHER INFORMATION

Pulmonary arterial hypertension Patients should be evaluated for signs and symptoms of underlying cardiopulmonary disease before starting treatment; echocardiography should be performed at the start of treatment in patients with symptoms of cardiac disease and considered for patients with risk factors for cardiac or pulmonary disease.

Treatment should be interrupted or the dose reduced in patients who develop dyspnoea or fatigue, while they are evaluated for signs of active infection.

If pulmonary arterial hypertension is confirmed, dasatinib should be permanently discontinued.

Patients who test positive for hepatitis B virus and in those patients who develop dyspnoea or fatigue, while they are evaluated for common aetiologies (e.g. pleural effusion, pulmonary oedema, anaemia or lung infiltration); pulmonary arterial hypertension should be considered in the absence of these conditions, and if there is no improvement following dose reduction or interruption.

Demand should be carried for hepatitis B virus should be closely monitored for signs and symptoms of active infection throughout treatment and for several months after stopping treatment; expert advice should be sought for patients who test positive for hepatitis B virus and in those with active infection.

INTERACTIONS ▶ Appendix 1: dasatinib

SIDE-EFFECTS

Common or very common Abdominal pain · acne · anorexia · arrhythmias · chest pain · CNS haemorrhage · colitis · congestive heart failure · constipation · cough · depression · dermatitis · diarrhoea · dizziness · dry skin · dyspepsia · dyspnoea · flushing · gastritis · gastro-intestinal haemorrhage · haemorrhage · headache · hypertension · influenza-like symptoms · insomnia · musculoskeletal pain · neuropathy · oedema (more common in patients over 65 years old) · palpitation · pleural effusion · pruritus · pulmonary hypertension · sweating · taste disturbance · tinnitus · uticaria · visual disturbances · weight changes

Uncommon Amnesia · asthma · cholecytis · cholestasis · drowsiness · erythema nodosum · gynaecomastia · hepatitis · hypersensitivity reactions · hypocalcaemia · hypotension · irregular menstruation · nail disorders · oesophagitis · pancreatitis · photosensitivity · pigmentation · proteinuria · rhabdomyolysis · seizures · syncope · thrombophlebitis · transient ischaemic attack · tremor · urinary frequency

Rare Cor pulmonale

Frequency not known Alopecia · bone-marrow suppression · hepatic failure (fatal cases reported) · hepatitis B reactivation · hyperuricaemia · interstitial lung disease · nausea · oral mucositis · thromboembolism · thrombosis · tumour lysis syndrome · vomiting

CONCEPTION AND CONCEPTION Effective contraception required during treatment.

PREGNANCY

Manufacturer advises avoid unless potential benefit outweighs risk—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

BREAST FEEDING

Discontinue breast-feeding.

HEPATIC IMPAIRMENT

Manufacturer advises caution in hepatic impairment.
### NATIONAL FUNDING/ACCESS DECISIONS

**NICE technology appraisals (TAs)**

- Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (CML) (December 2016) NICE TA426
  Dasatinib is recommended, within its marketing authorisation, as an option for untreated chronic phase Philadelphia-chromosome-positive CML, only if the manufacturer provides it with the discount agreed in the patient access scheme. [www.nice.org.uk/TA426](http://www.nice.org.uk/TA426)

- Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (CML) (December 2016) NICE TA425
  Dasatinib is recommended as an option for treating chronic or accelerated phase Philadelphia-chromosome-positive CML in adults, if they cannot have imatinib, or their disease is imatinib-resistant and the manufacturer provides dasatinib with the discount agreed in the patient access scheme.

  Patients whose treatment was started within the NHS before this guidance was published should have the option to continue treatment, without change to their funding arrangements, until they and their clinician consider it appropriate to stop. [www.nice.org.uk/TA425](http://www.nice.org.uk/TA425)

---

### SCOTTISH MEDICINES CONSORTIUM (SMC) DECISIONS

**The Scottish Medicines Consortium has advised** (September 2016) that dasatinib (Sprycel®) is accepted for use within NHS Scotland for the treatment of adults with chronic, accelerated or blast phase chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesilate, only if the manufacturer provides dasatinib with the discount agreed in the patient access scheme in NHS Scotland or a list price that is equivalent or lower.

The **Scottish Medicines Consortium has advised** (September 2016) that dasatinib (Sprycel®) is accepted for use within NHS Scotland for the treatment of adults with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase, only if the manufacturer provides dasatinib with the discount agreed in the patient access scheme in NHS Scotland or a list price that is equivalent or lower.

---

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

**CAUTIONARY AND ADVISORY LABELS**

<table>
<thead>
<tr>
<th>Sprycel® ( Bristol-Myers Squibb Pharmaceuticals Ltd)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dasatinib 20 mg Sprycel® 20mg tablets</td>
</tr>
<tr>
<td>Dasatinib 50 mg Sprycel® 50mg tablets</td>
</tr>
<tr>
<td>Dasatinib 80 mg Sprycel® 80mg tablets</td>
</tr>
<tr>
<td>Dasatinib 100 mg Sprycel® 100mg tablets</td>
</tr>
<tr>
<td>Dasatinib 140 mg Sprycel® 140mg tablets</td>
</tr>
</tbody>
</table>

---

### Erlotinib

**DRUG ACTION** Erlotinib is a tyrosine kinase inhibitor.

**INDICATIONS AND DOSE**

- Treatment of locally advanced or metastatic non-small cell lung cancer after failure of previous chemotherapy
- Monotherapy for maintenance treatment of locally advanced or metastatic non-small cell lung cancer with stable disease after four cycles of platinum-based chemotherapy

**BY MOUTH**

- Adult: 150 mg once daily

---

### Treatment of metastatic pancreatic cancer (in combination with gemcitabine)

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**

Manufacturer advises if concurrent use of potent inducers of CYP3A4 is unavoidable, increase dose to 300 mg daily, if well tolerated for more than 2 weeks, further increase to 450 mg daily could be considered with close monitoring.

**IMPORTANT SAFETY INFORMATION**

**EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS: SERIOUS CASES OF KERATITIS AND ULCERATIVE KERATITIS (MAY 2012)**

Keratitis and ulcerative keratitis have been reported following treatment with epidermal growth factor receptor (EGFR) inhibitors for cancer (cetuximab, erlotinib, gefitinib and panitumumab). In rare cases, this has resulted in corneal perforation and blindness. Patients undergoing treatment with EGFR inhibitors who present with acute or worsening signs and symptoms suggestive of keratitis should be referred promptly to an ophthalmology specialist. Treatment should be interrupted or discontinued if ulcerative keratitis is diagnosed.

**RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES**

See Cytotoxic drugs p. 825.

**CAUTIONS, FURTHER INFORMATION**

- Smoking: Dose adjustment may be necessary if smoking started or stopped during treatment.

**INTERACTIONS**

- Common or very common: Abdominal pain, anorexia, conjunctivitis, depression, diarrhoea, dry skin, dyspepsia, fatigue, flatulence, headache, neuropathy, pruritus, rigor.

**SIDE-EFFECTS**

- Uncommon: Eyelash changes, gastro-intestinal perforation, interstitial lung disease—discontinue if unexplained symptoms such as dyspnoea, cough or fever occur.

- Rare: Hepatic failure.

**CONCEPTION AND CONTRACEPTION**

Effective contraception required during and for at least 2 weeks after treatment.

**PREGNANCY**

Manufacturer advises avoid—toxicity in animal studies. See also *Pregnancy and reproductive function* in Cytotoxic drugs p. 825.

**BREAST FEEDING**

Manufacturer advises avoid—no information available.

**HEPATIC IMPAIRMENT**

Manufacturer advises caution in mild to moderate impairment. Avoid in severe impairment. Monitor liver function in pre-existing liver disease.

**RENAL IMPAIRMENT**

Manufacturer advises avoid in severe impairment.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer (June 2011) NICE TA227
  Erlotinib monotherapy is not recommended for maintenance treatment in patients with locally advanced...
Erlotinib is recommended as an option in patients for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer that has progressed after non-targeted chemotherapy in patients with tumours of unknown epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation status, only if all of the following criteria are met:

- the result of an EGFR-TK mutation diagnostic test is unobtainable because of an inadequate tissue sample or poor-quality DNA,
- the treating clinician considers that the tumour is very likely to be EGFR-TK mutation-positive,
- the patient’s condition responds to the first 2 cycles of treatment with erlotinib, and,
- the manufacturer provides erlotinib with the discount agreed in the patient access scheme.

Erlotinib is not recommended for treating locally advanced or metastatic non-small-cell lung cancer that has progressed after non-targeted chemotherapy in patients with tumours that are EGFR-TK mutation-negative.

Patients who are already receiving erlotinib should continue treatment until they and their clinician consider it appropriate to stop.

www.nice.org.uk/TA374

### Important Safety Information

**Risks of Incorrect Dosing of Oral Anti-cancer Medicines**

See Cytotoxic Drugs p. 825.

- **Caution** History of bleeding disorders
- **Interactions** → Appendix 1: erlotinib
- **Side-effects**
  - **Common or very common** Abdominal pain, anorexia, arthralgia, asthenia, chest pain, convulsions, dehydration, diarrhoea, dry mouth, dysphagia, electrolyte disturbance, epistaxis, eyelid oedema, fatigue, hand-foot syndrome, headache, hypercholesterolaemia, hyperglycaemia, hyperlipidaemia, hypertension, hypoglycaemia, increased susceptibility to aspergillosis, increased susceptibility to candidiasis, increased...
susceptibility to infections · increased susceptibility to pneumonia · insomnia · interstitial lung disease · irritability · nail disorders · peripheral oedema · pneumonitis · renal failure · skin disorders · taste disturbance

- **Uncommon** Agitation · agitation · congestive heart failure · flushing · impaired wound healing · rhadomyolysis
- **Frequency not known** Alopecia · bone-marrow suppression · haemorrhage · hepatitis B reactivation · hyperuricaemia · nausea · oral mucositis · thromboembolism · tumour lysis syndrome · vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**
Reduce dose or discontinue if severe side-effects occur—consult product literature.

- **CONCEPTION AND CONTRACEPTION** Effective contraception must be used during and for up to 8 weeks after treatment.
- **PREGNANCY** Manufacturer advises avoid (toxicity in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.
- **BREAST FEEDING** Manufacturer advises avoid.
- **HEPATIC IMPAIRMENT** Consult product literature.
- **MONITORING REQUIREMENTS**
  - For Votubia® preparations: manufacturer advises everolimus blood concentration monitoring is required—consult product literature.
  - For Certican®: manufacturer advises pre-dose (‘tough’) whole blood everolimus concentration should be 3–8 nanograms/mL; monitoring should be performed every 4–5 days (using chromatographic assay) after initiation or dose adjustment until 2 consecutive stable concentrations; monitor patients with hepatic impairment taking concomitant strong CYP3A4 inducers and inhibitors when switching formulation, and/or if concomitant ciclosporin dose is reduced.
  - Monitor blood-glucose concentration, serum-triglycerides and serum-cholesterol before treatment and periodically thereafter.
  - Monitor renal function before treatment and periodically thereafter.

- **DIRECTIONS FOR ADMINISTRATION**
  - **VOTUBIA® DISPERSBLE TABLETS** Manufacturer advises tablets must be dispersed in water before administration—consult product literature for details.
  - **VOTUBIA® TABLETS** Tablets may be dispersed in approximately 30 mL of water by gently stirring, immediately before drinking. After solution has been swallowed, any residue must be re-dispersed in the same volume of water and swallowed.

- **PRESCRIBING AND DISPENSING INFORMATION** Votubia® is available as both tablets and dispersible tablets. These formulations vary in their licensed indications and are not interchangeable—consult product literature for information on switching between formulations.

- **PATIENT AND CARER ADVICE**
Pneumonitis Non-infectious pneumonitis reported. Patients should be advised to seek urgent medical advice if new or worsening respiratory symptoms occur.

- **NATIONAL FUNDING/ACCESS DECISIONS**

  - **NICE technology appraisals (TAs)**
    - Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (December 2016) NICE TA421
    - Everolimus, in combination with exemestane, is recommended within its marketing authorisation for treating advanced human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor-positive breast cancer in postmenopausal women without symptomatic visceral disease that has recurred or progressed following treatment with a non-steroidal aromatase inhibitor. Everolimus is recommended only if the manufacturer provides it with the discount agreed in the patient access scheme.
    - www.nice.org.uk/TA421
  - **Everolimus for advanced renal cell carcinoma after previous treatment (February 2017) NICE TA432**
    - Everolimus is recommended within its marketing authorisation as an option for treating advanced renal cell carcinoma that has progressed during or after treatment with vascular endothelial growth factor targeted therapy. Everolimus is only recommended if the manufacturer provides it with the discount agreed in the patient access scheme.
    - www.nice.org.uk/TA432

  - **CERTICAN®**
    - **Scottish Medicines Consortium (SMC) Decisions**
      - The Scottish Medicines Consortium has advised (April 2012) that everolimus (Afinitor®) is accepted for restricted use within NHS Scotland for the treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin (pNET) in adults with progressive disease.
      - The Scottish Medicines Consortium has advised (February 2017) that everolimus (Afinitor®) is accepted for restricted use within NHS Scotland for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. The advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.

  - **AFINITOR®**
    - **NICE technology appraisals (TAs)**
      - Everolimus for preventing organ rejection in liver transplantation (July 2015) NICE TA348
      - Everolimus (Certican®) is not recommended within its marketing authorisation for preventing organ rejection in patients who have undergone a liver transplant. Patients currently receiving everolimus for this indication should have the option to continue treatment until they and their clinician consider it appropriate to stop.
      - www.nice.org.uk/TA348

- **MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

### Dispersible tablet

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>13</th>
</tr>
</thead>
<tbody>
<tr>
<td>Votubia (Novartis Pharmaceuticals UK Ltd)</td>
<td></td>
</tr>
<tr>
<td>Everolimus 2 mg</td>
<td>Votubia 2mg dispersible tablets sugar-free</td>
</tr>
<tr>
<td>Everolimus 3 mg</td>
<td>Votubia 3mg dispersible tablets sugar-free</td>
</tr>
<tr>
<td>Everolimus 5 mg</td>
<td>Votubia 5mg dispersible tablets sugar-free</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tablet</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAUTIONARY AND ADVISORY LABELS</td>
</tr>
<tr>
<td>Afinitor (Novartis Pharmaceuticals UK Ltd)</td>
</tr>
<tr>
<td>Everolimus 2.5 mg</td>
</tr>
<tr>
<td>Everolimus 5 mg</td>
</tr>
<tr>
<td>Everolimus 10 mg</td>
</tr>
<tr>
<td>Certican (Novartis Pharmaceuticals UK Ltd)</td>
</tr>
<tr>
<td>Everolimus 250 microgram</td>
</tr>
<tr>
<td>Everolimus 500 microgram</td>
</tr>
<tr>
<td>Everolimus 750 microgram</td>
</tr>
<tr>
<td>Votubia (Novartis Pharmaceuticals UK Ltd)</td>
</tr>
<tr>
<td>Everolimus 2.5 mg</td>
</tr>
<tr>
<td>Everolimus 5 mg</td>
</tr>
<tr>
<td>Everolimus 10 mg</td>
</tr>
</tbody>
</table>
**Gefitinib**

27-May-2016

**INDICATIONS AND DOSE**

Treatment of locally advanced or metastatic non-small cell lung cancer with activating mutations of epidermal growth factor receptor

- **BY MOUTH**
  - Adult: 250 mg once daily

**INDICATIONS AND DOSE**

Treatment of locally advanced or metastatic non-small cell lung cancer with activating mutations of epidermal growth factor receptor

- **BY MOUTH**
  - Adult: 250 mg once daily

**IMPORTANT SAFETY INFORMATION**

MHRA/CHM Advice: Epidermal Growth Factor Receptor (EGFR) Inhibitors: Serious Cases of Keratitis and Ulcerative Keratitis (May 2012)

Keratitis and ulcerative keratitis have been reported following treatment with epidermal growth factor receptor (EGFR) inhibitors for cancer (cefoxime, erlotinib, gefitinib and panitumumab). In rare cases, this has resulted in corneal perforation and blindness. Patients undergoing treatment with EGFR inhibitors who present with acute or worsening signs and symptoms suggestive of keratitis should be referred promptly to an ophthalmology specialist. Treatment should be interrupted or discontinued if ulcerative keratitis is diagnosed.

**RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES**

See Cytotoxic drugs p. 825.

**INTERACTIONS** → Appendix 1: gefitinib

**SIDE-EFFECTS**

- **Common or very common** Acne - anorexia - asthenia - blepharitis - conjunctivitis - diarrhea - dry eye - dry mouth - dry skin - epistaxis - haematuria - interstitial lung disease - discontinue if confirmed - nail disorder - proteinuria - pruritus - pyrexia - rash - skin reactions
- **Rare** Hepatitis - toxic epidermal necrosis
- **Frequency not known** Alopecia - bone-marrow suppression - hyperuricaemia - nausea - oral mucositis - thrombocytopenia - tumour lysis syndrome - vomiting

**CONCEPTION AND CONTRACEPTION** Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**PREGNANCY** Manufacturer advises avoid unless essential—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**BREAST FEEDING** Discontinue breast-feeding.

**HEPATIC IMPAIRMENT** Manufacturer advises caution in moderate to severe impairment due to cirrhosis.

**RENAL IMPAIRMENT** Manufacturer advises caution if creatinine clearance less than 20 mL/minute.

**MONITORING REQUIREMENTS**

- Monitor for worsening of dyspnoea, cough and fever—discontinue if interstitial lung disease confirmed.
- Monitor liver function—consider discontinuing if severe changes in liver function occur.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (July 2010) NICE TA192

Gefitinib is recommended as an option for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer if the patient tests positive for the epidermal growth receptor tyrosine kinase (EGFR-TK) mutation and the manufacturer provides gefitinib at the fixed price agreed under the patient access scheme.

www.nice.org.uk/TA192

**ERLOTINIB AND GEFITINIB FOR TREATING NON-SMALL-CELL LUNG CANCER THAT HAS PROGRESSED AFTER PRIOR CHEMOTHERAPY (DECEMBER 2015) NICE TA374**

Gefitinib is not recommended for treating locally advanced or metastatic non-small-cell lung cancer that has progressed after non-targeted chemotherapy in patients with tumours that are EGFR-TK mutation-positive.

Patients who are already receiving gefitinib should continue treatment until they and their clinician consider it appropriate to stop.

www.nice.org.uk/TA374

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (December 2015) that gefitinib (Iressa®) is accepted for restricted use within NHS Scotland for the treatment of adult patients with previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of epidermal growth factor receptor tyrosine kinase (EGFR-TK).

**MEDIICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Iressa** (AstraZeneca UK Ltd)
  - Gefitinib 250 mg
  - Iressa 250mg tablets | 30 tablet
  - **PO** £2,167.71

---

**Ibrutinib**

06-Jun-2017

**INDICATIONS AND DOSE**

Treatment of relapsed or refractory mantle cell lymphoma

- **BY MOUTH**
  - Adult: 560 mg once daily, for dose adjustments due to side effects consult product literature

Treatment of chronic lymphocytic leukaemia, in patients who have received at least one prior therapy, or as first-line treatment in patients with 17p deletion or TP53 mutation who are unsuitable for chemo-immunotherapy

- **BY MOUTH**
  - Adult: 420 mg once daily, for dose adjustments due to side effects consult product literature

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**

Manufacturer advises if concurrent use of moderate inhibitors of CYP3A4 or ciprofloxacin is unavoidable, reduce dose to 140 mg once daily.

Manufacturer advises if concurrent use of potent inhibitors of CYP3A4 is unavoidable, reduce dose to 140 mg once daily, or withhold ibrutinib for up to 7 days.

**IMPORTANT SAFETY INFORMATION**

**RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES**

See Cytotoxic drugs p. 825.

**INTERACTIONS** → Appendix 1: ibrutinib
Idelalisib

16-Nov-2016

**DRUG ACTION**

Idelalisib is a protein kinase inhibitor.

**INDICATIONS AND DOSE**

Treatment of chronic lymphocytic leukaemia in patients who have received at least one previous therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies (in combination with rituximab)

**SIDE-EFFECTS**

Common or very common
- Arthralgia, atrial fibrillation, blurred vision, bruising, constipation, dehydration, diarrhoea, diziness, dry mouth, epistaxis, haemorrhage, headache, musculoskeletal pain, peripheral oedema, petechiae, pyrexia, rash, respiratory tract infection, sepsis, sinusitis, skin infection, subdural haematoma, urinary tract infection

Uncommon
- Alopecia, bone-marrow suppression, hyperuricaemia, nausea, oral mucositis, thromboembolism, tumour lysis syndrome, vomiting

**CONCEPTION AND CONTRACEPTION**

Highly effective contraception (must include a non-hormonal method) required during and for 3 months after stopping treatment.

**PREGNANCY**

Manufacturer advises avoid—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**BREAST FEEDING**

Manufacturer advises discontinue breastfeeding—no information available.

**HEPATIC IMPAIRMENT**

Reduce dose to 280 mg daily in mild impairment and reduce dose to 140 mg daily in moderate impairment—monitor for toxicity and adjust dose if necessary (consult product literature). Avoid in severe impairment.

**RENAI IMPAIRMENT**

Use in severe impairment only if benefit outweighs risk and with close monitoring for toxicity. Maintain hydration and monitor serum creatinine periodically in mild to moderate renal impairment.

**MONITORING REQUIREMENTS**

- Monitor full blood count once a month.
- Monitor for atrial fibrillation (increased risk in cardiac risk factors, acute infections and history of atrial fibrillation), monitor all patients periodically and complete ECG if arrhythmic symptoms or dyspnoea develop—consult product literature for treatment options.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (January 2017) NICE TA429

Ibrutinib is recommended within its marketing authorisation as an option for treating chronic lymphocytic leukaemia in adults who have had at least one prior therapy or who have a 17p deletion or TP53 mutation, and in whom chemo-immunotherapy is unsuitable, only when the manufacturer provides ibrutinib with the discount agreed in the patient access scheme.

www.nice.org.uk/TA429

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (April 2017) that ibritunib (Imbruvica®) is accepted for restricted use within NHS Scotland for the treatment of relapsed or refractory chronic lymphocytic leukaemia in adults who have received at least one prior therapy and for whom fludarabine-based regimens are inappropriate. This advice is contingent upon the continuing availability of the Patient Access Scheme in NHS Scotland or a list price that is equivalent or lower.

**CAUTIONS**

Active hepatitis, diarrhoea—symptomatic management recommended (consult product literature) · pneumonitis— withhold treatment (consult product literature)

**INTERACTIONS**

- Appendix 1: idelalisib

**SIDE-EFFECTS**

Alopecia, bone-marrow suppression, diarrhoea, hyperuricaemia, nausea, oral mucositis, neutropenia, oral mucositis, pneumonitis, pyrexia, rash, thromboembolism, tumour lysis syndrome, vomiting

**CONCEPTION AND CONTRACEPTION**

Highly effective contraception (in addition to barrier method) required during and for one month after treatment.

**PREGNANCY**

Manufacturer advises avoid (toxicity in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**BREAST FEEDING**

Manufacturer advises avoid—no information available.

**HEPATIC IMPAIRMENT**

Manufacturer advises caution in hepatic impairment.

**MONITORING REQUIREMENTS**

- Manufacturer advises monitor liver function—consult product literature.

- Manufacturer advises monitor for signs and symptoms of infection, including cytomegalovirus infection and respiratory infections; new symptoms should be reported promptly. Neutrophil count should be monitored in all patients every 2 weeks for the first 6 months of treatment; patients with neutrophil count <1000 per mm³ should be monitored weekly.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Ibrutinib for treating chronic lymphocytic leukaemia (October 2015) NICE TA359

Ibrutinib, in combination with rituximab, is recommended as an option for treatment in adults:

- who have untreated chronic lymphocytic leukaemia
- who have chronic lymphocytic leukaemia when the disease has been treated but has relapsed within 24 months and

**IMPOR TANT SAFETY INFORMATION**

RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES

See Cytotoxic drugs p. 825.

MHRA/CHM ADVICE: IDELALISIB (ZYDELIG®): UPDATED INDICATIONS AND ADVICE ON MINIMISING THE RISK OF INFECTION (SEPTEMBER 2016)

In light of a recent safety review the indications for idelalisib have been updated. Manufacturer recommendations regarding monitoring for infection and prophylaxis of Pneumocystis jiroveci pneumonia have also been updated. Patients should be advised on the risk of serious or fatal infections during treatment, and idelalisib should not be initiated in patients with any evidence of infection.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

CAUTIONARY AND ADVISORY LABELS 25

- **Imbruvica** (Janssen-Cilag Ltd)

  * Ibrutinib 140 mg Imbruvica 140mg capsules | 90 capsule | £5,599.00 | 120 capsule | £6,132.00

---

**BNF 74**

Targeted therapy responsive malignancy 903

---

**Immune system and malignant disease**

---

downloaded from www.medicalbr.com
Targeted therapy responsive malignancy

Imatinib

- **DRUG ACTION** Imatinib is a tyrosine kinase inhibitor.

### MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Zydelig** (Gilead Sciences International Ltd) ▼
  - Imatinib 100 mg Zydelig 100mg tablets | 60 tablet £3,114.75 (Hospital only)
  - Imatinib 150 mg Zydelig 150mg tablets | 60 tablet £3,114.75 (Hospital only)

### INDICATIONS AND DOSE

- **Treatment of chronic myeloid leukaemia in chronic phase after failure with interferon alfa**
  - **BY MOUTH**
  - Adult: 400 mg once daily, increased if necessary up to 800 mg daily in 2 divided doses

- **Treatment of chronic myeloid leukaemia in accelerated phase, or in blast crisis**
  - **BY MOUTH**
  - Adult: 600 mg once daily, then increased if necessary up to 800 mg daily in 2 divided doses

- **Treatment of newly diagnosed acute lymphoblastic leukaemia (in combination with other chemotherapy)**
  - **BY MOUTH**
  - Adult: 600 mg once daily

- **Treatment of c-kit (CD117)-positive unresectable or metastatic malignant gastro-intestinal stromal tumours (GIST)**
  - **BY MOUTH**
  - Adult: 400 mg once daily

### SIDE-EFFECTS

- **Common** Abdominal pain, appetite changes, arthralgia, ascites, conjunctivitis, constipation, cough, cramps, diarrhoea, dizziness, dry eyes, dry mouth, dry skin, dyspnoea, epistaxis, fatigue, flatulence, flushing, gastro-oesophageal reflux, haemorrhage, headache, hypoaesthesia, increased lacrimation, influenza-like symptoms, insomnia, oedema, paraesthesia, photosensitivity, pleural effusion, pruritus, pulmonary oedema, rash, sweating, taste disturbance, visual disturbances, weight changes

- **Uncommon** Acute respiratory failure, anxiety, cold extremities, cough, depression, drowsiness, dysphagia, electrolyte disturbances, gastric ulceration, gout, gynaecomastia, haemoptysis, heart failure, hepatic dysfunction, hepatitis, hypertension, hypotension, impaired memory, irregular menstruation, menorrhagia, migraine, palpitation, pancreatitis, peripheral neuropathy, renal failure, sexual dysfunction, skin hyperpigmentation, syncope, tachycardia, tinnitus, tremor, urinary frequency, vertigo

- **Rare** Angina, angiodema, arthralgia, aseptic necrosis of bone, atrial fibrillation, cataract, confusion, convulsions, exfoliative dermatitis, gastro-intestinal perforation, glaucoma, haemolytic anaemia, hepatic failure, hepatic failure (fatal cases reported), hepatic necrosis, increased intracranial pressure, inflammatory bowel disease, intestinal obstruction, myocardial infarction, myopathy, pulmonary fibrosis, pulmonary hypertension, rhabdomyolysis, Stevens-Johnson syndrome

- **Frequency not known** Alopecia, bone marrow suppression, drug rash with eosinophilia and systemic symptoms (DRESS), growth retardation in children, hepatitis B reactivation, hyperuricaemia, menorrhagia, menorrhagia, myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor receptor gene rearrangement

### IMPORTANT SAFETY INFORMATION

- **RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES** See Cytotoxic drugs p. 825

- **MHRA/CHM ADVICE (MAY 2016): RISK OF HEPATITIS B VIRUS REACTIVATION WITH BCR-ABL TYROSINE KINASE INHIBITORS** An EU wide review has concluded that imatinib can cause hepatitis B reactivation; the MHRA recommends establishing hepatitis B virus status in all patients before initiation of treatment.

### CAUTIONS

- Cardiac disease
- Hepatitis B infection
- History of renal failure
- Risk factors for heart failure

### CONCEPTION AND CONTRACEPTION

Effective contraception required during treatment.

---

**Treatment of unresectable dermatofibrosarcoma protuberans | Recurrent or metastatic dermatofibrosarcoma protuberans, in patients who cannot have surgery**

- **BY MOUTH**

- Adult: 800 mg daily in 2 divided doses

**Treatment of advanced hypereosinophilic syndrome and chronic eosinophilic leukaemia**

- **BY MOUTH**

- Adult: 100–400 mg once daily

---

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (March 2015) that idelalisib (Zydelig<sup>®</sup>) is accepted for restricted use within NHS Scotland, in combination with rituximab, for the treatment of relapsed chronic lymphocytic leukaemia in patients who are unsuitable for chemotherapy and treatment naïve patients with 17p deletion or TP53 mutation who are unsuitable for chemo-immunotherapy, only whilst idelalisib is available at the price agreed in the patient access scheme.

**All Wales Medicines Strategy Group (AWMSG) Decisions**

The All Wales Medicines Strategy Group has advised (April 2017) that idelalisib (Zydelig<sup>®</sup>) is recommended as an option for use within NHS Wales as monotherapy for the treatment of patients with follicular lymphoma, that is refractory to two prior lines of treatment. The recommendation applies only if the approved Wales Patient Access Scheme (WPAS) is used or where the list price is equivalent or lower.
Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (October 2004) NICE TA86

Imatinib 400 mg daily is recommended as first-line management of KIT (CD117)-positive unresectable or metastatic, or both, gastrointestinal stromal tumours. Continued therapy is recommended only if a response to initial treatment [as defined by Southwest Oncology Group criteria available at www.nice.org.uk/TA86] is achieved within 12 weeks. Patients who have responded should be assessed at 12-week intervals. Discontinue if tumour ceases to respond.

www.nice.org.uk/TA86

Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (November 2010) NICE TA209

Imatinib 600 mg daily or 800 mg daily is not recommended for unresectable or metastatic, or both, gastrointestinal stromal tumours whose disease has progressed after treatment with imatinib 400 mg daily.

www.nice.org.uk/TA209

Dasatinib, nilotinib and imatinib for treatment until they and their NHS clinician consider it appropriate to stop.

www.nice.org.uk/TA425

Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (CML) (December 2016) NICE TA425

High-dose imatinib (600 mg in the chronic phase or 800 mg in the accelerated and blast-crisis phases) is not recommended for treating Philadelphia-chromosome-positive CML in adults whose disease is imatinib-resistant.

Patients whose treatment was started within the NHS before this guidance was published should have the option to continue treatment, without change to their funding arrangements, until they and their clinician consider it appropriate to stop.

Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (CML) (December 2016) NICE TA426

Imatinib is recommended as an option for untreated chronic phase Philadelphia-chromosome-positive CML in adults.

www.nice.org.uk/TA426

Lapatinib

Lapatinib is a tyrosine kinase inhibitor.

INDICATIONS AND DOSE

Treatment of advanced or metastatic breast cancer in patients with tumours that overexpress human epidermal growth factor receptor-2 (HER2) with hormone-receptor-negative disease who have had previous treatment with trastuzumab in combination with chemotherapy (in combination with trastuzumab)

BY MOUTH

Adult: 1 g once daily
PREGNANCY

NATIONAL FUNDING/ACCESS DECISIONS

Treatment of advanced or metastatic breast cancer in patients with tumours that overexpress human epidermal growth factor receptor-2 (HER2), for patients who have had previous treatment with an anthracycline, a taxane, and trastuzumab (in combination with capecitabine)

BY MOUTH
Adult: 1.25 g once daily

Treatment of advanced or metastatic breast cancer with tumours that overexpress human epidermal growth factor receptor-2 (HER2), for postmenopausal women with hormone-receptor-positive disease (in combination with an aromatase inhibitor)

BY MOUTH
Adult: 1.5 g once daily

CAUTIONS
Diarrhoea—withhold treatment if severe (consult product literature) • low gastric pH (reduced absorption) • susceptibility to QT-interval prolongation (including electrolyte disturbances)

INTERACTIONS
Appendix 1: lapatinib

SIDE-EFFECTS

Common or very common
Anorexia • cardiac failure (fatal cases reported) • decreased left ventricular ejection fraction • diarrhoea (treat promptly) • hepatotoxicity (discontinue permanently if severe) • hyperbilirubinaemia • malaise • nail disorders • rash

Uncommon
Interstitial lung disease

Frequency not known
Alopecia • bone-marrow suppression • hyperuricaemia • nausea • oral mucositis • respiratory failure (including fatal cases) • thromboembolism • tumour lysis syndrome • vomiting

CONCEPTION AND CONTRACEPTION
Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 825.

PREGNANCY
Avoid unless potential benefit outweighs risk— toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

BREAST FEEDING
Discontinue breast-feeding.

HEPATIC IMPAIRMENT
Caution in moderate to severe impairment—metabolism reduced.

RENAL IMPAIRMENT
Caution in severe impairment—no information available.

MONITORING REQUIREMENTS
Monitor left ventricular function.
Monitor for pulmonary toxicity.
Monitor liver function before treatment and at monthly intervals.

DIRECTIONS FOR ADMINISTRATION
Always take at the same time in relation to food: either one hour before or one hour after food.

PATIENT AND CARER ADVICE
Counselling advised (administration). Patients should be advised to report any unexpected changes in bowel habit.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (June 2012) NICE TA257
Lapatinib or trastuzumab in combination with an aromatase inhibitor is not recommended for first-line treatment in postmenopausal women of metastatic hormone-receptor-positive breast cancer that overexpresses human epidermal growth factor receptor 2 (HER2).

Postmenopausal women currently receiving lapatinib or trastuzumab in combination with an aromatase inhibitor for this indication should have the option to continue treatment until they and their clinician consider it appropriate to stop.

www.nice.org.uk/TA257

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet

Tyverb (Novartis Pharmaceuticals UK Ltd)
Lapatinib difosylate monohydrate 250 mg Tyverb 250mg tablets
64 tablet PCD £35.15 | 100 tablet PCD £54.65

Lenvatinib

DRUG ACTION
Lenvatinib is a multireceptor tyrosine kinase inhibitor.

INDICATIONS AND DOSE

KISPLYX®
Advanced renal cell carcinoma following one prior vascular endothelial growth factor-targeted therapy (in combination with everolimus) (specialist use only)

BY MOUTH
Adult: 18 mg once daily, dose should be taken at the same time every day, for dose adjustment due to side-effects—consult product literature

LENVIMA®
Progressive, locally advanced, or metastatic, differentiated thyroid carcinoma that is refractory to radioactive iodine (specialist use only)

BY MOUTH
Adult: 24 mg once daily, dose should be taken at the same time every day, for dose adjustments due to side-effects—consult product literature

CONTRA-INDICATIONS
Fistulae

CAUTIONS
Arterial thromboembolism within the previous 6 months • elderly (75 years and over)—reduced tolerability • hypertension—blood pressure should be well-controlled prior to treatment

SIDE-EFFECTS

Common or very common
Abdominal pain • alopecia • anal fistula • arthralgia • asthenia • back pain • cardiac failure • cerebrovascular accident • constipation • decreased appetite • dehydration • diarrhoea • dizziness • dry mouth • dysgeusia • dyspepsia • dysphonia • electrolyte disturbances • fatigue • flatulence • haemorrhage (including fatal cases of intracranial haemorrhage) • hand-foot syndrome • headache • hepatotoxicity • hypercholesterolaemia • hyperkeratosis • hypertension • hypotension • hypothyroidism • insomnia • lymphopenia • malaise • muscularkeletal pain • myalgia • myocardial infarction • nausea • oral inflammation and pain • pain in extremity • peripheral oedema • prolonged QT interval • proteinuria • pulmonary embolism • rash • reduced ejection fraction • renal failure • renal impairment • thrombocytopenia • urinary tract infection • vomiting • weight loss

Uncommon
Hepatitis • hepatocellular damage • hand-foot syndrome • splenic infarction • transient ischaemic attack

Frequency not known
Gastro-intestinal perforation • non-gastrointestinal fistulae

IMPORTANT SAFETY INFORMATION
RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES
See Cytotoxic drugs p. 825.

IMPORTANT SAFETY INFORMATION
RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES
See Cytotoxic drugs p. 825.

906 Targeted therapy responsive malignancy
BNF 74

Immune system and malignant disease
SIDE-EFFECTS, FURTHER INFORMATION
For further information on side-effects in special populations—consult product literature.

- Renal impairment and failure:
  Manufacturer advises gastrointestinal toxicity should be actively managed—dehydration and/or hypovolaemia caused by gastrointestinal toxicity are identified as primary risk factors for renal impairment or failure.

- CONCEPTION AND CONTRACEPTION:
  Manufacturer advises women of child-bearing potential should use highly effective contraception during treatment and for 1 month after the last dose, an additional barrier method of contraception should be used in women using oral hormonal contraceptives. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

- PREGNANCY:
  Manufacturer advises avoid unless potential benefit outweighs risk—teratogenic in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

- BREAST FEEDING:
  Manufacturer advises avoid—present in milk in animal studies.

- HEPATIC IMPAIRMENT:
  Kisplyx®
  Manufacturer advises reduce dose to 10 mg once daily in severe impairment; further dose adjustments may be necessary based on individual tolerability—consult product literature. Manufacturer advises use only if potential benefit outweighs risk in severe impairment.

  Lenvima®
  Manufacturer advises reduce dose to 14 mg once daily in severe impairment; further dose adjustments may be necessary based on tolerability—consult product literature.

- RENAL IMPAIRMENT:
  Kisplyx®
  Manufacturer advises reduce dose to 10 mg once daily in severe impairment; further dose adjustments may be necessary based on individual tolerability—consult product literature. Manufacturer advises avoid in end-stage renal disease.

  Lenvima®
  Manufacturer advises reduce dose to 14 mg once daily in severe impairment; further dose adjustments may be necessary based on tolerability—consult product literature. Manufacturer advises avoid in end-stage renal disease.

- MONITORING REQUIREMENTS:
  Manufacturer advises monitor blood pressure after 1 week of treatment, then every 2 weeks for the first 2 months, and then monthly thereafter; monitor for signs and symptoms of cardiac decompensation (adjust dose as necessary—consult product literature).

  Manufacturer advises monitor liver function before treatment, then every 2 weeks for the first 2 months, and then monthly thereafter; monitor urine protein regularly.

  Manufacturer advises monitor ECG and electrolytes before and periodically during treatment (calcium levels should be monitored at least monthly), correct electrolyte abnormalities prior to treatment; monitor thyroid function before and regularly during treatment.

- DIRECTIONS FOR ADMINISTRATION:
  Kisplyx®
  Manufacturer advises capsules should be swallowed whole, or alternatively, capsules may be dissolved in a tablespoon of water or apple juice (do not break or crush capsules), allow to sit for at least 10 minutes for capsule shell to dissolve.

- PATIENT AND CARER ADVICE:
  Missed doses:
  Manufacturer advises if a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

Driving and skilled tasks:
Manufacturer advises patients and carers should be counselled on the effects on driving and performance of skilled tasks—increased risk of fatigue and dizziness.

- NATIONAL FUNDING/ACCESS DECISIONS:
  Lenvima®

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium (SMC) has advised (October 2016) that lenvatinib (Lenvima®) is accepted for use within NHS Scotland for treatment of adults with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine. This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.

- MEDICINAL FORMS:
  There can be variation in the licensing of different medicines containing the same drug.

Capsule:
CAUTIONARY AND ADVISORY LABELS—25

- Kisplyx (Eisai Ltd)▼
  Lenvatinib (as Lenvatinib mesilate) 4 mg Kisplyx 4 mg capsules | 30 capsule POM £1,437.00 (Hospital only)
  Lenvatinib (as Lenvatinib mesilate) 10 mg Kisplyx 10 mg capsules | 30 capsule POM £1,437.00 (Hospital only)
  Lenvima (Eisai Ltd)▼
  Lenvatinib (as Lenvatinib mesilate) 4 mg Lenvima 4 mg capsules | 30 capsule POM £1,437.00
  Lenvatinib (as Lenvatinib mesilate) 10 mg Lenvima 10 mg capsules | 30 capsule POM £1,437.00

Independently of the NHS Scotland list price:

Scottish Medicines Consortium (SMC) Decisions—25

- Kisplyx (Eisai Ltd)▼
  Lenvatinib (as Lenvatinib mesilate) 4 mg Kisplyx 4 mg capsules | 30 capsule POM £1,437.00 (Hospital only)
  Lenvatinib (as Lenvatinib mesilate) 10 mg Kisplyx 10 mg capsules | 30 capsule POM £1,437.00 (Hospital only)
  Lenvima (Eisai Ltd)▼
  Lenvatinib (as Lenvatinib mesilate) 4 mg Lenvima 4 mg capsules | 30 capsule POM £1,437.00
  Lenvatinib (as Lenvatinib mesilate) 10 mg Lenvima 10 mg capsules | 30 capsule POM £1,437.00

- Important Safety Information:
  Risks of incorrect dosing of oral anti-cancer medicines
  See Cytotoxic drugs p. 825.

- MHRA/CHM Advice (May 2016): Risk of Hepatitis B Virus Reactivation with Tyrosine Kinase Inhibitors
  An EU wide review has concluded that nilotinib can cause hepatitis B virus reactivation; the MHRA recommends establishing hepatitis B virus status in all patients before initiation of treatment.

- CAUTIONS:
  Hepatitis B infection—history of pancreatitis—susceptibility to QT-interval prolongation (including electrolyte disturbances)

- CAUTIONS, FURTHER INFORMATION:
  - Hepatitis B infection
  The MHRA advises that patients who are carriers of hepatitis B virus should be closely monitored for signs and symptoms of active infection throughout treatment and for several months after stopping treatment; expert advice should be sought for patients who test positive for hepatitis B virus and in those with active infection.

- INTERACTIONS:
  → Appendix 1: nilotinib

Nilotinib
27-Jul-2016

- Drug Action:
  Nilotinib is a tyrosine kinase inhibitor.

- Indications and Dose:
  Treatment of newly diagnosed chronic myeloid leukaemia in the chronic phase
  ▶ By mouth
  Adult: 300 mg twice daily

  Treatment of chronic and accelerated phase chronic myeloid leukaemia in patients who have resistance to or intolerance of previous therapy, including imatinib
  ▶ By mouth
  Adult: 400 mg twice daily

- Appendix 1: nilotinib
908 Targeted therapy responsive malignancy

- **SIDE-EFFECTS**
  - Common or very common: Abdominal pain, anorexia, arthralgia, asthenia, blood glucose changes, bone pain, constipation, cough, diarrhoea, dizziness, dry skin, dyspepsia, dysphonia, erythema, fatigue, flatulence, flushing, headache, hyperhidrosis, hyperkalaemia, hypertension, hypomagnesaemia, insomnia, muscle spasm, oedema, palpitation, parasthesia, pruritus, QT-interval prolongation, rash, urticaria, vertigo, weight changes
  - Uncommon: Anxiety, arhythmias, bradycardia, breast pain, cardiac failure, cardiac murmur, cardiomyoalgia, chest pain, conjunctivitis, coronary artery disease, decreased visual acuity, dehydration, depression, dry eyes, dry mouth, dysuria, ecchymosis, epistaxis, erectile dysfunction, gynaecomastia, haematoma, haemorrhage, hepatitis, hyperaesthesia, hypertensive crisis, hyperthyroidism, hypoaesthesia, hypocalcaemia, hypokalaemia, hyponatraemia, hypophysphaetemaia, influenza-like symptoms, interstitial lung disease, melaena, migraine, pancreatitis, pericardial effusion, pleural effusion, tremor, urinary frequency
  - Frequency not known: Alopecia, bone-marrow suppression, hepatic failure (fatal cases reported), hepatitis B reactivation, hyperuricaemia, nausea, oral mucositis, thromboembolism, tumour lysis syndrome, vomiting

- **CONCEPTION AND CONTRACEPTION**
  - Effective contraception required during treatment.

- **PREGNANCY**
  - Manufacturer advises avoid unless potential benefit outweighs risk—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

- **BREAST FEEDING**
  - Manufacturer advises avoid—present in milk in animal studies.

- **HEPATIC IMPAIRMENT**
  - Manufacturer advises caution.

- **NATIONAL FUNDING/ACCESS DECISIONS**

  - **NICE technology appraisals (TAs)**
    - Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (CML) (December 2016) NICE TA426
    - Nilotinib is recommended, within its marketing authorisation, as an option for untreated chronic phase Philadelphia-chromosome-positive CML, only if the manufacturer provides it with the discount agreed in the patient access scheme.
      - www.nice.org.uk/TA426
    - Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (CML) (December 2016) NICE TA425
      - Nilotinib is recommended as an option for treating chronic or accelerated phase Philadelphia-chromosome-positive CML in adults, if they cannot have imatinib, or their disease is imatinib-resistant and the manufacturer provides nilotinib with the discount agreed in the patient access scheme.
      - www.nice.org.uk/TA425

  - **Scottish Medicines Consortium (SMC) Decisions**
    - The Scottish Medicines Consortium has advised (February 2008) that nilotinib (Tasigna®) is accepted for restricted use within NHS Scotland for the treatment of chronic-phase chronic myeloid leukaemia in adults resistant to or intolerant of at least one previous therapy, including imatinib, and (July 2011) for the treatment of adults with newly diagnosed chronic myeloid leukaemia in the chronic phase.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  - **Capsule**
    - CAUTIONARY AND ADVISORY LABELS 23, 25, 27
    - Tasigna (Novartis Pharmaceuticals UK Ltd)
      - 150 mg Tasigna 150mg capsules | 112 capsule (P) £2,432.85

---

### Osimertinib

- **DRUG ACTION**
  - Osimertinib is a tyrosine kinase inhibitor.

- **INDICATIONS AND DOSE**
  - Locally advanced or metastatic epidermal growth factor receptor T790M mutation-positive non-small-cell lung cancer (specialist use only)
    - **BY MOUTH**
      - Adult: 80 mg once daily, for dose adjustment due to side-effects—consult product literature

- **IMPORTANT SAFETY INFORMATION**
  - **RISKS OF INCORRECT DOING OF ORAL ANTI-CANCER MEDICINES**
    - See Cytotoxic drugs p. 825.

- **CONTRA-INDICATIONS**
  - Congenital long QT syndrome

- **CAUTIONS**
  - Elderly (more frequent dose adjustments may be required) — history of interstitial lung disease — radiation pneumonitis requiring steroid treatment — risk factors for QTc interval prolongation

- **INTERACTIONS**
  - Appendix 1: osimertinib

- **SIDE-EFFECTS**
  - Common or very common: Diarrhoea, dry skin disorders — interstitial lung disease (including pneumonitis) — nail disorders — pruritus — rash — stomatitis
  - Uncommon: QTc interval prolongation

- **CONCEPTION AND CONTRACEPTION**
  - Manufacturer advises use of effective, non-hormonal, contraception during and for 2 months after treatment in women, and 4 months after treatment in men.

- **PREGNANCY**
  - Manufacturer advises avoid unless essential—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

- **BREAST FEEDING**
  - Manufacturer advises avoid—may be present in milk based on animal studies.

- **HEPATIC IMPAIRMENT**
  - Manufacturer advises caution in mild impairment. Avoid in moderate and severe impairment—limited information available.

- **RENAL IMPAIRMENT**
  - Manufacturer advises caution in severe and end-stage impairment—limited information available.

- **MONITORING REQUIREMENTS**
  - Manufacturer advises monitor ECG and electrolytes periodically in patients with risk factors for QTc interval prolongation; dose adjustment is advised if QTc interval is more than 500 milliseconds on at least 2 separate ECGs—consult product literature.

- **DIRECTIONS FOR ADMINISTRATION**
  - Manufacturer advises tablet may be dispersed in 50 mL of non-carbonated water, by stirring until dispersed and swallowed immediately (do not crush). The residue must then be re-dispersed in an additional half a glass of water and immediately swallowed. Manufacturer advises if administration via a nasogastric tube is required, the tablet may be dispersed in 15 mL of non-carbonated water, by stirring until dispersed and the residue re-dispersed in an additional 15 mL of water (do not crush). The total 30 mL of liquid should then be administered as per the nasogastric tube manufacturer’s instructions with appropriate water flushes; the solution should be administered within 30 minutes of adding the tablets to water.

- **PATIENT AND CARER ADVICE**
  - Missed doses
    - Manufacturer advises if a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

---

**Osimertinib (as Osimertinib hydrochloride monohydrate)**

- 200 mg Tasigna 200mg capsules | 112 capsule (P) £2,432.85
NATIONAL FUNDING/ACCESS DECISIONS

Osimertinib for locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (October 2016) NICE TA416

Osimertinib is recommended as an option, for use within the Cancer Drugs Fund, for treating locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer in adults whose disease has progressed only:

- after first-line treatment with an EGFR tyrosine kinase inhibitor, and
- if the conditions in the managed access agreement for osimertinib are followed.

Patients whose treatment was started within the NHS before this guidance was published should have the option to continue treatment, without change to their funding arrangements, until they and their clinician consider it appropriate to stop.

www.nice.org.uk/TA416

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium (Tagrisso®) is accepted for restricted use within NHS Scotland for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer, only in patients who have received previous treatment with an EGFR tyrosine kinase inhibitor. This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet

- Tagrisso (AstraZeneca UK Ltd) 40 mg Tagrisso 40mg tablets | 30 tablet (Pom) £5,770.00
- Osimertinib (as Osimertinib mesylate) 80 mg Osimertinib 80mg tablets | 30 tablet (Pom) £5,770.00

Palbociclib

DRUG ACTION

Palbociclib is a highly selective inhibitor of cyclin–dependent kinases 4 and 6, which leads to disruption of cancer cell proliferation.

INDICATIONS AND DOSE

Locally advanced or metastatic breast cancer in patients with hormone-receptor positive, HER2-negative tumours, in combination with an aromatase inhibitor or fulvestrant (specialist use only)

- BY MOUTH
- Adult: 125 mg once daily for 21 consecutive days of repeated 28 day cycles, for dose adjustments due to side-effects—consult product literature

DOSE ADJUSTMENTS DUE TO INTERACTIONS

If concomitant use with potent CYP3A4 inhibitors (such as clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir boosted with ritonavir, posaconazole, saquinavir, telaprevir, or voriconazole) is unavoidable, reduce palbociclib dose to 75 mg once daily. If the CYP3A4 inhibitor is stopped, increase the palbociclib dose (after 3–5 half lives of the inhibitor) to the dose used before starting the CYP3A4 inhibitor.

IMPORTANT SAFETY INFORMATION

RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES

See Cytotoxic drugs p. 825.

INTERACTIONS

Appendix 1: palbociclib

SIDE-EFFECTS

- Common or very common Alopecia · anaemia · asthenia · blurred vision · decreased appetite · diarrhea · dry eye · dry skin · dysgeusia · epistaxis · fatigue · Increased lacrimation · infections · leukopenia · nausea · neutropenia · pyrexia · rash · stomatitis · thrombocytopenia · vomiting

SIDE-EFFECTS, FURTHER INFORMATION

Side-effects are reported when used in combination with letrozole or fulvestrant.

CONCEPTION AND CONTRACEPTION

Manufacturer advises effective contraception in women of childbearing potential during treatment and for at least 3 weeks after completing treatment. Male patients should use effective contraception during treatment and for at least 14 weeks after completing treatment if their partner is of childbearing potential. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

PREGNANCY

Manufacturer advises avoid—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

BREAST FEEDING

Manufacturer advises avoid—no information available.

HEPATIC IMPAIRMENT

Manufacturer advises caution in moderate-to-severe impairment—no information available.

RENAL IMPAIRMENT

Manufacturer advises caution in severe impairment—no information available.

MONITORING REQUIREMENTS

Manufacturer advises monitor full blood count prior to starting therapy, at the start of each cycle, on day 14 of the first 2 cycles and as clinically indicated.

PATIENT AND CARER ADVICE

Missed doses

Manufacturer advises to take palbociclib at the same time each day; if a dose is missed, the missed dose should not be taken and the next dose should be taken at the usual time.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Capsule

CAUTIONARY AND ADVISORY LABELS 1, 21, 25

Ibrance (Pfizer Ltd)

- Palbociclib 75 mg Ibrance 75mg capsules | 21 capsule (Pom) £2,950.00 (Hospital only)
- Palbociclib 100 mg Ibrance 100mg capsules | 21 capsule (Pom) £2,950.00 (Hospital only)
- Palbociclib 125 mg Ibrance 125mg capsules | 21 capsule (Pom) £2,950.00 (Hospital only)

Pazopanib

DRUG ACTION

Pazopanib is a tyrosine kinase inhibitor.

INDICATIONS AND DOSE

First-line treatment of advanced renal cell carcinoma

Treatment of advanced renal cell carcinoma in patients who have had previous treatment with cytokine therapy

- BY MOUTH
- Adult: 800 mg daily, adjust dose in steps of 200 mg according to tolerability; maximum 800 mg per day

Treatment of selective subtypes of advanced soft-tissue sarcoma

- BY MOUTH
- Adult: (consult product literature) continued

downloaded from www.medicalbr.com
DOSE ADJUSTMENTS DUE TO INTERACTIONS
Manufacturer advises if concurrent use of potent inhibitors of CYP3A4 is unavoidable, reduce dose to 400 mg daily.

IMPORTANT SAFETY INFORMATION
RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES
See Cytotoxic drugs p. 825.

CONTRA-INDICATIONS
Cerebral haemorrhage • clinically significant gastro-intestinal haemorrhage • haemoptysis in the past 6 months

CAUTIONS
Cardiac disease • increased risk of gastro-intestinal fistulas • increased risk of gastro-intestinal perforation • increased risk of haemorrhage • increased risk of thrombosis microangiopathy—permanently discontinue if symptoms develop • ischaemic stroke • myocardial infarction • risk of thrombotic events • susceptibility to QT-interval prolongation (including electrolyte disturbances) • transient ischaemic attack

CAUTIONS, FURTHER INFORMATION
Elective surgery: Discontinue treatment 7 days before elective surgery and restart only if adequate wound healing.

SIDE-EFFECTS
Common or very common Abdominal distension • abdominal pain • anorexia • blood disorders • blurred vision • chest pain • cough • dehydration • diarrhoea • dizziness • dry mouth • dry skin • dyspepsia • dyspnoea • epistaxis • flatulence • flushing • hair discoloration • headache • hepatic dysfunction • hiccups • hyperalbuminaemia • hyperbilirubinaemia • hypertension • hypothyroidism • increased amylase • insomnja • malaise • muscle spasm • myalgia • nail disorders • oedema • paraesthesia • pneumothorax • proteinuria (discontinue if grade 4) • skin discoloration • skin reactions • sweating • taste disturbance • thrombocytopenia • venous thromboembolic events • voice changes • weight loss

Uncommon Arthralgia • bradycardia • cardiac dysfunction • fistula • gastro-intestinal perforation • haemorrhage • hepatic failure • hypertensive crisis • hypomagnesaemia • menstrual disturbances • myocardial infarction • myocardial ischaemia • oropharyngeal pain • pancreatitis • peripheral neuropathy • peritonitis • photosensitivity reactions • pulmonary embolism • QT-interval prolongation • stroke • transient ischaemic attack

Rare Thrombotic microangiopathy

Frequency not known Alopecia • bone-marrow suppression • hyperuricaemia • nausea • oral mucositis • thromboembolism • tumour lysis syndrome • vomiting

CONCEPTION AND CONTRACEPTION
Effective contraception advised during treatment.

PREGNANCY
Avoid unless potential benefit outweighs risk—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

BREAST FEEDING
Discontinue breast-feeding.

HEPATIC IMPAIRMENT
Reduce dose to 200 mg once daily in moderate impairment. Use with caution in mild to moderate impairment. Avoid in severe impairment.

RENAL IMPAIRMENT
Use with caution if creatinine clearance less than 30 mL/minute—no information available.

MONITORING REQUIREMENTS
Monitor liver function before treatment and at weeks 3, 5, 7, and 9, then at months 3 and 4, and periodically thereafter as clinically indicated—consult product literature if elevated liver enzymes observed.

Monitor blood pressure within 1 week of treatment initiation, then frequently throughout treatment (consider dose reduction or interruption if hypertension uncontrolled despite anti-hypertensive therapy; discontinue if blood pressure persistently elevated despite anti-hypertensive therapy and pazopanib dose reduction—consult product literature).

Monitor for signs or symptoms of congestive heart failure—monitor left ventricular ejection fraction in patients at risk of heart failure before and during treatment.

Monitor for proteinuria.

Monitor thyroid function.

Monitor for signs and symptoms of posterior reversible encephalopathy syndrome (including headache, hypertension, seizure, lethargy, confusion, visual and neurological disturbances)—permanently discontinue treatment if symptoms occur.

PATIENT AND CARER ADVICE
Patients should be advised not to take antacids for at least 1 hour before or 2 hours after pazopanib.

NATIONAL FUNDING/ACCESS DECISIONS

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (February 2011) that pazopanib (Votrient®) is accepted for restricted use within NHS Scotland for the first-line treatment of advanced renal cell carcinoma and (December 2012) is not recommended for use within NHS Scotland for the treatment of selective subtypes of advanced soft tissue sarcoma in patients who have received prior chemotherapy for metastatic disease, or who have progressed within 12 months after neoadjuvant therapy.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet

<table>
<thead>
<tr>
<th>CAUTIONARY AND ADVISORY LABELS</th>
<th>23, 25</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Votrient (Novartis Pharmaceuticals UK Ltd)</td>
<td></td>
</tr>
<tr>
<td>Pazopanib (as Pazopanib hydrochloride) 200 mg Votrient 200mg tablets</td>
<td>30 tablet [PMS] £560.50</td>
</tr>
<tr>
<td>Pazopanib (as Pazopanib hydrochloride) 400 mg Votrient 400mg tablets</td>
<td>30 tablet [PMS] £1,121.00</td>
</tr>
</tbody>
</table>

---

910 Targeted therapy responsive malignancy

BNF 74

Immune system and malignant disease
**Ponatinib**

**INDICATIONS AND DOSE**

Treatment of chronic, accelerated, or blast phase chronic myeloid leukaemia in patients who have the T315I mutation or who have resistance to or intolerance of dasatinib or nilotinib, and for whom subsequent treatment with imatinib is not clinically appropriate.

Treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in patients who have the T315I mutation or who have resistance to or intolerance of dasatinib, and for whom subsequent treatment with imatinib is not clinically appropriate.

- **BY MOUTH**
  - Adult: 45 mg once daily, for dose adjustments due to side-effects or dose reduction due to risk of vascular occlusive events, consult product literature.

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**

Manufacturer advises consider a reduced initial dose of 30 mg daily with concurrent use of potent inhibitors of CYP3A4.

**IMPORTANT SAFETY INFORMATION**

**MHRA/CHM ADVICE: PONATINIB: RISK OF VASCULAR OCCLUSIVE EVENTS—UPDATED ADVICE ON POSSIBLE DOSE REDUCTION (UPDATED APRIL 2017)**

The benefits and risks of ponatinib were reviewed by the European Medicines Agency’s Committee on Medicinal Products for Human Use in 2014, which recommended that strengthened warnings should be added to the product information aimed at minimising the risk of blood clots and blockages in the arteries. Additional long-term follow-up data are now available that supports new advice on dose modification to reduce this risk. The MHRA advise that although the recommended starting dose of ponatinib remains unchanged, prescribers should consider reducing the dose for patients with chronic phase chronic myeloid leukaemia (CP-CML) who have achieved a major cytogenetic response while on treatment. The following factors should be taken into account in the individual patient assessment:

- cardiovascular risk;
- side-effects of ponatinib therapy (including cardiovascular and other dose-related toxicity);
- time to cytogenetic response;
- BCR-ABL transcript levels.

The MHRA recommends close monitoring of response, if dose reduction is undertaken.

**MHRA/CHM ADVICE (MAY 2016): RISK OF HEPATITIS B VIRUS REACTIVATION WITH BCR-ABL TYROSINE KINASE INHIBITORS**

An EU wide review has concluded that ponatinib can cause hepatitis B reactivation; the MHRA recommends establishing hepatitis B virus status in all patients before initiation of treatment.

**RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES**

See Cytotoxic drugs p. 825.

**CAUTIONS**

- Alcohol abuse—increased risk of pancreatitis.
- Current severe hypertriglyceridaemia—increased risk of pancreatitis.
- Discontinue treatment if a complete haematologic response has not occurred within 3 months.
- Hepatitis B infection—history of myocardial infarction—do not use unless potential benefit outweighs potential risk.
- History of pancreatitis—history of stroke—do not use unless potential benefit outweighs potential risk.
- Hypertension—medically control during treatment and interrupt treatment if uncontrolled.

**CAUTIONS, FURTHER INFORMATION**


**SIDE-EFFECTS**


- Frequency not known Alopecia—bone—narrow suppression—hepatic failure (fatal cases reported)—hepatitis—hepatitis B reactivation—hyperuricaemia—jaundice—oral mucositis—thromboembolism—tumour lysis syndrome—vomiting.

**CONCESSION AND CONTRACEPTION**

Ensure effective contraception during treatment in men and women; effectiveness of hormonal contraception unknown—alternative or additional methods of contraception should be used.

**PREGNANCY**

Avoid—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**BREAST FEEDING**

Manufacturer advises discontinue breastfeeding—no information available.

**HEPATIC IMPAIRMENT**

Manufacturer advises caution in severe impairment.

**RENAL IMPAIRMENT**

No information available—manufacturer advises caution if creatinine clearance less than 50 mL/minute.

**MONITORING REQUIREMENTS**

- Manufacturer advises monitor serum lipase every 2 weeks for the first 2 months and periodically thereafter— withhold treatment if lipase elevated and abdominal symptoms occur.
- Manufacturer advises a full blood count every 2 weeks for the first 3 months and then monthly thereafter or as clinically indicated.
- Manufacturer advises monitor liver function periodically.
- Manufacturer advises monitor for vascular occlusion or thromboembolism—interrupt treatment immediately if this occurs.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

**CAUTIONARY AND ADVISORY LABELS 3, 25**

- **Iclusig (Incyte Biosciences UK Ltd)**
  - **Ponatinib (as Ponatinib hydrochloride) 15 mg** Iclusig 15mg tablets | 60 tablet | £5,050.00
  - **Ponatinib (as Ponatinib hydrochloride) 45 mg** Iclusig 45mg tablets | 30 tablet | £5,050.00

**Targeted therapy responsive malignancy 911**
Regorafenib

**DRUG ACTION** Regorafenib is an inhibitor of several protein kinases.

**INDICATIONS AND DOSE**
Treatment of metastatic colorectal cancer in patients who have previously been treated with, or who are unsuitable for standard treatment including fluoropyrimidine-based chemotherapy, a vascular endothelial growth factor inhibitor, and an epidermal growth factor receptor inhibitor | Treatment of unresectable or metastatic gastrointestinal stromal tumours in patients who progressed on or are intolerant to previous treatment with imatinib and sunitinib.

- **BY MOUTH**
  - Adult: 160 mg once daily for 21 consecutive days of repeated 28-day cycles, for dose adjustment due to side effects—consult product literature

**CAUTIONS** Ensure measures to prevent hand-foot skin reaction - Gilbert’s syndrome—risk of hyperbilirubinaemia - history of ischaemic heart disease—monitor for signs and symptoms of myocardial ischaemia and interrupt treatment if signs of ischaemia or infarction develop - hypertension—control blood pressure before treatment initiation and monitor as clinically indicated during treatment (review dose and consider treatment interruption if severe or persistent hypertension develops; discontinue treatment if hypertensive crisis occurs) - may impair wound healing—withdraw treatment for major surgical procedures - predisposition to bleeding

**INTERACTIONS** → Appendix 1: regorafenib

**SIDE-EFFECTS**
- **Common or very common** Abnormal international normalised ratio - biochemical disturbances - decreased appetite - diarrhoea - dry mouth - dry skin - dysphonia - electrolyte disturbances - gastro-enteritis - gastro-oesophageal reflux - haemorrhage (including fatal) - hand-foot skin reaction - headache - hypertension - hypothyroidism - infection - malaise - mucosal inflammation - musculoskeletal stiffness - nail disorder - pain - pancytopenia - rash - taste disorders - tremor - weight loss
- **Uncommon** Gastro-intestinal perforation (including fatal cases) and fistula—discontinue treatment - hypertensive crisis - myocardial infarction - myocardial ischaemia - severe (including fatal) liver injury
- **Rare** Keratoacanthoma - posterior reversible encephalopathy syndrome - squamous cell carcinoma of the skin - Stevens-Johnson syndrome - toxic epidermal necrolysis
- **Frequency not known** Alopecia - bone-marrow suppression - hyperuricaemia - nausea - oral mucositis - thrombocytopenia - tumour lysis syndrome - vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**
- Hand-foot skin reaction Consult product literature if signs or symptoms develop.

**CONCEPTION AND CONTRACEPTION** Women of childbearing potential and men must use effective contraception during treatment and up to 8 weeks after last dose.

**PREGNANCY** Manufacturer advises avoid unless potential benefit outweighs risk—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**BREAST FEEDING** Avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT** Manufacturer advises caution in moderate impairment. Avoid in severe impairment.

**RENAL IMPAIRMENT** Caution in severe impairment—no information available.

**MONITORING REQUIREMENTS**
- Monitor blood count and coagulation parameters and consider permanent discontinuation in event of severe bleeding.
- Monitor hepatic function before treatment, then at least every two weeks for the first 2 months, then at least monthly thereafter and as clinically indicated—consult product literature if changes in liver function observed.
- Monitor for signs and symptoms of posterior reversible encephalopathy syndrome (including seizures, headache, altered mental status, visual disturbances or cortical blindness, with or without hypertension)—discontinue treatment if symptoms occur.
- Monitor biochemistry, electrolyte and metabolic parameters during treatment; ensure measures to prevent hand-foot skin reaction—consult product literature if signs or symptoms develop.

**DIRECTIONS FOR ADMINISTRATION** Tablets should be taken at the same time each day, swallowed whole with water after a light meal that contains less than 30% fat.

**PATIENT AND CARER ADVICE** Counselling advised (administration).

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- **CAUTIONARY AND ADVISORY LABELS** 21
- **ELECTROLYTES:** May contain Sodium
- **Stivarga** (Bayer Plc)
- Regorafenib 40 mg | 84 tablet
  - £3,744.00 (Hospital only)

Ruxolitinib

**DRUG ACTION** Ruxolitinib is a selective inhibitor of the Janus-associated tyrosine kinases JAK1 and JAK2.

**INDICATIONS AND DOSE**
Treatment of disease-related splenomegaly or symptoms in patients with primary myelofibrosis, post-polycythaemia vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis

- **BY MOUTH**
  - Adult: (consult product literature or local protocols)

**CAUTIONS** Assess risk of developing infection before treatment—do not initiate until active serious infections are resolved

**SIDE-EFFECTS**
- **Common or very common** Dizziness - flatulence - headache - hypercholesterolaemia - weight gain
- **Uncommon** Tuberculosis
- **Frequency not known** Alopecia - bone-marrow suppression - hyperuricaemia - nausea - oral mucositis - progressive multifocal leucoencephalopathy - thromboembolism - tumour lysis syndrome - vomiting

**CONCEPTION AND CONTRACEPTION** Women of childbearing potential and men must use effective contraception during treatment and up to 8 weeks after last dose.

**PREGNANCY** Manufacturer advises avoid unless potential benefit outweighs risk—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**BREAST FEEDING** Avoid—present in milk in animal studies.
CONCEPTION AND CONTRACEPTION Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 825.

PREGNANCY Avoid—toxicity in animal studies.

BREAST FEEDING Avoid—present in milk in animal studies.

HEPATIC IMPAIRMENT Reduce dose (consult product literature).

RENAL IMPAIRMENT Reduce dose in severe impairment (consult product literature).

MONITORING REQUIREMENTS
- Monitor full blood count (including differential white cell count) before treatment, then every 2–4 weeks until dose stabilised, then as clinically indicated.
- Monitor for infection during treatment.
- Monitor for symptoms of progressive multifocal leucoencephalopathy (presenting as new or worsening neurological, cognitive or psychiatric signs or symptoms)—withhold treatment if suspected.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)
- Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (March 2016) NICE TA386

Ruxolitinib is recommended as an option for treating disease-related splenomegaly or symptoms in patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only if the patient has intermediate-2 or high-risk disease, and if the manufacturer provides ruxolitinib with the discount agreed in the patient access scheme.

Patients currently receiving ruxolitinib whose disease does not meet the above criteria should have the option to continue their treatment until they and their clinician consider it appropriate to stop.

www.nice.org.uk/TA386

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet
- Jakavi (Novartis Pharmaceuticals UK Ltd) ▼
  - Ruxolitinib (as Ruxolitinib phosphate) 5 mg Jakavi 5mg tablets | 56 tablet box £1,428.00
  - Ruxolitinib (as Ruxolitinib phosphate) 10 mg Jakavi 10mg tablets | 56 tablet box £2,856.00
  - Ruxolitinib (as Ruxolitinib phosphate) 15 mg Jakavi 15mg tablets | 56 tablet box £2,856.00
  - Ruxolitinib (as Ruxolitinib phosphate) 20 mg Jakavi 20mg tablets | 56 tablet box £2,856.00

Sorafenib

27-May-2016

DRUG ACTION Sorafenib is an inhibitor of multiple kinases.

INDICATIONS AND DOSE
- Treatment of advanced renal cell carcinoma when treatment with interferon alfa or interleukin-2 has failed or is unsuitable | Treatment of progressive, locally advanced, or metastatic, differentiated thyroid carcinoma that is refractory to radioactive iodine | Treatment of hepatocellular carcinoma
- BY MOUTH
- Adult: 400 mg twice daily, for dose adjustments due to side effects, consult product literature

IMPORTANT SAFETY INFORMATION
RISK OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES
See Cytotoxic drugs p. 825.

CAUTIONS
- Cardiac ischaemia | major surgical procedures | potential risk of bleeding—treat tracheal, bronchial, or oesophageal infiltration with localised therapy before initiating sorafenib in patients with differentiated thyroid carcinoma (DTC) and consider permanent withdrawal of sorafenib in any patient that requires medical intervention for bleeding | susceptibility to QT-interval prolongation

INTERACTIONS → Appendix 1: sorafenib

SIDE-EFFECTS
- Common or very common Acne | anorexia | arthralgia | asthenia | congestive heart failure | constipation | depression | dermatitis | desquamation | diarrhoea | dry skin | dysgeusia | dyspepsia | dysphagia | electrolyte disturbances | erectile dysfunction | erythema | fatigue | fever | flushing | gastro-oesophageal reflux disease | haemorrhage | hand-foot skin reaction | hoarseness | hyperkeratosis | hypertension | hypophosphataemia | hypophosphataemia | keratoacanthoma | malaise | muscle spasms | myalgia | myocardial infarction | myocardial ischaemia | peripheral neuropathy | proteinuria | pruritus | rash | renal failure | rhinorrhoea | thyroid dysfunction | tinnitus
- Uncommon Altered INR | altered prothrombin time | cholangitis | cholecytitis | dehydration | eczema | erythema multiforme | gastritis | gastro-intestinal perforations | gynaecomastia | hypertensive crisis | interstitial lung disease-like events | pancreatitis | posterior reversible encephalopathy syndrome
- Rare Hepatitis | leucocytoclastic vasculitis | nephrotic syndrome | QT-interval prolongation | rhabdomyolysis | Stevens-Johnson syndrome | toxic epidermal necrolysis
- Frequency not known Alopecia | bone-marrow suppression | hyperuricaemia | nausea | oral mucositis | thromboembolism | tumour lysis syndrome | vomiting

CONCEPTION AND CONTRACEPTION Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 825.

PREGNANCY Manufacturer advises avoid unless essential—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

BREAST FEEDING Discontinue breast-feeding.

HEPATIC IMPAIRMENT Manufacturer advises caution in severe impairment—no information available.

MONITORING REQUIREMENTS
- Consider periodic monitoring of ECG and electrolytes in patients with severe impairment.
- Consider periodic monitoring of ECG and electrolytes in patients with severe impairment.
- Monitor blood pressure regularly and consider permanent discontinuation of sorafenib if resistant to antihypertensive therapy.
- Monitor plasma-calcium concentration (increased risk of hypercalcaemia if history of hypoparathyroidism).
- Monitor thyroid stimulating hormone in patients with differentiated thyroid carcinoma.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)
- Sorafenib for the treatment of advanced hepatocellular carcinoma (May 2010) NICE TA189

Sorafenib is not recommended for the treatment of advanced hepatocellular carcinoma in patients for whom surgical or locoregional therapies have failed or are unsuitable.

www.nice.org.uk/TA189

Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced or metastatic renal cell carcinoma
- (August 2009) NICE TA178

Bevacizumab, sorafenib, and temsirolimus are not recommended as first-line treatments for people with advanced or metastatic renal cell carcinoma.
Sorafenib and sunitinib are not recommended as second-line treatments for people with advanced or metastatic renal cell carcinoma.

www.nice.org.uk/TA178

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (January 2016) that sorafenib (Nexavar®) is accepted for restricted use within NHS Scotland for the treatment of advanced hepatocellular carcinoma in patients where surgical or loco-regional therapies have failed or are unsuitable.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS 23

Sorafenib (as Sorafenib tosylate) 200 mg Nexavar 200mg tablets 112 tablet (£3,576.56)

Sunitinib

DRUG ACTION Sunitinib is a tyrosine kinase inhibitor.

INDICATIONS AND DOSE
Treatment of unresectable or metastatic malignant gastro-intestinal stromal tumours, after failure of imatinib
Treatment of advanced or metastatic renal cell carcinoma

BY MOUTH

Adult: 50 mg once daily for 4 weeks, followed by a 2-week treatment-free period to complete a 6-week cycle, adjusted in steps of 12.5 mg, doses adjusted according to tolerability; usual dose 25–75 mg daily

Treatment of unresectable or metastatic pancreatic neuroendocrine tumours

BY MOUTH

Adult: 37.5 mg once daily without treatment-free period; adjusted in steps of 12.5 mg, doses adjusted according to tolerability; maximum 50 mg per day

DOSE ADJUSTMENTS DUE TO INTERACTIONS
Manufacturer advises if concurrent use of potent inducers of CYP3A4 is unavoidable, dose may need to be increased in steps of 12.5 mg to a max. dose of 87.5 mg per day for gastro-intestinal stromal tumours or renal cell carcinoma, or to a max. dose of 62.5 mg per day for pancreatic neuroendocrine tumours.

Manufacturer advises if concurrent use of potent inhibitors of CYP3A4 is unavoidable, dose may need to be decreased to a minimum of 37.5 mg per day for gastrointestinal stromal tumours or renal cell carcinoma, or to a minimum of 25 mg per day for pancreatic neuroendocrine tumours.

IMPORTANT SAFETY INFORMATION
RISK OF OSTEONECROSIS OF THE JAW (JANUARY 2011)
Treatment with sunitinib may be a risk factor for the development of osteonecrosis of the jaw.

Patients treated with sunitinib, who have previously received bisphosphonates, or are treated concurrently with bisphosphonates, may be particularly at risk.

Dental examination and appropriate preventive dentistry should be considered before treatment with sunitinib.

If possible, invasive dental procedures should be avoided in patients treated with sunitinib who have previously received, or who are currently receiving, intravenous bisphosphonates.

RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES
See Cytotoxic drugs p. 825.

CAUTIONS Cardiovascular disease—discontinue if congestive heart failure develops. Hypertension. Increased risk of bleeding—susceptibility to QT-interval prolongation

INTERACTIONS ▶ Appendix 1: sunitinib

SIDE-EFFECTS

Risks
Rare Nephrotic syndrome


CONCEPTION AND CONTRACEPTION Effective contraception required during treatment.

PREGNANCY Manufacturer advises avoid unless potential benefit outweighs risk—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

BREAST FEEDING Discontinue breast-feeding.

MONITORING REQUIREMENTS Monitor for thyroid dysfunction.

NATIONAL FUNDING/ACCESS DECISIONS
NICE technology appraisals (TAs)

Sunitinib for advanced or metastatic renal cell carcinoma
(March 2009) NICE TA169
Sunitinib is recommended as first-line treatment for advanced or metastatic renal cell carcinoma in patients who are suitable for immunotherapy and have an Eastern Cooperative Oncology Group performance status of 0 or 1.

www.nice.org.uk/TA169

Sunitinib for the treatment of gastrointestinal stromal tumours (September 2009) NICE TA179
Sunitinib is recommended as an option for treatment in patients with unresectable or metastatic gastrointestinal tumours if imatinib treatment has failed because of resistance or intolerance, and the cost of sunitinib for the first treatment cycle is met by the manufacturer.

www.nice.org.uk/TA179

Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced or metastatic renal cell carcinoma (August 2009) NICE TA178
Sorafenib and sunitinib are not recommended as second-line treatments for people with advanced or metastatic renal cell carcinoma.

www.nice.org.uk/TA178

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (October 2009 and April 2011) that sunitinib (Sutent®) is accepted for restricted use within NHS Scotland for the treatment of unresectable or metastatic malignant gastro-intestinal stromal tumours after failure of imatinib and for unresectable or metastatic pancreatic neuroendocrine tumours.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Capsule

CAUTIONARY AND ADVISORY LABELS 14

Sutent (Pfizer Ltd)
Sunitinib (as Sunitinib malate) 12.5 mg Sutent 12.5mg capsules 28 capsule (£784.70)
Sunitinib (as Sunitinib malate) 25 mg | Sunitin 25mg capsules | 28 capsule £1,569.40
Sunitinib (as Sunitinib malate) 50 mg | Sunitin 50mg capsules | 28 capsule £3,138.80

Temozolomide

**INDICATIONS AND DOSE**
First-line treatment of advanced renal cell carcinoma | Treatment of relapsed or refractory mantle cell lymphoma

- **BY INTRAVENOUS INFUSION**
- **Adult:** (consult product literature or local protocols)

**INTERACTIONS** → Appendix 1: temsirolimus

**SIDE-EFFECTS**
- Common or very common Abdominal pain • Acne • Anorexia • Anxiety • Arthralgia • Asthenia • Bowel perforation • Chest pain • Cough • Depression • Diarrhoea • Dizziness • Drowsiness • Dysphagia • Dyspnoea • Epistaxis • Eye disorders • Folliculitis • Gastro-intestinal haemorrhage • Hypercholesterolaemia • Hypersensitivity reactions • Hypertension • Hypokalaemia • Hypophosphataemia • Impaired wound healing • Increased susceptibility to infection • Increased susceptibility to pneumonia • Increased susceptibility to urinary tract infection • Insomnia • Intestinal lymphoma • Insulinoma • Intestinal tumours • Intestinal obstruction • Intestinal ulceration • Intussusception • Intracerebral bleeding • Interstitial lung disease • Irritation • Itching • Itching rash • Menstrual disorders • Migraine • Myalgia • Nausea • Nervousness • Nightmares • Oral mucositis • Ovarian hyperstimulation syndrome • Pruritus • Rash • Respiratory depression • Sodium retention • Sleep disorders • Skin disorder • Skin reactions • Soft tissue oedema • Skin ulcers • Stomatitis • Stomatitis painful • Stomatitis periorbital • Stomatitis perioral • Stomatitis perioral painful • Supraventricular tachycardia • Sympathetic stimulation • Syncope • Tactile hallucinations • Tachycardia • Tachypnoea • Tachypnoea painful • Thrombocytopenia • Thrombosis • Thrombophlebitis • Urinary tract infection • Urticaria • Vomiting

**CONCEPTION AND CONTRACEPTION**
Ensure effective contraception during treatment in men and women.

**PREGNANCY**
Manufacturer advises avoid (toxicity in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**BREAST FEEDING**
Manufacturer advises discontinue breast-feeding.

**HEPATIC IMPAIRMENT**
In renal cell carcinoma, reduce dose in severe impairment (consult product literature). Use with caution.
In mantle cell lymphoma, avoid in moderate or severe impairment.

**RENAI IMPAIRMENT**
Manufacturer advises caution in severe impairment — no information available.

**MONITORING REQUIREMENTS**
- Monitor respiratory function.
- Monitor blood lipids.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**
- Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced or metastatic renal cell carcinoma (August 2009) NICE TA178
Bevacizumab, sorafenib, and temsirolimus are not recommended as first-line treatments for people with advanced or metastatic renal cell carcinoma.

[www.nice.org.uk/TA178](http://www.nice.org.uk/TA178)

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Solution for infusion**

**EXCIPIENTS:** May contain Ethanol, propylene glycol
- **Torisel (Pfizer Ltd)**
  Temozolomide 25 mg per 1 ml Torisel 30mg/1.2ml concentrate for solution for infusion vials and diluent | 1 vial [POD] £620.00 (Hospital only)

**Trametinib**

04-May-2017

**DRUG ACTION**
Trametinib is a protein kinase inhibitor.

**INDICATIONS AND DOSE**
Unresectable or metastatic melanoma with a BRAF V600 mutation (as monotherapy or in combination with dabrafenib)
- **BY MOUTH**
- **Adult:** 2 mg once daily, when used in combination with dabrafenib, the dose should be taken at the same time each day with either the morning or evening dose of dabrafenib, for dose adjustments due to side-effects, consult product literature

**SIDE-EFFECTS**
- Common or very common Abdominal pain • Alopecia • Anorexia • Anxiety • Anorexia • Asthenia • Cough • Depression • Diarrhoea • Dizziness • Drowsiness • Dysphagia • Dyspnoea • Epistaxis • Eye disorders • Folliculitis • Gastro-intestinal haemorrhage • Hypercholesterolaemia • Hypersensitivity reactions • Hypertension • Hypokalaemia • Hypophosphataemia • Impaired wound healing • Increased susceptibility to infection • Increased susceptibility to pneumonia • Increased susceptibility to urinary tract infection • Insomnia • Intestinal lymphoma • Insulinoma • Intestinal tumours • Intestinal obstruction • Intestinal ulceration • Intussusception • Intracerebral bleeding • Interstitial lung disease • Irritation • Itching • Itching rash • Menstrual disorders • Migraine • Myalgia • Nausea • Nervousness • Nightmares • Oral mucositis • Ovarian hyperstimulation syndrome • Pruritus • Rash • Respiratory depression • Sodium retention • Sleep disorders • Skin disorders • Skin reactions • Soft tissue oedema • Skin ulcers • Stomatitis • Stomatitis painful • Stomatitis periorbital • Stomatitis perioral • Stomatitis perioral painful • Supraventricular tachycardia • Sympathetic stimulation • Syncope • Tachycardia • Tachypnoea • Tachypnoea painful • Thrombocytopenia • Thrombosis • Thrombophlebitis • Urinary tract infection • Urticaria • Vomiting

**CONTRA-INDICATIONS**
History of retinal vein occlusion

**CAUTIONS**
Concomitant antiplatelet or anticoagulant therapy — increased risk of haemorrhage - conditions that could impair left ventricular function - elderly (more frequent dose adjustments may be required) - impaired left ventricular function - predisposing factors for retinal vein occlusion - risk factors for gastrointestinal perforation

**INTERACTIONS** → Appendix 1: trametinib

**SIDE-EFFECTS**
- Common or very common Abdominal pain • Alopecia • Anaemia • Bradycardia • Cellulitis • Constipation • Cough • Dehydration • Dermatitis acnineform • Diarrhoea • Dry mouth • Dry skin • Dysphagia • Dyspnoea • Epithema • Folliculitis • Haemorrhage • Hand-foot syndrome • Hypertension • Left ventricular dysfunction • Lymphoedema • Malaise • Mucosal inflammation • Nausea • Oedema • Paronychia • Periorbital oedema • Pneumonitis • Pruritus • Pyrexia • Rash • Skin fissures • Stomatitis • Visual disturbances • Vomiting
Uncommon Cardiac failure, chorioretinopathy, colitis, gastrointestinal perforation, interstitial lung disease, papillodema, retinal detachment, retinal vein occlusion, rhabdomyolysis

Frequency not known Thromboembolism

SPECIAL EFFECTS, FURTHER INFORMATION

Additional side-effects reported when used in combination with dabrafenib include dizziness, hyperhidrosis, hypotension, leucopenia, muscle spasms, myocarditis, neutropenia, night sweats, and thrombocytopenia.

CONCEPTION AND CONTRACEPTION
Manufacturer advises women of child-bearing potential should use highly effective non-hormonal contraception during, and for 4 months after stopping treatment.

PREGNANCY
Manufacturer advises avoid—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

BREAST FEEDING
Manufacturer advises avoid—no information available.

HEPATIC IMPAIRMENT
Manufacturer advises caution in moderate to severe impairment—no information available.

RENAL IMPAIRMENT
Manufacturer advises caution in severe impairment—no information available.

MONITORING REQUIREMENTS
- Manufacturer advises measure blood pressure at baseline and monitor during treatment; evaluate left ventricular ejection fraction before treatment, after one month of treatment, and then approximately every 3 months thereafter.
- Monitor liver function every 4 weeks for 6 months after treatment initiation, and thereafter as clinically indicated.

HANDLING AND STORAGE
Manufacturer advises store in refrigerator (2–8°C); once opened, bottle may be stored for 30 days at not more than 30°C.

PATIENT AND CARER ADVICE
Manufacturer advises patients and their carers should be told to seek immediate medical attention if symptoms of pulmonary embolism or deep vein thrombosis occur; patients and their carers should also be advised to report new visual disturbances.

Missed doses
Manufacturer advises if a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

Driving and skilled tasks
Manufacturer advises patients and carers should be counselled on the effects on driving and performance of skilled tasks—risk of dizziness and visual disturbances.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)
- Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (June 2016) NICE TA396
Trametinib in combination with dabrafenib is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation only when the company provides trametinib and dabrafenib with the discounts agreed in the patient access schemes.

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (August 2016) that trametinib (Mekinist®), in combination with dabrafenib, is accepted for restricted use within NHS Scotland for first-line treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

MEDITICAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet
CAUTIONARY AND ADVISORY LABELS 3, 23, 25
- Mekinist (Novartis Pharmaceuticals UK Ltd)
Trametinib 500 microgram Mekinist 0.5mg tablets 7 tablet £280.00 30 tablet £1200.00
Trametinib 2 mg Mekinist 2mg tablets 7 tablet £1120.00 30 tablet £4800.00

Vandetanib

DRUG ACTION
Vandetanib is a tyrosine kinase inhibitor.

INDICATIONS AND DOSE
Treatment of aggressive and symptomatic medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease
- BY MOUTH
  - Adult: 300 mg once daily, for dose adjustment due to side effects—consult product literature

IMPORTANT SAFETY INFORMATION
RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES
See Cytotoxic drugs p. 825.

CONTRA-INDICATIONS
Congenital long QT syndrome—QT interval greater than 480 milliseconds

CAUTIONS
- Brain metastases (intracranial haemorrhage reported), electrolyte disturbances, history of torsades de pointes, hypertension, photosensitivity reactions reported (wear protective clothing and/or sunscreen), susceptibility to QT prolongation

INTERACTIONS
  → Appendix 1: vandetanib

SIDE-EFFECTS
- Common or very common Abdominal pain, alopecia, anxiety, asthenia, balance disorders, blurred vision, cholelithiasis, colitis, conjunctivitis, constipation, corneal changes (including opacity), corneal deposits, decreased appetite, dehydration, depression, diarrhoea, dizziness, dry eye, dry mouth, dysaesthesia, dyspepsia, dysphagia, dysuria, electrolyte disturbances, epistaxis, gastritis, gastrointestinal haemorrhage, glaucoma, haematuria, haemoptyisia, halo vision, hand-foot syndrome, headache, hyperglycaemia, hypertension, hypothyroidism, insomnia, ischaemic cerebrovascular conditions, keratopathy, lethargy, loss of consciousness, micturition urgency, nephrolithiasis, oedema, pain, paraesthesia, photopsia, photosensitivity reactions, pneumonitis, pollakiuria, proteinuria, pyrexia, QT-interval prolongation, taste disturbance, tremor
  - Uncommon Accommodation disorders, anuria, aspiration pneumonia, brain oedema, bullous dermatitis, cardiac arrest, cardiac conduction disorders, cardiac rate disorders, cardiac rhythm disorders, cataract, chromatoma, clonus, convulsions, crythema multiforme, faecal incontinence, heart failure, ileus, impaired healing, increased haemoglobin, interstitial lung disease (sometimes fatal), intestinal perforation, pancreatitis, peritonitis, posterior reversible encephalopathy syndrome, respiratory failure, Stevens-Johnson syndrome, ventricular arrhythmia

FREQUENCY not known
- Alopecia, bone-marrow suppression, hyperuricaemia, nausea, oral mucositis, thromboembolism, tumour lysis syndrome, vomiting

CONCEPTION AND CONTRACEPTION
Effective contraception required during and for at least 4 months after treatment.

PREGNANCY
Manufacturer advises avoid unless potential benefit outweighs risk. Most cytotoxic drugs are...
teratogenic and should not be administered during pregnancy, especially during the first trimester. Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.

- **BREAST FEEDING** Avoid—no information available.

- **HEPATIC IMPAIRMENT** Manufacturer advises avoid in severe impairment (serum bilirubin greater than 1.5 times the upper limit of normal).

- **RENAL IMPAIRMENT** Reduce dose to 200 mg if creatinine clearance 30–49 mL/minute. Avoid if creatinine clearance less than 30 mL/minute.

- **MONITORING REQUIREMENTS** Monitor ECG, serum potassium, calcium, magnesium and thyroid stimulating hormone before treatment, then 1, 3, 6 and 12 weeks after starting treatment and following dose adjustment or interruption, then every 3 months for at least 1 year.

- **DIRECTIONS FOR ADMINISTRATION** Tablets may be dispersed in half a glass of water by stirring until dispersed (approximately 10 minutes), immediately before drinking (do not crush). After solution has been swallowed, any residue must be re-dispersed in the same volume of water (approximately 10 minutes) and swallowed. The solution can also be administered via nasogastric or gastrostomy tubes.

- **PATIENT AND CARER ADVICE** Alert card should be provided. Patients or carers should be given advice on how to administer vandetanib tablets. Phototoxicity reactions Patients should be advised to wear protective clothing and/or sunscreen.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

  **Tablet**

  - **Caprelsa** (Genzyme Therapeutics Ltd)

    - Vandetanib 100 mg Caprelsa 100mg tablets | 30 tablet £2,500.00
    - Vandetanib 300 mg Caprelsa 300mg tablets | 30 tablet £5,000.00

### Vemurafenib

- **DRUG ACTION** Vemurafenib is a BRAF kinase inhibitor.

  - **INDICATIONS AND DOSE**

    - **Monotherapy for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma**
      - **BY MOUTH**
      - **Adult:** 960 mg twice daily, for dose adjustment due to side effects—consult product literature

  **IMPORTANT SAFETY INFORMATION**

  **DRUG RASH WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS SYNDROME)**

  DRESS syndrome has been reported in patients taking vemurafenib. DRESS syndrome starts with rash, fever, swollen glands, and increased white cell count, and it can affect the liver, kidneys and lungs; DRESS can also be fatal.

  Patients should be advised to stop taking vemurafenib and consult their doctor immediately if skin rash develops. Treatment with vemurafenib should not be restarted.

  **MHRA/CHM ADVICE (NOVEMBER 2015): RISK OF POTENTIATION OF RADIATION TOXICITY**

  Potentiation of radiation toxicity has been reported in patients treated with vemurafenib before, during, or after radiotherapy—use with caution.

  **RISKS OF INCORRECT DOZING OF ORAL ANTI-CANCER MEDICINES**

  See Cytotoxic drugs p. 825.

  - **CONTRA-INDICATIONS** Wild-type BRAF malignant melanoma

  - **CAUTIONS** Electrolyte disturbances • prior or concurrent cancer associated with RAS mutation—increased risk of tumour progression • susceptibility to QT-prolongation

  - **INTERACTIONS** → Appendix 1: vemurafenib

  - **SIDE-EFFECTS**

    ▶ **Common or very common** Actinic keratosis • alopecia • arthralgia • arthrosis • ataxia • basal cell carcinoma • Bell’s palsy • constipation • cough • cutaneous squamous cell carcinoma • decreased appetite • diarrhoea • dizziness • dry skin • erythema • erythema nodosum • fatigue • folliculitis • hand-foot syndrome • headache • hyperkeratosis • keratosis pilaris • musculoskeletal pain • myalgia • new primary melanoma • pain in extremities • peripheral oedema • photosensitivity reactions • pyrexia • QT-interval prolongation • seborrhoeic keratosis • skin papilloma • taste disturbance • uveitis

    ▶ **Uncommon** Non-cutaneous squamous cell carcinoma • peripheral neuropathy • retinal vein occlusion • Stevens-Johnson syndrome • toxic epidermal necrolysis • vasculitis

    ▶ **Rare** Progression of pre-existing NRAS mutated chronic myelomonocytic leukaemia

    ▶ **Frequency not known** Alopecia • bone-marrow suppression • hypersensitivity reactions • hyperuricaemia • nausea • oral mucositis • thromboembolism • tumour lysis syndrome • vomiting

  - **CONCEPTION AND CONTRACEPTION** Effective contraception required during for at least 6 months after treatment.

  - **PREGNANCY** Manufacturer advises avoid unless potential benefit outweighs risk. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

  - **BREAST FEEDING** Avoid—no information available.

  - **HEPATIC IMPAIRMENT** Manufacturer advises more frequent monitoring in moderate to severe hepatic impairment (including monthly ECG monitoring during first 3 months of treatment).

  - **RENAL IMPAIRMENT** Manufacturer advises caution in severe impairment.

  - **MONITORING REQUIREMENTS**

    ▶ Monitor ECG and electrolytes before treatment, after one month and following dose adjustment (treatment not recommended if QT interval greater than 500 milliseconds at baseline).

    ▶ Monitor liver function before treatment and periodically thereafter.

    ▶ Monitor for uveitis, iritis and retinal vein occlusion.

    ▶ Monitor for cutaneous and non-cutaneous squamous cell carcinoma and new primary melanoma before, during and for up to 6 months after treatment—consult product literature.

  - **DIRECTIONS FOR ADMINISTRATION** Food may affect absorption (take at the same time with respect to food).

  - **PATIENT AND CARER ADVICE** Counselling advised (administration).

    Drug rash with eosinophilia and systemic symptoms (DRESS syndrome) Patients should be advised to stop taking vemurafenib and consult their doctor immediately if skin rash develops.

  - **NATIONAL FUNDING/ACCESS DECISIONS**

    **NICE technology appraisals (TAs)**

    ▶ Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma (December 2012) NICE TA269

    Vemurafenib is recommended as an option for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma only if the manufacturer provides
vemurafenib with the discount agreed in the patient access scheme.
www.nice.org.uk/TA269

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (November 2013) that vemurafenib (Zelboraf®) is accepted for restricted use within NHS Scotland as monotherapy for the first-line treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  **Tablet**
  - CAUTIONARY AND ADVISORY LABELS 25
    - Zelboraf (Roche Products Ltd)
    - Vemurafenib 240 mg Zelboraf 240mg tablets | 56 tablet POM €1,750.00 (Hospital only)

**ANTINEOPLASTIC DRUGS > PROTEIN KINASE INHIBITORS > ANTIFIBROTICS**

**Nintedanib** 23-Feb-2016

- **DRUG ACTION** Nintedanib is a tyrosine protein kinase inhibitor.

- **INDICATIONS AND DOSE**
  - **OFEV®**
    - Treatment of idiopathic pulmonary fibrosis
      - **BY MOUTH**
        - Adult: 150 mg twice daily, reduced if not tolerated to 100 mg twice daily, for dose adjustments due to side-effects, consult product literature
  - **VARGATEF®**
    - Treatment of locally advanced, metastatic or locally recurrent non-small cell lung cancer of adenocarcinoma histology after first-line chemotherapy (in combination with docetaxel) (initiated under specialist supervision)
      - **BY MOUTH**
        - Adult: 200 mg twice daily on days 2–21 of a standard 21 day docetaxel cycle, for treatment following discontinuation of docetaxel and for dose adjustments due to side-effects, consult product literature

**IMPORTANT SAFETY INFORMATION FOR VARGATEF® — RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES**
See Cytotoxic drugs p. 825.

- **CAUTIONS** History of organ perforation - history or risk factors for QT prolongation - impaired wound healing - increased risk of bleeding - patients at high risk of cardiovascular disease - previous abdominal surgery - theoretical increased risk of gastrointestinal perforation - theoretical increased risk of venous thromboembolism

- **INTERACTIONS → Appendix 1: nintedanib**

- **SIDE-EFFECTS**
  - **Common or very common** Abdominal pain - decreased appetite - diarrhoea - hyperbilirubinaemia - hypertension - nausea - raised hepatic enzymes - vomiting
    - **OFEV®**
  - **Common or very common** Epistaxis - weight loss
    - **VARGATEF®**
  - **Common or very common** Abscesses - bleeding - dehydration - electrolyte imbalance - mucositis - neutropenia - peripheral neuropathy - venous thromboembolism
  - **Uncommon** Gastrointestinal perforation

- **ALLERGY AND CROSS-SENSITIVITY** Contra-indicated in patients with peanut or soya hypersensitivity.

- **CONCEPTION AND CONTRACEPTION** Manufacturer advises exclude pregnancy before treatment and ensure contraception (in addition to barrier method) during treatment and for at least 3 months after last dose.

- **PREGNANCY** Manufacturer advises — toxicity in animal studies.

  - **VARGATEF®** See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

- **BREAST FEEDING** Manufacturer advises — present in milk in animal studies.

- **HEPATIC IMPAIRMENT** Consult product literature for dose adjustment in worsening liver function. Manufacturer advises in moderate to severe impairment — no information available.

- **RENAL IMPAIRMENT** Manufacturer advises caution in severe impairment — no information available.

- **MONITORING REQUIREMENTS** For Vargatef®, monitor full blood count and hepatic function before each treatment cycle and regularly thereafter, monitor prothrombin time and INR if used concomitantly with anticoagulants and monitor for signs and symptoms of cerebral bleeding.

- **PRESCRIBING AND DISPENSING INFORMATION**

  - **VARGATEF®** Not to be taken on the same day as docetaxel therapy.

- **NATIONAL FUNDING/ACCESS DECISIONS**

  - **NICE technology appraisals (TAs)**
    - **Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small cell lung cancer (July 2015) NICE TA347**
      - Nintedanib (Vargatef®), in combination with docetaxel is recommended as an option for the treatment of patients with locally advanced, metastatic, or locally recurrent non-small cell lung cancer of adenocarcinoma histology, that has progressed after first-line chemotherapy, only if the manufacturer provides nintedanib with the discount agreed in the patient access scheme.
      - www.nice.org.uk/TA347

    - **Nintedanib for treating idiopathic pulmonary fibrosis (January 2016) NICE TA379**
      - Nintedanib is recommended as an option for treating idiopathic pulmonary fibrosis, only if:
        - the patient has a forced vital capacity (FVC) between 50% and 80% of predicted,
        - the manufacturer provides nintedanib with the discount agreed in the patient access scheme, and,
        - treatment is stopped if disease progresses (a confirmed decline in percent predicted FVC of 10% or more) in any 12-month period.
      - www.nice.org.uk/TA379

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (September 2015) that nintedanib (Ofev®) is accepted for restricted use within NHS Scotland for the treatment of idiopathic pulmonary fibrosis in patients with a predicted forced vital capacity less than or equal to 80%.

- **MEDICINAL FORMS**

  - There can be variation in the licensing of different medicines containing the same drug.

  **Capsule**
  - CAUTIONARY AND ADVISORY LABELS 25
    - EXCIPIENTS: May contain Lecithin
      - **Ofev** (Boehringer Ingelheim Ltd)
        - Nintedanib (as Nintedanib esilate) 100 mg | Ofev 100mg capsules | 60 capsule POM £2,151.10 (Hospital only)
        - Nintedanib (as Nintedanib esilate) 150 mg | Ofev 150mg capsules | 60 capsule POM £2,151.10 (Hospital only)
      - **Vargatef** (Boehringer Ingelheim Ltd)
        - Nintedanib (as Nintedanib esilate) 100 mg | Vargatef 100mg capsules | 120 capsule POM £2,151.10 (Hospital only)
        - Nintedanib (as Nintedanib esilate) 150 mg | Vargatef 150mg capsules | 60 capsule POM £2,151.10 (Hospital only)
Olaparib

**DRUG ACTION** Olaparib is a PARP inhibitor. PARP are enzymes that repair damaged DNA in cancer cells and, in the absence of functional BRCA, inhibition of PARP results in an inability of cancer cells to repair. Therefore inhibition of PARP results in an antineoplastic effect.

**INDICATIONS AND DOSE**

Monotherapy for the maintenance treatment of patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial response) to platinum-based chemotherapy (initiated under specialist supervision)

- **BY MOUTH**
  - Adult: 400 mg twice daily; reduced if not tolerated to 200 mg twice daily, then reduced if not tolerated to 100 mg twice daily, take at least 1 hour after food and avoid food for 2 hours after taking, patients should start treatment within 8 weeks of receiving the final dose of their platinum-containing chemotherapy regimen

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**

Manufacturer advises if concurrent use of moderate inhibitors of CYP3A4 is unavoidable, reduce dose to 200 mg twice daily.

Manufacturer advises if concurrent use of potent inhibitors of CYP3A4 is unavoidable, reduce dose to 150 mg twice daily.

**PHARMACOKINETICS**

Peak plasma concentrations are typically achieved 1 to 3 hours after dosing; steady-state is achieved within 3 to 4 days.

**IMPORTANT SAFETY INFORMATION**

**RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES**

See Cytotoxic drugs p. 825.

**INTERACTIONS** → Appendix 1: olaparib

**SIDE-EFFECTS**

- **Common or very common** Anaemia · decreased appetite · diarrhoea · dizziness · dysgeusia · dyspepsia · fatigue · headache · lymphopaenia · nausea · neutropenia · stomatitis · thrombocytopenia · upper abdominal pain · vomiting

- **Frequency not known** Pneumonitis (occasionally fatal)

**SIDE-EFFECTS, FURTHER INFORMATION**

- Haematological toxicity: Withhold treatment if severe haematological toxicity develops; further analysis recommended if toxicity still present 4 weeks after treatment withdrawal.

- Pneumonitis: If dyspnoea, cough and fever, or radiological abnormalities develop, withhold treatment and investigate; if pneumonitis confirmed, discontinue.

**CONCEPTION AND CONTRACEPTION**

Manufacturer advises effective contraception during treatment and for 1 month after receiving the last dose. Consider an additional non-hormonal method of contraception.

**PREGNANCY**

Manufacturer advises avoid—toxicity in animal studies.

**BREAST FEEDING**

Manufacturer advises avoid during treatment and for 1 month after last dose—no information available.

**HEPATIC IMPAIRMENT**

Manufacturer advises avoid—no information available.

**RENAL IMPAIRMENT**

Manufacturer advises avoid if creatinine clearance less than 50 mL/minute/1.73m² unless benefit outweighs potential risk—limited information available.

**MONITORING REQUIREMENTS**

Manufacturer advises monitor full blood count every month for the first 12 months of treatment and periodically thereafter.

**PATIENT AND CARER ADVICE**

- **Missed doses**
  - If a dose is missed, the missed dose should not be taken and the next dose should be taken at the usual time.

- **Driving and skilled tasks**
  - Malaise and dizziness may affect performance of skilled tasks e.g. driving or operating machinery.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (January 2016) NICE TA381

Olaparib is recommended as an option for treating adults with relapsed, platinum sensitive ovarian, fallopian tube or peritoneal cancer who have BRCA1 or BRCA2 mutations and whose disease has responded to platinum based chemotherapy only if:

- they have had 3 or more courses of platinum-based chemotherapy and;

- the drug cost of olaparib for people who remain on treatment after 15 months will be met by the company.

[www.nice.org.uk/guidance/ta381](http://www.nice.org.uk/guidance/ta381)

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (November 2016) that olaparib (Lynparza®) is accepted for use within NHS Scotland as monotherapy for the maintenance treatment of adults with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Capsule**
  - **Lynparza** (AstraZeneca UK Ltd) ▼
  - Olaparib 50 mg Lynparza 50mg capsules | 448 capsule [PMP] £3,550.00

**Venetoclax**

**DRUG ACTION** Venetoclax is a potent, selective inhibitor of B-cell lymphoma-2 (BCL-2).

**INDICATIONS AND DOSE**

**Chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation when a B-cell receptor pathway inhibitor is unsuitable or ineffective (specialist use only)**

**Chronic lymphocytic leukaemia in the absence of 17p deletion or TP53 mutation when both chemotherapy and a B-cell receptor pathway inhibitor has been ineffective (specialist use only)**

**BY MOUTH**

- Adult: Initially 20 mg once daily for 7 days, then increased to 50 mg once daily for 7 days, then increased to 100 mg once daily for 7 days, then increased to 200 mg once daily for 7 days, then maintenance 400 mg once daily, dose to be taken in the morning during dose-titration phase; dose should be taken at the same time every day, for dose adjustment due to side effects—consult product literature continued →

[downloaded from www.medicalbr.com](http://www.medicalbr.com)
DOSE ADJUSTMENTS DUE TO INTERACTIONS
Avoid concomitant use of potent or moderate CYP3A4 inhibitors during initiation and dose-titration; once stable reduce dose by 75% with concomitant use of potent CYP3A4 inhibitors and by 50% with concomitant use of moderate CYP3A4 inhibitors.

IMPORTANT SAFETY INFORMATION
RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES
See Cytotoxic drugs p. 825.

**CAUTIONS**
Ensure adequate hydration.

**INTERACTIONS** → Appendix 1: venetoclax

**SIDE-EFFECTS**
- Common or very common Anaemia · constipation · diarrhoea · fatigue · febrile neutropenia · hyperkalaemia · hyperphosphataemia · hyperuricaemia · hypocalcaemia · lymphopenia · nausea · neutropenia · pneumonia · tumour lysis syndrome · upper respiratory tract infection · urinary tract infection · vomiting

**CONCEPTION AND CONTRACEPTION**
Manufacturer advises ensure effective, non-hormonal contraception during and for 30 days after treatment in women of child-bearing potential. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**PREGNANCY**
Manufacturer advises avoid—toxicity in animal studies. See also Pregnancy and reproductive function in Cytotoxic drugs p. 825.

**BREAST FEEDING**
Manufacturer advises avoid—no information available.

**HEPATIC IMPAIRMENT**
Manufacturer advises close monitoring during initiation and dose titration in moderate impairment (increased risk of toxicity); avoid in severe impairment—no information available.

**RENAL IMPAIRMENT**
Manufacturer advises close monitoring (increased risk of tumour lysis syndrome); use only if potential benefit outweighs risk in severe impairment—no information available.

**MONITORING REQUIREMENTS**
Manufacturer advises monitor renal function before starting treatment.

**PATIENT AND CARER ADVICE**
Hydration  Manufacturer advises patients should drink 1.5–2 L of water daily, starting 2 days before and throughout the dose–titration phase; intravenous fluids should be administered for those who cannot maintain an adequate level of oral hydration with consideration of overall risk of tumour lysis syndrome.

Vomiting  Manufacturer advises that if vomiting occurs following dose administration, no additional doses should be taken on that day and the next dose should be taken at the normal time.

Missed doses  Manufacturer advises that if a dose is more than 8 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
CAUTIONARY AND ADVISORY LABELS 21, 25

- **Venclyxo (AbbVie Ltd)**
  - Venetoclax 10 mg Venclyxo 10mg tablets  | 14 tablet £59.87
  - Venetoclax 50 mg Venclyxo 50mg tablets  | 7 tablet £149.67
  - Venetoclax 100 mg Venclyxo 100mg tablets  | 7 tablet £299.34 | 14 tablet £598.68 | 112 tablet £4,789.47

**IMPORTANT SAFETY INFORMATION**
RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES
See Cytotoxic drugs p. 825.

**INTERACTIONS** → Appendix 1: vismodegib

**SIDE-EFFECTS**
- Common or very common Abdominal pain · abnormal hair growth · alopecia · amenorrhoea · arthralgia · constipation · decreased appetite · dehydration · diarrhoea · dyspepsia · hypoponatraemia · malaise · muscle spasms · musculoskeletal pain · nausea · pruritus · rash · taste disturbances · vomiting · weight loss

**CONCEPTION AND CONTRACEPTION**
For women of child-bearing potential, pregnancy must be excluded before initiation of treatment, and monthly during treatment. Women must use two contraceptive methods (including one highly effective method and one barrier method) during treatment and for 24 months after the final dose of vismodegib. Men must use a condom during treatment and for 2 months after the final dose.

**PREGNANCY**
Important: teratogenic risk—may cause severe birth defects and embryo-fetal death.

**BREAST FEEDING**
Avoid during treatment and for 24 months after final dose.

**HEPATIC IMPAIRMENT**
No information available—manufacturer advises caution in moderate to severe impairment.

**RENAL IMPAIRMENT**
No information available—manufacturer advises caution in severe impairment.

**PRESCRIBING AND DISPENSING INFORMATION**
Prescribers and pharmacists must comply with prescribing and dispensing restrictions as specified in the manufacturer’s Pregnancy Prevention Programme, and ensure that the patient fully acknowledges the programme’s pregnancy prevention measures—consult product literature for further information.

**PATIENT AND CARER ADVICE**
Patient advice required around conception and contraception Counselling on pregnancy and contraception advised. Patients must comply with the manufacturer’s pregnancy prevention programme.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Capsule**
CAUTIONARY AND ADVISORY LABELS 25

- **Erivedge (Roche Products Ltd)**
  - Vismodegib 150 mg Erivedge 150mg capsules  | 28 capsule £6,285.00 (Hospital only)
## Aflibercept

**DRUG ACTION**
Aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor and binds to vascular endothelial growth factors A and B (VEGF-A, VEGF-B) and placental growth factor (PIGF). Aflibercept inhibits the activation of VEGF receptors and the proliferation of endothelial cells, thereby inhibiting the growth of new vessels that supply tumours with oxygen and nutrients.

### INDICATIONS AND DOSE
In combination with irinotecan, fluorouracil and folinic acid (FOLFIRI) chemotherapy, in metastatic colorectal cancer that is resistant to, or has progressed after, an oxaliplatin-containing regimen
- **BY INTRAVENOUS INFUSION**
  - Adult: (consult local protocol)

### CONTRA-INDICATIONS
Moderate or severe congestive heart failure - uncontrolled hypertension

### CAUTIONS
Fever, neutropenia - history of cardiovascular disease (may be exacerbated by hypertension) - increased risk of haemorrhage (including fatal events) - increased risk of hypertension - increased risk of thromboembolic events (consult product literature if event occurs) - may impair wound healing — withhold treatment for at least 4 weeks before elective surgery and for at least 4 weeks after major surgery, or until wound fully healed — neutropenic infection - risk of fistula formation (discontinue if fistula develops) — risk of neutropenia - risk of thrombocytopenia

### INTERACTIONS
- **Appendix 1: aflibercept**

### SIDE-EFFECTS
- **Common or very common** Abdominal pain — aphthous stomatitis — decreased appetite — dehydration — diarrhoea — dysphonia — dyspnoea — fistula — haemorrhage (including nasal, rectal and gastro-intestinal) — haemorrhoids — hand-foot syndrome — headache — hypertension — infection — leucopenia — malaise — nasopharyngitis — neutropenia (including febrile neutropenia) — oropharyngeal pain — proctalgia — proteinuria — rhinorrhoea — sepsis — skin hyperpigmentation — stomatitis — thrombocytopenia — thromboembolic events (arterial and venous) — toothache — urinary tract infection — weight loss
- **Uncommon** Gastro-intestinal perforation — impaired wound healing — nephrotic syndrome — posterior reversible encephalopathy syndrome — thrombotic microangiopathy

### CONCEPTION AND CONTRACEPTION
Exclude pregnancy before treatment. Effective contraception required during and for at least 6 months after treatment in men and women. Contraceptive advice should be given to men and women before therapy begins (and should cover the duration of contraception required after therapy has ended).

### PREGNANCY
Manufacturer advises avoid — toxicity in animal studies. Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.

### BREAST FEEDING
Manufacturer advises avoid — no information available.

### HEPATIC IMPAIRMENT
Caution in severe impairment — no information available.

### RENAL IMPAIRMENT
Caution in severe impairment — no information available.

### MONITORING REQUIREMENTS
- Monitor blood pressure at initiation and at least fortnightly during treatment (do not initiate treatment if pre-existing hypertension is uncontrolled) — consult product literature if hypertension develops during treatment.
- Monitor for signs of gastro-intestinal perforation (discontinue if perforation develops).
- Monitor full blood count, including differential count and platelets at baseline and before each treatment cycle.
- Monitor for proteinuria before each treatment administration (consult product literature if symptoms develop).
- Monitor for signs and symptoms of diarrhoea and dehydration, particularly in elderly — consult product literature if severe diarrhoea occurs.
- Monitor for posterior reversible encephalopathy syndrome (presenting as seizures, altered mental status, nausea, vomiting, headache, or visual disturbance).

### NATIONAL FUNDING/ACCESS DECISIONS
**NICE technology appraisals (TAs)**
- Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (March 2014) **NICE TA307**
  - Aflibercept in combination with irinotecan and fluorouracil-based therapy is not recommended within its marketing authorisation for treating metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing regimen.
  - [www.nice.org.uk/TA307](http://www.nice.org.uk/TA307)

### MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

#### Solution for infusion
- **Zaltrap** (Sanofi) ▼
  - **Aflibercept 25 mg per 1 ml** Zaltrap 200mg/8ml concentrate for solution for infusion vials | 1 vial £591.30 (Hospital only)
  - Zaltrap 100mg/4ml concentrate for solution for infusion vials | 1 vial £295.65 (Hospital only)
Chapter 9
Blood and nutrition

Contents

Blood and blood-forming organs page 922
  1 Anaemias 922
    1.1 Hypoplastic, haemolytic, and renal anaemias 923
    1.1a Atypical haemolytic uraemic syndrome and paroxysmal nocturnal haemoglobinuria 930
    1.2 Iron deficiency anaemia 930
    1.3 Megaloblastic anaemia 936
  2 Iron overload 939
  3 Neutropenia and stem cell mobilisation 941
    3.1 Neutropenia 941
    3.2 Stem cell mobilisation 944
  4 Platelet disorders 944
    4.1 Essential thrombocythaemia 945
    4.2 Idiopathic thrombocytopenic purpura 945
Nutrition and metabolic disorders 947
  1 Fluid and electrolyte imbalances 947
    1.1 Calcium imbalance 957
    1.1a Hypercalcaemia and hypercalciuria 957
    1.1b Hypocalcaemia 958
    1.2 Low blood volume 960
    1.3 Magnesium imbalance 962
    1.3a Hypomagnesaemia 962
    1.4 Phosphate imbalance 964
    1.4a Hyperphosphataemia 964
    1.4b Hypophosphataemia 967
  1.5 Potassium imbalance 967
    1.5a Hyperkalaemia 967
    1.5b Hypokalaemia 968
  2 Metabolic disorders 969
    2.1 Acute porphyrias 969
    2.2 Carnitine deficiency 971
    2.3 Fabry’s disease 972
    2.4 Gaucher’s disease 972
    2.5 Homocystinuria 973
    2.6 Mucopolysaccharidosis 974
    2.7 Nephropathic cystinosis 975
    2.8 Niemann-Pick type C disease 976
    2.9 Pompe disease 976
    2.10 Tyrosinaemia type I 977
    2.11 Urea cycle disorders 977
    2.12 Wilson’s disease 978
  3 Mineral and trace elements deficiencies 978
    3.1 Selenium deficiency 978
    3.2 Zinc deficiency 979
  4 Nutrition (intravenous) 979
  5 Nutrition (oral) 985
    5.1 Special diets 986
    5.1a Phenylketonuria 986
  6 Vitamin deficiency 986
    6.1 Neural tube defects (prevention in pregnancy) 997

Blood and blood-forming organs

1 Anaemias

Anaemias

Initiation of treatment
Before initiating treatment for anaemia it is essential to determine which type is present. Iron salts may be harmful and result in iron overload if given alone to patients with anaemias other than those due to iron deficiency.

Sickle-cell anaemia
Sickle-cell disease is caused by a structural abnormality of haemoglobin resulting in deformed, less flexible red blood cells. Acute complications in the more severe forms include sickle-cell crisis, where infarction of the microvasculature and blood supply to organs results in severe pain. Sickle-cell crisis requires hospitalisation, intravenous fluids, analgesia and treatment of any concurrent infection. Chronic complications include skin ulceration, renal failure, and increased susceptibility to infection. Pneumococcal vaccine, haemophilus influenzae type b vaccine, an annual influenza vaccine and prophylactic penicillin reduce the risk of infection. Hepatitis B vaccine should be considered if the patient is not immune.

In most forms of sickle-cell disease, varying degrees of haemolytic anaemia are present accompanied by increased erythropoiesis; this may increase folate requirements and folate supplementation may be necessary.

Hydroxycarbamide p. 863 can reduce the frequency of crises and the need for blood transfusions in sickle-cell disease. The beneficial effects of hydroxycarbamide may not become evident for several months.

G6PD deficiency
Glucose 6-phosphate dehydrogenase (G6PD) deficiency is highly prevalent in individuals originating from most parts of Africa, from most parts of Asia, from Oceania, and from Southern Europe; it can also occur, rarely, in any other individuals. G6PD deficiency is more common in males than it is in females.

Individuals with G6PD deficiency are susceptible to developing acute haemolytic anaemia when they take a number of common drugs. They are also susceptible to developing acute haemolytic anaemia when they eat fava beans (broad beans, Vicia faba); this is termed favism and can be more severe in children or when the fresh fava beans are eaten raw.

When prescribing drugs for patients with G6PD deficiency, the following three points should be kept in mind:

- G6PD deficiency is genetically heterogeneous; susceptibility to the haemolytic risk from drugs varies;
thus, a drug found to be safe in some G6PD-deficient individuals may not be equally safe in others;
• manufacturers do not routinely test drugs for their effects in G6PD-deficient individuals;
• the risk and severity of haemolysis is almost always dose-related.

The lists below should be read with these points in mind. Ideally, information about G6PD deficiency should be available before prescribing a drug listed below. However, in the absence of this information, the possibility of haemolysis should be considered, especially if the patient belongs to a group in which G6PD deficiency is common.

A very few G6PD-deficient individuals with chronic non-spherocytic haemolytic anaemia have haemolysis even in the absence of an exogenous trigger. These patients must be regarded as being at high risk of severe exacerbation of haemolysis following administration of any of the drugs listed below.

Drugs with definite risk of haemolysis in most G6PD-deficient individuals
• Dapsone and other sulfones (higher doses for dermatitis herpetiformis more likely to cause problems)
• Methylthioninium chloride
• Nirmidazole (not on UK market)
• Nitrofurantoin
• Pamaquin (not on UK market)
• Primarquine (30 mg weekly for 8 weeks has been found to be without undue harmful effects in African and Asian people)
• Quinolones (including ciprofloxacin, moxifloxacin, nalidixic acid, norfloxacin, and ofloxacin)
• Rasburicase
• Sulfonamides (including co-trimoxazole; some sulfonamides, e.g. sulfadiazine, have been tested and found not to be haemolytic in many G6PD-deficient individuals)

Drugs with possible risk of haemolysis in some G6PD-deficient individuals
• Aspirin (acceptable up to a dose of at least 1 g daily in most G6PD-deficient individuals)
• Chloroquine (acceptable in acute malaria and malaria chemoprophylaxis)
• Menadione, water-soluble derivatives (e.g. menadiol sodium phosphate)
• Quinidine (acceptable in acute malaria) [not on UK market]
• Quinine (acceptable in acute malaria)
• Sulfonylureas

Naphthalene in mothballs also causes haemolysis in individuals with G6PD deficiency.

Drugs used in hypoplastic, haemolytic, and renal anaemias
Anabolic steroids, pyridoxine hydrochloride p. 988, antilymphocyte immunoglobulin, and various corticosteroids are used in hypoplastic and haemolytic anaemias.

Antilymphocyte immunoglobulin given intravenously through a central line over 12–18 hours each day for 5 days produces a response in about 50% of cases of acquired aplastic anaemia; the response rate may be increased when ciclosporin p. 788 is given as well. Severe reactions are common in the first 2 days and profound immunosuppression can occur; antilymphocyte immunoglobulin should be given under specialist supervision with appropriate resuscitation facilities. Alternatively, oxymetholone tablets (available from ‘special order’ manufacturers or specialist importing companies) can be used in aplastic anaemia for 3 to 6 months.

It is unlikely that dietary deprivation of pyridoxine hydrochloride produces clinically relevant haematological effects. However, certain forms of sideroblastic anaemia respond to pharmacological doses, possibly reflecting its role as a co-enzyme during haemoglobin synthesis. Pyridoxine hydrochloride is indicated in both idiopathic acquired and hereditary sideroblastic anaemias. Although complete cures have not been reported, some increase in haemoglobin can occur; the dose required is usually high. Reversible sideroblastic anaemias respond to treatment of the underlying cause but in pregnancy, haemolytic anaemias, and alcohol dependence, or during isoniazid p. 554 treatment, pyridoxine hydrochloride is also indicated.

Corticosteroids have an important place in the management of haematological disorders. They include conditions with an autoimmune haemolytic anaemia, immune thrombocytopenias and neutropenias, and major transfusion reactions. They are also used in chemotherapy schedules for many types of lymphoma, lymphoid leukemias, and paraproteinaemias, including multiple myeloma.

Erythropoietins (recombinant human erythropoietins) are used to treat the anaemia associated with erythropoietin deficiency in chronic renal failure, to increase the yield of autologous blood in normal individuals and to shorten the period of symptomatic anaemia in patients receiving cytotoxic chemotherapy.

Epoetin beta p. 927 is also used for the prevention of anaemia in preterm neonates of low birth-weight; only unpreserved formulations should be used in neonates because other preparations may contain benzyl alcohol.

Darbepoetin alfa p. 924 is a hyperglycosylated derivative of epoetin; it has a longer half life and can be administered less frequently than epoetin.

Mesotherapy polyethylene glycol-epoetin beta p. 929 is a continuous erythropoietin receptor activator that is licensed for the treatment of symptomatic anaemia associated with chronic kidney disease. It has a longer duration of action than epoetin.

1.1 Hypoplastic, haemolytic, and renal anaemias

Other drugs used for Hypoplastic, haemolytic, and renal anaemias Eltrombopag, p. 945

ANABOLIC STEROIDS ANDROSTAN DERIVATIVES

Oxymetholone

- INDICATIONS AND DOSE
  Aplastic anaemia
  - Adult: 1–5 mg/kg daily for 3 to 6 months

- INTERACTIONS Appendix 1: oxymetholone

- MEDICINAL FORMS
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension
  - Capsule
    - Oxymetholone (Non-proprietary)
      - Oxymetholone 50 mg Oxymetholone 50mg capsules | 50 capsule £475.00 (CD4-2)

downloaded from www.medicalbr.com
EPOETINS

**IMPORTANT SAFETY INFORMATION**

**MHRA/CHM ADVICE (DECEMBER 2007) ERYTHROPOIETINS—HAEMOGLOBIN CONCENTRATION**

Overcorrection of haemoglobin concentration in patients with chronic kidney disease may increase the risk of death and serious cardiovascular events, and in patients with cancer may increase the risk of thrombosis and related complications:

- patients should not be treated with erythropoietins for the licensed indications in chronic kidney disease or cancer in patients receiving chemotherapy unless symptoms of anaemia are present
- the haemoglobin concentration should be maintained within the range 10–12 g/100 mL
- haemoglobin concentrations higher than 12 g/100 mL should be avoided

- the aim of treatment is to relieve symptoms of anaemia, and in patients with chronic kidney disease to avoid the need for blood transfusion; the haemoglobin concentration should not be increased beyond that which provides adequate control of symptoms of anaemia (in some patients, this may be achieved at concentrations lower than the recommended range)

**MHRA/CHM ADVICE (DECEMBER 2007 AND JULY 2008) ERYTHROPOIETINS—TUMOUR PROGRESSION AND SURVIVAL IN PATIENTS WITH CANCER**

Clinical trial data show an unexplained excess mortality and increased risk of tumour progression in patients with anaemia associated with cancer who have been treated with erythropoietins. Many of these trials used erythropoietins outside of the licensed indications (i.e. overcorrected haemoglobin concentration or given to patients who have not received chemotherapy):

- erythropoietins licensed for the treatment of symptomatic anaemia associated with cancer, are licensed only for patients who are receiving chemotherapy
- the decision to use erythropoietins should be based on an assessment of the benefits and risks for individual patients; blood transfusion may be the preferred treatment for anaemia associated with cancer chemotherapy, particularly in those with a good cancer prognosis

- ***CONTRA-INDICATIONS*** Patients unable to receive thromboprophylaxis · pure red cell aplasia following erythropoietin therapy · uncontrolled hypertension

- ***CAUTIONS*** Aluminium toxicity (can impair the response to erythropoietin) · concurrent infection (can impair the response to erythropoietin) · correct factors that contribute to the anaemia of chronic renal failure, such as iron or folate deficiency, before treatment · during dialysis (increase in unfractioinated or low molecular weight heparin dose may be needed) · epilepsy · inadequately treated or poorly controlled blood pressure—interrupt treatment if blood pressure uncontrolled · ischaemic vascular disease · malignant disease · other inflammatory disease (can impair the response to erythropoietin) · risk of thrombosis may be increased when used for anaemia before orthopaedic surgery—avoid in cardiovascular disease including recent myocardial infarction or cerebrovascular accident · risk of thrombosis may be increased when used for anaemia in adults receiving cancer chemotherapy · sickle-cell disease (lower target haemoglobin concentration may be appropriate) · sudden stabbing migraine–like pain (warning of a hypertensive crisis) · thrombocytosis (monitor platelet count for first 8 weeks)

- ***SIDE-EFFECTS***

  - **Common or very common** Aggravation of hypertension (dose-dependent) · cardiovascular events · diarrhea · dose-dependent increase in platelet count regressing during treatment (but thrombocytosis rare) · headache · hypertensive crisis (in isolated patients with normal or low blood pressure) · increase in blood pressure (dose-dependent) · influenza-like symptoms (may be reduced if intravenous injection given over 5 minutes) · nausea · shunt thrombosis especially if tendency to hypotension or arteriovenous shunt complications · vomiting

  - **Very rare** Sudden loss of efficacy because of pure red cell aplasia, particularly following subcutaneous administration in patients with chronic renal failure

  - **Frequency not known** Anaphylaxis · angioedema · hyperkalaemia · hypersensitivity reactions · injection-site reactions · peripheral oedema · skin reactions

- ***SIDE-EFFECTS, FURTHER INFORMATION***

  - Hypertensive crisis · In isolated patients with normal or low blood pressure, hypertensive crisis with encephalopathy-like symptoms and generalised tonic-clonic seizures requiring immediate medical attention has occurred with epoetin.

  - Pure red cell aplasia · There have been very rare reports of pure red cell aplasia in patients treated with erythropoietins. In patients who develop a lack of efficacy with erythropoietin therapy and with a diagnosis of pure red cell aplasia, treatment with erythropoietins must be discontinued and testing for erythropoietin antibodies considered. Patients who develop pure red cell aplasia should not be switched to another form of erythropoietin.

- ***MONITORING REQUIREMENTS***

  - Monitor closely blood pressure, reticulocyte counts, haemoglobin, and electrolytes—interrupt treatment if blood pressure uncontrolled.

  - Other factors, such as iron or folate deficiency, that contribute to the anaemia of chronic renal failure should be corrected before treatment and monitored during therapy. Supplemental iron may improve the response in resistant patients.

---

**Darbepoetin alfa**

- ***INDICATIONS AND DOSE***

  - Symptomatic anaemia associated with chronic renal failure in patients on dialysis

    - **BY SUBCUTANEOUS INJECTION, OR BY INTRAVENOUS INJECTION**

      - Adult: Initially 450 nanograms/kg once weekly, dose to be adjusted according to response by approximately 25% at intervals of at least 4 weeks, maintenance dose to be given once weekly or once every 2 weeks, reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose, when changing route give same dose then adjust according to weekly or fortnightly haemoglobin measurements, adjust doses not more frequently than every 2 weeks during maintenance treatment

  - Symptomatic anaemia associated with chronic renal failure in patients not on dialysis

    - **BY SUBCUTANEOUS INJECTION**

      - Adult: Initially 450 nanograms/kg once weekly, alternatively initially 750 nanograms/kg every 2 weeks, dose to be adjusted according to response by
If different erythropoiesis-stimulating agents are equally suitable, the product with the lowest acquisition cost for the course of treatment should be used.

www.nice.org.uk/TA323

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Aranesp (Amgen Ltd)**
  - Darbepoetin alfa 25 microgram per 1 ml
    - Aranesp 10micrograms/0.4ml solution for injection pre-filled syringes | 4 pre-filled disposable injection (Pdt) £56.72
  - Darbepoetin alfa 40 microgram per 1 ml
    - Aranesp 20micrograms/0.5ml solution for injection pre-filled syringes | 4 pre-filled disposable injection (Pdt) £117.45
  - Darbepoetin alfa 100 microgram per 1 ml
    - Aranesp 50micrograms/0.5ml solution for injection pre-filled syringes | 4 pre-filled disposable injection (Pdt) £234.90
    - Aranesp 40micrograms/0.4ml solution for injection pre-filled syringes | 4 pre-filled disposable injection (Pdt) £176.17
  - Darbepoetin alfa 200 microgram per 1 ml
    - Aranesp 100micrograms/0.5ml solution for injection pre-filled syringes | 4 pre-filled disposable injection (Pdt) £587.24
    - Aranesp 100micrograms/0.65ml solution for injection pre-filled syringes | 4 pre-filled disposable injection (Pdt) £763.42
    - Aranesp 80micrograms/0.4ml solution for injection pre-filled syringes | 4 pre-filled disposable injection (Pdt) £489.79
    - Aranesp 60micrograms/0.3ml solution for injection pre-filled syringes | 4 pre-filled disposable injection (Pdt) £352.35
  - Darbepoetin alfa 500 microgram per 1 ml
    - Aranesp 300micrograms/0.6ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (Pdt) £440.43
    - Aranesp 200micrograms/0.5ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (Pdt) £734.05
    - Aranesp 150micrograms/0.3ml solution for injection pre-filled syringes | 4 pre-filled disposable injection (Pdt) £380.86
    - Aranesp SureClick (Amgen Ltd)
      - Darbepoetin alfa 40 microgram per 1 ml
        - Aranesp SureClick 10micrograms/0.5ml solution for injection pre-filled disposable devices | 1 pre-filled disposable injection (Pdt) £29.36
      - Darbepoetin alfa 100 microgram per 1 ml
        - Aranesp SureClick 40micrograms/0.4ml solution for injection pre-filled disposable devices | 1 pre-filled disposable injection (Pdt) £58.72
        - Aranesp SureClick 80micrograms/0.4ml solution for injection pre-filled disposable devices | 1 pre-filled disposable injection (Pdt) £117.45
      - Darbepoetin alfa 200 microgram per 1 ml
        - Aranesp SureClick 60micrograms/0.3ml solution for injection pre-filled disposable devices | 1 pre-filled disposable injection (Pdt) £88.09
        - Aranesp SureClick 100micrograms/0.5ml solution for injection pre-filled disposable devices | 1 pre-filled disposable injection (Pdt) £146.81
      - Darbepoetin alfa 500 microgram per 1 ml
        - Aranesp SureClick 150micrograms/0.3ml solution for injection pre-filled disposable devices | 1 pre-filled disposable injection (Pdt) £220.22
        - Aranesp SureClick 300micrograms/0.6ml solution for injection pre-filled disposable devices | 1 pre-filled disposable injection (Pdt) £440.43

- **Aranesp SureClick (Amgen Ltd)**
  - Darbepoetin alfa 40 microgram per 1 ml
    - Aranesp SureClick 20micrograms/0.5ml solution for injection pre-filled disposable devices | 1 pre-filled disposable injection (Pdt) £58.72
  - Darbepoetin alfa 100 microgram per 1 ml
    - Aranesp SureClick 40micrograms/0.5ml solution for injection pre-filled disposable devices | 1 pre-filled disposable injection (Pdt) £440.43
  - Darbepoetin alfa 200 microgram per 1 ml
    - Aranesp SureClick 80micrograms/0.4ml solution for injection pre-filled disposable devices | 1 pre-filled disposable injection (Pdt) £352.35
    - Aranesp SureClick 100micrograms/0.5ml solution for injection pre-filled disposable devices | 1 pre-filled disposable injection (Pdt) £380.86
    - Aranesp SureClick 150micrograms/0.3ml solution for injection pre-filled disposable devices | 4 pre-filled disposable injection (Pdt) £734.05

**Epoetin alfa**

**INDICATIONS AND DOSE**

**BINOCR® PRE-FILLED SYRINGES**

**Symptomatic anaemia associated with chronic renal failure in patients on haemodialysis**

- BY INTRAVENOUS INJECTION
  - Adult: Initially 50 units/kg 3 times a week, adjusted in steps of 25 units/kg 3 times a week, dose adjusted according to response at intervals of at least 4 weeks; maintenance 25–100 units/kg 3 times a week, intravenous injection to be given over 1–5 minutes, reduce dose by approximately 25% if rise in haemoglobin concentration exceeds...
2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose

Symptomatic anaemia associated with chronic renal failure in adults on peritoneal dialysis

- **BY INTRAVENOUS INJECTION**
  - Adult: Initially 50 units/kg twice weekly; maintenance 25–50 units/kg twice weekly, intravenous injection to be given over 1–5 minutes, reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose

Severe symptomatic anaemia of renal origin in adults with renal insufficiency not yet on dialysis

- **BY INTRAVENOUS INJECTION**
  - Adult: Initially 50 units/kg 3 times a week, increased in steps of 25 units/kg 3 times a week, adjusted according to response, dose to be increased at intervals of at least 4 weeks; maintenance 17–33 units/kg 3 times a week (max. per dose 200 units/kg 3 times a week), intravenous injection to be given over 1–5 minutes, reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose

Symptomatic anaemia in adults receiving cancer chemotherapy

- **BY SUBCUTANEOUS INJECTION**
  - Adult: Initially 150 units/kg 3 times a week, alternatively initially 450 units/kg once weekly, increased to 300 units/kg 3 times a week, increased if appropriate rise in haemoglobin (or reticulocyte count) not achieved after 4 weeks; discontinue if inadequate response after 4 weeks at higher dose, subcutaneous injection maximum 1 mL per injection site, reduce dose by approximately 25–50% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose. Discontinue approximately 4 weeks after ending chemotherapy

To increase yield of autologous blood (to avoid homologous blood) in predonation programme in moderate anaemia either when large volume of blood required or when sufficient blood cannot be saved for elective major surgery

- **BY INTRAVENOUS INJECTION**
  - Adult: 600 units/kg twice weekly for 3 weeks before surgery, consult product literature for details and advice on ensuring high iron stores, intravenous injection to be given over 1–5 minutes

Moderate anaemia (haemoglobin concentration 10–13 g/100 mL) before elective orthopaedic surgery in adults with expected moderate blood loss to reduce exposure to allogeneic blood transfusion or if autologous transfusion unavailable

- **BY SUBCUTANEOUS INJECTION**
  - Adult: 600 units/kg once weekly for 3 weeks before surgery and on day of surgery, alternatively 300 units/kg daily for 15 days starting 10 days before surgery, consult product literature for details, subcutaneous injection maximum 1 mL per injection site

EPREP® PRE-FILLED SYRINGES

Symptomatic anaemia associated with chronic renal failure in patients on haemodialysis

- **BY INTRAVENOUS INJECTION, OR BY SUBCUTANEOUS INJECTION**
  - Adult: Initially 50 units/kg 3 times a week, adjusted in steps of 25 units/kg 3 times a week, dose adjusted according to response at intervals of at least 4 weeks; maintenance 75–300 units/kg once weekly, intravenous route preferred, intravenous injection to be given over 1–5 minutes, subcutaneous injection, maximum 1 mL per injection site, maintenance dose can be given as a single dose or in divided doses, reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose

Symptomatic anaemia associated with chronic renal failure in adults on peritoneal dialysis

- **BY INTRAVENOUS INJECTION, OR BY SUBCUTANEOUS INJECTION**
  - Adult: Initially 50 units/kg twice weekly; maintenance 25–50 units/kg twice weekly, intravenous route preferred, intravenous injection to be given over 1–5 minutes, subcutaneous injection, maximum 1 mL per injection site, reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose

Severe symptomatic anaemia of renal origin in adults with renal insufficiency not yet on dialysis

- **BY INTRAVENOUS INJECTION, OR BY SUBCUTANEOUS INJECTION**
  - Adult: Initially 50 units/kg 3 times a week, increased in steps of 25 units/kg 3 times a week, increased if appropriate rise in haemoglobin (or reticulocyte count) not achieved after 4 weeks; discontinue if inadequate response after 4 weeks at higher dose, subcutaneous injection maximum 1 mL per injection site, reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose.
appropriate rise in haemoglobin (or reticulocyte count) not achieved after 4 weeks; discontinue if inadequate response after 4 weeks at higher dose, subcutaneous injection maximum 1 mL per injection site, reduce dose by approximately 25–50% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose. Discontinue approximately 4 weeks after ending chemotherapy

To increase yield of autologous (to avoid homologous blood) in predonation programme in moderate anaemia either when large volume of blood required or when sufficient blood cannot be saved for elective major surgery

» BY INTRAVENOUS INJECTION

» Adult: 600 units/kg twice weekly for 3 weeks before surgery, consult product literature for details and advice on ensuring high iron stores, intravenous injection to be given over 1–5 minutes

Moderate anaemia (haemoglobin concentration 10–13 g/100 mL) before elective orthopaedic surgery in adults with expected moderate blood loss to reduce exposure to allogeneic blood transfusion or if autologous transfusion unavailable

» BY SUBCUTANEOUS INJECTION

» Adult: 600 units/kg once weekly for 3 weeks before surgery and on day of surgery, alternatively 300 units/kg daily for 15 days starting 10 days before surgery, consult product literature for details, subcutaneous injection maximum 1 mL per injection site

**Epoetin alfa 4000 unit per 1 mL** Eprex 2,000 units/0.5 mL solution for injection pre-filled syringes | 6 pre-filled disposable injection | £66.37

**Epoetin alfa 10000 unit per 1 mL** Eprex 6,000 units/0.6 mL solution for injection pre-filled syringes | 6 pre-filled disposable injection | £199.11

Eprex 4,000 units/0.4 mL solution for injection pre-filled syringes | 6 pre-filled disposable injection | £132.74

Eprex 5,000 units/0.5 mL solution for injection pre-filled syringes | 6 pre-filled disposable injection | £165.92

Eprex 3,000 units/0.3 mL solution for injection pre-filled syringes | 6 pre-filled disposable injection | £99.55

Eprex 10,000 units/1 mL solution for injection pre-filled syringes | 6 pre-filled disposable injection | £331.85

Eprex 8,000 units/0.8 mL solution for injection pre-filled syringes | 6 pre-filled disposable injection | £265.48

**Epoetin alfa 40000 unit per 1 mL** Eprex 20,000 units/0.5 mL solution for injection pre-filled syringes | 1 pre-filled disposable injection | £110.62

Eprex 30,000 units/0.75 mL solution for injection pre-filled syringes | 1 pre-filled disposable injection | £199.11

Eprex 40,000 units/1 mL solution for injection pre-filled syringes | 1 pre-filled disposable injection | £265.48

**Epoetin alfa**

**Indications and dosage**

Symptomatic anaemia associated with chronic renal failure

» BY SUBCUTANEOUS INJECTION

» Adult: Initially 20 units/kg 3 times a week for 4 weeks, increased in steps of 20 units/kg 3 times a week, according to response at intervals of 4 weeks, total weekly dose may be divided into daily doses; maintenance dose, initially reduce dose by half then adjust according to response at intervals of 1–2 weeks, total weekly maintenance dose may be given as a single dose or in 3 or 7 divided doses. Subcutaneous route preferred in patients not on haemodialysis. Reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration approaches or exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose; maximum 720 units/kg per week

» BY INTRAVENOUS INJECTION

» Adult: Initially 40 units/kg 3 times a week for 4 weeks, then increased to 80 units/kg 3 times a week, then increased in steps of 20 units/kg 3 times a week if required, at intervals of 4 weeks; maintenance dose, initially reduce dose by half then adjust according to response at intervals of 1–2 weeks. Intravenous injection to be administered over 2 minutes. Subcutaneous route preferred in patients not on haemodialysis. Reduce dose by approximately 25% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration approaches or exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose; maximum 720 units/kg per week

**Symptomatic anaemia in adults with non-myeloid malignancies receiving chemotherapy**

» BY SUBCUTANEOUS INJECTION

» Adult: Initially 450 units/kg once weekly for 4 weeks, dose to be given weekly as a single dose or in 3–7 divided doses, increased dose after 4 weeks (if a rise in haemoglobin of at least 1 g/100 mL not achieved), increased to 900 units/kg once weekly, continued →

**Epoetin alfa**

**Solution for injection**

» Eprex (Janssen-Cilag Ltd)

**Epoetin alfa 2000 unit per 1 mL** Eprex 1,000 units/0.5 mL solution for injection pre-filled syringes | 6 pre-filled disposable injection | £33.18

**Epoetin alfa 5000 unit per 1 mL** Eprex 2,500 units/0.5 mL solution for injection pre-filled syringes | 6 pre-filled disposable injection | £42.98

**Epoetin alfa 10000 unit per 1 mL** Eprex 5,000 units/0.6 mL solution for injection pre-filled syringes | 6 pre-filled disposable injection | £111.12

**Epoetin alfa 20000 unit per 1 mL** Eprex 10,000 units/0.8 mL solution for injection pre-filled syringes | 6 pre-filled disposable injection | £201.48

**Epoetin alfa 40000 unit per 1 mL** Eprex 20,000 units/0.5 mL solution for injection pre-filled syringes | 6 pre-filled disposable injection | £395.76

**Epoetin alfa 60000 unit per 1 mL** Eprex 30,000 units/0.75 mL solution for injection pre-filled syringes | 6 pre-filled disposable injection | £729.84

**Epoetin alfa 80000 unit per 1 mL** Eprex 40,000 units/1 mL solution for injection pre-filled syringes | 6 pre-filled disposable injection | £941.92
dose to be given weekly as a single dose or in 3–7 divided doses, if adequate response obtained reduce dose by 25–50%, discontinue treatment if haemoglobin concentration does not increase by at least 1 g/100 mL after 8 weeks of therapy (response unlikely). Reduce dose by approximately 25–50% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose. Discontinue approximately 4 weeks after ending chemotherapy; maximum 60 000 units per week

To increase yield of autologous blood (to avoid homologous blood) in predonation programme in moderate anaemia when blood-conserving procedures are insufficient or unavailable

- BY INTRAVENOUS INJECTION, OR BY SUBCUTANEOUS INJECTION
- Adult: (consult product literature)

- INTERACTIONS
  - Appendix 1: epoetin beta
- PREGNANCY
- BREAST FEEDING
  - Unlikely to be present in milk. Minimal effect on infant.
- HEPATIC IMPAIRMENT
  - Manufacturers advise caution in chronic hepatic failure.

- NATIONAL FUNDING/ACCESS DECISIONS
  - NICE technology appraisals (TAs)
  - Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (November 2014) NICE TA323
  - Erythropoiesis-stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa) are recommended, within their marketing authorisations, as options for treating anaemia in people with cancer who are having chemotherapy.
  - If different erythropoiesis-stimulating agents are equally suitable, the product with the lowest acquisition cost for the course of treatment should be used.
  - www.nice.org.uk/TA323

- MEDICINAL FORMS
  - There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

EXCIPIENTS: May contain Phenylalanine

- NeoRecormon (Roche Products Ltd)
  - Epoetin beta 1667 unit per 1 ml NeoRecormon 500 units/0.3ml solution for injection pre-filled syringes | 6 pre-filled disposable injection (Pom) £21.05
  - Epoetin beta 6667 unit per 1 ml NeoRecormon 2,000 units/0.3ml solution for injection pre-filled syringes | 6 pre-filled disposable injection (Pom) £84.17
  - Epoetin beta 10000 unit per 1 ml NeoRecormon 3,000 units/0.3ml solution for injection pre-filled syringes | 6 pre-filled disposable injection (Pom) £126.25
  - Epoetin beta 13333 unit per 1 ml NeoRecormon 4,000 units/0.3ml solution for injection pre-filled syringes | 6 pre-filled disposable injection (Pom) £168.34
  - Epoetin beta 16667 unit per 1 ml NeoRecormon 10,000 units/0.6ml solution for injection pre-filled syringes | 6 pre-filled disposable injection (Pom) £420.85
  - NeoRecormon 5,000 units/0.3ml solution for injection pre-filled syringes | 6 pre-filled disposable injection (Pom) £210.42
  - Epoetin beta 20000 unit per 1 ml NeoRecormon 6,000 units/0.3ml solution for injection pre-filled syringes | 6 pre-filled disposable injection (Pom) £252.50
  - Epoetin beta 33333 unit per 1 ml NeoRecormon 20,000 units/0.6ml solution for injection pre-filled syringes | 6 pre-filled disposable injection (Pom) £841.71

Epoetin beta 50000 unit per 1 ml NeoRecormon 30,000 units/0.6ml solution for injection pre-filled disposable injection (Pom) £841.71

Epoetin zeta

- INDICATIONS AND DOSE
  - Symptomatic anaemia associated with chronic renal failure in patients on haemodialysis
    - BY INTRAVENOUS INJECTION, OR BY SUBCUTANEOUS INJECTION
    - Adult: Initially 50 units/kg 3 times a week, adjusted according to response, adjusted in steps of 25 units/kg 3 times a week, dose to be adjusted at intervals of at least 4 weeks; maintenance 25–50 units/kg 3 times a week, intravenous injection to be given over 1–5 minutes, if given by subcutaneous injection, a maximum of 1 mL can be given per injection site, avoid increasing haemoglobin concentration at a rate exceeding 2 g/100 mL over 4 weeks
  - Symptomatic anaemia associated with chronic renal failure in adults on peritoneal dialysis
    - BY INTRAVENOUS INJECTION, OR BY SUBCUTANEOUS INJECTION
    - Adult: Initially 50 units/kg twice weekly; maintenance 25–50 units/kg twice weekly, intravenous injection to be given over 1–5 minutes, if given by subcutaneous injection, a maximum of 1 mL can be given per injection site, avoid increasing haemoglobin concentration at a rate exceeding 2 g/100 mL over 4 weeks
  - Severe symptomatic anaemia of renal origin in adults with renal insufficiency not yet on dialysis
    - BY INTRAVENOUS INJECTION, OR BY SUBCUTANEOUS INJECTION
    - Adult: Initially 50 units/kg 3 times a week, adjusted according to response, adjusted in steps of 25 units/kg 3 times a week, dose to be increased at intervals of at least 4 weeks; maintenance 17–33 units/kg 3 times a week (max. per dose 200 units/kg 3 times a week), intravenous injection to be given over 1–5 minutes, if given by subcutaneous injection, a maximum of 1 mL can be given per injection site, avoid increasing haemoglobin concentration at a rate exceeding 2 g/100 mL over 4 weeks
  - Symptomatic anaemia in adults receiving cancer chemotherapy
    - BY SUBCUTANEOUS INJECTION
    - Adult: Initially 150 units/kg 3 times a week, alternatively initially 450 units/kg once weekly, increased to 300 units/kg 3 times a week, only increase dose if appropriate rise in haemoglobin (or reticulocyte count) not achieved after 4 weeks; discontinue if inadequate response after 4 weeks at higher dose, maximum 1 mL per injection site, reduce dose by approximately 25–50% if rise in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin concentration exceeds 12 g/100 mL; if haemoglobin concentration continues to rise, despite dose reduction, suspend treatment until haemoglobin concentration decreases and then restart at a dose approximately 25% lower than the previous dose. Discontinue approximately 4 weeks after ending chemotherapy

To increase yield of autologous blood (to avoid homologous blood) in predonation programme in moderate anaemia either when large volume of blood required or when sufficient blood cannot be saved for elective major surgery

- BY INTRAVENOUS INJECTION
  - Adult: 600 units/kg twice weekly for 3 weeks before surgery, intravenous injection to be given over...
1–5 minutes, consult product literature for details and advice on ensuring high iron stores

**Moderate anaemia (haemoglobin concentration 10–13 g/100 mL) before elective orthopaedic surgery in adults with expected moderate blood loss to reduce exposure to allogeneic blood transfusion or if autologous transfusion unavailable**

- **BY SUBCUTANEOUS INJECTION**
- **Adult:** 600 units/kg every week for 3 weeks before surgery and on day of surgery, alternatively 300 units/kg daily for 15 days starting 10 days before surgery, maximum 1 mL per injection site, consult product literature for details.

**INTERACTIONS**  
> Appendix 1: epoetin zeta

**PREGNANCY**  
No evidence of harm. Benefits probably outweigh risk of anaemia and of blood transfusion in pregnancy.

**BREAST FEEDING**  
Unlikely to be present in milk. Minimal effect on infant.

**HEPATIC IMPAIRMENT**  
Manufacturers advise caution in chronic hepatic failure.

**PRESCRIBING AND DISPENSING INFORMATION**  
Epoetin zeta is a biological medicine. Biological medicines must be prescribed and dispensed by brand name, see *Biological medicines* and *Biosimilar medicines*, under Guidance on prescribing p. 1.

**NATIONAL FUNDING/ACCESS DECISIONS NICE technology appraisals (TAs)**

- Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (November 2014) NICE TA323
- Erythropoiesis-stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa) are recommended, within their marketing authorisations, as options for treating anaemia in people with cancer who are having chemotherapy.

If different erythropoiesis-stimulating agents are equally suitable, the product with the lowest acquisition cost for the course of treatment should be used.

www.nice.org.uk/TA323

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

**EXCIPIENTS:** May contain Phenylalanine

- **Retacrit** (Pfizer Ltd)
  - Epoetin zeta 3333 unit per 1 mL  
    - Retacrit 2,000 units/0.6 mL solution for injection pre-filled syringes (Hospital only) £57.70  
    - Retacrit 3,000 units/0.9 mL solution for injection pre-filled syringes (Hospital only) £63.90  
    - Retacrit 1,000 units/0.3 mL solution for injection pre-filled syringes (Hospital only) £28.85

- Epoetin zeta 10000 unit per 1 mL  
  - Retacrit 6,000 units/0.6 mL solution for injection pre-filled syringes (Hospital only) £173.09

- Epoetin zeta 5000 unit per 1 mL (Hospital only)
  - Retacrit 5,000 units/0.5 mL solution for injection pre-filled syringes (Hospital only) £115.40

- Retacrit 10,000 units/1 mL solution for injection pre-filled syringes (Hospital only) £288.48

- Retacrit 8,000 units/0.8 mL solution for injection pre-filled syringes (Hospital only) £230.79

- Epoetin zeta 40000 unit per 1 mL  
  - Retacrit 20,000 units/0.5 mL solution for injection pre-filled syringes (Hospital only) £144.25

**SIDE-EFFECTS**  
Hot flushes

**PREGNANCY**  
No evidence of harm in animal studies—manufacturer advises caution.

**BREAST FEEDING**  
Manufacturer advises use only if potential benefit outweighs risk—present in milk in animal studies.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Miraca** (Roche Products Ltd)
  - Methoxy polyethylene glycol-epoetin beta 100 microgram per 1 mL Miraca 30 micrograms/0.3 mL solution for injection pre-filled syringes £44.05
  - Methoxy polyethylene glycol-epoetin beta 166.67 microgram per 1 mL Miraca 50 micrograms/0.3 mL solution for injection pre-filled syringes £73.41
  - Methoxy polyethylene glycol-epoetin beta 250 microgram per 1 mL Miraca 75 micrograms/0.3 mL solution for injection pre-filled syringes £110.11

- **Methoxy polyethylene glycol-epoetin beta 333.33 microgram per 1 mL Miraca 100 micrograms/0.3 mL solution for injection pre-filled syringes £146.81
1.1a Atypical haemolytic uremic syndrome and paroxysmal nocturnal haemoglobinuria

**IMMUNOSUPPRESSANTS > MONOCLONAL ANTIBODIES**

### Eculizumab

- **DRUG ACTION** Eculizumab, a recombinant monoclonal antibody, inhibits terminal complement activation at the C5 protein and thereby reduces haemolysis and thrombotic microangiopathy.

- **INDICATIONS AND DOSE**
  
  Reduce haemolysis in paroxysmal nocturnal haemoglobinuria (PNH), in those with a history of blood transfusions (under expert supervision)
  
  - **BY INTRAVENOUS INFUSION**
    
    Adult: Initially 600 mg once weekly for 4 weeks, then increased to 900 mg once weekly for 1 week; maintenance 900 mg every 12–16 days

  Reduce thrombotic microangiopathy in atypical haemolytic uremic syndrome (aHUS) (specialist use only)
  
  - **BY INTRAVENOUS INFUSION**
    
    Adult: Initially 900 mg once weekly for 4 weeks, then increased to 1.2 g once weekly for 1 week; maintenance 1.2 g every 12–16 days

- **CONTRA-INDICATIONS** Patients unvaccinated against *Neisseria meningitidis* - unresolved *Neisseria meningitidis* infection

- **CAUTIONS** Active systemic infection

- **MEDICAL FORMS**
  
  There can be variation in the licensing of different medicines containing the same drug.

- **SOLUTION FOR INFUSION**
  
  **ELECTROLYTES:** May contain Sodium

  - **Soliris** (Alexion Pharma UK Ltd)
    
    Eculizumab 10 mg per 1 ml Soliris 300mg/30ml concentrate for solution for infusion vials | 1 vial | £3,150.00 (Hospital only)

1.2 Iron deficiency anaemia

**Anaemia, iron deficiency**

### Treatment and prophylaxis

**Treatment** with an iron preparation is justified only in the presence of a demonstrable iron-deficiency state. Before starting treatment, it is important to exclude any serious underlying cause of the anaemia (e.g. gastric erosion, gastrointestinal cancer).

**Prophylaxis** with an iron preparation may be appropriate in malabsorption, menorrhagia, pregnancy, after subtotal or total gastrectomy, in haemodialysis patients, and in the management of low birth-weight infants such as preterm neonates.

**Oral iron**

Iron salts should be given by mouth unless there are good reasons for using another route.
Ferrous salts show only marginal differences between one another in efficiency of absorption of iron. Haemoglobin regeneration rate is little affected by the type of salt used provided sufficient iron is given, and in most patients the speed of response is not critical. Choice of preparation is thus usually decided by the incidence of side-effects and cost.

The oral dose of elemental iron for iron-deficiency anaemia should be 100 to 200 mg daily. It is customary to give this as dried ferrous sulfate; for prophylaxis of iron-deficiency anaemia, ferrous sulfate may be effective.

<table>
<thead>
<tr>
<th>Iron salt/amount</th>
<th>Content of ferrous iron</th>
</tr>
</thead>
<tbody>
<tr>
<td>ferrous fumarate</td>
<td>200 mg 65 mg</td>
</tr>
<tr>
<td>ferrous gluconate</td>
<td>300 mg 35 mg</td>
</tr>
<tr>
<td>ferrous sulfate</td>
<td>300 mg 60 mg</td>
</tr>
<tr>
<td>ferrous sulfate, dried</td>
<td>200 mg 65 mg</td>
</tr>
</tbody>
</table>

**Compound preparations**
Preparations containing iron and folic acid p. 937 are used during pregnancy in women who are at high risk of developing iron and folic acid deficiency; they should be distinguished from those used for the prevention of neural tube defects in women planning a pregnancy.

It is important to note that the small doses of folic acid contained in these preparations are inadequate for the treatment of megaloblastic anaemias.

Some oral preparations contain ascorbic acid p. 991 to aid absorption of the iron but the therapeutic advantage of such preparations is minimal and cost may be increased.

There is no justification for the inclusion of other ingredients, such as the B group of vitamins (except folic acid for pregnant women).

**Modified-release preparations**
Modified-release preparations of iron are licensed for once-daily dosage, but have no therapeutic advantage and should not be used. These preparations are formulated to release iron gradually; the low incidence of side-effects may reflect the small amounts of iron available for absorption as the iron is carried past the first part of the duodenum into an area of the gut where absorption may be poor.

**Parenteral iron**
Iron can be administered parenterally as iron dextran p. 932, iron sucrose p. 933, ferric carboxymaltose below, or iron isomaltoside 1000 p. 932. Parenteral iron is generally reserved for use when oral therapy is unsuccessful because the patient cannot tolerate oral iron, or does not take it reliably, or if there is continuing blood loss, or in malabsorption. Parenteral iron may also have a role in the management of chemotherapy-induced anaemia, when given with erythropoietins, in specific patient groups (see NIC methology). Many patients with chronic renal failure who are receiving haemodialysis (and some who are receiving peritoneal dialysis) also require iron by the intravenous route on a regular basis.

With the exception of patients with severe renal failure receiving haemodialysis, parenteral iron does not produce a faster haemoglobin response than oral iron provided that the oral iron preparation is taken reliably and is absorbed adequately. If parenteral iron is necessary, the dose should be calculated according to the patient’s body-weight and total iron deficit. Depending on the preparation used, parenteral iron is given as a total dose or in divided doses.

Further treatment should be guided by monitoring haemoglobin and serum iron concentrations.

**Iron (injectable)**

**MINERALS AND TRACE ELEMENTS > IRON, INJECTABLE**

**Iron-deficiency anaemia**

**INDICATIONS AND DOSE**

**Iron-deficiency anaemia**

- **By slow intravenous injection, or by intravenous infusion**
- **Adult:** Dose calculated according to body-weight and iron deficit (consult product literature)

**CAUTIONS**
Allergic disorders - asthma - eczema - hypersensitivity can occur with parenteral iron and facilities for cardiopulmonary resuscitation must be available.

**SIDE-EFFECTS**
Hypersensitivity reactions

**SIDE-EFFECTS, FURTHER INFORMATION**

- Anaphylactic reactions Anaphylactic reactions can occur with parenteral administration of iron complexes and facilities for cardiopulmonary resuscitation must be available.

**Overdose**
For details on the management of poisoning, see Iron salts, under Emergency treatment of poisoning p. 1249.

**Ferric carboxymaltose**

**INDICATIONS AND DOSE**

**Iron-deficiency anaemia**

- **By slow intravenous injection, or by intravenous infusion**
- **Adult:** Dose calculated according to body-weight and iron deficit (consult product literature)

**SIDE-EFFECTS**

- **Common or very common** Dizziness - gastro-intestinal disturbances - headache - injection-site reactions - rash
- **Uncommon** Anaphylaxis - arthralgia - back pain - chest pain - fatigue - flushing - hypertension - hypotension - malaise - myalgia - paraesthesia - peripheral oedema - pruritus - ptyrexia - rigors - urticaria
- **Rare** Dyspnoea
Blood and nutrition

**DIRECTIONS FOR ADMINISTRATION**

*For intravenous infusion (Ferinject®),* give immediately in Sodium chloride 0.9%, dilute 200–500 mg in up to 100 mL infusion fluid and give over at least 6 minutes; dilute 0.5–1 g in up to 250 mL infusion fluid and give over at least 15 minutes.

**PRESCRIBING AND DISPENSING INFORMATION**

A ferric carboxymaltose complex containing 5% (50 mg/mL) of iron.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

**ELECTROLYTES:**

*Iron-deficiency anaemia* 50 mg per 1 ml Ferinject

1000 mg/20ml solution for injection vials | 1 vial £154.23

Ferinject 100mg/2ml solution for injection vials | 5 vial £81.18

Ferinject 50mg/10ml solution for injection vials | 5 vial £40.88

**Iron isomaltoside 1000**

**INDICATIONS AND DOSE**

Iron-deficiency anaemia

*Adult:* Doses calculated according to body-weight and iron deficit (consult product literature)

**SIDE-EFFECTS**

*Uncommon* Abdominal pain, anaphylaxis, blurred vision, constipation, cramps, dysphonia, flushing, headache, hypertension, impotence, nausea, numbness, pruritus, rash, vomiting

*Rare* Altered mental status, angioedema, arrhythmias, chest pain, diarrhoea, dizziness, epistaxis, flushing, injection-site reactions, malaise, myalgia, restlessness, seizures, sweating, tachycardia, tremor

*Very rare* Anaphylaxis, chest pain, convulsions, dizziness, epistaxis, flushing, hyperventilation, injection-site reactions, impotence, malaise, myalgia, restlessness, numbness, pruritus, restlessness, tachycardia, tremor, vomiting

**PREGNANCY**

Avoid in first trimester.

**HEPATIC IMPAIRMENT**

Avoid in decompensated liver disease and hepatitis.

**DIRECTIONS FOR ADMINISTRATION**

For intravenous infusion (Monofer®), give immediately in Sodium chloride 0.9%, dilute 100–200 mg in 100 mL infusion fluid; give 25mg over 15 minutes initially, then give at a rate not exceeding 6.67 mg/minute; *total dose infusion* diluted in 500 mL infusion fluid and given over 4–6 hours (initial dose 25 mg over 15 minutes).

**PRESCRIBING AND DISPENSING INFORMATION**

A complex of ferric hydroxide with dextran containing 5% (50 mg/mL) of iron.
Iron deficiency anaemia

**Iron sucrone**

- **INDICATIONS AND DOSE**
  - **Iron-deficiency anaemia**
    - **BY SLOW INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION**
    - Adult: Doses calculated according to body-weight and iron deficit (consult product literature)
  - **CONTRA-INDICATIONS** Anaphylaxis · asthma · eczema · history of allergic disorders
  - **CAUTIONS** Hypersensitivity reactions can occur with parenteral iron and facilities for cardiopulmonary resuscitation must be available · infection (discontinue if ongoing bacteraemia · oral iron should not be given until 5 days after last injection
  - **INTERACTIONS** → Appendix 1: iron (injectable)
  - **SIDE-EFFECTS**
    - Common or very common Taste disturbances
    - Abdominal pain · bronchospasm · chest pain · diarrhoea · dizziness · dysphonia · fever · flushing · headache · hypotension · injection-site reactions · myalgia · nausea · palpititation · pruritus · rash · tachycardia · vomiting
    - Rare Anaphylaxis · asthenia · fatigue · hypertension · paraesthesia · peripheral oedema
    - Frequency not known Arthralgia · bradycardia · confusion · increased sweating
  - **PREGNANCY** Avoid in first trimester.
  - **HEPATIC IMPAIRMENT** Use with caution. Avoid in conditions where iron overload increases risk of impairment.
  - **DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Venoferr®), give intermittently in Sodium chloride 0.9%, dilute 100 mg in up to 100 mL infusion fluid; give 25 mg over 15 minutes initially, then give at a rate not exceeding 3.33 mg/minute.
  - **PRESCRIBING AND DISPENSING INFORMATION** A complex of ferric hydroxide with sucrose containing 2% (20 mg/mL) of iron.
  - **MEDICINAL FORMS**
    - There can be variation in the licensing of different medicines containing the same drug.
    - **Solution for injection**
      - Venoferr® (Vifor Pharma UK Ltd, Imported (United States))
      - Iron (as iron sucrose) 20 mg per 1 mL
      - Venoferr 100mg/5ml solution for injection vials | 5 vial | £43.52
      - Venoferr 50mg/2.5ml solution for injection vials | 5 vial | price available

**MINERALS AND TRACE ELEMENTS** › **IRON, ORAL**

**Iron (oral)**

- **SIDE-EFFECTS** Constipation · diarrhoea · epigastric pain (dose related) · faecal impaction · gastro-intestinal irritation · nausea (dose related)
- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Managing side-effects If side-effects occur, the dose may be reduced; alternatively, another iron salt may be used, but an improvement in tolerance may simply be a result of a lower content of elemental iron. The incidence of side-effects due to ferrous sulfate is no greater than with other iron salts when compared on the basis of equivalent amounts of elemental iron.
  - Altered bowel habit Iron preparations taken orally can be constipating and occasionally lead to faecal impaction. Oral iron, particularly modified-release preparations, can exacerbate diarrhoea in patients with inflammatory bowel disease; care is also needed in patients with intestinal strictures and diverticular disease.
  - The relationship between dose and altered bowel habit (constipation or diarrhoea) is less clear than for nausea and epigastric pain.
  - **Overdose** For details on the management of poisoning, see iron salts, under Emergency treatment of poisoning p. 1249.
    - In children Iron preparations are an important cause of accidental overdose in children and as little as 20 mg/kg of elemental iron can lead to symptoms of toxicity.
  - **MONITORING REQUIREMENTS**
    - Therapeutic response The haemoglobin concentration should rise by about 100–200 mg/100 mL (1–2 g/litre) per day or 2 g/100 mL (20 g/litre) over 3–4 weeks. When the haemoglobin is in the normal range, treatment should be continued for a further 3 months to replenish the iron stores. Epithelial tissue changes such as atrophic glossitis and koilonychia are usually improved, but the response is often slow.
  - **PRESCRIBING AND DISPENSING INFORMATION**
    - In children Express the dose in terms of elemental iron and iron salt and select the most appropriate preparation; specify both the iron salt and formulation on the prescription. The iron content of artificial formula feeds should also be considered. The most common reason for lack of response in children is poor compliance; poor absorption is rare in children.
  - **PATIENT AND CARER ADVICE** Although iron preparations are best absorbed on an empty stomach they can be taken after food to reduce gastro-intestinal side-effects. May discolour stools.

**Ferric maltol**

- **INDICATIONS AND DOSE**
  - **Treatment of iron-deficiency anaemia in patients with inflammatory bowel disease**
    - **BY MOUTH**
    - Adult: 30 mg twice daily continued until iron stores are replenished; usual duration at least 12 weeks
  - **CONTRA-INDICATIONS** Exacerbation of inflammatory bowel disease · haemochromatosis · haemoglobin less than 9.5 g/dL · iron overload syndromes · repeated blood transfusions
  - **INTERACTIONS** → Appendix 1: iron (oral)
  - **SIDE-EFFECTS**
    - Common or very common Abdominal distention · abdominal pain · flatulence
    - Uncommon Acne · erythema · headache · joint stiffness · pain in extremity · thirst · vomiting
  - **NATIONAL FUNDING/ACCESS DECISIONS**
    - Scottish Medicines Consortium (SMC) Decisions
      - The Scottish Medicines Consortium has advised (December 2016) that ferric maltol (Feraccru®) is not recommended for use within NHS Scotland for the treatment of iron deficiency anaemia in adults with inflammatory bowel disease as the economic case was not demonstrated.
  - **MEDICINAL FORMS**
    - There can be variation in the licensing of different medicines containing the same drug.
    - **Capsule**
      - Feraccru® (Shield Therapeutics (UK) Ltd)
      - Iron (as Ferric maltol) 30 mg
      - Feraccru 30mg capsules | 56 capsule | £47.60
### Ferrous fumarate

#### INDICATIONS AND DOSE

**Iron-deficiency anaemia (prophylactic)**
- **BY MOUTH USING TABLETS**
  - Child 12-17 years: 210 mg 1–2 times a day
  - Adult: 210 mg 1–2 times a day
- **BY MOUTH USING SYRUP**
  - Child 12-17 years: 140 mg twice daily
  - Adult: 140 mg twice daily

**Iron-deficiency anaemia (therapeutic)**
- **BY MOUTH USING TABLETS**
  - Child 12-17 years: 210 mg 2–3 times a day
  - Adult: 210 mg 2–3 times a day
- **BY MOUTH USING SYRUP**
  - Child 12-17 years: 280 mg twice daily
  - Adult: 280 mg twice daily

**GALFER® CAPSULES**
- **Iron-deficiency anaemia (prophylactic)**
  - **BY MOUTH**
    - Child 12-17 years: 305 mg daily
    - Adult: 305 mg daily
  - **Iron-deficiency anaemia (therapeutic)**
    - **BY MOUTH**
      - Child 12-17 years: 305 mg twice daily
      - Adult: 305 mg twice daily

**GALFER® SYRUP**
- **Iron-deficiency anaemia (prophylaxis)**
  - **BY MOUTH**
    - Child 1 month–11 years: 0.25 mL/kilogram twice daily, the total daily dose may alternatively be given in 3 divided doses, prophylactic iron supplementation may be required in babies of low birth-weight who are solely breast-fed; supplementation is started 4–6 weeks after birth and continued until mixed feeding is established; maximum 20 mL per day
    - Child 12-17 years: 10 mL once daily
    - Adult: 10 mL once daily
  - **Iron-deficiency anaemia (therapeutic)**
    - **BY MOUTH**
      - Child 1 month–11 years: 0.25 mL/kilogram twice daily, the total daily dose may alternatively be given in 3 divided doses; maximum 20 mL per day
      - Child 12-17 years: 10 mL 1–2 times a day
      - Adult: 10 mL 1–2 times a day

#### INTERACTIONS
Appendix 1: folates, iron (oral)

#### PRESCRIBING AND DISPENSING INFORMATION
Pregaday® contains ferrous fumarate 322 mg (100 mg iron), folic acid 350 micrograms; Galfer FA® contains ferrous fumarate 305 mg (100 mg iron), folic acid 350 micrograms.

### Ferrous fumarate with folic acid

The properties listed below are those particular to the combination only. For the properties of the components please consider, ferrous fumarate above, folic acid p. 937.

#### INDICATIONS AND DOSE

**Iron-deficiency anaemia**
- **BY MOUTH USING CAPSULES**
  - Adult: 1 capsule daily, to be taken before food
- **BY MOUTH USING TABLETS**
  - Adult: 1 tablet daily

#### INTERACTIONS
Appendix 1: iron (oral)

#### PRESCRIBING AND DISPENSING INFORMATION
Pregaday® contains ferrous fumarate 322 mg (100 mg iron), folic acid 350 micrograms; Galfer FA® contains ferrous fumarate 305 mg (100 mg iron), folic acid 350 micrograms.

### Ferrous gluconate

#### INDICATIONS AND DOSE

**Prophylaxis of iron-deficiency anaemia**
- **BY MOUTH USING TABLETS**
  - Child 6–11 years: 300–900 mg daily
  - Child 12–17 years: 600 mg daily
  - Adult: 600 mg daily

**Treatment of iron-deficiency anaemia**
- **BY MOUTH USING TABLETS**
  - Child 6–11 years: 300–900 mg daily
  - Child 12–17 years: 1.2–1.8 g daily in divided doses
  - Adult: 1.2–1.8 g daily in divided doses

#### INTERACTIONS
Appendix 1: iron (oral)

#### PRESCRIBING AND DISPENSING INFORMATION
Ferrous gluconate 300 mg contains 35 mg iron.
Iron-deficiency anaemia

**INDICATIONS AND DOSE**
- **Iron-deficiency anaemia (prophylactic)**
  - **By mouth using tablets**
  - Child 6–17 years: 200 mg daily
  - Adult: 200 mg daily
- **Iron-deficiency anaemia (therapeutic)**
  - **By mouth using tablets**
  - Child 6–17 years: 200 mg 2–3 times a day
  - Adult: 200 mg 2–3 times a day

**FEROGRAD**
- **Iron-deficiency anaemia (prophylactic and therapeutic)**
  - **By mouth**
  - Child 12–17 years: 1 tablet daily
  - Adult: 1 tablet daily

**IRONORM® DROPS**
- **Iron-deficiency anaemia (prophylactic)**
  - **By mouth**
  - Adult: 2.4–4.8 mL daily
- **Iron-deficiency anaemia (therapeutic)**
  - **By mouth**
  - Adult: 4 mL 1–2 times a day

**INTERACTIONS** → Appendix 1: iron (oral)

**PRESCRIBING AND DISPENSING INFORMATION**
- **Iron content**
  - Ferrous sulfate 200 mg is equivalent to 65 mg iron; **Ironorm® drops** contain ferrous sulfate 125 mg (equivalent to 25 mg iron)/mL; **Ferrosan®** spansules contain ferrous sulfate 150 mg (47 mg iron) (spanules = capsules m/v); **Ferrograd®** tablets contain ferrous sulfate 325 mg (105 mg iron).
- With oral use in adults Modified-release preparations of iron are licensed for once-daily dosage, but have no therapeutic advantage and should not be used. These preparations are formulated to release iron gradually; the low incidence of side-effects may reflect the small amounts of iron available for absorption as the iron is carried past the first part of the duodenum into an area of the gut where absorption may be poor.

**PATIENT AND CARER ADVICE**
- **NATIONAL FUNDING/ACCESS DECISIONS**
  - NHS restrictions **Feospan®** is not prescribable under the National Health Service.
  - **LESS SUITABLE FOR PRESCRIBING** **Feospan®** is less suitable for prescribing.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.
  - **Modified-release tablet**
    - **CAUTIONARY AND ADVISORY LABELS 25**
      - Ferrograd (Teofarma)
        - Ferrous sulfate dried 325 mg Ferrograd 325 mg modified-release tablets | 30 tablet £2.58 DT price = £2.58
  - **Tablet**
    - **Ferrous sulfate (Non-proprietary)**
      - Ferrous sulfate dried 200 mg Ferrous sulfate 200 mg tablets | 28 tablet £3.35 DT price = £1.95 | 100 tablet £119.64

**Ferrous sulfate with ascorbic acid**

The properties listed below are those particular to the combination only. For the properties of the components please consider, ferrous sulfate above, ascorbic acid p. 991.

**INDICATIONS AND DOSE**
- **Iron-deficiency anaemia**
  - **By mouth using modified-release tablets**
  - Adult: 1 tablet daily, dose to be taken before food

**INTERACTIONS** → Appendix 1: ascorbic acid, iron (oral)

**NATIONAL FUNDING/ACCESS DECISIONS**
- NHS restrictions **Ferrograd C®** is not prescribable on the National Health Service.
- **LESS SUITABLE FOR PRESCRIBING** **Ferrograd C®** is less suitable for prescribing.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.
  - **Modified-release tablet**
    - **CAUTIONARY AND ADVISORY LABELS 25**
      - Feospan Spansules (Intrapharm Laboratories Ltd)
        - Ferrous sulfate dried 150 mg Feospan 150 mg Spansules | 30 capsule £3.95
  - **Oral drops**
    - Ironorm (Wallace Manufacturing Chemists Ltd)
      - Ferrous sulfate 125 mg per 1 mL Ironorm 125 mg/mL oral drops sugar-free | 15 mL £30.00

**Ferrous sulfate with folic acid**

The properties listed below are those particular to the combination only. For the properties of the components please consider, ferrous sulfate above, folic acid p. 937.

**INDICATIONS AND DOSE**
- **Iron-deficiency anaemia**
  - **By mouth using modified-release capsules**
  - Adult: 1 capsule daily
  - **By mouth using modified-release tablets**
  - Child 12–17 years: 1 tablet daily, to be taken before food
  - Adult: 1 tablet daily, to be taken before food

**INTERACTIONS** → Appendix 1: folates, iron (oral)

**NATIONAL FUNDING/ACCESS DECISIONS**
- NHS restrictions **Fefol®** is not prescribable under the National Health Service.
- **LESS SUITABLE FOR PRESCRIBING** **Fefol®** is less suitable for prescribing. **Ferrograd Folic®** is less suitable for prescribing.
Polyascharide-iron complex

**INDICATIONS AND DOSE**

**Iron-deficiency anaemia (prophylactic)**
- **BY MOUTH**
  - Child 1 month–1 year: 1 drop (approximately 500 micrograms iron) per 450 g body-weight to be to be given 3 times a day, dose to be administered from dropper bottle, prophylactic iron supplementation may be required in babies of low birth-weight who are solely breast-fed; supplementation is started 4–6 weeks after birth and continued until mixed feeding is established
  - Child 12–17 years: 2.5 mL daily
- **Adult:** 2.5 mL daily

**Iron-deficiency anaemia (therapeutic)**
- **BY MOUTH**
  - Child 2–5 years: 2.5 mL daily
  - Child 6–11 years: 5 mL daily
  - Child 12–17 years: 5 mL 1–2 times a day
  - Adult: 5 mL 1–2 times a day

**Iron-deficiency anaemia (therapeutic) if required during second and third trimester of pregnancy**
- **BY MOUTH**
  - Child 12–17 years: 5 mL once daily
  - Adult: 5 mL once daily

**INTERACTIONS** → Appendix 1: iron (oral)

**PATIENT AND CARER ADVICE** Counselling on the use of the dropper advised.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NHS restrictions** Nifexer® is not available on prescription under NHS, except 30–mL paediatric dropper bottle for prophylaxis and treatment of iron deficiency in infants born prematurely; endorse prescription ‘SLS’.

**MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Oral solution**
- Nifexer® (Tilled Laboratories Ltd)
  - Iron (as Polyascharide-iron complex) 100 mg Nifexer 100 mg/5 mL
elixir sugar-free | 30 mL £2.16 sugar-free | 240 mL £6.06

Sodium feredetate (Sodium ironedetate)

**INDICATIONS AND DOSE**

**Iron-deficiency anaemia (therapeutic)**
- **BY MOUTH USING ORAL SOLUTION**
  - Child 1–11 months: Up to 2.5 mL twice daily, smaller doses to be used initially
  - Child 1–4 years: 2.5 mL 3 times a day
  - Child 5–11 years: 5 mL 3 times a day
  - Child 12–17 years: 5 mL 3 times a day, increased to 10 mL 3 times a day, dose to be increased gradually

**INTERACTIONS** → Appendix 1: iron (oral)

**PRESCRIBING AND DISPENSING INFORMATION** Sytron® contains 190 mg sodium feredetate, which is equivalent to 27.5 mg of iron/5 mL.

**PATIENT AND CARER ADVICE**

Medications for Children leaflet: Sytron (sodium feredetate) for the treatment of anaemia www.medicinesforchildren.org.uk/sytron-sodium-feredetate-for-treatment-of-anaemia

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Oral solution**
- Sytron feredetate (Non-proprietary)
  - Sodium feredetate 38 mg per 1 mL Sodium feredetate 190 mg/5 mL oral solution sugar-free sugar-free | 500 mL £14.95 DT price = £14.95
- Sytron (Forum Health Products Ltd)
  - Sodium feredetate 38 mg per 1 mL Sytron oral solution sugar-free | 500 mL £14.95 DT price = £14.95

### 1.3 Megaloblastic anaemia

**Anaemia, megaloblastic**

**Overview**

Most megaloblastic anaemias result from a lack of either vitamin B₁₂ or folate, and it is essential to establish in every case which deficiency is present and the underlying cause. In emergencies, when delay might be dangerous, it is sometimes necessary to administer both substances after the bone marrow test while plasma assay results are awaited. Normally, however, appropriate treatment should not be instituted until the results of tests are available.

One cause of megaloblastic anaemia in the UK is pernicious anaemia in which lack of gastric intrinsic factor resulting from an autoimmune gastritis causes malabsorption of vitamin B₁₂.

Vitamin B₁₂ is also needed in the treatment of megaloblastosis caused by prolonged nitrous oxide anaesthesia, which inactivates the vitamin, and in the rare syndrome of congenital transcobalamin II deficiency.

Vitamin B₁₂ should be given prophylactically after total gastrectomy or total ileal resection (or after partial gastrectomy if a vitamin B₁₂ absorption test shows vitamin B₁₂ malabsorption).

Apart from dietary deficiency, all other causes of vitamin B₁₂ deficiency are attributable to malabsorption. There is little place for the use of low-dose vitamin B₁₂ orally and none for vitamin B₁₂ intrinsic factor complexes given by mouth. Vitamin B₁₂ in larger oral doses [unlicensed] may be effective.

Hydroxocobalamin p. 938 has completely replaced cyanocobalamin p. 938 as the form of vitamin B₁₂ of choice for therapy; it is retained in the body longer than cyanocobalamin and thus for maintenance therapy can be given at intervals of up to 3 months. Treatment is generally initiated with frequent administration of intramuscular injections to replenish the depleted body stores. Thereafter, maintenance treatment, which is usually for life, can be instituted. There is no evidence that doses larger than those recommended provide any additional benefit in vitamin B₁₂ neuropathy.

Folic acid p. 937 has few indications for long-term therapy since most causes of folate deficiency are self-limiting or will yield to a short course of treatment. It should not be used in undiagnosed megaloblastic anaemia unless vitamin B₁₂ is
administered concurrently otherwise neuropathy may be precipitated.

In folate-deficient megaloblastic anaemia (e.g. because of poor nutrition, pregnancy, or antiepileptic drugs), daily folic acid supplementation for 4 months brings about haematological remission and replenishes body stores.

For prophylaxis in chronic haemolytic states, malabsorption, or in renal dialysis, folic acid is given daily or sometimes weekly, depending on the diet and the rate of haemolysis.

Folic acid is also used for the prevention of methotrexate-induced side-effects in severe Crohn’s disease, rheumatic disease, and severe psoriasis.

Folic acid p. 869 is also effective in the treatment of folic acid deficient megaloblastic anaemia but it is generally used in association with cytotoxic drugs; it is given as calcium folinate.

There is no justification for prescribing multiple ingredient vitamin preparations containing vitamin B₁₂ or folic acid.

For the use of folic acid before and during pregnancy, see Neural tube defects (prevention in pregnancy) p. .

VITAMINS AND TRACE ELEMENTS ➤ FOLATES

Folic Acid 09-Jun-2016

INDICATIONS AND DOSE

Folate-deficient megaloblastic anaemia ➤ BY MOUTH

Child 1-11 months: Initially 500 micrograms/kg once daily (max. per dose 5 mg) for up to 4 months, doses up to 10 mg daily may be required in malabsorption states

Child 1-17 years: 5 mg daily for 4 months (until term in pregnant women), doses up to 15 mg daily may be required in malabsorption states

Adult: 5 mg daily for 4 months (until term in pregnant women), doses up to 15 mg daily may be required in malabsorption states

Prevention of neural tube defects (in those at a low risk of conceiving a child with a neural tube defect see p. 997) ➤ BY MOUTH

Females of childbearing potential: 400 micrograms daily, to be taken before conception and until week 12 of pregnancy

Prevention of neural tube defects (in those in the high-risk group who wish to become pregnant or who are at risk of becoming pregnant see p. 997) ➤ BY MOUTH

Females of childbearing potential: 5 mg daily, to be taken before conception and until week 12 of pregnancy

Prevention of neural tube defects (in those with sickle-cell disease) ➤ BY MOUTH

Females of childbearing potential: 5 mg daily, patient should continue taking their normal dose of folic acid 5 mg daily (or increase the dose to 5 mg daily) before conception and continue this throughout pregnancy

Prevention of methotrexate-induced side-effects in rheumatic disease ➤ BY MOUTH

Adult: 5 mg once weekly, dose to be taken on a different day to methotrexate dose

Prevention of methotrexate side-effects in severe Crohn’s disease | Prevention of methotrexate side-effects in severe psoriasis ➤ BY MOUTH

Adult: 5 mg once weekly, dose to be taken on a different day to methotrexate dose

Prophylaxis in chronic haemolytic states ➤ BY MOUTH

Adult: 5 mg every 1–7 days, frequency dependent on underlying disease

Prophylaxis of folate deficiency in dialysis ➤ BY MOUTH

Child 1 month-11 years: 250 micrograms/kg once daily (max. per dose 10 mg)

Child 12-17 years: 5–10 mg once daily

Adult: 5 mg every 1–7 days

Prophylaxis of folate deficiency in patients receiving parenteral nutrition ➤ BY INTRAVENOUS INFUSION

Adult: 15 mg 1–2 times a week, usually given by intravenous infusion in the parenteral nutrition solution


CAUTIONS Should never be given alone for pernicious anaemia (may precipitate subacute combined degeneration of the spinal cord)

INTERACTIONS ➤ Appendix 1: folates

SIDE-EFFECTS ➤ Rare Gastro-intestinal disturbances

PATIENT AND CARER ADVICE


EXCEPTIONS TO LEGAL CATEGORY

With oral use Can be sold to the public provided daily doses do not exceed 500 micrograms.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule, oral suspension, oral solution, solution for injection

Tablet ➤

Folic acid (Non-proprietary)

Folic acid 400 microgram Folic acid 400microgram tablets | 90 tablet | price available DT price = £2.71

Folic acid 5 mg Folic acid 5mg tablets | 28 tablet | price = £0.90

Preconceive (G.R. Lane Health Products Ltd)

Folic acid 400 microgram Preconceive 400microgram tablets | 90 tablet | price = £2.71

Oral solution ➤

Folic acid (Non-proprietary)

Folic acid 500 microgram per 1 ml Folic acid 2.5mg/5ml oral solution sugar free sugar-free | 150 ml | price = £9.16

Folic acid 1 mg per 1 ml Folic acid 5mg/5ml oral solution sugar free sugar-free | 150 ml | price = £13.74

Lexpec (Rosemont Pharmaceuticals Ltd)

Folic acid 500 microgram per 1 ml Lexpec Folic Acid 2.5mg/5ml oral solution sugar-free | 150 ml | price = £9.16

downloaded from www.medicalbr.com
Blood and nutrition

VITAMINS AND TRACE ELEMENTS > VITAMIN B GROUP

Cyanocobalamin

- INDICATIONS AND DOSE
  Vitamin B<sub>12</sub> deficiency of dietary origin
  - BY MOUTH
    - Adult: 50–150 micrograms daily, dose to be taken between meals
  - BY INTRAMUSCULAR INJECTION
    - Adult: Initially 1 mg every 2–3 days for 11 doses; maintenance 1 mg every month

- PRESCRIBING AND DISPENSING INFORMATION
  The BP directs that when vitamin B<sub>12</sub> injection is prescribed or demanded hydroxocobalamin injection shall be dispensed or supplied. Currently available brands of the tablet may not be suitable for vegans.

- NATIONAL FUNDING/ACCESS DECISIONS
  NHS restrictions Cyanocobalamin liquid, Cytacon<sup>®</sup> tablets, and Cytacon<sup>®</sup> injection are not available on prescription under the NHS.

- LESS SUITABLE FOR PRESCRIBING
  Cyanocobalamin is less suitable for prescribing.

- MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet
  - Cyanocobalamin (Non-proprietary)
    - Cyanocobalamin 50 microgram Cyanocobalamin 50microgram tablets | 50 tablet [P] £6.24 DT price = £8.99
    - Cytacon (AMCo)
      - Cyanocobalamin 50 microgram Cytacon 50microgram tablets | 50 tablet [P] £8.99 DT price = £8.99
  - Solution for injection
    - Cytacon (Focus Pharmaceuticals Ltd)
      - Cyanocobalamin 1 mg per 1 ml Cyanobal-H<sup>®</sup> tablets | 5 ampoule [P] 14.50 DT price = £14.50
  - Oral solution
    - Cyanocobalamin (Non-proprietary)
      - Cyanocobalamin 7 microgram per 1 ml Cyanocobalamin 7microgram/5ml oral solution | 200 ml [P] £8.75

Hydroxocobalamin

- INDICATIONS AND DOSE
  Prophylaxis of macrocytic anaemias associated with vitamin B<sub>12</sub> deficiency
  - BY INTRAMUSCULAR INJECTION
    - Adult: 1 mg every 2–3 months
  Pernicious anaemia and other macrocytic anaemias without neurological involvement
  - BY INTRAMUSCULAR INJECTION
    - Adult: Initially 1 mg 3 times a week for 2 weeks, then 1 mg every 3 months
  Pernicious anaemia and other macrocytic anaemias with neurological involvement
  - BY INTRAMUSCULAR INJECTION
    - Adult: Initially 1 mg once daily on alternate days until no further improvement, then 1 mg every 2 months
  Tobacco ambylopia
  - BY INTRAMUSCULAR INJECTION
    - Adult: Initially 1 mg daily for 2 weeks, then 1 mg twice weekly until no further improvement, then 1 mg every 1–3 months

- PRESCRIBING AND DISPENSING INFORMATION
  Leber’s optic atrophy
  - BY INTRAMUSCULAR INJECTION
    - Adult: Initially 1 mg daily for 2 weeks, then 1 mg twice weekly until no further improvement, then 1 mg every 1–3 months
  CYANOKIT<sup>®</sup>
  Poisoning with cyanides
  - BY INTRAVENOUS INFUSION
    - Child (body-weight 5 kg and above): Initially 70 mg/kg (max. per dose 5 g), to be given over 15 minutes, then 70 mg/kg (max. per dose 5 g) if required, this second dose can be given over 15 minutes–2 hours depending on severity of poisoning and patient stability
    - Adult: Initially 5 g, to be given over 15 minutes, then 5 g if required, this second dose can be given over 15 minutes–2 hours depending on severity of poisoning and patient stability

- CAUTIONS
  - With intramuscular use or oral use Should not be given before diagnosis fully established

- SIDE-EFFECTS
  GENERAL SIDE-EFFECTS
  Dizziness · headache · pruritus
  SPECIFIC SIDE-EFFECTS
  With intramuscular use Hypokalaemia (during initial treatment) · injection-site reactions · rash · thrombocytosis (during initial treatment) · With intramuscular use or oral use Chromaturia · fever · hypersensitivity reactions · nausea · With intravenous use Dyspnoea · eye disorders · gastrointestinal disturbances · hot flush · lymphocytopenia · memory impairment · peripheral oedema · pustular rashes · red coloration of urine · restlessness · reversible red coloration of skin and mucous membranes · throat disorders · transient hypertension

- BREAST FEEDING
  Present in milk but not known to be harmful.

- EFFECT ON LABORATORY TESTS
  With intravenous use Deep red colour of hydroxocobalamin may interfere with laboratory tests.

- DIRECTIONS FOR ADMINISTRATION
  With intravenous use For intravenous infusion (Cyanokit)<sup>®</sup>, given intermittently in Sodium chloride 0.9%, reconstitute 5 g vial with 200 mL Sodium Chloride 0.9%; gently invert vial for at least 1 minute to mix (do not shake).

- PRESCRIBING AND DISPENSING INFORMATION
  - With intramuscular use The BP directs that when vitamin B<sub>12</sub> injection is prescribed or demanded, hydroxocobalamin injection shall be dispensed or supplied. Poisoning by cyanides
  - With intravenous use Cyanokit<sup>®</sup> is the only preparation of hydroxocobalamin that is suitable for use in victims of smoke inhalation who show signs of significant cyanide poisoning.

- NATIONAL FUNDING/ACCESS DECISIONS
  NHS restrictions Cobal-H<sup>®</sup> is not prescribable under National Health Service (NHS). Neo-Cytamen<sup>®</sup> is not prescribable under National Health Service (NHS).

- MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug.

  Solution for injection
  - Hydroxocobalamin (Non-proprietary)
    - Hydroxocobalamin 1 mg per 1 ml Hydroxocobalamin 1mg/1ml solution for injection ampoules | 5 ampoule [P] £12.49 DT price = £7.12
    - Hydroxocobalamin 2.5 mg per 1 ml Hepavit 5mg/2ml solution for injection ampoules | 2 ampoule [P] no price available
Iron overload

Overview
Severe tissue iron overload can occur in aplastic and other refractory anaemias, mainly as the result of repeated blood transfusions. It is a particular problem in refractory anaemias with hyperplastic bone marrow, especially thalassaemia major, where excessive iron absorption from the gut and inappropriate iron therapy can add to the tissue siderosis.

Iron overload associated with haemochromatosis can be treated with repeated venesection. Venesection may also be used for patients who have received multiple transfusions and whose bone marrow has recovered. Where venesection is used for patients who have received multiple transfusions, transfusion-related chronic iron overload may be given through the same cannula.

Iron excretion induced by desferrioxamine mesilate is enhanced by administration of ascorbic acid p. 991 (vitamin C) daily by mouth; it should be given separately from food since it also enhances iron absorption. Ascorbic acid should not be given to patients with cardiac dysfunction; in patients with normal cardiac function ascorbic acid should be introduced 1 month after starting desferrioxamine mesilate.

Desferrioxamine mesilate infusion can be used to treat aluminium overload in dialysis patients; theoretically 100 mg of desferrioxamine binds with 4.1 mg of aluminium.

ANTIDOTES AND CHELATORS

Deferasirox

Drug Action
Deferasirox is an oral iron chelator.

INDICATIONS AND DOSE

Transfusion-related chronic iron overload when desferrioxamine is contra-indicated or inadequate in patients with beta thalassaemia major who receive infrequent blood transfusions (less than 7 mL/kg/month of packed red blood cells) (specialist use only)

BY MOUTH USING DISPERSIBLE TABLETS
Adult: Initially 7–21 mg/kg once daily, dose adjusted according to serum-ferritin concentration and amount of transfused blood—consult product literature, then adjusted in steps of 3.5–7 mg/kg every 3–6 months, maintenance dose adjusted according to serum-ferritin concentration; maximum 28 mg/kg per day; Usual maximum 21 mg/kg

Dose equivalence and conversion
The bioavailability of dispersible tablets is lower than that of film-coated tablets; dispersible tablets are not interchangeable with film-coated tablets on a milligram-for-milligram basis—consult product literature for information on switching between formulations.

Transfusion-related chronic iron overload when desferrioxamine is contra-indicated or inadequate in patients with other anaemias (specialist use only)

BY MOUTH USING FILM-COATED TABLETS
Adult: Initially 7–21 mg/kg once daily, dose adjusted according to serum-ferritin concentration and amount of transfused blood—consult product literature, then adjusted in steps of 3.5–7 mg/kg every 3–6 months, maintenance dose adjusted according to serum-ferritin concentration; maximum 28 mg/kg per day; Usual maximum 21 mg/kg

Chronic iron overload when desferrioxamine is contra-indicated or inadequate in non-transfusion-dependent thalassaemia syndromes (specialist use only)

BY MOUTH USING FILM-COATED TABLETS
Adult: Initially 7–21 mg/kg once daily, dose adjusted according to serum-ferritin concentration and amount of transfused blood—consult product literature, then adjusted in steps of 3.5–7 mg/kg every 3–6 months, maintenance dose adjusted according to serum-ferritin concentration; maximum 28 mg/kg per day; Usual maximum 21 mg/kg

Chronic iron overload when desferrioxamine is contra-indicated or inadequate in non-transfusion-dependent thalassaemia syndromes (specialist use only)

BY MOUTH USING FILM-COATED TABLETS
Adult: Initially 10–30 mg/kg once daily, dose adjusted according to serum-ferritin concentration and amount of transfused blood—consult product literature, then adjusted in steps of 5–10 mg/kg every 3–6 months, maintenance dose adjusted according to serum-ferritin concentration; maximum 40 mg/kg per day; Usual maximum 30 mg/kg
Blood and nutrition

● **CAUTIONS** Elderly (increased risk of side-effects) - history of liver cirrhosis - not recommended in conditions which may reduce life expectancy (e.g. high-risk myelodysplastic syndromes) - platelet count less than 50x10^9/litre - risk of gastro-intestinal ulceration and haemorrhage - unexplained cytopenia - consider treatment interruption

● **INTERACTIONS** → Appendix 1: deferasirox

● **SIDE-EFFECTS**
  ▶ **Common or very common** Abdominal distension - abdominal pain - constipation - diarrhoea - dyspepsia - gastro-intestinal haemorrhage (including fatal cases) - gastro-intestinal ulceration - headache - nausea - proteinuria - pruritus - raised serum creatinine - raised transaminases - rash - vomiting
  ▶ **Uncommon** Anxieties - cataract - cholelithiasis - disturbances of hearing and vision - dizziness - fatigue - gastritis - glucosuria - hepatitis - laryngeal pain - maculopathy - oedema - pyrexia - renal tubulopathy - skin pigmentation - sleep disorder
  ▶ **Rare** Oesophagitis - optic neuritis
  ▶ **Frequency not known** Acute pancreatitis - acute renal failure - alopecia - anaphylaxis - angioedema - blood disorders - erythema multiforme - hepatic failure - hypersensitivity reactions - hypersensitivity vasculitis - metabolic acidosis - nephrolithiasis - Stevens-Johnson syndrome - toxic epidermal necrolysis - tubulointerstitial nephritis - urticaria

● **PREGNANCY** Manufacturer advises avoid unless essential - toxicity in animal studies.

● **BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.

● **HEPATIC IMPAIRMENT** Use with caution in moderate impairment, reduce dose considerably then gradually increase to max. 50% of normal dose. Avoid in severe impairment.

● **RENAL IMPAIRMENT** Manufacturer advises reduce dose if creatinine clearance less than 90 mL/minute and serum creatinine increased by more than 33% of baseline measurement on 2 consecutive occasions—consult product literature. Manufacturer advises avoid if estimated creatinine clearance less than 60 mL/minute.

● **MONITORING REQUIREMENTS** Manufacturer advises monitoring of the following patient parameters: baseline serum creatinine twice and creatinine clearance once before initiation of treatment, weekly in the first month after treatment initiation or modification, then monthly thereafter; proteinuria before treatment initiation then monthly thereafter, and other markers of renal tubular function as needed; liver function before treatment initiation, every 2 weeks during the first month of treatment, then monthly thereafter; eye and ear examinations before treatment and annually during treatment; serum-ferritin concentration monthly.

● **DIRECTIONS FOR ADMINISTRATION** For dispersible tablets, manufacturer advises tablets should be dispersed in 100–200 mL of water, orange juice, or apple juice; if necessary any residue should be resuspended in a small volume of water or juice then administered; do not chew or swallow whole. For film-coated tablets, manufacturer advises tablets may be crushed and sprinkled on to soft food (yoghurt or apple sauce), then administered immediately.

● **PATIENT AND CARER ADVICE** Patient or carers should be given advice on how to administer deferasirox dispersible tablets.

● **NATIONAL FUNDING/ACCESS DECISIONS**

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (January 2007) that deferasirox is accepted for restricted use within NHS Scotland for the treatment of chronic iron overload associated with the treatment of rare acquired or inherited anaemias requiring recurrent blood transfusions. It is not recommended for patients with myelodysplastic syndromes.

The Scottish Medicines Consortium has advised (January 2017) that deferasirox (Exjade®) is accepted for restricted use within NHS Scotland for the treatment of chronic iron overload due to blood transfusions when deferoxamine treatment is contra-indicated or inadequate, in adult and paediatric patients aged 2 years and older with rare acquired or inherited anaemias. This advice relates only for use in patients with myelodysplastic syndrome with an International Prognostic Scoring System score of low or intermediate -1 risk.

● **MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Dispersible tablet**

**CAUTIONARY AND ADVISORY LABELS 13, 22**

- [Exjade](Novartis Pharmaceuticals UK Ltd) ▼
  - Deferasirox 125 mg Exjade 125mg dispersible tablets sugar-free | 28 tablet [Pack] £117.60
  - Deferasirox 250 mg Exjade 250mg dispersible tablets sugar-free | 28 tablet [Pack] £235.20
  - Deferasirox 500 mg Exjade 500mg dispersible tablets sugar-free | 28 tablet [Pack] £470.40

**Tablet**

**CAUTIONARY AND ADVISORY LABELS 25**

- [Exjade](Novartis Pharmaceuticals UK Ltd) ▼
  - Deferasirox 90 mg Exjade 90mg tablets | 30 tablet [Pack] £126.00
  - Deferasirox 180 mg Exjade 180mg tablets | 30 tablet [Pack] £252.00
  - Deferasirox 360 mg Exjade 360mg tablets | 30 tablet [Pack] £504.00

**Deferiprone**

● **DRUG ACTION** Deferiprone is an oral iron chelator.

● **INDICATIONS AND DOSE**

Treatment of iron overload in patients with thalassaemia major in whom desferrioxamine is contra-indicated or is inadequate

- **BY MOUTH**
  - Adult: 25 mg/kg 3 times a day; maximum 100 mg/kg per day

● **CONTRA-INDICATIONS** History of agranulocytosis or recurrent neutropenia

● **INTERACTIONS** → Appendix 1: deferi proline

● **SIDE-EFFECTS** Agranulocytosis - arthropathy - blood dyscrasias - gastro-intestinal disturbances (reducing dose and increasing gradually may improve tolerance) - headache - increased appetite - neutropenia - red-brown urine discoloration - zinc deficiency

● **CONCEPTION AND CONCEPTION** Manufacturer advises avoid before intended conception—teratogenic and embryotoxic in animal studies. Contraception advised in females of child-bearing potential.

● **PREGNANCY** Manufacturer advises avoid during pregnancy—teratogenic and embryotoxic in animal studies.

● **BREAST FEEDING** Manufacturer advises avoid—no information available.

● **HEPATIC IMPAIRMENT** Manufacturer advises monitor liver function—inrupt treatment if persistent elevation in serum alanine aminotransferase.

● **RENAI IMPAIRMENT** Manufacturer advises caution—no information available.

● **MONITORING REQUIREMENTS**
  - Monitor neutrophil count weekly and discontinue treatment if neutropenia develops.
  - Monitor plasma-zinc concentration.

**Blood and nutrition**

**940 Iron overload**

**BNF 74**
### Desferrioxamine mesilate (Desferoxamine Mesilate)

#### INDICATIONS AND DOSE
**Iron poisoning**
- **Adult:** By continuous intravenous infusion
- **Adult:** Initially up to 15 mg/kg/hour, max. 80 mg/kg in 24 hours, dose to be reduced after 4–6 hours, in severe cases, higher doses may be given on advice from the National Poisons Information Service

**Aluminium overload in dialysis patients**
- **Adult:** By intravenous infusion
- **Adult:** Consult product literature or local protocols

**Chronic iron overload (low iron overload)**
- **Adult:** By subcutaneous infusion
- **Adult:** The dose should reflect the degree of iron overload

**Chronic iron overload (established overload)**
- **Adult:** By subcutaneous infusion
- **Adult:** 20–50 mg/kg daily

#### CAUTIONS
- Aluminium-related encephalopathy (may exacerbate neurological dysfunction)

#### INTERACTIONS
- Common or very common: Abdominal pain, arthralgia, bone disorders, growth retardation, headache, hearing disturbances, injection-site reactions, myalgia, nausea, peripheral neuropathy, thrombocytopenia, visual disturbances, Yersinia and mucormycosis infections
- Very rare: Acute respiratory distress, convulsions, dizziness, neurological disturbances, neuropathy, paraesthesia, renal impairment
- Frequency not known: Muscle spasms

#### PREGNANCY
- Teratogenic in animal studies. Manufacturer advises use only if potential benefit outweighs risk.

#### BREAST FEEDING
- Manufacturer advises use only if potential benefit outweighs risk—no information available.

#### RENAL IMPAIRMENT
- Use with caution.

### Neutropenia and stem cell mobilisation

#### 3 Neutropenia

### Neutropenia

#### Management

Recombinant human granulocyte-colony stimulating factor (rhG-CSF) stimulates the production of neutrophils and may reduce the duration of chemotherapy-induced neutropenia and thereby reduce the incidence of associated sepsis; there is as yet no evidence that it improves overall survival.

Filgrastim p. 942 (un glycosylated rhG-CSF) and lenograstim p. 943 (glycosylated rhG-CSF) have similar effects; both have been used in a variety of clinical settings, but they do not have any clear-cut routine indications. In congenital neutropenia filgrastim usually increases the neutrophil count with an appropriate clinical response. Pegyl filgrastim p. 944 is a polyethylene glycol-conjugated (‘pegylated’) derivative of filgrastim; pegylation increases the duration of filgrastim activity. Lipegfilgrastim p. 943 is a polyethylene glycol-conjugated via a glycine linker derivative of filgrastim.

Granulocyte-colony stimulating factors should only be prescribed by those experienced in their use.

### IMMUNOSTIMULANTS

#### 3.1 Neutropenia

### Granulocyte-colony stimulating factors

#### DRUG ACTION
- Recombinant human granulocyte-colony stimulating factor (rhG-CSF) stimulates the production of neutrophils.

#### CAUTIONS
- Malignant myeloid conditions, pre-malignant myeloid conditions, risk of splenomegaly and rupture—spleen size should be monitored, sickle-cell disease

#### CAUTIONS, FURTHER INFORMATION
- Acute respiratory distress syndrome There have been reports of pulmonary infiltrates leading to acute respiratory
distress syndrome—patients with a recent history of pulmonary infiltrates or pneumonia may be at higher risk.

- **SIDE-EFFECTS**
  - Common or very common: Alopecia, anorexia, asthenia, bone pain, chest pain, fever, gastrointestinal disturbances, headache, injection-site reactions, leucocytosis, musculoskeletal pain, rash, thrombocytopenia
  - Rare: Acute febrile neutrophilic dermatosis, cutaneous vasculitis, pulmonary side-effects (particularly interstitial pneumonia)

**SIDE-EFFECTS, FURTHER INFORMATION**

- Pulmonary infiltration: Treatment should be withdrawn in patients who develop signs of pulmonary infiltration.
- **PREGNANCY**: There have been reports of toxicity in animal studies and manufacturers advise not to use granulocyte-colony stimulating factors during pregnancy unless the potential benefit outweighs the risk.
- **BREAST FEEDING**: There is no evidence for the use of granulocyte-colony stimulating factors during breast-feeding and manufacturers advise avoiding their use.

**MONITORING REQUIREMENTS**

- Full blood counts including differential white cell and platelet counts should be monitored.
- Spleen size should be monitored during treatment—risk of splenomegaly and rupture.

---

**Filgrastim**

*(Recombinant human granulocyte-colony stimulating factor; G-CSF)*

- **INDICATIONS AND DOSE**
  - *Reduction in duration of neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy for malignancy (except chronic myeloid leukaemia and myelodysplastic syndromes) (specialist use only)*
  - **BY SUBCUTANEOUS INJECTION, OR BY INTRAVENOUS INFUSION**
    - Adult: 5 micrograms/kg daily until neutrophil count in normal range, usually for up to 14 days (up to 38 days in acute myeloid leukaemia), to be started at least 24 hours after cytotoxic chemotherapy. Preferably given by subcutaneous injection; if given by intravenous infusion, administer over 30 minutes.
  - *Reduction in duration of neutropenia (and associated sequelae) in myeloablative therapy followed by bone-marrow transplantation (specialist use only)*
    - **BY SUBCUTANEOUS INFUSION, OR BY INTRAVENOUS INFUSION**
    - Adult: 10 micrograms/kg daily, to be started at least 24 hours following cytotoxic chemotherapy and within 24 hours of bone-marrow infusion, then adjusted according to neutrophil count—consult product literature, doses administered over 30 minutes or 24 hours via intravenous route and over 24 hours via subcutaneous route.

**Mobilisation of peripheral blood progenitor cells for autologous infusion, used alone (specialist use only)**

- **BY SUBCUTANEOUS INFUSION, OR BY SUBCUTANEOUS INJECTION**
  - Adult: 10 micrograms/kg daily for 5–7 days, to be administered over 24 hours if given by subcutaneous infusion.

**Mobilisation of peripheral blood progenitor cells for autologous infusion, used following adjunctive myelosuppressive chemotherapy—to improve yield (specialist use only)**

- **BY SUBCUTANEOUS INJECTION**
  - Adult: 5 micrograms/kg daily until neutrophil count in normal range, to be started the day after completing chemotherapy, for timing of leucopheresis, consult product literature.

**Mobilisation of peripheral blood progenitor cells in normal donors for allogeneic infusion (specialist use only)**

- **BY SUBCUTANEOUS INJECTION**
  - Adult 18-59 years: 10 micrograms/kg daily for 4–5 days, for timing of leucopheresis, consult product literature.

**Severe congenital neutropenia and history of severe or recurrent infections (distinguish carefully from other haematological disorders) (specialist use only)**

- **BY SUBCUTANEOUS INJECTION**
  - Adult: Initially 12 micrograms/kg daily, adjusted according to response, can be given in single or divided doses, consult product literature and local protocol.

**Severe cyclic neutropenia, or idiopathic neutropenia and history of severe or recurrent infections (distinguish carefully from other haematological disorders) (specialist use only)**

- **BY SUBCUTANEOUS INJECTION**
  - Adult: Initially 5 micrograms/kg daily, adjusted according to response, can be given in single or divided doses, consult product literature and local protocol.

**Persistent neutropenia in HIV infection (specialist use only)**

- **BY SUBCUTANEOUS INJECTION**
  - Adult: Initially 1 microgram/kg daily, subsequent doses increased as necessary until neutrophil count in normal range, then adjusted to maintain neutrophil count in normal range—consult product literature; maximum 4 micrograms/kg per day.

---

**CONTRA-INDICATIONS**

- Severe congenital neutropenia (Kostmann’s syndrome) with abnormal cytogenetics.

**CAUTIONS**

- Osteoporotic bone disease (monitor bone density if given for more than 6 months) • secondary acute myeloid leukaemia.

**SIDE-EFFECTS**

- Common or very common: Anaemia, dysuria, epistaxis, exacerbation of rheumatoid arthritis, haematuria, hepatomegaly, mucositis, osteoporosis, proteinuria, pseudogout, raised uric acid, splenic enlargement, transient decrease in blood glucose, transient hypotension, urinary abnormalities.
- Uncommon: Capillary leak syndrome (including fatal cases).
- Rare: Splenic rupture.

**MONITORING REQUIREMENTS**

- Regular morphological and cytogenetic bone marrow examinations recommended in severe congenital neutropenia (possible risk of myelodysplastic syndromes or leukaemia).

**DIRECTIONS FOR ADMINISTRATION**

- With intravenous use For intravenous infusion (Neupogen®; Nivestim®; Ratiogranstim®; Zarzio®) give continuously or intermittently in Glucose 5%, for a filgrastim concentration of less than 1 500 000 units/mL (15 micrograms/mL albumin solution (human albumin solution) is added to produce a final albumin concentration of 2 mg/mL; should not be diluted to a filgrastim concentration of less than 200 000 units/mL (2 micrograms/mL) and should not be diluted with sodium chloride solution.

**PRESCRIBING AND DISPENSING INFORMATION**

- Filgrastim is a biological medicine. Biological medicines must be prescribed and dispensed by brand name, see Biological medicines and Biosimilar medicines, under Guidance on prescribing p. 1.

1 million units of filgrastim solution for injection contains 10 micrograms filgrastim.
Mobilisation of peripheral blood progenitor cells, used following adjunctive myelosuppressive chemotherapy (to improve yield) (specialist use only)

- By subcutaneous injection
  - Adult: 150 micrograms/m² daily until neutrophil count stable in acceptable range, to be started 1–5 days after completion of chemotherapy, for timing of leukopheresis, consult product literature

### Side-effects
- Mucositis - splenic rupture - toxic epidermal necrolysis

### Directions for Administration
- With intravenous use
  - For intravenous infusion (Granocyte®), give intermittently in Sodium chloride 0.9%; initially reconstitute with 1 mL water for injection provided (do not shake vigorously) then dilute with up to 50 mL infusion fluid for each vial of Granocyte-13 or up to 100 mL infusion fluid for Granocyte-34; give over 30 minutes

### Prescribing and Dispensing Information
- Granocyte® solution for injection contains 105 micrograms of lenograstim per 13.4 mega unit vial and 263 micrograms lenograstim per 33.6 mega unit vial.

### Medicinal Forms
- There can be variation in the licensing of different medicines containing the same drug.

#### Powder and solvent for solution for injection

EXCIPIENTS: May contain Phenylalanine

- **Granocyte** (Chugai Pharma UK Ltd)
  - Lenograstim 13.4 mega u Granocyte-13 powder and solvent for solution for injection vials | 1 vial (POM) £40.11 | 5 vial (POM) £200.55
  - Lenograstim 33.6 mega u Granocyte-34 powder and solvent for solution for injection vials | 1 vial (POM) £62.54 | 5 vial (POM) £312.69

### Lenograstim

(Recombinant human granulocyte-colony stimulating factor; rHuG-CSF)

#### Indications and dose

Reduction in the duration of neutropenia and associated complications following bone-marrow transplantation for non-myeloid malignancy (specialist use only).

Reduction in the duration of neutropenia and associated complications following peripheral stem cell transplantation for non-myeloid malignancy (specialist use only)

- By intravenous infusion, or by subcutaneous injection
  - Adult: 150 micrograms/m² daily until neutrophil count stable in acceptable range (max. 28 days), to be started the day after transplantation. Intravenous infusion to be given over 30 minutes

Reduction in the duration of neutropenia and associated complications following treatment with cytotoxic chemotherapy associated with a significant incidence of febrile neutropenia (specialist use only)

- By subcutaneous injection
  - Adult: 150 micrograms/m² daily until neutrophil count stable in acceptable range (max. 28 days), to be started on the day after completion of chemotherapy

Mobilisation of peripheral blood progenitor cells for harvesting and subsequent infusion, used alone (specialist use only)

- By subcutaneous injection
  - Adult: 10 micrograms/kg daily for 4–6 days (5–6 days in healthy donors)

### Lipegfilgrastim

(Glycopegylated recombinant methionyl human granulocyte-colony stimulating factor)

#### Indications and dose

Reduction in duration of neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy for malignancy (except chronic myeloid leukaemia and myelodysplastic syndromes)

- By subcutaneous injection
  - Adult (specialist use only): 6 mg, for each chemotherapy cycle, given approximately 24 hours after chemotherapy, dose expressed as filgrastim

#### Caution
- Myelosuppressive chemotherapy

#### Side-effects
- Hypokalaemia

### Medicinal Forms
- There can be variation in the licensing of different medicines containing the same drug.

#### Solution for injection

- Lonquex (Teva UK Ltd)
  - Lipegfilgrastim 10 mg per 1 ml Lonquex 6mg/0.6ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (POM) £652.06
Pegfilgrastim
(Pegylated recombinant methionyl human granulocyte-colony stimulating factor)

- **INDICATIONS AND DOSE**
  Reduction in duration of neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy for malignancy (except chronic myeloid leukaemia and myelodysplastic syndromes) (specialist use only)
  - By subcutaneous injection
  - Adult: 6 mg for each chemotherapy cycle, to be given at least 24 hours after chemotherapy, dose is expressed as filgrastim

- **CAUTIONS**
  - Acute leukaemia - myelosuppressive chemotherapy

- **SIDE-EFFECTS**
  - Rare Capillary leak syndrome (including fatal cases)
  - Very rare Splenic rupture

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.

  **Solution for injection**
  - Neulasta (Amgen Ltd)
    Filgrastim (as Pegfilgrastim) 10 mg per 1 ml
    Neulasta 6mg/0.6ml solution for injection pre-filled syringes | 1 pre-filled disposable injection $686.38

3.2 Stem cell mobilisation

**IMMUNOSTIMULANTS**

- **CHEMOKINE RECEPTOR ANTAGONISTS**

Plerixafor

- **DRUG ACTION**
  Plerixafor is a chemokine receptor antagonist.

- **INDICATIONS AND DOSE**
  Mobilise haematopoietic stem cells to peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma or multiple myeloma (specialist use only)
  - By subcutaneous injection
  - Adult: 240 micrograms/kg daily usually for 2–4 days (max 7 days), to be administered 6–11 hours before initiation of apheresis, dose to be given following 4 days treatment with a granulocyte-colony stimulating factor

- **SIDE-EFFECTS**
  - Common or very common Arthralgia - dizziness - dry mouth - erythema - fatigue - gastro-intestinal disturbances - headache - injection-site reactions - insomnia - musculoskeletal pain - oral hypoaesthesia - sweating
  - Uncommon Dyspnoea - hypersensitivity reactions - periorbital swelling

- **CONCEPTION AND CONCEPTION**
  Use effective contraception during treatment— teratogenic in animal studies.

- **PREGNANCY**
  Manufacturer advises avoid unless essential— teratogenic in animal studies.

- **BREAST FEEDING**
  Manufacturer advises avoid— no information available.

- **RENAL IMPAIRMENT**
  Reduce dose to 160 micrograms/kg daily if creatinine clearance 20–50 mL/minute. No information available if creatinine clearance less than 20 mL/minute.

4 Platelet disorders

**Platelet disorders**

**Idiopathic thrombocytopenic purpura**

Acute idiopathic thrombocytopenic purpura is usually self-limiting in children. In adults, idiopathic thrombocytopenic purpura can be treated with a corticosteroid, e.g. prednisolone p. 639, gradually reducing the dose over several weeks. Splenectomy is considered if a satisfactory platelet count is not achieved or if there is a relapse on reducing the dose of corticosteroid or withdrawing it.

**Immunoglobulin** preparations, are also used in idiopathic thrombocytopenic purpura or where a temporary rapid rise in platelets is needed, as in pregnancy or pre-operatively; they are also used for children often in preference to a corticosteroid. Anti-D (Rh) immunoglobulin p. 1185 is effective in raising the platelet count in about 80% of un splenectomised rhesus-positive individuals; its effects may last longer than normal immunoglobulin p. 1186 for intravenous use, but further doses are usually required.

Other therapy that has been tried in refractory idiopathic thrombocytopenic purpura includes azathioprine p. 787, cyclophosphamide p. 830, vincristine sulfate p. 858, cyclosporin p. 788, and danazol p. 699. Rituximab p. 820 may also be effective and in some cases induces prolonged remission. For patients with chronic severe thrombocytopenia refractory to other therapy, tranexamic acid p. 107 may be given to reduce the severity of haemorrhage.

Eltrombopag p. 945 and romiplostim p. 947 are thrombopoietin receptor agonists licensed for the treatment of chronic idiopathic thrombocytopenic purpura in splenectomised patients refractory to other treatments, such as corticosteroids or immunoglobulins, or as a second-line treatment in non-splenectomised patients when surgery is contra-indicated (see also NICE guidance). Eltrombopag is an oral preparation and romiplostim is an injection which is made biosynthetically by recombinant DNA technology; they should both be used under the supervision of a specialist.

**Essential thrombocythaemia**

Anagrelide p. 945 inhibits platelet formation. It is licensed for essential thrombocythaemia in patients at risk of thrombo-haemorrhagic events who have not responded adequately to other drugs or who cannot tolerate other drugs. An at risk patient is defined by one or more of the following features: over 60 years of age, or a platelet count greater than 1000 x 10^9/L or history of thrombo-haemorrhagic events. Anagrelide should be initiated under specialist supervision.
4.1 Essential thrombocythaemia

**ANTITHROMBOTIC DRUGS＞CYCLIC AMP PHOSPHODIESTERASE III INHIBITORS**

### Anagrelide

- **INDICATIONS AND DOSE**
  Essential thrombocythaemia in patients at risk of thrombo-haemorrhagic events who have not responded adequately to other drugs or who cannot tolerate other drugs (initiated under specialist supervision)
  - **BY MOUTH**
    - Adult: Initially 500 micrograms twice daily, dose to be adjusted at weekly intervals according to response, increased in steps of 500 micrograms daily; usual dose 1–3 mg daily in divided doses (max. per dose 2.5 mg); maximum 10 mg per day

- **CAUTIONS** Cardiovascular disease—assess cardiac function before and regularly during treatment; comitant use of drugs that prolong QT-interval—assess cardiac function before and regularly during treatment; risk factors for QT-interval prolongation—assess cardiac function before and regularly during treatment

- **INTERACTIONS**＞Appendix 1: anagrelide

- **SIDE-EFFECTS**
  - Common or very common Anaemia, dizziness, fatigue, fluid retention, gastro-intestinal disturbances, headache, palpitation, rash, tachycardia
  - Uncommon: Alopecia, amnesia, anorexia, arrhythmias, arthralgia, back pain, blood disorders, chest pain, confusion, congestive heart failure, depression, dry mouth, dyspnoea, ecchymosis, epistaxis, fever, gastrointestinal haemorrhage, haemorrhage, hypertension, hypoaesthesia, impotence, malaise, myalgia, nervousness, oedema, pancreatitis, paraesthesia, pneumonia, pleural effusion, pruritus, skin discoloration, sleep disturbances, syncope, weight changes
  - Rare: Angina, asthenia, cardiomegaly, cardiomyopathy, colitis, dry skin, dysarthria, gastritis, gingival bleeding, impaired coordination, migraine, myocardial infarction, nocturia, pericardial effusion, postural hypotension, pulmonary hypertension, pulmonary infiltrates, renal failure, somnolence, tinnitus, vasodilatation, visual disturbances
  - Frequency not known Hepatitis, interstitial lung disease, Torresade de pointes, tubulointerstitial nephritis

- **CONCEPTION AND CONTRACEPTION** Effective contraception required during treatment

- **PREGNANCY** Manufacturer advises avoid (toxicity in animal studies).

- ** BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.

- **HEPATIC IMPAIRMENT** Manufacturer advises caution in mild impairment. Avoid in moderate to severe impairment.

- **RENAL IMPAI RMENT** Manufacturer advises avoid if eGFR less than 50 mL/minute/1.73 m².

- **MONITORING REQUIREMENTS**
  - Monitor full blood count (monitor platelet count every 2 days for 1 week, then weekly until maintenance dose established).
  - Monitor liver function.
  - Monitor serum creatinine.
  - Monitor urea.
  - Monitor electrolytes (including potassium, magnesium and calcium) before and during treatment.

### Eltrombopag

- **INDICATIONS AND DOSE**
  Chronic immune (idiopathic) thrombocytopenic purpura in patients refractory to other treatments (such as corticosteroids or immunoglobulins) (under expert supervision)
  - **BY MOUTH**
    - Adult: Initially 50 mg once daily, dose to be adjusted to achieve a platelet count of 50x10⁹/litre or more—consult product literature for dose adjustments, discontinue if inadequate response after 4 weeks treatment at maximum dose; maximum 75 mg per day
    - Adult (patients of East Asian origin): Initially 25 mg once daily, dose to be adjusted to achieve a platelet count of 50x10⁹/litre or more—consult product literature for dose adjustments, discontinue if inadequate response after 4 weeks treatment at maximum dose; maximum 75 mg per day

  Treatment of thrombocytopenia associated with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (under expert supervision)
  - **BY MOUTH**
    - Adult: Initially 25 mg once daily, dose to be adjusted to achieve a platelet count sufficient to initiate antiviral therapy then a platelet count of 50–75x10⁹/litre during antiviral therapy—consult product literature for dose adjustments, discontinue if inadequate response after 2 weeks treatment at maximum dose; maximum 100 mg per day

  Acquired severe aplastic anaemia in patients either refractory to or heavily pretreated with prior immunosuppressive therapy and are unsuitable for haematopoietic stem cell transplantation (under expert supervision)
  - **BY MOUTH**
    - Adult: Initially 50 mg once daily, dose to be adjusted to achieve a platelet count of 50x10⁹/litre or more—consult product literature for dose adjustments, discontinue if no haematological response after 16 weeks treatment; maximum 150 mg per day
    - Adult (patients of East Asian origin): Initially 25 mg once daily, dose to be adjusted to achieve a platelet count of 50x10⁹/litre or more—consult product literature for dose adjustments, discontinue if no haematological response after 16 weeks treatment; maximum 150 mg per day.

- **PATIENT AND CARER ADVICE**
  Driving and skilled tasks
  Dizziness may affect performance of skilled tasks (e.g. cycling, driving).

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.

  **Capsule**
  - **Xagrid** (Shire Pharmaceuticals Ltd) ▼
    - Anagrelide (as Anagrelide hydrochloride) 500 microgram x Xagrid 500microgram capsules | 100 capsule | £40.57

4.2 Idiopathic thrombocytopenic purpura

**ANTIHAEMORRHAGICS＞THROMBOPOIETIN RECEPTOR AGONISTS**

- **INDICATIONS AND DOSE**
  9

Blood and nutrition

09-Jun-2017
- **CAUTIONS** Patients of East Asian origin - risk factors for thromboembolism
- **INTERACTIONS** → Appendix 1: eltrombopag
- **SIDE-EFFECTS**
  - **Frequency not known** Increased bone marrow reticulocyte - discontinue
- **CONCEPTION AND CONTRACEPTION** Ensure effective contraception during treatment.
- **PREGNANCY** Avoid - toxicity in animal studies.
- **BREAST FEEDING** Manufacturer advises avoid.
- **HEPATIC IMPAIRMENT** For *idiopathic thrombocytopenic purpura*, manufacturer advises avoid unless potential benefit outweighs risk - reduce initial dose to 25 mg once daily and wait at least 3 weeks before upwards titration of dose.
  For *severe aplastic anaemia*, manufacturer advises reduce initial dose to 25 mg once daily and wait at least 2 weeks before upwards titration of dose.
  For *thrombocytopenia associated with chronic hepatitis C infection*, manufacturer advises reduce initial dose to 25 mg once daily and wait at least 2 weeks before upwards titration of dose in moderate-to-severe impairment. For *thrombocytopenia associated with chronic hepatitis C infection*, manufacturer advises use only if potential benefit outweighs risk in severe impairment and monitor closely - increased risk of hepatic decompensation and thromboembolic events.
- **RENAL IMPAIRMENT** Use with caution.
- **PRE-TREATMENT SCREENING** For *severe aplastic anaemia*, manufacturer advises do not initiate if patients have existing cytogenetic abnormalities of chromosome 7.
- **MONITORING REQUIREMENTS**
  - Manufacturer advises monitor liver function before treatment, every two weeks when adjusting the dose, and monthly thereafter.
  - Manufacturer advises regular ophthalmological examinations for cataract formation.
  - Manufacturer advises peripheral blood smear prior to initiation to establish baseline level of cellular morphologic abnormalities; once stabilised, full blood count with white blood cell count differential should be performed monthly.
  - For *idiopathic thrombocytopenic purpura*, manufacturer advises monitor full blood count including platelet count and peripheral blood smears every week during treatment until a stable platelet count is reached (50x10⁹/litre or more for at least 4 weeks), then monthly thereafter; monitor platelet count weekly for 4 weeks following treatment discontinuation.
  - For *severe aplastic anaemia*, manufacturer advises bone marrow examination with aspirations for cytogenetics prior to initiation, at 3 months of treatment and 6 months thereafter.
  - For *thrombocytopenia associated with chronic hepatitis C infection*, manufacturer advises monitor platelet count every week before and during antiviral treatment until a stable platelet count is reached (50–75x10⁹/litre), then monitor full blood count including platelet count and peripheral blood smears monthly thereafter.
- **DIRECTIONS FOR ADMINISTRATION** Each dose should be taken at least 4 hours before or after any dairy products (or foods containing calcium), indigestion remedies, or medicines containing aluminium, calcium, iron, magnesium, zinc, or selenium to reduce possible interference with absorption.
- **PATIENT AND CARER ADVICE** Patient counselling is advised on how to administer eltrombopag tablets.
- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **NICE technology appraisals (TAs)**
    - **Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura** (*July 2013* NICE TA293)
      - Eltrombopag is recommended for the treatment of chronic immune (idiopathic) thrombocytopenic purpura in splenectomised adults refractory to other treatments, or as a second-line treatment in non-splenectomised adults when surgery is contra-indicated, only if:
        - the manufacturer provides eltrombopag at the agreed discount as part of the patient access scheme *and*
        - their condition is refractory to standard active treatments and rescue therapies or
        - they have severe disease and a high risk of bleeding that needs frequent courses of rescue therapies.
      - Patients currently receiving eltrombopag whose disease does not meet these criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop.
      - [www.nice.org.uk/TA293](http://www.nice.org.uk/TA293)
  - **Scottish Medicines Consortium (SMC) Decisions**
    - The Scottish Medicines Consortium has advised (*July 2010*) that eltrombopag (*Revolade®*) is accepted for restricted use within NHS Scotland for the treatment of both splenectomised and non-splenectomised patients with severe symptomatic immune (idiopathic) thrombocytopenic purpura or a high risk of bleeding.
- **MEDICINAL FORMS**
  - **Tablet**
    - *Revolade* (Novartis Pharmaceuticals UK Ltd)
      - Eltrombopag (as *Eltrombopag olamine*) 25 mg
        - Revolade 25mg tablets | 28 tablet pack | £770.00
        - Eltrombopag (as *Eltrombopag olamine*) 50 mg
          - Revolade 50mg tablets | 28 tablet pack | £1,540.00
Romiplostim

**INDICATIONS AND DOSE**

Treatment of chronic idiopathic thrombocytopenic purpura in splenectomised patients refractory to other treatments (such as corticosteroids or immunoglobulins) (under expert supervision) | Second-line treatment of chronic idiopathic thrombocytopenic purpura in non-splenectomised patients when surgery is contra-indicated (under expert supervision)

▶ **BY SUBCUTANEOUS INJECTION**

▶ Adult: Initially 1 microgram/kg once weekly, adjusted in steps of 1 microgram/kg once weekly (max. per dose 10 micrograms/kg once weekly) until a stable platelet count of 50x10⁹/litre or more is reached, discontinue treatment if inadequate response after 4 weeks at maximum dose, consult product literature for dose adjustments.

**SIDE-EFFECTS** Arthralgia · asthenia · bone pain · dizziness · ecchymosis · fatigue · flushing · gastro-intestinal disturbances · increased bone marrow reticulin · influenza-like symptoms · injection site reactions · insomnia · migraine · muscle spasm · myalgia · oedema · paraesthesia · rash

**PREGNANCY** Manufacturer advises use only if essential—toxicity in animal studies.

**BREAST FEEDING** Manufacturer advises avoid—no information available.

**HEPATIC IMPAIRMENT** Avoid in moderate or severe impairment unless potential benefit outweighs risk (e.g. of portal vein thrombosis).

**RENAL IMPAIRMENT** Manufacturer advises caution—no information available.

**MONITORING REQUIREMENTS**

▶ Monitor full blood count and peripheral blood smears for morphological abnormalities before and during treatment.

▶ Monitor platelet count weekly until platelet count reaches 50x10⁹/litre or more for at least 4 weeks without dose adjustment, then monthly thereafter.

**PATIENT AND CARER ADVICE**

Driving and skilled tasks

Dizziness may affect performance of skilled tasks (e.g. driving).

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (Tas)**

Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (April 2011) NICE TA221

Romiplostim is recommended for the treatment of chronic immune (idiopathic) thrombocytopenic purpura in adults:

◊ if the manufacturer provides romiplostim at the agreed discount as part of the patient access scheme and

◊ whose condition is refractory to standard active treatments and rescue therapies or

◊ who have severe disease and a high risk of bleeding that needs frequent courses of rescue therapies.

www.nice.org.uk/TA221

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (September 2009) that romiplostim (Nplate®) is accepted for restricted use within NHS Scotland for patients with severe symptomatic idiopathic thrombocytopenic purpura or those at high risk of bleeding.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder and solvent for solution for injection**

Nplate (Amgen Ltd)

Romiplostim 250 microgram Nplate 250microgram powder and solvent for solution for injection pre-filled disposable devices | 1 pre-filled disposable injection [P] £482.00

Nutrition and metabolic disorders

1 Fluid and electrolyte imbalances

**Fluids and electrolytes**

**Electrolyte replacement therapy**

The electrolyte concentrations (intravenous fluid) table and the electrolyte content (gastro-intestinal secretions) table may be helpful in planning replacement electrolyte therapy; faeces, vomit, or aspiration should be saved and analysed where possible if abnormal losses are suspected.

**Oral preparations for fluid and electrolyte imbalance**

Sodium and potassium salts, may be given by mouth to prevent deficiencies or to treat established deficiencies of mild or moderate degree.

**Oral potassium**

Compensation for potassium loss is especially necessary:

◊ in those taking digoxin or anti-arrhythmic drugs, where potassium depletion may induce arrhythmias;

◊ in patients in whom secondary hyperaldosteronism occurs, e.g. renal artery stenosis, cirrhosis of the liver, the nephrotic syndrome, and severe heart failure;

◊ in patients with excessive losses of potassium in the faeces, e.g. chronic diarrhoea associated with intestinal malabsorption or laxative abuse.

**Fluids and electrolytes**

Measures to compensate for potassium loss may also be required in the elderly since they frequently take inadequate amounts of potassium in the diet (but see **warning** on renal insufficiency). Measures may also be required during long-term administration of drugs known to induce potassium loss (e.g. corticosteroids). Potassium supplements are seldom required with the small doses of diuretics given to treat hypertension; potassium-sparing diuretics (rather than potassium supplements) are recommended for prevention of hypokalaemia due to diuretics such as furosemide p. 221 or the thiazides when these are given to eliminate oedema.

If potassium salts are used for the prevention of hypokalaemia, then doses of potassium chloride daily (in divided doses) by mouth are suitable in patients taking a normal diet. **Smaller doses must be used if there is renal insufficiency (common in the elderly) to reduce the risk of hyperkalaemia.**

Potassium salts cause nausea and vomiting and poor compliance is a major limitation to their effectiveness; when appropriate, potassium-sparing diuretics are preferable.

When there is established potassium depletion larger doses may be necessary, the quantity depending on the severity of any continuing potassium loss (monitoring of plasma-potassium concentration and specialist advice would be required). Potassium depletion is frequently associated with
chloride depletion and with metabolic alkalosis, and these disorders require correction.

Management of hyperkalaemia
Acute severe hyperkalaemia (plasma-potassium concentration above 6.5 mmol/litre or in the presence of ECG changes) calls for urgent treatment with calcium gluconate 10% p. 959 by slow intravenous injection, titrated and adjusted to ECG improvement, to temporarily protect against myocardial excitability. An intravenous injection of soluble insulin (5–10 units) with 50 mL glucose 50% p. 959 given over 5–15 minutes, reduces serum-potassium concentration; this is repeated if necessary or a continuous infusion instituted. Salbutamol p. 244 [unlicensed indication], by nebulisation or slow intravenous injection may also reduce plasma-potassium concentration; it should be used with caution in patients with cardiovascular disease. The correction of causal or compounding acidosis with sodium bicarbonate infusion p. 950 should be considered (important: preparations of sodium bicarbonate and calcium salts should not be administered in the same line—risk of precipitation). Drugs exacerbating hyperkalaemia should be reviewed and stopped as appropriate; occasionally haemodialysis is needed.

Ion-exchange resins may be used to remove excess potassium in mild hyperkalaemia or in moderate hyperkalaemia when there are no ECG changes.

Oral sodium and water
Sodium chloride p. 953 is indicated in states of sodium depletion and usually needs to be given intravenously. In chronic conditions associated with mild or moderate degrees of sodium depletion, e.g. in salt-losing bowel or renal disease, oral supplements of sodium chloride or sodium bicarbonate, according to the acid-base status of the patient, may be sufficient.

Oral rehydration therapy (ORT)
As a worldwide problem diarrhoea is by far the most important indication for fluid and electrolyte replacement. Intestinal absorption of sodium and water is enhanced by glucose (and other carbohydrates). Replacement of fluid and electrolytes lost through diarrhoea can therefore be achieved by giving solutions containing sodium, potassium, and glucose or another carbohydrate such as rice starch.

Oral rehydration solutions should:
- enhance the absorption of water and electrolytes;
- replace the electrolyte deficit adequately and safely;
- contain an alkalinising agent to counter acidosis;
- be slightly hypo-osmolar (about 250 mmol/litre) to prevent the possible induction of osmotic diarrhoea;
- be simple to use in hospital and at home;
- be palatable and acceptable, especially to children;
- be readily available.

It is the policy of the World Health Organization (WHO) to promote a single oral rehydration solution but to use it flexibly (e.g. by giving extra water between drinks of oral rehydration solution to moderately dehydrated infants).

The WHO oral rehydration salts formulation contains sodium chloride 2.6 g, potassium chloride 1.5 g, sodium citrate 2.9 g, anhydrous glucose 13.5 g. It is dissolved in sufficient water to produce 1 litre (providing Na+ 75 mmol, K+ 20 mmol, Cl− 65 mmol, citrate 10 mmol, glucose 75 mmol/litre). This formulation is recommended by the WHO and the United Nations Children’s fund, but it is not commonly used in the UK.

Oral rehydration solutions used in the UK are lower in sodium (50–60 mmol/litre) than the WHO formulation since, in general, patients suffer less severe sodium loss.

Rehydration should be rapid over 3 to 4 hours (except in hypernatraemic dehydration in which case rehydration should occur more slowly over 12 hours). The patient should be reassessed after initial rehydration and if still dehydrated rapid fluid replacement should continue.

Once rehydration is complete further dehydration is prevented by encouraging the patient to drink normal volumes of an appropriate fluid and by replacing continuing losses with an oral rehydration solution; in infants, breast-feeding or formula feeds should be offered between oral rehydration drinks.

Oral bicarbonate
Sodium bicarbonate is given by mouth for chronic acidotic states such as uraemic acidosis or renal tubular acidosis. The dose for correction of metabolic acidosis is not predictable and the response must be assessed. For severe metabolic acidosis, sodium bicarbonate can be given intravenously.

Sodium bicarbonate may also be used to increase the pH of the urine; it is also used in dyspepsia.

Sodium supplements may increase blood pressure or cause fluid retention and pulmonary oedema in those at risk; hypokalaemia may be exacerbated.

Where hyperchloeraemic acidosis is associated with potassium deficiency, as in some renal tubular and gastrointestinal disorders it may be appropriate to give oral potassium bicarbonate, although acute or severe deficiency should be managed by intravenous therapy.

Parenteral preparations for fluid and electrolyte imbalance
Electrolytes and water
Solutions of electrolytes are given intravenously, to meet normal fluid and electrolyte requirements or to replenish substantial deficits or continuing losses, when the patient is nauseated or vomiting and is unable to take adequate amounts by mouth. When intravenous administration is not possible, fluid (as sodium chloride 0.9% p. 953 or glucose 5% p. 955) can also be given by subcutaneous infusion (hypodermoclysis).

The nature and severity of the electrolyte imbalance must be assessed from the history and clinical and biochemical investigations. Sodium, potassium, chloride, magnesium, phosphate, and water depletion can occur singly and in combination with or without disturbances of acid-base balance.

Isotonic solutions may be infused safely into a peripheral vein. Solutions more concentrated than plasma, e.g. 20% glucose, are best given through an indwelling catheter positioned in a large vein.

Intravenous sodium
Sodium chloride in isotonic solution provides the most important extracellular ions in near physiological concentrations and is indicated in sodium depletion, which can arise from such conditions as gastro-enteritis, diabetic ketoacidosis, ileus, and ascites. In a severe deficit of 4 to 8 litres, 2 to 3 litres of isotonic sodium chloride may be given over 2 to 3 hours; thereafter the infusion can usually be at a slower rate.

Chronic hyponatraemia arising from inappropriate secretion of antidiuretic hormone should ideally be corrected by fluid restriction. However, if sodium chloride is required for acute or chronic hyponatraemia, regardless of the cause, the deficit should be corrected slowly to avoid the risk of osmotic demyelination syndrome and the rise in plasma-sodium concentration should not exceed 10 mmol/litre in 24 hours. In severe hyponatraemia, sodium chloride 1.8% may be used cautiously.

Compound sodium lactate (Hartmann’s solution) can be used instead of isotonic sodium chloride solution during or after surgery, or in the initial management of the injured or wounded; it may reduce the risk of hyperchloeraemic acidosis.

Sodium chloride with glucose p. 954 solutions are indicated when there is combined water and sodium depletion. A 1:1 mixture of isotonic sodium chloride and 5% glucose allows some of the water (free of sodium) to enter body cells which suffer most from dehydration while the
**Electrolyte concentrations—intravenous fluids**

<table>
<thead>
<tr>
<th>Type of fluid</th>
<th>Na⁺</th>
<th>K⁺</th>
<th>HCO₃⁻</th>
<th>Cl⁻</th>
<th>Ca²⁺</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium Chloride 0.9%</td>
<td>142</td>
<td>4.5</td>
<td>26</td>
<td>103</td>
<td>2.5</td>
</tr>
<tr>
<td>Compound Sodium Lactate (Hartmann’s)</td>
<td>131</td>
<td>5</td>
<td>29</td>
<td>111</td>
<td>2</td>
</tr>
<tr>
<td>Sodium Chloride 0.18% and Glucose 4% (Adults only)</td>
<td>30</td>
<td>-</td>
<td>-</td>
<td>30</td>
<td>-</td>
</tr>
<tr>
<td>Sodium Chloride 0.45% and Glucose 5% (Children only)</td>
<td>75</td>
<td>-</td>
<td>-</td>
<td>75</td>
<td>-</td>
</tr>
<tr>
<td>Potassium Chloride 0.15% and Glucose 5% (Children only)</td>
<td>-</td>
<td>20</td>
<td>-</td>
<td>20</td>
<td>-</td>
</tr>
<tr>
<td>Potassium Chloride 0.15% and Sodium Chloride 0.5% (Children only)</td>
<td>150</td>
<td>20</td>
<td>-</td>
<td>170</td>
<td>-</td>
</tr>
<tr>
<td>Potassium Chloride 0.3% and Glucose 5%</td>
<td>-</td>
<td>40</td>
<td>-</td>
<td>40</td>
<td>-</td>
</tr>
<tr>
<td>Potassium Chloride 0.3% and Sodium Chloride 0.9%</td>
<td>150</td>
<td>40</td>
<td>-</td>
<td>190</td>
<td>-</td>
</tr>
</tbody>
</table>

**To correct metabolic acidosis**

<table>
<thead>
<tr>
<th>Type of fluid</th>
<th>Na⁺</th>
<th>K⁺</th>
<th>HCO₃⁻</th>
<th>Cl⁻</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium Bicarbonate 1.26%</td>
<td>150</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sodium Bicarbonate 8.4% for cardiac arrest</td>
<td>1000</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sodium Lactate (m/6)</td>
<td>167</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

**Electrolyte content—gastro-intestinal secretions**

<table>
<thead>
<tr>
<th>Type of fluid</th>
<th>H⁺</th>
<th>Na⁺</th>
<th>K⁺</th>
<th>HCO₃⁻</th>
<th>Cl⁻</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastric</td>
<td>40–60</td>
<td>20–80</td>
<td>5–20</td>
<td>-</td>
<td>100–150</td>
</tr>
<tr>
<td>Biliary</td>
<td>-</td>
<td>120–140</td>
<td>5–15</td>
<td>30–50</td>
<td>80–120</td>
</tr>
<tr>
<td>Pancreatic</td>
<td>-</td>
<td>120–140</td>
<td>5–15</td>
<td>70–110</td>
<td>40–80</td>
</tr>
<tr>
<td>Small bowel</td>
<td>-</td>
<td>120–140</td>
<td>5–15</td>
<td>20–40</td>
<td>90–130</td>
</tr>
</tbody>
</table>

sodium salt with a volume of water determined by the normal plasma Na⁺ remains extracellular.

Combined sodium, potassium, chloride, and water depletion may occur, for example, with severe diarrhoea or persistent vomiting; replacement is carried out with sodium chloride intravenous infusion 0.9% and glucose intravenous infusion 5% with potassium as appropriate.

**Intravenous glucose**

Glucose solutions (5%) are used mainly to replace water deficit. Average water requirements in a healthy adult are 1.5 to 2.5 litres daily and this is needed to balance unavoidable losses of water through the skin and lungs and to provide sufficient for urinary excretion. Water depletion (dehydration) tends to occur when these losses are not matched by a comparable intake, as may occur in coma or dysphagia or in the elderly or apathetic who may not drink enough water on their own initiative.

Excessive loss of water without loss of electrolytes is uncommon, occurring in fevers, hyperthyroidism, and in uncommon water-losing renal states such as diabetes insipidus or hypercalcaemia. The volume of glucose solution needed to replace deficits varies with the severity of the disorder, but usually lies within the range of 2 to 6 litres.

Glucose solutions are also used to correct and prevent hypoglycaemia and to provide a source of energy in those too ill to be fed adequately by mouth; glucose solutions are a key component of parenteral nutrition.

Glucose solutions are given in regimens with calcium and insulin for the emergency management of hyperkalaemia. They are also given, after correction of hyperglycaemia, during treatment of diabetic ketoacidosis, when they must be accompanied by continuing insulin infusion.

**Intravenous potassium**

Potassium chloride with sodium chloride intravenous infusion p. 953 is the initial treatment for the correction of severe hypokalaemia and when sufficient potassium cannot be taken by mouth.

Repeated measurement of plasma-potassium concentration is necessary to determine whether further infusions are required and to avoid the development of hyperkalaemia, which is especially likely in renal impairment.

Initial potassium replacement therapy should not involve glucose infusions, because glucose may cause a further decrease in the plasma-potassium concentration.

**Bicarbonate and lactate**

Sodium bicarbonate p. 950 is used to control severe metabolic acidosis (pH<7.1) particularly that caused by loss of bicarbonate (as in renal tubular acidosis or from excessive gastro-intestinal losses). Mild metabolic acidosis associated with volume depletion should first be managed by appropriate fluid replacement because acidosis usually resolves as tissue and renal perfusion are restored. In more severe metabolic acidosis or when the acidosis remains unresponsive to correction of anoxia or hypovolaemia, sodium bicarbonate (1.26%) can be infused over 3–4 hours with plasma-pH and electrolyte monitoring. In severe shock, for example in cardiac arrest, metabolic acidosis can develop without sodium or volume depletion; in these circumstances sodium bicarbonate is best given as a small volume of hypertonic solution, such as 50 mL of 8.4% solution intravenously.

Sodium lactate intravenous infusion is no longer used in metabolic acidosis because of the risk of producing lactic acidosis.
acidity, particularly in seriously ill patients with poor tissue perfusion or impaired hepatic function.

For chronic acidotic states, sodium bicarbonate can be given by mouth.

**Plasma and plasma substitutes**

Plasma and plasma substitutes (‘colloids’) contain large molecules that do not readily leave the intravascular space where they exert osmotic pressure to maintain circulatory volume. Compared to fluids containing electrolytes such as sodium chloride and glucose (‘crystalloids’), a smaller volume of colloid is required to produce the same expansion of blood volume, thereby shifting salt and water from the extravascular space. If resuscitation requires a volume of fluid that exceeds the maximum dose of the colloid then crystalloids can be given; packed red cells may also be required.

Albumin solution p. 960, prepared from whole blood, contain soluble proteins and electrolytes but no clotting factors, blood group antibodies, or plasma cholinesterases; they may be given without regard to the recipient’s blood group.

Albumin is usually used after the acute phase of illness, to correct a plasma-volume deficit; hypoalbuminaemia itself is not an appropriate indication. The use of albumin solution in acute plasma or blood loss may be wasteful; plasma substitutes are more appropriate. Concentrated albumin solution (20%) can be used under specialist supervision in patients with an intravascular fluid deficit and oedema because of interstitial fluid overload, to restore intravascular plasma volume with less exacerbation of the salt and water overload than isotonic solutions. Concentrated albumin solution p. 960 may also be used to obtain a diuresis in hypoalbuminaemic patients (e.g. in hepatic cirrhosis).

Recent evidence does not support the previous view that the use of albumin increases mortality.

**Plasma substitutes**

Dextran, gelatin p. 961, and the hydroxyethyl starch, tetrasaccharide, are macromolecular substances which are metabolised slowly. Dextran and gelatin may be used at the outset to expand and maintain blood volume in shock arising from conditions such as burns or septicemia; they may also be used as an immediate short-term measure to treat haemorrhage until blood is available. Dextran and gelatin are rarely needed when shock is due to sodium and water depletion because, in these circumstances, the shock responds to water and electrolyte repletion.

Hydroxyethyl starches should only be used for the treatment of hypovolaemia due to acute blood loss when crystalloids alone are not sufficient; they should be used at the lowest effective dose for the first 24 hours of fluid resuscitation.

Plasma substitutes should not be used to maintain plasma volume in conditions such as burns or peritonitis where there is loss of plasma protein, water, and electrolytes over periods of several days or weeks. In these situations, plasma or plasma protein fractions containing large amounts of albumin should be given.

Large volumes of some plasma substitutes can increase the risk of bleeding through depletion of coagulation factors.

### BICARBONATE

**Sodium bicarbonate**

- **INDICATIONS AND DOSE**
  - **Alkalisation of urine** | **Relief of discomfort in mild urinary-tract infections**
    - **BY MOUTH**
    - **Adult:** 3 g every 2 hours until urinary pH exceeds 7, to be dissolved in water
**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule, oral suspension, oral solution, solution for injection, liquid

**Tablet**
- **Sodium bicarbonate (Non-proprietary)**
  - Sodium bicarbonate 600 mg Sodium bicarbonate 600mg tablets | 100 tablet GSL £29.75 DT price = £26.52

**Solution for injection**
- **Sodium bicarbonate (Non-proprietary)**
  - Sodium bicarbonate 84 mg per 1 ml Sodium bicarbonate 84 mg per 1 ml | 10 ampoule £81.27
  - Sodium bicarbonate 64 mg per 1 ml Sodium bicarbonate 64 mg per 1 ml | 10 ampoule £65.34
  - Sodium bicarbonate 25 mg per 1 ml Sodium bicarbonate 25 mg per 1 ml | 10 ampoule £62.04

**Oral solution**
- **Thamicarb** (Thame Laboratories Ltd)
  - Sodium bicarbonate 84 mg per 1 ml Thamicarb 84mg/1ml oral solution sugar-free | 100 ml P £39.80 DT price = £39.80 sugar-free | 500 ml P £199.20 DT price = £199.20

**Capsule**
- **Sodium bicarbonate (Non-proprietary)**
  - Sodium bicarbonate 500 mg Sodium bicarbonate 500mg capsules | 56 capsule P £17.06 DT price = £2.01 | 100 capsule P no price available

**Infusion**
- **Sodium bicarbonate (Non-proprietary)**
  - Sodium bicarbonate 12.6 mg per 1 ml Polyfusor BC sodium bicarbonate 1.26% infusion 500ml bottles | 1 bottle £9.86 | 12 bottle P no price available
  - Sodium bicarbonate 14 mg per 1 ml Polyfusor BD sodium bicarbonate 1.4% infusion 500ml bottles | 1 bottle £9.86 | 12 bottle P no price available
  - Sodium bicarbonate 27.4 mg per 1 ml Polyfusor V sodium bicarbonate 2.74% infusion 500ml bottles | 1 bottle £9.86 | 12 bottle P no price available
  - Sodium bicarbonate 42 mg per 1 ml Polyfusor BE sodium bicarbonate 4.2% infusion 500ml bottles | 1 bottle £9.86 | 12 bottle P no price available
  - Sodium bicarbonate 84 mg per 1 ml Polyfusor B sodium bicarbonate 8.4% infusion 200ml bottles | 1 bottle £9.86 | 12 bottle P no price available

**ELECTROLYTES AND MINERALS**

**Potassium chloride with calcium chloride and sodium chloride and sodium lactate**

*(Sodium Lactate Intravenous Infusion, Compound; Compound, Hartmann’s Solution for Injection; Ringer-Lactate Solution for Injection)*

The properties listed below are those particular to the combination only. For the properties of the components please consider, potassium chloride p. 968, sodium chloride p. 953, calcium chloride p. 959.

**INDICATIONS AND DOSE**
For prophylaxis, and replacement therapy, requiring the use of sodium chloride and lactate, with minimal amounts of calcium and potassium

- **BY INTRAVENOUS INFUSION**
- **Adult:** (consult product literature)

**INTERACTIONS** → Appendix 1: calcium salts, potassium chloride

**PRESCRIBING AND DISPENSING INFORMATION** Compound sodium lactate intravenous infusion contains Na⁺ 131 mmol, K⁺ 5 mmol, Ca²⁺ 2 mmol, HCO₃⁻ (as lactate) 29 mmol, Cl⁻ 111 mmol/litre.

**Potassium chloride with calcium chloride dihydrate and sodium chloride**

*(Ringer’s solution)*

The properties listed below are those particular to the combination only. For the properties of the components please consider, potassium chloride p. 968, sodium chloride p. 953.

**INDICATIONS AND DOSE**
Electrolyte imbalance

- **BY INTRAVENOUS INFUSION**
- **Adult:** Dosed according to the deficit or daily maintenance requirements (consult product literature)

**INTERACTIONS** → Appendix 1: potassium chloride

**PRESCRIBING AND DISPENSING INFORMATION** Ringer’s solution for injection provides the following ions (in mmol/litre), Ca⁺² 2.2, K⁺ 4, Na⁺ 147, Cl⁻ 156.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Infusion**
- **Potassium chloride with calcium chloride dihydrate and sodium chloride (Non-proprietary)**
  - Potassium chloride 300 microgram per 1 ml Calcium chloride 320 microgram per 1 ml Sodium chloride 8.6 mg per 1 ml Polyfusor C ringers infusion 500ml bottles | 1 bottle P £2.95 | 12 bottle P no price available
  - Steriflex No.9 ringers infusion 1 litre bags | 1 bag P £2.22 | 10 bag P no price available
  - Steriflex No.9 ringers infusion 500ml bags | 1 bag P £1.96 | 15 bag P no price available

**Potassium chloride with glucose**

The properties listed below are those particular to the combination only. For the properties of the components please consider, potassium chloride p. 968, glucose p. 955.

**INDICATIONS AND DOSE**
Electrolyte imbalance

- **BY INTRAVENOUS INFUSION**
- **Adult:** Dosed according to the deficit or daily maintenance requirements

**INTERACTIONS** → Appendix 1: glucose, potassium chloride

**PRESCRIBING AND DISPENSING INFORMATION** Potassium chloride 0.3% contains 40 mmol each of K⁺ and Cl⁻/litre or 0.15% contains 20 mmol each of K⁺ and Cl⁻/litre with 5% of anhydrous glucose.
Potassium chloride with glucose and sodium chloride

The properties listed below are those particular to the combination only. For the properties of the components please consider, potassium chloride p. 968, glucose p. 955, sodium chloride p. 953.

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: infusion, solution for infusion

### INTRAVENOUS INFUSION

- **Potassium chloride with glucose (Non-proprietary)**
  - Potassium chloride 3 mg per 1 ml, Glucose anhydrous 50 mg per 1 ml
    - Potassium chloride 0.3% (potassium 40mmol/1litre) / glucose 5% infusion 1litre Macoflex bags | 1 bag [Pom] no price available
    - Steriflex No.16 potassium chloride 0.3% (potassium 20mmol/500ml) / glucose 5% infusion 500ml bags | 1 bag [Pom] £1.67
  - Potassium chloride 0.2% (potassium 20mmol/500ml) / Glucose 5% infusion 500ml Macoflex bags | 1 bag [Pom] no price available
  - Potassium chloride 0.3% (potassium 40mmol/1litre) / Glucose 5% infusion 1litre bags | 1 bag [Pom] £2.82
  - Steriflex No.16 potassium chloride 0.3% (potassium 40mmol/1litre) / glucose 5% infusion 1litre bags | 1 bag [Pom] £2.20
  - Potassium chloride 0.3% (potassium 20mmol/500ml) / Glucose 5% infusion 500ml Viaflo bags | 1 bag [Pom] no price available
  - Potassium chloride 0.3% (potassium 40mmol/1litre) / Glucose 5% infusion 1litre Viaflo bags | 1 bag [Pom] no price available

- **Potassium chloride 2 mg per 1 ml, Glucose anhydrous 50 mg per 1 ml**
  - Steriflex No.13 potassium chloride 0.15% (potassium 10mmol/500ml) / glucose 5% infusion 500ml bags | 1 bag [Pom] £1.67
    - Steriflex No.13 potassium chloride 0.15% (potassium 20mmol/1litre) / glucose 5% infusion 1litre bags | 1 bag [Pom] £2.00
    - Potassium chloride 0.15% (potassium 20mmol/1litre) / Glucose 5% infusion 1litre Macoflex bags | 1 bag [Pom] £1.96
  - Potassium chloride 0.15% (potassium 10mmol/500ml) / Glucose 5% infusion 500ml bags | 10 bag [Pom] £10.67
  - Potassium chloride 0.15% (potassium 20mmol/500ml) / Glucose 5% infusion 500ml Macoflex bags | 1 bag [Pom] no price available
  - Potassium chloride 0.15% (potassium 20mmol/1litre) / Glucose 5% infusion 1litre Macoflex bags | 1 bag [Pom] no price available
  - Potassium chloride 0.15% (potassium 20mmol/1litre) / Glucose 5% infusion 1litre Viaflo bags | 1 bag [Pom] no price available

- **Potassium chloride 1.5 mg per 1 ml, Glucose anhydrous 50 mg per 1 ml**
  - Steriflex No.30 potassium chloride 0.2% (potassium 13.3mmol/500ml) / glucose 4% / sodium chloride 0.18% infusion 500ml bags | 1 bag [Pom] £1.67
    - Steriflex No.30 potassium chloride 0.2% (potassium 27mmol/1litre) / glucose 4% / sodium chloride 0.18% infusion 1litre bags | 1 bag [Pom] £2.20

- **Potassium chloride 1.0 mg per 1 ml, Glucose anhydrous 40 mg per 1 ml**
  - Steriflex No.30 potassium chloride 0.2% (potassium 13.3mmol/500ml) / glucose 4% / sodium chloride 0.18% infusion 500ml bags | 1 bag [Pom] £1.67
  - Potassium chloride 0.18% infusion 1litre bags | 1 bag [Pom] £2.20
  - Potassium chloride 0.18% infusion 500ml bags | 1 bag [Pom] no price available
  - Potassium chloride 0.18% infusion 1litre Viaflo bags | 1 bag [Pom] no price available

Potassium chloride 0.3% (potassium 20mmol/500ml) / Glucose 4% / Sodium chloride 0.18% infusion 500ml Macoflex bags | 1 bag [Pom] no price available

Potassium chloride 0.3% (potassium 40mmol/1litre) / Glucose 4% / Sodium chloride 0.18% infusion 1litre Viaflo bags | 1 bag [Pom] no price available

Potassium chloride 0.3% (potassium 20mmol/50ml) / Glucose 4% / Sodium chloride 0.18% infusion 500ml bags | 1 bag [Pom] £1.67

### Indications and doses

#### ELECTROLYTE IMBALANCE

- **By intravenous infusion**
  - Adult: Dosed according to the deficit or daily maintenance requirements

#### INTERACTIONS

- Appendix 1: potassium chloride

#### PRESCRIBING AND DISPENSING INFORMATION

Concentration of potassium chloride to be specified by the prescriber (usually K+ 10–40 mmol/litre).

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: infusion, solution for infusion

- **Potassium chloride with glucose and sodium chloride (Non-proprietary)**
  - Sodium chloride 1.8 mg per 1 ml, Potassium chloride 3 mg per 1 ml
    - Glucose anhydrous 40 mg per 1 ml
      - Steriflex No.17 potassium chloride 0.3% (potassium 40mmol/1litre) / glucose 4% / sodium chloride 0.18% infusion 1litre bags | 1 bag [Pom] £2.20
      - Potassium chloride 0.18% infusion 1litre bags | 1 bag [Pom] £2.20
    - Potassium chloride 0.3% (potassium 20mmol/500ml) / glucose 4% / sodium chloride 0.18% infusion 500ml bags | 1 bag [Pom] no price available

Potassium chloride 0.3% (potassium 20mmol/500ml) / Glucose 4% / Sodium chloride 0.18% infusion 500ml Macoflex bags | 1 bag [Pom] no price available

Potassium chloride 0.3% (potassium 40mmol/1litre) / Glucose 4% / Sodium chloride 0.18% infusion 1litre Viaflo bags | 1 bag [Pom] no price available

Potassium chloride 0.3% (potassium 20mmol/50ml) / Glucose 4% / Sodium chloride 0.18% infusion 500ml bags | 1 bag [Pom] £1.67

Potassium chloride 0.3% (potassium 20mmol/50ml) / Glucose 4% / Sodium chloride 0.18% infusion 1litre bags | 1 bag [Pom] £2.20

Potassium chloride 0.3% (potassium 20mmol/1litre) / glucose 4% / sodium chloride 0.18% infusion 1litre bags | 1 bag [Pom] £2.20

### DIRECT DEPLETION

Potassium depletion

- **By mouth**
  - Adult: Dosed according to the deficit or daily maintenance requirements (consult product literature)

### INTERACTIONS

- Appendix 1: potassium chloride

### PRESCRIBING AND DISPENSING INFORMATION

Each SandoK® tablet contains potassium 470 mg (12 mmol of K+) and chloride 285mg (8 mmol of CI−).

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

#### Effervescent tablet

- **CAUTIONARY AND ADVISORY LABELS**
  - 13, 21

#### Sando-K (HK Pharma Ltd)

- **Potassium bicarbonate 400 mg, Potassium chloride 600 mg**
  - Sando-K effervescent tablets | 100 tablet [P] £7.65 DT price = £7.65
INTERACTIONS

The properties listed below are those particular to the PRESCRIBING AND DISPENSING INFORMATION please consider, potassium chloride p. 968, sodium chloride below.

■ INDICATIONS AND DOSE

Electrolyte imbalance

BY INTRAVENOUS INFUSION

Adult: Depending on the deficit or the daily maintenance requirements (consult product literature)

■ INTERACTIONS

Appendix 1: potassium chloride

■ PRESCRIBING AND DISPENSING INFORMATION

Potassium chloride 0.15% with sodium chloride 0.9% contains K+ 20 mmol, Na+ 150 mmol, and Cl– 170 mmol/litre or potassium chloride 0.3% with sodium chloride 0.9% contains K+ 40 mmol, Na+ 150 mmol, and Cl– 190 mmol/litre.

■ MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: infusion, solution for infusion

Infusion

Potassium chloride with sodium chloride (Non-proprietary) Potassium chloride 3 mg per 1 ml, Sodium chloride 9 mg per 1 ml Sterifelex No.15 potassium chloride 0.3% (potassium 20mmol/500ml)/sodium chloride 0.9% infusion 500ml bags | 1 bag (Pot) £1.67 | 15 bag (Pot) no price available Potassium chloride 0.3% (potassium 20mmol/500ml)/sodium chloride 0.9% infusion 500ml bags | 1 bag (Pot) no price available | 10 bag (Pot) no price available Potassium chloride 0.3% (potassium 20mmol/500ml)/sodium chloride 0.9% infusion 500ml bags | 1 bag (Pot) no price available | 20 bag (Pot) no price available Potassium chloride 0.3% (potassium 20mmol/500ml)/sodium chloride 0.9% infusion 500ml bags | 1 bag (Pot) no price available | 50 bag (Pot) no price available Potassium chloride 0.3% (potassium 20mmol/500ml)/sodium chloride 0.9% infusion 500ml bags | 1 bag (Pot) no price available | 100 bag (Pot) no price available

Potassium chloride 1.5 mg per 1 ml, Sodium chloride 9 mg per 1 ml Sterifelex No.12 potassium chloride 0.15% (potassium 20mmol/1litre)/sodium chloride 0.9% infusion 1litre bags | 1 bag (Pot) £2.20 | 10 bag (Pot) no price available Sterifelex No.12 potassium chloride 0.15% (potassium 10mmol/500ml)/sodium chloride 0.9% infusion 500ml bags | 1 bag (Pot) £1.67 Potassium chloride 0.15% (potassium 10mmol/500ml)/sodium chloride 0.9% infusion 500ml bags | 1 bag (Pot) no price available | 20 bag (Pot) no price available Potassium chloride 0.15% (potassium 10mmol/500ml)/sodium chloride 0.9% infusion 500ml bags | 1 bag (Pot) no price available | 50 bag (Pot) no price available Potassium chloride 0.15% (potassium 10mmol/500ml)/sodium chloride 0.9% infusion 500ml bags | 1 bag (Pot) no price available | 100 bag (Pot) no price available Potassium chloride 0.15% (potassium 20mmol/1litre)/sodium chloride 0.9% infusion 1litre bags | 1 bag (Pot) no price available | 10 bag (Pot) no price available Potassium chloride 0.15% (potassium 20mmol/1litre)/sodium chloride 0.9% infusion 1litre bags | 1 bag (Pot) no price available | 12 bag (Pot) no price available Potassium chloride 2 mg per 1 ml, Sodium chloride 9 mg per 1 ml Sterifelex No.28 potassium chloride 0.2% (potassium 13.3mmol/500ml)/sodium chloride 0.9% infusion 500ml bags | 1 bag (Pot) £1.67 | 15 bag (Pot) no price available Sterifelex No.28 potassium chloride 0.2% (potassium 27mmol/1litre)/sodium chloride 0.9% infusion 1litre bags | 1 bag (Pot) £2.20

Electrolyte imbalance

BY INTRAVENOUS INFUSION

Adult: 4–8 tablets daily, to be taken with water, up to maximum 20 tablets daily in severe depletion

Chronic renal salt wasting

BY MOUTH

Adult: Up to 2 tablets daily, to be taken with appropriate fluid intake

Management of diabetic ketoacidosis (to restore circulating volume if systolic blood pressure is below 90 mmHg and adjusted for age, sex, and medication as appropriate)

BY INTRAVENOUS INFUSION

Adult: 500 mL, sodium chloride 0.9% to be given over 10–15 minutes, repeat if blood pressure remains below 90 mmHg and seek senior medical advice, when blood pressure is over 90 mmHg, sodium chloride 0.9% should be given by intravenous infusion at a rate that replaces deficit and provides maintenance, management regimen also includes administration of potassium chloride, soluble insulin, long acting insulin analogues and glucose 10% solution

Diluent for instillation of drugs to the bladder

BY INTRAVESICAL INSTILLATION

Adult: (consult product literature)

■ CAUTIONS

With intravenous use Avoid excessive administration • cardiac failure • dilutional hyponatraemia especially in the elderly • hypertension • peripheral oedema • pulmonary oedema • restrict intake in impaired renal function • toxemia of pregnancy

■ SIDE-EFFECTS

With intravenous use Administration of large doses may give rise to sodium accumulation • hyperchloraeamic acidosis • oedema

■ MONITORING REQUIREMENTS

With intravenous use The jugular venous pressure should be assessed, the bases of the lungs should be examined for crepitations, and in elderly or seriously ill patients it is often helpful to monitor the right atrial (central) venous pressure.

■ PRESCRIBING AND DISPENSING INFORMATION

Sodium chloride 0.9% intravenous infusion contains Na+ and Cl– each 150 mmol/litre. The term ‘normal saline’ should not be used to describe sodium chloride intravenous infusion 0.9%; the term ‘physiological saline’ is acceptable but it is preferable to give the composition (i.e. sodium chloride intravenous infusion 0.9%).

Each Slow Sodium® tablet contains approximately 10 mmol each of Na+ and Cl–; tablets can be crushed before administration.

■ MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule, solution for injection, infusion, solution for infusion

Modified-release tablet

CAUTIONARY AND ADVISORY LABELS 25

Slow Sodium® (HK Pharma Ltd)

Sodium chloride 600 mg Slow Sodium 600mg tablets | 100 tablet (GS) £6.05 DT price = £6.05
### Solution for injection

<table>
<thead>
<tr>
<th>Sodium chloride (Non-proprietary)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium chloride 9 mg per 1 ml</td>
<td>Sodium chloride 9% solution for infusion 5ml Sure-Amp ampoules</td>
</tr>
<tr>
<td>Sodium chloride 9 mg per 1 ml</td>
<td>Sodium chloride 9% solution for injection 50ml vials</td>
</tr>
<tr>
<td>Sodium chloride 9% solution for injection 10ml ampoules</td>
<td>10 ampoule (Pom)</td>
</tr>
<tr>
<td>Sodium chloride 9% solution for injection 20ml Mini-Plasco ampoules</td>
<td>20 ampoule (Pom)</td>
</tr>
<tr>
<td>Sodium chloride 9% solution for injection 5ml Mini-Plasco ampoules</td>
<td>20 ampoule (Pom)</td>
</tr>
<tr>
<td>Sodium chloride 9% solution for injection 2ml Sure-Amp ampoules</td>
<td>20 ampoule (Pom)</td>
</tr>
<tr>
<td>Sodium chloride 9% solution for injection 20ml ampoules</td>
<td>20 ampoule (Pom)</td>
</tr>
<tr>
<td>Sodium chloride 9% solution for injection 2ml ampoules</td>
<td>10 ampoule (Pom)</td>
</tr>
<tr>
<td>Sodium chloride 9% solution for injection 5ml ampoules</td>
<td>10 ampoule (Pom)</td>
</tr>
<tr>
<td>Sodium chloride 9% solution for injection 10ml Sure-Amp ampoules</td>
<td>20 ampoule (Pom)</td>
</tr>
<tr>
<td>Sodium chloride 9% solution for injection 10ml Mini-Plasco ampoules</td>
<td>20 ampoule (Pom)</td>
</tr>
<tr>
<td>Sodium chloride 300 mg per 1 ml</td>
<td>Sodium chloride 30% solution for injection 10ml ampoules</td>
</tr>
<tr>
<td>Sodium chloride 9 mg per 1 ml</td>
<td>Drytec saline (GE Healthcare Biosciences)</td>
</tr>
<tr>
<td>Sodium chloride 9 mg per 1 ml</td>
<td>Drytec saline eluent 5ml vials</td>
</tr>
<tr>
<td>Sodium chloride 9% solution for injection 10ml ampoules</td>
<td>10 ampoule (Pom)</td>
</tr>
<tr>
<td>Sodium chloride 300 mg per 1 ml</td>
<td>Sodium chloride 30% concentrate for solution for infusion 100ml vials</td>
</tr>
<tr>
<td>Sodium chloride 30% concentrate for solution for infusion 50ml vials</td>
<td>1 vial (Pom)</td>
</tr>
<tr>
<td>Sodium chloride 30% concentrate for solution for infusion 10ml ampoules</td>
<td>10 ampoule (Pom)</td>
</tr>
<tr>
<td>Sodium chloride 9 mg per 1 ml</td>
<td>Sodium chloride 9% intravesical solution 50ml bags</td>
</tr>
<tr>
<td>Sodium chloride 1.8 mg per 1 ml</td>
<td>Polyfusor 0 sodium chloride 0.18% infusion 500ml bottles</td>
</tr>
<tr>
<td>Sodium chloride 4.5 mg per 1 ml</td>
<td>Sodium chloride 0.45% infusion 500ml vials</td>
</tr>
<tr>
<td>Sodium chloride 0.45% infusion 500ml Viaflex bags</td>
<td>1 bag (Pom)</td>
</tr>
<tr>
<td>Sodium chloride 0.45% infusion 500ml Viaflex bags</td>
<td>1 bag (Pom)</td>
</tr>
<tr>
<td>Sodium chloride 9 mg per 1 ml</td>
<td>Sodium chloride 0.9% infusion 100ml bags</td>
</tr>
<tr>
<td>Sodium chloride 0.9% infusion 250ml Macronox N bags</td>
<td>1 bag (Pom) no price available</td>
</tr>
<tr>
<td>Sodium chloride 0.9% infusion 500ml Viaflo bags</td>
<td>1 bag (Pom) no price available</td>
</tr>
<tr>
<td>Sodium chloride 0.9% infusion 250ml Viaflo bags</td>
<td>1 bag (Pom) no price available</td>
</tr>
<tr>
<td>Sodium chloride 0.9% infusion 250ml Macronox N bags</td>
<td>1 bag (Pom) no price available</td>
</tr>
<tr>
<td>Sodium chloride 0.9% infusion 500ml Macronox N bags</td>
<td>1 bag (Pom) no price available</td>
</tr>
<tr>
<td>Sodium chloride 0.9% infusion 250ml Viaflo bags</td>
<td>1 bag (Pom) no price available</td>
</tr>
</tbody>
</table>

### Intravenous solution

| Sodium chloride (Non-proprietary) |  |
| Sodium chloride 9 mg per 1 ml    | Sodium chloride 0.9% intravenous solution 50ml bags | 1 bag (Pom) | £5.00 |

### Infusion

| Sodium chloride (Non-proprietary) |  |
| Sodium chloride 1.8 mg per 1 ml  | Polyfusor 0 sodium chloride 0.18% infusion 500ml bottles | 1 bottle (Pom) | £3.44 |
| Sodium chloride 4.5 mg per 1 ml  | Sodium chloride 0.45% infusion 500ml vials | 1 bag (Pom) no price available | Polyfusor 5b sodium chloride 0.45% infusion 500ml bottles | 1 bottle (Pom) | £3.44 |
| Sodium chloride 0.45% infusion 500ml Viaflex bags | 1 bag (Pom) no price available | Steriflex No.2 sodium chloride 0.45% infusion 500ml bags | 1 bag (Pom) | £1.26 | 15 bag (Pom) no price available |
| Sodium chloride 9 mg per 1 ml    | Sodium chloride 0.9% infusion 100ml bags | 1 bag (Pom) | £2.00 |
| Sodium chloride 0.9% infusion 250ml Macronox N bags | 1 bag (Pom) no price available | Sodium chloride 0.9% infusion 100ml Viaflo bags | 1 bag (Pom) no price available | 50 bag (Pom) no price available |
| Sodium chloride 0.9% infusion 500ml Viaflo bags | 1 bag (Pom) no price available | Sodium chloride 0.9% infusion 500ml Viaflo bags | 1 bag (Pom) no price available | 50 bag (Pom) no price available |
| Sodium chloride 0.9% infusion 250ml Viaflo bags | 1 bag (Pom) no price available | Sodium chloride 0.9% infusion 500ml Viaflo bags | 1 bag (Pom) no price available | 50 bag (Pom) no price available |
| Sodium chloride 0.9% infusion 250ml Macronox N bags | 1 bag (Pom) no price available | Sodium chloride 0.9% infusion 100ml Viaflo bags | 1 bag (Pom) no price available | 50 bag (Pom) no price available |
| Sodium chloride 0.9% infusion 500ml Viaflo bags | 1 bag (Pom) no price available | Sodium chloride 0.9% infusion 500ml Viaflo bags | 1 bag (Pom) no price available | 50 bag (Pom) no price available |
| Sodium chloride 0.9% infusion 250ml Viaflo bags | 1 bag (Pom) no price available | Sodium chloride 0.9% infusion 500ml Viaflo bags | 1 bag (Pom) no price available | 50 bag (Pom) no price available |

### Sodium chloride with glucose

The properties listed below are those particular to the combination only. For the properties of the components please consider, sodium chloride p. 953, glucose p. 955.

#### INDICATIONS AND DOSE

**Combined water and sodium depletion**

- **By intravenous infusion**
- **Adult:** (consult product literature)

#### INTERACTIONS

Appendix 1: glucose
MONITORING REQUIREMENTS  Maintenance fluid should accurately reflect daily requirements and close monitoring is required to avoid fluid and electrolyte imbalance.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for infusion

Infection
- Sodium chloride with glucose (Non-proprietary)
  Sodium chloride 4.5 mg per 1 ml, Glucose anhydrous 25 mg per 1 ml Sodium chloride 0.45% / Glucose 2.5% infusion 500ml Viaflex bags | 1 bottle (Ps) £2.40 | 12 bottle (Ps) no price available
  Sodium chloride 0.45% / Glucose 2.5% infusion 500ml Viaflo bags | 1 bag (Ps) no price available | 20 bag (Ps) no price available
  Sodium chloride 1.8 mg per 1 ml, Glucose anhydrous 40 mg per 1 ml Polyfuor T glucose 4% / sodium chloride 0.18% infusion 500ml bottles | 1 bottle (Ps) £2.40 | 12 bottle (Ps) no price available
  Sodium chloride 0.18% / Glucose 4% infusion 500ml Macoflex bags | 1 bag (Ps) no price available | 20 bag (Ps) no price available
  Sodium chloride 0.18% / Glucose 4% infusion 500ml Viaflex bags | 1 bag (Ps) no price available | 20 bag (Ps) no price available
  Sodium chloride 0.18% / Glucose 4% infusion 500ml Viaflo bags | 1 bag (Ps) no price available | 20 bag (Ps) no price available
  Sodium chloride 0.18% / Glucose 4% infusion 1 litre Macoflex bags | 1 bag (Ps) no price available | 12 bag (Ps) no price available
  Sodium chloride 0.18% / Glucose 4% infusion 1 litre Viaflex bags | 1 bag (Ps) no price available | 20 bag (Ps) no price available
  Sodium chloride 0.18% / Glucose 4% infusion 1 litre Viaflo bags | 1 bag (Ps) no price available | 10 bag (Ps) no price available
  Sodium chloride 9 mg per 1 ml, Glucose 50 mg per 1 ml Steriflex No.3 glucose 5% / sodium chloride 0.9% infusion 500ml bags | 1 bag (Ps) £1.37 | 15 bag (Ps) no price available
  Sodium chloride 0.9% / Glucose 5% infusion 500ml bags | 1 bag (Ps) £2.00
  Sodium chloride 0.9% / Glucose 5% infusion 500ml Viaflex bags | 1 bag (Ps) no price available | 20 bag (Ps) no price available
  Steriflex No.3 glucose 5% / sodium chloride 0.9% infusion 1 litre bags | 1 bag (Ps) £2.10 | 10 bag (Ps) no price available
  Sodium chloride 4.5 mg per 1 ml, Glucose anhydrous 50 mg per 1 ml Sodium chloride 0.45% / Glucose 5% infusion 500ml Viaflex bags | 1 bag (Ps) no price available | 20 bag (Ps) no price available
  Steriflex No.45 glucose 5% / sodium chloride 0.45% infusion 500ml bags | 1 bag (Ps) £2.02 | 15 bag (Ps) no price available
  Sodium chloride 1.8 mg per 1 ml, Glucose anhydrous 100 mg per 1 ml Steriflex No.19 glucose 10% / sodium chloride 0.18% infusion 500ml bags | 1 bag (Ps) £2.02 | 15 bag (Ps) no price available

NUTRIENTS  SUGARS

Glucose (Dextrose Monohydrate)

INDICATIONS AND DOSE
- Establish presence of gestational diabetes
  - Adult: Test dose 75 g, anhydrous glucose to be given to the fasting patient and blood-glucose concentrations measured at intervals, to be given with 200–300 ml fluid

Oral glucose tolerance test
- Adult: Test dose 75 g, anhydrous glucose to be given to the fasting patient and blood-glucose concentrations measured at intervals, to be given with 200–300 ml fluid

Hypoglycaemia
- By intravenous infusion
  - Child: 500 mg/kg, to be administered as Glucose 10% intravenous infusion into a large vein through a large-gauge needle; care is required since this concentration is irritant especially if extravasation occurs
  - Adult: 10 g, to be administered as Glucose 20% intravenous infusion into a large vein through a large-gauge needle; care is required since this concentration is irritant especially if extravasation occurs

Energy source
- By intravenous infusion
  - Adult: 1–3 litres daily, solution concentration of 20–50% to be administered

Water replacement
- By intravenous infusion
  - Adult: The volume of glucose solution needed to replace deficits may vary (consult product literature)

Persistent cyanosis (in combination with propranolol)
- By intravenous infusion
  - Child: 200 mg/kg, to be administered as Glucose 10% intravenous infusion over 10 minutes

Management of diabetic ketoacidosis
- By intravenous infusion
  - Child: Glucose 5% or 10% should be added to replacement fluid once blood-glucose concentration falls below 14 mmol/litre
  - Adult: Glucose 10% should be given once blood-glucose concentration falls below 14 mmol/litre, to be administered into a large vein through a large-gauge needle at a rate of 125 ml/hour, in addition to the sodium chloride 0.9% infusion

DOSE EQUIVALENCE AND CONVERSION
- 75 g anhydrous glucose is equivalent to Glucose BP 82.5 g.

CAUTIONS
- Do not give alone except when there is no significant loss of electrolytes · prolonged administration of glucose solutions without electrolytes can lead to hyponatraemia and other electrolyte disturbances

INTERACTIONS
- Appendix 1: glucose

SIDE-EFFECTS
- Glucose injections especially if hypertonic may have a low pH and may cause venous irritation and thrombophlebitis

DIRECTIONS FOR ADMINISTRATION
- In children Injections containing more than 10% glucose can be irritant and should be given into a central venous line; however, solutions containing up to 12.5% can be administered for a short period into a peripheral line

PRESCRIBING AND DISPENSING INFORMATION
- Glucose BP is the monohydrate but Glucose Intravenous Infusion BP is a sterile solution of anhydrous glucose or glucose monohydrate, potency being expressed in terms of anhydrous glucose

EXCEPTIONS TO LEGAL CATEGORY
- With intravenous use Prescription only medicine restriction does not apply to 50% solution where administration is for saving life in emergency

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution, solution for injection, solution for infusion

Solution for infusion
- Glucose (Non-proprietary)
  - Glucose anhydrous 200 mg per 1 ml Glucose 20% solution for infusion 100ml vials | 1 vial (Ps) £5.00
  - Glucose anhydrous 500 mg per 1 ml Glucose 50% solution for infusion 20ml ampoules | 10 ampoule (Ps) £10.00–£12.00
  - Glucose 50% solution for infusion 50ml vials | 1 vial (Ps) £2.01 DT price = £2.01 | 25 vial (Ps) £50.00

Oral solution
- Rapilose OGTT (Aspire Pharma Ltd)
  - Glucose 250 mg per 1 ml Rapilose OGTT solution | 300 ml £3.48

Oral gel
- Dextrogel (Neocuticals Ltd)
  - Glucose 400 mg per 1 gram Dextrogel 40% gel | 75 gram £7.16 OT price = £7.16 | 80 gram £6.84
Glucose (Non-proprietary) Infusion

Glucose anhydrous 50 mg per 1 ml Glucose 5% infusion lliitre Macoflex bags | 1 bag (Pom) no price available
Glucose 5% infusion 500ml bags | 1 bag (Pom) £1.91
Glucose 5% infusion 500ml Macoflex N bags | 1 bag (Pom) no price available
Glucose 5% infusion 100ml bags | 1 bag (Pom) £2.00
Glucose 5% infusion 11itre Easyflex N bags | 1 bag (Pom) no price available
Glucose 5% infusion 100ml Easyflex N bags | 1 bag (Pom) no price available
Glucose 5% infusion 500ml Viaflo bags | 1 bag (Pom) no price available
Glucose 5% infusion 500ml Vialflo bags | 1 bag (Pom) no price available
Glucose 5% infusion 250ml Macoflex N bags | 1 bag (Pom) no price available
Glucose 5% infusion 100ml Macoflex N bags | 1 bag (Pom) no price available
Glucose 5% infusion 250ml Easyflex N bags | 1 bag (Pom) no price available
Polyfusor D glucose 5% infusion 11itre bottles | 1 bottle (Pom) £3.02
Glucose 5% infusion 250ml Easyflex N bags | 1 bag (Pom) no price available
Glucose 5% infusion 100ml Macoflex N bags | 1 bag (Pom) no price available
Glucose 5% infusion 200ml Easyflex N bags | 1 bag (Pom) no price available
Glucose 5% infusion 11itre bags | 10 bag (Pom) £11.11
Glucose 5% infusion 500ml Macoflex bags | 1 bag (Pom) no price available
Glucose 5% infusion 500ml Vialflo bags | 1 bag (Pom) no price available
Glucose 5% infusion 500ml Viaflo bags | 1 bag (Pom) no price available
Glucose 5% infusion 500ml Macoflex N bags | 1 bag (Pom) no price available
Glucose 5% infusion 100ml Vialflo bags | 1 bag (Pom) no price available
Glucose 5% infusion 100ml Viaflo bags | 1 bag (Pom) no price available
Glucose 5% infusion 100ml Easyflex N bags | 1 bag (Pom) no price available
Glucose 5% infusion 100ml Macoflex N bags | 1 bag (Pom) no price available
Glucose 5% infusion 200ml Easyflex N bags | 1 bag (Pom) no price available
Glucose 5% infusion 200ml Macoflex bags | 1 bag (Pom) no price available
Glucose 5% infusion 200ml Macoflex N bags | 1 bag (Pom) no price available
Glucose 5% infusion 200ml Vialflo bags | 1 bag (Pom) no price available
Glucose 5% infusion 200ml Viaflo bags | 1 bag (Pom) no price available
Glucose 5% infusion 200ml Easyflex N bags | 1 bag (Pom) no price available
Glucose 5% infusion 200ml Macoflex N bags | 1 bag (Pom) no price available
Glucose 5% infusion 200ml Viaflo bags | 1 bag (Pom) no price available
Glucose 5% infusion 200ml Vialflo bags | 1 bag (Pom) no price available
Glucose 5% infusion 200ml Easyflex N bags | 1 bag (Pom) no price available
Glucose 5% infusion 11itre bags | 10 bag (Pom) £11.11
Glucose 5% infusion 11itre Macoflex N bags | 1 bag (Pom) no price available
Glucose 5% infusion 11itre Easyflex N bags | 1 bag (Pom) no price available
Glucose 5% infusion 11itre bags | 10 bag (Pom) £11.11
Glucose 5% infusion 100ml Macoflex N bags | 1 bag (Pom) no price available
Glucose 5% infusion 100ml Easyflex N bags | 1 bag (Pom) no price available
Glucose 5% infusion 100ml Viaflo bags | 1 bag (Pom) no price available
Glucose 5% infusion 100ml Vialflo bags | 1 bag (Pom) no price available
Glucose 5% infusion 100ml Easyflex N bags | 1 bag (Pom) no price available
Glucose 5% infusion 100ml Viaflo bags | 1 bag (Pom) no price available
Glucose 5% infusion 100ml Vialflo bags | 1 bag (Pom) no price available
Glucose anhydrous 100 mg per 1 ml Steriflex No.7 glucose 10% infusion lliitre bags | 1 bag (Pom) £2.54
Glucose 10% infusion lliitre Vialflo bags | 1 bag (Pom) no price available
Glucose 10% infusion lliitre bags | 1 bag (Pom) £2.54
Glucose 10% infusion 500ml bags | 1 bag (Pom) no price available
Glucose 10% infusion 500ml Viaflo bags | 1 bag (Pom) no price available
Glucose 10% infusion 500ml Vialflo bags | 1 bag (Pom) no price available
Glucose anhydrous 100 mg per 1 ml Steriflex No.33 glucose 40% infusion 500ml bags | 1 bag (Pom) £2.81
Glucose 40% infusion 500ml bags | 1 bag (Pom) no price available

ORAL REHYDRATION SALTS

Disodium hydrogen citrate with glucose, potassium chloride and sodium chloride
(Formulated as oral rehydration salts)

INDICATIONS AND DOSE
Fluid and electrolyte loss in diarrhoea

BY MOUTH
Child 1-11 months: 1-1.5 times usual feed volume to be given
Child 1-11 years: 200 mL, to be given after every loose motion
Child 12-17 years: 200-400 mL, to be given after every loose motion, dose according to fluid loss
Adult: 200-400 mL, to be given after every loose motion, dose according to fluid loss

DIRECTIONS FOR ADMINISTRATION
Reconstitute 1 sachet with 200mL of water (freshly boiled and cooled for infants); 5 sachets reconstituted with 1 litre of water provide Na+ 60 mmol, K+ 20 mmol, Cl- 60 mmol, citrate 10 mmol, and glucose 90 mmol.

PRESCRIBING AND DISPENSING INFORMATION
Flavours of oral powder formulations may include black currant, citrus, or natural.

PATIENT AND CARER ADVICE
After reconstitution any unused solution should be discarded no later than 1 hour after preparation unless stored in a refrigerator when it may be kept for up to 24 hours.

Medicines for Children leaflet: Oral rehydration salts www.medicinesforchildren.org.uk/oral-rehydration-salts

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Powder
Dioralyte (Sanofi)
Potassium chloride 300 mg, Sodium chloride 470 mg, Disodium hydrogen citrate 530 mg, Glucose 3.56 gram
Dioralyte oral powder sachets citrus | 20 sachet (P) £6.72
Dioralyte oral powder sachets plain | 20 sachet (P) £6.72
Dioralyte oral powder sachets blackcurrant | 20 sachet (P) £6.72

Potassium chloride with rice powder, sodium chloride and sodium citrate
(Formulated as oral rehydration salts)

INDICATIONS AND DOSE
Fluid and electrolyte loss in diarrhoea

BY MOUTH
Adult: 200-400 mL, to be given after every loose motion, dose according to fluid loss

DIRECTIONS FOR ADMINISTRATION
Reconstitute 1 sachet with 200 mL of water (freshly boiled and cooled for infants); 5 sachets when reconstituted with 1 litre of water
1.1 Calcium imbalance

Calcium

Calcium supplements are usually only required where dietary calcium intake is deficient. This dietary requirement varies with age and is relatively greater in childhood, pregnancy, and lactation, due to an increased demand, and in old age, due to impaired absorption. In osteoporosis, a calcium intake which is double the recommended amount reduces the rate of bone loss. If the actual dietary intake is less than the recommended amount, a supplement of as much as 40 mmol is appropriate.

In severe acute hypocalcaemia or hypocalcaemic tetany, an initial slow intravenous injection of calcium gluconate injection 10% p. 959 should be given, with plasma–calcium and ECG monitoring (risk of arrhythmias if given too rapidly), and either repeated as required or, if only temporary improvement, followed by a continuous intravenous infusion to prevent recurrence. Calcium chloride injection p. 959 is also available, but is more irritant; care should be taken to prevent extravasation. Oral supplements of calcium and vitamin D may also be required in persistent hypocalcaemia. Concurrent hypomagnesaemia should be corrected with magnesium sulfate p. 963.

See the role of calcium gluconate in temporarily reducing the toxic effects of hyperkalaemia.

Severe hypercalcaemia

Severe hypercalcaemia, which leads to a decrease in serum calcium concentrations.

Cinacalcet

**DRUG ACTION** Cinacalcet reduces parathyroid hormone

**INDICATIONS AND DOSE** Secondary hyperparathyroidism in patients with end-stage renal disease on dialysis

- **BY MOUTH**
  - Adult: Initially 30 mg once daily, dose to be adjusted every 2–4 weeks; maximum 180 mg per day

**Primary hyperparathyroidism in patients where parathyroidectomy is inappropriate**

- **BY MOUTH**
  - Adult: Initially 30 mg twice daily (max. per dose 90 mg 4 times a day), dose to be adjusted every 2–4 weeks according to response

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**

Dose adjustment may be necessary if smoking started or stopped during treatment.

**CAUTIONS** Treatment should not be initiated in patients with hypocalcaemia

**INTERACTIONS** → Appendix 1: cinacalcet

**SIDE-EFFECTS**

- Common or very common: Anorexia, asthenia, dizziness, myalgia, nausea, paraesthesia, rash, reduced testosterone concentrations, vomiting
- Uncommon: Diarrhoea, dyspepsia, seizures
- Frequency not known: Allergic reactions, angioedema, heart failure, hypotension

**PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk—no information available.

**BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT** Manufacturer advises caution in moderate to severe impairment. Monitor closely in hepatic impairment especially when increasing dose.

After treatment of severe hypercalcaemia the underlying cause must be established. Further treatment is governed by the same principles as for initial therapy. Salt and water depletion and drugs promoting hypercalcaemia should be avoided; oral administration of a bisphosphonate may be useful.

**Hyperparathyroidism**

Paricalcitol p. 995 is licensed for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. Parathyroidectomy may be indicated for hyperparathyroidism.

**Hypercalciuria**

Hypercalciuria should be investigated for an underlying cause, which should be treated. Where a cause is not identified (idiopathic hypercalciuria), the condition is managed by increasing fluid intake and giving bendroflumethiazide p. 161. Reducing dietary calcium intake may be beneficial but severe restriction of calcium intake has not proved beneficial and may even be harmful.
Blood and nutrition

[NATURAL_TEXT]

Calcium carbonate

**INDICATIONS AND DOSE**

**Phosphate binding in renal failure and hyper-phosphataemia**

- **By mouth**
  - Adult: (consult product literature)

**Calcium deficiency**

- **By mouth**
  - Adult: (consult product literature)

**INTERACTIONS** → Appendix 1: calcium salts

**PRESCRIBING AND DISPENSING INFORMATION**

- Adcal® contains calcium carbonate 1.5 g (calcium 600 mg or Ca\(^{2+}\)
  - 15 mmol); Calcichew® contains calcium carbonate 1.25 g (calcium 500 mg or Ca\(^{2+}\)
  - 12.5 mmol); Calcichew Forte® contains calcium carbonate 2.5 g (calcium 1 g or Ca\(^{2+}\)
  - 25 mmol); Cacit® contains calcium carbonate 1.25 g, providing calcium citrate when dispersed in water (calcium 500 mg or Ca\(^{2+}\)
  - 12.5 mmol); consult product literature for details of other available products.

Flavours of soluble tablet formulations may include orange or fruit flavour.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, capsule, oral suspension

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS** 25
  - **Calcium carbonate (Non-proprietary)**
  - Calcium carbonate 1.25 gram Calcium carbonate 1.25g tablets 100 tablet no price available
  - **Effervescent tablet**
    - **CAUTIONARY AND ADVISORY LABELS** 13
    - Cacit (Warner Chilcott Ltd)
      - Calcium carbonate 1.25 gram Cacit 500mg effervescent tablets sugar-free 76 tablet £11.81 DT price = £11.81
  - **Chewable tablet**
    - **CAUTIONARY AND ADVISORY LABELS** 24
    - EXCIPIENTS: May contain Aspartame
    - Calcium carbonate (Non-proprietary)
      - Calcium carbonate 1.25 gram Calcium carbonate 1.25g chewable tablets sugar-free 100 tablet £12.50 DT price = £9.33
      - Adcal (Kyowa Kirin Ltd)
        - Calcium carbonate 1.5 gram Adcal 1500mg chewable tablets sugar-free 100 tablet £8.70 DT price = £8.70
        - Calcichew (Forum Health Products Ltd)
          - Calcium carbonate 2.5 gram Calcichew 500mg chewable tablets sugar-free 60 tablet £13.16 DT price = £13.16

1.1b Hypocalcaemia

**ELECTROLYTES AND MINERALS** → CALCIUM

Calcium salts

- **CONTRA-INDICATIONS** Conditions associated with hypercalcaemia (e.g. some forms of malignant disease) - conditions associated with hypercalciuria (e.g. some forms of malignant disease)
- **CAUTIONS** History of nephrolithiasis - sarcoidosis
- **SIDE-EFFECTS**
  - **GENERAL SIDE-EFFECTS**
  - **Rare** Gastro-intestinal disturbances
  - **Frequency not known** Hypocalcaemia
- **SPECIFIC SIDE-EFFECTS**
  - With intravenous use: Arrhythmias - bradycardia - fall in blood pressure - injection-site reactions - peripheral vasodilatation - severe tissue damage with extravasation - sweating
- **RENA L IMPAIRMENT** Use with caution.

Calcium carbonate with calcium lactate gluconate

The properties listed below are those particular to the combination only. For the properties of the components please consider, calcium carbonate above.

**INDICATIONS AND DOSE**

**Calcium deficiency**

- **By mouth**
  - Adult: Dose according to requirements

**INTERACTIONS** → Appendix 1: calcium salts

**PRESCRIBING AND DISPENSING INFORMATION**

Each Sandocal® tablet contains 1 g calcium (Ca\(^{2+}\)
  - 25 mmol); flavours of soluble tablet formulations may include orange.
Calcium chloride

**INDICATIONS AND DOSE**

Severe acute hypocalcaemia or hypocalcaemic tetany

- **BY INTRAVENOUS INJECTION**
  - Adults: Dose according to requirements.

**CAUTIONS**

Avoid in respiratory acidosis - avoid in respiratory failure.

**INTERATIONS**

Appendix 1: calcium salts

**DIRECTIONS FOR ADMINISTRATION**

Care should be taken to avoid extravasation.

**PRESCRIBING AND DISPENSING INFORMATION**

Non-proprietary Calcium chloride dihydrate 7.35%(calcium 20 mg or Ca²⁺ 500 micromol/mL); Calcium chloride dihydrate 10%(calcium 27.3 mg or Ca²⁺ 680 micromol/mL); Calcium chloride dihydrate 14.7%(calcium 40.1 mg or Ca²⁺ 1000 micromol/mL).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for infusion

**Solution for injection**

- **Calcium chloride (Non-proprietary)**
  - Calcium chloride solution for injection 10ml ampoules | 10 ampoule
  - Calcium chloride dihydrate 73.5 mg per 1 ml | 10 ampoule
  - Solution for injection 10ml ampoules | 10 ampoule
  - Solution for injection 10ml prepared syringes | 1 pre-filled disposable injection
  - Calcium chloride dihydrate 100 mg per 1 ml | 10 ampoule
  - Calcium chloride dihydrate 147 mg per 1 ml | 10 ampoule
  - Solution for injection 10ml ampoules | 10 ampoule
  - Calcium chloride dihydrate 14.7% solution for injection 10ml ampoules | 10 ampoule

**Calcium gluconate**

**INDICATIONS AND DOSE**

Severe acute hypocalcaemia or hypocalcaemic tetany

- **BY INTRAVENOUS INJECTION**
  - Adults: Initially 10–20 mL, calcium gluconate injection 10% (providing approximately 2.25–4.5 mmol of calcium) should be administered with plasma-calcium and ECG monitoring, and either repeated as required or, if only temporary improvement, followed by a continuous intravenous infusion to prevent recurrence, alternatively (by continuous intravenous infusion), initially 50 mL/hour, adjusted according to response, infusion to be administered using 100 mL of calcium gluconate 10% diluted in 1 litre of glucose 5% or sodium chloride 0.9%

Acute severe hyperkalaemia (plasma-potassium concentration above 6.5 mmol/litre or in the presence of ECG changes)

- **BY SLOW INTRAVENOUS INJECTION**
  - Adults: 10–20 mL, calcium gluconate 10% should be administered, dose titrated and adjusted to ECG improvement.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Calcium gluconate (Non-proprietary)**
  - Calcium gluconate 100 mg per 1 ml | 10 ampoule
  - Solution for injection 10ml ampoules | 10 ampoule
  - Calcium gluconate 100 mg per 1 ml | 10 ampoule
  - Solution for injection 10ml ampoules | 10 ampoule
  - Calcium gluconate 147 mg per 1 ml | 10 ampoule
  - Calcium gluconate 14.7% solution for injection 10ml ampoules | 10 ampoule
  - Calcium gluconate 14.7% solution for injection 10ml ampoules | 10 ampoule

**Effervescent tablet**

- **Calcium gluconate (Non-proprietary)**
  - Calcium gluconate 500 mg | 10 tablet
  - Calcium gluconate 500 mg | 10 tablet
  - Calcium gluconate 500 mg | 10 tablet

**Calcium lactate**

**INDICATIONS AND DOSE**

Calcium deficiency

- **BY MOUTH**
  - Adult: Dose according to requirements.

**INTERATIONS**

Appendix 1: calcium salts

**DIRECTIONS FOR ADMINISTRATION**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **Calcium lactate (Non-proprietary)**
  - Calcium lactate 300 mg | 84 tablet
  - Calcium lactate 300 mg | 84 tablet

**Calcium phosphate**

**INDICATIONS AND DOSE**

Indications listed in combination monographs (available in the UK only in combination with other drugs)

- **BY MOUTH**
  - Adult: Doses listed in combination monographs.
1.2 Low blood volume

**BLOOD AND RELATED PRODUCTS  >  PLASMA PRODUCTS**

### Albumin solution

**Human Albumin Solution**

**INDICATIONS AND DOSE**

Acute or sub-acute loss of plasma volume e.g. in burns, pancreatitis, trauma, and complications of surgery (with isotonic solutions) | Plasma exchange (with isotonic solutions) | Severe hypoalbuminaemia associated with low plasma volume and generalised oedema where salt and water restriction with plasma volume expansion are required (with concentrated solutions 20%) | Paracentesis of large volume ascites associated with portal hypertension (with concentrated solutions 20%)

- **BY INTRAVENOUS INFUSION**
- **Adult:** (consult product literature)

**CONTRA-INDICATIONS** Cardiac failure • severe anaemia

**CAUTIONS** Correct dehydration when administering concentrated solution • history of cardiac disease (administer slowly to avoid rapid rise in blood pressure and cardiac failure, and monitor cardiovascular and respiratory function) • history of circulatory disease (administer slowly to avoid rapid rise in blood pressure and cardiac failure, and monitor cardiovascular and respiratory function) • increased capillary permeability

**SIDE-EFFECTS** Anaphylaxis • chills • fever • hypersensitivity reactions • hypotension • increased salivation • nausea • tachycardia • vomiting

**MONITORING REQUIREMENTS** Plasma and plasma substitutes are often used in very ill patients whose condition is unstable. Therefore, close monitoring is required and fluid and electrolyte therapy should be adjusted according to the patient’s condition at all times.

**PRESCRIBING AND DISPENSING INFORMATION** A solution containing protein derived from plasma, serum, or normal placentas; at least 95% of the protein is albumin. The solution may be isotonic (containing 3.5–5% protein) or concentrated (containing 15–25% protein).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Infusion**
  - **Flexbumin** (Baxalta UK Ltd)
    - Albumin solution human 200 gram per 1 litre | 1 vial | £34.00
  - **Biotest** (Biotest UK Ltd)
    - Albumin solution human 50 mg per 1 ml | 1 vial | £49.50
  - **Grifols** (Grifols UK Ltd)
    - Albumin solution human 50 mg per 1 ml | 1 bottle | £54.00

**PLASMA SUBSTITUTES**

### Dextran 70 with sodium chloride

**INDICATIONS AND DOSE**

Initial treatment of hypovolaemia with hypotension induced by traumatic injury

- **BY INTRAVENOUS INFUSION**
- **Adult:** 250 ml, to be given over 2–5 minutes using RescueFlow®, followed immediately by administration of isotonic fluids.

**CAUTIONS** Cardiac disease • hyperosmolality • severe hypoglycaemia • severe liver disease

**SIDE-EFFECTS**

- **Rare** Severe anaphylactic reactions
- **Frequency not known** Hypersensitivity reactions • transient increase in bleeding time

**PREGNANCY** Avoid—reports of anaphylaxis in mother causing fetal anoxia, neurological damage and death.

**HEPATIC IMPAIRMENT** Use with caution in severe impairment.

**RENAL IMPAIRMENT** Use with caution.

**MONITORING REQUIREMENTS**

Where possible, monitor central venous pressure.

- Urine output should be monitored. Care should be taken to avoid haematocrit concentration from falling below 25–30% and the patient should be monitored for hypersensitivity reactions.
- Plasma and plasma substitutes are often used in very ill patients whose condition is unstable. Therefore, close monitoring is required and fluid and electrolyte therapy should be adjusted according to the patient’s condition at all times.

**EFFECT ON LABORATORY TESTS** Can interfere with some laboratory tests—dextran may interfere with blood group cross-matching or biochemical measurements, and these should be carried out before infusion is begun.

**PRESCRIBING AND DISPENSING INFORMATION** Dextran 70 is dextran with an average molecular weight of about 70,000.
**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Infusion**

- **RescueFlow** (Pharmacosmos UK Ltd)
  - Gelatin 40 mg per 1 ml
  - Sodium chloride 75 mg per 1 ml
  - Rescuflow 6% infusion 250ml bags | 1 bag (POM) no price available (Hospital only)

**Gelatin**

**INDICATIONS AND DOSE**

**Low blood volume in hypovolaemic shock, burns and cardiopulmonary bypass**

- **BY INTRAVENOUS INFUSION**
  - Adult: Initially 500–1000 mL, use 3.5–4% solution

**Indications and Dose**

**VOLULYTE® INFUSION**

Treatment of hypovolaemia due to acute blood loss when crystalloids alone are not sufficient

- **BY INTRAVENOUS INFUSION**
  - Adult: Initially 10–20 mL, then increased to up to 30 mL/kg per hour for a maximum duration of treatment of 24 hours, the initial dose must be given slowly and with careful monitoring of the patient to allow any anaphylactic reaction to be detected as early as possible

**VOLUVEN® INFUSION**

Treatment of hypovolaemia due to acute blood loss when crystalloids alone are not sufficient

**SIDE-EFFECTS**

- Rare: Severe anaphylactic reactions
- Frequency not known: Hypersensitivity reactions: transient increase in bleeding time

**PREGNANCY**

Manufacturer of Geloplasma® advises avoid at the end of pregnancy.

**HEPATIC IMPAIRMENT**

Use with caution in severe impairment.

**RENAL IMPAIRMENT**

Use with caution in renal impairment.

**MONITORING REQUIREMENTS**

- Urine output should be monitored. Care should be taken to avoid haematuric concentration from falling below 25–30% and the patient should be monitored for hypersensitivity reactions.
- Plasma and plasma substitutes are often used in very ill patients whose condition is unstable. Therefore, close monitoring is required and fluid and electrolyte therapy should be adjusted according to the patient’s condition at all times.

**PRESCRIBING AND DISPENSING INFORMATION**

**Gelatin**

The gelatin is partially degraded.

**Gelavan®** contains succinylated gelatin (modified fluid gelatin, average molecular weight 26500) 40g, Na⁺ 151 mmol, K⁺ 4 mmol, Mg²⁺ 1 mmol, Cl⁻ 103 mmol, Ca²⁺ 1 mmol, acetate 24 mmol/litre; **Gelofusine®** contains succinylated gelatin (modified fluid gelatin, average molecular weight 30000) 40g (4%), Na⁺ 154 mmol, Cl⁻ 124 mmol/litre; **Gelofusine®** contains partially hydrolysed and succinylated gelatin (modified liquid gelatin) (as anhydrous gelatin) 30g (3%), Na⁺ 150 mmol, K⁺ 5 mmol, Mg²⁺ 1.5 mmol, Cl⁻ 100 mmol, lactate 30 mmol/litre; **Isoplex®** contains succinylated gelatin (modified fluid gelatin, average molecular weight 30000) 40g (4%), Na⁺ 145 mmol, K⁺ 4 mmol, Mg²⁺ 0.9 mmol, Cl⁻ 105 mmol, lactate 25 mmol/litre; **Volplex®** contains succinylated gelatin (modified fluid gelatin, average molecular weight 30000) 40g (4%), Na⁺ 154 mmol, Cl⁻ 125 mmol/litre.

**Tetrastarch**

**INDICATIONS AND DOSE**

**VOLULYTE® INFUSION**

Treatment of hypovolaemia due to acute blood loss when crystalloids alone are not sufficient

- **BY INTRAVENOUS INFUSION**
  - Adult: Initially 10–20 mL, then increased to up to 30 mL/kg per hour for a maximum duration of treatment of 24 hours, the initial dose must be given slowly and with careful monitoring of the patient to allow any anaphylactic reaction to be detected as early as possible

**VOLUVEN® INFUSION**

Treatment of hypovolaemia due to acute blood loss when crystalloids alone are not sufficient

**SIDE-EFFECTS**

- Rare: Severe anaphylactic reactions
- Frequency not known: Hypersensitivity reactions: pruritus raised serum amylase: transient increase in bleeding time

**HEPATIC IMPAIRMENT**

Avoid in severe impairment.

**RENAL IMPAIRMENT**

Avoid.

**MONITORING REQUIREMENTS**

- Plasma and plasma substitutes are often used in very ill patients whose condition is unstable. Therefore, close monitoring is required and fluid and electrolyte therapy should be adjusted according to the patient’s condition at all times. Treatment with hydroxyethyl starches should be guided by continuous haemodynamic monitoring so that the infusion is stopped as soon as appropriate haemodynamic goals have been achieved.
- Monitor renal function.
- Monitor for hypersensitivity reactions.
- Urine output should be monitored.

**PRESCRIBING AND DISPENSING INFORMATION**

Hydroxyethyl starch is composed of more than 90% of amylopectin that has been etherified with hydroxyethyl groups; the term tetrastarch reflects the degree of etherification. Hydroxyethyl starches should only be used for the treatment of hypovolaemia due to acute blood loss when crystalloids alone are not sufficient; they should be used at the lowest effective dose for the first 24 hours of fluid resuscitation.

**Volubelt®** contains hydroxyethyl starch 6% (average molecular weight 130 000) in sodium chloride intravenous
Blood and nutrition

1.3 Magnesium imbalance

Magnesium

Magnesium is an essential constituent of many enzyme systems, particularly those involved in energy generation; the largest stores are in the skeleton.

Magnesium salts are not well absorbed from the gastrointestinal tract, which explains the use of magnesium sulfate as an osmotic laxative.

Hypermagnesaemia

Since magnesium is secreted in large amounts in the gastrointestinal tract, excessive losses in diarrhoea, stoma or fistula are the most common causes of hypermagnesaemia; deficiency may also occur in alcoholism or as a result of treatment with certain drugs. Hypermagnesaemia often causes secondary hypocalcaemia, and also hypokalaemia and hyponatraemia.

Symptomatic hypermagnesaemia is associated with a deficit of 0.5–1 mmol/kg; up to 160 mmol Mg²⁺ over up to 5 days may be required to replace the deficit (allowing for urinary losses). Magnesium is given initially by intravenous infusion or by intramuscular injection of magnesium sulfate; the intramuscular injection is painful. Plasma magnesium concentration should be measured to determine the rate and duration of infusion and the dose should be reduced in renal impairment. To prevent recurrence of the deficit, magnesium may be given by mouth, but there is limited evidence of benefit. Magnesium aspartate powder for oral solution below is available as a licensed preparation and, magnesium glycerophosphate tablets p. 963 and liquid [unlicensed] are available from ‘special-order’ manufacturers or specialist importing companies.

Arrhythmias

Magnesium sulfate injection has also been recommended for the emergency treatment of serious arrhythmias, especially in the presence of hypokalaemia (when hypomagnesaemia may also be present) and when salvos of rapid ventricular tachycardia show the characteristic twisting wave front known as torsade de pointes.

Myocardial infarction

Limited evidence that magnesium sulfate prevents arrhythmias and reperfusion injury in patients with suspected myocardial infarction has not been confirmed by large studies. Routine use of magnesium sulfate for this purpose is not recommended.

Magnesium aspartate

Eclampsia and pre-eclampsia

Magnesium sulfate injection is the drug of choice for the treatment of seizures and the prevention of recurrent seizures in women with eclampsia. Regimens may vary between hospitals. Calcium gluconate injection is used for the management of magnesium toxicity.

Magnesium sulfate injection is also of benefit in women with pre-eclampsia in whom there is concern about developing eclampsia. The patient should be monitored carefully.

1.3a Hypomagnesaemia

ELECTROLYTES AND MINERALS > MAGNESIUM

Magnesium aspartate

INDICATIONS AND DOSE

Treatment and prevention of magnesium deficiency

BY MOUTH

Adult: 10–20 mmol daily, taken as 1–2 sachets of Magnaspartate® powder.

CONTRA-INDICATIONS

Disorders of cardiac conduction

INTERACTIONS

Appendix 1: magnesium

SIDE-EFFECTS

Uncommon Diarrhoea

Rare Hypermagnesaemia

Frequency not known Dental caries (on long term use) • gastrointestinal irritation

SIDE-EFFECTS, FURTHER INFORMATION

Side-effects generally occur at higher doses; if side-effects (such as diarrhoea) occur, consider interrupting treatment and restarting at a reduced dose.

Overdose

Symptoms of hypermagnesaemia may include nausea, vomiting, flushing of the skin, thirst, hypotension due to peripheral vasodilatation, drowsiness, confusion, loss of tendon reflexes and respiratory depression due to neuromuscular blockade, slurred speech, double vision, muscle weakness, bradycardia, cardiac arrhythmias, coma, and cardiac arrest.

RENAL IMPAIRMENT

Avoid in severe impairment (eGFR less than 30 mL/minute/1.7³).

DIRECTIONS FOR ADMINISTRATION

Dissolve sachet contents in 50–200 mL water, tea or orange juice and take immediately.

PRESCRIBING AND DISPENSING INFORMATION

Magnaspartate® contains magnesium aspartate 6.5 g (10 mmol Mg²⁺)/sachet.

PATIENT AND CARER ADVICE

Patients and carers should be given advice on how to administer magnesium aspartate powder.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Powder

EXCIPIENTS: May contain Sucrose

Magnaspartate (KoRa Healthcare)

Magnesium (as Magnesium aspartate) 243 mg Magnaspartate 243mg (magnesium 10mmol) oral powder sachets | 10 sachet PO £8.95

infusion 0.6%, containing Na⁺ 137 mmol, K⁺ 4 mmol, Mg²⁺ 1.5 mmol, Cl⁻ 110 mmol, acetate 34 mmol/litre.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Infusion

Volulyte (Fresenius Kabi Ltd) ▼

Magnesium chloride hexahydrate 300 mg per 1 litre, Potassium chloride 300 mg per 1 litre, Sodium acetate trihydrate 4.63 gram per 1 litre, Sodium chloride 6.02 gram per 1 litre, Tetrastarch 60 gram per 1 litre Volulyte 6% infusion 500ml Freeflex bags | 15 bag (POM) £22.60

Voluven (Fresenius Kabi Ltd) ▼

Tetrastarch 60 mg per 1 gram Voluven 6% infusion 500ml Freeflex bags | 1 bag (POM) £10.63 | 15 bag (POM) no price available

Tetrastarch 100 mg per 1 ml Voluven 10% infusion 500ml Freeflex bags | 20 bag (POM) no price available
Magnesium glycerophosphate 02-Jun-2016

- **INDICATIONS AND DOSE**
  - Prevent recurrence of magnesium deficit
    - **BY MOUTH**
    - Adult: 24 mmol daily in divided doses, dose expressed as Mg<sup>2+</sup>.

- **DOSE EQUIVALENCE AND CONVERSION**
  - Magnesium glycerophosphate 1 g is approximately equivalent to Mg<sup>2+</sup> 4 mmol or magnesium 97 mg.

- **UNLICENSED USE** Not licensed for use.
- **INTERACTIONS** → Appendix 1: magnesium
- **SIDE-EFFECTS** Arrhythmias · colic · coma · confusion · diarrhoea · drowsiness · flushing of skin · hypermagnesaemia associated side-effects · hypotension · loss of tendon reflexes · muscle weakness · nausea · respiratory depression · thirst · vomiting
- **RENAL IMPAIRMENT** Avoid or reduce dose. Increased risk of toxicity.
- **MONITORING REQUIREMENTS** Monitor blood pressure, respiratory rate, urinary output, and urine volume for signs of over dosage (loss of patellar reflexes, weakness, nausea, sensation of warmth, flushing, drowsiness, double vision, and slurred speech).
- **DIRECTIONS FOR ADMINISTRATION** Tablets may be dispersed in water.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, chewable tablet, capsule, oral suspension, oral solution, powder.
  - **Tablet**
    - Magnesium glycerophosphate (Non-proprietary)
      - Magnesium (as Magnesium glycerophosphate) 97.2 mg Mag-4 (magnesium 97.2mg (4mmol)) tablets | 30 tablet £84.50
    - **Oral solution**
      - LiquaMag GP (Fontus Health Ltd)
        - Magnesium (as Magnesium glycerophosphate) 24.25 mg per 1 ml LiquaMag GP (magnesium 121.25mg/5ml (5mmol/5ml)) oral solution sugar-free | 200 ml £49.99 sugar-free | 250 ml £55.00
  - **Chewable tablet**
    - MagnaPhate (Arjun Products Ltd)
      - Magnesium (as Magnesium glycerophosphate) 97.2 mg MagnaPhate (magnesium 97.2mg (4mmol)) chewable tablets sugar-free | 50 tablet £22.64
    - **Capsule**
      - Magnesium glycerophosphate (Non-proprietary)
        - Magnesium (as Magnesium glycerophosphate) 48.6 mg Mag-4 (magnesium 48.6mg (2mmol)) capsules | 30 capsule £85.70
        - MagnaPhos 48.6mg (2mmol) capsules | 50 capsule £35.87
        - Magnesium (as Magnesium glycerophosphate) 97.2 mg Mag-4 (magnesium 97.2mg (4mmol)) capsules | 30 capsule £89.30
        - MagnaPhos 97.2mg (4mmol) capsules | 50 capsule £37.87

---

Magnesium sulfate

- **INDICATIONS AND DOSE**
  - Severe acute asthma | Continuing respiratory deterioration in anaphylaxis
    - **BY INTRAVENOUS INFUSION**
    - Child 2-17 years: 40 mg/kg (max. per dose 2 g), to be given over 20 minutes
    - Adult: 1.2–2 g, to be given over 20 minutes
  - **Prevention of seizures in pre-eclampsia**
    - **INITIALLY BY INTRAVENOUS INJECTION**
    - Adult: Initially 4 g, to be given over 5–15 minutes, followed by (by intravenous infusion) 1 gram/hour for 24 hours, if seizure occurs, additional dose of 2 g by intravenous injection to be administered

---

Treatment of seizures and prevention of seizure recurrence in eclampsia

- **INITIALLY BY INTRAVENOUS INJECTION**
  - Adult: Initially 4 g, to be given over 5–15 minutes, followed by (by intravenous infusion) 1 gram/hour for 24 hours after seizure or delivery (whichever is later), if seizure recurs, increase the infusion rate to 1.5–2 g/hour or give an additional dose of 2 g by intravenous injection

**Hypomagnesaemia**

- **BY INTRAVENOUS INFUSION, OR BY INTRAMUSCULAR INJECTION**
  - Adult: Up to 40 g, given over a period of up to 5 days, dose given depends on the amount required to replace the deficit (allowing for urinary losses)

**Hypomagnesaemia maintenance (e.g. in intravenous nutrition)**

- **BY INTRAVENOUS INFUSION, OR BY INTRAMUSCULAR INJECTION**
  - Adult: 2.5–5 g daily, usual dose 3 g daily

**Emergency treatment of serious arrhythmias**

- **BY INTRAVENOUS INJECTION**
  - Adult: 2 g, to be given over 10–15 minutes, dose may be repeated once if necessary

**Rapid bowel evacuation (acts in 2–4 hours)**

- **BY MOUTH**
  - Adult: 5–10 g, dose to be mixed in a glass of water, taken preferably before breakfast

- **DOSE EQUIVALENCE AND CONVERSION**
  - Magnesium sulfate heptahydrate 1 g equivalent to Mg<sup>2+</sup> approx. 4 mmol.

- **UNLICENSED USE** Unlicensed indication in severe acute asthma. Continuing respiratory deterioration in anaphylaxis.
- **CONTRA-INDICATIONS**
  - With oral use in rapid bowel evacuation—acute gastrointestinal conditions (in adults)
- **CAUTIONS**
  - With oral use in rapid bowel evacuation—elderly and debilitated patients (in adults)
- **INTERACTIONS** → Appendix 1: magnesium
- **SIDE-EFFECTS**
  - Arrhythmias · colic · coma · confusion · drowsiness · flushing of skin · hypermagnesaemia associated side-effects · hypotension · loss of tendon reflexes · muscle weakness · nausea · respiratory depression · thirst · vomiting
  - **SPECIFIC SIDE-EFFECTS**
    - With oral use Colic · diarrhoea
  - **PREGNANCY**
    - When used for Hypomagnesaemia or Arrhythmias or Prevention of seizures in pre-eclampsia or Treatment of seizures and prevention of seizure recurrence in eclampsia or Severe acute asthma or Continuing respiratory deterioration in anaphylaxis. Not known to be harmful for short-term intravenous administration in eclampsia, but excessive doses in third trimester cause neonatal respiratory depression.
  - **HEPATIC IMPAIRMENT** Avoid in hepatic coma if risk of renal failure.
  - **RENAL IMPAIRMENT** Avoid or reduce dose. Increased risk of toxicity.
  - **MONITORING REQUIREMENTS** Monitor blood pressure, respiratory rate, urinary output and for signs of overdosage (loss of patellar reflexes, weakness, nausea, sensation of warmth, flushing, drowsiness, double vision, and slurred speech).
  - **DIRECTIONS FOR ADMINISTRATION**
    - With intravenous use In severe hypomagnesaemia administer initially via controlled infusion device (preferably syringe pump). For *intravenous injection*, in
Phosphorus

Phosphate supplements

Oral phosphate supplements are rarely used as phosphate-binding agents in the management of hyperphosphataemia complicating renal failure. Aluminium-containing preparations are rarely used as phosphate binding agents and can cause aluminium accumulation.

Sevelamer p. 966 is licensed for the treatment of hyperphosphataemia in patients on haemodialysis or peritoneal dialysis. Sevelamer carbonate is also licensed for the treatment of patients with chronic kidney disease not on dialysis who have a serum–phosphate concentration of 1.78 mmol/litre or more.

Lanthanum p. 965 is licensed for the control of hyperphosphataemia in patients with chronic renal failure on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD), and in patients with chronic kidney disease not on dialysis who have a serum–phosphate concentration of 1.78 mmol/litre or more that cannot be controlled by a low-phosphate diet.

Sucralfate oxyhydroxide p. 966 is licensed for the control of hyperphosphataemia in patients with chronic kidney disease on haemodialysis or peritoneal dialysis. It is used as part of a multiple therapeutic approach to control the development of renal bone disease; this could include the concomitant use of a calcium supplement, a vitamin D analogue or calcimimetics.

1.4a Hyperphosphataemia

ELECTROLYTES AND MINERALS ★ ALUMINIUM

Aluminium hydroxide

INDICATIONS AND DOSE

Hyperphosphataemia in renal failure

BY MOUTH USING CAPSULES

Adult: 4–20 capsules daily in divided doses, to be taken with meals

Antacid

BY MOUTH USING CAPSULES

Adult: 475 mg 5 times a day, last dose to be taken at bedtime

CONTRA-INDICATIONS

Hypophosphataemia

INTERACTIONS

Appendix 1: antacids

SIDE-EFFECTS

Constipation · hyperaluminaemia

HEPATIC IMPAIRMENT

Avoid; can cause constipation which may precipitate coma.

RENAI IMPAIRMENT

There is a risk of accumulation and aluminium toxicity with antacids containing aluminium salts. Absorption of aluminium from aluminium salts is increased by citrates, which are contained in many effervescent preparations (such as effervescent analgesics).

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Capsule

Alu-Cap (Meda Pharmaceuticals Ltd)

Aluminium hydroxide 475 mg Alu-Cap 475mg capsules 120 capsules £13.71 DT price = £13.71

CALCIUM

Calcium acetate

INDICATIONS AND DOSE

PHOSEX ® TABLETS

Hyperphosphataemia

BY MOUTH

Adult: Initially 1 tablet 3 times a day, to be taken with meals, dose to be adjusted according to serum–phosphate concentration, usual dose 4–6 tablets
daily in divided doses, (1 or 2 tablets with each meal); maximum 12 tablets per day

**RENACET® TABLETS**

**Hyperphosphataemia**

> **BY MOUTH**
> Adult: 475–950 mg, to be taken with breakfast and with snacks, 0.95–2.85 g, to be taken with main meals and 0.95–1.9 g, to be taken with supper, dose to be adjusted according to serum-phosphate concentration; maximum 6.65 g per day

**INTERACTIONS**

> Appendix 1: calcium salts

**DIRECTIONS FOR ADMINISTRATION**

**PHOSEX® TABLETS**

Phosex® tablets are taken with meals. Tablets can be broken to aid swallowing, but not chewed (bitter taste).

**RENACET® TABLETS**

Manufacturer advises that other drugs should be taken 1 to 2 hours before or after Renacet® to reduce the possible interference with absorption of other drugs. Renacet® tablets are taken with meals.

**PRESCRIBING AND DISPENSING INFORMATION**

PhosLo® capsules contain calcium acetate (anhydrous) 667 mg (equivalent to calcium 169 mg or Ca2+ 4.2 mmol); Renacet® tablets contain calcium acetate 475 mg (equivalent to calcium 120.25 mg or Ca2+ 3 mmol); Phosex® tablets contain calcium acetate 1 g (equivalent to calcium 250 mg or Ca2+ 6.2 mmol).

**PATIENT AND CARER ADVICE**

Phosex® tablets Patients or carers should be given advice on how to administer Phosex® tablets.

Renacet® tablets Patients or carers should be given advice on how to administer Renacet® tablets.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

**CAUTIONARY AND ADVISORY LABELS**

> Phosex (Pharmacosmos UK Ltd)
  > Calcium acetate 1 gram Phosex 1g tablets  |  180 tablet POM £19.79
  > DT price = £19.79
> Renacet (Stanningley Pharma Ltd)
  > Calcium acetate 475 mg Renacet 475mg tablets  |  200 tablet POM £9.71
  > Renacet 950 mg Renacet 950mg tablets  |  200 tablet POM £18.45
  > DT price = £18.45

Combinations available: Calcium acetate with magnesium carbonate, below

**PHOSPHATE BINDERS**

**Calcium acetate with magnesium carbonate**

The properties listed below are those particular to the combination only. For the properties of the components please consider, calcium acetate p. 964, magnesium carbonate p. 69.

**INDICATIONS AND DOSE**

**Hyperphosphataemia**

> **BY MOUTH**
> Adult: Initially 1 tablet 3 times a day, adjusted according to serum-phosphate concentration, to be taken with food; usual dose 3–10 tablets daily; maximum 12 tablets per day

**CONTRA-INDICATIONS**

Hypercalcaemia - hypermagnesaemia - myasthenia gravis - third-degree AV block

**INTERACTIONS**

> Appendix 1: antacids, calcium salts

**DIRECTIONS FOR ADMINISTRATION**

Manufacturer advises that other drugs should be taken at least 2 hours before or 3 hours after calcium acetate with magnesium carbonate to reduce possible interference with absorption of other drugs.

**PATIENT AND CARER ADVICE**

Patients or carers should be given advice on how to administer calcium acetate with magnesium carbonate tablets.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

**CAUTIONARY AND ADVISORY LABELS**

> Rephoren (Vifor Fresenius Medical Care Renal Pharma UK Ltd)
  > Magnesium carbonate heavy 235 mg, Calcium acetate 435 mg Osaven 435mg/235mg tablets  |  180 tablet (POM) £24.00

**Lanthanum**

**INDICATIONS AND DOSE**

Hyperphosphataemia in patients with chronic renal failure on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) Hyperphosphataemia in patients with chronic kidney disease not on dialysis who have a serum-phosphate concentration of 1.78 mmol/litre or more that cannot be controlled by a low-phosphate diet

> **BY MOUTH**
> Adult: 1.5–3 g daily in divided doses, dose to be adjusted according to serum-phosphate concentration every 2–3 weeks, to be taken with or immediately after meals

**CAUTIONS**

Acute peptic ulcer - bowel obstruction - Crohn’s disease - ulcerative colitis

**INTERACTIONS**

> Appendix 1: lanthanum

**SIDE-EFFECTS**

> Common or very common Gastro-intestinal disturbances - headache - hypocalcaemia
> Frequency not known Accumulation of lanthanum in bone - transient changes in QT interval

**PREGNANCY**

Manufacturer advises avoid—toxicity in animal studies.

**BREAST FEEDING**

Manufacturer advises caution—no information available.

**HEPATIC IMPAIRMENT**

Lanthanum excreted in bile—possible accumulation in obstructive jaundice.

**DIRECTIONS FOR ADMINISTRATION**

Tablets are to be chewed. Each sachet of powder to be mixed with soft food and consumed within 15 minutes.

**PATIENT AND CARER ADVICE**

Patient and carers should be given advice on how to administer lanthanum tablets and powder.

**NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (March 2007) that lanthanum (Fosrenol®) is accepted for restricted use within NHS Scotland for the control of hyperphosphataemia in patients with chronic renal failure on haemodialysis or continuous ambulatory peritoneal dialysis, as a second-line agent, where a non-aluminium, non-calcium phosphate binder is required.

---

Downloaded from www.medicalbr.com
Sevelamer
31-Oct-2016

**INDICATIONS AND DOSE**

RENAGEL®

Hyperphosphataemia in patients on haemodialysis or peritoneal dialysis

- **BY MOUTH**
  - Adult: Initially 2.4–4.8 g daily in 3 divided doses, dose to be given with meals and adjusted according to serum-phosphate concentration; usual dose 2.4–12 g daily in 3 divided doses

RENELA® 800MG TABLETS

Hyperphosphataemia in patients on haemodialysis or peritoneal dialysis | Hyperphosphataemia in patients with chronic kidney disease not on dialysis who have a serum-phosphate concentration of 1.78 mmol/litre or more

- **BY MOUTH**
  - Adult: Initially 2.4–4.8 g daily in 3 divided doses, dose to be taken with meals and adjusted according to serum-phosphate concentration every 2–4 weeks; usual dose 6 g daily in 3 divided doses

RENELA® 2.4G ORAL POWDER SACHETS

Hyperphosphataemia in patients on haemodialysis or peritoneal dialysis | Hyperphosphataemia in patients with chronic kidney disease not on dialysis who have a serum-phosphate concentration of 1.78 mmol/litre or more

- **BY MOUTH**
  - Adult: Initially 2.4–4.8 g daily in 3 divided doses, dose to be taken with meals and adjusted according to serum-phosphate concentration every 2–4 weeks; usual dose 6 g daily in 3 divided doses

**CONTRA-INDICATIONS**

Bowel obstruction

**CAUTIONS**

Gastro-intestinal disorders

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain | constipation | diarrhoea | dyspepsia | flatulence | nausea | vomiting

- **Frequency not known** Ileus | intestinal obstruction (higher incidence with sevelamer hydrochloride salt) | intestinal perforation | pruritus | rash

RENAGEL® Diverticulitis

**PREGNANCY**

Manufacturer advises use only if potential benefit outweighs risk.

**BREAST FEEDING**

RENELA® 2.4G ORAL POWDER SACHETS

Unlikely to be present in milk (however, manufacturer advises avoid).
### 1.5 Potassium imbalance

#### 1.5a Hyperkalaemia

**Other drugs used for Hyperkalaemia** Calcium gluconate, p. 959 · Insulin, p. 673

#### ANTIDOTES AND CHELATORS > CATION EXCHANGE RESINS

**Calcium polystyrene sulfonate**

- **INDICATIONS AND DOSE**
  - Hyperkalaemia associated with anuria or severe oliguria, and in dialysis patients
    - **BY MOUTH**
      - Adult: 15 g 3–4 times a day
    - **BY RECTUM**
      - Adult: 30 g, retained for 9 hours followed by irrigation to remove resin from colon

- **SORBISTERIT® POWDER**
  - Hyperkalaemia associated with anuria or severe oliguria, and in dialysis patients
    - **BY MOUTH**
      - Adult: 20 g 1–3 times a day
    - **BY RECTUM**
      - Adult: 40 g 1–3 times a day, retained for 6 hours followed by irrigation to remove resin from colon

- **CONTRA-INDICATIONS**
  - Hyperparathyroidism · metastatic carcinoma · multiple myeloma · obstructive bowel disease · sarcoidosis

- **INTERACTIONS** → Appendix 1: polystyrine sulfonate

- **SIDE-EFFECTS**
  - **GENERAL SIDE-EFFECTS**
    - Anorexia · constipation (discontinue treatment—avoid magnesium-containing laxatives) · diarrhea · gastric irritation · gastro-intestinal obstruction · hypercalcaemia (including in dialysed patients and occasionally in those with renal impairment) · hypomagnesaemia · intestinal necrosis (reported with concomitant sorbitol) · ischaemic colitis · nausea · necrosis · ulceration · vomiting
  - **SPECIFIC SIDE-EFFECTS**
    - With oral use: Gastro-intestinal concretions
    - With rectal use: Faecal impaction

- **PREGNANCY**
  - Manufacturers advise use only if potential benefit outweighs risk—no information available.

- **BREAST FEEDING**
  - Manufacturers advise use only if potential benefit outweighs risk—no information available.

- **MONITORING REQUIREMENTS**
  - Monitor for electrolyte disturbances (stop if plasma-potassium concentration below 5 mmol/litre). A wide range of patients, including dialysis patients, benefit from treatment with calcium polystyrene sulfonate.

## 1.4b Hypophosphataemia

**ELECTROLYTES AND MINERALS > PHOSPHATES**

### Phosphate

- **INDICATIONS AND DOSE**
  - Treatment of moderate to severe hypophosphataemia
    - **BY INTRAVENOUS INFUSION**
      - Adult: consult product literature
  - For established hypophosphataemia (with monobasic potassium phosphate)
    - **BY INTRAVENOUS INFUSION**
      - Adult: 9 mmol every 12 hours, increased if necessary up to 0.5 mmol/kg (max. per dose 50 mmol), dose only increased in critically ill patients; dose in critically ill patients is approximately equivalent to 30 mmol in adults, dose to be infused over 6–12 hours, according to severity

- **SIDE-EFFETS**
  - Common or very common
    - Diarrhoea
    - Frequency not known
      - Acute renal failure · hypocalcaemia · hypotension · metastatic calcification · nausea · oedema · phlebitis · tissue necrosis on extravasation
  - **SIDE-EFFETS, FURTHER INFORMATION**
    - Diarrhoea is a common side-effect and should prompt a reduction in dosage.

- **RENAI IMPAIRMENT**
  - Reduce dose. Monitor closely in renal impairment.

- **MONITORING REQUIREMENTS**
  - It is essential to monitor closely plasma concentrations of calcium, phosphate, potassium, and other electrolytes—excessive doses of phosphates may cause hypocalcaemia and metastatic calcification.

- **PRESCRIBING AND DISPENSING INFORMATION**
  - **Phosphate Sandoz®** contains sodium dihydrogen phosphate anhydrous (anhydrous sodium acid phosphate) 1.936 g, sodium bicarbonate 350 mg, potassium bicarbonate 315 mg, equivalent to phosphorus 500 mg (phosphate 16.1 mmol), sodium 468.8 mg (Na+ 20.4 mmol), potassium 123 mg (K+ 3.1 mmol); **Polyfusor NA®** contains Na+ 162 mmol/litre, K+ 19 mmol/litre, PO4 3— 100 mmol/litre; non-proprietary potassium dihydrogen phosphate injection (potassium acid phosphate) 13.6% may contain 1 mmol/mL phosphate, 1 mmol/mL potassium.

- **MEDICINA FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
    - **Effervescent tablet**
      - COMMONFULLY AND ADVISORY LABELS 13
        - **Phosphate Sandoz® (HK Pharma Ltd)**
          - Sodium dihydrogen phosphate anhydrous 1.936 gram
        - **Phosphate Sandoz effervescent tablets** 100 tablet (£16.43
    - **Solution for infusion**
      - **Phosphate (Non-proprietary)**
        - Potassium dihydrogen phosphate 136 mg per 1 ml (potassium dihydrogen phosphate 13.6% (potassium 10mmol/10ml) solution for infusion 10ml ampoules | 10 ampoule (£80.25–£85.00 DT price = £84.63

- **Infusion**
  - **Phosphate (Non-proprietary)**
    - Potassium dihydrogen phosphate 1.295 gram per 1 litre
    - **Diasodium hydrogen phosphate anhydrous 5.75 gram per 1 litre**
      - Polyfusor NA phosphates infusion 500mL bottles | 1 bottle (£5.15

**Downloaded from www.medicalbr.com**
Blood and nutrition

1.5b Hypokalaemia

**ELECTROLYTES AND MINERALS  >  POTASSIUM**

**Potassium bicarbonate with potassium acid tartrate**

- **INDICATIONS AND DOSE**
  - Hyperchloraemic acidosis associated with potassium deficiency (as in some renal tubular and gastrointestinal disorders)
    - **BY MOUTH**
    - Adult: consult product literature
  - **CONTRA-INDICATIONS**
    - Hypochloraemia · plasma-potassium concentration above 5 mmol/litre
  - **CAUTIONS**
    - Cardiac disease · elderly
  - **SIDE-EFFECTS**
    - Abdominal pain · diarrhoea · flatulence · nausea · vomiting
  - **RENAI IMPAIRMENT**
    - Avoid in severe impairment. Close monitoring required in renal impairment—high risk of hypokalaemia.
  - **DIRECTIONS FOR ADMINISTRATION**
    - To be dissolved in water before administration.
  - **PRESCRIBING AND DISPENSING INFORMATION**
    - These tablets do not contain chloride.

**Potassium chloride**

- **INDICATIONS AND DOSE**
  - Prevention of hypokalaemia (patients with normal diet)
    - **BY MOUTH**
    - Adult: 2–4 g daily in divided doses
  - **Electrolyte imbalance**
    - **BY INTRAVENOUS INFUSION**
    - Adult: Dose dependent on deficit or the daily maintenance requirements

**IMPORTANT SAFETY INFORMATION**

**SAFE PRACTICE**

Potassium overdose can be fatal. Ready-mixed infusion solutions containing potassium should be used. Exceptionally, if potassium chloride concentrate is used for preparing an infusion, the infusion solution should be thoroughly mixed. Local policies on avoiding inadvertent use of potassium chloride concentrate should be followed.

- **CONTRA-INDICATIONS**
  - Plasma-potassium concentration above 5 mmol/litre
- **CAUTIONS**
  - With intravenous use seek specialist advice in very severe potassium depletion or difficult cases
  - With oral use Cardiac disease · elderly · hiatus hernia (with modified-release preparations) · history of peptic ulcer (with modified-release preparations) · intestinal stricture (with modified-release preparations)

---

**Sodium polystyrene sulfonate**

- **INDICATIONS AND DOSE**
  - Hyperkalaemia associated with anuria or severe oliguria, and in dialysis patients
    - **BY MOUTH**
    - Adult: 15 g 3–4 times a day
    - **BY RECTUM**
    - Adult: 30 g, retain for 9 hours followed by irrigation to remove resin from colon

- **CONTRA-INDICATIONS**
  - Obstructive bowel disease
- **CAUTIONS**
  - Congestive heart failure · hypertension · oedema
- **INTERACTIONS**
  - Appendix 1: polystyrene sulfonate
- **SIDE-EFFECTS**
  - **GENERAL SIDE-EFFECTS**
    - Anorexia · constipation (discontinue treatment—avoid magnesium-containing laxatives) · diarrhoea · gastric irritation · gastro-intestinal obstruction · hypocalcaemia · hypomagnesaemia · intestinal necrosis (reported with concomitant use of sorbitol) · ischaemic colitis · nausea · necrosis · sodium retention · ulceration · vomiting
  - **SPECIFIC SIDE-EFFECTS**
    - With oral use · Gastro-intestinal concretions
    - With rectal use · Faecal impaction
- **PREGNANCY**
  - Manufacturers advise use only if potential benefit outweighs risk—no information available.
- **BREAST FEEDING**
  - Manufacturers advise use only if potential benefit outweighs risk—no information available.
- **RENAI IMPAIRMENT**
  - Use with caution.
- **MONITORING REQUIREMENTS**
  - Monitor for electrolyte disturbances (stop if plasma-potassium concentration below 5 mmol/litre).
- **DIRECTIONS FOR ADMINISTRATION**
  - With rectal use · Mix each 30 g of resin with 150 mL of water or 10% glucose.
  - With oral use · Administer dose (powder) in a small amount of water or honey—do not give with fruit juice or squash, which have a high potassium content.
- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension
    - **Powder**
    - CAUTIONARY AND ADVISORY LABELS 13
    - Resonium A (Sanofi)
      - Sodium polystyrene sulfonate 999.34 mg per 1 gram Resonium A powder sugar-free 454 gram £81.11

**MONITORING REQUIREMENTS**

- May contain Sucrose
- **Calcium Resonium** (Sanofi)
  - Calcium polystyrene sulfonate 999.34 mg per 1 gram
  - Calcium Resonium powder sugar-free 300 gram £82.16

---

**INTERACTIONS**

- **PREGNANCY**
  - Manufacturers advise use only if potential benefit outweighs risk—no information available.

**BLOOD AND NUTRITION**

**BR EAST FEEDING**

- **PREGNANCY**
  - Manufacturers advise use only if potential benefit outweighs risk—no information available.

**INDICATIONS AND DOSE**

- Hyperkalaemia · plasma-potassium concentration above 5 mmol/litre

**PRESCRIBING AND DISPENSING INFORMATION**

- These tablets do not contain chloride.

---

**SIDE-EFFECTS**

- Abdominal pain · diarrhoea · flatulence · nausea · vomiting
- **RENAI IMPAIRMENT**
  - Avoid in severe impairment. Close monitoring required in renal impairment—high risk of hypokalaemia.
- **DIRECTIONS FOR ADMINISTRATION**
  - To be dissolved in water before administration.

**SIGNIFICANT SIDE-EFFECTS**

- Hypomagnesaemia · loss of appetite · nausea · vomiting · weight loss · water retention · weight gain · hypocalcaemia · muscle cramps · muscle weakness

---

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension
  - **Powder**
  - CAUTIONARY AND ADVISORY LABELS 13
  - Resonium A (Sanofi)
    - Sodium polystyrene sulfonate 999.34 mg per 1 gram Resonium A powder sugar-free 454 gram £81.11

---

**CONTRA-INDICATIONS**

- Hypochloraemia · plasma-potassium concentration above 5 mmol/litre
INTERACTIONS  
Appendix 1: potassium chloride

SIDE-EFFECTS

- Common or very common
  - With oral use: Abdominal pain, diarrhoea, flatulence, nausea, vomiting
  - With intravenous use: Heart toxicity (with rapid infusion)
  - Frequency not known
    - With oral use: Bleeding (with modified-release preparations), gastrointestinal obstruction (with modified-release preparations), ulceration (with modified-release preparations)

RENAL IMPAIRMENT  
Smaller doses may be used in patients with renal impairment to reduce the risk of hyperkalaemia. Avoid in severe impairment. Close monitoring required in renal impairment—high risk of hyperkalaemia.

MONITORING REQUIREMENTS

- Regular monitoring of plasma-potassium concentration is essential in those taking potassium supplements.
- With intravenous use: ECG monitoring should be performed in difficult cases.

DIRECTIONS FOR ADMINISTRATION

- With oral use: Potassium salts are preferably given as a liquid (or effervescent) preparation, rather than modified-release tablets; they should be given as the chloride (the use of effervescent potassium tablets BPC 1968 should be restricted to hyperchloracemic states).
- With intravenous use: Potassium chloride concentrate must be diluted with not less than 50 times its volume of sodium chloride intravenous infusion 0.9% or other suitable diluent and mixed well.
  
  Ready-mixed infusion solutions should be used where possible; alternatively, potassium chloride concentrate as ampoules containing 1.5 g (K² 20 mmol) in 10 ml, is thoroughly mixed with 500 ml of sodium chloride 0.9% intravenous infusion and given slowly over 2 to 3 hours with specialist advice and ECG monitoring in difficult cases. For peripheral intravenous infusion, the concentration of potassium should not usually exceed 40 mmol/L. Higher concentrations of potassium chloride may be given in very severe depletion, but require specialist advice.

PRESCRIBING AND DISPENSING INFORMATION

Kay-Cee-L® contains 1 mmol/mL each of K⁺ and Cl⁻. Potassium Tablets Do not confuse Effervescent Potassium Tablets BPC 1968 with effervescent potassium chloride tablets. Effervescent Potassium Tablets BPC 1968 do not contain chloride ions and their use should be restricted to hyperchloracemic states.

PATIENT AND CARER ADVICE

- Patient or carers should be given advice on how to administer potassium chloride modified-release tablets.
- Salt substitutes: A number of salt substitutes which contain significant amounts of potassium chloride are readily available as health food products (e.g. LoSalt® and Ruthmol®). These should not be used by patients with renal failure as potassium intoxication may result.

LESS SUITABLE FOR PRESCRIBING

Modified-release tablets are less suitable for prescribing. Modified-release preparations should be avoided unless effervescent tablets or liquid preparations inappropriate.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: modified-release tablet, oral solution, solution for injection, infusion, solution for infusion

Solution for infusion

- Potassium chloride (Non-proprietary)
  - Potassium chloride 150 mg per 1 ml (potassium 20 mmol/10 ml) solution for infusion 10 ml ampoules 10 ampoules £6.50 / 20 ampoules £6.50
  - Potassium chloride 15% (potassium 20 mmol/10 ml) solution for infusion 10 ml Mini-Plasco ampoules 20 ampoule £10.70
  - Potassium chloride 200 mg per 1 ml (potassium 20% (potassium 13.3 mmol/5 ml) solution for infusion 5 ml ampoules 10 ampoule £3.84–£4.00
  - Potassium chloride 20% (potassium 27 mmol/10 ml) solution for infusion 10 ml ampoules 10 ampoule £121.25

Oral solution

CAUTIONARY AND ADVISORY LABELS 21

Kay-Cee-L® (Geistlich Sons Ltd)

Potassium chloride 75 mg per 1 ml Kay-Cee-L syrup sugar-free 500 ml £7.95

2  Metabolic disorders

2.1 Acute porphyrias

Acute porphyrias

Overview

The acute porphyrias (acute intermitent porphyria, variegate porphyria, hereditary coproporphyria, and 5-aminolaevulinic acid dehydratase deficiency porphyria) are hereditary disorders of haem biosynthesis; they have a prevalence of about 1 in 10 000 of the population.

Great care must be taken when prescribing for patients with acute porphyria, since certain drugs can induce acute porphoric crises. Since acute porphyrias are hereditary, relatives of affected individuals should be screened and advised about the potential danger of certain drugs.

Treatment of serious or life-threatening conditions should not be withheld from patients with acute porphyria. When there is no safe alternative, treatment should be started and urinary porphobiligenin excretion should be measured regularly; if it increases or symptoms occur, the drug can be withdrawn and the acute attack treated. If an acute attack of porphyria occurs during pregnancy, contact an expert porphyria service for further advice.

Haem arginate p. 971 is administered by short intravenous infusion as haem replacement in moderate, severe, or unremitting acute porphyria crises.

In the United Kingdom the National Acute Porphyrja Service (NAPS) provides clinical support and treatment with haem arginate from three centres (University Hospital of Wales, Addenbrooke’s Hospital, and King’s College Hospital). To access the service telephone (029) 2074 7747 and ask for the Acute Porphyrja Service.

Drugs unsafe for use in acute porphyrias

The following list contains drugs on the UK market that have been classified as ‘unsafe’ in porphyria because they have been shown to be porphyrinogenic in animals or in vivo, or have been associated with acute attacks in patients. Absence of a drug from the following lists does not necessarily imply that the drug is safe. For many drugs no information about porphyria is available.

An up-to-date list of drugs considered safe in acute porphyrias is available at www.wmic.wales.nhs.uk/specialist-services/drugs-in-porphyria/. Further information may be obtained from: www.porphyria-europe.org and also from:
Quite modest changes in chemical structure can lead to changes in porphyrinogenicity but where possible general statements have been made about groups of drugs; these should be checked first.

**Unsafe Drug Groups (check first)**

- Alkylating drugs (contact Welsh Medicines Information Centre for further advice)
- Anabolic steroids
- Antidepressants (includes tricyclic (and related) antidepressants and MAOIs; fluoxetine, duloxetine, venlafaxine, and trazodone thought to be safe)
- Antihistamines (alimemazine, chlorphenamine, desloratadine, fexofenadine, ketotifen, loratadine, and promethazine thought to be safe)
- Barbiturates (includes primidone and thiopental)
- Calcium channel blockers (amlodipine, felodipine, and nifedipine thought to be safe)
- Contraceptives, hormonal (progestogens are more porphyrinogenic than oestrogens; oestrogens may be safe at least in replacement doses. Progestogens should be avoided whenever possible by all women susceptible to acute porphyria; however, when non-hormonal contraception is inappropriate, progestogens may be used with extreme caution if the potential benefit outweighs risk. The risk of an acute attack is greatest in women who have had a previous attack or are aged under 30 years. Long-acting progestogen preparations should never be used in those at risk of acute porphyria.)
- Ergot derivatives (includes ergometrine (oxytocin probably safe) and pergolide)
- Hormone replacement therapy (progestogens are more porphyrinogenic than oestrogens; oestrogens may be safe at least in replacement doses. Progestogens should be avoided whenever possible by all women susceptible to acute porphyria; however, when non-hormonal contraception is inappropriate, progestogens may be used with extreme caution if the potential benefit outweighs risk. The risk of an acute attack is greatest in women who have had a previous attack or are aged under 30 years. Long-acting progestogen preparations should never be used in those at risk of acute porphyria.)
- Imidazole antifungals (applies to oral and intravenous use; topical antifungals are thought to be safe due to low systemic exposure)
- Non-nucleoside reverse transcriptase inhibitors (contact Welsh Medicines Information Centre for further advice)
- Progestogens (progestogens are more porphyrinogenic than oestrogens; oestrogens may be safe at least in replacement doses. Progestogens should be avoided whenever possible by all women susceptible to acute porphyria; however, when non-hormonal contraception is inappropriate, progestogens may be used with extreme caution if the potential benefit outweighs risk. The risk of an acute attack is greatest in women who have had a previous attack or are aged under 30 years. Long-acting progestogen preparations should never be used in those at risk of acute porphyria.)
- Triazole antifungals (applies to oral and intravenous use; topical antifungals are thought to be safe due to low systemic exposure)

**Unsafe Drugs (check groups above first)**

- Acriflavine
- Alcohol
- Amiodarone
- Aprepitant (contact Welsh Medicines Information Centre for further advice)
- Artemether with lumefantrine
- Bexarotene
- Bosentan
- Bromocriptine
- Buspirone
- Cabergoline
- Carbamazepine
- Chloral hydrate (although evidence of hazard is uncertain, manufacturer advises avoid)
- Chloramphenicol
- Chloroform (small amounts in medicines probably safe)
- Clindamycin
- Cocaine
- Colistimethate sodium
- Danazol
- Dapsone
- Dexfenfluramine
- Disopyramide
- Disulfiram
- Erythromycin
- Etamsylate
- Ethosuximide
- Etonidazole
- Fenfluramine
- Flupentixol
- Flutamide
- Fosaprepitant (contact Welsh Medicines Information Centre for further advice)
- Fosphenytoin
- Griseofulvin
- Hydralazine
- Indapamide
- Isometheptene mucate
- Isoniazid (safety uncertain, contact Welsh Medicines Information Centre for further advice)
- Ketamine
- Mefenamic acid (may be used with caution if safer alternative not available)
- Meprobamate
- Methyldopa
- Metolazone
- Metyrapone
- Mifepristone
- Minoxidil (may be used with caution if safer alternative not available)
- Mitotane
- Mitotane
- Metyrapone
- Nalidixic acid
- Nitrazepam
- Nitrofurantoin
- Orphenadrine
- Oxicarbazepine
- Oxycodone
- Pentazocine (buprenorphine, codeine, diamorphine, dihydrocodeine, fentanyl, methadone, morphine, oxycodeone, pethidine, and tramadol are thought to be safe)
- Pentoxyfilline
- Phenoxybenzamine
- Phenytoin
- Pimecrolimus
- Porfimer
- Raloxifene
- Triazolinediones (contact Welsh Medicines Information Centre for further advice)
Carnitine deficiency

2.2 Carnitine deficiency

AMINO ACIDS AND DERIVATIVES

Levocarnitine
(Carnitine)

- **INDICATIONS AND DOSE**
  - Primary carnitine deficiency due to inborn errors of metabolism
    - BY MOUTH
      - Adult: Up to 200 mg/kg daily in 2–4 divided doses; maximum 3 g per day
    - BY SLOW INTRAVENOUS INJECTION
      - Adult: Up to 100 mg/kg daily in 2–4 divided doses, to be administered over 2–3 minutes
  - Secondary carnitine deficiency in haemodialysis patients
    - INITIALLY BY SLOW INTRAVENOUS INJECTION
      - Adult: 20 mg/kg, to be administered over 2–3 minutes, after each dialysis session, dosage adjusted according to plasma-carnitine concentration, then (by mouth) maintenance 1 g daily, administered if benefit is gained from first intravenous course

- **CAUTIONS**
  - Diabetes mellitus
  - **SIDE-EFFECTS** Abdominal pain, body odour, diarrhoea, nausea, vomiting

SIDE-EFFECTS, FURTHER INFORMATION
Side-effects may be dose-related—monitor tolerance during first week and after any dose increase.

- **PREGNANCY** Appropriate to use; no evidence of teratogenicity in animal studies.
- **RENAL IMPAIRMENT** Accumulation of metabolites may occur with chronic oral administration in severe impairment.
- **MONITORING REQUIREMENTS**
  - Monitoring of free and acyl carnitine in blood and urine recommended.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include:
    - **Solution for injection**
    - Carnitor (Logixx Pharma Solutions Ltd)
    - L-Carnitine 200 mg per 1 ml Carnitor 1g/5ml solution for injection ampoules | 5 ampoule (PO) £59.50
    - **Oral solution**
      - Levocarnitine (Non-proprietary)
      - L-Carnitine 300 mg per 1 ml Levocarnitine 1.5g/5ml (30%) oral solution paediatric | 20 ml (PO) £71.40 DT price = £71.40
      - Carnitor (Logixx Pharma Solutions Ltd)
    - L-Carnitine 100 mg per 1 ml Carnitor oral single dose 1g solution sugar-free | 10 unit dose (PO) £35.00

Chewable tablet
- Carnitor (Logixx Pharma Solutions Ltd)
  - L-Carnitine 1 gram Carnitor 1g chewable tablets | 10 tablet (PO) £35.00

Capsule
- Levocarnitine (Non-proprietary)
  - L-Carnitine 250 mg Bio-Carnitine 250mg capsules | 125 capsule (PO) £11.06
  - L-Carnitine 500 mg Lamberts L-Carnitine 500mg capsules | 60 capsule (PO) £11.14
2.3 Fabry’s disease

**ENZYMES**

**Agalsidase alfa**

- **DRUG ACTION** Agalsidase alfa, an enzyme produced by recombinant DNA technology are licensed for long-term enzyme replacement therapy in Fabry’s disease (a lysosomal storage disorder caused by deficiency of alpha-galactosidase A).

- **INDICATIONS AND DOSE**

  **Fabry’s disease (specialist use only)**
  - By intravenous infusion
  - Adult: 200 micrograms/kg every 2 weeks

- **INTERACTIONS** → Appendix 1: agalsidase

- **SIDE-EFFECTS**

  **Common or very common** Acne · angioedema · arthralgia · asthenia · bradycardia · chest pain · cough · dizziness · dyspnoea · eye irritation · fatigue · flushing · gastrointestinal disturbances · headache · hypersensitivity reactions · hypertension · hypotension · influenza · like symptoms · muscle spasms · myalgia · nasopharyngitis · neuropathic pain · oedema · palpitation · paraesthesia · pruritus · rash · rhinorrhea · sleep disturbances · syncope · tachycardia · taste disturbances · tinnitus · tremor · urticaria

  **Uncommon** Cold extremities · ear pain · ear swelling · injection-site reactions · parosmia · skin discoloration

- **SIDE-EFFECTS, FURTHER INFORMATION**

  Infusion-related reactions Infusion-related reactions very common; manage by slowing the infusion rate or interrupting the infusion, or minimise by pre-treatment with an antihistamine, antipyretic, or corticosteroid—consult product literature.

- **PREGNANCY** Use with caution.

- **BREAST FEEDING** Use with caution—no information available.

- **DIRECTIONS FOR ADMINISTRATION** Administration for intravenous infusion, given intermittently in sodium chloride 0.9%; dilute requisite dose with 100 mL infusion fluid and give over 40 minutes using an in-line filter; use within 3 hours of dilution.

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug.

  **Solution for infusion**

  - Replagal (Shire Pharmaceuticals Ltd)
    - Agalsidase alfa 1 mg per 1 mL Replagal 3.5mg/3.5ml solution for infusion vials | 1 vial £1,068.64

- **Agalsidase beta**

  - **DRUG ACTION** Agalsidase beta, an enzyme produced by recombinant DNA technology are licensed for long-term enzyme replacement therapy in Fabry’s disease (a lysosomal storage disorder caused by deficiency of alpha-galactosidase A).

  - **INDICATIONS AND DOSE**

    **Fabry’s disease (specialist use only)**
    - By intravenous infusion
    - Adult: 1 mg/kg every 2 weeks

  - **INTERACTIONS** → Appendix 1: agalsidase

  - **SIDE-EFFECTS**

    **Common or very common** Acne · angioedema · arthralgia · asthenia · bradycardia · chest pain · cough · dizziness · dyspnoea · eye irritation · fatigue · flushing · gastrointestinal disturbances · headache · hypersensitivity reactions · hypertension · hypotension · influenza · like symptoms · muscle spasms · myalgia · nasopharyngitis · neuropathic pain · oedema · palpitation · paraesthesia · pruritus · rash · rhinorrhea · sleep disturbances · syncope · tachycardia · taste disturbances · tinnitus · tremor · urticaria

- **SIDE-EFFECTS, FURTHER INFORMATION**

  Infusion-related reactions Infusion-related reactions very common; manage by slowing the infusion rate or interrupting the infusion, or minimise by pre-treatment with an antihistamine, antipyretic, or corticosteroid—consult product literature.

- **PREGNANCY** Use with caution.

- **BREAST FEEDING** Use with caution—no information available.

- **DIRECTIONS FOR ADMINISTRATION** Administration for intravenous infusion, given intermittently in sodium chloride 0.9%; dilute requisite dose with 100 mL infusion fluid and give over 40 minutes using an in-line filter; use within 3 hours of dilution.

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug.

  **Powder for solution for infusion**

  - Fabrazyme (Genzyme Therapeutics Ltd)
    - Agalsidase beta 5 mg Fabrazyme 5mg powder for solution for infusion vials | 1 vial £315.08
    - Agalsidase beta 35 mg Fabrazyme 35mg powder for solution for infusion vials | 1 vial £2,196.59

2.4 Gaucher’s disease

**Other drugs used for Gaucher’s disease** Miglustat, p. 976

**ENZYMES**

**Imiglucerase**

- **DRUG ACTION** Imiglucerase is an enzyme produced by recombinant DNA technology that is administered as enzyme replacement therapy for non-neurological manifestations of type I or type III Gaucher’s disease, a familial disorder affecting principally the liver, spleen, bone marrow, and lymph nodes.

- **INDICATIONS AND DOSE**

  Non-neurological manifestations of type I Gaucher’s disease (specialist use only) · Non-neurological manifestations of type III Gaucher’s disease (specialist use only)

  - By intravenous infusion
  - Adult: Initially 60 units/kg every 2 weeks; maintenance, adjusted according to response, doses as low as 15 units/kg once every 2 weeks may improve haematological parameters and organomegaly

downloaded from www.medicalbr.com
SIDE-EFFECTS
- Common or very common: Angioedema, backache, cyanosis, flushing, hypersensitivity reactions, hypotension, paraesthesia, tachycardia, urticaria
- Uncommon: Abdominal cramps, arthralgia, diarrhoea, dizziness, fatigue, fever, headache, injection-site reactions, nausea, vomiting
- PREGNANCY: Manufacturer advises use with caution—limited information available.
- BREAST FEEDING: No information available.
- MONITORING REQUIREMENTS: Monitor for immunoglobulin G (IgG) antibodies to imiglucerase.
- When stabilised, monitor all parameters and response to treatment at intervals of 6–12 months.

DIRECTIONS FOR ADMINISTRATION
- For intravenous infusion (Cerezyme®), give intermittently in sodium chloride 0.9%; initially reconstitute with water for injections (200 units in 5.1 mL, 400 units in 10.2 mL) to give 40 units/mL solution; dilute requisite dose with infusion fluid to a final volume of 100–200 mL and give initial dose at a rate not exceeding 0.5 units/kg/minute, subsequent doses to be given at a rate not exceeding 1 unit/kg/minute; administer within 3 hours after reconstitution.

MEDICINAL FORMS
- There can be variation in the licensing of different medicines containing the same drug.
- Powder for solution for infusion
  - ELECTROLYTES: May contain sodium
  - Cerezyme (Genzyme Therapeutics Ltd)
    - Imiglucerase 400 unit Cerezyme 400 unit powder for solution for infusion vials | 1 vial (PO) £1,071.29

Velaglucerase alfa
- DRUG ACTION: Velaglucerase alfa is an enzyme produced by recombinant DNA technology that is administered as enzyme replacement therapy for the treatment of type 1 Gaucher’s disease.

INDICATIONS AND DOSE
- Type 1 Gaucher’s disease (specialist use only)
  - BY INTRAVENOUS INFUSION
    - Adult: Initially 60 units/kg every 2 weeks; adjusted according to response to 15–60 units/kg every 2 weeks

SIDE-EFFECTS
- Abdominal pain, arthralgia, back pain, bone pain, dizziness, flushing, headache, hypersensitivity reactions, hypertension, hypotension, malaise, nausea, pyrexia, rash, tachycardia, urticaria
- SIDE-EFFECTS, FURTHER INFORMATION
  - Infusion-related reactions
    - Infusion-related reactions very common; manage by slowing the infusion rate, or interrupting the infusion, or minimise by pre-treatment with an antihistamine, antipyretic, or corticosteroid—consult product literature.
- PREGNANCY: Manufacturer advises use with caution—limited information available.
- BREAST FEEDING: Manufacturer advises use with caution—no information available.
- MONITORING REQUIREMENTS: Monitor immunoglobulin G (IgG) antibody concentration in severe infusion-related reactions or if there is a lack of loss of effect with velaglucerase alfa.
- DIRECTIONS FOR ADMINISTRATION
  - For intravenous infusion (VPRIV®), give intermittently in sodium chloride 0.9%; reconstitute each 400-unit vial with 4.3 mL water for injections to produce a 100 units/mL solution; dilute requisite dose in 100 mL infusion fluid; give over 60 minutes through a 0.22 micron filter; start infusion within 24 hours of reconstitution.

MEDICINAL FORMS
- There can be variation in the licensing of different medicines containing the same drug.
- Powder for solution for infusion
  - ELECTROLYTES: May contain sodium
  - VPRIV (Shire Pharmaceuticals Ltd)
    - Velaglucerase alfa 400 unit VPRIV 400 units powder for solution for infusion vials | 1 vial (PO) £1,410.20

2.5 Homocystinuria

METHYL DONORS

Betaine
- INDICATIONS AND DOSE
  - Adjunctive treatment of homocystinuria involving deficiencies or defects in cystathionine beta-synthase, 5,10-methylene-tetrahydrofolate reductase, or cobalamin cofactor metabolism (specialist use only)
    - BY MOUTH
      - Adult: 3 g twice daily (max. per dose 10 g), adjusted according to response; maximum 20 g per day

SIDE-EFFECTS
- Uncommon: Agitation, alopecia, anorexia, depression, gastro-intestinal disorders, personality disorder, reversible cerebral oedema, sleep disturbances, urinary incontinence, urticaria
- PREGNANCY: Manufacturer advises avoid unless essential—limited information available.
- BREAST FEEDING: Manufacturer advises caution—no information available.
- MONITORING REQUIREMENTS: Monitor plasma-methionine concentration before and during treatment—interrupt treatment if symptoms of cerebral oedema occur.
- DIRECTIONS FOR ADMINISTRATION: Powder should be mixed with water, juice, milk, formula, or food until completely dissolved and taken immediately; measuring spoons are provided to measure 1 g, 150 mg, and 100 mg of Cystadane® powder.
- PRESCRIBING AND DISPENSING INFORMATION: Betaine should be used in conjunction with dietary restrictions and may be given with supplements of vitamin B₁₂, pyridoxine, and folate under specialist advice.

NATIONAL FUNDING/ACCESS DECISIONS

Scottish Medicines Consortium (SMC) Decisions
- The Scottish Medicines Consortium has advised (July 2010) that betaine anhydrous (Cystadane®) is accepted for restricted use within NHS Scotland for the adjunctive treatment of homocystinuria involving deficiencies or defects in cystathionine beta-synthase, 5,10-methylene-tetrahydrofolate reductase, or cobalamin cofactor metabolism in patients who are not responsive to pyridoxine treatment.

MEDICINAL FORMS
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, oral solution
- Powder
  - Cystadane (Orphan Europe (UK) Ltd)
    - Betaine 1 gram per 1 gram Cystadane oral powder | 180 gram (PO) £347.00

Downloaded from www.medicalbr.com
2.6 Mucopolysaccharidosis

ENZYMES

Elosulfase alfa

- **DRUG ACTION** Elosulfase alfa is an enzyme produced by recombinant DNA technology that provides replacement therapy in conditions caused by N-acetylgalactosamine-6-sulfatase (GALNS) deficiency.

- **INDICATIONS AND DOSE**
  - Mucopolysaccharidosis IVA (specialist use only)
    - **BY INTRAVENOUS INFUSION**
    - Adult: 2 mg/kg once weekly

- **CAUTIONS** Elderly—no information available · infusion-related reactions

- **SIDE-EFFECTS**
  - **Common or very common** Abdominal pain · chills · diarrhoea · dizziness · dyspnoea · headache · hypersensitivity · infusion-related reactions · myalgia · nausea · ophthalmological pain · pyrexia · vomiting
  - **Uncommon** Anaphylaxis
  - **PREGNANCY** Manufacturer advises avoid unless essential—limited information available.
  - **BREAST FEEDING** Manufacturer advises avoid—no information available.

- **DIRECTIONS FOR ADMINISTRATION**
  - For intravenous infusion (Vimizim®), give intermittently in Sodium chloride 0.9%; body-weight under 25 kg, dilute requisite dose to final volume of 100 mL infusion fluid and mix gently, give over 4 hours through in-line filter (0.2 micron) initially at a rate of 3 mL/hour, then increase to a rate of 6 mL/hour after 15 minutes, then increase gradually if tolerated every 15 minutes by 6 mL/hour to 36 mL/hour; body-weight 25 kg or over, dilute requisite dose to final volume of 250 mL and mix gently, give over 4 hours through in-line filter (0.2 micron) initially at a rate of 6 mL/hour, then increase to a rate of 12 mL/printed after 15 minutes, then increase gradually if tolerated every 15 minutes by 12 mL/hour to max. 72 mL/hour.

- **HANDLING AND STORAGE** Manufacturer advises store in a refrigerator at 2–8°C. After dilution use immediately or, if necessary, store at 2–8°C for max. 24 hours, followed by up to 24 hours at 23–27°C.

- **PATIENT AND CARER ADVICE**
  - Driving and skilled tasks
  - Manufacturer advises patients and carers should be counselled about the effects on driving and performance of skilled tasks—increased risk of dizziness.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  - **Solution for infusion**
    - **Vimizim** (BioMarin Europe Ltd) ▼
    - Elosulfase alfa 1 mg per 1 ml
    - Vimizim 5mg/5ml concentrate for solution for infusion vials | 1 vial £750.00

Galsulfase

- **INDICATIONS AND DOSE**
  - Mucopolysaccharidosis VI (specialist use only)
    - **BY INTRAVENOUS INFUSION**
    - Adult: 1 mg/kg once weekly

- **CAUTIONS** Acute febrile illness (consider delaying treatment) · acute respiratory illness (consider delaying treatment) · infusion-related reactions can occur · respiratory disease

- **SIDE-EFFECTS** Abdominal pain · apnoea · arreflexia · chest pain · conjunctivitis · corneal opacity · dyspnoea · ear pain · facial oedema · gastroenteritis · hypertension · infusion-related reactions · malaise · nasal congestion · pharyngitis · rigors · umbilical hernia

- **DIRECTIONS FOR ADMINISTRATION**
  - For intravenous infusion (Naglazyme®), give intermittently in Sodium chloride 0.9%; dilute requisite dose with infusion fluid to final volume of 250 mL and mix gently; infuse through a 0.2 micron in-line filter; give approx. 2.5% of the total volume over 1 hour, then infuse remaining volume over next 3 hours; if body-weight under 20 kg and at risk of fluid overload, dilute requisite dose in 100 mL infusion fluid and give over at least 4 hours.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  - **Solution for infusion**
    - **Naglazyme** (BioMarin Europe Ltd) ▼
    - Galsulfase 1 mg per 1 ml
    - Naglazyme 5mg/5ml solution for infusion vials | 1 vial £982.00

Idursulfase

- **DRUG ACTION** Idursulfase is an enzyme produced by recombinant DNA technology licensed for long-term replacement therapy in mucopolysaccharidosis II (Hunter syndrome), a lysosomal storage disorder caused by deficiency of iduronate-2-sulfatase.

- **INDICATIONS AND DOSE**
  - Mucopolysaccharidosis II (specialist use only)
    - **BY INTRAVENOUS INFUSION**
    - Adult: 500 micrograms/kg once weekly

- **CAUTIONS** Acute febrile respiratory illness (consider delaying treatment) · infusion-related reactions can occur · severe respiratory disease

- **SIDE-EFFECTS**
  - **Common or very common** Arrhythmia · arthralgia · bronchospasm · chest pain · cough · cyanosis · dizziness · dyspnoea · erythema · facial oedema · flushing · gastrointestinal disturbances · headache · hypertension · hypotension · hypoxia · infusion-site swelling · peripheral oedema · pruritus · pyrexia · rash · swollen tongue · tachycardia · tachypnoea · tremor · urticaria · wheezing
DIRECTIONS FOR ADMINISTRATION  
For intravenous infusion (Aldurazyme®), give intermittently in Sodium chloride 0.9%; body-weight under 20 kg, use 100 mL infusion fluid; body-weight over 20 kg use 250 mL infusion fluid; withdraw volume of infusion fluid equivalent to volume of laronidase concentrate being added; give through in-line filter (0.22 micron) initially at a rate of 2 units/kg/hour then increase gradually every 15 minutes to max. 43 units/kg/hour.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Solution for infusion
ELECTROLYTES: May contain Sodium Aldurazyme (Genzyme Therapeutics Ltd) Laronidase 100 unit per 1 ml Aldurazyme 500units/5ml solution for infusion vials | 1 vial £44.70

2.7 Nephropathic cystinosis

AMINO ACIDS AND DERIVATIVES

Mercaptamine
(Cysteamine)

INDICATIONS AND DOSE
Nephropathic cystinosis (specialist use only)

BY MOUTH
Adult (body-weight 50 kg and above): Initially one-sixth to one-quarter of the expected maintenance dose, increased gradually over 4–6 weeks to avoid intolerance, maintenance 2 g daily in 4 divided doses

DOSE EQUIVALENCES AND CONVERSION
1.3 g/m² is approximately equivalent to 50 mg/kg.

IMPORTANT SAFETY INFORMATION
SAFE PRACTICE
Mercaptamine has been confused with mercaptopurine; care must be taken to ensure the correct drug is prescribed and dispensed.

CAUTIONS
Dose of phosphate supplement may need to be adjusted if transferring from phosphocysteamine to mercaptamine

SIDE-EFFECTS
Common or very common Abdominal pain · anorexia · breath and body odour · diarrhea · dyspepsia · encephalopathy · fever · gastroenteritis · headache · malaise · nausea · rash · vomiting
Uncommon Drowsiness · gastro-intestinal ulcer · hallucinations · leucopenia · nephrotic syndrome · nervousness · seizures

ALLERGY AND CROSS-SENSITIVITY
Contra—indicated if history of hypersensitivity to penicillamine.

PREGNANCY
Avoid—teratogenic and toxic in animal studies.

BREAST FEEDING
Avoid.

MONITORING REQUIREMENTS
Leucocyte-cystine concentration and haematological monitoring required—consult product literature.

PRESCRIBING AND DISPENSING INFORMATION
Mercaptamine has a very unpleasant taste and smell, which can affect compliance.
2.8 Niemann-Pick type C disease

**ENZYME INHIBITORS**

**GLUCOSYLCERAMIDE SYNTHASE INHIBITORS**

### Miglustat

**DRUG ACTION** Miglustat is an inhibitor of glucosylceramide synthase.

**INDICATIONS AND DOSE**

Mild to moderate type I Gaucher’s disease for whom enzyme replacement therapy is unsuitable (under expert supervision)

- **By mouth**
  - Adult: 100 mg 3 times a day, reduced if not tolerated to 100 mg 1–2 times a day

*Treatment of progressive neurological manifestations of Niemann-Pick type C disease (under expert supervision)*

- **By mouth**
  - Adult: 200 mg 3 times a day

**SIDE-EFFECTS** Abdominal pain - anemia - anorexia - ataxia - chills - constipation - decreased libido - depression - diarrhoea - diziness - dyspepsia - flatulence - headache - hypoaesthesia - insomnia - malaise - muscle spasm - muscle weakness - nausea - paraesthesia - peripheral neuropathy - thrombocytopenia - tremor - vomiting - weight changes

**CONCEPTION AND CONTRACEPTION** Effective contraception must be used during treatment. Men should avoid fathering a child during and for 3 months after treatment.

**PREGNANCY** Manufacturer advises avoid—no information available.

**BREAST FEEDING** Manufacturer advises avoid—no information available.

**HEPATIC IMPAIRMENT** No information available—manufacturer advises caution.

**RENAL IMPAIRMENT** For Gaucher’s disease initially 100 mg twice daily if eGFR 50–70 mL/minute/1.73 m². Initially 100 mg once daily if eGFR 30–50 mL/minute/1.73 m². For Niemann-Pick type C disease, initially 200 mg twice daily if eGFR 50–70 mL/minute/1.73 m². Initially 100 mg twice daily if eGFR 30–50 mL/minute/1.73 m² Avoid if eGFR less than 30 mL/minute/1.73 m².

**MONITORING REQUIREMENTS**

- Monitor cognitive and neurological function.
- Monitor growth and platelet count in Niemann-Pick type C disease.

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Capsule**

- Zavesca (Actelion Pharmaceuticals UK Ltd) Miglustat 100 mg Zavesca 100mg capsules | 84 capsule £3,934.17 (Hospital only)

### 2.9 Pompe disease

**ENZYMES**

### Alglucosidase alfa

**DRUG ACTION** Alglucosidase alfa is an enzyme produced by recombinant DNA technology licensed for long-term replacement therapy in Pompe disease, a lysosomal storage disorder caused by deficiency of acid alpha-glucosidase.

**INDICATIONS AND DOSE**

**Pompe disease (specialist use only)**

- **By intravenous infusion**
  - Adult: 20 mg/kg every 2 weeks

**CAUTIONS** Cardiac dysfunction - infusion-related reactions—consult product literature - respiratory dysfunction

**SIDE-EFFECTS**


**FREQUENCY NOT KNOWN** Infusion-related reactions - necrotising skin lesions - severe skin reactions - ulcerative skin lesions

**SIDE-EFFECTS, FURTHER INFORMATION**

Infusion-related reactions - Infusion-related reactions very common, calling for use of antihistamine, antipyretic, or corticosteroid; consult product literature for details.

**PREGNANCY** Toxicity in animal studies, but treatment should not be withheld.

**BREAST FEEDING** Manufacturer advises avoid—no information available.

**MONITORING REQUIREMENTS**

- Monitor closely if cardiac dysfunction.
- Monitor closely if respiratory dysfunction.
- Monitor immunoglobulin G (IgG) antibody concentration.

**DIRECTIONS FOR ADMINISTRATION** For *intravenous infusion* (Myozyme®), give intermittent in Sodium chloride 0.9%; reconstitute 50 mg with 10.3 mL water for injections to produce 5 mg/mL solution; gently rotate vial without shaking; dilute requisite dose with infusion fluid to give a final concentration of 0.5–4 mg/mL; give through a low protein-binding in-line filter (0.2 micron) at an initial rate of 1 mg/kg/hour increased by 2 mg/kg/hour every 30 minutes to max. 7 mg/kg/hour.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for infusion**

- Myozyme (Genzyme Therapeutics Ltd) Alglucosidase alfa 50 mg Myozyme 50mg powder for concentrate for solution for infusion vials | 1 vial £356.06 (Hospital only)
2.10 Tyrosinaemia type I

**ENZYME INHIBITORS**

*4-HYDROXYPHENYLPYRUVATE DIOXYGENASE INHIBITORS*

### Nitisinone

**(NTBC)**

- **INDICATIONS AND DOSE**
  - Hereditary tyrosinaemia type I (in combination with dietary restriction of tyrosine and phenylalanine) (specialist use only)
    - **BY MOUTH**
    - Adult: Initially 500 micrograms/kg twice daily, adjusted according to response; maximum 2 mg/kg per day

- **INTERACTIONS** → Appendix 1: nitisinone
- **SIDE-EFFECTS**
  - Common or very common Conjunctivitis · conical opacity · eye pain · granulocytopenia · keratitis · leucopenia · photophobia · thrombocytopenia
  - Uncommon Blepharitis · erythematous rash · exfoliative dermatitis · leucocytosis · pruritus
- **PREGNANCY** Manufacturer advises avoid unless potential benefit outweighs risk—毒性 in animal studies.
- **BREAST FEEDING** Manufacturer advises avoid—adverse effects in animal studies.
- **PRE-TREATMENT SCREENING** Slit-lamp examination of eyes recommended before treatment.
- **MONITORING REQUIREMENTS**
  - Monitor liver function regularly.
  - Monitor platelet and white blood cell count every 6 months.
- **DIRECTIONS FOR ADMINISTRATION** Capsules can be opened and the contents suspended in a small amount of water or formula diet and taken immediately.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Oral suspension**
    - Nitisinone 4 mg per 1 ml Orfadin 4mg/1ml oral suspension sugar-free | 90 ml [Pom] £1.692.00
  - **Capsule**
    - Orfadin (Swedish Orphan Biovitrum Ltd)
      - Nitisinone 2 mg Orfadin 2mg capsules | 60 capsule [Pom] £564.00
      - Nitisinone 5 mg Orfadin 5mg capsules | 60 capsule [Pom] £1,127.00
      - Nitisinone 10 mg Orfadin 10mg capsules | 60 capsule [Pom] £2,062.00
      - Nitisinone 20 mg Orfadin 20mg capsules | 60 capsule [Pom] £4,512.00

2.11 Urea cycle disorders

**AMINO ACIDS AND DERIVATIVES**

### Carglumic acid

- **INDICATIONS AND DOSE**
  - Hyperammonaemia due to N-acetylglutamate synthase deficiency (under expert supervision)
    - **BY MOUTH**
    - Adult: Initially 50–125 mg/kg twice daily, to be taken immediately before food, dose adjusted according to plasma–ammonia concentration; maintenance 5–50 mg/kg twice daily, the total daily dose may alternatively be given in 3–4 divided doses
  - **Hyperammonaemia due to organic acidemia (under expert supervision)**
    - **BY MOUTH**
    - Adult: Initially 50–125 mg/kg twice daily, to be taken immediately before food, dose adjusted according to plasma–ammonia concentration, the total daily dose may alternatively be given in 3–4 divided doses

**IMPORTANT SAFETY INFORMATION**

**EMERGENCY MANAGEMENT OF UREA CYCLE DISORDERS**

For further information on the emergency management of urea cycle disorders consult the British Inherited Metabolic Disease Group (BIMDG) website at www.bimdg.org.uk.

- **SIDE-EFFECTS**
  - Common or very common Sweating
  - Uncommon Bradycardia · diarrhoea · pyrexia · vomiting
  - PREGNANCY Manufacturer advises avoid unless essential—no information available.
  - **BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.
  - **DIRECTIONS FOR ADMINISTRATION** Dispersible tablets must be dispersed in at least 5–10 mL of water and taken orally immediately, or administered via a nasogastric tube.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Dispersible tablet**
    - Cautionary and Advisory Labels 13
      - Carbaglu (Orphan Europe (UK) Ltd)
      - Carglumic acid 200 mg Carbaglu 200mg dispersible tablets sugar-free | 5 tablet [Pom] £299.00 sugar-free | 60 tablet [Pom] £3,499.00

**DRUGS FOR METABOLIC DISORDERS**

**AMMONIA LOWERING DRUGS**

### Sodium phenylbutyrate

- **INDICATIONS AND DOSE**
  - Long-term treatment of urea cycle disorders (as adjunctive therapy in all patients with neonatal-onset disease and in those with late-onset disease who have a history of hyperammonaemic encephalopathy) (under expert supervision)
    - **BY MOUTH**
    - Adult: 9.9–13 g/m² daily in divided doses, with meals; maximum 20 g per day

**IMPORTANT SAFETY INFORMATION**

**EMERGENCY MANAGEMENT OF UREA CYCLE DISORDERS**

For further information on the emergency management of urea cycle disorders consult the British Inherited Metabolic Disease Group (BIMDG) website at www.bimdg.org.uk.

- **CAUTIONS** Congestive heart failure (preparations contain significant amounts of sodium)
- **SIDE-EFFECTS**
  - Common or very common Alkalosis · blood disorders · body odour · decreased appetite · depression · gastro-intestinal disturbances · headache · irritability · menstrual disorders · metabolic acidosis · oedema · rash · renal tubular acidosis · syncope · taste disturbance · weight gain
  - Uncommon Arrhythmias · pancreatitis · peptic ulcer · rectal bleeding
2.12 Wilson’s disease

Other drugs used for Wilson’s disease

Penicillamine, p. 1002

2.12.1 Zinc acetate

**INDICATIONS AND DOSE**

Wilson’s disease (initiated under specialist supervision)

- **BY MOUTH**
  - Adult: 50 mg 3 times a day (max. per dose 50 mg 5 times a day), adjusted according to response

**DOSE EQUIVALENCE AND CONVERSION**

- Doses expressed as elemental zinc.

**PHARMACOKINETICS**

Symptomatic Wilson’s disease patients should be treated initially with a chelating agent because zinc has a slow onset of action. When transferring from chelating treatment to zinc maintenance therapy, chelating treatment should be co-administered for 2–3 weeks until zinc produces its maximal effect.

**CAUTIONS**

Portal hypertension (risk of hepatic decompensation when switching from chelating agent)

**INTERACTIONS** → Appendix 1: zinc

**SIDE-EFFECTS**

- Gastric irritation (usually transient)
- Leucopenia · sideroblastic anaemia

SIDE-EFFECTS, FURTHER INFORMATION

Transient gastric irritation may be reduced if first dose is taken mid-morning or with a little protein.

**PREGNANCY**

Reduce dose to 25 mg 3 times daily adjusted according to plasma-copper concentration and urinary copper excretion.

**BREAST FEEDING**

Manufacturer advises avoid; present in milk—may cause zinc-induced copper deficiency in infant.

**MONITORING REQUIREMENTS**

Monitor full blood count and serum cholesterol.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Capsule**
  - CAUTIONARY AND ADVISORY LABELS 23
  - Wilzin (Orphan Europe (UK) Ltd) 25 mg 50 mg

**ANTIDOTES AND CHELATORS**

**COPPER CHELATORS**

**Trientine dihydrochloride**

**INDICATIONS AND DOSE**

Wilson’s disease in patients intolerant of penicillamine

- **BY MOUTH**
  - Adult: 1.2–2.4 g daily in 2–4 divided doses, adjusted according to response, to be taken before food

**SIDE-EFFECTS**

- Nausea · rash
- Anaemia
- Colitis · duodenitis
- PREGNANCY Teratogenic in animal studies—use only if benefit outweighs risks. Monitor maternal and neonatal serum-copper concentrations.

**PRESCRIBING AND DISPENSING INFORMATION**

Trientine is not an alternative to penicillamine for rheumatoid arthritis or cystinuria. Penicillamine-induced systemic lupus erythematosus may not resolve on transfer to trientine.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Capsule**
  - CAUTIONARY AND ADVISORY LABELS 6, 22
  - Trientine dihydrochloride (Non-proprietary) 300 mg

**Manufacturers**

- **Trientine dihydrochloride (Non-proprietary)**
  - Trientine dihydrochloride 300 mg 100 capsule £3.090.00 DT price = £3.090.00

---

3 Mineral and trace elements deficiencies

3.1 Selenium deficiency

**Selenium**

Selenium deficiency can occur as a result of inadequate diet or prolonged parenteral nutrition. A selenium supplement should not be given unless there is good evidence of deficiency.
VITAMINS AND TRACE ELEMENTS

Selenium

- INDICATIONS AND DOSE
  - Selenium deficiency
    - BY MOUTH, OR BY INTRAMUSCULAR INJECTION, OR BY INTRAPERITONEAL INJECTION
    - Adult: 100–500 micrograms daily
  - INTERACTIONS  ➔ Appendix 1: selenium

- MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug.
  - Tablet
    - SelenoPrecise (Pharma Nord (UK) Ltd)
      - Selenium (as L-Selenomethionine) 100 microgram SelenoPrecise 100 microgram tablets | 60 tablet £4.02
      - L-Selenomethionine 200 microgram SelenoPrecise 200 microgram tablets | 60 tablet £4.02 | 150 tablet £8.01
  - Solution for injection
    - Selenase (Baxter Healthcare Ltd)
      - Selenium (as Sodium selenite) 50 microgram per 1 ml Selenase 100 microgram/2ml solution for injection ampoules | 10 ampuole | no price available
      - Selenase 500 micrograms/10ml solution for injection vials | 10 vial | no price available
  - Oral solution
    - Selenase (Baxter Healthcare Ltd)
      - Selenium (as Sodium selenite) 50 microgram per 1 ml Selenase 100 microgram/2ml oral solution 2ml unit dose ampoules | 20 unit dose | no price available
      - Selenase 500 micrograms/10ml oral solution unit dose vials | 10 unit dose | no price available
  - Capsule
    - Selenium (Non-proprietary)
      - L-Selenomethionine 200 microgram Selenium 200 microgram capsules | 30 capsule £3.20 | 60 capsule £5.79

3.2 Zinc deficiency

Zinc

Zinc supplements should not be given unless there is good evidence of deficiency (hypoproteinaemia spuriously lowers plasma-zinc concentration) or in zinc-losing conditions. Zinc deficiency can occur as a result of inadequate diet or malabsorption; excessive loss of zinc can occur in trauma, burns, and protein-losing conditions. A zinc supplement is given until clinical improvement occurs, but it may need to be continued in severe malabsorption, metabolic disorders, or in zinc-losing states.

Zinc is used in the treatment of Wilson’s disease and acrodernatitis enteropathica, a rare inherited abnormality of zinc absorption. Parenteral nutrition regimens usually include trace amounts of zinc. If necessary, further zinc can be added to intravenous feeding regimens.

ELECTROLYTES AND MINERALS ➔ ZINC

Zinc sulfate

- INDICATIONS AND DOSE
  - Zinc deficiency or supplementation in zinc-losing conditions
    - BY MOUTH USING EFFERVESCENT TABLETS
    - Child (body-weight up to 10 kg): 22.5 mg daily, dose to be adjusted as necessary, to be dissolved in water and taken after food, dose expressed as elemental zinc
  - INTERACTIONS  ➔ Appendix 1: zinc

4 Nutrition (intravenous)

Intravenous nutrition

Overview

When adequate feeding through the alimentary tract is not possible, nutrients may be given by intravenous infusion. This may be in addition to ordinary oral or tube feeding—supplemental parenteral nutrition, or may be the sole source of nutrition—total parenteral nutrition (TPN). Indications for this method include preparation of undernourished patients for surgery, chemotherapy, or radiation therapy; severe or prolonged disorders of the gastro-intestinal tract; major surgery, trauma, or burns; prolonged coma or refusal to eat; and some patients with renal or hepatic failure. The composition of proprietary preparations available is given under Proprietary Infusion Fluids for Parenteral Feeding p. 980.

Parenteral nutrition requires the use of a solution containing amino acids, glucose, fat, electrolytes, trace elements, and vitamins. This is now commonly provided by the pharmacy in the form of a 3-litre bag. A single dose of vitamin B₁₂, as hydroxocobalamin p. 938, is given by intramuscular injection; regular vitamin B₁₂ injections are not usually required unless total parenteral nutrition continues for many months. Folic acid p. 937 is given in a dose of 15 mg once or twice each week, usually in the
## Proprietary Infusion Fluids for Parenteral Feeding

<table>
<thead>
<tr>
<th>Preparation</th>
<th>Nitrogen g/litre</th>
<th>1 kcal Energy kJ/litre</th>
<th>Electrolytes mmol/litre</th>
<th>Other components/litre</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aminoven 25 (Fresenius Kabi Ltd)</td>
<td>25.7</td>
<td>25.8</td>
<td>1680</td>
<td>2.5</td>
</tr>
<tr>
<td>Clinimix N16G20E (Baxter Healthcare Ltd)</td>
<td>4.6</td>
<td>30.0</td>
<td>2.5</td>
<td>35.0</td>
</tr>
<tr>
<td>Clinimix N14G30E (Baxter Healthcare Ltd)</td>
<td>7.0</td>
<td>2520</td>
<td>30.0</td>
<td>2.5</td>
</tr>
<tr>
<td>ClinOleic 20% (Baxter Healthcare Ltd)</td>
<td>-</td>
<td>8360</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hyperamine 30 (B.Braun Medical Ltd)</td>
<td>30.0</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Intralipid 10% (Fresenius Kabi Ltd)</td>
<td>-</td>
<td>4600</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Intralipid 20% (Fresenius Kabi Ltd)</td>
<td>-</td>
<td>8400</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Intralipid 30% (Fresenius Kabi Ltd)</td>
<td>-</td>
<td>12600</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Kabiven (Fresenius Kabi Ltd)</td>
<td>5.3</td>
<td>3275</td>
<td>23.0</td>
<td>4.0</td>
</tr>
<tr>
<td>Kabiven peripheral (Fresenius Kabi Ltd)</td>
<td>3.75</td>
<td>2625</td>
<td>17.0</td>
<td>2.8</td>
</tr>
<tr>
<td>Lipidem (B.Braun Medical Ltd)</td>
<td>-</td>
<td>7900</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lipofundin MCT/LCT 10% (B.Braun Medical Ltd)</td>
<td>-</td>
<td>4430</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Lipofundin MCT/LCT 20% (B.Braun Medical Ltd)</td>
<td>-</td>
<td>8000</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

1. 1000 kcal = 4200kJ; 1000 kJ = 238.8 kcal. All entries are Prescription-only medicines.
2. Excludes protein- or amino acid-derived energy.
Nutrition (intravenous) 981

<table>
<thead>
<tr>
<th>Preparation</th>
<th>Nitrogen g/litre</th>
<th>1,2-Energy kJ/litre</th>
<th>Electrolytes mmol/litre</th>
<th>Other components/litre</th>
</tr>
</thead>
<tbody>
<tr>
<td>NuTRIflex basal (B.Braun Medical Ltd)</td>
<td>4.6</td>
<td>2095</td>
<td>K⁺ 30.0, Mg²⁺ 5.7, Na⁺ 49.9, Acet⁻ 35.0, Cl⁻ 50.0</td>
<td>Ca⁺⁺ 3.6 mmol, acid phosphate 12.8 mmol, anhydrous glucose 125 g</td>
</tr>
<tr>
<td>Net price (dual compartment bag of amino acids 400 mL or 800 mL; glucose 600 mL or 1200 mL) 1 litre: no price available; Net price 2 litre = £25.20</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NuTRIflex peri (B.Braun Medical Ltd)</td>
<td>5.7</td>
<td>1340</td>
<td>K⁺ 15.0, Mg²⁺ 4.0, Na⁺ 27.0, Acet⁻ 19.5, Cl⁻ 31.6</td>
<td>Ca⁺⁺ 2.5 mmol, acid phosphate 5.7 mmol, anhydrous glucose 80 g</td>
</tr>
<tr>
<td>Net price (dual compartment bag of amino acids 400 mL or 800 mL; glucose 600 mL or 1200 mL) 1 litre: no price available; Net price 2 litre = £30.47</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NuTRIflex plus (B.Braun Medical Ltd)</td>
<td>6.8</td>
<td>2510</td>
<td>K⁺ 25.0, Mg²⁺ 5.7, Na⁺ 37.2, Acet⁻ 22.9, Cl⁻ 35.5</td>
<td>Ca⁺⁺ 3.6 mmol, acid phosphate 20 mmol, anhydrous glucose 150 g</td>
</tr>
<tr>
<td>Net price (dual compartment bag of amino acids 400 mL or 800 mL; glucose 600 mL or 1200 mL) 1 litre: no price available; Net price 2 litre = £33.02</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NuTRIflex special (B.Braun Medical Ltd)</td>
<td>10.0</td>
<td>4020</td>
<td>K⁺ 25.7, Mg²⁺ 5.0, Na⁺ 40.5, Acet⁻ 22.0, Cl⁻ 49.5</td>
<td>Ca⁺⁺ 4.1 mmol, acid phosphate 14.7 mmol, anhydrous glucose 240 g</td>
</tr>
<tr>
<td>Net price (dual compartment bag of amino acids 500 mL or 750 mL; glucose 500 mL or 750 mL) 1 litre: no price available; Net price 1.5 litre = £27.60</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NuTRIflex Lipid peri (B.Braun Medical Ltd)</td>
<td>4.56</td>
<td>2664</td>
<td>K⁺ 24.0, Mg²⁺ 2.4, Na⁺ 40.0, Acet⁻ 32.0, Cl⁻ 38.4</td>
<td>Ca⁺⁺ 2.4 mmol, Zn²⁺ 24 micromol, phosphate 6 mmol, anhydrous glucose 64 g, soya oil 20 g, medium-chain triglycerides 20 g</td>
</tr>
<tr>
<td>Net price (triple compartment bag of amino acids 500 mL, 750 mL or 1000 mL; glucose 500 mL, 750 mL or 1000 mL; lipid emulsion 20% 250 mL, 375 mL or 500 mL) 1.25 litre = £42.83; Net price 1.875 litre = £54.37; Net price 2.5 litre = £64.22</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NuTRIflex Lipid plus (B.Braun Medical Ltd)</td>
<td>5.44</td>
<td>3600</td>
<td>K⁺ 28.0, Mg²⁺ 3.2, Na⁺ 40.0, Acet⁻ 36.0, Cl⁻ 36.0</td>
<td>Ca⁺⁺ 3.2 mmol, Zn²⁺ 24 micromol, phosphate 12 mmol, anhydrous glucose 120 g, soya oil 20 g, medium-chain triglycerides 20 g</td>
</tr>
<tr>
<td>Net price (triple compartment bag of amino acids 500 mL, 750 mL or 1000 mL; glucose 500 mL, 750 mL or 1000 mL; lipid emulsion 20% 250 mL, 375 mL or 500 mL) 1.25 litre = £46.56; Net price 1.875 litre = £59.46; Net price 2.5 litre = £68.39</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NuTRIflex Lipid plus without Electrolytes (B.Braun Medical Ltd)</td>
<td>5.44</td>
<td>3600</td>
<td>-</td>
<td>anhydrous glucose 120 g, soya oil 20 g, medium-chain triglycerides 20 g</td>
</tr>
<tr>
<td>Net price (triple compartment bag of amino acids 500 mL, 750 mL or 1000 mL; glucose 500 mL, 750 mL or 1000 mL; lipid emulsion 20% 250 mL, 375 mL or 500 mL) 1.25 litre = £46.56; Net price 1.875 litre = £59.45; Net price 2.5 litre = £68.39</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NuTRIflex Lipid special (B.Braun Medical Ltd)</td>
<td>8.0</td>
<td>4004</td>
<td>K⁺ 37.6, Mg²⁺ 4.24, Na⁺ 53.6, Acet⁻ 48.0, Cl⁻ 48.0</td>
<td>Ca⁺⁺ 4.24 mmol, Zn²⁺ 32 micromol, phosphate 16 mmol, anhydrous glucose 144 g, soya oil 20 g, medium-chain triglycerides 20 g</td>
</tr>
<tr>
<td>Net price (triple compartment bag of amino acids 500 mL, 750 mL or 1000 mL; glucose 500 mL, 750 mL or 1000 mL; lipid emulsion 20% 250 mL, 375 mL or 500 mL) 1.25 litre = £56.96; Net price 1.875 litre = £74.62; Net price 2.5 litre: no price available</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NuTRIflex Lipid special without Electrolytes (B.Braun Medical Ltd)</td>
<td>8.0</td>
<td>4004</td>
<td>-</td>
<td>anhydrous glucose 144 g, soya oil 20 g, medium-chain triglycerides 20 g</td>
</tr>
<tr>
<td>Net price (triple compartment bag of amino acids 500 mL, 750 mL or 1000 mL; glucose 500 mL, 750 mL or 1000 mL; lipid emulsion 20% 250 mL, 375 mL or 500 mL) 1.25 litre = £56.96; Net price 1.875 litre = £74.62</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. 1000 kcal = 4200kJ; 1000 kJ = 238.8 kcal. All entries are Prescription-only medicines.
2. Excludes protein- or amino acid-derived energy.
<table>
<thead>
<tr>
<th>Preparation</th>
<th>Nitrogen g/litre</th>
<th>(^1\text{kJ})/litre</th>
<th>Electrolytes mmol/litre</th>
<th>Other components/litre</th>
</tr>
</thead>
<tbody>
<tr>
<td>NuTrIflex Omega plus (B.Braun Medical Ltd)</td>
<td>5.4</td>
<td>3600</td>
<td>28.0 3.2 40.0 36.0 36.0</td>
<td>Ca(^{2+}) 2.2 mmol, Zn(^{2+}) 24 micromol, phosphate 12 mmol, anhydrous glucose 120 g, refined soya oil 16 g, medium-chain triglycerides 20 g, omega-3-acid triglycerides 4 g</td>
</tr>
<tr>
<td>NuTrIflex Omega special (B.Braun Medical Ltd)</td>
<td>8.0</td>
<td>4004</td>
<td>37.6 4.24 53.6 48.0 48.0</td>
<td>Ca(^{2+}) 4.24 mmol, Zn(^{2+}) 30 micromol, phosphate 16 mmol, anhydrous glucose 144 g, refined soya oil 16 g, medium-chain triglycerides 20 g, omega-3-acid triglycerides 4 g</td>
</tr>
<tr>
<td>OliClinomel N4-550E (Baxter Healthcare Ltd)</td>
<td>3.6</td>
<td>2184</td>
<td>16.0 2.2 21.0 30.0 33.0</td>
<td>Ca(^{2+}) 2 mmol, phosphate 8.5 mmol, refined olive and soya oil 20 g, anhydrous glucose 80 g</td>
</tr>
<tr>
<td>OliClinomel N4-720E (Baxter Healthcare Ltd)</td>
<td>3.64</td>
<td>3024</td>
<td>24.0 2.0 28.0 40.0 40.0</td>
<td>Ca(^{2+}) 1.8 mmol, phosphate 8 mmol, refined olive and soya oil 40 g, anhydrous glucose 80 g</td>
</tr>
<tr>
<td>OliClinomel N5-800E (Baxter Healthcare Ltd)</td>
<td>4.6</td>
<td>3360</td>
<td>24.0 2.2 32.0 49.0 44.0</td>
<td>Ca(^{2+}) 2 mmol, phosphate 10 mmol, refined olive and soya oil 40 g, anhydrous glucose 100 g</td>
</tr>
<tr>
<td>OliClinomel N6-900E (Baxter Healthcare Ltd)</td>
<td>5.6</td>
<td>3696</td>
<td>24.0 2.2 32.0 53.0 46.0</td>
<td>Ca(^{2+}) 2 mmol, phosphate 10 mmol, refined olive and soya oil 40 g, anhydrous glucose 120 g</td>
</tr>
<tr>
<td>OliClinomel N7-1000 (Baxter Healthcare Ltd)</td>
<td>6.6</td>
<td>4368</td>
<td>- - - 37.0 16.0</td>
<td>phosphate 3 mmol, refined olive and soya oil 40 g, anhydrous glucose 160 g</td>
</tr>
<tr>
<td>OliClinomel N7-1000E (Baxter Healthcare Ltd)</td>
<td>6.6</td>
<td>4368</td>
<td>24.0 2.2 32.0 57.0 48.0</td>
<td>Ca(^{2+}) 2 mmol, phosphate 10 mmol, refined olive and soya oil 40 g, anhydrous glucose 160 g</td>
</tr>
<tr>
<td>OliClinomel N8-800 (Baxter Healthcare Ltd)</td>
<td>8.25</td>
<td>3360</td>
<td>- - - 42.5 20.0</td>
<td>phosphate 2.25 mmol, refined olive and soya oil 30 g, anhydrous glucose 125 g</td>
</tr>
</tbody>
</table>

1. 1000 kcal = 4200kJ; 1000 kJ = 238.8 kcal. All entries are Prescription-only medicines.
2. Excludes protein- or amino acid-derived energy.
<table>
<thead>
<tr>
<th>Preparation</th>
<th>Nitrogen g/litre</th>
<th>1,2-Energy kJ/litre</th>
<th>Electrolytes mmol/litre</th>
<th>Other components/litre</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omegaven (Fresenius Kabi Ltd)</td>
<td>-</td>
<td>4700</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net price 100 ml: no price available</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma-Lyte 148 (water) (Baxter Healthcare Ltd)</td>
<td>-</td>
<td>-</td>
<td>5.0 1.5 140.0 27.0 98.0</td>
<td>gluconate 23 mmol</td>
</tr>
<tr>
<td>Net price 1 litre: no price available</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma-Lyte 148 (dextrose 5%) (Baxter Healthcare Ltd)</td>
<td>-</td>
<td>840</td>
<td>5.0 1.5 140.0 27.0 98.0</td>
<td>gluconate 23 mmol, anhydrous glucose 50 g</td>
</tr>
<tr>
<td>Net price 1 litre: no price available</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plasma-Lyte M (dextrose 5%) (Baxter Healthcare Ltd)</td>
<td>-</td>
<td>840</td>
<td>16.0 1.5 40.0 12.0 40.0</td>
<td>Ca++ 2.5 mmol, lactate 12 mmol, anhydrous glucose 50 g</td>
</tr>
<tr>
<td>Net price 1 litre: no price available</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SMOLipid (Fresenius Kabi Ltd)</td>
<td>9</td>
<td>8400</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net price 500 ml = £174.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synthamin 9 (Baxter Healthcare Ltd)</td>
<td>9.1</td>
<td>-</td>
<td>60.0 5.0 70.0 100.0 70.0</td>
<td>acid phosphate 30 mmol</td>
</tr>
<tr>
<td>Net price 500 ml: no price available; Net price 1 litre: no price available</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synthamin 9 EF (electrolyte-free) (Baxter Healthcare Ltd)</td>
<td>9.1</td>
<td>-</td>
<td>- - - - 44.0</td>
<td>22.0</td>
</tr>
<tr>
<td>Net price 500 ml: no price available; Net price 1 litre: no price available</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synthamin 14 (Baxter Healthcare Ltd)</td>
<td>14.0</td>
<td>-</td>
<td>60.0 5.0 70.0 140.0 70.0</td>
<td>acid phosphate 30 mmol</td>
</tr>
<tr>
<td>Net price 500 ml: no price available; Net price 3 litre: no price available</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synthamin 14 EF (electrolyte-free) (Baxter Healthcare Ltd)</td>
<td>14.0</td>
<td>-</td>
<td>- - - - 68.0</td>
<td>34.0</td>
</tr>
<tr>
<td>Net price 500 ml: no price available; Net price 1 litre: no price available</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synthamin 17 (Baxter Healthcare Ltd)</td>
<td>16.5</td>
<td>-</td>
<td>60.0 5.0 70.0 150.0 70.0</td>
<td>acid phosphate 30 mmol</td>
</tr>
<tr>
<td>Net price 500 ml: no price available; Net price 1 litre: no price available</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Synthamin 17 EF (electrolyte-free) (Baxter Healthcare Ltd)</td>
<td>16.5</td>
<td>-</td>
<td>- - - - 82.0</td>
<td>40.0</td>
</tr>
<tr>
<td>Net price 500 ml: no price available; Net price 3 litre: no price available</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vamin 9 Glucose (Fresenius Kabi Ltd)</td>
<td>9.4</td>
<td>1700</td>
<td>20.0 1.5 50.0 - 50.0</td>
<td>CA++ 2.5 mmol, anhydrous glucose 100 g</td>
</tr>
<tr>
<td>Net price 100 ml: no price available; Net price 500 ml: no price available; Net price 1 litre: no price available</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vamin 14 (Fresenius Kabi Ltd)</td>
<td>13.5</td>
<td>-</td>
<td>50.0 8.0 100.0 135.0 100.0</td>
<td>CA++ 5 mmol, SO42- 8 mmol</td>
</tr>
<tr>
<td>Net price 500 ml = £9.48; Net price 1 litre = £16.02</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vamin 14 (electrolyte-free) (Fresenius Kabi Ltd)</td>
<td>13.5</td>
<td>-</td>
<td>- - - - 90.0</td>
<td>-</td>
</tr>
<tr>
<td>Net price 500 ml = £9.48; Net price 1 litre = £16.02</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vamin 18 (electrolyte-free) (Fresenius Kabi Ltd)</td>
<td>18.0</td>
<td>-</td>
<td>- - - - 110.0</td>
<td>-</td>
</tr>
<tr>
<td>Net price 500 ml = £11.99; Net price 1 litre = £23.38</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 1000 kcal = 4200kJ; 1000 kJ = 238.8 kcal. All entries are Prescription-only medicines.
2 Excludes protein- or amino acid-derived energy
nutrition solution. Other vitamins are usually given daily; they are generally introduced in the parenteral nutrition solution. Alternatively, if the patient is able to take small amounts by mouth, vitamins may be given orally.

The nutrition solution is infused through a central venous catheter inserted under full surgical precautions. Alternatively, infusion through a peripheral vein may be used for supplementary as well as total parenteral nutrition for periods of up to a month, depending on the availability of peripheral veins; factors prolonging cannula life and preventing thrombophlebitis include the use of soft polyurethane paediatric cannulas and use of feeds of low osmolality and neutral pH. Only nutritional fluids should be given by the dedicated intravenous line.

Before starting, the patient should be well oxygenated with a near normal circulating blood volume and attention should be given to renal function and acid–base status. Appropriate biochemical tests should have been carried out beforehand and serious deficits corrected. Nutritional and electrolyte status must be monitored throughout treatment.

Complications of long-term parenteral nutrition include gall bladder sludging, gall stones, cholestasis and abnormal liver function tests. For details of the prevention and management of parenteral nutrition complications, specialist literature should be consulted.

Protein is given as mixtures of essential and non-essential synthetic L-amino acids. Ideally, all essential amino acids should be included with a wide variety of nonessential ones to provide sufficient nitrogen together with electrolytes. Solutions vary in their composition of amino acids; they often contain an energy source (usually glucose p. 955) and electrolytes.

Energy is provided in a ratio of 0.6 to 1.1 megajoules (150–250 kcal) per gram of protein nitrogen. Energy requirements must be met if amino acids are to be utilised for tissue maintenance. A mixture of carbohydrate and fat energy sources (usually 30–50% as fat) gives better utilisation of amino acids than glucose alone.

Glucose is the preferred source of carbohydrate, but if more than 180 g is given per day frequent monitoring of blood glucose is required, and insulin may be necessary. Glucose in various strengths from 10 to 50% must be infused through a central venous catheter to avoid thrombosis.

In parenteral nutrition regimens, it is necessary to provide adequate phosphate in order to allow phosphorylation of glucose and to prevent hypophosphataemia; between 20 and 30 mmol of phosphate is required daily.

Fructose and sorbitol have been used in an attempt to avoid the problem of hyperosmolar hyperglycaemic non-ketotic acidosis but other metabolic problems may occur, as with xylitol and ethanol which are now rarely used.

Fat emulsions have the advantages of a high energy to fluid volume ratio, neutral pH, and iso-osmolarity with plasma, and provide essential fatty acids. Several days of adaptation may be required to attain maximal utilisation. Reactions include occasional febrile episodes (usually only with 20% emulsions) and rare anaphylactic responses. Interference with biochemical measurements such as those for blood gases and calcium may occur if samples are taken before fat has been cleared. Daily checks are necessary to ensure complete clearance from the plasma in conditions where fat metabolism may be disturbed. Additives should not be mixed with fat emulsions unless compatibility is known.

Administration
Because of the complex requirements relating to parenteral nutrition full details relating to administration have been omitted. In all cases product literature and other specialist literature should be consulted.

## NUTRIENTS

### PARENTERAL NUTRITION

#### INDICATIONS AND DOSE

**Dipeptiven 20G/100ML Concentrate for Solution for Infusion Bottles**
Amino acid supplement for hypercatabolic or hypermetabolic states

- **By intravenous infusion**
- **Adult:** 300–400 mg/kg daily, dose not to exceed 20% of total amino acid intake

#### CAUTIONS

**Peditrace Solution for Infusion 10ML Vials** Reduced biliary excretion - reduced biliary excretion in cholestatic liver disease - reduced biliary excretion in markedly reduced urinary excretion (careful biochemical monitoring required) - total parenteral nutrition exceeding one month

**Cautions, Further Information**
- Total parenteral nutrition exceeding one month Measure serum manganese concentration and check liver function before commencing treatment and regularly during treatment—discontinue if manganese concentration raised or if cholestasis develops.

**Directions for Administration** Because of the complex requirements relating to parenteral nutrition, full details relating to administration have been omitted. In all cases specialist pharmacy advice, product literature, and other specialist literature should be consulted. Compatibility with the infusion solution must be ascertained before adding supplementary preparations. Additives should not be mixed with fat emulsions unless compatibility is known.

**Cernevit Solution for Infusion Vials and Diluent** Dissolve in 5 mL water for injections.

**Peditrace Solution for Infusion 10ML Vials** For addition to Vaminolact®, Vamin® 14 Electrolyte-Free solutions, and glucose intravenous infusions.

**Tracutil® Ampoules** For addition to infusion solutions.

**Decan Concentrate for Solution for Infusion 40ML Bottles** For addition to infusion solutions.

**Addiphos® Vials** For addition to Vamin® solutions and glucose intravenous infusions.

**Dipeptiven 20G/100ML Concentrate for Solution for Infusion Bottles** For addition to infusion solutions containing amino acids.

**Additrase Solution for Infusion 10ML Ampoules** For addition to Vamin® solutions and glucose intravenous infusions.

**Glycophos® Vials** For addition to Vamin® and Vaminolact® solutions, and glucose intravenous infusions.

**Solivito N Powder for Solution for Infusion Vials** Dissolve in water for injections or glucose intravenous infusion for adding to glucose intravenous infusion or Intralipid®; dissolve in Vitlipid N® or Intralipid® for adding to Intralipid® only.

**Vitlipid N Infant Emulsion for Injection 10ML Ampoules** For addition to Intralipid®

**Vitlipid N Adult Emulsion for Injection 10ML Ampoules** For addition to Intralipid®

#### PRESCRIBING AND DISPENSING INFORMATION

**Cernevit Solution for Infusion Vials and Diluent** Cernevit® solution contains dl-alpha tocopherol 11.2 units, ascorbic acid 125 mg, biotin 69 micrograms, colecacferol 220 units, cyanocobalamin 6 micrograms, folic acid 414 micrograms, glycine 250 mg, nicotinamide 46 mg, pantothenic acid (as dextaphenol) 17.25 mg, pyridoxine hydrochloride 5.5 mg, retinol (as palmitate)
3500 units, riboflavin (as dihydrated sodium phosphate) 4.14 mg, thiamine (as cocarboxylase tetrahydrate) 3.51 mg.

**PEDIATRIC SOLUTION FOR INFECTION 10ML VIALS** Peditrace® solution contains traces of Zn²⁺, Cu²⁺, Mn⁺⁺, Se⁴⁺, F⁻, I⁻.

**TRACUTIL® AMPOULES** Tracutil® solution contains trace elements Fe³⁺, Zn²⁺, Mn⁺⁺, Cu²⁺, Cr³⁺, Se⁴⁺, Mo⁶⁺, I⁻, F⁻.

**DECAN CONCENTRATE FOR SOLUTION FOR INFUSION 40ML BOTTLES** For patients over 40 kg, Decan® solution contains trace elements Fe³⁺, Zn²⁺, Cu²⁺, Cr³⁺, Se⁴⁺, Mo⁶⁺, Mo⁶⁺, I⁻, F⁻.

**ADDIPHOS® VIALS** Addiphos® sterile solution contains phosphate 40 mmol, K⁺ 30 mmol, Na⁺ 30 mmol/20 mL.

**Dipeptiven 20G/100ML CONCENTRATE FOR SOLUTION FOR INFUSION BOTTLES** Dipeptiven® solution contains N(2)-L-alanyl-L-glutamine 200 mg/ml (providing L-alanine 82 mg, L-glutamine 134.6 mg).

**ADDITRACE FOR SOLUTION FOR INFUSION 10ML AMPOULES** For patients over 40 kg, Additrace® solution contains traces of Fe³⁺, Zn²⁺, Mn⁺⁺, Cu²⁺, Cr³⁺, Se⁴⁺, Mo⁶⁺, F⁻, I⁻.

**GLYCOPHOS® VIALS** Glycophos® Sterile Concentrate solution contains phosphate 20 mmol, Na⁺ 40 mmol/20 mL.

**Solivito N Powder for Solution for Infusion VIALS** Solivito N® powder for reconstitution contains biotin 60 micrograms, cyanocobalamin 5 micrograms, folic acid 400 micrograms, thiamine nitrate 3.1 micrograms, pyridoxine hydrochloride 4.9 micrograms, riboflavin sodium phosphate 4.9 micrograms, sodium ascorbate 113 micrograms, sodium pantothenate 16.5 micrograms, nicotinamide 40 micrograms, copper chloride 340 micrograms, zinc chloride 681.5 micrograms, sodium ascorbate 113 micrograms.

**SOLIVITO N POWDER FOR SOLUTION FOR INFUSION VIALS** Solivito N® powder for reconstitution contains biotin 60 micrograms, cyanocobalamin 5 micrograms, folic acid 400 micrograms, thiamine nitrate 3.1 micrograms, pyridoxine hydrochloride 4.9 micrograms, riboflavin sodium phosphate 4.9 micrograms, sodium pantothenate 16.5 micrograms, nicotinamide 40 micrograms, copper chloride 340 micrograms, zinc chloride 681.5 micrograms, sodium ascorbate 113 micrograms.

**VITLIPID N INFANT EMULSION FOR INJECTION 10ML AMPOULES** Vitlipur N® infant emulsion contains vitamin A 230 units, ergocalciferol 40 units, dl-alpha tocopherol 0.7 unit, phytomenadione 20 micrograms/mL.

**VITLIPID N ADULT EMULSION FOR INJECTION 10ML AMPOULES** Vitlipur N® adult emulsion contains vitamin A 330 units, ergocalciferol 20 units, dl-alpha tocopherol 1 unit, phytomenadione 15 micrograms/mL. For adults and children over 11 years.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for infusion

**Solution for injection**

- **Cernevit** (Baxter Healthcare Ltd)
  Cyanocobalamin 6 micrograms, Biotin 69 micrograms, Folic acid 414 micrograms, Thiamine 3.51 mg, Riboflavin (as Riboflavin sodium phosphate) 4.14 mg, Pyridoxine (as Pyridoxine hydrochloride) 4.53 mg, Panthenol 16.5 mg, Manganese 1 microgram, Iodine 96 micrograms, Vitamin D₃ 204.6 micrograms, Folic acid 400 micrograms, Thiamine nitrate 3.1 micrograms, Pyridoxine hydrochloride 4.9 micrograms, Riboflavin sodium phosphate 4.9 micrograms, Sodium pantothenate 16.5 micrograms, Nicotinamide 40 micrograms, Copper chloride 340 micrograms, Zinc chloride 681.5 micrograms, Sodium ascorbate 113 micrograms, Ergocalciferol 1 microgram per 1 ml, Retinol palmitate 99 microgram per 1 ml, Alpha tocopherol 910 microgram per 1 ml, Retinol palmitate 99 microgram per 1 ml, Ergocalciferol 1 microgram per 1 ml, Retinol palmitate 99 microgram per 1 ml, Alpha tocopherol 910 microgram per 1 ml, Ergocalciferol 1 microgram per 1 ml, Retinol palmitate 99 microgram per 1 ml, Alpha tocopherol 910 microgram per 1 ml, Ergocalciferol 1 microgram per 1 ml.

**Solution for infusion**

- **Parenteral nutrition supplements (Non-proprietary)**
  Sodium glycerophosphate 216 mg per 1 ml, Sodium glycerophosphate 4.32g/20ml concentrate for solution for infusion 1 vial (Pom) £5.07 | 10 vials (Pom) no price available

- **Additrace** (Fresenius Kabi Ltd)
  Sodium molybdate 4.85 microgram per 1 ml, Chromic chloride 5.33 microgram per 1 ml, Sodium chelate 10.5 microgram per 1 ml, Potassium iodide 16.6 microgram per 1 ml, Manganese chloride 99 microgram per 1 ml, Sodium fluoride 210 microgram per 1 ml, Copper chloride 340 microgram per 1 ml, Ferric chloride 544 microgram per 1 ml, Zinc chloride 1.36 mg per 1 ml, Additrace solution for infusion 10ml ampoules | 1 ampoule (Pom) £1.96 | 20 ampoules (Pom) no price available

- **Dipeptiven** (Fresenius Kabi Ltd)
  N(2)-L-alanyl-L-glutamine 200 mg per 1 ml Dipeptiven 20g/100ml concentrate for solution for infusion bottles | 1 bottle (Pom) £25.93 | 10 bottle (Pom) no price available

Dipeptiven 10g/50ml concentrate for solution for infusion bottles | 1 bottle (Pom) £13.94 | 10 bottle (Pom) no price available

- **Peditrace** (Fresenius Kabi Ltd)
  Manganese (as Manganese chloride) 1 microgram per 1 ml, Iodine (as Potassium iodide) 1 microgram per 1 ml, Selenium (as Sodium selenite) 2 microgram per 1 ml, Copper (as Copper chloride) 20 microgram per 1 ml, Fluoride (as Sodium fluoride) 57 microgram per 1 ml, Zinc (as Zinc chloride) 250 microgram per 1 ml, Peditrace solution for infusion 10ml vials | 1 vial (Pom) £3.55 | 10 vials (Pom) no price available

- **Tracutil** (B.Braun Melsungen AG)
  Sodium molybdate dihydrate 2.42 microgram per 1 ml, Chronic chloride 5.3 microgram per 1 ml, Sodium selenite pentahydrate 7.89 microgram per 1 ml, Potassium iodide 16.6 microgram per 1 ml, Sodium fluoride 126 microgram per 1 ml, Manganese chloride 1979 microgram per 1 ml, Copper chloride 204.6 microgram per 1 ml, Zinc chloride 681.5 microgram per 1 ml, Feroxos chloride 695.8 microgram per 1 ml, Tracutil concentrate for solution for infusion 10ml ampoules | 5 ampoules (Pom) £7.96

**Powder for solution for infusion**

- **Solivito N** (Fresenius Kabi Ltd)
  Cyanocobalamin 5 micrograms, Biotin 60 micrograms, Folic acid 400 micrograms, Thiamine nitrate 3.1 micrograms, Pyridoxine hydrochloride 4.9 micrograms, Riboflavin sodium phosphate 4.9 micrograms, Sodium pantothenate 16.5 micrograms, Nicotinamide 40 micrograms, Copper chloride 340 micrograms, Zinc chloride 681.5 micrograms, Sodium ascorbate 113 micrograms.

**Emulsion for injection**

- **Vitlipur N Adult** (Fresenius Kabi Ltd)
  Ergocalciferol 500 nanogram per 1 ml, Phytomenadione 15 microgram per 1 ml, Retinol palmitate 99 microgram per 1 ml, Alpha tocopherol 910 microgram per 1 ml

- **Vitlipur N Infant** (Fresenius Kabi Ltd)
  Ergocalciferol 1 microgram per 1 ml, Phytomenadione 20 microgram per 1 ml, Retinol palmitate 69 microgram per 1 ml, Alpha tocopherol 640 microgram per 1 ml

**5 Nutrition (oral)**

**Enteral nutrition**

**Overview**

The body’s reserves of protein rapidly become exhausted in severely ill patients, especially during chronic illness or in those with severe burns, extensive trauma, pancreatitis, or intestinal fistula. Much can be achieved by frequent meals and by persuading the patient to take supplementary snacks of ordinary food between the meals.

However, extra calories, protein, other nutrients, and vitamins are often best given by supplementing ordinary meals with enteral sip or tube feeds.

When patients cannot feed normally, for example, patients with severe facial injury, oesophageal obstruction, or coma, a nutritionally complete diet of enteral feeds must be given. The advice of a dietitian should be sought to determine the protein and total energy requirement of the patient and the form and relative contribution of carbohydrate and fat to the energy requirements.

Most enteral feeds contain protein derived from cows’ milk or soya. Elemental feeds containing protein hydrolysates or free amino acids can be used for patients who have diminished ability to break down protein, for example in inflammatory bowel disease or pancreatic insufficiency.

Even when nutritionally complete feeds are given, water and electrolyte balance should be monitored. Haematological and biochemical parameters should also be monitored, particularly in clinically unstable patients. Extra minerals (e.g. magnesium and zinc) may be needed in

**BNF 74**

**Nutrition (oral) 985**
patients where gastro-intestinal secretions are being lost. Additional vitamins may also be needed.

**Enteral nutrition in children**

Children have special requirements and in most situations liquid feeds prepared for adults are totally unsuitable—the advice of a paediatric dietitian should be sought.

### 5.1 Special diets

#### Nutrition in special diets

**Overview**

These are preparations that have been modified to eliminate a particular constituent from a food or that are nutrient mixtures formulated as food substitutes for patients who either cannot tolerate or cannot metabolise certain common constituents of food. In certain clinical conditions, some food preparations are regarded as drugs and can be prescribed within the NHS if they have been approved by the Advisory Committee on Borderline Substances (ACBS).

**Coeliac disease**

Coeliac disease is caused by an abnormal immune response to gluten. For management and further information, see Coeliac disease p. 35.

**Phenylketonuria**

Phenylketonuria (hyperphenylalaninaemia, PKU), which results from the inability to metabolise phenylalanine, is managed by restricting dietary intake of phenylalanine to a small amount sufficient for tissue building and repair.

Sapropterin dihydrochloride below, a synthetic form of tetrahydrobiopterin, is licensed as an adjunct to dietary restriction of phenylalanine in the management of patients with phenylketonuria and tetrahydrobiopterin deficiency.

Aspartame (used as a sweetener in some foods and medicines) contributes to the phenylalanine intake and may affect control of phenylketonuria. Where the presence of aspartame is specified in the product literature this is indicated in the BNF against the preparation; the patient should be informed of this.

### 5.1a Phenylketonuria

**DRUGS FOR METABOLIC DISORDERS > TETRAHYDROBIOPTERIN AND DERIVATIVES**

#### Sapropterin dihydrochloride

- **INDICATIONS AND DOSE**
  - **Phenylketonuria (adjunct to dietary restriction of phenylalanine) (specialist use only)**
    - **BY MOUTH**
    - **Adult:** Initially 10 mg/kg once daily, adjusted according to response; usual dose 5–20 mg/kg once daily, dose to be taken preferably in the morning
  - **Tetrahydrobiopterin deficiency (adjunct to dietary restriction of phenylalanine) (specialist use only)**
    - **BY MOUTH**
    - **Adult:** Initially 2–5 mg/kg once daily, adjusted according to response, dose to be taken preferably in the morning, the total daily dose may alternatively be given in 2–3 divided doses; maximum 20 mg/kg per day

- **CAUTIONS** History of convulsions
- **INTERACTIONS** → Appendix 1: sapropterin

- **SIDE-EFFECTS**
  - **Common or very common** Abdominal pain · cough · diarrhoea · headache · nasal congestion · pharyngolaryngeal pain · vomiting
  - **Frequency not known** Hypersensitivity reactions
- **PREGNANCY** Manufacturer advises caution—consider only if strict dietary management inadequate.
- **BREAST FEEDING** Manufacturer advises avoid—no information available.
- **HEPATIC IMPAIRMENT** Manufacturer advises caution—no information available.
- **RENAL IMPAIRMENT** Manufacturer advises caution—no information available.
- **MONITORING REQUIREMENTS**
  - Monitor blood-phenylalanine concentration before and after first week of treatment—if unsatisfactory response increase dose at weekly intervals to max. dose and monitor blood-phenylalanine concentration weekly; discontinue treatment if unsatisfactory response after 1 month.
  - Monitor blood-phenylalanine and tyrosine concentrations 1–2 weeks after dose adjustment and during treatment.

#### DIRECTIONS FOR ADMINISTRATION

Tablets should be dissolved in water and taken within 20 minutes.

#### PRESCRIBING AND DISPENSING INFORMATION

Sapropterin dihydrochloride is a synthetic form of tetrahydrobiopterin.

**PATIENT AND CARER ADVICE**

Patient or carers should be given advice on how to administer sapropterin dihydrochloride dispersible tablets.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Soluble tablet**
    - **CAUTIONARY AND ADVISORY LABELS** 13, 21
    - **Kuvan (BioMarin Europe Ltd)**
    - Sapropterin dihydrochloride 100 mg Kuvan 100mg soluble tablets sugar-free | 30 tablet | £597.22

### 6 Vitamin deficiency

#### Vitamins

**Overview**

Vitamins are used for the prevention and treatment of specific deficiency states or where the diet is known to be inadequate; they may be prescribed in the NHS to prevent or treat deficiency but not as dietary supplements.

Their use as general ‘pick-me-ups’ is of unproven value and, in the case of preparations containing vitamin A or D, may actually be harmful if patients take more than the prescribed dose. The ‘fad’ for mega-vitamin therapy with water-soluble vitamins, such as ascorbic acid p. 991 and pyridoxine hydrochloride p. 988, is unscientific and can be harmful.

Dietary reference values for vitamins are available in the Department of Health publication:


**Dental patients**

It is unjustifiable to treat stomatitis or glossitis with mixtures of vitamin preparations; this delays diagnosis and correct treatment.

Most patients who develop a nutritional deficiency despite an adequate intake of vitamins have malabsorption and if
this is suspected the patient should be referred to a medical practitioner.

**Vitamin A**
Deficiency of vitamin A (retinol) p. 988 is associated with ocular defects (particularly xerophthalmia) and an increased susceptibility to infections, but deficiency is rare in the UK (even in disorders of fat absorption).

**Vitamin B group**
Deficiency of the B vitamins, other than vitamin B<sub>12</sub>, is rare in the UK and is usually treated by preparations containing thiamine (B<sub>1</sub>) p. 989, riboflavin (B<sub>2</sub>), and nicotinamide p. 1168, which is used in preference to nicotinic acid p. 194, as it does not cause vasodilatation. Other members (or substances traditionally classified as members) of the vitamin B complex such as aminobenzoic acid, biotin, choline, inositol nicotinate p. 227, and pantothenic acid or panthenol may be included in vitamin B preparations but there is no evidence of their value.

The severe deficiency states Wernicke’s encephalopathy and Korsakoff’s psychosis, especially as seen in chronic alcoholism, are best treated initially by the parenteral administration of B vitamins (Pabrinex®), followed by oral administration of thiamine in the longer term. Anaphylaxis has been reported with parenteral B vitamins.

As with other vitamins of the B group, pyridoxine hydrochloride (B<sub>6</sub>) deficiency is rare, but it may occur during isoniazid p. 554 therapy or penicillamine p. 1002 treatment in Wilson’s disease and is characterised by peripheral neuritis. High doses of pyridoxine hydrochloride are given in some metabolic disorders, such as hyperoxaluria, and it is also used in sideroblastic anaemia. There is evidence to suggest that pyridoxine hydrochloride may provide some benefit in premenstrual syndrome. It has been tried for a wide variety of other disorders, but there is little sound evidence to support the claims of efficacy.

Nicotinic acid inhibits the synthesis of cholesterol and triglyceride. Folic acid p. 937 and vitamin B<sub>12</sub> are used in the treatment of megaloblastic anaemia. Polynic acid p. 869 (available as calcium folinate) is used in association with cytotoxic therapy.

**Vitamin C**
Vitamin C (ascorbic acid) therapy is essential in scurvy, but less florid manifestations of vitamin C deficiency are commonly found, especially in the elderly.

Severe scurvy causes gingival swelling and bleeding margins as well as petechiae on the skin. This is, however, exceedingly rare and a patient with these signs is more likely to have leukaemia. Investigation should not be delayed by a trial period of vitamin treatment.

Claims that vitamin C ameliorates colds or promotes wound healing have not been proven.

**Vitamin D**
The term Vitamin D is used for a range of compounds which possess the activity of preventing or curing rickets. They include ergocalciferol (calciferol, vitamin D<sub>2</sub>) p. 994, colecalciferol (vitamin D<sub>3</sub>) p. 992, dihydrotachysterol p. 994, alfalcacidol (1α-hydroxycholecalciferol) p. 991, and calcitriol (1,25-dihydroxycholecalciferol) p. 992.

Simple vitamin D deficiency can be prevented by taking an oral supplement of ergocalciferol (calciferol, vitamin D<sub>2</sub>) or colecalciferol (vitamin D<sub>3</sub>) daily. Vitamin D deficiency can occur in people whose exposure to sunlight is limited and in those whose diet is deficient in vitamin D. In these individuals, ergocalciferol or colecalciferol daily by mouth may be given to treat vitamin D deficiency; higher doses may be necessary for severe deficiency. Patients who do not respond should be referred to a specialist.

Preparations containing colecalciferol with calcium carbonate p. 993 are available for the management of combined calcium and vitamin D deficiency, or for those at high risk of deficiency.

Vitamin D deficiency caused by intestinal malabsorption or chronic liver disease usually requires vitamin D in pharmacological doses.

Vitamin D requires hydroxylation by the kidney to its active form, therefore the hydroxylated derivatives alfalcacidol or calcitriol should be prescribed if patients with severe renal impairment require vitamin D therapy. Calcitriol is also licensed for the management of postmenopausal osteoporosis.

Paricalcitol p. 995, a synthetic vitamin D analogue, is licensed for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.

**Vitamin E**
The daily requirement of vitamin E (tocopherol) has not been well defined but is probably 3 to 15 mg daily. There is little evidence that oral supplements of vitamin E are essential in adults, even where there is fat malabsorption secondary to cholestasis. In young children with congenital cholestasis, abnormally low vitamin E concentrations may be found in association with neuromuscular abnormalities, which usually respond only to the parenteral administration of vitamin E.

Vitamin E has been tried for various other conditions but there is little scientific evidence of its value.

**Vitamin K**
Vitamin K is necessary for the production of blood clotting factors and proteins necessary for the normal calcification of bone.

Because vitamin K is fat soluble, patients with fat malabsorption, especially in biliary obstruction or hepatic disease, may become deficient. Menadiol sodium phosphate p. 996 is a water-soluble synthetic vitamin K derivative that can be given orally to prevent vitamin K deficiency in malabsorption syndromes.

Oral coumarin anticoagulants act by interfering with vitamin K metabolism in the hepatic cells and their effects can be antagonised by giving vitamin K.

**Other compounds**
Potassium aminobenzoate p. 988 has been used in the treatment of various disorders associated with excessive fibrosis such as sclerodema and Peyronie’s disease. In Peyronie’s disease there is some evidence to support efficacy in reducing progression when given early in the disease; however, there is no evidence for reversal of the condition. The therapeutic value of potassium aminobenzoate in sclerodema is doubtful.

**VITAMINS AND TRACE ELEMENTS**

**MULTIVITAMINS**

**Vitamins A and D**

**INDICATIONS AND DOSE**

**Prevention of vitamin A and D deficiency**

- **By mouth**
  - Child: 1 capsule daily, 1 capsule contains 4000 units vitamin A and 400 units (10 micrograms) vitamin D
  - Adult: (consult product literature)

**UNLICENSED USE** Not licensed in children under 6 months of age.

**SIDE-EFFECTS**

**Overdose**

Excessive ingestion Prolonged excessive ingestion of vitamins A and D can lead to hypervitaminosis.
Blood and nutrition

VITAMINS AND TRACE ELEMENTS

988 Vitamin deficiency

● INDICATIONS AND DOSE
Prevention of vitamin deficiency

» BY MOUTH

> Child 1 month-4 years: 5 drops daily, 5 drops contain vitamin A approx. 700 units, vitamin D approx. 300 units (7.5 micrograms), ascorbic acid approx. 20 mg

VITAMINS AND TRACE ELEMENTS

Potassium aminobenzoate

● INDICATIONS AND DOSE
Peyronie’s disease | Scleroderma

» BY MOUTH

> Adult: 12 g daily in divided doses, to be taken after food

VITAMINS AND TRACK ELEMENTS

Vitamin A

● INDICATIONS AND DOSE
Vitamin A deficiency

» BY MOUTH

> Child 1-11 months: 5000 units daily, to be taken with or after food, higher doses may be used initially for treatment of severe deficiency
> Child 1-17 years: 10 000 units daily, to be taken with or after food, higher doses may be used initially for treatment of severe deficiency

Pyridoxine hydrochloride

(Vitamin B₆)

● INDICATIONS AND DOSE
Deficiency states

» BY MOUTH

> Adult: 20–50 mg 1–3 times a day
> Isoniazid-induced neuropathy (prophylaxis)

» BY MOUTH

> Adult: 10–20 mg daily
> Isoniazid-induced neuropathy (treatment)

> Adult: 50 mg 3 times a day

● PRESCRIBING AND DISPENSING INFORMATION
This drug contains vitamin D; consult individual vitamin D monographs.

● MEDICINAL FORMS

Vitamins A and D (Non-proprietary)

Vitamin D 400 unit, Vitamin A 4000 unit

Capsule

Downloaded from www.medicalbr.com
Idiopathic sideroblastic anaemia
▶ BY MOUTH
▶ Adult: 100–400 mg daily in divided doses

Prevention of penicillamine-induced neuropathy in Wilson’s disease
▶ BY MOUTH
▶ Adult: 20 mg daily

Premenstrual syndrome
▶ BY MOUTH
▶ Adult: 50–100 mg daily


IMPORTANT SAFETY INFORMATION
Prolonged use of pyridoxine in a dose of 10 mg daily is considered safe but the long-term use of pyridoxine in a dose of 200 mg or more daily has been associated with neuropathy. The safety of long-term pyridoxine supplementation with doses above 10 mg daily has not been established.

SIDE-EFFECTS Sensory neuropathy (with high doses when given for extended periods)
Overdose
Overdosage induces toxic effects.

MILD DEFICIENCY
Thiamine hydrochloride 10 mg
Thiamine hydrochloride 50 mg

SEVERE DEFICIENCY
Thiamine hydrochloride 100 mg

Thiamine (Non-proprietary)
Thiamine hydrochloride 100 mg  HealthAid Vitamin B1 100mg modified-release tablets  |  90 tablet £4.18
Thiamine hydrochloride 25 mg  Vitamin B1 25mg tablets  |  100 tablet  |  no price available
Thiamine hydrochloride 50 mg  Thiamine 50mg tablets  |  28 tablet  |  £1.80–£2.00  |  100 tablet  |  £7.14 DT price = £7.14  |  100 tablet no price available DT price = £7.14
Thiamine hydrochloride 100 mg  Thiamine 100mg tablets  |  28 tablet  |  £2.50–£2.80  |  100 tablet no price available DT price = £10.00  |  100 tablet  |  £10.00 DT price = £10.00
Benerva
Thiamine hydrochloride 50 mg  Benerva 50mg tablets  |  100 tablet  |  £4.00 DT price = £7.14
Thiamine hydrochloride 100 mg  Benerva 100mg tablets  |  100 tablet  |  £6.59 DT price = £10.00
Tyvera (Auden McKenzie (Pharma Division) Ltd)
Thiamine hydrochloride 50 mg Tyvera 50mg tablets  |  100 tablet  |  £4.99 DT price = £7.14
Thiamine hydrochloride 100 mg Tyvera 100mg tablets  |  100 tablet  |  £6.99 DT price = £10.00

Thiamine (Vitamin B1)

INDICATIONS AND DOSE
Mild deficiency
▶ BY MOUTH
▶ Adult: 25–100 mg daily

Severe deficiency
▶ BY MOUTH
▶ Adult: 200–300 mg daily in divided doses

NATIONAL FUNDING/ACCESS DECISIONS
NHS restrictions Vigranon B® syrup is not prescribable under the National Health Service (NHS).

LESS SUITABLE FOR PRESCRIBING Vitamin B compound tablets, vitamin B compound strong tablets, and Vigranon B® syrup are less suitable for prescribing.

Vitamin B complex

INDICATIONS AND DOSE
Treatment of deficiency
▶ BY MOUTH USING TABLETS
▶ Adult: 1–2 tablets 3 times a day, this dose is for vitamin B compound strong tablets

Prophylaxis of deficiency
▶ BY MOUTH USING TABLETS
▶ Adult: 1–2 tablets daily, this dose is for vitamin B compound tablets
Blood and nutrition

990 Vitamin deficiency

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet
• Vitamin B complex (Non-proprietary)
  Riboflavin 1 mg, Thiamine hydrochloride 1 mg, Nicotinamide 15 mg
  Vitamin B compound tablets | 28 tablet [P] no price available
  DT price = £26.63
  Pyridoxine hydrochloride 2 mg, Riboflavin 2 mg, Thiamine hydrochloride 5 mg, Nicotinamide 20 mg
  Vitamin B compound strong tablets | 28 tablet [P] no price available | 1000 tablet no price available

Solution for injection
EXCIPIENTS: May contain Benzyl alcohol
• Pabrinex Intramuscular High Potency (Kyowa Kirin Ltd)
  Pabrinex Intramuscular High Potency solution for injection 5ml and 2ml ampoules | 20 ampoule [POM] £22.53 DT price = £22.53
• Pabrinex Intravenous High Potency (Kyowa Kirin Ltd)
  Pabrinex Intravenous High Potency solution for injection 5ml and 2ml ampoules | 12 ampoule [POM] £16.23 | 20 ampoule [POM] £22.53 DT price = £22.53

VITAMINS WITH MINERALS AND TRACE ELEMENTS

INDICATIONS AND DOSE
FORCEVAL® CAPSULES
Vitamin and mineral deficiency and as adjunct in synthetic diets
• BY MOUTH
  • Adult: 1 capsule daily, one hour after a meal
KETOVITE® LIQUID
Prevention of vitamin deficiency in disorders of carbohydrate or amino-acid metabolism | Adjunct in restricted, specialised, or synthetic diets
• BY MOUTH
  • Adult: 5 mL daily, use with Ketovite® Tablets for complete vitamin supplementation.
KETOVITE® TABLETS
Prevention of vitamin deficiency in disorders of carbohydrate or amino-acid metabolism | Adjunct in restricted, specialised, or synthetic diets
• BY MOUTH
  • Adult: 1 tablet 3 times a day, use with Ketovite® Liquid for complete vitamin supplementation.

INTEGRATIVE AND DISPENSING INFORMATION
To avoid potential toxicity, the content of all vitamin preparations, particularly vitamin A, should be considered when used together with other supplements.

PATIENT AND CARER ADVICE
KETOVITE® LIQUID Ketovite® liquid may be mixed with milk, cereal, or fruit juice.
KETOVITE® TABLETS Tablets may be crushed immediately before use.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Oral emulsion
• Vitamins with minerals and trace elements (Non-proprietary)
  Cyanocobalamin 2.5 microgram per 1 ml, Choline chloride 30 mg per 1 ml, Ergocalciferol 80 unit per 1 ml, Vitamin A 500 unit per 1 ml
  Ketovite liquid sugar-free | 150 ml [P] £19.10

Tablet
• Ketovite (Essential Pharmaceuticals Ltd)
  Cyanocobalamin 3 microgram, Selenium 50 microgram, Biotin 100 microgram, Iodine 140 microgram, Chromium 200 microgram, Molybdenum 250 microgram, Folic acid 400 microgram, Thiamine 1.2 mg, Riboflavin 1.6 mg, Copper 2 mg, Pyridoxine 2 mg, Manganese 3 mg, Pantothenic acid 4 mg, Potassium 4 mg, Tocopherol acetate 10 mg, Iron 12 mg,
VITAMINS AND TRACE ELEMENTS

Ascorbic acid
(Vitamin C)

• INDICATIONS AND DOSE
  Prevention of scurvy
    ▶ BY MOUTH
    ▶ Adult: 25–75 mg daily
  Treatment of scurvy
    ▶ BY MOUTH
    ▶ Adult: Not less than 250 mg daily in divided doses

• INTERACTIONS → Appendix 1: ascorbic acid

• PRESCRIBING AND DISPENSING INFORMATION
  It is rarely necessary to prescribe more than 100 mg daily except early in the treatment of scurvy.

• MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, solution for infusion

  Tablet
  EXCIPIENTS: May contain Aspartame
    ▶ Ascorbic acid (Non-proprietary)
    Ascorbic acid 50 mg Ascorbic acid 50mg tablets | 28 tablet GSE
    Ascorbic acid 100 mg Ascorbic acid 100mg tablets | 28 tablet GSE
    Ascorbic acid 200 mg Ascorbic acid 200mg tablets | 28 tablet no price available DT price = £13.86 | 28 tablet GSE £19.86 DT price = £19.86 | 100 tablet GSE no price available
    Ascorbic acid 250 mg Ascorbic acid 250mg tablets | 1000 tablet DRT no price available
    Ascorbic acid 500 mg Ascorbic acid 500mg tablets | 28 tablet GSE £26.87 DT price = £26.87 | 100 tablet GSE no price available

  Chewable tablet
  CAUTIONARY AND ADVISORY LABELS 24
  EXCIPIENTS: May contain Aspartame
    ▶ Ascorbic acid (Non-proprietary)
    Ascorbic acid 60 mg Vitamin C 60mg chewable tablets | 60 tablet no price available | 180 tablet no price available
    Ascorbic acid 500 mg Numark Vitamin C 500mg chewable tablets | 25 tablet £0.90 | 60 tablet £3.90 | 100 tablet £5.58
    Ascorbic acid 1 gram Vitamin C 1000mg chewable tablets | 30 tablet £2.35 | 60 tablet £4.29

  ➤ Ascur (Ennogen Healthcare Ltd)
    Ascorbic acid 100 mg Ascur 100mg chewable tablets | 30 tablet £3.95
    Ascorbic acid (as Sodium ascorbate) 500 mg Ascur 500mg chewable tablets sugar-free | 30 tablet £2.99

  Capsule
    ▶ Ascorbic acid (Non-proprietary)
    Ascorbic acid 500 mg Vitamin C 500mg capsules | 100 capsule no price available
    Ascorbic acid 1 gram Vitamin C 1000mg capsules | 100 capsule no price available | 250 capsule no price available

  Combinations available: Vitamin B substances with ascorbic acid, p. 990. Vitamins A, C and D, p. 988

VITAMINS AND TRACE ELEMENTS → VITAMIN D AND ANALOGUES

Vitamin D and analogues (systemic)

• CONTRA-INDICATIONS
  Hypercalcaemia - metastatic calcification

• SIDE-EFFECTS
  Overdose Symptoms of overdosage include anorexia, lasitude, nausea and vomiting, diarrhoea, constipation, weight loss, polyuria, sweating, headache, thirst, vertigo, and raised concentrations of calcium and phosphate in plasma and urine.
  Pregnancy High doses teratogenic in animals but therapeutic doses unlikely to be harmful.
  Breastfeeding Caution with high doses; may cause hypercalcaemia in infant – monitor serum-calcium concentration.

• MONITORING REQUIREMENTS
  Important: All patients receiving pharmacological doses of vitamin D should have their plasma-calcium concentration checked at intervals (initially once or twice weekly) and whenever nausea or vomiting occur.

Alfacalcidol
(1α-Hydroxycholecalciferol)

• INDICATIONS AND DOSE
  Patients with severe renal impairment requiring vitamin D therapy
    ▶ BY MOUTH, OR BY INTRAVENOUS INJECTION
    ▶ Adult: Initially 1 microgram daily, dose to be adjusted to avoid hypercalcaemia; maintenance 0.25–1 microgram daily
    ▶ Elderly: Initially 500 nanograms daily, dose adjusted to avoid hypercalcaemia; maintenance 0.25–1 microgram daily

  Hypophosphataemic rickets | Persistent hypocalcaemia due to hypoparathyroidism or pseudohypoparathyroidism
    ▶ BY MOUTH, OR BY INTRAVENOUS INJECTION
    ▶ Child 1–17 years: 1 microgram once daily, dose to be adjusted as necessary

  Prevention of vitamin D deficiency in renal or cholestatic liver disease
    ▶ BY MOUTH, OR BY INTRAVENOUS INJECTION
    ▶ Child 1 month–11 years: 25–50 nanograms/kg once daily, dose to be adjusted as necessary, maximum 1 microgram per day
    ▶ Child 12–17 years: 1 microgram once daily, dose to be adjusted as necessary

• DOSE EQUIVALENCE AND CONVERSION
  One drop of alfacalcidol 2 microgram/mL oral drops contains approximately 100 nanograms alfacalcidol.

• CAUTIONS
  Nephrolithiasis - take care to ensure correct dose in infants
  INTERACTIONS → Appendix 1: vitamin D substances
  SIDE-EFFECTS
  Rare Nephrocalcinosis - pruritus - rash - urticaria
RENAL IMPAIRMENT Monitor plasma-calcium concentration in renal impairment.

MONITORING REQUIREMENTS Monitor plasma-calcium concentration in patients receiving high doses.

DIRECTIONS FOR ADMINISTRATION For injection, shake ampoule for at least 5 seconds before use, and give over 30 seconds.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Capsule

Calcitriol (Non-proprietary)
Calcitriol 250 nanogram Calcitriol 250nanogram capsules | 30 capsule (Posm) £18.04 | 100 capsule (Posm) no price available DT price = £18.04
Calcitriol 500 nanogram Calcitriol 500nanogram capsules | 30 capsule (Posm) £32.25 | 100 capsule (Posm) no price available DT price = £32.25

Rocaltrol (Roche Products Ltd)
Calcitriol 250 nanogram Rocaltrol 250nanogram capsules | 100 capsule (Posm) £18.04 DT price = £18.04
Calcitriol 500 nanogram Rocaltrol 500nanogram capsules | 100 capsule (Posm) £32.25 DT price = £32.25

Colecalciferol (Cholecalciferol; Vitamin D₃)

INDICATIONS AND DOSE

Prevention of vitamin D deficiency
 BY MOUTH
 Adult: 400 units daily

Treatment of vitamin D deficiency
 BY MOUTH
 Adult: 800 units daily, higher doses may be necessary for severe deficiency

INTERACTIONS → Appendix 1: vitamin D substances

RENAL IMPAIRMENT Monitor plasma-calcium concentration in renal impairment.

MONITORING REQUIREMENTS Monitor plasma-calcium concentration in patients receiving high doses.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, capsule, oral suspension, oral solution, oral drops

Tablet

Colecalciferol (Non-proprietary)
Colecalciferol 400 unit Colecalciferol 400unit tablets | 30 tablet no price available | 60 tablet £15.50
Colecalciferol 800 unit Colecalciferol 800unit tablets | 30 tablet (Posm) £3.60–£4.32 DT price = £3.60
Colecalciferol 1000 unit Colecalciferol 1000unit tablets | 28 tablet £2.85–£2.95 DT price = £2.95 | 30 tablet no price available | 90 tablet £34.50 | 180 tablet no price available
Colecalciferol 5000 unit Vitamin D3 5,000unit tablets | 100 tablet £3.90
Colecalciferol 10000 unit Colecalciferol 10,000unit tablets | 30 tablet £36.00
Colecalciferol 20000 unit Colecalciferol 20,000unit tablets | 20 tablet £36.00 | 30 tablet no price available
Colecalciferol 50000 unit Vitamin D3 50,000unit tablets | 30 tablet £16.74

Desunin (Meda Pharmaceuticals Ltd)
Colecalciferol 500 unit Desunin 500unit tablets | 30 tablet (Posm) £3.60 DT price = £3.60 | 90 tablet (Posm) £10.17
Colecalciferol 4000 unit Desunin 4,000unit tablets | 70 tablet (Posm) £15.90 DT price = £15.90

Stexerol-D3 (Kyowa Kirin Ltd)
Colecalciferol 1000 unit Stexerol-D3 1,000unit tablets | 28 tablet (Posm) £2.95 DT price = £2.95
Colecalciferol 25000 unit Stexerol-D3 25,000unit tablets | 12 tablet (Posm) £17.00 DT price = £17.00

Calcitriol (1,25-Dihydroxycholecalciferol)

INDICATIONS AND DOSE

Renal osteodystrophy
 BY MOUTH
 Adult: Initially 250 nanograms daily, adjusted in steps of 250 nanograms every 2–4 weeks if required; usual dose 0.5–1 microgram daily

Renal osteodystrophy (in patients with normal or only slightly reduced plasma-calcium concentration)
 BY MOUTH
 Adult: Initially 250 nanograms once daily on alternate days, adjusted in steps of 250 nanograms every 2–4 weeks if required; usual dose 0.5–1 microgram daily

Established postmenopausal osteoporosis
 BY MOUTH
 Adult: 250 nanograms twice daily, plasma-calcium concentration and creatinine to be monitored (consult product literature)

INTERACTIONS → Appendix 1: vitamin D substances

HEPATIC IMPAIRMENT Manufacturer advises avoid—no information available.

RENAL IMPAIRMENT Manufacturer advises avoid—no information available. Monitor plasma-calcium concentration in renal impairment.

MONITORING REQUIREMENTS
Monitor plasma calcium, phosphate, and creatinine during dosage titration.
Monitor plasma-calcium concentration in patients receiving high doses.
Oral drops

- **Colecalciferol (Non-proprietary)**
  - Colecalciferol 200 unit per 1 drop: Vitamin D 200 units/drop for infants and children oral drops sugar-free | 50 ml £3.86
  - Colecalciferol 2500 unit per 1 drop: Vitamin D 2,500 units/drop oral drops sugar-free | 50 ml £6.64

- **Fultium-D** (Internis Pharmaceuticals Ltd)
  - Colecalciferol 2740 unit per 1 ml Fultium-D 2,740 units/ml oral drops sugar-free | 25 ml | £10.70 DT price = £10.70

- **InVita D** (Consilient Health Ltd)
  - Colecalciferol 2400 unit per 1 ml InVita D 2,400 units/ml oral drops sugar-free | 10 ml | £3.60

- **Thorens** (Galen Ltd)
  - Colecalciferol 10000 unit per 1 ml Thorens 10,000 units/ml oral drops sugar-free | 10 ml | £5.85 DT price = £5.85

**Oral solution**

**CAUTIONARY AND ADVISORY LABELS**

- **Colecalciferol (Non-proprietary)**
  - Colecalciferol 3000 unit per ml: Colecalciferol 3,000 units/ml oral solution | 100 ml | £4.40 DT price = £4.40
  - Colecalciferol 10000 unit per ml: ZymaD 10,000 units/ml oral solution | 10 ml | no price available

- **InVita D** (Consilient Health Ltd)
  - Colecalciferol 25000 unit per 1 ml: InVita D 25,000 units/1ml oral solution sugar-free | 3 ampoule | £4.45 DT price = £4.45
  - Colecalciferol 50000 unit per 1 ml: InVita D 50,000 units/1ml oral solution sugar-free | 3 ampoule | £6.25 DT price = £6.25

- **Thorens** (Galen Ltd)
  - Colecalciferol 10000 unit per 1 ml Thorens 25,000 units/2.5ml oral solution sugar-free | 2.5 ml | £1.55 DT price = £1.55 sugar-free | 10 ml | £5.85 DT price = £5.85

**Chewable tablet**

- **Colecalciferol (Non-proprietary)**
  - Colecalciferol 1000 unit: Vitamin D 1,000 unit chewable tablets | 100 tablet no price available

**Capsule**

**CAUTIONARY AND ADVISORY LABELS**

- **Colecalciferol (Non-proprietary)**
  - Colecalciferol 500U capsules: 90 capsule | £3.50
  - Colecalciferol 600 unit: Colecalciferol 600 unit capsules | 30 capsule no price available
  - Colecalciferol 800 unit: Colecalciferol 800 unit capsules | 30 capsule £3.60 DT price = £3.60
  - Colecalciferol 1000 unit: Colecalciferol 1,000 unit capsules | 28 capsule £2.05–£3.50 | 30 capsule £2.95 DT price = £2.34
  - Colecalciferol 2200 unit: Colecalciferol 2,200 unit capsules | 30 capsule no price available
  - Colecalciferol 2500 unit: Colecalciferol 2,500 unit capsules | 30 capsule no price available
  - Colecalciferol 3000 unit: Colecalciferol 3,000 unit capsules | 30 capsule no price available
  - Colecalciferol 4000 unit: Colecalciferol 4,000 unit capsules | 120 capsule | £6.11
  - Colecalciferol 5000 unit: Colecalciferol 5,000 unit capsules | 100 capsule | no price available
  - Colecalciferol 5600 unit: InVita D 5,600 unit capsules | 4 capsule | £2.50
  - Colecalciferol 10000 unit: InVita D 10,000 unit capsules | 30 capsule no price available
  - Colecalciferol 20000 unit: Colecalciferol 20,000 unit capsules | 20 capsule £3.75 | 30 capsule £3.95 DT price = £29.00 | 30 capsule | £20.00 DT price = £20.00
  - Colecalciferol 25000 unit: InVita D 25,000 unit capsules | 3 capsule | £3.95
  - Colecalciferol 30000 unit: Colecalciferol 30,000 unit capsules | 10 capsule no price available
  - Colecalciferol 50000 unit: Colecalciferol 50,000 unit capsules | 10 capsule £3.60 | 100 capsule | no price available

- **Aviticol** (Colonis Pharma Ltd)
  - Colecalciferol 800 unit: Aviticol 800 unit capsules | 30 capsule | £2.22 DT price = £3.60
  - Colecalciferol 1000 unit: Aviticol 1,000 unit capsules | 30 capsule | £2.34 DT price = £2.34
  - Colecalciferol 2000 unit: Aviticol 2,000 unit capsules | 30 capsule | £2.00 DT price = £2.00

- **Fultium-D** (Internis Pharmaceuticals Ltd)
  - Colecalciferol 800 unit: Fultium-D 800 unit capsules | 30 capsule | £3.60 DT price = £3.60 | 90 capsule | £8.85

### Colecalciferol with calcium carbonate

The properties listed below are those particular to the combination only. For the properties of the components please consider, colecalciferol p. 992, calcium carbonate p. 958.

- **INDICATIONS AND DOSE**
  - Prevention and treatment of vitamin D and calcium deficiency
    - **BY MOUTH**
    - **Adult:** Dosed according to the deficit or daily maintenance requirements (consult product literature)

- **INTERACTIONS**
  - Appendix 1: calcium salts, vitamin D substances

- **PRESCRIBING AND DISPENSING INFORMATION**
  - **Accrete D³** contains calcium carbonate 1.5 g (calcium 600 mg or Ca²⁺ 15 mmol), colecalciferol 10 micrograms (400 units); **Adcal-D³** tablets contain calcium carbonate 1.5 g (calcium 600 mg or Ca²⁺ 15 mmol), colecalciferol 10 micrograms (400 units); **Calcium D³** contains calcium carbonate 1.25 g (calcium 500 mg or Ca²⁺ 12.5 mmol), colecalciferol 11 micrograms (440 units)/sachet; **Calcexos** contains calcium carbonate 1.25 g (calcium 500 mg or Ca²⁺ 12.5 mmol), colecalciferol 10 micrograms (400 units); **Calcichew-D³** tablets contain calcium carbonate 1.25 g (calcium 500 mg or Ca²⁺ 12.5 mmol), colecalciferol 5 micrograms (200 units); **Calcichew-D³ Forte** tablets contain calcium carbonate 1.25 g (calcium 500 mg or Ca²⁺ 12.5 mmol), colecalciferol 10 micrograms (400 units); **Calcichew-D³** 500 mg 400 unit caplets contain calcium carbonate (calcium 500 mg or Ca²⁺ 12.5 mmol), colecalciferol 10 micrograms (400 units); **Calcichew-D³** contains calcium carbonate (calcium 500 mg or Ca²⁺ 12.5 mmol), colecalciferol 10 micrograms (800 units); **Natecal D³** contains calcium carbonate 1.5 g (calcium 600 mg or Ca²⁺ 15 mmol), colecalciferol 10 micrograms (400 units); consult product literature for details of other available products.

  Flavours of chewable and soluble forms may include orange, lemon, aniseed, peppermint, molasses, or tutti-frutti.
Blood and nutrition

**994  Vitamin deficiency**

- **MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Effervescent granules**

*CAUTIONARY AND ADVISORY LABELS 13*

- **Colecalciferol with calcium carbonate (Non-proprietary)**

  Calcium carbonate 2.5 g, Colecalciferol 880 unit

  - **Natecal D** (Teva UK Ltd)
  - **Calcichew D** (Teva UK Ltd)
  - **Evacal D** (Teva UK Ltd)
  - **Calcichew D forte** (Teva UK Ltd)

  Effervescent granules sachets | 24 sachet pack | price £2.95

**Effervescent tablet**

*CAUTIONARY AND ADVISORY LABELS 13*

- **Adcal-D** (Kyowa Kirin Ltd)

  - **Evacal D forte** (Teva UK Ltd)

  Effervescent tablet | 56 tablet pack | price £15.99

**Chewable tablet**

*CAUTIONARY AND ADVISORY LABELS 24*

- **Colecalciferol with calcium carbonate (Non-proprietary)**

  Calcium carbonate 2.5 g, Colecalciferol 400 unit

  - **Natecal D** (Teva UK Ltd)
  - **Calcichew D forte** (Teva UK Ltd)

  Chewable tablets | 30 tablet pack | price £4.21

**Dihydrotachysterol**

- **INDICATIONS AND DOSE**

  Acute, chronic, and latent forms of hypocalcaemia tetany due to hypoparathyroidism

  - **BY MOUTH**
  - **Adult:** consult product literature

- **INTERACTIONS** → Appendix 1: vitamin D substances

**Ergocalciferol**

(Calciferol; Vitamin D₂)

- **INDICATIONS AND DOSE**

  Vitamin D deficiency caused by intestinal malabsorption or chronic liver disease

  - **BY MOUTH**
  - **Adult:** Up to 40 000 units daily

**Colecalciferol with calcium phosphate**

The properties listed below are those particular to the combination only. For the properties of the components please consider, colecalficferol p. 992, calcium phosphate p. 959.

- **INDICATIONS AND DOSE**

  Calcium and vitamin D deficiency

  - **BY MOUTH**
  - **Adult:** consult product literature

- **INTERACTIONS** → Appendix 1: calcium salts, vitamin D substances

**Dihydrotachysterol**

- **INDICATIONS AND DOSE**

  Acute, chronic, and latent forms of hypocalcaemia tetany due to hypoparathyroidism

  - **BY MOUTH**
  - **Adult:** consult product literature

- **INTERACTIONS** → Appendix 1: vitamin D substances

**ERGOCALCIFEROL**

(Calciferol; Vitamin D₂)

- **INDICATIONS AND DOSE**

  Vitamin D deficiency caused by intestinal malabsorption or chronic liver disease

  - **BY MOUTH**
  - **Adult:** Up to 40 000 units daily

**Hypocalcaemia of hypoparathyroidism to achieve normocalcaemia**

- **BY MOUTH**
  - **Adult:** Up to 100 000 units daily

**Prevention of vitamin D deficiency**

- **BY MOUTH**
  - **Adult:** 400 units daily

**Treatment of vitamin D deficiency**

- **BY MOUTH**
  - **Adult:** 800 units daily, higher doses may be necessary for severe deficiency

---

**Blood and nutrition**

**994  Vitamin deficiency**

- **MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Effervescent granules**

*CAUTIONARY AND ADVISORY LABELS 13*

- **Colecalciferol with calcium carbonate (Non-proprietary)**

  Calcium carbonate 2.5 g, Colecalciferol 880 unit

  - **Natecal D** (Teva UK Ltd)
  - **Calcichew D** (Teva UK Ltd)
  - **Evacal D** (Teva UK Ltd)

  Effervescent granules sachets | 24 sachet pack | price £2.95

**Effervescent tablet**

*CAUTIONARY AND ADVISORY LABELS 13*

- **Adcal-D** (Kyowa Kirin Ltd)

  - **Evacal D forte** (Teva UK Ltd)

  Effervescent tablet | 56 tablet pack | price £15.99

**Chewable tablet**

*CAUTIONARY AND ADVISORY LABELS 24*

- **Colecalciferol with calcium carbonate (Non-proprietary)**

  Calcium carbonate 2.5 g, Colecalciferol 400 unit

  - **Natecal D** (Teva UK Ltd)
  - **Calcichew D forte** (Teva UK Ltd)

  Chewable tablets | 30 tablet pack | price £4.21

**Dihydrotachysterol**

- **INDICATIONS AND DOSE**

  Acute, chronic, and latent forms of hypocalcaemia tetany due to hypoparathyroidism

  - **BY MOUTH**
  - **Adult:** consult product literature

- **INTERACTIONS** → Appendix 1: vitamin D substances

**Ergocalciferol**

(Calciferol; Vitamin D₂)

- **INDICATIONS AND DOSE**

  Vitamin D deficiency caused by intestinal malabsorption or chronic liver disease

  - **BY MOUTH**
  - **Adult:** Up to 40 000 units daily

**Hypocalcaemia of hypoparathyroidism to achieve normocalcaemia**

- **BY MOUTH**
  - **Adult:** Up to 100 000 units daily

**Prevention of vitamin D deficiency**

- **BY MOUTH**
  - **Adult:** 400 units daily

**Treatment of vitamin D deficiency**

- **BY MOUTH**
  - **Adult:** 800 units daily, higher doses may be necessary for severe deficiency
**INTERACTIONS**  ➔ Appendix 1: vitamin D substances

**RENAL IMPAIRMENT**  Monitor plasma-calcium concentration in renal impairment.

**MONITORING REQUIREMENTS**  Monitor plasma-calcium concentration in patients receiving high doses.

**PRESCRIBING AND DISPENSING INFORMATION**  The BP directs that when calciferol is prescribed or demanded, colecalfol or ergocalciferol should be dispensed or supplied.

When the strength of the tablets ordered or prescribed is not clear, the intention of the prescriber with respect to the strength (expressed in micrograms or milligrams per tablet) should be ascertained.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, oral suspension, oral solution

**Tablet**
- Ergocalciferol (Non-proprietary)
  - Ergocalciferol 12.5 microgram: Ergocalciferol 12.5 microgram tablets | 30 tablet no price available
  - Ergoral (Cubic Pharmaceuticals Ltd)
    - Ergocalciferol 125 microgram: Ergoral D 5,000 unit tablets | 30 tablet £19.95
    - Ergocalciferol 250 microgram: Ergoral D 10,000 unit tablets | 30 tablet £23.95

**Oral solution**
- Ecfiferol (Rhodes Pharma Ltd)
  - Ergocalciferol 3000 unit per 1 ml: Ecfiferol D2 3,000 units/ml liquid | 60 ml £55.00 DT price = £102.44

**Capsule**
- Ergocalciferol (Non-proprietary)
  - Ergocalciferol 1.25 mg: Ergocalciferol 1.25 mg capsules | 30 capsule no price available | 50 capsule £230.00
  - Ecfiferol (Rhodes Pharma Ltd)
    - Ergocalciferol 1.25 mg: Ecfiferol D2 50,000 unit capsules | 10 capsule £29.99
  - Ergoral (Cubic Pharmaceuticals Ltd)
    - Ergocalciferol 1.25 mg: Ergoral D2 50,000 unit capsules | 10 capsule £19.95

### Ergocalciferol with calcium lactate and calcium phosphate

*(Calcium and vitamin D)*

The properties listed below are those particular to the combination only. For the properties of the components please consider, ergocalciferol p. 994, calcium lactate p. 959.

**INDICATIONS AND DOSE**

- Prevention of calcium and vitamin D deficiency
- Treatment of calcium and vitamin D deficiency
  - BY MOUTH
  - Adult: (consult product literature)

**INTERACTIONS**  ➔ Appendix 1: calcium salts, vitamin D substances

**DIRECTIONS FOR ADMINISTRATION**  Tablets may be crushed before administration, or may be chewed.

**PRESCRIBING AND DISPENSING INFORMATION**  Each tablet contains calcium lactate 300 mg, calcium phosphate 150 mg (calcium 97 mg or Ca²⁺ 2.4 mmol), ergocalciferol 10 micrograms (400 units).

**PATIENT AND CARER ADVICE**  Patient or carers should be given advice on how to administer calcium and ergocalciferol tablets.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- Ergocalciferol with calcium lactate and calcium phosphate (Non-proprietary)
  - Ergocalciferol 10 microgram, Calcium phosphate 150 mg, Calcium lactate 300 mg: Calcium and Ergocalciferol tablets | 28 tablet (£18.50 DT price = £18.26 | 28 tablet no price available DT price = £18.26 | 500 tablet DT no price available

---

**Paricalcitol**

**INDICATIONS AND DOSE**

For prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure

- BY MOUTH
- Adult: (consult product literature)

For prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure in patients on haemodialysis

- Adult: To be administered via haemodialysis access (consult product literature)

**INTERACTIONS**  ➔ Appendix 1: vitamin D substances

**SIDE-EFFECTS**  Acne · breast tenderness · dyspepsia · pruritus · rash · taste disturbance

**PREGNANCY**  Toxicity in animal studies—manufacturer advises avoid unless potential benefit outweighs risk.

**BREAST FEEDING**  Manufacturer advises caution—no information available.

**MONITORING REQUIREMENTS**

- Monitor plasma calcium and phosphate during dose titration and at least monthly when stabilised.
- Monitor parathyroid hormone concentration.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for Injection**

EXCIPIENTS: May contain Propylene glycol
- Zemplar (AbbVie Ltd)
  - Paricalcitol 5 microgram per 1 ml: Zemplar 5 microgram capsules/1ml solution for injection ampoules | 5 ampoule | £62.00 (Hospital only)
  - Zemplar 5 microgram/1ml solution for injection vials | 5 vial | £62.00 (Hospital only)

**Capsule**
- Zemplar (AbbVie Ltd)
  - Paricalcitol 1 microgram: Zemplar 1 microgram capsules | 28 capsule | £69.44
  - Paricalcitol 2 microgram: Zemplar 2 microgram capsules | 28 capsule | £138.88

**VITAMINS AND TRACE ELEMENTS ➔ VITAMIN E**

**Alpha tocopherol**

*(Tocopherol)*

**INDICATIONS AND DOSE**

Vitamin E deficiency because of malabsorption in congenital or hereditary chronic cholestasis

- BY MOUTH USING ORAL SOLUTION
  - Child: 17 mg/kg daily, dose to be adjusted as necessary

**CAUTIONS**  Predisposition to thrombosis

**INTERACTIONS**  ➔ Appendix 1: vitamin E substances

**SIDE-EFFECTS**  Common or very common: Diarrhoea
Uncommon Alopecia · asthenia · disturbances in serum-potassium concentration · disturbances in serum-sodium concentration · headache · pruritus · rash

PREGNANCY Manufacturer advises caution, no evidence of harm in animal studies.

BREAST FEEDING Manufacturer advises use only if potential benefit outweighs risk—no information available.

HEPATIC IMPAIRMENT Manufacturer advises caution—no information available. Manufacturer advises monitor closely in hepatic impairment.

RENAL IMPAIRMENT Manufacturer advises caution. Risk of renal toxicity due to polyethylene glycol content. Manufacturer advises monitor closely in renal impairment.

PREGNANCY There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: chewable tablet

Oral suspension EXCipients: May contain Sucrose

Alpha tocopheryl acetate (Non-proprietary) Alpha tocopheryl acetate 100 mg per 1 ml Alpha tocopheryl acetate 500mg/5ml oral suspension | 100 ml GSK £58.85 DT price = £58.85

Chewable tablet

Alpha tocopheryl acetate (Non-proprietary) Alpha tocopheryl acetate 100 mg Alpha tocopheryl acetate 100mg chewable tablets | 30 tablet no price available

E-Tabs (Ennogen Healthcare Ltd) Alpha tocopheryl acetate 100 mg E-Tabs 100mg chewable tablets | 30 tablet no price available

Capsule

Alpha tocopheryl acetate (Non-proprietary) Alpha tocopherol 100 unit capsules | 30 capsule £0.77 Alpha tocopherol 200 unit capsules | 100 capsule £6.60 Alpha tocopherol 250 unit capsules | 100 capsule £7.23

Alpha tocopherol 400 unit capsules | 30 capsule £8.37 | 60 capsule £13.95

Alpha tocopherol 600 unit capsules | 30 capsule £11.72

Alpha tocopherol 1000 unit capsules | 30 capsule £6.64

E-Caps (Ennogen Healthcare Ltd) Alpha tocopherol 75 unit capsules | 100 capsule £0.44

Alpha tocopherol 100 unit capsules | 30 capsule £0.44

Alpha tocopherol 200 unit capsules | 30 capsule £0.44

Alpha tocopherol 400 unit capsules | 30 capsule £0.44

Alpha tocopherol 600 unit capsules | 30 capsule £0.44

Alpha tocopherol 1000 unit capsules | 30 capsule £0.44

Vita-E (Typharm Ltd) Vita-E 75 unit capsules | 100 capsule £1.04

Vita-E 100 unit capsules | 100 capsule £1.04

Vita-E 200 unit capsules | 30 capsule £1.04

Vita-E 400 unit capsules | 30 capsule £1.04

Vita-E 800 unit capsules | 30 capsule £1.04

Vita-E 1000 unit capsules | 30 capsule £1.04

VITAMINS AND TRACE ELEMENTS Vitamin K

Menadiol sodium phosphate

INDICATIONS AND DOSE Prevention of Vitamin K deficiency in malabsorption syndromes

BY MOUTH

Adult: 10–40 mg daily, dose to be adjusted as necessary

CAUTIONS G6PD deficiency (risk of haemolysis) · vitamin E deficiency (risk of haemolysis)

PREGNANCY Avoid in late pregnancy and labour unless benefit outweighs risk of neonatal haemolytic anaemia, hyperbilirubinaemia, and kernicterus in neonate.
**Phytomenadione**

*(Vitamin K₁)*

**INDICATIONS AND DOSE**

- **Major bleeding in patients on warfarin (in combination with dried prothrombin complex or fresh frozen plasma)**
  - **By Slow Intravenous Injection**
  - Adult: 5 mg for 1 dose, stop warfarin treatment
  - INR > 8.0 with minor bleeding in patients on warfarin
    - **By Slow Intravenous Injection**
    - Adult: 1–3 mg, stop warfarin treatment, dose may be repeated if INR still too high after 24 hours, restart warfarin treatment when INR < 5
  - INR > 8.0 with no bleeding in patients on warfarin
    - **By Mouth**
    - Adult: 1–5 mg, intravenous preparation to be used orally, stop warfarin treatment, repeat dose if INR still too high after 24 hours, restart warfarin treatment when INR < 5
  - INR 5.0–8.0 with minor bleeding in patients on warfarin
    - **By Slow Intravenous Injection**
    - Adult: 1–3 mg, stop warfarin treatment, restart warfarin treatment when INR < 5
  - Reversal of anticoagulation prior to elective surgery (after warfarin stopped)
    - **By Mouth**
    - Adult: 1–5 mg, intravenous preparation to be used orally, dose to be given the day before surgery if INR ≥ 1.5
  - Reversal of anticoagulation prior to emergency surgery (when surgery can be delayed 6–12 hours)
    - **By Intravenous Injection**
    - Adult: 5 mg as a single dose, if surgery cannot be delayed, dried prothrombin complex can be given in addition to phytomenadione and the INR checked before surgery

**UNLICENSED USE** Oral use of intravenous preparations is unlicensed.

**CAUTIONS** Intravenous injections should be given very slowly—risk of vascular collapse

KONAKION® MM Reduce dose in elderly

**SIDE-EFFECTS**

KONAKION® MM Anaphylactoid reactions

**PREGNANCY** Use if potential benefit outweighs risk.

**BREAST FEEDING** Present in milk.

**HEPATIC IMPAIRMENT**

KONAKION® MM Caution—glycocholic acid may displace bilirubin.

**DIRECTIONS FOR ADMINISTRATION**

KONAKION® MM Paediatric Konakion® MM Paediatric may be administered by mouth or by intramuscular injection or by intravenous injection. For intravenous injection, may be diluted with Glucose 5%; may be injected into lower part of infusion apparatus.

**MEDICINAL FORMS**

- Konakion MM (Roche Products Ltd)
- Phytomenadione 10 mg per 1 ml Konakion MM Paediatric 2 mg/0.2 ml solution for injection ampoules 5 ampoule (Paediatric) £4.71
- Konakion MM 10 mg/1 ml solution for injection ampoules 10 ampoule (Paediatric) £3.78 DT price = £3.78

---

**6.1 Neural tube defects (prevention in pregnancy)**

**Neural tube defects (prevention in pregnancy)**

**Prevention in pregnancy**

Folic acid supplements p. 937 taken before and during pregnancy can reduce the occurrence of neural tube defects. The risk of a neural tube defect occurring in a child should be assessed and folic acid given as follows:

- Women at a low risk of conceiving a child with a neural tube defect should be advised to take folic acid as a medicinal or food supplement daily (at low-risk group dose) before conception and until week 12 of pregnancy. Women who have not been taking folic acid and who suspect they are pregnant should start at once and continue until week 12 of pregnancy.
- Couples are at a high risk of conceiving a child with a neural tube defect if either partner has a neural tube defect (or either partner has a family history of neural tube defects), if they have had a previous pregnancy affected by a neural tube defect, or if the woman has coeliac disease (or other malabsorption state), diabetes mellitus, sickle-cell anaemia, or is taking antiepileptic medicines.
- Women in the high-risk group who wish to become pregnant (or who are at risk of becoming pregnant) should be advised to take folic acid daily (at high-risk group dose) and continue until week 12 of pregnancy (women with sickle-cell disease should continue taking their normal dose of folic acid (or to increase the dose to high-risk group daily dose) and continue this throughout pregnancy).

There is no justification for prescribing multiple-ingredient vitamin preparations containing vitamin B₁₂ or folic acid.
Chapter 10
Musculoskeletal system

CONTENTS

1 Arthritis
  page 998
2 Hyperuricaemia and gout
  1019
3 Neuromuscular disorders
  1022
  3.1 Muscular dystrophy
  1024
  3.2 Myasthenia gravis and Lambert-Eaton myasthenic syndrome
  1024
  3.3 Nocturnal leg cramps
  1025
3.4 Spasticity
  1026
4 Pain and inflammation in musculoskeletal disorders
  1028
5 Soft tissue and joint disorders
  1053
  5.1 Local inflammation of joints and soft tissue
  1053
  5.2 Soft tissue disorders
  1055

1 Arthritis

Arthritis

Rheumatoid arthritis and other inflammatory disorders

A non-steroidal anti-inflammatory drug (NSAID) is indicated for pain and stiffness resulting from inflammatory rheumatic disease; analgesics such as paracetamol p. 422 or codeine phosphate p. 431 can also be used.

Drugs are also used to influence the rheumatic disease process itself. For *rheumatoid arthritis* these disease-modifying antirheumatic drugs (DMARDs) include methotrexate p. 844, cytokine modulators, azathioprine p. 787, ciclosporin p. 788, cyclophosphamide p. 830, leflunomide p. 1002, penicillamine p. 1002, gold, antimalarials (chloroquine p. 582 and hydroxychloroquine sulfate p. 1001), and sulfasalazine p. 42. Corticosteroids also have a significant role in the management of *rheumatoid arthritis*.

Drugs which may affect the disease process in *psoriatic arthritis* include sulfasalazine, gold, azathioprine, methotrexate, leflunomide, and cytokine modulators.

Osteoarthritis and soft-tissue disorders

For pain relief in osteoarthritis and soft-tissue disorders, paracetamol should be used first and may need to be taken regularly. A topical NSAID or topical capsaicin 0.025% p. 458 should also be considered, particularly in knee or hand osteoarthritis. An oral NSAID can be substituted for, or used in addition to, paracetamol. If further pain relief is required in osteoarthritis, then the addition of an opioid analgesic may be considered, but with a substantial risk of adverse effects; however, an opioid analgesic should also be considered before a NSAID in patients taking low-dose aspirin.

Intra-articular corticosteroid injections may produce temporary benefit in osteoarthritis, especially if associated with soft-tissue inflammation.

Non-drug measures, such as weight reduction and exercise, should also be encouraged.

Glucosamine p. 1000 and rabeprazole are not recommended for the treatment of osteoarthritis.

Hyaluronic acid and its derivatives are available for osteoarthritis of the knee, but are not recommended. Sodium hyaluronate p. 1068 (Duragel®, Euflexxa®, Fermathrom®), Orthovisc®, Ostenil®, Ostenil Plus®, RenehaVis®, SuplasyN®, Synocrom®, Synovis® or hylan G-F 20 (Synvisc®) is injected intra-articularly to supplement natural hyaluronic acid in the synovial fluid. These injections may reduce pain over 1–6 months, but are associated with a short-term increase in knee inflammation. Sodium hyaluronate (SportVis®) is also licensed for the relief of pain and optimisation of recovery following ankle sprain, and for the relief of chronic pain and disability associated with tennis elbow.

Rheumatic disease, suppressing drugs

Overview

Certain drugs such as those affecting the immune response can suppress the disease process in *rheumatoid arthritis* and *psoriatic arthritis*; gold, penicillamine p. 1002, hydroxychloroquine sulfate p. 1001, chloroquine p. 582, and sulfasalazine p. 42 can also suppress the disease process in *rheumatoid arthritis* while sulfasalazine and possibly gold can suppress the disease process in *psoriatic arthritis*. Unlike NSAIDs, which are used only for symptom control, disease-modifying anti-rheumatic drugs (DMARDs) can affect the progression of disease but may require 2–6 months of treatment for a full therapeutic response. Response to DMARDs may allow the NSAID dose to be reduced or withdrawn. All patients with suspected inflammatory joint disease should be referred to a specialist as soon as possible to confirm diagnosis and evaluate disease activity; early initiation of DMARDs is recommended to control the signs and symptoms, and to limit joint damage.

Choice

The choice of a disease-modifying antirheumatic drug should take into account co-morbidity and patient preference. Methotrexate p. 844, sulfasalazine, intramuscular gold, and penicillamine are similar in efficacy. However, methotrexate or sulfasalazine may be better tolerated.

A combination of DMARDs (including methotrexate and at least one other DMARD) and a short-term corticosteroid, should be given to patients with newly diagnosed active rheumatoid arthritis, ideally within 3 months of the onset of persistent symptoms. If the use of particular DMARDs is contra-indicated and combination therapy is not possible, monotherapy with a suitable DMARD should be given and the dose rapidly increased until clinically effective. In patients with established and stable rheumatoid arthritis, cautiously reduce drug doses to the lowest that are clinically effective. Response to drug treatment often produces a reduction in requirements of both corticosteroids and other drugs.
Gold and penicillamine are effective in **palindromic rheumatism**. **Systemic and discoid lupus erythematosus** are sometimes treated with chloroquine or hydroxychloroquine sulfate.

If a disease-modifying anti-rheumatic drug does not lead to an objective benefit within 6 months, it should be replaced by a different one.

**Gold**

**Gold** can be given as sodium aurothiomalate p. 1003 for active progressive rheumatoid arthritis; it must be given by deep intramuscular injection and the area gently massaged. A test dose must be given followed by doses at weekly intervals until there is definite evidence of remission. In patients who do respond, the interval between injections is then gradually increased to 4 weeks and treatment is continued for up to 5 years after complete remission. If relapse occurs the dosage frequency may be immediately increased and only once control has been obtained again should the dosage frequency be decreased; if no response is seen within 2 months, alternative treatment should be sought. It is important to avoid complete relapse since second courses of gold are not usually effective.

**Penicillamine**

Penicillamine has a similar action to gold. More patients are able to continue treatment than with gold but side-effects are common.

Patients should be warned not to expect improvement for at least 6 to 12 weeks after treatment is initiated. Penicillamine should be discontinued if there is no improvement within 1 year.

**Sulfasalazine**

Sulfasalazine has a beneficial effect in suppressing the inflammatory activity of rheumatoid arthritis. Sulfasalazine may also be used by specialists, in the management of psoriatic arthritis affecting peripheral joints [unlicensed indication]. Haematological abnormalities occur usually in the first 3 to 6 months of treatment and are reversible on cessation of treatment.

**Antimalarials**

The antimalarial hydroxychloroquine sulfate is used to treat rheumatoid arthritis of moderate inflammatory activity; chloroquine is also licensed for treating inflammatory disorders but is used much less frequently and is generally reserved for use if other drugs have failed.

Chloroquine and hydroxychloroquine sulfate are effective for mild systemic lupus erythematosus, particularly involving the skin and joints. These drugs should not be used for psoriatic arthritis. Chloroquine and hydroxychloroquine sulfate are better tolerated than gold or penicillamine.

Retinopathy rarely occurs provided that the recommended doses are not exceeded; in the elderly it is difficult to distinguish drug-induced retinopathy from changes of ageing.

Mepacrine hydrochloride p. 479 is sometimes used in discoid lupus erythematosus [unlicensed].

**Drugs affecting the immune response**

Methotrexate is a disease-modifying antirheumatic drug suitable for moderate to severe rheumatoid arthritis. **Azathioprine** p. 787, **ciclosporin** p. 786, **cyclophosphamide** p. 830, **leflunomide** p. 1002, and the **cytokine modulators** are considered more toxic and they are used in cases that have not responded to other disease-modifying drugs.

Methotrexate is usually given by mouth once a week, adjusted according to response. In patients who experience mucosal or gastro-intestinal side-effects with methotrexate, folic acid p. 937 given every week [unlicensed indication], on a different day from the methotrexate, may help to reduce the frequency of such side-effects.

Leflunomide acts on the immune system as a disease-modifying antirheumatic drug. Its therapeutic effect starts after 4–6 weeks and improvement may continue for a further 4–6 months. Leflunomide, which is similar in efficacy to sulfasalazine and methotrexate, may be chosen when these drugs cannot be used.

Ciclosporin is licensed for severe active rheumatoid arthritis when conventional second-line therapy is inappropriate or ineffective. There is some evidence that ciclosporin may retard the rate of erosive progression and improve symptom control in those who respond only partially to methotrexate.

Cyclophosphamide may be used for rheumatoid arthritis with severe systemic manifestations [unlicensed indication]; it is toxic and regular blood counts (including platelet counts) should be carried out. Cyclophosphamide can also be given for severe **systemic rheumatoid arthritis** and for other connective tissue disorders (especially with active vasculitis).

Drugs that affect the immune response are also used in the management of severe cases of **systemic lupus erythematosus** and other connective tissue disorders. They are often given in conjunction with corticosteroids for patients with severe or progressive renal disease. They may be used in cases of **polymyositis** that are resistant to corticosteroids. They are used for their corticosteroid-sparing effect in patients whose corticosteroid requirements are excessive. Azathioprine is usually used.

In the specialist management of psoriatic arthritis affecting peripheral joints, leflunomide, methotrexate, or azathioprine [unlicensed indication] may be used.

**Juvenile idiopathic arthritis**

Many children with **juvenile idiopathic arthritis** (juvenile chronic arthritis) do not require disease-modifying antirheumatic drugs. Methotrexate is effective; sulfasalazine is an alternative [unlicensed indication] but it should be avoided in **systemic-onset juvenile idiopathic arthritis**. Gold and penicillamine are no longer used. Cytokine modulators have a role in **juvenile idiopathic arthritis**.

**Cytokine modulators**

Cytokine modulators should be used under specialist supervision.


Adalimumab is licensed for moderate to severe active **rheumatoid arthritis** when response to other disease-modifying antirheumatic drugs (including methotrexate p. 844) has been inadequate; it is also licensed for severe, active, and progressive disease in adults not previously treated with methotrexate. In the treatment of rheumatoid arthritis, adalimumab should be used in combination with methotrexate, but it can be given alone if methotrexate is inappropriate. Adalimumab is also licensed for the treatment of active and progressive **psoriatic arthritis** and severe active **ankylosing spondylitis** that have not responded adequately to other disease-modifying antirheumatic drugs. It is also licensed for the treatment of severe axial spondyloarthritis without radiographic evidence of ankylosing spondylitis but with objective signs of inflammation, in patients who have had an inadequate response to, or are intolerant of NSAIDs. Adalimumab also has a role in inflammatory bowel disease and plaque psoriasis.

Certolizumab pegol is licensed for use in patients with moderate to severe active **rheumatoid arthritis** when response to disease-modifying antirheumatic drugs (including methotrexate) has been inadequate. Certolizumab pegol can be used in combination with methotrexate, or as a
monotherapy if methotrexate is not tolerated or is contra-indicated. Certolizumab pegol is also licensed for the treatment of severe active ankylosing spondylitis in patients who have had an inadequate response to, or are intolerant of, NSAIDs. It is also licensed for the treatment of severe active axial spondyloarthritis, without radiographic evidence of ankylosing spondylitis but with objective signs of inflammation, in patients who have had an inadequate response to or are intolerant of NSAIDs.

Etanercept is licensed for the treatment of moderate to severe active rheumatoid arthritis either alone or in combination with methotrexate when the response to other disease-modifying antirheumatic drugs is inadequate and in severe, active and progressive rheumatoid arthritis in patients not previously treated with methotrexate. It is also licensed for the treatment of active and progressive psoriatic arthritis inadequately responsive to other disease-modifying antirheumatic drugs, and for severe ankylosing spondylitis inadequately responsive to conventional therapy. Etanercept also has a role in plaque psoriasis.

Golimumab is licensed in combination with methotrexate for the treatment of moderate to severe active rheumatoid arthritis when response to disease-modifying antirheumatic drug (DMARD) therapy (including methotrexate) has been inadequate; it is also licensed in combination with methotrexate for patients with severe, active, and progressive rheumatoid arthritis not previously treated with methotrexate. Golimumab is also licensed for the treatment of active and progressive psoriatic arthritis, as monotherapy or in combination with methotrexate, when response to DMARD therapy has been inadequate; it is also licensed for the treatment of severe active ankylosing spondylitis when there is an inadequate response to conventional treatment.

Infliximab is licensed for the treatment of active rheumatoid arthritis in combination with methotrexate when the response to other disease-modifying antirheumatic drugs, including methotrexate, is inadequate; it is also licensed in combination with methotrexate for patients who have severe, active, and progressive rheumatoid arthritis. Infliximab is also licensed for the treatment of ankylosing spondylitis, in patients with severe axial symptoms who have not responded adequately to conventional therapy, and in combination with methotrexate (or alone if methotrexate is not tolerated or is contra-indicated) for the treatment of active and progressive psoriatic arthritis which has not responded adequately to disease-modifying antirheumatic drugs.

Rituximab p. 820 is licensed in combination with methotrexate for the treatment of severe active rheumatoid arthritis in patients whose condition has not responded adequately to other disease-modifying antirheumatic drugs (including one or more tumour necrosis factor inhibitors) or who are intolerant of them. Rituximab has a role in malignant disease.

Abatacept p. 1007 prevents the full activation of T-lymphocytes. It is licensed for moderate to severe active rheumatoid arthritis in combination with methotrexate, in patients unresponsive to other disease-modifying antirheumatic drugs (including methotrexate or a tumour necrosis factor (TNF) inhibitor). Abatacept is not recommended for use in combination with TNF inhibitors.

Anakinra (in combination with methotrexate) is licensed for the treatment of rheumatoid arthritis which has not responded to methotrexate alone. Anakinra is not recommended for the treatment of rheumatoid arthritis except when used in a controlled long-term clinical study. Patients who are already receiving anakinra for rheumatoid arthritis should continue treatment until they and their specialist consider it appropriate to stop.

Belimumab p. 795 inhibits the activity of B-lymphocyte stimulator. Belimumab is licensed as adjunctive therapy in patients with active, autoantibody-positive systemic lupus erythematosus with a high degree of disease activity despite standard therapy.

Secukinumab p. 1004 inhibits the activity of interleukin-17A. Secukinumab is licensed for the treatment of active psoriatic arthritis, in combination with methotrexate or alone, which has not responded adequately to disease-modifying antirheumatic drugs; it is also licensed for the treatment of ankylosing spondylitis, in patients who have not responded adequately to conventional therapy.

Secukinumab also has a role in plaque psoriasis.

Tocilizumab p. 1005 antagonises the actions of interleukin-6. Tocilizumab is licensed for use in patients with moderate to severe active rheumatoid arthritis when response to at least one disease-modifying antirheumatic drug or tumour necrosis factor inhibitor has been inadequate, or in those who are intolerant of these drugs. Tocilizumab can be used in combination with methotrexate, or as monotherapy if methotrexate is not tolerated or is contra-indicated.

Ustekinumab p. 1006 inhibits the activity of interleukins 12 and 23. It is licensed for the treatment of active psoriatic arthritis (in combination with methotrexate or alone) in patients who have had an inadequate response to one or more disease-modifying antirheumatic drugs.

Other drugs used for Arthritis

Glucosamine

- **Drug Action** Glucosamine is a natural substance found in mucopolysaccharides, mucoproteins, and chitin.

- **Indications and Dose**

  **Alateris®**

  Symptomatic relief of mild to moderate osteoarthritis of the knee

  - By mouth
  - Adult: 1250 mg once daily, review treatment if no benefit after 2–3 months

  **Dolenio®**

  Symptomatic relief of mild to moderate osteoarthritis of the knee

  - By mouth
  - Adult: 1500 mg once daily, review treatment if no benefit after 2–3 months

  **Glucartel®**

  Symptomatic relief of mild to moderate osteoarthritis of the knee

  - By mouth
  - Adult: 1500 mg once daily, dose to be dissolved in at least 250 mL of water, review treatment if no benefit after 2–3 months

- **Caution** Asthma, impaired glucose tolerance, predisposition to cardiovascular disease

- **Interactions** → Appendix 1: glucosamine
Hydroxychloroquine sulfate

**INDICATIONS AND DOSE**

Active rheumatoid arthritis (administered on expert advice) | Systemic and discoid lupus erythematosus (administered on expert advice) | Dermatological conditions caused or aggravated by sunlight (administered on expert advice)

- **BY MOUTH**
  - Adult: 200–400 mg daily, maximum dose to be based on ideal body-weight; maximum 6.5 mg/kg per day

**CAUTIONS**

- Acute porphyrias p. 969 | diabetes (may lower blood glucose) | elderly | G6PD deficiency | may aggravate myasthenia gravis | may exacerbate psoriasis | neurological disorders (especially in those with a history of epilepsy) | severe gastro-intestinal disorders

**CAUTIONS, FURTHER INFORMATION**

- Screening for ocular toxicity | A review group convened by the Royal College of Ophthalmologists has updated guidelines for screening to prevent ocular toxicity on long-term treatment with chloroquine and hydroxychloroquine (Hydroxychloroquine and Ocular Toxicity: Recommendations on Screening 2009). The following recommendations relate to hydroxychloroquine, which is only rarely associated with toxicity.

**Before treatment:**

- Assess renal and liver function (adjust dose if impaired)

- Ask patient about visual impairment (not corrected by glasses). If impairment or eye disease present, assessment by an ophthalmologist is advised and any abnormality should be immediately referred to an ophthalmologist.

- Record near visual acuity of each eye (with glasses where appropriate) using a standard reading chart.

- Initiate hydroxychloroquine treatment if no abnormality detected. (at a dose not exceeding hydroxychloroquine sulfate 6.5 mg/kg daily)

**During treatment:**

- Ask patient about visual symptoms and monitor visual acuity annually using the standard reading chart.

- Refer to ophthalmologist if visual acuity changes or if vision blurred and warn patient to seek prescribing doctor’s advice about stopping treatment.

- If long-term treatment is required (more than 5 years), individual arrangements should be agreed with the local ophthalmologist.

**INTERACTIONS**

- Appendix 1: hydroxychloroquine

**SIDE-EFFECTS**

- Common or very common | Gastro-intestinal disturbances | headache | pruritus | rashes | skin reactions

- Uncommon | Convulsions | discoloration of skin, nails, and mucous membranes | ECG changes | hair depigmentation | hair loss | keratopathy | ototoxicity | retinal damage | visual changes

- Rare | Acute generalised exanthematous pustulosis | agranulocytosis | angioedema | aplastic anaemia | blood disorders | cardiomyopathy | emotional disturbances | exfoliative dermatitis | hepatic damage | mental changes | myopathy | neuromyopathy | photosensitivity | psychosis | Stevens-Johnson syndrome | thrombocytopenia

**FREQUENCY NOT KNOWN**

- Bronchospasm | diffuse parenchymal lung disease | drug rash with eosinophilia | systemic symptoms

**OVERDOSE**

Hydroxychloroquine is toxic in overdose; overdosage is extremely hazardous and difficult to treat. Urgent advice from the National Poisons Information Service is essential. Life-threatening features include arrhythmias (which can have a very rapid onset) and convulsions (which can be intractable).

- **PREGNANCY**
  - It is not necessary to withdraw an antimalarial drug during pregnancy if the rheumatic disease is well controlled; however, the manufacturer of hydroxychloroquine advises avoiding use.

- **BREAST FEEDING**
  - Avoid—risk of toxicity in infant.

- **HEPATIC IMPAIRMENT**
  - Caution in moderate to severe hepatic impairment.

- **RENAL IMPAIRMENT**
  - Manufacturer advises caution. Monitor plasma-hydroxychloroquine concentration in severe renal impairment.

**MONITORING REQUIREMENTS**

- Manufacturers recommend regular ophthalmological examination but the evidence of practical value is unsatisfactory (see advice of the Royal College of Ophthalmologists).

**PRESCRIBING AND DISPENSING INFORMATION**

- To avoid excessive dosage in obese patients, the dose of hydroxychloroquine should be calculated on the basis of ideal body-weight.

- **PATIENT AND CARER ADVICE**
  - Do not take antacids for at least 4 hours before or after hydroxychloroquine to reduce possible interference with hydroxychloroquine absorption.

**NATIONAL FUNDING/ACCESS DECISIONS**

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (May 2008) that glucosamine (Alateris) and (July 2011) glucosamine (Glusartel) are not recommended for use within NHS Scotland for the symptomatic relief of mild to moderate cardiovascular disease.

- **LESS SUITABLE FOR PRESCRIBING**
  - Less suitable for prescribing—the mechanism of action is not understood and there is limited evidence to show it is effective.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- ELECTROLYTES: May contain Sodium

- **Alateris** (MW Healthcare Ltd)
  - Glucosamine (as Glucosamine hydrochloride) 625 mg
  - 625 mg tablets | 60 tablet (£18.40 DT price + £18.40)

- **Dolenio** (Alisa Healthcare Research Ltd)
  - Dolenio 1500mg tablets | 30 tablet (£18.20 DT price + £18.20)

**DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS**
Leflunomide

**INDICATIONS AND DOSE**
Moderate to severe active rheumatoid arthritis (specialist use only)
- BY MOUTH
  - Adult: Initially 100 mg once daily for 3 days, then reduced to 10–20 mg once daily

Active psoriatic arthritis (specialist use only)
- BY MOUTH
  - Adult: Initially 100 mg once daily for 3 days, then reduced to 20 mg once daily

**CONTRA-INDICATIONS**
- Serious infection
- Severe hypoproteinemia
- Severe immunodeficiency

**CAUTIONS**
- Anaemia (avoid if significant and due to causes other than rheumatoid arthritis)
- History of tuberculosis
- Impaired bone-marrow function
- Due to causes other than rheumatoid arthritis
- Leucopenia
- Avoid if significant and due to causes other than rheumatoid arthritis
- Thrombocytopenia
- Avoid if significant and due to causes other than rheumatoid arthritis

**INTERACTIONS**
- Appendix 1: leflunomide

**SIDE-EFFECTS**
- Common or very common
  - Abdominal pain
  - Alopecia
  - Anorexia
  - Arthralgia
  - Diarrhoea
  - Dizziness
  - Dry skin
  - Headache
  - Increased blood pressure
  - Leucopenia
  - Nausea
  - Oral mucosal disorders
  - Parasthesia
  - Pruritus
  - Rash
  - Tenoynovitis

- Uncommon
  - Anaemia
  - Anxiety
  - Hyperlipidaemia
  - Hypokalaemia
  - Hypophosphatemia
  - Taste disturbance
  - Tendon rupture
  - Thrombocytopenia

- Rare
  - Hepatitis
  - Eosinophilia
  - Intestinal lung disease
  - Jaundice
  - Pancytopenia
  - Severe infection

- Very rare
  - Hepatic failure
  - Pancreatitis
  - Peripheral neuropathy
  - Progressive multifocal leucoencephalopathy
  - Stevens–Johnson syndrome
  - Toxic epidermal necrolysis

- Frequency not known
  - Bone-marrow toxicity
  - Hypouricaemia
  - Malignancy
  - Reduced sperm count
  - Renal failure

**SIDE-EFFECTS, FURTHER INFORMATION**
- Discontinue treatment and institute washout procedure in case of serious side-effect (consult product literature).
- Hepatotoxicity
  - Potentially life-threatening hepatotoxicity reported usually in the first 6 months.
  - Discontinue treatment (and institute washout procedure—consult product literature) or reduce dose according to liver-function abnormality; if liver-function abnormality persists after dose reduction, discontinue treatment and institute washout procedure.

**CONCEPTION AND CONTRACEPTION**
- Effective contraception essential during treatment and for at least 2 years after treatment in women and at least 3 months after treatment in men (plasma concentration monitoring required; waiting time before conception may be reduced with washout procedure—consult product literature).
- The concentration of the active metabolite after washout should be less than 20 micrograms/litre (measured on 2 occasions 14 days apart) in men or women before conception—consult product literature.

**PREGNANCY**
- Avoid—active metabolite teratogenic in animal studies.

**BREAST FEEDING**
- Present in milk in animal studies—manufacturer advises avoid.

**HEPATIC IMPAIRMENT**
- Avoid—active metabolite may accumulate.

**RENAL IMPAIRMENT**
- Manufacturer advises avoid in moderate or severe impairment—no information available.

**PRE-TREATMENT SCREENING**
- Exclude pregnancy before treatment.

**MONITORING REQUIREMENTS**
- Monitor full blood count (including differential white cell count and platelet count) before treatment and every 2 weeks for 6 months then every 8 weeks.
- Monitor liver function before treatment and every 2 weeks for first 6 months then every 8 weeks.
- Monitor blood pressure.

**TREATMENT CESSATION**
- Washout Procedure
  - The active metabolite persists for a long period; to aid drug elimination in case of serious adverse effect, or before starting another disease-modifying antirheumatic drug, or before conception, stop treatment and give either colchicine or charcoal, activated p. 1256. Procedure may be repeated as necessary.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.

**Tablet**
- CAUTIONARY AND ADVISORY LABELS 21
  - **Leflunomide (Non-proprietary)**
    - Leflunomide 10 mg tablet | 30 tablet POM £46.00 DT price = £4.69
    - Leflunomide 15 mg tablet | 30 tablet POM £46.00 DT price = £4.69
    - Leflunomide 20 mg tablet | 30 tablet POM £61.36 DT price = £4.62
    - **Arava** (Sanofi)
      - Leflunomide 10 mg tablet | 30 tablet POM £51.13 DT price = £4.69
      - Leflunomide 20 mg tablet | 30 tablet POM £61.36 DT price = £4.62
      - Leflunomide 100 mg tablet | 3 tablet POM £30.67

Penicillamine

**DRUG ACTION**
- Penicillamine aids the elimination of copper ions in Wilson’s disease (hepatolenticular degeneration).

**INDICATIONS AND DOSE**
- Severe active rheumatoid arthritis (administered on expert advice)
- BY MOUTH
  - Adult: Initially 125–250 mg daily for 1 month, then increased in steps of 125–250 mg, at intervals of not less than 4 weeks; maintenance 500–750 mg daily in divided doses, then reduced in steps of 125–250 mg every 12 weeks, dose reduction attempted only if remission sustained for 6 months; maximum 1.5 g per day
  - Elderly: Initially up to 125 mg daily for 1 month, then increased in steps of up to 125 mg, at intervals of at least 4 weeks; maximum 1 g per day
Wilson’s disease

- **BY MOUTH**
- **Adult:** 1.5–2 g daily in divided doses, adjusted according to response, to be taken before food; maintenance 0.75–1 g daily, a dose of 2 g daily should not be continued for more than one year; maximum 2 g per day
- **Elderly:** 20 mg/kg daily in divided doses, adjusted according to response

Autoimmune hepatitis (used rarely; after disease controlled with corticosteroids)

- **BY MOUTH**
- **Adult:** Initially 500 mg daily in divided doses, to be increased slowly over 3 months; maintenance 1.25 g daily

Cystinuria, therapeutic

- **BY MOUTH**
- **Adult:** 1–3 g daily in divided doses, to be adjusted to maintain urinary cystine below 200 mg/litre, to be taken before food
- **Elderly:** Minimum dose to maintain urinary cystine below 200 mg/litre is recommended

- **SIDE-EFFECTS**
  - Common or very common: Anorexia, fever, nausea, proteinuria, rash, thrombocytopenia
  - Rare: Alopecia, breast enlargement (male and female), elastosis perforans haematuria (withdraw immediately if cause unknown), mouth ulceration, pseudoxanthoma elasticum, skin laxity, stomatitis
  - Frequency not known: Agranulocytosis, aplastic anaemia, blood disorders, bronchiolitis, cholestatic jaundice, dermatomyositis, glomerulonephritis, Goodpasture’s syndrome, haemolytic anaemia, haemolytic leucopenia, late rashes (consider dose reduction), lupus erythematosus, myasthenia gravis, nephrotic syndrome, neuropathy (especially if neurological involvement in Wilson’s disease—prophylactic pyridoxine recommended), neutropenia, pancreatitis, pemphigus, pemphigoid, polymyositis, pulmonary haemorrhage, rheumatoid arthritis, septic arthritis (in patients with rheumatoid arthritis), Stevens-Johnson syndrome, taste lost (mineral supplements not recommended), urticaria, vomiting

- **CONTRA-INDICATIONS** Lupus erythematosus
- **CAUTIONS** Neurological involvement in Wilson’s disease
- **INTERACTIONS** → Appendix 1: penicillamine

**MEDICINAL FORMS**

- **Tablet**
  - Cautions and Advisory Labels 6, 22
  - Penicillamine (Non-proprietary)
    - Penicillamine 125 mg Penicillamine 125mg tablets | 56 tablet Pot £45.00
      - Penicillamine 250 mg Penicillamine 250mg tablets | 56 tablet Pot £88.75
    - Distamine (Alliance Pharmaceuticals Ltd)
      - Penicillamine 125 mg Distamine 125mg tablets | 100 tablet Pot £10.34
      - Penicillamine 250 mg Distamine 250mg tablets | 100 tablet Pot £17.78

**Sodium aurothiomalate**

- **INDICATIONS AND DOSE**
  - Active progressive rheumatoid arthritis (administered on expert advice)
    - **BY DEEP INTRAMUSCULAR INJECTION**
      - **Adult:** Test dose 10 mg, followed by 50 mg once weekly until there is definite evidence of remission, then reduced to 50 mg every 4 weeks continued for up to 5 years after complete remission, dose to be reduced gradually. Benefit is not expected until 300–500 mg has been given; it should be discontinued if there is no remission after 1 year has been given
  - Relapse in patients who have previously received sodium aurothiomalate therapy for active progressive rheumatoid arthritis (administered on expert advice)
    - **BY DEEP INTRAMUSCULAR INJECTION**
      - **Adult:** 50 mg once weekly until control has been obtained again, then reduced to 50 mg every 4 weeks continued for up to 5 years after complete continued →
remission, if no response is seen within 2 months, alternative treatment should be sought

- **CONTRA-INDICATIONS** Exfoliative dermatitis - history of blood disorders - history of bone marrow aplasia - necrotising enterocolitis - pulmonary fibrosis - systemic lupus erythematosus
- **CAUTIONS** Colitis - eczema - elderly - history of urticaria

**CAUTIONS, FURTHER INFORMATION**

Sodium aurothiomalate should be discontinued in the presence of blood disorders, gastro-intestinal bleeding (associated with ulcerative enterocolitis), or unexplained proteinuria (associated with immune complex nephritis) which is repeatedly above 300 mg/litre.

- **INTERACTIONS** → Appendix 1: sodium aurothiomalate
- **SIDE-EFFECTS** Alopecia - blood disorders (sometimes sudden and fatal) - colitis - gold deposits in eye - hepatoxicity with cholestatic jaundice - irreversible pigmentation in sun-exposed areas (on prolonged parenteral treatment) - mouth ulcers - nephrotic syndrome - peripheral neuropathy - proteinuria - pulmonary fibrosis - severe anaphylactic reactions - skin reactions - stomatitis - taste disturbances

**SIDE-EFFECTS, FURTHER INFORMATION**

Rashes with pruritus often occur after reactions.

There can be variation in the licensing of different medicines containing the same drug.

**IMMUNOSUPPRESSANTS** → INTERLEUKIN INHIBITORS

**Anakinra**

- **INDICATIONS AND DOSE** Treatment of rheumatoid arthritis (in combination with methotrexate) which has not responded to methotrexate alone
  - BY SUBCUTANEOUS INJECTION
  - Adult: 100 mg once daily

**CONTRA-INDICATIONS** Neutropenia
- **CAUTIONS** History of asthma (risk of serious infection) - predisposition to infection
- **INTERACTIONS** → Appendix 1: anakinra
- **SIDE-EFFECTS**
  - Common or very common Neutropenia
  - Frequency not known Antibody formation - headache - infections - injection-site reactions - malignancy

**SIDE-EFFECTS, FURTHER INFORMATION**

Blood disorders Neutropenia reported commonly—discontinue if neutropenia develops.

**CONCEPTION AND CONTRACTION** Effective contraception must be used during treatment.

**PREGNANCY** Manufacturer advises avoid.

**BREAST FEEDING** Manufacturer advises avoid—no information available.

**RENAL IMPAIRMENT** Caution if eGFR 30–50 mL/minute/1.73 m². Avoid if eGFR less than 30 mL/minute/1.73 m².

**MONITORING REQUIREMENTS** Monitor neutrophil count before treatment, then every month for 6 months, then every 3 months.

**PATIENT AND CARER ADVICE**

Blood disorders Patients should be instructed to seek medical advice if symptoms suggestive of neutropenia (such as fever, sore throat, bruising or, bleeding) develop.

**NATIONAL FUNDING/ACCESS DECISIONS**

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (July 2002) that anakinra is not recommended for the treatment of rheumatoid arthritis within NHS Scotland.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Kineret** (Swedish Orphan Biovitrum Ltd)
  - Anakinra 150 mg per 1 ml Kineret 100mg/0.67ml solution for injection pre-filled syringes | 28 pre-filled disposable injection
  - £734.44

**Secukinumab**

16-Mar-2016

**DRUG ACTION** Secukinumab is a recombinant human monoclonal antibody that selectively binds to cytokine interleukin-17A (IL-17A) and inhibits the release of proinflammatory cytokines and chemokines.

**INDICATIONS AND DOSE**

Psoriatic arthritis | Ankylosing spondylitis

- **BY SUBCUTANEOUS INJECTION**
  - Adult: 150 mg every week for 5 doses, then maintenance 150 mg every month, review treatment if no response within 16 weeks of initial dose

Psoriatic arthritis with concomitant moderate to severe plaque psoriasis or if inadequate response to anti-TNFα treatment | Plaque psoriasis

- **BY SUBCUTANEOUS INJECTION**
  - Adult: 300 mg every week for 5 doses, then maintenance 300 mg every month, review treatment if no response within 16 weeks of initial dose

**CONTRA-INDICATIONS** Severe active infection

**CAUTIONS** Chronic infection - Crohn’s disease (monitor for exacerbations) - history of recurrent infection - predisposition to infection (discontinue if new serious infection develops)
CAUTIONS, FURTHER INFORMATION

- Tuberculosis: Manufacturer advises that patients with latent tuberculosis should complete anti-tuberculosis therapy before starting secukinumab.

INTERACTIONS → Appendix 1: monoclonal antibodies

SIDE-EFFECTS

- Common or very common: Diarrhoea, oral herpes, rhinorrhoea, upper respiratory tract infections
- Uncommon: Conjunctivitis, neutropenia (usually mild and reversible), oral candidiasis, otitis externa, tinea pedis
- Rare: Anaphylactic reactions

CONCEPTION AND CONTRACEPTION

Manufacturer advises that women of childbearing potential should use effective contraception during treatment and for at least 20 weeks after stopping treatment.

PREGNANCY

Manufacturer advises avoid—no information available.

BREAST FEEDING

Manufacturer advises avoid during treatment and for up to 20 weeks after discontinuing treatment—no information available.

DIRECTIONS FOR ADMINISTRATION

Manufacturer advises to take the syringe or pen out of the refrigerator 20 minutes before administration and to avoid injecting into areas of the skin that show psoriasis. Patients may self-administer Cosentyx® pre-filled pen.

PATIENT AND CARER ADVICE

Self-administration: Patients and their carers should be given training in subcutaneous injection technique. Injection: Patients and their carers should be advised to seek immediate medical attention if symptoms of infection develop during treatment with secukinumab.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

- Secukinumab for treating moderate to severe plaque psoriasis (July 2015) NICE TA350
Secukinumab is recommended as an option for the treatment of moderate to severe plaque psoriasis in adults if:

- the disease has failed to respond to standard systemic treatments (including ciclosporin, methotrexate, and PUVA), or when standard treatments are contra-indicated or not tolerated; and
- the manufacturer provides secukinumab with the discount agreed in the patient access scheme.

Secukinumab should be withdrawn in patients whose psoriasis has not responded adequately within 12 weeks of initial dose; further treatment cycles are not recommended.

Patients whose treatment with secukinumab was started before this guidance was published, but does not meet these criteria, should have the option to continue treatment until they and their clinician consider it appropriate to stop.

www.nice.org.uk/TA350

- Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (September 2016) NICE TA407
Secukinumab is recommended, within its marketing authorisation, as an option for treating active ankylosing spondylitis in adults who have responded inadequately to conventional therapy (non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors) only if the manufacturer provides secukinumab with the discount agreed in the patient access scheme.

Assess response to secukinumab after 16 weeks of treatment and continue only if there is clear evidence of response, defined as a reduction in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score to 50% of the pre-treatment value or by 2 or more units and a reduction in the spinal pain visual analogue scale (VAS) by 2 cm or more.

www.nice.org.uk/TA407

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (May 2015) that secukinumab (Cosentyx®) is accepted for restricted use within NHS Scotland for the treatment of moderate to severe plaque psoriasis in adults who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), or when standard treatments cannot be used because of intolerance or contra-indications.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

- Cosentyx (Novartis Pharmaceuticals UK Ltd)▼
  - Secukinumab 150 mg per 1 ml
  - Cosentyx 150mg/1ml solution for injection pre-filled pens | 2 pre-filled disposable injection PSM £1,218.78
  - Cosentyx 150mg/1ml solution for injection pre-filled syringes | 2 pre-filled disposable injection PSM £1,218.78

Tocilizumab

31-May-2016

INDICATIONS AND DOSE

Moderate to severe active rheumatoid arthritis (in combination with methotrexate or alone if methotrexate inappropriate) when response to at least one disease-modifying antirheumatic drug or tumour necrosis factor inhibitor has been inadequate, or in those who are intolerant of these drugs

BY INTRAVENOUS INFUSION

- Adult: 8 mg/kg every 4 weeks (max. per dose 800 mg), for dose adjustments in patients with liver enzyme abnormalities, or low absolute neutrophil or platelet count, consult product literature.

CONTRA-INDICATIONS

Do not initiate if absolute neutrophil count less than 2 × 10⁹/litre - severe active infection.

CAUTIONS

- History of diverticulitis - history of intestinal ulceration - history of recurrent or chronic infection (interrupt treatment if serious infection occurs) - low absolute neutrophil count - low platelet count - predisposition to infection (interrupt treatment if serious infection occurs).

CAUTIONS, FURTHER INFORMATION

- Tuberculosis: Patients with latent tuberculosis should be treated with standard therapy before starting tocilizumab.

INTERACTIONS → Appendix 1: monoclonal antibodies

SIDE-EFFECTS

- Common or very common: Abdominal pain, antibody formation, dizziness, gastritis, headache, hypercholesterolaemia, hypersensitivity, hypertension, infection, leucopenia, mouth ulceration, neutropenia, peripheral oedema, pruritus, raised hepatic transaminases, rash, upper respiratory tract infection.
- Uncommon: Anaphylaxis, gastric ulcer, gastro-intestinal perforation, hypertriglyceridaemia, hypothyroidism, infusion-related reactions, nephrolithiasis.
- Frequency not known: Thrombocytopenia.

SIDE-EFFECTS, FURTHER INFORMATION

- Neutrophil and platelet counts: Discontinue if absolute neutrophil count less than 0.5 × 10⁹/litre or platelet count less than 50 × 10⁹/microlitre.
● CONCEPTION AND CONTRACEPTION Effective contraception required during and for 3 months after treatment.
● PREGNANCY Manufacturer advises avoid unless essential—toxicity in animal studies.
● BREAST FEEDING Manufacturer advises use only if potential benefit outweighs risk—no information available.
● HEPATIC IMPAIRMENT Manufacturer advises caution—consult product literature.
● RENAL IMPAIRMENT Manufacturer advises monitor renal function closely in moderate or severe impairment.
● PRE-TREATMENT SCREENING Tuberculosis Patients should be evaluated for tuberculosis before treatment.

● MONITORING REQUIREMENTS
  ▶ Monitor lipid profile 4–8 weeks after starting treatment and then as indicated.
  ▶ Monitor for demyelinating disorders.
  ▶ Monitor hepatic transaminases every 4–8 weeks for first 6 months, then every 12 weeks.
  ▶ Monitor neutrophil and platelet counts 4–8 weeks after starting treatment and then as indicated.

● DIRECTIONS FOR ADMINISTRATION For intravenous infusion (RoActemra®), give intermittently in Sodium chloride 0.9%; dilute requisite dose to a volume of 100 mL with infusion fluid and give over 1 hour.

● PATIENT AND CARER ADVICE An alert card should be provided.

  Patients and their carers should be advised to seek immediate medical attention if symptoms of infection occur, or if symptoms of diverticular perforation such as abdominal pain, haemorrhage, or fever accompanying change in bowel habits occur.

● NATIONAL FUNDING/ACCESS DECISIONS
  NICE technology appraisals (TAs)
    ▶ Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (January 2016) NICE TA375
    ▶ Tocilizumab, in combination with methotrexate, is recommended as an option for treating rheumatoid arthritis, only if all the following criteria are met:
      1. disease is severe, that is, a disease activity score (DAS28) greater than 5.1,
      2. disease has not responded to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs),
      3. the manufacturer provides tocilizumab as agreed in the patient access schemes.
      Tocilizumab can be used as monotherapy in patients who cannot take methotrexate because it is contra-indicated or because of intolerance, when the criteria above are met.
      Continue treatment only if there is a moderate response measured using European League Against Rheumatism (EULAR) criteria at 6 months after starting therapy. After initial response within 6 months, withdraw treatment if a moderate EULAR response is not maintained.
      Patients currently receiving tocilizumab whose disease does not meet the above criteria should have the option to continue their treatment until they and their clinician consider it appropriate to stop.

  www.nice.org.uk/TA375

    ▶ Tocilizumab for the treatment of rheumatoid arthritis (February 2012–updated February 2016) NICE TA247
    Tocilizumab, in combination with methotrexate, is recommended as an option for the treatment of rheumatoid arthritis in adults if:
      1. the disease has responded inadequately to DMARDs and a TNF inhibitor and the patient cannot receive rituximab because of contra-indications or intolerance, and
tocilizumab is used as described for TNF inhibitor treatments (specifically the recommendations on disease activity) in the NICE guidance (August 2010)
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor, or
      2. the disease has responded inadequately to one or more TNF inhibitor treatments and to rituximab
      3. the manufacturer provides tocilizumab with the discount agreed as part of the patient access scheme.

  Patients currently receiving tocilizumab for the treatment of rheumatoid arthritis who do not meet these criteria should have the option to continue treatment until they and their clinicians consider it appropriate to stop.

  www.nice.org.uk/TA247

● MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug.

  Solution for infusion
  ▶ RoActemra (Roche Products Ltd)
    Tocilizumab 20 mg per 1 mL RoActemra 400 mg/20 mL concentrate for solution for infusion vials | 1 vial £512.00 (Hospital only)
    RoActemra 200 mg/10 mL concentrate for solution for infusion vials | 1 vial £256.00 (Hospital only)
    RoActemra 80 mg/4 mL concentrate for solution for infusion vials | 1 vial £102.40 (Hospital only)

Ustekinumab

● INDICATIONS AND DOSE
  Severe plaque psoriasis that has not responded to at least 2 standard systemic treatments and photochemotherapy, or when these treatments cannot be used because of intolerance or contra-indications
  ▶ BY SUBCUTANEOUS INJECTION
    Adult (body-weight up to 100 kg): Initially 45 mg, then 45 mg after 4 weeks, then 45 mg every 12 weeks, discontinue if no response within 16 weeks
    Adult (body-weight 100 kg and above): Initially 45–90 mg, then 45–90 mg after 4 weeks, then 45–90 mg every 12 weeks, discontinue if no response within 16 weeks
  Active psoriatic arthritis (in combination with methotrexate or alone) in patients who have had an inadequate response within the disease activity (in the NICE guidance (August 2010)
Abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor, or
the disease has responded inadequately to one or more TNF inhibitor treatments and to rituximab
the manufacturer provides tocilizumab with the discount agreed as part of the patient access scheme.

  Patients currently receiving tocilizumab for the treatment of rheumatoid arthritis who do not meet these criteria should have the option to continue treatment until they and their clinicians consider it appropriate to stop.

  www.nice.org.uk/TA247

● CONTRA-INDICATIONS Active infection
● CAUTIONS Development of malignancy • elderly • history of malignancy • predisposition to infection • start appropriate treatment if widespread erythema and skin exfoliation develop, and stop ustekinumab treatment if exfoliative dermatitis suspected

  CAUTIONS, FURTHER INFORMATION
  ▶ Tuberculosis Active tuberculosis should be treated with standard treatment for at least 2 months before starting ustekinumab. Patients who have previously received appropriate treatment for tuberculosis can start ustekinumab but should be monitored every 3 months for possible recurrence. In patients without active tuberculosis but who were previously not treated adequately, chemoprophylaxis should ideally be completed before...
starting ustekinumab. In patients at high risk of tuberculosis who cannot be assessed by tuberculin skin test, chemoprophylaxis may be given concurrently with ustekinumab.

- **INTERACTIONS**  ➔ Appendix 1: monoclonal antibodies
- **SIDE-EFFECTS**
  - **Common or very common**  Arthralgia, diarrhoea, dizziness, headache, infections (sometimes severe), injection-site reactions, malaise, myalgia, nausea, ophthalmological pain, pruritus
  - **Uncommon**  Depressions, facial palsy, hypersensitivity reactions (possibly delayed onset), nasal congestion, pustular psoriasis
  - **Rare**  Exfoliative dermatitis
- **CONCEPTION AND CONTRACEPTION**  Manufacturer advises effective contraception during treatment and for 15 weeks after stopping treatment.
- **PREGNANCY**  Avoid.
- **BREAST FEEDING**  Manufacturer advises avoid—present in milk in animal studies.
- **PRE-TREATMENT SCREENING**
  - Tuberculosis  Patients should be evaluated for tuberculosis before treatment.
- **MONITORING REQUIREMENTS**
  - Monitor for non-melanoma skin cancer, especially in patients with a history of PUVA treatment or prolonged immunosuppressant therapy, or those over 60 years of age.
  - Monitor for signs and symptoms of exfoliative dermatitis or erythrodermic psoriasis.
- **PATIENT AND CARER ADVICE**
  - Exfoliative dermatitis  Patients should be advised to seek prompt medical attention if symptoms suggestive of exfoliative dermatitis or erythrodermic psoriasis (such as increased redness and shedding of skin over a larger area of the body) develop.
  - Tuberculosis  Patients should be advised to seek medical attention if symptoms suggestive of tuberculosis (e.g. persistent cough, weight loss, and fever) develop.
- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **NICE technology appraisals (TAs)**
    - Ustekinumab for plaque psoriasis in adults (September 2009) NICE TA180
      - Ustekinumab is recommended for the treatment of severe plaque psoriasis which has failed to respond to standard systemic treatments (including ciclosporin and methotrexate) and to photochemotherapy, or when standard treatments cannot be used because of intolerance or contra-indications. Ustekinumab should be withdrawn if the response is not adequate after 16 weeks.
      - For patients weighing over 100 kg, the manufacturer should provide the 90-mg dose of ustekinumab at the same price as the 45-mg dose.
      - www.nice.org.uk/TA180
    - Ustekinumab for treating active psoriatic arthritis (June 2015) NICE TA340
      - Ustekinumab is an option, alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adults only when:
        - Treatment with tumour necrosis factor (TNF) alpha inhibitors is contra-indicated but would otherwise be considered (as described in the NICE guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (August 2010) and golimumab for the treatment of psoriatic arthritis (April 2011)) or
        - The patient has had treatment with 1 or more TNF-alpha inhibitors.
      - Ustekinumab is recommended only if the manufacturer provides the 90 mg dose of ustekinumab for patients who weigh more than 100 kg at the same cost as the 45 mg dose, as agreed in the patient access scheme.
      - Ustekinumab treatment should be stopped if the patient’s psoriatic arthritis has not shown an adequate response using the Psoriatic Arthritis Response Criteria (PsARC) at 24 weeks.
      - Patients currently receiving ustekinumab whose disease does not meet the above criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop.
      - www.nice.org.uk/TA340

**Scottish Medicines Consortium (SMC) Decisions**

The **Scottish Medicines Consortium** has advised (February 2014) that ustekinumab (Stelara®) is accepted for restricted use within NHS Scotland either alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adults who have responded inadequately to previous therapy with a non-biological disease-modifying anti-rheumatic drug, and failed on, or are unsuitable for, treatment with a TNF inhibitor.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Solution for injection**
    - **CAUTIONARY AND ADVISORY LABELS**
      - **Stelara** (Janssen-Cilag Ltd)
        - Ustekinumab 90 mg per 1 ml
        - Stealra 90mg/1ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (£2,147.00)
        - Stealra 45mg/0.5ml solution for injection vials | 1 vial (£2,147.00)
        - Stealra 45mg/0.5ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (£2,147.00)

**IMMUNOSUPPRESSANTS**

> **T-CELL ACTIVATION INHIBITORS**

**Abatacept**

- **INDICATIONS AND DOSE**
  - Moderate to severe active rheumatoid arthritis (in combination with methotrexate) in patients unresponsive to other disease-modifying antirheumatic drugs (including methotrexate or a tumour necrosis factor (TNF) inhibitor)
    - **INITIALLY BY INTRAVENOUS INJECTION**
      - Adult (body-weight up to 60 kg): 500 mg every 2 weeks for 3 doses (loading dose), then (by intravenous infusion) 500 mg every 4 weeks, alternatively (by subcutaneous injection) 125 mg once weekly, first subcutaneous dose to be given within 1 day of the intravenous loading dose; patients who are unable to receive an infusion may initiate subcutaneous abatacept without receiving an intravenous loading dose
      - Adult (body-weight 60-100 kg): 750 mg every 2 weeks for 3 doses (loading dose), then (by intravenous infusion) 750 mg every 4 weeks, alternatively (by subcutaneous injection) 125 mg once weekly, first subcutaneous dose to be given within 1 day of the intravenous loading dose; patients who are unable to receive an infusion may initiate subcutaneous abatacept without receiving an intravenous loading dose
      - Adult (body-weight 101 kg and above): 1 g every 2 weeks for 3 doses (loading dose), then (by intravenous infusion) 1 g every 4 weeks, alternatively (by subcutaneous injection) 125 mg once weekly, first subcutaneous dose to be given within 1 day of the intravenous loading dose; patients who are unable to receive an infusion may initiate subcutaneous abatacept without receiving an intravenous loading dose

---

**Arthritis** 1007

Musculoskeletal system
Musculoskeletal system

PREGNANCY

CONTRA-INDICATIONS
Severe infection

CAUTIONS
Do not initiate until active infections are controlled • elderly (increased risk of side-effects) • predisposition to infection (screen for latent tuberculosis and viral hepatitis) • progressive multifocal leucoencephalopathy (discontinue treatment if neurological symptoms present)

INTERACTIONS → Appendix 1: abatacept

SIDE-EFFECTS

Common or very common Abdominal pain • conjunctivitis • cough • diarrhea • dizziness • dyspepsia • fatigue • flushing • headache • hypertension • infection • leucopenia • nausea • pain in extremities • paraesthesia • stomatitis • vomiting

Uncommon Psoriasis • alopecia • anxiety • arthralgia • basal and squamous cell carcinoma • bradycardia • bronchospasm • bruising • depression • dry eye • dry skin • dyspnoea • gastritis • hyperhidrosis • hypotension • menstrual disturbances • palpitation • skin papilloma • sleep disorder • tachycardia • thrombocytopenia • visual disturbance • weight gain

Frequency not known Lung cancer • lymphoma

CONCEPTION AND CONTRACEPTION Effective contraception required during treatment and for 14 weeks after last dose.

PREGNANCY
Manufacturer advises avoid unless essential.

BREAST FEEDING
Present in milk in animal studies—manufacturer advises avoid breast-feeding during treatment and for 14 weeks after last dose.

DIRECTIONS FOR ADMINISTRATION
For intravenous
infusion, given intermittently in Sodium chloride 0.9%; reconstitute each vial with 10 mL water for injections using the silicone-free syringe provided; dilute requisite dose in Sodium Chloride 0.9% to 100 mL (using the same silicone-free syringe); give over 30 minutes through a low protein-binding filter (pore size 0.2–1.2 micron).

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (August 2010) NICE TA195

Abatacept, in combination with methotrexate, is an option for the treatment of severe active rheumatoid arthritis in adults who have had an inadequate response to, or have an intolerance of, other disease-modifying antirheumatic drugs (DMARDs) including at least 1 tumour necrosis factor (TNF) inhibitor, and who cannot use rituximab because of contra-indications or intolerance. Treatment should be continued only if there is adequate response. Patients should be monitored at least every 6 months.

www.nice.org.uk/TA195

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (January 2016) NICE TA375

Abatacept, in combination with methotrexate, is recommended as an option for treating rheumatoid arthritis, only if all the following criteria are met:

• disease is severe, that is, a disease activity score (DAS28) greater than 5.1,
• disease has not responded to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs),
• the manufacturers provides abatacept as agreed in the patient access schemes.

Continue treatment only if there is a moderate response measured using European League Against Rheumatism (EULAR) criteria at 6 months after starting therapy. After initial response within 6 months, withdraw treatment if a moderate EULAR response is not maintained.

Patients currently receiving abatacept whose disease does not meet the above criteria should have the option to continue their treatment until they and their clinician consider it appropriate to stop.

www.nice.org.uk/TA375

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for infusion

ELECTROLYTES: May contain Sodium

Orencia (Bristol-Myers Squibb Pharmaceuticals Ltd)
Abatacept 250 mg Orencia 250mg powder for concentrate for solution for infusion vials 1 vial £302.40 (Hospital only)

IMMUNOSUPPRESSANTS → TUMOR NECROSION FACTOR ALPHA (TNF-α) INHIBITORS

Adalimumab

INDICATIONS AND DOSE
Severe plaque psoriasis either refractory to at least 2 standard systemic treatments or photochemotherapy, or when standard treatments cannot be used because of intolerance or contra-indications

BY SUBCUTANEOUS INJECTION

Adult: Initially 80 mg, then 40 mg every 2 weeks, to be started 1 week after initial dose, discontinue treatment if no response within 16 weeks

Moderate-to-severe active rheumatoid arthritis (in combination with methotrexate or alone if methotrexate inappropriate) when response to other disease-modifying drugs (including methotrexate) has been inadequate • Severe, active, and progressive rheumatoid arthritis (in combination with methotrexate or alone if methotrexate inappropriate) not previously treated with methotrexate

BY SUBCUTANEOUS INJECTION

Adult: 40 mg every 2 weeks, then increased if necessary to 40 mg once weekly, dose to be increased only in patients receiving adalimumab alone, review treatment if no response within 12 weeks

Active and progressive psoriatic arthritis that has not responded adequately to other disease-modifying antirheumatic drugs • Severe active ankylosing spondylitis that has not responded adequately to other disease-modifying antirheumatic drugs • Severe axial spondyloarthritis without radiographic evidence of ankylosing spondylitis but with objective signs of inflammation, in patients who have had an inadequate response to, or are intolerant of, NSAIDs

BY SUBCUTANEOUS INJECTION

Adult: 40 mg every 2 weeks, discontinue treatment if no response within 12 weeks

Severe active Crohn’s disease

BY SUBCUTANEOUS INJECTION

Adult: Initially 80 mg, then 40 mg after 2 weeks; maintenance 40 mg every 2 weeks, increased if necessary to 40 mg once weekly, maximum 40 mg administered at a single site, review treatment if no response within 12 weeks of initial dose

Severe active Crohn’s disease (accelerated regimen)

BY SUBCUTANEOUS INJECTION

Adult: Initially 160 mg, dose can alternatively be given as divided injections over 2 days, then 80 mg after 2 weeks; maintenance 40 mg every 2 weeks, increased if necessary to 40 mg once weekly, maximum 40 mg administered at a single site, review treatment if no response within 12 weeks of initial dose

27-Apr-2017
Severe active ulcerative colitis

▶ By subcutaneous injection

- Adult: Initially 160 mg, dose can alternatively be given as divided injections over 2 days, then 80 mg after 2 weeks; maintenance 40 mg every 2 weeks, increased if necessary to 40 mg once weekly, maximum 40 mg administered at a single site, review treatment if no response within 8 weeks of initial dose.

Active moderate to severe hidradenitis suppurativa (acne inversa) in patients with an inadequate response to conventional systemic therapy

▶ By subcutaneous injection

- Adult: Initially 160 mg, given as either four 40 mg injections in one day or as two 40 mg injections per day for 2 consecutive days, followed by 80 mg after 2 weeks, given as two 40 mg injections in one day, then 40 mg after 2 weeks; maintenance 40 mg once weekly, review treatment if no response within 12 weeks; if treatment interrupted—consult product literature.

Uveitis (in combination with corticosteroids or alone if corticosteroids inappropriate), with or without other disease-modifying drugs (initiated under specialist supervision)

▶ By subcutaneous injection

- Adult: Initially 80 mg, given as two 40 mg injections in one day, then 40 mg after 1 week; maintenance 40 mg every 2 weeks.

Contraindications

- Moderate or severe heart failure
- Severe infection

Caution

- Demyelinating disorders (risk of exacerbation), development of malignancy. Do not initiate until active infections are controlled (discontinue if new serious infection develops), hepatitis B virus—monitor for active infection, history of malignancy, mild heart failure (discontinue if symptoms develop or worsen), predisposition to infection.

Caution, further information

- Tuberculosis: Active tuberculosis should be treated with standard treatment for at least 2 months before starting adalimumab. Patients who have previously received adequate treatment for tuberculosis can start adalimumab but should be monitored every 3 months for possible recurrence. In patients without active tuberculosis but who were previously not treated adequately, chemoprophylaxis should ideally be completed before starting adalimumab. In patients at high risk of tuberculosis who cannot be assessed by tuberculin skin test, chemoprophylaxis can be given concurrently with adalimumab.

Interactions

- Appendix 1: monoclonal antibodies.

Side-effects

- Common or very common: Anxiety, benign tumours, chest pain, cough, dehydration, dermatitis, dizziness, dyspepsia, dyspnoea, electrolyte disturbances, eye disorders, flushing, gastrointestinal haemorrhage, haematuria, hyperlipidaemia, hypertension, hyperuricaemia, impaired healing, mood changes, musculoskeletal pain, oedema, onycholysis, paraesthesia, rash, renal impairment, skin cancer, sleep disturbances, tachycardia, vomiting.

- Uncommon: Aortic aneurysm, arrhythmias, cholecystitis, cholelithiasis, dysphagia, erectile dysfunction, hearing loss, hepatic steatosis, interstitial lung disease, leukaemia, lymphoma, malignancy, neuropathy, nocturia, pancreatitis, pneumonitis, rhabdomyolysis, solid tumours, tinnitus, tremor, vascular occlusion.

- Rare: Autoimmune hepatitis, demyelinating disorders, myocardial infarction.

- Frequency not known: Abdominal pain, anaemia, antibody formation, aplastic anaemia, blood disorders, cutaneous vasculitis, depression, fever, headache, hypersensitivity reactions, injection-site reactions, leucopenia, lupus erythematosus-like syndrome, nausea, new onset psoriasis, pancytopenia, pleural effusion, pruritus, pulmonary embolism, sarcoidosis, Stevens-Johnson syndrome, thrombocytopenia, worsening heart failure, worsening of symptoms of dermatomyositis, worsening psoriasis.

Side-effects, further information

- Associated with infections, sometimes severe, including tuberculosis, septicaemia, and hepatitis B reactivation.

- Conception and contraception: Manufacturer advises effective contraception required during treatment and for at least 5 months after last dose.

- Pregnancy: Avoid.

- Breast feeding: Avoid; manufacturer advises avoid for at least 5 months after last dose.

- Pre-treatment screening:
  - Tuberculosis: Patients should be evaluated for tuberculosis before treatment.

- Monitoring requirements:
  - Manufacturer advises monitor for infection before, during, and for 4 months after treatment.
  - Manufacturer advises monitor for non-melanoma skin cancer before and during treatment, especially in patients with a history of PUVA treatment for psoriasis or extensive immunosuppressant therapy.

- For uveitis, manufacturer advises patients should be assessed for pre-existing or developing central demyelinating disorders before and at regular intervals during treatment.

- Patient and carer advice: An alert card should be provided.

When used to treat hidradenitis suppurativa, patients and their carers should be advised to use a daily topical antiseptic wash on lesions during treatment with adalimumab.

Tuberculosis: Patients and their carers should be advised to seek medical attention if symptoms suggestive of tuberculosis (e.g. persistent cough, weight loss, or fever) develop.

Blood disorders: Patients and their carers should be advised to seek medical attention if symptoms suggestive of blood disorders (such as fever, sore throat, bruising, or bleeding) develop.

National funding/access decisions

- NICE technology appraisals (TAs):
  - Adalimumab for plaque psoriasis in adults (June 2008)
  - NICE TA146
  - Adalimumab is recommended for the treatment of severe plaque psoriasis which has failed to respond to standard systemic treatments (including ciclosporin and methotrexate) and photochemotherapy, or when standard treatments cannot be used because of intolerance or contra-indications. Adalimumab should be withdrawn if the response is not adequate after 16 weeks.

  - Infliximab and adalimumab for Crohn’s disease (May 2010)
  - NICE TA187
  - Adalimumab is recommended for the treatment of severe active Crohn’s disease that has not responded to conventional therapy (including corticosteroids and other drugs affecting the immune response) or when conventional therapy cannot be used because of intolerance or contra-indications. Adalimumab should be used as a planned course of treatment for 12 months or until treatment failure, whichever is shorter. Treatment should be continued beyond 12 months only if there is evidence of active disease—in these cases the need for treatment should be...
reviewed at least annually. If the disease relapses after stopping treatment, adalimumab can be restarted.

www.nice.org.uk/TA187

▶ infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015) NICE TA329 Adalimumab is an option for treating moderately to severely active ulcerative colitis in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or in adults who are intolerant to or have contra-indications for conventional therapies. The choice of treatment should be made on an individual basis and if more than one treatment is suitable, the least expensive should be chosen.

Adalimumab should be given as a planned course of treatment until treatment fails (including the need for surgery) or until 12 months after starting treatment, whichever is shorter. Treatment should be continued only if there is clear evidence of a response. Patients who continue treatment should be reassessed at least every 12 months to determine whether ongoing treatment is still clinically appropriate.

www.nice.org.uk/TA329

▶ Etanercept, infliximab, and adalimumab for the treatment of psoriatic arthritis (August 2010) NICE TA199 Adalimumab is recommended for the treatment of active and progressive psoriatic arthritis in adults who have peripheral arthritis with at least 3 tender joints and at least 3 swollen joints, and who have not responded adequately to at least 2 standard disease-modifying antirheumatic drugs (used alone or in combination). Adalimumab should be discontinued if there is an inadequate response at 12 weeks.

www.nice.org.uk/TA199

▶ Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (August 2010) NICE TA195 Adalimumab, in combination with methotrexate, is an option for the treatment of severe active rheumatoid arthritis in adults who have had an inadequate response to, or have an intolerance of, other DMARDs including at least 1 TNF inhibitor, and who cannot use rituximab because of contra-indications or intolerance. In patients who cannot use methotrexate because of intolerance or contra-indications, adalimumab can be given as monotherapy. Treatment should be continued only if there is adequate response. Patients should be monitored at least every 6 months.

www.nice.org.uk/TA195

▶ Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (January 2016) NICE TA375 Adalimumab, in combination with methotrexate, is recommended as an option for treating rheumatoid arthritis, only if the following criteria are met:
- disease is severe, that is, a disease activity score (DAS28) greater than 5.1, and,
- disease has not responded to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs).

Adalimumab can be used as another therapy in patients who cannot take methotrexate because it is contra-indicated or because of intolerance, when the criteria above are met.

Continue treatment only if there is a moderate response measured using European League Against Rheumatism (EULAR) criteria at 6 months after starting therapy. After initial response within 6 months, withdraw treatment if a moderate EULAR response is not maintained.

Patients currently receiving adalimumab whose disease does not meet the above criteria should have the option to continue their treatment until they and their clinician consider it appropriate to stop.

www.nice.org.uk/TA375

▶ TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (February 2016) NICE TA383 Adalimumab, certolizumab pegol, etanercept, golimumab and infliximab are recommended as options for treating severe active ankylosing spondylitis in patients whose disease has responded inadequately to, or who are intolerant of, non-steroidal anti-inflammatory drugs (NSAIDs).

Adalimumab, certolizumab pegol and etanercept are also recommended as options for treating severe non-radiographic axial spondyloarthritis in patients whose disease has responded inadequately to, or who are intolerant of, NSAIDs.

The response to treatment should be assessed 12 weeks after the start of treatment and should only be continued if there is clear evidence of response.

Treatment with another tumour necrosis factor (TNF)-alpha inhibitor is recommended in those who cannot tolerate, or whose disease has not responded to, treatment with the first TNF-alpha inhibitor, or in those whose disease has stopped responding after an initial response.

www.nice.org.uk/TA383

▶ Adalimumab for treating moderate-to-severe hidradenitis suppurativa (June 2016) NICE TA392 Adalimumab is recommended, within its marketing authorisation, as an option for treating active moderate-to-severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy. The drug is recommended only if the manufacturer provides it at the price agreed in the patient access scheme. Response should be assessed after 12 weeks of treatment, and the drug continued only if there is clear evidence of response, defined as a reduction of 25% or more in the total abscess and inflammatory nodule count and no increase in abscesses and draining fistulas.

www.nice.org.uk/TA392

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium issued similar advice for plaque psoriasis to NICE TA146 in May 2008.

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug.

Solution for Injection

Cautionary and Advisory Labels

▶ Humira (Abbvie Ltd)

| Adalimumab 50 mg per 1 ml | Humira 40mg/0.8ml solution for injection pre-filled syringes | 2 pre-filled disposable injection | £704.28
| Humira 40mg/0.8ml solution for injection pre-filled pen | 2 pre-filled disposable injection | £704.28
| Humira 40mg/0.8ml solution for injection vials | 2 vial | £704.28
| Adalimumab 100 mg per 1 ml | Humira 40mg/0.4ml solution for injection pre-filled pen | 2 pre-filled disposable injection | £704.28
| Humira 40mg/0.4ml solution for injection pre-filled syringes | 2 pre-filled disposable injection | £704.28
Certolizumab pegol

**INDICATIONS AND DOSE**

Moderate to severe active rheumatoid arthritis when response to disease-modifying antirheumatic drugs (including methotrexate) has been inadequate (as monotherapy or in combination with methotrexate)

Severe, active and progressive rheumatoid arthritis in patients not previously treated with methotrexate or other disease-modifying antirheumatic drugs (in combination with methotrexate)

Active psoriatic arthritis when response to disease-modifying antirheumatic drugs has been inadequate (as monotherapy or in combination with methotrexate)

**BY SUBCUTANEOUS INJECTION**

Adult: Loading dose 400 mg every 2 weeks for 3 doses, then maintenance 200 mg every 2 weeks, once clinical response is confirmed, an alternative maintenance dosing of 400 mg every 4 weeks can be considered, review treatment if no response within 12 weeks

**TREATMENT OF SEVERE ACTIVE ANKYLOSING SPONDYLITIS IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO, OR ARE INTOLERANT OF NSAIADS**

Tuberculosis

**CONTRA-INDICATIONS**

Moderate to severe heart failure - severe active infection

**CAUTIONS**

Demyelinating CNS disorders (risk of exacerbation) - do not initiate until active infections are controlled (discontinue if new serious infection develops and until infection controlled) - hepatitis B virus (monitor for active infection) - history or development of malignancy - mild heart failure (discontinue if symptoms develop or worsen) - predisposition to infection

**CAUTIONS, FURTHER INFORMATION**

Tuberculosis

Active tuberculosis should be treated with standard treatment for at least 2 months before starting certolizumab pegol. Patients who have previously received adequate treatment for tuberculosis can start certolizumab pegol but should be monitored every 3 months for possible recurrence. In patients without active tuberculosis but who were previously not treated adequately, chemoprophylaxis should ideally be completed before starting certolizumab pegol. In patients at high risk of tuberculosis who cannot be assessed by tuberculin skin test, chemoprophylaxis can be given concurrently with certolizumab pegol.

**INTERACTIONS**

Appendix 1: monoclonal antibodies

**SIDE-EFFECTS**

Common or very common

Hypertension - rash - sensory abnormalities

Uncommon


Rare

Atioventricular block - cerebrovascular accident - cholelithiasis - impaired coordination - interstitial lung disease - nephropathy - Raynaud’s phenomenon - seizures - sexual dysfunction - splenomegaly - thyroid disorders - trigeminal neuralgia

Frequency not known


**SIDE-EFFECTS, FURTHER INFORMATION**

Infection

Associated with infections, sometimes severe, including tuberculosis, septicemia, and hepatitis B reactivation.

**CONCEPTION AND CONTRACEPTION**

Manufacturer advises adequate contraception during treatment and for at least 5 months after last dose.

**PREGNANCY**

Avoid.

**BREAST FEEDING**

Manufacturer advises use only if potential benefit outweighs risk — no information available.

**PRE-TREATMENT SCREENING**

Tuberculosis

Patients should be evaluated for tuberculosis before treatment.

**MONITORING REQUIREMENTS**

Monitor for infection before, during, and for 5 months after treatment.

**PATIENT AND CARER ADVICE**

An alert card should be provided.

Blood disorders

Patients should be advised to seek medical attention if symptoms suggestive of blood disorders (such as fever, sore throat, bruising, or bleeding) develop.

Tuberculosis

Patients should be advised to seek medical attention if symptoms suggestive of tuberculosis (e.g. persistent cough, weight loss and fever) develop.

**NATIONAL FUNDING/ACCESS DECISIONS**

NICE technology appraisals (TAs)

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (January 2016) NICE TA375

Certolizumab pegol, in combination with methotrexate, is recommended as an option for treating rheumatoid arthritis, only if the following criteria are met:

- disease is severe, that is, a disease activity score (DAS28) greater than 5.1,
- disease has not responded to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs),
- the manufacturers provide certolizumab pegol as agreed in the patient access schemes.

Certolizumab pegol can be used as monotherapy in patients who cannot take methotrexate because it is contra-indicated or because of intolerance, when the criteria above are met.

Continue treatment only if there is a moderate response measured using European League Against Rheumatism (EULAR) criteria at 6 months after starting therapy. After initial response within 6 months, withdraw treatment if a moderate EULAR response is not maintained.

Patients currently receiving certolizumab pegol within the NHS whose disease does not meet the above criteria should have the option to continue their treatment until they and their clinician consider it appropriate to stop.

www.nice.org.uk/TA375
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (February 2016)

NICE TA383

Adalimumab, certolizumab pegol, etanercept, golimumab and infliximab are recommended as options for treating severe active ankylosing spondylitis in adult patients whose disease has responded inadequately to, or who are intolerant of, non-steroidal anti-inflammatory drugs.

Adalimumab, certolizumab pegol and etanercept are also recommended as options for treating severe non-radiographic axial spondyloarthritis in patients whose disease has responded inadequately to, or who are intolerant of, non-steroidal anti-inflammatory drugs (NSAIDs).

The response to treatment should be assessed 12 weeks after the start of treatment. Treatment should only be continued if there is clear evidence of response.

Treatment with another tumour necrosis factor (TNF) alpha inhibitor is recommended in those who cannot tolerate, or whose disease has not responded to, treatment with the first TNF alpha inhibitor, or in those whose disease has stopped responding after an initial response.

www.nice.org.uk/TA383

Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor (October 2016)

NICE TA415

Certolizumab pegol, in combination with methotrexate, or as monotherapy, is recommended as an option for treating active rheumatoid arthritis in adults who have had an inadequate response to, or who cannot tolerate, other disease-modifying antirheumatic drugs (DMARDs) including at least 1 tumour necrosis factor-alpha (TNF-alpha) inhibitor, only if the following criteria are met:

- disease activity is severe and
- rituximab is contra-indicated or not tolerated, or if monotherapy, rituximab cannot be given because methotrexate is contra-indicated or not tolerated and
- the manufacturers provide certolizumab pegol as agreed in the patient access scheme.

Continue treatment only if there is at least a moderate response measured using European League Against Rheumatism (EULAR) criteria at 6 months after starting therapy. After initial response within 6 months, withdraw treatment if at least a moderate EULAR response is not maintained.

Patients whose treatment was started within the NHS before this guidance was published should have the option to continue treatment, without change to their funding arrangements, until they and their clinician consider it appropriate to stop.

www.nice.org.uk/TA415

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (July 2014) that certolizumab pegol is accepted for restricted use within NHS Scotland, in combination with methotrexate, for the treatment of active psoriatic arthritis in patients whose disease has not responded to adequate trials of at least two standard disease-modifying antirheumatic drugs (DMARDs), administered either individually or in combination.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

CAUTIONARY AND ADVISORY LABELS

- Cimzia (UCB Pharma Ltd)

Certolizumab pegol 200 mg per 1 ml Cimzia 200mg/1ml solution for injection pre-filled pen | 2 pre-filled disposable injection £115.00

Cimzia 200mg/1ml solution for injection pre-filled syringes | 2 syringe £115.00

Etanercept

07-Jun-2017

INDICATIONS AND DOSE

BENEPALE® SOLUTION FOR INJECTION

Moderate-to-severe active rheumatoid arthritis (alone or in combination with methotrexate) when the response to other disease-modifying antirheumatic drugs is inadequate | Severe, active and progressive rheumatoid arthritis not previously treated with methotrexate | Active and progressive psoriatic arthritis when the response to other disease-modifying antirheumatic drugs is inadequate | Severe active ankylosing spondylitis when the response to conventional therapy is inadequate | Severe, non-radiographic axial spondylarthropathy when the response to non-steroidal anti-inflammatory drugs is inadequate

- BY SUBCUTANEOUS INJECTION
- Adult: 50 mg once weekly, review treatment if no response within 12 weeks of initial dose

Moderate-to-severe plaque psoriasis when the response to other systemic therapies or psoralen and ultraviolet-A light (PUVA) is inadequate, or when these therapies cannot be used because of intolerance or contra-indications

- BY SUBCUTANEOUS INJECTION
- Adult: 50 mg once weekly, alternatively 50 mg twice weekly for up to 12 weeks, followed by 50 mg once weekly if required continue treatment for up to 24 weeks — continuous therapy beyond 24 weeks may be appropriate in some patients (consult product literature), discontinue if no response after 12 weeks

ENBREL® POWDER AND SOLVENT FOR SOLUTION FOR INJECTION

Moderate-to-severe active rheumatoid arthritis (alone or in combination with methotrexate) when the response to other disease-modifying antirheumatic drugs is inadequate | Severe, active and progressive rheumatoid arthritis not previously treated with methotrexate | Active and progressive psoriatic arthritis when the response to other disease-modifying antirheumatic drugs is inadequate | Severe active ankylosing spondylitis when the response to conventional therapy is inadequate | Severe, non-radiographic axial spondylarthropathy when the response to non-steroidal anti-inflammatory drugs is inadequate

- BY SUBCUTANEOUS INJECTION
- Adult: 25 mg twice weekly, alternatively 50 mg once weekly, review treatment if no response within 12 weeks of initial dose

Moderate-to-severe plaque psoriasis when the response to other systemic therapies or psoralen and ultraviolet-A light (PUVA) is inadequate, or when these therapies cannot be used because of intolerance or contra-indications

- BY SUBCUTANEOUS INJECTION
- Adult: 25 mg twice weekly, alternatively 50 mg once weekly, alternatively 50 mg twice weekly for up to 12 weeks, followed by 25 mg twice weekly, alternatively 50 mg once weekly if required continue treatment for up to 24 weeks — continuous therapy beyond 24 weeks may be appropriate in some patients (consult product literature), discontinue if no response after 12 weeks
■ CONTRA-INDICATIONS Active infection

■ CAUTIONS Development of malignancy · diabetes mellitus · heart failure (risk of exacerbation) · hepatitis B virus—monitor for active infection · hepatitis C infection (monitor for worsening infection) · history of blood disorders · history of malignancy · history or increased risk of demyelinating disorders · predisposition to infection (avoid if predisposition to septicemia) · significant exposure to herpes zoster virus—interrupt treatment and consider varicella—zoster immunoglobulin

CAUTIONS, FURTHER INFORMATION

■ Tuberculosis Active tuberculosis should be treated with standard treatment for at least 2 months before starting etanercept. Patients who have previously received adequate treatment for tuberculosis can start etanercept but should be monitored every 3 months for possible recurrence. In patients without active tuberculosis but who were previously not treated adequately, chemoprophylaxis should ideally be completed before starting etanercept. In patients at high risk of tuberculosis who cannot be assessed by tuberculin skin test, chemoprophylaxis can be given concurrently with etanercept.

■ INTERACTIONS ➔ Appendix 1: etanercept

■ SIDE-EFFECTS

■ Uncommon Intestinal lung disease · new onset or worsening psoriasis · rash · skin cancer · uveitis

■ Rare Demyelinating disorders · lymphoma · seizures · Stevens-Johnson syndrome · vasculitis

■ Very rare Toxic epidermal necrolysis

■ Frequency not known Abdominal pain · anaemia · antibody formation · aplastic anaemia · appendicitis · blood disorders · cutaneous ulcer · depression · diabetes mellitus · fever · gastritis · headache · hypersensitivity reactions · inflammatory bowel disease · injection-site reactions · leucopenia · leukaemia · lupus erythematosus-like syndrome · macrophage activation syndrome · malignancy · nausea · oesophagitis · pancytopenia · pruritus · solid tumours · thrombocytopenia · vomiting · worsening heart failure

SIDE-EFFECTS, FURTHER INFORMATION

Associated with infections, sometimes severe, including tuberculosis, septicemia, and hepatitis B reactivation.

■ CONCEPTION AND CONTRACEPTION Manufacturer advises effective contraception required during treatment and for 3 weeks after last dose.

■ PREGNANCY Avoid—limited information available.

■ BREAST FEEDING Manufacturer advises avoid—present in milk in animal studies.

■ HEPATIC IMPAIRMENT Use with caution in moderate to severe alcoholic hepatitis.

■ PRE-TREATMENT SCREENING

Tuberculosis Patients should be evaluated for tuberculosis before treatment.

■ MONITORING REQUIREMENTS Monitor for skin cancer before and during treatment, particularly in those at risk (including patients with psoriasis or a history of PUVA treatment).

■ PRESCRIBING AND DISPENSING INFORMATION

Etanercept is a biological medicine. Biological medicines must be prescribed and dispensed by brand name, see Biological medicines and Biosimilar medicines, under Guidance on prescribing p. 1.

■ PATIENT AND CARER ADVICE

An alert card should be provided.

Blood disorders Patients and their carers should be advised to seek medical attention if symptoms suggestive of blood disorders (such as fever, sore throat, bruising, or bleeding) develop.

Tuberculosis Patients and their carers should be advised to seek medical attention if symptoms suggestive of tuberculosis (e.g. persistent cough, weight loss, and fever) develop.

■ NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

■ Etanercept and efalizumab for plaque psoriasis (July 2006) NICE TA103

Etanercept is recommended for severe plaque psoriasis which has failed to respond to standard systemic treatments (including ciclosporin and methotrexate) and to photochemotherapy, or when standard treatments cannot be used because of intolerance or contra-indications. Etanercept should be withdrawn if the response is not adequate after 12 weeks.

www.nice.org.uk/TA103

■ Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (August 2010) NICE TA195

Etanercept, in combination with methotrexate, is an option for the treatment of severe active rheumatoid arthritis in adults who have had an inadequate response to, or have an intolerance of, other DMARDs including at least 1 TNF inhibitor, and who cannot use rituximab because of contra-indications or intolerance. In patients who cannot use methotrexate because of intolerance or contra-indications, etanercept can be given as monotherapy. Treatment should be continued only if there is adequate response. Patients should be monitored at least every 6 months.

www.nice.org.uk/TA195

■ Etanercept, infliximab, and adalimumab for the treatment of psoriatic arthritis (August 2010) NICE TA199

Etanercept is recommended for the treatment of active and progressive psoriatic arthritis in adults who have peripheral arthritis with at least 3 tender joints and at least 3 swollen joints, and who have not responded adequately to at least 2 standard disease-modifying antirheumatic drugs (used alone or in combination).
Enbrel etanercept should be discontinued if there is an inadequate response at 12 weeks. www.nice.org.uk/TA199

- Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (January 2016) NICE TA375

Etanercept, in combination with methotrexate, is recommended as an option for treating rheumatoid arthritis, only if the following criteria are met:
- disease is severe, that is, a disease activity score (DAS28) greater than 5.1, and
- disease has not responded to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs)

Etanercept can be used as monotherapy in patients who cannot take methotrexate because it is contra-indicated or because of intolerance, when the criteria above are met.

Continue treatment only if there is a moderate response measured using European League Against Rheumatism (EULAR) criteria at 6 months after starting therapy. After initial response within 6 months, withdraw treatment if a moderate EULAR response is not maintained.

Patients currently receiving etanercept whose disease does not meet the above criteria should have the option to continue their treatment until they and their clinician consider it appropriate to stop.

www.nice.org.uk/TA375

- TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (February 2016) NICE TA383

Adalimumab, certolizumab pegol, etanercept, golimumab and infliximab are recommended as options for treating severe active ankylosing spondylitis in patients whose disease has responded inadequately to, or who are intolerant of, non-steroidal anti-inflammatory drugs (NSAIDs).

Adalimumab, certolizumab pegol and etanercept are also recommended as options for treating severe non-radiographic axial spondyloarthritis in patients whose disease has responded inadequately to, or who are intolerant of, NSAIDs.

The response to treatment should be assessed 12 weeks after the start of treatment and should only be continued if there is clear evidence of response.

Treatment with another tumour necrosis factor (TNF)-alpha inhibitor is recommended in those who cannot tolerate, or whose disease has not responded to, treatment with the first TNF-alpha inhibitor, or in those whose disease has stopped responding after an initial response.

www.nice.org.uk/TA383

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium issued similar advice to NICE TA103 on the use of etanercept for severe plaque psoriasis in adults (August 2009) and children over 6 years old (April 2012).

- INDICATIONS AND DOSE

Treatment of severe ulcerative colitis in patients whose condition has not responded adequately to conventional therapy, or who are intolerant of it

- BY SUBCUTANEOUS INJECTION

  - Adult (body-weight up to 80 kg): Initially 200 mg, then 100 mg after 2 weeks; maintenance 50 mg every 4 weeks, review treatment if no response after 4 doses

  - Adult (body-weight 80 kg and above): Initially 200 mg, then 100 mg after 2 weeks; maintenance 100 mg every 4 weeks, review treatment if no response after 4 doses

- Treatment of moderate to severe active rheumatoid arthritis (in combination with methotrexate) when response to disease-modifying antirheumatic drug (DMARD) therapy (including methotrexate) has been inadequate | Treatment of severe, active, and progressive rheumatoid arthritis (in combination with methotrexate) in patients not previously treated with methotrexate | Treatment of active and progressive psoriatic arthritis as monotherapy or in combination with methotrexate when response to DMARD therapy has been inadequate | Treatment of severe active ankylosing spondylitis when there is inadequate response to conventional treatment

- BY SUBCUTANEOUS INJECTION

  - Adult (body-weight up to 100 kg): 50 mg once a month, on the same date each month, review treatment if no response after 3–4 doses

  - Adult (body-weight 100 kg and above): Initially 50 mg once a month for 3–4 doses, on the same date each month, dose may be increased if inadequate response, increased to 100 mg once a month, review treatment if inadequate response to this higher dose after 3–4 doses

- CONTRA-INDICATIONS

  - Moderate or severe heart failure - severe active infection

- CAUTIONS

  - Active infection (do not initiate until active infections are controlled; discontinue if new serious infection develops until infection controlled) - demyelinating disorders (risk of exacerbation) - hepatitis B virus—monitor for active infection - history or development of malignancy - mild heart failure (discontinue if symptoms develop or worsen) - predisposition to infection - risk factors for dysplasia or carcinoma of the colon—screen for dysplasia regularly

- CAUTIONS, FURTHER INFORMATION

  - Tuberculosis: Active tuberculosis should be treated with standard treatment for at least 2 months before starting golimumab. Patients who have previously received adequate treatment for tuberculosis can start golimumab but should be monitored every 3 months for possible recurrence. In patients without active tuberculosis but who were previously not treated adequately, chemoprophylaxis should ideally be completed before starting golimumab. In patients at high risk of tuberculosis who cannot be assessed by tuberculin skin test, chemoprophylaxis can be given concurrently with...
golimumab. Patients who have tested negative for latent tuberculosis, and those who are receiving or who have completed treatment for latent tuberculosis, should be monitored closely for symptoms of active infection.

**INTERACTIONS**  
Appendix 1: monoclonal antibodies

**SIDE-EFFECTS**

- **Common or very common**  
  Asthenia, dizziness, dyspepsia, hypertension

- **Uncommon**  
  Alopecia, arthralgia, bone fractures, bronchospasm, cholelithiasis, colitis, constipation, demyelinating disorders, dermatitis, eye irritation, flushing, gastritis, gastro-oesophageal reflux disease, heart failure, hepatic disorders, hyperglycaemia, hyperlipidaemia, insomnia, interstitial lung disease, ischaemic coronary artery disorders, lymphoma, malignancy, melasma, menstrual disorders, new onset or worsening psoriasis, paraesthesia, Raynaud’s syndrome, stomatitis, taste disturbance, thrombosis, thyroid disorders, visual disturbance

- **Rare**  
  Impaired wound healing

- **Frequency not known**  
  Abdominal pain, anaemia, antibody formation, aplastic anaemia, blood disorders, depression, fever, headache, hypersensitivity reactions, injection-site reactions, leukopenia, lupus erythematosus-like syndrome, nausea, pancytopenia, pruritus, thrombocytopenia, worsening heart failure

**SIDE-EFFECTS, FURTHER INFORMATION**

Associated with infections, sometimes severe, including tuberculosis, septicaemia, and hepatitis B reactivation.

**CONCEPTION AND CONTRACEPTION**

Manufacturer advises adequate contraception during treatment and for at least 6 months after last dose.

**PREGNANCY**

Use only if essential.

**BREAST FEEDING**

Manufacturer advises avoid during and for at least 6 months after treatment—present in milk in animal studies.

**HEPATIC IMPAIRMENT**

Manufacturer advises caution—no information available.

**PRE-TREATMENT SCREENING**

Tuberculosis  
Patients should be evaluated for tuberculosis before treatment.

**MONITORING REQUIREMENTS**

Monitor for infection before, during, and for 5 months after treatment.

**DIRECTIONS FOR ADMINISTRATION**

For doses requiring multiple injections, each injection should be administered at a different site.  
Missed dose  
If dose administered more than 2 weeks late, subsequent doses should be administered on a new monthly due date.

**PATIENT AND CARER ADVICE**

An alert card should be provided.  
Tuberculosis  
All patients and their carers should be advised to seek medical attention if symptoms suggestive of tuberculosis (e.g., persistent cough, weight loss, and fever) develop.  
Blood disorders  
Patients and their carers should be advised to seek medical attention if symptoms suggestive of blood disorders (such as fever, sore throat, bruising, or bleeding) develop.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- **Golimumab for the treatment of psoriatic arthritis (April 2011)** NICE TA220  
  Golimumab is an option for the treatment of active and progressive psoriatic arthritis in adults only if:  
  - golimumab is used as described in the NICE guidance (August 2010) for other tumour necrosis factor (TNF) inhibitors, and  
  - the manufacturer provides the 100-mg dose of golimumab at the same price as the 50-mg dose.  
  www.nice.org.uk/TA220

- **Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015)** NICE TA329  
  Golimumab is an option for treating moderately to severely active ulcerative colitis in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or in adults who are intolerant to or have contra-indications for conventional therapies.

  Golimumab is recommended only if the manufacturer provides the 100 mg dose of golimumab at the same dose as the 50 mg dose, as agreed in the patient access scheme.

  The choice of treatment should be made on an individual basis and if more than one treatment is suitable, the least expensive should be chosen.

  Golimumab should be given as a planned course of treatment until treatment fails (including the need for surgery) or until 12 months after starting treatment, whichever is shorter. Treatment should be continued only if there is clear evidence of a response. Patients who continue treatment should be reassessed at least every 12 months to determine whether ongoing treatment is still clinically appropriate.

  www.nice.org.uk/TA329

- **Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (January 2016)** NICE TA375  
  Golimumab, in combination with methotrexate, is recommended as an option for treating rheumatoid arthritis, only if all the following criteria are met:
  - disease is severe, that is, a disease activity score (DAS28) greater than 5.1,
  - disease has not responded to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs),
  - the manufacturer provides golimumab as agreed in the patient access schemes.

  Continue treatment only if there is a moderate response measured using European League Against Rheumatism (EULAR) criteria at 6 months after starting therapy. After initial response within 6 months, withdraw treatment if a moderate EULAR response is not maintained.

  Patients currently receiving treatment with golimumab whose disease does not meet the above criteria should have the option to continue their treatment until they and their clinician consider it appropriate to stop.

  www.nice.org.uk/TA375

- **TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (February 2016)** NICE TA383  
  Adalimumab, certolizumab pegol, etanercept, golimumab and infliximab are recommended as options for treating severe active ankylosing spondylitis in patients whose disease has responded inadequately to, or who are intolerant of, non-steroidal anti-inflammatory drugs (NSAIDs).

  The response to treatment should be assessed 12 weeks after the start of treatment. Treatment should only be continued if there is clear evidence of response.

  Treatment with another tumour necrosis factor (TNF) alpha inhibitor is recommended in those who cannot tolerate, or whose disease has not responded to, treatment with the first TNF-alpha inhibitor, or in those whose disease has stopped responding after an initial response.

  www.nice.org.uk/TA383
Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs (June 2011—updated February 2016) NICE TA225

Golimumab, in combination with methotrexate, is an option for the treatment of rheumatoid arthritis in patients who have had an inadequate response to DMARDs, including a TNF inhibitor, if golimumab is used as described in the NICE technology appraisal guidance 195 (August 2010) for other TNF inhibitors, and the manufacturer provides the 100-mg dose of golimumab at the same price as the 50-mg dose.

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (June 2012) that golimumab (Simponi®) is accepted for restricted use within NHS Scotland at a dose of 50 mg, alone or in combination with methotrexate, for the treatment of active and progressive psoriatic arthritis in adults whose disease has not responded to adequate trials of at least two standard DMARDs, administered either individually or in combination.

All Wales Medicines Strategy Group (AWMSG) Decisions

The All Wales Medicines Strategy Group has advised (October 2016) that Golimumab (Simponi®) is recommended as an option for use within NHS Wales for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation (indicated by elevated C reactive protein and/or magnetic resonance imaging evidence, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs. The recommendation applies only if the approved Wales Patient Access Scheme (WPAS) is used or where the list/contract price is equivalent or lower.

MEDICAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

CAUTIONARY AND ADVISORY LABELS 10

Simponi (Merk Sharp & Dohme Ltd)

Golimumab 100 mg per 1 ml Simponi 50mg/0.5ml solution for injection pre-filled disposable devices | 1 pre-filled disposable injection £762.97

Simponi 100mg/1ml solution for injection pre-filled pen | 1 pre-filled disposable injection £1,525.94

Simponi 50mg/0.5ml solution for injection pre-filled syringes | 1 pre-filled disposable injection £762.97

Infliximab

INDICATIONS AND DOSE

Severe active Crohn’s disease

BY INTRAVENOUS INFUSION

Adult: Initially 5 mg/kg, then 5 mg/kg after 2 weeks, then 5 mg/kg after 4 weeks, if condition has responded, then maintenance 5 mg/kg every 8 weeks

Fistulating Crohn’s disease

BY INTRAVENOUS INFUSION

Adult: Initially 5 mg/kg, then 5 mg/kg after 2 weeks, followed by 5 mg/kg after 4 weeks, if condition has responded consult product literature for guidance on further doses

Severe active ulcerative colitis

BY INTRAVENOUS INFUSION

Adult: Initially 5 mg/kg, then 5 mg/kg after 2 weeks, followed by 5 mg/kg after 4 weeks, then 5 mg/kg every 8 weeks, discontinue if no response 14 weeks after initial dose

Rheumatoid arthritis (in combination with methotrexate)

BY INTRAVENOUS INFUSION

Adult: Initially 3 mg/kg, then 3 mg/kg after 2 weeks, followed by 3 mg/kg after 4 weeks, then 3 mg/kg every 8 weeks, dose to be increased only if response is inadequate after 12 weeks of initial treatment; increased in steps of 1.5 mg/kg every 8 weeks, increased if necessary up to 7.5 mg/kg every 8 weeks, alternatively increased if necessary to 3 mg/kg every 4 weeks, discontinue if no response by 12 weeks of initial infusion or after dose adjustment

Ankylosing spondylitis

BY INTRAVENOUS INFUSION

Adult: 5 mg/kg, then 5 mg/kg after 2 weeks, followed by 5 mg/kg after 4 weeks, then 5 mg/kg every 6–8 weeks, discontinue if no response by 6 weeks of initial infusion

Psoriatic arthritis (in combination with methotrexate)

BY INTRAVENOUS INFUSION

Adult: 5 mg/kg, then 5 mg/kg after 2 weeks, followed by 5 mg/kg after 4 weeks, followed by 5 mg/kg every 8 weeks

Plaque psoriasis

BY INTRAVENOUS INFUSION

Adult: 5 mg/kg, then 5 mg/kg after 2 weeks, followed by 5 mg/kg after 4 weeks, then 5 mg/kg every 8 weeks, discontinue if no response within 14 weeks of initial infusion

IMPORTANT SAFETY INFORMATION

Adequate resuscitation facilities must be available when infliximab is used.

CONTRA-INDICATIONS

Moderate or severe heart failure • severe infections

CAUTIONS

Demyelinating disorders (risk of exacerbation) • dermatomyositis • development of malignancy • hepatitis B virus—monitor for active infection • history of colon carcinoma (in inflammatory bowel disease) • history of dysplasia (in inflammatory bowel disease) • history of malignancy • history of prolonged immunosuppressant or PUVA treatment in patients with psoriasis • mild heart failure (discontinue if symptoms develop or worsen) • predisposition to infection (discontinue if new serious infection develops) • risk of delayed hypersensitivity reactions if drug-free interval exceeds 16 weeks (re-administration after interval exceeding 16 weeks not recommended)

CAUTIONS, FURTHER INFORMATION

Tuberculosis

Manufacturer advises to evaluate patients for tuberculosis before treatment. Active tuberculosis should be treated with standard treatment for at least 2 months before starting infliximab. If latent tuberculosis is diagnosed, treatment should be started before commencing treatment with infliximab. Patients who have previously received adequate treatment for tuberculosis can start infliximab but should be monitored every 3 months for possible recurrence. In patients without active tuberculosis but who were previously not treated adequately, chemoprophylaxis should ideally be completed before starting infliximab. In patients at high risk of tuberculosis who cannot be assessed by tuberculin skin test, chemoprophylaxis can be given concurrently with infliximab. Patients should be advised to seek medical attention if symptoms suggestive of tuberculosis develop (e.g. persistent cough, weight loss and fever).

Hypersensitivity reactions

Hypersensitivity reactions (including fever, chest pain, hypotension, hypertension, dyspnoea, transient visual loss, pruritus, urticaria, serum sickness-like reactions, angioedema, anaphylaxis) reported during or within 1–2 hours after infusion (risk
greatest during first or second infusion or in patients who discontinue other immunosuppressants). Manufacturer advises prophylactic antipyretics, antihistamines, or hydrocortisone may be administered.

**INTERACTIONS** → Appendix 1: monoclonal antibodies

**SIDE-EFFECTS**

- **Common or very common** Alopecia · arthralgia · constipation · diarrhoea · dizziness · dry skin · dyspepsia · ecchymosis · epistaxis · flushing · gastro-intestinal haemorrhage · gastro-oesophageal reflux · hyperhydrosis · hypertension · hypoaesthesia · hypotension · myalgia · new onset or worsening psoriasis · palpitation · paraesthesia · rash · sleep disturbances · tachycardia

- **Uncommon** Abnormal skin pigmentation · agitation · amnesia · arrhythmia · bradycardia · bullous eruption · cheilitis · cholecystitis · confusion · eye disorders · heart failure · hepatitis · hyperkeratosis · impaired healing · intestinal perforation · nervoussness · neuropathy · pancreatitis · peripheral ischaemia · pleurisy · pulmonary oedema · rosacea · seborrhoea · seizures · syncope · vaginitis

- **Rare** Demyelinating disorders · interstitial lung disease · leukaemia · lymphoma · melanoma · pericardial effusion · Stevens-Johnson syndrome · toxic epidermal necrolysis · vasospasm

- **Frequency not known** Abdominal pain · anaemia · antibody formation · aplastic anaemia · blood disorders · depression · fever · headache · hepatic failure · hepatosplenic T-cell lymphoma (more likely in inflammatory bowel disease) · hypersensitivity reactions · injection-site reactions · leucopenia · lupus erythematosus-like syndrome · Merkel cell carcinoma · nausea · pancytopenia · pruritus · thrombocytopenia · worsening heart failure · worsening symptoms of dermatomyositis

**SIDE-EFFECTS, FURTHER INFORMATION**

Associated with infections, sometimes severe, including tuberculosis, septicemia, and hepatitis B reactivation.

**CONCEPTION AND CONTRACEPTION** Manufacturer advises adequate contraception during and for at least 6 months after last dose.

**PREGNANCY** Use only if essential.

**BREAST FEEDING** Amount probably too small to be harmful.

**PRE-TREATMENT SCREENING** Tuberculosis Patients should be evaluated for tuberculosis before treatment.

**MONITORING REQUIREMENTS**

- Monitor for infection before, during, and for 6 months after treatment.
- All patients should be observed carefully for 1–2 hours after infusion and resuscitation equipment should be available for immediate use (risk of hypersensitivity reactions).
- Monitor for symptoms of delayed hypersensitivity if re-administered after a prolonged period.
- Manufacturer advises periodic skin examination for non-melanoma skin cancer, particularly in patients with risk factors.

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (Remicade®), give intermittently in Sodium chloride 0.9%; reconstitute each 100–mg vial with 10 mL water for injections using a 21-gauge or smaller needle; gently swirl vial without shaking to dissolve; allow to stand for 5 minutes; dilute requisite dose with infusion fluid to a final volume of 250 mL and give through a low protein-binding filter (1.2 micron or less) over at least 2 hours (adults over 18 years who have tolerated 3 initial 2-hour infusions may be given subsequent infusions of up to 6 mg/kg over at least 1 hour); start infusion within 3 hours of reconstitution.

**PRESCRIBING AND DISPENSING INFORMATION** Infliximab is a biological medicine. Biological medicines must be prescribed and dispensed by brand name, see Biological medicines and Biosimilar medicines, under Guidance on prescribing p. 1.

**PATIENT AND CARER ADVICE** An alert card should be provided. Tuberculosis Patients and carers should be advised to seek medical attention if symptoms suggestive of tuberculosis (e.g. persistent cough, weight loss, and fever) develop. Blood disorders Patients and carers should be advised to seek medical attention if symptoms suggestive of blood disorders (such as fever, sore throat, bruising, or bleeding) develop. Hypersensitivity reactions Patients and carers should be advised to keep Alert card with them at all times and seek medical advice if symptoms of delayed hypersensitivity develop.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**

- **Infliximab for plaque psoriasis in adults (January 2008)** NICE TA134
  - Infliximab is recommended for the treatment of very severe plaque psoriasis which has failed to respond to standard systemic treatments (including ciclosporin and methotrexate) or to photochemotherapy, or when standard treatments cannot be used because of intolerance or contra-indications. Infliximab should be withdrawn if the response is not adequate after 10 weeks.
  - www.nice.org.uk/TA134

- **Infliximab for acute exacerbations of ulcerative colitis** (December 2008) NICE TA163
  - Infliximab is recommended as an option for the treatment of acute exacerbations of severe ulcerative colitis when treatment with ciclosporin is contra-indicated or inappropriate.
  - www.nice.org.uk/TA163

- **Infliximab and adalimumab for Crohn's disease** (May 2010) NICE TA187
  - Infliximab is recommended for the treatment of severe active Crohn's disease that has not responded to conventional therapy (including corticosteroids and other drugs affecting the immune response) or when conventional therapy cannot be used because of intolerance or contra-indications; infliximab can also be used in a similar way in children over 6 years of age. In adults over 18 years of age, infliximab is recommended for the treatment of fistulating Crohn's disease that has not responded to conventional therapy (including antibacterials, drainage, and other drugs affecting the immune response) or when conventional therapy cannot be used because of intolerance or contra-indications.
  - Infliximab should be given as a planned course of treatment for 12 months or until treatment failure, whichever is shorter. Treatment should be continued beyond 12 months only if there is evidence of active disease—in these cases the need for treatment should be reviewed at least annually. If the disease relapses after stopping treatment, infliximab can be restarted.
  - www.nice.org.uk/TA187

- **Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor** (August 2010) NICE TA195
  - Infliximab, in combination with methotrexate, is an option for the treatment of severe active rheumatoid arthritis in adults who have had an inadequate response to, or have an intolerance of, other DMARDs including at least 1 TNF inhibitor, and who cannot use rituximab because of contra-indications or intolerance. Treatment should be continued only if there is adequate response. Patients should be monitored at least every 6 months.
  - www.nice.org.uk/TA195
Musculoskeletal system

▶ Etanercept, infliximab, and adalimumab for the treatment of psoriatic arthritis (August 2010) NICE TA199

Etanercept is recommended for the treatment of active and progressive psoriatic arthritis in adults who have peripheral arthritis with at least 3 tender joints and at least 3 swollen joints, and who have not responded adequately to at least 2 standard disease-modifying antirheumatic drugs (used alone or in combination). Infliximab should be discontinued if there is an inadequate response at 12 weeks.

www.nice.org.uk/TA199

▶ Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015) NICE TA329

Infliximab is an option for treating moderately to severely active ulcerative colitis in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptapontine or azathioprine, or in adults who are intolerant to or have contra-indications for conventional therapies.

The choice of treatment should be made on an individual basis and if more than one treatment is suitable, the least expensive should be chosen.

Infliximab should be given as a planned course of treatment until treatment fails (including the need for surgery) or until 12 months after starting treatment, whichever is shorter. Treatment should be continued only if there is clear evidence of a response. Patients who continue treatment should be reassessed at least every 12 months to determine whether ongoing treatment is still clinically appropriate.

www.nice.org.uk/TA329

▶ Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (January 2016) NICE TA375

Infliximab, in combination with methotrexate, is recommended as an option for treating rheumatoid arthritis, only if the following criteria are met:

- disease is severe, that is, a disease activity score (DAS28) greater than 5.1, and,
- disease has not responded to intensive therapy with a combination of conventional disease-modifying antirheumatic drugs (DMARDs).

Continue treatment only if there is a moderate response measured using European League Against Rheumatism (EULAR) criteria at 6 months after starting therapy. After initial response within 6 months, withdraw treatment if a moderate EULAR response is not maintained.

Patients currently receiving infliximab whose disease does not meet the above criteria should have the option to continue their treatment until they and their clinician consider it appropriate to stop.

www.nice.org.uk/TA375

▶ TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (February 2016) NICE TA383

Adalimumab, certolizumab pegol, etanercept, golimumab and infliximab are recommended as options for treating severe active ankylosing spondylitis in patients whose disease has responded inadequately to, or who are intolerant of, non-steroidal anti-inflammatory drugs (NSAIDs). Infliximab is recommended only if treatment is started with the least expensive infliximab product.

Patients currently receiving infliximab should continue treatment with the same infliximab product until they and their clinician considers it appropriate to stop.

The response to treatment should be assessed 12 weeks after the start of treatment and should only be continued if there is clear evidence of response.

Treatment with another tumour necrosis factor (TNF)-alpha inhibitor is recommended in those who cannot tolerate, or whose disease has not responded to, treatment with the first TNF-alpha inhibitor, or in those whose disease has stopped responding after an initial response.

www.nice.org.uk/TA383

▶ MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Powder for solution for infusion

CAUTIONARY AND ADVISORY LABELS 10

▶ Flixabi (Biogen Idec Ltd) ▼

Infliximab 100 mg Flixabi 100mg powder for concentrate for solution for infusion vials | 1 vial £77.00 (Hospital only)

▶ Inflectra ( Hospira UK Ltd) ▼

Infliximab 100 mg Inflectra 100mg powder for concentrate for solution for infusion vials | 1 vial £77.66 (Hospital only)

▶ Remicade (Merck Sharp & Dohme Ltd)

Infliximab 100 mg Remicade 100mg powder for concentrate for solution for infusion vials | 1 vial £149.62 (Hospital only)

▶ Remsima (Napp Pharmaceuticals Ltd) ▼

Infliximab 100 mg Remsima 100mg powder for concentrate for solution for infusion vials | 1 vial £77.66 (Hospital only)

PHOSPHODIESTERASE TYPE-4 INHIBITORS

Apremilast

13-Apr-2017

▶ DRUG ACTION

Apremilast inhibits the activity of phosphodiesterase type-4 (PDE4) which results in suppression of pro-inflammatory mediator synthesis and promotes anti-inflammatory mediators.

▶ INDICATIONS AND DOSE

Active psoriatic arthritis (in combination with disease-modifying antirheumatic drugs or alone) in patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug therapy / Moderate to severe chronic plaque psoriasis that has not responded to standard systemic treatments or photochemotherapy, or when these treatments cannot be used because of intolerance or contra-indications

▶ BY MOUTH

Adult: Initially 10 mg daily on day 1, then 10 mg twice daily on day 2, then 10 mg in the morning and 20 mg in the evening on day 3, then 20 mg twice daily on day 4, then 20 mg in the morning and 30 mg in the evening on day 5, then maintenance 30 mg twice daily, doses should be taken approximately 12 hours apart; review treatment if no response within 24 weeks of initiation

IMPORTANT SAFETY INFORMATION

MHRA/CHM ADVICE (JANUARY 2017): APREMLAST (OTEZLA®): RISK OF SUICIDAL THOUGHTS AND BEHAVIOUR

A review of evidence from clinical trials and postmarketing cases has suggested a causal association between apremilast and suicidal thoughts and behaviour.

▶ CAUTIONS

Concomitant use of drugs likely to cause psychiatric symptoms — history of psychiatric illness — body weight—consider discontinuation if weight loss is unexplained or clinically significant

▶ INTERACTIONS

Common or very common

Back pain • bronchitis • cough • decreased appetite • depression • diarrhoea • dyspepsia • fatigue • gastroesophageal reflux disease • headache • insomnia • migraine • nasopharyngitis • nausea • tension headache • upper abdominal pain • upper respiratory tract infections • vomiting
Uncommon Rash • suicidal ideation and behaviour • weight loss

CONCEPTION AND CONTRACEPTION Exclude pregnancy before treatment and ensure effective contraception during treatment.

PREGNANCY Avoid—teratogenic in animal studies.

BREAST FEEDING Manufacturer advises avoid—present in milk in animal studies.

RENAL IMPAIRMENT Reduce dose if eGFR less than 30 mL/minute/1.73 m²; consult product literature for initial dose titration.

MONITORING REQUIREMENTS

Manufacturer advises monitor body-weight regularly in patients underweight at the start of treatment.

Manufacturer advises monitor for psychiatric symptoms (including depression, suicidal ideation and behaviour)—discontinue treatment if new or worsening psychiatric symptoms are identified.

PATIENT AND CARER ADVICE

Manufacturer advises patients and carers should be instructed to notify the prescriber of any changes in behaviour or mood, and of any suicidal ideation.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

Apremilast for treating active psoriatic arthritis (February 2017) NICE TA433

Apremilast, alone or in combination with disease-modifying antirheumatic drugs (DMARDs), is recommended as an option for treating active psoriatic arthritis in adults only if:

• they have peripheral arthritis with 3 or more tender joints and 3 or more swollen joints and
• their disease has not responded to adequate trials of at least 2 standard DMARDs, given either alone or in combination and
• the manufacturer provides apremilast with the discount agreed in the patient access scheme.

Patients whose treatment was started within the NHS before this guidance was published should have the option to continue treatment, without change to their funding arrangements, until they and their clinician consider it appropriate to stop. www.nice.org.uk/TA433

Apremilast for treating moderate to severe plaque psoriasis (November 2016) NICE TA419

Apremilast is recommended as an option for treating chronic plaque psoriasis in patients whose disease has not responded to other systemic therapies, including ciclosporin, methotrexate and PUVA, or when these treatments are contra-indicated or not tolerated, only if:

• the disease is severe, as defined by a total Psoriasis Area Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and
• treatment is stopped if the psoriasis has not responded adequately at 16 weeks (defined as a 75% reduction in the PASI score (PASI 75) from when treatment started or a 50% reduction in the PASI score (PASI 50) and a 5-point reduction in DLQI from start of treatment), and
• the manufacturer provides apremilast with the discount agreed in the patient access scheme.

Patients whose treatment was started within the NHS before this guidance was published should have the option to continue treatment, without change to their funding arrangements, until they and their clinician consider it appropriate to stop. www.nice.org.uk/TA419

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (June 2015) that apremilast (Otezla®) is accepted for restricted use within NHS Scotland for the treatment of active psoriatic arthritis in patients who have had an inadequate response with at least two prior Disease Modifying Antirheumatic Drug (DMARD) therapies or who are intolerant to such therapies.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Tablet CAUTIONARY AND ADVISORY LABELS 25

Otezla (Celgene Ltd) ▼

Apremilast 10 mg Otezla 10mg tablets | 4 tablet POM no price available
Apremilast 20 mg Otezla 20mg tablets | 4 tablet POM no price available
Apremilast 30 mg Otezla 30mg tablets | 19 tablet POM £550.00

2 Hyperuricaemia and gout

Gout

Overview

It is important to distinguish drugs used for the treatment of acute attacks of gout from those used in the long-term control of the disease. The latter exacerbate and prolong the acute manifestations if started during an attack. The management of gout in adolescents requires specialist supervision.

Acute attacks of gout

Acute attacks of gout are usually treated with high doses of NSAIDs such as diclofenac sodium p. 1034, diclofenac potassium p. 1033, etoricoxib p. 1038, indometacin p. 1043, ketoprofen p. 1044, naproxen p. 1048 or sulindac p. 1051. Colchicine p. 1020 is an alternative in patients in whom NSAIDs are contra-indicated. Aspirin p. 117 is not indicated in gout. Allopurinol p. 1021, febuxostat p. 1021, and uricosurics are not effective in treating an acute attack and may prolong it indefinitely if started during the acute episode.

The use of colchicine is limited by the development of toxicity at higher doses, but it is of value in patients with heart failure since, unlike NSAIDs, it does not induce fluid retention; moreover, it can be given to patients receiving anticoagulants.

Oral or parenteral corticosteroids are an effective alternative in those who cannot tolerate NSAIDs or who are resistant to other treatments. Intra-articular injection of a corticosteroid can be used in acute monoarticular gout [unlicensed indication]. A corticosteroid by intramuscular injection can be effective in podagra.

Canakinumab p. 794, a recombinant monoclonal antibody, can be used for the symptomatic treatment of frequent gouty arthritis attacks (at least 3 in the previous 12 months). It is licensed for use in patients whose condition has not responded adequately to treatment with NSAIDs or colchicine, or who are intolerant of them.

Long-term control of gout

Frequent recurrence of acute attacks of gout, the presence of tophi, or signs of chronic gouty arthritis may call for the initiation of long-term (“interval”) treatment. For long-term control of gout the formation of uric acid from purines may be reduced with the xanthine-oxidase inhibitors allopurinol or febuxostat alternatively the uricosuric drug sulfinpyrazone p. 1020 may be used to increase the excretion of uric acid in the urine. Treatment should be continued indefinitely to prevent further attacks of gout by correcting the hyperuricaemia. These drugs should never be started during an acute attack; they are usually started 1–2 weeks...
after the attack has settled. The initiation of treatment may precipitate an acute attack, and therefore an anti-inflammatory analgesic or colchicine should be used as a prophylactic and continued for at least one month after the hyperuricaemia has been corrected. However, if an acute attack develops during treatment, then the treatment should continue at the same dosage and the acute attack treated in its own right.

Allopurinol is widely used and is especially useful in patients with renal impairment or urate stones when uricosuric drugs cannot be used; it is not indicated for the treatment of asymptomatic hyperuricaemia. It can cause rashes.

Febuxostat is licensed for the treatment of chronic hyperuricaemia where urate deposition has already occurred; it is not indicated for patients in whom the rate of urate formation is greatly increased, such as in malignant disease or in Lesch-Nyhan syndrome.

Sulfinpyrazone can be used instead of allopurinol or in conjunction with it in cases that are resistant to treatment.

Benzbromarone (available from ‘special-order’ manufacturers or specialist importing companies) is a uricosuric drug that can be used in patients with mild renal impairment.

Crystalisation of urate in the urine can occur with the uricosuric drugs and it is important to ensure an adequate urine output especially in the first few weeks of treatment. As an additional precaution the urine may be rendered alkaline.

Aspirin and other salicylates antagonise the uricosuric drugs; they do not antagonise allopurinol but are nevertheless not indicated in gout.

**ALKALOIDS † PLANT ALKALOIDS**

### Colchicine

**INDICATIONS AND DOSE**

- **Acute gout**
  - **BY MOUTH**
  - Adult: 500 micrograms 2–4 times a day until symptoms relieved, maximum 6 mg per course, do not repeat course within 3 days

- **Short-term prophylaxis during initial therapy with allopurinol and uricosuric drugs**
  - **BY MOUTH**
  - Adult: 500 micrograms twice daily

- **Prophylaxis of familial Mediterranean fever (recurrent polyserositis)**
  - **BY MOUTH**
  - Adult: 0.5–2 mg once daily

**DOSE ADJUSTMENTS DUE TO INTERACTIONS**

Manufacturer advises reduce dose by half with concurrent use of moderate inhibitors of CYP3A4. Manufacturer advises reduce dose by 75% (to one quarter of usual dose) with concurrent use of potent inhibitors of CYP3A4 or P-glycoprotein inhibitors; avoid concurrent use in patients with hepatic or renal impairment.

**UNLICENSED USE** BNF doses may differ from those in the product literature. Use of colchicine for prophylaxis of familial Mediterranean fever (recurrent polyserositis) is an unlicensed indication.

**CONTRA-INDICATIONS** Blood disorders

**CAUTIONS** Cardiac disease · elderly · gastro-intestinal disease

**INTERACTIONS** → Appendix 1: colchicine

**SIDE-EFFECTS**

- Common or very common Abdominal pain · nausea · vomiting
- Rare Alopecia · blood disorders with prolonged treatment · inhibition of spermatogenesis · myopathy · peripheral neuritis
- **Frequency not known** Excessive doses may cause profuse diarrhoea · gastrointestinal haemorrhage · hepatic damage · rash · renal damage

**PREGNANCY** Avoid—teratogenicity in animal studies.

**BREAST FEEDING** Present in milk but no adverse effects reported. Manufacturers advise caution.

**HEPATIC IMPAIRMENT** Use with caution.

**RENAL IMPAIRMENT** Reduce dose or increase dosage interval if eGFR 10–50 mL/minute/1.73 m². Avoid if eGFR less than 10 mL/minute/1.73 m².

**MEDICINAL FORMS**

- **Tablet**
  - Colchicine (Non-proprietary)
  - Colchicine 500 microgram Colchicine 500microgram tablets | 100 tablet £45.56 DT price = £14.28

### Sulfinpyrazone

(Sulphinpyrazone)

**INDICATIONS AND DOSE**

- **Gout prophylaxis | Hyperuricaemia**
  - **BY MOUTH**
  - Adult: Initially 100–200 mg daily, dose to be taken with food (or milk); increased to 600–800 mg daily over 2–3 weeks, 800 mg daily is rarely given; continue until serum uric acid concentration normal then reduce dose for maintenance (maintenance dose may be as low as 200 mg daily)

**CONTRA-INDICATIONS** Acute gout attack · acute polyphorias p. 969 · history of blood disorders · peptic ulceration

**CAUTIONS** Cardiac disease (may cause salt and water retention) · ensure adequate fluid intake (about 2–3 litres daily) and render urine alkaline during initial treatment

**INTERACTIONS** → Appendix 1: sulfinpyrazone

**SIDE-EFFECTS**

- Rare Acute renal failure · blood disorders · gastrointestinal bleeding · gastrointestinal ulceration · hepatitis · jaundice · raised liver enzymes
- **Frequency not known** Allergic skin reactions · gastrointestinal disturbances · salt retention · water retention

**ALLERGY AND CROSS-SENSITIVITY** Avoid in hypersensitivity to aspirin, salicylates, NSAIDs.

**PREGNANCY** Manufacturer advises caution—no information available.

**BREAST FEEDING** No information available.

**HEPATIC IMPAIRMENT** Avoid in severe impairment.

**RENAL IMPAIRMENT** Reduce dose. Avoid in severe impairment.

**MONITORING REQUIREMENTS** Regular blood counts before treatment and at regular intervals during treatment.

**MEDIINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.
- **No licensed medicines listed.**
Xanthine Oxidase Inhibitors

Allopurinol

■ INDICATIONS AND DOSE

Prophylaxis of gout and of uric acid and calcium oxalate renal stones | Prophylaxis of hyperuricaemia associated with cancer chemotherapy

▲ BY MOUTH
Adult: Initially 100 mg daily, for maintenance adjust dose according to plasma or urinary uric acid concentration, dose to be taken preferably after food

Prophylaxis of gout and of uric acid and calcium oxalate renal stones (usual maintenance in mild conditions) | Prophylaxis of hyperuricaemia associated with cancer chemotherapy (usual maintenance in mild conditions)

▲ BY MOUTH
Adult: 100–200 mg daily, dose to be taken preferably after food

Prophylaxis of gout and of uric acid and calcium oxalate renal stones (usual maintenance in moderately severe conditions) | Prophylaxis of hyperuricaemia associated with cancer chemotherapy (usual maintenance in moderately severe conditions)

▲ BY MOUTH
Adult: 300–600 mg daily in divided doses (max. per dose 300 mg), dose to be taken preferably after food

■ CONTRA-INDICATIONS Not a treatment for acute gout but continue if attack develops when already receiving allopurinol, and treat attack separately

■ CAUTIONS Ensure adequate fluid intake (2–3 litres/day) for hyperuricaemia associated with cancer therapy, allopurinol treatment should be started before cancer therapy

CAUTIONS, FURTHER INFORMATION
Administer prophylactic NSAID (not aspirin or salicylates) or colchicine until at least 1 month after hyperuricaemia corrected (usually for first 3 months) to avoid precipitating an acute attack.

■ INTERACTIONS ▲ Appendix 1: allopurinol

■ SIDE-EFFECTS

▲ Common or very common Gastro-intestinal disorders - rashes (withdraw therapy; if rash mild re-introduce cautiously but discontinue promptly if recurrence)

▲ Rare Alopecia · alopaeic anaemia · arthralgia · blood disorders · drowsiness · eosinophilia resembling Stevens-Johnson syndrome · eosinophilia resembling toxic epidermal necrolysis · exfoliation · fever · gyneraenastia · haemolytic anaemia · headache · hepatitis · hepatotoxicity · hypersensitivity reactions · hypertension · leucopenia · lymphadenopathy · malaise · neuropathy · paraesthesia · renal impairment · taste disturbances · thrombocytopenia · vasculitis · vertigo · visual disturbances

▲ Very rare Seizures

■ PREGNANCY Toxicity not reported. Manufacturer advises use only if no safer alternative and disease carries risk for mother or child.

■ BREAST FEEDING Present in milk—not known to be harmful.

■ HEPATIC IMPAIRMENT Reduce dose.

■ RENAL IMPAIRMENT Max. 100 mg daily, increased only if response inadequate; in severe impairment, reduce daily dose below 100 mg, or increase dose interval; if facilities available, adjust dose to maintain plasma-oxipurinol concentration below 100 micromol/litre.

■ MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, mouthwash

■ Tablet

CAUTIONARY AND ADVISORY LABELS 8, 21, 27

▲ Allopurinol (Non-proprietary)
Allopurinol 100 mg | 28 tablet DT price = £0.77
Allopurinol 300 mg | 28 tablet DT price = £0.85

▲ Uricto (Ennogen Pharma Ltd)
Allopurinol 100 mg | 28 tablet DT price = £1.25
Allopurinol 300 mg | 28 tablet DT price = £0.94

▲ Zyloric (Aspen Pharma Trading Ltd)
Allopurinol 100 mg | 100 tablet DT price = £10.19
Allopurinol 300 mg | 28 tablet DT price = £0.85

Febuxostat

■ INDICATIONS AND DOSE

Treatment of chronic hyperuricaemia in gout

▲ BY MOUTH
Adult: Initially 80 mg once daily, if after 2–4 weeks of initial dose, serum uric acid greater than 6 mg/100 mL then increase dose; increased if necessary to 120 mg once daily

Prophylaxis and treatment of acute hyperuricaemia with initial chemotherapy for haematologic malignancies

▲ BY MOUTH
Adult: 120 mg once daily, to be started 2 days before start of cytotoxic therapy and continued for 7–9 days, according to chemotherapy duration

■ IMPORTANT SAFETY INFORMATION

MHRA/CHM ADVICE: SERIOUS HYPERSENSITIVITY REACTIONS (JUNE 2012)

There have been rare but serious reports of hypersensitivity reactions, including Stevens-Johnson syndrome and acute anaphylactic shock with febuxostat.

Patients should be advised of the signs and symptoms of severe hypersensitivity; febuxostat must be stopped immediately if these occur (early withdrawal is associated with a better prognosis), and must not be restarted in patients who have ever developed a hypersensitivity reaction to febuxostat. Most cases occur during the first month of treatment; a prior history of hypersensitivity to allopurinol and/or renal disease may indicate potential hypersensitivity to febuxostat.

■ CONTRA-INDICATIONS Not a treatment for acute gout but continue if attack develops when already receiving febuxostat, and treat attack separately

■ CAUTIONS Congestive heart failure · ischaemic heart disease · thyroid disorders · transplant recipients

CAUTIONS, FURTHER INFORMATION

Administer prophylactic NSAID (not aspirin or salicylates) or colchicine for at least 1 month after hyperuricaemia associated with a better prognosis, and must not be continued if these occur (early withdrawal is associated with a better prognosis), and must not be restarted in patients who have ever developed a hypersensitivity reaction to febuxostat. Most cases occur during the first month of treatment; a prior history of hypersensitivity to allopurinol and/or renal disease may indicate potential hypersensitivity to febuxostat.

■ INTERACTIONS ▲ Appendix 1: febuxostat

■ SIDE-EFFECTS

▲ Common or very common Abnormal liver function tests · gastro-intestinal disturbances · headache · oedema · rash
Uncommon Renal failure • appetite change • arthralgia • arthritis • atrial fibrillation • bronchitis • bursitis • chest pain • cholelithiasis • cough • decreased libido • dermatitis • diabetes mellitus • dizziness • drowsiness • dyspnoea • ECG abnormalities • erectile dysfunction • flushing • haematuria • haemophilia • hyperlipidaemia • hypertension • hypoaesthesia • increased thyroid stimulating hormone • increased urinary frequency • insomnia • muscle spasm • muscle weakness • myalgia • nephrolithiasis • palpitation • paraesthesia • proteinuria • smell disturbances • taste disturbances • upper respiratory tract infection • weight change

Rare Asthenia • blurred vision • hepatitis • jaundice • mouth ulceration • nervousness • pancreatitis • pancytopenia • rhabdomyolysis • thirst • thrombocytopenia • tinnitus • tubulointerstitial nephritis

Pregnancy Manufacturer advises avoid—limited information available.

Breast Feeding Manufacturer advises avoid—present in milk in animal studies.

Hepatic Impairment Max. 80 mg daily in mild impairment. No dose information available in moderate or severe impairment.

Renal Impairment Use with caution if eGFR less than 30 mL/minute/1.73 m²—no information available.

Pre-treatment Screening Monitor liver function tests before treatment as indicated.

Monitoring Requirements Monitor liver function tests periodically during treatment as indicated.

National Funding/Access Decisions

NICE Technology Appraisals (TAs)

Febuxostat for the management of hyperuricaemia in patients with gout (December 2008) NICE TA164

Febuxostat is recommended as an option for the management of chronic hyperuricaemia in gout only for patients who are intolerant of allopurinol or for whom allopurinol is contra-indicated.

For the purposes of this guidance, intolerance of allopurinol is defined as adverse effects that are sufficiently severe to warrant discontinuation, or to prevent full dose escalation for optimal effectiveness. www.nice.org.uk/TA164

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium issued similar advice to NICE guidance: Febuxostat for the management of hyperuricaemia in patients with gout (December 2008), in August 2010.

The Scottish Medicines Consortium has advised (June 2016) that febuxostat (Adenuric®) is accepted for restricted use within NHS Scotland for the prevention and treatment of hyperuricaemia in patients undergoing chemotherapy for haematological malignancies at intermediate to high risk of tumour lysis syndrome, only when allopurinol is not tolerated or contra-indicated.

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug.

Tablet

- Febuxostat (Non-proprietary)
  - Febuxostat 80 mg Febuxostat 80mg tablets | 28 tablet no price available DT price = £24.36
  - Febuxostat 120 mg Febuxostat 120mg tablets | 28 tablet no price available DT price = £24.36
- Adenuric (A. Menarini Farmaceutica Internazionale SRL)
  - Febuxostat 80 mg Adenuric 80mg tablets | 28 tablet £24.36
  - Febuxostat 120 mg Adenuric 120mg tablets | 28 tablet £24.36

3 Neuromuscular disorders

Neuromuscular disorders

Drugs that enhance neuromuscular transmission

Anticholinesterases are used as first-line treatment in oculare myasthenia gravis and as an adjunct to immunosuppressant therapy for generalised myasthenia gravis.

Corticosteroids are used when anticholinesterases do not control symptoms completely. A second-line immunosuppressant such as azathioprine p. 787 is frequently used to reduce the dose of corticosteroid.

Plasmapheresis or infusion of intravenous immunoglobulin [unlicensed indication] may induce temporary remission in severe relapses, particularly where bulbar or respiratory function is compromised or before thymectomy.

Anticholinesterases

Anticholinesterase drugs enhance neuromuscular transmission in voluntary and involuntory muscle in myasthenia gravis. Excessive dosage of these drugs can impair neuromuscular transmission and precipitate cholinergic crises by causing a depolarising block. This may be difficult to distinguish from a worsening myasthenic state.

Muscarinic side-effects of anticholinesterases include increased sweating, increased salivary and gastric secretions, increased gastro-intestinal and uterine motility, and bradycardia. These parasympathomimetic effects are antagonised by atropine sulfate p. 1224.

Neostigmine p. 1024 produces a therapeutic effect for up to 4 hours. Its pronounced muscarinic action is a disadvantage, and simultaneous administration of an antimuscarinic drug such as atropine sulfate or propantheline bromide p. 84 may be required to prevent colic, excessive salivation, or diarrhoea. In severe disease neostigmine can be given every 2 hours. The maximum that most patients can tolerate is 180 mg daily.

Pyridostigmine bromide p. 1025 is less powerful and slower in action than neostigmine but it has a longer duration of action. It is preferable to neostigmine because of its smoother action and the need for less frequent dosage. It is particularly preferred in patients whose muscles are weak on waking. It has a comparatively mild gastrointestinal effect but an antimuscarinic drug may still be required.

Neostigmine is also used to reverse the actions of the non-depolarising neuromuscular blocking drugs.

Immunosuppressant therapy

Corticosteroids are established as treatment for myasthenia gravis; although they are commonly given on alternate days there is little evidence of benefit over daily administration. Corticosteroid treatment is usually initiated under in-patient supervision and all patients should receive osteoporosis prophylaxis.

In generalised myasthenia gravis prednisolone p. 639 is given. About 10% of patients experience a transient but very serious worsening of symptoms in the first 2–3 weeks, especially if the corticosteroid is started at a high dose.

Smaller doses of corticosteroid are usually required in oculare myasthenia. Once clinical remission has occurred (usually after 2–6 months), the dose of prednisolone should be reduced slowly to the minimum effective dose.

In generalised myasthenia gravis azathioprine is usually started at the same time as the corticosteroid and it allows a lower maintenance dose of the corticosteroid to be used.

Ciclosporin p. 788, methotrexate p. 844, or mycophenolate mofetil p. 796 can be used in patients unresponsive or intolerant to other treatments [unlicensed indications].
Acetylcholine-release enhancers

Amifampridine p. 1025 is licensed for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS), a rare disorder of neuromuscular transmission.

Fampridine p. 799 is licensed for the improvement of walking in patients with multiple sclerosis p. 797 who have a walking disability.

Skeletal muscle relaxants

The drugs described are used for the relief of chronic muscle spasm or spasticity associated with multiple sclerosis p. 797 or other neurological damage; they are not indicated for spasm associated with minor injuries. Baclofen, diazepam, and tizanidine act principally on the central nervous system. Dantrolene has a peripheral site of action; cannabis extract has both a central and a peripheral action. Skeletal muscle relaxants differ in action from the muscle relaxants used in anaesthesia, which block transmission at the neuromuscular junction.

The underlying cause of spasticity should be treated and any aggravating factors (e.g. pressure sores, infection) remedied. Skeletal muscle relaxants are effective in most forms of spasticity except the rare alpha variety. The major disadvantage of treatment with these drugs is that reduction in muscle tone can cause a loss of splinting action of the spastic leg and trunk muscles and sometimes lead to an increase in disability.

Baclofen p. 1026 inhibits transmission at spinal level and also depresses the central nervous system. The dose should be increased slowly to avoid the major side-effects of sedation and muscular hypotonia (other adverse events are uncommon).

A cannabis extract p. 1026 containing dronabinol (delta-9-tetrahydrocannabinol) and cannabidiol is licensed as an adjunct treatment for moderate to severe spasticity associated with multiple sclerosis in patients who have not responded adequately to other skeletal muscle relaxants. The dose should be titrated over 2 weeks; response to treatment should be reviewed after 4 weeks and treatment stopped if an adequate response is not achieved.

Dantrolene sodium p. 1236 acts directly on skeletal muscle and produces fewer central adverse effects making it a drug of choice. The dose should be increased slowly. Diazepam p. 327 can also be used. Sedation and occasionally extensor hypotonus are disadvantages. Other benzodiazepines also have muscle-relaxant properties. Muscle-relaxant doses of benzodiazepines are similar to anxiolytic doses.

Tizanidine p. 1027 is an alpha2-adrenoceptor agonist indicated for spasticity associated with multiple sclerosis or spinal cord injury.

Other muscle relaxants

The clinical efficacy of methocarbamol p. 1027 and meprobamate p. 330 as muscle relaxants is not well established, although they have been included in compound analgesic preparations.

CAUTIONS, FURTHER INFORMATION

Interstial lung disease Perform chest radiography if symptoms such as dry cough or dyspnoea develop; discontinue if interstitial lung disease is diagnosed.

INTERACTIONS → Appendix 1: riluzole

SIDE-EFFECTS

Common or very common Abdominal pain · asthenia · diarrhoea · dizziness · drowsiness · headache · nausea · oral paraesthesia · tachycardia · vomiting

Uncommon Anaemia · angioedema · interstitial lung disease · pancreatitis

Rare Neutropenia

Very rare Hepatitis

SIDE-EFFECTS, FURTHER INFORMATION

Neutropenia White blood cell counts should be determined in febrile illness; neutropenia requires discontinuation of riluzole.

PREGNANCY Avoid—no information available.

BREAST FEEDING Avoid—no information available.

HEPATIC IMPAIRMENT Avoid.

RENAL IMPAIRMENT Avoid—no information available.

PATIENT AND CARER ADVICE

Blood disorders Patients or their carers should be told how to recognise signs of neutropenia and advised to seek immediate medical attention if symptoms such as fever occur.

Driving and skilled tasks Dizziness or vertigo may affect performance of skilled tasks (e.g. driving).

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)

Riluzole for motor neurone disease (January 2001) NICE TA20

Riluzole is recommended for treating the amyotrophic lateral sclerosis (ALS) form of motor neurone disease (MND). Treatment should be initiated by a specialist in MND but it can then be supervised under a shared-care arrangement involving the general practitioner. www.nice.org.uk/TA20

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, powder

Oral suspension

Teglutik (Martindale Pharmaceuticals Ltd)

Riluzole 5 mg per 1 ml Teglutik 5mg/1ml oral suspension sugar-free | 300 ml £100.00 DT price = £100.00

Tablet

Riluzole (Non-proprietary)

Riluzole 50 mg Riluzole 50mg tablets | 56 tablet £320.00 DT price = £14.37

Rilutek (Sanoﬁ)

Riluzole 50 mg Rilutek 50mg tablets | 56 tablet £320.33 DT price = £14.37

INDICATIONS AND DOSE

To extend life in patients with amyotrophic lateral sclerosis, initiated by specialist experienced in the management of motor neurone disease

BY MOUTH

Adult: 50 mg twice daily

CONTRA-INDICATIONS

Acute porphyria

CAUTIONS

History of abnormal hepatic function (consult product literature for details) · interstitial lung disease

NEUROPROTECTIVE DRUGS

Riluzole

- INDICATIONS AND DOSE

To extend life in patients with amyotrophic lateral sclerosis, initiated by specialist experienced in the management of motor neurone disease

- CONTRA-INDICATIONS

Acute porphyria

- CAUTIONS

History of abnormal hepatic function (consult product literature for details) · interstitial lung disease
3.1 Muscular dystrophy

**DRUGS FOR NEUROMUSCULAR DISORDERS**

**Ataluren**  
- **DRUG ACTION** Ataluren restores the synthesis of dystrophin by allowing ribosomes to read through premature stop codons that cause incomplete dystrophin synthesis in nonsense mutation Duchenne muscular dystrophy.

- **INDICATIONS AND DOSE**  
  Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients (initiated by a specialist)  
  - **BY MOUTH**  
    - Adult: (consult product literature)

- **INTERACTIONS** → Appendix 1: ataluren

- **SIDE-EFFECTS**  
  - **Common or very common** Abdominal discomfort - constipation - cough - decreased appetite - diarrhoea - enuresis - epistaxis - flatulence - haematuria - headache - hypertension - hypertriglyceridaemia - musculoskeletal chest pain - nausea - pain in extremity - pyrexia - rash - upper abdominal pain - vomiting - weight loss
  - **Frequency not known** Changes in renal function tests - raised cholesterol

- **PREGNANCY** Manufacturer advises avoid—toxicity in animal studies.

- **BREAST FEEDING** Manufacturer advises discontinue breastfeeding—present in milk in animal studies.

- **HEPATIC IMPAIRMENT** Manufacturer advises close monitoring—safety and efficacy not established.

- **RENAL IMPAIRMENT** Manufacturer advises close monitoring—safety and efficacy not established.

- **MONITORING REQUIREMENTS** Manufacturer advises monitor renal function at least every 6–12 months, and cholesterol and triglyceride concentrations at least annually.

- **DIRECTIONS FOR ADMINISTRATION** Manufacturer advises the contents of each sachet should be mixed with at least 30 mL of liquid (water, milk, fruit juice), or 3 tablespoons of semi-solid food (yoghurt or apple sauce).

- **PATIENT AND CARER ADVICE** Manufacturer advises patients should maintain adequate hydration during treatment.

  **Missed doses**  
  Manufacturer advises if a morning or midday dose is more than 3 hours late, or an evening dose is more than 6 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.

- **NATIONAL FUNDING/ACCESS DECISIONS**

  **Scottish Medicines Consortium (SMC) Decisions**  
  The Scottish Medicines Consortium has advised (April 2016) that ataluren (Translarna<sup>®</sup>) is not recommended for use within NHS Scotland for the treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 5 years and older as the economic case was not demonstrated.

**Granules**  
- **Translarna** (PTC Therapeutics Ltd)  
  - Ataluren 125 mg Translarna 125 mg granules for oral suspension sachets | 30 sachet (PoM) no price available
  - Ataluren 250 mg Translarna 250 mg granules for oral suspension sachets | 30 sachet (PoM) no price available
  - Ataluren 1 gram Translarna 1,000 mg granules for oral suspension sachets | 30 sachet (PoM) no price available

---

3.2 Myasthenia gravis and Lambert-Eaton myasthenic syndrome

**ANTICHOLINESTERASES**

**Anticholinesterases**

- **DRUG ACTION** They prolong the action of acetylcholine by inhibiting the action of the enzyme acetylcholinesterase.

- **CONTRA-INDICATIONS** Intestinal obstruction - urinary obstruction

- **CAUTIONS** Arrhythmias - asthma (extreme caution) - atropine or other antidote to muscarinic effects may be necessary (particularly when neostigmine is given by injection) but not given routinely because it may mask signs of overdosage - bradycardia - epilepsy - hyperthyroidism - hypotension - parkinsonism - peptic ulceration - recent myocardial infarction - vagotonia

- **SIDE-EFFECTS** Abdominal cramps (more marked with higher doses) - diarrhoea - increased salivation - nausea - vomiting

**Overdose**

Signs of overdosage include bronchoconstriction, increased bronchial secretions, lacrimation, excessive sweating, involuntary defaecation, involuntary micturition, miosis, nyctagmus, bradycardia, heart block, arrhythmias, hypotension, agitation, excessive dreaming, and weakness eventually leading to fasciculation and paralysis.

- **PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk.

- **BREAST FEEDING** Amount probably too small to be harmful.

**Neostigmine**

*(Neostigmine methylsulfate)*

- **INDICATIONS AND DOSE**  
  Treatment of myasthenia gravis  
  - **BY MOUTH**  
    - Adult: Initially 15–30 mg, dose repeated at suitable intervals throughout the day, total daily dose 75–300 mg, the maximum that most patients can tolerate is 180 mg daily
  - **BY SUBCUTANEOUS INJECTION, OR BY INTRAMUSCULAR INJECTION**  
    - Adult: 1–2.5 mg, dose repeated at suitable intervals throughout the day (usual total daily dose 5–20 mg)

**Reversal of non-depolarising (competitive) neuromuscular blockade**

- **BY INTRAVENOUS INJECTION**  
  - Adult: 2.5 mg (max. per dose 5 mg), repeated if necessary after or with glycopyrronium or atropine, to be given over 1 minute
Nocturnal leg cramps 1025

**CAUTIONS** Glycopyrronium or atropine should also be given when reversing neuromuscular blockade

**INTERACTIONS** → Appendix 1: neostigmine

**RENAI IMPAIRMENT** May need dose reduction.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

**Solution for injection**
- **Neostigmine (Non-proprietary)**
  - Neostigmine metilsulfate 2.5 mg per 1 ml
  - Neostigmine 2.5mg/1ml solution for injection ampoules | 10 ampoule £5.06-£5.45

**Tablet**
  - **Neostigmine (Non-proprietary)**
  - Neostigmine bromide 15 mg | Neostigmine 15mg tablets | 140 tablet £95.60 DT price = £95.60

**Pyridostigmine bromide**

**DRUG ACTION** Pyridostigmine bromide has weaker muscarinic action than neostigmine.

**INDICATIONS AND DOSE**

**Myasthenia gravis**
- Initially by mouth
- Adult: 30–120 mg, doses to be given at suitable intervals throughout day; (by mouth) usual dose 0.3–1.2 g daily in divided doses, it is inadvisable to exceed a total daily dose of 450 mg in order to avoid acetylcholine receptor down-regulation; patients requiring doses exceeding 450 mg daily will usually require input from a specialised neuromuscular service. Immunosuppressant therapy is usually considered if the dose of pyridostigmine exceeds 360 mg daily

**INTERACTIONS** → Appendix 1: pyridostigmine

**RENAI IMPAIRMENT** Reduce dose; excreted by kidney.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Tablet**
- **Pyridostigmine bromide (Non-proprietary)**
  - Pyridostigmine bromide 60 mg | Pyridostigmine bromide 60mg tablets | 200 tablet £45.54 DT price = £45.54
  - **Mestinon** (Meda Pharmaceuticals Ltd)
  - Pyridostigmine bromide 60 mg | Mestinon 60mg tablets | 200 tablet £45.57 DT price = £45.54

**CHOLINERGIC RECEPTOR STIMULATING DRUGS**

**Amifampridine**

**INDICATIONS AND DOSE**

**Symptomatic treatment of Lambert-Eaton myasthenic syndrome (specialist use only)**
- **BY MOUTH**
- Adult: Initially 15 mg daily in 3 divided doses, then increased in steps of 5 mg every 4–5 days, increased to up to 60 mg daily in 3–4 divided doses (max. per dose 20 mg); maximum 60 mg per day

**CONTRA-INDICATIONS** Congenital QT syndromes • epilepsy • uncontrolled asthma

**CAUTIONS** Non-paraneoplastic form of Lambert- Eaton myasthenic syndrome

**INTERACTIONS** → Appendix 1: amifampridine

**SIDE-EFFECTS** Anxiety • arrhythmias • blurred vision • bronchial hypersecretion • chorea • convulsions • cough • dizziness • drowsiness • exacerbation or precipitation of asthma • gastro-intestinal disorders • headache • myoclonia • palpitations • paraesthesia • Raynaud’s syndrome • sleep disturbances • weakness

**CONCEPTION AND CONTRACEPTION** Ensure effective contraception during treatment in men and women.

**PREGNANCY** Manufacturer advises avoid.

**BREAST FEEDING** Manufacturer advises avoid—no information available.

**HEPATIC IMPAIRMENT** In mild impairment reduce initial dose to 10 mg daily in divided doses, increased in steps of 5 mg every 7 days. In moderate or severe impairment reduce initial dose to 5 mg daily in divided doses, increased in steps of 5 mg every 7 days. Use with caution.

**RENAI IMPAIRMENT** In mild impairment reduce initial dose to 10 mg daily in divided doses, increased in steps of 5 mg every 7 days. In moderate or severe impairment reduce initial dose to 5 mg daily in divided doses, increased in steps of 5 mg every 7 days. Use with caution.

**MONITORING REQUIREMENTS** Clinical and ECG monitoring required at treatment initiation and yearly thereafter.

**NATIONAL FUNDING/ACCESS DECISIONS**

**Scottish Medicines Consortium (SMC) Decisions**
The Scottish Medicines Consortium (SMC) has advised (July 2012) that amifampridine phosphate (Firdapse®) is not recommended for use within NHS Scotland for the symptomatic treatment of Lambert–Eaton myasthenic syndrome (LEMS).

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet

**Tablet**
- **CAUTIONARY AND ADVISORY LABELS** 3, 21
- **Firdapse** (BioMarin Europe Ltd)
- Amifampridine (as Amifampridine phosphate) 10 mg | Firdapse 10mg tablets | 100 tablet £1,815.00

3.3 Nocturnal leg cramps

**Quinine salts**
Quinine salts p. 586, such as quinine sulfate are effective in reducing the frequency of nocturnal leg cramps by about 25% in ambulatory patients; however, because of potential toxicity, quinine is not recommended for routine treatment and should not be used unless cramps cause regular disruption to sleep. Quinine should only be considered when cramps are very painful or frequent; when other treatable causes of cramp have been excluded; and when non-pharmacological treatments have not worked (e.g. passive stretching exercises). It may take up to 4 weeks for improvement to become apparent; if there is benefit, quinine treatment can be continued. Treatment should be interrupted at intervals of approximately 3 months to assess the need for further quinine treatment. In patients taking quinine long term, a trial discontinuation may be considered. Quinine is toxic in overdosage and accidental fatalities have occurred.
3.4 Spasticity

Other drugs used for Spasticity Dantrolene sodium, p. 1236
• Diazepam, p. 327

CANNABINOIDS

Cannabis extract

● INDICATIONS AND DOSE
Adjuvant in moderate to severe spasticity in multiple sclerosis (specialist use only)
  • BY Buccal administration
  • Adult: (consult product literature)

● CONTRA-INDICATIONS Family history of psychosis • history of other severe psychiatric disorder • personal history of psychosis

● CAUTIONS History of epilepsy • significant cardiovascular disease

● INTERACTIONS → Appendix 1: cannabis extract

● SIDE-EFFECTS
  • Common or very common Amnesia • blurred vision • constipation • depression • diarrhoea • disorientation • dissociation • dizziness • drowsiness • dry mouth • dysarthria • impaired attention • increased or decreased appetite • malaise • mood disturbance • mouth ulcers • nausea • oral pain • taste disturbance • vertigo • vomiting
  • Uncommon Abdominal pain • delusions • hallucinations • hypertension • ophthalmological disorders • palpitation • paranoia • pharyngitis • stomatitis • suicidal thoughts • syncope • tachycardia • tooth discoloration
  • Frequency not known Anxiety • seizures

● CONCEPTION AND CONTRACEPTION Manufacturer recommends effective contraception during and for 3 months after treatment in men and women.

● PREGNANCY Manufacturer advises use only if potential benefit outweighs risks.

● BREAST FEEDING Avoid—present in milk.

● HEPATIC IMPAIRMENT Manufacturer advises more frequent monitoring in significant hepatic impairment—possible risk of prolonged or enhanced effect.

● RENAL IMPAIRMENT Manufacturer advises more frequent monitoring in significant renal impairment—possible risk of prolonged or enhanced effect.

● MONITORING REQUIREMENTS Monitor oral mucosa—interrupt treatment if lesions or persistent soreness.

● PATIENT AND CARER ADVICE
Driving and skilled tasks
For information on 2015 legislation regarding driving whilst taking certain controlled drugs, including cannabis, see Drugs and driving under Guidance on prescribing p. 1.

● MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Spray
EXCIPIENTS: May contain Propylene glycol
• Sativex (Bayer Plc)
  Cannabidiol 2.5 mg per 1 dose, Dronabinol 2.7 mg per 1 dose Sativex oromucosal spray | 270 dose [Pst] £375.00 (P4-1)

MUSCLE RELAXANTS → CENTRALEY ACTING

Baclofen

21-Nov-2016

● INDICATIONS AND DOSE
Pain of muscle spasm in palliative care
  • BY MOUTH
  • Adult: 5—10 mg 3 times a day

Hiccups due to gastric distension (in palliative care)
  • BY MOUTH
  • Adult: 5 mg twice daily

Chronic severe spasticity resulting from disorders such as multiple sclerosis or traumatic partial section of spinal cord
  • BY MOUTH
  • Adult: Initially 5 mg 3 times a day, gradually increased; maintenance up to 60 mg daily in divided doses, review treatment if no benefit within 6 weeks of achieving maximum dose; maximum 100 mg per day

Severe chronic spasticity unresponsive to oral antispastic drugs (or where side-effects of oral therapy unacceptable) or as an alternative to ablative neurosurgical procedures (specialist use only)
  • BY INTRATHECAL INJECTION
  • Adult: Test dose 25—50 micrograms, to be given over at least 1 minute via catheter or lumbar puncture, then increased in steps of 25 micrograms (max. per dose 100 micrograms), not given more often than every 24 hours to determine appropriate dose, then dose titration phase, most often using infusion pump (implanted into chest wall or abdominal wall tissues) to establish maintenance dose (ranging from 12 micrograms to 2 mg daily for spasticity of spinal origin or 22 micrograms to 1.4 mg daily for spasticity of cerebral origin) retaining some spasticity to avoid sensation of paralysis

IMPORTANT SAFETY INFORMATION
Consult product literature for details on test dose and titration—important to monitor patients closely in appropriately equipped and staffed environment during screening and immediately after pump implantation. Resuscitation equipment must be available for immediate use. Treatment with continuous pump-administered intrathecal baclofen should be initiated within 3 months of a satisfactory response to intrathecal baclofen testing.

● CONTRA-INDICATIONS
• With intrathecal use Local infection • systemic infection
• With oral use Avoid oral route in active peptic ulceration

● CAUTIONS

GENERAL CAUTIONS
Cerebrovascular disease • diabetes • elderly • epilepsy • history of peptic ulcer • hypertonic bladder sphincter • Parkinson’s disease • psychiatric illness • respiratory impairment

SPECIFIC CAUTIONS
• With intrathecal use Coagulation disorders • malnutrition (increased risk of post-surgical complications) • previous spinal fusion procedure

● INTERACTIONS → Appendix 1: baclofen

● SIDE-EFFECTS
  • Common or very common Agitation • anxiety • ataxia • cardiovascular depression • confusion • depression • dizziness • drowsiness • dry mouth • euphoria • gastro-intestinal disturbances • hallucinations • headache • hyperhidrosis • hypotension • insomnia • myalgia • nightmares • rash • respiratory depression • sedation • seizure • tremor • urinary disturbances • visual disorders
Rare Abdominal pain · changes in hepatic function · dysarthria · erectile dysfunction · paraesthesia · taste disturbances

Very rare Hypothermia

Pregnancy Manufacturer advises use only if potential benefit outweighs risk (toxicity in animal studies).

Breast feeding Present in milk—amount probably too small to be harmful.

Hepatic impairment With oral use Manufacturer advises use with caution.

Renal impairment With oral use Risk of toxicity—use smaller doses (e.g. 5 mg daily by mouth) and if necessary increase dosage interval; if eGFR less than 15 mL/minute/1.73 m² manufacturer advises use by mouth only if potential benefit outweighs risk. Excreted by the kidney.

Treatment cessation Avoid abrupt withdrawal (risk of hyperactive state, may exacerbate spasticity, and precipitate autonomic dysfunction including hyperthermia, psychotropic reactions and convulsions; to minimise risk, discontinue by gradual dose reduction over at least 1–2 weeks (longer if symptoms occur)).

Prescribing and dispensing information Flavours of oral liquid formulations may include raspberry.

Palliative care For further information on the use of baclofen in palliative care, see www.palliativedrugs.com/formulary/en/baclofen.html.

Patient and carer advice Driving and skilled tasks Drowsiness may affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced.

Medicinal forms There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, solution for injection

Tablet CAUTIONARY AND ADVISORY LABELS 2, 8, 21 EXCIPIENTS: May contain Gluten

Baclofen (Non-proprietary)

Baclofen 10 mg Baclofen 10mg tablets | 84 tablet £9.99 DT price = £6.55

Baclofen 50 microgram per 1 ml Baclofen 50micrograms/1ml solution for injection ampoules | 1 ampoule £25.00–£27.60

Baclofen 50 microgram per 1 ml (Novartis Pharmaceuticals UK Ltd) Baclofen 50 microgram per 1 ml | 100 tablet £14.86

Solution for injection

Baclofen (Non-proprietary)

Baclofen 50 microgram per 1 ml Baclofen 50 micrograms/1ml solution for injection ampoules | 1 ampoule £20.95

Baclofen 50 microgram per 1 ml (Novartis Pharmaceuticals UK Ltd) Baclofen 50 microgram per 1 ml | 100 tablet £95.00–£99.70

Baclofen 50 microgram per 1 ml (Novartis Pharmaceuticals UK Ltd) Baclofen 50 microgram per 1 ml | 100 tablet £95.00–£99.70

Baclofen 50 microgram per 1 ml (Novartis Pharmaceuticals UK Ltd) Baclofen 50 microgram per 1 ml | 100 tablet £95.00–£99.70

Baclofen 50 microgram per 1 ml Baclofen 50 micrograms/1ml solution for injection ampoules | 1 ampoule £3.16

Solution for infusion

Baclofen (Non-proprietary)

Baclofen 500 microgram per 1 ml Baclofen 10mg/20ml solution for infusion ampoules | 1 ampoule £48.62–£57.00

Baclofen 2 mg per 1 ml Baclofen 40mg/20ml solution for infusion ampoules | 1 ampoule £228.00–£250.00

Baclofen 10mg/5ml solution for infusion ampoules | 5 ampoule £243.10

Baclofen 2 mg per 1 ml Baclofen 2 mg/5 ml solution for infusion ampoules | 1 ampoule £50.00–£57.00

Baclofen 500 microgram per 1 ml Lioresal Intrathecal 10mg/20ml solution for infusion ampoules | 1 ampoule £70.01

Baclofen 500 microgram per 1 ml Lioresal Intrathecal 10mg/20ml solution for infusion ampoules | 1 ampoule £70.01

Oral solution

CAUTIONARY AND ADVISORY LABELS 2, 8, 21

Baclofen (Non-proprietary)

Baclofen 1 mg per 1 ml Baclofen 5mg/5ml oral solution sugar free | 300 ml £12.41 DT price = £3.22

Methocarbamol

Indications and dose

Short-term symptomatic relief of muscle spasm

By mouth

Adult: 1.5 g 4 times a day; reduced to 750 mg 3 times a day if required

Elderly: Up to 750 mg 4 times a day, dose may be sufficient

Contra-indications Brain damage · coma · epilepsy · myasthenia gravis · pre-coma

Interactions → Appendix 1: methocarbamol

Side-effects Amnesia · anaphylaxis · angioedema · anxiety · blurred vision · bradycardia · cholestatic jaundice · confusion · dizziness · drowsiness · dyspepsia · fever · headache · hypersensitivity reactions · hypotension · leucopenia · nasal congestion · nausea · pruritus · rash · restlessness · seizures · tremor · urticaria · vomiting

Pregnancy Manufacturer advises avoid unless potential benefit outweighs risk.

Breast feeding Present in milk in animal studies—manufacturer advises caution.

Hepatic impairment Manufacturer advises caution; half-life may be prolonged.

Renal impairment Manufacturer advises caution.

Patient and carer advice Driving and skilled tasks Drowsiness may affect performance of skilled tasks (e.g. driving); effects of alcohol enhanced.

Less suitable for prescribing Less suitable for prescribing.

Medicinal forms There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, solution for injection

Tablet CAUTIONARY AND ADVISORY LABELS 2

Methocarbamol (Non-proprietary)

Methocarbamol 750 mg Methocarbamol 750mg tablets | 100 tablet £28.84 DT price = £28.84

Robaxin (Almirall Ltd) Robaxin 750mg tablets | 100 tablet £12.65 DT price = £28.84

Tizanidine

Indications and dose

Spasticity associated with multiple sclerosis or spinal cord injury or disease

By mouth

Adult: Initially 2 mg daily, then increased in steps of 2 mg daily in divided doses, increased at intervals of at least 3–4 days and adjust according to response; usual dose up to 24 mg daily in 3–4 divided doses; maximum 36 mg per day

Caution Elderly

Interactions → Appendix 1: tizanidine

Side-effects Common or very common Altered liver enzymes (discontinue if persistently raised—consult product

Downloaded from www.medicalbr.com
4 Pain and inflammation in musculoskeletal disorders

Low back pain and sciatica

Description of condition
Low back pain is pain in the lumbosacral area of the back. It can be described as non-specific, mechanical, musculoskeletal or simple (if it is not associated with serious or potentially serious causes). Episodes of back pain do not usually last long, with rapid improvements in pain and disability seen within a few weeks to months.

Sciatica (radicular pain or radiculopathy) is neuropathic leg pain secondary to compressive lumbosacral nerve root pathology.

Non-drug treatment

Exercise programmes, manual therapy, and psychological therapies should be considered for managing low back pain with or without sciatica.

Spinal decompression may be considered in patients with sciatica when pain and function has not improved with non-surgical treatment (including drug treatment).

Drug treatment

An oral NSAID (see Non-steroidal anti-inflammatory drugs, below) should be considered for managing acute low back pain, taking into consideration the gastro-intestinal, cardio-renal and hepatic risks associated with NSAIDs; as well as the need for continued monitoring, and the possible need for gastroprotective treatment (see NSAID-associated ulcers under Peptic ulceration p. 70).

A weak opioid, either alone or with paracetamol p. 422, can be used to manage acute low back pain only if an NSAID is contra-indicated, not tolerated or ineffective (see Opioid analgesics under Analgesics p. 420). Paracetamol alone is ineffective for managing low back pain.

Benzodiazepines are sometimes used to manage acute low back pain (particularly in loss of lordosis); however evidence to support their use is very weak.

In patients with chronic low back pain who have had an inadequate response to non-drug treatment, NSAIDs should be considered as first-line therapy. Opioids should be the last treatment option considered and should be considered only in patients for whom other therapies have failed and only if the potential benefits outweigh the risks for individual patients. If indicated, opioids should only be prescribed for a limited period of time. Long term opioid therapy should be avoided.

Selective serotonin re-uptake inhibitors (SSRIs), serotonin and noradrenaline re-uptake inhibitors (SNRIs), tricyclic antidepressants, and antiepileptic drugs should not be offered for managing low back pain.

When non-surgical treatment is ineffective in patients with moderate and severe localised back pain arising from structures supplied by the medial branch nerve, radiofrequency denervation can be considered.

Sciatica

Patients with sciatica may require specific treatment for Neuropathic pain p. 457.

Patients with acute and severe sciatica may benefit from treatment with epidural injections of local anaesthetic and/or corticosteroid.

Useful Resources


Non-steroidal anti-inflammatory drugs

Therapeutic effects

In single doses non-steroidal anti-inflammatory drugs (NSAIDs) have analgesic activity comparable to that of paracetamol p. 422, but paracetamol is preferred, particularly in the elderly.

In regular full dosage NSAIDs have both a lasting analgesic and an anti-inflammatory effect which makes them particularly useful for the treatment of continuous or regular pain associated with inflammation. Therefore, although paracetamol often gives adequate pain control in osteoarthritis, NSAIDs are more appropriate than paracetamol or the opioid analgesics in the inflammatory arthritides (e.g. rheumatoid arthritis) and in some cases of advanced osteoarthritis. NSAIDs can also be of benefit in the less well defined conditions of back pain and soft-tissue disorders.

Choice

Differences in anti-inflammatory activity between NSAIDs are small, but there is considerable variation in individual response and tolerance to these drugs. About 60% of patients will respond to any NSAID; of the others, those who do not respond to one may well respond to another. Pain relief starts soon after taking the first dose and a full analgesic effect should normally be obtained within a week, whereas an anti-inflammatory effect may not be achieved (or may not be clinically assessable) for up to 3 weeks. If appropriate responses are not obtained within these times, another NSAID should be tried.
NSAIDs reduce the production of prostaglandins by inhibiting the enzyme cyclo-oxygenase. They vary in their selectivity for inhibiting different types of cyclo-oxygenase; selective inhibition of cyclo-oxygenase-2 is associated with less gastro-intestinal intolerance. Several other factors also influence susceptibility to gastrointestinal effects, and a NSAID should be chosen on the basis of the incidence of gastro-intestinal and other side-effects.

Ibuprofen p. 1041 is a propionic acid derivative with anti-inflammatory, analgesic, and antipyretic properties. It has fewer side-effects than other non-selective NSAIDs but its anti-inflammatory properties are weaker. It is unsuitable for conditions where inflammation is prominent, such as acute gout. Diclofenac p. 1032 is the active enantiomer of ibuprofen. It has similar properties to ibuprofen and is licensed for the relief of mild to moderate pain and inflammation.

Other propionic acid derivatives:
- Naproxen p. 1048 is one of the first choices because it combines good efficacy with a low incidence of side-effects (but more than ibuprofen).
- Diclofenac sodium p. 1034 and aceclofenac p. 1030 are similar in efficacy to naproxen.
- Etodolac p. 1037 is comparable in effect to naproxen; it is licensed for the short-term relief of pain in osteoarthritis and rheumatoid arthritis.
- Indomethacin p. 1043 has an action equal to or superior to that of naproxen, but with a high incidence of side-effects including headache, dizziness, and gastro-intestinal disturbances.
- Mefenamic acid p. 1046 has minor anti-inflammatory properties. It has occasionally been associated with diarrhoea and haemolytic anaemia which require discontinuation of treatment.
- Meloxicam p. 1046 is licensed for the short-term relief of pain in osteoarthritis and for long-term treatment of rheumatoid arthritis and ankylosing spondylitis.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a low risk of gastrointestinal side-effects than non-selective NSAIDs such as naproxen. Although selective inhibitors can cause serious gastrointestinal events, available evidence appears to indicate that the risk of serious upper gastrointestinal events is lower with selective inhibitors compared to non-selective NSAIDs; this advantage may be lost in patients who require concomitant low-dose aspirin.

Celecoxib and etoricoxib are licensed for the relief of pain in osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; etoricoxib is also licensed for the relief of pain from acute gout.

Aspirin p. 117 has been used in high doses to treat rheumatoid arthritis, but other NSAIDs are now preferred.

Dental and orofacial pain
Most mild to moderate dental pain and inflammation is effectively relieved by NSAIDs. Those used for dental pain include ibuprofen, diclofenac sodium, and diclofenac potassium p. 1033.

Asthma
Any degree of worsening of asthma may be related to the ingestion of NSAIDs, either prescribed or (in the case of ibuprofen and others) purchased over the counter.

NSAIDs and cardiovascular events
All NSAID use (including cyclo-oxygenase-2 selective inhibitors) can, to varying degrees, be associated with a small increased risk of thrombotic events (e.g. myocardial infarction and stroke) independent of baseline cardiovascular risk factors or duration of NSAID use; however, the greatest risk may be in those receiving high doses long term.

Cyclo-oxygenase-2 selective inhibitors, diclofenac (150 mg daily) and ibuprofen (2.4 g daily) are associated with an increased risk of thrombotic events. Although there are limited data regarding the thrombotic effects of acetylsalicylic acid, treatment advice has been updated in line with diclofenac, based on acetylsalicylic acid's structural similarity to diclofenac and its metabolism to diclofenac. The increased risk for diclofenac is similar to that of licensed doses of etoricoxib.

Naproxen (1 g daily) is associated with a lower thrombotic risk, and low doses of ibuprofen (1.2 g daily or less) have not been associated with an increased risk of myocardial infarction.

The lowest effective dose of NSAID should be prescribed for the shortest period of time to control symptoms and the need for long-term treatment should be reviewed periodically.

NSAIDs and gastro-intestinal events
All NSAIDs are associated with serious gastro-intestinal toxicity; the risk is higher in the elderly. Evidence on the relative safety of non-selective NSAIDs indicates differences in the risks of serious upper gastro-intestinal side-effects—pirprofen p. 1049, ketoprofen p. 1044, and ketorolac trometamol p. 1077 are associated with the highest risk; indomethacin p. 1043, diclofenac, and naproxen p. 1048 are associated with intermediate risk, and ibuprofen p. 1041 with the lowest risk (although high doses of ibuprofen have been associated with intermediate risk). Selective inhibitors of cyclo-oxygenase-2 are associated with a lower risk of serious upper gastro-intestinal side-effects than non-selective NSAIDs.

Recommendations are that NSAIDs associated with a low risk e.g. ibuprofen are generally preferred, to start at the lowest recommended dose and not to use more than one oral NSAID at a time.

The combination of a NSAID and low-dose aspirin can increase the risk of gastro-intestinal side-effects; this combination should be used only if absolutely necessary and the patient should be monitored closely.
While it is preferable to avoid NSAIDs in patients with active or previous gastro-intestinal ulceration or bleeding, and to withdraw them if gastro-intestinal lesions develop, nevertheless patients with serious rheumatic diseases (e.g. rheumatoid arthritis) are usually dependent on NSAIDs for effective relief of pain and stiffness. Patients at risk of gastro-intestinal ulceration (including the elderly), who need NSAID treatment should receive gastroprotective treatment.

Systemic as well as local effects of NSAIDs contribute to gastro-intestinal damage; taking oral formulations with milk or food, or using enteric-coated formulations, or changing the route of administration may only partially reduce symptoms such as dyspepsia.

**NSAIDs and alcohol**

Alcohol increases the risk of gastro-intestinal haemorrhage associated with NSAIDs. Specialist sources recommend that concurrent use need not be avoided with moderate alcohol intake, but greater caution is warranted in those who drink more than the recommended daily limits.

Some cases of acute kidney injury have been attributed to use of NSAIDs and acute excessive alcohol consumption.

** ANALGESICS > NON-STERoidal ANTI-INFLAMMATORY DRUGS  

<table>
<thead>
<tr>
<th>Aceclofenac</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INDICATIONS AND DOSE</strong></td>
</tr>
<tr>
<td>Pain and inflammation in rheumatoid arthritis, osteoarthritis and ankylosing spondylitis</td>
</tr>
<tr>
<td><strong>BY MOUTH</strong></td>
</tr>
<tr>
<td>Adult: 100 mg twice daily</td>
</tr>
</tbody>
</table>

| CONTRA-INDICATIONS  |
| Active gastro-intestinal bleeding  |
| active gastro-intestinal ulceration  |
| cerebrovascular disease  |
| history of gastro-intestinal bleeding related to previous NSAID therapy  |
| history of gastro-intestinal perforation related to previous NSAID therapy  |
| history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes)  |
| history of recurrent gastro-intestinal ulceration (two or more distinct episodes)  |
| ischaemic heart disease  |
| mild heart failure  |
| peripheral arterial disease  |
| severe heart failure |

| CAUTIONS  |
| Allergic disorders  |
| avoid in acute porphyrias p. 969  |
| cardiac impairment (NSAIDs may impair renal function)  |
| coagulation defects  |
| connective-tissue disorders  |
| Crohn’s disease (may be exacerbated)  |
| elderly (risk of serious side-effects and fatalities)  |
| history of cardiac failure  |
| hypertension  |
| left ventricular dysfunction  |
| oedema  |
| risk factors for cardiovascular events  |
| ulcerative colitis (may be exacerbated) |

| INTERACTIONS  |
| Appendix 1: NSAIDs |

| SIDE-EFFECTS  |
| Rare  |
| Alveolitis  |
| aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible)  |
| hepatic damage  |
| interstitial fibrosis associated with NSAIDs can lead to renal failure  |
| pancreatitis  |
| papillary necrosis associated with NSAIDs can lead to renal failure  |
| pulmonary eosinophilia  |
| Stevens-Johnson syndrome  |
| toxic epidermal necrolysis  |
| Frequency not known  |
| Angioedema  |
| blood disorders  |
| bronchospasm  |
| colitis (induction of or exacerbation of)  |
| Crohn’s disease (induction of or exacerbation of)  |
| depression  |
| diarrhoea  |
| dizziness  |
| drowsiness  |
| fluid retention (rarely precipitating congestive heart failure)  |
| gastro-intestinal bleeding  |
| gastro-intestinal discomfort  |
| gastro-intestinal disturbances  |
| gastro-intestinal ulceration  |
| haematuria  |
| headache  |
| hearing disturbances  |
| hypersensitivity reactions  |
| insomnia  |
| nausea  |
| nervousness  |
| photosensitivity  |
| raised blood pressure  |
| rashes  |
| renal failure (especially in patients with pre-existing renal impairment)  |
| tinnitus  |
| vertigo  |

| SIDE-EFFECTS, FURTHER INFORMATION  |
| Serious side-effects  |
| For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 1028. |

| ALLERGY AND CROSS-SENSITIVITY  |
| Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID. |

| CONCEPTION AND CONTRACEPTION  |
| Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment. |

| PREGNANCY  |
| Most manufacturers advise avoiding the use of NSAIDs during pregnancy or avoiding them unless the potential benefit outweighs the risk. NSAIDs should be avoided during the third trimester because use is associated with a risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn. In addition, the onset of labour may be delayed and its duration may be increased. |

| BREAST FEEDING  |
| Use with caution during breast-feeding. Manufacturer advises avoid. |

| HEPATIC IMPAIRMENT  |
| Initially 100 mg daily. Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease. |

| RENAL IMPAIRMENT  |
| Avoid if possible or use with caution; avoid in moderate to severe impairment. The lowest effective dose should be used for the shortest possible duration. Monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure. |

| MEDICINAL FORMS  |
| There can be variation in the licensing of different medicines containing the same drug. |

| Tablet |
| CAUTIONARY AND ADVISORY LABELS 21 |
| Aceclofenac (Non-proprietary) |
| Aceclofenac 100 mg | 60 tablet |
| £11.50 DT price = £9.63 |
| Preservex (Almirall Ltd) |
| Aceclofenac 100 mg | 60 tablet |
| £9.63 DT price = £9.63 |

| Acemetacin |
| **INDICATIONS AND DOSE** |
| Pain and inflammation in rheumatic disease  |
| Pain and inflammation in other musculoskeletal disorders  |
| Postoperative analgesia |
| **BY MOUTH** |
| Adult: 120 mg daily in divided doses, then increased if necessary to 180 mg daily in divided doses, dose to be taken with food |

| CONTRA-INDICATIONS  |
| Active gastro-intestinal bleeding  |
| active gastro-intestinal ulceration  |
| history of gastro-intestinal bleeding related to previous NSAID therapy  |
| history of gastro-intestinal perforation related to previous NSAID therapy  |
| history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes)  |
| history of recurrent gastro-intestinal ulceration (two or more distinct episodes)  |
| severe heart failure |
CAUTIONS
Allergic disorders • cardiac impairment (NSAIDs may impaire renal function) • cerebrovascular disease • coagulation defects • connective-tissue disorders • Cronh’s disease (may be exacerbated) • elderly (risk of serious side-effects and fatalities) • epilepsy • heart failure • ischaemic heart disease • parkinsonism • peripheral arterial disease • psychiatric disturbances • risk factors for cardiovascular events • ulcerative colitis (may be exacerbated) • uncontrolled hypertension

INTERACTIONS ▶ Appendix 1: NSAIDs

SIDE-EFFECTS
▶ Rare Alveolitis • asceptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) • blood disorders • confusion • convulsions • hepatic damage • hyperglycaemia • interstitial fibrosis associated with NSAIDs can lead to renal failure • intestinal strictures • pancreatitis • papillary necrosis associated with NSAIDs can lead to renal failure • peripheral neuropathy • psychiatric disturbances • pulmonary eosinophilia • Stevens-Johnson syndrome • syncope • thrombocytopenia • toxic epidermal necrolysis • visual disturbances

Frequency not known Angioedema • blood disorders • bronchospasm • colitis (induction of or exacerbation of) • Cronh’s disease (induction of or exacerbation of) • depression • diarrhoea • dizziness • drowsiness • fluid retention (rarely precipitating congestive heart failure) • gastro-intestinal bleeding • gastro-intestinal discomfort • gastro-intestinal ulceration • haematuria • headache • hearing disturbances • hyperkalaemia • hypersensitivity reactions • insomnia • nausea • nervousness • photosensitivity • raised blood pressure • rashes • renal failure (especially in patients with pre-existing renal impairment) • tinnitus • vertigo

SIDE-EFFECTS, FURTHER INFORMATION
Serious side-effects For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 1028.

ALLERGY AND CROSS-SENSITIVITY Contra–indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

CONCEPTION AND CONTRACEPTION Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

PREGNANCY Most manufacturers advise avoiding the use of NSAIDs during pregnancy or avoiding them unless the potential benefit outweighs the risk. NSAIDs should be avoided during the third trimester because use is associated with a risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn. In addition, the onset of labour may be delayed and its duration may be increased.

BREAST FEEDING Use with caution during breast-feeding. Manufacturer advises avoid.

HEPATIC IMPAIRMENT Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

RENAL IMPAIRMENT Avoid if possible or use with caution. The lowest effective dose should be used for the shortest possible duration. Monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

MONITORING REQUIREMENTS During prolonged therapy ophthalmic and blood examinations particularly advisable.

PATIENT AND CARER ADVICE
Driving and skilled tasks Driving Dizziness may affect performance of skilled tasks (e.g. driving).

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Capsule
CAUTIONARY AND ADVISORY LABELS 21
▶ Emflex (Merck Serono Ltd)
Acentacin 60 mg Emflex 60mg capsules | 90 capsule POM £28.20 DT price = £28.20

Celecoxib

INDICATIONS AND DOSE
Pain and inflammation in osteoarthritis
▶ BY MOUTH
Adult: 200 mg daily in 1–2 divided doses, then increased if necessary up to 200 mg twice daily, discontinue if no improvement after 2 weeks on maximum dose

Pain and inflammation in rheumatoid arthritis
▶ BY MOUTH
Adult: 100 mg twice daily, then increased if necessary to 200 mg twice daily, discontinue if no improvement after 2 weeks on maximum dose

Ankylosing spondylitis
▶ BY MOUTH
Adult: 200 mg daily in 1–2 divided doses, then increased if necessary up to 400 mg daily in 1–2 divided doses, discontinue if no improvement after 2 weeks on maximum dose

DOSE ADJUSTMENTS DUE TO INTERACTIONS
Manufacturer advises reduce dose by half with concurrent use of fluconazole.

CONTRA-INDICATIONS Active gastro-intestinal bleeding • active gastro-intestinal ulceration • cerebrovascular disease • inflammatory bowel disease • ischaemic heart disease • mild to severe heart failure • peripheral arterial disease

CAUTIONS Allergic disorders • cardiac impairment (NSAIDs may impair renal function) • coagulation defects • connective-tissue disorders • Cronh’s disease (may be exacerbated) • elderly (risk of serious side-effects and fatalities) • history of cardiac failure • hypertension • left ventricular dysfunction • oedema • risk factors for cardiovascular events • ulcerative colitis (may be exacerbated)

INTERACTIONS ▶ Appendix 1: NSAIDs

SIDE-EFFECTS
▶ Common or very common Dyspnoea • influenza-like symptoms
▶ Uncommon Cerebral infarction • fatigue • muscle cramps • palpitation • paraesthesia • stomatitis
▶ Rare Alopecia • alveolitis • asceptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) • hepatic damage • interstitial fibrosis associated with NSAIDs can lead to renal failure • pancreatitis • papillary necrosis associated with NSAIDs can lead to renal failure • pulmonary eosinophilia • Stevens-Johnson syndrome • taste disturbance • toxic epidermal necrolysis • visual disturbances

Very rare Seizures

Frequency not known Angioedema • blood disorders • bronchospasm • chest pain • colitis (induction of or exacerbation of) • Cronh’s disease (induction of or exacerbation of) • depression • diarrhoea • dizziness.
Musculoskeletal system

**CONCEPTION**

**MEDICINAL FORMS**

**ALLERGY AND CROSS-SENSITIVITY**

Serious side-effects

BY MOUTH

▶ Mild to moderate pain and inflammation in containing the

There can be variation in the licensing of different medicines

Pain and inflammation associated with osteoarthritis and other musculoskeletal disorders | Mild to moderate pain and inflammation including dental pain

▶ BY MOUTH

Adult: 600–900 mg daily in up to 3 divided doses; increased if necessary up to 1.2 g daily (max. per dose 400 mg)

Mild to moderate pain and inflammation in dysmenorrhoea

▶ BY MOUTH

Adult: 600–900 mg daily in up to 3 divided doses (max. per dose 300 mg); maximum 900 mg per day

CONTRA-INDICATIONS Active gastro-intestinal bleeding - active gastro-intestinal ulceration | history of gastro-intestinal bleeding related to previous NSAID therapy - history of gastro-intestinal perforation related to previous NSAID therapy - history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes) - history of recurrent gastro-intestinal ulceration (two or more distinct episodes) - severe heart failure

CAUTIONS Allergic disorders - cardiac impairment (NSAIDs may impair renal function) - cerebrovascular disease - coagulation defects - connective-tissue disorders - Crohn's disease (may be exacerbated) - elderly (risk of serious side-effects and fatalities) - heart failure - ischaemic heart disease - peripheral arterial disease - risk factors for cardiovascular events - ulcerative colitis (may be exacerbated) - uncontrolled hypertension

CAUTIONS, FURTHER INFORMATION

High-dose dexibuprofen A small increase in cardiovascular risk, similar to the risk associated with cyclo-oxygenase-2 inhibitors and diclofenac, has been reported with high-dose dexibuprofen (≥ 1.2 g daily); use should be avoided in patients with established ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, congestive heart failure (New York Heart Association classification II–III), and uncontrolled hypertension.

INTERACTIONS → Appendix 1: NSAIDs

SIDE-EFFECTS

Rare Alveolitis - asceptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) - hepatic damage - interstitial fibrosis associated with NSAIDs can lead to renal failure - pancreatitis - papillary necrosis associated with NSAIDs can lead to renal failure - pulmonary eosinophilia - Stevens-Johnson syndrome - toxic epidermal necrolysis - visual disturbances

Frequency not known Angioedema - blood disorders - bronchospasm - colitis (induction of or exacerbation of) - Crohn's disease (induction of or exacerbation of) - depression - diarrhoea - dizziness - drowsiness - fluid retention (rarely precipitating congestive heart failure) - gastro-intestinal bleeding - gastro-intestinal discomfort - gastro-intestinal disturbances - gastro-intestinal ulceration - haematuria - headache - hearing disturbances - hypersensitivity reactions - insomnia - nausea - nervousness - photosensitivity - raised blood pressure - rashes - renal failure (especially in patients with pre-existing renal impairment) - tinnitus - vertigo

SIDE-EFFECTS, FURTHER INFORMATION

Serious side-effects For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 1028.

ALLERGY AND CROSS-SENSITIVITY Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

Contra-indicated in patients with sulphonamide sensitivity.

CONCEPTION AND CONTRACEPTION Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

PREGNANCY Avoid (teratogenic in animal studies).

BREAST FEEDING Avoid—present in milk in animal studies.

HEPATIC IMPAIRMENT Halve initial dose in moderate impairment. Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

RENAL IMPAIRMENT Avoid if possible or use with caution. Avoid if eGFR less than 30 mL/minute/1.73 m². The lowest effective dose should be used for the shortest possible duration. Monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

MONITORING REQUIREMENTS Monitor blood pressure before and during treatment.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Capsule

▶ Celecoxib (Non-proprietary)

Celecoxib 100 mg Celecoxib 100mg capsules | 60 capsule £21.55 DT price = £1.81

Celecoxib 200 mg Celecoxib 200mg capsules | 30 capsule £21.55 DT price = £1.62

Celebrex (Pfizer Ltd)

Celecoxib 100 mg Celebrex 100mg capsules | 60 capsule £21.55 DT price = £1.81

Celecoxib 200 mg Celebrex 200mg capsules | 30 capsule £21.55 DT price = £1.62

Dexibuprofen

INDICATIONS AND DOSE

Pain and inflammation associated with osteoarthritis and other musculoskeletal disorders | Mild to moderate pain and inflammation including dental pain

▶ BY MOUTH

Adult: 600–900 mg daily in up to 3 divided doses; increased if necessary up to 1.2 g daily (max. per dose 400 mg)

Mild to moderate pain and inflammation in dysmenorrhoea

▶ BY MOUTH

Adult: 600–900 mg daily in up to 3 divided doses (max. per dose 300 mg); maximum 900 mg per day

CONTRA-INDICATIONS Active gastro-intestinal bleeding - active gastro-intestinal ulceration | history of gastro-intestinal bleeding related to previous NSAID therapy - history of gastro-intestinal perforation related to previous NSAID therapy - history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes) - history of recurrent gastro-intestinal ulceration (two or more distinct episodes) - severe heart failure

CAUTIONS Allergic disorders - cardiac impairment (NSAIDs may impair renal function) - cerebrovascular disease - coagulation defects - connective-tissue disorders - Crohn’s disease (may be exacerbated) - elderly (risk of serious side-effects and fatalities) - heart failure - ischaemic heart disease - peripheral arterial disease - risk factors for cardiovascular events - ulcerative colitis (may be exacerbated) - uncontrolled hypertension

CAUTIONS, FURTHER INFORMATION

High-dose dexibuprofen A small increase in cardiovascular risk, similar to the risk associated with cyclo-oxygenase-2 inhibitors and diclofenac, has been reported with high-dose dexibuprofen (≥ 1.2 g daily); use should be avoided in patients with established ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, congestive heart failure (New York Heart Association classification II–III), and uncontrolled hypertension.

INTERACTIONS ➔ Appendix 1: NSAIDs

SIDE-EFFECTS

Rare Alveolitis - asceptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) - hepatic damage - interstitial fibrosis associated with NSAIDs can lead to renal failure - pancreatitis - papillary necrosis associated with NSAIDs can lead to renal failure - pulmonary eosinophilia - Stevens-Johnson syndrome - toxic epidermal necrolysis - visual disturbances

Frequency not known Angioedema - blood disorders - bronchospasm - colitis (induction of or exacerbation of) - Crohn’s disease (induction of or exacerbation of) - depression - diarrhoea - dizziness - drowsiness - fluid retention (rarely precipitating congestive heart failure) - gastro-intestinal bleeding - gastro-intestinal discomfort - gastro-intestinal disturbances - gastro-intestinal ulceration - haematuria - headache - hearing disturbances - hypersensitivity reactions - insomnia - nausea - nervousness - photosensitivity - raised blood pressure - rashes - renal failure (especially in patients with pre-existing renal impairment) - tinnitus - vertigo

SIDE-EFFECTS, FURTHER INFORMATION

Serious side-effects For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 1028.

ALLERGY AND CROSS-SENSITIVITY Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

Contra-indicated in patients with sulphonamide sensitivity.

CONCEPTION AND CONTRACEPTION Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

PREGNANCY Avoid (teratogenic in animal studies).

BREAST FEEDING Avoid—present in milk in animal studies.

HEPATIC IMPAIRMENT Halve initial dose in moderate impairment. Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

RENAL IMPAIRMENT Avoid if possible or use with caution. Avoid if eGFR less than 30 mL/minute/1.73 m². The lowest effective dose should be used for the shortest possible duration. Monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

MONITORING REQUIREMENTS Monitor blood pressure before and during treatment.
RENAL IMPAIRMENT
Avoid if possible or use with caution. Avoid if eGFR less than 30 mL/minute/1.73 m². Reduce initial dose. The lowest effective dose should be used for the shortest possible duration. Monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS 21

▶ Seractil (Thornton & Ross Ltd)
Dexibuprofen 400 mg Seractil 400mg tablets | 60 tablet £8.47 DT price = £8.47

Dexketoprofen

INDICATIONS AND DOSE
Short-term treatment of mild to moderate pain including dysmenorrhoea

BY MOUTH

▶ Adult: 12.5 mg every 4–6 hours, alternatively 25 mg every 8 hours; maximum 75 mg per day
▶ Elderly: 12.5 mg every 4–6 hours, alternatively 25 mg every 8 hours, initial max. 50 mg; maximum 75 mg daily

CONTRA-INDICATIONS
Active gastro-intestinal bleeding • active gastro-intestinal ulceration • history of gastrointestinal bleeding related to previous NSAID therapy • history of gastro-intestinal perforation related to previous NSAID therapy • history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes) • history of recurrent gastro-intestinal ulceration (two or more distinct episodes) • severe heart failure

CAUTIONS
Allergic disorders • cardiac impairment (NSAIDs may impair renal function) • cerebrovascular disease • coagulation defects • connective-tissue disorders • Crohn’s disease (may be exacerbated) • elderly (risk of serious side-effects and fatalities) • heart failure • ischaemic heart disease • peripheral arterial disease • risk factors for cardiovascular events • ulcerative colitis (may be exacerbated) • uncontrolled hypertension

INTERACTIONS → Appendix 1: NSAIDs

SIDE-EFFECTS

▶ Rare
Alveolitis • aspetic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) • hepatic damage • interstitial fibrosis associated with NSAIDs can lead to renal failure • pancreatitis • papillary necrosis associated with NSAIDs can lead to renal failure • pulmonary eosinophilia • Stevens-Johnson syndrome • toxic epidermal necrolysis • visual disturbances

FREQUENCY NOT KNOWN
Angioedema • blood disorders • bronchospasm • colitis (induction of or exacerbation of) • Crohn’s disease (induction of or exacerbation of) • depression • diarrhoea • dizziness • drowsiness • fluid retention (rarely precipitating congestive heart failure) • gastro-intestinal bleeding • gastro-intestinal discomfort • gastro-intestinal ulceration • haematuria • headache • hearing disturbances • hypersensitivity reactions • insomnia • nausea • nervousness • photosensitivity • raised blood pressure • rashes • renal failure (especially in patients with pre-existing renal impairment) • tinnitus • vertigo

SIDE-EFFECTS, FURTHER INFORMATION

Serious side-effects For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 1028.

ALLERGY AND CROSS-SENSITIVITY
Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

CONCEPTION AND CONTRACEPTION
Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

PREGNANCY
Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

BREAST FEEDING
Use with caution during breast-feeding. Manufacturer advises avoid—no information available.

HEPATIC IMPAIRMENT
Reduce initial dose to max. 50 mg daily in mild to moderate impairment. Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

RENAL IMPAIRMENT
Avoid if possible or use with caution. Avoid in moderate to severe impairment. Reduce initial dose to 50 mg daily. The lowest effective dose should be used for the shortest possible duration. Monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS 22

▶ Keral (A. Menarini Farmaceutica Internazionale SRL)
Dexketoprofen (as Dexketoprofen trometamol) 25 mg Keral 25mg tablets | 20 tablet £3.67 | 50 tablet £9.18

Diclofenac potassium

INDICATIONS AND DOSE
Pain and inflammation in rheumatic disease and other musculoskeletal disorders

BY MOUTH

▶ Adult: 75–150 mg daily in 2–3 divided doses
▶ Child 14–17 years: 75–100 mg daily in 2–3 divided doses

Acute gout

BY MOUTH

▶ Adult: 75–150 mg daily in 2–3 divided doses
▶ Child 14–17 years: 75–100 mg daily in 2–3 divided doses

Postoperative pain

BY MOUTH

▶ Adult: 75–150 mg daily in 2–3 divided doses
▶ Child 9–13 years (body-weight 35 kg and above): Up to 2 mg/kg daily in 3 divided doses; maximum 100 mg per day
▶ Child 14–17 years: 75–100 mg daily in 2–3 divided doses

Migraine

BY MOUTH

▶ Adult: 50 mg, to be given at onset of migraine, then 50 mg after 2 hours if required, then 50 mg after 4–6 hours; maximum 200 mg per day

Fever in ear, nose, or throat infection

BY MOUTH

▶ Child 9–17 years (body-weight 35 kg and above): Up to 2 mg/kg daily in 3 divided doses; maximum 100 mg per day

UNLICENSED USE
Voltarol® Rapid not licensed for use in children under 14 years or in fever.

CONTRA-INDICATIONS
Active gastro-intestinal bleeding • active gastro-intestinal ulceration • cerebrovascular disease • history of gastro-intestinal bleeding related to...
previous NSAID therapy · history of gastro-intestinal perforation related to previous NSAID therapy · history of recurrent gastro-intestinal haemorrhage (two or more distinct perforations) · history of recurrent gastro-intestinal ulceration (two or more distinct episodes) · ischaemic heart disease · mild to severe heart failure · peripheral arterial disease

**CAUTIONS** Allergic disorders · cardiac impairment (NSAIDs may impair renal function) · coagulation defects · connective-tissue disorders · Crohn’s disease (may be exacerbated) · elderly (risk of serious side-effects and fatalities) (in adults) · history of cardiac failure · hypertension · left ventricular dysfunction · oedema · risk factors for cardiovascular events · ulcerative colitis (may be exacerbated)

**INTERACTIONS** → Appendix 1: NSAIDs

**SIDE-EFFECTS**
- Rare  Alveolitis · aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) · hepatic damage · interstitial fibrosis associated with NSAIDs can lead to renal failure · pancreatitis · papillary necrosis associated with NSAIDs can lead to renal failure · pulmonary eosinophilia · Stevens-Johnson syndrome · toxic epidermal necrolysis · visual disturbances
- Frequency not known  Angioedema · blood disorders · bronchospasm · colitis (induction of or exacerbation of) · Crohn’s disease (induction of or exacerbation of) · depression · diarrhoea · dizziness · drowsiness · fluid retention (rarely precipitating congestive heart failure) · gastro-intestinal bleeding · gastro-intestinal discomfort · gastro-intestinal ulceration · haematuria · headache · hearing disturbances · hypersensitivity reactions · insomnia · nausea · nervousness · photosensitivity · raised blood pressure · rashes · renal failure (especially in patients with pre-existing renal impairment) · tinnitus · vertigo

**ALLERGY AND CROSS-SENSITIVITY** Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

**CONCEPTION AND CONTRACEPTION** Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

**PREGNANCY** Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

**BREAST FEEDING** Use with caution during breast-feeding. Amount in milk too small to be harmful.

**HEPATIC IMPAIRMENT** Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

**RENAL IMPAIRMENT** Avoid if possible or use with caution. Avoid in severe impairment. The lowest effective dose should be used for the shortest possible duration. Monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

**PATIENT AND CARER ADVICE**
- Medicines for Children leaflet: Diclofenac for pain and inflammation
- www.medicinesforchildren.org.uk
- diclofenac-for-pain-and-inflammation

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

**CAUTIONARY AND ADVISORY LABELS** 21
- Diclofenac potassium (Non-proprietary)
- Diclofenac potassium 25 mg
- Diclofenac potassium 25 mg tablets 28 tablet £3.87 DT price = £3.87
- Diclofenac potassium 50 mg
- Diclofenac potassium 50 mg tablets 28 tablet £7.41
- Voltarol Rapid
- Voltarol Rapid 50 mg tablets 30 tablet £7.94 DT price = £7.94

**Diclofenac sodium**

**INDICATIONS AND DOSE**

**Pain and inflammation in musculoskeletal disorders**

**Acute gout**
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: 75–150 mg daily in 2–3 divided doses
  - **BY RECTUM**
  - Adult: 75–150 mg daily in divided doses

**Pain and inflammation in rheumatic disease including juvenile idiopathic arthritis**
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: 75–150 mg daily in 2–3 divided doses
  - **BY RECTUM**
  - Adult: 75–150 mg daily in divided doses

**Postoperative pain**
- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: 75–150 mg daily in 2–3 divided doses
  - **BY RECTUM**
  - Adult: 75–150 mg daily in divided doses

**DICLOMAX RETARD**

**Pain and inflammation in rheumatic disease (including juvenile idiopathic arthritis) and other musculoskeletal disorders**

**Acute gout**
- **BY MOUTH**
  - Adult: 1 capsule once daily

**DICLOMAX SR**

**Pain and inflammation in rheumatic disease (including juvenile idiopathic arthritis) and other musculoskeletal disorders**

**Acute gout**
- **BY MOUTH**
  - Adult: 1 capsule 1–2 times a day, alternatively 2 capsules once daily

**DYLOJECT**

**Acute exacerbations of pain and postoperative pain**
- **BY DEEP INTRAMUSCULAR INJECTION**
  - Adult: 75 mg once daily for maximum 2 days, to be administered into the gluteal muscle

**Acute exacerbations of pain and postoperative pain (severe cases)**
- **BY DEEP INTRAMUSCULAR INJECTION**
  - Adult: 75 mg twice daily for maximum 2 days, to be administered into the gluteal muscle

**Urteric colic**
- **BY DEEP INTRAMUSCULAR INJECTION**
  - Adult: 75 mg, then 75 mg after 30 minutes if required

**Acute postoperative pain (in supervised settings)**
- **BY INTRAVENOUS INJECTION**
  - Adult: 75 mg every 4–6 hours if required for maximum 2 days; maximum 150 mg per day

**Prevention of postoperative pain**
- **BY INTRAVENOUS INJECTION**
  - Adult: 25–50 mg, to be given after surgery; further doses given after 4–6 hours if necessary; maximum 150 mg in 24 hours for 2 days
CONTRA-INDICATIONS

With systemic use

- History of cardiac failure
- Hypertension
- Left ventricular dysfunction
- Oedema
- Risk factors for cardiovascular events
- Ulcerative colitis (may be exacerbated)

With topical use

- Avoid contact with eyes
- Avoid contact with inflamed or broken skin
- Avoid contact with mucous membranes
- Not for use with occlusive dressings

Topical application of large amounts can result in systemic effects, including hypersensitivity and asthma (renal disease has also been reported).

INTERACTIONS

Appendix 1: NSAIDs

SIDE-EFFECTS

Rare

With systemic use

- Alveolitis
- Aseptic meningitis

With connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible

- Hepatic damage
- Interstitial fibrosis associated with NSAIDs can lead to renal failure
- Pancreatitis
- Papillary necrosis associated with NSAIDs can lead to renal failure
- Pulmonary eosinophilia
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis
- Visual disturbances

Frequency not known

With intramuscular use or intravenous use

Injection site reactions

With rectal use

- Suppositories may cause rectal irritation

With systemic use

- Angioedema
- Blood disorders
- Bronchospasm
- Colitis (induction of or exacerbation of)
- Crohn’s disease (induction of or exacerbation of)
- Depression
- Diarrhoea
- Dizziness
- Drowsiness
- Fluid retention (rarely precipitating congestive heart failure)
- Gastro-intestinal bleeding
- Gastro-intestinal discomfort
- Gastro-intestinal disturbances
- Gastro-intestinal ulceration
- Haematuria
- Headache
- Hearing disturbances
- Hypersensitivity reactions
- Insomnia
- Nausea
- Nervousness
- Photosensitivity
- Raised blood pressure
- Rash
- Renal failure (especially in patients with pre-existing renal impairment)
- Tinnitus
- Vertigo

With topical use

- Paraesthesia
- Photosensitivity
- Rash (discontinue use if develops)

SIDE-EFFECTS, FURTHER INFORMATION

Serious side-effects

For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 1028.

With topical use

- Topical application of large amounts can result in systemic effects, including hypersensitivity and asthma (renal disease has also been reported).

ALLERGY AND CROSS-SENSITIVITY

Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

CONCEPTION AND CONTRACEPTION

With systemic use

- Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

PREGNANCY

With systemic use

- Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in uterus and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

With topical use

- Patient packs for topical preparations carry a warning to avoid during pregnancy.

BREAST FEEDING

With systemic use

- Use with caution during breast-feeding.
- Amount in milk too small to be harmful.

With topical use

- Patient packs for topical preparations carry a warning to avoid during breast-feeding.
**Musculoskeletal system**

**MEDICAL PROFESSIONAL INFORMATION**

**CLINICAL FORMS**

**PRESCRIBING AND DISPENSING INFORMATION**

**NATIONAL FUNDING/ACCESS DECISIONS**

**Dyloject®**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (February 2008) that Dyloject® is accepted for restricted use within NHS Scotland for the treatment or prevention of postoperative pain by intravenous injection in supervised healthcare settings.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: dispersible tablet, oral suspension, oral solution

**Gastro-resistant tablet**

**Diclofenac Sodium (Non-proprietary)**

- **Diclofenac sodium 25 mg** Diclofenac Sodium 25mg gastro-resistant tablets | 28 tablet (Pom) £2.49 | 84 tablet (Pom) £6.97
- **Diclofenac sodium 50 mg** Diclofenac Sodium 50mg gastro-resistant tablets | 28 tablet (Pom) £4.97 | 84 tablet (Pom) £15.00 | 100 tablet (Pom) no price available
- **Dicloflex** (Dexcel-Pharma Ltd) Diclofenac sodium 25 mg Dicloflex 25mg gastro-resistant tablets | 84 tablet (Pom) £4.42
- **Dicloflex** (Dexcel-Pharma Ltd) Diclofenac Sodium 50 mg Dicloflex 50mg gastro-resistant tablets | 28 tablet (Pom) £2.75 | 84 tablet (Pom) £8.05

- **Diclofenac Sodium with misoprostol**

**ARHTROTEC® 50/200**

Prophylaxis against NSAID-induced gastroduodenal ulceration in patients requiring diclofenac for rheumatoid arthritis or osteoarthritis

- Adult: 1 tablet 2–3 times a day, take with food

**ARHTROTEC® 75/200**

Prophylaxis against NSAID-induced gastroduodenal ulceration in patients requiring diclofenac for rheumatoid arthritis or osteoarthritis

- By mouth

- Adult: 1 tablet twice daily, take with food

-Diclofenac sodium with misoprostol

The properties listed below are those particular to the combination only. For the properties of the components please consider, diclofenac sodium p. 1034, misoprostol p. 75.
**MISOFEN® 50/200**
Prophylaxis against NSAID-induced gastroduodenal ulceration in patients requiring diclofenac for rheumatoid arthritis or osteoarthritis
▶ By mouth
▶ Adult: 1 tablet 2–3 times a day, take with food

**MISOFEN® 75/200**
Prophylaxis against NSAID-induced gastroduodenal ulceration in patients requiring diclofenac for rheumatoid arthritis or osteoarthritis
▶ By mouth
▶ Adult: 1 tablet twice daily, take with food

- **UNLICENSED USE** The BNF recommends a higher starting dose of misoprostol for prophylaxis against NSAID-induced gastroduodenal ulceration than that provided by the combination preparations of diclofenac and misoprostol.
- **INTERACTIONS** → Appendix 1: NSAIDs

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

#### Gastro-resistant tablet

**CAUTIONARY AND ADVISORY LABELS** 21, 25

- Arthrotec (Pfizer Ltd)
  Misoprostol 200 microgram, Diclofenac sodium 50 mg Arthrotec 50 gastro-resistant tablets | 60 tablet (PDM) £11.98 DT price = £11.98
- Misoprostol 200 microgram, Diclofenac sodium 75 mg Arthrotec 75 gastro-resistant tablets | 60 tablet (PDM) £15.83 DT price = £15.83
- Misofen (Morningside Healthcare Ltd)
  Misoprostol 200 microgram, Diclofenac sodium 50 mg Misofen 50mg/200microgram gastro-resistant tablets | 60 tablet (PDM) £11.98 DT price = £11.98
  Misoprostol 200 microgram, Diclofenac sodium 75 mg Misofen 75mg/200microgram gastro-resistant tablets | 60 tablet (PDM) £15.83 DT price = £15.83

### Etdolac

**INDICATIONS AND DOSE**
Pain and inflammation in rheumatoid arthritis and osteoarthritis
▶ By mouth using immediate-release medicines
▶ Adult: 300–600 mg daily in 1–2 divided doses
▶ By mouth using modified-release medicines
▶ Adult: 600 mg daily

**CONTRA-INDICATIONS** Active gastro-intestinal bleeding • active gastro-intestinal ulceration • history of gastro-intestinal bleeding related to previous NSAID therapy • history of gastro-intestinal haemorrhage (two or more distinct episodes) • history of recurrent gastro-intestinal ulceration (two or more distinct episodes) • severe heart failure

**CAUTIONS** Allergic disorders • cardiac impairment (NSAIDs may impair renal function) • cerebrovascular disease • coagulation defects • connective-tissue disorders • Crohn’s disease (may be exacerbated) • elderly (risk of serious side-effects and fatalities) • heart failure • ischaemic heart disease • peripheral arterial disease • risk factors for cardiovascular events • ulcerative colitis (may be exacerbated) • uncontrolled hypertension

**INTERACTIONS** → Appendix 1: NSAIDs

**SIDE-EFFECTS**
▶ Rare: Alveolitis • aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) • hepatic damage • interstitial fibrosis associated with NSAIDs can lead to renal failure • pancreatitis • papillary necrosis associated with NSAIDs can lead to renal failure •

- **Pulmonary eosinophilia • Stevens-Johnson syndrome • toxic epidermal necrolysis • visual disturbances**
  ▶ **Frequency not known** Angioedema • blood disorders • bronchospasm • colitis (induction of or exacerbation of) • confusion • Crohn’s disease (induction of or exacerbation of) • depression • diarrhoea • dizziness • drowsiness • dysphagia • dysuria • fatigue • fluid retention (rarely precipitating congestive heart failure) • gastro-intestinal bleeding • gastro-intestinal discomfort • gastro-intestinal disturbances • gastro-intestinal ulceration • haematuria • headache • hearing disturbances • hypersensitivity reactions • insomnia • nausea • nervousness • palpitation • paraesthesia • photosensitivity • pruritus • pyrexia • raised blood pressure • rashes • renal failure (especially in patients with pre-existing renal impairment) • stomatitis • tinnitus • tremor • urinary frequency • vasculitis • vertigo

### SIDE-EFFECTS, FURTHER INFORMATION

- **Serious side-effects** For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 1028.
- **ALLERGY AND CROSS-SENSITIVITY** Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.
- **CONCEPTION AND CONTRACEPTION** Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.
- **PREGNANCY** Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.
- **BREAST FEEDING** Use with caution during breast-feeding. Manufacturer advises avoid.
- **HEPATIC IMPAIRMENT** Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.
- **RENAL IMPAIRMENT** Avoid if possible or use with caution. Avoid in severe impairment. The lowest effective dose should be used for the shortest possible duration. Monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Modified-release tablet**

**CAUTIONARY AND ADVISORY LABELS** 25

- Etdolac (Non-proprietary)
  Etdolac 600 mg Etdolac 600mg modified-release tablets | 30 tablet (PDM) £21.40 DT price = £15.50
- Etolyn (Mylan Ltd)
  Etdolac 600 mg Etdolac 600mg modified-release tablets | 30 tablet (PDM) £22.40 DT price = £15.50
- Etopan XL (Ranbaxy (UK) Ltd)
  Etdolac 600 mg Etopan XL 600mg tablets | 30 tablet (PDM) £14.60 DT price = £15.50
- Lodine SR (Almirall Ltd)
  Etdolac 600 mg Etdolac 600 mg modified-release tablets | 30 tablet (PDM) £15.50 DT price = £15.50

**Capsule**

- Eccoxolac (Meda Pharmaceuticals Ltd)
  Etdolac 300 mg Eccoxolac 300mg capsules | 60 capsule (PDM) £8.14 DT price = £8.14
Etoricoxib 23-Nov-2016

**INDICATIONS AND DOSE**

**Pain and inflammation in osteoarthritis**

- **BY MOUTH**
  - Child 16-17 years: 30 mg once daily, increased if necessary to 60 mg once daily
  - Adult: 30 mg once daily, increased if necessary to 60 mg once daily

**Relief of pain in musculoskeletal conditions**

- **BY MOUTH**
  - Adult: 120 mg once daily for maximum 8 days

**CONTRA-INDICATIONS** Active gastro-intestinal bleeding - active gastro-intestinal ulceration - cerebrovascular disease - inflammatory bowel disease - ischaemic heart disease - mild to severe heart failure - peripheral arterial disease - uncontrolled hypertension (persistently above 140/90 mmHg)

**CAUTIONS** Allergic disorders - cardiac impairment (NSAIDs may impair renal function) - coagulation defects - connective-tissue disorders - Crohn's disease (may be exacerbated) - dehydration - elderly (risk of serious side-effects and fatalities) - history of cardiac failure - hypertension - left ventricular dysfunction - oedema - risk factors for cardiovascular events - ulcerative colitis (may be exacerbated)

**INTERACTIONS** → Appendix 1: NSAIDs

**SIDE-EFFECTS**

- **Common or very common** Ecchymosis - fatigue - influenza-like symptoms - palpitation
- **Uncommon** Anxiety - appetite change - arthralgia - atrial fibrillation - chest pain - cough - dry mouth - dysphagia - electrolyte disturbance - epistaxis - flushing - mental acuity impaired - mouth ulcer - myalgia - paraesthesia - taste disturbance - transient ischaemic attack - weight change
- **Rare** Alveolitis - aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) - hepatic damage - interstitial fibrosis associated with NSAIDs can lead to renal failure - pancreatitis - papillary necrosis associated with NSAIDs can lead to renal failure - pulmonary eosinophilia - Stevens-Johnson syndrome - toxic epidermal necrolysis - visual disturbances
- **Very rare** Confusion - hallucinations

- **Frequency not known** Angioedema - blood disorders - bronchospasm - colitis (induction of or exacerbation of) - Crohn's disease (induction of or exacerbation of) - depression - diarrhoea - dizziness - drowsiness - fluid retention (rarely precipitating congestive heart failure) - gastro-intestinal bleeding - gastro-intestinal discomfort - gastro-intestinal ulceration - haematuria - headache - hearing disturbances - hypersensitivity reactions - insomnia - nausea - nervousness - photosensitivity - raised blood pressure - rashes - renal failure (especially in patients with pre-existing renal impairment) - tinnitus - vertigo

**SIDE-EFFECTS, FURTHER INFORMATION**

- Serious side-effects For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 1028.

**ALLERGY AND CROSS-SENSITIVITY** Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

**CONCEPTION AND CONTRACEPTION** Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

**PREGNANCY** Manufacturer advises avoid (teratogenic in animal studies). Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

**BREAST FEEDING** Use with caution during breast-feeding. Manufacturer advises avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT** Max. 60 mg daily in mild impairment. Max. 60 mg on alternate days or 30 mg once daily in moderate impairment. Use with caution; there is an increased risk of gastrointestinal bleeding and fluid retention. Avoid in severe liver disease.

**RENAL IMPAIRMENT** Avoid if possible or use with caution. The lowest effective dose should be used for the shortest possible duration. Monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

- In adults Avoid if eGFR less than 30 mL/minute/1.73 m².
- In children Avoid if estimated glomerular filtration rate less than 30 mL/minute/1.73 m².

**MONITORING REQUIREMENTS** Monitor blood pressure before treatment, 2 weeks after initiation and periodically during treatment.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- Arcoxia (Grunenthal Ltd)
  - **Etoricoxib 30 mg** Etoricoxib 30 mg tablets | 28 tablet [POT] £13.99 DT price = £13.99
  - **Etoricoxib 60 mg** Arcoxia 60 mg tablets | 28 tablet [POT] £20.11 DT price = £20.11
  - **Etoricoxib 90 mg** Arcoxia 90 mg tablets | 5 tablet [POT] £4.10 | 28 tablet [POT] £22.96 DT price = £22.96
  - **Etoricoxib 120 mg** Arcoxia 120 mg tablets | 7 tablet [POT] £6.03 | 28 tablet [POT] £24.11 DT price = £24.11

Felbinac

**DRUG ACTION** Felbinac is an active metabolite of the NSAID fenbufen.

**INDICATIONS AND DOSE**

**Relief of pain in musculoskeletal conditions | Treatment in knee or hand osteoarthritis (adjunct)**

- **TO THE SKIN**
  - Adult: Apply 2–4 times a day, therapy should be reviewed after 14 days; maximum 25 g per day

**CONTRA-INDICATIONS** Active gastro-intestinal bleeding - active gastro-intestinal ulceration - history of gastrointestinal bleeding related to previous NSAID therapy - history of gastro-intestinal haemorrhage (two or more distinct episodes) - history of gastro-intestinal perforation related to previous NSAID therapy - history of recurrent gastro-intestinal ulceration (two or more distinct episodes) - severe heart failure

**CAUTIONS** Allergic disorders - avoid contact with eyes - avoid contact with inflamed or broken skin - avoid contact with mucous membranes - cardiac impairment (NSAIDs may impair renal function) - cerebrovascular disease - coagulation defects - connective-tissue disorders - Crohn's...
Pain and inflammation in musculoskeletal disorders

Medicinal forms

There can be variation in the licensing of different medicines containing the same drug.

Foam

CAUTIONARY AND ADVISORY LABELS

EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol)

Traxam (AMCo)

Felbinac 31.7 mg per 1 gram Traxam 3.17% foam | 100 gram Posm £8.41 DT price = £8.41

Gel

AMCo

Felbinac 30 mg per 1 gram Traxam 3% gel | 100 gram Posm £8.03 DT price = £8.03

Traxam Pain Relief 3% gel | 7.5 gram | £1.24 | 30 gram | £2.26 DT price = £2.26

Fenoprofen

Indications and dose

Pain and inflammation in rheumatic disease and other musculoskeletal disease | Mild to moderate pain

By mouth

Adult: 300–600 mg 3–4 times a day; maximum 3 g per day

Contra-indications

Active gastro-intestinal bleeding, active gastro-intestinal ulceration, history of gastro-intestinal bleeding related to previous NSAID therapy, history of gastro-intestinal perforation related to previous NSAID therapy, history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes), history of recurrent gastro-intestinal ulceration (two or more distinct episodes), severe heart failure

Caution

Allergic disorders - cardiac impairment (NSAIDs may impair renal function), cerebrovascular disease, coagulation defects, connective-tissue disorders, Crohn’s disease (may be exacerbated), elderly (risk of serious side-effects and fatalities), heart failure, ischaemic heart disease, peripheral arterial disease, risk factors for cardiovascular events, ulcerative colitis (may be exacerbated), uncontrolled hypertension

Interactions

Appendix 1: NSAIDs

Side-effects

Rare: Alveolitis - aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) - hepatic damage - interstitial fibrosis associated with NSAIDs can lead to renal failure - pancreatitis - papillary necrosis associated with NSAIDs can lead to renal failure - pulmonary eosinophilia - Stevens-Johnson syndrome - toxic epidermal necrolysis - visual disturbances

Frequency not known

Angioedema - blood disorders - bronchospasm - colitis (induction of or exacerbation of) - Crohn’s disease (induction of or exacerbation of) - depression - diarrhoea - dizziness - drowsiness - fluid retention (rarely precipitating congestive heart failure) - gastro-intestinal bleeding - gastro-intestinal discomfort - gastro-intestinal disturbances - gastro-intestinal ulceration - haematuria - headache - hearing disturbances - hypersensitivity reactions - insomnia - nausea - nervousness - Photosensitivity - raised blood pressure - rash (discontinue use if develops) - renal failure (especially in patients with pre-existing renal impairment) - tinnitus - vertigo

Side-effects, further information

Serious side-effects For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 1028.

Topical application of large amounts can result in systemic effects, including hypersensitivity and asthma (renal disease has also been reported).

Allergy and cross-sensitivity

Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

Conception and contraception

Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

Pregnancy

Patient packs for topical preparations carry a warning to avoid during pregnancy.

Breast feeding

Patient packs for topical preparations carry a warning to avoid during breast-feeding.

Hepatic impairment

Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

Renal impairment

Deterioration in renal function has been reported after topical use.

Directions for administration

For topical preparations, apply with gentle massage only.

Patient and carer advice

For topical preparations and carer advice should be advised to wash hands immediately after use.

Photosensitivity Patients should be advised against excessive exposure to sunlight of area treated in order to avoid possibility of photosensitivity.

disease (may be exacerbated) - elderly (risk of serious side-effects and fatalities) - heart failure - ischaemic heart disease - peripheral arterial disease - risk factors for cardiovascular events - ulcerative colitis (may be exacerbated) - uncontrolled hypertension
Flurbiprofen

**INDICATIONS AND DOSE**

Pain and inflammation in rheumatic disease and other musculoskeletal disorders | Migraine | Postoperative analgesia | Mild to moderate pain

- **BY MOUTH**
  - Child 12-17 years: 150–200 mg daily in 2–4 divided doses, then increased to 300 mg daily, dose to be increased only in acute conditions
  - Adult: 150–200 mg daily in 2–4 divided doses, then increased to 300 mg daily, dose to be increased only in acute conditions

**Dysmenorrhoea**

- **BY MOUTH**
  - Child 12-17 years: Initially 100 mg, then 50–100 mg every 4–6 hours; maximum 300 mg per day
  - Adult: Initially 100 mg, then 50–100 mg every 4–6 hours; maximum 300 mg per day

**CONTRA-INDICATIONS**

Active gastro-intestinal bleeding | active gastro-intestinal ulceration | history of gastro-intestinal bleeding related to previous NSAID therapy | history of gastro-intestinal perforation related to previous NSAID therapy | history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes) | history of recurrent gastro-intestinal ulceration (two or more distinct episodes) | severe heart failure

**CAUTIONS**

Allergic disorders | cardiac impairment (NSAIDs may impair renal function) | cerebrovascular disease | coagulation defects | connective-tissue disorders | Crohn’s disease (may be exacerbated) | elderly (risk of serious side-effects and fatalities) | heart failure | ischaemic heart disease | peripheral arterial disease | risk factors for cardiovascular events | ulcerative colitis (may be exacerbated) | uncontrolled hypertension

**INTERACTIONS**

Appendix 1: NSAIDs

**SIDE-EFFECTS**

- Common or very common: Stomatitis
- Uncommon: Confusion, fatigue, hallucinations, paranoia
- Rare: Alveolitis, aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) | hepatic damage | interstitial fibrosis associated with NSAIDs can lead to renal failure | pancreatitis | papillitis | possible leading to renal failure

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

CAUTIONARY AND ADVISORY LABELS 21

- Fenopron (Typharm Ltd)
  - Fenoprofen (as Fenoprofen calcium) 300 mg | Fenoprofen 300 tablets
  | 100 tablet | POM | £9.45

---

**Allergy and cross-sensitivity**

- Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

**Conception and contraception**

- Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

**Pregnancy**

- Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

**Breast feeding**

- Use with caution during breast-feeding. Amount too small to be harmful.

**Hepatic impairment**

- Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

**Renal impairment**

- Avoid if possible or use with caution.

The lowest effective dose should be used for the shortest possible duration. Monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

**Cautionary and advisory labels**

- Uncommon

**Frequency not known**

- Serious side-effects: For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 1028.

**Allergy and cross-sensitivity**

- Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

**Conception and contraception**

- Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

**Pregnancy**

- Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

**Breast feeding**

- Use with caution during breast-feeding. Small amount present in milk—manufacturer advises avoid.

**Hepatic impairment**

- Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

**Renal impairment**

- Avoid if possible or use with caution. Avoid in severe impairment. The lowest effective dose should be used for the shortest possible duration. Monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

CAUTIONARY AND ADVISORY LABELS 21

- Flurbiprofen (Non-proprietary)
  - Flurbiprofen 50 mg | Flurbiprofen 50mg tablets | 100 tablet | POM | £21.30–£35.97 DT price | £35.96
  - Flurbiprofen 100 mg | Flurbiprofen 100mg tablets | 100 tablet | POM | £64.34 DT price | £64.33
## Ibuprofen

### INDICATIONS AND DOSE

**Pain and inflammation in rheumatic disease and other musculoskeletal disorders | Mild to moderate pain including dysmenorrhea | Postoperative analgesia | Migraine | Dental pain**

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - **Adult:** Initially 300–400 mg 3–4 times a day; increased if necessary up to 600 mg 4 times a day; maintenance 200–400 mg 3 times a day, may be adequate
  - **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
    - **Adult:** 1.6 g once daily; dose to be taken in the early evening, increased if necessary to 2.4 g daily in 2 divided doses, dose to be increased only in severe cases

**Mild to moderate pain | Pain and inflammation of soft-tissue injuries | Pyrexia with discomfort**

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - **Child 3–5 months:** 50 mg 3 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30 mg/kg per day
  - **Child 6–11 months:** 50 mg 3–4 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30 mg/kg per day
  - **Child 1–3 years:** 100 mg 3 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30 mg/kg per day
  - **Child 4–6 years:** 150 mg 3 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30 mg/kg per day
  - **Child 7–9 years:** 200 mg 3 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30 mg/kg per day; maximum 2.4 g per day
  - **Child 10–11 years:** 300 mg 3 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30 mg/kg per day; maximum 2.4 g per day
  - **Child 12–17 years:** Initially 300–400 mg 3–4 times a day; increased if necessary up to 600 mg 4 times a day; maintenance 200–400 mg 3 times a day, may be adequate

**Pain and inflammation**

- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - **Child 12–17 years:** 1.6 g once daily, dose preferably taken in the early evening, increased to 2.4 g daily in 2 divided doses, dose to be increased only in severe cases

**Pain and inflammation in rheumatic disease including juvenile idiopathic arthritis**

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - **Child 3 months–17 years:** 30–40 mg/kg daily in 3–4 divided doses; maximum 2.4 g per day

**Pain and inflammation in systemic juvenile idiopathic arthritis**

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - **Child 3 months–17 years:** Up to 60 mg/kg daily in 4–6 divided doses; maximum 2.4 g per day

**Post-immunisation pyrexia in infants (on doctor’s advice only)**

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - **Child 2–3 months:** 50 mg for 1 dose, followed by 50 mg after 6 hours if required

**Pain relief in musculoskeletal conditions | Treatment in knee or hand osteoarthritis (adjunct)**

- **TO THE SKIN**
  - **Adult:** Apply up to 3 times a day, ibuprofen gel 5% gel to be administered

---

### CAUTIONS, FURTHER INFORMATION

**SIDE-EFFECTS**

- **Rare**
  - With systemic use: Alveolitis - aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) - hepatic damage - interstitial fibrosis associated with NSAIDs can lead to renal failure - pancreatitis - papillary necrosis associated with NSAIDs can lead to renal failure - pulmonary eosinophilia - Stevens-Johnson syndrome - toxic epidermal necrolysis - visual disturbances

**FREQUENCY not known**


---

**FENBID® FORTE**

**Pain relief in musculoskeletal conditions | Treatment in knee or hand osteoarthritis (adjunct)**

- **TO THE SKIN**
  - **Adult:** Apply up to 4 times a day, therapy should be reviewed after 14 days

**IBUGEL® FORTE**

**Pain relief in musculoskeletal conditions | Treatment in knee or hand osteoarthritis (adjunct)**

- **TO THE SKIN**
  - **Adult:** Apply up to 3 times a day

**UNLICENSED USE**

Not licensed for use in children under 3 months or body-weight under 5 kg. Maximum dose for systemic juvenile idiopathic arthritis is unlicensed.

**CONTRA-INDICATIONS**

- With systemic use: Active gastro-intestinal bleeding - active gastro-intestinal ulceration - history of gastro-intestinal bleeding related to previous NSAID therapy - history of gastro-intestinal perforation related to previous NSAID therapy - history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes) - history of recurrent gastro-intestinal ulceration (two or more distinct episodes) - severe heart failure

---

**UNLICENSED USE**

Not licensed for use in children under 3 months or body-weight under 5 kg. Maximum dose for systemic juvenile idiopathic arthritis is unlicensed.

**CONTRA-INDICATIONS**

- With systemic use: Active gastro-intestinal bleeding - active gastro-intestinal ulceration - history of gastro-intestinal bleeding related to previous NSAID therapy - history of gastro-intestinal perforation related to previous NSAID therapy - history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes) - history of recurrent gastro-intestinal ulceration (two or more distinct episodes) - severe heart failure

**CAUTIONS**

- With systemic use: Allergic disorders (in adults) - cardiac impairment (NSAIDs may impair renal function) - cerebrovascular disease - coagulation defects - connective-tissue disorders - Crohn’s disease (may be exacerbated) - elderly (risk of serious side-effects and fatalities) - heart failure - ischaemic heart disease - peripheral arterial disease - risk factors for cardiovascular events - risk factors for cardiovascular events - ulcerative colitis (may be exacerbated) - uncontrolled hypertension

- With topical use: Avoid contact with eyes - avoid contact with inflamed or broken skin - avoid contact with mucous membranes - not for use with occlusive dressings - topical application of large amounts can result in systemic effects, including hypersensitivity and asthma (renal disease has also been reported)

**CAUTIONS, FURTHER INFORMATION**

- **SIDE-EFFECTS**
  - **Rare**
    - With systemic use: Alveolitis - aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) - hepatic damage - interstitial fibrosis associated with NSAIDs can lead to renal failure - pancreatitis - papillary necrosis associated with NSAIDs can lead to renal failure - pulmonary eosinophilia - Stevens-Johnson syndrome - toxic epidermal necrolysis - visual disturbances

**FREQUENCY not known**


---

**INTERACTIONS**

Appendix 1: NSAIDs
### PROFESSION SPECIFIC INFORMATION

Dental practitioners’ formulation
Ibuprofen Oral Suspension Sugar-free may be prescribed. Ibuprofen Tablets may be prescribed.

### EXCEPTIONS TO LEGAL CATEGORY

Smaller pack sizes of gel preparations may be available on sale to the public. Oral preparations can be sold to the public in certain circumstances.

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

### Effervescent granules

CAUTIONARY AND ADVISORY LABELS 13, 21

ELECTROLYTES: May contain Sodium

- **Brufen (Mylan Ltd)**
  - Ibuprofen 600 mg Brufen 600mg effervescent granules sachets | 20 sachet [£6.80 DT price = £6.80](DT price = £6.80)

### Modified-release tablet

CAUTIONARY AND ADVISORY LABELS 25, 27

- **Brufen Retard (Mylan Ltd)**
  - Ibuprofen 800 mg Brufen Retard 800mg tablets | 56 tablet [£7.74 DT price = £7.74](DT price = £7.74)

### Tablet

CAUTIONARY AND ADVISORY LABELS 21

- **Ibuprofen (Non-proprietary)**
  - Ibuprofen 200 mg Ibuprofen 200mg tablets | 16 tablet [£0.20 DT price = £0.20](DT price = £0.20)
  - 24 tablet [£0.92 DT price = £0.92](DT price = £0.92)
  - 48 tablet [£1.84 DT price = £1.84](DT price = £1.84)
  - 84 tablet [£3.29 DT price = £3.29](DT price = £3.29)
  - 164 tablet [£6.79 DT price = £6.79](DT price = £6.79)

- **Ibuprofen 400 mg**
  - Ibuprofen 400mg tablets | 24 tablet [£0.89 DT price = £0.89](DT price = £0.89)
  - 12 tablet [£1.52 DT price = £1.52](DT price = £1.52)
  - 24 tablet [£3.01 DT price = £3.01](DT price = £3.01)

- **Ibuprofen 600 mg**
  - Ibuprofen 600mg tablets | 84 tablet [£0.64 DT price = £0.64](DT price = £0.64)
  - 16 tablet [£0.72 DT price = £0.72](DT price = £0.72)

- **Ibuprofen 800 mg**
  - Ibuprofen 800mg tablets | 56 tablet [£0.10 DT price = £0.10](DT price = £0.10)

- **Ibuprofen 1000 mg**
  - Ibuprofen 1000mg tablets | 24 tablet [£1.19 DT price = £1.19](DT price = £1.19)

- **Ibuprofen Retard 200 mg**
  - Ibuprofen Retard 200mg tablets | 16 tablet [£4.88 DT price = £4.88](DT price = £4.88)

- **Ibuprofen Retard 400 mg**
  - Ibuprofen Retard 400mg tablets | 24 tablet [£9.64 DT price = £9.64](DT price = £9.64)

- **Ibuprofen Retard 800 mg**
  - Ibuprofen Retard 800mg tablets | 56 tablet [£7.54 DT price = £7.54](DT price = £7.54)

- **Ibuprofen 1000 mg Retard**
  - Ibuprofen 1000mg Retard tablets | 24 tablet [£14.90 DT price = £14.90](DT price = £14.90)

- **Ibuprofen 2000 mg**
  - Ibuprofen 2000mg tablets | 16 tablet [£11.32 DT price = £11.32](DT price = £11.32)

- **Ibuprofen 2000 mg Retard**

- **Ibuprofen 4000 mg**
  - Ibuprofen 4000mg tablets | 60 tablet [£4.90 DT price = £4.90](DT price = £4.90)

- **Ibuprofen 6000 mg**
  - Ibuprofen 6000mg tablets | 60 tablet [£7.34 DT price = £7.34](DT price = £7.34)

- **Ibucalm (Aspar Pharmaceuticals Ltd)**
  - Ibucalm 200 mg Ibucalm 200mg tablets | 24 tablet [£0.77 DT price = £0.77](DT price = £0.77)

- **Nurofen (Reckitt Benckiser Healthcare (UK) Ltd)**
  - Nurofen 200 mg Nurofen 200mg tablets | 24 tablet [£0.92 DT price = £0.92](DT price = £0.92)
  - 10 tube [£2.48 DT price = £2.48](DT price = £2.48)
  - 10 tube [£11.41 DT price = £11.41](DT price = £11.41)
  - 20 tube [£20.70 DT price = £20.70](DT price = £20.70)

- **Nurofen 400 mg**
  - Nurofen 400mg tablets | 24 tablet [£2.37 DT price = £2.37](DT price = £2.37)

### Oral suspension

CAUTIONARY AND ADVISORY LABELS 21

- **Ibuprofen (Non-proprietary)**
  - Ibuprofen 20 mg per 1 ml Ibuprofen 20mg/5ml oral suspension sugar free-sugar-free | 100 ml [£0.90 DT price = £0.90](DT price = £0.90)
  - 200 ml [£1.32 DT price = £1.32](DT price = £1.32)

- **Nurofen (Reckitt Benckiser Healthcare (UK) Ltd)**
  - Nurofen 200 mg per 1 ml Nurofen 200mg/5ml oral suspension strawberry-sugar-free | 100 ml [£0.90 DT price = £0.90](DT price = £0.90)
  - 200 ml [£1.32 DT price = £1.32](DT price = £1.32)

- **Orbifen (Orbis Consumer Products Ltd)**
  - Ibuprofen 20 mg per 1 ml Orbifen For Children 200mg/5ml oral suspension sugar-free | 100 ml [£1.67 DT price = £1.67](DT price = £1.67)
  - 200 ml [£2.71 DT price = £2.71](DT price = £2.71)
**Indometacin**  
(Indomethacin)

<table>
<thead>
<tr>
<th><strong>INDICATIONS AND DOSE</strong></th>
<th><strong>Pain and moderate to severe inflammation in rheumatic disease and other musculoskeletal disorders</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BY MOUTH USING IMMEDIATE-RELEASE MEDICINES</strong></td>
<td>Adult: 50–200 mg daily in divided doses</td>
</tr>
<tr>
<td><strong>BY RECTUM</strong></td>
<td>Adult: 100 mg twice daily if required, dose to be administered at night and in the morning, combined oral and rectal treatment, maximum total daily dose 150–200 mg</td>
</tr>
<tr>
<td><strong>BY MOUTH USING MODIFIED-RELEASE MEDICINES</strong></td>
<td>Adult: 75 mg 1–2 times a day</td>
</tr>
<tr>
<td><strong>Acute gout</strong></td>
<td>Adult: 150–200 mg daily in divided doses</td>
</tr>
</tbody>
</table>

**CONTRA-INDICATIONS**  
Active gastro-intestinal bleeding: active gastro-intestinal ulceration, history of gastro-intestinal bleeding related to previous NSAID therapy, history of gastro-intestinal perforation related to previous NSAID therapy; history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes); history of recurrent gastro-intestinal ulceration (two or more distinct episodes): severe heart failure

**CAUTIONS**  

**INTERACTIONS**  
Appendix 1: NSAIDs

**SIDE-EFFECTS**  
Rare: Alveolitis: aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible): blood disorders: confusion: convulsions: hepatic damage: hyperglycaemia: interstitial fibrosis associated with NSAIDs can lead to renal failure: intestinal strictures: pancreatitis: papillary necrosis associated with NSAIDs can lead to renal failure: peripheral neuropathy: psychiatric disturbances: pulmonary eosinophilia: Stevens–Johnson syndrome: syncope: thrombocytopenia: toxic epidermal necrolysis: visual disturbances

**Frequency not known**  

With rectal use: Suppositories may cause occasional bleeding: suppositories may cause rectal irritation

**SIDE-EFFECTS, FURTHER INFORMATION**  
Serious side-effects: For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 1028

**ALLERGY AND CROSS-SENSITIVITY**  
Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of
asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

**CONCEPTION AND CONTRACEPTION** Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

**PREGNANCY** Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

**BREAST FEEDING** Amount probably too small to be harmful—manufacturers advise avoid. Use with caution during breast-feeding.

**HEPATIC IMPAIRMENT** Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in more severe liver disease.

**RENAL IMPAIRMENT** Avoid if possible or use with caution. Avoid in severe impairment. The lowest effective dose should be used for the shortest possible duration. Monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

**MONITORING REQUIREMENTS** During prolonged therapy ophthalmic and blood examinations particularly advisable.

**PATIENT AND CARER ADVICE**

Driving and skilled tasks Dizziness may affect performance of skilled tasks (e.g. driving).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Suppository**

- Indometacin (Non-proprietary)
  - Indometacin 100 mg Indometacin 100mg suppositories | 10 suppository (PoM) £17.61 DT price = £17.61
  - Indocid (Aspen Pharma Trading Ltd)
  - Indometacin 100 mg Indocid 100mg suppositories | 10 suppository (PoM) £17.61 DT price = £17.61

**Modified-release capsule**

CAUTIONARY AND ADVISORY LABELS 21, 25

- Indometacin (Non-proprietary)
  - Indometacin 75 mg Indometacin 75mg modified-release capsules | 100 capsule (PoM) no price available DT price = £8.65
  - Berlind Retard (Tillomed Laboratories Ltd)
  - Indometacin 75 mg Berlind 75 Retard capsules | 100 capsule (PoM) £8.65 DT price = £8.65

**Capsule**

CAUTIONARY AND ADVISORY LABELS 21

- Indometacin (Non-proprietary)
  - Indometacin 25 mg Indometacin 25mg capsules | 28 capsule (PoM) £5.00 DT price = £1.22
  - Indometacin 50 mg Indometacin 50mg capsules | 28 capsule (PoM) £7.50 DT price = £1.36

**Ketoprofen**

**INDICATIONS AND DOSE**

**Pain and mild inflammation in rheumatic disease**

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: 100–200 mg daily in 2–4 divided doses
  - **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Adult: 100–200 mg once daily, dose to be taken with food
  - **BY RECTUM**
  - Adult: 100 mg once daily, to be administered at bedtime, combined oral and rectal treatment, maximum total daily dose 200 mg

**Pain in musculoskeletal disorders | Pain after orthopaedic surgery | Dysmenorrhoea | Acute gout**

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES**
  - Adult: 50 mg up to 3 times a day
  - **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Adult: 100–200 mg once daily, dose to be taken with food

**Relief of pain in musculoskeletal disorders | Treatment in knee or hand osteoarthritis**

- **TO THE SKIN**
  - Adult: Apply 2–4 times a day for up to 7 days, ketoprofen 2.5% gel to be administered; maximum 15 g per day

**POWERGEL ®**

**Relief of pain in musculoskeletal conditions | Adjunctive treatment in knee or hand osteoarthritis**

- **TO THE SKIN**
  - Adult: Apply 2–3 times a day for up to max. 10 days

**CONTRA-INDICATIONS**

- With systemic use Active gastro-intestinal bleeding · active gastro-intestinal ulceration · history of gastro-intestinal bleeding · history of gastro-intestinal perforation · history of gastro-intestinal ulceration · severe heart failure

**CAUTIONS**

- With systemic use Allergic disorders · cardiac impairment (NSAIDs may impair renal function) · cerebrovascular disease · coagulation defects · connective-tissue disorders · Crohn’s disease (may be exacerbated) · elderly (risk of serious side-effects and fatalities) · heart failure · ischaemic heart disease · peripheral arterial disease · risk factors for cardiovascular events · ulcerative colitis (may be exacerbated) · uncontrolled hypertension

- With topical use Avoid contact with eyes · avoid contact with inflamed or broken skin · avoid contact with mucous membranes · not for use with occlusive dressings · topical application of large amounts can result in systemic effects, including hypersensitivity and asthma (renal disease has also been reported)

**INTERACTIONS** (Appendix 1: NSAIDs)

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**

Photosensitivity

**SPECIFIC SIDE-EFFECTS**

- **Rare**
  - With systemic use Alveolitis · aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) · hepatic damage · interstitial fibrosis associated with NSAIDs can lead to renal failure · pancreatitis · papillary necrosis associated with NSAIDs can lead to renal failure · pulmonary eosinophilia · Stevens-Johnson syndrome · toxic epidermal necrolysis · visual disturbances

- **Frequency not known**
  - With systemic use Angioedema · blood disorders · bronchospasm · colitis (induction of or exacerbation of) · Crohn’s disease (induction of or exacerbation of) · depression · diarrhoea · dizziness · drowsiness · fluid retention (rarely precipitating congestive heart failure) · gastro-intestinal bleeding · gastro-intestinal discomfort · gastro-intestinal disturbances · gastro-intestinal ulceration · haematuria · headache · hearing disturbances · hypersensitivity reactions · insomnia · nausea · nervousness · raised blood pressure · rashes · renal failure (especially in patients with pre-existing renal impairment) · tinnitus · vertigo

- With rectal use Suppositories may cause rectal irritation

- With topical use Rash (discontinue use if develops)
SIDE-EFFECTS, FURTHER INFORMATION

- Serious side-effects For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 1028.
- With topical use Topical application of large amounts can result in systemic effects, including hypersensitivity and asthma (renal disease has also been reported).

- ALLERGY AND CROSS-SENSITIVITY Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

- CONCEPTION AND CONTRACEPTION
- With systemic use Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

- PREGNANCY
- With systemic use Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.
- With topical use Patient packs for topical preparations carry a warning to avoid during pregnancy.

- BREAST FEEDING
- With systemic use Use with caution during breast-feeding. Amount probably too small to be harmful but manufacturers advise avoid.
- With topical use Patient packs for topical preparations carry a warning to avoid during breast-feeding.

- HEPATIC IMPAIRMENT
- With systemic use Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Should be avoided in severe liver disease.

- RENAL IMPAIRMENT
- With systemic use Avoid if possible or use with caution. Avoid in severe impairment. The lowest effective dose should be used for the shortest possible duration.
- With topical use Deterioration in renal function has also been reported after topical use.

- DIRECTIONS FOR ADMINISTRATION For topical preparations apply with gentle massage only.

- PRESCRIBING AND DISPENSING INFORMATION Flavours of oral liquid formulations may include strawberry.

- PATIENT AND CARER ADVICE
- With topical use For topical preparations, patients and their carers should be advised to wash hands immediately after use. Photosensitivity
- With topical use Patients should be advised against excessive exposure to sunlight of area treated in order to avoid possibility of photosensitivity. Patients should be advised not to expose area treated to sunbeds or sunlight (even on a bright but cloudy day) during, and for two weeks after stopping treatment; treated areas should be protected with clothing.

- EXCEPTIONS TO LEGAL CATEGORY Smaller pack sizes of gel preparations may be available on sale to the public.

- MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Modified-release capsule**

**CAUTIONARY AND ADVISORY LABELS** 21, 25

- **Ketoprofen (Non-proprietary)**
  - Ketoprofen 200 mg Ketoprofen 200mg modified-release capsules | 28 capsule [PoM] £23.85 DT price = £23.85
  - Larafen CR (Emgenex Pharma Ltd) Ketoprofen 200 mg Larafen CR 200mg capsules | 28 capsule [PoM] £19.08 DT price = £23.85
  - Oruvail (Sanofi) Ketoprofen 100 mg Oruvail 100mg modified-release capsules | 56 capsule [PoM] £23.93 DT price = £23.93
  - Ketoprofen 200 mg Oruvail 200mg modified-release capsules | 28 capsule [PoM] £23.85 DT price = £23.85
  - Tiloket CR (Tillomed Laboratories Ltd) Ketoprofen 100 mg Tiloket CR 100mg capsules | 56 capsule [PoM] £10.70 DT price = £23.85
  - Valsoket Retard (Tillomed Laboratories Ltd) Ketoprofen 200 mg Valsoket 200 Retard capsules | 28 capsule [PoM] £10.70 DT price = £23.85

**Gel**

EXCIPIENTS: May contain Fragrances

- **Ketoprofen (Non-proprietary)**
  - Ketoprofen 25 mg per 1 gram Ketoprofen 2.5% gel | 50 gram [PoM] £1.80 DT price = £1.64 | 100 gram [PoM] £3.28 DT price = £3.28
  - Oruvail (Sanofi) Ketoprofen 25 mg per 1 gram Oruvail 2.5% gel | 100 gram [PoM] £6.84 DT price = £3.28
  - Powergel (A. Menarini Farmaceutica Internazionale SRL) Ketoprofen 25 mg per 1 gram Powergel 2.5% gel | 50 gram [PoM] £3.06 DT price = £1.64 | 100 gram [PoM] £5.89 DT price = £3.28
  - Tiloket (Tillomed Laboratories Ltd) Ketoprofen 25 mg per 1 gram Tiloket 2.5% gel | 50 gram [PoM] £3.00 DT price = £1.64 | 100 gram [PoM] £6.00 DT price = £3.28

---

**Ketoprofen with omeprazole**

The properties listed below are those particular to the combination only. For the properties of the components please consider, ketoprofen p. 1044, omeprazole p. 78.

**INDICATIONS AND DOSE**

Patients requiring ketoprofen for osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, who are at risk of NSAID associated duodenal or gastric ulcer or gastroduodenal erosions

- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Adult: Initially 100/20 mg daily, increased if necessary to 200/20 mg daily, depending on severity of symptoms, dose expressed as x/y mg ketoprofen/omeprazole

**INTERACTIONS** → Appendix 1: NSAIDs, proton pump inhibitors

**PRESCRIBING AND DISPENSING INFORMATION** Capsules enclose microgranules containing modified-release ketoprofen and gastro-resistant omeprazole.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. No licensed medicines listed.
Mefenamic acid

- **INDICATIONS AND DOSE**

  **Pain and inflammation in rheumatoid arthritis and osteoarthritis | Postoperative pain | Mild to moderate pain**
  - BY MOUTH
    - Adult: 500 mg 3 times a day

  **Acute pain including dysmenorrhoea | Menorrhagia**
  - BY MOUTH
    - Child 12-17 years: 500 mg 3 times a day
    - Adult: 500 mg 3 times a day

- **CONTRA-INDICATIONS**

  Active gastro-intestinal bleeding; active gastro-intestinal ulceration; history of gastro-intestinal bleeding related to previous NSAID therapy; history of gastro-intestinal perforation related to previous NSAID therapy; history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes); history of recurrent gastro-intestinal ulceration (two or more distinct episodes); inflammatory bowel disease; severe heart failure

- **CAUTIONS**

  Acute porphyrias p. 969; allergic disorders; cardiac impairment (NSAIDs may impair renal function); cerebrovascular disease; coagulation defects; connective-tissue disorders; Crohn’s disease (may be exacerbated); elderly (risk of serious side-effects and fatalities); epilepsy; heart failure; ischaemic heart disease; peripheral arterial disease; risk factors for cardiovascular events; ulcerative colitis (may be exacerbated); uncontrolled hypertension

- **INTERACTIONS** → Appendix 1: NSAIDs

- **SIDE-EFFECTS**

  - Common or very common: Diarrhoea (withdraw treatment); rash (withdraw treatment); stomatitis
  - Uncommon: Fatigue; paraesthesia
  - Rare: Alveolitis; aplastic anaemia; aseptic meningitis (in patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible); glucose intolerance; haemolytic anaemia (positive Coombs’ test); hepatic damage; hypotension; interstitial fibrosis associated with NSAIDs can lead to renal failure; palpitation; pancreatitis; papillary necrosis associated with NSAIDs can lead to renal failure; pulmonary eosinophilia; Stevens-Johnson syndrome; thrombocytopenia; toxic epidermal necrolysis; visual disturbances
  - Frequency not known: Angioedema; blood disorders; bronchospasm; colitis (induction of or exacerbation of); Crohn’s disease (induction of or exacerbation of); depression; diziness; drowsiness; fluid retention (rarely precipitating congestive heart failure); gastro-intestinal bleeding; gastro-intestinal discomfort; gastro-intestinal disturbances; gastro-intestinal ulceration; haematuria; headache; hearing disturbances; hypersensitivity reactions; insomnia; nausea; nervousness; photosensitivity; raised blood pressure; renal failure (especially in patients with pre-existing renal impairment); tinnitus; vertigo

  **SIDE-EFFECTS, FURTHER INFORMATION**

  - Serious side-effects: For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 1028.
  - Overdose
    - Mefenamic acid has important consequences in overdosage because it can cause convulsions, which if prolonged or recurrent, require treatment.
    - For details on the management of poisoning, see Emergency treatment of poisoning p. 1249, in particular, Convulsions.

- **ALLERGY AND CROSS-SENSITIVITY**

  Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

- **CONCEPTION AND CONTRACEPTION**

  Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

- **PREGNANCY**

  Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

- **BREAST FEEDING**

  Use with caution during breast-feeding. Amount too small to be harmful but manufacturer advises avoid.

- **HEPATIC IMPAIRMENT**

  Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

- **RENAL IMPAIRMENT**

  Avoid if possible or use with caution. Avoid in severe impairment. The lowest effective dose should be used for the shortest possible duration. Monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

  **Oral suspension**

  CAUTIONARY AND ADVISORY LABELS 21

  EXCIPIENTS: May contain ethanol

  - Mefenamic acid (Non-proprietary)
    - Mefenamic acid 10 mg per 1 ml: Mefenamic acid 50mg/5ml oral suspension | 125 ml (Spm) £17.90 DT price = £17.90

  **Tablet**

  CAUTIONARY AND ADVISORY LABELS 21

  - Mefenamic acid (Non-proprietary)
    - Mefenamic acid 500 mg: Mefenamic acid 500mg tablets | 28 tablet (Spm) £50.20 DT price = £6.15 | 84 tablet (Spm) £44.99
    - Ponstan (Chemidex Pharma Ltd)
      - Mefenamic acid 500 mg: Ponstan Forte 500mg tablets | 100 tablet (Spm) £15.72

  **Capsule**

  CAUTIONARY AND ADVISORY LABELS 21

  - Mefenamic acid (Non-proprietary)
    - Mefenamic acid 250 mg: Mefenamic acid 250mg capsules | 100 capsule (Spm) £60.10 DT price = £5.94
    - Ponstan (Chemidex Pharma Ltd)
      - Mefenamic acid 250 mg: Ponstan 250mg capsules | 100 capsule (Spm) £6.17 DT price = £5.94

Meloxicam

- **INDICATIONS AND DOSE**

  **Exacerbation of osteoarthritis (short-term)**

  - BY MOUTH
    - Child 16–17 years: 7.5 mg once daily, then increased if necessary up to 15 mg once daily
    - Adult: 7.5 mg once daily, then increased if necessary up to 15 mg once daily

  **Pain and inflammation in rheumatic disease | Ankylosing spondylitis**

  - BY MOUTH
    - Child 16–17 years: 15 mg once daily, then reduced to 7.5 mg once daily if required
    - Adult: 15 mg once daily, then reduced to 7.5 mg once daily if required
    - Elderly: 7.5 mg once daily

Meloxicam
Relief of pain and inflammation in juvenile idiopathic arthritis and other musculoskeletal disorders in children intolerant to other NSAIDs

> BY MOUTH
  - Child 12-17 years (body-weight up to 50 kg): 7.5 mg once daily
  - Child 12-17 years (body-weight 50 kg and above): 15 mg once daily

### CONTRA-INDICATIONS
Active gastro-intestinal bleeding - active gastro-intestinal ulceration - history of gastro-intestinal bleeding related to previous NSAID therapy - history of gastro-intestinal perforation related to previous NSAID therapy - history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes) - history of recurrent gastro-intestinal ulceration (two or more distinct episodes) - severe heart failure

### CAUTIONS
Allergic disorders - cardiac impairment (NSAIDs may impair renal function) - cerebrovascular disease - coagulation defects - connective-tissue disorders - Crohn's disease (may be exacerbated) - elderly (risk of serious side-effects and fatalities) - heart failure - ischaemic heart disease - peripheral arterial disease - risk factors for cardiovascular events - ulcerative colitis (may be exacerbated) - uncontrolled hypertension

### INTERACTIONS
» Appendix 1: NSAIDs

### SIDE-EFFECTS
- Rare
  - Alveolitis - aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) - hepatic damage - interstitial fibrosis associated with NSAIDs can lead to renal failure - papillary necrosis associated with NSAIDs can lead to renal failure - pulmonary eosinophilia - Stevens-Johnson syndrome - toxic epidermal necrolysis - visual disturbances
- Frequency not known
  - Angioedema - blood disorders - bronchospasm - colitis (induction of or exacerbation of) - Crohn's disease (induction of or exacerbation of) - depression - diarrhoea - dizziness - drowsiness - fluid retention (rarely precipitating congestive heart failure) - gastro-intestinal bleeding - gastro-intestinal discomfort - gastro-intestinal disturbances - gastro-intestinal ulceration - haematuria - headache - hearing disturbances - hypersensitivity reactions - insomnia - nausea - nervousness - photosensitivity - raised blood pressure - rashes - renal failure (especially in patients with pre-existing renal impairment) - tinnitus - vertigo

### SIDE-EFFECTS, FURTHER INFORMATION
- Serious side-effects
  - For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 1028.
- ALLERGY AND CROSS-SENSITIVITY
  - Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.
- CONCEPTION AND CONTRACEPTION
  - Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.
- PREGNANCY
  - Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.
- BREAST FEEDING
  - Use with caution during breast-feeding. Present in milk in animal studies—manufacturer advises avoid.

### HEPATIC IMPAIRMENT
Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

### RENAL IMPAIRMENT
Avoid if possible or use with caution. The lowest effective dose should be used for the shortest possible duration. Monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

- In adults
  - Avoid if eGFR less than 25 mL/minute/1.73 m².
- In children
  - Avoid if estimated glomerular filtration rate less than 25 mL/minute/1.73 m².

### MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

<table>
<thead>
<tr>
<th>Formula</th>
<th>Strength/Key characteristics</th>
<th>Bulk dose</th>
<th>Price ( UK )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orodispersible tablet</td>
<td>Meloxicam 7.5 mg Meloxicam 7.5mg orodispersible tablets sugar free sugar-free</td>
<td>30 tablet (PoS)</td>
<td>£15.50</td>
</tr>
<tr>
<td></td>
<td>Meloxicam 15 mg Meloxicam 15mg orodispersible tablets sugar free sugar-free</td>
<td>30 tablet (PoS)</td>
<td>£15.50</td>
</tr>
</tbody>
</table>

### Table

<table>
<thead>
<tr>
<th>Cautionary and Advisory Labels</th>
<th>21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meloxicam (Non-proprietary)</td>
<td>21</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Formula</th>
<th>Strength/Key characteristics</th>
<th>Bulk dose</th>
<th>Price ( UK )</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Meloxicam 7.5 mg Meloxicam 7.5mg tablets</td>
<td>30 tablet</td>
<td>£4.00</td>
</tr>
<tr>
<td></td>
<td>Meloxicam 15 mg Meloxicam 15mg tablets</td>
<td>30 tablet</td>
<td>£1.06</td>
</tr>
</tbody>
</table>

### Nabumetone

### INDICATIONS AND DOSE

#### Pain and inflammation in osteoarthritis and rheumatoid arthritis

> BY MOUTH
  - Adult: 1 g once daily, dose to be taken at night
  - Elderly: 0.5–1 g daily

#### Pain and inflammation in osteoarthritis and rheumatoid arthritis (severe and persistent symptoms)

> BY MOUTH
  - Adult: 0.5–1 g, dose to be taken in the morning and 1 g, dose to be taken at night
  - Elderly: 0.5–1 g daily

### CONTRA-INDICATIONS
Active gastro-intestinal bleeding - active gastro-intestinal ulceration - history of gastro-intestinal bleeding related to previous NSAID therapy - history of gastro-intestinal perforation related to previous NSAID therapy - history of gastro-intestinal perforation related to previous NSAID therapy - history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes) - history of recurrent gastro-intestinal ulceration (two or more distinct episodes) - severe heart failure

### CAUTIONS
Allergic disorders - cardiac impairment (NSAIDs may impair renal function) - cerebrovascular disease - coagulation defects - connective-tissue disorders - Crohn's disease (may be exacerbated) - elderly (risk of serious side-effects and fatalities) - heart failure - ischaemic heart disease - peripheral arterial disease - risk factors for cardiovascular events - ulcerative colitis (may be exacerbated) - uncontrolled hypertension

### INTERACTIONS
» Appendix 1: NSAIDs

### SIDE-EFFECTS
- Rare
  - Alveolitis - aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) - hepatic damage - interstitial fibrosis associated with NSAIDs can lead to renal failure - papillary necrosis associated with NSAIDs can lead to renal failure - peripheral arterial disease (severe and persistent symptoms) - peripheral arterial disease — may impair renal function —visual disturbances

### Pain and inflammation in musculoskeletal disorders

10
Musculoskeletal system
Frequency not known  Angioedema · blood disorders · bronchospasm · colitis (induction of or exacerbation of) · Crohn’s disease (induction of or exacerbation of) · depression · diarrhoea · dizziness · drowsiness · fluid retention (rarely precipitating congestive heart failure) · gastro-intestinal bleeding · gastro-intestinal discomfort · gastro-intestinal disturbances · gastro-intestinal ulceration · haematuria · headache · hearing disturbances · hypersensitivity reactions · insomnia · nausea · nervousness · photosensitivity · raised blood pressure · rash · renal failure (especially in patients with pre-existing renal impairment) · tinnitus · vertigo

SIDE-EFFECTS, FURTHER INFORMATION

Serious side-effects  For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 1028.

ALLERGY AND CROSS-SENSITIVITY  Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

CONCEPTION AND CONTRACEPTION  Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

PREGNANCY  Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

BREAST FEEDING  Use with caution during breast-feeding. Manufacturer advises avoid.

HEPATIC IMPAIRMENT  Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

RENAL IMPAIRMENT  Avoid if possible or use with caution. Avoid in severe impairment. The lowest effective dose should be used for the shortest possible duration. Monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Table

<table>
<thead>
<tr>
<th>Medication</th>
<th>Pack Size</th>
<th>Dose</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nabumetone (Non-proprietary)</td>
<td>56 tablet</td>
<td>500 mg</td>
<td>£0.20 per DT price = £7.35</td>
</tr>
<tr>
<td>Reлизex (Meda Pharmaceuticals Ltd)</td>
<td>56 tablet</td>
<td>500 mg</td>
<td>£0.18 per DT price = £7.35</td>
</tr>
</tbody>
</table>

Naproxen

INDICATIONS AND DOSE

Pain and inflammation in musculoskeletal disorders

BY MOUTH

Adult: 0.5–1 g daily in 1–2 divided doses

Pain and inflammation in musculoskeletal disorders

BY MOUTH

Adult: Initially 500 mg, then 250 mg every 6–8 hours as required, maximum dose after the first day 1.25 g daily

Acute gout

BY MOUTH

Adult: Initially 750 mg, then 250 mg every 8 hours until attack has passed

CONTRA-INDICATIONS

Active gastro-intestinal bleeding · active gastro-intestinal ulceration · history of gastro-intestinal bleeding related to previous NSAID therapy · history of gastro-intestinal perforation related to previous NSAID therapy · history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes) · history of recurrent gastro-intestinal ulceration (two or more distinct episodes) · severe heart failure

CAUTIONS

Allergic disorders · cardiac impairment (NSAIDs may impair renal function) · cerebrovascular disease · coagulation defects · connective-tissue disorders · Crohn’s disease (may be exacerbated) · elderly (risk of serious side-effects and fatalities) · heart failure · ischaemic heart disease · peripheral arterial disease · risk factors for cardiovascular events · ulcerative colitis (may be exacerbated) · uncontrolled hypertension

INTERACTIONS  Appendix 1: NSAIDs

SIDE-EFFECTS

Rare  Alveolitis · aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) · hepatic damage · interstitial fibrosis associated with NSAIDs can lead to renal failure · pancreatitis · papillary necrosis associated with NSAIDs can lead to renal failure · pulmonary eosinophilia · Stevens-Johnson syndrome · toxic epidermal necrolysis · visual disturbances

FREQUENCY NOT KNOWN  Angioedema · blood disorders · bronchospasm · colitis (induction of or exacerbation of) · Crohn’s disease (induction of or exacerbation of) · depression · diarrhoea · dizziness · drowsiness · fluid retention (rarely precipitating congestive heart failure) · gastro-intestinal bleeding · gastro-intestinal discomfort · gastro-intestinal disturbances · gastro-intestinal ulceration · haematuria · headache · hearing disturbances · hypersensitivity reactions · insomnia · nausea · nervousness · photosensitivity · raised blood pressure · rash · renal failure (especially in patients with pre-existing renal impairment) · tinnitus · vertigo

FREQUENCY NOT KNOWN  Angioedema · blood disorders · bronchospasm · colitis (induction of or exacerbation of) · Crohn’s disease (induction of or exacerbation of) · depression · diarrhoea · dizziness · drowsiness · fluid retention (rarely precipitating congestive heart failure) · gastro-intestinal bleeding · gastro-intestinal discomfort · gastro-intestinal disturbances · gastro-intestinal ulceration · haematuria · headache · hearing disturbances · hypersensitivity reactions · insomnia · nausea · nervousness · photosensitivity · raised blood pressure · rash · renal failure (especially in patients with pre-existing renal impairment) · tinnitus · vertigo

SIDE-EFFECTS, FURTHER INFORMATION

Serious side-effects  For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 1028.

ALLERGY AND CROSS-SENSITIVITY  Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

CONCEPTION AND CONTRACEPTION  Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

PREGNANCY  Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

BREAST FEEDING  Use with caution during breast-feeding. Amount too small to be harmful but manufacturer advises avoid.

HEPATIC IMPAIRMENT  Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

RENAL IMPAIRMENT  Avoid if possible or use with caution. Avoid if potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.
women aged 15–50 years subject to max. single dose of 500 mg, max. daily dose of 750 mg for max. 3 days, and a max. pack size of 9 × 250 mg tablets.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Oral suspension**
- Naproxen (Non-proprietary)
  - Naproxen 25 mg per 1 ml Naproxen 25mg/ml oral suspension sugar free-sugar-free | 100 ml [pos] £110.00 DT price = £110.00
  - Naproxen 125mg/5ml oral suspension sugar free-sugar-free | 100 ml [pos] £110.00–£128.00 DT price = £110.00
- Naproxen 50 mg per 1 ml Naproxen 50mg/ml oral suspension | 100 ml [pos] £75.00

**Gastro-resistant tablet**

CAUTIONARY AND ADVISORY LABELS 5, 25
- Naproxen (Non-proprietary)
  - Naproxen 250 mg Naproxen 250mg gastro-resistant tablets | 56 tablet [pos] £7.00 DT price = £2.97
  - Naproxen 375 mg Naproxen 375mg gastro-resistant tablets | 56 tablet [pos] £26.62 DT price = £26.62
- Naproxen 500 mg Naproxen 500mg gastro-resistant tablets | 56 tablet [pos] £17.03 DT price = £7.01
- Naprosyn EC (Atnahn Pharma UK Ltd)
  - Naproxen 250 mg Naprosyn EC 250mg tablets | 56 tablet [pos] £4.29 DT price = £2.97
  - Naproxen 375 mg Naprosyn EC 375mg tablets | 56 tablet [pos] £6.42 DT price = £26.82
- Naproxen 500 mg Naproxen EC 500mg tablets | 56 tablet [pos] £8.56 DT price = £7.01

**Effervescent tablet**
- Stirlescent (Stirling Anglian Pharmaceuticals Ltd)
  - Naproxen 250 mg Stirlescent 250mg effervescent tablets sugar-free | 20 tablet [pos] £7.90 DT price = £7.90

**Tablet**

CAUTIONARY AND ADVISORY LABELS 21
- Naproxen (Non-proprietary)
  - Naproxen 250 mg Naproxen 250mg tablets | 28 tablet [pos] £2.10 DT price = £0.93
  - Naproxen 500 mg Naproxen 500mg tablets | 28 tablet [pos] £4.27 DT price = £1.42
- Naprosyn (Atnahn Pharma UK Ltd)
  - Naproxen 250 mg Naproxen 250mg tablets | 56 tablet [pos] £4.29
  - Naproxen 500 mg Naproxen 500mg tablets | 56 tablet [pos] £8.56

**Naproxen with misoprostol**
The properties listed below are those particular to the combination only. For the properties of the components please consider, naproxen p. 1048, misoprostol p. 75.

**INDICATIONS AND DOSE**
Patients requiring naproxen for rheumatoid arthritis, osteoarthritis, or ankylosing spondylitis, with prophylaxis against NSAID-induced gastroduodenal ulceration
- BY MOUTH
  - Adult: 500 mg twice daily, naproxen and 200 micrograms twice daily, misoprostol, taken together with food

**INTERACTIONS**
- Appendix 1: NSAIDs

**PRESCRIBING AND DISPENSING INFORMATION**
The BNF recommends a higher starting dose of misoprostol for prophylaxis against NSAID-induced gastroduodenal ulceration than that provided by the misoprostol with naproxen combination pack.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Modified-release tablet**

CAUTIONARY AND ADVISORY LABELS 22, 25
- Naproxen with misoprostol (Non-proprietary)
  - Esomeprazole (as Esomeprazole magnesium trihydrate) 20 mg, Naproxen 500 mg Naproxen 500mg / Esomeprazole 20mg modified-release tablets | 60 tablet [pos] no price available DT price = £14.95
  - Vimovo (AstraZeneca UK Ltd)
    - Esomeprazole (as Esomeprazole magnesium trihydrate) 20 mg, Naproxen 500 mg Vimovo 500mg/20mg modified-release tablets | 60 tablet [pos] £14.95 DT price = £14.95

**Piroxicam**

**INDICATIONS AND DOSE**
Rheumatoid arthritis (initiated by a specialist) | Osteoarthritis (initiated by a specialist) | Ankylosing spondylitis (initiated by a specialist)
- BY MOUTH
  - Adult: Up to 20 mg once daily

**PAIN RELIEF IN MUSCULOSKELETAL CONDITIONS**
Treatment in knee or hand osteoarthritis (adjunct)
- TO THE SKIN
  - Adult: Apply 3–4 times a day, 0.5% gel to be applied; review treatment after 4 weeks

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**CHMP ADVICE—PIROXICAM (JUNE 2007)**
The CHMP has recommended restrictions on the use of piroxicam because of the increased risk of gastrointestinal side effects and serious skin reactions. The CHMP has advised that:
- piroxicam should be initiated only by physicians experienced in treating inflammatory or degenerative rheumatic diseases
- piroxicam should not be used as first-line treatment
- in adults, use of piroxicam should be limited to the symptomatic relief of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis
- piroxicam dose should not exceed 20 mg daily
- piroxicam should no longer be used for the treatment

**IMPORTANT SAFETY INFORMATION**

The CHMP has recommended restrictions on the use of piroxicam because of the increased risk of gastrointestinal side effects and serious skin reactions. The CHMP has advised that:
- piroxicam should be initiated only by physicians experienced in treating inflammatory or degenerative rheumatic diseases
- piroxicam should not be used as first-line treatment
- in adults, use of piroxicam should be limited to the symptomatic relief of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis
- piroxicam dose should not exceed 20 mg daily
- piroxicam should no longer be used for the treatment
of acute painful and inflammatory conditions
- treatment should be reviewed 2 weeks after initiating piroxicam, and periodically thereafter
- concomitant administration of a gastro-protective agent should be considered. Topical preparations containing piroxicam are not affected by these restrictions.

**CONTRA-INDICATIONS**
- With systemic use Active gastro-intestinal bleeding - active gastro-intestinal ulceration - history of gastro-intestinal bleeding - history of gastro-intestinal perforation - history of gastro-intestinal ulceration - inflammatory bowel disease - severe heart failure
- CAUTIONS
- With systemic use Allergic disorders - cardiac impairment (NSAIDs may impair renal function) - cerebrovascular disease - coagulation defects - connective-tissue disorders - Crohn's disease (may be exacerbated) - elderly (risk of serious side-effects and fatalities) - heart failure - ischaemic heart disease - peripheral arterial disease - risk factors for cardiovascular events - ulcerative colitis (may be exacerbated) - uncontrolled hypertension
- With topical use Avoid contact with eyes - avoid contact with inflamed or broken skin - avoid contact with mucous membranes - not for use with occlusive dressings - topical application of large amounts can result in systemic effects, including hypersensitivity and asthma (renal disease has also been reported)

**INTERACTIONS**
- Appendix 1: NSAIDs
- SIDE-EFFECTS
- Rare
- With systemic use Alveolitis - aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) - hepatic damage - interstitial fibrosis associated with NSAIDs can lead to renal failure - pancreatitis - papillary necrosis associated with NSAIDs can lead to renal failure - pulmonary eosinophilia - Stevens-Johnson syndrome - toxic epidermal necrolysis - visual disturbances
- Frequency not known
- With topical use Photosensitivity - rash (discontinue use if develops)

**SIDE-EFFECTS, FURTHER INFORMATION**
- Serious side-effects For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 1028.
- With topical use Topical application of large amounts can result in systemic effects, including hypersensitivity and asthma (renal disease has also been reported).
- ALLERGY AND CROSS-SENSITIVITY Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

**CONCEPTION AND CONTRACEPTION**
- With systemic use Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

**PREGNANCY**
- With systemic use Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.
- With topical use Patient packs for topical preparations carry a warning to avoid during pregnancy.

**BREAST FEEDING**
- With systemic use Use with caution during breast-feeding. Amount too small to be harmful.
- With topical use Patient packs for topical preparations carry a warning to avoid during breast-feeding.

**HEPATIC IMPAIRMENT**
- With systemic use Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

**RENAL IMPAIRMENT**
- With systemic use Avoid if possible or use with caution. The lowest effective dose should be used for the shortest possible duration. Monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.
- With topical use Deterioration in renal function has also been reported after topical use.

**DIRECTIONS FOR ADMINISTRATION**
- For topical preparations apply with gentle massage only.

**MEDICINAL FORMS**
- Piroxicam orodispersible tablets can be taken by placing on the tongue and allowing to dissolve or by swallowing.

**PREGNANCY AND CONtraception**
- With systemic use May contain Asparagine

**MEDICATIONS**
- There can be variation in the licensing of different medicines containing the same drug.

**Orodispersible tablet**

**CAUTIONARY AND ADVISORY LABELS**

**10, 21**

**EXCIPIENTS:**
- May contain Asparagine

**Feldene Melt** (Pfizer Ltd)

**Piroxicam 20 mg** Feldene Melt 20mg tablets sugar-free | 30 tablet [Pm] £10.53 DT price = £10.53

**Gel**

**EXCIPIENTS:**
- May contain Benzyl alcohol, propylene glycol

**Piroxicam (Non proprietary)**

**Piroxicam 5 mg per 1 gram** Piroxicam 0.5% gel | 60 gram [Pm] £3.50 DT price = £2.07 | 100 gram [Pm] £4.80 | 112 gram [Pm] £7.25 DT price = £3.86

**Feldene** (Pfizer Ltd)

**Piroxicam 5 mg per 1 gram** Feldene 0.5% gel | 60 gram [Pm] £6.00 DT price = £2.07 | 112 gram [Pm] £9.41 DT price = £3.86

**Capsule**

**CAUTIONARY AND ADVISORY LABELS**

**21**

**Piroxicam (Non proprietary)**

**Piroxicam 10 mg** Piroxicam 10mg capsules | 56 capsule [Pm] £16.82 DT price = £4.18

**Piroxicam 20 mg** Piroxicam 20mg capsules | 28 capsule [Pm] £17.60 DT price = £3.61

**Feldene** (Pfizer Ltd)

**Piroxicam 10 mg** Feldene 10mg capsules | 30 capsule [Pm] £3.86

**Piroxicam 20 mg** Feldene 20 capsules | 30 capsule [Pm] £7.71

©RPS 2010
### Sulindac

**INDICATIONS AND DOSE**

**Pain and inflammation in musculoskeletal disorders**

- **Acute gout**
  - **BY MOUTH**
  - Adult: 200 mg twice daily for maximum duration 7–10 days in peri-articular disorders, dose may be reduced according to response; acute gout should respond within 7 days; maximum 400 mg per day

**CONTRA-INDICATIONS**

- Active gastro-intestinal bleeding
- active gastro-intestinal ulceration
- history of gastro-intestinal bleeding related to previous NSAID therapy
- history of gastro-intestinal perforation related to previous NSAID therapy
- history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes)
- history of recurrent gastro-intestinal ulceration (two or more distinct episodes)
- severe heart failure

**CAUTIONS**

- Allergic disorders
- cardiac impairment (NSAIDs may impair renal function)
- cerebrovascular disease
- coagulation defects
- connective-tissue disorders
- Crohn’s disease (may be exacerbated)
- elderly (risk of serious side-effects and fatalities)
- ensure adequate hydration
- heart failure
- history of renal stones
- ischaemic heart disease
- peripheral arterial disease
- risk factors for cardiovascular events
- ulcerative colitis (may be exacerbated)
- uncontrolled hypertension

**INTERACTIONS**

- Rare
  - Alveolitis
  - aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible)
  - hepatic damage
  - interstitial fibrosis associated with NSAIDs can lead to renal failure
  - pancreatitis
  - papillary necrosis associated with NSAIDs can lead to renal failure
  - pulmonary eosinophilia
  - Stevens-Johnson syndrome
  - toxic epidermal necrolysis
  - visual disturbances

**SIDE-EFFECTS**

- Serious side-effects
  - For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 1028.

- **ALLERGY AND CROSS-SENSITIVITY**
  - Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

- **CONCEPTION AND CONTRACEPTION**
  - Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

- **PREGNANCY**
  - Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

**INDICATIONS AND DOSE**

**Pain and inflammation in acute musculoskeletal disorders**

- **BY MOUTH**
- Adult: 20 mg once daily as initial treatment for 1–2 days if oral administration not possible

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS**
- 21
- Sulindac (Non-proprietary)
  - Sulindac 100 mg Sulindac 100mg tablets | 56 tablet | £48.00
  - Sulindac 200 mg Sulindac 200mg tablets | 56 tablet | £96.00
- DT price = £8.29

---

### Tenoxicam

**INDICATIONS AND DOSE**

**Pain and inflammation in rheumatic disease**

- **BY MOUTH**
- Adult: 20 mg once daily
- **BY INTRAVENOUS INJECTION, OR BY INTRAMUSCULAR INJECTION**
- Adult: 20 mg once daily as initial treatment for 1–2 days if oral administration not possible

**Pain and inflammation in acute musculoskeletal disorders**

- **BY MOUTH**
- Adult: 20 mg once daily for 7 days; maximum duration of treatment 14 days (including treatment by intravenous or intramuscular injection)
- **BY INTRAVENOUS INJECTION, OR BY INTRAMUSCULAR INJECTION**
- Adult: 20 mg once daily as initial treatment for 1–2 days if oral administration not possible

**CONTRA-INDICATIONS**

- Active gastro-intestinal bleeding
- active gastro-intestinal ulceration
- history of gastro-intestinal bleeding related to previous NSAID therapy
- history of gastro-intestinal perforation related to previous NSAID therapy
- history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes)
- history of recurrent gastro-intestinal ulceration (two or more distinct episodes)
- severe heart failure

**CAUTIONS**

- Allergic disorders
- cardiac impairment (NSAIDs may impair renal function)
- cerebrovascular disease
- coagulation defects
- connective-tissue disorders
- Crohn’s disease (may be exacerbated)
- elderly (risk of serious side-effects and fatalities)
- heart failure
- ischaemic heart disease
- peripheral arterial disease
- risk factors for cardiovascular events
- ulcerative colitis (may be exacerbated)
- uncontrolled hypertension

**INTERACTIONS**

- Rare
  - Alveolitis
  - aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible)
  - hepatic damage
  - interstitial fibrosis associated with NSAIDs can lead to renal failure
  - pancreatitis
  - papillary necrosis associated with NSAIDs can lead to renal failure
  - pulmonary eosinophilia
  - Stevens-Johnson syndrome
  - toxic epidermal necrolysis
  - visual disturbances

**SIDE-EFFECTS**

- Serious side-effects
  - For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 1028.

- **ALLERGY AND CROSS-SENSITIVITY**
  - Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

- **CONCEPTION AND CONTRACEPTION**
  - Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

- **PREGNANCY**
  - Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

**INDICATIONS AND DOSE**

**Pain and inflammation in acute musculoskeletal disorders**

- **BY MOUTH**
- Adult: 20 mg once daily as initial treatment for 1–2 days if oral administration not possible

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

**Tablet**

- **CAUTIONARY AND ADVISORY LABELS**
- 21
depression · diarrhoea · dizziness · drowsiness · fluid retention (rarely precipitating congestive heart failure) · gastro-intestinal bleeding · gastro-intestinal discomfort · gastro-intestinal ulceration · haematura· · headache · hearing disturbances · hypersensitivity reactions · insomnia · nausea · nervousness · photosensitivity · raised blood pressure · rashes · renal failure (especially in patients with pre-existing renal impairment) · tinnitus · vertigo

SIDE-EFFECTS, FURTHER INFORMATION
▶ Serious side-effects. For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 1028.

● ALLERGY AND CROSS-SENSITIVITY Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

● CONCEPTION AND CONTRACEPTION Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

● PREGNANCY Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

● BREAST FEEDING Use with caution during breast-feeding. Present in milk in animal studies.

● HEPATIC IMPAIRMENT Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

● RENAL IMPAIRMENT Avoid if possible or use with caution. Avoid in severe impairment. The lowest effective dose should be used for the shortest possible duration. Monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

● MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Powder and solvent for solution for injection
▶ Tenoxicam (Non-proprietary)
Tenoxicam 20 mg Tenoxicam 20mg powder and solvent for solution for injection vials | 1 vial [POM] £3.98

Tablet
CAUTIONARY AND ADVISORY LABELS 21
▶ Tenoxicam (Non-proprietary)
Tenoxicam 20 mg Tenoxicam 20mg tablets | 28 tablet [POM] £16.16
DT price = £16.16

Mobiflex (Meda Pharmaceuticals Ltd)
Tenoxicam 20 mg Mobiflex 20mg tablets | 30 tablet [POM] £13.42

Tiaprofenic acid

● INDICATIONS AND DOSE

Pain and inflammation in rheumatic disease and other musculoskeletal disorders
▶ BY MOUTH
▶ Adult: 300 mg twice daily

IMPORTANT SAFETY INFORMATION

CSM ADVICE

Following reports of severe cystitis the CSM has recommended that tiaprofenic acid should not be given to patients with urinary-tract disorders and should be stopped if urinary symptoms develop.

Patients should be advised to stop taking tiaprofenic acid and to report to their doctor promptly if they develop urinary-tract symptoms (such as increased frequency, nocturia, urgency, pain on urinating, or blood in urine).

CONTRA-INDICATIONS Active bladder disease (or symptoms) · active gastro-intestinal bleeding · active gastro-intestinal ulceration · active prostate disease (or symptoms) · history of gastro-intestinal bleeding related to previous NSAID therapy · history of gastro-intestinal perforation related to previous NSAID therapy · history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes) · history of recurrent gastro-intestinal ulceration (two or more distinct episodes) · history of recurrent urinary-tract disorders (if urinary symptoms develop discontinue immediately and perform urine tests and culture) · severe heart failure

CAUTIONS Allergic disorders · cardiac impairment (NSAIDs may impair renal function) · cerebrovascular disease · coagulation defects · connective-tissue disorders · Crohn’s disease (may be exacerbated) · elderly (risk of serious side-effects and fatalities) · heart failure · ischaemic heart disease · peripheral arterial disease · risk factors for cardiovascular events · ulcerative colitis (may be exacerbated) · uncontrolled hypertension

INTERACTIONS → Appendix 1: NSAIDs

SIDE-EFFECTS
▶ Rare Alveolitis · aspetic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) · hepatic damage · interstitial fibrosis associated with NSAIDs can lead to renal failure · pancreatitis · papillary necrosis associated with NSAIDs can lead to renal failure · pulmonary eosinophilia · Stevens-Johnson syndrome · toxic epidermal necrolysis · visual disturbances

Frequency not known Angioedema · blood disorders · bronchospasm · colitis (induction of or exacerbation of) · Crohn’s disease (induction of or exacerbation of) · depression · diarrhoea · dizziness · drowsiness · fluid retention (rarely precipitating congestive heart failure) · gastro-intestinal bleeding · gastro-intestinal discomfort · gastro-intestinal disturbances · gastro-intestinal ulceration · haematura · headache · hearing disturbances · hypersensitivity reactions · insomnia · nausea · nervousness · photosensitivity · raised blood pressure · rashes · renal failure (especially in patients with pre-existing renal impairment) · tinnitus · vertigo

SIDE-EFFECTS, FURTHER INFORMATION
▶ Serious side-effects. For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 1028.

ALLERGY AND CROSS-SENSITIVITY Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

CONCEPTION AND CONTRACEPTION Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

PREGNANCY Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

BREAST FEEDING Use with caution during breast-feeding. Amount too small to be harmful.

HEPATIC IMPAIRMENT Reduce dose in mild or moderate impairment. Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

downloaded from www.medicalbr.com
RENAL IMPAIRMENT Avoid if possible or use with caution. Avoid in severe impairment. Reduce dose in mild or moderate impairment. The lowest effective dose should be used for the shortest possible duration. Monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

MEDICINAL FORMS There can be variation in the licensing of different medicines containing the same drug.

Tablet

CAUTIONARY AND ADVISORY LABELS 21

- Surgam (Sanofi)

Tiaprofenic acid 300 mg Surgam 300mg tablets | 56 tablet £14.95 DT price = £14.95

5 Soft tissue and joint disorders

5.1 Local inflammation of joints and soft tissue

Other drugs used for local inflammation of joints and soft tissue Betamethasone p. 635

CORTICOSTEROIDS

Corticosteroids, inflammatory disorders

Systemic corticosteroids

Short-term treatment with corticosteroids can help to rapidly improve symptoms of rheumatoid arthritis. Long-term treatment in rheumatoid arthritis should be considered only after evaluating the risks and all other treatment options have been considered. Corticosteroids can induce osteoporosis, and prophylaxis should be considered on long-term treatment.

In severe, possibly life-threatening, situations a high initial dose of corticosteroid is given to induce remission and the dose is then reduced gradually and discontinued altogether. Relapse may occur as the dose of corticosteroid is reduced, particularly if the reduction is too rapid. The tendency is therefore to increase the maintenance dose and consequently the patient becomes dependent on corticosteroids. For this reason pulse doses of corticosteroids (e.g. methylprednisolone p. 1054 up to 1 g intravenously on 3 consecutive days) are used to suppress highly active inflammatory disease while longer-term treatment with a disease-modifying drug is commenced.

Prednisolone p. 1054 may reduce the rate of joint destruction in moderate to severe rheumatoid arthritis of less than 2 years’ duration. The reduction in joint destruction must be distinguished from mere symptomatic improvement (which lasts only 6 to 12 months at this dose) and care should be taken to avoid increasing the dose above 7.5 mg daily. Evidence supports maintenance of this anti-erosive dose for 2–4 years only after which treatment should be tapered off to reduce long-term adverse effects.

A modified-release preparation of prednisone p. 641 is also available for the treatment of moderate to severe rheumatoid arthritis.

Polymyalgia rheumatica and giant cell (temporal) arteritis are always treated with corticosteroids. Relapse is common if therapy is stopped prematurely. Many patients require treatment for at least 2 years and in some patients it may be necessary to continue long-term low-dose corticosteroid treatment.

Polyarteritis nodosa and polymyositis are usually treated with corticosteroids.

Systemic lupus erythematosus is treated with corticosteroids when necessary using a similar dosage regimen to that for polyarteritis nodosa and polymyositis. Patients with pleurisy, pericarditis, or other systemic manifestations will respond to corticosteroids. It may then be possible to reduce the dosage; alternate-day treatment is sometimes adequate, and the drug may be gradually withdrawn. In some mild cases corticosteroid treatment may be stopped after a few months. Many mild cases of systemic lupus erythematosus do not require corticosteroid treatment. Alternative treatment with anti-inflammatory analgesics, and possibly chloroquine p. 582 or hydroxychloroquine sulfate p. 1001, should be considered.

Ankylosing spondylitis should not be treated with long-term corticosteroids; rarely, pulse doses may be needed and may be useful in extremely active disease that does not respond to conventional treatment.

Local corticosteroid injections

Corticosteroids are injected locally for an anti-inflammatory effect. In inflammatory conditions of the joints, particularly in rheumatoid arthritis, they are given by intra-articular injection to relieve pain, increase mobility, and reduce deformity in one or a few joints; they can also provide symptomatic relief while waiting for DMARDs to take effect. Full aseptic precautions are essential; infected areas should be avoided. Occasionally an acute inflammatory reaction develops after an intra-articular or soft-tissue injection of a corticosteroid. This may be a reaction to the microcrystalline suspension of the corticosteroid used, but must be distinguished from sepsis introduced into the injection site.

Smaller amounts of corticosteroids may also be injected directly into soft tissues for the relief of inflammation in conditions such as tennis or golfer’s elbow or compression neuropathies. In tendinitis, injections should be made into the tendon sheath and not directly into the tendon (due to the absence of a true tendon sheath and a high risk of rupture, the Achilles tendon should not be injected).

Hydrocortisone acetate p. 1054 or one of the synthetic analogues is generally used for local injection. Intra-articular corticosteroid injections can cause flushing and may affect the hyaline cartilage. Each joint should not usually be treated more than 4 times in one year.

Corticosteroid injections are also injected into soft tissues for the treatment of skin lesions.

Dexamethasone

- INDICATIONS AND DOSE
  - Local inflammation of joints
    - By intra-articular injection
      - Adult: 0.3–3.3 mg, where appropriate, dose may be repeated at intervals of 3–21 days according to response, dose given according to size—consult product literature
  - Local inflammation of soft tissues
    - By local infiltration
      - Adult: 1.7–5 mg, dose given according to size—consult product literature, where appropriate may be repeated at intervals of 3–21 days, use the 3.3 mg/mL injection preparation for this dose

- INTERACTIONS Appendix 1: corticosteroids
- PREGNANCY Dexamethasone readily crosses the placenta.
- PRESCRIBING AND DISPENSING INFORMATION Dexamethasone 3.8 mg/mL Injection has replaced Dexamethasone 4 mg/mL Injection. All dosage
recommendations for intravenous, intramuscular, intrarticular use or local infiltration; are given in units of dexamethasone base.

**MEDICINAL FORMS**  
There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**  
**CAUTIONARY AND ADVISORY LABELS**

- **Dexamethasone (Non-proprietary)**
  - Dexamethasone (as Dexamethasone sodium phosphate) 3.3 mg per 1 ml Dexamethasone 6.6mg/2ml solution for injection vials | 5 vial [Pom] £20.00 DT price = £24.00  
  - Dexamethasone 6.6mg/2ml solution for injection vials | 5 ampoule [Pom] £11.00 DT price = £11.00  
  - 10 ampoule [Pom] £22.00  
  - Dexamethasone 3.3mg/1ml solution for injection vials | 5 ampoule [Pom] £12.00  
  - 10 ampoule [Pom] £12.00 DT price = £12.00  

- **Dexamethasone (as Dexamethasone sodium phosphate) 3.8 mg per 1 ml** Dexamethasone 3.8mg/1ml solution for injection vials | 10 vial [Pom] £19.99 DT price = £19.99

**Hydrocortisone**

**INDICATIONS AND DOSE**

- **HYDROCORTISTAB**

  **Local inflammation of joints and soft-tissues**
  - **BY INTRA-ARTICULAR INJECTION**
  - Adult: 5–50 mg, select dose according to size of patient and joint; where appropriate dose may be repeated at intervals of 21 days. Not more than 3 joints should be treated on any one day, for details consult product literature

- **Methylprednisolone with lidocaine**

  **Local inflammation of joints**
  - **BY INTRA-ARTICULAR INJECTION**
  - Adult: 4–80 mg, dose adjusted according to size; where appropriate may be repeated at intervals of 7–35 days, for details consult product literature

**INTERACTIONS** → Appendix 1: antiarrhythmics, corticosteroids

**Prednisolone**

**INDICATIONS AND DOSE**

- **DELTASTAB**

  **Local inflammation of joints**
  - **BY INTRA-ARTICULAR INJECTION**
  - Adult: 5–25 mg, dose according to size; not more than 3 joints should be treated on any one day; where appropriate may be repeated when relapse occurs, for details consult product literature

**INTERACTIONS** → Appendix 1: corticosteroids

**PREGNANCY** As it crosses the placenta 88% of prednisolone is inactivated.

**BREAST FEEDING** Prednisolone appears in small amounts in breast milk but maternal doses of up to 40 mg daily are unlikely to cause systemic effects in the infant.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Suspension for injection**

- **Deltastab (AMCo)**
  - Prednisolone acetate 25 mg per 1 ml Deltastab 25mg/1ml suspension for injection ampoules | 10 ampoule [Pom] £68.72

**Triamcinolone acetonide**

**INDICATIONS AND DOSE**

- **ADCORTYL INTRA-ARTICULAR/INTRADERMAL**

  **Local inflammation of joints and soft tissues**
  - **BY INTRA-ARTICULAR INJECTION**
  - Adult: 2.5–15 mg, adjusted according to size (for larger doses use Kenalog®). Where appropriate dose may be repeated when relapse occurs, for details consult product literature.

  **BY INTRADERMAL INJECTION**
  - Adult: 2–3 mg, max. 5 mg at any one site (total max. 30 mg). Where appropriate may be repeated at intervals of 1–2 weeks, for details consult product literature
administration into the subcutaneous or subdermal tissue. It must be dealt with promptly to prevent tissue necrosis. Acidic or alkaline preparations and those with an osmolarity greater than that of plasma can cause extravasation injury; excipients including alcohol and polyethylene glycol have also been implicated. Cytotoxic drugs commonly cause extravasation injury. In addition, certain patients such as the very young and the elderly are at increased risk. Those receiving anticoagulants are more likely to lose blood into surrounding tissues if extravasation occurs, while those receiving sedatives or analgesics may not notice the early signs or symptoms of extravasation.

Prevention of extravasation
Precautions should be taken to avoid extravasation; ideally, drugs likely to cause extravasation injury should be given through a central line and patients receiving repeated doses of hazardous drugs peripherally should have the cannula resited at regular intervals. Attention should be paid to the manufacturers’ recommendations for administration. Placing a glyceryl trinitrate patch p. 212 distal to the cannula may improve the patency of the vessel in patients with small veins or in those whose veins are prone to collapse.

Patients should be asked to report any pain or burning at the site of injection immediately.

Management of extravasation
If extravasation is suspected the infusion should be stopped immediately but the cannula should not be removed until after an attempt has been made to aspirate the area (through the cannula) in order to remove as much of the drug as possible. Aspiration is sometimes possible if the extravasation presents with a raised bleb or blister at the injection site and is surrounded by hardened tissue, but it is often unsuccessful if the tissue is soft or soggy.

Corticosteroids are usually given to treat inflammation, although there is little evidence to support their use in extravasation. Hydrocortisone p. 1054 or dexamethasone p. 1053 can be given either locally by subcutaneous injection or intravenously at a site distant from the injury. Antihistamines and analgesics may be required for symptom relief.

The management of extravasation beyond these measures is not well standardised and calls for specialist advice. Treatment depends on the nature of the offending substance; one approach is to localise and neutralise the substance whereas another is to spread and dilute it. The first method may be appropriate following extravasation of vesicant drugs and involves administration of an antidote (if available) and the application of cold compresses 3–4 times a day (consult specialist literature for details of specific antidotes). Spreading and diluting the offending substance involves infiltrating the area with physiological saline, applying warm compresses, elevating the affected limb, and administering hyaluronidase p. 1056. A saline flush-out technique (involving flushing the subcutaneous tissue with physiological saline) may be effective but requires specialist advice. Hyaluronidase should not be administered following extravasation of vesicant drugs (unless it is either specifically indicated or used in the saline flush-out technique). Dextrazoxane p. 868 is licensed for the treatment of anthracycline-induced extravasation.

Enzymes
Collagenase
Collagenase p. 1056 are proteolytic enzymes that are derived from the fermentation of Clostridium histolyticum and have the ability to break down collagen. A preparation containing a mixture of two collagenases is licensed for the treatment of Dupuytren’s contracture; the preparation should be injected into a palpable cord with a contracture of a metacarpophalangeal joint or proximal interphalangeal joint.
**Hyaluronidase**

Hyaluronidase is used to render the tissues more readily permeable to injected fluids, e.g. for introduction of fluids by subcutaneous infusion (termed hypodermoclysis).

**Rubefacients, topical NSAIDs, capsaicin, and poultries**

**Rubefacients** act by counter-irritation. Pain, whether superficial or deep-seated, is relieved by any method that itself produces irritation of the skin. Topical rubefacient preparations may contain nicotinate and salicylate compounds, essential oils, capsicum, and camphor. The evidence available does not support the use of topical rubefacients in acute or chronic musculoskeletal pain.

**Topical NSAIDs**

The use of a NSAID by mouth is effective for relieving musculoskeletal pain. Topical NSAIDs (e.g. felbinac p. 1038, ibuprofen p. 1041, ketoprofen p. 1044, and piroxicam p. 1049) may provide some relief of pain in musculoskeletal conditions; they can be considered as an adjunctive treatment in knee or hand osteoarthritis.

**Capsaicin**

A preparation containing capsaicin 0.025% p. 458 can be considered as an adjunct in hand or knee osteoarthritis. It may need to be used for 1–2 weeks before pain is relieved.

A capsaicin 0.075% cream is licensed for the symptomatic relief of postherpetic neuralgia after lesions have healed, and for the relief of painful diabetic neuropathy.

A self-adhesive patch containing capsaicin 8% is licensed for the treatment of peripheral neuropathic pain in non-diabetic patients.

**ENZYMES**

**Collagenase**

**INDICATIONS AND DOSE**

**Dupuytren’s contracture in patients with a palpable cord**

- **BY INTRALESIONAL INJECTION**
  - Adult: 580 micrograms, then 580 micrograms every 4 weeks if required, inject into palpable cord, maximum 3 injections per cord, maximum 8 injections in total and only one cord may be treated at a time

- **CONTRA-INDICATIONS** Avoid injecting into other structures containing collagen (e.g. tendons, nerves, and blood vessels)—risk of tendon rupture or ligament damage

- **CAUTIONS** Coagulation disorders • use of anticoagulants

- **SIDE-EFFECTS**
  - Common or very common Arthralgia • burning sensation • ecchymosis • hyperhidrosis • hypoesthesia • injection site reactions • joint swelling • lymphadenopathy • myalgia • paraesthesia
  - Uncommon Complex regional pain syndrome • crepitus • ligament injury • monoplegia • muscle spasm • muscle weakness • tendon rupture • tremor • wound dehiscence

- **PREGNANCY** Manufacturer advises avoid.

- **BREAST FEEDING** Systemic absorption by mother negligible.

- **DIRECTIONS FOR ADMINISTRATION** Reconstitution and injected volumes vary with site of injection—consult product literature.

- **NATIONAL FUNDING/ACCESS DECISIONS**

  **Scottish Medicines Consortium (SMC) Decisions**
  
  The Scottish Medicines Consortium has advised (April 2012) that collagenase Clostridium histolyticum (Xiapex®) is accepted for restricted use within NHS Scotland as an alternative to limited fasciectomy, for the treatment of Dupuytren’s contracture of moderate severity (as defined by the British Society for Surgery of the Hand) in patients with a palpable cord and up to two affected joints per hand, who are suitable for limited fasciectomy, but for whom percutaneous needle fasciectomy is not considered a suitable treatment option.

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug.

  **Powder and solvent for solution for injection**

  - Xiapex (Swedish Orphan Biovitrum Ltd)
    - Collagenase clostridium histolyticum 900 microgram Xiapex 0.5mg powder and solvent for solution for injection ampoules | 1 vial £50.00

**Hyaluronidase**

**INDICATIONS AND DOSE**

Enhance permeation of subcutaneous or intramuscular injections

- **BY SUBCUTANEOUS INJECTION, OR BY INTRAMUSCULAR INJECTION**
  - Adult: 1500 units, to be dissolved directly into the solution to be injected (ensure compatibility)

Enhance permeation of local anaesthetics

- **BY LOCAL INFILTRATION**
  - Adult: 1500 units, to be mixed with the local anaesthetic solution

Enhance permeation of ophthalmic local anaesthetic

- **TO THE EYE**
  - Adult: 15 units/mL, to be mixed with the local anaesthetic solution

**Hypodermoclysis**

- **BY SUBCUTANEOUS INJECTION**
  - Adult: 1500 units, to be dissolved in 1 mL water for injections or 0.9% sodium chloride and infiltrated into affected area as soon as possible after extravasation

**Extravasation**

- **BY LOCAL INFILTRATION**
  - Adult: 1500 units, to be dissolved in 1 mL water for injections or 0.9% sodium chloride and infiltrated into affected area

**Haematoma**

- **BY LOCAL INFILTRATION**
  - Adult: 1500 units, to be dissolved in 1 mL water for injections or 0.9% sodium chloride and infiltrated into affected area

- **CONTRA-INDICATIONS** Avoid sites where infection is present • avoid sites where malignancy is present • do not apply direct to cornea • not for anaesthesia in unexplained premature labour • not for intravenous administration • not to be used to enhance the absorption and dispersion of dopamine and/or alpha-adrenoceptor agonists • not to be used to reduce swelling of bites • not to be used to reduce swelling of stings

- **CAUTIONS** Elderly (control speed and total volume and avoid overhydration especially in renal impairment)

- **SIDE-EFFECTS**
  - Common or very common Oedema
  - Rare Bleeding • bruising • infection • local irritation
  - Frequency not known Anaphylaxis • severe allergy

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug.

  **Powder for solution for injection**

  - Hyaluronidase (Non-proprietary)
    - Hyaluronidase 1500 unit Hyaluronidase 1,500unit powder for solution for injection ampoules | 10 ampoule £36.55
**Chapter 11**

**Eye**

**Administration of drugs to the eye**

Drugs are most commonly administered to the eye by topical application as eye drops or eye ointments. When a higher drug concentration is required within the eye, a local injection may be necessary.

Eye-drop dispenser devices are available to aid the instillation of eye drops from plastic bottles and some are prescribable on the NHS (consult Drug Tariff—see Appliances and Reagents). Product-specific devices may be supplied by manufacturers—consult individual manufacturers for information. They are particularly useful for the elderly, visually impaired, arthritic, or otherwise physically limited patients.

**Eye drops and eye ointments**

Eye drops are generally instilled into the pocket formed by gently pulling down the lower eyelid and keeping the eye closed for as long as possible after application; one drop is all that is needed. Instillation of more than one drop should be discouraged because it may increase systemic side-effects. A small amount of eye ointment is applied similarly; the ointment melts rapidly and blinking helps to spread it.

When two different eye-drop preparations are used at the same time of day, dilution and overflow may occur when one immediately follows the other. The patient should therefore leave an interval of at least 5 minutes between the two; the interval should be extended when eye drops with a prolonged contact time, such as gels and suspensions, are used. Eye ointment should be applied after drops.

Systemic effects may arise from absorption of drugs into the general circulation from conjunctival vessels or from the nasal mucosa after the excess preparation has drained down through the tear ducts. The extent of systemic absorption following ocular administration is highly variable; nasal drainage of drugs is associated with eye drops much more often than with eye ointments. Pressure on the lacrimal punctum for at least a minute after applying eye drops reduces nasolacrimal drainage and therefore decreases systemic absorption from the nasal mucosa.

After using eye drops or eye ointments, patients should be warned not to drive or perform other skilled tasks until vision is clear.

Also see warnings relating to eye drops and contact lenses.

**Eye lotions**

These are solutions for the irrigation of the conjunctival sac. They act mechanically to flush out irritants or foreign bodies as a first-aid treatment. Sterile sodium chloride 0.9% p. 1068 solution is usually used. Clean water will suffice in an emergency.

**Other preparations administered to the eye**

Subconjunctival injection may be used to administer anti-infective drugs, mydriatics, or corticosteroids for conditions not responding to topical therapy; intracameral and intravitreal routes can also be used to administer certain drugs, for example antibacterials. These injections should only be used under specialist supervision.

Drugs such as antimicrobials and corticosteroids may be administered systemically to treat susceptible eye conditions.

**Ophthalmic Specials**

Certain eye drops, e.g. amphotericin p. 561, ceftazidime p. 500, cefuroxime p. 1070, colistimethate sodium p. 525, desferrioxamine mesilate p. 941, dexamethasone p. 1061, gentamicin p. 1070, and vancomycin p. 505 can be prepared aseptically from material supplied for injection.

The Royal College of Ophthalmologists and the UK Ophthalmic Specials Guidance can be accessed on the Royal College of Ophthalmologists website (www.rcophth.ac.uk). The guidance will be reviewed every six months to ensure the most accurate and up-to-date information is available.

**Preservatives and sensitisers**

Information on preservatives and substances identified as skin sensitisers is provided under Excipients statements in preparation entries. Very rarely, cases of corneal calcification have been reported with the use of phosphate-containing eye drops in patients with significantly damaged corneas—consult product literature for further information.

**Control of microbial contamination**

Preparations for the eye should be sterile when issued. Care should be taken to avoid contamination of the contents during use.

Eye drops in multiple-application containers for domiciliary use should not be used for more than 4 weeks after first opening (unless otherwise stated by the manufacturer).

Multiple application eye drops for use in hospital wards are
normally discarded 1 week after first opening—local practice may vary. Individual containers should be provided for each patient. A separate container should be supplied for each eye only if there are special concerns about contamination. Containers used before an eye operation should be discarded at the time of the operation and fresh containers supplied postoperatively. A fresh supply should also be provided upon discharge from hospital; in specialist ophthalmology units, it may be acceptable to issue containers that have been dispensed to the patient on the day of discharge.

In out-patient departments single-application containers should be used; if multiple-application containers are used, they should be discarded after single patient use within one clinical session.

In eye surgery single-application containers should be used if possible; if a multiple-application container is used, it should be discarded after single use. Preparations used during intra-ocular procedures and others that may penetrate into the anterior chamber must be isotonic and without preservatives and buffered if necessary to a neutral pH. Specially formulated fluids should be used for intraocular surgery; intravenous infusion preparations are not usually suitable for this purpose (Hartmann’s solution may be used in some ocular surgery). For all surgical procedures, a previously unopened container is used for each patient.

Contact lenses

For cosmetic reasons many people prefer to wear contact lenses rather than spectacles; contact lenses are also sometimes required for medical indications. Visual defects are corrected by either rigid (‘hard’ or gas permeable) lenses or soft (hydrogel or silicone hydrogel—in adults only) lenses; soft lenses are the most popular type, because they are initially the most comfortable, but they may not give the best vision. Lenses should usually be worn for a specified number of hours each day and removed for sleeping. The risk of infectious keratitis is increased by extended continuous contact lens wear, which is not recommended, except when medically indicated.

Contact lenses require meticulous care. Poor compliance with directions for use, and with daily cleaning and disinfection, can result in complications including ulcerative keratitis or conjunctivitis. One-day disposable lenses, which are worn only once and therefore require no disinfection or cleaning, are becoming increasingly popular.

Acanthamoeba keratitis, a painful and sight-threatening condition, is associated with ineffective lens cleaning and disinfection, the use of contaminated lens cases, or tap water coming into contact with the lenses. The condition is especially associated with the use of soft lenses (including frequently replaced lenses) and should be treated by specialists.

Contact lenses and drug treatment

Special care is required in prescribing eye preparations for contact lens users. Some drugs and preservatives in eye preparations can accumulate in hydrogel lenses and may induce toxic and adverse reactions. Therefore, unless medically indicated, the lenses should be removed before instillation of the eye preparation and not worn during the period of treatment. Alternatively, unpreserved drops can be used. Eye drops may, however, be instilled while patients are wearing rigid corneal contact lenses. Ointment preparations should never be used in conjunction with contact lens wear; oily eye drops should also be avoided.

Many drugs given systemically can also have adverse effects on contact lens wear. These include oral contraceptives (particularly those with a higher oestrogen content), drugs which reduce blink rate (e.g. anxiolytics, hypnotics, antihistamines, and muscle relaxants), drugs which reduce lacrimation (e.g. antihistamines, antimuscarinics, phenothiazines and related drugs, some beta-blockers, diuretics, and tricyclic antidepressants), and drugs which increase lacrimation (including ephedrine hydrochloride p. 261 and hyaluronic acid hydrochloride p. 175). Other drugs that may affect contact lens wear are isotretinoin p. 1166 (can cause conjunctival inflammation), aspirin p. 117 (salicylic acid appears in tears and can be absorbed by contact lenses—leading to irritation), and rifampicin p. 549 and sulfasalazine p. 42 (can discolor lenses).

1 Allergic and inflammatory eye conditions

Eye, allergy and inflammation

Corticosteroids

Corticosteroids administered locally to the eye or given by mouth are effective for treating anterior segment inflammation, including that which results from surgery.

Topical corticosteroids are applied frequently for the first 24–48 hours; once inflammation is controlled, the frequency of application is reduced. They should normally only be used under expert supervision; three main dangers are associated with their use:

- a ‘red eye’, when the diagnosis is unconfirmed, may be due to herpes simplex virus, and a corticosteroid may aggravate the condition, leading to corneal ulceration, with possible damage to vision and even loss of the eye. Bacterial, fungal, and amoebic infections pose a similar hazard;
- ‘steroid glaucoma’ can follow the use of corticosteroid eye preparations in susceptible individuals;
- a ‘steroid cataract’ can follow prolonged use.

Combination products containing a corticosteroid with an anti-infective drug are sometimes used after ocular surgery to reduce inflammation and prevent infection; use of combination products is otherwise rarely justified.

Systemic corticosteroids may be useful for ocular conditions. The risk of producing a ‘steroid cataract’ increases with the dose and duration of corticosteroid use.

Intravitreal corticosteroids

An intravitreal implant containing dexamethasone p. 1061 (Ozurdex®) is licensed for the treatment of adults with macular oedema following either branch retinal vein occlusion or central retinal vein occlusion; it is also licensed for the treatment of adult patients with inflammation of the posterior segment of the eye presenting as non-infectious uveitis.

An intravitreal implant containing flucinolone acetonide p. 1091 (Fluoven®) is licensed for the treatment of visual impairment associated with chronic diabetic macular oedema which is insufficiently responsive to available therapies. It should be administered by specialists experienced in the use of intravitreal injections.

Other anti-inflammatory preparations

Other preparations used for the topical treatment of inflammation and allergic conjunctivitis include antihistamines, lodoxamide p. 1060, and sodium cromoglicate p. 1060.

Eye drops containing antihistamines, such as antazoline (with xylometazoline hydrochloride p. 1100 as Otrivine-Antistin®), azelastine hydrochloride p. 1059, epinastine hydrochloride p. 1059, ketotifen p. 1059, and olopatadine p. 1060, can be used for allergic conjunctivitis.

Sodium cromoglicate (sodium cromoglycate) and nedocromil sodium eye drops p. 1060 can be useful for vernal keratoconjunctivitis and other allergic forms of conjunctivitis.
Lodoxamide eye drops are used for allergic conjunctival conditions including seasonal allergic conjunctivitis. Diclofenac sodium eye drops, p. 1077 and emedastine eye drops, below, are also licensed for seasonal allergic conjunctivitis.

Non-steroidal anti-inflammatory eye drops are used for the prophylaxis and treatment of inflammation of the eye following surgery or laser treatment.

Ciclosporin p. 1064 is licensed for severe keratitis in patients with dry eye disease, which has not improved despite treatment with tear substitutes.

1.1 Allergic conjunctivitis

### Antihistamines

#### Azelastine with xylometazoline

**INDICATIONS AND DOSE**

- **Allergic conjunctivitis**
  - **TO THE EYE**
  - Child 12-17 years: Apply 2–3 times a day for maximum 7 days
  - Adult: Apply 2–3 times a day for maximum 7 days

**CAUTIONS**

- Angle-closure glaucoma
- Cardiovascular disease
- Diabetes mellitus
- Hypertension
- Hyperthyroidism
- Phaeochromocytoma
- Urinary retention

**INTERACTIONS**

- Antihistamines (non-sedating)
- Mydriatics
- Non-steroidal anti-inflammatory agents

**SIDE-EFFECTS**

- Common or very common: Transient stinging
- Frequency not known: Blurred vision, eye irritation, mydriasis

**MEDICINAL FORMS**

- **Eye drops**
  - **EXCIPIENTS:** May contain Benzalkonium chloride, disodium edetate
  - **Antazoline with Xylometazoline**
    - Xylometazoline hydrochloride 500 microgram per 1 ml, Antazoline sulphate 5 mg per 1 ml
    - Otrivine Antistin (Thea Pharmaceuticals Ltd)
    - Optidrops (Hoffmann-La Roche Ltd)
      - Optidrops 0.05% eye drops | 8 ml ($\text{P}$$\text{X}) £6.40 DT price = £6.40

**SIDE-EFFECTS, FURTHER INFORMATION**

Absorption of antazoline and xylometazoline may result in systemic side-effects.

#### Azelastine hydrochloride

**INDICATIONS AND DOSE**

- **Seasonal allergic conjunctivitis**
  - **TO THE EYE**
  - Child 12–17 years: Apply twice daily for maximum 7 days
  - Adult: Apply twice daily for maximum 8 weeks

**INTERACTIONS**

- Appendices 1 and 2: antihistamines (sedating)

**SIDE-EFFECTS**

- Common or very common: Photophobia, rhinitis, transient burning, transient stinging

**MEDICINAL FORMS**

- **Eye drops**
  - **EXCIPIENTS:** May contain Benzalkonium chloride, disodium edetate
  - **Azelastine**
    - Azelastine hydrochloride 500 microgram per 1 ml
      - Optidrops 0.05% eye drops | 8 ml ($\text{P}$$\text{X}) £6.40 DT price = £6.40

**SIDE-EFFECTS**

- Common or very common: Photophobia, rhinitis, transient burning, transient stinging

**MEDICINAL FORMS**

- **Eye drops**
  - **EXCIPIENTS:** May contain Benzalkonium chloride
  - **Emedastine**
    - Emedastine (as Emedastine difumarate) 500 microgram per 1 ml
      - Emadine 0.5mg/ml eye drops | 5 ml ($\text{P}$$\text{X}) £7.31 DT price = £7.31

#### Epinastine hydrochloride

**INDICATIONS AND DOSE**

- **Seasonal allergic conjunctivitis**
  - **TO THE EYE**
  - Child 12–17 years: Apply twice daily for maximum 7 days
  - Adult: Apply twice daily for maximum 8 weeks

**INTERACTIONS**

- Appendices 1 and 2: antihistamines (sedating)

**SIDE-EFFECTS**

- Common or very common: Photophobia, rhinitis, transient burning, transient stinging

**MEDICINAL FORMS**

- **Eye drops**
  - **EXCIPIENTS:** May contain Benzalkonium chloride, disodium edetate
  - **Epinastine**
    - Epinastine hydrochloride 500 microgram per 1 ml
      - Relestat (Allergan Ltd)
        - Relestat 500micrograms/ml eye drops | 5 ml ($\text{P}$$\text{X}) £9.90 DT price = £9.90

#### Ketotifen

**INDICATIONS AND DOSE**

- **Seasonal allergic conjunctivitis**
  - **TO THE EYE**
  - Child 3–17 years: Apply twice daily
  - Adult: Apply twice daily

**INTERACTIONS**

- Appendices 1 and 2: antihistamines (sedating)

**SIDE-EFFECTS**

- Common or very common: Punctate corneal epithelial erosion, transient burning, transient stinging
- Uncommon: Dry eye, photophobia, subconjunctival haemorrhage
- Frequency not known: Drowsiness, dry mouth, headache, skin reactions
**1060 Allergic and inflammatory eye conditions**

**Mast-cell stabilisers**

**Lodoxamide**

- **indications and dose**
  - **seasonal allergic conjunctivitis**
    - TO THE EYE
    - Child 4–17 years: Apply 4 times a day, improvement of symptoms may sometimes require treatment for up to 4 weeks
    - Adult: Apply 4 times a day, improvement of symptoms may sometimes require treatment for up to 4 weeks

- **side-effects**
  - **common or very common**
    - Blurred vision
    - Burning
    - Itching
    - Ocular discomfort
    - Stinging
    - Tear production disturbance
  - **uncommon**
    - Blepharitis
    - Dizziness
    - Drowsiness
    - Flushing
    - Headache
    - Keratitis
    - Nasal dryness

- **exceptions to legal category**
  - **loadoxamide 0.1%**

- **medicinal forms**
  - There can be variation in the licensing of different medicines containing the same drug.

  **eye drops**
  - **excipients:** May contain benzalkonium chloride
  - **zaditen** (thea pharmaceuticals ltd)
    - Loadoxime (as loadoxime trometamol) 1 mg per 1 ml
  - **alomide** (alcon laboratories (uk) ltd)
    - Alomide 0.1% eye drops | 10 ml | £5.21
    - Alomide Allergy 0.1% eye drops | 5 ml | £3.12

**Nedocromil sodium**

- **indications and dose**
  - **seasonal and perennial conjunctivitis**
    - TO THE EYE
    - Child 6–17 years: Apply twice daily, increased if necessary to 4 times a day, max. 12 weeks duration of treatment for seasonal allergic conjunctivitis
    - Adult: Apply twice daily, increased if necessary to 4 times a day, max. 12 weeks duration of treatment for seasonal allergic conjunctivitis

- **medicinal forms**
  - There can be variation in the licensing of different medicines containing the same drug.

  **eye drops**
  - **excipients:** May contain benzalkonium chloride, disodium edetate
  - **rapitil** (sanofi)
    - Nedocromil sodium 20 mg per 1 ml
    - Rapitil 2% eye drops | 5 ml | £2.86

**sodium cromoglicate**

- **indications and dose**
  - **allergic conjunctivitis**
    - TO THE EYE
    - Child: Apply 4 times a day
    - Adult: Apply 4 times a day

- **side-effects**
  - Transient burning • transient stinging

- **exceptions to legal category**
  - Sodium cromoglicate 2% eye drops can be sold to the public (in max. pack size of 10 mL) for treatment of acute seasonal and perennial allergic conjunctivitis

- **medicinal forms**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops

  **eye drops**
  - **sodium cromoglicate (non-proprietary)**
    - Sodium cromoglicate 20 mg per 1 ml
    - Sodium cromoglicate 2% eye drops | 13.5 ml | £8.03
  - **cromolux** (tubilux pharma ltd)
    - Sodium cromoglicate 20 mg per 1 ml
    - Cromolux 2% eye drops | 13.5 ml | £3.20
  - **opticrom** (sanofi)
    - Sodium cromoglicate 20 mg per 1 ml
    - Opticrom aqueous 2% eye drops | 13.5 ml | £8.03
  - **vividrin** (bausch & lomb uk ltd)
    - Sodium cromoglicate 20 mg per 1 ml
    - Vividrin 2% eye drops | 13.5 ml | £10.95

---

**medicinal forms**

There can be variation in the licensing of different medicines containing the same drug.

**side-effects**

- **common or very common**
  - Local irritation
- **uncommon**
  - Asthenia
  - Dizziness
  - Dry eye
  - Headache
  - Keratitis
  - Local oedema
  - Photophobia
  - Tear production disturbance
  - Transient burning
  - Transient stinging

**exceptions to legal category**

- **Loadoxime**
  - Contains the same drug. Forms available from special-order manufacturers include: eye drops

  **eye drops**
  - **excipients:** May contain benzalkonium chloride, disodium edetate
  - **zaditen** (thea pharmaceuticals ltd)
    - Loadoxime (as loadoxime trometamol) 1 mg per 1 ml
  - **alomide** (alcon laboratories (uk) ltd)
    - Alomide 0.1% eye drops | 10 ml | £5.21
    - Alomide Allergy 0.1% eye drops | 5 ml | £3.12

---

**medicinal forms**

There can be variation in the licensing of different medicines containing the same drug.

**side-effects**

- **common or very common**
  - Local irritation
- **uncommon**
  - Asthenia
  - Dizziness
  - Dry eye
  - Headache
  - Keratitis
  - Local oedema
  - Photophobia
  - Tear production disturbance
  - Transient burning
  - Transient stinging

---

**indications and dose**

- **seasonal allergic conjunctivitis**
  - TO THE EYE
  - Child 3–17 years: Apply twice daily for maximum 4 months
  - Adult: Apply twice daily for maximum 4 months

**medicinal forms**

There can be variation in the licensing of different medicines containing the same drug.

**eye drops**

- **excipients:** May contain benzalkonium chloride
- **opatanol** (alcon laboratories (uk) ltd)
  - Loadoxime (as loadoxime hydrochloride) 1 mg per 1 ml
- **napatanol** (Q8 Laboratories Ltd)
  - Sodium cromoglicate 20 mg per 1 ml
    - Opatanol 1% eye drops | 5 ml | £4.68

---

**medicinal forms**

There can be variation in the licensing of different medicines containing the same drug.

**eye drops**

- **excipients:** May contain benzalkonium chloride, disodium edetate
- **rapitil** (sanofi)
  - Nedocromil sodium 20 mg per 1 ml
  - Rapitil 2% eye drops | 5 ml | £2.86

---

**medicinal forms**

There can be variation in the licensing of different medicines containing the same drug.

**eye drops**

- **excipients:** May contain benzalkonium chloride, disodium edetate
- **alomide** (alcon laboratories (uk) ltd)
  - Alomide 0.1% eye drops | 10 ml | £5.21
  - Alomide Allergy 0.1% eye drops | 5 ml | £3.12

---

**indications and dose**

- **seasonal allergic conjunctivitis**
  - TO THE EYE
  - Child 3–17 years: Apply twice daily for maximum 4 months
  - Adult: Apply twice daily for maximum 4 months

**medicinal forms**

There can be variation in the licensing of different medicines containing the same drug.

**eye drops**

- **excipients:** May contain benzalkonium chloride, disodium edetate
- **zaditen** (thea pharmaceuticals ltd)
  - Loadoxime (as loadoxime trometamol) 1 mg per 1 ml
- **alomide** (alcon laboratories (uk) ltd)
  - Alomide 0.1% eye drops | 10 ml | £5.21
  - Alomide Allergy 0.1% eye drops | 5 ml | £3.12
1.2 Inflammatory eye conditions

Other drugs used for Inflammatory eye conditions
Adalimumab, p. 1008

ANALGESICS ▶ NON-STERoidal ANTI-INFLAMMATORY DRUGS

Nepafenac

● INDICATIONS AND DOSE
Prophylaxis and treatment of postoperative pain and inflammation associated with cataract surgery
Reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients
▶ TO THE EYE
▶ Child:
▶ Adult:

● CAUTIONS
Avoid sunlight, corneal epithelial breakdown (if evidence of, then discontinue immediately)

● INTERACTIONS
▶ Appendix 1: NSAIDs

● SIDE-EFFECTS
▶ Common or very common
Punctate keratitis
▶ Uncommon
Allergic conjunctivitis, blurred vision, choroidal effusion, conjunctival hyperaemia, corneal deposits, corneal epithelial defect, dry eye, eye pruritus, headache, increased lacrimation, iris, keratitis, nausea, ocular discomfort, photophobia
▶ Frequency not known
Corneal opacity, dermatochalasis, dizziness, eye swelling, impaired corneal healing, reduced visual acuity

● NATIONAL FUNDING/ACCESS DECISIONS
Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (May 2017) that nepafenac (Nevanac®) 3 mg/mL eye drops are accepted for use within NHS Scotland for the reduction in risk of postoperative macular oedema associated with cataract surgery in diabetic patients.

● MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Eye drops
EXCIPIENTS: May contain Benzalkonium chloride, disodium edetate
▶ Nevanac (Acon Laboratories (UK) Ltd)
Nepafenac 1 mg per 1 ml Nevanac 1mg/ml eye drops | 5 ml £14.92

CORTICOSTEROIDS

Betamethasone

● INDICATIONS AND DOSE
Local treatment of inflammation (short-term)
▶ TO THE EYE USING EYE DROP
▶ Child:
▶ Adult:

▶ TO THE EYE USING EYE OINTMENT
▶ Child:
▶ Adult:

● INTERACTIONS
▶ Appendix 1: corticosteroids

● SIDE-EFFECTS
Corneal thinning, scleral thinning

● MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Ear/eye/nose drops solution
EXCIPIENTS: May contain Benzalkonium chloride, disodium edetate
▶ Betamethasone (Non-proprietary)
Betamethasone sodium phosphate 1 mg per 1 ml Betamethasone 0.1% eye/nose drops | 5 ml £0.87
▶ Betnesol (Focus Pharmaceuticals Ltd)
Betamethasone sodium phosphate 1 mg per 1 ml Betnesol 0.1% eye/nose drops | 10 ml £2.32
▶ Vistamethasone (Martindale Pharmaceuticals Ltd)
Betamethasone sodium phosphate 1 mg per 1 ml Vistamethasone 0.1% eye/ear/nose drops | 5 ml £0.99

Eye ointment
▶ Betnesol (Focus Pharmaceuticals Ltd)
Betamethasone sodium phosphate 1 mg per 1 gram Betnesol 0.1% eye ointment | 3 gram £1.41

Combinations available: Betamethasone with neomycin, p. 1063

Dexamethasone

● INDICATIONS AND DOSE
Local treatment of inflammation (short-term)
▶ TO THE EYE USING EYE DROP
▶ Child:
▶ Adult:

▶ TO THE EYE USING EYE OINTMENT
▶ Child:
▶ Adult:

● UNLICENSED USE

● CONTRA-INDICATIONS
▶ With intravitreal use
Active ocular herpes simplex - active or suspected ocular infection - active or suspected periorcular infection - rupture of the posterior lens capsule in patients with aphakia, iris or transscleral fixated intra-ocular lens or anterior chamber intra-ocular lens - uncontrolled advanced glaucoma

● CAUTIONS
▶ With intravitreal use
History of ocular viral infection (including herpes simplex) - posterior capsule tear or iris defect (risk of implant migration into the anterior chamber which may cause corneal oedema and, in persistent severe cases, the need for corneal transplantation) - retinal vein occlusion with significant retinal ischaemia

● INTERACTIONS
▶ Appendix 1: corticosteroids

Downloaded from www.medicalbr.com
**SIDE-EFFECTS**

- **Uncommon**
  - With intravitreal use: Eyelid pruritus · glaucoma · migraine · necrotising retinitis
- **Frequency not known**
  - When used by eye: Corneal thinning · scleral thinning
  - With intravitreal use: Bacterial endophthalmitis · endophthalmitis · intravitreal haemorrhage · necrotising retinitis

**PREGNANCY**

Dexamethasone readily crosses the placenta.

- With intravitreal use: Manufacturer advises avoid unless potential benefit outweighs risk — no information available.

**BREAST FEEDING**

- With intravitreal use: Manufacturer advises avoid unless potential benefit outweighs risk — no information available.

**MONITORING REQUIREMENTS**

- With intravitreal use: Monitor intra-ocular pressure and for signs of ocular infection. In patients with posterior capsule tear or iris defect monitor for implant migration to allow for; early diagnosis and management.

**PRESCRIBING AND DISPENSING INFORMATION**

Although multi-dose Dexamethasone eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

**NATIONAL FUNDING/ACCESS DECISIONS**

- **NICE technology appraisals (TAs)**

  Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion (July 2011) NICE TA229

  Dexamethasone intravitreal implant is recommended as an option for the treatment of macular oedema following central retinal vein occlusion. Dexamethasone intravitreal implant is also recommended as an option for the treatment of macular oedema following branch retinal vein occlusion when:
  - treatment with laser photocoagulation has not been beneficial, or
  - treatment with laser photocoagulation is not considered suitable because of the extent of macular haemorrhage.

  [www.nice.org.uk/TA229](http://www.nice.org.uk/TA229)

  Dexamethasone intravitreal implant for treating diabetic macular oedema (July 2015) NICE TA349

  Dexamethasone intravitreal implant is recommended as an option for treating diabetic macular oedema only if:
  - the implant is to be used in an eye with an intraocular (pseudophakic) lens and
  - the diabetic macular oedema does not respond to non-corticosteroid treatment, or such treatment is unsuitable.

  [www.nice.org.uk/TA349](http://www.nice.org.uk/TA349)

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (May 2012) that dexamethasone intravitreal implant (Ozurdex®) is accepted for restricted use within NHS Scotland for the treatment of adults with macular oedema (i) following central retinal vein occlusion, and (ii) with branch retinal vein occlusion who are not clinically suitable for laser treatment, including patients with dense macular haemorrhage, or patients who have received and failed on previous laser treatment.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops

- **Eye drops**

  **EXCIPIENTS:** May contain Benzalkonium chloride, disodium edetate, polysorbates

  » **Dexamethasone (Non-proprietary)**

  Dexamethasone sodium phosphate 1 mg per 1 ml (Dexamethasone 0.1% eye drops 0.4ml unit dose preservative free) | 20 unit dose (Pom) £9.75 DT price = £9.75

  Minims dexamethasone 0.1% eye drops 0.5ml unit dose | 20 unit dose (Pom) £11.46 DT price = £11.46

  » **Dexafree** (Thea Pharmaceuticals Ltd)

  Dexamethasone sodium phosphate 1 mg per 1 ml (Dexafree 1mg/1ml eye drops 0.4ml unit dose) | 30 unit dose (Pom) £9.70

  » **Droplex** (Rayner Pharmaceuticals Ltd)

  Dexamethasone sodium phosphate 1 mg per 1 ml (Droplex 0.1% eye drops 0.4ml unit dose) | 20 unit dose (Pom) £9.75 DT price = £9.75

  » **Maxided** (Alcon Laboratories (UK) Ltd)

  Dexamethasone 1 mg per 1 ml (Maxided 0.1% eye drops | 5 ml (Pom) £1.42 DT price = £1.42 | 10 ml (Pom) £2.80 DT price = £2.80

  **Implant**

  » **Ozurdex** (Allergan Ltd)

  Dexamethasone 700 microgram (Ozurdex 700microgram intravitreal implant in applicator | 1 device (Pom) £870.00 (Hospital only)

  **Combinations available:**

  » **Dexamethasone with framycetin sulfate and gramicidin**, p. 1063 · **Dexamethasone with hyromellose, neomycin and polymyxin B sulfate**, p. 1063 · **Dexamethasone with tobramycin**, p. 1064

**Fluorometholone**

- **INDICATIONS AND DOSE**

  **Local treatment of inflammation (short term)**

  » **TO THE EYE**

  Child 2–17 years: Apply every 1 hour for 24–48 hours, then reduced to 2–4 times a day

  Adult: Apply every 1 hour for 24–48 hours, then reduced to 2–4 times a day

- **SIDE-EFFECTS**

  Corneal thinning · scleral thinning

**Prednisolone**

- **INDICATIONS AND DOSE**

  **Local treatment of inflammation (short-term)**

  » **TO THE EYE**

  Child: Apply every 1–2 hours until controlled then reduce frequency

  Adult: Apply every 1–2 hours until controlled then reduce frequency

- **UNLICENSED USE**

  Pred Forte® not licensed for use in children (age range not specified by manufacturer).

- **INTERACTIONS**
  - Appendix 1: corticosteroids

- **SIDE-EFFECTS**
  - Corneal thinning · scleral thinning

- **PRESCRIBING AND DISPENSING INFORMATION**

  Although multi-dose prednisolone eye drops commonly contain preservatives, preservative-free unit dose vials may be available.
**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops

**Eye drops**
EXCIPIENTS: May contain Benzalkonium chloride, disodium edetate, polysorbates

▶ Prednisolone (Non-proprietary)
  Prednisolone sodium phosphate 5 mg per 1 ml. Minims prednisolone sodium phosphate 0.5% eye drops 0.5 ml unit dose | 20 unit dose (£9.55) £11.78 DT price = £11.78
  Pred Forte (Allergan Ltd)
  Prednisolone acetate 10 mg per 1 ml. Pred Forte 1% eye drops | 5 ml (£52) £1.82 DT price = £1.82 | 10 ml (£94) £3.66 DT price = £3.66

**Ey/ear drops solution**
EXCIPIENTS: May contain Benzalkonium chloride, disodium edetate

▶ Predsol (Focus Pharmaceuticals Ltd)
  Prednisolone sodium phosphate 5 mg per 1 ml. Predsol 0.5% eye/ear drops | 10 ml (£70) £2.00 DT price = £2.00

**SIDE-EFFECTS**
Corneal thinning • scleral thinning

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. No licensed medicines listed.

**CORTICOSTEROIDS**

**Rimexolone**

▶ **INDICATIONS AND DOSE**
Local treatment of postoperative inflammation (short term use)
▶ TO THE EYE
  Adult: Apply 4 times a day for 2 weeks, treatment to begin 24 hours after surgery

Local treatment of steroid-responsive inflammation (short term use)
▶ TO THE EYE
  Adult: Apply in at least 4 times a day divided doses for up to 4 weeks

Uveitis (short term use)
▶ TO THE EYE
  Adult: Apply every 1 hour during the day time for week 1, then apply every 2 hours for week 2, then apply 4 times a day for week 3, then apply twice daily for the first 4 days of week 4, then apply once daily for the remaining 3 days of week 4

**LESS SUITABLE FOR PRESCRIBING**

**Betamethasone with neomycin**

The properties listed below are those particular to the combination only. For the properties of the components please consider, betamethasone p. 1061, neomycin sulfate p. 492.

▶ **INDICATIONS AND DOSE**
Local treatment of eye inflammation and bacterial infection (short-term)
▶ TO THE EYE USING EYE DROP
  Adult: Apply up to 6 times a day

**LESS SUITABLE FOR PRESCRIBING**
Betamethasone with neomycin eye-drops are less suitable for prescribing.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Eye/ear/nose drops solution**
EXCIPIENTS: May contain Benzalkonium chloride, disodium edetate

▶ Betnesol-N (Focus Pharmaceuticals Ltd)
  Betamethasone (as Betamethasone sodium phosphate) 1 mg per 1 ml, Neomycin sulfate 5 mg per 1 ml. Betnesol-N ear/eye/nose drops | 10 ml (£70) £2.39 DT price = £2.39

**Dexamethasone with framycetin sulfate and gramicidin**

The properties listed below are those particular to the combination only. For the properties of the components please consider, dexamethasone p. 1061, framycetin sulfate p. 1094.

▶ **INDICATIONS AND DOSE**
Local treatment of inflammation (short-term)
▶ TO THE EYE
  Child: Apply 4–6 times a day, may be administered every 30–60 minutes in severe conditions until controlled, then reduce frequency
  Adult: Apply 4–6 times a day, may be administered every 30–60 minutes in severe conditions until controlled, then reduce frequency

**LESS SUITABLE FOR PRESCRIBING**

**Dexamethasone with hyromellose, neomycin and polymyxin B sulfate**

The properties listed below are those particular to the combination only. For the properties of the components please consider, dexamethasone p. 1061, neomycin sulfate p. 492.

▶ **INDICATIONS AND DOSE**
Local treatment of inflammation (short-term)
▶ TO THE EYE USING EYE DROP
  Adult: Apply every 30–60 minutes until controlled, then reduced to 4–6 times a day
  TO THE EYE USING EYE OINTMENT
  Adult: Apply 3–4 times a day, alternatively, apply at night when used with eye drops

**LESS SUITABLE FOR PRESCRIBING**
Dexamethasone with neomycin and polymyxin B sulfate is less suitable for prescribing.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Eye ointment**
EXCIPIENTS: May contain Hydroxybenzoates (parabens), wool fat and related substances including lanolin

▶ Maxitrol (Alcon Laboratories (UK) Ltd)
  Dexamethasone 1 mg per 1 gram, Neomycin (as Neomycin sulfate) 3500 unit per 1 gram, Polymyxin B sulfate 6000 unit per 1 gram. Maxitrol eye ointment | 3.5 gram (£70) £1.44

**Dexomethasone with neomycin**

The properties listed below are those particular to the combination only. For the properties of the components please consider, dexamethasone p. 1061, neomycin sulfate p. 1094.

▶ **INDICATIONS AND DOSE**
Local treatment of inflammation (short-term)
▶ TO THE EYE
  Adult: Apply 4–6 times a day, may be administered every 30–60 minutes in severe conditions until controlled, then reduce frequency

**LESS SUITABLE FOR PRESCRIBING**
Sofradex® is less suitable for prescribing.

**Dexamethasone with framycetin**

The properties listed below are those particular to the combination only. For the properties of the components please consider, dexamethasone p. 1061, framycetin sulfate p. 1094.

▶ **INDICATIONS AND DOSE**
Local treatment of inflammation (short-term)
▶ TO THE EYE
  Child: Apply 4–6 times a day, may be administered every 30–60 minutes in severe conditions until controlled, then reduce frequency
  Adult: Apply 4–6 times a day, may be administered every 30–60 minutes in severe conditions until controlled, then reduce frequency

**LESS SUITABLE FOR PRESCRIBING**

**Betamethasone with neomycin**

The properties listed below are those particular to the combination only. For the properties of the components please consider, betamethasone p. 1061, neomycin sulfate p. 492.

▶ **INDICATIONS AND DOSE**
Local treatment of eye inflammation and bacterial infection (short-term)
▶ TO THE EYE USING EYE DROP
  Adult: Apply up to 6 times a day

**LESS SUITABLE FOR PRESCRIBING**
Betamethasone with neomycin eye-drops are less suitable for prescribing.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Eye/ear/nose drops solution**
EXCIPIENTS: May contain Benzalkonium chloride, disodium edetate

▶ Betnesol-N (Focus Pharmaceuticals Ltd)
  Betamethasone (as Betamethasone sodium phosphate) 1 mg per 1 ml, Neomycin sulfate 5 mg per 1 ml. Betnesol-N ear/eye/nose drops | 10 ml (£70) £2.39 DT price = £2.39

**Dexamethasone with framycetin**

The properties listed below are those particular to the combination only. For the properties of the components please consider, dexamethasone p. 1061, framycetin sulfate p. 1094.

▶ **INDICATIONS AND DOSE**
Local treatment of inflammation (short-term)
▶ TO THE EYE
  Adult: Apply 4–6 times a day, may be administered every 30–60 minutes in severe conditions until controlled, then reduce frequency

**LESS SUITABLE FOR PRESCRIBING**
Sofradex® is less suitable for prescribing.

**Dexamethasone with framycetin**

The properties listed below are those particular to the combination only. For the properties of the components please consider, dexamethasone p. 1061, framycetin sulfate p. 1094.

▶ **INDICATIONS AND DOSE**
Local treatment of inflammation (short-term)
▶ TO THE EYE
  Child: Apply 4–6 times a day, may be administered every 30–60 minutes in severe conditions until controlled, then reduce frequency
  Adult: Apply 4–6 times a day, may be administered every 30–60 minutes in severe conditions until controlled, then reduce frequency

**LESS SUITABLE FOR PRESCRIBING**
Sofradex® is less suitable for prescribing.

**Dexamethasone with framycetin**

The properties listed below are those particular to the combination only. For the properties of the components please consider, dexamethasone p. 1061, framycetin sulfate p. 1094.

▶ **INDICATIONS AND DOSE**
Local treatment of inflammation (short-term)
▶ TO THE EYE
  Child: Apply 4–6 times a day, may be administered every 30–60 minutes in severe conditions until controlled, then reduce frequency
  Adult: Apply 4–6 times a day, may be administered every 30–60 minutes in severe conditions until controlled, then reduce frequency

**LESS SUITABLE FOR PRESCRIBING**
Sofradex® is less suitable for prescribing.

**Dexamethasone with framycetin**

The properties listed below are those particular to the combination only. For the properties of the components please consider, dexamethasone p. 1061, framycetin sulfate p. 1094.

▶ **INDICATIONS AND DOSE**
Local treatment of inflammation (short-term)
▶ TO THE EYE
  Child: Apply 4–6 times a day, may be administered every 30–60 minutes in severe conditions until controlled, then reduce frequency
  Adult: Apply 4–6 times a day, may be administered every 30–60 minutes in severe conditions until controlled, then reduce frequency

**LESS SUITABLE FOR PRESCRIBING**
Sofradex® is less suitable for prescribing.
Eye 
INHIBITORS AND RELATED DRUGS

LESS SUITABLE FOR PRESCRIBING  Dexamethasone with tobramycin eye-drops are less suitable for prescribing.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops, eye ointment

Eye drops
EXCIPIENTS: May contain Benzalkonium chloride, disodium edetate
- Maxitrol (Alcon Laboratories (UK) Ltd)
  Dexamethasone 1 mg per ml, Hyponemulose 5 mg per 1 ml, Neomycin (as Neomycin sulfate) 3500 unit per 1 ml, Polymyxin B sulfate 6000 unit per 1 ml Maxitrol eye drops | 5 ml | £1.68

IMMUNOSUPPRESSANTS ★ CALCINEURIN INHIBITORS AND RELATED DRUGS

Ciclosporin (Cyclosporin)

DRUG ACTION  Ciclosporin inhibits production and release of lymphokines, thereby suppressing cell-mediated immune response.

INDICATIONS AND DOSE
Severe keratitis in dry eye disease that has not responded to treatment with tear substitutes (initiated by a specialist)
- TO THE EYE
- Adult: Apply 1 drop at bedtime, review treatment at least every 6 months

CONTRA-INDICATIONS  Active or suspected ocular or periocular infection

CAUTIONS  Glaucome—limited information available · history of ocular herpes—no information available

INTERACTIONS  → Appendix 1: ciclosporin

SIDE-EFFECTS
- Common or very common  Blurred vision · instillation site pain · local erythema · local irritation · local oedema · local pain · ocular hyperaemia
- Uncommon  Bacterial keratitis · blepharitis · chalazion · conjunctivitis · corneal decompensation · corneal infiltrates · corneal scar · eye discharge · herpes zoster (ophthalmic) · iridocyclitis · keratitis · local pruritus

CONCEPTION AND CONTRACEPTION  Manufacturer recommends effective contraception during treatment in women of child-bearing potential.

PREGNANCY  Manufacturer advises avoid unless potential benefit outweighs risk—no information available.

BREAST FEEDING  Manufacturer advises avoid—limited information.

DIRECTIONS FOR ADMINISTRATION  Keep eyes closed for 2 minutes after using Ikervis® eye drops, to increase local drug action and reduce systemic absorption.

NATIONAL FUNDING/ACCESS DECISIONS
NICE technology appraisals (TAs)
- Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears (December 2015) NICE TA369
  Ciclosporin (Ikervis®) is recommended as an option for treating dry eye disease that has not improved despite treatment with tear substitutes.
  www.nice.org.uk/TA369

1.2a Anterior uveitis

ANTIMUSCARINICS

Antimuscarinics (eye)

CAUTIONS  Children under 3 months owing to the possible association between cycloplegia and the development of amblyopia · darkly pigmented iris is more resistant to pupillary dilatation and caution should be exercised to avoid overdosage · mydriasis can precipitate acute angle-closure glaucoma (usually in those aged over 60 years and hypermetropic (long-sighted), who are predisposed to the condition because of a shallow anterior chamber)

SIDE-EFFECTS  Conjunctivitis (on prolonged administration) · contact dermatitis · eye oedema (on prolonged administration) · hyperaemia (on prolonged administration) · local irritation (on prolonged administration) · raised intraocular pressure · transient stinging

PATIENT AND CARER ADVICE  Patients may not be able to undertake skilled tasks until vision clears after mydriasis.

Atropine sulfate

INDICATIONS AND DOSE
Cycloplegia
- TO THE EYE USING EYE DROP
- Adult: (consult product literature)

Anterior uveitis
- TO THE EYE USING EYE DROP
- Adult: (consult product literature)

INTERACTIONS  → Appendix 1: atropine

SIDE-EFFECTS  Systemic side-effects can occur, particularly in children and the elderly.

PRESCRIBING AND DISPENSING INFORMATION
Although multi-dose atropine sulphate eye drops commonly contain preservatives, preservative-free unit dose vials may be available.
Dry eye conditions

Dry eye

Tear deficiency, ocular lubricants, and astringents

Chronic soreness of the eyes associated with reduced or abnormal tear secretion (e.g. in Sjögren’s syndrome) often responds to tear replacement therapy or pilocarpine p. 1105 given by mouth in adults. The severity of the condition and patient preference will often guide the choice of preparation. Hypromellose p. 1067 is the traditional choice of treatment for tear deficiency. It may need to be instilled frequently (e.g. hourly) for adequate relief. Ocular surface mucin is often abnormal in tear deficiency and the combination of hypromellose with a mucolytic such as acetylcysteine below can be helpful.

The ability of carbomers to cling to the eye surface may help reduce frequency of application to 4 times daily. Polyvinyl alcohol p. 1068 increases the persistence of the tear film and is useful when the ocular surface mucin is reduced.

Sodium hyaluronate eye drops p. 1068 are also used in the management of tear deficiency. Sodium chloride 0.9% drops p. 1068 are sometimes useful in tear deficiency, and can be used as ‘comfort drops’ by contact lens wearers, and to facilitate lens removal. They are also used to irrigate the eye. Special presentations of sodium chloride 0.9% and other irrigation solutions are used routinely for intra-ocular surgery. Sodium chloride 5% eye drops are used for the short-term treatment of corneal oedema in adults.

Eye ointments containing a paraffin can be used to lubricate the eye surface, especially in cases of recurrent corneal epithelial erosion. They may cause temporary visual disturbance and are best suited for application before sleep. Ointments should not be used during contact lens wear.

Ocular lubricants

Acetylcysteine

07-Feb-2017

INDICATIONS AND DOSE

Tear deficiency | Impaired or abnormal mucus production

TO THE EYE

Adult: Apply 3–4 times a day

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops

Eye drops

EXCIPIENTS: May contain Benzalkonium chloride

Cyclopentolate hydrochloride (Bausch & Lomb UK Ltd)

Cyclopentolate hydrochloride 5 mg per 1 ml Minims cyclopentolate hydrochloride 0.5% eye drops 0.5ml unit dose | 20 unit dose Pom £10.97 DT price = £10.97

Cyclopentolate hydrochloride 10 mg per 1 ml Minims cyclopentolate hydrochloride 1% eye drops 0.5ml unit dose | 20 unit dose Pom £11.23 DT price = £11.23

Mydriate (Intrapharm Laboratories Ltd)

Cyclopentolate hydrochloride 5 mg per 1 ml Mydriate 0.5% solution | 5 ml Pom £6.73 DT price = £6.73

Cyclopentolate hydrochloride 10 mg per 1 ml Mydriate 1% solution | 5 ml Pom £6.73 DT price = £6.73

Carbomers

(Polycrylic acid)

INDICATIONS AND DOSE

Dry eyes including keratoconjunctivitis sicca, unstable tear film

TO THE EYE

Child: Apply 3–4 times a day or when required

Adult: Apply 3–4 times a day or when required

UNLICENSED USE

Some preparations not licensed for use in children.
**PRESCRIBING AND DISPENSING INFORMATION**  
Synthetic high molecular weight polymers of acrylic acid cross-linked with either allyl ethers of sucrose or allyl ethers of pentaerithryl.

**MEDICINAL FORMS**  
There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**  
**EXCipients:** May contain Benzalkonium chloride, cetrimide, disodium edetate.

- **Blephagel** (Thea Pharmaceuticals Ltd)
  - **Carbomer 3.5 mg per 1 gram** Blephagel 0.35% eye gel  |  40 gram £6.66
  - **Carbomer 3.6 mg per 1 gram** Blephagel 0.36% eye gel preservative free  |  30 gram £7.53

- **Liquivisc** (Thea Pharmaceuticals Ltd)
  - **Carbomer 974P 2.5 mg per 1 gram** Liquivisc 0.25% eye gel  |  10 gram £4.50 DT price = £4.50

**Eye drops**  
- **Carbomers (Non-proprietary)**
  - **Carbomer 980 2 mg per 1 gram** EyeGel 0.2% eye gel  |  10 gram £2.80 DT price = £2.80
  - **Carbomer 980 3 mg per 1 gram** EyeGel 0.3% eye gel  |  10 gram £2.80 DT price = £2.80
  - **Artelac Nighttime** (Bausch & Lomb UK Ltd)
    - **Artelac Nighttime 2.5 mg per 1 gram** Artelac Nighttime 0.2% eye gel  |  10 gram £2.96 DT price = £2.80
  - **Clinitas Carbomer** (Alltacor Ltd)
    - **Carbomer 980 2 mg per 1 gram** Clinitas Carbomer 0.2% eye gel  |  10 gram £1.49 DT price = £2.80
  - **GelTears** (Bausch & Lomb UK Ltd)
    - **Carbomer 980 2 mg per 1 gram** GelTears 0.2% gel  |  10 gram £2.80 DT price = £2.80
  - **Lumecare Long Lasting** (Medicomp Healthcare Ltd)
    - **Carbomer 980 2 mg per 1 gram** Lumecare Carbomer 0.2% eye gel  |  10 gram £1.51 DT price = £2.80
  - **Viscotears** (Bausch & Lomb UK Ltd)
    - **Carbomer 980 2 mg per 1 gram** Viscotears 2mg/g liquid gel  |  10 gram £1.59 DT price = £2.80
    - **Viscotears 5 mg/g eye gel 0.5ml unit dose**  |  30 unit dose £5.42 DT price = £5.42
  - **Xailin** (Nicox Pharma)
    - **Carbomer 980 2 mg per 1 gram** Xailin 0.2% eye gel  |  10 gram £3.25 DT price = £2.80

**Carmellose sodium**

**INDICATIONS AND DOSE**  
**Dry eye conditions**

- **TO THE EYE**
  - Child: Apply as required
  - Adult: Apply as required

**PRESCRIBING AND DISPENSING INFORMATION**  
Some preparations are contained units which are resealable and may be used for up to 12 hours.

**MEDICINAL FORMS**  
There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**

- **Carmellose sodium (Non-proprietary)**
  - Carmellose 0.5% eye drops  |  10 ml £7.49
  - Carmellose 1% eye drops 0.4ml unit dose preservative free  |  10 ml £4.99
  - Carmellose 0.5% eye drops 0.4ml unit dose preservative free  |  10 ml £3.00
  - Carmellose 1% eye drops 0.4ml unit dose preservative free  |  10 ml £3.00
  - Carmellose 0.5% eye drops 0.4ml unit dose preservative free  |  30 unit dose £3.00 DT price = £3.00
  - Carmellose 1% eye drops 0.4ml unit dose preservative free  |  60 unit dose £6.00 DT price = £6.00

- **Carmellose sodium 5 mg per 1 ml**
  - Carmellose 0.5% eye drops 0.4ml unit dose preservative free  |  10 ml £7.49
  - Carmellose 0.5% eye drops 0.4ml unit dose preservative free  |  30 unit dose £5.75 DT price = £5.75
  - Carmellose 0.5% eye drops 0.4ml unit dose preservative free  |  90 unit dose £15.53

- **Cellusan** (Farmigea S.p.A.)
  - Cellusan 1% eye drops preservative free  |  10 ml £4.80
  - Cellusan 1% eye drops 0.4ml unit dose preservative free  |  30 unit dose £3.00 DT price = £3.00
  - Cellusan Light 0.5% eye drops preservative free  |  10 ml £4.80
  - Cellusan Light 0.5% eye drops 0.4ml unit dose preservative free  |  30 unit dose £3.00 DT price = £3.00

- **Celluvic** (Allergan Ltd)
  - Celluvic 1% eye drops 0.4ml unit dose  |  30 unit dose £3.00 DT price = £3.00
  - Celluvic 1% eye drops 0.4ml unit dose preservative free  |  30 unit dose £3.00 DT price = £3.00

- **Lumecare (Carmellose)** (Medicomp Healthcare Ltd)
  - **Carmellose sodium 5 mg per 1 ml**
    - Lumecare Sodium 0.5% eye drops 0.4ml unit dose  |  30 unit dose £6.60 DT price = £6.60
  - **Ophtho-Lique** (Essential-Healthcare Ltd)
    - Ophtho-Lique 0.5% eye drops  |  10 ml £3.73
  - **Optive** (Allergan Ltd)
    - Optive Optive Plus 0.5% eye drops  |  10 ml £7.49
    - Optive Optive Plus 0.5% eye drops preservative free  |  10 ml £7.49
  - **Xailin Fresh** (Nicox Pharma)
    - **Carmellose sodium 5 mg per 1 ml**
      - Xailin Fresh 0.5% eye drops 0.4ml unit dose  |  30 unit dose £3.84 DT price = £3.84

**Hydroxyethylcellulose**

**INDICATIONS AND DOSE**  
**Tear deficiency**

- **TO THE EYE**
  - Child: Apply as required
  - Adult: Apply as required

**PRESCRIBING AND DISPENSING INFORMATION**  
Although multi-dose hydroxyethylcellulose eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

**MEDICINAL FORMS**  
There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**

- **Artificial tears** (Bausch & Lomb UK Ltd)
  - **Hydroxyethylcellulose 4.4 mg per 1 ml**
    - Minims artificial tears 0.44% eye drops 0.5ml unit dose  |  20 unit dose £8.97

**Hydroxypropyl guar with polyethylene glycol and propylene glycol**  
(Formulated as an ocular lubricant)

**INDICATIONS AND DOSE**  
**Dry eye conditions**

- **TO THE EYE**
  - Child: Apply as required
  - Adult: Apply as required
There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**
- **Systane** (Novartis Pharmaceuticals UK Ltd)
- Systane Gel eye drops | 10 ml £7.49

### Hypermellose

#### INDICATIONS AND DOSE

**Tear deficiency**
- **TO THE EYE**
- Child: Apply as required
- Adult: Apply as required

#### PRESCRIBING AND DISPENSING INFORMATION

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops

**Eye drops**

- **Hypermellose (Non-proprietary)**
  - **Hypermellose 3 mg per 1 ml**: Hypermellose 0.3% eye drops preservative free | 10 ml £5.75
  - Evolve Hypermellose 0.3% eye drops preservative free | 10 ml £1.98
  - Hypermellose 3% eye drops | 10 ml £0.99-£1.50 DT price = £1.42 | 10 ml £1.42 DT price = £1.42
  - **Artelac** (Bausch & Lomb UK Ltd)
    - Hypermellose 3.2 mg per 1 ml Artelac Single Dose Unit 0.32% eye drops 0.5ml unit dose | 30 unit dose £16.95 | 60 unit dose £32.85
    - Artelac 0.32% eye drops | 10 ml £4.99
  - **Brolene Cool** (Sanofi)
    - Hypermellose 3 mg per 1 ml Brolene Cool Eyes 0.3% eye drops | 10 ml £0.38 DT price = £1.42
  - **Hydromoor** (Moorfields Pharmaceuticals)
    - Hydromoor 0.3% eye drops 0.4ml unit dose preservative free | 30 unit dose £5.75
  - **Hypermellose** (Moorfields Pharmaceuticals)
    - Hypermellose 3 mg per 1 ml PF Drops Hypermellose 0.3% eye drops preservative free | 10 ml £5.75
  - **Hypromol** (Ennogen Healthcare Ltd)
    - Hypermellose 3 mg per 1 ml Hypromol 0.3% eye drops preservative free | 10 ml £4.55
  - **Isopo Alkaline** (Alcon Laboratories (UK) Ltd)
    - Hypermellose 10 mg per 1 ml Isopo Alkaline 1% eye drops | 10 ml £0.94 DT price = £0.94
  - **Isopo Plain** (Alcon Laboratories (UK) Ltd)
    - Hypermellose 5 mg per 1 ml Isopo Plain 0.5% eye drops | 10 ml £0.81 DT price = £0.81
  - **Lumecare (Hypermellose)** (Medicom Healthcare Ltd)
    - Hypermellose 3 mg per 1 ml Lumecare Hypermellose 0.3% eye drops | 10 ml £1.67 DT price = £1.42
  - **Lumecare Tear Drops** (Medicom Healthcare Ltd)
    - Hypermellose 3 mg per 1 ml Lumecare Tear Drops 0.3% eye drops | 10 ml £0.79 DT price = £1.42
  - **Mandalon (Hydroxypropyl methylcellulose)** (M & A Pharmachem Ltd)
    - Hypermellose 3 mg per 1 ml Mandalon eye drops | 10 ml £1.33 DT price = £1.42
  - **Ocu-Lube** (Sai-Meds Ltd)
    - Hypermellose 3 mg per 1 ml Ocu-Lube 0.3% eye drops preservative free | 10 ml £5.75
  - **SoftDrops** (Farmigea S.p.A.)
    - Hypermellose 3 mg per 1 ml SoftDrops 0.3% eye drops | 10 ml £1.67 DT price = £1.42

### Hypermellose with dextran 70

The properties listed below are those particular to the combination only. For the properties of the components please consider, hypermellose above.

#### INDICATIONS AND DOSE

**Tear deficiency**
- **TO THE EYE**
- Adult: Apply as required

#### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**

- **EXCIPIENTS**: May contain Benzalkonium chloride, disodium edetate
  - **Tears Naturale** (Alcon Laboratories (UK) Ltd)
    - Dextran 70 1 mg per 1 ml, Hypermellose 3 mg per 1 ml Tears Naturale eye drops | 15 ml £1.89
    - Tears Naturale eye drops 0.4ml unit dose | 28 unit dose £13.26

### Liquid paraffin with white soft paraffin and wool alcohols

#### INDICATIONS AND DOSE

**Dry eye conditions**
- **TO THE EYE**
- Child: Apply as required, best suited for application before sleep
- Adult: Apply as required, best suited for application before sleep

**PATIENT AND CARER ADVICE**

May cause temporary visual disturbance. Should not be used during contact lens wear.

#### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Eye ointment**

- **Lacrif-Lube** (Allergan Ltd)
  - Wool alcohols 2 mg per 1 gram, Liquid paraffin 425 mg per 1 gram, White soft paraffin 573 mg per 1 gram | Lacri-lube eye ointment | 3.5 gram £2.94 | 5 gram £3.88

### Paraffin, yellow, soft

#### INDICATIONS AND DOSE

**Eye surface lubrication**
- **TO THE EYE**
- Child: Apply every 2 hours as required
- Adult: Apply every 2 hours as required

**PATIENT AND CARER ADVICE**

Ophthalmic preparations may cause temporary visual disturbance. Should not be used during contact lens wear.
Retinol palmitate with white soft paraffin and light liquid paraffin and liquid paraffin and wool fat (Formulated as an ocular lubricant)

**INDICATIONS AND DOSE**
- **Dry eye conditions**
  - **TO THE EYE**
  - Adult: (consult product literature)

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.

**Eye ointment**
- **VITA-POS** (Scope Ophthalmics Ltd)
- VITA-POS eye ointment preservative free | 5 gram £2.75

Sodium hyaluronate

**INDICATIONS AND DOSE**
- **Dry eye conditions**
  - **TO THE EYE**
  - Adult: Apply as required

**PRESCRIBING AND DISPENSING INFORMATION**
- Some preparations are contained in units which are resealable and may be used for up to 12 hours.
- Although multi-dose sodium hyaluronate eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops, eye ointment, eye washes and suspensions.

**Eye drops**
- **Sodium hyaluronate (proprietary)**
  - *Artelac Rebalance* (Bausch & Lomb UK Ltd)
    - Artelac Rebalance 0.15% eye drops | 10 ml £4.00
  - *Artelac Splash* (Bausch & Lomb UK Ltd)
    - Artelac Splash 0.2% eye drops 0.5ml unit dose | 30 unit dose £7.00 | 60 unit dose £11.20
  - *Blink Intensive* (AMO UK Ltd)
    - Blink Intensive Tears 0.2% eye drops 0.4ml unit dose | 20 unit dose £2.97
  - *Clinitas* (Alcon Ltd)
    - Clinitas Multi 0.4% eye drops preservative free | 10 ml £6.99
    - Clinitas 0.4% eye drops 0.5ml unit dose | 30 unit dose £5.70
  - *Evolve HA* (Medicom Healthcare Ltd)
    - Evolve HA 0.2% eye drops preservative free | 10 ml £5.99
  - *Hy-Opti* (Alissia Healthcare Research Ltd)
    - Hy-Opti 0.1% eye drops preservative free | 10 ml £8.50
    - Hy-Opti 0.2% eye drops preservative free | 10 ml £9.50
  - *Hyabak* (Thea Pharmaceuticals Ltd)
    - Hyabak 0.15% eye drops preservative free | 10 ml £7.99
    - Hyabak UD 0.15% eye drops 0.4ml unit dose preservative free | 30 unit dose £4.99

**Eye ointment**
- **VITA-POS** (Scope Ophthalmics Ltd)
- VITA-POS eye ointment preservative free | 5 gram £2.75

**Sodium chloride**

**INDICATIONS AND DOSE**
- **Tear deficiency | Ocular lubricants and astringents | Irrigation, including first-aid removal of harmful substances | Intra-ocular or topical irrigation during surgical procedures**
  - **TO THE EYE**
  - Adult: Use 0.9% eye preparations

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops, eye ointment, eye washes and suspensions.

**Eye drops**
- **Sodium chloride (proprietary)**
  - *Sodium chloride 50 mg per 1 ml* Sodium chloride 5% eye drops | 10 ml £25.25
  - *Hypersal* (Ennogen Healthcare Ltd)
    - Sodium chloride 50 mg per 1 ml Hypersal 5% eye drops | 10 ml £25.25
  - *OMS* (Kestrel Ophthalmics Ltd)
    - Sodium chloride 50 mg per 1 ml OMS 5% eye drops preservative free | 10 ml £24.00 DT price = £0.00
  - *Saline* (Bausch & Lomb UK Ltd)
    - Sodium chloride 9 mg per 1 ml Minims saline 0.9% eye drops 0.5ml unit dose | 20 unit dose £7.14 DT price = £7.14
  - *Sodium chloride* (Essential Pharmaceuticals Ltd, Moorfields Pharmaceuticals)
    - Sodium chloride 50 mg per 1 ml NaCl 5% eye drops 0.45ml unit dose preservative free | 20 unit dose £19.70
    - PF Drops Sodium Chloride 5% eye drops preservative free | 10 ml £25.20 DT price = £0.00

**Eye ointment**
- **Sodium chloride (proprietary)**
  - *Sodium chloride 50 mg per 1 ml* Sodium chloride 5% eye ointment preservative free | 5 gram £22.50

**Polyvinyl alcohol**

**INDICATIONS AND DOSE**
- **Tear deficiency**
  - **TO THE EYE**
  - Child: Apply as required
  - Adult: Apply as required

**PRESCRIBING AND DISPENSING INFORMATION**
- Although multi-dose polyvinyl alcohol eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**
- **Polyvinyl alcohol 14 mg per 1 ml**
  - *Liquifilm Tears* (Allergan Ltd)
    - Liquifilm Tears 1.4% eye drops | 15 ml £1.93
  - *PVA* (Tubilux Pharma Ltd)
    - PVA 1.4% eye drops | 15 ml £1.63
  - *Refresh Ophthalmic* (Allergan Ltd)
    - Refresh Ophthalmic 1.4% eye drops 0.4ml unit dose | 30 unit dose £2.25
  - *Sno Tears* (Bausch & Lomb UK Ltd)
    - Sno Tears 1.4% eye drops | 10 ml £1.06

**Eye ointment**
- **Polyvinyl alcohol 800 mg per 1 gram**
  - *Hy-Opti* (Thea Pharmaceuticals Ltd)
  - *Blink Intensive* Tears (Allergan Ltd)
    - Blink Intensive Tears preservative free | 60 unit dose £11.20

**Sodium chloride**

**INDICATIONS AND DOSE**
- **TO THE EYE**
- Adult: Use 5% eye preparations (consult product literature)

**PRESCRIBING AND DISPENSING INFORMATION**
- Although multi-dose sodium chloride eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**
- **Sodium chloride (proprietary)**
  - *Sodium chloride 50 mg per 1 ml* Sodium chloride 5% eye drops | 10 ml £25.25
  - *Hypersal* (Ennogen Healthcare Ltd)
    - Sodium chloride 50 mg per 1 ml Hypersal 5% eye drops | 10 ml £25.25
  - *OMS* (Kestrel Ophthalmics Ltd)
    - Sodium chloride 50 mg per 1 ml OMS 5% eye drops preservative free | 10 ml £24.00 DT price = £0.00
  - *Saline* (Bausch & Lomb UK Ltd)
    - Sodium chloride 9 mg per 1 ml Minims saline 0.9% eye drops 0.5ml unit dose | 20 unit dose £7.14 DT price = £7.14
  - *Sodium chloride* (Essential Pharmaceuticals Ltd, Moorfields Pharmaceuticals)
    - Sodium chloride 50 mg per 1 ml NaCl 5% eye drops 0.45ml unit dose preservative free | 20 unit dose £19.70
    - PF Drops Sodium Chloride 5% eye drops preservative free | 10 ml £25.20 DT price = £0.00

**Eye ointment**
- **Sodium chloride (proprietary)**
  - *Sodium chloride 50 mg per 1 ml* Sodium chloride 5% eye ointment preservative free | 5 gram £22.50
Most acute superficial eye infections can be treated topically. Blepharitis and conjunctivitis are often caused by staphylococci; keratitis and endophthalmitis may be bacterial, viral, or fungal.

Bacterial blepharitis is treated by application of an antibacterial eye ointment to the conjunctival sac or to the lid margins. Systemic treatment may occasionally be required and is usually undertaken after culturing organisms from the lid margin and determining their antimicrobial sensitivity; antibiotics such as the tetracyclines given for 3 months or longer may be appropriate.

Most cases of acute bacterial conjunctivitis are self-limiting; where treatment is appropriate, antibacterial eye drops or an eye ointment are used. A poor response might indicate viral or allergic conjunctivitis.

Corneal ulcer and keratitis require specialist treatment and may call for hospital admission for intensive therapy. Endophthalmitis is a medical emergency which also calls for specialist management and requires intravitreal administration of antimicrobials; concomitant systemic treatment is required in some cases. Surgical intervention, such as vitrectomy, is sometimes indicated.

### Antibacterials

Bacterial eye infections are generally treated topically with eye drops and eye ointments. Systemic administration is sometimes appropriate in blepharitis.

Chloramphenicol p. 1072 has a broad spectrum of activity and is the drug of choice for superficial eye infections. Chloramphenicol eye drops are well tolerated and the recommendation that chloramphenicol eye drops should be avoided because of an increased risk of aplastic anaemia is not well founded.

Other antibacterials with a broad spectrum of activity include the quinolones, ciprofloxacin p. 1071, levofloxacin p. 1071, moxifloxacin p. 1071, and ofloxacin p. 1072; the aminoglycosides, gentamicin p. 1070 and tobramycin p. 1070 are also active against a wide variety of bacteria. Gentamicin, tobramycin, quinolones (except moxifloxacin), and polymyxin B are effective for infections caused by Pseudomonas aeruginosa.

Ciprofloxacin eye drops are licensed for corneal ulcers; intensive application (especially in the first 2 days) is required throughout the day and night.

Azithromycin eye drops p. 1070 are licensed for trachomatous conjunctivitis caused by Chlamydia trachomatis and for purulent bacterial conjunctivitis. Trachoma which results from chronic infection with Chlamydia trachomatis can be treated with azithromycin by mouth (unlicensed indication).

Fusidic acid is useful for staphylococcal infections. Propamidine isethionate p. 1073 is of little value in bacterial infections but is used by specialists to treat the rare, but potentially sight-threatening, condition of acanthamoeba keratitis [unlicensed indication].

Cefuroxime p. 1070 can be administered by intracameral injection for the prophylaxis of endophthalmitis following cataract surgery.

### With corticosteroids

Many antibacterial preparations also incorporate a corticosteroid but such mixtures should not be used unless a patient is under close specialist supervision. In particular they should not be prescribed for undiagnosed ‘red eye’ which is sometimes caused by the herpes simplex virus and may be difficult to diagnose.

### Administration

Frequency of application depends on the severity of the infection and the potential for irreversible ocular damage; antibacterial eye preparations are usually administered as follows:

- **Eye drops**, apply 1 drop at least every 2 hours then reduce frequency as infection is controlled and continue for 48 hours after healing.
- **Eye ointment**, apply either at night (if eye drops used during the day) or 3–4 times daily (if eye ointment used alone).

### Antifungals

Fungal infections of the cornea are rare but can occur after agricultural injuries, especially in hot and humid climates. Orbital mycosis is rarer, and when it occurs it is usually because of direct spread of infection from the paranasal sinuses. Increasing age, debility, or immunosuppression can encourage fungal proliferation. The spread of infection...

---

**Eye infections**

**Eye infections**

Most acute superficial eye infections can be treated topically. Blepharitis and conjunctivitis are often caused by staphylococci; keratitis and endophthalmitis may be bacterial, viral, or fungal.

Bacterial blepharitis is treated by application of an antibacterial eye ointment to the conjunctival sac or to the lid margins. Systemic treatment may occasionally be required and is usually undertaken after culturing organisms from the lid margin and determining their antimicrobial sensitivity; antibiotics such as the tetracyclines given for 3 months or longer may be appropriate.

Most cases of acute bacterial conjunctivitis are self-limiting; where treatment is appropriate, antibacterial eye drops or an eye ointment are used. A poor response might indicate viral or allergic conjunctivitis.

**Corneal ulcer and keratitis** require specialist treatment and may call for hospital admission for intensive therapy. **Endophthalmitis** is a medical emergency which also calls for specialist management and requires intravitreal administration of antimicrobials; concomitant systemic treatment is required in some cases. Surgical intervention, such as vitrectomy, is sometimes indicated.

### Antibacterials

Bacterial eye infections are generally treated topically with eye drops and eye ointments. Systemic administration is sometimes appropriate in blepharitis.

**Chloramphenicol** p. 1072 has a broad spectrum of activity and is the drug of choice for superficial eye infections. Chloramphenicol eye drops are well tolerated and the recommendation that chloramphenicol eye drops should be avoided because of an increased risk of aplastic anaemia is not well founded.

Other antibacterials with a broad spectrum of activity include the quinolones, ciprofloxacin p. 1071, levofloxacin p. 1071, moxifloxacin p. 1071, and ofloxacin p. 1072; the aminoglycosides, gentamicin p. 1070 and tobramycin p. 1070 are also active against a wide variety of bacteria. Gentamicin, tobramycin, quinolones (except moxifloxacin), and polymyxin B are effective for infections caused by Pseudomonas aeruginosa.

Ciprofloxacin eye drops are licensed for corneal ulcers; intensive application (especially in the first 2 days) is required throughout the day and night.

Azithromycin eye drops p. 1070 are licensed for trachomatous conjunctivitis caused by Chlamydia trachomatis and for purulent bacterial conjunctivitis. **Trachoma** which results from chronic infection with Chlamydia trachomatis can be treated with azithromycin by mouth (unlicensed indication).

**Fusidic acid** is useful for staphylococcal infections. Propamidine isethionate p. 1073 is of little value in bacterial infections but is used by specialists to treat the rare, but potentially sight-threatening, condition of acanthamoeba keratitis [unlicensed indication].

Cefuroxime p. 1070 can be administered by intracameral injection for the prophylaxis of endophthalmitis following cataract surgery.

### With corticosteroids

Many antibacterial preparations also incorporate a corticosteroid but such mixtures should not be used unless a patient is under close specialist supervision. In particular they should not be prescribed for undiagnosed ‘red eye’ which is sometimes caused by the herpes simplex virus and may be difficult to diagnose.

### Administration

Frequency of application depends on the severity of the infection and the potential for irreversible ocular damage; antibacterial eye preparations are usually administered as follows:

- **Eye drops**, apply 1 drop at least every 2 hours then reduce frequency as infection is controlled and continue for 48 hours after healing.
- **Eye ointment**, apply either at night (if eye drops used during the day) or 3–4 times daily (if eye ointment used alone).

### Antifungals

Fungal infections of the cornea are rare but can occur after agricultural injuries, especially in hot and humid climates. Orbital mycosis is rarer, and when it occurs it is usually because of direct spread of infection from the paranasal sinuses. Increasing age, debility, or immunosuppression can encourage fungal proliferation. The spread of infection...
through blood occasionally produces metastatic endophthalmitis.

Many different fungi are capable of producing ocular infection; they can be identified by appropriate laboratory procedures.

Antifungal preparations for the eye are not generally available. Treatment will normally be carried out at specialist centres, but requests for information about supplies of preparations not available commercially should be addressed to the Strategic Health Authority (or equivalent), or to the nearest hospital ophthalmology unit, or to Moorfields Eye Hospital, 162 City Road, London EC1V 2PD (tel. (020) 7253 3411) or www.moorfields.nhs.uk.

Antivirals

Herpes simplex infections producing, for example, dendritic corneal ulcers can be treated with aciclovir p. 1073 or ganciclovir p. 1073. Aciclovir eye ointment is used in combination with systemic treatment for ophthalmic zoster.

Slow-release ocular implants containing ganciclovir (available on a named-patient basis from specialist importing companies) may be inserted surgically to treat immediate sight-threatening CMV retinitis. Local treatments do not protect against systemic infection or infection in the other eye. See systemic treatment of CMV retinitis.

3.1 Bacterial eye infection

**ANTIBACTERIALS ➔ AMINOGLYCODIDES**

### Gentamicin

**INDICATIONS AND DOSE**

**Bacterial eye infections**

- **TO THE EYE**
  - **Child**: Apply 1 drop at least every 2 hours in severe infection, reduce frequency as infection is controlled and continue for 48 hours after healing. Frequency of eye drops depends on the severity of the infection and the potential for irreversible ocular damage; for less severe infection 3–4 times daily is generally sufficient.
  - **Adult**: Apply 1 drop at least every 2 hours, reduce frequency as infection is controlled and continue for 48 hours after healing. Frequency of eye drops depends on the severity of the infection and the potential for irreversible ocular damage; for less severe infection 3–4 times daily is generally sufficient.

- **INTERACTIONS** ➔ Appendix 1: aminoglycosides

- **PRESCRIBING AND DISPENSING INFORMATION**

  Eye drops may be sourced as a manufactured special or from specialist importing companies.

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops

  **Ear/eye drops solution**

  EXCIPIENTS: May contain Benzalkonium chloride

  - **Gentamicin (Non-proprietary)**

  - **Gentamicin (as Gentamicin sulphate) 3 mg per 1 ml**

  - **0.3% ear/eye drops**

  - **10 ml [POD] £2.14 DT price = £2.15**

### Tobramycin

**INDICATIONS AND DOSE**

**Local treatment of infections**

- **TO THE EYE**
  - **Child 1-17 years**: Apply twice daily for 6–8 days
  - **Adult**: Apply twice daily for 6–8 days

- **INTERACTIONS** ➔ Appendix 1: macrolides

- **SIDE-EFFECTS**

  - **Common or very common** Blurred vision • ocular burning • ocular discomfort • ocular pruritus
  - **Uncommon** Conjunctival hyperaemia • eyelid eczema • eyelid erythema • eyelid oedema • keratitis

- **ANTIBACTERIALS ➔ MACROLIDES**

### Cefuroxime

**INDICATIONS AND DOSE**

**APROKAM® INTRACAMERAL INJECTION**

**Prophylaxis of endophthalmitis after cataract surgery**

- **BY INTRACAMERAL INJECTION**

  - **Adult**: 1 mg, dose to be injected into the anterior chamber of the eye at the end of cataract surgery

- **INTERACTIONS** ➔ Appendix 1: cephhalosporins

- **PREGNANCY**

  Not known to be harmful.

- **BREAST FEEDING**

  Present in milk in low concentration, but appropriate to use.

- **NATIONAL FUNDING/ACCESS DECISIONS**

  **Scottish Medicines Consortium (SMC) Decisions**

  The Scottish Medicines Consortium has advised (December 2016) that cefuroxime (Aprokam®) is accepted for use within NHS Scotland for antibiotic prophylaxis of postoperative endophthalmitis after cataract surgery.

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for injections**

- **Aprokam** (Thea Pharmaceuticals Ltd)

  Cefuroxime sodium 50 mg Aprokam powder for solution for injection | 10 vial [POD] £49.95

- **ANTIBACTERIALS ➔ MACROLIDES**

### Azithromycin

**INDICATIONS AND DOSE**

**Trachomatous conjunctivitis caused by Chlamydia trachomatis**

**Purulent bacterial conjunctivitis**

- **TO THE EYE**

  - **Child**: Apply twice daily for 3 days, review if no improvement after 3 days of treatment
  - **Adult**: Apply twice daily for 3 days, review if no improvement after 3 days of treatment

- **INTERACTIONS** ➔ Appendix 1: macrolides

- **SIDE-EFFECTS**

  - **Common or very common** Blurred vision • ocular burning • ocular discomfort • ocular pruritus
  - **Uncommon** Conjunctival hyperaemia • eyelid eczema • eyelid erythema • eyelid oedema • keratitis

---

downloaded from www.medicalbr.com
**Uncommon MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**
- **Azter** (Thea Pharmaceuticals Ltd)
  - Azithromycin dihydrate 15 mg per 1 gram Azter 15mg/g eye drops 0.25g unit dose | 6 unit dose £6.99 DT price + £6.99

**SIDE-EFFECTS**
- Common or very common
  - lid exfoliation
  - conjunctival hyperaemia
  - increased lacrimation
  - pruritus
  - sensitivity to light
  - photophobia
  - ear pain
  - headache
- Uncommon
  - abdominal pain
  - taste disturbances
  - corneal deposits (reversible after completion of treatment)
  - corneal epithelial defect
  - keratitis
  - keratopathy
- Rare
  - maculopapular rash
  - corneal deposits (reversible after completion of treatment)

**TO THE EYE USING EYE DROP**

**INDICATIONS AND DOSE**

**Superficial bacterial eye infection**
- **TO THE EYE USING EYE DROP**
  - Adult: Apply 4 times a day for maximum duration of treatment 21 days
  - Child: Apply 4 times a day for maximum duration of treatment 21 days

**Superficial bacterial eye infection (severe infection)**
- **TO THE EYE USING EYE DROP**
  - Adult: Apply every 2 hours during waking hours for 2 days, then apply 4 times a day for maximum duration of treatment 21 days
  - Child: Apply every 2 hours during waking hours for 2 days, then apply 4 times a day for maximum duration of treatment 21 days

**Corneal ulcer**
- **TO THE EYE USING EYE DROP**
  - Adult: Apply every 15 minutes for 6 hours, then apply every 30 minutes for the remainder of day 1, then apply every 1 hour on day 2, then apply every 4 hours on days 3–14, maximum duration of treatment 21 days, to be administered throughout the day and night
  - Child: Apply every 15 minutes for 6 hours, then apply every 30 minutes for the remainder of day 1, then apply every 1 hour on day 2, then apply every 4 hours on days 3–14, maximum duration of treatment 21 days, to be administered throughout the day and night

**CONTRAINDICATIONS**
- Glaucoma
- Angle-closure glaucoma
- Hypersensitivity to any quinolone

**INTERACTIONS**
- Can discolour tears
- May cause visual disturbances

**PR EGNANCY**
- Manufacturer advises use only if potential benefit outweighs risk.

**BREAST FEEDING**
- Manufacturer advises caution.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops

**Eye drops**
- **Ciloxan** (Alcon Laboratories (UK) Ltd)
  - Ciprofloxacin (as Ciprofloxacin hydrochloride) 3 mg per 1 ml Ciloxan 0.3% eye drops | 5 ml £4.70 DT price + £4.70

**Eye ointment**
- **Ciloxan** (Alcon Laboratories (UK) Ltd)
  - Ciprofloxacin (as Ciprofloxacin hydrochloride) 3 mg per 1 gram Ciloxan 3mg/g ointment | 3.5 g £5.22

**Levofloxacin**

**INDICATIONS AND DOSE**

**Local treatment of eye infections**
- **TO THE EYE**
  - Adult: Apply every 2 hours for first 2 days, to be applied maximum 8 times a day, then apply 4 times a day for 3 days
  - Child: Apply every 2 hours for first 2 days, to be applied maximum 8 times a day, then apply 4 times a day for 3 days

**INTERACTIONS**
- Appendix 1: quinolones

**SIDE-EFFECTS**
- Common or very common
  - Ocular burning - visual disturbances
- Uncommon
  - Conjunctival follicles
  - Headache
  - Lid erythema
  - Lid oedema
  - Ocular discomfort
  - Ocular dryness
  - Ocular itching
  - Photophobia
  - Rhinitis

**PREGNANCY**
- Manufacturer advises use only if potential benefit outweighs risk.

**BREAST FEEDING**
- Manufacturer advises use only if potential benefit outweighs risk.

**PRESCRIBING AND DISPENSING INFORMATION**
- Although multi-dose levofloxacin eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**
- **Levofloxacin (Non-proprietary)**
  - Levofloxacin 5mg/ml eye drops | 30 unit dose £17.95
  - Oftaquix (Santen UK Ltd)
  - Levofloxacin (as Levofloxacin hemihydrate) 5 mg per 1 ml Oftaquix 5mg/ml eye drops | 30 unit dose £6.95

**Moxifloxacin**

**INDICATIONS AND DOSE**

**Local treatment of infections**
- **TO THE EYE**
  - Adult: Apply 3 times a day continue treatment for 2–3 days after infection improves; review if no improvement within 5 days
  - Child: Apply 3 times a day continue treatment for 2–3 days after infection improves; review if no improvement within 5 days

**INTERACTIONS**
- Appendix 1: quinolones
Eye infections

**SIDE-EFFECTS**

- **Common or very common** Hyperaemia - ocular discomfort - ocular dryness - ocular irritation - ocular pain - taste disturbances
- **Uncommon** Conjunctival haemorrhage - corneal disorders - corneal erosion - corneal keratitis - corneal staining - eyelid erythema - headache - nasal discomfort - paraesthesia - pharyngolaryngeal pain - visual disturbances - vomiting
- **Frequency not known** Dizziness - dyspnoea - nausea - palpitation - photophobia - pruritus - raised intra-ocular pressure - rash

**DRUG ACTION**

Conjunctival haemorrhage containing the There can be variation in the licensing of different medicines

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**

- **Moxivig** (Alcon Laboratories (UK) Ltd)
  Moxiﬂoxacin (as Moxiﬂoxacin hydrochloride) 5 mg per 1 ml Moxivig 0.5% eye drops | 5 ml £9.80

---

**SIDE-EFFECTS**

- **Common or very common** Eye irritation - ocular discomfort
- **Frequency not known** Dry eyes - facial oedema - increased lacrimation - keratitis - ocular hyperaemia - ocular oedema - photophobia - visual disturbances

**PREGNANCY**

Manufacturer advises use only if benefit outweighs risk (systemic quinolones have caused arthropathy in animal studies).

**BREAST FEEDING**

Manufacturer advises avoid.

**INDICATIONS AND DOSE**

**Local treatment of infections**

**TO THE EYE**

- **Child** 1-17 years: Apply every 2–4 hours for the first 2 days, then reduced to 4 times a day for maximum 10 days treatment.
- **Adult**: Apply every 2–4 hours for the first 2 days, then reduced to 4 times a day for maximum 10 days treatment.

---

**MECHANISMS OF ACTION**

There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**

EXCIPIENTS: May contain Phenylmercuric acetate

- **Chloromycetin** (AMCo)
  Chloromycetin 5 mg per 1 ml | 10 ml £99.20

**Eye ointment**

Chloramphenicol 1% eye ointment | 4 gram £4.25

**SIDE-EFFECTS**

- **Common or very common** Eye irritation - ocular discomfort
- **Frequency not known** Dry eyes - facial oedema - increased lacrimation - keratitis - ocular hyperaemia - ocular oedema - photophobia - visual disturbances

**PREGNANCY**

Manufacturer advises use only if benefit outweighs risk (systemic quinolones have caused arthropathy in animal studies).

**BREAST FEEDING**

Manufacturer advises avoid.

**MECHANISMS OF ACTION**

There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**

EXCIPIENTS: May contain Benzalkonium chloride

- **Exocin** (Allergan Ltd)
  Ofloxacin 3 mg per 1 ml | Exocin 0.3% eye drops | 5 ml £2.17

---

**INDICATIONS AND DOSE**

**Superficial eye infections**

- **TO THE EYE USING EYE DROP**
  - **Child**: Apply 1 drop every 2 hours then reduce frequency as infection is controlled and continue for 48 hours after healing, frequency dependent on the severity of the infection. For less severe infection 3–4 times daily is generally sufficient
  - **Adult**: Apply 1 drop every 2 hours then reduce frequency as infection is controlled and continue for 48 hours after healing, frequency dependent on the severity of the infection. For less severe infection 3–4 times daily is generally sufficient

**INTERACTIONS**

- **Appendix 1**: chloramphenicol

---

**SIDE-EFFECTS**

- **Transient stinging**

**PREGNANCY**

Avoid unless essential—no information on topical use but risk of ‘neonatal grey-baby syndrome’ with oral use in third trimester.

**BREAST FEEDING**

Avoid unless essential—**theoretical** risk of bone-marrow toxicity.

**PRESCRIBING AND DISPENSING INFORMATION**

Although multi-dose chloramphenicol eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

**PATIENT AND CARER ADVICE**

Medicines for Children leaflet: Chloramphenicol for eye infections www.medicinesforchildren.org.uk/chloramphenicol-eye-infections-0

**EXCEPTIONS TO LEGAL CATEGORY**

Chloramphenicol 0.5% eye drops (in max. pack size 10 mL) and 1% eye ointment (in max. pack size 4 g) can be sold to the public for treatment of acute bacterial conjunctivitis in adults and children over 2 years; max. duration of treatment 5 days.

---

**MECHANISMS OF ACTION**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops

**Eye drops**

EXCIPIENTS: May contain Phenylmercuric acetate

- **Chloramphenicol (Non-proprietary)**
  Chloramphenicol 5 mg per 1 ml | 20 unit dose £10.99

**Eye ointment**

**Chloramphenicol (Non-proprietary)**

Chloramphenicol 10 mg per 1gram Chloramphenicol 1% eye ointment | 4 gram £2.77

**Chloromycetin** (AMCo)

Chloromycetin 5 mg per 1 ml Chloromycetin Redidrops 0.9% | 10 ml £0.90

**Fusidic acid**

**DRUG ACTION**

Fusidic acid and its salts are narrow-spectrum antibiotics used for staphylococcal infections.

**INDICATIONS AND DOSE**

**Staphylococcal eye infections**

- **TO THE EYE**
  - **Child**: Apply twice daily
  - **Adult**: Apply twice daily

**INTERACTIONS**

- **Appendix 1**: fusidic acid
3.2  Viral eye infection

3.2a  Ophthalmic herpes simplex

**ANTIVIRALS > NUCLEOSIDE ANALOGUES**

**Aciclovir (Acyclovir)**

- **INDICATIONS AND DOSE**
  - **Herpes simplex infection (local treatment)**
    - TO THE EYE USING EYE OINTMENT
    - Child: Apply 1 centimetre 5 times a day continue for at least 3 days after complete healing
    - Adult: Apply 1 centimetre 5 times a day continue for at least 3 days after complete healing

- **INTERACTIONS** → Appendix 1: aciclovir

- **SIDE-EFFECTS**
  - Common or very common: Local inflammation · local irritation · superficial punctate keratopathy
  - Rare: Blepharitis

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

  **Eye ointment**
  - **Brolene (Dibrompropamidine)** (Sanofi)
    - Dibrompropamidine isetionate 1.5 mg per 1 gram
    - Golden Eye (dibrompropamidine)
    - Virgan

  **Eye drops**
  - **Brolene (Propamidine)** (Sanofi)
    - Propamidine isetionate 1 mg per 1 ml
    - Golden Eye (propamidine)
    - Propamidine isetionate 1 mg per 1 ml

**EXCIPIENTS:** May contain Benzalkonium chloride

**SIDE-EFFECTS**

- Burning sensation · superficial punctate keratitis · tingling

**ALLERGY AND CROSS-SENSITIVITY**

- Contra-indicated in patients hypersensitive to valganciclovir, aciclovir, or valaciclovir.

**MEDICINAL FORMS**

- There can be variation in the licensing of different medicines containing the same drug.

  **Eye gel**
  - **Ganciclovir 1.5 mg per 1 gram** (GlaxoSmithKline UK Ltd)
    - Ganciclovir 1.5 mg per 1 gram

  **Eye ointment**
  - **Zovirax (GlaxoSmithKline UK Ltd)**
    - Aciclovir 30 mg per 1 gram

**SIDE-EFFECTS**

- Very rare: Angioedema · hypersensitivity reactions

**PATIENT AND CARER ADVICE**

Medicines for Children leaflet: Aciclovir eye ointment for herpes simplex infections www.medicinesforchildren.org.uk/aciclovir-eye-ointment-for-herpes-simplex-infection

**Mydriatics and cycloplegics**

**Overview**

Antimuscarinics dilate the pupil and paralyse the ciliary muscle; they vary in potency and duration of action. Short-acting, relatively weak mydriatics, such as tropicamide 0.5% p. 1074 (action lasts for 4–6 hours), facilitate the examination of the fundus of the eye. Longer-acting options include cyclopentolate hydrochloride 1% p. 1065 (action up to 24 hours) or atropine sulfate p. 1064 (action up to 7 days).

Phenylephrine hydrochloride p. 1075 is used for mydriasis in diagnostic or therapeutic procedures; mydriasises occurs within 60–90 minutes and lasts up to 5–7 hours.

Mydriatics and cycloplegics are used in the treatment of anterior uveitis, usually as an adjunct to corticosteroids. Atropine sulfate is used in anterior uveitis mainly to prevent posterior synechiae and to relieve ciliary spasm; cyclopentolate hydrochloride or homatropine hydrobromide p. 1065 (action up to 3 days) can also be used and may be preferred because they have a shorter duration of action.

**Other drugs used for Eye procedures**

- Apraclonidine, p. 1086 · Lidocaine hydrochloride, p. 1242
ANTIMUSCARINICS

Tropicamide

- **INDICATIONS AND DOSE**
  - **Funduscopy**
    - Adult: Apply, leave for 2 minutes, then irrigate thoroughly with sodium chloride 0.9%

- **INTERACTIONS** → Appendix 1: tropicamide
- **PRESCRIBING AND DISPENSING INFORMATION**
  - Although multi-dose tropicamide eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Eye drops**
    - **EXCIPIENTS:** May contain Benzalkonium chloride, edetic acid (edta)
      - *Mydrical* (Alcon Laboratories (UK) Ltd)
        - **Tropicamide 5 mg per 1 ml** Mydriacyl 0.5% eye drops | 5 ml [POM] £1.29
        - **Tropicamide 10 mg per 1 ml** Mydriacyl 1% eye drops | 5 ml [POM] £1.60
      - *Tropicamide* (Bausch & Lomb UK Ltd)
        - **Tropicamide 5 mg per 1 ml** Minims tropicamide 0.5% eye drops 0.5ml unit dose | 20 unit dose [POM] £0.75
        - **Tropicamide 10 mg per 1 ml** Minims tropicamide 1% eye drops 0.5ml unit dose | 20 unit dose [POM] £0.77
  - Combinations available: *Phenylephrine with tropicamide*, p. 1075

ANTISEPTICS AND DISINFECTANTS › IODINE PRODUCTS

Povidone-iodine

- **INDICATIONS AND DOSE**
  - **Cutaneous peri-ocular and conjunctival antisepsis before ocular surgery**
    - **TO THE EYE**
      - Adult: Apply, leave for 2 minutes, then irrigate thoroughly with sodium chloride 0.9%

- **CONTRA-INDICATIONS**
  - Concomitant use of ocular antimicrobial drugs · concomitant use of ocular formulations containing mercury-based preservatives

- **SIDE-EFFECTS**
  - Rare Conjunctival hyperaemia · superficial punctuate keratitis
  - Frequency not known Cytotoxicity on deep tissue · cytotoxicity on mucous membranes · residual yellow coloration of the conjunctiva

- **PRESCRIBING AND DISPENSING INFORMATION**
  - Although multi-dose povidone iodine eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Eye drops**
    - **Povidone iodine** (Bausch & Lomb UK Ltd)
      - **Povidone-iodine 50 mg per 1 ml** Minims povidone iodine 5% eye drops 0.4ml unit dose | 20 unit dose [POM] £16.00

DIAGNOSTIC AGENTS › DYES

Fluorescein sodium

- **INDICATIONS AND DOSE**
  - **Detection of lesions and foreign bodies**
    - **TO THE EYE USING EYE DROP**
      - Adult: Use sufficient amount to stain damaged areas

- **PRESCRIBING AND DISPENSING INFORMATION**
  - Although multi-dose fluorescein eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  - **Eye drops**
    - *Fluorescein sodium* (Bausch & Lomb UK Ltd)
      - **Fluorescein sodium 10 mg per 1 ml** Minims fluorescein sodium 1% eye drops 0.5ml unit dose | 20 unit dose [P] £8.89
      - **Fluorescein sodium 20 mg per 1 ml** Minims fluorescein sodium 2% eye drops 0.5ml unit dose | 20 unit dose [P] £8.89

  - **Fluorescein with lidocaine**

- **INDICATIONS AND DOSE**
  - **Local anaesthesia**
    - **TO THE EYE**
      - Adult: Apply as required

- **PRESCRIBING AND DISPENSING INFORMATION**
  - Although multi-dose lidocaine and fluorescein eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  - **Eye drops**
    - *Lidocaine and Fluorescein* (Bausch & Lomb UK Ltd)
      - **Fluorescein sodium 2.5 mg per 1 ml, Lidocaine hydrochloride 40 mg per 1 ml** Minims lidocaine and fluorescein eye drops 0.5ml unit dose | 20 unit dose [POM] £11.24

MIOTICS › PARASYMPATHOMIMETICS

Acetylcholine chloride

- **INDICATIONS AND DOSE**
  - **Cataract surgery | Penetrating keratoplasty | Iridectomy | Anterior segment surgery requiring rapid complete miosis**
    - **TO THE EYE**
    - Adult: (consult product literature)

- **CAUTIONS**
  - Asthma · gastro-intestinal spasm · heart failure · hyperthyroidism · parkinsonism · peptic ulcer · urinary-tract obstruction

- **INTERACTIONS** → Appendix 1: acetylcholine

- **SIDE-EFFECTS**
  - Rare Bradycardia · breathing difficulty · flushing · hypotension · sweating

- **PREGNANCY**
  - Avoid unless potential benefit outweighs risk—no information available.

- **BREAST FEEDING**
  - Avoid unless potential benefit outweighs risk—no information available.
**Phenylephrine with tropicamide**

The properties listed below are those particular to the combination only. For the properties of the components please consider, phenylephrine hydrochloride above, tropicamide p. 1074.

**INDICATIONS AND DOSE**

**Pre-operative mydriasis**

- **To the eye**
- **Adult:** One insert to be applied into the lower conjunctival sac up to max. 2 hours before procedure; remove insert within 30 minutes of satisfactory mydriasis, and within 2 hours of application

**DIRECTIONS FOR ADMINISTRATION**

- **Patients with severe dry eyes may require a drop of saline to improve insert tolerance.**

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops

- **Eye drops**
  - **Excipients:** May contain Disodium edetate, sodium metabisulfite
  - **Phenylephrine hydrochloride** (Bausch & Lomb UK Ltd)
    - Phenylephrine hydrochloride 25 mg per 1 ml Minims phenylephrine hydrochloride 2.5% eye drops 0.5ml unit dose | 20 unit dose £11.41
    - Phenylephrine hydrochloride 100 mg per 1 ml Minims phenylephrine hydrochloride 10% eye drops 0.5ml unit dose | 20 unit dose £11.41

**OPHTHALMIC INSERT**

- **Mydriasant** (Thea Pharmaceuticals Ltd)
  - Tropicamide 28 mg, Phenylephrine hydrochloride 5.4 mg / 0.28mg ophthalmic inserts | 20 insert £64.00

---

**4.1 Post-operative pain and inflammation**

**Eye, surgical and peri-operative drug use**

**Ocular peri-operative drugs**

Drugs used to prepare the eye for surgery, drugs that are injected into the anterior chamber at the time of surgery, and those used after eye surgery, are included here.

- **Cefuroxime** p. 498, administered by intravenous injection into the anterior chamber of the eye (intracameral use), is used for the prophylaxis of endophthalmitis after cataract surgery.

- **Diclofenac sodium and flurbiprofen** are used for the prophylaxis of endophthalmitis after cataract surgery.

- **Naproxen sodium and ketorolac** are used for the prophylaxis and treatment of inflammation, pain, and other symptoms associated with ocular surgery or laser treatment of the eye. Cefuroxime p. 496 is used for the treatment of postoperative inflammation following cataract surgery.

- **Diclofenac sodium and flurbiprofen** are also used to prevent miosis during ocular surgery.

- **Apraclonidine, p. 1086, an alpha₁-adrenoceptor agonist, reduces intra-ocular pressure possibly by reducing the dilatation of the sphincter muscle of the iris and the blood flow in the iris.**

---

**Post-operative pain and inflammation**

- **1075**
production of aqueous humour. It is used to control increases in intra-ocular pressure associated with ocular surgery and as short-term treatment to reduce intraocular pressure prior to surgery.

Acetylcholine chloride p. 1074, administered into the anterior chamber of the eye during surgery, rapidly produces miosis which lasts approximately 20 minutes. If prolonged miosis is required, it can be applied again. Intra-ocular sodium hyaluronate p. 1068 and balanced salt solution are used during surgical procedures on the eye.

Povidone-iodine p. 1074 is used for peri-ocular and conjunctival antisepsis before ocular surgery to support postoperative infection control.

**Local anaesthetics**

Oxybuprocaine hydrochloride below and tetracaine below are widely used topical local anaesthetics. Proxymetacaine hydrochloride below causes less initial stinging and is useful for children. Oxybuprocaine hydrochloride or a combined preparation of lidocaine hydrochloride and fluorescein sodium p. 1074 is used for tonometry. Tetracaine produces a more profound anaesthesia and is suitable for use before minor surgical procedures, such as the removal of corneal sutures. It has a temporary disruptive effect on the corneal epithelium. Lidocaine hydrochloride, with or without adrenaline/epinephrine p. 216, is injected into the eyelids for minor surgery. Local anaesthetics should never be used for the management of ocular symptoms.

**ANAESTHETICS, LOCAL**

*Oxybuprocaine hydrochloride* (Benoxinate hydrochloride)

- **INDICATIONS AND DOSE**
  - Local anaesthetic
    - Adult: Apply as required

- **INTERACTIONS** → Appendix 1: anaesthetics, local

- **PRESCRIBING AND DISPENSING INFORMATION** Although multi-dose oxybuprocaine eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  **Eye drops**
  - Oxybuprocaine hydrochloride *(Bausch & Lomb UK Ltd)*
    - Oxybuprocaine hydrochloride 4 mg per 1 ml *Minims*  oxybuprocaine hydrochloride 0.4% eye drops 0.5ml unit dose | 20 unit dose *POM* £10.15

*Proxymetacaine hydrochloride*

- **INDICATIONS AND DOSE**
  - Local anaesthetic
    - Adult: Apply as required

- **INTERACTIONS** → Appendix 1: anaesthetics, local

- **PRESCRIBING AND DISPENSING INFORMATION** Although multi-dose proxymetacaine eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  **Eye drops**
  - Proxymetacaine *(Bausch & Lomb UK Ltd)*
    - Proxymetacaine hydrochloride 5 mg per 1 ml Minims proxymetacaine 0.5% eye drops 0.5ml unit dose | 20 unit dose *POM* £11.54

---

**Tetracaine**

*(Amethocaine)*

- **INDICATIONS AND DOSE**
  - Local anaesthetic
    - TO THE EYE
    - Adult: Apply as required

- **INTERACTIONS** → Appendix 1: anaesthetics, local

- **PRESCRIBING AND DISPENSING INFORMATION** Although multi-dose tetracaine eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  **Eye drops**
  - Tetracaine *(Non-proprietary)*
    - Tetracaine hydrochloride 5 mg per 1 ml Minims tetracaine hydrochloride 0.5% eye drops 0.5ml unit dose | 20 unit dose *POM* £10.16
    - Tetracaine hydrochloride 10 mg per 1 ml Minims tetracaine hydrochloride 1% eye drops 0.5ml unit dose | 20 unit dose *POM* £10.16

---

**Bromfenac**

- **INDICATIONS AND DOSE**
  - Postoperative inflammation following cataract surgery
    - TO THE EYE
    - Adult: (consult product literature)

- **INTERACTIONS** → Appendix 1: NSAIDs

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  **Eye drops**
  - **Bromfenac (Non-proprietary)**
    - Bromfenac (as Bromfenac sodium sesquihydrate)
      - 900 microgram per 1 ml Bromfenac 900micrograms/ml eye drops | 5 ml *POM* no price available
      - **Yellow** *(Bausch & Lomb UK Ltd)*
        - Bromfenac (as Bromfenac sodium sesquihydrate)
          - 900 microgram per 1 ml Yellow 900micrograms/ml eye drops | 5 ml *POM* £8.50

---

**ANALGESICS > NON-Steroidal ANTI-INFLAMMATORY DRUGS**
Diclofenac sodium

- **INDICATIONS AND DOSE**
  Inhibition of intra-operative miosis during cataract surgery (but does not possess intrinsic mydriatic properties) | Postoperative inflammation in cataract surgery, strabismus surgery or argon laser trabecuoplasty | Pain in corneal epithelial defects after photorefractive keratectomy, radial keratotomy or accidental trauma | Seasonal allergic conjunctivitis
  
  ▶ **TO THE EYE**
  ▶ Adult: (consult product literature)

- **INTERACTIONS**  ➔ Appendix 1: NSAIDs

- **ALLERGY AND CROSS-SENSITIVITY** Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

- **PRESCRIBING AND DISPENSING INFORMATION** Although multi-dose diclofenac sodium eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.

  **Eye drops**
  EXCIPIENTS: May contain Benzalkonium chloride, disodium edetate, propylene glycol
  ▶ Voltarol Ophtha (Thea Pharmaceuticals Ltd)
  Diclofenac sodium 1 mg per 1 ml Voltarol Ophtha 0.1% eye drops 0.3ml unit dose | 5 unit dose [Pincl] £4.00 | 40 unit dose [Pincl] £32.00
  ▶ Voltarol Ophtha Multidose (Thea Pharmaceuticals Ltd)
  Diclofenac sodium 1 mg per 1 ml Voltarol Ophtha Multidose 0.1% eye drops | 5 ml [Pincl] £6.68

Flurbiprofen

- **INDICATIONS AND DOSE**
  Inhibition of intra-operative miosis (but does not possess intrinsic mydriatic properties) | Control of anterior segment inflammation following postoperative and post-laser trabecuoplasty when corticosteroids contra-indicated
  
  ▶ **TO THE EYE**
  ▶ Adult: (consult product literature)

- **INTERACTIONS**  ➔ Appendix 1: NSAIDs

- **ALLERGY AND CROSS-SENSITIVITY** Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.

  **Eye drops**
  EXCIPIENTS: May contain Benzalkonium chloride, disodium edetate
  ▶ Acular (Allergan Ltd)
  Ketorolac trometamol 5 mg per 1 ml Acular 0.5% eye drops | 5 ml [Pincl] £3.00 DT price + £3.00

Corticosteroids

- **INDICATIONS AND DOSE**
  Treatment of post-operative inflammation following ocular surgery
  
  ▶ **TO THE EYE**
  ▶ Adult: Apply 4 times a day for maximum duration of treatment of 14 days, to be started 24 hours after surgery

- **SIDE-EFFECTS** Corneal thinning - scleral thinning

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.

  **Eye drops**
  EXCIPIENTS: May contain Benzalkonium chloride, disodium edetate
  ▶ Lotemax (Bausch & Lomb UK Ltd)
  Loteprednol etabonate 5 mg per 1 ml Lotemax 0.5% eye drops | 5 ml [Pincl] £5.50 DT price + £5.50

Ketorolac trometamol

- **INDICATIONS AND DOSE**
  Prophylaxis and reduction of inflammation and associated symptoms following ocular surgery
  
  ▶ **TO THE EYE**
  ▶ Adult: (consult product literature)

- **INTERACTIONS**  ➔ Appendix 1: NSAIDs

Glucoma and ocular hypertension

Glucoma

**Overview**

Glucoma describes a group of disorders characterised by a loss of visual field associated with cupping of the optic disc and optic nerve damage. While glucoma is generally associated with raised intra-ocular pressure, it can occur when the intra-ocular pressure is within the normal range.

The most common form of glucoma is primary open-angle glucoma (chronic open-angle glucoma), where drainage of the aqueous humour through the trabecular meshwork is restricted. The condition is often asymptomatic, but the patient may present with significant loss of visual-field. Patients with ocular hypertension are at high risk of developing primary open-angle glucoma.

Drugs that reduce intra-ocular pressure by different mechanisms are available for managing ocular hypertension and glucoma. A topical beta-blocker or a prostaglandin analogue is usually the drug of first choice for the treatment of ocular hypertension. A prostaglandin analogue should be used to manage patients with early or moderate primary open-angle glucoma. After checking compliance and eye drop instillation technique, it may be necessary to combine these drugs or add others, such as sympathomimetics, carbonic anhydrase inhibitors, or miotics to control intra-ocular pressure.
Acute angle-closure glaucoma

Acute angle-closure glaucoma occurs when the outflow of aqueous humour from the eye is obstructed by bowing of the iris against the trabecular meshwork; it is a medical emergency that requires urgent reduction of intra-ocular pressure to prevent loss of vision. Patients with acute angle-closure glaucoma should be referred immediately for specialist ophthalmology assessment and treatment.

Standard antiglaucoma therapy is used if supplementary treatment is required after iridotomy, iridectomy, laser treatment, or drainage surgery in either primary open-angle or acute angle-closure glaucoma.

Beta-blockers

Topical application of a beta-blocker to the eye reduces intra-ocular pressure effectively in primary open-angle glaucoma, probably by reducing the rate of production of aqueous humour. Administration by mouth also reduces intra-ocular pressure but this route is not used since side-effects may be troublesome.

Beta-blockers used as eye drops include betaxolol p. 1079, carteolol hydrochloride below, levobunolol hydrochloride below, and timolol maleate p. 1079.

Prostaglandin analogues and prostamides

The prostaglandin analogues latanoprost p. 1083, tafluprost p. 1084 and travoprost p. 1085, and the synthetic prostamide, bimatoprost p. 1082, increase uveoscleral outflow and subsequently reduce intra-ocular pressure. They are used to reduce intra-ocular pressure in ocular hypertension or open-angle glaucoma.

Sympathomimetics

Brimonidine tartrate, a selective alpha2-adrenoceptor agonist, is thought to lower intra-ocular pressure by reducing aqueous humour formation and increasing uveoscleral outflow. It is licensed for the reduction of intra-ocular pressure in open-angle glaucoma or ocular hypertension in patients for whom beta-blockers are inappropriate; it may also be used as adjunctive therapy when intra-ocular pressure is inadequately controlled by other anti-glucoma therapy.

Apraclonidine p. 1086 is another alpha2-adrenoceptor agonist that lowers intra-ocular pressure by reducing aqueous humour formation. Eye drops containing apraclonidine 0.5% are used short-term to delay laser treatment or surgery in patients with glaucoma not adequately controlled by another drug; eye drops containing 1% are used for control of intra-ocular pressure after anterior segment laser surgery. Apraclonidine may not provide additional benefit in patients already using two drugs that suppress the production of aqueous humour.

Carbonic anhydrase inhibitors and systemic drugs

The carbonic anhydrase inhibitors, acetazolamide p. 1080, brinzolamide p. 1080, and dorzolamide p. 1081, reduce intra-ocular pressure by reducing aqueous humour production. Systemic use of acetazolamide also produces weak diuresis.

Acetazolamide is given by mouth or by intravenous injection (intramuscular injections are painful because of the alkaline pH of the solution). It is used as an adjunct to other treatment for reducing intra-ocular pressure. Acetazolamide is not generally recommended for long-term use.

Dorzolamide and brinzolamide are topical carbonic anhydrase inhibitors. They are licensed for use in patients resistant to beta-blockers or those in whom beta-blockers are contra-indicated. They are used alone or as an adjunct to a topical beta-blocker. Brinzolamide can also be used as an adjunct to a prostaglandin analogue or the alpha2-adrenoceptor agonist, brimonidine tartrate p. 1086. Systemic absorption can rarely cause sulfonamide-like side-effects and may require discontinuation if severe.

The osmotic diuretics, intravenous hypertonic mannitol p. 222 or glycerol p. 61 by mouth are useful short-term ocular hypotensive drugs.

Miotics

Miotics act by opening the inefficient drainage channels in the trabecular meshwork.

Pilocarpine p. 1082, a miotic, is not commonly used for the treatment of primary open-angle glaucoma because side-effects are poorly tolerated. It is used mainly in the treatment of primary angle-closure glaucoma and in some secondary glaucomas.

BETA-ADRENOCEPTOR BLOCKERS ❯ NON-SELECTIVE

Carteolol hydrochloride

● INDICATIONS AND DOSE

Primary open-angle glaucoma

➢ TO THE EYE

Adult: Apply twice daily

➢ CONTRA-INDICATIONS

Also consider contra-indications listed for systemically administered beta blockers - bradycardia - heart block

➢ CAUTIONS

Patients with corneal disease

CAUTIONS, FURTHER INFORMATION

Systemic absorption can follow topical application to the eyes; consider cautions listed for systemically administered beta blockers.

➢ INTERACTIONS ➢ Appendix 1: beta blockers (non-selective)

➢ SIDE-EFFECTS

Anaphylaxis, blepharoconjunctivitis, burning, corneal disorders, dry eyes, erythema, itching, ocular stinging, pain

SIDE-EFFECTS, FURTHER INFORMATION

Systemic absorption can follow topical application to the eyes; consider side effects listed for systemically administered beta blockers.

➢ MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Eye drops

EXCIPIENTS: May contain Benzalkonium chloride

➢ Teoptic (Thea Pharmaceuticals Ltd)

Carteolol hydrochloride 10 mg per 1 ml ➢ Teoptic 1% eye drops | 5 ml £7.60 DT price = £7.60

Carteolol hydrochloride 20 mg per 1 ml ➢ Teoptic 2% eye drops | 5 ml £8.40 DT price = £8.40

Levobunolol hydrochloride

● INDICATIONS AND DOSE

Primary open-angle glaucoma

➢ TO THE EYE

Adult: Apply 1–2 times a day

➢ CONTRA-INDICATIONS

Also consider contra-indications listed for systemically administered beta blockers - bradycardia - heart block

➢ CAUTIONS

Patients with corneal disease

CAUTIONS, FURTHER INFORMATION

Systemic absorption can follow topical application to the eyes; consider cautions listed for systemically administered beta blockers.

➢ INTERACTIONS ➢ Appendix 1: beta blockers (non-selective)
CONTRA-INDICATIONS

Interaction with timolol

SIDE-EFFECTS

Anaphylaxis - anterior uveitis - blepharoconjunctivitis - burning - corneal disorders - dry eyes - erythema - itching - ocular stinging - pain

SIDE-EFFECTS, FURTHER INFORMATION

Systemic absorption can follow topical application to the eyes; consider side effects listed for systemically administered beta blockers.

PRESCRIBING AND DISPENSING INFORMATION

Although multi-dose (Levbunolol) eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

PRESCRIBING AND DISPENSING INFORMATION

NATIONAL FUNDING/ACCESS DECISIONS

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (February 2014) that timolol gel eye drops (Timoptic®) are accepted for restricted use within NHS Scotland for the reduction of elevated intraocular pressure in patients with ocular hypertension or chronic open angle glaucoma who have proven sensitivity to preservatives.

MEDICATION FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops

Eye drops

EXCIPIENTS: May contain Benzalkonium chloride, disodium edetate, sodium metabisulphite

Betagan (Allergan Ltd)

Levbunolol hydrochloride 5 mg per 1 ml Betagan 0.5% eye drops

5 ml (Pom) £1.85 DT price + £1.85

Betagan Unit Dose 0.5% eye drops 0.4ml unit dose 30 unit dose (Pom) £9.98

TIMOPTOL-LA ®

Reduction of intra-ocular pressure in primary open-angle glaucoma

TO THE EYE

Adult: Apply twice daily

TIMOPTOL-LA ®

Reduction of intra-ocular pressure in primary open-angle glaucoma

TO THE EYE

Adult: Apply once daily

TIOPLEX ®

Reduction of intra-ocular pressure in primary open-angle glaucoma

TO THE EYE

Adult: Apply once daily, to be applied in the morning

CONTRA-INDICATIONS Also consider contra-indications listed for systemically administered beta blockers - bradycardia - heart block

CAUTIONS Consider also cautions listed for systemically administered beta blockers - patients with corneal disease

INTERACTIONS → Appendix 1: beta blockers (non-selective)

SIDE-EFFECTS Anaphylaxis - blepharoconjunctivitis - burning - corneal disorders - dry eyes - erythema - itching - ocular stinging - pain

SIDE-EFFECTS, FURTHER INFORMATION

Systemic absorption can follow topical application to the eyes; consider side effects listed for systemically administered beta blockers.

BREAST FEEDING Manufacturer advises avoidance.

PRESCRIBING AND DISPENSING INFORMATION

Although multi-dose timolol eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

NATIONAL FUNDING/ACCESS DECISIONS

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (February 2014) that timolol gel eye drops (Timoptic®) are accepted for restricted use within NHS Scotland for the reduction of elevated intraocular pressure in patients with ocular hypertension or chronic open angle glaucoma who have proven sensitivity to preservatives.

MEDI C INICATIONS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops

Eye gel

EXCIPIENTS: May contain Benzododecinium bromide

Timolol (as Timolol maleate) 2.5 mg per 1 ml Timolol-LA 0.25% ophthalmic gel-forming solution

2.5 ml (Pom) £3.12 DT price + £3.12

Timolol (as Timolol maleate) 5 mg per 1 ml Timolol-LA 0.5% ophthalmic gel-forming solution

2.5 ml (Pom) £3.12 DT price + £3.12

Eye drops

EXCIPIENTS: May contain Benzalkonium chloride

Timolol maleate (Non-proprietary)

Timolol (as Timolol maleate) 2.5 mg per 1 ml Timolol 0.25% eye drops

5 ml (Pom) £1.76 DT price + £1.43

Timolol (as Timolol maleate) 5 mg per 1 ml Timolol 0.5% eye drops

5 ml (Pom) £1.95 DT price + £1.25

Timolol (as Timolol maleate) 2.5 mg per 1 ml Timolol 0.25% eye drops

5 ml (Pom) £3.12 DT price + £1.43

Timolol Unit Dose 0.25% ophthalmic solution 0.2ml unit dose

30 unit dose (Pom) £8.45 DT price + £8.45

Timolol (as Timolol maleate) 5 mg per 1 ml Timolol 0.5% eye drops

5 ml (Pom) £3.12 DT price + £1.25

Timolol Unit Dose 0.5% ophthalmic solution 0.2ml unit dose

30 unit dose (Pom) £9.65 DT price + £9.65

Timolol maleate (Betaxolol)

Applying twice daily

Timolol maleate (Betaxolol)

Applying twice daily

BETA-ADRENERGIC BLOCKER BLOCKERS → SELECTIVE

Betaxolol

INDICATIONS AND DOSE

Primary open-angle glaucoma

TO THE EYE

Adult: Apply twice daily

CONTRA-INDICATIONS Also consider contra-indications listed for systemically administered beta blockers - bradycardia - heart block

CAUTIONS Patients with corneal disease

INTERACTIONS → Appendix 1: beta blockers (selective)

SIDE-EFFECTS Anaphylaxis - blepharoconjunctivitis - burning - corneal disorders - dry eyes - erythema - itching - ocular stinging - pain

SIDE-EFFECTS, FURTHER INFORMATION

Systemic absorption can follow topical application to the eyes; consider side effects listed for systemically administered beta blockers.

PRESCRIBING AND DISPENSING INFORMATION

Although multi-dose betaxolol eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

downloaded from www.medicalbr.com
**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**

**EXCipients:** May contain Benzalkonium chloride, disodium edetate

- Betaxolol (Non-proprietary)
- Betaxolol (as Betaxolol hydrochloride) 2.5 mg per 1 ml Betaxolol 0.25% eye drops 0.25ml unit dose preservative free | 50 unit dose
- Betaxolol (as Betaxolol hydrochloride) 5 mg per 1 ml Betaxolol 0.5% eye drops | 5 ml | £1.90 DT price = £1.90
- Betoptic (Alcon Laboratories (UK) Ltd)
- Betaxolol (as Betaxolol hydrochloride) 2.5 mg per 1 ml Betoptic 0.25% suspension eye drops | 5 ml | £2.66 DT price = £2.66
- Betoptic 0.25% eye drops suspension 0.25% unit dose | 50 unit dose | £13.77
- Betaxolol (as Betaxolol hydrochloride) 2.5 mg per 1 ml Betoptic 0.5% eye drops | 5 ml | £1.90 DT price = £1.90

**CARBONIC ANHYDRASE INHIBITORS**

### Acetazolamide

**INDICATIONS AND DOSE**

Reduction of intra-ocular pressure in open-angle glaucoma | Reduction of intra-pressure in secondary glaucoma | Reduction of intra-ocular pressure perioperatively in angle-closure glaucoma

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES, OR BY INTRAVENOUS INJECTION, OR BY INTRAMUSCULAR INJECTION**
  - Adult: 0.25 – 1 g daily in divided doses, intramuscular injection preferably avoided because of alkalinity

Glaucoma

- **BY MOUTH USING MODIFIED-RELEASE MEDICINES**
  - Adult: 250 – 500 mg daily

Epilepsy

- **BY MOUTH USING IMMEDIATE-RELEASE MEDICINES, OR BY INTRAVENOUS INJECTION, OR BY INTRAMUSCULAR INJECTION**
  - Adult: 0.25 – 1 g daily in divided doses, intramuscular injection preferably avoided because of alkalinity

**CONTRA-INDICATIONS**

Adrenocortical insufficiency · hyperchloreaemic acidosis · hypokalaemia · hypernatraemia · long-term administration in chronic angle-closure glaucoma

**CAUTIONS**

Avoid extravasation at injection site (risk of necrosis) · diabetes mellitus · elderly · impaired alveolar ventilation (risk of acidosis) · not generally recommended for long-term use · pulmonary obstruction (risk of acidosis) · renal calculi

**INTERACTIONS** → Appendix 1: acetazolamide

**SIDE-EFFECTS**

- **Common or very common** Ataxia · depression · diarrhoea · dizziness · excitement · fatigue · flushing · headache · irritability · loss of appetite · nausea · paraesthesia · polyuria · reduced libido · taste disturbance · thirst · vomiting
- **Uncommon** Blood disorders · bone marrow suppression · confusion · crystalluria · drowsiness · electrolyte disturbances on long-term therapy · fever · glycosuria · haematuria · hearing disturbances · melaena · metabolic acidosis · rash · renal calculi · renal colic · renal failure · renal lesions · Stevens-Johnson syndrome · toxic epidermal necrosis · urederic colic
- **Rare** Cholestatic jaundice · convulsions · flaccid paralysis · fulminant hepatic necrosis · hepatitis · photosensitivity
- **Frequency not known** Transient myopia

SIDE-EFFECTS, FURTHER INFORMATION

Acetazolamide is a sulfonamide derivative; blood disorders, rashes, and other sulfonamide-related side-effects occur occasionally—patients should be told to report any unusual skin rash.

If electrolyte disturbances and metabolic acidosis occur, these can be corrected by administering potassium bicarbonate (as effervescent potassium tablets).

**ALLERGY AND CROSS-SENSITIVITY**

Contra-indicated if history of sulfonamide hypersensitivity.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

**Tablet**

CAUTIONARY AND ADVISORY LABELS 3

- **Acetazolamide (Non-proprietary)**
  - Acetazolamide 250 mg Acetazolamide 250mg tablets | 112 tablet | £75.36 DT price = £28.20

Powder for solution for injection

- **Diamox (AMCo)**
  - Acetazolamide 500 mg Diamox Sodium Parenteral 500mg powder for solution for injection vials | 1 vial | £14.76

Modified-release capsule

CAUTIONARY AND ADVISORY LABELS 3, 25

- **Diamox SR (AMCo)**
  - Acetazolamide 250 mg Diamox SR 250mg capsules | 30 capsule | £16.66 DT price = £16.66
  - **Eytaox (Teva UK Ltd)**
    - Acetazolamide 250 mg Eytaox 250mg modified-release capsules | 30 capsule | £16.60 DT price = £16.66

**Brinzolamide**

**INDICATIONS AND DOSE**

Reduction of intra-ocular pressure in ocular hypertension and open-angle glaucoma either as adjunct to beta-blockers or prostaglandin analogues or used alone in patients unresponsive to beta-blockers or if beta-blockers contra-indicated

- TO THE EYE
  - Adult: Apply twice daily, then increased if necessary up to 3 times a day

**CONTRA-INDICATIONS**

Hyperchloreaemic acidosis

**CAUTIONS**

Renal tubular immaturity or abnormality · systemic absorption follows topical application

**INTERACTIONS** → Appendix 1: brinzolamide

**SIDE-EFFECTS**

- **Common or very common** Corneal erosion · corneal oedema · dry mouth · headache · ocular disturbances · photophobia · reduced visual acuity · taste disturbances
- **Uncommon** Alopecia · amnesia · bradycardia · chest pain · cough · decreased libido · depression · diarrhoea · dizziness · drowsiness · dyspepsia · dysphonia · epistaxis · erectile dysfunction · flattulence · malaise · nasal dryness · nausea · nervousness · oesophagitis · oral hypoesthesia and paraesthesia · palpititation · paraesthesia · pharyngitis · renal pain · sinusitis · sleep disturbances · throat irritation · tinnitus · upper respiratory tract congestion · vomiting
- **Frequency not known** Arrhythmia · asthma · dermatitis · erythema · hypertension · peripheral oedema · rhinitis · tachycardia · tremor · vertigo

SIDE-EFFECTS, FURTHER INFORMATION

Systemic absorption can rarely cause sulfonamide-like side-effects and may require discontinuation if severe.

**ALLERGY AND CROSS-SENSITIVITY**

Contra-indicated if history of sulfonamide hypersensitivity.
BRINZOLAMIDE WITH BRIMONIDINE

27-Sep-2016

The properties listed below are those particular to the combination only. For the properties of the components please consider, brinzolamide p. 1080, brimonidine tartrate p. 1086.

**INDICATIONS AND DOSE**

- **Raised intra-ocular pressure in open-angle glaucoma and in ocular hypertension when monotherapy is inadequate**
  - **TO THE EYE**
  - **Adult:** Apply 1 drop twice daily

**SIDE-EFFECTS**

- **Common or very common** Somnolence
- **Uncommon** Dermatitis - dry throat - hypotension - vertigo

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**

- **EXCIPIENTS:** May contain Benzalkonium chloride, disodium edetate
- **Simbrinza** (Alcon Laboratories (UK) Ltd)
  - Brimonidine tartrate 2 mg per 1 ml, Brinzolamide 10 mg per 1 ml
  - Simbrinidine 10 mg/ml / 2mg/ml eye drops | 5 ml £9.23 DT price = £9.23

**Brinzolamide with timolol**

The properties listed below are those particular to the combination only. For the properties of the components please consider, brinzolamide p. 1080, timolol maleate p. 1079.

**INDICATIONS AND DOSE**

- **Raised intra-ocular pressure in open-angle glaucoma or ocular hypertension when beta-blocker alone not adequate**
  - **TO THE EYE**
  - **Adult:** Apply twice daily

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**

- **EXCIPIENTS:** May contain Benzalkonium chloride, disodium edetate
- **Azarga** (Alcon Laboratories (UK) Ltd)
  - Timolol (as Timolol maleate) 5 mg per 1 ml, Brinzolamide 10 mg per 1 ml
  - Azarga 10mg/ml / 5mg/ml eye drops | 5 ml £11.05
  - DT price = £11.05

**Dorzolamide**

**INDICATIONS AND DOSE**

Raised intra-ocular pressure in ocular hypertension used alone in patients unresponsive to beta-blockers or if beta-blockers contra-indicated | Open-angle glaucoma used alone in patients unresponsive to beta-blockers or if beta-blockers contra-indicated | Pseudo-exfoliative glaucoma used alone in patients unresponsive to beta-blockers or if beta-blockers contra-indicated

- **TO THE EYE**
- **Adult:** Apply 3 times a day
- **Raised intra-ocular pressure in ocular hypertension as adjunct to beta-blocker** | Open-angle glaucoma as adjunct to beta-blocker | Pseudo-exfoliative glaucoma as adjunct to beta-blocker

- **TO THE EYE**
- **Adult:** Apply twice daily

**CONTRA-INDICATIONS**

- Hyperchloraemic acidosis
- Chronic corneal defects - history of intra-ocular surgery - history of renal calculi - low endothelial cell count - systemic absorption follows topical application

**INTERACTIONS**

- Appendix 1: dorzolamide

**SIDE-EFFECTS**

- Common or very common Asthenia - bitter taste - blurred vision - conjunctivitis - eyelid inflammation - headache - lacrimation - nausea - ocular irritation - superficial punctate keratitis
- Uncommon Iridocyclitis
- Rare Contact dermatitis - corneal oedema - dizziness - dry mouth - epistaxis - eyelid crusting - paraesthesia - Stevens-Johnson syndrome - throat irritation - toxic epidermal necrolysis - transient myopia - urolithiasis

**SIDE-EFFECTS, FURTHER INFORMATION**

Systemic absorption can rarely cause sulfonamide-like side-effects and may require discontinuation if severe.

- **ALLERGY AND CROSS-SENSITIVITY** Contra-indicated if history of sulfonamide hypersensitivity.
- **PREGNANCY** Manufacturer advises avoid — toxicity in animal studies.
- **BREAST FEEDING** Manufacturer advises avoid — no information available.
- **HEPATIC IMPAIRMENT** Manufacturer advises caution — no information available.
- **RENAL IMPAIRMENT** Avoid if eGFR less than 30 ml/minute/1.73 m².
- **PRESCRIBING AND DISPENSING INFORMATION** Although multi-dose dorzolamide eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**

- **EXCIPIENTS:** May contain Benzalkonium chloride
- **Dorzolamide (Non-proprietary)**
  - Dorzolamide (as Dorzolamide hydrochloride) 20 mg per 1 ml
  - Dorzolamide 2% eye drops | 5 ml £6.33 DT price = £6.33
- **Trusopt** (Santen UK Ltd)
  - Dorzolamide (as Dorzolamide hydrochloride) 20 mg per 1 ml
  - Trusopt 2% eye drops | 5 ml £1.90
  - Trusopt 2% eye drops 0.2ml unit dose preservative free | 60 unit dose £24.18
Dorzolamide with timolol

The properties listed below are those particular to the combination only. For the properties of the components please consider, dorzolamide p. 1081, timolol maleate p. 1079.

- **INDICATIONS AND DOSE**
  - **INDICATIONS**
    - Raised intra-ocular pressure in open-angle glaucoma when beta-blockers alone not adequate | Raised intra-ocular pressure in pseudo-exfoliative glaucoma when beta-blockers alone not adequate
  - **DOSE**
    - TO THE EYE
    - Adult: Apply twice daily

- **PRESCRIBING AND DISPENSING INFORMATION**
  - Although multi-dose dorzolamide with timolol eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Eye drops**
    - **Excipients**: May contain Benzalkonium chloride | Dorzolamide with timolol (Non-proprietary)
    - Timolol (as Timolol maleate) 5 mg per 1 ml, Dorzolamide (as Dorzolamide hydrochloride) 20 mg per 1 ml Dorzolamide 2% / Timolol 0.5% eye drops | 5 ml [POM] | £27.16 DT price = £1.81
    - Dorzolamide 2% / Timolol 0.5% eye drops 0.2ml unit dose | 60 unit dose [POM] | £28.59 DT price = £28.59
    - Cosopt (Santen UK Ltd)
    - Timolol (as Timolol maleate) 5 mg per 1 ml, Dorzolamide (as Dorzolamide hydrochloride) 20 mg per 1 ml Cosopt eye drops 0.2ml unit dose preservative free | 60 unit dose [POM] | £28.59 DT price = £28.59
    - Cosopt eye drops | 5 ml [POM] | £10.05 DT price = £1.81

- **MIOTICS → PARASYMPATHOMIMETICS**

Pilocarpine

- **DRUG ACTION**
  - Pilocarpine acts by opening the inefficient drainage channels in the trabecular meshwork.

- **INDICATIONS AND DOSE**
  - **INDICATIONS**
    - Primary angle-closure glaucoma | Some secondary glaucomas
  - **DOSE**
    - TO THE EYE
    - Adult: Apply up to 4 times a day

- **CONTRA-INDICATIONS**
  - Acute inflammatory disease of the anterior segment - acute iritis - anterior uveitis - conditions where pupillary constriction is undesirable - some forms of secondary glaucoma (where pupillary constriction is undesirable)

- **CAUTIONS**
  - Darkly pigmented iris may require a higher concentration of the miotic or more frequent administration and care should be taken to avoid overdosage - asthma - cardiac disease - care in conjunctival damage - care in corneal damage - epilepsy - gastro-intestinal spasm - hypertension - hyperthyroidism - hypotension - marked vasomotor instability - Parkinson’s disease - peptic ulceration - retinal detachment has occurred in susceptible individuals and those with retinal disease - urinary-tract obstruction

- **INTERACTIONS**
  - Appendix 1: pilocarpine

- **SIDE-EFFECTS**
  - Rare Parasympathomimetics systemic side effects
  - Frequency not known Blurred vision - ciliary spasm (leads to headache and browache which may be more severe in the initial 2–4 weeks of treatment—a particular disadvantage in patients under 40 years of age) - conjunctival vascular congestion - lens changes (with chronic use) - myopia - ocular burning - ocular itching - pupillary block - smarting - vitreous haemorrhage

- **PREGNANCY**
  - Avoid unless the potential benefit outweighs risk—limited information available.

- **BREAST FEEDING**
  - Avoid unless the potential benefit outweighs risk—no information available.

- **PRE-TREATMENT SCREENING**
  - Fundus examination is advised before starting treatment with a miotic (retinal detachment has occurred).

- **MONITORING REQUIREMENTS**
  - Intra-ocular pressure and visual fields should be monitored in those with chronic simple glaucoma and those receiving long-term treatment with a miotic.

- **PRESCRIBING AND DISPENSING INFORMATION**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: eye drops

- **Eye drops**
  - **Excipients**: May contain Benzalkonium chloride
  - **Pilocarpine (Non-proprietary)**
    - Pilocarpine hydrochloride 2% eye drops | 10 ml [POM] | £16.10 DT price = £13.44
    - Pilocarpine hydrochloride 2% eye drops | 10 ml [POM] | £19.71 DT price = £16.48
    - Pilocarpine hydrochloride 4% eye drops | 10 ml [POM] | £21.99 DT price = £18.35
  - **Pilocarpine nitrate** (Bausch & Lomb UK Ltd)
    - Pilocarpine nitrate 20 mg per 1 ml
      - Minims pilocarpine nitrate 2% eye drops 0.5ml unit dose | 20 unit dose [POM] | £11.99

- **PROSTAGLANDIN ANALOGUES AND PROSTAMIDES**

Bimatoprost

- **INDICATIONS AND DOSE**
  - Raised intra-ocular pressure in open-angle glaucoma | Ocular hypertension
  - TO THE EYE
  - Adult: Apply once daily, to be administered preferably in the evening

- **CAUTIONS**
  - Angle-closure glaucoma (no experience of use) - aphakia - asthma - chronic obstructive pulmonary disease - compromised respiratory function - congenital glaucoma (no experience of use) - contact lens wearers - history of significant ocular viral infections - inflammatory ocular conditions (no experience of use) - narrow-angle glaucoma (no experience of use) - neovascular glaucoma (no experience of use) - predisposition to hypotension - pseudophakia with torn posterior lens capsule or anterior chamber lenses - risk factors for cystoid macular oedema - risk factors for iritis - risk factors for uveitis
**SIDE-EFFECTS**

- **Common or very common** Blepharitis • blood pressure changes • brown pigmentation particularly in those with mixed–colour irides • conjunctival disorders • corneal erosion • darkening, thickening and lengthening of eye lashes • eyelash and vellus hair changes • headache • ocular discomfort • photophobia • pigmentation of periorcular skin • punctate keratitis • reduced visual acuity • transient punctate epithelial erosion
- **Uncommon** Asthenopia • dizziness • skin rash
- **Rare** Arthralgia • darkening of palpebral skin • facial oedema • iritis • macular oedema • myalgia • uveitis
- **Very rare** Chest pain • exacerbation of angina • palpitation • periorbital changes resulting in deepening of the eyelid sulcus

**Frequency not known** Asthma • blepharospasm • bradycardia • dyspnoea • exacerbation of COPD • eyelid retraction • malaise • nausea • ocular infection • reactivation of previous corneal infiltrates • retinal haemorrhage

**PREGNANCY** Manufacturer advises use only if potential benefit outweighs risk.
**BREAST FEEDING** Manufacturer advises avoid—present in milk in animal studies.

**HEPATIC IMPAIRMENT** Use with caution in moderate to severe impairment—no information available.

**RENAL IMPAIRMENT** Use with caution—no information available.

**PRESCRIBING AND DISPENSING INFORMATION** Although multi-dose bimatoprost eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

**PATIENT AND CARER ADVICE**

Changes to eye colour Before initiating treatment, patients should be warned of a possible change in eye colour as an increase in the brown pigment in the iris can occur, which may be permanent; particular care is required in those with mixed coloured irides and those receiving treatment to one eye only. Changes in eyelashes and vellus hair can also occur, and patients should also be advised to avoid repeated contact of the eye drop solution with skin as this can lead to hair growth or skin pigmentation.

**INDICATIONS AND DOSE**

- **Raised intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension when beta-blocker or prostaglandin analogue alone not adequate**
  - TO THE EYE
  - Adult: Apply once daily

**NATIONAL FUNDING/ACCESS DECISIONS**

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (October 2013) that Ganfort® unit dose eye drops are accepted for restricted use within NHS Scotland for the reduction of intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension insufficiently responsive to topical beta-blockers or prostaglandin analogues who have proven sensitivity to preservatives.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**

- **EXCIPIENTS:** May contain Benzalkonium chloride
- **Lumigan®** (Allergan Ltd)
- **Bimatoprost 100 microgram per 1 ml**
  - Lumigan 100micrograms/ml eye drops 3 ml (PST) £11.71 DT price = £11.71
  - 9 ml (PST) £35.13
- **Bimatoprost 300 microgram per 1 ml**
  - Lumigan 300micrograms/ml eye drops 0.4ml unit dose 30 unit dose (PST) £13.75 DT price = £13.75

**CONTRA-INDICATIONS** Active herpes simplex keratitis • history of recurrent herpetic keratitis associated with prostaglandin analogues

**CAUTIONS** Angle-closure glaucoma (no experience of use) • aphaikia • asthma • chronic obstructive pulmonary disease • compromised respiratory function • congenital glaucoma (no experience of use) • contact lens wearers • do not use within 5 minutes of thiomersal-containing preparations • history of significant ocular viral infections • inflammatory ocular conditions (no experience of use) • narrow-angle glaucoma (no experience of use) • neovascular glaucoma (no experience of use) • peri-operative period of cataract surgery • pseudophakia with torn posterior lens capsule or...
anterior chamber lenses - risk factors for cystoid macular oedema - risk factors for iritis - risk factors for uveitis

- **SIDE-EFFECTS**
  - Common or very common: Blepharitis - blood pressure changes - brown pigmentation particularly in those with mixed-colour irides - conjunctival disorders - corneal erosion - darkening, thickening and lengthening of eye lashes - eyelash and vellus hair changes - headache - ocular discomfort - photophobia - pigmentation of periocular skin - punctate keratitis - reduced visual acuity - transient punctate epithelial erosion
  - Uncommon: Asthenopia - dizziness - skin rash
  - Rare: Arthralgia - darkening of palpebral skin - facial oedema - iritis - macular oedema - myalgia - uveitis
  - Very rare: Chest pain - exacerbation of angina - palpitation - periorbital changes resulting in deepening of the eyelid sulcus
  - Frequency not known: Asthma - dyspnoea - exacerbation of asthma - exacerbation of COPD - iris cyst - nasopharyngitis - pyrexia

- **PREGNANCY** Manufacturer advises avoid.

- **BREAST FEEDING** May be present in milk—manufacturer advises avoid.

- **PRESCRIBING AND DISPENSING INFORMATION** Although multi-dose latanoprost eye drops commonly contain preservatives, preservative-free unit dose vials may be available.

- **PATIENT AND CARER ADVICE** Changes in eye colour
  - Before initiating treatment, patients should be warned of a possible change in eye colour as an increase in the brown pigment in the iris can occur, which may be permanent; particular care is required in those with mixed coloured irides and those receiving treatment to one eye only. Changes in eyelashes and vellus hair can also occur, and patients should also be advised to avoid repeated contact of the eye drop solution with skin as this can lead to hair growth or skin pigmentation.

- **NATIONAL FUNDING/ACCESS DECISIONS**
  - Scottish Medicines Consortium (SMC) Decisions
    - The Scottish Medicines Consortium has advised (June 2013) that Monopost® is accepted for restricted use within NHS Scotland for the reduction of elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension who have proven sensitivity to benzalkonium chloride.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  - **Eye drops**
    - EXCipients: May contain benzalkonium chloride
      - Latanoprost with timolol (Non-proprietary)
        - Latanoprost 50 microgram per 1 ml Latanoprost 50 micrograms/ml eye drops | 2.5 ml (£4.09), 5 ml (£7.40), 10 ml (£14.80)
        - Monopost (Thea Pharmaceuticals Ltd)
          - Latanoprost 50 microgram per 1 ml Latanoprost 50 micrograms/ml eye drops 0.2 ml unit dose | 30 unit dose (£0.25), 90 unit dose (£0.75)
          - Xalatan (Pfizer Ltd)
            - Latanoprost 50 microgram per 1 ml Xalatan 50 micrograms/ml eye drops | 2.5 ml (£4.09), 5 ml (£7.40)

  - **Tafnuprost**
    - INDICATIONS AND DOSE
      - Raised intraocular pressure in patients with open-angle glaucoma or ocular hypertension when beta-blocker or prostaglandin analogue alone not adequate
        - TO THE EYE
        - Adult: Apply once daily

  - **INDICATIONS AND DOSE**
    - There can be variation in the licensing of different medicines containing the same drug.

    - **Eye drops**
      - EXCipients: May contain benzalkonium chloride
        - Latanoprost with timolol (Non-proprietary)
          - Latanoprost 50 microgram per 1 ml Timolol (as Timolol maleate) 5 mg per 1 ml Latanoprost 50 micrograms/ml | Timolol 5 mg/eye drops | 2.5 ml (£14.32), 5 ml (£28.64)
            - Xalacom (Pfizer Ltd)
              - Latanoprost 50 microgram per 1 ml Timolol (as Timolol maleate) 5 mg per 1 ml Xalacom eye drops | 2.5 ml (£14.32), 5 ml (£28.64)

  - **CAUTIONS**
    - Angle-closure glaucoma (no experience of use) - aphakia - asthma - chronic obstructive pulmonary disease - compromised respiratory function - congenital glaucoma (no experience of use) - contact lens wearers - history of significant ocular viral infections - inflammatory ocular conditions (no experience of use) - narrow-angle glaucoma (no experience of use) - neovascular glaucoma (no experience of use) - pseudophakia with torn posterior lens capsule or anterior chamber lenses - risk factors for cystoid macular oedema - risk factors for iritis - risk factors for uveitis

  - **SIDE-EFFECTS**
    - Common or very common: Blepharitis - blood pressure changes - brown pigmentation particularly in those with mixed-colour irides - conjunctival disorders - corneal erosion - darkening, thickening and lengthening of eye lashes - eyelash and vellus hair changes - headache - ocular discomfort - photophobia - pigmentation of periocular skin - punctate keratitis - reduced visual acuity - transient punctate epithelial erosion
        - Uncommon: Asthenopia - dizziness - skin rash
        - Rare: Arthralgia - darkening of palpebral skin - facial oedema - iritis - macular oedema - myalgia - uveitis
        - Very rare: Chest pain - exacerbation of angina - palpitation - periorbital changes resulting in deepening of the eyelid sulcus
        - Frequency not known: Asthma - dyspnoea - exacerbation of asthma - exacerbation of COPD
      - PREGNANCY: Manufacturer advises avoid unless potential benefit outweighs risk—toxicity in animal studies.
      - BREAST FEEDING: Manufacturer advises avoid—present in milk in animal studies.
      - HEPATIC IMPAIRMENT: Use with caution—no information available.
**Travoprost**

**INDICATIONS AND DOSE**

**Raised intra-ocular pressure in open-angle glaucoma**

**Ocular hypertension**

- **TO THE EYE**
- **Adult:** Apply once daily, to be administered preferably in the evening.

**CAUTIONS**

- History of significant ocular viral infections: angle-closure glaucoma (no experience of use).
- Asthma: chronic obstructive pulmonary disease.
- Compromised respiratory function: congenital glaucoma (no experience of use).
- Contact lens wearers: inflammatory ocular conditions (no experience of use).
- Narrow-angle glaucoma (no experience of use).
- Neovascular glaucoma (no experience of use).
- Pseudophakia with torn posterior lens capsule or anterior chamber lenses.
- Risk factors for cystoid macular oedema: risk factors for iritis.
- Risk factors for uveitis.

**SIDE-EFFECTS**

- Common or very common: Blepharitis, blood pressure changes.
- Rare: Arthralgia, darkening of palpebral skin.
- Very rare: Chest pain, exacerbation of angina.

**MEDICINAL FORMS**

- **Eye drops:** Travoprost 40 microgram per 1 ml (Santen UK Ltd).
- **EXCIPIENTS:** May contain Disodium edetate.

---

**Tafloproust with timolol**

30-Mar-2016

The properties listed below are those particular to the combination only. For the properties of the components please consider, tafluprost p. 1084, timolol maleate p. 1079.

**INDICATIONS AND DOSE**

**Raised intra-ocular pressure in open-angle glaucoma and ocular hypertension when beta-blocker or prostaglandin analogue alone not adequate**

- **Adult:** Apply 1 drop once daily.

**SIDE-EFFECTS**

- Common or very common: Blurred vision, ocular hyperaemia.
- Uncommon: Anterior chamber inflammation, conjunctivitis.

**PATIENT AND CARER ADVICE**

- **Driving and skilled tasks:** Blurred vision may affect performance of skilled tasks (e.g. driving or operating machinery).

**NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (September 2015) that Travatan® (tafluprost with timolol) is accepted for restricted use within NHS Scotland, within the licensed indications, in patients who have proven sensitivity to preservatives.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Eye drops:** Travoprost 40 microgram per 1 ml (Travatan 40micrograms/ml eye drops) 2.5 ml (£10.95 DT price + £10.95).
Travoprost with timolol

The properties listed below are those particular to the combination only. For the properties of the components please consider, travoprost p. 1085, timolol maleate p. 1079.

**INDICATIONS AND DOSE**

**Raised intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension when beta-blocker or prostaglandin analogue alone not adequate**

- **TO THE EYE**
  - **Adult:** Apply once daily

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**

**EXCIPIENTS:** May contain Propylene glycol

- **DuoTrav** (Alcon Laboratories (UK) Ltd)
  - Travoprost 40 microgram per 1 ml, Timolol (as Timolol maleate) 5 mg per 1 ml DuoTrav 40micrograms/ml / 5mg/ml eye drops | 2.5 ml [POD] £13.95 DT price + £3.95 | 7.5 ml [POD] £39.68

**SYMPATHOMIMETICS**

> **ALPHA₂-ADRENOCEPTOR AGONISTS**

**Apraclonidine**

**DRUG ACTION**

Apraclonidine is an alpha₂-adrenoceptor agonist that lowers intra-ocular pressure by reducing aqueous humour formation. It is a derivative of clonidine.

**INDICATIONS AND DOSE**

Control or prevention of postoperative elevation of intra-ocular pressure after anterior segment laser surgery

- **TO THE EYE**
  - **Adult:** Apply 1 drop, 1 hour before laser procedure, then 1 drop, immediately after completion of procedure, 1% eye drops to be administered

Short-term adjunctive treatment of chronic glaucoma in patients not adequately controlled by another drug

- **TO THE EYE**
  - **Adult:** Apply 1 drop 3 times a day usually for maximum 1 month, 0.5% eye drops to be administered, may not provide additional benefit if patient already using two drugs that suppress the production of aqueous humour

**CONTRA-INDICATIONS**

History of severe or unstable and uncontrolled cardiovascular disease

**CAUTIONS**

Cerebrovascular disease - depression - heart failure - history of angina - hypertension - loss of effect may occur over time - Parkinson’s syndrome - Raynaud’s syndrome - recent myocardial infarction - reduction in vision in end-stage glaucoma (suspend treatment) - severe coronary insufficiency - thromboangiitis obliterans - vasovagal attack

**INTERACTIONS**

- **Appendix 1: apraclonidine**

**SIDE-EFFECTS**

- **Common or very common** Conjunctivitis - dry eye - ocular intolerance - rhinitis - taste disturbance

- **Uncommon** Asthma - blepharitis - blepharospasm - chest pain - conjunctival vascular disorders - corneal erosion and infiltrates - dyspnoea - eyelid ptosis or retraction - impaired co-ordination - irritability - keratitis - keratopathy - myalgia - mydriasis - nervousness - parosmia - photophobia - rhinorrhoea - throat irritation - visual impairment

**SIDE-EFFECTS, FURTHER INFORMATION**

- **Ocular intolerance** Withdraw if eye pruritus, ocular hyperaemia, increased lacrimation, or oedema of the eyelids and conjunctiva occur.

- **Systemic effects** Since absorption may follow topical application, see clonidine hydrochloride p. 139.

**PREGNANCY**

Manufacturer advises avoid—no information available.

**BREAST FEEDING**

Manufacturer advises avoid—no information available.

**HEPATIC IMPAIRMENT**

Manufacturer advises caution.

**RENAL IMPAIRMENT**

Use with caution in chronic renal failure.

**MONITORING REQUIREMENTS**

- Monitor intra-ocular pressure and visual fields.
- Monitor for excessive reduction in intra-ocular pressure following peri-operative use.

**PATIENT AND CARER ADVICE**

Driving and skilled tasks

Drowsiness may affect performance of skilled tasks (e.g. driving).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Eye drops**

**EXCIPIENTS:** May contain Benzoalkonium chloride

- **Iopidine** (Alcon Laboratories (UK) Ltd)
  - Apraclonidine (as Apraclonidine hydrochloride) 5 mg per 1 ml Iopidine 5mg/ml eye drops | 5 ml [POD] £10.88 DT price = £10.88
  - Apraclonidine (as Apraclonidine hydrochloride) 10 mg per 1 ml Iopidine 1% eye drops 0.25ml unit dose | 24 unit dose [POD] £77.85 DT price = £77.85

**Brimonidine tartrate**

**DRUG ACTION**

Brimonidine, an alpha₂-adrenoceptor agonist, is thought to lower intra-ocular pressure by reducing aqueous humour formation and increasing uveoscleral outflow.

**INDICATIONS AND DOSE**

Raised intra-ocular pressure in open-angle glaucoma in patients for whom beta-blockers are inappropriate

Ocular hypertension in patients for whom beta-blockers are inappropriate

- **Adjunctive therapy when intra-ocular pressure is inadequately controlled by other antiglaucoma therapy**

- **TO THE EYE**
  - **Adult:** Apply twice daily

**CAUTIONS**

Cerebral insufficiency - coronary insufficiency - depression - postural hypotension - Raynaud’s syndrome - severe cardiovascular disease - thromboangiitis obliterans

**INTERACTIONS**

- **Appendix 1: brimonidine**

**SIDE-EFFECTS**

- **Common or very common** Burning sensation at application site - conjunctival blanching - conjunctival disturbances - conjunctival follicles - conjunctival infection - corneal erosion - corneal staining - dizziness - dryness - dry mouth - eyelid inflammation - gastro-intestinal disturbances - headache - malaise - ocular disturbances - ocular dryness - ocular hyperaemia - ocular pain - ocular pruritus - photophobia - stinging at application site - taste disturbances - upper respiratory symptoms - visual disturbances

- **Uncommon** Arrhythmia - bradycardia - depression - nasal dryness - palpitation - tachycardia

- **Rare**

- **Very rare** Hypertension - hypotension - insomnia - iritis - miosis - syncope

**PREGNANCY**

Manufacturer advises use only if benefit outweighs risk—limited information available.
6 Retinal disorders

6.1 Macular degeneration

Subfoveal choroidal neovascularisation

Treatment

Aflibercept below, pegaptanib sodium p. 1088 and ranibizumab p. 1089 are vascular endothelial growth factor inhibitors licensed for the treatment of neovascular (wet) age-related macular degeneration. Aflibercept is also licensed for the treatment of macular oedema secondary to central retinal vein occlusion, and diabetic macular oedema; ranibizumab is also licensed for the treatment of visual impairment due to diabetic macular oedema, macular oedema secondary to branch or central retinal vein occlusion, and choroidal neovascularisation secondary to pathologic myopia. Ranibizumab can be administered concomitantly with laser photocoagulation for the treatment of diabetic macular oedema and for macular oedema secondary to branch retinal vein occlusion.

ANTINEOVOCA RISATION DRUGS

VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS

Aflibercept

- **DRUG ACTION** Aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor and binds to vascular endothelial growth factors A and B (VEGF-A, VEGF-B) and placent al growth factor (PIGF). Aflibercept inhibits the activation of VEGF receptors and the proliferation of endothelial cells, thereby inhibiting the growth of new vessels that supply tumours with oxygen and nutrients.

- **INDICATIONS AND DOSE**

  Neovascular (wet) age-related macular degeneration (specialist use only)

  - **BY INTRAVITREAL INJECTION**
    - Adult: Initially 2 mg once a month for 3 months, then 2 mg every 2 months, review treatment frequency after 12 months

  Macular oedema secondary to retinal vein occlusion (specialist use only)

  - **BY INTRAVITREAL INJECTION**
    - Adult: Initially 2 mg once a month until maximum visual acuity is achieved or there are no signs of disease activity (discontinue treatment if no improvement in visual and anatomic outcomes)

  Diabetic macular oedema (specialist use only)

  - **BY INTRAVITREAL INJECTION**
    - Adult: Initially 2 mg once a month for 5 months, then maintenance 2 mg every 2 months, review treatment frequency after 12 months (discontinue treatment if no improvement in visual and anatomic outcomes)

  Myopic choroidal neovascularisation (specialist use only)

  - **BY INTRAVITREAL INJECTION**
    - Adult: 2 mg for 1 dose, if visual or anatomic outcomes indicate that disease persists, additional doses may be administered; the interval between 2 doses should be greater than 1 month

- **CONTRA-INDICATIONS** Clinical signs of irreversible ischaemic visual function loss · ocular or periorbital infection · severe intra-ocular inflammation

- **CAUTIONS** Active systemic infection · diabetic patients with uncontrolled hypertension · discontinue treatment if stage 3 or 4 macular holes develop—consult product literature for full details · discontinue treatment in the event of a retinal break—consult product literature for full details · discontinue treatment in the event of rhegmatogenous retinal detachment—consult product literature for full details · patients at risk of retinal pigment epithelial tear · poorly controlled glaucoma · recent history of myocardial infarction · recent history of stroke · recent history of transient ischaemic attack

CAUTIONS, FURTHER INFORMATION

Aflibercept is given by intravitreal injection by specialists experienced in the management of this condition. There is a potential risk of arterial thromboembolic events and non-ocular haemorrhage following the intravitreal injection of vascular endothelial growth factor inhibitors. Endophthalmitis can occur after intravitreal injections—patients should be advised to report any signs of infection immediately.

- **INTERACTIONS** • Appendix 1: aflibercept
Aflibercept for pregnancy

- **Common or very common** Treating visual impairment caused by diabetic macular oedema (July 2016) NICE TA305

Aflibercept solution for injection is recommended as an option for use within NHS Wales for the treatment of adult patients with visual impairment due to myopic choroidal neovascularisation. This recommendation applies only if the approved Wales Patient Access Scheme (PAS) is used or where the list/contract price is equivalent or lower.

### Pegaptanib sodium

#### INDICATIONS AND DOSE

Treatment of neovascular (wet) age-related macular degeneration (specialist use only)

- **By intravitreal injection**
- **Adults:** 300 micrograms every 6 weeks, to be administered into the affected eye, review treatment if no benefit after 2 consecutive injections

#### CONTRA-INDICATIONS

Ocular or periocular infection

#### CAUTIONS

**CAUTIONS, FURTHER INFORMATION**

Pegaptanib is given by intravitreal injection by specialists. There is a potential risk of arterial thromboembolic events and non-ocular haemorrhage following the intravitreal injection of vascular endothelial growth factor inhibitors. Endophthalmitis can occur after intravitreal injections—patients should be advised to report any signs of infection immediately.

#### SIDE-EFFECTS

- **Common or very common** Anterior chamber inflammation - cataract - conjunctival haemorrhage - conjunctivitis - corneal dystrophy - dry eye - eye discharge - eye irritation - eye pain - flashing lights - headache - local oedema - macular degeneration - mydriasis - periorbital haematoma - photophobia - punctate keratitis - raised intra-ocular pressure - retinal haemorrhage - rhinorrhoea - retinal disorders - vitreous disorders - vitreous floaters

#### PREGNANCY

Manufacturer advises avoid unless potential benefit outweighs risk.

#### BREAST FEEDING

Manufacturer advises avoid—no information available.
MONITORING REQUIREMENTS
- Monitor intra-ocular pressure (transient increase may occur following injection, and small, sustained increases reported after repeated dosing).
- Monitor for vitreous haemorrhage and for signs of ocular infection for 2 weeks following injection.

DIRECTIONS FOR ADMINISTRATION
For further information on administration, consult product literature.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)
- Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (updated May 2012) NICE TA155
- Pegaptanib is not recommended for the treatment of wet age-related macular degeneration; patients currently receiving pegaptanib for any lesion type can continue therapy until they and their specialist consider it appropriate to stop. www.nice.org.uk/TA155

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. No licensed medicines listed.

Ranibizumab

INDICATIONS AND DOSE
Neovascular (wet) age-related macular degeneration (specialist use only)
- BY INTRAVITREAL INJECTION
  - Adult: 500 micrograms once a month, to be administered into the affected eye, monitor visual acuity monthly, continue treatment until visual acuity is stable for 3 consecutive months, thereafter monitor visual acuity monthly, if necessary subsequent doses may be given at least 1 month apart

Diabetic macular oedema / Macular oedema secondary to retinal vein occlusion (specialist use only)
- BY INTRAVITREAL INJECTION
  - Adult: Initially 500 micrograms once a month, to be administered into the affected eye, monitor visual acuity monthly, continue treatment until visual acuity is stable for 3 consecutive months (discontinue treatment if no improvement in visual acuity after initial 3 injections), thereafter monitor visual acuity monthly, if necessary subsequent doses may be given at least 1 month apart

Choroidal neovascularisation secondary to pathologic myopia (specialist use only)
- BY INTRAVITREAL INJECTION
  - Adult: Initially 500 micrograms, to be administered as a single injection into the affected eye, monitor for disease activity monthly for first 2 months, then at least every 3 months thereafter during the first year, then as required, if necessary subsequent doses may be given at least 1 month apart

Concomitant treatment of diabetic macular oedema, or macular oedema secondary to branch retinal vein occlusion, with laser photocoagulation (specialist use only)
- BY INTRAVITREAL INJECTION
  - Adult: 500 micrograms, to be administered at least 30 minutes after laser photocoagulation

CONTRA-INDICATIONS
- Ocular or periocular infection • severe intra-ocular inflammation • signs of irreversible ischaemic visual function loss in patients with retinal vein occlusion

CAUTIONS
- Active systemic infection • diabetic macular oedema due to type 1 diabetes (limited information available) • diabetic patients with HbA1c over 12% • history of stroke • history of transient ischaemic attack • patients at risk of retinal pigment epithelial tear • previous intravitreal injections • proliferative diabetic retinopathy • retinal detachment or macular hole (discontinue treatment if rhegmatogenous retinal detachment or stage 3 or 4 macular holes develop) • uncontrolled hypertension

CAUTIONS, FURTHER INFORMATION
Ranibizumab is given by intravitreal injection by specialists. There is a potential risk of arterial thromboembolic events and non-ocular haemorrhage following the intravitreal injection of vascular endothelial growth factor inhibitors. Endophthalmitis can occur after intravitreal injections—patients should be advised to report any signs of infection immediately.

INTERACTIONS
- Appendix 1: ranibizumab

SIDE-EFFECTS
- Common or very common Allergic skin reactions • anaemia • anterior chamber flare • anxiety • arthralgia • blepharitis • cataract • conjunctival disorders • conjunctivitis • cough • eye haemorrhage • eyelid oedema • headache • iridocyclitis • iritis • nasopharyngitis • nausea • ocular discomfort • photophobia • photopsia • posterior capsule opacification • punctuate keratitis • raised intra-ocular pressure • retinal disorders • urinary tract infection • uveitis • visual disturbance • vitreous disorders
- Uncommon Blindness • corneal disorders • hyphaema • hypopyon • iris adhesion • keratopathy

CONCEPTION AND CONTRACEPTION
Manufacturer recommends women use effective contraception during and for at least 3 months after treatment.

PREGNANCY
Manufacturer advises avoid unless potential benefit outweighs risk.

BREAST FEEDING
Manufacturer advises avoid—no information available.

MONITORING REQUIREMENTS
- Monitor intra-ocular pressure, perfusion of the optic nerve head, and for signs of ocular infection following injection.
- Monitor visual acuity, see individual indications and dose for frequency.

DIRECTIONS FOR ADMINISTRATION
For further information on administration, consult product literature.

NATIONAL FUNDING/ACCESS DECISIONS

NICE technology appraisals (TAs)
- Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (November 2013) NICE TA298
Ranibizumab is recommended as an option for treating visual impairment due to choroidal neovascularisation secondary to pathological myopia when the manufacturer provides ranibizumab with the discount agreed in the patient access scheme. www.nice.org.uk/TA298

Ranibizumab for the treatment of visual impairment caused by macular oedema secondary to retinal vein occlusion (May 2013) NICE TA283
Ranibizumab is recommended as an option for treating visual impairment caused by macular oedema:
- following central retinal vein occlusion
- following branch retinal vein occlusion only if treatment with laser photocoagulation has not been beneficial, or when laser photocoagulation is not suitable because of the extent of macular haemorrhage and
- only if the manufacturer provides ranibizumab with the discount agreed in the patient access scheme revised in the context of NICE technology appraisal guidance 274. www.nice.org.uk/TA283

Ranibizumab for the treatment of diabetic macular oedema (February 2011) NICE TA274
Ranibizumab is recommended as an option for the
treatment of visual impairment due to diabetic macular oedema only if:

- the eye has a central retinal thickness of 400 micrometres or more at the start of treatment and
- the manufacturer provides ranibizumab with the discount agreed in the patient access scheme (as revised in 2012).

Patients currently receiving ranibizumab for treating visual impairment due to diabetic macular oedema whose disease does not meet the criteria should be able to continue treatment until they and their clinician consider it appropriate to stop.

www.nice.org.uk/TA274

- Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (updated May 2012) NICE TA155

Ranibizumab is recommended for the treatment of wet age-related macular degeneration if all of the following apply:

- the best corrected visual acuity is between 6/12 and 6/96;
- there is no permanent structural damage to the central fovea;
- the lesion size is less than or equal to 12 disc areas in greatest linear dimension;
- there is evidence of recent disease progression;
- the manufacturer provides ranibizumab with the discount agreed in the patient access scheme (as revised in 2012).

Ranibizumab should only be continued in patients who maintain adequate response to therapy.

www.nice.org.uk/TA155

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (May 2007) that ranibizumab (Lucentis®) is accepted for use within NHS Scotland for the treatment of neovascular (wet) age-related macular degeneration.

The Scottish Medicines Consortium has advised (October 2011 and April 2013) that ranibizumab (Lucentis®) is accepted for use within NHS Scotland for the treatment of macular oedema secondary to branch or central retinal vein occlusion, and (November 2012) for restricted use for the treatment of visual impairment due to diabetic macular oedema in adults with best corrected visual acuity 75 Early Treatment Diabetic Retinopathy Study letters or less at baseline, and (October 2013) for the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia in adults; SMC advice is contingent upon the continuing availability of ranibizumab at the price agreed in the patient access scheme.

**MEDICAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- Lucentis (Novartis Pharmaceuticals UK Ltd)

  Ranibizumab 10 mg per 1 ml: Lucentis 2.3mg/0.23ml solution for injection vials | 1 vial (£55.00 (Hospital only))
  Lucentis 1.65mg/0.165ml solution for injection pre-filled syringes | 1 pre-filled disposable injection (POM) £55.00

**PHOTOSENSITISERS**

**Verteporfin**

- **DRUG ACTION** Following intravenous infusion, verteporfin is activated by local irradiation using non-thermal red light to produce cytotoxic derivatives.

- **INDICATIONS AND DOSE**

  Photodynamic treatment of age-related macular degeneration associated with predominantly classic subfoveal choroidal neovascularisation or with pathological myopia (specialist use only)

  - **BY INTRAVENOUS INFUSION**
  - **Adult:** 6 mg/m², dose to be given over 10 minutes

- **CONTRA-INDICATIONS**
  - Acute porphyria

- **CAUTIONS**
  - Avoid extravasation - biliary obstruction - photosensitivity

- **INTERACTIONS**
  - Frequency not known

- **SIDE-EFFECTS**

  - Common or very common
    - Back pain - flashing lights - hypercholesterolaemia - malaise - nausea - photosensitivity - reduced visual acuity - visual disturbances - visual-field defects

  - Uncommon
    - Hyperaesthesia - hypertension - pyrexia - retinal detachment - subretinal, retinal or vitreous haemorrhage

  - Rare
    - Retinal or choroidal vessel non-perfusion

  - Frequency not known
    - Chest pain - macular oedema - myocardial infarction - retinal oedema - vasovagal reactions

- **PREGNANCY**
  - Manufacturer advises use only if potential benefit outweighs risk (teratogenic in animal studies).

- **BREAST FEEDING**
  - No information available—manufacturer advises avoid breast-feeding for 48 hours after administration.

- **HEPATIC IMPAIRMENT**
  - Use with caution in moderate hepatic impairment. Avoid in severe hepatic impairment.

- **DIRECTIONS FOR ADMINISTRATION**
  - For information on administration and light activation, consult product literature.

  - For intravenous infusion (Visudyne®), give intermittently in Glucose 5%; reconstitute each 15 mg with 7 ml water for injections to produce a 2 mg/ml solution then dilute requisite dose with infusion fluid to a final volume of 30 ml and give over 10 minutes; protect infusion from light and administer within 4 hours of reconstitution. Incompatible with sodium chloride infusion.

- **PATIENT AND CARER ADVICE**
  - Photosensitivity—avoid exposure of unprotected skin and eyes to bright light during infusion and for 48 hours afterwards.

- **NATIONAL FUNDING/ACCESS DECISIONS**

  - NICE technology appraisals (TAs)

  - Verteporfin photodynamic therapy for wet age-related macular degeneration (September 2003) NICE TA68

  Photodynamic therapy is recommended for wet age-related macular degeneration with a confirmed diagnosis of classic (no occult) subfoveal choroidal neovascularisation and best-corrected visual acuity of 6/60 or better.

  Photodynamic therapy is **not** recommended for wet age-related macular degeneration with predominantly classic but partly occult subfoveal choroidal neovascularisation except in clinical studies.

  www.nice.org.uk/TA68

---

**Eye**
6.2 Macular oedema

Other drugs used for Macular oedema
Aflibercept, p. 921 · Dexamethasone, p. 1061 · Ranibizumab, p. 1089

CORTICOSTEROIDS

Fluocinolone acetonide

- **INDICATIONS AND DOSE**
  - Treatment of visual impairment associated with chronic diabetic macular oedema which is insufficiently responsive to available therapies (specialist use only)
  - **BY INTRAVITREAL INJECTION**
  - **Adult:** 190 micrograms, to be administered into the affected eye

- **CONTRA-INDICATIONS**
  - Active or suspected ocular infection
  - Pre-existing glaucoma

- **CAUTIONS**
  - Raised baseline intra-ocular pressure

- **SIDE-EFFECTS**
  - **Common or very common**
    - Blurred vision
cat
    - Cataract
    - Conjunctival haemorrhage
glaucoma
    - Ocular discomfort
    - Raised intra-ocular pressure
    - Reduced visual acuity
    - Vitreous floaters
    - Vitreous haemorrhage
  - **Uncommon**
    - Conjunctival ulcer
    - Endophthalmitis
    - Eye discharge
    - Eye pruritus
    - Headache
    - Iris adhesions
    - Iris neovascularisation
    - Maculopathy
    - Ocular haeryema
    - Optic atrophy
    - Optic nerve disorder
    - Posterior capsule opacification
    - Retinal exudates
    - Retinal vascular occlusion
    - Scleral thinning
    - Vitreous degeneration
    - Vitreous detachment

- **PREGNANCY**
  - Manufacturer advises avoid unless potential benefit outweighs risk—no information available.

- **BREAST FEEDING**
  - Manufacturer advises avoid unless essential.

- **MONITORING REQUIREMENTS**
  - Monitor for raised intra-ocular pressure (particularly if raised at baseline), retinal detachment, endophthalmitis, vitreous haemorrhage or detachment within 2–7 days following the procedure.
  - Monitor intra-ocular pressure at least every 2 months thereafter (for approximately 36 months).

- **DIRECTIONS FOR ADMINISTRATION**
  - Concurrent administration to both eyes not recommended. For further information on administration and repeat dosing, consult product literature.

- **PRESCRIBING AND DISPENSING INFORMATION**
  - Gel is useful for application to the scalp and other hairy areas.

- **NATIONAL FUNDING/ACCESS DECISIONS**
  - NICE technology appraisals (TAs)
    - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (November 2013) NICE TA301
    - Fluocinolone acetonide intravitreal implant is recommended as an option for treating chronic diabetic macular oedema that is insufficiently responsive to available therapies only if:
    - the implant is to be used in an eye with an intra-ocular (pseudophakic lens) and
    - the manufacturer provides fluocinolone acetonide intravitreal implant with the discount agreed in the patient access scheme.

  - [www.nice.org.uk/TA301](http://www.nice.org.uk/TA301)

Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (February 2014) that fluocinolone acetonide intravitreal implant ([Iluvien](http://www.nice.org.uk/TA301)) is recommended for restricted use within NHS Scotland for the treatment of vision impairment associated with chronic diabetic macular oedema, considered insufficiently responsive to available therapies, only in patients in whom the affected eye is pseudophakic (has an artificial lens after cataract surgery), and retreatment would take place only if the patient had previously responded to treatment with fluocinolone acetonide and subsequently best corrected visual acuity had deteriorated to less than 20/32.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  - **Implant**
    - [Iluvien](http://www.nice.org.uk/TA301) (Alimera Sciences Ltd)
    - Fluocinolone acetonide 190 microgram Iluvien 190 mcg intravitreal implant in applicator 1 device £5,500.00

6.3 Optic neuropathy

DRUGS FOR METABOLIC DISORDERS > ANTIOXIDANTS

Idebenone

- **DRUG ACTION**
  - Idebenone is a nootropic and antioxidant that is thought to act by restoring cellular ATP generation, thereby reactivating retinal ganglion cells.

- **INDICATIONS AND DOSE**
  - [Leber’s Hereditary Optic Neuropathy (initiated by a specialist)](http://www.nice.org.uk/TA301)
  - **BY MOUTH**
  - **Adult:** 300 mg 3 times a day

- **SIDE-EFFECTS**
  - **Common or very common**
    - Back pain
    - Cough
    - Diarrhoea
    - Nasopharyngitis
  - **Frequency not known**
    - Anorexia
    - Azotaemia
    - Blood disorders
    - Bronchitis
    - Chromatia
    - Dyspepsia
    - Hepatitis
    - Malaise
    - Nausea
    - Nervous system disorders
    - Pain in extremity
    - Pruritus
    - Raised lipids
    - Raised liver enzymes
    - Rash
    - Vomiting

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Chromatia
  - The metabolites of idebenone may cause red-brown discolouration of the urine. This effect is harmless, but the manufacturer advises caution as this may mask colour changes due to other causes (e.g. renal or blood disorders).

- **PREGNANCY**
  - Manufacturer advises avoid unless potential benefit outweighs risk—no information available.

- **BREAST FEEDING**
  - Manufacturer advises avoid—present in milk in animal studies.

- **HEPATIC IMPAIRMENT**
  - Manufacturer advises use with caution—no information available.

- **RENAL IMPAIRMENT**
  - Manufacturer advises use with caution—no information available.
6.4 Vitreomacular traction

RECOMBINANT PROTEOLYTIC ENZYMES

Ocriplasmin

**INDICATIONS AND DOSE**
Treatment of vitreomacular traction, including when associated with a macular hole of diameter less than or equal to 400 microns (specialist use only)

- **BY INTRAVITREAL INJECTION**
- Adult: 125 micrograms for 1 dose, to be administered into the affected eye, concurrent administration to both eyes is not recommended

**CONTRA-INDICATIONS**
Active or suspected ocular or periocular infection • aphakia • exudative age-related macular degeneration • high myopia • history of rhegmatogenous retinal detachment • ischaemic retinopathies • large diameter macular hole (> 400 microns) • lens zonule instability • proliferative diabetic retinopathy • recent intra-ocular injection (including laser therapy) • recent ocular surgery • retinal vein occlusions • vitreous haemorrhage

**CAUTIONS**
History of uveitis (including severe active inflammation) • non-proliferative diabetic retinopathy • significant eye trauma

**SIDE-EFFECTS**
- **Common or very common** Abnormal retinograph • anterior chamber cell or flare • chromatosia • conjunctival disorders • eyelid oedema • iritis • macular degeneration • macular hole • macular oedema • metamorphopsia • ocular discomfort • ocular hyperaemia • photophobia • photopsia • raised intra-ocular pressure • reduced visual acuity • retinal disorders • retinal pigment epitheliopathy • vitreous disorders
- **Uncommon** Anterior chamber inflammation • corneal abrasion • diplopia • eye inflammation • hyphaema • lens subluxation • miosis • scotoma • transient blindness • unequal pupils • visual field defect

**PREGNANCY**
Manufacturer advises use only if potential benefit outweighs risk — no information available.

**BREAST FEEDING**
Manufacturer advises use only if potential benefit outweighs risk — no information available.

**MONITORING REQUIREMENTS**
Monitor intra-ocular pressure, visual acuity, and for signs of intra-ocular inflammation or infection following injection.
Chapter 12
Ear, nose and oropharynx

CONTENTS

<table>
<thead>
<tr>
<th>Ear</th>
<th>page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Otitis externa</td>
<td>1094</td>
</tr>
<tr>
<td>2 Removal of earwax</td>
<td>1097</td>
</tr>
<tr>
<td>Nose</td>
<td>page 1098</td>
</tr>
<tr>
<td>1 Nasal congestion</td>
<td>1099</td>
</tr>
<tr>
<td>2 Nasal infection</td>
<td>1101</td>
</tr>
<tr>
<td>3 Nasal inflammation, nasal polyps and rhinitis</td>
<td>1102</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>1105</td>
</tr>
<tr>
<td>1 Dry mouth</td>
<td>1105</td>
</tr>
</tbody>
</table>

1 Oral hygiene | page 1107
2.1 Dental caries | 1109
3 Oral ulceration and inflammation | 1111
4 Oropharyngeal bacterial infections | 1114
5 Oropharyngeal fungal infections | 1115
6 Oropharyngeal viral infections | 1116

Ear

Otitis externa

Otitis externa is an inflammatory reaction of the meatal skin. It is important to exclude an underlying chronic otitis media before treatment is commenced. Many cases recover after thorough cleansing of the external ear canal by suction or dry mopping. A frequent problem in resistant cases is the difficulty in applying lotions and ointments satisfactorily to the relatively inaccessible affected skin. The most effective method is to introduce a ribbon gauze dressing or sponge wick soaked with corticosteroid ear drops or with an astringent such as aluminium acetate solution p. 1097. When this is not practical, the ear should be gently cleansed with a probe covered in cotton wool and the patient encouraged to lie with the affected ear uppermost for ten minutes after the canal has been filled with a liberal quantity of the appropriate solution.

If infection is present, a topical anti-infective which is not used systemically (such as neomycin sulfate p. 1095 or clioquinol) may be used, but for only about a week as excessive use may result in fungal infections; these may be difficult to treat and require expert advice. Sensitivity to the anti-infective or solvent may occur and resistance to antibacterials is a possibility with prolonged use. Aluminium acetate ear drops are also effective against bacterial infection and inflammation of the ear. Chloramphenicol p. 1095 may be used but the ear drops contain propylene glycol and cause hypersensitivity reactions in about 10% of patients. Solutions containing an anti-infective and a corticosteroid are used for treating cases where infection is present with inflammation and eczema.

In view of reports of ototoxicity, manufacturers contra-indicate treatment with topical aminoglycosides or polymyxins in patients with a perforated tympanic membrane (eardrum) or patent grommet. However, some specialists do use these drops cautiously in the presence of a perforation or patent grommet in patients with chronic suppurative otitis media and when other measures have failed for otitis externa; treatment should be considered only by specialists in the following circumstances:

- drops should only be used in the presence of obvious infection;
- treatment should be for no longer than 2 weeks;
- patients should be counselled on the risk of ototoxicity and given justification for the use of these topical antibiotics;
- baseline audiometry should be performed, if possible, before treatment is commenced.

Clinical expertise and judgement should be used to assess the risk of treatment versus the benefit to the patient in such circumstances.

A solution of acetic acid 2% acts as an antifungal and antibacterial in the external ear canal. It may be used to treat mild otitis externa but in severe cases an anti-inflammatory preparation with or without an anti-infective drug is required. A proprietary preparation containing acetic acid 2% (EarCalm® spray) is on sale to the public.

For severe pain associated with otitis externa, a simple analgesic, such as paracetamol p. 422 or ibuprofen p. 1041, can be used. A systemic antibacterial can be used if there is spreading cellulitis or if the patient is systemically unwell. When a resistant staphylococcal infection (a boil) is present in the external auditory meatus, flucloxacillin p. 523 is the drug of choice; ciprofloxacin p. 527 (or an aminoglycoside) may be needed in pseudomonal infections which may occur if the patient has diabetes or is immunocompromised.

The skin of the pinna adjacent to the ear canal is often affected by eczema. A topical corticosteroid cream or ointment is then required, but prolonged use should be avoided.

Otitis media

Acute otitis media

Acute otitis media is the commonest cause of severe aural pain in small children. Many infections, especially those accompanying coryza, are caused by viruses. Most uncomplicated cases resolve without antibacterial treatment and a simple analgesic, such as paracetamol, may be sufficient. In children without systemic features, a systemic antibacterial may be started after 72 hours if there is no improvement, or earlier if there is deterioration, if the patient is systemically unwell, if the patient is at high risk of serious complications (e.g. in immunosuppression, cystic fibrosis), if mastoiditis is present, or in children under 2 years of age with bilateral otitis media. Perforation of the tympanic membrane in patients with acute otitis media usually heals spontaneously without treatment; if there is no improvement, e.g. pain or discharge persists, a systemic antibacterial can be given. Topical treatment of acute otitis media is ineffective and there is no place for drops containing a local anaesthetic.
Otitis media with effusion
Otitis media with effusion (glue ear) occurs in about 10% of children and in 90% of children with cleft palates. Systemic antibiotics are not usually required. If glue ear persists for more than a month or two, the child should be referred for assessment and follow up because of the risk of long-term hearing impairment which can delay language development. Untreated or resistant glue ear may be responsible for some types of chronic otitis media.

Chronic otitis media
Opportunistic organisms are often present in the debris, keratin, and necrotic bone of the middle ear and mastoid in patients with chronic otitis media. The mainstay of treatment is thorough cleansing with aural microsuction which may completely resolve long-standing infection. Local cleansing of the meatal and middle ear may be followed by treatment with a sponge wick or ribbon gauze dressing soaked with corticosteroid ear drops or with an astringent such as aluminium acetate solution; this is particularly beneficial for discharging ears or infections of the mastoid cavity. An antibacterial ear ointment may also be used. Acute exacerbations of chronic infection may also require systemic treatment with amoxicillin p. 518 (or erythromycin p. 510 if penicillin-allergic); treatment is adjusted according to the results of sensitivity testing.

In view of reports of ototoxicity, manufacturers contraindicate topical treatment with ototoxic antibiotics in the presence of a tympanic perforation or patent grommet. Ciprofloxacin or ofloxacin eye drops p. 530 used in the ear [unlicensed use] or ear drops [both unlicensed; available from ‘special-order’ manufacturers or specialist importing companies] are an effective alternative to such ototoxic ear drops for chronic otitis media in patients with perforation of the tympanic membrane.

However, some specialists do use ear drops containing aminoglycosides or polymyxins [unlicensed indications] cautiously in patients with chronic suppurrative otitis media and a perforation of the tympanic membrane, if the otitis media has failed to settle with systemic antibacterials; treatment should be considered only by specialists in the following circumstances:

- drops should only be used in the presence of obvious infection;
- treatment should be for no longer than 2 weeks;
- patients should be counselled on the risk of ototoxicity and given justification for the use of these topical antibiotics;
- baseline audiometry should be performed, if possible, before treatment is commenced.

Clinical expertise and judgement should be used to assess the risk of treatment versus the benefit to the patient in such circumstances. It is considered that the pus in the middle ear associated with otitis media also carries a risk of ototoxicity.

Removal of ear wax
Ear wax (cerumen) is a normal bodily secretion which provides a protective film on the meatal skin and need only be removed if it causes hearing loss or interferes with a proper view of the ear drum.

Ear wax can be softened using simple remedies such as olive oil ear drops or almond oil ear drops; sodium bicarbonate ear drops p. 1097 are also effective, but may cause dryness of the ear canal. If the wax is hard and impacted, the drops can be used twice daily for several days and this may reduce the need for mechanical removal of the wax. The patient should lie with the affected ear uppermost for 5 to 10 minutes after a generous amount of the softening remedy has been introduced into the ear. Some proprietary preparations containing organic solvents can irritate the meatal skin, and in most cases the simple remedies indicated above are just as effective and less likely to cause irritation. Docusate sodium p. 1098 or urea hydrogen peroxide p. 1098 are ingredients in a number of proprietary preparations for softening ear wax.

If necessary, wax may be removed by irrigation with water (warmed to body temperature). Ear irrigation is generally best avoided in young children, in patients unable to cooperate with the procedure, in those with otitis media in the last six weeks, in otitis externa, in patients with cleft palate, a history of ear drum perforation, or previous ear surgery. A person who has hearing in one ear only should not have that ear irrigated because even a very slight risk of damage is unacceptable in this situation.

1 Otitis externa

Other drugs used for Otitis externa Hydrocortisone with miconazole, p. 1150

ANTIBACTERIALS \ AMINOGLYCOSIDES

Framycetin sulfate

- INDICATIONS AND DOSE
- Bacterial infection in otitis externa
  - TO THE EAR
  - Adult: (consult product literature)

- CONTRA-INDICATIONS
- Perforated tympanic membrane

- CAUTIONS
- Avoid prolonged use

- SIDE-EFFECTS
- Local sensitivity

Gentamicin

- INDICATIONS AND DOSE
- Bacterial infection in otitis externa
  - TO THE EAR
  - Child: Apply 2–3 drops 4–5 times a day, (including a dose at bedtime)
  - Adult: Apply 2–3 drops 4–5 times a day, (including a dose at bedtime)

- CONTRA-INDICATIONS
- Patent grommet (although may be used by specialists, see Ear p. 1093) · perforated tympanic membrane (although may be used by specialists, see Ear p. 1095)

- CAUTIONS
- Avoid prolonged use

- SIDE-EFFECTS
- Local sensitivity

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Ear/eye drops solution

EXCIPIENTS: May contain Benzalkonium chloride

- Gentamicin (Non-proprietary)
  - Gentamicin (as Gentamicin sulfate) 3 mg per 1 ml
  - Gentamicin 0.3% ear/eye drops | 10 ml | £2.14 OT price = £2.15

---

downloaded from www.medicalbr.com
### Gentamicin with hydrocortisone

#### INDICATIONS AND DOSE

**Bacterial infection in otitis externa**

- **TO THE EAR**
  - Child: Apply 2–4 drops 4–5 times a day, (including a dose at bedtime)
  - Adult: Apply 2–4 drops 4–5 times a day, (including a dose at bedtime)

#### CONTRA-INDICATIONS

- Patent grommet (although may be used by specialists, see Ear p. 1093) - perforated tympanic membrane (although may be used by specialists, see Ear p. 1093)

#### CAUTIONS

- Avoid prolonged use

#### SIDE-EFFECTS

- Local sensitivity reactions

#### PATIENT AND CARER ADVICE

- Medicines for Children leaflet: Gentamicin and hydrocortisone ear drops for inflammatory ear infections

#### MEDICINAL FORMS

- No licensed medicines listed

### Neomycin sulfate

#### INDICATIONS AND DOSE

**Bacterial infection in otitis externa**

- **TO THE EAR**
  - Child: (consult product literature)
  - Adult: (consult product literature)

#### CONTRA-INDICATIONS

- Patent grommet (although may be used by specialists, see Ear p. 1093) - perforated tympanic membrane (although may be used by specialists, see Ear p. 1093)

#### CAUTIONS

- Avoid prolonged use

#### SIDE-EFFECTS

- Local sensitivity

#### MEDICINAL FORMS

- There can be variation in the licensing of different medicines containing the same drug.

  **Ear drops**
  - **EXCIPIENTS:** May contain Benzalkonium chloride, disodium edetate
  - Gentamicin with hydrocortisone (Non-proprietary)
    - Gentamicin (as Gentamicin sulfate) 3 mg per 1 ml, Hydrocortisone acetate 10 mg per 1 ml, Gentamicin 0.3% / Hydrocortisone acetate 3% ear drops | 10 ml [Posm] £23.92 DT price = £23.92

### Chloramphenicol

#### DRUG ACTION

- Chloramphenicol is a potent broad-spectrum antibiotic.

#### INDICATIONS AND DOSE

**Bacterial infection in otitis externa**

- **TO THE EAR**
  - Child: Apply 2–3 drops 2–3 times a day
  - Adult: Apply 2–3 drops 2–3 times a day

#### CONTRA-INDICATIONS

- Avoid alone in the presence of untreated infection (combine with suitable anti-infective)

#### CAUTIONS

- Avoid prolonged use

#### SIDE-EFFECTS

- Local sensitivity reactions

#### MEDICINAL FORMS

- There can be variation in the licensing of different medicines containing the same drug.

  **Ear/eye/nose drops solution**
  - **EXCIPIENTS:** May contain Benzalkonium chloride, disodium edetate
  - Chloramphenicol 50 mg per 1 ml | 10 ml [Posm] £78.17 DT price = £57.90
  - Chloramphenicol 100 mg per 1 ml | 10 ml [Posm] £48.21 DT price = £38.95

### ANTIFUNGALS

#### Clotrimazole

#### INDICATIONS AND DOSE

**Fungal infection in otitis externa**

- **TO THE EAR**
  - Child: Apply 2–3 times a day continue for at least 14 days after disappearance of infection
  - Adult: Apply 2–3 times a day continue for at least 14 days after disappearance of infection

#### SIDE-EFFECTS

- Local irritation - local sensitivity

#### MEDICINAL FORMS

- There can be variation in the licensing of different medicines containing the same drug.

  **Liquid**
  - Canesten (clotrimazole) (Bayer Plc)
    - Clotrimazole 10 mg per 1 ml | 20 ml [P] £2.30 DT price = £2.30

### CORTICOSTEROIDS

#### Betamethasone

#### INDICATIONS AND DOSE

**Bacterial inflammation in otitis externa**

- **TO THE EAR**
  - Adult: Apply 2–3 drops every 2–3 hours, reduce frequency when relief obtained

**Betnesol**

- **INDICATIONS AND DOSE**

  **Eczematous inflammation in otitis externa**

  - **TO THE EAR**
    - Adult: Apply 2–3 drops every 3–4 hours, reduce frequency when relief obtained

#### CONTRA-INDICATIONS

- Avoid alone in the presence of untreated infection (combine with suitable anti-infective)

#### CAUTIONS

- Avoid prolonged use

#### SIDE-EFFECTS

- Local sensitivity reactions

#### MEDICINAL FORMS

- There can be variation in the licensing of different medicines containing the same drug.

  **Ear/eye/nose drops solution**
  - **EXCIPIENTS:** May contain Benzalkonium chloride, disodium edetate
  - Betnesol (Focus Pharmaceuticals Ltd)
    - Betamethasone sodium phosphate 1 mg per 1 ml | 10 ml [Posm] £2.32 DT price = £2.32
Corticosteroids > Corticosteroid combinations with anti-infectives

**Betamethasone with neomycin**

The properties listed below are those particular to the combination only. For the properties of the components please consider, betamethasone p. 1095, neomycin sulfate p. 1095.

**INDICATIONS AND DOSE**

Eczematous inflammation in otitis externa

**TO THE EAR**

- Child: Apply 2–3 drops 3–4 times a day
- Adult: Apply 2–3 drops 3–4 times a day

**CONTRA-INDICATIONS**

- Patent grommet (although may be used by specialists, see Ear p. 1093) • perforated tympanic membrane (although may be used by specialists, see Ear p. 1093)
- Avoid prolonged use

**SIDE-EFFECTS**

- Local sensitivity

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Ear/eye/nose drops solution**

**EXCIPIENTS:** May contain Benzalkonium chloride, disodium edetate

- **Betnesol-N** (Focus Pharmaceuticals Ltd)

**Betamethasone (as Betamethasone sodium phosphate) 1 mg per 1 ml, Neomycin sulfate 5 mg per 1 ml**

 Betnesol-N ear/eye/nose drops | 10 ml [Pos] £2.39 DT price = £2.39

**Dexamethasone with ciprofloxacin**

09-Mar-2017

**INDICATIONS AND DOSE**

Acute otitis media in patients with tympanostomy tubes

**TO THE EAR**

- Adult: Apply 4 drops twice daily for 7 days

Acute otitis externa

**TO THE EAR**

- Adult: Apply 4 drops twice daily for 7 days

**CONTRA-INDICATIONS**

- Fungal ear infections • viral ear infections
- Avoid prolonged use

**SIDE-EFFECTS**

- Common or very common Ear pain
- Uncommon Ear congestion • flushing • fungal ear infections • irritability • malaise • otorrhoea • paraesthesia of the ear • skin exfoliation • taste disturbances • vomiting
- Rare Dizziness • erythematous rash • headache • hearing loss • tinnitus

**SIDE-EFFECTS, FURTHER INFORMATION**

- Otorrhoea Manufacturer advises further evaluation of underlying conditions if otorrhoea persists after a full course, or if at least two episodes of otorrhoea occur within 6 months.
- Pregnancy Manufacturer advises use only if potential benefit outweighs risk—no information available.
- Breastfeeding Manufacturer advises caution—no information available.

**PATIENT AND CARER ADVICE**

Manufacturer advises counselling on administration.
CONTRA-INDICATIONS

MEDICINAL FORMS

The properties listed below are those particular to the same drug.

Ear drops
EXCIPIENTS: May contain Benzalkonium chloride, disodium edetate

- Cilodex (Alcon Laboratories (UK) Ltd)
  - Dexamethasone 1 mg per 1 ml, Ciprofloxacine (as Ciprofloxacine hydrochloride) 3 mg per 1 ml
  - Cilodex ear drops | 5 ml £0.62
  - DT price = £6.12

Dexamethasone with framycetin sulfate and gramicidin

INDICATIONS AND DOSE

Eczematous inflammation in otitis externa

- TO THE EAR
- Child: 2–3 drops 3–4 times a day
- Adult: 2–3 drops 3–4 times a day

LESS SUITABLE FOR PRESCRIBING  Sofradex® is less suitable for prescribing.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Eye/Ear drops solution
EXCIPIENTS: May contain Polysorbates

- Sofradex (Sanofi)
  - Dexamethasone (as dexamethasone sodium metasulfobenzoate)
    - 500 microgram per 1 ml, Framycetin sulfate 5 mg per 1 ml,
    - Gramicidin 50 micrograms per 1 ml
  - Sofradex ear/eye drops | 10 ml | £7.50

Dexamethasone with glacial acetic acid and neomycin sulfate

The properties listed below are those particular to the combination only. For the properties of the components please consider, dexamethasone p. 635, neomycin sulfate p. 1095.

INDICATIONS AND DOSE

Eczematous inflammation in otitis externa

- TO THE EAR
- Child 2–17 years: Apply 1 spray 3 times a day
- Adult: Apply 1 spray 3 times a day

CONTRA-INDICATIONS  Patent grommet (although may be used by specialists, see Ear p. 1093) · perforated tympanic membrane (although may be used by specialists, see Ear p. 1093)

CAUTIONS  Avoid prolonged use

SIDE-EFFECTS  Local sensitivity

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Spray
EXCIPIENTS: May contain Hydroybenzoates (parabens)

- Otomize (Teva UK Ltd)
  - Dexamethasone 1 mg per 1 gram, Neomycin sulfate 5 mg per 1 gram, Acetic acid glacial 20 mg per 1 gram
  - Otomize ear spray | 5 ml £3.27

DERMATOLOGICAL DRUGS  ASTRINGENTS

Aluminium acetate

INDICATIONS AND DOSE

Inflammation in otitis externa

- TO THE EAR
- Adult: To be inserted into meatus or apply on a ribbon gauze dressing or sponge wick which should be kept saturated with the ear drops

DIRECTIONS FOR ADMINISTRATION  For ear drops 8% — dilute 8 parts aluminium acetate ear drops (13%) with 5 parts purified water. Must be freshly prepared.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: ear drops

BICARBONATE

Sodium bicarbonate

INDICATIONS AND DOSE

Removal of earwax (with 5% ear drop solution)

- TO THE EAR
- Child: (consult product literature)
- Adult: (consult product literature)

SIDE-EFFECTS  Dryness of the ear canal

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Ear drops

- Sodium bicarbonate (Non-proprietary)
  - Sodium bicarbonate 50 mg per 1 ml
  - Sodium bicarbonate 5% ear drops | 10 ml £1.23–£1.25

SOFTENING DRUGS

Almond oil

INDICATIONS AND DOSE

Removal of earwax

- TO THE EAR
- Child: Allow drops to warm to room temperature before use (consult product literature)
- Adult: Allow drops to warm to room temperature before use (consult product literature)

DIRECTIONS FOR ADMINISTRATION  The patient should lie with the affected ear uppermost for 5 to 10 minutes after a generous amount of the softening remedy has been introduced into the ear.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Liquid

- Almond oil (Non-proprietary)
  - Almond oil liquid | 50 ml £0.91
  - 50 ml £0.73–£0.82
  - 200 ml £2.54
  - 500 ml £11.90

Parents of the Ear: Otitis Externa and the Softening Drugs

INSTRUCTIONS FOR ADMINISTRATION

DIRECTIONS FOR ADMINISTRATION

Topical

- Almond oil is a softening drug and can be used alone without any medication.
- May contain Hydroxybenzoates (parabens)

- Almond oil 1 ml per 1 ml
- Almond oil 2%
- Almond oil 5%
- Almond oil 10%
- Almond oil 20%
- Almond oil 50%

Other drugs

- Dexamethasone 1 mg per 1 ml
- Dexamethasone with framycetin sulfate
- Dexamethasone with glacial acetic acid and neomycin sulfate
- Sodium bicarbonate 50 mg per 1 ml
- Sodium bicarbonate 5% ear drops

INDICATIONS AND DOSE

Eczematous inflammation in otitis externa

- TO THE EAR
- Child: 2–3 drops 3–4 times a day
- Adult: 2–3 drops 3–4 times a day

DIRECTIONS FOR ADMINISTRATION

- Almond oil is a softening drug and can be used alone without any medication.
- May contain Hydroxybenzoates (parabens)

- Almond oil 1 ml per 1 ml
- Almond oil 2%
- Almond oil 5%
- Almond oil 10%
- Almond oil 20%
- Almond oil 50%
Arachis oil with chlorobutanol

**INDICATIONS AND DOSE**
- Removal of ear wax
  - TO THE EAR
  - Adult: (consult product literature)

**LESS SUITABLE FOR PRESCRIBING** Arachis (peanut) oil with chlorobutanol ear drops are less suitable for prescribing.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.
- **Ear drops**
  - Cerumol (Thornton & Ross Ltd)
    - Chlorobutanol 50 mg per 1 ml, Arachis oil 573 mg per 1 ml Cerumol ear drops | 11 ml | £2.05
  - Oleax (Arjun Products Ltd)
    - Arjun ear drops | 10 ml | £1.26
  - Cerumol (olive oil) (Thornton & Ross Ltd)
    - Cerumol olive oil ear drops | 10 ml no price available
  - Oteax (JR Biomedical Ltd)
    - Oteax ear drops | 15 ml | £1.40
  - Ceramic (Cerumol Ltd)
    - Ceramic olive oil ear drops | 10 ml | £1.42

Olive oil

**INDICATIONS AND DOSE**
- Removal of ear wax
  - TO THE EAR
  - Child: Apply twice daily for several days (if wax is hard and impacted)
  - Adult: Apply twice daily for several days (if wax is hard and impacted)

**DIRECTIONS FOR ADMINISTRATION** The patient should lie with the affected ear uppermost for 5 to 10 minutes after a generous amount of the softening remedy has been introduced into the ear. Allow ear drops to warm to room temperature before use.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.
- **Ear drops**
  - Olive oil
    - Olive oil ear drops | 10 ml | £1.35–£1.42 | 15 ml | £0.92 | 20 ml | £2.70
  - Arjun (Arjun Products Ltd)
    - Arjun ear drops | 10 ml | £1.26
  - Cerumol (olive oil) (Thornton & Ross Ltd)
    - Cerumol olive oil ear drops | 10 ml no price available
  - Oteax (JR Biomedical Ltd)
    - Oteax ear drops | 15 ml | £1.40
  - Ceramic (Cerumol Ltd)
    - Ceramic olive oil ear drops | 10 ml | £1.42

Urea hydrogen peroxide

**INDICATIONS AND DOSE**
- Softening and removal of ear wax
  - TO THE EAR
  - Adult: (consult product literature)

**PATIENT AND CARER ADVICE** The patient should lie with the affected ear uppermost for 5 to 10 minutes after a generous amount of the softening remedy has been introduced into the ear.

**LESS SUITABLE FOR PRESCRIBING** Urea-hydrogen peroxide ear drops are less suitable for prescribing.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.
- **Ear drops**
  - Exterol (Dermal Laboratories Ltd)
    - Urea hydrogen peroxide 50 mg per 1 gram Exterol 5% ear drops | 8 ml | £1.75 DT price = £2.89
  - Oteax (Dendron Ltd)
    - Urea hydrogen peroxide 50 mg per 1 gram Oteax 5% ear drops | 8 ml | £2.89

Nose

**Rhinitis and bacterial sinusitis**
Rhinitis is often self-limiting but bacterial sinusitis may require treatment with antibacterials. There are few indications for nasal sprays and drops except in allergic rhinitis and perennial rhinitis. Many nasal preparations contain sympathomimetic drugs which may damage the nasal cilia. Sodium chloride 0.9% p. 953 solution may be used as a douche or ‘sniff’ following endonasal surgery.

**Drugs used in nasal allergy**
Mild allergic rhinitis is controlled by **antihistamines** (see Antihistamines, allergen immunotherapy and allergic emergencies p. 265) or topical **nasal corticosteroids**; systemic nasal decongestants are of doubtful value. Topical nasal decongestants can be used for a short period to relieve congestion and allow penetration of a topical nasal corticosteroid.

More persistent symptoms and nasal congestion can be relieved by topical nasal corticosteroids; sodium cromoglicate p. 1105 is an alternative, but may be less effective. The topical antihistamine azelastine hydrochloride p. 1059 is useful for controlling breakthrough symptoms in allergic rhinitis. Topical antihistamines are considered less effective than topical corticosteroids but probably more effective than cromoglicate. In seasonal allergic rhinitis (e.g. hay fever), treatment should begin 2 to 3 weeks before the season commences and may have to be continued for several months; continuous treatment may be required for years in perennial rhinitis.

Montelukast p. 258 is less effective than topical nasal corticosteroids; montelukast can be used in patients with seasonal allergic rhinitis and concomitant asthma.

Sometimes allergic rhinitis is accompanied by vasomotor rhinitis. In this situation, the addition of topical nasal ipratropium bromide can reduce watery rhinorrhea.

Very disabling symptoms occasionally justify the use of **systemic corticosteroids** for short periods, for example, in...
students taking important examinations. They may also be used at the beginning of a course of treatment with a corticosteroid spray to relieve severe mucosal oedema and allow the spray to penetrate the nasal cavity.

**Corticosteroids**
Corticosteroid nasal preparations should be avoided in the presence of untreated nasal infections, after nasal surgery (until healing has occurred), and in pulmonary tuberculosis. Patients transferred from systemic corticosteroids may experience exacerbation of some symptoms. Systemic absorption may follow nasal administration particularly if high doses are used or if treatment is prolonged; for cautions and side-effects of systemic corticosteroids. The risk of systemic effects may be greater with nasal drops than with nasal sprays; drops are administered incorrectly more often than sprays. The height of children receiving prolonged treatment with nasal corticosteroids should be monitored; if growth is slowed, referral to a paediatrician should be considered.

**Nasal polyps**
Short-term use of corticosteroid nasal drops helps to shrink nasal polyps; to be effective, the drops must be administered with the patient in the ‘head down’ position. A short course of a systemic corticosteroid may be required initially to shrink large polyps. A corticosteroid nasal spray can be used to maintain the reduction in swelling and also for the initial treatment of small polyps.

**Pregnancy**
If a pregnant woman cannot tolerate the symptoms of allergic rhinitis, treatment with nasal beclometasone dipropionate p. 1102, budesonide p. 1103, fluticasone p. 1103, or sodium cromoglicate may be considered.

**Topical nasal decongestants**
The nasal mucosa is sensitive to changes in atmospheric temperature and humidity and these alone may cause slight nasal congestion. The nose and nasal sinuses produce a litre of mucus in 24 hours and much of this finds its way silently into the stomach via the nasopharynx. Slight changes in the nasal airway, accompanied by an awareness of mucus passing along the nasopharynx causes some patients to be inaccurately diagnosed as suffering from chronic sinusitis. These symptoms are particularly noticeable in the later stages of the common cold. Sodium chloride 0.9% given as nasal drops or spray may relieve nasal congestion by helping to liquefy mucous secretions.

Inhalation of warm moist air is useful in the treatment of symptoms of acute infective conditions. The addition of volatile substances such as menthol and eucalyptus may encourage the use of warm moist air (see under Aromatic inhalations, cough preparations and systemic nasal decongestants p. 282).

Symptoms of nasal congestion associated with vasomotor rhinitis and the common cold can be relieved by the short-term use (usually not longer than 7 days) of decongestant nasal drops and sprays. These all contain sympathomimetic drugs which exert their effect by vasoconstriction of the mucosal blood vessels which in turn reduces oedema of the nasal mucosa. They are of limited value because they can give rise to a rebound congestion (rhinitis medicamentosa) on withdrawal, due to a secondary vasodilatation with a subsequent temporary increase in nasal congestion. This in turn tempts the further use of the decongestant, leading to a vicious cycle of events. Ephedrine hydrochloride nasal drops, below, are the safest sympathomimetic preparation and can give relief for several hours. The more potent sympathomimetic drugs oxymetazoline and xylometazoline hydrochloride p. 1100 are more likely to cause a rebound effect.

Non-allergic watery rhinorrhea often responds well to treatment with the antimuscarinic ipratropium bromide p. 1102.

**Sinusitis and oral pain**
Sinusitis affecting the maxillary antrum can cause pain in the upper jaw. Where this is associated with blockage of the opening from the sinus into the nasal cavity, it may be helpful to relieve the congestion with inhalation of warm moist air or with ephedrine hydrochloride nasal drops.

Systemic antibacterials may sometimes be required for sinusitis (see under Nose infections, bacterial p. 467).

**Nasal preparations for infection**
There is no evidence that topical anti-infective nasal preparations have any therapeutic value in rhinitis or sinusitis; see elimination of nasal staphylococci.

**Nasal staphylococci**
Elimination of organisms such as staphylococci from the nasal vestibule can be achieved by the use of a cream containing chlorhexidine and neomycin (Naseptin®), but re-colonisation frequently occurs. Coagulase-positive staphylococci are present in the noses of 40% of the population.

A nasal ointment containing mupirocin p. 1101 is also available; it should probably be held in reserve for resistant infections. In hospitals or in care establishments, mupirocin nasal ointment should be reserved for the eradication (in both patients and staff) of nasal carriage of meticillin-resistant *Staphylococcus aureus* (MRSA). A sample should be taken 2 days after treatment to confirm eradication. The course may be repeated if the sample is positive (and the throat is not colonised). To avoid the development of resistance, the treatment course should not exceed 7 days and the course should not be repeated on more than one occasion. If the MRSA strain is mupirocin-resistant or does not respond after 2 courses, consider alternative products such as chlorhexidine and neomycin cream.

# 1 Nasal congestion

**SYMPATHOMIMETICS **

**Ephedrine hydrochloride**

- **INDICATIONS AND DOSE**
  - Nasal congestion | Sinusitis affecting the maxillary antrum
  - **BY INTRanasAL ADMINISTRATION**
  - Child 12-17 years: Apply 1–2 drops up to 4 times a day as required for a maximum of 7 days, to be instilled into each nostril, administer ephedrine 0.5% nasal drops
  - Adult: Apply 1–2 drops up to 4 times a day as required for a maximum of 7 days, to be instilled into each nostril

**IMPORTANT SAFETY INFORMATION**

**CHM/MHRA ADVICE**
The CHM/MHRA has stated that non-prescription cough and cold medicines containing ephedrine can be considered for up to 5 days’ treatment in children aged 6–12 years after basic principles of best care have been tried; these medicines should not be used in children under 6 years of age.

- **CAUTIONS** Avoid excessive or prolonged use • cardiovascular disease (in children) • diabetes mellitus • elderly • hypertension • hyperthyroidism • ischaemic heart disease • prostatic hypertrophy (risk of acute urinary retention) (in adults)
Pseudoephedrine hydrochloride

INDICATIONS AND DOSE
Congestion of mucous membranes of upper respiratory tract
  - BY MOUTH
    - Child 6–11 years: 30 mg 3–4 times a day
    - Child 12–17 years: 60 mg 3–4 times a day
    - Adult: 60 mg 3–4 times a day

IMPORTANT SAFETY INFORMATION
Children under 6 years should not be given over-the-counter cough and cold medicines containing pseudoephedrine.

CAUTIONS
- Diabetes
- Heart disease
- Hypertension
- Hyperthyroidism
- Ischaemic heart disease
- Prostatic hypertrophy
- Raised intra-ocular pressure (in children)
- Susceptibility to angle-closure glaucoma

INTERACTIONS
  - Appendix 1: sympathomimetics, vasoconstrictor

SIDE-EFFECTS
  - Common or very common
    - Anxiety
    - Headache
    - Hypertension
    - Insomnia
    - Nausea
    - Restlessness
    - Tachycardia
    - Vomiting
  - Rare
    - Hallucinations
    - Rash
  - Very rare
    - Angle-closure glaucoma
  - Frequency not known
    - Urinary retention

PREGNANCY
Defective closure of the abdominal wall (gastrochisis) reported very rarely in newborns after first trimester exposure.

BREAST FEEDING
May suppress lactation; avoid if lactation not well established or if milk production insufficient.

Hepatic Impairment
Manufacturer advises use with caution in severe impairment.

Renal Impairment
Use with caution in mild to moderate renal impairment. Manufacturer advises avoid in severe renal impairment.

Less Suitable for Prescribing
Pseudoephedrine hydrochloride is less suitable for prescribing.

EXCEPTIONS TO LEGAL CATEGORY
Galpseud® and Sudafed® can be sold to the public provided no more than 720 mg of pseudoephedrine salts are supplied, and ephedrine base (or salts) are not supplied at the same time; for details see Medicines, Ethics and Practice, London, Pharmaceutical Press (always consult latest edition).

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Oral solution
EXCIPIENTS: May contain Alcohol
- Galpseud (Thornton & Ross Ltd)
  Pseudoephedrine hydrochloride 6 mg per 1 ml
  30 mg/5 ml: £0.14
- Galpseud (Thornton & Ross Ltd)
  Pseudoephedrine hydrochloride 60 mg
  60 mg tablets: £0.25

Tablet
- Galpseud (Thornton & Ross Ltd)
  Pseudoephedrine hydrochloride 60 mg
  60 mg tablets: £0.52

Xylometazoline hydrochloride

DRUG ACTION
Xylometazoline is a sympathomimetic.

INDICATIONS AND DOSE
Nasal congestion
  - BY INTRanasal administration using nasal drops
    - Child 6–11 years: 1–2 drops 1–2 times a day as required for maximum duration of 5 days, 0.05% solution to be administered into each nostril
    - Child 12–17 years: 2–3 drops 2–3 times a day as required for maximum duration of 7 days, 0.1% solution to be administered into each nostril
    - Adult: 2–3 drops 2–3 times a day as required for maximum duration of 7 days, 0.1% solution to be administered into each nostril
  - BY INTRanasal administration using nasal spray
    - Child 12–17 years: 1 spray 1–3 times a day as required for maximum duration of 7 days, to be administered into each nostril
    - Adult: 1 spray 1–3 times a day as required for maximum duration of 7 days, to be administered into each nostril

IMPORTANT SAFETY INFORMATION
The CHM/MHRA has stated that non-prescription cough and cold medicines containing oxymetazoline or xylometazoline can be considered for up to 5 days' treatment in children aged 6–12 years after basic principles of best care have been tried; these medicines should not be used in children under 6 years of age.

CAUTIONS
- Angle-closure glaucoma
- Avoid excessive or prolonged use
- Cardiovascular disease (in children)
- Diabetes mellitus
- Elderly
- Hypertension
- Hyperthyroidism
- Ischaemic heart disease
- Prostatic hypertrophy (risk of acute retention)
- Rebound congestion

CAUTIONS, FURTHER INFORMATION
- Rebound congestion
  - Sympathomimetic drugs are of limited value in the treatment of nasal congestion because they can, following prolonged use (more than 7 days), give rise to a rebound congestion (rhinitis medicamentosa) on withdrawal, due to a secondary vasodilatation with a subsequent temporary increase in nasal congestion. This

Downloaded from www.medicalbr.com
in turn tempts the further use of the decongestant, leading to a vicious cycle of events.

**INTERACTIONS**  
Appendix 1: sympathomimetics, vasoconstrictors

**SIDE-EFFECTS**  
Cardiovascular effects • hallucinations in small children • headache • local irritation • nausea • rebound congestion • restlessness in small children • sleep disturbances in small children • tolerance with diminished effect (after excessive use) • transient visual disturbances

**SIDE-EFFECTS, FURTHER INFORMATION**  
Hallucinations in small children. Discontinue treatment if hallucinations occur.

**PREGNANCY**  
Manufacturer advises caution — no information available.

**MEDICINAL FORMS**  
There can be variation in the licensing of different medicines containing the same drug.

**Spray**
- Otrivine (GlaxoSmithKline Consumer Healthcare)
  - Xylometazoline hydrochloride 1 mg per 1 ml Otrivine Congestion Relief 0.1% nasal spray | 10 ml [GSL] £0.05 DT price = £2.18
  - Otrivine Adult Measured Dose Sinusitis spray | 10 ml [GSL] £2.62 DT price = £2.18
  - Otrivine Allergy Relief 0.1% nasal spray | 10 ml [GSL] £2.62 DT price = £2.18
  - Otrivine Adult nasal spray | 10 ml [GSL] £2.18 DT price = £2.18
  - Otrivine Adult Metered Dose 0.1% nasal spray | 10 ml [GSL] £2.62 DT price = £2.18
- Sudafed Congestion Relief (McNeil Products Ltd)
  - Xylometazoline hydrochloride 1 mg per 1 ml Sudafed Congestion Relief 0.1% nasal spray | 10 ml [GSL] £0.25 DT price = £2.18
- Sudafed Mucus Relief (McNeil Products Ltd)
  - Xylometazoline hydrochloride 1 mg per 1 ml Sudafed Mucus Relief 0.1% nasal spray | 10 ml [GSL] £2.57
  - Sudafed Non-Drowsy Decongestant (xylometazoline) (McNeil Products Ltd)
  - Xylometazoline hydrochloride 1 mg per 1 ml Sudafed Blocked Nose 0.1% spray | 10 ml [GSL] £2.38

**Nasal drops**
- Otrivine (GlaxoSmithKline Consumer Healthcare)
  - Xylometazoline hydrochloride 500 microgram per 1 ml Otrivine Child nasal drops | 10 ml [P] £1.91 DT price = £1.91
  - Xylometazoline hydrochloride 1 mg per 1 ml Otrivine Adult 0.1% nasal drops | 10 ml [GSL] £2.18 DT price = £2.18

## 2 Nasal infection

### ANTIBACTERIALS

#### Chlorhexidine with neomycin

**INDICATIONS AND DOSE**

**Eradication of nasal carriage of staphylococci**
- **BY INTRANASAL ADMINISTRATION**
  - Child: Apply 4 times a day for 10 days
  - Adult: Apply 4 times a day for 10 days

**Preventing nasal carriage of staphylococci**
- **BY INTRANASAL ADMINISTRATION**
  - Child: Apply twice daily
  - Adult: Apply twice daily

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Cream**
- **EXCIPIENTS:** May contain Arachis (peanut) oil, cetostearyl alcohol (including cetyl and stearyl alcohol)

**ANTIBACTERIALS**

#### Mupirocin

**INDICATIONS AND DOSE**

**BACTROBAN NASAL**
For eradication of nasal carriage of staphylococci, including meticillin-resistant *Staphylococcus aureus* (MRSA)
- **BY INTRANASAL ADMINISTRATION**
  - Child: Apply 2–3 times a day for 5 days; a sample should be taken 2 days after treatment to confirm eradication. Course may be repeated once if sample positive (and throat not colonised), dose to be applied to the inner surface of each nostril
  - Adult: Apply 2–3 times a day for 5 days; a sample should be taken 2 days after treatment to confirm eradication. Course may be repeated once if sample positive (and throat not colonised), dose to be applied to the inner surface of each nostril

**PREGNANCY**
Manufacturer advises avoid unless potential benefit outweighs risk — no information available.

**BREAST FEEDING**
No information available.

**RENAL IMPAIRMENT**
Manufacturer advises caution when mupirocin ointment used in moderate or severe impairment because it contains macrogols (polyethylene glycol).

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Nasal ointment**
- Bactroban (GlaxoSmithKline UK Ltd)
  - Mupirocin (as Mupirocin calcium) 20 mg per 1 gram Bactroban 2% nasal ointment | 3 gram [POM] £4.24 DT price = £4.24

### CORTICOSTEROIDS

#### CORTICOSTEROID COMBINATIONS WITH ANTI-INFECCIVES

**Betamethasone with neomycin**

The properties listed below are those particular to the combination only. For the properties of the components please consider, betamethasone p. 1095, neomycin sulfate p. 492.

**INDICATIONS AND DOSE**

**Nasal infection**
- **BY INTRANASAL ADMINISTRATION USING NASAL DROPS**
  - Child: Apply 2–3 drops 2–3 times a day, to be applied into each nostril
  - Adult: Apply 2–3 drops 2–3 times a day, to be applied into each nostril

**LESS SUITABLE FOR PRESCRIBING**
Betamethasone with neomycin nasal-drops are less suitable for prescribing; there is no evidence that topical anti-infective nasal preparations have any therapeutic value in rhinitis or sinusitis.
Nasal inflammation, nasal polyps and rhinitis

Other drugs used for Nasal inflammation, nasal polyps and rhinitis Desloratadine, p. 269 · Fexofenadine hydrochloride, p. 269 · Ketotifen, p. 275

ANTIMUSCARINICS

Ipratropium bromide 24-Feb-2016

- INDICATIONS AND DOSE Rhinorrhoea associated with allergic and non-allergic rhinitis
  → BY INTRANASAL ADMINISTRATION
  - Child 12-17 years: 2 sprays 2–3 times a day, dose to be sprayed into each nostril
  - Adult: 2 sprays 2–3 times a day, dose to be sprayed into each nostril
- SIDE-EFFECTS
  - Common or very common Epistaxis · nasal dryness · nasal irritation
  - Uncommon Headache · nausea
  - Very rare Gastro-intestinal motility disturbances · palpitations · urinary retention

- MEDICINAL FORMS
  - There can be variation in the licensing of different medicines containing the same drug.
  - Spray
    - EXCipients: May contain Benzalkonium chloride, disodium edetate
      → Beconase (GlaxoSmithKline UK Ltd, Omega Pharma Ltd)
        Ipratropium bromide 21 microgram per 1 dose Beconase
  - Dose equivalence and conversion
    - 1 metered spray of nasal spray = 21 micrograms.

- MONITORING REQUIREMENTS
  - The height of children receiving prolonged treatment with nasal corticosteroids should be monitored; if growth is slowed, referral to a paediatrician should be considered.

Beclometasone dipropionate (Beclometasone dipropionate)

- INDICATIONS AND DOSE
  Prophylaxis and treatment of allergic and vasomotor rhinitis
  → BY INTRANASAL ADMINISTRATION
  - Child 6-17 years: 100 micrograms twice daily, dose to be administered into each nostril, reduced to 50 micrograms twice daily, dose to be administered into each nostril, dose to be reduced when symptoms controlled; maximum 400 micrograms per day
  - Adult: 100 micrograms twice daily, dose to be administered into each nostril, reduced to 50 micrograms twice daily, dose to be administered into each nostril, dose to be reduced when symptoms controlled; maximum 400 micrograms per day

- MEDICINAL FORMS
  - There can be variation in the licensing of different medicines containing the same drug.
  - Spray
    - EXCipients: May contain Benzalkonium chloride, polysorbates
      → Beclometasone dipropionate (Non-proprietary)
        Beclometasone dipropionate 50 microgram per 1 dose Beclometasone dipropionate 50 microgram per 1 dose
  - Price
    - Beclometasone dipropionate 50 microgram per 1 dose Beclometasone dipropionate 50 microgram per 1 dose
      - no price available DT price = £2.10
      - Beconase Aqueous 50microgram/dose nasal spray | 200 micrograms per nostril for 18 years subject to max. single dose of 100 micrograms per nostril, max. daily dose of 200 micrograms per nostril for max. 3 months, and a pack size of 20 mg.

Corticosteroids (intranasal)

- CAUTIONS
  - Avoid after nasal surgery (until healing has occurred); avoid in pulmonary tuberculosis; avoid in the presence of untreated nasal infections; patients transferred from systemic corticosteroids may experience exacerbation of some symptoms

- MEDICINAL FORMS
  - There can be variation in the licensing of different medicines containing the same drug.
  - Spray
    - EXCipients: May contain Benzalkonium chloride, disodium edetate
      → Beconase (GlaxoSmithKline UK Ltd, Omega Pharma Ltd)
        Beclometasone dipropionate 50 microgram per 1 dose Beclometasone dipropionate 50 microgram per 1 dose
      → Beconase Aqueous 50 microgram/dose nasal spray | 200 micrograms per nostril for 18 years subject to max. single dose of 100 micrograms per nostril, max. daily dose of 200 micrograms per nostril for max. 3 months, and a pack size of 20 mg.

- MEDICINAL FORMS
  - There can be variation in the licensing of different medicines containing the same drug.
**Betamethasone**

### INDICATIONS AND DOSE

**BETNESOL**

Non-infected inflammatory conditions of nose

- **BY INTRANASAL ADMINISTRATION**
  - Adult: Apply 2–3 drops 2–3 times a day, dose to be applied into each nostril

**VISTAMETHASONE**

Non-infected inflammatory conditions of nose

- **BY INTRANASAL ADMINISTRATION**
  - Adult: Apply 2–3 drops twice daily, dose to be applied into each nostril

### INTERACTIONS

Appendix 1: corticosteroids

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Ear/eye/nose drops solution**

**EXCIPIENTS:** May contain Benzalkonium chloride, disodium edetate

- **Betnesol** (Focus Pharmaceuticals Ltd)
  - Betnesol sodium phosphate 1 mg per 1 ml Betnesol 0.1% eye/ear/nose drops | 10 ml [POM] £2.32 DT price = £2.32
- **Vistamethasone** (Martindale Pharmaceuticals Ltd)
  - Vistamethasone sodium phosphate 1 mg per 1 ml Vistamethasone 0.1% eye/ear/nose drops | 5 ml [POM] £0.87 | 10 ml [POM] £0.99 DT price = £2.32

---

**Budesonide**

### INDICATIONS AND DOSE

Prophylaxis and treatment of allergic rhinitis and perennial rhinitis

- **BY INTRANASAL ADMINISTRATION USING NASAL SPRAY**
  - Child 4–11 years: 50 micrograms once daily, to be administered into each nostril preferably in the morning, increased if necessary to 50 micrograms twice daily
  - Child 12–16 years: 100 micrograms once daily, to be administered into each nostril preferably in the morning, increased if necessary to 100 micrograms twice daily; reduced to 50 micrograms once daily, dose to be administered into each nostril, dose to be reduced when control achieved
  - Adult: 100 micrograms once daily, to be administered into each nostril preferably in the morning, increased if necessary to 100 micrograms twice daily; reduced to 50 micrograms once daily, dose to be reduced when control achieved

**Nasal polyps**

- **BY INTRANASAL ADMINISTRATION**
  - Child 12–17 years: 100 micrograms twice daily for up to 3 months, dose to be administered into each nostril
  - Adult: 100 micrograms twice daily for up to 3 months, dose to be administered into each nostril

**Rhinitis**

- **BY INTRANASAL ADMINISTRATION**
  - Adult: 128 micrograms once daily, dose to be administered into each nostril in the morning, alternatively 64 micrograms twice daily, dose to be administered into each nostril; reduced to 64 micrograms once daily when control achieved. Use for maximum 3 months, doses to be administered into each nostril

**Nasal polyps**

- **BY INTRANASAL ADMINISTRATION**
  - Adult: 64 micrograms twice daily for up to 3 months, dose to be administered into each nostril

---

---

**Fluticasone**

### INDICATIONS AND DOSE

Prophylaxis and treatment of allergic rhinitis and perennial rhinitis

- **BY INTRANASAL ADMINISTRATION USING NASAL SPRAY**
  - Child 4–11 years: 50 micrograms once daily, to be administered into each nostril preferably in the morning, increased if necessary to 50 micrograms twice daily
  - Child 12–16 years: 100 micrograms once daily, to be administered into each nostril preferably in the morning, increased if necessary to 100 micrograms twice daily; reduced to 50 micrograms once daily, dose to be administered into each nostril, dose to be reduced when control achieved
  - Adult: 100 micrograms once daily, to be administered into each nostril preferably in the morning, increased if necessary to 100 micrograms twice daily; reduced to 50 micrograms once daily, dose to be reduced when control achieved

**Nasal polyps**

- **BY INTRANASAL ADMINISTRATION USING NASAL DROPS**
  - Child 16–17 years: 200 micrograms 1–2 times a day, to be administered into each nostril, alternative treatment should be considered if no improvement after 4–6 weeks, (200 micrograms is equivalent to approximately 6 drops)
  - Adult: 200 micrograms 1–2 times a day, to be administered into each nostril, alternative treatment should be considered if no improvement after 4–6 weeks, (200 micrograms is equivalent to approximately 6 drops)

**AVAMYS® SPRAY**

Prophylaxis and treatment of allergic rhinitis

- **BY INTRANASAL ADMINISTRATION**
  - Child 4–11 years: 27.5 micrograms once daily, dose to be sprayed into each nostril, then increased if necessary to 55 micrograms once daily, dose to be sprayed into each nostril, reduced to 27.5 micrograms once daily, to be sprayed into each nostril, dose to be reduced once control achieved; use minimum effective dose
  - Child 12–17 years: 55 micrograms once daily, dose to be sprayed into each nostril, continued →
 reduced to 27.5 micrograms once daily, to be sprayed into each nostril, dose to be reduced once control achieved; use minimum effective dose

- Adult: 55 micrograms once daily, dose to be sprayed into each nostril, reduced to 27.5 micrograms once daily, to be sprayed into each nostril, dose to be reduced once control achieved; use minimum effective dose

**DOSE EQUIVALENCE AND CONVERSION**
- For Avamys® spray: 1 spray equivalent to 27.5 micrograms.

**INTERACTIONS** → Appendix 1: corticosteroids

**SIDE-EFFECTS** Nasal ulceration occurs commonly with nasal preparations containing fluticasone furoate.

**EXCEPTIONS TO LEGAL CATEGORY**
Preparations of fluticasone propionate can be sold to the public for nasal administration (other than by pressurised nasal spray) if supplied for the prevention and treatment of allergic rhinitis in adults over 18 years, subject to max. single dose of 100 micrograms per nostril, max. daily dose of 200 micrograms per nostril for max. 3 months, and a pack size of 3 mg.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Spray**

- **EXCIPENTS**: May contain Benzalkonium chloride, disodium edetate, polysorbates
- Fluticasone (Non-proprietary)
  - Fluticasone propionate 50 microgram per 1 dose (GlaxoSmithKline UK Ltd) Fluticasone propionate 50micrograms/dose nasal spray | 60 dose (Pos) no price available | 150 dose (Pos) no price available DT price = £11.01
- Avamys® (GlaxoSmithKline UK Ltd)
  - Fluticasone furoate 27.5 microgram per 1 dose Avamys 27.5micrograms/dose nasal spray | 120 dose (Pos) £6.44 DT price = £6.44
- Flixonase® (GlaxoSmithKline UK Ltd)
  - Fluticasone propionate 50 microgram per 1 dose Flixonase 50micrograms/dose aqueous nasal spray | 150 dose (Pos) £11.01 DT price = £11.01
- Nasofan® (Teva UK Ltd)
  - Fluticasone propionate 50 microgram per 1 dose Nasofan 50micrograms/dose aqueous nasal spray | 150 dose (Pos) £8.04 DT price = £11.01

**Nasal drops**

- **EXCIPENTS**: May contain Polysorbates
- Flixonase® (GlaxoSmithKline UK Ltd)
  - Fluticasone propionate 400 microgram Flixonase Nasule 400microgram/unit dose nasal drops | 28 unit dose (Pos) £12.99 DT price = £12.99

### Fluticasone with azelastine

The properties listed below are those particular to the combination only. For the properties of the components please consider, fluticasone p. 1103, azelastine hydrochloride p. 1059.

**INDICATIONS AND DOSE**
Moderate to severe seasonal and perennial allergic rhinitis, if monotherapy with antihistamine or corticosteroid is inadequate

- **BY INTRanasal ADMINISTRATION**
- Child 12-17 years: 1 spray twice daily, dose to be administered into each nostril
- Adult: 1 spray twice daily, dose to be administered into each nostril

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Spray**

- **EXCIPENTS**: May contain Benzalkonium chloride, polysorbates
- Fluticasone with azelastine (Non-proprietary)
  - Fluticasone propionate 50 microgram per 1 actuation, Azelastine hydrochloride 137 microgram per 1 actuation Fluticasone propionate 50micrograms/dose / Azelastine 137micrograms/dose nasal spray | 120 dose (Pos) no price available DT price = £14.80
- Dymista® (Meda Pharmaceuticals Ltd)
  - Fluticasone propionate 50 microgram per 1 actuation, Azelastine hydrochloride 137 microgram per 1 actuation Dymista 137micrograms/dose / 50micrograms/dose nasal spray | 120 dose (Pos) £14.80 DT price = £14.80

### Mometasone furoate

**INDICATIONS AND DOSE**
Prophylaxis and treatment of allergic rhinitis

- **BY INTRanasal ADMINISTRATION**
- Child 6-11 years: 50 micrograms daily, dose to be sprayed into each nostril
- Child 12-17 years: 100 micrograms daily, increased if necessary up to 200 micrograms daily, dose to be sprayed into each nostril; reduced to 50 micrograms daily, dose to be reduced when control achieved, dose to be sprayed into each nostril
- Adult: 100 micrograms daily, increased if necessary up to 200 micrograms daily, dose to be sprayed into each nostril; reduced to 50 micrograms daily, dose to be reduced when control achieved, dose to be sprayed into each nostril

**Nasal polyps**

- **BY INTRanasal ADMINISTRATION**
- Adult: Initially 100 micrograms daily for 5–6 weeks, dose to be sprayed into each nostril, then increased if necessary to 100 micrograms twice daily, dose to be sprayed into each nostril; consider alternative treatment if no improvement after further 5–6 weeks, reduce to the lowest effective dose when control achieved

**INTERACTIONS** → Appendix 1: corticosteroids

**SIDE-EFFECTS** Nasal ulceration occurs commonly with preparations containing mometasone furoate.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Spray**

- **EXCIPENTS**: May contain Benzalkonium chloride, polysorbates
- Mometasone furoate (Non-proprietary)
  - Mometasone furoate 50 microgram per 1 dose Mometasone 50micrograms/dose nasal spray | 120 dose (Pos) £7.30 DT price = £2.12
- Nasonex® (Merck Sharp & Dohme Ltd)
  - Mometasone furoate 50 microgram per 1 dose Nasonex 50micrograms/dose nasal spray | 140 dose (Pos) £7.68 DT price = £2.12

### Triamcinolone acetonide

**INDICATIONS AND DOSE**
Prophylaxis and treatment of allergic rhinitis

- **BY INTRanasal ADMINISTRATION**
- Child 6-11 years: 55 micrograms once daily, dose to be sprayed into each nostril, increased if necessary to 110 micrograms once daily, dose to be sprayed into each nostril; reduced to 55 micrograms once daily, dose to be sprayed into each nostril, reduce dose when
control achieved; maximum duration of treatment 3 months

- Child 12-17 years: 110 micrograms once daily, dose to be sprayed into each nostril, reduced to 55 micrograms once daily, dose to be sprayed into each nostril, reduce dose when control achieved
- Adult: 110 micrograms once daily, dose to be sprayed into each nostril, reduced to 55 micrograms once daily, dose to be sprayed into each nostril, reduce dose when control achieved

- **UNLICENSED USE**
  Not licensed for use in children under 6 years.

- **INTERACTIONS** → Appendix 1: corticosteroids

- **EXCEPTIONS TO LEGAL CATEGORY**
  Preparations of triamcinolone acetonide can be sold to the public for nasal administration as a non-pressurised nasal spray if supplied for the symptomatic treatment of seasonal allergic rhinitis in adults over 18 years, subject to maximum daily dose of 110 micrograms per nostril for maximum 3 months, and a pack size of 3.575 mg.

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.

  **Spray**

  **EXCIPIENTS:** May contain Benzalkonium chloride, disodium edetate, polysorbates

  **Nasacort (Sanofi)**

  **Triamcinolone acetonide 55 microgram per 1 dose**

  Nasacort
  Allergy 55 micrograms/dose nasal spray | 30 dose [P] £3.01
  Nasacort 55 micrograms/dose nasal spray | 120 dose [POM] £7.39 DT price = £7.39

  **MUST-CELL STABILISERS**

  **Sodium cromoglicate**

  *(Sodium cromoglycate)*

  - **INDICATIONS AND DOSE**
    - **Prophylaxis of allergic rhinitis**
      - **BY INTRanasAL ADMINISTRATION**
      - Child: 1 spray 2–4 times a day, to be administered into each nostril
      - Adult: 1 spray 2–4 times a day, to be administered into each nostril

  - **UNLICENSED USE**
    Licensed for use in children (age range not specified by manufacturers).

  - **SIDE-EFFECTS**
    - Rare Transient bronchospasm
    - Frequency not known Local irritation

  - **MEDICINAL FORMS**
    There can be variation in the licensing of different medicines containing the same drug.
    No licensed medicines listed.

### Oropharynx

#### 1 Dry mouth

**Treatment of dry mouth**

**Overview**

Dry mouth (xerostomia) may be caused by drugs with antimuscarinic (anticholinergic) side-effects (e.g. antispasmodics, tricyclic antidepressants, and some antipsychotics), by diuretics, by irradiation of the head and neck region or by damage to or disease of the salivary glands. Patients with a persistently dry mouth may develop a burning or scalded sensation and have poor oral hygiene; they may develop increased dental caries, periodontal disease, intolerance of dentures, and oral infections (particularly candidiasis). Dry mouth may be relieved in many patients by simple measures such as frequent sips of cool drinks or sucking pieces of ice or sugar-free fruit pastilles. Sugar-free chewing gum stimulates salivation in patients with residual salivary function.

**Artificial saliva** can provide useful relief of dry mouth. A properly balanced artificial saliva should be of a neutral pH and contain electrolytes (including fluoride) to correspond approximately to the composition of saliva. The acidic pH of some artificial saliva products may be inappropriate. Of the proprietary preparations, Aquoral® & Biotène Oralbalance® gel or Xerolin® can be used for any condition giving rise to a dry mouth. BioXtra®, Glandosane®, Saline Orithna®, and Saliveze®, have ACBS approval for dry mouth associated with radiotherapy or sicca syndrome. Salix® pastilles, which act locally as salivary stimulants, are also available for any condition leading to a dry mouth and SST tablets may be prescribed for dry mouth in patients with salivary gland impairment (and patent salivary ducts).

Pilocarpine pastilles are licensed for the treatment of xerostomia following irradiation for head and neck cancer and for dry mouth and dry eyes (xerophthalmia) in Sjögren’s syndrome. They are effective only in patients who have some residual salivary gland function, and therefore should be withdrawn if there is no response.

**PARASYMPATHOMIMETICS**

**Pilocarpine**

- **INDICATIONS AND DOSE**
  - **Xerostomia following irradiation for head and neck cancer**
    - **BY MOUTH**
    - Adult: 5 mg 3 times a day for 4 weeks, then increased if tolerated to up to 30 mg daily in divided doses if required, dose to be taken with or immediately after meals (last dose always with evening meal), maximum therapeutic effect normally within 4–8 weeks; discontinue if no improvement after 2–3 months
  - **Dry mouth and dry eyes in Sjögren’s syndrome**
    - **BY MOUTH**
    - Adult: 5 mg 4 times a day; increased if tolerated to up to 30 mg daily in divided doses if required, dose to be taken with meals and at bedtime, discontinue if no improvement after 2–3 months

- **CONTRA-INDICATIONS** Acute iritis - chronic obstructive pulmonary disease (increased bronchial secretions and increased airways resistance) - uncontrolled asthma (increased bronchial secretions and increased airways resistance) - uncontrolled cardiorenal disease

- **CAUTIONS** Asthma (avoid if uncontrolled) - biliary-tract disease - cardiovascular disease (avoid if uncontrolled) - cholelithiasis - chronic obstructive pulmonary disease (avoid if uncontrolled) - cognitive disturbances - maintain adequate fluid intake to avoid dehydration associated with excessive sweating - peptic ulceration - psychiatric disturbances - risk of increased renal colic - risk of increased urethral smooth muscle tone - susceptibility to angle-closure glaucoma

- **INTERACTIONS** → Appendix 1: pilocarpine

- **SIDE-EFFECTS**
  - Common or very common Influenza-like symptoms - abdominal pain - asthenia - conjunctivitis - constipation - diarrhea - dizziness - dyspepsia - flushing - headache -
hypertension, increased urinary frequency, lacrimation, nausea, ocular pain, palpitation, pruritus, rash, rhinitis, sweating, visual disturbances, vomiting

- **Uncommon** Flatulence, urinary urgency
- **Pregnancy** Avoid—smooth muscle stimulant; toxicity in animal studies.
- **Breastfeeding** Manufacturer advises avoid—present in milk in animal studies.
- **Hepatic Impairment** Reduce initial oral dose in moderate or severe cirrhosis.
- **Renal Impairment** Manufacturer advises caution with tablets.
- **Patient and Carer Advice**
  Driving and skilled tasks
  Blurred vision may affect performance of skilled tasks (e.g. driving) particularly at night or in reduced lighting.

- **Medicinal Forms**
  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral solution

  **Tablet**
  CAUTIONARY AND ADVISORY LABELS 21, 27
  - Salagen (Merus Labs Luxco S.A R.L.)

  - Pilocarpine hydrochloride 5 mg Salagen 5mg tablets | 84 tablet (£4.14 OT price = £4.14

  **Capsule**
  Biotene Oralbalance dry mouth saliva replacement gel
  (GlaxoSmithKline Consumer Healthcare) Glucose oxidase 12000 unit, Lactoferrin 12 mg, Lactoperoxidase 12000 unit, Muramidase 12 mg 50 gram • NHS indicative price = £4.46 • Drug Tariff (Part IXa)

- **Pregnancy**
  Uncommon

- **Glandosane**
  Carmellose sodium 500 mg, sorbitol 1.5 g, potassium chloride 60 mg, sodium chloride 42.2 mg, magnesium chloride 2.6 mg, calcium chloride 7.3 mg, and dipotassium hydrogen phosphate 17.1 mg/50 g, pH 5.75.

- **Indications and Dose**
  Dry mouth as a result of having (or having undergone) radiotherapy (ACBS) | Dry mouth as a result of sicca syndrome (ACBS)
  ▶ BY MOUTH
  ▶ Adult: Apply as required, spray onto oral and pharyngeal mucosa

- **Prescribing and Dispensing Information**
  AS Saliva Orthana® lozenges do not contain fluoride.

  **AS Saliva Orthana® lozenges**
  A S Pharma Ltd
  30lozenge(ACBS) • NHS indicative price = £3.50

- **AS Saliva Orthana® spray**
  Gastric mucin (porcine) 3.5%, xylitol 2%, sodium fluoride 4.2 mg/litre, with preservatives and flavouring agents, pH neutral.

- **Indications and Dose**
  Symptomatic treatment of dry mouth
  ▶ BY MOUTH
  ▶ Adult: Apply 2–3 sprays as required, spray onto oral and pharyngeal mucosa

- **Prescribing and Dispensing Information**
  Contains traces of milk protein and egg white protein.

  **Oralieve Moisturising Mouth Gel**
  (Inspiration Pharma Ltd)
  50ml • NHS indicative price = £2.96 • Drug Tariff (Part IXa)

- **Indications and Dose**
  Symptomatic treatment of dry mouth
  ▶ BY MOUTH
  ▶ Adult: Apply as required, particularly at night, to oral mucosa

- **Prescribing and Dispensing Information**
  Lactoperoxidase, lactoferrin, lysozyme, glucose oxidase, xylitol in a gel basis.

- **Indications and Dose**
  Symptomatic treatment of dry mouth
  ▶ BY MOUTH
  ▶ Adult: Apply as required, apply to gums and tongue

- **Prescribing and Dispensing Information**
  Lactoperoxidase, lactoferrin, lysozyme, glucose oxidase, xylitol in a gel basis.

- **Prescribing and Dispensing Information**
  Contains traces of milk protein and egg white protein.
2 Oral hygiene

Mouthwashes and other preparations for oropharyngeal use

Lozenges and sprays

There is no convincing evidence that antiseptic lozenges and sprays have a beneficial action and they sometimes irritate and cause sore tongue and sore lips. Some of these preparations also contain local anaesthetics which relieve pain but may cause sensitisation.

Mouthwashes, gargles, and dentifrices

Superficial infections of the mouth are often helped by warm mouthwashes which have a mechanical cleansing effect and cause some local hyperaemia. However, to be effective, they must be used frequently and vigorously. A warm saline mouthwash is ideal and can be prepared either by dissolving half a teaspoonful of salt in a glassful of warm water or by diluting compound sodium chloride mouthwash p. 1109 with an equal volume of warm water.

Mouthwashes containing an oxidising agent, such as hydrogen peroxide p. 1109, may be useful in the treatment of acute ulcerative gingivitis (Vincent’s infection) since the organisms involved are anaerobes. It also has a mechanical cleansing effect arising from frothing when in contact with oral debris.

Chlorhexidine p. 1108 is an effective antiseptic which has the advantage of inhibiting plaque formation on the teeth. It does not, however, completely control plaque deposition and is not a substitute for effective toothbrushing. Moreover, chlorhexidine preparations do not penetrate significantly into stagnation areas and are therefore of little value in the control of dental caries or of periodontal disease once pocketing has developed.

Chlorhexidine mouthwash is used in the treatment of denture stomatitis. It is also used in the prevention of oral candidiasis in immunocompromised patients. Chlorhexidine mouthwash reduces the incidence of alveolar osteitis (Vincent’s infection) since the organisms involved are anaerobes. It also has a mechanical cleansing effect arising from frothing when in contact with oral debris.

Chlorhexidine can be used as a mouthwash, spray or gel for secondary infection in mucosal ulceration and for controlling gingivitis, as an adjunct to other oral hygiene measures. These preparations may also be used instead of toothbrushing where there is a painful periodontal condition (e.g. primary herpetic stomatitis) or if the patient has a haemorrhagic disorder, or is disabled.

Chlorhexidine preparations are of little value in the control of acute necrotising ulcerative gingivitis. With prolonged use, chlorhexidine causes reversible brown staining of teeth and tongue. Chlorhexidine may be incompatible with some ingredients in toothpaste, causing an unpleasant taste in the mouth; rinse the mouth thoroughly with water between using toothpaste and chlorhexidine-containing products.

There is no convincing evidence that gargles are effective in adults.
ANTISEPTICS AND DISINFECTANTS

Chlorhexidine

- **INDICATIONS AND DOSE**
  - Oral hygiene and plaque inhibition | Oral candidiasis | Gingivitis | Management of apthous ulcers
    - BY MOUTH USING MOUTHWASH
      - Child: Rinse or gargle 10 mL twice daily (rinse or gargle for about 1 minute)
      - Adult: Rinse or gargle 10 mL twice daily (rinse or gargle for about 1 minute)
  - Denture stomatitis
    - MOUTHWASH
    - Adult: Cleanse and soak dentures in mouthwash solution for 15 minutes twice daily
  - Oral hygiene and plaque inhibition and gingivitis
    - BY MOUTH USING DENTAL GEL
      - Child: Apply 1–2 times a day, to be brushed on the teeth
      - Adult: Apply 1–2 times a day, to be brushed on the teeth
  - Oral candidiasis | Management of apthous ulcers
    - BY MOUTH USING OROMUCOSAL SPRAY
      - Child: Apply up to 12 sprays twice daily as required, to be applied tooth, gingival, or ulcer surfaces
      - Adult: Apply up to 12 sprays twice daily as required, to be applied tooth, gingival, or ulcer surfaces
  - Bladder irrigation and catheter patency solutions
    - BY INTRAVESICAL INSTILLATION
    - Adult: (consult product literature)

- **UNLICENSED USE** Corsodyl® not licensed for use in children under 12 years (unless on the advice of a healthcare professional).

- **SIDE-EFFECTS** Anaphylaxis | Hypersensitivity | Mucosal irritation | Parotid gland swelling | Reversible brown staining of composite restorations | Reversible brown staining of silicate compositions | Reversible brown staining of teeth | Taste disturbance | Tongue discolouration

  **SIDE-EFFECTS, FURTHER INFORMATION** If desquamation occurs with mucosal irritation, discontinue treatment or dilute mouthwash with an equal volume of water.

- **PATIENT AND CARER ADVICE** Chlorhexidine gluconate may be incompatible with some ingredients in toothpaste; rinse the mouth thoroughly with water between using toothpaste and chlorhexidine-containing product.

- **PROFESSION SPECIFIC INFORMATION**

  **Dental practitioners’ formulary**
  Corsodyl® dental gel may be prescribed as Chlorhexidine Gluconate Gel; Corsodyl® mouthwash may be prescribed as Chlorhexidine Mouthwash; Corsodyl® oral spray may be prescribed as Chlorhexidine Oral Spray.

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: liquid, irrigation solution

  **Dental gel**
  - Corsodyl® (GlaxoSmithKline Consumer Healthcare)
    Chlorhexidine gluconate 10 mg per 1 gram | 50 gram [G] £1.26 DT price = £1.26
  - Spray
    - Corsodyl® (GlaxoSmithKline Consumer Healthcare)
      Chlorhexidine gluconate 2 mg per 1 ml | 60 mL [G] £4.28 DT price = £1.26

  **Oral hygiene and plaque inhibition and gingivitis**
  - Adult: Rinse or gargle 10 mL twice daily (rinse or gargle for about 1 minute)

  **Denture stomatitis**
  - MOUTHWASH
  - Adult: Cleanse and soak dentures in mouthwash solution for 15 minutes twice daily

  **Oral hygiene and plaque inhibition and gingivitis**
  - MOUTHWASH
  - Adult: Apply 1–2 times a day, to be brushed on the teeth

  **Oral candidiasis | Management of apthous ulcers**
  - MOUTHWASH
  - Adult: Apply 1–2 times a day, to affect areas

  **Oral hygiene and plaque inhibition | Oral candidiasis | Gingivitis | Management of apthous ulcers**
  - MOUTH WASHING
  - Adult: Apply up to 12 sprays twice daily as required, to be applied tooth, gingival, or ulcer surfaces

  **Bladder irrigation and catheter patency solutions**
  - BY INTRAVESICAL INSTILLATION
  - Adult: (consult product literature)

  **Chlorhexidine with chlorobutanol**

  The properties listed below are those particular to the combination only. For the properties of the components please consider, chlorhexidine above.

- **INDICATIONS AND DOSE**
  - Oral hygiene and plaque inhibition
    - BY MOUTH USING MOUTHWASH
      - Child 6-17 years: Rinse or gargle 10–15 mL 2–3 times a day, to be diluted with lukewarm water in measuring cup provided
      - Adult: Rinse or gargle 10–15 mL 2–3 times a day, to be diluted with lukewarm water in measuring cup provided
  - Denture disinfection
    - Adult: Soak previously cleansed dentures in mouthwash (diluted with 2 volumes of water) for 60 minutes

  **PRESCRIBING AND DISPENSING INFORMATION**
  Flavours of mouthwash may include mint.

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug. No licensed medicines listed.

**Hexetidine**

- **INDICATIONS AND DOSE**
  - Oral hygiene
    - BY MOUTH USING MOUTHWASH
      - Child 6-17 years: Rinse or gargle 15 mL 2–3 times a day, to be used undiluted
      - Adult: Rinse or gargle 15 mL 2–3 times a day, to be used undiluted

下载自 www.medicalbr.com
**SIDE-EFFECTS**
- Very rare: Taste disturbance, transient anaesthesia
- Frequency not known: Local irritation

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. No licensed medicines listed.

---

**Hydrogen peroxide**

**INDICATIONS AND DOSE**

**Oral hygiene (with hydrogen peroxide 6%)**
- **By mouth using mouthwash**
- Child: Rinse or gargle 15 mL 2–3 times a day for 2–3 minutes, to be diluted in half a tumblerful of warm water
- Adult: Rinse or gargle 15 mL 2–3 times a day for 2–3 minutes, to be diluted in half a tumblerful of warm water

**Peroxyl®**

**Oral hygiene**
- **By mouth using mouthwash**
- Child 6–17 years: Rinse or gargle 10 mL 3 times a day for about 1 minute, for maximum 7 days, to be used after meals and at bedtime
- Adult: Rinse or gargle 10 mL up to 4 times a day for about 1 minute, to be used after meals and at bedtime

**SIDE-EFFECTS**
Hypertrophy of papillae of tongue on prolonged use.

**PRESCRIBING AND DISPENSING INFORMATION**
When prepared extemporaneously, the BP states Hydrogen Peroxide Mouthwash, BP consists of hydrogen peroxide 6% solution (= approx. 20 volume) BP.

**HANDLING AND STORAGE**
Hydrogen peroxide bleaches fabric.

**PROFESSION SPECIFIC INFORMATION**
Dental practitioners’ formulary
Hydrogen Peroxide Mouthwash may be prescribed.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. No licensed medicines listed.

---

**Sodium chloride**

**INDICATIONS AND DOSE**

**Oral hygiene**
- **By mouth using mouthwash**
- Child: Rinse or gargle as required
- Adult: Rinse or gargle as required

**DIRECTIONS FOR ADMINISTRATION**
Extemporaneous mouthwash preparations should be prepared according to the following formula: sodium chloride 1.5 g, sodium bicarbonate 1 g, concentrated peppermint emulsion 2.5 mL, double-strength chloroform water 50 mL, water to 100 mL. To be diluted with an equal volume of warm water.

**PRESCRIBING AND DISPENSING INFORMATION**
No mouthwash preparations available—when prepared extemporaneously, the BP states Sodium Chloride Mouthwash, Compound, BP consists of sodium bicarbonate 1%, sodium chloride 1.5% in a suitable vehicle with peppermint flavour.

**PROFESSION SPECIFIC INFORMATION**
Dental practitioners’ formulary
Compound Sodium Chloride Mouthwash may be prescribed.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. No licensed medicines listed.

---

2.1 Dental caries

**Fluoride**

Availability of adequate fluoride confers significant resistance to dental caries. It is now considered that the topical action of fluoride on enamel and plaque is more important than the systemic effect.

When the fluoride content of drinking water is less than 700 micrograms per litre (0.7 parts per million), daily administration of fluoride tablets or drops provides suitable supplementation. Systemic fluoride supplements should not be prescribed without reference to the fluoride content of the local water supply. Infants need not receive fluoride supplements until the age of 6 months.

Dentifrices which incorporate sodium fluoride or monofluorophosphate are also a convenient source of fluoride.

Individuals who are either particularly caries prone or medically compromised may be given additional protection by use of fluoride rinses or by application of fluoride gels. Rinses may be used daily or weekly; daily use of a less concentrated rinse is more effective than weekly use of a more concentrated one. High-strength gels must be applied regularly under professional supervision; extreme caution is necessary to prevent children from swallowing any excess. Less concentrated gels are available for home use. Varnishes are also available and are particularly valuable for young or disabled children since they adhere to the teeth and set in the presence of moisture.
VITAMINS AND TRACE ELEMENTS

Sodium fluoride

- **INDICATIONS AND DOSE**
  - Prophylaxis of dental caries for water content less than 300 micrograms/litre (0.3 parts per million) of fluoride ion
    - **BY MOUTH USING TABLETS**
    - Child 6 months–2 years: 250 micrograms daily, doses expressed as fluoride ion (F⁻)
    - Child 3–5 years: 500 micrograms daily, doses expressed as fluoride ion (F⁻)
    - Child 6–17 years: 1 mg daily, doses expressed as fluoride ion (F⁻)
    - Adult: 1 mg daily, doses expressed as fluoride ion (F⁻)
  - Prophylaxis of dental caries for water content between 300 and 700 micrograms/litre (0.3–0.7 parts per million) of fluoride ion
    - **BY MOUTH USING TABLETS**
    - Child 6 months–17 years: Supplements not advised
    - Adult: Supplements not advised
  - Prophylaxis of dental caries for individuals who are caries prone or medically compromised
    - **BY MOUTH USING TABLETS**
    - Child 10–17 years: Apply 1 centimetre twice daily, to be applied using a toothbrush
    - Adult: Apply 1 centimetre twice daily, to be applied using a toothbrush

- **DIRECTIONS FOR ADMINISTRATION**
  - **COLGATE DURAPHAT® 2800PPM FLUORIDE TOOTHPASTE** Brush teeth for 1 minute before spitting out.
  - **COLGATE DURAPHAT® 5000PPM FLUORIDE TOOTHPASTE** Brush teeth for 3 minutes before spitting out.
  - **PRESCRIBING AND DISPENSING INFORMATION** Flavours of oral tablet formulations may include orange.

- **PATIENT AND CARER ADVICE**
  - Mouthwash Avoid eating, drinking, or rinsing mouth for 15 minutes after use.
  - **COLGATE DURAPHAT® 2800PPM FLUORIDE TOOTHPASTE** Patients or carers should be given advice on how to administer sodium fluoride toothpaste. Avoid drinking or rinsing mouth for 30 minutes after use.
  - **COLGATE DURAPHAT® 5000PPM FLUORIDE TOOTHPASTE** Patients or carers should be given advice on how to administer Sodium fluoride toothpaste.

- **PROFESSIONAL INFORMATION**
  - Dental practitioners’ formulary
  - Tablets may be prescribed as Sodium Fluoride Tablets. Oral drops may be prescribed as Sodium Fluoride Oral Drops. Mouthwashes may be prescribed as Sodium Fluoride Mouthwash 0.05% or Sodium Fluoride Mouthwash 2%
  - **COLGATE DURAPHAT® 2800PPM FLUORIDE TOOTHPASTE** May be prescribed as Sodium Fluoride Toothpaste 0.619%.
  - **COLGATE DURAPHAT® 5000PPM FLUORIDE TOOTHPASTE** May be prescribed as Sodium Fluoride Toothpaste 1.1%

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: capsule, oral solution

- **Tablet**
  - **Endekay** (Manx Healthcare Ltd)
    - Sodium fluoride 1.1 mg
      - 200 tablet £0.38 280 ppm fluoride toothpaste sugar-free 1 280 ppm fluoride toothpaste sugar-free 1
      - 200 table £0.38 280 ppm fluoride toothpaste sugar-free 1
    - Sodium fluoride 2.2 mg
      - 200 tablet £0.38 280 ppm fluoride toothpaste sugar-free 1 280 ppm fluoride toothpaste sugar-free 1

- **Paste**
  - **Colgate Duraphat** (Colgate-Palmolive (UK) Ltd)
    - Fluoride (as Sodium fluoride) 2.8 mg per 1 gram
      - Colgate Duraphat 2800 ppm fluoride toothpaste sugar-free 1 75 ml (POM) £3.26 DT price + £3.26
    - Fluoride (as Sodium fluoride) 5 mg per 1 gram
      - Colgate Duraphat 5000 ppm fluoride toothpaste sugar-free 1 51 gram (POM) £6.50 DT price + £6.50

- **Oral drops**
  - **Endekay** (Manx Healthcare Ltd)
    - Sodium fluoride 3.7 mg per 1 ml
      - Endekay Fluodrops 0.37% drops pediatric sugar-free 1 60 ml (POM) £0.38 DT price + £0.38
Oral ulceration and inflammation

3 Oral ulceration and inflammation

Oral ulceration and inflammation

Ulcration and inflammation

Ulcration of the oral mucosa may be caused by trauma (physical or chemical), recurrent aphthae, infections, carcinoma, dermatological disorders, nutritional deficiencies, gastro-intestinal disease, haematopoietic disorders, and drug therapy (see also Chemotherapy induced mucositis and myelosuppression under Cytotoxic drugs p. 825). It is important to establish the diagnosis in each case as the majority of these lesions require specific management in addition to local treatment. Local treatment aims to protect the ulcerated area, to relieve pain, to reduce inflammation, or to control secondary infection. Patients with an unexplained mouth ulcer of more than 3 weeks' duration require urgent referral to hospital to exclude oral cancer.

Simple mouthwashes

A saline mouthwash may relieve the pain of traumatic ulceration. The mouthwash is made up with warm water and used at frequent intervals until the discomfort and swelling subsides.

Antiseptic mouthwashes

Secondary bacterial infection may be a feature of any mucosal ulceration; it can increase discomfort and delay healing. Use of a chlorhexidine mouthwash p. 1108 is often beneficial and may accelerate healing of recurrent aphthae.

Corticosteroids

Topical corticosteroid therapy may be used for some forms of oral ulceration. In the case of aphthous ulcers it is most effective if applied in the ‘prodromal’ phase. Thrush or other types of candidiasis are recognised complications of corticosteroid treatment.

Hydrocortisone oromucosal tablets p. 1113 are allowed to dissolve next to an ulcer and are useful in recurrent aphthae and erosive lichenoid lesions.

Beclometasone dipropionate inhaler p. 1113 sprayed on the oral mucosa is used to manage oral ulceration [unlicensed indication]. Alternatively, betamethasone soluble tablets p. 1113 dissolved in water can be used as a mouthwash to treat oral ulceration [unlicensed indication]. Systemic corticosteroid therapy (see under Corticosteroids, inflammatory disorders p. 1053), is reserved for severe conditions such as pemphigus vulgaris.

Local analgesics

Local analgesics have a limited role in the management of oral ulceration. When applied topically their action is of a relatively short duration so that analgesia cannot be maintained continuously throughout the day. The main indication for a topical local analgesic is to relieve the pain of otherwise intractable oral ulceration particularly when it is due to major aphthae. For this purpose lidocaine hydrochloride 5% ointment below or lozenges containing a local anaesthetic are applied to the ulcer. Lidocaine hydrochloride 10% solution as spray can be applied thinly to the ulcer [unlicensed indication] using a cotton bud. When local anaesthetics are used in the mouth care must be taken not to produce anaesthesia of the pharynx before meals as this might lead to choking.

Preparations on sale to the public: many mouth ulcer preparations, throat lozenges, and throat sprays on sale to the public contain a local anaesthetic. To identify the active ingredients in such preparations, consult the product literature of the manufacturer—the correct proprietary name should be ascertained as many products have very similar names but different active ingredients.

Benzydamine hydrochloride p. 1112 and flurbiprofen p. 1113 are non-steroidal anti-inflammatory drugs (NSAIDs). Benzydamine hydrochloride mouthwash or spray may be useful in reducing the discomfort associated with a variety of ulcerative conditions. It has also been found to be effective in reducing the discomfort of tonsillitis and post-irradiation mucositis. Some patients find the full-strength mouthwash causes some stinging and, for them, it should be diluted with an equal volume of water. Flurbiprofen lozenges are licensed for the relief of sore throat.

Choline salicylate p. 1113 is a derivative of salicylic acid and has some analgesic action. The dental gel may provide relief for recurrent aphthae, but excessive application or confinement under a denture irritates the mucosa and can itself cause ulceration.

Other preparations

Doxycycline p. 1114 rinsed in the mouth may be of value for recurrent aphthous ulceration.

Periodontitis

Low-dose doxycycline (Periostat®) is licensed as an adjunct to scaling and root planing for the treatment of periodontitis; a low dose of doxycycline reduces collagenase activity without inhibiting bacteria associated with periodontitis.

For anti-infectives used in the treatment of destructive (refractory) forms of periodontal disease, see under Oropharyngeal bacterial infections p. 1114. See also Mouthwashes and other preparations for oropharyngeal use p. 1107 for mouthwashes used for oral hygiene and plaque inhibition.

ANAESTHETICS, LOCAL

<table>
<thead>
<tr>
<th>Lidocaine hydrochloride  (Lignocaine hydrochloride)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INDICATIONS AND DOSE</strong></td>
</tr>
<tr>
<td>◆ BY BUCCAL ADMINISTRATION USING OINTMENT</td>
</tr>
<tr>
<td>Dental practice</td>
</tr>
</tbody>
</table>
| Adult: Rub gently into dry gum           | continued ➔
Relief of pain in oral lesions
- TO THE LESION USING OINTMENT
- Adult: Apply as required, rub sparingly and gently on affected areas

**LARYNGOJECT**

Anesthesia of mucous membranes of oropharynx, trachea, or respiratory tract
- TO MUCOUS MEMBRANES
- Adult: 40–200 mg, to be given as a single dose sprayed, instilled (if a cavity), or applied with a swab (reduce dose according to size, age and condition of patient); usual dose 160 mg

XYLOCAINE

**Bronchoscopy | Laryngoscopy | Oesophagoscopy | Endotracheal intubation**
- TO MUCOUS MEMBRANES
- Adult: Up to 20 doses

**Dental practice**
- TO MUCOUS MEMBRANES
- Adult: 1–5 doses

**Maxillary sinus puncture**
- TO MUCOUS MEMBRANES
- Adult: 3 doses

Relief of pain in oral lesions
- TO THE LESION
- Adult: Apply thinly to the ulcer using a cotton bud

**UNLICENSED USE**  Spray not licensed for the relief of pain in oral lesions.

**CAUTIONS**  Avoid anaesthesia of the pharynx before meals—risk of choking · can damage plastic cuffs of endotracheal tubes

**INTERACTIONS** → Appendix 1: antiarrhythmics

**SIDE-EFFECTS**  Affects a topical lidocaine preparation does not generally cause systemic side-effects.

**ALLERGY AND CROSS-SENSITIVITY**
- Hypersensitivity and cross-sensitivity  Hypersensitivity reactions occur mainly with the ester-type local anaesthetics, such as tetracaine and chloroprocaine; reactions are less frequent with the amide types, such as articaine, bupivacaine, levobupivacaine, lidocaine, mepivacaine, prilocaine, and ropivacaine. Cross-sensitivity reactions may be avoided by using the alternative chemical type.

**PREGNANCY**  Crosses the placenta but not known to be harmful in animal studies—use if benefit outweighs risk. When used as a local anaesthetic, large doses can cause fetal bradycardia; if given during delivery can also cause neonatal respiratory depression, hypotonia, or bradycardia after paracervical or epidural block.

**BREAST FEEDING**  Present in milk but amount too small to be harmful.

**HEPATIC IMPAIRMENT**  Caution—increased risk of side-effects.

**RENAL IMPAIRMENT**  Possible accumulation of lidocaine and active metabolite; caution in severe impairment.

**PROFESSION SPECIFIC INFORMATION**

**Dental practitioners’ formulary**
Lidocaine ointment 5% may be prescribed. Spray may be prescribed as Lidocaine Spray 10%.

XYLOCAINE  May be prescribed as lidocaine spray 10%.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: liquid, ointment

**Spray**
- **XYLOCAINE** (Aspen Pharma Trading Ltd)
  - Lidocaine 10 mg per 1 actuation  Xylocaine 10mg/dose spray sugar-free  | 50 ml  £6.29

**Ointment**
- **Lidocaine hydrochloride (Non-proprietary)**
  - Lidocaine hydrochloride 50 mg per 1 gram  Lidocaine 5% ointment  | 15 gram  £6.50 DT price = £6.18

**Liquid**
- **Laryngo Jet** (UCB Pharma Ltd)
  - Lidocaine hydrochloride 40 mg per 1 mL  Lidocaine 4% oromucosal solution Laryngojet pre-filled syringes  | 1 pre-filled disposable injection  £5.10

**ANALGESICS | Non-steroidal anti-inflammatory drugs**

**Benzydamine hydrochloride**

**INDICATIONS AND DOSE**

**Painful inflammatory conditions of oropharynx**
- TO THE LESION USING MOUTHWASH
  - Child 1–5 years: Rinse or gargle 15 mL every 1.5–3 hours as required usually for not more than 7 days, dilute with an equal volume of water if stinging occurs
  - Adult: Rinse or gargle 15 mL every 1.5–3 hours as required usually for not more than 7 days, dilute with an equal volume of water if stinging occurs
  - TO THE LESION USING OROMUCOSAL SPRAY
    - Child 1 month–5 years (body-weight 4–7 kg): 1 spray every 1.5–3 hours, to be administered onto the affected area
    - Child 1 month–5 years (body-weight 8–11 kg): 2 sprays every 1.5–3 hours, to be administered onto the affected area
    - Child 1 month–5 years (body-weight 12–15 kg): 3 sprays every 1.5–3 hours, to be administered onto the affected area
    - Child 1 month–5 years (body-weight 16 kg and above): 4 sprays every 1.5–3 hours, to be administered onto the affected area
    - Child 6–11 years: 4 sprays every 1.5–3 hours, to be administered onto affected area
    - Child 12–17 years: 4–8 sprays every 1.5–3 hours, to be administered onto affected area
  - Adult: 4–8 sprays every 1.5–3 hours, to be administered onto affected area

**INTERACTIONS** → Appendix 1: NSAIDs

**SIDE-EFFECTS**
- Rare  Hypersensitivity reactions
- Frequency not known  Occasional numbness or stinging

**PROFESSION SPECIFIC INFORMATION**

**Dental practitioners’ formulary**
Benzydamine Oromucosal Spray 0.15% may be prescribed. Benzydamine mouthwash may be prescribed as Benzydamine Mouthwash 0.15%.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Spray**
- **Benzydamine hydrochloride (Non-proprietary)**
  - Benzydamine hydrochloride 1.5 mg per 1 ml  Benzydamine 0.15% oromucosal spray sugar-free  | 30 ml  £4.53 DT price = £4.10
  - **Difflam** (Meda Pharmaceuticals Ltd)
  - Benzydamine hydrochloride 1.5 mg per 1 ml  Difflam 0.15% spray sugar-free  | 30 ml  £4.24 DT price = £4.10
Mouthwash

- **Betamethasone dipropionate**
- **Hydrocortisone**

### CORTICOSTEROIDS

#### Beclometasone dipropionate (Beclomethasone dipropionate)

- **INDICATIONS AND DOSE**
  - **Management of oral ulceration**
  - **BY BUCCAL ADMINISTRATION**
  - **Adult:** 50–100 micrograms twice daily, use inhaler device to spray dose on to the oral mucosa

- **UNLICENSED USE** Use of inhaler unlicensed in oral ulceration.

- **INTERACTIONS** → Appendix 1: corticosteroids

- **MEDICINAL FORMS**
  - For preparations, see inhaled beclometasone, p. 249.

#### Betamethasone

- **INDICATIONS AND DOSE**
  - **Oral ulceration**
  - **TO THE LESION USING SOLUBLE TABLETS**
  - **Child 12-17 years:** 500 micrograms 4 times a day, to be dissolved in 20 mL water and rinsed around the mouth; not to be swallowed
  - **Adult:** 500 micrograms 4 times a day, to be dissolved in 20 mL water and rinsed around the mouth; not to be swallowed

- **UNLICENSED USE**
  - In children Betamethasone soluble tablets not licensed for use as mouthwash or in oral ulceration.

---

**Flurbiprofen**

- **INDICATIONS AND DOSE**
  - **Relief of sore throat**
    - **BY MOUTH USING LOZENGES**
    - **Child 12-17 years:** 1 lozenge every 3–6 hours for maximum 3 days, allow lozenge to dissolve slowly in the mouth; maximum 5 lozenges per day
    - **Adult:** 1 lozenge every 3–6 hours for maximum 3 days, allow lozenge to dissolve slowly in the mouth; maximum 5 lozenges per day

- **INTERACTIONS** → Appendix 1: NSAIDs

- **SIDE-EFFECTS**
  - Mouth ulcers (move lozenge around mouth)
  - Taste disturbance

- **ALLERGY AND CROSS-SENSITIVITY** Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

- **Lozenge**
  - **Strefen** (Reckitt Benckiser Healthcare (UK) Ltd)
  - **Flurbiprofen 8.75 mg** Strefen 8.75mg lozenges | 16 lozenges [P] £2.58
  - DT price = £4.42

- **UNLICENSED USE**
  - Use of inhaler unlicensed in oral ulceration.

- **INTERACTIONS** → Appendix 1: corticosteroids

- **MEDICINAL FORMS**
  - For preparations, see inhaled beclometasone, p. 249.

#### Hydrocortisone

- **INDICATIONS AND DOSE**
  - **Oral and perioral lesions**
  - **TO THE LESION USING BUCCAL TABLET**
  - **Child 1-11 years:** Only on medical advice
  - **Child 12-17 years:** 1 lozenge 4 times a day, allowed to dissolve slowly in the mouth in contact with the ulcer
  - **Adult:** 1 lozenge 4 times a day, allowed to dissolve slowly in the mouth in contact with the ulcer

- **UNLICENSED USE**
  - **Hydrocortisone mucoadhesive buccal tablets** licensed for use in children (under 12 years—on medical advice only).

- **CONTRA-INDICATIONS** Untreated local infection

- **INTERACTIONS** → Appendix 1: corticosteroids

- **SIDE-EFFECTS** Candidal infection · exacerbation of local infection

- **PROFESSION SPECIFIC INFORMATION**
  - Dental practitioners’ formulary
  - Mucosal tablets may be prescribed as Hydrocortisone Oromucosal Tablets.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

- **Muco-adhesive buccal tablet**
  - **Hydrocortisone (Non-proprietary)**
  - Hydrocortisone (as Hydrocortisone sodium succinate)
  - 2.5 mg Hydrocortisone 2.5mg muco-adhesive buccal tablets sugar free sugar-free | 20 tablet [P] £6.30
  - DT price = £7.20

#### Sалиclic acid and derivatives

#### Choline salicylate

- **INDICATIONS AND DOSE**
  - **Mild oral and perioral lesions**
  - **TO THE LESION**
  - **Child 16-17 years:** Apply 0.5 inch, apply with gentle massage, not more often than every 3 hours
  - **Adult:** Apply 0.5 inch, apply with gentle massage, not more often than every 3 hours

- **CONTRA-INDICATIONS** Children under 16 years

- **CONTRA-INDICATIONS, FURTHER INFORMATION**
  - Reye’s syndrome The CHM has advised that topical oral pain relief products containing salicylate salts should not be prescribed.
used in children under 16 years, as a cautionary measure due to the theoretical risk of Reye’s syndrome.

- **CAUTIONS** Frequent application, especially in children, may give rise to salicylate poisoning - not to be applied to dentures—leave at least 30 minutes before re-insertion of dentures (in adults)

- **INTERACTIONS**  → Appendix 1: choline salicylate

- **SIDE-EFFECTS** Transient local burning sensation

- **PRESCRIBING AND DISPENSING INFORMATION** When prepared extemporaneously, the BP states Choline Salicylate Dental Gel, BP consists of choline salicylate 8.7% in a flavoured gel basis.

- **PROFESSION SPECIFIC INFORMATION**
  - Dental practitioners’ formulary
    - Choline Salicylate Dental Gel may be prescribed.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

  - **Oromucosal gel**
    - **Bonjela** (Reckitt Benckiser Healthcare (UK) Ltd)
      - Choline salicylate 87 mg per 1 gram Bonjela Cool Mint gel sugar-free 15 gram [GSL] £3.55 DT price = £2.58
      - Bonjela Original gel sugar-free 15 gram [GSL] £2.58 DT price = £2.58

**Salicylic acid with rhubarb extract**

- **INDICATIONS AND DOSE**
  - Mild oral and perioral lesions
    - **TO THE LESION**
      - Child 16-17 years: Apply 3–4 times a day maximum duration 7 days
      - Adult: Apply 3–4 times a day maximum duration 7 days

- **CONTRA-INDICATIONS** Children under 16 years

- **CONTRA-INDICATIONS, FURTHER INFORMATION**
  - Reye's syndrome The CHM has advised that topical oral pain relief products containing salicylate salts should not be used in children under 16 years, as a cautionary measure due to the theoretical risk of Reye’s syndrome.

- **CAUTIONS** Frequent application, especially in children, may give rise to salicylate poisoning - not to be applied to dentures—leave at least 30 minutes before re-insertion of dentures (in adults)

- **SIDE-EFFECTS** Temporary discolouration of oral mucosa - temporary discoloration of teeth - transient local burning sensation

- **PATIENT AND CARER ADVICE**  May cause temporary discolouration of teeth and oral mucosa.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

  - **Paint**
    - **EXCIPIENTS:** May contain Ethanol
      - **Pyralvex** (Meda Pharmaceuticals Ltd)
        - Salicylic acid 10 mg per 1 ml, Rhubarb extract 50 mg per 1 ml Pyralvex solution 10 ml [GSL] £3.25

4 **Oropharyngeal bacterial infections**

**Oropharyngeal bacterial infections**

**Antibacterial therapy for periconititis**

Antibacterial required only in presence of systemic features of infection, or of trismus, or persistent swelling despite local treatment.

- Metronidazole p. 512, or alternatively, amoxicillin p. 518
  - **Suggested duration of treatment** 3 days or until symptoms resolve.

**Antibacterial therapy for gingivitis: acute necrotising ulcerative**

Antibacterial required only if systemic features of infection.

- Metronidazole, or alternatively, amoxicillin
  - **Suggested duration of treatment** 3 days or until symptoms resolve.

**Antibacterial therapy for periapical or periodontal abscess**

Antibacterial required only in severe disease with cellulitis or if systemic features of infection.

- Amoxicillin, or alternatively, metronidazole
  - **Suggested duration of treatment** 5 days.

**Antibacterial therapy for periodontitis**

Antibacterial used as an adjunct to debridement in severe disease or disease unresponsive to local treatment alone.

- Metronidazole, or alternatively in adults and children over 12 years, doxycycline below

**Antibacterial therapy for throat infections**

Most throat infections are caused by viruses and many do not require antibacterial therapy. Consider antibacterial, if history of valvular heart disease, if marked systemic upset, if peritonsillar cellulitis or abscess, or if at increased risk from acute infection (e.g. in immunosuppression, cystic fibrosis); prescribe antibacterial for beta-haemolytic streptococcal pharyngitis.

- Phenoxymethylpenicillin p. 518
  - In severe infection, initial parenteral therapy with benzylpenicillin sodium p. 517, then oral therapy with phenoxymethylpenicillin or amoxicillin (or ampicillin p. 520). **Avoid** amoxicillin if possibility of glandular fever.
  - **Suggested duration of treatment** 10 days.

- **If penicillin-allergic**, clarithromycin p. 508 (or azithromycin p. 507 or erythromycin p. 510)
  - **Suggested duration of treatment** 10 days

**ANTIBACTERIALS ▶ TETRACYCLINES AND RELATED DRUGS**

**Doxycycline**

- **INDICATIONS AND DOSE**
  - Treatment of recurrent aphthous ulceration
    - **BY MOUTH USING SOLUBLE TABLETS**
      - Child 12-17 years: 100 mg 4 times a day usually for 3 days, dispersible tablet can be stirred into a small amount of water then rinsed around the mouth for 2–3 minutes, it should preferably not be swallowed
      - Adult: 100 mg 4 times a day usually for 3 days, dispersible tablet can be stirred into a small amount of
water then rinsed around the mouth for 2–3 minutes, it should preferably not be swallowed

- **UNLICENSED USE** Not licensed for use in children under 12 years.
- **CAUTIONS** Alcohol dependence
- **INTERACTIONS** → Appendix 1: tetracyclines
- **SIDE-EFFECTS** Anorexia · anxiety · dry mouth · flushing · tinnitus
- **RENAL IMPAIRMENT** Use with caution (avoid excessive doses).
- **PATIENT AND CARER ADVICE** Counselling on administration advised (posture). Photosensitivity Patients should be advised to avoid exposure to sunlight or sun lamps.
- **PROFESSION SPECIFIC INFORMATION**

  **Dental practitioners’ formulary**

  Doxycycline Capsules 100 mg may be prescribed. Dispersible tablets may be prescribed as Dispersible Doxycycline Tablets. Tablets may be prescribed as Doxycycline Tablets 20 mg.

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug.

  **Dispersible tablet**

  CAUTIONARY AND ADVISORY LABELS 6, 9, 11, 13

  → Vibramycin-D (Pfizer Ltd)

  Doxycycline (as Doxycycline monohydrate) 100 mg Vibramycin-D 100mg dispersible tablets sugar-free | 8 tablet [Pack] £4.91 DT price = £4.91

### 5 Oropharyngeal fungal infections

**Oropharyngeal fungal infections**

**Overview**

Fungal infections of the mouth are usually caused by Candida spp. (candidiasis or candidosis). Different types of oropharyngeal candidiasis are managed as follows:

- **Thrush**

  Acute pseudomembranous candidiasis (thrush), is usually an acute infection but it may persist for months in patients receiving inhaled corticosteroids, cytotoxics or broad-spectrum antibacterials. Thrush also occurs in patients with serious systemic disease associated with reduced immunity such as leukaemia, other malignancies, and HIV infection. Any predisposing condition should be managed appropriately. When thrush is associated with corticosteroid inhalers, rinsing the mouth with water (or cleaning a child’s teeth) immediately after using the inhaler may avoid the problem. Treatment with nystatin p. 1116 or miconazole p. 1116 may be needed. Fluconazole p. 562 is effective for unresponsive infections or if a topical antifungal drug cannot be used or if the patient has dry mouth. Topical therapy may not be adequate in immunocompromised patients and an oral triazole antifungal is preferred.

- **Acute erythematous candidiasis**

  Acute erythematous (atrophic) candidiasis is a relatively uncommon condition associated with corticosteroid and broad-spectrum antibacterial use and with HIV disease. It is usually treated with fluconazole.

- **Denture stomatitis**

  Patients with denture stomatitis (chronic atrophic candidiasis), should cleanse their dentures thoroughly and leave them out as often as possible during the treatment period. To prevent recurrence of the problem, dentures should not normally be worn at night. New dentures may be required if these measures fail despite good compliance.

  Miconazole oral gel can be applied to the fitting surface of the denture before insertion (for short periods only). Denture stomatitis is not always associated with candidiasis and other factors such as mechanical or chemical irritation, bacterial infection, or rarely allergy to the dental base material, may be the cause.

- **Chronic hyperplastic candidiasis**

  Chronic hyperplastic candidiasis (candidal leucoplakia) carries an increased risk of malignancy; biopsy is essential—this type of candidiasis may be associated with varying degrees of dysplasia, with oral cancer present in a high proportion of cases. Chronic hyperplastic candidiasis is treated with a systemic antifungal such as fluconazole to eliminate candidal overlay. Patients should avoid the use of tobacco.

- **Angular cheilitis**

  Angular cheilitis (angular stomatitis) is characterised by soreness, erythema and fissuring at the angles of the mouth. It is commonly associated with denture stomatitis but may represent a nutritional deficiency or it may be related to orofacial granulomatosis or HIV infection. Both yeasts (Candida spp.) and bacteria (Staphylococcus aureus and beta-haemolytic streptococci) are commonly involved as interacting, infective factors. A reduction in facial height related to ageing and tooth loss with maceration in the deep occlusive folds that may subsequently arise, predisposes to such infection. While the underlying cause is being identified and treated, it is often helpful to apply miconazole cream or fusidic acid ointment p. 539; if the angular cheilitis is unresponsive to treatment, hydrocortisone with miconazole cream or ointment p. 1150 can be used.

**Immunocompromised patients**

See advice on prevention of fungal infections in Immunocompromised patients under Antifungals, systemic use p. 558.

**Drugs used in oropharyngeal candidiasis**

Nystatin is not absorbed from the gastro-intestinal tract and is applied locally (as a suspension) to the mouth for treating local fungal infections. Miconazole is applied locally (as an oral gel) in the mouth but it is absorbed to the extent that potential interactions need to be considered. Miconazole also has some activity against Gram-positive bacteria including streptococci and staphylococci. Fluconazole is given by mouth for infections that do not respond to topical therapy or when topical therapy cannot be used. It is reliably absorbed and effective. Itraconazole p. 564 can be used for fluconazole-resistant infections.

If candidal infection fails to respond to 1 to 2 weeks of treatment with antifungal drugs the patient should be sent for investigation to eliminate the possibility of underlying disease. Persistent infection may also be caused by reinfection from the genito-urinary or gastro-intestinal tract. Infection can be eliminated from these sources by appropriate anticalendial therapy; the patient’s partner may also require treatment to prevent reinfection.

Antiseptic mouthwashes are used in the prevention of oral candidiasis in immunocompromised patients and in the treatment of denture stomatitis.
**Oropharyngeal viral infections**

**Miconazole**

**INDICATIONS AND DOSE**

Prevention and treatment of oral candidiasis
- **BY MOUTH USING ORAL GEL**
  - Child 2-17 years: 2.5 mL 4 times a day treatment should be continued for at least 7 days after lesions have healed or symptoms have cleared, to be administered after meals, retain near oral lesions before swallowing (dental prostheses and orthodontic appliances should be removed at night and brushed with gel)
  - Adult: 2.5 mL 4 times a day treatment should be continued for at least 7 days after lesions have healed or symptoms have cleared, to be administered after meals, retain near oral lesions before swallowing (dental prostheses and orthodontic appliances should be removed at night and brushed with gel)

Prevention and treatment of intestinal candidiasis
- **BY MOUTH USING ORAL GEL**
  - Child 4 months-17 years: 5 mg/kg 4 times a day (max. per dose 250 mg 4 times a day) treatment should be continued for at least 7 days after lesions have healed or symptoms have cleared
  - Adult: 5 mg/kg 4 times a day (max. per dose 250 mg 4 times a day) treatment should be continued for at least 7 days after lesions have healed or symptoms have cleared

**SIDE-EFFECTS**
- Common or very common: Nausea, rash, vomiting
- Rare: Diarrhoea (usually on long term treatment), hepatitis (rash in children), Stevens-Johnson syndrome, toxic epidermal necrolysis
- Pregnancy: Manufacturer advises avoid if possible—no information available.
- Breast feeding: Manufacturer advises caution—no information available.
- Hepatic impairment: Avoid.
- DIRECTIONS FOR ADMINISTRATION: Oral gel should be held in mouth, after food.
- PRESCRIBING AND DISPENSING INFORMATION: Flavours of oral gel may include orange.
- PATIENT AND CARER ADVICE: Patients or carers should be given advice on how to administer miconazole oromucosal gel.
- PROFESSION SPECIFIC INFORMATION:
  - Dental practitioners’ formulary: Miconazole Oromucosal Gel may be prescribed.
  - EXCEPTIONS TO LEGAL CATEGORY: 15-g tube of oral gel can be sold to the public.

**INUNICATED USE**
- Not licensed for use in children under 4 months of age or during first 5–6 months of life of an infant born pre-term.

**CONTRA-INDICATIONS**
- Infants with impaired swallowing reflex

**INTERACTIONS**
- → Appendix 1: antifungals, azoles

**CAUTIONS**
- Avoid in acute porphyrias p. 969

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension

**Oral suspension**
- **CAUTIONARY AND ADVISORY LABELS**
  - 9
- **EXCIPIENTS:** May contain Ethanol
- **Nystatin (Non-proprietary)**
  - Nystatin 100,000 unit per 1 ml
  - Nystatin 100,000 units/ml oral suspension | 30 ml (Psd) £2.33 DT price = £2.09
  - Nystatin (Bristol-Myers Squibb Pharmaceuticals Ltd)
  - Nystatin 100,000 unit per 1 ml
  - Nystatin 100,000 units/ml oral suspension (ready mixed) | 30 ml (Psd) £1.80 DT price = £2.09

**SIDE-EFFECTS**
- Local irritation, local sensitisation, nausea

**Nystatin**

**INDICATIONS AND DOSE**

Oral candidiasis
- **BY MOUTH**
  - Child: 100,000 units 4 times a day usually for 7 days, and continued for 48 hours after lesions have resolved
  - Adult: 100,000 units 4 times a day usually for 7 days, and continued for 48 hours after lesions have resolved

**PROFESSION SPECIFIC INFORMATION**
- Dental practitioners’ formulary: Nystatin Oral Suspension may be prescribed.

**ANTIFUNGALS › POLYENE ANTIFUNGALS**

**Oropharyngeal viral infections**

**Management**

Viral infections are the most common cause of a sore throat. They do not benefit from anti-infective treatment. The management of primary herpetic gingivostomatitis is a soft diet, adequate fluid intake, and analgesics as required, including local use of benzylamine hydrochloride p. 1112. The use of chlorhexidine mouthwash p. 1108 will control plaque accumulation if toothbrushing is painful and will also help to control secondary infection in general. In the case of severe herpetic stomatitis, a systemic antiviral such as aciclovir p. 599 is required. Valaciclovir p. 602 and famciclovir p. 601 are suitable alternatives for oral lesions associated with herpes zoster. Aciclovir and valaciclovir are also used for the prevention of frequently recurring herpes simplex lesions of the mouth, particularly when implicated in the initiation of erythema multiforme.
Chapter 13
Skin

CONTENTS
1 Dry and scaling skin disorders page 1118
2 Infections of the skin 1125
  2.1 Bacterial skin infections 1127
  2.2 Fungal skin infections 1130
  2.3 Parasitic skin infections 1134
  2.4 Viral skin infections 1135
3 Inflammatory skin conditions 1136
  3.1 Eczema and psoriasis 1136
4 Perspiration 1159
  4.1 Hyperhidrosis 1159
5 Pruritus 1160
6 Rosacea and acne 1162
  6.1 Acne 1163
6.2 Rosacea page 1169
7 Scalp and hair conditions 1170
  7.1 Alopecia 1171
  7.2 Hirsutism 1171
8 Skin cleansers, antiseptics and desloughing agents 1172
  8.1 Minor cuts and abrasions 1175
9 Skin disfigurement 1176
10 Sun protection and photodamage 1176
11 Superficial soft-tissue injuries and superficial thrombophlebitis 1179
12 Warts and calluses 1179

Skin conditions, management

Vehicles
The British Association of Dermatologists list of preferred unlicensed dermatological preparations (specials) is available at www.bad.org.uk/specials.

Both vehicle and active ingredients are important in the treatment of skin conditions; the vehicle alone may have more than a mere placebo effect. The vehicle affects the degree of hydration of the skin, has a mild anti-inflammatory effect, and aids the penetration of active drug.

Applications are usually viscous solutions, emulsions, or suspensions for application to the skin (including the scalp) or nails.

Collodions are painted on the skin and allowed to dry to leave a flexible film over the site of application.

Creams are emulsions of oil and water and are generally well absorbed into the skin. They may contain an antimicrobial preservative unless the active ingredient or basis is intrinsically bactericidal and fungicidal. Generally, creams are cosmetically more acceptable than ointments because they are less greasy and easier to apply.

Gels consist of active ingredients in suitable hydrophilic or hydrophobic bases; they generally have a high water content. Gels are particularly suitable for application to the face and scalp.

Lotions have a cooling effect and may be preferred to ointments or creams for application over a hairy area. Lotions in alcoholic basis can sting if used on broken skin. Shake lotions (such as calamine lotion) contain insoluble powders which leave a deposit on the skin surface.

Ointments are greasy preparations which are normally anhydrous and insoluble in water, and are more occlusive than creams. They are particularly suitable for chronic, dry lesions. The most commonly used ointment bases consist of soft paraffin or a combination of soft, liquid, and hard paraffin. Some ointment bases have both hydrophilic and lipophilic properties; they may have occlusive properties on the skin surface, encourage hydration, and also be miscible with water; they often have a mild anti-inflammatory effect. Water-soluble ointments contain macrogols which are freely soluble in water and are therefore readily washed off; they have a limited but useful role where ready removal is desirable.

Pastes are stiff preparations containing a high proportion of finely powdered solids such as zinc oxide and starch suspended in an ointment. They are used for circumscribed lesions such as those which occur in lichen simplex, chronic eczema, or psoriasis. They are less occlusive than ointments and can be used to protect inflamed, lichenified, or excoriated skin.

Dusting powders are used only rarely. They reduce friction between opposing skin surfaces. Dusting powders should not be applied to moist areas because they can cake and abrade the skin. Talc is a lubricant but it does not absorb moisture; it can cause respiratory irritation. Starch is less lubricant but absorbs water.

Dilution
The BP directs that creams and ointments should not normally be diluted but that should dilution be necessary care should be taken, in particular, to prevent microbial contamination. The appropriate diluent should be used and heating should be avoided during mixing; excessive dilution may affect the stability of some creams. Diluted creams should normally be used within 2 weeks of preparation.

Suitable quantities for prescribing

<table>
<thead>
<tr>
<th>Suitable quantities of dermatological preparations to be prescribed for specific areas of the body</th>
</tr>
</thead>
<tbody>
<tr>
<td>Area of body</td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>Face</td>
</tr>
<tr>
<td>Both hands</td>
</tr>
<tr>
<td>Scalp</td>
</tr>
<tr>
<td>Both arms or both legs</td>
</tr>
<tr>
<td>Trunk</td>
</tr>
<tr>
<td>Groins and genitalia</td>
</tr>
</tbody>
</table>

These amounts are usually suitable for an adult for twice daily application for 1 week. The recommendations do not apply to corticosteroid preparations. For suitable quantities of corticosteroid preparations, see relevant table.
**Excipients and sensitisation**

Excipients in topical products rarely cause problems. If a patch test indicates allergy to an excipient, products containing the substance should be avoided. The following excipients in topical preparations are associated, rarely, with sensitisation; the presence of these excipients is indicated in the entries for topical products.

- Beeswax
- Benzyl alcohol
- Butylated hydroxyanisole
- Butylated hydroxytoluene
- Cetostearyl alcohol (including cetyl and stearyl alcohol)
- Chlororesol
- Edetic acid (EDTA)
- Ethylhexylamine
- Fragrances
- Hydroxybenzoates (parabens)
- Imidurea
- Isopropyl palmitate
- N-(3-Chloroallyl)hexaminium chloride (quaternium 15)
- Polysorbates
- Propylene glycol
- Sodium metabisulphite
- Sorbic acid
- Wool fat and related substances including lanolin (purified versions of wool fat have reduced the problem)

**1 Dry and scaling skin disorders**

**Emollient and barrier preparations**

**Borderline substances**

The preparations marked ‘ACBS’ are regarded as drugs when prescribed in accordance with the advice of the Advisory Committee on Borderline Substances for the clinical conditions listed. Prescriptions issued in accordance with this advice and endorsed ‘ACBS’ will normally not be investigated.

**Emollients**

Emollients soothe, smooth and hydrate the skin and are indicated for all dry or scaling disorders. Their effects are short lived and they should be applied frequently even after improvement occurs. They are useful in dry and eczematous disorders, and to a lesser extent in psoriasis. The choice of an appropriate emollient will depend on the severity of the condition, patient preference, and the site of application. Some ingredients rarely cause sensitisation and this should be suspected if an eczematous reaction occurs. The use of aqueous cream as a leave-on emollient may increase the risk of skin reactions, particularly in eczema.

Preparations such as aqueous cream and emulsifying ointment can be used as soap substitutes for hand washing and in the bath; the preparation is rubbed on the skin before rinsing off completely. The addition of a bath oil may also be helpful.

Urea is occasionally used with other topical agents such as corticosteroids to enhance penetration of the skin.

**Emollient bath and shower preparations**

Emollient bath additives should be added to bath water; hydration can be improved by soaking in the bath for 10–20 minutes. Some bath emollients can be applied to wet skin undiluted and rinsed off. In dry skin conditions soap should be avoided.

The quantities of bath additives recommended for adults are suitable for an adult-size bath. Proportionately less should be used for a child-size bath or a washbasin; recommended bath additive quantities for children reflect this.

**Barriers**

Barrier preparations often contain water-repellent substances such as dimeticone p. 1134 or other silicones. They are used on the skin around stomas, bedsores, and pressure areas in the elderly where the skin is intact. Where the skin has broken down, barrier preparations have a limited role in protecting adjacent skin. Barrier preparations are not a substitute for adequate nursing care.

**Nappy rash**

The first line of treatment is to ensure that nappies are changed frequently and that tightly fitting water-proof pants are avoided. The rash may clear when left exposed to the air and a barrier preparation, applied with each nappy change, can be helpful. A mild corticosteroid such as hydrocortisone 0.5% or 1% p. 1145 can be used if inflammation is causing discomfort, but it should be avoided in neonates. The barrier preparation should be applied after the corticosteroid preparation to prevent further damage. Preparations containing hydrocortisone should be applied for no more than a week; the hydrocortisone should be discontinued as soon as the inflammation subsides. The occlusive effect of nappies and waterproof pants may increase absorption of corticosteroids. If the rash is associated with candidal infection, a topical antifungal such as clotrimazole cream p. 1130 can be used. Topical antibacterial preparations can be used if bacterial infection is present; treatment with an oral antibacterial may occasionally be required in severe or recurrent infection. Hydrocortisone may be used in combination with antimicrobial preparations if there is considerable inflammation, erosion, and infection.

**Barrier creams and ointments**

**INDICATIONS AND DOSE**

For use as a barrier preparation

- To the skin
- Child: (consult product literature)
- Adult: (consult product literature)

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Ointment**

**EXCIPIENTS:** May contain Wool fat and related substances including lanolin.

- **Barrier creams and ointments (Non-proprietary)**
  - Cetostearyl alcohol 20 mg per 1 gram, Zinc oxide 75 mg per 1 gram, Beeswax white 100 mg per 1 gram, Arachis oil 305 mg per 1 gram, Castor oil 500 mg per 1 gram
  - Zinc and Castor oil cream | 100 gram [GSL] £1.45
  - Brands may include Metanium
DERMATOLOGICAL DRUGS

**EMOLLIENTS**

**Dermol**® **200 SHOWER EMOLLIENT**

**Dry and pruritic skin conditions including eczema and dermatitis**

- **TO THE SKIN**
- **Child:** To be applied to the skin or used as a soap substitute
- **Adult:** To be applied to the skin or used as a soap substitute

**Dermol**® **600®** **BATH EMOLLIENT**

**Dry and pruritic skin conditions including eczema and dermatitis**

- **TO THE SKIN**
- **Child 1–23 months:** 5–15 mL/bath, not to be used undiluted
- **Child 2–17 years:** 15–30 mL/bath, not to be used undiluted
- **Adult:** Up to 30 mL/bath, not to be used undiluted

**Dermol**® **WASH EMULSION**

**Dry and pruritic skin conditions including eczema and dermatitis**

- **TO THE SKIN**
- **Child:** To be applied to the skin or used as a soap substitute
- **Adult:** To be applied to the skin or used as a soap substitute

**Emulsiderm**®

**Dry skin conditions including eczema and ichthyosis**

- **TO THE SKIN**
- **Child 1–23 months:** 5–10 mL/bath, alternatively, to be rubbed into dry skin until absorbed
- **Child 2–17 years:** 7–30 mL/bath, alternatively, to be rubbed into dry skin until absorbed
- **Adult:** 7–30 mL/bath, alternatively, to be rubbed into dry skin until absorbed

**OILATUM® PLUS**

**Topical treatment of eczema, including eczema at risk from infection**

- **TO THE SKIN**
- **Child 6–11 months:** 1 mL/bath, not to be used undiluted
- **Child 1–17 years:** 1–2 capfuls/bath, not to be used undiluted
- **Adult:** 1–2 capfuls/bath, not to be used undiluted

**IMPORTANT SAFETY INFORMATION**

These preparations make skin and surfaces slippery—particular care is needed when bathing.

**MHRA/CHM UPDATE (APRIL 2016): FIRE RISK WITH PARAFFIN-BASED SKIN EMOLLIENTS ON DRESSINGS OR CLOTHING**

See Emollient and barrier preparations p. 1118.

**DIRECTIONS FOR ADMINISTRATION**

Emollient bath additives should be added to bath water; hydration can be improved by soaking in the bath for 10–20 minutes. Some bath emollients can be applied to wet skin undiluted and rinsed off. Emollient preparations contained in tubs should be removed with a clean spoon or spatula to reduce bacterial contamination of the emollient. Emollients should be applied in the direction of hair growth to reduce the risk of folliculitis.

**PRESCRIBING AND DISPENSING INFORMATION**

Preparations containing an antibacterial should be avoided unless infection is present or is a frequent complication.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Bath additive**

**CAUTIONARY AND ADVISORY LABELS 15**

**EXCIPIENTS:** May contain Acetylated lanolin alcohols, isopropyl palmitate, poloxamers

- **Dermol 600®** (Dermal Laboratories Ltd)
  - Benzalkonium chloride 5 mg per 1 gram, Isopropyl myristate 250 mg per 1 gram, Liquid paraffin 250 mg per 1 gram Dermol 600 bath emollient | 600 mL | £7.55
- **Emulsiderm** (Dermal Laboratories Ltd)
  - Benzalkonium chloride 5 mg per 1 gram, Isopropyl myristate 250 mg per 1 gram, Liquid paraffin 250 mg per 1 gram Emulsiderm emollient | 300 mL | £3.85 | 1000 mL | £12.00
- **Oilatum Plus** (GlaxoSmithKline Consumer Healthcare)
  - Triclosan 20 mg per 1 gram, Benzalkonium chloride 60 mg per 1 gram, Liquid paraffin light 525 mg per 1 gram Oilatum Plus bath additive | 500 mL | £7.22

**Liquids**

**CAUTIONARY AND ADVISORY LABELS 15**

**EXCIPIENTS:** May contain Cetostearyl alcohol (including cetyl and stearyl alcohol)

- **Dermol 200®** (Dermal Laboratories Ltd)
  - Benzalkonium chloride 1 mg per 1 gram, Chlorhexidine hydrochloride 1 mg per 1 gram, Isopropyl myristate 25 mg per 1 gram, Liquid paraffin 25 mg per 1 gram Dermol 200 shower emollient | 200 mL | £3.55
- **Dermol Wash** (Dermal Laboratories Ltd)
  - Benzalkonium chloride 1 mg per 1 gram, Chlorhexidine hydrochloride 1 mg per 1 gram, Isopropyl myristate 25 mg per 1 gram, Liquid paraffin 25 mg per 1 gram Dermol Wash cutaneous emulsion | 200 mL | £3.55

**Spray**

**CAUTIONARY AND ADVISORY LABELS 15**

**EXCIPIENTS:** May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), hydroxybenzoates (parabens), wool fat and related substances including lanolin,

- Sprilon (J M Loveridge Ltd)
  - Dimeticone 10.4 mg per 1 gram, Zinc oxide 125 mg per 1 gram Sprilon aerosol spray | 115 g | GSL | £8.90 DT price = £8.90

**Cream**

**EXCIPIENTS:** May contain Beeswax, butylated hydroxyanisole, butylated hydroxytoluene, cetylstearyl alcohol (including cetyl and stearyl alcohol), chlorocresol, fragrances, hydroxybenzoates (parabens), propylene glycol, wool fat and related substances including lanolin

- Conotran® (LEO Pharma)
  - Benzalkonium chloride 1 mg per 1 gram, Dimeticone 220 mg per 1 gram Conotran cream | 100 g | GSL | £0.88 DT price = £0.88 | 500 g | GSL | £3.51
- Drapolene® (Omega Pharma Ltd)
  - Benzalkonium chloride 100 microgram per 1 gram, Cetrimide 2 mg per 1 gram Drapolene cream | 100 g | GSL | £1.76 | 200 g | GSL | £2.86 | 350 g | GSL | £4.28
- Siopel® (Derma UK Ltd)
  - Cetrimide 3 mg per 1 gram, Dimeticone 1000 100 mg per 1 gram Siopel cream | 50 g | GSL | £4.65
- Sudocrem® (Teva UK Ltd)
  - Benzyl cinnamate 1.5 mg per 1 gram, Benzyl alcohol 3.9 mg per 1 gram, Benzyl benzoate 10.1 mg per 1 gram, Wool fat hydrolysate 40 mg per 1 gram, Zinc oxide 125.5 mg per 1 gram Sudocrem antiseptic healing cream | 60 g | GSL | £1.45 | 125 g | GSL | £2.15 | 250 g | GSL | £3.67 | 400 g | GSL | £5.25

**DERMOL® SHOWERS**
**Emollient bath and shower products, colloidal oatmeal-containing**

**INDICATIONS AND DOSE**

Endogenous and exogenous eczema | Xeroderma | Ichthyosis

- TO THE SKIN
  - Child 2-17 years: 20–30 mL/bath, alternatively apply to wet skin and rinse
  - Adult: 20–30 mL/bath, alternatively apply to wet skin and rinse

Pruritus of the elderly associated with dry skin

- TO THE SKIN
  - Elderly: 20–30 mL/bath, alternatively apply to wet skin and rinse

**IMPORTANT SAFETY INFORMATION**

These preparations make skin and surfaces slippery—particular care is needed when bathing.

**DIRECTIONS FOR ADMINISTRATION**

Emollient bath additives should be added to bath water; hydration can be improved by soaking in the bath for 10–20 minutes. Some bath emollients can be applied to wet skin undiluted and rinsed off. Emollient preparations contained in tubs should be removed with a clean spoon or spatula to reduce bacterial contamination of the emollient. Emollients should be applied in the direction of hair growth to reduce the risk of folliculitis.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. No licensed medicines listed.

**Emollient bath and shower products, paraffin-containing**

**INDICATIONS AND DOSE**

AQUAMAX® WASH

Dry skin conditions

- TO THE SKIN
  - Child: To be applied to wet or dry skin and rinse
  - Adult: To be applied to wet or dry skin and rinse

CETRABEN® BATH

Dry skin conditions, including eczema

- TO THE SKIN
  - Child 1 month-11 years: 0.5–1 capful/bath, alternatively, to be applied to wet skin and rinse
  - Child 12-17 years: 1–2 capfuls/bath, alternatively, to be applied to wet skin and rinse
  - Adult: 1–2 capfuls/bath, alternatively, to be applied to wet skin and rinse

DERMALO®

Dermatitis | Dry skin conditions, including ichthyosis

- TO THE SKIN
  - Child 1 month-11 years: 5–10 mL/bath, alternatively, to be applied to wet skin and rinse
  - Child 12-17 years: 15–20 mL/bath, alternatively, to be applied to wet skin and rinse
  - Adult: 15–20 mL/bath, alternatively, to be applied to wet skin and rinse

Pruritus of the elderly

- TO THE SKIN
  - Elderly: 15–20 mL/bath, alternatively, to be applied to wet skin and rinse

**DOUBLEBASE® EMBOLIEN BATH ADDITIVE**

Dry skin conditions including dermatitis and ichthyosis

- TO THE SKIN
  - Child 1 month-11 years: 5–10 mL/bath
  - Child 12-17 years: 15–20 mL/bath
  - Adult: 15–20 mL/bath

Pruritus of the elderly

- TO THE SKIN
  - Elderly: 15–20 mL/bath

**DOUBLEBASE® EMBOLIEN SHOWER GEL**

Dry, chapped, or itchy skin conditions

- TO THE SKIN
  - Child: To be applied to wet or dry skin and rinse, or apply to dry skin after showering
  - Adult: To be applied to wet or dry skin and rinse, or apply to dry skin after showering

**E45® BATH OIL**

Endogenous and exogenous eczema, xeroderma, and ichthyosis

- TO THE SKIN
  - Child 1 month-11 years: 5–10 mL/bath, alternatively, to be applied to wet skin and rinse
  - Child 12-17 years: 15 mL/bath, alternatively, to be applied to wet skin and rinse
  - Adult: 15 mL/bath, alternatively, to be applied to wet skin and rinse

Pruritus of the elderly associated with dry skin

- TO THE SKIN
  - Elderly: 15 mL/bath, alternatively, to be applied to wet skin and rinse

**E45® WASH CREAM**

Endogenous and exogenous eczema, xeroderma, and ichthyosis

- TO THE SKIN
  - Child: To be used as a soap substitute
  - Adult: To be used as a soap substitute

Pruritus of the elderly associated with dry skin

- TO THE SKIN
  - Elderly: To be used as a soap substitute

**HYDROMOL® BATH AND SHOWER EMOLLIENT**

Dry skin conditions | Eczema | Ichthyosis

- TO THE SKIN
  - Child 1 month-11 years: 0.5–2 capfuls/bath, alternatively apply to wet skin and rinse
  - Child 12-17 years: 1–3 capfuls/bath, alternatively apply to wet skin and rinse
  - Adult: 1–3 capfuls/bath, alternatively apply to wet skin and rinse

Pruritus of the elderly

- TO THE SKIN
  - Elderly: 1–3 capfuls/bath, alternatively apply to wet skin and rinse

**LPL 63.4®**

Dry skin conditions

- TO THE SKIN
  - Child 1 month-11 years: 0.5–2 capfuls/bath, alternatively, to be applied to wet skin and rinse
  - Child 12-17 years: 1–3 capfuls/bath, alternatively, to be applied to wet skin and rinse
  - Adult: 1–3 capfuls/bath, alternatively, to be applied to wet skin and rinse
OILATUM® EMOLLIENT BATH ADDITIVE

Dry skin conditions including dermatitis and ichthyosis

▷ TO THE SKIN
▷ Child 1 month-11 years: Apply 0.5–2 capfuls/bath, alternatively, to be applied to wet skin and rinse
▷ Child 12-17 years: 1–3 capfuls/bath, alternatively, to be applied to wet skin and rinse
▷ Adult: 1–3 capfuls/bath, alternatively, to be applied to wet skin and rinse

Pruritus of the elderly

▷ TO THE SKIN
▷ Elderly: 1–3 capfuls/bath, alternatively, to be applied to wet skin and rinse

OILATUM® JUNIOR BATH ADDITIVE

Dry skin conditions including dermatitis and ichthyosis

▷ TO THE SKIN
▷ Child 1 month-11 years: 0.5–2 capfuls/bath, alternatively, apply to wet skin and rinse
▷ Child 12-17 years: 1–3 capfuls/bath, alternatively, apply to wet skin and rinse
▷ Adult: 1–3 capfuls/bath, alternatively, apply to wet skin and rinse

Pruritus of the elderly

▷ TO THE SKIN
▷ Elderly: 1–3 capfuls/bath, alternatively, apply to wet skin and rinse

QV® BATH OIL

Dry skin conditions including eczema, psoriasis, ichthyosis, and pruritus

▷ TO THE SKIN
▷ Child: 1-11 months: 5 mL/bath, alternatively, to be applied to wet skin and rinse
▷ Child 1-7 years: 10 mL/bath, alternatively, to be applied to wet skin and rinse
▷ Adult: 10 mL/bath, alternatively, to be applied to wet skin and rinse

QV® GENTLE WASH

Dry skin conditions including eczema, psoriasis, ichthyosis, and pruritus

▷ TO THE SKIN
▷ Child: To be used as a soap substitute
▷ Adult: To be used as a soap substitute

ZEROLATUM®

Dry skin conditions | Dermatitis | Ichthyosis

▷ TO THE SKIN
▷ Child 1 month-11 years: 5–10 mL/bath
▷ Child 12-17 years: 15–20 mL/bath
▷ Adult: 15–20 mL/bath

Pruritus of the elderly

▷ TO THE SKIN
▷ Elderly: 15–20 mL/bath

IMPORANT SAFETY INFORMATION

These preparations make the skin and surfaces slippery—particular care is needed when bathing.

MHRA/CHM UPDATE (APRIL 2016): FIRE RISK WITH PARAFFIN-BASED SKIN EMOLLIENTS ON DRESSINGS OR CLOTHING

See Emollient and barrier preparations p. 1118.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Bath additive

CAUTIONARY AND ADVISORY LABELS 15

EXCIPIENTS: May contain Acetylated lanolin alcohols, cetostearyl alcohol (including cetyl and stearyl alcohol), fragrances, isopropyl palmitate

▷ Cetraben (Genus Pharmaceuticals Ltd)
  Liquid paraffin light 828 mg per 1 gram Cetraben emollient 8.2% bath additive | 500 mL £5.75
▷ Dermal (Dermal Laboratories Ltd)
  Acetylated wool alcohols 50 mg per 1 gram, Liquid paraffin 650 mg per 1 gram Dermal bath emollient | 500 mL £3.44

▷ Doublebase emollient bath (Dermal Laboratories Ltd)
  Liquid paraffin 650 mg per 1 gram Doublebase emollient bath additive | 500 mL £5.45
  E45 emollient bath (Forum Health Products Ltd)
  E45 emollient bath oil | 250 mL(ACBS) £3.30 | 500 mL(ACBS) £5.29
  Hydromol (Alliance Pharmaceuticals Ltd)
  Isopropyl myristate 130 mg per 1 mL, Liquid paraffin light 378 mg per 1 mL Hydromol Bath & Shower emollient | 350 mL £3.88 | 500 mL £4.42 | 1000 mL £8.80
  LPL (Huxley Europe Ltd)
  Liquid paraffin light 634 mg per 1 mL LPL 63.4 bath additive and emollient | 500 mL £3.10 DT price = £4.57
  Oilatum (GlaxoSmithKline Consumer Healthcare)
  Liquid paraffin light 634 mg per 1 mL Oiatus Bath Formula | 150 mL £2.95 DT price = £2.84 | 300 mL £5.02 DT price = £4.88
  Oilatum Emollient | 250 mL £2.75 DT price = £2.75 | 500 mL £5.27 DT price = £4.57
  Oiatus junior (GlaxoSmithKline Consumer Healthcare)
  Liquid paraffin light 634 mg per 1 mL Oiatus Junior bath additive | 150 mL £2.95 DT price = £2.84 | 250 mL £4.44 DT price = £2.75 | 300 mL £4.02 DT price = £4.88 | 600 mL £6.67 DT price = £5.89
  QV (Crawford Healthcare Ltd)
  Liquid paraffin light 850.9 mg per 1 gram QV 85.09% bath oil | 250 mL £2.91 | 500 mL £4.76
  Zerolatum (Thornton & Ross Ltd)
  Acetylated wool alcohols 50 mg per 1 gram, Liquid paraffin 650 mg per 1 gram Zerolatum Emollient bath additive | 500 mL £4.79

Gel

CAUTIONARY AND ADVISORY LABELS 15

EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol)

▷ Doublebase (Dermal Laboratories Ltd)
  Isopropyl myristate 150 mg per 1 gram, Liquid paraffin 150 mg per 1 gram Doublebase emollient wash gel | 200 gram £5.21
  Doublebase emollient shower gel | 200 gram £5.21

Cream

CAUTIONARY AND ADVISORY LABELS 15

EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol)

▷ Emollient bath and shower products, paraffin-containing (Non proprietary)
  Phenoxyethanol 10 mg per 1 gram, Liquid paraffin 60 mg per 1 gram, Emulsifying wax 90 mg per 1 gram, White soft paraffin 150 mg per 1 gram, Purified water 690 mg per 1 gram Aqueous cream | 100 gram £1.81 DT price = £0.87 | 500 gram £6.35 DT price = £4.35

Wash

CAUTIONARY AND ADVISORY LABELS 15

EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), hydroxybenzoates (parabens), polyesters

▷ Aquamax (Intrapharm Laboratories Ltd)
  Aquamax wash | 250 gram £2.99
  E45 emollient wash (Forum Health Products Ltd)
  E45 emollient wash cream | 250 mL(ACBS) £3.30
  QV Gentle (Crawford Healthcare Ltd)
  QV Gentle wash | 250 mL £3.17 | 500 mL £5.29
**Emollient bath and shower products, soya-bean oil-containing**

- **INDICATIONS AND DOSE**
  - **BALNEUM® BATH OIL**
    - **Dry skin conditions including those associated with dermatitis and eczema**
      - **TO THE SKIN**
        - Child 1-23 months: 5–15 mL/bath, not to be used undiluted
        - Child 2-17 years: 20–60 mL/bath, not to be used undiluted
        - Adult: 20–60 mL/bath, not to be used undiluted
  - **BALNEUM® PLUS BATH OIL**
    - **Dry skin conditions including those associated with dermatitis and eczema where pruritus also experienced**
      - **TO THE SKIN**
        - Child 1-23 months: 5 mL/bath, alternatively, to be applied to wet skin and rinse
        - Child 2-17 years: 10–20 mL/bath, alternatively, to be applied to wet skin and rinse
        - Adult: 20 mL/bath, alternatively, to be applied to wet skin and rinse

**IMPORTANT SAFETY INFORMATION**
These preparations make skin and surfaces slippery—particular care is needed when bathing.

- **DIRECTIONS FOR ADMINISTRATION** Emollient bath additives should be added to bath water; hydration can be improved by soaking in the bath for 10–20 minutes. Some bath emollients can be applied to wet skin undiluted and rinsed off. Emollient preparations contained in tubs should be removed with a clean spoon or spatula to reduce bacterial contamination of the emollient. Emollients should be applied in the direction of hair growth to reduce the risk of folliculitis.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Bath additive**
    - **EXCIPIENTS:** May contain Butylated hydroxytoluene, fragrances, propylene glycol
    - **Lauramicrogols 150 mg per 1 gram, Soya oil 829.5 mg per 1 gram**
    - Balneum Plus bath oil | 500 ml [GSL] £6.66
    - Soya oil 847.5 mg per 1 gram
    - Balneum 84.75% bath oil | 200 ml [GSL] £2.48 | 500 ml [GSL] £3.58 | 1000 ml [GSL] £10.39
    - Zeroneum (Thornton & Ross Ltd)
    - Soya oil 833.5 mg per 1 gram
      - Zeroneum 83.35% bath additive | 500 ml £4.48

**Emollient creams and ointments, antimicrobial-containing**

- **INDICATIONS AND DOSE**
  - **Psoriderm® EMULSION**
    - **Psoriasis**
      - **TO THE SKIN**
        - Adult: Up to 30 mL/bath, use 30 mL in adult-size bath, soak for 5 minutes

**IMPORTANT SAFETY INFORMATION**
These preparations make skin and surfaces slippery—particular care is needed when bathing.

- **DIRECTIONS FOR ADMINISTRATION** Emollient bath additives should be added to bath water; hydration can be improved by soaking in the bath for 10–20 minutes. Some bath emollients can be applied to wet skin undiluted and rinsed off. Emollient preparations contained in tubs should be removed with a clean spoon or spatula to reduce bacterial contamination of the emollient. Emollients should be applied in the direction of hair growth to reduce the risk of folliculitis.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Bath additive**
    - **EXCIPIENTS:** May contain Isopropyl palmitate, polysorbates
    - **Coal tar distilled 400 mg per 1 ml**
    - **Psoriderm® Emulsion 40% bath additive** | 200 ml [GSL] £2.74

**Emollient bath and shower products, tar-containing**

- **INDICATIONS AND DOSE**
  - **POLYTAR EMOLLIENT®**
    - **Psoriasis, eczema, atopic and pruritic dermatoses**
      - **TO THE SKIN**
        - Adult: 2–4 capfuls/bath, add 15–30 mL to an adult-size bath; soak for 20 minutes

**IMPORTANT SAFETY INFORMATION**
See Emollient and barrier preparations p. 1118.

**DIRECTIONS FOR ADMINISTRATION** Emollients should be applied immediately after washing or bathing to maximise the effect of skin hydration. Emollient preparations contained in tubs should be removed with a clean spoon or spatula to reduce bacterial contamination of the emollient. Emollients should be applied in the direction of hair growth to reduce the risk of folliculitis.

**PRESCRIBING AND DISPENSING INFORMATION**
Preparations containing an antibacterial should be avoided unless infection is present or is a frequent complication.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Cream**

- **CAUTIONARY AND ADVISORY LABELS**
- **EXCIPIENTS:** May contain Cetostearyl alcohol (including cetyl and stearyl alcohol)
- **Dermol** (Dermal Laboratories Ltd)
  - Benzalcohol chloride 1 mg per 1 gram, Chlorhexidine hydrochloride 1 mg per 1 gram, Isopropyl myristate 100 mg per
Emollients should be applied in the direction of hair growth to reduce the risk of folliculitis.

### Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug.

**Spray**

- **Cautionary and Advisory Labels 15**
- **Dermamist (Alliance Pharmaceuticals Ltd)**
- White soft paraffin 100 mg per 1 gram
- Dermamist 10% spray
- 250 ml £0.97

### Cream

- **Cautionary and Advisory Labels 15**
- **Dermol 100 mg per 1 gram**
- White soft paraffin 100 mg per 1 gram
- Dermol 10% spray
- 250 ml £0.97

**Emollients should be applied immediately after washing or bathing to maximise the effect of skin hydration. Emollient preparations contained in tubs should be removed with a clean spoon or spatula to reduce bacterial contamination of the emollient.**

### Directions for Administration

Emollients should be applied in the direction of hair growth to reduce the risk of folliculitis.

### Directions for Application

Emollients should be applied immediately after washing or bathing to maximise the effect of skin hydration. Emollient preparations contained in tubs should be removed with a clean spoon or spatula to reduce bacterial contamination of the emollient.
3 Emollients, urea-containing

- **DRUG ACTION** Urea is a keratin softener and hydrating agent used in the treatment of dry, scaling conditions (including ichthyosis) and may be useful in elderly patients.

### INDICATIONS AND DOSE

#### AQUADRATE ®

- **Dry, scaling, and itching skin**
  - **TO THE SKIN**
  - Child: Apply twice daily, to be applied thinly
  - Adult: Apply twice daily, to be applied thinly

#### BALNEUM ® CREAM

- **Dry skin conditions**
  - **TO THE SKIN**
  - Child: Apply twice daily
  - Adult: Apply twice daily

#### BALNEUM ® PLUS CREAM

- **Dry, scaling, and itching skin**
  - **TO THE SKIN**
  - Child: Apply twice daily
  - Adult: Apply twice daily

#### CALMURID ®

- **Dry, scaling, and itching skin**
  - **TO THE SKIN**
  - Child: Apply twice daily, apply a thick layer for 3–5 minutes, massage into area, and remove excess. Can be diluted with aqueous cream (life of diluted cream is 14 days). Half-strength cream can be used for 1 week if stinging occurs.
  - Adult: Apply twice daily, apply a thick layer for 3–5 minutes, massage into area, and remove excess. Can be diluted with aqueous cream (life of diluted cream is 14 days). Half-strength cream can be used for 1 week if stinging occurs.

#### DERMATONICS ONCE HEEL BALM ®

- **Dry skin on soles of feet**
  - **TO THE SKIN**
  - Child 12–17 years: Apply once daily
  - Adult: Apply once daily

#### E45 ® ITCH RELIEF CREAM

- **Dry, scaling, and itching skin**
  - **TO THE SKIN**
  - Child: Apply twice daily
  - Adult: Apply twice daily

#### EUCERIN ® INTENSIVE CREAM

- **Dry skin conditions including eczema, ichthyosis, xeroderma, and hyperkeratosis**
  - **TO THE SKIN**
  - Child: Apply twice daily, to be applied thinly and rubbed into area
  - Adult: Apply twice daily, to be applied thinly and rubbed into area

#### EUCERIN ® INTENSIVE LOTION

- **Dry skin conditions including eczema, ichthyosis, xeroderma, and hyperkeratosis**
  - **TO THE SKIN**
  - Child: Apply twice daily, to be applied sparingly and rubbed into area
  - Adult: Apply twice daily, to be applied sparingly and rubbed into area

#### FLEXITOL ®

- **Dry skin on soles of feet and heels**
  - **TO THE SKIN**
  - Child 12–17 years: Apply 1–2 times a day
  - Adult: Apply 1–2 times a day

---

**1124 Dry and scaling skin disorders**

- **Zeroguent (Thorton & Ross Ltd)**
  - White soft paraffin 40 mg per 1 gram, Soya oil 50 mg per 1 gram, Liquid paraffin light 80 mg per 1 gram Zeroguent cream | 100 gram £2.33 | 500 gram £6.99

- **Ointment**

  - **CAUTIONARY AND ADVISORY LABELS**
  - 15 EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), polysorbates, QV

  - **Emollient creams and ointments, paraffin-containing (Non-proprietary)**
    - Liquid paraffin 200 mg per 1 gram, Emulsifying wax 300 mg per 1 gram, White soft paraffin 500 mg per 1 gram Emulsifying ointment | 100 gram [GSL] no price available | 500 gram [POM] no price available DT price = £2.92 | 500 gram [GSL] £3.43 DT price = £2.92
    - Liquid paraffin 500 mg per 1 gram, White soft paraffin 500 mg per 1 gram Aquaderm Liquid Paraffin 50% in White Soft Paraffin ointment | 250 gram £1.75 | 500 gram £3.49 DT price = £4.57
      - The 50:50 Ointment | 500 gram [P] no price available DT price = £4.57
      - White soft paraffin 50% / Liquid paraffin 50% ointment | 250 gram £1.87 | 500 gram £4.19 DT price = £4.57 | 500 gram [P] £4.57 DT price = £4.57
    - Pure Health Liquid Paraffin 50% in White Soft Paraffin ointment | 500 gram £3.66 DT price = £4.57
    - Bell’s Emollient 50 ointment | 250 gram £1.99 | 500 gram £3.17 DT price = £4.57
    - Magnesium sulfate dried 5 mg per 1 gram, Phenoxethanol 10 mg per 1 gram, Wool alcohols ointment 500 mg per 1 gram Aquaderm Hydrous ointment | 500 gram £4.15 DT price = £4.89
    - Hydrous ointment | 500 gram [GSL] £4.89 DT price = £4.89
    - White soft paraffin 1 mg per 1 mg White soft paraffin solid | 500 gram [GSL] £4.33 DT price = £3.23 | 4500 gram [GSL] £19.17–£29.07
    - Yellow soft paraffin 1 mg per 1 mg Yellow soft paraffin solid | 15 gram [GSL] £1.16 | 500 gram [GSL] £15.44 DT price = £15.44 | 4500 gram [GSL] £19.02

  - **Diprobase (Bayer Plc)**
    - Liquid paraffin 50 mg per 1 gram, White soft paraffin 950 mg per 1 gram Diprobase ointment | 50 gram [GSL] £1.28 DT price = £1.28 | 500 gram [GSL] £5.99 DT price = £5.99

  - **Emelpin (Vitame Ltd)**
    - Emulsifying wax 300 mg per 1 gram, Yellow soft paraffin 300 mg per 1 gram Emelpin ointment | 125 gram £3.08 | 500 gram £5.22

  - **Epaderm (Mohlycke Health Care Ltd)**
    - Emulsifying wax 300 mg per 1 gram, Yellow soft paraffin 300 mg per 1 gram Epaderm ointment | 125 gram £3.85 | 500 gram £6.53 | 1000 gram £12.02

  - **Fifty:50 (Ennogen Healthcare Ltd)**
    - Liquid paraffin 500 mg per 1 gram, White soft paraffin 500 mg per 1 gram Fifty:50 ointment | 250 gram £1.83 | 500 gram £3.66 DT price = £4.57

  - **Hydromol (Alliance Pharmaceuticals Ltd)**
    - Emulsifying wax 300 mg per 1 gram, Yellow soft paraffin 300 mg per 1 gram Hydromol ointment | 125 gram £2.88 | 500 gram £4.89 | 1000 gram £9.09

  - **Thirty:30 (Ennogen Healthcare Ltd)**
    - Emulsifying wax 300 mg per 1 gram, Yellow soft paraffin 300 mg per 1 gram Thirty:30 ointment | 125 gram £3.81 | 250 gram £4.29 | 500 gram £6.47

  - **Vaseline (Unilever UK Home & Personal Care)**
    - White soft paraffin 1 mg per 1 mg Vaseline Pure Petroleum jelly | 50 ml [GSL] no price available | 100 ml [GSL] no price available | 250 ml [GSL] no price available

- **Liquid**

  - **CAUTIONARY AND ADVISORY LABELS**
  - 15 EXCIPIENTS: May contain Benzyl alcohol, cetostearyl alcohol (including cetyl and stearyl alcohol), hydroxybenzoates (parabens), isopropyl palmitate

    - **E45 (Forum Health Products Ltd)**
      - E45 lotion | 200 ml £2.45 | 500 ml £4.59

    - **QV (Crawford Healthcare Ltd)**
      - White soft paraffin 50 mg per 1 gram QV 5% skin lotion | 250 ml £3.17 | 500 ml £5.29

---

---
HYDROMOL® INTENSIVE

Dry, scaling, and itching skin

- TO THE SKIN
- Child: Apply twice daily, to be applied thinly
- Adult: Apply twice daily, to be applied thinly

IMUSCERM® EMOLLIENT

Dry skin conditions including eczema, psoriasis or dermatitis

- TO THE SKIN
- Adult: Apply to skin or use as a soap substitute

NUTRAPLUS®

Dry, scaling, and itching skin

- TO THE SKIN
- Child: Apply 2–3 times a day
- Adult: Apply 2–3 times a day

**DIRECTIONS FOR ADMINISTRATION** Emollients should be applied immediately after washing or bathing to maximise the effect of skin hydration. Emollient preparations contained in tubes should be removed with a clean spoon or spatula to reduce bacterial contamination of the emollient. Emollients should be applied in the direction of hair growth to reduce the risk of folliculitis.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Cream**

EXCIPIENTS: May contain Benzyl alcohol, cetostearyl alcohol (including cetyl and stearyl alcohol), hydroxybenzoates (parabens), isopropyl palmitate, polysorbates, propylene glycol, wool fat and related substances including lanolin

- Aquadrate (Alliance Pharmaceuticals Ltd)
  Urea 100 mg per 1 gram Aquadrate 10% cream | 100 gram | £4.37
  Balneum (Almirall Ltd)
  Balneum cream | 50 gram £2.85 | 500 gram £9.97
  Balneum Plus (Almirall Ltd)
  Lauramucogolo 30 mg per 1 gram, Urea 50 mg per 1 gram Balneum Plus cream | 100 gram | £3.29 | 500 gram | £14.99
  Calmurid (Galderma (UK) Ltd)
  Lactic acid 50 mg per 1 gram, Urea 100 mg per 1 gram Calmurid cream | 100 gram | £5.75 DT price = £5.75 | 500 gram | £33.40 DT price = £33.40
  £45 Itch Relief (Forum Health Products Ltd)
  Lauramucogolo 30 mg per 1 gram, Urea 50 mg per 1 gram E45 Itch Relief cream | 50 gram | £2.81 | 100 gram | £4.28 | 500 gram | £14.99
  Eucerin (Beiersdorf UK Ltd)
  Urea 100 mg per 1 gram Eucerin Intensive 10% cream | 100 ml | £7.59
  Hydromol Intensive (Alliance Pharmaceuticals Ltd)
  Urea 100 mg per 1 gram Hydromol Intensive 10% cream | 30 gram | £1.64 | 100 gram | £4.37
  Nutraplus (Galderma (UK) Ltd)
  Urea 100 mg per 1 gram Nutraplus 10% cream | 100 gram | £4.37

**Liquid**

EXCIPIENTS: May contain Benzyl alcohol, isopropyl palmitate

- Eucerin (Beiersdorf UK Ltd)
  Urea 100 mg per 1 gram Eucerin Intensive 10% lotion | 250 ml | £7.93 DT price = £7.93

**Balsams**

EXCIPIENTS: May contain Beeswax, benzyl alcohol, cetostearyl alcohol (including cetyl and stearyl alcohol), fragrances, lanolin

- ImuDERM (Clinisupplies Ltd)
  ImuDERM emollient | 500 gram | £6.50
  Dermatonic Ointment (Dermatonics Ltd)
  Dermatonics Ointment Heel Balm | 75 ml £3.60 | 200 ml £8.50
  Flexitol (Thornton & Ross Ltd)
  Flexitol Heel Balm | 40 gram £2.75 | 56 gram no price available | 75 gram £3.80 | 112 gram no price available | 200 gram £9.40 | 500 gram £14.75

**2 Infections of the skin**

### Skin infections

#### Antibacterial preparations

**Cellulitis**, a rapidly spreading deeply seated inflammation of the skin and subcutaneous tissue, requires systemic antibacterial treatment. Lower leg infections or infections spreading around wounds are almost always cellulitis. *Erysipelas*, a superficial infection with clearly defined edges (and often affecting the face), is also treated with a systemic antibacterial.

In the community, acute *impetigo* on small areas of the skin may be treated by short-term topical application of fusidic acid p. 539; mupirocin p. 1129 should be used only to treat meticillin-resistant *Staphylococcus aureus*. If the impetigo is extensive or longstanding, an oral antibacterial such as flucloxacillin p. 523 (or clarithromycin p. 508 in penicillin allergy) should be used. Mild antiseptics can be used to soften crusts.

Although many antibacterial drugs are available in topical preparations, some are potentially hazardous and frequently their use is not necessary if adequate hygienic measures can be taken. Moreover, not all skin conditions that are oozing, crusts, or characterised by pustules are actually infected.

Topical antibacterials should be *avoided* on leg ulcers unless used in short courses for defined infections; treatment of bacterial colonisation is generally inappropriate.

To minimise the development of resistant organisms it is advisable to limit the choice of antibacterials applied topically to those not used systemically. Unfortunately some of these, for example neomycin sulfate p. 1127, may cause sensitisation, and there is cross-sensitivity with other aminoglycoside antibiotics, such as gentamicin p. 491. If *large areas of skin* are being treated, ototoxicity may also be a hazard with aminoglycoside antibiotics (and also with polymyxins p. 1128), particularly in children, in the elderly, and those with renal impairment. *Resistant organisms* are more common in hospitals, and whenever possible swabs should be taken for bacteriological examination before beginning treatment.

Mupirocin is not related to any other antibacterial in use; it is effective for skin infections, particularly those due to Gram-positive organisms but it is not indicated for pseudomonal infection. Although *Staphylococcus aureus* strains with low–level resistance to mupirocin are emerging, it is generally useful in infections resistant to other antibacterials. To avoid the development of resistance, mupirocin or fusidic acid should not be used for longer than 10 days and local microbiology advice should be sought before using it in hospital. In the presence of mupirocin-resistant MRSA infection, a topical antiseptic such as povidone–iodine p. 1172, chlorhexidine p. 1173, or alcohol can be used; their use should be discussed with the local microbiologist.

Retapamulin p. 1129 can be used for impetigo and other superficial bacterial skin infections caused by *Staphylococcus aureus* and *Streptococcus pyogenes* that are resistant to first-line topical antibacterials. However, it is not effective against MRSA.

*Tedizolid* p. 541 is licensed for the treatment of acute bacterial skin and skin structure infections. Silver sulfadiazine p. 1128 is used in the treatment of infected burns.

**Antibacterial preparations also used systemically**

Fusidic acid is a narrow-spectrum antibacterial used for *staphylococcal* infections. Fusidic acid has a role in the treatment of impetigo.
An ointment containing fusidic acid is used in the fissures of angular cheilitis when associated with staphylococcal infection. See Oropharyngeal fungal infections p. 1115 for further information on angular cheilitis.

Metronidazole p. 1127 is used topically for rosacea and to reduce the odour associated with anaerobic infections; oral metronidazole is used to treat wounds infected with anaerobic bacteria.

**Antifungal preparations**

Most localised fungal infections are treated with topical preparations. To prevent relapse, local antifungal treatment should be continued for 1–2 weeks after the disappearance of all signs of infection. Systemic therapy is necessary for scalp infection or if the skin infection is widespread, disseminated, or intractable; although topical therapy may be used to treat some nail infections, systemic therapy is more effective. Skin scrapings should be examined if systemic therapy is being considered or where there is doubt about the diagnosis.

**Dermatophytoes**

Ringworm infection can affect the scalp (tinea capitis), body (tinea corporis), groin (tinea cruris), hand (tinea manuum), foot (tinea pedis, athlete’s foot), or nail (tinea unguium). Scalp infection requires systemic treatment; additional application of a topical antifungal, during the early stages of treatment, may reduce the risk of transmission. A topical antifungal can also be used to treat asymptomatic carriers of scalp ringworm. Most other local ringworm infections can be treated adequately with topical antifungal preparations (including shampoos). The imidazole antifungals clotrimazole p. 1130, econazole nitrate p. 1130, ketoconazole p. 1130, and miconazole p. 1131 are all effective. Terbinafine cream p. 1132 is also effective but it is more expensive. Other topical antifungals include griseofulvin p. 1132 and the **undecenoates. Compound benzoic acid ointment** (Whitfield’s ointment) has been used for ringworm infections but it is cosmetically less acceptable than proprietary preparations. Topical preparations for athlete’s foot containing **tolnaftate** are on sale to the public.

Antifungal dusting powders are of little therapeutic value in the treatment of fungal skin infections and may cause skin irritation; they may have some role in preventing re-infection.

Antifungal treatment may not be necessary in asymptomatic patients with tinea infection of the nails. If treatment is necessary, a systemic antifungal is more effective than topical therapy. However, topical application of amorolfine p. 1131 or toconazole p. 1131 may be useful for treating early onychomycosis when involvement is limited to mild distal disease, or for superficial white onychomycosis, or where there are contra-indications to systemic therapy.

**Pityriasis versicolor**

Pityriasis (tinea) versicolor can be treated with ketoconazole shampoo. Alternatively, **selenium sulphide** shampoo [unlicensed indication] can be used as a lotion (diluting with a small amount of water can reduce irritation) and left on the affected area for 10 minutes before rinsing off; it should be applied once daily for 7 days, and the course repeated if necessary.

Topical imidazole antifungals such as clotrimazole, econazole nitrate, ketoconazole, and miconazole, or topical terbinafine are alternatives, but large quantities may be required.

If topical therapy fails, or if the infection is widespread, pityriasis versicolor is treated systemically with a triazole antifungal. Relapse is common, especially in the immunocompromised.

**Candidiasis**

Candidal skin infections can be treated with a topical imidazole antifungal, such as clotrimazole, econazole nitrate, ketoconazole, or miconazole; topical terbinafine is an alternative. Topical application of nystatin is also effective for candidiasis but it is ineffective against dermatophytosis. Refractory candidiasis requires systemic treatment generally with a triazole such as fluconazole p. 562; systemic treatment with terbinafine is not appropriate for refractory candidiasis.

**Angular cheilitis**

Miconazole cream is used in the fissures of angular cheilitis when associated with Candida.

**Compound topical preparations**

Combination of an imidazole and a mild corticosteroid (such as hydrocortisone 1% p. 1145) may be of value in the treatment of eczematous intertrigo and, in the first few days only, of a severely inflamed patch of ringworm.

Combination of a mild corticosteroid with either an imidazole or nystatin may be of use in the treatment of intertrigo associated with candida.

**Antiviral preparations**

Aciclovir p. 1135 cream is licensed for the treatment of initial and recurrent labial and genital herpes simplex infections; treatment should begin as early as possible. Systemic treatment is necessary for buccal or vaginal infections and for herpes zoster (shingles).

**Herpes labialis**

Aciclovir cream can be used for the treatment of initial and recurrent labial herpes simplex infections (cold sores). It is best applied at the earliest possible stage, usually when prodromal changes of sensation are felt in the lip and before vesicles appear.

Penciclovir cream is also licensed for the treatment of herpes labialis; it needs to be applied more frequently than aciclovir cream.

Systemic treatment is necessary if cold sores recur frequently or for infections in the mouth.

**Parasiticidal preparations**

<table>
<thead>
<tr>
<th>Suitable quantities of parasiticidal preparations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Area of body</strong></td>
</tr>
<tr>
<td>Scalp (head lice)</td>
</tr>
<tr>
<td>Body (scabies)</td>
</tr>
<tr>
<td>Body (crab lice)</td>
</tr>
</tbody>
</table>

These amounts are usually suitable for an adult for single application.

**Scabies**

Permethrin p. 1135 is used for the treatment of scabies (Sarcoptes scabiei); malathion p. 1135 can be used if permethrin is inappropriate.

Benzyl benzoate p. 1134 is an irritant and should be avoided in children; it is less effective than malathion and permethrin.

Ivermectin p. 571 (available on a named patient basis from ‘special-order’ manufacturers or specialist importing companies) by mouth has been used, in combination with topical drugs, for the treatment of hyperkeratotic (crusted or ‘Norwegian’) scabies that does not respond to topical treatment alone; further doses may be required.

**Application**

Although acaricides have traditionally been applied after a hot bath, this is not necessary and there is even evidence that a hot bath may increase absorption into the blood, removing them from their site of action on the skin.
All members of the affected household should be treated simultaneously. Treatment should be applied to the whole body including the scalp, neck, face, and ears. Particular attention should be paid to the webs of the fingers and toes and lotion brushed under the ends of nails. It is now recommended that malathion and permethrin should be applied twice, one week apart; in the case of benzyl benzoate in adults, up to 3 applications on consecutive days may be needed. It is important to warn users to reapply treatment to the hands if they are washed. Patients with hyperkeratotic scabies may require 2 or 3 applications of acaricide on consecutive days to ensure that enough penetrates the skin crusts to kill all the mites.

Itching
The itch and eczema of scabies persists for some weeks after the infestation has been eliminated and treatment for pruritus and eczema may be required. Application of crotamiton p. 1161 can be used to control itching after treatment with more effective acaricides. A topical corticosteroid may help to reduce itch and inflammation after scabies has been treated successfully; however, persistent symptoms suggest that scabies eradication was not successful. Oral administration of a sedating antihistamine at night may also be useful.

Head lice
Dimeticone p. 1134 is effective against head lice (Pediculus humanus capitis). It coats head lice and interferes with water balance in lice by preventing the excretion of water; it is less active against eggs and treatment should be repeated after 7 days. Malathion, an organophosphorus insecticide, is an alternative, but resistance has been reported. Benzyl benzoate is licensed for the treatment of head lice but it is less effective than other drugs and not recommended for use in children. Permethrin is active against head lice but the formulation and licensed methods of application of the current products make them unsuitable for the treatment of head lice.

Head lice infestation (pediculosis) should be treated using lotion or liquid formulations only if live lice are present. Shampoos are diluted too much in use to be effective. A contact time of 8–12 hours or overnight treatment is recommended for lotions and liquids; a 2-hour treatment is not sufficient to kill eggs.

In general, a course of treatment for head lice should be 2 applications of product 7 days apart to kill lice emerging from any eggs that survive the first application. All affected household members should be treated simultaneously.

Wet combing methods
Head lice can be mechanically removed by combing wet hair meticulously with a plastic detection comb (probably for at least 30 minutes each time) over the whole scalp at 4-day intervals for a minimum of 2 weeks, and continued until no lice are found on 3 consecutive sessions; hair conditioner or vegetable oil can be used to facilitate the process.

Several devices for the removal of head lice such as combs and topical solutions, are available and some are prescribable on the NHS. The Drug Tariffs can be accessed online at:
- National Health Service Drug Tariff for England and Wales: www.ppa.org.uk/ppa/edt_intro.htm
- Health and Personal Social Services for Northern Ireland Drug Tariff: www.hscbusiness.hscni.net/services/2034.htm
- Scottish Drug Tariff: www.isdscotland.org/Health-topics/Prescribing-and-Medicines/Scottish-Drug-Tariff/

Crab lice
Permethrin and malathion are used to eliminate crab lice (Pthirus pubis). An aqueous preparation should be applied, allowed to dry naturally and washed off after 12 hours; a second treatment is needed after 7 days to kill lice emerging from surviving eggs. All surfaces of the body should be treated, including the scalp, neck, and face (paying particular attention to the eyebrows and other facial hair). A different insecticide should be used if a course of treatment fails.

2.1 Bacterial skin infections

ANTIBACTERIALS > AMINOGLYCOSIDES

Neomycin sulfate

- INDICATIONS AND DOSE
  - Bacterial skin infections
    - TO THE SKIN
      - Child: Apply up to 3 times a day, for short-term use only
      - Adult: Apply up to 3 times a day, for short-term use only

- UNLICENSED USE
  - In children Neomycin Cream BPC—no information available.

- CONTRA-INDICATIONS
  - Neonates

- CAUTIONS
  - If large areas of skin are being treated ototoxicity may be a hazard, particularly in children, the elderly, and in those with renal impairment.

- INTERACTIONS
  - Appendix 1: neomycin

- SIDE-EFFECTS
  - Sensitisation (cross sensitivity with other aminoglycosides may occur)

- RENAL IMPAIRMENT
  - Ototoxicity may be a hazard if large areas of skin are treated.

- LESS SUITABLE FOR PRESCRIBING
  - Neomycin sulfate cream is less suitable for prescribing.

ANTIBACTERIALS > NITROIMIDAZOLE DERIVATIVES

Metronidazole

- DRUG ACTION
  - Metronidazole is an antimicrobial drug with high activity against anaerobic bacteria and protozoa.

- INDICATIONS AND DOSE
  - ACEA ®
    - Acute inflammatory exacerbation of rosacea
      - TO THE SKIN
        - Adult: Apply twice daily for 8 weeks, to be applied thinly
  - ANABACT ®
    - Malodorous fungating tumours and malodorous gravitational and decubitus ulcers
      - TO THE SKIN
        - Adult: Apply 1–2 times a day, to be applied clean wound and covered with non-adherent dressing
  - METROGEL ®
    - Acute inflammatory exacerbation of rosacea
      - TO THE SKIN
        - Adult: Apply twice daily for 8–9 weeks, to be applied thinly

- Malodorous fungating tumours
  - TO THE SKIN
  - Adult: Apply 1–2 times a day, to be applied clean wound and covered with non-adherent dressing
  - continued →
Skin

**ANTIBACTERIALS**

**ROZEX®**

Inflammatory papules and pustules of rosacea

- **TO THE SKIN**
- **Adult:** Apply twice daily for 3–4 months

**ROZEX® CREAM**

Inflammatory papules, pustules and erythema of rosacea

- **TO THE SKIN**
- **Adult:** Apply twice daily for 3–4 months

**GEL**

Inflammatory papules, pustules and erythema of rosacea

- **TO THE SKIN**
- **Adult:** Apply twice daily for very exudative sites and extensive abrasions

**CAUTIONS** Avoid exposure to strong sunlight or UV light

**INTERACTIONS** → Appendix 1: metronidazole

**SIDE-EFFECTS** Skin irritation

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Gel**

**EXCIPIENTS:** May contain Benzyl alcohol, disodium edetate, hydroxybenzoates (parabens), propylene glycol

- **Aceca** (Pierre Fabre Dermo-Cosmetique)
  - **Metronidazole 75 mg per 1 gram** Aceca 0.75% gel | 40 gram **PoS** £9.95 DT price = £22.63
- **Anabact** (Cambridge Healthcare Supplies Ltd)
  - **Metronidazole 75 mg per 1 gram** Anabact 0.75% gel | 15 gram **PoS** £4.47 DT price = £4.47 | 30 gram **PoS** £7.89
- **Metrogel** (Galderma (UK) Ltd)
  - **Metronidazole 75 mg per 1 gram** Metrogel 0.75% gel | 40 gram **PoS** £22.63 DT price = £22.63
- **Metrosa** (M & A Pharmachem Ltd)
  - **Metronidazole 75 mg per 1 gram** Metrosa 0.75% gel | 30 gram **PoS** £12.00 | 40 gram **PoS** £19.90 DT price = £22.63
- **Rozex** (Galderma (UK) Ltd)
  - **Metronidazole 75 mg per 1 gram** Rozex 0.75% gel | 30 gram **PoS** £6.60 | 40 gram **PoS** £9.88 DT price = £22.63
- **Zyomet (AMCo)**
  - **Metronidazole 75 mg per 1 gram** Zyomet 0.75% gel | 30 gram **PoS** £12.00

**Cream**

**EXCIPIENTS:** May contain Benzyl alcohol, isopropyl palmitate, propylene glycol

- **Rosiced** (Pierre Fabre Dermo-Cosmetique)
  - **Metronidazole 75 mg per 1 gram** Rosiced 0.75% cream | 30 gram **PoS** £7.50 DT price = £6.60
- **Rozex** (Galderma (UK) Ltd)
  - **Metronidazole 75 mg per 1 gram** Rozex 0.75% cream | 30 gram **PoS** £6.60 DT price = £6.60 | 40 gram **PoS** £9.88 DT price = £9.88

**ANTIBACTERIALS** → **SULFONAMIDES**

**Silver sulfadiazine**

**INDICATIONS AND DOSE**

Prophylaxis and treatment of infection in burn wounds

- **TO THE SKIN**
  - **Child:** Apply daily, may be applied more frequently if very exudative
  - **Adult:** Apply daily, may be applied more frequently if very exudative

For conservative management of finger-tip injuries

- **TO THE SKIN**
  - **Child:** Apply every 2–3 days, consult product literature for details
  - **Adult:** Apply every 2–3 days, consult product literature for details

As an adjunct to short-term treatment of infection in leg ulcers

- **TO THE SKIN**
  - **Adult:** Apply once daily or on alternate days

**SIDE-EFFECTS**

- Allergic reactions
- **FOR THERAPEUTIC LEVELS WITH METRONIDAZOLE**
- **Nephrotoxicity and neurotoxicity may be a hazard,** particularly in children, in the elderly, and in those with renal impairment.

**INTERACTIONS** → Appendix 1: silver sulfadiazine

**SIDE-EFFECTS**

- **Sensitisation**

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

No licensed medicines listed.

Combinations available: *Bacitracin with polymyxin B*, p. 1129

**UNLICENSED USE**

- In children No age range specified by manufacturer.
- **CONTRA-INDICATIONS** Not recommended for neonates (in children)

**CAUTIONS** G6PD deficiency

**CAUTIONS, FURTHER INFORMATION**

- Large areas Plasma-sulfadiazine concentrations may approach therapeutic levels with *side-effects* and *interactions* as for sulfonamides if large areas of skin are treated.

**INTERACTIONS** → Appendix 1: silver sulfadiazine

**SIDE-EFFECTS** Allergic reactions • argyria (following treatment of large areas of skin or prolonged use) • burning • itching • leucopenia • rashes

**SIDE-EFFECTS, FURTHER INFORMATION**

- Severe blood and skin disorders Owing to the association of sulfonamides with severe blood and skin disorders, treatment should be stopped immediately if blood disorders or rashes develop.

Leucopenia developing 2–3 days after starting treatment of burns patients is reported usually to be self-limiting and silver sulfadiazine need not usually be discontinued provided blood counts are monitored carefully to ensure return to normality within a few days.

**ALLERGY AND CROSS-SENSITIVITY** Contra-indicated in patients with sensitivity to sulfonamides.
**PRENANCY** Risk of neonatal haemolysis and methaemoglobinemia in third trimester.

**BREAST FEEDING** Small risk of kernicterus in jaundiced infants and of haemolysis in G6PD-deficient infants.

**HEPATIC IMPAIRMENT** Manufacturer advises caution if significant impairment.

**RENAL IMPAIRMENT** Manufacturer advises caution if significant impairment.

**MONITORING REQUIREMENTS** Monitor for leucopenia.

**DIRECTIONS FOR ADMINISTRATION** Apply with sterile applicator.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Cream**
EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), polysorbates, propylene glycol

- **Flamazine** (Smith & Nephew Healthcare Ltd)
  - Sulfadiazine silver 10 mg per 1 gram Flamazine 1% cream | 20 gram £2.91 | 50 gram £3.85 DT price = £3.85 | 250 gram £10.32 DT price = £10.32 | 500 gram £18.27 DT price = £18.27

**ANTIBACTERIALS**

### Bacitracin with polymyxin B

#### INDICATIONS AND DOSE

**Bacterial skin infections**

- **TO THE SKIN**
  - Child: Apply twice daily, can be applied more frequently if required
  - Adult: Apply twice daily, can be applied more frequently if required

#### UNLICENSED USE
Licensed for use in children (age range not specified by manufacturer).

#### CAUTIONS
Nephrotoxicity · neurotoxicity

#### MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

**Ointment**
- **Polyfax** (Teva UK Ltd)
  - Bacitracin zinc 500 unit per 1 gram, Polymyxin B sulfate 10000 unit per 1 gram Polyfax ointment | 4 gram £3.26 | 20 gram £4.62 DT price = £4.62

### Mupirocin

#### INDICATIONS AND DOSE

**Bacterial skin infections, particularly those caused by Gram-positive organisms (except pseudomonal infection)**

- **TO THE SKIN**
  - Child: Apply up to 3 times a day for up to 10 days
  - Adult: Apply up to 3 times a day for up to 10 days

#### UNLICENSED USE

**SIDE-EFFECTS**
- Burning sensation · local reactions · pruritus · rash · urticaria

**PREGNANCY**
Manufacturer advises avoid unless potential benefit outweighs risk—no information available.

**BREAST FEEDING**
No information available.

**RENAL IMPAIRMENT**
Manufacturer advises caution when mupirocin ointment used in moderate or severe impairment because it contains macrogols (polyethylene glycol).

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Ointment**
- **Mupirocin (Non-proprietary)**
  - Mupirocin 20 mg per 1 gram Mupirocin 2% ointment | 15 gram £12.50 DT price = £5.26
  - **Bactroban** (GlaxoSmithKline UK Ltd)
    - Mupirocin 20 mg per 1 gram Bactroban 2% ointment | 15 gram £5.26 DT price = £5.26

**Cream**
EXCIPIENTS: May contain Benzyl alcohol, cetostearyl alcohol (including cetyl and stearyl alcohol)

- **Bactroban** (GlaxoSmithKline UK Ltd)
  - Mupirocin (as Mupirocin calcium) 20 mg per 1 gram Bactroban 2% cream | 15 gram £5.26 DT price = £5.26

### Retapamulin

#### INDICATIONS AND DOSE

Superficial bacterial skin infection caused by *Staphylococcus aureus* and *Streptococcus pyogenes* (if resistant to first line topical antibacterials)

- **TO THE SKIN**
  - Child 9 months-17 years: Apply twice daily for 5 days, to be applied thinly, maximum area of skin treated 2% of body surface area, review treatment if no response within 2–3 days
  - Adult: Apply twice daily for 5 days, to be applied thinly, maximum area of skin treated 100 cm² or lesion length 10 cm, review treatment if no response within 2–3 days

#### CONTRA-INDICATIONS
Contact with eyes · contact with mucous membranes

#### SIDE-EFFECTS
Contact dermatitis · localised erythema · localised irritation · localised pain · pruritus

#### NATIONAL FUNDING/ACCESS DECISIONS
Scottish Medicines Consortium (SMC) Decisions
The Scottish Medicines Consortium has advised (March 2008) that retapamulin (Altargo®) is not recommended for use within NHS Scotland for the treatment of superficial skin infections.

#### MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

**Ointment**

CAUTIONARY AND ADVISORY LABELS 28
EXCIPIENTS: May contain Butylated hydroxytoluene

- **Altargo** (GlaxoSmithKline UK Ltd)
  - Retapamulin 10 mg per 1 gram Altargo 10mg/g ointment | 5 gram £7.89

Downloaded from www.medicalbr.com
2.2 Fungal skin infections

ANTIFUNGALS > IMIDAZOLE ANTIFUNGALS

Clotrimazole

- **INDICATIONS AND DOSE**
  - **Fungal skin infections**
    - **TO THE SKIN**
      - Child: Apply 2–3 times a day
      - Adult: Apply 2–3 times a day
  - **Fungal nail infections**
    - **BY TRANSUNGUAL APPLICATION**
      - Child: Apply once daily, applied under occlusive dressing
      - Adult: Apply once daily, applied under occlusive dressing
  - **Cautions** Contact with eyes and mucous membranes should be avoided
  - **INTERACTIONS** → Appendix 1: antifungals, azoles
  - **SIDE-EFFECTS** Local irritation · erythema · hypersensitivity reactions · itching · mild burning sensation

SIDE-EFFECTS, FURTHER INFORMATION

Treatment should be discontinued if side-effects are severe.

- **PREGNANCY** Minimal absorption from skin; not known to be harmful.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Cream**

- **EXCIPIENTS:** May contain Benzyl alcohol, cetostearyl alcohol (including cetyl and stearyl alcohol), polysorbates

  - **Clotrimazole (Non-proprietary)**
    - Clotrimazole 10 mg per 1 gram Clotrimazole 1% cream | 20 gram £2.06 DT price = £1.12 | 50 gram £5.45 DT price = £2.80
    - Canesten (clotrimazole) (Bayer Plc)
      - Clotrimazole 10 mg per 1 gram Canesten 1% cream | 20 gram £2.14 DT price = £1.12 | 50 gram £3.50 DT price = £2.80
      - Canesten Antifungal 1% cream | 20 gram £1.85 DT price = £1.12
      - Canesten Dual Action 1% cream
    - Clotrimazole 20 mg per 1 gram Canesten 2% thrush cream | 10 gram £ no price available | 20 gram £4.46 DT price = £4.46
    - Clotrimazole 100 mg per 1 gram Canesten 10% VC cream | 5 gram £4.50 DT price = £6.23

- **Liquids**
  - Canesten (clotrimazole) (Bayer Plc)
    - Clotrimazole 10 mg per 1 ml Canesten 1% solution | 20 ml £2.30 DT price = £2.30

Combinations available: **Hydrocortisone with clotrimazole**, p. 1150

Econazole nitrate

- **INDICATIONS AND DOSE**
  - **Fungal skin infections**
    - **TO THE SKIN**
      - Child: Apply twice daily
      - Adult: Apply twice daily
  - **Fungal nail infections**
    - **BY TRANSUNGUAL APPLICATION**
      - Child: Apply once daily, applied under occlusive dressing
      - Adult: Apply once daily, applied under occlusive dressing
  - **Cautions** Avoid contact with eyes and mucous membranes
  - **SIDE-EFFECTS** Burning sensation · erythema · hypersensitivity reactions · itching · occasional local irritation

- **PREGNANCY** Minimal absorption from skin; not known to be harmful.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Cream**

- **EXCIPIENTS:** May contain Butylated hydroxyanisole, fragrances

  - Pevaryl (Janssen-Cilag Ltd)
    - Econazole nitrate 10 mg per 1 gram Pevaryl 1% cream | 30 gram £3.71

Ketoconazole

- **INDICATIONS AND DOSE**
  - **Tinea pedis**
    - **TO THE SKIN USING CREAM**
      - Adult: Apply twice daily
  - **Fungal skin infection (not Tinea pedis)**
    - **TO THE SKIN USING CREAM**
      - Adult: Apply 1–2 times a day
  - **Treatment of seborrhoeic dermatitis and dandruff**
    - **TO THE SKIN USING SHAMPOO**
      - Child 12–17 years: Apply twice weekly for 2–4 weeks, leave preparation on for 3–5 minutes before rinsing
      - Adult: Apply twice weekly for 2–4 weeks, leave preparation on for 3–5 minutes before rinsing
  - **Prophylaxis of seborrhoeic dermatitis and dandruff**
    - **TO THE SKIN USING SHAMPOO**
      - Child 12–17 years: Apply every 1–2 weeks, leave preparation on for 3–5 minutes before rinsing
      - Adult: Apply every 1–2 weeks, leave preparation on for 3–5 minutes before rinsing
  - **Treatment of pityriasis versicolor**
    - **TO THE SKIN USING SHAMPOO**
      - Child 12–17 years: Apply once daily for maximum 5 days, leave preparation on for 3–5 minutes before rinsing
      - Adult: Apply once daily for maximum 5 days, leave preparation on for 3–5 minutes before rinsing
  - **Prophylaxis of pityriasis versicolor**
    - **TO THE SKIN USING SHAMPOO**
      - Child 12–17 years: Apply once daily for up to 3 days before sun exposure, leave preparation on for 3–5 minutes before rinsing
      - Adult: Apply once daily for up to 3 days before sun exposure, leave preparation on for 3–5 minutes before rinsing

- **CAUTIONS** Avoid contact with eyes · avoid contact with mucous membranes
- **INTERACTIONS** → Appendix 1: antifungals, azoles
- **SIDE-EFFECTS** Erythema · hypersensitivity reactions · itching · mild burning sensation · occasional local irritation

SIDE-EFFECTS, FURTHER INFORMATION

Treatment should be discontinued if side-effects are severe.

- **CONCEPTION AND CONTRACEPTION** Effect on latex condoms and diaphragms not yet known.
- **NATIONAL FUNDING/ACCESS DECISIONS** Ketoconazole cream is not prescribable on the NHS except for seborrhoeic dermatitis and pityriasis versicolor and endorsed ‘SLS’.
- **EXCEPTIONS TO LEGAL CATEGORY**
  A 15-g tube is available for sale to the public for the treatment of tinea pedis, tinea cruris, and candidal intertrigo.
Miconazole

**INDICATIONS AND DOSE**

**Fungal skin infections**
- **TO THE SKIN**
  - Child: Apply twice daily continuing for 10 days after lesions have healed
  - Adult: Apply twice daily continuing for 10 days after lesions have healed

**Fungal nail infections**
- **TO THE SKIN**
  - Child: Apply 1–2 times a day
  - Adult: Apply 1–2 times a day

**SIDE-EFFECTS**
- Common or very common: Nausea, rash, vomiting
- Frequency not known: Burning sensation, erythema, hypersensitivity reactions, itching, occasional local irritation

**SIDE-EFFECTS, FURTHER INFORMATION**
Treatment should be discontinued if side effects are severe.

**PREGNANCY**
Manufacturer advises avoid.

**MEDICAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Cream**
- **EXCIPIENTS:** May contain Butylated hydroxyanisole
  - Daktarin (McNeil Products Ltd)
    - Miconazole nitrate 20 mg per 1 gram | Daktarin 2% cream | 15 gram £2.14 | 30 gram £1.82 DT price = £1.82
  - Daktarin (McNeil Products Ltd)
    - Miconazole nitrate 20 mg per 1 gram | Daktarin 2% powder | 20 gram £2.58 DT price = £2.58

**Shampoo**
- **EXCIPIENTS:** May contain Imidurea
  - Ketoconazole (Non-proprietary)
    - Ketoconazole 20 mg per 1 gram | 283 mg per 1 ml shampoo | 120 ml £2.77 DT price = £2.77
  - Dandraxol (Transdermal Ltd)
    - Ketoconazole 20 mg per 1 gram | Dandraxol 2% shampoo | 120 ml £5.20 DT price = £5.20
  - Nizoral (Janssen-Cilag Ltd, McNeil Products Ltd)
    - Ketoconazole 20 mg per 1 gram | Nizoral 2% shampoo | 120 ml £3.59 DT price = £3.77

**Antifungals > Other**

Amorolfin

**INDICATIONS AND DOSE**

**Fungal nail infections**
- **BY TRANSGUNGAL APPLICATION**
  - Child 12–17 years: Apply 1–2 times a week for 6 months to treat finger nails and for toe nails 9–12 months (review at intervals of 3 months), apply to infected nails after filing and cleansing, allow to dry for approximately 3 minutes
  - Adult: Apply 1–2 times a week for 6 months to treat finger nails and for toe nails 9–12 months (review at intervals of 3 months), apply to infected nails after filing and cleansing, allow to dry for approximately 3 minutes

**UNLICENSED USE**
Not licensed for use in children under 12 years.
**Infections of the skin**

**Side Effects**

- **Side Effects, Further Information**
  Treatment should be discontinued if side-effects are severe.

**Patient and Carer Advice**

- **Avoid nail varnish or artificial nails during treatment.**

**Exceptions to Legal Category**

- **In adults** Amorolfine nail lacquer can be sold to the public if supplied for the treatment of mild cases of distal and lateral subungual onychomycoses caused by dermatophytes, yeasts and moulds; subject to treatment of max. 2 nails, max. strength of nail lacquer amorolfine 5% and a pack size of 3 mL.

**Medicinal Forms**

- **There can be variation in the licensing of different medicines containing the same drug.**

**Medicated nail lacquer**

**INDICATIONS AND ADVISORY LABELS**

**Amorolfine (Non-proprietary)**

- Amorolfine (as Amorolfine hydrochloride) 50 mg per 1 ml
  - Medicated nail lacquer
  - **Amorolfine (as Amorolfine hydrochloride) 50 mg per 1 ml**
  - **Loceryl** (Galderma (UK) Ltd)
  - 5% medicated nail lacquer | 2.5 ml [POM] £7.26 | 5 ml [POM] £9.08 DT price = £6.99
  - **Omicur** (Morningside Healthcare Ltd)
  - 5% medicated nail lacquer | 2.5 ml [POM] £3.09 | 5 ml [POM] £9.09 DT price = £6.99

**TERBINAFINE**

**Indications and Dose**

**Tinea pedis**

- **TO THE SKIN USING CREAM**
  - Adult: Apply 1–2 times a day for up to 1 week, to be applied thinly
  - **BY MOUTH USING TABLETS**
  - Adult: 250 mg once daily for 2–6 weeks

**Tinea corporis**

- **TO THE SKIN USING CREAM**
  - Adult: Apply 1–2 times a day for up to 1–2 weeks, to be applied thinly, review treatment after 2 weeks
  - **BY MOUTH USING TABLETS**
  - Adult: 250 mg once daily for 4 weeks

**Tinea cruris**

- **TO THE SKIN USING CREAM**
  - Adult: Apply 1–2 times a day for up to 1–2 weeks, to be applied thinly, review treatment after 2 weeks
  - **BY MOUTH USING TABLETS**
  - Adult: 250 mg once daily for 2–4 weeks

**Dermatophyte infections of the nails**

- **BY MOUTH USING TABLETS**
  - Adult: 250 mg once daily for 6 weeks-3 months (occasionally longer in toenail infections)

**Cutaneous candidiasis / Pityriasis versicolor**

- **TO THE SKIN USING CREAM**
  - Adult: Apply 1–2 times a day for 2 weeks, to be applied thinly, review treatment after 2 weeks

**Caution**

- With oral use autoimmune disease (risk of lupus-erythematosus-like effect) • psoriasis (risk of exacerbation)

**Interactions**

- **Appendix 1: terbinafine**

**Side Effects**

- **Common or very common**
  - With oral use Abdominal discomfort • anorexia • arthralgia • diarrhoea • dyspepsia • headache • myalgia • nausea • rash • urticaria

- **Rare**
  - With oral use Taste disturbance

- **Very rare**
  - With oral use Alopecia • blood disorders • lupus erythematosus-like effect • neutropenia • photosensitivity • serious skin reactions • Stevens-Johnson syndrome • thrombocytopenia • toxic epidermal necrolysis

- **Frequency not known**
  - With oral use Disturbances in smell • exacerbation of psoriasis • hearing disturbances • influenza-like symptoms • pancreatitis • rhabdomyolysis • vasculitis

- **With topical use**
  - Erythema • hypersensitivity reactions • itching • mild burning sensation • occasional local irritation

**Medicinal Forms**

- **There can be variation in the licensing of different medicines containing the same drug.**

**Spray**

**INDICATIONS AND ADVISORY LABELS**

**EXCIPIENTS:** May contain Benzyl alcohol

- **Grisol AF** (Transdermal Ltd)
  - Griseofulvin 10 mg per 1 gram
  - **Grisol AF 1% spray** | 20 ml [P] £3.35

**Griseofulvin**

**Indications and Dose**

**Tinea pedis**

- **TO THE SKIN USING CREAM**
  - Adult: Apply 400 micrograms once daily, apply to an area approximately 13 cm²; increased if necessary to 1.2 mg once daily for maximum treatment duration of 4 weeks, allow each spray to dry between application

**Caution**

- Avoid contact with eyes and mucous membranes

**Interactions**

- **Appendix 1: griseofulvin**

**Side Effects**

- **Common or very common**
  - With oral use Application at margins of lesions • burning sensation systemically • erythema • flushing

- **Uncommon**
  - With oral use Alopecia • anaglyphia • auditory distractibility • dizziness • epistaxis • extrapyramidal disorders • gallbladder disorder • gingival hyperplasia • glaucoma • hair loss • headache • hypoglycaemia • hypokalaemia • hyporeflexia • hypothermia • hyperuricaemia • insomnia • hypothyroidism • impotence • itching • irritative effects • leucopenia • liver function disturbance • mouth ulcers • myalgia • myasthenia • nasal septum deviation on the affected side • tinnitus • urticaria • vasculitis

- **Very rare**
  - With oral use Alopecia • blood disorders • lupus erythematosus-like effect • neutropenia • photosensitivity • serious skin reactions • Stevens-Johnson syndrome • thrombocytopenia • toxic epidermal necrolysis

- **Frequency not known**
  - With oral use Disturbances in smell • exacerbation of psoriasis • hearing disturbances • influenza-like symptoms • pancreatitis • rhabdomyolysis • vasculitis

- **With topical use**
  - Erythema • hypersensitivity reactions • itching • mild burning sensation • occasional local irritation

**Medicinal Forms**

- **There can be variation in the licensing of different medicines containing the same drug.**

**Spray**

**INDICATIONS AND ADVISORY LABELS**

**EXCIPIENTS:** May contain Benzyl alcohol

- **Grisol AF** (Transdermal Ltd)
  - **Grisol AF 1% spray** | 20 ml [P] £3.35

**Terbinafine**

- **Indications and Dose**
  - **Tinea pedis**
    - Adult: Apply 1–2 times a day for up to 1 week, to be applied thinly
  - **By mouth using tablets**
    - Adult: 250 mg once daily for 2–6 weeks

**Tinea corporis**

- **To the skin using cream**
  - Adult: Apply 1–2 times a day for up to 1–2 weeks, to be applied thinly, review treatment after 2 weeks
  - **By mouth using tablets**
    - Adult: 250 mg once daily for 4 weeks

**Tinea cruris**

- **To the skin using cream**
  - Adult: Apply 1–2 times a day for up to 1–2 weeks, to be applied thinly, review treatment after 2 weeks
  - **By mouth using tablets**
    - Adult: 250 mg once daily for 2–4 weeks

**Dermatophyte infections of the nails**

- **By mouth using tablets**
  - Adult: 250 mg once daily for 6 weeks-3 months (occasionally longer in toenail infections)

**Cutaneous candidiasis / Pityriasis versicolor**

- **To the skin using cream**
  - Adult: Apply 1–2 times a day for 2 weeks, to be applied thinly, review treatment after 2 weeks
BENEFITS AND POTENTIAL HARM OF DEVICES

- **PREGNANCY**
  - With oral use: Manufacturer advises use only if potential benefit outweighs risk—animal studies suggest no adverse effects.
  - With topical use: Manufacturer advises use only if potential benefit outweighs risk—no information available.
  - With oral use: Manufacturer advises avoid—elimination reduced.

- **BREAST FEEDING**
  - With topical use: Manufacturer advises avoid—present in milk.
  - With oral use: Manufacturer advises avoid—present in milk.

- **HEPATIC IMPAIRMENT**
  - With oral use: Manufacturer advises avoid—elimination reduced.

- **RENAL IMPAIRMENT**
  - With oral use: Use half normal dose if eGFR less than 30 mL/minute/1.73 m² and no suitable alternative available.

- **MONITORING REQUIREMENTS**
  - With oral use: Monitor hepatic function before treatment and then every 4–6 weeks during treatment—discontinue if abnormalities in liver function tests.

- **EXCEPTIONS TO LEGAL CATEGORY**
  - With topical use: Preparations of terbinfine hydrochloride (maximum 1%) can be sold to the public for use in those over 16 years for external use for the treatment of tinea pedis as a cream in a pack containing maximum 15 g, or for the treatment of tinea pedis and cruris as a cream in a pack containing maximum 15 g, or for the treatment of tinea pedis, cruris, and corporis as a spray in a pack containing 30 mL spray or as a gel in a pack containing maximum 30 g gel.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  **Tablet**
  - **Terbinafine (Non-proprietary)**
    - Terbinafine hydrochloride 250 mg: 28 tablet [Dos] £34.93
    - Lamisil (Novartis Pharmaceuticals UK Ltd)
      - Terbinafine (as Terbinafine hydrochloride) 250 mg: 28 tablet [Dos] £41.09
  - **Cream**
    - EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), fragrances
    - Terbinafine hydrochloride 10 mg per 1 gram: 28 tablet [Dos] £1.29

- **ANTISEPTICS AND DISINFECTANTS**

  **UNDECENOATES**

  **Terbinafine (Non-proprietary)**
  - Terbinafine hydrochloride 10 mg per 1 gram: 28 tablet [Dos] £1.29

  **Mycota (zinc undecenoate / undecenoic acid)** (Thornton & Ross Ltd)
  - Undecenoic acid 50 mg per 1 gram: Mycota cream | 25 gram [Dos] £2.01
  -UNDENINDOZOCRZNDAO
  - **Terbinafine (as Terbinafine hydrochloride)** (Novartis Pharmaceuticals UK Ltd)
    - Terbinafine hydrochloride 250 mg: 28 tablet [Dos] £41.09

  **Chlorhexidine with nystatin**

  **Skin infections due to Candida spp.**

  **INDICATIONS AND DOSE**
  - TO THE SKIN
    - Child: Apply 2–3 times a day, continuing for 7 days after lesions have healed
    - Adult: Apply 2–3 times a day, continuing for 7 days after lesions have healed

  **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  **Cream**
  - EXCIPIENTS: May contain Benzyl alcohol, cetostearyl alcohol (including cetyl and stearyl alcohol), polyol, sorbites
    - Chlorhexidine with nystatin (Non-proprietary)
      - Chlorhexidine hydrochloride 10 mg per 1 gram, Nystatin 100 000 unit per 1 gram: Nystatin 100 000 units/g / Chlorhexidine hydrochloride 1% cream | 30 gram [Dos] £4.99 DT price = £2.62
    - Nystaform (Typharm Ltd)
      - Chlorhexidine hydrochloride 10 mg per 1 gram, Nystatin 100 000 unit per 1 gram: Nystaform cream | 30 gram [Dos] £2.62

  **Prevention of athletes foot**
  - TO THE SKIN
    - Child: Apply once daily
    - Adult: Apply once daily

  **UNLICENSED USE** Mycota® licensed for use in children (age range not specified by manufacturer).

  **SAFETY**
  - Avoid broken skin - contact with eyes should be avoided - contact with mucous membranes should be avoided.

  **SIDE-EFFECTS** Erythema - hypersensitivity reactions - itching - local irritation - mild burning sensation.

  **SIDE-EFFECTS, FURTHER INFORMATION**
  - Treatment should be discontinued if side effects are severe.

  **UNLICENSED USE** Licensed for use in children (age range not specified by manufacturer).

  **SAFETY**
  - Avoid contact with eyes and mucous membranes.

  **SIDE-EFFECTS** Burning sensation - erythema - hypersensitivity reactions - itching - occasional local irritation.

  **SIDE-EFFECTS, FURTHER INFORMATION**
  - Treatment should be discontinued if side effects are severe.
BENZOATES

Benzoic acid with salicylic acid

- **INDICATIONS AND DOSE**

  **Ringworm (tinea)**
  - **TO THE SKIN**
  - **Child:** Apply twice daily
  - **Adult:** Apply twice daily

- **UNLICENSED USE** Licensed for use in children (age range not specified by manufacturer).

- **CAUTIONS** Avoid broken or inflamed skin - avoid contact with eyes - avoid contact with mucous membranes

- **SIDE-EFFECTS** Erythema - hypersensitivity reactions - itching - mild burning sensation - occasional local irritation

- **PRESCRIBING AND DISPENSING INFORMATION**

  Benzoic Acid Ointment, BP has also been referred to as Whitfield's ointment.

SALICYLIC ACID AND DERIVATIVES

Boric acid with salicylic acid and tannic acid

- **INDICATIONS AND DOSE**

  **Fungal nail infection, particularly tinea**
  - **TO TRANUNGUAL APPLICATION**
  - **Child 5–17 years:** Apply twice daily, and after washing
  - **Adult:** Apply twice daily, and after washing

- **CAUTIONS** Avoid broken or inflamed skin - contact with eyes and mucous membranes should be avoided - use with caution in children likely to suck affected digits

- **SIDE-EFFECTS** Burning sensation - erythema - hypersensitivity reactions - itching - occasional local irritation

- **PREGNANCY** Avoid.

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: cream, ointment

PARASITICIDES

Benzy1 benzoate

- **INDICATIONS AND DOSE**

  **Scabies**
  - **TO THE SKIN**
  - **Adult:** Apply over the whole body; repeat without bathing on the following day and wash off 24 hours later; a third application may be required in some cases

  - **Adult:** Apply over the whole body; repeat without bathing on the following day and wash off 24 hours later; a third application may be required in some cases

  - **Child:** Apply once weekly for 2 doses, rub into dry hair and scalp, allow to dry naturally, shampoo after minimum 8 hours (or overnight)

  - **Child:** Apply once weekly for 2 doses, rub into dry hair and scalp, allow to dry naturally, shampoo after minimum 8 hours (or overnight)

- **UNLICENSED USE** Not licensed for use in children under 6 months except under medical supervision.

- **CAUTIONS** Avoid contact with eyes - children under 6 months, medical supervision required

- **SIDE-EFFECTS** Skin irritation

- **PATIENT AND CARER ADVICE** Patients should be told to keep hair away from fire and flames during treatment.

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug. Liquid

  - **Hedrin** (Thornton & Ross Ltd)
    - Dimeticone 40 mg per 1 gram
    - Hedrin 4% lotion | 50 ml | £3.06
    - DT price = £3.06 | 150 ml | £7.13
    - DT price = £7.13

  - **Lyclear (dimeticone)** (Omega Pharma Ltd)
    - Dimeticone 40 mg per 1 gram
    - Lyclear lotion | 100 ml no price available

Dimeticone

- **INDICATIONS AND DOSE**

  **Head lice**
  - **TO THE SKIN**
  - **Child:** Apply once weekly for 2 doses, rub into dry hair and scalp, allow to dry naturally, shampoo after minimum 8 hours (or overnight)

  - **Child:** Apply once weekly for 2 doses, rub into dry hair and scalp, allow to dry naturally, shampoo after minimum 8 hours (or overnight)

- **UNLICENSED USE** Not licensed for use in children under 6 months except under medical supervision.

- **CAUTIONS** Avoid contact with eyes - children under 6 months, medical supervision required

- **SIDE-EFFECTS** Skin irritation

- **PATIENT AND CARER ADVICE** Patients should be told to keep hair away from fire and flames during treatment.

- **MEDICINAL FORMS**

  There can be variation in the licensing of different medicines containing the same drug. Liquid

  - **Hedrin** (Thornton & Ross Ltd)
    - Dimeticone 40 mg per 1 gram
    - Hedrin 4% lotion | 50 ml | £3.06
    - DT price = £3.06 | 150 ml | £7.13
    - DT price = £7.13

  - **Lyclear (dimeticone)** (Omega Pharma Ltd)
    - Dimeticone 40 mg per 1 gram
    - Lyclear lotion | 100 ml no price available
**Malathion**

### INDICATIONS AND DOSE

**TO THE SKIN**

- **Child:** Apply once weekly for 2 doses, apply preparation over whole body, allow to dry naturally, toothbrush and comb to hair and allow to dry, wash off after 12 hours or after leaving on overnight.
- **Adult:** Apply once weekly for 2 doses, apply preparation over whole body, allow to dry naturally, toothbrush and comb to hair and allow to dry, wash off after 12 hours or after leaving on overnight.

### SIDE-EFFECTS

Chemical burns - hypersensitivity reactions - skin irritation

### PRESCRIBING AND DISPENSING INFORMATION

For scabies, manufacturer recommends application to the body but to exclude head and neck. However, application should be extended to the scalp, neck, face, and ears.

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Cream**

- **Permethrin (Non-proprietary)**
  - Permethrin 50 mg per 1 gram
  - £7.46 DT price = £7.46

- **Lyclear (Omega Pharma Ltd)**
  - Lyclear 5% cream
  - 30 g £5.71 DT price = £5.71

**Liquid**

- **Lyclear (Omega Pharma Ltd)**
  - Lyclear 1% creme rinse
  - 59 ml £3.55 DT price = £3.55
  - 118 ml £6.46 DT price = £6.46

### Malathion

- **INDICATIONS**
  - **Head lice**
    - **Child:** Apply once weekly for 2 doses, rub preparation into dry hair and scalp, allow to dry naturally, remove by washing after 12 hours.
    - **Adult:** Apply once weekly for 2 doses, rub preparation into dry hair and scalp, allow to dry naturally, remove by washing after 12 hours.

- **Crab lice**
  - **Child:** Apply once weekly for 2 doses, apply preparation over whole body, allow to dry naturally, wash off after 12 hours or overnight.
  - **Adult:** Apply once weekly for 2 doses, apply preparation over whole body, allow to dry naturally, wash off after 12 hours or overnight.

- **Scabies**
  - **Child:** Apply once weekly for 2 doses, apply preparation over whole body, wash off after 24 hours, if hands are washed with soap within 24 hours, they should be retreated.
  - **Adult:** Apply once weekly for 2 doses, apply preparation over whole body, wash off after 24 hours, if hands are washed with soap within 24 hours, they should be retreated.

- **SIDE-EFFECTS**
  - Chemical burns - hypersensitivity reactions - skin irritation

- **PRESCRIBING AND DISPENSING INFORMATION**
  - For scabies, manufacturer recommends application to the body but to exclude head and neck. However, application should be extended to the scalp, neck, face, and ears.
  - Larger patients may require up to two 30-g packs for adequate treatment.

- **LESS SUITABLE FOR PRESCRIBING**
  - Lyclear® Creme Rinse is less suitable for prescribing.

### UNLICENSED USE

- **Not licensed for use in children under 6 months except under medical supervision.**

### CAUTIONS

- **Alcoholic lotions not recommended for head lice in children with severe eczema or asthma, or for scabies or crab lice - avoid contact with eyes - children under 6 months, medical supervision required - do not use lotion more than once a week for 3 consecutive weeks - do not use on broken or secondarily infected skin.**

### EXCIPIENTS:

- **May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), fragrances, hydroxybenzoates (parabens)**

**Permethrin**

### INDICATIONS AND DOSE

**Scabies**

- **Child:** Apply once weekly for 2 doses, apply preparation over whole body including face, neck, scalp and ears then wash off after 8–12 hours. If hands are washed with soap within 8 hours of application, they should be treated again with cream.

**Crab lice**

- **Child:** Apply once weekly for 2 doses, apply 5% preparation over whole body including face, neck, scalp and ears then wash off after 8–12 hours. If hands are washed with soap within 8 hours of application, they should be treated again with cream.

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

**Cream**

- **Permethrin (Non-proprietary)**
  - Permethrin 50 mg per 1 gram
  - £7.46 DT price = £7.46

- **Lyclear (Omega Pharma Ltd)**
  - Lyclear 5% cream
  - 30 gram £5.71 DT price = £5.71

**Liquid**

- **Lyclear (Omega Pharma Ltd)**
  - Lyclear 1% creme rinse
  - 59 ml £3.55 DT price = £3.55
  - 118 ml £6.46 DT price = £6.46

### Antivirals > Nucleoside Analogues

**Aciclovir** *(Acyclovir)*

### INDICATIONS AND DOSE

**Herpes simplex infection (local treatment)**

- **Child:** Apply 5 times a day for 5–10 days, to be applied to lesions approximately every 4 hours, starting at first sign of attack.
Skin INTERACTIONS

Eczema (dermatitis) has several causes, which may in

Eczema and psoriasis

Drying of the skin • erythema • itching of the skin • transient burning • transient stinging

PREGNANCY

Limited absorption from topical aciclovir preparations.

PA TIENT AND CARER ADVICE

Medicines for Children leaflet: Aciclovir cream for herpes

www.medicinesforchildren.org.uk/aciclovir-cream-for-herpes

EXCIPIENTS:

Cream

▶ Medicines for Children leaflet: Aciclovir cream for herpes

DT price = £ 0.50

Aciclovir 50 mg per 1 gram

£ 0.63

Zovirax (GlaxoSmithKline Consumer Healthcare, GlaxoSmithKline UK Ltd)

Aciclovir 50 mg per 1 gram

£ 1.10

10 gram

£ 13.96 DT price = £ 5.50

3.1 Eczema and psoriasis

Eczema

Types and management

Eczema (dermatitis) has several causes, which may influence treatment. The main types of eczema are irritant, allergic contact, atopic, venous and discoid; different types may coexist. Lichenification, due to scratching and rubbing, may complicate any chronic eczema. Atopic eczema is the most common type and it usually involves dry skin as well as infection and lichenification.

Management of eczema involves the removal or treatment of contributory factors including occupational and domestic irritants. Known or suspected contact allergens should be avoided. Rarely, ingredients in topical medicinal products may sensitise the skin; the BNF lists active ingredients together with excipients that have been associated with skin sensitisation.

Skin dryness and the consequent irritant eczema requires emollients applied regularly (at least twice daily) and liberally to the affected area; this can be supplemented with bath or shower emollients. The use of emollients should continue even if the eczema improves or if other treatment is being used.

Topical corticosteroids are also required in the management of eczema; the potency of the corticosteroid should be appropriate to the severity and site of the condition. Mild corticosteroids are generally used on the face and on flexures; potent corticosteroids are generally required for use on adults with discoid or lichenified eczema or with eczema on the scalp, limbs, and trunk. Treatment should be reviewed regularly, especially if a potent corticosteroid is required. In patients with frequent flares (2–3 per month), a topical corticosteroid can be applied on 2 consecutive days each week to prevent further flares.

Bandages (including those containing ichthammol with zinc oxide p. 1151) are sometimes applied over topical corticosteroids or emollients to treat eczema of the limbs. Dry-wrap dressings can be used to provide a physical barrier to help prevent scratching and improve retention of emollients. See Wound management products and elasticated garments for details of elasticated viscose stockinette tubular bandages and garments, and silk clothing.


Infection

Bacterial infection (commonly with Staphylococcus aureus and occasionally with Streptococcus pyogenes) can exacerbate eczema and requires treatment with topical or systemic antibacterial drugs. Antibacterial drugs should be used in short courses (typically 1 week) to reduce the risk of drug resistance or skin sensitisation. Associated eczema is treated simultaneously with a topical corticosteroid which can be combined with a topical antimicrobial.

Eczema involving widespread or recurrent infection requires the use of a systemic antimicrobial that is active against the infecting organism. Products that combine an antiseptic with an emollient application and with a bath emollient can also be used; antiseptic shampoos can be used on the scalp.

Intertriginous eczema commonly involves candida and bacteria; it is best treated with a mild or moderately potent topical corticosteroid and a suitable antimicrobial drug.

Widespread herpes simplex infection may complicate atopic eczema and treatment with a systemic antiviral drug is indicated.

Management of other features of eczema

Lichenification, which results from repeated scratching is treated initially with a potent corticosteroid. Bandages containing ichthammol paste p. 1151 (to reduce pruritus) and other substances such as zinc oxide can be applied over the corticosteroid or emollient. Coal tar and ichthammol can be useful in some cases of chronic eczema. A non-sedating antihistamine may be of some value in relieving severe itching or urticaria associated with eczema. A sedating antihistamine can be used if itching causes sleep disturbance.

Exudative (‘weeping’) eczema requires a potent corticosteroid initially; infection may also be present and require specific treatment. Potassium permanganate solution (1 in 10,000) p. 1172 can be used in exudating eczema for its antiseptic and astringent effects; treatment should be stopped when exudation stops.

Severe refractory eczema

Severe refractory eczema is best managed under specialist supervision; it may require phototherapy or drugs that act on the immune system; Alitretinoin p. 1157 is licensed for the treatment of severe chronic hand eczema refractory to potent topical corticosteroids; patients with hyperkeratotic features are more likely to respond to altretinoin than those with pompholyx.

Seborrhoeic dermatitis

Seborrhoeic dermatitis (seborrhoeic eczema) is associated with species of the yeast Malassezia and affects the scalp, paranasal areas, and eyebrows. Shampoos active against the yeast (including those containing ketoconazole p. 1130 and
Eczema and psoriasis, drugs affecting the immune response

Overview

Drugs affecting the immune response are used for eczema or psoriasis. Systemic drugs acting on the immune system are used under specialist supervision.

Pimecrolimus p. 1154 by topical application is licensed for mild to moderate atopic eczema. Tacrolimus p. 1155 is licensed for topical use in moderate to severe atopic eczema. Both are drugs whose long-term safety is still being evaluated and they should not usually be considered first-line treatments unless there is a specific reason to avoid or reduce the use of topical corticosteroids. Treatment of atopic eczema with topical pimecrolimus or topical tacrolimus should be initiated only by prescribers experienced in managing the condition. Topical tacrolimus and pimecrolimus have a role in the treatment of psoriasis.

A short course of a systemic corticosteroid can be given for eczema flares that have not improved despite appropriate topical treatment.

Ciclosporin p. 788 by mouth can be used for severe psoriasis and for severe eczema. Azathioprine p. 787 or mycophenolate mofetil p. 796 are used for severe refractory eczema [unlicensed indication].

Methotrexate p. 844 can be used for severe psoriasis, the dose being adjusted according to severity of the condition and haematological and biochemical measurements. Folic acid p. 937 should be given to reduce the possibility of side-effects associated with methotrexate. Folic acid can be given once weekly [unlicensed indication], on a different day from the methotrexate; alternative regimens of folic acid may be used in some settings.

Etanercept p. 1012, adalimumab p. 1008, and infliximab p. 1016 inhibit the activity of tumour necrosis factor (TNFs).

They are used for severe plaque psoriasis either refractory to at least 2 standard systemic treatments and phototherapy, or when standard treatments cannot be used because of intolerance or contra-indications; while either etanercept or adalimumab is considered to be the first choice in stable disease, infliximab or adalimumab may be useful when rapid disease control is required. Secukinumab p. 1004 and ixekizumab p. 1155 inhibit the activity of interleukin-17A. They are used for moderate to severe plaque psoriasis in patients who are candidates for systemic therapy.

Secukinumab is also licensed for psoriatic arthritis and ankylosing spondylitis. Ustekinumab p. 1006 (a monoclonal antibody that inhibits interleukins 12 and 23) can be used for severe plaque psoriasis that has not responded to at least 2 standard systemic treatments and phototherapy, or when these treatments cannot be used because of intolerance or contra-indications. Adalimumab is also licensed for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in patients who have had inadequate response to conventional systemic therapy. Adalimumab, etanercept, infliximab and ustekinumab are also licensed for psoriatic arthritis.

Psoriasis

Management

Psoriasis is characterised by epidermal thickening and scaling. It commonly affects extensor surfaces and the scalp.

Occasionally, psoriasis is provoked or exacerbated by drugs such as lithium, chloroquine and hydroxychloroquine, beta-blockers, non-steroidal anti-inflammatory drugs, and ACE inhibitors. Psoriasis may not be seen until the drug has been taken for weeks or months.

Emollients, in addition to their effects on dryness, scaling and cracking, may have an anti-proliferative effect in psoriasis, and may be the only treatment necessary for mild psoriasis. They are particularly useful in inflammatory psoriasis and in plaque psoriasis of palms and soles, in which irritant factors can perpetuate the condition. Emollients are useful adjuncts to other more specific treatment.

More specific topical treatment for chronic stable plaque psoriasis on extensor surfaces of trunk and limbs involves the use of vitamin D analogues, coal tar p. 1152, dithranol p. 1151, and the retinoid tazarotene p. 1158. However, they can irritate the skin and they are not suitable for the more inflammatory forms of psoriasis; their use should be suspended during an inflammatory phase of psoriasis. The efficacy and the irritancy of each substance varies between patients. If a substance irritates significantly, it should be stopped or the concentration reduced; if it is tolerated, its effects should be assessed after 4 to 6 weeks and treatment continued if it is effective.

Scalp psoriasis is usually scaly, and the scale may be thick and adherent; this will require softening with an emollient cream, ointment, or oil. A tar-based shampoo is first-line treatment for scalp psoriasis; a keratolytic, such as salicylic acid, should also be used if there is significant scaling, to allow other treatments to work.

Some preparations prescribed for psoriasis affecting the scalp, combine salicylic acid with coal tar or sulfur. The product should be applied generously, and an adequate quantity should be prescribed. It should be left on for at least an hour, often more conveniently overnight, before washing off. The use of scalp preparations containing a potent corticosteroid or a vitamin D analogue, either alone or in combination, can also be helpful.

Facial, flexural and genital psoriasis can be managed with short-term use of a mild or moderate potency topical corticosteroid (a mild potency topical corticosteroid is preferred for the initial treatment of facial psoriasis). Calcipotriol p. 1159 or tacalcitol p. 1159 can be used for longer-term treatment, or if the response to mild or moderate potency topical corticosteroids is inadequate; calcipotriol p. 1158 may be more likely to cause irritation. Low strength tar preparations can also be used. Pimecrolimus p. 1154 or tacrolimus p. 1155 by topical application [unlicensed indication] can be used short-term, under specialist supervision, in patients whose condition has not responded adequately to other treatments, or who are intolerant of them.

Widespread unstable psoriasis of erythrodernia or generalised pustular type requires urgent specialist assessment. Initial topical treatment should be limited to using emollients frequently and generously; emollients should be prescribed in quantities of 1 kg or more. More localised acute or subacute inflammatory psoriasis with hot, spreading or itchy lesions, should be treated topically with emollients or with a corticosteroid of moderate potency.

Calcipotriol and tacalcitol are analogues of vitamin D that affect cell division and differentiation. Calcipotriol is an active form of vitamin D. Vitamin D and its analogues are used first-line for the long-term treatment of plaque psoriasis; they do not smell or stain and they may be more acceptable than tar or dithranol products. Of the vitamin D analogues, tacalcitol and calcipotriol are less likely to irritate.

Coal tar has anti-inflammatory properties that are useful in chronic plaque psoriasis; it also has antiscaling properties. Crude coal tar (coal tar, BP) is the most effective form, typically in a concentration of 1 to 10% in a soft paraffin base, but few outpatients tolerate the smell and mess. Cleaner extracts of coal tar included in proprietary preparations, are more practicable for home use but they are
less effective and improvement takes longer. Contact of coal tar products with normal skin is not normally harmful and they can be used for widespread small lesions; however, irritation, contact allergy, and sterile folliculitis can occur. The milder tar extracts can be used on the face and flexures. Tar baths and tar shampoos are also helpful.

Dithranol is effective for chronic plaque psoriasis. Its major disadvantages are irritation (for which individual susceptibility varies) and staining of skin and of clothing. Dithranol is not generally suitable for widespread small lesions nor should it be used in the flexures or on the face. Proprietary preparations are more suitable for home use; they are usually washed off after 5 to 60 minutes (‘short contact’). Specialist nurses may apply intensive treatment with dithranol paste which is covered by stockinette dressings and usually retained overnight. Dithranol should be discontinued if even a low concentration causes acute inflammation; continued use can result in the psoriasis becoming unstable.

Tazarotene, a retinoid, has a similar efficacy to vitamin D and its analogues, but is associated with a greater incidence of irritation. Although irritation is common, it is minimised by applying sparingly to the plaques and avoiding normal skin; application to the face and in flexures should also be avoided. Tazarotene does not stain and is odourless.

A topical corticosteroid is not generally suitable for long-term use or as the sole treatment of extensive chronic plaque psoriasis; any early improvement is not usually maintained and there is a risk of the condition deteriorating or of precipitating an unstable form of psoriasis (e.g. erythrodermic psoriasis or generalised pustular psoriasis) on withdrawal. Topical use of potent corticosteroids on widespread psoriasis can also lead to systemic as well as local side-effects. However, topical corticosteroids used short-term may be appropriate to treat psoriasis in specific sites such as the face or flexures (with a mild or moderate corticosteroid), and psoriasis of the scalp, palms, and soles (with a potent corticosteroid). Very potent corticosteroids should only be used under specialist supervision.

Combining the use of a corticosteroid with another specific topical treatment may be beneficial in chronic plaque psoriasis; the drugs may be used separately at different times of the day or used together in a single formulation. Eczema co-existing with psoriasis may be treated with a corticosteroid, or coal tar, or both.

**Phototherapy**

Phototherapy is available in specialist centres under the supervision of a dermatologist. Ultraviolet B (UVB) radiation is usually effective for chronic stable psoriasis and for guttate psoriasis. It may be considered for patients with moderately severe psoriasis in whom topical treatment has failed, but it may irritate inflammatory psoriasis.

Photochemotherapy combining long-wave ultraviolet A radiation with a psoralen (PUVA) is available in specialist centres under the supervision of a dermatologist. The psoralen, which enhances the effect of irradiation, is administered either by mouth or topically. PUVA is effective in most forms of psoriasis, including localised palmar plantar pustular psoriasis. Early adverse effects include phototoxicity and pruritus. Higher cumulative doses exaggerate skin ageing, increase the risk of dysplastic and neoplastic skin lesions, especially squamous cancer, and pose a theoretical risk of cataracts.

Phototherapy combined with coal tar, dithranol, tazarotene, topical vitamin D or vitamin D analogues, or oral acitretin, allows reduction of the cumulative dose of phototherapy required to treat psoriasis.

**Systemic treatment**

Systemic treatment is required for severe, resistant, unstable or complicated forms of psoriasis, and it should be initiated only under specialist supervision. Systemic drugs for psoriasis include acitretin and drugs that affect the immune response (such as ciclosporin p. 788 and methotrexate p. 844).

Systemic corticosteroids should be used only rarely in psoriasis because rebound deterioration may occur on reducing the dose.

Acitretin p. 1156, a metabolite of etretinate, is a retinoid (vitamin A derivative); it is prescribed by specialists. The main indication for acitretin is psoriasis, but it is also used in disorders of keratinisation such as severe Darier’s disease (keratosis follicularis), and some forms of ichthyosis.

Although a minority of cases of psoriasis respond well to acitretin alone, it is only moderately effective in many cases and it is combined with other treatments. A therapeutic effect occurs after 2 to 4 weeks and the maximum benefit after 4 months. Consideration should be given to stopping acitretin if the response is inadequate after 4 months at the optimum dose. The manufacturers of acitretin do not recommend continuous treatment for longer than 6 months. However, some patients may benefit from longer treatment, provided that the lowest effective dose is used, patients are monitored carefully for adverse effects, and the need for treatment is reviewed regularly.

Apart from teratogenicity, which remains a risk for 3 years after stopping, acitretin is the least toxic systemic treatment for psoriasis; in women with a potential for child-bearing, the possibility of pregnancy must be excluded before treatment and effective contraception must be used during treatment and for at least 3 years afterwards (oral progestogen-only contraceptives not considered effective).

**Topical treatment**

The vitamin D and analogues, calcipotriol p. 1158, calcitriol p. 1159, and tacalcitol p. 1159 are used for the management of plaque psoriasis. They should be avoided by those with calcium metabolism disorders, and used with caution in generalised pustular or erythrodermic exfoliative psoriasis (enhanced risk of hypercalcaemia).
Potent corticosteroids should generally be avoided on the face and skin flexures, but specialists occasionally prescribe them for use on these areas in certain circumstances. When topical treatment has failed, intralvesional corticosteroid injections may be used. These are more effective than the very potent topical corticosteroid preparations and should be reserved for severe cases where there are localised lesions such as keloid scars, hypertrophic lichen planus, or localised alopecia areata.

Perioral lesions
Hydrocortisone cream 1% p. 1145 can be used for up to 7 days to treat uninfected inflammatory lesions on the lips. Hydrocortisone with miconazole cream or ointment p. 1150 is useful where infection by susceptible organisms and inflammation co-exist, particularly for initial treatment (up to 7 days) e.g. in angular cheilitis. Organisms susceptible to miconazole include Candida spp. and many Gram-positive bacteria including streptococci and staphylococci.

Choice of formulation
Water-miscible corticosteroid creams are suitable for moist or weeping lesions whereas ointments are generally chosen for dry, lichenified or scaly lesions or where a more occlusive effect is required. Lotions may be useful when minimal application to a large or hair-bearing area is required or for the treatment of exudative lesions. Occlusive polythene or hydrocolloid dressings increase absorption, but also increase the risk of side effects; they are therefore used only under supervision on a short-term basis for areas of very thick skin (such as the palms and soles). The inclusion of urea or salicylic acid also increases the penetration of the corticosteroid.

In the BNF publications topical corticosteroids for the skin are categorised as ‘mild’, ‘moderately potent’, ‘potent’ or ‘very potent’; the least potent preparation which is effective should be chosen but dilution should be avoided whenever possible.

Absorption through the skin
Mild and moderately potent topical corticosteroids are associated with few side-effects but care is required in the use of potent and very potent corticosteroids. Absorption through the skin can rarely cause adrenal suppression and even Cushting’s syndrome, depending on the area of the body being treated and the duration of treatment. Absorption is greatest where the skin is thin or raw, and from intertriginous areas; it is increased by occlusion.

### Suitable quantities of corticosteroid preparations to be prescribed for specific areas of the body

<table>
<thead>
<tr>
<th>Area of body</th>
<th>Creams and Ointments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Face and neck</td>
<td>15 to 30 g</td>
</tr>
<tr>
<td>Both hands</td>
<td>15 to 30 g</td>
</tr>
<tr>
<td>Scalp</td>
<td>15 to 30 g</td>
</tr>
<tr>
<td>Both arms</td>
<td>30 to 60 g</td>
</tr>
<tr>
<td>Both legs</td>
<td>100 g</td>
</tr>
<tr>
<td>Trunk</td>
<td>100 g</td>
</tr>
<tr>
<td>Groins and genitalia</td>
<td>15 to 30 g</td>
</tr>
</tbody>
</table>

These amounts are usually suitable for an adult for a single daily application for 2 weeks

### Compound preparations
The advantages of including other substances (such as antibacterials or antifungals) with corticosteroids in topical preparations are uncertain, but such combinations may have a place where inflammatory skin conditions are associated with bacterial or fungal infection, such as infected eczema. In these cases the antimicrobial drug should be chosen according to the sensitivity of the infecting organism and used regularly for a short period (typically twice daily for 1 week). Longer use increases the likelihood of resistance and of sensitisation.

The keratolytic effect of salicylic acid p. 1182 facilitates the absorption of topical corticosteroids; however, excessive and prolonged use of topical preparations containing salicylic acid may cause salicylism.

**Topical corticosteroid preparation potencies**

Potency of a topical corticosteroid preparation is a result of the formulation as well as the corticosteroid. Therefore, proprietary names are shown.

**Mild**
- Hydrocortisone 0.1–2.5%
- Dioderm
- Mildison
- Synalar 1 in 10 dilution

**Mild with antimicrobials**
- Canesten HC
- Daktapect
- Econacort
- Fucidin H
- Nystaform–HC
- Terra-Cortril
- Timodine

**Moderate**
- Betnovate–RD
- Eumovate
- Haelan
- Modrasone
- Synalar 1 in 4 Dilution
- Ultralanum Plain

**Moderate with antimicrobials**
- Trimovate

**Moderate with urea:**
- Alphaderm

**Potent**
- Beclometasone dipropionate 0.025%
- Betamethasone valerate 0.1%
- Betacap
- Betesil
- Bettamousse
- Betnovate
- Cutivate
- Diprosonene
- Elocon
- Hydrocortisone butyrate
- Locoid
- Locoid Crelo
- Metosyn
- Mometasone furoate 0.1%
- Nerisone
- Synalar

**Potent with antimicrobials**
- Aureocort
- Betamethasone and cloquinol
- Betamethasone and neomycin
- Fucibet
- Lotriderm
- Synalar C
- Synalar N

**Potent with salicylic acid**
- Diprosalic

**Very potent**
- Clarelux
- Dermovate
- Etrivex
- Nerisone Forte
Skin Clobetasol with neomycin. CAUTION S A potent corticosteroid may be appropriate for severe atopic dermatitis. Frequency not known as possible; inadequate treatment will perpetuate the condition. The aim is to control the condition as well as possible; the worst areas should be treated. The aim is to control the condition as well as possible; inadequate treatment will perpetuate the condition. A mild corticosteroid such as hydrocortisone 0.5% or 1% is useful for treating nappy rash and hydrocortisone 1% for atopic eczema in childhood. A moderately potent or potent corticosteroid may be appropriate for severe atopic eczema on the limbs, for 1–2 weeks only, switching to a less potent preparation as the condition improves. In an acute flare-up of atopic eczema, it may be appropriate to use more potent formulations of topical corticosteroids for a short period to regain control of the condition. A very potent corticosteroid should be initiated under the supervision of a specialist. Carers of young children should be advised that treatment should not necessarily be reserved to ‘treat only the worst areas’ and they may need to be advised that patient information leaflets may contain inappropriate advice for the patient’s condition.

Corticosteroids (topical)

INTERNATIONAL nonproprietary names (INNs) Beclometasone dipropionate cream and ointment. INN Beclometasone dipropionate is used as a cream or ointment. If a patient is using topical corticosteroids containing the INN beclometasone dipropionate cream. Use of topical corticosteroids should be initiated under the supervision of a specialist. Treatment should be limited to the affected areas. Once a day, to be applied thinly on the skin should be avoided where possible; several minutes should elapse between application of different preparations.

In children ‘Wet-wrap bandaging’ increases absorption into the skin, but should be initiated only by a dermatologist and application supervised by a healthcare professional trained in the technique.

PRESCRIBING AND DISPENSING INFORMATION The potency of each topical corticosteroid should be included on the label with the directions for use. The label should be attached to the container (for example, the tube) rather than the outer packaging.

PATIENT AND CARER ADVICE Patients or carers should be given advice on how to administer corticosteroid creams and ointments. If a patient is using topical corticosteroids of different potencies, the patient should be told when to use each corticosteroid. Patients and their carers should be reassured that side effects such as skin thinning and systemic effects rarely occur when topical corticosteroids are used appropriately.

Alclometasone dipropionate

INDICATIONS AND DOSE Inflammatory skin disorders such as eczemas TO THE SKIN Child: Apply 1–2 times a day, to be applied thinly Adult: Apply 1–2 times a day, to be applied thinly POTENCY Alclometasone dipropionate cream 0.05%: moderate UNLICENSED USE Licensed for use in children (age range not specified by manufacturer).

PATIENT AND CARER ADVICE Patients or carers should be counselled on the application of alclometasone dipropionate cream.

MEDICINAL FORMS There can be variation in the licensing of different medicines containing the same drug.

Cream CAUTIONARY AND ADVISORY LABELS 28 EXCIPIENTS: May contain Cetostearyl alcohol (including cetaryl alcohol), cholesterol, propylene glycol Alclometasone dipropionate (Non-proprietary) Alclometasone dipropionate 500 microgram per 1 gram Boots Dermar Care Eczema & Dermatitis Flare-Up 0.05% cream 15 gram p no price available

Beclometasone dipropionate (Beclohexasone dipropionate)

INDICATIONS AND DOSE Severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids | Psoriasis TO THE SKIN Child: Apply 1–2 times a day, thin layer to be applied Adult: Apply 1–2 times a day, thin layer to be applied POTENCY Beclometasone dipropionate cream and ointment 0.025%: potent.

UNLICENSED USE Not licensed for use in children under 1 year.

INTERACTIONS Appendix 1: corticosteroids

Very potent with antimicrobials
- Clobetasol with neomycin and nystatin

Use in children
Children, especially infants, are particularly susceptible to side-effects. However, concern about the safety of topical corticosteroids in children should not result in the child being undertreated. The aim is to control the condition as well as possible; inadequate treatment will perpetuate the condition. A mild corticosteroid such as hydrocortisone 0.5% or 1% is useful for treating nappy rash and hydrocortisone 1% for atopic eczema in childhood. A moderately potent or potent corticosteroid may be appropriate for severe atopic eczema on the limbs, for 1–2 weeks only, switching to a less potent preparation as the condition improves. In an acute flare-up of atopic eczema, it may be appropriate to use more potent formulations of topical corticosteroids for a short period to regain control of the condition. A very potent corticosteroid should be initiated under the supervision of a specialist. Carers of young children should be advised that treatment should not necessarily be reserved to ‘treat only the worst areas’ and they may need to be advised that patient information leaflets may contain inappropriate advice for the patient’s condition.
Betamethasone is not licensed for use in children under 6 years.

**CAUTIONS** Use of more than 10 g per week of 0.1% preparation likely to cause adrenal suppression

**INTERACTIONS** → Appendix 1: corticosteroids

**PATIENT AND CARER ADVICE** Patient counselling is advised for betamethasone cream, ointment, scalp application and foam (application).

**MEDICINAL FORMS**

<table>
<thead>
<tr>
<th>Medicinal Form</th>
<th>Potency</th>
<th>Dose</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Betamethasone (as Betamethasone valerate) 1 mg per 1 gram</td>
<td>Betnovate 0.1% cream</td>
<td>30 gram</td>
<td>£1.43 DT price = £2.67</td>
</tr>
<tr>
<td>Betamethasone (as Betamethasone valerate) 1 mg per 1 gram</td>
<td>Diprosone (Merck Sharp &amp; Dohme Ltd)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Betamethasone (as Betamethasone dipropionate) 1 mg per 1 gram</td>
<td>Audavate (Auden McKenzie (Pharma Division) Ltd)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Betamethasone (as Betamethasone valerate) 1 mg per 1 gram</td>
<td>Audavate RD 0.025% ointment</td>
<td>100 gram</td>
<td>£3.00</td>
</tr>
<tr>
<td>Betamethasone (as Betamethasone dipropionate) 1 mg per 1 gram</td>
<td>Diprosone (Merck Sharp &amp; Dohme Ltd)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Calcipotriol with betamethasone

30-May-2017

The properties listed below are those particular to the combination only. For the properties of the components please consider, calcipotriol p. 1158, betamethasone above.

**INDICATIONS AND DOSE**

**DOVOBET® GEL**

**Scalp psoriasis**

**TO THE SKIN**

**Adults**: Apply 1–4 g once daily usual duration of therapy 4 weeks; if necessary, treatment may be continued beyond 4 weeks or repeated, on the advice of a specialist, shampoo off after leaving on scalp overnight or during day, when different preparations containing calcipotriol used together, maximum total calcipotriol 5 mg in any one week continued →
Mild to moderate plaque psoriasis

 Mell to moderate plaque psoriasis

▶ TO THE SKIN
▶ Adult: Apply once daily for 4 weeks; if necessary, treatment may be continued beyond 8 weeks or repeated, on the advice of a specialist, apply to a maximum of 30% of body surface, when different preparations containing calcipotriol used together, maximum 10% calcipotriol 5 mg in any one week; maximum 15 g per day

DOVOBET® OINTMENT

Stable plaque psoriasis
▶ TO THE SKIN
▶ Adult: Apply once daily for 4 weeks; if necessary, treatment may be continued beyond 4 weeks or repeated, on the advice of a specialist, apply to a maximum 30% of body surface, when different preparations containing calcipotriol used together, maximum 10% calcipotriol 5 mg in any one week; maximum 15 g per day

ENSTILAR®

Psoriasis
▶ TO THE SKIN
▶ Adult: Apply once daily to be applied to the affected area for up to 4 weeks—consult product literature for further information; maximum 15 g per day

CONTRA-INDICATIONS

ENSTILAR® Erythrodermic psoriasis - pustular psoriasis

NATIONAL FUNDING/ACCESS DECISIONS

ENSTILAR®

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium (SMC) has advised (September 2016) that calcipotriol with betamethasone (Enstilar®) is accepted for use within NHS Scotland for the treatment of psoriasis vulgaris.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Ointment

CAUTIONARY AND ADVISORY LABELS 28

EXCIPIENTS: May contain Butylated hydroxytoluene

Dovobet (LEO Pharma)
Calcipotriol (as Calcipotriol hydrate) 50 microgram per 1 gram, Betamethasone (as Betamethasone dipropionate) 500 microgram per 1 gram Dovobet ointment 30 gram POM £19.84 DT price = £19.84 | 60 gram POM £39.68 | 120 gram POM £73.86

Foam

Enstilar (LEO Pharma)
Calcipotriol (as Calcipotriol monohydrate) 50 microgram per 1 gram, Betamethasone (as Betamethasone dipropionate) 500 microgram per 1 gram Enstilar 50 micrograms/g | 0.5 mg/g cutaneous foam 60 gram POM £39.68 DT price = £39.68

Gel

CAUTIONARY AND ADVISORY LABELS 28

EXCIPIENTS: May contain Butylated hydroxytoluene

Dovobet (LEO Pharma)
Calcipotriol (as Calcipotriol monohydrate) 50 microgram per 1 gram, Betamethasone (as Betamethasone dipropionate) 500 microgram per 1 gram Dovobet gel Applicator 60 gram POM £37.21 DT price = £37.21

Dovobet gel 60 gram POM £37.21 DT price = £37.21 | 120 gram POM £60.11

Clobetasol propionate

INDICATIONS AND DOSE

Short-term treatment only of severe resistant inflammatory skin disorders such as recalcitrant eczemas unresponsive to less potent corticosteroids

Psoriasis
▶ TO THE SKIN
▶ Child: Apply 1–2 times a day for up to 4 weeks, to be applied thinly
▶ Adult: Apply 1–2 times a day for up to 4 weeks, to be applied thinly, maximum 50 g of 0.05% preparation per week

ETRIVEX®

Moderate scalp psoriasis
▶ TO THE SKIN
▶ Adult: Apply once daily maximum duration of treatment 4 weeks, to be applied thinly then rinsed off after 15 minutes; frequency of application should be reduced after clinical improvement

POTENCY

Clobetasol propionate 0.05% cream, foam, ointment, scalp application, and shampoo: very potent.

UNLICENSED USE Dermovate® not licensed for use in children under 1 year.

PATIENT AND CARER ADVICE

Patients or carers should be given advice on how to administer clobetasol propionate foam, liquid (scalp application), cream, ointment and shampoo.

Scalp application Patients or carers should be advised to apply foam directly to scalp lesions (foam begins to subside immediately on contact with skin).

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: cream, ointment, paste

Foam

CAUTIONARY AND ADVISORY LABELS 15, 28

EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), chlorocresol, propylene glycol

Clarelux (Pierre Fabre Dermo-Cosmetique)
Clobetasol propionate 500 microgram per 1 gram Clarelux 500 micrograms/g foam 100 gram POM £11.06

Shampoo

CAUTIONARY AND ADVISORY LABELS 28

EXCIPIENTS: May contain Beeswax, cetostearyl alcohol (including cetyl and stearyl alcohol), chlororesol, propylene glycol

Clarelax (Galderma (UK) Ltd)
Clobetasol propionate 500 microgram per 1 gram Clarelax 500 micrograms/g shampoo 125 ml POM £9.15 DT price = £9.15

Cream

CAUTIONARY AND ADVISORY LABELS 28

EXCIPIENTS: May contain Beeswax, cetostearyl alcohol (including cetyl and stearyl alcohol), chlororesol, propylene glycol

Clarelax (Galderma (UK) Ltd)
Clobetasol propionate 500 microgram per 1 gram Clarelax 500 micrograms/g cream 50 g POM £12.75 DT price = £12.75

Ointment

CAUTIONARY AND ADVISORY LABELS 28

EXCIPIENTS: May contain Propylene glycol

Clarelax (Galderma (UK) Ltd)
Clobetasol propionate 500 microgram per 1 gram Clarelax 500 micrograms/g ointment 50 g POM £14.50 DT price = £14.50

1140 Inflammatory skin conditions
**ClobetaDerm** (Auden McKenzie (Pharma Division) Ltd)

- **Clobetasol propionate 500 microgram per 1 gram** ClobaDerm
  - 0.05% ointment | 30 gram (PoB) £2.15 DT price = £2.69 | 100 gram (PoB) £6.32 DT price = £7.90
- **Dermovate** (GlaxoSmithKline UK Ltd)
  - **Clobetasol propionate 500 microgram per 1 gram** Dermovate
    - 0.05% ointment | 30 gram (PoB) £2.69 DT price = £2.69 | 100 gram (PoB) £7.90 DT price = £7.90

**Fludroxicortide** (Flurandrenolone)

- **INDICATIONS AND DOSE**
  - **Inflammatory skin disorders such as eczemas**
    - **TO THE SKIN**
      - **Child:** Apply 1–2 times a day, to be applied thinly
      - **Adult:** Apply 1–2 times a day, to be applied thinly

**Diflucortolone valerate**

- **INDICATIONS AND DOSE**
  - **Severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids (using 0.3% diflucortolone valerate)**
  - **Short-term treatment of severe exacerbations (using 0.3% diflucortolone valerate)**
  - **Psoriasis (using 0.3% diflucortolone valerate)**
    - **TO THE SKIN**
      - **Child:** Apply 1–2 times a day for up to 2 weeks, reducing strength as condition responds, to be applied thinly; maximum 60 g per week
      - **Adult:** Apply 1–2 times a day for up to 2 weeks, reducing strength as condition responds, to be applied thinly; maximum 60 g per week

**Severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids (using 0.1% diflucortolone valerate)**

- **TO THE SKIN**
  - **Child:** Apply 1–2 times a day for up to 4 weeks, to be applied thinly
  - **Adult:** Apply 1–2 times a day for up to 4 weeks, to be applied thinly

**Potency**

- Diflucortolone valerate 0.1% cream and ointment: potent.
- Diflucortolone valerate 0.3% cream and ointment: very potent.

- **UNLICENSED USE** Nerisone® licensed for use in children (age range not specified by manufacturer); Nerisone Forte® not licensed for use in children under 4 years.

- **Prescribing and dispensing information**
  - Patients or carers should be advised on application of diflucortolone valerate containing preparations.

- **Medicinal Forms**
  - There can be variation in the licensing of different medicines containing the same drug.

**Ointment**

- **CAUTIONARY AND ADVISORY LABELS** 28
  - **Nerisone** (Meadow Laboratories Ltd)
    - **Diflucortolone valerate 1 mg per 1 gram** Nerisone 0.1% ointment
      - 30 gram (PoB) £3.98
    - **Diflucortolone valerate 3 mg per 1 gram** Nerisone Forte 0.3% ointment
      - 15 gram (PoB) £4.70

**Cream**

- **CAUTIONARY AND ADVISORY LABELS** 28
  - **Excipients:** May contain Beeswax, cetostearyl alcohol (including ceteryl and stearyl alcohol), disodium edetate, hydroxybenzoates (parabens)
  - **Nerisone** (Meadow Laboratories Ltd)
    - **Diflucortolone valerate 1 mg per 1 gram** Nerisone 0.1% cream
      - 30 gram (PoB) £3.98
    - Nerisone 0.1% oily cream | 30 gram (PoB) £4.95 DT price = £4.95
    - **Diflucortolone valerate 3 mg per 1 gram** Nerisone Forte 0.3% oily cream
      - 15 gram (PoB) £4.70 DT price = £4.70

**Clobetasone butyrate**

- **INDICATIONS AND DOSE**
  - Eczemas and dermatitis of all types
  - Maintenance between courses of more potent corticosteroids
    - **TO THE SKIN**
      - **Child:** Apply 1–2 times a day, to be applied thinly
      - **Adult:** Apply 1–2 times a day, to be applied thinly

- **POTENCY**
  - Clobetasone butyrate 0.05% cream and ointment: moderate.

- **UNLICENSED USE** Licensed for use in children (age range not specified by manufacturer).

- **Patient and carer advice**
  - Patients or carers should be advised on the application of clobetasone butyrate containing preparations.

- **Exceptions to legal category**
  - Cream can be sold to the public for short-term symptomatic treatment and control of patches of eczema and dermatitis (but not seborrhoeic dermatitis) in adults and children over 12 years provided pack does not contain more than 15 g.

- **Medicinal forms**
  - There can be variation in the licensing of different medicines containing the same drug.

**Ointment**

- **CAUTIONARY AND ADVISORY LABELS** 28
  - **ClobaDerm** (Auden McKenzie (Pharma Division) Ltd)
    - **Clobetasol propionate 500 microgram per 1 gram** ClobaDerm
      - 0.05% ointment | 30 gram (PoB) £2.15 DT price = £2.69 | 100 gram (PoB) £6.32 DT price = £7.90
  - **Dermovate** (GlaxoSmithKline UK Ltd)
    - **Clobetasol propionate 500 microgram per 1 gram** Dermovate
      - 0.05% ointment | 30 gram (PoB) £2.69 DT price = £2.69 | 100 gram (PoB) £7.90 DT price = £7.90

**Cream**

- **CAUTIONARY AND ADVISORY LABELS** 28
  - **Excipients:** May contain Beeswax, cetostearyl alcohol (including ceteryl and stearyl alcohol), disodium edetate, hydroxybenzoates (parabens)
  - **ClobaDerm** (Auden McKenzie (Pharma Division) Ltd)
    - **Clobetasol propionate 500 microgram per 1 gram** ClobaDerm
      - 0.05% cream | 30 gram (PoB) £1.86 DT price = £1.86 | 100 gram (PoB) £5.44 DT price = £5.44

- **Combination Available:** Clobetasol butyrate with neomycin sulfate and nystatin, p. 1148

---

Downloaded from www.medicalbr.com
HAELAN® TAPE

Chronic localised recalcitrant dermatoses (but not acute or weeping)

- TO THE SKIN
  - Child: Cut tape to fit lesion, apply to clean, dry skin
    - shorn of hair, usually for 12 hours daily
  - Adult: Cut tape to fit lesion, apply to clean, dry skin
    - shorn of hair, usually for 12 hours daily

**POTENCY**

Fludrocortisone 0.0125% cream and ointment: moderate

- UNLICENSED USE
  - Licensed for use in children (age range not specified by manufacturer).

- PATIENT AND CARER ADVICE
  - Patients or carers should be counselled on application of fludrocortisone cream and ointment.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Ointment**

- **CAUTIONARY AND ADVISORY LABELS**
- **EXCIPIENTS:** May contain Propylene glycol, wool fat and related substances including lanolin
- Synalar (Reig Jofre UK Ltd)
  - Fludrocortisone 125 microgram per 1 gram
    - Synalar 1 in 4
      - Dilution 0.00625% ointment | 50 gram £30 | 100 gram £11.75 DT price = £37.35
  - Fludrocortisone 250 microgram per 1 gram
    - Synalar 1 in 4
      - Dilution 0.0125% ointment | 30 gram £14.14 DT price = £4.14 | 100 gram £11.75 DT price = £11.75

**Cream**

- **CAUTIONARY AND ADVISORY LABELS**
- **EXCIPIENTS:** May contain Benzyl alcohol, cetostearyl alcohol (including cetyl and stearyl alcohol), polysorbates, propylene glycol
- Synalar (Reig Jofre UK Ltd)
  - Fludrocortisone 25 microgram per 1 gram
    - Synalar 1 in 10
      - Dilution 0.0025% cream | 50 gram £6.58 DT price = £6.58
  - Fludrocortisone 62.5 microgram per 1 gram
    - Synalar 1 in 4
      - Dilution 0.00625% cream | 50 gram £8.44 DT price = £8.44
  - Fludrocortisone 250 microgram per 1 gram
    - Synalar 1 in 4
      - Dilution 0.025% cream | 30 gram £9.14 DT price = £4.14 | 100 gram £11.75 DT price = £11.75

**Gel**

- **CAUTIONARY AND ADVISORY LABELS**
- **EXCIPIENTS:** May contain Hydroxybenzoates (parabens), propylene glycol
- Synalar (Reig Jofre UK Ltd)
  - Fludrocortisone 250 microgram per 1 gram
    - Synalar 0.025% gel | 30 gram £8.56 DT price = £5.56 | 60 gram £10.02 DT price = £10.02

Combined preparations: Fludrocortisone with clociquinol, p. 1149 - Fludrocortisone with neomycin, p. 1149

Fluocinolone acetonide

**INDICATIONS AND DOSE**

Severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids | Psoriasis

- **TO THE SKIN**
  - **Child:** Apply 1–2 times a day, to be applied thinly
  - **Adult:** Apply 1–2 times a day, to be applied thinly

**POTENCY**

Fluocinolone acetonide 0.05% cream and ointment: potent.

- **UNLICENSED USE**
  - Not licensed for use in children under 1 year.

- **PATIENT AND CARER ADVICE**
  - Patients or carers should be advised on the application of fluocinolone preparations.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Ointment**

- **CAUTIONARY AND ADVISORY LABELS**
- **EXCIPIENTS:** May contain Propylene glycol, wool fat and related substances including lanolin
- Synalar (Reig Jofre UK Ltd)
  - Flucinolone acetonide 3 microgram per 1 gram
    - Metosyn 0.05% ointment | 25 gram £6.58 DT price = £3.50 | 100 gram £13.15 DT price = £13.15
  - Flucinolone acetonide 6 microgram per 1 gram
    - Metosyn 0.1% ointment | 25 gram £9.50 DT price = £3.96 | 100 gram £13.34 DT price = £13.34
  - Flucinolone acetonide 12 microgram per 1 gram
    - Metosyn 0.2% ointment | 25 gram £10.49 DT price = £3.49 | 100 gram £13.34 DT price = £13.34
Fluocortolone

● INDICATIONS AND DOSE
Severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids | Psoriasis

► TO THE SKIN
► Adult: Apply 1–2 times a day, to be applied thinly, reducing strength as condition responds

POTENCY
Fluocortolone hexanoate 0.25% cream and ointment; fluocortolone pivalate 0.25% cream and fluocortolone 0.25% ointment: moderate.

● PRESCRIBING AND DISPENSING INFORMATION
Patients or carers should be counselled on the application of fluocortolone preparations.

● MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.
No licensed medicines listed.

04-Jan-2016

Fluticasone

● INDICATIONS AND DOSE
Severe inflammatory skin disorders such as dermatitis and eczemas unresponsive to less potent corticosteroids | Psoriasis

► TO THE SKIN
► Child 3 months–17 years: Apply 1–2 times a day, to be applied thinly
► Adult: Apply 1–2 times a day, to be applied thinly

POTENCY
Fluticasone cream 0.05%: potent. Fluticasone ointment 0.005%: potent.

● UNLICENSED USE
Not licensed for use in children under 3 months.

● INTERACTIONS → Appendix 1: corticosteroids

● PATIENT AND CARER ADVICE
Patients or carers should be given advice on application of fluticasone creams and ointments.

● MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Cream

CAUTIONARY AND ADVISORY LABELS 28
EXCIPIENTS: May contain Benzyl alcohol, cetostearyl alcohol (including cetyl and stearyl alcohol), imidurea, propylene glycol
► Fluticasone (Non-proprietary)
Hydrocortisone 5 mg per 1 gram Hydrocortisone 0.5% cream | 15 gram £3.55 DT price = £2.36 | 30 gram £5.55 DT price = £3.30

Hydrocortisone 1% cream | 15 gram £10.50 DT price = £6.90 | 30 gram £23.83 DT price = £13.80 | 50 gram £36.12 DT price = £22.00

Hydrocortisone 25 mg per 1 gram Hydrocortisone 2.5% cream | 15 gram £44.00 DT price = £26.90 | 30 gram £88.00

Dioderm (Dermal Laboratories Ltd)
Hydrocortisone 1% cream | 30 gram £2.03 DT price = £2.03

Mildison Lipocream (LEO Pharma)
Hydrocortisone 10 mg per 1 gram Mildison Lipocream 1% cream | 30 gram £1.71 DT price = £1.80

Ointment

CAUTIONARY AND ADVISORY LABELS 28
EXCIPIENTS: May contain Propylene glycol
► Fluticasone (Non-proprietary)
Hydrocortisone 5 mg per 1 gram Hydrocortisone 0.5% ointment | 15 gram £3.55 DT price = £2.36 | 30 gram £5.55 DT price = £3.30

Hydrocortisone 1% ointment | 15 gram £10.50 DT price = £6.90 | 30 gram £23.83 DT price = £13.80 | 50 gram £36.12 DT price = £22.00

Hydrocortisone 25 mg per 1 gram Hydrocortisone 2.5% ointment | 15 gram £44.00 DT price = £26.90 | 30 gram £88.00


04-Jan-2016

Hydrocortisone

● INDICATIONS AND DOSE
Mild inflammatory skin disorders such as eczemas

► TO THE SKIN
► Child: Apply 1–2 times a day, to be applied thinly
► Adult: Apply 1–2 times a day, to be applied thinly

Nappy rash
► TO THE SKIN
► Child: Apply 1–2 times a day for no longer than 1 week, discontinued as soon as the inflammation subsides

POTENCY
Hydrocortisone cream and ointment 0.5 to 2.5%: mild

● INTERACTIONS → Appendix 1: corticosteroids

● PRESCRIBING AND DISPENSING INFORMATION
When hydrocortisone cream or ointment is prescribed and no strength is stated, the 1% strength should be supplied. Although Dioderm® contains only 0.1% hydrocortisone, the formulation is designed to provide a clinical activity comparable to that of Hydrocortisone Cream 1% BP.

● PATIENT AND CARER ADVICE
Patient counselling is advised for hydrocortisone cream and ointment (application).

● PROFESSION SPECIFIC INFORMATION
Dental practitioners’ formulary Hydrocortisone Cream 1% BP may be prescribed.

● EXCEPTIONS TO LEGAL CATEGORY
Over-the-counter hydrocortisone preparations Skin creams and ointments containing hydrocortisone (alone or with other ingredients) can be sold to the public for the treatment of allergic contact dermatitis, irritant dermatitis, insect bite reactions and mild to moderate eczema in patients over 10 years, to be applied sparingly over the affected area 1–2 times daily for max. 1 week. Over-the-counter hydrocortisone preparations should not be sold without medical advice for children under 10 years or for pregnant women; they should not be sold for application to the face, anogenital region, broken or infected skin (including cold sores, acne, and athlete’s foot).

● MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Cream

CAUTIONARY AND ADVISORY LABELS 28
EXCIPIENTS: May contain Benzyalcohol, cetostearyl alcohol (including cetyl and stearyl alcohol), hydroxybenzoates (parabens), propylene glycol
► Hydrocortisone (Non-proprietary)

Hydrocortisone 5 mg per 1 gram Hydrocortisone 0.5% cream | 15 gram £3.00 DT price = £1.13 | 30 gram £5.55 DT price = £2.69–4.90

Hydrocortisone 1% cream | 15 gram £10.50 DT price = £6.90 | 30 gram £23.83 DT price = £13.80 | 50 gram £36.12 DT price = £22.00

Hydrocortisone 25 mg per 1 gram Hydrocortisone 2.5% cream | 15 gram £44.00 DT price = £26.90 | 30 gram £88.00

Dioderm (Dermal Laboratories Ltd)
Hydrocortisone 1% cream | 30 gram £2.03 DT price = £2.03

Mildison Lipocream (LEO Pharma)
Hydrocortisone 10 mg per 1 gram Mildison Lipocream 1% cream | 30 gram £1.71 DT price = £1.80

Ointment

CAUTIONARY AND ADVISORY LABELS 28
EXCIPIENTS: May contain Propylene glycol
► Hydrocortisone (Non-proprietary)

Hydrocortisone 5 mg per 1 gram Hydrocortisone 0.5% ointment | 15 gram £3.00 DT price = £1.13 | 30 gram £5.55 DT price = £2.69–12.00

Hydrocortisone 1% ointment | 15 gram £10.50 DT price = £6.90 | 30 gram £23.83 DT price = £13.80 | 50 gram £36.12 DT price = £22.00

Hydrocortisone 25 mg per 1 gram Hydrocortisone 2.5% ointment | 15 gram £44.00 DT price = £24.43 | 30 gram £88.00

Hydrocortisone butyrate

**INDICATIONS AND DOSE**
Severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids | Psoriasis

- **TO THE SKIN**
  - Child 1-17 years: Apply 1–2 times a day, to be applied thinly
  - Adult: Apply 1–2 times a day, to be applied thinly

**POTENCY**
Hydrocortisone butyrate 0.1% cream, liquid, and ointment: potent

**PATIENT AND CARER ADVICE**
Patients or carers should be given advice on how to administer hydrocortisone butyrate lotion, cream, ointment and scalp lotion. Medicines for Children leaflet: Hydrocortisone topical for eczema www.medicinesforchildren.org.uk/hydrocortisone-topical-for-eczema

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: ointment

**Ointment**
CAUTIONARY AND ADVISORY LABELS 28
- **Locoid** (LEO Pharma)
  - Hydrocortisone butyrate 1 mg per 1 gram | Locoid 0.1% ointment | 30 gram (Posm) £1.60 DT price = £1.60 | 100 gram (Posm) £4.93 DT price = £4.93

**Cream**
CAUTIONARY AND ADVISORY LABELS 28
EXCIPIENTS: May contain Benzyl alcohol, cetostearyl alcohol (including cetyl and stearyl alcohol), hydroxybenzoates (parabens)
- **Locoid** (LEO Pharma)
  - Hydrocortisone butyrate 1 mg per 1 gram | Locoid 0.1% cream | 30 gram (Posm) £1.60 DT price = £1.60 | 100 gram (Posm) £4.93 DT price = £4.93

**Locoid Lipocream** (LEO Pharma)
- Hydrocortisone butyrate 1 mg per 1 gram | Locoid 0.1% Lipocream | 30 gram (Posm) £1.69 DT price = £1.60 | 100 gram (Posm) £5.17 DT price = £4.93

**Liquid**
CAUTIONARY AND ADVISORY LABELS 15(excluding Locoid Crelo topical emulsion), 28
EXCIPIENTS: May contain Butylated hydroxytoluene, cetostearyl alcohol (including cetyl and stearyl alcohol), hydroxybenzoates (parabens), propylene glycol
- **Locoid** (LEO Pharma)
  - Hydrocortisone butyrate 1 mg per 1 ml | Locoid 0.1% scalp lotion | 100 ml (Posm) £6.83 DT price = £6.83

**Locoid Crelo** (LEO Pharma)
- Hydrocortisone butyrate 1 mg per 1 gram | Locoid Crelo 0.1% topical emulsion | 100 gram (Posm) £5.91

Hydrocortisone with urea

**INDICATIONS AND DOSE**
Mild inflammatory skin disorders such as eczemas

- **TO THE SKIN**
  - Child: To be applied thinly (consult product literature)
  - Adult: To be applied thinly (consult product literature)

**POTENCY**
Hydrocortisone 1% with urea cream: moderate

**PATIENT AND CARER ADVICE**
Patients or carers should be advised on application of hydrocortisone with urea cream.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Cream**
CAUTIONARY AND ADVISORY LABELS 28
- **Alphaderm** (Alliance Pharmaceuticals Ltd)
  - Hydrocortisone 10 mg per 1 gram, Urea 100 mg per 1 gram | Alphaderm 1%/10% cream | 30 gram (Posm) £2.38 DT price = £2.38 | 100 gram (Posm) £7.03 DT price = £7.03

**Mometasone furoate**

**INDICATIONS AND DOSE**
Severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids | Psoriasis

- **TO THE SKIN**
  - Child 2-7 years: Apply once daily, to be applied thinly (to scalp in case of lotion)
  - Adult: Apply once daily, to be applied thinly (to scalp in case of lotion)

**POTENCY**
Mometasone furoate 0.1% cream, ointment, and scalp lotion: potent.

**INTERACTIONS** → Appendix 1: corticosteroids

**PATIENT AND CARER ADVICE**
Patients and carers should be advised on the application of topical mometasone.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: ointment

**Cream**
CAUTIONARY AND ADVISORY LABELS 28
EXCIPIENTS: May contain Beeswax, propylene glycol
- **Mometasone furoate (Non-proprietary)**
  - Mometasone furoate 1 mg per 1 gram | Mometasone 0.1% cream | 30 gram (Posm) £4.36 DT price = £1.81 | 100 gram (Posm) £12.58 DT price = £6.03

**Elocon** (Merck Sharp & Dohme Ltd)
- Mometasone furoate 1 mg per 1 gram | Elocon 0.1% cream | 30 gram (Posm) £4.80 DT price = £1.81 | 100 gram (Posm) £15.10 DT price = £6.03

**Ointment**
CAUTIONARY AND ADVISORY LABELS 28
EXCIPIENTS: May contain Propylene glycol
- **Mometasone furoate (Non-proprietary)**
  - Mometasone furoate 1 mg per 1 gram | Mometasone 0.1% ointment | 15 gram (Posm) £4.32 | 30 gram (Posm) £4.45 DT price = £1.86 | 50 gram (Posm) £12.44 | 100 gram (Posm) £12.82 DT price = £6.20

**Elocon** (Merck Sharp & Dohme Ltd)
- Mometasone furoate 1 mg per 1 gram | Elocon 0.1% ointment | 30 gram (Posm) £4.32 DT price = £1.86 | 100 gram (Posm) £12.44 DT price = £6.20

**Liquid**
CAUTIONARY AND ADVISORY LABELS 28
EXCIPIENTS: May contain Propylene glycol
- **Elocon** (Merck Sharp & Dohme Ltd)
  - Mometasone furoate 1 mg per 1 gram | Elocon 0.1% scalp lotion | 30 ml (Posm) £4.36 DT price = £4.36
**Betamethasone with clioquinol**

The properties listed below are those particular to the combination only. For the properties of the components please consider, betamethasone p. 1141.

- **INDICATIONS AND DOSE**
  - Severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids | Psoriasis
  - **TO THE SKIN**
  - Child: (consult product literature)
  - Adult: (consult product literature)
  - **POTENCY**
  - Betamethasone (as valerate) 0.1% with clioquinol cream and ointment: potent.

- **UNLICENSED USE** Betamethasone and clioquinol preparations is not licensed for use in children under 1 year.

- **PATIENT AND CARER ADVICE** Stains clothing. Patients or carers should be counselled on application of betamethasone with clioquinol preparations.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Ointment**
    - CAUTIONARY AND ADVISORY LABELS 28
    - Betamethasone with clioquinol (Non-proprietary)
      - Betamethasone (as Betamethasone valerate) 1 mg per 1 gram, Clioquinol 30 mg per 1 gram Betamethasone valerate 0.1% / Clioquinol 3% ointment | 30 gram [Pos] £38.88 DT price = £38.88
  - **Cream**
    - CAUTIONARY AND ADVISORY LABELS 28
    - EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), propylene glycol
    - Betamethasone with clioquinol (Non-proprietary)
      - Betamethasone (as Betamethasone valerate) 1 mg per 1 gram, Clioquinol 30 mg per 1 gram Betamethasone valerate 0.1% / Clioquinol 3% cream | 30 gram [Pos] £38.88 DT price = £38.88

---

**Betamethasone with fusidic acid**

The properties listed below are those particular to the combination only. For the properties of the components please consider, betamethasone p. 1141, fusidic acid p. 539.

- **INDICATIONS AND DOSE**
  - Severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids | Psoriasis
  - **TO THE SKIN**
  - Child: (consult product literature)
  - Adult: (consult product literature)
  - **POTENCY**
  - Betamethasone (as valerate) 0.1% with fusidic acid cream: potent.

- **UNLICENSED USE** Fucibet® Lipid Cream is not licensed for use in children under 6 years.

- **PATIENT AND CARER ADVICE** Patients or carers should be counselled on application of betamethasone with fusidic acid preparations.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Cream**
    - CAUTIONARY AND ADVISORY LABELS 28
    - EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), chloroacresol
    - Betamethasone with fusidic acid (Non-proprietary)
      - Betamethasone (as Betamethasone valerate) 1 mg per 1 gram, Fusidic acid 20 mg per 1 gram Betamethasone valerate 0.1% / Fusidic acid 2% cream | 30 gram [Pos] £7.71 DT price = £6.38 | 60 gram [Pos] £15.42 DT price = £12.76
      - Fucibet (LEO Pharma)
        - Betamethasone (as Betamethasone valerate) 1 mg per 1 gram, Fusidic acid 20 mg per 1 gram Fucibet cream | 30 gram [Pos] £6.38 DT price = £6.38 | 60 gram [Pos] £12.76 DT price = £12.76
        - Fucibet Lipid cream | 30 gram [Pos] £6.74 DT price = £6.38
        - Xemacort (Mylan Ltd)
          - Betamethasone (as Betamethasone valerate) 1 mg per 1 gram, Fusidic acid 20 mg per 1 gram Xemacort cream | 30 gram [Pos] £6.05 DT price = £6.38 | 60 gram [Pos] £12.45 DT price = £12.76

---

**Betamethasone with clotrimazole**

The properties listed below are those particular to the combination only. For the properties of the components please consider, betamethasone p. 1141, clotrimazole p. 781.

- **INDICATIONS AND DOSE**
  - Severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids | Psoriasis
  - **TO THE SKIN**
  - Child: (consult product literature)
  - Adult: (consult product literature)
  - **POTENCY**
  - Betamethasone dipropionate 0.064% (~betamethasone 0.5%) with clotrimazole cream: potent.

- **UNLICENSED USE** Lotriderm® not licensed for use in children under 12 years.

- **PATIENT AND CARER ADVICE** Patients or carers should be given advice on how to administer betamethasone with clotrimazole cream.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Cream**
    - CAUTIONARY AND ADVISORY LABELS 28
    - EXCIPIENTS: May contain Benzyal alcohol, cetostearyl alcohol (including cetyl and stearyl alcohol), propylene glycol
    - Betamethasone with neomycin and clotrimazole preparations 640 microgram per 1 gram, Clotrimazole 10 mg per 1 gram Lotriderm cream | 30 gram [Pos] £6.34 DT price = £6.34

---

**Betamethasone with neomycin**

The properties listed below are those particular to the combination only. For the properties of the components please consider, betamethasone p. 1141, neomycin sulphate p. 492.

- **INDICATIONS AND DOSE**
  - Severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids | Psoriasis
  - **TO THE SKIN**
  - Child 2–17 years: Apply 1–2 times a day, to be applied thinly
  - Adult: Apply 1–2 times a day, to be applied thinly
  - **POTENCY**
  - Betamethasone (as valerate) 0.1% with neomycin cream and ointment: potent.

- **UNLICENSED USE** Betamethasone and neomycin preparations not licensed for use in children under 2 years.

- **PATIENT AND CARER ADVICE** Patient counselling is advised for betamethasone with neomycin cream and ointment (application).
Skin MEDICINAL FORMS There can be variation in the licensing of different medicines containing the same drug.

Ointment
CAUTIONARY AND ADVISORY LABELS 28
- Betamethasone with neomycin (Non-proprietary)
  Betamethasone (as Betamethasone valerate) 1 mg per 1 gram, Neomycin sulfate 5 mg per 1 gram Betamethasone valerate 0.1% / Neomycin 0.5% ointment | 30 gram POM £38.88 DT price = £31.36 | 100 gram POM £97.00 DT price = £104.52

Cream
CAUTIONARY AND ADVISORY LABELS 28
EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), chlorocresol
- Betamethasone with neomycin (Non-proprietary)
  Betamethasone (as Betamethasone valerate) 1 mg per 1 gram, Neomycin sulfate 5 mg per 1 gram Betamethasone valerate 0.1% / Neomycin 0.5% cream | 30 gram POM £38.88 DT price = £31.36 | 100 gram POM £97.00 DT price = £104.52

Betamethasone with salicylic acid
The properties listed below are those particular to the combination only. For the properties of the components please consider, betamethasone p. 1141, salicylic acid p. 1162.

INDICATIONS AND DOSE DIPROSALIC® OINTMENT
Severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids | Psoriasis
TO THE SKIN
- Child: Apply 1–2 times a day, max. 60 g per week
- Adult: Apply 1–2 times a day, max. 60 g per week
POTENCY
For Diprosalic® ointment: Betamethasone (as dipropionate) 0.05% with salicylic acid 3%: potent.

DIPROSALIC® SCALP APPLICATION
Severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids | Psoriasis
TO THE SKIN
- Child: Apply 1–2 times a day, apply a few drops
- Adult: Apply 1–2 times a day, apply a few drops
POTENCY
For Diprosalic® scalp application: Betamethasone (as dipropionate) 0.05% with salicylic acid 2%: potent.

INTERACTIONS → Appendix 1: corticosteroids
POTENCY
PATIENT AND CARER ADVICE Patients or carers should be counselled on application of betamethasone and salicylic acid preparations.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Ointment
CAUTIONARY AND ADVISORY LABELS 28
- Diprosalic (Merck Sharp & Dohme Ltd)
  Betamethasone (as Betamethasone dipropionate) 500 microgram per 1 gram, Salicylic acid 30 mg per 1 gram Diprosalic 0.05%/2% scalp application | 100 ml POM £10.10 DT price = £10.10

Chlortetracycline with triamcinolone

INDICATIONS AND DOSE
Severe inflammatory skin disorders such as eczemas unresponsive to less potent corticosteroids (associated with infection) | Psoriasis (associated with infection)
TO THE SKIN
- Adult: To be applied thinly (consult product literature)
POTENCY
Triamcinolone acetonide 0.1%, chlortetracycline hydrochloride 3% ointment: potent.

PATIENT AND CARER ADVICE Stains clothing. Patients or carers should be counselled on the application of chlortetracycline with triamcinolone products.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Ointment
CAUTIONARY AND ADVISORY LABELS 28
- Diprosalic propionate with neomycin sulfate and nystatin (Non-proprietary)
  Clobetasol propionate 500 microgram per 1 gram, Neomycin sulfate 5 mg per 1 gram, Nystatin 100000 unit per 1 gram Diprosalic propionate 0.05% with neomycin sulfate and nystatin cream and ointment: very potent.

PATIENT AND CARER ADVICE Patients or carers should be advised on application of clobetasol propionate, neomycin sulfate and nystatin containing preparations.

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Ointment
CAUTIONARY AND ADVISORY LABELS 28
- Diprosalic propionate with neomycin sulfate and nystatin (Non-proprietary)
  Clobetasol propionate 500 microgram per 1 gram, Neomycin sulfate 5 mg per 1 gram, Nystatin 100000 unit per 1 gram Diprosalic propionate 0.05% with neomycin sulfate and nystatin cream and ointment: very potent.
Clobetasone butyrate with nystatin and oxytetracycline

The properties listed below are those particular to the combination only. For the properties of the components please consider, clobetasone butyrate p. 1143, oxytetracycline p. 536.

**INDICATIONS AND DOSE**

Steroid-responsive dermatoses where candidal or bacterial infection is present

- **TO THE SKIN**
- **Adults**: (consult product literature)

**POTENCY**

Clobetasone butyrate 0.05% with nystatin and oxytetracycline cream: moderate.

**PATIENT AND CARER ADVICE**

Stains clothing.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Cream**

**EXCIPIENTS**: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), chlorocresol, sodium metabisulfite

- **Trimovate** (GlaxoSmithKline UK Ltd)
  Clobetasone butyrate 500 microgram per 1 gram, Oxytetracycline (as Oxytetracycline calcium) 30 mg per 1 gram, Nystatin 100000 unit per 1 gram Trimovate cream | 30 gram [FPs] £3.29

Fluocinolone acetonide with neomycin

The properties listed below are those particular to the combination only. For the properties of the components please consider, fluocinolone acetonide p. 1144, neomycin sulfate p. 492.

**INDICATIONS AND DOSE**

Inflammatory skin disorders such as eczemas associated with infection | Psoriasis associated with infection

- **TO THE SKIN**
- **Child 1-17 years**: Apply 1–2 times a day, to be applied thinly, reducing strength as condition responds
- **Adult**: Apply 1–2 times a day, to be applied thinly, reducing strength as condition responds

**POTENCY**

Fluocinolone acetonide 0.025% with neomycin 0.5% cream and ointment: potent.

**PATIENT AND CARER ADVICE**

Patients or carers should be counselled on the application of fluocinolone acetonide with neomycin preparations.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Ointment**

**EXCIPIENTS**: May contain Propylene glycol, wool fat and related substances including lanolin

- **Synalar N** (Reig Jofre UK Ltd)
  Fluocinolone acetonide 250 microgram per 1 gram, Neomycin sulfate 5 mg per 1 gram Synalar N ointment | 30 gram [FPs] £4.36

**Cream**

**EXCIPIENTS**: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), hydroxybenzoates (parabens), propylene glycol

- **Synalar N** (Reig Jofre UK Ltd)
  Fluocinolone acetonide 250 microgram per 1 gram, Neomycin sulfate 5 mg per 1 gram Synalar N cream | 30 gram [FPs] £4.36

Fluocinolone acetonide with clioquinol

The properties listed below are those particular to the combination only. For the properties of the components please consider, fluocinolone acetonide p. 1144.

**INDICATIONS AND DOSE**

Inflammatory skin disorders such as eczemas associated with infection | Psoriasis associated with infection

- **TO THE SKIN**
- **Adult**: Apply 1–2 times a day, to be applied thinly, reducing strength as condition responds

**POTENCY**

Clioquinol 3% with fluocinolone acetonide 0.025% cream and ointment: potent

**PATIENT AND CARER ADVICE**

Patient counselling is advised for clioquinol with fluocinolone acetonide cream and ointment (application). Ointment stains clothing.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Ointment**

**EXCIPIENTS**: May contain Propylene glycol, wool fat and related substances including lanolin

- **Synalar C** (Reig Jofre UK Ltd)
  Fluocinolone acetonide 250 microgram per 1 gram, Clioquinol 0.25% Synalar C ointment | 15 gram [FPs] £2.66

**Cream**

**EXCIPIENTS**: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), disodium edetate, hydroxybenzoates (parabens), polysorbates, propylene glycol

- **Synalar C** (Reig Jofre UK Ltd)
  Fluocinolone acetonide 250 microgram per 1 gram, Clioquinol 0.25% Synalar C cream | 15 gram [FPs] £2.66

Hydrocortisone with benzalkonium chloride, dimeticone and nystatin

The properties listed below are those particular to the combination only. For the properties of the components please consider, hydrocortisone p. 1145, dimeticone p. 1134.

**INDICATIONS AND DOSE**

Mild inflammatory skin disorders such as eczemas associated with infection

- **TO THE SKIN**
- **Child**: Apply 3 times a day until lesion has healed, to be applied thinly
- **Adult**: Apply 3 times a day until lesion has healed, to be applied thinly

**POTENCY**

Benzalkonium with dimeticone, hydrocortisone acetate 0.5%, and nystatin cream: mild.

**PATIENT AND CARER ADVICE**

Patients or carers should be advised on application of benzalkonium with dimeticone and hydrocortisone and nystatin preparations.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Cream**

**EXCIPIENTS**: May contain Butylated hydroxyanisole, cetostearyl alcohol (including cetyl and stearyl alcohol), hydrocortisone acetate (including cetyl and stearyl alcohol), hydroxybenzoates (parabens), sodium metabisulfite, sorbic acid

downloaded from www.medicalbr.com
Hydrocortisone with chlorhexidine hydrochloride and nystatin

The properties listed below are those particular to the combination only. For the properties of the components please consider, hydrocortisone p. 1145, chlorhexidine p. 1108.

● INDICATIONS AND DOSE
Mild inflammatory skin disorders such as eczemas
  ▶ TO THE SKIN
  ▶ Child: To be applied thinly (consult product literature)
  ▶ Adult: To be applied thinly (consult product literature)

POTENCY
Hydrocortisone 0.5% with chlorhexidine hydrochloride 1% and nystatin cream: mild
Hydrocortisone 1% with chlorhexidine hydrochloride 1% and nystatin ointment: mild

● PATIENT AND CARER ADVICE
Patients or carers should be given advice on how to administer clotrimazole with hydrocortisone cream.

● EXCEPTONS TO LEGAL CATEGORY
A 15-g tube is on sale to the public for the treatment of athlete’s foot and fungal infection of skin folds with associated inflammation in patients 10 years and over.

● MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Cream

CAUTIONARY AND ADVISORY LABELS 28
EXCIPIENTS: May contain Benzyl alcohol, cetostearyl alcohol (including cetyl and stearyl alcohol)
  ▶ Canesten HC (Bayer Plc)
Clotrimazole 10 mg per 1 gram, Hydrocortisone 10 mg per 1 gram Canesten HC cream | 30 gram £2.42 DT price = £2.42

Hydrocortisone with fusidic acid

The properties listed below are those particular to the combination only. For the properties of the components please consider, hydrocortisone p. 1145, fusidic acid p. 539.

● INDICATIONS AND DOSE
Mild inflammatory skin disorders such as eczemas
  ▶ TO THE SKIN
  ▶ Child: To be applied thinly (consult product literature)
  ▶ Adult: To be applied thinly (consult product literature)

POTENCY
Hydrocortisone with fusidic acid cream: mild

● PATIENT AND CARER ADVICE
Patients or carers should be advised on application of hydrocortisone with fusidic acid preparations.

● MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Cream

CAUTIONARY AND ADVISORY LABELS 28
EXCIPIENTS: May contain Butylated hydroxyanisole, cetostearyl alcohol (including cetyl and stearyl alcohol), polysorbates, potassium sorbate
  ▶ Fucidin H (Fusidic acid / Hydrocortisone) (LEO Pharma) Hydrocortisone acetate 10 mg per 1 gram, Fusidic acid 20 mg per 1 gram Fucidin H cream | 30 gram £6.02 DT price = £6.02 | 60 gram £12.05 DT price = £12.05

Hydrocortisone with miconazole

The properties listed below are those particular to the combination only. For the properties of the components please consider, hydrocortisone p. 1145, miconazole p. 782.

● INDICATIONS AND DOSE
Mild inflammatory skin disorders such as eczemas associated with infections
  ▶ TO THE SKIN
  ▶ Adult: (consult product literature)

POTENCY
Hydrocortisone 1% with miconazole cream and ointment: mild

● PATIENT AND CARER ADVICE
Patients or carers should be advised on application of hydrocortisone with miconazole preparations.

● PROFESSION SPECIFIC INFORMATION
Dental practitioners’ formulary
May be prescribed as Miconazole and Hydrocortisone Cream or Ointment for max. 7 days.

● EXCEPTIONS TO LEGAL CATEGORY
A 15-g tube of hydrocortisone with miconazole cream is on sale to the public for the treatment of athlete’s foot and fungal infection of skin folds with associated inflammation in patients 10 years and over.

Hydrocortisone with clotrimazole

The properties listed below are those particular to the combination only. For the properties of the components please consider, hydrocortisone p. 1145, clotrimazole p. 781.

● INDICATIONS AND DOSE
Mild inflammatory skin disorders such as eczemas (associated with fungal infection)
  ▶ TO THE SKIN
  ▶ Child: (consult product literature)
  ▶ Adult: (consult product literature)

POTENCY
Clotrimazole with hydrocortisone 1% cream: mild
public for the treatment of athlete’s foot and candidal intertrigo.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Ointment**
CAUTIONARY AND ADVISORY LABELS 28

- **Daktacort** (Janssen-Cilag Ltd)
  Hydrocortisone 10 mg per 1 gram, Miconazole nitrate 20 mg per 1 gram Daktacort ointment | 30 gram | £0.29 per 1 gram
d- **Daktacort** (McNeil Products Ltd, Janssen-Cilag Ltd)
  Hydrocortisone 10 mg per 1 gram, Miconazole nitrate 20 mg per 1 gram Daktacort 2%/1% cream | 30 gram | £2.49 per 1 gram

**Cream**
CAUTIONARY AND ADVISORY LABELS 28

EXCIPIENTS: May contain Butylated hydroxyanisole, disodium edetate

- **Daktacort**
  Hydrocortisone 10 mg per 1 gram, Miconazole nitrate 20 mg per 1 gram Daktacort ointment | 500 gram | £3.42 per 1 gram

---

**Hydrocortisone with oxytetracycline**

The properties listed below are those particular to the combination only. For the properties of the components please consider, hydrocortisone p. 1145, oxytetracycline p. 536.

**INDICATIONS AND DOSE**

**Mild inflammatory skin disorders such as eczemas**

- TO THE SKIN
  - Child 1-17 years: (consult product literature)
  - Adult: (consult product literature)

**PORENCY**

Hydrocortisone 1% with oxytetracycline ointment: mild.

**CONTRA-INDICATIONS**
Children under 12 years

**PREGNANCY**
Tetracyclines should not be given to pregnant women. Effects on skeletal development have been documented when tetracyclines have been used in the first trimester in animal studies. Administration during the second or third trimester may cause discoloration of the child’s teeth.

**BREAST FEEDING**
Tetracyclines should not be given to women who are breast-feeding (although absorption and therefore discoloration of teeth in the infant is probably usually prevented by chelation with calcium in milk).

**PATIENT AND CARER ADVICE**
Patients should be given advice on the application of hydrocortisone with oxytetracycline ointment.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Ointment**
CAUTIONARY AND ADVISORY LABELS 28

- **Terra-Cortril** (Intrapharm Laboratories Ltd)
  Hydrocortisone 10 mg per 1 gram, Oxytetracycline (as Oxytetracycline hydrochloride) 30 mg per 1 gram Terra-Cortril ointment | 30 gram | £5.01 per 1 gram

**DERMATOLOGICAL DRUGS > ANTI-INFECTIVES**

**Ichthammol**

**INDICATIONS AND DOSE**

**Chronic lichenified eczema**

- TO THE SKIN
  - Child 1-17 years: Apply 1–3 times a day
  - Adult: Apply 1–3 times a day

**UNLICENSED USE**

- In children: No information available.

**SIDE-EFFECTS**
Skin irritation

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: ointment, paste

**Liquid**

- **Ichthammol (Non-proprietary)**
  Ichthammol liquid | 100 gram | G 111.42 DT price = £11.42

**Ichthammol with zinc oxide**

The properties listed below are those particular to the combination only. For the properties of the components please consider, ichthammol above.

**INDICATIONS AND DOSE**

**Chronic lichenified eczema**

- TO THE SKIN
  - Adult: (consult product literature)

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: cream, ointment

**Impregnated dressing**

- **Ichthopaste** (Smith & Nephew Healthcare Ltd)
  Ichthopaste bandage 7.5cm x 6m | 1 bandage | £3.72

**Dermatological Drugs > Antracen Derivatives**

**Dithranol**

(Anthralin)

**INDICATIONS AND DOSE**

**Subacute and chronic psoriasis**

- TO THE SKIN
  - Adult: (consult product literature)

**DITHRCREAM®**

**Subacute and chronic psoriasis**

- TO THE SKIN
  - Adult: For application to skin or scalp, 0.1–0.5% cream suitable for overnight treatment, 1–2% cream for maximum 1 hour (consult product literature)

**MICANOL®**

**Subacute and chronic psoriasis**

- TO THE SKIN
  - Adult: Apply once daily, for application to skin or scalp, to be applied for up to 30 minutes, apply 1% cream, if necessary 3% cream can be used under medical supervision

**CONTRA-INDICATIONS**
Acute and postular psoriasis • hypersensitivity

**CAUTIONS**
Avoid sensitive areas of skin • avoid use near eyes

**SIDE-EFFECTS**
Local burning sensation • local irritation • stains hair • stains skin

**PREGNANCY**
No adverse effects reported.

**BREAST FEEDING**
No adverse effects reported.

**DIRECTIONS FOR ADMINISTRATION**
When applying dithranol, hands should be protected by gloves or they should be washed thoroughly afterwards. Dithranol should be applied to chronic extensor plaques only, carefully avoiding normal skin.

**MICANOL®**
At the end of contact time, use plenty of lukewarm (not hot) water to rinse off cream; soap may be used after the cream has been rinsed off; use shampoo
Dithranol with salicylic acid and zinc oxide

The properties listed below are those particular to the combination only. For the properties of the components please consider, dithranol p. 1151, salicylic acid p. 1182.

- **INDICATIONS AND DOSE**
  - **Subacute and chronic psoriasis**
    - TO THE SKIN
    - Adult: (consult local protocol)

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: ointment, paste

**DERMATOLOGICAL DRUGS TARS**

**Coal tar**

- **INDICATIONS AND DOSE**
  - **Psoriasis** | **Chronic atopic eczema**
    - TO THE SKIN USING PASTE
    - Child: Apply 1–3 times a day, start application with low-strength preparations
    - Adult: Apply 1–3 times a day, start application with low-strength preparations
    - TO THE SKIN
    - Child: 100 mL/bath, to be added to an adult sized bath; add proportionally less for a child’s bath. Use Coal Tar Solution BP

- **Adult**: 100 mL/bath, to be added to an adult sized bath. Use Coal Tar Solution BP

**ALPHOSYL 2 IN 1® SHAMPOO**

- **Psoriasis** | **Seborrhoeic dermatitis** | **Scaling** | **Itching**
  - TO THE SKIN
  - Adult: Apply every 2–3 days

**Dandruff**

- TO THE SKIN
  - Adult: Apply 1–2 times a week as required

**EXOREX® LOTION**

- **Psoriasis**
  - TO THE SKIN
  - Adult: Apply 2–3 times a day, to be applied to skin or scalp; in elderly, lotion can be diluted with a few drops of water before applying

- **CONTRA-INDICATIONS**
  - Avoid broken or inflamed skin.
  - Avoid eye area.
  - Avoid genital area.
  - Avoid mucosal areas.
  - Avoid rectal area.
  - Infection: sore, acute, or pustular psoriasis

- **CAUTIONS**
  - Application to face.
  - Application to skin flexures

- **SIDE-EFFECTS**
  - Acne-like eruptions.
  - Photosensitivity.
  - Skin irritation

- **PRESCRIBING AND DISPENSING INFORMATION**
  - Coal Tar Solution BP contains coal tar 20%, Strong Coal Tar Solution BP contains coal tar 40%.

- **HANDLING AND STORAGE**
  - Use suitable chemical protection gloves for extemporaneous preparation.
  - May stain skin, hair and fabric.

- **PATIENT AND CARER ADVICE**
  - May stain skin, hair and fabric.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: paste

**Bath additive**

- **Psoriderm** (Dermal Laboratories Ltd)
  - Coal tar distilled 400 mg per 1 mL

- **Psoriderm Emulsion 40% bath additive**
  - 200 mL (BTL) £0.74

**Cutaneous emulsion**

- **EXOREX®** (Teva UK Ltd)
  - **Coal tar solution 50 mg per 1 gram**
    - Exorex lotion 100 mL (GSL) £8.11 DT price = £8.11 | 250 mL (GSL) £16.24 DT price = £16.24

**Shampoo**

- **EXOREX** (May contain Fragrances, Hydroxybenzoates (parabens))
  - **Coal tar (Non-proprietary)**
    - **Coal tar extract 20 mg per 1 gram**
      - Coal tar extract 2% shampoo
        - 125 mL (GSL) no price available DT price = £3.61 | 250 mL (GSL) no price available DT price = £5.38
      - Brands may include Alphosyl Z 2 in 1, Neutrogena T/Gel Therapeutic, Polytar Scalp

**Coal tar with arachis oil extract of coal tar, cade oil, light liquid paraffin and tar**

The properties listed below are those particular to the combination only. For the properties of the components please consider, coal tar above.

- **INDICATIONS AND DOSE**
  - **Psoriasis** | **Eczema** | **Atopic dermatoses** | **Pruritic dermatoses**
    - TO THE SKIN
    - Child: 2–4 capfuls/bath, alternatively 15–30 mL, to be added in an adult-size bath and soak for 20 minutes (proportionally less for a child’s bath)
    - Adult: 2–4 capfuls/bath, alternatively 15–30 mL, to be added in an adult-size bath and soak for 20 minutes
Coal tar with calamine 31-Aug-2016

The properties listed below are those particular to the combination only. For the properties of the components please consider, coal tar p. 1152.

**INDICATIONS AND DOSE**

Psoriasis | Chronic atopic eczema (occasionally)
- **TO THE SKIN**
- Adult: Apply 1–2 times a day

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. No licensed medicines listed.

**PREScribing AND DISPENSING INFORMATION**

When prepared extemporaneously, the BP states Calamine and Coal Tar Ointment BP, consists of calamine 12.5 g, strong coal tar solution 2.5 g, zinc oxide 12.5 g, hydrous wool fat 25 g, white soft paraffin 47.5 g.

Coal tar with coconut oil and salicylic acid

The properties listed below are those particular to the combination only. For the properties of the components please consider, coal tar p. 1152, salicylic acid p. 1182.

**INDICATIONS AND DOSE**

Scaly scalp disorders | Psoriasis | Seborrhoeic dermatitis | Dandruff | Cradle cap
- **TO THE SKIN USING SHAMPOO**
- Child: Apply daily as required
- Adult: Apply daily as required

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. No licensed medicines listed.

Coal tar with dithranol and salicylic acid

The properties listed below are those particular to the combination only. For the properties of the components please consider, coal tar p. 1152, dithranol p. 1151, salicylic acid p. 1182.

**INDICATIONS AND DOSE**

Subacute and chronic psoriasis
- **TO THE SKIN**
- Child: Apply up to twice daily
- Adult: Apply up to twice daily

**UNLICENSED USE** Psorin® is licensed for use in children (age range not specified by manufacturer).

Coal tar with lecithin

The properties listed below are those particular to the combination only. For the properties of the components please consider, coal tar p. 1152.

**INDICATIONS AND DOSE**

Psoriasis
- **TO THE SKIN**
- Child: Apply as required
- Adult: Apply as required

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

- **Cream**
  - EXCIPIENTS: May contain Isopropyl palmitate, propylene glycol
  - Psoriderm (Dermal Laboratories Ltd)
  - Lecithin 4 mg per 1 gram, Coal tar distilled 60 mg per 1 gram
  - Psoriderm cream | 225 ml | £9.42

- **Shampoo**
  - EXCIPIENTS: May contain Disodium edetate
  - Psoriderm (Dermal Laboratories Ltd)
  - Lecithin 3 mg per 1 ml, Coal tar distilled 25 mg per 1 ml
  - Psoriderm scalp lotion | 250 ml | £4.74

Coal tar with salicylic acid 26-Aug-2016

The properties listed below are those particular to the combination only. For the properties of the components please consider, coal tar p. 1152, salicylic acid p. 1182.

**INDICATIONS AND DOSE**

Psoriasis | Chronic atopic eczema
- **TO THE SKIN USING OINTMENT**
- Adult: Apply 1–2 times a day

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: ointment.

**PREScribing AND DISPENSING INFORMATION**

When prepared extemporaneously, the BP states Coal Tar and Salicyclic Acid Ointment, BP consists of coal tar 2 g, salicylic acid 2 g, emulsifying wax 11.4 g, white soft paraffin 19 g, coconut oil 54 g, polysorbate ‘80’ 4 g, liquid paraffin 7.6 g.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: ointment.
Coal tar with salicylic acid and precipitated sulfur

The properties listed below are those particular to the combination only. For the properties of the components please consider, coal tar p. 1152, salicylic acid p. 1182.

- **INDICATIONS AND DOSE**
  **COCOIS® OINTMENT**
  Scaly scalp disorders including psoriasis, eczema, seborrhoeic dermatitis and dandruff
  - **INITIALLY TO THE SKIN USING SCALP OINTMENT**
  - Child 6–11 years: Medical supervision required
  - Child 12–17 years: Apply once weekly as required, alternatively (to the skin) apply daily for the first 3–7 days (if severe), shampoo off after 1 hour
  - Adult: Apply once weekly as required, alternatively (to the skin) apply daily for the first 3–7 days (if severe), shampoo off after 1 hour

  **SEBCO® OINTMENT**
  Scaly scalp disorders including psoriasis, eczema, seborrhoeic dermatitis and dandruff
  - **TO THE SKIN USING SCALP OINTMENT**
  - Child 6–11 years: Medical supervision required
  - Child 12–17 years: Apply as required, alternatively apply daily for the first 3–7 days (if severe), shampoo off after 1 hour
  - Adult: Apply as required, alternatively apply daily for the first 3–7 days (if severe), shampoo off after 1 hour

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.
  **Ointment**
  EXCipients: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol).
  - Cocos (Focus Pharmaceuticals Ltd)
    - Salicylic acid 20 mg per 1 gram, Sulfur precipitated 40 mg per 1 gram, Coal tar solution 120 mg per 1 gram  Cocos ointment | 40 gram GEL £6.22 | 100 gram GEL £11.69
  - Sebco (Derma UK Ltd)
    - Salicylic acid 20 mg per 1 gram, Sulfur precipitated 40 mg per 1 gram, Coal tar solution 120 mg per 1 gram Sebco ointment | 40 gram GEL £5.91 | 100 gram GEL £11.11

Coal tar with zinc oxide

26-Aug-2016

The properties listed below are those particular to the combination only. For the properties of the components please consider, coal tar p. 1152.

- **INDICATIONS AND DOSE**
  **Psoriasis** | **Chronic atopic eczema**
  - **TO THE SKIN**
    - Child: Apply 1–2 times a day
    - Adult: Apply 1–2 times a day

- **IMPORTANT SAFETY INFORMATION**
  **MHRA/CHM UPDATE (APRIL 2016): FIRE RISK WITH PARAFFIN-BASED SKIN EMOLLIENTS ON DRESSINGS OR CLOTHING**
  See Emollient and barrier preparations p. 1118.

- **PRESCRIBING AND DISPENSING INFORMATION**
  No preparations available—when prepared extemporaneously, the BP states Zinc and Coal Tar Paste, BP consists of zinc oxide 6%, coal tar 6%, emulsifying wax 5%, starch 38%, yellow soft paraffin 45%.

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: ointment, paste

Extract of coal tar with arachis oil

The properties listed below are those particular to the combination only. For the properties of the components please consider, coal tar p. 1152.

- **INDICATIONS AND DOSE**
  **Scalp disorders** | **Psoriasis** | **Seborrhoea** | **Eczema** | **Pruritus** | **Dandruff**
  - **TO THE SKIN**
    - Child: Apply 1–2 times a week, to the scalp
    - Adult: Apply 1–2 times a week, to the scalp

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.
  No licensed medicines listed.

- **IMMUNOSUPPRESSANTS** | **CALCINEURIN INHIBITORS AND RELATED DRUGS**
  **Pimecrolimus**

- **INDICATIONS AND DOSE**
  Short-term treatment of mild to moderate atopic eczema (including flares) when topical corticosteroids cannot be used (initiated by a specialist)
  - **TO THE SKIN**
    - Adult: Apply twice daily until symptoms resolve (stop treatment if eczema worsens or no response after 6 weeks)
  Short-term treatment of facial, flexural, or genital psoriasis in patients unresponsive to, or intolerant of other topical therapy (initiated by a specialist)
  - **TO THE SKIN**
    - Adult: Apply twice daily until symptoms resolve (maximum duration of treatment 4 weeks)

- **UNLICENSED USE**
  Pimecrolimus is not licensed for short-term treatment of facial, flexural, or genital psoriasis in patients unresponsive to, or intolerant of other topical therapy.

- **CONTRA-INDICATIONS**
  Application to malignant or potentially malignant skin lesions · application under occlusion · congenital epidermal barrier defects · contact with eyes · contact with mucous membranes · generalised erythroderma · immunodeficiency · infection at treatment site

- **CAUTIONS**
  Alcohol consumption (risk of facial flushing and skin irritation) · avoid other topical treatments except emollients at treatment site · UV light (avoid excessive exposure to sunlight and sunlamps)

- **INTERACTIONS**
  Appendix 1: pimecrolimus

- **SIDE-EFFECTS**
  - **Common or very common** Burning sensation · erythema · folliculitis · pruritus · skin infections
  - **Uncommon** Herpes simplex · herpes zoster · impetigo · molluscum contagiosum
  - **Rare** Dryness · local reactions including pain · oedema · papilloma · paraesthesia · peeling · skin discoloration · worsening of eczema
  - **Frequency not known** Skin malignancy

- **PREGNANCY**
  Manufacturer advises avoid; toxicity in animal studies following systemic administration.

- **BREAST FEEDING**
  Manufacturer advises caution; ensure infant does not come in contact with treated areas.
**Tacrolimus**

**DRUG ACTION** Tacrolimus is a calcineurin inhibitor.

**INDICATIONS AND DOSE**

### Short-term treatment of moderate to severe atopic eczema (including flares) in patients unresponsive to, or intolerant of conventional therapy (initiated by a specialist)

- **TO THE SKIN**
  - Adult: Apply twice daily until lesion clears (consider other treatment if eczema worsens or no improvement after 2 weeks), initially 0.1% ointment to be applied thinly, reduce frequency to once daily or strength of ointment to 0.03% if condition allows

### Prevention of flares in patients with moderate to severe atopic eczema and 4 or more flares a year who have responded to initial treatment with topical tacrolimus (initiated by a specialist)

- **TO THE SKIN**
  - Adult: Apply twice weekly, 0.1% ointment to be applied thinly, with an interval of 2–3 days between applications, use short-term treatment regimen during an acute flare; review need for preventative therapy after 1 year

### Short-term treatment of facial, flexural, or genital psoriasis in patients unresponsive to, or intolerant of other topical therapy (initiated under specialist supervision)

- **TO THE SKIN**
  - Adult: Apply twice daily until symptoms resolve, 0.1% ointment to be applied thinly, reduce to once daily or switch to 0.03% ointment if condition allows, maximum duration of treatment 4 weeks

**UNLICENSED USE** Short-term treatment of facial, flexural, or genital psoriasis is unlicensed.

**CONTRA-INDICATIONS** Application to malignant or potentially malignant skin lesions - application under occlusion - avoid contact with eyes - avoid contact with mucous membranes - congenital epidermal barrier defects - generalised erythroderma - immunodeficiency - infection at treatment site

**CAUTIONS** UV light (avoid excessive exposure to sunlight and sunlamps)

**INTERACTIONS** → Appendix 1: tacrolimus

**SIDE-EFFECTS**

- **Common or very common** Application-site infections - application-site reactions - herpes simplex infection - irritation (at application-site) - Kaposi’s varicelliform eruption - pain at application-site - rash
- **Uncommon** Acne
- **Frequency not known** Cutaneous lymphoma - malignancies - other types of lymphomas - rosacea - skin malignancy

**ALLERGY AND CROSS-SENSITIVITY** Contra-indicated if history of hypersensitivity to macrolides.

**PREGNANCY** Manufacturer advises avoid unless essential; toxicity in animal studies following systemic administration.

**MEDICINAL FORMS**

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Strength</th>
<th>BNF 74</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ointment</td>
<td>0.1%</td>
<td>74</td>
</tr>
<tr>
<td>Cream</td>
<td>0.1%</td>
<td>74</td>
</tr>
</tbody>
</table>

**Breast Feeding** Avoid — present in breast milk (following systemic administration).

**Patient and Carer Advice** Avoid excessive exposure to UV light including sunlight.

**NATIONAL FUNDING/ACCESS DECISIONS**

### NICE technology appraisals (TAs)

- **Tacrolimus and pimecrolimus for atopic eczema** (August 2004) NICE TA82
  - Topical tacrolimus is an option for atopic eczema not controlled by maximal topical corticosteroid treatment or if there is a risk of important corticosteroid side-effects (particularly skin atrophy).
  - Tacrolimus is recommended for moderate to severe atopic eczema. Tacrolimus should be used within its licensed indications. [www.nice.org.uk/TA82](http://www.nice.org.uk/TA82)

**Scottish Medicines Consortium (SMC) Decisions**

The Scottish Medicines Consortium has advised (March 2010) that tacrolimus ointment (Protopic) is accepted for restricted use within NHS Scotland for the prevention of flares in patients with moderate to severe atopic eczema in accordance with the licensed indications; initiation of treatment is restricted to doctors (including general practitioners) with a specialist interest and experience in treating atopic eczema with immunomodulatory therapy.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Strength</th>
<th>BNF 74</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ointment</td>
<td>0.1%</td>
<td>74</td>
</tr>
</tbody>
</table>

**Drug Action**

**IMMUNOSUPPRESSANTS > INTERLEUKIN INHIBITORS**

**Ixekizumab**

**DRUG ACTION** Ixekizumab is a human monoclonal antibody that binds to interleukin-17A and inhibits the release of pro-inflammatory cytokines and chemokines.

**INDICATIONS AND DOSE**

Moderate-to-severe plaque psoriasis (under expert supervision)

- **BY SUBCUTANEOUS INJECTION**
  - Adult: Initially 160 mg for 1 dose, followed by 80 mg after 2 weeks, then 80 mg every 2 weeks for 5 further doses (at weeks 4, 6, 8, 10 and 12) and maintenance 80 mg every 4 weeks, consider discontinuation of treatment if no response after 16–20 weeks

**CONTRA-INDICATIONS** Active infections (including active tuberculosis)

**CAUTIONS** Chronic infection — monitor carefully and discontinue if serious, unresponsive infection develops - Crohn’s disease - ulcerative colitis

**FURTHER INFORMATION**

- Severe hypersensitivity reactions
- Severe hypersensitivity reactions have been reported — discontinue treatment immediately if symptoms occur.
- Latent tuberculosis
- Manufacturer advises that patients with latent tuberculosis should complete anti-tuberculosis therapy before starting ixekizumab.
- Inflammatory bowel disease
- Manufacturer advises to monitor closely for exacerbation.
Acitretin

**DRUG ACTION** Acitretin is a metabolite of etretinate.

**INDICATIONS AND DOSE**

- **Severe extensive psoriasis resistant to other forms of therapy (under expert supervision)** | **Palmoplantar pustular psoriasis (under expert supervision)** | **Severe congenital ichthyosis (under expert supervision)**
  - **BY MOUTH**
  - Adult: Initially 25–30 mg daily for 2–4 weeks, then adjusted according to response to 25–50 mg daily, increased to up to 75 mg daily, dose only increased to 75 mg daily for short periods in psoriasis

- **CONTRA-INDICATIONS** Hyperlipidaemia

- **CAUTIONS** Avoid excessive exposure to sunlight and unsupervised use of sunlamps - diabetes (can alter glucose tolerance - initial frequent blood glucose checks), do not donate blood during and for 2 years after stopping therapy (teratogenic risk) - in children use only in exceptional circumstances and monitor growth parameters and bone development (premature epiphyseal closure reported) - investigate atypical musculoskeletal symptoms

**DIRECTIONS FOR ADMINISTRATION** Manufacturer advises avoid - limited information available.

**HANDLING AND STORAGE** Manufacturer advises store in a refrigerator (2–8°C).

**PATIENT AND CARER ADVICE**

Self-administration If appropriate, patients and their carers should be given training in subcutaneous injection technique.

**NATIONAL FUNDING/ACCESS DECISIONS**

*Scottish Medicines Consortium (SMC) Decisions*

The *Scottish Medicines Consortium* has advised (April 2017) that ixekizumab (Taltz)® is accepted for restricted use in NHS Scotland for the treatment of moderate-to-severe plaque psoriasis only in patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these treatments. This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland, or a list price that is equivalent or lower.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

*Solution for injection*

**EXCIPIENTS:** May contain Polysorbates

- **Taltz** (Eli Lilly and Company Ltd)
  - Ixekizumab 80 mg per 1 ml | Taltz 80mg/0.25ml solution for injection pre-filled syringes | 1 pre-filled disposable injection | £1,125.00 (Hospital only)
  - Taltz 80mg/1ml solution for injection pre-filled pen | 1 pre-filled disposable injection | £1,125.00 (Hospital only) | 2 pre-filled disposable injection | £2,250.00 (Hospital only)

**RETINOID AND RELATED DRUGS**

Severe Darier's disease (keratosis follicularis) (under expert supervision)

- **BY MOUTH**
  - Adult: Initially 10 mg daily for 2–4 weeks, then adjusted according to response to 25–50 mg daily

- **CONTRA-INDICATIONS** Hyperlipidaemia

- **CAUTIONS** Avoid excessive exposure to sunlight and unsupervised use of sunlamps - diabetes (can alter glucose tolerance - initial frequent blood glucose checks), do not donate blood during and for 2 years after stopping therapy (teratogenic risk) - in children use only in exceptional circumstances and monitor growth parameters and bone development (premature epiphyseal closure reported) - investigate atypical musculoskeletal symptoms

- **INTERACTIONS** Appendix 1: monoclonal antibodies

**SIDE-EFFECTS**

- **Common or very common** Infection - nausea - oropharyngeal pain
  - **Uncommon** Bone marrow suppression - urticaria
  - **Frequency not known** Hypersensitivity reactions (occasionally late-onset) - inflammatory bowel disease (new or exacerbation)

**PREGNANCY** Manufacturer advises avoid - limited information available.

**BREAST FEEDING** Manufacturer advises avoid - present in milk in *animal* studies.

**DIRECTIONS FOR ADMINISTRATION** Manufacturer advises to avoid injecting into areas of the skin that show psoriasis; injection sites may be alternated. Patients may self-administer Taltz®, after appropriate training in subcutaneous injection technique.

**HANDLING AND STORAGE** Manufacturer advises store in a refrigerator (2–8°C).

**PATIENT AND CARER ADVICE**

Self-administration If appropriate, patients and their carers should be given training in subcutaneous injection technique.

**NATIONAL FUNDING/ACCESS DECISIONS**

*Scottish Medicines Consortium (SMC) Decisions*

The *Scottish Medicines Consortium* has advised (April 2017) that ixekizumab (Taltz)® is accepted for restricted use in NHS Scotland for the treatment of moderate-to-severe plaque psoriasis only in patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these treatments. This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland, or a list price that is equivalent or lower.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

*Solution for injection*

**EXCIPIENTS:** May contain Polysorbates

- **Taltz** (Eli Lilly and Company Ltd)
  - Ixekizumab 80 mg per 1 ml | Taltz 80mg/0.25ml solution for injection pre-filled syringes | 1 pre-filled disposable injection | £1,125.00 (Hospital only)
  - Taltz 80mg/1ml solution for injection pre-filled pen | 1 pre-filled disposable injection | £1,125.00 (Hospital only) | 2 pre-filled disposable injection | £2,250.00 (Hospital only)

**RETINOID AND RELATED DRUGS**

Acitretin

**DRUG ACTION** Acitretin is a metabolite of etretinate.

**INDICATIONS AND DOSE**

- **Severe extensive psoriasis resistant to other forms of therapy (under expert supervision)** | **Palmoplantar pustular psoriasis (under expert supervision)** | **Severe congenital ichthyosis (under expert supervision)**
  - **BY MOUTH**
  - Adult: Initially 25–30 mg daily for 2–4 weeks, then adjusted according to response to 25–50 mg daily, increased to up to 75 mg daily, dose only increased to 75 mg daily for short periods in psoriasis

- **CONTRA-INDICATIONS** Hyperlipidaemia

- **CAUTIONS** Avoid excessive exposure to sunlight and unsupervised use of sunlamps - diabetes (can alter glucose tolerance - initial frequent blood glucose checks), do not donate blood during and for 2 years after stopping therapy (teratogenic risk) - in children use only in exceptional circumstances and monitor growth parameters and bone development (premature epiphyseal closure reported) - investigate atypical musculoskeletal symptoms

- **INTERACTIONS** Appendix 1: retinoids

**SIDE-EFFECTS**

- **Common or very common** Abdominal pain - abnormal hair texture - alopecia (reversible on withdrawal) - arthralgia - brittle nails - dermatitis - diarrhoea - dryness and inflammation of mucous membranes - dryness of conjunctiva (causing conjunctivitis and decreased tolerance to contact lenses) - epidermal fragility - erythema - headache - myalgia - nausea - paronychia - peripheral oedema - pruritus - reversible increase in serum-cholesterol (with high doses) - reversible increase in serum-triglyceride concentrations (with high doses) - skin exfoliation - sticky skin - vomiting

- **Uncommon** Dizziness - hepatitis - photosensitivity - visual disturbances

- **Rare** Peripheral neuropathy

- **Very rare** Benign intracranial hypertension - bone pain - exostosis - night blindness - ulcerative keratitis

- **Frequency not known** Drowsiness - dry skin - flushing - granulomatous lesions - impaired hearing - initial worsening of psoriasis - malaise - rectal haemorrhage - sweating - taste disturbance - tinnitus

**SIDE-EFFECTS, FURTHER INFORMATION**

- **Exostosis** Skeletal hyperostosis and extra-osseous calcification reported following long-term treatment with etretinate (of which Acitretin is a metabolite) and premature epiphyseal closure in children.

- **Benign intracranial hypertension** Discontinue if severe headache, nausea, vomiting, or visual disturbances occur.

**CONCEPTION AND CONTRACEPTION** Effective contraception must be used.

Pregnancy prevention In females of child-bearing potential (including those with a history of infertility), exclude pregnancy up to 3 days before treatment, every month during treatment, and every 1–3 months for 3 years after stopping treatment. Treatment should be started on day 2 or 3 of menstrual cycle. Females of child-bearing age must practise effective contraception for at least 1 month before starting treatment, during treatment, and for at least 3 years after stopping treatment. Females should be advised to use at least 1 method of contraception, but ideally they should use 2 methods of contraception. Oral progestogen-only contraceptives are not considered effective. Barrier methods should not be used alone but can be used in conjunction with other contraceptive methods. Females should be advised to seek medical attention immediately if they become pregnant during treatment or within 3 years of stopping treatment. They should also be advised to avoid alcohol during treatment and for 2 months after stopping treatment.

- **PREGNANCY** Avoid—teratogenic.

- **BREAST FEEDING** Avoid.

- **HEPATIC IMPAIRMENT** Avoid in severe impairment—risk of further impairment.
● RENAL IMPAIRMENT  Avoid in severe impairment; increased risk of toxicity.

● MONITORING REQUIREMENTS
  ▶ Monitor serum-triglyceride and serum-cholesterol concentrations before treatment, 1 month after starting, then every 3 months.
  ▶ Check liver function at start, then every 2–4 weeks for first 2 months and then every 3 months.

● PRESCRIBING AND DISPENSING INFORMATION
  Prescribing for women of child-bearing potential Each prescription for acitretin should be limited to a supply of up to 30 days’ treatment and dispensed within 7 days of the date stated on the prescription.

● PATIENT AND CARER ADVICE
  A patient information leaflet should be provided. Females of child-bearing potential must be advised on pregnancy prevention.

● MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

Capsule
  CAUTIONARY AND ADVISORY LABELS  10, 11, 21
  ▶ Acitretin (Non-proprietary)
    Acitretin 10 mg  Acitretin 10mg capsules  |  60 capsule  |  £23.80
    DT price = £23.80
    Acitretin 25 mg  Acitretin 25mg capsules  |  60 capsule  |  £55.24
    DT price = £55.24
  ▶ Neotigason (Teva UK Ltd)
    Acitretin 10 mg  Neotigason 10mg capsules  |  60 capsule  |  £17.30
    DT price = £23.80 (Hospital only)
    Acitretin 25 mg  Neotigason 25mg capsules  |  60 capsule  |  £43.00
    DT price = £55.24 (Hospital only)

Alitretinoin

● INDICATIONS AND DOSE
  Severe chronic hand eczema refractory to potent topical corticosteroids
  ▶ BY MOUTH
    Adult (prescribed by or under supervision of a consultant dermatologist): 30 mg once daily; reduced if not tolerated to 10 mg once daily for 12–24 weeks total duration of treatment, discontinue if no response after 12 weeks, course may be repeated in those who relapse

  Severe chronic hand eczema refractory to potent topical corticosteroids in patients with diabetes, history of hyperlipidaemia, or risk factors for cardiovascular disease
  ▶ BY MOUTH
    Adult (prescribed by or under supervision of a consultant dermatologist): Initially 10 mg once daily, increased if necessary up to 30 mg once daily for 12–24 weeks total duration of treatment, discontinue if no response after 12 weeks, course may be repeated in those who relapse

DOSE ADJUSTMENTS DUE TO INTERACTIONS
  Manufacturer advises reduce dose to 10 mg once daily with concurrent use of potent inhibitors of CYP3A4, CYP2C8 and moderate inhibitors of CYP2C9.

● CONTRA-INDICATIONS
  Hypervitaminosis A  • uncontrolled hyperlipidaemia  • uncontrolled hypothyroidism

● CAUTIONS
  Avoid blood donation during treatment and for at least 1 month after stopping treatment  • dry eye syndrome  • history of depression

● INTERACTIONS
  ▶ Appendix 1: retinoids

● SIDE-EFFECTS
  ▶ Common or very common
    Alopecia  • anaemia  • arthralgia  • changes in thyroid function tests  • cheilitis  • conjunctivitis  • dry eyes  • dryness of lips  • dryness of skin  • erythema  • eye irritation  • flushing  • headache  • myalgia  • raised creatine kinase  • raised serum concentration of triglycerides and of cholesterol (risk of pancreatitis if triglycerides above 9 mmol/litre)
  ▶ Uncommon
    Ankylosing spondylitis  • osteoarthritic eczema  • blurred vision  • cataracts  • epistaxis  • hyperostosis  • pruritus
  ▶ Rare
    Benign intracranial hypertension  • vasculitis
  ▶ Frequency not known
    Decreased tolerance to contact lenses  • depression  • impaired night vision  • keratitis  • mood changes  • suicidal ideation

SIDE-EFFECTS, FURTHER INFORMATION
  ▶ Dry eyes  Dry eyes may respond to lubricating eye ointment or tear replacement therapy.
  ▶ Benign intracranial hypertension Discontinue treatment if severe headache, nausea, vomiting, papilloedema, or visual disturbances occur.

● CONCEPTION AND CONTRACEPTION
  Effective contraception must be used.
  Pregnancy prevention  In women of child-bearing potential, exclude pregnancy 1 month before treatment, up to 3 days before treatment, every month during treatment (unless there are compelling reasons to indicate that there is no risk of pregnancy), and 5 weeks after stopping treatment—perform pregnancy test in the first 3 days of the menstrual cycle.
  Women should practise effective contraception for at least 1 month before starting treatment, during treatment, and for at least 1 month after stopping treatment. Women should be advised to use at least 1 method of contraception but ideally they should use 2 methods of contraception. Oral progestogen-only contraceptives are not considered effective. Barrier methods should not be used alone but can be used in conjunction with other contraceptive methods.
  Women should be advised to discontinue treatment and to seek prompt medical attention if they become pregnant during treatment or within 1 month of stopping treatment.

● PREGNANCY
  Avoid—teratogenic.

● BREAST FEEDING
  Manufacturer advises avoid.

● HEPATIC IMPAIRMENT
  Manufacturer advises avoid—no information available.

● RENAL IMPAIRMENT
  Manufacturer advises avoid in severe impairment—no information available.

● MONITORING REQUIREMENTS
  Monitor serum lipids (more frequently in those with diabetes, history of hyperlipidaemia, or risk factors for cardiovascular disease)—discontinue if uncontrolled hyperlipidaemia.

● PRESCRIBING AND DISPENSING INFORMATION
  Prescribing for women of child-bearing potential Each prescription for alitretinoin should be limited to a supply of up to 30 days’ treatment and dispensed within 7 days of the date stated on the prescription.
  Alitretinoin is -teratogenic and must not be given to women of child-bearing potential unless they practise effective contraception and then only after detailed assessment and explanation by the physician.

● PATIENT AND CARER ADVICE
  A patient information leaflet should be provided.
  Patient advice required around conception and contraception Women of child-bearing potential must be counselled on pregnancy prevention.

● NATIONAL FUNDING/ACCESS DECISIONS

NIce technology appraisals (Tas)
  ▶ Alitretinoin for the treatment of severe chronic hand eczema in adults (August 2009) NIce TA177
  Alitretinoin is recommended for the treatment of severe chronic hand eczema that has not responded to potent topical corticosteroids. Treatment should be stopped as soon as an adequate response has been achieved (hands clear or almost clear), or if the eczema remains severe after...
12 weeks, or if an adequate response has not been achieved by 24 weeks.
www.nice.org.uk/TA177

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Capsule**
CAUTIONARY AND ADVISORY LABELS 10, 11, 21
- **Toctino** (Stiefel Laboratories (UK) Ltd)
  - Allretinoin 10 mg Toctino 10mg capsules | 30 capsule £411.43
  - Allretinoin 30 mg Toctino 30mg capsules | 30 capsule £411.43

**Tazarotene**

**INDICATIONS AND DOSE**
Mild to moderate plaque psoriasis affecting up to 10% of skin area
- **TO THE SKIN**
- Adult: Apply once daily usually for up to 12 weeks, apply in the evening

**CAUTIONS**
Avoid contact with eczematous skin - avoid contact with eyes - avoid contact with face - avoid contact with hair-covered scalp - avoid contact with inflamed skin - avoid contact with intertriginous areas

**SIDE-EFFECTS**
- Rare: Dry or painful skin - stinging and inflamed skin
- Frequency not known: Burning - contact dermatitis - desquamation - erythema - local irritation - non-specific rash - pruritus - worsening of psoriasis

**SIDE-EFFECTS, FURTHER INFORMATION**
Local irritation is more common with higher concentrations and may require discontinuation.

**CONCEPTION AND CONTRACEPTION**
Effective contraception required (oral progestogen-only contraceptives not considered effective).

**PREGNANCY**
Avoid.

**BREAST FEEDING**
Manufacturer advises avoid—present in milk in animal studies.

**PATIENT AND CARER ADVICE**
Avoid excessive exposure to UV light (including sunlight, sunlamps, PUVA or UVB treatment). Do not apply emollients or cosmetics within 1 hour of application. Wash hands immediately after use.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Gel**
EXCIPIENTS: May contain Benzyl alcohol, butylated hydroxyanisole, butylated hydroxytoluene, disodium edetate, polysorbates
- **Zorac** (Allergan Ltd)
  - Tazarotene 500 microgram per 1 gram Zorac 0.05% gel | 30 gram £14.93
  - Tazarotene 1 mg per 1 gram Zorac 0.1% gel | 30 gram £14.80

**SALICYLIC ACID AND DERIVATIVES**

**Salicylic acid with zinc oxide**

**INDICATIONS AND DOSE**
Hyperkeratotic skin disorders
- **TO THE SKIN**
- Adult: Apply twice daily

**CAUTIONS**
Avoid broken skin - avoid inflamed skin

**CAUTIONS, FURTHER INFORMATION**
- Salicylate toxicity: Salicylate toxicity may occur particularly if applied on large areas of skin or neonatal skin.

**SIDE-EFFECTS**
Excessive drying - irritation - sensitivity - systemic effects (after widespread use)

**PRESCRIBING AND DISPENSING INFORMATION**
Zinc and Salicylic Acid Paste BP is also referred to as Lassar’s Paste. When prepared extemporaneously, the BP states Zinc and Salicylic Acid Paste, BP (Lassar’s Paste) consists of zinc oxide 24%, salicylic acid 2%, starch 24%, white soft paraffin 50%.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: paste

**VITAMINS AND TRACE ELEMENTS**

**Calcipotriol**

**INDICATIONS AND DOSE**
Plaque psoriasis
- **TO THE SKIN USING OINTMENT**
- Adult: Apply 1–2 times a day, when preparations are used together maximum total calcipotriol 5 mg in any one week (e.g. scalp solution 60 mL with ointment 30 g or scalp solution 30 mL with ointment 60 g); maximum 100 g per week

**Scalp psoriasis**
- **TO THE SKIN USING SCALP LOTION**
- Adult: Apply twice daily, when preparations are used together maximum total calcipotriol 5 mg in any one week (e.g. scalp solution 60 mL with ointment 30 g or scalp solution 30 mL with ointment 60 g); maximum 60 mL per week

**CONTRA-INDICATIONS**
Calcium metabolism disorders

**CAUTIONS**
Avoid excessive exposure to sunlight and sunlamps - avoid use on face - erythrodemecic exfoliative psoriasis (enhanced risk of hypercalcaemia) - generalised pustular psoriasis (enhanced risk of hypercalcaemia)

**INTERACTIONS**
- **Appendix 1: vitamin D substances**

**SIDE-EFFECTS**
- Common or very common: Burning - dermatitis - erythema - itching - local skin reactions - paraesthesia
- Rare: Facial dermatitis - perioral dermatitis
- Frequency not known: Aggravation of psoriasis - dry skin - photosensitivity

**PREGNANCY**
Manufacturers advise avoid unless essential.

**BREAST FEEDING**
No information available.

**PATIENT AND CARER ADVICE**
Advice on application Patient information leaflet for Doxovex® ointment advises liberal application. However, patients should be advised of maximum recommended weekly dose.

Hands should be washed thoroughly after application to avoid inadvertent transfer to other body areas.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: ointment

**Ointment**
EXCIPIENTS: May contain Disodium edetate, propylene glycol
- **Calcipotriol (Non-proprietary)**
  - Calcipotriol 50 microgram per 1 gram Calcipotriol 50 micromg/g ointment | 30 gram £7.57 DT price = £5.78 | 60 gram £11.56–£13.86 | 120 gram £23.12–£27.75

- **Calcipotriene**
  - Calcipotriene 0.005% ointment | 30 gram £5.39–£6.93 | 60 gram £10.78–£13.86

- **Calcipotriene**
  - Calcipotriene 0.005% ointment | 30 gram £5.39–£6.93 | 60 gram £10.78–£13.86

- **Intact**
  - Intact 500 g | 120 mg g £3.02
Calcitriol
(1,25-Dihydroxycholecalciferol)

**INDICATIONS AND DOSE**

- **Mild to moderate plaque psoriasis**
  - **TO THE SKIN**
  - **Adult:** Apply twice daily, not more than 35% of body surface to be treated daily; maximum 30 g per day

- **CONTRA-INDICATIONS** Do not apply under occlusion - patients with calcium metabolism disorders
- **CAUTIONS** Erythrodermic exfoliative psoriasis (enhanced risk of hypercalcaemia) - generalised pustular psoriasis (enhanced risk of hypercalcaemia)
- **INTERACTIONS** → Appendix 1: vitamin D substances
- **SIDE-EFFECTS**
  - **Common or very common** Burning, dermatitis, erythema, itching, local skin reactions, paraesthesia
  - **Frequency not known** Aggravation of psoriasis
- **PREGNANCY** Manufacturer advises use in restricted amounts only if clearly necessary. Monitor urine- and serum-calcium concentration in pregnancy.
- **BREAST FEEDING** Manufacturer advises avoid.
- **HEPATIC IMPAIRMENT** Manufacturer advises avoid — no information available.
- **RENAL IMPAIRMENT** Manufacturer advises avoid — no information available.
- **HANDLING AND STORAGE** Hands should be washed thoroughly after application to avoid inadvertent transfer to other body areas.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution

- **Ointment**
  - **Siliks** (Galderma (UK) Ltd)
    - **Calcitriol 3 microgram per 1 gram** Siliks ointment | 100 gram (POM) £18.06 DT price = £18.06

- **Calcitriol**
  - **Non-proprietary**
    - **Calcitriol (as Calcitriol hydrate) 50 microgram per 1 ml** Calcitriol 50 micrograms/ml scalp solution | 60 ml (POM) £66.94 DT price = £56.94 | 120 ml (POM) £113.88 DT price = £113.88

Combinations available: *Calcitriol with betamethasone*, p. 1141

---

**Hyperhidrosis**

**Overview**

Aluminium chloride hexahydrate p. 1160 is a potent antiperspirant used in the treatment of hyperhidrosis. Aluminium salts are also incorporated in preparations used for minor fungal skin infections associated with hyperhidrosis.

Limited evidence suggests that oxybutynin hydrochloride p. 733 [unlicensed indication] can be used to treat hyperhidrosis in patients whose symptoms are not adequately managed through lifestyle modifications and antiperspirants.

In more severe cases specialists use glycopyrronium bromide p. 1160 as a 0.05% solution in the iontophoretic treatment of hyperhidrosis of plantar and palmar areas. Botox® contains botulinum toxin type A complex p. 387 and is licensed for use intradermally for severe hyperhidrosis of the axillae unresponsive to topical antiperspirant or other antihidrotic treatment.
5 Pruritus

Topical local antipruritics

Overview

Pruritus may be caused by systemic disease (such as obstructive jaundice, endocrine disease, chronic renal disease, iron deficiency, and certain malignant diseases), skin disease (e.g. psoriasis, eczema, urticaria, and scabies), drug hypersensitivity, or as a side-effect of opioid analgesics. Where possible, the underlying causes should be treated. An emollient may be of value where the pruritus is associated with dry skin. Pruritus that occurs in otherwise healthy elderly people can also be treated with an emollient.

Preparations containing crotamiton p. 1161 are sometimes used but are of uncertain value. Preparations containing calamine are often ineffective.

A topical preparation containing doxepin 5% p. 1161 is licensed for the relief of pruritus in eczema; it can cause drowsiness and there may be a risk of sensitisation.

Pruritus is common in biliary obstruction, especially in primary biliary cirrhosis and drug-induced cholestasis. Oral administration of colestyramine p. 191 is the treatment of choice.

Topical antihistamines and local anaesthetics are only marginally effective and occasionally cause hypersensitivity. For insect stings and insect bites, a short course of a topical corticosteroid is appropriate. Short-term treatment with a sedating antihistamine may help in insect stings and in intractable pruritus where sedation is desirable. Calamine preparations are of little value for the treatment of insect stings or bites.

Topical local anaesthetics are indicated for the relief of local pain. Preparations may be absorbed, especially through mucosal surfaces, therefore excessive application should be avoided and they should preferably not be used for more than 3 days; not generally suitable for young children and are less suitable for prescribing.

Topical antihistamines should be avoided in eczema and are not recommended for longer than 3 days. They are less suitable for prescribing.

Other drugs used for Pruritus

Alimemazine tartrate, p. 271 · Cetirizine hydrochloride, p. 268 · Chlorphenamine maleate, p. 272 · Hydroxyzine hydrochloride, p. 274 · Levocetirizine hydrochloride, p. 270
**Antipruritics**

**Calamine with zinc oxide**

31-Aug-2016

**Indications and dose**

- **Pruritus**
  - To the skin
  - Child: (consult product literature)
  - Adult: (consult product literature)

**Important safety information**

**Contra-indications** Avoid application of preparations containing zinc oxide prior to x-ray (zinc oxide may affect outcome of x-ray)

**Less suitable for prescribing** Less suitable for prescribing.

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug.

**Cream**

- **Calamine with zinc oxide (Non-proprietary)**
  - Phenoxethanol 5% per 1 gram, Zinc oxide 30% per 1 gram, Calamine 40% per 1 gram, Cetomacrogol emulsifying wax 50% per 1 gram, Self-emulsifying glyceryl monostearate 50% per 1 gram, Liquid paraffin 200% per 1 gram Aqueous calamine cream | 100 gram | £1.38
  - **Cala Soothe** (Ennogen Healthcare Ltd)
    - Phenoxethanol 5% per 1 gram, Zinc oxide 30% per 1 gram, Calamine 40% per 1 gram, Cetomacrogol emulsifying wax 50% per 1 gram, Self-emulsifying glyceryl monostearate 50% per 1 gram, Liquid paraffin 200% per 1 gram Cala Soothe cream | 100 ml | £18.80

- **Liquid**
  - **Calamine with zinc oxide (Non-proprietary)**
    - Phenol liquefied 5% per 1 ml, Sodium citrate 5% per 1 ml, Bentonite 30% per 1 ml, Glycerol 50% per 1 ml, Zinc oxide 50% per 1 ml, Calamine 150% per 1 ml Calamine lotion | 200 ml | £0.74
    - **Cala Soothe** (Ennogen Healthcare Ltd)
      - Phenol liquefied 5% per 1 ml, Sodium citrate 5% per 1 ml, Bentonite 30% per 1 ml, Glycerol 50% per 1 ml, Zinc oxide 50% per 1 ml, Calamine 150% per 1 ml Cala Soothe lotion | 200 ml | £19.50

**Doxepin**

**Indications and dose**

- **Pruritus in eczema**
  - To the skin
  - Child 12–17 years: Apply up to 3 g 3–4 times a day, apply thinly; coverage should be less than 10% of body surface area; maximum 12 g per day
  - Adult: Apply up to 3 g 3–4 times a day, apply thinly; coverage should be less than 10% of body surface area; maximum 12 g per day

**Caution**

Avoid application to large areas · cardiac arrhythmias · mania · severe heart disease · susceptibility to angle-closure glaucoma · urinary retention

**Interactions** Appendix 1: tricyclic antidepressants

**Side-effects**

- Common or very common Dizziness · drowsiness
- Frequency not known Antimuscarinic effects · fever · gastro-intestinal disturbances · headache · irritation · local burning · rash · stinging · tingling

**Pregnancy**

Manufacturer advises use only if potential benefit outweighs risk.

**Breast feeding**

Manufacturer advises use only if potential benefit outweighs risk.

**Hepatic impairment**

Manufacturer advises caution in severe liver disease.

**Patient and carer advice**

A patient information leaflet should be provided.

Driving and skilled tasks

Drowsiness may affect performance of skilled tasks (e.g. driving).

Effects of alcohol enhanced.

**Medicinal forms**

There can be variation in the licensing of different medicines containing the same drug.

**Cream**

- **Xepin** (Cambridge Healthcare Supplies Ltd)
  - Doxepin hydrochloride 50% per 1 gram Xepin 5% cream | 30 gram | £11.70

**Levomenthol and derivatives**

**Levomenthol**

**Indications and dose**

- **Pruritus**
  - To the skin
  - Adult: Apply 1–2 times a day

**Caution**

Avoid use in buccal mucosa · avoid use near eyes · avoid use on broken skin · avoid use on very inflamed skin · use on doctor's advice for children under 5 years

**Pregnancy**

Manufacturer advises avoid, especially during the first trimester — no information available.

**Breast feeding**

No information available; avoid application to nipple area.
6 Rosacea and acne

Rosacea and Acne

Acne

Treatment of acne should be commenced early to prevent scarring. Patients should be counselled that an improvement may not be seen for at least a couple of months. The choice of treatment depends on whether the acne is predominantly inflammatory or comedonal and its severity.

Mild to moderate acne is generally treated with topical preparations. Systemic treatment with oral antibacterials is generally used for moderate to severe acne or where topical preparations are not tolerated or are ineffective or where application to the site is difficult. Another oral preparation used for acne is the hormone treatment co-cyproterone acetate (cyproterone acetate with ethinylestradiol) p. 1163; it is for women only.

Severe acne, acne unresponsive to prolonged courses of oral antibacterials, scarring, or acne associated with psychological problems calls for early referral to a consultant dermatologist who may prescribe isotretinoin p. 1166 for administration by mouth.

Topical preparations for acne

In mild to moderate acne, comedones and inflamed lesions respond well to benzoyl peroxide p. 1164 or to a topical retinoid. Alternatively, topical application of an antibacterial such as erythromycin p. 510 or clindamycin p. 1164 may be effective for inflammatory acne. If topical preparations prove inadequate, oral preparations may be needed.

Benzoyl peroxide and azelaic acid

Benzoyl peroxide is effective in mild to moderate acne. Both comedones and inflamed lesions respond well to benzoyl peroxide. The lower concentrations seem to be as effective as higher concentrations in reducing inflammation. It is usual to start with a lower strength and to increase the concentration of benzoyl peroxide gradually. Adverse effects include local skin irritation, particularly when therapy is initiated, but the scaling and redness often subside with treatment continued at a reduced frequency of application. If the acne does not respond after 2 months then use of a topical antibacterial should be considered.

Azelaic acid p. 1165 has antimicrobial and anticomedonal properties. It may be an alternative to benzoyl peroxide or to a topical retinoid for treating mild to moderate comedonal acne, particularly of the face. Some patients prefer azelaic acid because it is less likely to cause local irritation than benzoyl peroxide.

Topical antibacterials for acne

For many patients with mild to moderate inflammatory acne, topical antibacterials may be no more effective than topical benzoyl peroxide or tretinoin p. 867. Topical antibacterials are probably best reserved for patients who wish to avoid oral antibacterials or who cannot tolerate them. Topical preparations of erythromycin and clindamycin are effective for inflammatory acne. Topical antibacterials can produce mild irritation of the skin, and on rare occasions cause sensitisation; gastro-intestinal disturbances have been reported with topical clindamycin.

Antibacterial resistance of Propionibacterium acnes is increasing; there is cross-resistance between erythromycin and clindamycin. To avoid development of resistance:

- when possible use non-antibiotic antimicrobials (such as benzoyl peroxide or azelaic acid);
- avoid concomitant treatment with different oral and topical antibacterials;
- if a particular antibacterial is effective, use it for repeat courses if needed (short intervening courses of benzoyl peroxide or azelaic acid may eliminate any resistant propionibacteria);
- do not continue treatment for longer than necessary (however, treatment with a topical preparation should be continued for at least 6 months).

Some manufacturers of topical antibacterial preparations for acne advise that preparations containing alcohol are not suitable for use with benzoyl peroxide.

Topical retinoids and related preparations for acne

Topical tretinoin, its isomer isotretinoin, and adapalene p. 1165 (a retinoid-like drug), are useful for treating comedones and inflammatory lesions in mild to moderate acne. Several months of treatment may be needed to achieve an optimal response and the treatment should be continued until no new lesions develop. Isotretinoin is given by mouth in severe acne.

Other topical preparations for acne

Preparations containing aluminium oxide p. 1168 are available for inflammatory acne.

A topical preparation of nicotinamide p. 1165 is not considered beneficial in acne.

Oral preparations for acne

Systemic antibacterial treatment is useful for inflammatory acne if topical treatment is not adequately effective or if it is inappropriate. Anticomendonal treatment (e.g. with topical benzoyl peroxide) may also be required.

Either oxytetracycline p. 536 or tetracycline p. 536 is usually given for acne. If there is no improvement after the first 3 months another oral antibacterial should be used. Maximum improvement usually occurs after 4 to 6 months but in more severe cases treatment may need to be continued for 2 years or longer.

Doxycycline p. 534 and lymecycline p. 535 are alternatives to tetracycline.

Although minocycline p. 535 is as effective as other tetracyclines for acne, it is associated with a greater risk of lupus erythematosus-like syndrome. Minocycline sometimes causes irreversible pigmentation; it is given in a once or twice daily dose.

Erythromycin in a twice daily dose is an alternative for the management of acne but propionibacteria strains resistant to erythromycin are becoming widespread and this may explain poor response.
Triclosan 1.8 may be used for acne resistant to other antibacterials [unlicensed indication]. Prolonged treatment with triclosan may depress haematopoiesis; it should generally be initiated by specialists.

Concomitant use of different topical and systemic antibacterials is undesirable owing to the increased likelihood of the development of bacterial resistance.

**Hormone treatment for acne**

Co-cyprindiol (cyproterone acetate with ethinyleradiol) contains an anti-androgen. It is licensed for use in women with moderate to severe acne that has not responded to topical therapy or oral antibiotics, and for moderately severe hirsutism. Although it is an effective hormonal contraceptive, it should not be used solely for contraception.

Improvement of acne with co-cyprindiol probably occurs because of decreased sebum secretion which is under androgen control. Some women with moderately severe hirsutism may also benefit because hair growth is also androgen-dependent.

**Oral retinoid for acne**

The retinoid isotretinoin reduces sebum secretion. It is used for the systemic treatment of nodulo-cystic and conglobate acne, severe acne, scarring, acne which has not responded to an adequate course of a systemic antibacterial, or acne which is associated with psychological problems. It is also useful in women who develop acne in the third or fourth decades of life, since late onset acne is frequently unresponsive to antibacterials.

Isotretinoin is a toxic drug that should be prescribed only by, or under the supervision of, a consultant dermatologist. It is given for at least 16 weeks; repeat courses are not normally required.

Side-effects of isotretinoin include severe dryness of the skin and mucous membranes, nose bleeds, and joint pains. The drug is teratogenic and must not be given to women of child-bearing age unless they practise effective contraception (oral progestogen-only contraceptives not considered effective) and then only after detailed assessment and explanation by the physician. Women must also be registered with a pregnancy prevention programme.

Although a causal link between isotretinoin p. 1166 use and psychiatric changes (including suicidal ideation) has not been established, the possibility should be considered before initiating treatment; if psychiatric changes occur during treatment, isotretinoin should be stopped, the prescriber informed, and specialist psychiatric advice should be sought.

**Rosacea**

Rosacea is not comedonal (but may exist with acne which may be comedonal). Brimonidine tartrate p. 1169 is licensed for the treatment of facial erythema in rosacea. The pustules and papules of rosacea respond to topical azelaic acid p. 1165, topical ivermectin p. 1169 or to topical metronidazole p. 1127. Alternatively oral administration of oxytetracycline p. 536 or tetracycline p. 536, or erythromycin p. 510, can be used; courses usually last 6–12 weeks and are repeated intermittently. Doxycycline p. 534 can be used [unlicensed indication] if oxytetracycline or tetracycline is inappropriate (e.g. in renal impairment). A modified-release preparation of doxycycline is licensed in low daily doses for the treatment of facial rosacea. Isotretinoin is occasionally given in refractory cases [unlicensed indication]. Camouflagers may be required for the redness.

**6.1 Acne**

### Anti-androgens

#### Co-cyprindiol

<table>
<thead>
<tr>
<th><strong>INDICATIONS AND DOSE</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderate to severe acne in females of child-bearing age refractory to topical therapy or oral antibacterials</td>
</tr>
</tbody>
</table>

- **By mouth**
- Females of childbearing potential: 1 tablet daily for 21 days, to be started on day 1 of menstrual cycle; subsequent courses repeated after a 7–day interval (during which withdrawal bleeding occurs), time to symptom remission, at least 3 months; review need for treatment regularly

| **CONTRA-INDICATIONS** |
| Acute porphyria • gallstones • heart disease associated with pulmonary hypertension or risk of embolus • history during pregnancy of cholestatic jaundice • history during pregnancy of chorea • history during pregnancy of pemphigoid gestationis • history during pregnancy of pruritus • history of breast cancer but can be used after 5 years if no evidence of disease and non-hormonal methods unacceptable • history of venous or arterial thrombosis • sclerosing treatment for varicose veins • severe or multiple risk factors for arterial disease or for venous thromboembolism • systemic lupus erythematosus with (or unknown) antiphospholipid antibodies • transient cerebral ischaemic attacks without headache |

| **SIDE-EFFECTS** |
| **CAUTIONS** |
| Active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration) • seek specialist advice • arterial disease • gene mutations associated with breast cancer (e.g. BRCA 1) • history of severe depression especially if induced by hormonal contraceptive • hyperprolactinemia • seek specialist advice • inflammatory bowel disease including inflammatory bowel disease including Crohn's disease • headache |

**Co-cyprindiol**

- **By mouth**
- Females of childbearing potential: 1 tablet daily for 21 days, to be started on day 1 of menstrual cycle; subsequent courses repeated after a 7–day interval (during which withdrawal bleeding occurs), time to symptom remission, at least 3 months; review need for treatment regularly

| **CONTRA-INDICATIONS** |
| Acute porphyria • gallstones • heart disease associated with pulmonary hypertension or risk of embolus • history during pregnancy of cholestatic jaundice • history during pregnancy of chorea • history during pregnancy of pemphigoid gestationis • history during pregnancy of pruritus • history of breast cancer but can be used after 5 years if no evidence of disease and non-hormonal methods unacceptable • history of venous or arterial thrombosis • sclerosing treatment for varicose veins • severe or multiple risk factors for arterial disease or for venous thromboembolism • systemic lupus erythematosus with (or unknown) antiphospholipid antibodies • transient cerebral ischaemic attacks without headache |

| **SIDE-EFFECTS** |
| **CAUTIONS** |
| Active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration) • seek specialist advice • arterial disease • gene mutations associated with breast cancer (e.g. BRCA 1) • history of severe depression especially if induced by hormonal contraceptive • hyperprolactinemia • seek specialist advice • inflammatory bowel disease including inflammatory bowel disease including Crohn's disease • headache |

---

**Skin**

- **Antibacterials**
  - Antibacterials [unlicensed indication]. Prolonged treatment may be required for the redness.
thrombosis (more common when factor V Leiden present or in blood groups A, B, and AB) • visual disturbances • vomiting • ‘spotting’ in early cycles

- PREGNANCY Avoid—risk of feminisation of male fetus with cyproterone.
- BREAST FEEDING Manufacturer advises avoid; possibility of anti-androgen effects in neonate with cyproterone.
- HEPATIC IMPAIRMENT Avoid in active liver disease including disorders of hepatic excretion (e.g. Dubin-Johnson or Rotor syndromes), infective hepatitis (until liver function returns to normal), and liver tumours.
- PRESCRIBING AND DISPENSING INFORMATION A mixture of cyproterone acetate and ethinylestradiol in the mass proportions 2000 parts to 35 parts, respectively.

- MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug.
  - Tablet
    - Co-cyprindiol (Non-proprietary)
      Ethinylestradiol 35 microgram, Cyproterone acetate 2 mg Co-cyprindiol 2000microgram/35microgram tablets | 63 tablet £5.70 (Pom)
    - Clairette (Stragen UK Ltd)
      Ethinylestradiol 35 microgram, Cyproterone acetate 2 mg Clairette 2000/35 tablets | 63 tablet £5.90 (Pom) £5.70
    - Dianette (Bayer Plc)
      Ethinylestradiol 35 microgram, Cyproterone acetate 2 mg Dianette tablets | 63 tablet £5.50 (Pom)
    - Terazeeza (Morningside Healthcare Ltd)
      Ethinylestradiol 35 microgram, Cyproterone acetate 2 mg Terazeeza 2000microgram/35microgram tablets | 63 tablet £11.10 (Pom) £5.70

ANTIBACTERIALS ▶ LINCOSAMIDES

Clindamycin

- INDICATIONS AND DOSE
  DALACIN T® LOTION
  Acne vulgaris
  ▶ TO THE SKIN
  ▶ Child: Apply twice daily, to be applied thinly
  ▶ Adult: Apply twice daily, to be applied thinly

DALACIN T® SOLUTION
  Acne vulgaris
  ▶ TO THE SKIN
  ▶ Child: Apply twice daily, to be applied thinly
  ▶ Adult: Apply twice daily, to be applied thinly

ZINDACLIN® GEL
  Acne vulgaris
  ▶ TO THE SKIN
  ▶ Child 12-17 years: Apply once daily, to be applied thinly
  ▶ Adult: Apply once daily, to be applied thinly

- INTERACTIONS → Appendix 1: clindamycin

- MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug.
  - Gel
    - EXCIPIENTS: May contain Propylene glycol
      - Zindacin (Crawford Healthcare Ltd)
        Clindamycin (as Clindamycin phosphate) 10 mg per 1 gram Zindacin 1% gel | 30 gram (Pom) £8.66 DT price = £8.66
    - EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), hydroxybenzoates (parabens), propylene glycol
      - Dalacin T (Pfizer Ltd)
        Clindamycin (as Clindamycin phosphate) 10 mg per 1 ml Dalacin T 1% topical lotion | 30 ml (Pom) £5.08 DT price = £5.08 | 60 ml (Pom) £10.16

Dalacin T 1% topical solution | 30 ml (Pom) £4.34 DT price = £4.34 | 50 ml (Pom) £7.23

Combinations available: Benzoyl peroxide with clindamycin, p. 1165 - Tretinoin with clindamycin, p. 1168

ANTIBACTERIALS ▶ MACROLIDES

Erythromycin with zinc acetate

- INDICATIONS AND DOSE
  Acne vulgaris
  ▶ TO THE SKIN
  ▶ Child: Apply twice daily
  ▶ Adult: Apply twice daily

- CAUTIONS Some manufacturers advise preparations containing alcohol are not suitable for use with benzoyl peroxide

- MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug.
  - Liquid
    - Zineryt (LEO Pharma)
      Zinc acetate 12 mg per 1 ml, Erythromycin 40 mg per 1 ml Zineryt lotion | 30 ml (Pom) £9.25 DT price = £9.25 | 90 ml (Pom) £20.02 DT price = £20.02

ANTISEPTICS AND DISINFECTANTS ▶ PEROXIDES

Benzoyl peroxide

- INDICATIONS AND DOSE
  Acne vulgaris
  ▶ TO THE SKIN
  ▶ Child 12-17 years: Apply 1–2 times a day, preferably apply after washing with soap and water, start treatment with lower-strength preparations
  ▶ Adult: Apply 1–2 times a day, preferably apply after washing with soap and water, start treatment with lower-strength preparations

- UNLICENSED USE Not licensed for use in treatment of infantile acne.
- CAUTIONS Avoid contact with broken skin • avoid contact with eyes • avoid contact with mouth • avoid contact with mucous membranes • avoid excessive exposure to sunlight
- SIDE-EFFECTS Skin irritation
  SIDE-EFFECTS, FURTHER INFORMATION
  ▶ Skin irritation Reduce frequency or suspend use until irritation subsides and re-introduce at reduced frequency.
  ▶ PATIENT AND CARER ADVICE May bleach fabrics and hair.

- MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug.
  - Cream
    - EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), fragrances, isopropyl palmitate, propylene glycol
      - Brevoxy (GlaxoSmithKline Consumer Healthcare)
        Benzoyl peroxide 40 mg per 1 gram Brevoxy 4% cream | 50 gram (P) £4.13 DT price = £4.13
    - EXCIPIENTS: May contain Propylene glycol
      - Acnecide (Galdenera (UK) Ltd)
        Benzoyl peroxide 50 mg per 1 gram Acnecide 5% gel | 30 gram (P) £5.44 DT price = £5.44 | 60 gram (P) £10.68 DT price = £10.68
        Benzoyl peroxide 50 mg per 1 gram Acnecide Wash 5% gel | 50 gram (P) £5.44 DT price = £5.44

Combinations available: Adapalene with benzoyl peroxide, p. 1166
Benzoyl peroxide with clindamycin

The properties listed below are those particular to the combination only. For the properties of the components please consider, benzoyl peroxide p. 1164, clindamycin p. 1164.

### INDICATIONS AND DOSE

**Acne vulgaris**
- **TO THE SKIN**
- Child 12-17 years: Apply once daily, dose to be applied in the evening
- Adult: Apply once daily, dose to be applied in the evening

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

- **Gel**
  - **EXCIPIENTS:** May contain Disodium edetate
  - Clindamycin (as Clindamycin phosphate) 10 mg per 1 gram
  - Benzoyl peroxide 30 mg per 1 gram
    - Duac Once Daily gel (3% and 1%) | 30 gram [PoM] £13.14 DT price = £13.14 | 60 gram [PoM] £26.28
  - Clindamycin (as Clindamycin phosphate) 10 mg per 1 gram
  - Benzoyl peroxide 50 mg per 1 gram

### DERMATOLOGICAL DRUGS > ABRASIVE AGENTS

**Aluminium oxide**

### INDICATIONS AND DOSE

**Acne vulgaris**
- **TO THE SKIN**
- Adult: Apply 1–3 times a day, to be used instead of soap

**CONTRA-INDICATIONS**
Superficial venules • telangiectasia

**CAUTIONS**
Avoid contact with eyes

**SIDE-EFFECTS**
Skin irritation (discontinue use temporarily)

**PATIENT AND CARER ADVICE**
Patients should discontinue use temporarily if skin becomes irritated.

**LESS SUITABLE FOR PRESCRIBING**
Less suitable for prescribing (not considered beneficial).

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

- **Paste**
  - **EXCIPIENTS:** May contain Fragrances, n-(3-chloroallyl)hexaminium chloride (quaternium 15)
  - Brasivol (GlaxoSmithKline Consumer Healthcare)
    - Aluminium oxide 380 mg per 1 gram
    - Brasivol Fine No. 1 38% paste | 75 gram [GSL] £2.76

### RETINOID AND RELATED DRUGS

**Adapalene**

### INDICATIONS AND DOSE

**Mild to moderate acne vulgaris**
- **TO THE SKIN**
- Child 12-17 years: Apply once daily, apply thinly in the evening
- Adult: Apply once daily, apply thinly in the evening

**CAUTIONS**
Avoid accumulation in angles of the nose • avoid contact with eyes, nostrils, mouth and mucous membranes

**SIDE-EFFECTS**
- Common or very common Local irritation (reduce frequency or discontinue temporarily)
- Uncommon Skin discoloration
- Frequency not known Worsening of asthma

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

- **Cream**
  - **EXCIPIENTS:** May contain Propylene glycol
  - Skinoren (Bayer Plc)
    - Azelaic acid 200 mg per 1 gram
    - Skinoren 20% cream | 30 gram [PoM] £3.74 DT price = £3.74
  - Gel
    - **EXCIPIENTS:** May contain Disodium edetate, polysorbates, propylene glycol
    - Finacea (Bayer Plc)
      - Azelaic acid 150 mg per 1 gram
      - Finacea 15% gel | 30 gram [PoM] £7.48 DT price = £7.48

### Papulopustular rosacea

- **TO THE SKIN**
- Adult: Apply twice daily, discontinue if no improvement after 2 months

**SKINOREN®**

- **Acne vulgaris**
  - **TO THE SKIN**
  - Child 12-17 years: Apply twice daily
  - Adult: Apply twice daily

- **Acne vulgaris in patients with sensitive skin**
  - **TO THE SKIN**
  - Child 12-17 years: Apply once daily for 1 week, then apply twice daily
  - Adult: Apply once daily for 1 week, then apply twice daily

**CONCEPTION AND CONTRACEPTION**
Females of child-bearing age must use effective contraception (oral progestogen-only contraceptives not considered effective).

**PREGNANCY**
Avoid.

**BREAST FEEDING**
Amount of drug in milk probably too small to be harmful; ensure infant does not come in contact with treated areas.

**PATIENT AND CARER ADVICE**
If sun exposure is unavoidable, an appropriate sunscreen or protective clothing should be used.
Adapalene with benzoyl peroxide

The properties listed below are those particular to the combination only. For the properties of the components please consider, adapalene p. 1165, benzoyl peroxide p. 1164.

- **INDICATIONS AND DOSE**
  - **Acne vulgaris**
    - **TO THE SKIN**
    - Child 9–17 years: Apply once daily, to be applied thinly in the evening
    - Adult: Apply once daily, to be applied thinly in the evening

- **INTERACTIONS** → Appendix 1: retinoids
- **CONCEPTION AND CONTRACEPTION** Females of child-bearing age must use effective contraception (oral progestogen-only contraceptives not considered effective).
- **PATIENT AND CARER ADVICE** Gel may bleach clothing and hair.
- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **Scottish Medicines Consortium (SMC) Decisions**
    - The *Scottish Medicines Consortium* has advised (March 2014) that **Epiduo®** should be restricted for use in mild to moderate facial acne when monotherapy with benzoyl peroxide or adapalene is inappropriate.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Cream**
    - **CAUTIONARY AND ADVISORY LABELS**
    - **EXCIPIENTS:** May contain Disodium edetate, hydroxybenzoates (parabens)
    - **Adapalene (Non-proprietary)**
      - Adapalene 1 mg per 1 gram Adapalene 0.1% cream | 45 gram (POM) £19.73 DT price = £16.43
      - **Differin** (Galderma (UK) Ltd)
        - Adapalene 1 mg per 1 gram Differin 0.1% cream | 45 gram (POM) £16.43 DT price = £16.43
  - **Gel**
    - **CAUTIONARY AND ADVISORY LABELS**
    - **EXCIPIENTS:** May contain Disodium edetate, hydroxybenzoates (parabens), propylene glycol
    - **Adapalene (Non-proprietary)**
      - Adapalene 1 mg per 1 gram Adapalene 0.1% gel | 45 gram (POM) £19.73 DT price = £16.43
      - **Differin** (Galderma (UK) Ltd)
        - Adapalene 1 mg per 1 gram Differin 0.1% gel | 45 gram (POM) £16.43 DT price = £16.43

---

Isotretinoin

- **INDICATIONS AND DOSE**
  - **Topical treatment of mild to moderate acne**
    - **TO THE SKIN**
    - Adult: Apply 1–2 times a day, to be applied thinly
  - **Severe acne (under expert supervision)**
    - Acne which is associated with psychological problems (under expert supervision)
    - Acne which has not responded to an adequate course of a systemic antibacterial (under expert supervision)
    - Acne with scarring (under expert supervision)
  - **SYSTEMIC TREATMENT OF NODULO-CYSTIC AND CONGLOMBATE ACNE (UNDER EXPERT SUPERVISION)**
    - **BY MOUTH**
    - Adult: Initially 500 micrograms/kg daily in 1–2 divided doses, increased if necessary to 1 mg/kg daily for 16–24 weeks, repeat treatment course after a period of at least 8 weeks if relapse after first course; maximum 150 mg/kg per course

- **CONTRA-INDICATIONS**
  - With oral use Hyperlipidaemia · Hypervitaminosis A
  - With topical use Perioral dermatitis · Rosacea

- **CAUTIONS**
  - With oral use avoid blood donation during treatment and for at least 1 month after treatment · Diabetes · Dry eye syndrome (associated with risk of keratitis) · History of depression · Monitor for depression
  - With topical use allow peeling (resulting from other irritant treatments) to subside before using a topical retinoid · Alternating a preparation that causes peeling with a topical retinoid may give rise to contact dermatitis (reduce frequency of retinoid application) · Avoid accumulation in angles of the nose · Avoid contact with eyes, nostrils, mouth and mucous membranes, eczematous, broken or sunburned skin · Avoid exposure to UV light (including sunlight, solariums) · Avoid in severe acne involving large areas · Avoid use of topical retinoids with abrasive cleaners, comedogenic or astringent cosmetics · Caution in sensitive areas such as the neck · Personal or familial history of non-melanoma skin cancer

- **INTERACTIONS** → Appendix 1: retinoids

- **SIDE-EFFECTS**
  - Common or very common
  - With oral use
    - Anaemia · Arthralgia · Dryness of eyes (with blepharitis and conjunctivitis) · Dryness of lips (sometimes cheilitis) · Dryness of nasal mucosa (with epistaxis) · Dryness of pharyngeal mucosa (with hoarseness) · Dryness of skin (with dermatitis, scaling, thinning, erythema, pruritus) · Epidermal fragility (trauma may cause blistering) · Haematuria · Headache · Myalgia · Proteinuria · Raised blood-glucose concentration · Raised plasma-triglyceride concentration · Raised serum-cholesterol concentration · Reduced high-density lipoprotein concentration · Raised serum-transaminase concentration · Thrombocytopenia · Thrombocytosis
  - Rare
    - With oral use Aggressive behaviour · Alopecia · Anxiety · Depression · Mood changes · Skin reactions
  - Very rare
    - With oral use
      - Acne fulminans · Allergic vasculitis · Arthritis · Benign intracranial hypertension · Blurred vision · Bone changes following long-term administration · Calcification of tendons and ligaments following long-term administration · Cataracts · Colour blindness · Convulsions · Corneal opacities · Decreased night vision · Decreased tolerance to contact lenses · Diabetes mellitus · Dizziness · Drowsiness · Early epiphysial closure following long-term administration · Exacerbation of acne · Gastrointestinal haemorrhage · Glomerulonephritis · Gram-positive infections of skin and mucous membranes · Granulomatous...
lesions • haemorrhagic diarrhoea • hepatitis • hirsutism • hyperuricaemia • impaired hearing • increased sweating • inflammatory bowel disease • keratitis • lymphadenopathy • malaise • nail dystrophy • nausea • papilloedema • paronychia • photophobia • photosensitivity • psychosis • raised serum–creatinine kinase concentration • reduced bone density following long-term administration • skeletal hyperostosis following long-term administration • skin hyperpigmentation • suicidal ideation • tendinitis • visual disturbances

- Frequency not known
- With oral use Stevens–Johnson syndrome • toxic epidermal necrolysis
- With topical use Blistering of skin • burning • crusting of skin • dry or peeling skin • erythema • eye irritation • increased sensitivity to UVB light or sunlight • oedema • pruritus • stinging

SIDE-EFFECTS, FURTHER INFORMATION
- Management of side-effects Risk of pancreatitis if triglycerides above 9 mmol/litre—discontinue if uncontrolled hypertriglyceridaemia or pancreatitis. Psychiatric side-effects require expert referral. Discontinue treatment if skin peeling severe or haemorrhagic diarrhoea develops. Visual disturbances require expert referral and possible withdrawal.

CONCEPTION AND CONTRACEPTION
- Pregnancy prevention
  - With oral use Effective contraception must be used. In women of child-bearing potential, exclude pregnancy up to 3 days before treatment (start treatment on day 2 or 3 of menstrual cycle), every month during treatment (unless there are compelling reasons to indicate that there is no risk of pregnancy), and 5 weeks after stopping treatment—perform pregnancy test in the first 3 days of the menstrual cycle. Women must practise effective contraception for at least 1 month before starting treatment, during treatment, and for at least 1 month after stopping treatment. Women should be advised to use at least 1 method of contraception, but ideally they should use 2 methods of contraception. Oral progestogen-only contraceptives are not considered effective. Barrier methods should not be used alone, but can be used in conjunction with other contraceptive methods. Each prescription for isotretinoin should be limited to a supply of up to 30 days’ treatment and dispensed within 7 days of the date stated on the prescription; repeat prescriptions or fixed prescriptions are not acceptable. Women should be advised to discontinue treatment and to seek prompt medical attention if they become pregnant during treatment or within 1 month of stopping treatment.
  - With topical use Females of child-bearing age must use effective contraception (oral progestogen–only contraceptives not considered effective).

PREGNANCY Contra-indicated in pregnancy (teratogenic).

BREAST FEEDING Avoid.

HEPATIC IMPAIRMENT
- With oral use Avoid—further impairment may occur.

RENAL IMPAIRMENT
- With oral use In severe impairment, reduce initial dose (e.g. 10 mg daily) and increase gradually up to 1 mg/kg daily as tolerated.

MONITORING REQUIREMENTS
- With oral use Measure hepatic function and serum lipids before treatment, 1 month after starting and then every 3 months (reduce dose or discontinue if transaminase or serum lipids persistently raised).

PRESCRIBING AND DISPENSING INFORMATION Isotretinoin is an isomer of tretinoin.

- PATIENT AND CARER ADVICE
  - With oral use Warn patient to avoid wax epilation (risk of epidermal stripping), dermabrasion, and laser skin treatments (risk of scarring) during treatment and for at least 6 months after stopping; patient should avoid exposure to UV light (including sunlight) and use sunscreen and emollient (including lip balm) preparations from the start of treatment.
  - Patients and carers should be told how to recognise signs and symptoms of psychiatric disorders such as depression, anxiety, and rarely suicidal thoughts.
  - With topical use Patients should be warned that some redness and skin peeling can occur initially but settles with time. If undue irritation occurs, the frequency of application should be reduced or treatment suspended until the reaction subsides; if irritation persists, discontinue treatment. Several months of treatment may be needed to achieve an optimal response and the treatment should be continued until no new lesions develop. If sun exposure is unavoidable, an appropriate sunscreen or protective clothing should be used.

MEDICINAL FORMS

Isotretinoin with erythromycin

The properties listed below are those particular to the combination only. For the properties of the components please consider, isotretinoin p. 1166, erythromycin p. 510.

INDICATIONS AND DOSE
- Topical treatment of mild to moderate acne
  - TO THE SKIN
  - Adult: (consult product literature)

INTERACTIONS Appendix 1: macrolides, retinoids

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Gel

CAUTIONARY AND ADVISORY LABELS 11

EXCIPIENTS: May contain Butylated hydroxytoluene

- Isotrexin (Siefel Laboratories (UK) Ltd)
- Isotretinoin 500 microgram per 1 gram, Erythromycin 20 mg per 1 gram Isotrexin gel | 30 gram PBM £7.47 DT price + £7.47
Tretinoin with clindamycin

The properties listed below are those particular to the combination only. For the properties of the components please consider, tretinoin p. 867, clindamycin p. 1164.

**INDICATIONS AND DOSE**

**Facial acne**
- **Child 12-17 years**: Apply daily, (to be applied thinly at bedtime)
- **Adult**: Apply daily, (to be applied thinly at bedtime)

**CONTRA-INDICATIONS** Perioral dermatitis - personal or familial history of non-melanoma skin cancer - rosacea

**CAUTIONS** Allow peeling (resulting from other irritant treatments) to subside before using a topical retinoid - alternating a preparation that causes peeling with a topical retinoid may give rise to contact dermatitis (reduce frequency of retinoid application) - avoid accumulation in angles of the nose - avoid contact with eyes, nostrils, mouth and mucous membranes, eczematous, broken or sunburned skin - avoid exposure to UV light (including sunlight, solariums) - avoid in severe acne involving large areas - avoid use of topical retinoids with abrasive cleaners, comedogenic or astringent cosmetics - caution in sensitive areas such as the neck

**INTERACTIONS** → Appendix 1: clindamycin, retinoids

**SIDE-EFFECTS** Blistering of skin - burning - crusting of skin - dry or peeling skin (discontinue if severe) - erythema - eye irritation - increased sensitivity to UVB light or sunlight - oedema - pruritus - stinging - temporary changes of skin pigmentation

**CONCEPTION AND CONTRACEPTION** Females of child-bearing age must use effective contraception (oral progestogen-only contraceptives not considered effective).

**PREGNANCY** Contra-indicated in pregnancy.

**BREAST FEEDING** Amount of drug in milk after topical application probably too small to be harmful; ensure infant does not come in contact with treated areas.

**PATIENT AND CARER ADVICE** If sun exposure is unavoidable, an appropriate sunscreen or protective clothing should be used.

Patients and carers should be warned that some redness and skin peeling can occur initially but settles with time. If undue irritation occurs, the frequency of application should be reduced or treatment suspended until the reaction subsides; if irritation persists, discontinue treatment. Several months of treatment may be needed to achieve an optimal response and the treatment should be continued until no new lesions develop.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Gel**
- **CAUTIONARY AND ADVISORY LABELS**: May contain Butylated hydroxytoluene, hydroxybenzoates (parabens), polysorbates
- **Treclin** (Meda Pharmaceuticals Ltd)
  - Tretinoin 250 microgram per 1 gram, Clindamycin (as Clindamycin phosphate) 10 mg per 1 gram Treclin 1%/0.025% gel
  - 30 gram

**Tretinoin with erythromycin**

The properties listed below are those particular to the combination only. For the properties of the components please consider, tretinoin p. 867, erythromycin p. 510.

**INDICATIONS AND DOSE**

**Acne**
- **Child**: Apply 1–2 times a day, apply thinly
- **Adult**: Apply 1–2 times a day, apply thinly

**CONTRA-INDICATIONS** Perioral dermatitis - personal or familial history of non-melanoma skin cancer - rosacea

**CAUTIONS** Allow peeling (resulting from other irritant treatments) to subside before using a topical retinoid - alternating a preparation that causes peeling with a topical retinoid may give rise to contact dermatitis (reduce frequency of retinoid application) - avoid accumulation in angles of the nose - avoid contact with eyes, nostrils, mouth and mucous membranes, eczematous, broken or sunburned skin - avoid exposure to UV light (including sunlight, solariums) - avoid in severe acne involving large areas - avoid use of topical retinoids with abrasive cleaners, comedogenic or astringent cosmetics - caution in sensitive areas such as the neck

**INTERACTIONS** → Appendix 1: macrolides, retinoids

**SIDE-EFFECTS** Blistering of skin - burning - crusting of skin - dry or peeling skin (discontinue if severe) - erythema - eye irritation - increased sensitivity to UVB light or sunlight - oedema - pruritus - stinging - temporary changes of skin pigmentation

**CONCEPTION AND CONTRACEPTION** Females of child-bearing age must use effective contraception (oral progestogen-only contraceptives not considered effective).

**PREGNANCY** Contra-indicated in pregnancy.

**BREAST FEEDING** Amount of drug in milk after topical application probably too small to be harmful; ensure infant does not come in contact with treated areas.

**PATIENT AND CARER ADVICE** Patients and carers should be warned that some redness and skin peeling can occur initially but settles with time. If undue irritation occurs, the frequency of application should be reduced or treatment suspended until the reaction subsides; if irritation persists, discontinue treatment. Several months of treatment may be needed to achieve an optimal response and the treatment should be continued until no new lesions develop. If sun exposure is unavoidable, an appropriate sunscreen or protective clothing should be used.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Liquid**
- **CAUTIONARY AND ADVISORY LABELS**: May contain Butylated hydroxytoluene, hydroxybenzoates (parabens), polysorbates
- **Aknemycin Plus** (Almirall Ltd)
  - Tretinoin 250 microgram per 1 gram, Erythromycin 40 mg per 1 gram Aknemycin Plus solution 25 ml

**VITAMINS AND TRACE ELEMENTS** → VITAMIN B GROUP

**Nicotinamide**

**INDICATIONS AND DOSE**

**Inflammatory acne vulgaris**
- **TO THE SKIN**
- **Adult**: Apply twice daily, reduced to once daily or on alternate days, dose reduced if irritation occurs
6.2 Rosacea

Other drugs used for Rosacea
Azelaic acid, p. 1165

ANTHELMINTICS

Ivermectin

17-May-2017

<table>
<thead>
<tr>
<th>INDICATIONS AND DOSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Papulopustular rosacea</td>
</tr>
<tr>
<td>▶ TO THE SKIN</td>
</tr>
<tr>
<td>▶ Adult: Apply daily for up to 4 months, the treatment course may be repeated; discontinue if no improvement after 3 months</td>
</tr>
</tbody>
</table>

SIDE-EFFECTS

- Common or very common: Burning sensation
- Uncommon: Dry skin, pruritus, skin irritation
- Frequency not known: Contact dermatitis, erythema

PREGNANCY

Manufacturer advises avoid—limited information but toxicity following oral use in animal studies.

BREAST FEEDING

Manufacturer advises avoid—limited information but present in milk following oral use.

HEPATIC IMPAIRMENT

Manufacturer advises use with caution in severe impairment—no information available.

DIRECTIONS FOR ADMINISTRATION

Manufacturer advises apply thinly to the face only, avoiding contact with eyes, lips and mucosa.

PATIENT AND CARER ADVICE

Wash hands immediately after use.

NATIONAL FUNDING/ACCESS DECISIONS

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (December 2015) that ivermectin (Soolantra®) is accepted for restricted use within NHS Scotland for the treatment of moderate-to-severe inflammatory lesions of rosacea (papulopustular) where a topical treatment is considered appropriate.

All Wales Medicines Strategy Group (AWMSG) Decisions

The All Wales Medicines Strategy Group has advised (April 2016) that ivermectin (Soolantra®) is recommended as an option for use within NHS Wales for the topical treatment of inflammatory lesions of rosacea (papulopustular) in adult patients.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Cream

CAUTIONARY AND ADVISORY LABELS 28

EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), disodium edetate, isopropyl palmitate, propylene glycol containing the same drug.

DRUG ACTION

Brimonidine, an alpha2-adrenoceptor agonist, is used to reduce erythema in rosacea by cutaneous vasoconstriction.

INDICATIONS AND DOSE

Facial erythema in rosacea

▶ TO THE SKIN

▶ Adult: Apply once daily until erythema subsides, apply thinly, divide dose over forehead, chin, nose, and cheeks, max. 1 g of gel per day

DOSE EQUIVALENCE AND CONVERSION

1 g of gel contains 5 mg of brimonidine tartrate (equivalent to 3.3 mg of brimonidine).

CONTRA-INDICATIONS

Neonates and children under 2 years (risk of severe systemic side-effects)

CAUTIONS

Cerebral insufficiency—coronary insufficiency—depression—postural hypotension—Raynaud’s syndrome—severe cardiovascular disease—thromboangiitis obliterans

INTERACTIONS

Appendix 1: brimonidine

SIDE-EFFECTS

- Common or very common: Burning sensation at application site—stinging at application site
- Uncommon: Dry mouth, dry skin, headache, paraesthesia, skin irritation

PREGNANCY

Manufacturer advises avoid—limited information available.

BREAST FEEDING

Manufacturer advises avoid—no information available.

HEPATIC IMPAIRMENT

Manufacturer advises use with caution.

RENAL IMPAIRMENT

Manufacturer advises use with caution.

DIRECTIONS FOR ADMINISTRATION

Avoid contact with eyes, mouth, and mucous membranes; avoid use on irritated skin or open wounds; apply other topical preparations (including cosmetics) only after brimonidine gel has dried on skin.

PATIENT AND CARER ADVICE

Patients should be advised on administration of gel.

Driving and skilled tasks

Drowsiness may affect performance of skilled tasks (e.g. driving).

NATIONAL FUNDING/ACCESS DECISIONS

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (December 2014) that brimonidine (Mirvaso®) is accepted for restricted use within NHS Scotland for the symptomatic treatment of inflammatory rosacea (papulopustular) in adult patients.

IMPORTANT SAFETY INFORMATION

MHRA/CHM ADVICE: BRIMONIDINE GEL (MIRVASO®): RISK OF EXACERBATION OF ROSACEA (NOVEMBER 2016)

Symptom exacerbation has been reported very commonly in patients treated with brimonidine gel. Treatment should be initiated with a small amount of gel (less than the maximum dose) for at least 1 week, then increased gradually, based on tolerability and response. Patients should be counselled on the importance of not exceeding the maximum daily dose, and advised to stop treatment and seek medical advice if symptoms worsen during treatment.
treatment of moderate to severe persistent facial erythema associated with rosacea in adult patients.

● MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

Gel

CAUTIONARY AND ADVISORY LABELS 28

EXCipients: May contain Hydroxybenzoates (parabens), propylene glycol

▶ Mirvaso (Galderma (UK) Ltd)

Brimonidine (as Brimonidine tartrate) 3 mg per 1 gram  Mirvaso
3mg/g gel  30 gram  £33.69

7 Scalp and hair conditions

Scalp and hair conditions

Overview

Dandruff is considered to be a mild form of seborrhoeic dermatitis. Shampoos containing antimicrobial agents such as pyrithione zinc (which are widely available) and selenium sulﬁde shampoo as an antibacterial agent also may be used. A cream or an ointment containing coal tar with salicylic acid is very helpful in Psoriasis. Ketocnazole shampoo p. 1130 should be considered for more persistent or severe dandruff or for seborrhoeic dermatitis of the scalp.

Corticosteroid gels and lotions can also be used. Shampoos containing coal tar with salicylic acid p. 1153 may also be useful. A cream or an ointment containing coal tar with salicylic acid is very helpful in Psoriasis. Ketocnazole shampoo p. 1130 should be considered for more persistent or severe dandruff or for seborrhoeic dermatitis of the scalp.

Corticosteroid gels and lotions can also be used. Shampoos containing coal tar with salicylic acid p. 1153 may also be useful. A cream or an ointment containing coal tar with salicylic acid is very helpful in Psoriasis. Ketocnazole shampoo p. 1130 should be considered for more persistent or severe dandruff or for seborrhoeic dermatitis of the scalp.

Corticosteroid gels and lotions can also be used. Shampoos containing coal tar with salicylic acid p. 1153 may also be useful. A cream or an ointment containing coal tar with salicylic acid is very helpful in Psoriasis. Ketocnazole shampoo p. 1130 should be considered for more persistent or severe dandruff or for seborrhoeic dermatitis of the scalp.

Corticosteroid gels and lotions can also be used. Shampoos containing coal tar with salicylic acid p. 1153 may also be useful. A cream or an ointment containing coal tar with salicylic acid is very helpful in Psoriasis. Ketocnazole shampoo p. 1130 should be considered for more persistent or severe dandruff or for seborrhoeic dermatitis of the scalp.

Corticosteroid gels and lotions can also be used. Shampoos containing coal tar with salicylic acid p. 1153 may also be useful. A cream or an ointment containing coal tar with salicylic acid is very helpful in Psoriasis. Ketocnazole shampoo p. 1130 should be considered for more persistent or severe dandruff or for seborrhoeic dermatitis of the scalp.

Corticosteroid gels and lotions can also be used. Shampoos containing coal tar with salicylic acid p. 1153 may also be useful. A cream or an ointment containing coal tar with salicylic acid is very helpful in Psoriasis. Ketocnazole shampoo p. 1130 should be considered for more persistent or severe dandruff or for seborrhoeic dermatitis of the scalp.

Corticosteroid gels and lotions can also be used. Shampoos containing coal tar with salicylic acid p. 1153 may also be useful. A cream or an ointment containing coal tar with salicylic acid is very helpful in Psoriasis. Ketocnazole shampoo p. 1130 should be considered for more persistent or severe dandruff or for seborrhoeic dermatitis of the scalp.

Corticosteroid gels and lotions can also be used. Shampoos containing coal tar with salicylic acid p. 1153 may also be useful. A cream or an ointment containing coal tar with salicylic acid is very helpful in Psoriasis. Ketocnazole shampoo p. 1130 should be considered for more persistent or severe dandruff or for seborrhoeic dermatitis of the scalp.

Corticosteroid gels and lotions can also be used. Shampoos containing coal tar with salicylic acid p. 1153 may also be useful. A cream or an ointment containing coal tar with salicylic acid is very helpful in Psoriasis. Ketocnazole shampoo p. 1130 should be considered for more persistent or severe dandruff or for seborrhoeic dermatitis of the scalp.

Corticosteroid gels and lotions can also be used. Shampoos containing coal tar with salicylic acid p. 1153 may also be useful. A cream or an ointment containing coal tar with salicylic acid is very helpful in Psoriasis. Ketocnazole shampoo p. 1130 should be considered for more persistent or severe dandruff or for seborrhoeic dermatitis of the scalp.

Corticosteroid gels and lotions can also be used. Shampoos containing coal tar with salicylic acid p. 1153 may also be useful. A cream or an ointment containing coal tar with salicylic acid is very helpful in Psoriasis. Ketocnazole shampoo p. 1130 should be considered for more persistent or severe dandruff or for seborrhoeic dermatitis of the scalp.

Corticosteroid gels and lotions can also be used. Shampoos containing coal tar with salicylic acid p. 1153 may also be useful. A cream or an ointment containing coal tar with salicylic acid is very helpful in Psoriasis. Ketocnazole shampoo p. 1130 should be considered for more persistent or severe dandruff or for seborrhoeic dermatitis of the scalp.

Corticosteroid gels and lotions can also be used. Shampoos containing coal tar with salicylic acid p. 1153 may also be useful. A cream or an ointment containing coal tar with salicylic acid is very helpful in Psoriasis. Ketocnazole shampoo p. 1130 should be considered for more persistent or severe dandruff or for seborrhoeic dermatitis of the scalp.

Corticosteroid gels and lotions can also be used. Shampoos containing coal tar with salicylic acid p. 1153 may also be useful. A cream or an ointment containing coal tar with salicylic acid is very helpful in Psoriasis. Ketocnazole shampoo p. 1130 should be considered for more persistent or severe dandruff or for seborrhoeic dermatitis of the scalp.

Corticosteroid gels and lotions can also be used. Shampoos containing coal tar with salicylic acid p. 1153 may also be useful. A cream or an ointment containing coal tar with salicylic acid is very helpful in Psoriasis. Ketocnazole shampoo p. 1130 should be considered for more persistent or severe dandruff or for seborrhoeic dermatitis of the scalp.

Corticosteroid gels and lotions can also be used. Shampoos containing coal tar with salicylic acid p. 1153 may also be useful. A cream or an ointment containing coal tar with salicylic acid is very helpful in Psoriasis. Ketocnazole shampoo p. 1130 should be considered for more persistent or severe dandruff or for seborrhoeic dermatitis of the scalp.

Corticosteroid gels and lotions can also be used. Shampoos containing coal tar with salicylic acid p. 1153 may also be useful. A cream or an ointment containing coal tar with salicylic acid is very helpful in Psoriasis. Ketocnazole shampoo p. 1130 should be considered for more persistent or severe dandruff or for seborrhoeic dermatitis of the scalp.

Corticosteroid gels and lotions can also be used. Shampoos containing coal tar with salicylic acid p. 1153 may also be useful. A cream or an ointment containing coal tar with salicylic acid is very helpful in Psoriasis. Ketocnazole shampoo p. 1130 should be considered for more persistent or severe dandruff or for seborrhoeic dermatitis of the scalp.

Corticosteroid gels and lotions can also be used. Shampoos containing coal tar with salicylic acid p. 1153 may also be useful. A cream or an ointment containing coal tar with salicylic acid is very helpful in Psoriasis. Ketocnazole shampoo p. 1130 should be considered for more persistent or severe dandruff or for seborrhoeic dermatitis of the scalp.

Corticosteroid gels and lotions can also be used. Shampoos containing coal tar with salicylic acid p. 1153 may also be useful. A cream or an ointment containing coal tar with salicylic acid is very helpful in Psoriasis. Ketocnazole shampoo p. 1130 should be considered for more persistent or severe dandruff or for seborrhoeic dermatitis of the scalp.
7.1 Alopecia

Other drugs used for Alopecia

Finasteride, p. 742

Minoxidil

## INDICATIONS AND DOSE

**REGAINE® FOR MEN EXTRA STRENGTH FOAM**

Androgenetic alopecia

- **TO THE SKIN**
- Adult: Apply 0.5 capful twice daily, to be applied to the affected areas of scalp; discontinue if no improvement after 16 weeks

**REGAINE® FOR MEN EXTRA STRENGTH SOLUTION**

Androgenetic alopecia

- **TO THE SKIN**
- Adult: Apply 1 mL twice daily, to be applied to the affected areas of scalp; discontinue if no improvement after 1 year

**REGAINE® FOR WOMEN REGULAR STRENGTH**

Androgenetic alopecia

- **TO THE SKIN**
- Adult: Apply 1 mL twice daily, to be applied to the affected areas of scalp; discontinue if no improvement after 1 year

## CONTRA-INDICATIONS

Phaeochromocytoma

## CAUTIONS

- Avoid contact with broken, infected, shaved, or inflamed skin.
- Avoid contact with eyes.
- Avoid contact with mucous membranes.
- Avoid inhalation of spray mist.
- Avoid occlusive dressings.

## CAUTIONS, FURTHER INFORMATION

When used topically system effects unlikely; only about 1–2% absorbed (greater absorption may occur with use on inflamed skin).

## INTERACTIONS

Appendix 1: minoxidil

## SIDE-EFFECTS

- Common or very common: Headache, local irritation
- Uncommon: Changes in hair colour or texture (discontinue if increased hair loss persists for more than 2 weeks).
- Hypotension

## SIDE-EFFECTS, FURTHER INFORMATION

When used topically systemic effects unlikely; only about 1–2% absorbed (greater absorption may occur with use on inflamed skin).

## PREGNANCY

Avoid—possible toxicity including reduced placental perfusion. Neonatal hirsutism reported.

## BREAST FEEDING

Present in milk but not known to be harmful.

## PATIENT AND CARER ADVICE

Ensure hair and scalp dry before application. Patients and their carers should be advised to wash hands after application of liquid or foam.

7.2 Hirsutism

Other drugs used for Hirsutism

Co-cyprindiol, p. 1163

## ANTIPROTOZOALS

### Eflornithine

**DRUG ACTION**

An antiprotozoal drug that inhibits the enzyme ornithine decarboxylase in hair follicles.

### INDICATIONS AND DOSE

Adjunct to laser therapy for focal hirsutism in women

- **TO THE SKIN**
- Adult: Apply twice daily, to be applied thinly, discontinue use if no improvement after 4 months of treatment

### SIDE-EFFECTS

- Common or very common: Acne, burning at application site
- Uncommon: Abnormal hair growth, abnormal hair texture

### PREGNANCY

Toxicity in animal studies—manufacturer advises avoid.

### BREAST FEEDING

Manufacturer advises avoid—no information available.

### PATIENT AND CARER ADVICE

Medicines must be rubbed in thoroughly. Cosmetics may be applied over treated area 5 minutes after eflornithine, do not wash treated area for 4 hours after application.

### NATIONAL FUNDING/ACCESS DECISIONS

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (September 2005) that eflornithine for facial hirsutism is restricted for use in women in whom alternative drug treatment cannot be used.

## MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

### Cream

EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), hydroxybenzoates (parabens)

- Vaniqa (Almirall Ltd)
  - Eflornithine (as Eflornithine monohydrate chloride) 115 mg per 1 gram
    - Vaniqa 11.5% cream | 60 gram | £56.87
    - Vaniqa 11.5% foam | 50 gram | £39.13

### Liquid

EXCIPIENTS: May contain Propylene glycol

- Regaine (McNeil Products Ltd)
  - Minoxidil 20 mg per 1 mL
    - Regaine for Women Regular Strength 2% solution | 60 mL (GSL) | £14.16
    - Regaine for Men Extra Strength 5% solution | 180 mL (GSL) | £39.71

### Foam

EXCIPIENTS: May contain Butylated hydroxytoluene, cetostearyl alcohol (including cetyl and stearyl alcohol), polysorbates

- Regaine (McNeil Products Ltd)
  - Minoxidil 50 mg per 1 gram
    - Regaine for Men Extra Strength 5% scalp foam | 60 gram (GSL) | £21.84
    - Regaine for Men Extra Strength 5% scalp foam | 180 gram (GSL) | £46.33

### Other drugs used for Hirsutism

Co-cyprindiol, p. 1163

### VASODILATORS

#### Minoxidil

**REGAINE® FOR MEN EXTRA STRENGTH FOAM**

Androgenetic alopecia

- **TO THE SKIN**
- Adult: Apply 0.5 capful twice daily, to be applied to the affected areas of scalp; discontinue if no improvement after 16 weeks

**REGAINE® FOR MEN EXTRA STRENGTH SOLUTION**

Androgenetic alopecia

- **TO THE SKIN**
- Adult: Apply 1 mL twice daily, to be applied to the affected areas of scalp; discontinue if no improvement after 1 year

**REGAINE® FOR WOMEN REGULAR STRENGTH**

Androgenetic alopecia

- **TO THE SKIN**
- Adult: Apply 1 mL twice daily, to be applied to the affected areas of scalp; discontinue if no improvement after 1 year

**CONTRA-INDICATIONS**

Phaeochromocytoma

**CAUTIONS**

- Avoid contact with broken, infected, shaved, or inflamed skin.
- Avoid contact with eyes.
- Avoid contact with mucous membranes.
- Avoid inhalation of spray mist.
- Avoid occlusive dressings.

**CAUTIONS, FURTHER INFORMATION**

When used topically systemic effects unlikely; only about 1–2% absorbed (greater absorption may occur with use on inflamed skin).

**INTERACTIONS**

Appendix 1: minoxidil

**SIDE-EFFECTS**

- Common or very common: Headache, local irritation
- Uncommon: Changes in hair colour or texture (discontinue if increased hair loss persists for more than 2 weeks).
- Hypotension

**SIDE-EFFECTS, FURTHER INFORMATION**

When used topically systemic effects unlikely; only about 1–2% absorbed (greater absorption may occur with use on inflamed skin).

**PREGNANCY**

Avoid—possible toxicity including reduced placental perfusion. Neonatal hirsutism reported.

**BREAST FEEDING**

Present in milk but not known to be harmful.

**PATIENT AND CARER ADVICE**

Ensure hair and scalp dry before application. Patients and their carers should be advised to wash hands after application of liquid or foam.
8 Skin cleansers, antiseptics and desloughing agents

Skin cleansers, antiseptics and desloughing agents

Skin cleansers and antiseptics
Soap or detergent is used with water to cleanse intact skin; emollient preparations such as aqueous cream or emulsifying ointment can be used in place of soap or detergent for cleansing dry skin.

An antiseptic is used for skin that is infected or that is susceptible to recurrent infection. Detergent preparations containing chlorhexidine p. 1173 or povidone-iodine below, which should be thoroughly rinsed off, are used. Emollients may also contain antiseptics.

Antiseptics such as chlorhexidine or povidone-iodine are used on intact skin before surgical procedures; their antiseptic effect is enhanced by an alcoholic solvent. Antiseptic solutions containing cetrimide can be used if a detergent effect is also required.

Hydrogen peroxide p. 1174, an oxidising agent, can be used in solutions of up to 6% for skin disinfection, such as cleansing and deodorising wounds and ulcers. Hydrogen peroxide is also available as a cream for superficial bacterial skin infections.

For irrigating ulcers or wounds, lukewarm sterile sodium chloride 0.9% solution is used, but tap water is often appropriate.

Potassium permanganate below solution 1 in 10000, a mild antiseptic with astringent properties, can be used for exudative eczematous areas; treatment should be stopped when the skin becomes dry.

Desloughing agents
Alginate, hydrogel and hydrocolloid dressings are effective at wound debridement. Sterile larvae (maggots) (available from BioMonde) are also used for managing sloughing wounds and are prescribable on the NHS.

Desloughing solutions and creams are of little clinical value. Substances applied to an open area are easily absorbed and perilesional skin is easily sensitised. Gravitational dermatitis may be complicated by absorbed and perilesional skin is easily sensitised.

VALENTINE AND CARER ADVICE Can stain clothing, skin and nails (especially with prolonged use).

ANTISEPTICS AND DISINFECTANTS

Potassium permanganate

- INDICATIONS AND DOSE
  - Cleansing and deodorising suppurating eczematous reactions and wounds
    - TO THE SKIN
    - Adult: For wet dressings or baths, use approximately 0.01% (1 in 10 000) solution

- CAUTIONS
  - Irritant to mucous membranes

- DIRECTIONS FOR ADMINISTRATION
  - Potassium permanganate 0.1% solution to be diluted 1 in 10 to provide a 0.01% (1 in 10 000) solution. With potassium permanganate tablets for solution, 1 tablet dissolved in 4 litres of water provides a 0.01% (1 in 10 000) solution.

- PATIENT AND CARER ADVICE
  - Can stain clothing, skin and nails (especially with prolonged use).

- MEDICINAL FORMS
  - There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: liquid

    - Tablet for cutaneous solution
      - Potassium permanganate (Non-proprietary)

        - Potassium permanganate 400 mg Potassium permanganate 400mg tablets for cutaneous solution | 30 tablet no price available DT price = £17.50
      - Permitabs (Alliance Pharmaceuticals Ltd)

        - Potassium permanganate 400 mg Permitabs 400mg tablets for cutaneous solution | 30 tablet £17.50 DT price = £17.50

Alcohol

(Industrial methylated spirit)

- INDICATIONS AND DOSE
  - Skin preparation before injection
    - TO THE SKIN
    - Child: Apply as required
    - Adult: Apply as required

- CONTRA-INDICATIONS
  - Neonates

- CAUTIONS
  - Avoid broken skin • flammable • patients have suffered severe burns when diathermy has been preceded by application of alcoholic skin disinfectants

- SIDE-EFFECTS
  - Overdose
  - Features of acute alcohol intoxication include ataxia, dysarthria, nystagmus, and drowsiness, which may progress to coma, with hypotension and acidosis.

  - For details on the management of poisoning, see Alcohol, under Emergency treatment of poisoning p. 1249.

- PRESCRIBING AND DISPENSING INFORMATION
  - Industrial methylated spirits defined by the BP as a mixture of 19 volumes of ethyl alcohol of an appropriate strength with 1 volume of approved wood naphtha.

- MEDICINAL FORMS
  - There can be variation in the licensing of different medicines containing the same drug.

  - Liquid
    - Alcohol (Non-proprietary)
      - Industrial methylated spirit 70% | 600 ml £6.30
      - Wood naphtha 50 ml per 1 litre, Ethanol 950 ml per 1 litre Industrial methylated spirit 95% | 600 ml £5.04 | 1000 ml £4.46–£12.45

Povidone-iodine

- INDICATIONS AND DOSE
  - Skin disinfection
    - TO THE SKIN
    - Child: (consult product literature)
    - Adult: (consult product literature)

- BETADINE ® DRY POWDER SPRAY
  - Skin disinfection, particularly minor wounds and infections
    - TO THE SKIN
    - Adult: Not for use in serous cavities (consult product literature)
### ANTISEPTICS AND DISINFECTANTS > OTHER

#### Chlorhexidine

<table>
<thead>
<tr>
<th>INDICATIONS AND DOSE</th>
<th>OTHER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CX ANTISEPTIC DUSTING POWDER</strong></td>
<td>For skin disinfection</td>
</tr>
<tr>
<td>Adult: (consult product literature)</td>
<td>Child: (consult product literature)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CEPTON ® LOTION</th>
<th>For skin disinfection in acne</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adult: (consult product literature)</td>
<td>Child: (consult product literature)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CEPTON ® SKIN WASH</th>
<th>For use as skin wash in acne</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adult: (consult product literature)</td>
<td>Child: (consult product literature)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HIBITANE ® PLUS 5% CONCENTRATE SOLUTION</th>
<th>General and pre-operative skin disinfection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adult: (consult product literature)</td>
<td>Child: (consult product literature)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HIBISCUB ®</th>
<th>Pre-operative hand and skin disinfection</th>
<th>General hand and skin disinfection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adult: (consult product literature)</td>
<td>Child: (consult product literature)</td>
<td>Adult: (consult product literature)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HYDREX ® SOLUTION</th>
<th>For pre-operative skin disinfection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adult: (consult product literature)</td>
<td>Child: (consult product literature)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HYDREX ® SURGICAL SCRUB</th>
<th>For pre-operative hand and skin disinfection</th>
<th>General hand disinfection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adult: (consult product literature)</td>
<td>Child: (consult product literature)</td>
<td>Adult: (consult product literature)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>UNISEPT ®</th>
<th>For cleansing and disinfecting wounds and burns and swabbing in obstetrics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adult: (consult product literature)</td>
<td>Child: (consult product literature)</td>
</tr>
</tbody>
</table>

#### CONTRA-INDICATIONS  Avoid regular use in patients with thyroid disorders (in adults) • concomitant use of lithium • corrected gestational age under 32 weeks • infants body-weight under 1.5 kg • regular use in neonates

#### CAUTIONS  Broken skin • large open wounds

- Large open wounds: The application of povidone–iodine to large wounds or severe burns may produce systemic adverse effects such as metabolic acidosis, hypernatraemia and impairment of renal function.

#### SIDE-EFFECTS  Rare  Sensitivity

- **PREGNANCY**  Sufficient iodine may be absorbed to affect the fetal thyroid in the second and third trimester.

- **BREAST FEEDING**  Avoid regular or excessive use.

- **RENAL IMPAIRMENT**  Avoid regular application to inflamed or broken skin or mucosa.

#### EFFECT ON LABORATORY TESTS  May interfere with thyroid function tests.

#### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: liquid

- **Spray**
  - Betadine (Aspire Pharma Ltd)
    - Povidone-iodine 25 mg per 1 gram  Betadine 2.5% dry powder spray 100 ml [GEL] £9.95 DT price = £9.95

- **Liquid**
  - CAUTIONARY AND ADVISORY LABELS  15 (Only for use with alcoholic solutions)
    - Videne (Ecolab Healthcare Division)
      - Povidone-iodine 75 mg per 1 ml  Videne 7.5% surgical scrub solution 500 ml [GEL] £7.67
      - Povidone-iodine 100 mg per 1 ml  Videne 10% antiseptic solution 500 ml [GEL] £7.67

### Skin cleansers, antiseptics and desloughing agents 1173

**SAVLON ® DRY**

**Skin disinfection of minor wounds**
- TO THE SKIN
- Adult: (consult product literature)

**VIDENE ® SOLUTION**

**Skin disinfection**
- TO THE SKIN
- Child: Apply undiluted in pre-operative skin disinfection and general antisepsis
- Adult: Apply undiluted in pre-operative skin disinfection and general antisepsis

**VIDENE ® SURGICAL SCRUB ®**

**Skin disinfection**
- TO THE SKIN
- Child: Use as a pre-operative scrub for hand and skin disinfection
- Adult: Use as a pre-operative scrub for hand and skin disinfection

**VIDENE ® TINCTURE**

**Skin disinfection**
- TO THE SKIN
- Adult: Apply undiluted in pre-operative skin disinfection

- **CONTRA-INDICATIONS**  Avoid regular use in patients with thyroid disorders (in adults) • concomitant use of lithium • corrected gestational age under 32 weeks • infants body-weight under 1.5 kg • regular use in neonates

- **CAUTIONS**  Broken skin • large open wounds

- **SIDE-EFFECTS**  Rare  Sensitivity

- **PREGNANCY**  Sufficient iodine may be absorbed to affect the fetal thyroid in the second and third trimester.

- **BREAST FEEDING**  Avoid regular or excessive use.

- **RENAL IMPAIRMENT**  Avoid regular application to inflamed or broken skin or mucosa.

- **EFFECT ON LABORATORY TESTS**  May interfere with thyroid function tests.
**Chlorhexidine with cetrimide**

The properties listed below are those particular to the combination only. For the properties of the components please consider, chlorhexidine p. 1173.

### Indications and Dose

**Skin disinfection such as wound cleansing and obstetrics**
- **To the skin**
- **Child:** To be used undiluted
- **Adult:** To be used undiluted

### Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug.

**Cream**
- **Chlorhexidine with cetrimide (Non-proprietary)**
  - Chlorhexidine gluconate 1 mg per 1 gram, Cetrimide 5 mg per 1 gram
  - **Savlon antiseptic cream**
    - 15 gram [GSL] £1.19
    - 60 gram [GSL] £1.91
    - 100 gram [GSL] £2.78

**Irrigation solution**
- **Chlorhexidine with cetrimide (Non-proprietary)**
  - Chlorhexidine acetate 150 microgram per 1 ml, Cetrimide 1.5 mg per 1 ml
  - Chlorhexidine acetate 0.015% / Cetrimide 0.15% irrigation solution 3 litre bottles
  - 1 bottle [P] no price available

**Liquid**
- **Savlon disinfectant** (GlaxoSmithKline Consumer Healthcare)
  - Chlorhexidine gluconate 3 mg per 1 ml, Cetrimide 30 mg per 1 ml
  - **Savlon disinfectant liquid**
    - 500 ml £1.32

- **Sterets Tisept (Molnlycke Health Care Ltd)**
  - Chlorhexidine gluconate 150 microgram per 1 ml, Cetrimide 1.5 mg per 1 ml
  - **Sterets Tisept solution 25ml sachets**
    - 25 sachet [P] £5.33
  - **Sterets Tisept solution 100ml sachets**
    - 10 sachet [P] £6.85

---

**Diethyl phthalate with methyl salicylate**

### Indications and Dose

**Skin preparation before injection**
- **To the skin**
- **Adult:** Apply to the area to be disinfected

### Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug.

**Liquid**
- **Diethyl phthalate with methyl salicylate (Non-proprietary)**
  - **Methyl salicylate** 5 ml per 1 litre, **Diethyl phthalate** 20 ml per 1 litre
  - Castor oil 25 ml per 1 litre, **Industrial methylated spirit** 950 ml per 1 litre
  - **Surgical spirit**
    - 200 ml [GSL] £1.15 DT price = £1.15
    - 1000 ml [GSL] £3.62

---

**Hydrogen peroxide**

### Indications and Dose

**For skin disinfection, particularly cleansing and deodorising wounds and ulcers**
- **To the skin**
- **Adult:** Use 3% and 6% solutions (consult product literature)

### Drug Action

Hydrogen peroxide is an oxidising agent.

---

**Chlorhexidine gluconate with isopropyl alcohol**

The properties listed below are those particular to the combination only. For the properties of the components please consider, chlorhexidine p. 1173.

### Indications and Dose

**Skin disinfection before invasive procedures**
- **To the skin**
- **Child:** 2 months-17 years: (consult product literature)
- **Adult:** (consult product literature)

### Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: liquid

**Liquid**
- **Chloraprep** (CareFusion U.K. Ltd)
  - Chlorhexidine gluconate 20 mg per 1 ml, Isopropyl alcohol
    - **700 ml per 1 litre** Chloraprep with Tint solution 10.5ml applicators
      - 25 applicator [GSL] £76.65
      - Chloraprep with Tint solution 26ml applicators
        - 25 applicator [GSL] £170.75
      - Chloraprep solution 3ml applicators
        - 25 applicator [GSL] £21.25
    - Chloraprep solution 1.5ml applicators
      - 20 applicator [GSL] £11.00
    - Chloraprep with Tint solution 3ml applicators
      - 25 applicator [GSL] £22.31
      - Chloraprep solution 0.67ml applicators
        - 200 applicator [GSL] £60.00

**Chloraprep solution 10.5ml applicators**
- **25 applicator** [GSL] £73.00

**Chloraprep solution 26ml applicators**
- **25 applicator** [GSL] £162.50

---

**Skin cleansers, antiseptics and desloughing agents**

BNF 74
Proflavine

The properties listed below are those particular to the combination only. For the properties of the components please consider, liquid paraffin p. 59.

● INDICATIONS AND DOSE
Infected wounds | Infected burns
► TO THE SKIN
► Adult: (consult product literature)

● PATIENT AND CARER ADVICE
Stains clothing.

● MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: liquid

Cream
EXCIPIENTS: May contain Edetac acid (edta), propylene glycol
► Crystacide (Reig Jofre UK Ltd)
  Hydrogen peroxide 10 mg per 1 gram Crystacide 1% cream | 25 gram £8.07 Dose price = £8.07 | 40 gram £11.62

Liquid
► Hydrogen peroxide (Non-proprietary)
  Hydrogen peroxide 60 mg per 1 ml Hydrogen peroxide 6% solution | 200 ml £0.64 | 500 ml £1.89 | 2000 ml £7.81
  Hydrogen peroxide 90 mg per 1 ml Hydrogen peroxide 9% solution | 200 ml £0.69
  Hydrogen peroxide 30 ml per 1 litre Hydrogen peroxide 3% solution | 200 ml £0.80

Irrigation solutions

● IRRIGATION SOLUTIONS
Flowfusor sodium chloride 0.9% irrigation solution 120ml bottles (Fresenius Kabi Ltd) Sodium chloride 9 mg per 1 ml | bottle • NHS indicative price = £1.53 • Drug Tariff (Part Ixa)
Irriclens sodium chloride 0.9% irrigation solution aerosol spray (Convatec Ltd) Sodium chloride 9 mg per 1 ml | 240ml • NHS indicative price = £3.54 • Drug Tariff (Part Ixa)
Normasol sodium chloride 0.9% irrigation solution 100ml sachets (Molynlycke Health Care Ltd) Sodium chloride 9 mg per 1 ml | 10 unit dose • NHS indicative price = £7.92 • Drug Tariff (Part Ixa)
Normasol sodium chloride 0.9% irrigation solution 25ml sachets (Molynlycke Health Care Ltd) Sodium chloride 9 mg per 1 ml | 25 unit dose • NHS indicative price = £6.42 • Drug Tariff (Part Ixa)
Sodium chloride 0.9% irrigation solution 20ml Clinipod unit dose (Mayors Healthcare Ltd) Sodium chloride 9 mg per 1 ml | 25 unit dose • NHS indicative price = £4.80 • Drug Tariff (Part Ixa)
Sodium chloride 0.9% irrigation solution 20ml ISO-POD unit dose (St Georges Medical Ltd) Sodium chloride 9 mg per 1 ml | 25 unit dose • NHS indicative price = £4.95 • Drug Tariff (Part Ixa)
Sodium chloride 0.9% irrigation solution 20ml Sal-e Pods unit dose (Einogen Healthcare Ltd) Sodium chloride 9 mg per 1 ml | 25 unit dose • NHS indicative price = £4.80 • Drug Tariff (Part Ixa)
Sodium chloride 0.9% irrigation solution 20ml Salipod unit dose (Sai-Meds Ltd) Sodium chloride 9 mg per 1 ml | 25 unit dose • NHS indicative price = £4.99 • Drug Tariff (Part Ixa)
Sodium chloride 0.9% irrigation solution 20ml Steripod unit dose (Sai-Meds Ltd) Sodium chloride 9 mg per 1 ml | 25 unit dose • NHS indicative price = £7.90 • Drug Tariff (Part Ixa)
Sodium chloride 0.9% irrigation solution 20ml Sterowash unit dose (Steroplast Healthcare Ltd) Sodium chloride 9 mg per 1 ml | 25 unit dose • NHS indicative price = £5.40 • Drug Tariff (Part Ixa)
Sodium chloride 0.9% irrigation solution 20ml unit dose (Alissa Healthcare Ltd) Sodium chloride 9 mg per 1 ml | 25 unit dose • NHS indicative price = £7.36 • Drug Tariff (Part Ixa)
Sodium chloride 0.9% irrigation solution 20ml unit dose (Crest Medical Ltd) Sodium chloride 9 mg per 1 ml | 25 unit dose • NHS indicative price = £4.99 • Drug Tariff (Part Ixa)
Sodium chloride 0.9% irrigation solution 20ml unit dose (Mylan Ltd) Sodium chloride 9 mg per 1 ml | 25 unit dose • NHS indicative price = £5.50 • Drug Tariff (Part Ixa)
Stericlens sodium chloride 0.9% irrigation solution aerosol spray (C D Medical Ltd) Sodium chloride 9 mg per 1 ml | 100ml • NHS indicative price = £2.07 • Drug Tariff (Part Ixa) | 240ml • NHS indicative price = £3.15 • Drug Tariff (Part Ixa)

8.1 Minor cuts and abrasions

Minor cuts and abrasions

Management
Many preparations traditionally used to manage minor burns, and abrasions have fallen out of favour. Preparations containing camphor and sulfonamides should be avoided. Preparations such as magnesium sulfate paste are now rarely used to treat carbuncles and boils as these are best treated with antibiotics.

Cetrimide is used to treat minor cuts and abrasions and proflavine above may be used to treat infected wounds or burns, but its use has now been largely superseded by other antiseptics or suitable antibacterials. The effervescent effect of hydrogen peroxide p. 1174 is used to clean minor cuts and abrasions.

Flexible collodion (see castor oil with collodion and flexible collodion) may be used to seal minor cuts and wounds that have partially healed; skin tissue adhesives are used similarly, and also for additional suture support.
● DIRECTIONS FOR ADMINISTRATION  Paste should be stirred before use.

● MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug.
  Paste
  ▶ Glycerol with magnesium sulfate and phenol (Non-proprietary)
    Phenol 5 mg per 1 gram, Magnesium sulfate dried 450 mg per 1 gram, Glycerol 550 mg per 1 gram  Magnesium sulfate paste  | 25 gram £1.24  | 50 gram £2.48  | NHS indicative price = £2.48

DERMATOLOGICAL DRUGS  COLLODIONS

Castor oil with collodion and colophony

● INDICATIONS AND DOSE
  Used to seal minor cuts and wounds that have partially healed
  ▶ TO THE SKIN
  ▶ Child: (consult product literature)
  ▶ Adult: (consult product literature)

● ALLERGY AND CROSS-SENSITIVITY
  Contra-indicated if patient has an allergy to colophony in elastic adhesive plasters and tape.

● MEDICINAL FORMS
  There can be variation in the licensing of different medicines containing the same drug.
  Liquid
  ▶ Castor oil with collodion and colophony (Non-proprietary)
    Castor oil 25 mg per 1 ml, Colophony 25 mg per 1 ml, Collodion methylated 950 micro litre per 1 ml Flexible collodion methylated | 100 ml £13.54  | 500 ml £27.79

Skin adhesives

● SKIN ADHESIVES
  DermaFlex skin adhesive (Chemence Ltd)  0.5 ml  |  NHS indicative price = £5.36  | Drug Tariff (Part IXa)
  Dermabond ProPen skin adhesive (Ethicon Ltd)  0.5 ml  |  NHS indicative price = £19.46  | Drug Tariff (Part IXa)
  Histoacryl L skin adhesive (B. Braun Medical Ltd)  0.5 ml  |  NHS indicative price = £6.72  | Drug Tariff (Part IXa)
  Histoacryl skin adhesive (B. Braun Medical Ltd)  0.5 ml  |  NHS indicative price = £6.50  | Drug Tariff (Part IXa)
  Indermil skin adhesive (Covidien (UK) Commercial Ltd)  5 gram  |  NHS indicative price = £6.50  | Drug Tariff (Part IXa)
  LiquiBand flow control tissue adhesive (MedLogic Global Ltd)  0.5 gram  |  NHS indicative price = £5.50  | Drug Tariff (Part IXa)
  LiquiBand tissue adhesive (MedLogic Global Ltd)  0.5 gram  |  NHS indicative price = £5.50  | Drug Tariff (Part IXa)

9  Skin disfigurement

Camouflagers

Overview
Disfigurement of the skin can be very distressing to patients and may have a marked psychological effect. Skilled hands, or with experience, camouflage cosmetics can be very effective in concealing scars and birchmarks. The depigmented patches in vitiligo are also very disfiguring and camouflage creams are of great cosmetic value. Opaque cover foundation or cream is used to mask skin pigment abnormalities; careful application using a combination of dark- and light-coloured cover creams set with powder helps to minimise the appearance of skin deformities.

Borderline substances
The preparations marked ‘ACBS’ can be prescribed on the NHS for postoperative scars and other deformities and as adjunctive therapy in the relief of emotional disturbances due to disfiguring skin disease, such as vitiligo.

Camouflages

● CAMOUFLAGES
  Covermark classic foundation (Derma UK Ltd)  15 ml (ACBS)  |  NHS indicative price = £11.86
  Covermark finishing powder (Derma UK Ltd)  25 gram (ACBS)  |  NHS indicative price = £11.86
  Covermark removing cream (Derma UK Ltd)  200 ml  |  No NHS indicative price available
  Dermablend Dermasmooth Corrective Foundation (Vichy)  30 ml  |  No NHS indicative price available
  Dermacolor Creme Effectiv (Kryolan UK Ltd)  50 ml  |  NHS indicative price = £5.73
  Dermacolor body camouflage (Kryolan UK Ltd)  50 ml  |  NHS indicative price = £8.94
  Dermacolor camouflage creme (Kryolan UK Ltd)  30 gram  |  NHS indicative price = £11.00
  Dermacolor cleansing cream (Kryolan UK Ltd)  75 gram  |  No NHS indicative price available
  Dermacolor fixing powder (Kryolan UK Ltd)  60 gram (ACBS)  |  NHS indicative price = £9.85
  Keromask finishing powder (Bellava Ltd)  20 gram (ACBS)  |  NHS indicative price = £5.80
  Keromask masking cream (Bellava Ltd)  15 ml (ACBS)  |  NHS indicative price = £5.90
  Veil cleansing cream (Thomas Blake Cosmetic Creams Ltd)  50 gram  |  NHS indicative price = £2.45  |  100 gram  |  NHS indicative price = £3.90
  Veil cover cream (Thomas Blake Cosmetic Creams Ltd)  19 gram (ACBS)  |  NHS indicative price = £22.42  |  44 gram (ACBS)  |  NHS indicative price = £33.35  |  70 gram (ACBS)  |  NHS indicative price = £42.10
  Veil finishing powder (Thomas Blake Cosmetic Creams Ltd)  35 gram (ACBS)  |  NHS indicative price = £24.58

10  Sun protection and photodamage

Photodamage

Overview
Patients should be advised to use a high-SPF sunscreen and to minimise exposure of the skin to direct sunlight or sun lamps.

Topical treatments can be used for actinic keratosis. An emollient may be sufficient for mild lesions. Diclofenac sodium gel p. 1177 is suitable for the treatment of superficial lesions in mild disease. Fluorouracil cream p. 1178 is effective against most types of non-hypertrophic actinic keratosis; a solution containing fluorouracil with salicylic acid p. 1178 is available for the treatment of low or moderately thick hyperkeratotic actinic keratoses. Imiquimod p. 1181 is used for lesions on the face and scalp when cryotherapy or other topical treatments cannot be used. Fluorouracil and imiquimod produce a more marked inflammatory reaction than diclofenac sodium but lesions resolve faster. A short course of ingenol mebutate p. 1178 is licensed for the treatment of non-hypertrophic actinic keratoses; response to treatment can usually be assessed 8 weeks after the course. Photodynamic therapy in
combination with methyl-5-aminolevulinate cream (Metvix®, available from Galderma) or 5-aminolevulinic acid gel (Ameluz®, available from Spirit Healthcare) is used in specialist centres for treating superficial and confluent, non-hypertrophic actinic keratosis when other treatments are inadequate or unsuitable; it is particularly suitable for multiple lesions, for periorbital lesions, or for lesions located at sites of poor healing.

Imiquimod or topical fluorouracil is used for treating superficial basal cell carcinomas. Photodynamic therapy in combination with methyl-5-aminolevulinate cream is used in specialist centres for treating superficial, nodular basal cell carcinomas when other treatments are unsuitable.

**Sunscreen**

**Sunscreen preparations**

Solar ultraviolet irradiation can be harmful to the skin. It is responsible for disorders such as polymorphic light eruption, solar urticaria, and it provokes the various cutaneous porphyrias. It also provokes (or at least aggravates) skin lesions of lupus erythematosus and may aggravate rosacea and some other dermatoses. Certain drugs, such as demeclocycline, phenothiazines, or amiodarone, can cause photosensitivity. All these conditions (as well as sunburn) may occur after relatively short periods of exposure to the sun. Solar ultraviolet radiation may provoke attacks of recurrent herpes labialis (but it is not known whether the effect of sunlight exposure is local or systemic).

The effects of exposure over longer periods include ageing changes and more importantly the initiation of skin cancer. Solar ultraviolet radiation is approximately 200–400 nm in wavelength. The medium wavelengths (290–320 nm, known as UVB) cause sunburn. The long wavelengths (320–400 nm, known as UVA) are responsible for many photosensitivity reactions and photodermatoses. Both UVA and UVB contribute to long-term photodamage and to the changes responsible for skin cancer and ageing.

Sunscreen preparations contain substances that protect the skin against UVA and UVB radiation, but they are no substitute for covering the skin and avoiding sunlight. The sun protection factor (SPF, usually indicated in the preparation title) provides guidance on the degree of protection offered against UVB; it indicates the multiples of protection provided against burning, compared with unprotected skin; for example, an SPF of 8 should enable a person to remain 8 times longer in the sun without burning. However, in practice, users do not apply sufficient sunscreen product and the protection is lower than that found in experimental studies.

Some manufacturers use a star rating system to indicate the protection against UVA relative to protection against UVB for sunscreen products. However, the usefulness of the star rating system remains controversial. The EU Commission (September 2006) has recommended that the UVA protection factor for a sunscreen should be at least one-third of the sun protection factor (SPF); products that achieve this requirement will be labelled with a UVA logo alongside the SPF classification. Preparations that also contain reflective substances, such as titanium dioxide, provide the most effective protection against UVA.

Sunscreen preparations may rarely cause allergic reactions.

For optimum photoprotection, sunscreen preparations should be applied thickly and frequently (approximately 2 hourly). In photodermatoses, they should be used from spring to autumn. As maximum protection from sunlight is desirable, preparations with the highest SPF should be prescribed.

### Ingredient nomenclature in sunscreen preparations

<table>
<thead>
<tr>
<th>rINN</th>
<th>INCI</th>
</tr>
</thead>
<tbody>
<tr>
<td>amiloxate</td>
<td>isomyl p-methoxycinnamate</td>
</tr>
<tr>
<td>avobenzone</td>
<td>butyl methoxydibenzoylmethane</td>
</tr>
<tr>
<td>bemotrizinol</td>
<td>bis-ethylhexyloxyphenol methoxyphenyl triazine</td>
</tr>
<tr>
<td>bisoctrizole</td>
<td>methylene bis-benzotriazolyl tetramethylbutylphenol</td>
</tr>
<tr>
<td>ecamsule</td>
<td>terephthahylidene dicamphor sulfonic acid</td>
</tr>
<tr>
<td>ensulzole</td>
<td>phenylbenzimidazolone sulfonic acid</td>
</tr>
<tr>
<td>enzacamene</td>
<td>4-methylbenzylidene camphor</td>
</tr>
<tr>
<td>octinoxate</td>
<td>octyl (or ethylhexyl) methoxycinnamate</td>
</tr>
<tr>
<td>octocrilene</td>
<td>octocrylene</td>
</tr>
<tr>
<td>oxybenzone</td>
<td>benzophenone-3</td>
</tr>
</tbody>
</table>

The European Commission Cosmetic Products Regulation (EC) 1223/2009 requires the use of INCI (International Nomenclature of Cosmetic Ingredients) for cosmetics and sunscreens. This table includes the rINN and the INCI synonym for the active ingredients of sunscreen preparations in the BNF.

### Borderline substances

*Antheias®* XL SPF 50+ Melt-in cream; *Sunsense®* Ultra; *Uvistat®* Lipscreen SPF 50; and *Uvistat®* Suncream SPF 30 and 50 (see *Borderline substances*) are regarded as drugs when prescribed for skin protection against ultraviolet radiation in abnormal cutaneous photosensitivity resulting from genetic disorders or photodermatoses, including vitiligo and those resulting from radiotherapy; chronic or recurrent herpes simplex labialis. Preparations with SPF less than 30 should not normally be prescribed.

### ANALGESICS » NON-Steroidal ANTI-INFLAMMATORY DRUGS

#### Diclofenac sodium

- **INDICATIONS AND DOSE**

  **SOLARAZE®**

  **Actinic keratosis**

  ➤ TO THE SKIN

  ➤ Adult: Apply twice daily for 60–90 days, to be applied thinly; maximum 8 g per day

- **CAUTIONS** Avoid contact with eyes - avoid contact with inflamed or broken skin - avoid contact with mucous membranes - not for use with occlusive dressings - topical application of large amounts can result in systemic effects, including hypersensitivity and asthma (renal disease has also been reported)

- **INTERACTIONS** ➤ Appendix 1: NSAIDs

- **SIDE-EFFECTS** Paraesthesia - photosensitivity - rash (discontinue use if develops)

  ➤ **SIDE-EFFECTS, FURTHER INFORMATION** Topical application of large amounts can result in systemic effects, including hypersensitivity and asthma (renal disease has also been reported).

- **ALLERGY AND CROSS-SENSITIVITY** Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.

- **PREGNANCY** Patient packs for topical preparations carry a warning to avoid during pregnancy.
Fluorouracil with salicylic acid

The properties listed below are those particular to the combination only. For the properties of the components please consider, fluorouracil above, salicylic acid p. 1182.

**INDICATIONS AND DOSE**

**Low or moderately thick hyperkeratotic actinic keratosis**

- **TO THE SKIN**
  - Adult: Apply once daily for up to 12 weeks, reduced to 3 times a week if severe side effects occur and until side-effects improve, to be applied to the affected area, if treating area with thin epidermis, reduce frequency of application and monitor response more often; maximum area of skin treated at one time, 25 cm² (e.g. 5 cm × 5 cm)

**INTERACTIONS** → Appendix 1: fluorouracil

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Gel**

EXCIPIENTS: May contain Benzyl alcohol, fragrances, propylene glycol

- Solaraze (Almirall Ltd)
  - Diclofenac sodium 30 mg per 1 gram Solaraze 3% gel | 50 gram [POM] £38.30 DT price = £38.30 | 100 gram [POM] £76.60

**ANTINEOPLASTIC DRUGS** → ANTIMETABOLITES

**Fluorouracil**

**INDICATIONS AND DOSE**

Superficial malignant and pre-malignant skin lesions

- **TO THE SKIN USING CREAM**
  - Adult: Apply 1–2 times a day for 3–4 weeks (usual duration of initial therapy), apply thinly to the affected area, maximum area of skin 500 cm² (e.g. 23 cm × 23 cm) treated at one time, alternative regimens may be used in some settings

- **CAUTIONS** Avoid contact with eyes and mucous membranes • do not apply to bleeding lesions

- **INTERACTIONS** → Appendix 1: fluorouracil

- **SIDE-EFFECTS** Erythema multiforme • local irritation (use a topical corticosteroid for severe discomfort associated with inflammatory reactions) • photosensitivity

- **CONCEPTION AND CONTRACEPTION** Contraceptive advice required, see Pregnancy and reproductive function in Cytotoxic drugs p. 825.

- **PREGNANCY** Manufacturers advise avoid (teratogenic). 

- **BREAST FEEDING** Manufacturers advise avoid.

- **HANDLING AND STORAGE** Caution in handling—irritant to tissues.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Cream**

EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), hydroxybenzoates (parabens), polysorbates, propylene glycol

- Efudix (Meda Pharmaceuticals Ltd)
  - Fluorouracil 50 mg per 1 gram Efudix 5% cream | 40 gram [POM] £32.90 DT price = £32.90

**PROTEIN KINASE C ACTIVATORS**

**Ingenol mebutate**

**INDICATIONS AND DOSE**

Actinic keratosis on trunk and extremities

- **TO THE SKIN**
  - Adult: Apply once daily for 3 days, use the 150 microgram/g gel

Actinic keratosis on face and scalp

- **TO THE SKIN**
  - Adult: Apply once daily for 2 days, use the 500 microgram/g gel

- **CAUTIONS** Avoid contact with broken skin • avoid contact with eyes • avoid contact with inside of ears • avoid contact with with inside of nostrils • avoid contact with lips • avoid occlusive dressings on treated area

- **SIDE-EFFECTS**
  - **Common or very common** Blistering • local irritation • local oedema • pain • pruritus

- **Uncommon** Local ulceration • paraesthesia

- **PREGNANCY** Not absorbed from skin, but manufacturer advises avoid.

- **BREAST FEEDING** Not absorbed from skin; ensure infant does not come in contact with treated area for 6 hours after application.

**DIRECTIONS FOR ADMINISTRATION** One tube covers skin area of 25 cm². Allow gel to dry on treatment area for 15 minutes. Avoid washing or touching the treated area for 6 hours after application; after this time, area may be washed with mild soap and water. Avoid use immediately after shower or less than 2 hours before bedtime.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Gel**

EXCIPIENTS: May contain Benzyl alcohol

- Picato (LEO Pharma)
  - Ingenol mebutate 150 microgram per 1 gram Picato 150 micrograms/g gel | 1.41 gram [POM] £65.00
  - Ingenol mebutate 500 microgram per 1 gram Picato 500 micrograms/g gel | .94 gram [POM] £65.00
11 Superficial soft-tissue injuries and superficial thrombophlebitis

Topical circulatory preparations

Overview
These preparations are used to improve circulation in conditions such as bruising, superficial thrombophlebitis, chilblains and varicose veins but are of little value. Chilblains are best managed by avoidance of exposure to cold; neither systemic nor topical vasodilator therapy is established as being effective.

HEPARINOIDS

Heparinoid

- INDICATIONS AND DOSE
  - Superficial thrombophlebitis | Bruising | Haematoma
    - TO THE SKIN
    - Adult: Apply up to 4 times a day

- CONTRA-INDICATIONS
  - Should not be used on large areas of skin, broken or sensitive skin, or mucous membranes

- LESS SUITABLE FOR PRESCRIBING
  - Hirudoid is less suitable for prescribing.

- MEDICINAL FORMS
  - There can be variation in the licensing of different medicines containing the same drug.
  - Cream
    - EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), hydroxybenzoates (parabens)
    - Hirudoid (Genus Pharmaceuticals Ltd)
      - Heparinoid 3 mg per 1 gram Hirudoid 0.3% cream | 50 gram P £3.99 DT price = £3.99
  - Gel
    - EXCIPIENTS: May contain Fragrances, propylene glycol
    - Hirudoid (Genus Pharmaceuticals Ltd)
      - Heparinoid 3 mg per 1 gram Hirudoid 0.3% gel | 50 gram P £3.99 DT price = £3.99

12 Warts and calluses

Warts and calluses

Overview
Warts (verrucas) are caused by a human papillomavirus, which most frequently affects the hands, feet (plantar warts), and the anogenital region; treatment usually relies on local tissue destruction. Warts may regress on their own and treatment is required only if the warts are painful, unsightly, persistent, or cause distress.

Preparations of salicylic acid p. 1182, formaldehyde p. 1180, glutaraldehyde p. 1180 or silver nitrate p. 1181 are available for purchase by the public; they are suitable for the removal of warts on hands and feet. Salicylic acid is a useful keratolytic which may be considered first-line; it is also suitable for the removal of corns and calluses. Preparations of salicylic acid in a collodion basis are available but some patients may develop an allergy to colophony in the formulation; colloid should be avoided in children allergic to elastic adhesive plaster. Cryotherapy causes pain, swelling, and blistering, and may be no more effective than topical salicylic acid in the treatment of warts.

Anogenital warts
The treatment of anogenital warts (condylomata acuminata) should be accompanied by screening for other sexually transmitted infections. Podophyllotoxin p. 1180 (the major active ingredient of podophyll) may be used for soft, non-keratinised external anogenital warts. Patients with a limited number of external warts or keratinised lesions may be better treated with cryotherapy or other forms of physical ablation. Imiquimod cream p. 1181 is licensed for the treatment of external anogenital warts; it may be used for both keratinised and non-keratinised lesions. It is also licensed for the treatment of superficial basal cell carcinoma and actinic keratosis. Camellia sinensis below ointment is licensed for the treatment of external anogenital warts. Inosine pranobex p. 599 is licensed for adjunctive treatment of genital warts but it has been superseded by more effective drugs.

ANTINEOPLASTIC DRUGS > PLANT ALKALOIDS

Camellia sinensis

- DRUG ACTION
  - Camellia sinensis is an extract from green tea leaves. The exact mechanism of action is not known; non-clinical studies have shown inhibition of the growth of activated keratinocytes, and anti-oxidative effects at the site of application.

- INDICATIONS AND DOSE
  - Warts (external genital and perianal) in immunocompetent patients
  - TO THE LESION
  - Adult: Apply up to 250 mg 3 times a day until complete clearance of warts (maximum 16 weeks), do not exceed treatment period even if new warts develop; maximum 750 mg per day

- DOSE EQUIVALENCE AND CONVERSION
  - 250 mg is equivalent to 0.5 cm of ointment.

- CAUTIONS
  - Avoid broken skin · avoid contact with eyes · avoid contact with lips · avoid contact with mouth · avoid contact with nostrils · avoid inflamed skin · uncircumcised males (risk of phimosis) · vulvar region

- SIDE-EFFECTS
  - Common or very common · Local reactions · lymphadenopathy · phimosis
  - Uncommon · Balanitis · dyspareunia · dysuria · local infection · pollakisuria · rash · urinary urgency · vulvovaginitis

- CONCEPTION AND CONTRACEPTION
  - Manufacturer advises Catephen® may weaken condoms and vaginal diaphragms—alternative methods of contraception should be considered.

- PREGNANCY
  - Manufacturer advises avoid—toxicity in animal studies.

- BREAST FEEDING
  - Manufacturer advises risk to infant cannot be excluded—no information available.

- HEPATIC IMPAIRMENT
  - Manufacturer advises avoid in severe impairment—no information available.

- DIRECTIONS FOR ADMINISTRATION
  - Manufacturer advises apply to each wart, ensuring a thin layer is left on the wart. It is not necessary to wash off the ointment from the area before next application.

- PATIENT AND CARER ADVICE
  - Manufacturer advises the ointment should be washed off before sexual activity. Manufacturer advises female patients using tampons should insert tampon before applying the ointment.

- NATIONAL FUNDING/ACCESS DECISIONS
  - Scottish Medicines Consortium (SMC) Decisions
    - The Scottish Medicines Consortium has advised (April 2016) that camellia sinensis (green tea) leaf extract (Catephen®)
is accepted for restricted use within NHS Scotland for the treatment of external genital and perianal warts in patients not suitable for podophyllotoxin or who have not responded to treatment with podophyllotoxin.

**All Wales Medicines Strategy Group (AWMSG) Decisions**
The All Wales Medicines Strategy Group has advised (October 2016) that green tea leaf extract (camellia sinensis), (Catephen®), is recommended for restricted use within NHS Wales for the treatment of external genital and perianal warts in patients not suitable for podophyllotoxin or who have not responded to treatment with podophyllotoxin.

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.
  - **Ointment**
    - Catephen (KoRa Healthcare)
    - Camellia sinensis extract 100 mg per 1 gram Catephen 10% ointment | 15 gram [POM] £39.00

**Podophyllotoxin**

- **INDICATIONS AND DOSE**
  **CONDYLINE®**
  Condylomata acuminata affecting the penis or the female external genitalia
  - TO THE LESION
  - Adult: Apply twice daily for 3 consecutive days, treatment may be repeated at weekly intervals if necessary for a total of five 3-day treatment courses, direct medical supervision for lesions in the female and for lesions greater than 4 cm² in the male, maximum 50 single applications (‘loops’) per session (consult product literature)

**WARTICON® CREAM**
Condylomata acuminata affecting the penis or the female external genitalia
- TO THE LESION
- Adult: Apply twice daily for 3 consecutive days, treatment may be repeated at weekly intervals if necessary for a total of four 3-day treatment courses, direct medical supervision for lesions greater than 4 cm²

**WARTICON® LIQUID**
Condylomata acuminata affecting the penis or the female external genitalia
- TO THE LESION
- Adult: Apply twice daily for 3 consecutive days, treatment may be repeated at weekly intervals if necessary for a total of four 3-day treatment courses, direct medical supervision for lesions greater than 4 cm², maximum 50 single applications (‘loops’) per session (consult product literature)

- **CAUTIONS**
  - Avoid normal skin · avoid open wounds · keep away from face · very irritant to eyes
  - **SIDE-EFFECTS**
  - Local irritation
  - **PREGNANCY**
  - Avoid.
  - **BREAST FEEDING**
  - Avoid.

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.
  - **Cream**
    - EXCIPIENTS: May contain Butylated hydroxyanisole, cetostearyl alcohol (including cetyl and stearyl alcohol), hydroxybenzoates (parabens), sorbic acid
    - **Warticon** (Stiefel Laboratories (UK) Ltd)
      - Podophyllotoxin 1.5 mg per 1 gram Warticon 0.15% cream | 5 gram [POM] £17.83 DT price = £17.83

**Antiseptics and Disinfectants**

**Glutaraldehyde**

- **INDICATIONS AND DOSE**
  Warts, particularly plantar warts
  - TO THE LESION
  - Child: Apply twice daily
  - Adult: Apply twice daily

- **UNLICENSED USE**
  Licensed for use in children (age range not specified by manufacturer).

- **CAUTIONS**
  Impaired peripheral circulation · not suitable for application to anogenital region · not suitable for application to face · not suitable for application to large areas · patients with diabetes at risk of neuropathic ulcers · protect surrounding skin and avoid broken skin · significant peripheral neuropathy

- **SIDE-EFFECTS**
  Skin irritation · skin ulceration (with high concentrations)

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: liquid
  - **Gel**
    - Veracur (Typharm Ltd)
      - Formaldehyde 7.5 mg per 1 ml Veracur 0.75% gel | 15 gram [GEL] £2.41
  - **Liquid**
    - Formaldehyde (Non-proprietary)
      - Formaldehyde 40 mg per 1 ml Formaldehyde (Buffered) 4% solution | 1000 ml £3.90
      - Formaldehyde 350 mg per 1 gram Formaldehyde solution | 500 ml £5.90 DT price = £5.90 | 2000 ml £16.98

**Glutaraldehyde**

- **INDICATIONS AND DOSE**
  Warts, particularly plantar warts
  - TO THE LESION
  - Child: Apply twice daily
  - Adult: Apply twice daily

- **UNLICENSED USE**
  Licensed for use in children (age range not specified by manufacturer).

- **CAUTIONS**
  Not for application to anogenital areas · not for application to face · not for application to mucosa · protect surrounding skin

- **SIDE-EFFECTS**
  Rashes · skin irritation (discontinue if severe) · stains skin brown

- **MEDICINAL FORMS**
  There can be variation in the licensing of different medicines containing the same drug.
  - **Paint**
    - Glutarol (Dermal Laboratories Ltd)
      - Glutaraldehyde 100 mg per 1 ml Glutarol 10% cutaneous solution | 10 ml [P] £2.07 DT price = £2.07
Silver nitrate

- **INDICATIONS AND DOSE**

  **Common warts**
  - **TO THE LESION**
  - Child: Apply every 24 hours for up to 3 applications, apply moistened caustic pencil tip for 1–2 minutes. Instructions in proprietary packs generally incorporate advice to remove dead skin before use by gentle filing and to cover with adhesive dressing after application.
  - Adult: Apply every 24 hours for up to 3 applications, apply moistened caustic pencil tip for 1–2 minutes. Instructions in proprietary packs generally incorporate advice to remove dead skin before use by gentle filing and to cover with adhesive dressing after application.

  **Verrucas**
  - **TO THE LESION**
  - Child: Apply every 24 hours for up to 6 applications, apply moistened caustic pencil tip for 1–2 minutes. Instructions in proprietary packs generally incorporate advice to remove dead skin before use by gentle filing and to cover with adhesive dressing after application.
  - Adult: Apply every 24 hours for up to 6 applications, apply moistened caustic pencil tip for 1–2 minutes. Instructions in proprietary packs generally incorporate advice to remove dead skin before use by gentle filing and to cover with adhesive dressing after application.

  **Umbilical granulomas**
  - **TO THE SKIN**
  - Child: Apply moistened caustic pencil tip (usually containing silver nitrate 40%) for 1–2 minutes, protect surrounding skin with soft paraffin.
  - Adult: Apply moistened caustic pencil tip (usually containing silver nitrate 40%) for 1–2 minutes, protect surrounding skin with soft paraffin.

- **UNLICENSED USE**
  - In children: No age range specified by manufacturer.

- **CAUTIONS**
  - Avoid broken skin: not suitable for application to large areas. Protect surrounding skin.

- **SIDE-EFFECTS**
  - Chemical burns on surrounding skin: Stains skin

- **PATIENT AND CARER ADVICE**
  - Patients should be advised that silver nitrate may stain fabric.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

  **Stick**
  - **Silver nitrate (Non-proprietary)**
    - Silver nitrate 400 mg per 1 gram: Silver nitrate 40% caustic pencils (1 applicator, no price available).
    - Avoca (Bray Group Ltd): Silver nitrate 400 mg per 1 gram: Avoca 40% silver nitrate pencils (1 applicator, £1.03).
    - Silver nitrate 750 mg per 1 gram: Avoca 75% silver nitrate applicators (100 applicator, £44.48).
    - Avoca 75% silver nitrate applicators with thick handles (50 applicator, £43.41).
    - Silver nitrate 950 mg per 1 gram: Avoca 95% silver nitrate applicators (100 applicator, £44.52).
    - Avoca 95% silver nitrate pencils (1 applicator, £1.99 DT price = £2.44).
    - Avoca wart and verruca treatment set (1 applicator, £2.44 DT price = £2.44).

- **ANTIVIRALS › IMMUNE RESPONSE MODIFIERS**

  - **Imiquimod**
    - **INDICATIONS AND DOSE**
      - **ALDARA®**
        - **Warts (external genital and perianal)**
          - **TO THE LESION**
          - Adult: Apply 3 times a week until lesions resolve (maximum 16 weeks), to be applied thinly at night.

        - **Superficial basal cell carcinoma**
          - **TO THE LESION**
          - Adult: Apply daily for 5 nights of each week for 6 weeks, to be applied to lesion and 1 cm beyond it, assess response 12 weeks after completing treatment.

        - **Actinic keratosis**
          - **TO THE LESION**
          - Adult: Apply once daily for 2 weeks, to be applied at bedtime to lesion on face or balding scalp, repeat course after a 2-week treatment-free interval; repeat 4-week course if lesions persist, maximum 2 courses.

      - **ZYCLARA®**
        - **Actinic keratosis**
          - **TO THE SKIN**
          - Adult: Apply once daily for 2 weeks, to be applied at bedtime to lesion on face or balding scalp, repeat course after a 2-week treatment-free interval, assess response 8 weeks after second course; maximum 2 sachets per day.

    - **CAUTIONS**
      - Autoimmune disease: avoid broken skin.
      - Avoid contact with eyes.
      - Avoid contact with lips.
      - Avoid contact with nostrils.
      - Avoid open wounds.
      - Immunosuppressed patients: not suitable for internal genital warts.
      - Uncircumcised males (risk of phimosis or stricture of foreskin).

    - **SIDE-EFFECTS**

    - **Uncommon**
      - Alopecia: local ulceration.

    - **Rare**
      - Cutaneous lupus erythematosus-like effect: Stevens-Johnson syndrome.

    - **Very rare**
      - Dysuria.

    - **Frequency not known**
      - Permanent hyperpigmentation: permanent hypopigmentation.

    - **CONCEPTION AND CONTRACEPTION**
      - May damage latex condoms and diaphragms.

    - **PREGNANCY**
      - No evidence of teratogenicity or toxicity in animal studies; manufacturer advises caution.

    - **BREAST FEEDING**
      - No information available.

    - **DIRECTIONS FOR ADMINISTRATION**
      - ZYCLARA®
        - **Important**
          - Should be rubbed in and allowed to stay on the treated area for 8 hours, then washed off with mild soap and water.

      - ALDARA®
        - **Important**
          - Should be rubbed in and allowed to stay on the treated area for 6–10 hours for warts or for 8 hours for basal cell carcinoma and actinic keratosis, then washed off with mild soap and water (uncircumcised males treating warts under foreskin should wash the area daily). The cream should be washed off before sexual contact.

      - **PATIENT AND CARER ADVICE**
        - A patient information leaflet should be provided.
**Skin**

---

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Cream**

**CAUTIONARY AND ADVISORY LABELS**

- **UNLICENSED USE** Not licensed for use in children under 2 years.
- **CAUTIONS** Avoid broken skin - impaired peripheral circulation - not suitable for application to anogenital region - not suitable for application to face - not suitable for application to large areas - patients with diabetes at risk of neuropathic ulcer - significant peripheral neuropathy
- **SIDE-EFFECTS** Skin irritation - skin ulceration (with high concentrations)
- **PATIENT AND CARER ADVICE** Advise patient to apply carefully to wart and to protect surrounding skin (e.g. with soft paraffin or specially designed plaster); rub wart surface gently with file or pumice stone once weekly.

**SALICYLIC ACID AND DERIVATIVES**

### Salicylic acid

**INDICATIONS AND DOSE**

**OCCLUSAL**

- **Common and plantar warts**
  - **TO THE LESION**
  - Child: Apply daily, treatment may need to be continued for up to 3 months
  - Adult: Apply daily, treatment may need to be continued for up to 3 months

**VERRUGON**

- **For plantar warts**
  - **TO THE LESION**
  - Child: Apply daily, treatment may need to be continued for up to 3 months
  - Adult: Apply daily, treatment may need to be continued for up to 3 months

**SALICYLIC ACID WITH LACTIC ACID**

The properties listed below are those particular to the combination only. For the properties of the components please consider, salicylic acid above.

**INDICATIONS AND DOSE**

**CUPLEX**

- **Plantar and mosaic warts | Corns | Calluses**
  - **TO THE LESION**
  - Adult: Apply daily, treatment may need to be continued for up to 3 months

**DUOFILM**

- **Plantar and mosaic warts**
  - **TO THE LESION**
  - Adult: Apply daily, treatment may need to be continued for up to 3 months

**SALACTOL**

- **Warts, particularly plantar warts | Verrucas | Corns | Calluses**
  - **TO THE LESION**
  - Adult: Apply daily, treatment may need to be continued for up to 3 months

**PRESCRIBING AND DISPENSING INFORMATION**

Preparations of salicylic acid in a collodion basis (Cuplex and Salactol) are available but some patients may develop an allergy to colophony in the formulation.

---

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Paint**

- **Duofilm** (GlaxoSmithKline UK Ltd)
  - Lactic acid 150 mg per 1 gram, Salicylic acid 167 mg per 1 gram 15 ml £2.25

- **Salactol** (Dermal Laboratories Ltd)
  - Lactic acid 167 mg per 1 gram, Salicylic acid 167 mg per 1 gram 10 ml £1.71

**Gel**

- **Cuplex** (Crawford Healthcare Ltd)
  - Lactic acid 40 mg per 1 gram, Salicylic acid 110 mg per 1 gram 5 gram £2.88

- **Salatac** (Dermal Laboratories Ltd)
  - Lactic acid 40 mg per 1 gram, Salicylic acid 120 mg per 1 gram 8 gram £2.98

---

**SALICYLIC ACID IN COMBINATION WITH OTHER ACTIVES**

### Occlusal

- **Common and plantar warts**
  - **TO THE LESION**
  - Child: Apply daily, treatment may need to be continued for up to 3 months
  - Adult: Apply daily, treatment may need to be continued for up to 3 months

---

**EXCIPIENTS:** May contain Benzyl alcohol, cetostearyl alcohol (including cetyl and stearyl alcohol), hydroxybenzoates (parabens), polysorbates

- Aldara (Meda Pharmaceuticals Ltd)
  - Imiquimod 50 mg per 1 gram Aldara 5% cream 250 mg sachets 12 sachets £48.60
  - Zyclara (Meda Pharmaceuticals Ltd)
  - Imiquimod 37.5 mg per 1 gram Zyclara 3.75% cream 250 mg sachets 28 sachets £113.00

---

**SALATAC**

- **Warts | Verrucas | Corns | Calluses**
  - **TO THE LESION**
  - Adult: Apply daily, treatment may need to be continued for up to 3 months

---

**SALACTOL**

- **Warts, particularly plantar warts | Verrucas | Corns | Calluses**
  - **TO THE LESION**
  - Adult: Apply daily, treatment may need to be continued for up to 3 months

---

**VERRUGON**

- **For plantar warts**
  - **TO THE LESION**
  - Child: Apply daily, treatment may need to be continued for up to 3 months
  - Adult: Apply daily, treatment may need to be continued for up to 3 months

---

**SALICYLIC ACID AND LACTIC ACID COMBINATION**

- **TO THE LESION**
  - Child: Apply daily, treatment may need to be continued for up to 3 months
  - Adult: Apply daily, treatment may need to be continued for up to 3 months

---

**SALICYLIC ACID AND LACTIC ACID COMBINATION IN COMBINATION WITH OTHER ACTIVES**

- **TO THE LESION**
  - Child: Apply daily, treatment may need to be continued for up to 3 months
  - Adult: Apply daily, treatment may need to be continued for up to 3 months
Chapter 14

Vaccines

## 1 Immunoglobulin therapy

### IMMUNE SERA AND IMMUNOGLOBULINS

### IMMUNOGLOBULINS

**Immunoglobulins**

**Passive immunity**

Immunity with immediate protection against certain infective organisms can be obtained by injecting preparations made from the plasma of immune individuals with adequate levels of antibody to the disease for which protection is sought. The duration of this passive immunity varies according to the dose and the type of immunoglobulin. Passive immunity may last only a few weeks; when necessary, passive immunisation can be repeated. Antibodies of human origin are usually termed immunoglobulins. The term antiserum is applied to material prepared in animals. Because of serum sickness and other allergic-type reactions that may follow injections of antisera, this therapy has been replaced wherever possible by the use of immunoglobulins. Reactions are theoretically possible after injection of human immunoglobulins but reports of such reactions are very rare.

Two types of human immunoglobulin preparation are available, normal immunoglobulin p. 1186 and disease-specific immunoglobulins.

Human immunoglobulin is a sterile preparation of concentrated antibodies (immune globulins) recovered from pooled human plasma or serum obtained from outside the UK, tested and found non-reactive for hepatitis B surface antigen and for antibodies against hepatitis C virus and human immunodeficiency virus (types 1 and 2). A global shortage of human immunoglobulin and the rapidly increasing range of clinical indications for treatment with immunoglobulins has resulted in the need for a Demand Management programme in the UK, for further information consult [www.ivig.nhs.uk](http://www.ivig.nhs.uk) and [Clinical Guidelines for Immunoglobulin Use, www.gov.uk/dh](http://www.gov.uk/dh).

Further information on the use of immunoglobulins is included in Public Health England’s [Immunoglobulin Handbook www.gov.uk/phe](http://www.gov.uk/phe), and in the Department of Health’s publication, [Immunisation against Infectious Disease, www.gov.uk/dh](http://www.gov.uk/dh).

**Availability**

Normal immunoglobulin for intramuscular administration is available from some regional Public Health laboratories for protection of contacts and the control of outbreaks of hepatitis A, measles, and rubella only. For other indications, subcutaneous or intravenous normal immunoglobulin should be purchased from the manufacturer.

Disease-specific immunoglobulins are available from some regional Public Health laboratories, with the exception of tetanus immunoglobulin p. 1188 which is available from BPL, hospital pharmacies, or blood transfusion departments. Rabies immunoglobulin p. 1188 is available from the Specialist and Reference Microbiology Division, Public Health England, Colindale. Hepatitis B immunoglobulin p. 1186 required by transplant centres should be obtained commercially.

In Scotland all immunoglobulins are available from the [Scottish National Blood Transfusion Service (SNBTS)](http://www.scottishnhsbt.org.uk).

In Wales all immunoglobulins are available from the [Welsh Blood Service (WBS)](http://www.welshbloodservice.co.uk).

In Northern Ireland all immunoglobulins are available from the [Northern Ireland Blood Transfusion Service (NIBTS)](http://www.nibts.org.uk).

**Normal immunoglobulin**

Human normal immunoglobulin ('HNIG') is prepared from pools of at least 1000 donations of human plasma; it contains immunoglobulin G (IgG) and antibodies to hepatitis A, measles, mumps, rubella, varicella, and other viruses that are currently prevalent in the general population.

**Uses**

Normal immunoglobulin (containing 10%–18% protein) is administered by intramuscular injection for the protection of susceptible contacts against [hepatitis A](http://www.gov.uk/phe), measles, mumps, [rubella](http://www.gov.uk/phe), and, to a lesser extent, varicella. Injection of immunoglobulin produces immediate protection lasting several weeks.

Normal immunoglobulin (containing 3%–12% protein) for intravenous administration is used as replacement therapy for patients with congenital agammaglobulinaemia and hypogammaglobulinaemia, and for the short-term treatment of idiopathic thrombocytopenic purpura and Kawasaki disease; it is also used for the prophylaxis of infection following bone-marrow transplantation and in children with symptomatic HIV infection who have recurrent bacterial infections. Normal immunoglobulin for replacement therapy may also be given intramuscularly or subcutaneously, but intravenous formulations are normally preferred. Intravenous immunoglobulin is also used in the treatment of Guillain-Barré syndrome as an alternative to plasma exchange.


**Hepatitis A**

Hepatitis A vaccine p. 1209 is preferred for individuals at risk of infection including those visiting areas where the disease is highly endemic (all countries excluding Northern and Western Europe, North America, Japan, Australia, and New Zealand). In unimmunised individuals, transmission of hepatitis A is reduced by good hygiene. Intramuscular normal immunoglobulin is no longer recommended for routine prophylaxis in travellers, but it may be indicated for immunocompromised patients if their antibody response to the vaccine is unlikely to be adequate.
Intramuscular normal immunoglobulin is recommended for prevention of infection in close contacts (of confirmed cases of hepatitis A) who have chronic liver disease or HIV infection, or who are immunosuppressed or over 50 years of age; normal immunoglobulin should be given as soon as possible, preferably within 14 days of exposure to the primary case. However, normal immunoglobulin can still be given to contacts at risk of severe disease up to 28 days after exposure to the primary case. Hepatitis A vaccine can be given at the same time, but it should be given at a separate injection site.

**Measles**

Intravenous or subcutaneous normal immunoglobulin may be given to prevent or attenuate an attack of measles in individuals who do not have adequate immunity. Patients with compromised immunity who have come into contact with measles should receive intravenous or subcutaneous normal immunoglobulin as soon as possible after exposure. It is most effective if given within 72 hours but can be effective if given within 6 days.

Subcutaneous or intramuscular normal immunoglobulin should also be considered for the following individuals if they have been in contact with a confirmed case of measles or with a person associated with a local outbreak:

- non-immune pregnant women
- infants under 9 months

Further advice should be sought from the Centre for Infections, Public Health England (tel. (020) 8200 6868).

Individuals with normal immunity who are not in the above categories and who have not been fully immunised against measles, can be given measles, mumps and rubella vaccine, live p. 1213 for prophylaxis following exposure to measles.

**Rubella**

Intramuscular immunoglobulin after exposure to rubella does not prevent infection in non-immune contacts and is not recommended for protection of pregnant women exposed to rubella. It may, however, reduce the likelihood of a clinical attack which may possibly reduce the risk to the fetus. Risk of intra-uterine transmission is greatest in the first 11 weeks of pregnancy, between 16 and 20 weeks there is minimal risk of deafness only, after 20 weeks there is no increased risk. Intramuscular normal immunoglobulin should be used only if termination of pregnancy would be unacceptable to the pregnant woman—it should be given as soon as possible after exposure. Serological follow-up of recipients is essential to determine if the woman has become infected despite receiving immunoglobulin.

For routine prophylaxis against Rubella, see measles, mumps and rubella vaccine, live p. 1213.

**Disease-specific immunoglobulins**

Specific immunoglobulins are prepared by pooling the plasma of selected human donors with high levels of the specific antibody required. For further information, see Immunoglobulin Handbook (www.gov.uk/phe).

There are no specific immunoglobulins for hepatitis A, measles, or rubella—normal immunoglobulin p. 1186 is used in certain circumstances. There is no specific immunoglobulin for mumps; neither normal immunoglobulin nor measles, mumps and rubella vaccine, live is effective as post-exposure prophylaxis.

**Hepatitis B immunoglobulin**

Disease-specific hepatitis B immunoglobulin p. 1186 (‘HBIG’) is available for use in association with hepatitis B vaccine p. 1210 for the prevention of infection in laboratory and other personnel who have been accidentally inoculated with hepatitis B virus, and in infants born to mothers who have become infected with this virus in pregnancy or who are high-risk carriers. Hepatitis B immunoglobulin will not inhibit the antibody response when given at the same time as hepatitis B vaccine but should be given at different sites.

An intravenous and subcutaneous preparation of hepatitis B immunoglobulin is licensed for the prevention of hepatitis B recurrence in HBV-DNA negative patients who have undergone liver transplantation for liver failure caused by the virus.

**Rabies immunoglobulin**

Following exposure of an unimmunised individual to an animal in or from a country where the risk of rabies is high the site of the bite should be washed with soapy water and specific rabies immunoglobulin p. 1188 of human origin administered. All of the dose should be injected around the site of the wound; if this is difficult or the wound has completely healed it can be given in the anterolateral thigh (remote from the site used for vaccination).

Rabies vaccine p. 1214 should also be given intramuscularly at a different site (for details see rabies vaccine). If there is delay in giving the rabies immunoglobulin, it should be given within 7 days of starting the course of rabies vaccine.

**Tetanus immunoglobulin**

For the management of tetanus-prone wounds, tetanus immunoglobulin p. 1188 should be used in addition to wound cleansing and, where appropriate, antibacterial prophylaxis and a tetanus-containing vaccine. Tetanus immunoglobulin, together with metronidazole p. 512 and wound cleansing, should also be used for the treatment of established cases of tetanus.

**Varicella-zoster immunoglobulin**

Varicella-zoster immunoglobulin p. 1189 (VZIG) is recommended for individuals who are at increased risk of severe varicella and who have no antibodies to varicella-zoster virus and who have significant exposure to chickenpox or herpes zoster. Those at increased risk include:

- neonates whose mothers develop chickenpox in the period 7 days before to 7 days after delivery;
- susceptible neonates exposed in the first 7 days of life;
- susceptible neonates or infants exposed whilst requiring intensive or prolonged special care nursing;
- susceptible women exposed at any stage of pregnancy (but when supplies of VZIG are short, may only be issued to those exposed in the first 20 weeks’ gestation or to those near term) providing VZIG is given within 10 days of contact;
- immunocompromised individuals including those who have received corticosteroids in the previous 3 months at the following dose equivalents of prednisolone; children 2 mg/kg daily for at least 1 week or 1 mg/kg daily for 1 month; adults about 40 mg daily for more than 1 week.

**Important:** for full details consult Immunisation against Infectious Disease. Varicella-zoster vaccine p. 1216 is available.

**Anti-D (Rh0) immunoglobulin**

Anti-D (Rh0) immunoglobulin p. 1185 is prepared from plasma taken from rhesus-negative donors who have been immunised against the anti-D-antigen. Anti-D (Rh0) immunoglobulin is used to prevent a rhesus-negative mother from forming antibodies to fetal rhesus-positive cells which may pass into the maternal circulation. The objective is to protect any subsequent child from the hazard of haemolytic disease of the newborn.

Anti-D (Rh0) immunoglobulin should be administered to the mother following any sensitising episode (e.g. abortion, miscarriage and birth); it should be injected within 72 hours of the episode but even if a longer period has elapsed it may still give protection and should be administered.

Anti-D (Rh0) immunoglobulin is also given when significant foetal-maternal haemorrhage occurs in rhesus-negative women during delivery. The dose of Anti-D (Rh0)
immunoglobulin is determined according to the level of exposure to rhesus-positive blood.

Use of routine antenatal anti-D prophylaxis should be given irrespective of previous anti-D prophylaxis for a sensitising event early in the same pregnancy. Similarly, postpartum anti-D prophylaxis should be given irrespective of previous routine antenatal anti-D prophylaxis or antenatal anti-D prophylaxis for a sensitising event in the same pregnancy.

Anti-D (Rh\textsubscript{D}) immunoglobulin is also given to women of child-bearing potential after the inadvertent transfusion of rhesus-incompatible blood components and is used for the treatment of idiopathic thrombocytopenia purpura.

**MMR vaccine**

Measles, mumps and rubella vaccine, live may be given in the postpartum period with Anti-D (Rh\textsubscript{D}) immunoglobulin injection provided that separate syringes are used and the products are administered into different limbs. If blood is transfused, the antibody response to the vaccine may be inhibited—measure rubella antibodies after 6–8 weeks and revaccinate if necessary.

### Anti-D (Rh\textsubscript{D}) immunoglobulin

- **INDICATIONS AND DOSE**
  - **To rhesus-negative woman for prevention of Rh\textsubscript{D}(D) sensitisation, following birth of rhesus-positive infant**
    - BY DEEP INTRAMUSCULAR INJECTION
    - Females of childbearing potential: 500 units per episode, dose to be administered immediately or within 72 hours; for transplacental bleed of over 4 mL fetal red cells, extra 100–125 units per mL fetal red cells, subcutaneous route used for patients with bleeding disorders
  - **To rhesus-negative woman for prevention of Rh\textsubscript{D}(D) sensitisation, following any potentially sensitising episode (e.g. stillbirth, abortion, amniocentesis) up to 20 weeks' gestation**
    - BY DEEP INTRAMUSCULAR INJECTION
    - Females of childbearing potential: 250 units per episode, dose to be administered immediately or within 72 hours, subcutaneous route used for patients with bleeding disorders
  - **To rhesus-negative woman for prevention of Rh\textsubscript{D}(D) sensitisation, following any potentially sensitising episode (e.g. stillbirth, abortion, amniocentesis) after 20 weeks' gestation**
    - BY DEEP INTRAMUSCULAR INJECTION
    - Females of childbearing potential: 500 units per episode, dose to be administered immediately or within 72 hours, subcutaneous route used for patients with bleeding disorders
  - **To rhesus-negative woman for prevention of Rh\textsubscript{D}(D) sensitisation, antenatal prophylaxis**
    - BY DEEP INTRAMUSCULAR INJECTION
    - Females of childbearing potential: 500 units per episode, dose to be given at weeks 28 and 34 of pregnancy, if infant rhesus-positive, a further dose is still needed immediately or within 72 hours of delivery, subcutaneous route used for patients with bleeding disorders
  - **To rhesus-negative woman for prevention of Rh\textsubscript{D}(D) sensitisation, antenatal prophylaxis (alternative NICE recommendation)**
    - BY DEEP INTRAMUSCULAR INJECTION
    - Females of childbearing potential: 1000–1650 units, dose to be given at weeks 28 and 34 of pregnancy, alternatively 1500 units for 1 dose, dose to be given between 28 and 30 weeks gestation
  - **To rhesus-negative woman for prevention of Rh\textsubscript{D}(D) sensitisation, following Rh\textsubscript{D}(D) incompatible blood transfusion**
    - BY DEEP INTRAMUSCULAR INJECTION
    - Females of childbearing potential: 100–125 units per mL of transfused rhesus-positive red cells, subcutaneous route used for patients with bleeding disorders
  - **RHOPHYLAC\textsuperscript{®}**
    - **To rhesus-negative woman for prevention of Rh\textsubscript{D}(D) sensitisation, following birth of rhesus-positive infant**
      - BY INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INJECTION
      - Females of childbearing potential: 1000–1500 units, dose to be administered immediately or within 72 hours for large transplacental bleed, extra 100 units per mL fetal red cells (preferably by intravenous injection), intravenous route recommended for patients with bleeding disorders
    - **To rhesus-negative woman for prevention of Rh\textsubscript{D}(D) sensitisation, following any potentially sensitising episode (e.g. abortion, amniocentesis, chorionic villous sampling) up to 12 weeks' gestation**
      - BY INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INJECTION
      - Females of childbearing potential: 1000 units per episode, dose to be administered immediately or within 72 hours, intravenous route recommended for patients with bleeding disorders, higher doses may be required after 12 weeks gestation
    - **To rhesus-negative woman for prevention of Rh\textsubscript{D}(D) sensitisation, antenatal prophylaxis**
      - BY INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INJECTION
      - Females of childbearing potential: 1500 units, dose to be given between weeks 28–30 of pregnancy; if infant rhesus-positive, a further dose is still needed immediately or within 72 hours of delivery, intravenous route recommended for patients with bleeding disorders
    - **To rhesus-negative woman for prevention of Rh\textsubscript{D}(D) sensitisation, following Rh\textsubscript{D}(D) incompatible blood transfusion**
      - BY INTRAVENOUS INJECTION
      - Females of childbearing potential: 50 units per mL of transfused rhesus-positive blood, alternatively 100 units per mL of erythrocyte concentrate, intravenous route recommended for patients with bleeding disorders

- **CONTRA-INDICATIONS**
  - Treatment of idiopathic thrombocytopenia purpura in rhesus negative patients.
  - Treatment of idiopathic thrombocytopenia purpura in splenectomised patients.

- **CAUTIONS**
  - Immunoglobulin A deficiency.
  - Possible interference with live virus vaccines.

- **CAUTIONS, FURTHER INFORMATION**
  - MMR vaccine may be given in the postpartum period with anti-D (Rh\textsubscript{D}) immunoglobulin injection provided that separate syringes are used and the products are administered into different limbs. If blood is transfused, the antibody response to the vaccine may be inhibited—measure rubella antibodies after 6–8 weeks and revaccinate if necessary.

- **SIDE-EFFECTS**
  - **GENERAL SIDE-EFFECTS**
    - Rare: Anaphylaxis, dyspnoea, hypotension, tachycardia, urticaria.
    - Frequency not known: Abdominal pain, arthralgia, asthenia, back pain, diarrhoea, dizziness, drowsiness, fever, headache, hypertension, hypotension, injection site pain.
Immunoglobulin therapy

1186

- malaise • myalgia • nausea • pruritus • rash • sweating • vomiting

**SPECIFIC SIDE-EFFECTS**
- With intravenous use: Abdominal distension • blood pressure fluctuations • deep vein thrombosis • haemolytic anaemia • injection site reactions • myocardial infarction • pulmonary embolism • stroke • thromboembolic events

**HANDLING AND STORAGE** Care must be taken to store all immunological products under the conditions recommended in the product literature, otherwise the preparation may become ineffective. **Refrigerated storage** is usually necessary; many immunoglobulins need to be stored at 2–8°C and not allowed to freeze. Immunoglobulins should be protected from light. Opened multidose vials must be used within the period recommended in the product literature.

**NATIONAL FUNDING/ACCESS DECISIONS**

**NICE technology appraisals (TAs)**
- Routine antenatal anti-D prophylaxis for rhesus-negative women (August 2008) NICE TA156
  - Routine antenatal anti-D prophylaxis should be offered to all non-sensitised pregnant women who are rhesus negative.
  
  www.nice.org.uk/TA156

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**
- **D-Gam (Bio Products Laboratory Ltd)**
  - **Anti-D (RH<sub>D</sub>) immunoglobulin 500 unit**
    - D-Gam Anti-D immunoglobulin 500 unit solution for injection vials 1 vial £33.75
  - **Anti-D (RH<sub>D</sub>) immunoglobulin 1500 unit**
    - D-Gam Anti-D immunoglobulin 1,500 unit solution for injection vials 1 vial £58.00
  - **Rhophylac (CSL Behring UK Ltd)**
    - **Anti-D (RH<sub>D</sub>) immunoglobulin 750 unit per 1 ml**
      - Rhophylac 1,500 units/ml solution for injection pre-filled syringes 1 pre-filled disposable injection £39.52

### Hepatitis B immunoglobulin

**INDICATIONS AND DOSE**

- **Prophylaxis against hepatitis B infection**
  - **BY INTRAMUSCULAR INJECTION**
    - Adult: 500 units, dose to be administered as soon as possible after exposure; ideally within 12–48 hours, but no later than 7 days after exposure

- **Prophylaxis against hepatitis B infection, after exposure to hepatitis B virus-contaminated material**
  - **BY INTRAVENOUS INFUSION**
    - Adult: Dose to be administered as soon as possible after exposure, but no later than 72 hours (consult product literature)

- **Prevention of hepatitis B in haemodialysed patients**
  - **BY INTRAVENOUS INFUSION**
    - Adult: (consult product literature)

- **Prophylaxis against re-infection of transplanted liver**
  - **BY INTRAVENOUS INFUSION**
    - Adult: (consult product literature)

- **Prevention of hepatitis B re-infection more than 6 months after liver transplantation in stable HBV-DNA negative patients**
  - **BY SUBCUTANEOUS INJECTION**
    - Adult (body-weight up to 75 kg): 500 units once weekly, increased if necessary up to 1000 units once weekly, dose to be started 2–3 weeks after last dose of intravenous hepatitis B immunoglobulin

**CAUTIONS**

- IgA deficiency • interference with live virus vaccines

**SIDE-EFFECTS**

**GENERAL SIDE-EFFECTS**

- **Common or very common** Injection site reactions
- **Uncommon** Abdominal pain • anaphylaxis • arthralgia • buccal ulceration • chest pain • dizziness • dysphonia • glossitis • headache • tremor

**SPECIFIC SIDE-EFFECTS**

- With intravenous use: Abdominal distension • blood pressure fluctuations • deep vein thrombosis • haemolytic anaemia • injection site reactions • myocardial infarction • pulmonary embolism • stroke • thromboembolic events

**PRESCRIBING AND DISPENSING INFORMATION**

- Vials containing 200 units or 500 units (for intramuscular injection), available from selected Public Health England and NHS laboratories (except for Transplant Centres), also available from BPL.

**HANDLING AND STORAGE**

Care must be taken to store all immunological products under the conditions recommended in the product literature, otherwise the preparation may become ineffective. **Refrigerated storage** is usually necessary; many immunoglobulins need to be stored at 2–8°C and not allowed to freeze. Immunoglobulins should be protected from light. Opened multidose vials must be used within the period recommended in the product literature.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Hepatitis B immunoglobulin (Non-proprietary)**
  - Hepatitis B immunoglobulin human 200 unit
  - Hepatitis B immunoglobulin human 200 unit solution for injection vials 1 vial £150.00
  - Hepatitis B immunoglobulin human 500 unit
  - Hepatitis B immunoglobulin human 500 unit solution for injection vials 1 vial £300.00

- **Zutectra (Biotest (UK) Ltd)**
  - Zutectra 500 units/ml solution for injection pre-filled syringes 5 syringe £1,275.00

**Solution for infusion**

- **Hepact CP (Biotest (UK) Ltd)**
  - Hepact B immunoglobulin human 50 unit per 1 ml
  - Hepact B immunoglobulin human 50 unit per 1 ml solution for infusion vials 1 vial £51.00
  - Hepact B immunoglobulin human 50 unit per 1 ml solution for infusion vials 1 vial £935.00
  - Hepact B immunoglobulin human 50 unit per 1 ml solution for infusion vials 1 vial £593.50
  - Hepact B immunoglobulin human 50 unit per 1 ml solution for infusion vials 1 vial £2,337.50

- **Omni-Hep-B (Imported (Israel))**
  - Hepatitis B immunoglobulin human 50 unit per 1 ml
  - Hepatitis B immunoglobulin human 50 unit per 1 ml solution for infusion vials 1 vial £175.00

**Normal immunoglobulin**

**INDICATIONS AND DOSE**

To control outbreaks of hepatitis A
- **BY DEEP INTRAMUSCULAR INJECTION**
  - Adult: 500 mg

Rubella in pregnancy, prevention of clinical attack
- **BY DEEP INTRAMUSCULAR INJECTION**
  - Females of childbearing potential: 750 mg
Contraindications

- Frequency not known

Restricted use

- Subgam® is not licensed for prophylactic use, but due to difficulty in obtaining suitable immunoglobulin products, the Public Health England recommends intramuscular use for prophylaxis against Hepatitis A or rubella.

Contra-indications

- Patients with selective IgA deficiency who have known antibody against IgA
- Hizentra® Hyperprolinaemia (contains -proline)
- Flebogamma® DIF Hereditary fructose intolerance (contains sorbitol)
- Privigen® Hyperprolinaemia (contains -proline)
- Gammaplex® Hereditary fructose intolerance (contains sorbitol)

Caution

- Agammaglobulinaemia with or without IgA deficiency - hypogammaglobulinaemia with or without IgA deficiency - interference with live virus vaccines

Caution, further information

- Interference with live virus vaccines Normal immunoglobulin may interfere with the immune response to live virus vaccines which should therefore only be given at least 3 weeks before or 3 months after an injection of normal immunoglobulin (this does not apply to yellow fever vaccine since normal immunoglobulin does not contain antibody to this virus).
- OCTAGAM® Falsely elevated results with blood glucose testing systems (contains maltose)

Side-effects

- Rare
  - Acute renal failure - anaphylaxis - aseptic meningitis - cutaneous skin reactions - hypotension
- Frequency not known
  - Arthralgia - chills - diarrhoea - dizziness - fever - headache - low back pain - muscle spasms - myalgia - nausea

Side-effects, further information

- Adverse reactions are more likely to occur in patients receiving normal immunoglobulin for the first time, or following a prolonged period between treatments, or when a different brand of normal immunoglobulin is administered.

Monitoring requirements

- Monitor for acute renal failure; consider discontinuation if renal function deteriorates. Intravenous preparations with added sucrose have been associated with cases of renal dysfunction and acute renal failure.

Directions for administration

- Preparations for subcutaneous use May be administered by intramuscular injection if subcutaneous route not possible; intramuscular route not for patients with thrombocytopenia or other bleeding disorders.
- Gamunex® Use Glucose 5% intravenous infusion if dilution prior to infusion is required.
- Kiovig® Use Glucose 5% intravenous infusion if dilution prior to infusion is required.

Prescribing and dispensing information

- Antibody titres can vary widely between normal immunoglobulin preparations from different manufacturers—formulations are not interchangeable; patients should be maintained on the same formulation throughout long-term treatment to avoid adverse effects.

With intramuscular use Available from the Centre for Infections and other regional Public Health England offices (for contacts and control of outbreaks only).

Handling and storage

- Care must be taken to store all immunological products under the conditions recommended in the product literature, otherwise the preparation may become ineffective. Refrigerated storage is usually necessary; many immunoglobulins need to be stored at 2–8°C and not allowed to freeze. Immunoglobulins should be protected from light. Opened multidose vials must be used within the period recommended in the product literature.
Vaccines

1188 Immunoglobulin therapy

Gammaplex 5g/100ml solution for infusion vials | 1 vial £205.00 (Hospital only)
Gammaplex 20g/400ml solution for infusion vials | 1 vial £836.00 (Hospital only)

- Gamunex (Grifols Ltd)
  Normal immunoglobulin human 100mg per 1ml Gamunex 10% 1g/10ml solution for infusion vials | 1 vial £42.50
  Gamunex 10% 10g/100ml solution for infusion vials | 1 vial £425.00
  Gamunex 10% 20g/200ml solution for infusion vials | 1 vial £850.00
  Gamunex 10% 5g/50ml solution for infusion vials | 1 vial £212.50
- Hizentra (CSL Behring UK Ltd)
  Normal immunoglobulin human 200mg per 1ml Hizentra 2g/10ml solution for infusion vials | 1 vial £91.80
  Hizentra 1g/5ml solution for infusion vials | 1 vial £45.90
  Hizentra 4g/20ml solution for infusion vials | 1 vial £183.60
- Intratect (Biostec UK Ltd)
  Normal immunoglobulin human 50mg per 1ml Intratect 5g/100ml solution for infusion vials | 1 vial £191.25
  Intratect 1g/20ml solution for infusion vials | 1 vial £38.25
  Intratect 2.5g/50ml solution for infusion vials | 1 vial £95.63
  Intratect 10g/200ml solution for infusion vials | 1 vial £382.50
- Octagam (Octapharma Ltd)
  Normal immunoglobulin human 50mg per 1ml Octagam 5g/100ml solution for infusion bottles | 1 bottle £408.00 (Hospital only)
  Octagam 5g/100ml solution for infusion bottles | 1 bottle £204.00 (Hospital only)
  Octagam 5g/100ml solution for infusion bottles | 1 bottle £102.00 (Hospital only)
- Privigen (CSL Behring Ltd)
  Normal immunoglobulin human 100mg per 1ml Privigen 5g/50ml solution for infusion vials | 1 vial £229.50
  Privigen 20g/200ml solution for infusion vials | 1 vial £918.00
  Privigen 10g/100ml solution for infusion vials | 1 vial £459.00
  Privigen 2.5g/25ml solution for infusion vials | 1 vial £114.75
- Vigm (Bio Products Laboratory Ltd)
  Normal immunoglobulin human 50mg per 1ml Vigm Liquid 5g/100ml solution for infusion vials | 1 vial £209.00
  Vigm Liquid 10g/200ml solution for infusion vials | 1 vial £415.00

Powder and solvent for solution for injection
- Gammagard S/D (Baxalta UK Ltd)
  Normal immunoglobulin human 5 gramm Gammagard S/D 5g powder and solvent for solution for injection bottles | 1 bottle no price available

- Kiovig (Baxalta UK Ltd)
  Normal immunoglobulin human 100mg per 1ml Kiovig 5g/50ml solution for infusion vials | 1 vial no price available
  Kiovig 10g/100ml solution for infusion vials | 1 vial no price available
  Kiovig 30g/300ml solution for infusion vials | 1 vial £1470.00
  Kiovig 2.5g/25ml solution for infusion vials | 1 vial no price available
  Kiovig 1g/10ml solution for infusion vials | 1 vial no price available
- Octagam (Octapharma Ltd)
  Normal immunoglobulin human 50mg per 1ml Octagam 5g/100ml solution for infusion bottles | 1 bottle £408.00 (Hospital only)
  Octagam 5g/100ml solution for infusion bottles | 1 bottle £204.00 (Hospital only)
  Octagam 5g/100ml solution for infusion bottles | 1 bottle £102.00 (Hospital only)
- Privigen (CSL Behring Ltd)
  Normal immunoglobulin human 100mg per 1ml Privigen 5g/50ml solution for infusion vials | 1 vial £229.50
  Privigen 20g/200ml solution for infusion vials | 1 vial £918.00
  Privigen 10g/100ml solution for infusion vials | 1 vial £459.00
  Privigen 2.5g/25ml solution for infusion vials | 1 vial £114.75

Tetanus immunoglobulin

- INDICATIONS AND DOSE

  Post-exposure prophylaxis against rabies infection
  - BY INTRAMUSCULAR INJECTION
    - Child: Initially 250 units, then increased to 500 units, dose is only increased if more than 24 hours have elapsed or there is risk of heavy contamination or following burns
    - Adult: Initially 250 units, then increased to 500 units, dose is only increased if more than 24 hours have elapsed or there is risk of heavy contamination or following burns

  Treatment of tetanus infection
  - BY INTRAMUSCULAR INJECTION
    - Child: 150 units/kg, dose may be given over multiple sites
    - Adult: 150 units/kg, dose may be given over multiple sites

- CAUTIONS
  - IgA deficiency - interference with live virus vaccines

- SIDE-EFFECTS
  - Rare Anaphylaxis - arthralgia - buccal ulceration - chest tightness - dizziness - dyspnoea - glossitis - tremor
  - Frequency not known Facial oedema - injection site pain - injection site swelling

- PRESCRIBING AND DISPENSING INFORMATION
  - The potency of individual batches of rabies immunoglobulin from the manufacturer may vary; potency may also be described differently by different manufacturers. It is therefore critical to know the potency of the batch to be used and the weight of the patient in order to calculate the specific volume required to provide the necessary dose.
  - Available from Specialist and Reference Microbiology Division, Public Health England (also from BPL).

- HANDLING AND STORAGE
  - Care must be taken to store all immunological products under the conditions recommended in the product literature, otherwise the preparation may become ineffective. Refrigerated storage is usually necessary; many immunoglobulins need to be stored at 2–8°C and not allowed to freeze.
  - Immunoglobulins should be protected from light. Opened multidose vials must be used within the period recommended in the product literature.

- MEDICINAL FORMS
  - There can be variation in the licensing of different medicines containing the same drug.

Solution for injection
- Rabies immunoglobulin (Non-proprietary)
  Rabies immunoglobulin human 500 unit Rabies immunoglobulin human 500 unit solution for injection vials | 1 vial £600.00
2 Post-exposure prophylaxis

IMMUNE SERA AND IMMUNOGLOBULINS

ANTITOXINS

Botulism antitoxin

DRUG ACTION A preparation containing the specific antitoxic globulins that have the power of neutralising the toxins formed by types A, B, and E of Clostridium botulinum.

INDICATIONS AND DOSE

Post exposure prophylaxis of botulism

- By intramuscular injection
- Adult: (consult product literature)

SIDE-EFFECTS

Hypersensitivity reactions

SIDE-EFFECTS, FURTHER INFORMATION

- Hypersensitivity reactions It is essential to read the contra-indications, warnings, and details of sensitivity tests on the package insert. Prior to treatment checks should be made regarding previous administration of any antitoxin and history of any allergic condition, e.g. asthma, hay fever, etc.

PRE-TREATMENT SCREENING

All patients should be tested for sensitivity (diluting the antitoxin if history of allergy).

PRESCRIBING AND DISPENSING INFORMATION

Available from local designated centres, for details see TOXBASE (requires registration) www.toxbase.org. For supplies outside working hours apply to other designated centres or to the Public Health England Colindale duty doctor (Tel (020) 8200 6868). For major incidents, obtain supplies from the local blood bank.

The BP title Botulinum Antitoxin is not used because the preparation currently in use may have a different specification.

Varicella-zoster immunoglobulin

(Antivaricella-zoster Immunoglobulin)

INDICATIONS AND DOSE

Prophylaxis against varicella infection

- By deep intramuscular injection
- Adult: 1 g, to be administered as soon as possible—not later than 10 days after exposure, second dose to be given if further exposure occurs more than 3 weeks after first dose, no evidence that effective in severe disease

CAUTIONS

IgA deficiency · interference with live virus vaccines

SIDE-EFFECTS

- Rare Anaphylaxis
- Frequency not known Injection site pain · injection site swelling

DIRECTIONS FOR ADMINISTRATION

Normal immunoglobulin for intravenous use may be used in those unable to receive intramuscular injections.

PRESCRIBING AND DISPENSING INFORMATION

Available from selected Public Health England and NHS laboratories (also from BPL).

HANDLING AND STORAGE

Care must be taken to store all immunological products under the conditions recommended in the product literature, otherwise the preparation may become ineffective. Refrigerated storage is usually necessary; many immunoglobulins need to be stored at 2–8°C and not allowed to freeze. Immunoglobulins should be protected from light. Opened multidose vials must be used within the period recommended in the product literature.

MEDICINAL FORMS

Available from Centre for Infections (Tel (020) 8200 6868) or in

Diphtheria antitoxin

(Dip/Ser)

INDICATIONS AND DOSE

Passive immunisation in suspected cases of diphtheria

- By intravenous infusion
- Adult: Dose should be given without waiting for bacteriological confirmation (consult product literature)

CAUTIONS

CAUTIONS, FURTHER INFORMATION

- Hypersensitivity Hypersensitivity is common after administration; resuscitation facilities should be available. Diphtheria antitoxin is no longer used for prophylaxis because of the risk of hypersensitivity; unimmunised contacts should be promptly investigated and given antibacterial prophylaxis and vaccine.

SIDE-EFFECTS

- Common or very common Hypersensitivity reactions

PRESCRIBING AND DISPENSING INFORMATION

Available from Centre for Infections (Tel (020) 8200 6868) or in
3 Tuberculosis diagnostic test

Tuberculin purified protein derivative (Tuberculin PPD)

**INDICATIONS AND DOSE**

Mantoux test
- **BY INTRADERMAL INJECTION**
  - Child: 2 units for one dose
  - Adult: 2 units for one dose

Mantoux test (if first test is negative and a further test is considered appropriate)
- **BY INTRADERMAL INJECTION**
  - Child: 10 units for 1 dose
  - Adult: 10 units for 1 dose

**DOSE EQUIVALENCE AND CONVERSION**
- 2 units is equivalent to 0.1 mL of 20 units/mL strength.
- 10 units is equivalent to 0.1 mL of 100 units/mL strength.

**CAUTIONS, FURTHER INFORMATION**

- Mantoux test: Response to tuberculin may be suppressed by viral infection, sarcoidosis, corticosteroid therapy, or immunosuppression due to disease or treatment and the MMR vaccine. If a tuberculin skin test has already been initiated, then the MMR should be delayed until the skin test has been read unless protection against measles is required urgently. If a child has had a recent MMR, and requires a tuberculin test, then a 4 week interval should be observed. Apart from tuberculin and MMR, all other live vaccines can be administered at any time before or after tuberculin.

**PRESCRIBING AND DISPENSING INFORMATION**

Available from ImmForm (SSI brand).

- The strength of tuberculin PPD in currently available products may be different to the strengths of products used previously for the Mantoux test; care is required to select the correct strength.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Tuberculin purified protein derivative (Non-proprietary)**
  - Tuberculin purified protein derivative 20 tuberculin unit per 1 mL Tuberculin PPD RT 23 SSI 20 tuberculin units/mL solution for injection 1.5 mL vials | 1 vial no price available
  - Tuberculin purified protein derivative 100 tuberculin unit per 1 mL Tuberculin PPD RT 23 SSI 100 tuberculin units/mL solution for injection 1.5 mL vials | 1 vial no price available

---

4 Vaccination

**Vaccines**

14-Jun-2017

**Active immunity**

Active immunity can be acquired by natural disease or by vaccination. **Vaccines** stimulate production of antibodies and other components of the immune mechanism; they consist of either:

- a live attenuated form of a virus (e.g. measles, mumps and rubella vaccine) or bacteria (e.g. BCG vaccine), or
- inactivated preparations of the virus (e.g. influenza vaccine) or bacteria, or
- detoxified exotoxins produced by a micro-organism (e.g. tetanus vaccine), or
- extracts of a micro-organism, which may be derived from the organism (e.g. pneumococcal vaccine) or produced by recombinant DNA technology (e.g. hepatitis B vaccine).

**Live attenuated vaccines** usually produce a durable immunity, but not always as long-lasting as that resulting from natural infection.

**Inactive vaccines** may require a primary series of injections of vaccine to produce an adequate antibody response, and in most cases booster (reinforcing) injections are required; the duration of immunity varies from months to many years. Some inactivated vaccines are adsorbed onto an adjuvant (such as aluminium hydroxide) to enhance the antibody response.

Advice reflects that in the handbook *Immunisation against Infectious Disease* (2013), which in turn reflects the guidance of the Joint Committee on Vaccination and Immunisation (JCVI).


- The advice also incorporates changes announced by the Chief Medical Officer and Health Department Updates.

**Immunisation schedule**

Vaccines for the childhood immunisation schedule should be obtained from local health organisations or from ImmForm (www.immform.dh.gov.uk)—not to be prescribed on FP10 (HS21 in Northern Ireland; GP10 in Scotland; WP10 in Wales).

- For the most up to date immunisation schedule consult 'The complete routine immunisation schedule’, available at www.gov.uk.

**Preterm birth**

Babies born preterm should receive all routine immunisations based on their actual date of birth. The risk of apnoea following vaccination is increased in preterm babies, particularly in those born at or before 28 weeks gestational age. If babies at risk of apnoea are in hospital at the time of their first immunisation, they should be monitored for 48–72 hours after immunisation. If a baby develops apnoea, bradycardia, or desaturation after the first immunisation, the second immunisation should also be given in hospital with similar monitoring. Seroconversion may be unreliable in babies born earlier than 28 weeks’ gestation or in babies treated with corticosteroids for chronic lung disease; consideration should be given to testing for antibodies against *Haemophilus influenzae* type b, meningococcal C, and hepatitis B after primary immunisation.

**Vaccines and HIV infection**

HIV-positive individuals with or without symptoms can receive the following live vaccines:

- MMR (but avoid if immunity significantly impaired); use of normal immunoglobulin should be considered after...
### Routine immunisation schedule

<table>
<thead>
<tr>
<th>When to immunise</th>
<th>Vaccine given and dose schedule (for details of dose, see under individual vaccines)</th>
</tr>
</thead>
</table>
| **Neonates at risk only (see BCG vaccine and Hepatitis B vaccine, below)** | ✷ Bacillus Calmette-Guérin vaccine p. 1204  
    ✷ Hepatitis B vaccine p. 1210 |
| **2 months** | ✷ Diphtheria with haemophilus influenzae type b vaccine, pertussis, poliomyelitis and tetanus p. 1203 First dose  
    ✷ Meningococcal group B vaccine (rDNA, component, adsorbed) p. 1206 First dose  
    ✷ Pneumococcal polysaccharide conjugate vaccine (adsorbed) p. 1207 First dose  
    ✷ Rotavirus vaccine p. 1215 First dose |
| **3 months** | ✷ Diphtheria with haemophilus influenzae type b vaccine, pertussis, poliomyelitis and tetanus p. 1203 Second dose  
    ✷ Rotavirus vaccine p. 1215 Second dose |
| **4 months** | ✷ Diphtheria with haemophilus influenzae type b vaccine, pertussis, poliomyelitis and tetanus p. 1203 Third dose  
    ✷ Meningococcal group B vaccine (rDNA, component, adsorbed) p. 1206 Second dose  
    ✷ Pneumococcal polysaccharide conjugate vaccine (adsorbed) p. 1207 Second dose |
| **12-13 months** | ✷ Measles, mumps and rubella vaccine, live p. 1213 First dose  
    ✷ Meningococcal group B vaccine (rDNA, component, adsorbed) p. 1206 Single booster dose  
    ✷ Pneumococcal polysaccharide conjugate vaccine (adsorbed) p. 1207 Single booster dose  
    ✷ Haemophilus influenzae type B with meningococcal group C vaccine p. 1205 Single booster dose |
| **2–8 years (including children in school years 1, 2, 3 and 4)** | ✷ Influenza vaccine p. 1212 Each year from September. **Note:** Flu nasal spray is recommended (Fluenz Tetra<sup>®</sup>). If contra-indicated and child is in clinical risk group, use inactivated flu vaccine |
| **Between 3 years and 4 months, and 5 years** | ✷ Diphtheria with pertussis, poliomyelitis vaccine and tetanus p. 1203 Booster dose. **Note:** Preferably allow interval of at least 3 years after completing primary course  
    ✷ Measles, mumps and rubella vaccine, live p. 1213 Second dose |
| **11–14 years (females only). First dose of HPV vaccine will be offered to females aged 12–13 years of age in England, Wales, and Northern Ireland, and 11–13 years of age in Scotland.** | ✷ Human papillomavirus vaccines p. 1212 two doses; second dose 6–24 months after first dose. If a 3-dose course of HPV vaccine has been started under the 2013/2014 programme, where possible, the course should be completed (2 doses less than 6 months apart does not provide long-term protection). The two human papillomavirus vaccines are not interchangeable and, ideally, one vaccine product should be used for the entire course. However, since 2012, only Gardasil<sup>®</sup> is offered as part of the national immunisation programme; for those females who started the schedule with Cervarix<sup>®</sup> under the national immunisation programme, but did not complete the vaccination course, the course can be completed with Gardasil<sup>®</sup> |
| **13–15 years** | ✷ Meningococcal groups A with C and W135 and Y vaccine p. 1206 Single booster dose |
| **13–18 years** | ✷ Diphtheria with poliomyelitis and tetanus vaccine p. 1203 Single booster dose. **Note:** Can be given at the same time as the dose of meningococcal group A with C and W135 and Y vaccine at 13–15 years of age. |
| **During adult life, women of child-bearing age susceptible to rubella** | ✷ Measles, mumps and rubella vaccine, live p. 1213 Women of child-bearing age who have not received 2 doses of a rubella-containing vaccine or who do not have a positive antibody test for rubella should be offered rubella immunisation (using the MMR vaccine)—exclude pregnancy before immunisation. |
| **Pregnant women** | ✷ Acellular pertussis-containing vaccine administered as diphtheria with pertussis, poliomyelitis vaccine and tetanus p. 1203 (Boostrix-IPV<sup>®</sup>) 1 dose from the 16th week of pregnancy, preferably after the foetal anomaly scan (weeks 18–20)  
    ✷ Influenza vaccine p. 1212 (inactivated), Single dose administered from September, regardless of the stage of pregnancy |
| **Under 25 years, those entering university who are at risk of meningococcal disease** | ✷ Meningococcal groups A with C and W135 and Y vaccine p. 1206 Single dose. **Note:** Should be offered to those aged under 25 years entering university who have not received the meningococcal groups A with C and W135 and Y vaccine over the age of 10 years |
| **During adult life, if not previously immunised** | ✷ Diphtheria with poliomyelitis and tetanus vaccine p. 1203 |
| **65 years** | ✷ Pneumococcal polysaccharide vaccine p. 1207 |
| **From 65 years** | ✷ Influenza vaccine p. 1212 Each year from September |
| **70 years** | ✷ Varicella-zoster vaccine p. 1216 Single dose |

### Additional Information

- Exposure to measles, varicella-zoster vaccine against chickenpox (but avoid if immunity significantly impaired—consult product literature; varicella-zoster immunoglobulin should be considered after exposure to chickenpox or herpes zoster), rotavirus; and the following inactivated vaccines:
  - anthrax, chola (oral), diphtheria, haemophilus influenzae type b, hepatitis A, hepatitis B, human papillomavirus, influenza (injection), meningococcal, pertussis, pneumococcal, poliomyelitis, rabies, tetanus, tick-borne encephalitis, typhoid (injection).
- HIV-positive individuals should **not** receive:
  - BCG, influenza nasal spray (unless stable HIV infection and receiving antiretroviral therapy), typhoid (oral), yellow fever (if yellow fever risk is unavoidable, specialist advice should be sought)
The above advice differs from that for other immunocompromised patients; *Immunisation Guidelines for HIV-infected Adults* issued by British HIV Association (BHIVA) are available at www.bhiva.org and, *Immunisation of HIV-infected Children* issued by Children’s HIV Association (CHIVA) are available at www.chiva.org.uk.

**Vaccines and asplenia**

The following vaccines are recommended for asplenic patients, those with splenic dysfunction or complement disorders, depending on the age at which their condition is diagnosed:

- Haemophilus influenzae type B with meningococcal group C vaccine p. 1205;
- Influenza vaccine p. 1212;
- Meningococcal groups A with C and W135 and Y vaccine p. 1206 and meningococcal group B vaccine (rDNA, component, adsorbed) p. 1206;
- Pneumococcal polysaccharide vaccine.

Children first diagnosed under 1 year of age should be vaccinated according to the Immunisation Schedule. Additionally, one dose of meningococcal groups A with C and W135 and Y vaccine should be given during infancy followed by a second dose at least one month apart. Two months following the routine 12 month booster vaccines, give a dose of meningococcal groups A with C and W135 and Y vaccine and an additional dose of 13-valent pneumococcal polysaccharide vaccine. An additional dose of haemophilus influenzae type B with meningococcal group C vaccine and 23-valent pneumococcal polysaccharide vaccine should be given after the second birthday. The influenza vaccine should be administered annually in children aged 6 months or older.

Children first diagnosed between 1 and 2 years of age should be vaccinated according to the Immunisation Schedule, including the 12 month boosters. Two months after the routine 12 month booster vaccines, give a dose of meningococcal groups A with C and W135 and Y vaccine and an additional dose of 13-valent pneumococcal polysaccharide vaccine. An additional dose of haemophilus influenzae type B with meningococcal group C vaccine and 23-valent pneumococcal polysaccharide vaccine should be given after the second birthday. The influenza vaccine should be administered annually.

Children first diagnosed over 2 years of age should be vaccinated according to the Immunisation schedule, including the 12 month boosters. The child should receive one additional booster dose of haemophilus influenzae type B with meningococcal group C vaccine along with the 23-valent pneumococcal polysaccharide vaccine, followed by one dose of meningococcal groups A with C and W135 and Y vaccine after 2 months. The influenza vaccine should be administered annually.

**Vaccines and antisera availability**

Anthrax vaccine p. 1204 and yellow fever vaccine, live p. 1217, botulism antitoxin p. 1189, diphtheria antitoxin p. 1189, and snake and spider venom antitoxins are available from local designated holding centres.

For antivenom, see Emergency treatment of poisoning p. 1249.

Enquiries for vaccines not available commercially can also be made to:

- Vaccines and Countermeasures Response Department
- Public Health England
- Wellington House
- 133–155 Waterloo Road
- London
- SE1 8UG
- vaccinesupply@phe.gov.uk

In Scotland information about availability of vaccines can be obtained from a Specialist in Pharmaceutical Public Health.

In Wales enquiries for vaccines not available commercially should be directed to:

- Welsh Medicines Information Centre
- University Hospital of Wales
- Cardiff
- CF14 4XW
- (029) 2074 2979

In Northern Ireland:

- Pharmacy and Medicines Management Centre
- Northern Health and Social Care Trust
- Beech House
- Antrim Hospital Site
- Bush Road
- Antrim
- BT41 2RL
- rphps.admin@northerntrust.hscni.net

For further details of availability, see under individual vaccines.

**Anthrax vaccine**

Anthrax vaccine is made from antigens from *B. anthracis*. Anthrax immunisation is indicated for individuals who handle infected animals, for those exposed to imported infected animal products, and for laboratory staff who work with *B. anthracis*. A 4-dose regimen is used for primary immunisation; booster doses should be given annually to workers at continued risk of exposure to anthrax.

In the event of possible contact with *B. anthracis*, post-exposure immunisation may be indicated, in addition to antimicrobial prophylaxis. Advice on the use of anthrax vaccine for post-exposure prophylaxis must be obtained from Public Health England Colindale (tel. 020 8200 4400).

**BCG vaccine**

Bacillus Calmette-Guérin vaccine p. 1204 should be given intradermally by operators skilled in the technique.

The expected reaction to successful Bacillus Calmette-Guérin vaccine is induration at the site of injection followed by a local lesion which starts as a papule 2 or more weeks after vaccination; the lesion may ulcerate then subside over several weeks or months, leaving a small, flat scar. A dry dressing may be used if the ulcer discharges, but air should not be excluded.

BCG is recommended for the following groups if BCG immunisation has not previously been carried out and they are negative for tuberculoprotein hypersensitivity:

- neonates with a family history of tuberculosis in the last 5 years;
- all neonates and infants (0–12 months) born in areas where the incidence of tuberculosis is greater than 40 per 100 000;
- all neonates, infants, and children under 16 years with a parent or grandparent born in a country with an incidence of tuberculosis greater than 40 per 100 000;
- new immigrants aged under 16 years who were born in, or lived for more than 3 months in a country with an incidence of tuberculosis greater than 40 per 100 000;
- new immigrants aged 16–35 years from Sub-Saharan Africa or a country with an incidence of tuberculosis greater than 500 per 100 000;
- contacts aged under 36 years of those with active respiratory tuberculosis (for healthcare or laboratory workers who have had contact with clinical materials or patients with tuberculosis, age limit does not apply);
- healthcare workers and laboratory staff (irrespective of age) who are likely to have contact with patients, clinical materials, or derived isolates; other individuals under 35 years (there is inadequate evidence of protection by BCG vaccine in adults aged over 35 years; however, vaccination is recommended for healthcare workers irrespective of age based on the increased risk to them or their patients) at occupational risk including veterinary
and other staff who handle animal species susceptible to tuberculosis, and staff working directly with prisoners, in care homes for the elderly, or in hostels or facilities for the homeless or refugees;

- individuals under 16 years intending to live with local people for more than 3 months in a country with an incidence of tuberculosis greater than 40 per 100 000.

List of countries or primary care trusts where the incidence of tuberculosis is greater than 40 cases per 100 000 is available at www.gov.uk/ phe.

Bladder instillations of BCG are licensed for the management of bladder carcinoma.

See also Tuberculosis p. 546 for advice on chemoprophylaxis; for the treatment of infection following vaccination, seek expert advice.

**Tuberculosis Diagnostic Agents**

The Mantoux test is recommended for tuberculin skin testing, but no licensed preparation is currently available. Guidance for healthcare professionals is available at www.dh.gov.uk/ immunisation.

In the Mantoux test, the diagnostic dose is administered by intradermal injection of tuberculin purified protein derivative (PPD) p. 1190.

The Huf test (involving the use of multiple—puncture apparatus) is no longer available.

Two interferon gamma release assay (IGRA) tests are also available as an aid in the diagnosis of tuberculosis infection: QuantIFERON® TB Gold and T-SPOT. Both tests measure T-cell mediated immune response to synthetic antigens. For further information on the use of interferon gamma release assay tests for tuberculosis, see www.gov.uk/ phe.

**Botulism antitoxin**

A polyvalent botulism antitoxin p. 1189 is available for the post—exposure prophylaxis of botulism and for the treatment of persons thought to be suffering from botulism. It specifically neutralises the toxins produced by *Clostridium botulinum* types A, B, and E. It is not effective against infantile botulism as the toxin (type A) is seldom, if ever, found in the blood in this type of infection.

**Cholera vaccine**

Cholera vaccine (oral) p. 1205 contains inactivated Inaba (including El-Tor type) and Ogawa strains of *Vibrio cholerae*, serotype O1 together with recombinant B-subunit of the cholera toxin produced in Inaba strains of *V.cholerae*, serotype O1.

Oral cholera vaccine is licensed for travellers to endemic or epidemic areas on the basis of current recommendations. Immunisation should be completed at least 1 week before potential exposure. However, there is no requirement for cholera vaccination for international travel. Injectable cholera vaccine provides unreliable protection and is no longer available in the UK.

**Diphtheria vaccine**

Diphtheria—containing vaccines are prepared from the toxin of *Corynebacterium diphtheriae* and adsorption on aluminium hydroxide or aluminium phosphate improves antigenicity. The vaccine stimulates the production of the protective antibody. The quantity of diphtheria toxoid in a preparation determines whether the vaccine is defined as 'high dose' or 'low dose'. Vaccines containing the higher dose of diphtheria toxoid are used for primary immunisation in adults and children over 10 years. Single—antigen diphtheria vaccine is not available and adsorbed diphtheria vaccine is given as a combination product containing other vaccines.

For primary immunisation of children aged between 2 months and 10 years vaccination is recommended usually in the form of 3 doses (separated by 1—month intervals) of *(242,462),(290,477) diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) and haemophilus type b conjugate vaccine (adsorbed)* (see Immunisation schedule). In unimmunised individuals aged over 10 years the primary course comprises of 3 doses of *adsorbed diphtheria* [low dose], *tetanus and poliomyelitis (inactivated) vaccine*.

A booster dose should be given 3 years after the primary course (this interval can be reduced to a minimum of 1 year if the primary course was delayed). Children under 10 years should receive either *adsorbed diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine* or *adsorbed diphtheria* [low dose], *tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine*. Individuals aged over 10 years should receive *adsorbed diphtheria* [low dose], *tetanus, and poliomyelitis (inactivated) vaccine*.

A second booster dose, of adsorbed diphtheria [low dose], tetanus and poliomyelitis (inactivated) vaccine, should be given 10 years after the previous booster dose (this interval can be reduced to a minimum of 5 years if previous doses were delayed).

**Diphtheria-containing vaccines for children over 10 years and adults**

A low dose of diphtheria toxoid is sufficient to recall immunity in individuals previously immunised against diphtheria but whose immunity may have diminished with time; it is insufficient to cause serious reactions in an individual who is already immune. Preparations containing low dose diphtheria should be used for adults and children over 10 years, for both primary immunisation and booster doses.

**Travel**

Those intending to travel to areas with a risk of diphtheria infection should be fully immunised according to the UK schedule. If more than 10 years have lapsed since completion of the UK schedule, a dose of *adsorbed diphtheria* [low dose], *tetanus and poliomyelitis (inactivated) vaccine* should be administered.

**Contacts**

Staff in contact with diphtheria patients or with potentially pathogenic clinical specimens or working directly with *C. diphtheriae* or *C. ulcerans* should receive a booster dose if fully immunised (with 5 doses of diphtheria—containing vaccine given at appropriate intervals); further doses should be given at 10—year intervals if risk persists. Individuals at risk who are not fully immunised should complete the primary course; a booster dose should be given after 5 years and then at 10—year intervals. *Adsorbed diphtheria* [low dose], *tetanus and poliomyelitis (inactivated) vaccine* is used for this purpose; immunity should be checked by antibody testing at least 3 months after completion of immunisation.

Advice on the management of cases, carriers, contacts and outbreaks must be sought from health protection units. The immunisation history of infected individuals and their contacts should be determined; those who have been incompletely immunised should complete their immunisation and fully immunised individuals should receive a reinforcing dose. See advice on antibacterial treatment to prevent a secondary case of diphtheria in a non—immune individual.

**Haemophilus influenzae type b**

Haemophilus influenzae type b (Hib) vaccine is made from capsular polysaccharide; it is conjugated with a protein such as tetanus toxoid to increase immunogenicity, especially in young children. Haemophilus influenzae type b vaccine immunisation is given in combination with
Vaccines

Immunisation should be considered for:

- immunocompromised individuals.

A booster dose of Haemophilus influenzae type b vaccine (combined with meningococcal group C conjugate vaccine) should be given annually at 12–13 months of age.

Children 1–10 years who have not been immunised against Haemophilus influenzae type b need to receive only 1 dose of Haemophilus influenzae type b vaccine (combined with meningococcal group C conjugate vaccine). However, if a primary course of immunisation has not been completed, these children should be given 3 doses of diphtheria with Haemophilus influenzae type b vaccine, pertussis, poliomyelitis and tetanus p. 1203. The risk of infection falls sharply in older children and the vaccine is not normally required for children over 10 years.

Haemophilus influenzae type b vaccine may be given to those over 10 years who are considered to be at increased risk of invasive Haemophilus influenzae type b disease (such as those with sickle-cell disease or complement deficiency, or those receiving treatment for malignancy).

**Invasive Haemophilus influenzae type b disease**

After recovery from infection, unimmunised and partially immunised index cases under 10 years of age should complete their age-specific course of immunisation. Previously vaccinated cases under 10 years of age should be given an additional dose of Haemophilus influenzae type b vaccine (combined with meningococcal group C conjugate vaccine) if Hib antibody concentrations are low or if it is not possible to measure antibody concentrations. Index cases of any age with asplenia or splenic dysfunction should complete their immunisation according to the recommendations below; fully vaccinated cases with asplenia or splenic dysfunction should be given an additional dose of Haemophilus influenzae type b vaccine (combined with meningococcal group C conjugate vaccine) if they received their previous dose over 1 year ago.

See also use of rifampicin p. 549 in the prevention of secondary cases of Haemophilus influenzae type b disease.

**Hepatitis A vaccine**

Hepatitis A vaccine p. 1209 is prepared from formaldehyde-inactivated hepatitis A virus grown in human diploid cells. Immunisation is recommended for:

- laboratory staff who work directly with the virus;
- staff and residents of homes for those with severe learning difficulties;
- workers at risk of exposure to untreated sewage;
- individuals who work with primates;
- patients with haemophilia or other conditions treated with plasma-derived clotting factors;
- patients with severe liver disease;
- travellers to high-risk areas;
- individuals who are at risk due to their sexual behaviour;
- parenteral drug abusers.

Immunisation should be considered for:

- patients with chronic liver disease including chronic hepatitis B or chronic hepatitis C;
- prevention of secondary cases in close contacts of confirmed or otherwise hepatitis A, within 14 days of exposure to the primary case (within 8 weeks of exposure to the primary case where there is more than 1 contact in the household).

A booster dose is usually given 6–12 months after the initial dose. A second booster dose can be given 20 years after the previous booster dose to those who continue to be at risk. Specialist advice should be sought on re-immunisation of immunocompromised individuals.

For rapid protection against hepatitis A after exposure or during an outbreak, in adults a single dose of a monovalent vaccine is recommended; for children under 16 years, a single dose of the combined vaccine Ambirix® can also be used.

Intramuscular normal immunoglobulin p. 1186 is recommended for use in addition to hepatitis A vaccine for close contacts (of confirmed cases of hepatitis A) who have chronic liver disease or HIV infection, or who are immunosuppressed or over 50 years of age.

Post-exposure prophylaxis is not required for healthy children under 1 year of age, so long as all those involved in nappy changing are vaccinated against hepatitis A. However, children 2–12 months of age can be given a dose of hepatitis A vaccine if it is not possible to vaccinate their carers, or if the child becomes a source of infection to others [unlicensed use]; in these cases, if the child goes on to require long-term protection against hepatitis A after the first birthday, the full course of 2 doses should be given.

**Hepatitis B vaccine**

Hepatitis B vaccine p. 1210 contains inactivated hepatitis B virus surface antigen (HBsAg) adsorbed onto aluminium hydroxide adjuvant. It is made biosynthetically using recombinant DNA technology. The vaccine is used in individuals at high risk of contracting hepatitis B.

In the UK, groups at high-risk of hepatitis B include:

- parenteral drug misusers, their sexual partners, and household contacts; other drug misusers who are likely to ‘progress’ to injecting;
- individuals who share sexual partners frequently;
- close family contacts of a case or individual with chronic hepatitis B infection;
- babies whose mothers have had acute hepatitis B during pregnancy or are positive for hepatitis B surface antigen (regardless of e-antigen markers); hepatitis B vaccination is started immediately on delivery and hepatitis B immunoglobulin given at the same time (but preferably at a different site). Babies whose mothers are positive for hepatitis B surface antigen and for e-antigen antibody should receive the vaccine only (but babies weighing 1.5 kg or less should also receive the immunoglobulin regardless of the mother’s e-antigen antibody status);
- individuals with haemophilia, those receiving regular blood transfusions or blood products, and carers responsible for the administration of such products;
- patients with chronic renal failure including those on haemodialysis. Haemodialysis patients should be monitored for antibodies annually and re-immunised if necessary. Home carers (of dialysis patients) should be vaccinated;
- individuals with chronic liver disease;
- healthcare personnel (including trainees) who have direct contact with blood or blood-stained body fluids or with patients’ tissues;
- laboratory staff who handle material that may contain the virus;
- other occupational risk groups such as morticians and embalmers;
- staff and patients of day-care or residential accommodation for those with severe learning difficulties;
- staff and inmates of custodial institutions;
- those travelling to areas of high or intermediate prevalence who are at increased risk or who plan to remain there for lengthy periods;
- families adopting children from countries with a high or intermediate prevalence of hepatitis B;
- foster carers and their families.

Different immunisation schedules for hepatitis B vaccine are recommended for specific circumstances. Generally, three or four doses are required for primary immunisation; an ‘accelerated schedule’ is recommended for pre-exposure...
prophylaxis in high-risk groups where rapid protection is required, and for post-exposure prophylaxis.

Immunisation may take up to 6 months to confer adequate protection; the duration of immunity is not known precisely, but a single booster 5 years after the primary course may be sufficient to maintain immunity for those who continue to be at risk.

Immunisation does not eliminate the need for commonsense precautions for avoiding the risk of infection from known carriers by the routes of infection which have been clearly established, consult Guidance for Clinical Health Care Workers: Protection against Infection with Blood-borne Viruses (available at www.dh.gov.uk). Accidental inoculation of hepatitis B virus-infected blood into a wound, incision, needle-prick, or abrasion may lead to infection, whereas it is unlikely that indirect exposure to a carrier will do so.

Following significant exposure to hepatitis B, an accelerated schedule, with the second dose given 1 month, and the third dose 2 months after the first dose, is recommended. For those at continued risk, a fourth dose should be given 12 months after the first dose. More detailed guidance is given in the handbook Immunisation against Infectious Disease. Specific hepatitis B immunoglobulin (HBIG) is available. Where appropriate, immunisation with human papillomavirus vaccine should be offered to females coming into the UK as they may not have been offered protection in their country of origin. The duration of protection has not been established, but current studies suggest that protection is maintained for at least 6 years after completion of the primary course. As the vaccines do not protect against all strains of human papillomavirus, routine cervical screening should continue.

**Influenza vaccine**

While most viruses are antigenically stable, the influenza viruses A and B (especially A) are constantly altering their antigenic structure as indicated by changes in the haemagglutinins (H) and neuraminidases (N) on the surface of the viruses. It is essential that influenza vaccine p. 1212 in use contain the H and N components of the prevalent strain or strains as recommended each year by the World Health Organization.

Immunisation is recommended for persons at high risk, and to reduce transmission of infection. Annual immunisation is strongly recommended for individuals aged over 6 months with the following conditions:

- chronic respiratory disease (includes asthma treated with continuous or repeated use of inhaled or systemic corticosteroids or asthma with previous exacerbations requiring hospital admission);
- chronic heart disease;
- chronic liver disease;
- chronic renal disease at stage 3, 4 or 5;
- chronic neurological disease;
- complement disorders;
- diabetes mellitus;
- immunosuppression because of disease (including asplenia or splenic dysfunction) or treatment (including prolonged systemic corticosteroid treatment [for over 1 month at dose equivalents of prednisolone: adult and child over 20 kg, 20 mg or more daily; child under 20 kg, 1 mg/kg or more daily] and chemotherapy);
- HIV infection (regardless of immune status);
- morbid obesity (BMI of 40 kg/m² and above).

Seasonal influenza vaccine (inactivated) is also recommended for all pregnant women, for all persons aged over 65 years, for residents of nursing or residential homes for the elderly and other long-stay facilities, and for carers of persons whose welfare may be at risk if the carer falls ill. Influenza immunisation should also be considered for household contacts of immunocompromised individuals.

As part of winter planning, NHS employers should offer vaccination to health and social care workers who are directly involved in patient care.

Unless contra-indicated, the live influenza vaccine, administered as a nasal spray (Fluenz Tetra®), is preferred in children aged 2–17 years because it provides a higher level of protection than the inactivated vaccine. In the 2017/2018 national influenza immunisation programme, seasonal influenza vaccine will also be offered to all children aged 2–8 years on 31 August 2017 (including those in school years 1, 2, 3 and 4) and to all primary school-aged children in former primary school pilot areas.

Information on pandemic influenza, avian influenza and swine influenza may be found at www.gov.uk/pandemic-flu and at www.gov.uk/phe.

**Japanese encephalitis vaccine**

Japanese encephalitis vaccine p. 1213 is indicated for travellers to areas in Asia and the Far East where infection is endemic and for laboratory staff at risk of exposure to the virus. The primary immunisation course of 2 doses should be completed at least one week before potential exposure to Japanese encephalitis virus.

---

**Human papillomavirus vaccine**

Human papillomavirus vaccine is available as a bivalent vaccine (Cervarix®) or a quadrivalent vaccine (Gardasil®). Since 2012, only Gardasil® is offered as part of the national immunisation programme. Cervarix® is licensed for use in females for the prevention of cervical cancer and other pre-cancerous lesions caused by human papillomavirus types 16 and 18. Gardasil® is licensed for use in females for the prevention of cervical and anal cancers, genital warts and pre-cancerous genital (cervical, vulvar, and vaginal) and anal lesions caused by human papillomavirus types 6, 11, 16, and 18. The vaccines may also provide limited protection against disease caused by other types of human papillomavirus. The two vaccines are not interchangeable and one vaccine product should be used for an entire course.

Human papillomavirus vaccine will be most effective if given before sexual activity starts. From September 2014, a 2-dose schedule is recommended, as long as the first dose is received before the age of 15 years. The first dose is given to females aged 11 to 14 years, and the second dose is given 6–24 months after the first dose (for the purpose of planning the national immunisation programme, it is appropriate to give the second dose 12 months after the first—see Immunisation schedule). If the course is interrupted, it should be resumed (using the same vaccine) but not repeated, even if more than 24 months have elapsed since the first dose or if the girl is then aged 15 years or more.

Females receiving their first dose aged 15 years or older require a 3-dose schedule (see Cervarix® and Gardasil®), with the second and third doses given 1 and 4–6 months after the first dose; all 3 doses should be given within a 12-month period. If the course is interrupted, it should be resumed (using the same vaccine) but not repeated, allowing the appropriate interval between the remaining doses.

If a 3-dose course of vaccination had been started before September 2014 in a female aged under 15 years, then where possible this should be completed; the interrupted course should be resumed (using the same vaccine) but not repeated, allowing the appropriate interval between the remaining doses.

Under the national programme in England, females remain eligible to receive the human papillomavirus vaccine up to the age of 18 years if they did not receive the vaccine when scheduled. Where appropriate, immunisation with human papillomavirus vaccine should be offered to females coming into the UK as they may not have been offered protection in their country of origin. The duration of protection has not been established, but current studies suggest that protection is maintained for at least 6 years after completion of the primary course. As the vaccines do not protect against all strains of human papillomavirus, routine cervical screening should continue.
Up-to-date information on the risk of Japanese encephalitis in specific countries can be obtained from the National Travel Health Network and Centre (www.nathnac.org).

**Measles, Mumps and Rubella vaccine**

**Measles vaccine** has been replaced by a combined live measles, mumps and rubella vaccine, live p. 1213 (MMR vaccine).

Measles, mumps and rubella vaccine, live aims to eliminate measles, mumps, and rubella (German measles) and congential rubella syndrome. Every child should receive two doses of measles, mumps and rubella vaccine, live by entry to primary school, unless there is a valid contra-indication. Measles, mumps and rubella vaccine, live should be given irrespective of previous measles, mumps, or rubella infection or vaccination.

The first dose of measles, mumps and rubella vaccine, live is given to children aged 12–13 months. A second dose is given before starting school at 3 years and 4 months–5 years of age (see Immunisation Schedule).

Children presenting for pre-school booster who have not received the first dose of measles, mumps and rubella vaccine, live should be given a dose of measles, mumps and rubella vaccine, live followed 3 months later by a second dose.

At school-leaving age or at entry into further education, measles, mumps and rubella vaccine, live immunisation should be offered to individuals of both sexes who have not received 2 doses during childhood. In those who have received only a single dose of measles, mumps and rubella vaccine, live in childhood, a second dose is recommended to achieve full protection. If 2 doses of measles, mumps and rubella vaccine, live are required, the second dose should be given one month after the initial dose. The decision on whether to vaccinate adults should take into consideration their vaccination history, the likelihood of the individual remaining susceptible, and the future risk of exposure and disease.

Measles, mumps and rubella vaccine, live p. 1213 should be used to protect against rubella in seronegative women of child-bearing age (see Immunisation Schedule); unimmunised healthcare workers who might put pregnant women and other vulnerable groups at risk of rubella or measles should be vaccinated. Measles, mumps and rubella vaccine, live may also be offered to previously unimmunised and seronegative post-partum women (see measles, mumps and rubella vaccine, live)–vaccination a few days after delivery is important because about 60% of congenital abnormalities from rubella infection occur in babies of women who have borne more than one child. Immigrants arriving after the age of school immunisation are particularly likely to require immunisation.

**Contacts**

Measles, mumps and rubella vaccine, live may also be used in the control of outbreaks of measles and should be offered to susceptible children aged over 6 months who are contacts of a case, within 3 days of exposure to infection. Children immunised before 12 months of age should still receive two doses of measles, mumps and rubella vaccine, live at the recommended ages. If one dose of measles, mumps and rubella vaccine, live has already been given to a child, then the second dose may be brought forward to at least one month after the first, to ensure complete protection. If the child is under 18 months of age and the second dose is given within 3 months of the first, then the routine dose before starting school at 3 years and 4 months–5 years should still be given. Children aged under 9 months for whom avoidance of measles infection is particularly important (such as those with history of recent severe illness) can be given normal immunoglobulin after exposure to measles; routine measles, mumps and rubella vaccine, live immunisation should then be given after at least 3 months at the appropriate age.

Measles, mumps and rubella vaccine, live is **not suitable** for prophylaxis following exposure to mumps or rubella since the antibody response to the mumps and rubella components is too slow for effective prophylaxis.

Children and adults with impaired immune response should not receive live vaccines (see advice on HIV). If they have been exposed to measles infection they should be given normal immunoglobulin.

**Travel**

Unimmunised travellers, including children over 6 months, to areas where measles is endemic or epidemic should receive measles, mumps and rubella vaccine, live. Children immunised before 12 months of age should still receive two doses of measles, mumps and rubella vaccine, live at the recommended ages. If one dose of measles, mumps and rubella vaccine, live has already been given to a child, then the second dose should be brought forward to at least one month after the first, to ensure complete protection. If the child is under 18 months of age and the second dose is given within 3 months of the first, then the routine dose before starting school at 3 years and 4 months–5 years should still be given.

**Meningococcal vaccines**

Almost all childhood meningococcal disease in the UK is caused by *Neisseria meningitidis* serogroups B and C.

**Meningococcal group C conjugate vaccine** protects only against infection by serogroup C and **Meningococcal group B vaccine** protects only against infection by serogroup B. The risk of meningococcal disease declines with age, immunisation is not generally recommended after the age of 25 years.

Tetravalent meningococcal vaccines that cover serogroups A, C, W135, and Y are available. Although the duration of protection has not been established, the **meningococcal groups A, C, W135, and Y conjugate vaccine** is likely to provide longer-lasting protection than the unconjugated meningococcal polysaccharide vaccine. The antibody response to serogroup C in unconjugated meningococcal polysaccharide vaccines in young children may be suboptimal [not currently available in the UK].

A **meningococcal group B vaccine**, Bexsero®, is licensed in the UK against infection caused by *Neisseria meningitidis* serogroup B and is recommended in the Immunisation Schedule. Bexsero® contains 3 recombinant *Neisseria meningitidis* serogroup B proteins and the outer membrane vesicles from the NZ 98/254 strain, in order to achieve broad protection against *Neisseria meningitidis* serogroup B; the proteins are adsorbed onto an aluminium compound to stimulate an enhanced immune response.

**Childhood immunisation**

**Meningococcal group C conjugate vaccine** provides long-term protection against infection by serogroup C of *Neisseria meningitidis*. Immunisation consists of 1 dose given at 12 months of age (as the haemophilus influenzae type B with meningococcal group C vaccine p. 1205) and a second dose given at 13−15 years of age (as the meningococcal groups A with C and W135 and Y vaccine p. 1206) (see Immunisation Schedule).

**Meningococcal group B vaccine** provides protection against infection by serogroup B of *Neisseria meningitidis*. Immunisation consists of 1 dose given at 2 months of age, a second dose at 4 months of age, and a booster dose at 12 months of age (see Immunisation Schedule above).

Unimmunised children aged under 12 months should be given 1 dose of meningococcal group B vaccine (rDNA, component, adsorbed) p. 1206 followed by a second dose of meningococcal group B vaccine (rDNA, component, adsorbed) two months later. They should then be vaccinated according to the Immunisation Schedule (ensuring at least a two month interval between doses of meningococcal group B vaccines). Unimmunised children aged 12–23 months should
be given 2 doses of meningococcal group B vaccine (rDNA, component, adsorbed) separated by an interval of two months if they have received less than 2 doses in the first year of life. Unimmunised children aged 2–9 years should be given a single dose of meningococcal group C vaccine (as the haemophilus influenzae type B with meningococcal group C vaccine) followed by a booster dose of meningococcal groups A with C and W135 and Y vaccine at 13–15 years of age.

From 2015, unimmunised individuals aged 10–25 years, including those aged under 25 years who are attending university for the first time, should be given a single dose of meningococcal groups A with C and W135 and Y vaccine; a booster dose is not required.

Patients under 25 years of age with confirmed serogroup C disease, who have previously been immunised with meningococcal group C vaccine, should be offered meningococcal group C conjugate vaccine before discharge from hospital.

Travel
Individuals travelling to countries of risk should be immunised with meningococcal groups A, C, W135, and Y conjugate vaccine, even if they have previously received meningococcal group C conjugate vaccine. If an individual has recently received meningococcal group C conjugate vaccine, an interval of at least 4 weeks should be allowed before administration of the tetravalent (meningococcal groups A, C, W135, and Y) vaccine.

Vaccination is particularly important for those living or working with local people or visiting an area of risk during outbreaks.

Immunisation recommendations and requirements for visa entry for individual countries should be checked before travelling, particularly to countries in Sub-Saharan Africa, Asia, and the Indian sub-continent where epidemics of meningococcal outbreaks and infection are reported. Country-by-country information is available from the National Travel Health Network and Centre (www.nathnac.org).

Proof of vaccination with the tetravalent meningococcal groups A with C and W135 and Y vaccine is required for those travelling to Saudi Arabia during the Hajj and Umrah pilgrimages (where outbreaks of the W135 strain have occurred).

Contacts
For advice on the immunisation of laboratory workers and close contacts of cases of meningococcal disease in the UK and on the role of the vaccine in the control of local outbreaks, consult Guidance for Public Health Management of Meningococcal Disease in the UK at www.gov.uk/phe. Also see for antibacterial prophylaxis for prevention of secondary cases of meningococcal meningitis.

The need for immunisation of laboratory staff who work directly with Neisseria meningitidis should be considered.

Pertussis vaccine
Pertussis vaccine is given as a combination preparation containing other vaccines. Acellular vaccines are derived from highly purified components of Bordetella pertussis. Primary immunisation against pertussis (whooping cough) requires 3 doses of an acellular pertussis-containing vaccine (see Immunisation schedule), given at intervals of 1 month from the age of 2 months.

All children up to the age of 10 years should receive primary immunisation with diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) and haemophilus type b conjugate vaccine (adsorbed).

A booster dose of an acellular pertussis-containing vaccine should ideally be given 3 years after the primary course, although, the interval can be reduced to 1 year if the primary course was delayed. Children aged 1–10 years who have not received a pertussis-containing vaccine as part of their primary immunisation should be offered 1 dose of a suitable pertussis-containing vaccine; after an interval of at least 1 year, a booster dose of a suitable pertussis-containing vaccine should be given. Immunisation against pertussis is not routinely recommended in individuals over 10 years of age.

Vaccination of pregnant women against pertussis
In response to the pertussis outbreak, the UK health departments introduced a temporary programme (October 2012) to vaccinate pregnant women against pertussis, and this programme will continue until further notice. The aim of the programme is to boost the levels of pertussis–specific antibodies that are transferred through the placenta, from the mother to the fetus, so that the newborn is protected before routine immunisation begins at 2 months of age.

Pregnant women should be offered a single dose of acellular pertussis-containing vaccine (as adsorbed diphtheria [low dose], tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine; Boostrix-IPV®) between 16 and 32 weeks of pregnancy.

Public Health England has advised (2016) that the vaccine is probably best offered after the foetal anomaly scan at around 18–20 weeks. Pregnant women should be offered a single dose of acellular pertussis–containing vaccine up to the onset of labour if they missed the opportunity for vaccination at 16–32 weeks of pregnancy. A single dose of acellular pertussis–containing vaccine may also be offered to new mothers, who have never previously been vaccinated against pertussis, until the child receives the first vaccination.

While this programme is in place, women who become pregnant again should be offered vaccination during each pregnancy to maximise transplacental transfer of antibody.

Contacts
Vaccination against pertussis should be considered for close contacts of cases with pertussis who have been offered antibacterial prophylaxis. Unimmunised or partially immunised contacts under 10 years of age should complete their vaccination against pertussis. A booster dose of an acellular pertussis–containing vaccine is recommended for contacts aged over 10 years who have not received a pertussis–containing vaccine in the last 5 years and who have not received adsorbed diphtheria [low dose], tetanus, and poliomyelitis (inactivated) vaccine in the last month.

Side-effects
Local reactions do not contra-indicate further doses.

The vaccine should not be withheld from children with a history to a preceding dose of:

- fever, irrespective of severity;
- persistent crying or screaming for more than 3 hours;
- severe local reaction, irrespective of extent.

Pneumococcal vaccine
Pneumococcal polysaccharide conjugate vaccine (adsorbed) p. 1207 protects against infection with Streptococcus pneumoniae (pneumococcus); the vaccines contain polysaccharide from capsular pneumococci. Pneumococcal polysaccharide vaccine contains purified polysaccharide from 23 capsular types of pneumococci, whereas pneumococcal polysaccharide conjugate vaccine (adsorbed) is recommended for individuals at increased risk of pneumococcal infection as follows:

- age over 65 years;
Children under 2 years at increased risk of pneumococcal infection (see list) should receive the 13-valent pneumococcal polysaccharide conjugate vaccine (adsorbed) at the recommended ages, followed by a single dose of the 23-valent pneumococcal polysaccharide vaccine after their second birthday. Children at increased risk of pneumococcal infection presenting late for vaccination should receive 2 doses (separated by at least 1 month) of the 13-valent pneumococcal polysaccharide conjugate vaccine (adsorbed) before the age of 12 months, and a third dose at 12–13 months. Children over 12 months and under 5 years (who have not been vaccinated or who have completed the primary course) should receive a single dose of the 13-valent pneumococcal polysaccharide conjugate vaccine (adsorbed) (2 doses separated by an interval of 2 months in the immunocompromised or those with asplenia or splenic dysfunction). All children under 5 years at increased risk of pneumococcal infection should receive a single dose of the 23-valent pneumococcal polysaccharide vaccine after their second birthday and at least 2 months after the final dose of the 13-valent pneumococcal polysaccharide conjugate vaccine (adsorbed).

Children over 5 years and adults who are at increased risk of pneumococcal disease should receive a single dose of the 23-valent unconjugated pneumococcal polysaccharide vaccine.

Revaccination
In individuals with higher concentrations of antibodies to pneumococcal polysaccharides, revaccination with the 23-valent pneumococcal polysaccharide vaccine more commonly produces adverse reactions. Revaccination is therefore not recommended, except every 5 years in individuals in whom the antibody concentration is likely to decline rapidly (e.g. asplenia, splenic dysfunction and nephrotic syndrome). If there is doubt, the need for revaccination should be discussed with a haematologist, immunologist, or microbiologist.

Poliomyelitis vaccine
Two types of poliomyelitis vaccines (containing strains of poliovirus types 1, 2, and 3) are available, inactivated poliomyelitis vaccine (for injection) and live (oral) poliomyelitis vaccine. Inactivated poliomyelitis vaccines, only available in combined preparation, is recommended for routine immunisation.

A course of primary immunisation consists of 3 doses of a combined preparation containing inactivated poliomyelitis vaccines, starting at 2 months of age with intervals of 1 month between doses (see Immunisation schedule). A course of 3 doses should also be given to all unimmunised adults; no adult should remain unimmunised against poliomyelitis.

Two booster doses of a preparation containing inactivated poliomyelitis vaccines are recommended, the first before school entry and the second before leaving school (see Immunisation schedule). Further booster doses are only necessary for adults at special risk, such as travellers to endemic areas, or laboratory staff likely to be exposed to the viruses, or healthcare workers in possible contact with cases; booster doses should be given to such individuals every 10 years.

Live (oral) poliomyelitis vaccine is no longer available for routine use; its use may be considered during large outbreaks, but advice should be sought from Public Health England. The live (oral) vaccine poses a very rare risk of vaccine-associated paralytic polio because the attenuated strain of the virus can revert to a virulent form. For this reason the live (oral) vaccine must not be used for immunosuppressed individuals or their household contacts. The use of inactivated poliomyelitis vaccines removes the risk of vaccine-associated paralytic polio altogether.

Travel
Unimmunised travellers to areas with a high incidence of poliomyelitis should receive a full 3-dose course of a preparation containing inactivated poliomyelitis vaccines. Those who have not been vaccinated in the last 10 years should receive a booster dose of absorbed diphtheria [low dose], tetanus and poliomyelitis (inactivated) vaccine. Information about countries with a high incidence of poliomyelitis can be obtained from www.travax.nhs.uk or from the National Travel Health Network and Centre (www.nathnac.org).

Rabies vaccine
Rabies vaccine p. 1214 contains inactivated rabies virus cultivated in either human diploid cells or purified chick embryo cells; vaccines are used for pre- and post-exposure prophylaxis.

Pre-exposure prophylaxis
Immunisation should be offered to those at high risk of exposure to rabies—laboratory staff who handle the rabies virus, those working in quarantine stations, animal handlers, veterinary surgeons and field workers who are likely to be bitten by infected wild animals, certain port officials, and bat handlers. Transmission of rabies by humans has not been recorded but it is advised that those caring for patients with the disease should be vaccinated.

Immunisation against rabies is also recommended where there is limited access to prompt medical care for those living in areas where rabies is enzootic, for those travelling to such areas for longer than 1 month, and for those on shorter visits who may be exposed to unusual risk.
Immunisation against rabies is indicated during pregnancy if there is substantial risk of exposure to rabies and rapid access to post-exposure prophylaxis is likely to be limited.

Up-to-date country-by-country information on the incidence of rabies can be obtained from the National Travel Health Network and Centre (www.nathnacl.org) and, in Scotland, from Health Protection Scotland (www.hps.scot.nhs.uk).

Immunisation against rabies requires 3 doses of rabies vaccine, with further booster doses for those who remain at frequent risk. To ensure continued protection in persons at high risk (e.g. laboratory workers), the concentration of antirabies antibodies in plasma is used to determine the intervals between doses.

**Post-exposure management**

Following potential exposure to rabies, the wound or site of exposure (e.g. mucous membrane) should be cleansed under running water and washed for several minutes with soapy water as soon as possible after exposure. Disinfectant and a simple dressing can be applied, but suturing should be delayed because it may increase the risk of introducing rabies virus into the nerves.

Post-exposure prophylaxis against rabies depends on the level of risk in the country, the nature of exposure, and the individual’s immunity. In each case, expert risk assessment and advice on appropriate management should be obtained from the local Public Health England Centre or Public Health England’s Virus Reference Department, Colindale (tel. (020) 8200 4400) or the PHE Colindale Duty Doctor (tel. (020) 8200 6868), in Wales from the Public Health Wales local Health Protection Team or Public Health Wales Virus Reference Laboratory (tel. (029) 2074 7747), in Scotland from the local on-call infectious diseases consultant, and in Northern Ireland from the Public Health Agency Duty Room (tel (028) 9055 3997/(028) 9063 2662) or the Regional Virology Service (tel. (028) 9024 0503).

There are no specific contra-indications to the use of rabies vaccine for post-exposure prophylaxis and its use should be considered whenever a patient has been attacked by an animal in a country where rabies is enzootic, even if there is no direct evidence of rabies in the attacking animal. Because of the potential consequences of untreated rabies exposure and because rabies vaccination has not been associated with fetal abnormalities, pregnancy is not considered a contra-indication to post-exposure prophylaxis.

For post-exposure prophylaxis of **fully immunised** individuals (who have previously received pre-exposure or post-exposure prophylaxis with cell-derived rabies vaccine), 2 doses of cell-derived vaccine are likely to be sufficient; the first dose is given on day 0 and the second dose is given between day 3–7. Rabies immunoglobulin p. 1188 is not necessary in such cases.

Post-exposure treatment for **unimmunised individuals** (or those whose prophylaxis is possibly incomplete) comprises 5 doses of rabies vaccine given over 1 month (on days 0, 3, 7, 14, and the fifth dose is given between day 28–30); also, depending on the level of risk (determined by factors such as the nature of the bite and the country where it was sustained), rabies immunoglobulin p. 1188 is given to unimmunised individuals on day 0 or within 7 days of starting the course of rabies vaccine p. 1214. The immunisation course can be discontinued if it is proved that the individual was not at risk.

**Rotavirus vaccine**

Rotavirus vaccine p. 1215 is a live, oral vaccine that protects young children against gastro-enteritis caused by rotavirus infection. The recommended schedule consists of 2 doses, the first at 2 months of age, and the second at 3 months of age (see Immunisation schedule). The first dose of rotavirus vaccine must be given between 6–15 weeks of age and the second dose should be given after an interval of at least 4 weeks; the vaccine should not be started in children 15 weeks of age or older. Ideally, the full course should be completed before 16 weeks of age to provide protection before the main burden of disease, and to avoid a temporal association between vaccination and intussusception; the course must be completed before 24 weeks of age.

The rotavirus vaccine virus is excreted in the stool and may be transmitted to close contacts; however, vaccination of those with <span class="highlight">immunosuppressed</span> close contacts may protect the contacts from wild-type rotavirus disease and outweigh any risk from transmission of vaccine virus. Carers of a recently vaccinated baby should be advised of the need to wash their hands after changing the baby’s nappies.

**Smallpox vaccine**

Limited supplies of smallpox vaccine are held at the Specialist and Reference Microbiology Division, Public Health England Colindale (Tel. (020) 8200 4400) for the exclusive use of workers in laboratories where pox viruses (such as vaccinia) are handled.

If a wider use of the vaccine is being considered, Guidelines for smallpox response and management in the post-eradication era should be consulted at www.gov.uk/phe.

**Tetanus vaccine**

Tetanus vaccine contains a cell-free purified toxin of Clostridium tetani adsorbed on aluminium hydroxide or aluminium phosphate to improve antigenicity.

Primary immunisation for children under 10 years consists of 3 doses of a combined preparation containing adsorbed tetanus vaccine, with an interval of 1 month between doses. Following routine childhood vaccination, 2 booster doses of a preparation containing adsorbed tetanus vaccine are recommended, the first before school entry and the second before leaving school (see Immunisation schedule). The recommended schedule of tetanus vaccination not only gives protection against tetanus in childhood but also gives the basic immunity for subsequent booster doses. In most circumstances, a total of 5 doses of tetanus vaccine is considered sufficient for long term protection.

For primary immunisation of adults and children over 10 years previously unimmunised against tetanus, 3 doses of adsorbed diphtheria [low dose], tetanus and poliomyelitis (inactivated) vaccine are given with an interval of 1 month between doses (see Diphtheria-containing Vaccines).

When an individual presents for a booster dose but has been vaccinated following a tetanus-prone wound, the vaccine preparation administered at the time of injury should be determined. If this is not possible, the booster should still be given to ensure adequate protection against all antigens in the booster vaccine.

Very rarely, tetanus has developed after abdominal surgery; patients awaiting elective surgery should be asked about tetanus immunisation and immunised if necessary. Parenteral drug abuse is also associated with tetanus; those abusing drugs by injection should be vaccinated if unimmunised—booster doses should be given if there is any doubt about their immunisation status.

All laboratory staff should be offered a primary course if unimmunised.

**Wounds**

Wounds are considered to be tetanus-prone if they are sustained more than 6 hours before surgical treatment or at any interval after injury and are puncture-type (particularly if contaminated with soil or manure) or show much devitalised tissue or are septic or are compound fractures or contain foreign bodies. All wounds should receive thorough cleansing.

- For clean wounds: fully immunised individuals (those who have received a total of 5 doses of a tetanus-containing
Vaccines

Vaccines for travel

**Immunisation**

See advice on Malaria, treatment p. 580.

No special immunisation is required for travellers to the United States, Europe, Australia, or New Zealand, although all travellers should have immunity to tetanus and close contact with individuals at high risk of severe varicella infections. The Department of Health recommends these vaccines for seronegative healthcare workers who come into direct contact with patients. Those with a history of chickenpox or shingles can be considered immune, but healthcare workers with a negative or uncertain history should be tested.

Rarely, the varicella-zoster vaccine virus has been transmitted from the vaccinated individual to close contacts. Therefore, contact with the following should be avoided if a vaccine-related cutaneous rash develops within 4–6 weeks of the first or second dose:

- varicella-susceptible pregnant women;
- individuals at high risk of severe varicella, including those with immunodeficiency or those receiving immunosuppressive therapy;
- Healthcare workers who develop a generalised popular or vesicular rash on vaccination should avoid contact with patients until the lesions have crusted. Those who develop a localised rash after vaccination should cover the lesions and be allowed to continue working unless in contact with patients at high risk of severe varicella.

**National shingles immunisation programme**

The aim of the national shingles immunisation programme is to lower the incidence and severity of shingles in older people using the high potency, live varicella-zoster vaccine, Zostavax®. It is recommended that vaccination is routinely offered to people aged 70 years. A catch-up programme has also been rolled out (since 2013) in those aged 70–79 years, as this age group is likely to have the greatest benefit from vaccination.

In the 2016–2017 immunisation programme, varicella-zoster vaccine is recommended in adults who were 70 or 78 years of age on 1st September 2016. Patients who were eligible for vaccination in the first 3 years of the programme but have not been vaccinated against herpes zoster remain eligible until their 80th birthday; this includes patients who were aged 71–73 or 79 on 1st September 2016. Patients who have reached 80 years are no longer eligible for vaccination. A single dose of Zostavax® is likely to give protection for at least 7 years, but the need for, or timing of, a booster dose has not been established. Although Zostavax® is not recommended for the treatment of shingles or post-herpetic neuralgia, it can be given to those with a previous history of shingles; ideally the vaccine should be delayed until systemic antiviral therapy has been completed.

Varicella-zoster immunoglobulin p. 1189 is used to protect susceptible individuals at increased risk of varicella infection.

**Yellow fever vaccine**

Yellow fever vaccine, live p. 1217 is indicated for those travelling or living in areas where infection is endemic and for laboratory staff who handle the virus or who handle clinical material from suspected cases. Infants under 6 months of age should not be vaccinated because there is a small risk of encephalitis; infants aged 6–9 months should be vaccinated only if the risk of yellow fever is high and unavoidable (seek expert advice). The immunity which probably lasts for life is officially accepted for 10 years starting from 10 days after primary immunisation and for a further 10 years immediately after revaccination.

**Tick-borne encephalitis vaccine**

Tick-borne encephalitis vaccine, inactivated p. 1216 contains inactivated tick-borne encephalitis virus cultivated in chick embryo cells. It is recommended for immunisation of those working in, or visiting, high-risk areas (see International Travel). Those working, walking or camping in warm forested areas of Central and Eastern Europe, Scandinavia, Northern and Eastern China, and some parts of Japan, particularly from April to November when ticks are most prevalent, are at greatest risk of tick-borne encephalitis. For full protection, 3 doses of the vaccine are required; booster doses are required every 3–5 years for those still at risk. Ideally, immunisation should be completed at least one month before travel.

**Typhoid vaccine**

Typhoid vaccine p. 1208 is available as Vi capsular polysaccharide (from Salmonella typhi) vaccine for injection and as live attenuated Salmonella typhi for oral use.

Typhoid immunisation is advised for:

- travellers to areas where typhoid is endemic, especially if staying with or visiting local people;
- travellers to endemic areas where frequent or prolonged exposure to poor sanitation and poor food hygiene is likely;
- laboratory personnel who, in the course of their work, may be exposed to Salmonella typhi.

Typhoid vaccination is not a substitute for scrupulous personal hygiene.

Capsular polysaccharide typhoid vaccine is usually given by intramuscular injection. Children under 2 years may respond suboptimally to the vaccine, but children aged between 1–2 years should be immunised if the risk of typhoid fever is considered high (immunisation is not recommended for infants under 12 months). Revaccination is needed every 3 years on continued exposure.

Oral typhoid vaccine p. 1208 is a live attenuated vaccine contained in an enteric-coated capsule. One capsule taken on alternate days for a total of 3 doses, provides protection 7–10 days after the last dose. Protection may persist for up to 3 years in those constantly (or repeatedly) exposed to Salmonella typhi, but those who only occasionally travel to endemic areas require further courses at intervals of 1 year.

**Varicella-zoster vaccine**

The live varicella-zoster vaccine p. 1216, Varilrix® and Varivax®, are licensed for immunisation against varicella (chickenpox) in seronegative individuals. They are not recommended for routine use in children, but can be given to seronegative healthy children over 1 year who come into
poliomyelitis (and childhood immunisations should be up to date); Tick-borne encephalitis vaccine is recommended for immunisation of those working in, or visiting, high-risk areas. Certain special precautions are required in non-European areas surrounding the Mediterranean, in Africa, the Middle East, Asia, and South America.

Travellers to areas that have a high incidence of poliomyelitis or tuberculosis should be immunised with the appropriate vaccine; in the case of poliomyelitis, previously immunised travellers may be given a booster dose of a preparation containing inactivated poliomyelitis vaccine. BCG immunisation is recommended for travellers aged under 16 years proposing to stay for longer than 3 months (or in close contact with the local population) in countries with an incidence of tuberculosis greater than 40 per 100 000 (list of countries where the incidence of tuberculosis is greater than 40 cases per 100 000 is available from www.gov.uk/phc); it should preferably be given 3 months or more before departure.

Yellow fever immunisation is recommended for travel to the endemic zones of Africa and South America. Many countries require an International Certificate of Vaccination from individuals arriving from, or who have been travelling through, endemic areas; other countries require a certificate from all entering travellers (consult the Department of Health handbook, Health Information for Overseas Travel, www.dh.gov.uk).

Immunisation against meningococcal meningitis is recommended for a number of areas of the world. Protection against hepatitis A is recommended for travellers to high-risk areas outside Northern and Western Europe, North America, Japan, Australia and New Zealand. Hepatitis A vaccine is preferred and it is likely to be effective even if given shortly before departure; normal immunoglobulin is no longer given routinely but may be indicated in the immunocompromised. Special care must also be taken with food hygiene.

Hepatitis B vaccine is recommended for those travelling to areas of high or intermediate prevalence who intend to seek employment as healthcare workers or who plan to remain there for lengthy periods and who may therefore be at increased risk of acquiring infection as the result of medical or dental procedures carried out in those countries. Short-term tourists or business travellers are not generally at increased risk of infection but may put themselves at risk by their sexual behaviour when abroad.

Prophylactic immunisation against rabies is recommended for travellers to enzootic areas on long journeys or to areas out of reach of immediate medical attention.

Travellers who have not had a tetanus booster in the last 10 years and are visiting areas where medical attention may not be accessible should receive a booster dose of adsorbed diphtheria [low dose], tetanus and poliomyelitis (inactivated) vaccine, even if they have received 5 doses of a tetanus-containing vaccine previously.

Typhoid vaccine is indicated for travellers to countries where typhoid is endemic, but the vaccine is no substitute for personal precautions.

There is no requirement for cholera vaccination as a condition for entry into any country, but oral cholera vaccine should be considered for backpackers and those travelling to situations where the risk is greatest (e.g. refugee camps). Regardless of vaccination, travellers to areas where cholera is endemic should take special care with food hygiene.

Advice on diphtheria, on Japanese encephalitis, and on tick-borne encephalitis is included in Health Information for Overseas Travel.

Food hygiene
In areas where sanitation is poor, good food hygiene is important to help prevent hepatitis A, typhoid, cholera, and other diarrhoeal diseases (including travellers’ diarrhoea). Food should be freshly prepared and hot, and uncooked vegetables (including green salads) should be avoided; only fruits which can be peeled should be eaten. Only suitable bottled water, or tap water that has been boiled or treated with sterilising tablets, should be used for drinking.

Information on health advice for travellers
Health professionals and travellers can find the latest information on immunisation requirements and precautions for avoiding disease while travelling from: www.nathnac.org. The handbook, Health Information for Overseas Travel (2010), which draws together essential information for healthcare professionals regarding health advice for travellers, can also be obtained from this website.

Immunisation requirements change from time to time, and information on the current requirements for any particular country may be obtained from the embassy or legation of the appropriate country or from:

National Travel Health Network and Centre
UCLH NHS Foundation Trust
3rd Floor Central
250 Euston Road
London
NW1 2PG
Tel: 0845 602 6712
(8:30–11:45 a.m., 1–3:15 p.m. weekdays for healthcare professionals only)
www.nathnac.org

Travel Medicine Team
Health Protection Scotland
Meridian Court
5 Cadogan Street
Glasgow
G2 6QE
Tel: (0141) 301 1130
(2–4 p.m. Monday to Wednesday, 9:30–11:30 a.m. Friday; for registered TRAVAX users only)
www.travax.nhs.uk
(TRAVAX is free for NHS Scotland users (registration required); subscription fee may be payable for users outside NHS Scotland)

Welsh Assembly Government
Tel (029) 2082 5397
(9 a.m.–5:30 p.m. weekdays)

Department of Health, Social Services and Public Safety
Castle Buildings
Stormont
Belfast
BT4 3SQ
Tel: (028) 9052 2118
(9 a.m.–5 p.m. weekdays)
www.dhsspsni.gov.uk

VACCINES

Vaccines

Vaccines

IMPORTANT SAFETY INFORMATION

MHRA/CHM ADVICE (APRIL 2016)

Following reports of death in neonates who received a live attenuated vaccine after exposure to a tumor necrosis factor alpha (TNF-a) inhibitor in utero, the MHRA has issued the following advice:


**CONTRA-INDICATIONS**

- Impaired immune response 
  Severely immunosuppressed patients should not be given live vaccines (including those with severe primary immunodeficiency).

- **CAUTIONS** Acute illness - minor illnesses

### CAUTIONS, FURTHER INFORMATION

Vaccination may be postponed if the individual is suffering from an acute illness; however, it is not necessary to postpone immunisation in patients with minor illnesses without fever or systemic upset.

- Impaired immune response and drugs affecting immune response 
  Immune response to vaccines may be reduced in immunosuppressed patients and there is also a risk of generalised infection with live vaccines.

  Specialist advice should be sought for those being treated with high doses of corticosteroids (dose equivalents of prednisolone: **adults**, at least 40 mg daily for more than 1 week; **children**, 2 mg/kg (or more than 40 mg) daily for at least 1 week or 1 mg/kg daily for 1 month), or other immunosuppressive drugs, and those being treated for malignant conditions with chemotherapy or generalised radiotherapy. Live vaccines should be postponed until at least 3 months after stopping high-dose systemic corticosteroids and at least 6 months after stopping other immunosuppressive drugs or generalised radiotherapy (at least 12 months after discontinuing immunosuppressants following bone-marrow transplantation).

  The Royal College of Paediatrics and Child Health has produced a statement, *Immunisation of the Immunocompromised Child (2002)* (available at [www.rchp.ac.uk](http://www.rchp.ac.uk)).

- Predisposition to neurological problems
  When there is a personal or family history of febrile convulsions, there is an increased risk of these occurring during fever from any cause including immunisation, but this is not a contra-indication to immunisation. In children who have had a seizure associated with fever without neurological deterioration, immunisation is **recommended**; advice on the management of fever (see Post-immunisation Pyrexia in Infants) should be given before immunisation. When a child has had a convulsion not associated with fever, and the neurological condition is not deteriorating, immunisation is **recommended**.

  Children with stable neurological disorders (e.g. spina bifida, congenital brain abnormality, and peri-natal hypoxic-ischaemic encephalopathy) should be immunised according to the recommended schedule.

  When there is a **still evolving neurological problem**, including poorly controlled epilepsy, immunisation should be deferred and the child referred to a specialist. Immunisation is **recommended** if a cause for the neurological disorder is identified. If a cause is not identified, immunisation should be deferred until the condition is stable.

### SIDE-EFFECTS

#### GENERAL SIDE-EFFECTS

- **Common or very common** Fatigue - fever - gastro-intestinal disturbances - headache - irritability - loss of appetite - lymphangitis - malaise - myalgia

- **Very rare** Anaphylaxis (can be fatal) - angioedema (can be fatal) - bronchospasm (can be fatal) - hypersensitivity reactions (can be fatal) - urticaria (can be fatal)

- **Frequency not known** Arthralgia - asthenia - dizziness - drowsiness - influenza-like symptoms - lymphadenopathy - paraesthesia - rash

#### SPECIFIC SIDE-EFFECTS

- **Common or very common**
  - With intradermal use or intramuscular use or subcutaneous use
    - Induration may develop at the injection site - inflammation - local reactions - pain - redness - sterile abscess may develop at the injection site

### SIDE-EFFECTS, FURTHER INFORMATION

Occasionally serious adverse reactions can occur—these should always be reported to the CHM.

- Post-immunisation pyrexia in infants
  - The parent should be advised that if pyrexia develops after childhood immunisation, and the infant seems distressed, paracetamol can be given. Ibuprofen can be used if paracetamol is unsuitable. The parent should be warned to seek medical advice if the pyrexia persists.

#### ALLERGY AND CROSS-SENSITIVITY

Contra-indicated in patients with a confirmed anaphylactic reaction to a preceding dose of a vaccine containing the same antigens or vaccine component (such as antibiotics in viral vaccines).

### PREGNANCY

- Live vaccines should not be administered routinely to pregnant women because of the theoretical risk of fetal infection but where there is a significant risk of exposure to disease, the need for vaccination usually outweighs any possible risk to the fetus. Termination of pregnancy following inadvertent immunisation is not recommended. There is no evidence of risk from vaccinating pregnant women with inactivated viral or bacterial vaccines or toxoids.

### BREAST FEEDING

- Although there is a theoretical risk of live vaccine being present in breast milk, vaccination is not contra-indicated for women who are breast-feeding when there is significant risk of exposure to disease. There is no evidence of risk from vaccinating women who are breast-feeding, with inactivated viral or bacterial vaccines or toxoids.

### DIRECTIONS FOR ADMINISTRATION

- If alcohol or disinfectant is used for cleansing the skin it should be allowed to evaporate before vaccination to prevent possible inactivation of live vaccines.

  When 2 or more live vaccines are required (and are not available as a combined preparation), they can be administered at any time before or after each other at different sites, preferably in a different limb; if more than one injection is to be given in the same limb, they should be administered at least 2.5 cm apart. See also Bacillus Calmette-Guérin vaccine p. 1204.

  Vaccines should not be given intravenously. Most vaccines are given by the intramuscular route, although some are given by either the intradermal, deep subcutaneous, or oral route. The intramuscular route should not be used in patients with bleeding disorders such as haemophilia or thrombocytopenia, vaccines usually given by the intramuscular route should be given by deep subcutaneous injection instead.

  The Department of Health has advised against the use of jet guns for vaccination owing to the risk of transmitting blood borne infections, such as HIV.

  Particular attention must be paid to instructions on the use of diluents. Vaccines which are liquid suspensions or...
are reconstituted before use should be adequately mixed to ensure uniformity of the material to be injected.

**HANDLING AND STORAGE** Care must be taken to store all vaccines under the conditions recommended in the product literature, otherwise the preparation may become ineffective. Refrigerated storage is usually necessary; many vaccines need to be stored at 2–8°C and not allowed to freeze. Vaccines should be protected from light. Reconstituted vaccines and opened multidose vials must be used within the period recommended in the product literature. Unused vaccines should be disposed of by incineration at a registered disposal contractor.

**VACCINES › BACTERIAL AND VIRAL VACCINES, COMBINED**

### Diphtheria with haemophilus influenzae type b vaccine, pertussis, poliomyelitis and tetanus

**INDICATIONS AND DOSE**

**Primary immunisation**
- **BY INTRAMUSCULAR INJECTION**
  - Child 2 months–10 years: 0.5 mL every month for 3 doses

**UNLICENSED USE** Infanrix-IPV + Hib® not licensed for use in children over 36 months; Pediacel® not licensed in children over 4 years. However, the Department of Health recommends that these be used for children up to 10 years.

**SIDE-EFFECTS** Atopic dermatitis • hypotonia • restlessness • sleep disturbances • unusual crying in infants

**SIDE-EFFECTS, FURTHER INFORMATION**
- Side effects of vaccines containing pertussis. The incidence of local and systemic effects is generally lower with vaccines containing acellular pertussis components than with the whole-cell pertussis vaccine used previously. However, compared with primary vaccination, booster doses with vaccines containing acellular pertussis are reported to increase the risk of injection-site reactions (some of which affect the entire limb); local reactions do not contra-indicate further doses.

The vaccine should not be withheld from children with a history to a preceding dose of:
- fever, irrespective of severity;
- persistent crying or screaming for more than 3 hours;
- severe local reaction, irrespective of extent.

**PREGNANCY** Contra-indicated in pregnant women with a history of encephalopathy of unknown origin within 7 days of previous immunisation with a pertussis-containing vaccine. Contra-indicated in pregnant women with a history of transient thrombocytopenia or neurological complications following previous immunisation against diphtheria or tetanus.

**PRESCRIBING AND DISPENSING INFORMATION** Available as part of childhood schedule from health organisations or ImmForm. Available for vaccination of pregnant women from ImmForm.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

#### Suspension for injection

**EXCIPIENTS:** May contain Neomycin, polymyxin b, streptomycin
- Boostrix-IPV (GlaxoSmithKline UK Ltd)
  - Boostrix-IPV suspension for injection 0.5ml pre-filled syringes | 1 pre-filled disposable injection [POM] £22.74
- Infanrix-IPV (GlaxoSmithKline UK Ltd)
  - Infanrix-IPV vaccine suspension for injection 0.5ml pre-filled syringes | 1 pre-filled disposable injection [POM] £17.56
- Repevax (sanofi pasteur MSD Ltd)
  - Repevax vaccine suspension for injection 0.5ml pre-filled syringes | 1 pre-filled disposable injection [POM] £20.00

### Diphtheria with poliomyelitis and tetanus vaccine

**INDICATIONS AND DOSE**

**Primary immunisation**
- **BY INTRAMUSCULAR INJECTION**
  - Child 10–17 years: 0.5 mL every month for 3 doses
  - Adult: 0.5 mL every month for 3 doses continued →

**SIDE-EFFECTS** Restlessness • sleep disturbances • unusual crying in infants

**SIDE-EFFECTS, FURTHER INFORMATION**
- Side effects of vaccines containing pertussis. The incidence of local and systemic effects is generally lower with vaccines containing acellular pertussis components than with the whole-cell pertussis vaccine used previously. However, compared with primary vaccination, booster doses with vaccines containing acellular pertussis are reported to increase the risk of injection-site reactions (some of which affect the entire limb); local reactions do not contra-indicate further doses.

The vaccine should not be withheld from children with a history to a preceding dose of:
- fever, irrespective of severity;
- persistent crying or screaming for more than 3 hours;
- severe local reaction, irrespective of extent.

**PREGNANCY** Contra-indicated in pregnant women with a history of encephalopathy of unknown origin within 7 days of previous immunisation with a pertussis-containing vaccine. Contra-indicated in pregnant women with a history of transient thrombocytopenia or neurological complications following previous immunisation against diphtheria or tetanus.

**PRESCRIBING AND DISPENSING INFORMATION**

- There can be variation in the licensing of different medicines containing the same drug.
- Available as part of childhood immunisation schedule from health organisations or ImmForm.
- Available for vaccination of pregnant women from ImmForm.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

#### Suspension for injection

**EXCIPIENTS:** May contain Neomycin, polymyxin b, streptomycin
- Boostrix-IPV (GlaxoSmithKline UK Ltd)
  - Boostrix-IPV suspension for injection 0.5ml pre-filled syringes | 1 pre-filled disposable injection [POM] £22.74
- Infanrix-IPV (GlaxoSmithKline UK Ltd)
  - Infanrix-IPV vaccine suspension for injection 0.5ml pre-filled syringes | 1 pre-filled disposable injection [POM] £17.56
- Repevax (sanofi pasteur MSD Ltd)
  - Repevax vaccine suspension for injection 0.5ml pre-filled syringes | 1 pre-filled disposable injection [POM] £20.00

---
**Booster doses**

- **BY INTRAMUSCULAR INJECTION**
  - Child 10-17 years: 0.5 mL for 1 dose, first booster dose—should be given 3 years after primary course (this interval can be reduced to a minimum of 1 year if the primary course was delayed), then 0.5 mL for 1 dose, second booster dose—should be given 10 years after first booster dose (this interval can be reduced to a minimum of 5 years if previous doses were delayed), second booster dose may also be used as first booster dose in those over 10 years who have received only 3 previous doses of a diphtheria-containing vaccine
  - Adult: 0.5 mL for 1 dose, first booster dose—should be given 3 years after primary course (this interval can be reduced to a minimum of 1 year if the primary course was delayed), then 0.5 mL for 1 dose, second booster dose—should be given 10 years after first booster dose (this interval can be reduced to a minimum of 5 years if previous doses were delayed), second booster dose may also be used as first booster dose in those over 10 years who have received only 3 previous doses of a diphtheria-containing vaccine

**SIDE-EFFECTS** Restlessness · sleep disturbances · unusual crying in infants

**PRESCRIBING AND DISPENSING INFORMATION** Available as part of childhood schedule from health organisations or ImmunForm.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Suspension for injection**

- **Revaxis** (sanofi pasteur MSD Ltd)
  - Revaxis vaccine suspension for injection 0.5ml pre-filled syringes | 1 pre-filled disposable injection (£6.50)

**VACCINES**

** Anthrax vaccine**

**INDICATIONS AND DOSE**

- **Pre-exposure immunisation against anthrax** | **Post-exposure immunisation**
  - **BY INTRAMUSCULAR INJECTION**
  - **Adult:** Initially 1 dose every 3 weeks for 3 doses, followed by 1 dose after 6 months, to be administered in the deltoid region, 1 dose is equivalent to 0.5 mL

**Booster**

- **BY INTRAMUSCULAR INJECTION**
  - **Adult:** 1 dose every 12 months, to be administered in deltoid region, 1 dose is equivalent to 0.5 mL


**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Suspension for injection**

- **EXCIPIENTS:** May contain Thiomersal
  - **Anthrax vaccine (Non-proprietary)**
    - Anthrax vaccine (alum precipitated sterile filtrate) suspension for injection 0.5ml ampoules | 5 ampoule (£5.50) no price available

**Bacillus Calmette-Guérin vaccine**

**(BCG Vaccine)**

**DRUG ACTION** BCG (Bacillus Calmette-Guérin) is a live attenuated strain derived from *Mycobacterium bovis* which stimulates the development of immunity to *M. tuberculosis*.

**INDICATIONS AND DOSE**

- **Immunisation against tuberculosis**
  - **BY INTRADERMAL INJECTION**
  - **Child 1-11 months:** 0.05 mL, to be injected at insertion of deltoid muscle onto humerus (keloid formation more likely with sites higher on arm); tip of shoulder should be **avoided**
  - **Child 1-17 years:** 0.1 mL, to be injected at insertion of deltoid muscle onto humerus (keloid formation more likely with sites higher on arm); tip of shoulder should be **avoided**
  - **Adult:** 0.1 mL, to be injected at insertion of deltoid muscle onto humerus (keloid formation more likely with sites higher on arm); tip of shoulder should be **avoided**

**CONTRA-INDICATIONS** Generalised septic skin conditions

**CONTRA-INDICATIONS, FURTHER INFORMATION**

A lesion-free site should be used to administer BCG vaccine to patients with eczema.

**CAUTIONS**

**CAUTIONS, FURTHER INFORMATION**

BCG vaccine can be given simultaneously with another live vaccine, but if they are not given at the same time an interval of 4 weeks should normally be allowed. When BCG is given to infants, there is no need to delay routine primary immunisations. No further vaccination should be given in the arm used for BCG vaccination for at least 3 months because of the risk of regional lymphadenitis.

**INTERACTIONS** → Appendix 1: live vaccines

**SIDE-EFFECTS**

- **Rare** Disseminated complications · osteitis · osteomyelitis
- **Frequency not known** Prolonged ulceration at the injection site · subcutaneous abscess at the injection site

**PRE-TREATMENT SCREENING**

Apart from children under 6 years, any person being considered for BCG immunisation must first be given a skin test for hypersensitivity to tuberculoprotein (see tuberculin purified protein derivative p. 1190). A skin test is not necessary for a child under 6 years provided that the child has not stayed for longer than 3 months in a country with an incidence of tuberculosis greater than 40 per 100 000, the child has not had contact with a person with tuberculosis, and there is no family history of tuberculosis within the last 5 years.

**DIRECTIONS FOR ADMINISTRATION**

**Intradermal injection technique**

Skin is stretched between thumb and forefinger and needle (size 25G or 26G) inserted (bevel upwards) for about 3 mm into superficial layers of dermis (almost parallel with surface). Needle should be short with short bevel (can usually be seen through epidermis during insertion). Tense raised blanched bleb showing tips of hair follicles is sign of correct injection; 7 mm bleb = 0.1 mL injection, 3 mm bleb = 0.05 mL injection; if considerable resistance not felt, needle too deep and should be removed and reinserted before giving more vaccine.

**PRESCRIBING AND DISPENSING INFORMATION** Available from health organisations or direct from ImmunForm www.immform.dh.gov.uk (SSI brand, multidose vial with diluent).
Cholera vaccine

**INDICATIONS AND DOSE**

Immunisation against cholera (for travellers to endemic or epidemic areas on the basis of current recommendations)

- **BY MOUTH**
  - Child 2–5 years: 1 dose every 1–6 weeks for 3 doses, if more than 6 weeks have elapsed between doses, the primary course should be restarted, immunisation should be completed at least one week before potential exposure.
  - Child 6–17 years: 1 dose every 1–6 weeks for 2 doses, if more than 6 weeks have elapsed between doses, the primary course should be restarted, immunisation should be completed at least one week before potential exposure.
  - Adult: 1 dose every 1–6 weeks for 2 doses, if more than 6 weeks have elapsed between doses, the primary course should be restarted, immunisation should be completed at least one week before potential exposure.

**Booster**

- **BY MOUTH**
  - Child 2–5 years: A single booster dose can be given within 6 months after primary course, if more than 6 months have elapsed since the last vaccination, the primary course should be repeated.
  - Child 6–17 years: A single booster dose can be given within 2 years after primary course, if more than 2 years have elapsed since the last vaccination, the primary course should be repeated.
  - Adult: A single booster dose can be given within 2 years after primary course, if more than 2 years have elapsed since the last vaccination, the primary course should be repeated.

**CONTRA-INDICATIONS**

Acute gastro-intestinal illness

**INTERACTIONS**

-Appendix 1: cholera vaccine

**SIDE-EFFECTS**

- Rare: Cough - respiratory symptoms - rhinitis
- Very rare: Insomnia - sore throat
- Frequency not known: Abdominal pain and cramps - diarrhoea - nausea - vomiting

**DIRECTIONS FOR ADMINISTRATION**

- In children: Dissolve effervescent sodium bicarbonate granules in a glassful of water or chlorinated water (approximately 150 mL). For children over 6 years, add vaccine suspension to make one dose. For child 2–5 years, discard half (approximately 75 mL) of the solution, then add vaccine suspension to make one dose. Drink within 2 hours. Food, drink, and other oral medicines should be avoided for 1 hour before and after vaccination.
- In adults: Dissolve effervescent sodium bicarbonate granules in a glassful of water or chlorinated water (approximately 150 mL). Add vaccine suspension to make one dose. Drink within 2 hours. Food, drink, and other oral medicines should be avoided for 1 hour before and after vaccination.

**PATIENT AND CARER ADVICE**

Counselling on administration advised. Immunisation with cholera vaccine does not provide complete protection and all travellers to a country where cholera exists should be warned that scrupulous attention to food, water, and personal hygiene is essential.

Haemophilus influenzae type B with meningococcal group C vaccine

**INDICATIONS AND DOSE**

Booster dose (for infants who have received primary immunisation with a vaccine containing *Haemophilus influenzae type b* component) and primary immunisation against *Neisseria meningitidis*

- **BY INTRAMUSCULAR INJECTION**
  - Child 12-13 months: 0.5 mL for 1 dose

Immunisation against *Neisseria meningitidis* in an unimmunised patient

- **BY INTRAMUSCULAR INJECTION**
  - Child 1-9 years: 0.5 mL for 1 dose

Booster dose (for children who have not been immunised against *Haemophilus influenzae type b*): Booster dose after recovery from *Haemophilus influenzae type b* disease (for index cases previously vaccinated, with low Hib antibody concentration or if it is not possible to measure antibody concentration)

- **BY INTRAMUSCULAR INJECTION**
  - Child 1-9 years: 0.5 mL for 1 dose

Booster dose after recovery from *Haemophilus influenzae type b* disease (for fully vaccinated index cases with asplenia or splenic dysfunction, if previous dose received over 1 year ago)

- **BY INTRAMUSCULAR INJECTION**
  - Child 1-9 years: 0.5 mL for 1 dose

Booster dose for patients diagnosed with asplenia, splenic dysfunction or complement deficiency at under 2 years of age)

- **BY INTRAMUSCULAR INJECTION**
  - Child 2–17 years: 0.5 mL for 1 dose
  - Adult: 0.5 mL for 1 dose

Booster dose (for patients diagnosed with asplenia, splenic dysfunction or complement deficiency at over 2 years of age)

- **BY INTRAMUSCULAR INJECTION**
  - Child 2–17 years: 0.5 mL for 1 dose

**SIDE-EFFECTS**

- Rare: Symptoms of meningitis reported (but no evidence that the vaccine causes meningococcal C meningitis)
- Frequency not known: Atopic dermatitis - hypotonia

**UNLICENSED USE**

Not licensed for use in patients over 2 years.

**SIDE-EFFECTS**

- Rare: Symptoms of meningitis reported (but no evidence that the vaccine causes meningococcal C meningitis)
- Frequency not known: Atopic dermatitis - hypotonia
**Meningococcal group B vaccine (rDNA, component, adsorbed)**

**INDICATIONS AND DOSE**
- **Immunoisation against Neisseria meningitidis, primary immunisation**
  - **By deep intramuscular injection**
    - Child 2 months: 0.5 mL for 1 dose, injected preferably into deltoid region (or anterolateral thigh in infants), for information about the use of paracetamol for prophylaxis of post-immunisation pyrexia, see p. 422.
    - Child 4 months: 0.5 mL for 1 dose, injected preferably into deltoid region (or anterolateral thigh in infants), for information about the use of paracetamol for prophylaxis of post-immunisation pyrexia, see p. 422.

**Immunoisation against Neisseria meningitidis, primary immunisation booster dose**
- **By deep intramuscular injection**
  - Child 12-23 months: 0.5 mL for 1 dose, injected preferably into deltoid region (or anterolateral thigh in infants)

**Immunoisation against Neisseria meningitidis, primary immunisation (in unimmunised patients)**
- **By deep intramuscular injection**
  - Child 6-11 months: 0.5 mL for 2 doses, separated by an interval of at least 2 months; booster dose of 0.5 mL given between 1-2 years of age and at least 2 months after completion of primary immunisation, injected preferably into deltoid region (or anterolateral thigh in infants)
  - Child 12-23 months: 0.5 mL for 2 doses, separated by an interval of at least 2 months; booster dose of 0.5 mL given 12-24 months after completion of primary immunisation, injected preferably into deltoid region (or anterolateral thigh in infants)
  - Child 2-10 years: 0.5 mL for 2 doses, separated by an interval of at least 2 months. Injected preferably into deltoid region (or anterolateral thigh in infants)
  - Child 11-17 years: 0.5 mL for 2 doses, separated by an interval of at least 1 month. Injected preferably into deltoid region
  - Adult: 0.5 mL for 2 doses, separated by an interval of at least 1 month. Injected preferably into deltoid region

**SIDE-EFFECTS**
- **Rare** Kawasaki disease (in children) - symptoms of meningitis reported (but no evidence that the vaccine causes meningococcal C meningitis)
- **Frequency not known** Unusual crying (in children)

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.
  - **Suspension for injection**
    - **EXCIPIENTS:** May contain Kanamycin
      - Bexsero (GlaxoSmithKline UK Ltd)
        - Bexsero vaccine suspension for injection 0.5ml pre-filled syringes | 1 pre-filled disposable injection | £75.00
Immunisation against *Neisseria meningitidis* in an unimmunised patient

- **BY INTRAMUSCULAR INJECTION**
  - Child 10–17 years: 0.5 mL for 1 dose, booster dose is not required
  - Adult 18–24 years: 0.5 mL for 1 dose, booster dose is not required

Immunisation against *Neisseria meningitidis* in those at risk of exposure

- **BY INTRAMUSCULAR INJECTION**
  - Child 1–7 years: 0.5 mL for 1 dose, to be injected preferably into deltoid region (or anterolateral thigh in children 12–23 months), then 0.5 mL after 1 year if required for 1 dose, second dose should be considered in those who continue to be at risk of *Neisseria meningitidis* serogroup A infection
  - Adult: 0.5 mL for 1 dose, to be injected preferably into deltoid region, then 0.5 mL after 1 year if required for 1 dose, second dose should be considered in those who continue to be at risk of *Neisseria meningitidis* serogroup A infection

Patients attending university for the first time (who have not received the routine meningococcal A, C, W135, and Y conjugate vaccine over the age of 10 years)

- **BY INTRAMUSCULAR INJECTION**
  - Adult 18–24 years: 0.5 mL for 1 dose

**UNLICENSED USE** *Menveo*® is not licensed for use in children under 2 years.

**SIDE-EFFECTS**

- Rare: Symptoms of meningitis reported (but no evidence that the vaccine causes meningococcal C meningitis)

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder and solvent for solution for injection**

- *Menveo* (GlaxoSmithKline UK Ltd)
  - Menveo vaccine powder and solvent for solution for injection 0.5ml vials | 1 vial (£30.00)
- *Nimenrix* (Pfizer Ltd)
  - Nimenrix vaccine powder and solvent for solution for injection 0.5ml pre-filled syringes | 1 pre-filled disposable injection (£30.00)

**Pneumococcal polysaccharide conjugate vaccine (adsorbed)**

**INDICATIONS AND DOSE**

**PREVENAR 13®**

**Primary immunisation against pneumococcal infection (first dose)**

- **BY INTRAMUSCULAR INJECTION**
  - Child 2 months: 0.5 mL for 1 dose, anterolateral thigh is preferred site of injection in infants

**Primary immunisation against pneumococcal infection (second dose)**

- **BY INTRAMUSCULAR INJECTION**
  - Child 4 months: 0.5 mL for 1 dose, anterolateral thigh is preferred site of injection in infants

**Primary immunisation against pneumococcal infection (booster dose)**

- **BY INTRAMUSCULAR INJECTION**
  - Child 12–13 months: 0.5 mL for 1 dose, anterolateral thigh is preferred site of injection in infants

**Immunisation against pneumococcal infection (in patients who have not been vaccinated or not completed the primary course)**

- **BY INTRAMUSCULAR INJECTION**
  - Child 12 months–4 years: 0.5 mL for 1 dose, deltoid muscle is preferred site of injection in young children; anterolateral thigh is preferred site in infants

**Immunisation against pneumococcal infection, in immunocompromised or asplenic patients or patients with splenic dysfunction (who have not been vaccinated or not completed the primary course)**

- **BY INTRAMUSCULAR INJECTION**
  - Child 12 months–4 years: 0.5 mL every 2 months for 2 doses, deltoid muscle is preferred site of injection in young children; anterolateral thigh is preferred site in infants

**SYNFLORIX®**

**Immunisation against pneumococcal infection**

- **BY INTRAMUSCULAR INJECTION**
  - Child 6 weeks–4 years: Deltoid muscle is preferred site of injection in young children; anterolateral thigh is preferred site in infants (consult product literature)

**UNLICENSED USE**

**PREVENAR 13®** The dose in BNF publications may differ from that in product literature.

**CONTRA-INDICATIONS** Concomitant use of high potency varicella-zoster vaccine (*Zostavax®*) with pneumococcal polysaccharide vaccine (in adults)

**PRESCRIBING AND DISPENSING INFORMATION**

**PREVENAR 13®** Available as part of childhood immunisation schedule from ImmForm www.immform.dh.gov.uk.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Suspension for injection**

- **Prevenar** (Pfizer Ltd)
  - Prevenar 13 vaccine suspension for injection 0.5ml pre-filled syringes | 1 pre-filled disposable injection (£39.10) | 10 pre-filled disposable injection (£491.00)
- **Synflorix** (GlaxoSmithKline UK Ltd)
  - Synflorix vaccine suspension for injection 0.5ml pre-filled syringes | 1 pre-filled disposable injection (£27.60)

**Pneumococcal polysaccharide vaccine**

**INDICATIONS AND DOSE**

**Immunisation against pneumococcal infection**

- **BY INTRAMUSCULAR INJECTION, OR BY SUBCUTANEOUS INJECTION**
  - Child 2–17 years: 0.5 mL for 1 dose
  - Adult: 0.5 mL for 1 dose

**Immunisation in patients at increased risk of pneumococcal disease**

- **BY INTRAMUSCULAR INJECTION, OR BY SUBCUTANEOUS INJECTION**
  - Child 2–4 years: 0.5 mL for 1 dose, dose should be administered after the second birthday or at least 2 months after the final dose of the 13-valent pneumococcal polysaccharide conjugate vaccine (adsorbed)
  - Child 5–17 years: 0.5 mL for 1 dose
  - Adult: 0.5 mL for 1 dose
Typhoid vaccine

**INDICATIONS AND DOSE**

Immunisation against typhoid fever in children at high risk of typhoid fever

- **BY INTRAMUSCULAR INJECTION**
  - Child 12-23 months: 0.5 mL for 1 dose, dose should be given at least 2 weeks before potential exposure to typhoid infection, response may be suboptimal

Immunisation against typhoid fever

- **BY INTRAMUSCULAR INJECTION**
  - Child 2-17 years: 0.5 mL for 1 dose, dose should be given at least 2 weeks before potential exposure to typhoid infection
  - Adult: 0.5 mL for 1 dose, dose should be given at least 2 weeks before potential exposure to typhoid infection
  - **BY MOUTH**
  - Child 6-17 years: 1 capsule every 2 days for 3 doses (on days 1, 3, and 5)
  - Adult: 1 capsule every 2 days for 3 doses (on days 1, 3, and 5)

**UNLICENSED USE** Not licensed for use in children under 2 years.

**CONTRA-INDICATIONS**

- With oral use Acute gastro-intestinal illness

**INTERACTIONS** → Appendix 1: live vaccines

**SIDE-EFFECTS**

- With oral use Abdominal cramps - abdominal pain - diarrhoea - nausea - vomiting

**DIRECTIONS FOR ADMINISTRATION** Capsule should be taken one hour before a meal. Swallow as soon as possible after placing in mouth with a cold or lukewarm drink.

**HANDLING AND STORAGE**

- With oral use It is important to store capsules in a refrigerator.

**PATIENT AND CARER ADVICE**

- With oral use Patients or carers should be given advice on how to administer and store typhoid vaccine capsules.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Pneumococcal polysaccharide vaccine (Non-proprietary)**
  - Pneumococcal polysaccharide vaccine solution for injection 0.5ml vials | 1 vial (£0.32)

**Gastro-resistant capsule**

**CAUTIONARY AND ADVISORY LABELS** 25

- **Vivotif** (PaxVax Ltd)
  - Vivotif vaccine gastro-resistant capsules | 3 capsule (£14.77)

Combinations available: *Hepatitis A with typhoid vaccine*, p. 1209

**VACCINES** > **VIRAL VACCINES**

**Hepatitis A and B vaccine**

The properties listed below are those particular to the combination only. For the properties of the components please consider, hepatitis A vaccine p. 1209, hepatitis B vaccine p. 1210.

**INDICATIONS AND DOSE**

**AMBRIX®**

Immunisation against hepatitis A and hepatitis B infection (primary course)

- **BY INTRAMUSCULAR INJECTION**
  - Child 1-15 years: Initially 1 mL for 1 dose, then 1 mL after 6-12 months for 1 dose, the deltoid region is the preferred site of injection in older children; anterolateral thigh is the preferred site in infants; not to be injected into the buttock (vaccine efficacy reduced), subcutaneous route used for patients with bleeding disorders (but immune response may be reduced)

**TWINRIX® ADULT**

Immunisation against hepatitis A and hepatitis B infection (primary course)

- **BY INTRAMUSCULAR INJECTION**
  - Child 16-17 years: Initially 1 mL every month for 2 doses, then 1 mL after 5 months for 1 dose, the deltoid region is the preferred site of injection; not to be injected into the buttock (vaccine efficacy reduced), subcutaneous route used for patients with bleeding disorders (but immune response may be reduced)

Immunisation against hepatitis A and hepatitis B infection—accelerated schedule for travellers departing within 1 month

- **BY INTRAMUSCULAR INJECTION**
  - Child 16-17 years: Initially 1 mL for 1 dose, then 1 mL after 7 days for 1 dose, then 1 mL after 14 days for 1 dose, then 1 mL for 1 dose given 12 months after the first dose, the deltoid region is the preferred site of injection; not to be injected into the buttock (vaccine efficacy reduced), subcutaneous route used for patients with bleeding disorders (but immune response may be reduced)

**TWINRIX® PAEDIATRIC**

Immunisation against hepatitis A and hepatitis B infection (primary course)

- **BY INTRAMUSCULAR INJECTION**
  - Child 1-15 years: Initially 0.5 mL every month for 2 doses, then 0.5 mL after 5 months for 1 dose, the deltoid region is the preferred site of injection in older children; anterolateral thigh is the preferred site in infants; not to be injected into the buttock (vaccine efficacy reduced), subcutaneous route used for patients...
with bleeding disorders (but immune response may be reduced)

**IMPORTANT SAFETY INFORMATION**

Ambririx® and Twinrix® are not recommended for post-exposure prophylaxis following percutaneous (needle-stick), ocular, or mucous membrane exposure to hepatitis B virus.

**PRESCRIBING AND DISPENSING INFORMATION**

**TWINRIX® PAEDIATRIC** Primary course should be completed with Twinrix® (single component vaccines given at appropriate intervals may be used for booster dose).

**AMBRIRIX®** Primary course should be completed with Ambirix® (single component vaccines given at appropriate intervals may be used for booster dose).

**TWINRIX® ADULT** Primary course should be completed with Twinrix® (single component vaccines given at appropriate intervals may be used for booster dose).

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Suspension for injection**

**EXCIPIENTS:** May contain Neomycin

- **Ambirix®** (GliaSmiThKlne UN Ltd) Ambirix vaccine suspension for injection 1ml pre-filled syringes | 1 pre-filled disposable injection (£31.18)
- **Twinrix®** (GliaSmiThKlne UN Ltd) Twinrix Paediatric vaccine suspension for injection 0.5ml pre-filled syringes | 1 pre-filled disposable injection (£20.79) Twinrix Adult vaccine suspension for injection 1ml pre-filled syringes | 1 pre-filled disposable injection (£33.31) | 10 pre-filled disposable syringes (£33.13)

**Hepatitis A vaccine**

**INDICATIONS AND DOSE**

**AVAXIM®**

**Immunisation against hepatitis A infection**

- **BY INTRAMUSCULAR INJECTION**
  - Child 16-17 years: Initially 0.5 mL for 1 dose, then 0.5 mL after 6–12 months, dose given as booster; booster dose may be delayed by up to 3 years if not given after recommended interval following primary dose, the deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders.
  - Adult: Initially 0.5 mL for 1 dose, then 0.5 mL after 6–12 months, dose given as booster; booster dose may be delayed by up to 3 years if not given after recommended interval following primary dose, the deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders.

**HAVRIX MONODOSE®**

**Immunisation against hepatitis A infection**

- **BY INTRAMUSCULAR INJECTION**
  - Child 16-17 years: Initially 1 mL for 1 dose, then 1 mL after 6–12 months, dose given as booster; booster dose may be delayed by up to 3 years if not given after recommended interval following primary dose, the deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders.

**VAQTA® ADULT**

**Immunisation against hepatitis A infection**

- **BY INTRAMUSCULAR INJECTION**
  - Adult: Initially 1 mL for 1 dose, then 1 mL after 6–12 months, dose given as booster; booster dose may be delayed by up to 3 years if not given after recommended interval following primary dose, the deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders.

**VAQTA® PAEDIATRIC**

**Immunisation against hepatitis A infection**

- **BY INTRAMUSCULAR INJECTION**
  - Child 1–17 years: Initially 0.5 mL for 1 dose, then 0.5 mL after 6–18 months, dose given as booster, the deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders (but immune response may be delayed)

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Suspension for injection**

**EXCIPIENTS:** May contain Neomycin

- **Avaxim** (sanofi pasteur MSD Ltd) Avaxim vaccine suspension for injection 0.5ml pre-filled syringes | 1 pre-filled disposable injection (£18.10) | 10 pre-filled disposable injection (£181.00)
- **Havrix®** (GliaSmiThKlne UN Ltd) Havrix Monodose vaccine suspension for injection 1ml pre-filled syringes | 1 pre-filled disposable injection (£22.14) | 10 pre-filled disposable injection (£211.43) Havrix Junior Monodose vaccine suspension for injection 0.5ml pre-filled syringes | 1 pre-filled disposable injection (£18.77) | 10 pre-filled disposable injection (£167.68) Havrix Junior Monodose vaccine suspension for injection 0.5ml vials | 1 vial (£16.77) Havrix Monodose vaccine suspension for injection 1ml vials | 1 vial (£22.14)
- **VAQTA** (Merck Sharp & Dohme Ltd) VAQTA Adult vaccine suspension for injection 1ml pre-filled syringes | 1 pre-filled disposable injection (£18.10) VAQTA Adult vaccine suspension for injection 1ml vials | 1 vial (£18.10) VAQTA Paediatric vaccine suspension for injection 0.5ml pre-filled syringes | 1 pre-filled disposable injection (£14.74)

**Hepatitis A with typhoid vaccine**

The properties listed below are those particular to the combination only. For the properties of the components please consider, hepatitis A vaccine above, typhoid vaccine p. 1208.

**INDICATIONS AND DOSE**

**HEPATYRIX®**

**Immunisation against hepatitis A and typhoid infection**

- **BY INTRAMUSCULAR INJECTION**
  - Child 15-17 years: 1 mL for 1 dose, the deltoid region is the preferred site of injection; not to be continued
Vaccines

1210 Vaccination

INTERACTIONS

VIATIM®

▶ Neonate: 10 micrograms every month for 3 doses, followed by 10 micrograms after 10 months for 1 dose, deltoid muscle is preferred site of injection in older children; anterolateral thigh is preferred site in infants and young children; not to be injected into the buttoc (vaccine efficacy reduced).

▶ Child 1-month-15 years: 10 micrograms every month for 3 doses, followed by 10 micrograms after 10 months for 1 dose, deltoid muscle is preferred site of injection in older children; anterolateral thigh is preferred site in infants and young children; not to be injected into the buttoc (vaccine efficacy reduced).

▶ Child 16-17 years: 20 micrograms every month for 3 doses, followed by 20 micrograms after 10 months for 1 dose, deltoid muscle is preferred site of injection; not to be injected into the buttoc (vaccine efficacy reduced).

Immunisation against hepatitis B infection, alternative accelerated schedule

▶ By intramuscular injection

Adult: 20 micrograms for 1 dose, followed by 20 micrograms after 6 months, this schedule is not suitable if high risk of infection between doses or if compliance with second dose uncertain, deltoid muscle is preferred site of injection; not to be injected into the buttoc (vaccine efficacy reduced).

Immunisation against hepatitis B infection (accelerated schedule in exceptional cases, e.g. for travellers departing within 1 month)

▶ By intramuscular injection

Adult: 20 micrograms for 1 dose, then 20 micrograms after 7 days for 1 dose, followed by 20 micrograms after 14 days for 1 dose, followed by 20 micrograms for 1 dose, to be given 12 months after the first dose, deltoid muscle is preferred site of injection; not to be injected into the buttoc (vaccine efficacy reduced).

Immunisation against hepatitis B infection (in renal insufficiency, including haemodialysis patients)

▶ By intramuscular injection

Child 1-month-15 years: 10 micrograms every month for 2 doses, followed by 10 micrograms after 5 months for 1 dose, immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration, deltoid muscle is preferred site of injection in older children; anterolateral thigh is preferred site in infants and young children; not to be injected into the buttoc (vaccine efficacy reduced).

Child 16-17 years: 40 micrograms every month for 3 doses, followed by 40 micrograms after 4 months for 1 dose, immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration, deltoid muscle is preferred site of injection; not to be injected into the buttoc (vaccine efficacy reduced).

Immunisation against hepatitis B infection (in renal insufficiency, including haemodialysis patients (accelerated schedule))

▶ By intramuscular injection

Child 1-month-15 years: 10 micrograms every month for 2 doses, followed by 10 micrograms after 5 months for 1 dose, immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration, deltoid muscle is preferred site of injection in older children; anterolateral thigh is preferred site in infants and young children; not to be injected into the buttoc (vaccine efficacy reduced).

Child 16-17 years: 40 micrograms every month for 3 doses, followed by 40 micrograms after 4 months for 1 dose, immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration, deltoid muscle is preferred site of injection; not to be injected into the buttoc (vaccine efficacy reduced).

Medicinal forms

There can be variation in the licensing of different medicines containing the same drug.

Suspension for injection

Excipients: May contain Neomycin

▶ Hepatryx (GlaucosSmithKline Ltd)

Hepatryx vaccine suspension for injection 1ml pre-filled syringes | 10 pre-filled disposable injection (Pud) £37.21 | 10 pre-filled disposable injection (Pud) £37.21

▶ VIATIM (Sanofi Pasteur MSD Ltd)

VIATIM vaccine suspension for injection 1ml pre-filled syringes | 1 pre-filled disposable injection (Pud) £29.80

Hepatitis B vaccine

Indications and dose

ENGEXIR B®

Immunisation against hepatitis B infection

▶ By intramuscular injection

Child 1 month-15 years: 10 micrograms for 1 dose, then 10 micrograms after 1 month for 1 dose, followed by 10 micrograms after 5 months for 1 dose, deltoid muscle is preferred site of injection in older children; anterolateral thigh is preferred site in infants and young children; not to be injected into the buttoc (vaccine efficacy reduced).

Child 16-17 years: 20 micrograms for 1 dose, then 20 micrograms after 1 month for 1 dose, followed by 20 micrograms after 5 months for 1 dose, deltoid muscle is preferred site of injection; not to be injected into the buttoc (vaccine efficacy reduced).

Adult: 20 micrograms for 1 dose, then 20 micrograms after 1 month for 1 dose, followed by 20 micrograms after 5 months for 1 dose, deltoid muscle is preferred site of injection; not to be injected into the buttoc (vaccine efficacy reduced).

Immunisation against hepatitis B infection (accelerated schedule)

▶ By intramuscular injection

Neonate: 10 micrograms every month for 3 doses, followed by 10 micrograms after 10 months for 1 dose, anterolateral thigh is preferred site in neonates; not to be injected into the buttoc (vaccine efficacy reduced), this dose should not be given to neonates born to hepatitis B surface antigen positive mother.
FENDRIX®
Immunisation against hepatitis B infection in renal insufficiency (including pre-haemodialysis and haemodialysis patients)
▶ BY INTRAMUSCULAR INJECTION
▶ Child 15-17 years: 20 micrograms every month for 3 doses, followed by 20 micrograms after 4 months for 1 dose, immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration, deltoid muscle is preferred site of injection; not to be injected into the buttock (vaccine efficacy reduced)
▶ Child 1 month-15 years: 5 micrograms for 1 dose, followed by 5 micrograms after 1 month for 1 dose, then 5 micrograms after 5 months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced), dose not to be used for neonate born to hepatitis B surface antigen positive mother.
▶ Adult: 20 micrograms every month for 3 doses, followed by 20 micrograms after 4 months for 1 dose, immunisation schedule and booster doses may need to be adjusted in those with low antibody concentration, deltoid muscle is preferred site of injection; not to be injected into the buttock (vaccine efficacy reduced)

HBVAXPRO®
Immunisation against hepatitis B infection
▶ BY INTRAMUSCULAR INJECTION
▶ Neonate: 5 micrograms for 1 dose, followed by 5 micrograms after 1 month for 1 dose, then 5 micrograms after 5 months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced), dose not to be used for neonate born to hepatitis B surface antigen positive mother.
▶ Child 1 month-15 years: 5 micrograms for 1 dose, followed by 5 micrograms after 1 month for 1 dose, then 5 micrograms after 5 months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, anterolateral thigh is preferred site in infants; not to be injected into the buttock (vaccine efficacy reduced)
▶ Child 16-17 years: 10 micrograms for 1 dose, followed by 10 micrograms after 10 months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, deltoid muscle is preferred site of injection in children; not to be injected into the buttock (vaccine efficacy reduced)
▶ Adult: 10 micrograms every month for 3 doses, followed by 10 micrograms after 10 months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, deltoid muscle is preferred site of injection; not to be injected into the buttock (vaccine efficacy reduced)

Immunisation against hepatitis B infection (accelerated schedule)
▶ BY INTRAMUSCULAR INJECTION
▶ Neonate: 5 micrograms every month for 3 doses, followed by 5 micrograms after 10 months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced), dose not to be used for neonate born to hepatitis B surface antigen positive mother.
▶ Child 1 month-15 years: 5 micrograms every month for 3 doses, followed by 5 micrograms after 10 months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, deltoid muscle is preferred site of injection in infants; not to be injected into the buttock (vaccine efficacy reduced)

Injection in older children; anterolateral thigh is preferred site in infants; not to be injected into the buttock (vaccine efficacy reduced)
▶ Child 16-17 years: 10 micrograms every month for 3 doses, followed by 10 micrograms after 10 months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, deltoid muscle is preferred site of injection in children; not to be injected into the buttock (vaccine efficacy reduced)
▶ Adult: 10 micrograms every month for 3 doses, followed by 10 micrograms after 10 months for 1 dose, booster doses may be required in immunocompromised patients with low antibody concentration, deltoid muscle is preferred site of injection; not to be injected into the buttock (vaccine efficacy reduced)

Neonate born to hepatitis B surface antigen-positive mother
▶ BY INTRAMUSCULAR INJECTION
▶ Neonate: 5 micrograms every month for 3 doses, first dose given at birth with hepatitis B immunoglobulin injection (separate site), followed by 5 micrograms after 10 months for 1 dose, anterolateral thigh is preferred site in neonates; not to be injected into the buttock (vaccine efficacy reduced).

Chronic haemodialysis patients
▶ BY INTRAMUSCULAR INJECTION
▶ Child 16-17 years: 40 micrograms every month for 2 doses, followed by 40 micrograms after 5 months for 1 dose, booster doses may be required in those with low antibody concentration, deltoid muscle is preferred site of injection in children; not to be injected into the buttock (vaccine efficacy reduced)
▶ Adult: 40 micrograms every month for 2 doses, followed by 40 micrograms after 5 months for 1 dose, booster doses may be required in those with low antibody concentration, deltoid muscle is preferred site of injection; not to be injected into the buttock (vaccine efficacy reduced)

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.
Suspension for injection
EXCIPIENTS: May contain Thiomersal
▶ Engerix B (GlaxoSmithKline UK Ltd)
Hepatitis B virus surface antigen 20 microgram per 1 ml Engerix B 20micrograms/1ml vaccine suspension for injection vials | 1 vial £12.34 | 10 vial £123.41
Engerix B 10micrograms/0.5ml vaccine suspension for injection pre-filled syringes | 1 pre-filled disposable injection £9.67
Engerix B 20micrograms/1ml vaccine suspension for injection pre-filled syringes | 1 pre-filled disposable injection £12.99 | 10 pre-filled disposable injection £129.92

▶ HBVAXPRO (Merck Sharp & Dohme Ltd)
Hepatitis B virus surface antigen 40 microgram per 1 ml HBVAXPRO 20micrograms/0.5ml vaccine suspension for injection pre-filled syringes | 1 pre-filled disposable injection £38.10

▶ HBVAXPRO 10micrograms/1ml vaccine suspension for injection pre-filled syringes | 1 pre-filled disposable injection £12.20
HBVAXPRO 5micrograms/0.5ml vaccine suspension for injection pre-filled syringes | 1 pre-filled disposable injection £8.95
Hepatitis B virus surface antigen 40 microgram per 1 ml HBVAXPRO 40micrograms/1ml vaccine suspension for injection vials | 1 vial £7.60
Human papillomavirus vaccines
02-Mar-2017

**INDICATIONS AND DOSE**

**CERVARIX ®**

Prevention of premalignant genital lesions and cervical cancer

- **BY INTRAMUSCULAR INJECTION**
  - Child 9–14 years (female): 0.5 mL for 1 dose, followed by 0.5 mL after 5–7 months for 1 dose, if second dose administered earlier than 5 months after the first, a third dose should be administered, dose to be administered into deltoid region, if the course is interrupted, it should be resumed (using the same vaccine) but not repeated, even if more than 24 months have elapsed since the first dose or if the girl is then aged 15 years or more.
  - Child 15–17 years (female): 0.5 mL for 1 dose, followed by 0.5 mL after 1–2.5 months for 1 dose, then 0.5 mL after 5–12 months from the first dose for 1 dose, dose to be administered into deltoid region, if the course is interrupted, it should be resumed (using the same vaccine) but not repeated, allowing the appropriate interval between the remaining doses.
  - Adult (female): 0.5 mL for 1 dose, followed by 0.5 mL after 1–2.5 months for 1 dose, then 0.5 mL after 5–12 months from the first dose for 1 dose, dose to be administered into deltoid region, if the course is interrupted, it should be resumed (using the same vaccine) but not repeated, allowing the appropriate interval between the remaining doses.

**GARDASIL ®**

Prevention of premalignant genital (cervical, vulvar and vaginal) and anal lesions, cervical and anal cancers, and genital warts

- **BY INTRAMUSCULAR INJECTION**
  - Child 9–14 years (female): 0.5 mL for 1 dose, followed by 0.5 mL for 1 dose, second dose to be given at least 1 month after the first dose, then 0.5 mL for 1 dose, third dose to be given at least 3 months after the second dose, schedule should be completed within 12 months of the first dose, dose to be administered preferably into deltoid region or higher anterolateral thigh, if the course is interrupted, it should be resumed (using the same vaccine) but not repeated, allowing the appropriate interval between the remaining doses.
  - Child 15–17 years (female): 0.5 mL for 1 dose, second dose to be given at least 1 month after the first dose, then 0.5 mL for 1 dose, third dose to be given at least 3 months after the second dose, schedule should be completed within 12 months of the first dose, dose to be administered preferably into deltoid region or higher anterolateral thigh, if the course is interrupted, it should be resumed (using the same vaccine) but not repeated, allowing the appropriate interval between the remaining doses.
  - Adult (female): 0.5 mL for 1 dose, followed by 0.5 mL for 1 dose, second dose to be given at least 1 month after the first dose, then 0.5 mL for 1 dose, third dose to be given at least 3 months after the second dose, schedule should be completed within 12 months of the first dose, dose to be administered preferably into deltoid region or higher anterolateral thigh, if the course is interrupted, it should be resumed (using the same vaccine) but not repeated, allowing the appropriate interval between the remaining doses.

Prevention of premalignant genital (cervical, vulvar, and vaginal) and anal lesions, cervical and anal cancers, and genital warts (alternative schedule)

- **BY INTRAMUSCULAR INJECTION**
  - Child 9–14 years (female): 0.5 mL for 1 dose, followed by 0.5 mL for 1 dose, second dose to be given at least 1 month after the first dose, then 0.5 mL for 1 dose, third dose to be given at least 3 months after the second dose, schedule should be completed within 12 months of the first dose, dose to be administered preferably into deltoid region or higher anterolateral thigh, if the course is interrupted, it should be resumed (using the same vaccine) but not repeated, allowing the appropriate interval between the remaining doses.

**UNLICENSED USE**

- **GARDASIL ®** Two dose schedule not licensed for use in girls aged 14 years.
  - **PREGNANCY** Not known to be harmful, but vaccination should be postponed until completion of pregnancy.
  - **PRESCRIBING AND DISPENSING INFORMATION** To avoid confusion, prescribers should specify the brand to be dispensed.

**MEDI CINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Suspension for injection**

- **Cervarix** (GlaxoSmithKline UK Ltd)
  - Cervarix vaccine suspension for injection 0.5mL pre-filled syringes | 1 pre-filled disposable injection (PfP) £80.50
- **Gardasil** (Merck Sharp & Dohme Ltd)
  - Gardasil vaccine suspension for injection 0.5mL pre-filled syringes | 1 pre-filled disposable injection (PfP) £86.50

**Influenza vaccine**

**INDICATIONS AND DOSE**

Annual immunisation against seasonal influenza

- **BY INTRAMUSCULAR INJECTION**
  - Child 6 months–17 years: 0.5 mL for 1 dose
  - Adult: 0.5 mL for 1 dose
  - **BY INTRADERMAL INJECTION**
  - Adult 18–59 years: 9 micrograms for 1 dose, dose to be injected into deltoid region
  - Adult 60 years and over: 15 micrograms for 1 dose, dose to be injected into deltoid region
  - **BY INTRANASAL ADMINISTRATION**
  - Child 2–17 years: 0.1 mL for 1 dose, dose to be administered into each nostril

**UNLICENSED USE** Some products containing inactivated influenza vaccine (surface antigen) are not licensed for use in children under 4 years—check product literature.

- **FLU VIN ®** Not licensed for use in children under 4 years.
- **FLUA RIX TETRA ®** Not licensed for use in children under 3 years of age.
- **OPTAFLU ®** Not licensed for use in children and adolescents under 18 years.

**CONTRA-INDICATIONS** Preparations marketed by Pfizer, or CSL Biotherapies in child under 5 years—increased risk of febrile convulsions

- **FLUENZ TETRA ®** Active wheezing - concomitant use with antiviral therapy for influenza - severe asthma

**CONTRA-INDICATIONS, FURTHER INFORMATION**

- Concomitant use with antivirals Avoid antivirals for at least 2 weeks after immunisation; avoid immunisation for at least 48 hours after stopping the antiviral.
- **ENZIRA ®** Child under 5 years—increased risk of febrile convulsions
- **CAUTIONS** Increased risk of fever in child 5–9 years with preparations marketed by Pfizer or CSL Biotherapies—use alternative influenza vaccine if available

**ENZIRA**® Child 5–9 years (increased risk of fever)—use alternative influenza vaccine if available

- **INTERACTIONS** → Appendix 1: live vaccines

- **SIDE-EFFECTS**
  
  **GENERAL SIDE-EFFECTS**
  
  - **Uncommon** Epistaxis
  
  - **Frequency not known** Febrile convulsions · transient thrombocytopenia · vasculitis (in adults)

  **SPECIFIC SIDE-EFFECTS**
  
  - With intranasal use Rhinorrhea

- **ALLERGY AND CROSS-SENSITIVITY** Individuals with a history of egg allergy can be immunised with either an egg free influenza vaccine, if available, or an influenza vaccine with an ovalbumin content less than 120 nanograms/mL. (facilities should be available to treat anaphylaxis). Vaccines with an ovalbumin content more than 120 nanograms/mL or where content is not stated should not be used in individuals with egg allergy. If an influenza vaccine containing ovalbumin is being considered in those with a history of anaphylaxis to egg or egg allergy with uncontrolled asthma, these individuals should be referred to a specialist in hospital.

- **PREGNANCY** Inactivated vaccines not known to be harmful.

**FLUENZ TETRA**® Avoid in pregnancy.

- **BREAST FEEDING** Inactivated vaccines not known to be harmful.

**FLUENZ TETRA**® Avoid in breast-feeding.

- **PRESCRIBING AND DISPENSING INFORMATION**

**FLUARIX TETRA**® Ovalbumin content less than 100 nanograms/mL.

- **PATIENT AND CARER ADVICE**

**FLUENZ TETRA**® Avoid close contact with severely immunocompromised patients for 1–2 weeks after vaccination.

- **MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Spray**

EXCIPIENTS: May contain Gelatin, gentamicin

- **FluMist Quadrivalent** (AstraZeneca UK Ltd)
  FluMist Quadrivalent vaccine nasal suspension 0.2ml unit dose | 10 unit dose **£180.00**

- **Fluenz Tetra** (AstraZeneca UK Ltd) ▼
  Fluenz Tetra vaccine nasal suspension 0.2ml unit dose | 10 unit dose **£180.00**

**Suspension for injection**

EXCIPIENTS: May contain Gentamicin, kanamycin, neomycin penicillins, polymyxin b, thiomersal.

- **Influenza vaccine (Non-proprietary)**
  Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes | 1 pre-filled disposable injection **£5.00–6.59** | 10 pre-filled disposable injection **£65.90**

- **Agripal** (Sepracor Ltd)
  Agripal vaccine suspension for injection 0.5ml pre-filled syringes | 10 pre-filled disposable injection **£58.50**

- **Enzira** (Pfizer Ltd)
  Enzira vaccine suspension for injection 0.5ml pre-filled syringes | 10 pre-filled disposable injection **£52.50**

- **Fluarix Tetra** (GlaxoSmithKline UK Ltd) ▼
  Fluarix Tetra vaccine suspension for injection 0.5ml pre-filled syringes | 1 pre-filled disposable injection **£9.94** | 10 pre-filled disposable injection **£99.40**

- **Imuvac** (BGP Products Ltd)
  Imuvac vaccine suspension for injection 0.5ml pre-filled syringes | 1 pre-filled disposable injection **£5.59** | 10 pre-filled disposable injection **£65.50**

- **Influvac Sub-unit** (BGP Products Ltd)
  Influvac Sub-unit vaccine suspension for injection 0.5ml pre-filled syringes | 1 pre-filled disposable injection **£5.22** | 10 pre-filled disposable injection **£52.20**

- **Intanza** (sanofi pasteur MSD Ltd)
  Intanza 15microgram strain vaccine suspension for injection 0.1ml pre-filled syringes | 1 pre-filled disposable injection **£9.05** | 10 pre-filled disposable injection **£90.50**

**Japanese encephalitis vaccine**

- **INDICATIONS AND DOSE**

**Immunisation against Japanese encephalitis**

- **BY INTRAMUSCULAR INJECTION**
  - Child 2 months–2 years: 0.25 mL every 28 days for 2 doses, anterolateral thigh is preferred site of injection in infants, the subcutaneous route may be used for patients with bleeding disorders
  - Child 3–17 years: 0.5 mL every 28 days for 2 doses, deltoid muscle is preferred site in older children; anterolateral thigh is preferred in infants, the subcutaneous route may be used for patients with bleeding disorders
  - Adult: 0.5 mL every 28 days for 2 doses, deltoid muscle is preferred site of injection, the subcutaneous route may be used for patients with bleeding disorders

**Booster dose**

- **BY INTRAMUSCULAR INJECTION**
  - Adult: 0.5 mL after 1–2 years, deltoid muscle is preferred site of injection, the subcutaneous route may be used for patients with bleeding disorders, for those at continued risk, the booster dose should be given 1 year after completing the primary course

- **SIDE-EFFECTS**

  - **Uncommon** Cough (in children) · migrane (in adults) · vertigo (in adults)
  - **Rare** Dyspnœa (in adults) · neuritis (in adults) · palpitation (in adults) · tachycardia (in adults) · thrombocytopenia (in adults)

- **PREGNANCY** Although manufacturer advises avoid because of limited information, miscarriage has been associated with Japanese encephalitis virus infection acquired during the first 2 trimesters of pregnancy.

- **MEDICAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Suspension for injection**

- **Ixiaro (Valneva UK Ltd)**
  Ixiaro vaccine suspension for injection 0.5ml pre-filled syringes | 1 pre-filled disposable injection **£5.95**

**Measles, mumps and rubella vaccine, live**

- **INDICATIONS AND DOSE**

**Primary immunisation against measles, mumps, and rubella (first dose)**

- **BY INTRAMUSCULAR INJECTION, OR BY DEEP SUBCUTANEOUS INJECTION**
  - Child 12–13 months: 0.5 mL for 1 dose

**Primary immunisation against measles, mumps, and rubella (second dose)**

- **BY INTRAMUSCULAR INJECTION, OR BY DEEP SUBCUTANEOUS INJECTION**
  - Child 40 months–5 years: 0.5 mL for 1 dose

continued →
Rubella immunisation (in seronegative women, susceptible to rubella and in unimmunised, seronegative women, post-partum)
- By intramuscular injection, or by deep subcutaneous injection
- Females of childbearing potential: (consult product literature or local protocols)

Children presenting for pre-school booster, who have not received the primary immunisation (first dose) | Immunisation for patients at school-leaving age or at entry into further education, who have not completed the primary immunisation course | Control of measles outbreak | Immunisation for patients travelling to areas where measles is endemic or epidemic, who have not completed the primary immunisation
- By intramuscular injection, or by deep subcutaneous injection
- Child 6 months-17 years: (consult product literature or local protocols)
- Adult: (consult product literature or local protocols)

**SIDE-EFFECTS**

- Uncommon Parotid swelling (usually in the third week) · sleep disturbances · unusual crying in infants
- Rare Arthrophy (2 to 3 weeks after immunisation) · idiopathic thrombocytopenic purpura
- Frequency not known Optic neuritis · peripheral neuritis

**SIDE-EFFECTS, FURTHER INFORMATION**

Malaise, fever, or a rash can occur after the first dose of MMR vaccine—most commonly about a week after vaccination and lasting about 2 to 3 days. Leaflets are available for parents on advice for reducing fever (including the use of paracetamol).

Febrile seizures—occur rarely 6 to 11 days after MMR vaccination (the incidence is lower than that following measles infection)

Idiopathic thrombocytopenic purpura. Idiopathic thrombocytopenic purpura has occurred rarely following MMR vaccination, usually within 6 weeks of the first dose.

The risk of idiopathic thrombocytopenic purpura after MMR vaccine is much less than the risk after infection with wild measles or rubella virus. Children who develop idiopathic thrombocytopenic purpura within 6 weeks of the first dose of MMR should undergo serological testing before the second dose is due; if the results suggest incomplete immunity against measles, mumps or rubella then a second dose of MMR is recommended. The Specialist and Reference Microbiology Division, Health Protection Agency offers free serological testing for children who develop idiopathic thrombocytopenic purpura within 6 weeks of the first dose of MMR.

- Aseptic meningitis Post-vaccination aseptic meningitis was reported (rarely and with complete recovery) following vaccination with MMR vaccine containing Ũrabe mumps vaccine, which has now been discontinued; no cases have been confirmed in association with the currently used Jeryl Lynn mumps vaccine. Children with post-vaccination symptoms are not infectious.
- Frequency of side effects Adverse reactions are considerably less frequent after the second dose of MMR vaccine than after the first.

**ALLERGY AND CROSS-SENSITIVITY**

MMR vaccine can be given safely even when the child has had an anaphylactic reaction to food containing egg. Dislike of eggs, refusal to eat egg, or confirmed anaphylactic reactions to egg-containing food is not a contra-indication to MMR vaccination. Children with a confirmed anaphylactic reaction to the MMR vaccine should be assessed by a specialist.

**CONCEPTION AND CONTRACEPTION**

Exclude pregnancy before immunisation. Avoid pregnancy for at least 1 month after vaccination.

**PRESCRIBING AND DISPENSING INFORMATION**

Available as part of childhood immunisation schedule from health organisations or ImmForm www.immform.dh.gov.uk.

**IMPORTANT SAFETY INFORMATION**

MMR VACCINATION AND BOWEL DISEASE OR AUTISM

Reviews undertaken on behalf of the CSM, the Medical Research Council, and the Cochrane Collaboration, have not found any evidence of a link between MMR vaccination and bowel disease or autism. The Chief Medical Officers have advised that the MMR vaccine is the safest and best way to protect children against measles, mumps, and rubella. Information (including fact sheets and a list of references) may be obtained from www.dh.gov.uk/immunisation.

**CAUTIONS**

Antibody response to measles component may be reduced after immunoglobulin administration or blood transfusion—leave an interval of at least 3 months before MMR immunisation.

**CAUTIONS, FURTHER INFORMATION**

- Administration with other vaccines. MMR vaccine should not be administered on the same day as yellow fever vaccine; there should be a 4-week minimum interval between the vaccines. When protection is rapidly required, the vaccines can be given at any interval and an additional dose of MMR may be considered.

MMR and varicella-zoster vaccine can be given on the same day or separated by a 4-week minimum interval. When protection is rapidly required, the vaccines can be given at any interval and an additional dose of the vaccine given second may be considered.

**INTERACTIONS**

- Appendix 1: live vaccines

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder and solvent for suspension for injection**

**EXCIPIENTS:** May contain Gelatin, neomycin
- **M-M-RVAXPRO** (Merck Sharp & Dohme Ltd)
  - M-M-RVAXPRO vaccine powder and solvent for suspension for injection 0.5ml pre-filled syringes | 1 pre-filled disposable injection (POE) £1.00
- **Powder and solvent for solution for injection**
  - **EXCIPIENTS:** May contain Neomycin
  - Priorix (GlaxoSmithKline UK Ltd)
  - Priorix vaccine powder and solvent for solution for injection 0.5ml vials | 1 vial £0.64

**INDICATIONS AND DOSE**

**Pre-exposure prophylaxis**
- By intramuscular injection

**Child:** 1 ml for 2 doses (on days 0 and 7), followed by 1 ml for 1 dose (on day 28), to be administered in deltoid region or anterolateral thigh in infants, for those at continuous risk, measure plasma-concentration of antirabies antibodies every 6 months and give a booster dose if the titre is less than 0.5 units/ml, final dose may be given from day 21, if insufficient time before travel

**Adult:** 1 ml for 2 doses (on days 0 and 7), followed by 1 ml for 1 dose (on day 28), to be administered in deltoid region, for those at continuous risk, measure plasma-concentration of antirabies antibodies every 6 months and give a booster dose if the titre is less than

**Rabies vaccine**
0.5 units/mL, final dose may be given from day 21, if insufficient time before travel

**Pre-exposure prophylaxis booster dose (for patients at frequent risk of exposure)**
- **BY INTRAMUSCULAR INJECTION**
  - Child: 1 mL after 1 year for 1 dose, to be given 1 year after primary course is completed, then 1 mL every 3–5 years, to be administered in deltoid region or anterolateral thigh in infants, the frequency of booster doses may alternatively be determined according to plasma-concentration of antirabies antibodies
  - Adult: 1 mL for 1 dose, to be given 1 year after primary course is completed, then 1 mL every 3–5 years, to be administered in deltoid region, the frequency of booster doses may alternatively be determined according to plasma-concentration of antirabies antibodies

**Pre-exposure prophylaxis booster dose (for patients at infrequent risk of exposure)**
- **BY INTRAMUSCULAR INJECTION**
  - Child: 1 mL for 1 dose, to be given 10 years after primary course is completed, administered in deltoid region or anterolateral thigh in infants
  - Adult: 1 mL for 1 dose, to be given 10 years after primary course is completed, administered in deltoid region

**Post-exposure prophylaxis of fully immunised individuals (who have previously received pre-exposure or post-exposure prophylaxis with cell-derived rabies vaccine)**
- **BY INTRAMUSCULAR INJECTION**
  - Child (administered on expert advice): 1 mL for 1 dose, followed by 1 mL after 3–7 days for 1 dose, to be administered in deltoid region or anterolateral thigh in infants, rabies immunoglobulin is not necessary
  - Adult (administered on expert advice): 1 mL for 1 dose, followed by 1 mL after 3–7 days for 1 dose, to be administered in deltoid region, rabies immunoglobulin is not necessary

**Post-exposure treatment for unimmunised individuals (or those whose prophylaxis is possibly incomplete)**
- **BY INTRAMUSCULAR INJECTION**
  - Child (administered on expert advice): 1 mL 5 times a month for 1 month, doses should be given on days 0, 3, 7, 14, and the fifth dose is given between day 28–30, to be administered in deltoid region or anterolateral thigh in infants, depending on the level of risk (determined by factors such as the nature of the bite and the country where it was sustained), rabies immunoglobulin is given to unimmunised individuals on day 0 or within 7 days of starting the course of rabies vaccine, the immunisation course can be discontinued if it is proved that the individual was not at risk
  - Adult (administered on expert advice): 1 mL 5 times a month for 1 month, doses should be given on days 0, 3, 7, 14, and the fifth dose is given between day 28–30, to be administered in deltoid region, depending on the level of risk (determined by factors such as the nature of the bite and the country where it was sustained), rabies immunoglobulin is given to unimmunised individuals on day 0 or within 7 days of starting the course of rabies vaccine, the immunisation course can be discontinued if it is proved that the individual was not at risk

**INTERACTIONS**
- Appendix 1: rabies vaccine

**SIDE-EFFECTS**
- Paralysis

**PREGNANCY**
- Because of the potential consequences of untreated rabies exposure and because rabies vaccination has not been associated with fetal abnormalities, pregnancy is not considered a contra-indication to post-exposure prophylaxis. Immunisation against rabies is indicated during pregnancy if there is substantial risk of exposure to rabies and rapid access to post-exposure prophylaxis is likely to be limited.

**CONTRA-INDICATIONS**
- History of intussusception • predisposition to intussusception • severe combined immunosuppression

**CONTRA-INDICATIONS, FURTHER INFORMATION**
- Immunosuppression With the exception of severe combined immunodeficiency, rotavirus vaccine is not contra-indicated in immunosuppressed patients—benefit from vaccination is likely to outweigh the risk, if there is any doubt, seek specialist advice.

**CAUTIONS**
- Diarrhoea (postpone vaccination) • immunosuppressed close contacts • vomiting (postpone vaccination)

**CAUTIONS, FURTHER INFORMATION**
- The rotavirus vaccine virus is excreted in the stool and may be transmitted to close contacts; however, vaccination of those with immunosuppressed close contacts may protect the contacts from wild-type rotavirus disease and outweigh any risk from transmission of vaccine virus.

**INTERACTIONS**
- Appendix 1: live vaccines

**SIDE-EFFECTS**
- Abdominal cramps • abdominal pain • diarrhoea • nausea • vomiting

**PATIENT AND CARER ADVICE**
- The rotavirus vaccine virus is excreted in the stool and may be transmitted to close contacts; carers of a recently vaccinated baby should be advised of the need to wash their hands after changing the baby’s nappies.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.

**Powder and solvent for suspension for injection**
- **EXCIPIENTS:** May contain Neomycin
  - Rabies vaccine (Non-proprietary)
    - Rabies vaccine powder and solvent for suspension for injection 1 mL vials | 1 vial (Pst) £60.34

**Powder and solvent for solution for injection**
- **EXCIPIENTS:** May contain Neomycin
  - Rabipur (GlaxoSmithKline UK Ltd)
    - Rabipur vaccine powder and solvent for solution for injection 1 mL vials | 1 vial (Pst) £34.56

---

**Rotavirus vaccine**

**DRUG ACTION**
- Rotavirus vaccine is a live, oral vaccine that protects young children against gastro-enteritis caused by rotavirus infection.

**INDICATIONS AND DOSE**
- **Immunisation against gastro-enteritis caused by rotavirus**
  - **BY MOUTH**
    - Child 6–23 weeks: 1.5 mL for 2 doses separated by an interval of at least 4 weeks, first dose must be given between 6–14 weeks of age; course should be completed before 24 weeks of age (preferably before 16 weeks)

**CONTRA-INDICATIONS**
- History of intussusception • predisposition to intussusception • severe combined immunosuppression

**CONTRA-INDICATIONS, FURTHER INFORMATION**
- Immunosuppression With the exception of severe combined immunodeficiency, rotavirus vaccine is not contra-indicated in immunosuppressed patients—benefit from vaccination is likely to outweigh the risk, if there is any doubt, seek specialist advice.

**CAUTIONS**
- Diarrhoea (postpone vaccination) • immunosuppressed close contacts • vomiting (postpone vaccination)

**CAUTIONS, FURTHER INFORMATION**
- The rotavirus vaccine virus is excreted in the stool and may be transmitted to close contacts; however, vaccination of those with immunosuppressed close contacts may protect the contacts from wild-type rotavirus disease and outweigh any risk from transmission of vaccine virus.

**INTERACTIONS**
- Appendix 1: live vaccines

**SIDE-EFFECTS**
- Abdominal cramps • abdominal pain • diarrhoea • nausea • vomiting

**PATIENT AND CARER ADVICE**
- The rotavirus vaccine virus is excreted in the stool and may be transmitted to close contacts; carers of a recently vaccinated baby should be advised of the need to wash their hands after changing the baby’s nappies.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.

**Vaccines**
- Rotarix (GlaxoSmithKline UK Ltd)
  - Rotarix vaccine live oral suspension 1.5 mL pre-filled syringes | 1 unit dose (Pst) £34.76
Tick-borne encephalitis vaccine, inactivated

- **INDICATIONS AND DOSE**
  - Initial immunisation against tick-borne encephalitis
    - **BY INTRAMUSCULAR INJECTION**
    - Child 1-15 years: 0.25 mL for 1 dose, followed by 0.25 mL after 1–3 months for 1 dose, then 0.25 mL after further 5–12 months for 1 dose, to achieve more rapid protection, second dose may be given 14 days after first dose, dose to be administered in deltoid region or anterolateral thigh in infants, in immunocompromised patients (including those receiving immunosuppressants), antibody concentration may be measured 4 weeks after second dose and dose repeated if protective levels not achieved
    - Child 16–17 years: 0.5 mL for 1 dose, followed by 0.5 mL after 1–3 months for 1 dose, then 0.5 mL after further 5–12 months for 1 dose, to achieve more rapid protection, second dose may be given 14 days after first dose, dose to be administered in deltoid region, in immunocompromised patients (including those receiving immunosuppressants), antibody concentration may be measured 4 weeks after second dose and dose repeated if protective levels not achieved
    - Adult: 0.5 mL for 1 dose, followed by 0.5 mL after 1–3 months for 1 dose, then 0.5 mL after further 5–12 months for 1 dose, to achieve more rapid protection, second dose may be given 14 days after first dose, dose to be administered in deltoid region, antibody concentration may be measured 4 weeks after second dose and dose repeated if protective levels not achieved
    - Elderly: 0.5 mL for 1 dose, followed by 0.5 mL after 1–3 months for 1 dose, then 0.5 mL after further 5–12 months for 1 dose, to achieve more rapid protection, second dose may be given 14 days after first dose, dose to be administered in deltoid region, antibody concentration may be measured 4 weeks after second dose and dose repeated if protective levels not achieved
  - Immunisation against tick-borne encephalitis, booster doses
    - **BY INTRAMUSCULAR INJECTION**
    - Child 1-17 years: First dose to be given within 3 years after initial course completed and then every 3–5 years, dose to be administered in deltoid region or anterolateral thigh in infants (consult product literature)
    - Adult: First dose to be given within 3 years after initial course completed and then every 3–5 years, dose to be administered in deltoid region (consult product literature)

- **ALLERGY AND CROSS-SENSITIVITY** Individuals with evidence of previous anaphylactic reaction to egg should not be given tick-borne encephalitis vaccine.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Suspension for injection**
    - **EXCIPiENTS:** May contain Gentamicin, neomycin
    - **TicoVac** (Masta Ltd)
      - TicoVac Junior vaccine suspension for injection 0.25mL pre-filled syringes | 1 pre-filled disposable injection [PoS] £28.00
      - TicoVac vaccine suspension for injection 0.5mL pre-filled syringes | 1 pre-filled disposable injection [PoS] £32.00

Varicella-zoster vaccine

- **INDICATIONS AND DOSE**
  - **VARILRIX®**
    - Prevention of varicella infection (chickenpox)
      - **BY SUBCUTANEOUS INJECTION**
      - Child 1-17 years: 0.5 mL every 4–6 weeks for 2 doses, to be administered into the deltoid region or anterolateral thigh
      - Adult: 0.5 mL every 4–6 weeks for 2 doses, to be administered into the deltoid region or anterolateral thigh
    - **VARIVAX®**
      - Prevention of varicella infection (chickenpox)
        - **BY SUBCUTANEOUS INJECTION, OR BY INTRAMUSCULAR INJECTION**
        - Child 1-12 years: 0.5 mL for 2 doses, interval of at least 4 weeks between each dose, to be administered into the deltoid region (or higher anterolateral thigh in young children)
        - Child 13–17 years: 0.5 mL every 4–8 weeks for 2 doses, to be administered preferably into the deltoid region
        - Adult: 0.5 mL every 4–8 weeks for 2 doses, to be administered preferably into the deltoid region
    - **Prevention of varicella infection (chickenpox) in children with asymptomatic HIV infection**
      - **BY SUBCUTANEOUS INJECTION, OR BY INTRAMUSCULAR INJECTION**
      - Child 1-12 years: 0.5 mL every 12 weeks for 2 doses, to be administered into the deltoid region (or higher anterolateral thigh in young children)
    - **ZOSTAVAX®**
      - Prevention of herpes zoster (shingles)
        - **BY SUBCUTANEOUS INJECTION**
        - Adult 70–79 years: 0.65 mL for 1 dose, to be administered preferably into the deltoid region

- **CAUTIONS** Post-vaccination close contact with susceptible individuals

- **CAUTIONS, FURTHER INFORMATION**
  - Rarely, the varicella–zoster vaccine virus has been transmitted from the vaccinated individual to close contacts. Therefore, contact with the following should be avoided if a vaccine-related cutaneous rash develops within 4–6 weeks of the first or second dose:
    - varicella-susceptible pregnant women;
    - individuals at high risk of severe varicella, including those with immunodeficiency or those receiving immunosuppressive therapy.
  - Healthcare workers who develop a generalised papular or vesicular rash on vaccination should avoid contact with patients until the lesions have crusted. Those who develop a localised rash after vaccination should cover the lesions and be allowed to continue working unless in contact with patients at high risk of severe varicella.
  - Administration with MMR vaccine Varicella–zoster and MMR vaccines can be given on the same day or separated by a 4-week minimum interval. When protection is rapidly required, the vaccines can be given at any interval and an additional dose of the vaccine given second may be considered.

- **INTERACTIONS** → Appendix 1: live vaccines
  - **SIDE-EFFECTS**
    - Rare: Thrombocytopenia
    - Frequency not known: Conjunctivitis, varicella-like rash
  - **CONCEPTION AND CONTRACEPTION** Avoid pregnancy for 3 months after vaccination.
PRESCRIBING AND DISPENSING INFORMATION

ZOSTAVAX ®. Advice in the BNF may differ from that in product literature.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Powder and solvent for suspension for injection

EXCIPIENTS: May contain Gelatin, neomycin

VARIVAX (Merck Sharp & Dohme Ltd)
Varivax vaccine powder and solvent for suspension for injection 0.5ml vials | 1 vial (PoS) £30.28

ZOSTAVAX (Merck Sharp & Dohme Ltd)
Zostavax vaccine powder and solvent for suspension for injection 0.65ml pre-filled syringes | 1 pre-filled disposable injection (PoS) £99.96

Powder and solvent for solution for injection

EXCIPIENTS: May contain Neomycin

VARILRIX (GlaxoSmithKline UK Ltd)
Varilrix vaccine powder and solvent for solution for injection 0.5ml vials | 1 vial (PoS) £27.31

INDICATIONS AND DOSE

Immunisation against yellow fever

BY DEEP SUBCUTANEOUS INJECTION

Child 6–8 months (administered on expert advice): Infants under 9 months should be vaccinated only if the risk of yellow fever is high and unavoidable (consult product literature or local protocols)

Child 9 months–17 years: 0.5 mL for 1 dose

Adult: 0.5 mL for 1 dose

CONTRA-INDICATIONS

Children under 6 months - history of thymus dysfunction

CAUTIONS

Individuals over 60 years—greater risk of vaccine-associated adverse effects (in adults)

CAUTIONS, FURTHER INFORMATION

Administration with MMR vaccine Yellow fever and MMR vaccines should not be administered on the same day; there should be a 4-week minimum interval between the vaccines. When protection is rapidly required, the vaccines can be given at any interval and an additional dose of MMR may be considered.

INTERACTIONS

→ Appendix 1: live vaccines

SIDE-EFFECTS

Neurotropic disease - viscerotropic disease

SIDE-EFFECTS, FURTHER INFORMATION

Vaccine-associated adverse effects Very rare adverse effects, such as viscerotropic disease (yellow-fever vaccine-associated viscerotropic disease, YEL-AVD), a syndrome which may include metabolic acidosis, muscle and liver cirrhosis, and multi-organ failure. Neurological disorders (yellow fever vaccine-associated neurotropic disease, YEL-AND) such as encephalitis have also been reported. These very rare adverse effects usually occur after the first dose of yellow fever vaccine in those with no previous immunity.

ALLERGY AND CROSS-SENSITIVITY

Yellow fever vaccine should only be considered under the guidance of a specialist in individuals with evidence of previous anaphylactic reaction to egg.

PREGNANCY

Live yellow fever vaccine should not be given during pregnancy because there is a theoretical risk of fetal infection. Pregnant women should be advised not to travel to areas at high risk of yellow fever. If exposure cannot be avoided during pregnancy, then the vaccine should be given if the risk from disease in the mother outweighs the risk to the fetus from vaccination.

BREAST FEEDING

Avoid; seek specialist advice if exposure to virus cannot be avoided.
Chapter 15
Anaesthesia

General anaesthesia

Overview
Several different types of drug are given together during general anaesthesia. Anaesthesia is induced with either a volatile drug given by inhalation or with an intravenously administered drug; anaesthesia is maintained with an intravenous or inhalational anaesthetic. Analgesics, usually short-acting opioids, are also used. The use of neuromuscular blocking drugs necessitates intermittent positive-pressure ventilation. Following surgery, anticholinesterases can be given to reverse the effects of neuromuscular blocking drugs; specific antagonists can be used to reverse central and respiratory depression caused by some drugs used in surgery. A local topical anaesthetic can be used to reduce pain at the injection site.

Individual requirements vary considerably and the recommended doses are only a guide. Smaller doses are indicated in ill, shocked, or debilitated patients and in significant hepatic impairment, while robust individuals may require larger doses. The required dose of induction agent may be less if the patient has been premedicated with a sedative agent or if an opioid analgesic has been used.

Intravenous anaesthetics
Intravenous anaesthetics may be used either to induce anaesthesia or for maintenance of anaesthesia throughout surgery. Intravenous anaesthetics nearly all produce their effect in one arm-brain circulation time. Extreme care is required in surgery of the mouth, pharynx, or larynx where the airway may be difficult to maintain (e.g. in the presence of a tumour in the pharynx or larynx).

To facilitate tracheal intubation, induction is usually followed by a neuromuscular blocking drug or a short-acting opioid.

The doses of all intravenous anaesthetic drugs should be titrated to effect (except when using ‘rapid sequence induction’); lower doses may be required in premedicated patients.

Total intravenous anaesthesia
This is a technique in which major surgery is carried out with all drugs given intravenously. Respiration can be spontaneous, or controlled with oxygen-enriched air. Neuromuscular blocking drugs can be used to provide relaxation and prevent reflex muscle movements. The main problem to be overcome is the assessment of depth of anaesthesia. Target Controlled Infusion (TCI) systems can be used to titrate intravenous anaesthetic infusions to predicted plasma–drug concentrations in ventilated adult patients.

Drugs used for intravenous anaesthesia
Propofol p. 1220, the most widely used intravenous anaesthetic, can be used for induction or maintenance of anaesthesia in adults and children, but it is not commonly used in neonates. Propofol is associated with rapid recovery and less hangover effect than other intravenous anaesthetics. Propofol can also be used for sedation during diagnostic procedures and sedation in adults in intensive care.

Thiopental p. 322 is a barbiturate that is used for induction of anaesthesia, but has no analgesic properties. Induction is generally smooth and rapid, but dose-related cardiovascular and respiratory depression can occur. Awakening from a moderate dose of thiopental sodium is rapid because the drug redistributes into other tissues, particularly fat. However, metabolism is slow and sedative effects can persist for 24 hours. Repeated doses have a cumulative effect and recovery is much slower.

Etomidate p. 1220 is an intravenous agent associated with rapid recovery without a hangover effect. Etomidate causes less hypotension than thiopental sodium and propofol during induction. It produces a high incidence of extraneous muscle movements, which can be minimised by an opioid analgesic or a short-acting benzodiazepine given just before induction.

Ketamine p. 1234 is used rarely. Ketamine causes less hypotension than thiopental sodium and propofol during induction. It is used mainly for paediatric anaesthesia, particularly when repeated administration is required (such as for serial burns dressings); recovery is relatively slow and there is a high incidence of extraneous muscle movements. The main disadvantage of ketamine is the high incidence of hallucinations, nightmares, and other transient psychotic effects; these can be reduced by a benzodiazepine such as diazepam p. 327 or midazolam p. 323.

Inhalational anaesthetics
Inhalational anaesthetics include gases and volatile liquids. Gaseous anaesthetics require suitable equipment for storage and administration. Volatile liquid anaesthetics are administered using calibrated vaporisers, using air, oxygen, or nitrous oxide–oxygen mixtures as the carrier gas. To prevent hypoxia, the inspired gas mixture should contain a minimum of 25% oxygen at all times. Higher concentrations of oxygen (greater than 30%) are usually required during inhalational anaesthesia when nitrous oxide p. 1222 is being administered.
Volatile liquid anaesthetics
Volatile liquid anaesthetics can be used for induction and maintenance of anaesthesia, and following induction with an intravenous anaesthetic.

Isoflurane p. 1222 is a volatile liquid anaesthetic. Heart rhythm is generally stable during isoflurane anaesthesia, but heart-rate can rise, particularly in younger patients. Systemic arterial pressure and cardiac output can fall, owing to a decrease in systemic vascular resistance. Muscle relaxation occurs and the effects of muscle relaxant drugs are potentiated. Isoflurane is the preferred inhalational anaesthetic for use in obstetrics.

Desflurane p. 1222 is a rapid acting volatile liquid anaesthetic; it is reported to have about one-fifth the potency of isoflurane. Emergence and recovery from anaesthesia are particularly rapid because of its low solubility. Desflurane is not recommended for induction of anaesthesia as it is irritant to the upper respiratory tract.

Sevoflurane p. 1223 is a rapid acting volatile liquid anaesthetic and is more potent than desflurane. Emergence and recovery are particularly rapid, but slower than desflurane. Sevoflurane is non-irritant and is therefore often used for inhalational induction of anaesthesia; it has little effect on heart rhythm compared with other volatile liquid anaesthetics.

Nitrous oxide
Nitrous oxide is used for maintenance of anaesthesia and, in sub-anaesthetic concentrations, for analgesia. For anaesthesia, nitrous oxide is commonly used in a concentration of 50 to 66% in oxygen as part of a balanced technique in association with other inhalational or intravenous agents. Nitrous oxide is unsatisfactory as a sole anaesthetic owing to lack of potency, but is useful as part of a combination of drugs since it allows a significant reduction in dosage.

For analgesia (without loss of consciousness), a mixture of nitrous oxide and oxygen containing 50% of each gas (Entonox®, Equanox®) is used. Self-administration using a demand valve is popular in obstetric practice, for changing painful dressings, as an aid to postoperative physiotherapy, and in emergency ambulances.

Nitrous oxide may have a deleterious effect if used in patients with an air-containing closed space since nitrous oxide diffuses into such a space with a resulting increase in pressure. This effect may be dangerous in conditions such as pneumothorax, which may enlarge to compromise respiration, or in the presence of intracranial air after head injury, entrapped air following recent underwater dive, or recent intra-ocular gas injection.

Malignant hyperthermia
Malignant hyperthermia is a rare but potentially lethal complication of anaesthesia. It is characterised by a rapid rise in temperature, increased muscle rigidity, tachycardia, and acidosis. The most common triggers of malignant hyperthermia are the volatile anaesthetics. Suxamethonium chloride p. 1226 has also been implicated, but malignant hyperthermia is more likely if it is given following a volatile anaesthetic. Volatile anaesthetics and suxamethonium chloride should be avoided during anaesthesia in patients at high risk of malignant hyperthermia.

Dantrolene sodium p. 1236 is used in the treatment of malignant hyperthermia.

Sedation, anaesthesia, and resuscitation in dental practice
Overview
Sedation for dental procedures should be limited to conscious sedation. Diazepam p. 327 and temazepam p. 463 are effective anxiolytics for dental treatment in adults.

For details of sedation, anaesthesia, and resuscitation in dental practice see A Conscious Decision: A review of the use of general anaesthesia and conscious sedation in primary dental care; report by a group chaired by the Chief Medical Officer and Chief Dental Officer, July 2000 and associated documents. Further details can also be found in Standards for Conscious Sedation in the Provision of Dental Care; report of an Intercollegiate Advisory Committee for Sedation in Dentistry, 2015 www.rcseng.ac.uk/library-and-publications/college-publications/docs/dental-sedation-report.

Surgery and long-term medication
Overview
The risk of losing disease control on stopping long-term medication before surgery is often greater than the risk posed by continuing it during surgery. It is vital that the anaesthetist knows about all drugs that a patient is (or has been) taking.

Patients with adrenal atrophy resulting from long-term corticosteroid use may suffer a precipitous fall in blood pressure unless corticosteroid cover is provided during anaesthesia and in the immediate postoperative period.

Anaesthetists must therefore know whether a patient is, or has been, receiving corticosteroids (including high-dose inhaled corticosteroids).

Other drugs that should normally not be stopped before surgery include antiepileptics, antiparkinsonian drugs, antipsychotics, anxiolytics, bronchodilators, cardiovascular drugs (but see potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, and angiotensin–II receptor antagonists), glaucoma drugs, immunosuppressants, drugs of dependence, and thyroid or antithyroid drugs. Expert advice is required for patients receiving antivirals for HIV infection. See general advice on surgery in diabetic patients in Diabetes, surgery and medical illness p. 649.

Patients taking antiplatelet medication or an oral anticoagulant present an increased risk for surgery. In these circumstances, the anaesthetist and surgeon should assess the relative risks and decide jointly whether the antiplatelet or the anticoagulant drug should be stopped or replaced with heparin (unfractionated) p. 128 or low molecular weight heparin therapy.

Drugs that should be stopped before surgery include combined oral contraceptives, see Contraceptives, hormonal p. 745; for advice on hormone replacement therapy, see Sex hormones p. 707. MAOIs can have important interactions with some drugs used during surgery, such as pethidine hydrochloride p. 445. Tricyclic antidepressants need not be stopped, but there may be an increased risk of arrhythmias and hypotension (and dangerous interactions with vasopressor drugs); therefore, the anaesthetist should be informed if they are not stopped. Lithium should be stopped 24 hours before major surgery but the normal dose can be continued for minor surgery (with careful monitoring of fluids and electrolytes). Potassium-sparing diuretics may need to be withheld on the morning of surgery because hyperkalaemia may develop if renal perfusion is impaired or if there is tissue damage. Angiotensin–converting enzyme (ACE) inhibitors and angiotensin–II receptor antagonists can be associated with severe hypotension after induction of anaesthesia; these drugs may need to be discontinued.
24 hours before surgery. Herbal medicines may be associated with adverse effects when given with anaesthetic drugs and consideration should be given to stopping them before surgery.

ANAESTHETICS, GENERAL › INTRAVENOUS ANAESTHETICS

Etomidate

- INDICATIONS AND DOSE
  - Induction of anaesthesia
    - BY SLOW INTRAVENOUS INJECTION
      - Adult: 150–300 micrograms/kg (max. per dose 60 mg), to be administered over 30–60 seconds (60 seconds in patients in whom hypotension might be hazardous)
      - Elderly: 150–200 micrograms/kg (max. per dose 60 mg), to be administered over 30–60 seconds (60 seconds in patients in whom hypotension might be hazardous)

IMPORTANT SAFETY INFORMATION
Etomidate should only be administered by, or under the direct supervision of, personnel experienced in its use, with adequate training in anaesthesia and airway management, and when resuscitation equipment is available.

- CAUTIONS
  - Acute circulatory failure (shock)
  - Acute porphyrias
  - 969 (avoid)
  - Adrenal insufficiency
  - Cardiovascular disease
  - Elderly
  - Fixed cardiac output
  - Hypervolaemia

CAUTIONS, FURTHER INFORMATION
- Adrenal insufficiency
  - Etomidate suppresses adrenocortical function, particularly during continuous administration, and it should not be used for maintenance of anaesthesia. It should be used with caution in patients with underlying adrenal insufficiency, for example, those with sepsis.

- INTERACTIONS
  - Appendix 1: etomidate

- SIDE-EFFECTS
  - Common or very common
    - Apnoea
    - Hyperventilation
    - Hypotension
    - Nausea
    - Rash
    - Stridor
    - Vomiting
  - Uncommon
    - Arrhythmias
    - Cough
    - Hiccups
    - Hypersalivation
    - Hypertension
    - Phlebitis
  - Frequency not known
    - AV block
    - Cardiac arrest
    - Extraneous muscle movement (high incidence)
    - Pain on injection
    - Respiratory depression
    - Seizures
    - Shivering
    - Stevens-Johnson syndrome

SIDE-EFFECTS, FURTHER INFORMATION
- Pain on injection
  - Can be reduced by injecting into a larger vein or by giving an opioid analgesic just before induction.
- Extraneous muscle movement
  - Extraneous muscle movements can be minimised by an opioid analgesic or a short-acting benzodiazepine given just before induction.
- PREGNANCY
  - May depress neonatal respiration if used during delivery.

- BREAST FEEDING
  - Breast-feeding can be resumed as soon as mother has recovered sufficiently from anaesthesia.

- HEPATIC IMPAIRMENT
  - Reduce dose in liver cirrhosis.

- DIRECTIONS FOR ADMINISTRATION
  - To be administered over 30–60 seconds (60 seconds in patients in whom hypotension might be hazardous).

- PATIENT AND CARER ADVICE
  - Driving and skilled tasks
    - Patients given sedatives and analgesics during minor outpatient procedures should be very carefully warned about the risk of driving or undertaking skilled tasks afterwards. For a short general anaesthetic the risk extends to at least 24 hours after administration. Responsible persons should be available to take patients home. The dangers of taking alcohol should also be emphasised.

MEDICINAL FORMS
- There can be variation in the licensing of different medicines containing the same drug.

Solution for injection
- EXCIPIENTS: May contain Propylene glycol
  - Hypnomidate (Janssen-Cilag Ltd)
    - Etomidate 2 mg per 1 ml
      - Hypnomidate 20mg/10ml solution for injection ampoules | 5 ampoule £0.60
  - Emulsion for injection
    - Etomidate-Lipuro (B.Braun Medical Ltd)
      - Etomidate 2 mg per 1 ml
        - Etomidate-Lipuro 20mg/10ml emulsion for injection ampoules | 10 ampoule £0.62

Propofol

- INDICATIONS AND DOSE
  - Induction of anaesthesia using 0.5% or 1% injection
    - BY SLOW INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION
      - Adult 18–54 years: Usual dose 1.5–2.5 mg/kg, to be administered at a rate of 20–40 mg every 10 seconds until response, for debilitated patients use dose for 55 years and over
      - Adult 55 years and over: Usual dose 1–1.5 mg/kg, to be administered at a rate of 20 mg every 10 seconds until response
  - Induction of anaesthesia using 2% injection
    - BY INTRAVENOUS INFUSION
      - Adult 18–54 years: Usual dose 1.5–2.5 mg/kg, to be administered at a rate of 20–40 mg every 10 seconds until response. For debilitated patients use dose for 55 years and over
      - Adult 55 years and over: Usual dose 1–1.5 mg/kg, to be administered at a rate of 20 mg every 10 seconds until response
  - Maintenance of anaesthesia using 1% injection
    - INITIALLY BY INTRAVENOUS INFUSION
      - Adult: Usual dose 4–12 mg/kg/hour, alternatively (by slow intravenous injection) 25–50 mg, dose may be repeated according to response, for debilitated patients use dose for elderly
      - Elderly: Usual dose 3–6 mg/kg/hour, alternatively (by slow intravenous injection) 25–50 mg, dose may be repeated according to response
  - Maintenance of anaesthesia using 2% injection
    - BY INTRAVENOUS INFUSION
      - Adult: Usual dose 4–12 mg/kg/hour, for debilitated patients use dose for elderly
      - Elderly: Usual dose 3–6 mg/kg/hour
  - Sedation of ventilated patients in intensive care using 1% or 2% injection
    - BY CONTINUOUS INTRAVENOUS INFUSION
      - Adult: Usual dose 0.3–4 mg/kg/hour, adjusted according to response
  - Induction of sedation for surgical and diagnostic procedures using 0.5% or 1% injection
    - BY SLOW INTRAVENOUS INJECTION
      - Adult: Initially 0.5–1 mg/kg, to be administered over 1–5 minutes, dose and rate of administration adjusted according to desired level of sedation and response
  - Maintenance of sedation for surgical and diagnostic procedures using 0.5% injection
    - INITIALLY BY INTRAVENOUS INFUSION
      - Adult: Initially 1.5–4.5 mg/kg/hour, dose and rate of administration adjusted according to desired level of sedation and response, followed by (by slow intravenous injection) 10–20 mg, (if rapid increase in
sedation required), patients over 55 years or debilitated may require lower initial dose and rate of administration

**Maintenance of sedation for surgical and diagnostic procedures using 1% injection**

- **INITIALLY BY INTRAVENOUS INFUSION**
- **Adult:** Initially 1.5–4.5 mg/kg/hour, dose and rate of administration adjusted according to desired level of sedation and response, followed by (by slow intravenous injection) 10–20 mg, (if rapid increase in sedation required), patients over 55 years or debilitated may require lower initial dose and rate of administration

**Maintenance of sedation for surgical and diagnostic procedures using 2% injection**

- **INITIALLY BY INTRAVENOUS INFUSION**
- **Adult:** Initially 1.5–4.5 mg/kg/hour, dose and rate of administration adjusted according to desired level of sedation and response, followed by (by slow intravenous injection) 10–20 mg, using 0.5% or 1% injection (if rapid increase in sedation required), patients over 55 years or debilitated may require lower initial dose and rate of administration

**IMPORTANT SAFETY INFORMATION**

Propofol should only be administered by, or under the direct supervision of, personnel experienced in its use, with adequate training in anaesthesia and airway management, and when resuscitation equipment is available.

- **CAUTIONS**
  - Acute circulatory failure (shock)
  - Cardiac impairment
  - Cardiovascular disease
  - Elderly
  - Epilepsy
  - Fixed cardiac output
  - Hypotension
  - Hypovolaemia
  - Raised intracranial pressure
  - Respiratory impairment

- **INTERACTIONS** → Appendix 1: propofol

- **SIDE-EFFECTS**
  - **Common or very common**
    - Headache
    - Hypotension
    - Tachycardia
    - Transient apnoea
  - **Uncommon**
    - Phlebitis
    - Thrombosis
  - **Rare**
    - Anaphylaxis
    - Arrhythmia
    - Convulsions (onset can be delayed)
    - Delayed recovery from anaesthesia
    - Euphoria
    - Discoloration of urine
    - Pancreatitis
    - Pulmonary oedema
    - Sexual disinhibition
  - **Frequency not known**
    - Bradycardia
    - Pain on intravenous injection
    - Propofol infusion syndrome
    - Significant extraneous muscle movements

**SIDE-EFFECTS, FURTHER INFORMATION**

- Bradycardia
  - Bardycardia may be profound and may be treated with intravenous administration of an antimuscarinic drug.
- Extraneous muscle movement
  - Extraneous muscle movements can be minimised by an opioid analgesic or a short-acting benzodiazepine given just before induction.
- Pain on injection
  - Can be reduced by intravenous lidocaine.
- Propofol infusion syndrome
  - Prolonged infusion of propofol doses exceeding 4 mg/kg/hour may result in potentially fatal effects, including metabolic acidosis, arrhythmias, cardiac failure, rhabdomyolysis, hyperlipidaemia, hyperkalaemia, hepatomegaly, and renal failure.

- **PREGNANCY**
  - Max. dose for maintenance of anaesthesia
  - 6 mg/kg/hour. May depress neonatal respiration if used during delivery.

- **BREAST FEEDING**
  - Breast-feeding can be resumed as soon as mother has recovered sufficiently from anaesthesia.

- **HEPATIC IMPAIRMENT**
  - Use with caution.

- **RENAL IMPAIRMENT**
  - Use with caution.

- **MONITORING REQUIREMENTS**
  - Monitor blood-lipid concentration if risk of fat overload or if sedation longer than 3 days.

- **DIRECTIONS FOR ADMINISTRATION**
  - Shake before use; microbiological filter not recommended; may be administered via a Y-piece close to injection site co-administered with Glucose 5% or Sodium chloride 0.9%.
  - 0.5% emulsion for injection or intermittent infusion; may be administered undiluted, or diluted with Glucose 5% (Diprivan®) or (Propofol-Lipuro®) or Sodium chloride 0.9% (Propofol-Lipuro® only); dilute to a concentration not less than 1 mg/mL. 1% emulsion for injection or infusion; may be administered undiluted, or diluted with Glucose 5% (Diprivan®) or (Propofol-Lipuro®) or Sodium chloride 0.9% (Propofol-Lipuro® only); dilute to a concentration not less than 2 mg/mL; use within 6 hours of preparation. 2% emulsion for infusion; do not dilute.

- **PATIENT AND CARER ADVICE**
  - Driving and skilled tasks
  - Patients given sedatives and analgesics during minor outpatient procedures should be very carefully warned about the risk of driving or undertaking skilled tasks afterwards. For a short general anaesthetic the risk extends to at least 24 hours after administration. Responsible persons should be available to take patients home. The dangers of taking alcohol should also be emphasised.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

**Emulsion for infusion**

- **Propofol-Lipuro®** (B.Braun Melsungen AG)
  - **Propofol 10 mg per 1 ml**
    - Propofol-Lipuro 1% emulsion for infusion 50ml ampoules £10.68 (Hospital only)
  - **Diprivan®**
    - (Aspen Pharma Trading Ltd)
  - **Propofol 10 mg per 1 ml**
    - Diprivan 1% emulsion for infusion 50ml pre-filled syringes £15.16
  - **Propofol 20 mg per 1 ml**
    - Diprivan 2% emulsion for infusion 50ml pre-filled syringes £15.16

**Emulsion for injection**

- **Diprivan®**
  - (Aspen Pharma Trading Ltd)
  - **Propofol 10 mg per 1 ml**
    - Diprivan 1% emulsion for injection 20ml ampoules £15.36 (Hospital only)
  - **Propofol-Lipuro®**
    - (B.Braun Melsungen AG)
  - **Propofol 5 mg per 1 ml**
    - Propofol-Lipuro 0.5% emulsion for injection 20ml ampoules £14.71

**ANAESTHETICS, GENERAL › VOLATILE LIQUID ANAESTHETICS**

Volatile halogenated anaesthetics

**IMPORTANT SAFETY INFORMATION**

Should only be administered by, or under the direct supervision of, personnel experienced in their use, with adequate training in anaesthesia and airway management, and when resuscitation equipment is available.

- **CONTRA-INDICATIONS**
  - Susceptibility to malignant hyperthermia

- **CAUTIONS**
  - Can trigger malignant hyperthermia - raised intracranial pressure (can increase cerebrospinal pressure)

- **SIDE-EFFECTS**
  - **Common or very common**
    - Arrhythmias
    - Cardiorespiratory depression
    - Hypotension
  - **Frequency not known**
    - Convulsions

- **ALLERGY AND CROSS-SENSITIVITY**
  - Can cause hepatotoxicity in those sensitised to halogenated anaesthetics.

- **DIRECTIONS FOR ADMINISTRATION**
  - Volatile liquid anaesthetics are administered using calibrated vaporisers, using air, oxygen, or nitrous oxide- oxygen mixtures as the
carrier gas. To prevent hypoxia, the inspired gas mixture should contain a minimum of 25% oxygen at all times.

**PATIENT AND CARER ADVICE**

Driving and skilled tasks
Patients given sedatives and analgesics during minor outpatient procedures should be very carefully warned about the risks of driving or undertaking skilled tasks afterwards. For a short general anaesthetic, the risk extends to at least 24 hours after administration. Responsible persons should be available to take patients home. The dangers of taking alcohol should also be emphasised.

### Desflurane

**INDICATIONS AND DOSE**

Induction of anaesthesia (but not recommended)
- **BY INHALATION**
  - Adult: 4–11%, to be inhaled through specifically calibrated vaporiser

Maintenance of anaesthesia (in nitrous oxide–oxygen)
- **BY INHALATION**
  - Adult: 2–6%, to be inhaled through a specifically calibrated vaporiser

Maintenance of anaesthesia (in oxygen or oxygen-enriched air)
- **BY INHALATION**
  - Adult: 2.5–8.5%, to be inhaled through a specifically calibrated vaporiser

**INTERACTIONS** → Appendix 1: volatile halogenated anaesthetics

**SIDE-EFFECTS**
- Apnoea, breath-holding, cough, increased secretions, laryngospasm

**PREGNANCY**
- May depress neonatal respiration if used during delivery.

**BREAST FEEDING**
- Breast-feeding can be resumed as soon as mother has recovered sufficiently from anaesthesia.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.

**Inhalation vapour**
- **Desflurane (Non-proprietary)**
  - Desflurane 1 ml per 1 ml | 240 ml
  - No price available (Hospital only)

**Nitrous oxide**

**INDICATIONS AND DOSE**

Maintenance of anaesthesia in conjunction with other anaesthetic agents
- **BY INHALATION**
  - Adult: 50–66%, to be administered using suitable anaesthetic apparatus in oxygen

Analgesia
- **BY INHALATION**
  - Adult: Up to 50%, to be administered using suitable anaesthetic apparatus in oxygen, adjusted according to the patient’s needs

**IMPORTANT SAFETY INFORMATION**

Nitrous oxide should only be administered by, or under the direct supervision of, personnel experienced in its use, with adequate training in anaesthesia and airway management, and when resuscitation equipment is available.

**CAUTIONS**
- Entrapped air following recent underwater dive
- Pneumothorax
- Presence of intracranial air after head injury
- Recent intra–ocular gas injection

**FURTHER INFORMATION**
- Nitrous oxide may have a deleterious effect if used in patients with an air-containing closed space since nitrous oxide diffuses into such a space with a resulting increase in pressure. This effect may be dangerous in conditions such as pneumothorax, which may enlarge to compromise respiration, or in the presence of intracranial air after head injury, entrapped air following recent underwater dive, or recent intra–ocular gas injection.

**INTERACTIONS** → Appendix 1: volatile halogenated anaesthetics

**SIDE-EFFECTS**
- Depresssion of white cell formation
- Megaloblastic anaemia

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.

**Inhalation vapour**
- **Isoflurane (Non-proprietary)**
  - Isoflurane 1 ml per 1 ml | 250 ml
  - Isoflurane volatile liquid | 250 ml
  - No price available (Hospital only)

**Isoflurane**

**INDICATIONS AND DOSE**

Induction of anaesthesia (in oxygen or nitrous oxide–oxygen)
- **BY INHALATION**
  - Adult: Initially 0.5%, increased to 3%, adjusted according to response, administered using specifically calibrated vaporiser

Maintenance of anaesthesia (in nitrous oxide–oxygen)
- **BY INHALATION**
  - Adult: 1–2.5%, to be administered using specifically calibrated vaporiser; an additional 0.5–1% may be required when given with oxygen alone

Maintenance of anaesthesia in caesarean section (in nitrous oxide–oxygen)
- **BY INHALATION**
  - Adult: 0.5–0.75%, to be administered using specifically calibrated vaporiser

**INTERACTIONS** → Appendix 1: volatile halogenated anaesthetics

**SIDE-EFFECTS**
- Breath-holding, cough, irritate mucous membrane, laryngospasm

**PREGNANCY**
- May depress neonatal respiration if used during delivery.

**IMMEDIATE SAFETY INFORMATION**

Nitrous oxide may cause immediate apnoea in the presence of intracranial air following recent underwater dive, or recent intra–ocular gas injection.

**CAUTIONS**
- Entrained air following recent underwater dive
- Pneumothorax
- Presence of intracranial air after head injury
- Recent intra–ocular gas injection

**FURTHER INFORMATION**
- Nitrous oxide may have a deleterious effect if used in patients with an air-containing closed space since nitrous oxide diffuses into such a space with a resulting increase in pressure. This effect may be dangerous in conditions such as pneumothorax, which may enlarge to compromise respiration, or in the presence of intracranial air after head injury, entrapped air following recent underwater dive, or recent intra–ocular gas injection.

**INTERACTIONS** → Appendix 1: volatile halogenated anaesthetics

**SIDE-EFFECTS**
- Depresssion of white cell formation
- Megaloblastic anaemia
- Neurological toxic effects

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug.

**Inhalation vapour**
- **Isoflurane (Non-proprietary)**
  - Isoflurane 1 ml per 1 ml | 250 ml
  - Isoflurane volatile liquid | 250 ml
  - No price available (Hospital only)

**Anesthesia**

**MEDICINE FORMS**
- There can be variation in the licensing of different medicines containing the same drug.

**Inhalation vapour**
- **Isoflurane (Non-proprietary)**
  - Isoflurane 1 ml per 1 ml | 250 ml
  - Isoflurane volatile liquid | 250 ml
  - No price available (Hospital only)

**Nitrous oxide**

**INDICATIONS AND DOSE**

Maintenance of anaesthesia in conjunction with other anaesthetic agents
- **BY INHALATION**
  - Adult: 50–66%, to be administered using suitable anaesthetic apparatus in oxygen

Analgesia
- **BY INHALATION**
  - Adult: Up to 50%, to be administered using suitable anaesthetic apparatus in oxygen, adjusted according to the patient’s needs

**IMPORTANT SAFETY INFORMATION**

Nitrous oxide should only be administered by, or under the direct supervision of, personnel experienced in its use, with adequate training in anaesthesia and airway management, and when resuscitation equipment is available.

**CAUTIONS**
- Entrapped air following recent underwater dive
- Pneumothorax
- Presence of intracranial air after head injury
- Recent intra–ocular gas injection

**FURTHER INFORMATION**
- Nitrous oxide may have a deleterious effect if used in patients with an air-containing closed space since nitrous oxide diffuses into such a space with a resulting increase in pressure. This effect may be dangerous in conditions such as pneumothorax, which may enlarge to compromise respiration, or in the presence of intracranial air after head injury, entrapped air following recent underwater dive, or recent intra–ocular gas injection.

**INTERACTIONS** → Appendix 1: volatile halogenated anaesthetics

**SIDE-EFFECTS**
- Depression of white cell formation
- Megaloblastic anaemia
- Neurological toxic effects
Breast-feeding can be resumed as soon as mother has recovered sufficiently from anaesthesia.

**Monitoring requirements**
- Assessment of plasma-vitamin B₁₂ concentration should be considered in those at risk of deficiency, including the elderly, those who have a poor, vegetarian, or vegan diet, and those with a history of anaemia.
- Nitrous oxide should not be given continuously for longer than 24 hours or more frequently than every 4 days without close supervision and haemato logical monitoring.

**Directions for administration**
For analgesia (without loss of consciousness), a mixture of nitrous oxide and oxygen containing 50% of each gas (Entonox®, Equanox®) is used.

**Handling and storage**
Exposure of theatre staff to nitrous oxide should be minimised (risk of serious side-effects).

**Medicinal forms**
- There can be variation in the licensing of different medicines containing the same drug.

**Inhalation gas**
- Nitrous oxide (Non-proprietary)
  - Nitrous oxide 1 ml per 1 ml Nitrous oxide cylinders size E (1800 litre) no price available
  - Medical Nitrous Oxide cylinders size D (900 litre) no price available
  - Medical Nitrous Oxide cylinders size G (9000 litre) no price available
  - Nitrous oxide cylinders size F (3600 litre) no price available
  - Nitrous oxide cylinders size J (18000 litre) no price available
  - Nitrous oxide cylinders size G (9000 litre) no price available
  - Medical Nitrous Oxide cylinders size G (9000 litre) no price available
  - Nitrous oxide cylinders size D (900 litre) no price available
  - Medical Nitrous Oxide cylinders size E (1800 litre) no price available

**Sevoflurane**

**Indications and dose**
- **Induction of anaesthesia (in oxygen or nitrous oxide-oxygen)**
  - **By inhalation**
    - Adult: Initially 0.5–1%, then increased to up to 8%, increased gradually, according to response, to be administered using specifically calibrated vaporiser
- **Maintenance of anaesthesia (in oxygen or nitrous oxide-oxygen)**
  - **By inhalation**
    - Adult: 0.5–3%, adjusted according to response, to be administered using specifically calibrated vaporiser

**Cautions**
- Susceptibility to QT-interval prolongation

**Interactions**
- Appendix 1: volatile halogenated anaesthetics

**Side-effects**
- Cardiac arrest • dystonia • leucopenia • torsade de pointes • urinary retention

**Pregnancy**
- May depress neonatal respiration if used during delivery.

**Breast-feeding**
- Breast-feeding can be resumed as soon as mother has recovered sufficiently from anaesthesia.

**Renal impairment**
- Use with caution.

**Medicinal forms**
- There can be variation in the licensing of different medicines containing the same drug.

**Inhalation vapour**
- Sevoflurane (Non-proprietary)
  - Sevoflurane 1 ml per 1 ml Sevoflurane volatile liquid | 250 ml POM £123.00 (Hospital only)

---

**1 Anaesthesia adjuvants**

**Pre-medication and peri-operative drugs**

**Drugs that affect gastric pH**
Regurgitation and aspiration of gastric contents (Mendelson’s syndrome) can be an important complication of general anaesthesia, particularly in obstetrics and during emergency surgery, and requires prophylaxis against acid aspiration. Prophylaxis is also needed in those with gastro-oesophageal reflux disease and in circumstances where gastric emptying may be delayed.

A H₂-receptor antagonist can be used before surgery to increase the pH and reduce the volume of gastric fluid. It does not affect the pH of fluid already in the stomach and this limits its value in emergency procedures; an oral H₂-receptor antagonist can be given 1–2 hours before the procedure. Antacids are frequently used to neutralise the acidity of the fluid already in the stomach; ‘clear’ (non-particulate) antacids such as sodium citrate p. 743 are preferred.

**Antimuscarinic drugs**
Antimuscarinic drugs are used (less commonly nowadays) as premedicants to dry bronchial and salivary secretions which are increased by intubation, upper airway surgery, or some inhalational anaesthetics. They are also used before or with neostigmine p. 1024 to prevent bradycardia, excessive salivation, and other muscarinic actions of neostigmine. They also prevent bradycardia and hypotension associated with drugs such as propofol p. 1220 and suxamethonium chloride p. 1226.

Atropine sulphate p. 1224 is now rarely used for premedication but still has an emergency role in the treatment of vagotonic side-effects. Atropine sulphate may have a role in acute arrhythmias after myocardial infarction.

Hyoscyamine sulphate p. 417 reduces secretions and also provides a degree of amnesia, sedation, and anti-emesis. Unlike atropine sulphate it may produce bradycardia rather than tachycardia.

Oxymetazoline p. 1225 reduces salivary secretions. When given intravenously it produces less tachycardia than atropine sulphate. It is widely used with neostigmine for reversal of non-depolarising neuromuscular blocking drugs.

**Phenothiazines** do not effectively reduce secretions when used alone.

**Sedative drugs**
Fear and anxiety before a procedure (including the night before) can be minimised by using a sedative drug, usually a benzodiazepine. Premedication may also augment the action of anaesthetics and provide some degree of pre-operative amnesia. The choice of drug depends on the individual, the nature of the procedure, the anaesthetic to be used, and other prevailing circumstances such as outpatients, obstetrics, and availability of recovery facilities. The choice also varies between elective and emergency procedures.

Premedics can be given the night before major surgery; a further, smaller dose may be required before surgery. Alternatively, the first dose may be given on the day of the procedure.

**Benzodiazepines**
Benzodiazepines possess useful properties for premedication including relief of anxiety, sedation, and amnesia; short-acting benzodiazepines taken by mouth are the most common premedicants. Benzodiazepines are also used in...
intensive care units for sedation, particularly in those receiving assisted ventilation. Flumazenil p. 1258 is used to antagonise the effects of benzodiazepines.

Diazepam p. 327 is used to produce mild sedation with amnesia. It is a long-acting drug with active metabolites and a second period of drowsiness can occur several hours after its administration. Peri-operative use of diazepam in children is not recommended; its effect and timing of response are unreliable and paradoxical effects may occur.

Diazepam is relatively insoluble in water and preparations formulated in organic solvents are painful on intravenous injection and give rise to a high incidence of venous thrombosis (which may not be noticed for several days after the injection). Intramuscular injection of diazepam is painful and absorption is erratic. An emulsion formulated for intravenous injection is less irritant and reduces the risk of venous thrombosis; it is not suitable for intramuscular injection.

Temazepam p. 463 is given by mouth for premedication and has a shorter duration of action and a more rapid onset than oral diazepam; anxiolytic and sedative effects last about 90 minutes although there may be residual drowsiness.

Lorazepam p. 322 produces more prolonged sedation than temazepam and it has marked amnesic effects.

Midazolam p. 323 is a water-soluble benzodiazepine that is often used in preference to intravenous diazepam; recovery is faster than from diazepam, but may be significantly longer in the elderly, in patients with a low cardiac output, or after repeated dosing. Midazolam is associated with profound sedation when high doses are given intravenously or when it is used with certain other drugs.

Other drugs for sedation
Dexmedetomidine p. 1235 and clonidine hydrochloride p. 139 are alpha₂-adrenergic agonists with sedative properties. Dexmedetomidine is licensed for the sedation of patients receiving intensive care who need to remain responsive to verbal stimulation. Clonidine hydrochloride [unlicensed indication] can be used by mouth or by intravenous injection as a sedative agent when adequate sedation cannot be achieved with standard treatment.

Antagonists for central and respiratory depression
Respiratory depression is a major concern with opioid analgesics and it may be treated by artificial ventilation or be reversed by naloxone hydrochloride p. 1259. Naloxone hydrochloride will immediately reverse opioid-induced respiratory depression but the dose may have to be repeated because of the short duration of action of naloxone hydrochloride; however, naloxone hydrochloride will also antagonise the analgesic effect.

Flumazenil is a benzodiazepine antagonist for the reversal of the central sedative effects of benzodiazepines after anaesthetic and similar procedures. Flumazenil has a shorter half-life and duration of action than diazepam or midazolam so patients may become reasated.

Doxapram hydrochloride p. 286 is a central and respiratory stimulant but is of limited value in anaesthesia.

ANTIMUSCARINICS

Atropine sulfate

- INDICATIONS AND DOSE
  Bradydrysma due to acute massive overdosage of beta-blockers
  - BY INTRAVENOUS INJECTION
    - Child: 40 micrograms/kg (max. per dose 3 mg)
    - Adult: 3 mg

Treatment of poisoning by organophosphorus insecticide or nerve agent (in combination with pralidoxime chloride)
- BY INTRAVENOUS INJECTION
  - Child: 20 micrograms/kg every 5–10 minutes (max. per dose 2 mg) until the skin becomes flushed and dry, the pupils dilate, and bradycardia is abolished, frequency of administration dependent on the severity of poisoning
  - Adult: 2 mg every 5–10 minutes until the skin becomes flushed and dry, the pupils dilate, and bradycardia is abolished, frequency of administration dependent on the severity of poisoning

Symptomatic relief of gastro-intestinal disorders characterised by smooth muscle spasm
- BY MOUTH
  - Adult: 0.6–1.2 mg daily, dose to be taken at night

Premedication
- BY INTRAVENOUS INJECTION
  - Child 12–17 years: 300–600 micrograms, to be administered immediately before induction of anaesthesia
  - Adult: 300–600 micrograms, to be administered immediately before induction of anaesthesia

Intra-operative bradycardia
- BY INTRAVENOUS INJECTION
  - Child 12–17 years: 300–600 micrograms, larger doses may be used in emergencies
  - Adult: 300–600 micrograms, larger doses may be used in emergencies

Control of muscarinic side-effects of neostigmine in reversal of competitive neuromuscular block
- BY INTRAVENOUS INJECTION
  - Child 12–17 years: 0.6–1.2 mg
  - Adult: 0.6–1.2 mg

Excessive bradycardia associated with beta-blocker use
- BY INTRAVENOUS INJECTION
  - Adult: 0.6–2.4 mg in divided doses (max. per dose 600 micrograms)

Bradycardia following myocardial infarction (particularly if complicated by hypotension)
- BY INTRAVENOUS INJECTION
  - Adult: 500 micrograms every 3–5 minutes; maximum 3 mg per course

UNLICENSED USE Not licensed for use in children under 12 years for intra-operative bradycardia or by intravenous route for premedication.

IMPORTANT SAFETY INFORMATION
Antimuscarinic drugs used for premedication to general anaesthesia should only be administered by, or under the direct supervision of, personnel experienced in their use.

- INTERACTIONS → Appendix 1: atropine
- PREGNANCY Not known to be harmful; manufacturer advises caution.
- BREAST FEEDING May suppress lactation; small amount present in milk—manufacturer advises caution.
- MONITORING REQUIREMENTS
  - Control of muscarinic side-effects of neostigmine in reversal of competitive neuromuscular block. Since atropine has a shorter duration of action than neostigmine, late unopposed...
bradycardia may result; close monitoring of the patient is necessary.

- **LESS SUITABLE FOR PRESCRIBING** Atropine tablets less suitable for prescribing. Any clinical benefit as a gastrointestinal antispasmodic is outweighed by atropinic side-effects.

- **EXCEPTIONS TO LEGAL CATEGORY** Prescription only medicine restriction does not apply where administration is for saving life in emergency.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution, solution for injection, solution for infusion

  **Tablet**
  - **Atropine sulfate (Non-proprietary)**
    - Atropine sulfate 600 microgram | Atropine 600microgram tablets | 28 tablet | £52.92 DT price = £49.53
  - **Solution for injection**
    - **Atropine sulfate (Non-proprietary)**
      - Atropine sulfate 100 microgram per 1 ml | Atropine 500micrograms/5ml solution for injection pre-filled syringes | 1 pre-filled disposable injection | £7.40–£13.00 | 10 pre-filled disposable injection | £60.00–£130.00
      - Atropine sulfate 200 microgram per 1 ml | Atropine 1mg/5ml solution for injection pre-filled syringes | 1 pre-filled disposable injection | £7.08–£13.00 | 10 pre-filled disposable injection | £130.00
      - Atropine sulfate 300 microgram per 1 ml | Atropine 3mg/10ml solution for injection pre-filled syringes | 1 pre-filled disposable injection | £130.00
      - Atropine sulfate 400 microgram per 1 ml | Atropine 400micrograms/1ml solution for injection ampoules | 10 ampoule | £80.48–£82.22 DT price = £75.11
      - Atropine sulfate 600 microgram per 1 ml | Atropine 600micrograms/1ml solution for injection ampoules | 10 ampoule | £11.71 DT price = £11.70
    - Atropine sulfate 1 mg per 1 ml | Atropine 1mg/1ml solution for injection ampoules | 10 ampoule | £74.29–£75.98 DT price = £73.03

### Glycopyrronium bromide

(Glycopyrronium)

#### 1.1 Neuromuscular blockade

**Neuromuscular blocking drugs**

Neuromuscular blocking drugs used in anaesthesia are also known as **muscle relaxants**. By specific blockade of the neuromuscular junction they enable light anaesthesia to be used with adequate relaxation of the muscles of the abdomen and diaphragm. They also relax the vocal cords and allow the passage of a tracheal tube. Their action differs from the muscle relaxants used in musculoskeletal disorders that act on the spinal cord or brain.

Patients who have received a neuromuscular blocking drug should **always** have their respiration assisted or controlled until the drug has been inactivated or antagonised. They should also receive sufficient concomitant inhalational or intravenous anaesthetic or sedative drugs to prevent awareness.

**Non-depolarising neuromuscular blocking drugs** Non-depolarising neuromuscular blocking drugs (also known as competitive muscle relaxants) compete with acetylcholine for receptor sites at the neuromuscular junction and their action can be reversed with anticholinesterases such as neostigmine p. 1024. Non-depolarising neuromuscular blocking drugs can be divided into the **aminosteroid** group, comprising pancuronium bromide p. 1228, rocuronium bromide p. 1228, and vecuronium bromide p. 1229, and the **benzylisoquinolinium** group, comprising atracurium besilate p. 1227, cisatracurium p. 1227, and mivacurium p. 1228.

Non-depolarising neuromuscular blocking drugs have a slower onset of action than suxamethonium chloride p. 1226. These drugs can be classified by their duration of action as short-acting (15–30 minutes), intermediate-acting (30–40 minutes), and long-acting (60–120 minutes), although duration of action is dose-dependent. Drugs with a shorter or intermediate duration of action, such as atracurium besilate and vecuronium bromide, are more

---

**IMPORTANT SAFETY INFORMATION**

Antimuscarinic drugs used for premedication to general anaesthesia should only be administered by, or under the direct supervision of, personnel experienced in their use.
widely used than those with a longer duration of action, such as pancuronium bromide. 

Non-depolarising neuromuscular blocking drugs have no sedative or analgesic effects and are not considered to trigger malignant hyperthermia.

For patients receiving intensive care and who require tracheal intubation and mechanical ventilation, a non-depolarising neuromuscular blocking drug is chosen according to its onset of effect, duration of action, and side-effects. Rocuronium bromide, with a rapid onset of effect, may facilitate intubation. Atracurium besilate or cisatracurium may be suitable for long-term neuromuscular blockade since their duration of action is not dependent on elimination by the liver or the kidneys.

Atracurium besilate, a mixture of 10 isomers, is a benzylisoquinolinium neuromuscular blocking drug with an intermediate duration of action. It undergoes non-enzymatic metabolism which is independent of liver and kidney function, thus allowing its use in patients with hepatic or renal impairment. Cardiovascular effects are associated with significant histamine release; histamine release can be minimised by administering slowly or in divided doses over at least 1 minute.

Cisatracurium is a single isomer of atracurium besilate. It is more potent and has a slightly longer duration of action than atracurium besilate and provides greater cardiovascular stability because cisatracurium lacks histamine-releasing effects.

Mivacurium, a benzylisoquinolinium neuromuscular blocking drug, has a short duration of action. It is metabolised by plasma cholinesterase and muscle paralysis is prolonged in individuals deficient in this enzyme. It is not associated with vagolytic activity or ganglionic blockade although histamine release can occur, particularly with rapid injection.

Pancuronium bromide, an aminosteroid neuromuscular blocking drug, has a long duration of action and is often used in patients receiving long-term mechanical ventilation in intensive care units. It lacks a histamine-releasing effect, but vagolytic and sympathomimetic effects can cause tachycardia and hypertension.

Rocuronium bromide exerts an effect within 2 minutes and has the most rapid onset of any of the non-depolarising neuromuscular blocking drugs. It is an aminosteroid neuromuscular blocking drug with an intermediate duration of action. It is reported to have minimal cardiovascular effects; high doses produce mild vagolytic activity.

Vecuronium bromide, an aminosteroid neuromuscular blocking drug, has an intermediate duration of action. It does not generally produce histamine release and lacks cardiovascular effects.

**Depolarising neuromuscular blocking drugs**

Suxamethonium chloride has the most rapid onset of action of any of the neuromuscular blocking drugs and is ideal if fast onset and brief duration of action are required, e.g. with tracheal intubation. Unlike the non-depolarising neuromuscular blocking drugs, its action cannot be reversed and recovery is spontaneous; anticholinesterases such as neostigmine potentiate the neuromuscular block.

Suxamethonium chloride should be given after anaesthetic induction because paralysis is usually preceded by painful muscle fasciculations. While tachycardia occurs with single use, bradycardia may occur with repeated doses in adults and with the first dose in children. Premedication with atropine reduces bradycardia as well as the excessive salivation associated with suxamethonium chloride use.

Prolonged paralysis may occur in **dual block**, which occurs with high or repeated doses of suxamethonium chloride and is caused by the development of a non-depolarising block following the initial depolarising block. Individuals with myasthenia gravis are resistant to suxamethonium chloride but can develop dual block resulting in delayed recovery.

Prolonged paralysis may also occur in those with low or atypical plasma cholinesterase. Assisted ventilation should be continued until muscle function is restored.

**NEUROMUSCULAR BLOCKING DRUGS > DEPOLARISING**

### Suxamethonium chloride

*(Succinylcholine chloride)*

- **DRUG ACTION** Suxamethonium acts by mimicking acetylcholine at the neuromuscular junction but hydrolysis is much slower than for acetylcholine; depolarisation is therefore prolonged, resulting in neuromuscular blockade.

- **INDICATIONS AND DOSE**

  Neuromuscular blockade (short duration) during surgery and intubation

  → **BY INTRAVENOUS INJECTION**

  **Adult:** 1–1.5 mg/kg

- **UNLICENSED USE** Doses of suxamethonium in BNF may differ from those in product literature.

**IMPORTANT SAFETY INFORMATION**

Should only be administered by, or under the direct supervision of, personnel experienced in its use.

- **CONTRA-INDICATIONS** Duchenne muscular dystrophy - family history of malignant hyperthermia - hyperkalaemia - low plasma-cholinesterase activity (including severe liver disease) - major trauma - neurological disease involving acute wasting of major muscle - personal or family history of congenital myotonic disease - prolonged immobilisation (risk of hyperkaemia) - severe burns

- **CAUTIONS** Cardiac disease - neuromuscular disease - raised intra-ocular pressure (avoid in penetrating eye injury) - respiratory disease - severe sepsis (risk of hyperkaemia)

- **INTERACTIONS** → Appendix 1: suxamethonium

- **SIDE-EFFECTS**

  → **Common or very common** Flushing - hyperkaemia - increased gastric pressure - increased intra-ocular pressure - myoglobinemia - myoglobinuria - postoperative muscle pain - rash

  → **Rare** Apnoea - arrhythmias - bronchospasm - cardiac arrest - limited jaw mobility - prolonged respiratory depression

  → **Very rare** Anaphylactic reactions - malignant hyperthermia

- **Frequency not known** Bradycardia (may occur with repeated doses) - hypertension - hypotension - rhabdomyolysis - tachycardia (occurs with single use)

**SIDE-EFFECTS, FURTHER INFORMATION**

Bradycardia - Premedication with atropine reduces bradycardia as well as the excessive salivation associated with suxamethonium use.

- **ALLERGY AND CROSS-SENSITIVITY** Allergic cross-reactivity between neuromuscular blocking drugs has been reported; caution is advised in cases of hypersensitivity to these drugs.

- **PREGNANCY** Mildly prolonged maternal neuromuscular blockade may occur.

- **BREAST FEEDING** Unlikely to be present in breast milk in significant amounts (ionised at physiological pH). Breast-feeding may be resumed once the mother recovered from neuromuscular block.

- **HEPATIC IMPAIRMENT** Prolonged apnoea may occur in severe liver disease because of reduced hepatic synthesis of pseudocholinesterase.
### Neuromuscular blocking drugs

#### Non-depolarising

**Importantly Safety Information**

Non-depolarising neuromuscular blocking drugs should only be administered by, or under direct supervision of, personnel experienced in their use, with adequate training in anaesthesia and airway management.

**Caution**

Burns (resistance can develop, increased doses may be required) - cardiovascular disease (reduce rate of administration) - electrolyte disturbances (response unpredictable) - fluid disturbances (response unpredictable) - hypothermia (activity prolonged, lower doses required) - myasthenia gravis (activity prolonged, lower doses required) - neuromuscular disorders (response unpredictable)

**Allergy and Cross-sensitivity**

Allergic cross-reactivity between neuromuscular blocking drugs has been reported; caution is advised in cases of hypersensitivity to these drugs.

**Pregnancy**

Non-depolarising neuromuscular blocking drugs are highly ionised at physiological pH and are therefore unlikely to cross the placenta in significant amounts.

**Breastfeeding**

Non-depolarising neuromuscular blocking drugs are ionised at physiological pH and are unlikely to be present in milk in significant amounts. Breast-feeding may be resumed once the mother has recovered from neuromuscular block.

### Atracurium besilate

(Atracurium besylate)

**Indications and Dose**

**Neuromuscular blockade (short to intermediate duration) for surgery and intubation**

- *Initially by intravenous injection*
  - Adult: Initially 300–600 micrograms/kg, then (by intravenous injection) 100–200 micrograms/kg as required, alternatively (by intravenous injection) initially 300–600 micrograms/kg, followed by (by intravenous infusion) 300–600 micrograms/kg/hour

**Neuromuscular blockade during intensive care**

- *Initially by intravenous injection*
  - Adult: Initially 300–600 micrograms/kg, initial dose is optional, then (by intravenous infusion) 270–1770 micrograms/kg/hour; (by intravenous infusion) usual dose 650–780 micrograms/kg/hour

**Doses at extremes of body-weight**

To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal body-weight.

### Interactions

- Appendix 1: neuromuscular blocking drugs, non-depolarising

### Side-effects

- **Very rare** Anaphylactoid reactions
- **Frequency not known** Acute myopathy (after prolonged use in intensive care) - bronchospasm - hypotension - seizures - skin flushing - tachycardia

### Directions for Administration

For intravenous infusion (Tracrium®; Atracurium besilate injection, Hospira; Atracurium injection/infusion, Genus), give continuously in Glucose 5% or Sodium Chloride 0.9%; stability varies with diluent; dilute requisite dose with infusion fluid to a concentration of 0.3–5 mg/mL.

### Medicinal forms

There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Atracurium besilate (Non-proprietary)**
  - Atracurium besilate 10 mg per 1 ml Atracurium besilate 250mg/25ml solution for injection vials | 1 vial (POM) £16.50
  - Atracurium besilate 25mg/2.5ml solution for injection ampoules | 5 ampoule (POM) £9.25
  - Atracurium besilate 50mg/5ml solution for injection ampoules | 5 ampoule (POM) £17.50 | 10 ampoule (POM) £35.00
  - Tracrium (GlaxoSmithKline UK Ltd)
  - Atracurium besilate 10 mg per 1 ml Tracrium 250mg/25ml solution for injection vials | 2 vial (POM) £25.81
  - Tracrium 25mg/2.5ml solution for injection ampoules | 5 ampoule (POM) £8.28

### Cisatracurium

**Indications and Dose**

Neuromuscular blockade (intermediate duration) during surgery and intubation

- *Initially by intravenous injection*
  - Adult: Initially 150 micrograms/kg, then (by intravenous injection) maintenance 30 micrograms/kg every 20 minutes; alternatively (by intravenous infusion) initially 180 micrograms/kg/hour, then (by intravenous infusion) maintenance 60–120 micrograms/kg/hour, maintenance dose administered after stabilisation

Neuromuscular blockade (intermediate duration) during intensive care

- *Initially by intravenous injection*
  - Adult: Initially 150 micrograms/kg, initial dose is optional, then (by intravenous infusion) 180 micrograms/kg/hour, adjusted according to response; (by intravenous infusion) usual dose 30–600 micrograms/kg/hour

**Doses at extremes of body-weight**

To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal body-weight.

**Interactions**

- Appendix 1: neuromuscular blocking drugs, non-depolarising

**Side-effects**

Acute myopathy (after prolonged use in intensive care) - bradycardia

**Directions for Administration**

For intravenous infusion (Nimbex®, Nimbex Forte®), give continuously in Glucose 5% or Sodium Chloride 0.9%; solutions of 2 mg/mL and 5 mg/mL may be infused undiluted; alternatively dilute with infusion fluid to a concentration of 0.1–2 mg/mL.
Pancuronium bromide

**INDICATIONS AND DOSE**

Neuromuscular blockade (long duration) during surgery and intubation
- BY INTRAVENOUS INJECTION
  - Adult: Initially 100 micrograms/kg, then 20 micrograms/kg as required

Neuromuscular blockade (long duration) during intensive care
- BY INTRAVENOUS INJECTION
  - Adult: Initially 100 micrograms/kg, initial dose is optional, then 60 micrograms/kg every 60–90 minutes

**DOSES AT EXTREMES OF BODY-WEIGHT**

To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal bodyweight.

**INTERACTIONS** → Appendix 1: neuromuscular blocking drugs, non-depolarising

**SIDE-EFFECTS**
- Acute myopathy (after prolonged use in intensive care)
- Hypertension · tachycardia

**SIDE-EFFECTS, FURTHER INFORMATION**

Pancuronium lacks histamine-releasing effect, but vagolytic and sympathomimetic effects can cause tachycardia and hypertension.

**HEPATIC IMPAIRMENT**
Possible slower onset, higher dose requirement, and prolonged recovery time.

**RENAL IMPAIRMENT**
Use with caution; prolonged duration of block.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**
- Pancuronium bromide (Non-proprietary)
  - Pancuronium bromide 2 mg per 1 ml Pancuronium bromide 4mg/2ml solution for injection ampoules | 10 ampoule £50.00

**Mivacurium**

**INDICATIONS AND DOSE**

Neuromuscular blockade (short duration) during surgery and intubation
- INITIALLY BY INTRAVENOUS INJECTION

**SIDE-EFFECTS**
- Very rare Anaphylactoid reactions
- Frequency not known Bronchospasm · hypotension · skin flushing · tachycardia

**HEPATIC IMPAIRMENT**
Reduce dose in severe impairment.

**RENAL IMPAIRMENT**
Clinical effect prolonged in renal failure—reduce dose according to response.

**DIRECTIONS FOR ADMINISTRATION**
For intravenous infusion, give continuously in Glucose 5% or Sodium chloride 0.9%. Dilute to a concentration of 500 micrograms/mL; may also be given undiluted. Doses up to 150 micrograms/kg may be given over 5–15 seconds, higher doses should be given over 30 seconds. In asthma, cardiovascular disease or in those sensitive to reduced arterial blood pressure, give over 60 seconds.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**
- Mivacron (GlaxoSmithKline UK Ltd)
  - Mivacurium (as Mivacurium chloride) 2 mg per 1 ml Mivacron 10mg/5ml solution for injection ampoules | 5 ampoule £13.95
  - Mivacurium 20mg/10ml solution for injection ampoules | 5 ampoule £22.57

**Rocuronium bromide**

**INDICATIONS AND DOSE**

Neuromuscular blockade (intermediate duration) during surgery and intubation
- INITIALLY BY INTRAVENOUS INJECTION

**SIDE-EFFECTS**
- Very rare Anaphylactoid reactions

**HEPATIC IMPAIRMENT**
Reduce dose in severe impairment.

**RENAL IMPAIRMENT**
Clinical effect prolonged in renal failure—reduce dose according to response.

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion, give continuously in Glucose 5% or Sodium chloride 0.9%. Dilute to a concentration of 500 micrograms/mL; may also be given undiluted. Doses up to 150 micrograms/kg may be given over 5–15 seconds, higher doses should be given over 30 seconds. In asthma, cardiovascular disease or in those sensitive to reduced arterial blood pressure, give over 60 seconds.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**
- Rocuronium (as Rocuronium bromide) 2 mg per 1 ml Rocuronium bromide 2mg/2ml solution for injection ampoules | 10 ampoule £45.00
- Rocuronium (as Rocuronium bromide) 5 mg per 1 ml Rocuronium bromide 10mg/2ml solution for injection ampoules | 10 ampoule £90.00
- Rocuronium (as Rocuronium bromide) 15 mg per 1 ml Rocuronium bromide 15mg/5ml solution for injection ampoules | 10 ampoule £225.00

**DOSES AT EXTREMES OF BODY-WEIGHT**
To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal bodyweight.

**INTERACTIONS** → Appendix 1: neuromuscular blocking drugs, non-depolarising
1.2 Neuromuscular blockade reversal

Neuromuscular blockade reversal

Drugs for reversal of neuromuscular blockade

Anticholinesterases

Anticholinesterases reverse the effects of the non-depolarising (competitive) neuromuscular blocking drugs such as pancuronium bromide but they prolong the action of the depolarising neuromuscular blocking drug suxamethonium chloride.

Neostigmine is used specifically for reversal of non-depolarising (competitive) blockade. It acts within one minute of intravenous injection and its effects last for 20 to 30 minutes; a second dose may then be necessary. Glycopyrronium bromide p. 1225 or alternatively atropine sulfate p. 1224, given before or with neostigmine, prevent bradycardia, excessive salivation, and other muscarinic effects of neostigmine.

Other drugs for reversal of neuromuscular blockade

Sugammadex p. 1230 is a modified gamma cyclodextrin that can be used for rapid reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide. In practice, sugammadex is used mainly for rapid reversal of neuromuscular blockade in an emergency.

ANTICHOLINESTERASES

Neostigmine with glycopyrronium bromide

The properties listed below are those particular to the combination only. For the properties of the components please consider, neostigmine p. 1024, glycopyrronium bromide p. 1225.

INDICATIONS AND DOSE

Reversal of non-depolarising neuromuscular blockade

BY INTRAVENOUS INJECTION

Adult: 1–2 mL, repeated if necessary, alternatively 0.02 mL/kilogram, repeated if necessary; maximum 2 mL per course

INTERACTIONS

Appendix 1: glycopyrronium, neostigmine

DIRECTIONS FOR ADMINISTRATION

For intravenous injection, give over 10–30 seconds.

MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

Neostigmine with glycopyrronium bromide (Non-proprietary)

Glycopyrronium bromide 50 microgram per 1 mL, Neostigmine metilsulfate 2.5 mg per 1 mL

Neostigmine 2.5mg/1mL

Glycopyrronium bromide 500micrograms/mL solution for injection ampoules | 10 ampoule £11.50

downloaded from www.medicalbr.com
Antidotes and Chelators

Sugammadex

- **Indications and Dose**
  - Routine reversal of neuromuscular blockade induced by rocuronium or vecuronium
    - By intravenous injection
    - Adult: Initially 2–4 mg/kg, then 4 mg/kg if required, administered if recurrence of neuromuscular blockade occurs; consult product literature for further details
  - Immediate reversal of neuromuscular blockade induced by rocuronium
    - By intravenous injection
    - Adult: 16 mg/kg (consult product literature)

**Important Safety Information**

Should only be administered by, or under the direct supervision of, personnel experienced in its use.

- **Caution**
  - Cardiovascular disease (recovery may be delayed)
  - Elderly (recovery may be delayed)
  - Pre-existing coagulation disorders
  - Recurrence of neuromuscular blockade—monitor respiratory function until fully recovered
  - Use of anticoagulants (unrelated to surgery)
  - Wait 24 hours before re-administering rocuronium
  - Wait 24 hours before re-administering vecuronium

- **Interactions**
  - Appendix 1: sugammadex

- **Side-effects**
  - Bradycardia
  - Bronchospasm
  - Cardiac arrest
  - Hypersensitivity reactions

- **Pregnancy**
  - Use with caution—no information available.

- **Renal Impairment**
  - Avoid if eGFR less than 30 mL/minute/1.73 m²

- **National Funding/Access Decisions**
  - Scottish Medicines Consortium (SMC) Decisions
    - The Scottish Medicines Consortium, has advised (February 2013) that sugammadex (Bridion®) is accepted for restricted use within NHS Scotland for the routine reversal of neuromuscular blockade in high-risk patients only, or where prompt reversal of neuromuscular block is required.

- **Medicinal Forms**
  - There can be variation in the licensing of different medicines containing the same drug.
  - Solution for injection
  - Electrolytes: May contain sodium
    - Bridion: (Mercer Sharp & Dohme Ltd)
    - Sugammadex (as Sugammadex sodium) 100 mg per 1 ml
    - Bridion 500 mg/5 ml solution for injection vials | 10 vial | £1,491.00
      (Hospital only)
    - Bridion 200 mg/2 ml solution for injection vials | 10 vial | £596.40
      (Hospital only)

1.3 Peri-operative Analgesia

Peri-operative Analgesia

Non-opioid Analgesics

Since non-steroidal anti-inflammatory drugs (NSAIDs) do not depress respiration, do not impair gastrointestinal motility, and do not cause dependence, they may be useful alternatives or adjuncts to opioids for the relief of postoperative pain. NSAIDs may be inadequate for the relief of severe pain. Acemetacin p. 1030, diclofenac sodium p. 1034, diclofenac potassium p. 1033, flurbiprofen p. 1040, ibuprofen p. 1041, ketoprofen p. 1044, paracetamol p. 422, parecoxib p. 1232, and ketorolac trometamol p. 1231 are licensed for postoperative use. Diclofenac and paracetamol can be given by injection as well as by mouth. Diclofenac sodium can be given by intravenous infusion for the treatment or prevention of postoperative pain. Intramuscular injections of diclofenac sodium and ketoprofen are rarely used; they are given deep into the gluteal muscle to minimise pain and tissue damage. Ketonolac trometamol is less irritant on intramuscular injection but pain has been reported; it can also be given by intravenous injection.

Suppositories of diclofenac sodium and ketoprofen may be effective alternatives to the parenteral use of these drugs.

Opioid Analgesics

Opioid Analgesics are now rarely used as premedicants; they are more likely to be administered at induction. Pre-operative use of opioid analgesics is generally limited to those patients who require control of existing pain. See general notes on opioid analgesics and their use in postoperative pain.

See the management of opioid-induced respiratory depression in Pre-medications and peri-operative drugs p. 1223.

Intra-operative Analgesia

Opioid Analgesics given in small doses before or with induction reduce the dose requirement of some drugs used during anaesthesia.

Alfentanil p. 1232, fentanyl p. 434, and remifentanil p. 1233 are particularly useful because they act within 1–2 minutes and have short durations of action. The initial doses of alfentanil or fentanyl are followed either by successive intravenous injections or by an intravenous infusion; prolonged infusions increase the duration of effect. Repeated intra-operative doses of alfentanil or fentanyl should be given with care since the resulting respiratory depression can persist postoperatively and occasionally it may become apparent for the first time postoperatively when monitoring of the patient might be less intensive. Alfentanil, fentanyl, and remifentanil can cause muscle rigidity, particularly of the chest wall or jaw; this can be managed by the use of neuromuscular blocking drugs.

In contrast to other opioids which are metabolised in the liver, remifentanil undergoes rapid metabolism by nonspecific blood and tissue esterases; its short duration of action allows prolonged administration at high dosage, without accumulation, and with little risk of residual postoperative respiratory depression. Remifentanil should not be given by intravenous injection intraoperatively, but it is well suited to continuous infusion; a supplementary analgesic is given before stopping the infusion of remifentanil.

Anaesthetics, Local

Bupivacaine with fentanyl

The properties listed below are those particular to the combination only. For the properties of the components please consider, bupivacaine hydrochloride p. 1238, fentanyl p. 434.

- **Indications and Dose**
  - During labour (once epidural block established)
    - By continuous lumbar epidural infusion
    - Adult: 10–18.75 mg/hour, dose of bupivacaine to be administered, maximum 400 mg bupivacaine in 24 hours and 16–30 micrograms/hour, dose of fentanyl to be administered, maximum 720 micrograms fentanyl in 24 hours
  - Postoperative pain (once epidural block established)
    - By continuous epidural infusion
    - Adult: 4–18.75 mg/hour, dose of bupivacaine to be administered, maximum 400 mg bupivacaine in...
Ketorolac trometamol

**INDICATIONS AND DOSE**

Short-term management of moderate to severe acute postoperative pain only

- By intramuscular injection, or by intravenous injection
  - Adult (body-weight up to 50 kg): Initially 10 mg, then 10–30 mg every 4–6 hours as required for maximum duration of treatment 2 days, frequency may be increased to up to every 2 hours during initial postoperative period; maximum 60 mg per day
  - Adult (body-weight 50 kg and above): Initially 10 mg, then 10–30 mg every 4–6 hours as required for maximum duration of treatment 2 days, frequency may be increased to up to every 2 hours during initial postoperative period; maximum 90 mg per day
  - Elderly: Initially 10 mg, then 10–30 mg every 4–6 hours as required for maximum duration of treatment 2 days, frequency may be increased to up to every 2 hours during initial postoperative period; maximum 60 mg per day

- **CONTRA-INDICATIONS** Active or history of gastro-intestinal bleeding, active or history of gastro-intestinal ulceration, coagulation disorders, complete or partial syndrome of nasal polyps, confirmed or suspected cerebrovascular bleeding, dehydration, following operations with high risk of haemorrhage or incomplete haemostasis, haemorrhagic diathesis, history of gastro-intestinal perforation, hypovolaemia, severe heart failure

- **CAUTIONS** Allergic disorders, cardiac impairment (NSAIDs may impair renal function), cerebrovascular disease, coagulation defects, connective-tissue disorders, Crohn’s disease (may be exacerbated), elderly (risk of serious side-effects and fatalities), heart failure, ischaemic heart disease, peripheral arterial disease, risk factors for cardiovascular events, ulcerative colitis (may be exacerbated), uncontrolled hypertension

- **INTERACTIONS** → Appendix 1: NSAIDs

- **SIDE-EFFECTS**
  - Rare: Alveolitis, aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible), hepatic damage, interstitial fibrosis associated with NSAIDs can lead to renal failure, pancreatitis, papillary necrosis associated with NSAIDs can lead to renal failure, pulmonary eosinophilia, Stevens–Johnson syndrome, toxic epidermal necrolysis

- **Frequency not known** Abnormal dreams, angioedema, asthma, blood disorders, bradycardia, bronchospasm, chest pain, colitis (induction of or exacerbation of), confusion, convulsions, Crohn’s disease (induction of or exacerbation of), depression, diarrhoea, dizziness, drowsiness, dry mouth, dysphagia, euphoria, fluid retention (rarely precipitating congestive heart failure), flushing, gastro-intestinal bleeding, gastro-intestinal discomfort, gastro-intestinal disturbances, gastro-intestinal ulceration, haematuria, hallucinations, headache, hearing disturbances, hyperkalaemia, hyperkinesia, hypersensitivity reactions, hypertension, hynopatraemia, insomnia, malaise, myalgia, nausea, nervousness, optic neuritis, pain at injection site, pallor, palpitation, paraesthesia, photosensitivity, psychosis, purpura, raised blood pressure, rashes, renal failure (especially in patients with pre-existing renal impairment), sweating, taste disturbances, thirst, tinnitus, urinary frequency, vertigo, visual disturbances

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Serious side-effects For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 1028.
  - **ALLERGY AND CROSS-SENSITIVITY** Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.
  - **CONCEPTION AND CONTRACEPTION** Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.
  - **PREGNANCY** Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.
  - **BREAST FEEDING** Amount too small to be harmful.
  - **HEPATIC IMPAIRMENT** Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.
  - **RENAI IMPAIRMENT** Avoid if possible or use with caution. Avoid if serum creatinine greater than 160 micromol/litre. The lowest effective dose should be used for the shortest possible duration. Max. 60 mg daily by intramuscular injection or intravenous injection.

Monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

- **DIRECTIONS FOR ADMINISTRATION** For intravenous injection, give over at least 15 seconds.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

- **Ketorolac trometamol 30 mg per ml**
  - Ketorolac trometamol 30 mg/1 ml solution for injection ampoules | 5 ampoule (Fr) £5.47 (Hospital only) | 6 ampoule (Fr) £6.56
  - **Toraldo** (Atahns Pharma UK Ltd)
    - **Ketorolac trometamol 30 mg per ml**
      - Toraldo 30mg/1ml solution for injection ampoules | 5 ampoule (Fr) £5.36
**Parecoxib**

- **DRUG ACTION** Parecoxib is a selective inhibitor of cyclo-oxygenase-2.

- **INDICATIONS AND DOSE**
  - **Short-term management of acute postoperative pain**
    - **BY DEEP INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INJECTION**
      - Adult: Initially 40 mg, then 20–40 mg every 6–12 hours as required for up to 3 days; maximum 80 mg per day
      - Elderly (body-weight up to 50 kg): Initially 20 mg; maximum 40 mg per day

- **CONTRA-INDICATIONS** Active gastro-intestinal bleeding; active gastro-intestinal ulceration; cerebrovascular disease; inflammatory bowel disease; ischaemic heart disease; mild to severe heart failure; peripheral arterial disease

- **CAUTIONS** Allergic disorders; cardiac impairment (NSAIDs may impair renal function); coagulation defects; connective-tissue disorders; Crohn’s disease (may be exacerbated); dehydration; elderly (risk of serious side-effects and fatalities); following coronary artery bypass graft surgery; history of cardiac failure; hypertension; left ventricular dysfunction; oedema; risk factors for cardiovascular events; ulcerative colitis (may be exacerbated)

- **INTERACTIONS** → Appendix 1: NSAIDs

- **SIDE-EFFECTS**
  - **Common or very common**
    - Alveolar oestitis; flatulence; hypoaesthesia; hypokalaemia; hypotension; postoperative anaemia; sweating
  - **Uncommon**
    - Anorexia; arthralgia; bradycardia; cardiovascular events; ecchymosis; hyperglycaemia; malaise; pulmonary embolism
  - **Rare**
    - Alveolitis; aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible); hepatic damage; interstitial fibrosis associated with NSAIDs can lead to renal failure; pancreatitis; papillary necrosis associated with NSAIDs can lead to renal failure; pulmonary eosinophilia; Stevens-Johnson syndrome; toxic epidermal necrolysis; visual disturbances

- **Frequency not known**
  - Angioedema; blood disorders; blood pressure may be raised; bronchospasm; circulatory collapse; colitis (induction of or exacerbation of); Crohn’s disease (induction of or exacerbation of); depression; diarrhoea; dizziness; drowsiness; fluid retention (rarely precipitating congestive heart failure); gastro-intestinal bleeding; gastro-intestinal discomfort; gastro-intestinal disturbances; gastro-intestinal ulceration; haematuria; headache; hearing disturbances; hypersensitivity reactions; insomnia; nausea; nervousness; photosensitivity; rashes; renal failure (especially in patients with pre-existing renal impairment); tachycardia; tinnitus; vertigo

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Serious side-effects For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs p. 1028.

- **ALLERGY AND CROSS-SENSITIVITY** Contra-indicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID. Contra-indicated in patients with a history of allergic drug reactions including sulfonamide hypersensitivity.

- **CONCEPTION AND CONTRACEPTION** Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.

- **PREGNANCY** Avoid unless the potential benefit outweighs the risk. Avoid during the third trimester (risk of closure of fetal ductus arteriosus in utero and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.

- **BREAST FEEDING** Avoid—present in milk.

- **HEPATIC IMPAIRMENT** Halve dose in moderate impairment (max. 40 mg daily). Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention. Avoid in severe liver disease.

- **RENAL IMPAIRMENT** The lowest effective dose should be used for the shortest possible duration. Avoid if possible or use with caution. In renal impairment monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

- **NATIONAL FUNDING/ACCESS DECISIONS**
  - **Scottish Medicines Consortium (SMC) Decisions** The Scottish Medicines Consortium has advised (January 2003) that parecoxib is not recommended for use within NHS Scotland.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.

**Powder and solvent for solution for injection**

- **Dynastat** (Pfizer Ltd)
  - **Parecoxib (as Parecoxib sodium) 40 mg** Dynastat 40mg powder and solvent for solution for injection vials | 5 vial | £28.34

- **Powder for solution for injection**
  - **Dynastat** (Pfizer Ltd)
  - **Parecoxib (as Parecoxib sodium) 40 mg** Dynastat 40mg powder for solution for injection vials | 10 vial | £49.60

**Analgesics > Opioids**

**Alfentanil**

- **INDICATIONS AND DOSE**
  - **Spontaneous respiration: analgesia and enhancement of anaesthesia for short procedures**
    - **BY INTRAVENOUS INJECTION**
      - Adult: Initially up to 500 micrograms, dose to be administered over 30 seconds; supplemental doses 250 micrograms

- **Assisted ventilation: analgesia and enhancement of anaesthesia for short procedures**
  - **BY INTRAVENOUS INJECTION**
    - Adult: Initially 30–50 micrograms/kg, supplemental doses 15 micrograms/kg

- **Assisted ventilation: analgesia and enhancement of anaesthesia during maintenance of anaesthesia for longer procedures**
  - **BY INTRAVENOUS INFUSION**
    - Adult: Initially 50–100 micrograms/kg, dose to be administered over 10 minutes or as a bolus, followed by maintenance 30–60 micrograms/kg/hour

- **Assisted ventilation: analgesia and suppression of respiratory activity during intensive care for up to 4 days**
  - **BY INTRAVENOUS INFUSION**
    - Adult: Initially 2 mg/hour, adjusted according to response; usual dose 0.5–10 mg/hour, alternatively initially 5 mg in divided doses, to be administered over 10 minutes; dose used for more rapid initial control, reduce rate of administration if hypotension or bradycardia occur; additional doses of 0.5–1 mg may be
given by intravenous injection during short painful procedures

**DOSES AT EXTREMES OF BODY-WEIGHT**
To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal body-weight.

**CAUTIONS**

**CAUTIONS, FURTHER INFORMATION**
- Repeated intra-operative doses: Repeated intra-operative doses of alfentanil should be given with care since the resulting respiratory depression can persist postoperatively and occasionally it may become apparent for the first time postoperatively when monitoring of the patient might be less intensive.

**SIDE-EFFECTS**
- Common or very common: Hypertension, myoclonic movements
- Uncommon: Arrhythmias, hiccups, laryngospasm
- Rare: Epistaxis
- Frequency not known: Cardiac arrest, convulsions, cough, muscle rigidity, pyrexia

**SIDE-EFFECTS, FURTHER INFORMATION**
- Muscle rigidity: Alfentanil can cause muscle rigidity, particularly of the chest wall or jaw; this can be managed by the use of neuromuscular blocking drugs.

**BREAST FEEDING**
Present in milk—withhold breast-feeding for 24 hours.

**RENAL IMPAIRMENT**
Avoid use or reduce dose; opioid effects increased and prolonged and increased cerebral sensitivity occurs.

**DIRECTIONS FOR ADMINISTRATION**
5 mg/mL injection to be diluted before use. For continuous or intermittent intravenous infusion dilute in Glucose 5% or Sodium Chloride 0.9%.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection

**Solution for injection**
- **Alfentanil (Non-proprietary)**
  - Alfentanil (as Alfentanil hydrochloride) 500 microgram per 1 ml: Alfentanil 1mg/2ml solution for injection ampoules | 10 amponge [PSM] £5.95 [CD]
  - Alfentanil 5mg/10ml solution for injection ampoules | 5 amponge [PSM] £13.90 [CD]
  - Alfentanil (as Alfentanil hydrochloride) 5 mg per 1 ml: Alfentanil 5mg/1ml solution for injection ampoules | 10 amponge [PSM] £21.95 [CD]
- **Rapifen (Janssen-Cilag Ltd)**
  - Alfentanil (as Alfentanil hydrochloride) 500 microgram per 1 ml: Rapifen 5mg/10ml solution for injection ampoules | 5 amponge [PSM] £14.50 [CD]
  - Rapifen 1mg/2ml solution for injection ampoules | 10 amponge [PSM] £6.34 [CD]
  - Alfentanil (as Alfentanil hydrochloride) 5 mg per 1 ml: Rapifen Intensive Care 5mg/1ml solution for injection ampoules | 10 amponge [PSM] £23.19 (Hospital only) [CD]

**INTERACTIONS**
- Appendix 1: opioids

**INDICATIONS AND DOSE**

**Premedication**
- BY SUBCUTANEOUS INJECTION, OR BY INTRAMUSCULAR INJECTION
  - Adult: 0.5–1 mL

**INTERACTIONS**
- Appendix 1: hyoscine, opioids

**LESS SUITABLE FOR PRESCRIBING**
Hyoscine hydrobromide with papaveretum is less suitable for prescribing.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug. No licensed medicines listed.

**Remifentanil**

**INDICATIONS AND DOSE**

**Analgesia and enhancement of anaesthesia at induction (initial bolus injection)**
- **BY INTRAVENOUS INJECTION**
  - Adult: Initially 0.25–1 microgram/kg, dose to be administered over at least 30 seconds, if patient is to be intubated more than 8 minutes after start of intravenous infusion, initial bolus intravenous injection dose is not necessary

**Analgesia and enhancement of anaesthesia at induction with or without initial bolus dose**
- **BY INTRAVENOUS INJECTION**
  - Adult: 30–60 micrograms/kg/hour, if patient is to be intubated more than 8 minutes after start of intravenous infusion, initial bolus intravenous injection dose is not necessary

**Assisted ventilation: analgesia and enhancement of anaesthesia during maintenance of anaesthesia (initial bolus injection)**
- **BY INTRAVENOUS INJECTION**
  - Adult: Initially 0.25–1 microgram/kg, dose to be administered over at least 30 seconds

**Assisted ventilation: analgesia and enhancement of anaesthesia during maintenance of anaesthesia with or without initial bolus dose**
- **BY INTRAVENOUS INJECTION**
  - Adult: 3–120 micrograms/kg/hour, dose to be administered according to anaesthetic technique and adjusted according to response, in light anaesthesia additional doses can be given by intravenous injection every 2–5 minutes during the intravenous infusion

**Spontaneous respiration: analgesia and enhancement of anaesthesia during maintenance of anaesthesia**
- **BY INTRAVENOUS INJECTION**
  - Adult: Initially 2.4 micrograms/kg/hour, adjusted according to response; usual dose 1.5–6 micrograms/kg/hour

**Assisted ventilation: analgesia and sedation in intensive-care patients (for max 3 days)**
- **BY INTRAVENOUS INJECTION**
  - Adult: Initially 6–9 micrograms/kg/hour, then adjusted in steps of 1.5 micrograms/kg/hour, allow at least 5 minutes between dose adjustments; usual dose 0.36–4.4 micrograms/kg/hour, if an infusion rate of 12 micrograms/kg/hour does not produce...
adequate sedation add another sedative (consult product literature for details).

Assisted ventilation: additional analgesia during stimulating or painful procedures in intensive-care patients

- **BY INTRAVENOUS INFUSION**
  - Adult: Usual dose 15–45 micrograms/kg/hour, maintain infusion rate of at least 6 micrograms/kg/hour for at least 5 minutes before procedure and adjust every 2–5 minutes according to requirements

Cardiac surgery

- Adult: (consult product literature)

**DOSES AT EXTREMES OF BODY-WEIGHT**

To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal body-weight.

- **UNLICENSED USE** Remifentanil doses in BNF may differ from those in product literature.
- **CONTRA-INDICATIONS** Analgesia in conscious patients
- **INTERACTIONS** \(\rightarrow\) Appendix 1: opioids
- **SIDE-EFFECTS**
  - Common or very common Hypoxia
  - Uncommon Hypoxia
  - Rare Asystole
  - Frequency not known AV block - convulsions

**SIDE-EFFECTS, FURTHER INFORMATION**

- Muscle rigidity Alfentanil can cause muscle rigidity, particularly of the chest wall or jaw; this can be managed by the use of neuromuscular blocking drugs.
- Respiratory depression In contrast to other opioids which are metabolised in the liver, remifentanil undergoes rapid metabolism by non-specific blood and tissue esterases; its short duration of action allows prolonged administration at high dosage, without accumulation, and with little risk of residual postoperative respiratory depression.
- **PREGNANCY** No information available.
- **BREAST FEEDING** Avoid breast-feeding for 24 hours after administration—present in milk in *animal* studies.
- **RENAI IMPAIRMENT** No dose adjustment necessary in renal impairment.

**DIRECTIONS FOR ADMINISTRATION** For intravenous infusion (*Ultiva*⁶), give continuously in Glucose 5% or Sodium Chloride 0.9% or Water for Injections; reconstitute with infusion fluid to a concentration of 1 mg/ml then dilute further to a concentration of 20–250 micrograms/ml (50 micrograms/ml recommended for general anaesthesia, 20–50 micrograms/ml recommended when used with target controlled infusion (TCI) device).

**PRESCRIBING AND DISPENSING INFORMATION**

Remifentanil should not be given by intravenous injection intra-operatively, but it is well suited to continuous infusion; a supplementary analgesic is given before stopping the infusion of remifentanil.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Powder for solution for injection**

- **Remifentanil (Non-proprietary)**
  - Remifentanil (as Remifentanyl hydrochloride) 1 mg
  - Remifentanil 1 mg powder for concentrate for solution for injection vials \(\times\) 5 vial (£Pm £25.58–£25.60 (Hospital only) [CD]
  - Remifentanil (as Remifentanyl hydrochloride) 2 mg
  - Remifentanil 2 mg powder for concentrate for solution for injection vials \(\times\) 5 vial (£Pm £51.13–£51.15 (Hospital only) [CD]
  - Remifentanil (as Remifentanyl hydrochloride) 5 mg
  - Remifentanil 5 mg powder for concentrate for solution for injection vials \(\times\) 5 vial (£Pm £127.88–£127.90 (Hospital only) [CD]
  - *Ultiva* (GlaxoSmithKline UK Ltd)
  - Remifentanil (as Remifentanyl hydrochloride) 1 mg
  - Remifentanil 1 mg powder for solution for injection vials \(\times\) 5 vial (£Pm £25.58 (Hospital only) [CD]

**Remifentanil (as Remifentanyl hydrochloride) 2 mg** *Ultiva* 2 mg powder for solution for injection vials \(\times\) 5 vial (£Pm £51.15 (Hospital only) [CD]

**Remifentanil (as Remifentanyl hydrochloride) 5 mg** *Ultiva* 5 mg powder for solution for injection vials \(\times\) 5 vial (£Pm £127.88 (Hospital only) [CD]

### 1.4 Peri-operative sedation

**Conscious sedation for clinical procedures**

**Overview**

Sedation of patients during diagnostic and therapeutic procedures is used to reduce fear and anxiety, to control pain, and to minimise excessive movement. The choice of sedative drug will depend upon the intended procedure; some procedures are safer and more successful under anaesthesia. The patient should be monitored carefully; monitoring should begin as soon as the sedative is given or when the patient becomes drowsy, and should be continued until the patient wakes up.

**ANAESTHETICS, GENERAL > NMDA RECEPTOR ANTAGONISTS**

**Ketamine**

- **INDICATIONS AND DOSE**
  - **Induction and maintenance of anaesthesia for short procedures**
    - **BY INTRAMUSCULAR INJECTION**
      - Adult: Initially 6.5–13 mg/kg, adjusted according to response, a dose of 10 mg/kg usually produces 12–25 minutes of surgical anaesthesia
  - **BY INTRAVENOUS INJECTION**
    - Adult: Initially 1–4.5 mg/kg, adjusted according to response, to be administered over at least 60 seconds, a dose of 2 mg/kg usually produces 5–10 minutes of surgical anaesthesia
  - **Diagnostic manoeuvres and procedures not involving intense pain**
    - **BY INTRAMUSCULAR INJECTION**
      - Adult: Initially 4 mg/kg
  - **Induction and maintenance of anaesthesia for long procedures**
    - **BY INTRAVENOUS INJECTION**
      - Adult: Initially 0.5–2 mg/kg, using an infusion solution containing 1 mg/ml; maintenance 10–45 micrograms/kg/minute, adjusted according to response

**IMPORTANT SAFETY INFORMATION**

Ketamine should only be administered by, or under the direct supervision of, personnel experienced in its use, with adequate training in anaesthesia and airway management, and when resuscitation equipment is available.

- **CONTRA-INDICATIONS** Acute porphyrias p. 969 • eclampsia • head trauma • hypertension • pre-eclampsia • raised intracranial pressure • severe cardiac disease • stroke
  - **CAUTIONS** Acute circulatory failure (shock) • cardiovascular disease • dehydration • elderly • fixed cardiac output • hallucinations • head injury • hypertension • hypovolaemia • increased cerebrospinal fluid pressure • intracranial mass lesions • nightmares • predisposition to
seizures • psychotic disorders • raised intra-ocular pressure • respiratory tract infection • thyroid dysfunction

**INTERACTIONS** ➔ Appendix 1: ketamine

**SIDE-EFFECTS**

- **Common or very common** Diplopia • hallucinations • hypertension • nausea • nightmares • nystagmus • rash • tachycardia • transient psychotic effects • vomiting
- **Uncommon** Arrhythmias • bradycardia • hypotension • laryngospasm • respiratory depression
- **Rare** Aponoea • cystitis • cystitis • haemorrhagic cystitis • hypersalivation • insomnia
- **Frequency not known** Raised intra-ocular pressure

**SIDE-EFFECTS, FURTHER INFORMATION**

- Transient psychotic effects Incidence of hallucinations, nightmares, and other transient psychotic effects can be reduced by a benzodiazepine such as diazepam or midazolam.

**PREGNANCY** May depress neonatal respiration if used during delivery.

**BREAST FEEDING** Avoid for at least 12 hours after last dose.

**HEPATIC IMPAIRMENT** Consider dose reduction.

**DIRECTIONS FOR ADMINISTRATION** For continuous intravenous infusion, dilute to a concentration of 1 mg/mL with Glucose 5% or Sodium Chloride 0.9%; use microdrip infusion for maintenance of anaesthesia. For intravenous injection, dilute 100 mg/mL strength to a concentration of not more than 50 mg/mL with Glucose 5% or Sodium Chloride 0.9% or Water for Injections.

**PATIENT AND CARER ADVICE**

Driving and skilled tasks

Patients given sedatives and analgesics during minor outpatient procedures should be very carefully warned about the risk of driving or undertaking skilled tasks afterwards. For a short general anaesthetic the risk extends to at least 24 hours after administration. Responsible persons should be available to take patients home. The dangers of taking alcohol should also be emphasised.

For information on 2015 legislation regarding driving whilst taking certain controlled drugs, including ketamine, see Drugs and driving under Guidance on prescribing p. 1.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection

**Solution for injection**

- **Ketamine (Non-proprietary)**
  - Ketamine (as Ketamine hydrochloride) 50 mg per 1 mL
  - Ketalar (Pfizer Ltd)
  - Ketalar (as Ketamine hydrochloride) 10 mg per 1 mL
  - Ketalar 200mg/20ml solution for injection vials | 1 vial (£1.21)
  - Ketalar 500mg/10ml solution for injection vials | 1 vial (£0.92)

- **Dexmedetomidine**
  - **INDICATIONS AND DOSE**
    - Maintenance of sedation during intensive care
      - **BY INTRAVENOUS INFUSION**
      - Adult: 0.7 microgram/kg/hour, adjusted according to response; usual dose 0.2–1.4 micrograms/kg/hour

**IMPORTANT SAFETY INFORMATION**

Dexmedetomidine should only be administered by, or under the direct supervision of, personnel experienced in its use, with adequate training in anaesthesia and airway management.

- **CONTRA-INDICATIONS** Acute cerebrovascular disorders • second- or third-degree AV block (unless pacemaker fitted) • uncontrolled hypotension
- **CAUTIONS** Abrupt withdrawal after prolonged use • bradycardia • ischaemic heart disease • malignant hyperthermia • severe cerebrovascular disease (especially at higher doses) • severe neurological disorders • spinal cord injury

- **INTERACTIONS** ➔ Appendix 1: dexmedetomidine

**SIDE-EFFECTS**

- **Common or very common** Agitation • blood pressure changes • bradycardia • changes in blood sugar • dry mouth • hyperthermia • myocardial infarction • myocardial ischaemia • nausea • tachycardia • vomiting
- **Uncommon** Abdominal distension • AV block • decreased cardiac output • dyspnoea • hallucination • hypoaalbuminaemia • metabolic acidosis • thirst
- **PREGNANCY** Manufacturer advises avoid unless potential benefit outweighs risk—toxicity in animal studies.
- **BREAST FEEDING** Manufacturer advises avoid unless potential benefit outweighs risk—present in milk in animal studies.
- **HEPATIC IMPAIRMENT** Dose reduction may be required. Manufacturer advises caution.

**MONITORING REQUIREMENTS**

- Monitor cardiac function.
- Monitor respiratory function in non-intubated patients.

**DIRECTIONS FOR ADMINISTRATION** To be diluted before use. For intravenous infusion given continuously in Glucose 5% or Sodium chloride 0.9%, dilute to a concentration of 4 micrograms/mL.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug.

**Solution for infusion**

- **Dexdor** (Orion Pharma (UK) Ltd)
  - Dexmedetomidine (as Dexmedetomidine hydrochloride) 100 microgram per 1 mL
    - Dexdor 1mg/10ml concentrate for solution for infusion vials | 4 vial (£3.13)
    - Dexdor 400micrograms/4ml concentrate for solution for infusion vials | 4 vial (£1.25)
    - Dexdor 200micrograms/2ml concentrate for solution for infusion ampoules | 5 ampoule (£0.78)
  - 25 ampoule (£3.90) (Hospital only)
2 Malignant hyperthermia

**MUSCLE RELAXANTS**

Dantrolene sodium

- **DRUG ACTION** Acts on skeletal muscle cells by interfering with calcium efflux, thereby stopping the contractile process.

- **INDICATIONS AND DOSE**
  - **Malignant hyperthermia**
    - **BY RAPID INTRAVENOUS INJECTION**
      - Adult: Initially 2–3 mg/kg, then 1 mg/kg, repeated if necessary; maximum 10 mg/kg per course
  - **Chronic severe spasticity of voluntary muscle**
    - **BY MOUTH**
      - Adult: Initially 25 mg daily, then increased to up to 100 mg 4 times a day; dose increased at weekly intervals; usual dose 75 mg 3 times a day

**SIDE-EFFECTS**

- **Common or very common**
  - Confusion
  - Constipation
  - Crystalluria
  - Depression
  - Dysphagia
  - Dyspnoea
  - Erratic blood pressure
  - Exacerbation of cardiac insufficiency
  - Haematuria
  - Increased sweating
  - Increased urinary frequency
  - Insomnia
  - Nervousness
  - Tachycardia
  - Urinary incontinence
  - Urinary retention

- **Uncommon**
  - Confusion
  - Constipation
  - Crystalluria
  - Depression
  - Dysphagia
  - Dyspnoea
  - Erratic blood pressure
  - Exacerbation of cardiac insufficiency
  - Haematuria
  - Increased sweating
  - Increased urinary frequency
  - Insomnia
  - Nervousness
  - Tachycardia
  - Urinary incontinence
  - Urinary retention

- **Frequency not known**
  - Confusion
  - Constipation
  - Crystalluria
  - Depression
  - Dysphagia
  - Dyspnoea
  - Erratic blood pressure
  - Exacerbation of cardiac insufficiency
  - Haematuria
  - Increased sweating
  - Increased urinary frequency
  - Insomnia
  - Nervousness
  - Tachycardia
  - Urinary incontinence
  - Urinary retention

**SIDE-EFFECTS, FURTHER INFORMATION**

- Hepatotoxicity: Potentially life-threatening hepatotoxicity reported—discontinue if abnormal liver function tests or symptoms of liver disorder; re-introduce only if complete reversal of hepatotoxicity.

**PREGNANCY**

- **With intravenous use** Use only if potential benefit outweighs risk.

- **With oral use** Avoid use in chronic spasticity—embryotoxic in animal studies.

**IMPORTANT SAFETY INFORMATION**

- Should only be administered by, or under the direct supervision of, personnel experienced in the use of dantrolene when used for malignant hyperthermia.

**CONTRA-INDICATIONS**

- With oral use: Acute muscle spasm: avoid when spasticity is useful, for example, locomotion.

**CAUTIONS**

- With intravenous use: Avoid extravasation (risk of tissue necrosis).

**INTERACTIONS**

- With oral use: Females (hepatotoxicity): history of liver disorders (hepatotoxicity) - if doses greater than 400 mg daily (hepatotoxicity), impaired cardiac function, impaired pulmonary function; patients over 50 years (hepatotoxicity): therapeutic effect may take a few weeks to develop—discontinue if no response within 6–8 weeks.

**Medicinal forms**

- **Powder for solution for injection**
  - **Dantrolen** (Norgine Pharmaceuticals Ltd)
    - Dantrolene sodium 20 mg: Dantrolen Intravenous 20mg powder for solution for injection vials | 12 vial (Hospital only) | 36 vial (Hospital only) £1,836.00 (Hospital only)
  - **Capsule**
    - **Dantrium** (Norgine Pharmaceuticals Ltd)
      - Dantrolene sodium 25 mg: Dantrium capsules | 100 capsule (Hospital only) £16.87 DT price = £16.87
      - Dantrolene sodium 100 mg: Dantrium capsules | 100 capsule (Hospital only) £43.07 DT price = £43.07

Local anaesthesia

Local anaesthesia

**Local anaesthetic drugs**

The use of local anaesthetics by injection or by application to mucous membranes to produce local analgesia is discussed in this section.

Local anaesthetic drugs act by causing a reversible block to conduction along nerve fibres. They vary widely in their potency, toxicity, duration of action, stability, solubility in water, and ability to penetrate mucous membranes. These factors determine their application, e.g. topical (surface), infiltration, peripheral nerve block, intravenous regional anaesthesia (Bier’s block), plexus, epidural (extradural), or spinal (intrathecal or subarachnoid) block. Local anaesthetics may also be used for postoperative pain relief, thereby reducing the need for analgesics such as opioids.

Bupivacaine hydrochloride p. 1238 has a longer duration of action than other local anaesthetics. It has a slow onset of action, taking up to 30 minutes for full effect. It is often used in lumbar epidural blockade and is particularly suitable for continuous epidural analgesia in labour, or for postoperative pain relief. It is the principal drug used for spinal anaesthesia. Hyperbaric solutions containing glucose may be used for spinal block.

Chloroprocaine hydrochloride p. 1240, a para-amino benzoic acid ester, is used for spinal anaesthesia in adults where the planned procedure should not exceed 40 minutes.

Levobupivacaine p. 1241, an isomer of bupivacaine, has anaesthetic and analgesic properties similar to bupivacaine hydrochloride, but is thought to have fewer adverse effects.
Lidocaine hydrochloride p. 1242 is effectively absorbed from mucous membranes and is a useful surface anaesthetic in concentrations up to 10%. Except for surface anaesthesia and dental anaesthesia, solutions should not usually exceed 1% in strength. The duration of the block (with adrenaline/epinephrine p. 216) is about 90 minutes.

Prilocaine hydrochloride p. 1246 is a local anaesthetic of low toxicity which is similar to lidocaine hydrochloride. A hyperbaric solution of prilocaine hydrochloride (containing glucose) may be used for spinal anaesthesia.

Ropivacaine hydrochloride p. 1247 is an amide-type local anaesthetic agent similar to bupivacaine hydrochloride. It is less cardiotoxic than bupivacaine hydrochloride, but also less potent.

Tetracaine p. 1248, a para-aminobenzoic acid ester, is an effective local anaesthetic for topical application; a 4% gel is indicated for anaesthesia before venepuncture or venous cannulation. It is rapidly absorbed from mucous membranes and should never be applied to inflamed, traumatised, or highly vascular surfaces. It should never be used to provide anaesthesia for bronchoscopy or cystoscopy because lidocaine hydrochloride is a safer alternative.

Administration by injection
The dose of local anaesthetic depends on the injection site and the procedure used. In determining the safe dosage, it is important to take account of the rate of absorption and excretion, and of the potency. The patient’s age, weight, physique, and clinical condition, and the vascularity of the administration site and the duration of administration, must also be considered.

Uptake of local anaesthetics into the systemic circulation determines their duration of action and produces toxicity.

NHS Improvement has advised (September 2016) that, prior to administration, all injectable medicines must be drawn directly from their original ampoule or container into a syringe and should never be decanted into gallipots or open containers. This is to avoid the risk of medicines being confused with other substances, e.g. skin disinfectants, and to reduce the risk of contamination.

Great care must be taken to avoid accidental intravascular injection; local anaesthetic injections should be given slowly in order to detect inadvertent intravascular administration. When prolonged analgesia is required, a long-acting local anaesthetic is preferred to minimise the likelihood of cumulative systemic toxicity. Local anaesthesia around the oral cavity may impair swallowing and therefore increases the risk of aspiration.

Epidual anaesthesia is commonly used during surgery, often combined with general anaesthesia, because of its protective effect against the stress response of surgery. It is often used when good postoperative pain relief is essential.

Use of vasoconstrictors
Local anaesthetics cause dilatation of blood vessels. The addition of a vasoconstrictor such as adrenaline/epinephrine to the local anaesthetic preparation diminishes local blood flow, slowing the rate of absorption and thereby prolonging the anaesthetic effect. Great care should be taken to avoid inadvertent intravenous administration of a preparation containing adrenaline/epinephrine, and it is not advisable to give adrenaline/epinephrine with a local anaesthetic injection in digits or appendages because of the risk of ischaemic necrosis.

Adrenaline/epinephrine must be used in a low concentration when administered with a local anaesthetic. Care must also be taken to calculate a safe maximum dose of local anaesthetic when using combination products.

In patients with severe hypertension or unstable cardiac rhythm, the use of adrenaline/epinephrine with a local anaesthetic may be hazardous. For these patients an anaesthetic without adrenaline/epinephrine should be used.

**Dental anaesthesia**
Lidocaine hydrochloride is widely used in dental procedures; it is most often used in combination with adrenaline/epinephrine. Lidocaine hydrochloride 2% combined with adrenaline/epinephrine 1 in 80 000 (12.5 micrograms/mL) is a safe and effective preparation; there is no justification for using higher concentrations of adrenaline/epinephrine.

The amide-type local anaesthetics articaine and mepivacaine hydrochloride p. 1245 are also used in dentistry; they are available in cartridges suitable for dental use. Mepivacaine hydrochloride is available with or without adrenaline/epinephrine and articaine is available with adrenaline.

In patients with severe hypertension or unstable cardiac rhythm, mepivacaine hydrochloride without adrenaline/epinephrine may be used. Alternatively, prilocaine hydrochloride with or without felypressin can be used but there is no evidence that it is any safer. Felypressin can cause coronary vasoconstriction when used at high doses; limit dose in patients with coronary artery disease.

**Toxicity**
For management of toxicity see Severe local anaesthetic-induced cardiovascular toxicity below.

**Severe local anaesthetic-induced cardiovascular toxicity**

**Overview**
After injection of a bolus of local anaesthetic, toxicity may develop at any time in the following hour. In the event of signs of toxicity during injection, the administration of the local anaesthetic must be stopped immediately.

Cardiovascular status must be assessed and cardiopulmonary resuscitation procedures must be followed.

In the event of local anaesthetic-induced cardiac arrest, standard cardiopulmonary resuscitation should be initiated immediately. Lidocaine must not be used as anti-arrhythmic therapy.

If the patient does not respond rapidly to standard procedures, 20% lipid emulsion such as Intralipid® [unlicensed indication] should be given intravenously at an initial bolus dose of 1.5 mL/kg over 1 minute, followed by an infusion of 15 mL/kg/hour. After 5 minutes, if cardiovascular stability has not been restored or circulation deteriorates, give a maximum of two further bolus doses of 1.5 mL/kg over 1 minute, 5 minutes apart, and increase the infusion rate to 30 mL/kg/hour. Continue infusion until cardiovascular stability and adequate circulation are restored or maximum cumulative dose of 12 mL/kg is given.

Standard cardiopulmonary resuscitation must be maintained throughout lipid emulsion treatment. Propofol is not a suitable alternative to lipid emulsion. Further advice on ongoing treatment should be obtained from the National Poisons Information Service.

Detailed treatment algorithms and accompanying notes are available at www.toxbase.org or can be found in the Association of Anaesthetists of Great Britain and Ireland safety guideline, Management of Severe Local Anaesthetic Toxicity and Management of Severe Local Anaesthetic Toxicity – Accompanying notes.
ANAESTHETICS, LOCAL

Adrenaline with articaine hydrochloride

(Carticaine hydrochloride with epinephrine)

- INDICATIONS AND DOSE
  - infiltration anaesthesia in dentistry
    - BY REGIONAL ADMINISTRATION
    - Adult: Consult expert dental sources
  - DOSES AT EXTREMES OF BODY-WEIGHT
    To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal body-weight.

IMPORTANT SAFETY INFORMATION

Should only be administered by, or under the direct supervision of, personnel experienced in their use, with adequate training in anaesthesia and airway management, and should not be administered parenterally unless adequate resuscitation equipment is available.

Adrenaline/epinephrine must be used in a low concentration when administered with a local anaesthetic. The total dose of adrenaline should not exceed 500 micrograms and it is essential not to exceed a concentration of 1 in 200 000 (5 micrograms/mL) if more than 50 mL of the mixture is to be injected.

CONTRA-INDICATIONS

Application to damaged skin - application to the middle ear (may cause ototoxicity) - complete heart block - injection into infected tissues - infection into inflamed tissues - preparations containing preservatives should not be used for caudal, epidural, or spinal block, or for intravenous regional anaesthesia (Bier's block)

CONTRA-INDICATIONS, FURTHER INFORMATION

- injection site Local anaesthetics should not be injected into inflamed or infected tissues nor should they be applied to damaged skin. Increased absorption into the blood increases the possibility of systemic side-effects, and the local anaesthetic effect may also be reduced by altered local pH.
- CAUTIONS
  - use of vasoconstrictors In patients with severe hypertension or unstable cardiac rhythm, the use of adrenaline with a local anaesthetic may be hazardous. For these patients an anaesthetic without adrenaline should be used.
  - INTERACTIONS → Appendix 1: articaine, sympathomimetics, vasoconstrictor
  - SIDE-EFFECTS
    - Angina - angle-closure glaucoma - anorexia - anxiety - arrhythmias - blurred vision - cardiac arrest - cold extremities - confusion - convulsions - difficulty in micturition - dizziness - drowsiness - dry mouth - dyspnoea - feeling of inebriation - headache - hyperglycaemia - hypersalivation - hypertension (risk of cerebral haemorrhage) - hypokalaemia - insomnia - lightheadedness - metabolic acidosis - methaemoglobinemia - muscle twitching - mydriasis - myocardial depression (resulting in hypotension and bradycardia) - myocardial infarction - nausea - numbness of the tongue and perioral region - pallor - palpitation - paraesthesia (including sensations of hot and cold) - peripheral vasodilatation (resulting in hypotension and bradycardia) - psychosis - pulmonary oedema (on excessive dosage or extreme sensitivity) - restlessness - sweating - tachycardia - tinnitus - tissue necrosis at injection site and of extremities, bowel, liver and kidneys - transient excitation (followed by depression with drowsiness, respiratory failure, unconsciousness, and coma) - tremor - urinary retention - vomiting - weakness

SIDE-EFFECTS, FURTHER INFORMATION

- Toxic effects
  - Toxic effects after administration of local anaesthetics are a result of excessively high plasma concentrations; severe toxicity usually results from inadvertent intravascular injection or too rapid injection.
  - Following most regional anaesthetic procedures, maximum arterial plasma concentration of anaesthetic develops within about 10 to 25 minutes, so careful surveillance for toxic effects is necessary during the first 30 minutes after injection.
  - The systemic toxicity of local anaesthetics mainly involves the central nervous and cardiovascular systems.

- ALLERGY AND CROSS-SENSITIVITY
  - Hypersensitivity and cross-sensitivity
  - Hypersensitivity reactions occur mainly with the ester-type local anaesthetics, such as tetracaine and chloroprocaine; reactions are less frequent with the amide types, such as articaine, bupivacaine, levobupivacaine, lidocaine, mepivacaine, prilocaine, and ropivacaine. Cross-sensitivity reactions may be avoided by using the alternative chemical type.

- PREGNANCY
  - Use only if potential benefit outweighs risk—no information available.

- BREAST FEEDING
  - Avoid breast-feeding for 48 hours after administration.

- HEPATIC IMPAIRMENT
  - Use with caution; increased risk of side-effects in severe impairment.

- RENAL IMPAIRMENT
  - Manufacturers advise use with caution in severe impairment.

- MONITORING REQUIREMENTS
  - Consider monitoring blood pressure and ECG (advised with systemic adrenaline/epinephrine).

- MEDICINAL FORMS
  - There can be variation in the licensing of different medicines containing the same drug.

Solution for injection

EXCIPIENTS: May contain Sulfites

- Septanest (Septodont Ltd)
  - Adrenaline (as Adrenaline acid tartrate) 10 microgram per 1 mL
  - Articaine hydrochloride 40 mg per 1 mL

Septanest 1 in 100,000 solution for injection cartridges | 50 cartridge no price available

Adrenaline (as Adrenaline acid tartrate) 5 microgram per 1 mL, Articaine hydrochloride 40 mg per 1 mL

Septanest 1 in 200,000 solution for injection cartridges | 50 cartridge no price available

Bupivacaine hydrochloride

- INDICATIONS AND DOSE
  - Surgical anaesthesia, lumbar epidural block
    - BY REGIONAL ADMINISTRATION
    - Adult: 75–150 mg, dose administered using a 5 mg/mL (0.5%) solution
Surgical anaesthesia, field block
- **BY REGIONAL ADMINISTRATION**
- Adult: Up to 150 mg, dose administered using a 2.5 mg/mL (0.25%) or 5 mg/mL (0.5%) solution

Surgical anaesthesia, thoracic epidural block
- **BY THORACIC EPIDURAL**
- Adult: 12.5–50 mg, dose administered using a 2.5 mg/mL (0.25%) or 5 mg/mL (0.5%) solution

Surgical anaesthesia, caudal epidural block
- **BY REGIONAL ADMINISTRATION**
- Adult: 50–150 mg, dose administered using a 2.5 mg/mL (0.25%) or 5 mg/mL (0.5%) solution

Surgical anaesthesia, major nerve block
- **BY REGIONAL ADMINISTRATION**
- Adult: 50–175 mg, dose administered using 5 mg/mL (0.5%) solution

Acute pain, intra-articular block
- **BY INTRA-ARTICULAR INJECTION**
- Adult: Up to 100 mg, dose administered using a 2.5 mg/mL (0.25%) solution; when co-administered with bupivacaine by another route, total max. 150 mg

Acute pain, thoracic epidural block
- **BY CONTINUOUS EPIDURAL INFUSION**
- Adult: 6.3–18.8 mg/hour, dose administered using a 1.25 mg/mL (0.125%) or 2.5 mg/mL (0.25%) solution; maximum 400 mg per day

Acute pain, labour
- **BY CONTINUOUS EPIDURAL INFUSION**
- Adult: 6.25–12.5 mg/hour, dose administered using a 1.25 mg/mL (0.125%) solution; maximum 400 mg per day

Acute pain, lumbar epidural block
- **INITIALLY BY LUMBAR EPIDURAL**
- Adult: 15–37.5 mg, then (by lumbar epidural) 15–37.5 mg, repeated when required at intervals of at least 30 minutes, dose administered by intermittent injection using a 2.5 mg/mL (0.25%) solution, alternatively (by continuous epidural infusion) 12.5–18.8 mg/hour, dose administered using a 1.25 mg/mL (0.125%) or 2.5 mg/mL (0.25%) solution; maximum 400 mg per day

Acute pain, field block
- **BY REGIONAL ADMINISTRATION**
- Adult: Up to 150 mg, dose administered using a 2.5 mg/mL (0.25%) solution

**MARCAIN HEAVY**

Intrathecal anaesthesia for surgery
- **BY INTRATHECAL INJECTION**
- Adult: 10–20 mg

**DOSES AT EXTREMES OF BODY-WEIGHT**
To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal body-weight.

**IMPORTANT SAFETY INFORMATION**
The licensed doses stated may not be appropriate in some settings and expert advice should be sought. Should only be administered by, or under the direct supervision of, personnel experienced in their use, with adequate training in anaesthesia and airway management, and should not be administered parenterally unless adequate resuscitation equipment is available.

**CONTRA-INDICATIONS** Application to the middle ear (can cause ototoxicity) - avoid injection into infected tissues - avoid injection into inflamed tissues - complete heart block - preparations containing preservatives should not be used for caudal, epidural, or spinal block, or for intravenous regional anaesthesia (Bier’s block) - should not be applied to damaged skin

**CONTRA-INDICATIONS, FURTHER INFORMATION**
- Injection site Local anaesthetics should not be injected into inflamed or infected tissues nor should they be applied to damaged skin. Increased absorption into the blood increases the possibility of systemic side-effects, and the local anaesthetic effect may also be reduced by altered local pH.
- **CAUTIONS** Cardiovascular disease - cerebral atheroma - debilitated patients (consider dose reduction) - elderly (consider dose reduction) - epilepsy - hypotension - hypovolaemia - impaired cardiac conduction - impaired respiratory function - myasthenia gravis - myocardial depression may be more severe and more resistant to treatment - shock
- **INTERACTIONS** - Appendix 1: anaesthetics, local
- **SIDE-EFFECTS** Arhythmias - blurred vision - cardiac arrest - convulsions - dizziness - drowsiness - feeling of inebriation - headache - lightheadedness - muscle twitching - myocardial depression (resulting in hypotension and bradycardia) - nausea - numbness of the tongue and perioral region - paraesthesia (including sensations of hot and cold) - peripheral vasodilatation (resulting in hypotension and bradycardia) - restlessness - tinnitus - transient excitation (followed by depression with drowsiness, respiratory failure, unconsciousness, and coma) - tremors - vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**
- Toxic effects Toxic effects after administration of local anaesthetics are a result of excessively high plasma concentrations; severe toxicity usually results from inadvertent intravascular injection or too rapid injection.

Following most regional anaesthetic procedures, maximum arterial plasma concentration of anaesthetic develops within about 10 to 25 minutes, so careful surveillance for toxic effects is necessary during the first 30 minutes after injection.

The systemic toxicity of local anaesthetics mainly involves the central nervous and cardiovascular systems.

**ALLERGY AND CROSS-SENSITIVITY**
- Hypersensitivity and cross-sensitivity Hypersensitivity reactions occur mainly with the ester-type local anaesthetics, such as tetracaine and chloroprocaine; reactions are less frequent with the amide types, such as articaine, bupivacaine, levobupivacaine, lidocaine, mepivacaine, prilocaine, and ropivacaine. Cross-sensitivity reactions may be avoided by using the alternative chemical type.

**PREGNANCY** Use lower doses for intrathecal use during late pregnancy. Large doses during delivery can cause neonatal respiratory depression, hypotonia, and bradycardia after epidural block.

**BREAST FEEDING** Amount too small to be harmful.

**HEPATIC IMPAIRMENT** Use with caution in severe impairment.

**RENAL IMPAIRMENT** Use with caution in severe impairment.

**MEDIcular FORMS** There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection, infusion, solution for infusion

**Solution for Injection**
- **Bupivacaine hydrochloride (Non-proprietary)**
  - Bupivacaine hydrochloride 2.5 mg per 1 ml Bupivacaine 0.25% solution for injection 10ml Sure-Amp ampoules | 20 ampoule PM £17.50
  - Bupivacaine hydrochloride 5 mg per 1 ml Bupivacaine 0.5% solution for injection 10ml Sure-Amp ampoules | 20 ampoule PM £18.30

Downloaded from www.medicalbr.com
Bupivacaine 50mg/10ml (0.5%) solution for injection ampoules | 10 ampoule (£3.8) no price available

- **Marcain** (Aspen Pharma Trading Ltd)
  - **Bupivacaine hydrochloride 2.5 mg per 1 ml** Marcain 0.25% solution for injection 10ml Polyanephar ampoules | 5 ampoule (£3.92)
  - **Bupivacaine hydrochloride 5 mg per 1 ml** Marcain 0.5% solution for injection 10ml Polyanephar ampoules | 5 ampoule (£3.25)
  - **Marcain Heavy** (Aspen Pharma Trading Ltd)
  - **Bupivacaine hydrochloride 5 mg per 1 ml** Marcain Heavy 0.5% solution for injection 4ml ampoules | 5 ampoule (£3.72)

**Infusion**
- **Bupivacaine hydrochloride (Non-proprietary)**
  - **Bupivacaine hydrochloride 1 mg per 1 ml** Bupivacaine 100mg/100ml (0.1%) infusion bags | 20 bag (£110) no price available
  - **Bupivacaine hydrochloride 250mg/250ml (0.1%)** infusion bags | 20 bag (£280) no price available
  - **Bupivacaine hydrochloride 1.25 mg per 1 ml** Bupivacaine 312.5mg/250ml (0.125%) infusion bags | 20 bag (£7.27) no price available

**Bupivacaine with adrenaline**
The properties listed below are those particular to the combination only. For the properties of the components please consider, bupivacaine hydrochloride p. 1238, adrenaline/epinephrine p. 216.

- **INDICATIONS AND DOSE**
  - **Surgical anaesthesia**
    - By lumbar epidural, or by local infiltration, or by caudal epidural
    - Adult: (consult product literature)
  - **Acute pain management**
    - By lumbar epidural, or by local infiltration
    - Adult: (consult product literature)

**IMPORTANT SAFETY INFORMATION**
Adrenaline/epinephrine must be used in a low concentration when administered with a local anaesthetic. The total dose of adrenaline should not exceed 500 micrograms and it is essential not to exceed a concentration of 1 in 200 000 (5 micrograms/mL) if more than 50 mL of the mixture is to be injected.

- **CAUTIONS**
  - **CAUTIONS, FURTHER INFORMATION**
  In patients with severe hypertension or unstable cardiac rhythm, the use of adrenaline with a local anaesthetic may be hazardous. For these patients an anaesthetic without adrenaline should be used.
  - **INTERACTIONS** → Appendix 1: anaesthetics, local, sympathomimetics, vasoconstrictor

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Solution for injection**
    - **Bupivacaine with adrenaline (Non-proprietary)**
      - **Adrenaline (as Adrenaline acid tartrate) 5 microgram per 1 ml, Bupivacaine hydrochloride 2.5 mg per 1 ml** Bupivacaine 25mg/10ml (0.25%) / Adrenaline (base) 50micrograms/10ml (1 in 200,000) solution for injection ampoules | 10 ampoule (£3.8) £40.00
      - **Adrenaline (as Adrenaline acid tartrate) 5 microgram per 1 ml, Bupivacaine hydrochloride 5 mg per 1 ml** Bupivacaine 50mg/10ml (0.5%) / Adrenaline (base) 50micrograms/10ml (1 in 200,000) solution for injection ampoules | 10 ampoule (£3.8) £45.00

**Chloroprocaine hydrochloride**
- **INDICATIONS AND DOSE**
  - Intrathecal anaesthesia for surgical procedures lasting up to 40 minutes
  - By slow intrathecal injection
  - Adult: 40–50 mg, dose depends on desired length of block

**DOSES AT EXTREMES OF BODY-WEIGHT**
To avoid excessive dosage in obese patients, dose may need to be calculated on the basis of ideal body-weight.

**IMPORTANT SAFETY INFORMATION**
The licensed doses stated above may not be appropriate in some settings and expert advice should be sought. Should only be administered by, or under the direct supervision of, personnel experienced in their use, with adequate training in anaesthesia and airway management, and should not be administered parenterally unless adequate resuscitation equipment is available.

- **CONTRA-INDICATIONS**
  - Application to the middle ear (can cause ototoxicity) - avoid injection into infected tissues - avoid injection into inflamed tissues - complete heart block - preparations containing preservatives should not be used for caudal, epidural, or spinal block, for intravenous regional anaesthesia (Bier’s block) - severe anaemia - should not be applied to damaged skin

**CONTRA-INDICATIONS, FURTHER INFORMATION**
- Injection site Local anaesthetics should not be injected into inflamed or infected tissues nor should they be applied to damaged skin. Increased absorption into the blood increases the possibility of systemic side-effects, and the local anaesthetic effect may also be reduced by altered local pH.

- **CAUTIONS**
  - Acute porphyrias p. 969 - cardiovascular disease - debilitated patients (consider dose reduction) - elderly (consider dose reduction) - epilepsy - hypovolaemia - impaired cardiac conduction - impaired respiratory function - myasthenia gravis - shock

- **INTERACTIONS** → Appendix 1: chloroprocaine

- **SIDE-EFFECTS**
  - Uncommon Hypertension

  - Frequency not known Arrhythmias - blurred vision - cardiac arrest - convulsions - dizziness - drowsiness - feeling of inebriation - headache - lightheadedness - muscle twitching - myocardial depression (resulting in hypotension and bradycardia) - nausea - numbness of the tongue and perioral region - paraesthesia (including sensations of hot and cold) - peripheral vasodilation (resulting in hypotension and bradycardia) - restlessness - tinnitus - transient excitation (followed by depression with drowsiness, respiratory failure, unconsciousness, and coma) - tremors - vomiting

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Toxic effects Toxic effects after administration of local anaesthetics are a result of excessively high plasma concentrations; severe toxicity usually results from inadvertent intravascular injection or too rapid injection. Following most regional anaesthetic procedures, maximum arterial plasma concentration of anaesthetic develops within about 10 to 25 minutes, so careful surveillance for toxic effects is necessary during the first 30 minutes after injection.

  - The systemic toxicity of local anaesthetics mainly involves the central nervous and cardiovascular systems.

- **ALLERGY AND CROSS-SENSITIVITY**
  - Hypersensitivity and cross-sensitivity Hypersensitivity reactions occur mainly with the ester-type local
anaesthetics, such as tetracaine and chlorprocaine; reactions are less frequent with the amide types, such as articaine, bupivacaine, levobupivacaine, lidocaine, mepivacaine, prilocaine, and ropivacaine. Cross-sensitivity reactions may be avoided by using the alternative chemical type.

- **PREGNANCY** Avoid—no information available.
- **BREAST FEEDING** Avoid—no information available.
- **HEPATIC IMPAIRMENT** Use with caution in severe impairment.
- **RENAL IMPAIRMENT** Use with caution in severe impairment.

### MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**
- Ampres (AMCo)
  - Chloroprocaine hydrochloride 10 mg per 1 ml Ampres 50mg/5ml solution for injection ampoules | 10 ampoule £87.50

### Levobupivacaine

#### INDICATIONS AND DOSE

**Acute postoperative pain**
- **BY CONTINUOUS EPIDURAL INFUSION**
  - Adult: 12.5–18.75 mg/hour, dose administered using a 1.25 mg/mL (0.125%) or 2.5 mg/mL (0.25%) solution; maximum 400 mg per day

**Acute labour pain**
- **BY LUMBAR EPIDURAL**
  - Adult: 15–25 mg, repeated at intervals of at least 15 minutes, dose administered using a 2.5 mg/mL (0.25%) solution; maximum 400 mg per day
  - **BY CONTINUOUS EPIDURAL INFUSION**
  - Adult: 5–12.5 mg/hour, dose administered using a 1.25 mg/mL (0.125%) solution; maximum 400 mg per day

**Surgical anaesthesia, peripheral nerve block**
- **BY REGIONAL ADMINISTRATION**
  - Adult: 2.5–150 mg, dose administered using a 2.5 mg/mL (0.25%) or 5 mg/mL (0.5%) solution

**Surgical anaesthesia, peribulbar nerve block**
- **BY REGIONAL ADMINISTRATION**
  - Adult: 37.5–112.5 mg, dose administered using a 7.5 mg/mL (0.75%) solution

**Surgical anaesthesia for caesarean section**
- **BY LUMBAR EPIDURAL**
  - Adult: 75–150 mg, to be given over 15–20 minutes, dose administered using a 5 mg/mL (0.5%) solution

**Surgical anaesthesia**
- **BY LUMBAR EPIDURAL**
  - Adult: 50–150 mg, to be given over 5 minutes, dose administered using a 5 mg/mL (0.5%) or 7.5 mg/mL (0.75%) solution
  - **BY INTRATHecal INJECTION**
  - Adult: 15 mg, dose administered using a 5 mg/mL (0.5%) solution
  - **BY LOCAL INFILTRATION**
  - Adult: 2.5–150 mg, dose administered using a 2.5 mg/mL (0.25%) solution

**DOSES AT EXTREMES OF BODY-WEIGHT**

To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal body-weight.

### IMPORTANT SAFETY INFORMATION

The licensed doses stated may not be appropriate in some settings and expert advice should be sought.

Should only be administered by, or under the direct supervision of, personnel experienced in their use, with adequate training in anaesthesia and airway management, and should not be administered parenterally unless adequate resuscitation equipment is available.

- **CONTRA-INDICATIONS** Application to the middle ear (can cause ototoxicity) • avoid injection into infected tissues • avoid injection into inflamed tissues • complete heart block • preparations containing preservatives should not be used for caudal, epidural, or spinal block, or for intravenous regional anaesthesia (Bier’s block) • should not be applied to damaged skin

- **CONTRA-INDICATIONS, FURTHER INFORMATION**
  - Injection site Local anaesthetics should not be injected into inflamed or infected tissues nor should they be applied to damaged skin. Increased absorption into the blood increases the possibility of systemic side-effects, and the local anaesthetic effect may also be reduced by altered local pH.

- **CAUTIONS** Cardiovascular disease • debilitated patients (consider dose reduction) • elderly (consider dose reduction) • epilepsy • hypovolaemia • impaired cardiac conduction • impaired respiratory function • myasthenia gravis • shock

- **INTERACTIONS** → Appendix 1: anaesthetics, local

- **SIDE-EFFECTS** Anaemia • arrhythmias • blurred vision • cardiac arrest • convulsions • dizziness • drowsiness • feeling of inebriation • headache • lightheadedness • muscle twitching • myocardial depression (resulting in hypotension and bradycardia) • nausea • numbness of the tongue and perioral region • paraesthesia (including sensations of heat and cold) • peripheral vasodilatation (resulting in hypotension and bradycardia) • pyrexia • restlessness • sweating • tinnitus • transient excitement (followed by depression with drowsiness, respiratory failure, unconsciousness, and coma) • tremors • vomiting

- **SIDE-EFFECTS, FURTHER INFORMATION**
  - Toxic effects
    - Toxic effects after administration of local anaesthetics are a result of excessively high plasma concentrations; severe toxicity usually results from inadvertent intravascular injection or too rapid injection.
    - Following most regional anaesthetic procedures, maximum arterial plasma concentration of anaesthetic develops within about 10 to 25 minutes, so careful surveillance for toxic effects is necessary during the first 30 minutes after injection.
    - The systemic toxicity of local anaesthetics mainly involves the central nervous and cardiovascular systems.

- **ALLERGY AND CROSS-SENSITIVITY**
  - Hypersensitivity and cross-sensitivity
    - Hypersensitivity reactions occur mainly with the ester-type local anaesthetics, such as tetracaine and chlorprocaine; reactions are less frequent with the amide types, such as articaine, bupivacaine, levobupivacaine, lidocaine, mepivacaine, prilocaine, and ropivacaine. Cross-sensitivity reactions may be avoided by using the alternative chemical type.

- **PREGNANCY** Large doses during delivery can cause neonatal respiratory depression, hypotonia, and bradycardia after epidural block. Avoid if possible in the first trimester—toxicity in animal studies. May cause fetal distress syndrome. Do not use for paracervical block in obstetrics. Do not use 7.5 mg/mL strength in obstetrics.

- **BREAST FEEDING** Amount too small to be harmful.

- **HEPATIC IMPAIRMENT** Use with caution.

- **DIRECTIONS FOR ADMINISTRATION** For 1.25 mg/mL concentration dilute standard solutions with sodium chloride 0.9%.
Lidocaine hydrochloride (Lignocaine hydrochloride)

**INDICATIONS AND DOSE**

**Infiltration anaesthesia**
- **BY LOCAL INFILTRATION**
  - Adult: Dose to be given according to patient’s weight and nature of procedure; max. 200 mg, maximum dose 500 mg if given in solutions containing adrenaline

**DOSES AT EXTREMES OF BODY-WEIGHT**
- When used by local infiltration To avoid excessive dosage in obese patients, weight-based doses for non-emergency indications may need to be calculated on the basis of ideal body-weight.

**Intravenous regional anaesthesia and nerve block**
- **BY REGIONAL ADMINISTRATION**
  - Adult: Seek expert advice

**Pain relief (in anal fissures, haemorrhoids, pruritus ani, pruritus vulvae, herpes zoster, or herpes labialis)**
- **TO THE SKIN USING OINTMENT**
  - Adult: Apply 1–2 mL as required, avoid long-term use

**Sore nipples from breast-feeding**
- **TO THE SKIN USING OINTMENT**
  - Adult: Apply using gauze and wash off immediately before next feed

**LMX 4**

**Anaesthesia before venous cannulation or venepuncture**
- **TO THE SKIN**
  - Child 1–2 months: Apply up to 1 g, apply thick layer to small area (2.5 cm × 2.5 cm) of non-irritated skin at least 30 minutes before procedure; may be applied under an occlusive dressing; max. application time 60 minutes, remove cream with gauze and perform procedure after approximately 5 minutes
  - Child 3–11 months: Apply up to 1 g, apply thick layer to small area (2.5 cm × 2.5 cm) of non-irritated skin at least 30 minutes before procedure; may be applied under an occlusive dressing; max. application time 4 hours, remove cream with gauze and perform procedure after approximately 5 minutes
  - Child 1–17 years: Apply 1–2.5 g, apply thick layer to small area (2.5 cm × 2.5 cm) of non-irritated skin at least 30 minutes before procedure; may be applied under an occlusive dressing; max. application time 5 hours, remove cream with gauze and perform procedure after approximately 5 minutes

**VERSATIS**
- **Postherpetic neuralgia**
  - **TO THE SKIN**
  - Adult: Apply once daily for up to 12 hours, followed by a 12-hour plaster-free period; discontinue if no response after 4 weeks, to be applied to intact, dry, non-hairy, non-irritated skin, up to 3 plasters may be used to cover large areas; plasters may be cut

**XYLOCAINE**
- **During delivery in obstetrics**
  - **TO THE SKIN**
  - Adult: Up to 20 doses

**IMPORTANT SAFETY INFORMATION**
- **When used by local infiltration**
  - The licensed doses stated may not be appropriate in some settings and expert advice should be sought. Should only be administered by, or under the direct supervision of, personnel experienced in their use, with adequate training in anaesthesia and airway management, and should not be administered parenterally unless adequate resuscitation equipment is available.

**CONTRA-INDICATIONS, FURTHER INFORMATION**
- **When used by regional administration All grades of atrioventricular block - application to the middle ear (can cause ototoxicity) - avoid injection into infected tissues - avoid injection into inflamed tissues - preparations containing preservatives should not be used for caudal, epidural, or spinal block, or for intravenous regional anaesthesia (Bier’s block) - severe myocardial depression - should not be applied to damaged skin - sino-atrial disorders**

**CONTRA-INDICATIONS, FURTHER INFORMATION**
- **When used by regional administration**
  - Local anaesthetics should not be injected into inflamed or infected tissues nor should they be applied to damaged skin. Increased absorption into the blood increases the possibility of systemic side-effects, and the local anaesthetic effect may also be reduced by altered local pH.

**CAUTIONS**
- **When used by regional administration**
  - Acute porphyria (consider infusion with glucose for its anti-porphyrinogenic effects) - children (consider dose reduction) - congestive cardiac failure (consider lower dose) - debilitated patients (consider dose reduction) - elderly (consider dose reduction) - epilepsy - hypovolaemia - impaired cardiac conduction - impaired respiratory function - myasthenia gravis - post cardiac surgery (consider lower dose) - shock

**INTERACTIONS**
- Appendix 1: antiarrhythmics

**SIDE-EFFECTS**
- **Common or very common**
  - When used by regional administration Bradycardia (may lead to cardiac arrest) - confusion - convulsions - dizziness (particularly if injection too rapid) - drowsiness (particularly if injection too rapid) - hypotension (may lead to cardiac arrest) - paraesthesia (particularly if injection too rapid) - respiratory depression
  - Rare
  - When used by regional administration Anaphylaxis
Frequency not known
- When used by regional administration Transient excitation (followed by depression with drowsiness, respiratory failure, unconsciousness, and coma) • arrhythmias • blurred vision • cardiac arrest • feeling of inebriation • headache • hypoglycaemia (following intrathecal or extradural administration) • methaemoglobinemia • muscle twitching • myocardial depression (resulting in hypotension and bradycardia) • nausea • numbness of the tongue and perioral region •ystagnus • peripheral vasodilatation (resulting in hypotension and bradycardia) • rash • restlessness • tinnitus • tremors • vomiting

SIDE-EFFECTS, FURTHER INFORMATION
- Topical application A single application of a topical lidocaine preparation does not generally cause systemic side-effects.
- Toxic effects
  - When used by regional administration Toxic effects after administration of local anaesthetics are a result of excessively high plasma concentrations; severe toxicity usually results from inadvertent intravascular injection or too rapid injection. Following most regional anaesthetic procedures, maximum arterial plasma concentration of anaesthetic develops within about 10 to 25 minutes, so careful surveillance for toxic effects is necessary during the first 30 minutes after injection. The systemic toxicity of local anaesthetics mainly involves the central nervous and cardiovascular systems.
  - Methaemoglobinemia
  - When used by regional administration Methaemoglobinemia can be treated with an intravenous injection of methylenithioninium chloride.

ALLERGY AND CROSS-SENSITIVITY
- Hypersensitivity and cross-sensitivity Hypersensitivity reactions occur mainly with the ester-type local anaesthetics, such as tetracaine and chloroprocaine; reactions are less frequent with the amide types, such as articaine, bupivacaine, levobupivacaine, lidocaine, mepivacaine, prilocaine, and ropivacaine. Cross-sensitivity reactions may be avoided by using the alternative chemical type.

PREGNANCY
- Crosses the placenta but not known to be harmful in animal studies—use if benefit outweighs risk. When used as a local anaesthetic, large doses can cause fetal bradycardia; if given during delivery can also cause neonatal respiratory depression, hypotonia, or bradycardia after paracervical or epidural block.

BREAST FEEDING
- Present in milk but amount too small to be harmful.

HEPATIC IMPAIRMENT
- Caution—increased risk of side-effects.

RENAL IMPAIRMENT
- Possible accumulation of lidocaine and active metabolite; caution in severe impairment.

MONITORING REQUIREMENTS
- With systemic use Monitor ECG and have resuscitation facilities available.

PROFESSION SPECIFIC INFORMATION
- Dental practitioners’ formulary
  - Lidocaine ointment 5% may be prescribed. Spray may be prescribed as Lidocaine Spray 10%

NATIONAL FUNDING/ACCESS DECISIONS
- Versatis
  - Scottish Medicines Consortium (SMC) Decisions
    - The Scottish Medicines Consortium has advised (July 2008) that Versatis™ is accepted for restricted use within NHS Scotland for the treatment of postherpetic neuralgia in patients who are intolerant of first-line systemic therapies or when they have been ineffective.

MEDICINAL FORMS
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection, ointment

Solution for injection
- **Lidocaine hydrochloride (Non-proprietary)**
  - Lidocaine hydrochloride 5 mg per 1 ml
    - Lidocaine 50mg/10ml (0.5%) solution for injection ampoules | 10 ampoule (Pbm) | £7.00
  - Lidocaine hydrochloride 10 mg per 1 ml
    - Lidocaine 100mg/10ml (1%) solution for injection Mini-Plasco ampoules | 20 ampoule (Pbm) | £10.89
  - Lidocaine 100mg/10ml (1%) solution for injection ampoules | 10 ampoule (Pbm) | £4.40 DT price = £4.36
  - Lidocaine 100mg/10ml (1%) solution for injection Sure-Amp ampoules | 20 ampoule (Pbm) | £8.80
  - Lidocaine 200mg/20ml (1%) solution for injection vials | 10 vial (Pbm) | £19.00
  - Lidocaine 200mg/20ml (1%) solution for injection ampoules | 10 ampoule (Pbm) | £7.00–£9.63 DT price = £9.63
  - Lidocaine 50mg/5ml (1%) solution for injection ampoules | 10 ampoule (Pbm) | £2.57–£3.10 DT price = £2.57
  - Lidocaine 20mg/2ml (1%) solution for injection ampoules | 10 ampoule (Pbm) | £3.50 DT price = £2.18
  - Lidocaine 50mg/5ml (1%) solution for injection Sure-Amp ampoules | 20 ampoule (Pbm) | £6.00
  - Lidocaine hydrochloride 20 mg per 1 ml
    - Lidocaine 100mg/5ml (2%) solution for injection ampoules | 10 ampoule (Pbm) | £2.67–£3.80 DT price = £2.67
    - Lidocaine 400mg/20ml (2%) solution for injection vials | 10 vial (Pbm) | £19.50
    - Lidocaine 200mg/10ml (2%) solution for injection Mini-Plasco ampoules | 20 ampoule (Pbm) | £14.52
    - Lidocaine 400mg/20ml (2%) solution for injection ampoules | 10 ampoule (Pbm) | £4.00 DT price = £2.34
    - Lidocaine 100mg/5ml (2%) solution for injection Sure-Amp ampoules | 20 ampoule (Pbm) | £6.00
    - Lidocaine 400mg/20ml (2%) solution for injection ampoules | 10 ampoule (Pbm) | £8.00–£9.90 DT price = £9.90

Medicated plaster
- EXCIPIENTS: May contain Hydroxybenzoates (parabens), propylene glycol
  - **Versatis** (Grunenthal Ltd)
    - Lidocaine 50 mg per 1 gram Versatis 5% medicated plasters | 30 plaster (Pbm) | £72.40 DT price = £72.40
  - Cream
    - EXCIPIENTS: May contain Benzyl alcohol, propylene glycol
      - **LMX 4** (Ferndale Pharmaceuticals Ltd)
        - Lidocaine 40 mg per 1 gram LMX 4 cream | 5 gram (P) £2.98 DT price = £2.98 | 30 gram (P) £14.90 DT price = £14.90
  - Ointment
    - **Lidocaine hydrochloride (Non-proprietary)**
      - Lidocaine hydrochloride 50 mg per 1 gram Lidocaine 5% ointment | 15 gram (P) £6.50 DT price = £6.18
  - Spray
    - **Xylocaine** (Aspen Pharma Trading Ltd)
      - Lidocaine 10 mg per actuation Xylocaine 10mg/dose spray | 50 ml (P) £6.29

Lidocaine with adrenaline

The properties listed below are those particular to the combination only. For the properties of the components please consider, lidocaine hydrochloride p. 1242, adrenaline/epinephrine p. 216.

INDICATIONS AND DOSE
- **Local anaesthesia**
  - BY LOCAL INfiltrATION
    - Adult: Dosed according to the type of nerve block required (consult product literature)

IMPORTANT SAFETY INFORMATION
- Adrenaline/epinephrine must be used in a low concentration when administered with a local anaesthetic. The total dose of adrenaline should not exceed 500 micrograms and it is essential not to exceed a
Lidocaine with phenylephrine

The properties listed below are those particular to the combination only. For the properties of the components please consider, lidocaine hydrochloride p. 1242, phenylephrine hydrochloride p. 183.

INDICATIONS AND DOSE
Anaesthesia before nasal surgery, endoscopy, laryngoscopy, or removal of foreign bodies from the nose
  » BY INTRanasAL ADMINISTRATION
  » Adult: Up to 8 sprays

INTERACTIONS  Appendix 1: antiarrhythmics, sympathomimetics, vasoconstrictor

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection
Solution for injection
EXCipients: May contain Sulfites
  » Lignospan Special (Kent Pharmaceuticals Ltd)
  » Adrenaline (as Adrenaline acid tartrate) 12.5 microgram per 1 ml, Lidocaine hydrochloride 20 mg per 1 ml Lignospan Special 2% injection 2.0 ml cartridges
  » 50 cartridge (post) £19.95
  » Rexocaine (Henley Schein Ltd)
  » Adrenaline (as Adrenaline acid tartrate) 12.5 microgram per 1 ml, Lidocaine hydrochloride 20 mg per 1 ml Rexocan 2% injection 2.0 ml cartridges
  » 50 cartridge (post) no price available
  » Xylocaine with Adrenaline (Aspen Pharma Trading Ltd)
  » Adrenaline (as Adrenaline acid tartrate) 5 microgram per 1 ml, Lidocaine hydrochloride 10 mg per 1 ml Xylocaine 1% with Adrenaline 100 micrograms/20 ml (1 in 200,000) solution for injection vials
  » 5 vial (post) £9.66 OT price = £9.66
  » Adrenaline (as Adrenaline acid tartrate) 5 microgram per 1 ml, Lidocaine hydrochloride 20 mg per 1 ml Xylocaine 2% with Adrenaline 100 micrograms/20 ml (1 in 200,000) solution for injection vials
  » 5 vial (post) £8.85 OT price = £8.85

Lidocaine with prilocaine

The properties listed below are those particular to the combination only. For the properties of the components please consider, lidocaine hydrochloride p. 1242, prilocaine hydrochloride p. 1246.

INDICATIONS AND DOSE
Anaesthesia before minor skin procedures including venepuncture
  » TO THE SKIN
  » Child 1-2 months: Apply up to 1 g for maximum 1 hour before procedure, to be applied under occlusive dressing, shorter application time of 15–30 minutes is recommended for children with atopic dermatitis (30 minutes before removal of mollusca); maximum 1 dose per day
  » Child 3-11 months: Apply up to 2 g for maximum 1 hour before procedure, to be applied under occlusive dressing, shorter application time of 15–30 minutes is recommended for children with atopic dermatitis (30 minutes before removal of mollusca); maximum 2 doses per day
  » Child 1-11 years: Apply 1–5 hours before procedure, a thick layer should be applied under occlusive dressing, shorter application time of 15–30 minutes is recommended for children with atopic dermatitis (30 minutes before removal of mollusca); maximum 2 doses per day
  » Child 12-17 years: Apply 1–5 hours before procedure (2–5 hours before procedures on large areas e.g. split skin grafting), a thick layer should be applied under occlusive dressing, shorter application time of 15–30 minutes is recommended for children with atopic dermatitis (30 minutes before removal of mollusca); maximum 2 doses per day
  » Adult: Apply 1–5 hours before procedure (2–5 hours before procedures on large areas e.g. split skin grafting), a thick layer should be applied under occlusive dressing

Anaesthesia on genital skin before injection of local anaesthetics
  » TO THE SKIN
  » Adult: Apply under occlusive dressing for 15 minutes (males) or 60 minutes (females) before procedure

Anaesthesia before surgical treatment of lesions on genital mucosa
  » TO THE SKIN
  » Adult: Apply up to 10 g, to be applied 5–10 minutes before procedure

Anaesthesia before cervical curettage
  » TO THE SKIN
  » Adult: Apply 10 g in lateral vaginal fornices for 10 minutes

Anaesthesia before mechanical cleansing or debridement of leg ulcer
  » TO THE SKIN
  » Adult: Apply up to 10 g for 30–60 minutes, to be applied under occlusive dressing

CONTRAINDICATIONS
Use in child less than 37 weeks corrected gestational age
INTERACTIONS  Appendix 1: anaesthetics, local, antiarrhythmics

PATIENT AND CARER ADVICE
Medicines for Children leaflet: EMLA cream for local anaesthesia
www.medicinesforchildren.org.uk/emla-cream-for-local-anaesthesia

MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.
Cream
  » Lidocaine with prilocaine (Non-proprietary)
  » Lidocaine 25 mg per 1 gram, Prilocaine 25 mg per 1 gram
  » Lidocaine 2.5% / Prilocaine 2.5% cream
  » 5 gram (po) £2.84–£3.29 / 25 gram (po) £12.99 / 30 gram (po) £14.75 OT price = £12.30
  » Denela (Teva UK Ltd)
  » Lidocaine 25 mg per 1 gram, Prilocaine 25 mg per 1 gram
  » 5% cream
  » 5 gram (po) £2.84–£3.29 / 25 gram (po) £12.99 / 30 gram (po) £14.75 OT price = £12.30
  » Emla (Aspen Pharma Trading Ltd)
  » Lidocaine 25 mg per 1 gram, Prilocaine 25 mg per 1 gram
  » 5% cream
  » 5 gram (po) £2.25–£2.99 / 25 gram (po) £11.70 / 30 gram (po) £12.30 OT price = £12.30

The properties listed above are those particular to the combination only. For the properties of the components please consider, lidocaine hydrochloride p. 1242, prilocaine hydrochloride p. 1246.
Lidocaine with tetracaine

The properties listed below are those particular to the combination only. For the properties of the components please consider, lidocaine hydrochloride p. 1242, tetracaine p. 1248.

- **INDICATIONS AND DOSE**
  
  **Anaesthesia before dermatological procedures and venepuncture**
  
  - TO THE SKIN
  - Adult: Apply 1 mm layer using a spatula 30 minutes before procedure, then peel off immediately before procedure; max. application area 400 cm², application time of 60 minutes indicated for certain procedures, such as laser-assisted tattoo removal and laser leg vein ablation

- **INTERACTIONS** → Appendix 1: anaesthetics, local, antiarrhythmics

- **MEDICINAL FORMS**
  
  There can be variation in the licensing of different medicines containing the same drug.

  **Cream**
  
  EXCIPIENTS: May contain Hydroxybenzoates (parabens)

  - Pliaglis (Galderma (UK) Ltd)
  
  Lidocaine 70 mg, Tetracaine 70 mg
  
  Pliaglis 70mg/g / 70mg/g cream | 15 gram | £22.95

Mepivacaine hydrochloride

- **INDICATIONS AND DOSE**
  
  **Infiltration anaesthesia and nerve block in dentistry**
  
  - Child 3-17 years: Consult expert dental sources
  - Adult: Consult expert dental sources

  **DOSES AT EXTREMES OF BODY-WEIGHT**
  
  To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal body-weight.

- **IMPORTANT SAFETY INFORMATION**
  
  Should only be administered by, or under the direct supervision of, personnel experienced in their use, with adequate training in anaesthesia and airway management, and should not be administered parenterally unless adequate resuscitation equipment is available.

- **CONTRA-INDICATIONS**
  
  Application to the middle ear (can cause ototoxicity) · avoid injection into infected tissues · avoid injection into inflamed tissues · complete heart block · preparations containing preservatives should not be used for caudal, epidural, or spinal block, or for intravenous regional anaesthesia (Bier’s block) · should not be applied to damaged skin

  **CONTRA-INDICATIONS, FURTHER INFORMATION**
  
  - Injection site Local anaesthetics should not be injected into inflamed or infected tissues nor should they be applied to damaged skin. Increased absorption into the blood increases the possibility of systemic side-effects, and the local anaesthetic effect may also be reduced by altered local pH.

  **CAUTIONS**
  
  Cardiovascular disease · children (consider dose reduction) · debilitated patients (consider dose reduction) · elderly (consider dose reduction) · epilepsy · hypovolaemia · impaired cardiac conduction · impaired respiratory function · myasthenia gravis · shock

  **INTERACTIONS** → Appendix 1: anaesthetics, local

  **SIDE-EFFECTS**
  
  Arrhythmias · blurred vision · cardiac arrest · convulsions · dizziness · drowsiness · feeling of inebriation · headache · lightheadedness · muscle twitching · myocardial depression (resulting in hypotension and bradycardia) · nausea · numbness of the tongue and perioral region · paraesthesia (including sensations of hot and cold) · peripheral vasodilatation (resulting in hypotension and bradycardia) · restlessness · tinnitus · transient excitation (followed by depression with drowsiness, respiratory failure, unconsciousness, and coma) · tremors · vomiting

- **SIDE-EFFECTS, FURTHER INFORMATION**
  
  - Toxic effects Toxic effects after administration of local anaesthetics are a result of excessively high plasma concentrations; severe toxicity usually results from inadvertent intravascular injection or too rapid injection.
  
  Following most regional anaesthetic procedures, maximum arterial plasma concentration of anaesthetic develops within about 10 to 25 minutes, so careful surveillance for toxic effects is necessary during the first 30 minutes after injection.

  The systemic toxicity of local anaesthetics mainly involves the central nervous and cardiovascular systems.

- **ALLERGY AND CROSS-SENSITIVITY**
  
  - Hypersensitivity and cross-sensitivity Hypersensitivity reactions occur mainly with the ester-type local anaesthetics, such as tetracaine and chloroprocaine; reactions are less frequent with the amide types, such as articaine, bupivacaine, levobupivacaine, lidocaine, mepivacaine, prilocaine, and ropivacaine. Cross-sensitivity reactions may be avoided by using the alternative chemical type.

- **PREGNANCY**
  
  Use with caution in early pregnancy.

- **BREAST FEEDING**
  
  Use with caution.

- **HEPATIC IMPAIRMENT**
  
  Use with caution; increased risk of side-effects in severe impairment.

- **RENAL IMPAIRMENT**
  
  Use with caution; increased risk of side-effects.

- **MEDICINAL FORMS**
  
  There can be variation in the licensing of different medicines containing the same drug.

  **Solution for injection**
  
  - Scandonest plain (Deproco UK Ltd)
  
  Mepivacaine hydrochloride 30 mg per 1 ml Scandonest plain 3% solution for injection 2.2ml cartridges | 50 cartridge no price available

Mepivacaine with adrenaline

The properties listed below are those particular to the combination only. For the properties of the components please consider, mepivacaine hydrochloride above, adrenaline/epinephrine p. 216.

- **INDICATIONS AND DOSE**
  
  **Infiltration anaesthesia and nerve block in dentistry**
  
  - BY LOCAL INfiltrATION
  - Adult: (consult product literature)

- **IMPORTANT SAFETY INFORMATION**
  
  Adrenaline/epinephrine must be used in a low concentration when administered with a local anaesthetic. The total dose of adrenaline should not exceed 500 micrograms and it is essential not to exceed a concentration of 1 in 200 000 (5 micrograms/mL) if more than 50 mL of the mixture is to be injected.

- **INTERACTIONS** → Appendix 1: anaesthetics, local, sympathomimetics, vasoconstrictor
Prilocaine hydrochloride

**INDICATIONS AND DOSE**

**DOSES AT EXTREMES OF BODY-WEIGHT**

To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal body-weight.

CITANEST 1%®

**Infiltration anaesthesia | Nerve block**

- By regional administration
  - Adult: 100–200 mg/minute, alternatively may be given in incremental doses; dose adjusted according to site of administration and response, and in elderly and debilitated patients (smaller doses may be required); maximum 400 mg per course

PRILOTEKAL®

**Spinal anaesthesia**

- By intrathecal injection
  - Adult: Usual dose 40–60 mg (max. per dose 80 mg), dose may need to be reduced in elderly or debilitated patients, or in late pregnancy

**IMPORTANT SAFETY INFORMATION**

Should only be administered by, or under the direct supervision of, personnel experienced in their use, with adequate training in anaesthesia and airway management, and should not be administered parenterally unless adequate resuscitation equipment is available.

**CONTRA-INDICATIONS**

Acquired methaemoglobinaemia - anaemia - application to the middle ear (can cause ototoxicity) - avoid injection into infected tissues - avoid injection into inflamed tissues - complete heart block - congenital methaemoglobinaemia - preparations containing preservatives should not be used for caudal, epidural, or spinal block, or for intravenous regional anaesthesia (Bier’s block) - should not be applied to damaged skin

**CONTRA-INDICATIONS, FURTHER INFORMATION**

- Injection site Local anaesthetics should not be injected into inflamed or infected tissues nor should they be applied to damaged skin. Increased absorption into the blood increases the possibility of systemic side-effects, and the local anaesthetic effect may also be reduced by altered local pH.

**CAUTIONS**

Acute porphyrias p. 969 - cardiovascular disease - debilitated patients (consider dose reduction) - elderly (consider dose reduction) - epilepsy - hypovolaemia - impaired cardiac conduction - impaired respiratory function - myasthenia gravis - severe or untreated hypertension - shock

**INTERACTIONS**

- Appendix 1: anaesthetics, local

**SIDE-EFFECTS**

Arrhythmias - blurred vision - cardiac arrest - convulsions - dizziness - drowsiness - feeling of inebriation - headache - hypertension - lightheadedness - methaemoglobinaemia (with high doses) - muscle twitching - myocardial depression (resulting in hypotension and bradycardia) - nausea - numbness of the tongue and perioral region - paraesthesia (including sensations of hot and cold) - peripheral vasodilatation (resulting in hypotension and bradycardia) - restlessness - tinnitus - transient excitation (followed by depression with drowsiness, respiratory failure, unconsciousness, and coma) - tremors - vomiting

**SIDE-EFFECTS, FURTHER INFORMATION**

- Toxic effects Toxic effects after administration of local anaesthetics are a result of excessively high plasma concentrations; severe toxicity usually results from inadvertent intravascular injection or too rapid injection.

- Following most regional anaesthetic procedures, maximum arterial plasma concentration of anaesthetic develops within about 10 to 25 minutes, so careful surveillance for toxic effects is necessary during the first 30 minutes after injection.

- The systemic toxicity of local anaesthetics mainly involves the central nervous and cardiovascular systems.

- Methaemoglobinaemia Methaemoglobinaemia can be treated with an intravenous injection of methylthioninium chloride.

**ALLERGY AND CROSS-SENSITIVITY**

- Hypersensitivity and cross-sensitivity Hypersensitivity reactions occur mainly with the ester-type local anaesthetics, such as tetracaine and chloroprocaine; reactions are less frequent with the amide types, such as articaine, bupivacaine, levobupivacaine, lidocaine, mepivacaine, prilocaine, and ropivacaine. Cross-sensitivity reactions may be avoided by using the alternative chemical type.

**PREGNANCY**

Use lower doses for intrathecal use during late pregnancy. Large doses during delivery can cause neonatal respiratory depression, hypotonia, and bradycardia after epidural block. Avoid paracervical or pudendal block in obstetrics (neonatal methaemoglobinaemia reported).

**BREAST FEEDING**

Present in milk but not known to be harmful.

**HEPATIC IMPAIRMENT**

Lower doses may be required for intrathecal anaesthesia. Use with caution.

**RENAL IMPAIRMENT**

Lower doses may be required for intrathecal anaesthesia. Use with caution.

**NATIONAL FUNDING/ACCESS DECISIONS**

**PRILOTEKAL®**

Scottish Medicines Consortium (SMC) Decisions

The Scottish Medicines Consortium has advised (December 2010) that prilocaine 2% hyperbaric solution for injection (Prilotekal®) is accepted for restricted use within NHS Scotland for use in spinal anaesthesia in ambulatory surgery settings.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection

**Solution for injection**

- Citanest (Aspen Pharma Trading Ltd)
  - Prilocaine hydrochloride 10 mg per 1 ml Citanest 1% solution for injection 50ml vials | 1 vial [POM] £5.06

- Prilotekal (AMCo)
  - Prilocaine hydrochloride 20 mg per 1 ml Prilotekal 100mg/5ml hyperbaric solution for injection ampoules | 10 ampoule [POM] £7.75
**Prilocaine with felypressin**

The properties listed below are those particular to the combination only. For the properties of the components please consider, prilocaine hydrochloride p. 1246.

### INDICATIONS AND DOSE

#### Dental anaesthesia
- **BY REGIONAL ADMINISTRATION**
- Adult: Consult expert dental sources for specific advice

#### INTERACTIONS
- Appendix 1: anaesthetics, local

### MEDICINAL FORMS

There can be variation in the licensing of different medicines containing the same drug.

#### Solution for injection
- **Citranest with Octapressin** (Dentsply Ltd)
  - Prilocaine hydrochloride 30 mg per 1 ml, Felypressin 0.3 unit per 1 ml
  - Citranest 3% with Octapressin Dental 0.054 units/1.8 ml solution for injection self-aspirating cartridges | 100 cartridge (PQM), no price available

Citranest 3% with Octapressin Dental 0.066 units/2.2 ml solution for injection self-aspirating cartridges | 100 cartridge (PQM) no price available

---

**Ropivacaine hydrochloride**

### INDICATIONS AND DOSE

#### Acute pain, peripheral nerve block
- **BY REGIONAL ADMINISTRATION**
- Adult: 10–20 mg/hour, dose administered as a continuous infusion or by intermittent injection using a 2 mg/mL (0.2%) solution

#### Acute pain, field block
- **BY REGIONAL ADMINISTRATION**
- Adult: 2–200 mg, dose administered using a 2 mg/mL (0.2%) solution

#### Acute pain, lumbar epidural block
- **BY LUMBAR EPIDURAL**
- Adult: 20–40 mg, followed by 20–30 mg at least every 30 minutes, dose administered using a 2 mg/mL (0.2%) solution

#### Acute labour pain
- **BY CONTINUOUS EPIDURAL INFUSION**
- Adult: 12–20 mg/hour, dose administered using a 2 mg/mL (0.2%) solution

#### Acute postoperative pain
- **BY CONTINUOUS EPIDURAL INFUSION**
- Adult: Up to 28 mg/hour, dose administered using a 2 mg/mL (0.2%) solution

#### Postoperative pain, thoracic epidural block
- **BY CONTINUOUS EPIDURAL INFUSION**
- Adult: 12–28 mg/hour, dose administered using a 2 mg/mL (0.2%) solution

#### Surgical anaesthesia, field block
- **BY REGIONAL ADMINISTRATION**
- Adult: 7.5–225 mg, dose administered using a 7.5 mg/mL (0.75%) solution

#### Surgical anaesthesia, major nerve block (brachial plexus block)
- **BY REGIONAL ADMINISTRATION**
- Adult: 225–300 mg, dose administered using a 7.5 mg/mL (0.75%) solution

#### Surgical anaesthesia, thoracic epidural block (to establish block for postoperative pain)
- **BY THORACIC EPIDURAL**
- Adult: 38–113 mg, dose administered using a 7.5 mg/mL (0.75%) solution

---

**Surgical anaesthesia for caesarean section**

- **BY LUMBAR EPIDURAL**
- Adult: 113–150 mg, to be administered in incremental doses using a 7.5 mg/mL (0.75%) solution

**Surgical anaesthesia, lumbar epidural block**

- **BY LUMBAR EPIDURAL**
- Adult: 113–200 mg, dose administered using a 7.5 mg/mL (0.75%) or 10 mg/mL (1%) solution

### DOSES AT EXTREMES OF BODY-WEIGHT

To avoid excessive dosage in obese patients, dose may need to be calculated on the basis of ideal bodyweight.

### IMPORTANT SAFETY INFORMATION

Should only be administered by, or under the direct supervision of, personnel experienced in their use, with adequate training in anaesthesia and airway management, and should not be administered parenterally unless adequate resuscitation equipment is available.

#### CONTRA-INDICATIONS
- Application to the middle ear (can cause ototoxicity)
- Avoid injection into infected tissues
- Avoid injection into inflamed tissues
- Complete heart block
- Preparations containing preservatives should not be used for caudal, epidural, or spinal block, or for intravenous regional anaesthesia (Bier’s block)
- Should not be applied to damaged skin

#### CONTRA-INDICATIONS, FURTHER INFORMATION
- Injection site
  - Local anaesthetics should not be injected into inflamed or infected tissues nor should they be applied to damaged skin.
  - Increased absorption into the blood increases the possibility of systemic side-effects, and the local anaesthetic effect may also be reduced by altered local pH.

#### CAUTIONS
- Acute porphyrias p. 969
- Cardiovascular disease
- Debilitated patients (consider dose reduction)
- Elderly (consider dose reduction)
- Epilepsy
- Hypovolaemia
- Impaired cardiac conduction
- Impaired respiratory function
- Myasthenia gravis
- Shock

#### INTERACTIONS
- Appendix 1: anaesthetics, local

#### SIDE-EFFECTS

- **Common or very common**
  - Hypertension
  - Pyrexia

- **Uncommon**
  - Hypothermia
  - Syncope

- **Frequency not known**
  - Arrhythmias
  - Blurred vision
  - Cardiac arrest
  - Convulsions
  - Dizziness
  - Drowsiness
  - Feeling of inebriation
  - Headache
  - Lightheadedness
  - Muscle twitching
  - Myocardial depression (resulting in hypotension and bradycardia)
  - Nausea
  - Numness of the tongue and perioral region
  - Paralysis (including sensations of hot and cold)
  - Peripheral vasodilatation (resulting in hypotension and bradycardia)
  - Restlessness
  - Transient excitation (followed by depression with drowsiness, respiratory failure, unconsciousness, and coma)
  - Tremors
  - Vomiting

#### SIDE-EFFECTS, FURTHER INFORMATION
- Toxic effects
  - Toxic effects after administration of local anaesthetics are a result of excessively high plasma concentrations; severe toxicity usually results from inadvertent intravascular injection or too rapid injection.
  - Following most regional anaesthetic procedures, maximum arterial plasma concentration of anaesthetic develops within about 10 to 25 minutes, so careful surveillance for toxic effects is necessary during the first 30 minutes after injection.
  - The systemic toxicity of local anaesthetics mainly involves the central nervous and cardiovascular systems.

#### ALLERGY AND CROSS-SENSITIVITY
- Hypersensitivity
  - Hypersensitivity and cross-sensitivity
  - Hypersensitivity reactions occur mainly with the ester-type local anaesthetics, such as tetracaine and chloroprocaine;
reactions are less frequent with the amide types, such as articaine, bupivacaine, levobupivacaine, lidocaine, mepivacaine, prilocaine, and ropivacaine. Cross-sensitivity reactions may be avoided by using the alternative chemical type.

- **PREGNANCY** Not known to be harmful. Do not use for paracervical block in obstetrics.
- **BREAST FEEDING** Not known to be harmful.
- **HEPATIC IMPAIRMENT** Use with caution in severe impairment.
- **RENAL IMPAIRMENT** Caution in severe impairment. Increased risk of systemic toxicity in chronic renal failure.

#### MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**

**ELECTROLYTES:** May contain Sodium

- **Ropivacaine hydrochloride** (Non-proprietary)
  - Ropivacaine hydrochloride 2 mg per 1 ml Ropivacaine 20mg/10ml solution for injection ampoules | 10 amoule (PoM) £16.50 (Hospital only)
  - Ropivacaine hydrochloride 7.5 mg per 1 ml Ropivacaine 75mg/10ml solution for injection ampoules | 10 amoule (PoM) £25.00 (Hospital only)
  - Ropivacaine hydrochloride 10 mg per 1 ml Ropivacaine 100mg/10ml solution for injection ampoules | 10 amoule (PoM) £30.00 (Hospital only)

- **Naropin** (Aspen Pharma Trading Ltd)
  - Ropivacaine hydrochloride 2 mg per 1 ml Naropin 20mg/10ml solution for injection ampoules | 5 amoule (PoM) £12.79
  - Ropivacaine hydrochloride 7.5 mg per 1 ml Naropin 75mg/10ml solution for injection ampoules | 5 amoule (PoM) £15.90
  - Ropivacaine hydrochloride 10 mg per 1 ml Naropin 100mg/10ml solution for injection ampoules | 5 amoule (PoM) £19.22

**Infusion**

**ELECTROLYTES:** May contain Sodium

- **Ropivacaine hydrochloride** (Non-proprietary)
  - Ropivacaine hydrochloride 2 mg per 1 ml Ropivacaine 400mg/200ml infusion bags | 5 bag (PoM) £72.25 | 10 bag (PoM) £137.00 (Hospital only)
  - **Naropin** (AstraZeneca UK Ltd)
  - Ropivacaine hydrochloride 2 mg per 1 ml Naropin 400mg/200ml infusion Polybags | 5 bag (PoM) £86.70

#### SIDE-EFFECTS
Local skin reactions

**SIDE-EFFECTS, FURTHER INFORMATION**

The systemic toxicity of local anaesthetics mainly involves the central nervous and cardiovascular systems; systemic side effects unlikely as minimal absorption following topical application.

- **ALLERGY AND CROSS-SENSITIVITY**
  - Hypersensitivity and cross-sensitivity Hypersensitivity reactions occur mainly with the ester-type local anaesthetics, such as tetracaine and chloroprocaine; reactions are less frequent with the amide types, such as articaine, bupivacaine, levobupivacaine, lidocaine, mepivacaine, prilocaine, and ropivacaine. Cross-sensitivity reactions may be avoided by using the alternative chemical type.

- **BREAST FEEDING** Not known to be harmful.

- **PATIENT AND CARER ADVICE**
  - Medicines for Children leaflet: Tetracaine gel for local anaesthesia [www.medicinesforchildren.org.uk/tetracaine-gel-for-local-anaesthesia](http://www.medicinesforchildren.org.uk/tetracaine-gel-for-local-anaesthesia)

#### MEDICINAL FORMS
There can be variation in the licensing of different medicines containing the same drug.

**Gel**

**EXCIPIENTS:** May contain Hydroxybenzoates (parabens)

- **Ametop** (Smith & Nephew Healthcare Ltd)
  - Tetracaine 40 mg per 1 gram Ametop 4% gel | 1.5 gram (PoM) £1.08 | 18 gram (PoM) no price available

### Tetracaine
(Amethocaine)

#### INDICATIONS AND DOSE

**Anaesthesia before venepuncture or venous cannulation**

- **TO THE SKIN**
  - Child 1 month–4 years: Apply contents of up to 1 tube (applied at separate sites at a single time or appropriate proportion) to site of venepuncture or venous cannulation and cover with occlusive dressing; remove gel and dressing after 30 minutes for venepuncture and after 45 minutes for venous cannulation
  - Child 5-17 years: Apply contents of up to 5 tubes (applied at separate sites at a single time or appropriate proportion) to site of venepuncture or venous cannulation and cover with occlusive dressing; remove gel and dressing after 30 minutes for venepuncture and after 45 minutes for venous cannulation
  - Adult: Apply contents of up to 5 tubes (applied at separate sites at a single time or appropriate proportion) to site of venepuncture or venous cannulation and cover with occlusive dressing; remove gel and dressing after 30 minutes for venepuncture and after 45 minutes for venous cannulation

- **CONTRA-INDICATIONS** Should not be applied to damaged skin

- **INTERACTIONS** → Appendix 1: anaesthetics, local
Chapter 16
Emergency treatment of poisoning

CONTENTS

1 Active elimination from the gastrointestinal tract page 1256
2 Chemical toxicity 1257
   2.1 Cyanide toxicity 1257
   2.2 Organophosphorus toxicity 1257
3 Drug toxicity 1258
   3.1 Benzodiazepine toxicity 1258
3.2 Digoxin toxicity page 1258
3.3 Heparin toxicity 1258
3.4 Opioid toxicity 1259
3.5 Paracetamol toxicity 1260
4 Methaemoglobinaemia 1261
5 Snake bites 1261

Emergency treatment of poisoning

Overview
These notes provide only an overview of the treatment of poisoning, and it is strongly recommended that either TOXBASE or the UK National Poisons Information Service be consulted when there is doubt about the degree of risk or about management.

Hospital admission
Patients who have features of poisoning should generally be admitted to hospital. Patients who have taken poisons with delayed action should also be admitted, even if they appear well. Delayed-action poisons include aspirin p. 117, iron, paracetamol p. 422, tricyclic antidepressants, and co-phenotrope p. 64 (diphenoxylate with atropine, Lomotil®); the effects of modified-release preparations are also delayed. A note of all relevant information, including what treatment has been given, should accompany the patient to hospital.

Further information
TOXBASE, the primary clinical toxicology database of the National Poisons Information Service, is available on the internet to registered users at www.toxbase.org (a backup site is available at www.toxbasebackup.org if the main site cannot be accessed). It provides information about routine diagnosis, treatment, and management of patients exposed to drugs, household products, and industrial and agricultural chemicals.

Specialist information and advice on the treatment of poisoning is available day and night from the UK National Poisons Information Service on the following number: Tel: 0344 892 0111.

Advice on laboratory analytical services can be obtained from TOXBASE or from the National Poisons Information Service. Help with identifying capsules or tablets may be available from a regional medicines information centre or from the National Poisons Information Service (out of hours).

General care
It is often impossible to establish with certainty the identity of the poison and the size of the dose. This is not usually important because only a few poisons (such as opioids, paracetamol, and iron) have specific antidotes; few patients require active removal of the poison. In most patients, treatment is directed at managing symptoms as they arise. Nevertheless, knowledge of the type and timing of poisoning can help in anticipating the course of events. All relevant information should be sought from the poisoned individual and from carers or parents. However, such information should be interpreted with care because it may not be complete or entirely reliable. Sometimes symptoms arise from other illnesses and patients should be assessed carefully. Accidents may involve domestic and industrial products (the contents of which are not generally known). The National Poisons Information Service should be consulted when there is doubt about any aspect of suspected poisoning.

Respiration
Respiration is often impaired in unconscious patients. An obstructed airway requires immediate attention. In the absence of trauma, the airway should be opened with simple measures such as chin lift or jaw thrust. An oropharyngeal or nasopharyngeal airway may be useful in patients with reduced consciousness to prevent obstruction, provided ventilation is adequate. Intubation and ventilation should be considered in patients whose airway cannot be protected or who have respiratory acidosis because of inadequate ventilation; such patients should be monitored in a critical care area.

Most poisons that impair consciousness also depress respiration. Assisted ventilation (either mouth-to-mouth or using a bag-valve-mask device) may be needed. Oxygen is not a substitute for adequate ventilation, although it should be given in the highest concentration possible in poisoning with carbon monoxide and irritant gases.

Blood pressure
Hypotension is common in severe poisoning with central nervous system depressants. A systolic blood pressure of less than 70 mmHg may lead to irreversible brain damage or renal tubular necrosis. Hypotension should be corrected initially by raising the foot of the bed and administration of an infusion of either sodium chloride p. 953 or a colloid.

Vasoconstrictor sympathomimetics are rarely required and their use may be discussed with the National Poisons Information Service.

Fluid depletion without hypotension is common after prolonged coma and after aspirin poisoning due to vomiting, sweating, and hyperpnoea.

Hypertension, often transient, occurs less frequently than hypotension in poisoning; it may be associated with sympathomimetic drugs such as amphetamines, phencyclidine, and cocaine.

Heart
Cardiac conduction defects and arrhythmias can occur in acute poisoning, notably with tricyclic antidepressants, some antipsychotics, and some antihistamines. Arrhythmias often respond to correction of underlying hypoxia, acidosis,
or other biochemical abnormalities, but ventricular arrhythmias that cause serious hypotension require treatment. If the QT interval is prolonged, specialist advice should be sought because the use of some anti-arrhythmic drugs may be inappropriate. Supraventricular arrhythmias are seldom life-threatening and drug treatment is best withheld until the patient reaches hospital.

**Body temperature**

Hypothermia may develop in patients of any age who have been deeply unconscious for some hours, particularly following overdose with barbiturates or phenothiazines. It may be missed unless core temperature is measured using a low-reading rectal thermometer or by some other means. Hypothermia should be managed by prevention of further heat loss and appropriate re-warming as clinically indicated.

Hypothermia can develop in patients taking CNS stimulants; children and the elderly are also at risk when taking therapeutic doses of drugs with antimuscarinic properties. Hyperthermia is initially managed by removing all unnecessary clothing and using a fan. Sponging with tepid water will promote evaporation. Advice should be sought from the National Poisons Information Service on the management of severe hyperthermia resulting from conditions such as the serotonin syndrome.

Both hypothermia and hyperthermia require urgent hospitalisation for assessment and supportive treatment.

**Convulsions**

Single short-lived convulsions (lasting less than 5 minutes) do not require treatment. If convulsions are protracted or recur frequently, lorazepam p. 322 or diazepam p. 327 (preferably as emulsion) should be given by slow intravenous injection into a large vein. Benzodiazepines should not be given by the intramuscular route for convulsions. If the patient has frequent convulsions, lorazepam p. 324 or midazolam injection into a large vein. Benzodiazepines should not be given by the intramuscular route for convulsions. If the patient has frequent convulsions, lorazepam p. 324 or midazolam should be given by the intramuscular route for convulsions.

**Methaemoglobinemia**

Drug- or chemical-induced methaemoglobinemia should be treated with methylthioninium chloride p. 1261 if the methaemoglobin concentration is 30% or higher, or if symptoms of tissue hypoxia are present despite oxygen therapy. Methylthioninium chloride reduces the ferric iron of methaemoglobin back to the ferrous iron of haemoglobin; in high doses, methylthioninium chloride can itself cause methaemoglobinemia.

**Removal and elimination**

**Prevention of absorption**

Given by mouth, charcoal, activated p. 1256 can bind many poisons in the gastro-intestinal system, thereby reducing their absorption. The sooner it is given the more effective it is, but it may still be effective up to 1 hour after ingestion of the poison—longer in the case of modified-release preparations or of drugs with antimuscarinic (anticholinergic) properties. It is particularly useful for the prevention of absorption of poisons that are toxic in small amounts, such as antidepressants.

**Active elimination techniques**

Repeated doses of charcoal, activated p. 1256 by mouth enhance the elimination of some drugs after they have been absorbed; repeated doses are given after overdosage with:

- Carbamazepine
- Dapsone
- Phenobarbital
- Quinine
- Theophylline

If vomiting occurs after dosing it should be treated (e.g. with an antiemetic drug) since it may reduce the efficacy of charcoal treatment. In cases of intolerance, the dose may be reduced and the frequency increased but this may compromise efficacy.

Charcoal, activated should not be used for poisoning with petroleum distillates, corrosive substances, alcohols, malathion, cyanides and metal salts including iron and lithium salts.

Other techniques intended to enhance the elimination of poisons after absorption are only practicable in hospital and are only suitable for a small number of severely poisoned patients. Moreover, they only apply to a limited number of poisons. Examples include:

- haemodialysis for ethylene glycol, lithium, methanol, phenobarbital, salicylates, and sodium valproate;
- alkalinisation of the urine for salicylates.

**Removal from the gastro-intestinal tract**

Gastric lavage is rarely required; for substances that cannot be removed effectively by other means (e.g. iron), it should be considered only if a life-threatening amount has been ingested within the previous hour. It should be carried out only if the airway can be protected adequately. Gastric lavage is contra-indicated if a corrosive substance or a petroleum distillate has been ingested, but it may occasionally be considered in patients who have ingested drugs that are not adsorbed by charcoal, such as iron or lithium. Induction of emesis (e.g. with ipecacuanha) is not recommended because there is no evidence that it affects absorption and it may increase the risk of aspiration.

**Whole bowel irrigation (by means of a bowel cleansing preparation)** has been used in poisoning with certain modified-release or enteric-coated formulations, in severe poisoning with iron and lithium salts, and if illicit drugs are carried in the gastro-intestinal tract (‘body-packing’). However, it is not clear that the procedure improves outcome and advice should be sought from the National Poisons Information Service.

**Alcohol**

Acute intoxication with alcohol (ethanol) is common in adults but also occurs in children. The features include ataxia, dysarthria, nystagmus, and drowsiness, which may progress to coma, with hypotension and acidosis. Aspiration of vomit is a special hazard and hypoglycaemia may occur in children and some adults. Patients are managed supportively, with particular attention to maintaining a clear airway and measures to reduce the risk of aspiration of gastric contents. The blood glucose is measured and glucose given if indicated.

**Aspirin**

The main features of salicylate poisoning are hyperventilation, tinnitus, deafness, vasodilatation, and sweating. Coma is uncommon but indicates very severe poisoning. The associated acid-base disturbances are complex.

Treatment must be in hospital, where plasma salicylate, pH, and electrolytes can be measured; absorption of aspirin may be slow and the plasma-salicylate concentration may continue to rise for several hours, requiring repeated measurement. Plasma-salicylate concentration may not correlate with clinical severity in the young and the elderly, and clinical and biochemical assessment is necessary. Generally, the clinical severity of poisoning is less below a plasma-salicylate concentration of 500 mg/litre (3.6 mmol/litre), unless there is evidence of metabolic acidosis. Activated charcoal can be given within 1 hour of ingesting more than 125 mg/kg of aspirin. Fluid losses should be replaced and intravenous sodium bicarbonate may be given (ensuring plasma-potassium concentration is within the reference range) to enhance urinary salicylate excretion (optimum urinary pH 7.5–8.5).

**Hypothermia**

Hypothermia may develop in patients of any age who have been deeply unconscious for some hours, particularly following overdose with barbiturates or phenothiazines. It may be missed unless core temperature is measured using a low-reading rectal thermometer or by some other means. Hypothermia should be managed by prevention of further heat loss and appropriate re-warming as clinically indicated.

Hypothermia can develop in patients taking CNS stimulants; children and the elderly are also at risk when taking therapeutic doses of drugs with antimuscarinic properties. Hyperthermia is initially managed by removing all unnecessary clothing and using a fan. Sponging with tepid water will promote evaporation. Advice should be sought from the National Poisons Information Service on the management of severe hyperthermia resulting from conditions such as the serotonin syndrome.

Both hypothermia and hyperthermia require urgent hospitalisation for assessment and supportive treatment.

**Convulsions**

Single short-lived convulsions (lasting less than 5 minutes) do not require treatment. If convulsions are protracted or recur frequently, lorazepam p. 322 or diazepam p. 327 (preferably as emulsion) should be given by slow intravenous injection into a large vein. Benzodiazepines should not be given by the intramuscular route for convulsions. If the intravenous route is not readily available, midazolam should be given by the intramuscular route for convulsions. If the pr...
Plasma-potassium concentration should be corrected before giving sodium bicarbonate as hypokalaemia may complicate alkalinisation of the urine.

Haemodialysis is the treatment of choice for severe salicylate poisoning and should be considered when the plasma-salicylate concentration exceeds 700 mg/litre (5.1 mmol/litre) or in the presence of severe metabolic acidosis.

Opioids
Opioids (narcotic analgesics) cause coma, respiratory depression, and pinpoint pupils. The specific antidote naloxone hydrochloride p. 1259 is indicated if there is coma or bradypnoea. Since naloxone has a shorter duration of action than many opioids, close monitoring and repeated injections are necessary according to the respiratory rate and depth of coma. When repeated administration of naloxone is required, it can be given by continuous intravenous infusion instead and the rate of infusion adjusted according to vital signs. The effects of some opioids, such as buprenorphine, are only partially reversed by naloxone.

Dextropropoxyphene and methadone have very long durations of action; patients may need to be monitored for long periods following large overdoses.

Naloxone reverses the opioid effects of dextropropoxyphene. The long duration of action of dextropropoxyphene calls for prolonged monitoring and further doses of naloxone may be required.

Norpropoxyphene, a metabolite of dextropropoxyphene, also has cardiotoxic effects which may require treatment with sodium bicarbonate p. 950 or magnesium sulfate p. 963, or both. Arrhythmias may occur for up to 12 hours.

Paracetamol
In cases of intravenous paracetamol poisoning contact the National Poisons Information Service for advice on risk assessment and management.

Toxic doses of paracetamol p. 422 may cause severe hepatocellular necrosis and, much less frequently, renal tubular necrosis. Nausea and vomiting, the only early features of poisoning, usually settle within 24 hours. Persistence beyond this time, often associated with the onset of right subcostal pain and tenderness, usually indicates development of hepatic necrosis. Liver damage is maximal 3–4 days after paracetamol overdose and may lead to encephalopathy, haemorrhage, hypoglycaemia, cerebral oedema, and death. Therefore, despite a lack of significant early symptoms, patients who have taken an overdose of paracetamol should be transferred to hospital urgently.

To avoid underestimating the potentially toxic paracetamol dose ingested by obese patients who weigh more than 110 kg, use a body-weight of 110 kg (rather than their actual body-weight) when calculating the total dose of paracetamol ingested (in mg/kg).

Acetylcysteine p. 1260 protects the liver if infused up to, and possibly beyond, 24 hours of ingesting paracetamol. It is most effective if given within 8 hours of ingestion, after which effectiveness declines. Very rarely, giving acetylcysteine by mouth [unlicensed route] is an alternative if intravenous access is not possible—contact the National Poisons Information Service for advice on risk assessment and management.
Emergency treatment of poisoning

The prognostic accuracy of a plasma-paracetamol concentration, related to the time from ingestion, provided this time interval is not less than 4 hours; earlier samples may be misleading. The concentration is plotted on a paracetamol treatment graph, with a reference line (‘treatment line’) joining plots of 100 mg/litre (0.66 mmol/litre) at 4 hours and 3.13 mg/litre (0.02 mmol/litre) at 24 hours. Acetylcysteine treatment should commence immediately in patients:

- whose plasma-paracetamol concentration falls on or above the treatment line on the paracetamol treatment graph;
- who present 8–24 hours after taking an acute overdose of more than 150 mg/kg of paracetamol, even if the plasma-paracetamol concentration is not yet available; acetylcysteine can be discontinued if the plasma-paracetamol concentration is later reported to be below the treatment line on the paracetamol treatment graph, provided that the patient is asymptomatic and liver function tests, serum creatinine and INR are normal.

The prognostic accuracy of a plasma-paracetamol concentration taken after 15 hours is uncertain, but a concentration on or above the treatment line on the paracetamol treatment graph should be regarded as carrying a serious risk of liver damage. If more than 15 hours have elapsed since ingestion, or there is doubt about appropriate management, advice should be sought from the National Poisons Information Service.

**‘Staggered’ overdose, uncertain time of overdose, or therapeutic excess**

A ‘staggered’ overdose involves ingestion of a potentially toxic dose of paracetamol over more than one hour, with the possible intention of causing self-harm. Therapeutic excess is the inadvertent ingestion of a potentially toxic dose of paracetamol during its clinical use. The paracetamol treatment graph is unreliable if a ‘staggered’ overdose is taken, if there is uncertainty about the time of the overdose, or if there is therapeutic excess. In these cases, patients who have taken more than 150 mg/kg of paracetamol in any 24-hour period are at risk of toxicity and should be commenced on acetylcysteine immediately, unless it is more than 24 hours since the last ingestion, the patient is asymptomatic, the plasma-paracetamol concentration is undetectable, and liver function tests, serum creatinine and INR are normal.

Rarely, toxicity can occur with paracetamol doses between 75–150 mg/kg in any 24-hour period; clinical judgement of the individual case is necessary to determine whether to treat those who have ingested this amount of paracetamol. For small adults, this may be within the licensed dose, but ingestion of a licensed dose of paracetamol is not considered an overdose.

Although there is some evidence suggesting that factors such as the use of liver enzyme-inducing drugs (e.g. carbamazepine p. 297, efavirenz p. 608, nevirapine p. 609, phenobarbital p. 318, phenytoin p. 308, primidone p. 319, rifabutin p. 543, rifampicin p. 549, St John’s wort), chronic alcoholism, and starvation may increase the risk of hepatotoxicity, the CHM has advised that these should no longer be used in the assessment of paracetamol toxicity.

Significant toxicity is unlikely if, 24 hours or longer after the last paracetamol ingestion, the patient is asymptomatic, the plasma-paracetamol concentration is undetectable, and liver function tests, serum creatinine and INR are normal. Patients with clinical features of hepatic injury such as jaundice or hepatic tenderness should be treated urgently with acetylcysteine. If there is uncertainty about a patient’s risk of toxicity after paracetamol overdose, treatment with acetylcysteine should be commenced. Advice should be sought from the National Poisons Information Service whenever necessary.

**Acetylcysteine dose and administration**

For paracetamol overdosage, acetylcysteine is given in a total dose that is divided into 3 consecutive intravenous infusions over a total of 21 hours. The tables below include the dose of acetylcysteine, for adults and children of body-weight 40 kg and over, in terms of the volume of acetylcysteine Concentrate for Intravenous Infusion required for each of the 3 infusions. The requisite dose of acetylcysteine is added to glucose intravenous infusion 5% p. 955.

### First infusion

<table>
<thead>
<tr>
<th>Body-weight</th>
<th>Volume of Acetylcysteine Concentrate for Intravenous Infusion 200 mg/mL required to prepare first infusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>40–49 kg</td>
<td>34 mL</td>
</tr>
<tr>
<td>50–59 kg</td>
<td>42 mL</td>
</tr>
<tr>
<td>60–69 kg</td>
<td>49 mL</td>
</tr>
<tr>
<td>70–79 kg</td>
<td>57 mL</td>
</tr>
<tr>
<td>80–89 kg</td>
<td>64 mL</td>
</tr>
<tr>
<td>90–99 kg</td>
<td>72 mL</td>
</tr>
<tr>
<td>≥100–109 kg</td>
<td>79 mL</td>
</tr>
<tr>
<td>≥110 kg</td>
<td>83 mL (max. dose)</td>
</tr>
</tbody>
</table>

**First infusion (based on an acetylcysteine dose of approx. 150 mg/kg)—add requisite volume of Acetylcysteine Concentrate for Intravenous Infusion to 200 mL Glucose Intravenous Infusion 5%; infuse over 1 hour.**

### Second infusion

<table>
<thead>
<tr>
<th>Body-weight</th>
<th>Volume of Acetylcysteine Concentrate for Intravenous Infusion 200 mg/mL required to prepare second infusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>40–49 kg</td>
<td>12 mL</td>
</tr>
<tr>
<td>50–59 kg</td>
<td>14 mL</td>
</tr>
<tr>
<td>60–69 kg</td>
<td>17 mL</td>
</tr>
<tr>
<td>70–79 kg</td>
<td>19 mL</td>
</tr>
<tr>
<td>80–89 kg</td>
<td>22 mL</td>
</tr>
<tr>
<td>90–99 kg</td>
<td>24 mL</td>
</tr>
<tr>
<td>100–109 kg</td>
<td>27 mL</td>
</tr>
<tr>
<td>≥110 kg</td>
<td>28 mL (max. dose)</td>
</tr>
</tbody>
</table>

**Second infusion (based on an acetylcysteine dose of approx. 50 mg/kg; start immediately after completion of first infusion)—add requisite volume of Acetylcysteine Concentrate for Intravenous Infusion to 500 mL Glucose Intravenous Infusion 5%; infuse over 4 hours.**
### Third infusion

<table>
<thead>
<tr>
<th>Body-weight</th>
<th>Volume of Acetylcysteine Concentrate for intravenous infusion 200 mg/mL required to prepare third infusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>40–49 kg</td>
<td>23 mL</td>
</tr>
<tr>
<td>50–59 kg</td>
<td>28 mL</td>
</tr>
<tr>
<td>60–69 kg</td>
<td>33 mL</td>
</tr>
<tr>
<td>70–79 kg</td>
<td>38 mL</td>
</tr>
<tr>
<td>80–89 kg</td>
<td>43 mL</td>
</tr>
<tr>
<td>90–99 kg</td>
<td>48 mL</td>
</tr>
<tr>
<td>100–109 kg</td>
<td>53 mL</td>
</tr>
<tr>
<td>&gt;110 kg</td>
<td>55 mL (max. dose)</td>
</tr>
</tbody>
</table>

*Third infusion* (based on an acetylcysteine dose of approx. 100 mg/kg; start immediately after completion of second infusion)—add requisite volume of Acetylcysteine Concentrate for Intravenous Infusion to 1 litre Glucose Intravenous Infusion 5%; infuse over 16 hours.

### Antidepressants

#### Tricyclic and related antidepressants

Tricyclic and related antidepressants cause dry mouth, coma of varying degree, hypotension, hypothermia, hyperreflexia, extensor plantar responses, convulsions, respiratory failure, cardiac conduction defects, and arrhythmias. Dilated pupils and urinary retention also occur. Metabolic acidosis may complicate severe poisoning; delirium with confusion, agitation, and visual and auditory hallucinations are common during recovery. Assessment in hospital is strongly advised in case of poisoning by tricyclic and related antidepressants but symptomatic treatment can be given before transfer. Supportive measures to ensure a clear airway and adequate ventilation during transfer are mandatory. Intravenous lorazepam or intravenous diazepam (preferably in emulsion form) may be required to treat convulsions. Activated charcoal given within 1 hour of the overdose reduces absorption of the drug. Although arrhythmias are worrying, some will respond to correction of hypoxia and acidosis. The use of anti-arrhythmic drugs is best avoided, but intravenous infusion of sodium bicarbonate can arrest arrhythmias or prevent them in those with an extended QRS duration. Diazepam given by mouth is usually adequate to sedate delirious patients but large doses may be required.

#### Selective serotonin re-uptake inhibitors (SSRIs)

Symptoms of poisoning by selective serotonin re-uptake inhibitors include nausea, vomiting, agitation, tremor, nystagmus, drowsiness, and sinus tachycardia; convulsions may occur. Rarely, severe poisoning results in the serotonin syndrome, with marked neuropsychiatric effects, neuromuscular hyperactivity, and autonomic instability; hyperthermia, rhabdomyolysis, renal failure, and coagulopathies may develop.

Management of SSRI poisoning is supportive. Activated charcoal given within 1 hour of the overdose reduces absorption of the drug. Convulsions can be treated with lorazepam, diazepam, or midazolam oromucosal solution [unlicensed use in adults and children under 3 months] (see *Convulsions*). Contact the National Poisons Information Service for the management of hyperthermia or the serotonin syndrome.

### Antimalarials

Overdosage with quinine, chloroquine, or hydroxychloroquine is extremely hazardous and difficult to treat. Urgent advice from the National Poisons Information Service is essential. Life-threatening features include arrhythmias (which can have a very rapid onset) and convulsions (which can be intractable).

### Antipsychotics

#### Phenothiazines and related drugs

Phenothiazines cause less depression of consciousness and respiration than other sedatives. Hypotension, hypothermia, sinus tachycardia, and arrhythmias may complicate poisoning. Dystonic reactions can occur with therapeutic doses (particularly with prochlorperazine and trifluoperazine), and convulsions may occur in severe cases. Arrhythmias may respond to correction of hypoxia, acidosis, and other biochemical abnormalities, but specialist advice should be sought if arrhythmias result from a prolonged QT interval; the use of some anti-arrhythmic drugs can worsen such arrhythmias. Dystonic reactions are rapidly abolished by injection of drugs such as procyclidine hydrochloride p. 391 or diazepam p. 327 (emulsion preferred).

#### Second-generation antipsychotic drugs

Features of poisoning by second-generation antipsychotic drugs include drowsiness, convulsions, extrapyramidal symptoms, hypotension, and ECG abnormalities (including prolongation of the QT interval). Management is supportive. Charcoal, activated p. 1256 can be given within 1 hour of ingesting a significant quantity of a second-generation antipsychotic drug.

### Benzodiazepines

Benzodiazepines taken alone cause drowsiness, ataxia, dysarthria, nystagmus, and occasionally respiratory depression, and coma. Charcoal, activated can be given within 1 hour of ingesting a significant quantity of benzodiazepine, provided the patient is awake and the airway is protected. Benzodiazepines potentiate the effects of other central nervous system depressants taken concomitantly. Use of the benzodiazepine antagonist flumazenil p. 1258 [unlicensed indication] can be hazardous, particularly in mixed overdoses involving tricyclic antidepressants or in benzodiazepine-dependent patients. Flumazenil may prevent the need for ventilation, particularly in patients with severe respiratory disorders; it should be used on expert advice only and not as a diagnostic test in patients with a reduced level of consciousness.

### Beta blockers

Therapeutic overdoses with beta-blockers may cause lightheadedness, dizziness, and possibly syncope as a result of bradycardia and hypotension; heart failure may be precipitated or exacerbated. These complications are most likely in patients with conduction system disorders or impaired myocardial function. Bradycardia is the most common arrhythmia caused by beta-blockers, but sotalol may induce ventricular tachyarrhythmias (sometimes of the torsade de pointes type). The effects of massive overdose can vary from one beta-blocker to another; propranolol overdose in particular may cause coma and convulsions. **Acute massive overdose** must be managed in hospital and expert advice should be obtained. Maintenance of a clear airway and adequate ventilation is mandatory. An intravenous injection of atropine sulfate p. 1224 is required to treat bradycardia. Cardiogenic shock unresponsive to atropine sulfate is probably best treated with an intravenous injection of glucagon p. 681 [unlicensed] in glucose 5% (with precautions to protect the airway in case of vomiting) followed by an intravenous infusion. If glucagon is not available, intravenous isoprenaline (available from 'special-order' manufacturers or specialist importing companies) is an alternative. A cardiac pacemaker can be used to increase the heart rate.
Calcium-channel blockers

Features of calcium-channel blocker poisoning include nausea, vomiting, dizziness, agitation, confusion, and coma in severe poisoning. Metabolic acidosis and hyperglycaemia may occur. Verapamil and diltiazem have a profound cardiac depressant effect causing hypotension and arrhythmias, including complete heart block and asystole. The dihydropyridine calcium-channel blockers cause severe hypotension secondary to profound peripheral vasodilatation.

Charcoal, activated should be considered if the patient presents within 1 hour of overdosage with a calcium-channel blocker; repeated doses of activated charcoal are considered if a modified-release preparation is involved. In patients with significant features of poisoning, calcium chloride p. 959 or calcium gluconate p. 959 is given by injection; atropine sulfate is given to correct symptomatic bradycardia. In severe cases, an insulin and glucose infusion may be required in the management of hypotension and myocardial failure. For the management of hypotension, the choice of inotropic sympathomimetic depends on whether hypotension is secondary to vasodilatation or to myocardial depression—advice should be sought from the National Poisons Information Service.

Iron salts

Iron poisoning in childhood is usually accidental. The symptoms are nausea, vomiting, abdominal pain, diarrhoea, haematemesis, and rectal bleeding. Hypotension and hepatocellular necrosis can occur later. Coma, shock, and metabolic acidosis indicate severe poisoning. Advice should be sought from the National Poisons Information Service if a significant quantity of iron has been ingested within the previous hour.

Mortality is reduced by intensive and specific therapy with desferrioxamine mesilate p. 941, which chelates iron. The serum-iron concentration is measured as an emergency and intravenous desferrioxamine mesilate given to chelate absorbed iron in excess of the expected iron binding capacity. In severe toxicity intravenous desferrioxamine mesilate should be given immediately without waiting for the result of the serum-iron measurement.

Lithium

Most cases of lithium intoxication occur as a complication of long-term therapy and are caused by reduced excretion of the drug because of a variety of factors including dehydration, deterioration of renal function, infections, and co-administration of diuretics or NSAIDs (or other drugs that interact). Acute deliberate overdoses may also occur with delayed onset of symptoms (12 hours or more) owing to slow entry of lithium into the tissues and continuing absorption from modified-release formulations.

The early clinical features are non-specific and may include apathy and restlessness which could be confused with mental changes arising from the patient’s depressive illness. Vomiting, diarrhoea, ataxia, weakness, dysarthria, muscle twitching, and tremor may follow. Severe poisoning is associated with convulsions, coma, renal failure, electrolyte imbalance, dehydration, and hypotension.

Therapeutic serum-lithium concentrations are within the range of 0.4–1 mmol/litre; concentrations in excess of 2 mmol/litre are usually associated with serious toxicity and such cases may need treatment with haemodialysis if neurological symptoms or renal failure are present. In acute overdosage much higher serum-lithium concentrations may be present without features of toxicity and all that is usually necessary is to take measures to increase urine output (e.g. by increasing fluid intake but avoiding diuretics). Otherwise, treatment is supportive with special regard to electrolyte balance, renal function, and control of convulsions. Gastric lavage may be considered if it can be performed within 1 hour of ingesting significant quantities of lithium. Whole-bowel irrigation should be considered for significant ingestion, but advice should be sought from the National Poisons Information Service.

Stimulants

Amphetamines cause wakefulness, excessive activity, paranoia, hallucinations, and hypertension followed by exhaustion, convulsions, hyperthermia, and coma. The early stages can be controlled by diazepam p. 327 or lorazepam p. 322; advice should be sought from the National Poisons Information Service on the management of hypertension. Later, tepid sponging, anticonvulsants, and artificial respiration may be needed.

Cocaine

Cocaine stimulates the central nervous system, causing agitation, dilated pupils, tachycardia, hypertension, hallucinations, hyperthermia, hypertonia, and hyperreflexia; cardiac effects include chest pain, myocardial infarction, and arrhythmias.

Initial treatment of cocaine poisoning involves intravenous administration of diazepam to control agitation and cooling measures for hyperthermia (see Body temperature); hypertension and cardiac effects require specific treatment and expert advice should be sought.

Ecstasy

Ecstasy (methyleneoxymethamfetamine, MDMA) may cause severe reactions, even at doses that were previously tolerated. The most serious effects are delirium, coma, convulsions, ventricular arrhythmias, hyperthermia, rhabdomyolysis, acute renal failure, acute hepatitis, disseminated intravascular coagulation, adult respiratory distress syndrome, hyperreflexia, hypotension and intracerebral haemorrhage; hypoponatraemia has also been associated with ecstasy use.

Treatment of methyleneoxymethamfetamine poisoning is supportive, with diazepam to control severe agitation or persistent convulsions and close monitoring including ECG. Self-induced water intoxication should be considered in patients with ecstasy poisoning.

‘Liquid ecstasy’ is a term used for sodium oxybate (gamma-hydroxybutyrate, GHB), which is a sedative.

Theophylline

Theophylline and related drugs are often prescribed as modified-release formulations and toxicity can therefore be delayed. They cause vomiting (which may be severe and intractable), agitation, restlessness, dilated pupils, sinus tachycardia, and hyperglycaemia. More serious effects are haematemesis, convulsions, and supraventricular and ventricular arrhythmias. Severe hypokalaemia may develop rapidly.

Repeated doses of activated charcoal can be used to eliminate theophylline even if more than 1 hour has elapsed after ingestion and especially if a modified-release preparation has been taken (see also under Active Elimination Techniques). Ondansetron p. 414 may be effective for severe vomiting that is resistant to other antiemetics [unlicensed indication]. Hypokalaemia is corrected by intravenous infusion of potassium chloride p. 968 and may be so severe as to require 60 mmol/hour (high doses require ECG monitoring). Convulsions should be controlled by intravenous administration of lorazepam or diazepam (see Convulsions). Sedation with diazepam may be necessary in agitated patients.

Provided the patient does not suffer from asthma, a short-acting beta-blocker can be administered intravenously to reverse severe tachycardia, hypokalaemia, and hyperglycaemia.
Other poisons
Consult either the National Poisons Information Service day and night or TOXBASE, see under the National Poisons Information Service.

Cyanides
Oxygen should be administered to patients with cyanide poisoning. The choice of antidote depends on the severity of poisoning, certainty of diagnosis, and the cause. Dicobalt edetate p. 1257 is the antidote of choice when there is a strong clinical suspicion of severe cyanide poisoning, but it should not be used as a precautionary measure. Dicobalt edetate itself is toxic, associated with anaphylactoid reactions, and is potentially fatal if administered in the absence of cyanide poisoning. A regimen of sodium nitrite p. 1257 followed by sodium thiosulfate p. 1257 is an alternative if dicobalt edetate is not available.

Hydroxocobalamin p. 938 ('Cynamikit ®')—no other preparation of hydroxocobalamin is suitable—can be considered for use in victims of smoke inhalation who show signs of significant cyanide poisoning.

Ethylene glycol and methanol
Fomepizole (available from 'special-order' manufacturers or specialist importing companies) is the treatment of choice for ethylene glycol and methanol (methyl alcohol) poisoning. If necessary, ethanolo (by mouth or by intravenous infusion) can be used, but with caution. Advice on the treatment of ethylene glycol and methanol poisoning should be obtained from the National Poisons Information Service. It is important to start antidote treatment promptly in cases of suspected poisoning with these agents.

Heavy metals
Heavy metal antidotes include succimer (DMSA) [unlicensed], unithiol (DMPS) [unlicensed], sodium calcium edetate [unlicensed], and dimercaprol. Dimercaprol in the management of heavy metal poisoning has been superseded by other chelating agents. In all cases of heavy metal poisoning, the advice of the National Poisons Information Service should be sought.

Noxious gases
Carbon monoxide
Carbon monoxide poisoning is usually due to inhalation of smoke, car exhaust, or fumes caused by blocked flues or incomplete combustion of fuel gases in confined spaces. Immediate treatment of carbon monoxide poisoning is essential. The person should be moved to fresh air, the airway cleared, and high-flow oxygen 100% administered through a tight-fitting mask with an inflated face seal. Artificial respiration should be given as necessary and continued until adequate spontaneous breathing starts, or stopped only after persistent and efficient treatment of cardiac arrest has failed. The patient should be admitted to hospital because complications may arise after a delay of hours or days. Cerebral oedema may occur in severe poisoning and is treated with an intravenous infusion of mannitol p. 222. Referral for hyperbaric oxygen treatment should be discussed with the National Poisons Information Service if the patient is pregnant or in cases of severe poisoning, such as if the patient is or has been unconscious, or has psychiatric or neurological features other than a headache, or has myocardial ischaemia or an arrhythmia, or has a blood carboxyhaemoglobin concentration of more than 20%.

Sulfur dioxide, chlorine, phosgene, ammonia
All of these gases can cause upper respiratory tract and conjunctival irritation. Pulmonary oedema, with severe breathlessness and cyanosis may develop suddenly up to 36 hours after exposure. Death may occur. Patients are kept under observation and those who develop pulmonary oedema are given oxygen. Assisted ventilation may be necessary in the most serious cases.

CS Spray
CS spray, which is used for riot control, irritates the eyes (hence ‘tear gas’) and the respiratory tract; symptoms normally settle spontaneously within 15 minutes. If symptoms persist, the patient should be removed to a well-ventilated area, and the exposed skin washed with soap and water after removal of contaminated clothing. Contact lenses should be removed and rigid ones washed (soft ones should be discarded). Eye symptoms should be treated by irrigating the eyes with physiological saline (or water if saline is not available) and advice sought from an ophthalmologist. Patients with features of severe poisoning, particularly respiratory complications, should be admitted to hospital for symptomatic treatment.

Nerve agents
Treatment of nerve agent poisoning is similar to organophosphorus insecticide poisoning, but advice must be sought from the National Poisons Information Service. The risk of cross-contamination is significant; adequate decontamination and protective clothing for healthcare personnel are essential. In emergencies involving the release of nerve agents, kits ('NAAS pods') containing pralidoxime chloride p. 1257 can be obtained through the Ambulance Service from the National Blood Service (or the Welsh Blood Service in South Wales or designated hospital pharmacies in Northern Ireland and Scotland—see TOXBASE for list of designated centres).

Pesticides
Organophosphorus insecticides
Organophosphorus insecticides are usually supplied as powders or dissolved in organic solvents. All are absorbed through the bronchi and intact skin as well as through the gut and inhibit cholinesterase activity, thereby prolonging and intensifying the effects of acetylcholine. Toxicity between different compounds varies considerably, and onset may be delayed after skin exposure. Anxiety, restlessness, dizziness, headache, miosis, nausea, hypersalivation, vomiting, abdominal colic, diarrhoea, bradycardia, and sweating are common features of organophosphorus poisoning. Muscle weakness and fasciculation may develop and progress to generalised flaccid paralysis, including the ocular and respiratory muscles. Convulsions, coma, pulmonary oedema with copious bronchial secretions, hypoxia, and arrhythmias occur in severe cases. Hyperglycaemia and glycosuria without ketonuria may also be present.

Further absorption of the organophosphorus insecticide should be prevented by moving the patient to fresh air, removing soiled clothing, and washing contaminated skin. In severe poisoning it is vital to ensure a clear airway, frequent removal of bronchial secretions, and adequate ventilation and oxygenation; gastric lavage may be considered provided that the airway is protected. Atropine sulfate p. 1224 will reverse the muscarinic effects of acetylcholine and is given by intravenous injection until the skin becomes flushed and dry, the pupils dilate, and bradycardia is abolished.

Pralidoxime chloride, a cholinesterase reactivator, is used as an adjunct to atropine sulfate in moderate or severe poisoning. It improves muscle tone within 30 minutes of administration. Pralidoxime chloride is continued until the patient has not required atropine sulfate for 12 hours. Pralidoxime chloride can be obtained from designated centres, the names of which are held by the National Poisons Information Service.
Snakes and animal stings

Snake bites

Envenoming from snake bite is uncommon in the UK. Many exotic snakes are kept, some illegally, but the only indigenous venomous snake is theadder (Vipera berus). The bite may cause local and systemic effects. Local effects include pain, swelling, bruising, and tendon enlargement of regional lymph nodes. Systemic effects include early anaphylactic reactions (transient hypotension with syncope, angioedema, urticaria, abdominal colic, diarrhoea, and vomiting), with later persistent or recurrent hypotension, ECG abnormalities, spontaneous systemic bleeding, coagulopathy, adult respiratory distress syndrome, and acute renal failure. Fatal envenoming is rare but the potential for severe envenoming must not be underestimated.

Early anaphylactic symptoms should be treated with adrenaline/epinephrine p. 216. Indications for European viper snake venom antiserum p. 1261. Treatment includes systemic envenoming, especially hypotension, ECG abnormalities, vomiting, haemostatic abnormalities, and marked local envenoming such that after bites on the hand or foot, swelling extends beyond the wrist or ankle within 4 hours of the bite. For those patients who present with clinical features of severe envenoming (e.g. shock, ECG abnormalities, or local swelling that has advanced from the foot to above the knee or from the hand to above the elbow within 2 hours of the bite), a higher initial dose of the European viper snake venom antiserum is recommended; if symptoms of systemic envenoming persist contact the National Poisons Information Service.

Adrenaline/epinephrine injection must be immediately to hand for treatment of anaphylactic reactions to the European viper snake venom antiserum.

European viper snake venom antiserum is available for bites by certain foreign snakes and spiders, stings by scorpions and fish. For information on identification, management, and for supply in an emergency, telephone the National Poisons Information Service. Whenever possible the TOXBASE entry should be read, and relevant information collected, before telephoning the National Poisons Information Service.

Insect stings

Stings from ants, wasps, hornets, and bees cause local pain and swelling but seldom cause severe direct toxicity unless many stings are inflicted at the same time. If the sting is in the mouth or on the tongue local swelling may threaten the upper airway. The stings from these insects are usually treated by cleaning the area with a topical antiseptic. Bee stings should be removed as quickly as possible. Anaphylactic reactions require immediate treatment with intramuscular adrenaline/epinephrine; self-administered intramuscular adrenaline/epinephrine (e.g. EpiPen®) is the best first-aid treatment for patients with severe hypersensitivity. An inhaled bronchodilator should be used for asthmatic reactions, see also the management of anaphylaxis. A short course of an oral antihistamine or a topical corticosteroid may help to reduce inflammation and relieve itching. A vaccine containing extracts of bee and wasp venom can be used to reduce the risk of anaphylaxis and systemic reactions in patients with systemic hypersensitivity to bee or wasp stings.

Marine stings

The severe pain of weeverfish (Trachinus draco) and Portuguese man-o’-war stings can be relieved by immersing the sting area immediately in uncomfortably hot, but not scalding, water (not more than 45°C). People stung by jellyfish and Portuguese man-o’-war around the UK coast should be removed from the sea as soon as possible. Adherent tentacles should be lifted off carefully (wearing gloves or using tweezers) or washed off with seawater. Alcoholic solutions, including suntan lotions, should not be applied because they can cause further discharge of stinging hairs. Ice packs can be used to reduce pain.

Other poisons

Consult either the National Poisons Information Service or TOXBASE.

1  Active elimination from the gastro-intestinal tract

ANTIDOTES AND CHELATORS > INTESTINAL ADSORBENTS

Charcoal, activated

- INDICATIONS AND DOSE

Reduction of absorption of poisons in the gastro-intestinal system

- BY MOUTH

  > Child 1 month–11 years: 1 g/kg (max. per dose 50 g)
  > Child 12–17 years: 50 g
  > Adult: 50 g

Active elimination of poisons

- BY MOUTH

  > Child 1 month–11 years: 1 g/kg every 4 hours (max. per dose 50 g), dose may be reduced and the frequency increased if not tolerated, reduced dose may compromise efficacy
  > Child 12–17 years: Initially 50 g, then 50 g every 4 hours, reduced if not tolerated to 25 g every 2 hours, alternatively 12.5 g every 1 hour, reduced dose may compromise efficacy
  > Adult: Initially 50 g, then 50 g every 4 hours, reduced if not tolerated to 25 g every 2 hours, alternatively 12.5 g every 1 hour, reduced dose may compromise efficacy

Accelerated elimination of teriflunomide

- BY MOUTH USING GRANULES

  > Adult: 50 g every 12 hours for 11 days

Accelerated elimination of leflunomide (washout procedure)

- BY MOUTH USING GRANULES

  > Adult: 50 g 4 times a day for 11 days

- UNLICENSED USE  Activated charcoal doses in BNF may differ from those in product literature.

- CAUTIONS  Comatose patient (risk of aspiration—ensure airway is protected) · drowsy patient (risk of aspiration—ensure airway protected) · reduced gastrointestinal motility (risk of obstruction)

- SIDE-EFFECTS  Black stools

- DIRECTIONS FOR ADMINISTRATION  Suspension or reconstituted powder may be mixed with soft drinks (e.g. caffeine-free diet cola) or fruit juices to mask the taste.

- MEDICINAL FORMS  There can be variation in the licensing of different medicines containing the same drug

Oral suspension

- Actidose-Aqua Advance (Alliance Pharmaceuticals Ltd)
  Activated charcoal 208 mg per 1 ml Actidose-Aqua Advance 1.04g/5ml oral suspension 1 240 ml £12.89
- Charcordote (Teva UK Ltd)
  Activated charcoal 200 mg per 1 ml Charcordote 200mg/ml oral suspension sugar-free 1 250 ml £11.89

Granules

- Carbomix (Beacon Pharmaceuticals Ltd)
  Activated charcoal 813 mg per 1 gram Carbomix 81.3% granules sugar-free 1 50 gram £11.90
2 Chemical toxicity

2.1 Cyanide toxicity

ANTIDOTES AND CHELATORS

Dicobalt edetate

**INDICATIONS AND DOSE**

**Severe poisoning with cyanides**

- **BY INTRAVENOUS INJECTION**
  - Child: Consult the National Poisons Information Service
  - Adult: 300 mg, to be given over 1 minute (or 5 minutes if condition less serious), dose to be followed immediately by 50 mL of glucose intravenous infusion 50%; if response inadequate a second dose of both may be given, but risk of cobalt toxicity

**CAUTIONS** Owing to toxicity to be used only for definite cyanide poisoning when patient tending to lose, or has lost, consciousness

**SIDE-EFFECTS** Anaphylactoid reactions • cardiac abnormalities • facial oedema • hypotension • laryngeal oedema • tachycardia • vomiting

**EXCEPTIONS TO LEGAL CATEGORY** Prescription only medicine restriction does not apply where administration is for saving life in emergency.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection, solution for injection ampoules • 6 ampoule [Pst] £11.72

Sodium nitrate

**INDICATIONS AND DOSE**

Poisoning with cyanides (used in conjunction with sodium thiosulfate)

- **BY INTRAVENOUS INJECTION**
  - Child: 4–10 mg/kg (max. per dose 300 mg), to be given over 5–20 minutes followed by sodium thiosulphate injection
  - Adult: 300 mg, to be given over 5–20 minutes (as sodium nitrite injection 30 mg/mL)

**DOSE EQUIVALENCE AND CONVERSION**

- 4–10 mg/kg equates to 0.13–0.33 mL/kg of a 3% solution.
- Dose max. of 300 mg equates to 10 mL of a 3% solution.

**SIDE-EFFECTS** Flushing (due to vasodilatation) • headache (due to vasodilatation)

**EXCEPTIONS TO LEGAL CATEGORY** Prescription only medicine restriction does not apply where administration is for saving life in emergency.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection

Sodium thiosulfate

**INDICATIONS AND DOSE**

Poisoning with cyanides (used in conjunction with sodium nitrite)

- **BY INTRAVENOUS INJECTION**
  - Child: 400 mg/kg (max. per dose 12.5 g), to be given over 10 minutes, dose may be repeated in severe cyanide poisoning if dicobalt edetate not available
  - Adult: 12.5 g, to be given over 10 minutes (as sodium thiosulfate injection 500 mg/mL), dose may be repeated in severe cyanide poisoning if dicobalt edetate not available

**DOSE EQUIVALENCE AND CONVERSION**

- 400 mg/kg equates to 0.8 mL/kg of a 50% solution.
- 12.5 g equates to 25 mL of a 50% solution.

**EXCEPTIONS TO LEGAL CATEGORY** Prescription only medicine restriction does not apply where administration is for saving life in emergency.

**MEDICINAL FORMS**

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection, solution for injection ampoules • 6 ampoule [Pst] £11.72

2.2 Other drugs used for Organophosphorus toxicity

**Antidotes and chelators**

Pralidoxime chloride

**INDICATIONS AND DOSE**

Adjunct to atropine in the treatment of poisoning by organophosphorus insecticide or nerve agent

- **BY INTRAVENOUS INFUSION**
  - Child: Initially 30 mg/kg, to be given over 20 minutes, followed by 8 mg/kg/hour; maximum 12 g per day
  - Adult: Initially 30 mg/kg, to be given over 20 minutes, followed by 8 mg/kg/hour; maximum 12 g per day

**UNLICENSED USE** Pralidoxime chloride doses may differ from those in product literature. Licensed for use in children (age range not specified by manufacturer).

**CONTRA-INDICATIONS** Poisoning with carbamates • poisoning with organophosphorus compounds without anticholinesterase activity

**CAUTIONS** Myasthenia gravis

**SIDE-EFFECTS** Disturbances of vision • dizziness • drowsiness • headache • hyperventilation • muscular weakness • nausea • tachycardia

**RENAL IMPAIRMENT** Use with caution.

**DIRECTIONS FOR ADMINISTRATION** The loading dose may be administered by intravenous injection (diluted to a concentration of 50 mg/mL with water for injections) over at least 5 minutes if pulmonary oedema is present or if it is not practical to administer an intravenous infusion.

**IN CHILDREN** For intravenous infusion, reconstitute each vial with 20 mL Water for Injections, then dilute to a concentration of 10–20 mg/mL with Sodium Chloride 0.9%.

**PRESCRIBING AND DISPENSING INFORMATION** Available from designated centres for organophosphorus insecticide poisoning or from the National Blood Service (or Welsh
3 Drug toxicity

3.1 Benzodiazepine toxicity

ANTIDOTES AND CHELATORS

BENZODIAZEPINE ANTAGONISTS

Flumazenil

- **INDICATIONS AND DOSE**
  - Reversal of sedative effects of benzodiazepines in anaesthesia and clinical procedures
    - **BY INTRAVENOUS INJECTION**
    - Adult: 200 micrograms, dose to be administered over 15 seconds, then 100 micrograms every 1 minute if required; usual dose 300–600 micrograms; maximum 1 mg per course
  - Reversal of sedative effects of benzodiazepines in intensive care
    - **BY INTRAVENOUS INJECTION**
    - Adult: 300 micrograms, dose to be administered over 15 seconds, then 100 micrograms every 1 minute if required; maximum 2 mg per course
  - Reversal of sedative effects of benzodiazepines in intensive care (if drowsiness recurs after injection)
    - **INITIALLY BY INTRAVENOUS INFUSION**
    - Adult: 100–400 micrograms/hour, adjusted according to response, alternatively (by intravenous injection) 300 micrograms, adjusted according to response

**IMPORTANT SAFETY INFORMATION**

Flumazenil should only be administered by, or under the direct supervision of, personnel experienced in its use.

- **CONTRA-INDICATIONS**
  - Life-threatening condition (e.g. raised intracranial pressure, status epilepticus) controlled by benzodiazepines
- **CAUTIONS**
  - Avoid rapid injection following major surgery; avoid rapid injection in high-risk or anxious patients; benzodiazepine dependence (may precipitate withdrawal symptoms) - elderly - ensure neuromuscular blockade cleared before giving - head injury (rapid reversal of benzodiazepine sedation may cause convulsions) - history of panic disorders (risk of recurrence) - prolonged benzodiazepine therapy for epilepsy (risk of convulsions) - short-acting (repeat doses may be necessary - benzodiazepine effects may persist for at least 24 hours)
- **SIDE-EFFECTS**
  - Common or very common: Nausea, vomiting
  - Uncommon: Anxiety, fear, palpitation
  - Frequency not known: Agitation, chills, convulsions
  - Pregnancy: Not known to be harmful.

- **BREAST FEEDING**
  - Avoid breast-feeding for 24 hours.
- **HEPATIC IMPAIRMENT**
  - Carefully titrate dose.
- **DIRECTIONS FOR ADMINISTRATION**
  - For continuous intravenous infusion, dilute with Glucose 5% or Sodium Chloride 0.9%.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Solution for injection**
    - Flumazenil (Non-proprietary)
      - Flumazenil 100 microgram per 1 ml
      - Flumazenil 500 micrograms/5 ml solution for injection ampoules | 5 ampoul
      - £65.50–£72.46

3.2 Digoxin toxicity

ANTIDOTES AND CHELATORS

DIGOXIN-SPECIFIC ANTIBODIES

Digoxin-specific antibody

- **INDICATIONS AND DOSE**
  - Treatment of known or strongly suspected life-threatening digoxin toxicity associated with ventricular arrhythmias or bradyarrhythmias unresponsive to atropine and when measures beyond the withdrawal of digoxin and correction of any electrolyte abnormalities are considered necessary
  - **BY INTRAVENOUS INFUSION**
    - Child: Serious cases of digoxin toxicity should be discussed with the National Poisons Information Service (consult product literature)
    - Adult: Serious cases of digoxin toxicity should be discussed with the National Poisons Information Service (consult product literature)

- **DIRECTIONS FOR ADMINISTRATION**
  - In adults
    - For intravenous infusion (DigiFab®), given intermittently in Sodium chloride 0.9%. Reconstitute with water for injections (4 ml/vial), then dilute with infusion fluid and give over 30 minutes.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Powder for solution for infusion**
    - DigiFab (BTG International Ltd)
      - Digoxin-specific antibody fragments 40 mg
      - DigiFab 40 mg powder for solution for infusion vials | 1 vial
      - £750.00 (Hospital only)

3.3 Heparin toxicity

ANTIDOTES AND CHELATORS

Protamine sulfate

- **INDICATIONS AND DOSE**
  - Overdose with intravenous injection of unfractionated heparin
    - **BY INTRAVENOUS INJECTION**
      - Adult: Dose to be administered at a rate not exceeding 5 mg/min, 1 mg neutralises 80–100 units heparin when given within 15 minutes; if longer than 15 minute since heparin, less protamine required (consult product literature for details) as heparin rapidly excreted; maximum 50 mg
3.4 Opioid toxicity

**OPIOID RECEPTOR ANTAGONISTS**

**Naloxone hydrochloride**

- **INDICATIONS AND DOSE**
  - **Overdose with opioids**
    - By intravenous injection, or by subcutaneous injection, or by intramuscular injection
    - Child 1 month–11 years: Initially 100 micrograms/kg, if no response, repeat at intervals of 1 minute to a total max. 2 mg, then review diagnosis; further doses may be required if respiratory function deteriorates

**Overdosage with intravenous infusion of unfractionated heparin**
- By intravenous injection
- Adult: 25–50 mg, to be administered once heparin infusion stopped at a rate not exceeding 5 mg/minute

**Overdosage with subcutaneous injection of unfractionated heparin**
- Initially by intravenous injection
- Adult: Initially 25–50 mg, to be administered at a rate not exceeding 5 mg/minute, 1 mg neutralises 100 units heparin, then (by intravenous infusion), any remaining dose to be administered over 8–16 hours; maximum 50 mg per course

**Overdosage with subcutaneous injection of low molecular weight heparin**
- By intravenous injection, or by continuous intravenous infusion
- Adult: Dose to be administered by intermittent intravenous injection at a rate not exceeding 5 mg/minute, 1 mg neutralises approx. 100 units low molecular weight heparin (consult product literature of low molecular weight heparin for details); maximum 50 mg

- **CAUTIONS** Excessive doses can have an anticoagulant effect
- **SIDE-EFFECTS** Anaphylaxis · angioedema · back pain · bradycardia · dyspnoea · flushing · hypersensitivity reactions · hypertension · hypotension · lassitude · nausea · pulmonary oedema · rebound bleeding · vomiting
- **ALLERGY AND CROSS-SENSITIVITY** Caution if increased risk of allergic reaction to protamine (includes previous treatment with protamine or protamine insulin, allergy to fish, men who are infertile or who have had a vasectomy and who may have antibodies to protamine).
- **MONITORING REQUIREMENTS** Monitor activated partial thromboplastin time or other appropriate blood clotting parameters.
- **PRESCRIBING AND DISPENSING INFORMATION** The long half-life of low molecular weight heparins should be taken into consideration when determining the dose of protamine sulfate; the effects of low molecular weight heparins can persist for up to 24 hours after administration.

**MEDICINAL FORMS**
There can be variation in the licensing of different medicines containing the same drug.

**Solution for injection**
- **Protamine sulfate (Non-proprietary)**
  - Protamine sulfate 10 mg per 1 ml Protamine sulfate 100 mg/10 ml solution for injection ampoules  | 5 ampoule [Pass] no price available Protamine sulfate 50 mg/5 ml solution for injection ampoules  | 10 ampoule [Pass] £49.55

**Overdosage with opioids in a non-medical setting**
- By intramuscular injection
- Adult: 400 micrograms every 2–3 minutes, each dose given in subsequent resuscitation cycles if patient not breathing normally, continue until consciousness regained, breathing normally, medical assistance available, or contents of syringe used up; to be injected into deltoid region or anterolateral thigh

**Reversal of postoperative respiratory depression**
- Initially by intravenous injection
- Child 1 month–11 years: 1 microgram/kg, repeated every 2–3 minutes if required
- Child 12–17 years: Initially 100–200 micrograms, alternatively (by intravenous injection) initially 1.5–3 micrograms/kg, if response inadequate, give subsequent doses, (by intravenous injection) 100 micrograms every 2 minutes, alternatively (by intramuscular injection) 100 micrograms every 1–2 hours
- Adult: Initially 100–200 micrograms, alternatively (by intravenous injection) initially 1.5–3 micrograms/kg, if response inadequate, give subsequent doses, (by intravenous injection) 100 micrograms every 2 minutes, alternatively (by intramuscular injection) 100 micrograms every 1–2 hours

**PHARMACOKINETICS**
Naloxone has a short duration of action; repeated doses or infusion may be necessary to reverse effects of opioids with longer duration of action.

**IMPORTANT SAFETY INFORMATION**

**SAFE PRACTICE**
Doses used in acute opioid overdose may not be appropriate for the management of opioid-induced respiratory depression and sedation in those receiving palliative care and in chronic opioid use.

- **CAUTIONS** Cardiovascular disease or those receiving cardiotoxic drugs (serious adverse cardiovascular effects

**UNLICENSED USE** Naloxone doses in BNF may differ from those in product literature.
3.5 Paracetamol toxicity

ANTIDOTES AND CHELATORS

Acetylcysteine

- **INDICATIONS AND DOSE**
  - **Paracetamol overdose**
    - **BY INTRAVENOUS INFUSION**
      - **Child (body-weight up to 20 kg):** Initially 150 mg/kg over 1 hour, dose to be administered in 3 mL/kg glucose 5%, followed by 50 mg/kg over 4 hours, dose to be administered in 7 mL/kg glucose 5%, then 100 mg/kg over 16 hours, dose to be administered in 14 mL/kg glucose 5%.
      - **Child (body-weight 20–39 kg):** Initially 150 mg/kg over 1 hour, dose to be administered in 100 mL glucose 5%, followed by 50 mg/kg over 4 hours, dose to be administered in 250 mL glucose 5%, then 100 mg/kg over 16 hours, dose to be administered in 500 mL glucose 5%.
      - **Child (body-weight 40 kg and above):** 150 mg/kg over 1 hour, dose to be administered in 200 mL glucose Intravenous Infusion 5%, then 50 mg/kg over 4 hours, to be started immediately after completion of first infusion, dose to be administered in 500 mL glucose Intravenous Infusion 5%, then 100 mg/kg over 16 hours, to be started immediately after completion of second infusion, dose to be administered in 1 litre glucose Intravenous Infusion 5%.
      - **Adult (body-weight 40 kg and above):** 150 mg/kg over 1 hour, dose to be administered in 200 mL glucose Intravenous Infusion 5%, then 50 mg/kg over 4 hours, to be started immediately after completion of first infusion, dose to be administered in 500 mL glucose Intravenous Infusion 5%, then 100 mg/kg over 16 hours, to be started immediately after completion of second infusion, dose to be administered in 1 litre glucose Intravenous Infusion 5%.

**DOSES AT EXTREMES OF BODY-WEIGHT**
To avoid excessive dosage in obese patients, a ceiling weight of 110 kg should be used when calculating the dose for paracetamol overdose.

**IMPORTANT SAFETY INFORMATION**
**MHRA/CHM ADVICE:** INTRAVENOUS ACETYLCYSTEINE FOR PARACETAMOL OVERDOSE: REMINDER OF AUTHORISED DOSE REGIMEN; POSSIBLE NEED FOR CONTINUED TREATMENT (JANUARY 2017)
The authorised dose regimen for acetylcysteine in paracetamol overdose is 3 consecutive intravenous infusions given over a total of 21 hours.
Continued treatment (given at the dose and rate as used in the third infusion) may be necessary depending on the clinical evaluation of the individual patient.

- **CAUTIONS** Asthma (see Side-effects for management of asthma but do not delay acetylcysteine treatment) - atopy - may slightly increase INR - may slightly increase prothrombin time
- **SIDE-EFFECTS** Hypersensitivity-like reactions - rash - slight increase in INR and prothrombin time

**SIDE-EFFECTS, FURTHER INFORMATION**
Hypersensitivity-like reactions: Hypersensitivity-like reactions managed by reducing infusion rate or suspending until reaction settled (rash also managed by giving antihistamine; acute asthma managed by giving nebulised short-acting beta agonist) — contact the National Poisons Information Service if reaction severe.

- **DIRECTIONS FOR ADMINISTRATION**
  - **In children** Glucose 5% is preferred fluid; Sodium Chloride 0.9% is an alternative if Glucose 5% is unsuitable.
  - **In adults** *For intravenous infusion (Parvolex)*, give continuously in Glucose 5% or Sodium chloride 0.9%. Glucose Intravenous Infusion 5% is the preferred fluid; Sodium Chloride Intravenous Infusion 0.9% is an alternative if Glucose Intravenous Infusion 5% is unsuitable.
4 Methaemoglobinaemia

**Methylothioninium chloride**
**(Methylene blue)**

- **INDICATIONS AND DOSE**
  - **Drug- or chemical-induced methaemoglobinaemia**
    - **By slow intravenous injection**
      - Child: 3 months–17 years: Initially 1–2 mg/kg, then 1–2 mg/kg after 30–60 minutes if required, to be given over 5 minutes, seek advice from National Poisons Information Service if further repeat doses are required; maximum 7 mg/kg per course
      - Adult: Initially 1–2 mg/kg, then 1–2 mg/kg after 30–60 minutes if required, to be given over 5 minutes, seek advice from National Poisons Information Service if further repeat doses are required; maximum 7 mg/kg per course
  - **Aniline- or dapsone-induced methaemoglobinaemia**
    - **By slow intravenous injection**
      - Child: 3 months–17 years: Initially 1–2 mg/kg, then 1–2 mg/kg after 30–60 minutes if required, to be given over 5 minutes, seek advice from National Poisons Information Service if further repeat doses are required; maximum 4 mg/kg per course
      - Adult: Initially 1–2 mg/kg, then 1–2 mg/kg after 30–60 minutes if required, to be given over 5 minutes, seek advice from National Poisons Information Service if further repeat doses are required; maximum 4 mg/kg per course

- **CAUTIONS**
  - Children under 3 months (more susceptible to methaemoglobinaemia from high doses of methylothioninium) - chlorate poisoning (reduces efficacy of methylothioninium). G6PD deficiency (seek advice from National Poisons Information Service).
  - Methaemoglobinaemia due to treatment of cyanide poisoning with sodium nitrite (seek advice from National Poisons Information Service).
  - Pulse oximetry may give false estimation of oxygen saturation.

- **INTERACTIONS**
  - Appendix 1: methylothioninium chloride

- **SIDE-EFFECTS**
  - Abdominal pain, agitation, anxiety, arrhythmia, blue-green discoloration of faeces, blue-green discoloration of skin, blue-green discoloration of urine, chest pain, confusion, dizziness, dysphoea, fever, haemolytic anaemia, headache, hyperbilirubinaemia (in infants), hypotension, hypertension, methaemoglobinemia, mydriasis, nausea, sweating, tachypnoea, tremor, vomiting.

- **PREGNANCY**
  - No information available, but risk to fetus of untreated methaemoglobinaemia likely to be significantly higher than risk of treatment.

- **BREAST FEEDING**
  - Manufacturer advises avoid breastfeeding for up to 6 days after administration—no information available.

**RENAL IMPAIRMENT**
Use with caution in severe impairment; dose reduction may be required.

**DIRECTIONS FOR ADMINISTRATION**
- In children For intravenous injection, may be diluted with Glucose 5% to minimise injection-site pain; not compatible with Sodium Chloride 0.9%.

**MEDICINAL FORMS**
- There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: solution for injection.

- **Solution for injection**
  - **Methylothioninium chloride (Non-proprietary)**
    - Methylothioninium chloride 5 mg per 1 ml
  - **Solution for injection ampoules**
    - Parvolex 200 mg (Phoenix Labs Ltd)
    - Parvolex 200 mg per 1 ml
  - **Solution for infusion**
    - Parvolex 2 g/10 ml concentrate for solution for infusion ampoules 10 ampoule £22.50

5 Snake bites

**IMMUNE SERA AND IMMUNOGLOBULINS**

**European viper snake venom antiserum**

- **INDICATIONS AND DOSE**
  - **Systemic envenoming from snake bites | Marked local envenoming**
    - **By intravenous injection, or by intravenous infusion**
      - Child: Initially 10 mL for 1 dose, then 10 mL after 1–2 hours if required, the second dose should only be given if symptoms of systemic envenoming persist after the first dose, if symptoms of systemic envenoming persist contact the National Poisons Information Service
      - Adult: Initially 10 mL for 1 dose, then 10 mL after 1–2 hours if required, the second dose should only be given if symptoms of systemic envenoming persist after the first dose, if symptoms of systemic envenoming persist contact the National Poisons Information Service
  - **Severe systemic envenoming from snake bites in patients presenting with clinical features**
    - **By intravenous injection, or by intravenous infusion**
      - Child: Initially 20 mL for 1 dose, if symptoms of systemic envenoming persist contact the National Poisons Information Service
      - Adult: Initially 20 mL for 1 dose, if symptoms of systemic envenoming persist contact the National Poisons Information Service

- **DIRECTIONS FOR ADMINISTRATION**
  - By intravenous injection given over 10–15 minutes or by intravenous infusion over 30 minutes after diluting in sodium chloride 0.9% (use 5 mL diluent/kg body-weight).

- **PRESCRIBING AND DISPENSING INFORMATION**
  - To order, email immform@dhh.gsi.gov.uk.

- **MEDICINAL FORMS**
  - There can be variation in the licensing of different medicines containing the same drug.
  - **Solution for injection**
    - **European viper snake venom antiserum (Non-proprietary)**
      - European viper snake venom antiserum 100 mg per 1 ml
      - Viper venom antiserum, European (equine) 1 g/10 ml solution for injection vials 1 vial £0.0 no price available
Appendix 1
Interactions

Changes have been made to Appendix 1. For more information, see www.bnf.org.

Two or more drugs given at the same time can exert their effects independently or they can interact. Interactions may be beneficial and exploited therapeutically; this type of interaction is not within the scope of this appendix. Many interactions are harmless, and even those that are potentially harmful can often be managed, allowing the drugs to be used safely together. Nevertheless, adverse drug interactions should be reported to the Medicines and Healthcare products Regulatory Agency (MHRA), through the Yellow Card Scheme (see Adverse Reactions to Drugs, p. 12), as for other adverse drug reactions.

Potentially harmful drug interactions may occur in only a small number of patients, but the true incidence is often hard to establish. Furthermore the severity of a harmful interaction is likely to vary from one patient to another. Patients at increased risk from drug interactions include the elderly and those with impaired renal or hepatic function.

Interactions can result in the potentiation or antagonism of one drug by another, or result in another effect, such as renal impairment. Drug interactions may develop either through pharmacokinetic or pharmacodynamic mechanisms.

Pharmacodynamic interactions
These are interactions between drugs that have similar or antagonistic pharmacological effects or side-effects. They might be due to competition at receptor sites, or occur between drugs acting on the same physiological system. They are usually predictable from a knowledge of the pharmacology of the interacting drugs; in general, those demonstrated with one drug are likely to occur with related drugs.

Pharmacokinetic interactions
These occur when one drug alters the absorption, distribution, metabolism, or excretion of another, thus increasing or decreasing the amount of drug available to produce its pharmacological effects. Pharmacokinetic interactions occurring with one drug do not necessarily occur uniformly across a group of related drugs.

Affecting absorption
The rate of absorption and the total amount absorbed can both be altered by drug interactions. Delayed absorption is rarely of clinical importance unless a rapid effect is required (e.g. when giving an analgesic). Reduction in the total amount absorbed, however, can result in ineffective therapy.

Affecting distribution
Due to changes in protein binding
To a variable extent most drugs are loosely bound to plasma proteins. Protein-binding sites are non-specific and one drug can displace another thereby increasing the proportion free to diffuse from the plasma to its site of action. This only produces a detectable increase in effect if it is an extensively bound drug (more than 90%) that is not widely distributed throughout the body. Even so displacement rarely produces more than transient potentiation because this increased concentration of free drug will usually be eliminated.

Displacement from protein binding does play a part in the potentiation of warfarin by sulfonamides but these interactions become clinically relevant mainly because warfarin metabolism is also inhibited.

Induction or inhibition of drug transporter proteins
Drug transporter proteins, such as P-glycoprotein, actively transport drugs across biological membranes. Transporters can be induced or inhibited, resulting in changes in the concentrations of drugs that are substrates for the transporter. For example, rifampicin induces P-glycoprotein, particularly in the gut wall, resulting in decreased plasma concentrations of digoxin, a P-glycoprotein substrate.

Affecting metabolism
Many drugs are metabolised in the liver. Drugs are either metabolised by phase I reactions (oxidation, reduction, or hydrolysis) or by phase II reactions (e.g. glucuronidation).

Phase I reactions are mainly carried out by the cytochrome P450 family of isoenzymes, of which CYP3A4 is the most important isoenzyme involved in the metabolism of drugs. Induction of cytochrome P450 isoenzymes by one drug can increase the rate of metabolism of another, resulting in lower plasma concentrations and a reduced effect. On withdrawal of the inducing drug, plasma concentrations increase and toxicity can occur.

Conversely when one drug inhibits cytochrome P450 isoenzymes, it can decrease the metabolism of another, leading to higher plasma concentrations, resulting in an increased effect with a risk of toxicity.

Isoenzymes of the hepatic cytochrome P450 system interact with a wide range of drugs. With knowledge of which isoenzymes are involved in a drug’s metabolism, it is possible to predict whether certain pharmacokinetic interactions will occur. For example, carbamazepine is a potent inducer, ketoconazole is a potent inhibitor, and midazolam is a substrate of CYP3A4. Carbamazepine increases midazolam concentrations, and it is therefore likely that other drugs that are potent inducers of CYP3A4 will interact similarly with midazolam. Ketoconazole, however, increases midazolam concentrations, and it can be predicted that other drugs that are potent inhibitors of CYP3A4 will interact similarly.

Less is known about the enzymes involved in phase II reactions. These include UDP-glucuronosyltransferases which, for example, might be induced by rifampicin, resulting in decreased metabolism of mycophenolate (a substrate for this enzyme) to its active form, mycophenolic acid.

Affecting renal excretion
Drugs are eliminated through the kidney both by glomerular filtration and by active tubular secretion. Competition occurs between those which share active transport mechanisms in the proximal tubule. For example, salicylates and some other NSAIDs delay the excretion of methotrexate; serious methotrexate toxicity is possible. Changes in urinary pH can also affect the reabsorption of a small number of drugs, including methenamine.
Relative importance of interactions

Severity of interactions

Most interactions have been assigned a severity; this describes the likely effect of an unmanaged interaction on the patient.

- **Severe** – the result may be a life-threatening event or have a permanent detrimental effect.
- **Moderate** – the result could cause considerable distress or partially incapacitate a patient; they are unlikely to be life-threatening or result in long-term effects.
- **Mild** – the result is unlikely to cause concern or incapacitate the majority of patients.
- **Unknown** – used for those interactions that are predicted, but there is insufficient evidence to hazard a guess at the outcome.

Appendix 1 structure

1. **Drugs**

Drugs are listed alphabetically. If a drug is a member of a drug class, all interactions for that drug will be listed under the drug class entry; in this case the drug entry provides direction to the relevant drug class where its interactions can be found.

Within a drug or drug class entry, interactions are listed alphabetically by the interacting drug or drug class. The interactions describe the effect that occurs, and the action to be taken, either based on manufacturer’s advice from the relevant Summary of Product Characteristics or advice from a relevant authority (e.g. MHRA). An action message is only included where the combination is to be avoided, where a dose adjustment is required, or where specific administration requirements (e.g. timing of doses) are recommended. If two drugs have a pharmacodynamic effect in addition to a pharmacokinetic interaction, a cross-reference to the relevant pharmacodynamic effect table is included at the end of the pharmacokinetic message.

2. **Drug classes**

The drugs that are members of a drug class are listed underneath the drug class entry in a blue box. Interactions for the class are then listed alphabetically by the interacting drug or drug class. If the interaction only applies to certain drugs in the class, these drugs will be shown in brackets after the drug class name.

3. **Supplementary information**

If a drug has additional important information to be considered, this is shown in a blue box underneath the drug or drug class entry. This information might be food and lifestyle advice (including smoking and alcohol consumption), relate to the pharmacology of the drug or applicability of interactions to certain routes of administration, or it might be advice about separating administration times.

Evidence for interactions

Most interactions have been assigned a rating to indicate the weight of evidence behind the interaction.

- **Study** – for interactions where the information is based on formal study including those for other drugs with the same mechanism (e.g. known inducers, inhibitors, or substrates of cytochrome P450 isoenzymes or P-glycoprotein).
- **Anecdotal** – interactions based on either a single case report or a limited number of case reports.
- **Theoretical** – interactions that are predicted based on sound theoretical considerations. The information may have been derived from *in vitro* studies or based on the way other members in the same class act.

### Table 1

**Name of pharmacodynamic effect**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Drug</th>
<th>Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>B</td>
<td>C</td>
</tr>
</tbody>
</table>

### Table 2

**Drug entry**

- Details of interaction between drug entry and another drug or drug class. Action statement. [Severity] Evidence
- Details of interaction between drug entry and another drug or drug class. Action statement. [Severity] Evidence

### Table 3

**Drug class entry**

- Details of interaction between drug class entry and another drug or drug class. Action statement. [Severity] Evidence

### Table 4

**Drug entry or Drug class entry**

- Also see TABLE 1

**Drug entry or Drug class entry**

- see TABLE 1

### Table 5

**Pharmacodynamic effects**

Tables at the beginning of Appendix 1 cover pharmacodynamic effects. If a drug is included in one or more of these tables, this will be indicated at the top of the list of interactions for the drug or drug class. In addition to the list of interactions for a drug or drug class, these tables should always be consulted.

Each table describes the relevant pharmacodynamic effect and lists those drugs that are commonly associated with the effect. Concurrent use of two or more drugs from the same table is expected to increase the risk of the pharmacodynamic effect occurring. Please note these tables are not exhaustive.

Other than for QT interval prolongation, actions for pharmacodynamic effects are not included in the BNF, as these will depend on individual patient circumstances.
## TABLE 1
### Drugs that cause hepatotoxicity

The following is a list of some drugs that cause hepatotoxicity (note that this list is not exhaustive). Concurrent use of two or more drugs from the list might increase this risk.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Drug</th>
<th>Drug</th>
<th>Drug</th>
<th>Drug</th>
<th>Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>alcohol (beverage)</td>
<td>demeclocycline</td>
<td>leflunomide</td>
<td>minocycline</td>
<td>sulfasalazine</td>
<td>tetracycline</td>
</tr>
<tr>
<td>asparaginase</td>
<td>didanosine</td>
<td>lenalidomide</td>
<td>oxycycline</td>
<td>tirofiban</td>
<td>ticagrelor</td>
</tr>
<tr>
<td>atorvastatin</td>
<td>doxycycline</td>
<td>lomipiptide</td>
<td>paracetamol</td>
<td>toremifene</td>
<td>trastuzumab</td>
</tr>
<tr>
<td>carbamazepine</td>
<td>fluconazole</td>
<td>lymecycline</td>
<td>pegaspargase</td>
<td>trastuzumab</td>
<td>trastuzumab emtansine</td>
</tr>
<tr>
<td>crisantaspase</td>
<td>fluvastatin</td>
<td>mercaptopurine</td>
<td>pravastatin</td>
<td>tretinoin</td>
<td>vireadine</td>
</tr>
<tr>
<td>dactinomycin</td>
<td>isoniazid</td>
<td>methotrexate</td>
<td>rosuvastatin</td>
<td>vireadine</td>
<td>vinblastine</td>
</tr>
<tr>
<td>dantrolene</td>
<td>itraconazole</td>
<td>micafungin</td>
<td>simvastatin</td>
<td>vireadine</td>
<td>vinblastine</td>
</tr>
</tbody>
</table>

## TABLE 2
### Drugs that cause nephrotoxicity

The following is a list of some drugs that cause nephrotoxicity (note that this list is not exhaustive). Concurrent use of two or more drugs from the list might increase this risk.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>bivalirudin</td>
<td>acenocoumarol</td>
<td>celecoxib</td>
<td>colistimethate</td>
<td>demeclocycline</td>
<td>cefuroxime</td>
<td>cefetin</td>
<td>ciclosporin</td>
<td>ceftriaxone</td>
<td>cefuroxime</td>
</tr>
<tr>
<td>argatroban</td>
<td>acetaminophen</td>
<td>cefixime</td>
<td>dexamethasone</td>
<td>cefuroxime</td>
<td>cefuroxime</td>
<td>cefuroxime</td>
<td>cefuroxime</td>
<td>cefuroxime</td>
<td>cefuroxime</td>
</tr>
<tr>
<td>clopidogrel</td>
<td>acetaminophen</td>
<td>cefoperazone</td>
<td>dexamethasone</td>
<td>cefuroxime</td>
<td>cefuroxime</td>
<td>cefuroxime</td>
<td>cefuroxime</td>
<td>cefuroxime</td>
<td>cefuroxime</td>
</tr>
<tr>
<td>acetaminophen</td>
<td>acetaminophen</td>
<td>cefoperazone</td>
<td>dexamethasone</td>
<td>cefuroxime</td>
<td>cefuroxime</td>
<td>cefuroxime</td>
<td>cefuroxime</td>
<td>cefuroxime</td>
<td>cefuroxime</td>
</tr>
</tbody>
</table>

## TABLE 3
### Drugs with anticoagulant effects

The following is a list of drugs that have anticoagulant effects. Concurrent use of two or more drugs from this list might increase the risk of bleeding; concurrent use of drugs with antiplatelet effects (see table of drugs with antiplatelet effects) might also increase this risk.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>acenocoumarol</td>
<td>dabigatran</td>
<td>fondaparinux</td>
<td>phenindione</td>
<td>tinzaparins</td>
<td>alteplase</td>
<td>dalteparin</td>
<td>retaplas</td>
<td>tenecteplase</td>
<td>tirofiban</td>
</tr>
<tr>
<td>apixaban</td>
<td>edoxaban</td>
<td>glucose</td>
<td>reteplase</td>
<td>ticagrelor</td>
<td>argatroban</td>
<td>enoxaparin</td>
<td>rivaroxaban</td>
<td>telaparinux</td>
<td>tirofiban</td>
</tr>
<tr>
<td>argatroban</td>
<td>edoxaban</td>
<td>heparin (unfractionated)</td>
<td>streptokinase</td>
<td>warfarin</td>
<td>bivalirudin</td>
<td>enoxaparin</td>
<td>streptokinase</td>
<td>tenecteplase</td>
<td>tubocurarin</td>
</tr>
</tbody>
</table>

## TABLE 4
### Drugs with antiplatelet effects

The following is a list of drugs that have antiplatelet effects (note that this list is not exhaustive). Concurrent use of two or more drugs from this list might increase the risk of bleeding; concurrent use of drugs with anticoagulant effects (see table of drugs with antiplatelet effects) might also increase this risk.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>abciximab</td>
<td>daptomycin</td>
<td>etoricoxib</td>
<td>meloxicam</td>
<td>sulindac</td>
<td>acalabrutinib</td>
<td>daxibotin</td>
<td>meloxicam</td>
<td>sulindac</td>
<td>tenoxicam</td>
</tr>
<tr>
<td>acelofenac</td>
<td>daxibotin</td>
<td>meloxicam</td>
<td>sulindac</td>
<td>tenoxicam</td>
<td>acenocoumarol</td>
<td>dabigatran</td>
<td>meloptic</td>
<td>sulindac</td>
<td>tenoxicam</td>
</tr>
<tr>
<td>acemeticin</td>
<td>daxibotin</td>
<td>meloxicam</td>
<td>sulindac</td>
<td>tenoxicam</td>
<td>acenocoumarol</td>
<td>dabigatran</td>
<td>meloptic</td>
<td>sulindac</td>
<td>tenoxicam</td>
</tr>
<tr>
<td>acinet</td>
<td>daxibotin</td>
<td>meloxicam</td>
<td>sulindac</td>
<td>tenoxicam</td>
<td>acenocoumarol</td>
<td>dabigatran</td>
<td>meloptic</td>
<td>sulindac</td>
<td>tenoxicam</td>
</tr>
<tr>
<td>acinet</td>
<td>daxibotin</td>
<td>meloxicam</td>
<td>sulindac</td>
<td>tenoxicam</td>
<td>acenocoumarol</td>
<td>dabigatran</td>
<td>meloptic</td>
<td>sulindac</td>
<td>tenoxicam</td>
</tr>
</tbody>
</table>

## TABLE 5
### Drugs that cause thromboembolism

The following is a list of some drugs that cause thromboembolism (note that this list is not exhaustive). Concurrent use of two or more drugs from the list might increase this risk.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>bleomycin</td>
<td>eoplatin</td>
<td>etoposide</td>
<td>melphalan</td>
<td>vincristine</td>
<td>cyclophosphamide</td>
<td>epoetin alfa</td>
<td>melphalan</td>
<td>vincristine</td>
<td>vincristine</td>
</tr>
<tr>
<td>darbepoetin alfa</td>
<td>eoplatin</td>
<td>etoposide</td>
<td>melphalan</td>
<td>vincristine</td>
<td>doxorubicin</td>
<td>epoetin alfa</td>
<td>melphalan</td>
<td>vincristine</td>
<td>vincristine</td>
</tr>
<tr>
<td>epoetin alfa</td>
<td>eoplatin</td>
<td>etoposide</td>
<td>melphalan</td>
<td>vincristine</td>
<td>epoetin zeta</td>
<td>epoetin alfa</td>
<td>melphalan</td>
<td>vincristine</td>
<td>vincristine</td>
</tr>
<tr>
<td>epoetin beta</td>
<td>eoplatin</td>
<td>etoposide</td>
<td>melphalan</td>
<td>vincristine</td>
<td>epoetin alfa</td>
<td>epoetin alfa</td>
<td>melphalan</td>
<td>vincristine</td>
<td>vincristine</td>
</tr>
</tbody>
</table>

---

Appendix 1 Interactions

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>bleomycin</td>
<td>eoplatin</td>
<td>etoposide</td>
<td>melphalan</td>
<td>vincristine</td>
<td>cyclophosphamide</td>
<td>epoetin alfa</td>
<td>melphalan</td>
<td>vincristine</td>
<td>vincristine</td>
</tr>
<tr>
<td>darbepoetin alfa</td>
<td>eoplatin</td>
<td>etoposide</td>
<td>melphalan</td>
<td>vincristine</td>
<td>doxorubicin</td>
<td>epoetin alfa</td>
<td>melphalan</td>
<td>vincristine</td>
<td>vincristine</td>
</tr>
<tr>
<td>epoetin alfa</td>
<td>eoplatin</td>
<td>etoposide</td>
<td>melphalan</td>
<td>vincristine</td>
<td>epoetin zeta</td>
<td>epoetin alfa</td>
<td>melphalan</td>
<td>vincristine</td>
<td>vincristine</td>
</tr>
<tr>
<td>epoetin beta</td>
<td>eoplatin</td>
<td>etoposide</td>
<td>melphalan</td>
<td>vincristine</td>
<td>epoetin alfa</td>
<td>epoetin alfa</td>
<td>melphalan</td>
<td>vincristine</td>
<td>vincristine</td>
</tr>
</tbody>
</table>
### TABLE 6
Drugs that cause bradycardia
The following is a list of drugs that cause bradycardia (note that this list is not exhaustive). Concurrent use of two or more drugs from the list might increase this risk.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Drug</th>
<th>Drug</th>
<th>Drug</th>
<th>Drug</th>
<th>Drug</th>
<th>Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>acebutolol</td>
<td>carvedilol</td>
<td>fentanyl</td>
<td>nadolol</td>
<td>rivastigmine</td>
<td>selegiline</td>
<td>sotalol</td>
</tr>
<tr>
<td>alfentanil</td>
<td>celiprolol</td>
<td>fingolimod</td>
<td>nebulolol</td>
<td>selegiline</td>
<td>sotalol</td>
<td>sufentanil</td>
</tr>
<tr>
<td>amiodarone</td>
<td>cisatracurium</td>
<td>flecanide</td>
<td>neostigmine</td>
<td>thalidomide</td>
<td>timolol</td>
<td>tizanidine</td>
</tr>
<tr>
<td>apraclonidine</td>
<td>clonidine</td>
<td>galantamine</td>
<td>oxprenolol</td>
<td>timolol</td>
<td>tizanidine</td>
<td>verapamil</td>
</tr>
<tr>
<td>atenolol</td>
<td>crizotinib</td>
<td>ivabradine</td>
<td>pasireotide</td>
<td>thalidomide</td>
<td>timolol</td>
<td>verapamil</td>
</tr>
<tr>
<td>betaxolol</td>
<td>digoxin</td>
<td>labetalol</td>
<td>pindolol</td>
<td>timolol</td>
<td>tizanidine</td>
<td>verapamil</td>
</tr>
<tr>
<td>bisoprolol</td>
<td>diltiazem</td>
<td>levobunolol</td>
<td>propranolol</td>
<td>timolol</td>
<td>tizanidine</td>
<td>verapamil</td>
</tr>
<tr>
<td>brimonidine</td>
<td>donepezil</td>
<td>methadone</td>
<td>pyridostigmine</td>
<td>timolol</td>
<td>tizanidine</td>
<td>verapamil</td>
</tr>
<tr>
<td>carteolol</td>
<td>esmolol</td>
<td>metoprolol</td>
<td>remifentanil</td>
<td>timolol</td>
<td>tizanidine</td>
<td>verapamil</td>
</tr>
<tr>
<td>celiprolol</td>
<td>guanfacine</td>
<td>moexipril</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### TABLE 7
Drugs that cause first dose hypotension
The following is a list of some drugs that can cause first-dose hypotension (note that this list is not exhaustive). Concurrent use of two or more drugs from the list might increase this risk.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Drug</th>
<th>Drug</th>
<th>Drug</th>
<th>Drug</th>
<th>Drug</th>
<th>Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>alfuzosin</td>
<td>eprosartan</td>
<td>isosorbide dinitrate</td>
<td>losartan</td>
<td>tamsulosin</td>
<td>terazosin</td>
<td>trandolapril</td>
</tr>
<tr>
<td>azilsartan</td>
<td>fosinopril</td>
<td>isosorbide mononitrate</td>
<td>moexipril</td>
<td>telmisartan</td>
<td>valsartan</td>
<td></td>
</tr>
<tr>
<td>candesartan</td>
<td>glyceryl trinitrate</td>
<td>lisinopril</td>
<td>olmesartan</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>captopril</td>
<td>imidapril</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>doxazosin</td>
<td>indoramin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>enalapril</td>
<td>irbesartan</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### TABLE 8
Drugs that cause hypotension
The following is a list of some drugs that cause hypotension (note that this list is not exhaustive). Concurrent use of two or more drugs from the list might increase this risk.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Drug</th>
<th>Drug</th>
<th>Drug</th>
<th>Drug</th>
<th>Drug</th>
<th>Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>acebutolol</td>
<td>chlorpromazine</td>
<td>haloperidol</td>
<td>moxisylyte</td>
<td>riociguat</td>
<td></td>
<td></td>
</tr>
<tr>
<td>alcohol (beverage)</td>
<td>chlortalidone</td>
<td>histamine</td>
<td>moxonidine</td>
<td>risperidone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>alfuzosin</td>
<td>clevidipine</td>
<td>hydrochlorothiazide</td>
<td>nebivolol</td>
<td>rotigotine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>aliskiren</td>
<td>clompramine</td>
<td>imidapril</td>
<td>nicardipine</td>
<td>sacubitril</td>
<td></td>
<td></td>
</tr>
<tr>
<td>alprostadil</td>
<td>clonidine</td>
<td>impiramine</td>
<td>nicorandil</td>
<td>saproterin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>amantadine</td>
<td>clopamide</td>
<td>indapamide</td>
<td>nifedipine</td>
<td>selegline</td>
<td></td>
<td></td>
</tr>
<tr>
<td>amitriptyline</td>
<td>clozapine</td>
<td>indoramin</td>
<td>nimodipine</td>
<td>sevoflurane</td>
<td></td>
<td></td>
</tr>
<tr>
<td>amiodipine</td>
<td>cyclopenthiazide</td>
<td>isradipine</td>
<td>nitrous oxide</td>
<td>sildenafil</td>
<td></td>
<td></td>
</tr>
<tr>
<td>apomorphine</td>
<td>dapagliflozin</td>
<td>ketamine</td>
<td>nortriptyline</td>
<td>sodium nitroprusside</td>
<td></td>
<td></td>
</tr>
<tr>
<td>apraclonidine</td>
<td>desflurane</td>
<td>labetalol</td>
<td>olanzapine</td>
<td>sodium o xoate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>asenapine</td>
<td>diazoxide</td>
<td>lecanidipine</td>
<td>olmesartan</td>
<td>sotalol</td>
<td></td>
<td></td>
</tr>
<tr>
<td>atenolol</td>
<td>diltiazem</td>
<td>levobunolol</td>
<td>oxprenolol</td>
<td>spironolactone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>avanal</td>
<td>dipyriramidole</td>
<td>levodopa</td>
<td>paliperidone</td>
<td>sulpiride</td>
<td></td>
<td></td>
</tr>
<tr>
<td>azilsartan</td>
<td>dosulepin</td>
<td>levomepromazine</td>
<td>pergolide</td>
<td>tadalafil</td>
<td></td>
<td></td>
</tr>
<tr>
<td>baclofen</td>
<td>doxepin</td>
<td>lisinopril</td>
<td>pericyazine</td>
<td>tamsulosin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>bendrofluethazide</td>
<td>droperidol</td>
<td>lopresane</td>
<td>perindopril</td>
<td>telmisartan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>benperidol</td>
<td>empagliflozin</td>
<td>losartan</td>
<td>perphenazine</td>
<td>terazosin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>betaxolol</td>
<td>enalapril</td>
<td>losapine</td>
<td>phenelzine</td>
<td>thioridazine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>bisoprolol</td>
<td>eplerenone</td>
<td>lurasidone</td>
<td>pimozide</td>
<td>tizanidine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>bortezomib</td>
<td>eprosartan</td>
<td>methyldopa</td>
<td>pindolol</td>
<td>torsemide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>brimonidine</td>
<td>esmolol</td>
<td>metolazone</td>
<td>pramipecole</td>
<td>trandolapril</td>
<td></td>
<td></td>
</tr>
<tr>
<td>bromocriptine</td>
<td>etomate</td>
<td>metoprolol</td>
<td>prazosin</td>
<td>triamcinolone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>bumetanide</td>
<td>felodipine</td>
<td>minoxidil</td>
<td>prochloprerazine</td>
<td>trifluoperazine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>cabergoline</td>
<td>flupeptolox</td>
<td>moexipril</td>
<td>promazine</td>
<td>trimipramine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>canagliflozin</td>
<td>fluphenazine</td>
<td>methyldopa</td>
<td>propofol</td>
<td>valsartan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>candesartan</td>
<td>fosinopril</td>
<td>metolazone</td>
<td>propranolol</td>
<td>vardenafil</td>
<td></td>
<td></td>
</tr>
<tr>
<td>captopril</td>
<td>furosemide</td>
<td>methyldopa</td>
<td>quetiapine</td>
<td>verapamil</td>
<td></td>
<td></td>
</tr>
<tr>
<td>carteolol</td>
<td>glyceryl trinitrate</td>
<td>methyldopa</td>
<td>quinapril</td>
<td>xipamide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>carvedilol</td>
<td>guanethidine</td>
<td>mibefradil</td>
<td>ramipril</td>
<td>zuclopenthixol</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### TABLE 9
**Drugs that prolong the QT interval**

The following is a list of some drugs that prolong the QT-interval (note that this list is not exhaustive). In general, manufacturers advise that the use of two or more drugs that are associated with QT prolongation should be avoided. Increasing age, female sex, cardiac disease, and some metabolic disturbances (notably hypokalaemia) predispose to QT prolongation—concurrent use of drugs that reduce serum potassium might further increase this risk (see table of drugs that reduce serum potassium). Drugs that are not known to prolong the QT interval but are predicted (by the manufacturer) to increase the risk of QT prolongation include: domperidone, erythromycin, fingolimod, granisetron, ivabradine, mepfoline, mizolastine, palonosetron, and pentamidine.

Most manufacturers advise avoiding concurrent use with drugs that prolong the QT interval.

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Targets for QT Prolongation</th>
</tr>
</thead>
<tbody>
<tr>
<td>amifamipride</td>
<td>clarithromycin, clomipramine, hydroxyzine</td>
</tr>
<tr>
<td>amiodarone</td>
<td>clomipramine, crizotinib, levomepromazine</td>
</tr>
<tr>
<td>amisulpride</td>
<td>dasatinib, lithium, levofloxidine</td>
</tr>
<tr>
<td>apomorphine</td>
<td>delamanid, methadone, mofloxacin</td>
</tr>
<tr>
<td>arsenic trioxide</td>
<td>disopyramide, nilotinib, ondansetron</td>
</tr>
<tr>
<td>artemether</td>
<td>dronedarone, osimertinib, paliperidone</td>
</tr>
<tr>
<td>arteminol</td>
<td>droperidol, pasireotide, panobinostat</td>
</tr>
<tr>
<td>bedaquiline</td>
<td>eribulin, telavancin, tetrabenazine</td>
</tr>
<tr>
<td>bosutinib</td>
<td>escitalopram, telavancin, tetrabenazine</td>
</tr>
<tr>
<td>cabazitabine</td>
<td>fenofibrate, nilotinib, pasireotide</td>
</tr>
<tr>
<td>certitinib</td>
<td>fenofibrate, pasireotide, tetrabenazine</td>
</tr>
<tr>
<td>chlorpromazine</td>
<td>fluphenazine, haloperidol, hydroxyzine</td>
</tr>
<tr>
<td>citalopram</td>
<td>haloperidol, hydroxyzine, pazopanib</td>
</tr>
<tr>
<td>clozapine</td>
<td>haloperidol, hydroxyzine, pazopanib</td>
</tr>
<tr>
<td>cyclophosphamide</td>
<td>haloperidol, hydroxyzine, pazopanib</td>
</tr>
<tr>
<td>cyclizine</td>
<td>haloperidol, hydroxyzine, pazopanib</td>
</tr>
</tbody>
</table>

### TABLE 10
**Drugs with antimuscarinic effects**

The following is a list of some drugs that have antimuscarinic effects (note that this list is not exhaustive). Concurrent use of two or more drugs from this list might increase the risk of these effects occurring.

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>acclidinium</td>
<td>cyclohexylamine, desflurane, lidocaine</td>
</tr>
<tr>
<td>amantadine</td>
<td>cyproheptadine, darifenac, hydroxyzine</td>
</tr>
<tr>
<td>amitriptiline</td>
<td>dicycloverine, dimenhydrinate, imipramine</td>
</tr>
<tr>
<td>atropine</td>
<td>disopyramide, ipratropium, levomepromazine</td>
</tr>
<tr>
<td>baclofen</td>
<td>doxepin, levomepromazine, lopinapone</td>
</tr>
<tr>
<td>chlorpromazine</td>
<td>doxepin, levomepromazine, lorozepam</td>
</tr>
<tr>
<td>clonazepam</td>
<td>doxepin, levomepromazine, lorozepam</td>
</tr>
<tr>
<td>cyclopropamine</td>
<td>doxepin, levomepromazine, lorozepam</td>
</tr>
<tr>
<td>cyclohexine</td>
<td>doxepin, levomepromazine, lorozepam</td>
</tr>
<tr>
<td>cyclizine</td>
<td>doxepin, levomepromazine, lorozepam</td>
</tr>
</tbody>
</table>

### TABLE 11
**Drugs with CNS depressant effects**

The following is a list of some drugs with CNS depressant effects (note that this list is not exhaustive). Concurrent use of two or more drugs from this list might increase the risk of CNS depressant effects, such as drowsiness, which might affect the ability to perform skilled tasks (see Drugs and Driving p. 3).

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>agomelatine</td>
<td>clomethazole, clomipramine, hydroxyzine</td>
</tr>
<tr>
<td>alcohol</td>
<td>clozapine, clonazepam, ketamine</td>
</tr>
<tr>
<td>alfentanil</td>
<td>clenazepam, clonidine, ketotifen</td>
</tr>
<tr>
<td>alimemazine</td>
<td>clotiapine, clonidine, lamotrigine</td>
</tr>
<tr>
<td>alprazolam</td>
<td>codeine, clonidine, levitracetam</td>
</tr>
<tr>
<td>amisulpride</td>
<td>clozapine, clonidine, levomepromazine</td>
</tr>
<tr>
<td>apraclonidine</td>
<td>cyclopropamine, desflurane, levocepinparine</td>
</tr>
<tr>
<td>aripiprazole</td>
<td>cyanocobalamin, diazepam, lorazepam</td>
</tr>
<tr>
<td>artecaine</td>
<td>dexamethasone, diazepam, lorazepam</td>
</tr>
<tr>
<td>asenapine</td>
<td>dexamethasone, diazepam, lorazepam</td>
</tr>
<tr>
<td>baclofen</td>
<td>diazepam, diazepam, lorazepam</td>
</tr>
<tr>
<td>benperidol</td>
<td>dihydrocodeine, diazepam, lorazepam</td>
</tr>
<tr>
<td>bromidone</td>
<td>dipiperone, diazepam, lorazepam</td>
</tr>
<tr>
<td>buclizine</td>
<td>dipiperone, diazepam, lorazepam</td>
</tr>
<tr>
<td>bupivacaine</td>
<td>dipiperone, diazepam, lorazepam</td>
</tr>
<tr>
<td>buprenorphine</td>
<td>dipiperone, diazepam, lorazepam</td>
</tr>
<tr>
<td>cannabis extract</td>
<td>dipiperone, diazepam, lorazepam</td>
</tr>
<tr>
<td>chloral hydrate</td>
<td>dipiperone, diazepam, lorazepam</td>
</tr>
<tr>
<td>chloralhydrate</td>
<td>dipiperone, diazepam, lorazepam</td>
</tr>
<tr>
<td>chloridiazepoxide</td>
<td>dipiperone, diazepam, lorazepam</td>
</tr>
<tr>
<td>chlorpromazine</td>
<td>dipiperone, diazepam, lorazepam</td>
</tr>
<tr>
<td>cinarizine</td>
<td>dipiperone, diazepam, lorazepam</td>
</tr>
<tr>
<td>clenacline</td>
<td>dipiperone, diazepam, lorazepam</td>
</tr>
</tbody>
</table>
### TABLE 12
**Drugs that cause peripheral neuropathy**
The following is a list of some drugs that cause peripheral neuropathy (note that this list is not exhaustive). Concurrent use of two or more drugs from the list might increase this risk.

<table>
<thead>
<tr>
<th>Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>amiodarone</td>
</tr>
<tr>
<td>bortezomib</td>
</tr>
<tr>
<td>brentuximab vedotin</td>
</tr>
<tr>
<td>cabazitaxel</td>
</tr>
<tr>
<td>cisplatin</td>
</tr>
</tbody>
</table>

### TABLE 13
**Drugs that cause serotonin syndrome**
The following is a list of some drugs that cause serotonin syndrome (note that this list is not exhaustive). See Antidepressant drugs p. 342 for more information and specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.

<table>
<thead>
<tr>
<th>Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>almotriptan</td>
</tr>
<tr>
<td>bupropion</td>
</tr>
<tr>
<td>buspirone</td>
</tr>
<tr>
<td>citalopram</td>
</tr>
<tr>
<td>clomipramine</td>
</tr>
<tr>
<td>dapoxetine</td>
</tr>
<tr>
<td>dexamfetamine</td>
</tr>
<tr>
<td>duloxetine</td>
</tr>
<tr>
<td>eletriptan</td>
</tr>
<tr>
<td>escitalopram</td>
</tr>
</tbody>
</table>

### TABLE 14
**Antidiabetic drugs**
The following is a list of antidiabetic drugs (note that this list is not exhaustive). Concurrent use of two or more drugs from the list might increase the risk of hypoglycaemia.

<table>
<thead>
<tr>
<th>Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>acarbose</td>
</tr>
<tr>
<td>albiglutide</td>
</tr>
<tr>
<td>alogliptin</td>
</tr>
<tr>
<td>biphasic insulin aspart</td>
</tr>
<tr>
<td>biphasic insulin lispro</td>
</tr>
<tr>
<td>biphasic insulin lispro</td>
</tr>
<tr>
<td>canagliflozin</td>
</tr>
<tr>
<td>dapagliflozin</td>
</tr>
</tbody>
</table>

### TABLE 15
**Drugs that cause myelosuppression**
The following is a list of some drugs that cause myelosuppression (note that this list is not exhaustive). Concurrent use of two or more drugs from the list might increase this risk.

<table>
<thead>
<tr>
<th>Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>afatinib</td>
</tr>
<tr>
<td>afibercept</td>
</tr>
<tr>
<td>alectuzumab</td>
</tr>
<tr>
<td>amsacrine</td>
</tr>
<tr>
<td>anakinra</td>
</tr>
<tr>
<td>arsenic trioxide</td>
</tr>
<tr>
<td>asparaginase</td>
</tr>
<tr>
<td>axitinib</td>
</tr>
<tr>
<td>azacitidine</td>
</tr>
<tr>
<td>azathioprine</td>
</tr>
<tr>
<td>bafosetaxi</td>
</tr>
<tr>
<td>belinumab</td>
</tr>
<tr>
<td>bendamustine</td>
</tr>
<tr>
<td>bevacizumab</td>
</tr>
<tr>
<td>bleomycin</td>
</tr>
<tr>
<td>blinatumomab</td>
</tr>
<tr>
<td>bortezomib</td>
</tr>
<tr>
<td>bosutinib</td>
</tr>
<tr>
<td>brentuximab vedotin</td>
</tr>
<tr>
<td>busulfan</td>
</tr>
<tr>
<td>cabazitaxel</td>
</tr>
<tr>
<td>cedazuribitibib</td>
</tr>
<tr>
<td>capecitabine</td>
</tr>
<tr>
<td>carbimazole</td>
</tr>
<tr>
<td>carboptin</td>
</tr>
<tr>
<td>carfilzomib</td>
</tr>
</tbody>
</table>

Downloaded from www.medicalbr.com
### TABLE 16  
**Drugs that increase serum potassium**

The following is a list of some drugs that increase serum potassium concentrations (note that this list is not exhaustive). Concurrent use of two or more drugs from this list might increase the risk of hyperkalaemia. Hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Drug Name</th>
<th>Drug Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>acceclofenac</td>
<td>dexibuprofen</td>
<td>felbinac</td>
</tr>
<tr>
<td>acemetacin</td>
<td>dexketoprofen</td>
<td>meloxicam</td>
</tr>
<tr>
<td>aliskiren</td>
<td>diclofenac</td>
<td>spironolactone</td>
</tr>
<tr>
<td>amiloride</td>
<td>drosipirenone</td>
<td>nabumetone</td>
</tr>
<tr>
<td>azilsartan</td>
<td>enalapril</td>
<td>naphrofen</td>
</tr>
<tr>
<td>benzydamine</td>
<td>enoxaparin</td>
<td>nepafenac</td>
</tr>
<tr>
<td>bromfenac</td>
<td>eplerenone</td>
<td>olmesartan</td>
</tr>
<tr>
<td>candesartan</td>
<td>epetoin alfa</td>
<td>parecoxib</td>
</tr>
<tr>
<td>captopril</td>
<td>epetoin beta</td>
<td>perindopril</td>
</tr>
<tr>
<td>celecoxib</td>
<td>eprosartan</td>
<td>piroxicam</td>
</tr>
<tr>
<td>ciclosporin</td>
<td>etodolac</td>
<td>potassium canrenoate</td>
</tr>
<tr>
<td>dalteparin</td>
<td>etoricoxib</td>
<td>potassium chloride</td>
</tr>
<tr>
<td>darbepoetin alfa</td>
<td></td>
<td>quinapril</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ramipril</td>
</tr>
</tbody>
</table>

### TABLE 17  
**Drugs that reduce serum potassium**

The following is a list of some drugs that reduce serum potassium concentrations (note that this list is not exhaustive). Concurrent use of two or more drugs from this list might increase the risk of hypokalaemia. Hypokalaemia can increase the risk of torsade de pointes, which might be additive with the effects of drugs that prolong the QT interval.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Drug Name</th>
<th>Drug Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>acceclofenac</td>
<td>bumetanide</td>
<td>fluodrocortisone</td>
</tr>
<tr>
<td>acemetacin</td>
<td>chlorotaldione</td>
<td>formoterol</td>
</tr>
<tr>
<td>amiloride</td>
<td>clopamide</td>
<td>furosemide</td>
</tr>
<tr>
<td>amitriptyline</td>
<td>cyclophenthiazide</td>
<td>glycerol</td>
</tr>
<tr>
<td>bendroflumethiazide</td>
<td>dantron</td>
<td>hydrochlorothiazide</td>
</tr>
<tr>
<td>betamethasone</td>
<td>deflazacort</td>
<td>hydrocortisone</td>
</tr>
<tr>
<td>bisacodyl</td>
<td>dexamethasone</td>
<td>hydrofluormethiazide</td>
</tr>
<tr>
<td>budesonide</td>
<td>docusate sodium</td>
<td>indacaterol</td>
</tr>
<tr>
<td></td>
<td></td>
<td>indapamide</td>
</tr>
<tr>
<td></td>
<td></td>
<td>methylprednisolone</td>
</tr>
<tr>
<td></td>
<td></td>
<td>metolazone</td>
</tr>
<tr>
<td></td>
<td></td>
<td>navonifolone</td>
</tr>
<tr>
<td></td>
<td></td>
<td>salbutamol</td>
</tr>
<tr>
<td></td>
<td></td>
<td>salmeterol</td>
</tr>
<tr>
<td></td>
<td></td>
<td>senna</td>
</tr>
<tr>
<td></td>
<td></td>
<td>sodium picosulfate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>terbutaline</td>
</tr>
<tr>
<td></td>
<td></td>
<td>theophylline</td>
</tr>
<tr>
<td></td>
<td></td>
<td>torasemide</td>
</tr>
<tr>
<td></td>
<td></td>
<td>triamcinolone</td>
</tr>
<tr>
<td></td>
<td></td>
<td>vilanterol</td>
</tr>
<tr>
<td></td>
<td></td>
<td>xipamide</td>
</tr>
</tbody>
</table>

### TABLE 18  
**Drugs that cause hypotraemia**

The following is a list of some drugs that reduce sodium concentrations (note that this list is not exhaustive). Concurrent use of two or more drugs from this list might increase the risk of hypotraemia.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Drug Name</th>
<th>Drug Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>acceclofenac</td>
<td>cyclophenthiazide</td>
<td>etoricoxib</td>
</tr>
<tr>
<td>acemetacin</td>
<td>dapoxetine</td>
<td>felbinac</td>
</tr>
<tr>
<td>amiloride</td>
<td>desmopressin</td>
<td>meloxicam</td>
</tr>
<tr>
<td>amitriptyline</td>
<td>dexibuprofen</td>
<td>spironolactone</td>
</tr>
<tr>
<td>bendroflumethiazide</td>
<td>dextroprofen</td>
<td>nabumetone</td>
</tr>
<tr>
<td>bumetanide</td>
<td>diclofenac</td>
<td>naphrofen</td>
</tr>
<tr>
<td>carbamazepine</td>
<td>dosulepin</td>
<td>nepafenac</td>
</tr>
<tr>
<td>celecoxib</td>
<td>doxepin</td>
<td>olmesartan</td>
</tr>
<tr>
<td>chlortaldone</td>
<td>duloxetine</td>
<td>parecoxib</td>
</tr>
<tr>
<td>citalopram</td>
<td>eplerenone</td>
<td>perindopril</td>
</tr>
<tr>
<td>clomipramine</td>
<td>escitalopram</td>
<td>piroxicam</td>
</tr>
<tr>
<td>clopamide</td>
<td>etodolac</td>
<td>potassium canrenoate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>potassium chloride</td>
</tr>
<tr>
<td></td>
<td></td>
<td>quinapril</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ramipril</td>
</tr>
</tbody>
</table>

### TABLE 19  
**Drugs that cause ototoxicity**

The following is a list of some drugs that cause ototoxicity (note that this list is not exhaustive). Concurrent use of two or more drugs from the list might increase this risk.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Drug Name</th>
<th>Drug Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>amikacin</td>
<td>cisplatin</td>
<td>oxaliplatin</td>
</tr>
<tr>
<td>bumetanide</td>
<td>furosemide</td>
<td>streptomycin</td>
</tr>
<tr>
<td>capreomycin</td>
<td>gentamicin</td>
<td>telavancin</td>
</tr>
<tr>
<td>carboplatin</td>
<td>neomycin</td>
<td>tobramycin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>tosasemide</td>
</tr>
<tr>
<td></td>
<td></td>
<td>vancomycin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>vinblastine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>vincristine</td>
</tr>
</tbody>
</table>

### TABLE 20  
**Drugs with neuromuscular blocking effects**

The following is a list of some drugs with neuromuscular blocking effects (note that this list is not exhaustive). Concurrent use of two or more drugs from the list might increase this risk.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Drug Name</th>
<th>Drug Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>amikacin</td>
<td>cisatracurium</td>
<td>neomycin</td>
</tr>
<tr>
<td>atracurium</td>
<td>colistimethate</td>
<td>neostigmine</td>
</tr>
<tr>
<td>botulinum toxin type A</td>
<td>gentamicin</td>
<td>pancuronium</td>
</tr>
<tr>
<td>botulinum toxin type B</td>
<td>mivacurium</td>
<td>polymyxins</td>
</tr>
<tr>
<td></td>
<td>pyridostigmine</td>
<td>spironolactone</td>
</tr>
<tr>
<td></td>
<td>rocuronium</td>
<td>sulindac</td>
</tr>
<tr>
<td></td>
<td>vecuronium</td>
<td>tacrolimus</td>
</tr>
<tr>
<td></td>
<td></td>
<td>telmisartan</td>
</tr>
<tr>
<td></td>
<td></td>
<td>tenoxiam</td>
</tr>
<tr>
<td></td>
<td></td>
<td>tiapronenic acid</td>
</tr>
<tr>
<td></td>
<td></td>
<td>tizaparin</td>
</tr>
<tr>
<td></td>
<td></td>
<td>tolenamic acid</td>
</tr>
<tr>
<td></td>
<td></td>
<td>tolvaptan</td>
</tr>
<tr>
<td></td>
<td></td>
<td>trandolapril</td>
</tr>
<tr>
<td></td>
<td></td>
<td>triamterene</td>
</tr>
<tr>
<td></td>
<td></td>
<td>trimethoprim</td>
</tr>
<tr>
<td></td>
<td></td>
<td>xipamide</td>
</tr>
</tbody>
</table>
List of drug interactions

The following is an alphabetical list of drugs and their interactions; to avoid excessive cross-referencing each drug or group is listed twice: in the alphabetical list and also against the drug or group with which it interacts.

**Abacavir**
- **Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone)** are predicted to decrease the exposure to abacavir. [Moderate] Theoretical
- **Enalaprilat** is predicted to decrease the exposure to abacavir. [Moderate] Theoretical
- HIV-protease inhibitors (tipranavir) slightly decrease the exposure to abacavir. Avoid. [Severe] Study
- **Rifampicin** is predicted to decrease the exposure to abacavir. [Moderate] Theoretical

**Abatacept**
- **Live vaccines** are predicted to increase the risk of generalised infection (possibly life-threatening) when given with abatacept. Public Health England advises avoid. [Severe] Theoretical

**Abciximab** → see TABLE 4. p. 1264 (antiplatelet effects)

**Abiraterone**
- **General Information** Caution with concurrent chemotherapy—safety and efficacy not established.
- **Abiraterone** is predicted to increase the exposure to antiarrhythmics (flcainide). [Severe] Theoretical
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to abiraterone. Avoid. [Severe] Theoretical
- **Antifungals, azoles (itraconazole, ketoconazole, voriconazole)** are predicted to increase the exposure to abiraterone. [Severe] Theoretical
- **Acarbose** is predicted to increase the exposure to abiraterone. [Severe] Theoretical
- **Enalaprilat** is predicted to decrease the exposure to abiraterone. [Severe] Theoretical
- **Lisinopril** is predicted to increase the exposure to abiraterone. [Severe] Theoretical
- **Mexiletine** is predicted to increase the exposure to abiraterone. [Severe] Theoretical
- **Perindopril** is predicted to increase the exposure to abiraterone. [Severe] Theoretical
- **Ranolazine** is predicted to increase the exposure to abiraterone. [Severe] Theoretical
- **Captopril** is predicted to decrease the exposure to abiraterone. Use with caution and adjust dose. [Moderate] Study
- **Rifampicin** is predicted to increase the exposure to abiraterone. Avoid. [Severe] Theoretical
- **Abiraterone** is predicted to decrease the exposure to pilosulinate. Use with caution and adjust dose. [Moderate] Study
- **Rifampicin** is predicted to decrease the exposure to abiraterone. Avoid. [Severe] Theoretical
- **Abiraterone** potentially increases the exposure to venlafaxine. [Severe] Theoretical
- **Acarbose** → see TABLE 14. p. 1267 (antidiabetic drugs)
- **Acarbose** decreases the concentration of digoxin. [Moderate] Study
- **Pancreatin** is predicted to decrease the effects of acarbose. [Avoid. [Moderate] Theoretical
- **ACE inhibitors** → see TABLE 7. p. 1265 (first-dose hypotension), TABLE 8 p. 1265 (hypotension), TABLE 16 p. 1268 (increased serum potassium)
- Captopril,enalapril,fosinopril,imidapril,lisinopril,moexipril,perindopril,quinapril,ramipril,trandolapril
- **ACE inhibitors** increase the risk of renal impairment when given with aliskiren. Use with caution or avoid aliskiren in selected patients, p. 175. [Severe] Study → Also see TABLE 8 p. 1265 → Also see TABLE 16 p. 1268
- **ACE inhibitors** are predicted to increase the risk of hypersensitivity and haematological reactions when given with allopurinol. [Severe] Anecdotal
- **ACE inhibitors** are predicted to increase the risk of anaemia and/or leucopenia when given with azathioprine. [Severe] Anecdotal
- **ACE inhibitors** increase the risk of hypersensitivity when given with bee venom extract. Avoid. [Severe] Study
- **ACE inhibitors** are predicted to decrease the efficacy of icatibant and icatibant is predicted to decrease the efficacy of ACE inhibitors. Avoid. [Moderate] Theoretical
- **ACE inhibitors** are predicted to increase the concentration of lithium. Monitor and adjust dose. [Severe] Anecdotal
- **ACE inhibitors** are predicted to increase the risk of hypersensitivity when given with sodium aurothiomalate. [Severe] Anecdotal
- **Quinapril** (tablet) decreases the absorption of oral tetracyclines (tetracycline). Avoid. [Moderate] Study
- **ACE inhibitors** increase the risk of hypersensitivity when given with wasp venom extract. Avoid. [Severe] Study
- **Acenocoumarol** → see coumarins
- **Acetazolamide**
  - **Acetazolamide** potentially increases the risk of overheating and dehydration when given with antiepileptics (zonisamide). Avoid in children. [Severe] Theoretical
  - **Acetazolamide** increases the risk of severe toxic reaction when given with aspirin (high-dose). [Severe] Study
  - **Acetazolamide** alters the concentration of lithium. [Severe] Anecdotal
  - **Acetazolamide** is predicted to decrease the efficacy of methotrexate. [Moderate] Study
  - **Acetazolamide** increases the urinary excretion of methotrexate. [Moderate] Study

**Aciclovir** → see TABLE 2. p. 1264 (nephrotoxicity)

ROUTE-SPECIFIC INFORMATION Since systemic absorption can follow topical application, the possibility of interactions should be borne in mind.
- **Aciclovir** increases the exposure to aminophylline. Monitor theophylline concentration and adjust dose. [Severe] Anecdotal
- **Myophenolate** is predicted to increase the risk of haematological toxicity when given with aciclovir. [Moderate] Theoretical
- **Aciclovir** is predicted to increase the exposure to theophylline. Monitor theophylline concentration and adjust dose. [Severe] Theoretical
- **Aciclovir** → see retinoids
- **Aclidium** → see TABLE 10. p. 1266 (antimuscarnicins)
- **Aciclovir** → see sympathomimetics, vasoconstrictor
- **Aciclovir** → see antihistamines, non-sedating
- **Adalimumab** → see monoclonal antibodies
- **Adapalene** → see retinoids
- **Adefovir**
  - **Ataluren** increases the exposure to adefovir. [Moderate] Study
- **Adenosine** → see antihypertensives
- **Adrenaline/epinephrine** → see sympathomimetics, vasoconstrictor
- **Afinitor** → see TABLE 15. p. 1267 (myelosuppression)
  - **Anticholinergics (amiodarone, dronedarone)** are predicted to increase the exposure to aitinib. Separate administration by 12 hours. [Moderate] Study
  - **Antiepileptics (carbamazepine)** are predicted to decrease the exposure to aitinib. [Moderate] Study
  - **Antifungals, azoles (itraconazole, ketoconazole)** are predicted to increase the exposure to aitinib. Separate administration by 12 hours. [Moderate] Study
  - **Calcium channel blockers (verapamil)** are predicted to increase the exposure to aitinib. Separate administration by 12 hours. [Moderate] Study
  - **Ciclosporin** is predicted to increase the exposure to aitinib. Separate administration by 12 hours. [Moderate] Study
  - **HIV-protease inhibitors (lopinavir, ritonavir, saquinavir)** are predicted to increase the exposure to aitinib. Separate administration by 12 hours. [Moderate] Study
  - **Lapatinib** is predicted to increase the exposure to aitinib. Separate administration by 12 hours. [Moderate] Study
  - **Macrolides** are predicted to increase the exposure to aitinib. Separate administration by 12 hours. [Moderate] Study

---

A1

Interactions | Appendix 1
Afatinib (continued)
- **Ranolazine** is predicted to increase the exposure to afatinib. Separate administration by 12 hours. [Moderate] Study
- **Rifampicin** is predicted to decrease the exposure to afatinib. [Moderate] Study
- **St John's Wort** is predicted to decrease the exposure to afatinib. Separate administration by 12 hours. [Moderate] Study
- **Vemurafenib** is predicted to increase the exposure to afatinib. [Moderate] Study

**Afflithercept → see TABLE 15 p. 1267 (myelosuppression)**

**Agalsidase**
- **Aminoglycosides** are predicted to decrease the effects of agalsidase. Avoid. [Moderate] Theoretical
- **Antiarrhythmics (amiodarone)** are predicted to decrease the effects of agalsidase. Avoid. [Moderate] Theoretical
- **Antimalarial (chloroquine)** are predicted to decrease the effects of agalsidase. Avoid. [Moderate] Theoretical
- **Hydroxychloroquine** is predicted to decrease the effects of agalsidase. [Moderate] Theoretical

**Agomelatine → see TABLE 11 p. 1266 (CNS depressant effects)**
- Dose adjustment might be necessary if smoking started or stopped during treatment.
- Caution with concomitant use of drugs associated with hepatic injury.
- **Antiepileptics (fosphenytoin, phenytoin)** are predicted to decrease the exposure to agomelatine. [Moderate] Theoretical
- **Combined hormonal contraceptives** are predicted to increase the exposure to agomelatine. [Moderate] Study
- **HIV-protease inhibitors (ritonavir)** are predicted to decrease the exposure to agomelatine. [Moderate] Study
- **Quinolones (ciprofloxacin)** are predicted to increase the exposure to agomelatine. [Moderate] Study
- **Rifampicin** is predicted to decrease the exposure to agomelatine. [Moderate] Theoretical
- **SSRIs (fluvoxamine)** very markedly increase the exposure to agomelatine. Avoid. [Severe] Study

**Albendazole**
- **Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone)** decrease the concentration of albendazole. [Moderate] Study
- **H$_2$ receptor antagonists (cimetidine)** decrease the clearance of albendazole. [Moderate] Study
- **HIV-protease inhibitors (ritonavir)** decrease the exposure to albendazole. [Moderate] Study
- Albendazole slightly decreases the exposure to levasimole and levasimole moderately decreases the exposure to albendazole. [Moderate] Study

**Albiglutide → see TABLE 14 p. 1267 (antidiabetic drugs)**

**Alcohol (beverage)** → see TABLE 1 p. 1264 (hepatotoxicity), TABLE 8 p. 1265 (hypotension), TABLE 11 p. 1266 (CNS depressant effects)

**Aldosterone antagonists → see TABLE 18 p. 1268 (hypotension), TABLE 8 p. 1268 (hypotension), TABLE 16 p. 1268 (increased serum potassium)**

**Eplerenone - spironolactone**
- **Antiarrhythmics (amiodarone)** are predicted to increase the exposure to eplerenone. Adjust eplerenone dose, p. 185. [Severe] Theoretical
- **Antiarrhythmics (dronedarone)** are predicted to increase the exposure to eplerenone. Adjust eplerenone dose, p. 185. [Severe] Study
- **Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone)** are predicted to decrease the exposure to eplerenone. Avoid. [Moderate] Study
- **Antifungals, azoles (fluconazole, itraconazole, posaconazole)** are predicted to markedly increase the exposure to eplerenone. Adjust eplerenone dose, p. 185. [Severe] Study
- **Aprepitant** is predicted to increase the exposure to eplerenone. Adjust eplerenone dose, p. 185. [Severe] Study
- **Calcium channel blockers (diltiazem, verapamil)** are predicted to increase the exposure to eplerenone. Adjust eplerenone dose, p. 185. [Severe] Study → Also see TABLE 8 p. 1265
- **Cobicistat** is predicted to markedly increase the exposure to eplerenone. Avoid. [Severe] Study
- **Crizotinib** is predicted to increase the exposure to eplerenone. Adjust eplerenone dose, p. 185. [Severe] Study
- **Eplerenone very slightly increases the exposure to digoxin.** [Mild] Study
- **Spirinolactone increases the concentration of digoxin.** Monitor and adjust dose. [Moderate] Study
- **Enalaprilamide** is predicted to decrease the exposure to eplerenone. Avoid. [Moderate] Theoretical
- **HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to markedly increase the exposure to eplerenone. Avoid. [Severe] Study
- **HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to eplerenone. Adjust eplerenone dose, p. 185. [Severe] Study
- **Idelalisib** is predicted to markedly increase the exposure to eplerenone. Avoid. [Severe] Study
- **Imatinib** is predicted to increase the exposure to eplerenone. Adjust eplerenone dose, p. 185. [Severe] Study
- **Eplerenone is predicted to increase the concentration of lithium.** Avoid. [Moderate] Theoretical
- **Spirinolactone potentially increases the concentration of lithium.** [Moderate] Study
- **Macrolides (clarithromycin)** are predicted to markedly increase the exposure to eplerenone. Avoid. [Severe] Study
- **Macrolides (erythromycin)** are predicted to increase the exposure to eplerenone. Adjust eplerenone dose, p. 185. [Severe] Study
- **Spirinolactone is predicted to decrease the effects of mitotane.** Avoid. [Severe] Anecdotal
- **Netupitant** is predicted to increase the exposure to eplerenone. Adjust eplerenone dose, p. 185. [Severe] Study
- **Nilotinib** is predicted to increase the exposure to eplerenone. Adjust eplerenone dose, p. 185. [Severe] Study
- **Rifampicin** is predicted to decrease the exposure to eplerenone. Avoid. [Moderate] Theoretical
- **St John's Wort** is predicted to slightly decrease the exposure to eplerenone. Avoid. [Moderate] Study
- **Alemtezumab → see monoclonal antibodies**
- **Alendronic acid** → see bisphosphonates
- **Alfacalcidol → see vitamin D substances**
- **Alfentanil → see opioids**
- **Alfuzosin → see alpha blockers**
- **Aliiminemazone → see antihistamines, sedating**
- **Alirocumab → see monoclonal antibodies**
- **Aliskiren → see TABLE 8 p. 1265 (hypotension), TABLE 16 p. 1268 (increased serum potassium)**

**Food and lifestyle** Avoid apple juice and orange juice as they greatly decrease aliskiren concentrations and plasma renin activity.
Ciclosporin markedly increases the exposure to aliskiren. Avoid. [Severe] Study → Also see TABLE 16 p. 1268

Grapefruit juice moderately decreases the exposure to aliskiren. Avoid. [Severe] Study

HIV-protease inhibitors (ritonavir, saquinavir) are predicted to increase the exposure to aliskiren. [Moderate] Theoretical

Lapatinib is predicted to increase the exposure to aliskiren. [Moderate] Theoretical

Aliskiren slightly decreases the exposure to loop diuretics (furosemide). [Moderate] Study → Also see TABLE 8 p. 1265

Lumacaftor is predicted to affect the exposure to aliskiren. [Moderate] Theoretical

Macrolides (azithromycin) are predicted to increase the exposure to aliskiren. [Moderate] Theoretical

Macrolides (clarithromycin, erythromycin) are predicted to increase the exposure to aliskiren. [Moderate] Study

Mirabegron is predicted to increase the exposure to aliskiren. [Mild] Study

Aliskiren increases the exposure to rifampicin. [Mild] Study

St John’s Wort decreases the exposure to aliskiren. [Moderate] Study

Statin (atorvastatin) slightly to moderately increase the exposure to aliskiren. [Moderate] Study

Velpatasvir is predicted to increase the exposure to aliskiren. [Severe] Theoretical

Venlafaxine is predicted to increase the exposure to aliskiren. Use with caution and adjust dose. [Moderate] Theoretical

Alitretinoin → see retinoids

Alkylating agents → see TABLE 15 p. 1267 (myelosuppression), TABLE 2 p. 1264 (nephrotoxicity), TABLE 5 p. 1264 (thromboembolism)

Bendamustine • busulfan • carmustine • chlorambucil • cyclophosphamide • dacarbazine • estramustine • ifosfamide • lomustine • melphalan • temozolomide • thiopeta • treosulfan

Antacids are predicted to decrease the absorption of estramustine. Avoid. [Moderate] Study

Antifungals, azoles (itraconazole) increase the risk of busulfan toxicity when given with busulfan. Monitor and adjust dose. [Moderate] Study

Antifungals, azoles (miconazole) are predicted to increase the concentration of busulfan. Use with caution and adjust dose. [Moderate] Theoretical

Oral calcium salts decrease the absorption of estramustine. [Severe] Study

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with alkylating agents. Public Health England advises avoid. [Severe] Theoretical

Metronidazole increases the risk of toxicity when given with busulfan. [Severe] Study

Paracetamol is predicted to decrease the clearance of busulfan. [Moderate] Theoretical

Cyclophosphamide (high-dose) increases the risk of toxicity when given with pentostatin. Avoid. [Severe] Anecdotal → Also see TABLE 15 p. 1267 → Also see TABLE 5 p. 1264

Cyclophosphamide increases the risk of prolonged neuromuscular blockade when given with suxamethonium. [Moderate] Study

Allopurinol

ACE inhibitors are predicted to increase the risk of hypersensitivity and haematological reactions when given with allopurinol. [Severe] Anecdotal

Allopurinol potentially increases the risk of haematological toxicity when given with azathioprine. Adjust azathioprine dose, p. 787. [Severe] Study

Allopurinol is predicted to decrease the effects of capetabine. Avoid. [Severe] Study

Allopurinol moderately increases the exposure to didanosine. Avoid. [Severe] Study

Allopurinol potentially increases the risk of haematological toxicity when given with mercaptopurine. Adjust mercaptopurine dose, p. 844. [Severe] Study

Allopurinol increases the risk of skin rash when given with penicillins (amoxicillin, ampicillin). [Moderate] Study

Allopurinol is predicted to increase the risk of hyperuricaemia when given with pyrazinamide. [Moderate] Theoretical

Thiazide diuretics are predicted to increase the risk of hypersensitivity reactions when given with allopurinol. [Severe] Theoretical

Almotriptan → see TABLE 13 p. 1267 (serotonin syndrome)

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) increase the exposure to almotriptan. [Mild] Study

Cobicistat increases the exposure to almotriptan. [Mild] Study

Almotriptan is predicted to increase the risk of vasocostriction when given with ergotamine. Ergotamine should be taken at least 24 hours before or 6 hours after almotriptan. [Severe] Theoretical

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) increase the exposure to almotriptan. [Mild] Study

Idealisib increases the exposure to almotriptan. [Mild] Study

Macrolides (clarithromycin) increase the exposure to almotriptan. [Mild] Study

Alogliptin → see TABLE 14 p. 1267 (antidiabetic drugs)

Alpha blockers → see TABLE 7 p. 1265 (first-dose hypotension), TABLE 8 p. 1265 (hypotension)

alfuzosin • doxazosin • indoramin • prazosin • tamsulosin • terazosin

Antiarrhythmics (dronedarone) are predicted to increase the exposure to tamsulosin. [Moderate] Theoretical

Antifungals, azoles (fluconazole, itraconazole, posaconazole) are predicted to increase the exposure to tamsulosin. [Moderate] Theoretical

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to doxazosin. [Moderate] Study

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to moderately increase the exposure to alpha blockers (alfuzosin, tamsulosin). Use with caution or avoid. [Moderate] Study

Aprepitant is predicted to increase the exposure to tamsulosin. [Moderate] Theoretical

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to tamsulosin. [Moderate] Theoretical → Also see TABLE 8 p. 1265

Cobicistat is predicted to moderately increase the exposure to alpha blockers (alfuzosin, tamsulosin). Use with caution or avoid. [Moderate] Study

Cobicistat is predicted to increase the exposure to doxazosin. [Moderate] Study

Crizotinib is predicted to increase the exposure to tamsulosin. [Moderate] Theoretical

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to doxazosin. [Moderate] Study

HIV-protease inhibitors (indinavir) are predicted to increase the exposure to tamsulosin. [Moderate] Theoretical

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to moderately increase the exposure to alpha blockers (alfuzosin, tamsulosin). Use with caution or avoid. [Moderate] Study

Idealisib is predicted to moderately increase the exposure to alpha blockers (alfuzosin, tamsulosin). Use with caution or avoid. [Moderate] Study

Idealisib is predicted to increase the exposure to doxazosin. [Moderate] Study

Imatinib is predicted to increase the exposure to tamsulosin. [Moderate] Theoretical

Macrolides (clarithromycin) are predicted to increase the exposure to tamsulosin. [Moderate] Study

Macrolides (erythromycin) are predicted to increase the exposure to tamsulosin. [Moderate] Theoretical

Monamine-oxidase A and B inhibitors, irreversible are predicted to increase the effects of indoramin. Avoid. [Severe] Theoretical → Also see TABLE 8 p. 1265

Netupitant is predicted to increase the exposure to tamsulosin. [Moderate] Theoretical
Alpha blockers (continued)

- **Nilotinib** is predicted to increase the exposure to tamsulosin.
  
- **Alpha blockers** cause significant hypotensive effects when given with **phosphodiesterase type-5 inhibitors**. Patient should be stabilised on first drug then second drug should be added at the lowest recommended dose. **(Severe) Study**  
  Also see TABLE 8 p. 1265

**Alpha tocopherol** → see vitamin E substances

**Alpha tocopheryl acetate** → see vitamin E substances

**Alprazolam**  
- **Antidepressants** (dronedarone) are predicted to increase the exposure to alprazolam. **(Severe) Study**
- **Antiepileptics** (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to alprazolam. Adjust alprazolam dose. **(Moderate) Theoretical**  
  Also see TABLE 11 p. 1266
- **Antifungals, azoles** (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to alprazolam. **(Severe) Study**
- **Antifungals, azoles** (itraconazole, ketoconazole, voriconazole) moderately increase the exposure to alprazolam. Avoid. **(Moderate) Study**
- **Crizotinib** is predicted to increase the exposure to alprazolam. **(Severe) Study**
- **Enalaprilat** is predicted to decrease the exposure to alprazolam. Adjust alprazolam dose. **(Moderate) Theoretical**
- **HIV- protease inhibitors** (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) moderately increase the exposure to alprazolam. Avoid. **(Moderate) Study**
- **Hydralazine** is predicted to increase the exposure to alprazolam. **(Severe) Study**
- **Ipratropium bromide** is predicted to increase the exposure to alprazolam. **(Severe) Study**
- **Lidocaine** is predicted to increase the exposure to alprazolam. **(Severe) Study**
- **Nicardipine** is predicted to increase the exposure to alprazolam. **(Severe) Study**
- **Nitroglycerin** is predicted to increase the exposure to alprazolam. **(Severe) Study**
- **Nitroprusside** is predicted to increase the exposure to alprazolam. **(Severe) Study**
- **Rifampicin** is predicted to decrease the exposure to alprazolam. Adjust alprazolam dose. **(Moderate) Theoretical**
- **SSRIs** (fluvoxamine) moderately increase the exposure to alprazolam. **(Moderate) Study**
- **St John’s Wort** moderately decreases the exposure to alprazolam. **(Moderate) Study**
- **Alprazolam**  
  Separate administration by 12 hours. **(Moderate) Theoretical**
  - **Macrolides** (clarithromycin) moderately increase the exposure to alprazolam. Avoid. **(Moderate) Study**
  - **Macrolides** (erythromycin) are predicted to increase the exposure to alprazolam. **(Severe) Study**
  - **Nitritopenton** is predicted to increase the exposure to alprazolam. **(Severe) Study**

**Amfetamines** → see TABLE 13 p. 1267 (serotonin syndrome)
- **Dexamfetamine** • **Lisdexamfetamine**
- **Amfetamines** are predicted to decrease the risk of side-effects when given with **atomoxetine**. **(Severe) Theoretical**
- **Dexamfetamine** decreases the effects of **guanethidine**. **(Severe) Study**
- **HIV-protease inhibitors** (ritonavir, tipranavir) are predicted to increase the exposure to amfetamines. **(Severe) Theoretical**
  Also see TABLE 13 p. 1267
- **Moclobemide** is predicted to increase the risk of a hypertensive crisis when given with **dexamfetamine**. Avoid. **(Severe) Theoretical**  
  Also see TABLE 13 p. 1267
- **Monoamine-oxidase A and B inhibitors, irreversible** are predicted to increase the risk of a hypertensive crisis when given with amfetamines. Avoid and for 14 days after stopping the MAOI. **(Severe) Anecdotal**  
  Also see TABLE 13 p. 1267
- **Monoamine-oxidase B inhibitors** (rasagiline, selegiline) are predicted to increase the risk of severe hypertension when given with amfetamines. Avoid. **(Severe) Theoretical**  
  Also see TABLE 13 p. 1267
- **Aminoglycosides** (rifampicin, ethambutol, isoniazid) are predicted to decrease the effects of amfetamines. **(Severe) Study**
- **Amfetamines** are predicted to decrease the effects of phenothiazines (chlorpromazine). **(Moderate) Study**
- **SSRIs** (fluoxetine, paroxetine) are predicted to increase the exposure to amfetamines. **(Severe) Theoretical**  
  Also see TABLE 13 p. 1267
- **Amifampridine** → see TABLE 9 p. 1266 (QT-interval prolongation)
- **Amikacin** → see aminoglycosides
- **Amiloride** → see potassium-sparing diuretics

**Aminoglycosides** → see TABLE 2 p. 1264 (nephrotoxicity), TABLE 19 p. 1268 (ototoxicity), TABLE 20 p. 1268 (neuromuscular blocking effects)
- **Amikacin** • **Gentamicin** • **Streptomycin** • **Tobramycin**
- **Aminoglycosides** are predicted to decrease the effects of **agalasidase**. Avoid. **(Moderate) Theoretical**
- **Antifungals, azoles** (itraconazole) potentially decrease the exposure to tobramycin. **(Moderate) Anecdotal**
- **Talutaren** is predicted to increase the risk of nephrotoxicity when given with intravenous **aminoglycosides**. Avoid. **(Severe) Study**
- **Aminoglycosides** increase the risk of hypocalcaemia when given with **bisphosphonates**. **(Moderate) Anecdotal**  
  Also see TABLE 2 p. 1264
- **Aminoglycosides** potentially increase the concentration of digoxin. Monitor and adjust dose. **(Mild) Study**
- **Loop diuretics** increase the risk of nephrotoxicity and ototoxicity when given with **aminoglycosides**. Avoid. **(Moderate) Study**  
  Also see TABLE 19 p. 1268
- **Aminoglycosides** are predicted to decrease the effects of **neostigmine**. **(Moderate) Theoretical**  
  Also see TABLE 20 p. 1268
- **Aminoglycosides** are predicted to increase the risk of prolonged neuromuscular blockade when given with **neuromuscular blocking drugs, non-depolarising**. **(Severe) Theoretical**  
  Also see TABLE 20 p. 1268
- **Aminoglycosides** are predicted to decrease the effects of **pyridostigmine**. **(Moderate) Theoretical**  
  Also see TABLE 20 p. 1268
- **Aminoglycosides** are predicted to increase the risk of prolonged neuromuscular blockade when given with **suxamethonium**. **(Severe) Theoretical**  
  Also see TABLE 20 p. 1268
- **Telavancin** is predicted to increase the risk of ototoxicity when given with **aminoglycosides**. **(Moderate) Theoretical**  
  Also see TABLE 20 p. 1268
- **Vancomycin** increases the risk of nephrotoxicity when given with **aminoglycosides**. Avoid. **(Moderate) Study**  
  Also see TABLE 20 p. 1264  
  Also see TABLE 19 p. 1268

**Aminophylline** → see TABLE 17 p. 1268 (reduced serum potassium)

**F O O D A N D L I F E S T Y L E**  
- Smoking can increase aminophylline clearance and increased doses of aminophylline are therefore
Aminosalicylic acid is predicted to increase the risk of methaemoglobinaemia when given with topical prilocaine. Use with caution or avoid. Avoid. [Severe] Theoretical

Amiodarone  → see antiarrhythmics
Amisulpride  → see TABLE 9 p. 1266 (QT-interval prolongation), TABLE 11 p. 1266 (CNS depressant effects)
→ Amisulpride is predicted to decrease the effects of dopamine receptor antagonists. Avoid. [Moderate] Theoretical  → Also see TABLE 9 p. 1266
→ Amisulpride is predicted to decrease the effects of levodopa. Avoid. [Severe] Theoretical

Amniotriptyline  → see tricyclic antidepressants
Amlodipine  → see calcium channel blockers
Amoxicillin  → see penicillins
Anacin  → see TABLE 15 p. 1267 (myelosuppression)
Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with amsacrine. Public Health England advises avoid. [Severe] Theoretical

Aminosalicylic acid is predicted to increase the risk of methaemoglobinaemia when given with topical prilocaine. Use with caution or avoid. Avoid. [Severe] Theoretical

Antidepressants, local  → see TABLE 9 p. 1266 (CNS depressant effects)
bupivacaine - levobupivacaine - mepivacaine - oxybuprocaine - prilocaine - proxymetacaine - ropivacaine - tetracaine

Aminosalicylic acid is predicted to increase the risk of methaemoglobinaemia when given with topical prilocaine. Use with caution or avoid. Avoid. [Severe] Theoretical

Antitussives  → see TABLE 10 p. 1250 (bronchodilator effects)
Antihistamines  → see TABLE 10 p. 1250 (antihistaminic effects)

Amiodarone  → see antiarrhythmics
Amisulpride  → see TABLE 9 p. 1266 (QT-interval prolongation), TABLE 11 p. 1266 (CNS depressant effects)
→ Amisulpride is predicted to decrease the effects of dopamine receptor antagonists. Avoid. [Moderate] Theoretical  → Also see TABLE 9 p. 1266
→ Amisulpride is predicted to decrease the effects of levodopa. Avoid. [Severe] Theoretical

Amniotriptyline  → see tricyclic antidepressants
Amlodipine  → see calcium channel blockers
Amoxicillin  → see penicillins
Anacin  → see TABLE 15 p. 1267 (myelosuppression)
Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with amsacrine. Public Health England advises avoid. [Severe] Theoretical

Aminosalicylic acid is predicted to increase the risk of methaemoglobinaemia when given with topical prilocaine. Use with caution or avoid. Avoid. [Severe] Theoretical

Antidepressants, local  → see TABLE 9 p. 1266 (CNS depressant effects)
bupivacaine - levobupivacaine - mepivacaine - oxybuprocaine - prilocaine - proxymetacaine - ropivacaine - tetracaine

Aminosalicylic acid is predicted to increase the risk of methaemoglobinaemia when given with topical prilocaine. Use with caution or avoid. Avoid. [Severe] Theoretical

Antitussives  → see TABLE 10 p. 1250 (bronchodilator effects)
Antihistamines  → see TABLE 10 p. 1250 (antihistaminic effects)

Amiodarone  → see antiarrhythmics
Amisulpride  → see TABLE 9 p. 1266 (QT-interval prolongation), TABLE 11 p. 1266 (CNS depressant effects)
→ Amisulpride is predicted to decrease the effects of dopamine receptor antagonists. Avoid. [Moderate] Theoretical  → Also see TABLE 9 p. 1266
→ Amisulpride is predicted to decrease the effects of levodopa. Avoid. [Severe] Theoretical

Amniotriptyline  → see tricyclic antidepressants
Amlodipine  → see calcium channel blockers
Amoxicillin  → see penicillins
Anacin  → see TABLE 15 p. 1267 (myelosuppression)
Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with amsacrine. Public Health England advises avoid. [Severe] Theoretical

Aminosalicylic acid is predicted to increase the risk of methaemoglobinaemia when given with topical prilocaine. Use with caution or avoid. Avoid. [Severe] Theoretical

Antidepressants, local  → see TABLE 9 p. 1266 (CNS depressant effects)
bupivacaine - levobupivacaine - mepivacaine - oxybuprocaine - prilocaine - proxymetacaine - ropivacaine - tetracaine

Aminosalicylic acid is predicted to increase the risk of methaemoglobinaemia when given with topical prilocaine. Use with caution or avoid. Avoid. [Severe] Theoretical

Antitussives  → see TABLE 10 p. 1250 (bronchodilator effects)
Antihistamines  → see TABLE 10 p. 1250 (antihistaminic effects)

Amiodarone  → see antiarrhythmics
Amisulpride  → see TABLE 9 p. 1266 (QT-interval prolongation), TABLE 11 p. 1266 (CNS depressant effects)
→ Amisulpride is predicted to decrease the effects of dopamine receptor antagonists. Avoid. [Moderate] Theoretical  → Also see TABLE 9 p. 1266
→ Amisulpride is predicted to decrease the effects of levodopa. Avoid. [Severe] Theoretical

Amniotriptyline  → see tricyclic antidepressants
Amlodipine  → see calcium channel blockers
Amoxicillin  → see penicillins
Anacin  → see TABLE 15 p. 1267 (myelosuppression)
Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with amsacrine. Public Health England advises avoid. [Severe] Theoretical

Aminosalicylic acid is predicted to increase the risk of methaemoglobinaemia when given with topical prilocaine. Use with caution or avoid. Avoid. [Severe] Theoretical

Antidepressants, local  → see TABLE 9 p. 1266 (CNS depressant effects)
bupivacaine - levobupivacaine - mepivacaine - oxybuprocaine - prilocaine - proxymetacaine - ropivacaine - tetracaine

Aminosalicylic acid is predicted to increase the risk of methaemoglobinaemia when given with topical prilocaine. Use with caution or avoid. Avoid. [Severe] Theoretical

Antitussives  → see TABLE 10 p. 1250 (bronchodilator effects)
Antihistamines  → see TABLE 10 p. 1250 (antihistaminic effects)

Amiodarone  → see antiarrhythmics
Amisulpride  → see TABLE 9 p. 1266 (QT-interval prolongation), TABLE 11 p. 1266 (CNS depressant effects)
→ Amisulpride is predicted to decrease the effects of dopamine receptor antagonists. Avoid. [Moderate] Theoretical  → Also see TABLE 9 p. 1266
→ Amisulpride is predicted to decrease the effects of levodopa. Avoid. [Severe] Theoretical

Amniotriptyline  → see tricyclic antidepressants
Amlodipine  → see calcium channel blockers
Amoxicillin  → see penicillins
Anacin  → see TABLE 15 p. 1267 (myelosuppression)
Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with amsacrine. Public Health England advises avoid. [Severe] Theoretical

Aminosalicylic acid is predicted to increase the risk of methaemoglobinaemia when given with topical prilocaine. Use with caution or avoid. Avoid. [Severe] Theoretical

Antidepressants, local  → see TABLE 9 p. 1266 (CNS depressant effects)
bupivacaine - levobupivacaine - mepivacaine - oxybuprocaine - prilocaine - proxymetacaine - ropivacaine - tetracaine

Aminosalicylic acid is predicted to increase the risk of methaemoglobinaemia when given with topical prilocaine. Use with caution or avoid. Avoid. [Severe] Theoretical

Antitussives  → see TABLE 10 p. 1250 (bronchodilator effects)
Antihistamines  → see TABLE 10 p. 1250 (antihistaminic effects)
Anakinra (continued)

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with anakinra. Public Health England advises avoid. [Severe] Theoretical

Angiotensin-II receptor antagonists  
> see TABLE 7 p. 1265 (first-dose hypotension), TABLE 8 p. 1265 (hypotension), TABLE 16 p. 1268 (increased serum potassium)

Azilsartan | candesartan | eprosartan | irbesartan | losartan | olmesartan | telmisartan | valsartan

Angiotensin-II receptor antagonists increase the risk of renal impairment when given with aliskiren. Use with caution or avoid aliskiren in selected patients. p. 17. [Severe] Study  
Also see TABLE 8 p. 1265  
Also see TABLE 16 p. 1268

Angiotensin-II receptor antagonists potentially increase the concentration of lithium. Monitor concentration and adjust dose. [Severe] Anecdotal

Antacids
aluminium hydroxide · magnesium carbonate · magnesium trisilicate

Separation of administration  
Antacids should preferably not be taken at the same time as other drugs since they might impair absorption. Antacids might damage enteric coatings designed to prevent dissolution in the stomach.

Antacids are predicted to decrease the absorption of alkylation agents (etramustine). Avoid. [Moderate] Study

Antacids decrease the absorption of antiemetics (gabapentin). Gabapentin should be taken 2 hours after antacids. [Moderate] Study

Antacids decrease the absorption of antiinflammatory agents (azelaic acid, aspirin (acetylsalicylic acid), ibuprofen, naproxen, ketoprofen). Separate administration by at least 2 hours. [Moderate] Study

Antacids decrease the absorption of antivirals (protease inhibitors, nucleoside reverse transcriptase inhibitors, nucleotide reverse transcriptase inhibitors). Separate administration by at least 4 hours. [Moderate] Study

Antacids are predicted to decrease the absorption of antimalarials (chloroquine). Separate administration by at least 2 hours. [Moderate] Study

Antacids decrease the absorption of aspirin (high-dose). [Moderate] Study

Antacids decrease the absorption of biphosphonates (alendronic acid, risedronate). Separate administration by at least 6 hours before or 1 hour after biphosphonate. [Moderate] Theoretical

Antacids decrease the absorption of biphosphonates (salicylate). Avoid antacids for at least 6 hours before or 1 hour after biphosphonate. [Moderate] Theoretical

Antacids decrease the absorption of biphosphonates (sodium clodronate). Avoid antacids for 2 hours before or 1 hour after sodium clodronate. [Moderate] Study

Antacids are predicted to decrease the absorption of bosutinib. Bosutinib should be taken at least 12 hours before antacids. [Moderate] Theoretical

Antacids are predicted to decrease the absorption of ceritinib. Separate administration by 2 hours. [Moderate] Theoretical

Antacids are predicted to decrease the absorption of chenodeoxycholic acid. Separate administration by 5 hours. [Mild] Theoretical

Antacids are predicted to decrease the absorption of probenecid. Separate administration by 2 hours. [Moderate] Theoretical

Antacids decrease the absorption of corticosteroids (deflazacort). Separate administration by 2 hours. [Moderate] Theoretical

Antacids decrease the absorption of corticosteroids (dexamethasone). [Moderate] Study

Antacids are predicted to decrease the absorption of dabrafenib. Avoid. [Severe] Theoretical

Antacids decrease the absorption of dasatinib. Separate administration by at least 2 hours. [Moderate] Study

Aluminium hydroxide is predicted to decrease the absorption of deferiprone. Avoid. [Moderate] Theoretical

Antacids decrease the absorption of digoxin. Separate administration by 2 hours. [Mild] Study

Antacids are predicted to decrease the absorption of dipyridamole (immediate release tablets). [Moderate] Theoretical

Antacids moderately decrease the exposure to dolutegravir. Dolutegravir should be taken 2 hours before or 6 hours after antacids. [Moderate] Study

Antacids decrease the absorption of eltorbopag. Eltorbopag should be taken 2 hours before or 4 hours after antacids. [Severe] Study

Antacids moderately decrease the exposure to elvitegravir. Separate administration by at least 4 hours. [Moderate] Study

Antacins increase the risk of blocked enteral or nasogastric tubes when given with enteral feeds. [Moderate] Study

Antacids are predicted to decrease the absorption of erlotinib. Antacids should be taken 4 hours before or 2 hours after erlotinib. [Moderate] Theoretical

Antacids slightly to moderately decrease the exposure to fribates (gemfibrozil). [Mild] Study

Antacids are predicted to slightly decrease the exposure to gefitinib. [Moderate] Theoretical

Antacids are predicted to decrease the absorption of HIV-protease inhibitors (atazanavir). Atazanavir should be taken 2 hours before or 1 hour after antacids. [Severe] Theoretical

Antacids are predicted to decrease the absorption of HIV-protease inhibitors (tipranavir). Separate administration by 2 hours. [Moderate] Study

Antacids decrease the absorption of hydroxychloroquine. Separate administration by at least 4 hours. [Moderate] Study

Antacids decrease the absorption of iron (oral). Iron (oral) should be taken 1 hour before or 2 hours after antacids. [Moderate] Study

Aluminium hydroxide is predicted to decrease the exposure to iron chelators (deferasirox). Avoid. [Moderate] Theoretical

Antacids are predicted to decrease the absorption of lapatinib. Avoid. [Moderate] Theoretical

Antacids are predicted to decrease the exposure to ledipasvir. Separate administration by 4 hours. [Mild] Theoretical

Antacids are predicted to decrease the absorption of levothyroxine. Separate administration by at least 4 hours. [Mild] Anecdotal

Antacids decrease the exposure to mycophenolate. [Mild] Study

Antacids are predicted to decrease the absorption of nilotinib. Separate administration by at least 2 hours. [Mild] Theoretical

Magnesium trisilicate decreases the absorption of nitrofurantoin. [Mild] Study

Antacids are predicted to decrease the absorption of pazopanib. Pazopanib should be taken 1 hour before or 2 hours after antacids. [Mild] Theoretical

Antacids decrease the absorption of penicillamine. Separate administration by 2 hours. [Mild] Study

Antacids decrease the absorption of phenothiazines. [Mild] Anecdotal

Antacids increase the risk of metabolic alkalosis when given with polystyrene sulfonate. [Severe] Anecdotal

Antacids decrease the absorption of quinolones. Quinolones should be taken 2 hours before or 4 hours after antacids. [Mild] Study

Antacids slightly decrease the exposure to raltegravir. Avoid. [Mild] Study

Antacids decrease the absorption of rifampicin. Rifampicin should be taken 1 hour before antacids. [Mild] Study

Antacids are predicted to decrease the exposure to sunitinib. Sunitinib should be taken 2 hours before or 4 hours after sunitinib. [Severe] Theoretical

Antacids slightly decrease the exposure to riociguat. Antacids should be taken 2 hours before or 1 hour after riociguat. [Mild] Study

Downloaded from www.medicalbr.com
Antacids moderately decrease the absorption of statins (rosuvastatin). Separate administration by 2 hours. [Moderate] Study

Antacids decrease the absorption of strontium ranelate. Separate administration by 2 hours. [Moderate] Study

Antacids increase the absorption of tetracyclines. Separate administration by 2 to 3 hours. [Moderate] Study

Antacids are predicted to decrease the absorption of ursodeoxycholic acid. Separate administration by 2 hours. [Moderate] Theoretical

Antacids are predicted to decrease the concentration of velpatasvir. Separate administration by 4 hours. [Moderate] Theoretical

Anthracyclines → see TABLE 15 p. 1267 (myelosuppression), TABLE 5 p. 1264 (thromboembolism)

daunorubicin · doxorubicin · epirubicin · idarubicin · mitoxantrone · paxitane

GENERAL INFORMATION Caution is necessary with concurrent use of cardiototoxic drugs, or drugs that reduce cardiac contractility.

Calcium channel blockers (verapamil) moderately increase the exposure to doxorubicin. [Moderate] Study

Ciclosporin increases the concentration of anthracyclines (daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone). [Severe] Study

H₂ receptor antagonists (cimetidine) slightly increase the exposure to epirubicin. Avoid. [Moderate] Study

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with anthracyclines. Public Health England advises avoid. [Severe] Theoretical

Anthracyclines are predicted to increase the risk of cardiotoxicity when given with monoclonal antibodies (trastuzumab, trastuzumab emtansine). Avoid. [Severe] Theoretical

Anthracyclines are predicted to increase the risk of cardiotoxicity when given with aldosterone antagonists (trastuzumab, trastuzumab emtansine). Avoid. [Severe] Theoretical

Adenosine · amiodarone · disopyramide · dronedarone · flecainide · lidocaine · propafenone

Amiodarone has a long half-life; there is potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped.

Since systemic absorption can follow topical application of lidocaine, the possibility of interactions should be borne in mind.

Abiraterone is predicted to increase the exposure to flecainide. [Severe] Theoretical

Antiarhythmics (amiodarone, dronedarone) are predicted to increase the exposure to abiraterone. Separate administration by 12 hours. [Moderate] Study

Amiodarone is predicted to decrease the effects of agalsidase. Avoid. [Moderate] Theoretical

Amiodarone is predicted to increase the exposure to aldosterone antagonists (eplerenone). Adjust eplerenone dose, p. 185. [Severe] Theoretical

Dronedarone is predicted to increase the exposure to aldosterone antagonists (eplerenone). Adjust eplerenone dose, p. 185. [Severe] Study

Antiarrhythmics (amiodarone, dronedarone) are predicted to increase the exposure to aliskiren. [Severe] Study

Dronedarone is predicted to increase the exposure to alpha blockers (tamsulosin). [Moderate] Theoretical

Dronedarone is predicted to increase the exposure to alprazolam. [Severe] Study

Aminophylline is predicted to decrease the efficacy of adenosine. Separate administration by 24 hours. [Mild] Theoretical

Anaesthetics, local are predicted to increase the risk of cardiodepression when given with antiarrhythmics. [Severe] Theoretical → Also see TABLE 11 p. 1266

Antiarrhythmics (propafenone) are predicted to increase the risk of cardiodepression when given with antiarrhythmics (amiodarone). Monitor and adjust dose. [Severe] Theoretical

Antiarrhythmics (amiodarone) increase the concentration of antiarrhythmics (flecainide). Adjust flecainide dose and monitor side effects. [Severe] Study → Also see TABLE 6 p. 1265 → Also see TABLE 9 p. 1266

Antiarrhythmics (propafenone) are predicted to increase the exposure to antiarrhythmics (flecainide). [Severe] Theoretical

Antiarrhythmics (propafenone) are predicted to increase the risk of cardiodepression when given with antiarrhythmics (lidocaine). [Moderate] Study

Antiarrhythmics (dronedarone) are predicted to increase the exposure to antiarrhythmics (propafenone). Monitor and adjust dose. [Moderate] Study

Amiodarone increases the risk of bradycardia when given with anticholinesterases, centrally acting. [Moderate] Anecdotal → Also see TABLE 6 p. 1265

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the efficacy of propafenone. [Moderate] Study

Antiepileptics (fosphenytoin, phenytoin) are predicted to decrease the exposure to lidocaine. [Severe] Anecdotal

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to increase the exposure to antiarrhythmics (disopyramide, dronedarone). Avoid. [Severe] Study

Amiodarone is predicted to slightly increase the concentration of antiepileptics (fosphenytoin, phenytoin). Monitor and adjust dose. [Severe] Study → Also see TABLE 12 p. 1267

Antifungals, azoles (fluconazole) are predicted to increase the exposure to disopyramide. Monitor and adjust dose. [Moderate] Study

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to disopyramide. Avoid. [Severe] Study → Also see TABLE 9 p. 1266

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) very markedly increase the exposure to disopyramide. Avoid. [Severe] Study → Also see TABLE 9 p. 1266

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to propafenone. Monitor and adjust dose. [Moderate] Study

Antifungals, azoles (miconazole) are predicted to increase the exposure to disopyramide. Use with caution and adjust dose. [Severe] Theoretical

Antifungals, azoles (posaconazole) are predicted to increase the exposure to antiarrhythmics (disopyramide, dronedarone). Avoid. [Severe] Theoretical

Dronedarone is predicted to increase the exposure to antifungals, azoles (isavuconazole). [Severe] Theoretical

Dronedarone is predicted to increase the exposure to antihistamines, non-sedating (fexofenadine, mizolastine). [Severe] Theoretical

Dronedarone is predicted to increase the concentration of antimalarials (piperazine). [Severe] Theoretical

Dronedarone is predicted to increase the exposure to apixaban. [Moderate] Theoretical

Aprepitant increases the exposure to dronedarone. [Severe] Theoretical

Aprepitant is predicted to increase the exposure to propafenone. Monitor and adjust dose. [Moderate] Study

Dronedarone is predicted to increase the exposure to apixaban. [Moderate] Theoretical

Dronedarone is predicted to increase the exposure to bedaquiline. Avoid prolonged use. [Mild] Theoretical → Also see TABLE 9 p. 1266

Antiarrhythmics (amiodarone, disopyramide, dronedarone, flecainide, lidocaine) are predicted to increase the risk of cardiovascular side-effects when given with beta blockers, non-selective. Use with caution or avoid. [Severe] Study → Also see TABLE 6 p. 1265 → Also see TABLE 9 p. 1266

Propafenone is predicted to increase the risk of cardiovascular
Antiarrhythmics (continued) side-effects when given with beta blockers, non-selective (carotolol, labetalol, levobunolol, nadolol, oxprenolol, pindolol, sotalol). Use with caution or avoid. [Severe] Study

- **Propafenone** is predicted to increase the exposure to beta blockers, non-selective (carvedilol). [Moderate] Theoretical
- **Propafenone** is predicted to increase the exposure to beta blockers, selective (metoprolol). [Moderate] Theoretical
- **Propafenone** is predicted to increase the exposure to beta blockers, selective (nebivolol) and beta blockers, selective (nebivolol) are predicted to increase the risk of cardiovascular side-effects when given with beta blockers, selective. Use with caution or avoid. [Severe] Study

- **Propafenone** is predicted to increase the exposure to beta blockers, non-selective (timolol) and beta blockers, non-selective (timolol) are predicted to increase the risk of cardiodepression when given with propafenone. [Severe] Anecdotal
- **Antiarrhythmics** (amiodarone, disopyramide, dronedarone, flecainide, lidocaine) are predicted to increase the risk of cardiovascular side-effects when given with beta blockers, selective. Use with caution or avoid. [Severe] Study

- **Propafenone** is predicted to increase the exposure to beta blockers, non-selective (timolol) and beta blockers, non-selective (timolol) are predicted to increase the risk of cardiodepression when given with propafenone. [Severe] Study

- **Propafenone** is predicted to increase the exposure to beta blockers, selective (metoprolol). [Moderate] Theoretical
- **Propafenone** is predicted to increase the exposure to beta blockers, selective (nebivolol) and beta blockers, selective (nebivolol) are predicted to increase the risk of cardiodepression when given with propafenone. Avoid. [Severe] Theoretical
  - **Bosantan** is predicted to decrease the exposure to dronedarone. [Severe] Theoretical
- **Dronedarone** is predicted to increase the exposure to bosutinib. Avoid or adjust bosutinib dose. [Severe] Theoretical
- **Bupropion** is predicted to increase the exposure to flecainide. [Severe] Theoretical
- **Bupropion** is predicted to increase the exposure to propafenone. Monitor and adjust dose. [Moderate] Study
- **Dronedarone** is predicted to increase the exposure to bupropione. Use with caution and adjust dose. [Moderate] Study
- **Dronedarone** is predicted to increase the exposure to cabozantinib. [Moderate] Theoretical
- **Caffeine citrate** decreases the efficacy of adenosine. Separate administration by 24 hours. [Mild] Study
- **Calcium channel blockers (diltiazem, verapamil)** increase the exposure to dronedarone and dronedarone increases the exposure to calcium channel blockers (diltiazem, verapamil). [Moderate] Study
- **Calcium channel blockers (diltiazem, verapamil)** are predicted to increase the exposure to propafenone. Monitor and adjust dose. [Moderate] Study
- **Calcium channel blockers (verapamil)** increase the risk of cardiodepression when given with flecainide. [Severe] Anecdotal
- **Calcium channel blockers (diltiazem, verapamil)** are predicted to increase the exposure to propafenone. [Moderate] Study
- **Dronedarone** is predicted to increase the exposure to calcium channel blockers (amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose. [Moderate] Study
- **Amiodarone** is predicted to increase the risk of cardiodepression when given with calcium channel blockers (verapamil). [Severe] Theoretical
- **Disopyramide** is predicted to increase the risk of cardiodepression when given with calcium channel blockers (verapamil). [Severe] Theoretical
- **Antiarrhythmics** (amiodarone, dronedarone) are predicted to increase the exposure to ceritinib. [Moderate] Theoretical
- **Amiodarone** increases the concentration of cilosporin. Monitor cilosporin concentration and adjust dose. [Severe] Study
- **Dronedarone** increases the concentration of cilosporin. [Severe] Study
- **Ciclosporin** increases the exposure to dronedarone. Avoid. [Severe] Theoretical
  - **Ciclosporin** is predicted to increase the exposure to flecainide. [Severe] Theoretical
  - **Ciclosporin** is predicted to increase the exposure to propafenone. Monitor and adjust dose. [Moderate] Study
  - **Cobicistat** very markedly increases the exposure to dronedarone. Avoid. [Severe] Study
  - **Cobicistat** is predicted to increase the exposure to propafenone. Monitor and adjust dose. [Severe] Study
  - **Dronedarone** is predicted to increase the exposure to cobimetinib. [Severe] Theoretical
  - **Dronedarone** is predicted to increase the exposure to colchicine. Adjust colchicine dose, p. 1020. [Severe] Study
  - **Dronedarone** is predicted to increase the exposure to corticosteroids (methylprednisolone). Monitor and adjust dose. [Moderate] Study
  - **Amiodarone** increases the antiocoagulant effect of coumarins. Monitor INR and adjust dose. [Moderate] Study
  - **Dronedarone** is predicted to slightly increase the exposure to darifenacin. [Moderate] Study
  - **Darifenacin** is predicted to increase the concentration of flecainide. [Moderate] Theoretical
  - **Dronedarone** is predicted to increase the exposure to dasatinib. [Severe] Study
  - **Antiarrhythmics** (amiodarone, dronedarone) are predicted to moderately increase the exposure to digoxin. Monitor and adjust digoxin dose p. 106. [Severe] Study
  - **Propafenone** increases the concentration of digoxin. Monitor and adjust dose. [Severe] Study
  - **Daclatasvir** is predicted to increase the risk of severe bradycardia or heart block when given with amiodarone. Refer to specialist literature. [Severe] Anecdotal
  - **Dronedarone** is predicted to slightly increase the exposure to darifenacin. [Moderate] Study
  - **Darifenacin** is predicted to increase the concentration of flecainide. [Moderate] Theoretical
  - **Dronedarone** is predicted to increase the exposure to dabigatran. Adjust dabigatran dose, p. 131. [Moderate] Study
  - **Dronedarone** slightly increases the exposure to dabigatran. Avoid. [Severe] Study
  - **Dapagliflozin** increases the exposure to adenosine. Avoid. [Moderate] Study
  - **Dronedarone** increases the risk of QT-prolongation when given with domperidone. Avoid. [Severe] Study
  - **Dronedarone** is predicted to increase the exposure to dopamine receptor agonists ( bromocriptine, cabergoline). [Severe] Theoretical
  - **Duloxetine** is predicted to increase the exposure to flecainide. [Severe] Theoretical
  - **Dronedarone** is predicted to moderately increase the exposure to dutasteride. [Mild] Study
  - **Amiodarone** slightly increases the exposure to edoxaban. [Severe] Study
  - **Dronedarone** slightly increases the exposure to edoxaban. Adjust edoxaban dose, p. 122. [Severe] Study
  - **Efavirenz** is predicted to decrease the exposure to dronedarone. [Severe] Theoretical
  - **Enalaprilat** is predicted to decrease the exposure to antiarrhythmics (disopyramide, dronedarone). Avoid. [Severe] Study
  - **Enalaprilat** is predicted to decrease the efficacy of propafenone. [Moderate] Study
  - **Dronedarone** is predicted to increase the exposure to ergometrine. [Severe] Theoretical
  - **Dronedarone** is predicted to increase the risk of ergotism when given with ergometrine. [Severe] Theoretical
  - **Antiarrhythmics** (amiodarone, dronedarone) are predicted to increase the exposure to ergotamine. [Severe] Theoretical
  - **Antiarrhythmics** (amiodarone, dronedarone) are predicted to increase the exposure to everolimus. Avoid or adjust dose. [Moderate] Study
  - **Dronedarone** is predicted to increase the exposure to fesoterodine. Adjust fesoterodine dose in hepatic and renal impairment, p. 732. [Mild] Study
  - **Antiarrhythmics** (amiodarone, dronedarone) are predicted to increase the exposure to fidaxomicin. Avoid. [Moderate] Study
HIV-protease inhibitors are predicted to increase the exposure to idelalisib. {Moderate} Theoretical

Grapefruit juice increases the exposure to amiodarone. Avoid. {Moderate} Study

Grapefruit juice moderately increases the exposure to dronedarone. Avoid. {Severe} Study

Grapefruit juice increases the exposure to propafenone. Monitor and adjust dose. {Moderate} Study

Dronedarone is predicted to increase the concentration of guanfacine. Adjust guanfacine dose, p. 335. {Moderate} Theoretical

H₂ receptor antagonists (cimetidine) increase the exposure to amiodarone. {Moderate} Study

H₂ receptor antagonists (cimetidine) slightly increase the exposure to flecainide. Monitor and adjust dose. {Severe} Study

H₂ receptor antagonists (cimetidine) increase the exposure to lidocaine. Monitor and adjust dose. {Moderate} Study

H₂ receptor antagonists (cimetidine) are predicted to increase the exposure to propafenone. Monitor and adjust dose. {Moderate} Theoretical

HIV-protease inhibitors are predicted to increase the exposure to amiodarone. Avoid. {Severe} Theoretical

HIV-protease inhibitors are predicted to increase the exposure to disopyramide. {Severe} Theoretical

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) very markedly increase the exposure to dronedarone. Avoid. {Severe} Study

HIV-protease inhibitors (indinavir) are predicted to increase the exposure to propafenone. Monitor and adjust dose. {Moderate} Study

HIV-protease inhibitors (ritonavir) are predicted to increase the exposure to flecainide. {Severe} Theoretical

Dronedarone is predicted to increase the exposure to ibritunib. Avoid or adjust ibritunib dose, p. 902. {Severe} Theoretical

Idelalisib very markedly increases the exposure to dronedarone. Avoid. {Severe} Study

Idelalisib is predicted to increase the exposure to propafenone. Monitor and adjust dose. {Severe} Study

Idelalisib is predicted to increase the exposure to dronedarone. {Severe} Theoretical

Idelalisib is predicted to increase the exposure to propafenone. {Severe} Study

Dronedarone is predicted to increase the exposure to propafenone. Monitor and adjust dose. {Moderate} Study

Dronedarone is predicted to increase the exposure to ivabradine. Adjust ivabradine dose, p. 205. {Severe} Theoretical

Dronedarone is predicted to increase the exposure to ivacaftor. Adjust ivacaftor dose, p. 281. {Severe} Study

Dronedarone is predicted to increase the exposure to lapatinib. {Moderate} Study

Dronedarone is predicted to increase the exposure to lapatinib. {Moderate} Study

Dronedarone is predicted to increase the exposure to lapatinib. {Moderate} Study

Dronedarone is predicted to increase the exposure to lapatinib. {Moderate} Study

Dronedarone is predicted to increase the exposure to lapatinib. {Moderate} Study

Dronedarone is predicted to increase the exposure to lapatinib. {Moderate} Study

Dronedarone is predicted to increase the exposure to lapatinib. {Moderate} Study

Dronedarone is predicted to increase the exposure to lapatinib. {Moderate} Study

Dronedarone is predicted to increase the exposure to lapatinib. {Moderate} Study

Dronedarone is predicted to increase the exposure to lapatinib. {Moderate} Study

Dronedarone is predicted to increase the exposure to lapatinib. {Moderate} Study

Dronedarone is predicted to increase the exposure to lapatinib. {Moderate} Study

Dronedarone is predicted to increase the exposure to lapatinib. {Moderate} Study

Dronedarone is predicted to increase the exposure to lapatinib. {Moderate} Study

Dronedarone is predicted to increase the exposure to lapatinib. {Moderate} Study

Dronedarone is predicted to increase the exposure to lapatinib. {Moderate} Study

Dronedarone is predicted to increase the exposure to lapatinib. {Moderate} Study

Dronedarone is predicted to increase the exposure to lapatinib. {Moderate} Study

Dronedarone is predicted to increase the exposure to lapatinib. {Moderate} Study

Dronedarone is predicted to increase the exposure to lapatinib. {Moderate} Study

Dronedarone is predicted to increase the exposure to lapatinib. {Moderate} Study

Dronedarone is predicted to increase the exposure to lapatinib. {Moderate} Study

Dronedarone is predicted to increase the exposure to lapatinib. {Moderate} Study

Dronedarone is predicted to increase the exposure to lapatinib. {Moderate} Study

Dronedarone is predicted to increase the exposure to lapatinib. {Moderate} Study

Dronedarone is predicted to increase the exposure to lapatinib. {Moderate} Study

Dronedarone is predicted to increase the exposure to lapatinib. {Moderate} Study

Dronedarone is predicted to increase the exposure to lapatinib. {Moderate} Study

Macrolides (clarithromycin) are predicted to increase the exposure to propafenone. Monitor and adjust dose. {Severe} Study

Macrolides (clarithromycin, erythromycin) are predicted to increase the exposure to lidocaine. {Moderate} Theoretical

Macrolides (erythromycin) are predicted to moderately increase the exposure to dronedarone. Avoid. {Severe} Theoretical

Macrolides (erythromycin) are predicted to increase the exposure to propafenone. Monitor and adjust dose. {Moderate} Study

Dronedarone is predicted to increase the exposure to midazolam. Monitor side effects and adjust dose. {Severe} Study

Mirabegron is predicted to increase the exposure to flecainide. {Severe} Theoretical

Dronedarone increases the risk of neutropenia when given with monoclonal antibodies (brentuximab vedotin). Monitor and adjust dose. {Severe} Theoretical

Dronedarone is predicted to increase the exposure to nabixegol. Adjust nabixegol dose and monitor side effects, p. 63. {Moderate} Study

Netupitant is predicted to increase the exposure to propafenone. Monitor and adjust dose. {Moderate} Study

Nevirapine is predicted to decrease the exposure to dronedarone. {Severe} Theoretical

Dronedarone is predicted to increase the exposure to nilotinib. {Moderate} Theoretical

Nilotinib is predicted to increase the exposure to propafenone. Monitor and adjust dose. {Moderate} Study

Antiarrhythmics (amiodarone, dronedarone) are predicted to increase the exposure to nintedanib. {Moderate} Study

NSAIDs, (celecoxib) are predicted to increase the exposure to antiarrhythmics (flecainide, propafenone). Monitor and adjust dose. {Moderate} Theoretical

Dronedarone is predicted to increase the exposure to oloparib. Avoid or adjust oloparib dose, p. 919. {Moderate} Theoretical

Dronedarone is predicted to increase the exposure to opioids (alfentanil, buprenorphine, fentanyl, oxycodone). Monitor and adjust dose. {Moderate} Study

Propafenone is predicted to decrease the efficacy of opioids (tramadol). {Moderate} Study

Dronedarone is predicted to increase the exposure to oxybutynin. {Mild} Theoretical

Dronedarone is predicted to increase the exposure to pazopanib. {Moderate} Theoretical

Propafenone is predicted to increase the anticoagulant effect of phenindione. Monitor and adjust dose. {Moderate} Theoretical

Dronedarone is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (avanafil). Adjust avanafil dose, p. 765. {Moderate} Theoretical

Dronedarone is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (sildenafil). Monitor and adjust sildenafil dose, p. 766. {Moderate} Study

Dronedarone is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (tadalafil). {Severe} Theoretical

Dronedarone is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (vardenafil). Adjust dose. {Severe} Theoretical

Dronedarone is predicted to increase the exposure to pimozide. Avoid. {Severe} Theoretical

Propafenone is predicted to increase the exposure to pitolisant. Use with caution and adjust dose. {Moderate} Study

Dronedarone is predicted to increase the exposure to quetiapine. Avoid. {Moderate} Study

Quinolones (ciprofloxacin) slightly increase the exposure to lidocaine. {Mild} Study

Dronedarone is predicted to increase the exposure to ranolazine. {Severe} Study

Table 9...
Antiarrhythmics (continued)

- **Amiodarone** is predicted to increase the exposure to retinoids (all-transretinoin). Adjust all-transretinoin dose, p. 1157. [Moderate] Theoretical
- **Rifampicin** is predicted to decrease the exposure to antiarrhythmics (disopyramide, dronedarone). Avoid. [Severe] Theoretical
- **Rifampicin** is predicted to decrease the efficacy of propafenone. [Moderate] Study
- **Dronedarone** is predicted to increase the exposure to rivaroxaban. Avoid. [Moderate] Theoretical
- **Dronedarone** is predicted to increase the exposure to rufoxitinib. [Moderate] Theoretical
- **Dronedarone** is predicted to increase the exposure to saxagliptin. [Mild] Study
- **Simeprevir** is predicted to increase the concentration of amiodarone. Refer to specialist literature. [Severe] Anecdotal
- **Dronedarone** is predicted to increase the concentration of simeprevir. Avoid. [Severe] Study
- **Amiodarone** is predicted to increase the concentration of sirolimus. [Severe] Anecdotal
- **Dronedarone** increases the concentration of sirolimus. Monitor and adjust dose. [Moderate] Study
- **Sofosbuvir** is predicted to increase the risk of severe bradycardia or heart block when given with amiodarone. Refer to specialist literature. [Severe] Anecdotal
- **SSRIs:** fluoxetine, fluvoxamine, paroxetine) are predicted to increase the exposure to propafenone. Monitor and adjust dose. [Moderate] Study
- **SSRIs:** fluoxetine, paroxetine) are predicted to increase the exposure to flecainide. [Severe] Theoretical
- **Dronedarone** is predicted to increase the exposure to SSRIs (dapofoxetine). Adjust dapofoxetine dose, p. 773. [Moderate] Theoretical
- **St John’s Wort** is predicted to decrease the exposure to flecainide. Avoid. [Severe] Theoretical
- **Amiodarone** is predicted to increase the risk of rhabdomyolysis when given with statins (atorvastatin). Monitor and adjust dose. [Moderate] Theoretical
- **Dronedarone** is predicted to increase the exposure to statins (atorvastatin). Monitor and adjust dose. [Severe] Theoretical
- **Amiodarone** is predicted to increase the exposure to statins (fluvastatin). [Severe] Theoretical
- **Dronedarone** slightly increases the exposure to statins (rosuvastatin). Adjust dose. [Severe] Study
- **Amiodarone** increases the risk of rhabdomyolysis when given with statins (simvastatin). Adjust simvastatin dose, p. 198. [Severe] Study
- **Dronedarone** is predicted to increase the exposure to statins (simvastatin). Use with caution and adjust simvastatin dose, p. 196. [Severe] Study
- **Amiodarone** is predicted to increase the exposure to sulfonylureas. Use with caution and adjust dose. [Moderate] Study
- **Dronedarone** is predicted to increase the exposure to sunitinib. [Moderate] Theoretical → Also see TABLE 9 p. 1266
- **Lidocaine** is predicted to increase the effects of suxamethonium. [Moderate] Study
- **Amiodarone** is predicted to increase the concentration of tacrolimus. [Severe] Anecdotal
- **Dronedarone** is predicted to increase the concentration of tacrolimus. [Severe] Study
- **Dronedarone** is predicted to increase the exposure to taxanes (cabazitaxel). [Moderate] Theoretical
- **Dronedarone** is predicted to increase the exposure to taxanes (paclitaxel). [Severe] Theoretical
- **Dronedarone** is predicted to increase the concentration of temsirolimus. [Mild] Study
- **Terbinafine** is predicted to increase the exposure to flecainide. [Severe] Theoretical
- **Terbinafine** is predicted to increase the exposure to propafenone. Monitor and adjust dose. [Moderate] Study
- **Theophylline** decreases the efficacy of adenosine. Separate administration by 24 hours. [Mild] Study
- **Amiodarone** is predicted to increase the exposure to ticagrelor. Use with caution or avoid. [Severe] Study
- **Dronedarone** is predicted to increase the exposure to tofroterodine. [Mild] Theoretical → Also see TABLE 9 p. 1266
- **Dronedarone** is predicted to increase the exposure to tolvaptan. Adjust dose. [Moderate] Theoretical
- **Antiarrhythmics (amiodarone, dronedarone) are predicted to increase the exposure to topotecan. [Severe] Study
- **Antiarrhythmics (amiodarone, dronedarone) are predicted to increase the concentration of trametinib. [Moderate] Theoretical
- **Dronedarone** is predicted to increase the exposure to trazodone. [Moderate] Theoretical
- **Dronedarone** is predicted to increase the risk of torsade de pointes when given with tricyclic antidepressants. Avoid. [Severe] Theoretical → Also see TABLE 9 p. 1266
- **Propafenone** is predicted to increase the concentration of tricyclic antidepressants. [Moderate] Theoretical → Also see TABLE 10 p. 1266
- **Dronedarone** is predicted to increase the exposure to ulipristal. Avoid if used for uterine fibroids. [Moderate] Study
- **Amiodarone** is predicted to increase the concentration of velpatasvir. Avoid or monitor. [Moderate] Theoretical
- **Amiodarone** is predicted to increase the exposure to venetoclax. Avoid or monitor for toxicity. [Severe] Theoretical
- **Dronedarone** is predicted to increase the exposure to venetoclax. Avoid or adjust venetoclax dose, p. 919. [Severe] Study
- **Dronedarone** is predicted to increase the exposure to vinca alkaloids. [Severe] Theoretical → Also see TABLE 9 p. 1266
- **Dronedarone** is predicted to increase the exposure to zopiclone. Adjust dose. [Moderate] Study

### Anticholinesterases, centrally acting → Also see TABLE 6 p. 1265

- DONEPEZIL - GALANTAMINE - RIVASTIGMINE

- **Antiarrhythmics (amiodarone)** increase the risk of bradycardia when given with anticholinesterases, centrally acting. [Moderate] Anecdotal → Also see TABLE 6 p. 1265
- **Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone)** are predicted to decrease the exposure to donepezil. [Mild] Study
- **Antifungals, azoles (itraconazole, ketoconazole, voriconazole)** are predicted to increase the exposure to galantamine. Monitor and adjust dose. [Moderate] Study
- **Anticholinesterases, centrally acting** are predicted to increase the risk of bradycardia when given with beta blockers, non-selective. [Moderate] Anecdotal → Also see TABLE 6 p. 1265
- **Anticholinesterases, centrally acting** are predicted to increase the risk of bradycardia when given with beta blockers, selective. [Moderate] Anecdotal → Also see TABLE 6 p. 1265
- **Bupropion** is predicted to increase the exposure to donepezil. [Moderate] Theoretical
- **Bupropion** is predicted to increase the exposure to galantamine. Monitor and adjust dose. [Moderate] Study
- **Calcium channel blockers (diltiazem, verapamil)** increase the risk of bradycardia when given with anticholinesterases, centrally acting. [Moderate] Anecdotal → Also see TABLE 6 p. 1265
- **Ciclosporin** is predicted to increase the exposure to donepezil. [Moderate] Theoretical
- **Ciclosporin** is predicted to increase the exposure to galantamine. Monitor and adjust dose. [Moderate] Study
- **Enalaprilat** is predicted to decrease the exposure to donepezil. [Mild] Study
- **HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to increase the exposure to galantamine. Monitor and adjust dose. [Moderate] Study
- **Idelalisib** is predicted to increase the exposure to galantamine. Monitor and adjust dose. [Moderate] Study
- **Macrolides (clarithromycin)** are predicted to increase the exposure to galantamine. Monitor and adjust dose. [Moderate] Study

---

**BNF 74**

A1

Interactions | Appendix 1

---

Downloaded from www.medicalbr.com
Anticholinesterases, centrally acting – Antiepileptics

Acetazolamide

▶ Antiepileptics

Rifampicin is predicted to decrease the exposure to donepezil.

(Mild) Study

SSRIs (fluoxetine, paroxetine) are predicted to increase the exposure to donepezil.

(Theoretical) Study

SSRIs (fluoxetine, paroxetine) are predicted to increase the exposure to galantamine. Monitor and adjust dose.

(Moderate) Study

Anticholinesterases, centrally acting increase the effects of suxamethonium.

(Moderate) Theoretical

Terbinafine is predicted to increase the exposure to donepezil.

(Theoretical) Study

Terbinafine is predicted to increase the exposure to galantamine. Monitor and adjust dose.

(Moderate) Study

Antiepileptics → see TABLE 1 p. 1264 (hepatotoxicity), TABLE 18 p. 1268 (hyponatraemia), TABLE 15 p. 1267 (myelosuppression), TABLE 12 p. 1267 (peripheral neuropathy), TABLE 11 p. 1266 (CNS depressant effects)

brivaracetam • carbamazepine • eslicarbazepine a • ethosuximide • fosphenytoin • gabapentin • lacosamide • lamotrigine • levetiracetam • oxcarbazepine • paraldehyde • perampanel • phenytoin • pregabalin • primidone • retigabine • rufinamide • stiripentol • tiagabine • topiramate • valproate • vigabatrin • zonisamide

FOOD AND LIFESTYLE

Increased risk of blurred vision when retigabine taken with alcohol.

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to abacavir.

(Moderate) Theoretical

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to abiraterone. Avoid.

(Severe) Theoretical

Acetazolamide potentially increases the risk of overheating and dehydration when given with zonisamide. Avoid in children.

(Severe) Theoretical

Carbamazepine is predicted to decrease the exposure to aminophylline.

(Moderate) Study

Antiepileptics (fosphenytoin, phenytoin) are predicted to decrease the exposure to agomelatine.

(Moderate) Theoretical

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) decrease the concentration of albendazole.

(Moderate) Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to aldosterone antagonists (eplerenone). Avoid.

(Moderate) Theoretical → Also see TABLE 18 p. 1268

Carbamazepine decreases the exposure to aliskiren.

(Moderate) Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to alprazolam. Adjust alprazolam dose.

(Moderate) Theoretical → Also see TABLE 11 p. 1266

Fosphenytoin is predicted to decrease the exposure to aminophylline. Adjust dose.

(Moderate) Study

Phenobarbital is predicted to decrease the exposure to aminophylline. Adjust dose.

(Moderate) Theoretical

Phenytoin decreases the exposure to aminophylline. Adjust dose.

(Moderate) Study

Primidone is predicted to increase the clearance of aminophylline. Adjust dose.

(Moderate) Theoretical

Antiepileptics (fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to increase the risk of methaemoglobinaemia when given with topical anaesthetics, local (prilocaine). Use with caution or avoid.

(Severe) Theoretical → Also see TABLE 11 p. 1266

Antacids decrease the absorption of gabapentin. Gabapentin should be taken 2 hours after antacids.

(Moderate) Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to antihypertensives (disopyramide, droxidopa). Avoid.

(Severe) Study

Antihypertensives (amiodarone) are predicted to slightly increase the concentration of antiepileptics (fosphenytoin, phenytoin). Monitor and adjust dose.

(Severe) Study → Also see TABLE 12 p. 1267

Antiepileptics (fosphenytoin, phenytoin) are predicted to decrease the exposure to antihypertensives (lidocaine). Severe

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the efficacy of antihypertensives (propafenone). Moderate Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to anticholinesterases, centrally acting (donepezil).

(Mild) Study

Antiepileptics (carbamazepine) decrease the concentration of antiepileptics (brivaracetam).

(Moderate) Study

Antiepileptics (fosphenytoin, phenytoin) decrease the concentration of antiepileptics (brivaracetam).

(Moderate) Study

Antiepileptics (lamotrigine) potentially increase the concentration of antiepileptics (carbamazepine) and antiepileptics (carbamazepine) decrease the concentration of antiepileptics (lamotrigine). Adjust lamotrigine dose and monitor carbamazepine concentration, p. 303.

(Moderate) Study

Antiepileptics (phenobarbital) affect the concentration of antiepileptics (carbamazepine) and antiepileptics (carbamazepine) increase the concentration of antiepileptics (phenobarbital). Adjust dose.

(Moderate) Study

Antiepileptics (stiripentol) increase the concentration of antiepileptics (carbamazepine).

(Severe) Study

Antiepileptics (topiramate) increase the risk of carbamazepine toxicity when given with antiepileptics (carbamazepine).

(Moderate) Study

Antiepileptics (carbamazepine) slightly decrease the exposure to antiepileptics (eslicarbazepine, oxcarbazepine).

(Monitor and adjust dose.

(Moderate) Study

Antiepileptics (oxcarbazepine) are predicted to increase the concentration of antiepileptics (fosphenytoin). Monitor concentration and adjust dose.

(Moderate) Study

Antiepileptics (carbamazepine) affect the concentration of antiepileptics (fosphenytoin, phenytoin) and antiepileptics (fosphenytoin, phenytoin) decrease the concentration of antiepileptics (carbamazepine). Monitor and adjust dose.

(Severe) Study

Antiepileptics (eslicarbazepine) increase the exposure to antiepileptics (fosphenytoin, phenytoin) and antiepileptics (carbamazepine) decrease the exposure to antiepileptics (eslicarbazepine).

(Monitor and adjust dose.

(Moderate) Study

Antiepileptics (stiripentol) are predicted to increase the concentration of antiepileptics (fosphenytoin, phenytoin).

(Severe) Study

Antiepileptics (valproate) affect the concentration of antiepileptics (fosphenytoin, phenytoin) and antiepileptics (carbamazepine) decrease the concentration of antiepileptics (valproate).

(Severe) Study

Antiepileptics (vagabatrin) decrease the concentration of antiepileptics (fosphenytoin, phenytoin).

(Mild) Study

Antiepileptics (fosphenytoin) decrease the concentration of antiepileptics (lamotrigine). Monitor and adjust lamotrigine dose, p. 303.

(Moderate) Study

Antiepileptics (phenobarbital, phenytoin, primidone) decrease the concentration of antiepileptics (lamotrigine). Monitor and adjust lamotrigine dose, p. 303.

(Moderate) Study → Also see TABLE 11 p. 1266

Antiepileptics (valproate) increase the exposure to antiepileptics (lamotrigine). Adjust lamotrigine dose and monitor rash, p. 303.

(Severe) Study

Antiepileptics (lamotrigine) are predicted to increase the concentration of antiepileptics (oxcarbazepine) and antiepileptics (oxcarbazepine) are predicted to decrease the concentration of antiepileptics (lamotrigine). Monitor side effects and adjust dose.

(Moderate) Study

Antiepileptics (carbamazepine, fosphenytoin) are predicted to decrease the exposure to antiepileptics (perampanel). Monitor and adjust dose.

(Moderate) Study

Antiepileptics (oxcarbazepine) decrease the concentration of antiepileptics (perampanel) and antiepileptics (perampanel)
Antiepileptics (continued)

increase the concentration of antiepileptics (oxcarbazepine). Monitor and adjust dose. [Moderate] Study

- Antiepileptics (phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to antiepileptics (perampanel). Monitor and adjust dose. [Moderate] Study  Also see TABLE 11 p. 1266

- Antiepileptics (phenytoin) increase the concentration of antiepileptics (phenobarbital) and antiepileptics (phenobarbital) affect the concentration of antiepileptics (phenytoin). [Moderate] Study

- Antiepileptics (fosphenytoin) increase the concentration of antiepileptics (phenobarbital, primidone) and antiepileptics (phenobarbital, primidone) affect the concentration of antiepileptics (phenytoin). [Moderate] Study

- Antiepileptics (triamterene) are predicted to increase the concentration of antiepileptics (phenobarbital, primidone). [Severe] Theoretical

- Antiepileptics (oxcarbazepine) are predicted to increase the concentration of antiepileptics (phenytoin). Monitor concentration and adjust dose. [Moderate] Study

- Antiepileptics (carbamazepine) potentially decrease the concentration of antiepileptics (primidone) and antiepileptics (primidone) potentially decrease the concentration of antiepileptics (carbamazepine). Adjust dose. [Moderate] Anecdotal

- Antiepileptics (phenytoin) increase the concentration of antiepileptics (primidone) and antiepileptics (primidone) affect the concentration of antiepileptics (phenytoin). [Moderate] Study

- Antiepileptics (valproate) affect the concentration of antiepileptics (primidone). Monitor and adjust dose. [Severe] Study

- Antiepileptics (carbamazepine, fosphenytoin, phenytoin) decrease the exposure to antiepileptics (retigabine). [Moderate] Study

- Antiepileptics (valproate) increase the exposure to antiepileptics (rufinamide). Adjust rufinamide dose, p. 311. [Moderate] Study

- Antiepileptics (carbamazepine, fosphenytoin, phenytoin, phenobarbital, primidone) decrease the exposure to antiepileptics (tiagabine). Monitor and adjust tiagabine dose, p. 314. [Moderate] Study

- Antiepileptics (fosphenytoin, phenytoin) decrease the concentration of antiepileptics (topiramate) and antiepileptics (topiramate) increase the concentration of antiepileptics (fosphenytoin, phenytoin). Monitor and adjust dose. [Moderate] Study

- Antiepileptics (phenobarbital, primidone) are predicted to decrease the concentration of antiepileptics (topiramate). [Mild] Study

- Antiepileptics (phenobarbital) decrease the concentration of antiepileptics (valproate) and antiepileptics (valproate) increase the concentration of antiepileptics (phenobarbital). Monitor and adjust dose. [Moderate] Study

- Antiepileptics (topiramate) increase the risk of toxicity when given with antiepileptics (valproate). [Severe] Study

- Antiepileptics (carbamazepine) slightly to moderately decrease the concentration of antiepileptics (zonisamide) and antiepileptics (zonisamide) affect the concentration of antiepileptics (carbamazepine). Monitor and adjust dose. [Moderate] Study

- Antiepileptics (fosphenytoin, phenytoin) slightly to moderately decrease the concentration of antiepileptics (zonisamide). Monitor and adjust dose. [Moderate] Study

- Antiepileptics (phenobarbital, primidone) are predicted to decrease the concentration of antiepileptics (zonisamide). Monitor and adjust dose. [Moderate] Study

- Antiepileptics (topiramate) potentially increase the risk of overheating and dehydration when given with antiepileptics (zonisamide). Avoid in children. [Severe] Theoretical

- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to slightly increase the exposure to perampanel. [Mild] Study

- Antifungals, azoles (miconazole) increase the risk of carbamazepine toxicity when given with carbamazepine. Monitor and adjust dose. [Severe] Anecdotal

- Antifungals, azoles (miconazole) increase the risk of phenytoin toxicity when given with fosphenytoin. Monitor and adjust dose. [Severe] Anecdotal

- Antifungals, azoles (miconazole) increase the risk of phenytoin toxicity when given with phenytoin. Monitor and adjust dose. [Severe] Anecdotal

- Carbamazepine is predicted to decrease the efficacy of antifungals, azoles (flucytosine) and antifungals, azoles (fluconazole) increase the concentration of carbamazepine. Avoid or monitor carbamazepine concentration and adjust dose accordingly. [Severe] Theoretical  Also see TABLE 1 p. 1264

- Antifungals, azoles (flucytosine) increase the concentration of antiepileptics (fosphenytoin, phenytoin). Monitor concentration and adjust dose. [Moderate] Study

- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to antifungals, azoles (isavuconazole). Avoid. [Severe] Study

- Fosphenytoin very markedly decreases the exposure to antifungals, azoles (itraconazole). Avoid. Fosphenytoin for 14 days before and during treatment with itraconazole. [Moderate] Study

- Phenobarbital decreases the concentration of antifungals, azoles (itraconazole). Avoid phenobarbital for 14 days before and during treatment with itraconazole. [Moderate] Study

- Phenytoin very markedly decreases the exposure to antifungals, azoles (itraconazole). Avoid phenytoin for 14 days before and during treatment with itraconazole. [Moderate] Study

- Primidone is predicted to decrease the concentration of antifungals, azoles (itraconazole). [Moderate] Theoretical

- Carbamazepine is predicted to decrease the efficacy of antifungals, azoles (itraconazole, voriconazole) and antifungals, azoles (itraconazole, voriconazole) increase the concentration of carbamazepine. Avoid or adjust dose. [Moderate] Theoretical  Also see TABLE 1 p. 1264

- Carbamazepine is predicted to decrease the efficacy of antifungals, azoles (ketocconazole) and antifungals, azoles (ketocconazole) slightly increase the concentration of carbamazepine. Avoid or monitor carbamazepine concentration and adjust dose accordingly. [Moderate] Study

- Phenobarbital is predicted to decrease the concentration of antifungals, azoles (ketocconazole). Avoid. [Moderate] Study

- Antiepileptics (fosphenytoin, phenytoin) decrease the exposure to antifungals, azoles (ketocconazole). Avoid. [Moderate] Study

- Primidone is predicted to decrease the concentration of antifungals, azoles (ketocconazole, posaconazole). Avoid. [Moderate] Study

- Carbamazepine is predicted to decrease the efficacy of antifungals, azoles (posaconazole) and antifungals, azoles (posaconazole) increase the concentration of carbamazepine. Avoid. [Mild] Study

- Phenobarbital is predicted to decrease the concentration of antifungals, azoles (posaconazole). Avoid. [Mild] Study

- Antiepileptics (fosphenytoin, phenytoin) are predicted to decrease the exposure to antifungals, azoles (posaconazole). Avoid. [Mild] Study

- Fosphenytoin decreases the exposure to antifungals, azoles (voriconazole) and antifungals, azoles (voriconazole) increase the exposure to fosphenytoin. Avoid or adjust voriconazole dose and monitor phenytoin concentration, p. 566. [Moderate] Study

- Phenytoin decreases the exposure to antifungals, azoles (voriconazole) and antifungals, azoles (voriconazole) increase the exposure to phenytoin. Avoid or adjust voriconazole dose and monitor phentoin concentration, p. 566. [Moderate] Study

- Antiepileptics (phenobarbital, primidone) are predicted to decrease the concentration of antifungals, azoles (voriconazole). Avoid. [Mild] Study

- Antifungals, sedating antihistamines (hydroxyzine) potentially increase the risk of overheating and dehydration when given with zonisamide. Avoid in children. [Severe] Theoretical

- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to antimalarials (artemether) (with lumefantrine). Avoid. [Severe] Study

- Antihistamines, sedating (hydroxyzine) potentially increase the risk of overheating and dehydration when given with zonisamide. Avoid in children. [Severe] Theoretical

- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to antimalarials (artemether) (with lumefantrine). Avoid. [Severe] Study

- Antihistamines, sedating (hydroxyzine) potentially increase the risk of overheating and dehydration when given with zonisamide. Avoid in children. [Severe] Theoretical
Antiepileptics (pyrimethamine) increase the risk of haematological toxicity when given with antiepileptics (fosphenytoin, phenytoin). (Severe) Study

Antimalarials (pyrimethamine) are predicted to increase the risk of haematological toxicity when given with antiepileptics (phenobarbital, primidone). (Severe) Theoretical

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the concentration of antimalarials (piperaquine). Avoid. (Moderate) Theoretical

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to moderately decrease the exposure to apixaban. Use with caution or avoid. (Severe) Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to moderately decrease the exposure to aripiprazole. Adjust aripiprazole dose, p. 376. (Moderate) Study. Also see Table 11 p. 1266

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to apremilast. Avoid. (Severe) Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to markedly decrease the exposure to aprepitant. Avoid. (Moderate) Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to azithromycin. Avoid. (Moderate) Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to bazedoxifene. (Moderate) Theoretical

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) decrease the exposure to bedaquiline. Avoid. (Severe) Study

Antiepileptics (phenobarbital, primidone) are predicted to decrease the exposure to beta blockers, non-selective (carvedilol, labetalol). (Moderate) Theoretical

Antiepileptics (phenobarbital, primidone) are predicted to decrease the exposure to beta blockers, non-selective (propranolol). (Moderate) Study

Antiepileptics (phenobarbital, primidone) are predicted to decrease the exposure to beta blockers, selective (acebutolol, bisoprolol, metoprolol, nebivolol). (Moderate) Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) slightly decrease the exposure to bortezomib. Avoid. (Severe) Study. Also see Table 12 p. 1267

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) affect the exposure to bosentan. Avoid. (Severe) Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to very markedly decrease the exposure to bupropion. (Severe) Study

Valproate increases the exposure to bupropion. (Severe) Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to markedly decrease the exposure to buspirone. Use with caution and adjust dose. (Severe) Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to markedly decrease the exposure to cabozantinib. Avoid. (Moderate) Study

Antiepileptics (fosphenytoin, phenytoin) are predicted to moderately increase the clearance of caffeine citrate. Monitor and adjust dose. (Moderate) Study

Calcium channel blockers (diltiazem, verapamil) increase the concentration of carbamazepine. (Severe) Anecdotal

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to calcium channel blockers (amiodipine, felodipine, lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose. (Moderate) Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) decrease the exposure to calcium channel blockers (diltiazem). (Severe) Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) decrease the exposure to calcium channel blockers (irtraconazole). Avoid. (Moderate) Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to calcium channel blockers (verapamil). (Severe) Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to cannabis extract. Avoid. (Severe) Theoretical. Also see Table 11 p. 1266

Capcetibaine increases the concentration of antiepileptics (fosphenytoin, phenytoin). (Severe) Anecdotal

Carbogenem decreases the concentration of valproate. Avoid. (Severe) Anecdotal

Antiepileptics (carbamazepine, fosphenytoin, phenytoin) are predicted to decrease the concentration of caspofungin. Adjust caspofungin dose, p. 560. (Moderate) Theoretical

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to ceritinib. Avoid. (Severe) Study

Antiepileptics (phenobarbital, primidone) decrease the concentration of chloramphenicol. (Moderate) Study

Intravenous chloramphenicol increases the concentration of antiepileptics (fosphenytoin, phenytoin) and antiepileptics (fosphenytoin, phenytoin) affect the concentration of intravenous chloramphenicol. Monitor concentration and adjust dose. (Severe) Study

Chlorbidipoxide affects the concentration of antiepileptics (fosphenytoin, phenytoin). (Severe) Study

Phenobarbital decreases the effects of cholic acid. Avoid. (Moderate) Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) decrease the concentration of ciclosporin. (Severe) Anecdotal

Oxcarbazepine decreases the concentration of ciclosporin. (Severe) Anecdotal

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to alter the effects of cisatrazol. (Moderate) Theoretical

Clozam potentially affects the concentration of antiepileptics (fosphenytoin, phenytoin). (Severe) Anecdotal

Stiripentol increases the concentration of clozam. (Severe) Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) decrease the exposure to clomethiazole. Monitor and adjust dose. (Moderate) Study. Also see Table 11 p. 1266

Clonazepam potentially affects the concentration of antiepileptics (fosphenytoin, phenytoin). (Severe) Anecdotal

Antiepileptics (fosphenytoin, phenytoin) are predicted to decrease the exposure to clozaopine. (Moderate) Anecdotal

Antiepileptics (phenobarbital, primidone) decrease the exposure to clozapine. (Moderate) Anecdotal. Also see Table 11 p. 1266

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to cobicistat. Avoid. (Severe) Theoretical

Oxcarbazepine is predicted to decrease the concentration of cobicistat. (Severe) Theoretical

Cobicistat is predicted to slightly increase the exposure to perampanel. (Moder) Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to cobicistat. Avoid. (Severe) Theoretical

Antiepileptics (carbamazepine, eslicarbazepine, fosphenytoin, oxcarbazepine, perampanel, phenobarbital, phenytoin, primidone, rufinamide, topiramate) are predicted to decrease the efficacy of combined hormonal contraceptives. For FHSG guidance, see Contraceptives, interactions p. 747. (Severe) Study

Combined hormonal contraceptives alter the exposure to lamotrigine. Adjust lamotrigine dose, p. 303. (Moderate) Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to corticosteroids (budesonide, dexamethasone, methylprednisolone, prednisolone). Monitor and adjust dose. (Moderate) Study
Antiepileptics (continued)

- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to corticosteroids (fluticasone). [Unknown] Theoretical
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to corticosteroids (prednisone). [BNF]
- Antiepileptics (fosphenytoin, phenytoin) are predicted to alter the anticoagulant effect of coumarins. [Moderate] Anecdotal
- Antiepileptics (phenobarbital, primidone) decrease the anticoagulant effect of coumarins. Monitor INR and adjust dose. [Moderate] Study
- Carbamazepine decreases the effects of coumarins. Monitor and adjust dose. [Severe] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to markedly decrease the exposure to crizotinib. Avoid. [Severe] Study
- Carbamazepine is predicted to decrease the exposure to dabigatran. Avoid. [Severe] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to dabrafenib. Avoid. [Moderate] Theoretical
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to moderately decrease the exposure to daclatasvir. Avoid. [Severe] Study
- Oxcarbazepine is predicted to decrease the exposure to daclatasvir. Avoid. [Severe] Theoretical
- Danazol moderately increases the concentration of carbamazepine. Monitor carbamazepine concentration and adjust dose. [Severe] Study
- Antiepileptics (fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to increase the risk of methaemoglobinemia when given with dapsone. [Severe] Theoretical
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to darifenacin. [Moderate] Theoretical
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to dasabuvir. Avoid. [Severe] Theoretical
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to markedly decrease the exposure to dasatinib. Avoid. [Severe] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to slightly decrease the exposure to delamanid. Avoid. [Moderate] Study
- Lamotrigine is predicted to increase the risk of hynopatraemia when given with desmopressin. [Severe] Theoretical
- Antiepileptics (carbamazepine, eslicarbazepine, fosphenytoin, oxcarbazepine, perampanel, phenobarbital, phenytoin, primidone, rufinamide, topiramate) are predicted to decrease the efficacy of desogestrel. For FSH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical
- Desogestrel is predicted to increase the exposure to lamotrigine. [Moderate] Study
- Diazepam potentially affects the concentration of antiepileptics (fosphenytoin, phenytoin). Monitor concentration and adjust dose. [Severe] Study
- Diazoxide decreases the concentration of antiepileptics (fosphenytoin, phenytoin) and antiepileptics (fosphenytoin, phenytoin) are predicted to decrease the effects of diazoxide. Monitor concentration and adjust dose. [Moderate] Anecdotal
- Antiepileptics (fosphenytoin, phenytoin) are predicted to decrease the concentration of digoxin. [Moderate] Anecdotal
- Disulfiram increases the concentration of antiepileptics (fosphenytoin, phenytoin). Monitor concentration and adjust dose. [Severe] Study → Also see TABLE 12 p. 1267
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) decrease the exposure to dolutegravir. Adjust dose. [Severe] Study
- Oxcarbazepine is predicted to decrease the exposure to dolutegravir. Adjust dose. [Severe] Theoretical
- Carbamazepine is predicted to decrease the exposure to edoxaban. [Moderate] Study
- Antiepileptics (fosphenytoin, phenytoin) slightly decrease the exposure to efavirenz and efavirenz affects the concentration of antiepileptics (fosphenytoin, phenytoin). [Severe] Theoretical
- Carbamazepine slightly decreases the exposure to efavirenz and efavirenz slightly decreases the exposure to carbamazepine. [Severe] Study
- Phenobarbital is predicted to decrease the exposure to efavirenz and efavirenz affects the concentration of phenobarbital. [Severe] Theoretical
- Efavirenz is predicted to affect the efficacy of primidone and primidone is predicted to slightly decrease the exposure to efavirenz. [Severe] Theoretical
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to elbasvir. Avoid. [Severe] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the concentration of elvitegravir. Avoid. [Severe] Theoretical
- Enteral feeds decreases the absorption of phenytoin. [Severe] Study
- Enzalutamide is predicted to slightly decrease the exposure to brivaracetam. [Moderate] Theoretical
- Enzalutamide is predicted to decrease the exposure to perampanel. Monitor and adjust dose. [Moderate] Study
- Antiepileptics (carbamazepine, dasabuvir, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the effects of ergotamine. [Moderate] Theoretical
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to ergotamine. [Moderate] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to etoricoxib. Avoid or adjust etoricoxib dose. [Severe] Study
- Antiepileptics (carbamazepine, eslicarbazepine, fosphenytoin, oxcarbazepine, perampanel, phenobarbital, phenytoin, primidone, rufinamide, topiramate) are predicted to decrease the efficacy of estradiol. For FSH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the efficacy of etoposide. [Moderate] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to etravirine. Avoid. [Severe] Theoretical
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the concentration of everolimus. Avoid or adjust everolimus dose. [Severe] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) moderately decrease the exposure to exemestane. [Moderate] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to fesoterodine. Avoid. [Moderate] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to fingolimod. [Moderate] Study
- Fluoroouracil increases the concentration of antiepileptics (fosphenytoin, phenytoin). Monitor concentration and adjust dose. [Severe] Anecdotal
- Folic acid (folate) decreases the concentration of antiepileptics (fosphenytoin, phenobarbital, phenobarbital, phenytoin, primidone). Monitor concentration and adjust dose. [Severe] Study
- Folic acid (folinic acid) are predicted to decrease the concentration of antiepileptics (fosphenytoin, phenobarbital, phenobarbital, phenytoin, primidone). [Severe] Theoretical
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to fosaprepitant. Avoid. [Moderate] Theoretical
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to gefitinib. Avoid. [Severe] Study
- Grapefruit juice slightly increases the exposure to carbamazepine. Monitor carbamazepine concentration and adjust dose. [Moderate] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to grazoprevir. Avoid. [Severe] Study
Antiepileptics (phenobarbital, primidone) decrease the effects of griseofulvin. [Moderate] Study
Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the concentration of guanfacine. Adjust guanfacine dose, p. 335. [Moderate] Study → Also see TABLE 11, p. 1266
Oxcarbazepine is predicted to decrease the concentration of guanfacine. Monitor and adjust guanfacine dose, p. 335. [Moderate] Theoretical
Guanfacine increases the concentration of valproate. Monitor and adjust dose. [Moderate] Study
H₂ receptor antagonists (cimetidine) transiently increase the concentration of carbamazepine. [Moderate] Study
H₂ receptor antagonists (cimetidine) increase the concentration of fosphenytoin. Monitor phenytoin concentration and adjust dose. [Severe] Theoretical
H₂ receptor antagonists (cimetidine) increase the concentration of phenytoin. Monitor phenytoin concentration and adjust dose. [Severe] Study
Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) decrease the concentration of haloperidol. Adjust dose. [Moderate] Study → Also see TABLE 11, p. 1266
Haloperidol potentially increases the risk of overheating and dehydration when given with zonisamide. Avoid in children. [Severe] Theoretical
HIV-protease inhibitors (ritonavir) are predicted to decrease the concentration of valproate. [Severe] Anecdotal
HIV-protease inhibitors are predicted to affect the exposure to antiepileptics (fosphenytoin, phenytoin) and antiepileptics (fosphenytoin, phenytoin) decrease the concentration of HIV-protease inhibitors. [Severe] Theoretical
HIV-protease inhibitors are predicted to affect the concentration of antiepileptics (phenobarbital, primidone) and antiepileptics (phenobarbital, primidone) are predicted to decrease the concentration of HIV-protease inhibitors. [Severe] Theoretical
HIV-protease inhibitors are predicted to increase the exposure to carbamazepine and carbamazepine is predicted to decrease the exposure to HIV-protease inhibitors. Monitor and adjust dose. [Severe] Theoretical
HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to significantly increase the exposure to perampanel. [Mild] Study
HIV-protease inhibitors (ritonavir) slightly decrease the exposure to lamotrigine. [Severe] Study
Antiepileptics (carbamazepine, eslicarbazepine, fosphenytoin, oxcarbazepine, perampanel, phenobarbital, phenytoin, primidone, rufinamide, topiramate) are predicted to decrease the effects of hormone replacement therapy. [Moderate] Anecdotal
Hormone replacement therapy is predicted to alter the exposure to lamotrigine. [Moderate] Theoretical
Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to ibritinib. Avoid. [Severe] Study
Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to idealisib. Avoid. [Severe] Study
Idealisib is predicted to slightly increase the exposure to perampanel. [Mild] Study
Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to imatinib. Avoid. [Moderate] Study
Oxcarbazepine decreases the exposure to imatinib. Avoid. [Moderate] Study
Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to irinotecan. Avoid. [Severe] Study
Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to iron chelators (deferasirox). Monitor serum ferritin and adjust dose. [Moderate] Theoretical
Isoniazid increases the concentration of antiepileptics (fosphenytoin, phenytoin). [Moderate] Study → Also see TABLE 12, p. 1267
Isoniazid increases the concentration of carbamazepine and carbamazepine increases the risk of hepatotoxicity when given with isoniazid. Monitor carbamazepine concentration and adjust dose. [Severe] Study → Also see TABLE 1, p. 1264
Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to ivabradine. Adjust dose. [Moderate] Theoretical
Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) markedly decrease the exposure to ivacaftor. Avoid. [Severe] Study
Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to lopinavir. Avoid. [Severe] Study
Carbamazepine is predicted to decrease the exposure to lipiodol. Avoid. [Severe] Theoretical
Antiepileptics (fosphenytoin, phenytoin) decrease the effects of levodopa. [Moderate] Study
Antiepileptics (carbamazepine, eslicarbazepine, fosphenytoin, oxcarbazepine, perampanel, phenobarbital, phenytoin, primidone, rufinamide, topiramate) are predicted to decrease the efficacy of levonorgestrel. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical
Antiepileptics (fosphenytoin, phenytoin) increase the risk of hypothyroidism when given with levothyroxine. [Moderate] Study
Antiepileptics (phenobarbital, primidone) are predicted to decrease the effects of levothyrione. [Moderate] Theoretical
Carbamazepine increases the risk of hypothyroidism when given with levothyrione. Monitor and adjust dose. [Moderate] Study
Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to linagliptin. [Moderate] Study
Antiepileptics (fosphenytoin, phenytoin) are predicted to increase the risk of hypothyroidism when given with liothyronine. [Moderate] Theoretical
Antiepileptics (phenobarbital, primidone) are predicted to decrease the effects of liothyronine. [Moderate] Theoretical
Carbamazepine increases the risk of neurotoxicity when given with lithium. [Severe] Anecdotal
Oxcarbazepine is predicted to increase the risk of neurotoxicity when given with lithium. [Severe] Theoretical
Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to lomitapide. Monitor and adjust dose. [Moderate] Theoretical → Also see TABLE 1, p. 1264
Antiepileptics (fosphenytoin, phenytoin) decrease the effects of loop diuretics (furosemide). [Moderate] Study
Lumacaftor is predicted to decrease the exposure to antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone). Avoid. [Severe] Theoretical
Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to luridone. Avoid. [Moderate] Study → Also see TABLE 11, p. 1266
Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to macitentan. Avoid. [Severe] Study
Macrolides (clarithromycin) slightly increase the concentration of carbamazepine. Monitor carbamazepine concentration and adjust dose. [Severe] Study
Macrolides (clarithromycin) are predicted to slightly increase the exposure to perampanel. [Mild] Study
Macrolides (erythromycin) markedly increase the concentration of carbamazepine. Monitor carbamazepine concentration and adjust dose. [Severe] Study
Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to maraviroc. Adjust dose. [Severe] Study
Levetiracetam decreases the clearance of methotrexate. [Severe] Anecdotal
Antiepileptics (phenobarbital, primidone) are predicted to decrease the exposure to metronidazole. [Moderate] Study
Antiepileptics — Antiepileptics

Antiepileptics (continued)

- Antiepileptics (fosphenytoin, phenobarbital, phenytoin primidone) decrease the effects of metyrapone. Avoid. [Moderate] Study
- Antiepileptics (phenobarbital, primidone) are predicted to decrease the exposure to mianserin. [Moderate] Study → Also see TABLE 11 p. 1266

» Carbamazepine markedly decreases the exposure to mianserin. Adjust dose. [Moderate] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to midazolam. Monitor and adjust dose. [Moderate] Study → Also see TABLE 11 p. 1266

» Carbamazepine markedly decreases the exposure to mianserin. Adjust dose. [Moderate] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to mirtazapine. Adjust dose. [Moderate] Study → Also see TABLE 11 p. 1266

» Carbamazepine (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to modafinil. [Mild] Theoretical
- Antiepileptics (fosphenytoin, phenytoin) are predicted to decrease the exposure to modafinil and modafinil is predicted to increase the concentration of antiepileptics (fosphenytoin, phenytoin). Monitor concentration and adjust dose. [Moderate] Theoretical
- Antiepileptics (phenobarbital, primidone) are predicted to increase the effects of monoamine-oxidase A and B inhibitors, irreversible. [Severe] Theoretical

» Carbamazepine is predicted to decrease the effects of monoclonal antibodies (brentuximab vedotin). [Severe] Theoretical
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to monoclonal antibodies (trastuzumab emtansine). [Severe] Theoretical
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to montelukast. [Mild] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to markedly decrease the exposure to naloxegol. Avoid. [Moderate] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to slightly decrease the exposure to netupitant. Avoid. [Moderate] Study
- Antiepileptics (fosphenytoin, phenytoin) decrease the effects of (but acute use increases the effects of) neuromuscular blocking drugs, non-depolarising (atracurium, cisatracurium, pancuronium, rocuronium, vecuronium). [Moderate] Study

» Carbamazepine is predicted to decrease the effects of (but acute use increases the effects of) neuromuscular blocking drugs, non-depolarising (atracurium, cisatracurium, pancuronium, rocuronium, vecuronium). [Moderate] Study

» Nevirapine is predicted to decrease the concentration of antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) and antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the concentration of nevirapine. [Severe] Theoretical

- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to moderately decrease the exposure to nilotinib. Avoid. [Severe] Study

» Carbamazepine is predicted to decrease the exposure to nintedanib. [Moderate] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to nitisine. Adjust nitisine dose. [Moderate] Theoretical
- Antiepileptics (carbamazepine, eslicarbazepine, fosphenytoin, oxcarbazepine, perampanel, phenobarbital, phenytoin, primidone, rufinamide, topiramate) are predicted to decrease the efficacy of noxurex. FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Anecdotal

» Carbamazepine potentially decreases the exposure to olanzapine. Monitor and adjust dose. [Moderate] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to olaparib. Avoid. [Moderate] Theoretical

» Carbamazepine is predicted to decrease the exposure to omibasvir. Avoid. [Severe] Theoretical
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to ondansetron. [Moderate] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to opioids (alfentanil, fentanyl). [Moderate] Study → Also see TABLE 11 p. 1266

» Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to opioids (buprenorphine). Monitor and adjust dose. [Moderate] Theoretical → Also see TABLE 11 p. 1266

» Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) decrease the exposure to opioids (methadone). Monitor and adjust dose. [Severe] Study → Also see TABLE 11 p. 1266

» Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to opioids (oxycodeine). Monitor and adjust dose. [Moderate] Study → Also see TABLE 11 p. 1266

» Carbamazepine decreases the concentration of opioids (tramadol). Adjust dose. [Severe] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to moderately decrease the exposure to osimertinib. Avoid. [Moderate] Study

» Oxbutynin potentially increases the risk of overheating and dehydration when given with zonisamide. Avoid in children. [Severe] Theoretical
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to palbociclib. Avoid. [Severe] Study

» Carbamazepine decreases the concentration of paliperidone. Adjust dose. [Moderate] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to panobinostat. Avoid. [Moderate] Theoretical
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to paracetamol. [Moderate] Study → Also see TABLE 1 p. 1264

» Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to paritaprevir (with ritonavir and ombitasvir). Avoid. [Severe] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to pazopanib. Avoid. [Severe] Theoretical

» Phenothiazines (chlorpromazine) decrease the concentration of antiepileptics (phenobarbital, primidone) and antiepileptics (phenobarbital, primidone) decrease the concentration of phenothiazines (chlorpromazine). [Moderate] Study → Also see TABLE 11 p. 1266

» Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to phosphodiesterase type-5 inhibitors (sildenafil, tadalafil). Avoid. [Severe] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to phosphodiesterase type-5 inhibitors (sildenafil, vardenafil). Avoid. [Moderate] Theoretical

» Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to pirfenidone. Avoid. [Moderate] Theoretical

- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to moderately decrease the exposure to pinitol. Avoid. [Moderate] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to praziquantel. Avoid. [Moderate] Study
Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to increase the risk of hypersensitivity reactions when given with procarbazine. 
Severe Anecdotal

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to quetiapine. Moderate Study  Also see Table 11 p. 1266

Quinolones (ciprofloxacin) affect the concentration of antiepileptics (fosphenytoin, phenytoin). Monitor concentration and adjust dose. Severe Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to ranolazine. Avoid. Severe Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to rifampicin. Moderate Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to reboxetine. Moderate Anecdotal

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to regorafenib. Avoid. Moderate Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to repaglinide. Monitor blood glucose and adjust dose. Moderate Study

Antiepileptics (phenobarbital, primidone) are predicted to decrease the exposure to rifampicin and rifampicin is predicted to decrease the exposure to antiepileptics (phenobarbital, primidone). Use with caution and adjust dose. Moderate Study

Rifampicin decreases the concentration of antiepileptics (fosphenytoin, phenytoin). Use with caution and adjust dose. Moderate Study

Rifampicin slightly decreases the exposure to brivaracetam. Adjust dose. Moderate Study

Rifampicin markedly increases the clearance of lamotrigine. Adjust lamotrigine dose. p. 303. Moderate Study

Rifampicin is predicted to decrease the exposure to perampanel. Monitor and adjust dose. Moderate Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) markedly decrease the exposure to rilpivirine. Avoid. Severe Study

Oxcarbazepine is predicted to decrease the concentration of rilpivirine. Avoid. Severe Theoretical

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to risperidone. Adjust risperidone dose. Moderate Study  Also see Table 11 p. 1266

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to moderately decrease the exposure to rivaroxaban. Avoid unless patient can be monitored for signs of thrombosis. Severe Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to ruxolitinib. Monitor and adjust dose. Moderate Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to saxaglitin. Moderate Study

Valproate is predicted to increase the exposure to selexipag. Unknown Theoretical

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to simeprevir. Avoid. Severe Study

Oxcarbazepine is predicted to decrease the exposure to simeprevir. Avoid. Severe Theoretical

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the concentration of sirolimus. Avoid. Severe Study

Valproate increases the exposure to sodium oxybate. Adjust sodium oxybate dose. p. 466. Moderate Study

Valproate potentially decreases the effects of sodium phenylbutyrate. Moderate Anecdotal

Antiepileptics (carbamazepine, fosphenytoin, oxcarbazepine, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to sofosbuvir. Avoid. Severe Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to solifenacín. Moderate Theoretical

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to sorafenib. Moderate Theoretical

SSRIs (fluoxetine, fluvoxamine) are predicted to increase the concentration of antiepileptics (fosphenytoin, phenytoin). Monitor and adjust dose. Severe Anecdotal

SSRIs (sertaline) potentially increase the risk of toxicity when given with antiepileptics (fosphenytoin, phenytoin). Monitor concentration and adjust dose. Severe Anecdotal

Antiepileptics (fosphenytoin, phenytoin) decrease the concentration of SSRIs (paroxetine). Moderate Study

St John’s Wort is predicted to decrease the concentration of antiepileptics (fosphenytoin, phenobarbital, phenytoin, primidone). Avoid. Severe Theoretical

St John’s Wort is predicted to decrease the exposure to brivaracetam. Moderate Theoretical

St John’s Wort is predicted to decrease the concentration of carbamazepine. Monitor and adjust dose. Moderate Theoretical

St John’s Wort is predicted to decrease the exposure to perampanel. Monitor and adjust dose. Moderate Theoretical

Antiepileptics (carbamazepine, eslicarbazepine) are predicted to decrease the exposure to stavudine (atazanavir, simvastatin). Monitor and adjust dose. Moderate Theoretical

Carbamazepine moderately decreases the exposure to statins (simvastatin). Monitor and adjust dose. Severe Study  Also see Table 1 p. 1264

Elisacarbazepine moderately decreases the exposure to statins (simvastatin). Monitor and adjust dose. Moderate Study

Sulfipyrazone increases the concentration of antiepileptics (fosphenytoin, phenytoin). Moderate Study

Sulfonamides (sulfadiazine) are predicted to increase the concentration of fosphenytoin. Monitor and adjust dose. Moderate Study

Sulfonamides (sulfadiazine) increase the concentration of phenytoin. Monitor and adjust dose. Moderate Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to sunitinib. Avoid or adjust sunitinib dose. p. 914. Moderate Study

Antiepileptics (fosphenytoin, phenytoin) increase the effects of suxamethonium. Moderate Study

Carbamazepine increases the risk of prolongued neuromuscular blockade when given with suxamethonium. Moderate Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) decrease the concentration of tacrolimus. Monitor and adjust dose. Severe Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to taxanes (cabazitaxel, paclitaxel). Avoid. Severe Study  Also see Table 12 p. 1267

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to taxanes (docetaxel). Severe Theoretical  Also see Table 12 p. 1267

toga fumar potentially increases the concentration of antiepileptics (fosphenytoin, phenytoin). Monitor concentration and adjust dose. Severe Anecdotal

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the concentration of temsirolimus. Avoid. Severe Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) decrease the exposure to tacrolimus (doycylcine). Monitor and adjust dose. Moderate Study  Also see Table 1 p. 1264

Antiepileptics (phenobarbital, primidone) are predicted to increase the clearance of theophylline. Adjust dose. Moderate Theoretical

Downloaded from www.medicalbr.com
Antiepileptics (continued)

- Carbamazepine potentially increases the clearance of theophylline and theophylline decreases the exposure to carbamazepine. Adjust dose. [Moderate] Anecdotal
- Phenytoin is predicted to increase the clearance of theophylline. Adjust dose. [Moderate] Study
- Phenytoin is predicted to decrease the exposure to theophylline. Adjust dose. [Moderate] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to markedly decrease the exposure to ticagrelor. Avoid. [Severe] Study
- Antiepileptics (fosphenytoin, phenytoin) moderately decrease the exposure to tizanidine. [Mild] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to tolvaptan. Avoid. [Severe] Study
- Antiepileptics (fosphenytoin, phenytoin) increase the clearance of topotecan. [Moderate] Study
- Carbamazepine decreases the exposure to tricyclic antidepressants. Adjust dose. [Moderate] Study
- Tricyclic antidepressants (clomipramine, imipramine) potentially increase the risk of overheating and dehydration when given with zonisamide. Avoid in children. [Severe] Theoretical
- Trimethoprim increases the concentration of antiepileptics (fosphenytoin, phenytoin). [Moderate] Study
- Antiepileptics (carbamazepine, eslicarbazepine, fosphenytoin, oxcarbazepine, perampanel, phenobarbital, phenytoin, primidone, rufinamide, topiramate) are predicted to decrease the exposure to toremifene. Avoid. [Moderate] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to trimethoprim. Avoid. [Severe] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to vandetanib. Avoid. [Moderate] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to velpatasvir. Avoid. [Severe] Study
- Oxcarbazepine is predicted to decrease the exposure to velpatasvir. Avoid. [Severe] Theoretical
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to vemurafenib. Avoid. [Severe] Theoretical
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to venetoclax. Avoid. [Severe] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to vinca alkaloids (vinblastine, vincristine, vindesine). [Severe] Theoretical → Also see TABLE 1 p. 1264 → Also see TABLE 12 p. 1267
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to vinca alkaloids (vinflunine). Avoid. [Severe] Theoretical → Also see TABLE 12 p. 1267
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to vinorelbine. Use with caution or avoid. [Severe] Theoretical → Also see TABLE 12 p. 1267
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to vismodegib. Avoid. [Moderate] Theoretical
- Antiepileptics (fosphenytoin, phenytoin) decrease the effects of vitamin D substances. [Moderate] Study
- Antiepileptics (phenobarbital, primidone) are predicted to decrease the effects of vitamin D substances. [Moderate] Theoretical
- Carbamazepine is predicted to decrease the effects of vitamin D substances. [Moderate] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to vortioxetine. Monitor and adjust dose. [Moderate] Study
- Valproate slightly increases the exposure to zidovudine. [Moderate] Study
- Carbamazepine moderately decreases the exposure to zolpidem. [Moderate] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to zopiclone. Adjust dose. [Moderate] Study → Also see TABLE 11 p. 1266

Antifungals, azoles → see TABLE 1 p. 1264 (hepatotoxicity), TABLE 9 p. 1266 (QT-interval prolongation)

clotrimazole - fluconazole - isavuconazole - itraconazole - ketoconazole - miconazole - posaconazole - voriconazole

- In general, fluconazole interactions relate to multiple-dose treatment.
- The use of carbonated drinks, such as cola, improves itraconazole, ketoconazole, and posaconazole bioavailability.
- Disulfiram-like reaction might occur with ketoconazole on consumption of alcohol.
- Since systemic absorption can follow topical application, the possibility of interactions with topical ketoconazole should be borne in mind.
- Interactions of miconazole apply to the oral gel formulation, as a sufficient quantity can be absorbed to cause systemic effects. Systemic absorption from intravaginal and topical formulations might also occur.
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to abiraterone. [Severe] Theoretical
- Antifungals, azoles (itraconazole, ketoconazole) are predicted to increase the exposure to alfalbine. Separate administration by 1.2 hours. [Moderate] Study
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to aldosterone antagonists (eplerenone). Adjust eplerenone dose, p. 185. [Severe] Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to markedly increase the exposure to aldosterone antagonists (eplerenone). Avoid. [Severe] Study
- Itraconazole markedly increases the exposure to aliskiren. Avoid. [Severe] Study
- Ketoconazole moderately increases the exposure to aliskiren. [Moderate] Study
- Itraconazole increases the risk of busulfan toxicity when given with alkylating agents (busulfan). Monitor and adjust dose. [Moderate] Study
- Miconazole is predicted to increase the concentration of alkylating agents (busulfan). Use with caution and adjust dose. [Moderate] Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) increase the exposure to almotriptan. [Mild] Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to moderately increase the exposure to alpha blockers (alfuzosin, tamsulosin). Use with caution or avoid. [Moderate] Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to alpha blockers (doxazosin). [Moderate] Study
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to alpha blockers (tamsulosin). [Moderate] Theoretical
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to alprazolam. [Severe] Study
Antifungals, azoles — Antifungals, azoles

- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) moderately increase the exposure to alprazolam. Avoid. (Moderate) Study
- Miconazole is predicted to increase the exposure to alprazolam. Use with caution and adjust dose. (Moderate) Theoretical
- Miconazole potentially decreases the exposure to aminoglycosides (tobramycin). (Moderate) Anecdotal
- Antacids decrease the absorption of itraconazole. Antacids should be taken 1 hour before or 2 hours after itraconazole. (Moderate) Study
- Antacids decrease the absorption of ketoconazole. Separate administration by at least 2 hours. (Moderate) Study
- Antiarrhythmics (dronedarone) are predicted to increase the exposure to ketoconazole. (Severe) Theoretical
- Miconazole is predicted to increase the exposure to antiarrhythmics (disopyramide). Use with caution and adjust dose. (Severe) Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to antifungals, azoles (itraconazole, ketoconazole, voriconazole). Avoid. (Severe) Theoretical
- Fluconazole is predicted to increase the exposure to antifungals, azoles (itraconazole, ketoconazole, voriconazole). Avoid. (Severe) Study → Also see TABLE 9 p. 1266
- Posaconazole is predicted to increase the exposure to antifungals, azoles (itraconazole, ketoconazole, voriconazole). Avoid. (Severe) Theoretical
- Antiepileptics (Carbamazepine) are predicted to decrease the efficacy of fluconazole and fluconazole increases the concentration of antiepileptics (carbamazepine). Avoid or monitor carbamazepine concentration and adjust dose accordingly. (Severe) Theoretical → Also see TABLE 1 p. 1264
- Antiepileptics (Carbamazepine) are predicted to decrease the efficacy of ketoconazole and ketoconazole slightly increases the concentration of antiepileptics (carbamazepine). Avoid or monitor carbamazepine concentration and adjust dose accordingly. (Moderate) Study
- Antiepileptics (Carbamazepine) are predicted to decrease the efficacy of posaconazole and posaconazole increases the concentration of antiepileptics (carbamazepine). Avoid. (Moderate) Theoretical
- Antiepileptics (Carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to isavuconazole. Avoid. (Severe) Study
- Antiepileptics (Fosphenytoin) very markedly decrease the exposure to phenobarbital. Avoid for 14 days before and during treatment with itraconazole. (Moderate) Study
- Antiepileptics (Phenobarbital) decrease the concentration of itraconazole. Avoid phenobarbital for 14 days before and during treatment with itraconazole. (Moderate) Study
- Antiepileptics (Phenobarbital) are predicted to decrease the concentration of ketoconazole. Avoid. (Moderate) Study
- Antiepileptics (Phenobarbital) are predicted to decrease the concentration of posaconazole. Avoid. (Moderate) Study
- Antiepileptics (Phenobarbital, primidone) are predicted to decrease the concentration of voriconazole. Avoid. (Moderate) Theoretical
- Antiepileptics (Phenytoin) very markedly decrease the exposure to itraconazole. Avoid phenytoin for 14 days before and during treatment with itraconazole. (Moderate) Study
- Antiepileptics (Phenytoin) decrease the exposure to voriconazole and voriconazole increases the exposure to antiepileptics (phenytoin). Avoid or adjust voriconazole dose and monitor phenytoin concentration, p. 566. (Moderate) Study
- Antiepileptics (Primidone) are predicted to decrease the concentration of itraconazole. (Moderate) Theoretical
- Miconazole increases the risk of carbamazepine toxicity when given with antiepileptics (carbamazepine). Monitor and adjust dose. (Severe) Anecdotal
- Miconazole increases the risk of phenytoin toxicity when given with antiepileptics (fosphenytoin). Monitor and adjust dose. (Severe) Anecdotal
- Fluconazole increases the concentration of antiepileptics (fosphenytoin, phenytoin). Monitor concentration and adjust dose. (Moderate) Study
- Antiepileptics (Carbamazepine) are predicted to decrease the concentration of antiepileptics (itraconazole, voriconazole) and antifungals, azoles (itraconazole, voriconazole) and antifungals, azoles (itraconazole, voriconazole) increase the concentration of antiepileptics (carbamazepine). Avoid or adjust dose. (Moderate) Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to slightly increase the exposure to antiepileptics (perampanel). (Mid) Study
- Miconazole increases the risk of phenytoin toxicity when given with antiepileptics (phenytoin). Monitor and adjust dose. (Severe) Anecdotal
- Antifungals, azoles (fluconazole) are predicted to increase the exposure to antifungals, azoles (itraconazole, voriconazole). Avoid. (Severe) Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to antifungals, azoles (itraconazole, ketoconazole, voriconazole). Avoid or monitor side effects. (Severe) Study
- Antifungals, azoles (posaconazole) are predicted to increase the exposure to antifungals, azoles (isavuconazole). Avoid. (Moderate) Theoretical
- Miconazole is predicted to increase the exposure to antihistamines, non-sedating (mizolastine). Avoid. (Moderate) Theoretical
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to antihistamines, non-sedating (mizolastine). (Severe) Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to antihistamines, non-sedating (mizolastine). Avoid. (Severe) Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to antimalarials (artemether) (with lumefantrine). (Moderate) Study → Also see TABLE 9 p. 1266
- Ketoconazole increases the exposure to antimalarials (mefloquine). (Moderate) Study
- Antifungals, azoles (fluconazole, itraconazole, posaconazole, voriconazole) are predicted to increase the exposure to antimalarials (mefloquine). (Moderate) Theoretical
- Antifungals, azoles (fluconazole, isavuconazole, itraconazole, ketoconazole, posaconazole, voriconazole) are predicted to increase the concentration of antimalarials (piperaquine). (Severe) Theoretical
- Itraconazole is predicted to increase the exposure to apixaban. Avoid. (Severe) Theoretical
- Ketoconazole slightly to moderately increases the exposure to apixaban. Avoid. (Severe) Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to markedly increase the exposure to aprepitant. (Moderate) Study
- Aprepitant is predicted to increase the exposure to isavuconazole. (Moderate) Theoretical
Antifungals, azoles (continued)

- **Antifungals, azoles** (itraconazole, ketoconazole, voriconazole) are predicted to slightly increase the exposure to *aripiprazole*. Adjust aripiprazole dose, p. 376. [Moderate Study]
- **Antifungals, azoles** (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to *axitinib*. [Moderate] *Theoretical*
- **Antifungals, azoles** (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to *axitinib*. Avoid or adjust dose. [Moderate Study]
- **Antifungals, azoles** (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to *bedaquiline*. Avoid prolonged use. [Mild] *Theoretical*
- **Antifungals, azoles** (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to *bedaquiline*. Avoid prolonged use. [Mild] *Study* → Also see TABLE 9 p. 1266
- **Antifungals, azoles** (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to *beta blockers*, non-selective (nadolol). [Moderate] *Study*
- **Antifungals, azoles** (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to *beta, agonists (salmeterol)*. Avoid. [Severe] *Study*
- **Antifungals, azoles** (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to *bosentan*. Avoid. [Severe] *Study*
- **Itraconazole** is predicted to decrease the exposure to *isavuconazole*. Avoid. [Severe] *Theoretical*
- **Itraconazole** is predicted to increase the exposure to *bosentan*. [Moderate] *Theoretical*
- **Ketoconazole** moderately increases the exposure to *bosentan*. [Moderate] *Study*
- **Voriconazole** is predicted to increase the exposure to *bosentan*. Avoid. [Severe] *Theoretical*
- **Fluconazole** is predicted to increase the exposure to *bosutinib*. Avoid or adjust bosutinib dose. [Severe] *Theoretical*
- **Antifungals, azoles** (itraconazole, ketoconazole, voriconazole) are predicted to markedly increase the exposure to *bosutinib*. Avoid or adjust bosutinib dose. [Severe] *Study* → Also see TABLE 9 p. 1266
- **Antifungals, azoles** (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to *buspirone*. Use with caution and adjust dose. [Moderate] *Study*
- **Antifungals, azoles** (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to *buspirone*. Adjust buspirone dose, p. 325. [Severe] *Study*
- **Miconazole** is predicted to increase the concentration of *buspirone*. Use with caution and adjust dose. [Moderate] *Theoretical*
- **Antifungals, azoles** (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to *cabozantinib*. [Moderate] *Theoretical*
- **Antifungals, azoles** (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to *cabozantinib*. [Moderate] *Study* → Also see TABLE 9 p. 1266
- **Calcium channel blockers** (diltiazem, verapamil) are predicted to increase the exposure to *isavuconazole*. [Moderate] *Theoretical*
- **Miconazole** is predicted to increase the exposure to *calcium channel blockers* (amlodipine, clevidipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine). Use with caution and adjust dose. [Moderate] *Theoretical*
- **Antifungals, azoles** (fluconazole, isavuconazole, itraconazole, ketoconazole, posaconazole, voriconazole) are predicted to increase the exposure to *calcium channel blockers* (amlodipine, felodipine, isradipine, lacidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose. [Moderate] *Study*
- **Fluconazole** (high-dose) is predicted to increase the exposure to *calcium channel blockers* (diltiazem, verapamil). [Moderate] *Theoretical*
- **Posaconazole** is predicted to increase the exposure to *calcium channel blockers* (diltiazem, verapamil). [Moderate] *Theoretical*
- **Antifungals, azoles** (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to *calcium channel blockers* (diltiazem, verapamil). [Moderate] *Theoretical*
- **Antifungals, azoles** (itraconazole, ketoconazole, voriconazole) are predicted to markedly increase the exposure to *calcium channel blockers* (amlodipine, verapamil). [Severe] *Study*
- **Antifungals, azoles** (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to *cannabin extract*. Use with caution and adjust dose. [Moderate] *Theoretical*
- **Antifungals, azoles** (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to *ciclosporin*. [Severe] *Study*
- **Miconazole** increases the concentration of *ciclosporin*. Monitor and adjust dose. [Severe] *Anecdotal*
- **Antifungals, azoles** (itraconazole, ketoconazole, voriconazole) are predicted to moderately increase the exposure to *ciclosporin*. Adjust *ciclosporin* dose, p. 226. [Moderate] *Study*
- **Fluconazole** is predicted to increase the exposure to *ciclosporin*. Adjust *ciclosporin* dose, p. 226. [Moderate] *Theoretical*
- **Miconazole** is predicted to increase the exposure to *ciclosporin*. Use with caution and adjust dose. [Moderate] *Theoretical*
- **Antifungals, azoles** (itraconazole, ketoconazole, voriconazole) are predicted to moderately increase the exposure to *ciclosporin*. Adjust dose. [Moderate] *Study*
- **Fluconazole** is predicted to decrease the efficacy of *clopidogrel*. Avoid. [Severe] *Theoretical*
- **Voriconazole** is predicted to decrease the efficacy of *clopidogrel*. Avoid. [Severe] *Study*
- **Cobicistat** is predicted to increase the exposure to antifungals, azoles (fluconazole, posaconazole). [Moderate] *Theoretical*
- **Cobicistat** is predicted to increase the exposure to *isavuconazole*. Avoid or monitor side effects. [Severe] *Study*
- **Cobicistat** is predicted to increase the exposure to *itraconazole*. Adjust *itraconazole* dose, p. 564. [Moderate] *Theoretical*
- **Cobicistat** is predicted to increase the exposure to *ketonazole*. Adjust *ketonazole* dose, p. 641. [Moderate] *Theoretical*
- **Cobicistat** is predicted to affect the exposure to *voriconazole*. Avoid. [Moderate] *Theoretical*
- **Antifungals, azoles** (fluconazole, isavuconazole, miconazole, posaconazole) are predicted to increase the exposure to *cimetidine*. [Severe] *Theoretical*
- **Antifungals, azoles** (itraconazole, ketoconazole, voriconazole) are predicted to markedly increase the exposure to *cimetidine*. Avoid or monitor for toxicity. [Severe] *Study*
- **Antifungals, azoles** (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to *colchicine*. Adjust *colchicine* dose, p. 1020. [Severe] *Study*
- **Antifungals, azoles** (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to *colchicine*. Avoid or adjust *colchicine* dose, p. 1020. [Severe] *Study*
- **Antifungals, azoles** (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to corticosteroids (budesonide). Avoid. [Severe] *Study*
- **Antifungals, azoles** (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to corticosteroids (budesonide). Avoid. [Severe] *Study*
- **Antifungals, azoles** (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to corticosteroids (budesonide). Avoid. [Severe] *Study*
- **Antifungals, azoles** (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to corticosteroids (budesonide). Avoid. [Severe] *Study*
- **Miconazole** is predicted to increase the concentration of *corticosteroids* (methylprednisolone). Monitor and adjust dose. [Moderate] *Theoretical*
Antifungals, azoles

- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to corticosteroids (methylprednisolone). Monitor and adjust dose. (Moderate) Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to corticosteroids (mometasone). (Moderate) Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the risk of side-effects when given with corticosteroids (triamcinolone). (Severe) Theoretical
- Fluconazole increases the anticoagulant effect of coumarins. Monitor INR and adjust dose. (Severe) Study
- Itraconazole potentially increases the anticoagulant effect of coumarins. (Severe) Anecdotal
- Ketoconazole potentially increases the anticoagulant effect of coumarins (warfarin). Monitor INR and adjust dose. (Severe) Anecdotal
- Miconazole greatly increases the anticoagulant effect of coumarins. (Severe) Study
- Voriconazole increases the anticoagulant effect of coumarins. Monitor INR and adjust dose. (Moderate) Study
- Antifungals, azoles (fluconazole, posaconazole) are predicted to increase the exposure to crizotinib. (Moderate) Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to moderately increase the exposure to crizotinib. Avoid. (Moderate) Study
- Crizotinib is predicted to increase the exposure to isavuconazole. (Moderate) Theoretical
- Antifungals, azoles, (itraconazole, ketoconazole) are predicted to increase the exposure to dabigatran. Avoid. (Severe) Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to dabrafenib. Use with caution or avoid. (Moderate) Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to moderately increase the exposure to dacatasvir. Adjust dacetasvir dose, p. 591. (Moderate) Study
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to slightly increase the exposure to darifenacin. (Moderate) Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to markedly very markedly increase the exposure to darifenacin. Avoid. (Severe) Study
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to dasatinib. (Severe) Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to markedly increase the exposure to dasatinib. Avoid. (Severe) Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) very slightly increase the exposure to delamanid. (Severe) Study
- Antifungals, azoles (fluconazole, voriconazole) moderately increase the exposure to diazepam. Monitor and adjust dose. (Moderate) Study
- Didanosine (buffered) decreases the exposure to antifungals, azoles (itraconazole, ketoconazole). Separate administration by 2 hours. (Severe) Study
- Itraconazole markedly increases the concentration of digoxin. Monitor and adjust dose. (Severe) Study
- Ketoconazole is predicted to markedly increase the concentration of digoxin. (Severe) Theoretical
- Posaconazole is predicted to increase the concentration of digoxin. (Severe) Theoretical
- Antifungals, azoles (fluconazole, isavuconazole, itraconazole, ketoconazole, posaconazole, voriconazole) increase the risk of QT-prolongation when given with domperidone. Avoid. (Severe) Study
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to dopamine receptor agonists (bromocriptine, cabergoline). (Severe) Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) increase the exposure to dopamine receptor agonists (bromocriptine, cabergoline). (Severe) Study
- Ketoconazole moderately increases the exposure to drospirenone. (Severe) Study
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to moderately increase the exposure to dutasteride. (Mild) Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to dutasteride. Monitor side effects and adjust dose. (Moderate) Theoretical
- Itraconazole is predicted to slightly increase the exposure to edoxaban. (Theoretical)
- Ketoconazole slightly increases the exposure to edoxaban. Adjust edoxaban dose, p. 122. (Severe) Study
- Efavirenz is predicted to decrease the exposure to isavuconazole. Avoid. (Severe) Theoretical
- Efavirenz slightly decreases the exposure to itraconazole. Avoid efavirenz for 14 days before and during treatment with itraconazole. (Moderate) Study
- Efavirenz moderately decreases the exposure to ketoconazole. (Severe) Study
- Efavirenz slightly decreases the exposure to posaconazole. Avoid. (Moderate) Study
- Efavirenz moderately decreases the exposure to voriconazole and voriconazole slightly increases the exposure to efavirenz. Adjust dose. (Severe) Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) slightly to moderately increase the exposure to elbasvir. Avoid. (Moderate) Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to markedly increase the exposure to eleriptan. Avoid. (Severe) Study
- Enzalutamide is predicted to decrease the exposure to isavuconazole. Avoid. (Severe) Study
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the risk of ergotism when given with ergometrine. (Severe) Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the risk of ergotism when given with ergotamine. Avoid. (Severe) Theoretical
- Miconazole is predicted to increase the exposure to ergotamine. Avoid. (Moderate) Theoretical
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the risk of ergotism when given with ergotamine. Avoid. (Theoretical)
- Miconazole is predicted to increase the exposure to ergotamine. Avoid. (Moderate) Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to erlotinib. (Moderate) Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to slightly increase the exposure to erlotinib. Use with caution and adjust dose. (Moderate) Study
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the concentration of everolimus. Avoid or adjust dose. (Moderate) Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the concentration of everolimus. Avoid. (Severe) Study
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to fosfoterodine. Adjust fosfoterodine dose in hepatic and renal impairment, p. 732. (Mild) Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to moderately increase the exposure to fosfoterodine. Adjust fosfoterodine dose; avoid in hepatic and renal impairment, p. 732. (Severe) Study
- Antifungals, azoles (itraconazole, ketoconazole) are predicted to increase the exposure to fidaxomicin. Avoid. (Moderate) Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to fosaprepitant. (Moderate) Theoretical
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to gefitinib. (Moderate) Theoretical
Antifungals, azoles (continued)

- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to gefitinib. [Moderate] Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to moderately to markedly increase the exposure to grapefruit juice. Avoid. [Moderate] Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to guanfacine. Adjust guanfacine dose, p. 335. [Moderate] Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to guanfacine. Adjust guanfacine dose, p. 335. [Moderate] Study
- H₂ receptor antagonists are predicted to decrease the absorption of itraconazole. Administer itraconazole capsules with an acidic beverage. [Moderate] Study
- H₂ receptor antagonists are predicted to decrease the absorption of ketoconazole. Administer ketoconazole with an acidic beverage. [Moderate] Study
- H₂ receptor antagonists are predicted to slightly decrease the exposure to posaconazole. Avoid use of posaconazole oral suspension. [Moderate] Study
- Itraconazole increases the concentration of haloperidol. [Moderate] Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to isavuconazole. Avoid or monitor side effects. [Severe] Study
- Fluconazole slightly increases the exposure to HIV-protease inhibitors (tipranavir). Avoid or adjust dose. [Moderate] Study
- HIV-protease inhibitors are predicted to increase the exposure to itraconazole. Use with caution and adjust dose. [Severe] Study
- HIV-protease inhibitors are predicted to increase the exposure to ketoconazole. Use with caution and adjust dose. [Moderate] Study
- Miconazole is predicted to increase the concentration of HIV-protease inhibitors. Use with caution and adjust dose. [Moderate] Theoretical
- Posaconazole is predicted to increase the exposure to HIV-protease inhibitors. [Moderate] Study
- HIV-protease inhibitors are predicted to affect the exposure to voriconazole and voriconazole potentially affects the exposure to HIV-protease inhibitors. [Severe] Study → Also see TABLE 9 p. 1266
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to ibritinib. Avoid or adjust ibritinib dose, p. 902. [Severe] Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to very markedly increase the exposure to ibritinib. Avoid or adjust ibritinib dose, p. 902. [Severe] Study
- Idelalisib is predicted to increase the exposure to isavuconazole. Avoid or monitor side effects. [Severe] Study
- Antifungals, azoles (fluconazole, posaconazole) are predicted to increase the exposure to imatinib. [Moderate] Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to imatinib. [Moderate] Study
- Imatinib is predicted to decrease the exposure to isavuconazole. [Moderate] Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the risk of toxicity when given with irinotecan. Avoid. [Moderate] Study
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to ivabradine. Adjust ivabradine dose, p. 205. [Severe] Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to ivabradine. Avoid. [Severe] Study
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to ivacaftor. Adjust ivacaftor dose, p. 281. [Severe] Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to ivacaftor. Adjust ivacaftor or lumacaftor with ivacaftor dose, p. 281. [Severe] Study
- Lanthanum is predicted to decrease the absorption of ketoconazole. Separate administration by at least 2 hours. [Moderate] Theoretical
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to lapatinib. [Moderate] Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to lapatinib. Avoid. [Moderate] Study → Also see TABLE 9 p. 1266
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to lomitapide. Avoid. [Severe] Study → Also see TABLE 1 p. 1264
- Clotrimazole is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. [Moderate] Theoretical
- Lumacaftor is predicted to decrease the exposure to antifungals, azoles (itraconazole, ketoconazole, voriconazole). [Moderate] Theoretical
- Lumacaftor is predicted to decrease the exposure to fluconazole. Adjust dose. [Mild] Theoretical
- Lumacaftor is predicted to decrease the exposure to posaconazole. Avoid. [Moderate] Theoretical
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to luridascine. [Moderate] Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to luridascine. Avoid. [Severe] Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to maraviroc. Adjust dose. [Severe] Study
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to midazolam. Monitor side effects and adjust dose. [Severe] Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to markedly increase the exposure to midazolam. Avoid or adjust midazolam dose. [Severe] Study
- Miconazole is predicted to increase the exposure to intravenous midazolam. Use with caution and adjust dose. [Moderate] Theoretical
- Miconazole is predicted to increase the exposure to oral midazolam. Avoid. [Moderate] Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to mirabegron. Adjust mirabegron dose in hepatic and renal impairment, p. 736. [Moderate] Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to mirtazapine. [Moderate] Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to modafinil. [Mild] Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) increase the risk of neutropenia when given with monoclonal antibodies (brentuximab vedotin). Monitor and adjust dose. [Severe] Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to monoclonal antibodies (trastuzumab emtansine). Avoid. [Severe] Theoretical
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to naloxegol. Adjust naloxegol dose and monitor side effects, p. 63. [Moderate] Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to markedly increase the exposure to naloxegol. Avoid. [Severe] Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to netupitant. [Mild] Study
Antifungals, azoles – Antifungals, azoles 1291

- **Netupitant** is predicted to decrease the exposure to isavuconazole. [Moderate] Theoretical
- **Fluconazole** slightly to moderately increases the exposure to **nivinavirine**. [Moderate] Study
- **Nevirapine** is predicted to decrease the exposure to **isavuconazole**. Avoid. [Severe] Theoretical
- **Nevirapine** moderately decreases the exposure to **itraconazole**. Avoid nevirapine for 14 days before and during treatment with itraconazole. [Moderate] Study
- **Nevirapine** moderately decreases the exposure to ketoconazole. Avoid. [Severe] Study
- **Nevirapine** is predicted to decrease the exposure to voriconazole and **voriconazole** increases the exposure to **nevirapine**. Monitor and adjust dose. [Severe] Theoretical
- Antifungals, azoles (fluconazole, posaconazole) are predicted to increase the exposure to nitinolin. [Moderate] Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to moderately increase the exposure to nitinolin. Avoid. [Severe] Study → Also see TABLE 9 p. 1266
- **Nilotinib** is predicted to increase the exposure to isavuconazole. [Moderate] Theoretical
- Antifungals, azoles (itraconazole, ketoconazole) are predicted to increase the exposure to nintedanib. [Moderate] Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to nitinol. Adjust nitinol dose. [Moderate] Theoretical
- Fluconazole moderately increases the exposure to **NSAID** (ciclofenac). Adjust ciclofenac dose, p. 1031. [Moderate] Study
- Voriconazole slightly increases the exposure to **NSAID** (diclofenac). Monitor and adjust dose. [Moderate] Study
- Voriconazole moderately increases the exposure to **NSAID** (ibuprofen). Adjust dose. [Moderate] Study
- Fluconazole increases the exposure to **NSAID** (paraxoxib). Monitor and adjust dose. [Moderate] Study
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to olaparib. Avoid or adjust olaparib dose, p. 919. [Moderate] Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to olaparib. Avoid or adjust olaparib dose, p. 919. [Moderate] Study
- **Miconazole** is predicted to increase the exposure to opioids (afentanil). Use with caution and adjust dose. [Moderate] Theoretical
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to opioids (afentanil, buprenorphine, fentanyl, oxycodone). Monitor and adjust dose. [Moderate] Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to opioids (afentanil, buprenorphine, fentanyl, oxycodone, sufentanil). Monitor and adjust dose. [Severe] Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to opioids (methadone). [Moderate] Theoretical → Also see TABLE 9 p. 1266
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to opioids (methadone, sufentanil). [Moderate] Theoretical
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to oxobutynin. [Mild] Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to oxobutynin. [Mild] Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to paflobicil. Avoid or adjust paflobicil dose, p. 909. [Severe] Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to panobinostat. Adjust panobinostat dose; in hepatic impairment avoid, p. 864. [Moderate] Study → Also see TABLE 9 p. 1266
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to partiprevir (with ritonavir and omibitasir). Avoid. [Severe] Theoretical
- **Posaconazole** is predicted to increase the exposure to paritaprevir (with ritonavir and omibitasir) and paritaprevir (with ritonavir and omibitasir) is predicted to increase the exposure to posaconazole. Avoid. [Severe] Theoretical
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to pazopanib. [Moderate] Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to pazopanib. Avoid or adjust pazopanib dose, p. 909. [Moderate] Study → Also see TABLE 9 p. 1266
- **Miconazole** greatly increases the anticoagulant effect of **phenindione**. [Severe] Theoretical
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to phosphodiesterase type-5 inhibitors (avanafil). Adjust avanafil dose, p. 765. [Moderate] Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to phosphodiesterase type-5 inhibitors (avanafil, vardenafil). Avoid. [Severe] Study → Also see TABLE 9 p. 1266
- **Miconazole** is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (sildenafil). Use with caution and adjust dose. [Severe] Theoretical
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to phosphodiesterase type-5 inhibitors (sildenafil). Monitor and adjust sildenafil dose, p. 766. [Moderate] Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to phosphodiesterase type-5 inhibitors (sildenafil). Avoid or adjust sildenafil dose, p. 766. [Severe] Study → Also see TABLE 9 p. 1266
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to phosphodiesterase type-5 inhibitors (tadalafil). [Severe] Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to phosphodiesterase type-5 inhibitors (tadalafil). Use with caution or avoid. [Severe] Study
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to phosphodiesterase type-5 inhibitors (tadalafil). Adjust dose. [Severe] Theoretical
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to pimozide. Avoid. [Severe] Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to pimozide. Avoid. [Severe] Study → Also see TABLE 9 p. 1266
- **Miconazole** is predicted to increase the exposure to pimozide. Avoid. [Moderate] Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to slightly increase the exposure to **ponatinib**. Monitor and adjust ponatinib dose, p. 911. [Moderate] Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to moderately increase the exposure to **praziquantel**. [Mild] Study
- Fluconazole is predicted to increase the exposure to **proton pump inhibitors**. [Mild] Study
- **Proton pump inhibitors** decrease the absorption of itraconazole. Administer itraconazole capsules with an acidic beverage. [Moderate] Study
- **Proton pump inhibitors** decrease the absorption of ketoconazole. Administer ketoconazole with an acidic beverage. [Moderate] Study
- **Proton pump inhibitors** decrease the absorption of posaconazole (oral suspension). Avoid. [Moderate] Study
- Voriconazole increases the exposure to proton pump inhibitors (esomeprazole, omeprazole). Adjust dose. [Moderate] Study
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to quetiapine. Avoid. [Moderate] Study
- Voriconazole increases the exposure to proton pump inhibitors (esomeprazole, omeprazole). Adjust dose. [Moderate] Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to quetiapine. Avoid. [Severe] Study
- **Posaconazole** increases the exposure to proton pump inhibitors (esomeprazole, omeprazole). Adjust dose. [Severe] Study
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to ranolazine. [Severe] Study

Also see

- TABLE 9 p. 1266
- Study
- TA p. 919
- BLE 9
- Appendix 1

A1

Interactions | Appendix 1

Downloaded from www.medicalbr.com
Antifungals, azoles (continued)

- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to ranolazine. Avoid. (Severe) Study → Also see TABLE 9 p. 1266

- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to reboxetine. Avoid. (Moderate) Study

- Miconazole is predicted to increase the concentration of reboxetine. Use with caution and adjust dose. (Moderate) Theoretical

- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to regorafenib. Avoid. (Moderate) Study

- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to repaglinide. (Moderate) Study

- Antifungals, azoles (fluconazole, itraconazole, ketoconazole, miconazole, voriconazole, posaconazole) are predicted to increase the exposure to retinoids (altretinoin). Adjust altretinoin dose, p. 1157. (Moderate) Theoretical

- Antifungals, azoles (fluconazole, ketoconazole, voriconazole) are predicted to increase the risk of tretinoin toxicity when given with retinoids (tretinoin). (Moderate) Study

- Antifungals, azoles (itraconazole, posaconazole) increase the concentration of rifabutin and rifabutin decreases the concentration of antifungals, azoles (itraconazole, posaconazole). Avoid. (Severe) Study

- Fluconazole increases the risk of uveitis when given with rifabutin. Adjust dose. (Severe) Study

- Rifabutin is predicted to decrease the exposure to isavuconazole. Avoid. (Severe) Theoretical

- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to decrease the concentration of ketoconazole. Avoid, (Severe) Theoretical

- Fluconazole increases the concentration of voriconazole and voriconazole increases the concentration of ketoconazole. Avoid or adjust voriconazole dose, p. 566. (Severe) Study

- Rifampicin slightly decreases the exposure to fluconazole. Adjust dose. (Moderate) Study

- Rifampicin is predicted to decrease the exposure to isavuconazole. Avoid. (Severe) Study

- Rifampicin markedly decreases the exposure to itraconazole. Avoid rifampicin for 14 days before and during treatment with itraconazole. (Moderate) Study

- Rifampicin markedly decreases the exposure to ketoconazole and ketoconazole potentially decreases the exposure to rifampicin. Avoid. (Moderate) Study

- Rifampicin is predicted to decrease the exposure to posaconazole. Avoid. (Moderate) Anecdotal

- Rifampicin very markedly decreases the exposure to voriconazole. Avoid. (Moderate) Study

- Itraconazole is predicted to increase the exposure to riociguat. Avoid. (Moderate) Study

- Ketoconazole moderately increases the exposure to riociguat. Avoid. (Moderate) Study

- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to risperidone. Adjust dose. (Moderate) Study → Also see TABLE 9 p. 1266

- Antifungals, azoles (itraconazole, ketoconazole) increase the exposure to rivaroxaban. Avoid. (Severe) Study

- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to rivaroxaban. Avoid. (Moderate) Theoretical

- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to ruxolitinib. (Moderate) Theoretical

- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to saxagliptin. (Mild) Study

- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to saxagliptin. (Moderate) Study

- Fluconazole is predicted to increase the exposure to selexipag. (Unknown) Theoretical

- Antifungals, azoles (fluconazole, isavuconazole, itraconazole, ketoconazole, posaconazole, voriconazole) are predicted to increase the exposure to simprevir. Avoid. (Severe) Study

- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) increase the concentration of sirolimus. Monitor and adjust dose. (Moderate) Study

- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the concentration of sirolimus. Avoid. (Severe) Study

- Miconazole is predicted to increase the concentration of sirolimus. Monitor and adjust dose. (Moderate) Study

- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the concentration of sirolimus. (Moderate) Anecdotal

- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to SSRIs (citalopram). (Severe) Theoretical → Also see TABLE 9 p. 1266

- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to SSRIs (dapoxetine). Adjust dapoxetine dose, p. 773. (Moderate) Theoretical

- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to moderately increase the exposure to SSRIs (dapsone). Avoid, or adjust dapoxetine dose, p. 773. (Severe) Study

- St John’s Wort is predicted to decrease the exposure to isavuconazole. Avoid. (Severe) Theoretical

- St John’s Wort moderately decreases the exposure to voriconazole. Avoid. (Moderate) Study

- Miconazole potentially increases the exposure to statins (atorvastatin). (Severe) Anecdotal

- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to statins (atorvastatin). Monitor and adjust dose. (Severe) Theoretical → Also see TABLE 1 p. 1264

- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to statins (atorvastatin). Avoid or adjust dose and monitor rhabdomyolysis. (Severe) Study → Also see TABLE 1 p. 1264

- Antifungals, azoles (fluconazole, miconazole) are predicted to increase the exposure to statins (fluvastatin). Avoid. (Severe) Study → Also see TABLE 1 p. 1264

- Miconazole is predicted to increase the exposure to statins (simvastatin). Avoid. (Severe) Theoretical

- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to statins (simvastatin). Use with caution and adjust simvastatin dose, p. 198. (Severe) Study → Also see TABLE 1 p. 1264

- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to statins (simvastatin). Avoid. (Severe) Study → Also see TABLE 1 p. 1264

- Antifungals, azoles (fluconazole, miconazole, voriconazole) are predicted to increase the exposure to sulfonyleurases. Use with caution and adjust dose. (Moderate) Study

- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to sunitinib. (Moderate) Theoretical

- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to slightly increase the exposure to sunitinib. Avoid or adjust sunitinib dose, p. 914. (Moderate) Study → Also see TABLE 9 p. 1266

- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the concentration of tacrolimus. (Severe) Study

- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the concentration of tacrolimus. Monitor and adjust dose. (Severe) Study

- Miconazole is predicted to increase the concentration of tacrolimus. Monitor and adjust dose. (Severe) Theoretical

- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to tasaden (cabazitaxel). (Moderate) Theoretical
Antifungals, azoles

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to taxanes (cabazitaxel). Avoid. (Severe) Study

Miconazole is predicted to increase the concentration of taxanes (docetaxel). Use with caution and adjust dose. (Moderate) Theoretical

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to moderately increase the exposure to taxanes (docetaxel). Avoid or adjust dose. (Severe) Study

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to taxanes (paclitaxel). (Severe) Theoretical

Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the concentration of temsirolimus. (Moderate) Theoretical

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the concentration of temsirolimus. Avoid. (Severe) Theoretical

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to markedly increase the exposure to ticagrelor. Avoid. (Severe) Study

Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to tolvaptan. Adjust dose. (Moderate) Theoretical

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to tolvaptan. Avoid. (Severe) Study → Also see TABLE 9 p. 1266

Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to topotecan. (Severe) Study

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to toremifene. (Moderate) Theoretical → Also see TABLE 9 p. 1266

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to trabectedin. Avoid or adjust dose. (Severe) Theoretical → Also see TABLE 1 p. 1264

Antifungals, azoles (itraconazole, ketoconazole) are predicted to increase the concentration of tramepralin. (Moderate) Theoretical

Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to trazodone. (Moderate) Theoretical

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to moderately increase the exposure to trazodone. Avoid or adjust dose. (Moderate) Study

Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to uliprastal. Avoid if used for uterine fibroids. (Moderate) Study

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to ulipristal. Avoid if used for uterine fibroids. (Severe) Study

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to vemurafenib. (Severe) Theoretical → Also see TABLE 9 p. 1266

Antifungals, azoles (fluconazole, isavuconazole, itraconazole, ketoconazole, posaconazole, voriconazole) are predicted to increase the exposure to venetoclax. Avoid or adjust venetoclax dose, p. 919. (Severe) Study → Also see TABLE 9 p. 1266

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to venlafaxine. (Moderate) Theoretical

Antifungals, azoles (fluconazole, isavuconazole, itraconazole, ketoconazole, posaconazole, voriconazole) are predicted to increase the exposure to vinca alkaloids. (Severe) Theoretical → Also see TABLE 1 p. 1264 → Also see TABLE 9 p. 1266

Miconazole is predicted to increase the concentration of vinca alkaloids. Use with caution and adjust dose. (Moderate) Theoretical

Antifungals, azoles (clotrimazole, ketoconazole) are predicted to decrease the exposure to vitamin D substances (colecalciferol). (Moderate) Theoretical

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to vitamin D substances (paricalcitol). (Moderate) Study

Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to zopiclone. Adjust dose. (Moderate) Theoretical

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to zopiclone. Adjust dose. (Moderate) Theoretical

Antihistamines, non-sedating → see TABLE 9 p. 1266 (QT-interval prolongation)

Acrivastine · Azelastine · Bilastine · Citizine · Desloratadine · Fexofenadine · Levocetirizine · Loratadine · Mizolastine

**Food and Lifestyle**

Apple juice and orange juice decrease the exposure to fexofenadine.

**Antacids** decrease the absorption of fexofenadine. Separate administration by 2 hours. (Mild) Study

Antiarrhythmics (dronedarone) are predicted to increase the exposure to antihistamines, non-sedating (fexofenadine, mizolastine). (Severe) Theoretical

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to mizolastine. Avoid. (Severe) Study

Antifungals, azoles (miconazole) are predicted to increase the exposure to mizolastine. Avoid. (Moderate) Theoretical

Aprepitant is predicted to increase the exposure to mizolastine. (Severe) Theoretical

Antihistamines, non-sedating are predicted to decrease the effects of betahistine. (Moderate) Theoretical

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to mizolastine. (Severe) Theoretical

Ceritinib is predicted to increase the exposure to fexofenadine. (Moderate) Theoretical

Cobicistat is predicted to increase the exposure to mizolastine. Avoid. (Severe) Study

Crizotinib is predicted to increase the exposure to mizolastine. (Severe) Theoretical

Grapefruit juice slightly decreases the exposure to bilastine. Bilastine should be taken 1 hour before or 2 hours after grapefruit juice. (Moderate) Study

Antihistamines, non-sedating are predicted to decrease the effects of histamine. Avoid. (Severe) Theoretical

HIV- protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to mizolastine. Avoid. (Severe) Study

HIV- protease inhibitors (indinavir) are predicted to increase the exposure to mizolastine. (Severe) Theoretical

Idealisib is predicted to increase the exposure to mizolastine. Avoid. (Severe) Study

Imatinib is predicted to increase the exposure to mizolastine. (Severe) Theoretical

Lapatinib is predicted to increase the exposure to fexofenadine. (Moderate) Theoretical

Lumacaftor is predicted to affect the exposure to fexofenadine. Monitor and adjust dose. (Moderate) Theoretical

Macrolides (clarithromycin) are predicted to increase the exposure to mizolastine. Avoid. (Severe) Study

Macrolides (erythromycin) are predicted to increase the exposure to mizolastine. (Severe) Theoretical

Mirabegron is predicted to increase the exposure to fexofenadine. (Mild) Theoretical

Monoamine-oxidase A and B inhibitors, irreversible are predicted to increase the risk of antimuscarinic side-effects when given with antihistamines, non-sedating. Avoid. (Severe) Theoretical

Netupitant is predicted to increase the exposure to mizolastine. (Severe) Theoretical

Nilotinib is predicted to increase the exposure to mizolastine. (Severe) Theoretical

Rifampicin is predicted to decrease the exposure to bilastine. (Moderate) Theoretical
Antihistamines, non-sedating — Antimalarials

Antimalarials

- **Rifampicin** increases the clearance of **fexofenadine**. [Moderate Study]
- **Velpatasvir** is predicted to increase the exposure to **fexofenadine**. [Severe Theoretical]

**Antimalarials** (procaine) → see TABLE 9 p. 1266 (QT-interval prolongation), TABLE 11 p. 1266 (CNS depressant effects), TABLE 10 p. 1266 (antimuscarnics)


**ROUTE-SPECIFIC INFORMATION** Since systemic absorption can follow topical application of **ketotifen**, the possibility of interactions should be borne in mind.

- **Hydroxyzine** potentially increases the risk of overheating and dehydration when given with **antiplatelets** (**zonisamide**). Avoid in children. [Severe Theoretical]
- **Antihistamines**, **sedating** are predicted to decrease the effects of **betahistine**. [Moderate Theoretical]
- **Antihistamines, sedating** are predicted to decrease the effects of **histamine**. Avoid. [Severe Theoretical]
- **Cyproheptadine** decreases the effects of **metyrapone**. Avoid. [Moderate Study]
- **Monoamine-oxidase A and B inhibitors, irreversible** are predicted to increase the risk of antimuscarnic side-effects when given with **antihistamines**, **sedating**. Avoid. [Severe Theoretical]
- **Antihistamines, sedating** are predicted to decrease the efficacy of **pitolisant**. [Unknown] Theoretical
- **Cyproheptadine** potentially decreases the effects of **SSRIs**. [Anecdotal] Theoretical

Antimalarials → see TABLE 15 p. 1267 (myelosuppression), TABLE 9 p. 1266 (QT-interval prolongation)


**PHARMACOLOGY** Piperaquine has a long half-life; there is a potential for drug interactions to occur for up to 3 months after treatment has been stopped.

- **Chloroquine** is predicted to decrease the effects of **agalsidase**. Avoid. [Moderate Theoretical]
- **Antimalarials** (**chloroquine**, **primaquine**) are predicted to increase the risk of methaemoglobinemia when given with topical **anesthetics**, local (**prilocaine**). Use with caution or avoid. [Severe Theoretical]
- **Antacids** decrease the absorption of **chloroquine**. Separate administration by at least 4 hours. [Moderate Study]
- **Antacids** are predicted to decrease the absorption of **proguanil**. Separate administration by at least 2 hours. [Moderate Study]
- **Antiarrhythmics** (**dronedarone**) are predicted to increase the concentration of **piperaquine**. [Severe Theoretical]
- **Antiplatelets** (**carbamazepine**, **fosphenytoin**, **phenobarbital**, **phenytoin**, **primidone**) are predicted to decrease the exposure to **artemether** (with lumafantrine). Avoid. [Severe Study]
- **Antiplatelets** (**carbamazepine**, **fosphenytoin**, **phenobarbital**, **phenytoin**, **primidone**) are predicted to decrease the concentration of **piperaquine**. Avoid. [Moderate Theoretical]
- **Pyrimethamine** increases the risk of haematological toxicity when given with **antiplatelets** (**fosphenytoin**, **phenytoin**). [Severe Study]
- **Pyrimethamine** is predicted to increase the risk of haematological toxicity when given with **antiplatelets** (**phenobarbital**, **primidone**). [Severe Theoretical]
- **Antifungals, azoles** (**fluconazole**, **itraconazole**, **mefloquine**, **itraconazole**), **pyrimethamine**, **posaconazole**, **voriconazole**) are predicted to increase the concentration of **piperaquine**. [Severe Theoretical]
- **Antifungals, azoles** (**itraconazole**, **ketocanozone**, **voriconazole**) are predicted to increase the exposure to **mefloquine**. [Moderate Theoretical]
- **Antifungals, azoles** (**itraconazole**, **ketocanozone**, **voriconazole**) are predicted to increase the exposure to **artemether** (with lumafantrine). [Moderate Study] 

**HIV**

- **Antifungals, azoles** (**ketocanozone**) increase the exposure to **mefloquine**. [Moderate Study]
- **Antimalarials** (**proguanil**) are predicted to increase the risk of side-effects when given with **antimalarials** (**pyrimethamine**). [Severe Theoretical]
- **Aprepitant** is predicted to increase the concentration of **piperaquine**. [Severe Theoretical]
- **Mefloquine** is predicted to increase the risk of bradycardia when given with **beta blockers, non-selective**. [Severe Theoretical]
- **Mefloquine** is predicted to increase the risk of bradycardia when given with **calcium channel blockers**. [Severe Theoretical]
- **Calcium channel blockers** (**diltiazem**, **verapamil**) are predicted to increase the concentration of **piperaquine**. [Severe Theoretical]
- **Calcium salts** (**calcium carbonate**) decrease the absorption of **chloroquine**. Separate administration by at least 4 hours. [Moderate Study]
- **Calcium salts** (**calcium carbonate**) are predicted to decrease the absorption of **proguanil**. Separate administration by at least 2 hours. [Moderate Study]
- **Chloroquine** decreases the efficacy of **oral cholera vaccine**. [Moderate Study]
- **Cobicistat** is predicted to increase the exposure to **artemether** (with **lumafantrine**). [Moderate Study]
- **Cobicistat** is predicted to increase the concentration of **piperaquine**. [Severe Theoretical]
- **Clobimetazol** is predicted to increase the concentration of **piperaquine**. [Severe Theoretical]
- **Antimalarials** (**chloroquine**, **primaquine**) are predicted to increase the risk of methaemoglobinemia when given with **dapsone**. [Severe Theoretical]
- **Mefloquine** is predicted to increase the risk of bradycardia when given with **digoxin**. [Severe Theoretical]
- **Quinine** increases the concentration of **digoxin**. Monitor and adjust **digoxin** dose. [Severe] Anecdotal
- **Efavirenz** decreases the concentration of **artemether**. [Severe Study]
- **Efavirenz** moderately decreases the exposure to **atovaquone**. Avoid. [Moderate Study]
- **Efavirenz** affects the exposure to **proguanil**. Avoid. [Moderate Study]
- **Enzalutamide** is predicted to decrease the exposure to **artemether** (with lumafantrine). Avoid. [Severe Study]
- **Enzalutamide** is predicted to decrease the concentration of **piperaquine**. Avoid. [Moderate Theoretical]
- **Etravirine** decreases the exposure to **artemether**. [Moderate Study]
- **Grapefruit juice** increases the exposure to **artemether**. [Unknown] Study
- **Grapefruit juice** is predicted to increase the concentration of **piperaquine**. Avoid. [Severe Study]
- **H₂ receptor antagonists** (**cimetidine**) decrease the clearance of **chloroquine**. [Moderate Study]
- **H₂ receptor antagonists** (**cimetidine**) slightly increase the exposure to **quinine**. [Moderate Study]
- **Antimalarials** (**artemether**, **atovaquone**, **chloroquine**, **mefloquine**, **primaquine**, **proguanil**, **pyrimethamine**, **quinine**) are predicted to affect the exposure to **histamine**. Avoid. [Severe Theoretical]
- **HIV-protease inhibitors** (**atazanavir**, **darunavir**, **fosamprenavir**, **lopinavir**, **ritonavir**, **saquinavir**, **tipranavir**) are predicted to increase the exposure to **artemether** (with lumafantrine). [Moderate Study] → Also see TABLE 9 p. 1266
- **HIV-protease inhibitors** decrease the exposure to **atovaquone**. Avoid if boosted with ritonavir. [Moderate Study]
- **HIV-protease inhibitors** are predicted to increase the concentration of **piperaquine**. [Severe Theoretical]
- **HIV-protease inhibitors** are predicted to decrease the exposure to **proguanil**. Avoid. [Moderate Study]
- **HIV-protease inhibitors** are predicted to affect the exposure to **quinine**. [Severe] Study → Also see TABLE 9 p. 1266
- **Idelalisib** is predicted to increase the exposure to **artemether** (with lumafantrine). [Moderate Study]
- **Idelalisib** is predicted to increase the concentration of **piperaquine**. [Severe Theoretical]
**Imatinib** is predicted to increase the concentration of piperazine. **Severe** Theoretical

**Lanthanum** is predicted to decrease the absorption of chloroquine. Separate administration by at least 2 hours. **Moderate** Theoretical

**Chloroquine** is predicted to decrease the exposure to laronidase. Avoid simultaneous administration. **Severe** Theoretical

**Macrolides (clarithromycin)** are predicted to increase the exposure to pyrimethamin. **Severe** Theoretical

**Aprepitant** is predicted to increase the exposure to apixaban. Avoid. **Severe** Theoretical

**Macrolides (erythromycin)** are predicted to increase the exposure to apixaban. **Moderate** Theoretical

**Rifampicin** is predicted to moderately decrease the exposure to apixaban. Use with caution or avoid. **Severe** Study

**St John’s Wort** is predicted to decrease the exposure to apixaban. Use with caution or avoid. **Moderate** Theoretical

**Apomorphine** → see dopamine receptor agonists

**Apremilast** is predicted to increase the exposure to apixaban. Avoid. **Severe** Theoretical

**Theoretical**

**Pyrimethamine** is predicted to increase the risk of side-effects when given with *methotrexate*. **Severe** Theoretical → Also see TABLE 15 p. 1267

**Metoclopramide** decreases the concentration of atovaquone. Avoid. **Moderate** Study

**Netupitant** is predicted to increase the concentration of piperazine. **Severe** Theoretical

**Nilotinib** is predicted to increase the concentration of piperazine. **Severe** Theoretical

**Pyrimethamine** is predicted to increase the risk of side-effects when given with *pemetrexed*. **Severe** Theoretical → Also see TABLE 15 p. 1267

**Chloroquine** is predicted to increase the risk of haematological toxicity when given with *penicillamine*. Avoid. **Severe** Theoretical

**Chloroquine** moderately decreases the exposure to praziquantel. Use with caution and adjust dose. **Moderate** Study

**Chloroquine** decreases the efficacy of *rabies vaccine*. Avoid. **Moderate** Study

**Rifaximin** slightly decreases the exposure to atovaquone. Avoid. **Moderate** Study

**Rifaximin** is predicted to decrease the exposure to artemether (with lumafantrine). Avoid. **Severe** Study

**Rifaximin** moderately decreases the exposure to atovaquone and atovaquone slightly increases the exposure to rifampicin. Avoid. **Moderate** Study

**Rifaximin** moderately decreases the exposure to *mefloquine*. **Severe** Study

**Rifaximin** is predicted to decrease the concentration of piperazine. Avoid. **Moderate** Theoretical

**Rifaximin** decreases the exposure to quinine. **Severe** Study

**St John’s Wort** is predicted to decrease the concentration of piperazine. Avoid. **Moderate** Theoretical

**Pyrimethamine** increases the risk of side-effects when given with *sulfonamides*. **Severe** Study → Also see TABLE 15 p. 1267

**Tetracyclines (tetracycline)** decrease the concentration of atovaquone. **Moderate** Study

**Pyrimethamine** increases the risk of side-effects when given with *trimethoprim*. **Severe** Study

**Pyrimethamine** is predicted to increase the risk of side-effects when given with *zidovudine*. **Severe** Theoretical → Also see TABLE 15 p. 1267

**Apixaban** → see TABLE 3 p. 1264 (anticoagulant effects)

**Antiarrhythmics (dronedarone)** are predicted to increase the exposure to apixaban. **Moderate** Theoretical

**Antiarrhythmics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone)** are predicted to moderately decrease the exposure to apixaban. Use with caution or avoid. **Severe** Study

**Antifungals, azoles (itraconazole, ketoconazole, voriconazole)** are predicted to markedly decrease the exposure to aprepiant. Avoid. **Moderate** Study

**Antifungals, azoles (isavuconazole)** are predicted to markedly decrease the exposure to aprepiant. **Moderate** Study

**Apixaban** is predicted to increase the exposure to aldoosterone antagonists (eplerenone). Adjust eplerenone dose, p. 185. **Severe** Study

**Apixaban** is predicted to increase the exposure to alpha blockers (tamsulosin). **Moderate** Theoretical

**Apixaban** is predicted to increase the exposure to alprazolam. **Severe** Study

**Apixaban** increases the exposure to antiarrhythmics (dronedarone). **Severe** Theoretical

**Apixaban** is predicted to increase the exposure to antiarrhythmics (propafenone). Monitor and adjust dose. **Moderate** Study

**Apixaban** is predicted to increase the exposure to antidepressants (amitriptyline, desipramine, imipramine). **Severe** Theoretical

**Apixaban** is predicted to increase the concentration of antimalarials (piperazine). **Severe** Theoretical

**Apixaban** is predicted to increase the exposure to axitinib. **Moderate** Theoretical

**Apixaban** is predicted to increase the exposure to bedaquiline. Avoid prolonged use. **Mild** Theoretical

**Apixaban** is predicted to increase the exposure to bosutinib. Avoid or adjust bosutinib dose. **Severe** Theoretical

**Apixaban** is predicted to increase the exposure to buspirone. Use with caution and adjust dose. **Moderate** Study

**Apixaban** is predicted to increase the exposure to cabozantinib. **Moderate** Theoretical

**Calcium channel blockers** are predicted to increase the exposure to aprepiant and aprepiant increases the exposure to calcium channel blockers. **Moderate** Study

**Calcium channel blockers (verapamil)** are predicted to increase the exposure to aprepiant and aprepiant is predicted to increase the exposure to calcium channel blockers. **Moderate** Theoretical

**Aprepitant** is predicted to increase the exposure to calcium channel blockers (amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose. **Moderate** Study
Aprepitant (continued)
▶ Aprepitant is predicted to increase the exposure to ceritinib. Moderate Theoretical
▶ Aprepitant increases the concentration of ciclosporin. Severe Study
▶ Cobimetinib is predicted to markedly increase the exposure to cobimetinib. Severe Theoretical
▶ Aprepitant is predicted to increase the exposure to colchicine. Adjust colchicine dose, p. 1020. Severe Study
▶ Aprepitant is predicted to decrease the efficacy of combined hormonal contraceptives. For FSRH guidance, see Contraceptives, interactions p. 747. Severe Study
▶ Aprepitant moderately increases the exposure to corticosteroids (dexamethasone). Monitor and adjust dose. Moderate Study
▶ Aprepitant is predicted to increase the exposure to corticosteroids (methylprednisolone). Monitor and adjust dose. Moderate Study
▶ Aprepitant decreases the anticoagulant effect of coumarins. Moderate Study
▶ Aprepitant is predicted to increase the exposure to crizotinib. Moderate Theoretical
▶ Aprepitant is predicted to slightly increase the exposure to darifenacin. Moderate Study
▶ Aprepitant is predicted to increase the exposure to dasatinib. Severe Study
▶ Aprepitant is predicted to decrease the efficacy of desogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. Severe Theoretical
▶ Aprepitant increases the risk of QT-prolongation when given with domperidone. Avoid. Severe Study
▶ Aprepitant is predicted to increase the exposure to dopamine receptor agonists (溴隐亭, cabergoline). Severe Theoretical
▶ Aprepitant is predicted to moderately increase the exposure to dutasteride. Mild Study
▶ Enzalutamide is predicted to markedly decrease the exposure to aprepitant. Avoid. Moderate Study
▶ Aprepitant is predicted to increase the risk of ergotism when given with ergometrine. Severe Theoretical
▶ Aprepitant is predicted to increase the risk of ergotism when given with ergotamine. Severe Theoretical
▶ Aprepitant is predicted to increase the exposure to erlotinib. Moderate Theoretical
▶ Aprepitant is predicted to decrease the efficacy of etonogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. Severe Theoretical
▶ Aprepitant is predicted to increase the concentration of everolimus. Avoid or adjust dose. Moderate Study
▶ Aprepitant is predicted to increase the exposure to fesoterodine. Adjust fesoterodine dose in hepatic and renal impairment, p. 732. Mild Study
▶ Aprepitant is predicted to increase the concentration of guanfacine. Adjust guanfacine dose, p. 335. Moderate Theoretical
▶ HIV- protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to markedly increase the exposure to aprepitant. Moderate Study
▶ Aprepitant is predicted to decrease the effects of Hormone replacement therapy. Moderate Anecdotal
▶ Aprepitant is predicted to increase the exposure to irbutinib. Avoid or adjust irbutinib dose, p. 902. Severe Theoretical
▶ Idelalisib is predicted to markedly increase the exposure to aprepitant. Moderate Study
▶ Aprepitant is predicted to increase the exposure to imatinib. Moderate Theoretical
▶ Aprepitant is predicted to increase the exposure to ivabradine. Adjust ivabradine dose, p. 205. Severe Theoretical
▶ Aprepitant is predicted to increase the exposure to ivacaftor. Adjust ivacaftor dose, p. 281. Severe Study
▶ Aprepitant is predicted to increase the exposure to lapiatinib. Moderate Study
▶ Aprepitant is predicted to decrease the efficacy of levonorgestrel. For FSRH guidance, see Contraceptives, interactions p. 747. Severe Theoretical
▶ Aprepitant is predicted to increase the exposure to lomitapide. Avoid. Moderate Theoretical
▶ Aprepitant is predicted to increase the exposure to lurusidone. Moderate Study
▶ Aprepitant is predicted to increase the exposure to midazolam. Monitor side effects and adjust dose. Severe Study
▶ Aprepitant is predicted to increase the exposure to naloxegol. Adjust naloxegol dose and monitor side effects, p. 63. Moderate Study
▶ Aprepitant is predicted to increase the exposure to nilotinib. Moderate Theoretical
▶ Aprepitant is predicted to decrease the efficacy of norethisterone. For FSRH guidance, see Contraceptives, interactions p. 747. Severe Anecdotal
▶ Aprepitant is predicted to increase the exposure to olaparib. Avoid or adjust olaparib dose, p. 919. Moderate Theoretical
▶ Aprepitant is predicted to increase the exposure to opioids (alfentanil, buprenorphine, fentanyl, oxycodone). Monitor and adjust dose. Moderate Study
▶ Aprepitant is predicted to increase the exposure to opioids (methadone, sufentanil). Moderate Theoretical
▶ Aprepitant is predicted to increase the exposure to oxabutolin. Mild Theoretical
▶ Aprepitant is predicted to increase the exposure to pazopanib. Moderate Theoretical
▶ Aprepitant is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (avanafil). Adjust avanafil dose, p. 765. Moderate Theoretical
▶ Aprepitant is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (sildenafil). Monitor and adjust sildenafil dose, p. 766. Moderate Study
▶ Aprepitant is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (tadalafil). Severe Theoretical
▶ Aprepitant is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (vardenafil). Adjust dose. Severe Theoretical
▶ Aprepitant is predicted to increase the exposure to pimozide. Avoid. Moderate Theoretical
▶ Aprepitant is predicted to increase the exposure to quetiapine. Avoid. Moderate Study
▶ Aprepitant is predicted to increase the exposure to ranolazine. Severe Study
▶ Aprepitant is predicted to markedly decrease the exposure to aprepitant. Avoid. Moderate Study
▶ Aprepitant is predicted to increase the exposure to ruxolitinib. Moderate Theoretical
▶ Aprepitant is predicted to increase the exposure to saxagliptin. Mild Study
▶ Aprepitant is predicted to increase the exposure to simeprevir. Avoid. Severe Study
▶ Aprepitant increases the concentration of sirolimus. Monitor and adjust dose. Moderate Study
▶ Aprepitant is predicted to increase the exposure to SSRIs. (dapoxetine). Adjust dapoxetine dose, p. 773. Moderate Theoretical
▶ St John’s Wort is predicted to decrease the exposure to aprepitant. Avoid. Moderate Theoretical
▶ Aprepitant is predicted to increase the exposure to atorvastatin. Monitor and adjust dose. Severe Theoretical
▶ Aprepitant is predicted to increase the exposure to simvastatin. Use with caution and adjust simvastatin dose, p. 198. Severe Study
▶ Aprepitant is predicted to increase the exposure to sunifatinib. Moderate Theoretical
▶ Aprepitant is predicted to increase the concentration of tacrolimus. Severe Study
▶ Aprepitant is predicted to increase the exposure to taxanes (cabazitaxel). Moderate Theoretical
▶ Aprepitant is predicted to increase the concentration of temsirolimus. Moderate Theoretical
Aprepitant – Atomoxetine 1297

- Aprepitant is predicted to increase the exposure to tolterodine. [Mild] Theoretical
- Aprepitant is predicted to increase the exposure to tolvaptan. Adjust dose. [Moderate] Theoretical
- Aprepitant is predicted to increase the exposure to trazodone. [Moderate] Theoretical
- Aprepitant decreases the efficacy of ulipristal. For FSHR guidance, see Contraceptives, interactions p. 747. [Severe] Anecdotal
- Aprepitant is predicted to increase the exposure to venetoclax. Avoid or adjust venetoclax dose, p. 919. [Severe] Study
- Aprepitant is predicted to increase the exposure to vinca alkaloids. [Severe] Theoretical
- Aprepitant is predicted to increase the exposure to zopiclone. Adjust dose. [Moderate] Study
- Argatroban → see TABLE 3 p. 1264 (anticoagulant effects)
- Ranibizumab is predicted to increase the risk of bleeding events when given with argatroban. [Severe] Theoretical
- Arripiiprazole → see TABLE 8 p. 1265 (hypotension), TABLE 11 p. 1266 (CNS depressant effects)
- Antiepileptics (Carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to moderately decrease the exposure to arripiiprazole. Adjust arripiiprazole dose, p. 376. [Moderate] Study → Also see TABLE 11 p. 1266
- Antifungals (itraconazole, ketoconazole, voriconazole) are predicted to slightly increase the exposure to arripiiprazole. Adjust arripiiprazole dose, p. 376. [Moderate] Study
- Bupropion is predicted to moderately increase the exposure to arripiiprazole. Adjust arripiiprazole dose, p. 376. [Moderate] Study
- Cinacalcet is predicted to moderately increase the exposure to arripiiprazole. Adjust arripiiprazole dose, p. 376. [Moderate] Study
- Ciclosporin is predicted to slightly increase the exposure to arripiiprazole. Adjust arripiiprazole dose, p. 376. [Moderate] Study
- Arripiiprazole is predicted to decrease the effects of dopamine receptor agonists. [Moderate] Theoretical → Also see TABLE 8 p. 1265
- Enzalutamide is predicted to moderately decrease the exposure to arripiiprazole. Adjust arripiiprazole dose, p. 376. [Moderate] Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to slightly increase the exposure to arripiiprazole. Adjust arripiiprazole dose, p. 376. [Moderate] Study
- Rifampicin is predicted to moderately decrease the exposure to arripiiprazole. Adjust arripiiprazole dose, p. 376. [Moderate] Study
- Arripiiprazole is predicted to decrease the effects of levodopa. [Severe] Theoretical → Also see TABLE 8 p. 1265
- Macrolides (clarithromycin) are predicted to slightly increase the exposure to arripiiprazole. Adjust arripiiprazole dose, p. 376. [Moderate] Study
- Terbinafine is predicted to moderately increase the exposure to arripiiprazole. Adjust arripiiprazole dose, p. 376. [Moderate] Study
- Arsenic trioxide → see TABLE 15 p. 1267 (myelosuppression), TABLE 9 p. 1266 (QT-interval prolongation)
- Artemether → see antimalarials
- Arteminol → see antimalarials
- Articaine → see TABLE 11 p. 1266 (CNS depressant effects)
- Ascorbic acid is predicted to increase the risk of cardiovascular side-effects when given with deferiprone. [Severe] Theoretical
- Ascorbic acid is predicted to increase the risk of cardiovascular side-effects when given with iron chelators (desferrioxamine). [Severe] Theoretical
- Asenapine → see TABLE 8 p. 1265 (hypotension), TABLE 11 p. 1266 (CNS depressant effects)
- Asenapine is predicted to decrease the effects of dopamine receptor agonists. Adjust dose. [Moderate] Theoretical → Also see TABLE 8 p. 1265
- Asenapine is predicted to decrease the effects of levodopa. Adjust dose. [Severe] Theoretical → Also see TABLE 8 p. 1265
- SSRIs (fluvoxamine) increase the exposure to asenapine. [Moderate] Study
- SSRIs (paroxetine) moderately increase the exposure to asenapine. [Moderate] Study
- Asparaginase → see TABLE 1 p. 1264 (hepatotoxicity), TABLE 15 p. 1267 (myelosuppression)
- Asparaginase is predicted to increase the risk of hepatotoxicity when given with imatinib. [Severe] Theoretical → Also see TABLE 15 p. 1267
- Asparaginase affects the efficacy of methotrexate. [Severe] Anecdotal → Also see TABLE 1 p. 1264 → Also see TABLE 15 p. 1267
- Asparaginase potentially increases the risk of neurotoxicity when given with vinca alkaloids (vincristine). Vincristine should be taken 3 to 24 hours before asparaginase. [Severe] Anecdotal → Also see TABLE 1 p. 1264 → Also see TABLE 15 p. 1267
- Aspirin → see TABLE 4 p. 1264 (antiplatelet effects)
- Acetazolamide increases the risk of severe toxic reaction when given with aspirin (high-dose). [Severe] Study
- Antacids decrease the absorption of aspirin (high-dose). [Moderate] Study
- Aspirin (high-dose) is predicted to increase the risk of gastrointestinal irritation when given with bisphosphonates (alendronic acid, ibandronic acid). [Moderate] Study
- Aspirin (high-dose) is predicted to increase the risk of renal impairment when given with bisphosphonates (sodium clodronate). [Severe] Theoretical
- Corticosteroids are predicted to decrease the concentration of aspirin (high-dose) and aspirin (high-dose) increases the risk of gastrointestinal bleeding when given with corticosteroids. [Moderate] Study
- Aspirin (high-dose) is predicted to increase the risk of gastrointestinal bleeds when given with iron chelators (deferasirox). [Severe] Theoretical
- Aspirin (high-dose) is predicted to increase the risk of toxicity when given with methotrexate. [Severe] Theoretical
- Aspirin is predicted to increase the risk of gastrointestinal perforation when given with aspirin (high-dose). [Severe] Theoretical
- Aspirin (high-dose) potentially increases the risk of seizures when given with quinolones. [Severe] Theoretical
- Aspirin decreases the effects of sulfipyrazone. [Moderate] Study → Also see TABLE 4 p. 1264
- Aspirin (high-dose) increases the risk of acute renal failure when given with thiazide diuretics. [Severe] Theoretical
- Zidovudine increases the risk of haematological toxicity when given with aspirin (high-dose). [Severe] Study
- Ataluren
- Ataluren increases the exposure to adeovir. [Moderate] Study
- Ataluren is predicted to increase the risk of nephrotoxicity when given with intravenous aminoglycosides. Avoid. [Severe] Study
- Rifampicin decreases the exposure to ataluren. [Moderate] Study
- Atenolol → see beta blockers, selective
- Atomoxetine
- Amfetamines are predicted to increase the risk of side-effects when given with atomoxetine. [Severe] Theoretical
- Atomoxetine is predicted to increase the risk of cardiovascular side-effects when given with beta2 agonists (high-dose). [Moderate] Study
- Bupropion is predicted to markedly increase the exposure to atomoxetine. Adjust dose. [Severe] Study
- Cinacalcet is predicted to markedly increase the exposure to atomoxetine. Adjust dose. [Severe] Study
- Monoamine-oxidase A and B inhibitors, irreversible are predicted to increase the risk of side-effects when given with atomoxetine. Avoid and for 2 weeks after stopping the MAOI. [Severe] Theoretical
1298 Atomoxetine — Bedaquiline
Atomoxetine (continued)
▶ Panobinostat is predicted to increase the exposure to
atomoxetine. Monitor and adjust dose. r Theoretical
▶ SSRIs (fluoxetine, paroxetine) are predicted to markedly
increase the exposure to atomoxetine. Adjust dose. r

BNF 74

▶

Anecdotal
▶

Study

Terbinafine is predicted to markedly increase the exposure to
atomoxetine. Adjust dose. r Study
Atorvastatin → see statins
Atovaquone → see antimalarials
Atracurium → see neuromuscular blocking drugs, non-depolarising
Atropine → see TABLE 10 p. 1266 (antimuscarinics)
▶ Atropine increases the risk of severe hypertension when given
with sympathomimetics, vasoconstrictor (phenylephrine). r
▶

Study

Interactions | Appendix 1

A1

Avanafil → see phosphodiesterase type-5 inhibitors
Axitinib → see TABLE 15 p. 1267 (myelosuppression)
▶ Antiarrhythmics (dronedarone) are predicted to increase the
exposure to axitinib. o Theoretical
▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone) are predicted to decrease the exposure
to axitinib. Avoid or adjust dose. o Study
▶ Antifungals, azoles (fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure to axitinib. o
Theoretical

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are
predicted to increase the exposure to axitinib. Avoid or adjust
dose. o Study
▶ Aprepitant is predicted to increase the exposure to axitinib.
▶

o Theoretical
▶

Bosentan is predicted to decrease the exposure to axitinib.

▶

Calcium channel blockers (diltiazem, verapamil) are predicted to
increase the exposure to axitinib. o Theoretical
Cobicistat is predicted to increase the exposure to axitinib.
Avoid or adjust dose. o Study
Axitinib is predicted to increase the risk of bleeding events
when given with coumarins. r Theoretical
Crizotinib is predicted to increase the exposure to axitinib.
o Theoretical → Also see TABLE 15 p. 1267
Efavirenz is predicted to decrease the exposure to axitinib.

o Theoretical

▶
▶
▶
▶

o Theoretical

Enzalutamide is predicted to decrease the exposure to axitinib.
Avoid or adjust dose. o Study
▶ Grapefruit juice is predicted to increase the exposure to
axitinib. o Theoretical
▶ HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir,
lopinavir, ritonavir, saquinavir, tipranavir) are predicted to
increase the exposure to axitinib. Avoid or adjust dose.
▶

o Study
▶
▶
▶
▶
▶
▶

HIV-protease inhibitors (indinavir) are predicted to increase the
exposure to axitinib. o Theoretical
Idelalisib is predicted to increase the exposure to axitinib.
Avoid or adjust dose. o Study → Also see TABLE 15 p. 1267
Imatinib is predicted to increase the exposure to axitinib.
o Theoretical → Also see TABLE 15 p. 1267
Macrolides (clarithromycin) are predicted to increase the
exposure to axitinib. Avoid or adjust dose. o Study
Macrolides (erythromycin) are predicted to increase the
exposure to axitinib. o Theoretical
Netupitant is predicted to increase the exposure to axitinib.
o Theoretical

▶

▶
▶
▶

▶

▶

Theoretical

n Theoretical
▶
▶
▶

▶

o Theoretical

Azacitidine → see TABLE 15 p. 1267 (myelosuppression)
Azathioprine → see TABLE 15 p. 1267 (myelosuppression)

Febuxostat is predicted to increase the exposure to
azathioprine. Avoid. r Theoretical
Live vaccines are predicted to increase the risk of generalised
infection (possibly life-threatening) when given with
azathioprine. Public Health England advises avoid. r

Azelastine → see antihistamines, non-sedating
Azilsartan → see angiotensin-II receptor antagonists
Azithromycin → see macrolides
Bacillus Calmette-Guérin vaccine → see live vaccines
Bacitracin → see TABLE 2 p. 1264 (nephrotoxicity)
Baclofen → see TABLE 8 p. 1265 (hypotension), TABLE 11 p. 1266 (CNS
depressant effects), TABLE 10 p. 1266 (antimuscarinics)
▶ Baclofen is predicted to increase the risk of side-effects when
given with levodopa. r Anecdotal → Also see TABLE 8 p. 1265
Balsalazide → see TABLE 15 p. 1267 (myelosuppression)
▶ Balsalazide is predicted to decrease the concentration of
digoxin. o Theoretical
Bambuterol → see beta2 agonists
Basiliximab → see monoclonal antibodies
Bazedoxifene
▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone) are predicted to decrease the exposure
to bazedoxifene. o Theoretical
▶ Rifampicin is predicted to decrease the exposure to
bazedoxifene. o Theoretical
Beclometasone → see corticosteroids
Bedaquiline → see TABLE 9 p. 1266 (QT-interval prolongation)
▶ Antiarrhythmics (dronedarone) are predicted to increase the
exposure to bedaquiline. Avoid prolonged use. n
Theoretical → Also see TABLE 9 p. 1266
▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone) decrease the exposure to bedaquiline.
Avoid. r Study
▶ Antifungals, azoles (fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure to bedaquiline. Avoid
prolonged use. n Theoretical
▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are
predicted to increase the exposure to bedaquiline. Avoid
prolonged use. n Study → Also see TABLE 9 p. 1266
▶ Aprepitant is predicted to increase the exposure to
bedaquiline. Avoid prolonged use. n Theoretical
▶ Bosentan is predicted to decrease the exposure to bedaquiline.
Avoid. r Study
▶ Calcium channel blockers (diltiazem, verapamil) are predicted to
increase the exposure to bedaquiline. Avoid prolonged use.

Nevirapine is predicted to decrease the exposure to axitinib.
Nilotinib is predicted to increase the exposure to axitinib.
o Theoretical → Also see TABLE 15 p. 1267
Axitinib is predicted to increase the risk of bleeding events
when given with phenindione. r Theoretical
Rifampicin is predicted to decrease the exposure to axitinib.
Avoid or adjust dose. o Study
St John’s Wort is predicted to decrease the exposure to axitinib.

Allopurinol potentially increases the risk of haematological
toxicity when given with azathioprine. Adjust azathioprine
dose, p. 787. r Study
Azathioprine decreases the anticoagulant effect of coumarins.
o Study

▶

▶

o Theoretical
▶

ACE inhibitors are predicted to increase the risk of anaemia
and/or leucopenia when given with azathioprine. r

Clofazimine potentially increases the risk of QT-prolongation
when given with bedaquiline. r Study
Cobicistat is predicted to increase the exposure to bedaquiline.
Avoid prolonged use. n Study
Crizotinib is predicted to increase the exposure to bedaquiline.
Avoid prolonged use. n Theoretical → Also see TABLE 9 p. 1266
Efavirenz is predicted to decrease the exposure to bedaquiline.
Avoid. r Study
Enzalutamide decreases the exposure to bedaquiline. Avoid.
r Study

Etravirine is predicted to decrease the exposure to bedaquiline.
Avoid. r Theoretical
▶ HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir,
lopinavir, ritonavir, saquinavir, tipranavir) are predicted to
increase the exposure to bedaquiline. Avoid prolonged use.
n Study → Also see TABLE 9 p. 1266
▶ HIV-protease inhibitors (indinavir) are predicted to increase the
exposure to bedaquiline. Avoid prolonged use. n Theoretical
▶ Idelalisib is predicted to increase the exposure to bedaquiline.
Avoid prolonged use. n Study
▶

downloaded from www.medicalbr.com


Imatinib is predicted to increase the exposure to bedaquiline. Avoid prolonged use. [Mild] Theoretical

Macrolides (clarithromycin) are predicted to increase the exposure to bedaquiline. Avoid prolonged use. [Mild] Study

Also see TABLE 9 p. 1266

Macrolides (erythromycin) are predicted to increase the exposure to bedaquiline. Avoid prolonged use. [Mild] Theoretical

Netupitant is predicted to increase the exposure to bedaquiline. Avoid prolonged use. [Mild] Theoretical

Nevirapine is predicted to decrease the exposure to bedaquiline. Avoid. [Severe] Study

Nilotinib is predicted to increase the exposure to bedaquiline. Avoid prolonged use. [Mild] Theoretical

St John’s Wort is predicted to decrease the exposure to bedaquiline. Avoid. [Severe] Study

Bee venom extract

General information Desensitising vaccines should be avoided in patients taking beta-blockers (adrenaline might be ineffective in case of a hypersensitivity reaction) or ACE inhibitors (risk of severe anaphylactoid reactions).

• ACE inhibitors increase the risk of hypersensitivity when given with bee venom extract. Avoid. [Severe] Study

Belatacept

• Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with belatacept. Public Health England advises avoid. [Severe] Theoretical

Betamethasone → see monoclonal antibodies

Betaxolol → see alkylation agents

Bendroflumethiazide → see thiazide diuretics

Benperidol → see TABLE 8 p. 1265 (hypotension), TABLE 11 p. 1266 (CNS depressant effects)

Benperidol is predicted to decrease the effects of dopamine receptor agonists. Avoid. [Moderate] Theoretical → Also see TABLE 8 p. 1265

Benperidol is predicted to decrease the effects of guanethidine. [Moderate] Theoretical → Also see TABLE 8 p. 1265

Benperidol is predicted to decrease the effects of levodopa. [Severe] Study → Also see TABLE 8 p. 1265

Benzylamine → see NSAIDs

Benzylpenicillin → see penicillins

Beta blockers, non-selective → see TABLE 6 p. 1265 (bradycardia), TABLE 8 p. 1265 (hypotension), TABLE 9 p. 1266 (QT-interval prolongation)

carteolol · carvedilol · labetalol · levobunolol · nadolol · oxprenolol · pindolol · propranolol · sotalol · timolol

Route-specific information Since systemic absorption can follow topical application of carteolol, levobunolol, and timolol, the possibility of interactions should be borne in mind.

Abrisnate is predicted to increase the exposure to beta blockers, non-selective (carvedilol, timolol). [Moderate] Theoretical

Beta blockers, non-selective are predicted to increase the risk of bronchospasm when given with aminophylline. Avoid. [Severe] Theoretical

Antiarrhythmics (amiodarone, disopyramide, droterenone, flecainide, lidocaine) are predicted to increase the risk of cardiovascular side-effects when given with beta blockers, non-selective. Use with caution or avoid. [Severe] Study → Also see TABLE 6 p. 1265 → Also see TABLE 9 p. 1266

Antiarrhythmics (propafenone) are predicted to increase the exposure to carvedilol. [Moderate] Theoretical

Antiarrhythmics (propafenone) increase the risk of cardiovascular side-effects when given with propranolol. Use with caution or avoid. [Severe] Study

Antiarrhythmics (propafenone) are predicted to increase the exposure to timolol and timolol is predicted to increase the risk of cardiodepression when given with antiarrhythmics (propafenone). [Severe] Anecdotal

Antiarrhythmics (propafenone) are predicted to increase the risk of cardiovascular side-effects when given with beta blockers, non-selective (carteolol, labetalol, levobunolol, nadolol, oxprenolol, pindolol, sotalol). Use with caution or avoid. [Severe] Study

Anticholinesterases, centrally acting are predicted to increase the risk of bradycardia when given with beta blockers, non-selective. [Moderate] Anecdotal → Also see TABLE 6 p. 1265

Antiepileptics (phenobarbital, primidone) are predicted to decrease the exposure to propranolol. [Moderate] Study

Antiepileptics (phenobarbital, primidone) are predicted to decrease the exposure to beta blockers, non-selective (carvedilol, labetalol). [Moderate] Theoretical

Antifungals, azoles (itraconazole, ketoconazole) are predicted to increase the exposure to nadolol. [Moderate] Study

Antimalarials (methloquine) are predicted to increase the risk of bradycardia when given with beta blockers, non-selective. [Severe] Theoretical

Bupropion is predicted to increase the exposure to beta blockers, non-selective (carvedilol, timolol). [Moderate] Study

Calcium channel blockers (diltiazem) are predicted to increase the risk of cardiodepression when given with beta blockers, non-selective. [Severe] Study → Also see TABLE 6 p. 1265 → Also see TABLE 8 p. 1265

Intravenous calcium channel blockers (verapamil) increase the risk of cardiovascular side-effects when given with beta blockers, non-selective. Avoid. [Severe] Study → Also see TABLE 6 p. 1265 → Also see TABLE 8 p. 1265

Oral calcium channel blockers (verapamil) increase the risk of cardiovascular side-effects when given with beta blockers, non-selective. [Severe] Study → Also see TABLE 6 p. 1265 → Also see TABLE 8 p. 1265

Ciclosporin is predicted to increase the exposure to nadolol. [Moderate] Study

Cinacalcet is predicted to increase the exposure to beta blockers, non-selective (carvedilol, timolol). [Moderate] Study

Duloxetine is predicted to increase the exposure to beta blockers, non-selective (carvedilol, timolol). [Moderate] Theoretical

Beta blockers, non-selective are predicted to increase the risk of peripheral vasoconstriction when given with ergometrine. [Severe] Theoretical

Beta blockers, non-selective are predicted to increase the risk of peripheral vasoconstriction when given with ergotamine. [Severe] Study

HIV-protease inhibitors (lopinavir, ritonavir, saquinavir) are predicted to increase the exposure to nadolol. [Moderate] Study

HIV-protease inhibitors (ritonavir) are predicted to increase the exposure to carvedilol. [Moderate] Theoretical

HIV-protease inhibitors (ritonavir) (high-dose) are predicted to increase the exposure to timolol. [Moderate] Theoretical

Beta blockers, non-selective are predicted to increase the risk of bradycardia when given with lanreotide. [Moderate] Theoretical

Lapatinib is predicted to increase the exposure to nadolol. [Moderate] Study

Macrolides are predicted to increase the exposure to nadolol. [Moderate] Study

Mirabegron is predicted to increase the exposure to beta blockers, non-selective (carvedilol, timolol). [Moderate] Theoretical

Ranolazine is predicted to increase the exposure to nadolol. [Moderate] Study

Rifampicin moderately decreases the exposure to carvedilol. [Moderate] Study

Rifampicin decreases the exposure to propranolol. Monitor and adjust propranolol dose. [Moderate] Study

Propranolol slightly to moderately increases the exposure to ritaziptan. Adjust ritaziptan dose and separate administration by at least 2 hours. [Moderate] Study

SSRIs (fluvoxamine) moderately increase the concentration of propranolol. [Moderate] Study

SSRIs (fluoxetine, paroxetine) are predicted to increase the exposure to beta blockers, non-selective (carvedilol, timolol). [Moderate] Study

Beta blockers, non-selective are predicted to increase the risk of hypertension and bradycardia when given with sympotomimetics, inotropes (dobutamine). [Severe] Theoretical

Beta blockers, non-selective are predicted to increase the risk of hypertension and bradycardia when given with...
Beta blockers, non-selective (continued)

sympathomimetics, vasoconstrictor (adrenaline/epinephrine, noradrenaline/norepinephrine). Severe Study

- Terbinafine is predicted to increase the exposure to beta blockers, non-selective (carvedilol, timolol). Moderate Study
- Beta blockers, non-selective are predicted to increase the risk of bronchospasm when given with theophylline. Avoid. Severe Theoretical
- Vemurafenib is predicted to increase the exposure to nadolol. Moderate Study

Beta blockers, selective → see TABLE 6 p. 1265 (bradycardia), TABLE 8 p. 1265 (hypotension)

- acetylbutol · atenolol · betaxolol · bisoprolol · celiprolol · esmolol · metoprolol · nebivolol

Since systemic absorption can follow topical application of betaxolol, the possibility of interactions should be borne in mind.
- Orange juice greatly decreases the exposure to celiprolol.

- Abratherone is predicted to increase the exposure to beta blockers, selective (metoprolol, nebivolol). Moderate Study
- Beta blockers, selective are predicted to increase the risk of bronchospasm when given with aminophylline. Avoid. Severe Theoretical
- Antiarrhythmics (amiodarone, disopyramid, dronedarone, flecainide, lidocaine) are predicted to increase the risk of cardiovascular side-effects when given with beta blockers, selective. Use with caution or avoid. Severe Study → Also see TABLE 6 p. 1265
- Antiarrhythmics (propafenone) are predicted to increase the exposure to metoprolol. Moderate Study
- Antiarrhythmics (propafenone) are predicted to increase the exposure to nebivolol and nebivolol is predicted to increase the risk of cardiodepression when given with antiarrhythmics (propafenone). Avoid. Severe Theoretical
- Antiarrhythmics (propafenone) are predicted to increase the risk of cardiovascular side-effects when given with beta blockers, selective (acebutolol, atenolol, betaxolol, bisoprolol, celiprolol, esmolol). Use with caution or avoid. Severe Study
- Anticholinesterases, centrally acting are predicted to increase the risk of bradycardia when given with beta blockers, selective. Moderate Anecdotal → Also see TABLE 6 p. 1265
- Antiepileptics (phenobarbital, primidone) are predicted to decrease the exposure to beta blockers, selective (acebutolol, bisoprolol, metoprolol, nebivolol). Moderate Study
- Antimarialis (mefloquine) are predicted to increase the risk of bradycardia when given with beta blockers, selective. Moderate Study
- Bupropion is predicted to increase the exposure to beta blockers, selective (metoprolol, nebivolol). Moderate Study
- Calcium channel blockers (diltiazem) are predicted to increase the risk of cardiodepression when given with beta blockers, selective. Severe Study → Also see TABLE 6 p. 1265 → Also see TABLE 8 p. 1265
- Intravenous calcium channel blockers (verapamil) increase the risk of cardiovascular side-effects when given with beta blockers, selective. Avoid. Severe Study → Also see TABLE 6 p. 1265 → Also see TABLE 8 p. 1265
- Oral calcium channel blockers (verapamil) increase the risk of cardiovascular side-effects when given with beta blockers, selective. Severe Study → Also see TABLE 6 p. 1265 → Also see TABLE 8 p. 1265
- Cinacalcet is predicted to increase the exposure to beta blockers, selective (metoprolol, nebivolol). Moderate Study
- Duloxetine is predicted to increase the exposure to beta blockers, selective (metoprolol, nebivolol). Moderate Study
- Beta blockers, selective are predicted to increase the risk of peripheral vasoconstriction when given with ergotamine. Severe Theoretical
- Beta blockers, selective are predicted to increase the risk of peripheral vasoconstriction when given with ergotamine. Severe Study
- Grapefruit juice greatly decreases the exposure to celiprolol. Moderate Study
- HIV-protease inhibitors (ritonavir) are predicted to increase the exposure to beta blockers, selective (metoprolol, nebivolol). Moderate Study
- Beta blockers, selective are predicted to increase the risk of bradycardia when given with lanreotide. Moderate Theoretical
- Mirabegron is predicted to increase the exposure to beta blockers, selective (metoprolol, nebivolol). Moderate Study
- Panobinostat is predicted to increase the exposure to metoprolol. Monitor and adjust dose. Moderate Theoretical
- Rifampicin slightly decreases the exposure to beta blockers, selective (bisoprolol, metoprolol). Mild Study
- Rifampicin moderately decreases the exposure to celpiropl. Moderate Study
- SSRI, (fluoxetine, paroxetine) are predicted to increase the exposure to beta blockers, selective (metoprolol, nebivolol). Moderate Study
- Beta blockers, selective increase the risk of hypertension and bradycardia when given with sympathomimetics, inotropic (dobutamine). Severe Theoretical
- Beta blockers, selective are predicted to increase the risk of hypertenison and bradycardia when given with sympathomimetics, vasoconstrictor (adrenaline/epinephrine, noradrenaline/norepinephrine). Severe Study
- Terbinafine is predicted to increase the exposure to beta blockers, selective (metoprolol, nebivolol). Moderate Study
- Beta blockers, selective are predicted to increase the risk of bronchospasm when given with theophylline. Avoid. Severe Theoretical

Beta, agonists → see TABLE 17 p. 1268 (reduced serum potassium) bumbetol · formoterol · indacaterol · olodaterol · salbutamol · salmeterol · terbutaline · vilanterol

- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to salmeterol. Avoid. Severe Study
- Atomoxetine is predicted to increase the risk of cardiovascular side-effects when given with beta, agonists (high-dose). Moderate Study
- Cobicistat is predicted to increase the exposure to salmeterol. Avoid. Severe Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to salmeterol. Avoid. Severe Study
- Idealisib is predicted to increase the exposure to salmeterol. Avoid. Severe Study
- Beta, agonists are predicted to increase the risk of glaucoma when given with irtrapatropium. Moderate Anecdotal
- Beta, agonists are predicted to increase the risk of elevated blood pressure when given with linezolid. Avoid. Severe Theoretical
- Macrolides (clarithromycin) are predicted to increase the exposure to salmeterol. Avoid. Severe Study
- Monoamine-oxidase A and B inhibitors, irreversible are predicted to increase the risk of cardiovascular side-effects when given with beta, agonists. Moderate Anecdotal
- Monoamine-oxidase B inhibitors (rasagiline, selegiline) are predicted to increase the risk of severe hypertension when given with beta, agonists. Avoid. Severe Theoretical
- Monoamine-oxidase B inhibitors (safinamide) are predicted to increase the risk of severe hypertension when given with beta2 agonists. Severe Theoretical

Betahistine
- Antihistamines, non-sedating are predicted to decrease the effects of betahistine. Moderate Theoretical
- Antihistamines, sedating are predicted to decrease the effects of betahistine. Moderate Theoretical
- Betamethasone → see corticosteroids
- Betaxolol → see beta blockers, selective
- Bevacizumab → see monoclonal antibodies
- Bexarotene → see retinoids
- Beaflazate → see fibrates
- Bicalutamide
- Bilastine → see antihistamines, non-sedating
Biphasic insulin aspart → see insulins
Biphasic insulin lispro → see insulins
Biphasic isophane insulin → see insulins
Bisacodyl → see TABLE 17 p. 1268 (reduced serum potassium)
Bisoprolol → see beta blockers, selective
Bisphosphonates → see TABLE 2 p. 1264 (nephrotoxicity)

Aminoglycosides increase the risk of hypocalcaemia when given with bisphosphonates. [Moderate] Anecdotal → Also see TABLE 2 p. 1264

Antacids decrease the absorption of alendronic acid. Alendronic acid should be taken at least 30 minutes before antacids. [Moderate] Study

Antacids are predicted to decrease the absorption of ibandronic acid. Avoid antacids for at least 6 hours before or 1 hour after ibandronic acid. [Moderate] Theoretical

Antacids decrease the absorption of risedronate. Separate administration by at least 2 hours. [Moderate] Study

Antacids decrease the absorption of sodium clodronate. Avoid antacids for 2 hours before or 1 hour after sodium clodronate. [Moderate] Study

Aspirin (high-dose) is predicted to increase the risk of gastrointestinal irritation when given with bisphosphonates (alendronic acid, ibandronic acid). [Moderate] Study

Aspirin (high-dose) is predicted to increase the risk of renal impairment when given with sodium clodronate. [Severe] Theoretical

Oral calcium salts decrease the absorption of alendronic acid. Alendronic acid should be taken at least 30 minutes before calcium salts. [Moderate] Study

Oral calcium salts are predicted to decrease the absorption of oral ibandronic acid. Avoid calcium salts for at least 6 hours before or 1 hour after ibandronic acid. [Moderate] Theoretical

Oral calcium salts decrease the absorption of risedronate. Separate administration by at least 2 hours. [Moderate] Study

Oral calcium salts decrease the absorption of sodium clodronate. Avoid calcium salts for 2 hours before or 1 hour after sodium clodronate. [Moderate] Study

Iron (oral) is predicted to decrease the absorption of oral ibandronic acid. Avoid iron (oral) for at least 6 hours before or 1 hour after ibandronic acid. [Moderate] Theoretical

Iron (oral) decreases the absorption of risedronate. Separate administration by at least 2 hours. [Moderate] Study

Iron (oral) decreases the absorption of sodium clodronate. Avoid iron (oral) for 2 hours before or 1 hour after sodium clodronate. [Moderate] Study

Bisphosphonates are predicted to increase the risk of gastrointestinal bleeding when given with iron chelators (deferasirox). [Severe] Theoretical

Oral magnesium decreases the absorption of alendronic acid. Alendronic acid should be taken at least 30 minutes before magnesium. [Moderate] Study

Oral magnesium is predicted to decrease the absorption of oral ibandronic acid. Avoid magnesium for at least 6 hours before or 1 hour after ibandronic acid. [Moderate] Theoretical

Oral magnesium decreases the absorption of risedronate. Separate administration by at least 2 hours. [Moderate] Study

Oral magnesium decreases the absorption of sodium clodronate. Avoid magnesium for 2 hours before or 1 hour after sodium clodronate. [Moderate] Study

NSAIDs are predicted to increase the risk of gastrointestinal irritation when given with bisphosphonates (alendronic acid, ibandronic acid). [Moderate] Study

NSAIDs are predicted to increase the risk of renal impairment when given with sodium clodronate. [Severe] Theoretical

Oral zinc decreases the absorption of oral alendronic acid. Zinc should be taken at least 30 minutes before alendronic acid. [Moderate] Study

Oral zinc is predicted to decrease the absorption of oral ibandronic acid. Avoid zinc for at least 6 hours before or 1 hour after ibandronic acid. [Moderate] Theoretical

Oral zinc decreases the absorption of oral risedronate. Separate administration by at least 2 hours. [Moderate] Study

Oral zinc decreases the absorption of oral sodium clodronate. Avoid zinc for 2 hours before or 1 hour after sodium clodronate. [Moderate] Study

Bivalirudin → see TABLE 3 p. 1264 (anticoagulant effects)

Ranibizumab is predicted to increase the risk of bleeding events when given with bivalirudin. [Moderate] Theoretical

Bleomycin → see TABLE 15 p. 1267 (myelosuppression), TABLE 5 p. 1264 (thromboembolism)

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with bleomycin. Public Health England advises avoid. [Severe] Theoretical

Monoclonal antibodies (brentuximab vedotin) increase the risk of pulmonary toxicity when given with bleomycin. Avoid. [Severe] → Also see TABLE 15 p. 1267

Platinum compounds (cisplatin) increase the risk of pulmonary toxicity when given with bleomycin. [Severe] Study → Also see TABLE 15 p. 1267

Blinatumomab → see monoclonal antibodies

Bortezomib → see TABLE 8 p. 1265 (hypotension), TABLE 15 p. 1267 (myelosuppression), TABLE 12 p. 1267 (peripheral neuropathy)

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) slightly decrease the exposure to bortezomib. Avoid. [Severe] Study → Also see TABLE 12 p. 1267

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) slightly increase the exposure to bortezomib. [Moderate] Study

Cobicistat slightly decreases the exposure to bortezomib. [Moderate] Study

Enzalutamide slightly decreases the exposure to bortezomib. Avoid. [Severe] Study

HIV- protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) slightly increase the exposure to bortezomib. [Moderate] Study

Idealis slightly increases the exposure to bortezomib. [Moderate] Study → Also see TABLE 15 p. 1267

Macrolides (clarithromycin) slightly increase the exposure to bortezomib. [Moderate] Study

Rifampicin slightly decreases the exposure to bortezomib. Avoid. [Severe] Study

Bosentan

Bosentan is predicted to decrease the exposure to antiarrhythmics (dronedarone). [Severe] Theoretical

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) affect the exposure to bosentan. Avoid. [Severe] Study

Antifungals, azoles (fluconazole) are predicted to increase the exposure to bosentan. Avoid. [Severe] Study

Antifungals, azoles (itraconazole) are predicted to increase the exposure to bosentan. [Moderate] Theoretical

Antifungals, azoles (ketoconazole) moderately increase the exposure to bosentan. [Moderate] Study

Antifungals, azoles (voriconazole) are predicted to increase the exposure to bosentan. Avoid. [Severe] Theoretical

Bosentan is predicted to decrease the exposure to antifungals, azoles (isavuconazole). Avoid. [Severe] Theoretical

Bosentan is predicted to decrease the exposure to axitinib. [Moderate] Theoretical

Bosentan is predicted to decrease the exposure to bedaquiline. Avoid. [Severe] Study

Bosentan is predicted to decrease the exposure to bosutinib. Avoid. [Severe] Theoretical

Bosentan is predicted to decrease the exposure to cabozantinib. [Moderate] Theoretical

Bosentan is predicted to decrease the exposure to calcium channel blockers (amilodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose. [Moderate] Theoretical

Bosentan is predicted to decrease the exposure to calcium channel blockers (diltiazem, verapamil). [Moderate] Theoretical

Cephalosporins (ceftobiprole) are predicted to increase the exposure to bosentan. [Moderate] Theoretical

Bosentan moderately decreases the exposure to ciclosporin and ciclosporin moderately increases the exposure to bosentan. Avoid. [Severe] Study
Bosentan (continued)

▶ Bosentan is predicted to decrease the exposure to cobicistat. Avoid. [Severe] Theoretical

▶ Bosentan is predicted to decrease the exposure to cobimetinib. Avoid. [Severe] Theoretical

▶ Bosentan is predicted to decrease the efficacy of combined hormonal contraceptives. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Study

▶ Bosentan decreases the anticoagulant effect of coumarins. [Moderate] Study

▶ Bosentan is predicted to decrease the exposure to crizotinib. Avoid. [Severe] Theoretical

▶ Bosentan is predicted to decrease the exposure to dabrafenib. [Moderate] Theoretical

▶ Bosentan is predicted to decrease the efficacy of desogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical

▶ Bosentan decreases the exposure to duloxetine. Adjust dose. [Severe] Study

▶ Bosentan is predicted to moderately decrease the exposure to elbasvir. Avoid. [Severe] Study

▶ Bosentan is predicted to decrease the concentration of elvitegravir. Avoid. [Severe] Theoretical

▶ Enzalutamide affects the exposure to bosentan. Avoid. [Severe] Study

▶ Bosentan is predicted to decrease the effects of ergotamine. [Moderate] Theoretical

▶ Bosentan is predicted to decrease the exposure to erlotinib. Avoid. [Severe] Theoretical

▶ Bosentan is predicted to decrease the efficacy of etonogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical

▶ Bosentan is predicted to decrease the exposure to etravirine. Avoid. [Severe] Study

▶ Bosentan is predicted to decrease the concentration of everolimus. Avoid or adjust dose. [Severe] Study

▶ Bosentan is predicted to decrease the exposure to gefitinib. Avoid. [Severe] Theoretical

▶ Bosentan is predicted to markedly decrease the exposure to grazoprevir. Avoid. [Severe] Study

▶ Bosentan is predicted to decrease the concentration of guanfacine. Adjust dose. [Moderate] Theoretical

▶ HIV-protease inhibitors are predicted to increase the exposure to bosentan. [Severe] Study

▶ Bosentan is predicted to decrease the effects of Hormone replacement therapy. [Moderate] Anecdotal

▶ Bosentan is predicted to decrease the exposure to imatinib. Avoid. [Moderate] Study

▶ Bosentan is predicted to decrease the exposure to lapatinib. Avoid. [Severe] Study

▶ Bosentan is predicted to decrease the efficacy of levonorgestrel. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical

▶ Bosentan is predicted to decrease the exposure to lurapidone. Monitor and adjust dose. [Moderate] Theoretical

▶ Macrolides (clarithromycin) are predicted to increase the exposure to bosentan. [Moderate] Theoretical

▶ Bosentan is predicted to decrease the exposure to maraviroc. Avoid. [Moderate] Theoretical

▶ Bosentan is predicted to decrease the concentration of midazolam. Monitor and adjust dose. [Moderate] Theoretical

▶ Bosentan is predicted to decrease the exposure to nilotinib. Avoid. [Severe] Theoretical

▶ Bosentan is predicted to decrease the efficacy of norethisterone. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Anecdotal

▶ Bosentan is predicted to decrease the exposure to olaparib. Avoid. [Moderate] Theoretical

▶ Bosentan decreases the exposure to opioids (methadone). Monitor and adjust dose. [Severe] Study

▶ Bosentan is predicted to decrease the exposure to osimertinib. [Moderate] Theoretical

▶ Bosentan is predicted to decrease the exposure to paritaprevir (with ritonavir and ombitasvir). Avoid. [Severe] Study

▶ Bosentan decreases the exposure to phosphodiesterase type-5 inhibitors. [Moderate] Study

▶ Rifampicin affects the exposure to bosentan. Avoid. [Severe] Study

▶ Bosentan is predicted to decrease the exposure to rilpivirine. Avoid. [Severe] Theoretical

▶ Bosentan is predicted to decrease the exposure to ruxolitinib. Monitor and adjust dose. [Moderate] Theoretical

▶ Bosentan is predicted to decrease the concentration of sirolimus and sirolimus potentially increases the concentration of bosentan. Avoid. [Severe] Theoretical

▶ St John’s Wort is predicted to decrease the exposure to bosentan. Avoid. [Moderate] Theoretical

▶ Bosentan slightly decreases the exposure to statins (atorvastatin). [Mild] Study

▶ Bosentan moderately decreases the exposure to statins (simvastatin). [Moderate] Study

▶ Bosentan increases the risk of hepatotoxicity when given with sulfonyleureas (glibenclamide). Avoid. [Severe] Study

▶ Bosentan is predicted to decrease the concentration of tariquidar. Avoid. [Severe] Theoretical

▶ Bosentan decreases the concentration of temsirolimus. Avoid. [Severe] Theoretical

▶ Bosentan is predicted to decrease the concentration of ticagrelor. [Moderate] Theoretical

▶ Bosentan is predicted to decrease the exposure to tolvaptan. [Moderate] Theoretical

▶ Bosentan decreases the efficacy of ulipristal. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Anecdotal

▶ Bosentan is predicted to decrease the exposure to velpatasvir. Avoid. [Moderate] Theoretical

Bosutinib → see TABLE 15 p. 1267 (myelosuppression), TABLE 9 p. 1266 (QT-interval prolongation)

▶ Antacids are predicted to decrease the absorption of bosutinib. Bosutinib should be taken at least 12 hours before antacids. [Moderate] Theoretical

▶ Antirhythmic drugs (dronedarone) are predicted to increase the exposure to bosutinib. Avoid or adjust bosutinib dose. [Severe] Theoretical → Also see TABLE 9 p. 1266

▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to very markedly decrease the exposure to bosutinib. Avoid. [Severe] Study

▶ Antifungals, azoles (itraconazole, isavuconazole, posaconazole) are predicted to increase the exposure to bosutinib. Avoid or adjust bosutinib dose. [Severe] Theoretical

▶ Antifungals, azoles (fluconazole, itraconazole, ketoconazole, voriconazole) are predicted to markedly increase the exposure to bosutinib. Avoid or adjust bosutinib dose. [Severe] Theoretical

▶ Aprepitant is predicted to increase the exposure to bosutinib. Avoid or adjust bosutinib dose. [Severe] Theoretical

▶ Bosentan is predicted to decrease the exposure to bosutinib. Avoid. [Severe] Theoretical

▶ Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to bosutinib. Avoid or adjust bosutinib dose. [Severe] Theoretical

▶ Cobicistat is predicted to markedly increase the exposure to bosutinib. Avoid or adjust bosutinib dose. [Severe] Study

▶ Bosutinib is predicted to increase the risk of bleeding events when given with coumarins. [Severe] Theoretical

▶ Crizotinib is predicted to increase the exposure to bosutinib. Avoid or adjust bosutinib dose. [Severe] Theoretical → Also see TABLE 15 p. 1267 → Also see TABLE 9 p. 1266

▶ Efavirenz is predicted to decrease the exposure to bosutinib. Avoid. [Severe] Theoretical

▶ Enzalutamide is predicted to very markedly decrease the exposure to bosutinib. Avoid. [Severe] Study
Bosutinib – Bupropion 1303

- Etravirine is predicted to decrease the exposure to bosutinib. Avoid. [Severe] Theoretical
- Fosaprepitant is predicted to increase the exposure to bosutinib. [Severe] Theoretical
- Grapefruit juice is predicted to increase the exposure to bosutinib. Avoid. [Moderate] Theoretical
- H₂ receptor antagonists are predicted to decrease the absorption of bosutinib. [Moderate] Theoretical
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to markedly increase the exposure to bosutinib. Avoid or adjust bosutinib dose. [Severe] Study → Also see TABLE 9 p. 1266
- HIV-protease inhibitors (indinavir) are predicted to increase the exposure to bosutinib. Avoid or adjust bosutinib dose. [Severe] Theoretical
- Idelalisib is predicted to markedly increase the exposure to bosutinib. Avoid or adjust bosutinib dose. [Severe] Study → Also see TABLE 15 p. 1267
- Imatinib is predicted to increase the exposure to bosutinib. Avoid or adjust bosutinib dose. [Severe] Theoretical → Also see TABLE 15 p. 1267
- Macrolides (clarithromycin) are predicted to markedly increase the exposure to bosutinib. Avoid or adjust bosutinib dose. [Severe] Study → Also see TABLE 9 p. 1266
- Macrolides (erythromycin) are predicted to increase the exposure to bosutinib. Avoid or adjust bosutinib dose. [Severe] Theoretical
- Modafinil is predicted to decrease the exposure to bosutinib. Avoid. [Severe] Theoretical
- Netupitant is predicted to increase the exposure to bosutinib. Avoid or adjust bosutinib dose. [Severe] Theoretical
- Nevirapine is predicted to decrease the exposure to bosutinib. Avoid. [Severe] Theoretical
- Nilotinib is predicted to increase the exposure to bosutinib. Avoid or adjust bosutinib dose. [Severe] Theoretical → Also see TABLE 15 p. 1267 → Also see TABLE 9 p. 1266
- Bosutinib is predicted to increase the risk of bleeding events when given with phenindione. [Severe] Theoretical
- Pitolisant is predicted to decrease the exposure to bosutinib. Avoid. [Severe] Theoretical
- Proton pump inhibitors are predicted to decrease the absorption of bosutinib. [Moderate] Study
- Rifampicin is predicted to very markedly decrease the exposure to bosutinib. Avoid. [Severe] Study → Also see TABLE 13 p. 1267
- St John’s Wort is predicted to decrease the exposure to bosutinib. Avoid. [Severe] Theoretical

Botulinum toxin type A → see TABLE 20 p. 1268 (neuromuscular blocking effects)

Botulinum toxin type B → see TABLE 20 p. 1268 (neuromuscular blocking effects)

Bowel cleansing preparations

ROUTE-SPECIFIC INFORMATION Other oral drugs should not be taken 1 hour before, or after, administration of bowel cleansing preparations because absorption may be impaired. Consider withholding ACE inhibitors, angiotensin-II receptor antagonists, and NSAIDs on the day that bowel cleansing preparations are given and for up to 72 hours after the procedure. Also consider withholding diuretics on the day that bowel cleansing preparations are given.

Brentuximab vedotin → see monoclonal antibodies
Brimonidine → see TABLE 6 p. 1265 (bradycardia), TABLE B p. 1265 (hypotension), TABLE 11 p. 1266 (CNS depressant effects)
Brinzolamide

ROUTE-SPECIFIC INFORMATION Since systemic absorption can follow topical application, the possibility of interactions should be borne in mind.

Brimonidine → see antiepileptics
Bupropion → see table 13 p. 1267 (serotonin syndrome)
Bupropion is predicted to increase the exposure to antihistamines (flecainide). [Severe] Theoretical
Bupropion is predicted to increase the exposure to antihistamines (propafenone). Monitor and adjust dose. [Moderate] Study
Bupropion is predicted to increase the exposure to anticholinesterases, centrally acting (donepezil). Moderate Theoretical
Bupropion is predicted to increase the exposure to anticholinesterases, centrally acting (galantamine). Moderate Study
Bupropion is predicted to increase the exposure to beta blockers, non-selective (carvedilol, timolol). [Moderate] Study
Bupropion is predicted to increase the exposure to beta blockers, selective (metoprolol, nebivolol). [Moderate] Study
Bupropion is predicted to slightly increase the exposure to darifenacin. [Mild] Study
Bupropion increases the risk of side-effects when given with dopamine receptor agonists (amantadine). Moderate Study
Efavirenz moderately decreases the exposure to bupropion. Moderate Study
Enzalutamide is predicted to markedly decrease the exposure to bupropion. [Severe] Theoretical
HIV-protease inhibitors (ritonavir) slightly to moderately decrease the exposure to bupropion. Moderate Study
Bupropion increases the risk of side-effects when given with levodopa. [Moderate] Study
Bupropion increases the risk of intraoperative hypertension when given with linezolid. [Severe] Anecdotal → Also see TABLE 13 p. 1267
Lumacaftor is predicted to decrease the exposure to bupropion. Adjust dose. [Moderate] Theoretical
Mefloquine is predicted to decrease the efficacy of bupropion. Avoid. [Severe] Theoretical
Methyldopa decreases the exposure to bupropion. Avoid. [Severe] Theoretical 
Methylxanthines are predicted to increase the risk of severe hypertension when given with bupropion. [Severe] Theoretical → Also see TABLE 13 p. 1267
Moclobemide is predicted to increase the risk of severe hypertension when given with bupropion. Avoid. [Severe] Theoretical → Also see TABLE 13 p. 1267
Monoamine-oxidase A and B inhibitors, irreversible are predicted to increase the risk of severe hypertension when given with bupropion. Avoid and for 14 days after stopping the MAOI. [Severe] Theoretical → Also see TABLE 13 p. 1267
Monoamine-oxidase B inhibitors are predicted to increase the risk of severe hypertension when given with bupropion. Avoid. [Moderate] Theoretical → Also see TABLE 13 p. 1267
Bupropion is predicted to increase the efficacy of opioids (codeine). [Moderate] Theoretical
Bupropion is predicted to decrease the efficacy of opioids (tramadol). [Severe] Study → Also see TABLE 13 p. 1267
Bupropion is predicted to moderately increase the exposure to pitolisant. Use with caution and adjust dose. [Moderate] Study
Rifampicin is predicted to markedly decrease the exposure to bupropion. [Severe] Study
Bupropion is predicted to increase the exposure to risperidone. Adjust dose. [Moderate] Study
Bupropion is predicted to increase the exposure to SSRIs (dapoxetine). [Moderate] Theoretical → Also see TABLE 13 p. 1267
Bupropion is predicted to decrease the efficacy of tamoxifen. Avoid. [Severe] Study
Bupropion is predicted to increase the exposure to tricyclic antidepressants. Monitor for toxicity and adjust dose. [Severe] Study → Also see TABLE 13 p. 1267
Bupropion is predicted to increase the exposure to vortioxetine. Monitor and adjust dose. [Moderate] Study → Also see TABLE 13 p. 1267
1304 Buspirone — Calcium channel blockers
Buspirone → see TABLE 13 p. 1267 (serotonin syndrome)
▶ Antiarrhythmics (dronedarone) are predicted to increase the
exposure to buspirone. Use with caution and adjust dose.

BNF 74

▶
▶

o Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone) are predicted to decrease the exposure
to buspirone. Use with caution and adjust dose. r Study
▶ Antifungals, azoles (fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure to buspirone. Use with
caution and adjust dose. o Study
▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are
predicted to increase the exposure to buspirone. Adjust
buspirone dose, p. 325. r Study
▶ Antifungals, azoles (miconazole) are predicted to increase the
concentration of buspirone. Use with caution and adjust dose.
▶

o Theoretical
▶
▶

▶

Interactions | Appendix 1

A1

▶
▶
▶

▶
▶

o Study
▶
▶

▶
▶

Aprepitant is predicted to increase the exposure to buspirone.
Use with caution and adjust dose. o Study
Calcium channel blockers (diltiazem, verapamil) are predicted to
increase the exposure to buspirone. Use with caution and
adjust dose. o Study
Cobicistat is predicted to increase the exposure to buspirone.
Adjust buspirone dose, p. 325. r Study
Crizotinib is predicted to increase the exposure to buspirone.
Use with caution and adjust dose. o Study
Enzalutamide is predicted to decrease the exposure to
buspirone. Use with caution and adjust dose. r Study
Grapefruit juice increases the exposure to buspirone. Avoid.

▶
▶

▶
▶

n Study

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir,
lopinavir, ritonavir, saquinavir, tipranavir) are predicted to
increase the exposure to buspirone. Adjust buspirone dose,

▶

HIV-protease inhibitors (indinavir) are predicted to increase the
exposure to buspirone. Use with caution and adjust dose.

▶

o Study

▶

▶
▶

p. 325. r Study

▶

Study
▶

Macrolides (erythromycin) are predicted to increase the
exposure to buspirone. Use with caution and adjust dose.
o Study

▶

Buspirone is predicted to increase the risk of elevated blood
pressure when given with monoamine-oxidase A and B
inhibitors, irreversible. Avoid. r Anecdotal → Also see
TABLE 13 p. 1267

Netupitant is predicted to increase the exposure to buspirone.
Use with caution and adjust dose. o Study
▶ Nilotinib is predicted to increase the exposure to buspirone.
Use with caution and adjust dose. o Study
▶ Rifampicin is predicted to decrease the exposure to buspirone.
Use with caution and adjust dose. r Study
Busulfan → see alkylating agents
Cabazitaxel → see taxanes
Cabergoline → see dopamine receptor agonists
Cabozantinib → see TABLE 15 p. 1267 (myelosuppression), TABLE 9

▶

p. 1266 (QT-interval prolongation)
▶

Antiarrhythmics (dronedarone) are predicted to increase the
exposure to cabozantinib. o Theoretical → Also see TABLE 9
p. 1266

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone) moderately decrease the exposure to
cabozantinib. Avoid. o Study
▶ Antifungals, azoles (fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure to cabozantinib.

▶

▶

Antifungals, azoles (itraconazole, ketoconazole, voriconazole)
slightly increase the exposure to cabozantinib. o
Study → Also see TABLE 9 p. 1266

HIV-protease inhibitors (indinavir) are predicted to increase the
exposure to cabozantinib. o Theoretical
Idelalisib slightly increases the exposure to cabozantinib.
o Study → Also see TABLE 15 p. 1267
Imatinib is predicted to increase the exposure to cabozantinib.
o Theoretical → Also see TABLE 15 p. 1267
Macrolides (clarithromycin) slightly increase the exposure to
cabozantinib. o Study → Also see TABLE 9 p. 1266
Macrolides (erythromycin) are predicted to increase the
exposure to cabozantinib. o Theoretical
Netupitant is predicted to increase the exposure to
cabozantinib. o Theoretical
Nevirapine is predicted to decrease the exposure to
cabozantinib. o Theoretical
Nilotinib is predicted to increase the exposure to cabozantinib.
o Theoretical → Also see TABLE 15 p. 1267 → Also see TABLE 9
p. 1266

Cabozantinib is predicted to increase the risk of bleeding
events when given with phenindione. r Theoretical
Rifampicin moderately decreases the exposure to cabozantinib.
Avoid. o Study
▶ St John’s Wort is predicted to decrease the exposure to
cabozantinib. o Theoretical
Caffeine citrate
▶ Caffeine citrate decreases the efﬁcacy of antiarrhythmics
(adenosine). Separate administration by 24 hours. n Study
▶ Antiepileptics (fosphenytoin, phenytoin) are predicted to
moderately increase the clearance of caffeine citrate. Monitor
and adjust dose. o Study
▶ HIV-protease inhibitors (ritonavir) are predicted to moderately
increase the clearance of caffeine citrate. Monitor and adjust
dose. o Study
▶ Rifampicin is predicted to moderately increase the clearance of
caffeine citrate. Monitor and adjust dose. o Study
▶ SSRIs (fluvoxamine) markedly decrease the clearance of
caffeine citrate. Monitor and adjust dose. r Study
▶ Caffeine citrate decreases the clearance of theophylline.
▶

▶

o Study

Calcipotriol → see vitamin D substances
Calcitonin (salmon)
▶ Calcitonin (salmon) decreases the concentration of lithium.
Monitor lithium concentration and adjust dose. o Study
Calcitriol → see vitamin D substances
Calcium acetate → see calcium salts
Calcium carbonate → see calcium salts
Calcium channel blockers → see TABLE 6 p. 1265 (bradycardia),
TABLE 8 p. 1265 (hypotension)

amlodipine . clevidipine . diltiazem . felodipine . isradipine .
lacidipine . lercanidipine . nicardipine . nifedipine . nimodipine .
verapamil .

.

o Theoretical
▶

Cabozantinib is predicted to increase the risk of bleeding
events when given with coumarins. r Theoretical
Crizotinib is predicted to increase the exposure to
cabozantinib. o Theoretical → Also see TABLE 15 p. 1267
→ Also see TABLE 9 p. 1266
Efavirenz is predicted to decrease the exposure to
cabozantinib. o Theoretical
Enzalutamide moderately decreases the exposure to
cabozantinib. Avoid. o Study
Grapefruit juice is predicted to increase the exposure to
cabozantinib. o Theoretical
HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir,
lopinavir, ritonavir, saquinavir, tipranavir) slightly increase the
exposure to cabozantinib. o Study → Also see TABLE 9
p. 1266

▶

▶

Idelalisib is predicted to increase the exposure to buspirone.
Adjust buspirone dose, p. 325. r Study
▶ Imatinib is predicted to increase the exposure to buspirone.
Use with caution and adjust dose. o Study
▶ Buspirone is predicted to increase the risk of elevated blood
pressure when given with linezolid. Avoid. r Theoretical
→ Also see TABLE 13 p. 1267
▶ Macrolides (clarithromycin) are predicted to increase the
exposure to buspirone. Adjust buspirone dose, p. 325. r

Aprepitant is predicted to increase the exposure to
cabozantinib. o Theoretical
Bosentan is predicted to decrease the exposure to
cabozantinib. o Theoretical
Calcium channel blockers (diltiazem, verapamil) are predicted to
increase the exposure to cabozantinib. o Theoretical
Cobicistat slightly increases the exposure to cabozantinib.

▶

Verapamil is predicted to increase the exposure to afatinib.
Separate administration by 12 hours. o Study

downloaded from www.medicalbr.com


Calcium channel blockers

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to aldosterone antagonists (eplerenone). Adjust eplerenone dose. [Severe] Study → Also see TABLE 8 p. 1265

Verapamil moderately increases the exposure to atorvastatin. [Moderate] Study → Also see TABLE 8 p. 1265

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to alpha blockers (tamsulosin). [Moderate] Theoretical → Also see TABLE 8 p. 1265

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to aliskiren. [Moderate] Study → Also see TABLE 8 p. 1265

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to calcium channel blockers (diltiazem, verapamil). [Moderate] Theoretical

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to alprazolam. [Severe] Study

Verapamil moderately increases the exposure to anthracyclines (doxorubicin). [Moderate] Study

Antiarrhythmics (disopyramide) are predicted to increase the risk of cardiodepression when given with verapamil. [Severe] Theoretical

Antiarrhythmics (dronedarone) are predicted to increase the exposure to calcium channel blockers (amlodipine, felodipine, isradipine, lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose. [Moderate] Study

Antifungals (amidodarone) are predicted to increase the risk of cardiodepression when given with calcium channel blockers (diltiazem, verapamil). Avoid. [Severe] Theoretical → Also see TABLE 6 p. 1265

Calcium channel blockers (diltiazem, verapamil) increase the exposure to antiarrhythmics (dronedarone) and antiarrhythmics (amidodarone) increase the exposure to calcium channel blockers (diltiazem, verapamil). [Moderate] Study

Verapamil increases the risk of cardiodepression when given with antiarrhythmics (flexicainide). [Severe] Anecdotal → Also see TABLE 6 p. 1265

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to antiarrhythmics (propafenone). Monitor and adjust dose. [Moderate] Study

Calcium channel blockers (diltiazem, verapamil) increase the risk of bradycardia when given with anticholinesterases, centrally acting. [Moderate] Anecdotal → Also see TABLE 6 p. 1265

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) decrease the exposure to diltiazem. [Severe] Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) decrease the exposure to isradipine. Avoid. [Moderate] Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to verapamil. [Severe] Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to calcium channel blockers (amlodipine, felodipine, lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose. [Moderate] Study

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the concentration of antiepileptics (carbamazepine). [Severe] Anecdotal

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to markedly increase the exposure to lercanidipine. Avoid. [Severe] Study

Antifungals, azoles (miconazole) are predicted to increase the exposure to calcium channel blockers (amlodipine, clevidipine, felodipine, isradipine, lercanidipine, nicardipine, nifedipine, nimodipine). Use with caution and adjust dose. [Moderate] Theoretical

Antifungals, azoles (fluconazole, itraconazole, ketoconazole, posaconazole, voriconazole) are predicted to increase the exposure to calcium channel blockers (amlodipine, felodipine, isradipine, lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose. [Moderate] Study

Antifungals, azoles (fluconazole) (high-dose) are predicted to increase the exposure to calcium channel blockers (diltiazem, verapamil). [Moderate] Theoretical

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to calcium channel blockers (diltiazem, verapamil). [Severe] Study

Antifungals, azoles (posaconazole) are predicted to increase the exposure to calcium channel blockers (diltiazem, verapamil). [Moderate] Theoretical

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to antifungals, azoles (isavuconazole). [Moderate] Theoretical

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to antihistamines, non-sedating (mizolastine). [Severe] Theoretical

Antiarrhythmics (mefloquine) are predicted to increase the risk of bradyarrhythmia when given with calcium channel blockers. [Severe] Theoretical

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the concentration of antiarrhythmics (piperacaine). [Moderate] Theoretical

Verapamil is predicted to increase the exposure to apixaban. [Moderate] Theoretical

Aprepitant is predicted to increase the exposure to calcium channel blockers (amlodipine, felodipine, isradipine, laccadipine, lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose. [Moderate] Study

Diltiazem increases the exposure to aprepitant and aprepitant increases the exposure to diltiazem. [Moderate] Study

Verapamil is predicted to increase the exposure to aprepitant and aprepitant is predicted to increase the exposure to verapamil. [Moderate] Theoretical

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to axitinib. [Moderate] Theoretical

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to bedaquiline. Avoid prolonged use. [Mild] Theoretical

Diltiazem is predicted to increase the risk of cardiodepression when given with beta blockers, non-selective. [Severe] Study → Also see TABLE 6 p. 1265 → Also see TABLE 8 p. 1265

Intravenous verapamil increases the risk of cardiovascular side-effects when given with beta blockers, non-selective. Avoid. [Severe] Study → Also see TABLE 6 p. 1265 → Also see TABLE 8 p. 1265

Oral verapamil increases the risk of cardiovascular side-effects when given with beta blockers, non-selective. [Severe] Study → Also see TABLE 6 p. 1265 → Also see TABLE 8 p. 1265

Diltiazem is predicted to increase the risk of cardiodepression when given with beta blockers, selective. [Severe] Study → Also see TABLE 6 p. 1265 → Also see TABLE 8 p. 1265

Intravenous verapamil increases the risk of cardiovascular side-effects when given with beta blockers, selective. Avoid. [Severe] Study → Also see TABLE 6 p. 1265 → Also see TABLE 8 p. 1265

Oral verapamil increases the risk of cardiovascular side-effects when given with beta blockers, selective. Avoid. [Severe] Study → Also see TABLE 6 p. 1265 → Also see TABLE 8 p. 1265

Bosentan is predicted to decrease the exposure to calcium channel blockers (amlodipine, felodipine, isradipine, lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose. [Moderate] Theoretical

Bosentan is predicted to decrease the exposure to calcium channel blockers (diltiazem, verapamil). [Moderate] Theoretical

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to bosutinib. Avoid or adjust bosutinib dose. [Severe] Theoretical

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to buspirone. Use with caution and adjust dose. [Moderate] Study

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to cabozantinib. [Moderate] Theoretical

Calcium channel blockers (diltiazem) are predicted to increase the exposure to calcium channel blockers (amlodipine, felodipine, isradipine, lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose. [Moderate] Study → Also see TABLE 8 p. 1265

Calcium channel blockers (verapamil) are predicted to increase the exposure to calcium channel blockers (amlodipine, felodipine, isradipine, lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose. [Moderate] Study → Also see TABLE 8 p. 1265

Calcium channel blockers (diltiazem) are predicted to increase the exposure to calcium channel blockers (felodipine, isradipine, lercanidipine, nicardipine, nifedipine, nimodipine).
Calcium channel blockers (continued)

Monitor and adjust dose. [Moderate] Study → Also see TABLE 8 p. 1265

- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to certitinib. [Moderate] Theoretical
- Calcium channel blockers (diltiazem, nicardipine, verapamil) increase the concentration of ciclosporin. [Severe] Study
- Ciclosporin moderately increases the exposure to lercanidipine. Use with caution or avoid. [Severe] Study
- Cobicistat is predicted to increase the exposure to calcium channel blockers (amlodipine, felodipine, isradipine, lacidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose. [Moderate] Study
- Cobicistat is predicted to increase the exposure to calcium channel blockers (diltiazem, verapamil). [Severe] Theoretical
- Cobicistat is predicted to markedly increase the exposure to lercanidipine. Avoid. [Severe] Study
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to cobimetinib. [Severe] Theoretical
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to colchicine. Adjust colchicine dose, p. 1020. [Severe] Study
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to corticosteroids (methylprednisolone). Monitor and adjust dose. [Moderate] Study
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to crizotinib. [Moderate] Theoretical → Also see TABLE 6 p. 1265
- Crizotinib is predicted to increase the exposure to calcium channel blockers (amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose. [Moderate] Study
- Verapamil increases the exposure to dabigatran. Adjust dabigatran dose, p. 131. [Severe] Study
- Intravenous dantrolene potentially increases the risk of acute hyperkalaemia and cardiovascular collapse when given with calcium channel blockers (diltiazem, verapamil). Avoid. [Severe] Anecdotal
- Calcium channel blockers (diltiazem, verapamil) are predicted to slightly increase the exposure to darifenacin. [Moderate] Study
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to dasatinib. [Severe] Study
- Intravenous dantrolene potentially increases the risk of QT-prolongation when given with domperidone. Avoid. [Severe] Study
→ Also see TABLE 6 p. 1265
- Calcium channel blockers (diltiazem, verapamil) increase the risk of QT-prolongation when given with domperidone. Avoid. [Severe] Study
- Calcium channel blockers (diltiazem, verapamil) increase the concentration of digoxin. Monitor and adjust dose. [Severe] Study → Also see TABLE 8 p. 1265
- Calcium channel blockers (diltiazem, verapamil) increase the risk of QT-prolongation when given with domperidone. Avoid. [Severe] Study
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to dopamine receptor agonists (bromocriptine, cabergoline). [Severe] Theoretical → Also see TABLE 8 p. 1265
- Calcium channel blockers (diltiazem, verapamil) are predicted to moderately increase the exposure to dutasteride. [Moderate] Study
- Verapamil is predicted to slightly increase the exposure to edoxaban. [Severe] Theoretical
- Efavirenz is predicted to decrease the exposure to calcium channel blockers (amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose. [Moderate] Theoretical
- Efavirenz is predicted to decrease the exposure to calcium channel blockers (diltiazem, verapamil). [Moderate] Theoretical
- Enalaprilat is predicted to decrease the exposure to calcium channel blockers (amlodipine, felodipine, lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose. [Moderate] Study
- Enalaprilat decreases the exposure to diltiazem. [Severe] Study
- Enalaprilat decreases the exposure to isradipine. Avoid. [Moderate] Study
- Enalaprilat is predicted to decrease the exposure to verapamil. [Severe] Study
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the risk of ergotism when given with ergometrine. [Severe] Theoretical
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the risk of ergotism when given with ergometrine. [Severe] Theoretical
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to everolimus. Avoid or adjust dose. [Moderate] Study
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to fesoterodine. Adjust fesoterodine dose in hepatic and renal impairment, p. 732. [Mild] Study
- Verapamil is predicted to increase the exposure to fidaxomicin. Avoid. [Moderate] Study
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to fingolimod. Avoid. [Moderate] Theoretical → Also see TABLE 6 p. 1265
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to gefitinib. [Moderate] Theoretical
- Grapefruit juice very slightly increases the exposure to amiodipine. Avoid. [Mild] Study
- Grapefruit juice increases the exposure to calcium channel blockers (nifedipine, verapamil). Avoid. [Mild] Study
- Grapefruit juice increases the exposure to felodipine. Avoid. [Mild] Study
- Grapefruit juice is predicted to increase the exposure to lercanidipine. Avoid. [Moderate] Theoretical
- Grapefruit juice increases the exposure to nicardipine. [Mild] Study
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the concentration of guanfacine. Adjust guanfacine dose, p. 335. [Moderate] Theoretical → Also see TABLE 8 p. 1265
- H1 receptor antagonists (cimetidine) (high-dose) are predicted to increase the exposure to lercanidipine. [Moderate] Theoretical
- H1 receptor antagonists (cimetidine) moderately increase the exposure to nifedipine. Monitor and adjust dose. [Severe] Study
- H1 receptor antagonists (cimetidine) increase the exposure to verapamil. [Moderate] Study
- H1 receptor antagonists (cimetidine) slightly increase the exposure to calcium channel blockers (diltiazem, isradipine, nimodipine). Monitor and adjust dose. [Moderate] Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to markedly increase the exposure to lercanidipine. Avoid. [Severe] Study
- HIV-protease inhibitors are predicted to increase the exposure to calcium channel blockers (amlodipine, felodipine, isradipine, lacidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose. [Moderate] Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to calcium channel blockers (diltiazem, verapamil). [Severe] Study
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to ibrutinib. Avoid or adjust ibrutinib dose, p. 902. [Severe] Theoretical
- Idelalisib is predicted to increase the exposure to calcium channel blockers (amlodipine, felodipine, isradipine, lacidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose. [Moderate] Study
- Idelalisib is predicted to increase the exposure to calcium channel blockers (diltiazem, verapamil). [Severe] Study
- Idelalisib is predicted to markedly increase the exposure to lercanidipine. Avoid. [Severe] Study
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to imatinib. [Moderate] Theoretical
- Imatinib is predicted to increase the exposure to calcium channel blockers (amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose. [Moderate] Study
- Imatinib is predicted to increase the exposure to calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to ibavrafidine. Avoid. [Moderate] Study
→ Also see TABLE 6 p. 1265
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to ivaacaftor. Adjust ivaacaftor dose, p. 281. [Severe] Study
Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to lapatinib. [Moderate] Study
Calcium channel blockers (diltiazem, verapamil) are predicted to increase the risk of neurotoxicity when given with lithium. [Severe] Anecdotal
Calcium channel blockers (amlodipine, lacidipine) are predicted to increase the exposure to lomitapide. Separate administration by 12 hours. [Moderate] Theoretical
Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to lomitapide. Avoid. [Moderate] Theoretical
Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to lurasidone. [Moderate] Study → Also see TABLE 8 p. 1265
Macrolides (clarithromycin) are predicted to markedly increase the exposure to verapamil. Avoid. [Severe] Study
Macrolides (erythromycin) are predicted to increase the exposure to diltiazem. [Severe] Theoretical
Macrolides (clarithromycin, erythromycin) are predicted to increase the exposure to calcium channel blockers (amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nifedipine, nimodipine). Monitor and adjust dose. [Moderate] Study
Macrolides (clarithromycin) are predicted to increase the exposure to calcium channel blockers (diltiazem, verapamil). [Severe] Study
Calcium channel blockers (amlodipine, clevidipine, felodipine, isradipine, lacidipine, lercanidipine, nifedipine, nimodipine, verapamil) in pregnant women. [Severe] Anecdotal
Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to midazolam. Monitor side effects and adjust dose. [Severe] Study
Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to naloxegol. Adjust naloxegol dose and monitor side effects, p. 63. [Moderate] Study
Netupitant is predicted to increase the exposure to calcium channel blockers (amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nifedipine, nimodipine). Monitor and adjust dose. [Moderate] Study
Nevirapine is predicted to decrease the exposure to calcium channel blockers (amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nifedipine, nimodipine). Monitor and adjust dose. [Moderate] Theoretical
Nevirapine is predicted to decrease the exposure to calcium channel blockers (diltiazem, verapamil). [Moderate] Theoretical
Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to nilotinib. [Moderate] Theoretical
Nilotinib is predicted to increase the exposure to calcium channel blockers (amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nifedipine, nimodipine). Monitor and adjust dose. [Moderate] Study
Verapamil is predicted to increase the exposure to nintedanib. [Moderate] Study
Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to olaparib. Avoid or adjust olaparib dose, p. 919. [Moderate] Theoretical
Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to alfentanil, buprenorphone, fentanyl, oxycodone). Monitor and adjust dose. [Moderate] Study → Also see TABLE 6 p. 1265
Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to opioids (methadone, sufentanil). [Moderate] Theoretical → Also see TABLE 6 p. 1265
Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to oxybutynin. [Mild] Theoretical
Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to oxycodone. [Mild] Theoretical
Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to phosphodiesterase type-5 inhibitors (avanafil). Adjust avanafil dose, p. 765. [Moderate] Theoretical → Also see TABLE 8 p. 1265
Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to phosphodiesterase type-5 inhibitors (sildenafil). Monitor and adjust sildenafil dose, p. 766. [Moderate] Study → Also see TABLE 8 p. 1265
Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to phosphodiesterase type-5 inhibitors (tadalafil). [Severe] Theoretical → Also see TABLE 8 p. 1265
Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to phosphodiesterase type-5 inhibitors (vardenafil). Adjust dose. [Severe] Theoretical → Also see TABLE 8 p. 1265
Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to pimozide. Avoid. [Severe] Theoretical → Also see TABLE 8 p. 1265
Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to quetiapine. Avoid. [Moderate] Study → Also see TABLE 8 p. 1265
Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to ranolazine. [Severe] Study
Rifampicin is predicted to decrease the exposure to calcium channel blockers (amlodipine, felodipine, lacidipine, lercanidipine, nicardipine, nimodipine). Monitor and adjust dose. [Moderate] Study
Rifampicin decreases the exposure to diltiazem. [Severe] Study
Rifampicin decreases the exposure to isradipine. Avoid. [Moderate] Study
Rifampicin moderately decreases the exposure to nifedipine. Avoid. [Severe] Study
Rifampicin is predicted to decrease the exposure to verapamil. [Severe] Study
Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to ruxolitinib. [Moderate] Theoretical
Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to saxagliptin. [Mild] Study
Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to simiprevir. Avoid. [Severe] Study
Calcium channel blockers (diltiazem, verapamil) increase the concentration of sirolimus. Monitor and adjust dose. [Moderate] Study
Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to SSRI (dapoxetine). Adjust dapoxetine dose, p. 773. [Moderate] Theoretical
St John’s Wort is predicted to decrease the exposure to calcium channel blockers (amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nimodipine). Monitor and adjust dose. [Moderate] Theoretical
St John’s Wort is predicted to decrease the exposure to statins (atorvastatin). Monitor and adjust dose. [Severe] Theoretical
Amlodipine slightly increases the exposure to statins (simvastatin). Adjust simvastatin dose, p. 198. [Mild] Study
Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to statins (simvastatin). Use with caution and adjust simvastatin dose, p. 198. [Severe] Study
Sulfipyrazone decreases the exposure to verapamil. [Moderate] Study
Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to sunitinib. [Moderate] Theoretical
Calcium channel blockers (diltiazem, verapamil) are predicted to increase the concentration of tacrolimus. [Severe] Study
Nicardipine potentially increases the concentration of tacrolimus. Monitor concentration and adjust dose. [Severe] Anecdotal
Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to taxanes (cabazitaxel. [Moderate] Theoretical
Calcium channel blockers (diltiazem, verapamil) are predicted to increase the concentration of temsirolimus. [Moderate] Theoretical
Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to tolterodine. [Mild] Theoretical
Calcium channel blockers (continued)
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to tolvaptan. Adjust dose. [Moderate] Theoretical
- Verapamil is predicted to increase the exposure to topotecan. [Severe] Study
- Verapamil is predicted to increase the concentration of trametinib. [Moderate] Theoretical
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to trazodone. [Moderate] Theoretical
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to venetoclax. Avoid or adjust venetoclax dose. p. 919. [Severe] Study
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to vinca alkaloids. [Severe] Theoretical
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to zopiclone. Adjust dose. [Moderate] Study

Calcium chloride → see calcium salts
Calcium gluconate → see calcium salts
Calcium lactate → see calcium salts
Calcium phosphate → see calcium salts
Calcium salts

calcium acetate • calcium carbonate • calcium chloride • calcium gluconate • calcium lactate • calcium phosphate

Separation of administration Calcium carbonate-containing antacids should preferably not be taken at the same time as other drugs since they might impair absorption. Antacids might damage enteric coatings designed to prevent dissolution in the stomach.

- Oral calcium salts decrease the absorption of alkylating agents (estramustine). [Severe] Study
- Calcium carbonate decreases the absorption of antimalarials (chloroquine). Separate administration by at least 4 hours. [Moderate] Study
- Calcium carbonate is predicted to decrease the absorption of antimalarials (proguanil). Separate administration by at least 2 hours. [Moderate] Study
- Oral calcium salts decrease the absorption of biphosphonates (alendronic acid). Alendronic acid should be taken at least 30 minutes before calcium salts. [Moderate] Study
- Oral calcium salts are predicted to decrease the absorption of oral biphosphonates (ibandronic acid). Avoid calcium salts for at least 6 hours before or 1 hour after ibandronic acid. [Moderate] Theoretical
- Oral calcium carbonate is predicted to decrease the absorption of biphosphonates (risedronate). Separate administration by at least 2 hours. [Moderate] Study
- Oral calcium salts decrease the absorption of biphosphonates (sodium clodronate). Avoid calcium salts for 2 hours before or 1 hour after sodium clodronate. [Moderate] Study
- Cephalosporins (ceftriaxone) increase the risk of cardio-respiratory arrest when given with calcium chloride. Avoid. [Severe] Anecdotal
- Cephalosporins (ceftriaxone) increase the risk of cardio-respiratory arrest when given with intravenous calcium gluconate. Avoid. [Severe] Anecdotal
- Intravenous calcium salts increase the concentration of digoxin. Avoid. [Moderate] Anecdotal
- Oral calcium salts decrease the absorption of dolasetron. Dolasetron should be taken 2 hours before or 6 hours after calcium salts. [Moderate] Study
- Oral calcium salts decrease the absorption of etoricoxib. Etoricoxib should be taken 2 hours before or 4 hours after calcium salts. [Severe] Study
- Calcium carbonate decreases the absorption of hydroxychloroquine. Separate administration by at least 4 hours. [Moderate] Study
- Calcium carbonate decreases the absorption of iron (oral). Calcium carbonate should be taken 1 hour before or 2 hours after iron (oral). [Moderate] Study
- Calcium carbonate is predicted to decrease the exposure to ledipasvir. Separate administration by 4 hours. [Moderate] Theoretical
- Oral calcium salts are predicted to decrease the absorption of levothyroxine. Separate administration by at least 4 hours. [Moderate] Anecdotal
- Calcium carbonate decreases the absorption of quinolones (ciprofloxacin, nalidixic acid). Separate administration by 2 hours. [Moderate] Study
- Calcium carbonate decreases the absorption of quinolones (norfloxacin). Norfloxacin should be taken 2 hours before or 4 hours after calcium carbonate. [Moderate] Study
- Calcium carbonate is predicted to slightly decrease the exposure to rifampirine. Calcium carbonate should be taken 2 hours before or 4 hours after rifampirine. [Severe] Theoretical
- Oral calcium salts decrease the absorption of strontium ranelate. Separate administration by 2 hours. [Moderate] Study
- Calcium carbonate is predicted to decrease the absorption of tetracyclines. Separate administration by 2 to 3 hours. [Moderate] Theoretical
- Thiadiazide diuretics increase the risk of hypercalcaemia when given with calcium salts. [Severe] Anecdotal
- Oral calcium carbonate decreases the concentration of velpatasvir. Separate administration by 4 hours. [Moderate] Anecdotal
- Oral calcium salts decrease the absorption of zinc. [Moderate] Study

Canagliflozin → see TABLE 14 p. 1267 (antidiabetic drugs), TABLE 8 p. 1265 (hypotension)
- Rifampicin moderately decreases the exposure to canagliflozin. Adjust canagliflozin dose, p. 661. [Moderate] Study
Canakinumab → see monoclonal antibodies
Candesartan → see angiotensin-II receptor antagonists
Cangrelor → see TABLE 4 p. 1264 (platelet effects)
Cannabis extract → see TABLE 11 p. 1266 (CNS depressant effects)
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to cannabis extract. Avoid. [Severe] Theoretical Also see TABLE 11 p. 1266
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to cannabis extract. Use with caution and adjust dose. [Moderate] Theoretical
- Enalapril is predicted to decrease the exposure to cannabis extract. Avoid. [Severe] Theoretical
- Theoretical study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to cannabis extract. Use with caution and adjust dose. [Moderate] Theoretical
- Idelalisib is predicted to increase the exposure to cannabis extract. Use with caution and adjust dose. [Moderate] Theoretical
- Macrolides (clarithromycin) are predicted to increase the exposure to cannabis extract. Use with caution and adjust dose. [Moderate] Theoretical
- Rifampicin is predicted to decrease the exposure to cannabis extract. Avoid. [Severe] Theoretical

Calcitabine → see TABLE 15 p. 1267 (myelosuppression)
- Allopurinol is predicted to decrease the effects of capcitabine. Avoid. [Severe] Study
- Capcitabine increases the concentration of antiepileptics (fosphenytoin, phenytoin). [Severe] Anecdotal
- Capcitabine increases the effects of coumarins. Monitor INR and adjust dose. [Moderate] Anecdotal
- Folates (folic acid) are predicted to increase the risk of toxicity when given with capcitabine. [Severe] Anecdotal
- Folates (folic acid) increase the risk of toxicity when given with capcitabine. [Severe] Study
- H2 receptor antagonists (cimetidine) are predicted to slightly increase the exposure to capcitabine. [Severe] Theoretical
- Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with capcitabine. Public Health England advises avoid. [Severe] Theoretical
**Ceftobiprole** is predicted to increase the concentration of statins. [Moderate] Theoretical

**Ceftobiprole** is predicted to increase the concentration of sulfonamide [glibenclamide]. [Moderate] Theoretical

**Ceftobiprole** is predicted to increase the concentration of sulfonamide [glibenclamide]. [Moderate] Theoretical

**Carbamazepine** is predicted to increase the exposure to aliskiren. [Moderate] Theoretical

**Antacids** are predicted to decrease the absorption of ceritinib. Separate administration by 2 hours. [Moderate] Theoretical

**Antifungals (amiodarone, dronedarone)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**Antifungals (amiodarone, dronedarone)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**Antifungals (amiodarone, dronedarone)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**Calcium channel blockers (diltiazem, verapamil)** are predicted to increase the dose of ceritinib. [Moderate] Theoretical

**Cobicistat** is predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**Cobicistat** is predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**Cobicistat** is predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**Cobicistat** is predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**Coumarins** (warfarin) are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**H₂ receptor antagonists** are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to increase the exposure to ceritinib. Avoid or adjust ceritinib dose, p. 895. [Severe] Study

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ceritinib. [Moderate] Theoretical
Chloral hydrate is predicted to increase the concentration of tacrolimus. Avoid. (Severe) Study

Chloramphenicol

ROUTE-SPECIFIC INFORMATION Since systemic absorption can follow topical application, the possibility of interactions should be borne in mind.

- Antiepileptics (phenobarbital, primidone) decrease the concentration of chloramphenicol. (Moderate) Study
- Intravenous chlormphenicol increases the concentration of antiepileptics (fosphenytoin, phenytoin) and antiepileptics (fosphenytoin, phenytoin) affect the concentration of intravenous chlormphenicol. Monitor concentration and adjust dose. (Severe) Study
- Chloramphenicol potentially increases the anticoagulant effect of coumarins. (Moderate) Anecdotal
- Chloramphenicol decreases the efficacy of intravenous iron (injectable). (Moderate) Anecdotal
- Chloramphenicol decreases the efficacy of oral iron (oral). (Moderate) Theoretical
- Rifampicin decreases the concentration of chloramphenicol. (Moderate) Study
- Chloramphenicol is predicted to increase the exposure to sulfonylureas. (Severe) Study
- Chloramphenicol increases the concentration of tacroliumus. (Severe) Study

Chloridiazepoxide → see TABLE 11 p. 1266 (CNS depressant effects)
- Chloridiazepoxide affects the concentration of antiepileptics (fosphenytoin, phenytoin). (Severe) Study
- Rifampicin is predicted to decrease the exposure to chloridiazepoxide. (Moderate) Theoretical
- Chloroproprazine → see TABLE 11 p. 1266 (CNS depressant effects)
- Chloroquine → see antimalarials
- Chlorphenamine → see antihistamines, sedating
- Chlorpromazine → see phenothiazines
- Chlortaldione → see thiazide diuretics

Chlorine salicylate
- Corticosteroids are predicted to decrease the concentration of chlorine salicylate. (Moderate) Study

Ciclesonide → see corticosteroids

Ciclosporin → see TABLE 2 p. 1264 (nephrotoxicity), TABLE 16 p. 1268 (increased serum potassium)
- Pomelo juice is predicted to increase ciclosporin exposure, and purple grape juice is predicted to decrease ciclosporin exposure.
- Since systemic absorption can follow topical application, the possibility of interactions should be borne in mind.

- Ciclosporin is predicted to increase the exposure to afatinib. Separate administration by 12 hours. (Moderate) Study
- Ciclosporin markedly increases the exposure to aliskiren. Avoid. (Severe) Study → Also see TABLE 16 p. 1268
- Ciclosporin moderately increases the exposure to bosentan. Adjust ambrisantan dose, p. 179. (Moderate) Study
- Ciclosporin increases the concentration of anthracyclines (daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone). (Severe) Study
- Antiarhythmics (amiodarone) increase the concentration of ciclosporin. Monitor ciclosporin concentration and adjust dose. (Severe) Study
- Antiarhythmics (dronedarone) increase the concentration of ciclosporin. (Severe) Study
- Ciclosporin increases the exposure to antiarhythmics (dronedarone). Avoid. (Severe) Theoretical
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) decrease the concentration of ciclosporin. (Severe) Study
- Antiepileptics (oxcarbazepine) decrease the concentration of ciclosporin. (Severe) Anecdotal
- Antifungals, azoles (fluconazole, isavuconazole, itraconazole, ketoconazole, posaconazole, voriconazole) increase the concentration of ciclosporin. (Severe) Study
- Antifungals, azoles (miconazole) increase the concentration of ciclosporin. Monitor and adjust dose. (Severe) Anecdotal
- Aprepitant increases the concentration of ciclosporin. (Severe) Study
- Ciclosporin is predicted to increase the exposure to beta blockers, non-selective (nadodol). (Moderate) Study
- Bosentan moderately decreases the exposure to ciclosporin and ciclosporin moderately increases the exposure to bosentan. Avoid. (Severe) Study
- Calcium channel blockers (diltiazem, nicardipine, verapamil) increase the concentration of ciclosporin. (Severe) Study
- Ciclosporin moderately increases the exposure to calcium channel blockers (verapamil). Use with caution or avoid. (Severe) Study
- Ciclosporin slightly increases the exposure to caspofungin. (Severe) Study
- Ciclosporin is predicted to increase the exposure to ceritinib. Avoid. (Severe) Theoretical
- Ciclosporin affects the concentration of cholic acid. Avoid. (Moderate) Study
- Ciclosporin increases the exposure to colchicine. Avoid or adjust colchicine dose, p. 1020. (Severe) Study
- Crizotinib increases the concentration of ciclosporin. (Severe) Study

Chlorinerale (chloroquine) decrease the efficacy of oral chlorera vaccine. (Moderate) Study
- Hydroxychloroquine is predicted to decrease the efficacy of oral choleravaccine. (Moderate) Theoretical

Cholic acid
- Antacids are predicted to decrease the absorption of cholic acid. Separate administration by 5 hours. (Mild) Theoretical
- Antiepileptics (phenobarbital) decrease the effects of cholic acid. Avoid. (Moderate) Study
- Ciclosporin affects the concentration of cholic acid. Avoid. (Moderate) Study

Appendix 1

Chloramphenicol
- Cetirizine increases the concentration of chloramphenicol. Avoid. (Severe) Study
- Cetirizine is predicted to increase the exposure to sirolimus. Avoid. (Severe) Theoretical
- Clotrimazole povidon gel → see monocalonal antibodies
- Cetirizine → see antihistamines, non-sedating
- Cetuximab → see monoclonal antibodies

Choleoeoxycholic acid
- Antacids are predicted to decrease the absorption of choleoeoxycholic acid. (Mild) Theoretical

Chloral hydrate → see TABLE 11 p. 1266 (CNS depressant effects)
- Intravenous loop diuretics (furosemide) potentially increase the risk of sweating, variable blood pressure, and tachycardia when given after chloral hydrate. (Moderate) Anecdotal

Chlorambucil → see alkylating agents

Chlorphenamcin

Table 2

1310 Ceritinib — Ciclosporin
**Ciclosporin** is predicted to increase the exposure to **dabigatran**. Avoid. [Severe] Theoretical

**Danazo** increases the concentration of **ciclosporin**. [Severe] Study

**Ciclosporin** is predicted to increase the risk of rhabdomyolysis when given with **daptomycin**. [Severe] Theoretical

**Ciclosporin** is predicted to increase the exposure to **darifenacin**. Avoid. [Moderate] Theoretical

**Ciclosporin** increases the concentration of **digoxin**. Monitor and adjust dose. [Severe] Theoretical

**Ciclosporin** slightly increases the exposure to **edoxyaban**. Adjust edoxyaban dose, p. 122. [Severe] Study

**Efavirenz** decreases the concentration of **ciclosporin**. Monitor **ciclosporin** concentration and adjust dose. [Moderate] Study

**Enzalutamide** decreases the concentration of **ciclosporin**. [Severe] Study

**Ciclosporin** is predicted to increase the exposure to **erlotinib**. [Moderate] Theoretical

**Ciclosporin** increases the exposure to **etoposide**. Monitor and adjust dose. [Severe] Study

**Ciclosporin** moderately increases the exposure to **everolimus**. Avoid or adjust dose. [Severe] Study

**Ciclosporin** moderately increases the exposure to **ezetimibe** and **ezetimibe** slightly increases the exposure to **ciclosporin**. [Moderate] Study

**Fibrates** (bezafibrate) are predicted to increase the risk of nephrotoxicity when given with **ciclosporin**. [Severe] Theoretical

**Fibrates** (fenofibrate) increase the risk of nephrotoxicity when given with **ciclosporin**. [Severe] Study

**Ciclosporin** is predicted to increase the exposure to **fidaxomicin**. Avoid. [Moderate] Study

**Grapefruit Juice** increases the concentration of **ciclosporin**. Avoid. [Severe] Study

**Ciclosporin** greatly increases the exposure to **grazoprevir**. Avoid. [Severe] Study

**H₂ receptor antagonists** (cimetidine) increase the concentration of **ciclosporin**. [Moderate] Study

**HIV-protease inhibitors** increase the concentration of **ciclosporin**. [Severe] Study

**Idelalisib** increases the concentration of **ciclosporin**. [Severe] Study

**Imatinib** increases the concentration of **ciclosporin**. [Severe] Study

**Lansoprazole** is predicted to decrease the absorption of oral **ciclosporin**. Adjust dose. [Severe] Theoretical

**Live vaccines** are predicted to increase the risk of generalised infection (possibly life-threatening) when given with **ciclosporin**. Public Health England advises avoid. [Severe] Theoretical

**Ciclosporin** is predicted to increase the exposure to **lomitapide**. Separate administration by 12 hours. [Moderate] Theoretical

**Lumacaftor** is predicted to decrease the exposure to **ciclosporin**. Avoid. [Severe] Theoretical

**Macrolides** (clarithromycin, erythromycin) increase the concentration of **ciclosporin**. [Severe] Study

**Ciclosporin** is predicted to decrease the efficacy of **mifamurtide**. Avoid. [Severe] Theoretical

**Monoclonal antibodies** (blinatumomab) are predicted to transiently increase the exposure to **ciclosporin**. Monitor and adjust dose. [Moderate] Theoretical

**Netupitant** increases the concentration of **ciclosporin**. [Severe] Study

**Nevirapine** is predicted to decrease the concentration of **ciclosporin**. [Moderate] Study

**Nilotinib** increases the concentration of **ciclosporin**. [Severe] Study

**Ciclosporin** is predicted to increase the exposure to **nintedanib**. [Moderate] Study

**Ciclosporin** increases the concentration of **NSAID** (diclofenac). [Severe] Study

**Enzalutamide** increases the concentration of **ciclosporin**. [Severe] Study

**Octreotide** decreases the absorption of oral **ciclosporin**. Adjust ciclosporin dose, p. 788. [Severe] Anecdotal

**Palbociclib** is predicted to increase the exposure to **ciclosporin**. Adjust dose. [Moderate] Theoretical

**Pasireotide** is predicted to decrease the absorption of oral **ciclosporin**. Adjust dose. [Severe] Theoretical

**Pitolisant** is predicted to decrease the exposure to **ciclosporin**. Avoid. [Severe] Theoretical

**Ciclosporin** is predicted to increase the concentration of **ranolazine** and **ranolazine** is predicted to increase the concentration of **ciclosporin**. [Moderate] Theoretical

**Ciclosporin** moderately increases the exposure to **repaglinide**. [Moderate] Study

**Rifampicin** decreases the concentration of **ciclosporin**. [Severe] Study

**Ciclosporin** very markedly increases the exposure to **rifaximin**. [Severe] Study

**Ciclosporin** is predicted to increase the exposure to **riociguat**. [Moderate] Theoretical

**Ciclosporin** is predicted to increase the exposure to **sacubitril**. [Moderate] Theoretical

**Ciclosporin** moderately increases the exposure to **sirolimus**. Separate administration by 4 hours. [Severe] Study

**St John's Wort** decreases the concentration of **ciclosporin**. Avoid. [Moderate] Study

**Ciclosporin** very markedly increases the exposure to **statins** (atorvastatin). Avoid or adjust **atorvastatin** dose, p. 196. [Severe] Study

**Ciclosporin** moderately increases the exposure to **statins** (fluvastatin). [Severe] Study

**Ciclosporin** markedly very markedly increases the exposure to **statins** (pravastatin). Adjust **pravastatin** dose. [Severe] Study

**Ciclosporin** markedly increases the exposure to **statins** (rosuvastatin, simvastatin). Avoid. [Severe] Study

**Sulfipyrazone** decreases the concentration of **ciclosporin**. [Severe] Study

**Ciclosporin** increases the concentration of **tacrolimus**. Avoid. [Severe] Study

→ Also see TABLE 2 p. 1264 → Also see TABLE 16 p. 1268

**Ciclosporin** is predicted to increase the exposure to **ticagrelor**. Use with caution or avoid. [Severe] Study

**Ciclosporin** is predicted to increase the exposure to **topotecan**. [Severe] Study

**Ciclosporin** is predicted to increase the concentration of **trametinib**. [Moderate] Theoretical

**Ursodeoxycholic acid** affects the concentration of **ciclosporin**. Use with caution and adjust dose. [Severe] Anecdotal

**Ciclosporin** is predicted to increase the exposure to **venetoclax**. Avoid or monitor for toxicity. [Severe] Theoretical

**Vitamin E substances** affect the exposure to **ciclosporin**. [Moderate] Study

**Cilostazol** → see TABLE 4 p. 1264 (antiplatelet effects)

### GENERAL INFORMATION

Concurrent use with 2 or more antiplatelets or anticoagulants is contra-indicated.

<table>
<thead>
<tr>
<th>Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone)</th>
<th>are predicted to alter the effects of cilostazol. [Moderate] Theoretical</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antifungals</strong>, azoles (fluconazole)</td>
<td>are predicted to increase the exposure to cilostazol. Adjust <strong>cilostazol</strong> dose, p. 226. [Moderate] Theoretical</td>
</tr>
<tr>
<td><strong>Antifungals</strong>, azoles (itraconazole, ketoconazole, voriconazole)</td>
<td>are predicted to moderately increase the exposure to cilostazol. Adjust <strong>cilostazol</strong> dose, p. 226. [Moderate] Study</td>
</tr>
<tr>
<td><strong>Antifungals</strong>, azoles (miconazole)</td>
<td>are predicted to increase the exposure to cilostazol. Use with caution and adjust dose. [Moderate] Theoretical</td>
</tr>
<tr>
<td><strong>Cobicistat</strong></td>
<td>is predicted to moderately increase the exposure to cilostazol. Adjust <strong>cilostazol</strong> dose, p. 226. [Moderate] Study</td>
</tr>
<tr>
<td><strong>Enzalutamide</strong></td>
<td>is predicted to alter the effects of cilostazol. [Moderate] Theoretical</td>
</tr>
<tr>
<td><strong>HIV-protease inhibitors</strong> (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)</td>
<td>are predicted to moderately increase the exposure to cilostazol. Adjust <strong>cilostazol</strong> dose, p. 226. [Moderate] Study</td>
</tr>
<tr>
<td><strong>Idelalisib</strong></td>
<td>is predicted to moderately increase the exposure to cilostazol. Adjust <strong>cilostazol</strong> dose, p. 226. [Moderate] Study</td>
</tr>
<tr>
<td><strong>Cilostazol</strong></td>
<td>is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. [Moderate] Theoretical</td>
</tr>
</tbody>
</table>
1312 Cilostazol — Clopidogrel
Cilostazol (continued)
▶ Macrolides (clarithromycin) are predicted to moderately
increase the exposure to cilostazol. Adjust cilostazol dose,
p. 226. o Study

o Study

Rifampicin is predicted to alter the effects of cilostazol.
o Theoretical

▶

▶

SSRIs (fluvoxamine) are predicted to increase the exposure to
cilostazol. Adjust cilostazol dose, p. 226. o Theoretical
→ Also see TABLE 4 p. 1264
St John’s Wort is predicted to alter the effects of cilostazol.
o Theoretical

A1

Cimetidine → see H2 receptor antagonists
Cinacalcet
FOOD AND LIFESTYLE Dose adjustment might be necessary if
smoking started or stopped during treatment.

Interactions | Appendix 1

▶
▶

Cinacalcet is predicted to increase the exposure to
antiarrhythmics (flecainide). r Theoretical
Cinacalcet is predicted to increase the exposure to
antiarrhythmics (propafenone). Monitor and adjust dose.
o Study

▶

Cinacalcet is predicted to increase the exposure to
anticholinesterases, centrally acting (donepezil). o

▶

Cinacalcet is predicted to increase the exposure to
anticholinesterases, centrally acting (galantamine). Monitor and
adjust dose. o Study
Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are
predicted to moderately increase the exposure to cinacalcet.
Adjust dose. o Study
Cinacalcet is predicted to moderately increase the exposure to
aripiprazole. Adjust aripiprazole dose, p. 376. o Study
Cinacalcet is predicted to markedly increase the exposure to
atomoxetine. Adjust dose. r Study
Cinacalcet is predicted to increase the exposure to beta
blockers, non-selective (carvedilol, timolol). o Study
Cinacalcet is predicted to increase the exposure to beta
blockers, selective (metoprolol, nebivolol). o Study
Cobicistat is predicted to moderately increase the exposure to
cinacalcet. Adjust dose. o Study
Cinacalcet is predicted to slightly increase the exposure to
darifenacin. n Study
HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir,
lopinavir, ritonavir, saquinavir, tipranavir) are predicted to
moderately increase the exposure to cinacalcet. Adjust dose.

Theoretical

▶

▶
▶
▶
▶
▶
▶
▶

o Study
▶
▶

Idelalisib is predicted to moderately increase the exposure to
cinacalcet. Adjust dose. o Study
Macrolides (clarithromycin) are predicted to moderately
increase the exposure to cinacalcet. Adjust dose. o
Study

▶
▶
▶
▶
▶
▶
▶

▶

Cinacalcet is predicted to increase the exposure to tricyclic
antidepressants. Monitor for toxicity and adjust dose. r
Study

Cinacalcet is predicted to increase the exposure to vortioxetine.
Monitor and adjust dose. o Study
Cinnarizine → see antihistamines, sedating
Ciprofibrate → see fibrates
Ciprofloxacin → see quinolones
Cisatracurium → see neuromuscular blocking drugs, non-depolarising
Cisplatin → see platinum compounds
Citalopram → see SSRIs
Cladribine → see TABLE 15 p. 1267 (myelosuppression)
▶ Live vaccines are predicted to increase the risk of generalised
infection (possibly life-threatening) when given with
cladribine. Public Health England advises avoid. r
▶

Macrolides (erythromycin) slightly increase the exposure to
cilostazol. Adjust cilostazol dose, p. 226. o Study
▶ Moclobemide is predicted to increase the exposure to
cilostazol. o Theoretical
▶ Proton pump inhibitors (esomeprazole) are predicted to increase
the exposure to cilostazol. o Theoretical
▶ Proton pump inhibitors (omeprazole) are predicted to increase
the exposure to cilostazol. Adjust cilostazol dose, p. 226.
▶

▶

BNF 74

Cinacalcet is predicted to decrease the efﬁcacy of opioids
(codeine). o Theoretical
Cinacalcet is predicted to decrease the efﬁcacy of opioids
(tramadol). r Study
Cinacalcet is predicted to moderately increase the exposure to
pitolisant. Use with caution and adjust dose. o Study
Cinacalcet is predicted to increase the exposure to risperidone.
Adjust dose. o Study
SSRIs (fluvoxamine) are predicted to increase the exposure to
cinacalcet. Adjust dose. o Theoretical
Cinacalcet is predicted to increase the exposure to SSRIs
(dapoxetine). o Theoretical
Cinacalcet is predicted to decrease the efﬁcacy of tamoxifen.
Avoid. r Study

Theoretical

Clarithromycin → see macrolides
Clemastine → see antihistamines, sedating
Clevidipine → see calcium channel blockers
Clindamycin
ROUTE-SPECIFIC INFORMATION Since systemic absorption can
follow topical application, the possibility of interactions
should be borne in mind.
▶
▶

Clindamycin increases the effects of neuromuscular blocking
drugs, non-depolarising. r Anecdotal
Clindamycin increases the effects of suxamethonium. r
Anecdotal

Clobazam
▶ Antiepileptics (stiripentol) increase the concentration of
clobazam. r Study
▶ Clobazam potentially affects the concentration of antiepileptics
(fosphenytoin, phenytoin). r Anecdotal
Clofarabine → see TABLE 15 p. 1267 (myelosuppression)
▶ Live vaccines are predicted to increase the risk of generalised
infection (possibly life-threatening) when given with
clofarabine. Public Health England advises avoid. r
Theoretical

Clofazimine
▶ Clofazimine potentially increases the risk of QT-prolongation
when given with bedaquiline. r Study
Clomethiazole → see TABLE 11 p. 1266 (CNS depressant effects)
FOOD AND LIFESTYLE Alcohol consumption can cause serious,
potentially fatal, CNS depression with clomethiazole.
▶

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone) decrease the exposure to clomethiazole.
Monitor and adjust dose. o Study → Also see TABLE 11
p. 1266

Enzalutamide decreases the exposure to clomethiazole.
Monitor and adjust dose. o Study
▶ Rifampicin decreases the exposure to clomethiazole. Monitor
and adjust dose. o Study
Clomipramine → see tricyclic antidepressants
Clonazepam → see TABLE 11 p. 1266 (CNS depressant effects)
▶ Clonazepam potentially affects the concentration of
antiepileptics (fosphenytoin, phenytoin). r Anecdotal
Clonidine → see TABLE 6 p. 1265 (bradycardia), TABLE 8 p. 1265
(hypotension), TABLE 11 p. 1266 (CNS depressant effects)
▶ Clonidine is predicted to decrease the effects of histamine.
Avoid. r Theoretical → Also see TABLE 8 p. 1265
▶ Tricyclic antidepressants decrease the antihypertensive effects
of clonidine. Monitor and adjust dose. o Anecdotal
→ Also see TABLE 8 p. 1265
Clopamide → see thiazide diuretics
Clopidogrel → see TABLE 4 p. 1264 (antiplatelet effects)
▶ Antifungals, azoles (fluconazole) are predicted to decrease the
efﬁcacy of clopidogrel. Avoid. r Theoretical
▶ Antifungals, azoles (voriconazole) are predicted to decrease the
efﬁcacy of clopidogrel. Avoid. o Study
▶ Grapefruit juice markedly decreases the exposure to
clopidogrel. r Study
▶ Clopidogrel is predicted to increase the exposure to
loperamide. r Theoretical
▶ Moclobemide is predicted to decrease the efﬁcacy of
clopidogrel. Avoid. o Study
▶

downloaded from www.medicalbr.com


Clobidogrel is predicted to increase the exposure to pioglitazone. **Severe** Theoretical

Proton pump inhibitors (esomeprazole, omeprazole) are predicted to decrease the efficacy of clobidogrel. **Avoid.** **Moderate** Study

Cobicistat increases the exposure to repaglinide. **Severe** Study

SSRIs (fluvoxamine) are predicted to decrease the efficacy of clobidogrel. **Avoid.** **Severe** Theoretical → Also see TABLE 4 p. 1264

Clobidogrel increases the exposure to statins (rosuvastatin). Adjust rosuvastatin dose, p. 197. **Moderate** Study

Cobicistat → see antifungals, azoles

Clobidogrel → see antifungals, azoles

Clobidogrel is predicted to decrease the effects of dopamine receptor agonists. **Moderate** Theoretical → Also see TABLE 8 p. 1265 → Also see TABLE 10 p. 1266

Clobidogrel is predicted to decrease the effects of levodopa. **Severe** Theoretical → Also see TABLE 8 p. 1265

Quinolones (ciprofloxacin) increase the concentration of clozapine. Monitor side effects and adjust dose. **Severe** Study

Rifampicin decreases the exposure to clozapine. **Severe** Anecdotal

55Rs (fluvoxamine) increase the concentration of clozapine. Monitor side effects and adjust dose. **Severe** Study

Co-trimoxazolae → see sulphonamides

Cobicistat

Cobicistat is predicted to increase the exposure to abiraterone. **Severe** Theoretical

Cobicistat is predicted to markedly increase the exposure to aldosterone antagonists (spironolactone). **Avoid.** **Severe** Study

Cobicistat increases the exposure to almotriptan. **Mild** Study

Cobicistat is predicted to moderately increase the exposure to alpha blockers (alfuzosin, tamsulosin). Use with caution or avoid. **Moderate** Study

Cobicistat is predicted to increase the exposure to alpha blockers (doxazosin). **Moderate** Study

Cobicistat moderately increases the exposure to alprazolam. **Avoid.** **Moderate** Study

Cobicistat very markedly increases the exposure to antiarrhythmics (dronedarone). **Avoid.** **Severe** Study

Cobicistat is predicted to increase the exposure to antiarrhythmics (propafenone). Monitor and adjust dose. **Severe** Study

Cobicistat is predicted to increase the exposure to anticholinesterases, centrally acting (galantamine). Monitor and adjust dose. **Moderate** Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to cobicistat. Avoid. **Severe** Theoretical

Antiepileptics (oxcarbazepine) are predicted to decrease the concentration of cobicistat. **Severe** Theoretical

Cobicistat is predicted to slightly increase the exposure to antiepileptics (perampanel). **Mild** Study

Cobicistat is predicted to increase the exposure to antifungals, azoles (fluconazolae, posaconazolae). **Moderate** Theoretical

Cobicistat is predicted to increase the exposure to antifungals, azoles (isavuconazole). Avoid or monitor side effects. **Severe** Study

Cobicistat is predicted to increase the exposure to antifungals, azoles (itraconazole). Adjust itraconazole dose, p. 564. **Moderate** Study

Cobicistat is predicted to increase the exposure to antifungals, azoles (ketokonazole). Adjust ketokonazole dose, p. 641. **Moderate** Theoretical

Cobicistat is predicted to affect the exposure to antifungals, azoles (voriconazole). **Avoid.** **Moderate** Theoretical

Cobicistat is predicted to increase the exposure to antihistamines, non-sedating (mizolastine). **Avoid.** **Severe** Study

Cobicistat is predicted to increase the exposure to antimalarials (artemether) (with lumefantrine). **Moderate** Study

Cobicistat is predicted to increase the concentration of antimalarials (piperazine). **Severe** Theoretical

Cobicistat is predicted to markedly increase the exposure to aripiprazole. **Severe** Study

Cobicistat is predicted to increase the exposure to aripiprazole. Adjust aripiprazole dose, p. 376. **Moderate** Study

Cobicistat is predicted to increase the exposure to axitinib. Avoid or adjust dose. **Moderate** Study

Cobicistat is predicted to increase the exposure to bedaquiline. Avoid prolonged use. **Moderate** Study

Cobicistat is predicted to increase the exposure to beta agonists (salmeterol). **Avoid.** **Severe** Study

Cobicistat slightly increases the exposure to bortezomib. **Moderate** Study

Bosentan is predicted to decrease the exposure to cobicistat. **Avoid.** **Severe** Theoretical

Cobicistat is predicted to markedly increase the exposure to bosutinib. **Avoid or adjust bosutinib dose.** **Severe** Study

Cobicistat is predicted to increase the exposure to bupirone. Adjust busiprone dose, p. 325. **Severe** Study

Cobicistat slightly increases the exposure to cabozantinib. **Moderate** Study

Cobicistat is predicted to increase the exposure to calcium channel blockers (amlodipine, felodipine, isradipine, lacidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose. **Moderate** Study

Cobicistat is predicted to increase the exposure to calcium channel blockers (diltiazem, verapamil). **Severe** Study

Cobicistat is predicted to markedly increase the exposure to calcium channel blockers (amlodipine, felodipine, isradipine, lacidipine, nicardipine, nifedipine, nimodipine). **Avoid.** **Severe** Study

Cobicistat is predicted to increase the exposure to cannabis extract. Use with caution and adjust dose. **Moderate** Theoretical

Cobicistat is predicted to increase the exposure to ceritinib. Avoid or adjust ceritinib dose, p. 895. **Severe** Study

Cobicistat increases the concentration of ciclosporin. **Severe** Study

Cobicistat is predicted to moderately increase the exposure to clobazolae. Adjust clobazolae dose, p. 226. **Moderate** Study

Cobicistat is predicted to moderately increase the exposure to cinacalcet. Adjust dose, **Moderate** Study

Cobicistat is predicted to markedly increase the exposure to cobimetinib. Avoid or monitor for toxicity. **Severe** Study

Cobicistat is predicted to increase the exposure to colchicine. Avoid or adjust colchicine dose, p. 1020. **Severe** Study

Cobicistat is predicted to decrease the efficacy of combined hormonal contraceptives. **Avoid.** **Severe** Study

Cobicistat is predicted to increase the concentration of corticosteroids (beclometasone) (risk with beclometasone is likely to be lower than with other corticosteroids). MHRA advises avoid or monitor for beclometasone side effects. **Moderate** Theoretical

Cobicistat is predicted to increase the concentration of corticosteroids (betamethasone). MHRA advises avoid or monitor side effects and consider beclometasone as an alternative. **Severe** Theoretical

Cobicistat is predicted to increase the concentration of corticosteroids (budesonide). MHRA advises avoid or monitor side effects and consider beclometasone as an alternative. **Severe** Theoretical
Cobicistat — Cobicistat

Cobicistat (continued)

- **Corticosteroids (ciclesonide)**. Avoid. [Moderate] Theoretical

- **Cobicistat** is predicted to increase the concentration of corticosteroids (dexamethasone). MHRAs advises avoid or monitor side effects and consider beclomethasone as an alternative. [Severe] Theoretical

- **Cobicistat** is predicted to increase the concentration of corticosteroids (hydrocortisone). MHRAs advises avoid or monitor side effects and consider beclomethasone as an alternative. [Severe] Theoretical

- **Cobicistat** is predicted to increase the concentration of corticosteroids (mometasone). MHRAs advises avoid or monitor side effects and consider beclomethasone as an alternative. [Severe] Theoretical

- **Cobicistat** is predicted to increase the concentration of corticosteroids (prednisolone). MHRAs advises avoid or monitor side effects and consider beclomethasone as an alternative. [Severe] Theoretical

- **Cobicistat** is predicted to moderately increase the exposure to dabrafenib. Use with caution or avoid. [Moderate] Study

- **Cobicistat** is predicted to moderately increase the exposure to daclatasvir. Adjust daclatasvir dose, p. 591. [Moderate] Study

- **Cobicistat** is predicted to markedly increase the exposure to dabatinib. Avoid. [Severe] Study

- **Cobicistat** very slightly increases the exposure to delamanid. [Severe] Study

- **Cobicistat** increases the risk of QT-prolongation when given with doperidone. Avoid. [Severe] Study

- **Cobicistat** increases the exposure to dopamine receptor antagonists (bromocriptine, cabergoline). [Severe] Study

- **Cobicistat** is predicted to increase the exposure to dutasteride. Monitor side effects and adjust dose. [Moderate] Theoretical

- **Eflavirenz** is predicted to decrease the exposure to cobicistat. Avoid. [Severe] Theoretical

- **Cobicistat** slightly to moderately increases the exposure to elbasvir. Avoid. [Moderate] Study

- **Cobicistat** is predicted to markedly increase the exposure to eleriptan. Avoid. [Severe] Study

- **Enzalutamide** is predicted to decrease the exposure to cobicistat. Avoid. [Severe] Theoretical

- **Cobicistat** is predicted to increase the risk of ergotism when given with ergometrine. Avoid. [Severe] Theoretical

- **Cobicistat** is predicted to increase the risk of ergotism when given with ergotamine. Avoid. [Severe] Theoretical

- **Cobicistat** is predicted to slightly increase the exposure to erlotinib. Use with caution and adjust dose. [Moderate] Study

- **Cobicistat** is predicted to increase the concentration of everolimus. Avoid. [Severe] Study

- **Cobicistat** is predicted to moderately increase the exposure to fesoterodine. Adjust fesoterodine dose; avoid in hepatic and renal impairment, p. 732. [Severe] Study

- **Cobicistat** is predicted to increase the exposure to fosaprepitant. [Moderate] Theoretical

- **Cobicistat** is predicted to increase the exposure to gefitinib. [Moderate] Study

- **Cobicistat** is predicted to moderately to markedly increase the exposure to grazoprevir. Avoid. [Severe] Study

- **Cobicistat** is predicted to increase the exposure to guanfacine. Adjust guanfacine dose, p. 335. [Moderate] Study

- **Cobicistat** is predicted to very markedly increase the exposure to ibrutinib. Avoid or adjust ibrutinib dose, p. 902. [Severe] Study

- **Cobicistat** is predicted to increase the exposure to imatinib. [Moderate] Study

- **Cobicistat** is predicted to increase the risk of toxicity when given with irinotecan. Avoid. [Moderate] Study

- **Cobicistat** is predicted to increase the exposure to ivabradine. Avoid. [Severe] Study

- **Cobicistat** is predicted to increase the exposure to ivacaftor. Adjust ivacaftor or lumacaftor with ivacaftor dose, p. 281. [Severe] Study

- **Cobicistat** is predicted to increase the exposure to lapatinib. Avoid. [Moderate] Study

- **Cobicistat** is predicted to markedly increase the exposure to lenalidomide. Avoid. [Severe] Study

- **Cobicistat** is predicted to increase the exposure to lurasidone. Avoid. [Severe] Study

- **Cobicistat** is predicted to increase the exposure to macitentan. Moderate Study

- **Cobicistat** markedly increases the exposure to maraviroc. Refer to specialist literature. [Severe] Study

- **Cobicistat** is predicted to markedly to very markedly increase the exposure to midazolam. Avoid or adjust midazolam dose. [Severe] Study

- **Cobicistat** is predicted to increase the exposure to mirabegron. Adjust mirabegron dose in hepatic and renal impairment, p. 736. [Moderate] Study

- **Cobicistat** is predicted to increase the exposure to mirtazapine. [Moderate] Study

- **Cobicistat** is predicted to increase the exposure to modafinil. [Mild] Theoretical

- **Cobicistat** is predicted to increase the exposure to monoclonal antibodies (trastuzumab emtansine). Avoid. [Severe] Theoretical

- **Cobicistat** is predicted to markedly increase the exposure to naloxegol. Avoid. [Severe] Study

- **Cobicistat** is predicted to increase the exposure to netupitant. [Mild] Study

- **Nevirapine** is predicted to decrease the exposure to cobicistat. Avoid. [Severe] Theoretical

- **Cobicistat** is predicted to moderately increase the exposure to nilotinib. Avoid. [Severe] Study

- **Cobicistat** is predicted to increase the exposure to nitisineone. Adjust nitisinolone dose. [Moderate] Theoretical

- **Cobicistat** is predicted to increase the exposure to olaparib. Avoid or adjust olaparib dose, p. 919. [Moderate] Study

- **Cobicistat** is predicted to increase the exposure to opioids (alfentanil, buprenorphine, fentanyl, oxycodone, sufentanil). Monitor and adjust dose. [Severe] Study

- **Cobicistat** is predicted to increase the exposure to opioids (methadone). [Moderate] Theoretical

- **Cobicistat** is predicted to increase the exposure to oxabutynin. [Mild] Study

- **Cobicistat** is predicted to increase the exposure to palbociclib. Avoid or adjust palbociclib dose, p. 909. [Severe] Study

- **Cobicistat** is predicted to increase the exposure to panobinostat. Adjust panobinostat dose; in hepatic impairment avoid, p. 864. [Moderate] Study

- **Cobicistat** is predicted to increase the exposure to paritaprevir (with ritonavir and ombitasvir). Avoid. [Severe] Theoretical

- **Cobicistat** is predicted to increase the exposure to pazopanib. Avoid or adjust pazopanib dose, p. 909. [Moderate] Study

- **Cobicistat** is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (avanafil, vardenafil). Avoid. [Severe] Study

- **Cobicistat** is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (sildenafil). Avoid or adjust sildenafil dose, p. 766. [Severe] Study

- **Cobicistat** is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (tadalafil). Use with caution or avoid. [Severe] Study

- **Cobicistat** is predicted to increase the exposure to pimozide. Avoid. [Severe] Study

- **Cobicistat** is predicted to slightly increase the exposure to ponatinib. Monitor and adjust ponatinib dose, p. 911. [Moderate] Study
Cobicistat – Colchicine

- Cobicistat is predicted to moderately increase the exposure to praziquantel. [Mild] Study
- Cobicistat is predicted to increase the exposure to quetiapine. Avoid. [Severe] Study
- Cobicistat is predicted to increase the exposure to ranolazine. Avoid. [Severe] Study
- Cobicistat is predicted to increase the exposure to reboxetine. Avoid. [Moderate] Study
- Cobicistat is predicted to increase the exposure to regorafenib. Avoid. [Moderate] Study
- Cobicistat is predicted to increase the exposure to rapaglinide. [Moderate] Study
- Cobicistat is predicted to increase the exposure to retinoids (alitretinoin). Adjust altiretinoin dose, p. 1157. [Moderate] Theoretical
- Rifabutin decreases the concentration of cobicistat and cobicistat increases the exposure to rifabutin. Avoid or adjust dose. [Severe] Study
- Rifampicin is predicted to decrease the exposure to cobicistat. Avoid. [Severe] Theoretical
- Cobicistat is predicted to increase the exposure to risperidone. Adjust dose. [Moderate] Study
- Cobicistat is predicted to increase the exposure to ruxolitinib. Adjust dose and monitor side effects. [Moderate] Study
- Cobicistat is predicted to moderately increase the exposure to SSRIs (dapoxetine). Avoid or adjust dapoxetine dose, p. 772. [Severe] Study
- St John’s Wort is predicted to decrease the exposure to cobicistat. Avoid. [Severe] Theoretical
- Cobicistat is predicted to increase the exposure to statins (atorvastatin). Avoid or adjust dose and monitor rhabdomyolysis. [Severe] Study
- Cobicistat is predicted to increase the exposure to statins (simvastatin). Avoid. [Severe] Study
- Cobicistat is predicted to slightly increase the exposure to sunitinib. Avoid or adjust sunitinib dose, p. 914. [Moderate] Study
- Cobicistat is predicted to increase the concentration of tacrolimus. Monitor and adjust dose. [Severe] Study
- Cobicistat is predicted to increase the exposure to taxanes (cabazitaxel). Avoid. [Severe] Study
- Cobicistat is predicted to moderately increase the exposure to taxanes (docetaxel). Avoid or adjust dose. [Severe] Study
- Cobicistat is predicted to increase the exposure to taxanes (paclitaxel). [Severe] Theoretical
- Cobicistat is predicted to increase the concentration of temsirilimus. Avoid. [Severe] Theoretical
- Cobicistat is predicted to markedly increase the exposure to ticagrelor. Avoid. [Severe] Study
- Cobicistat is predicted to increase the exposure to tolterodine. Avoid. [Severe] Study
- Cobicistat is predicted to increase the exposure to tolvaptan. [Moderate] Theoretical
- Cobicistat is predicted to increase the exposure to toremifene. Avoid or adjust dose. [Severe] Study
- Cobicistat is predicted to increase the exposure to trabectedin. Avoid or adjust dose. [Severe] Theoretical
- Cobicistat is predicted to moderately increase the exposure to trazodone. Avoid or adjust dose. [Moderate] Study
- Cobicistat is predicted to slightly increase the exposure to tricyclic antidepressants. [Mild] Study
- Cobicistat is predicted to increase the exposure to ulipristal. Avoid if used for uterine fibroids. [Severe] Study
- Cobicistat is predicted to increase the exposure to vemurafenib. [Severe] Theoretical
- Cobicistat is predicted to increase the exposure to venetoclax. Avoid or adjust venetoclax dose, p. 919. [Severe] Study
- Cobicistat is predicted to increase the exposure to venlafaxine. Moderate] Study
- Cobicistat is predicted to increase the exposure to vinca alkaloids. [Severe] Theoretical
- Cobicistat is predicted to increase the exposure to vitamin D substances (paricalcitol). Moderate] Study
- Cobicistat is predicted to increase the exposure to zopiclone. Adjust dose. [Moderate] Theoretical

Cobimetinib
- Antiarrhythmics (dronedarone) are predicted to increase the exposure to cobimetinib. [Severe] Theoretical
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to cobimetinib. Avoid. [Severe] Study
- Antifungals, azoles (fluconazole, isavuconazole, miconazole, posaconazole) are predicted to increase the exposure to cobimetinib. [Severe] Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to markedly increase the exposure to cobimetinib. Avoid or monitor for toxicity. [Severe] Study
- Aprepitant is predicted to increase the exposure to cobimetinib. [Severe] Theoretical
- Bosentan is predicted to decrease the exposure to cobimetinib. Avoid. [Severe] Theoretical
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to cobimetinib. [Severe] Theoretical
- Cobimetinib is predicted to markedly increase the exposure to cobimetinib. Avoid or monitor for toxicity. [Severe] Study
- Crizotinib is predicted to increase the exposure to cobimetinib. [Severe] Theoretical
- Elafirenz is predicted to decrease the exposure to cobimetinib. Avoid. [Severe] Theoretical
- Enzalutamide is predicted to decrease the exposure to cobimetinib. Avoid. [Severe] Theoretical
- Grapefruit juice is predicted to increase the exposure to cobimetinib. Avoid. [Severe] Theoretical
- HIV-protase inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to markedly increase the exposure to cobimetinib. Avoid or monitor for toxicity. [Severe] Study
- HIV-protase inhibitors (indinavir) are predicted to increase the exposure to cobimetinib. [Severe] Theoretical
- Idelalisib is predicted to markedly increase the exposure to cobimetinib. Avoid or monitor for toxicity. [Severe] Study
- Imatinib is predicted to increase the exposure to cobimetinib. [Severe] Theoretical
- Macrolides (clarithromycin) are predicted to markedly increase the exposure to cobimetinib. Avoid or monitor for toxicity. [Severe] Study
- Macrolides (erythromycin) are predicted to increase the exposure to cobimetinib. [Severe] Theoretical
- Netupitant is predicted to increase the exposure to cobimetinib. [Severe] Theoretical
- Nevirapine is predicted to decrease the exposure to cobimetinib. Avoid. [Severe] Theoretical
- Nilotinib is predicted to increase the exposure to cobimetinib. [Severe] Theoretical
- Rifampicin is predicted to decrease the exposure to cobimetinib. Avoid. [Severe] Theoretical
- St John’s Wort is predicted to decrease the exposure to cobimetinib. Avoid. [Severe] Theoretical
- Colchicine
- Antiarrhythmics (dronedarone) are predicted to increase the exposure to colchicine. Adjust colchicine dose, p. 1020. [Severe] Study
- Antifungals, azoles (fluconazole, isavuconazole, miconazole, posaconazole) are predicted to increase the exposure to colchicine. Adjust colchicine dose, p. 1020. [Severe] Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to colchicine. Adjust colchicine dose, p. 1020. [Severe] Study
- Aprepitant is predicted to increase the exposure to colchicine. Adjust colchicine dose, p. 1020. [Severe] Study

Codeine – see opioids
Colchicine (continued)

- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to colchicine. Adjust colchicine dose, p. 1020. [Severe] Study
- Ceritinib is predicted to increase the exposure to colchicine. [Moderate] Theoretical
- Ciclosporin increases the exposure to colchicine. Avoid or adjust colchicine dose, p. 1020. [Severe] Study
- Cobicistat is predicted to increase the exposure to colchicine. Avoid or adjust colchicine dose, p. 1020. [Severe] Study
- Crizotinib is predicted to increase the exposure to colchicine. Adjust colchicine dose, p. 1020. [Severe] Study
- Colchicine increases the risk of rhabdomyolysis when given with fibrates. [Severe] Anecdotal
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to colchicine. Avoid or adjust colchicine dose, p. 1020. [Severe] Study
- HIV-protease inhibitors (indinavir) are predicted to increase the exposure to colchicine. Adjust colchicine dose, p. 1020. [Severe] Study
- Idelalisib is predicted to increase the exposure to colchicine. Avoid or adjust colchicine dose, p. 1020. [Severe] Study
- Imatinib is predicted to increase the exposure to colchicine. Adjust colchicine dose, p. 1020. [Severe] Study
- Lapatinib is predicted to increase the exposure to colchicine. Avoid or adjust colchicine dose, p. 1020. [Moderate] Theoretical
- Lumacaftor is predicted to affect the exposure to colchicine. [Moderate] Theoretical
- Macrolides (azithromycin) are predicted to increase the exposure to colchicine. Avoid or adjust colchicine dose, p. 1020. [Severe] Study
- Macrolides (clarithromycin) are predicted to increase the exposure to colchicine. Avoid or adjust colchicine dose, p. 1020. [Severe] Study
- Macrolides (erythromycin) are predicted to increase the exposure to colchicine. Adjust colchicine dose, p. 1020. [Severe] Study
- Mirabegron is predicted to increase the exposure to colchicine. [Mild] Theoretical
- Netupitant is predicted to increase the exposure to colchicine. Adjust colchicine dose, p. 1020. [Severe] Study
- Nilotinib is predicted to increase the exposure to colchicine. Adjust colchicine dose, p. 1020. [Severe] Study
- Ranolazine is predicted to increase the exposure to colchicine. Avoid or adjust colchicine dose, p. 1020. [Theoretical]
- Colchicine increases the risk of rhabdomyolysis when given with statins. [Severe] Anecdotal
- Vemurafenib is predicted to increase the exposure to colchicine. [Severe] Theoretical
- Vemurafenib is predicted to increase the exposure to colchicine. [Moderate] Theoretical
- Colecalciferol → see vitamin D substances

Colestipol

**SEPARATION OF ADMINISTRATION** Manufacturer advises take 4 hours before, or after, other drugs.

Colestyramine

**SEPARATION OF ADMINISTRATION** Manufacturer advises take other drugs at least 1 hour before, or 4–6 hours after, colestipol.

Colistimethate → see TABLE 2 p. 1264 (nephrotoxicity), TABLE 20 p. 1268 (neuromuscular blocking effects)

- Colistimethate increases the effects of neuromuscular blocking drugs, non-depolarising. Monitor and adjust dose. [Moderate] Study → Also see TABLE 20 p. 1268
- Colistimethate increases the effects of suxamethonium. Monitor and adjust dose. [Moderate] Study → Also see TABLE 20 p. 1268

Combined hormonal contraceptives

- Combined hormonal contraceptives are predicted to increase the exposure to agomelatine. [Moderate] Study
- Combined hormonal contraceptives are predicted to increase the exposure to aminophylline. [Moderate] Theoretical
- Combined hormonal contraceptives are predicted to increase the exposure to anagrelide. [Moderate] Theoretical
- Antiepileptics (carbamazepine, eslicarbazepine, fosphenytoin, oxcarbazepine, perampanel, phenobarbital, phenytoin, primidone, rufinamide, topiramate) are predicted to decrease the efficacy of combined hormonal contraceptives. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Study
- Combined hormonal contraceptives alter the exposure to antiepileptics (lamotrigine). Adjust lamotrigine dose. [Moderate] Study
- Aprepitant is predicted to decrease the efficacy of combined hormonal contraceptives. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Study
- Bosentan is predicted to decrease the efficacy of combined hormonal contraceptives. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Study
- Combined hormonal contraceptives increases the concentration of clozapine. Monitor side effects and adjust dose. [Severe] Study
- Cobicistat is predicted to decrease the efficacy of combined hormonal contraceptives. Avoid. [Severe] Study
- Combined hormonal contraceptives increase the risk of raised liver function tests when given with dasabuvir. Avoid. [Severe] Study
- Combined hormonal contraceptives are predicted to increase the exposure to dopamine receptor agonists (ropinirol). Adjust dose. [Moderate] Study
- Efavirenz is predicted to decrease the efficacy of combined hormonal contraceptives. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Study
- Combined hormonal contraceptives slightly increases the exposure to erlotinib. Monitor side effects and adjust dose. [Moderate] Study
- Combined hormonal contraceptives are predicted to increase the exposure to dopamine receptor agonists (ropinirol). Adjust dose. [Moderate] Study
- Efavirenz is predicted to decrease the efficacy of combined hormonal contraceptives. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Study
- Combined hormonal contraceptives are predicted to decrease the effect of venous thromboembolism when given with lenalidomide. Avoid. [Severe] Theoretical
- Oral combined hormonal contraceptives slightly increase the exposure to lomitapide. Separate administration by 12 hours. [Moderate] Theoretical
- Combined hormonal contraceptives are predicted to increase the exposure to loxapine. Avoid. [Unknown] Theoretical
- Lumacaftor is predicted to decrease the efficacy of combined hormonal contraceptives. Use additional contraceptive precautions. [Severe] Theoretical
- Combined hormonal contraceptives are predicted to increase the exposure to melatonin. [Moderate] Theoretical
- Combined hormonal contraceptives decrease the effects of metyrapone. Avoid. [Moderate] Theoretical
- Modafinil is predicted to decrease the efficacy of combined hormonal contraceptives. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Study
- Combined hormonal contraceptives slightly increase the exposure to monoamine-oxidase B inhibitors (rasagiline). [Moderate] Study
- Combined hormonal contraceptives increase the exposure to monoamine-oxidase B inhibitors (selegiline). Avoid. [Severe] Study
Combined hormonal contraceptives — Corticosteroids

- **Nevirapine** is predicted to decrease the efficacy of combined hormonal contraceptives. For FSRH guidance, see Contraceptives, interactions p. 747. **Severe** Study
- **NSAID. (etoricoxib)** slightly increase the exposure to combined hormonal contraceptives. **Moderate** Study
- **Paritaprevir (with ritonavir and omibitasvir)** increases the risk of raised liver function tests when given with combined hormonal contraceptives. Avoid. **Severe** Study
- **Combined hormonal contraceptives** are predicted to increase the exposure to **pirfenidone**. Use with caution and adjust dose. **Moderate** Study
- **Pitolisant** is predicted to decrease the efficacy of combined hormonal contraceptives. Avoid. **Severe** Theoretical
- **Combined hormonal contraceptives** are predicted to increase the risk of venous thromboembolism when given with **gemildamide**. Avoid. **Severe** Theoretical
- **Rifabutin** is predicted to decrease the efficacy of combined hormonal contraceptives. For FSRH guidance, see Contraceptives, interactions p. 747. **Severe** Study
- **Rifampicin** is predicted to decrease the efficacy of combined hormonal contraceptives. For FSRH guidance, see Contraceptives, interactions p. 747. **Severe** Study
- **Combined hormonal contraceptives** are predicted to increase the exposure to **roflumilast**. **Moderate** Theoretical
- **St John's Wort** decreases the efficacy of combined hormonal contraceptives. MHRA advises avoid. For FSRH guidance, see Contraceptives, interactions p. 747. **Severe** Anecdotal
- **Sugammadex** is predicted to decrease the exposure to oral combined hormonal contraceptives. Refer to patient information leaflet for missed pill advice. **Severe** Theoretical
- **Combined hormonal contraceptives** are predicted to increase the risk of venous thromboembolism when given with **thalidomide**. Avoid. **Severe** Study
- **Combined hormonal contraceptives** are predicted to increase the exposure to **theophylline**. Monitor and adjust dose. **Moderate** Theoretical
- **Combined hormonal contraceptives** increase the exposure to **tizanidine**. Avoid. **Moderate** Study
- **Ulipristal** is predicted to decrease the efficacy of combined hormonal contraceptives. Avoid. **Severe** Theoretical
- **Combined hormonal contraceptives** are predicted to increase the exposure to **zolmitriptan**. Adjust **zolmitriptan** dose, p. 456. **Moderate** Theoretical

**Corticosteroids** → see TABLE 17 p. 1268 (reduced serum potassium)

- **Betamethasone** • **Betamethasone** • **Budesonide** • **Ciclesonide** • **Deflazacort** • **Dexamethasone** • **Fluticasone** • **Hydrocortisone** • **Methylprednisolone** • **Mometasone** • **Prednisolone** • **Prednisone** • **Triamcinolone**

- Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified.
- With intravital use of **dexamethasone**: caution with concurrent administration of anticoagulant or antiplatelet drugs—increased risk of haemorrhagic events.

- **Antacids** are predicted to decrease the absorption of **deflazacort**. Separate administration by 2 hours. **Moderate** Theoretical
- **Antacids** decrease the absorption of **dexamethasone**. **Moderate** Study
- **Antiarrhythmics (dronedarone)** are predicted to increase the exposure to **methylprednisolone**. Monitor and adjust dose. **Moderate** Study
- **Antiepileptics (Carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone)** are predicted to decrease the exposure to **deflazacort** (unknown) Theoretical
- **Antiepileptics (Carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone)** are predicted to decrease the exposure to **prednisone**. **MDM** Study
- **Antiepileptics (Carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone)** are predicted to decrease the exposure to corticosteroids (Budesonide, Dexamethasone, Methylprednisolone, Prednisolone). Monitor and adjust dose. **Moderate** Study
- **Antifungals, azoles (fluconazole, isavuconazole, posaconazole)** are predicted to increase the exposure to methylprednisolone. Monitor and adjust dose. **Moderate** Study
- **Antifungals, azoles (itraconazole, ketoconazole, voriconazole)** are predicted to increase the exposure to budesonide. Avoid. **Severe** Study
- **Antifungals, azoles (itraconazole, ketoconazole, voriconazole)** are predicted to increase the exposure to ciclesonide. Avoid. **Moderate** Theoretical
- **Antifungals, azoles (itraconazole, ketoconazole, voriconazole)** are predicted to increase the exposure to inhaled fluticasone. **Severe** Study
- **Antifungals, azoles (itraconazole, ketoconazole, voriconazole)** are predicted to increase the exposure to mometasone. **Moderate** Theoretical
- **Antifungals, azoles (itraconazole, ketoconazole, voriconazole)** are predicted to increase the risk of side-effects when given with triamcinolone. **Severe** Theoretical
- **Antifungals, azoles (miconazole)** are predicted to increase the concentration of methylprednisolone. Monitor and adjust dose. **Moderate** Theoretical
- **Antifungals, azoles (itraconazole, ketoconazole, voriconazole)** are predicted to increase the exposure to corticosteroids (Dexamethasone, Methylprednisolone). Monitor and adjust dose. **Moderate** Study
- **Aprepitant** moderately increases the exposure to dexamethasone. Monitor and adjust dose. **Moderate** Study
- **Aprepitant** is predicted to increase the exposure to methylprednisolone. Monitor and adjust dose. **Moderate** Study
- **Corticosteroids** are predicted to decrease the concentration of **dexamethasone**. **Moderate** Study
- **Cobicistat** is predicted to increase the concentration of **betamethasone**. MHRA advises avoid or monitor side effects and consider beclometasone as an alternative. **Severe** Theoretical
- **Cobicistat** is predicted to increase the concentration of **dexamethasone**. MHRA advises avoid or monitor side effects and consider beclometasone as an alternative. **Severe** Theoretical
- **Cobicistat** is predicted to increase the concentration of **beclometasone**. MHRA advises avoid or monitor side effects and consider beclometasone as an alternative. **Severe** Theoretical
- **Cobicistat** is predicted to increase the concentration of **beclometasone**. MHRA advises avoid or monitor side effects and consider beclometasone as an alternative. **Severe** Theoretical
- **Cobicistat** is predicted to increase the concentration of **beclometasone**. MHRA advises avoid or monitor side effects and consider beclometasone as an alternative. **Severe** Theoretical
- **Cobicistat** is predicted to increase the concentration of **beclometasone**. MHRA advises avoid or monitor side effects and consider beclometasone as an alternative. **Severe** Theoretical
- **Cobicistat** is predicted to increase the concentration of **beclometasone**. MHRA advises avoid or monitor side effects and consider beclometasone as an alternative. **Severe** Theoretical

**BNF 74**

**Interactions | Appendix 1**
Corticosteroids

- **Cobicistat** is predicted to increase the concentration of prednisolone. MHRA advises avoid or monitor side effects and consider beclomethasone as an alternative. (Severe) Theoretical
- **Cobicistat** is predicted to increase the concentration of prednisone. MHRA advises avoid or monitor side effects and consider beclomethasone as an alternative. (Severe) Theoretical
- **Cobicistat** is predicted to increase the concentration of triamcinolone. MHRA advises avoid or monitor side effects and consider beclomethasone as an alternative. (Severe) Theoretical

**Corticosteroids** are predicted to increase the effects of
- **Counarins**. (Moderate) Study
- **Crizotinib** is predicted to increase the exposure to methylprednisolone. Monitor and adjust dose. (Moderate) Study
- **Enzalutamide** is predicted to decrease the exposure to corticosteroids (budesonide, dexamethasone, methylprednisolone, prednisolone). Monitor and adjust dose. (Moderate) Study
- **Enzalutamide** is predicted to decrease the exposure to fluticasone. (Unknown) Theoretical
- **Enzalutamide** is predicted to decrease the exposure to methylprednisolone. (HiLo) Study
- **HIV-protease inhibitors** (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to ciclesonide. Avoid. (Moderate) Theoretical
- **HIV-protease inhibitors** (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to inhaled fluticasone. (Severe) Study
- **HIV-protease inhibitors** (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to methylprednisolone. Monitor and adjust dose. (Moderate) Theoretical
- **HIV-protease inhibitors** (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the risk of side-effects when given with triamcinolone. (Severe) Theoretical

**Corticosteroids** are predicted to increase the risk of gastrointestinal bleeding when given with iron chelators (deferasirox). (Severe) Theoretical

- **Live vaccines** are predicted to increase the risk of generalised infection (possibly life-threatening) when given with corticosteroids (high-dose). Public Health England advises avoid. (Severe) Theoretical
- **Lumacaftor** is predicted to decrease the exposure to corticosteroids (methylprednisolone, prednisolone). Adjust dose. (Severe) Theoretical
- **Macrolides** (clarithromycin) are predicted to increase the exposure to budesonide. Avoid. (Severe) Study
- **Macrolides** (clarithromycin) are predicted to increase the exposure to ciclesonide. Avoid. (Moderate) Theoretical
- **Macrolides** (clarithromycin) are predicted to increase the exposure to methylprednisolone. Monitor and adjust dose. (Moderate) Study
- **Corticosteroids** are predicted to decrease the efficacy of mifamurtide. Avoid. (Severe) Theoretical
- **Mifepristone** is predicted to decrease the efficacy of corticosteroids. Use with caution and adjust dose. (Moderate) Theoretical
- **Netupitant** increases the exposure to dexamethasone. Adjust dose. (Moderate) Study
- **Netupitant** is predicted to increase the exposure to methylprednisolone. Monitor and adjust dose. (Moderate) Study
- **Corticosteroids** are predicted to decrease the effects of neuromuscular blocking drugs, non-depolarising. (Severe) Anecdotal
- **Corticosteroids** increase the risk of gastrointestinal perforation when given with nicorandil. (Severe) Anecdotal
- **Nilotinib** is predicted to increase the exposure to methylprednisolone. Monitor and adjust dose. (Moderate) Study
- **NSAIDs** increase the risk of gastrointestinal bleeding when given with corticosteroids. (Severe) Study
- **Corticosteroids** are predicted to increase the effects of phenindione. (Moderate) Anecdotal
- **Dexamethasone** decreases the exposure to praziquantel. (Moderate) Study
- **Rifampicin** is predicted to decrease the exposure to corticosteroids (budesonide, dexamethasone, methylprednisolone, prednisolone). Monitor and adjust dose. (Moderate) Study
- **Rifampicin** is predicted to decrease the exposure to trilostane. (Unknown) Theoretical
- **Rifampicin** is predicted to decrease the exposure to fluticasone. (Unknown) Theoretical
- **Carbamazepine** is predicted to decrease the exposure to methylprednisolone. (HiLo) Study
- **Corticosteroids** potentially decrease the effects of sodium phenylbutyrate. (Moderate) Anecdotal
- **Corticosteroids** are predicted to decrease the effects of somatropin. (Moderate) Theoretical
- **Corticosteroids** are predicted to decrease the effects of suxamethonium. (Severe) Anecdotal

**Counarins** → see TABLE 3 p. 1264 (anticoagulant effects)

acencoumarol - warfarin

**FOOD AND LIFESTYLE** The effects of counarins can be reduced or abolished by vitamin K, including that found in health
foods, food supplements, enteral feeds, or large amounts of some green vegetables or green tea. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption can affect anticoagulant control. Pomegranate increases the INR in response to warfarin and is predicted to increase the INR in response to acenocoumarol.

- **Antiarrhythmics (amiodarone)** increase the anticoagulant effect of coumarins. *Severe* Study
- **Antiarrhythmics (propafenone)** increase the anticoagulant effect of coumarins. Monitor INR and adjust dose. *Moderate* Study
- **Antiepileptics (carbamazepine)** decrease the effects of coumarins. Monitor and adjust dose. *Severe* Study
- **Antiepileptics (fosphenytoin, phenytoin)** are predicted to alter the anticoagulant effect of coumarins. *Moderate* Anecdotal
- **Antiepileptics (phenobarbital, primidone)** decrease the anticoagulant effect of coumarins. Monitor INR and adjust dose. *Moderate* Study
- **Antifungals, azoles (fluconazole)** increase the anticoagulant effect of coumarins. Monitor INR and adjust dose. *Severe* Study
- **Antifungals, azoles (itraconazole)** potentially increase the anticoagulant effect of coumarins. *Severe* Anecdotal
- **Antifungals, azoles (ketocconazole)** potentially increase the anticoagulant effect of warfarin. Monitor INR and adjust dose. *Severe* Anecdotal
- **Antifungals, azoles (miconazole)** greatly increase the anticoagulant effect of coumarins. *Severe* Study
- **Antifungals, azoles (vorkonazole)** increase the anticoagulant effect of coumarins. Monitor INR and adjust dose. *Moderate* Study
- **Aprepitant** decreases the anticoagulant effect of coumarins. *Moderate* Study
- **Axitinib** is predicted to increase the risk of bleeding events when given with coumarins. *Severe* Theoretical
- **Azathioprine** decreases the anticoagulant effect of coumarins. *Moderate* Study
- **Bosentan** decreases the anticoagulant effect of coumarins. *Moderate* Study
- **Bosutinib** is predicted to increase the risk of bleeding events when given with coumarins. *Severe* Theoretical
- **Cabozantinib** is predicted to increase the risk of bleeding events when given with coumarins. *Severe* Theoretical
- **Capecitabine** increases the effects of coumarins. Monitor INR and adjust dose. *Moderate* Anecdotal
- **Cephalosporins (ceftriaxone)** potentially increase the risk of bleeding events when given with coumarins. *Severe* Anecdotal
- **Ceritinib** is predicted to increase the exposure to warfarin. Avoid. *Severe* Theoretical
- **Chloramphenicol** potentially increases the anticoagulant effect of coumarins. *Moderate* Anecdotal
- **Corticosteroids** are predicted to increase the effects of coumarins. *Moderate* Study
- **Cranberry juice** potentially increases the anticoagulant effect of warfarin. Avoid. *Severe* Anecdotal
- **Crizotinib** is predicted to increase the risk of bleeding events when given with coumarins. *Severe* Theoretical
- **Dabrafenib** is predicted to decrease the anticoagulant effect of coumarins. *Severe* Theoretical
- **Danazol** potentially increases the anticoagulant effect of coumarins. *Severe* Anecdotal
- **Dasatinib** is predicted to increase the risk of bleeding events when given with coumarins. *Severe* Theoretical
- **Disulfiram** increases the anticoagulant effect of coumarins. *Moderate* Study
- **Efavirenz** is predicted to affect the concentration of coumarins. Adjust dose. *Moderate* Theoretical
- **Elvitegravir** is predicted to decrease the anticoagulant effect of coumarins. *Moderate* Theoretical
- **Enteral feeds** (vitamin-K containing) potentially decrease the anticoagulant effect of coumarins. *Severe* Anecdotal
- **Enzalutamide** potentially decreases the exposure to coumarins. Avoid or adjust dose and monitor INR. *Severe* Study
- **Erlotinib** increases the anticoagulant effect of coumarins. *Severe* Anecdotal
- **Etravirine** increases the anticoagulant effect of coumarins. *Moderate* Theoretical
- **Fibrates** are predicted to increase the anticoagulant effect of coumarins. Monitor INR and adjust dose. *Severe* Study
- **Fluorouracil** increases the anticoagulant effect of coumarins. *Moderate* Anecdotal
- **Fosaprepitant** is predicted to decrease the anticoagulant effect of coumarins. *Moderate* Study
- **Gefitinib** is predicted to increase the anticoagulant effect of coumarins. *Moderate* Theoretical
- **Glucagon** increases the anticoagulant effect of warfarin. *Severe* Study
- **Glucosamine** increases the anticoagulant effect of warfarin. *Moderate* Anecdotal
- **Griseofulvin** potentially decreases the anticoagulant effect of coumarins. *Moderate* Anecdotal
- **H₃ receptor antagonists (cimetidine)** increase the anticoagulant effect of coumarins. *Severe* Study
- **HIV-protease inhibitors** are predicted to affect the anticoagulant effect of coumarins. *Moderate* Study
- **Imatinib** is predicted to increase the risk of bleeding events when given with coumarins. *Severe* Theoretical
- **Ivacafarin** is predicted to increase the anticoagulant effect of warfarin. *Severe* Theoretical
- **Ivermectin** potentially increases the anticoagulant effect of coumarins. *Severe* Anecdotal
- **Lapatinib** is predicted to increase the risk of bleeding events when given with coumarins. *Severe* Theoretical
- **Leflunomide** increases the anticoagulant effect of coumarins. *Severe* Anecdotal
- **Live vaccines (influenza vaccine)** potentially increase the risk of bleeding events when given with coumarins. *Severe* Anecdotal
- **Lomitapide** increases the exposure to warfarin. Monitor INR and adjust warfarin dose. *Moderate* Study
- **Lumacaftor** is predicted to affect the exposure to warfarin. *Severe* Theoretical
- **Macrolides (clarithromycin, erythromycin)** increase the anticoagulant effect of coumarins. Monitor INR and adjust dose. *Severe* Anecdotal
- **Mercaptopurine** decreases the anticoagulant effect of coumarins. *Moderate* Anecdotal
- **Metronidazole** increases the anticoagulant effect of coumarins. Monitor INR and adjust dose. *Severe* Study
- **Monoclonal antibodies (blinatumomab)** are predicted to transiently increase the exposure to warfarin. Monitor and adjust dose. *Moderate* Theoretical
- **Nandrolone** is predicted to increase the anticoagulant effect of coumarins. Monitor and adjust dose. *Severe* Theoretical
- **Nevirapine** potentially alters the anticoagulant effect of coumarins. *Severe* Anecdotal
- **Nilotinib** is predicted to increase the risk of bleeding events when given with coumarins. *Severe* Theoretical
- **Oxymetholone** increases the anticoagulant effect of coumarins. *Severe* Anecdotal
- **Paracetamol** increases the anticoagulant effect of coumarins. *Moderate* Anecdotal
- **Penicillins** potentially alter the anticoagulant effect of coumarins. Monitor INR and adjust dose. *Moderate* Theoretical
- **Pazopanib** is predicted to increase the risk of bleeding events when given with coumarins. *Severe* Theoretical
- **Pemetrexed** potentially decreases the anticoagulant effect of coumarins. *Moderate* Study
- **Ponatinib** is predicted to decrease the exposure to warfarin. *Unknown* Theoretical
- **Ponatinib** is predicted to increase the risk of bleeding events when given with coumarins. *Severe* Theoretical
- **Quinolones** increase the anticoagulant effect of coumarins. *Severe* Anecdotal
- **Ranibizumab** increases the risk of bleeding events when given with coumarins. *Severe* Theoretical
- **Regorafenib** is predicted to increase the risk of bleeding events when given with coumarins. *Severe* Study
- **Rifampicin** decreases the anticoagulant effect of coumarins. *Severe* Study
- **Ruxolitinib** is predicted to increase the risk of bleeding events when given with coumarins. *Severe* Theoretical
Interactions

Appendix 1

Crizotinib

- **Sorafenib** increases the anticoagulant effect of coumarins. [Severe] Anecdotal
- **St John's Wort** decreases the anticoagulant effect of coumarins. Avoid. [Severe] Anecdotal
- Statins (fluvastatin, rosuvastatin) increase the anticoagulant effect of coumarins. Monitor INR and adjust dose. [Severe] Study
- **Sucralfate** potentially decreases the effects of warfarin. Separate administration by 2 hours. [Moderate] Anecdotal
- **Sulfamethoxazole** increases the anticoagulant effect of coumarins. [Severe] Study
- **Bosentan** decreases the anticoagulant effect of coumarins. [Severe] Theoretical
- **Tamoxifen** increases the anticoagulant effect of coumarins. [Moderate] Study
- **Grapefruit juice** increases the anticoagulant effect of coumarins. [Severe] Study
- **Cranberry juice** increases the anticoagulant effect of coumarins. [Moderate] Anecdotal
- **Teriflunomide** affects the anticoagulant effect of coumarins. [Severe] Study
- **Tetracyclines** increase the risk of bleeding events when given with coumarins. [Moderate] Anecdotal
- **Tiludronate** is predicted to increase the anticoagulant effect of coumarins. Monitor INR and adjust dose. [Severe] Theoretical
- **Toremifene** is predicted to increase the anticoagulant effect of coumarins. [Severe] Theoretical
- **Trimethoprim** is predicted to increase the anticoagulant effect of coumarins. [Severe] Study
- **Vandetanib** is predicted to increase the risk of bleeding events when given with coumarins. [Severe] Theoretical
- **Venetoclax** slightly increases the exposure to warfarin. [Moderate] Study

**Cranberry juice** potentially increases the anticoagulant effect of coumarins (warfarin). Avoid. [Severe] Anecdotal

**Crisantaspase** → see TABLE 1 p. 1264 (hepatotoxicity), TABLE 15 p. 1267 (myelosuppression)

**Crisantaspase** is predicted to increase the risk of hepatotoxicity when given with imatinib. [Severe] Theoretical → Also see TABLE 15 p. 1267

**Crisantaspase** affecls the efficacy of methotrexate. [Severe] Anecdotal → Also see TABLE 1 p. 1264 → Also see TABLE 15 p. 1267

**Crisantaspase** potentially increases the risk of neurotoxicity when given with vinca alkaloids (vincristine). [Severe] Anecdotal → Also see TABLE 1 p. 1264 → Also see TABLE 15 p. 1267

**Crizotinib** → see TABLE 6 p. 1265 (bradycardia), TABLE 15 p. 1267 (myelosuppression), TABLE 9 p. 1266 (QT-interval prolongation)

**Crizotinib** is predicted to increase the exposure to aldosterone antagonists (eplerenone). Adjust eplerenone dose, p. 185. [Severe] Study

**Crizotinib** is predicted to increase the exposure to alpha blockers (tamsulosin). [Moderate] Theoretical

**Crizotinib** is predicted to increase the exposure to alprazolam. [Severe] Study

**Antiarrhythmics (dronedarone)** are predicted to increase the exposure to crizotinib. [Moderate] Theoretical → Also see TABLE 9 p. 1266

**Crizotinib** is predicted to increase the exposure to antianginal drugs (propafenone). Monitor and adjust dose. [Moderate] Study

**Antiepileptics** (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to markedly decrease the exposure to crizotinib. Avoid. [Severe] Study

**Antifungals, azoles (fluconazole, posaconazole)** are predicted to increase the exposure to crizotinib. Avoid. [Moderate] Study

**Antifungals, azoles (itraconazole, ketoconazole, voriconazole)** are predicted to moderately increase the exposure to crizotinib. Avoid. [Moderate] Study → Also see TABLE 9 p. 1266

- **Crizotinib** is predicted to increase the exposure to antifungals, azoles (isavuconazole). [Moderate] Theoretical
- **Crizotinib** is predicted to increase the exposure to antihistamines, non-sedating (mizolastine). [Severe] Theoretical
- **Crizotinib** is predicted to increase the concentration of antimailarials (piperazaine). [Severe] Theoretical
- **Aprepitant** is predicted to increase the exposure to crizotinib. [Moderate] Theoretical
- **Crizotinib** is predicted to increase the exposure to axitinib. [Moderate] Theoretical → Also see TABLE 15 p. 1267
- **Crizotinib** is predicted to increase the exposure to bedaquiline. Avoid prolonged use. [Mid] Theoretical → Also see TABLE 9 p. 1266
- **Bosentan** is predicted to decrease the exposure to crizotinib. Avoid. [Severe] Theoretical
- **Crizotinib** is predicted to increase the exposure to bosutinib. Avoid or adjust bosutinib dose. [Severe] Theoretical → Also see TABLE 15 p. 1267 → Also see TABLE 9 p. 1266
- **Crizotinib** is predicted to increase the exposure to buspirone. Use with caution and adjust dose. [Moderate] Study
- **Crizotinib** is predicted to increase the exposure to cabozantinib. [Moderate] Theoretical → Also see TABLE 15 p. 1267 → Also see TABLE 9 p. 1266
- **Calcium channel blockers** (diltiazem, verapamil) are predicted to increase the exposure to crizotinib. [Moderate] Theoretical → Also see TABLE 6 p. 1267
- **Crizotinib** is predicted to increase the exposure to calcium channel blockers (amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose. [Moderate] Study
- **Crizotinib** is predicted to increase the exposure to ceritinib. [Moderate] Theoretical → Also see TABLE 15 p. 1267 → Also see TABLE 9 p. 1266
- **Crizotinib** increases the concentration of ciclosporin. [Severe] Study
- **Cobicistat** is predicted to moderately increase the exposure to crizotinib. Avoid. [Moderate] Study
- **Crizotinib** is predicted to increase the exposure to cobimetinib. [Severe] Theoretical
- **Crizotinib** is predicted to increase the exposure to colchicine. Adjust colchicine dose, p. 1020. [Severe] Study
- **Crizotinib** is predicted to increase the exposure to corticosteroids (methylprednisolone). Monitor and adjust dose. [Moderate] Study
- **Crizotinib** is predicted to increase the risk of bleeding events when given with coumarins. [Severe] Theoretical
- **Crizotinib** is predicted to slightly increase the exposure to darifenacin. [Moderate] Study
- **Crizotinib** is predicted to increase the exposure to dasatinib. [Severe] Study → Also see TABLE 15 p. 1267 → Also see TABLE 9 p. 1266
- **Crizotinib** increases the risk of QT-prolongation when given with dorperidone. Avoid. [Severe] Study
- **Crizotinib** is predicted to increase the exposure to dopamine receptor agonists (bromocriptine, cabergoline). [Severe] Theoretical
- **Crizotinib** is predicted to moderately increase the exposure to dutasteride. [Mid] Study
- **Efavirenz** is predicted to decrease the exposure to crizotinib. Avoid. [Severe] Theoretical
- **Enalapril** is predicted to markedly decrease the exposure to crizotinib. Avoid. [Severe] Study
- **Crizotinib** is predicted to increase the risk of ergotism when given with ergotamine. [Severe] Theoretical
- **Crizotinib** is predicted to increase the risk of ergotism when given with ergotamine. [Severe] Theoretical
- **Crizotinib** is predicted to increase the exposure to erlotinib. [Moderate] Theoretical
- **Crizotinib** is predicted to increase the concentration of everolimus. Avoid or adjust dose. [Moderate] Study → Also see TABLE 15 p. 1267
- **Crizotinib** is predicted to increase the exposure to fesoterodine. Adjust fesoterodine dose in hepatic and renal impairment, p. 732. [Mid] Study
- **Crizotinib** is predicted to increase the exposure to gefitinib. [Moderate] Theoretical → Also see TABLE 15 p. 1267
- **Grapefruit juice** is predicted to increase the exposure to crizotinib. Avoid. [Moderate] Theoretical
Crizotinib is predicted to increase the concentration of guanfacine. Adjust guanfacine dose, p. 335. [Moderate] Theoretical

▶ HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to moderately increase the exposure to crizotinib. Avoid. [Moderate] Study ▶ Also see TABLE 9 p. 1266

▶ HIV-protease inhibitors (indinavir) are predicted to increase the exposure to crizotinib. [Moderate] Theoretical

Crizotinib is predicted to increase the exposure to ibritinib. Avoid or adjust ibritinib dose, p. 902. [Severe] Theoretical ▶ Also see TABLE 15 p. 1267

Idelalisib is predicted to moderately increase the exposure to crizotinib. Avoid. [Moderate] Study ▶ Also see TABLE 15 p. 1267

Crizotinib is predicted to increase the exposure to irabradine. Adjust irabradine dose, p. 205. [Severe] Theoretical ▶ Also see TABLE 6 p. 1265

Crizotinib is predicted to increase the exposure to ivacaftor. Adjust ivacaftor dose, p. 281. [Severe] Study

Crizotinib is predicted to increase the exposure to lopatinib. [Moderate] Study ▶ Also see TABLE 9 p. 1266

Crizotinib is predicted to increase the exposure to lomitapide. Avoid. [Moderate] Theoretical

▶ Macrolides (clarithromycin) are predicted to moderately increase the exposure to crizotinib. Avoid. [Moderate] Study ▶ Also see TABLE 9 p. 1266

▶ Macrolides (erythromycin) are predicted to increase the exposure to crizotinib. [Moderate] Theoretical

Crizotinib is predicted to increase the exposure to midazolam. Monitor side effects and adjust dose. [Severe] Study

Crizotinib is predicted to increase the exposure to naloxegol. Adjust naloxegol dose and monitor side effects, p. 63. [Moderate] Study

Netupitant is predicted to increase the exposure to crizotinib. [Severe] Theoretical

▶ Nevirapine is predicted to decrease the exposure to crizotinib. Avoid. [Severe] Theoretical

▶ Crizotinib is predicted to increase the exposure to olaparib. Avoid or adjust olaparib dose, p. 919. [Moderate] Theoretical ▶ Also see TABLE 15 p. 1267

Crizotinib is predicted to increase the exposure to opioids (alfentanil, buprenorphine, fentanyl, oxycodone). Monitor and adjust dose. [Moderate] Study ▶ Also see TABLE 6 p. 1266

Crizotinib is predicted to increase the exposure to opioids (methadone, sufentanil). [Moderate] Theoretical ▶ Also see TABLE 6 p. 1265 ▶ Also see TABLE 9 p. 1266

▶ Crizotinib is predicted to increase the exposure to oxycodone. [Mild] Theoretical

Crizotinib is predicted to increase the exposure to oxycodone. [Mild] Theoretical ▶ Also see TABLE 15 p. 1267 ▶ Also see TABLE 9 p. 1266

Crizotinib is predicted to increase the risk of bleeding events when given with phenindione. [Severe] Theoretical

Crizotinib is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (avanafil). Adjust avanafil dose, p. 765. [Moderate] Theoretical

Crizotinib is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (sildenafil). Monitor and adjust sildenafil dose, p. 766. [Moderate] Study ▶ Also see TABLE 9 p. 1266

Crizotinib is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (tadalafil). [Severe] Theoretical

Crizotinib is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (vardenafil). Adjust dose. [Severe] Theoretical ▶ Also see TABLE 9 p. 1266

Crizotinib is predicted to increase the exposure to pimozone. Avoid. [Severe] Theoretical ▶ Also see TABLE 9 p. 1266

Pitolisant is predicted to decrease the exposure to crizotinib. [Severe] Theoretical

Crizotinib is predicted to increase the exposure to quetiapine. Avoid. [Moderate] Study

Crizotinib is predicted to increase the exposure to ranolazine. [Severe] Study ▶ Also see TABLE 9 p. 1266

▶ Rifampicin is predicted to markedly decrease the exposure to crizotinib. Avoid. [Severe] Study

Crizotinib is predicted to increase the exposure to ruxolitinib. [Moderate] Theoretical ▶ Also see TABLE 15 p. 1267

Crizotinib is predicted to increase the exposure to saxagliptin. [Moderate] Theoretical

Crizotinib is predicted to increase the exposure to simprevir. Avoid. [Severe] Study

Crizotinib increases the concentration of sirolimus. Monitor and adjust dose. [Moderate] Study

Crizotinib is predicted to increase the exposure to SSRIs (dapoxetine). Adjust dapoxetine dose, p. 773. [Moderate] Theoretical

▶ St John’s Wort is predicted to decrease the exposure to crizotinib. Avoid. [Severe] Theoretical

Crizotinib is predicted to increase the exposure to statins (atorvastatin). Monitor and adjust dose. [Severe] Theoretical

Crizotinib is predicted to increase the exposure to statins (simvastatin). Use with caution and adjust simvastatin dose, p. 198. [Severe] Study

Crizotinib is predicted to increase the exposure to sunifatinib. [Moderate] Theoretical ▶ Also see TABLE 15 p. 1267 ▶ Also see TABLE 9 p. 1266

Crizotinib is predicted to increase the concentration of tacrolimus. [Severe] Study

Crizotinib is predicted to increase the exposure to temsirolimus. [Mild] Theoretical ▶ Also see TABLE 9 p. 1266

Crizotinib is predicted to increase the exposure to tocotrienol. [Mild] Theoretical

Crizotinib is predicted to increase the exposure to trazodone. [Mild] Theoretical

Crizotinib is predicted to increase the exposure to ulipristal. Avoid if used for uterine fibroids. [Moderate] Study

Crizotinib is predicted to increase the exposure to venoctalax. Avoid or adjust venoctalax dose, p. 919. [Severe] Study

Crizotinib is predicted to increase the exposure to vinca alkaloids. [Severe] Theoretical ▶ Also see TABLE 9 p. 1266 ▶ Also see TABLE 15 p. 1267

Crizotinib is predicted to increase the exposure to zopiclone. Adjust dose. [Moderate] Study

Cyclizine ▶ see antihistamines, sedating

Cyclopenthiazide ▶ see thiazide diuretics

Cyclophosphamide ▶ see alkylating agents

Cycloserine ▶ Cycloserine increases the risk of CNS toxicity when given with isoniazid. Monitor and adjust dose. [Moderate] Study

Cyproheptadine ▶ see antihistamines, sedating

Cytarabine ▶ see TABLE 15 p. 1267 (myelosuppression)

Cytarabine decreases the concentration of flucytosine. Avoid. [Severe] Study

▶ Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with cytarabine. Public Health England advises avoid. [Severe] Theoretical

Dabigatran ▶ see TABLE 3 p. 1264 (anticoagulant effects)

▶ Antiarrhythmics (amiodarone) increase the exposure to dabigatran. Adjust dabigatran dose, p. 131. [Moderate] Study

▶ Antiarrhythmics (dronedarone) slightly increase the exposure to dabigatran. Avoid. [Severe] Study

▶ Antiepileptics (carbamazepine) are predicted to decrease the exposure to dabigatran. Avoid. [Severe] Study

▶ Antifungals, azoles (itraconazole, ketoconazole) are predicted to increase the exposure to dabigatran. Avoid. [Severe] Study

▶ Calcium channel blockers (verapamil) increase the exposure to dabigatran. Adjust dabigatran dose, p. 131. [Severe] Study

Certitinib is predicted to increase the exposure to dabigatran. [Moderate] Theoretical

Ciclosporin is predicted to increase the exposure to dabigatran. Avoid. [Severe] Theoretical

Elbasvir is predicted to increase the concentration of dabigatran. [Moderate] Theoretical
Dabrafenib (continued)

- HIV-protease inhibitors (lopinavir, ritonavir, saquinavir) are predicted to increase the exposure to dabrafenib. Avoid. [Severe] Theoretical
- Lapatinib is predicted to increase the exposure to dabrafenib. [Severe] Theoretical
- Lumacaftor is predicted to affect the exposure to dabrafenib. Monitor and adjust dose. [Moderate] Theoretical
- Macrolides (azithromycin, clarithromycin, erythromycin) are predicted to increase the exposure to dabrafenib. [Moderate] Theoretical
- Mirabegron is predicted to increase the exposure to dabrafenib. [Severe] Theoretical
- Pilotisant is predicted to decrease the exposure to dabrafenib. [Uncommon]
- Ranolazine is predicted to increase the exposure to dabrafenib. [Severe] Theoretical
- Rifampicin is predicted to decrease the exposure to dabrafenib. Avoid. [Severe] Study
- St John’s Wort is predicted to decrease the exposure to dabrafenib. Avoid. [Severe] Study
- Velpatasvir is predicted to increase the exposure to dabrafenib. Avoid. [Severe] Study
- Vemurafenib increases the exposure to dabrafenib. Use with caution and adjust dose. [Severe] Theoretical

Dabrafenib → see TABLE 15 p. 1267 (myelosupression)

- Antacids are predicted to decrease the absorption of dabrafenib. Avoid. [Severe] Theoretical
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to dabrafenib. Avoid. [Moderate] Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to dabrafenib. Use with caution or avoid. [Moderate] Study
- Cobicistat is predicted to increase the exposure to dabrafenib. Use with caution or avoid. [Moderate] Study
- Dabrafenib is predicted to decrease the anticoagulant effect of coumarins. [Severe] Theoretical
- Enzalutamide is predicted to decrease the exposure to dabrafenib. Avoid. [Moderate] Theoretical
- Fibres (gemfibrozil) are predicted to increase the exposure to dabrafenib. [Moderate] Theoretical
- H₂ receptor antagonists are predicted to decrease the exposure to dabrafenib. Avoid. [Severe] Theoretical
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to dabrafenib. Use with caution or avoid. [Moderate] Study
- Idelalisib is predicted to increase the exposure to dabrafenib. Use with caution or avoid. [Moderate] Study
- Dabrafenib is predicted to decrease the exposure to midazolam. Monitor and adjust dose. [Moderate] Study
- Proton pump inhibitors are predicted to decrease the exposure to dabrafenib. Avoid. [Severe] Theoretical
- Rifampicin is predicted to decrease the exposure to dabrafenib. Avoid. [Moderate] Theoretical
- Dacarbazine → see alkylating agents

Dacitasvir
- Dacitasvir is predicted to increase the risk of severe bradycardia or heart block when given with antiarrhythmics (amiodarone). Refer to specialist literature. [Severe] Anecdotal
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to moderately decrease the exposure to dacitasvir. Avoid. [Severe] study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to moderately increase the exposure to dacitasvir. Adjust dacitasvir dose, p. 591. [Moderate] Study
- Bosentan is predicted to decrease the exposure to dacitasvir. Adjust dacitasvir dose, p. 591. [Moderate] Theoretical
- Cobicistat is predicted to moderately increase the exposure to dacitasvir. Adjust dacitasvir dose, p. 591. [Moderate] Study
- Dacitasvir slightly increases the concentration of digoxin. [Severe] Study
- Efavirenz is predicted to decrease the exposure to dacitasvir. Adjust dose. [Severe] Study
- Enzalutamide is predicted to moderately decrease the exposure to dacitasvir. Avoid. [Severe] Study
- Etravirine is predicted to decrease the exposure to dacitasvir. Avoid. [Severe] Study
- Macrolides (clarithromycin) are predicted to moderately increase the exposure to dacitasvir. Adjust dacitasvir dose, p. 591. [Moderate] Study
- Dabrafenib is predicted to increase the exposure to dacitasvir. Avoid. [Moderate] Theoretical
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to moderately increase the exposure to dacitasvir. Adjust dacitasvir dose, p. 591. [Moderate] Study
- Idelalisib is predicted to moderately increase the exposure to dacitasvir. Adjust dacitasvir dose, p. 591. [Moderate] Study
- Dacelizumab → see monoclonal antibodies

Dactinomycin → see TABLE 1 p. 1264 (hepatotoxicity), TABLE 15 p. 1267 (myelosuppression)

- Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with dactinomycin. Public Health England advises avoid. [Severe] Theoretical

Dairy products
- Dairy products are predicted to decreases the absorption of eltrombopag. Eltrombopag should be taken 2 hours before or 4 hours after dairy products. [Severe] Theoretical
- Dairy products decrease the exposure to tetracyclines (demeclocycline, oxytetracycline, tetracycline). Avoid. [Moderate] Study

Dalteparin → see low molecular-weight heparins

Danaparoid → see TABLE 3 p. 1264 (anticoagulant effects)

- Ranibizumab is predicted to increase the risk of bleeding events when given with danaparoid. [Severe] Theoretical

Danazol
- Danazol moderately increases the concentration of antiepileptics (carbamazepine). Monitor carbamazepine concentration and adjust dose. [Severe] Study
- Danazol increases the concentration of ciclosporin. [Severe] Study
- Danazol potentially increases the anticoagulant effect of coumarins. [Severe] Anecdotal
- Danazol is predicted to increase the risk of rhabdomyolysis when given with statins (atorvastatin). [Severe] Theoretical
- Danazol increases the risk of rhabdomyolysis when given with statins (simvastatin). Avoid. [Severe] Anecdotal
- Danazol potentially increases the concentration of tacrolimus. [Severe] Anecdotal

Dantronolene → see TABLE 1 p. 1264 (hepatotoxicity)

- Intravenous dantronolene potentially increases the risk of acute hyperkalaemia and cardiovascular collapse when given with calcium channel blockers (diltiazem, verapamil). Avoid. [Severe] Anecdotal

Dantron → see TABLE 17 p. 1268 (reduced serum potassium)

Dapagliflozin → see TABLE 14 p. 1267 (antidiabetic drugs), TABLE 8 p. 1265 (hypotension)

Dapoxetine → see SSRIs

Dapsone
- Aminosalicylic acid is predicted to increase the risk of methaemoglobinemia when given with dapsone. [Severe] Theoretical
- Dapsone is predicted to increase the risk of methaemoglobinemia when given with topical anaesthetics, local (prilocaine). Use with caution or avoid. [Severe] Theoretical
- Antiepileptics (fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to increase the risk of...
Grapefruit juice is predicted to decrease the exposure to darifenacin. [Severe] Theoretical

Antimalarials (chloroquine, primaquine) are predicted to increase the risk of methaemoglobinemia when given with darifenacin. [Severe] Theoretical

Nitrates are predicted to increase the risk of methaemoglobinemia when given with darifenacin. [Severe] Theoretical

Nitrofurantoin is predicted to increase the risk of methaemoglobinemia when given with darifenacin. [Severe] Theoretical

Paracetamol is predicted to increase the risk of methaemoglobinemia when given with darifenacin. [Severe] Theoretical

Rifabutin increases the clearance of darifenacin. [Moderate] Study

rifampicin moderately decreases the exposure to darifenacin. [Moderate] Study

Sodium nitroprusside is predicted to increase the risk of methaemoglobinemia when given with darifenacin. [Severe] Theoretical

Sulfonamides are predicted to increase the risk of methaemoglobinemia when given with darifenacin. [Severe] Theoretical

Dapson increases the exposure to trimethoprim and trimethoprim increases the exposure to dapson. [Severe] Study

Daptomycin

Aspirin (high-dose) increases the risk of renal impairment when given with daptomycin. [Moderate] Theoretical

Ciclosporin is predicted to increase the risk of rhabdomyolysis when given with daptomycin. [Severe] Theoretical

Fibrates are predicted to increase the risk of rhabdomyolysis when given with daptomycin. [Severe] Theoretical

NSAIDs increase the risk of renal impairment when given with daptomycin. [Moderate] Theoretical

Statins are predicted to increase the risk of rhabdomyolysis when given with daptomycin. [Severe] Theoretical

Daratumumab ➔ see monoclonal antibodies

Darbepoetin alfa ➔ see TABLE 5 p. 1264 (thromboembolism), TABLE 16 p. 1266 (increased serum potassium)

Darifenacin ➔ see TABLE 10 p. 1266 (antimuscarinics)

Antiarrhythmics (dronedarone) are predicted to slightly increase the exposure to darifenacin. [Moderate] Study

Darifenacin is predicted to increase the concentration of antiarrhythmics (flecainide). [Moderate] Theoretical

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to darifenacin. [Moderate] Theoretical

Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to slightly increase the exposure to darifenacin. [Moderate] Study

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to markedly to very markedly increase the exposure to darifenacin. Avoid. [Severe] Study

Aprepitant is predicted to slightly increase the exposure to darifenacin. [Moderate] Study

Bupropion is predicted to slightly increase the exposure to darifenacin. [Mild] Study

Calcium channel blockers (diltiazem, verapamil) are predicted to slightly increase the exposure to darifenacin. [Moderate] Study

Ciclosporin is predicted to increase the exposure to darifenacin. Avoid. [Moderate] Theoretical

Cincalcet is predicted to slightly increase the exposure to darifenacin. [Mild] Study

Cobicistat is predicted to markedly to very markedly increase the exposure to darifenacin. Avoid. [Severe] Study

Crizotinib is predicted to slightly increase the exposure to darifenacin. [Moderate] Study

Enzalutamide is predicted to decrease the exposure to darifenacin. [Moderate] Theoretical

Grapefruit juice is predicted to increase the exposure to darifenacin. [Moderate] Study

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to markedly to very markedly increase the exposure to darifenacin. Avoid. [Severe] Study

HIV-protease inhibitors (indinavir) are predicted to slightly increase the exposure to darifenacin. [Moderate] Study

Idelalisib is predicted to markedly to very markedly increase the exposure to darifenacin. Avoid. [Severe] Study

Imatinib is predicted to slightly increase the exposure to darifenacin. [Moderate] Study

Macrolides (clarithromycin) are predicted to markedly to very markedly increase the exposure to darifenacin. Avoid. [Severe] Study

Macrolides (erythromycin) are predicted to slightly increase the exposure to darifenacin. [Moderate] Study

Netupitant is predicted to slightly increase the exposure to darifenacin. [Moderate] Study

Nilotinib is predicted to slightly increase the exposure to darifenacin. [Moderate] Study

rifampicin is predicted to decrease the exposure to darifenacin. [Moderate] Theoretical

SSRIs (fluoxetine, paroxetine) are predicted to slightly increase the exposure to darifenacin. [Mild] Study

St John’s Wort is predicted to decrease the exposure to darifenacin. [Moderate] Theoretical

Terbinafine is predicted to slightly increase the exposure to darifenacin. [Mild] Study

Darifenacin is predicted to increase the exposure to tricyclic antidepressants. [Moderate] Theoretical ➔ also see TABLE 10 p. 1266

Darunavir ➔ see HIV-protease inhibitors

Dasabuvir

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to dasabuvir. Avoid. [Severe] Theoretical

Combined hormonal contraceptives increase the risk of raised liver function tests when given with dasabuvir. Avoid. [Severe] Study

Enzalutamide is predicted to decrease the exposure to dasabuvir. Avoid. [Severe] Theoretical

Fibrates (gemfibrozil) very markedly increase the exposure to dasabuvir. Avoid. [Severe] Study

Dasabuvir (with ombitasvir, paritaprevir and ritonavir) increases the concentration of loop diuretics (furosemide). Adjust dose. [Moderate] Study

rifampicin is predicted to decrease the exposure to dasabuvir. Avoid. [Severe] Theoretical

St John’s Wort is predicted to decrease the exposure to dasabuvir. Avoid. [Severe] Theoretical

Dasabuvir increases the exposure to statins (rosuvastatin). Adjust rosuvastatin dose, p. 197. [Moderate] Study

Dasatinib ➔ see TABLE 15 p. 1267 (myelosuppression), TABLE 9 p. 1266 (QT-interval prolongation), TABLE 4 p. 1264 (antiplatelet effects)

Antacids decrease the absorption of dasatinib. Separate administration by at least 2 hours. [Moderate] Study

Antiarrhythmics (dronedarone) are predicted to increase the exposure to dasatinib. [Severe] Study ➔ also see TABLE 9 p. 1266

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to markedly decrease the exposure to dasatinib. Avoid. [Severe] Study

Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to dasatinib. [Severe] Study

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to markedly to very markedly increase the exposure to dasatinib. Avoid. [Severe] Study

Aprepitant is predicted to increase the exposure to dasatinib. [Severe] Study

Bosentan is predicted to decrease the exposure to dasatinib. [Severe] Study

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to dasatinib. [Severe] Study

Cobicistat is predicted to markedly increase the exposure to dasatinib. [Severe] Study

Crizotinib is predicted to increase the exposure to dasatinib. [Severe] Study ➔ also see TABLE 15 p. 1267 ➔ also see TABLE 9 p. 1266

Efavirenz is predicted to decrease the exposure to dasatinib. [Severe] Study
Dasatinib (continued)

- **Enzalutamide** is predicted to markedly decrease the exposure to dasatinib. Avoid. **Severe** Study
- **Grapefruit juice** is predicted to increase the exposure to dasatinib. Avoid. **Moderate** Theoretical
- H2 receptor antagonists are predicted to decrease the exposure to dasatinib. Avoid. **Moderate** Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to markedly increase the exposure to dasatinib. Avoid. **Severe** Study → Also see TABLE 9 p. 1266
- HIV-protease inhibitors (indinavir) are predicted to increase the exposure to dasatinib. **Severe** Study
- **Idelalisib** is predicted to markedly increase the exposure to dasatinib. Avoid. **Severe** Study → Also see TABLE 15 p. 1267
- **Imatinib** is predicted to increase the exposure to dasatinib. **Severe** Study → Also see TABLE 15 p. 1267
- **Macrolides (clarithromycin)** are predicted to markedly increase the exposure to dasatinib. Avoid. **Severe** Study → Also see TABLE 9 p. 1266
- **Macrolides (erythromycin)** are predicted to increase the exposure to dasatinib. **Severe** Study
- **Netupitant** is predicted to increase the exposure to dasatinib. **Severe** Study
- **Nevirapine** is predicted to decrease the exposure to dasatinib. **Severe** Study
- **Nilotinib** is predicted to increase the exposure to dasatinib. **Severe** Study → Also see TABLE 15 p. 1267 → Also see TABLE 9 p. 1266
- Dasatinib is predicted to increase the risk of bleeding events when given with **phenindione. **Severe** Theoretical
- **Pitolisant** is predicted to decrease the exposure to dasatinib. Avoid. **Severe** Theoretical
- **Proton pump inhibitors** are predicted to slightly to moderately decrease the exposure to dasatinib. Avoid. **Severe** Study
- **Rifampicin** is predicted to markedly decrease the exposure to dasatinib. Avoid. **Severe** Study
- **St John’s Wort** is predicted to decrease the exposure to dasatinib. **Severe** Study
- Dasatinib is predicted to increase the exposure to **statins (simvastatin). **Moderate** Theoretical
- Daunorubicin → see anthracyclines
- **Decitabine** → see TABLE 15 p. 1267 (myelosuppression)
- **Deferasirox** → see iron chelators
- **Deferriprone** → see TABLE 15 p. 1267 (myelosuppression)
- Antacids (aluminium hydroxide) are predicted to decrease the absorption of deferriprone. Avoid. **Moderate** Theoretical
- **Ascorbic acid** is predicted to increase the risk of cardiovascular side-effects when given with deferriprone. **Severe** Theoretical
- **Deflazacort** → see corticosteroids
- **Delamanid** → see TABLE 9 p. 1266 (QT-interval prolongation)
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone, rufinamide, topiramate) are predicted to decrease the efficacy of **desogestrel.** For FSRH guidance, see Contraceptives, interactions p. 747. **Severe** Theoretical
- **Desogestrel** is predicted to decrease the exposure to antiepileptics (lamotrigine). **Moderate** Study
- **Aprepitant** is predicted to decrease the efficacy of desogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. **Severe** Theoretical
- **Bosentan** is predicted to decrease the efficacy of desogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. **Severe** Theoretical
- **Davirenz** is predicted to decrease the efficacy of desogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. **Severe** Theoretical
- **Fosaprepitant** is predicted to decrease the efficacy of desogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. **Severe** Theoretical
- **Grisofulvin** potentially decreases the efficacy of desogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. **Severe** Theoretical
- **Modafinil** is predicted to decrease the efficacy of desogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. **Severe** Theoretical
- **Nevirapine** is predicted to decrease the efficacy of desogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. **Severe** Theoretical
- **Rifabutin** is predicted to decrease the efficacy of desogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. **Severe** Theoretical
- **Rifampicin** is predicted to decrease the efficacy of desogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. **Severe** Theoretical
- **St John’s Wort** is predicted to decrease the efficacy of desogestrel. **Severe** Theoretical
- **Ulipristal** is predicted to decrease the efficacy of desogestrel. Avoid. **Severe** Theoretical
- Dexamethasone → see corticosteroids
- **Dexamfetamine** → see amphetamines
- **Dexibuprofen** → see NSAIDs
- **Dexketoprofen** → see NSAIDs
- **Dexmedetomidine** → see TABLE 11 p. 1266 (CNS depressant effects)
- **Dexrazoxane** → see iron chelators
- Diamorphine → see opioids
- **Diazepam** → see TABLE 11 p. 1266 (CNS depressant effects)
- Diazepam potentially affects the concentration of antiepileptics (fosphenytoin, phenytoin). Monitor concentration and adjust dose. **Severe** Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) very slightly increase the exposure to delamanid. **Moderate** Study
- **Cobicistat** very slightly increases the exposure to delamanid. **Severe** Study → Also see TABLE 9 p. 1266
- **Enzalutamide** is predicted to slightly decrease the exposure to delamanid. Avoid. **Moderate** Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) very slightly increase the exposure to delamanid. **Severe** Study → Also see TABLE 9 p. 1266
- **Idelalisib** very slightly increases the exposure to delamanid. **Severe** Study
- **Macrolides (clarithromycin)** very slightly increase the exposure to delamanid. **Severe** Study → Also see TABLE 9 p. 1266
- **Rifampicin** is predicted to slightly decrease the exposure to delamanid. Avoid. **Moderate** Study
- **Demeclomycin** → see tetracyclines
- **Denosumab** → see monoclonal antibodies
- **Desferrioxamine** → see iron chelators
- Desflurane → see volatile halogenated anaesthetics
- Desloratadine → see antihistamines, non-sedating

Desmopressin → see TABLE 18 p. 1268 (hyponatraemia)
- Antiepileptics (lamotrigine) are predicted to increase the risk of hyponatraemia when given with desmopressin. **Severe** Theoretical
- **Loperamide** greatly increases the absorption of oral desmopressin (and possibly sublingual). **Moderate** Study
- Phenothiazines (chlorpromazine) are predicted to increase the risk of hyponatraemia when given with desmopressin. **Severe** Theoretical

Desogestrel
- Antiepileptics (carbamazepine, eslicarbazepine, fosphenytoin, oxcarbazepine, perampanel, phenobarbital, phenytoin, primidone, rufinamide, topiramate) are predicted to decrease the efficacy of desogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. **Severe** Theoretical
- **Desogestrel** is predicted to increase the exposure to antiepileptics (lamotrigine). **Moderate** Study
- **Aprepitant** is predicted to decrease the efficacy of desogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. **Severe** Theoretical
Diazoxide ➔ see TABLE 8 p. 1265 (hypotension)

- Diazoxide decreases the concentration of antiepileptics (fosphenytoin, phenytoin) and antiepileptics (fosphenytoin, phenytoin) are predicted to decrease the effects of diazoxide. Monitor concentration and adjust dose. [Moderate] Anecdotal
- Diazoxide increases the risk of severe hypotension when given with hydralazine. [Severe] Study ➔ Also see TABLE 8 p. 1265

Diclofenac ➔ see NSAIDs

Dicyclomine ➔ see TABLE 10 p. 1266 (anantispasmodics)

Didanosine ➔ see TABLE 1 p. 1264 (hepatotoxicity), TABLE 12 p. 1267 (peripheral neuropathy)

ROUTE-SPECIFIC INFORMATION  Antacids in tablet formulation might affect absorption of other drugs—give at least 2 hours apart.

- Allopurinol moderately increases the exposure to didanosine. Avoid. [Severe] Study
- Didanosine (buffered) decreases the exposure to antifungals, azoles (itraconazole, ketoconazole). Separate administration by 2 hours. [Severe] Study ➔ Also see TABLE 1 p. 1264
- Febuxostat is predicted to increase the exposure to didanosine. [Severe] Theoretical
- Ganciclovir is predicted to increase the exposure to didanosine. [Moderate] Study

- HIV-protease inhibitors (tipranavir) decrease the exposure to didanosine. Separate administration by 2 hours. [Moderate] Study
- Didanosine (buffered) decreases the exposure to HIV-protease inhibitors (atazanavir). Didanosine should be taken 2 hours after atazanavir. [Severe] Study
- Didanosine (buffered) is predicted to decrease the exposure to HIV-protease inhibitors (darunavir) boosted with ritonavir. Didanosine should be taken 1 hour before or 2 hours after darunavir. [Moderate] Theoretical
- Didanosine (buffered) decreases the exposure to HIV-protease inhibitors (indinavir). Separate administration by 1 hour. [Severe] Study
- Hydroxycarbamide increases the risk of toxicity when given with didanosine. Avoid. [Severe] Study
- Isoniazid is predicted to increase the risk of peripheral neuropathy when given with didanosine. [Severe] Theoretical ➔ Also see TABLE 1 p. 1264 ➔ Also see TABLE 12 p. 1267
- Didanosine is predicted to increase the risk of pancreatitis when given with pentamidine. Avoid. [Severe] Study
- Didanosine (buffered) is predicted to greatly decrease the exposure to oral quinolones. Didanosine should be taken 2 hours after quinolones. [Moderate] Study
- Ribavirin is predicted to increase the exposure to didanosine. Avoid. [Severe] Study
- Didanosine increases the risk of toxicity when given with stavudine. Avoid. [Severe] Study ➔ Also see TABLE 12 p. 1267
- Tenofovir increases the risk of toxicity when given with didanosine. Avoid. [Severe] Study
- Valganciclovir is predicted to increase the exposure to didanosine. [Moderate] Study

Digoxin ➔ see TABLE 6 p. 1265 (bradycardia)

GENERAL INFORMATION  Drugs that reduce serum potassium are predicted to increase the risk of digoxin toxicity, see TABLE 17 p. 1268.

- Acarbose decreases the concentration of digoxin. [Moderate] Study
- Aldosterone antagonists (eplerenone) very slightly increase the exposure to digoxin. [Minor] Study
- Aldosterone antagonists (spironolactone) increase the concentration of digoxin. Monitor and adjust dose. [Moderate] Study
- Aminoglycosides potentially increase the concentration of digoxin. Monitor and adjust dose. [Minor] Study
- Antacids decrease the absorption of digoxin. Separate administration by 2 hours. [Minor] Study
- Antiarrhythmics (amiodarone, dronedarone) are predicted to moderately increase the exposure to digoxin. Monitor and adjust digoxin dose, p. 106. [Severe] Study ➔ Also see TABLE 6 p. 1265
- Antiarrhythmics (propafenone) increase the concentration of digoxin. Monitor and adjust dose. [Severe] Study

- Antiepileptics (fosphenytoin, phenytoin) are predicted to decrease the concentration of digoxin. [Moderate] Anecdotal
- Antifungals, azoles (itraconazole) markedly increase the concentration of digoxin. Monitor and adjust dose. [Severe] Study
- Antifungals, azoles (ketoconazole) are predicted to markedly increase the concentration of digoxin. [Severe] Theoretical
- Antifungals, azoles (posaconazole) are predicted to increase the concentration of digoxin. [Severe] Theoretical
- Antimalarial agents (mefloquine) are predicted to increase the risk of bradycardia when given with digoxin. [Severe] Theoretical
- Antimalarial agents (quinine) increase the concentration of digoxin. Monitor and adjust digoxin dose, p. 106. [Severe] Anecdotal
- Balsalazide is predicted to increase the concentration of digoxin. [Moderate] Theoretical
- Calcium channel blockers (diltiazem, verapamil) increase the concentration of digoxin. Monitor and adjust dose. [Severe] Study ➔ Also see TABLE 6 p. 1265
- Intravenous calcium salts increase the concentration of digoxin. Avoid. [Moderate] Anecdotal
- Carbimazole affects the concentration of digoxin. Monitor and adjust dose. [Moderate] Theoretical
- Certitinib is predicted to increase the risk of bradycardia when given with digoxin. Avoid. [Severe] Theoretical
- Ciclosporin increases the concentration of digoxin. Monitor and adjust dose. [Severe] Theoretical
- Daclatasvir slightly increases the concentration of digoxin. [Severe] Study
- HIV-protease inhibitors (ritonavir) increase the concentration of digoxin. Adjust dose and monitor concentration. [Severe] Study
- Lapatinib is predicted to increase the exposure to digoxin. [Moderate] Theoretical
- Levothyroxine is predicted to affect the concentration of digoxin. Monitor and adjust dose. [Moderate] Theoretical
- Liothyronine is predicted to affect the concentration of digoxin. Monitor and adjust dose. [Moderate] Theoretical
- Lumacaftor is predicted to affect the exposure to digoxin. Monitor and adjust dose. [Moderate] Theoretical
- Macrolides increase the concentration of digoxin. [Severe] Anecdotal
- Mirabegron slightly increases the exposure to digoxin. Monitor digoxin concentration and adjust dose. [Severe] Study
- Neomycin decreases the absorption of digoxin. [Moderate] Study
- Neuromuscular blocking drugs, non-depolarising (pancuronium) are predicted to increase the risk of cardiovascular side-effects when given with digoxin. [Severe] Anecdotal
- NSAIDs (indomethacin) increase the concentration of digoxin. [Severe] Study
- Penicillamine potentially decreases the concentration of digoxin. Separate administration by 2 hours. [Severe] Anecdotal
- Pitolisant is predicted to decrease the exposure to digoxin. [Unknown] Theoretical
- Ranolazine increases the concentration of digoxin. [Moderate] Study
- Rifampicin decreases the concentration of digoxin. [Moderate] Study
- St John’s Wort decreases the concentration of digoxin. Avoid. [Severe] Anecdotal
- Sucrafate decreases the absorption of digoxin. Separate administration by 2 hours. [Severe] Anecdotal
- Sulfasalazine decreases the concentration of digoxin. [Moderate] Study
- Suxamethonium is predicted to increase the risk of cardiovascular side-effects when given with digoxin. [Severe] Anecdotal
- Ticagrelor increases the concentration of digoxin. [Moderate] Study
- Tolvaptan increases the concentration of digoxin. [Minor] Study
- Trimethoprim increases the concentration of digoxin. [Moderate] Study
- Vandetanib slightly increases the exposure to digoxin. Monitor ECG and adjust dose. [Moderate] Study
- Velpatasvir is predicted to increase the exposure to digoxin. [Severe] Study

Downloaded from www.medicalbr.com
Digoxin (continued)
- Vitamin D substances are predicted to increase the risk of toxicity when given with digoxin. [Severe] Theoretical
Dihydrocodeine → see opioids
Dihydrotachysterol → see vitamin D substances
Diltiazem → see calcium channel blockers
Dimenhydrinate → see TABLE 10 p. 1266 (antimuscarinics)
Dimethyl fumarate
- Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with dimethyl fumarate. Public Health England advises avoid. [Severe] Theoretical
Dimethyl sulfoxide
- Topical dimethyl sulfoxide potentially increases the risk of peripheral neuropathy when given with NSAI Ds. [sulindac]. Avoid. [Severe] Anecdotal
Diphenoxylate → see opioids
Dipryramide → see TABLE 8 p. 1265 (hypotension), TABLE 4 p. 1264 (antiplatelet effects)
- Anticids are predicted to decrease the absorption of dipryramide (immediate release tablets). [Moderate] Theoretical
Dipyridamole → see TABLE 11 p. 1265 (hypotension), TABLE 4 p. 1264
- Anticids are predicted to decrease the absorption of dipyridamole (immediate exposure to antihypertensive (adenosine). Avoid or adjust dose. [Severe] Study
- H2 Receptor antagonists are predicted to decrease the absorption of dipyridamole (immediate release tablets). [Moderate] Theoretical
- Proton pump inhibitors are predicted to decrease the absorption of dipyridamole (immediate release tablets). [Moderate] Theoretical
Disopryamide → see antihistamines
Disulfiram → see TABLE 12 p. 1267 (peripheral neuropathy)

FOOD AND LIFESTYLE
Disulfiram gives rise to an extremely unpleasant systemic reaction after the ingestion of even a small amount of alcohol. Ensure that alcohol is not consumed for at least 24 hours before initiating treatment and should be avoided for at least 1 week after stopping treatment.
- Disulfiram increases the concentration of antiepileptics (fosphenytoin, phenytoin). Monitor concentration and adjust dose. [Severe] Study → Also see TABLE 12 p. 1267
- Disulfiram increases the anticoagulant effect of coumarins. Monitor and adjust dose. [Severe] Study
- Disulfiram increases the risk of acute psychoses when given with metronidazole. [Severe] Study → Also see TABLE 12 p. 1267
- Disulfiram is predicted to increase the anticoagulant effect of phenindione. [Severe] Theoretical
Dobutamine → see sympathomimetics, inotropic
Docetaxel → see taxanes
Doxycycline sodium → see TABLE 17 p. 1268 (reduced serum potassium)
Dolutegravir
- Antacids moderately decrease the exposure to dolutegravir. Dolutegravir should be taken 2 hours before or 6 hours after antacids. [Moderate] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) decrease the exposure to dolutegravir. Adjust dose. [Severe] Study
- Antiepileptics (oxcarbazepine) are predicted to decrease the exposure to dolutegravir. Adjust dose. [Severe] Theoretical
- Bosentan decreases the exposure to dolutegravir. Adjust dose. [Severe] Study
- Oral calcium salts decrease the absorption of dolutegravir. Dolutegravir should be taken 2 hours before or 6 hours after calcium salts. [Moderate] Study
- Efavirenz decreases the exposure to dolutegravir. Adjust dose. [Severe] Study
- Enzalutamide decreases the exposure to dolutegravir. Adjust dose. [Severe] Study
- Estravir moderately decreases the exposure to dolutegravir. Avoid unless given with atazanavir, darunavir, or lopinavir (all boosted with ritonavir). [Severe] Study
- HIV-1 protease inhibitors (fosamprenavir) boosted with ritonavir slightly decrease the exposure to dolutegravir. Avoid if resistant to HIV-integrase inhibitors. [Severe] Study
- HIV-2 protease inhibitors (tipranavir) moderately decrease the exposure to dolutegravir. Refer to specialist literature. [Severe] Study
- Iron (oral) decreases the absorption of dolutegravir. Iron (oral) should be taken 2 hours before or 6 hours after dolutegravir. [Moderate] Study
- Dolutegravir slightly to moderately increases the exposure to metformin. Use with caution and adjust dose. [Severe] Study
- Nevirapine decreases the exposure to dolutegravir. Adjust dose. [Severe] Study
- Rifampicin decreases the exposure to dolutegravir. Adjust dose. [Severe] Study
- St John’s Wort decreases the exposure to dolutegravir. Adjust dose. [Severe] Study
- Sucralfate decreases the absorption of dolutegravir. [Moderate] Anecdotal

Domperidone
- See TABLE 9 p. 1266 (QT-interval prolongation)
- Antiarhythmics (dronedarone) increase the risk of QT-prolongation when given with domperidone. Avoid. [Severe] Study
- Antifungals, azoles (fluconazole, itraconazole, ketoconazole, posaconazole, voriconazole) increase the risk of QT-prolongation when given with domperidone. Avoid. [Severe] Study
- Dolutegravir is predicted to increase the anticoagulant effect of dopamine receptor agonists (bromocriptine, cabergoline). [Moderate] Theoretical
- HIV-1 protease inhibitors increase the risk of QT-prolongation when given with domperidone. Avoid. [Severe] Study
- Aprepitant increases the risk of QT-prolongation when given with domperidone. Avoid. [Severe] Study
- Calcium channel blockers (diltiazem, verapamil) increase the risk of QT-prolongation when given with domperidone. Avoid. [Severe] Study
- Ciclosporin increases the risk of QT-prolongation when given with domperidone. Avoid. [Severe] Study
- Crizotinib increases the risk of QT-prolongation when given with domperidone. Avoid. [Severe] Study
- Domperidone is predicted to decrease the prolactin-lowering effect of dopamine receptor agonists (bromocriptine, cabergoline). [Moderate] Theoretical
- HIV-1 protease inhibitors increase the risk of QT-prolongation when given with domperidone. Avoid. [Severe] Study
- Idelalisib increases the risk of QT-prolongation when given with domperidone. Avoid. [Severe] Study
- Imatinib increases the risk of QT-prolongation when given with domperidone. Avoid. [Severe] Study
- Macrolides (clarithromycin, erythromycin) increase the risk of QT-prolongation when given with domperidone. Avoid. [Severe] Study
- Netupitant increases the risk of QT-prolongation when given with domperidone. Avoid. [Severe] Study
- Nilotinib increases the risk of QT-prolongation when given with domperidone. Avoid. [Severe] Study
- Donepezil → see anticholinesterases, centrally acting
- Dopamine → see sympathomimetics, inotropic
- Dopamine receptor agonists → see TABLE 8 p. 1265 (hypotension), TABLE 9 p. 1266 (QT-interval prolongation), TABLE 10 p. 1266 (antimuscarinics)
- Antimicrobials (itraconazole, ketoconazole, posaconazole) are predicted to increase the exposure to dopamine receptor agonists (bromocriptine, cabergoline). [Severe] Theoretical
- Antifungals, azoles (fluconazole, itraconazole, posaconazole) are predicted to increase the exposure to dopamine receptor agonists (bromocriptine, cabergoline). [Severe] Theoretical
- Aripiprazole is predicted to decrease the effects of dopamine receptor agonists. [Moderate] Theoretical → Also see TABLE 8 p. 1265

1326 Digoxin – Dopamine receptor agonists BNF 74

A1
Dopamine receptor agonists — Droperidol 1327

- Asenapine is predicted to decrease the effects of dopamine receptor agonists. Adjust dose. [Moderate] Theoretical \(\rightarrow\) Also see TABLE 8 p. 1265
- Benperidol is predicted to decrease the effects of dopamine receptor agonists. Avoid. [Moderate] Theoretical \(\rightarrow\) Also see TABLE 8 p. 1265
- Bupropion increases the risk of side-effects when given with amantadine. [Moderate] Study
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to dopamine receptor agonists (bromocriptine, cabergoline). [Severe] Theoretical
- Clozapine is predicted to decrease the effects of dopamine receptor agonists. [Moderate] Theoretical \(\rightarrow\) Also see TABLE 8 p. 1265
- Cobicistat increases the exposure to dopamine receptor agonists (bromocriptine, cabergoline). [Severe] Study
- Combined hormonal contraceptives are predicted to increase the exposure to ropinirole. Adjust dose. [Moderate] Study
- Crixotinib is predicted to increase the exposure to dopamine receptor agonists (bromocriptine, cabergoline). [Severe] Theoretical
- Dopamine receptor agonists (bromocriptine) are predicted to increase the risk of ergotism when given with dopamine receptor agonists (bromocriptine, cabergoline). Avoid. [Moderate] Theoretical \(\rightarrow\) Also see TABLE 8 p. 1265
- Dopamine receptor agonists (cabergoline) are predicted to increase the risk of ergotism when given with dopamine receptor agonists (bromocriptine, pergolide). Avoid. [Moderate] Theoretical \(\rightarrow\) Also see TABLE 8 p. 1265
- Dopamine receptor agonists (bromocriptine) are predicted to increase the risk of ergotism when given with dopamine receptor agonists (bromocriptine, cabergoline). Avoid. [Moderate] Theoretical \(\rightarrow\) Also see TABLE 8 p. 1265
- Dopamine receptor agonists (amantadine) are predicted to increase the exposure to dopamine receptor agonists (pramipexole). Adjust pramipexole dose. [Moderate] Theoretical \(\rightarrow\) Also see TABLE 8 p. 1265
- Droperidol is predicted to decrease the effects of dopamine receptor agonists. Avoid. [Moderate] Theoretical \(\rightarrow\) Also see TABLE 8 p. 1265 \(\rightarrow\) Also see TABLE 9 p. 1266
- Ergometrine is predicted to increase the risk of ergotism when given with dopamine receptor agonists (cabergoline, pergolide). Avoid. [Moderate] Theoretical
- Ergotamine is predicted to increase the risk of ergotism when given with dopamine receptor agonists (bromocriptine, cabergoline). Avoid. [Moderate] Theoretical
- Ergotamine is predicted to increase the risk of ergotism when given with pergolide. [Moderate] Theoretical
- Flupentixol is predicted to decrease side effects dopamine receptor agonists. Avoid. [Moderate] Theoretical \(\rightarrow\) Also see TABLE 8 p. 1265
- Apomorphine is predicted to increase the risk of severe hypotension when given with granisetron. [Severe] Theoretical
- H₂ receptor antagonists (cimetidine) slightly increase the exposure to pramipexole. Adjust dose. [Moderate] Study
- Haloperidol is predicted to decrease the effects of dopamine receptor agonists. Avoid. [Moderate] Theoretical \(\rightarrow\) Also see TABLE 8 p. 1265 \(\rightarrow\) Also see TABLE 9 p. 1266 \(\rightarrow\) Also see TABLE 10 p. 1266
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) increase the exposure to dopamine receptor agonists (bromocriptine, cabergoline). [Severe] Study
- HIV-protease inhibitors (indinavir) are predicted to increase the exposure to dopamine receptor agonists (bromocriptine, cabergoline). [Severe] Theoretical
- Hormone replacement therapy decreases the clearance of ropinirole. Monitor and adjust dose. [Moderate] Study
- Idealalisib increases the exposure to dopamine receptor agonists (bromocriptine, cabergoline). [Severe] Study
- Imatinib is predicted to increase the exposure to dopamine receptor agonists (bromocriptine, cabergoline). [Severe] Theoretical
- Loxapine is predicted to decrease the effects of dopamine receptor agonists. [Moderate] Theoretical \(\rightarrow\) Also see TABLE 8 p. 1265 \(\rightarrow\) Also see TABLE 10 p. 1266
- Macrolides (clarithromycin) are predicted to increase the exposure to dopamine receptor agonists (bromocriptine, cabergoline). [Severe] Theoretical
- Macrolides (erythromycin) are predicted to increase the exposure to dopamine receptor agonists (bromocriptine, cabergoline). [Severe] Theoretical
- Amantadine increases the risk of CNS toxicity when given with memantine. Use with caution or avoid. [Severe] Theoretical
- Memantine is predicted to increase the effects of dopamine receptor agonists (apomorphine, bromocriptine, cabergoline, pergolide, pramipexole, quinagolide, ropinirole, rotigotine). Avoid. [Moderate] Study
- Metoclopramide is predicted to decrease the effects of dopamine receptor agonists (apomorphine, bromocriptine, cabergoline, pergolide, pramipexole, quinagolide, ropinirole, rotigotine). Avoid. [Moderate] Study
- Nefopam is predicted to increase the exposure to dopamine receptor agonists (bromocriptine, cabergoline). [Severe] Theoretical
- Nitroprusside is predicted to increase the exposure to dopamine receptor agonists (bromocriptine, cabergoline). [Severe] Theoretical
- Olanzapine is predicted to decrease the effects of dopamine receptor agonists. Avoid. [Moderate] Theoretical \(\rightarrow\) Also see TABLE 8 p. 1265
- Apomorphine increases the risk of severe hypotension when given with ondansetron. Avoid. [Severe] Study \(\rightarrow\) Also see TABLE 9 p. 1266
- Paliperidone is predicted to decrease the effects of dopamine receptor agonists. Avoid. [Moderate] Theoretical \(\rightarrow\) Also see TABLE 8 p. 1265 \(\rightarrow\) Also see TABLE 9 p. 1266
- Amantadine increases the risk of ergotism when given with pergolide. Avoid. [Moderate] Study \(\rightarrow\) Also see TABLE 10 p. 1266
- Pramipexole increases the risk of severe hypotension when given with palonosetron. [Severe] Theoretical
- Phenothiazines are predicted to decrease the effects of dopamine receptor agonists. Avoid. [Moderate] Theoretical \(\rightarrow\) Also see TABLE 8 p. 1265 \(\rightarrow\) Also see TABLE 9 p. 1266 \(\rightarrow\) Also see TABLE 10 p. 1266
- Pinelidone is predicted to decrease the effects of dopamine receptor agonists. Avoid. [Moderate] Theoretical \(\rightarrow\) Also see TABLE 8 p. 1265 \(\rightarrow\) Also see TABLE 9 p. 1266 \(\rightarrow\) Also see TABLE 10 p. 1266
- Quetiapine is predicted to decrease the effects of dopamine receptor agonists. Avoid. [Moderate] Theoretical \(\rightarrow\) Also see TABLE 8 p. 1265 \(\rightarrow\) Also see TABLE 9 p. 1266 \(\rightarrow\) Also see TABLE 10 p. 1266
- Quinolones (ciprofloxacin) are predicted to increase the exposure to ropinirole. Adjust dose. [Moderate] Study
- Risperidone is predicted to decrease the effects of dopamine receptor agonists. Avoid. [Moderate] Theoretical \(\rightarrow\) Also see TABLE 8 p. 1265 \(\rightarrow\) Also see TABLE 9 p. 1266 \(\rightarrow\) Also see TABLE 10 p. 1266
- Sulfpride is predicted to decrease the effects of dopamine receptor agonists. Avoid. [Moderate] Theoretical \(\rightarrow\) Also see TABLE 8 p. 1265 \(\rightarrow\) Also see TABLE 9 p. 1266
- Zuclopenthixol is predicted to decrease the effects of dopamine receptor agonists. Avoid. [Moderate] Theoretical \(\rightarrow\) Also see TABLE 8 p. 1265 \(\rightarrow\) Also see TABLE 9 p. 1266
- Dopexamine → sympathomimetics, inotropic

Dorzolamide

ROUTE-SPECIFIC INFORMATION Since systemic absorption can follow topical application, the possibility of interactions should be borne in mind.

Doxsuleno → see tricyclic antidepressants

Doxapram

- Aminophylline increases the risk of agitation when given with doxapram. [Moderate] Study
- Monoamine-oxidase A and B inhibitors, irreversible are predicted to increase the effects of doxapram. [Moderate] Theoretical
- Theophylline increases the risk of agitation when given with doxapram. [Moderate] Study
- Doxazosin → see alpha blockers
- Doxepin → see tricyclic antidepressants
- Dorzolamide → see sympathomimetics, inotropic

Dorzolamide
Aprepitant
▶ Duloxetin
▶ Imatinib
▶ Calcium channel blockers
▶ Macrolides
▶ HIV-protease inhibitors
▶ SSRI
▶ Eculizumab
▶ Dutasteride

Exposure to antiarhythmics is predicted to moderately increase the exposure to drospirenone. Use with caution and adjust dose. [Moderate] Theoretical

Duloxetin is predicted to increase the exposure to antiarhythmics (flecainide). [Severe] Theoretical

Duloxetin is predicted to increase the exposure to beta blockers, non-selective (carvedilol, timolol). [Moderate] Theoretical

Duloxetin is predicted to increase the exposure to beta blockers, selective (metoprolol, nebivolol). [Moderate] Study

Duloxetin is predicted to increase the efficacy of opioids (tramadol). [Moderate] Study → Also see Table 13 p. 1267

Duloxetin is predicted to increase the exposure to pitolisant. Use with caution and adjust dose. [Moderate] Study

Quinolones (ciprofloxacin) are predicted to increase the exposure to duloxetine. Avoid. [Moderate] Theoretical

SSRI (fluoxetine) markedly increases the exposure to duloxetine. Avoid. [Severe] Study → Also see Table 18 p. 1268 → Also see Table 4 p. 1264

Dutasteride
▶ Antiarrhythmics (droxidone) are predicted to moderately increase the exposure to dutasteride. [Mild] Study

Antiarrhythmics (dronectone, isavuconazole, posaconazole) are predicted to moderately increase the exposure to dutasteride. [Mild] Study

Antiarrhythmics (itraconazole) are predicted to moderately increase the exposure to dutasteride. [Mild] Study

Cobicistat is predicted to increase the exposure to dutasteride. [Mild] Study

Cobicistat is predicted to increase the exposure to dutasteride. Monitor side effects and adjust dose. [Moderate] Theoretical

Cobicistat is predicted to increase the exposure to dutasteride. Monitor side effects and adjust dose. [Mild] Study

Calcium channel blockers (verapamil) are predicted to slightly increase the exposure to edoxaban. [Severe] Theoretical

Calcium channel blockers (verapamil) are predicted to slightly increase the exposure to edoxaban. [Severe] Theoretical

Ceritinib is predicted to increase the exposure to edoxaban. [Moderate] Theoretical

Ciclosporin slightly increases the exposure to edoxaban. Adjust edoxaban dose, p. 122. [Severe] Study

HIV-protease inhibitors (lopinavir, ritonavir, saquinavir) are predicted to slightly increase the exposure to edoxaban. [Severe] Theoretical

Lapatinib is predicted to slightly increase the exposure to edoxaban. [Severe] Theoretical

Lumacafor is predicted to affect the exposure to edoxaban. [Moderate] Theoretical

Macrolides (azithromycin, clarithromycin) are predicted to slightly increase the exposure to edoxaban. [Severe] Theoretical

Macrolides (erythromycin) slightly increase the exposure to edoxaban. Adjust edoxaban dose, p. 122. [Severe] Study

Mirabegron is predicted to increase the exposure to edoxaban. [Mild] Theoretical

Ranolazine is predicted to slightly increase the exposure to edoxaban. [Severe] Theoretical

Rifampicin is predicted to decrease the exposure to edoxaban. [Moderate] Study

St John's Wort is predicted to decrease the exposure to edoxaban. [Moderate] Study

Velpatasvir is predicted to increase the exposure to edoxaban. [Severe] Theoretical

Vemurafenib is predicted to slightly increase the exposure to edoxaban. [Severe] Theoretical

Efavirenz
▶ Efavirenz is predicted to increase the exposure to antiarhythms (dronedaron). [Severe] Theoretical

Antiepileptics (carbamazepine) slightly decrease the exposure to efavirenz and efavirenz decreases the exposure to antiepileptics (carbamazepine). [Severe] Study

Antiepileptics (fosphenytoin, phenytoin) slightly decrease the exposure to efavirenz and efavirenz affects the concentration of antiepileptics (fosphenytoin, phenytoin). [Severe] Theoretical

Antiepileptics (phenobarbital) are predicted to decrease the exposure to efavirenz and efavirenz affects the concentration of antiepileptics (phenobarbital). [Severe] Theoretical

Efavirenz is predicted to affect the efficacy of antiepileptics (primidon) and antiepileptics (primidon) are predicted to slightly decrease the exposure to efavirenz. [Severe] Theoretical

Efavirenz is predicted to decrease the exposure to antifungals, azoles (isavuconazole). Avoid. [Severe] Theoretical

Efavirenz slightly decreases the exposure to antifungals, azoles (itraconazole). Avoid efavirenz for 14 days before and during treatment with itraconazole. [Mild] Theoretical

Efavirenz moderately decreases the exposure to antifungals, azoles (ketoconazole). [Severe] Study

Efavirenz moderately decreases the exposure to antifungals, azoles (posaconazole). Avoid. [Moderate] Study

Efavirenz moderately decreases the exposure to antifungals, azoles (voriconazole) and antifungals, azoles (voriconazole) slightly increase the exposure to efavirenz. Adjust dose. [Severe] Study

Efavirenz decreases the concentration of antimalarials (artemether). [Severe] Study

Efavirenz moderately decreases the exposure to antimalarials (atovaquone). Avoid. [Moderate] Study

Efavirenz affects the exposure to antimalarials (proguanil). Avoid. [Moderate] Study

Efavirenz is predicted to decrease the exposure to axitinib. [Moderate] Theoretical

Efavirenz is predicted to decrease the exposure to bedaquiline. Avoid. [Severe] Study

Efavirenz is predicted to decrease the exposure to bosutinib. Avoid. [Severe] Theoretical

Efavirenz moderately decreases the exposure to buproprion. [Moderate] Study

Efavirenz is predicted to decrease the exposure to cabozantinib. [Moderate] Theoretical

Efavirenz is predicted to decrease the exposure to calcium channel blockers (amlodipine, felodipine, isradipine, lacidipine, pimozide, prazosin, nitrendipine, nifedipine).
Efavirenz is predicted to decrease the exposure to calcium channel blockers (diltiazem, verapamil). (Moderate) Theoretical

Efavirenz is predicted to decrease the efficacy of combined hormonal contraceptives. For FSRH guidance, see Contraceptives, interactions p. 747. (Severe) Study

Efavirenz increases the concentration of ciclosporin. Monitor ciclosporin concentration and adjust dose. (Moderate) Study

Efavirenz is predicted to decrease the exposure to cobicistat. Avoid. (Severe) Theoretical

Efavirenz is predicted to decrease the efficacy of efavirenz. (Moderate) Study

Efavirenz is predicted to decrease the exposure to etravirine. (Severe) Study

Efavirenz is predicted to decrease the concentration of elbasvir. Avoid. (Severe) Study

Efavirenz is predicted to decrease the concentration of elbasvir. Avoid. (Severe) Theoretical

Efavirenz is predicted to decrease the exposure to dasatinib. Adjust dose. (Severe) Study

Efavirenz is predicted to decrease the efficacy of desogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. (Severe) Study

Efavirenz decreases the exposure to dolutegravir. Adjust dose. (Severe) Study

Efavirenz is predicted to moderately decrease the exposure to elbasvir. Avoid. (Severe) Study

Efavirenz is predicted to decrease the concentration of everolimus. Avoid or adjust dose. (Severe) Study

Efavirenz is predicted to decrease the exposure to gefitinib. Avoid. (Severe) Study

Efavirenz is predicted to markedly decrease the exposure to grazoprevir. Avoid. (Severe) Study

Efavirenz is predicted to decrease the concentration of guanfacine. Adjust dose. (Moderate) Theoretical

Efavirenz decreases the exposure to HIV-protease inhibitors. Refer to specialist literature. (Severe) Study

Efavirenz is predicted to decrease the effects of hormone replacement therapy. (Moderate) Anecdotal

Efavirenz is predicted to decrease the exposure to imatinib. Avoid. (Moderate) Study

Efavirenz is predicted to decrease the exposure to lopatinib. Avoid. (Severe) Study

Efavirenz is predicted to decrease the efficacy of levonorgestrel. For FSRH guidance, see Contraceptives, interactions p. 747. (Severe) Theoretical

Efavirenz is predicted to decrease the exposure to lurasidone. Monitor and adjust dose. (Moderate) Theoretical

Efavirenz decreases the exposure to macrolides (clarithromycin). (Moderate) Study

Efavirenz decreases the exposure to maraviroc. Refer to specialist literature. (Severe) Theoretical

Efavirenz is predicted to alter the effects of midazolam. Avoid. (Moderate) Theoretical

Efavirenz decreases the concentration of efavirenz. Avoid. (Severe) Study

Efavirenz is predicted to decrease the exposure to niotilinib. Avoid. (Severe) Theoretical

Efavirenz is predicted to decrease the efficacy of norethisterone. For FSRH guidance, see Contraceptives, interactions p. 747. (Severe) Anecdotal

Efavirenz is predicted to decrease the exposure to olaparib. Avoid. (Moderate) Theoretical

Efavirenz decreases the exposure to opioids (methadone). Monitor and adjust dose. (Severe) Study

Efavirenz is predicted to decrease the exposure to osimertinib. (Moderate) Theoretical

Efavirenz is predicted to decrease the exposure to paritaprevir with ritonavir and omibitasvir. Avoid. (Severe) Study

Efavirenz is predicted to decrease the exposure to phosphodiesterase type-5 inhibitors. (Moderate) Theoretical

Efavirenz is predicted to decrease the exposure to efavirenz. (Unknown) Theoretical

Efavirenz slightly decreases the exposure to rifabutin. Adjust dose. (Severe) Study

Rifampicin slightly decreases the exposure to efavirenz. Adjust dose. (Severe) Study

Efavirenz is predicted to decrease the exposure to rifampicin. Avoid. (Severe) Theoretical

Efavirenz is predicted to decrease the exposure to rilpivirine. Avoid. (Severe) Theoretical

Efavirenz is predicted to decrease the exposure to ruxolitinib. Monitor and adjust dose. (Moderate) Theoretical

Efavirenz is predicted to decrease the exposure to simeprevir. (Severe) Study

Efavirenz is predicted to decrease the concentration of sirolimus. Monitor and adjust dose. (Moderate) Theoretical

St John’s Wort is predicted to decrease the concentration of efavirenz. Avoid. (Severe) Theoretical

Efavirenz slightly decreases the exposure to statins (atorvastatin). (Mild) Study

Efavirenz moderately decreases the exposure to statins (simvastatin). (Moderate) Study

Efavirenz is predicted to decrease the concentration of tacrolimus. Monitor and adjust dose. (Moderate) Theoretical

Efavirenz is predicted to decrease the concentration of temsirolimus. Avoid. (Severe) Theoretical

Efavirenz is predicted to decrease the exposure to ticagrelor. (Moderate) Theoretical

Efavirenz is predicted to decrease the exposure to tolvaptan. (Moderate) Theoretical

Efavirenz decreases the efficacy of ulipristal. For FSRH guidance, see Contraceptives, interactions p. 747. (Severe) Anecdotal

Efavirenz is predicted to decrease the exposure to velpatasvir. Avoid. (Moderate) Theoretical

Elbasvir

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to elbasvir. Avoid. (Severe) Study

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) slightly to moderately increase the exposure to elbasvir. Avoid. (Moderate) Study

Bosentan is predicted to moderately decrease the exposure to elbasvir. Avoid. (Severe) Study

Cobicistat slightly to moderately increases the exposure to elbasvir. Avoid. (Moderate) Study

Elbasvir is predicted to increase the concentration of dabigatran. (Moderate) Theoretical

Efavirenz is predicted to moderately decrease the exposure to elbasvir. Avoid. (Severe) Study

Enzalutamide is predicted to decrease the exposure to elbasvir. Avoid. (Severe) Study

Etravirine is predicted to decrease the exposure to elbasvir. Avoid. (Unknown) Theoretical

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lapinavir, ritonavir, saquinavir, tipranavir) slightly to moderately increase the exposure to elbasvir. Avoid. (Moderate) Study

Idelalisib slightly to moderately increases the exposure to elbasvir. Avoid. (Moderate) Study

Macrolides (clarithromycin) slightly to moderately increase the exposure to elbasvir. Avoid. (Moderate) Study
Elbasvir (continued)

- **Modafnil** is predicted to decrease the exposure to elbasvir. Avoid. [Unknown] Theoretical
- **Nevirapine** is predicted to moderately decrease the exposure to elbasvir. Avoid. [Severe] Study
- **Rifampin** is predicted to decrease the exposure to elbasvir. Avoid. [Severe] Study
- **St John’s Wort** is predicted to moderately decrease the exposure to elbasvir. Avoid. [Severe] Study
- Elbasvir potentially increases the exposure to **statins** (atorvastatin). Adjust atorvastatin dose, p. 196. [Moderate] Study
- Elbasvir is predicted to increase the exposure to **statins** (fluvastatin). Adjust fluvastatin dose, p. 196. [Unknown] Theoretical
- Elbasvir increases the exposure to **statins** (rosuvastatin). Adjust rosuvastatin dose, p. 197. [Moderate] Study
- Elbasvir is predicted to increase the exposure to **statins** (simvastatin). Adjust simvastatin dose, p. 198. [Unknown] Theoretical

**Eletroptan** → see TABLE 13 p. 1267 (serotonin syndrome)
- **Antifungals, azoles** (itraconazole, ketoconazole, voriconazole) are predicted to markedly increase the exposure to eletroptan. Avoid. [Severe] Study
- **Cobicistat** is predicted to markedly increase the exposure to eletroptan. Avoid. [Severe] Study
- Eletroptan increases the risk of vasoconstriction when given with **ergotamine**. Separate administration by 24 hours. [Severe] Study
- **HIV-protease inhibitors** (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to markedly increase the exposure to eletroptan. Avoid. [Severe] Study
- **Idelalisib** is predicted to markedly increase the exposure to eletroptan. Avoid. [Severe] Study
- Macrolides (clarithromycin) are predicted to markedly increase the exposure to eletroptan. Avoid. [Severe] Study
- Macrolides (erythromycin) moderately increase the exposure to eletroptan. Avoid. [Moderate] Study

**Eltumuzumab** → see monoclonal antibodies

**Eltrombopag**
- **Antacids** decrease the absorption of eltrombopag. Eltrombopag should be taken 2 hours before or 4 hours after antacids. [Severe] Study
- **Dairy products** are predicted to decrease the absorption of eltrombopag. Eltrombopag should be taken 2 hours before or 4 hours after dairy products. [Severe] Theoretical
- **Iron (oral)** is predicted to decrease the absorption of eltrombopag. Eltrombopag should be taken 2 hours before or 4 hours after iron (oral). [Severe] Theoretical
- **Selenium** is predicted to decrease the absorption of eltrombopag. Eltrombopag should be taken 2 hours before or 4 hours after selenium. [Severe] Theoretical
- **Eltrombopag** is predicted to increase the exposure to **statins**. Monitor and adjust dose. [Moderate] Study
- **Zinc** is predicted to decrease the absorption of eltrombopag. Eltrombopag should be taken 2 hours before or 4 hours after zinc (zinc acetate, zinc sulfate). [Severe] Theoretical

**Elvitegravir**
- **Antacids** moderately decrease the exposure to elvitegravir. Separate administration by at least 5 hours. [Moderate] Study
- **Antiepileptics** (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the concentration of elvitegravir. Avoid. [Severe] Theoretical
- **Bosentan** is predicted to decrease the concentration of elvitegravir. Avoid. [Severe] Theoretical
- **Elvitegravir** is predicted to decrease the anticoagulant effect of **coumarins**. [Moderate] Theoretical
- **Efavirenz** is predicted to decrease the concentration of elvitegravir. Avoid. [Severe] Theoretical
- Elvitegravir is predicted to decrease the concentration of elvitegravir. Avoid. [Severe] Theoretical
- **HIV-protease inhibitors** (atazanavir, lopinavir) boosted with ritonavir increase the concentration of elvitegravir. Refer to specialist literature. [Moderate] Study
- **Nevirapine** is predicted to decrease the concentration of elvitegravir. Avoid. [Severe] Theoretical
- **Rifampin** is predicted to decrease the concentration of elvitegravir. Avoid. [Severe] Theoretical
- **St John’s Wort** is predicted to decrease the concentration of elvitegravir. Avoid. [Severe] Theoretical

Empagliflozin → see TABLE 1 p. 1267 (antidiabetic drugs), TABLE 8 p. 1265 (hypotension)
- **Enalapril** → see ACE inhibitors
- **Enoxaparin** → see low molecular-weight heparins

**Entacapone**
- **Iron (oral)** is predicted to decrease the absorption of entacapone. Separate administration by at least 2 hours. [Moderate] Theoretical
- **Entacapone** is predicted to increase the exposure to **levodopa**. Monitor side effects and adjust dose. [Moderate] Study
- **Entacapone** is predicted to increase the exposure to **methylodopa**. [Moderate] Theoretical
- **Entacapone** is predicted to increase the risk of elevated blood pressure when given with **monoamine-oxidase A and B inhibitors**, irreversibly. Avoid. [Severe] Theoretical
- **Entacapone** is predicted to increase the risk of cardiovascular side-effects when given with sympathomimetics, inotropic (doxbutamine, dopamine). [Moderate] Theoretical
- **Entacapone** is predicted to increase the risk of cardiovascular side-effects when given with sympathomimetics, vasoconstrictor (adrenaline/epinephrine, noradrenaline/norepinephrine). [Moderate] Study

**Enteral feeds**
- **Antacids** (aluminium hydroxide) increase the risk of blocked enteral or nasogastric tubes when given with **enteral feeds**. [Moderate] Study
- **Enteral feeds** decrease the absorption of antiepileptics (phenytoin). [Severe] Study
- **Enteral feeds** (vitamin-K containing) potentially decrease the anticoagulant effect of coumarins. [Severe] Anecdotal
- **Enteral feeds** (vitamin-K containing) potentially decrease the effects of phenindione. [Severe] Theoretical
- **Enteral feeds** decrease the exposure to quinolones (ciprofloxacin). [Moderate] Study
- **Sucralfate** increases the risk of blocked enteral or nasogastric tubes when given with **enteral feeds**. Separate administration by 1 hour. [Moderate] Study
- **Enteral feeds** decrease the exposure to **theophylline**. [Moderate] Study

**Enzalutamide**

**GENERAL INFORMATION** Caution with concurrent chemotherapy—safety and efficacy not established.
- **Enzalutamide** is predicted to decrease the exposure to **abacavir**. [Moderate] Theoretical
- **Enzalutamide** is predicted to decrease the exposure to **abiraterone**. Avoid. [Severe] Theoretical
- **Enzalutamide** is predicted to decrease the exposure to aldosterone antagonists (spironolactone). Avoid. [Moderate] Theoretical
- **Enzalutamide** is predicted to decrease the exposure to **alprazolam**. Adjust alprazolam dose. [Moderate] Theoretical
- **Enzalutamide** is predicted to decrease the exposure to antihyrrhysis (disopyramide, dronedarone). Avoid. [Severe] Study
- **Enzalutamide** is predicted to decrease the efficacy of antihyrrhysis (propafenone). [Moderate] Study
- **Enzalutamide** is predicted to decrease the exposure to anticholinesterases, centrally acting (donepezil). [Mild] Study
- **Enzalutamide** is predicted to slightly decrease the exposure to antiepileptics (brivaracetam). [Moderate] Theoretical
- **Enzalutamide** is predicted to decrease the exposure to antiepileptics (perampanel). Monitor and adjust dose. [Moderate] Study
- **Enzalutamide** is predicted to decrease the exposure to antifungals, azoles (isavuconazole). Avoid. [Severe] Study
Enzalutamide is predicted to decrease the exposure to antimalarials (artemether) with lumefantrine. Avoid. 

Enzalutamide is predicted to decrease the concentration of antimalarials (piperaquine). Avoid. 

Enzalutamide is predicted to moderately decrease the exposure to apixaban. Use with caution or avoid. 

Enzalutamide moderately decreases the exposure to apremilast. Avoid. 

Enzalutamide is predicted to markedly decrease the exposure to aprepitant. Avoid. 

Enzalutamide is predicted to moderately decrease the exposure to aripiprazole. Adjust aripiprazole dose, p. 376. 

Enzalutamide is predicted to decrease the exposure to axitinib. Avoid or adjust dose. 

Enzalutamide decreases the exposure to bedaquiline. Avoid. 

Enzalutamide slightly decreases the exposure to bortezomib. Avoid. 

Enzalutamide affects the exposure to bosantan. Avoid. 

Enzalutamide is predicted to very markedly decrease the exposure to bosutinib. Avoid. 

Enzalutamide is predicted to markedly decrease the exposure to bupropion. 

Enzalutamide is predicted to decrease the exposure to buspirone. Use with caution and adjust dose. 

Enzalutamide moderately decreases the exposure to cabozantinib. Avoid. 

Enzalutamide is predicted to decrease the exposure to calcium channel blockers (amlodipine, felodipine, lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose. 

Enzalutamide decreases the exposure to calcium channel blockers (diltiazem). 

Enzalutamide decreases the exposure to calcium channel blockers (isradipine). Avoid. 

Enzalutamide is predicted to decrease the exposure to calcium channel blockers (verapamil). 

Enzalutamide is predicted to decrease the exposure to cannabis extract. Avoid. 

Enzalutamide is predicted to decrease the exposure to ceritinib. Avoid. 

Enzalutamide decreases the concentration of ciclosporin. 

Enzalutamide is predicted to alter the effects of cilostazol. 

Enzalutamide decreases the exposure to clomethiazole. Monitor and adjust dose. 

Enzalutamide is predicted to decrease the exposure to cobimetinib. Avoid. 

Enzalutamide is predicted to decrease the exposure to corticosteroids (budesonide, dexmethasone, methylprednisolone, prednisolone). Monitor and adjust dose. 

Enzalutamide is predicted to decrease the exposure to corticosteroids (fluticasone). 

Enzalutamide is predicted to decrease the exposure to corticosteroids (prednisone). 

Enzalutamide potentially decreases the exposure to coumarins. Avoid or adjust dose and monitor INR. 

Enzalutamide is predicted to markedly decrease the exposure to crizotinib. Avoid. 

Enzalutamide is predicted to decrease the exposure to dabrafenib. Avoid. 

Enzalutamide is predicted to moderately decrease the exposure to dacarbazine. Avoid. 

Enzalutamide is predicted to decrease the exposure to darifenacin. 

Enzalutamide is predicted to decrease the exposure to dasabuvir. Avoid. 

Enzalutamide is predicted to markedly decrease the exposure to dasatinib. Avoid. 

Enzalutamide is predicted to slightly decrease the exposure to delamanid. Avoid. 

Enzalutamide decreases the exposure to dolutegravir. Adjust dose. 

Enzalutamide is predicted to decrease the exposure to elbasvir. Avoid. 

Enzalutamide is predicted to decrease the concentration of elvitegravir. Avoid. 

Enzalutamide is predicted to decrease the effects of ergotamine. 

Enzalutamide is predicted to decrease the exposure to erlotinib. Avoid or adjust erlotinib dose, p. 899. 

Enzalutamide is predicted to decrease the exposure to etravirine. Avoid. 

Enzalutamide is predicted to decrease the concentration of everolimus. Avoid or adjust dose. 

Enzalutamide moderately decreases the exposure to exemestane. 

Enzalutamide is predicted to decrease the exposure to fesoterodine. Avoid. 

Fibrates (gemfibrozil) moderately increase the exposure to enzalutamide. Avoid or adjust enzalutamide dose, p. 874. 

Enzalutamide is predicted to decrease the exposure to fingolimod. 

Enzalutamide is predicted to decrease the exposure to fosaprepitant. Avoid. 

Enzalutamide is predicted to decrease the exposure to gefitinib. Avoid. 

Enzalutamide is predicted to decrease the exposure to grazoprevir. Avoid. 

Enzalutamide is predicted to decrease the concentration of guanfacine. Adjust guanfacine dose, p. 335. 

Enzalutamide decreases the concentration of haloperidol. Adjust dose. 

Enzalutamide is predicted to decrease the exposure to ibrutinib. Avoid. 

Enzalutamide is predicted to decrease the exposure to idelalisib. Avoid. 

Enzalutamide is predicted to decrease the exposure to imatinib. Avoid. 

Enzalutamide is predicted to decrease the exposure to irinotecan. Avoid. 

Enzalutamide is predicted to decrease the exposure to ivabradine. Adjust dose. 

Enzalutamide markedly decreases the exposure to ivacaftor. Avoid. 

Enzalutamide is predicted to decrease the exposure to ixazomib. Avoid. 

Enzalutamide is predicted to decrease the exposure to lapatinib. Avoid. 

Enzalutamide is predicted to decrease the exposure to linagliptin. 

Enzalutamide is predicted to decrease the exposure to lomitapide. Monitor and adjust dose. 

Enzalutamide is predicted to decrease the exposure to luracidine. Avoid. 

Enzalutamide is predicted to decrease the exposure to macitentan. Avoid. 

Enzalutamide is predicted to decrease the exposure to maraviroc. Adjust dose. 

Enzalutamide is predicted to decrease the exposure to midazolam. Monitor and adjust dose. 

Enzalutamide is predicted to decrease the exposure to mirtazapine. Adjust dose. 

Enzalutamide is predicted to decrease the exposure to monoclonal antibodies (trastuzumab emtansine). 

Enzalutamide is predicted to decrease the exposure to montelukast. 

Enzalutamide is predicted to markedly decrease the exposure to nalorexogol. Avoid. 

Downloaded from www.medicalbr.com
Enzalutamide is predicted to slightly decrease the exposure to nateglinide. [Mild] Study

Enzalutamide is predicted to decrease the exposure to netupitant. Avoid. [Moderate] Study

Enzalutamide is predicted to moderately decrease the exposure to nilotinib. Avoid. [Severe] Study

Enzalutamide is predicted to decrease the exposure to nitisinone. Adjust nitisinone dose. [Moderate] Theoretical

Enzalutamide is predicted to decrease the exposure to olaparib. Avoid. [Moderate] Theoretical

Enzalutamide is predicted to decrease the exposure to ondansetron. [Moderate] Study

Enzalutamide is predicted to decrease the exposure to opioids (alfentanil, fentanyl). [Moderate] Study

Enzalutamide is predicted to decrease the exposure to opioids (buprenorphine). Monitor and adjust dose. [Moderate] Theoretical

Enzalutamide decreases the exposure to opioids (methadone). Monitor and adjust dose. [Severe] Study

Enzalutamide is predicted to decrease the exposure to opioids (oxycodone). Monitor and adjust dose. [Moderate] Study

Enzalutamide is predicted to moderately decrease the exposure to osimertinib. Avoid. [Moderate] Study

Enzalutamide is predicted to decrease the exposure to paclitaxel. Avoid. [Severe] Study

Enzalutamide is predicted to decrease the exposure to phosphodiesterase type-5 inhibitors (avanafil, tadalfafil). Avoid. [Severe] Study

Enzalutamide is predicted to decrease the exposure to phosphodiesterase type-5 inhibitors (sildenafil, vardafenafil). [Moderate] Theoretical

Enzalutamide is predicted to moderately decrease the exposure to pioglitazone. [Mild] Study

Enzalutamide is predicted to decrease the exposure to pizotifen. [Moderate] Study

Enzalutamide is predicted to markedly decrease the exposure to praziquantel. Avoid. [Moderate] Study

Enzalutamide is predicted to moderately decrease the exposure to proton pump inhibitors (omeprazole). [Moderate] Study

Enzalutamide is predicted to decrease the exposure to quetiapine. [Moderate] Study

Enzalutamide is predicted to decrease the exposure to ranolazine. Avoid. [Severe] Study

Enzalutamide is predicted to decrease the exposure to reboxetine. [Moderate] Aneodal

Enzalutamide is predicted to decrease the exposure to regorafenib. Avoid. [Moderate] Study

Enzalutamide is predicted to decrease the exposure to repaglinide. Monitor blood glucose and adjust dose. [Moderate] Study

Enzalutamide markedly decreases the exposure to ripirvirine. Avoid. [Severe] Study

Enzalutamide is predicted to decrease the exposure to risperidone. Adjust risperidone dose. [Moderate] Study

Enzalutamide is predicted to moderately decrease the exposure to rivaroxaban. Avoid unless patient can be monitored for signs of thrombosis. [Severe] Study

Enzalutamide is predicted to decrease the exposure to roflumilast. Avoid. [Moderate] Study

Enzalutamide is predicted to decrease the exposure to ruxolitinib. Monitor and adjust dose. [Moderate] Study

Enzalutamide is predicted to moderate decrease the exposure to saxagliptin. [Moderate] Study

Enzalutamide is predicted to decrease the exposure to simeprevir. Avoid. [Severe] Study

Enzalutamide is predicted to decrease the concentration of sirolimus. Avoid. [Severe] Study

Enzalutamide is predicted to decrease the exposure to solifenacin. [Moderate] Theoretical

Enzalutamide is predicted to decrease the exposure to sorafenib. [Moderate] Theoretical

Enzalutamide is predicted to decrease the exposure to sunitinib. Avoid or adjust sunitinib dose, p. 914. [Moderate] Study

Enzalutamide decreases the concentration of tacrolimus. Monitor and adjust dose. [Severe] Study

Enzalutamide is predicted to decrease the exposure to taxanes (cabazitaxel, paclitaxel). Avoid. [Severe] Study

Enzalutamide is predicted to decrease the exposure to taxanes (docetaxel). [Severe] Theoretical

Enzalutamide is predicted to decrease the concentration of temsirolimus. Avoid. [Severe] Study

Enzalutamide decreases the exposure to tetracyclines (doxycycline). Monitor and adjust dose. [Moderate] Study

Enzalutamide is predicted to markedly decrease the exposure to ticagrelor. Avoid. [Severe] Study

Enzalutamide is predicted to decrease the exposure to tolvaptan. Avoid. [Severe] Study

Enzalutamide is predicted to decrease the exposure to toremifene. Adjust dose. [Moderate] Study

Enzalutamide is predicted to decrease the exposure to trametinib. Avoid. [Severe] Study

Enzalutamide is predicted to markedly decrease the exposure to ulipristal. Avoid and for 4 weeks after stopping ulipristal. [Severe] Theoretical

Enzalutamide is predicted to decrease the exposure to vandetanib. Avoid. [Moderate] Study

Enzalutamide is predicted to moderately decrease the exposure to velpatasvir. Avoid. [Severe] Study

Enzalutamide is predicted to decrease the exposure to vemurafenib. Avoid. [Severe] Theoretical

Enzalutamide is predicted to decrease the exposure to venetoclax. Avoid. [Severe] Study

Enzalutamide is predicted to decrease the exposure to vinca alkaloids (vinblastine, vincristine, vindesine). [Severe] Theoretical

Enzalutamide is predicted to decrease the exposure to vinflunine. Avoid. [Severe] Theoretical

Enzalutamide is predicted to decrease the exposure to vinorelbine. Use with caution or avoid. [Severe] Theoretical

Enzalutamide is predicted to decrease the exposure to vismodegib. Avoid. [Moderate] Theoretical

Enzalutamide is predicted to decrease the exposure to vortioxetine. Monitor and adjust dose. [Moderate] Study

Enzalutamide is predicted to decrease the exposure to zopiclone. Adjust dose. [Moderate] Study

Epidermide — see sympathomimetics, vasoconstrictor

Ephedrine — see sympathomimetics

Ephedrine — see adrenergic antagonists

Epoetin alfa — see TABLE 5 p. 1264 (thromboembolism), TABLE 16 p. 1268 (increased serum potassium)

Epoetin beta — see TABLE 5 p. 1264 (thromboembolism), TABLE 16 p. 1268 (increased serum potassium)

Epoprostenol — see TABLE 4 p. 1264 (ant platelet effects)

Eprosartan — see angiotensin-II receptor antagonists

Eptifibatide — see TABLE 4 p. 1264 (ant platelet effects)

Ergocalciferol — see vitamin D substances

Ergometrine

Antiarrhythmics (dronedaron) are predicted to increase the risk of ergotism when given with ergometrine. [Severe] Theoretical

Antifungals, azoles (fluconazole, itraconazole, posaconazole) are predicted to increase the risk of ergotism when given with ergometrine. [Severe] Theoretical

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the risk of ergotism when given with ergometrine. Avoid. [Severe] theoretical

Antifungals, azoles (miconazole) are predicted to increase the exposure to ergometrine. Avoid. [Moderate] Theoretical

Aprepitant is predicted to increase the risk of ergotism when given with ergometrine. [Severe] Theoretical
Beta blockers, non-selective are predicted to increase the risk of peripheral vasoconstriction when given with ergometrine. 
Avoid. [Severe] Theoretical

Beta blockers, selective are predicted to increase the risk of peripheral vasoconstriction when given with ergometrine. 
Avoid. [Severe] Theoretical

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the risk of ergotism when given with ergometrine. 
Avoid. [Severe] Theoretical

Cobicistat is predicted to increase the risk of ergotism when given with ergometrine. Avoid. [Severe] Theoretical

Crizotinib is predicted to increase the risk of ergotism when given with ergometrine. [Severe] Theoretical

Ergometrine is predicted to increase the risk of ergotism when given with ergometrine. [Severe] Theoretical

Favipiravir is predicted to decrease the effects of ergotamine. [Moderate] Theoretical

Eletriptan increases the risk of vasoconstriction when given with ergotamine. Separate administration by 24 hours. [Severe] Study

Enzalutamide is predicted to decrease the effects of ergotamine. [Moderate] Theoretical

Grapefruit juice is predicted to increase the exposure to ergotamine. Avoid. [Severe] Theoretical

Cobicistat is predicted to increase the risk of ergotism when given with ergotamine. Avoid. [Severe] Theoretical

Crizotinib is predicted to increase the risk of ergotism when given with ergotamine. Avoid. [Severe] Theoretical

Ergometrine is predicted to increase the risk of ergotism when given with ergotamine. [Severe] Theoretical

Efavirenz is predicted to decrease the effects of ergotamine. [Moderate] Theoretical

Eletriptan increases the risk of vasoconstriction when given with ergotamine. Separate administration by 24 hours. [Severe] Study

Enzalutamide is predicted to decrease the effects of ergotamine. [Moderate] Theoretical

Grapefruit juice is predicted to increase the exposure to ergotamine. Avoid. [Severe] Theoretical

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the risk of ergotism when given with ergometrine. 
Avoid. [Severe] Theoretical

HIV-protease inhibitors (indinavir) are predicted to increase the risk of ergotism when given with ergometrine. 
Avoid. [Severe] Theoretical

Idealisib is predicted to increase the risk of ergotism when given with ergometrine. [Severe] Theoretical

Imatinib is predicted to increase the risk of ergotism when given with ergometrine. [Severe] Theoretical

Macrolides (clarithromycin) are predicted to increase the risk of ergotism when given with ergometrine. [Severe] Theoretical

Macrolides (erythromycin) are predicted to increase the risk of ergotism when given with ergometrine. [Severe] Theoretical

Netupitant is predicted to increase the risk of ergotism when given with ergometrine. [Severe] Theoretical

Nilotinib is predicted to increase the risk of ergotism when given with ergometrine. [Severe] Theoretical

Ergometrine potentially increases the risk of peripheral vasoconstriction when given with sympathomimetics, inotropic (dopamine). 
Avoid. [Severe] Anecdotal

Ergometrine is predicted to increase the risk of peripheral vasoconstriction when given with sympathomimetics, vasoconstrictor (noradrenaline/norepinephrine). 
[Severe] Anecdotal

Ergotamine

Almotriptan is predicted to increase the risk of vasoconstriction when given with ergotamine. Ergotamine should be taken at least 24 hours before or 6 hours after almotriptan. [Severe] Theoretical

Antiarrhythmics (dronedarone) are predicted to increase the risk of ergotism when given with ergotamine. [Severe] Theoretical

Antiarrhythmics (sotalol) are predicted to increase the risk of ergotism when given with ergotamine. [Severe] Theoretical

Aprepitant is predicted to increase the risk of ergotism when given with ergotamine. [Moderate] Theoretical

Beta blockers, non-selective are predicted to increase the risk of peripheral vasoconstriction when given with ergotamine. 
[Severe] Study

Beta blockers, selective are predicted to increase the risk of peripheral vasoconstriction when given with ergotamine. 
[Severe] Study

Beta blockers, selective are predicted to increase the risk of peripheral vasoconstriction when given with ergotamine. 
[Moderate] Theoretical

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the risk of ergotism when given with ergotamine. 
[Severe] Theoretical

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the risk of ergotism when given with ergotamine. 
[Severe] Theoretical

Ceritinib is predicted to increase the exposure to ergotamine. 
Avoid. [Severe] Theoretical

Efavirenz is predicted to decrease the effects of ergotamine. [Moderate] Theoretical

Eletriptan increases the risk of vasoconstriction when given with ergotamine. Separate administration by 24 hours. [Severe] Study

Erlotinib

Food and lifestyle: Dose adjustment may be necessary if smoking started or stopped during treatment.

Antacids are predicted to decrease the absorption of erlotinib. Antacids should be taken 4 hours before or 2 hours after erlotinib. [Moderate] Theoretical

Antiarrhythmics (amiodarone, dronedarone) are predicted to increase the exposure to erlotinib [Moderate] Theoretical

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to erlotinib. Avoid or adjust erlotinib dose, p. 899. [Severe] Study

Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the risk of ergotism when given with ergotamine. 
[Severe] Theoretical

Beta blockers, selective are predicted to increase the risk of peripheral vasoconstriction when given with ergotamine. 
[Severe] Study

Beta blockers, selective are predicted to increase the risk of peripheral vasoconstriction when given with ergotamine. 
[Severe] Study

Ceritinib is predicted to increase the exposure to ergotamine. Avoid. [Severe] Theoretical

Erlotinib increases the risk of vasoconstriction when given with ergotamine. 
[Severe] Theoretical

Erlotinib increases the risk of ergotism when given with dopamine receptor agonists (bromocriptine, cabergoline). 
Avoid. [Moderate] Theoretical

Erlotinib increases the risk of ergotism when given with dopamine receptor agonists (bromocriptine, cabergoline). Avoid. [Moderate] Theoretical

Erlotinib increases the risk of vasoconstriction when given with ergotamine. 
[Severe] Study

Enzalutamide is predicted to decrease the effects of ergotamine. [Moderate] Theoretical

Grapefruit juice is predicted to increase the exposure to ergotamine. Avoid. [Severe] Theoretical

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the risk of ergotism when given with ergotamine. 
Avoid. [Severe] Theoretical

HIV-protease inhibitors (indinavir) are predicted to increase the risk of ergotism when given with ergotamine. 
Avoid. [Severe] Theoretical

Idealisib is predicted to increase the risk of ergotism when given with ergotamine. [Severe] Theoretical

Imatinib is predicted to increase the risk of ergotism when given with ergotamine. [Severe] Theoretical

Macrolides (clarithromycin) are predicted to increase the risk of ergotism when given with ergotamine. [Severe] Theoretical

Macrolides (erythromycin) are predicted to increase the risk of ergotism when given with ergotamine. [Severe] Theoretical

Nilotinib is predicted to increase the risk of ergotism when given with ergotamine. [Severe] Theoretical

Nilotinib is predicted to increase the exposure to ergotamine. 
[Severe] Theoretical

Palbociclib is predicted to increase the exposure to ergotamine. Adjust dose. [Moderate] Theoretical

Rifaximin is predicted to decrease the effects of ergotamine. [Moderate] Theoretical

Rizatriptan is predicted to increase the risk of vasoconstriction when given with ergotamine. 
[Severe] Study

St. John's Wort is predicted to decrease the effects of ergotamine. [Moderate] Theoretical

Sumatriptan increases the risk of vasoconstriction when given with ergotamine. 
[Severe] Study

Erlotinib
Erlotinib (continued)

- Anti-infectives, zoles (itraconazole, ketoconazole, voriconazole) are predicted to slightly increase the exposure to erlotinib. Use with caution and adjust dose. [Moderate] Study
- Aprepitant is predicted to increase the exposure to erlotinib. [Theoretical] Study
- Erlotinib is predicted to increase the risk of gastrointestinal perforation when given with aspirin (high-dose). [Severe] Theoretical
- Bosantan is predicted to decrease the exposure to erlotinib. [Severe] Theoretical
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to erlotinib. [Moderate] Theoretical
- Ciclosporin is predicted to increase the exposure to erlotinib. [Theoretical] Study
- Cobichstat is predicted to slightly increase the exposure to erlotinib. Use with caution and adjust dose. [Moderate] Study
- Combined hormonal contraceptives slightly increase the exposure to erlotinib. Monitor side effects and adjust dose. [Moderate] Study
- Corticosteroids increase the risk of gastrointestinal perforation when given with erlotinib. [Severe] Theoretical
- Erlotinib increases the anticoagulant effect of coumarins. [Severe] Anecdotal
- Crizotinib is predicted to increase the exposure to erlotinib. [Moderate] Theoretical
- Efavirenz is predicted to decrease the exposure to erlotinib. [Severe] Theoretical
- Enzalutamide is predicted to decrease the exposure to erlotinib. Avoid or adjust erlotinib dose, p. 899. [Severe] Study
- Grapefruit juice is predicted to increase the exposure to erlotinib. [Moderate] Theoretical
- H₂ receptor antagonists are predicted to decrease the exposure to erlotinib. Erlotinib should be taken 2 hours before or 10 hours after H₂ receptor antagonists. [Moderate] Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to slightly increase the exposure to erlotinib. Use with caution and adjust dose. [Moderate] Study
- HIV-protease inhibitors (indinavir) are predicted to increase the exposure to erlotinib. [Moderate] Theoretical
- Idelalisib is predicted to increase the exposure to erlotinib. [Moderate] Theoretical
- Ixazomib is predicted to increase the exposure to erlotinib. [Moderate] Theoretical
- Laptalimib is predicted to increase the exposure to erlotinib. [Moderate] Theoretical
- Macrolides (azithromycin, erythromycin) are predicted to increase the exposure to erlotinib. [Moderate] Theoretical
- Macrolides (clarithromycin) are predicted to slightly increase the exposure to erlotinib. Use with caution and adjust dose. [Moderate] Study
- Netupitant is predicted to increase the exposure to erlotinib. [Moderate] Theoretical
- Nevirapine is predicted to decrease the exposure to erlotinib. [Severe] Theoretical
- Nitotinib is predicted to increase the exposure to erlotinib. [Moderate] Theoretical
- Erlotinib is predicted to increase the risk of gastrointestinal perforation when given with NSAIDs. [Severe] Theoretical
- Erlotinib is predicted to increase the risk of bleeding events when given with phenindione. [Severe] Theoretical
- Proton pump inhibitors are predicted to slightly decrease the exposure to erlotinib. Avoid. [Moderate] Study
- Quinolones (ciprofloxacin) slightly increase the exposure to erlotinib. Monitor side effects and adjust dose. [Moderate] Study
- Ranolazine is predicted to increase the exposure to erlotinib. [Moderate] Theoretical
- Rifapentina is predicted to decrease the exposure to erlotinib. [Theoretical]
- St John’s Wort is predicted to decrease the exposure to erlotinib. [Severe] Theoretical
- Vemurafenib is predicted to increase the exposure to erlotinib. [Moderate] Theoretical
- Ertapenem → see carbapenems
- Erythromycin → see macrolides
- Escitalopram → see SSRIs
- Escitalopram → see antiepileptics
- Esomolol → see beta blockers, selective
- Esomeprazole → see proton pump inhibitors
- Estramustine → see alkylating agents
- Etanercept
- Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with etanercept. Public Health England advises avoid. [Severe] Theoretical
- Ethambutol
- Isoniazid increases the risk of optic neuropathy when given with ethambutol. [Severe] Anecdotal
- Ethosuximide → see antiepileptics
- Etodolac → see NSAIDs
- Etopimide → see TABLE 8 p. 1265 (hypotension), TABLE 11 p. 1266 (CNS depressant effects)

Etonogestrel

- Antiepileptics (carbamazepine, eslicarbazepine, fosphenytoin, oxcarbazepine, perampanel, phenobarbital, phenytoin, primidone, rufinamide, topiramate) are predicted to decrease the efficacy of etonogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical
- Aprepitant is predicted to decrease the efficacy of etonogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical
- Bosantan is predicted to decrease the efficacy of etonogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical
- Enzalutamide is predicted to slightly increase the exposure to etonogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical
- Efavirenz is predicted to decrease the efficacy of etonogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical
- Bosantan is predicted to decrease the efficacy of etonogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical
- Estrophan is predicted to decrease the efficacy of etonogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Anecdotal
- HIV-protease inhibitors (ritonavir) are predicted to decrease the efficacy of etonogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical
- Glinemide decreases the efficacy of etonogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical
- Griseofulvin decreases the efficacy of etonogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical
- Modafinil is predicted to decrease the efficacy of etonogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical
- Nevirapine is predicted to decrease the efficacy of etonogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical
- Rifabutin is predicted to decrease the efficacy of etonogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical
- Rifampicin is predicted to decrease the efficacy of etonogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical
- St John’s Wort is predicted to decrease the efficacy of etonogestrel. MHRA advises avoid. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical
- Suguayminadex is predicted to decrease the efficacy of etonogestrel. Use additional contraceptive precautions. [Severe] Theoretical
- Ulipristal is predicted to decrease the efficacy of etonogestrel. Avoid. [Severe] Theoretical
- Etoposide → see TABLE 15 p. 1267 (myelosuppression)
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone, rufinamide, topiramate) are predicted to decrease the efficacy of etoposide. [Moderate] Study
- Ciclosporin increases the exposure to etoposide. Monitor and adjust dose. [Severe] Study
- Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with etoposide. Public Health England advises avoid. [Severe] Theoretical
Etiravirine

- Etravirine (Carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to etravirine. Avoid. (Severe) Theoretical
- Etravirine decreases the exposure to antimalarials (artemether). (Moderate) Study
- Etravirine is predicted to decrease the exposure to bedaquiline. Avoid. (Severe) Theoretical
- Etravirine is predicted to decrease the exposure to etravirine. Avoid. (Severe) Study
- Etravirine is predicted to decrease the exposure to bosutinib. Avoid. (Severe) Theoretical
- Etravirine increases the anticoagulant effect of coumarins. (Moderate) Theoretical
- Etravirine is predicted to decrease the exposure to daclatasvir. Avoid. (Moderate) Theoretical
- Etravirine moderately decreases the exposure to dolutegravir. Avoid unless given with atazanavir, darunavir, or lopinavir (all boosted with ritonavir). (Severe) Study
- Efavirenz is predicted to decrease the exposure to etravirine. Avoid. (Severe) Study
- Etravirine is predicted to decrease the exposure to elbasvir. Avoid. (Unknown) Theoretical
- Enzalutamide is predicted to decrease the exposure to etravirine. Avoid. (Severe) Theoretical
- Etravirine is predicted to decrease the exposure to grazoprevir. Avoid. (Mild) Theoretical
- HIV-protease inhibitors (tipranavir) decrease the exposure to etravirine. Avoid. (Severe) Study
- Etravirine increases the exposure to HIV-protease inhibitors (fosamprenavir) boosted with ritonavir. Refer to specialist literature. (Moderate) Study
- Etravirine is predicted to decrease the exposure to HIV-protease inhibitors (indinavir). Avoid. (Severe) Theoretical
- Etravirine decreases the exposure to macrolides (clarithromycin). (Severe) Study
- Etravirine (with a boosted protease inhibitor) increases the exposure to maraviroc. Avoid or adjust dose. (Moderate) Study
- Nevirapine is predicted to decrease the exposure to etravirine. Avoid. (Severe) Study
- Etravirine moderately decreases the exposure to phosphodiesterase type-5 inhibitors. Adjust dose. (Moderate) Study
- Rifabutin decreases the exposure to etravirine. (Moderate) Study
- Rifampicin is predicted to decrease the exposure to etravirine. Avoid. (Severe) Theoretical
- Etravirine is predicted to decrease the exposure to rifapentine. Avoid. (Severe) Theoretical
- Etravirine is predicted to decrease the exposure to simprevir. Avoid. (Moderate) Study
- St John’s Wort is predicted to decrease the exposure to etravirine. Avoid. (Severe) Study
- Everolimus is predicted to increase the concentration of everolimus. Avoid or adjust dose. (Moderate) Study
- Antiarhythmics (dronedarone) are predicted to increase the concentration of everolimus. Avoid or adjust dose. (Moderate) Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the concentration of everolimus. Avoid or adjust dose. (Severe) Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the concentration of everolimus. Avoid or adjust dose. (Moderate) Study
- Aprepitant is predicted to increase the concentration of everolimus. Avoid or adjust dose. (Moderate) Study
- Bosentan is predicted to decrease the concentration of everolimus. Avoid or adjust dose. (Severe) Study
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the concentration of everolimus. Avoid or adjust dose. (Moderate) Study
- Ceritinib is predicted to increase the exposure to everolimus. (Moderate) Theoretical
- Cobicistat is predicted to increase the concentration of everolimus. Avoid. (Severe) Study
- Crizotinib is predicted to increase the concentration of everolimus. Avoid or adjust dose. (Moderate) Study
- Grapefruit juice is predicted to increase the exposure to everolimus. Avoid. (Severe) Theoretical
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the concentration of everolimus. Avoid. (Severe) Study
- HIV-protease inhibitors (indinavir) are predicted to increase the concentration of everolimus. Avoid or adjust dose. (Moderate) Study

Avoid or adjust dose. (Severe) Study
- Idelalisib is predicted to increase the concentration of everolimus. Avoid. (Severe) Study
- Imatinib is predicted to increase the concentration of everolimus. Avoid or adjust dose. (Moderate) Study
- Lapatinib is predicted to increase the exposure to everolimus. (Moderate) Theoretical
- Mirabegron is predicted to increase the exposure to everolimus. (Mild) Theoretical
- Netupitant is predicted to increase the concentration of everolimus. Avoid or adjust dose. (Moderate) Study
- Nevirapine is predicted to decrease the concentration of everolimus. Avoid or adjust dose. (Severe) Study
- Nilotinib is predicted to increase the concentration of everolimus. Avoid or adjust dose. (Moderate) Study
- Palbociclib is predicted to increase the exposure to everolimus. Adjust dose. (Moderate) Theoretical
- Pitolisant is predicted to decrease the exposure to everolimus. Avoid. (Severe) Theoretical
- Rifampicin is predicted to decrease the concentration of everolimus. Avoid or adjust dose. (Severe) Study
- St John’s Wort is predicted to decrease the concentration of everolimus. Avoid or adjust dose. (Severe) Study
- Velpatasvir is predicted to increase the exposure to everolimus. (Severe) Theoretical

Evolocumab → see monoclonal antibodies

Exemestane

- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) moderately decrease the exposure to exemestane. (Moderate) Study
- Enzalutamide moderately decreases the exposure to exemestane. (Moderate) Study
- Rifampicin moderately decreases the exposure to exemestane. (Moderate) Study
- St John’s Wort is predicted to decrease the exposure to exemestane. (Moderate) Theoretical

Exenatide → see Table 14 p. 1267 (antidiabetic drugs)

SEPARATION OF ADMINISTRATION With standard-release exenatide: some orally administered drugs should be taken at least 1 hour before, or 4 hours after, exenatide injection.
Ezetimibe

- Ciclosporin moderately increases the exposure to ezetimibe and ezetimibe slightly increases the exposure to ciclosporin. [Moderate Study]
- Fibrates are predicted to slightly increase the risk of gallstones when given with ezetimibe. [Severe] Theoretical
- Ezetimibe potentially increases the risk of rhabdomyolysis when given with statins. [Severe] Anecdotal

Fampridine

- H₂ receptor antagonists (cimetidine) increase the concentration of fampridine. Avoid. [Severe] Theoretical

Febuxostat

- Febuxostat is predicted to increase the exposure to azaithioprine. [Severe] Theoretical
- Febuxostat is predicted to increase the exposure to didanosine. [Severe] Theoretical
- Febuxostat is predicted to increase the exposure to mercaptopurine. Avoid. [Severe] Theoretical

Felbakin → see NSAIDs
Felodipine → see calcium channel blockers
Fenofibrate → see fibrates
Fenoprofen → see NSAIDs
Fentanyl → see opioids
Ferric carboxymaltose → see iron (injectable)
Ferric maltol → see iron (oral)
Ferroas fumarate → see iron (oral)
Ferroas gluconate → see iron (oral)
Ferroas sulfate → see iron (oral)

Fesoterodine → see Table 10 p. 1266 (antimuscarinics)
- Antiarrhythmics (dronedarone) are predicted to increase the exposure to fesoterodine. Adjust fesoterodine dose in hepatic and renal impairment, p. 732. [Mild] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to fesoterodine. Avoid. [Moderate] Study
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to fesoterodine. Adjust fesoterodine dose in hepatic and renal impairment, p. 732. [Mild] Study
- Aprepitant is predicted to increase the exposure to fesoterodine. Adjust fesoterodine dose in hepatic and renal impairment, p. 732. [Mild] Study
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to fesoterodine. Adjust fesoterodine dose in hepatic and renal impairment, p. 732. [Mild] Study
- Cobicistat is predicted to moderately increase the exposure to fesoterodine. Adjust fesoterodine dose; avoid in hepatic and renal impairment, p. 732. [Severe] Study
- Crizotinib is predicted to increase the exposure to fesoterodine. Adjust fesoterodine dose in hepatic and renal impairment, p. 732. [Mild] Study
- Enzalutamide is predicted to decrease the exposure to fesoterodine. Avoid. [Moderate] Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to moderately increase the exposure to fesoterodine. Adjust fesoterodine dose; avoid in hepatic and renal impairment, p. 732. [Severe] Study
- HIV-protease inhibitors (indinavir) are predicted to increase the exposure to fesoterodine. Adjust fesoterodine dose in hepatic and renal impairment, p. 732. [Mild] Study
- Idelalisib is predicted to moderately increase the exposure to fesoterodine. Adjust fesoterodine dose; avoid in hepatic and renal impairment, p. 732. [Severe] Study
- Imatinib is predicted to increase the exposure to fesoterodine. Adjust fesoterodine dose in hepatic and renal impairment, p. 732. [Mild] Study
- Macrolides (clarithromycin) are predicted to moderately increase the exposure to fesoterodine. Adjust fesoterodine dose; avoid in hepatic and renal impairment, p. 732. [Severe] Study
- Macrolides (erythromycin) are predicted to increase the exposure to fesoterodine. Adjust fesoterodine dose in hepatic and renal impairment, p. 732. [Mild] Study
- Netupitant is predicted to increase the exposure to fesoterodine. Adjust fesoterodine dose in hepatic and renal impairment, p. 732. [Mild] Study
- Nilotinib is predicted to increase the exposure to fesoterodine. Adjust fesoterodine dose in hepatic and renal impairment, p. 732. [Mild] Study
- Rifampicin is predicted to decrease the exposure to fesoterodine. Avoid. [Moderate] Study
- St John’s Wort is predicted to decrease the exposure to fesoterodine. Avoid. [Severe] Theoretical
- Fexofenadine → see antihistamines, non-sedating

Fibrates

bezafibrate - cipofibrate - fenofibrate - gemfibrozil
- Antacids slightly to moderately decrease the exposure to gemfibrozil. [Moderate] Study
- Bezafibrate is predicted to increase the risk of nephrotoxicity when given with ciclosporin. [Severe] Theoretical
- Fenofobrate increases the risk of nephrotoxicity when given with ciclosporin. [Severe] Study
- Colchicine increases the risk of rhabdomyolysis when given with fibrates. [Severe] Anecdotal
- Fibrates are predicted to increase the anticoagulant effect of coumarins. Monitor INR and adjust dose. [Severe] Study
- Gemfibrozil is predicted to increase the exposure to dabrafenib. [Moderate] Theoretical
- Fibrates are predicted to increase the risk of rhabdomyolysis when given with dapometin. [Severe] Theoretical
- Gemfibrozil very markedly increases the exposure to dasabuvir. Avoid. [Severe] Study
- Gemfibrozil moderately increases the exposure to enzalutamide. Avoid or adjust enzalutamide dose, p. 874. [Severe] Study
- Fibrates are predicted to increase the risk of gallstones when given with ezetimibe. [Severe] Theoretical
- Fibrates are predicted to increase the risk of hypoglycaemia when given with insulin. [Moderate] Theoretical
- Gemfibrozil is predicted to moderately increase the exposure to montelukast. [Moderate] Study
- Fibrates are predicted to increase the anticoagulant effect of phenindione. Monitor INR and adjust dose. [Severe] Study
- Gemfibrozil markedly increases the exposure to pioglitazone. Monitor blood glucose and adjust dose. [Severe] Study
- Gemfibrozil markedly increases the exposure to repaglinide. Avoid. [Severe] Study
- Gemfibrozil is predicted to increase the exposure to retinoids (alitretinoin). Adjust alitretinoin dose, p. 1157. [Moderate] Theoretical
- Gemfibrozil increases the concentration of retinoids (bexarotene). Avoid. [Severe] Study
- Gemfibrozil is predicted to increase the exposure to selexipag. Avoid. [Severe] Theoretical
- Cipofibrate increases the risk of rhabdomyolysis when given with statins (atorvastatin). Avoid or adjust dose. [Severe] Study
- Bezaabifibrate increases the risk of rhabdomyolysis when given with statins (atorvastatin, fluvastatin). [Severe] Study
- Fenofibrate increases the risk of rhabdomyolysis when given with statins (atorvastatin, simvastatin). Adjust fenofibrate dose, p. 193. [Severe] Anecdotal
- Cipofibrate increases the risk of rhabdomyolysis when given with statins (fluvastatin). [Severe] Study
- Fenofibrate is predicted to increase the risk of rhabdomyolysis when given with statins (fluvastatin). Adjust fenofibrate dose, p. 193. [Severe] Theoretical
- Fenofibrate is predicted to increase the risk of rhabdomyolysis when given with statins (pravastatin). Avoid. [Severe] Theoretical
- Fibrates (bezaabifibrate, cipofibrate) increase the risk of rhabdomyolysis when given with statins (pravastatin). Avoid. [Severe] Study
Fenofibrate increases the risk of rhabdomyolysis when given with statins (rosuvastatin). Adjust fenofibrate and rosuvastatin doses, p. 193, p. 197. (Severe) Anecdotal

Fibrates (bezafibrate, clofibrate) increase the risk of rhabdomyolysis when given with statins (rosuvastatin). Adjust rosuvastatin dose, p. 197. (Severe) Study

Fibrates (bezafibrate, clofibrate) increase the risk of rhabdomyolysis when given with statins (simvastatin). Adjust simvastatin dose, p. 198. (Severe) Study

Gemfibrozil increases the risk of rhabdomyolysis when given with statins. Avoid. (Severe) Anecdotal

Fibrates are predicted to increase the risk of hypoglycaemia when given with sulfonylureas. (Moderate) Theoretical

Fibrates are predicted to decrease the efficacy of ursodeoxycholic acid. Avoid. (Severe) Theoretical

Fidaxomicin

Antiarrhythmics (amiodarone, dronedarone) are predicted to increase the exposure to fidaxomicin. Avoid. (Moderate) Study

Antifungals, azoles (itraconazole, ketoconazole) are predicted to increase the exposure to fidaxomicin. Avoid. (Moderate) Study

Calcium channel blockers (verapamil) are predicted to increase the exposure to fidaxomicin. Avoid. (Moderate) Study

Ciclosporin is predicted to increase the exposure to fidaxomicin. Avoid. (Moderate) Study

HIV-protease inhibitors (lopinavir, ritonavir, saquinavir) are predicted to increase the exposure to fidaxomicin. Avoid. (Moderate) Study

Fingerblind is predicted to increase the exposure to fidaxomicin. Avoid. (Moderate) Study

Macrolides are predicted to increase the exposure to fidaxomicin. Avoid. (Moderate) Study

Ranolazine is predicted to increase the exposure to fidaxomicin. Avoid. (Moderate) Study

Vemurafenib is predicted to increase the exposure to fidaxomicin. Avoid. (Moderate) Study

Fingolimod → see TABLE 6 p. 1265 (bradycardia), TABLE 9 p. 1266 (QT-interval prolongation)

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to fingolimod. (Moderate) Study

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to fingolimod. Avoid. (Moderate) Study

Enzalutamide is predicted to decrease the exposure to fingolimod. (Moderate) Study

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with fingolimod. Public Health England advises avoid. (Severe) Theoretical

Rifampicin is predicted to decrease the exposure to fingolimod. (Moderate) Study

St John’s Wort is predicted to decrease the exposure to fingolimod. Avoid. (Moderate) Theoretical

Flavoxate → see TABLE 10 p. 1266 (antimuscarinics)

Flecainide → see antiarrhythmics

Fluoxacillin → see penicillins

Flucytosine → see antifungals, azoles

Flucytosine is predicted to increase the risk of toxicity when given with levofolinic acid. (Severe) Theoretical

Folinic acid is predicted to decrease the concentration of fluocytosine. Avoid. (Severe) Study

Fludarabine → see TABLE 15 p. 1267 (myelosuppression)

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with fludarabine. Public Health England advises avoid. (Severe) Theoretical

Fludarabine increases the risk of pulmonary toxicity when given with pentostatin. Avoid. (Severe) Study → Also see TABLE 15 p. 1267

Fludrocortisone → see TABLE 17 p. 1268 (reduced serum potassium)

Fluocinolone

ROUTE-SPECIFIC INFORMATION With intravitreal use in adults: caution with concurrent administration of antiocoagulant or antiplatelet drugs (higher incidence of conjunctival haemorrhage).

Fluorouracil → see TABLE 15 p. 1267 (myelosuppression), TABLE 5 p. 1264 (thromboembolism)

ROUTE-SPECIFIC INFORMATION Since systemic absorption can follow topical application, the possibility of interactions should be borne in mind.

Fluorouracil increases the concentration of antiepileptics (fosphenytoin, phenytoin). Monitor concentration and adjust dose. (Severe) Anecdotal

Fluorouracil increases the antiocoagulant effect of coumarins. (Severe) Anecdotal

Fluridone (folic acid) are predicted to increase the risk of toxicity when given with fluorouracil. Avoid. (Severe) Theoretical

Flurbiprofen is predicted to increase the risk of toxicity when given with fluorouracil. (Severe) Study

Fluvastatin → see statins

Fluvonoxime → see SSRIss

Folic acid - folinic acid - levofolinic acid

Folic acid decreases the concentration of antiepileptics (fosphenytoin, phenobarbital, phenytoin, primidone). Monitor concentration and adjust dose. (Severe) Study

Folinic acid is predicted to decrease the concentration of antiepileptics (fosphenytoin, phenobarbital, phenytoin, primidone). (Severe) Theoretical

Folic acid is predicted to increase the risk of toxicity when given with capecitabine. (Severe) Anecdotal

Folic acid increases the risk of toxicity when given with capecitabine. (Severe) Study

Folic acid is predicted to increase the risk of toxicity when given with fluorouracil. Avoid. (Severe) Theoretical

Folic acid is predicted to increase the risk of toxicity when given with fluorouracil. (Severe) Theoretical

Folic acid is predicted to alter the effects of raltitrexed. Avoid. (Moderate) Theoretical

Folic acid alters the effects of raltitrexed. Avoid. (Moderate) Study

Sulfasalazine decreases the absorption of folic acid. (Moderate) Study

Sulfasalazine is predicted to decrease the absorption of folinic acid. (Moderate) Theoretical

Folic acid is predicted to increase the risk of tegafur toxicity when given with tegafur. (Severe) Theoretical

Folic acid is predicted to increase the risk of toxicity when given with tegafur. (Severe) Theoretical

Folic acid → see folates

Fondaparinux → see TABLE 3 p. 1264 (antiocoagulant effects)

Formoterol → see beta, agonists
Fosaprepitant  
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to fosaprepitant. Avoid. [Moderate] Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to fosaprepitant. [Moderate] Theoretical
- Fusidic acid is predicted to increase the exposure to fosaprepitant. [Moderate] Theoretical
- Gabapentin is predicted to increase the exposure to fosaprepitant. [Moderate] Theoretical

Fusidic acid  
- Fusidic acid increases the risk of rhabdomyolysis when given with statins. Avoid. [Severe] Anecdotal

Gabapentin  
- see antiepileptics

Galantamine  
- see anticholinesterases, centrally acting

Ganciclovir  
- see TABLE 15 p. 1267 (myelosuppression), TABLE 2 p. 1264 (nephrotoxicity)

ROUTE-SPECIFIC INFORMATION  
Since systemic absorption can follow topical application, the possibility of interactions should be borne in mind.

Ganciclovir is predicted to increase the risk of seizures when given with carbapenems (imipenem). Avoid. [Severe] Anecdotal

Ganciclovir is predicted to increase the exposure to didanosine. [Moderate] Study

Mycopl熟悉 alate is predicted to increase the risk of haematological toxicity when given with ganciclovir. [Moderate] Theoretical

Also see TABLE 15 p. 1267

Gefitinib  
- see TABLE 15 p. 1267 (myelosuppression)

Antacids are predicted to slightly decrease the exposure to gefitinib. [Moderate] Theoretical

Antirhythmic (dronedarone) are predicted to increase the exposure to gefitinib. [Moderate] Theoretical

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to gefitinib. Avoid. [Severe] Study

Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to gefitinib. [Moderate] Theoretical

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to gefitinib. [Moderate] Study

Aprepitant is predicted to increase the exposure to gefitinib. [Moderate] Theoretical

Bosentan is predicted to increase the exposure to gefitinib. Avoid. [Severe] Theoretical

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to gefitinib. [Moderate] Theoretical

Cobicistat is predicted to increase the exposure to gefitinib. [Moderate] Study

Gefitinib is predicted to increase the anticoagulant effect of coumarins. [Severe] Anecdotal

Crizotinib is predicted to increase the exposure to gefitinib. [Moderate] Theoretical

Elavirex is predicted to decrease the exposure to gefitinib. Avoid. [Severe] Theoretical

Elacridar is predicted to decrease the exposure to gefitinib. Avoid. [Severe] Theoretical

H2 receptor antagonists are predicted to slightly to moderately decrease the exposure to gefitinib. [Moderate] Study

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to gefitinib. [Moderate] Theoretical

HIV-protease inhibitors (indinavir) are predicted to increase the exposure to gefitinib. [Moderate] Theoretical

Indinavir is predicted to decrease the exposure to gefitinib. Avoid. [Severe] Study

Irinotecan is predicted to increase the exposure to gefitinib. [Moderate] Theoretical

Irinotecan is predicted to decrease the exposure to gefitinib. Avoid. [Severe] Theoretical

Metronidazole is predicted to increase the exposure to gefitinib. [Moderate] Theoretical

Netupitant is predicted to increase the exposure to gefitinib. [Moderate] Theoretical

Nevirapine is predicted to increase the exposure to gefitinib. Avoid. [Severe] Theoretical

Nilotinib is predicted to increase the exposure to gefitinib. [Moderate] Theoretical

Nilotinib is predicted to decrease the exposure to gefitinib. [Moderate] Theoretical

Pimozide is predicted to increase the exposure to gefitinib. Avoid. [Severe] Study

St John’s Wort is predicted to decrease the exposure to gefitinib. Avoid. [Severe] Study

TABLE 15 p. 1267

Imatinib is predicted to increase the exposure to gefitinib. [Moderate] Study

Imatinib is predicted to increase the exposure to gefitinib. [Moderate] Study

Macrolides (clarithromycin) are predicted to increase the exposure to gefitinib. [Moderate] Study

Macrolides (eriythromycin) are predicted to increase the exposure to gefitinib. [Moderate] Theoretical

Methotrexate is predicted to increase the exposure to gefitinib. [Moderate] Theoretical

Nefopam is predicted to increase the exposure to gefitinib. Avoid. [Severe] Theoretical

Nelfinavir is predicted to increase the exposure to gefitinib. Avoid. [Severe] Study

St John’s Wort is predicted to decrease the exposure to gefitinib. Avoid. [Severe] Theoretical

TABLE 15 p. 1267

Gefitinib is predicted to increase the risk of bleeding events when given with phenidone. [Severe] Theoretical

Proton pump inhibitors are predicted to decrease the exposure to gefitinib. [Severe] Theoretical

Rifampicin is predicted to decrease the exposure to gefitinib. Avoid. [Severe] Study

St John’s Wort is predicted to decrease the exposure to gefitinib. Avoid. [Severe] Theoretical

TABLE 5

Ganciclovir  
- see TABLE 15 p. 1267 (myelosuppression)

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to gefitinib. [Moderate] Theoretical
Grapefruit juice

▶ Glucosamine increases the anticoagulant effect of coumarins (warfarin). [Severe] Study

Glucosamine

Glucose ▶ see TABLE 3 p. 1264 (anticoagulant effects)

Glycerol ▶ see TABLE 17 p. 1268 (reduced serum potassium)

Glycercyl trinitrate ▶ see nitrates

Glycopyrronium ▶ see sulfonylureas

Glomimubab ▶ see monoclonal antibodies

Granisetron ▶ see TABLE 13 p. 1267 (serotonin syndrome), TABLE 9 p. 1266 (QT-interval prolongation)

Dopamine receptor agonists (apomorphine) are predicted to increase the risk of severe hypotension when given with granisetron. [Severe] Theoretical

Grapefruit juice
▶ Grapefruit juice moderately decreases the exposure to aliskiren. [Avoid. Severe] Study

Grapefruit juice increases the exposure to antiarrhythmics (amiodarone). [Avoid. Moderate] Study

Grapefruit juice moderately increases the exposure to antiarrhythmics (dronedaron). [Avoid. Severe] Study

Grapefruit juice increases the exposure to antiarrhythmics (propafenone). Monitor and adjust dose. [Moderate] Study

Grapefruit juice slightly increases the exposure to antiepileptics (carbamazepine). Monitor carbamazepine concentration and adjust dose. [Moderate] Study

Grapefruit juice slightly decreases the exposure to antihistamines, non-sedating (biliastine). Biliastine should be taken 1 hour before or 2 hours after grapefruit juice. [Moderate] Study

Grapefruit juice increases the exposure to antimalarials (atremether). [Unknown] Study

Grapefruit juice is predicted to increase the concentration of antimalarials (piperaquine). [Avoid. Severe] Theoretical

Grapefruit juice is predicted to increase the exposure to axitinib. [Moderate] Theoretical

Grapefruit juice greatly decreases the exposure to beta blockers, selective (celiprolol). [Moderate] Study

Grapefruit juice is predicted to increase the exposure to bosutinib. [Avoid. Moderate] Theoretical

Grapefruit juice increases the exposure to buspirone. [Avoid. Mild] Study

Grapefruit juice is predicted to increase the exposure to cabozantinib. [Moderate] Theoretical

Grapefruit juice very slightly increases the exposure to calcium channel blockers (amlodipine). [Avoid. Mild] Study

Grapefruit juice increases the exposure to calcium channel blockers (felodipine). [Avoid. Moderate] Study

Grapefruit juice is predicted to increase the exposure to calcium channel blockers (lercanidipine). [Avoid. Moderate] Theoretical

Grapefruit juice increases the exposure to calcium channel blockers (nicardipine). [Mild] Study

Grapefruit juice increases the exposure to calcium channel blockers (nifedipine, verapamil). [Avoid. Mild] Study

Grapefruit juice is predicted to increase the exposure to ceritinib. [Avoid. Severe] Theoretical

Grapefruit juice increases the concentration of cyclosporin. [Avoid. Severe] Study

Grapefruit juice markedly decreases the exposure to clopidogrel. [Severe] Study

Grapefruit juice is predicted to increase the exposure to cobicetinib. [Avoid. Severe] Theoretical

Grapefruit juice moderately increases the exposure to oral corticosteroids (budesonide). [Avoid. Moderate] Study

Grapefruit juice is predicted to increase the exposure to crizotinib. [Avoid. Moderate] Theoretical

Grapefruit juice is predicted to increase the exposure to darifenacin. [Moderate] Study

Grapefruit juice is predicted to increase the exposure to dasatinib. [Avoid. Moderate] Theoretical

Grapefruit juice is predicted to increase the risk of ergotism when given with ergotamine. [Severe] Theoretical

Grapefruit juice is predicted to increase the exposure to ergotamine. [Severe] Theoretical

Grapefruit juice is predicted to increase the exposure to erlotinib. [Moderate] Theoretical

Grapefruit juice is predicted to increase the exposure to everolimus. [Avoid. Severe] Theoretical

Grapefruit juice is predicted to increase the exposure to ibritinib. [Avoid. Moderate] Theoretical

Grapefruit juice is predicted to increase the exposure to imatinib. [Moderate] Theoretical

Grapefruit juice is predicted to increase the exposure to ivabradine. [Avoid. Moderate] Study

Grapefruit juice is predicted to increase the exposure to ivacaftor. [Avoid. Moderate] Theoretical

Grapefruit juice is predicted to increase the exposure to lapatinib. [Avoid. Moderate] Theoretical

Grapefruit juice is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. [Moderate] Theoretical

Grapefruit juice is predicted to increase the exposure to luridosione. [Avoid. Severe] Theoretical

Grapefruit juice is predicted to increase the exposure to naloxegol. [Avoid. Moderate] Theoretical

Grapefruit juice is predicted to increase the exposure to nilotinib. [Avoid. Severe] Theoretical

Grapefruit juice is predicted to increase the exposure to olaparib. [Avoid. Moderate] Theoretical

Grapefruit juice is predicted to increase the exposure to palbociclib. [Avoid. Severe] Theoretical

Grapefruit juice is predicted to increase the exposure to pazopanib. [Avoid. Severe] Theoretical

Grapefruit juice is predicted to increase the exposure to phosphodiesterase type-5 inhibitors. Use with caution or avoid. [Moderate] Study

Grapefruit juice increases the exposure to pimozide. [Avoid. Severe] Theoretical

Grapefruit juice is predicted to increase the exposure to ponatinib. [Moderate] Theoretical

Grapefruit juice is predicted to increase the exposure to praziquantel. [Moderate] Study

Grapefruit juice is predicted to increase the exposure to quetiapine. [Avoid. Severe] Theoretical

Grapefruit juice is predicted to increase the concentration of ranolazine. [Avoid. Severe] Theoretical

Grapefruit juice is predicted to increase the exposure to regorafenib. [Avoid. Moderate] Theoretical

Grapefruit juice is predicted to increase the exposure to ruxolitinib. [Severe] Theoretical

Grapefruit juice is predicted to increase the exposure to saxagliptin. [Mild] Theoretical

Grapefruit juice increases the concentration of sirolimus. [Avoid. Moderate] Study

Grapefruit juice moderately increases the exposure to SSRIs (sertraline). [Avoid. Moderate] Study

Grapefruit juice increases the exposure to statins (atorvastatin). [Mild] Study

Grapefruit juice increases the exposure to statins (simvastatin). [Avoid. Severe] Study

Grapefruit juice is predicted to increase the exposure to sunitinib. [Avoid. Moderate] Theoretical

Grapefruit juice increases the concentration of tacrolimus. [Avoid. Severe] Study

Grapefruit juice is predicted to increase the concentration of temsirolimus. Use with caution or avoid. [Moderate] Theoretical

Grapefruit juice moderately increases the exposure to ticagrelor. [Moderate] Study

Grapefruit juice is predicted to increase the exposure to crizotinib. [Avoid. Moderate] Theoretical

Grapefruit juice is predicted to increase the exposure to darifenacin. [Moderate] Study

Grapefruit juice is predicted to increase the exposure to dasatinib. [Avoid. Moderate] Theoretical

Grapefruit juice is predicted to increase the risk of ergotism when given with ergotamine. [Severe] Theoretical

Grapefruit juice is predicted to increase the exposure to ergotamine. [Severe] Theoretical

Grapefruit juice is predicted to increase the exposure to erlotinib. [Moderate] Theoretical

Grapefruit juice is predicted to increase the exposure to everolimus. [Avoid. Severe] Theoretical

Grapefruit juice is predicted to increase the exposure to ibritinib. [Avoid. Moderate] Theoretical

Grapefruit juice is predicted to increase the exposure to imatinib. [Moderate] Theoretical

Grapefruit juice is predicted to increase the exposure to ivabradine. [Avoid. Moderate] Study

Grapefruit juice is predicted to increase the exposure to ivacaftor. [Avoid. Moderate] Theoretical

Grapefruit juice is predicted to increase the exposure to lapatinib. [Avoid. Moderate] Theoretical

Grapefruit juice is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. [Moderate] Theoretical

Grapefruit juice is predicted to increase the exposure to luridosione. [Avoid. Severe] Theoretical

Grapefruit juice is predicted to increase the exposure to naloxegol. [Avoid. Moderate] Theoretical

Grapefruit juice is predicted to increase the exposure to nilotinib. [Avoid. Severe] Theoretical

Grapefruit juice is predicted to increase the exposure to olaparib. [Avoid. Moderate] Theoretical

Grapefruit juice is predicted to increase the exposure to palbociclib. [Avoid. Severe] Theoretical

Grapefruit juice is predicted to increase the exposure to pazopanib. [Avoid. Severe] Theoretical

Grapefruit juice is predicted to increase the exposure to phosphodiesterase type-5 inhibitors. Use with caution or avoid. [Moderate] Study

Grapefruit juice increases the exposure to pimozide. [Avoid. Severe] Theoretical

Grapefruit juice is predicted to increase the exposure to ponatinib. [Moderate] Theoretical

Grapefruit juice is predicted to increase the exposure to praziquantel. [Moderate] Study

Grapefruit juice is predicted to increase the exposure to quetiapine. [Avoid. Severe] Theoretical

Grapefruit juice is predicted to increase the concentration of ranolazine. [Avoid. Severe] Theoretical

Grapefruit juice is predicted to increase the exposure to regorafenib. [Avoid. Moderate] Theoretical

Grapefruit juice is predicted to increase the exposure to ruxolitinib. [Severe] Theoretical

Grapefruit juice is predicted to increase the exposure to saxagliptin. [Mild] Theoretical

Grapefruit juice increases the concentration of sirolimus. [Avoid. Moderate] Study

Grapefruit juice moderately increases the exposure to SSRIs (sertraline). [Avoid. Moderate] Study

Grapefruit juice increases the exposure to statins (atorvastatin). [Mild] Study

Grapefruit juice increases the exposure to statins (simvastatin). [Avoid. Severe] Study

Grapefruit juice is predicted to increase the exposure to sunitinib. [Avoid. Moderate] Theoretical

Grapefruit juice increases the concentration of tacrolimus. [Avoid. Severe] Study

Grapefruit juice is predicted to increase the concentration of temsirolimus. Use with caution or avoid. [Moderate] Theoretical

Grapefruit juice moderately increases the exposure to ticagrelor. [Moderate] Study
Grapefruit juice — Guanfacine

Grapefruit juice (continued)

- Grapefruit juice increases the exposure to tolvaptan. Avoid.
  [Moderate] Study
- Grapefruit juice is predicted to increase the exposure to ulipristal. Avoid if used for uterine fibroids. [Moderate] Theoretical
- Grapefruit juice is predicted to increase the exposure to venetoclax. Avoid. [Severe] Theoretical

Grass pollen extract

GENERAL INFORMATION Desensitising vaccines should be avoided in patients taking beta-blockers (adenaline might be ineffective in case of a hypersensitivity reaction) or ACE inhibitors (risk of severe anaphylactoid reactions).

Grazoprevir

- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to grazoprevir. Avoid. [Severe] Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to moderately to markedly increase the exposure to grazoprevir. Avoid. [Severe] Study
- Bosentan is predicted to markedly decrease the exposure to grazoprevir. Avoid. [Severe] Study
- Ciclosporin greatly increases the exposure to grazoprevir. Avoid. [Severe] Study
- Cobicitat is predicted to moderately to markedly increase the exposure to grazoprevir. Avoid. [Severe] Study
- Efavirenz is predicted to markedly decrease the exposure to grazoprevir. Avoid. [Severe] Study
- Enzalutamide is predicted to decrease the exposure to grazoprevir. Avoid. [Severe] Study
- Efavirenz is predicted to decrease the exposure to grazoprevir. Avoid. [Mild] Theoretical
- HIV- protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to moderately to markedly increase the exposure to grazoprevir. Avoid. [Severe] Study
- Idelalisib is predicted to moderately to markedly increase the exposure to grazoprevir. Avoid. [Severe] Study
- Modafinil is predicted to decrease the exposure to grazoprevir. Avoid. [Unknown] Theoretical
- Nevirapine is predicted to markedly decrease the exposure to grazoprevir. Avoid. [Severe] Study
- Rifampicin is predicted to decrease the exposure to grazoprevir. Avoid. [Severe] Study
- St John’s Wort is predicted to markedly decrease the exposure to grazoprevir. Avoid. [Severe] Study
- Grazoprevir increases the exposure to statins (atorvastatin). Adjust atorvastatin dose, p. 196. [Moderate] Study
- Grazoprevir is predicted to increase the exposure to statins (fluvastatin). Adjust fluvastatin dose, p. 196. [Unknown] Theoretical
- Grazoprevir increases the exposure to statins (rosuvastatin). Adjust rosuvastatin dose, p. 197. [Moderate] Study
- Grazoprevir is predicted to increase the exposure to statins (simvastatin). Adjust simvastatin dose, p. 198. [Unknown] Theoretical
- Grazoprevir increases the exposure to tacrolimus. [Moderate] Study

Griselofulvin

FOOD AND LIFESTYLE Disulfram-like reaction might occur on consumption of alcohol.

- Antiepileptics (phenobarbital, primidone) decrease the effects of griselofulvin. [Moderate] Study
- Griselofulvin potentially decreases the efficacy of combined hormonal contraceptives. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Anecdotal
- Griselofulvin potentially decreases the anticoagulant effect of coumarins. [Moderate] Anecdotal
- Griselofulvin potentially decreases the efficacy of desogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Anecdotal
- Griselofulvin decreases the efficacy of etonogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. [Moderate] Anecdotal
- Griselofulvin potentially decreases the efficacy of oral levonorgestrel. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Anecdotal
- Griselofulvin potentially decreases the efficacy of norethisterone. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Anecdotal
- Griselofulvin potentially decreases the efficacy of ulipristal. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Anecdotal
- Guanfacine → see TABLE 8 p. 1265 (hypotension)
- Benperidol is predicted to decrease the efficacy of guanethidine. [Moderate] Theoretical → Also see TABLE 8 p. 1265
- Droperidol is predicted to decrease the efficacy of guanethidine. Monitor and adjust dose. [Moderate] Theoretical → Also see TABLE 8 p. 1265
- Haloperidol is predicted to decrease the antihypertensive effects of guanethidine. Avoid and for 14 days after stopping the MAOI. [Severe] Theoretical → Also see TABLE 8 p. 1265
- Monoamine-oxidase A and B inhibitors, irreversible are predicted to decrease the antihypertensive effects of guanethidine. Avoid and for 14 days after stopping the MAOI. [Severe] Theoretical → Also see TABLE 8 p. 1265
- Monamine- oxidase A and B inhibitors, reversible are predicted to decrease the antihypertensive effects of guanethidine. Avoid and for 14 days after stopping the MAOI. [Severe] Theoretical → Also see TABLE 8 p. 1266
- Guanethidine increases the concentration of sympathomimetics, inotropic (dopamine). [Severe] Theoretical
- Guanethidine is predicted to increase the effects of sympathomimetics, vasoconstrictor (adrenaline/epinephrine, noradrenaline/norepinephrine). [Moderate] Study
- Guanethidine increases the effects of sympathomimetics, vasoconstrictor (phenylephrine). [Severe] Study
- Guanethidine increases the effects of sympathomimetics, vasoconstrictor (metaraminol). [Severe] Anecdotal
- Guanethidine increases the effects of sympathomimetics, vasoconstrictor (metaraminol). [Severe] Study → Also see TABLE 8 p. 1265
- Guanethidine → see TABLE 8 p. 1265 (hypotension), TABLE 11 p. 1266 (CNS depressant effects)
- Antiarrhythmics (dronedaron) are predicted to increase the concentration of guanfacine. Adjust guanfacine dose, p. 335. [Moderate] Theoretical

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the concentration of guanfacine. Adjust guanfacine dose, p. 335. [Moderate] Theoretical
- Antiepileptics (oxcarbazepine) are predicted to increase the concentration of guanfacine. Adjust guanfacine dose, p. 335. [Moderate] Study
- Aprepitant is predicted to increase the concentration of guanfacine. Adjust guanfacine dose, p. 335. [Moderate] Theoretical
- Bosentan is predicted to decrease the concentration of guanfacine. Adjust dose. [Moderate] Theoretical
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the concentration of guanfacine. Adjust guanfacine dose, p. 335. [Moderate] Theoretical → Also see TABLE 8 p. 1265
- Ciclosporin is predicted to increase the concentration of guanfacine. Adjust guanfacine dose, p. 335. [Moderate] Study
- Crizotinib is predicted to increase the concentration of guanfacine. Adjust guanfacine dose, p. 335. [Moderate] Theoretical
- Efavirenz is predicted to decrease the concentration of guanfacine. Adjust dose. [Moderate] Theoretical
Guanfacine — H₂ receptor antagonists

- **Enzalutamide** is predicted to decrease the concentration of guanfacine. Adjust guanfacine dose, p. 335. [Moderate] Study
- **Fosaprepitant** is predicted to increase the concentration of guanfacine. [Moderate] Theoretical
- **HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to increase the exposure to guanfacine. Adjust guanfacine dose, p. 335. [Moderate] Study
- **HIV-protease inhibitors (indinavir)** are predicted to increase the concentration of guanfacine. Adjust guanfacine dose, p. 335. [Moderate] Theoretical
- **Idelalisib** is predicted to increase the exposure to guanfacine. Adjust guanfacine dose, p. 335. [Moderate] Study
- **Imatinib** is predicted to increase the concentration of guanfacine. Adjust guanfacine dose, p. 335. [Moderate] Theoretical
- **Macrolides (clarithromycin)** are predicted to decrease the exposure to guanfacine. Adjust guanfacine dose, p. 335. [Moderate] Study
- **Macrolides (erythromycin)** are predicted to increase the concentration of guanfacine. Adjust guanfacine dose, p. 335. [Moderate] Theoretical
- **Netupitant** is predicted to increase the concentration of guanfacine. Adjust guanfacine dose, p. 335. [Moderate] Theoretical
- **Nevirapine** is predicted to decrease the concentration of guanfacine. Adjust dose. [Moderate] Theoretical
- **Nilotinib** is predicted to increase the concentration of guanfacine. Adjust guanfacine dose, p. 335. [Moderate] Theoretical
- **Rifampicin** is predicted to decrease the concentration of guanfacine. Adjust guanfacine dose, p. 335. [Moderate] Study
- **St John's Wort** is predicted to decrease the concentration of guanfacine. Adjust dose. [Moderate] Theoretical

**H₂ receptor antagonists**

- Cimetidine decreases the clearance of albendazole. [Moderate] Study
- Cimetidine decreases the concentration of aminophylline. Adjust dose. [Severe] Study
- Cimetidine slightly increases the exposure to anthracyclines (epirubicin). Avoid. [Moderate] Study
- Cimetidine increases the exposure to antihistamines (aminadorene). [Moderate] Study
- Cimetidine slightly increases the exposure to antihistamines (flecainide). Monitor and adjust dose. [Mild] Study
- Cimetidine increases the exposure to antihistamines (lidocaine). Monitor and adjust dose. [Moderate] Study
- Cimetidine is predicted to increase the exposure to antihistamines (propafenone). Monitor and adjust dose. [Moderate] Theoretical
- Cimetidine transiently increases the concentration of antiepileptics (carbamazepine). [Moderate] Study
- Cimetidine increases the concentration of antiepileptics (fosphenytoin). Monitor phenytoin concentration and adjust dose. [Severe] Study
- Cimetidine increases the concentration of antiepileptics (phenytoin). Monitor phenytoin concentration and adjust dose. [Severe] Study
- H₂ receptor antagonists are predicted to decrease the absorption of antifungals, azoles (itraconazole). Administer itraconazole capsules with an acidic beverage. [Moderate] Study
- H₂ receptor antagonists are predicted to decrease the absorption of antifungals, azoles (ketoconazole). Administer ketoconazole with an acidic beverage. [Moderate] Study
- H₂ receptor antagonists are predicted to slightly decrease the exposure to antifungals, azoles (posaconazole). Avoid use of posaconazole oral suspension. [Moderate] Study
- Cimetidine decreases the clearance of antimalarials (chloroquine). [Moderate] Study
- Cimetidine slightly increases the exposure to antimalarials (quinine). [Moderate] Study
- H₂ receptor antagonists are predicted to decrease the absorption of bosutinib. [Moderate] Theoretical
- Cimetidine slightly increases the exposure to calcium channel blockers (diltiazem, isradipine, nimodipine). Monitor and adjust dose. [Moderate] Study
- Cimetidine (high-dose) is predicted to increase the exposure to calcium channel blockers (lercanidipine). [Moderate] Theoretical
- Cimetidine moderately increases the exposure to calcium channel blockers (nifedipine). Monitor and adjust dose. [Severe] Study
- Cimetidine increases the exposure to calcium channel blockers (verapamil). [Moderate] Study
- Cimetidine is predicted to slightly increase the exposure to capcetibine. [Severe] Theoretical
- H₂ receptor antagonists are predicted to decrease the absorption of ceritinib. [Moderate] Theoretical
- Cimetidine increases the concentration of ciclosporin. [Mild] Study
- Cimetidine increases the anticoagulant effect of coumarins. [Severe] Study
- H₂ receptor antagonists are predicted to decrease the exposure to dabrafenib. Avoid. [Severe] Theoretical
- H₂ receptor antagonists are predicted to decrease the exposure to dasatinib. Avoid. [Moderate] Study
- H₂ receptor antagonists are predicted to decrease the absorption of dipridamole (immediate release tablets). [Moderate] Theoretical
- Cimetidine slightly increases the exposure to dopamine receptor antagonists (pramipexole). Adjust dose. [Moderate] Study
- H₂ receptor antagonists are predicted to decrease the effects of histamine. Avoid. [Severe] Theoretical
- H₂ receptor antagonists decrease the exposure to HIV-protease inhibitors (atazanavir). Monitor and adjust dose. [Moderate] Study
- Cimetidine is predicted to decrease the clearance of hydroxychloroquine. [Moderate] Theoretical
- H₂ receptor antagonists are predicted to decrease the absorption of lapatinib. Avoid. [Moderate] Theoretical
- H₂ receptor antagonists are predicted to decrease the exposure to ledipasvir. Adjust dose, see sofosbuvir with ledipasvir p. 596. [Moderate] Study
- H₂ receptor antagonists (cimetidine, ranitidine) are predicted to increase the exposure to lomitapide. Separate administration by 12 hours. [Moderate] Theoretical
- Lumacaftor is predicted to affect the exposure to ranitidine. Monitor and adjust dose. [Moderate] Theoretical
- Cimetidine slightly increases the exposure to macrolides (erythromycin). [Moderate] Study
- Cimetidine increases the concentration of mebendazole. [Moderate] Study
- Cimetidine slightly increases the exposure to metformin. Monitor and adjust dose. [Moderate] Study
- Cimetidine slightly increases the exposure to mirtazapine. Use with caution and adjust dose. [Moderate] Theoretical
- Cimetidine increases the exposure to moclubebide. Adjust moclubebide dose, p. 346. [Mild] Study
- H₂ receptor antagonists are predicted to decrease the absorption of nilotinib. H₂ receptor antagonists should be taken 10 hours before or 2 hours after nilotinib. [Mild] Theoretical
- Cimetidine increases the concentration of opioids (alfentanil). Use with caution and adjust dose. [Severe] Study
- Cimetidine increases the exposure to opioids (fentanyl). [Moderate] Study
- H₂ receptor antagonists are predicted to decrease the exposure to pazopanib. H₂ receptor antagonists should be taken 10 hours before or 2 hours after pazopanib. [Moderate] Theoretical
- Cimetidine increases the exposure to phenindione. [Severe] Anecdotal
- Cimetidine moderately increases the exposure to praziquantel. [Moderate] Study
H₂ receptor antagonists (continued)

- H₂ receptor antagonists are predicted to decrease the exposure to rifampirin. H₂ receptor antagonists should be taken 12 hours before or 4 hours after rifampirin. [Severe] Study
- Cimetidine slightly increases the exposure to rofumilast. [Moderate] Study
- H₂ receptor antagonists potentially decrease the exposure to sofosbuvir. Adjust dose, see sofosbuvir with ledipasvir and sofosbuvir with velpatasvir p. 596. [Moderate] Study
- Cimetidine slightly increases the exposure to SSRI (citalopram, escitalopram). Adjust dose. [Moderate] Study
- Cimetidine slightly increases the exposure to SSRI (paroxetine, sertraline). [Moderate] Study
- Cimetidine is predicted to increase the risk of toxicity when given with abacavir. [Severe] Theoretical
- Cimetidine increases the concentration of theophylline. Adjust dose. [Severe] Study
- Cimetidine increases the exposure to tricyclic antidepressants. [Moderate] Study
- Haloperidol are predicted to decrease the concentration of velpatasvir. Adjust dose, see sofosbuvir with velpatasvir p. 596. [Moderate] Study
- Cimetidine slightly increases the exposure to venlafaxine. [Mild] Study
- Cimetidine slightly increases the exposure to zolmitriptan. Adjust zolmitriptan dose, p. 456. [Mild] Study

**Haloperidol** → see TABLE 8 p. 1265 (hypotension), TABLE 9 p. 1266 (QT interval prolongation), TABLE 10 p. 1266 (CNS depressant effects), TABLE 10 p. 1266 (antimuscarinics)

**FOOD AND LIFESTYLE** Dose adjustment might be necessary if smoking started or stopped during treatment.

- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) decrease the concentration of haloperidol. Adjust dose. [Moderate] Study → also see TABLE 11 p. 1266
- Haloperidol potentially increases the risk of overheating and dehydration when given with antiepileptics (zonisamide). Avoid in children. [Severe] Theoretical
- Antifungals, azoles (itraconazole) increase the concentration of haloperidol. [Moderate] Study
- Haloperidol is predicted to decrease the effects of dopamine receptor agonists. Avoid. [Moderate] Theoretical → also see TABLE 8 p. 1265 → also see TABLE 9 p. 1266 → also see TABLE 10 p. 1266
- Enzalutamide decreases the concentration of haloperidol. Adjust dose. [Moderate] Study
- Haloperidol is predicted to decrease the antihypertensive effects of guanethidine. Monitor and adjust dose. [Moderate] Theoretical → also see TABLE 8 p. 1265
- HIV-protease inhibitors (ritonavir) are predicted to increase the exposure to haloperidol. [Severe] Theoretical
- Haloperidol decreases the effects of levodopa. [Severe] Study → also see TABLE 8 p. 1265
- Rifampicin decreases the concentration of haloperidol. Adjust dose. [Moderate] Study
- Haloperidol is predicted to decrease the antihypertensive effects of sodium phenytoibutyrate. [Moderate] Anecdotal
- SSRIs (fluoxetine) increase the concentration of haloperidol. Adjust dose. [Moderate] Anecdotal
- SSRIs (fluvoxamine) increase the concentration of haloperidol. Adjust dose. [Moderate] Study
- Venlafaxine slightly increases the exposure to haloperidol. [Severe] Study → also see TABLE 9 p. 1266 → also see TABLE 11 p. 1266

**Heparin (unfractionated)** → see TABLE 16 p. 1268 (increased serum potassium), TABLE 3 p. 1264 (anticoagulant effects)
- Ranibizumab increases the risk of bleeding events when given with heparin (unfractionated). [Severe] Theoretical

**Histamine** → see TABLE 8 p. 1265 (hypotension)

- Antihistamines, non-sedating are predicted to decrease the effects of histamine. Avoid. [Severe] Theoretical
- Antihistamines, sedating are predicted to decrease the effects of histamine. Avoid. [Severe] Theoretical
- Antimalarials (artemether, atovaquone, chloroquine, mefloquine, primaquine, proguaoin, pyrimethamine, quinine) are predicted to affect the exposure to histamine. Avoid. [Severe] Theoretical
- Clonidine is predicted to decrease the effects of histamine. Avoid. [Severe] Theoretical → also see TABLE 8 p. 1265
- Clozapine is predicted to decrease the effects of histamine. Avoid. [Severe] Theoretical → also see TABLE 8 p. 1265
- Corticosteroids are predicted to decrease the effects of histamine. Avoid. [Severe] Theoretical
- H₂ receptor antagonists are predicted to decrease the effects of histamine. Avoid. [Severe] Theoretical
- Monoamine-oxidase A and B inhibitors, irreversible are predicted to affect the exposure to histamine. Avoid. [Severe] Theoretical → also see TABLE 8 p. 1265
- Olanzapine is predicted to decrease the effects of histamine. Avoid. [Severe] Theoretical → also see TABLE 8 p. 1265
- Phenothiazines are predicted to decrease the effects of histamine. Avoid. [Severe] Theoretical → also see TABLE 8 p. 1265
- Quetiapine is predicted to decrease the effects of histamine. Avoid. [Severe] Theoretical → also see TABLE 8 p. 1265
- Risperidone is predicted to decrease the effects of histamine. Avoid. [Severe] Theoretical → also see TABLE 8 p. 1265
- Tricyclic antidepressants are predicted to decrease the effects of histamine. Avoid. [Severe] Theoretical → also see TABLE 8 p. 1265
- Zuclopenthixol is predicted to decrease the effects of histamine. Avoid. [Severe] Theoretical → also see TABLE 8 p. 1265

**HIV-protease inhibitors** → see TABLE 9 p. 1266 (QT-interval prolongation)

- atazanavir - darunavir - fosamprenavir - indinavir - lopinavir - ritonavir - saquinavir - tipranavir

- Caution on concurrent use of atazanavir, lopinavir with ritonavir, or ritonavir with drugs that prolong the PR interval.
- Concurrent use of saquinavir with drugs that prolong the PR interval is contra-indicated.
- Caution with concurrent use of tipranavir with drugs that increase risk of bleeding.

- Tipranavir slightly decreases the exposure to abacavir. Avoid. [Severe] Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to abiraterone. [Severe] Theoretical
- HIV-protease inhibitors (lopinavir, ritonavir, saquinavir) are predicted to increase the exposure to amlodipine. Separate administration by 12 hours. [Moderate] Study
- Ritonavir is predicted to decrease the exposure to agomelatine. [Moderate] Theoretical
- Ritonavir decreases the exposure to albendazole. [Moderate] Study
- Indinavir is predicted to increase the exposure to aldosterone antagonists (eplerenone). Adjust eplerenone dose, p. 185. [Severe] Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to markedly increase the exposure to aldosterone antagonists (eplerenone). Avoid. [Severe] Study
- HIV-protease inhibitors (ritonavir, saquinavir) are predicted to increase the exposure to aliskiren. [Moderate] Theoretical
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) increase the exposure to almitrine. [Mild] Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to moderately increase the exposure to alpha blockers (alfuzosin, tamsulosin). Use with caution or avoid. [Moderate] Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to alpha blockers (doxazosin). [Moderate] Study
- Indinavir is predicted to increase the exposure to alpha blockers (tamsulosin). [Moderate] Theoretical
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to moderately increase the exposure to alprazolam. Avoid. [Moderate] Study
- Indinavir is predicted to increase the exposure to alprazolam. [Severe] Study
HIV-protease inhibitors (ritonavir, tipranavir) are predicted to increase the exposure to amfetamines. **Severe** Theoretical

- **Ritonavir** decreases the exposure to aminophylline. Adjust dose. **Moderate** Study

- **Antacids** are predicted to decrease the absorption of atazanavir. **Severe** Theoretical

- **HIV-protease inhibitors** are predicted to increase the exposure to antifungals (azoles, fluconazole). Use with caution and adjust dose. **Moderate** Study

- **Indinavir** is predicted to increase the exposure to antifungals (valproate). **Severe** Anecdotal

- Antifungals, azoles (fluconazole) slightly increase the exposure to tipranavir. Avoid or adjust dose. **Moderate** Study

- **HIV-protease inhibitors** are predicted to increase the concentration of HIV-protease inhibitors. **Severe** Theoretical

- **Ritonavir** is predicted to decrease the absorption of tipranavir. **Severely** Theoretical

- **HIV-protease inhibitors** are predicted to increase the exposure to antifungals (azoles, ketoconazole). Use with caution and adjust dose. **Moderate** Study

- **HIV-protease inhibitors** are predicted to increase the exposure to antifungals, azoles (voriconazole) and antifungals, azoles (itraconazole) potentially affect the exposure to HIV-protease inhibitors. **Severe** Study → Also see **TABLE 9** p. 1266

- **Indinavir** is predicted to increase the exposure to antihistamines, non-sedating (mizolastine). **Severe** Theoretical

- **HIV-protease inhibitors** (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to antimalarials (mefloquine) with lumefantrine. **Moderate** Study → Also see **TABLE 9** p. 1266

- **HIV-protease inhibitors** decrease the exposure to antimalarials (atovaquone). Avoid if boosted with ritonavir. **Moderate** Study

- **HIV-protease inhibitors** are predicted to increase the concentration of antimalarials (piperaquine). **Severe** Theoretical

- **HIV-protease inhibitors** are predicted to decrease the exposure to antimalarials (proguanil). **Avoid**. **Moderate** Study

- **HIV-protease inhibitors** are predicted to affect the exposure to antimalarials (quinine). **Severe** Study → Also see **TABLE 9** p. 1266

- **Ritonavir** is predicted to increase the exposure to apixaban. **Avoid**. **Severe** Theoretical

- **HIV-protease inhibitors** (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to affect the exposure to antiepileptics (carbamazepine) and antiepileptics (carbamazepine) are predicted to decrease the exposure to HIV-protease inhibitors. **Moderate** Theoretical

- **HIV-protease inhibitors** are predicted to affect the exposure to antiepileptics (fosphenytoin, phenytoin) and antiepileptics (fosphenytoin, phenytoin) decrease the concentration of HIV-protease inhibitors. **Severe** Theoretical

- **Ritonavir** slightly decreases the exposure to antiepileptics (lamotrigine). **Severe** Study

- **HIV-protease inhibitors** (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to slightly increase the exposure to antiepileptics (perampanel). **Mild** Study

- **HIV-protease inhibitors** are predicted to affect the concentration of antiepileptics (phenobarbital, primidone) and antiepileptics (phenobarbital, primidone) are predicted to decrease the concentration of HIV-protease inhibitors. **Severe** Theoretical

- **Ritonavir** is predicted to decrease the concentration of antiepileptics (valproate). **Severe** Anecdotal

- **Antifungals, azoles (fluconazole)** slightly increase the exposure to tipranavir. Avoid or adjust dose. **Moderate** Study

- **Antifungals, azoles (miconazole)** are predicted to increase the concentration of HIV-protease inhibitors. Use with caution and adjust dose. **Moderate** Theoretical

- **Antifungals, azoles (posaconazole)** are predicted to increase the exposure to HIV-protease inhibitors. **Moderate** Study

- **HIV-protease inhibitors** (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to antifungals, azoles (isavuconazole). Avoid or monitor side effects. **Severe** Study

- **HIV-protease inhibitors** are predicted to increase the exposure to antifungals, azoles (itraconazole). Use with caution and adjust dose. **Moderate** Study

- **HIV-protease inhibitors** are predicted to increase the exposure to antifungals, azoles (ketoconazole). Use with caution and adjust dose. **Moderate** Study

- **HIV-protease inhibitors** are predicted to increase the exposure to antifungals, azoles (voriconazole) and antifungals, azoles (itraconazole) are predicted to increase the exposure to antifungals, azoles (isavuconazole). Avoid or monitor side effects. **Severe** Study
HIV-protease inhibitors (continued)

- Indinavir is predicted to increase the exposure to cobicistat.  [Moderate] Study
- Ritonavir is predicted to moderately increase the clearance of cobicistat. Monitor and adjust dose.  [Moderate] Study
- HIV-protease inhibitors are predicted to increase the exposure to calcium channel blockers (amlodipine, felodipine, isradipine, lacidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose.  [Moderate] Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to calcium channel blockers (eriocandine). Avoid.  [Severe] Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to markedly increase the exposure to calcium channel blockers (eriocandine). Avoid.  [Severe] Study

Modular protease inhibitors increase the concentration of ciclosporin.  [Severe] Study

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to ciclosporin. Adjust ciclosporin dose, p. 1020.  [Severe] Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to markedly increase the exposure to ciclosporin. Adjust ciclosporin dose.  [Moderate] Study
- Indinavir is predicted to increase the exposure to ciclosporin. Avoid.  [Severe] Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to markedly increase the exposure to ciclosporin. Avoid or monitor for toxicity.  [Severe] Study
- Indinavir is predicted to increase the exposure to cobicistat. Avoid.  [Moderate] Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to markedly increase the exposure to cobicistat. Avoid or monitor for toxicity.  [Severe] Study
- Indinavir is predicted to increase the exposure to cobicistat. Avoid.  [Severe] Study
- Atazanavir (unboosted) increases the exposure to combined hormonal contraceptives. Adjust dose.  [Severe] Study
- Ritonavir is predicted to decrease the efficacy of combined hormonal contraceptives. For FSRH guidance, see Contraceptives, interactions p. 747.  [Severe] Study
- Ritonavir is predicted to increase the concentration of corticosteroids (beclometasone) (risk with beclometasone is likely to be lower than with other corticosteroids). MHRA advises avoid or monitor for beclometasone side effects.  [Moderate] Study
- Ritonavir is predicted to increase the concentration of corticosteroids (betamethasone, budesonide, deflazacort, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone). MHRA advises avoid or monitor for beclometasone side effects.  [Moderate] Study
- Ritonavir is predicted to increase the concentration of corticosteroids (budesonide). MHRA advises avoid or monitor side effects and consider beclometasone as an alternative.  [Severe] Study

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, saquinavir, tipranavir) are predicted to increase the exposure to corticosteroids (budesonide). Avoid.  [Severe] Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to corticosteroids (budesonide). Avoid.  [Severe] Study
- Indinavir is predicted to increase the exposure to corticosteroids (ciclesonide). Avoid.  [Moderate] Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, saquinavir, tipranavir) are predicted to increase the exposure to corticosteroids (dexamethasone, methylprednisolone). Monitor and adjust dose.  [Moderate] Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to corticosteroids (fluticasone).  [Severe] Study
- Indinavir is predicted to increase the exposure to corticosteroids (methylprednisolone). Monitor and adjust dose.  [Moderate] Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to corticosteroids (mometasone).  [Moderate] Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, saquinavir, tipranavir) are predicted to increase the risk of side-effects when given with corticosteroids (triamcinolone).  [Severe] Study
- HIV-protease inhibitors are predicted to affect the anticoagulant effect of coumarins.  [Moderate] Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to moderately increase the exposure to dabrafenib. Use with caution or avoid.  [Moderate] Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to moderately increase the exposure to dabrafenib. Adjust dabrafenib dose, p. 591.  [Moderate] Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to markedly increase the exposure to dabrafenib. Adjust dabrafenib dose, p. 591.  [Moderate] Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to markedly increase the exposure to dabrafenib. Adjust dabrafenib dose.  [Moderate] Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to markedly increase the exposure to dabrafenib. Adjust dabrafenib dose.  [Moderate] Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to markedly increase the exposure to dabrafenib. Adjust dabrafenib dose.  [Moderate] Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) very slightly increase the exposure to delamanid.  [Severe] Study
- Ritonavir is predicted to decrease the efficacy of desogestrel. For FSRH guidance, see Contraceptives, interactions p. 747.  [Severe] Study
- Ritonavir is predicted to increase the exposure to diazepam. Avoid.  [Moderate] Study
- Didanosine (buffered) decreases the exposure to atazanavir. Didanosine should be taken 2 hours after atazanavir.  [Severe] Study
- Didanosine (buffered) is predicted to decrease the exposure to darunavir (boosted with ritonavir). Didanosine should be taken 1 hour before or 2 hours after darunavir.  [Moderate] Study
- Didanosine (buffered) decreases the exposure to indinavir. Separate administration by 1 hour.  [Severe] Study
- Tipranavir decreases the exposure to didanosine. Separate administration by 2 hours.  [Moderate] Study
- Ritonavir increases the concentration of digoxin. Adjust dose and monitor concentration.  [Severe] Study

HIV-protease inhibitors — HIV-protease inhibitors

BNF 74

A1
HIV-protease inhibitors — HIV-protease inhibitors

- **Fosamprenavir** (boosted with ritonavir) slightly decreases the exposure to **dolutegravir**. Avoid if resistant to HIV-integrase inhibitors. [Severe] Study

- **Tipranavir** moderately decreases the exposure to **dolutegravir**. Refer to specialist literature. [Severe] Study

- HIV-protease inhibitors increase the risk of QT-prolongation when given with **dopemidine**. Avoid. [Severe] Study

- **Indinavir** is predicted to increase the exposure to dopamine receptor agonists **(bromocriptine, cabergoline)**. [Severe] Theoretical

- HIV-protease inhibitors **(atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** increase the exposure to dopamine receptor agonists **(bromocriptine, cabergoline)**. [Severe] Study

- HIV-protease inhibitors **(atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to increase the exposure to **elbasvir**. Avoid. [Moderate] Study

- HIV-protease inhibitors **(atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to markedly increase the exposure to **elvitegravir**. Avoid. [Severe] Study

- **Atazanavir** increases the concentration of **elvitegravir**. Refer to specialist literature. [Moderate] Study

- **Lopinavir** increases the concentration of **elvitegravir**. Refer to specialist literature. [Moderate] Study

- HIV-protease inhibitors **(atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to increase the risk of ergotism when given with **ergotamine**. Avoid. [Severe] Study

- **Indinavir** is predicted to increase the risk of ergotism when given with **ergotamine**. [Severe] Theoretical

- HIV-protease inhibitors **(atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to increase the risk of ergotism when given with **ergotamine**. Avoid. [Severe] Theoretical

- **Indinavir** is predicted to increase the risk of ergotism when given with **ergotamine**. [Severe] Theoretical

- HIV-protease inhibitors **(atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to increase the risk of ergotism when given with **ergotamine**. Avoid. [Severe] Theoretical

- **Indinavir** is predicted to increase the risk of ergotism when given with **ergotamine**. [Severe] Theoretical

- HIV-protease inhibitors **(atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to increase the risk of ergotism when given with **ergotamine**. Avoid. [Severe] Study

- **Indinavir** is predicted to increase the exposure to **erlotinib**. [Moderate] Theoretical

- **Ritonavir** is predicted to decrease the efficacy of **etanercept**. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Study

- **Etravirine** increases the exposure to **fosamprenavir** (boosted with ritonavir). Refer to specialist literature. [Moderate] Study

- **Etravirine** is predicted to decrease the exposure to **indinavir**. [Moderate] Study

- **Tipranavir** decreases the exposure to **etravirine**. Avoid. [Severe] Study

- HIV-protease inhibitors **(atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to increase the concentration of **everolimus**. Avoid. [Severe] Study

- **Indinavir** is predicted to increase the concentration of **everolimus**. Avoid or adjust dose. [Moderate] Study

- HIV-protease inhibitors **(atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to moderately increase the exposure to **fesoterodine**. Adjust **fesoterodine** dose; avoid in hepatic and renal impairment, p. 732. [Severe] Study

- **Indinavir** is predicted to increase the exposure to **fesoterodine**. Adjust **fesoterodine** dose in hepatic and renal impairment, p. 732. [Mild] Study

- HIV-protease inhibitors **(lopinavir, ritonavir, saquinavir)** are predicted to increase the exposure to **fidaxomycin**. Avoid. [Severe] Study

- **Ritonavir** is predicted to increase the exposure to **flurazepam**. Avoid. [Moderate] Theoretical

- HIV-protease inhibitors **(atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to increase the exposure to **fosaprepitant**. [Moderate] Theoretical

- HIV-protease inhibitors **(atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to increase the exposure to **gefitinib**. [Moderate] Study

- **Indinavir** is predicted to increase the exposure to **gefitinib**. [Moderate] Theoretical

- HIV-protease inhibitors **(atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to moderately to markedly increase the exposure to **grazoprevir**. Avoid. [Severe] Study

- HIV-protease inhibitors **(atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to increase the exposure to **guanfacine**. Adjust **guanfacine** dose, p. 335. [Moderate] Study

- **Indinavir** is predicted to increase the concentration of **guanfacine**. Adjust **guanfacine** dose, p. 335. [Moderate] Theoretical

- **H₂ receptor antagonists** decrease the exposure to **atazanavir**. Monitor and adjust dose. [Moderate] Study

- **Ritonavir** is predicted to increase the exposure to **haloperidol**. [Severe] Theoretical

- **Ritonavir** is predicted to decrease the effects of **Hormone replacement therapy**. [Moderate] Anecdotal

- HIV-protease inhibitors **(atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to very markedly increase the exposure to **ibrutinib**. Avoid or adjust **ibrutinib** dose, p. 902. [Severe] Study

- **Indinavir** is predicted to increase the exposure to **ibrutinib**. Avoid or adjust **ibrutinib** dose, p. 902. [Severe] Theoretical

- HIV-protease inhibitors **(atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to increase the exposure to **imatinib**. [Moderate] Study

- HIV-protease inhibitors **(atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to increase the risk of toxicity when given with **irinotecan**. Avoid. [Moderate] Study

- **Ritonavir** is predicted to decrease the exposure to **iron chelators** (deferasirox). Monitor serum ferritin and adjust dose. [Moderate] Theoretical

- HIV-protease inhibitors **(atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to increase the exposure to **ivacaftor**. Adjust **ivacaftor** or lumacaftor with ivacaftor dose, p. 281. [Severe] Study

- **Indinavir** is predicted to increase the exposure to **ivacaftor**. Adjust **ivacaftor** dose, p. 281. [Severe] Study

- HIV-protease inhibitors **(atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to increase the exposure to **ivabradine**. Avoid. [Severe] Study

- **Indinavir** increases the exposure to **ivabradine**. Adjust dose. [Severe] Theoretical

- HIV-protease inhibitors **(atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to increase the exposure to **ivacaftror** or lumacaftor with ivacaftor dose. Also see TABLE 9 p. 1266

- **Indinavir** is predicted to increase the exposure to **lapiatinib**. [Moderate] Study

- **Ritonavir** is predicted to decrease the efficacy of **levonorgestrel**. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical

- HIV-protease inhibitors **(atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to increase the exposure to **lapiatinib**. Avoid. [Moderate] Study

- **Indinavir** is predicted to increase the exposure to **lapiatinib**. Avoid. [Moderate] Theoretical

- **Ritonavir** is predicted to decrease the efficacy of **levonorgestrel**. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical

- HIV-protease inhibitors **(atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to moderately increase the exposure to **lomitapide**. Avoid. [Severe] Study

- **Indinavir** is predicted to increase the exposure to **lomitapide**. Avoid. [Moderate] Theoretical

Downloaded from www.medicalbr.com on 2023-11-25.
HIV-protease inhibitors (continued)

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to lurasidone. Avoid. [Severe] Study

- Indinavir is predicted to increase the exposure to lurasidone. [Moderate] Study

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to macitentan. [Moderate] Study

- Macrolides (clarithromycin) increase the exposure to saquinavir and saquinavir increases the exposure to macrolides (clarithromycin). Avoid. [Severe] Study → Also see TABLE 9 p. 1266

- Macrolides (erythromycin) are predicted to increase the exposure to saquinavir. Avoid. [Severe] Theoretical

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir) increase the exposure to maraviroc. Refer to specialist literature. [Severe] Study

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to midazolam. Avoid or adjust midazolam dose. [Severe] Study

- Indinavir is predicted to increase the exposure to midazolam. Monitor side effects and adjust dose. [Severe] Study

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to mirabegron. Adjust mirabegron dose in hepatic and renal impairment, p. 736. [Moderate] Study

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to mirtazapine. [Moderate] Study

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to modafinil. [Mild] Theoretical

- HIV-protease inhibitors (lopinavir, ritonavir, saquinavir) are predicted to increase the risk of neutropenia when given with monoclonal antibodies (brentuximab vedotin). Monitor and adjust dose. [Severe] Study

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to monoclonal antibodies (trastuzumab emtansine). Avoid. [Severe] Theoretical

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to markedly increase the exposure to naxolegol. Avoid. [Severe] Study

- Indinavir is predicted to increase the exposure to naxolegol. Adjust naxolegol dose and monitor side effects, p. 63. [Mild] Study

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to netupitant. [Mild] Study

- Nevirapine decreases the exposure to HIV-protease inhibitors. Refer to specialist literature. [Moderate] Study

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to moderately increase the exposure to nilotinib. Avoid. [Severe] Study → Also see TABLE 9 p. 1266

- HIV-protease inhibitors (lopinavir, ritonavir, saquinavir) are predicted to increase the exposure to nintedanib. [Moderate] Study

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to nitisine. Adjust nitisine dose. [Moderate] Theoretical

- Ritonavir is predicted to decrease the efficacy of norethisterone. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Anecdotal

- Ritonavir moderately decreases the exposure to olanzapine. [Moderate] Study

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to olaparib. Avoid or adjust olaparib dose, p. 919. [Moderate] Study

- Indinavir is predicted to increase the exposure to olaparib. Avoid or adjust olaparib dose, p. 919. [Moderate] Theoretical

- Indinavir is predicted to increase the exposure to opioids (alfentanil, buprenorphine, fentanyl, oxycodone). Monitor and adjust dose. [Moderate] Study

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to opioids (alfentanil, buprenorphine, fentanyl, oxycodone, sufentanil). Monitor and adjust dose. [Severe] Study

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to opioids (methadone). [Mild] Study

- Indinavir is predicted to increase the exposure to opioids (morphine). [Moderate] Theoretical

- Ritonavir is predicted to decrease the concentration of opioids (morphine). [Moderate] Theoretical

- Ritonavir increases the risk of CNS toxicity when given with opioids (pethidine). Avoid. [Severe] Study

- Ritonavir is predicted to decrease the efficacy of opioids (tramadol). [Moderate] Study

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to oxycodyn. [Mild] Study

- Indinavir is predicted to increase the exposure to oxycodyn. [Mild] Theoretical

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to palbociclib. Avoid or adjust palbociclib dose, p. 909. [Severe] Study

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to panobinostat. Adjust panobinostat dose; in hepatic impairment avoid, p. 864. [Moderate] Study → Also see TABLE 9 p. 1266

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to paritaprevir with ritonavir and ombitasvir. Avoid. [Severe] Theoretical

- Indinavir potentially increases the exposure to paritaprevir. Avoid. [Severe] Theoretical

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to pazopanib. Avoid or adjust pazopanib dose, p. 909. [Moderate] Study → Also see TABLE 9 p. 1266

- Indinavir is predicted to increase the exposure to pazopanib. [Moderate] Theoretical

- Indinavir is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (avanafil). Adjust avanafil dose, p. 785. [Moderate] Theoretical

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to phosphodiesterase type-5 inhibitors (avanafil, vardenafil). Avoid. [Severe] Study → Also see TABLE 9 p. 1266

- Indinavir is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (sildenafil). Monitor and adjust sildenafil dose, p. 766. [Moderate] Study

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to phosphodiesterase type-5 inhibitors (sildenafil). Avoid or adjust sildenafil dose, p. 766. [Severe] Study → Also see TABLE 9 p. 1266

- Indinavir is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (tadalafil). [Severe] Theoretical
HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to phosphodiesterase type-5 inhibitors (tadalafil). Use with caution or avoid. (Severe) Study

Indinavir is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (vardenafil). Adjust dose. (Severe) Theoretical

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to pimozide. Avoid. (Severe) Study  Also see TABLE 9 p. 1266

Indinavir is predicted to increase the exposure to pimozide. Avoid. (Severe) Theoretical

Ritonavir is predicted to decrease the exposure to pirfenidone. Avoid. (Moderate) Theoretical

Ritonavir is predicted to increase the exposure to pitolisant. Use with caution and adjust dose. (Moderate) Study

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to slightly increase the exposure to ponatinib. Monitor and adjust ponatinib dose. (Moderate) Study

Ritonavir is predicted to increase the exposure to raltegravir. (Moderate) Study

Fosamprenavir (boosted with ritonavir) decreases the exposure to raltegravir and raltegravir decreases the exposure to fosamprenavir (boosted with ritonavir). Avoid. (Severe) Study

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to quetiapine. Avoid. (Severe) Study

Indinavir is predicted to increase the exposure to quetiapine. Avoid. (Moderate) Study

Darunavir increases the risk of rash when given with raltegravir. (Moderate) Study

Fosamprenavir (boosted with ritonavir) decreases the exposure to raltegravir and raltegravir decreases the exposure to fosamprenavir (boosted with ritonavir). Avoid. (Severe) Study

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to ranolazine. Avoid. (Severe) Study  Also see TABLE 9 p. 1266

Indinavir is predicted to increase the exposure to ranolazine. (Severe) Study

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to reboxetine. Avoid. (Moderate) Study

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to regorafenib. Avoid. (Moderate) Study

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to repaglinide. (Moderate) Study

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to retinooids (alitretinoin). Adjust alitretinoin dose, p. 1557. (Moderate) Theoretical

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, saquinavir, tipranavir) increase the exposure to rifabutin. Monitor and adjust dose. (Severe) Study

Indinavir increases the exposure to rifabutin and rifabutin decreases the exposure to indinavir. Avoid. (Severe) Study

Ritonavir markedly increases the exposure to rifabutin. Avoid or adjust dose. (Severe) Study

Rifampicin is predicted to moderately to markedly decrease the exposure to HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir). Avoid. (Severe) Study

Rifampicin slightly decreases the exposure to ritonavir. Avoid. (Moderate) Theoretical

Ritonavir is predicted to increase the exposure to riociguat. Avoid. (Severe) Study

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to risperidone. Adjust dose. (Moderate) Study  Also see TABLE 9 p. 1266

Ritonavir moderately increases the exposure to rivaroxaban. Avoid. (Severe) Study

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to ruxolitinib. Adjust dose and monitor side effects. (Moderate) Study

Indinavir is predicted to increase the exposure to ruxolitinib. (Moderate) Theoretical

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to simeprevir. Avoid. (Severe) Study

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the concentration of sirolimus. Avoid. (Severe) Study

Indinavir increases the concentration of sirolimus. Monitor and adjust dose. (Moderate) Study

Tipranavir is predicted to decrease the exposure to sofosbuvir. Avoid. (Severe) Theoretical

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to solifenacin. Adjust solifenacin or tamsulosin with solifenacin dose; avoid in hepatic and renal impairment, p. 734, p. 740. (Severe) Study

Indinavir is predicted to increase the exposure to SSI Rs. (dapoxetine). Adjust dapoxetine dose, p. 773. (Moderate) Theoretical

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to SSI Rs. (dopoxetine). Avoid, or adjust dapoxetine dose, p. 773. (Severe) Study

St John’s Wort is predicted to decrease the exposure to HIV-protease inhibitors. Avoid. (Severe) Study

Indinavir is predicted to increase the exposure to statins (atorvastatin). Monitor and adjust dose. (Severe) Theoretical

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to statins (atorvastatin). Avoid or adjust dose and monitor rhabdomyolysis. (Severe) Study

HIV-protease inhibitors slightly to moderately increase the exposure to statins (rosuvastatin). Avoid or adjust dose. (Severe) Study

Indinavir is predicted to increase the exposure to statins (simvastatin). Use with caution and adjust simvastatin dose, p. 198. (Severe) Study

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to statins (simvastatin). Avoid or adjust dose and monitor rhabdomyolysis. (Severe) Study

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to statins (simvastatin). Avoid. (Severe) Study

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to slightly increase the exposure to sunitinib. Avoid or adjust sunitinib dose, p. 914. (Moderate) Study  Also see TABLE 9 p. 1266

Indinavir is predicted to increase the exposure to sunitinib. (Moderate) Theoretical

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the concentration of tacrolimus. Monitor and adjust dose. (Severe) Study

Indinavir is predicted to increase the concentration of tacrolimus. (Severe) Study

Indinavir is predicted to increase the exposure to taxanes (cabazitaxel). (Moderate) Theoretical

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to taxanes (cabazitaxel). Avoid. (Severe) Study

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to
HIV-protease inhibitors (continued) moderately increase the exposure to taxanes (docetaxel). Avoid or adjust dose. (Severe) Study

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to taxanes (paclitaxel). (Severe) Theoretical

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the concentration of temsirolimus. Avoid. (Severe) Theoretical

- Indinavir is predicted to increase the concentration of temsirolimus. (Moderate) Theoretical

- Ritonavir is predicted to decrease the exposure to theophylline. Adjust dose. (Moderate) Study

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to markedly increase the exposure to ticagrelor. Avoid. (Severe) Study

- Ritonavir moderately decreases the exposure to tizanidine. (Mild) Study

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to tolterodine. Avoid. (Severe) Study Also see TABLE 9 p. 1266

- Indinavir is predicted to increase the exposure to tolterodine. Adjust dose. (Mild) Study

- HIV-protease inhibitors (lopinavir, ritonavir, saquinavir) are predicted to increase the exposure to troleifene. (Moderate) Theoretical Also see TABLE 9 p. 1266

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to trabectedin. Avoid or adjust dose. (Severe) Study

- HIV-protease inhibitors (lopinavir, ritonavir, saquinavir) are predicted to increase the concentration of trametinib. (Moderate) Theoretical

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to moderately increase the exposure to trazodone. Avoid or adjust dose. (Moderate) Study

- Indinavir is predicted to increase the exposure to trazodone. (Moderate) Theoretical

- HIV-protease inhibitors (ritonavir, tipranavir) are predicted to increase the exposure to trycyclic antidepressants. (Moderate) Theoretical

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to ulipristal. Avoid if used for uterine fibroids. (Severe) Study

- Indinavir is predicted to increase the exposure to ulipristal. Avoid if used for uterine fibroids. (Moderate) Study

- Ritonavir decreases the efficacy of ulipristal. For FSRH guidance, see Contraceptives, interactions p. 747. (Severe) Aneodctal

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to vemurafenib. (Severe) Theoretical Also see TABLE 9 p. 1266

- HIV-protease inhibitors are predicted to increase the exposure to venoconax. Avoid or adjust venoconax dose, p. 919. (Severe) Study

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to venlafaxine. (Moderate) Study Also see TABLE 9 p. 1266

- HIV-protease inhibitors are predicted to increase the exposure to vinca alkaloids. (Severe) Theoretical Also see TABLE 9 p. 1266

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to vitamin D substances (paricalcitol). (Moderate) Study

- Tipranavir slightly decreases the exposure to zidovudine. Avoid. (Moderate) Study

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to zopiclone. Adjust dose. (Moderate) Theoretical

- Indinavir is predicted to increase the exposure to zopiclone. Adjust dose. (Moderate) Study

Hormone replacement therapy

- Antiepileptics (carbamazepine, felbamate, lamotrigine, fosphenytoin, oxcarbazepine, perampanel, pheonobarbital, phenytoin, primidone, rufinamide, topiramate) are predicted to decrease the effects of Hormone replacement therapy. (Moderate) Aneodctal

- Hormone replacement therapy is predicted to alter the exposure to antiepileptics (lamotrigine). (Moderate) Theoretical

- Aprepitant is predicted to decrease the effects of Hormone replacement therapy. (Moderate) Aneodctal

- Bosentan is predicted to decrease the effects of Hormone replacement therapy. (Moderate) Aneodctal

- Hormone replacement therapy decreases the clearance of dopamine receptor agonists (ropinirole). Monitor and adjust dose. (Moderate) Study

- Efavirenz is predicted to decrease the effects of Hormone replacement therapy. (Moderate) Aneodctal

- Fosaprepitant is predicted to decrease the effects of Hormone replacement therapy. (Moderate) Aneodctal

- HIV-protease inhibitors (ritonavir) are predicted to decrease the effects of Hormone replacement therapy. (Moderate) Aneodctal

- Hormone replacement therapy is predicted to increase the risk of venous thromboembolism when given with lenalidomide. (Severe) Theoretical

- Oral Hormone replacement therapy is predicted to decrease the effects of levothyroxine. (Moderate) Theoretical

- Oral Hormone replacement therapy is predicted to decrease the effects of lithium. (Moderate) Theoretical

- Modafinil is predicted to decrease the effects of Hormone replacement therapy. (Moderate) Aneodctal

- Hormone replacement therapy is predicted to increase the risk of venous thromboembolism when given with pomalidomide. (Severe) Theoretical

- Rifabutin is predicted to decrease the effects of Hormone replacement therapy. (Moderate) Aneodctal

- Rifampicin is predicted to decrease the effects of Hormone replacement therapy. (Moderate) Aneodctal

- St John's Wort is predicted to decrease the efficacy of Hormone replacement therapy. (Moderate) Theoretical

- Hormone replacement therapy is predicted to increase the risk of venous thromboembolism when given with thalidomide. (Severe) Theoretical

- Hydralazine → see TABLE 8 p. 1265 (hypotension)

- Diazoxide increases the risk of severe hypotension when given with hydralazine. (Severe) Study Also see TABLE 8 p. 1265

- Hydrochlorothiazide → see thiazide diuretics

- Hydrocortisone → see corticosteroids

- Hydroflumethiazide → see thiazide diuretics

- Hydromorphone → see opioids

- Hydroxybenzoic acid (e.g. hydroxydecanoic acid) increases the risk of toxicity when given with didanosine. Avoid. (Severe) Study

- Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with hydroxyurea. Public Health England advises avoid. (Severe) Theoretical
Hydroxycarbamide — Idelalisib 1349

BNF 74

Theoretical
▶

Hydroxychloroquine is predicted to increase the risk of
haematological toxicity when given with penicillamine. Avoid.
r Theoretical

Hydroxychloroquine is predicted to decrease efﬁcacy rabies
vaccine. o Theoretical
Hydroxyzine → see antihistamines, sedating
Hyoscine → see TABLE 10 p. 1266 (antimuscarinics)
Ibandronic acid → see bisphosphonates
Ibrutinib → see TABLE 15 p. 1267 (myelosuppression), TABLE 4 p. 1264
▶

Macrolides (clarithromycin) are predicted to very markedly
increase the exposure to ibrutinib. Avoid or adjust ibrutinib
dose, p. 902. r Study
▶ Macrolides (erythromycin) are predicted to increase the
exposure to ibrutinib. Avoid or adjust ibrutinib dose, p. 902.
▶

r Theoretical
▶
▶

see TABLE 15 p. 1267
▶

(Seville) oranges as they are predicted to increase the
exposure to ibrutinib.
▶

Antiarrhythmics (dronedarone) are predicted to increase the
exposure to ibrutinib. Avoid or adjust ibrutinib dose, p. 902.
r Theoretical

▶

▶

▶

▶
▶

▶
▶

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone) are predicted to decrease the exposure
to ibrutinib. Avoid. r Study
Antifungals, azoles (fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure to ibrutinib. Avoid or
adjust ibrutinib dose, p. 902. r Theoretical
Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are
predicted to very markedly increase the exposure to ibrutinib.
Avoid or adjust ibrutinib dose, p. 902. r Study
Aprepitant is predicted to increase the exposure to ibrutinib.
Avoid or adjust ibrutinib dose, p. 902. r Theoretical
Calcium channel blockers (diltiazem, verapamil) are predicted to
increase the exposure to ibrutinib. Avoid or adjust ibrutinib
dose, p. 902. r Theoretical
Cobicistat is predicted to very markedly increase the exposure
to ibrutinib. Avoid or adjust ibrutinib dose, p. 902. r Study
Crizotinib is predicted to increase the exposure to ibrutinib.
Avoid or adjust ibrutinib dose, p. 902. r Theoretical → Also
see TABLE 15 p. 1267

▶
▶
▶
▶

▶

Enzalutamide is predicted to decrease the exposure to
ibrutinib. Avoid. r Study
Fosaprepitant is predicted to slightly increase the exposure to
ibrutinib. o Theoretical
Grapefruit juice is predicted to increase the exposure to
ibrutinib. Avoid. o Theoretical
HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir,
lopinavir, ritonavir, saquinavir, tipranavir) are predicted to very
markedly increase the exposure to ibrutinib. Avoid or adjust
ibrutinib dose, p. 902. r Study
HIV-protease inhibitors (indinavir) are predicted to increase the
exposure to ibrutinib. Avoid or adjust ibrutinib dose, p. 902.
r Theoretical

▶

▶

Idelalisib is predicted to very markedly increase the exposure
to ibrutinib. Avoid or adjust ibrutinib dose, p. 902. r
Study → Also see TABLE 15 p. 1267
Imatinib is predicted to increase the exposure to ibrutinib.
Avoid or adjust ibrutinib dose, p. 902. r Theoretical → Also
see TABLE 15 p. 1267

Quinolones (ciprofloxacin) are predicted to increase the
exposure to ibrutinib. Avoid or adjust ibrutinib dose, p. 902.
r Theoretical

Rifampicin is predicted to decrease the exposure to ibrutinib.
Avoid. r Study
▶ St John’s Wort is predicted to decrease the exposure to
ibrutinib. Avoid. r Theoretical
Ibuprofen → see NSAIDs
Icatibant
▶ ACE inhibitors are predicted to decrease the efﬁcacy of
icatibant and icatibant is predicted to decrease the efﬁcacy of
ACE inhibitors. Avoid. o Theoretical
Idarubicin → see anthracyclines
Idarucizumab → see monoclonal antibodies
Idelalisib → see TABLE 15 p. 1267 (myelosuppression)
▶ Idelalisib is predicted to increase the exposure to abiraterone.
▶

r Theoretical
▶

(antiplatelet effects)
FOOD AND LIFESTYLE Avoid food or drink containing bitter

Netupitant is predicted to increase the exposure to ibrutinib.
Avoid or adjust ibrutinib dose, p. 902. r Theoretical
Nilotinib is predicted to increase the exposure to ibrutinib.
Avoid or adjust ibrutinib dose, p. 902. r Theoretical → Also

▶
▶

▶
▶
▶
▶

Idelalisib is predicted to markedly increase the exposure to
aldosterone antagonists (eplerenone). Avoid. r Study
Idelalisib increases the exposure to almotriptan. n Study
Idelalisib is predicted to moderately increase the exposure to
alpha blockers (alfuzosin, tamsulosin). Use with caution or
avoid. o Study
Idelalisib is predicted to increase the exposure to alpha blockers
(doxazosin). o Study
Idelalisib moderately increases the exposure to alprazolam.
Avoid. o Study
Idelalisib very markedly increases the exposure to
antiarrhythmics (dronedarone). Avoid. r Study
Idelalisib is predicted to increase the exposure to
antiarrhythmics (propafenone). Monitor and adjust dose. r
Study

▶

▶

▶
▶

Idelalisib is predicted to increase the exposure to
anticholinesterases, centrally acting (galantamine). Monitor and
adjust dose. o Study
Antiepileptics (carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone) are predicted to decrease the exposure
to idelalisib. Avoid. r Study
Idelalisib is predicted to slightly increase the exposure to
antiepileptics (perampanel). n Study
Idelalisib is predicted to increase the exposure to antifungals,
azoles (isavuconazole). Avoid or monitor side effects. r
Study

▶
▶
▶
▶
▶
▶
▶
▶
▶
▶

Idelalisib is predicted to increase the exposure to
antihistamines, non-sedating (mizolastine). Avoid. r Study
Idelalisib is predicted to increase the exposure to antimalarials
(artemether) with lumafantrine. o Study
Idelalisib is predicted to increase the concentration of
antimalarials (piperaquine). r Theoretical
Idelalisib is predicted to markedly increase the exposure to
aprepitant. o Study
Idelalisib is predicted to slightly increase the exposure to
aripiprazole. Adjust aripiprazole dose, p. 376. o Study
Idelalisib is predicted to increase the exposure to axitinib.
Avoid or adjust dose. o Study → Also see TABLE 15 p. 1267
Idelalisib is predicted to increase the exposure to bedaquiline.
Avoid prolonged use. n Study
Idelalisib is predicted to increase the exposure to beta2 agonists
(salmeterol). Avoid. r Study
Idelalisib slightly increases the exposure to bortezomib.
o Study → Also see TABLE 15 p. 1267
Idelalisib is predicted to markedly increase the exposure to
bosutinib. Avoid or adjust bosutinib dose. r Study → Also
see TABLE 15 p. 1267

downloaded from www.medicalbr.com

A1
Interactions | Appendix 1

Hydroxycarbamide increases the risk of toxicity when given
with stavudine. Avoid. r Study
Hydroxychloroquine
▶ Hydroxychloroquine is predicted to decrease the effects of
agalsidase. o Theoretical
▶ Antacids decrease the absorption of hydroxychloroquine.
Separate administration by at least 4 hours. o Study
▶ Calcium salts (calcium carbonate) decrease the absorption of
hydroxychloroquine. Separate administration by at least
4 hours. o Study
▶ Hydroxychloroquine is predicted to decrease the efﬁcacy of
oral cholera vaccine. o Theoretical
▶ H2 receptor antagonists (cimetidine) are predicted to decrease
the clearance of hydroxychloroquine. o Theoretical
▶ Lanthanum is predicted to decrease the absorption of
hydroxychloroquine. Separate administration by at least
2 hours. o Theoretical
▶ Hydroxychloroquine is predicted to decrease the exposure to
laronidase. Avoid simultaneous administration. r
▶


Idelalisib (continued)

- Idelalisib is predicted to increase the exposure to buspirone. Adjust buspirone dose, p. 325. [Severe] Study
- Idelalisib slightly increases the exposure to cabozantinib. [Moderate] Study → Also see TABLE 15 p. 1267
- Idelalisib is predicted to increase the exposure to calcium channel blockers (amlodipine, felodipine, isradipine, lacidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose. [Moderate] Study
- Idelalisib is predicted to increase the exposure to calcium channel blockers (diltiazem, verapamil). [Severe] Study
- Idelalisib is predicted to markedly increase the exposure to calcium channel blockers (tercanipide). Avoid. [Severe] Study
- Idelalisib is predicted to increase the exposure to cannabis extract. Use with caution and adjust dose. [Moderate] Theoretical
- Idelalisib is predicted to increase the exposure to corticosteroids (dexamethasone, methylprednisolone). Monitor and adjust dose. [Moderate] Study
- Idelalisib is predicted to increase the exposure to corticosteroids (budesonide). Avoid. [Severe] Study
- Idelalisib is predicted to increase the exposure to corticosteroids (ciclesonide). Avoid. [Severe] Study
- Idelalisib is predicted to increase the exposure to inhaled corticosteroids (fluticasone). [Severe] Study
- Idelalisib is predicted to increase the exposure to corticosteroids (mometasone). [Moderate] Theoretical
- Idelalisib is predicted to increase the exposure to corticosteroids (ciclesonide). Avoid. [Moderate] Theoretical
- Idelalisib is predicted to increase the exposure to corticosteroids (dexamethasone, methylprednisolone). Monitor and adjust dose. [Moderate] Study
- Idelalisib is predicted to increase the exposure to dabrafenib. Use with caution or avoid. [Moderate] Study → Also see TABLE 15 p. 1267
- Idelalisib is predicted to moderately increase the exposure to daclatasvir. Adjust daclatasvir dose, p. 591. [Moderate] Study
- Idelalisib is predicted to markedly to very markedly increase the exposure to darifenacin. Avoid. [Severe] Study
- Idelalisib is predicted to markedly increase the exposure to dasatinib. Avoid. [Severe] Study → Also see TABLE 15 p. 1267
- Idelalisib very slightly increases the exposure to delamanid. [Severe] Study
- Idelalisib increases the risk of QT-prolongation when given with domperidone. Avoid. [Severe] Study
- Idelalisib increases the exposure to dopamine receptor agonists (bromocriptine, cabergoline). [Severe] Study
- Idelalisib is predicted to increase the exposure to dutasteride. Monitor side effects and adjust dose. [Moderate] Theoretical
- Idelalisib slightly to moderately increases the exposure to elbasvir. Avoid. [Moderate] Study
- Idelalisib is predicted to markedly increase the exposure to elotriptan. Avoid. [Severe] Study
- Enzalutamide is predicted to decrease the exposure to idelalisib. Avoid. [Severe] Study
- Idelalisib is predicted to increase the risk of ergotism when given with ergometrine. Avoid. [Severe] Theoretical
- Idelalisib is predicted to increase the risk of ergotism when given with ergonovine. Avoid. [Severe] Theoretical
- Idelalisib is predicted to slightly increase the exposure to erlotinib. Use with caution and adjust dose. [Moderate] Study
- Idelalisib is predicted to increase the concentration of everolimus. Avoid. [Severe] Study → Also see TABLE 15 p. 1267

- Idelalisib is predicted to moderately increase the exposure to fesoterodine. Adjust fesoterodine dose; avoid in hepatic and renal impairment, p. 732. [Severe] Study
- Idelalisib is predicted to increase the exposure to fosaprepitant. [Moderate] Theoretical
- Idelalisib is predicted to increase the exposure to gefitinib. [Moderate] Study → Also see TABLE 15 p. 1267
- Idelalisib is predicted to moderately to markedly increase the exposure to grazoprevir. Avoid. [Severe] Study
- Idelalisib is predicted to increase the exposure to guanfacine. Adjust guanfacine dose, p. 335. [Moderate] Study
- Idelalisib is predicted to increase the exposure to ivacaftor. Adjust ivacaftor or lumacaftor with ivacaftor dose, p. 281. [Severe] Study
- Idelalisib is predicted to increase the exposure to lapatinib. Avoid. [Moderate] Study
- Idelalisib is predicted to markedly increase the exposure to lomitapide. Avoid. [Severe] Study
- Idelalisib is predicted to increase the exposure to lurasidone. Avoid. [Severe] Study
- Idelalisib is predicted to increase the exposure to macitentan. [Moderate] Study
- Idelalisib markedly increases the exposure to maraviroc. Adjust dose. [Severe] Theoretical
- Idelalisib is predicted to markedly to very markedly increase the exposure to midazolam. Avoid or adjust midazolam dose. [Severe] Study
- Idelalisib is predicted to increase the exposure to mirabegron. Adjust mirabegron dose in hepatic and renal impairment, p. 736. [Moderate] Study
- Idelalisib is predicted to increase the exposure to mirtazapine. [Moderate] Study
- Idelalisib is predicted to increase the exposure to modafinil. [Mild] Theoretical
- Idelalisib is predicted to increase the exposure to monoclonal antibodies (trastuzumab emtansine). Avoid. [Severe] Theoretical → Also see TABLE 15 p. 1267
- Idelalisib is predicted to markedly increase the exposure to naloxegol. Avoid. [Severe] Study
- Idelalisib is predicted to increase the exposure to netupitant. [Mild] Study
- Idelalisib is predicted to markedly increase the exposure to nilotinib. Avoid. [Severe] Study → Also see TABLE 15 p. 1267
- Idelalisib is predicted to increase the exposure to nitisine. Adjust nitisine dose. [Moderate] Theoretical
- Idelalisib is predicted to increase the exposure to olaparib. Avoid or adjust olaparib dose, p. 919. [Moderate] Study → Also see TABLE 15 p. 1267
- Idelalisib is predicted to increase the exposure to opioids (alfentanil, buprenorphine, fentanyl, oxycodone, sufentanil). Monitor and adjust dose. [Severe] Study
- Idelalisib is predicted to increase the exposure to opioids (methadone). [Moderate] Theoretical
- Idelalisib is predicted to increase the exposure to oxbutynin. [Mild] Study
- Idelalisib is predicted to increase the exposure to palbociclib. Avoid or adjust palbociclib dose, p. 909. [Severe] Study
- Idelalisib is predicted to increase the exposure to panobinostat. Adjust panobinostat dose; in hepatic impairment avoid, p. 864. [Moderate] Study → Also see TABLE 15 p. 1267
- Idelalisib is predicted to increase the exposure to pariparibrevir with ritonavir and ombravir. Adjust. [Severe] Theoretical
Idelalisib is predicted to increase the exposure to pazopanib. Avoid or adjust pazopanib dose, p. 909. [Moderate] Study → Also see TABLE 15 p. 1267

Idelalisib is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (avanafil, vardenafil). Avoid. [Severe] Study

Idelalisib is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (sildenafil). Avoid or adjust sildenafil dose, p. 766. [Severe] Study

Idelalisib is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (tadalafil). Use with caution or avoid. [Severe] Study

Idelalisib is predicted to increase the exposure to pimozone. Avoid. [Severe] Study

Idelalisib is predicted to slightly increase the exposure to ponatinib. Monitor and adjust ponatinib dose, p. 911. [Moderate] Study

Idelalisib is predicted to moderately increase the exposure to praziquantel. [Mild] Study

Idelalisib is predicted to increase the exposure to quetiapine. Avoid. [Severe] Study

Idelalisib is predicted to increase the exposure to ranolazine. Avoid. [Severe] Study

Idelalisib is predicted to increase the exposure to reboxetine. Avoid. [Moderate] Study → Also see TABLE 15 p. 1267

Idelalisib is predicted to increase the exposure to regorafenib. Avoid. [Moderate] Study → Also see TABLE 15 p. 1267

Idelalisib is predicted to increase the exposure to repaglinide. [Moderate] Study

Idelalisib is predicted to increase the exposure to retinoids (all-transretinoin). Adjust all-transretinoin dose, p. 1157. [Moderate] Theoretical

Rifaximin is predicted to decrease the exposure to idelalisib. [Mild] Study

Idelalisib is predicted to increase the exposure to risperidone. Adjust dose. [Moderate] Study

Idelalisib is predicted to increase the exposure to ruxolitinib. Adjust dose and monitor side effects. [Moderate] Study → Also see TABLE 15 p. 1267

Idelalisib is predicted to increase the exposure to saxagliptin. [Moderate] Study

Idelalisib is predicted to increase the exposure to simprevir. Avoid. [Severe] Study

Idelalisib is predicted to increase the concentration of sirolimus. Avoid. [Severe] Study

Idelalisib is predicted to increase the exposure to solifenacin. Adjust solifenacin or tamsulosin with solifenacin dose; avoid in hepatic and renal impairment, p. 734, p. 740. [Severe] Study

Idelalisib is predicted to moderately increase the exposure to SSRI (dapoxetine). Avoid, or adjust dapoxetine dose, 773. [Severe] Study

St John’s Wort is predicted to decrease the exposure to idelalisib. Avoid. [Severe] Theoretical

Idelalisib is predicted to increase the exposure to statins (atorvastatin). Avoid or adjust dose and monitor rhabdomyolysis. [Severe] Study

Idelalisib is predicted to increase the exposure to statins (simvastatin). Avoid. [Severe] Study

Idelalisib is predicted to slightly increase the exposure to sunitinib. Avoid or adjust sunitinib dose, p. 914. [Moderate] Study → Also see TABLE 15 p. 1267

Idelalisib is predicted to increase the concentration of tacrolimus. Monitor and adjust dose. [Severe] Study

Idelalisib is predicted to increase the exposure to taxanes (cabazitaxel). Avoid. [Severe] Study → Also see TABLE 15 p. 1267

Idelalisib is predicted to moderately increase the exposure to taxanes (docetaxel). Avoid or adjust dose. [Severe] Study → Also see TABLE 15 p. 1267

Idelalisib is predicted to increase the exposure to taxanes (paclitaxel). [Severe] Theoretical → Also see TABLE 15 p. 1267

Idelalisib is predicted to increase the concentration of temsirolimus. Avoid. [Severe] Theoretical → Also see TABLE 15 p. 1267

Idelalisib is predicted to markedly increase the exposure to ticagrelor. Avoid. [Severe] Study

Idelalisib is predicted to increase the exposure to tolterodine. Avoid. [Severe] Study

Idelalisib is predicted to increase the exposure to tolvaptan. Adjust dose. [Severe] Study

Idelalisib is predicted to increase the exposure to toremifene. [Moderate] Theoretical

Idelalisib is predicted to increase the exposure to trabectedin. Avoid or adjust dose. [Severe] Theoretical → Also see TABLE 15 p. 1267

Idelalisib is predicted to moderately increase the exposure to trazodone. Avoid or adjust dose. [Moderate] Study

Idelalisib is predicted to increase the exposure to ulipristal. Avoid if used for uterine fibroids. [Severe] Study

Idelalisib is predicted to increase the exposure to vemurafenib. [Moderate] Theoretical

Idelalisib is predicted to increase the exposure to venetoclax. Avoid or adjust venetoclax dose, p. 919. [Severe] Study

Idelalisib is predicted to increase the exposure to venlafaxine. [Moderate] Study

Idelalisib is predicted to increase the exposure to vinca alkaloids. [Severe] Theoretical → Also see TABLE 15 p. 1267

Idelalisib is predicted to increase the exposure to vitamin D substances (paricalcitol). [Moderate] Study

Idelalisib is predicted to increase the exposure to zopiclone. Adjust dose. [Moderate] Theoretical

Ifosfamide is predicted to increase the exposure to alitretinoin. Avoid. [Severe] Study

Iloprost is predicted to increase the exposure to amiodarone. Avoid or adjust dose. [Severe] Study

Idelalisib is predicted to increase the exposure to antihistamines, non-sedating (mizolastine). Avoid or adjust dose. [Severe] Study

Idelalisib is predicted to increase the exposure to antihistamines, non-sedating (cetirizine). Avoid or adjust dose. [Severe] Study

Idelalisib is predicted to increase the exposure to antihistamines, non-sedating (loratadine). Avoid or adjust dose. [Severe] Study

Idelalisib is predicted to increase the exposure to statins (atorvastatin). Avoid or adjust dose and monitor rhabdomyolysis. [Severe] Study

Idelalisib is predicted to increase the exposure to statins (simvastatin). Avoid. [Severe] Study

Idelalisib is predicted to slightly increase the exposure to sunitinib. Avoid or adjust sunitinib dose, p. 914. [Moderate] Study → Also see TABLE 15 p. 1267

Idelalisib is predicted to increase the concentration of tacrolimus. Monitor and adjust dose. [Severe] Study

Idelalisib is predicted to increase the exposure to taxanes (docetaxel). Avoid or adjust dose. [Severe] Study → Also see TABLE 15 p. 1267

Idelalisib is predicted to increase the exposure to taxanes (paclitaxel). [Severe] Theoretical → Also see TABLE 15 p. 1267

Idelalisib is predicted to increase the concentration of temsirolimus. Avoid. [Severe] Theoretical → Also see TABLE 15 p. 1267

Idelalisib is predicted to markedly increase the exposure to ticagrelor. Avoid. [Severe] Study

Idelalisib is predicted to increase the exposure to tolvaptan. Adjust dose. [Severe] Study

Idelalisib is predicted to increase the exposure to toremifene. [Moderate] Theoretical

Idelalisib is predicted to increase the exposure to trabectedin. Avoid or adjust dose. [Severe] Theoretical → Also see TABLE 15 p. 1267

Idelalisib is predicted to moderately increase the exposure to trazodone. Avoid or adjust dose. [Moderate] Study

Idelalisib is predicted to increase the exposure to ulipristal. Avoid if used for uterine fibroids. [Severe] Study

Idelalisib is predicted to increase the exposure to vemurafenib. [Moderate] Theoretical

Idelalisib is predicted to increase the exposure to venetoclax. Avoid or adjust venetoclax dose, p. 919. [Severe] Study

Idelalisib is predicted to increase the exposure to venlafaxine. [Moderate] Study

Idelalisib is predicted to increase the exposure to vinca alkaloids. [Severe] Theoretical → Also see TABLE 15 p. 1267

Idelalisib is predicted to increase the exposure to vitamin D substances (paricalcitol). [Moderate] Study

Idelalisib is predicted to increase the exposure to zopiclone. Adjust dose. [Moderate] Theoretical

Idelalisib is predicted to increase the exposure to antihistamines, non-sedating (mizolastine). Avoid or adjust dose. [Severe] Study

Idelalisib is predicted to increase the exposure to antihistamines, non-sedating (cetirizine). Avoid or adjust dose. [Severe] Study

Idelalisib is predicted to increase the exposure to antihistamines, non-sedating (loratadine). Avoid or adjust dose. [Severe] Study

Idelalisib is predicted to increase the concentration of antimalarials (piperazine). [Severe] Theoretical

Aprepitant is predicted to increase the exposure to imatinib. [Moderate] Theoretical

Asparaginase is predicted to increase the risk of hepatotoxicity when given with imatinib. [Severe] Theoretical → Also see TABLE 15 p. 1267

Imatinib is predicted to increase the exposure to axitinib. [Moderate] Theoretical → Also see TABLE 15 p. 1267

Imatinib is predicted to increase the exposure to bedaquiline. Avoid prolonged use. [Mild] Theoretical

Bosentan is predicted to decrease the exposure to imatinib. [Moderate] Study

Imatinib is predicted to increase the exposure to bosutinib. Avoid or adjust bosutinib dose. [Severe] Theoretical → Also see TABLE 15 p. 1267

Imatinib is predicted to increase the exposure to cabozantinib. [Moderate] Theoretical → Also see TABLE 15 p. 1267

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to imatinib. [Moderate] Theoretical

Downloaded from www.medicalbr.com
Imatinib (continued)
- **Imatinib** is predicted to increase the exposure to calcium channel blockers (amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose. (Moderate) Study

- Imatinib is predicted to increase the exposure to *ceritinib*. (Moderate) Theoretical → Also see TABLE 15 p. 1267
- **Imatinib** increases the concentration of *ciclosporin*. (Severe) Study

- **Cobicistat** is predicted to increase the exposure to imatinib. (Moderate) Study

- **Imatinib** is predicted to increase the exposure to *cobicistat*. (Severe) Theoretical

- **Imatinib** is predicted to increase the exposure to corticosteroids (methylprednisolone). Monitor and adjust dose. (Moderate) Study

- Imatinib is predicted to increase the risk of bleeding events when given with *coumarins*. (Severe) Theoretical

- **Crisantaspase** is predicted to increase the risk of hepatotoxicity when given with imatinib. (Severe) Theoretical → Also see TABLE 15 p. 1267

- **Imatinib** is predicted to slightly increase the exposure to *darifenacin*. (Moderate) Study

- **Imatinib** is predicted to increase the exposure to *colchicine*. Adjust colchicine dose, p. 1020. (Severe) Study

- **Imatinib** is predicted to increase the exposure to *dostinex*. (Moderate) Study

- **Imatinib** is predicted to increase the exposure to *dasatinib*. (Severe) Study → Also see TABLE 15 p. 1267

- **Imatinib** increases the risk of QT-prolongation when given with *domperidone*. Avoid. (Severe) Study

- **Imatinib** is predicted to increase the exposure to dopamine receptor agonists (bromocriptine, cabergoline). (Severe) Theoretical

- **Imatinib** is predicted to moderately increase the exposure to *dutasteride*. (Mild) Study

- **Efavirenz** is predicted to decrease the exposure to imatinib. (Moderate) Study

- **Enzalutamide** is predicted to decrease the exposure to imatinib. Avoid. (Moderate) Study

- **Imatinib** is predicted to increase the risk of ergotism when given with *ergometrine*. (Severe) Theoretical

- **Imatinib** is predicted to increase the risk of ergotism when given with *ergotamine*. (Severe) Theoretical

- **Imatinib** is predicted to increase the exposure to *erlotinib*. (Moderate) Theoretical

- **Imatinib** is predicted to increase the concentration of *everolimus*. Avoid or adjust dose. (Moderate) Study → Also see TABLE 15 p. 1267

- **Imatinib** is predicted to increase the exposure to *felodipine*. Adjust felodipine dose, p. 732. (Mild) Study

- **Imatinib** is predicted to increase the exposure to *gefitinib*. (Moderate) Theoretical → Also see TABLE 15 p. 1267

- **Grapefruit juice** is predicted to increase the exposure to imatinib. (Moderate) Theoretical

- **Imatinib** is predicted to increase the concentration of *guanfacine*. Adjust guanfacine dose, p. 335. (Moderate) Theoretical

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to imatinib. (Moderate) Study

- **Imatinib** is predicted to increase the exposure to *ibrutinib*. Avoid or adjust ibrutinib dose, p. 902. (Severe) Theoretical → Also see TABLE 15 p. 1267

- **Grapefruit juice** is predicted to increase the exposure to *fexefos rodone*. Adjust fexefos rodone dose, p. 205. (Severe) Theoretical

- **Imatinib** is predicted to increase the exposure to *iavabradine*. Adjust iavabradine dose, p. 281. (Severe) Study

- **Imatinib** is predicted to increase the exposure to *ivacaftor*. Adjust ivacaftor dose, p. 281. (Severe) Study

- **Imatinib** is predicted to increase the exposure to *lapatinib*. (Moderate) Study

- **Imatinib** is predicted to increase the exposure to *lomitapide*. Avoid. (Moderate) Theoretical

- **Imatinib** is predicted to increase the exposure to *lurasidone*. (Moderate) Study

- Macrolides (erythromycin) are predicted to increase the exposure to imatinib. (Moderate) Theoretical

- **Imatinib** is predicted to increase the exposure to midazolam. Monitor side effects and adjust dose. (Severe) Study

- **Imatinib** is predicted to increase the exposure to *naloxegol*. Adjust naloxegol dose and monitor side effects, p. 63. (Moderate) Study

- **Netupitant** is predicted to increase the exposure to imatinib. (Moderate) Theoretical

- **Nevirapine** is predicted to decrease the exposure to imatinib. (Moderate) Study

- **Imatinib** is predicted to increase the exposure to *olaparib*. Avoid or adjust olaparib dose, p. 919. (Moderate) Theoretical → Also see TABLE 15 p. 1267

- **Imatinib** is predicted to increase the exposure to *opioids* (alfentanil, buprenorphine, fentanyl, oxycodone). Monitor and adjust dose. (Moderate) Study

- **Imatinib** is predicted to increase the exposure to *opioids* (methadone, sufentanil). (Moderate) Theoretical

- **Imatinib** is predicted to increase the exposure to *oxybutynin*. (Mild) Theoretical

- **Imatinib** increases the risk of hepatotoxicity when given with *paracetamol*. (Severe) Anecdotal

- **Imatinib** is predicted to increase the exposure to *pazopanib*. (Moderate) Theoretical → Also see TABLE 15 p. 1267

- **Pegasparagse** is predicted to increase the risk of hepatotoxicity when given with imatinib. (Severe) Theoretical → Also see TABLE 15 p. 1267

- **Imatinib** is predicted to increase the risk of bleeding events when given with *phenindione*. (Severe) Theoretical

- **Imatinib** is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (avanafil). Adjust avanafil dose, p. 765. (Moderate) Theoretical

- **Imatinib** is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (tadalafil). Monitor and adjust sildenafil dose, p. 766. (Moderate) Study

- **Imatinib** is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (vardenafil). Adjust dose. (Severe) Theoretical

- **Imatinib** is predicted to increase the exposure to *pimozone*. Avoid. (Severe) Theoretical

- **Imatinib** is predicted to increase the exposure to *quetiapine*. Avoid. (Moderate) Study

- **Imatinib** is predicted to increase the exposure to *ranolazine*. Avoid. (Severe) Study

- **Rifaximin** is predicted to increase the exposure to *ruxolitinib*. (Moderate) Theoretical → Also see TABLE 15 p. 1267

- **Imatinib** is predicted to increase the exposure to saxagliptin. (Mild) Study

- **Imatinib** is predicted to increase the exposure to *simeprevir*. Avoid. (Severe) Study

- **Imatinib** increases the concentration of *sirolimus*. Monitor and adjust dose. (Moderate) Study

- **Imatinib** is predicted to increase the exposure to *SSRIs* (dapoxetine). Adjust dapoxetine dose, p. 773. (Moderate) Theoretical

- **St John’s Wort** is predicted to decrease the exposure to imatinib. (Moderate) Study

- **Imatinib** is predicted to increase the exposure to *statins* (atorvastatin). Monitor and adjust dose. (Severe) Theoretical

- **Imatinib** is predicted to increase the exposure to *statins* (simvastatin). Use with caution and adjust simvastatin dose, p. 198. (Severe) Study

- **Imatinib** is predicted to increase the exposure to *sunitinib*. Avoid. (Moderate) Theoretical

- **Imatinib** is predicted to increase the exposure to tacrolimus. (Severe) Study

- **Imatinib** is predicted to increase the exposure to *taxanes* (cabazitaxel). (Moderate) Theoretical → Also see TABLE 15 p. 1267

- **Tedorzol** is predicted to increase the exposure to imatinib. Avoid. (Moderate) Theoretical
**Imatinib** is predicted to increase the concentration of temsiroliimus. [Moderate] Theoretical  Also see TABLE 15 p. 1267

**Imatinib** is predicted to increase the exposure to tolvaptan. Adjust dose. [Moderate] Theoretical

**Imatinib** is predicted to increase the exposure to olaparib. Adjust dose. [Moderate] Theoretical

**Imatinib** is predicted to increase the exposure to trazodone. [Moderate] Theoretical

**Imatinib** is predicted to increase the exposure to ulipristal. Avoid if used for uterine fibroids. [Moderate] Study

**Imatinib** is predicted to increase the exposure to venoject. Avoid or adjust venoject dose, p. 919. [Severe] Study

**Imatinib** is predicted to increase the exposure to vinca alkaloids. [Severe] Theoretical  Also see TABLE 15 p. 1267

**Imatinib** is predicted to increase the exposure to zopiclone. Adjust dose. [Moderate] Study

Imidapril  see ACE inhibitors

Imipenem  see carbapenems

Imipramine  see tricyclic antidepressants

Indacaterol  see beta, agonists

Indapamide  see thiazide diuretics

Indinavir  see HIV- protease inhibitors

Indometacin  see alpha blockers

Infliximab  see monoclonal antibodies

Influenza vaccine  see live vaccines

Insulin  see insulins

Insulin aspart  see insulins

Insulin degludec  see insulins

Insulin detemir  see insulins

Insulin glargine  see insulins

Insulin glulisine  see insulins

Insulin lispro  see insulins

Insulin zinc suspension  see insulins

Insulins  see TABLE 14 p. 1267 (anti diabetic drugs)

Biphasic insulin aspart - Biphasic insulin lispro - Biphasic isophane insulin - insulin aspart - insulin degludec - insulin detemir - insulin glargine - insulin glulisine - insulin lispro - insulin zinc suspension - isophane insulin - protamine zinc insulin

**Fibrates** are predicted to increase the risk of hypoglycaemia when given with insulins. [Moderate] Theoretical

**Interferon alfa**  see interferons

**Interferon beta**  see interferons

**Interferons**  see TABLE 15 p. 1267 (myelosuppression)

Interferon alfa - interferon beta - peginterferon alfa

**Interferons** are predicted to slightly increase the exposure to aminophylline. Adjust dose. [Moderate] Theoretical

**Interferon alfa** is predicted to increase the risk of peripheral neuropathy when given with telbivudine. Avoid. [Severe] Theoretical

**Peginterferon alfa** increases the risk of peripheral neuropathy when given with telbivudine. Avoid. [Severe] Study

**Interferons** slightly increase the exposure to theophylline. Adjust dose. [Moderate] Study

**Interferon alfa** is predicted to increase the risk of glaucoma when given with irapronium. [Moderate] Anecdotal

Ibepesartan  see angiotensin-II receptor antagonists

Irinotecan  see TABLE 15 p. 1267 (myelosuppression)

Antiepileptics (Carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to irinotecan. Avoid. [Severe] Study

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the risk of toxicity when given with irinotecan. Avoid. [Moderate] Study

Cobicistat is predicted to increase the risk of toxicity when given with irinotecan. Avoid. [Moderate] Study

Enalaprilat is predicted to decrease the exposure to irinotecan. Avoid. [Severe] Study

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the risk of toxicity when given with irinotecan. Avoid. [Moderate] Study

**Idealisib** is predicted to increase the risk of toxicity when given with irinotecan. Avoid. [Moderate] Study  Also see TABLE 15 p. 1267

**Live vaccines** are predicted to increase the risk of generalised infection (possibly life-threatening) when given with irinotecan. Public Health England advises avoid. [Severe] Theoretical

**Macrolides (clarithromycin)** are predicted to increase the risk of toxicity when given with irinotecan. Avoid. [Moderate] Study

**Irinotecan** is predicted to decrease the effects of neuromuscular blocking drugs, non-depolarising. [Moderate] Theoretical

**Pitolisant** is predicted to decrease the exposure to irinotecan. [Unknown] Theoretical

**Rifampicin** is predicted to decrease the exposure to irinotecan. Avoid. [Severe] Study

**St John’s Wort** slightly decreases the exposure to irinotecan. Avoid. [Severe] Study

**Irinotecan** is predicted to increase the risk of prolonged neuromuscular blockade when given with suxamethonium. [Moderate] Theoretical

**Iron (injectable)**

- Ferric carboxymaltose - iron dextran - iron isomaltoside 1000 - iron sucrose

Chloramphenicol decreases the efficacy of intravenous iron (injectable). [Moderate] Anecdotal

**Iron (oral)**

- Ferric maltol - ferrous fumarate - ferrous gluconate - ferrous sulfate - polysaccharide-iron complex - sodium feredate

Antacids decrease the absorption of iron (oral). Iron (oral) should be taken 1 hour before or 2 hours after antacids. [Moderate] Study

Iron (oral) is predicted to decrease the absorption of oral bisphosphonates (ibandronic acid). Avoid iron (oral) for at least 6 hours before or 1 hour after ibandronic acid. [Moderate] Theoretical

**Iron (oral)** decreases the absorption of bisphosphonates (risendronate). Separate administration by at least 2 hours. [Moderate] Study

Iron (oral) decreases the absorption of bisphosphonates (sodium clodronate). Avoid iron (oral) for 2 hours before or 1 hour after sodium clodronate. [Moderate] Study

Calcium salts (calcium carbonate) decrease the absorption of iron (oral). Calcium carbonate should be taken 1 hour before or 2 hours after iron (oral). [Moderate] Study

Iron (oral) is predicted to decrease the exposure to carbidopa. [Moderate] Theoretical

Chloramphenicol decreases the efficacy of oral iron (oral). [Moderate] Theoretical

Iron (oral) decreases the absorption of duloxetine. Iron (oral) should be taken 2 hours before or 6 hours after duloxetine. [Moderate] Study

Iron (oral) is predicted to decrease the absorption of eltrombopag. Eltrombopag should be taken 2 hours before or 4 hours after iron (oral). [Severe] Theoretical

Iron (oral) is predicted to decrease the absorption of entacapone. Separate administration by at least 2 hours. [Moderate] Theoretical

Iron (oral) decreases the absorption of levodopa. [Moderate] Study

Iron (oral) decreases the absorption of levothyroxine. Separate administration by at least 4 hours. [Moderate] Study

Iron (oral) decreases the effects of methylxanthine. [Moderate] Study

Iron (oral) is predicted to decrease the absorption of penicillamine. Separate administration by at least 2 hours. [Mild] Study

Iron (oral) decreases the exposure to quinolones. Separate administration by at least 2 hours. [Moderate] Study

Iron (oral) decreases the absorption of tetracyclines. Tetracyclines should be taken 2 to 3 hours after iron (oral). [Moderate] Study

Trientine potentially decreases the absorption of iron (oral). [Moderate] Theoretical
Iron (oral) — Ivacaftor

Iron (oral) (continued)

- Zinc is predicted to decrease the efficacy of iron (oral) and iron (oral) are predicted to decrease the efficacy of zinc. [Moderate]

Iron chelators

deferasirox - desferrioxamine - deferoxamine

- Deferasirox is predicted to increase the exposure to aminophylline. Avoid. [Moderate] Theoretical

- Antacids (aluminium hydroxide) are predicted to decrease the exposure to deferasirox. Avoid. [Moderate] Theoretical

- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to deferasirox. Monitor serum ferritin and adjust dose. [Moderate] Theoretical

- Ascorbic acid is predicted to increase the risk of cardiovascular side-effects when given with desferrioxamine. Severe Theoretical

- Aspirin (high-dose) is predicted to increase the risk of gastrointestinal bleedings when given with deferasirox. Severe Theoretical

- Bisphosphonates are predicted to increase the risk of gastrointestinal bleeding when given with deferasirox. Severe Theoretical

- Deferasirox is predicted to increase the exposure to clozapine. Avoid. [Moderate] Theoretical

- Corticosteroids are predicted to increase the risk of gastrointestinal bleeding when given with deferasirox. Severe Theoretical

- AIDS are predicted to increase the risk of gastrointestinal bleeding when given with deferasirox. Severe Theoretical

- Deferasirox moderately increases the exposure to repaglinide. Avoid. [Moderate] Study

- Rifampicin is predicted to decrease the exposure to deferasirox. Monitor serum ferritin and adjust dose. [Moderate] Study

- Deferasirox increases the exposure to theophylline. Avoid. [Moderate] Study

- Deferasirox is predicted to increase the exposure to tizanidine. Avoid. [Moderate] Theoretical

Iron dextran → see iron (injectable)

Iron isomsaltsolide 1000 → see iron (injectable)

Iron sucrose → see iron (injectable)

Isavunozanol → see antifungals, azoles

Iscarboxazid → see monoamine-oxidase A and B inhibitors, irreversible

Isonflurane → see volatile halogenated anaesthetics

Isonetemepene → see sympathomimetics, vasconstrictor

Isoniazid → see TABLE 1. p. 1264 (hepatotoxicity), TABLE 12 p. 1267 (peripheral neuropathy)

FOOD AND LIFESTYLE Avoid tanyrime or histamine rich foods, as tachycardia, palpitation, hypotension, flushing, headache, dizziness, and sweating reported.

- Isoniazid is predicted to affect the clearance of aminophylline. Severe Theoretical

- Isoniazid markedly increases the concentration of antiepileptics (carbamazepine) and antiepileptics (carbamazepine) increase the risk of hepatotoxicity when given with isoniazid. Monitor carbamazepine concentration and adjust dose. [Severe] Study Also see TABLE 1 p. 1264

- Isoniazid increases the concentration of antiepileptics (fosphenytoin, phenytoin). Moderate Study Also see TABLE 12 p. 1267

- Cyclophosphine increases the risk of CNS toxicity when given with isoniazid. Monitor and adjust dose. [Moderate] Study

- Isoniazid is predicted to increase the risk of peripheral neuropathy when given with didanosine. Severe Theoretical Also see TABLE 1 p. 1264 Also see TABLE 12 p. 1267

- Isoniazid increases the risk of optic neuropathy when given with etambutol. Severe Anecdotal

- Isoniazid decreases the effects of levodopa. [Moderate] Study

- Isoniazid is predicted to increase the exposure to tomatipide. Separate administration by 12 hours. [Unknown] Theoretical Also see TABLE 1 p. 1264

- Isoniazid is predicted to increase the risk of peripheral neuropathy when given with stavudine. [Severe] Theoretical Also see TABLE 12 p. 1267

- Isoniazid is predicted to affect the clearance of theophylline. Severe Anecdotal

Iron (oral) — Ivacaftor

Isoniazid insulin → see insulins

Iosorbide dinitrate → see nitrates

Iosorbide mononitrate → see nitrates

Isotretinoin → see retinoids

Isradipine → see calcium channel blockers

Itracnozole → see antifungals, azoles

Ivabradine → see TABLE 6 p. 1265 (bradycardia), TABLE 9 p. 1266 (QT-interval prolongation)

- Antiarhythms (dronedarone) are predicted to increase the exposure to ivabradine. Adjust ivabradine dose, p. 205. Severe Theoretical

- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to ivabradine. Adjust dose. [Moderate] Theoretical

- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to ivabradine. Adjust ivabradine dose, p. 205. [Severe] Theoretical

- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to ivabradine. Avoid. [Severe] Study

- Aprepitant is predicted to increase the exposure to ivabradine. Adjust ivabradine dose, p. 205. Severe Theoretical

- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to ivabradine. Avoid. [Moderate] Study Also see TABLE 6 p. 1265

- Cobicistat is predicted to increase the exposure to ivabradine. Avoid. [Severe] Study

- Crizotinib is predicted to increase the exposure to ivabradine. Adjust ivabradine dose, p. 205. Severe Theoretical Also see TABLE 6 p. 1265

- Enalapril is predicted to decrease the exposure to ivabradine. Adjust dose. [Moderate] Theoretical

- Grapefruit juice is predicted to increase the exposure to ivabradine. Avoid. [Moderate] Study

- HIV-protase inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to ivabradine. Avoid. [Severe] Study

- HIV-protase inhibitors (indinavir) increase the exposure to ivabradine. Adjust dose. [Severe] Theoretical

- Idealalisb is predicted to increase the exposure to ivabradine. Avoid. [Severe] Study

- Imatinib is predicted to increase the exposure to ivabradine. Adjust ivabradine dose, p. 205. Severe Theoretical

- Macrolides (clarithromycin) are predicted to increase the exposure to ivabradine. Avoid. [Severe] Study

- Macrolides (erythromycin) are predicted to increase the exposure to ivabradine. Avoid. [Severe] Study

- Netupitant is predicted to increase the exposure to ivabradine. Adjust ivabradine dose, p. 205. Severe Theoretical

- Nilotinib is predicted to increase the exposure to ivabradine. Adjust ivabradine dose, p. 205. Severe Theoretical

- Rilpaminc is predicted to decrease the exposure to ivabradine. Adjust dose. [Moderate] Theoretical

- St John’s Wort decreases the exposure to ivabradine. Avoid. [Moderate] Study

Ivacaftor

FOOD AND LIFESTYLE Avoid bitter (Seville) oranges as they are predicted to increase the exposure to ivacafior.

- Antiarhythms (dronedarone) are predicted to increase the exposure to ivacaftor. Adjust ivacaftor dose, p. 281. [Severe] Study

- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) markedly decrease the exposure to ivacaftor. Avoid. [Severe] Study

- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to ivacaftor. Adjust ivacaftor dose, p. 281. [Severe] Study
### Enzalutamide

- **Rifampicin**
  - Adjust ivacaftor dose, p. 281. **(Severe)** Study

### Calcium channel blockers (diltiazem, verapamil)

- Decrease exposure to ivacaftor. **(Severe)** Study

### Aprepitant

- **Calcium channel blockers** decrease exposure to ivacaftor. **(Severe)** Study

### Calcium

- **Antifungals, azoles**
  - (itraconazole, ketoconazole, voriconazole)
  - Increase exposure to ivacaftor. **(Severe)** Study

### Lanreotide

- **Beta blockers, non-selective**
  - Decrease absorption of oral ciclosporin. **(Moderate)** Study

### Lansoprazole

- Proton pump inhibitors

### Memantine

- **Antifungals, azoles**
  - (itraconazole, ketoconazole, voriconazole)

### Ketorolac

- **Ivermectin**

- Potential increases the anticoagulant effect of coumarins. **(Severe)** Theoretical

### Ketamine

- **St John’s Wort**

### Ixazomib

- **Antifungals, azoles**
  - (itraconazole, ketoconazole, voriconazole)

### Ivermectin

- **St John's Wort**

### Ixekizumab

- **Antiepileptic**

### Kaolin

- **Antifungals, azoles**

### Ketamine

- **Colchicine**

### Lamivudine

- **Prednisolone**

### Lamotrigine

- **Antiepileptic**

### Lanreotide

- **Beta blockers, selective**

### Levothyroxine

- **Antifungals, azoles**

### Levamisole

- **Antifungals, azoles**

### Levodopa

- **Antifungals, azoles**

### Lacidipine

- **Antifungals, azoles**

### Lacosamide

<table>
<thead>
<tr>
<th>Interaction</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antifungals, azoles</strong> (itraconazole, ketoconazole, voriconazole)</td>
<td>Increase exposure to ivacaftor. <strong>(Severe)</strong> Study</td>
</tr>
<tr>
<td><strong>Calcium channel blockers</strong> (diltiazem, verapamil)</td>
<td>Decrease exposure to ivacaftor. <strong>(Severe)</strong> Study</td>
</tr>
<tr>
<td><strong>Aprepitant</strong></td>
<td>Decrease exposure to ivacaftor. <strong>(Severe)</strong> Study</td>
</tr>
<tr>
<td><strong>Calcium channel blockers</strong></td>
<td>Decrease absorption of oral ciclosporin. <strong>(Moderate)</strong> Study</td>
</tr>
<tr>
<td><strong>Lansoprazole</strong></td>
<td>Proton pump inhibitors</td>
</tr>
<tr>
<td><strong>Memantine</strong></td>
<td>Decrease absorption of oral ciclosporin. <strong>(Severe)</strong> Theoretical</td>
</tr>
<tr>
<td><strong>Ivermectin</strong></td>
<td>Increase anticoagulant effect of coumarins. <strong>(Severe)</strong> Theoretical</td>
</tr>
<tr>
<td><strong>Ketamine</strong></td>
<td>Decrease absorption of oral ciclosporin. <strong>(Severe)</strong> Theoretical</td>
</tr>
<tr>
<td><strong>Colchicine</strong></td>
<td>Increase absorption of oral ciclosporin. <strong>(Severe)</strong> Theoretical</td>
</tr>
</tbody>
</table>

**TABLE 11**

- **Lanreotide**
  - **Beta blockers, non-selective**

- **Lansoprazole**
  - **Proton pump inhibitors**

- **Lamivudine**
  - **Prednisolone**

- **Lamotrigine**
  - **Antiepileptic**

- **Lanreotide**
  - **Beta blockers, selective**

- **Levamisole**
  - **Antifungals, azoles**

- **Levothyroxine**
  - **Antifungals, azoles**

- **Lacidipine**
  - **Calcium channel blockers**

- **Lacosamide**
  - **Antiepileptic**

**TABLE 9**

- **Lanreotide**
  - **Beta blockers**

- **Lansoprazole**
  - **Proton pump inhibitors**

- **Lamivudine**
  - **Prednisolone**

- **Lamotrigine**
  - **Antiepileptic**

- **Lanreotide**
  - **Beta blockers**

- **Levamisole**
  - **Antifungals, azoles**

- **Levothyroxine**
  - **Antifungals, azoles**

- **Lacidipine**
  - **Calcium channel blockers**

- **Lacosamide**
  - **Antiepileptic**
Lapatinib (continued)

- **Lapatinib** is predicted to slightly increase the exposure to edoxaban. [Severe] Theoretical
- **Efavirenz** is predicted to decrease the exposure to lapatinib. Avoid. [Severe] Study
- **Enzalutamide** is predicted to decrease the exposure to lapatinib. Avoid. [Severe] Study
- **Lapatinib** is predicted to increase the exposure to erlotinib.
  - Moderate Theoretical
- **Lapatinib** is predicted to increase the exposure to everolimus.
  - Moderate Theoretical
- **Lapatinib** is predicted to increase the exposure to fidaromacin. Avoid. [Moderate] Study
- **Grapefruit juice** is predicted to increase the exposure to lapatinib. Avoid. [Moderate] Study
- **H₂ receptor antagonists** are predicted to decrease the absorption of lapatinib.
  - Moderate Theoretical
- **HIV-protease inhibitors** (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to lapatinib. Avoid. [Moderate] Study
  - Also see TABLE 9 p. 1266
- **HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to loperamide.
  - Moderate Study
- **Lapatinib** is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. [Moderate] Theoretical
- **Lapatinib** is predicted to increase the exposure to loperamide.
  - Moderate Theoretical
- **Macrolides (clarithromycin)** are predicted to increase the exposure to lapatinib. Avoid. [Moderate] Study
  - Also see TABLE 9 p. 1266
- **Macrolides (erythromycin)** are predicted to increase the exposure to lapatinib. [Moderate] Study
- **Netupitant** is predicted to increase the exposure to lapatinib.
  - Moderate Study
- **Nevirapine** is predicted to decrease the exposure to lapatinib. Avoid. [Severe] Study
- **Nilotinib** is predicted to increase the exposure to lapatinib.
  - Moderate Study
  - Also see TABLE 9 p. 1266
- **Lapatinib** is predicted to increase the exposure to nintedanib.
  - Moderate Study
- **Lapatinib** is predicted to increase the risk of bleeding events when given with phenindione. [Severe] Theoretical
- **Rifampicin** is predicted to decrease the exposure to lapatinib. Avoid. [Severe] Study
- **Lapatinib** is predicted to increase the exposure to sirolimus.
  - Moderate Theoretical
- **St John’s Wort** is predicted to decrease the exposure to lapatinib. Avoid. [Severe] Study
- **Lapatinib** slightly increases the exposure to taxanes (paclitaxel). [Severe] Study
- **Tedizolid** is predicted to increase the exposure to lapatinib. Avoid. [Moderate] Theoretical
- **Lapatinib** is predicted to increase the exposure to topotecan.
  - Severe Study
- **Lapatinib** is predicted to increase the concentration of trametinib. [Moderate] Theoretical
- **Lapatinib** is predicted to increase the exposure to venetoclax. Avoid or monitor for toxicity. [Severe] Theoretical

Laronidase

- **Antimalarials (chloroquine)** are predicted to decrease the exposure to laronidase. Avoid simultaneous administration.
  - Severe Theoretical
- **Hydroxychloroquine** is predicted to decrease the exposure to laronidase. Avoid simultaneous administration. [Severe] Theoretical

Ledipasvir

- **Antacids** are predicted to decrease the exposure to ledipasvir. Separate administration by 4 hours. [Moderate] Theoretical
- **Ledipasvir** increases the risk of severe bradycardia or heart block when given with antiarrhythmics (amiodarone). Refer to specialist literature. [Severe] Anecdotal

- **Antiepileptics (carbamazepine)** are predicted to decrease the exposure to ledipasvir. Avoid. [Severe] Theoretical
- **Calcium salts (calcium carbonate)** are predicted to decrease the exposure to ledipasvir. Separate administration by 4 hours. [Moderate] Theoretical
- **H₂ receptor antagonists** are predicted to decrease the exposure to ledipasvir. Adjust dose, see sofosbuvir with ledipasvir p. 596. [Moderate] Study
- **Proton pump inhibitors** are predicted to decrease the exposure to ledipasvir. Adjust dose, see sofosbuvir with ledipasvir p. 596. [Moderate] Theoretical
- **Rifampicin** is predicted to decrease the exposure to ledipasvir. Avoid. [Severe] Theoretical
- **Ledipasvir** moderately increases the exposure to simprevir and simprevir slightly increases the exposure to ledipasvir. Avoid. [Severe] Study
- **St John’s Wort** is predicted to decrease the exposure to ledipasvir. Avoid. [Severe] Theoretical
- **Ledipasvir** is predicted to increase the exposure to statins (atorvastatin, simvastatin). Monitor and adjust dose. [Moderate] Theoretical
- **Ledipasvir** (with sofosbuvir) is predicted to increase the exposure to statins (fluvastatin, pravastatin). Monitor and adjust dose. [Moderate] Theoretical
- **Ledipasvir** is predicted to increase the exposure to statins (rosuvastatin). Avoid. [Severe] Theoretical
- **Ledipasvir** (with sofosbuvir) slightly increases the exposure to tenofovir. [Moderate] Study

Leflunomide → see TABLE 1 p. 1264 (hepatotoxicity), TABLE 15 p. 1267 (myelosuppression)

PHARMACOLOGY

Leflunomide has a long half-life; washout procedure recommended before switching to other DMARDS (consult product literature).

- **Leflunomide** increases the anticoagulant effect of coumarine.
  - Severe Anecdotal
- **Live vaccines** are predicted to increase the risk of generalised infection (possibly life-threatening) when given with leflunomide. Public Health England advises avoid. [Severe] Theoretical

Levallosofa

- **Lenvlumaride** is predicted to increase the risk of venous thromboembolism when given with lenalidomide. Avoid. [Severe] Theoretical
- **Combined hormonal contraceptives** are predicted to increase the risk of venous thromboembolism when given with lenalidomide.
  - Severe Theoretical
- **Lercanidipine** → see calcium channel blockers

Levamisole

FOOD AND LIFESTYLE

Disulfiram-like reaction might occur on consumption of alcohol.

- **Albendazole** slightly decreases the exposure to levamisole and levamisole moderately decreases the exposure to albendazole. [Moderate] Study
- **Levamisole** increases the exposure to ivermectin. [Moderate] Study

Levetiracetam → see antiepileptics

Levobunolol → see beta blockers, non-selective

Levobupivacaine → see anaesthetics, local

Levocetirizine → see antihistamines, non-sedating

Levodopa → see TABLE 8 p. 1265 (hypotension)

GENERAL INFORMATION

Drugs with antimuscarinic effects might reduce the absorption of levodopa.

- **Amisulpride** is predicted to decrease the effects of levodopa. Avoid. [Severe] Theoretical
- **Antiepileptics (fosphenytoin, phenytoin)** decrease the effects of levodopa. [Moderate] Study
- **Aripiprazole** is predicted to decrease the effects of levodopa. [Severe] Theoretical
  - Also see TABLE 8 p. 1265
- **Asenapine** is predicted to decrease the effects of levodopa. Adjust dose. [Severe] Theoretical
  - Also see TABLE 8 p. 1265
- **Baclofen** is predicted to increase the risk of side-effects when given with levodopa. [Severe] Anecdotal
  - Also see TABLE 8 p. 1265
Benperidol is predicted to decrease the effects of levodopa. 

Bupropion increases the risk of side-effects when given with levodopa. Moderately predicted by study. Also see TABLE 8 p. 1265

Clozapine is predicted to decrease the effects of levodopa. Theoretical. Also see TABLE 8 p. 1265

Droperidol decreases the effects of levodopa. Severe. Published study. Also see TABLE 8 p. 1265

Entacapone increases the exposure to levodopa. Monitor side effects and adjust dose. Moderate. Published study. Also see TABLE 8 p. 1265

Flupentixol decreases the effects of levodopa. Avoid or monitor worsening parkinsonian symptoms. Severe. Theoretical. Also see TABLE 8 p. 1265

Haloperidol decreases the effects of levodopa. Severe. Published study. Also see TABLE 8 p. 1265

Iron (oral) decreases the absorption of levodopa. Moderate. Study

Isorniazid decreases the effects of levodopa. Moderate. Study

Levodopa is predicted to increase the risk of elevated blood pressure when given with linezolid. Avoid. Severe. Theoretical. Also see TABLE 8 p. 1265

Loxapine is predicted to decrease the effects of levodopa. Severe. Published study. Also see TABLE 8 p. 1265

Metoclopramide decreases the effects of levodopa. Avoid. Moderate. Study

Levodopa increases the risk of side-effects when given with moclobemide. Moderate. Study

Levodopa increases the risk of a hypertensive crisis when given with monoamine-oxidase A and B inhibitors, irreversible. Avoid and for 14 days after stopping the MAOI. Severe. Published study. Also see TABLE 8 p. 1265

Monoamine-oxidase B inhibitors are predicted to increase the effects of levodopa. Adjust dose. Medium. Published study. Also see TABLE 8 p. 1265

Olanzapine decreases the effects of levodopa. Avoid or monitor worsening parkinsonian symptoms. Severe. Anecdotal. Also see TABLE 8 p. 1265

Opicapone increases the exposure to levodopa. Adjust levodopa dose. Moderate. Study

Phenothiazines decrease the effects of levodopa. Avoid or monitor worsening parkinsonian symptoms. Severe. Published study. Also see TABLE 8 p. 1265

Pimozide decreases the effects of levodopa. Severe. Theoretical. Also see TABLE 8 p. 1265

Quetiapine decreases the effects of levodopa. Severe. Anecdotal. Also see TABLE 8 p. 1265

Risperidone is predicted to decrease the effects of levodopa. Avoid or adjust dose. Severe. Anecdotal. Also see TABLE 8 p. 1265

Sulpiride is predicted to decrease the effects of levodopa. Avoid. Severe. Theoretical. Also see TABLE 8 p. 1265

Tetramazepam is predicted to decrease the effects of levodopa. Use with caution or avoid. Moderate. Theoretical

Tolcapone increases the exposure to levodopa. Monitor and adjust dose. Moderate. Study

Zuclopenthixol is predicted to decrease the effects of levodopa. Avoid or monitor worsening parkinsonian symptoms. Severe. Published study. Also see TABLE 8 p. 1265

Levofloxacin → see quinolones

Levofolinic acid → see folates

Levomepromazine → see phenothiazines

Levonorgestrel is predicted to decrease the efficacy of levonorgestrel. For FSRH guidance, see Contraceptives, interactions p. 747. Severe. Theoretical

Bosantan is predicted to decrease the efficacy of levonorgestrel. For FSRH guidance, see Contraceptives, interactions p. 747. Severe. Theoretical

Efavirenz is predicted to decrease the efficacy of levonorgestrel. For FSRH guidance, see Contraceptives, interactions p. 747. Severe. Theoretical

Fosaprepitant is predicted to decrease the efficacy of levonorgestrel. For FSRH guidance, see Contraceptives, interactions p. 747. Severe. Theoretical

Griseofulvin potentially decreases the efficacy of oral levonorgestrel. For FSRH guidance, see Contraceptives, interactions p. 747. Severe. Anecdotal

HIV-protease inhibitors (ritonavir) are predicted to decrease the efficacy of levonorgestrel. For FSRH guidance, see Contraceptives, interactions p. 747. Severe. Theoretical

Modafinil is predicted to decrease the efficacy of levonorgestrel. For FSRH guidance, see Contraceptives, interactions p. 747. Severe. Theoretical

Nevirapine is predicted to decrease the efficacy of levonorgestrel. For FSRH guidance, see Contraceptives, interactions p. 747. Severe. Theoretical

Rifabutin is predicted to decrease the efficacy of levonorgestrel. For FSRH guidance, see Contraceptives, interactions p. 747. Severe. Theoretical

Rifampicin is predicted to decrease the efficacy of levonorgestrel. For FSRH guidance, see Contraceptives, interactions p. 747. Severe. Theoretical

St John’s Wort is predicted to decrease the efficacy of levonorgestrel. MHRA advises avoid. For FSRH guidance, see Contraceptives, interactions p. 747. Severe. Theoretical

Sugar mandex is predicted to decrease the exposure to levonorgestrel. Use additional contraceptive precautions. Severe. Theoretical

Ulipristal is predicted to decrease the efficacy of levonorgestrel. Avoid. Severe. Theoretical

Levotiroxine

Antacids are predicted to decrease the absorption of levothyroxine. Separate administration by at least 4 hours. Moderate. Anecdotal

Antihypertensives (amlodipine) increase the risk of thyroid dysfunction when given with levothyroxine. Avoid. Moderate. Study

Antiepileptics (carbamazepine) increase the risk of hypothyroidism when given with levothyroxine. Monitor and adjust dose. Moderate. Study

Antiepileptics (fosphenytoin, phenytoin) increase the risk of hypothyroidism when given with levothyroxine. Moderate. Study

Antiepileptics (phenobarbital, primidone) are predicted to decrease the effects of levothyroxine. Moderate. Theoretical

Calcium salts are predicted to decrease the absorption of levothyroxine. Separate administration by at least 4 hours. Moderate. Anecdotal

Levothyroxine is predicted to affect the concentration of digoxin. Monitor and adjust dose. Moderate. Theoretical

Levothyroxine is predicted to decrease the effects of levotiroxine. Moderate. Theoretical

Iron (oral) decreases the absorption of levothyroxine. Separate administration by at least 4 hours. Moderate. Study

Lanthanum decreases the absorption of levothyroxine. Separate administration by 2 hours. Moderate. Study

Polystyrene sulfonate is predicted to decrease the absorption of levothyroxine. Separate administration by at least 4 hours. Moderate. Theoretical

Sucralfate decreases the absorption of levothyroxine. Separate administration by at least 4 hours. Moderate. Study

Lidocaine → see antihypertensives

Linaclotide is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. Moderate. Theoretical

Downloaded from www.medicalbr.com
**Linagliptin**

**Interactions**

- **Rifampicin** is predicted to decrease the exposure to linagliptin. **Moderate** Study

- **Linezolid** → see TABLE 15 p. 1267 (myelosuppression), **TABLE 13** p. 1267 (serotonin syndrome) **FOOD AND LIFESTYLE** Patients taking linezolid should avoid consuming large amounts of tyramine-rich foods (such as mature cheese, salami, pickled herring, Bovril®, Oxo®, Marmite® or any similar meat or yeast extract or fermented soya bean extract, and some beers, lagers or wines).

- **β2 agonists** are predicted to increase the risk of elevated blood pressure when given with **linezolid**. Avoid. **Severe** Theoretical

- **Bupropion** is predicted to increase the risk of intraoperative hypertension when given with **linezolid**. **Severe** Anecdotal → Also see **TABLE 13** p. 1267

- **Buspirone** is predicted to increase the risk of elevated blood pressure when given with **linezolid**. Avoid. **Severe** Theoretical → Also see **TABLE 13** p. 1267

- **Lenvadopa** is predicted to increase the risk of elevated blood pressure when given with **linezolid**. Avoid. **Severe** Theoretical

- **Methylphenidate** is predicted to increase the risk of elevated blood pressure when given with **linezolid**. Avoid. **Severe** Theoretical

- **Moclobemide** is predicted to increase the risk of side-effects when given with **linezolid**. Avoid and for 14 days after stopping **moclobemide**. **Severe** Theoretical → Also see **TABLE 13** p. 1267

- **Monoamine-oxidase A and B inhibitors, irreversible** are predicted to increase the risk of side-effects when given with **linezolid**. Avoid and for 14 days after stopping **moclobemide**. **Severe** Theoretical → Also see **TABLE 13** p. 1267

- **Monoamine-oxidase B inhibitors (rasagline, selegiline)** are predicted to increase the risk of side-effects when given with **linezolid**. Avoid and for 14 days after stopping the MAOI. **Severe** Theoretical → Also see **TABLE 13** p. 1267

- **Monoamine-oxidase B inhibitors (safinamide)** are predicted to increase the risk of side-effects when given with **linezolid**. Avoid and for 1 week after stopping **safinamide**. **Severe** Theoretical → Also see **TABLE 13** p. 1267

- **Reboxetine** is predicted to increase the risk of a hypertensive crisis when given with **linezolid**. Avoid. **Severe** Theoretical

- **Rifampicin** slightly decreases the exposure to **linezolid**. **Moderate** Study

- **Sympathomimetics, inotropic (dobutamine, dopamine)** are predicted to increase the risk of elevated blood pressure when given with **linezolid**. Avoid. **Severe** Theoretical

- **Sympathomimetics, vasoconstrictor (pseudoephedrine)** increase the risk of elevated blood pressure when given with **linezolid**. Avoid. **Severe** Study

**Liothyronine**

- **Antiarhythmic (amiodarone)** are predicted to increase the risk of thyroid dysfunction when given with **liothyronine**. Avoid. **Moderate** Theoretical

- **Antiepileptics (fosphenytoin, phenytoin)** are predicted to increase the risk of hypothyroidism when given with **liothyronine**. **Moderate** Theoretical

- **Antiepileptics (phenobarbital, primidone)** are predicted to decrease the effects of **liothyronine**. **Moderate** Theoretical

- **Liothyronine** is predicted to affect the concentration of **lithium**. Monitor and adjust dose. **Moderate** Theoretical

- **Oral Hormone replacement therapy** is predicted to decrease the effects of **liothyronine**. **Moderate** Theoretical

- **Lanthanum** decreases the absorption of **liothyronine**. Separate administration by 2 hours. **Moderate** Study

**Liraglutide** → see **TABLE 14** p. 1267 (antidiabetic drugs)

**Lisdexamfetamine** → see amphetamines

**Lisinopril** → see ACE inhibitors

**Lithium** → see **TABLE 13** p. 1267 (serotonin syndrome), **TABLE 9** p. 1266 (QT-interval prolongation)

- **ACE inhibitors** are predicted to increase the concentration of **lithium**. Monitor and adjust dose. **Severe** Anecdotal

- **Acetazolamide** alters the concentration of **lithium**. **Severe** Anecdotal

- **Aldosterone antagonists (spironolactone)** potentially increase the concentration of **lithium**. **Moderate** Study

- **Aminophylline** is predicted to decrease the concentration of **lithium**. **Moderate** Theoretical

- **Angiotensin-II receptor antagonists** potentially increase the concentration of **lithium**. Monitor concentration and adjust dose. **Severe** Anecdotal

- **Antiepileptics (carbamazepine)** increase the risk of neurotoxicity when given with **lithium**. **Severe** Anecdotal

- **Antiepileptics (oxcarbazepine)** are predicted to increase the risk of neurotoxicity when given with **lithium**. **Severe** Theoretical

- **Calcitonin (salmon)** decreases the concentration of **lithium**. **Moderate** Study

- **Calcium channel blockers (diltiazem, verapamil)** are predicted to increase the risk of neurotoxicity when given with **lithium**. **Severe** Anecdotal

- **Loop diuretics** increase the concentration of **lithium**. **Moderate** Study

- **Methylprednisolone** increases the risk of neurotoxicity when given with **lithium**. **Severe** Anecdotal

- **NSAID** increase the concentration of **lithium**. **Moderate** Study

- **Phenothiazines** potentially increase the risk of neurotoxicity when given with **lithium**. **Severe** Anecdotal

- **Quetiapine** potentially increases the risk of neurotoxicity when given with **lithium**. **Severe** Anecdotal

- **Risperidone** potentially increases the risk of neurotoxicity when given with **lithium**. **Severe** Anecdotal

- **Potassium-sparing diuretics (triamterene)** potentially increase the clearance of **lithium**. **Moderate** Study

- **Sodium bicarbonate** decreases the concentration of **lithium**. **Severe** Anecdotal

- **Sulpiride** potentially increases the risk of neurotoxicity when given with **lithium**. **Severe** Anecdotal

- **Thiazide diuretics** increase the concentration of **lithium**. Avoid or adjust **lithium** (lithium carbonate, lithium citrate) dose and monitor **lithium** (lithium carbonate, lithium citrate) concentration. **Severe** Study

- **Tricyclic antidepressants** potentially increase the risk of neurotoxicity when given with **lithium**. **Severe** Anecdotal → Also see **TABLE 9** p. 1266

- **Zuclopenthixol** potentially increases the risk of neurotoxicity when given with **lithium**. **Severe** Anecdotal → Also see **TABLE 9** p. 1266

**Live vaccines**

- Bacillus Calmette-Guérin vaccine · influenza vaccine · measles, mumps and rubella vaccine, live · rotavirus vaccine · typhoid vaccine · varicella-zoster vaccine · yellow fever vaccine, live

**ROUTE-SPECIFIC INFORMATION** Oral typhoid vaccine is inactivated by concurrent administration of antibacterials or antimalarials; antibacterials should be avoided for 3 days before and after oral typhoid vaccination; mefloquine should be avoided for at least 12 hours before or after oral typhoid vaccination; for other antimalarials oral typhoid vaccine vaccination should be completed at least 3 days before the first dose of the antimalarial (except proguanil hydchloride with atovaquone, which can be given concurrently).

- **Live vaccines** are predicted to increase the risk of generalised infection (possibly life-threatening) when given with **abatacept**. Public Health England advises avoid. **Severe** Theoretical
Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
alkylating agents. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
amsacrine. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
anakinra. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
anthracyclines. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
azathioprine. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
betalactam. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
bleomycin. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
capetibatine. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
ciclosporin. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
cladribine. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
clofarabine. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
corticosteroids (high-dose). Public Health England advises avoid. **Severe**

Influenza vaccine potentially increases the risk of bleeding events when given with coumarins. **Severe** Anecdotal

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
cytarabine. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
dactinomycin. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
dimethyl fumarate. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
etanercept. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
etoposide. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
everolimus. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
fingolimod. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
fluorouracil. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
hydroxyurea. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
irinotecan. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
leflunomide. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
methotrexate. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
mitomycin. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
monoclonal antibodies. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
mycophenolate. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
pemetrexed. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
platinum compounds. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
procabazine. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
ralitrexed. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
sirolimus. Public Health England advises avoid. **Severe**

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with
tacrolimus. Public Health England advises avoid. **Severe**
Live vaccines – Lomitapide

**Live vaccines** are predicted to increase the risk of generalised infection (possibly life-threatening) when given with taxanes (docetaxel, paclitaxel). Public Health England advises avoid. (Severe) Theoretical

**Live vaccines** are predicted to increase the risk of generalised infection (possibly life-threatening) when given with tegafur. Public Health England advises avoid. (Severe) Theoretical

**Live vaccines** are predicted to increase the risk of generalised infection (possibly life-threatening) when given with temsirolimus. Public Health England advises avoid. (Severe) Theoretical

**Live vaccines** are predicted to increase the risk of generalised infection (possibly life-threatening) when given with teriflunomide. Public Health England advises avoid. (Severe) Theoretical

**Live vaccines** are predicted to increase the risk of generalised infection (possibly life-threatening) when given with tioguanine. Public Health England advises avoid. (Severe) Theoretical

**Live vaccines** are predicted to increase the risk of generalised infection (possibly life-threatening) when given with topotecan. Public Health England advises avoid. (Severe) Theoretical

**Live vaccines** are predicted to increase the risk of generalised infection (possibly life-threatening) when given with trabectedin. Public Health England advises avoid. (Severe) Theoretical

**Venetoclax** potentially decreases the efficacy of live vaccines. Avoid. (Severe) theoretical

**Lofepramine** see tricyclic antidepressants

**Lofexidine** see Table 8 p. 1265 (hypotension), Table 9 p. 1266 (QT-interval prolongation), Table 11 p. 1266 (CNS depressant effects)

**Lomitapide** see Table 1 p. 1264 (hepatotoxicity)

**FOD AND LIFESTYLE** Bitter (Seville) orange is predicted to increase the exposure to lomitapide; separate administration by 12 hours.

**Alprazolam** is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. (Moderate) Theoretical

**Antiarhythmic (amiodarone)** are predicted to increase the exposure to lomitapide. Separate administration by 12 hours. (Moderate) Theoretical

**Antiarhythmic (dronedarone)** are predicted to increase the exposure to lomitapide. Avoid. (Moderate) Theoretical

**Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone)** are predicted to decrease the exposure to lomitapide. Monitor and adjust dose. (Moderate) Theoretical

Also see Table 1 p. 1264

**Antifungals, azoles (clotrimazole)** are predicted to increase the exposure to lomitapide. Separate administration by 12 hours. (Moderate) Theoretical

**Antifungals, azoles (fluconazole, isavuconazole, posaconazole)** are predicted to increase the exposure to lomitapide. Avoid. (Moderate) Theoretical Also see Table 1 p. 1264

**Antifungals, azoles (itraconazole, ketoconazole, voriconazole)** are predicted to markedly increase the exposure to lomitapide. Avoid. (Severe) Study Also see Table 1 p. 1264

**Aprepitant** is predicted to increase the exposure to lomitapide. Avoid. (Moderate) Theoretical

**Bicalutamide** is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. (Moderate) Theoretical

**Calcium channel blockers (amlodipine, lacidipine)** are predicted to increase the exposure to lomitapide. Separate administration by 12 hours. (Moderate) Theoretical

**Calcium channel blockers (diltiazem, verapamil)** are predicted to increase the exposure to lomitapide. Avoid. (Moderate) Theoretical

**Ciclosporin** is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. (Moderate) Theoretical

**Clofazimine** is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. (Moderate) Theoretical

**Cobicistat** is predicted to markedly increase the exposure to lomitapide. Avoid. (Severe) Study

**Oral combined hormonal contraceptives** slightly increase the exposure to lomitapide. Separate administration by 12 hours. (Moderate) Theoretical

**Lomitapide** increases the exposure to coumarins (warfarin). Monitor INR and adjust warfarin dose. (Severe) Study

**Crizotinib** is predicted to increase the exposure to lomitapide. Avoid. (Moderate) Theoretical

**Enzalutamide** is predicted to decrease the exposure to lomitapide. Monitor and adjust dose. (Moderate) Theoretical

**Everolimus** is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. (Moderate) Theoretical

**Fosaprepitant** is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. (Moderate) Theoretical

**Grapefruit juice** is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. (Moderate) Theoretical

**H2 receptor antagonists (cimetidine, ranitidine)** are predicted to increase the exposure to lomitapide. Separate administration by 12 hours. (Moderate) Theoretical

**HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to markedly increase the exposure to lomitapide. Avoid. (Severe) Study

**HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to lomitapide. Avoid. (Moderate) Theoretical

**Idelalisib** is predicted to markedly increase the exposure to lomitapide. Avoid. (Severe) Study

**Imatinib** is predicted to increase the exposure to lomitapide. Avoid. (Moderate) Theoretical

**Isoniazid** is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. (Unknown) Theoretical Also see Table 1 p. 1264

**Ivacaftor** is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. (Moderate) Theoretical

**Lapatinib** is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. (Moderate) Theoretical

**Linagliptin** is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. (Moderate) Theoretical

**Macrolides (azithromycin)** are predicted to increase the exposure to lomitapide. Separate administration by 12 hours. (Moderate) Theoretical

**Macrolides (clarithromycin)** are predicted to markedly increase the exposure to lomitapide. Avoid. (Severe) Study

**Macrolides (erythromycin)** are predicted to increase the exposure to lomitapide. Avoid. (Moderate) Theoretical

**Nilotinib** is predicted to increase the exposure to lomitapide. Avoid. (Moderate) Theoretical

**Netupitant** is predicted to increase the exposure to lomitapide. Avoid. (Moderate) Theoretical

**Pazopanib** is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. (Moderate) Theoretical

**Peppermint oil** is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. (Moderate) Theoretical

**Pexelizumab (fluoxetine)** are predicted to increase the exposure to lomitapide. Separate administration by 12 hours. (Unknown) Theoretical

**Propiverine** is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. (Moderate) Theoretical

**Ranolazine** is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. (Moderate) Theoretical

**Rifampicin** is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. (Moderate) Theoretical

**Sibilities (fluoxetine)** are predicted to increase the exposure to lomitapide. Separate administration by 12 hours. (Unknown) Theoretical
SSRIs (fluvoxamine) are predicted to increase the exposure to lomitapide. Separate administration by 12 hours. [Moderate] Theoretical

Lomitapide increases the exposure to statins (atorvastatin). Adjust lomitapide dose or separate administration by 12 hours. [Mild] Study → Also see TABLE 1 p. 1264

Lomitapide increases the exposure to simvastatin. Monitor and adjust simvastatin dose, p. 198. [Moderate] Study → Also see TABLE 1 p. 1264

Tacrolimus is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. [Moderate] Theoretical

Ticagrelor is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. [Moderate] Theoretical

Tolvaptan is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. [Moderate] Theoretical

Lomustine is predicted to decrease the exposure to antifungals, azoles (fluconazole). Adjust dose. [Mild] Theoretical

Lumacaftor is predicted to affect the exposure to aliskiren. [Moderate] Theoretical

Lumacaftor is predicted to decrease the exposure to antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone). Avoid. [Severe] Theoretical

Lumacaftor is predicted to decrease the exposure to antifungals, azoles (itraconazole, ketoconazole, voriconazole). [Moderate] Theoretical

Lumacaftor is predicted to decrease the exposure to antihistamines, non-sedating (fexofenadine). Monitor and adjust dose. [Moderate] Theoretical

Lumacaftor is predicted to decrease the exposure to bupropion. Adjust dose. [Moderate] Theoretical

Lumacaftor is predicted to decrease the exposure to circlosporin. Avoid. [Severe] Theoretical

Lumacaftor is predicted to affect the exposure to colchicine. [Moderate] Theoretical

Lumacaftor is predicted to affect the exposure to coumarins (warfarin). [Severe] Theoretical

Lumacaftor is predicted to affect the exposure to digoxin. Monitor and adjust dose. [Moderate] Theoretical

Lumacaftor is predicted to affect the exposure to edoxaban. [Moderate] Theoretical

Lumacaftor is predicted to decrease the exposure to everolimus. Avoid. [Severe] Theoretical

Lumacaftor is predicted to affect the exposure to H2 receptor antagonists (ranitidine). Monitor and adjust dose. [Moderate] Theoretical

Lumacaftor is predicted to affect the exposure to loperamide. [Moderate] Theoretical

Lumacaftor is predicted to decrease the exposure to macrolides (clarithromycin, erythromycin). [Moderate] Theoretical

Lumacaftor is predicted to decrease the exposure to midazolam. Avoid. [Severe] Theoretical

Lumacaftor is predicted to decrease the exposure to montelukast. [Moderate] Theoretical

Lumacaftor is predicted to decrease the exposure to NSAIDs (ibuprofen). Adjust dose. [Moderate] Theoretical

Lumacaftor is predicted to decrease the exposure to proton pump inhibitors (esomeprazole, lansoprazole, omeprazole). Adjust dose. [Moderate] Theoretical

Lumacaftor is predicted to decrease the exposure to repaglinide. Adjust dose. [Moderate] Theoretical

Lumacaftor is predicted to decrease the exposure to rifabutin. Adjust dose. [Moderate] Theoretical

Lumacaftor is predicted to decrease the exposure to sirolimus. Avoid. [Severe] Theoretical

Lumacaftor is predicted to decrease the exposure to SSRLs. (citalopram, escitalopram, sertraline). Adjust dose. [Moderate] Theoretical

Lumacaftor is predicted to decrease the exposure to tacrolimus. Avoid. [Severe] Theoretical
Lumacaftor — Macrolides

Lumacaftor (continued)

▶ Aprepitant is predicted to affect the exposure to temsirolimus. [Severe] Theoretical
▶ Lumacaftor is predicted to decrease the exposure to topotecan. [Moderate] Theoretical

Lumeferon fume → see antimalarials

Lurasidone → see TABLE 8 p. 1265 (hypotension), TABLE 11 p. 1266 (CNS depressant effects)

▶ Antiarrhythmics (dronedarone) are predicted to increase the exposure to lurasidone. [Moderate] Study
▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to lurasidone. Avoid. [Moderate] Study → Also see TABLE 11 p. 1266
▶ Antiinfective agents (clarithromycin, tsaunconazole, posaconazole) are predicted to increase the exposure to lurasidone. [Moderate] Study
▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to lurasidone. Avoid. [Severe] Study
▶ Enzalutamide is predicted to increase the exposure to lurasidone. Avoid. [Severe] Study

A1 1362 Lumacaftor — Macrolides

Macrolides → see TABLE 9 p. 1266 (QT-interval prolongation)

Azithromycin - clarithromycin - erythromycin

ROUTE-SPECIFIC INFORMATION
Since systemic absorption can follow topical application, the possibility of interactions should be borne in mind.

▶ Clarithromycin is predicted to increase the exposure to abiraterone. [Severe] Theoretical
▶ Macrolides are predicted to increase the exposure to afatinib. Separate administration by 12 hours. [Moderate] Study
▶ Clarithromycin is predicted to markedly increase the exposure to aldosterone antagonists (eplerenone). Avoid. [Severe] Study
▶ Erythromycin is predicted to increase the exposure to aldosterone antagonists (eplerenone). Adjust eplerenone dose, p. 185. [Severe] Study
▶ Azithromycin is predicted to increase the exposure to aliskiren. [Moderate] Theoretical
▶ Macrolides (clarithromycin, erythromycin) are predicted to increase the exposure to aliskiren. [Moderate] Study
▶ Clarithromycin increases the exposure to almotriptan. [Mild] Study
▶ Clarithromycin is predicted to moderately increase the exposure to alpha blockers (alfuzosin, tamsulosin). Use with caution or avoid. [Moderate] Study
▶ Clarithromycin is predicted to increase the exposure to alpha blockers (doxazosin). [Moderate] Study
▶ Erythromycin is predicted to increase the exposure to alpha blockers (tamsulosin). [Moderate] Theoretical
▶ Clarithromycin moderately increases the exposure to alprazolam. Avoid. [Moderate] Study
▶ Erythromycin is predicted to increase the exposure to alprazolam. [Severe] Study
▶ Azithromycin is predicted to increase the exposure to aminophylline. [Moderate] Theoretical
▶ Clarithromycin is predicted to increase the exposure to aminophylline. Adjust aminophylline dose. [Moderate] Theoretical
▶ Aminophylline is predicted to decrease the exposure to erythromycin. Adjust dose. [Severe] Study
▶ Clarithromycin very markedly increases the exposure to antiarrhythmics (dronedarone). Avoid. [Severe] Study → Also see TABLE 9 p. 1266
▶ Erythromycin is predicted to moderately increase the exposure to antiarrhythmics (dronedarone). Avoid. [Severe] Theoretical
▶ Macrolides (clarithromycin, erythromycin) are predicted to increase the exposure to antiarrhythmics (lidocaine). [Moderate] Theoretical
▶ Clarithromycin is predicted to increase the exposure to antiarrhythmics (propafenone). Monitor and adjust dose. [Severe] Study
▶ Erythromycin is predicted to increase the exposure to antiarrhythmics (propafenone). Monitor and adjust dose. [Moderate] Study
▶ Clarithromycin is predicted to increase the exposure to anticholinesterases, centrally acting (galantamine). Monitor and adjust dose. [Moderate] Study
▶ Clarithromycin slightly increases the concentration of antiepileptics (carbamazepine). Monitor carbamazepine concentration and adjust dose. [Severe] Study
▶ Erythromycin markedly increases the concentration of antiepileptics (carbamazepine). Monitor carbamazepine concentration and adjust dose. [Severe] Study
▶ Clarithromycin is predicted to slightly increase the exposure to antiepileptics (perampanel). [Mild] Study
Clarithromycin is predicted to increase the exposure to antifungals, azoles (isavuconazole). Avoid or monitor side effects. [Severe] Study

Erythromycin is predicted to increase the exposure to antifungals, azoles (isavuconazole). [Moderate] Theoretical

Clarithromycin is predicted to increase the exposure to antihistamines, non-sedating (mizolastine). Avoid. [Severe] Study

Erythromycin is predicted to increase the exposure to antihistamines, non-sedating (mizolastine). [Severe] Theoretical

Clarithromycin is predicted to increase the exposure to antimalarials (artemether) with lumefantrine. [Moderate] Study → Also see TABLE 9 p. 1266

Macrolides (clarithromycin, erythromycin) are predicted to increase the concentration of antimalarials (piperaquine). [Severe] Theoretical

Clarithromycin is predicted to increase the exposure to apixaban. Avoid. [Severe] Theoretical

Erythromycin is predicted to increase the exposure to apixaban. [Moderate] Theoretical

Clarithromycin is predicted to markedly increase the exposure to aprepitant. [Moderate] Study

Clarithromycin is predicted to slightly increase the exposure to aripiprazole. Adjust aripiprazole dose, p. 376. [Moderate] Study

Clarithromycin is predicted to increase the exposure to axitinib. [Moderate] Study

Erythromycin is predicted to increase the exposure to axitinib. [Moderate] Theoretical

Clarithromycin is predicted to increase the exposure to bedaquiline. Avoid prolonged use. [Mild] Study → Also see TABLE 9 p. 1266

Erythromycin is predicted to increase the exposure to bedaquiline. Avoid prolonged use. [Mild] Theoretical

Macrolides are predicted to increase the exposure to beta blockers, non-selective (nadolol). [Moderate] Study

Clarithromycin is predicted to increase the exposure to beta-agonists (salmeterol). Avoid. [Severe] Study

Clarithromycin slightly increases the exposure to bortezomib. [Moderate] Study

Clarithromycin is predicted to increase the exposure to bosentan. [Moderate] Theoretical

Clarithromycin is predicted to markedly increase the exposure to bosutinib. Avoid or adjust bosutinib dose. [Severe] Study → Also see TABLE 9 p. 1266

Erythromycin is predicted to increase the exposure to bosutinib. Avoid or adjust bosutinib dose. [Severe] Theoretical

Clarithromycin is predicted to increase the exposure to buprine. Adjust buprine dose, p. 325. [Severe] Study

Erythromycin is predicted to increase the exposure to buprine. Use with caution and adjust dose. [Moderate] Study

Clarithromycin slightly increases the exposure to cabozantinib. [Moderate] Study → Also see TABLE 9 p. 1266

Erythromycin is predicted to increase the exposure to cabozantinib. [Moderate] Theoretical

Macrolides (clarithromycin, erythromycin) are predicted to increase the exposure to calcium channel blockers (amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose. [Moderate] Study

Erythromycin is predicted to increase the exposure to calcium channel blockers (diltiazem). [Severe] Theoretical

Clarithromycin is predicted to increase the exposure to calcium channel blockers (diltiazem, verapamil). [Severe] Study

Clarithromycin is predicted to markedly increase the exposure to calcium channel blockers (lercanidipine). Avoid. [Severe] Study

Erythromycin is predicted to increase the exposure to calcium channel blockers (verapamil). [Severe] Study

Clarithromycin is predicted to increase the exposure to cannabis extract. Use with caution and adjust dose. [Moderate] Theoretical

Clarithromycin is predicted to increase the exposure to certinib. Avoid or adjust certinib dose, p. 895. [Severe] Study → Also see TABLE 9 p. 1266

Macrolides (azithromycin, erythromycin) are predicted to increase the exposure to certinib. [Moderate] Theoretical

Macrolides (clarithromycin, erythromycin) increase the concentration of ciclosporin. [Severe] Study

Clarithromycin is predicted to moderately increase the exposure to cilostazol. Adjust cilostazol dose, p. 226. [Moderate] Study

Erythromycin slightly increases the exposure to cilostazol. Adjust cilostazol dose, p. 226. [Moderate] Study

Clarithromycin is predicted to moderately increase the exposure to cinacalcet. Adjust dose. [Moderate] Study

Clarithromycin is predicted to markedly increase the exposure to cobimetinib. Avoid or monitor for toxicity. [Severe] Study

Erythromycin is predicted to increase the exposure to cobimetinib. [Severe] Theoretical

Azithromycin is predicted to increase the exposure to colchicine. Avoid or adjust colchicine dose, p. 1020. [Severe] Theoretical

Clarithromycin is predicted to increase the exposure to colchicine. Avoid or adjust colchicine dose, p. 1020. [Severe] Study

Erythromycin is predicted to increase the exposure to colchicine. Adjust colchicine dose, p. 1020. [Severe] Study

Clarithromycin is predicted to increase the exposure to corticosteroids (budesonide). Avoid. [Severe] Study

Clarithromycin is predicted to increase the exposure to corticosteroids (ciclesonide). Avoid. [Moderate] Theoretical

Clarithromycin is predicted to increase the risk of side-effects when given with corticosteroids (triamcinolone). [Severe] Theoretical

Macrolides (clarithromycin, erythromycin) increase the anticoagulant effect of coumarins. Monitor INR and adjust dose. [Severe] Anecdotal

Clarithromycin is predicted to moderately increase the exposure to crizotinib. Avoid. [Moderate] Study → Also see TABLE 9 p. 1266

Erythromycin is predicted to increase the exposure to crizotinib. [Moderate] Theoretical

Macrolides (azithromycin, clarithromycin, erythromycin) are predicted to increase the exposure to dabigatran. [Moderate] Theoretical

Clarithromycin is predicted to increase the exposure to dabrafenib. Use with caution or avoid. [Moderate] Study

Clarithromycin is predicted to moderately increase the exposure to dacitoxsvir. Adjust dacitoxsvir dose, p. 591. [Moderate] Study

Clarithromycin is predicted to markedly to very markedly increase the exposure to darifenacin. Avoid. [Severe] Study

Erythromycin is predicted to slightly increase the exposure to darifenacin. [Severe] Study

Clarithromycin is predicted to markedly increase the exposure to dasatinib. Avoid. [Severe] Study → Also see TABLE 9 p. 1266

Erythromycin is predicted to increase the exposure to dasatinib. [Severe] Study

Clarithromycin very slightly increases the exposure to delamanid. [Severe] Study → Also see TABLE 9 p. 1266

Macrolides increase the concentration of digoxin. [Severe] Anecdotal

Macrolides (clarithromycin, erythromycin) increase the risk of QT-prolongation when given with domperidone. Avoid. [Severe] Study

Clarithromycin increases the exposure to dopamine receptor agonists (bromocriptine, cabergoline). [Severe] Study

Erythromycin is predicted to increase the exposure to dopamine receptor agonists (bromocriptine, cabergoline). [Severe] Theoretical
Appendix 1

Macrolides

- Clarithromycin is predicted to increase the exposure to dutasteride. Monitor side effects and adjust dose. **Moderate**
- Theoretical

- Erythromycin is predicted to moderately increase the exposure to dutasteride. **Moderate** Study
- Erythromycin slightly increases the exposure to edoxaban. Adjust edoxaban dose, p. 122. **Severe** Study

- Macrolides (azithromycin, clarithromycin) are predicted to slightly increase the exposure to edoxaban. **Severe** Theoretical Study
- Efavirenz decreases the exposure to clarithromycin. **Moderate** Study

- Clarithromycin slightly to moderately increases the exposure to elbasvir. Avoid. **Severe** Study
- Clarithromycin is predicted to markedly increase the exposure to eletriptan. Avoid. **Severe** Study
- Erythromycin moderately increases the exposure to eletriptan. Avoid. **Moderate** Study

- Clarithromycin is predicted to increase the risk of ergotism when given with ergotamine. Avoid. **Severe** Theoretical Study
- Erythromycin is predicted to increase the risk of ergotism when given with ergotamine. Avoid. **Severe** Theoretical Study
- Clarithromycin is predicted to slightly increase the exposure to erlotinib. Use with caution and adjust dose. **Moderate** Study
- Macrolides (azithromycin, erythromycin) are predicted to increase the exposure to erlotinib. **Moderate** Theoretical Study
- Etatravine decreases the exposure to clarithromycin. **Severe** Study

- Clarithromycin is predicted to increase the concentration of everolimus. Avoid. **Severe** Study
- Erythromycin is predicted to increase the concentration of everolimus. Avoid or adjust dose. **Moderate** Study
- Clarithromycin is predicted to moderately increase the exposure to fosoterodine. Adjust fosoterodine dose; avoid in hepatic and renal impairment, p. 732. **Severe** Study
- Erythromycin is predicted to increase the exposure to fosoterodine. Adjust fosoterodine dose in hepatic and renal impairment, p. 732. **Mild** Study
- Macrolides are predicted to increase the exposure to fidaxomicin. Avoid. **Moderate** Study
- Clarithromycin is predicted to increase the exposure to fosaprepitant. **Moderate** Theoretical
- Clarithromycin is predicted to increase the exposure to gefitinib. **Moderate** Study
- Erythromycin is predicted to increase the exposure to gefitinib. **Moderate** Theoretical
- Clarithromycin is predicted to moderately to markedly increase the exposure to grazoprevir. Avoid. **Severe** Study
- Clarithromycin is predicted to increase the exposure to guanfacine. Adjust guanfacine dose, p. 335. **Moderate** Study
- Erythromycin is predicted to increase the concentration of guanfacine. Adjust guanfacine dose, p. 335. **Moderate** Theoretical
- H2 receptor antagonists (cimetidine) slightly increase the exposure to erythromycin. **Moderate** Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, ritonavir) slightly to moderately increase the exposure to clarithromycin. Adjust dose in renal impairment. **Severe** Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, ritonavir, tipranavir) are predicted to increase the exposure to erythromycin. **Severe** Theoretical Study
- Clarithromycin increases the exposure to HIV-protease inhibitors (saquinavir) and HIV-protease inhibitors (saquinavir) increase the exposure to clarithromycin. Avoid. **Severe** Study → Also see TABLE 9 p. 1266
- Erythromycin is predicted to increase the exposure to HIV-protease inhibitors (saquinavir). Avoid. **Severe** Theoretical
- Clarithromycin is predicted to very markedly increase the exposure to ibrutinib. Avoid or adjust ibrutinib dose, p. 902. **Severe** Study
- Erythromycin is predicted to increase the exposure to ibritunib. Avoid or adjust ibritunib dose, p. 902. **Severe** Theoretical Study
- Clarithromycin is predicted to increase the exposure to imatinib. **Moderate** Study
- Erythromycin is predicted to increase the exposure to imatinib. **Moderate** Theoretical Study
- Clarithromycin is predicted to increase the risk of toxicity when given with rituximab. Avoid. **Moderate** Study
- Clarithromycin is predicted to increase the exposure to ivabradine. Avoid. **Severe** Study
- Erythromycin is predicted to increase the exposure to ivabradine. Avoid. **Severe** Theoretical Study
- Clarithromycin is predicted to increase the exposure to ivacaftor. Adjust ivacaftor or lumacaftor with ivacaftor dose, p. 281. **Severe** Study
- Erythromycin is predicted to increase the exposure to ivacaftor. Adjust ivacaftor dose, p. 281. **Severe** Study
- Clarithromycin is predicted to increase the exposure to lapatinib. Avoid. **Moderate** Study → Also see TABLE 9 p. 1266
- Erythromycin is predicted to increase the exposure to lapatinib. **Moderate** Study
- Azithromycin is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. **Moderate** Theoretical Study
- Clarithromycin is predicted to markedly increase the exposure to lurasidone. Avoid. **Severe** Study
- Erythromycin is predicted to increase the exposure to lurasidone. Avoid. **Moderate** Theoretical Study
- Clarithromycin is predicted to increase the exposure to maraviroc. Adjust dose. **Severe** Study
- Clarithromycin is predicted to markedly to very markedly increase the exposure to midazolam. Avoid or adjust midazolam dose. **Severe** Study
- Erythromycin is predicted to increase the exposure to midazolam. Monitor side effects and adjust dose. **Severe** Study
- Clarithromycin is predicted to increase the exposure to mirabegron. Adjust mirabegron dose in hepatic and renal impairment, p. 736. **Moderate** Study
- Clarithromycin is predicted to increase the exposure to mirtazapine. **Moderate** Study
- Clarithromycin is predicted to increase the exposure to modafinil. **Mild** Theoretical
- Clarithromycin increases the risk of neutropenia when given with monoclonal antibodies (brentuximab vedotin). Monitor and adjust dose. **Severe** Theoretical Study
- Clarithromycin is predicted to increase the exposure to monoclonal antibodies (trastuzumab emtansine). Avoid. **Severe** Theoretical
- Clarithromycin is predicted to markedly increase the exposure to naxogol. Avoid. **Severe** Study
- Erythromycin is predicted to increase the exposure to naxogol. Adjust naxogol dose and monitor side effects, p. 63. **Moderate** Study
- Clarithromycin is predicted to increase the exposure to netupitant. **Mild** Study
- Nevirapine decreases the exposure to clarithromycin. **Moderate** Study
- Clarithromycin is predicted to moderately increase the exposure to nilotinib. Avoid. **Severe** Study → Also see TABLE 9 p. 1286
- Erythromycin is predicted to increase the exposure to nilotinib. **Moderate** Theoretical Study
- Clarithromycin is predicted to increase the exposure to nilotinib. **Moderate** Theoretical Study
- Macrolides are predicted to increase the exposure to nintedanib. **Moderate** Study
- Clarithromycin is predicted to increase the exposure to nitidine. **Severe** Study
Macrolides – Macrolides 1365

- Clarithromycin is predicted to increase the exposure to olaparib. Avoid or adjust olaparib dose, p. 919. [Moderate] Study
- Erythromycin is predicted to increase the exposure to olaparib. Avoid or adjust olaparib dose, p. 919. [Moderate] Theoretical
- Clarithromycin is predicted to increase the exposure to opioids (alfentanil, buprenorphine, fentanyl,oxycodeone). Monitor and adjust dose. [Moderate] Study
- Clarithromycin is predicted to increase the exposure to opioids (alfentanil, buprenorphine, fentanyl, oxycodeone, sufentanil). Monitor and adjust dose. [Severe] Study
- Clarithromycin is predicted to increase the exposure to opioids (methadone). [Moderate] Theoretical → Also see TABLE 9 p. 1266
- Erythromycin is predicted to increase the exposure to opioids (methadone, sufentanil). [Moderate] Theoretical
- Clarithromycin is predicted to increase the exposure to oxybutynin. [Mild] Theoretical
- Clarithromycin is predicted to increase the exposure to palbociclib. Avoid or adjust palbociclib dose, p. 909. [Severe] Study
- Clarithromycin is predicted to increase the exposure to panobinostat. Adjust panobinostat dose; in hepatic impairment avoid, p. 864. [Moderate] Study → Also see TABLE 9 p. 1266
- Clarithromycin is predicted to increase the exposure to paritaprevir (with ritonavir and ombitasvir). Avoid. [Severe] Study
- Clarithromycin is predicted to increase the exposure to pazopanib. Avoid or adjust pazopanib dose, p. 909. [Moderate] Study → Also see TABLE 9 p. 1266
- Erythromycin is predicted to increase the exposure to pazopanib. [Moderate] Theoretical
- Erythromycin is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (avanafil). Adjust avanafil dose, p. 765. [Moderate] Theoretical
- Clarithromycin is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (avanafil, vardenafil). Avoid. [Severe] Study → Also see TABLE 9 p. 1266
- Clarithromycin is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (sildenafil). Avoid or adjust sildenafil dose, p. 766. [Severe] Study → Also see TABLE 9 p. 1266
- Erythromycin is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (sildenafil). Monitor and adjust sildenafil dose, p. 766. [Moderate] Study
- Clarithromycin is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (tadalafil). Use with caution or avoid. [Severe] Study
- Erythromycin is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (tadalafil). [Severe] Theoretical
- Clarithromycin is predicted to increase the exposure to pimozide. Avoid. [Severe] Study → Also see TABLE 9 p. 1266
- Erythromycin is predicted to increase the exposure to pimozide. Avoid. [Severe] Theoretical
- Clarithromycin is predicted to slightly increase the exposure to ponatinib. Monitor and adjust ponatinib dose, p. 911. [Moderate] Study
- Clarithromycin is predicted to moderately increase the exposure to praziquantel. [Mild] Study
- Clarithromycin is predicted to increase the exposure to quetiapine. Avoid. [Severe] Study
- Erythromycin is predicted to increase the exposure to quetiapine. Avoid. [Moderate] Study
- Clarithromycin is predicted to increase the exposure to ranolazine. Avoid. [Severe] Study → Also see TABLE 9 p. 1266
- Erythromycin is predicted to increase the exposure to ranolazine. [Severe] Study
- Clarithromycin is predicted to increase the exposure to reboxetine. Avoid. [Moderate] Study
- Clarithromycin is predicted to increase the exposure to regorafenib. Avoid. [Moderate] Study
- Clarithromycin is predicted to increase the exposure to repaglinide. [Moderate] Study
- Clarithromycin is predicted to increase the exposure to ranolazine. Avoid. [Severe] Study
- Clarithromycin is predicted to increase the concentration of sirolimus. Avoid. [Severe] Theoretical
- Clarithromycin is predicted to increase the concentration of temsirolimus. Avoid. [Severe] Theoretical
- Clarithromycin is predicted to increase the concentration of temsirolimus. [Moderate] Theoretical
- Clarithromycin is predicted to increase the exposure to retinooids (alitretinoin). Adjust alitretinoin dose, p. 1157. [Moderate] Theoretical
- Azithromycin increases the risk of neutropenia when given with rifabutin. [Severe] Study
- Clarithromycin increases the risk of uveitis when given with rifabutin. Adjust dose. [Severe] Study
- Rifampicin decreases the concentration of clarithromycin. [Severe] Study
- Clarithromycin is predicted to increase the exposure to risperidone. Adjust dose. [Moderate] Study → Also see TABLE 9 p. 1266
- Clarithromycin is predicted to increase the exposure to ruxolitinib. Adjust dose and monitor side effects. [Moderate] Study
- Erythromycin is predicted to increase the exposure to ruxolitinib. [Moderate] Theoretical
- Clarithromycin is predicted to increase the exposure to saxagliptin. [Mild] Study
- Erythromycin is predicted to increase the exposure to saxagliptin. [Mild] Theoretical
- Clarithromycin is predicted to increase the concentration of simvastatin. [Severe] Study
- Clarithromycin is predicted to increase the concentration of sirolimus. Monitor and adjust dose. [Moderate] Study
- Clarithromycin is predicted to increase the exposure to sofinafenac. Adjust sofinafenac or tamsulosin with sofinafenac dose; in hepatic and renal impairment, p. 734, p. 740. [Severe] Study
- Erythromycin is predicted to moderately increase the exposure to SSRIs (dapoxetine). Adjust or avoid dapoxetine dose, p. 773. [Severe] Study
- Erythromycin is predicted to increase the exposure to SSRIs (dapoxetine). Adjust dapoxetine dose, p. 773. [Moderate] Theoretical
- Clarithromycin is predicted to increase the exposure to statins (atorvastatin). Avoid or adjust dose and monitor rhabdomyolysis. [Severe] Study
- Erythromycin is predicted to increase the exposure to statins (atorvastatin). Monitor and adjust dose. [Severe] Theoretical
- Clarithromycin moderately increases the exposure to statins (pravastatin). [Severe] Study
- Erythromycin is predicted to increase the exposure to statins (pravastatin). [Severe] Theoretical
- Clarithromycin is predicted to increase the exposure to statins (simvastatin). Avoid. [Severe] Study
- Erythromycin is predicted to increase the exposure to statins (simvastatin). Use with caution and adjust simvastatin dose, p. 198. [Severe] Study
- Clarithromycin is predicted to slightly increase the exposure to sulfonylureas. [Moderate] Theoretical
- Clarithromycin is predicted to slightly increase the exposure to sunitinib. Avoid or adjust sunitinib dose, p. 914. [Moderate] Study → Also see TABLE 9 p. 1266
- Erythromycin is predicted to increase the exposure to sunitinib. [Moderate] Theoretical
- Clarithromycin is predicted to increase the concentration of tacrolimus. Monitor and adjust dose. [Severe] Study
- Erythromycin is predicted to increase the concentration of tacrolimus. [Severe] Study
- Clarithromycin is predicted to increase the exposure to taxanes (cabazitaxel). Avoid. [Severe] Study
- Erythromycin is predicted to increase the exposure to taxanes (cabazitaxel). [Moderate] Theoretical
- Clarithromycin is predicted to moderately increase the exposure to taxanes (docetaxel). Avoid or adjust dose. [Severe] Study
- Clarithromycin is predicted to increase the exposure to taxanes (docetaxel). [Severe] Theoretical
- Erythromycin is predicted to increase the exposure to taxanes (docetaxel). [Moderate] Theoretical
- Clarithromycin is predicted to increase the concentration of temsirolimus. Avoid. [Severe] Theoretical
- Erythromycin is predicted to increase the concentration of temsirolimus. [Moderate] Theoretical
Macrolides (continued)

- **Erythromycin** decreases the clearance of **theophylline** and **theophylline** potentially decreases the clearance of erythromycin. Adjust dose. [Severe] Study
- **Macrolides** (azithromycin, clarithromycin) are predicted to increase the exposure to **theophylline**. Adjust dose. [Moderate] Anecdotal
- **Azithromycin** is predicted to increase the exposure to **ticagrelor**. Use with caution or avoid. [Severe] Study
- **Clarithromycin** is predicted to markedly increase the exposure to **ticagrelor**. Avoid. [Severe] Study
- **Clarithromycin** is predicted to increase the exposure to **tolterodine**. Avoid. [Severe] Study ○ Also see [TABLE 9] p. 1266
- **Erythromycin** is predicted to increase the exposure to **tolterodine**. [Theoretical]
- **Clarithromycin** is predicted to increase the exposure to **tolvaptan**. Adjust dose. [Severe] Study
- **Erythromycin** is predicted to increase the exposure to **tolvaptan**. Adjust dose. [Moderate] Theoretical
- **Macrolides** are predicted to increase the exposure to **topotecan**. [Severe] Study
- **Clarithromycin** is predicted to increase the exposure to **toremifene**. [Moderate] Theoretical ○ Also see [TABLE 9] p. 1266
- **Clarithromycin** is predicted to increase the exposure to **trabectedin**. Avoid or adjust dose. [Severe] Theoretical
- **Macrolides** are predicted to increase the concentration of **trametinib**. [Moderate] Theoretical
- **Clarithromycin** is predicted to moderately increase the exposure to **trazodone**. Avoid or adjust dose. [Moderate] Study
- **Erythromycin** is predicted to increase the exposure to **trazodone**. [Moderate] Theoretical
- **Clarithromycin** is predicted to increase the exposure to **ulipristal**. Avoid if used for uterine fibroids. [Severe] Study
- **Erythromycin** is predicted to increase the exposure to **ulipristal**. Avoid if used for uterine fibroids. [Moderate] Study
- **Clarithromycin** is predicted to increase the exposure to **vemurafenib**. [Severe] Theoretical ○ Also see [TABLE 9] p. 1266
- **Azithromycin** is predicted to increase the exposure to **venetoclax**. Avoid or monitor for toxicity. [Severe] Theoretical
- **Macrolides** (clarithromycin, erythromycin) are predicted to increase the exposure to **venetoclax**. Avoid or adjust venetoclax dose. p. 919. [Severe] Study
- **Clarithromycin** is predicted to increase the exposure to **venlafaxine**. [Moderate] Study ○ Also see [TABLE 9] p. 1266
- **Macrolides** (clarithromycin, erythromycin) are predicted to increase the exposure to **vinca alkaloids**. [Severe] Theoretical
- **Clarithromycin** is predicted to increase the exposure to vitamin D substances (paricalcitol). [Moderate] Study
- **Clarithromycin** decreases the absorption of **zidovudine**. Separate administration by at least 2 hours. [Moderate] Study
- **Clarithromycin** is predicted to increase the exposure to **zopiclone**. Adjust dose. [Moderate] Theoretical
- **Erythromycin** is predicted to increase the exposure to **zopiclone**. Adjust dose. [Moderate] Study

**Magnesium**

- **Oral magnesium** decreases the absorption of **bisphosphonates (alendronic acid)**. Alendronic acid should be taken at least 30 minutes before magnesium. [Moderate] Study
- **Oral magnesium** is predicted to decrease the absorption of oral bisphosphonates (ibandronic acid). Avoid magnesium for at least 6 hours before or 1 hour after ibandronic acid. [Moderate] Theoretical
- **Oral magnesium** decreases the absorption of **bisphosphonates (risendronate)**. Separate administration by at least 2 hours. [Moderate] Study
- **Oral magnesium** decreases the absorption of bisphosphonates **(sodium clodronate)**. Avoid magnesium for 2 hours before or 1 hour after sodium clodronate. [Moderate] Study
- **Intravenous magnesium** potentially increases the risk of hypotension when given with calcium channel blockers **(amlodipine, clevidipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine, verapamil)** in pregnant women. [Severe] Anecdotal
- **Intravenous magnesium** increases the effects of **neuromuscular blocking drugs, non-depolarising**. [Moderate] Study
- **Intravenous magnesium** is predicted to increase the effects of **suxamethonium**. [Moderate] Study
- **Magnesium carbonate** → see antacids
- **Magnesium trisilicate** → see antacids

**Maraviroc**

- **Antiepileptics** (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to maraviroc. Adjust dose. [Severe] Study
- **Antifungals, azoles (itraconazole, ketoconazole, voriconazole)** markedly increase the exposure to maraviroc. Adjust dose. [Severe] Study
- **Bosentan** is predicted to decrease the exposure to maraviroc. Avoid. [Moderate] Theoretical
- **Cobicistat** markedly increases the exposure to maraviroc. Refer to specialist literature. [Severe] Study
- **Efavirenz** decreases the exposure to maraviroc. Refer to specialist literature. [Severe] Theoretical
- **Enzalutamide** is predicted to decrease the exposure to maraviroc. Adjust dose. [Severe] Study
- **Etravirine** (with a boosted protease inhibitor) increases the exposure to maraviroc. Avoid or adjust dose. [Moderate] Study
- **HIV-protease inhibitors (atazanavir, darunavir, lopinavir, ritonavir, saquinavir)** increase the exposure to maraviroc. Refer to specialist literature. [Severe] Study
- **Maraviroc** potentially decreases the exposure to HIV-protease inhibitors **(fosamprenavir)** and HIV-protease inhibitors **(fosamprenavir)** potentially decrease the exposure to maraviroc. Avoid. [Severe] Study
- **Idelalisib** markedly increases the exposure to maraviroc. Adjust dose. [Severe] Theoretical
- **Macrolides** (clarithromycin) are predicted to markedly increase the exposure to maraviroc. Adjust dose. [Severe] Study
- **Rifampicin** is predicted to decrease the exposure to maraviroc. Adjust dose. [Severe] Study
- **St John’s Wort** is predicted to decrease the exposure to maraviroc. Avoid. [Severe] Theoretical

**Medicines affecting platelet function**

- **Measles, mumps and rubella vaccine, live** → see live vaccines
- **Mebendazole**
  - H2 receptor antagonists (cimetidine) increase the concentration of mebendazole. [Moderate] Study
- **Medroxyprogesterone**
  - **Sugammadex** is predicted to decrease the exposure to medroxyprogesterone. Use additional contraceptive precautions. [Severe] Theoretical
- **Mefenamic acid** → see NSAIDs
- **Mefloquine** → see antimalarials
- **Melatonin** → see [TABLE 11] p. 1266 (CNS depressant effects)
- **Combined hormonal contraceptives** are predicted to increase the exposure to melatonin. [Moderate] Theoretical
- **Quinolones (ciprofloxacin)** are predicted to increase the exposure to melatonin. [Moderate] Theoretical
- **SSRIs (fluvoxamine)** very markedly increase the exposure to melatonin. Avoid. [Severe] Study
- **Meloxicam** → see NSAIDs
- **Melphalan** → see alkylating agents
- **Mempamine**
  - Dopamine receptor agonists (amantadine) increase the risk of CNS toxicity when given with memantine. Use with caution or avoid. [Severe] Theoretical
  - Memantine is predicted to increase the effects of dopamine receptor agonists **(apomorphine, bromocriptine, cabergoline, pergolide, pramipexole, quinagolide, ropinirole, rotigotine)**. [Moderate] Theoretical
  - Memantine is predicted to increase the risk of CNS side-effects when given with **ketamine**. Avoid. [Severe] Theoretical
  - Memantine is predicted to increase the effects of levodopa. [Moderate] Theoretical
- **Mepacrine**
  - **Mepacrine** is predicted to increase the concentration of antimalarials **(primamquine)**. Avoid. [Moderate] Theoretical
- **Mepivacaine** → see anaesthetics, local
- **Mepolizumab** → see monoclonal antibodies
- **Meprobamate** → see [TABLE 11] p. 1266 (CNS depressant effects)
Meptazinol ▶ see opioids
Mercaptopurine ▶ see TABLE 1 p. 1264 (hepatotoxicity), TABLE 15 p. 1267 (myelosuppression)
▶ Allopurinol potentially increases the risk of haematological toxicity when given with mercaptopurine. Adjust mercaptopurine dose. [Severity] Severe
▶ Mercaptopurine decreases the anticoagulant effect of coumarins. [Severity] Moderate
▶ Febuxostat is predicted to increase the exposure to mercaptopurine. Avoid. [Severity] Severe
▶ Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with mercaptopurine. Public Health England advises avoid. [Severity] Severe
Metoponem ▶ see carbapenems
Mesalazine
ROUTE-SPECIFIC INFORMATION The manufacturers of some mesalazine gastro-resistant and modified-release medicines (Asacol MR tablets, Ipocol, Salofalk granules) suggest that preparations that lower stool pH (e.g. lactulose) might prevent the release of mesalazine.
Metaraminol ▶ see sympathomimetics, vasoconstrictor
Metformin ▶ see TABLE 14 p. 1267 (antidiabetic drugs)
FOOD AND LIFESTYLE Excessive alcohol consumption might increase the risk of lactic acidosis with metformin.
▶ Dolutegravir slightly to moderately increases the exposure to metformin. Use with caution and adjust dose. [Severity] Severe
▶ H2 receptor antagonists (cimetidine) slightly increase the exposure to metformin. Monitor and adjust dose. [Severity] Moderate
▶ Pitolistan is predicted to increase the exposure to metformin. [Severity] Unknown
▶ Vandetanib slightly increases the exposure to metformin. Monitor and adjust dose. [Severity] Moderate
Methadone ▶ see opioids
Methenamine is predicted to decrease the efficacy of methotrexate. Avoid. [Severity] Moderate
▶ Acetazolamide is predicted to decrease the efficacy of methotrexate. Avoid. [Severity] Moderate
▶ Potassium citrate is predicted to decrease the efficacy of methotrexate. Avoid. [Severity] Moderate
▶ Sodium bicarbonate is predicted to decrease the efficacy of methotrexate. Avoid. [Severity] Moderate
▶ Sodium citrate is predicted to decrease the efficacy of methotrexate. Avoid. [Severity] Moderate
▶ Methotrexate ▶ see TABLE 11 p. 1266 (CNS depressant effects)
▶ Methotrexate ▶ see TABLE 1 p. 1264 (hepatotoxicity), TABLE 15 p. 1267 (myelosuppression), TABLE 2 p. 1264 (nephrotoxicity), TABLE 5 p. 1264 (tromboembolism)
▶ Acetazolamide increases the urinary excretion of methotrexate. [Severity] Moderate
▶ Methotrexate is predicted to decrease the clearance of aminophylline. [Severity] Moderate
▶ Antiepileptics (levetiracetam) decrease the clearance of methotrexate. [Severity] Severe
▶ Antimalarials (pyrimethamine) are predicted to increase the risk of side-effects when given with methotrexate. [Severity] Severe
▶ Asparaginase affects the efficacy of methotrexate. [Severity] Severe
▶ Aspirin (high-dose) is predicted to increase the risk of toxicity when given with methotrexate. [Severity] Severe
▶ Crisantaspase affects the efficacy of methotrexate. [Severity] Severe
▶ Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with methotrexate. Public Health England advises avoid. [Severity] Severe
▶ NSAIDs are predicted to increase the risk of toxicity when given with methotrexate. Monitor and adjust dose. [Severity] Severe
▶ Pegaspargase affects the efficacy of methotrexate. [Severity] Severe
▶ Penicillins are predicted to increase the risk of toxicity when given with methotrexate. [Severity] Severe
▶ Proton pump inhibitors decrease the clearance of methotrexate. Use with caution or avoid. [Severity] Severe
▶ Quinolones (ciprofloxacin) potentially increase the risk of toxicity when given with methotrexate. Avoid. [Severity] Severe
▶ Regorafenib is predicted to increase the exposure to methotrexate. [Severity] Severe
▶ Retinoids (acitretin) are predicted to increase the concentration of methotrexate. Avoid. [Severity] Moderate
▶ Methotrexate is predicted to decrease the efficacy of sarpopterin. [Severity] Moderate
▶ Sulfonamides are predicted to increase the exposure to methotrexate. Use with caution or avoid. [Severity] Severe
▶ Tedizolid is predicted to increase the exposure to methotrexate. Avoid. [Severity] Moderate
▶ Methotrexate is predicted to increase the risk of toxicity when given with tegafur. [Severity] Severe
▶ Methotrexate decreases the clearance of theophylline. [Severity] Moderate
▶ Trimethoprim is predicted to increase the risk of side-effects when given with methotrexate. Avoid. [Severity] Severe
▶ Methotrexate is predicted to decrease the effects of apomorphine. Avoid. [Severity] Severe
▶ Methotrexate is predicted to increase the risk of elevated blood pressure when given with linzolide. Avoid. [Severity] Severe
▶ Methylenediphenylated is predicted to increase the risk of a hypertensive crisis when given with moclomide. [Severity] Severe
▶ Methylenidium chloride is predicted to increase the risk of severe hypertension when given with bupropion. Avoid. [Severity] Severe
▶ Metoclopromide ▶ see TABLE 13 p. 1267 (serotonin syndrome)
▶ Methylenidium chloride is predicted to increase the risk of severe hypertension when given with bupropion. Avoid. [Severity] Severe
▶ Metclopromide is predicted to increase the risk of methaemoglobinemia when given with topical anaesthetics, local (prilocaine). Avoid. [Severity] Moderate
▶ Metclopromide decreases the concentration of antimalarials (atovaquone). Avoid. [Severity] Moderate
▶ Metclopromide is predicted to decrease the effects of dopamine receptor agonists (apomorphine, bromocriptine, cabergoline, pergolide, pramipexole, quinagolide, ropinirole, rotigotine). Avoid. [Severity] Moderate
▶ Metclopromide decreases the effects of levodopa. Avoid. [Severity] Moderate
▶ Metclopromide is predicted to increase the effects of neuromuscular blocking drugs, non-depolarising. [Severity] Moderate
▶ Metclopromide increases the effects of suxamethonium. [Severity] Moderate
▶ Metolazone ▶ see thiazide diuretics
▶ Metoprolol ▶ see beta blockers, selective
Metrodinazole ▶ see TABLE 12 p. 1267 (peripheral neuropathy)
▶ Disulfiram-like reaction can occur on the ingestion of alcohol. Ensure that alcohol is not consumed for at least
48 hours after stopping miconazole.

- **Miconazole** increases the risk of toxicity when given with alkylating agents (**busulfan**). *(Severe)* Study
- **Antiepileptics (phenobarbital, primidone)** are predicted to decrease the exposure to miconazole. *(Moderate)* Study
- **Miconazole** is predicted to increase the risk of **capacitabine** p. 839 toxicity when given with **capacitabine**. *(Severe)* Theoretical
- **Miconazole** increases the anticoagulant effect of **coumarins**. Monitor INR and adjust dose. *(Severe)* Study
- **Disulfiram** increases the risk of acute psychoses when given with **miconazole**. *(Severe)* Study  Also see **TABLE 12** p. 1267
- **Miconazole** increases the risk of toxicity when given with **fluourouracil**. *(Severe)* Study

**Metyrapone**

- **Antiepileptics (fosphenytoin, phenobarbital, phenytoin, primidone)** decrease the effects of metyrapone. Avoid. *(Moderate)* Study
- **Antihistamines, sedating (cyproheptadine)** decrease the effects of metyrapone. Avoid. *(Moderate)* Study
- **Carbamazepine** decreases the effects of metyrapone. Avoid. *(Moderate)* Theoretical
- **Combined hormonal contraceptives** decrease the effects of metyrapone. Avoid. *(Moderate)* Theoretical
- **Phenothiazines (chlorpromazine)** decrease the effects of metyrapone. Avoid. *(Moderate)* Theoretical
- **Propylthiouracil** is predicted to decrease the effects of metyrapone. Avoid. *(Moderate)* Theoretical
- **Tricyclic antidepressants (amitriptyline)** decrease the effects of metyrapone. Avoid. *(Moderate)* Theoretical

**Mianserin**  Also see **TABLE 13** p. 1267 (serotonin syndrome). **TABLE 11** p. 1266 (CNS depressant effects)

- **Antiepileptics (carbamazepine)** markedly decrease the exposure to mianserin. Adjust dose. *(Moderate)* Study
- **Antiepileptics (phenobarbital, primidone)** are predicted to decrease the exposure to mianserin. *(Moderate)* Study  Also see **TABLE 11** p. 1266
- **Mianserin** is predicted to increase the risk of toxicity when given with **moclubemide**. Avoid and for 1 week after stopping mianserin. *(Severe)* Theoretical  Also see **TABLE 13** p. 1267
- **Mianserin** is predicted to increase the risk of toxicity when given with **monoamine-oxidase A and B inhibitors, irreversible**. Avoid and for 14 days after stopping the MAOI. *(Severe)* Theoretical  Also see **TABLE 13** p. 1267
- **Mianserin** is predicted to decrease the efficacy of **pitolisant**. *(Unknown)* Theoretical
- **Mianserin** decreases the effects of sympathomimetics, vasoconstrictor (**ephedrine**). *(Severe)* Anecdotal

**Micafungin**  Also see **TABLE 1** p. 1264 (hepatotoxicity)

- **Micafungin** slightly increases the exposure to **amphotericin**. Avoid or monitor toxicity. *(Moderate)* Study

**Miconazole**  Also see **antifungals, azoles**

**Miconazole** is predicted to increase the exposure to **midazolam**. Monitor side effects and adjust dose. *(Severe)* Study

- **Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone)** are predicted to decrease the exposure to miconazole. *(Moderate)* Study  Also see **TABLE 11** p. 1266
- **Antifungals, azoles (fluconazole, itraconazole, ketoconazole)** are predicted to increase the exposure to miconazole. Monitor side effects and adjust dose. *(Moderate)* Study
- **Antifungals, azoles (miconazole)** are predicted to increase the exposure to intravenous miconazole. Use with caution and adjust dose. *(Moderate)* Theoretical
- **Antifungals, azoles (miconazole)** are predicted to increase the exposure to oral **midazolam**. Avoid. *(Moderate)* Theoretical
- **Aprepitant** is predicted to increase the exposure to miconazole. Monitor side effects and adjust dose. *(Severe)* Study
- **Boventan** is predicted to decrease the concentration of midazolam. Monitor and adjust dose. *(Moderate)* Theoretical
- **Calcium channel blockers (diltiazem, verapamil)** are predicted to increase the exposure to midazolam. Monitor side effects and adjust dose. *(Severe)* Study
- **Cobicistat** is predicted to markedly to very markedly increase the exposure to midazolam. Avoid or adjust midazolam dose. *(Severe)* Study
- **Crizotinib** is predicted to increase the exposure to midazolam. Monitor side effects and adjust dose. *(Severe)* Study
- **Darifenacin** decreases the exposure to midazolam. Monitor and adjust dose. *(Moderate)* Study
- **Efavirenz** is predicted to alter the effects of midazolam. Avoid. *(Moderate)* Theoretical
- **Enalaprilat** is predicted to decrease the exposure to midazolam. Monitor and adjust dose. *(Moderate)* Study
- **Fosaprepitant** slightly increases the exposure to midazolam. *(Moderate)* Study
- **HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to markedly to very markedly increase the exposure to midazolam. Avoid or adjust midazolam dose. *(Severe)* Study
- **HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to midazolam. Monitor side effects and adjust dose. *(Severe)* Study
- **Idealisib** is predicted to markedly to very markedly increase the exposure to midazolam. Avoid or adjust midazolam dose. *(Severe)* Study
- **Lumacaftor** is predicted to decrease the exposure to midazolam. Avoid. *(Severe)* Theoretical
- **Macrolides (clarithromycin)** are predicted to markedly to very markedly increase the exposure to midazolam. Avoid or adjust midazolam dose. *(Severe)* Study
- **Macrolides (erythromycin)** are predicted to increase the exposure to midazolam. Monitor side effects and adjust dose. *(Severe)* Study
- **Netapentin** is predicted to increase the exposure to midazolam. Monitor side effects and adjust dose. *(Severe)* Study
- **Nevirapine** decreases the concentration of midazolam. Monitor and adjust dose. *(Moderate)* Study
- **Nilotinib** is predicted to decrease the exposure to midazolam. Monitor side effects and adjust dose. *(Severe)* Study
- **Palbociclib** increases the exposure to midazolam. *(Moderate)* Study
- **Rifampicin** is predicted to decrease the exposure to midazolam. Monitor and adjust dose. *(Moderate)* Study
- **St John’s Wort** moderately decreases the exposure to midazolam. Monitor and adjust dose. *(Moderate)* Study
- **Midodrine**  Also see sympathomimetics, vasoconstrictor

**Mifamurtide**

- **Ciclosporin** is predicted to decrease the efficacy of mifamurtide. Avoid. *(Severe)* Theoretical
- **Corticosteroids** are predicted to decrease the efficacy of mifamurtide. Avoid. *(Severe)* Theoretical
- **NSAIDs** (high-dose) are predicted to decrease the efficacy of mifamurtide. Avoid. *(Severe)* Theoretical
- **Pimecrolimus** is predicted to decrease the efficacy of mifamurtide. Avoid. *(Severe)* Theoretical
- **Sirolimus** is predicted to decrease the efficacy of mifamurtide. Avoid. *(Severe)* Theoretical
- **Tacrolimus** is predicted to affect the efficacy of mifamurtide. Avoid. *(Severe)* Theoretical

**Mifepristone**

- **Mifepristone** is predicted to decrease the efficacy of corticosteroids. Use with caution and adjust dose. *(Moderate)* Theoretical

**Minocycline**  Also see tetracyclines

**Minoxidil**  Also see **TABLE 8** p. 1265 (hypotension)

**Mirabegron**

- **Mirabegron** is predicted to increase the exposure to **aliskiren**. *(Mild)* Theoretical
- **Mirabegron** is predicted to increase the exposure to **antiarhythmics (flecainide)**. *(Severe)* Theoretical
Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to mirabegron. Adjust mirabegron dose in hepatic and renal impairment, p. 736. [Moderate] Study

Mirabegron is predicted to increase the exposure to antihistamines, non-sedating (fexofenadine). [Mild] Theoretical

Mirabegron is predicted to increase the exposure to beta blockers, non-selective (carvedilol, timolol). [Moderate] Theoretical

Mirabegron is predicted to increase the exposure to beta blockers, selective (metoprolol, nebivolol). [Moderate] Study

Cobicistat is predicted to increase the exposure to mirabegron. Adjust mirabegron dose in hepatic and renal impairment, p. 736. [Moderate] Study

Mirabegron is predicted to increase the exposure to colchicine. [Mild] Theoretical

Mirabegron is predicted to increase the exposure to dabigatran. [Severe] Theoretical

Mirabegron slightly increases the exposure to digoxin. Monitor digoxin concentration and adjust dose. [Severe] Study

Mirabegron is predicted to increase the exposure to edoxaban. [Mild] Theoretical

Mirabegron is predicted to increase the exposure to everolimus. [Mild] Theoretical

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir,perindinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to mirabegron. Adjust mirabegron dose in hepatic and renal impairment, p. 736. [Moderate] Study

Idelalisib is predicted to increase the exposure to mirabegron. Adjust mirabegron dose in hepatic and renal impairment, p. 736. [Moderate] Study

Mirabegron is predicted to increase the exposure to loperamide. [Mild] Theoretical

Macrolides (clarithromycin) are predicted to increase the exposure to mirabegron. Adjust mirabegron dose in hepatic and renal impairment, p. 736. [Moderate] Study

Mirabegron is predicted to increase the exposure to sirolimus. [Mild] Theoretical

Mirabegron is predicted to increase the exposure to taxanes (paclitaxel). [Mild] Theoretical

Mirabegron is predicted to increase the exposure to topotecan. [Mild] Theoretical

Mirtazapine → see TABLE 13 p. 1267 (serotonin syndrome), TABLE 11 p. 1266 (CNS depressant effects)

Antiepileptics (Carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to mirtazapine. Adjust dose. [Moderate] Study → Also see TABLE 11 p. 1266

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to mirtazapine. [Moderate] Study

Cobicistat is predicted to increase the exposure to mirtazapine. [Moderate] Study

Enalaprilat is predicted to decrease the exposure to mirtazapine. Adjust dose. [Moderate] Study

H2 receptor antagonists (cimetidine) slightly increase the exposure to mirtazapine. Use with caution and adjust dose. [Moderate] Study

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir,perindinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to mirtazapine. [Moderate] Study

Idelalisib is predicted to increase the exposure to mirtazapine. [Moderate] Study

Macrolides (clarithromycin) are predicted to increase the exposure to mirtazapine. [Moderate] Study

Mirtazapine is predicted to increase the efficacy of pitolisant. [Unknown] Theoretical

Rifampicin is predicted to decrease the exposure to mirtazapine. Adjust dose. [Moderate] Study

Mitomycin → see TABLE 15 p. 1267 (myelosuppression), TABLE 5 p. 1264 (thromboembolism)

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with mitomycin. Public Health England advises avoid. [Severe] Theoretical

Mitotane → see TABLE 15 p. 1267 (myelosuppression)

Aldosterone antagonists (spironolactone) are predicted to decrease the effects of mitotane. Avoid. [Severe] Anecdotal

Mitoxantrone → see antarhycines

Mivacurium → see neuromuscular blocking drugs, non-depolarising

Mizolastine → see antihistamines, non-sedating

Moclobemide → see TABLE 13 p. 1267 (serotonin syndrome)

FOOD AND LIFESTYLE  Moclobemide is claimed to cause less potentiation of the presor effect of tyramine than the traditional (irreversible) MAOIs, but patients should avoid consuming large amounts of tyramine-rich foods (such as mature cheese, salami, pickled herring, Bovril®, Oxo®, Marmit® or any similar meat or yeast extract or fermented soya bean extract, and some beers, lagers or wines).

Moclobemide is predicted to increase the risk of a hypertensive crisis when given with amifetamine (dexamfetamine). Avoid. [Severe] Theoretical → Also see TABLE 13 p. 1267

Moclobemide is predicted to increase the risk of a hypertensive crisis when given with amifetamines (lisdexamfetamine). Avoid. [Severe] Anecdotal → Also see TABLE 13 p. 1267

Moclobemide is predicted to increase the risk of severe hypertension when given with buproprion. Avoid. [Severe] Theoretical → Also see TABLE 13 p. 1267

Moclobemide is predicted to increase the exposure to cilostazol. [Moderate] Theoretical

Moclobemide is predicted to decrease the efficacy of clopidogrel. Avoid. [Moderate] Study

H2 receptor antagonists (cimetidine) increase the exposure to moclobemide. Adjust moclobemide dose, p. 346. [Mild] Study

Levodopa increases the risk of side-effects when given with moclobemide. [Mild] Study

Moclobemide is predicted to increase the risk of side-effects when given with linezolid. Avoid and for 14 days after stopping moclobemide. [Severe] Theoretical → Also see TABLE 13 p. 1267

Methylphenidate is predicted to increase the risk of a hypertensive crisis when given with moclobemide. [Severe] Theoretical

Mianserin is predicted to increase the risk of toxicity when given with moclobemide. Avoid for 1 week after stopping mianserin. [Severe] Theoretical → Also see TABLE 13 p. 1267

Moclobemide is predicted to increase the effects of monoamine oxidase B inhibitors (rasagiline, selegiline). Avoid. [Severe] Theoretical → Also see TABLE 13 p. 1267

Moclobemide is predicted to increase the risk of side-effects when given with monoamine-oxidase B inhibitors (safinamide). Avoid and for 1 week after stopping safinamide. [Severe] Theoretical → Also see TABLE 13 p. 1267

Opicapone is predicted to increase the risk of elevated blood pressure when given with moclobemide. Avoid. [Severe] Theoretical

Moclobemide increases the risk of side-effects when given with phenothiazines (levomepromazine). [Moderate] Study

Reboxetine is predicted to increase the risk of a hypertensive crisis when given with moclobemide. Avoid. [Severe] Theoretical

Moclobemide moderately increases the exposure to rizatRIPTAN. Avoid. [Moderate] Study → Also see TABLE 13 p. 1267

Moclobemide moderately increases the exposure to sumatriptan. Avoid. [Moderate] Study → Also see TABLE 13 p. 1267

Moclobemide is predicted to increase the risk of a hypertensive crisis when given with sympathomimetics, vasoconstrictor (ephedrine, isomethepene, phenylephrine, pseudoephedrine). Avoid. [Severe] Study

Moclobemide is predicted to increase the risk of side-effects when given with tedizolid. [Severe] Theoretical → Also see TABLE 13 p. 1267

Tricyclic antidepressants are predicted to increase the effects of moclobemide. Avoid. [Severe] Theoretical → Also see TABLE 13 p. 1267
Modafinil

- **Antiepileptics (carbamazepine, phenobarbital, primidone)** are predicted to decrease the exposure to modafinil. **[Mid] Theoretical**
- **Antiepileptics (fosphenytoin, phenytoin)** are predicted to decrease the exposure to modafinil and modafinil is predicted to increase the concentration of antiepileptics (fosphenytoin, phenytoin). Monitor concentration and adjust dose. **[Moderate] Theoretical**
- **Antifungals, azoles** (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to modafinil. **[Mid] theoretical**
- **Modafinil** is predicted to decrease the exposure to bosutinib. Avoid. **[Severe] Theoretical**
- **Cobicistat** is predicted to increase the exposure to modafinil. **[Mid] Theoretical**
- **Modafinil** is predicted to decrease the efficacy of combined hormonal contraceptives. For FSRH guidance, see Contraceptives, interactions p. 747. **[Severe] Study**
- **Modafinil** is predicted to decrease the efficacy of desogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. **[Severe] Theoretical**
- **Modafinil** is predicted to decrease the exposure to elbashvir. Avoid. **[Unknown] Theoretical**
- **Modafinil** is predicted to decrease the efficacy of etonogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. **[Severe] Theoretical**
- **Modafinil** is predicted to decrease the exposure to grazeprevir. Avoid. **[Unknown] Theoretical**
- **HIV-protease inhibitors** (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to modafinil. **[Mid] Theoretical**
- **Modafinil** is predicted to decrease the effects of Hormone replacement therapy. **[Moderate] Anecdotal**
- **Idelalisib** is predicted to increase the exposure to modafinil. **[Mid] Theoretical**
- **Modafinil** is predicted to decrease the efficacy of levonorgestrel. For FSRH guidance, see Contraceptives, interactions p. 747. **[Severe] Theoretical**
- **Macrolides (clarithromycin)** are predicted to increase the exposure to modafinil. **[Mid] Theoretical**
- **Modafinil** is predicted to decrease the efficacy of norethisterone. For FSRH guidance, see Contraceptives, interactions p. 747. **[Severe] Anecdotal**
- **Rifampicin** is predicted to decrease the exposure to modafinil. **[Moderate] Theoretical**
- **Modafinil** decreases the efficacy of ulipristal. For FSRH guidance, see Contraceptives, interactions p. 747. **[Severe] Anecdotal**

Moxeipril  see ACE inhibitors
Mometasone  see corticosteroids

**FOOD AND LIFESTYLE** Potentially life-threatening hypertensive crisis can develop in those taking MAOIs who eat tyramine-rich food (such as mature cheese, salami, pickled herring, Bovril®, Oxo®, Marmite® or any similar meat or yeast extract or fermented soya bean extract, and some beers, lagers or wines) or foods containing dopa (such as broad bean pods). Avoid tyramine-rich or dopa-rich food or drinks with, or for 2 to 3 weeks after stopping, the MAOI.

- **Modafinil** is predicted to decrease the effects of alpha blockers (indoramin). Avoid. **[Severe] Theoretical**  Also see TABLE 8 p. 1265
- **Modafinil** is predicted to increase the risk of a hypertensive crisis when given with amfetamines. Avoid and for 14 days after stopping the MAOI. **[Severe] Anecdotal** Also see TABLE 13 p. 1267
- **Antiepileptics (phenobarbital, primidone)** are predicted to increase the effects of modafinil. **[Severe] Theoretical**
- **Modafinil** is predicted to increase the risk of antimuscarinic side-effects when given with antihistamines, non-sedating. Avoid. **[Severe] Theoretical**
- **Modafinil** is predicted to increase the risk of antimuscarinic side-effects when given with antihistamines, sedating. Avoid. **[Severe] Theoretical**
- **Modafinil** is predicted to increase the risk of side-effects when given with atomoxetine. Avoid and for 2 weeks after stopping the MAOI. **[Severe] Theoretical**  Also see TABLE 13 p. 1267
- **Bupropine** is predicted to increase the risk of elevated blood pressure when given with modafinil and B inhibitors, irreversible. Avoid. **[Severe] Anecdotal** Also see TABLE 13 p. 1267
- **Modafinil** is predicted to increase the effects of doxapram. **[Moderate] Theoretical**
- **Modafinil** is predicted to increase the risk of elevated blood pressure when given with modafinil and B inhibitors, irreversible. Avoid. **[Severe] Theoretical**
- **Modafinil** is predicted to decrease the antihypertensive effects of guanethidine. Avoid and for 14 days after stopping the MAOI. **[Severe] Theoretical**  Also see TABLE 8 p. 1265
- **Modafinil** is predicted to affect the exposure to histamine. Avoid. **[Severe] Theoretical**  Also see TABLE 8 p. 1265
- **Levodopa** increases the risk of a hypertensive crisis when given with modafinil and B inhibitors, irreversible. Avoid and for 14 days after stopping the MAOI. **[Severe] Study**  Also see TABLE 8 p. 1265
- **Modafinil** is predicted to increase the risk of side-effects when given with linezolid. Avoid and for 14 days after stopping the MAOI. **[Severe] Theoretical**  Also see TABLE 13 p. 1267
- **Modafinil** is predicted to alter the antihypertensive effects of methylprednisolone. Avoid. **[Severe] Theoretical**  Also see TABLE 8 p. 1265
- **Methylyphenidate** is predicted to increase the risk of a hypertensive crisis when given with modafinil and B inhibitors, irreversible. Avoid and for 14 days after stopping the MAOI. **[Severe] Theoretical**
- **Mianserin** is predicted to increase the risk of toxicity when given with modafinil and B inhibitors, irreversible. Avoid and for 14 days after stopping the MAOI. **[Severe] Theoretical**  Also see TABLE 13 p. 1267
- **Modafinil** is predicted to increase the risk of side-effects when given with modafinil and B inhibitors, irreversible. Avoid and for 1 week after stopping safinamide. **[Severe] Theoretical**  Also see TABLE 13 p. 1267
- **Nefopam** is predicted to increase the risk of serious elevations in blood pressure when given with modafinil and B inhibitors, irreversible. Avoid. **[Severe] Theoretical**
- **Opicapone** is predicted to increase the risk of elevated blood pressure when given with modafinil and B inhibitors, irreversible. Avoid. **[Severe] Theoretical**
Monoamine-oxidase A and B inhibitors — Monoamine-oxidase B inhibitors

- **Opioids** are predicted to increase the risk of CNS excitation or depression when given with monoamine-oxidase A and B inhibitors, irreversible. Avoid. [Severe] Study → Also see TABLE 13 p. 1267
- Monoamine-oxidase A and B inhibitors, irreversible are predicted to increase the risk of neuroleptic malignant syndrome when given with phenothiazines. [Severe] Theoretical → Also see TABLE 8 p. 1265
- **Pholcodine** is predicted to increase the risk of CNS excitation or depression when given with monoamine-oxidase A and B inhibitors, irreversible. Avoid and for 14 days after stopping the MAOI. [Severe] Theoretical
- **Reboxetine** is predicted to increase the risk of a hypertensive crisis when given with monoamine-oxidase A and B inhibitors, irreversible. Avoid. [Severe] Theoretical
- Monoamine-oxidase A and B inhibitors, irreversible are predicted to increase the exposure to **rifampicin**. Avoid and for 14 days after stopping the MAOI. [Severe] Theoretical → Also see TABLE 13 p. 1267
- Monoamine-oxidase A and B inhibitors, irreversible are predicted to increase the risk of a hypertensive crisis when given with sympathomimetics, inotropic. Avoid and for 14 days after stopping the MAOI. [Severe] Theoretical
- **Tolcapone** is predicted to increase the risk of a hypertensive crisis when given with monoamine-oxidase A and B inhibitors, irreversible. Avoid. [Severe] Theoretical
- Monoamine-oxidase A and B inhibitors, irreversible are predicted to increase the risk of side-effects when given with **methylphenidate**. Avoid and for 14 days after stopping the MAOI. [Severe] Theoretical → Also see TABLE 13 p. 1267
- Monoamine-oxidase A and B inhibitors, irreversible are predicted to increase the risk of a hypertensive crisis when given with sympatheticomimetics, vasoconstrictor. Avoid and for 14 days after stopping the MAOI. [Severe] Theoretical
- **Tetrabenazine** is predicted to increase the risk of CNS toxicity when given with monoamine-oxidase A and B inhibitors, irreversible. Avoid and for 14 days after stopping the MAOI. [Severe] Theoretical → Also see TABLE 13 p. 1267
- Monoamine-oxidase A and B inhibitors, irreversible are predicted to increase the risk of side-effects when given with **tedizolid**. [Severe] Theoretical → Also see TABLE 13 p. 1267
- Monoamine-oxidase A and B inhibitors, irreversible are predicted to increase the risk of side-effects when given with **sumatriptan**. Avoid and for 14 days after stopping the MAOI. [Severe] Theoretical → Also see TABLE 13 p. 1267
- Monoamine-oxidase A and B inhibitors, irreversible are predicted to increase the exposure to **zolmitriptan**. [Severe] Theoretical → Also see TABLE 13 p. 1267
- Monoamine-oxidase B inhibitors → see TABLE 6 p. 1265
  - (bradycardia), TABLE 8 p. 1265 (hypotension), TABLE 13 p. 1267 (serotonin syndrome)

Rasagiline | Safinamide | Selegiline

**FOOD AND LIFESTYLE**

Hypertension is predicted to occur when high-dose selegiline is taken with tyramine-rich foods (such as mature cheese, salami, pickled herring, Bovril®, Oxo®, Marmite® or any similar meat or yeast extract or fermented soya bean extract, and some beers, lagers or wines).

- Monoamine-oxidase B inhibitors (rasagiline, selegiline) are predicted to increase the risk of severe hypertension when given with amfetamines. Avoid. [Severe] Theoretical → Also see TABLE 13 p. 1267
- Safinamide is predicted to increase the risk of severe hypertension when given with amfetamines. [Severe] Theoretical → Also see TABLE 13 p. 1267
- Monoamine-oxidase B inhibitors (rasagiline, selegiline) are predicted to increase the risk of severe hypertension when given with betas, agonists. Avoid. [Severe] Theoretical
- Safinamide is predicted to increase the risk of severe hypertension when given with betas, agonists. [Severe] Theoretical
- Monoamine-oxidase B inhibitors are predicted to increase the risk of severe hypertension when given with buproprion. Avoid. [Moderate] Theoretical → Also see TABLE 13 p. 1267
- Combined hormonal contraceptives slightly increase the exposure to rasagiline. [Moderate] Study
- Combined hormonal contraceptives increase the exposure to selegiline. Avoid. [Severe] Study
- Hormone replacement therapy is predicted to increase the exposure to selegiline. Avoid. [Moderate] Study
- Monoamine-oxidase B inhibitors are predicted to increase the effects of levodopa. Adjust dose. [Mild] Study → Also see TABLE 8 p. 1265
- Monoamine-oxidase B inhibitors (rasagiline, selegiline) are predicted to increase the risk of side-effects when given with linezolid. Avoid and for 14 days after stopping the MAOI. [Severe] Theoretical → Also see TABLE 13 p. 1267
- Safinamide is predicted to increase the risk of side-effects when given with linezolid. Avoid and for 1 week after stopping safinamide. [Severe] Theoretical → Also see TABLE 13 p. 1267
- Monoamine-oxidase B inhibitors (rasagiline, selegiline) are predicted to increase the risk of a hypertensive crisis when given with methylphenidate. Avoid. [Severe] Theoretical
- Moclobemide is predicted to increase the effects of monoamine-oxidase B inhibitors (rasagiline, selegiline). Avoid. [Severe] Theoretical → Also see TABLE 13 p. 1267
- Moclobemide is predicted to increase the risk of side-effects when given with safinamide. Avoid and for 1 week after stopping safinamide. [Severe] Theoretical → Also see TABLE 13 p. 1267
- Monoamine-oxidase B inhibitors (rasagiline, selegiline) are predicted to increase the risk of side-effects when given with monoamine-oxidase A and B inhibitors, irreversible. Avoid and for 14 days after stopping the MAOI. [Severe] Theoretical → Also see TABLE 8 p. 1265 → Also see TABLE 13 p. 1267
- Safinamide is predicted to increase the risk of side-effects when given with monoamine-oxidase A and B inhibitors, irreversible. Avoid and for 1 week after stopping safinamide. [Severe] Theoretical → Also see TABLE 13 p. 1267
- Opicapone is predicted to increase the risk of elevated blood pressure when given with monoamine-oxidase B inhibitors (rasagiline, selegiline). [Severe] Theoretical
- Rasagiline is predicted to increase the risk of side-effects when given with opioids (pethidine). Avoid and for 14 days after stopping rasagiline. [Severe] Theoretical → Also see TABLE 13 p. 1267
- Safinamide is predicted to increase the risk of side-effects when given with opioids (pethidine). Avoid and for 1 week after stopping safinamide. [Severe] Theoretical → Also see TABLE 13 p. 1267
- Selegiline increases the risk of side-effects when given with opioids (pethidine). Avoid. [Severe] Anecdotal → Also see TABLE 13 p. 1267
- Quinolones (ciprofloxacin) slightly increase the exposure to rasagiline. [Moderate] Study
- Reboxetine is predicted to increase the risk of a hypertensive crisis when given with monoamine-oxidase B inhibitors (rasagiline, selegiline). Avoid. [Severe] Theoretical
- Monoamine-oxidase B inhibitors are predicted to increase the risk of a hypertensive crisis when given with sympathomimetics, inotropic. Avoid. [Severe] Anecdotal
- Monoamine-oxidase B inhibitors are predicted to increase the risk of a hypertensive crisis when given with sympathomimetics, vasoconstrictor. Avoid. [Severe] Anecdotal
- Monoamine-oxidase B inhibitors are predicted to increase the risk of a hypertensive crisis when given with sympathomimetics, vasoconstrictor. Avoid. [Severe] Anecdotal
- Monoamine-oxidase B inhibitors (rasagiline, selegiline) are predicted to increase the risk of side-effects when given with tedizolid. [Severe] Theoretical → Also see TABLE 13 p. 1267
- Safinamide is predicted to increase the risk of side-effects when given with tedizolid. Avoid and for 1 week after stopping safinamide. [Severe] Theoretical → Also see TABLE 13 p. 1267
- Monoclonal antibodies → see TABLE 15 p. 1267 (myelosuppression), TABLE 12 p. 1267 (peripheral neuropathy), TABLE 4 p. 1264 (antiplatelet effects)
  - adalimumab | alemtuzumab | alirocumab | basiliximab | belimumab | bevacizumab | blinatumomab | brentuximab vedotin | canakinumab | catumaxomab | certolizumab pegol | cetuximab | daclizumab | daratumumab | denosumab | eclizumab | elotuzumab | evolocumab | golimumab | idarucizumab | infliximab | ilipimumab | ixekizumab | mepolizumab | natalizumab | necitumumab | nivolumab | obinutuzumab | ofatumumab | omalizumab | panitumumab | pembrolizumab | pertuzumab | ramucirumab | reslizumab | rituximab | secukinumab | siltuximab | tocilizumab | trastuzumab | vedolizumab
  - Blinatumomab is predicted to transiently increase the exposure to aminophylline. Monitor and adjust dose. [Moderate] Theoretical
Monoclonal antibodies (continued)

- **Anthracyclines** are predicted to increase the risk of cardiotoxicity when given with monoclonal antibodies (trastuzumab, trastuzumab emtansine). Avoid. **Severe**
  - **Theoretical** → Also see TABLE 15 p. 1267
- **Antiarhythmics (dronedarone)** increase the risk of neutropenia when given with brentuximab vedotin. Monitor and adjust dose. **Severe** **Theoretical**
  - **Antiepileptics (carbamazepine)** are predicted to decrease the effects of brentuximab vedotin. **Severe** **Theoretical**
  - **Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone)** are predicted to decrease the exposure to trastuzumab emtansine. **Severe** **Theoretical**
  - **Antifungals, azoles (itraconazole, ketoconazole)** increase the risk of neutropenia when given with brentuximab vedotin. Monitor and adjust dose. **Severe** **Study**
  - **Antifungals, azoles (itraconazole, ketoconazole, voriconazole)** are predicted to increase the exposure to trastuzumab emtansine. Avoid. **Severe** **Theoretical**
  - **Brentuximab vedotin** increases the risk of pulmonary toxicity when given with **bleomycin**. Avoid. **Severe** **Study** → Also see TABLE 15 p. 1267
- **Blinatumomab** is predicted to transiently increase the exposure to **ciclosporin (warfarin)**. Monitor and adjust dose. **Moderate** **Theoretical**
  - **Cobicistat** is predicted to increase the exposure to **trastuzumab emtansine**. Avoid. **Severe** **Theoretical**
  - **Blinatumomab** is predicted to transiently increase the exposure to **coumarins (warfarin)**. Monitor and adjust dose. **Moderate** **Theoretical**
- **Enzalutamide** is predicted to decrease the exposure to **trastuzumab emtansine**. **Severe** **Theoretical**
- **HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to increase the exposure to **trastuzumab emtansine**. Avoid. **Severe** **Theoretical**
- **HIV-protease inhibitors (lopinavir, ritonavir, saquinavir)** are predicted to increase the risk of neutropenia when given with brentuximab vedotin. Monitor and adjust dose. **Severe** **Study**
- **HIV-protease inhibitors (saquinavir, ritonavir)** are predicted to increase the risk of generalised infection (possibly life-threatening) when given with mycophenolate. Public Health England advises avoid. **Severe** **Theoretical**
  - **Rifampicin** decreases the concentration of mycophenolate. Monitor and adjust dose. **Severe** **Study**
- **Moxifloxacin** is predicted to decrease the exposure to **trastuzumab emtansine**. **Severe** **Study** → Also see TABLE 15 p. 1267
  - **Nabumetone** is predicted to increase the risk of cardiovascular side-effects when given with amfetamines. **Severe** **Theoretical**
  - **Nadolol** is predicted to increase the risk of cardiovascular side-effects when given with amfetamines. **Severe** **Theoretical**
  - **Nalmefene** decreases the efficacy of **opioids**. Avoid. **Severe** **Theoretical**

### General information

- Discontinue treatment 1 week before anticipated use of opioids; if emergency analgesia is required during treatment, an increased dose of opioid analgesic might be necessary (monitor for opioid intoxication).

- **Nalmefene** is predicted to decrease the efficacy of **opioids**. Avoid. **Severe** **Theoretical**

### Naloxegol

- **Antiarhythmics (dronedarone)** are predicted to increase the exposure to **naloxegol**. Adjust **naloxegol** dose and monitor side effects, p. 63. **Moderate** **Study**
- **Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone)** are predicted to markedly decrease the exposure to **naloxegol**. Avoid. **Moderate** **Study**
- **Antifungals, azoles (itraconazole, ketoconazole, posaconazole)** are predicted to increase the exposure to **naloxegol**. Adjust **naloxegol** dose and monitor side effects, p. 63. **Moderate** **Study**
- **Antifungals, azoles (itraconazole, ketoconazole, voriconazole)** are predicted to markedly increase the exposure to **naloxegol**. Avoid. **Severe** **Study**
- **Aprepitant** is predicted to increase the exposure to **naloxegol**. Adjust **naloxegol** dose and monitor side effects, p. 63. **Moderate** **Study**
  - **Calcium channel blockers (diltiazem, verapamil)** are predicted to increase the exposure to **naloxegol**. Adjust **naloxegol** dose and monitor side effects, p. 63. **Moderate** **Study**
  - **Cobicistat** is predicted to markedly increase the exposure to **naloxegol**. Avoid. **Severe** **Study**
  - **Crizotinib** is predicted to increase the exposure to **naloxegol**. Adjust **naloxegol** dose and monitor side effects, p. 63. **Moderate** **Study**
- **Enzalutamide** is predicted to markedly decrease the exposure to **naloxegol**. Avoid. **Moderate** **Study**
- **Grapefruit juice** is predicted to increase the exposure to **naloxegol**. Avoid. **Moderate** **Theoretical**
- **HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to markedly increase the exposure to **naloxegol**. Avoid. **Severe** **Study**
- **HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to **naloxegol**. Adjust **naloxegol** dose and monitor side effects, p. 63. **Moderate** **Study**

### Montelukast

- **Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone)** are predicted to decrease the exposure to **montelukast**. **Mid** **Study**
- **Enzalutamide** is predicted to decrease the exposure to **montelukast**. **Mid** **Study**
- **Fibrates (gemfibrozil)** are predicted to moderately increase the exposure to **montelukast**. **Moderate** **Study**
- **Lumeflunast** is predicted to decrease the exposure to **montelukast**. **Moderate** **Theoretical**
- **Rifampicin** is predicted to decrease the exposure to **montelukast**. **Mid** **Study**

### Morphine

- **Morphine** see **opioids**

### Moxifloxacin

- **Moxifloxacin** see **quinolones**
Naloxegol — Netupitant 1373

- **Idelalisib** is predicted to markedly increase the exposure to naloxegol. Avoid. **(Severe) Study**
- **Imatinib** is predicted to increase the exposure to naloxegol. Adjust naloxegol dose and monitor side effects, p. 63. **(Moderate) Study**
- **Macrolides (clarithromycin)** are predicted to markedly increase the exposure to naloxegol. Avoid. **(Severe) Study**
- **Macrolides (erythromycin)** are predicted to increase the exposure to naloxegol. Adjust naloxegol dose and monitor side effects, p. 63. **(Moderate) Study**
- **Netupitant** is predicted to increase the exposure to naloxegol. Adjust naloxegol dose and monitor side effects, p. 63. **(Moderate) Study**
- **Nilotinib** is predicted to increase the exposure to naloxegol. Adjust naloxegol dose and monitor side effects, p. 63. **(Moderate) Study**
- **Rifampicin** is predicted to markedly decrease the exposure to naloxegol. Avoid. **(Moderate) Study**
- **St John's Wort** is predicted to decrease the exposure to naloxegol. Avoid. **(Moderate) Theoretical**

### Naltrexone

**General Information**

Avoid concurrent use of opioids.

### Nandrolone

- **Nandrolone** is predicted to increase the anticoagulant effect of coumarins. Monitor and adjust dose. **(Severe) Theoretical**
- **Nandrolone** is predicted to increase the anticoagulant effect of phenindione. Monitor and adjust dose. **(Severe) Theoretical**

### Naproxen → see NSAIDs

### Naratriptan → see Table 13 p. 1267 (serotonin syndrome)

### Natalizumab → see monoclonal antibodies

### Nateglinide → see Table 14 p. 1267 (anti diabetic drugs)

### Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to slightly decrease the exposure to nateglinide. **(Mild) Study**

### Rifampicin is predicted to slightly decrease the exposure to nateglinide. **(Mild) Study**

### Sulfinpyrazone slightly increases the exposure to nateglinide. **(Mild) Study**

### Nebivolol → see beta blockers, selective

### Necitumumab → see monoclonal antibodies

### Nefopam → see Table 10 p. 1266 (antimacinics)

### Nefopam is predicted to increase the risk of vasocstriction when given with ergotamine. Separate administration by 24 hours. **(Severe) Theoretical**

### Natalizumab → see monoclonal antibodies

### Netupitant is predicted to increase the exposure of the aldosterone antagonists (eplerenone). Adjust eplerenone dose, p. 185. **(Severe) Study**

### Netupitant is predicted to increase the exposure to alpha blockers (tamsulosin). **(Moderate) Theoretical**

### Netupitant is predicted to increase the exposure to alprazolam. **(Severe) Study**

### Netupitant is predicted to increase the exposure to antiarrhythmics (propafenone). Monitor and adjust dose. **(Moderate) Study**

### Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to netupitant. Avoid. **(Moderate) Study**

### Antiinfectives, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to netupitant. **(Mild) Study**

### Netupitant is predicted to decrease the exposure to antiinfectives, azoles (isavuconazole). **(Moderate) Theoretical**

### Netupitant is predicted to increase the exposure to antihistamines, non-sedating (azelastine). **(Severe) Theoretical**

### Netupitant is predicted to increase the concentration of antimalarials (piperaquene). **(Severe) Theoretical**

### Netupitant is predicted to increase the exposure to axitinib. **(Moderate) Theoretical**

### Netupitant is predicted to increase the exposure to bedaquiline. Avoid prolonged use. **(Mild) Theoretical**

### Netupitant is predicted to increase the exposure to bosutinib. Avoid or adjust bosutinib dose. **(Severe) Theoretical**

### Netupitant is predicted to increase the exposure to buspirone. Use with caution and adjust dose. **(Moderate) Study**

### Netupitant is predicted to increase the exposure to caborbouznib. **(Moderate) Theoretical**

### Netupitant is predicted to increase the exposure to calcium channel blockers (amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose. **(Moderate) Study**

### Netupitant is predicted to increase the exposure to ceritinib. **(Moderate) Theoretical**

### Netupitant increases the concentration of cyclosporin. **(Severe) Study**

### Netupitant is predicted to increase the exposure to cobimetinib. **(Severe) Theoretical**

### Netupitant is predicted to increase the exposure to colchicine. Adjust colchicine dose, p. 1020. **(Severe) Study**

### Netupitant is predicted to increase the exposure to corticosteroids (dexamethasone, methylprednisolone). Monitor and adjust dose. **(Moderate) Study**

### Netupitant is predicted to increase the exposure to crizotinib. **(Severe) Theoretical**

### Netupitant is predicted to slightly increase the exposure to darifenacin. **(Moderate) Study**

### Netupitant is predicted to increase the exposure to dasatinib. **(Severe) Study**

### Netupitant increases the risk of QT-prolongation when given with domperidone. Avoid. **(Severe) Study**

### Netupitant is predicted to increase the exposure to dopamine receptor agonists (bromocriptine, cabergoline). **(Severe) Theoretical**

### Netupitant is predicted to moderately increase the exposure to dutasteride. **(Mild) Study**

### Enzalutamide is predicted to decrease the exposure to netupitant. Avoid. **(Moderate) Study**

### Netupitant is predicted to increase the exposure to ergot derivatives (dihydroergotamine, ergonovine). **(Severe) Theoretical**

### Netupitant is predicted to increase the exposure to ergotamine. **(Severe) Theoretical**

### Netupitant is predicted to increase the exposure to erlotinib. **(Moderate) Theoretical**

### Netupitant is predicted to increase the concentration of everolimus. Avoid or adjust dose. **(Moderate) Study**

### Netupitant is predicted to increase the exposure to fosoterodine. Adjust fosoterodine dose in hepatic and renal impairment, p. 732. **(Mild) Study**

### Netupitant is predicted to increase the exposure to gefitinib. **(Moderate) Theoretical**

### Netupitant is predicted to increase the concentration of guanfacine. Adjust guanfacine dose, p. 335. **(Moderate) Theoretical**

### HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to netupitant. **(Mild) Study**

### Netupitant is predicted to increase the exposure to ibritinib. Avoid or adjust ibritinib dose, p. 902. **(Severe) Theoretical**

### Idelalisib is predicted to increase the exposure to netupitant. **(Mild) Study**

### Netupitant is predicted to increase the exposure to imatinib. **(Moderate) Theoretical**

### Netupitant is predicted to increase the exposure to ivabradine. Adjust ivabradine dose, p. 205. **(Severe) Theoretical**
Netupitant (continued)

- **Netupitant** is predicted to increase the exposure to *ivacaftor*. Adjust *ivacaftor* dose, p. 281. [Severe] Study

- **Netupitant** is predicted to increase the exposure to *lapatinib*. [Moderate] Study

- **Netupitant** is predicted to increase the exposure to *lomitapide*. Avoid. [Moderate] Theoretical

- **Netupitant** is predicted to increase the exposure to *lurasidone*. [Moderate] Study

- **Macrolides** (clarithromycin) are predicted to increase the exposure to netupitant. [Mild] Study

- **Netupitant** is predicted to increase the exposure to *midazolam*. Monitor side effects and adjust dose. [Severe] Study

- **Netupitant** is predicted to increase the exposure to *naloxegol*. Adjust naloxegol dose and monitor side effects, p. 63. [Moderate] Study

- **Netupitant** is predicted to increase the exposure to *nilotinib*. [Moderate] Theoretical

- **Netupitant** is predicted to increase the exposure to *olaparib*. Avoid or adjust olaparib dose, p. 919. [Moderate] Theoretical

- **Netupitant** is predicted to increase the exposure to opioids (alfentanil, buprenorphine, fentanyl, oxycodone). Monitor and adjust dose. [Moderate] Study

- **Netupitant** is predicted to increase the exposure to opioids (methadone, sufentanil). [Moderate] Theoretical

- **Netupitant** is predicted to increase the exposure to *oxybutynin*. [Mild] Theoretical

- **Netupitant** is predicted to increase the exposure to *pazopanib*. [Moderate] Theoretical

- **Netupitant** is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (avanafil). Adjust avanafil dose, p. 765. [Moderate] Theoretical

- **Netupitant** is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (sildenafil). Monitor and adjust sildenafil dose, p. 766. [Moderate] Study

- **Netupitant** is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (tadalafil). [Severe] Theoretical

- **Netupitant** is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (vardenafil). Adjust dose. [Severe] Theoretical

- **Netupitant** is predicted to increase the exposure to *pimozone*. Avoid. [Severe] Theoretical

- **Netupitant** is predicted to increase the exposure to *quetiapine*. Avoid. [Moderate] Study

- **Rifampicin** is predicted to decrease the exposure to netupitant. Avoid. [Moderate] Study

- **Netupitant** is predicted to increase the exposure to *ranolazine*. [Severe] Study

- **Netupitant** is predicted to increase the exposure to *rifampicin*. Adjust rifampicin dose, p. 773. [Moderate] Theoretical

- **Netupitant** is predicted to increase the exposure to statins (atorvastatin). Monitor and adjust dose. [Severe] Theoretical

- **Netupitant** is predicted to increase the exposure to stavastatin. Use with caution and adjust stavastatin dose, p. 196. [Severe] Study

- **Netupitant** is predicted to increase the exposure to *simprevir*. Avoid. [Severe] Study

- **Netupitant** increases the concentration of *sirolimus*. Monitor and adjust dose. [Moderate] Study

- **Netupitant** is predicted to increase the exposure to *SSRIs* (dapoxetine). Adjust dapoxetine dose, p. 773. [Moderate] Theoretical

- **Netupitant** is predicted to increase the exposure to *statins* (lovastatin), Monitor and adjust dose. [Severe] Theoretical

- **Netupitant** is predicted to increase the exposure to stavastatin. Use with caution and adjust stavastatin dose, p. 196. [Severe] Study

- **Netupitant** is predicted to increase the exposure to *sunitinib*. [Moderate] Theoretical

- **Netupitant** is predicted to increase the concentration of *tacrolimus*. [Severe] Study

- **Netupitant** is predicted to increase the exposure to *taxanes* (cabazitaxel). [Moderate] Theoretical

- **Netupitant** is predicted to increase the concentration of *tepsiroliimus*. [Moderate] Theoretical

- **Netupitant** is predicted to increase the exposure to *tolerodine*. [Mild] Theoretical

- **Netupitant** is predicted to increase the exposure to *tolvaptan*. Adjust dose. [Moderate] Theoretical

- **Netupitant** is predicted to increase the exposure to *trazodone*. [Moderate] Theoretical

- **Netupitant** is predicted to increase the exposure to *ulipristal*. Avoid if used for uterine fibroids. [Moderate] Study

- **Netupitant** is predicted to increase the exposure to *venetoclax*. Avoid or adjust venetoclax dose, p. 919. [Severe] Study

- **Netupitant** is predicted to increase the exposure to *vinca alkaloids*. [Severe] Theoretical

- **Netupitant** is predicted to increase the exposure to *zopiclone*. Adjust dose. [Moderate] Study

**Neuromuscular blocking drugs, non-depolarising** → see TABLE 6 p. 1265 (bradycardia), TABLE 20 p. 1268 (neuromuscular blocking effects) atracurium - cisatracurium - mivacurium - pancuronium - rocuronium - vecuronium

- **Aminoglycosides** are predicted to increase the risk of prolonged neuromuscular blockade when given with neuromuscular blocking drugs, non-depolarising. [Severe] Theoretical → Also see TABLE 20 p. 1268

- **Anticholinesterases, centrally acting** are predicted to decrease the effects of neuromuscular blocking drugs, non-depolarising. [Moderate] Theoretical → Also see TABLE 6 p. 1265

- **Antiepileptics (carbamazepine)** are predicted to decrease the effects of (but acute use increases the effects of) neuromuscular blocking drugs, non-depolarising. Monitor and adjust dose. [Moderate] Study

- **Antiepileptics (fosphenytoin, phenytoin)** decrease the effects of (but acute use increases the effects of) neuromuscular blocking drugs, non-depolarising (atracurium, cisatracurium, pancuronium, rocuronium, vecuronium). [Moderate] Study

- **Cldamycin** increases the effects of neuromuscular blocking drugs, non-depolarising. [Severe] Anecdotal

- **Colistimethate** increases the effects of neuromuscular blocking drugs, non-depolarising. [Moderate] Study

- **Dopamine** are predicted to increase the effects of neuromuscular blocking drugs, non-depolarising. [Severe] Anecdotal

- **Pancuronium** is predicted to increase the risk of cardiovascular side-effects when given with digoxin. [Severe] Anecdotal

- **Irinotecan** is predicted to decrease the effects of neuromuscular blocking drugs, non-depolarising. [Severe] Theoretical

- **Magnesium** increases the effects of neuromuscular blocking drugs, non-depolarising. [Moderate] Theoretical

- **Metoclopramide** is predicted to increase the effects of neuromuscular blocking drugs, non-depolarising. [Moderate] Theoretical

- **Penicillins (piperacillin)** increase the effects of neuromuscular blocking drugs, non-depolarising. [Moderate] Study

- **SSRIs potentially increase the risk of prolonged neuromuscular blockade when given with mivacurium.** [Unknown] Theoretical

**Nevirapine**

- **Nevirapine** is predicted to decrease the exposure to antiarrhythmics (dronedarone). [Severe] Theoretical

- **Nevirapine** is predicted to decrease the concentration of antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) and antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the concentration of nevirapine. [Severe] Study

- **Fungals, azoles (fluconazole)** slightly to moderately increase the exposure to nevirapine. [Moderate] Study

- **Nevirapine** is predicted to decrease the exposure to antifungals, azoles (isavuconazole). Avoid. [Severe] Theoretical

- **Nevirapine** moderately decreases the exposure to antifungals, azoles (itraconazole). Avoid nevirapine for 14 days before and during treatment with itraconazole. [Moderate] Study

- **Nevirapine** moderately decreases the exposure to antifungals, azoles ( ketoconazole). Avoid. [Severe] Study

- **Nevirapine** is predicted to decrease the exposure to antifungals, azoles (voriconazole) and antifungals, azoles (voriconazole) increase the exposure to nevirapine. Monitor and adjust dose. [Severe] Theoretical
Nevirapine is predicted to decrease the exposure to **axitinib**. [Moderate] Theoretical

Nevirapine is predicted to decrease the exposure to **bedaquiline**. Avoid. [Severe] Study

Nevirapine is predicted to decrease the exposure to **bosutinib**. Avoid. [Severe] Theoretical

Nevirapine is predicted to decrease the exposure to **cabozantinib**. [Moderate] Theoretical

Nevirapine is predicted to decrease the exposure to **calcium channel blockers (amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine)**. Monitor and adjust dose. [Moderate] Theoretical

Nevirapine is predicted to decrease the exposure to **caspofungin**. Adjust dose. [Moderate] Theoretical

Nevirapine is predicted to decrease the concentration of **ciclosporin**. [Moderate] Study

Nevirapine is predicted to decrease the exposure to **cobicistat**. Avoid. [Severe] Theoretical

Nevirapine is predicted to decrease the exposure to **cobimetinib**. Avoid. [Severe] Theoretical

Nevirapine is predicted to decrease the efficacy of **combined hormonal contraceptives**. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Study

Nevirapine potentially alters the antiocagulant effect of **coumarins**. [Severe] Anecdotal

Nevirapine is predicted to decrease the exposure to **crizotinib**. Avoid. [Severe] Theoretical

Nevirapine is predicted to decrease the exposure to **daclatasvir**. Avoid. [Severe] Theoretical

Nevirapine is predicted to decrease the exposure to **dasatinib**. [Severe] Study

Nevirapine is predicted to decrease the efficacy of **desogestrel**. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical

Nevirapine decreases the exposure to **dolutegravir**. Adjust dose. [Severe] Study

Nevirapine decreases the concentration of **efavirenz**. Avoid. [Severe] Study

Nevirapine is predicted to moderately decrease the exposure to **elbasvir**. Avoid. [Severe] Study

Nevirapine is predicted to decrease the concentration of **elvitegravir**. Avoid. [Severe] Theoretical

Nevirapine is predicted to decrease the effects of **ergotamine**. [Moderate] Theoretical

Nevirapine is predicted to decrease the exposure to **erlotinib**. [Severe] Theoretical

Nevirapine is predicted to decrease the efficacy of **etanercept**. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical

Nevirapine is predicted to decrease the exposure to **etrapirine**. Avoid. [Severe] Study

Nevirapine is predicted to decrease the concentration of **everolimus**. Avoid or adjust dose. [Severe] Study

Nevirapine is predicted to decrease the exposure to ** Gefitinib**. Avoid. [Severe] Theoretical

Nevirapine is predicted to markedly decrease the exposure to **grazoprevir**. Avoid. [Severe] Study

Nevirapine is predicted to decrease the concentration of **guanfacine**. Adjust dose. [Moderate] Theoretical

Nevirapine decreases the exposure to **HIV-protease inhibitors**. Refer to specialist literature. [Moderate] Study

Nevirapine is predicted to decrease the effects of **Hormone replacement therapy**. [Moderate] Anecdotal

Nevirapine is predicted to decrease the exposure to **imatinib**. [Moderate] Study

Nevirapine is predicted to decrease the exposure to **lapatinib**. Avoid. [Severe] Study

Nevirapine is predicted to decrease the efficacy of **levonorgestrel**. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical

Nevirapine is predicted to decrease the exposure to **lurasidone**. Monitor and adjust dose. [Moderate] Theoretical

Nevirapine decreases the exposure to **macrolides (clarithromycin)**. [Moderate] Study

Nevirapine decreases the concentration of **midazolam**. Monitor and adjust dose. [Moderate] Study

Nevirapine is predicted to decrease the exposure to **nelfinavir**. Avoid. [Severe] Theoretical

Nevirapine is predicted to decrease the efficacy of **norethisterone**. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Anecdotal

Nevirapine is predicted to decrease the exposure to **olaparib**. Avoid. [Moderate] Theoretical

Nevirapine decreases the exposure to **opioids (methadone)**. Monitor and adjust dose. [Severe] Study

Nevirapine is predicted to decrease the exposure to **osimertinib**. [Severe] Theoretical

Nevirapine is predicted to decrease the exposure to **paritaprevir** (with ritonavir and obitavir). Avoid. [Severe] Study

Nevirapine is predicted to decrease the exposure to **phosphodiesterase type-5 inhibitors**. [Moderate] Theoretical

Rifampicin decreases the concentration of **nevirapine**. Avoid. [Severe] Study

Nevirapine is predicted to decrease the exposure to **rilpivirine**. Avoid. [Severe] Theoretical

Nevirapine is predicted to decrease the exposure to **ruxolitinib**. Monitor and adjust dose. [Moderate] Theoretical

Nevirapine is predicted to decrease the exposure to **simeprevir**. Avoid. [Severe] Study

Nevirapine is predicted to decrease the concentration of **sirolimus**. Monitor and adjust dose. [Moderate] Theoretical

St John’s Wort is predicted to decrease the concentration of **nevirapine**. Avoid. [Severe] Theoretical

Nevirapine slightly decreases the exposure to **statins** (atorvastatin). [Mild] Study

Nevirapine moderately decreases the exposure to **statins (simvastatin)**. [Moderate] Study

Nevirapine is predicted to decrease the concentration of **tacrolimus**. Monitor and adjust dose. [Moderate] Theoretical

Nevirapine is predicted to decrease the exposure to **taxanes (cabazitaxel)**. Avoid. [Severe] Study

Nevirapine is predicted to decrease the concentration of **tepsirimus**. Avoid. [Severe] Theoretical

Nevirapine is predicted to decrease the exposure to **ticagrelor**. [Moderate] Theoretical

Nevirapine is predicted to decrease the exposure to **tolvaptan**. [Moderate] Theoretical

Nevirapine decreases the efficacy of **ulipristal**. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Anecdotal

Nevirapine is predicted to decrease the exposure to **velpatasvir**. Avoid. [Moderate] Theoretical

Nevirapine is predicted to decrease the concentration of **zidovudine**. Refer to specialist literature. [Severe] Theoretical

Nicardipine → see calcium channel blockers

Niconrandil → see **TABLE 8** p. 1265 (hypotension)

Astrin is predicted to increase the risk of gastrointestinal perforation when given with niconrandil. [Severe] Theoretical

Corticosteroids increase the risk of gastrointestinal perforation when given with niconrandil. [Severe] Anecdotal

Nicorandil is predicted to increase the risk of gastrointestinal perforation when given with NSAIDs. [Severe] Theoretical

Nicorandil is predicted to increase the risk of hypotension when given with **phosphodiesterase type-5 inhibitors**. Avoid. [Severe] Theoretical → Also see **TABLE 8** p. 1265

Nicotinic acid → see **TABLE 3** p. 1264 (anticoagulant effects)

Nicotinic acid is predicted to increase the risk of rhabdomyolysis when given with statins. [Severe] Theoretical

Nifupeptin = see calcium channel blockers

Nifotinib → see **TABLE 15** p. 1267 (myelosuppression), **TABLE 9** p. 1266

Nifotinib is predicted to increase the exposure to aldosterone antagonists (eplerenone). Adjust eplerenone dose, p. 185. [Severe] Study

Nifotinib is predicted to increase the exposure to alpha blockers (tamsulosin). [Moderate] Theoretical
Nilotinib (continued)

- **Nilotinib** is predicted to increase the exposure to alprazolam.  
  [Severe] Study

- **Antacids** are predicted to decrease the absorption of nilotinib. Separate administration by at least 2 hours. [Moderate] Theoretical

- **Antiarrhythmics (dronedarone)** are predicted to increase the exposure to nilotinib. [Moderate] Theoretical → Also see TABLE 9 p. 1266

- **Nilotinib** is predicted to increase the exposure to antiarrhythmics (propafenone). Monitor and adjust dose. [Moderate] Study

- **Antiarrhythmics** (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to moderately decrease the exposure to nilotinib. Avoid. [Severe] Study

- **Antifungals, azoles** (fluconazole, posaconazole) are predicted to increase the exposure to nilotinib. [Moderate] Theoretical

- **Antifungals, azoles** (itraconazole, ketoconazole, voriconazole) are predicted to moderately increase the exposure to nilotinib. Avoid. [Severe] Study → Also see TABLE 9 p. 1266

- Nilotinib is predicted to increase the exposure to aprepitant. [Moderate] Theoretical

- Nilotinib is predicted to increase the exposure to axitinib. [Moderate] Theoretical → Also see TABLE 15 p. 1267

- Nilotinib is predicted to increase the exposure to bedaquiline. Avoid prolonged use. [Mild] Theoretical → Also see TABLE 9 p. 1266

- **Bosantan** is predicted to decrease the exposure to nilotinib. Avoid. [Severe] Theoretical

- **Nilotinib** is predicted to moderate the exposure to antimalarials (piperazine). [Severe] Theoretical

- **Aprepitant** is predicted to increase the exposure to nilotinib. [Mild] Study

- **Nilotinib** is predicted to increase the exposure to aripiprazole. [Moderate] Theoretical → Also see TABLE 9 p. 1267

- **Nilotinib** is predicted to change the concentration of amiodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose. [Moderate] Study

- **Nilotinib** is predicted to increase the exposure to azacitidine. [Mild] Theoretical → Also see TABLE 15 p. 1267 → Also see TABLE 9 p. 1266

- **Calcium channel blockers (diltiazem, verapamil)** are predicted to increase the exposure to nilotinib. [Moderate] Theoretical

- **Nilotinib** is predicted to increase the exposure to calcium channel blockers (amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose. [Moderate] Study

- **Nilotinib** is predicted to increase the exposure to ceritinib. [Moderate] Theoretical → Also see TABLE 15 p. 1267 → Also see TABLE 9 p. 1266

- **Nilotinib** increases the concentration of ciclosporin. [Severe] Study

- **Cobicistat** is predicted to moderately increase the exposure to nilotinib. Avoid. [Severe] Study

- **Nilotinib** is predicted to increase the exposure to cobimetinib. [Severe] Theoretical

- **Nilotinib** is predicted to increase the exposure to colchicine. Adjust colchicine dose, p. 1020. [Severe] Study

- **Nilotinib** is predicted to increase the exposure to corticosteroids (methylprednisolone). Monitor and adjust dose. [Moderate] Study

- **Nilotinib** is predicted to increase the risk of bleeding events when given with coumarins. [Severe] Theoretical

- **Nilotinib** is predicted to slightly increase the exposure to darifenacin. [Moderate] Study

- **Nilotinib** is predicted to increase the exposure to dasatinib. [Severe] Study → Also see TABLE 15 p. 1267 → Also see TABLE 9 p. 1266

- **Nilotinib** increases the risk of QT-prolongation when given with domperidone. Avoid. [Severe] Study

- **Nilotinib** is predicted to increase the exposure to dopamine receptor agonists (bromocriptine, cabergoline). [Severe] Theoretical

- **Nilotinib** is predicted to moderately increase the exposure to dutasteride. [Mild] Study

- **Efavirenz** is predicted to decrease the exposure to nilotinib. Avoid. [Severe] Theoretical

- **Enzalutamide** is predicted to moderately decrease the exposure to nilotinib. Avoid. [Severe] Study

- **Nilotinib** is predicted to increase the risk of ergotism when given with ergometrine. [Severe] Theoretical

- **Nilotinib** is predicted to increase the risk of ergotism when given with ergotamine. [Severe] Theoretical

- **Nilotinib** is predicted to increase the exposure to erlotinib. [Mild] Theoretical

- **Nilotinib** is predicted to increase the concentration of everolimus. Avoid or adjust dose. [Moderate] Study → Also see TABLE 15 p. 1267

- **Nilotinib** is predicted to increase the exposure to fesoterodine. Adjust fesoterodine dose in hepatic and renal impairment, p. 732. [Mild] Study

- **Nilotinib** is predicted to increase the exposure to gefitinib. [Moderate] Theoretical → Also see TABLE 15 p. 1267

- **Grapefruit juice** is predicted to increase the exposure to nilotinib. Avoid. [Severe] Theoretical

- **Nilotinib** is predicted to increase the concentration of guanfacine. Adjust guanfacine dose, p. 335. [Moderate] Theoretical

- **H₂ receptor antagonists** are predicted to decrease the absorption of nilotinib. [Mild] Theoretical

- **HiV protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to moderately increase the exposure to nilotinib. Avoid. [Severe] Study → Also see TABLE 9 p. 1266

- **Nilotinib** is predicted to increase the exposure to ibudrulin. Avoid or adjust ibudrulin dose, p. 902. [Severe] Theoretical → Also see TABLE 15 p. 1267

- **Idelalisib** is predicted to moderately increase the exposure to nilotinib. Avoid. [Severe] Study → Also see TABLE 15 p. 1267

- **Nilotinib** is predicted to increase the exposure to icravirudin. Adjust icravirudin dose, p. 205. [Severe] Theoretical

- **Nilotinib** is predicted to increase the exposure to icravirudin. Adjust icravirudin dose, p. 281. [Severe] Study

- **Nilotinib** is predicted to increase the exposure to ivermectin. Adjust ivermectin dose and monitor side effects, p. 63. [Moderate] Study

- **Nilotinib** is predicted to increase the exposure to lurasidone. [Moderate] Study

- **Macrolides (clarithromycin)** are predicted to moderately increase the exposure to nilotinib. Avoid. [Severe] Study → Also see TABLE 9 p. 1266

- **Macrolides (erythromycin)** are predicted to increase the exposure to nilotinib. [Moderate] Theoretical

- **Nilotinib** is predicted to increase the exposure to midazolam. Monitor side effects and adjust dose. [Severe] Study

- **Nilotinib** is predicted to increase the exposure to naloxegol. Adjust naloxegol dose and monitor side effects, p. 63. [Moderate] Study

- **Netupitant** is predicted to increase the exposure to nilotinib. [Moderate] Theoretical

- **Nevirapine** is predicted to decrease the exposure to nilotinib. Avoid. [Severe] Theoretical

- **Nilotinib** is predicted to increase the exposure to olaparib. Avoid or adjust olaparib dose, p. 919. [Moderate] Theoretical → Also see TABLE 15 p. 1267

- **Nilotinib** is predicted to increase the exposure to opioids (alfentanil, buprenorphine, fentanyl, oxycodone). Monitor and adjust dose. [Moderate] Study

- **Nilotinib** is predicted to increase the exposure to opioids (methylprednisolone). [Moderate] Theoretical → Also see TABLE 9 p. 1266

- **Nilotinib** is predicted to increase the exposure to oxycodone. [Mild] Theoretical

- **Nilotinib** is predicted to increase the exposure to pazopanib. [Moderate] Theoretical → Also see TABLE 15 p. 1267 → Also see TABLE 9 p. 1266

- **Nilotinib** is predicted to increase the risk of bleeding events when given with phenindione. [Severe] Theoretical

- **Nilotinib** is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (avanafil). Adjust avanafil dose, p. 765. [Moderate] Theoretical
### Nilotinib — Norethisterone 1377

- **Nilotinib** is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (sildenafil). Monitor and adjust sildenafil dose, p. 766. **[Moderate] Study** → Also see TABLE 9 p. 1266
- **Nilotinib** is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (tadalafil). **[Severe] Theoretical**
- **Nilotinib** is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (vardenafil). Adjust dose. **(Severe) Theoretical** → Also see TABLE 9 p. 1266
- **Nilotinib** is predicted to increase the exposure to pimozide. Avoid. **(Severe) Theoretical** → Also see TABLE 9 p. 1266
- **Nilotinib** is predicted to increase the exposure to quetiapine. Avoid. **[Moderate] Study**
- **Nilotinib** is predicted to increase the exposure to ranolazine. **(Severe) Study** → Also see TABLE 9 p. 1266
- **Rifampicin** is predicted to moderately decrease the exposure to nilotinib. Avoid. **(Severe) Study**
- **Nilotinib** is predicted to increase the exposure to ruxolitinib. **[Moderate] Theoretical** → Also see TABLE 15 p. 1267
- **Nilotinib** is predicted to increase the exposure to sunitinib. **[Moderate] Theoretical** → Also see TABLE 15 p. 1267 → Also see TABLE 9 p. 1266
- **Nilotinib** is predicted to increase the concentration of sirolimus. Monitor and adjust dose. **(Moderate) Study**
- **Nilotinib** is predicted to increase the exposure to SSRIs (dapoxetine). Adjust dapoxetine dose, p. 773. **[Moderate] Theoretical**
- **St John’s Wort** is predicted to decrease the exposure to nilotinib. Avoid. **(Severe) Theoretical**
- **Nilotinib** is predicted to increase the exposure to statins (atorvastatin). Monitor and adjust dose. **(Severe) Theoretical**
- **Nilotinib** is predicted to increase the exposure to statins (simvastatin). Use with caution and adjust simvastatin dose, p. 198. **(Severe) Study**
- **Nilotinib** is predicted to increase the exposure to sunitinib. **[Moderate] Theoretical** → Also see TABLE 15 p. 1267 → Also see TABLE 9 p. 1266
- **Nilotinib** is predicted to increase the concentration of tacrolimus. **(Severe) Study**
- **Nilotinib** is predicted to increase the exposure to taxanes (cabazitaxel). **[Moderate] Theoretical** → Also see TABLE 15 p. 1267
- **Nilotinib** is predicted to increase the concentration of temsirolimus. **[Moderate] Theoretical** → Also see TABLE 15 p. 1267
- **Nilotinib** is predicted to increase the exposure to tolterodine. **(Mild) Theoretical** → Also see TABLE 9 p. 1266
- **Nilotinib** is predicted to increase the exposure to tolvaptan. Adjust dose. **[Moderate] Theoretical**
- **Nilotinib** is predicted to increase the exposure to trazodone. **(Moderate) Theoretical**
- **Nilotinib** is predicted to increase the exposure to ulipristal. Avoid if used for uterine fibroids. **[Moderate] Study**
- **Nilotinib** is predicted to increase the exposure to venetoclax. Avoid or adjust venetoclax dose, p. 919. **(Severe) Study**
- **Nilotinib** is predicted to increase the exposure to vinca alkaloids. **(Severe) Theoretical** → Also see TABLE 9 p. 1266 → Also see TABLE 15 p. 1267
- **Nilotinib** is predicted to increase the exposure to zopiclone. Adjust dose. **(Moderate) Study**
- **Nimodipine** → see calcium channel blockers
- **Nintedanib**
  - Antiarrhythmics (amiloradone, dronedarone) are predicted to increase the exposure to nintedanib. **[Moderate] Study**
  - Antiepileptics (carbamazepine) are predicted to decrease the exposure to nintedanib. **[Moderate] Study**
  - Antifungals, azoles (itraconazole, ketoconazole) are predicted to increase the exposure to nintedanib. **[Moderate] Study**
  - Calcium channel blockers (verapamil) are predicted to increase the exposure to nintedanib. **[Moderate] Study**
  - Ciclosporin is predicted to increase the exposure to nintedanib. **[Moderate] Study**
  - HIV-protease inhibitors (lopinavir, ritonavir, saquinavir) are predicted to increase the exposure to nintedanib. **[Moderate] Study**
  - Lapaatinib is predicted to increase the exposure to nintedanib. **[Moderate] Study**
- **Macrolides** are predicted to increase the exposure to nintedanib. **[Moderate] Study**
- **Ranolazine** is predicted to increase the exposure to nintedanib. **[Moderate] Study**
- **Rifampicin** is predicted to decrease the exposure to nintedanib. **[Moderate] Study**
- **St John’s Wort** is predicted to decrease the exposure to nintedanib. **[Moderate] Study**
- **Vemurafenib** is predicted to increase the exposure to nintedanib. **[Moderate] Study**

### Nitrisinone

- **Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone)** are predicted to decrease the exposure to nitrisinone. Adjust nitrisinone dose. **[Moderate] Theoretical**
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to nitrisinone. Adjust nitrisinone dose. **[Moderate] Theoretical**
- **Cobicistat** is predicted to decrease the exposure to nitrisinone. Adjust nitrisinone dose. **[Moderate] Theoretical**
- **Enalaprilat** is predicted to decrease the exposure to nitrisinone. Adjust nitrisinone dose. **[Moderate] Theoretical**
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to nitrisinone. Adjust nitrisinone dose. **[Moderate] Theoretical**
- **Idelalisib** is predicted to increase the exposure to nitrisinone. Adjust nitrisinone dose. **[Moderate] Theoretical**
- **Macrolides (clarithromycin)** are predicted to increase the exposure to nitrisinone. Adjust nitrisinone dose. **[Moderate] Theoretical**
- **Rifampicin** is predicted to decrease the exposure to nitrisinone. Adjust nitrisinone dose. **[Moderate] Theoretical**

### Nitrates

- **Nitrates** → see TABLE 7 p. 1265 (first-dose hypotension), TABLE 8 p. 1265 (hypotension)
  - glycercyl trinitrate • isosorbide dinitrate • isosorbide mononitrate

### Pharmacology

**Drugs with antimuscarinic effects can cause dry mouth, which can reduce the effectiveness of sublingual glyceryl trinitrate tablets.**

- **Nitrates** are predicted to increase the risk of methaemoglobinemia when given with topical anaesthetics, local (prilocaine). Avoid. **(Severe) Theoretical**
- **Nitrates** are predicted to increase the risk of methaemoglobinemia when given with dapsone. **(Severe) Theoretical**
- **Nitrates** potentially increase the risk of hypotension when given with phosphodiesterase type-5 inhibitors. Avoid. **(Severe) Study** → Also see TABLE 8 p. 1265
- **Nitrazepam** → see TABLE 11 p. 1266 (CNS depressant effects)
- **Rifampicin** increases the clearance of nitrazepam. **[Moderate] Study**

### Nitrofurantoin

- **Nitrofurantoin** is predicted to increase the risk of methaemoglobinemia when given with topical anaesthetics, local (prilocaine). Use with caution or avoid. **(Severe) Theoretical**
- Anticds (magnesium trisilicate) decrease the absorption of nitrofurantoin. **[Moderate] Study**
- **Nitrofurantoin** is predicted to increase the risk of methaemoglobinemia when given with dapsone. **(Severe) Theoretical**

### Nitrous oxide

- **Nitrous oxide** → see TABLE 8 p. 1265 (hypotension), TABLE 11 p. 1266 (CNS depressant effects)
- **Nivolumab** → see monoclonal antibodies
- **Nizatidine** → see H2 receptor antagonists
- **Noradrenaline/norepinephrine** → see sympathomimetics, vasoconstrictor

### Norethisterone

- **Antiepileptics (carbamazepine, eslicarbazepine, fosphenytoin, oxcarbazepine, perampanel, phenobarbital, phenytoin, primidone, rufinamide, topiramate)** are predicted to decrease the efficacy of norethisterone. For FSRH guidance, see Contraceptives, interactions p. 747. **(Severe) Anecdotal**
- **Aprepitant** is predicted to decrease the efficacy of norethisterone. For FSRH guidance, see Contraceptives, interactions p. 747. **(Severe) Anecdotal**
Norethisterone (continued)

- **Boventan** is predicted to decrease the efficacy of norethisterone. For FSRH guidance, see Contraceptives, interactions p. 747. (Severe) Anecdotal
- **Eavirenz** is predicted to decrease the efficacy of norethisterone. For FSRH guidance, see Contraceptives, interactions p. 747. (Severe) Anecdotal
- **Fosaprepitant** is predicted to decrease the efficacy of norethisterone. For FSRH guidance, see Contraceptives, interactions p. 747. (Severe) Anecdotal
- **Grisofulvin** potentially decreases the efficacy of norethisterone. For FSRH guidance, see Contraceptives, interactions p. 747. (Severe) Anecdotal
- **HIV-protease inhibitors (ritonavir)** are predicted to decrease the efficacy of norethisterone. For FSRH guidance, see Contraceptives, interactions p. 747. (Severe) Anecdotal
- **Modafinil** is predicted to decrease the efficacy of norethisterone. For FSRH guidance, see Contraceptives, interactions p. 747. (Severe) Anecdotal
- **Nevirapine** is predicted to decrease the efficacy of norethisterone. For FSRH guidance, see Contraceptives, interactions p. 747. (Severe) Anecdotal
- **Rifapentin** is predicted to decrease the efficacy of norethisterone. For FSRH guidance, see Contraceptives, interactions p. 747. (Severe) Anecdotal
- **St John's Wort** is predicted to decrease the efficacy of norethisterone. MHRA advises avoid. For FSRH guidance, see Contraceptives, interactions p. 747. (Severe) Anecdotal
- **Sugammadex** is predicted to decrease the exposure to norethisterone. Use additional contraceptive precautions. (Severe) Anecdotal
- **Ulipristal** is predicted to decrease the efficacy of norethisterone. Avoid. (Severe) Theoretical
- **Norfloxacin** see quinolones

Nortriptyline see tricyclic antidepressants

**NSAIDs** see Table 18 p. 1268 (hypotension), Table 2 p. 1264 (nephrototoxicity), Table 16 p. 1268 (increased serum potassium), Table 4 p. 1264 (antiplaetlet effects)


ROUTE-SPECIFIC INFORMATION

Since systemic absorption can follow topical application, the possibility of interactions should be borne in mind.

- **Celecoxib** is predicted to increase the exposure to antirhythmic (flecainide, propafenone). Monitor and adjust dose. (Moderate) Theoretical
- **Antifungals, azoles (fluconazole)** moderately increase the exposure to celecoxib. Adjust celecoxib dose, p. 1031. (Moderate) Study
- **Antifungals, azoles (fluconazole)** increase the exposure to parecoxib. Monitor and adjust dose. (Moderate) Study
- **Antifungals, azoles (voriconazole)** slightly increase the exposure to diclofenac. Monitor and adjust dose. (Moderate) Study
- **Antifungals, azoles (voriconazole)** moderately increase the exposure to ibuprofen. Adjust dose. (Moderate) Study
- **NSAIDs** are predicted to increase the risk of gastrointestinal irritation when given with bisphosphonates (alendronic acid, ibandronic acid). (Moderate) Study
- **NSAIDs** are predicted to increase the risk of renal impairment when given with bisphosphonates (sodium clodronate). (Severe) Theoretical
- **Ceritinib** is predicted to increase the exposure to NSAIDs (celecoxib, diclofenac). Adjust dose. (Moderate) Theoretical
- **Ciclosporin** increases the concentration of diclofenac. (Severe) Study
- Also see Table 2 p. 1264
- Also see Table 16 p. 1268
- **Etoricoxib** slightly increases the exposure to combined hormonal contraceptives. (Moderate) Study
- **NSAIDs** increase the risk of gastrointestinal bleeding when given with corticosteroids. (Severe) Study
- **NSAIDs** increase the risk of renal impairment when given with daptomycin. (Moderate) Theoretical
- **Indomethacin** increases the concentration of digoxin. (Severe) Study
- **Topical dimethyl sulfoxide** potentially increases the risk of peripheral neuropathy when given with sulindac. Avoid. (Severe) Anecdotal
- **Erlotinib** is predicted to increase the risk of gastrointestinal perforation when given with NSAIDs. (Severe) Theoretical
- **Etoricoxib** slightly increases the exposure to Hormone replacement therapy. (Moderate) Study
- **NSAIDs** are predicted to increase the risk of gastrointestinal bleeding when given with iron chelators (deferasirox). (Severe) Theoretical
- **NSAIDs** increase the concentration of lithium. Monitor and adjust lithium (lithium carbonate, lithium citrate) dose. (Severe) Study
- **Lumacafor** is predicted to decrease the exposure to ibuprofen. Adjust dose. (Moderate) Theoretical
- **NSAIDs** are predicted to increase the risk of toxicity when given with methotrexate. Monitor and adjust dose. (Severe) Study
- Also see Table 2 p. 1264
- **NSAIDs** (high-dose) are predicted to decrease the efficacy of ifosfamide. Avoid. (Severe) Theoretical
- **Nicorandil** is predicted to increase the risk of gastrointestinal perforation when given with NSAIDs. (Severe) Theoretical
- **NSAIDs** are predicted to increase the exposure to pemtrexed. Use with caution or avoid. (Severe) Theoretical
- Also see Table 2 p. 1264
- **NSAIDs** potentially increase the risk of seizures when given with quinolones. (Severe) Theoretical
- **Regorafenib** is predicted to increase the exposure to mafenamic acid. Avoid. (Moderate) Theoretical
- Also see Table 4 p. 1264
- **Rifampicin** moderately decreases the exposure to NSAIDs (celecoxib, diclofenac, etoricoxib). (Moderate) Study
- **NSAIDs** increase the risk of acute renal failure when given with thiazide diuretics. (Severe) Theoretical
- Also see Table 18 p. 1268
- **Zidovudine** increases the risk of haematological toxicity when given with NSAIDs. (Severe) Study
- Also see Table 2 p. 1264
- **Obinutuzumab** see monoclonal antibodies
- **Octreotide**
- **Octreotide** decreases the absorption of oral ciclosporin. Adjust ciclosporin dose, p. 788. (Severe) Anecdotal
- Also see monoclonal antibodies
- **Olanzapine** see Table 8 p. 1265 (hypotension), Table 15 p. 1267 (myelosuppression), Table 11 p. 1266 (CNS depressant effects)

**FOOD AND LIFESTYLE** Dose adjustment might be necessary if smoking started or stopped during treatment.

- **Antiepileptics (carbamazepine)** potentially decrease the exposure to olanzapine. Monitor and adjust dose. (Moderate) Study
- **Olanzapine** is predicted to decrease the effects of dopamine receptor agonists. Avoid. (Moderate) Theoretical
- Also see Table 8 p. 1265
- **Olanzapine** is predicted to decrease the effects of histamine. Avoid. (Severe) Theoretical
- Also see Table 8 p. 1265
- **HIV-protease inhibitors (ritonavir)** moderately decrease the exposure to olanzapine. (Moderate) Study
- **Olanzapine** decreases the effects of levodopa. Avoid or monitor worsening parkinsonian symptoms. (Severe) Anecdotal
- Also see Table 8 p. 1265
- **SSRIs (fluvoxamine)** moderately increase the exposure to olanzapine. Adjust dose. (Severe) Anecdotal
- **Olaparib** see Table 15 p. 1267 (myelosuppression)

**FOOD AND LIFESTYLE** Bitter (Seville) orange is predicted to increase the exposure to olaparib.

- **Antirhythmic (dronedaron)** are predicted to increase the exposure to olaparib. Avoid or adjust olaparib dose, p. 919. (Moderate) Theoretical
Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to olaparib. Avoid. [Moderate] Theoretical

Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to olaparib. Avoid or adjust olaparib dose. [p. 919] [Moderate] Theoretical

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to olaparib. Avoid or adjust olaparib dose, p. 919. [Moderate] Study

Aprepitant is predicted to increase the exposure to olaparib. Avoid or adjust olaparib dose, p. 919. [Moderate] Theoretical

Bosentan is predicted to decrease the exposure to olaparib. Avoid. [Moderate] Theoretical

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to olaparib. Avoid or adjust olaparib dose, p. 919. [Moderate] Theoretical

Cobicistat is predicted to increase the exposure to olaparib. Avoid or adjust olaparib dose, p. 919. [Moderate] Study

Crizotinib is predicted to increase the exposure to olaparib. Avoid or adjust olaparib dose, p. 919. [Moderate] Theoretical

Efavirenz is predicted to decrease the exposure to olaparib. [Table 15] Avoid. [Study]

Enzalutamide is predicted to decrease the exposure to olaparib. Avoid. [Moderate] Theoretical

Grapefruit juice is predicted to increase the exposure to olaparib. Avoid. [Moderate] Theoretical

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to olaparib. Avoid or adjust olaparib dose, p. 919. [Moderate] Study

HIV-protease inhibitors (indinavir) are predicted to increase the exposure to olaparib. Avoid or adjust olaparib dose, p. 919. [Moderate] Theoretical

Idelalisib is predicted to increase the exposure to olaparib. Avoid or adjust olaparib dose, p. 919. [Moderate] Study [Also see Table 15 p. 1267]

Imatinib is predicted to increase the exposure to olaparib. Avoid or adjust olaparib dose, p. 919. [Moderate] Theoretical [Also see Table 15 p. 1267]

Macrolides (clarithromycin) are predicted to increase the exposure to olaparib. Avoid or adjust olaparib dose, p. 919. [Moderate] Study

Macrolides (erythromycin) are predicted to increase the exposure to olaparib. Avoid or adjust olaparib dose, p. 919. [Moderate] Theoretical

Netupitant is predicted to increase the exposure to olaparib. Avoid or adjust olaparib dose, p. 919. [Moderate] Theoretical

Nevirapine is predicted to decrease the exposure to olaparib. Avoid. [Moderate] Theoretical

Nilotinib is predicted to increase the exposure to olaparib. Avoid or adjust olaparib dose, p. 919. [Moderate] Theoretical [Also see Table 15 p. 1267]

Rifampicin is predicted to decrease the exposure to olaparib. Avoid. [Moderate] Theoretical

St John’s Wort is predicted to decrease the exposure to olaparib. Avoid. [Moderate] Theoretical

Olmesartan → see angiotensin-II receptor antagonists

Oxitotrol → see beta, agonists

Olsalazine → see Table 15 p. 1267 (myelosuppression)

Omazolam → see monoclonal antibodies

Ombitasvir

Antiepileptics (carbamazepine) are predicted to decrease the exposure to ombitasvir. Avoid. [Severe] Theoretical

Rifampicin is predicted to decrease the exposure to ombitasvir. Avoid. [Severe] Theoretical

St John’s Wort is predicted to decrease the exposure to ombitasvir. Avoid. [Severe] Theoretical

Omega-3 acid ethyl esters → see Table 3 p. 1264 (anticoagulant effects)

Omeprazole → see proton pump inhibitors

Ondansetron → see Table 13 p. 1267 (serotonin syndrome), Table 9 p. 1266 (QT-interval prolongation)

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to ondansetron. [Moderate] Study

Dopamine receptor agonists (apomorphine) increase the risk of severe hypotension when given with ondansetron. Avoid. [Severe] Study [Also see Table 9 p. 1266]

Enzalutamide is predicted to decrease the exposure to ondansetron. [Moderate] Study

Rifampicin is predicted to decrease the exposure to ondansetron. [Moderate] Study

Opicapone

Opicapone increases the exposure to levodopa. Adjust levodopa dose. [Moderate] Study

Opicapone is predicted to increase the risk of elevated blood pressure when given with moclobemide. Avoid. [Severe] Theoretical

Opicapone is predicted to increase the risk of elevated blood pressure when given with monoamine-oxidase A and B inhibitors, irreversible. Avoid. [Severe] Theoretical

Opicapone is predicted to increase the risk of elevated blood pressure when given with monoamine-oxidase B inhibitors (rasagiline, selegiline). [Severe] Theoretical

Opicapone is predicted to increase the risk of cardiovascular side-effects when given with sympathicomimetics, inotropic (dobutamine, dopamine). [Severe] Theoretical

Opicapone is predicted to increase the risk of cardiovascular side-effects when given with sympathicomimetics, vasoconstrictor (adrenaline/epinephrine, noradrenaline/norepinephrine). [Severe] Theoretical

Opioids → see Table 6 p. 1265 (bradycardia), Table 13 p. 1267 (serotonin syndrome), Table 9 p. 1266 (QT-interval prolongation), Table 11 p. 1266 (CNS depressant effects)

Alfentanil • buprenorphine • codeine • diamorphine • dihydromorphone • diphenoxylate • dipipanone • fentanyl • hydromorphone • meptazinol • methadone • morphine • oxycodone • papaveretum • pentazocine • pethidine • remifentanil • sufentanil • tapentadol • tramadol

Food and lifestyle Alcohol has been associated with rapid release of hydromorphone and morphine from extended-release preparations. Avoid alcohol consumption with extended-release preparations.

Abricerone is predicted to decrease the efficacy of tramadol. [Moderate] Study

Antiarrhythmics (amiodarone) are predicted to increase the concentration of fentanyl. [Moderate] Theoretical [Also see Table 6 p. 1265]

Antiarrhythmics (propafenone) are predicted to decrease the efficacy of tramadol. [Moderate] Study

Antiarrhythmics (dronedarone) are predicted to increase the exposure to opioids (alfentanil, buprenorphine, fentanyl, oxycodone). Monitor and adjust dose. [Moderate] Study

Antiarrhythmics (dronedarone) are predicted to increase the exposure to opioids (methadone, sufentanil). [Moderate] Theoretical [Also see Table 9 p. 1266]

Antiepileptics (carbamazepine) decrease the concentration of tramadol. Adjust dose. [Severe] Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to buprenorphine. Monitor and adjust dose. [Moderate] Theoretical [Also see Table 11 p. 1266]

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) decrease the exposure to methadone. Monitor and adjust dose. [Moderate] Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to opioids (alfentanil, fentanyl). [Moderate] Study [Also see Table 11 p. 1266]

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to opioids (alfentanil, fentanyl). [Moderate] Theoretical [Also see Table 9 p. 1266]

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to methadone. [Moderate] Theoretical [Also see Table 9 p. 1266]

Olaparib – Opioids 1379

BNF 74

Interactions | Appendix 1
Opioids (continued)

- **Antifungals, azoles (micazoside)** are predicted to increase the exposure to alfentanil. Use with caution and adjust dose. [Moderate] Theoretical
- **Antifungals, azoles (fluconazole, isavuconazole, posaconazole)** are predicted to increase the exposure to opioids (alfentanil, buprenorphine, fentanyl, oxycodone). Monitor and adjust dose. [Moderate] Study
- **Antifungals, azoles (itraconazole, ketoconazole, voriconazole)** are predicted to increase the exposure to opioids (alfentanil, buprenorphine, fentanyl, oxycodone). Monitor and adjust dose. [Severe] Study
- **Bupropion** is predicted to decrease the efficacy of codeine. [Moderate] Theoretical
- **Bupropion** is predicted to decrease the efficacy of tramadol. [Severe] Study → Also see **TABLE 13** p. 1267
- **Calcium channel blockers (diltiazem, verapamil)** are predicted to increase the exposure to opioids (alfentanil, buprenorphine, fentanyl, oxycodone). Monitor and adjust dose. [Moderate] Study → Also see **TABLE 6** p. 1265
- **Calcium channel blockers (diltiazem, verapamil)** are predicted to increase the exposure to opioids (methadone, sufentanil). [Moderate] Theoretical → Also see **TABLE 6** p. 1265
- **Ceritinib** is predicted to increase the exposure to opioids (alfentanil, buprenorphine, fentanyl, oxycodone). Avoid. [Severe] Theoretical
- **Cinacalcet** is predicted to decrease the efficacy of codeine. [Moderate] Theoretical
- **Cinacalcet** is predicted to decrease the efficacy of tramadol. [Severe] Study
- **Cobicistat** is predicted to increase the exposure to methadone. [Moderate] Theoretical
- **Cobicistat** is predicted to increase the exposure to opioids (alfentanil, buprenorphine, fentanyl, oxycodone, sufentanil). Monitor and adjust dose. [Severe] Study
- **Crizotinib** is predicted to increase the exposure to opioids (alfentanil, buprenorphine, fentanyl, oxycodone). Monitor and adjust dose. [Moderate] Study → Also see **TABLE 6** p. 1265
- **Crizotinib** is predicted to increase the exposure to opioids (methadone, sufentanil). [Moderate] Theoretical → Also see **TABLE 6** p. 1265 → Also see **TABLE 9** p. 1266
- **Dolutexte** is predicted to decrease the efficacy of tramadol. [Moderate] Study → Also see **TABLE 13** p. 1267
- **Efavirenz** decreases the exposure to methadone. Monitor and adjust dose. [Severe] Study
- **Enalaprilat** is predicted to decrease the exposure to buprenorphine. Monitor and adjust dose. [Moderate] Theoretical
- **Enalaprilat** decreases the exposure to methadone. Monitor and adjust dose. [Severe] Study
- **Enalaprilat** is predicted to decrease the exposure to opioids (alfentanil, fentanyl). [Moderate] Study
- **Enalaprilat** is predicted to decrease the exposure to oxycodone. Monitor and adjust dose. [Moderate] Study
- **H₂ receptor antagonists (cimetidine)** increase the concentration of alfentanil. Use with caution and adjust dose. [Severe] Study
- **H₂ receptor antagonists (cimetidine)** increase the exposure to fentanyl. [Moderate] Study
- **HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to increase the exposure to methadone. [Moderate] Theoretical → Also see **TABLE 9** p. 1266
- **HIV-protease inhibitors (ritonavir)** are predicted to decrease the concentration of morphine. [Moderate] Theoretical
- **HIV-protease inhibitors (ritonavir)** increase the risk of CNS toxicity when given with pethidine. Avoid. [Severe] Study
- **HIV-protease inhibitors (ritonavir)** are predicted to decrease the efficacy of tramadol. [Moderate] Study
- **HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to opioids (alfentanil, buprenorphine, fentanyl, oxycodone). Monitor and adjust dose. [Moderate] Study
- **HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to increase the exposure to opioids (alfentanil, buprenorphine, fentanyl, oxycodone, sufentanil). Monitor and adjust dose. [Severe] Study
- **HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to opioids (methadone, sufentanil). [Moderate] Theoretical
- **Idelalisib** is predicted to increase the exposure to methadone. [Moderate] Theoretical
- **Idelalisib** is predicted to increase the exposure to opioids (alfentanil, buprenorphine, fentanyl, oxycodone, sufentanil). Monitor and adjust dose. [Severe] Study
- **Imatinib** is predicted to increase the exposure to opioids (alfentanil, buprenorphine, fentanyl, oxycodone). Monitor and adjust dose. [Moderate] Study
- **Imatinib** is predicted to increase the exposure to opioids (methadone, sufentanil). [Moderate] Study
- **Macrolides (clarithromycin)** are predicted to increase the exposure to methadone. [Moderate] Theoretical → Also see **TABLE 9** p. 1266
- **Macrolides (erythromycin)** are predicted to increase the exposure to opioids (alfentanil, buprenorphine, fentanyl, oxycodone). Monitor and adjust dose. [Moderate] Study
- **Macrolides (erythromycin)** are predicted to increase the exposure to opioids (methadone, sufentanil). [Moderate] Theoretical
- **Mirabegron** is predicted to decrease the efficacy of tramadol. [Moderate] Study
- **Opioids** are predicted to increase the risk of CNS excitation or depression when given with monoamine-oxidase A and B inhibitors, irreversible. Avoid. [Severe] Study → Also see **TABLE 13** p. 1267
- **Monoamine-oxidase B inhibitors (rasagiline)** are predicted to increase the risk of side-effects when given with pethidine. Avoid and for 14 days after stopping rasagiline. [Severe] Theoretical → Also see **TABLE 13** p. 1267
- **Monoamine-oxidase B inhibitors (saframidale)** are predicted to increase the risk of side-effects when given with pethidine. Avoid and for 1 week after stopping saframidale. [Severe] Theoretical → Also see **TABLE 13** p. 1267
- **Nalbuphine** is predicted to decrease the efficacy of opioids. Avoid. [Severe] Theoretical
- **Netupitant** is predicted to increase the exposure to opioids (alfentanil, buprenorphine, fentanyl, oxycodone). Monitor and adjust dose. [Moderate] Study
- **Netupitant** is predicted to increase the exposure to opioids (methadone, sufentanil). [Moderate] Theoretical
- **Nevirapine** decreases the exposure to methadone. Monitor and adjust dose. [Severe] Study
- **Nilotinib** is predicted to increase the exposure to opioids (alfentanil, buprenorphine, fentanyl, oxycodone). Monitor and adjust dose. [Moderate] Study
- **Nilotinib** is predicted to increase the exposure to methadone (alfentanil, buprenorphine, fentanyl, oxycodone, sufentanil). [Moderate] Theoretical → Also see **TABLE 9** p. 1266
- **Opioids (buprenorphine)** are predicted to increase the risk of opiate withdrawal when given with opioids (alfentanil, pethidine, remifentanil, sufentanil, tapentadol, tramadol). [Severe] Theoretical → Also see **TABLE 11** p. 1266 → Also see **TABLE 13** p. 1267
- **Opioids (pentazocine)** are predicted to increase the risk of opiate withdrawal when given with opioids (alfentanil, codeine, diamorphine, dihydrocodeine, dipipanone, fentanyl,
Rifampicin is predicted to decrease the exposure to buprenorphine. Monitor and adjust dose. [Moderate] Theoretical

Rifampicin is predicted to decrease the exposure to methadone. Monitor and adjust dose. [Severe] Study

Rifampicin is predicted to decrease the exposure to opioids (alfentanil, fentanyl). [Moderate] Study

Rifampicin is predicted to decrease the exposure to codeine, phenytion, primidone) are predicted to moderately decrease the exposure to osimertinib. Avoid. [Moderate] Study

Bosentan is predicted to decrease the exposure to osimertinib. Avoid. [Moderate] Study

Efavirenz is predicted to decrease the exposure to osimertinib. [Moderate] Theoretical

Enzalutamide is predicted to moderately decrease the exposure to osimertinib. Avoid. [Moderate] Study

St John’s Wort is predicted to decrease the exposure to osimertinib. Avoid. [Moderate] Study

Osimertinib slightly increases the exposure to statins (rosuvastatin). [Moderate] Study

Oxaliplatin is predicted to increase the exposure to oxystibutynin. [Mild] Theoretical

Oxazepam → see TABLE 11 p. 1266 (CNS depressant effects)

Oxenbolone → see antagonists

Oxybutynin is predicted to increase the exposure to oxystibutynin. [Mild] Theoretical

Oxystibutynin potentially increases the risk of overheating and dehydration when given with antiepileptics (zonisamide). Avoid in children. [Severe] Theoretical

Antifungals, azoles (fluconazole, itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to oxystibutynin. [Mild] Theoretical

Aprepitant is predicted to increase the exposure to oxystibutynin. [Mild] Theoretical

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to oxystibutynin. [Mild] Theoretical

Cobicistat is predicted to increase the exposure to oxystibutynin. [Mild] Study

Crizotinib is predicted to increase the exposure to oxystibutynin. [Mild] Theoretical

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to oxystibutynin. [Mild] Study

HIV-protease inhibitors (indinavir) are predicted to increase the exposure to oxystibutynin. [Mild] Study

Idelalisib is predicted to increase the exposure to oxystibutynin. [Mild] Study

Imatinib is predicted to increase the exposure to oxystibutynin. [Mild] Theoretical

Macrolides (clarithromycin) are predicted to increase the exposure to oxystibutynin. [Mild] Study

Macrolides (erythromycin) are predicted to increase the exposure to oxystibutynin. [Mild] Theoretical

Netupitant is predicted to increase the exposure to oxystibutynin. [Mild] Theoretical

Nilotinib is predicted to increase the exposure to oxystibutynin. [Mild] Theoretical

Oxybutynin → see opioids

Oxymetholone → see oxymetholone

Oxybutynin increases the antiocoagulant effect of coumarins. [Severe] Anecdotal

Oxymetholone increases the antiocoagulant effect of phenindione. [Severe] Anecdotal

Oxytetraycline → see tetracyclines

Palbociclib is predicted to increase the exposure to palbociclib. Avoid or adjust palbociclib dose, p. 909. [Severe] Study

Palbociclib is predicted to increase the exposure to cyclosporin. Adjust dose. [Moderate] Theoretical

Cobicistat is predicted to increase the exposure to palbociclib. Avoid or adjust palbociclib dose, p. 909. [Severe] Study

Enzalutamide is predicted to decrease the exposure to palbociclib. Avoid. [Severe] Study

Palbociclib is predicted to increase the exposure to ergotamine. Adjust dose. [Moderate] Theoretical

Palbociclib is predicted to increase the exposure to everolimus. Adjust dose. [Moderate] Theoretical

Grapefruit juice is predicted to increase the exposure to palbociclib. Avoid. [Severe] Theoretical

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to palbociclib. Avoid or adjust palbociclib dose, p. 909. [Severe] Study

Idelalisib is predicted to increase the exposure to palbociclib. Avoid or adjust palbociclib dose, p. 909. [Severe] Study

Palbociclib increases the exposure to midazolam. Adjust dose. [Moderate] Study

Palbociclib is predicted to increase the exposure to opioids (alfentanil, fentanyl). Adjust dose. [Moderate] Theoretical

Palbociclib is predicted to increase the exposure to pimozide. Adjust dose. [Moderate] Theoretical

Rifampicinc is predicted to decrease the exposure to palbociclib. Avoid. [Severe] Study

Palbociclib is predicted to increase the exposure to sirolimus. Adjust dose. [Moderate] Theoretical

St John’s Wort is predicted to decrease the exposure to palbociclib. Avoid. [Severe] Theoretical

Palbociclib is predicted to increase the exposure to tacrolimus. Adjust dose. [Moderate] Theoretical

Paliperidone is predicted to increase the concentration of paliperidone. Adjust dose. [Moderate] Study

Orlistat might affect the absorption of concurrently administered drugs—consider separating administration. Particular care should be taken with antiepileptics, antiretrovirals, and drugs that have a narrow therapeutic index.
Paliperidone (continued)

- Paliperidone is predicted to decrease the effects of dopamine receptor agonists. Avoid. (Moderate) Theoretical
- Paliperidone is predicted to decrease the effects of levodopa. (Severe) Theoretical
- Rifampicin is predicted to decrease the exposure to paliperidone. Monitor and adjust paliperidone dose. (Moderate) Theoretical

Palonosetron → see TABLE 13 p. 1267 (serotonin syndrome), TABLE 9 p. 1266 (QT-interval prolongation)

- Dopamine receptor agonists (apomorphine) are predicted to increase the risk of severe hypotension when given with palonosetron. (Severe) Theoretical

Pancreatin → see bishosphonates

- Pancreatin is predicted to decrease the effects of acarbose. Avoid. (Moderate) Theoretical

Pancuronium → see neuromuscular blocking drugs, non-depolarising

Panitumumab → see monoclonal antibodies

Panobinostat → see TABLE 15 p. 1267 (myelosuppression), TABLE 9 p. 1266 (QT-interval prolongation)

FOOD AND LIFESTYLE

- Avoid pomegranate, pomegranate juice, and star fruit as they are predicted to increase panobinostat exposure.

- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to panobinostat. Avoid. (Moderate) Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to panobinostat. Adjust panobinostat dose; in hepatic impairment avoid, p. 864. (Moderate) Study → Also see TABLE 9 p. 1266
- Panobinostat is predicted to increase the exposure to atomoxetine. Monitor and adjust dose. (Severe) Theoretical
- Panobinostat is predicted to increase the exposure to beta blockers, selective (metoprolol). Monitor and adjust dose. (Moderate) Theoretical
- Cobicistat is predicted to increase the exposure to panobinostat. Adjust panobinostat dose; in hepatic impairment avoid, p. 864. (Moderate) Study
- Enzalutamide is predicted to decrease the exposure to panobinostat. Avoid. (Moderate) Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to panobinostat. Adjust panobinostat dose; in hepatic impairment avoid, p. 864. (Moderate) Study → Also see TABLE 9 p. 1266
- Idelalisib is predicted to increase the exposure to panobinostat. Adjust panobinostat dose; in hepatic impairment avoid, p. 864. (Moderate) Study → Also see TABLE 15 p. 1267
- Macrolides (clarithromycin) are predicted to increase the exposure to panobinostat. Adjust panobinostat dose; in hepatic impairment avoid, p. 864. (Moderate) Study → Also see TABLE 9 p. 1266
- Panobinostat is predicted to increase the exposure to phenothiazines (perphenazine). Monitor and adjust dose. (Severe) Theoretical
- Panobinostat is predicted to increase the exposure to pimozone. Avoid. (Severe) Theoretical
- Rifampicin is predicted to decrease the exposure to panobinostat. Avoid. (Moderate) Theoretical
- St John’s Wort is predicted to decrease the exposure to panobinostat. Avoid. (Severe) Theoretical
- Panoprazole → see proton pump inhibitors
- Papaveretum → see opioids
- Paracetamol → see TABLE 1 p. 1264 (hepatotoxicity)

FOOD AND LIFESTYLE

- Severe liver damage can occur with chronic alcohol consumption in some alcoholic and persistent heavy drinkers who take only moderate doses of paracetamol.
- Paracetamol is predicted to decrease the clearance of alkylation agents (busulfan). (Moderate) Theoretical
- Paracetamol is predicted to increase the risk of methaemoglobinemia when given with topical anaesthetics, local (proparacaine). Use with caution or avoid. (Severe) Theoretical
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to paracetamol. (Moderate) Study → Also see TABLE 1 p. 1264
- Paracetamol increases the anticoagulant effect of coumarins. (Severe) Study
- Paracetamol is predicted to increase the risk of methaemoglobinemia when given with dapsone. (Severe) Theoretical
- Enzalutamide is predicted to decrease the exposure to paracetamol. (Moderate) Study
- Imatinib increases the risk of hepatotoxicity when given with paracetamol. (Severe) Ancrodatal
- Paracetamol is predicted to increase the anticoagulant effect of phenindione. (Severe) Theoretical
- Pitolisant is predicted to decrease the exposure to paracetamol. (Unknown) Theoretical
- Rifampicin is predicted to decrease the exposure to paracetamol. (Moderate) Study
- Paraldehyde → see antiepileptics
- Parecoxib → see NSAIDs
- Paricalcitol → see vitamin D substances

Paritaprevir

- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to paritaprevir (with ritonavir and ombitasvir). Avoid. (Severe) Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to paritaprevir (with ritonavir and ombitasvir). Avoid. (Severe) Theoretical
- Antifungals, azoles (posaconazole) are predicted to increase the exposure to paritaprevir (with ritonavir and ombitasvir) and paritaprevir (with ritonavir and ombitasvir) is predicted to increase the exposure to antifungals, azoles (posaconazole). Avoid. (Severe) Theoretical
- Bosentan is predicted to decrease the exposure to paritaprevir (with ritonavir and ombitasvir). Avoid. (Severe) Study
- Cobicistat is predicted to increase the exposure to paritaprevir (with ritonavir and ombitasvir). Avoid. (Severe) Study
- Paritaprevir (with ritonavir and ombitasvir) increases the risk of raised liver function tests when given with combined hormonal contraceptives. Avoid. (Severe) Study
- Efavirenz is predicted to decrease the exposure to paritaprevir (with ritonavir and ombitasvir). Avoid. (Severe) Study
- Enzalutamide is predicted to decrease the exposure to paritaprevir (with ritonavir and ombitasvir). Avoid. (Severe) Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to paritaprevir (with ritonavir and ombitasvir). Avoid. (Severe) Study
- HIV-protease inhibitors (indinavir) potentially increase the exposure to paritaprevir. Avoid. (Severe) Theoretical
- Idelalisib is predicted to increase the exposure to paritaprevir (with ritonavir and ombitasvir). Avoid. (Severe) Theoretical
- Paritaprevir (with ritonavir and ombitasvir) is predicted to increase the exposure to loop diuretics (furosemide). Adjust furosemide dose. (Moderate) Study
- Macrolides (clarithromycin) are predicted to increase the exposure to paritaprevir (with ritonavir and ombitasvir). Avoid. (Severe) Theoretical
- Nevirapine is predicted to decrease the exposure to paritaprevir (with ritonavir and ombitasvir). Avoid. (Severe) Study
- Rifampicin is predicted to decrease the exposure to paritaprevir (with ritonavir and ombitasvir). Avoid. (Severe) Study
- St John’s Wort is predicted to decrease the exposure to paritaprevir (with ritonavir and ombitasvir). Avoid. (Severe) Study

1382 Paliperidone – Paritaprevir
Paritaprevir

- Paritaprevir (with ritonavir and ombitasvir) is predicted to increase the exposure to statins (fluvacastatin). Avoid. [Moderate] Theoretical
- Paritaprevir (with ritonavir and ombitasvir) increases the exposure to statins (pravastatin). Adjust pravastatin dose, p. 197. [Moderate] Study
- Paritaprevir (with ritonavir and ombitasvir) increases the exposure to statins (rosuvastatin). Adjust rosuvastatin dose, p. 197. [Moderate] Study
- Paroxetine → see SSRIs
- Paritaprevir → see TABLE 6 p. 1265 (bradycardia), TABLE 9 p. 1266 (QT-interval prolongation)
- Paritaprevir is predicted to decrease the absorption of oral ciclosporin. Adjust dose. [Severe] Theoretical
- Pazopanib → see TABLE 15 p. 1267 (myelosuppression); TABLE 9 p. 1266 (QT-interval prolongation)
- Antacids are predicted to decrease the absorption of pazopanib. Pazopanib should be taken 1 hour before or 2 hours after antacids. [Moderate] Theoretical
- Antiarhythmics (dronedarone) are predicted to increase the exposure to pazopanib. [Moderate] Theoretical → Also see TABLE 9 p. 1266
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to pazopanib. Avoid. [Severe] Theoretical
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to pazopanib. [Moderate] Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to pazopanib. Avoid or adjust pazopanib dose, p. 909. [Moderate] Study → Also see TABLE 9 p. 1266
- Aprepitant is predicted to increase the exposure to pazopanib. [Moderate] Theoretical
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to pazopanib. [Moderate] Theoretical
- Cobicistat is predicted to increase the exposure to pazopanib. Avoid or adjust pazopanib dose, p. 909. [Moderate] Study
- Pazopanib is predicted to increase the risk of bleeding events when given with coumarins. [Severe] Theoretical
- Crizotinib is predicted to increase the exposure to pazopanib. [Moderate] Theoretical → Also see TABLE 15 p. 1267 → Also see TABLE 9 p. 1266
- Enzalutamide is predicted to decrease the exposure to pazopanib. Avoid. [Severe] Theoretical
- Grapefruit juice is predicted to increase the exposure to pazopanib. Avoid. [Severe] Theoretical
- H₂ receptor antagonists are predicted to decrease the exposure to pazopanib. H₂ receptor antagonists should be taken 10 hours before or 2 hours after pazopanib. [Moderate] Theoretical
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to pazopanib. Avoid or adjust pazopanib dose, p. 909. [Moderate] Study → Also see TABLE 9 p. 1266
- HIV-protease inhibitors (indinavir) are predicted to increase the exposure to pazopanib. [Moderate] Theoretical
- Idelalisib is predicted to increase the exposure to pazopanib. Avoid or adjust pazopanib dose, p. 909. [Moderate] Study → Also see TABLE 15 p. 1267
- Imatinib is predicted to increase the exposure to pazopanib. [Moderate] Theoretical → Also see TABLE 15 p. 1267
- Pazopanib is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. [Moderate] Theoretical
- Macrolides (clarithromycin) are predicted to increase the exposure to pazopanib. Avoid or adjust pazopanib dose, p. 909. [Moderate] Study → Also see TABLE 9 p. 1266
- Macrolides (erythromycin) are predicted to increase the exposure to pazopanib. [Moderate] Theoretical
- Netupitant is predicted to increase the exposure to pazopanib. [Moderate] Theoretical
- Nilotinib is predicted to increase the exposure to pazopanib. [Moderate] Theoretical → Also see TABLE 15 p. 1267 → Also see TABLE 9 p. 1266
- Pazopanib is predicted to increase the risk of bleeding events when given with phenindione. [Severe] Theoretical
- Proton pump inhibitors are predicted to decrease the exposure to pazopanib. Avoid or administer concurrently without food. [Moderate] Study
- Rifampicin is predicted to decrease the exposure to pazopanib. Avoid. [Severe] Theoretical
- Pegaspargase → see TABLE 1 p. 1264 (hepatotoxicity), TABLE 15 p. 1267 (myelosuppression)
- Pegaspargase is predicted to increase the risk of hepatotoxicity when given with imatinib. [Severe] Theoretical → Also see TABLE 15 p. 1267
- Pegaspargase affects the efficacy of methotrexate. [Severe] Anecdotal → Also see TABLE 1 p. 1264 → Also see TABLE 15 p. 1267
- Pegaspargase potentially increases the risk of neurotoxicity when given with vinca alkaloids (vincristine). Vincristine should be taken 3 to 24 hours before pegaspargase. [Severe] Anecdotal → Also see TABLE 1 p. 1264 → Also see TABLE 15 p. 1267
- Peginterferon alfa → see interferons
- Peginterferon beta-1a → see TABLE 15 p. 1267 (myelosuppression)
- Pembrolizumab → see monoclonal antibodies
- Pemetrexed → see TABLE 15 p. 1267 (myelosuppression), TABLE 2 p. 1264 (nephrotoxicity)
- Antimalarialys (pyrimethamine) are predicted to increase the risk of side-effects when given with pemetrexed. [Severe] Theoretical → Also see TABLE 15 p. 1267
- Asparin (high-dose) potentially increases the exposure to pemetrexed. Use with caution or avoid. [Severe] Theoretical
- Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with pemetrexed. Public Health England advises avoid. [Severe] Theoretical
- NSAIDs are predicted to increase the exposure to pemetrexed. Use with caution or avoid. [Severe] Theoretical → Also see TABLE 2 p. 1264
- Penicillamine → see TABLE 2 p. 1264 (nephrotoxicity)
- Antacids decrease the absorption of penicillamine. Separate administration by 2 hours. [Mild] Study
- Antimalarialys (chloroquine) are predicted to increase the risk of haematological toxicity when given with penicillamine. Avoid. [Severe] Theoretical
- Penicillamine potentially decreases the concentration of digoxin. Separate administration by 2 hours. [Severe] Anecdotal
- Hydroxychloroquine is predicted to increase the risk of haematological toxicity when given with penicillamine. Avoid. [Severe] Theoretical
- Iron (oral) is predicted to decrease the absorption of penicillamine. Separate administration by at least 2 hours. [Mild] Study
- Sodium aurothiomalate potentially increases the risk of side-effects when given with penicillamine (in those who have had previous adverse reactions to gold). Avoid. [Severe] Study
- Zinc is predicted to decrease the absorption of penicillamine. [Mild] Theoretical

Penicillins

amoxicillin - ampicillin - benzylpenicillin - flucloxacillin - phenoxymethylpenicillin - piperacillin - pivmecillinam - temocillin - ticarcillin

- Allopurinol increases the risk of skin rash when given with penicillins (amoxicillin, ampicillin). [Moderate] Study
- Penicillins potentially alter the anticoagulant effect of coumarins. Monitor INR and adjust dose. [Severe] Anecdotal
- Penicillins are predicted to increase the risk of toxicity when given with methotrexate. [Severe] Theoretical
- Piperacillin increases the effects of neuromuscular blocking drugs, non-depolarising. [Moderate] Study
- Penicillins are predicted to increase the risk of bleeding events when given with phenindione. [Severe] Theoretical
- Piperacillin increases the effects of suxamethonium. [Moderate] Study
- Pentamidine → see TABLE 15 p. 1267 (myelosuppression), TABLE 2 p. 1264 (nephrotoxicity), TABLE 9 p. 1266 (QT-interval prolongation)
- Didanosine is predicted to increase the risk of pancreatitis when given with pentamidine. Avoid. [Severe] Study
- Foscarnet increases the risk of hypocalcaemia when given with pentamidine. [Severe] Anecdotal → Also see TABLE 2 p. 1264
- Pentazocine → see opioids
### Pentostatin – Phenothiazines

**Pentostatin** → see TABLE 15 p. 1267 (myelosuppression), TABLE 5 p. 1264 (thromboembolism)

- Alkylating agents (cyclophosphamide) (high-dose) increase the risk of toxicity when given with pentostatin. Avoid. [Severe] Anecdotal → Also see TABLE 15 p. 1267 → Also see TABLE 5 p. 1264
- Fluorarabine increases the risk of pulmonary toxicity when given with pentostatin. Avoid. [Severe] Study → Also see TABLE 15 p. 1267

**Pentoxifylline**

- Pentoxifylline is predicted to increase the concentration of aminophylline. Use with caution or avoid. [Severe] Theoretical
- Quinolones (ciprofloxacin) very slightly increase the exposure to pentoxifylline. [Moderate] Study
- SSRI (fluvoxamine) are predicted to increase the exposure to pentoxifylline. [Moderate] Study
- Pentoxifylline increases the concentration of theophylline. Monitor and adjust dose. [Severe] Study

**Peppermint oil**

- Peppermint oil is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. [Moderate] Theoretical

### Peppermint oil

- Phenelzine
- Perindopril
- → Pethidine
- → Pertuzumab
- Perinephrine
- Perphenazine
- Pertuzumab
- Pethidine
- → Phenindione

**Phenindione** → see TABLE 3 p. 1264 (anticoagulant effects)

**FOOD AND LIFESTYLE** The effects of phenindione can be reduced or abolished by vitamin K, including that found in foods and in alcohol consumption can affect anticoagulant control.

- Antiarrhythmics (propafenone) are predicted to increase the anticoagulant effect of phenindione. Monitor and adjust dose. [Moderate] Theoretical
- Antifungals, azoles (miconazole) greatly increase the anticoagulant effect of phenindione. [Severe] Theoretical
- Axitinib is predicted to increase the risk of bleeding events when given with phenindione. [Severe] Theoretical
- Bosutinib is predicted to increase the risk of bleeding events when given with phenindione. [Severe] Theoretical
- Cabozantinib is predicted to increase the risk of bleeding events when given with phenindione. [Severe] Theoretical
- Cephalosporins (ceftriaxone) potentially increase the risk of bleeding events when given with phenindione. [Severe] Anecdotal
- Corticosteroids are predicted to increase the effects of phenindione. [Moderate] Theoretical
- Crizotinib is predicted to increase the risk of bleeding events when given with phenindione. [Severe] Theoretical
- Dasatinib is predicted to increase the risk of bleeding events when given with phenindone. [Severe] Theoretical
- Disulfiram is predicted to increase the anticoagulant effect of phenindione. [Severe] Theoretical
- Enteral feeds (vitamin-K containing) potentially decreases the effects of phenindione. [Severe] Theoretical
- Erlotinib is predicted to increase the risk of bleeding events when given with phenindione. [Severe] Theoretical
- Fibrates are predicted to increase the anticoagulant effect of phenindione. Monitor INR and adjust dose. [Severe] Study
- Gefitinib is predicted to increase the risk of bleeding events when given with phenindione. [Severe] Theoretical
- H2 receptor antagonists (cimetidine) increase the exposure to phenindione. [Severe] Anecdotal
- Imatinib is predicted to increase the risk of bleeding events when given with phenindone. [Severe] Theoretical
- Lapatinib is predicted to increase the risk of bleeding events when given with phenindone. [Severe] Theoretical
- Nandrolone is predicted to increase the anticoagulant effect of phenindone. Monitor and adjust dose. [Severe] Theoretical
- Nilotinib is predicted to increase the risk of bleeding events when given with phenindione. [Severe] Theoretical
- Oxyxemolone increases the anticoagulant effect of phenindione. [Severe] Anecdotal
- Paracetamol is predicted to increase the anticoagulant effect of phenindione. [Severe] Theoretical
- Pazopanib is predicted to increase the risk of bleeding events when given with phenindione. [Severe] Theoretical
- Pentamidine are predicted to increase the risk of bleeding events when given with phenindione. [Severe] Theoretical
- Ponatinib is predicted to increase the risk of bleeding events when given with phenindione. [Severe] Theoretical
- Ranibizumab is predicted to increase the risk of bleeding events when given with phenindione. [Severe] Theoretical
- Regorafenib is predicted to increase the risk of bleeding events when given with phenindione. [Severe] Theoretical
- Ruxolitinib is predicted to increase the risk of bleeding events when given with phenindione. [Severe] Theoretical
- Sorafenib is predicted to increase the risk of bleeding events when given with phenindione. [Severe] Theoretical
- Statins (rosuvastatin) are predicted to increase the anticoagulant effect of phenindione. Monitor INR and adjust dose. [Severe] Theoretical
- Sunifiram is predicted to increase the risk of bleeding events when given with phenindione. [Severe] Theoretical
- Vandetanib is predicted to increase the risk of bleeding events when given with phenindone. [Severe] Theoretical
- Phenobarbital → see antiepileptics

**Phenothiazines** → see TABLE 8 p. 1265 (hypotension), TABLE 9 p. 1266 (QT-interval prolongation), TABLE 11 p. 1266 (CNS depressant effects), TABLE 10 p. 1266 (antimuscarinics)

- Chlorpromazine · fluphenazine · levomepromazine · perphenazine · perphenazine · prochlorperazine · promazine · trifluoperazine

**FOOD AND LIFESTYLE** Dose adjustment might be necessary if smoking started or stopped during treatment with chlorpromazine and fluphenazine.

- Amfetamines are predicted to decrease the effects of chlorpromazine. [Moderate] Study
- Phenothiazines are predicted to decrease the effects of amfetamines. [Moderate] Study
- Antacids decrease the absorption of phenothiazines. [Severe] Anecdotal
- Chlorpromazine decreases the concentration of antiepileptics (phenobarbital, primidone) and antiepileptics (phenobarbital, primidone) decrease the concentration of chlorpromazine. [Moderate] Study → Also see TABLE 11 p. 1266
- Chlorpromazine is predicted to increase the risk of hyponatraemia when given with desmopressin. [Severe] Theoretical
- Phenothiazines are predicted to decrease the effects of dopamine receptor agonists. Avoid. [Moderate] Study → Also see TABLE 8 p. 1265 → Also see TABLE 9 p. 1266 → Also see TABLE 10 p. 1266
- Phenothiazines are predicted to decrease the antihypertensive effects of guanethidine. [Moderate] Theoretical → Also see TABLE 8 p. 1265
- Phenothiazines are predicted to decrease the effects of histamine. Avoid. [Severe] Theoretical → Also see TABLE 8 p. 1265
- Phenothiazines decrease the effects of levodopa. Avoid or monitor worsening parkinsonian symptoms. [Severe] Study → Also see TABLE 8 p. 1265
- Phenothiazines potentially increase the risk of neurotoxicity when given with lithium. [Severe] Anecdotal → Also see TABLE 9 p. 1266
- Chlorpromazine decreases the effects of metyrapone. Avoid. [Moderate] Theoretical
- Moclubemide increases the risk of side-effects when given with levomepromazine. [Moderate] Study
- Monoamine-oxidase A and B inhibitors, irreversible are predicted to increase the risk of neuroleptic malignant syndrome when given with phenothiazines. [Severe] Theoretical → Also see TABLE 8 p. 1265
- Panobinostat is predicted to increase the exposure to perphenazine. Monitor and adjust dose. [Severe] Theoretical
- SSRI (paroxetine) markedly increase the exposure to perphenazine. [Severe] Study
Phenoxyethylpenicillin – Phosphodiesterase type-5 inhibitors

Antiarrhythmics

▶ Antifungals, azoles

Antiepileptics

▶ Phenytoin

Pharmacodynamics

Phenoxyethylpenicillin – see penicillins
Phenytoin – see antiepileptics
Pholcodine

▶ Pholcodine is predicted to increase the risk of CNS excitation or depression when given with monoamine-oxidase A and B inhibitors, irreversible. Avoid and for 14 days after stopping the MAOI. (Severe) Theoretical

Phosphodiesterase type-5 inhibitors – see TABLE 8 p. 1265 (hypotension), TABLE 9 p. 1266 (QT-interval prolongation)

alpha blockers cause significant hypotensive effects when given with phosphodiesterase type-5 inhibitors. Patient should be stabilised on first drug then second drug should be added at the lowest recommended dose. (Severe) Study → Also see TABLE 8 p. 1265

Antiarrhythmics (dronedarone) are predicted to increase the exposure to avanafil. Adjust avanafil dose, p. 765. (Moderate) Theoretical

Antiarrhythmics (dronedarone) are predicted to increase the exposure to sildenafil. Monitor and adjust sildenafil dose, p. 766. (Moderate) Study → Also see TABLE 8 p. 1265

Antiarrhythmics (dronedarone) are predicted to increase the exposure to tadalafil. (Severe) Theoretical

Antiarrhythmics (dronedarone) are predicted to increase the exposure to vardenafil. Adjust dose. (Severe) Theoretical → Also see TABLE 8 p. 1265

Cobicistat is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (avanafil, vardenafil). Avoid. (Severe) Study

Cobicistat is predicted to increase the exposure to sildenafil. Avoid or adjust sildenafil dose, p. 766. (Severe) Study

Cobicistat is predicted to increase the exposure to tadalafil. Use with caution or avoid. (Severe) Study

Crizotinib is predicted to increase the exposure to avanafil. Adjust avanafil dose, p. 765. (Moderate) Theoretical

Crizotinib is predicted to increase the exposure to sildenafil. Monitor and adjust sildenafil dose, p. 766. (Moderate) Study → Also see TABLE 9 p. 1266

Crizotinib is predicted to increase the exposure to tadalafil. Adjust dose. (Severe) Theoretical

Crizotinib is predicted to increase the exposure to vardenafil. Adjust dose, p. 765. (Moderate) Theoretical

Enzalutamide is predicted to decrease the exposure to phosphodiesterase type-5 inhibitors (avanafil, vardenafil). (Moderate) Theoretical

Enzalutamide is predicted to decrease the exposure to phosphodiesterase type-5 inhibitors (sildenafil, vardenafil). (Moderate) Theoretical

Etravirine moderately decreases the exposure to phosphodiesterase type-5 inhibitors. Adjust dose. (Moderate) Study

Grapefruit juice is predicted to increase the exposure to phosphodiesterase type-5 inhibitors. Use with caution or avoid. (Moderate) Study

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to phosphodiesterase type-5 inhibitors (avanafil, vardenafil). Avoid. (Severe) Study → Also see TABLE 9 p. 1266

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to sildenafil. Avoid or adjust sildenafil dose, p. 766. (Severe) Study → Also see TABLE 9 p. 1266

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to tadalafil. Use with caution or avoid. (Severe) Study

HIV-protease inhibitors (indinavir) are predicted to increase the exposure to avanafil. Adjust avanafil dose, p. 765. (Moderate) Theoretical

HIV-protease inhibitors (indinavir) are predicted to increase the exposure to phosphodiesterase type-5 inhibitors (avanafil, vardenafil). Avoid. (Severe) Study

Idelalisib is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (avanafil, vardenafil). Avoid. (Severe) Study

Idelalisib is predicted to increase the exposure to sildenafil. Monitor and adjust sildenafil dose, p. 766. (Moderate) Study

Idelalisib is predicted to increase the exposure to tadalafil. (Severe) Theoretical

Idelalisib is predicted to increase the exposure to vardenafil. Adjust dose. (Severe) Theoretical

Idelalisib is predicted to increase the exposure to sildenafil. Avoid or adjust sildenafil dose, p. 766. (Severe) Study

Imatinib is predicted to increase the exposure to avanafil. Adjust avanafil dose, p. 765. (Moderate) Theoretical

Imatinib is predicted to increase the exposure to phosphodiesterase type-5 inhibitors (avanafil, vardenafil). Avoid. (Severe) Study

Imatinib is predicted to increase the exposure to sildenafil. Monitor and adjust sildenafil dose, p. 766. (Moderate) Study

Imatinib is predicted to increase the exposure to tadalafil. (Severe) Theoretical

Interactions | Appendix 1
Phosphodiesterase type-5 inhibitors (continued)

- **Imatinib** is predicted to increase the exposure to vardenafil. Adjust dose. *Severe* Theoretical

- **Macrolides** *(clarithromycin)* are predicted to increase the exposure to sildenafil. Avoid or adjust sildenafil dose, p. 766. *Severe* Study → Also see TABLE 9 p. 1266

- **Macrolides** *(erythromycin)* are predicted to increase the exposure to vardenafil. Use with caution or avoid. *Severe* Study

- **Macrolides** *(erythromycin)* are predicted to increase the exposure to tadalafil. Adjust dose. *Severe* Theoretical

- **Macrolides** *(erythromycin)* are predicted to increase the exposure to vardenafil. Adjust tadalafil dose, p. 766. *Moderate* Theoretical

- **Nilotinib** is predicted to increase the exposure to sildenafil. Adjust tadalafil dose, p. 766. *Moderate* Theoretical

- **Nilotinib** is predicted to increase the exposure to vardenafil. Adjust tadalafil dose, p. 766. *Moderate* Theoretical

- **Nilotinib** is predicted to increase the exposure to vardenafil. Monitor and adjust sildenafil dose, p. 766. *Moderate* Study

- **Netupitant** is predicted to increase the exposure to vardenafil. Adjust dose. *Severe* Theoretical

- **Netupitant** is predicted to increase the exposure to vardenafil. Adjust dose. *Severe* Theoretical

- **Nevirapine** is predicted to decrease the exposure to phosphodiesterase type-5 inhibitors. *Moderate* Theoretical

- **Nicoardil** is predicted to increase the risk of hypotension when given with phosphodiesterase type-5 inhibitors. Avoid. *Severe* Theoretical → Also see TABLE 8 p. 1265

- **Nilotinib** is predicted to increase the exposure to vardenafil. Adjust avanafil dose, p. 765. *Moderate* Theoretical

- **Nilotinib** is predicted to increase the exposure to sildenafil. Monitor and adjust sildenafil dose, p. 766. *Moderate* Study

- **Nilotinib** is predicted to increase the exposure to vardenafil. Monitor and adjust sildenafil dose, p. 766. *Moderate* Study

- **Netupitant** is predicted to increase the exposure to vardenafil. Adjust dose. *Severe* Theoretical

- **Netupitant** is predicted to increase the exposure to vardenafil. Adjust dose. *Severe* Theoretical

- **Netupitant** is predicted to increase the exposure to vardenafil. Monitor and adjust sildenafil dose, p. 766. *Moderate* Study

- **Netupitant** is predicted to increase the exposure to vardenafil. Adjust dose. *Severe* Theoretical

- **Nitrate**s potentially increase the risk of hypotension when given with phosphodiesterase type-5 inhibitors. Avoid. *Severe* Study → Also see TABLE 8 p. 1265

- **Rifampicin** is predicted to decrease the exposure to phosphodiesterase type-5 inhibitors *(avanafil, tadalafil)*. Avoid. *Severe* Study

- **Rifampicin** is predicted to decrease the exposure to phosphodiesterase type-5 inhibitors *(sildenafil, vardenafil)*. *Moderate* Theoretical

- **Riociguat** is predicted to increase the risk of hypotension when given with phosphodiesterase type-5 inhibitors. Avoid. *Severe* Theoretical → Also see TABLE 8 p. 1265

- **Phosphodiesterase type-5 inhibitors** are predicted to increase the risk of hypotension when given with *sapropterin*. *Moderate* Theoretical → Also see TABLE 8 p. 1265

- **St John’s Wort** is predicted to decrease the exposure to phosphodiesterase type-5 inhibitors. *Moderate* Theoretical

#### Pilocarpine

**ROUTE-SPECIFIC INFORMATION** Since systemic absorption can follow topical application, the possibility of interactions should be borne in mind.

#### Pimecrolimus

**FOOD AND LIFESTYLE** Risk of facial flushing and skin irritation with alcohol consumption.

- **Pimecrolimus** is predicted to decrease the efficacy of *mifamurtide*. Avoid. *Severe* Theoretical

**Pimozide** → Also see TABLE 9 p. 1266 (hypotension), **TABLE 10 p. 1266 (QT-interval prolongation)**, **TABLE 11 p. 1266 (CNS depressant effects)**, **TABLE 10 p. 1266 (antimuscarinics)**

- **Antiarrhythmics** *(dronedarone)* are predicted to increase the exposure to *pimozide*. Avoid. *Severe* Theoretical → Also see **TABLE 9 p. 1266**

- **Antifungals, azoles** *(fluconazole, itraconazole, ketoconazole, voriconazole)* are predicted to increase the exposure to *pimozide*. Avoid. *Severe* Theoretical → Also see **TABLE 9 p. 1266**

- **Antifungals, azoles** *(miconazole)* are predicted to increase the exposure to *pimozide*. Avoid. *Severe* Theoretical

- **Aprepitant** is predicted to increase the exposure to *pimozide*. Avoid. *Severe* Theoretical

- **Calcium channel blockers** *(diltiazem, verapamil)* are predicted to increase the exposure to *pimozide*. Avoid. *Severe* Theoretical → Also see **TABLE 8 p. 1265**

- **Certitinib** is predicted to increase the exposure to *pimozide*. Avoid. *Severe* Theoretical

- **Cobicistat** is predicted to increase the exposure to *pimozide*. Avoid. *Severe* Study

- **Crizotinib** is predicted to increase the exposure to *pimozide*. Avoid. *Severe* Theoretical → Also see **TABLE 9 p. 1266**

- **Pimozide** is predicted to decrease the effects of dopamine receptor agonists. Avoid. *Moderate* Theoretical → Also see **TABLE 8 p. 1265**

- **Fosaprepitant** is predicted to increase the exposure to *pimozide*. Avoid. *Severe* Theoretical

- **Grapefruit juice** increases the exposure to *pimozide*. Avoid. *Severe* Theoretical

- **HIV- protease inhibitors** *(atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)* are predicted to increase the exposure to *pimozide*. Avoid. *Severe* Study → Also see **TABLE 9 p. 1266**

- **Itraconazole** is predicted to increase the exposure to *pimozide*. Avoid. *Severe* Theoretical → Also see **TABLE 10 p. 1266**

- **Lopinavir, ritonavir, saquinavir, tipranavir** are predicted to increase the exposure to *pimozide*. Avoid. *Severe* Theoretical → Also see **TABLE 11 p. 1266**

- **Macrolides** *(clarithromycin)* are predicted to increase the exposure to *pimozide*. Avoid. *Severe* Study → Also see **TABLE 8 p. 1265**

- **Macrolides** *(erythromycin)* are predicted to increase the exposure to *pimozide*. Avoid. *Severe* Study → Also see **TABLE 9 p. 1266**

- **Panobinostat** is predicted to increase the exposure to *pimozide*. Avoid. *Severe* Theoretical → Also see **TABLE 9 p. 1266**

- **Pentamidine** is predicted to increase the exposure to *pimozide*. Avoid. *Severe* Theoretical → Also see **TABLE 9 p. 1266**

- **Piroxicam** is predicted to increase the exposure to *pimozide*. Avoid. *Severe* Theoretical → Also see **TABLE 10 p. 1266**

- **Ponazuril** is predicted to increase the exposure to *pimozide*. Avoid. *Severe* Theoretical → Also see **TABLE 10 p. 1266**

- **Pral Rugiline** is predicted to increase the exposure to *pimozide*. Avoid. *Severe* Theoretical → Also see **TABLE 10 p. 1266**

- **Pimozide** is predicted to increase the exposure to *pimozide*. Avoid. *Severe* Theoretical → Also see **TABLE 9 p. 1266**

- **Pineal hormones** *(melatonin)* are predicted to increase the exposure to *pimozide*. Avoid. *Severe* Theoretical → Also see **TABLE 9 p. 1266**

- **Pimozide** decreases the effects of levodopa. Avoid. *Severe* Theoretical → Also see **TABLE 8 p. 1265**

- **Piroxicam** is predicted to increase the exposure to *pimozide*. Avoid. *Severe* Theoretical → Also see **TABLE 9 p. 1266**

- **Pitolisant** is predicted to increase the exposure to *pimozide*. Avoid. *Severe* Study

- **Pindolol** → Also see beta blockers, non-selective

**Pioglitazone** → Also see **TABLE 14 p. 1267 (antidiabetic drugs)**

- **Clodigrel** is predicted to increase the exposure to *pioglitazone*. *Severe* Theoretical

- **Fibrates** *(gemfibrozil)* markedly increase the exposure to *pioglitazone*. Monitor blood glucose and adjust dose. *Severe* Study

- **Rifampicin** moderately decreases the exposure to *pioglitazone*. Monitor and adjust *pioglitazone* dose. *Moderate* Theoretical

- **St John’s Wort** slightly decreases the exposure to *pioglitazone*. *Mild* Study

- **Piperacillin** → Also see penicillins

- **Piperacillin** → Also see antimalarials

**Pirfenidone**

**FOOD AND LIFESTYLE** Smoking increases pirfenidone clearance; patients should be encouraged to stop smoking before and during treatment with pirfenidone.
Pirfenidone – Ponatinib

Antiepileptics (fosphenytoin, phenytoin) are predicted to decrease the exposure to pirfenidone. Avoid. [Moderate]

**Theoretical**

- Combined hormonal contraceptives are predicted to increase the exposure to pirfenidone. Use with caution and adjust dose. [Moderate]
- HIV-protease inhibitors (ritonavir) are predicted to decrease the exposure to pirfenidone. Avoid. [Moderate] Theoretical
- Quinolones (ciprofloxacin) are predicted to increase the exposure to pirfenidone. Avoid. [Moderate] Theoretical

Abiraterone is predicted to decrease the exposure to pirfenidone. Avoid. [Moderate] Theoretical

Piroxicam is predicted to moderately decrease the exposure to pirfenidone. Use with caution and adjust dose. [Moderate] Study

**Rifampicin** is predicted to moderately reduce the exposure to ponatinib. [Moderate] Study

**Pitolisant** is predicted to decrease the exposure to sirolimus. Avoid. [Severe] Theoretical

SSRIs (fluvoxamine) are predicted to moderately increase the exposure to ponatinib. Avoid. [Severe] Theoretical

**St John’s Wort** is predicted to decrease the exposure to ponatinib. Monitor and adjust dose. [Moderate] Theoretical

**Pitolisant** is predicted to decrease the exposure to tacrolimus. Avoid. [Severe] Theoretical

**Pitolisant** is predicted to decrease the exposure to taxanes (docetaxel). Avoid. [Severe] Theoretical

**Pitolisant** is predicted to decrease the exposure to temsirolimus. Avoid. [Severe] Theoretical

**Terbinaine** is predicted to moderately increase the exposure to ponatinib. Use with caution and adjust dose. [Moderate] Study

**Tricyclic antidepressants** are predicted to decrease the efficacy of ponatinib. [Mild] Theoretical

**Pimecrolimus** → see penicillins

**Pikantrone** → see anticholinergics

**Pizotifen** → see antihistamines, sedating

**Platinum compounds** → see TABLE 15 p. 1267 (myelosuppression), TABLE 2 p. 1264 (nephrotoxicity), TABLE 19 p. 1268 (ototoxicity), TABLE 12 p. 1267 (peripheral neuropathy)

**Cisplatin – cisplatin - oxaliplatin**

- Cisplatin increases the risk of pulmonary toxicity when given with bleomycin. [Severe] Study Also see TABLE 15 p. 1267
- Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with platinum compounds. Public Health England advises avoid. [Severe] Theoretical

**Polymyxins** → see TABLE 2 p. 1264 (nephrotoxicity), TABLE 20 p. 1268 (neuromuscular blocking effects)

**Poly saccharide-iron complex** → see iron (oral)

**Poly styrene sulfonate**

- **Antacid** increases the risk of metabolic alkalosis when given with polystyrene sulfonate. [Severe] Theoretical
- **Poly styrene sulfonate** is predicted to decrease the absorption of levethyroxine. Separate administration by at least 4 hours. [Moderate] Theoretical

**Pomalidomide** → see TABLE 15 p. 1267 (myelosuppression), TABLE 5 p. 1264 (thromboembolism)

- **Combined hormonal contraceptives** are predicted to increase the risk of venous thromboembolism when given with pomalidomide. Avoid. [Severe] Theoretical
- **Hormone replacement therapy** is predicted to increase the risk of venous thromboembolism when given with pomalidomide. [Severe] Theoretical
- **Quinolones (ciprofloxacin)** are predicted to increase the exposure to pomalidomide. Adjust pomalidomide dose, p. 886. [Moderate] Theoretical

**Pomalidomide** is predicted to moderately increase the exposure to pomalidomide. Adjust pomalidomide dose, p. 886. [Moderate] Study

**Ponatinib**

- **Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone)** are predicted to decrease the exposure to ponatinib. Avoid. [Moderate] Theoretical
- **Anti fungs, azoles (itraconazole, ketoconazole, voriconazole)** are predicted to slightly increase the exposure to ponatinib. Monitor and adjust ponatinib dose, p. 911. [Moderate] Study
- **Cobicistat** is predicted to slightly increase the exposure to ponatinib. Monitor and adjust ponatinib dose, p. 911. [Moderate] Study

**Ponatinib** is predicted to increase the risk of bleeding events when given with coumarins. [Severe] Theoretical

- **Enzalutamide** is predicted to decrease the exposure to ponatinib. Avoid. [Moderate] Theoretical
- **Grapefruit juice** is predicted to increase the exposure to ponatinib. [Moderate] Theoretical

- **HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to...
Ponatinib (continued)  
slightly increase the exposure to ponatinib. Monitor and adjust ponatinib dose, p. 911. (Moderate) Study
  ▶ **idelalisib** is predicted to slightly increase the exposure to ponatinib. Monitor and adjust ponatinib dose, p. 911. (Moderate) Study
  ▶ **Macrolides (clarithromycin)** are predicted to slightly increase the exposure to ponatinib. Monitor and adjust ponatinib dose, p. 911. (Moderate) Study
  ▶ **Ponatinib** is predicted to increase the risk of bleeding events when given with **phenindione**. (Severe) Theoretical
  ▶ **Rifampicin** is predicted to decrease the exposure to ponatinib. Avoid. (Moderate) Theoretical
  ▶ **St John’s Wort** is predicted to decrease the exposure to ponatinib. Avoid. (Severe) Theoretical
  ▶ **Posaconazole** is predicted to increase the exposure to ponatinib. Avoid. (Moderate) Theoretical
  ▶ **Prasugrel** is predicted to increase the risk of bleeding events when given with **cobicistat**. Avoid. (Moderate) Theoretical
  ▶ **Potassium canrenoate** is predicted to slightly increase the exposure to ponatinib. Avoid. (Moderate) Theoretical
  ▶ **Potassium citrate** is predicted to decrease the exposure to ponatinib. Avoid. (Moderate) Theoretical
  ▶ **Potassium chloride** is predicted to decrease the exposure to ponatinib. Avoid. (Moderate) Theoretical
  ▶ **Potassium citrate** is predicted to decrease the efficacy of methenamine. Avoid. (Moderate) Theoretical
  ▶ **Potassium citrate** is predicted to decrease the risk of side-effects when given with **sucralfate**. Avoid. (Moderate) Theoretical
  ▶ **Potassium-sparing diuretics** (**amiloride** and **spironolactone**). Avoid. (Moderate) Theoretical
  ▶ **Proton pump inhibitors** (**omeprazole** and **pantoprazole**). Avoid. (Moderate) Theoretical
  ▶ **Promazine** is predicted to slightly increase the exposure to ponatinib. Avoid. (Moderate) Theoretical
  ▶ **Promethazine** is predicted to decrease the exposure to ponatinib. Avoid. (Severe) Theoretical
  ▶ **Promazine** is predicted to slightly increase the exposure to ponatinib. Avoid. (Moderate) Theoretical
  ▶ **Propantheline** is predicted to increase the risk of bleeding events when given with **cobicistat**. Avoid. (Moderate) Theoretical
  ▶ **Praziquantel** is predicted to decrease the exposure to ponatinib. Avoid. (Moderate) Theoretical
  ▶ **Prasugrel** is predicted to increase the exposure to ponatinib. Avoid. (Moderate) Theoretical
  ▶ **Proton pump inhibitors** (**omeprazole**, **lansoprazole**, **esomeprazole**, **rabeprazole**). Avoid. (Moderate) Theoretical
  ▶ **Proton pump inhibitors** are predicted to decrease the absorption of **antifungals**. Avoid. (Moderate) Theoretical
  ▶ **Proton pump inhibitors** are predicted to decrease the absorption of **antifungals**. Avoid. (Moderate) Theoretical
  ▶ **Proton pump inhibitors** are predicted to decrease the absorption of **antifungals**. Avoid. (Moderate) Theoretical
  ▶ **Proton pump inhibitors** are predicted to decrease the absorption of **cetirizine**. Avoid. (Moderate) Theoretical
  ▶ **Proton pump inhibitors** are predicted to decrease the absorption of **dipivinil**. Avoid. (Moderate) Theoretical
  ▶ **Proton pump inhibitors** are predicted to decrease the absorption of **dipivinil**. Avoid. (Moderate) Theoretical
  ▶ **Proton pump inhibitors** are predicted to decrease the absorption of **dipivinil**. Avoid. (Moderate) Theoretical
  ▶ **Proton pump inhibitors** are predicted to decrease the absorption of **dipivinil**. Avoid. (Moderate) Theoretical
  ▶ **Proton pump inhibitors** are predicted to decrease the absorption of **dipivinil**. Avoid. (Moderate) Theoretical

**FOOD AND LIFESTYLE**  
Procarbazine is a mild monoamine-oxidase inhibitor and might rarely interact with tyramine-rich foods (such as mature cheese, salami, pickled herring, Bovril®).
Proton pump inhibitors decrease the exposure to HIV-protease inhibitors (atazanavir). Avoid or adjust dose. (Severe) Study

Proton pump inhibitors increase the exposure to HIV-protease inhibitors (saquinavir). Avoid. (Severe) Study

HIV-protease inhibitors (tipranavir) decrease the exposure to proton pump inhibitors. Avoid. (Severe) Study

Proton pump inhibitors are predicted to decrease the exposure to ledipasvir. Adjust dose, see sofosbuvir with ledipasvir p. 596. (Moderate) Theoretical

Lumacaftor is predicted to decrease the exposure to proton pump inhibitors (esomprazole, lanosprazole, omeprazole). Adjust dose. (Moderate) Theoretical

Proton pump inhibitors decrease the clearance of methotrexate. Use with caution or avoid. (Severe) Study

Proton pump inhibitors are predicted to decrease the exposure to pazzipanib. Avoid or administer concurrently without food. (Moderate) Study

Rifampicin is predicted to moderately decrease the exposure to omeprazole. (Moderate) Study

Proton pump inhibitors are predicted to decrease the exposure to rilpivirine. Avoid. (Severe) Study

Proton pump inhibitors potentially decrease the exposure to sofosbuvir. Adjust dose, see sofosbuvir with ledipasvir and sofosbuvir with velpatavir p. 596. (Moderate) Study

SSRs (fluvoxamine) are predicted to increase the exposure to proton pump inhibitors. (Mild) Study

Esomprazole is predicted to slightly to moderately increase the exposure to SSRIs (citalopram, escitalopram). Monitor and adjust dose. (Severe) Theoretical

Omeprazole slightly to moderately increases the exposure to SSRIs (citalopram, escitalopram). Monitor and adjust dose. (Severe) Study

Proton pump inhibitors are predicted to decrease the concentration of velpatavir. Adjust dose, see sofosbuvir with velpatavir p. 596. (Moderate) Study

Proxymetacaine → see anaesthetics, local

Pseudoephedrine → see sympathomimetics, vasoconstrictor

Pyrazinamide

Allopurinol is predicted to increase the risk of hyperuricaemia when given with pyrazinamide. (Moderate) Theoretical

Pyrazinamide is predicted to decrease the effects of sulfamethoxazole. (Moderate) Theoretical

Pyridostigmine → see antimuscarinics, anticholinesterase

Quetiapine → see antimuscarinics, anticholinesterase

Quetiapine is predicted to slightly to moderately increase the exposure to SSRIs (citalopram, escitalopram). Monitor and adjust dose. (Severe) Study

Omeprazole slightly to moderately increases the exposure to SSRIs (citalopram, escitalopram). Monitor and adjust dose. (Severe) Study

Proton pump inhibitors are predicted to decrease the concentration of velpatavir. Adjust dose, see sofosbuvir with velpatavir p. 596. (Moderate) Study

Proxymetacaine → see anaesthetics, local

Pseudoephedrine → see sympathomimetics, vasoconstrictor

Pyrazinamide

Allopurinol is predicted to increase the risk of hyperuricaemia when given with pyrazinamide. (Moderate) Theoretical

Pyrazinamide is predicted to decrease the effects of sulfamethoxazole. (Moderate) Theoretical

Pyridostigmine → see TABLE 6 p. 1265 (bradycardia), TABLE 20 p. 1268 (neuromuscular blocking effects)

Aminoglycosides are predicted to decrease the effects of pyridostigmine. (Moderate) Theoretical → Also see TABLE 20 p. 1268

Pyrimethamine → see antimalarials

Quetiapine → see TABLE 8 p. 1268 (hypotension), TABLE 11 p. 1266 (CNS depressant effects)

Antiarhythmics (dronedarone) are predicted to increase the exposure to quetiapine. Avoid. (Moderate) Study

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to quetiapine. (Moderate) Study → Also see TABLE 11 p. 1266

Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to quetiapine. Avoid. (Moderate) Study

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to quetiapine. Avoid. (Severe) Study

Aprepitant is predicted to increase the exposure to quetiapine. Avoid. (Moderate) Study

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to quetiapine. Avoid. (Moderate) Study → Also see TABLE 8 p. 1265

Cobicistat is predicted to increase the exposure to quetiapine. Avoid. (Severe) Study

Crizotinib is predicted to increase the exposure to quetiapine. Avoid. (Moderate) Study

Quetiapine is predicted to decrease the effects of dopamine receptor agonists. Avoid. (Moderate) Theoretical → Also see TABLE 8 p. 1265

Enzalutamide is predicted to decrease the exposure to quetiapine. (Moderate) Study

Grapefruit juice is predicted to increase the exposure to quetiapine. Avoid. (Severe) Theoretical

Quetiapine is predicted to decrease the effects of histamine. Avoid. (Severe) Theoretical → Also see TABLE 8 p. 1265

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to quetiapine. Avoid. (Severe) Study

HIV-protease inhibitors (indinavir) are predicted to increase the exposure to quetiapine. Avoid. (Moderate) Study

Idelalisib is predicted to increase the exposure to quetiapine. Avoid. (Severe) Study

Imatinib is predicted to increase the exposure to quetiapine. Avoid. (Moderate) Study

Quetiapine decreases the effects of levodopa. (Severe) Anecdotal → Also see TABLE 8 p. 1265

Quetiapine potentially increases the risk of neurotoxicity when given with lithium. (Severe) Anecdotal

Macrolides (clarithromycin) are predicted to increase the exposure to quetiapine. Avoid. (Severe) Study

Macrolides (erythromycin) are predicted to increase the exposure to quetiapine. Avoid. (Moderate) Study

Rifampicin is predicted to decrease the exposure to quetiapine. (Moderate) Study

Quinagolide → see dopamine receptor agonists

Quinapril → see ACE inhibitors

Quinoline → see antimalarials

Quinolones → see TABLE 9 p. 1266 (QT-interval prolongation)

ciprofloxacin • levofloxacin • moxifloxacin • nalidixic acid • norfloxacin • ofloxacin

ROUTE-SPECIFIC INFORMATION Since systemic absorption can follow topical application, the possibility of interactions should be borne in mind.

Ciprofloxacin is predicted to increase the exposure to agomelatine. (Moderate) Study

Quinolones (ciprofloxacin, norfloxacin) are predicted to increase the exposure to aminophylline. Adjust dose. (Moderate) Theoretical

Ciprofloxacin is predicted to increase the exposure to anagrelide. (Moderate) Theoretical

Antacids decrease the absorption of quinolones. Quinolones should be taken 2 hours before or 4 hours after antacids. (Moderate) Study

Ciprofloxacin slightly increases the exposure to antihistamines (lisdexa). (Mild) Study

Ciprofloxacin affects the concentration of antiepileptics (fosphenytoin, phenytoin). Monitor concentration and adjust dose. (Severe) Study

Aspirin (high-dose) potentially increases the risk of seizures when given with quinolones. (Severe) Theoretical

Calcium salts (calcium carbonate) decrease the absorption of norfloxacin. Norfloxacin should be taken 2 hours before or 4 hours after calcium carbonate. (Moderate) Study

Calcium salts (calcium carbonate) decrease the absorption of quinolones (ciprofloxacin, nalidixic acid). Separate administration by 2 hours. (Moderate) Study

Ciprofloxacin increases the concentration of clozapine. Monitor side effects and adjust dose. (Severe) Study

Quinolones increase the anticoagulant effect of coumarins. (Severe) Anecdotal

Didanosine (buffered) is predicted to greatly decrease the exposure to oral quinolones. Didanosine should be taken 2 hours after quinolones. (Moderate) Study

Ciprofloxacin is predicted to increase the exposure to dopamine receptor agonists (ropinirole). Adjust dose. (Moderate) Study

Ciprofloxacin is predicted to increase the exposure to duloxetine. Avoid. (Moderate) Theoretical

Enteral feeds decreases the exposure to ciprofloxacin. (Moderate) Study

Ciprofloxacin slightly increases the exposure to erlotinib. Monitor side effects and adjust dose. (Moderate) Study
**Quinolones (continued)**

- **Ciprofloxacin** is predicted to increase the exposure to ibritunib. Avoid or adjust ibritunib dose. p. 902. [Severe] Theoretical
- **Iron (oral)** decreases the exposure to quinolones. Separate administration by at least 2 hours. [Moderate] Study
- **Lanthanum moderately decreases the exposure to quinolones. Quinolones should be taken 2 hours before or 4 hours after lanthanum.** [Moderate] Study
- **Ciprofloxacin** is predicted to increase the exposure to ioxapine. Avoid. [Unknown] Theoretical
- **Ciprofloxacin** is predicted to increase the exposure to melatonin. [Moderate] Theoretical
- **Ciprofloxacin** potentially increases the risk of toxicity when given with methotrexate. Avoid. [Severe] Anecdotal
- **Ciprofloxacin** slightly increases the exposure to monoamine-oxidase B inhibitors (rasagiline). [Moderate] Study
- **NSAIDs**: potentially increase the risk of seizures when given with quinolones. [Severe] Theoretical
- **Ciprofloxacin** very slightly increases the exposure to pentoxifylline. [Moderate] Study
- **Ciprofloxacin** is predicted to increase the exposure to pifremidine. Use with caution and adjust dose. [Moderate] Study
- **Ciprofloxacin** is predicted to increase the exposure to pomalidomide. Adjust pomalidomide dose. p. 886. [Moderate] Theoretical
- **Ciprofloxacin** is predicted to increase the exposure to riflumilast. [Moderate] Theoretical
- **Strontium ranelate** is predicted to decrease the absorption of quinolones. Avoid. [Moderate] Theoretical
- **Sucralfate** decreases the exposure to quinolones. Separate administration by 2 hours. [Moderate] Study
- **Ciprofloxacin** is predicted to increase the exposure to theophylline. Monitor and adjust dose. [Moderate] Theoretical
- **Norfloxacin** is predicted to increase the exposure to theophylline. Adjust dose. [Moderate] Anecdotal
- **Ciprofloxacin** increases the exposure to tizanidine. Avoid. [Moderate] Study
- **Zinc** is predicted to decrease the exposure to quinolones. Separate administration by 2 hours. [Moderate] Study
- **Ciprofloxacin** is predicted to increase the exposure to zolmitriptan. Adjust zolmitriptan dose. p. 456. [Moderate] Theoretical

**Rabeprazole** → see proton pump inhibitors

**Rabies vaccine**
- **Antimalarials (chloroquine)** decrease the efficacy of rabies vaccine. Avoid. [Moderate] Study
- **Hydroxychloroquine** is predicted to decrease efficacy rabies vaccine. Avoid. [Moderate] Study

**Raloxifene** → see TABLE 5 p. 1264 (thromboembolism)

**Raltegravir**
- **Antacids** slightly decrease the exposure to raltegravir. Avoid. [Moderate] Study
- **HIV-protease inhibitors (darunavir)** increase the risk of rash when given with raltegravir. [Moderate] Study
- **HIV-protease inhibitors (fosamprenavir)** boosted with ritonavir decrease the exposure to raltegravir and raltegravir decreases the exposure to HIV-protease inhibitors (fosamprenavir) boosted with ritonavir. Avoid. [Severe] Study
- **Rifampicin** slightly decreases the exposure to raltegravir. Avoid or adjust dose. [Moderate] Study
- **Folates (folic acid)** are predicted to alter the effects of raltitrexed. Avoid. [Moderate] Theoretical
- **Folates (folic acid)** alter the effects of raltitrexed. Avoid. [Moderate] Study
- **Live vaccines** are predicted to increase the risk of generalised infection (possibly life-threatening) when given with raltitrexed. Public Health England advises avoid. [Severe] Theoretical

**Ramipril** → see ACE inhibitors

**Ranucumab** → see monoclonal antibodies

**Ranibizumab**
- **Ranibizumab** is predicted to increase the risk of bleeding events when given with argatroban. [Severe] Theoretical
- **Ranibizumab** is predicted to increase the risk of bleeding events when given with bivalirudin. [Moderate] Theoretical
- **Ranibizumab** increases the risk of bleeding events when given with coumarins. [Severe] Theoretical
- **Ranibizumab** is predicted to increase the risk of bleeding events when given with danaparoid. [Severe] Theoretical
- **Ranibizumab** increases the risk of bleeding events when given with heparin (unfractionated). [Severe] Theoretical
- **Ranibizumab** increases the risk of bleeding events when given with low molecular-weight heparins. [Severe] Theoretical
- **Ranibizumab** is predicted to increase the risk of bleeding events when given with phenytoin, primidone. [Severe] Theoretical
- **Ranibizumab** is predicted to increase the exposure to aliskiren. [Moderate] Theoretical
- **Antiarhythmic drugs (dronedarone)** are predicted to increase the exposure to ranolazine. [Severe] Study → Also see TABLE 9 p. 1266
- **Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone)** are predicted to decrease the exposure to ranolazine. Avoid. [Severe] Study
- **Antifungals, azoles (fluconazole, itraconazole, posaconazole)** are predicted to increase the exposure to ranolazine. [Severe] Study
- **Ranolazine** is predicted to increase the exposure to ceritinib. [Moderate] Theoretical → Also see TABLE 9 p. 1266
- **Ciclosporin** is predicted to increase the concentration of ranolazine and ranolazine is predicted to increase the concentration of ciclosporin. [Moderate] Theoretical
- **Cobicistat** is predicted to increase the exposure to ranolazine. Avoid. [Severe] Study
- **Ranolazine is predicted to increase the exposure to beta blockers, non-selective (nadolol). [Moderate] Study
- **Calcium channel blockers (diltiazem, verapamil)** are predicted to increase the exposure to ranolazine. [Severe] Study
- **Ranolazine is predicted to increase the exposure to erlotinib.** [Moderate] Theoretical
- **Ranolazine is predicted to increase the exposure to fidaxomicin.** Avoid. [Moderate] Study
- **Ranolazine is predicted to slightly increase the exposure to edoxaban.** [Severe] Theoretical
- **Enalapril** is predicted to decrease the exposure to edoxaban. [Severe] Theoretical
- **Ranolazine is predicted to increase the exposure to ebolavir.** Avoid or adjust ebolavir dose. p. 1020. [Severe] Theoretical
- **Crizotinib** is predicted to increase the exposure to ranolazine. [Severe] Study → Also see TABLE 9 p. 1266
- **Ranolazine is predicted to increase the exposure to dabigatran.** [Severe] Theoretical
- **Ranolazine increases the concentration of digoxin.** [Moderate] Study
- **Ranolazine is predicted to increase the exposure to ebrantib.** [Severe] Theoretical
- **Grapefruit juice** is predicted to increase the concentration of ranolazine. Avoid. [Severe] Theoretical
- **HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to increase the exposure to ranolazine. Avoid. [Severe] Study → Also see TABLE 9 p. 1266
- **HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to ranolazine. [Severe] Study
- **Idelalisib** is predicted to increase the exposure to ranolazine. Avoid. [Severe] Study
- **Imatinib** is predicted to increase the exposure to ranolazine. [Severe] Study
- **Ranolazine is predicted to increase the exposure to lomitapide.** Separate administration by 12 hours. [Moderate] Theoretical
- **Macrolides (clarithromycin)** are predicted to increase the exposure to ranolazine. Avoid. [Severe] Study → Also see TABLE 9 p. 1266
Macrolides (erythromycin) are predicted to increase the exposure to ranolazine. **Severe** Study

Netupitant is predicted to increase the exposure to ranolazine. **Severe** Study

Nilotinib is predicted to increase the exposure to ranolazine. **Severe** Study   
→ Also see TABLE 9 p. 1266

Ranolazine is predicted to increase the exposure to nintedanib. **Moderate** Study

Rifaximin is predicted to decrease the exposure to ranolazine. Avoid. **Severe** Study

St John's Wort is predicted to decrease the exposure to ranolazine. Avoid. **Severe** Study

Ranolazine is predicted to increase the exposure to statins (atorvastatin). **Moderate** Theoretical

Ranolazine slightly increases the exposure to statins (simvastatin). Adjust simvastatin dose, p. 198. **Moderate** Study

Ranolazine increases the concentration of tacrolimus. Adjust dose. **Severe** Anecdotal

Ranolazine is predicted to increase the exposure to ticagrelor. Use with caution or avoid. **Severe** Study

Ranolazine is predicted to increase the exposure to topotecan. **Severe** Study

Ranolazine is predicted to increase the concentration of trametinib. **Moderate** Theoretical

Ranolazine is predicted to increase the exposure to venetoclax. Avoid or monitor for toxicity. **Severe** Theoretical

Rasagiline → see monoamine-oxidase B inhibitors

Reboxetine

Antiplatelets (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to reboxetine. **Moderate** Anecdotal

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to reboxetine. Avoid. **Moderate** Study

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the concentration of reboxetine. Use with caution and adjust dose. **Moderate** Theoretical

Cobicistat is predicted to increase the exposure to reboxetine. Avoid. **Moderate** Study

Enzalutamide is predicted to decrease the exposure to reboxetine. **Moderate** Anecdotal

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to reboxetine. Avoid. **Moderate** Study

Reboxetine is predicted to increase the risk of a hypertensive crisis when given with linezolid. Avoid. **Severe** Theoretical

Reboxetine is predicted to increase the risk of hypokalaemia when given with loop diuretics. **Moderate** Theoretical

Macrolides (clarithromycin) are predicted to increase the exposure to reboxetine. Avoid. **Moderate** Study

Reboxetine is predicted to increase the risk of a hypertensive crisis when given with moclobemide. Avoid. **Severe** Theoretical

Reboxetine is predicted to increase the risk of a hypertensive crisis when given with monoamine-oxidase A and B inhibitors, irreversible. Avoid. **Severe** Theoretical

Reboxetine is predicted to increase the risk of a hypertensive crisis when given with monoamine-oxidase B inhibitors (rasagiline, selegiline). Avoid. **Severe** Theoretical

Reboxetine is predicted to decrease the exposure to reboxetine. **Moderate** Anecdotal

Reboxetine is predicted to increase the risk of hypokalaemia when given with thiazide diuretics. **Moderate** Anecdotal

Regorafenib → see TABLE 15 p. 1267 (myelosuppression), TABLE 4 p. 1264 (antiplatelet effects)

Antiplatelets (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to regorafenib. Avoid. **Moderate** Study

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to regorafenib. Avoid. **Moderate** Study

Cobicistat is predicted to increase the exposure to regorafenib. Avoid. **Moderate** Study

Regorafenib is predicted to increase the risk of bleeding events when given with coumarins. **Severe** Study

Enzalutamide is predicted to decrease the exposure to regorafenib. Avoid. **Moderate** Study

Grapefruit juice is predicted to increase the exposure to regorafenib. Avoid. **Moderate** Theoretical

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to regorafenib. Avoid. **Moderate** Study

Idelalisib is predicted to increase the exposure to regorafenib. Avoid. **Moderate** Study   
→ Also see TABLE 15 p. 1267

Macrolides (clarithromycin) are predicted to increase the exposure to regorafenib. Avoid. **Moderate** Study

Regorafenib is predicted to increase the exposure to méthotrexate. **Severe** Theoretical   
→ Also see TABLE 15 p. 1267

Regorafenib is predicted to increase the exposure to NSAIDs (mefenamic acid). Avoid. **Moderate** Theoretical   
→ Also see TABLE 4 p. 1264

Regorafenib is predicted to increase the risk of bleeding events when given with phenindione. **Severe** Theoretical

Rifaximin is predicted to decrease the exposure to regorafenib. Avoid. **Moderate** Study

Regorafenib is predicted to increase the exposure to statins (atorvastatin, fluvastatin, rosuvastatin). **Severe** Theoretical

Remifentanil → see opioids

Repaglinide → see TABLE 14 p. 1267 (antidiabetic drugs)

Antiplatelets (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to repaglinide. Monitor blood glucose and adjust dose. **Moderate** Study

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to repaglinide. **Moderate** Study

Ciclosporin moderately increases the exposure to repaglinide. **Moderate** Study

Clopigogrel increases the exposure to repaglinide. **Severe** Study

Cobicistat is predicted to increase the exposure to repaglinide. Avoid. **Moderate** Study

Enzalutamide is predicted to decrease the exposure to repaglinide. Monitor blood glucose and adjust dose. **Moderate** Study

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to repaglinide. **Moderate** Study

Idelalisib is predicted to increase the exposure to repaglinide. **Moderate** Study

Iron chelators (deferasirox) moderately increase the exposure to repaglinide. Avoid. **Moderate** Study

Lumacaftor is predicted to decrease the exposure to repaglinide. Adjust dose. **Moderate** Theoretical

Macrolides (clarithromycin) are predicted to increase the exposure to repaglinide. **Moderate** Study

Pitolisant is predicted to decrease the exposure to repaglinide. **Unknown** Theoretical

Rifaximin is predicted to decrease the exposure to repaglinide. Monitor blood glucose and adjust dose. **Moderate** Study

Teriflunomide increases the exposure to repaglinide. **Moderate** Study

Trimethoprim slightly increases the exposure to repaglinide. Avoid or monitor blood glucose. **Moderate** Study

Resilzumab → see monoclonal antibodies

Replease → see TABLE 3 p. 1264 (anticoagulant effects)

Retigabine → see antiplatelets

Retinoids → see TABLE 5 p. 1264 (thromboembolism)

Acitretin, adalapene, alitretinoin, bexarotene, isotretinoin, tazarotene, tretinoin

→ Consumption of alcohol might increase the serum concentration of etretinate in patients taking acitretin. Avoid alcohol during and for 2 months after stopping acitretin.
Retinoids (continued)

- Avoid concomitant use of keratolytics in patients taking acitretin and isotretinoin.

- Since systemic absorption can follow topical application, the possibility of interactions should be borne in mind.

- Antiarrhythmics (amiodarone) are predicted to increase the exposure to alitretinoin. Adjust alitretinoin dose, p. 1157. [Moderate] Theoretical

- Antifungals, azoles (fluconazole, itraconazole, ketoconazole, miconazole, voriconazole) are predicted to increase the exposure to alitretinoin. Adjust alitretinoin dose, p. 1157. [Moderate] Theoretical

- Alitretinoin, acitretin (fluconazole, ketoconazole, voriconazole) are predicted to increase the risk of tretinoin toxicity when given with tretinoin. [Moderate] Study

- Cobicistat is predicted to increase the exposure to alitretinoin. Adjust alitretinoin dose, p. 1157. [Moderate] Theoretical

- Azithromycin is predicted to increase the exposure to alitretinoin. Adjust alitretinoin dose, p. 1157. [Moderate] Theoretical

- Cobicistat is predicted to increase the exposure to alitretinoin. Adjust alitretinoin dose, p. 1157. [Moderate] Theoretical

- Fibrates (gemfibrozil) are predicted to increase the exposure to alitretinoin. Adjust alitretinoin dose, p. 1157. [Moderate] Theoretical

- Fibrates (gemfibrozil) increase the concentration of bexarotene. Avoid. [Severe] Study

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, saquinavir, tipranavir) are predicted to increase the exposure to alitretinoin. Adjust alitretinoin dose, p. 1157. [Moderate] Theoretical

- Idelalisib is predicted to increase the exposure to alitretinoin. Adjust alitretinoin dose, p. 1157. [Moderate] Theoretical

- Indinavir, ritonavir, saquinavir, tipranavir decreases the concentration of miconazole. Avoid. [Severe] Study

- Isavuconazole is predicted to decrease the concentration of ketoconazole. Avoid. [Severe] Study

- Acitretin, alitretinoin, isotretinoin, tretinoin increase the risk of benign intracranial hypertension when given with tetracyclines. Avoid. [Severe] Anecdotal

- Bexarotene is predicted to increase the risk of toxicity when given with vitamin A. Adjust dose. [Moderate] Theoretical

- Sulfinpyrazone is predicted to increase the exposure to alitretinoin. Adjust alitretinoin dose, p. 1157. [Moderate] Theoretical

- Retinoids (acitretin, alitretinoin, isotretinoin, tretinoin) increase the risk of benign intracranial hypertension when given with tetracyclines. Avoid. [Severe] Anecdotal

- Vitamin A is predicted to increase the risk of vitamin A toxicity when given with vitamin A. Avoid. [Severe] Study

Ribavirin

- Ribavirin is predicted to increase the exposure to didanosine. Avoid. [Severe] Study

- Ribavirin increases the risk of toxicity when given with stavudine. Avoid. [Severe] Study

- Ribavirin increases the risk of anaemia and/or leucopenia when given with zidovudine. Avoid. [Severe] Study

Rifabutin

GENERAL INFORMATION Although some manufacturers classify rifabutin as a potent inducer of CYP3A4, clinical data suggests it is potentially a weak inducer, and therefore the BNF does not extrapolate the interactions of potent CYP3A4 inducers to rifabutin. For those who wish to err on the side of caution, see the interactions of rifampicin but bear in mind other mechanisms might be involved.

- Antifungals, azoles (fluconazole) increase the risk of uveitis when given with rifabutin. Adjust dose. [Severe] Study

- Antifungals, azoles (itraconazole, posaconazole) increase the concentration of rifabutin and rifabutin decreases the concentration of antifungals, azoles (itraconazole, posaconazole). Avoid. [Severe] Study

- Antifungals, azoles (ketoconazole) are predicted to increase the concentration of rifabutin and rifabutin is predicted to decrease the concentration of antifungals, azoles (ketoconazole). Avoid. [Severe] Theoretical

- Antifungals, azoles (miconazole) are predicted to increase the concentration of rifabutin. Use with caution and adjust dose. [Moderate] Theoretical

- Rifabutin is predicted to decrease the exposure to antifungals, azoles (isavuconazole). Avoid. [Severe] Theoretical

- Rifabutin decreases the concentration of antifungals, azoles (voriconazole) and antifungals, azoles (voriconazole) increase the concentration of rifabutin. Avoid or adjust voriconazole dose, p. 566. [Severe] Study

- Rifabutin slightly decreases the exposure to antimalarials (atovaquone). Avoid. [Moderate] Study

- Rifabutin decreases the concentration of cobicistat and cobicistat increases the exposure to rifabutin. Avoid or adjust dose. [Severe] Study

- Rifabutin is predicted to decrease the efficacy of combined hormonal contraceptives. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Study

- Rifabutin increases the clearance of dapsone. [Moderate] Study

- Rifabutin is predicted to decrease the efficacy of desogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical

- Efavirenz slightly decreases the exposure to rifabutin. Adjust dose. [Severe] Study

- Rifabutin is predicted to decrease the efficacy of etonogestrel. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical

- Rifabutin decreases the exposure to etravirine. [Moderate] Study

- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, saquinavir, tipranavir) markedly increase the exposure to rifabutin. Monitor and adjust dose. [Severe] Study

- HIV-protease inhibitors (indinavir) increase the exposure to rifabutin and rifabutin decreases the exposure to HIV-protease inhibitors (indinavir). Avoid. [Severe] Study

- HIV-protease inhibitors (ritonavir) markedly increase the exposure to rifabutin. Avoid or adjust dose. [Severe] Study

- Rifabutin is predicted to decrease the effects of Hormone replacement therapy. [Moderate] Anecdotal

- Rifabutin is predicted to decrease the efficacy of levonorgestrel. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical

- Lumacaftor is predicted to decrease the exposure to rifabutin. Adjust dose. [Moderate] Theoretical

- Macrolides (azithromycin) increase the risk of neutropenia when given with rifabutin. [Severe] Study

- Macrolides (clarithromycin) increase the risk of uveitis when given with rifabutin. [Severe] Study

- Rifabutin is predicted to decrease the efficacy of norethisterone. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Anecdotal

- Rifabutin slightly decreases the exposure to rilpivirine. Adjust dose. [Severe] Study

- Rifabutin is predicted to decrease the exposure to simprevir. Avoid. [Moderate] Theoretical

- Rifabutin decreases the efficacy of ulipristal. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Anecdotal

Rifampicin

- Rifampicin is predicted to decrease the exposure to abacavir. [Moderate] Theoretical

- Rifampicin is predicted to decrease the exposure to abiraterone. Avoid. [Severe] Theoretical

- Rifampicin is predicted to decrease the exposure to afatinib. [Moderate] Study

- Rifampicin is predicted to decrease the exposure to agomelatine. [Moderate] Theoretical

- Rifampicin decreases the exposure to aliskiren. [Moderate] Study

- Rifampicin is predicted to decrease the exposure to alprazolam. Adjust alprazolam dose. [Moderate] Theoretical

- Rifampicin transiently increases the exposure to ambrisentan. [Moderate] Study

- Rifampicin decreases the exposure to aminophylline. Adjust dose. [Moderate] Study

- Antacids decrease the absorption of rifampicin. Rifampicin should be taken 1 hour before antacids. [Moderate] Study

- Rifampicin is predicted to decrease the exposure to antiarhythmics (disopyramide, droxidone). Avoid. [Severe] Study
Rifampicin

- Rifampicin is predicted to decrease the efficacy of antiarrhythmics (propafenone). [Moderate] Study
- Rifampicin is predicted to decrease the exposure to anticholinesterases, centrally acting (donepezil). [High] Study
- Antiepileptics (phenobarbital, primidone) are predicted to decrease the exposure to rifampicin and rifampin is predicted to decrease the exposure to antiepileptics (phenobarbital, primidone). Use with caution and adjust dose. [Moderate] Study
- Rifampicin slightly decreases the exposure to antiepileptics (brivaracetam). Adjust dose. [Moderate] Study
- Rifampicin decreases the concentration of antiepileptics (fosphenytoin, phenytoin). Use with caution and adjust dose. [Moderate] Study
- Rifampicin markedly increases the clearance of antiepileptics (lamotrigine). Adjust lamotrigine dose, p. 303. [Moderate] Study
- Rifampicin is predicted to decrease the exposure to antiepileptics (perampanel). Monitor and adjust dose. [Moderate] Study
- Rifampicin slightly decreases the exposure to antifungals, azoles (fluconazole). Adjust dose. [Moderate] Study
- Rifampicin is predicted to decrease the exposure to antifungals, azoles (isavuconazole). Avoid. [Severe] Study
- Rifampicin markedly decreases the exposure to antifungals, azoles (itraconazole). Avoid rifampicin for 14 days before and during treatment with itraconazole. [Moderate] Study
- Rifampicin markedly decreases the exposure to antifungals, azoles (ketonazole) and antifungals, azoles (ketocazole) potentially decrease the exposure to rifampicin. Avoid. [Moderate] Study
- Rifampicin is predicted to decrease the exposure to antimalarials (artemether) with lumefantrine. Avoid. [Severe] Study
- Rifampicin moderately decreases the exposure to antimalarials (atovaquone) and antimalarials (atovaquone) slightly increase the exposure to rifampicin. Avoid. [Moderate] Study
- Rifampicin moderately decreases the exposure to antimalarials (mefloquine). [Severe] Study
- Rifampicin is predicted to decrease the concentration of antimalarials (piperaquine). Avoid. [Moderate] Theoretical
- Rifampicin decreases the exposure to antimalarials (quinine). Avoid. [Severe] Study
- Rifampicin is predicted to moderately decrease the exposure to apixaban. Use with caution or avoid. [Severe] Study
- Rifampicin moderately decreases the exposure to apremilast. Avoid. [Severe] Study
- Rifampicin is predicted to markedly decrease the exposure to aprepitant. Avoid. [Moderate] Study
- Rifampicin is predicted to moderately decrease the exposure to arispiprazole. Adjust arispiprazole dose, p. 376. [Moderate] Study
- Rifampicin decreases the exposure to ataluren. [Moderate] Study
- Rifampicin is predicted to decrease the exposure to axitinib. Avoid or adjust dose. [Moderate] Study
- Rifampicin is predicted to decrease the exposure to bazadoxifene. [Moderate] Theoretical
- Rifampicin decreases the exposure to bedaquiline. Avoid. [Severe] Study
- Rifampicin decreases the exposure to beta blockers, non-selective (carvedilol). [Moderate] Study
- Rifampicin decreases the exposure to beta blockers, non-selective (propranolol). Monitor and adjust propranolol dose, p. 145. [Moderate] Study
- Rifampicin slightly decreases the exposure to beta blockers, selective (bisoprolol, metoprolol). [Mild] Study
- Rifampicin moderately decreases the exposure to beta blockers, selective (cecroprol). [Moderate] Study
- Rifampicin slightly decreases the exposure to bortezomib. Avoid. [Severe] Study
- Rifampicin affects the exposure to bosentan. Avoid. [Severe] Study
- Rifampicin is predicted to very markedly decrease the exposure to bosutinib. Avoid. [Severe] Study
- Rifampicin is predicted to markedly decrease the exposure to bupropion. [Severe] Study
- Rifampicin is predicted to decrease the exposure to buspirone. Use with caution and adjust dose. [Severe] Study
- Rifampicin moderately decreases the exposure to cabozantinib. Avoid. [Moderate] Study
- Rifampicin is predicted to moderately increase the clearance of caffeine citrate. Monitor and adjust dose. [Moderate] Study
- Rifampicin is predicted to decrease the exposure to calcium channel blockers (amlodipine, felodipine, lacidipine, lercanidipine, nicardipine, nifedipine). Monitor and adjust dose. [Moderate] Study
- Rifampicin decreases the exposure to calcium channel blockers (diltiazem). [Severe] Study
- Rifampicin decreases the exposure to calcium channel blockers (isradipine). Avoid. [Moderate] Study
- Rifampicin moderately decreases the exposure to calcium channel blockers (nifedipine). Avoid. [Severe] Study
- Rifampicin is predicted to decrease the exposure to calcium channel blockers (verapamil). Avoid. [Severe] Study
- Rifampicin is predicted to decrease the exposure to cannabidiol. Avoid. [Severe] Study
- Rifampicin decreases the concentration of cannabidiol. Adjust cannabidiol dose, p. 661. [Moderate] Study
- Rifampicin is predicted to decrease the exposure to cannabis extract. Avoid. [Severe] Theoretical
- Rifampicin decreases the concentration of citalopram. Avoid. [Severe] Study
- Rifampicin is predicted to alter the effects of cilostazol. [Moderate] Theoretical
- Rifampicin decreases the exposure to clomethiazole. Monitor and adjust dose. [Moderate] Study
- Rifampicin decreases the exposure to clozapine. Avoid. [Severe] Study
- Rifampicin is predicted to decrease the exposure to cobicistat. Avoid. [Severe] Theoretical
- Rifampicin is predicted to decrease the exposure to cobimetinib. Avoid. [Severe] Theoretical
- Rifampicin is predicted to decrease the efficacy of combined hormonal contraceptives. For FSHR guidance, see Contraceptives, interactions p. 747. [Severe] Study
- Rifampicin decreases the exposure to corticosteroids (budesonide, dexamethasone, methylprednisolone, prednisolone). Monitor and adjust dose. [Moderate] Study
- Rifampicin is predicted to decrease the exposure to corticosteroids (fluticasone). [Unknown] Theoretical
- Rifampicin is predicted to decrease the exposure to corticosteroids (prednisone). [Mild] Study
- Rifampicin decreases the anticoagulant effect of coumarins. [Mild] Study
- Rifampicin is predicted to markedly decrease the exposure to crizotinib. Avoid. [Severe] Study
- Rifampicin is predicted to decrease the exposure to dabigatran. Avoid. [Severe] Study
- Rifampicin is predicted to decrease the exposure to dabrafenib. Avoid. [Moderate] Theoretical
- Rifampicin is predicted to moderately decrease the exposure to daclatasvir. Avoid. [Severe] Study
- Rifampicin moderately decreases the exposure to daspone. [Moderate] Study
- Rifampicin is predicted to decrease the exposure to darifenacin. [Moderate] Theoretical
- Rifampicin is predicted to decrease the exposure to dasabuvir. Avoid. [Severe] Theoretical
Rifampicin (continued)

- **Rifampicin** is predicted to markedly decrease the exposure to **dasatinib**. Avoid. [Severe] Study
- **Rifampicin** is predicted to slightly decrease the exposure to **delamanid**. Avoid. [Moderate] Study
- **Rifampicin** is predicted to decrease the efficacy of **desogestrel**. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical
- **Rifampicin** moderately decreases the exposure to **diazepam**. Avoid. [Moderate] Study
- **Rifampicin** decreases the concentration of **digoxin**. [Moderate] Study
- **Rifampicin** decreases the exposure to **dolutegravir**. Adjust dose. [Severe] Study
- **Rifampicin** is predicted to decrease the exposure to **edoxaban**. [Moderate] Study
- **Rifampicin** slightly decreases the exposure to **efavirenz**. Adjust dose. [Severe] Study
- **Rifampicin** is predicted to decrease the exposure to **elbasvir**. Avoid. [Severe] Study
- **Rifampicin** is predicted to decrease the concentration of **elvitegravir**. Avoid. [Severe] Theoretical
- **Rifampicin** is predicted to decrease the effects of **ergotamine**. [Moderate] Theoretical
- **Rifampicin** is predicted to decrease the exposure to **erlotinib**. Avoid or adjust erlotinib dose, p. 899. [Severe] Study
- **Rifampicin** is predicted to decrease the efficacy of **etogonastrel**. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical
- **Rifampicin** is predicted to decrease the exposure to **etritavirine**. Avoid. [Severe] Theoretical
- **Rifampicin** is predicted to decrease the concentration of **everolimus**. Avoid or adjust dose. [Severe] Study
- **Rifampicin** moderately decreases the exposure to **exemestane**. [Moderate] Study
- **Rifampicin** is predicted to decrease the exposure to **fesoterodine**. Avoid. [Moderate] Study
- **Rifampicin** is predicted to decrease the exposure to **fingolimod**. [Moderate] Study
- **Rifampicin** is predicted to decrease the exposure to **gefitinib**. [Moderate] Study
- **Rifampicin** is predicted to decrease the exposure to **grazoprevir**. Avoid. [Severe] Study
- **Rifampicin** is predicted to decrease the exposure to **guanfacine**. Adjust guanfacine dose, p. 335. [Moderate] Study
- **Rifampicin** decreases the concentration of **haloperidol**. Adjust dose. [Moderate] Study
- **Rifampicin** moderately to markedly decreases the exposure to HIV-protease inhibitors (**atazanavir**, **darunavir**, **fosamprenavir**, **indinavir**, **lopinavir**, **saquinavir**, **tipranavir**). Avoid. [Severe] Study
- **Rifampicin** slightly decreases the exposure to HIV-protease inhibitors (**ritonavir**). [Severe] Study
- **Rifampicin** is predicted to decrease the effects of **Hormone replacement therapy**. [Moderate] Anecdotal
- **Rifampicin** is predicted to decrease the exposure to **ibrutinib**. Avoid. [Severe] Study
- **Rifampicin** is predicted to decrease the exposure to **idelalisib**. Avoid. [Severe] Study
- **Rifampicin** is predicted to decrease the exposure to **imatinib**. Avoid. [Moderate] Study
- **Rifampicin** is predicted to decrease the exposure to **irinotecan**. Avoid. [Severe] Study
- **Rifampicin** is predicted to decrease the exposure to **iron chelators** (**deferasirox**). Monitor serum ferritin and adjust dose. [Moderate] Study
- **Rifampicin** is predicted to decrease the exposure to **ivabradine**. Adjust dose. [Moderate] Theoretical
- **Rifampicin** markedly decreases the exposure to **ivacaftor**. Avoid. [Severe] Study
- **Rifampicin** is predicted to decrease the exposure to **izakomib**. Avoid. [Severe] Study
- **Rifampicin** is predicted to decrease the exposure to **lapanitib**. Avoid. [Severe] Study
- **Rifampicin** is predicted to decrease the exposure to **ledipasvir**. Avoid. [Severe] Theoretical
- **Rifampicin** is predicted to decrease the efficacy of **levonorgestrel**. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical
- **Rifampicin** is predicted to decrease the exposure to **linagliptin**. [Moderate] Study
- **Rifampicin** slightly decreases the exposure to **linezolid**. [Moderate] Study
- **Rifampicin** is predicted to decrease the exposure to **lofatapide**. Monitor and adjust dose. [Moderate] Theoretical
- **Rifampicin** increases the clearance of **lorazepam**. [Moderate] Study
- **Rifampicin** is predicted to decrease the exposure to **lurasidone**. Avoid. [Moderate] Study
- **Rifampicin** is predicted to decrease the exposure to **macrolides (clarithromycin)**. [Severe] Study
- **Rifampicin** is predicted to decrease the exposure to **maraviroc**. Adjust dose. [Severe] Study
- **Rifampicin** is predicted to decrease the exposure to **midazolam**. Monitor and adjust dose. [Moderate] Study
- **Rifampicin** is predicted to decrease the exposure to **mirtazapine**. Adjust dose. [Moderate] Study
- **Rifampicin** is predicted to decrease the exposure to **modafinil**. [Moderate] Theoretical
- **Rifampicin** decreases the effects of monoclonal antibodies (**brentuximab vedotin**). [Severe] Study
- **Rifampicin** is predicted to decrease the exposure to monoclonal antibodies (trastuzumab emtansine). [Severe] Theoretical
- **Rifampicin** is predicted to decrease the exposure to **montelukast**. [Mild] Study
- **Rifampicin** decreases the concentration of **mycophenolate**. Monitor and adjust dose. [Severe] Study
- **Rifampicin** is predicted to markedly decrease the exposure to **naloxegol**. Avoid. [Moderate] Study
- **Rifampicin** is predicted to slightly decrease the exposure to **nateglinide**. [Mild] Study
- **Rifampicin** is predicted to decrease the exposure to **netupitant**. Avoid. [Moderate] Study
- **Rifampicin** decreases the concentration of **nevirapine**. Avoid. [Severe] Study
- **Rifampicin** is predicted to moderately decrease the exposure to **nilotinib**. Avoid. [Severe] Study
- **Rifampicin** is predicted to decrease the exposure to **nintedanib**. [Moderate] Study
- **Rifampicin** is predicted to decrease the exposure to **nitisinone**. Adjust nitisinone dose. [Moderate] Theoretical
- **Rifampicin** increases the clearance of **nirAZYapine**. [Moderate] Study
- **Rifampicin** is predicted to decrease the efficacy of **noothistone**. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Anecdotal
- **Rifampicin** moderately decreases the exposure to NSAIDs (cecloxib, diclofenac, etoricoxib). [Moderate] Study
- **Rifampicin** is predicted to decrease the exposure to **olaparib**. Avoid. [Moderate] Theoretical
- **Rifampicin** is predicted to decrease the exposure to **ombitasvir**. Avoid. [Severe] Theoretical
- **Rifampicin** is predicted to decrease the exposure to **ondansetron**. [Moderate] Study
- **Rifampicin** is predicted to decrease the exposure to **opioids (alfentanil, fentanyl)**. [Moderate] Study
- **Rifampicin** is predicted to decrease the exposure to **opioids (buprenorphine)**. Monitor and adjust dose. [Moderate] Theoretical
- **Rifampicin** decreases the exposure to **opioids (codeine, morphine)**. [Moderate] Study
- **Rifampicin** decreases the exposure to **opioids (methadone)**. Monitor and adjust dose. [Severe] Study
- **Rifampicin** is predicted to decrease the exposure to **opioids (oxycodone)**. Monitor and adjust dose. [Moderate] Study
- **Rifampicin** is predicted to moderately decrease the exposure to **osimertinib**. Avoid. [Moderate] Study
- Rifampicin is predicted to decrease the exposure to palbociclib. Avoid. [Severe] Study
- Rifampicin is predicted to decrease the exposure to paliperdone. Monitor and adjust paliperdone dose. [Moderate] Theoretical
- Rifampicin is predicted to decrease the exposure to panobinostat. Avoid. [Moderate] Theoretical
- Rifampicin is predicted to decrease the exposure to paracetamol. [Moderate] Study
- Rifampicin is predicted to decrease the exposure to paritaprevir (with ritonavir and ombitasvir). Avoid. [Severe] Study
- Rifampicin is predicted to decrease the exposure to pazopanib. Avoid. [Severe] Theoretical
- Rifampicin is predicted to decrease the exposure to phosphodiesterase type-5 inhibitors (avansafir, tadalaflif). Avoid. [Severe] Study
- Rifampicin is predicted to decrease the exposure to phosphodiesterase type-5 inhibitors (sildenafil, vardenaflin). [Moderate] Theoretical
- Rifampicin moderately decreases the exposure to pioglitazone. Monitor and adjust pioglitazone dose. [Moderate] Study
- Rifampicin is predicted to decrease the exposure to pifennidine. Avoid. [Moderate] Theoretical
- Rifampicin is predicted to moderately decrease the exposure to proton pump inhibitors (omeprazole). [Moderate] Study
- Rifampicin is predicted to decrease the exposure to raltegravir. Avoid or adjust dose. [Moderate] Study
- Rifampicin is predicted to decrease the exposure to ranolazine. Avoid. [Severe] Study
- Rifampicin is predicted to decrease the exposure to reboxetine. Avoid. [Moderate] Anecdotal
- Rifampicin is predicted to decrease the exposure to revaguline. Monitor blood glucose and adjust dose. [Moderate] Study
- Rifampicin markedly decreases the exposure to rilpivirine. Avoid. [Severe] Study
- Rifampicin is predicted to decrease the exposure to risperidone. Adjust risperidone dose. [Moderate] Study
- Rifampicin is predicted to moderately decrease the exposure to rivaroxaban. Avoid unless patient can be monitored for signs of thrombosis. [Severe] Study
- Rifampicin is predicted to decrease the exposure to roflumilast. Avoid. [Moderate] Study
- Rifampicin is predicted to decrease the exposure to ruxolitinib. Monitor and adjust dose. [Moderate] Study
- Rifampicin is predicted to increase the exposure to sacubitril. [Moderate] Theoretical
- Rifampicin is predicted to moderately decrease the exposure to saxagliptin. [Moderate] Study
- Rifampicin is predicted to decrease the exposure to selexipag. [Unknown] Theoretical
- Rifampicin is predicted to decrease the exposure to simprevir. Avoid. [Severe] Study
- Rifampicin is predicted to decrease the concentration of sirolimus. Avoid. [Severe] Study
- Rifampicin is predicted to decrease the exposure to sofosbuvir. Avoid. [Severe] Study
- Rifampicin is predicted to decrease the exposure to sofinenacin. [Moderate] Theoretical
- Rifampicin is predicted to decrease the exposure to sorafenin. [Moderate] Theoretical
- Rifampicin markedly decreases the exposure to statins (atorvastatin). Atorvastatin should be taken at the same time as rifampicin. [Moderate] Study
- Rifampicin moderately decreases the exposure to statins (fluvasatin). Monitor and adjust dose. [Moderate] Study
- Rifampicin very markedly decreases the exposure to statins (simvastatin). [Moderate] Study
- Rifampicin is predicted to decrease the exposure to sulfoniyureas. Avoid. [Moderate] Study
- Rifampicin is predicted to decrease the exposure to sunitinib. Avoid or adjust sunitinib dose. p. 914. [Moderate] Study
- Rifampicin decreases the concentration of tacrolimus. Monitor and adjust dose. [Severe] Study
- Rifampicin markedly decreases the exposure to tamoxifen. [Unknown] Study
- Rifampicin is predicted to decrease the exposure to tadalafil (vafladafil, tadalafil). Avoid. [Severe] Study
- Rifampicin is predicted to decrease the exposure to taxanes (cabazitaxel, paclitaxel). Avoid. [Severe] Study
- Rifampicin is predicted to decrease the exposure to taxanes (docetaxel). [Severe] Theoretical
- Rifampicin is predicted to decrease the concentration of temsirolimus. Avoid. [Severe] Study
- Rifampicin decreases the exposure to terbinafine. Adjust dose. [Moderate] Study
- Rifampicin decreases the exposure to tetracyclines (doxycycline). Monitor and adjust dose. [Moderate] Study
- Rifampicin is predicted to decrease the exposure to theophylline. Adjust dose. [Moderate] Study
- Rifampicin is predicted to decrease the exposure to ticagrelor. Avoid. [Severe] Study
- Rifampicin moderately decreases the exposure to tizanidine. [Mild] Study
- Rifampicin is predicted to decrease the exposure to tolvaptan. Avoid. [Severe] Study
- Rifampicin is predicted to decrease the exposure to toremifene. Adjust dose. [Moderate] Study
- Rifampicin is predicted to decrease the exposure to trabectedin. Avoid. [Severe] Theoretical
- Rifampicin decreases the exposure to trimethoprim. [Moderate] Study
- Rifampicin decreases the efficacy of ulipristal. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Anecdotal
- Rifampicin is predicted to decrease the exposure to vandetanib. Avoid. [Moderate] Study
- Rifampicin is predicted to moderately decrease the exposure to velpatasvir. Avoid. [Severe] Study
- Rifampicin is predicted to decrease the exposure to vemurafenib. Avoid. [Severe] Theoretical
- Rifampicin is predicted to decrease the exposure to venetoclax. Avoid. [Severe] Study
- Rifampicin is predicted to decrease the exposure to vinca alkaloids (vinblastine, vincristine, vinodines). [Severe] Theoretical
- Rifampicin is predicted to decrease the exposure to vinca alkaloids (vinfunine). Avoid. [Severe] Theoretical
- Rifampicin is predicted to decrease the exposure to vinca alkaloids (vinorelbine). Use with caution or avoid. [Severe] Theoretical
- Rifampicin is predicted to decrease the exposure to vismodegib. Avoid. [Moderate] Theoretical
- Rifampicin is predicted to decrease the exposure to vortoxetine. Monitor and adjust dose. [Moderate] Study
- Rifampicin markedly decreases the exposure to zaleplon. [Moderate] Study
- Rifampicin moderately decreases the exposure to zolpidem. [Moderate] Study
- Rifampicin is predicted to decrease the exposure to zopiclone. Adjust dose. [Moderate] Study
- Rifeximin
  - Ciclosporin very markedly increases the exposure to rifaximin. [Severe] Study
  - Rilpivirine
    - Antacids are predicted to decrease the exposure to rilpivirine. Antacids should be taken 2 hours before or 4 hours after rilpivirine. [Severe] Theoretical
    - Antileptigicales (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) markedly decrease the exposure to rilpivirine. Avoid. [Severe] Study
Rilpivirine (continued)

- Antiepileptics (oxcarbazepine) are predicted to decrease the concentration of rilpivirine. Avoid. [Severe] Theoretical
- Bosentan is predicted to decrease the exposure to rilpivirine. Avoid. [Severe] Theoretical
- Calcium salts (calcium carbonate) are predicted to slightly decrease the exposure to rilpivirine. Calcium carbonate should be taken 2 hours before or 4 hours after rilpivirine. [Severe] Theoretical
- Efavirenz is predicted to decrease the exposure to rilpivirine. Avoid. [Severe] Theoretical
- Enzalutamide markedly decreases the exposure to rilpivirine. Avoid. [Severe] Study
- Extravire is predicted to decrease the exposure to rilpivirine. Avoid. [Severe] Theoretical
- H₂ receptor antagonists are predicted to decrease the exposure to rilpivirine. H₂ receptor antagonists should be taken 12 hours before or 4 hours after rilpivirine. [Severe] Study
- Nevinirine is predicted to decrease the exposure to rilpivirine. Avoid. [Severe] Theoretical
- Proton pump inhibitors are predicted to decrease the exposure to rilpivirine. Avoid. [Severe] Study
- Rifabutin slightly decreases the exposure to rilpivirine. Adjust dose. [Severe] Study
- Rifampin reportedly decreases the exposure to rilpivirine. Avoid. [Severe] Study
- St John’s Wort is predicted to decrease the exposure to rilpivirine. Avoid. [Severe] Theoretical

Riluzole

FOOD AND LIFESTYLE Charcoal-grilled foods are predicted to decrease the exposure to riluzole.

- SSRIs (fluvoxamine) are predicted to increase the exposure to riluzole. [Moderate] Theoretical
- Riociguat is predicted to decrease the exposure to riociguat. Antacids should be taken 2 hours before or 1 hour after riociguat. [Mild] Study
- Antifungals, azoles (itraconazole, ketoconazole) are predicted to increase the exposure to riociguat. Avoid. [Moderate] Study
- Antifungals, azoles (ketocazole) moderately increase the exposure to riociguat. Avoid. [Moderate] Study
- Ciclosporin is predicted to increase the exposure to riociguat. [Moderate] Theoretical
- HIV-protease inhibitors (ritonavir) are predicted to increase the exposure to riociguat. Avoid. [Moderate] Theoretical
- Rocephin is predicted to increase the exposure to riociguat. Avoid. [Moderate] Theoretical
- HIV-protease inhibitors (ritonavir) are predicted to moderately decrease the exposure to riociguat. Avoid unless patient can be monitored for signs of thrombosis. [Severe] Study
- Antifungals, azoles (itraconazole, ketoconazole) are predicted to increase the exposure to riociguat. Avoid. [Moderate] Study

Risenedronate

- See bisphosphonates
- Risperidone is predicted to increase the exposure to risperidone. Adjust risperidone dose. [Moderate] Study
- Also see TABLE 8 p. 1265 (hypotension), TABLE 9 p. 1266 (QT-interval prolongation), TABLE 11 p. 1266 (CNS depressant effects)
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to risperidone. Adjust dose. [Moderate] Study
- Also see TABLE 8 p. 1265
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to risperidone. Adjust dose. [Moderate] Study
- Also see TABLE 9 p. 1266
- Bupropion is predicted to increase the exposure to risperidone. Adjust dose. [Moderate] Study
- Cilnidipine is predicted to increase the exposure to risperidone. Adjust dose. [Moderate] Study
- Cobicistat is predicted to increase the exposure to risperidone. Adjust dose. [Moderate] Study
- Risperidone is predicted to decrease the effects of dopamine receptor agonists. Avoid. [Moderate] Theoretical
- Also see TABLE 8 p. 1265
- Enzalutamide is predicted to decrease the exposure to risperidone. Adjust risperidone dose. [Moderate] Study
- Risperidone is predicted to decrease the effects of histamine. Avoid. [Severe] Theoretical
- Also see TABLE 8 p. 1265
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to risperidone. Adjust dose. [Moderate] Study

- Idelalisib is predicted to increase the exposure to risperidone. Adjust dose. [Moderate] Study
- Risperidone is predicted to decrease the effects of levodopa. Avoid or adjust dose. [Severe] Anecdotal
- Also see TABLE 8 p. 1265
- Risperidone potentially increases the risk of neurotoxicity when given with lithium. [Severe] Anecdotal
- Also see TABLE 9 p. 1266
- Macrolides (clarithromycin) are predicted to increase the exposure to risperidone. Adjust dose. [Moderate] Study
- Also see TABLE 9 p. 1266
- Rifampicin is predicted to decrease the exposure to risperidone. Adjust risperidone dose. [Moderate] Study
- SSRIs (fluoxetine, paroxetine) are predicted to increase the exposure to risperidone. Adjust dose. [Moderate] Study
- Terbinafine is predicted to increase the exposure to risperidone. Adjust dose. [Moderate] Study
- Ritonavir is predicted to increase the exposure to HIV-protease inhibitors

Rivaroxaban

- Also see TABLE 3 p. 1264 (anticoagulant effects)
- Antiarrhythmics (dronedarone) are predicted to increase the exposure to rivaroxaban. Avoid. [Moderate] Theoretical
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to moderately decrease the exposure to rivaroxaban. Avoid unless patient can be monitored for signs of thrombosis. [Severe] Study
- Antifungals, azoles (itraconazole, ketoconazole) are predicted to increase the exposure to rivaroxaban. Avoid. [Moderate] Study
- Enzalutamide is predicted to moderately decrease the exposure to rivaroxaban. Avoid unless patient can be monitored for signs of thrombosis. [Severe] Study
- HIV-protease inhibitors (ritonavir) moderately increase the exposure to rivaroxaban. Avoid. [Severe] Study
- Rifaximin is predicted to moderately decrease the exposure to rivaroxaban. Avoid unless patient can be monitored for signs of thrombosis. [Severe] Study
- Rivastigmine is predicted to increase the risk of vasoconstriction when given with ergotamine. Ergotamine should be taken at least 24 hours before or 6 hours after rivastriptan. [Severe] Theoretical
- Myclobutin moderately increases the exposure to rivaroxaban. Avoid. [Moderate] Study
- Also see TABLE 13 p. 1267
- Monoamine-oxidase A and B inhibitors, irreversible are predicted to increase the exposure to rivaroxaban. Avoid and separate administration by at least 2 hours. [Moderate] Study
- Rivastriptan is predicted to increase the risk of vasoconstriction when given with ergotamine. Ergotamine should be taken at least 24 hours before or 6 hours after rivastriptan. [Severe] Theoretical
- Roflumilast moderately increases the exposure to rivaroxaban. Avoid. [Moderate] Study
- Also see TABLE 13 p. 1267
- Roflumilast is predicted to increase the exposure to rivaroxaban. Avoid. [Moderate] Study
- Also see TABLE 13 p. 1267
- Rocuronium is predicted to increase the exposure to rivaroxaban. Avoid. [Moderate] Study
- Also see TABLE 13 p. 1267
- Rocuronium is predicted to increase the exposure to rifampicin. Avoid. [Moderate] Theoretical
- Combined hormonal contraceptives are predicted to increase the exposure to roflumilast. [Moderate] Theoretical
- Enzalutamide is predicted to decrease the exposure to roflumilast. Avoid. [Moderate] Study
- H₂ receptor antagonists (cimetidine) slightly increase the exposure to roflumilast. [Moderate] Study
- Quinolones (ciprofloxacin) are predicted to decrease the exposure to roflumilast. Avoid. [Moderate] Study
- Theophylline is predicted to slightly increase the exposure to roflumilast. Avoid. [Moderate] Theoretical
- Ropivacaine is predicted to decrease the exposure to roflumilast. Avoid. [Moderate] Theoretical
- Ropivacaine is predicted to decrease the exposure to roflumilast. Avoid. [Moderate] Theoretical
- Ropivacaine is predicted to decrease the exposure to roflumilast. Avoid. [Moderate] Theoretical
- Ropivacaine is predicted to decrease the exposure to roflumilast. Avoid. [Moderate] Theoretical

Downloaded from www.medicalbr.com
Rotavirus vaccine 

Rotigotine → see dopamine receptor agonists
Rufinamide → see antiepileptics

Ruxolitinib → see TABLE 15 p. 1267 (myelosuppression)
  > Antirrhinums (dronedarone) are predicted to increase the exposure to ruxolitinib. [Moderate] Theoretical
  > Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to ruxolitinib. Monitor and adjust dose. [Moderate] Study
  > Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to ruxolitinib. [Moderate] Theoretical
  > Aprepitant is predicted to increase the exposure to ruxolitinib. [Moderate] Theoretical
  > Bosantan is predicted to decrease the exposure to ruxolitinib. Monitor and adjust dose. [Moderate] Theoretical
  > Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to ruxolitinib. [Moderate] Theoretical
  > Cobicistat is predicted to increase the exposure to ruxolitinib. Adjust dose and monitor side effects. [Moderate] Study
  > Ruxolitinib is predicted to increase the risk of bleeding events when given with coumarins. [Severe] Theoretical
  > Crizotinib is predicted to increase the exposure to ruxolitinib. [Moderate] Theoretical → Also see TABLE 15 p. 1267
  > Efavirenz is predicted to decrease the exposure to ruxolitinib. Monitor and adjust dose. [Moderate] Theoretical
  > Enalaprilat is predicted to decrease the exposure to ruxolitinib. Monitor and adjust dose. [Moderate] Study
  > Grapefruit juice is predicted to increase the exposure to ruxolitinib. [Severe] Theoretical
  > HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to ruxolitinib. Adjust dose and monitor side effects. [Moderate] Study
  > HIV-protease inhibitors (indinavir) are predicted to increase the exposure to ruxolitinib. [Moderate] Theoretical
  > Idelalisib is predicted to increase the exposure to ruxolitinib. Adjust dose and monitor side effects. [Moderate] Study → Also see TABLE 15 p. 1267
  > Macrolides (clarithromycin) are predicted to increase the exposure to ruxolitinib. Adjust dose and monitor side effects. [Moderate] Study
  > Macrolides (erythromycin) are predicted to increase the exposure to ruxolitinib. [Moderate] Theoretical
  > Netupitant is predicted to increase the exposure to ruxolitinib. [Moderate] Theoretical
  > Nevirapine is predicted to decrease the exposure to ruxolitinib. Monitor and adjust dose. [Moderate] Theoretical
  > Nilotinib is predicted to increase the exposure to ruxolitinib. [Moderate] Theoretical → Also see TABLE 15 p. 1267
  > Ruxolitinib is predicted to increase the risk of bleeding events when given with phenindione. [Severe] Theoretical
  > Rifaximin is predicted to decrease the exposure to ruxolitinib. Monitor and adjust dose. [Moderate] Study
  > St John's Wort is predicted to decrease the exposure to ruxolitinib. [Moderate] Theoretical
  > Sacubitril → see TABLE 8 p. 1265 (hypotension)
  > Ciclosporin is predicted to increase the exposure to sacubitril. [Moderate] Theoretical
  > Rifaximin is predicted to increase the exposure to sacubitril. [Moderate] Theoretical
  > Sacubitril is predicted to increase the exposure to statins. [Severe] Study
  > Tenofovir is predicted to increase the exposure to sacubitril. [Moderate] Theoretical
  > Sildenafil is predicted to decrease the exposure to sacubitril. [Severe] Study
  > Sartans → see monoamine-oxidase B inhibitors
  > Sildenafil is predicted to increase the exposure to statins. [Severe] Study
  > Methotrexate is predicted to decrease the efficacy of sapropterin. [Moderate] Theoretical
  > Phosphodiesterase type 5 inhibitors are predicted to increase the risk of hypotension when given with sapropterin. [Moderate] Theoretical → Also see TABLE 8 p. 1265
  > Trimethoprim is predicted to decrease the efficacy of sapropterin. [Moderate] Theoretical
  > Saquinavir → see HIV-protease inhibitors

Saxagliptin → see TABLE 14 p. 1267 (antidiabetic drugs)
  > Antirrhinums (dronedarone) are predicted to increase the exposure to saxagliptin. [Mild] Study
  > Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to saxagliptin. [Moderate] Study
  > Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to saxagliptin. [Mild] Study
  > Aprepitant is predicted to increase the exposure to saxagliptin. [Mild] Study
  > Enalaprilat is predicted to moderate decrease the exposure to saxagliptin. [Moderate] Study
  > Grapefruit juice is predicted to increase the exposure to saxagliptin. [Mild] Theoretical
  > HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to saxagliptin. [Moderate] Study
  > HIV-protease inhibitors (indinavir) are predicted to increase the exposure to saxagliptin. [Mild] Study
  > Idelalisib is predicted to increase the exposure to saxagliptin. [Moderate] Study
  > Imatinib is predicted to increase the exposure to saxagliptin. [Mild] Study
  > Macrolides (clarithromycin) are predicted to increase the exposure to saxagliptin. [Moderate] Study
  > Macrolides (erythromycin) are predicted to increase the exposure to saxagliptin. [Moderate] Study
  > Netupitant is predicted to increase the exposure to saxagliptin. [Mild] Study
  > Nilotinib is predicted to increase the exposure to saxagliptin. [Mild] Study
  > Rifaximin is predicted to moderately decrease the exposure to saxagliptin. [Moderate] Study
  > Secukinumab → see monoclonal antibodies
  > Sildenafil is predicted to increase the exposure to saxagliptin. [Unknown] Theoretical
  > Silver sulfadiazine

Silver might inactivate enzymatic debriding agents—concurrent use might not be appropriate.

Silver sulfadiazine

PHARMACOLOGY Silver might inactivate enzymatic debriding agents—concurrent use might not be appropriate.
Simeprevir

- **Interactions**

  - **Antiarrhythmics (dronedaron)** are predicted to increase the exposure to **simeprevir**. Avoid. (Severe) Study
  - **Simeprevir** is predicted to increase the concentration of **antiarrhythmics (amiodaron)**. Refer to specialist literature. (Severe) Anecdotal
  - **Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone)** are predicted to decrease the exposure to **simeprevir**. Avoid. (Severe) Study
  - **Antiepileptics (oxcarbazepine)** are predicted to decrease the exposure to **simeprevir**. Avoid. (Severe) Theoretical
  - **Antifungals, azoles (fluconazole, isavuconazole, itraconazole, ketoconazole, posaconazole, voriconazole)** are predicted to increase the exposure to **simeprevir**. Avoid. (Severe) Study
  - **Aprepitant** is predicted to increase the exposure to **simeprevir**. Avoid. (Severe) Study
  - **Bosantan** is predicted to decrease the exposure to **simeprevir**. Avoid. (Severe) Study
  - **Calcium channel blockers (diltiazem, verapamil)** are predicted to increase the exposure to **simeprevir**. Avoid. (Severe) Study
  - **Cobicistat** is predicted to increase the exposure to **simeprevir**. Avoid. (Severe) Study
  - **Crizotinib** is predicted to increase the exposure to **simeprevir**. Avoid. (Severe) Study
  - **Efavirenz** is predicted to decrease the exposure to **simeprevir**. Avoid. (Severe) Study
  - **Enzalutamide** is predicted to decrease the exposure to **simeprevir**. Avoid. (Severe) Study
  - **Etravirine** is predicted to decrease the exposure to **simeprevir**. Avoid. (Moderate) Study
  - **HIV-protease inhibitors** are predicted to increase the exposure to **simeprevir**. Avoid. (Severe) Study
  - **Idelalisib** is predicted to increase the exposure to **simeprevir**. Avoid. (Severe) Study
  - **Imatinib** is predicted to increase the exposure to **simeprevir**. Avoid. (Severe) Study
  - **Ledipasvir** moderately increases the exposure to **simeprevir** and **simeprevir** slightly increases the exposure to **ledipasvir**. Avoid. (Severe) Study
  - **Macrolides (clarithromycin, erythromycin)** are predicted to increase the exposure to **simeprevir**. Avoid. (Severe) Study
  - **Netupitant** is predicted to increase the exposure to **simeprevir**. Avoid. (Severe) Study
  - **Nevirapine** is predicted to decrease the exposure to **simeprevir**. Avoid. (Severe) Study
  - **Nilotinib** is predicted to increase the exposure to **simeprevir**. Avoid. (Severe) Study
  - **Rifabutin** is predicted to decrease the exposure to **simeprevir**. Avoid. (Moderate) Theoretical
  - **Rifampicin** is predicted to decrease the exposure to **simeprevir**. Avoid. (Severe) Study
  - **St John’s Wort** is predicted to decrease the exposure to **simeprevir**. Avoid. (Severe) Study
  - **Simeprevir** moderately increases the exposure to **statins (atorvastatin)**. Monitor and adjust dose. (Moderate) Study
  - **Simeprevir** is predicted to increase the exposure to **statins (pravastatin)**. Monitor and adjust dose. (Severe) Theoretical
  - **Simeprevir** moderately increases the exposure to **statins (rosuvastatin)**. Adjust **rosuvastatin** dose, p. 197. (Moderate) Study
  - **Simeprevir** slightly increases the exposure to **statins (simvastatin)**. Monitor and adjust dose. (Moderate) Study
  - **Simvastatin** ▶ see statins

**Sirolimus**

- **Antiarrhythmics (amiodaron)** are predicted to increase the concentration of **sirolimus**. (Severe) Anecdotal
- **Antiarrhythmics (dronedaron)** increase the concentration of **sirolimus**. Monitor and adjust dose. (Moderate) Study
- **Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone)** are predicted to decrease the concentration of **sirolimus**. Avoid. (Moderate) Study
- **Antifungals, azoles (fluconazole, isavuconazole, posaconazole)** increase the concentration of **sirolimus**. Monitor and adjust dose. (Moderate) Study
- **Antifungals, azoles (itraconazole, ketoconazole, voriconazole)** are predicted to increase the concentration of **sirolimus**. Avoid. (Severe) Study
- **Efavirenz** is predicted to decrease the concentration of **sirolimus** and **sirolimus** potentially increases the concentration of **bosantan**. Avoid. (Severe) Theoretical
- **Calcium channel blockers (diltiazem, verapamil)** increase the concentration of **sirolimus**. Monitor and adjust dose. (Moderate) Study
- **Ceritinib** is predicted to increase the exposure to **sirolimus**. Avoid. (Severe) Theoretical
- **Ciclosporin** moderately increases the exposure to **sirolimus**. Separate administration by 4 hours. (Severe) Study
- **Cobicistat** is predicted to increase the concentration of **sirolimus**. Avoid. (Severe) Study
- **Crizotinib** increases the concentration of **sirolimus**. Monitor and adjust dose. (Moderate) Study
- **Efavirenz** is predicted to decrease the concentration of **sirolimus**. Monitor and adjust dose. (Moderate) Theoretical
- **Enzalutamide** is predicted to decrease the concentration of **sirolimus**. Avoid. (Severe) Study
- **Grapefruit juice** increases the concentration of **sirolimus**. Avoid. (Moderate) Study
- **HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to increase the concentration of **sirolimus**. Avoid. (Severe) Study
- **HIV-protease inhibitors (indinavir)** increase the concentration of **sirolimus**. Monitor and adjust dose. (Moderate) Study
- **Idelalisib** is predicted to increase the concentration of **sirolimus**. Avoid. (Severe) Study
- **Imatinib** increases the concentration of **sirolimus**. Monitor and adjust dose. (Moderate) Study
- **Lapatinib** is predicted to increase the exposure to **sirolimus**. (Moderate) Theoretical
- **Live vaccines** are predicted to increase the risk of generalised infection (possibly life-threatening) when given with **sirolimus**. Public Health England advises avoid. (Severe) Theoretical
- **Lumacaftor** is predicted to decrease the exposure to **sirolimus**. Avoid. (Severe) Theoretical
- **Macrolides (clarithromycin)** are predicted to increase the concentration of **sirolimus**. Avoid. (Severe) Study
- **Macrolides (erythromycin)** increase the concentration of **sirolimus**. Monitor and adjust dose. (Moderate) Study
- **Sirolimus** is predicted to decrease the efficacy of **infacumabtid**. Avoid. (Severe) Theoretical
- **Mirabegron** is predicted to increase the exposure to **sirolimus**. (Mild) Theoretical
- **Netupitant** increases the concentration of **sirolimus**. Monitor and adjust dose. (Moderate) Study
- **Nevirapine** is predicted to decrease the concentration of **sirolimus**. Monitor and adjust dose. (Moderate) Study
- **Nilotinib** increases the concentration of **sirolimus**. Monitor and adjust dose. (Moderate) Study
- **Palbociclib** is predicted to increase the exposure to **sirolimus**. Adjust dose. (Moderate) Theoretical
- **Pitolisant** is predicted to decrease the exposure to **sirolimus**. Avoid. (Severe) Theoretical
- **Rifampicin** is predicted to decrease the concentration of **sirolimus**. Avoid. (Severe) Study
- **St John’s Wort** is predicted to decrease the concentration of **sirolimus**. Monitor and adjust dose. (Severe) Theoretical
- **Sirolimus** is predicted to decrease the concentration of **tacrolimus** and **tacrolimus** increases the exposure to **sirolimus**. (Severe) Study
- **Velpatasvir** is predicted to increase the exposure to **sirolimus**. (Severe) Theoretical

Sitagliptin ▶ see TABLE 14 p. 1267 (antidiabetic drugs)
Sodium aurothiomalate → ACE inhibitors are predicted to increase the risk of hypotension when given with sodium aurothiomalate. (Severe) Anecdotal

Sodium aurothiomalate potentially increases the risk of side-effects when given with penicillamine (in those who have had previous adverse reactions to gold). Avoid. (Severe) Study

Sodium bicarbonate → Sodium bicarbonate decreases the concentration of lithium. (Severe) Anecdotal

Sodium bicarbonate is predicted to decrease the efficacy of methenamine. Avoid. (Moderate) Theoretical

Sodium citrate → Sodium citrate is predicted to decrease the efficacy of methenamine. Avoid. (Moderate) Theoretical

Sodium citrate is predicted to increase the risk of side-effects when given with sulfafate. Avoid. (Moderate) Theoretical

Sodium clodronate → see bisphosphonates

Sodium feredetate → see iron (oral)

Sodium nitroprusside → see TABLE 8 p. 1265 (hypotension)

Sodium nitroprusside is predicted to increase the risk of methaemoglobinemia when given with topical anaesthetics, local (prilocaine). Use with caution or avoid. (Severe) Theoretical

Sodium nitroprusside is predicted to increase the risk of methaemoglobinemia when given with dapone. (Severe) Theoretical

Sodium oxybate → see TABLE 8 p. 1265 (hypotension), TABLE 11 p. 1266 (CNs depressant effects)

Antiepileptics (valproate) increase the exposure to sodium oxybate. Adjust sodium oxybate dose, p. 466. (Moderate) Study

Sodium phenylbutyrate → Antiepileptics (valproate) potentially decrease the effects of sodium phenylbutyrate. (Moderate) Anecdotal

Corticosteroids potentially decrease the effects of sodium phenylbutyrate. (Moderate) Anecdotal

Haloperidol potentially decreases the effects of sodium phenylbutyrate. (Moderate) Anecdotal

Sodium picosulfate → see TABLE 18 p. 1268 (hyponatraemia), TABLE 17 p. 1268 (reduced serum potassium)

Sodium stibogluconate → Sodium stibogluconate increases the risk of cardiovascular side-effects when given with amphotericin. Separate administration by 14 days. (Severe) Study

Sofosbuvir → Sofosbuvir is predicted to increase the risk of severe bradycardia or heart block when given with antiepileptics (amiodarone). Refer to specialist literature. (Severe) Anecdotal

Antiepileptics (carbamazepine, fosphenytoin, oxcarbazepine, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to sofosbuvir. Adjust dose. (Moderate) Theoretical

H₂ receptor antagonists potentially decrease the exposure to sofosbuvir. Adjust dose, see sofosbuvir with ledipasvir and sofosbuvir with velpatasvir p. 596. (Moderate) Study

HIV-protease inhibitors (tipranavir) are predicted to decrease the exposure to sofosbuvir. (Tipranavir). Adjust dose. (Severe) Theoretical

Proton pump inhibitors potentially decrease the exposure to sofosbuvir. Adjust dose, see sofosbuvir with ledipasvir and sofosbuvir with velpatasvir p. 596. (Moderate) Study

Rifampicin is predicted to decrease the exposure to sofosbuvir. Avoid. (Severe) Study

St. John’s Wort is predicted to decrease the exposure to sofosbuvir. Avoid. (Severe) Study

Solfenacin → see TABLE 10 p. 1266 (antimuscarinics)

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to solifenacin. (Moderate) Theoretical

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to solifenacin. Adjust solifenacin or tamsulosin with solifenacin dose; avoid in hepatic and renal impairment. (Moderate) Theoretical

Cobicistat is predicted to increase the exposure to solifenacin. Adjust solifenacin or tamsulosin with solifenacin dose; avoid in hepatic and renal impairment, p. 734, p. 740. (Severe) Study

Enalaprilat is predicted to decrease the exposure to solifenacin. (Moderate) Theoretical

Sofosbuvir with ledipasvir and sofosbuvir with velpatasvir are predicted to decrease the exposure to solifenacin. Adjust solifenacin or tamsulosin with solifenacin dose; avoid in hepatic and renal impairment, p. 734, p. 740. (Severe) Study

Macrolides (clarithromycin) are predicted to increase the exposure to solifenacin. Adjust solifenacin or tamsulosin with solifenacin dose; avoid in hepatic and renal impairment, p. 734, p. 740. (Severe) Study

Rifampicin is predicted to decrease the exposure to solifenacin. (Moderate) Theoretical

Somatropin → Corticosteroids are predicted to decrease the effects of somatropin. (Moderate) Theoretical

Sorafenib → see TABLE 15 p. 1267 (myelosuppression), TABLE 9 p. 1266 (QT-interval prolongation)

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to sorafenib. (Moderate) Theoretical

Sorafenib increases the anticoagulant effect of coumarins. (Severe) Anecdotal

Enalaprilat is predicted to decrease the exposure to sorafenib. (Moderate) Theoretical

Neomycin moderately decreases the exposure to sorafenib. (Moderate) Study

Sorafenib is predicted to increase the risk of bleeding events when given with phenindione. (Severe) Theoretical

Rifampicin is predicted to decrease the exposure to sorafenib. (Moderate) Theoretical

Sotalol → see beta blockers, non-selective

Spirolactone → see aldosterone antagonists

Sorafenib → see TABLE 18 p. 1268 (hyponatraemia), TABLE 13 p. 1267 (serotonin syndrome), TABLE 9 p. 1266 (QT-interval prolongation), TABLE 4 p. 1264 (antiplatelet effects)

citalopram - dapoxetine - escitalopram - fluoxetine - fluvaxamine - paroxetine - sertraline

Fluvoxamine very markedly increases the exposure to agomelatine. Avoid. (Severe) Study

Fluvoxamine moderately increases the exposure to alprazolam. Adjust dose. (Moderate) Study

SSRIs (fluoxetine, paroxetine) are predicted to increase the exposure to amfetamines. (Severe) Theoretical → Also see TABLE 13 p. 1267

Fluvoxamine moderately to markedly increases the exposure to aminophylline. Avoid. (Severe) Study

Fluvoxamine decreases the clearance of anaesthetics, local (ropivacaine). Avoid prolonged use. (Moderate) Study

Fluvoxamine is predicted to increase the exposure to anagrelide. (Moderate) Theoretical → Also see TABLE 4 p. 1264

Antiarrrhythmics (dronedarone) are predicted to increase the exposure to dapoxetine. Adjust dapoxetine dose, p. 773. (Moderate) Theoretical

Antiarrrhythmics (dronedarone) are predicted to increase the exposure to SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline). (Severe) Theoretical → Also see TABLE 9 p. 1266

SSRIs (fluoxetine, paroxetine) are predicted to increase the exposure to antiarrhythmics (flecainide). (Severe) Theoretical

SSRIs (fluoxetine, fluvoxamine, paroxetine) are predicted to increase the exposure to anticholinesterases, centrally acting (donepezil). (Moderate) Theoretical

SSRIs (fluoxetine, paroxetine) are predicted to increase the exposure to anticholinesterases, centrally acting (galantamine). Monitor and adjust dose. (Moderate) Study

Antiepileptics (fosphenytoin, phenytoin) decrease the concentration of paroxetine. (Moderate) Study

Sertraline potentially increases the risk of toxicity when given with antiepileptics (fosphenytoin, phenytoin). Monitor concentration and adjust dose. (Severe) Anecdotal
### SSRIs — SSRIs

**SSRIs (continued)**

- SSRIs (fluoxetine, fluvoxamine) are predicted to increase the concentration of antiepileptics (fosphenytoin, phenytoin). Monitor and adjust dose. **Severe** Anecdotal
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to moderately increase the exposure to fluvoxamine. Adjust dapoxetine dose, p. 773. **Moderate** Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to moderately increase the exposure to fluvoxamine. Avoid or adjust dapoxetine dose, p. 773. **Severe** Study
- Antifungals, azoles (voriconazole) are predicted to increase the exposure to citalopram. **Severe** Theoretical
- SSRIs (fluoxetine, paroxetine) are predicted to increase the exposure to citalopram. Adjust dapoxetine dose, p. 773. **Severe** Study
- SSRIs (fluoxetine, paroxetine) are predicted to moderately increase the exposure to atomoxetine. Adjust dose. **Severe** Study
- Fluvoxamine moderately increases the concentration of beta blockers, non-selective (carvedilol, timolol). **Moderate** Study
- Fluvoxamine moderately increases the concentration of beta blockers, non-selective (propranolol). **Moderate** Study
- SSRIs (fluoxetine, paroxetine) are predicted to increase the exposure to beta blockers, selective (metoprolol, nebivolol). **Moderate** Study
- Bupropion is predicted to increase the exposure to dapoxetine. **Moderate** Theoretical → Also see TABLE 13 p. 1267
- Fluvoxamine markedly decreases the clearance of caffeine citrate. Monitor and adjust dose. **Severe** Study
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to dapoxetine. Adjust dapoxetine dose, p. 773. **Moderate** Theoretical
- Fluvoxamine is predicted to increase the exposure to cilostazol. Adjust cilostazol dose, p. 226. **Moderate** Theoretical → Also see TABLE 4 p. 1264
- Cinacalcet is predicted to increase the exposure to dapoxetine. **Moderate** Theoretical
- Fluvoxamine is predicted to increase the exposure to cinacalcet. Adjust dose. **Moderate** Theoretical
- Fluvoxamine is predicted to decrease the efficacy of clopidogrel. Avoid. **Severe** Theoretical → Also see TABLE 4 p. 1264
- Fluvoxamine increases the concentration of clozapine. Monitor side effects and adjust dose. **Severe** Study
- Cobicistat is predicted to moderately increase the exposure to dapoxetine. Avoid or adjust dapoxetine dose, p. 773. **Severe** Study
- Crizotinib is predicted to increase the exposure to dapoxetine. Adjust dapoxetine dose, p. 773. **Moderate** Theoretical
- SSRIs (fluoxetine, paroxetine) are predicted to slightly increase the exposure to darifenacin. **Mild** Study
- Fluvoxamine moderately increases the exposure to diazepam. **Moderate** Study
- Fluvoxamine is predicted to increase the exposure to dopamine receptor agonists (ropinirole). Adjust dose. **Moderate** Study
- Fluvoxamine is predicted to increase the exposure to duloxetine. Avoid. **Severe** Study → Also see TABLE 18 p. 1268 → Also see TABLE 13 p. 1267 → Also see TABLE 4 p. 1264
- Fluvoxamine is predicted to increase the exposure to erlotinib. Monitor side effects and adjust dose. **Moderate** Theoretical
- Fluvoxamine increases the concentration of frowiantin. **Severe** Study → Also see TABLE 13 p. 1267
- Grapefruit juice moderately increases the exposure to sertraline. Avoid. **Moderate** Study
- H₂ receptor antagonists (cimetidine) slightly increase the exposure to SSRIs (citalopram, escitalopram). Adjust dose. **Moderate** Study
- H₂ receptor antagonists (cimetidine) slightly increase the exposure to SSRIs (paroxetine, sertraline), **Moderate** Study
- Fluoxetine increases the concentration of haloperidol. Adjust dose. **Moderate** Anecdotal
- Fluvoxamine increases the concentration of haloperidol. Adjust dose. **Moderate** Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to moderately increase the exposure to dapoxetine. Avoid or adjust dapoxetine dose, p. 773. **Severe** Study
- HIV-protease inhibitors (indinavir) are predicted to increase the exposure to dapoxetine. Adjust dapoxetine dose, p. 773. **Moderate** Theoretical
- Fluoxetine is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. **Unknown** Theoretical
- Fluvoxamine is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. **Moderate** Theoretical
- Fluvoxamine is predicted to increase the exposure to lioxyline. Avoid. **Unknown** Theoretical
- Lumacaftor is predicted to decrease the exposure to SSRIs (citalopram, escitalopram, sertraline). Adjust dose. **Moderate** Theoretical
- Macrolides (clarithromycin) are predicted to moderately increase the exposure to dapoxetine. Avoid or adjust dapoxetine dose, p. 773. **Severe** Study
- Macrolides (erythromycin) are predicted to increase the exposure to dapoxetine. Adjust dapoxetine dose, p. 773. **Moderate** Theoretical
- SSRIs potentially increase the risk of prolonged neuromuscular blockade when given with neuromuscular blocking drugs, non-depolarising (miyacurium). **Unknown** Theoretical
- Nilotinib is predicted to increase the exposure to dapoxetine. Adjust dapoxetine dose, p. 773. **Moderate** Theoretical
- Fluvoxamine very markedly increases the exposure to melatonin. Avoid. **Severe** Study
- Netupitant is predicted to increase the exposure to dapoxetine. Adjust dapoxetine dose, p. 773. **Moderate** Theoretical
- SSRIs (fluoxetine, paroxetine) are predicted to decrease the efficacy of opioids (codeine). **Moderate** Theoretical
- SSRIs (fluoxetine, paroxetine) are predicted to decrease the efficacy of opioids (tramadol). **Severe** Study → Also see TABLE 13 p. 1267
- Fluvoxamine is predicted to increase the exposure to pentoxifylline. **Moderate** Theoretical
- Paroxetine markedly increases the exposure to phenothiazines (perphenazine). **Severe** Study
- Fluvoxamine is predicted to moderately increase the exposure to pirfenidone. Avoid. **Moderate** Study
- SSRIs (fluoxetine, paroxetine) are predicted to moderately increase the exposure to pitolisant. Use with caution and adjust dose. **Moderate** Study
- Fluvoxamine moderately increases the exposure to pomalidomide. Adjust pomalidomide dose, p. 886. **Moderate** Study
- Paroxetine slightly increases the exposure to procyclidine. Monitor and adjust procyclidine dose. **Moderate** Study
- Proton pump inhibitors (esomeprazole) are predicted to slightly to moderately increase the exposure to citalopram. Monitor and adjust dose. **Severe** Theoretical
- Proton pump inhibitors (esomeprazole) are predicted to increase the exposure to escitalopram. Monitor and adjust dose. **Severe** Theoretical
- Fluvoxamine is predicted to increase the exposure to proton pump inhibitors. **Mild** Study
- Proton pump inhibitors (omeprazole) slightly to moderately increase the exposure to SSRIs (cITALOPRAM, escITALOPRAM). Monitor and adjust dose. **Severe** Study
Fluvoxamine is predicted to increase the exposure to rituximab. [Moderate] Theoretical

SSRIs (fluoxetine, paroxetine) are predicted to increase the exposure to risperidone. Adjust dose. [Moderate] Study

Fluvoxamine is predicted to increase the exposure to roflumilast. [Moderate] Theoretical

SSRIs (fluoxetine, paroxetine) are predicted to increase the exposure to SSRIs (dapoxetine). [Moderate] Theoretical → Also see table 18 p. 1268 also see table 13 p. 1267 also see table 4 p. 1264

SSRs potentially increase the risk of prolonged neuromuscular blockade when given with saximumethion. [Unknown] Theoretical

SSRIs (fluoxetine, paroxetine) are predicted to increase the exposure to theophylline. Avoid. [Severe] Study

Terbinafine is predicted to increase the exposure to fluoxetine. Adjust dose. [Moderate] Theoretical

Terbinafine moderately increases the exposure to paroxetine. [Moderate] Study

Terbinafine is predicted to increase the exposure to SSRIs (citalopram, dapoxetine, escitalopram, fluvoxamine, sertraline). [Moderate] Theoretical

Fluvoxamine moderately to markedly increases the exposure to tricyclic antidepressants (amitriptyline, imipramine). Adjust dose. [Severe] Study → Also see table 18 p. 1268 also see table 13 p. 1267 also see table 4 p. 1264

Fluvoxamine markedly increases the exposure to tricyclic antidepressants (clomipramine). Adjust dose. [Severe] Study → Also see table 18 p. 1268 also see table 13 p. 1267 also see table 4 p. 1264

SSRIs (fluoxetine, paroxetine) are predicted to increase the exposure to vortioxetine. Monitor and adjust dose. [Moderate] Study → Also see table 13 p. 1267 also see table 13 p. 1267 also see table 4 p. 1264

Fluvoxamine is predicted to increase the exposure to zolmitriptan. Adjust zolmitriptan dose, p. 456. [Severe] Theoretical → Also see table 13 p. 1267

St John’s Wort is predicted to decrease the exposure to afatinib. [Moderate] Study

St John’s Wort is predicted to slightly decrease the exposure to aldosterone antagonists (eplerenone). Avoid. [Moderate] Study

St John’s Wort decreases the exposure to ailskiren. [Moderate] Study

St John’s Wort moderately decreases the exposure to alprazolam. [Moderate] Study

St John’s Wort is predicted to decrease the concentration of aminophylline. [Severe] Theoretical

St John’s Wort is predicted to decrease the exposure to antiarrhythmics (dronedarone). Avoid. [Severe] Theoretical

St John’s Wort is predicted to decrease the exposure to antiepileptics (brivaracetam). [Moderate] Theoretical

St John’s Wort is predicted to decrease the concentration of antiepileptics (carbamazepine). Monitor and adjust dose. [Moderate] Theoretical

St John’s Wort is predicted to decrease the concentration of antiepileptics (fosphenytoin, phenobarbital, phenytoin, primidone). Avoid. [Severe] Theoretical

St John’s Wort is predicted to decrease the exposure to antiepileptics (perampanel). Monitor and adjust dose. [Moderate] Theoretical

St John’s Wort is predicted to decrease the exposure to antifungals, azoles (isavuconazole). Avoid. [Severe] Theoretical

St John’s Wort moderately decreases the exposure to antifungals, azoles (voriconazole). Avoid. [Moderate] Study

St John’s Wort is predicted to decrease the concentration of antimalarials (piperaquiline). Avoid. [Moderate] Theoretical

St John’s Wort is predicted to decrease the exposure to apixaban. Use with caution or avoid. [Moderate] Theoretical

St John’s Wort is predicted to decrease the exposure to apremilast. Avoid. [Severe] Theoretical

St John’s Wort is predicted to decrease the exposure to aprepitant. Avoid. [Moderate] Theoretical

St John’s Wort is predicted to decrease the exposure to axitinib. [Moderate] Theoretical

St John’s Wort is predicted to decrease the exposure to bedaquiline. Avoid. [Severe] Study

St John’s Wort is predicted to decrease the exposure to bosentan. Avoid. [Moderate] Theoretical

St John’s Wort is predicted to decrease the exposure to bosutinib. Avoid. [Severe] Theoretical

St John’s Wort is predicted to decrease the exposure to cabozantinib. [Moderate] Theoretical

St John’s Wort is predicted to decrease the exposure to calcium channel blockers (amiodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and adjust dose. [Moderate] Theoretical

St John’s Wort is predicted to decrease the exposure to calcium channel blockers (diltiazem, verapamil). [Moderate] Theoretical

St John’s Wort is predicted to decrease the exposure to certinib. Avoid. [Severe] Theoretical

St John’s Wort decreases the concentration of ciclosporin. Avoid. [Moderate] Study

St John’s Wort is predicted to alter the effects of cilostazol. [Moderate] Theoretical

St John’s Wort is predicted to decrease the exposure to cobimetinib. Avoid. [Severe] Theoretical

St John’s Wort decreases the efficacy of combined hormonal contraceptives. MHRA advises avoid. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Aneotald

St John’s Wort decreases the anticoagulant effect of coumarins. Avoid. [Severe] Aneotald

St John’s Wort is predicted to decrease the exposure to crizotinib. Avoid. [Severe] Theoretical

St John’s Wort is predicted to decrease the exposure to dabigatran. Avoid. [Severe] Study

St John’s Wort is predicted to decrease the exposure to daclatasvir. Avoid. [Severe] Theoretical

St John’s Wort is predicted to decrease the exposure to darifenacin. [Moderate] Theoretical

St John’s Wort is predicted to decrease the exposure to dasabuvir. Avoid. [Severe] Theoretical

St John’s Wort is predicted to decrease the exposure to dasatinib. [Severe] Study

St John’s Wort is predicted to decrease the efficacy of desogestrel. MHRA advises avoid. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical

St John’s Wort decreases the concentration of digoxin. Avoid. [Severe] Aneotald

St John’s Wort is predicted to decrease the exposure to dolasetrobin. Adjust dose. [Severe] Study

St John’s Wort is predicted to decrease the exposure to edoxaban. [Moderate] Study

St John’s Wort is predicted to decrease the concentration of efavirenz. Avoid. [Severe] Theoretical

St John’s Wort is predicted to moderately decrease the exposure to elbasvir. Avoid. [Severe] Study

St John’s Wort is predicted to decrease the concentration of elvitegravir. Avoid. [Severe] Theoretical

St John’s Wort is predicted to decrease the effects of ergotamine. [Moderate] Theoretical

St John’s Wort is predicted to decrease the exposure to erlotinib. [Severe] Theoretical

St John’s Wort is predicted to decrease the efficacy of etonogestrel. MHRA advises avoid. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Theoretical

St John’s Wort is predicted to decrease the exposure to etravirine. Avoid. [Severe] Study

St John’s Wort is predicted to decrease the concentration of everolimus. Avoid or adjust dose. [Severe] Study

St John’s Wort is predicted to decrease the exposure to exemestane. [Moderate] Theoretical
St John’s Wort is continued.

- **St John’s Wort** is predicted to decrease the exposure to **fesoterodine**. Avoid. [Mild] Theoretical
- **St John’s Wort** is predicted to decrease the exposure to **felodipine**. Avoid. [Moderate] Theoretical
- **St John’s Wort** is predicted to decrease the exposure to **vodaprepitant**. Avoid. [Mild] Theoretical
- **St John’s Wort** is predicted to decrease the exposure to **gefitinib**. Avoid. [Severe] Theoretical
- **St John’s Wort** is predicted to markedly decrease the exposure to **grazoprevir**. Avoid. [Severe] Study
- **St John’s Wort** is predicted to decrease the concentration of **guanfacine**. Adjust dose. [Mild] Theoretical
- **St John’s Wort** is predicted to decrease the exposure to **HIV-1 protease inhibitors**. Avoid. [Severe] Study
- **St John’s Wort** is predicted to decrease the efficacy of **Hormone replacement therapy**. [Mild] Theoretical
- **St John’s Wort** is predicted to decrease the exposure to **ibritunib**. Avoid. [Severe] Theoretical
- **St John’s Wort** is predicted to decrease the exposure to **idelalisib**. Avoid. [Severe] Theoretical
- **St John’s Wort** is predicted to decrease the exposure to **imatinib**. [Mild] Study
- **St John’s Wort** slightly decreases the exposure to **irinotecan**. Avoid. [Severe] Study
- **St John’s Wort** decreases the exposure to **ivanabradine**. Avoid. [Mild] Study
- **St John’s Wort** is predicted to decrease the exposure to **ivacaftor**. Avoid. [Severe] Theoretical
- **St John’s Wort** is predicted to decrease the exposure to **ixazomib**. Avoid. [Severe] Theoretical
- **St John’s Wort** is predicted to decrease the exposure to **lapatinib**. Avoid. [Severe] Study
- **St John’s Wort** is predicted to decrease the exposure to **ledipasvir**. Avoid. [Severe] Theoretical
- **St John’s Wort** is predicted to decrease the efficacy of **levonordestrol**. MHRA advises avoid. For FSRH guidance, see Contraceptives, interactions p. 747. [Mild] Theoretical
- **St John’s Wort** is predicted to decrease the exposure to **lurasidone**. Monitor and adjust dose. [Mild] Theoretical
- **St John’s Wort** is predicted to decrease the exposure to **macitentan**. Avoid. [Severe] Theoretical
- **St John’s Wort** moderately decreases the exposure to **mibefradil**. Monitor and adjust dose. [Mild] Theoretical
- **St John’s Wort** is predicted to decrease the exposure to **midazolam**. Monitor and adjust dose. [Mild] Theoretical
- **St John’s Wort** is predicted to decrease the exposure to **naloxegol**. Avoid. [Mild] Theoretical
- **St John’s Wort** is predicted to decrease the concentration of **nevirapine**. Avoid. [Severe] Theoretical
- **St John’s Wort** is predicted to decrease the exposure to **nicotinib**. Avoid. [Severe] Theoretical
- **St John’s Wort** is predicted to decrease the exposure to **nintedanib**. [Mild] Study
- **St John’s Wort** is predicted to decrease the efficacy of **norethisterone**. MHRA advises avoid. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Anecdotal
- **St John’s Wort** is predicted to decrease the exposure to **olaparib**. Avoid. [Mild] Theoretical
- **St John’s Wort** is predicted to decrease the exposure to **opioids (methadone)**. Monitor and adjust dose. [Severe] Study → Also see TABLE 13 p. 1267
- **St John’s Wort** moderately decreases the exposure to **opioids (oxycodeone)**. Adjust dose. [Mild] Study
- **St John’s Wort** is predicted to decrease the exposure to **osimertinib**. Avoid. [Moderate] Theoretical
- **St John’s Wort** is predicted to decrease the exposure to **pablociclib**. Avoid. [Severe] Theoretical
- **St John’s Wort** is predicted to decrease the exposure to **panobinostat**. Avoid. [Moderate] Theoretical
- **St John’s Wort** is predicted to decrease the exposure to **paritaprevir** (with ritonavir and ombitasvir). Avoid. [Severe] Study
- **St John’s Wort** is predicted to decrease the exposure to **phosphodiesterase type-5 inhibitors**. [Mild] Theoretical
- **St John’s Wort** slightly decreases the exposure to **pioglitazone**. [Mild] Study
- **St John’s Wort** is predicted to decrease the exposure to **pitolisant**. Monitor and adjust dose. [Mild] Theoretical
- **St John’s Wort** is predicted to decrease the exposure to **ponatinib**. Avoid. [Severe] Theoretical
- **St John’s Wort** is predicted to decrease the exposure to **ranolazine**. Avoid. [Severe] Study
- **St John’s Wort** is predicted to decrease the exposure to **rilpivirine**. Avoid. [Severe] Theoretical
- **St John’s Wort** is predicted to decrease the exposure to **rufoxatinib**. Monitor and adjust dose. [Mild] Theoretical
- **St John’s Wort** is predicted to decrease the exposure to **simeprevir**. Avoid. [Severe] Study
- **St John’s Wort** is predicted to decrease the concentration of **sirolimus**. Monitor and adjust dose. [Severe] Study
- **St John’s Wort** is predicted to decrease the exposure to **sofosbuvir**. Avoid. [Mild] Study
- **St John’s Wort** slightly decreases the exposure to **statins (atorvastatin)**. [Mild] Study
- **St John’s Wort** moderately decreases the exposure to **statins (simvastatin)**. [Mild] Study
- **St John’s Wort** decreases the concentration of **tacrolimus**. Avoid. [Severe] Study
- **St John’s Wort** is predicted to decrease the exposure to **taxanes (cabazitaxel)**. Avoid. [Severe] Study
- **St John’s Wort** is predicted to decrease the concentration of **temsirolimus**. Avoid. [Severe] Theoretical
- **St John’s Wort** potentially decreases the exposure to **theophylline**. Avoid. [Mild] Anecdotal
- **St John’s Wort** is predicted to decrease the exposure to **ticagrelor**. [Mild] Theoretical
- **St John’s Wort** is predicted to decrease the exposure to **tolvaptan**. [Mild] Theoretical
- **St John’s Wort** is predicted to decrease the exposure to **topotecan**. [Mild] Theoretical
- **St John’s Wort** is predicted to decrease the exposure to **velpatasvir**. Avoid. [Mild] Theoretical
- **St John’s Wort** is predicted to decrease the exposure to **vismodegib**. Avoid. [Moderate] Theoretical

**Statins** → see TABLE 1 p. 1264 (hepatotoxicity)
- **Antiepileptics (fosphenytoin, phenytoin)** potentially decrease the exposure to statins (atorvastatin, simvastatin). (Moderate Anecdotal)

- **Antifungals, azoles (fluconazole, isavuconazole, posaconazole)** are predicted to increase the exposure to atorvastatin. Monitor and adjust dose. (Severe Theoretical) → Also see TABLE 1 p. 1264

- **Antifungals, azoles (fluconazole, miconazole)** are predicted to increase the exposure to fluvastatin. (Severe Theoretical) → Also see TABLE 1 p. 1264

- **Antifungals, azoles (itraconazole, ketoconazole, voriconazole)** are predicted to increase the exposure to atorvastatin. Avoid or adjust dose and monitor rhabdomyolysis. (Severe Study) → Also see TABLE 1 p. 1264

- **Antifungals, azoles (itraconazole, ketoconazole, voriconazole)** are predicted to increase the exposure to simvastatin. Use with caution and adjust simvastatin dose, p. 198. (Severe Study) → Also see TABLE 1 p. 1264

- **Antifungals, azoles (miconazole)** are predicted to increase the exposure to atorvastatin. (Severe Anecdotal)

- **Antifungals, azoles (miconazole)** are predicted to increase the exposure to simvastatin. (Severe Theoretical)

- **Aprepitant** is predicted to increase the exposure to atorvastatin. Monitor and adjust dose. (Severe Theoretical)

- **Aprepitant** is predicted to increase the exposure to simvastatin. Use with caution and adjust simvastatin dose, p. 198. (Severe Study)

- **Bosentan** slightly decreases the exposure to atorvastatin. (Mid Study)

- **Bosentan** moderately decreases the exposure to simvastatin. (Moderate Study)

- **Calcium channel blockers (amlodipine)** slightly increase the exposure to simvastatin. Adjust simvastatin dose, p. 198. (Mid Study)

- **Calcium channel blockers (diltiazem, verapamil)** are predicted to increase the exposure to atorvastatin. Monitor and adjust dose. (Severe Theoretical)

- **Calcium channel blockers (diltiazem, verapamil)** are predicted to increase the exposure to simvastatin. Use with caution and adjust simvastatin dose, p. 198. (Severe Study)

- **Cephalosporins (ceftobiprole)** are predicted to increase the concentration of statins. (Moderate Theoretical)

- **Ciclosporin** very markedly increases the exposure to atorvastatin. Avoid or adjust atorvastatin dose, p. 196. (Severe Study)

- **Ciclosporin** moderately increases the exposure to fluvastatin. (Severe Study)

- **Ciclosporin** markedly to very markedly increases the exposure to pravastatin. Adjust pravastatin dose, p. 197. (Severe Study)

- **Ciclosporin** markedly increases the exposure to statins (rosuvastatin, simvastatin). Avoid. (Severe Study)

- **Clopidogrel** increases the exposure to rosuvastatin. Adjust rosuvastatin dose, p. 197. (Moderate Study)

- **Cobicistat** is predicted to increase the exposure to atorvastatin. Avoid or adjust dose and monitor rhabdomyolysis. (Severe Study)

- **Cobicistat** is predicted to increase the exposure to simvastatin. Avoid. (Severe Study)

- **Colchicine** increases the risk of rhabdomyolysis when given with statins. (Severe Anecdotal)

- **Statins (fluvastatin, rosuvastatin)** increase the anticoagulant effect of coumarins. Monitor INR and adjust dose. (Severe Study)

- **Crizotinib** is predicted to increase the exposure to atorvastatin. Monitor and adjust dose. (Severe Theoretical)

- **Crizotinib** is predicted to increase the exposure to simvastatin. Use with caution and adjust simvastatin dose, p. 198. (Severe Study)

- **Danazol** is predicted to increase the risk of rhabdomyolysis when given with atorvastatin. (Severe Theoretical)

- **Danazol** increases the risk of rhabdomyolysis when given with simvastatin. Avoid. (Severe Anecdotal)

- **Statins** are predicted to increase the risk of rhabdomyolysis when given with daptomycin. (Severe Theoretical)

- **Dasabuvir** increases the exposure to rosuvastatin. Adjust rosuvastatin dose, p. 197. (Moderate Study)

- **Dasatinib** is predicted to increase the exposure to simvastatin. (Moderate Theoretical)

- **Efavirenz** slightly decreases the exposure to atorvastatin. (Mid Study)

- **Efavirenz** moderately decreases the exposure to simvastatin. (Moderate Study)

- **Elbasvir** potentially increases the exposure to atorvastatin. Adjust atorvastatin dose, p. 196. (Moderate Study)

- **Elbasvir** is predicted to increase the exposure to fluvastatin. Adjust fluvastatin dose, p. 196. (Unknown Theoretical)

- **Elbasvir** increases the exposure to rosuvastatin. Adjust rosuvastatin dose, p. 197. (Moderate Study)

- **Elbasvir** is predicted to increase the exposure to simvastatin. Adjust simvastatin dose, p. 198. (Unknown Theoretical)

- **Eltrombopag** is predicted to increase the exposure to statins. Monitor and adjust dose. (Moderate Study)

- **Ezetimibe** potentially increases the risk of rhabdomyolysis when given with simvastatin. (Severe Anecdotal)

- **Fibrates (bezafibrate, ciprofibrate)** increase the risk of rhabdomyolysis when given with pravastatin. Avoid. (Severe Study)

- **Fibrates (bezafibrate, ciprofibrate)** increase the risk of rhabdomyolysis when given with rosuvastatin. Adjust rosuvastatin dose, p. 197. (Severe Study)

- **Fibrates (ciprofibrate)** increase the risk of rhabdomyolysis when given with atorvastatin. Avoid or adjust dose. (Severe Study)

- **Fibrates (ciprofibrate)** increase the risk of rhabdomyolysis when given with fluvastatin. Adjust fluvastatin dose, p. 197. (Severe Study)

- **Fibrates (fenofibrate)** are predicted to increase the risk of rhabdomyolysis when given with fluvastatin. Adjust fenofibrate dose, p. 193. (Severe Theoretical)

- **Fibrates (fenofibrate)** are predicted to increase the risk of rhabdomyolysis when given with simvastatin. Adjust fenofibrate dose, p. 193. (Severe Anecdotal)

- **Fusidic acid** increases the risk of rhabdomyolysis when given with statins. Avoid. (Severe Anecdotal)

- **Grapefruit juice** increases the exposure to atorvastatin. (Mid Study)

- **Grapefruit juice** increases the exposure to simvastatin. Avoid. (Severe Study)

- **Grazoprevir** increases the exposure to atorvastatin. Adjust atorvastatin dose, p. 196. (Moderate Study)

- **Grazoprevir** is predicted to increase the exposure to fluvastatin. Adjust fluvastatin dose, p. 196. (Unknown Theoretical)

- **Grazoprevir** increases the exposure to rosuvastatin. Adjust rosuvastatin dose, p. 197. (Moderate Study)

- **Grazoprevir** is predicted to increase the exposure to simvastatin. Adjust simvastatin dose, p. 198. (Unknown Theoretical)

- **HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to increase the exposure to atorvastatin. Avoid or adjust dose and monitor rhabdomyolysis. (Moderate Study)

- **HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to increase the exposure to simvastatin. Avoid. (Severe Study)
Statin interactions

- HIV-protease inhibitors (indinavir) are predicted to increase the exposure to atorvastatin. Monitor and adjust dose. **Severe**
- HIV-protease inhibitors slightly to moderately increase the exposure to rosuvastatin. Avoid or adjust dose. **Severe**
- HIV-protease inhibitors (indinavir) are predicted to increase the exposure to simvastatin. Use with caution and adjust simvastatin dose, p. 198. **Severe** Study
- Idelalisib is predicted to increase the exposure to atorvastatin. Avoid or adjust dose and monitor rhabdomyolysis. **Severe** Study
- Idelalisib is predicted to increase the exposure to simvastatin. Avoid. **Severe** Study
- Lomitapide increases the exposure to atorvastatin. Adjust lomitapide dose or separate administration by 12 hours. **Mild** Study → Also see TABLE 1 p. 1264
- Lomitapide increases the exposure to simvastatin. Monitor and adjust simvastatin dose, p. 198. **Moderate** Study → Also see TABLE 1 p. 1264
- Macrolides (clarithromycin) are predicted to increase the exposure to atorvastatin. Avoid or adjust dose and monitor rhabdomyolysis. **Severe** Study
- Macrolides (clarithromycin) moderately increase the exposure to pravastatin. **Severe** Study
- Macrolides (erythromycin) are predicted to increase the exposure to simvastatin. Avoid. **Severe** Study
- Macrolides (erythromycin) are predicted to increase the exposure to pravastatin. **Severe** Study
- Macrolides (erythromycin) are predicted to increase the exposure to simvastatin. Use with caution and adjust simvastatin dose, p. 198. **Severe** Study
- Monoclonal antibodies (tocilizumab) are predicted to decrease the exposure to atorvastatin. Monitor and adjust dose. **Moderate** Theoretical
- Monoclonal antibodies (tocilizumab) moderately decrease the exposure to simvastatin. Monitor and adjust dose. **Moderate** Study
- Netupitant is predicted to increase the exposure to atorvastatin. Monitor and adjust dose. **Severe** Theoretical
- Netupitant is predicted to increase the exposure to simvastatin. Use with caution and adjust simvastatin dose, p. 198. **Severe** Study
- Nevirapine slightly decreases the exposure to atorvastatin. **Mild** Study
- Nevirapine moderately decreases the exposure to simvastatin. **Moderate** Study
- Paritaprevir (with ritonavir and ombitasvir) is predicted to increase the exposure to pravastatin. Adjust pravastatin dose, p. 197. **Moderate** Study
- Paritaprevir (with ritonavir and ombitasvir) increases the exposure to rosuvastatin. Adjust rosuvastatin dose, p. 197. **Moderate** Study
- Rosuvastatin is predicted to increase the anticoagulant effect of phenindione. Monitor INR and adjust dose. **Severe** Theoretical
- Ranolazine is predicted to increase the exposure to atorvastatin. **Moderate** Theoretical
- Ranolazine slightly increases the exposure to simvastatin. Adjust simvastatin dose, p. 198. **Moderate** Study
- Regorafenib is predicted to increase the exposure to statins (atorvastatin, fluvastatin, rosuvastatin). **Severe** Theoretical
- Rifampicin markedly decreases the exposure to atorvastatin. Atorvastatin should be taken at the same time as rifampicin. **Moderate** Study
- Rifampicin moderately decreases the exposure to fluvastatin. Monitor and adjust dose. **Moderate** Study
- Rifampicin very markedly decreases the exposure to simvastatin. **Moderate** Study
- Simeprevir moderately increases the exposure to atorvastatin. Monitor and adjust dose. **Moderate** Study
- Simeprevir is predicted to increase the exposure to pravastatin. Monitor and adjust dose. **Severe** Theoretical
- Simvastatin decreases the exposure to statins. **Mild** Study
- Simvastatin is predicted to increase the exposure to pravastatin. **Moderate** Study
- Simvastatin is predicted to increase the exposure to rosuvastatin. **Moderate** Study
- Simeprevir slightly increases the exposure to simvastatin. Monitor and adjust dose. **Moderate** Study
- ST John’s Wort slightly decreases the exposure to atorvastatin. **Mild** Study
- ST John’s Wort moderately decreases the exposure to simvastatin. **Moderate** Study
- Sulfinpyrazone is predicted to increase the exposure to fluvastatin. **Severe** Theoretical
- Fluvastatin slightly increases the exposure to sulfonylureas (glibenclamide). **Mild** Study
- Tedizolid is predicted to increase the exposure to rosvastatin. Avoid. **Moderate** Theoretical
- Teriflunomide moderately increases the exposure to rosvastatin. Adjust rosvastatin dose, p. 197. **Moderate** Study
- Tigracorol slightly increases the exposure to simvastatin. Adjust simvastatin dose, p. 198. **Moderate** Study
- Velpatasvir increases the exposure to rosuvastatin. Adjust rosuvastatin dose and monitor side effects, p. 197. **Severe** Study
- Velpatasvir is predicted to increase the exposure to statins (atorvastatin, simvastatin). Monitor side effects and adjust dose. **Severe** Theoretical
- Statin interactions see TABLE 12 p. 1267
- Didanosine increases the risk of toxicity when given with stavudine. Avoid. **Severe** Study → Also see TABLE 12 p. 1267
- Hydroxypropamide increases the risk of toxicity when given with stavudine. Avoid. **Severe** Study
- Isoniazid is predicted to increase the risk of peripheral neuropathy when given with stavudine. **Severe** Theoretical → Also see TABLE 12 p. 1267
- Ribavirin increases the risk of toxicity when given with stavudine. Avoid. **Severe** Study
- Stavudine is predicted to decrease the efficacy of stavudine. Avoid. **Severe** Theoretical
- Stavudine → see TABLE 12 p. 1267 (peripheral neuropathy)
- Didanosine increases the risk of toxicity when given with stavudine. Avoid. **Severe** Study → Also see TABLE 12 p. 1267
- Hydroxypropamide increases the risk of toxicity when given with stavudine. Avoid. **Severe** Study
- Isoniazid is predicted to increase the risk of peripheral neuropathy when given with stavudine. **Severe** Theoretical → Also see TABLE 12 p. 1267
- Ribavirin increases the risk of toxicity when given with stavudine. Avoid. **Severe** Study
- Stavudine is predicted to decrease the efficacy of stavudine. Avoid. **Severe** Theoretical
- Stavudine → see antiepileptics
- Streptokinase → see TABLE 3 p. 1264 (anticoagulant effects)
- Streptokinase → see aminoglycosides
- Strontium ranelate → see TABLE 5 p. 1264 (thromboembolism)
- Antacids decrease the absorption of strontium ranelate. Separate administration by 2 hours. **Moderate** Study
- Oral calcium salts decrease the absorption of strontium ranelate. Separate administration by 2 hours. **Moderate** Study
- Strontium ranelate is predicted to decrease the absorption of quinolones. Avoid. **Moderate** Theoretical
- Strontium ranelate is predicted to decrease the absorption of tetracyclines. Avoid. **Moderate** Theoretical
Sucralfate
- Sucralfate potentially decreases the effects of coumarins (warfarin). Separate administration by 2 hours. [Moderate] Anecdotal
- Sucralfate decreases the absorption of digoxin. Separate administration by 2 hours. [Severe] Anecdotal
- Sucralfate decreases the absorption of dolutegravir. [Moderate] Study
- Sucralfate increases the risk of blocked enteral or nasogastric tubes when given with enteral feeds. Separate administration by 1 hour. [Moderate] Study
- Sucralfate decreases the absorption of levothyroxine. Separate administration by at least 4 hours. [Moderate] Study
- Potassium citrate increases the risk of side-effects when given with sucralfate. Avoid. [Moderate] Theoretical
- Sucralfate decreases the exposure to quinolones. Separate administration by 2 hours. [Moderate] Study
- Sodium citrate is predicted to increase the risk of side-effects when given with sucralfate. Avoid. [Moderate] Theoretical
- Sucralfate decreases the absorption of sulphasalazine. Separate administration by 2 hours. [Moderate] Study
- Sucralfate potentially decreases the absorption of theophylline. Separate administration by at least 2 hours. [Moderate] Study
- Sucralfate is predicted to decrease the absorption of tricyclic antidepressants. [Moderate] Study

Sufentanil
- Sufentanil is predicted to decrease the absorption of oral combined hormonal contraceptives. Refer to patient information leaflet for missed pill advice. [Severe] Theoretical
- Sufentanil is predicted to decrease the exposure to desogestrel. Refer to patient information leaflet for missed pill advice. [Severe] Theoretical
- Sufentanil is predicted to decrease the efficacy of etonogestrel. Use additional contraceptive precautions. [Severe] Theoretical
- Sufentanil is predicted to decrease the exposure to levonorgestrel. Use additional contraceptive precautions. [Severe] Theoretical
- Sufentanil is predicted to decrease the exposure to medroxyprogesterone. Use additional contraceptive precautions. [Severe] Theoretical
- Sufentanil is predicted to decrease the exposure to norethisterone. Use additional contraceptive precautions. [Severe] Theoretical

Sulfinpyrazone
- Sulfinpyrazone is predicted to increase the exposure to retinoids (alitretinoin). Adjust alitretinoin dose, p. 1157. [Moderate] Theoretical
- Sulfinpyrazone is predicted to increase the exposure to statins (fluvastatin). [Severe] Theoretical
- Sulfinpyrazone is predicted to increase the exposure to sulfonlureas. Use with caution and adjust dose. [Moderate] Study

Sulfonamides
- See table 15 p. 1267 (myelosuppression) co-trimoxazole - sulfaadoxine
- Sulfonamides potentially increase the risk of methaemoglobinemia when given with topical anaesthetics, local (prilocaine). Use with caution or avoid. [Severe] Anecdotal
- Sulfinpyrazone is predicted to increase the concentration of antiepileptics (fosphenytoin). Monitor and adjust dose. [Moderate] Study
- Sulfinpyrazone increases the concentration of antiepileptics (phenytoin). Monitor and adjust dose. [Moderate] Study
- Antimalarials (pyrimethamine) increase the risk of side-effects when given with sulfonamides. [Severe] Study  Also see table 15 p. 1267
- Sulfinpyrazone is predicted to increase the anticoagulant effect of coumarins. [Severe] Theoretical
- Sulfinpyrazone are predicted to increase the risk of methaemoglobinemia when given with dapsone. [Severe] Theoretical
- Sulfinpyrazone are predicted to increase the exposure to methotrexate. Use with caution or avoid. [Severe] Theoretical  Also see table 15 p. 1267
- Sulfinpyrazone are predicted to increase the exposure to sulfonlureas. [Moderate] Study
- Sulfinpyrazone are predicted to increase the effects of thiopental. [Moderate] Theoretical

Sulfonylureas
- See table 14 p. 1267 (antidiabetic drugs) glibenclamide - gliclazide - glimepiride - glipizide - tolbutamide
- Antiarrhythmics (amiodarone) are predicted to increase the exposure to sulfonylureas. Use with caution and adjust dose. [Moderate] Study
- Antifungals, azoles (fluconazole, miconazole, voriconazole) are predicted to increase the exposure to sulfonylureas. Use with caution and adjust dose. [Moderate] Study
- Bosentan increases the risk of hepatotoxicity when given with glibenclamide. Avoid. [Severe] Study
- Cephalosporins (cefotibiprole) are predicted to increase the concentration of glibenclamide. [Moderate] Theoretical
- Ceritinib is predicted to increase the exposure to glimepiride. Adjust dose. [Moderate] Theoretical
- Chloramphenicol is predicted to increase the exposure to sulfonylureas. [Severe] Study
- Fibrates are predicted to increase the risk of hypoglycaemia when given with sulfonylureas. [Moderate] Theoretical
- Macrolides (clarithromycin) are predicted to slightly increase the exposure to sulfonylureas. [Moderate] Theoretical
- Rifampicin is predicted to decrease the exposure to sulfonylureas. [Moderate] Study
- Statins (fluvastatin) slightly increase the exposure to glibenclamide. [Mild] Study
- Sulfinpyrazone is predicted to increase the exposure to sulfonylureas. Use with caution and adjust dose. [Moderate] Study
- Sulfinpyrazone are predicted to increase the exposure to sulfonylureas. [Moderate] Study
- Sulfinpyrazone are predicted to increase the exposure to sulfonlureas. [Moderate] Study

Sulindac  See NSAIDs
Sulpiride
- See table 8 p. 1265 (hypotension), table 9 p. 1266 (QT-interval prolongation), table 11 p. 1266 (CNS depressant effects)
- Sulpiride is predicted to decrease the effects of dopamine receptor agonists. Avoid. [Moderate] Theoretical  Also see table 8 p. 1265 Also see table 9 p. 1266
- Sulpiride is predicted to decrease the effects of levodopa. Avoid. [Severe] Theoretical  Also see table 8 p. 1265
- Sulpiride potentially increases the risk of neurotoxicity when given with lithium. [Severe] Anecdotal  Also see table 9 p. 1266
- Sucralfate decreases the absorption of sulpiride. Separate administration by 2 hours. [Moderate] Study

Sugammadex
- Sugammadex decreases the concentration of folic acid. [Moderate] Study
- Sugammadex increases the anticoagulant effect of coumarins. [Severe] Study

Sulphasalazine
- See table 1 p. 1264 (hepatotoxicity), table 15 p. 1267 (myelosuppression)
- Sulphasalazine decreases the concentration of digoxin. [Moderate] Study
- Sulphasalazine decreases the absorption of folates (folic acid). [Moderate] Study
- Sulphasalazine is predicted to decrease the absorption of folates (folic acid). [Moderate] Theoretical
- Tedizolid is predicted to increase the exposure to sulphasalazine. Avoid. [Moderate] Theoretical
- Sulfinpyrazone is predicted to increase the concentration of antiepileptics (fosphenytoin, phenytoin). [Moderate] Study
- Aspirin decreases the effects of sulfinpyrazone. [Moderate] Study Also see table 4 p. 1264
- Sulfinpyrazone decreases the exposure to calcium channel blockers (verapamil). [Moderate] Study
- Sulfinpyrazone decreases the concentration of ciclosporin. [Severe] Study
- Sulfinpyrazone increases the anticoagulant effect of coumarins. Avoid. [Severe] Study
- Sulfinpyrazone slightly increases the exposure to nateglinide. [Mild] Study
- Pyrazinamide is predicted to decrease the effects of sulfinpyrazone. [Moderate] Theoretical

Sulphate - Sulpiride 1405
Sumatriptan  ▶ see TABLE 13 p. 1267 (serotonin syndrome)
  ▶ Sumatriptan increases the risk of vasovagal event which can occur with ergotamine. Ergotamine should be taken at least 24 hours before or 6 hours after sumatriptan. Severe  Study  Also see TABLE 13 p. 1267
  ▶ Moclobemide moderately increases the exposure to sumatriptan. Avoid. Moderate  Study  Also see TABLE 13 p. 1267
  ▶ Monoamine-oxidase A and B inhibitors, irreversible are predicted to increase the exposure to sumatriptan. Avoid and for 14 days after stopping the MAOI. Severe  Theoretical  Also see TABLE 13 p. 1267
Sunitinib  ▶ see TABLE 15 p. 1267 (myelosuppression), TABLE 9 p. 1266 (QT-interval prolongation)
  ▶ Antiarrhythmics (dronedarone) are predicted to increase the exposure to sunitinib. Moderate  Theoretical  Also see TABLE 9 p. 1266
  ▶ Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to sunitinib. Avoid or adjust sunitinib dose, p. 914. Moderate  Study
  ▶ Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to sunitinib. Moderate  Theoretical
  ▶ Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to slightly increase the exposure to sunitinib. Avoid or adjust sunitinib dose, p. 914. Moderate  Study  Also see TABLE 9 p. 1266
  ▶ Aprepitant is predicted to increase the exposure to sunitinib. Moderate  Theoretical
  ▶ Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to sunitinib. Moderate  Theoretical
  ▶ Cobicistat is predicted to slightly increase the exposure to sunitinib. Avoid or adjust sunitinib dose, p. 914. Moderate  Study  Also see TABLE 9 p. 1266
  ▶ Sunitinib is predicted to increase the risk of bleeding events when given with coumarins. Severe  Theoretical
  ▶ Crizotinib is predicted to increase the exposure to sunitinib. Moderate  Theoretical  Also see TABLE 15 p. 1267  Also see TABLE 9 p. 1266
  ▶ Enzalutamide is predicted to decrease the exposure to sunitinib. Avoid or adjust sunitinib dose, p. 914. Moderate  Study
  ▶ Grapefruit juice is predicted to increase the exposure to sunitinib. Avoid. Moderate  Theoretical
  ▶ HIV- protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to slightly increase the exposure to sunitinib. Avoid or adjust sunitinib dose, p. 914. Moderate  Study  Also see TABLE 9 p. 1266
  ▶ HIV- protease inhibitors (indinavir) are predicted to increase the exposure to sunitinib. Moderate  Theoretical
  ▶ Idelalisib is predicted to slightly increase the exposure to sunitinib. Avoid or adjust sunitinib dose, p. 914. Moderate  Study  Also see TABLE 15 p. 1267
  ▶ Imatinib is predicted to increase the exposure to sunitinib. Moderate  Theoretical  Also see TABLE 15 p. 1267
  ▶ Macrolides (clarithromycin) are predicted to slightly increase the exposure to sunitinib. Avoid or adjust sunitinib dose, p. 914. Moderate  Study  Also see TABLE 9 p. 1266
  ▶ Macrolides (erythromycin) are predicted to increase the exposure to sunitinib. Moderate  Theoretical
  ▶ Netupitant is predicted to increase the exposure to sunitinib. Moderate  Theoretical
  ▶ Nilotinib is predicted to increase the exposure to sunitinib. Moderate  Theoretical  Also see TABLE 15 p. 1267  Also see TABLE 9 p. 1266
  ▶ Sunitinib is predicted to increase the risk of bleeding events when given with phenindione. Severe  Theoretical
  ▶ Rifampicin is predicted to decrease the exposure to sunitinib. Avoid or adjust sunitinib dose, p. 914. Moderate  Study
Suxamethonium  ▶ see TABLE 20 p. 1268 (neuromuscular blocking effects)
  ▶ Alkylating agents (cyclophosphamide) increase the risk of prolonged neuromuscular blockade when given with suxamethonium. Moderate  Study
  ▶ Aminoglycosides are predicted to increase the risk of prolonged neuromuscular blockade when given with suxamethonium. Severe  Theoretical  Also see TABLE 20 p. 1268
  ▶ Antiarhythmic effects (lidocaine) are predicted to increase the effects of suxamethonium. Moderate  Study
  ▶ Anticholinesterases, centrally acting increase the effects of suxamethonium. Moderate  Theoretical
  ▶ Antiepileptics (carbamazepine) increase the risk of prolonged neuromuscular blockade when given with suxamethonium. Moderate  Study
  ▶ Antiepileptics (fosphenytoin, phenytoin) increase the effects of suxamethonium. Moderate  Study
  ▶ Clindamycin increases the effects of suxamethonium. Severe  Anecdotal
  ▶ Colistimethate increases the effects of suxamethonium. Monitor and adjust dose. Moderate  Study  Also see TABLE 20 p. 1268
  ▶ Corticosteroids are predicted to decrease the effects of suxamethonium. Severe  Anecdotal
  ▶ Suxamethonium is predicted to increase the risk of cardiovascular side-effects when given with digoxin. Severe  Anecdotal
  ▶ Irinotecan is predicted to increase the risk of prolonged neuromuscular blockade when given with suxamethonium. Moderate  Theoretical
  ▶ Intravenous magnesium is predicted to increase the effects of suxamethonium. Moderate  Study
  ▶ Metoclopromide increases the effects of suxamethonium. Moderate  Study
  ▶ Penicillins (piperaclillin) increase the effects of suxamethonium. Moderate  Study
  ▶ SSRI: potentially increase the risk of prolonged neuromuscular blockade when given with suxamethonium. Unknown  Theoretical

### Sympathomimetics, inotropic

- Dobutamine - dopamine - doxepamine
  - Sympathomimetics, inotropic are predicted to increase the effects of apraclonidine. Avoid. Severe  Theoretical
  - Beta blockers, non-selective increase the risk of hypertension and bradycardia when given with dobutamine. Severe  Theoretical
  - Beta blockers, selective increase the risk of hypertension and bradycardia when given with dobutamine. Moderate  Theoretical
  - Entacapone is predicted to increase the risk of cardiovascular side-effects when given with sympathomimetics, inotropic (dobutamine, dopamine). Moderate  Theoretical
  - Ergotamine potentially increases the risk of peripheral vasosconstriction when given with dopamine. Avoid. Severe  Anecdotal
  - Guanethidine is predicted to increase the effects of dopamine. Severe  Theoretical
  - Sympathomimetics, inotropic (dobutamine, dopamine) are predicted to increase the risk of elevated blood pressure when given with linezolid. Avoid. Severe  Theoretical
  - Monoamine-oxidase A and B inhibitors, irreversible are predicted to increase the risk of a hypertensive crisis when given with sympathomimetics, inotropic. Avoid and for 14 days after stopping the MAOI. Severe  Theoretical
  - Monoamine-oxidase B inhibitors are predicted to increase the risk of a hypertensive crisis when given with sympathomimetics, inotropic. Avoid. Severe  Anecdotal
  - Opicapone is predicted to increase the risk of cardiovascular side-effects when given with sympathomimetics, inotropic (dobutamine, dopamine). Severe  Theoretical
  - Tolcapone is predicted to increase the risk of cardiovascular side-effects when given with sympathomimetics, inotropic (dobutamine, dopamine). Moderate  Theoretical

### Sympathomimetics, vasoconstrictor

- Adrenaline - ephedrine - epinephrine - isomethepeine - metaraminol - midodrine - noradrenaline/norepinephrine - phenylephrine - pseudoephedrine - xylometazoline

**ROUTE-SPECIFIC INFORMATION**  Since systemic absorption can follow topical application, the possibility of interactions should be borne in mind.
Sympathomimetics, vasoconstrictor ↔ Tacrolimus

- Sympathomimetics, vasoconstrictor are predicted to decrease the effects of apraclonidine. Avoid. [Severe] Theoretical
- Atropine increases the risk of severe hypertension when given with phenylephrine. [Severe] Study
- Beta blockers, non-selective are predicted to increase the risk of hypertension and bradycardia when given with sympathomimetics, vasoconstrictor (adrenaline/epinephrine, noradrenaline/norepinephrine). [Severe] Study
- Beta blockers, selective are predicted to increase the risk of hypertension and bradycardia when given with sympathomimetics, vasoconstrictor (adrenaline/epinephrine, noradrenaline/norepinephrine). [Severe] Study
- Entacapone is predicted to increase the risk of cardiovascular side-effects when given with sympathomimetics, vasoconstrictor (adrenaline/epinephrine, noradrenaline/norepinephrine). [Moderate] Study
- Ergometrine is predicted to increase the risk of peripheral vasocostriction when given with noradrenaline/norepinephrine. [Severe] Anecdotal
- Guanethidine increases the effects of metaraminol. [Severe] Anecdotal
- Guanethidine increases the effects of phenylephrine. [Severe] Study
- Guanethidine is predicted to increase the effects of sympathomimetics, vasoconstrictor (adrenaline/epinephrine, noradrenaline/norepinephrine). [Moderate] Study
- Pseudoephedrine increases the risk of elevated blood pressure when given with linezolid. Avoid. [Severe] Study
- Sympathomimetics, vasoconstrictor (adrenaline/epinephrine, ephedrine, isomethepene, noradrenaline/norepinephrine, phenylephrine) are predicted to increase the risk of elevated blood pressure when given with linezolid. Avoid. [Severe] Theoretical
- Mianserin decreases the effects of ephedrine. [Severe] Anecdotal
- Moclubemide is predicted to increase the risk of a hypertensive crisis when given with sympathomimetics, vasoconstrictor (ephedrine, isomethepene, phenylephrine, pseudoephedrine). Avoid. [Severe] Study
- Monoamine-oxidase A and B inhibitors, irreversible are predicted to increase the risk of a hypertensive crisis when given with sympathomimetics, vasoconstrictor. Avoid and for 14 days after stopping the MAOI. [Severe] Study
- Monoamine-oxidase B inhibitors are predicted to increase the risk of a hypertensive crisis when given with sympathomimetics, vasoconstrictor (adrenaline/epinephrine, noradrenaline/norepinephrine). [Severe] Anecdotal
- Opicapone is predicted to increase the risk of cardiovascular side-effects when given with sympathomimetics, vasoconstrictor (adrenaline/epinephrine, noradrenaline/norepinephrine). [Severe] Theoretical
- Ephedrine increases the risk of side-effects when given with theophylline. Avoid in children. [Moderate] Study
- Tolcapone is predicted to increase the effects of sympathomimetics, vasoconstrictor (adrenaline/epinephrine, noradrenaline/norepinephrine). [Moderate] Theoretical
- Tricyclic antidepressants are predicted to decrease the effects of ephedrine. Avoid. [Severe] Study
- Tricyclic antidepressants increase the effects of sympathomimetics, vasoconstrictor (adrenaline/epinephrine, noradrenaline/norepinephrine, phenylephrine). Avoid. [Severe] Study
- Tacalcitol → see vitamin D substances
- Tacrolimus → see TABLE 2 p. 1264 (nephrotoxicity), TABLE 16 p. 1268 (increased serum potassium)
  - Risk of facial flushing and skin irritation with alcohol consumption in those using topical tacrolimus (does not apply to tacrolimus taken systemically). Pomelo might greatly increase the concentration of tacrolimus.
  - Since systemic absorption can follow topical application, the possibility of interactions should be borne in mind.
- Antihistamines (amiodarone) are predicted to increase the concentration of tacrolimus. [Severe] Anecdotal
- Antihistamines (dronedarone) are predicted to increase the concentration of tacrolimus. [Severe] Study
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) decrease the concentration of tacrolimus. Monitor and adjust dose. [Severe] Study
- Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the concentration of tacrolimus. [Severe] Study
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the concentration of tacrolimus. Monitor and adjust dose. [Severe] Study
- Antifungals, azoles (miconazole) are predicted to increase the concentration of tacrolimus. Monitor and adjust dose. [Severe] Study
- Theoretical
- Aprepitant is predicted to increase the concentration of tacrolimus. [Severe] Study
- Bosentan is predicted to decrease the concentration of tacrolimus and tacrolimus potentially increases the concentration of bosentan. Avoid. [Severe] Theoretical
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the concentration of tacrolimus. [Severe] Study
- Calcium channel blockers (nicardipine) potentially increase the concentration of tacrolimus. Monitor concentration and adjust dose. [Severe] Anecdotal
- Certitinib is predicted to increase the exposure to tacrolimus. Avoid. [Severe] Theoretical
- Chloramphenicol increases the concentration of tacrolimus. [Severe] Study
- Ciclosporin increases the concentration of tacrolimus. Avoid. [Severe] Study → Also see TABLE 2 p. 1264 → Also see TABLE 16 p. 1268
- Cobicistat is predicted to increase the concentration of tacrolimus. Monitor and adjust dose. [Severe] Study
- Crizotinib is predicted to increase the concentration of tacrolimus. [Severe] Study
- Danazol potentially increases the concentration of tacrolimus. [Severe] Anecdotal
- Efavirenz is predicted to decrease the concentration of tacrolimus. Monitor and adjust dose. [Moderate] Theoretical
- Enzalutamide decreases the concentration of tacrolimus. Monitor and adjust dose. [Severe] Study
- Grapefruit juice increases the concentration of tacrolimus. Avoid. [Severe] Study
- Grazoprevir increases the exposure to tacrolimus. [Moderate] Study
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the concentration of tacrolimus. Monitor and adjust dose. [Severe] Study
- HIV-protease inhibitors (indinavir) are predicted to increase the concentration of tacrolimus. [Severe] Study
- Idelalisib is predicted to increase the concentration of tacrolimus. Monitor and adjust dose. [Severe] Study
- Imatinib is predicted to increase the concentration of tacrolimus. [Severe] Study
- Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with tacrolimus. Public Health England advises avoid. [Severe] Theoretical
- Tacrolimus is predicted to increase the exposure to lomitapide. Separate administration by 12 hours. [Moderate] Theoretical
- Lumacaftor is predicted to decrease the exposure to tacrolimus. Avoid. [Severe] Theoretical
- Macrolides (clarithromycin) are predicted to increase the concentration of tacrolimus. Monitor and adjust dose. [Severe] Study
- Macrolides (erythromycin) are predicted to increase the concentration of tacrolimus. [Severe] Study
- Tacrolimus is predicted to affect the efficacy of mifamurtide. Avoid. [Severe] Theoretical
- Netupitant is predicted to increase the concentration of tacrolimus. [Severe] Study
- Nevirapine is predicted to decrease the concentration of tacrolimus. Monitor and adjust dose. [Moderate] Theoretical
- Nilotinib is predicted to increase the concentration of tacrolimus. [Severe] Study
- Palbociclib is predicted to increase the exposure to tacrolimus. Adjust dose. [Moderate] Theoretical

Downloaded from www.medicalbr.com
Tacrolimus (continued)

- **Pitolisant** is predicted to decrease the exposure to tacrolimus. Avoid. [Severe] Theoretical
- **Ranolazine** increases the concentration of tacrolimus. Adjust dose. [Severe] Anecdotal
- **Rifampicin** decreases the concentration of tacrolimus. Monitor and adjust dose. [Severe] study
- **Sirolimus** is predicted to decrease the concentration of tacrolimus and tacrolimus increases the exposure to sirolimus. [Severe] Study
- **St John’s Wort** decreases the concentration of tacrolimus. Avoid. [Severe] Study
- **Tacrolimus** potentially increases the risk of serotonin syndrome when given with *venlafaxine*. [Severe] Anecdotal

**Tamoxifen**

- **Bupropion** is predicted to decrease the efficacy of tamoxifen. Avoid. [Severe] Study
- **Cinacalcet** is predicted to decrease the efficacy of tamoxifen. Avoid. [Severe] Study
- **Terbinafine** is predicted to decrease the efficacy of tamoxifen. Avoid. [Severe] Study
- **Antifungals, azoles** are predicted to decrease the concentration of tamoxifen. [Unknown] Study
- **Rifampicin** is predicted to decrease the efficacy of tamoxifen. [Severe] Study
- **Antiepileptics** are predicted to decrease the exposure to taxanes (cabazitaxel, paclitaxel). Avoid. [Severe] Study
- **Tamsulosin** is predicted to decrease the efficacy of tamoxifen. [Severe] Study
- **Tamsulosin** is predicted to decrease the efficacy of tamoxifen. [Severe] Study
- **Taxanes** are predicted to decrease the exposure to taxanes (cabazitaxel, paclitaxel). [Severe] Study
- **Tapiental** is predicted to decrease the efficacy of tamoxifen. [Severe] Study
- **Caution.** Food and lifestyle factors and co-administered drugs may influence the concentration of tamoxifen. Avoid any similar meat or yeast extract or fermented mature cheese, salami, pickled herring, Bovril. See Food and lifestyle.

- **Antithrombotics**
  - **Droxtia** is predicted to decrease the exposure to taxanes (cabazitaxel, paclitaxel). Avoid. [Moderate] Theoretical
  - **Enoxaparin** is predicted to moderate increase the exposure to taxanes (cabazitaxel, paclitaxel). Avoid. [Moderate] Theoretical
  - **Fabrazyme** is predicted to increase the exposure to taxanes (cabazitaxel, paclitaxel). Avoid. [Moderate] Theoretical
  - **Naproxen** is predicted to moderate increase the exposure to taxanes (cabazitaxel, paclitaxel). Avoid. [Moderate] Theoretical
  - **Pentoxifylline** is predicted to decrease the exposure to taxanes (cabazitaxel, paclitaxel). Avoid. [Moderate] Theoretical
  - **St John’s Wort** decreases the concentration of taxanes (cabazitaxel, paclitaxel). Avoid. [Severe] Study

**Antithrombotics**

- **Droxtia** is predicted to decrease the exposure to taxanes (cabazitaxel, paclitaxel). Avoid. [Moderate] Theoretical
- **Enoxaparin** is predicted to moderate increase the exposure to taxanes (cabazitaxel, paclitaxel). Avoid. [Moderate] Theoretical
- **Fabrazyme** is predicted to increase the exposure to taxanes (cabazitaxel, paclitaxel). Avoid. [Moderate] Theoretical
- **Naproxen** is predicted to moderate increase the exposure to taxanes (cabazitaxel, paclitaxel). Avoid. [Moderate] Theoretical
- **Pentoxifylline** is predicted to decrease the exposure to taxanes (cabazitaxel, paclitaxel). Avoid. [Moderate] Theoretical
- **St John’s Wort** decreases the concentration of taxanes (cabazitaxel, paclitaxel). Avoid. [Severe] Study

**Antithrombotics**
Moclobemide is predicted to increase the risk of side-effects when given with tedizolid. [Severe] Theoretical → Also see TABLE 13 p. 1267

Monoamine-oxidase A and B inhibitors, irreversible are predicted to increase the risk of side-effects when given with tedizolid. [Severe] Theoretical → Also see TABLE 13 p. 1267

Monoamine-oxidase B inhibitors (rasagline, selegiline) are predicted to increase the risk of side-effects when given with tedizolid. [Severe] Theoretical → Also see TABLE 13 p. 1267

Monoamine-oxidase B inhibitors (safinamide) are predicted to increase the risk of side-effects when given with tedizolid. [Severe] Theoretical → Also see TABLE 13 p. 1267

Tedizolid is predicted to increase the exposure to statins (Rosuvastatin). Avoid. [Moderate] Theoretical

Tedizolid is predicted to increase the exposure to sulfasalazine. Avoid. [Moderate] Theoretical

Tedizolid is predicted to increase the exposure to topotecan. Avoid. [Moderate] Theoretical

Tegafur

Tegafur potentially increases the concentration of antiepileptics (fosphenytoin, phenytoin). Monitor concentration and adjust dose. [Severe] Anecdotal

Tegafur increases the anticoagulant effect of coumarins. [Moderate] Theoretical

Folates (folic acid, folinic acid) are predicted to increase the risk of tegafur toxicity when given with tegafur. [Severe] Theoretical

H₂ receptor antagonists (cimetidine) are predicted to increase the risk of toxicity when given with tegafur. [Severe] Theoretical

Live vaccines are predicted to increase the risk of generalisation infection (possibly life-threatening) when given with tegafur. Public Health England advises avoid. [Severe] Theoretical

Methotrexate is predicted to increase the risk of toxicity when given with tegafur. [Severe] Theoretical

Teicoplanin

GENERAL INFORMATION If other nephrotoxic or neurotoxic drugs are given, monitor renal and auditory function on prolonged administration.

Telavancin → see TABLE 2 p. 1264 (nephrotoxicity), TABLE 19 p. 1268 (ototoxicity), TABLE 9 p. 1266 (QT-interval prolongation)

Telavancin is predicted to increase the risk of ototoxicity when given with aminoglycosides. [Moderate] Theoretical → Also see TABLE 2 p. 1264 → Also see TABLE 19 p. 1268

Telbivudine

Interferon (interferon alfa) are predicted to increase the risk of peripheral neuropathy when given with telbivudine. Avoid. [Severe] Theoretical

Interferons (peginterferon alfa) increase the risk of peripheral neuropathy when given with telbivudine. Avoid. [Severe] Study

Telmisartan → see angiotensin-II receptor antagonists

Temazepam → see TABLE 11 p. 1266 (CNS depressant effects)

Temocillin → see penicillins

Temozolomide → see alkylating agents

Temsirolimus → see TABLE 15 p. 1267 (myelosuppression)

Antiarrhythmics (dronedarone) are predicted to increase the concentration of temsirolimus. [Moderate] Theoretical

Antiarrhythmics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the concentration of temsirolimus. Avoid. [Severe] Study

Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the concentration of temsirolimus. [Moderate] Theoretical

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the concentration of temsirolimus. Avoid. [Severe] Theoretical

Aprepitant is predicted to increase the concentration of temsirolimus. [Moderate] Theoretical

Bosentan is predicted to decrease the concentration of temsirolimus. Avoid. [Severe] Theoretical

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the concentration of temsirolimus. [Moderate] Theoretical

Cobicistat is predicted to increase the concentration of temsirolimus. Avoid. [Severe] Theoretical

Crizotinib is predicted to increase the concentration of temsirolimus. [Moderate] Theoretical → Also see TABLE 15 p. 1267

Efavirenz is predicted to decrease the concentration of temsirolimus. Avoid. [Severe] Theoretical

Enzalutamide is predicted to decrease the concentration of temsirolimus. Avoid. [Severe] Study

Grapefruit juice is predicted to increase the concentration of temsirolimus. Use with caution or avoid. [Moderate] Theoretical

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the concentration of temsirolimus. Avoid. [Severe] Theoretical

HIV-protease inhibitors (indinavir) are predicted to increase the concentration of temsirolimus. [Moderate] Theoretical

Idelalisib is predicted to increase the concentration of temsirolimus. Avoid. [Severe] Theoretical → Also see TABLE 15 p. 1267

Imatinib is predicted to increase the concentration of temsirolimus. [Moderate] Theoretical → Also see TABLE 15 p. 1267

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with temsirolimus. Public Health England advises avoid. [Severe] Theoretical

St John’s Wort is predicted to decrease the concentration of temsirolimus. Avoid. [Severe] Theoretical

Temseplase → see TABLE 3 p. 1264 (anticoagulant effects)

Tenofovir → see TABLE 2 p. 1264 (nephrotoxicity)

Tenofovir increases the risk of toxicity when given with didanosine. Avoid. [Severe] Study

Ledipasvir (with sofosbuvir) slightly increases the exposure to tenofovir. [Moderate] Study

Tenofovir is predicted to increase the exposure to sacubitril. [Moderate] Theoretical

Velpatasvir increases the exposure to tenofovir. [Moderate] Study

Tenoxican → see NSAIDs

Terazosin → see alpha blockers

Terbinafine

ROUTE-SPECIFIC INFORMATION Since systemic absorption can follow topical application, the possibility of interactions should be borne in mind.

Terbinafine is predicted to increase the exposure to antiarrhythmics (flecainide). [Severe] Theoretical

Terbinafine is predicted to increase the exposure to antiarrhythmics (propafenone). Monitor and adjust dose. [Moderate] Study

Terbinafine is predicted to increase the exposure to anticholinesterases, centrally acting (donepezil). [Moderate] Theoretical

Terbinafine is predicted to increase the exposure to anticholinesterases, centrally acting (galantamine). Monitor and adjust dose. [Moderate] Theoretical

Terbinafine is predicted to moderately increase the exposure to aripiprazole. Adjust aripiprazole dose, p. 376. [Moderate] Study

Terbinafine is predicted to markedly increase the exposure to atomoxetine. Adjust dose. [Severe] Study

Terbinafine is predicted to increase the exposure to beta blockers, non-selective (carvedilol, timolol). [Moderate] Study

Terbinafine is predicted to increase the exposure to beta blockers, selective (metoprolol, nebivolol). [Moderate] Study
Terbinafine (continued)

- **Terbinafine** is predicted to slightly increase the exposure to **darafenib**. [Mild] Study
- **Terbinafine** is predicted to decrease the efficacy of **opioids (codeine)**. [Moderate] Theoretical
- **Terbinafine** is predicted to decrease the efficacy of **opioids (tramadol)**. [Severe] Study
- **Terbinafine** is predicted to moderately increase the exposure to **pitolisant**. Use with caution and adjust dose. [Moderate] Study
- **Rifampicin** decreases the exposure to **terbinafine**. Adjust dose. [Moderate] Study
- **Terbinafine** is predicted to increase the exposure to **risperidone**. Adjust dose. [Moderate] Study
- **Terbinafine** is predicted to increase the exposure to **SSRIs (citalopram, dапoxetine, escitalopram, fluoxetine, sertraline)**. [Moderate] Theoretical
- **Terbinafine** is predicted to increase the exposure to **SSRIs (fluoxetine)**. Adjust dose. [Moderate] Theoretical
- **Terbinafine** moderately increases the exposure to **SSRIs (paroxetine)**. [Moderate] Study
- **Terbinafine** is predicted to decrease the efficacy of **tamoxifen**. Avoid. [Severe] Study
- **Terbinafine** is predicted to increase the exposure to **tricyclic antidepressants**. Monitor for toxicity and adjust dose. [Severe] Study
- **Terbinafine** is predicted to increase the exposure to **vortioxetine**. Monitor and adjust dose. [Moderate] Study

Terbutaline → see beta agonists

**Teriflunomide**

- **Teriflunomide** affects the anticoagulant effect of **coumarins**. [Severe] Study
- **Live vaccines** are predicted to increase the risk of generalised infection (possibly life-threatening) when given with **teriflunomide**. Public Health England advises avoid. [Severe] Theoretical
- **Teriflunomide** increases the exposure to **repaglinide**. [Moderate] Study
- **Teriflunomide** moderately increases the exposure to **statins (rosuvastatin)**. Adjust **rosuvastatin** dose, p. 197. [Moderate] Study

*Tetrabenazine* → see TABLE 9 p. 1266 (QT-interval prolongation)

- **Tetrabenazine** is predicted to decrease the effects of **levodopa**. Use with caution or avoid. [Moderate] Theoretical
- **Tetrabenazine** is predicted to increase the risk of CNS toxicity when given with **monoamine-oxidase A and B inhibitors**, irreversible. Avoid and for 14 days after stopping the MAOI. [Severe] Theoretical

*Tetracaine* → see anaesthetics, local

**Tetracyclines** → see tetracyclines

- **demeclocycline**, **doxycycline**, **lymecycline**, **minocycline**, **oxytetracycline**, **tetracycline**, **tigecycline**
- **ACE inhibitors (quinapril)** (tablet) decrease the absorption of oral **tetracycline**. Avoid. [Moderate] Study
- **Antacids** decrease the absorption of **tetracyclines**. Separate administration by 2 to 3 hours. [Moderate] Study
- **Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone)** decrease the exposure to **doxycycline**. Monitor and adjust dose. [Moderate] Study → Also see TABLE 1 p. 1264
- **Tetracycline** decreases the concentration of **antimalarials (atovaquone)**. [Moderate] Study
- **Calcium salts (calcium carbonate)** are predicted to decrease the absorption of **tetracyclines**. Separate administration by 2 to 3 hours. [Moderate] Theoretical
- **Tetracyclines** increase the risk of bleeding events when given with **coumarins**. [Moderate] Anecdotal
- **Dairy products** decreases the exposure to tetracyclines. (demeclocycline, oxytetracycline, tetracycline). Avoid. [Moderate] Study
- **Enzalutamide** decreases the exposure to **doxycycline**. Monitor and adjust dose. [Moderate] Study
- **Iron (oral)** decreases the absorption of **tetracyclines**. Tetracyclines should be taken 2 to 3 hours after iron (oral). [Moderate] Study

- **Kaolin** is predicted to decrease the absorption of **tetracyclines**. [Moderate] Theoretical
- **Lanthanum** is predicted to decrease the absorption of **tetracyclines**. Separate administration by 2 hours. [Moderate] Theoretical
- **Retinoids (acitretin, allitretinoin, isotretinoin, tretinoin)** increase the risk of benign intracranial hypertension when given with **tetracyclines**. Avoid. [Severe] Anecdotal
- **Rifampicin** decreases the exposure to **doxycycline**. Monitor and adjust dose. [Moderate] Study
- **Strontium ranelate** is predicted to decrease the absorption of **tetracyclines**. Avoid. [Moderate] Theoretical
- **Oral zinc** is predicted to decrease the absorption of **tetracyclines**. Separate administration by 2 to 3 hours. [Moderate] Theoretical

**Thalidomide** → see TABLE 6 p. 1265 (bradycardia), TABLE 15 p. 1267 (myelosuppression), TABLE 12 p. 1267 (peripheral neuropathy), TABLE 5 p. 1264 (thromboembolism), TABLE 11 p. 1266 (CNS depressant effects)

- **Combined hormonal contraceptives** are predicted to increase the risk of venous thromboembolism when given with **thalidomide**. Avoid. [Severe] Study
- **Hormone replacement therapy** is predicted to increase the risk of venous thromboembolism when given with **thalidomide**. [Severe] Theoretical

**Theophylline** → see TABLE 17 p. 1268 (reduced serum potassium)

**FOOD AND LIFESTYLE** Smoking can increase **theophylline** clearance and increased doses of **theophylline** are therefore required; dose adjustments are likely to be necessary if smoking started or stopped during treatment.

- **Aclidirovir** is predicted to increase the exposure to **theophylline**. Monitor **theophylline** concentration and adjust dose. [Severe] Theoretical
- **Theophylline** decreases the efficacy of **antiarrhythmics (adenosine)**. Separate administration by 24 hours. [Mild] Study
- **Antiepileptics (carbamazepine)** potentially increase the clearance of **theophylline** and **theophylline** decreases the exposure to **antiepileptics (carbamazepine)**. Adjust dose. [Moderate] Anecdotal
- **Antiepileptics (fosphenytoin)** are predicted to increase the clearance of **theophylline**. Adjust dose. [Moderate] Study
- **Antiepileptics (phenobarbital, primidone)** are predicted to increase the clearance of **theophylline**. Adjust dose. [Moderate] Theoretical
- **Antiepileptics (phenytoin)** are predicted to decrease the exposure to **theophylline**. Adjust dose. [Moderate] Study
- **Beta blockers, non-selective** are predicted to increase the risk of bronchospasm when given with **theophylline**. Avoid. [Severe] Theoretical
- **Beta blockers, selective** are predicted to increase the risk of bronchospasm when given with **theophylline**. Avoid. [Severe] Theoretical
- **Caffeine citrate** decreases the clearance of **theophylline**. [Moderate] Study
- **Combined hormonal contraceptives** are predicted to increase the exposure to **theophylline**. Monitor and adjust dose. [Moderate] Theoretical
- **Theophylline** increases the risk of agitation when given with **antidepressants**. [Theoretical]
- **Theophylline** increases the risk of agitation when given with **monoamine-oxidase A and B inhibitors**, irreversible. Avoid. [Theoretical]
- **Theophylline** decreases the exposure to **theophylline**. [Theoretical]
- **Iron (oral)** decreases the absorption of **tetracyclines**. Tetracyclines should be taken 2 to 3 hours after iron (oral). [Moderate] Study
- **H2 receptor antagonists (cimetidin)** increase the concentration of **theophylline**. Adjust dose. [Severe] Study
- **HIV-protease inhibitors (ritonavir)** are predicted to decrease the exposure to **theophylline**. Adjust dose. [Moderate] Study
- **Interferon** slightly increase the exposure to **theophylline**. Adjust dose. [Moderate] Study
- **Iron chelators (deferasirox)** increase the exposure to **theophylline**. Avoid. [Moderate] Study
- **Isoniazid** is predicted to affect the clearance of **theophylline**. [Severe] Anecdotal
- **Theophylline** is predicted to decrease the concentration of **lithium**. [Moderate] Anecdotal
- **Theophylline** is predicted to decrease the absorption of **azithromycin, clarithromycin** are predicted to increase the exposure to **theophylline**. Adjust dose. [Moderate] Anecdotal
- **Theophylline** decreases the exposure to **theophylline**. [Theoretical]
Macrolides (erythromycin) decrease the clearance of theophylline and theophylline potentially decreases the clearance of macrolides (erythromycin). Adjust dose. **Severe** Study

**Methotrexate** decreases the clearance of theophylline. **Moderate** Study

Monoclonal antibodies (blinatumomab) are predicted to transiently increase the exposure to theophylline. Monitor and adjust dose. **Moderate** Theoretical

**Pentoxifylline** increases the concentration of theophylline. Monitor and adjust dose. **Severe** Study

Quinolones (ciprofloxacin) are predicted to increase the exposure to theophylline. Monitor and adjust dose. **Moderate** Theoretical

Quinolones (norfloxacin) are predicted to increase the exposure to theophylline. Adjust dose. **Moderate** Anecdotal

**Rifampicin** is predicted to decrease the exposure to theophylline. Adjust dose. **Moderate** Study

Theophylline is predicted to slightly increase the exposure to **rolflumilast**. Avoid. **Moderate** Theoretical

SSRIs (fluvoxamine) moderately to markedly increase the exposure to theophylline. Avoid. **Severe** Study

**St John’s Wort** potentially decreases the exposure to theophylline. **Severe** Anecdotal

Sucralfate potentially decreases the absorption of theophylline. Separate administration by at least 2 hours. **Moderate** Study

**Symptomimetics, vasoconstrictor (ephrine)** increase the risk of side-effects when given with theophylline. Avoid in children. **Moderate** Study

**Valaciclovir** is predicted to increase the exposure to theophylline. **Severe** Theoretical

Thiazide diuretics → see TABLE 18 p. 1268 (hyponatraemia), TABLE 8 p. 1265 (hypoosmolarity), TABLE 17 p. 1268 (reduced serum potassium)

- Bendroflumethiazide
- Chlorthalidone
- Clopamide
- Cyclopenthiazide
- Hydrochlorothiazide
- Hydroflumethiazide
- Indapamide
- Metolazone
- Xipamide

Thiazide diuretics are predicted to increase the risk of hypersensitivity reactions when given with allopurinol. **Severe** Theoretical

**Aspirin** (high-dose) increases the risk of acute renal failure when given with thiazide diuretics. **Severe** Theoretical

Thiazide diuretics increase the concentration of lithium. Avoid or adjust lithium (lithium carbonate, lithium citrate) dose and monitor lithium (lithium carbonate, lithium citrate) concentration. **Severe** Study

**NSAIDs** increase the risk of acute renal failure when given with thiazide diuretics. **Severe** Theoretical. Also see TABLE 18 p. 1268

**Reboxetine** is predicted to increase the risk of hyponatraemia when given with thiazide diuretics. **Moderate** Anecdotal

Thiazide diuretics are predicted to increase the risk of hypercalcaemia when given with calcium salts. **Severe** Anecdotal

**Ticagrelor** is predicted to markedly increase the exposure to ticagrelor. Avoid. **Severe** Study

**Tricyclic antidepressants** increase the risk of cardiac arrhythmias and hypotension when given with thioridazepine. **Severe** Theoretical

**Tricyclic antidepressants** increase the risk of atrioventricular block when given with tricyclic antidepressants. **Severe** Theoretical

Thiopental → see TABLE 8 p. 1265 (hypotension), TABLE 11 p. 1266 (CNS depressant effects)

Sulfonylureas are predicted to increase the effects of thioridazepine. **Moderate** Theoretical

**Tricyclic antidepressants** increase the risk of cardiac arrhythmias and hypotension when given with thioridazepine. **Severe** Moderate Study

Thioridazine → see also see TABLE 8 p. 1265

**Ticagrelor** is predicted to markedly increase the exposure to ticagrelor. Use with caution or avoid. **Severe** Study

Antiplatelet agents (Carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to markedly decrease the exposure to ticagrelor. Avoid. **Severe** Study

Antifungals, azaoles (itraconazole, ketoconazole, voriconazole) are predicted to markedly increase the exposure to ticagrelor. Avoid. **Severe** Study

**Bosentan** is predicted to decrease the exposure to ticagrelor. **Moderate** Theoretical

**Ciclosporin** is predicted to increase the exposure to ticagrelor. Use with caution or avoid. **Severe** Study

**Cobicistat** is predicted to markedly increase the exposure to ticagrelor. Avoid. **Severe** Study

**Ticagrelor** increases the concentration of digoxin. **Moderate** Study

**Elafirenz** is predicted to decrease the exposure to ticagrelor. **Moderate** Theoretical

Enzalutamide is predicted to markedly decrease the exposure to ticagrelor. Avoid. **Severe** Study

Grapefruit juice moderately increases the exposure to ticagrelor. **Moderate** Study

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to markedly increase the exposure to ticagrelor. Avoid. **Severe** Study

**Idelalisib** is predicted to markedly increase the exposure to ticagrelor. Avoid. **Severe** Study

**Ticagrelor** is predicted to increase the exposure to tolimipide. Separate administration by 12 hours. **Moderate** Theoretical

Macrolides (azithromycin) are predicted to increase the exposure to ticagrelor. Use with caution or avoid. **Severe** Study

**Ticagrelor** moderately increases the exposure to ticagrelor. Avoid. **Severe** Study

**Ticagrelor** increases the exposure to thioridazepine. Use with caution or avoid. **Severe** Study

**Ticagrelor** is predicted to increase the exposure to tolimipide. Separate administration by 12 hours. **Moderate** Theoretical

**Valproic acid** is predicted to increase the exposure to ticagrelor. Avoid. **Severe** Study

**Tizanidine** increases the exposure to theophylline when given with thrombolytics (alteplase, anistreplase, urokinase, tenecteplase). Use with caution or avoid. **Severe** Study

**Tioguanine** is predicted to increase the exposure to ticagrelor. Avoid. **Severe** Study

**Ticarcillin** see penicillins

**Timolol** see beta blockers, non-selective

**Tinidazole**

**FOOD AND LIFESTYLE** Disulfiram-like reaction is predicted to occur on the ingestion of alcohol. Ensure that alcohol is not consumed for 72 hours after stopping tinidazole.

**Tinidazole** is predicted to increase the anticoagulant effect of warfarin. **Moderate** Theoretical

**Tinzaparin** see low molecular-weight heparins

**Tioguanine** see TABLE 15 p. 1267 (myelosuppression)

**Live vaccines** are predicted to increase the risk of generalised infection (possibly life-threatening) when given with tioguanine. Public Health England advises avoid. **Severe** Theoretical

**Tiopronin** see TABLE 10 p. 1266 (antimucarins)

**Tirapamil** see HIV-protease inhibitors

**Tirofiban** see TABLE 1 p. 1264 (antiplatelet effects)

**Tizanidine** see TABLE 6 p. 1265 (bradycardia), TABLE 8 p. 1265 (hypoosmolarity), TABLE 9 p. 1266 (QT-interval prolongation), TABLE 11 p. 1266 (CNS depressant effects)

Antiepileptics (fosphenytoin, phenytoin) moderately decrease the exposure to tizanidine. **Mild** Study

**Combined hormonal contraceptives** increases the exposure to tizanidine. **Moderate** Study

HIV-protease inhibitors (ritonavir) moderately decrease the exposure to tizanidine. **Mild** Study

**Iron chelators (deferasirox)** are predicted to increase the exposure to tizanidine. **Mild** Study

Rifampicin moderately decreases the exposure to tizanidine. **Mild** Study
Tolcapone ▶

Tolcapone increases the exposure to levodopa. Monitor and adjust dose. (Moderate) Study

Tolcapone is predicted to increase the effects of monoamine-oxidase A and B inhibitors, irreversible. Avoid. (Severe) Study

Tolcapone is predicted to increase the risk of cardiovascular side-effects when given with sympathomimetics, isotropic (dobutamine, dopamine). (Moderate) Theoretical

Tolcapone is predicted to increase the effects of sympathomimetics, vasoconstrictor (adrenaline/epinephrine, noradrenaline/norepinephrine). (Moderate) Theoretical

Tolfinamic acid ▶ see NSAIDs

Tolterodine ▶ see TABLE 9 p. 1266 (QT-interval prolongation), TABLE 10 p. 1266 (antimuscarinics)

Antiarrhythmics (dronedarone) are predicted to increase the exposure to tolterodine. (Mild) Theoretical Also see TABLE 9 p. 1266

Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to tolterodine. Avoid. (Severe) Study Also see TABLE 9 p. 1266

Aprepitant is predicted to increase the exposure to tolterodine. (Mild) Theoretical

Calcium Channel blockers (diltiazem, verapamil) are predicted to increase the exposure to tolterodine. (Mild) Theoretical

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to tolterodine. Avoid. (Severe) Study

Cobicistat is predicted to increase the exposure to tolterodine. Avoid. (Severe) Study

Crizotinib is predicted to increase the exposure to tolterodine. (Mild) Theoretical Also see TABLE 9 p. 1266

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to tolterodine. Avoid. (Severe) Study Also see TABLE 9 p. 1266

HIV-protease inhibitors (indinavir) are predicted to increase the exposure to tolterodine. Adjust dose. (Mild) Theoretical

Idelalisib is predicted to increase the exposure to tolterodine. (Mild) Theoretical Also see TABLE 9 p. 1266

Nevirapine is predicted to increase the exposure to tolterodine. Avoid. (Severe) Study Also see TABLE 9 p. 1266

Imatinib is predicted to increase the exposure to tolterodine. (Mild) Theoretical

Macrolides (clarithromycin) are predicted to increase the exposure to tolterodine. Avoid. (Severe) Study Also see TABLE 9 p. 1266

Macrolides (erythromycin) are predicted to increase the exposure to tolterodine. (Mild) Theoretical

Idelalisib is predicted to increase the exposure to tolterodine. (Mild) Theoretical Also see TABLE 9 p. 1266

Netupitant is predicted to increase the exposure to tolterodine. (Mild) Theoretical Also see TABLE 9 p. 1266

Nilotinib is predicted to increase the exposure to tolterodine. (Mild) Theoretical Also see TABLE 9 p. 1266

Panobinostat is predicted to increase the exposure to tolterodine. (Moderate) Theoretical Also see TABLE 9 p. 1266

Tolvaptan ▶ see TABLE 16 p. 1268 (increased serum potassium)

GENERAL INFORMATION Avoid concurrent use of drugs that increase serum-sodium concentrations.

Antiarrhythmics (dronedarone) are predicted to increase the exposure to tolvaptan. Adjust dose. (Moderate) Theoretical

Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to tolvaptan. Avoid. (Severe) Study

Antifungals, azoles (fluconazole, isavuconazole, posaconazole) are predicted to increase the exposure to tolvaptan. Adjust dose. (Moderate) Theoretical

Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to tolvaptan. Adjust dose. (Severe) Study

Aprepitant is predicted to increase the exposure to tolvaptan. Adjust dose. (Moderate) Theoretical

Boventan is predicted to decrease the exposure to tolvaptan. (Moderate) Theoretical

Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to tolvaptan. Adjust dose. (Moderate) Theoretical

Cobicistat is predicted to increase the exposure to tolvaptan. Adjust dose. (Severe) Study

Crizotinib is predicted to increase the exposure to tolvaptan. Adjust dose. (Moderate) Theoretical

Tolvaptan increases the concentration of digoxin. (Mild) Study

Efavirenz is predicted to decrease the exposure to tolvaptan. (Moderate) Theoretical

Enzalutamide is predicted to decrease the exposure to tolvaptan. Avoid. (Severe) Study

Grapefruit juice increases the exposure to tolvaptan. Avoid. (Mild) Study

HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to tolvaptan. Adjust dose. (Severe) Study

HIV-protease inhibitors (indinavir) are predicted to increase the exposure to tolvaptan. Adjust dose. (Moderate) Theoretical

Idelalisib is predicted to increase the exposure to tolvaptan. Adjust dose. (Mild) Theoretical

Netupitant is predicted to increase the exposure to tolvaptan. Adjust dose. (Mild) Theoretical

Nilotinib is predicted to increase the exposure to tolvaptan. Adjust dose. (Mild) Theoretical

Rifampicin is predicted to decrease the exposure to tolvaptan. Avoid. (Severe) Study

ST John’s Wort is predicted to decrease the exposure to tolvaptan. (Moderate) Theoretical

Topiramate ▶ see antiepileptics

Topotecan ▶ see TABLE 15 p. 1267 (myelosuppression)

Antiarrhythmics (amiodarone, dronedarone) are predicted to increase the exposure to topotecan. (Severe) Study

Antiepileptics ( fosphenytoin, phenytoin) increase the clearance of topotecan. (Moderate) Study

Antifungals, azoles (itraconazole, ketoconazole) are predicted to increase the exposure to topotecan. (Severe) Study

Calcium channel blockers (verapamil) are predicted to increase the exposure to topotecan. (Severe) Study

Ciclosporin is predicted to increase the exposure to topotecan. (Mild) Theoretical Also see TABLE 15 p. 1267

Cyclosporin is predicted to increase the exposure to topotecan. (Severe) Study

HIV-protease inhibitors (lopinavir, ritonavir, saquinavir) are predicted to increase the exposure to topotecan. Adjust dose. (Severe) Study

Lapatinib is predicted to increase the exposure to topotecan. (Severe) Study

Live vaccines are predicted to increase the risk of generalised infection (possibly life-threatening) when given with topotecan. Public Health England advises avoid. (Severe) Theoretical

Lumacaftor is predicted to affect the exposure to topotecan. (Moderate) Theoretical

Macrolides are predicted to increase the exposure to topotecan. (Severe) Study

Mirabegron is predicted to increase the exposure to topotecan. (Mild) Theoretical

Ranolazine is predicted to increase the exposure to topotecan. (Severe) Study

ST John’s Wort is predicted to increase the exposure to topotecan. (Severe) Theoretical

Tedizolid is predicted to decrease the exposure to topotecan. Avoid. (Moderate) Theoretical
Topotecan – Tricyclic antidepressants

- **Velpatasvir** is predicted to increase the exposure to topotecan. [Severe] Theoretical
- **Vemurafenib** is predicted to increase the exposure to topotecan. [Severe] Study

**Torsemide**
- See loop diuretics

**Toremifene**
- See TABLE 5 p. 1264 (thromboembolism), TABLE 9 p. 1266 (QT-interval prolongation)

- **Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone)** are predicted to decrease the exposure to toremifene. Adjust dose. [Moderate] Study

- **Antifungals, azoles (itraconazole, ketoconazole, voriconazole)** are predicted to increase the exposure to toremifene. [Moderate] Theoretical -> Also see TABLE 9 p. 1266

- **Cobicistat** is predicted to increase the exposure to toremifene. [Moderate] Theoretical

- **Toremifene** is predicted to increase the anticoagulant effect of warfarin. [Severe] Theoretical

- **Enzalutamide** is predicted to decrease the exposure to toremifene. Adjust dose. [Moderate] Study

- **Thiazide diuretics** are predicted to increase the risk of hypercalcaemia when given with toremifene. [Severe] Theoretical

**Trabectedin**
- See TABLE 1 p. 1264 (hepatotoxicity), TABLE 15 p. 1267 (myelosuppression)

- **Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone)** are predicted to decrease the exposure to trabectedin. Avoid. [Severe] Theoretical -> Also see TABLE 1 p. 1264

- **Antifungals, azoles (itraconazole, ketoconazole, voriconazole)** are predicted to decrease the exposure to trabectedin. Avoid or adjust dose. [Severe] Theoretical -> Also see TABLE 1 p. 1264

- **Cobicistat** is predicted to increase the exposure to trabectedin. Avoid or adjust dose. [Severe] Theoretical

- **Enzalutamide** is predicted to decrease the exposure to trabectedin. Avoid. [Severe] Theoretical

- **HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to increase the exposure to trabectedin. Avoid or adjust dose. [Severe] Theoretical

- **Idelalisib** is predicted to increase the exposure to trabectedin. Avoid or adjust dose. [Severe] Theoretical

- **Toremifene** is predicted to increase the exposure to trabectedin. Avoid or adjust dose. [Severe] Theoretical

- **HIV-protease inhibitors (indinavir)** are predicted to increase the exposure to trabectedin. Avoid or adjust dose. [Moderate] Study

- **Idelalisib** is predicted to moderately increase the exposure to trabectedin. Avoid or adjust dose. [Moderate] Study

- **Imatinib** is predicted to increase the exposure to trabectedin. [Moderate] Theoretical

- **Macrolides (clarithromycin)** are predicted to increase the exposure to trabectedin. Avoid or adjust dose. [Moderate] Study

- **Vemurafenib** is predicted to increase the concentration of trabectedin. [Moderate] Theoretical

- **Ranolazine** is predicted to increase the concentration of trabectedin. [Moderate] Theoretical

- **Vemurafenib** is predicted to increase the concentration of trabectedin. [Moderate] Theoretical

- **Trandolapril** is predicted to increase the concentration of trabectedin. [Moderate] Theoretical

- **Tramexamic acid** is predicted to increase the concentration of trabectedin. Adjust dose. [Moderate] Theoretical

- **Tranylcypromine** is predicted to increase the concentration of trabectedin. [Moderate] Theoretical

**Triflusal**
- See nonsteroidal anti-inflammatory drugs

- **Trazodone** is predicted to increase the exposure to trabectedin. [Moderate] Theoretical

- **Anticonvulsants (carbamazepine)** are predicted to increase the concentration of trabectedin. [Moderate] Theoretical

- **Imatinib** is predicted to increase the concentration of trabectedin. [Moderate] Theoretical

- **Trazodone** is predicted to increase the concentration of trabectedin. [Moderate] Theoretical

- **Tramazulam** is predicted to increase the concentration of trabectedin. [Moderate] Theoretical

- **Trazodone** is predicted to increase the concentration of trabectedin. [Moderate] Theoretical

**Tricyclic antidepressants**

- **Amitriptyline**
- **Clomipramine**
- **Dosulepin**
- **Doxepin**
- **Imipramine**
- **Lofepramine**
- **Nortriptyline**
- **Trimipramine**

- **Antiarrhythmics (dronedarone)** are predicted to increase the risk of torsade de pointes when given with tricyclic antidepressants. Avoid. [Severe] Theoretical -> Also see TABLE 9 p. 1266

- **Antiarrhythmics (propafenone)** are predicted to increase the concentration of tricyclic antidepressants. [Moderate] Theoretical -> Also see TABLE 10 p. 1266
Tricyclic antidepressants (continued)

- **Antiepileptics (carbamazepine)** decrease the exposure to tricyclic antidepressants. Adjust dose. [Moderate] Study → Also see TABLE 18 p. 1268
- **Antiepileptics (phenobarbital, primidone)** are predicted to decrease the exposure to tricyclic antidepressants. [Moderate] Study
- **Tricyclic antidepressants (clomipramine, imipramine)** potentially increase the risk of overheating and dehydration when given with antiepileptics (zonisamide). Avoid in children. [Severe] Theoretical
- **Bupropion** is predicted to increase the exposure to tricyclic antidepressants. Monitor for toxicity and adjust dose. [Severe] Study → Also see TABLE 13 p. 1267
- **Cinacalcet** is predicted to increase the exposure to tricyclic antidepressants. Monitor for toxicity and adjust dose. [Severe] Study
- **Tricyclic antidepressants** decrease the antihypertensive effects of *Clonidine*. Monitor and adjust dose. [Moderate] Anecdotal
  → Also see TABLE 8 p. 1265
- **Cobicistat** is predicted to slightly increase the exposure to tricyclic antidepressants. [MID] Study
- **Darifenacin** is predicted to decrease the antihypertensive effects of *guanethidine*. [Moderate] Study → Also see TABLE 8 p. 1265
- **H₂ receptor antagonists (cimetidine)** increase the exposure to tricyclic antidepressants. [Moderate] Study
- **Tricyclic antidepressants** are predicted to decrease the effects of *histamine*. Avoid. [Severe] Theoretical → Also see TABLE 8 p. 1265
- **HIV- protease inhibitors (ritonavir, tipranavir)** are predicted to increase the exposure to tricyclic antidepressants. [Moderate] Theoretical
- **Tricyclic antidepressants** potentially increase the risk of neurotoxicity when given with *lithium*. [Severe] Anecdotal → Also see TABLE 8 p. 1266 → Also see TABLE 13 p. 1267
- **Amitriptyline** decreases the effects of *metyrapone*. Avoid. [Moderate] Theoretical
- **Tricyclic antidepressants** are predicted to increase the effects of *moclobemide*. Avoid. [Severe] Theoretical → Also see TABLE 13 p. 1267
- **Tricyclic antidepressants** are predicted to increase the effects of *monoamine-oxidase A and B inhibitors, irreversible*. Avoid. [Severe] Theoretical → Also see TABLE 8 p. 1265 → Also see TABLE 13 p. 1267
- **Tricyclic antidepressants** are predicted to decrease the effects of *moxonidine*. Avoid. [Moderate] Theoretical → Also see TABLE 8 p. 1265
- **Tricyclic antidepressants** are predicted to decrease the efficacy of *pituitary*. [MID] Theoretical
- **SSRIs (fluoxetine, paroxetine)** are predicted to increase the exposure to tricyclic antidepressants. Monitor for toxicity and adjust dose. [Severe] Study → Also see TABLE 13 p. 1267 → Also see TABLE 18 p. 1268
- **SSRIs (fluvoxamine)** markedly increase the exposure to clomipramine. Adjust dose. [Severe] Study → Also see TABLE 18 p. 1268 → Also see TABLE 13 p. 1267
- **SSRIs (fluvoxamine)** increase the exposure to tricyclic antidepressants (amitriptyline, imipramine). Adjust dose. [Severe] Study → Also see TABLE 18 p. 1268 → Also see TABLE 13 p. 1267
- **Sucralfate** is predicted to decrease the absorption of tricyclic antidepressants. [Moderate] Study
- **Tricyclic antidepressants** increase the effects of sympathomimetics, vasoconstrictor (adrenaline/epinephrine, noradrenaline/norepinephrine, phenylephrine). Avoid. [Severe] Study
- **Tricyclic antidepressants** are predicted to decrease the effects of sympathomimetics, vasoconstrictor (*ephedrine*). Avoid. [Severe] Study
- **Terbutaline** is predicted to increase the exposure to tricyclic antidepressants. Monitor for toxicity and adjust dose. [Severe] Study
- **Tricyclic antidepressants** increase the risk of cardiac arrhythmias and hypotension when given with *thiopental*. [Moderate] Study → Also see TABLE 8 p. 1265
- **Trientine** potentially decreases the absorption of *iron (oral)*. [Moderate] Theoretical
- **Trientine** potentially decreases the absorption of *zinc*. [Moderate] Theoretical
- **Trifluoperazine** → see phenothiazines
- **Trilexphenidyl** → see TABLE 10 p. 1266 (antimuscarinics)
- **Trimethoprim** → see TABLE 18 p. 1268 (hyponatraemia), TABLE 2 p. 1264 (nephrotoxicity), TABLE 16 p. 1268 (increased serum potassium)
- **Trimethoprim** increases the concentration of antiepileptics ( fosphenytoin, phenytoin). [Moderate] Study
- **Antimalarials (pyrimethamine) increase the risk of side-effects when given with trimethoprim. [Severe] Study
- **Trimethoprim** is predicted to increase the antiocoagulant effect of *coumarins*. [Severe] Study
- **Dapsone** increases the exposure to *trimethoprim* and trimethoprim increases the exposure to *dapsone*. [Severe] Study
- **Trimethoprim** increases the concentration of *digoxin*. [Moderate] Study
- **Trimethoprim** slightly increases the exposure to *lamivudine*. [Moderate] Study
- **Trimethoprim** is predicted to increase the risk of side-effects when given with *methotrexate*. Avoid. [Severe] Theoretical → Also see TABLE 2 p. 1264
- **Trimethoprim** slightly increases the exposure to *repaglinide*. Avoid or monitor blood glucose. [Moderate] Study
- **Rifampicin** decreases the exposure to *trimethoprim*. [Moderate] Study
- **Trimethoprim** is predicted to decrease the efficacy of *sapropterin*. [Moderate] Theoretical
- **Trimipramine** → see tricyclic antidepressants
- **Tropicamide** → see TABLE 10 p. 1266 (antimuscarinics)
- **Trosplium** → see live vaccines

**Ulipristal**

- **Antiarhythmics (dronedarone)** are predicted to increase the exposure to ulipristal. Avoid if used for uterine fibroids. [Moderate] Study
- **Antiepileptics (carbamazepine, eslicarbazepine, fosphenytoin, oxcarbazepine, perampanel, phenobarbital, phenytoin, primidone, rufinamide, topiramate)** decrease the efficacy of ulipristal. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Anecdotal
- **Antifungals, azoles (fluconazole, isavuconazole, posaconazole)** are predicted to increase the exposure to ulipristal. Avoid if used for uterine fibroids. [Moderate] Study
- **Antifungals, azoles (itraconazole, ketoconazole, voriconazole)** are predicted to increase the exposure to ulipristal. Avoid if used for uterine fibroids. [Severe] Study
- **Aprepitant** decreases the efficacy of ulipristal. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Anecdotal
- **Bozentan** decreases the efficacy of ulipristal. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Anecdotal
- **Calcium channel blockers (diltiazem, verapamil)** are predicted to increase the exposure to ulipristal. Avoid if used for uterine fibroids. [Moderate] Study
- **Cobicistat** is predicted to increase the exposure to ulipristal. Avoid if used for uterine fibroids. [Severe] Study
- **Ulipristal** is predicted to decrease the efficacy of combined hormonal contraceptives. Avoid. [Severe] Theoretical
- **Crizotinib** is predicted to increase the exposure to ulipristal. Avoid if used for uterine fibroids. [Moderate] Study
- **Efavirenz** decreases the efficacy of ulipristal. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Anecdotal
- **Enzalutamide** is predicted to markedly decrease the exposure to ulipristal. Avoid and for 4 weeks after stopping ulipristal. [Severe] Theoretical
Ulipristal is predicted to decrease the efficacy of etonogestrel. Avoid. [Severe] Theoretical

- Fosaprepitant decreases the efficacy of ulipristal. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Anecdotal
- Grapefruit juice is predicted to increase the exposure to ulipristal. Avoid if used for uterine fibroids. [Moderate] Theoretical
- Griseofulvin potentially decreases the efficacy of ulipristal. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Anecdotal
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, saquinavir, tipranavir) are predicted to increase the exposure to ulipristal. Avoid if used for uterine fibroids. [Severe] Study
- HIV-protease inhibitors (indinavir) are predicted to increase the exposure to ulipristal. Avoid if used for uterine fibroids. [Moderate] Study
- HIV-protease inhibitors (ritonavir) decrease the efficacy of ulipristal. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Anecdotal
- Idelalisib is predicted to increase the exposure to ulipristal. Avoid if used for uterine fibroids. [Severe] Study
- Imatinib is predicted to increase the exposure to ulipristal. Avoid if used for uterine fibroids. [Moderate] Study
- Ulipristal is predicted to decrease the efficacy of levonorgestrel. Avoid. [Severe] Theoretical
- Macrolides (clarithromycin) are predicted to increase the exposure to ulipristal. Avoid if used for uterine fibroids. [Severe] Study
- Macrolides (erythromycin) are predicted to increase the exposure to ulipristal. Avoid if used for uterine fibroids. [Moderate] Study
- Modafinil decreases the efficacy of ulipristal. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Anecdotal
- Netupitant is predicted to increase the exposure to ulipristal. Avoid if used for uterine fibroids. [Moderate] Study
- Nevirapine decreases the efficacy of ulipristal. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Anecdotal
- Nitotinib is predicted to increase the exposure to ulipristal. Avoid if used for uterine fibroids. [Moderate] Study
- Ulipristal is predicted to decrease the efficacy of norethisterone. Avoid. [Severe] Theoretical
- Rifabutin decreases the efficacy of ulipristal. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Anecdotal
- Rifampicin decreases the efficacy of ulipristal. For FSRH guidance, see Contraceptives, interactions p. 747. [Severe] Anecdotal
- Umeclidinium → see TABLE 10 p. 1266 (antimuscarinics)
- Urokinase → see TABLE 3 p. 1264 (anticoagulant effects)
- Ursodeoxycholic acid
  - Antacids are predicted to decrease the absorption of ursodeoxycholic acid. Separate administration by 2 hours. [Moderate] Theoretical
  - Ursodeoxycholic acid affects the concentration of ciclosporin. Use with caution and adjust dose. [Severe] Anecdotal
  - Fibrates are predicted to decrease the efficacy of ursodeoxycholic acid. Avoid. [Severe] Theoretical
- Ustekinumab → see monoclonal antibodies
- Valaciclovir → see TABLE 2 p. 1264 (nephrotoxicity)
- Valaciclovir is predicted to increase the exposure to aminophylline. [Severe] Anecdotal
- Mycophenolate is predicted to increase the risk of haematological toxicity when given with valaciclovir. [Moderate] Theoretical
- Valaciclovir is predicted to increase the exposure to theophylline. [Severe] Theoretical
- Valganciclovir → see TABLE 15 p. 1267 (myelosuppression), TABLE 2 p. 1264 (nephrotoxicity)
- Valganciclovir is predicted to increase the risk of seizures when given with carbapenems (imipenem). Avoid. [Severe] Anecdotal
- Valganciclovir is predicted to increase the exposure to didanosine. [Moderate] Study
- Mycophenolate is predicted to increase the risk of haematological toxicity when given with valganciclovir. [Moderate] Theoretical → Also see TABLE 15 p. 1267
- Valproate → see antiepileptics
- Valsartan → see angiotensin-II receptor antagonists
- Vancomycin → see TABLE 2 p. 1264 (nephrotoxicity), TABLE 19 p. 1268 (ototoxicity)
- Vancomycin increases the risk of nephrotoxicity when given with aminoglycosides. Avoid. [Moderate] Study → Also see TABLE 2 p. 1264 → Also see TABLE 19 p. 1268
- Vandetanib → see TABLE 9 p. 1266 (QT-interval prolongation)
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to vandetanib. Avoid. [Moderate] Study
- Vandetanib is predicted to increase the risk of bleeding events when given with coumarins. [Severe] Theoretical
- Vandetanib slightly increases the exposure to digoxin. Monitor ECG and adjust dose. [Moderate] Study
- Enzalutamide is predicted to decrease the exposure to vandetanib. Avoid. [Moderate] Study
- Vandetanib slightly increases the exposure to metformin. Monitor and adjust dose. [Moderate] Study
- Vandetanib is predicted to increase the risk of bleeding events when given with phenindione. [Severe] Theoretical
- Rifampicin is predicted to decrease the exposure to vandetanib. Avoid. [Moderate] Study
- Vardenafil → see phosphodiesterase type-5 inhibitors
- Varicella-zoster vaccine → see live vaccines
- Vecuronium → see neuromuscular blocking drugs, non-depolarising
- Vedolizumab → see monoclonal antibodies
- Velpatasvir
  - Velpatasvir is predicted to increase the exposure to aliskiren. [Severe] Theoretical
  - Antacids are predicted to decrease the concentration of velpatasvir. Separate administration by 4 hours. [Moderate] Theoretical
  - Antiarrhythmics (amiodarone) are predicted to increase the concentration of velpatasvir. Avoid or monitor. [Moderate] Theoretical
  - Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to moderately decrease the exposure to velpatasvir. Avoid. [Severe] Study
  - Antiepileptics (oxcarbazepine) are predicted to decrease the exposure to velpatasvir. Avoid. [Severe] Theoretical
  - Velpatasvir is predicted to increase the exposure to antihistamines, non-sedating (fexofenadine). [Severe] Theoretical
  - Bosantan is predicted to decrease the exposure to velpatasvir. Avoid. [Moderate] Theoretical
  - Calcium salts (calcium carbonate) are predicted to decrease the concentration of velpatasvir. Separate administration by 4 hours. [Moderate] Anecdotal
  - Velpatasvir is predicted to increase the exposure to colchicine. [Severe] Theoretical
  - Velpatasvir is predicted to increase the exposure to dabigatran. [Severe] Theoretical
  - Velpatasvir is predicted to increase the exposure to digoxin. [Severe] Study
  - Velpatasvir is predicted to increase the exposure to edoxaban. [Severe] Theoretical
  - Elafirenz is predicted to decrease the exposure to velpatasvir. Avoid. [Moderate] Theoretical
  - Enzalutamide is predicted to moderately decrease the exposure to velpatasvir. Avoid. [Severe] Study
  - Velpatasvir is predicted to increase the exposure to everolimus. [Severe] Theoretical
  - H2 receptor antagonists are predicted to decrease the concentration of velpatasvir. Adjust dose, see sofosbuvir with velpatasvir p. 596. [Moderate] Study
  - Velpatasvir is predicted to increase the exposure to loperamide. [Severe] Theoretical
  - Nevirapine is predicted to decrease the exposure to velpatasvir. Avoid. [Moderate] Theoretical
  - Proton pump inhibitors are predicted to decrease the concentration of velpatasvir. Adjust dose, see sofosbuvir with velpatasvir p. 596. [Moderate] Study
Velpatasvir (continued)

- Rifampicin is predicted to moderately decrease the exposure to velpatasvir. Avoid. [Severe] Study
- Velpatasvir is predicted to increase the exposure to sirolimus. [Severe] Theoretical
- St John’s Wort is predicted to decrease the exposure to velpatasvir. Avoid. [Moderate] Theoretical
- Velpatasvir is predicted to increase the exposure to statins (atorvastatin, simvastatin). Monitor side effects and adjust dose. [Severe] Theoretical
- Velpatasvir increases the exposure to statins (rosuvastatin). Adjust rosuvastatin dose and monitor side effects, p. 197. [Severe] Study
- Velpatasvir is predicted to increase the exposure to taxanes (paclitaxel). Use with caution and adjust dose. [Moderate] Theoretical
- Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone) are predicted to decrease the exposure to velpatasvir. Avoid. [Severe] Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to velpatasvir. Avoid. [Severe] Theoretical
- Velpatasvir is predicted to increase the exposure to topotecan. [Severe] Theoretical
- Venetoclax is predicted to increase the exposure to venetoclax. Avoid or adjust venetoclax dose, p. 919. [Severe] Study
- Aprepitant is predicted to increase the exposure to venetoclax. Avoid or adjust venetoclax dose, p. 919. [Severe] Study
- Calcium channel blockers (diltiazem, verapamil) are predicted to increase the exposure to venetoclax. Avoid or adjust venetoclax dose, p. 919. [Severe] Study
- Ciclosporin is predicted to increase the exposure to venetoclax. Avoid or monitor for toxicity. [Severe] Theoretical
- Cobicistat is predicted to increase the exposure to venetoclax. Avoid or adjust venetoclax dose, p. 919. [Severe] Study
- Venetoclax slightly increases the exposure to coumarins (warfarin). [Moderate] Study
- Crizotinib is predicted to increase the exposure to venetoclax. Avoid or adjust venetoclax dose, p. 919. [Severe] Study
- Enzalutamide is predicted to decrease the exposure to venetoclax. Avoid. [Severe] Study
- Grapefruit juice is predicted to increase the exposure to venetoclax. Avoid. [Severe] Theoretical
- HIV-protease inhibitors are predicted to increase the exposure to venetoclax. Avoid or adjust venetoclax dose, p. 919. [Severe] Study
- Idelalisib is predicted to increase the exposure to venetoclax. Avoid or adjust venetoclax dose, p. 919. [Severe] Study
- Imatinib is predicted to increase the exposure to venetoclax. Avoid or adjust venetoclax dose, p. 919. [Severe] Study
- Lapatinib is predicted to increase the exposure to venetoclax. Avoid or monitor for toxicity. [Severe] Theoretical
- Venetoclax potentially decreases the efficacy of live vaccines. Avoid. [Severe] Theoretical
- Macrolides (azithromycin) are predicted to increase the exposure to venetoclax. Avoid or monitor for toxicity. [Severe] Theoretical
- Macrolides (clarithromycin, erythromycin) are predicted to increase the exposure to venetoclax. Avoid or adjust venetoclax dose, p. 919. [Severe] Study
- Netupitant is predicted to increase the exposure to venetoclax. Avoid or adjust venetoclax dose, p. 919. [Severe] Study
- Nilotinib is predicted to increase the exposure to venetoclax. Avoid or adjust venetoclax dose, p. 919. [Severe] Study
- Ranolazine is predicted to increase the exposure to venetoclax. Avoid or monitor for toxicity. [Severe] Theoretical
- Rifampicin is predicted to decrease the exposure to venetoclax. Avoid. [Severe] Study
- Venlafaxine is predicted to increase the serotonin syndrome, TABLE 9 p. 1267 (serotonin syndrome). TABLE 9 p. 1266 (QT-interval prolongation), TABLE 11 p. 1266 (CNS depressant effects), TABLE 4 p. 1264 (antiplatelet effects)
- Abiraterone potentially increases the exposure to venlafaxine. [Severe] Theoretical
- Antifungals, azoles (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to venlafaxine. Avoid or adjust venlafaxine dose, p. 919. [Severe] Study
- H<sub>2</sub> receptor antagonists (cimetidine) slightly increase the exposure to venlafaxine. [Moderate] Study
- Venlafaxine slightly increases the exposure to haloperidol. [Severe] Study → Also see TABLE 9 p. 1266
- HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir) are predicted to increase the exposure to venlafaxine. Avoid or adjust venlafaxine dose, p. 919. [Severe] Study
- Idelalisib is predicted to increase the exposure to venlafaxine. [Moderate] Study
- Macrolides (clarithromycin) are predicted to increase the exposure to venlafaxine. [Moderate] Study
- Tacrolimus potentially increases the risk of serotonin syndrome when given with venlafaxine. [Severe] Anecdotal

**Verapamil** → see calcium channel blockers
Verteporfin

**General Information**
Caution on concurrent use with other photosensitising drugs.

**Vigabatrin** ➔ anti-epileptics

**Valterol** ➔ see beta agonists

**Vildagliptin** ➔ see Table 14 p.1267 (antidiabetic drugs)

**Vinblastine** ➔ see vinclozols

**Vinca alkaloids** ➔ see Table 1 p.1264 (hepatotoxicity), Table 15 p.1267 (myelosuppression), Table 19 p.1268 (ototoxicity), Table 12 p.1267 (peripheral neuropathy), Table 5 p.1264 (thromboembolism), Table 9 p.1266 (QT-interval prolongation)

Vinblastine • vincristine • vindesine • vinflunine • vinorelbine

- **Antiarhythmics (dronedaran)** are predicted to increase the exposure to vinca alkaloids. *Severe* Theoretical ➔ Also see Table 9 p.1266
- **Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone)** are predicted to decrease the exposure to vinflunine. Avoid. *Severe* Theoretical ➔ Also see Table 12 p.1267
- **Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone)** are predicted to decrease the exposure to vinorelbine. Use with caution or avoid. *Severe* Theoretical ➔ Also see Table 12 p.1267
- **Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone)** are predicted to decrease the exposure to vinca alkaloids (vinblastine, vincristine, vindesine). *Severe* Theoretical ➔ Also see Table 12 p.1267
- **Antifungals, azoles** (itraconazole, ketoconazole, voriconazole) are predicted to increase the exposure to vinca alkaloids. *Severe* Theoretical ➔ Also see Table 1 p.1264 ➔ Also see Table 12 p.1267
- **Calcium channel blockers (diltiazem, verapamil)** are predicted to increase the exposure to vinca alkaloids. *Severe* Theoretical ➔ Also see Table 1 p.1264 ➔ Also see Table 15 p.1267
- **Cobicistat** is predicted to increase the exposure to vinca alkaloids. *Severe* Theoretical
- **Crisantaspase** potentially increases the risk of neurotoxicity when given with vincristine. Vincristine should be taken 3 to 24 hours before crisantaspase. *Severe* Anecdotal ➔ Also see Table 1 p.1264 ➔ Also see Table 15 p.1267
- **Cobimetinib** is predicted to increase the exposure to vinca alkaloids. *Severe* Theoretical ➔ Also see Table 9 p.1266 ➔ Also see Table 15 p.1267
- **Enzalutamide** is predicted to decrease the exposure to vinca alkaloids (vinblastine, vincristine, vindesine). *Severe* Theoretical
- **Enzalutamide** is predicted to decrease the exposure to vinflunine. Avoid. *Severe* Theoretical
- **Enzalutamide** is predicted to decrease the exposure to vinorelbine. Use with caution or avoid. *Severe* Theoretical
- **HIV-protease inhibitors** are predicted to increase the exposure to vinca alkaloids. *Severe* Theoretical ➔ Also see Table 9 p.1266
- **Idelalisib** is predicted to increase the exposure to vinca alkaloids. *Severe* Theoretical ➔ Also see Table 15 p.1267
- **Imatinib** is predicted to increase the exposure to vinca alkaloids. *Severe* Theoretical ➔ Also see Table 15 p.1267
- **Live vaccines** are predicted to increase the risk of generalised infection (possibly life-threatening) when given with vinclozols. Public Health England advises avoid. *Severe* Theoretical
- **Macrolides (clarithromycin, erythromycin)** are predicted to increase the exposure to vinca alkaloids. *Severe* Theoretical ➔ Also see Table 9 p.1266
- **Netupitant** is predicted to increase the exposure to vinca alkaloids. *Severe* Theoretical
- **Nilotinib** is predicted to increase the exposure to vinca alkaloids. *Severe* Theoretical
- **Pegasparagase** potentially increases the risk of neurotoxicity when given with vincristine. Vincristine should be taken 3 to 24 hours before pegasparagase. *Severe* Anecdotal ➔ Also see Table 1 p.1264 ➔ Also see Table 15 p.1267
- **Rifampicin** is predicted to decrease the exposure to vinca alkaloids (vinblastine, vincristine, vindesine). *Severe* Theoretical
- **Rifampicin** is predicted to decrease the exposure to vinflunine. Use with caution or avoid. *Severe* Theoretical
- **Rifampicin** is predicted to decrease the exposure to vinorelbine. Use with caution or avoid. *Severe* Theoretical
- **Vincristine** ➔ see vinca alkaloids
- **Vinflunine** ➔ see vinca alkaloids
- **Vinorelbine** ➔ see vinca alkaloids
- **Vismodegib** ➔ see Table 15 p.1267 (myelosuppression)
- **Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone)** are predicted to decrease the exposure to vismodegib. Avoid. *Moderate* Theoretical
- **Enzalutamide** is predicted to decrease the exposure to vismodegib. Avoid. *Moderate* Theoretical
- **Rifampicin** is predicted to decrease the exposure to vismodegib. Avoid. *Moderate* Theoretical
- **St John’s Wort** is predicted to decrease the exposure to vismodegib. Avoid. *Moderate* Theoretical
- **Vitamin A**
  - **Retinoids (acitretin, altiretinoin, isotretinoin)** are predicted to increase the risk of vitamin A toxicity when given with vitamin A. Avoid. *Severe* Theoretical
  - **Retinoids (bexarotene)** are predicted to increase the risk of toxicity when given with vitamin A. Adjust dose. *Moderate* Theoretical
  - **Retinoids (tretinoin)** are predicted to increase the risk of vitamin A toxicity when given with vitamin A. Avoid. *Severe* Study

**Vitamin D substances**
- alfalcacidol • calcipotriol • calcitriol • cokedicaliferol • dihydrotachysterol • ergocalciferol • paricalcitol • tachicalitol
- **Antiepileptics (carbamazepine)** are predicted to decrease the effects of vitamin D substances. *Moderate* Study
- **Antiepileptics (fosphenytoin, phenytoin)** decrease the effects of vitamin D substances. *Moderate* Study
- **Antiepileptics (phenobarbital, primidone)** are predicted to decrease the effects of vitamin D substances. *Moderate* Theoretical
- **Antifungals, azoles (clotrimazole, ketoconazole)** are predicted to decrease the exposure to cokedicaliferol. *Moderate* Theoretical
- **Antifungals, azoles (itraconazole, ketoconazole, voriconazole)** are predicted to increase the exposure to paricalcitol. *Moderate* Study
- **Cobicistat** is predicted to increase the exposure to paricalcitol. *Moderate* Study
- **Vitamin D substances** are predicted to increase the risk of toxicity when given with digoxin. *Severe* Theoretical
- **HIV-protease inhibitors (atazanavir, darunavir, fosamprenavir, lopinavir, ritonavir, saquinavir, tipranavir)** are predicted to increase the exposure to paricalcitol. *Moderate* Study
- **Idelalisib** is predicted to increase the exposure to paricalcitol. *Moderate* Study
- **Macrolides (clarithromycin)** are predicted to increase the exposure to paricalcitol. *Moderate* Study
- **Thiazide diuretics** increase the risk of hypercalcæmia when given with vitamin D substances. *Moderate* Theoretical

**Vitamin E substances**
- alpha tocopherol • alpha tocopheryl acetate
- **Vitamin E substances** affect the exposure to ciclosporin. *Moderate* Study

**Volatile halogenated anaesthetics** ➔ see Table 8 p.1265 (hypotension), Table 11 p.1266 (CNS depressant effects)
- desflurane • isoflurane • sevoflurane
- **Voriconazole** ➔ see antifungals, azoles
- **Vortioxetine** ➔ see Table 13 p.1267 (serotonin syndrome), Table 4 p.1264 (antiplatelet effects)
Vortioxetine – Zopiclone

Interactions

**Appendix 1**

**Zinc**

- **Terbinafine** predicted to increase the exposure to vortioxetine. Monitor and adjust dose. **(Moderate) Study**

- **Enalapril** is predicted to decrease the absorption of zinc. **(Moderate) Study**

- **Zidovudine** predicted to decrease the absorption of oral zinc. **(Moderate) Study**

- **Zinc** is predicted to decrease the absorption of penicillamine. **(Mild) Theoretical**

- **Zinc** is predicted to decrease the exposure to quinolones. Separate administration by 2 hours. **(Moderate) Study**

- **Oral zinc** is predicted to decrease the absorption of tetracyclines. Separate administration by 2 to 3 hours. **(Moderate) Study**

- **Tricaine** potentially decreases the absorption of zinc. **(Moderate) Theoretical**

**Zoledronic acid** → see bisphosphonates

**Zolmitrip坦** → see TABLE 13 p. 1267 (serotonin syndrome)

- **Combined hormonal contraceptives** are predicted to increase the exposure to zolmitrip坦. Adjust zolmitrip坦 dose, p. 456. **(Moderate) Theoretical**

- **H₃ receptor antagonists (cimetidine)** slightly increase the exposure to zolmitrip坦. Adjust zolmitrip坦 dose, p. 456. **(Mild) Study**

- **Moclobemide** slightly increases the exposure to zolmitrip坦. Adjust zolmitrip坦 dose, p. 456. **(Moderate) Study**

- **Monoamine-oxidase A and B inhibitors, irreversible** are predicted to increase the exposure to zolmitrip坦. **(Severe) Theoretical** → Also see TABLE 13 p. 1267

- **Quinolones (ciprofloxacin)** are predicted to increase the exposure to zolmitrip坦. Adjust zolmitrip坦 dose, p. 456. **(Moderate) Theoretical**

- **SSRIs (fluvoxamine)** are predicted to increase the exposure to zolmitrip坦. Adjust zolmitrip坦 dose, p. 456. **(Severe) Theoretical** → Also see TABLE 13 p. 1267

**Zolpidem** → see TABLE 11 p. 1266 (CNS depressant effects)

- **Antiepileptics (carbamazepine)** moderately decrease the exposure to zolpidem. **(Moderate) Study**

- **Zopiclone** is predicted to decrease the exposure to zolpidem. **(Moderate) Study**

- **Zonisamide** → see antiepileptics

**Zopiclone** → see TABLE 11 p. 1266 (CNS depressant effects)

- **Antarrhythms (dronedarone)** are predicted to increase the exposure to zopiclone. Adjust dose. **(Moderate) Study**

- **Antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone)** are predicted to decrease the exposure to zopiclone. Adjust dose. **(Moderate) Study** → Also see TABLE 11 p. 1266

- **Antifungals, azoles (fluconazole, itraconazole, posaconazole)** are predicted to increase the exposure to zopiclone. Adjust dose. **(Moderate) Study**

- **Antifungals, azoles (fluconazole, isavuconazole, posaconazole)** are predicted to decrease the exposure to zopiclone. Adjust dose. **(Moderate) Study**

- **Calcium channel blockers (diltiazem, verapamil)** are predicted to increase the exposure to zopiclone. Adjust dose. **(Moderate) Study**

- **Cobicistat** is predicted to increase the exposure to zopiclone. Adjust dose. **(Moderate) Theoretical**

- **Crixotinib** is predicted to increase the exposure to zopiclone. Adjust dose. **(Moderate) Study**

- **Enalapril** is predicted to decrease the exposure to zopiclone. Adjust dose. **(Moderate) Study**

- **Zopiclone** is predicted to decrease the exposure to zopiclone. Adjust dose. **(Moderate) Study**

- **Imatinib** is predicted to increase the exposure to zopiclone. Adjust dose. **(Moderate) Theoretical**

- **Macrolides (clarithromycin)** are predicted to increase the exposure to zopiclone. Adjust dose. **(Moderate) Theoretical**

- **Macrolides (erythromycin)** are predicted to increase the exposure to zopiclone. Adjust dose. **(Moderate) Study**

- **Netupitant** is predicted to increase the exposure to zopiclone. Adjust dose. **(Moderate) Study**
- **Nilotinib** is predicted to increase the exposure to zopiclone. Adjust dose. [Moderate] Study
- **Rifampicin** is predicted to decrease the exposure to zopiclone. Adjust dose. [Moderate] Study

**Zuclopenthixol** → see TABLE 8 p. 1265 (hypotension), TABLE 9 p. 1266 (QT-interval prolongation), TABLE 11 p. 1266 (CNS depressant effects)
- **Zuclopenthixol** is predicted to decrease the effects of dopamine receptor agonists. Avoid. [Moderate] Theoretical → Also see TABLE 8 p. 1265 → Also see TABLE 9 p. 1266
- **Zuclopenthixol** is predicted to decrease the effects of histamine. Avoid. [Severe] Theoretical → Also see TABLE 8 p. 1265
- **Zuclopenthixol** is predicted to decrease the effects of levodopa. Avoid or monitor worsening parkinsonian symptoms. [Severe] Theoretical → Also see TABLE 8 p. 1265
- **Zuclopenthixol** potentially increases the risk of neurotoxicity when given with lithium. [Severe] Anecdotal → Also see TABLE 9 p. 1266
Appendix 2
Borderline substances

CONTENTS
Enteral feeds (non-disease specific) ........................................ page 1422
Enteral feeds (non-disease specific): less than 5 g protein/100 mL 1422
Enteral feeds (non-disease specific): 5 g (or more) protein/100 mL 1424
Enteral feeds (non-disease specific); Child under 12 years 1427
Nutritional supplements (non-disease specific) .......................... 1427
Nutritional supplements: less than 5 g protein/100 mL 1427
Nutritional supplements: 5 g (or more) protein/100 mL 1428
Specialised formulas ................................................................. 1432
Specialised formulas: Infant and child 1432
Specialised formulas for specific clinical conditions 1432
Feed supplements .................................................................... 1434
High-energy supplements ......................................................... 1434
Fibre, vitamin, and mineral supplements .................................. 1439
Feed additives .......................................................................... 1440
Special feed additives for conditions of intolerance ................. 1440
Feed thickeners and pre-thickened drinks ......................... page 1440
Flavouring preparations ......................................................... 1441
Foods for special diets .............................................................. 1441
Gluten-free foods .................................................................... 1441
Low-protein foods .................................................................. 1445
Nutritional supplements for metabolic diseases ......................... 1447
Glutaric aciduria (type 1) ......................................................... 1447
Glycogen storage disease ......................................................... 1447
Homocystinuria or hypermethioninaemia ................................. 1447
Hyperlysinaemia .................................................................... 1448
Isovaleric acidemia .................................................................. 1448
Maple syrup urine disease ....................................................... 1448
Methylmalonic or propionic acidaemia ..................................... 1449
Other inborn errors of metabolism ........................................... 1449
Phenylketonuria ...................................................................... 1450
Tyrosinaemia .......................................................................... 1452

In certain conditions some foods (and toilet preparations) have characteristics of drugs and the Advisory Committee on Borderline Substances (ACBS) advises as to the circumstances in which such substances may be regarded as drugs. Prescriptions issued in accordance with the Committee’s advice and endorsed ‘ACBS’ will normally not be investigated.

Information
General Practitioners are reminded that the ACBS recommends products on the basis that they may be regarded as drugs for the management of specified conditions. Doctors should satisfy themselves that the products can safely be prescribed, that patients are adequately monitored and that, where necessary, expert hospital supervision is available.

Foods which may be prescribed on FP10, GP10 (Scotland), or WP10 (Wales)
All the food products listed in this appendix have ACBS approval. The clinical condition for which the product has been approved is included with each entry.

Note Foods included in this appendix may contain cariogenic sugars and patients should be advised to take appropriate oral hygiene measures.

Enteral feeds and supplements
For most enteral feeds and nutritional supplements, the main source of carbohydrate is either maltodextrin or glucose syrup; other carbohydrate sources are listed in the relevant table, below. Feeds containing residual lactose (less than 1 g lactose/100 mL formula) are described as ‘clinically lactose-free’ or ‘lactose-free’ by some manufacturers. The presence of lactose (including residual lactose) in feeds is indicated in the relevant table, below. The primary sources of protein or amino acids are included with each product entry. The fat or oil content is derived from a variety of sources such as vegetables, soya bean, corn, palm nuts, and seeds; where the fat content is derived from animal or fish sources, this information is included in the relevant table, below. The presence of medium chain triglycerides (MCT) is also noted where the quantity exceeds 30% of the fat content.

Enteral feeds and nutritional supplements can contain varying amounts of vitamins, minerals, and trace elements—the manufacturer’s product literature should be consulted for more detailed information. Feeds containing vitamin K may affect the INR in patients receiving warfarin; see Interactions: Appendix 1: Enteral feeds.

The suitability of food products for patients requiring a vegan, kosher, halal, or other compliant diet should be confirmed with individual manufacturers.

Note Feeds containing more than 6 g/100 mL protein or 2 g/100 mL fibre should be avoided in children unless recommended by an appropriate specialist or dietician.

Nutritional values
Nutritional values of products vary with flavour and pack size—consult product literature.

Other conditions for which ACBS products can be prescribed
This is a list of clinical conditions for which the ACBS has approved toilet preparations.

Birthmarks
Dermatitis
Eczema and Pruritus
Aveeno® Bath Oil; Aveeno® Cream; Aveeno® Lotion; E45® Emollient Bath Oil; E45® Emollient Wash Cream; E45® Lotion
Disfiguring skin lesions (birthmarks, mutilating lesions, scars, vitiligo)
Covermark® classic foundation and finishing powder; Dermoblend® Ultra corrective foundation; Dermacolor® Camouflage cream and fixing powder; Keromask® masking cream and finishing powder; Veil® Cover cream and Finishing Powder. (Cleansing Creams, Cleansing Milks, and Cleansing Lotions are excluded).
Disinfectants (antiseptics)
May be prescribed on an FP10 only when ordered in such quantities and with such directions as are appropriate for
the treatment of patients, but not for general hygenic purposes.

**Dry mouth (xerostomia)**
For patients suffering from dry mouth as a result of having (or having undergone) radiotherapy, or sicca syndrome.  
AS Saliva Orthana®; Biotène Oralbalance®; Glandosane®; Saliveze®

**Photodermatoses (skin protection in)**
Anthelios® XL SPF 50+ Melt-in cream; Sunsense® Ultra; Uvistat® Lipscreen SPF 50, Uvistat® Suncream SPF 30 and 50

**Standard ACBS indications:** Disease-related malnutrition, intractable malabsorption, pre-operative preparation of malnourished patients, dysphagia, proven inflammatory bowel disease, following total gastrectomy, short-bowel syndrome, bowel fistula
### Table 1 Enteral feeds (non-disease specific)

#### Less than 5 g protein/100 mL

**Enteral feeds: 1 kcal/mL and less than 5 g protein/100 mL**

Not suitable for use in child under 1 year unless otherwise stated; not recommended for child 1-6 years

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fresubin® 1500 Complete</td>
<td>Liquid (tube feed)</td>
<td>420 kJ (100 kcal)</td>
<td>3.8 g cows’ milk soya</td>
<td>13 g (sugars 0.9 g)</td>
<td>3.4 g</td>
<td>1.5 g</td>
<td>Gluten-free Residual lactose Contains fish oil</td>
<td>Borderline substances standard ACBS indications p. 1421 except bowel fistula and pre-operative preparation of malnourished patients. Not suitable for child under 2 years</td>
<td>Fresubin 1500 Complete liquid: 1.5 litre = £13.52</td>
</tr>
<tr>
<td>(Fresenius Kabi Ltd)</td>
<td>per 100 mL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fresubin® Original</td>
<td>Liquid (sip or tube</td>
<td>420 kJ (100 kcal)</td>
<td>3.8 g cows’ milk soya</td>
<td>13.8 g (sugars 3.5 g)</td>
<td>3.4 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose Contains fish gelatin Feed in flexible pack contains fish oil and fish gelatin</td>
<td>Borderline substances standard ACBS indications p. 1421</td>
<td>Fresubin Original drink: blackcurrant, chocolate, nut, peach, vanilla 200 ml = £2.18; Fresubin Original tube feed liquid: 1000 ml = £8.41; 500 ml = £4.25; 1500 ml = £12.61</td>
</tr>
<tr>
<td>(Fresenius Kabi Ltd)</td>
<td>feed) per 100 mL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fresubin® Original Fibre</td>
<td>Liquid (tube feed)</td>
<td>420 kJ (100 kcal)</td>
<td>3.8 g cows’ milk soya</td>
<td>13 g (sugars 0.9 g)</td>
<td>3.4 g</td>
<td>1.5 g</td>
<td>Gluten-free Residual lactose Contains fish oil</td>
<td>Borderline substances standard ACBS indications p. 1421 except bowel fistula and pre-operative preparation of malnourished patients. Not suitable for child under 2 years</td>
<td>Fresubin Original Fibre liquid: 1000 ml = £9.59; 500 ml = £4.80</td>
</tr>
<tr>
<td>(Fresenius Kabi Ltd)</td>
<td>per 100 mL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jeevity®</td>
<td>Liquid (tube feed)</td>
<td>449 kJ (107 kcal)</td>
<td>4 g caseinates</td>
<td>14.1 g (sugars 470 mg)</td>
<td>3.47 g</td>
<td>1.76 g</td>
<td>Gluten-free Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421 except bowel fistula. Not suitable for child under 2 years</td>
<td>Jeevity liquid: 500 ml = £5.20; 1500 ml = £14.14; 1000 ml = £9.46</td>
</tr>
<tr>
<td>(Abbott Laboratories Ltd)</td>
<td>per 100 mL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nutrison®</td>
<td>Liquid (tube feed)</td>
<td>420 kJ (100 kcal)</td>
<td>4 g cows’ milk</td>
<td>12.3 g (sugars 1 g)</td>
<td>3.9 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421</td>
<td>Nutrison liquid: 500 ml = £5.01; 1500 ml = £13.18; 1000 ml = £8.79; 500 ml = £4.51</td>
</tr>
<tr>
<td>(Nutricia Ltd)</td>
<td>per 100 mL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nutrison® Multi Fibre</td>
<td>Liquid (tube feed)</td>
<td>420 kJ (100 kcal)</td>
<td>4 g caseinates</td>
<td>13.6 g (sugars 630 mg)</td>
<td>3.4 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421 except bowel fistula</td>
<td>Nutrison Multi Fibre liquid: 1000 ml = £10.18; 1500 ml = £15.25; 500 ml = £5.08; 500 ml = £5.41</td>
</tr>
<tr>
<td>(Nutricia Ltd)</td>
<td>per 100 mL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Osmolite®</td>
<td>Liquid (tube feed)</td>
<td>424 kJ (100 kcal)</td>
<td>4 g caseinates soy isolate</td>
<td>13.6 g (sugars 630 mg)</td>
<td>3.4 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421</td>
<td>Osmolite liquid: 500 ml = £4.65; 1500 ml = £12.65; 1000 ml = £8.46</td>
</tr>
<tr>
<td>SOYA PROTEIN FORMULA</td>
<td>Product</td>
<td>Formulation</td>
<td>Energy</td>
<td>Protein</td>
<td>Carbohydrate</td>
<td>Fat</td>
<td>Fibre</td>
<td>Special Characteristics</td>
<td>ACBS Indications</td>
</tr>
<tr>
<td>----------------------</td>
<td>---------</td>
<td>-------------</td>
<td>--------</td>
<td>---------</td>
<td>--------------</td>
<td>-----</td>
<td>-------</td>
<td>-------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Fresubin® Soya Fibre (Fresenius Kabi Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>420 kJ (100 kcal)</td>
<td>3.8 g soya protein</td>
<td>13.3 g (sugars 4.1 g)</td>
<td>3.6 g</td>
<td>2 g</td>
<td>Gluten-free Lactose-free Contains fish oil</td>
<td>Borderline substances standard ACBS indications p. 1421; also cows’ milk protein intolerance, lactose intolerance</td>
<td>Fresubin Soya Fibre liquid: 500 mL = £4.97</td>
</tr>
<tr>
<td>Nutrison® Soya (Nutricia Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>420 kJ (100 kcal)</td>
<td>4 g soy isolate</td>
<td>12.3 g (sugars 1 g)</td>
<td>3.9 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose Milk protein-free</td>
<td>Borderline substances standard ACBS indications p. 1421; also cows’ milk protein and lactose intolerance</td>
<td>Nutrison Soya liquid: 500 mL = £5.40; 1000 mL = £10.82</td>
</tr>
<tr>
<td>Nutrison® Soya Multi Fibre (Nutricia Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>420 kJ (100 kcal)</td>
<td>4 g soy isolate</td>
<td>12.3 g (sugars 700 mg)</td>
<td>3.9 g</td>
<td>1.5 g</td>
<td>Gluten-free Residual lactose Milk protein-free</td>
<td>Borderline substances standard ACBS indications p. 1421 except bowel fistula; also cows’ milk protein and lactose intolerance</td>
<td>Nutrison Soya Multi Fibre liquid: 1.5 litre = £18.00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PEPTIDE-BASED FORMULA</th>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nutrison Peptisorb® (Nutricia Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>425 kJ (100 kcal)</td>
<td>4 g whey protein hydrolysate</td>
<td>17.6 g (sugars 1.7 g)</td>
<td>1.7 g (MCT 47 %)</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Short bowel syndrome, intractable malabsorption, proven inflammatory bowel disease, bowel fistula</td>
<td>Nutrison Peptisorb liquid: 1000 mL = £14.20; 500 mL = £7.88; 500 mL = £7.17</td>
<td></td>
</tr>
<tr>
<td>Peptamen® (Nestle Health Science)</td>
<td>Liquid (sip or tube feed) per 100 mL</td>
<td>420 kJ (100 kcal)</td>
<td>4 g whey peptides</td>
<td>12.7 g (sugars 480 mg)</td>
<td>3.7 g (MCT 70 %)</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Short bowel syndrome, intractable malabsorption, proven inflammatory bowel disease, bowel fistula</td>
<td>Peptamen liquid: vanilla 800 mL = £12.14; unflavoured 500 mL = £6.82; 1000 mL = £12.80</td>
<td></td>
</tr>
<tr>
<td>Survivmed® OPD (Fresenius Kabi Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>420 kJ (100 kcal)</td>
<td>4.5 g whey protein hydrolysate</td>
<td>14.3 g (sugars 1.1 g)</td>
<td>2.8 g (MCT 51 %)</td>
<td>0.1 g</td>
<td>Gluten-free Residual lactose Contains fish oil</td>
<td>Borderline substances standard ACBS indications p. 1421; also growth failure</td>
<td>Survivmed OPD: FN liquid 500 mL = £6.82; liquid 500 mL = £7.09; 800 mL = £13.08; 1000 mL = £14.17</td>
<td></td>
</tr>
</tbody>
</table>

**Enteral feeds: Less than 1 kcal/mL and less than 5 g protein/100 mL**

### AMINO ACID FORMULA (ESSENTIAL AND NON-ESSENTIAL AMINO ACIDS)
Not suitable for use in child under 1 year unless otherwise stated; not recommended for child 1-6 years

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elemental 028® Extra (Nutricia Ltd)</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>360 kJ (86 kcal)</td>
<td>2.5 g (protein equivalent)</td>
<td>11 g (sugars 4.7 g)</td>
<td>3.5 g (MCT 35 %)</td>
<td>Nil</td>
<td>Short bowel syndrome, intractable malabsorption, proven inflammatory bowel disease, bowel fistula</td>
<td>Elemental 028 Extra liquid summer fruits: 250 mL = £3.73</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Standard dilution (20 %) of powder (sip or tube feed) per 100 mL</td>
<td>374 kJ (89 kcal)</td>
<td>2.5 g (protein equivalent)</td>
<td>11.8 g (sugars 1.8 g)</td>
<td>3.5 g (MCT 35 %)</td>
<td>Nil</td>
<td>Short bowel syndrome, intractable malabsorption, proven inflammatory bowel disease, bowel fistula.</td>
<td>Elemental 028 Extra powder: plain, orange, banana 100 gram = £7.24</td>
<td></td>
</tr>
</tbody>
</table>

Powder provides protein equivalent 12.5 g, carbohydrate 59 g, fat 17.45 g, energy 1871 kJ (443 kcal)/100 g.
### Enteral feeds (non-disease specific): 5 g (or more) protein/100 mL

#### Enteral feeds: 1.5 kcal/mL and 5 g (or more) protein/100 mL

Not suitable for use in child under 1 year unless otherwise stated; not recommended for child 1–6 years

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fresubin® 2250 Complete (Fresenius Kabi Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>630 kJ (150 kcal)</td>
<td>5.6 g cows’ milk</td>
<td>18.8 g (sugars 1.5 g)</td>
<td>5.8 g</td>
<td>2 g</td>
<td>Gluten-free Residual lactose Contains fish oil and fish gelatin</td>
<td>Borderline substances standard ACBS indications p. 1421</td>
<td>Fresubin 2250 Complete liquid: 1.5 litre = £15.09</td>
</tr>
<tr>
<td>Fresubin® Energy (Fresenius Kabi Ltd)</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>630 kJ (150 kcal)</td>
<td>5.6 g cows’ milk</td>
<td>18.8 g (sugar content varies with flavour)</td>
<td>5.8 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose Contains fish gelatin Strawberry flavour may contain traces of wheat starch and egg.</td>
<td>Borderline substances standard ACBS indications p. 1421</td>
<td>Fresubin Energy liquid: unflavoured 200 ml = £1.40; 500 ml = £5.20; banana, blackcurrant, cappuccino, chocolate, lemon, strawberry, tropical fruits, vanilla 200 ml = £1.40</td>
</tr>
<tr>
<td>Fresubin® Energy Fibre (Fresenius Kabi Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>630 kJ (150 kcal)</td>
<td>5.6 g cows’ milk</td>
<td>18.8 g (sugars 1.4 g)</td>
<td>5.8 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose Contains fish oil and fish gelatin</td>
<td>Borderline substances standard ACBS indications p. 1421</td>
<td>Fresubin Energy liquid: 1000 ml = £10.21; 1500 ml = £13.69;</td>
</tr>
<tr>
<td>Fresubin® HP Energy (Fresenius Kabi Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>630 kJ (150 kcal)</td>
<td>7.5 g cows’ milk</td>
<td>17 g (sugars 1 g)</td>
<td>5.8 g (MCT 57 %)</td>
<td>Nil</td>
<td>Gluten-free Residual lactose Contains fish oil and fish gelatin</td>
<td>Borderline substances standard ACBS indications p. 1421; also CAPD and haemodialysis</td>
<td>Fresubin HP Energy liquid: 500 ml = £5.29; 1000 ml = £10.59</td>
</tr>
<tr>
<td>Jevity® 1.5 kcal (Abbott Laboratories Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>649 kJ (154 kcal)</td>
<td>6.38 g caseinates and soy isolate</td>
<td>20.1 g (sugars 1.47 g)</td>
<td>4.9 g</td>
<td>2.2 g</td>
<td>Gluten-free Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421 Not suitable for child under 2 years; not recommended for child 2-10 years</td>
<td>Jevity 1.5 kcal liquid: 500 ml = £6.24; 1000 ml = £11.36; 1500 ml = £16.97</td>
</tr>
<tr>
<td>Nutrison® Energy (Nutricia Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>630 kJ (150 kcal)</td>
<td>6 g cows’ milk</td>
<td>18.5 g (sugars 1.5 g)</td>
<td>5.8 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421</td>
<td>Nutrison Energy liquid: 1500 ml = £16.41; 500 ml = £5.83; 1000 ml = £10.97; 500 ml = £5.45</td>
</tr>
<tr>
<td>Nutrison® Energy Multi Fibre (Nutricia Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>630 kJ (150 kcal)</td>
<td>6 g cows’ milk</td>
<td>18.5 g (sugars 1.5 g)</td>
<td>5.8 g</td>
<td>1.5 g</td>
<td>Gluten-free Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421</td>
<td>Nutrison Energy Multi Fibre liquid: 1500 ml = £18.80; 500 ml = £6.10; 500 ml = £6.47; 1000 ml = £12.18</td>
</tr>
<tr>
<td>Osmolite® 1.5 kcal (Abbott Laboratories Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>632 kJ (150 kcal)</td>
<td>6.25 g cows’ milk soya protein isolate</td>
<td>20 g (sugars 4.9 g)</td>
<td>5 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421</td>
<td>Osmolite 1.5 kcal tube feed liquid: 1000 ml = £10.19; 1500 ml = £15.23; 500 ml = £5.60</td>
</tr>
</tbody>
</table>
## Enteral feeds: Less than 1.5 kcal/mL and 5 g (or more) protein/100 mL

Not suitable for use in child under 1 year unless otherwise stated; not recommended for child 1-6 years

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fresubin® 1000 Complete (Fresenius Kabi Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>420 kJ (100 kcal)</td>
<td>5.5 g cows’ milk</td>
<td>12.5 g (sugars 1.1 g)</td>
<td>3.1 g</td>
<td>2 g</td>
<td>Gluten-free Residual lactose Contains fish oil</td>
<td>Borderline substances standard ACBS indications p. 1421</td>
<td>Fresubin 1000 Complete liquid: 1 litre = £10.87</td>
</tr>
<tr>
<td>Fresubin® 1200 Complete (Fresenius Kabi Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>500 kJ (120 kcal)</td>
<td>6 g cows’ milk</td>
<td>15 g (sugars 1.22 g)</td>
<td>4.1 g</td>
<td>2 g</td>
<td>Gluten-free Residual lactose Contains fish oil</td>
<td>Borderline substances standard ACBS indications p. 1421</td>
<td>Fresubin 1200 Complete liquid: 1 litre = £13.84</td>
</tr>
<tr>
<td>Fresubin® 1800 Complete (Fresenius Kabi Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>500 kJ (120 kcal)</td>
<td>6 g cows’ milk</td>
<td>15 g (sugars 1.22 g)</td>
<td>4.1 g</td>
<td>2 g</td>
<td>Gluten-free Residual lactose Contains fish oil</td>
<td>Borderline substances standard ACBS indications p. 1421</td>
<td>Fresubin 1800 Complete liquid: 1.5 litre = £13.84</td>
</tr>
<tr>
<td>Jevelly® Plus (Abbott Laboratories Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>514 kJ (122 kcal)</td>
<td>5.5 g caseinates soy isolates</td>
<td>15.1 g (sugars 890 mg)</td>
<td>3.93 g</td>
<td>2.2 g</td>
<td>Gluten-free Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421 Not suitable for child under 2 years; not recommended for child 2-10 years</td>
<td>Jevelly Plus liquid: 500 ml = £6.20; 1000 ml = £11.28; 1500 ml = £16.86</td>
</tr>
<tr>
<td>Jevelly® Plus HP (Abbott Laboratories Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>551 kJ (131 kcal)</td>
<td>8.13 g cows’ milk soya isolates</td>
<td>14.2 g (sugars 950 mg)</td>
<td>4.33 g</td>
<td>1.5 g</td>
<td>Gluten-free Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421; also CAPD, haemodialysis Not suitable for child under 2 years; not recommended for child 2-10 years</td>
<td>Jevelly Plus HP gluten free liquid: 500 ml = £6.20</td>
</tr>
<tr>
<td>Jevelly® Promote (Abbott Laboratories Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>434 kJ (103 kcal)</td>
<td>5.55 g caseinates soy isolates</td>
<td>12 g (sugars 670 mg)</td>
<td>3.32 g</td>
<td>1.7 g</td>
<td>Gluten-free Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421 Not suitable for child under 2 years; not recommended for child 2-10 years</td>
<td>Jevelly Promote liquid: 1 litre = £10.80</td>
</tr>
<tr>
<td>Nutrison® 800 Complete Multi Fibre (Nutricia Ltd)</td>
<td>Liquid (tube feed) per 100 mL</td>
<td>345 kJ (83 kcal)</td>
<td>5.5 g cows’ milk pea protein soya protein</td>
<td>8.8 g (sugars 600 mg)</td>
<td>2.5 g</td>
<td>1.5 g</td>
<td>Gluten-free Residual lactose Contains fish oil</td>
<td>Borderline substances standard ACBS indications p. 1421 except bowel fistula Not suitable for child under 6 years; not recommended for child 6-12 years</td>
<td>Nutrison 800 Complete Multi Fibre liquid: 1 litre = £10.65</td>
</tr>
</tbody>
</table>
### Enteral feeds: Less than 1.5 kcal/mL and 5 g (or more) protein/100 mL (product list continued)

Not suitable for use in child under 1 year unless otherwise stated; not recommended for child 1-6 years

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nutrison® 1000 Complete Multi Fibre (Nutricia Ltd)</td>
<td>Liquid (tube feed per 100 mL)</td>
<td>420 kJ (100 kcal)</td>
<td>5.5 g cows’ milk</td>
<td>11.3 g (sugars 700 mg)</td>
<td>3.7 g</td>
<td>2 g</td>
<td>Gluten-free Residual lactose</td>
<td>Disease related malnutrition in patients with low energy and/or low fluid requirements</td>
<td>Nutrison 1000 Complete Multi Fibre liquid: 1 litre = £11.29</td>
</tr>
<tr>
<td>Nutrison® 1200 Complete Multi Fibre (Nutricia Ltd)</td>
<td>Liquid (tube feed per 100 mL)</td>
<td>505 kJ (120 kcal)</td>
<td>5.5 g cows’ milk</td>
<td>15 g (sugars 1.2 g)</td>
<td>4.3 g</td>
<td>2 g</td>
<td>Gluten-free Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421 except bowel fistula</td>
<td>Nutrison 1200 Complete Multi Fibre liquid: 1000 ml = £11.95; 1500 ml = £17.94</td>
</tr>
<tr>
<td>Nutrison® MCT (Nutricia Ltd)</td>
<td>Liquid (tube feed per 100 mL)</td>
<td>420 kJ (100 kcal)</td>
<td>5 g cows’ milk</td>
<td>12.6 g (sugars 1 g)</td>
<td>3.3 g (MCT 61%)</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421</td>
<td>Nutrison MCT liquid: 1000 ml = £10.17</td>
</tr>
<tr>
<td>Nutrison® Protein Plus (Nutricia Ltd)</td>
<td>Liquid (tube feed per 100 mL)</td>
<td>525 kJ (125 kcal)</td>
<td>6.3 g cows’ milk</td>
<td>14.2 g (sugars 1.1 g)</td>
<td>4.9 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421</td>
<td>Nutrison Protein Plus liquid: 1 litre = £10.44</td>
</tr>
<tr>
<td>Nutrison® Protein Plus Multi Fibre (Nutricia Ltd)</td>
<td>Liquid (tube feed per 100 mL)</td>
<td>535 kJ (128 kcal)</td>
<td>6.3 g cows’ milk</td>
<td>14.1 g (sugars 1.0 g)</td>
<td>4.9 g</td>
<td>1.5 g</td>
<td>Gluten-free Residual lactose</td>
<td>Disease related malnutrition</td>
<td>Nutrison Protein Plus Multifibre liquid: 1 litre = £11.64</td>
</tr>
<tr>
<td>Osmolite® Plus (Abbott Laboratories Ltd)</td>
<td>Liquid (tube feed per 100 mL)</td>
<td>508 kJ (121 kcal)</td>
<td>5.55 g caseinates</td>
<td>15.8 g (sugars 730 mg)</td>
<td>3.93 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421 Not suitable for child under 10 years</td>
<td>Osmolite Plus liquid: 1500 ml = £14.15; 1000 ml = £9.46; 500 ml = £5.20</td>
</tr>
<tr>
<td>Peptamen® HN (Nestle Health Science)</td>
<td>Liquid (tube feed per 100 mL)</td>
<td>556 kJ (133 kcal)</td>
<td>6.6 g whey protein hydrolysates</td>
<td>15.6 g (sugars 1.4 g)</td>
<td>4.9 g (MCT 70%)</td>
<td>Nil</td>
<td>Gluten-free Residual lactose Hydrolysed with pork trypsin</td>
<td>Short bowel syndrome, intractable malabsorption, proven inflammatory bowel disease, bowel fistula Not suitable for child under 3 years</td>
<td>Peptamen HN liquid: 500 ml = £7.34</td>
</tr>
<tr>
<td>Perative® (Abbott Laboratories Ltd)</td>
<td>Liquid (sip or tube feed per 100 mL)</td>
<td>552 kJ (131 kcal)</td>
<td>6.7 g casein hydrolysates</td>
<td>17.7 g (sugars 660 mg)</td>
<td>3.7 g (MCT 42%)</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421 Not suitable for child under 5 years</td>
<td>Perative liquid: 1000 ml = £13.66; 500 ml = £7.50</td>
</tr>
</tbody>
</table>

### Enteral feeds: More than 1.5 kcal/mL and 5 g (or more) protein/100 mL

Not suitable for use in child under 1 year unless otherwise stated; not recommended for child 1-6 years

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ensure® Twocol (Abbott Laboratories Ltd)</td>
<td>Liquid (sip or tube feed per 100 mL)</td>
<td>838 kJ (200 kcal)</td>
<td>8.4 g cows’ milk</td>
<td>21 g (sugars 4.5 g)</td>
<td>8.9 g</td>
<td>1 g</td>
<td>Gluten-free Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421; also haemodialysis and CAPD</td>
<td>Ensure TwoCal liquid: banana, neutral, strawberry, vanilla; 200 ml = £2.22</td>
</tr>
<tr>
<td>TwoCal® (Abbott Laboratories Ltd)</td>
<td>Liquid (tube feed per 100 mL)</td>
<td>837 kJ (200 kcal)</td>
<td>8.4 g cows’ milk caseinates</td>
<td>21 g (sugars 4.5 g)</td>
<td>8.9 g</td>
<td>1 g</td>
<td>Gluten-free Residual lactose</td>
<td>Adults with or at risk of disease-related malnutrition, catabolic or fluid-restricted patients, and other patients requiring a 2 kcal/mL feed</td>
<td>TwoCal liquid: 1 litre = £14.80</td>
</tr>
</tbody>
</table>
## Enteral feeds (non-disease specific): Child under 12 years see BNF for Children

### Table 2 Nutritional supplements (non-disease specific)

#### Nutritional supplements: 1 kcal/mL and less than 5 g protein/100 mL

Not suitable for use in child under 1 year; use with caution in child 1-5 years unless otherwise stated.

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ensure® (Abbott Laboratories Ltd)</td>
<td>Liquid (sip or tube feed) per 100 mL</td>
<td>423 kJ (100 kcal)</td>
<td>4 g caseinates soy isolate</td>
<td>13.6 g (sugars 3.93 g)</td>
<td>3.36 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421</td>
<td>Ensure liquid: vanilla, chocolate, coffee 250 ml = £2.26</td>
</tr>
</tbody>
</table>

#### Nutritional supplements: More than 1 kcal/mL and less than 5 g protein/100 mL

Not suitable for use in child under 1 year; use with caution in child 1-5 years unless otherwise stated.

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>AYMES® Shake (Aymes International Ltd)</td>
<td>Standard dilution of powder (57 g in 200 mL water) (sip feed) per 100 mL</td>
<td>530.5 kJ (126 kcal)</td>
<td>4.5 g cows’ milk</td>
<td>17.5 g (sugars 8.4 g)</td>
<td>4.2 g</td>
<td>Nil</td>
<td>Gluten-free Contains lactose</td>
<td>Borderline substances standard ACBS indications p. 1421</td>
<td>Aymes Shake Sample Pack powder: 285 gram = £4.78; Aymes Shake powder: banana, strawberry 399 gram = £4.27; chocolate, neutral, vanilla 399 gram = £4.27</td>
</tr>
<tr>
<td>Ensure® Plus Juice (Abbott Laboratories Ltd)</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>638 kJ (150 kcal)</td>
<td>4.8 g whey protein isolate</td>
<td>32.7 g (sugars 9.4 g)</td>
<td>Nil</td>
<td>Nil</td>
<td>Gluten-free Residual lactose Non-milk taste</td>
<td>Borderline substances standard ACBS indications p. 1421</td>
<td>Ensure Plus Juice liquid: apple, fruit punch, lemon &amp; lime, orange, peach 220 ml = £1.97</td>
</tr>
<tr>
<td>Fortijuce® (Nutricia Ltd)</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>640 kJ (150 kcal)</td>
<td>4.0 g cows’ milk</td>
<td>33.5 g (sugars 13.1 g)</td>
<td>Nil</td>
<td>Nil</td>
<td>Gluten-free Residual lactose Non-milk taste</td>
<td>Borderline substances standard ACBS indications p. 1421</td>
<td>Fortijuce Starter Pack liquid: 800 ml = £8.08; Fortijuce liquid: apple, blackcurrant, lemon, orange, strawberry, tropical 200 ml = £2.02; forest fruits 200 ml = £2.02</td>
</tr>
<tr>
<td>Fresubin® Jucy Drink (Fresenius Kabi Ltd)</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>630 kJ (150 kcal)</td>
<td>4 g whey protein</td>
<td>33.5 g (sugars 8 g)</td>
<td>Nil</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421; also CAPD, haemodialysis</td>
<td>Fresubin Jucy drink: apple, blackcurrant, cherry, orange, pineapple 800 ml = £7.96</td>
</tr>
<tr>
<td>Resource® Dessert Energy (Nestle Health Science)</td>
<td>Semi-solid per 100 g</td>
<td>671 kJ (160 kcal)</td>
<td>4.8 g cows’ milk</td>
<td>21.2 g (sugars 9.9 g)</td>
<td>6.2 g</td>
<td>Nil</td>
<td>Gluten-free Contains lactose</td>
<td>Borderline substances standard ACBS indications p. 1421; also CAPD, haemodialysis.</td>
<td>Resource Dessert Energy semi-solid food: caramel, chocolate, vanilla 125 gram = £1.63</td>
</tr>
<tr>
<td>Resource® Fruit (Nestle Health Science)</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>520 kJ (125 kcal)</td>
<td>4 g whey protein hydrolysate</td>
<td>27 g (sugars 9.5 g)</td>
<td>less than 0.2 g</td>
<td>less than 0.2 g</td>
<td>Gluten-free Residual lactose Non-milk taste</td>
<td>Borderline substances standard ACBS indications p. 1421</td>
<td>Resource Fruit liquid: apple, orange, pear &amp; cherry, raspberry &amp; blackcurrant 800 ml = £7.35</td>
</tr>
</tbody>
</table>
### Nutritional supplements: 5 g (or more) protein/100 mL

**Not suitable for use in child under 1 year; use with caution in child 1-5 years unless otherwise stated.**

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Altraplen® Protein</strong></td>
<td>Liquid (sip feed) per 100 mL</td>
<td>632 kJ (150 kcal)</td>
<td>10 g cows’ milk soya protein concentrate</td>
<td>15 g (sugars 4.6 g)</td>
<td>5.6 g</td>
<td>Nil</td>
<td>Gluten-free, Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421; Not suitable for child under 3 years; use with caution in child 3-6 years</td>
<td>Altraplen Protein liquid: strawberry, vanilla 800 ml = £5.96</td>
</tr>
<tr>
<td><strong>Ensure® Plus Advance</strong></td>
<td>Liquid (sip or tube feed) per 100 mL</td>
<td>631 kJ (150 kcal)</td>
<td>9.1 g cows’ milk soya protein isolate whey protein concentrate</td>
<td>16.8 g (sugars 6.8 g)</td>
<td>4.8 g</td>
<td>0.75 g</td>
<td>Gluten-free, Residual lactose</td>
<td>Frail elderly people (this is defined as older than 65 years with BMI less than or equal to 23 kg/m² where clinical assessment and nutritional screening show the individual to be at risk of undernutrition). Not suitable as the sole source of nutrition.</td>
<td>Ensure Plus Advance liquid: banana, chocolate, coffee, strawberry, vanilla 820 ml = £2.08</td>
</tr>
<tr>
<td><strong>Ensure® Plus Fibre</strong></td>
<td>Starter pack (5-10 day’s supply), contains Ensure® Plus Commence (various flavours), 1 pack (10 × 200 mL) = £11.20</td>
<td>652 kJ (155 kcal)</td>
<td>6.25 g cows’ milk soya protein isolate</td>
<td>20.2 g (sugars 5.5 g)</td>
<td>4.92 g</td>
<td>2.5 g</td>
<td>Gluten-free, Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421; also CAPD, haemodialysis.</td>
<td>Ensure Plus Fibre liquid: banana, chocolate, raspberry, vanilla 200 ml = £2.02</td>
</tr>
<tr>
<td><strong>Ensure® Plus Milkshake style</strong></td>
<td>Liquid (sip or tube feed) per 100 mL</td>
<td>632 kJ (150 kcal)</td>
<td>6.25 g cows’ milk soya protein isolate</td>
<td>20.2 g (sugars 6.89 g)</td>
<td>4.92 g</td>
<td>Nil</td>
<td>Gluten-free, Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421; also CAPD, haemodialysis</td>
<td>Ensure Plus milkshake style liquid: banana, chocolate, coffee, fruits of the forest, neutral, orange, peach, raspberry, strawberry, vanilla 220 ml = £1.40</td>
</tr>
<tr>
<td><strong>Ensure® Plus Savoury</strong></td>
<td>Liquid (sip or tube feed) per 100 mL</td>
<td>632 kJ (150 kcal)</td>
<td>6.25 g cows’ milk soya protein isolate</td>
<td>20.2 g (sugars 1.13 g)</td>
<td>4.92 g</td>
<td>Nil</td>
<td>Gluten-free, Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421; also CAPD, haemodialysis</td>
<td>Ensure Plus savoury liquid: chicken, mushroom 220 ml = £1.40</td>
</tr>
<tr>
<td><strong>Ensure® Plus Yoghurt style</strong></td>
<td>Liquid (sip feed) per 100 mL</td>
<td>632 kJ (150 kcal)</td>
<td>6.25 g cows’ milk</td>
<td>20.2 g (sugars 11.7 g)</td>
<td>4.92 g</td>
<td>Nil</td>
<td>Gluten-free, Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421; also CAPD, haemodialysis</td>
<td>Ensure Plus yoghurt style liquid: orchard peach, strawberry swirl 200 ml = £1.40</td>
</tr>
<tr>
<td><strong>Fortisip® Bottle</strong></td>
<td>Liquid (sip feed) per 100 mL</td>
<td>630 kJ (150 kcal)</td>
<td>6 g cows’ milk</td>
<td>18.4 g</td>
<td>5.8 g</td>
<td>Nil</td>
<td>Gluten-free, Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421; Not suitable for child under 3 years; use with caution in child 3-5 years.</td>
<td>Fortisip Bottle: banana, caramel, chocolate, neutral, orange, strawberry, tropical fruit, vanilla 200 ml = £1.40</td>
</tr>
<tr>
<td>Product</td>
<td>Formulation</td>
<td>Energy</td>
<td>Protein</td>
<td>Carbohydrate</td>
<td>Fat</td>
<td>Fibre</td>
<td>Special Characteristics</td>
<td>ACBS Indications</td>
<td>Presentation &amp; Flavour</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
<td>--------</td>
<td>---------</td>
<td>--------------</td>
<td>-----</td>
<td>-------</td>
<td>------------------------</td>
<td>-----------------</td>
<td>------------------------</td>
</tr>
<tr>
<td><strong>Ensure® Plus Crème</strong>&lt;br&gt;(Abbott Laboratories Ltd)</td>
<td>Semi-solid per 100 g</td>
<td>574 kJ (137 kcal)</td>
<td>5.68 g cow’s milk soy protein isolates</td>
<td>18.4 g (sugars 12.4 g)</td>
<td>4.47 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose Contains soya</td>
<td>Borderline substances standard ACBS indications p. 1421; also CAPD, haemodialysis. Not suitable for child under 3 years; use with caution in child 3-5 years.</td>
<td>Ensure Plus Creme: chocolate, neutral, vanilla 500 gram = £7.51</td>
</tr>
<tr>
<td><strong>Nutilis® Fruit Stage 3</strong>&lt;br&gt;(Nutricia Ltd)</td>
<td>Semi-Solid per 100 g</td>
<td>560 kJ (133 kcal)</td>
<td>7 g whey isolate</td>
<td>16.7 g (sugars 11.3 g)</td>
<td>4 g</td>
<td>2.6 g</td>
<td>Gluten-free Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421 except bowel fistula; also CAPD, haemodialysis. Not suitable for child under 3 years; use with caution in child 3-5 years.</td>
<td>Nutilis Fruit Stage 3: apple, strawberry 450 gram = £7.08</td>
</tr>
<tr>
<td><strong>Oral Impact®</strong>&lt;br&gt;(Nestle Health Science)</td>
<td>Standard dilution of powder (74 g in 250 mL water) (sip feed) per 100 mL</td>
<td>425 kJ (101 kcal)</td>
<td>5.6 g cows’ milk</td>
<td>13.4 g (sugars 7.4 g)</td>
<td>2.8 g</td>
<td>1 g</td>
<td>Residual lactose Contains fish oil</td>
<td>Pre-operative nutritional supplement for malnourished patients or patients at risk of malnourishment. Not suitable for child under 3 years; use with caution in child 3-5 years.</td>
<td>Oral Impact oral powder 74g sachets: citrus, coffee, tropical 5 sachet = £16.93</td>
</tr>
</tbody>
</table>

**Nutritional supplements: Less than 1.5 kcal/mL and 5 g (or more) protein/100 mL**

Not suitable for use in child under 1 year; use with caution in child 1-5 years unless otherwise stated.

<table>
<thead>
<tr>
<th>Fortisip® Range (Nutricia Ltd)</th>
<th>Starter pack contains 4 × Fortisip® Bottle, 4 × Fortijuce® 2 × Fortisip® Yoghurt Style, 1 pack (10 × 200 mL) = £20.20</th>
</tr>
</thead>
</table>

| Fortisip® Yoghurt Style (Nutricia Ltd) | Liquid (sip feed) per 100 mL | 630 kJ (150 kcal) | 6 g cows’ milk | 18.7 g (sugars 10.8 g) | 5.8 g | 0.2 g | Gluten-free Contains lactose | Borderline substances standard ACBS indications p. 1421 Not suitable for child under 3 years | Fortisip Yoghurt Style liquid vanilla & lemon: 200 ml = £2.06 |

| Fresubin® Protein Energy Drink (Fresenius Kabi Ltd) | Liquid (sip feed) per 100 mL | 630 kJ (150 kcal) | 10 g cows’ milk | 12.4 g (sugars 6.4 g) | 6.7 g | Nil | Gluten-free Residual lactose Contains fish gelatin | Borderline substances standard ACBS indications p. 1421; also CAPD, haemodialysis. Fresubin Protein Energy drink: cappuccino, chocolate, tropical fruits, vanilla, wild strawberry 200 ml = £2.08 |

| Fresubin® Thickened (Fresenius Kabi Ltd) | Liquid (sip feed) per 100 mL | 630 kJ (150 kcal) | 10 g cows’ milk | 12.2 g (sugars 7.1 g) | 6.7 g | 0.48 g | Gluten-free Residual lactose | Dysphagia or disease-related malnutrition. Not suitable for child under 3 years; use with caution in child 3-4 years. Fresubin Thickened Stage 1 syrup: vanilla, wild strawberry 800 ml = £9.40; Fresubin Thickened Stage 2 custard: vanilla, wild strawberry 800 ml = £9.40 |

| Fresubin® YOcrème (Fresenius Kabi Ltd) | Semi-solid per 100 g | 630 kJ (150 kcal) | 7.5 g whey protein | 19.5 g (sugars 16.8 g) | 4.7 g | Nil | Gluten-free Contains lactose | Dysphagia, or presence or risk of malnutrition Not suitable for child under 3 years | Fresubin YOcreme dessert: apricot-peach, biscuit, lemon, raspberry 500 gram = £8.16 |

Powder provides: protein 16.8 g, carbohydrate 40.2 g, fat 8.3 g, fibre 3 g, energy 1276 kJ (303 kcal)/74 g.
### Nutritional supplements: More than 1.5 kcal/mL and 5 g (or more) protein/100 mL

Not suitable for use in child under 1 year; use with caution in child 1-5 years unless otherwise stated.

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Altraplen® Compact</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>1008 kJ (240 kcal)</td>
<td>9.6 g cows' milk soya protein</td>
<td>28.8 g (sugars 11.6 g)</td>
<td>9.6 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421</td>
<td>Altraplen Compact liquid: vanilla 500 ml = £5.80; strawberry 500 ml = £5.80</td>
</tr>
<tr>
<td>Complan® Shake</td>
<td>Powder per 57 g</td>
<td>1057 kJ (251 kcal)</td>
<td>8.8 g cows' milk</td>
<td>35.2 g (sugars 22.7 g)</td>
<td>8.4 g</td>
<td>Trace</td>
<td>Gluten-free Contains lactose</td>
<td>Borderline substances standard ACBS indications p. 1421</td>
<td>Complan Shake Starter Pack sachets: 5 sachet = £4.39; Complan Shake oral powder 57 g sachets: banana, chocolate, milk, strawberry 4 sachet = £2.80; vanilla 4 sachet = £2.80</td>
</tr>
<tr>
<td>Ensure® Compact (Abbott Labs)</td>
<td>Liquid (sip or tube feed) per 100 mL</td>
<td>1008 kJ (240 kcal)</td>
<td>10.2 g cows' milk</td>
<td>28.8 g (sugars 6.2 g)</td>
<td>9.35 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Borderline substances standard ACBS indications, p. 1421</td>
<td>Ensure Compact liquid: banana, strawberry, vanilla 4 x 125 ml = £5.40</td>
</tr>
<tr>
<td>Ensure® Shake (Abbott Labs)</td>
<td>Powder per 100 mL</td>
<td>1852 kJ (443 kcal)</td>
<td>17.8 g cows' milk whey protein concentrate</td>
<td>59 g (sugars 33.7 g)</td>
<td>15.1 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Borderline substances standard ACBS indications, p. 1421</td>
<td>Ensure Shake oral powder 57 g sachets: banana, chocolate, strawberry, vanilla 7 sachet = £4.90</td>
</tr>
<tr>
<td>Foodlink® Complete (Nualtra)</td>
<td>Powder per 100 g</td>
<td>1826 kJ (434 kcal)</td>
<td>21.3 g cows' milk</td>
<td>56.7 g</td>
<td>13.5 g</td>
<td>Nil</td>
<td>Contains lactose</td>
<td>Borderline substances standard ACBS indications p. 1421</td>
<td>Foodlink Complete powder: banana, chocolate, natural strawberry 399 gram = £4.27</td>
</tr>
<tr>
<td>Fortisip® Compact (Nualtra)</td>
<td>Semi-solid per 100 g</td>
<td>675 kJ (160 kcal)</td>
<td>9.5 g cows' milk</td>
<td>19.2 g (sugars 10.6 g)</td>
<td>5 g</td>
<td>0.1 g</td>
<td>Gluten-free Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421; also CAPD, haemodialysis. Not suitable for child under 3 years; use with caution in child 3-5 years.</td>
<td>Fortisip Complete dessert: banana, chocolate, forest fruits, vanilla 500 gram = £7.84</td>
</tr>
</tbody>
</table>

Powder 57 g reconstituted with 200 mL whole milk provides: protein 15.6 g, carbohydrate 44.5 g, fat 16.4 g, energy 1621 kJ (387 kcal).

Powder 57 g reconstituted with 200 mL whole milk provides: protein 17 g, carbohydrate 43.2 g, fat 16.6 g, energy 1626 kJ (389 kcal).

Recommended serving = 4 heaped dessertspoonfuls in 200 mL full cream milk provides: protein 18.9 g, carbohydrate 41.8 g, fat 15.7 g, energy 1605 kJ (383 kcal).

Recommended serving = 4 heaped dessertspoonfuls (or the contents of a 63-g sachet) in 200 mL full cream milk provides: protein 19 g, carbohydrate 42.7 g, fat 15.8 g, fibre 4.5 g, energy 1624 kJ (388 kcal).
<table>
<thead>
<tr>
<th>Product</th>
<th>Type</th>
<th>Nutritional Info</th>
<th>Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fortisip^® Compact Fibre</td>
<td>Liquid (sip feed)</td>
<td>1000 kJ (240 kcal), 9.4 g cows’ milk, 25.2 g (sugars 13.9 g), 10.4 g, 3.6 g</td>
<td>Borderline substances standard ACBS indications p. 1421 Not suitable for child under 3 years; use with caution in child 3-5 years.</td>
</tr>
<tr>
<td>Nutricia Ltd</td>
<td>per 100 mL</td>
<td>100 kL (240 kcal)</td>
<td>Fortisip Compact Fibre Starter Pack liquid: 500 ml = £8.36; Fortisip Compact Fibre liquid: mocha, strawberry, vanilla 500 ml = £8.36</td>
</tr>
<tr>
<td>Fortisip^® Compact Protein</td>
<td>Liquid (sip feed)</td>
<td>1010 kJ (240 kcal), 14.4 g cows’ milk, 24.4 g (sugars 13.3 g), 9.4 g, Nil</td>
<td>Borderline substances standard ACBS indications p. 1421 Not suitable for child under 3 years; use with caution in child 3-5 years.</td>
</tr>
<tr>
<td>Nutricia Ltd</td>
<td>per 100 mL</td>
<td>100 kL (240 kcal)</td>
<td>Fortisip Compact Protein Starter Pack liquid: 500 ml = £8.00; Fortisip Compact Protein liquid: banana, mocha, strawberry, vanilla 500 ml = £8.00</td>
</tr>
<tr>
<td>Fortisip^® Extra</td>
<td>Liquid (sip feed)</td>
<td>675 kJ (160 kcal), 10 g cows’ milk, 18.1 g (sugars 9 g), 5.3 g, Nil</td>
<td>Borderline substances standard ACBS indications p. 1421 Not suitable for child under 3 years; use with caution in child 3-5 years.</td>
</tr>
<tr>
<td>Nutricia Ltd</td>
<td>per 100 mL</td>
<td>100 kL (240 kcal)</td>
<td>Fortisip Extra liquid: strawberry, vanilla 200 ml = £2.22</td>
</tr>
<tr>
<td>Fresubin^® 2 kcal Drink</td>
<td>Liquid (sip feed)</td>
<td>840 kJ (200 kcal), 10 g cows’ milk, 22.5 g (sugars 5.8 g), 7.8 g, Nil</td>
<td>Borderline substances standard ACBS indications p. 1421; also CAPD, haemodialysis. Not suitable for use in child under 1 year; use with caution in child 1-5 years.</td>
</tr>
<tr>
<td>Fresenius Kabi Ltd</td>
<td>per 100 mL</td>
<td>200 kL (500 kcal)</td>
<td>Fresubin 2 kcal drink: apricot-peach, cappuccino, chocolate, lemon, neutral 200 ml = £2.02</td>
</tr>
<tr>
<td>Fresubin^® 2 kcal Fibre Drink</td>
<td>Liquid (sip feed)</td>
<td>840 kJ (200 kcal), 10 g cows’ milk, 22.5 g (sugars 5.8 g), 7.8 g, 1.6 g</td>
<td>Borderline substances standard ACBS indications p. 1421; also CAPD, haemodialysis. Not suitable for use in child under 1 year; use with caution in child 1-5 years.</td>
</tr>
<tr>
<td>Fresenius Kabi Ltd</td>
<td>per 100 mL</td>
<td>200 kL (500 kcal)</td>
<td>Fresubin 2 kcal Fibre drink: apricot-peach, cappuccino, chocolate, lemon, neutral 200 ml = £2.02</td>
</tr>
<tr>
<td>Fresubin^® Powder Extra</td>
<td>Powder</td>
<td>1764 kJ (420 kcal), 17.5 g cows’ milk whey protein, 63 g (sugars 24.7 g), 10.9 g, Nil</td>
<td>Borderline substances standard ACBS indications p. 1421 Not suitable for child under 1 year; use with caution in child 1-5 years.</td>
</tr>
<tr>
<td>Fresenius Kabi Ltd</td>
<td>per 100 g</td>
<td>420 kL (1050 kcal)</td>
<td>Fresubin Powder Extra oral powder 62 g sachets: chocolate, neutral, strawberry, vanilla 7 sachet = £5.32</td>
</tr>
<tr>
<td>Nutrilis^® Complete Stage 1</td>
<td>Liquid (pre-</td>
<td>1010 kJ (240 kcal), 9.6 g cows’ milk, 29.1 g (sugars 5.4 g), 9.3 g, 3.2 g</td>
<td>Borderline substances standard ACBS indications p. 1421 Not suitable for child under 3 years; use with caution in child 3-5 years.</td>
</tr>
<tr>
<td>Nutricia Ltd</td>
<td>thickened)</td>
<td>100 kL (240 kcal)</td>
<td>Nutrilis Complete Stage 1 liquid: strawberry, vanilla 500 ml = £8.84</td>
</tr>
<tr>
<td>Nutrilis^® Complete Stage 2</td>
<td>Semi-solid</td>
<td>1030 kJ (245 kcal), 9.6 g cows’ milk, 29.1 g (sugars 11.8 g), 9.4 g, 3.2 g</td>
<td>Borderline substances standard ACBS indications p. 1421 Not suitable for child under 3 years; use with caution in child 3-6 years.</td>
</tr>
<tr>
<td>Nutricia Ltd</td>
<td>per 100 g</td>
<td>245 kL (600 kcal)</td>
<td>Nutrilis Complete Stage 2 custard: chocolate, strawberry, vanilla 500 gram = £8.84</td>
</tr>
<tr>
<td>Nutricrem^®</td>
<td>Semi-solid</td>
<td>756 kJ (180 kcal), 10 g cows’ milk soya protein, 18.8 g (sugars 9.7 g), 7.2 g, Nil</td>
<td>Borderline substances standard ACBS indications p. 1421 Not suitable for child under 3 years; use with caution in child 3-6 years.</td>
</tr>
<tr>
<td>Nualtra Ltd</td>
<td>per 100 g</td>
<td>180 kL (450 kcal)</td>
<td>Nutricrem desserts: strawberry, vanilla 500 gram = £5.76</td>
</tr>
</tbody>
</table>

Powder 62 g reconstituted with 200 ml whole milk provides: protein 17.7 g, carbohydrate 48.5 g, fat 14.8 g, energy 1658 kJ (397 kcal).
<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Renilon® 7.5 (Nutricia Ltd)</td>
<td>Liquid (sip feed)</td>
<td>840 kJ</td>
<td>7.5 g</td>
<td>20 g</td>
<td>10 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421</td>
<td>Renilon 7.5 liquid: apricot, caramel 500 ml = £8.80</td>
</tr>
<tr>
<td>Resource® 2.0 Fibre</td>
<td>Liquid (sip feed)</td>
<td>836 kJ</td>
<td>9 g</td>
<td>21.4 g</td>
<td>8.7 g</td>
<td>2.5 g</td>
<td>Gluten-free Residual lactose</td>
<td>Borderline substances standard ACBS indications p. 1421</td>
<td>Resource Fibre 2.0 liquid: apricot, coffee, neutral, strawberry, summer fruit, vanilla 200 ml = £1.88</td>
</tr>
</tbody>
</table>

**Table 3 Specialised formulas**

Specialised formulas: Infant and child see BNF for Children

Specialised formulas for specific clinical conditions

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcalcit® (Nutricia Ltd)</td>
<td>Standard dilution (30%) of powder per 100 mL</td>
<td>567 kJ (135 kcal)</td>
<td>4.5 g caseinate whey</td>
<td>17.4 g (sugars 3.2 g)</td>
<td>5.3 g</td>
<td>Nil</td>
<td>Residual lactose</td>
<td>Crohn's disease Not suitable for child under 1 year; use as nutritional supplement only in children 1-6 years.</td>
<td>Alcalcit oral powder: 400 gram = £21.79</td>
</tr>
</tbody>
</table>

Powder provides: protein 15 g, carbohydrate 58 g, fat 17.5 g, energy 1889 kJ (450 kcal)/100 g.

| Forticare® (Nutricia Ltd)     | Liquid (sip feed) per 100 mL | 675 kJ (160 kcal) | 9 g cows’ milk | 19.1 g (sugars 13.6 g) | 5.3 g | 2.1 g | Gluten-free Residual lactose Contains fish oil | Nutritional supplement in patients with lung cancer undergoing chemotherapy, or with pancreatic cancer Not suitable in child under 3 years | Forticare liquid: cappuccino, orange & lemon, peach & ginger 500 ml = £9.08 |

| Heparon® Junior (Nutricia Ltd) | Standard dilution (18%) of powder per 100 mL | 363 kJ (86 kcal) | 2 g cows’ milk | 11.6 g (sugars 2.9 g) | 3.6 g | Nil | Electrolytes/100 mL: Na⁺ 0.56 mmol K⁺ 1.9 mmol Ca⁺⁺ 2.3 mmol P⁺ 1.6 mmol | Enteral feed or nutritional supplement for children with acute or chronic liver failure | Heparon Junior powder: 400 gram = £21.95 |

Powder provides: protein 11.1 g, carbohydrate 64.2 g, fat 19.9 g, energy 2016 kJ (480 kcal)/100 g.

| KetoCal® (Nutricia Ltd)       | Standard dilution (20%) of powder per 100 mL | 602 kJ (146 kcal) | 3.1 g cows’ milk with additional amino acids | 600 mg (sugars 120 mg) | 14.6 g (LCT 100 %) | Nil | Electrolytes/100 mL: Na⁺ 4.3 mmol K⁺ 4.1 mmol Ca⁺⁺ 2.15 mmol P⁺ 2.77 mmol | Enteral feed or nutritional supplement as part of ketogenic diet in management of epilepsy resistant to drug therapy, in children over 1 year, only on the advice of secondary care physician with experience of ketogenic diet. | KetoCal 4:1 powder: unflavoured, vanilla 300 gram = £30.91 |

Powder provides: protein 15.25 g, carbohydrate 3 g, fat 73 g, energy 3011 kJ (730 kcal)/100 g.
<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Calories</th>
<th>Proteins</th>
<th>Carbohydrates</th>
<th>Fats</th>
<th>Energy</th>
<th>Electrolytes</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>KetoCal® 3:1 (Nutricia Ltd)</td>
<td>Powder (sip or tube feed when reconstituted) per 100 g</td>
<td>2003 kJ (477 kcal)</td>
<td>4.6 g casein and whey with additional amino acids</td>
<td>70.8 g</td>
<td>19.3 g</td>
<td>Nil</td>
<td>Electrolytes/100 mL: Na⁺ 1.3 mmol K⁺ 2.4 mmol Ca²⁺ 2.2 mmol P⁺ 1.7 mmol</td>
<td>Enteral feed or nutritional supplement for adults and children over 1 year with chronic renal failure.</td>
</tr>
<tr>
<td>KetoCal® 4:1 LQ (Nutricia Ltd)</td>
<td>Liquid (sip or tube feed) per 100 mL</td>
<td>620 kJ (150 kcal)</td>
<td>3.09 g casein and whey with additional amino acids</td>
<td>610 mg (sugars 230 mg)</td>
<td>14.8 g (LCT 100 %)</td>
<td>1.12 g</td>
<td>Electrolytes/100 mL: Na⁺ 4.9 mmol K⁺ 0.6 mmol Ca²⁺ 2.8 mmol P⁺ 3.1 mmol</td>
<td>Enteral feed or nutritional supplement as part of ketogenic diet in management of drug resistant epilepsy or other conditions for which a ketogenic diet is indicated in children from birth to 6 years; as a nutritional supplement in children over 6 years.</td>
</tr>
<tr>
<td>Kindergen® (Nutricia Ltd)</td>
<td>Standard dilution (20%) of powder per 100 mL</td>
<td>421 kJ (101 kcal)</td>
<td>1.5 g whey protein</td>
<td>11.8 g (sugars 1.2 g)</td>
<td>5.3 g (LCT 93 %)</td>
<td>Nil</td>
<td>Electrolytes/100 mL: Na⁺ 2 mmol K⁺ 0.6 mmol Ca²⁺ 2.8 mmol P⁺ 3 mmol</td>
<td>Enteral feed or nutritional supplement for children with chronic renal failure receiving peritoneal rapid overnight dialysis.</td>
</tr>
<tr>
<td>Modulen IBD® (Nestle Health Science)</td>
<td>Powder (sip or tube feed when reconstituted) per 100 g</td>
<td>420 kJ (100 kcal)</td>
<td>3.6 g casein</td>
<td>11 g (sugars 3.98 g)</td>
<td>4.7 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose</td>
<td>Crohn's disease active phase, and in remission if malnourished.</td>
</tr>
<tr>
<td>ProSure® (Abbott Laboratories Ltd)</td>
<td>Liquid (sip or tube feed) per 100 mL</td>
<td>536 kJ (127 kcal)</td>
<td>6.65 g cows' milk</td>
<td>18.3 g (sugars 2.95 g)</td>
<td>2.56 g</td>
<td>2.07 g</td>
<td>Gluten-free Residual lactose Contains fish oil</td>
<td>Nutritional supplement for patients with pancreatic cancer. Not suitable for child under 1 year; use with caution in child 1-4 years.</td>
</tr>
<tr>
<td>Renamil® (Stanningley Pharma Ltd)</td>
<td>Powder (sip or tube feed when reconstituted) per 100 g</td>
<td>2003 kJ (477 kcal)</td>
<td>4.6 g cows' milk</td>
<td>70.8 g</td>
<td>19.3 g</td>
<td>Nil</td>
<td>Contains lactose Gluten-free Electrolytes/100 g: Na⁺ 1.04 mmol K⁺ 0.13 mmol Ca²⁺ 10.22 mmol P⁺ 1.06 mmol</td>
<td>Enteral feed or nutritional supplement for adults and children over 1 year with chronic renal failure.</td>
</tr>
</tbody>
</table>

Powder provides: protein 15.3 g, carbohydrate 7.2 g, fat 67.7 g, energy 2927 kJ (699 kcal)/100 g.

KetoCal® 3.1 powder: 300 gram = £29.91
KetoCal 4:1 LQ liquid; unflavoured, vanilla 200 ml = £4.41
Kindergen powder: 400 gram = £29.47
Modulen IBD® powder: 400 gram = £15.06
ProSure® liquid: 220 ml = £3.34; 240 ml = £3.34
Renamil® powder: 1000 gram = £25.40
### Table 3 Specialised formulas (product list continued)

**Specialised formulas for specific clinical conditions**

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Renapro® (Stanningley Pharma Ltd)</td>
<td>Powder per 100 g</td>
<td>1580 kJ (372 kcal)</td>
<td>90 g whey protein</td>
<td>800 mg</td>
<td>1 g</td>
<td>Nil</td>
<td>Gluten-free, Residual lactose, Electrolytes/100 g: Na⁺ 23 mmol, K⁺ 2 mmol, Ca²⁺ 4.99 mmol, P³ 4.84 mmol</td>
<td>Nutritional supplement for biochemically proven hypoproteinaemia and patients undergoing dialysis. Not suitable for child under 1 year.</td>
<td>Renapro powder: 600 gram = £69.60</td>
</tr>
<tr>
<td>Renastart® (Vitaflo International Ltd)</td>
<td>Standard dilution (20%) of powder per 100 mL</td>
<td>414 kJ (99 kcal)</td>
<td>1.5 g cows’ milk soya</td>
<td>12.5 g (sugars 1.3 g)</td>
<td>4.8 g</td>
<td>Nil</td>
<td>Contains lactose</td>
<td>Dietary management of renal failure in child from birth to 10 years.</td>
<td>Renastart powder: 400 gram = £26.87</td>
</tr>
<tr>
<td>Respirin® (Nutricia Ltd)</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>633 kJ (150 kcal)</td>
<td>7.5 g cows’ milk</td>
<td>22.5 g (sugars 6.4 g)</td>
<td>3.3 g</td>
<td>Nil</td>
<td>Contains lactose</td>
<td>Nutritional supplement for dietary management of disease-related malnutrition in patients with chronic obstructive pulmonary disease and body-mass index less than 20.</td>
<td>Respirin milkshake style liquid: chocolate, strawberry, vanilla 500 ml = £8.64</td>
</tr>
<tr>
<td>Supportan® (Fresenius Kabi Ltd)</td>
<td>Liquid (sip feed) per 100 mL</td>
<td>630 kJ (150 kcal)</td>
<td>10 g cows’ milk</td>
<td>12.4 g (sugars 7.5 g)</td>
<td>6.7 g</td>
<td>1.5 g</td>
<td>Gluten-free, Residual lactose, Contains fish oil</td>
<td>Nutritional supplement in patients with pancreatic cancer or with lung cancer undergoing chemotherapy Not suitable for child under 1 year; use with caution in child 1–4 years</td>
<td>Supportan drink: cappuccino, tropical fruits 800 ml = £10.84</td>
</tr>
</tbody>
</table>

### Table 4 Feed supplements

**High-energy supplements**

**High-energy supplements: carbohydrate**

Flavoured carbohydrate supplements are not suitable for child under 1 year; liquid supplements should be diluted before use in child under 5 years.

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maxijul® Super Soluble (Nutricia Ltd)</td>
<td>Powder per 100 g</td>
<td>1615 kJ (380 kcal)</td>
<td>Nil</td>
<td>95 g Glucose polymer (sugars 8.6 g)</td>
<td>Nil</td>
<td>Nil</td>
<td>Gluten-free, Lactose-free</td>
<td>Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high or readily available carbohydrate supplement.</td>
<td>Maxijul Super Soluble powder: 200 gram = £2.64; 528 gram = £6.56; 25000 gram = £157.74</td>
</tr>
</tbody>
</table>
### Polycal<sup>®</sup> (Nutricia Ltd)

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Energy</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high or readily available carbohydrate supplement. Liquid not suitable for child under 3 years.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liquid per 100 mL</td>
<td>1050 kJ (247 kcal)</td>
<td>61.9 g Maltodextrin (sugars 12.2 g)</td>
<td>Nil</td>
<td>Nil</td>
<td>Gluten-free Lactose-free</td>
<td>Polycal liquid: neutral, orange 200 ml = £1.75</td>
</tr>
<tr>
<td>Powder per 100 g</td>
<td>1630 kJ (384 kcal)</td>
<td>96 g Maltodextrin (sugars 6 g)</td>
<td>Nil</td>
<td>Nil</td>
<td>Gluten-free Lactose-free</td>
<td>Polycal powder: 400 gram = £4.36</td>
</tr>
</tbody>
</table>

### S.O.S.<sup>®</sup> (Vitaflo International Ltd)

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Energy</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high or readily available carbohydrate supplement.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder per 100 g</td>
<td>1590 kJ (380 kcal)</td>
<td>95 g (sugars 9 g)</td>
<td>Nil</td>
<td>Nil</td>
<td>Nil</td>
<td>S.O.S. products are age-range specific – consult product literature</td>
</tr>
</tbody>
</table>

### Vitajoule<sup>®</sup> (Vitaflo International Ltd)

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Energy</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high or readily available carbohydrate supplement.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Powder per 100 g</td>
<td>1590 kJ (380 kcal)</td>
<td>95 g Dried glucose syrup (sugars 9 g)</td>
<td>Nil</td>
<td>Nil</td>
<td>Gluten-free Lactose-free</td>
<td>Vitajoule powder: 500 gram = £4.46</td>
</tr>
</tbody>
</table>

### High-energy supplements: fat

Liquid supplements should be diluted before use in child under 5 years

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calogen&lt;sup&gt;®&lt;/sup&gt; (Nutricia Ltd)</td>
<td>Liquid (emulsion) per 100 mL</td>
<td>1850 kJ (450 kcal)</td>
<td>Nil</td>
<td>100 mg</td>
<td>50 g (LCT 100 %)</td>
<td>Nil</td>
<td>Gluten-free Lactose-free</td>
<td>Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat (or fat and carbohydrate) supplement.</td>
<td>Calogen emulsion: neutral, strawberry 200 ml = £4.44; 500 ml = £10.92; banana 500 ml = £10.92</td>
</tr>
<tr>
<td>Fresubin&lt;sup&gt;®&lt;/sup&gt; 5 kcal Shot (Fresenius Kabi Ltd)</td>
<td>Liquid (emulsion) per 100 mL</td>
<td>2100 kJ (500 kcal)</td>
<td>Nil</td>
<td>4.0 g (sucrose)</td>
<td>53.8 g</td>
<td>400 mg</td>
<td>Gluten-free Lactose-free</td>
<td>Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat (or fat and carbohydrate) supplement. Not suitable for child under 3 years.</td>
<td>Fresubin 5 kcal shot drink neutral: 480 ml = £11.40</td>
</tr>
<tr>
<td>Liquigen&lt;sup&gt;®&lt;/sup&gt; (Nutricia Ltd)</td>
<td>Liquid (emulsion) per 100 mL</td>
<td>1850 kJ (450 kcal)</td>
<td>Nil</td>
<td>Nil</td>
<td>50 g (MCT 97 %) Fractionated coconut oil</td>
<td>Nil</td>
<td>Gluten-free Lactose-free</td>
<td>Steatorrhoea associated with cystic fibrosis of the pancreas, intestinal lymphangiectasia, intestinal surgery, chronic liver disease, liver cirrhosis, other proven malabsorption syndromes, ketogenic diet in epilepsy, and in type I lipoproteinaemia Not suitable for child under 1 year</td>
<td>Liquigen emulsion: 250 ml = £9.39</td>
</tr>
</tbody>
</table>
### High-energy supplements: fat
Liquid supplements should be diluted before use in child under 5 years

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medium-chain Triglyceride (MCT) Oil</td>
<td>Liquid</td>
<td>3515 kJ</td>
<td>Nil</td>
<td>Nil</td>
<td>MCT</td>
<td>Nil</td>
<td></td>
<td>Nutritional supplement for steatorrhoea associated with cystic fibrosis of the pancreas, infectious lymphangiectasia, intestinal surgery, chronic liver disease and liver cirrhosis, other proven malabsorption syndromes, ketogenic diet in management of epilepsy, type 1 hyperlipoproteinaemia</td>
<td>MCT oil: 500 ml = £14.89</td>
</tr>
</tbody>
</table>

*Medium-chain Triglyceride (MCT) Oil (Nutricia Ltd)*

FAT AND CARBOHYDRATE

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duocal® Super Soluble</td>
<td>Powder</td>
<td>2061 kJ</td>
<td>Nil</td>
<td>72.7 g</td>
<td>22.3 g</td>
<td>Nil</td>
<td>Gluten-free Lactose-free</td>
<td>Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat (or fat and carbohydrate) supplement.</td>
<td>Duocal Super Soluble powder: 400 gram = £18.34</td>
</tr>
<tr>
<td>(Nutricia Ltd)</td>
<td>per 100 g</td>
<td>(492 kcal)</td>
<td></td>
<td>(sugars 6.5 g)</td>
<td>(MCT 35 %)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Energivit®</td>
<td>Standard dilution</td>
<td>309 kJ</td>
<td>Nil</td>
<td>10 g</td>
<td>3.75 g</td>
<td>Nil</td>
<td>Lactose-free With vitamins, minerals, and trace elements</td>
<td>For children requiring additional energy, vitamins, minerals, and trace elements following a protein-restricted diet</td>
<td>Energivit powder: 400 gram = £22.30</td>
</tr>
<tr>
<td>(Nutricia Ltd)</td>
<td>(15%) of powder</td>
<td>(74 kcal)</td>
<td></td>
<td>(sugars 900 mg)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Duocal® Super Soluble Powder (Nutricia Ltd)*

Energivit® Powder provides: carbohydrate 66.7 g, fat 25 g, energy 2059 kJ (492 kcal)/100 g.

### High-energy supplements: protein

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>ProSource® Jelly</td>
<td>Semi-solid</td>
<td>315 kJ</td>
<td>16.9 g</td>
<td>Less than 1 g</td>
<td>Nil</td>
<td>Less than 1 g</td>
<td>Gluten-free Lactose-free Contains porcine derivatives</td>
<td>Hypoproteinaemia Not recommended for child under 3 years</td>
<td>ProSource jelly: fruit punch, orange 118 ml = £1.83</td>
</tr>
<tr>
<td>(Nutrinovo Ltd)</td>
<td>per 100 mL</td>
<td>(75 kcal)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protifar®</td>
<td>Powder</td>
<td>1580 kJ</td>
<td>88.5 g</td>
<td>less than 1.5 g</td>
<td>1.6 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose Electrolytes/100 mL: Na+ 1.3 mmol K+ 1.28 mmol Ca++ 33.75 mmol P+ 22.58 mmol</td>
<td>Nutritional supplement for use in biochemically proven hypoproteinaemia.</td>
<td>Protifar powder: 225 gram = £8.86</td>
</tr>
<tr>
<td>(Nutricia Ltd)</td>
<td>per 100 g</td>
<td>(373 kcal)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*ProSource® Jelly (Nutrinovo Ltd)*

*Protifar® (Nutricia Ltd)*

Powder provides: protein 2.2 g per 2.5 g scoopful.
<table>
<thead>
<tr>
<th>PROTEIN AND CARBOHYDRATE</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dialamine® (Nutricia Ltd)</td>
<td>Standard dilution (20%) of powder per 100 mL</td>
<td>264 kJ (62 kcal)</td>
<td>4.3 g protein equivalent (essential and non-essential amino acids)</td>
<td>11.2 g (sugars 10.2 g)</td>
<td>Nil</td>
<td>Nil</td>
<td>Contains vitamin C</td>
<td>Hypoproteinaemia, chronic renal failure, wound fistula leakage with excessive protein loss, conditions requiring a controlled nitrogen intake, and haemodialysis. Not suitable for child under 6 months.</td>
</tr>
</tbody>
</table>

Powder provides: protein equivalent 25 g, carbohydrate 65 g, vitamin C 125 mg, energy 1530 kJ (360 kcal)/100 g.

| ProSource® Liquid (Nutrinovo Ltd) | Liquid per 30 mL | 420 kJ (100 kcal) | 10 g collagen protein whey protein isolate | 15 g (sugars 8 g) | Nil | Nil | Gluten-free Lactose-free May contain porcine derivatives | Biochemically proven hypoproteinaemia Not recommended for child under 3 years. |

Biochemically proven hypoproteinaemia Not recommended for child under 3 years. ProSource liquid 30ml sachets: citrus berry, lemon, orange creme, neutral 100 sachet = £98.79

| ProSource® Plus (Nutrinovo Ltd) | Liquid per 30 mL | 420 kJ (100 kcal) | 15 g collagen protein whey protein isolate | 11 g (sugars 10 g) | Nil | Nil | Gluten-free Lactose-free May contain porcine derivatives | Hypoproteinaemia Not recommended for child under 3 years |

Hypoproteinaemia Not recommended for child under 3 years. ProSource Plus liquid 100 x 30 ml sachets: unflavoured: £143.90

<table>
<thead>
<tr>
<th>PROTEIN, FAT, AND CARBOHYDRATE</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calogen® Extra (Nutricia Ltd)</td>
<td>Liquid per 100 mL</td>
<td>1650 kJ (400 kcal)</td>
<td>5 g cows’ milk</td>
<td>4.5 g (sugars 3.5 g)</td>
<td>40.3 g</td>
<td>Nil</td>
<td>Gluten-free Residual lactose Contains vitamins and minerals</td>
<td>Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement. Not suitable for child under 3 years; use with caution in child 3-6 years. May require dilution for child 3-5 years.</td>
</tr>
</tbody>
</table>

Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement. Not suitable for child under 3 years; use with caution in child 3-6 years. May require dilution for child 3-5 years. Calogen Extra emulsion: neutral, strawberry 200 ml = £4.98

| Calogen® Extra Shots (Nutricia Ltd) | Liquid per 100 mL | 1650 kJ (400 kcal) | 5 g cows’ milk | 4.5 g (sugars 3.5 g) | 40.3 g | Nil | Gluten-free Residual lactose With vitamins and minerals | Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement. Not suitable for child under 3 years; use with caution in child 3-6 years. May require dilution for child 3-5 years. |

Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement. Not suitable for child under 3 years; use with caution in child 3-6 years. May require dilution for child 3-5 years. Calogen Extra Shots emulsion: neutral, strawberry 240 ml = £5.75
### High-energy supplements: protein (product list continued)

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calshake® (Fresenius Kabi Ltd)</td>
<td>Powder per 87 g</td>
<td>1841 kJ (439 kcal)</td>
<td>4.1 g cows’ milk</td>
<td>56.4 g (sugars 20 g)</td>
<td>22 g</td>
<td>Nil</td>
<td>Contains lactose Gluten-free</td>
<td>Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement. Not suitable for child under 1 year.</td>
<td>Calshake powder: chocolate 630 gram = £17.01; banana, neutral, strawberry, vanilla 609 gram = £17.01</td>
</tr>
<tr>
<td>Powder: one sachet reconstituted with 240 mL whole milk provides approx. 2 kcal/mL and protein 12 g.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enshake® (Abbott Laboratories Ltd)</td>
<td>Powder per 100 g</td>
<td>1893 kJ (450 kcal)</td>
<td>8.4 g cows’ milk, soy protein isolate</td>
<td>69 g (sugars 14.5 g)</td>
<td>15.6 g</td>
<td>Nil</td>
<td>Residual lactose Contains vitamins and minerals</td>
<td>Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement. Not suitable for child under 1 year; use with caution in child 1-6 years.</td>
<td>Enshake oral powder: 96.5 g sachets: banana, chocolate, strawberry, vanilla 6 sachet = £12.93</td>
</tr>
<tr>
<td>Powder: 96.5 g reconstituted with 240 mL whole milk provides approx. 2 kcal/mL and protein 16 g.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MCT Procál® (Vitaflo International Ltd)</td>
<td>Powder per 100 g</td>
<td>2742 kJ (657 kcal)</td>
<td>12.5 g cows’ milk</td>
<td>20.6 g (sugars 3.1 g)</td>
<td>63.1 g (MCT 99%)</td>
<td>Nil</td>
<td>Contains lactose</td>
<td>Dietary management of disorders of long-chain fatty acid oxidation, fat malabsorption, and other disorders requiring a low LCT, high MCT supplement. Not suitable for child under 1 year.</td>
<td>MCT procal oral powder: 16 g sachets: 30 sachet = £24.21</td>
</tr>
<tr>
<td>Powder 16 g provides: protein 2 g, carbohydrate 3.3 g, fat 10.1 g, energy 439 kJ (105 kcal).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pro-Cal® (Vitaflo International Ltd)</td>
<td>Powder per 100 g</td>
<td>2787 kJ (667 kcal)</td>
<td>13.6 g cows’ milk</td>
<td>28.2 g (sugars 16 g)</td>
<td>55.5 g</td>
<td>Nil</td>
<td>Contains lactose Gluten-free</td>
<td>Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement. Not suitable for child under 1 year; use with caution in child 1-5 years.</td>
<td>Pro-Cal powder: 510 gram = £14.95; 1250 gram = £216.41; 1500 gram = £30.45; 375 gram = £16.13; 3000 gram = £71.88</td>
</tr>
<tr>
<td>Powder 15 g provides: protein 2 g, carbohydrate 4.2 g, fat 8.3 g, energy 418 kJ (100 kcal).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pro-Cal® Shot (Vitaflo International Ltd)</td>
<td>Liquid per 100 mL</td>
<td>1385 kJ (334 kcal)</td>
<td>6.7 g cows’ milk</td>
<td>13.4 g (sugars 13.3 g)</td>
<td>28.2 g</td>
<td>Nil</td>
<td>Contains lactose Gluten-free Contains soya</td>
<td>Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement. Not suitable for child under 3 years.</td>
<td>Pro-Cal: shot starter pack: 360 ml = £7.37; shot strawberry 720 ml = £14.71; shot banana, shot neutral 720 ml = £14.71</td>
</tr>
<tr>
<td>Powder 85 g reconstituted with 240 mL whole milk provides: protein 11.7 g, carbohydrate 66.8 g, fat 30.4 g, energy 2457 kJ (588 kcal).</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scandishake® Mix (Nutricia Ltd)</td>
<td>Powder per 100 g</td>
<td>2099 kJ (500 kcal)</td>
<td>4.7 g cows’ milk</td>
<td>65 g (sugars 14.3 g)</td>
<td>24.7 g</td>
<td>Nil</td>
<td>Gluten-free Contains lactose</td>
<td>Disease-related malnutrition, malabsorption states, or other conditions requiring fortification with a high fat or carbohydrate (with protein) supplement. Not suitable for child under 3 years.</td>
<td>Scandishake Mix oral powder: 85 g sachets: banana, caramel, chocolate, strawberry, unflavoured, vanilla 6 sachet = £15.00</td>
</tr>
</tbody>
</table>
### Fibre, vitamin, and mineral supplements

#### High-fibre supplements

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resource® Optifibre®&lt;sup&gt;®&lt;/sup&gt; (Nestle Health Science)</td>
<td>Powder per 100 g</td>
<td>323 kJ (76 kcal)</td>
<td>Nil</td>
<td>19 g guar gum, partially hydrolysed</td>
<td>Nil</td>
<td>78 g</td>
<td>Gluten-free, Lactose-free</td>
<td>Borderline substances standard ACBS indications p. 1421 except dysphagia</td>
<td>Resource Optifibre powder: 250 gram = £10.28; 80 gram = £4.18</td>
</tr>
</tbody>
</table>

#### Vitamin and Mineral supplements

<table>
<thead>
<tr>
<th>Product</th>
<th>Formulation</th>
<th>Energy</th>
<th>Protein</th>
<th>Carbohydrate</th>
<th>Fat</th>
<th>Fibre</th>
<th>Special Characteristics</th>
<th>ACBS Indications</th>
<th>Presentation &amp; Flavour</th>
</tr>
</thead>
<tbody>
<tr>
<td>FruitiVits®&lt;sup&gt;®&lt;/sup&gt; (Vitaflo International Ltd)</td>
<td>Powder per 100 g</td>
<td>133 kJ (33 kcal)</td>
<td>Nil</td>
<td>8.3 g (sugars 400 mg)</td>
<td>less than 100 mg</td>
<td>3.3 g</td>
<td></td>
<td>Vitamin, mineral, and trace element supplement in children 3–10 years with restrictive therapeutic diets</td>
<td>FruitiVits oral powder 6g sachets: 30 sachet = £65.45</td>
</tr>
<tr>
<td>Paediatric Seravit®&lt;sup&gt;®&lt;/sup&gt; (Nutricia Ltd)</td>
<td>Powder per 100 g</td>
<td>1275 kJ (300 kcal)</td>
<td>Nil</td>
<td>75 g (sugars 6.75 g)</td>
<td>Nil</td>
<td>Nil</td>
<td>Pineapple flavour not suitable for child under 6 months</td>
<td>Vitamin, mineral, and trace element supplement in infants and children with restrictive therapeutic diets.</td>
<td>Seravit Paediatric powder: unflavoured 200 gram = £18.16; pineapple 200 gram = £19.35</td>
</tr>
<tr>
<td>Renavit®&lt;sup&gt;®&lt;/sup&gt; (Stanningley Pharma Ltd)</td>
<td>Tablet per 450 mg</td>
<td>3.15 kJ (0.75 kcal)</td>
<td>Nil</td>
<td>170 mg</td>
<td>Nil</td>
<td>Nil</td>
<td></td>
<td>Dietary management of water-soluble vitamin deficiency in adults with renal failure on dialysis</td>
<td>Renavit tablets: 100 tablet = £12.50</td>
</tr>
</tbody>
</table>
Feed additives

Special additives for conditions of intolerance

Colief®
- For the relief of symptoms associated with lactose intolerance in infants, provided that lactose intolerance is confirmed by the presence of reducing substances and/or excessive acid in stools, a low concentration of the corresponding disaccharide enzyme on intestinal biopsy or by breath hydrogen test or lactose intolerance test. For dosage and administration details, consult product literature.
- LQUID, lactase 50 000 units/g
- Colief 50,000 units/g infant drops (Forum Health Products Ltd)
  7ml (ACBS) • NHS indicative price = £8.40
- Fructose
  - (Laevulose) For proven glucose/galactose intolerance
- Glucose
  - (Dextrose monohydrate) For use as an energy supplement in sucrose-isomaltase deficiency
- VSL#3®
  - Nutritional supplement for use under the supervision of a physician, for the maintenance of remission of ileoanal pouchitis induced by antibacterials in adults. For dosage and administration details, consult product literature.
  - POWDER, containing 8 strains of live, freeze-dried, lactic acid bacteria. Contains traces of soya, gluten, and lactose.
- VSL#3 Probiotic Food Supplement oral powder 4.4g sachets (Ferring Pharmaceuticals Ltd)
  30 sachet (ACBS) • NHS indicative price = £34.36

Feed thickeners and pre-thickened drinks

Carobel, Instant®
- For thickening feeds in the treatment of vomiting.
- POWDER, carob seed flour.

Instant Carobel powder (Cow & Gate Ltd)
  135gram (ACBS) • NHS indicative price = £2.84
- Multi-thick®
- For thickening of liquids and foods in dysphagia. Not suitable for children under 1 year except in cases of failure to thrive.
  - POWDER, modified maize starch, gluten- and lactose-free.
- Multi-thick powder (Abbott Laboratories Ltd)
  250gram (ACBS) • NHS indicative price = £4.83
- Nutillis® Clear
  - For thickening of liquids or foods in dysphagia. Not suitable for children under 3 years.
  - POWDER, maltodextrin, xanthan gum, guar gum, gluten- and lactose-free.
- Nutillis Clear powder (Nutricia Ltd)
  72gram (ACBS) • NHS indicative price = £11.04 | 175gram (ACBS) • NHS indicative price = £8.46
- Nutillis® Powder
- For thickening of foods in dysphagia. Not suitable for child under 3 years.
  - POWDER, carbohydrate 86g, energy 1520 kJ (358 kcal)/100g, modified maize starch, gluten- and lactose-free.
- Nutillis powder (Nutricia Ltd)
  240gram (ACBS) • NHS indicative price = £6.80 | 300gram (ACBS) • NHS indicative price = £5.11
- Resource® Thickened Drink
  - For dysphagia. Not suitable for children under 1 year.
  - LIQUID, carbohydrate 22 g, energy: orange 382 kJ (90 kcal); apple 376 kJ (89 kcal)/100 mL, Gluten- and lactose-free.
- Resource Thickened Drink custard apple (Nestle Health Science)
  114ml (ACBS) • NHS indicative price = £0.73
- Resource Thickened Drink custard orange (Nestle Health Science)
  114ml (ACBS) • NHS indicative price = £0.73
- Resource Thickened Drink syrup apple (Nestle Health Science)
  114ml (ACBS) • NHS indicative price = £0.73
- Resource Thickened Drink syrup orange (Nestle Health Science)
  114ml (ACBS) • NHS indicative price = £0.73
- Resource® ThickenUp Clear
  - For thickening of liquids or foods in dysphagia. Not suitable for children under 3 years.
  - POWDER, maltodextrin, xanthan gum, gluten- and lactose-free.
- Resource ThickenUp Clear powder (Nestle Health Science)
  28.8gram (ACBS) • NHS indicative price = £5.28 | 125gram (ACBS) • NHS indicative price = £8.46
- Resource® ThickenUp®
  - For thickening of foods in dysphagia. Not suitable for children under 1 year.
  - POWDER, modified maize starch. Gluten- and lactose-free.
- Resource ThickenUp powder (Nestle Health Science)
  227gram (ACBS) • NHS indicative price = £4.66 | 337.5gram (ACBS) • NHS indicative price = £17.86
- SLO Drinks®
  - Nutritional supplement for patient hydration in the dietary management of dysphagia. Not suitable for children under 3 years.
  - POWDER, carbohydrate content varies with flavour and chosen consistency (3 consistencies available), see product literature.
- SLO Drink 1 oral powder lemon (SLO Drinks Ltd)
  25 cup (ACBS) • NHS indicative price = £7.50
- SLO Drink 1 oral powder orange (SLO Drinks Ltd)
  25 cup (ACBS) • NHS indicative price = £7.50
- SLO Drink 1 oral powder hot chocolate (SLO Drinks Ltd)
  25 cup (ACBS) • NHS indicative price = £7.50
- SLO Drink 1 oral powder white coffee (SLO Drinks Ltd)
  25 cup (ACBS) • NHS indicative price = £7.50
- SLO Drink 1 oral powder white tea (SLO Drinks Ltd)
  25 cup (ACBS) • NHS indicative price = £7.50
- SLO Drink 2 oral powder hot chocolate (SLO Drinks Ltd)
  25 cup (ACBS) • NHS indicative price = £7.50
- SLO Drink 2 oral powder lemon (SLO Drinks Ltd)
  25 cup (ACBS) • NHS indicative price = £7.50
- SLO Drink 2 oral powder orange (SLO Drinks Ltd)
  25 cup (ACBS) • NHS indicative price = £7.50
- SLO Drink 2 oral powder white tea (SLO Drinks Ltd)
  25 cup (ACBS) • NHS indicative price = £7.50
- SLO Drink 3 oral powder orange (SLO Drinks Ltd)
  25 cup (ACBS) • NHS indicative price = £7.50
- SLO Milkshakes®
  - Nutritional supplement in the dietary management of dysphagia. Not suitable for children under 3 years.
  - POWDER, carbohydrate content varies with flavour and chosen consistency (3 consistencies available), see product literature.
- SLO Milkshake+ 1 oral powder chocolate (SLO Drinks Ltd)
  7 × 50 gram (ACBS) • NHS indicative price = £5.88
- SLO Milkshake+ 1 oral powder strawberry (SLO Drinks Ltd)
  7 × 50 gram (ACBS) • NHS indicative price = £5.88
- SLO Milkshake+ 2 oral powder chocolate (SLO Drinks Ltd)
  7 × 50 gram (ACBS) • NHS indicative price = £5.88
- SLO Milkshake+ 2 oral powder strawberry (SLO Drinks Ltd)
  7 × 50 gram (ACBS) • NHS indicative price = £5.88
- Thick and Easy®
  - For thickening of foods in dysphagia. Not suitable for children under 1 year except in cases of failure to thrive.
  - POWDER, modified maize starch
- Thick & Easy powder (Fresenius Kabi Ltd)
  225gram (ACBS) • NHS indicative price = £5.21 | 900gram (ACBS) • NHS indicative price = £22.00 | 4500gram (ACBS) • NHS indicative price = £87.18
- Thicken Aid®
  - For thickening of foods in dysphagia. Not suitable for children under 1 year.
  - POWDER, modified maize starch, maltodextrin, gluten- and lactose-free.
Thicken Aid powder (M & A Pharmacem Ltd)
225gram (ACBS) - NHS indicative price = £3.71 | 900gram (ACBS) - NHS indicative price = £22.40
Thixo-D ®
For thickening of foods in dysphagia. Not suitable for children under 1 year except in cases of failure to thrive. POWDER, modified maize starch, gluten-free.
Thixo-D powder (Sutherland Health Ltd)
375gram (ACBS) - NHS indicative price = £7.15
Thixo-D Cal-Free powder (Sutherland Health Ltd)
30gram (ACBS) - NHS indicative price = £2.85
Vitaquick ®
For thickening of foods in dysphagia. Not suitable for children under 1 year except in cases of failure to thrive. POWDER. Modified maize starch.
Vitaquick powder (Vitafood International Ltd)
500gram (ACBS) - NHS indicative price = £7.27

Flavouring preparations
FlavourPac ®
For use with Vitafood’s range of unflavoured protein substitutes for metabolic diseases; not suitable for child under 3 years.
POWDER
FlavourPac oral powder 4g sachets blackcurrant (Vitafood International Ltd)
30 sachet (ACBS) - NHS indicative price = £14.05 | 120 sachet (ACBS) - No NHS indicative price available
FlavourPac oral powder 4g sachets lemon (Vitafood International Ltd)
30 sachet (ACBS) - NHS indicative price = £14.05 | 120 sachet (ACBS) - No NHS indicative price available
FlavourPac oral powder 4g sachets orange (Vitafood International Ltd)
30 sachet (ACBS) - NHS indicative price = £14.05 | 120 sachet (ACBS) - No NHS indicative price available
FlavourPac oral powder 4g sachets raspberry (Vitafood International Ltd)
30 sachet (ACBS) - NHS indicative price = £14.05 | 120 sachet (ACBS) - No NHS indicative price available
FlavourPac oral powder 4g sachets tropical (Vitafood International Ltd)
30 sachet (ACBS) - NHS indicative price = £14.05 | 120 sachet (ACBS) - No NHS indicative price available

Foods for special diets
Gluten-free foods
ACBS indications: established gluten-sensitive enteropathies including coeliac disease, and dermatitis herpetiformis.

Bread
LOAVES
Barkat ® Loaf
GLUTEN-FREE
Barkat gluten free brown rice bread (Gluten Free Foods Ltd)
500gram (ACBS) - NHS indicative price = £5.73
Barkat gluten free par baked white bread sliced (Gluten Free Foods Ltd)
300gram (ACBS) - NHS indicative price = £4.13
Barkat gluten free home fresh country loaf (Gluten Free Foods Ltd)
250gram (ACBS) - NHS indicative price = £4.35
Barkat gluten free wheat free multigrain bread (Gluten Free Foods Ltd)
500gram (ACBS) - NHS indicative price = £5.73
Barkat gluten free wholemeal bread sliced (Gluten Free Foods Ltd)
500gram (ACBS) - NHS indicative price = £3.98
Barkat gluten free white rice bread (Gluten Free Foods Ltd)
500gram (ACBS) - NHS indicative price = £5.73
Ener-G ® Loaves
GLUTEN-FREE
Ener-G gluten free brown rice bread (General Dietary Ltd)
474gram (ACBS) - NHS indicative price = £5.47
Ener-G gluten free tapioca bread (General Dietary Ltd)
480gram (ACBS) - NHS indicative price = £5.47
Ener-G gluten free rice loaf (General Dietary Ltd)
612gram (ACBS) - NHS indicative price = £5.47
Ener-G gluten free Seattle brown loaf (General Dietary Ltd)
454gram (ACBS) - NHS indicative price = £6.22
Ener-G gluten free white rice bread (General Dietary Ltd)
456gram (ACBS) - NHS indicative price = £5.47
Genius Gluten Free ® Loaf
GLUTEN-FREE
Genius gluten free brown bread sliced (Genius Foods Ltd)
400gram (ACBS) - NHS indicative price = £2.88
Genius gluten free brown bread unsliced (Genius Foods Ltd)
400gram (ACBS) - NHS indicative price = £2.77
Genius gluten free brown sandwich bread sliced (Genius Foods Ltd)
555gram (ACBS) - NHS indicative price = £3.73
Genius gluten free white bread sliced (Genius Foods Ltd)
400gram (ACBS) - NHS indicative price = £2.88
Genius gluten free white bread unsliced (Genius Foods Ltd)
400gram (ACBS) - NHS indicative price = £2.77
Genius gluten free white sandwich bread sliced (Genius Foods Ltd)
555gram (ACBS) - NHS indicative price = £3.73
Glutafin ® Loaves
GLUTEN-FREE
Glutafin gluten free fibre loaf sliced (Dr Schar UK Ltd)
300gram (ACBS) - NHS indicative price = £2.89
Glutafin gluten free white loaf sliced (Dr Schar UK Ltd)
300gram (ACBS) - NHS indicative price = £2.89
Glutafin ® Select Loaves
GLUTEN-FREE
Glutafin gluten free Select fibre loaf sliced (Dr Schar UK Ltd)
400gram (ACBS) - NHS indicative price = £3.43
Glutafin gluten free Select fresh brown loaf sliced (Dr Schar UK Ltd)
400gram (ACBS) - NHS indicative price = £3.43
Glutafin gluten free Select fresh white loaf sliced (Dr Schar UK Ltd)
400gram (ACBS) - NHS indicative price = £3.43
Glutafin gluten free Select seeded loaf sliced (Dr Schar UK Ltd)
400gram (ACBS) - NHS indicative price = £3.72
Glutafin gluten free Select white loaf sliced (Dr Schar UK Ltd)
400gram (ACBS) - NHS indicative price = £3.43
Juvela ® Loaf
GLUTEN-FREE
Juvela gluten fresh fibre loaf sliced (Hero UK Ltd)
400gram (ACBS) - NHS indicative price = £3.39
Juvela gluten fresh white loaf sliced (Hero UK Ltd)
400gram (ACBS) - NHS indicative price = £3.69
Juvela gluten fibre loaf sliced (Hero UK Ltd)
400gram (ACBS) - NHS indicative price = £3.54
Juvela gluten free part baked loaf (Hero UK Ltd)
400gram (ACBS) - NHS indicative price = £3.95
Juvela gluten free part baked fibre loaf (Hero UK Ltd)
400gram (ACBS) - NHS indicative price = £3.80
Juvela gluten free loaf unsliced (Hero UK Ltd)
400gram (ACBS) - NHS indicative price = £3.54
Juvela gluten free fibre loaf unsliced (Hero UK Ltd)
400gram (ACBS) - NHS indicative price = £3.54
Lifestyle ® Loaf
GLUTEN-FREE
Lifestyle gluten free brown bread sliced (Ultrapharm Ltd)
400gram (ACBS) - NHS indicative price = £2.82
Lifestyle gluten free high fibre bread sliced (Ultrapharm Ltd)
400gram - NHS indicative price = £2.82
Lifestyle gluten free white bread sliced (Ultrapharm Ltd)
400gram (ACBS) - NHS indicative price = £2.82
Warburtons ® Loaf
GLUTEN-FREE
Warburtons gluten free brown bread sliced (Warburtons Ltd)
400gram (ACBS) • NHS indicative price = £3.06
Warburtons gluten free white bread sliced (Warburtons Ltd)
400gram (ACBS) • NHS indicative price = £3.06
Wellfoods ® Loaf
GLUTEN-FREE
Wellfoods gluten free loaf sliced (Wellfoods Ltd)
600gram (ACBS) • NHS indicative price = £5.05
Wellfoods gluten free loaf unsliced (Wellfoods Ltd)
600gram (ACBS) • NHS indicative price = £4.95
BAGUETTES, BUNS AND ROLLS
Barkat ® Baguettes and rolls
GLUTEN-FREE
Barkat gluten free par baked rolls (Gluten Free Foods Ltd)
200gram (ACBS) • NHS indicative price = £3.98
Barkat gluten free par baked baguette (Gluten Free Foods Ltd)
200gram (ACBS) • NHS indicative price = £3.98
Ener-G ® Rolls
GLUTEN-FREE
Ener-G gluten free dinner rolls (General Dietary Ltd)
280gram (ACBS) • NHS indicative price = £3.71
Ener-G gluten free white round rolls (General Dietary Ltd)
220gram (ACBS) • NHS indicative price = £2.98
Ener-G gluten free white long rolls (General Dietary Ltd)
220gram (ACBS) • NHS indicative price = £2.98
Glutafin ® Baguettes and rolls
GLUTEN-FREE
Glutafin gluten free baguette (Dr Schar UK Ltd)
350gram (ACBS) • NHS indicative price = £3.51
Glutafin gluten free 4 white rolls (Dr Schar UK Ltd)
200gram (ACBS) • NHS indicative price = £3.68
Glutafin gluten free part baked 4 fibre rolls (Dr Schar UK Ltd)
200gram (ACBS) • NHS indicative price = £3.68
Glutafin ® Select Rolls
GLUTEN-FREE
Glutafin gluten free part baked 4 white rolls (Dr Schar UK Ltd)
200gram (ACBS) • NHS indicative price = £3.68
Glutafin gluten free part baked 2 long white rolls (Dr Schar UK Ltd)
150gram (ACBS) • NHS indicative price = £2.81
Juvela ® Rolls
GLUTEN-FREE
Juvela gluten free fresh fibre rolls (Hero UK Ltd)
425gram (ACBS) • NHS indicative price = £4.42
Juvela gluten free fresh white rolls (Hero UK Ltd)
425gram (ACBS) • NHS indicative price = £4.42
Juvela gluten free fibre bread rolls (Hero UK Ltd)
425gram (ACBS) • NHS indicative price = £4.77
Juvela gluten free bread rolls (Hero UK Ltd)
425gram (ACBS) • NHS indicative price = £4.77
Juvela gluten free part baked fibre bread rolls (Hero UK Ltd)
375gram (ACBS) • NHS indicative price = £4.94
Juvela gluten free part baked white bread rolls (Hero UK Ltd)
375gram (ACBS) • NHS indicative price = £4.94
Lifestyle ® Rolls
GLUTEN-FREE
Lifestyle gluten free brown bread rolls (Ultrapharm Ltd)
400gram (ACBS) • NHS indicative price = £2.82
Lifestyle gluten free high fibre bread rolls (Ultrapharm Ltd)
400gram (ACBS) • NHS indicative price = £2.82
Lifestyle gluten free white bread rolls (Ultrapharm Ltd)
400gram (ACBS) • NHS indicative price = £2.82
Proceli ® Baguettes, buns and rolls
GLUTEN-FREE
Proceli gluten free part baked baguette (Ambe Ltd)
250gram (ACBS) • NHS indicative price = £3.24
Warburtons ® Baguettes and rolls
GLUTEN-FREE
Warburtons gluten free baguettes (Warburtons Ltd)
150gram (ACBS) • NHS indicative price = £2.86
Warburtons gluten free brown rolls (Warburtons Ltd)
220gram (ACBS) • NHS indicative price = £2.55
Warburtons gluten free white rolls (Warburtons Ltd)
220gram (ACBS) • NHS indicative price = £2.55
Wellfoods ® Buns and rolls
GLUTEN-FREE
Wellfoods gluten free burger buns (Wellfoods Ltd)
380gram (ACBS) • NHS indicative price = £4.03
Wellfoods gluten free rolls (Wellfoods Ltd)
560gram (ACBS) • NHS indicative price = £3.73
Cereals
Juvela ® Fibre flakes and oats
GLUTEN-FREE
Juvela gluten free fibre flakes (Hero UK Ltd)
300gram (ACBS) • NHS indicative price = £2.78
Juvela gluten free flakes (Hero UK Ltd)
300gram (ACBS) • NHS indicative price = £2.78
Juvela gluten free pure oats (Hero UK Ltd)
300gram (ACBS) • NHS indicative price = £2.78
Nairns ® Porridge
GLUTEN-FREE
Nairns gluten free oat porridge (Nairns Oatcakes Ltd)
500gram (ACBS) • NHS indicative price = £3.05
Cookies and biscuits
Barkat ® Biscuits
GLUTEN-FREE
Barkat gluten free digestive biscuits (Gluten Free Foods Ltd)
175gram (ACBS) • NHS indicative price = £2.61
Barkat gluten free coffee biscuits (Gluten Free Foods Ltd)
200gram (ACBS) • NHS indicative price = £3.38
Ener-G ® Cookies
GLUTEN-FREE
Ener-G gluten free vanilla cookies (General Dietary Ltd)
435gram (ACBS) • NHS indicative price = £6.23
Glutafin ® Cookies and biscuits
GLUTEN-FREE
Glutafin gluten free tea biscuits (Dr Schar UK Ltd)
150gram (ACBS) • NHS indicative price = £2.09
Glutafin gluten free digestive biscuits (Dr Schar UK Ltd)
150gram (ACBS) • NHS indicative price = £2.13
Glutafin gluten free shortbread biscuits (Dr Schar UK Ltd)
100gram (ACBS) • NHS indicative price = £1.73
Juvela ® Biscuits
GLUTEN-FREE
Juvela gluten free digestive biscuits (Hero UK Ltd)
150gram (ACBS) • NHS indicative price = £3.05
Juvela gluten free savoury biscuits (Hero UK Ltd)
150gram (ACBS) • NHS indicative price = £3.82
Juvela gluten free sweet biscuits (Hero UK Ltd)
150gram (ACBS) • NHS indicative price = £2.88
Juvela gluten free tea biscuits (Hero UK Ltd)
150gram (ACBS) • NHS indicative price = £3.05
Crackers, crispbreads, and breadsticks
Barkat ® Crackers
GLUTEN-FREE
Barkat gluten free matzo crackers (Gluten Free Foods Ltd)
200gram (ACBS) • NHS indicative price = £3.52
Glutafin ® Crackers
GLUTEN-FREE
Glutafin gluten free high fibre crackers (Dr Schar UK Ltd)
200gram (ACBS) • NHS indicative price = £2.90
Glutafin gluten free crackers (Dr Schar UK Ltd) 200gram (ACBS) • NHS indicative price = £3.46

Glutafin gluten free mini crackers (Dr Schar UK Ltd) 175gram (ACBS) • NHS indicative price = £2.96

Juvela® Crispbread GLUTEN-FREE

Juvela gluten free crispbread (Hero UK Ltd) 200gram (ACBS) • NHS indicative price = £4.64

Warburtons® Crackers GLUTEN-FREE

Warburtons gluten free bran crackers (Warburtons Ltd) 150gram (ACBS) • NHS indicative price = £2.34

Flour mixes and xanthan gum FLOUR MIXES

Barkat® Flour mix GLUTEN-FREE

Barkat gluten free bread mix (Gluten Free Foods Ltd) 500gram (ACBS) • NHS indicative price = £6.81

Barkat gluten free bread and cake mix (Gluten Free Foods Ltd) 500gram (ACBS) • NHS indicative price = £8.96

Barkat gluten free high fibre bread mix (Gluten Free Foods Ltd) 500gram (ACBS) • NHS indicative price = £8.96

Barkat gluten free all purpose flour mix (Gluten Free Foods Ltd) 500gram (ACBS) • NHS indicative price = £4.65

Finax® Flour mix GLUTEN-FREE

Finax gluten free coarse flour mix (Drossa Ltd) 900gram (ACBS) • NHS indicative price = £8.85

Finax gluten free fibre mix (Drossa Ltd) 1000gram (ACBS) • NHS indicative price = £10.14

Finax gluten free flour mix (Drossa Ltd) 900gram (ACBS) • NHS indicative price = £8.85

Glutafin Select® Flour mix GLUTEN-FREE

Glutafin gluten free Select bread mix (Dr Schar UK Ltd) 500gram (ACBS) • NHS indicative price = £6.66

Glutafin gluten free Select fibre mix (Dr Schar UK Ltd) 500gram (ACBS) • NHS indicative price = £6.66

Glutafin gluten free Select multipurpose fibre mix (Dr Schar UK Ltd) 500gram (ACBS) • NHS indicative price = £6.66

Glutafin gluten free Select multipurpose white mix (Dr Schar UK Ltd) 500gram (ACBS) • NHS indicative price = £6.66

Glutafin® Flour mix GLUTEN-FREE

Glutafin gluten free multipurpose white mix (Dr Schar UK Ltd) 500gram (ACBS) • NHS indicative price = £6.66

Heron Foods® Flour mix GLUTEN-FREE

Heron Hi-Fibre gluten free organic bread mix (Gluten Free Foods Ltd) 500gram (ACBS) • NHS indicative price = £8.96

Juvela® Flour mix GLUTEN-FREE

Juvela gluten free fibre mix (Hero UK Ltd) 500gram (ACBS) • NHS indicative price = £7.35

Juvela gluten free harvest mix (Hero UK Ltd) 500gram (ACBS) • NHS indicative price = £7.35

Juvela gluten free mix (Hero UK Ltd) 500gram (ACBS) • NHS indicative price = £7.35

Mrs Crimbles® Flour mixes GLUTEN-FREE

Mrs Crimbles’s gluten free bread mix (Stiletto Foods (UK) Ltd) 275gram (ACBS) • NHS indicative price = £1.09

Mrs Crimbles’s gluten free pastry mix (Stiletto Foods (UK) Ltd) 200gram (ACBS) • NHS indicative price = £1.09

Orgran® Flour mix GLUTEN-FREE

Orgran gluten free pizza & pastry mix (Naturally Good Food Ltd) 375gram (ACBS) • NHS indicative price = £3.80

Orgran gluten free self-raising flour (Naturally Good Food Ltd) 500gram (ACBS) • NHS indicative price = £3.10

Orgran gluten free all purpose plain flour (Naturally Good Food Ltd) 500gram • NHS indicative price = £3.10

Proceli® Flour mix GLUTEN-FREE

Proceli gluten free white plain flour (Ambe Ltd) 1000gram (ACBS) • NHS indicative price = £9.95

Pure® Flour mix GLUTEN-FREE

Innovative Solutions Pure gluten free blended flour (Innovative Solutions (UK) Ltd) 1000gram (ACBS) • NHS indicative price = £4.35

Innovative Solutions Pure gluten free brown rice flour (Innovative Solutions (UK) Ltd) 500gram (ACBS) • NHS indicative price = £1.63

Innovative Solutions Pure gluten free white rice flour (Innovative Solutions (UK) Ltd) 500gram (ACBS) • NHS indicative price = £1.73

Innovative Solutions Pure gluten free potato flour (Innovative Solutions (UK) Ltd) 500gram (ACBS) • NHS indicative price = £1.73

Innovative Solutions Pure gluten free tapioca flour (Innovative Solutions (UK) Ltd) 500gram (ACBS) • NHS indicative price = £2.33

Innovative Solutions Pure gluten free brown teff flour (Innovative Solutions (UK) Ltd) 1000gram (ACBS) • NHS indicative price = £4.91

Innovative Solutions Pure gluten free white teff flour (Innovative Solutions (UK) Ltd) 1000gram (ACBS) • NHS indicative price = £4.91

Tobia® Flour mix GLUTEN-FREE

Tobia Teff gluten free brown teff flour (Tobia Teff UK Ltd) 1000gram (ACBS) • NHS indicative price = £3.40

Tobia Teff gluten free white teff flour (Tobia Teff UK Ltd) 1000gram (ACBS) • NHS indicative price = £3.40

Tritamyl® Flour mix GLUTEN-FREE

Tritamyl gluten free brown bread mix (Gluten Free Foods Ltd) 1000gram (ACBS) • NHS indicative price = £7.10

Tritamyl gluten free flour mix (Gluten Free Foods Ltd) 2000gram (ACBS) • NHS indicative price = £14.26

Tritamyl gluten free white bread mix (Gluten Free Foods Ltd) 2000gram (ACBS) • NHS indicative price = £14.26

Wellfoods® Flour mix GLUTEN-FREE

Wellfoods gluten free flour alternative (Wellfoods Ltd) 1000gram (ACBS) • NHS indicative price = £7.80

XANTHAN GUM

Ener-G® Xanthan gum GLUTEN-FREE

Ener-G xanthan gum (General Dietary Ltd) 170gram (ACBS) • NHS indicative price = £8.63

Pure® Xanthan gum GLUTEN-FREE

Innovative Solutions Pure xanthan gum (Innovative Solutions (UK) Ltd) 1000gram (ACBS) • NHS indicative price = £6.85

Pasta

Barkat® Pasta GLUTEN-FREE

Barkat gluten free pasta shapes (Gluten Free Foods Ltd) 500gram (ACBS) • NHS indicative price = £5.88
Borderline substances

Appendix 2

Barkat gluten free pasta macaroni (Gluten Free Foods Ltd)
500gram (ACBS) · NHS indicative price = £5.88

Barkat gluten free pasta spaghetti (Gluten Free Foods Ltd)
500gram (ACBS) · NHS indicative price = £5.88

Barkat gluten free pasta spirals (Gluten Free Foods Ltd)
500gram (ACBS) · NHS indicative price = £5.88

Barkat gluten free pasta tagliatelle (Gluten Free Foods Ltd)
500gram (ACBS) · NHS indicative price = £5.88

Barkat gluten free pasta buckwheat penne (Gluten Free Foods Ltd)
250gram (ACBS) · NHS indicative price = £2.93

Barkat gluten free pasta buckwheat spirals (Gluten Free Foods Ltd)
250gram (ACBS) · NHS indicative price = £2.93

BiAlimenta ® Pasta
GLUTEN-FREE

BiAlimenta gluten free pasta spirals (Drossa Ltd)
spirals, sagnette 500 gram (ACBS) · NHS indicative price = £5.11

Ener-G ® Pasta
GLUTEN-FREE

General Dietary gluten free macaroni (General Dietary Ltd)
454gram (ACBS) · NHS indicative price = £5.03

General Dietary gluten free spaghetti (General Dietary Ltd)
454gram (ACBS) · NHS indicative price = £5.03

General Dietary gluten free vermicelli (General Dietary Ltd)
300gram (ACBS) · NHS indicative price = £5.03

Glutafin ® Pasta
GLUTEN-FREE

Glutafin gluten free pasta macaroni penne (Dr Schar UK Ltd)
500gram (ACBS) · NHS indicative price = £6.73

Glutafin gluten free pasta shells (Dr Schar UK Ltd)
500gram (ACBS) · NHS indicative price = £6.73

Glutafin gluten free pasta spirals (Dr Schar UK Ltd)
500gram (ACBS) · NHS indicative price = £6.73

Glutafin gluten free pasta long-cut spaghetti (Dr Schar UK Ltd)
500gram (ACBS) · NHS indicative price = £6.73

Juvela ® Pasta
GLUTEN-FREE

Juvela gluten free fibre penne (Hero UK Ltd)
500gram (ACBS) · NHS indicative price = £6.61

Juvela gluten free pasta fusilli (Hero UK Ltd)
500gram (ACBS) · NHS indicative price = £7.21

Juvela gluten free pasta lasagne (Hero UK Ltd)
250gram (ACBS) · NHS indicative price = £3.68

Juvela gluten free pasta macaroni (Hero UK Ltd)
500gram (ACBS) · NHS indicative price = £7.21

Juvela gluten free pasta spaghetti (Hero UK Ltd)
500gram (ACBS) · NHS indicative price = £7.21

Juvela gluten free pasta tagliatelle (Hero UK Ltd)
250gram (ACBS) · NHS indicative price = £3.47

Orgran ® Pasta
GLUTEN-FREE

Orgran gluten free pasta rice & corn lasagne (Naturally Good Food Ltd)
200gram (ACBS) · NHS indicative price = £3.13

Orgran gluten free pasta rice & corn macaroni (Naturally Good Food Ltd)
250gram (ACBS) · NHS indicative price = £2.42

Orgran gluten free pasta buckwheat spirals (Naturally Good Food Ltd)
250gram (ACBS) · NHS indicative price = £2.42

Orgran gluten free pasta corn spirals (Naturally Good Food Ltd)
250gram (ACBS) · NHS indicative price = £2.42

Orgran gluten free pasta brown rice spirals (Naturally Good Food Ltd)
250gram (ACBS) · NHS indicative price = £2.42

Orgran gluten free pasta rice & corn spirals (Naturally Good Food Ltd)
250gram (ACBS) · NHS indicative price = £2.42

Orgran gluten free pasta rice & millet spirals (Naturally Good Food Ltd)
250gram (ACBS) · NHS indicative price = £2.42

Rizopia ® Pasta
GLUTEN-FREE

Rizopia gluten free organic brown rice pasta fusilli (PGR Health Foods Ltd)
500gram (ACBS) · NHS indicative price = £2.72

Rizopia gluten free organic brown rice pasta lasagne (PGR Health Foods Ltd)
575gram (ACBS) · NHS indicative price = £2.72

Rizopia gluten free organic brown rice pasta penne (PGR Health Foods Ltd)
500gram (ACBS) · NHS indicative price = £2.72

Rizopia gluten free organic brown rice pasta spaghetti (PGR Health Foods Ltd)
500gram (ACBS) · NHS indicative price = £2.72

Pizza bases

Barkat ®, Pizza crust
GLUTEN-FREE

Barkat gluten free brown rice pizza crust (Gluten Free Foods Ltd)
150gram (ACBS) · NHS indicative price = £5.00

Barkat gluten free white rice pizza crust (Gluten Free Foods Ltd)
150gram (ACBS) · NHS indicative price = £5.00

Glutafin ® Pizza base
GLUTEN-FREE

Glutafin gluten free pizza base (Dr Schar UK Ltd)
300gram (ACBS) · NHS indicative price = £6.56

Juvela ® Pizza base
GLUTEN-FREE

Juvela gluten free pizza base (Hero UK Ltd)
360gram (ACBS) · NHS indicative price = £8.78

Proceli ® Pizza base
GLUTEN-FREE

Proceli gluten free pizza base (Ambe Ltd)
250gram (ACBS) · NHS indicative price = £3.90

Wellfoods ® Pizza base
GLUTEN-FREE

Wellfoods gluten free pizza base (Wellfoods Ltd)
600gram (ACBS) · NHS indicative price = £9.13

Gluten- and wheat-free foods

ACBS indications: established gluten-sensitive enteropathies with coexisting established wheat sensitivity only.

Ener-G ® Bread loaves, rolls and pizza bases
GLUTEN-FREE, WHEAT-FREE

Ener-G gluten free Seattle brown hamburger rolls (General Dietary Ltd)
320gram (ACBS) · NHS indicative price = £4.08

Ener-G gluten free Seattle brown hot dog rolls (General Dietary Ltd)
320gram (ACBS) · NHS indicative price = £4.08

Glutafin ® Flour mix, fibre and crispbread
GLUTEN-FREE, WHEAT-FREE

Glutafin gluten free crispbread (Dr Schar UK Ltd)
150gram (ACBS) · NHS indicative price = £3.25

Glutafin gluten free bread mix (Dr Schar UK Ltd)
500gram (ACBS) · NHS indicative price = £6.66

Glutafin gluten free fibre bread mix (Dr Schar UK Ltd)
500gram (ACBS) · NHS indicative price = £6.66

Glutafin gluten free wheat free fibre mix (Dr Schar UK Ltd)
500gram (ACBS) · NHS indicative price = £6.66

Heron Foods ® Flour mixes
GLUTEN-FREE, WHEAT-FREE

Heron gluten free organic bread mix (Gluten Free Foods Ltd)
500gram (ACBS) · NHS indicative price = £8.96

downloaded from www.medicalbr.com
Low-protein foods

ACBS indications: inherited metabolic disorders, renal or liver failure, requiring a low-protein diet.

Bread

**Ener-G® Rice bread**
LOW PROTEIN

**Ener-G low protein rice bread** (General Dietary Ltd)
600g (ACBS) · NHS indicative price = £5.60

**Juvela® Loaf and rolls**
LOW PROTEIN

Juvela gluten free loaf sliced (Hero UK Ltd)
400g (ACBS) · NHS indicative price = £3.54

Juvela low protein bread rolls (Hero UK Ltd)
350g (ACBS) · NHS indicative price = £4.52

Juvela low protein loaf sliced (Hero UK Ltd)
400g (ACBS) · NHS indicative price = £3.64

**PK Foods low protein loaf**
LOW PROTEIN

PK Foods low protein white bread sliced (Gluten Free Foods Ltd)
550g (ACBS) · NHS indicative price = £4.75

Cake, cookies, and snacks

**Juvela® cookies**
LOW-PROTEIN

Juvela low protein cinnamon cookies (Hero UK Ltd)
125g (ACBS) · NHS indicative price = £7.62

Juvela low protein chocolate chip cookies (Hero UK Ltd)
110g (ACBS) · NHS indicative price = £7.62

Juvela low protein orange cookies (Hero UK Ltd)
125g (ACBS) · NHS indicative price = £7.62

**Loprofin® Wafer**
LOW-PROTEIN

Loprofin low protein wafer cookies (Nutricia Ltd)
150g (ACBS) · NHS indicative price = £3.67

Loprofin low protein chocolate cookies (Nutricia Ltd)
150g (ACBS) · NHS indicative price = £3.67

Loprofin low protein vanilla cream wafers (Nutricia Ltd)
100g (ACBS) · NHS indicative price = £2.62

**PK Foods® Biscuits**
LOW-PROTEIN

PK Foods Aminex low protein biscuits (Gluten Free Foods Ltd)
200g (ACBS) · NHS indicative price = £5.04

PK Foods Aminex low protein cookies (Gluten Free Foods Ltd)
150g (ACBS) · NHS indicative price = £5.04

PK Foods Aminex low protein rusk (Gluten Free Foods Ltd)
200g (ACBS) · NHS indicative price = £5.04

PK Foods low protein chocolate chip cookies (Gluten Free Foods Ltd)
150g (ACBS) · NHS indicative price = £5.04

PK Foods low protein cinnamon cookies (Gluten Free Foods Ltd)
150g (ACBS) · NHS indicative price = £5.04

PK Foods low protein crispbread (Gluten Free Foods Ltd)
75g (ACBS) · NHS indicative price = £2.42

PK Foods low protein orange cookies (Gluten Free Foods Ltd)
150g (ACBS) · NHS indicative price = £5.04

**Promin® Cooked and flavoured pasta snax**
LOW-PROTEIN

Promin low protein Snax salt & vinegar 25g sachets (Firstplay Dietary Foods Ltd)
3 sachet · No NHS indicative price available | 12 sachet (ACBS) · NHS indicative price = £10.58

**Promin low protein Snax ready salted 25g sachets** (Firstplay Dietary Foods Ltd)
5 sachet · No NHS indicative price available | 12 sachet (ACBS) · NHS indicative price = £10.58

**Promin low protein Snax cheese & onion 25g sachets** (Firstplay Dietary Foods Ltd)
3 sachet · No NHS indicative price available | 12 sachet (ACBS) · NHS indicative price = £10.58

**Taranis® Cake bars**
LOW-PROTEIN

Taranis low protein apricot cake (Lactalis Nutrition Sante)
240g (ACBS) · NHS indicative price = £6.08

Taranis low protein lemon cake (Lactalis Nutrition Sante)
240g (ACBS) · NHS indicative price = £6.08

Taranis low protein pear cake (Lactalis Nutrition Sante)
240g (ACBS) · NHS indicative price = £6.08

**VitaBite®**

Not recommended for any child under 1 year.

LOW-PROTEIN.

Bar, protein 30 mg (less than 2.5 mg phenylalanine), carbohydrate 15.35 g, fat 8.4 g, energy 572 kJ (137 kcal)/25 g.

**VitaBite bar** (VitaFol International Ltd)
175g (ACBS) · NHS indicative price = £8.77

**VitaBite Choices® Mini crackers**
LOW-PROTEIN

VitaBite Choices mini crackers (VitaFol International Ltd)
40g (ACBS) · NHS indicative price = £0.87

Cereals

**Loprofin® Breakfast cereal**
LOW-PROTEIN

Loprofin low protein breakfast cereal flakes apple (Nutricia Ltd)
375g (ACBS) · NHS indicative price = £8.09

Loprofin low protein breakfast cereal flakes chocolate (Nutricia Ltd)
375g (ACBS) · NHS indicative price = £8.09

Loprofin low protein breakfast cereal flakes strawberry (Nutricia Ltd)
375g (ACBS) · NHS indicative price = £8.09

Loprofin low protein breakfast cereal loops (Nutricia Ltd)
375g (ACBS) · NHS indicative price = £8.39

**Promin® Hot breakfast**
LOW-PROTEIN

Promin low protein hot breakfast powder sachets apple & cinnamon (Firstplay Dietary Foods Ltd)
342g (ACBS) · NHS indicative price = £8.09

Promin low protein hot breakfast powder sachets banana (Firstplay Dietary Foods Ltd)
342g (ACBS) · NHS indicative price = £8.09

Promin low protein hot breakfast powder sachets chocolate (Firstplay Dietary Foods Ltd)
342g (ACBS) · NHS indicative price = £8.09

Promin low protein hot breakfast powder sachets original (Firstplay Dietary Foods Ltd)
336g (ACBS) · NHS indicative price = £8.09

Desserts

**PK Foods® Jelly**
LOW-PROTEIN

PK Foods low protein jelly mix dessert cherry (Gluten Free Foods Ltd)
320g (ACBS) · NHS indicative price = £8.03

PK Foods low protein jelly mix dessert orange (Gluten Free Foods Ltd)
320g (ACBS) · NHS indicative price = £8.03

**Promin® Desserts**
LOW-PROTEIN

Promin low protein imitation rice pudding apple (Firstplay Dietary Foods Ltd)
276g (ACBS) · NHS indicative price = £6.33
Flour mixes and egg substitutes

Ener-G® Egg replacer
LOW-PROTEIN

Ener-G low protein egg replacer (General Dietary Ltd)
454gram (ACBS) - NHS indicative price = £5.17

Fate® Flour mix
LOW PROTEIN

Fate low protein all purpose mix (Fate Special Foods)
500gram (ACBS) - NHS indicative price = £6.97

Fate low protein chocolate cake mix (Fate Special Foods)
500gram (ACBS) - NHS indicative price = £6.97

Fate low protein plain cake mix (Fate Special Foods)
500gram (ACBS) - NHS indicative price = £6.97

Juvela® Mix
LOW-PROTEIN

Juvela low protein mix (Hero UK Ltd)
500gram (ACBS) - NHS indicative price = £7.79

Loprofin® Flour mixes and egg substitutes
LOW-PROTEIN

Loprofin low protein egg replacer (Nutricia Ltd)
500gram (ACBS) - NHS indicative price = £15.72

Loprofin low protein egg white replacer (Nutricia Ltd)
100gram (ACBS) - NHS indicative price = £10.12

Loprofin low protein cake mix chocolate (Nutricia Ltd)
500gram (ACBS) - NHS indicative price = £9.06

Loprofin low protein mix (Nutricia Ltd)
500gram (ACBS) - NHS indicative price = £8.43

PK Foods® Flour mix and egg substitute
LOW-PROTEIN

PK Foods low protein egg replacer (Gluten Free Foods Ltd)
200gram (ACBS) - NHS indicative price = £4.08

PK Foods low protein flour mix (Gluten Free Foods Ltd)
750gram (ACBS) - NHS indicative price = £10.71

Pasta

Loprofin® Pasta
LOW-PROTEIN

Loprofin low protein pasta animal shapes (Nutricia Ltd)
500gram (ACBS) - NHS indicative price = £8.61

Loprofin low protein pasta lasagne (Nutricia Ltd)
250gram (ACBS) - NHS indicative price = £4.35

Loprofin low protein pasta penne (Nutricia Ltd)
500gram (ACBS) - NHS indicative price = £8.94

Loprofin low protein pasta tagliatelle (Nutricia Ltd)
250gram (ACBS) - NHS indicative price = £4.30

Loprofin low protein pasta macaroni elbows (Nutricia Ltd)
250gram (ACBS) - NHS indicative price = £4.30

Loprofin low protein rice (Nutricia Ltd)
500gram (ACBS) - NHS indicative price = £8.68

Loprofin low protein pasta long cut spaghetti (Nutricia Ltd)
500gram (ACBS) - NHS indicative price = £8.94

Promin® Pasta
LOW-PROTEIN

Promin low protein pasta alphabets (Firstplay Dietary Foods Ltd)
500gram (ACBS) - NHS indicative price = £6.99

Promin Plus low protein pasta macaroni (Firstplay Dietary Foods Ltd)
500gram (ACBS) - NHS indicative price = £6.99

Promin Plus low protein pasta flat noodles (Firstplay Dietary Foods Ltd)
500gram (ACBS) - NHS indicative price = £6.99

Promin low protein pasta shells (Firstplay Dietary Foods Ltd)
500gram (ACBS) - NHS indicative price = £6.99

Promin low protein pasta short cut spaghetti (Firstplay Dietary Foods Ltd)
500gram (ACBS) - NHS indicative price = £6.99

Promin low protein tricolour pasta spirals (Firstplay Dietary Foods Ltd)
500gram (ACBS) - NHS indicative price = £6.99

Promin low protein tricolour pasta alphabets (Firstplay Dietary Foods Ltd)
500gram (ACBS) - NHS indicative price = £6.99

Promin low protein tricolour pasta shells (Firstplay Dietary Foods Ltd)
500gram (ACBS) - NHS indicative price = £6.99

Promin low protein lasagne sheets (Firstplay Dietary Foods Ltd)
200gram (ACBS) - NHS indicative price = £3.03

Pizza bases

Juvela® Pizza base
LOW-PROTEIN

Juvela low protein pizza base (Hero UK Ltd)
360gram (ACBS) - NHS indicative price = £8.61

Savoury meals and mixes

Promin® Savoury meals and mixes
LOW-PROTEIN

Promin low protein burger mix (Firstplay Dietary Foods Ltd)
124gram (ACBS) - NHS indicative price = £6.36

Promin low protein cous cous (Firstplay Dietary Foods Ltd)
500gram (ACBS) - NHS indicative price = £6.99

Promin low protein pasta elbows (Firstplay Dietary Foods Ltd)
500gram - NHS indicative price = £6.99

Promin low protein pastameal (Firstplay Dietary Foods Ltd)
500gram (ACBS) - NHS indicative price = £6.99

Promin low protein pasta macaroni (Firstplay Dietary Foods Ltd)
500gram (ACBS) - NHS indicative price = £6.99

Promin Plus low protein pasta spirals (Firstplay Dietary Foods Ltd)
500gram (ACBS) - NHS indicative price = £6.99

Promin low protein lamb and mint burger mix (Firstplay Dietary Foods Ltd)
124gram (ACBS) - NHS indicative price = £6.36

Promin low protein sausage mix apple and sage (Firstplay Dietary Foods Ltd)
120gram (ACBS) - NHS indicative price = £7.15

Promin low protein sausage mix original (Firstplay Dietary Foods Ltd)
120gram (ACBS) - NHS indicative price = £7.15

Promin low protein sausage mix tomato and basil (Firstplay Dietary Foods Ltd)
120gram (ACBS) - NHS indicative price = £7.15

Promin low protein pasta in cheese and broccoli sauce (Firstplay Dietary Foods Ltd)
264gram (ACBS) - NHS indicative price = £8.31

Promin low protein pasta spirals in Moroccan sauce (Firstplay Dietary Foods Ltd)
288gram (ACBS) - NHS indicative price = £8.31

Promin low protein pasta in tomato, pepper and herb sauce (Firstplay Dietary Foods Ltd)
288gram (ACBS) - NHS indicative price = £8.31

Promin low protein potato pot with croutons onion (Firstplay Dietary Foods Ltd)
200gram (ACBS) - NHS indicative price = £16.40
Promin low protein potato pot with croutons cabbage & bacon (Firstplay Dietary Foods Ltd)
200gram (ACBS) • NHS indicative price = £16.40
Promin low protein potato pot with croutons sausage (Firstplay Dietary Foods Ltd)
200gram (ACBS) • NHS indicative price = £16.40
Promin low protein X-Pot all day scramble (Firstplay Dietary Foods Ltd)
240gram (ACBS) • NHS indicative price = £20.94
Promin low protein X-Pot beef & tomato (Firstplay Dietary Foods Ltd)
240gram (ACBS) • NHS indicative price = £20.94
Promin low protein X-Pot chip shop curry (Firstplay Dietary Foods Ltd)
240gram (ACBS) • NHS indicative price = £20.94
Promin low protein X-Pot rogan style curry (Firstplay Dietary Foods Ltd)
240gram (ACBS) • NHS indicative price = £20.94
Spreads
Taranis Spread
LOW-PROTEIN
Taranis low protein hazelnut spread (Lactalis Nutrition Sante)
250gram (ACBS) • NHS indicative price = £7.87

**Nutritional supplements for metabolic diseases**

**Glutaric aciduria (type 1)**

**GA Gel**
- Nutritional supplement for dietary management of type 1 glutaric aciduria in children 6 months–10 years.
  - Gel, protein equivalent (essential and non-essential amino acids except lysine, and low tryptophan) 10 g, carbohydrate 10.3 g, fat trace, energy 339 kJ (81 kcal)/24 g, with vitamins, minerals, and trace elements. To flavour unflavoured products, see FlavourPac p. 1441.

**GA gel oral powder 24g sachets** (Vitaflor International Ltd)
30 sachet (ACBS) • NHS indicative price = £216.48

**GA1 Anamix Infant**
- Nutritional supplement for the dietary management of proven glutaric aciduria (type 1) in children from birth to 3 years.
  - Powder, protein equivalent (essential and non-essential amino acids except lysine, and low tryptophan) 13.1 g, carbohydrate 49.5 g, fat 23.5 g, energy 1915 kJ (457 kcal)/100 g, with vitamins, minerals, and trace elements; standard dilution (15%) provides protein equivalent 2 g, carbohydrate 7.4 g, fat 3.5 g, fibre 800 mg, energy 287 kJ (69 kcal)/100 mL.

**GA1 Anamix infant powder** (Nutricia Ltd)
400gram (ACBS) • NHS indicative price = £39.45

**GA1 Maxamaid**
- Nutritional supplement for the dietary management of type 1 glutaric aciduria.
  - Powder, protein equivalent (essential and non-essential amino acids except lysine, and low tryptophan) 25 g, carbohydrate 51 g, fat less than 500 mg, energy 1511 kJ (309 kcal)/100 g, with vitamins, minerals, and trace elements. Maxamaid products are generally intended for use in children 1–8 years.

**GA1 Maxamaid powder** (Nutricia Ltd)
500gram (ACBS) • NHS indicative price = £99.61

**XL5S TRY Glutaridon**
- Nutritional supplement for the dietary management of type 1 glutaric aciduria in children and adults; requires additional source of vitamins, minerals, and trace elements.
  - Powder, protein equivalent (essential and non-essential amino acids except lysine and tryptophan) 79 g, carbohydrate 4 g, energy 1411 kJ (352 kcal)/100 g.

**XL5S TRY Glutaridon powder** (Nutricia Ltd)
500gram (ACBS) • NHS indicative price = £188.69

**Glycogen storage disease**

**Corn flour and corn starch**
- For glycogen storage disease

**Glycosade**
- A nutritional supplement for use in the dietary management of glycogen storage disease and other metabolic conditions where a constant supply of glucose is essential. Not suitable for use in children under 2 years.
  - Powder, protein 200 mg, carbohydrate (maize starch) 47.6 g, fat 100 mg, fibre less than 600 mg, energy 803 kJ (192 kcal)/60 g.

**Glycosade oral powder 60g sachets** (Vitaflor International Ltd)
30 sachet (ACBS) • NHS indicative price = £113.77

**Homocystinuria or hypermethioninaemia**

**HCU Anamix Infant**
- Nutritional supplement for the dietary management of proven vitamin B6 non-responsive homocystinuria or hypermethioninaemia in children from birth to 3 years.
  - Powder, protein equivalent (essential and non-essential amino acids except methionine) 15.1 g, carbohydrate 49.5 g, fat 23 g, fibre 5.3 g, energy 1915 kJ (457 kcal)/100 g, with vitamins, minerals, and trace elements; standard dilution (15%) provides protein equivalent 2 g, carbohydrate 7.4 g, fat 3.5 g, fibre 800 mg, energy 287 kJ (69 kcal)/100 mL.

**HCU Anamix Infant powder** (Nutricia Ltd)
400gram (ACBS) • NHS indicative price = £39.45

**HCU cooler 15 liquid**
- A methionine-free protein substitute for use as a nutritional supplement in children over 3 years with homocystinuria.
  - Liquid, protein (essential and non-essential amino acids except methionine) 15 g, carbohydrate 7 g, fat 500 mg, energy 393 kJ (92 kcal)/150 mL, with vitamins, minerals, and trace elements.

**HCU orange cooler 15 liquid** (Vitaflor International Ltd)
150ml (ACBS) • NHS indicative price = £11.42

**HCU Express 15**
- A methionine-free protein substitute for use as a nutritional supplement in children over 8 years with homocystinuria.
  - Powder, protein (essential and non-essential amino acids except methionine) 15 g, carbohydrate 3.8 g, fat 30 mg, energy 315 kJ (75.3 kcal)/25 g with vitamins, minerals, and trace elements. To flavour unflavoured products, see FlavourPac p. 1441.

**HCU express 15 oral powder 25g sachets** (Vitaflor International Ltd)
30 sachet (ACBS) • NHS indicative price = £33.16

**HCU Express 20**
- A methionine-free protein substitute for use as a nutritional supplement in children over 8 years with homocystinuria.
  - Powder, protein (essential and non-essential amino acids except methionine) 20 g, carbohydrate 4.7 g, fat 70 mg, energy 416 kJ (99 kcal)/34 g with vitamins, minerals, and trace elements. To flavour unflavoured products, see FlavourPac p. 1441.

**HCU express 20 oral powder 34g sachets** (Vitaflor International Ltd)
30 sachet (ACBS) • NHS indicative price = £43.31

**HCU gel**
- A methionine-free protein substitute for use as a nutritional supplement for the dietary management of children 1–10 years with homocystinuria.
  - Powder, protein (essential and non-essential amino acids except methionine) 10 g, carbohydrate 10.3 g, fat 20 mg, energy 339 kJ (81 kcal)/24 g with vitamins, minerals, and trace elements. To flavour unflavoured products, see FlavourPac p. 1441.

**HCU gel oral powder 24g sachets** (Vitaflor International Ltd)
30 sachet (ACBS) • NHS indicative price = £216.42
HCU Lophex ® LQ 20
- Nutritional supplement for the dietary management of homocystinuria in children over 3 years.
- LIQUID, protein equivalent (essential and non-essential amino acids except methionine) 20 g, carbohydrate 8.8 g, fat 440 mg, energy 509 kJ (120 kcal)/125 mL, with vitamins, minerals, and trace elements.

HCU Lophex LQ 20 liquid (Nutricia Ltd)
- 125 mL (ACBS) - NHS indicative price = £16.27

HCU LV ®
- Nutritional supplement for the dietary management of hypermethioninaemia or vitamin B6 non-responsive homocystinuria in children over 8 years.
- POWDER, protein (essential and non-essential amino acids except methionine) 20 g, carbohydrate 2.5 g, fat 190 mg, energy 390 kJ (92 kcal)/27.8-g sachet, with vitamins, minerals, and trace elements.

HCU LV oral powder 27.8g sachets tropical (Nutricia Ltd)
- 30 sachet (ACBS) - NHS indicative price = £500.10

HCU LV oral powder 27.8g sachets unflavoured (Nutricia Ltd)
- 30 sachet (ACBS) - NHS indicative price = £500.10

XMET Homidon ®
- Nutritional supplement for the dietary management of hypermethioninaemia or homocystinuria in children and adults.
- POWDER, protein equivalent (essential and non-essential amino acids, except methionine) 77 g, carbohydrate 4.5 g, fat nil, energy 1386 kJ (326 kcal)/100 g.

XMET Homidon powder (Nutricia Ltd)
- 500 g (ACBS) - NHS indicative price = £188.69

HCU Maxamaid ®
- Nutritional supplement for the dietary management of hypermethioninaemia or homocystinuria.
- POWDER, protein equivalent (essential and non-essential amino acids except methionine) 25 g, carbohydrate 51 g, fat less than 500 mg, energy 1311 kJ (309 kcal)/100 g, with vitamins, minerals, and trace elements. Maxamaid products are generally intended for use in children 1-8 years.

HCU Maxamaid powder (Nutricia Ltd)
- 500 g (ACBS) - NHS indicative price = £99.61

HCU Maxamum ®
- Nutritional supplement for the dietary management of hypermethioninaemia or homocystinuria.
- POWDER, protein equivalent (essential and non-essential amino acids except methionine) 39 g, carbohydrate 54 g, fat less than 500 mg, energy 1260 kJ (297 kcal)/100 g, with vitamins, minerals, and trace elements. Maxamum products are generally intended for use in children 1-8 years.

HCU Maxamum powder (Nutricia Ltd)
- 500 g (ACBS) - NHS indicative price = £159.66

Hyperlysinaemia

HYPER LYS Anamix ® Infant
- Nutritional supplement for the dietary management of hyperlysinaemia in children from birth to 3 years.
- POWDER, protein equivalent (essential and non-essential amino acids except lysine) 13.1 g, carbohydrate 49.5 g, fat 23 g, fibre 5.3 g, energy 1915 kJ (457 kcal)/100 g, with vitamins, minerals, and trace elements; standard dilution (15%) provides protein equivalent 2 g, carbohydrate 7.4 g, fat 3.5 g, fibre 800 mg, energy 287 kJ (69 kcal)/100 mL.

HYPER LYS Anamix Infant powder (Nutricia Ltd)
- 400 g (ACBS) - NHS indicative price = £39.45

HYPER LYS Maxamaid ®
- Nutritional supplement for the dietary management of hyperlysinaemia.
- POWDER, protein equivalent (essential and non-essential amino acids except lysine) 25 g, carbohydrate 51 g, fat less than 500 mg, energy 1311 kJ (309 kcal)/100 g with vitamins, minerals, and trace elements. Maxamaid products are generally intended for use in children 1-8 years.

HYPER LYS Maxamaid powder (Nutricia Ltd)
- 500 g (ACBS) - NHS indicative price = £99.61

Isovaleric acidaemia

IVA Anamix ® Infant
- Nutritional supplement for the dietary management of proven isovaleric acidaemia or other proven disorders of leucine metabolism in children from birth to 3 years.
- POWDER, protein equivalent (essential and non-essential amino acids except leucine) 15.1 g, carbohydrate 49.5 g, fat 23 g, fibre 5.3 g, energy 1915 kJ (457 kcal)/100 g, with vitamins, minerals, and trace elements; standard dilution (15%) provides protein equivalent 2 g, carbohydrate 7.4 g, fat 3.5 g, fibre 800 mg, energy 287 kJ (69 kcal)/100 mL.

IVA Anamix Infant powder (Nutricia Ltd)
- 400 g (ACBS) - NHS indicative price = £39.45

IVA Maxamaid ®
- Nutritional supplement for the dietary management of isovaleric acidaemia.
- POWDER, protein equivalent (essential and non-essential amino acids except leucine) 25 g, carbohydrate 51 g, fat less than 500 mg, energy 1311 kJ (309 kcal)/100 g with vitamins, minerals, and trace elements. Maxamaid products are generally intended for use in children 1-8 years.

IVA Maxamaid powder (Nutricia Ltd)
- 500 g (ACBS) - NHS indicative price = £99.61

Maple syrup urine disease

MSUD Aid III ®
- Nutritional supplement for the dietary management of maple syrup urine disease and related conditions in children and adults where it is necessary to limit the intake of branched chain amino acids.
- POWDER, protein equivalent (essential and non-essential amino acids except isoleucine, leucine, and valine) 77 g, carbohydrate 4.5 g, fat nil, energy 1386 kJ (326 kcal)/100 g.

MSUD Aid III powder (Nutricia Ltd)
- 500 g (ACBS) - NHS indicative price = £188.69

MSUD Anamix ® Infant
- Nutritional supplement for the dietary management of proven maple syrup urine disease in children from birth to 3 years.
- POWDER, protein equivalent (essential and non-essential amino acids except isoleucine, leucine, and valine) 13.1 g, carbohydrate 49.5 g, fat 23 g, fibre 5.3 g, energy 1915 kJ (457 kcal)/100 g, with vitamins, minerals, and trace elements; standard dilution (15%) provides protein equivalent 2 g, carbohydrate 7.4 g, fat 3.5 g, fibre 800 mg, energy 287 kJ (69 kcal)/100 mL.

MSUD Anamix Infant powder (Nutricia Ltd)
- 400 g (ACBS) - NHS indicative price = £39.45

MSUD Anamix ® Junior
- Nutritional supplement for the dietary management of maple syrup urine disease in children 1-10 years.
- POWDER, protein equivalent (essential and non-essential amino acids except isoleucine, leucine, and valine) 8.4 g, carbohydrate 11 g, fat 3.9 g, energy 474 kJ (113 kcal)/29-g sachet, with vitamins, minerals, and trace elements.

MSUD Anamix Junior oral powder 36g sachets (Nutricia Ltd)
- 30 sachet (ACBS) - NHS indicative price = £210.90

MSUD Anamix ® Junior LQ
- Nutritional supplement for the dietary management of maple syrup urine disease in children 1-10 years.
- LIQUID, protein equivalent (essential and non-essential amino acids except isoleucine, leucine, and valine) 10 g, carbohydrate 8.8 g, fat 4.8 g, fibre 310 mg, energy 497 kJ (118 kcal)/125 mL, with vitamins, minerals, and trace elements. Lactose-free.
Nutritional supplements for the dietary management of inborn errors of metabolism

- **MSUD Anamix Junior LQ liquid** (Nutricia Ltd)
  125ml (ACBS) - NHS indicative price = £9.15

- **MSUD Maxamum powder orange** (Nutricia Ltd)
  500gram (ACBS) - NHS indicative price = £159.66

- **MSUD Maxamum powder unflavoured** (Nutricia Ltd)
  500gram (ACBS) - NHS indicative price = £159.66

**Methylmalonic or propionic acidaemia**

- **MMA/PA Anamix® Infant**
  - Nutritional supplement for the dietary management of proven methylmalonic acidaemia or propionic acidaemia in children from birth to 3 years.
  - POWDER, protein equivalent (essential and non-essential amino acids except methionine, threonine, and valine, and low isoleucine) 13.1 g, carbohydrate 49.5 g, fat 25 g, fibre 5.3 g, energy 1915 kJ (457 kcal)/100 g, with vitamins, minerals, and trace elements; standard dilution (15%) provides protein equivalent 2 g, carbohydrate 7.4 g, fat 3.5 g, fibre 800 mg, energy 287 kJ (69 kcal)/100 mL.

- **MMA / PA Anamix Infant powder** (Nutricia Ltd)
  400gram (ACBS) - NHS indicative price = £39.45

- **XMTVI Asadon**
  - Nutritional supplement for the dietary management of methylmalonic acidaemia or propionic acidaemia in children and adults.
  - POWDER, protein equivalent (essential and non-essential amino acids except methionine, threonine, and valine, and low isoleucine) 77 g, carbohydrate 4.5 g, fat nil, energy 1386 kJ (326 kcal)/100 g.

- **XMTVI Asadon powder** (Nutricia Ltd)
  200gram (ACBS) - NHS indicative price = £75.47

- **MMA/PA Maxamaid®**
  - Nutritional supplement for the dietary management of methylmalonic acidaemia or propionic acidaemia.
  - POWDER, protein equivalent (essential and non-essential amino acids except methionine, threonine, and valine, and low isoleucine) 32 g, carbohydrate 4.5 g, fat nil, energy 800 kJ (186 kcal)/25 g, with vitamins, minerals, and trace elements. Maxamaid products are generally intended for use in children 1–8 years.

- **MMA/PA Maxamaid powder** (Nutricia Ltd)
  500gram (ACBS) - NHS indicative price = £99.61

- **MMA/PA Maxamum®**
  - Nutritional supplement for the dietary management of methylmalonic acidaemia or propionic acidaemia.
  - POWDER, protein equivalent (essential and non-essential amino acids except methionine, threonine, and valine, and low isoleucine) 39 g, carbohydrate 34 g, fat less than 500 mg, energy 1260 kJ (297 kcal)/100 g, with vitamins, minerals, and trace elements. Maxamum products are generally intended for use in children over 8 years.

- **MMA/PA Maxamum powder** (Nutricia Ltd)
  500gram (ACBS) - NHS indicative price = £159.66

Other inborn errors of metabolism

- **Cystine500®**
  - Nutritional supplement for the dietary management of inborn errors of amino acid metabolism in adults and children from birth.
  - POWDER, cystine 500 mg, carbohydrate 3.5 g, fat nil, energy 63 kJ (15 kcal)/4 g

- **Cystine500 oral powder 4g sachets** (Vitaflor International Ltd)
  30 sachet (ACBS) - NHS indicative price = £55.00

- **DocOmega®**
  - Nutritional supplement for the dietary management of inborn errors of metabolism for adults and children from birth.
  - POWDER, protein (cows’ milk, soya) 100 mg, carbohydrate 5.2 g, fat 500 mg (of which docosahexaenoic acid 200 mg), fibre nil, energy 74 kJ (18 kcal)/4 g, with minerals

- **DocOmega oral powder 4g sachets** (Vitaflor International Ltd)
  30 sachet (ACBS) - NHS indicative price = £39.80

Downloaded from www.medicalbr.com
Nutritional supplements for metabolic diseases

EAA® Supplement
- Nutritional supplement for the dietary management of disorders of protein metabolism including urea cycle disorders in children over 5 years. POWDER, protein equivalent (essential amino acids) 5 g, carbohydrate 4 g, fat nil, energy 151 kJ (36 kcal)/12.5 g, with vitamins, minerals, and trace elements.

EAA Supplement oral powder 12.5g sachets (Vitaflo International Ltd) 50 sachet (ACBS) - NHS indicative price = £207.51

Isoleucine50®
- Nutritional supplement for use in the dietary management of inborn errors of amino acid metabolism in adults and children from birth.
POWDER, isoleucine 50 mg, carbohydrate 3.8 g, fat nil, energy 63 kJ (15 kcal)/4 g

Isoleucine50 oral powder 4g sachets (Vitaflo International Ltd) 30 sachet (ACBS) - NHS indicative price = £55.00

KeyOmega®
- Nutritional supplement for the dietary management of inborn errors of metabolism.
POWDER, protein (cows’ milk, soya) 170 mg, carbohydrate 2.8 g, fat 800 mg (of which arachidonic acid 200 mg, docosahexaenoic acid 100 mg), energy 80 kJ (19 kcal)/4 g.

KeyOmega oral powder 4g sachets (Vitaflo International Ltd) 30 sachet (ACBS) - NHS indicative price = £40.70

Leucine100®
- Nutritional supplement for the dietary management of inborn errors of amino acid metabolism in adults and children from birth.
POWDER, leucine 100 mg, carbohydrate 3.7 g, fat nil, energy 63 kJ (15 kcal)/4 g

Leucine100 oral powder 4g sachets (Vitaflo International Ltd) 30 sachet (ACBS) - NHS indicative price = £55.00

Low protein drink
- Nutritional supplement for the dietary management of inborn errors of amino acid metabolism in adults and children over 1 year.
POWDER, protein (cows’ milk) 4.5 g (phenylalanine 100 mg), carbohydrate 59.5 g, fat 29.9 g, fibre nil, energy 2194 kJ (528 kcal)/100 g, with vitamins, minerals, and trace elements. Contains lactose. Termed Milupa® lp-drink by manufacturer.

Milupa LP drink (Nutricia Ltd) 400gram (ACBS) - NHS indicative price = £9.36

Phenylalanine50®
- Nutritional supplement for use in the dietary management of inborn errors of metabolism in adults and children from birth.
POWDER, phenylalanine 50 mg, carbohydrate 5.8 g, fat nil, energy 63 kJ (15 kcal)/4 g

Phenylalanine50 oral powder sachets (Vitaflo International Ltd) 30 sachet (ACBS) - NHS indicative price = £55.00

ProZero®
- A protein-free nutritional supplement for the dietary management of inborn errors of metabolism in children over 6 months and adults.
LIQUID, carbohydrate 8.1 g (of which sugars 3.5 g), fat 3.8 g, energy 278 kJ (66 kcal)/100 mL. Contains lactose.

ProZero liquid (Vitaflo International Ltd) 250ml (ACBS) - NHS indicative price = £1.46

Tyrosine1000®
- Nutritional supplement for the dietary management of inborn errors of amino acid metabolism in adults and children from birth.
POWDER, tyrosine 1 g, carbohydrate 2.9 g, fat nil, energy 63 kJ (15 kcal)/4 g sachet.

Tyrosine1000 oral powder 4g sachets (Vitaflo International Ltd) 30 sachet (ACBS) - NHS indicative price = £5.04

Valine50®
- Nutritional supplement for the dietary management of inborn errors of amino acid metabolism in adults and children from birth.
POWDER, valine 50 mg, carbohydrate 3.8 g, fat nil, energy 63 kJ (15 kcal)/4 g

Valine50 oral powder 4g sachets (Vitaflo International Ltd) 30 sachet (ACBS) - NHS indicative price = £55.00

Phenylketonuria

Add-Ins®
- Nutritional supplement for the dietary management of proven phenylketonuria in children over 4 years.
POWDER, protein equivalent (containing essential and non-essential amino acids except phenylalanine) 10 g, carbohydrate nil, fat 5.1 g, energy 359 kJ (86 kcal)/18.2 g sachet, with vitamins, minerals, and trace elements.

Add ins oral powder 18.2g sachets (Nutricia Ltd) 60 sachet (ACBS) - NHS indicative price = £381.00

Easiphen®
- Nutritional supplement for the dietary management of proven phenylketonuria in children over 8 years.
LIQUID, protein equivalent (containing essential and non-essential amino acids except phenylalanine) 6.7 g, carbohydrate 5.1 g, fat 2 g, energy 275 kJ (65 kcal)/100 mL with vitamins, minerals, and trace elements.

Easiphen liquid (Nutricia Ltd) 250ml (ACBS) - NHS indicative price = £9.79

L-Tyrosine
- Nutritional supplement for the dietary management of phenylketonuria in pregnant women with low plasma tyrosine concentrations.
POWDER, L-tyrosine 20 g, carbohydrate 76.8 g, fat nil, energy 1612 kJ (379 kcal)/100 g.

L-Tyrosine powder (Nutricia Ltd) 100gram (ACBS) - NHS indicative price = £22.22

Lophlex®
- Nutritional supplement for the dietary management of proven phenylketonuria in children over 8 years and adults including pregnant women.
POWDER, protein equivalent (essential and non-essential amino acids except phenylalanine) 20 g, carbohydrate 2.5 g, fat 60 mg, fibre 220 mg, energy 385 kJ (91 kcal)/27.8 g sachet, with vitamins, minerals, and trace elements.

Lophlex powder 27.8g sachets berry (Nutricia Ltd) 30 sachet (ACBS) - NHS indicative price = £294.00

Lophlex powder 27.8g sachets orange (Nutricia Ltd) 30 sachet (ACBS) - NHS indicative price = £294.00

Lophlex powder 27.8g sachets unflavoured (Nutricia Ltd) 30 sachet (ACBS) - NHS indicative price = £294.00

Loprofin® PKU Drink
- Nutritional supplement for the dietary management of phenylketonuria in children over 1 year and adults.
LIQUID, protein (cows’ milk) 400 mg (phenylalanine 10 mg), lactose 9.4 g, fat 2 g, energy 165 kJ (40 kcal)/100 mL.

Loprofin PKU drink (Nutricia Ltd) 200ml (ACBS) - NHS indicative price = £0.76

Loprofin® Sno-Pro
- Nutritional supplement for the dietary management of phenylketonuria, chronic renal failure and other inborn errors of amino acid metabolism.
LIQUID, protein (cows’ milk) 220 mg (phenylalanine 12.5 mg), carbohydrate 8 g, fat 3.8 g, energy 275 kJ (65 kcal)/100 mL. Contains lactose.

Loprofin SNO-PRO drink (Nutricia Ltd) 200ml (ACBS) - NHS indicative price = £1.27
Phlexy-10® Exchange System

- Nutritional supplement for the dietary management of phenylketonuria.

**CAPSULES**, protein equivalent (essential and non-essential amino acids except phenylalanine) 416.5 mg/capsule.

**Phlexy-10 500mg capsules** (Nutricia Ltd)
- 200 capsule (ACBS) · NHS indicative price = £44.00
- TABLETS, protein equivalent (essential and non-essential amino acids except phenylalanine) 833 mg tablet.

**Phlexy-10 tablets** (Nutricia Ltd)
- 75 tablet (ACBS) · NHS indicative price = £28.50

**DRINK MIX**, powder, protein equivalent (essential and non-essential amino acids except phenylalanine) 8.33 g, carbohydrate 8.8 g/20-g sachet.

**Phlexy-10 drink mix apple & blackcurrant** (Nutricia Ltd)
- 600 gram (ACBS) · NHS indicative price = £130.20

**Phlexy-10 drink mix citrus burst** (Nutricia Ltd)
- 600 gram (ACBS) · NHS indicative price = £130.20

**Phlexy-Vits**
- For use as a vitamin and mineral component of restricted therapeutic diets in children over 11 years and adults with phenylketonuria and similar amino acid abnormalities.

**POWDER**, vitamins, minerals, and trace elements

**Phlexy-Vits powder** (Nutricia Ltd)
- 210 gram (ACBS) · NHS indicative price = £72.30
- TABLETS, vitamins, minerals, and trace elements

**Phlexy-Vits tablets** (Nutricia Ltd)
- 180 tablet (ACBS) · NHS indicative price = £82.80

**PK Aid 4®**
- Nutritional supplement for the dietary management of phenylketonuria in children and adults.

**POWDER**, protein equivalent (essential and non-essential amino acids except phenylalanine) 79 g, carbohydrate 4.5 g, fat nil, energy 1420 kJ (354 kcal)/100 g.

**PK Aid 4 powder** (Nutricia Ltd)
- 500 gram (ACBS) · NHS indicative price = £145.04

**PKU Anamix Junior LQ®**
- LIQUID, protein equivalent (essential and non-essential amino acids except phenylalanine) 10 g, carbohydrate 8.8 g, fat 4.8 g, fibre 310 mg, energy 497 kJ (118 kcal)/125 mL, with vitamins, minerals, and trace elements. Lactose-free.

**PKU Anamix Junior LQ liquid berry** (Nutricia Ltd)
- 125 mL (ACBS) · NHS indicative price = £5.69

**PKU Anamix Infant®**
- Nutritional supplement for the dietary management of proven phenylketonuria in children from birth to 3 years.

**POWDER**, protein equivalent (essential and non-essential amino acids except phenylalanine) 15.1 g, carbohydrate 49.5 g, fat 25 g, fibre 5.3 g, energy 1915 kJ (457 kcal)/100 g, with vitamins, minerals, and trace elements; standard dilution (15%) provides protein equivalent 2 g, carbohydrate 7.4 g, fat 3.5 g, fibre 800 mg, energy 287 kJ (69 kcal)/100 mL.

**PKU Anamix Infant powder** (Nutricia Ltd)
- 400 gram (ACBS) · NHS indicative price = £35.86

**PKU Anamix® Junior**
- Nutritional supplement for the dietary management of phenylketonuria in children 1–10 years.

**POWDER**, protein equivalent (essential and non-essential amino acids except phenylalanine) 8.4 g, carbohydrate 9.9 g, fat 3.9 g, energy 455 kJ (108 kcal)/29-g sachet, with vitamins, minerals, and trace elements

**PKU Anamix Junior powder chocolate** (Nutricia Ltd)
- 1080 gram (ACBS) · NHS indicative price = £128.10

**PKU Anamix Junior powder neutral** (Nutricia Ltd)
- 1080 gram (ACBS) · NHS indicative price = £128.10

PKU Anamix® Junior LQ
- Nutritional supplement for the dietary management of phenylketonuria in children 1–10 years.

**LIQUID**, protein equivalent (essential and non-essential amino acids except phenylalanine) 10 g, carbohydrate 8.8 g, fat 4.8 g, fibre 310 mg, energy 497 kJ (118 kcal)/125 mL, with vitamins, minerals, and trace elements. Lactose-free.

**PKU Anamix Junior LQ liquid berry** (Nutricia Ltd)
- 125 mL (ACBS) · NHS indicative price = £5.69

**PKU Anamix Junior LQ liquid orange** (Nutricia Ltd)
- 125 mL (ACBS) · NHS indicative price = £5.69

**PKU cooler10®**
- Nutritional supplement for the dietary management of phenylketonuria in children over 3 years.

**LIQUID**, protein equivalent (essential and non-essential amino acids except phenylalanine) 10 g, carbohydrate 5.1 g, energy 258 kJ (62 kcal)/87-mL pouch, with vitamins, minerals, and trace elements.

**PKU orange cooler 10 liquid** (Vitaflo International Ltd)
- 87 mL (ACBS) · NHS indicative price = £4.65

**PKU purple cooler 10 liquid** (Vitaflo International Ltd)
- 87 mL (ACBS) · NHS indicative price = £4.65

**PKU red cooler 10 liquid** (Vitaflo International Ltd)
- 87 mL (ACBS) · NHS indicative price = £4.65

**PKU white cooler 10 liquid** (Vitaflo International Ltd)
- 87 mL (ACBS) · NHS indicative price = £4.65

**PKU cooler15®**
- Nutritional supplement for the dietary management of phenylketonuria in children over 5 years.

**LIQUID**, protein equivalent (essential and non-essential amino acids except phenylalanine) 15 g, carbohydrate 7.8 g, energy 386 kJ (92 kcal)/130-mL pouch, with vitamins, minerals, and trace elements.

**PKU orange cooler 15 liquid** (Vitaflo International Ltd)
- 130 mL (ACBS) · NHS indicative price = £6.92

**PKU purple cooler 15 liquid** (Vitaflo International Ltd)
- 130 mL (ACBS) · NHS indicative price = £6.92

**PKU red cooler 15 liquid** (Vitaflo International Ltd)
- 130 mL (ACBS) · NHS indicative price = £6.92

**PKU white cooler 15 liquid** (Vitaflo International Ltd)
- 130 mL (ACBS) · NHS indicative price = £6.92

**PKU cooler20®**
- Nutritional supplement for the dietary management of phenylketonuria in children over 5 years.

**LIQUID**, protein equivalent (essential and non-essential amino acids except phenylalanine) 20 g, carbohydrate 10.2 g, energy 287 kJ (69 kcal)/87-mL pouch, with vitamins, minerals, and trace elements.

**PKU orange cooler 20 liquid** (Vitaflo International Ltd)
- 174 mL (ACBS) · NHS indicative price = £9.30

**PKU purple cooler 20 liquid** (Vitaflo International Ltd)
- 174 mL (ACBS) · NHS indicative price = £9.30

**PKU red cooler 20 liquid** (Vitaflo International Ltd)
- 174 mL (ACBS) · NHS indicative price = £9.30

**PKU white cooler 20 liquid** (Vitaflo International Ltd)
- 174 mL (ACBS) · NHS indicative price = £9.30

**PKU express15®**
- Nutritional supplement for the dietary management of phenylketonuria. Not recommended for children under 3 years.

**POWDER**, protein equivalent (essential and non-essential amino acids except phenylalanine) 15 g, carbohydrate 2.4 g, energy 295 kJ (70 kcal)/25 g, with vitamins, minerals, and trace elements. To flavour unflavoured products, see FlavourPac p. 1441.

**PKU express 15 powder lemon** (Vitaflo International Ltd)
- 750 g (ACBS) · NHS indicative price = £203.80

**PKU express 15 powder orange** (Vitaflo International Ltd)
- 750 g (ACBS) · NHS indicative price = £203.80
Nutritional supplements for metabolic diseases

PKU express 15 powder tropical (Vitaflor International Ltd)
750g (ACBS) - NHS indicative price = £203.80
PKU express 15 powder unflavoured (Vitaflor International Ltd)
750g (ACBS) - NHS indicative price = £203.80
PKU express 20®
Nutritional supplement for the dietary management of phenylketonuria. Not recommended for children under 3 years. POWDER, protein equivalent (essential and non-essential amino acids except phenylalanine) 10 g, carbohydrate 5.3 g, energy 389 kJ (93 kcal)/34 g, with vitamins, minerals, and trace elements. To flavour unflavoured products, see FlavourPac p. 1441.
PKU express 20 powder lemon (Vitaflor International Ltd)
1020g (ACBS) - NHS indicative price = £263.30
PKU express 20 powder orange (Vitaflor International Ltd)
1020g (ACBS) - NHS indicative price = £263.30
PKU express 20 powder tropical (Vitaflor International Ltd)
1020g (ACBS) - NHS indicative price = £263.30
PKU express 20 powder unflavoured (Vitaflor International Ltd)
1020g (ACBS) - NHS indicative price = £263.30
PKU gel®
For use as part of the low-protein dietary management of phenylketonuria in children 1-10 years. POWDER, protein equivalent (essential and non-essential amino acids except phenylalanine) 10 g, carbohydrate 8.9 g, fat less than 100 mg, energy 318 kJ (76 kcal)/24 g, with vitamins, minerals, and trace elements. To flavour unflavoured products, see FlavourPac p. 1441.
PKU gel powder orange (Vitaflor International Ltd)
720g (ACBS) - NHS indicative price = £140.99
PKU gel powder raspberry (Vitaflor International Ltd)
720g (ACBS) - NHS indicative price = £140.99
PKU gel powder unflavoured (Vitaflor International Ltd)
720g (ACBS) - NHS indicative price = £140.99
PKU Lophlex® LQ 10
Nutritional supplement for the dietary management of phenylketonuria in children under 4 years and adults including pregnant women. LIQUID, protein equivalent (essential and non-essential amino acids except phenylalanine) 10 g, carbohydrate 4.4 g, fibre 250 mg, energy 245 kJ (58 kcal)/62.5 mL, with vitamins, minerals, and trace elements.
PKU Lophlex LQ 10 liquid berry (Nutricia Ltd)
62.5ml (ACBS) - NHS indicative price = £5.25
PKU Lophlex LQ 10 liquid juicy berries (Nutricia Ltd)
62.5ml (ACBS) - NHS indicative price = £5.25
PKU Lophlex LQ 10 liquid juicy orange (Nutricia Ltd)
62.5ml (ACBS) - NHS indicative price = £5.25
PKU Lophlex® LQ 20
Nutritional supplement for the dietary management of phenylketonuria in children under 4 years and adults including pregnant women. LIQUID, protein equivalent (essential and non-essential amino acids except phenylalanine) 20 g, carbohydrate 8.8 g, fibre 340 mg, energy 490 kJ (115 kcal)/125 mL, with vitamins, minerals, and trace elements.
PKU Lophlex LQ 20 liquid berry (Nutricia Ltd)
125ml (ACBS) - NHS indicative price = £10.47
PKU Lophlex LQ 20 liquid juicy berries (Nutricia Ltd)
125ml (ACBS) - NHS indicative price = £10.47
PKU Lophlex LQ 20 liquid orange (Nutricia Ltd)
125ml (ACBS) - NHS indicative price = £10.47
PKU Lophlex® Sensation 20
Nutritional supplement for the dietary management of phenylketonuria in children under 4 years and adults including pregnant women. SEMI-SOILD, protein equivalent (containing essential and non-essential amino acids except phenylalanine) 20 g, carbohydrate 20.2 g, fibre 1 g, energy 706 kJ (166 kcal)/109 g, with vitamins, minerals, and trace elements.
PKU Lophlex Sensation 20 berries (Nutricia Ltd)
327g (ACBS) - NHS indicative price = £33.45
PKU Lophlex Sensation 20 orange (Nutricia Ltd)
327g (ACBS) - NHS indicative price = £33.45
PKU squeeze®
Nutritional supplement for the dietary management of phenylketonuria in children from 6 months to 10 years. LIQUID, protein equivalent (essential and non-essential amino acids except phenylalanine) 10 g, carbohydrate 22.5 g, fat 500 mg, energy 565 kJ (135 kcal)/85 g, with vitamins, minerals, and trace elements.
PKU squeeze liquid (Vitaflor International Ltd)
2550g (ACBS) - NHS indicative price = £134.78
PKU Maxamaid®
Nutritional supplement for the dietary management of phenylketonuria in children 1-8 years. POWDER, protein equivalent (essential and non-essential amino acids except phenylalanine) 25 g, carbohydrate 51 g, fat less than 500 mg, energy 1311 kJ (309 kcal)/100 g, with vitamins, minerals, and trace elements.
PKU Maxamaid powder orange (Nutricia Ltd)
500g (ACBS) - NHS indicative price = £58.92
PKU Maxamaid powder unflavoured (Nutricia Ltd)
500g (ACBS) - NHS indicative price = £58.92
PKU Maxamum®
Nutritional supplement for the dietary management of phenylketonuria in children over 8 years and adults. POWDER, protein equivalent (essential and non-essential amino acids except phenylalanine) 39 g, carbohydrate 34 g, fat less than 500 mg, energy 1260 kJ (297 kcal)/100 g, with vitamins, minerals, and trace elements.
PKU Maxamum oral powder 50g sachets orange (Nutricia Ltd)
30 sachet (ACBS) - NHS indicative price = £273.30
PKU Maxamum oral powder 50g sachets unflavoured (Nutricia Ltd)
30 sachet (ACBS) - NHS indicative price = £273.30
PKU Maxamum powder orange (Nutricia Ltd)
500g (ACBS) - NHS indicative price = £91.14
PKU Maxamum powder unflavoured (Nutricia Ltd)
500g (ACBS) - NHS indicative price = £91.14

Tyrosinaemia
Methionine-free TYR Anamix® Infant
Nutritional supplement for the dietary management of proven tyrosinaemia type 1 in children from birth to 3 years. POWDER, protein equivalent (essential and non-essential amino acids except methionine, phenylalanine, and tyrosine) 13.1 g, carbohydrate 49.5 g, fat 23 g, fibre 5.5 g, energy 1915 kJ (457 kcal)/100 g, with vitamins, minerals, and trace elements; standard dilution (15%) provides protein equivalent 2 g, carbohydrate 7.4 g, fat 5.5 g, fibre 800 mg, energy 287 kJ (69 kcal)/100 mL.
TYR Anamix Infant methionine free powder (Nutricia Ltd)
400g (ACBS) - NHS indicative price = £93.45
TYR Anamix® Infant
Nutritional supplement for the dietary management of proven tyrosinaemia where plasma-methionine concentrations are normal in children from birth to 3 years. POWDER, protein equivalent (essential and non-essential amino acids except phenylalanine and tyrosine) 13.1 g, carbohydrate 49.5 g, fat 23 g, fibre 5.3 g, energy 1915 kJ (457 kcal)/100 g, with vitamins, minerals, and trace elements; standard dilution (15%) provides protein equivalent 2 g, carbohydrate 7.4 g, fat 5.5 g, fibre 800 mg, energy 287 kJ (69 kcal)/100 mL.
TYR Anamix Infant methionine free powder (Nutricia Ltd)
400g (ACBS) - NHS indicative price = £93.45
TYR Anamix Infant powder (Nutricia Ltd)
400g (ACBS) - NHS indicative price = £93.45
**TYR Anamix® Junior**
- Nutritional supplement for the dietary management of proven tyrosinaemia in children 1–10 years.
- POWDER, protein equivalent (essential and non-essential amino acids except phenylalanine and tyrosine) 8.4 g, carbohydrate 11 g, fat 5.9 g, energy 475 kJ (115 kcal)/29-g sachet, with vitamins, minerals, and trace elements.

**TYR Anamix® Junior Oral powder 29g sachets** (Nutricia Ltd)
- 30 sachet (ACBS) · NHS indicative price = £206.40

**TYR Anamix® Junior LQ**
- Nutritional supplement for the dietary management of tyrosinaemia in children over 3 years and adults.
- LIQUID, protein equivalent (essential and non-essential amino acids except phenylalanine and tyrosine) 8.8 g, fat 4.8 g, fibre 310 mg, energy 500 kJ (119 kcal)/125 mL, with vitamins, minerals, and trace elements.

**TYR Anamix® Junior LQ liquid** (Nutricia Ltd)
- 125ml (ACBS) · NHS indicative price = £9.15

**TYR cooler® 15**
- Nutritional supplement for the dietary management of tyrosinaemia in children over 5 years and adults.
- LIQUID, protein equivalent (essential and non-essential amino acids except tyrosine and phenylalanine) 15 g, carbohydrate 7 g, fat 500 mg, energy 593 kJ (92 kcal)/150 mL, with vitamins, minerals, and trace elements.

**TYR orange cooler 15 liquid** (Vitaflo International Ltd)
- 150ml (ACBS) · NHS indicative price = £11.42

**TYR red cooler 10 liquid** (Vitaflo International Ltd)
- 87 ml (ACBS) · NHS indicative price = £7.32

**TYR red cooler 15 liquid** (Vitaflo International Ltd)
- 150 ml (ACBS) · NHS indicative price = £11.42

**TYR red cooler 20 liquid** (Vitaflo International Ltd)
- 174 ml (ACBS) · NHS indicative price = £15.29

**TYR expressS®**
- Nutritional supplement for the dietary management of tyrosinaemia in children over 8 years and adults.
- POWDER, protein equivalent (essential and non-essential amino acids except tyrosine and phenylalanine) 15 g, carbohydrate 3.4 g, fat less than 100 mg, energy 310 kJ (74 kcal)/25 g, with vitamins, minerals, and trace elements. To flavour unflavoured products, see FlavourPac p. 1441.

**TYR express 15 oral powder 25g sachets** (Vitaflo International Ltd)
- 30 sachet (ACBS) · NHS indicative price = £336.16

**TYR express 20®**
- Nutritional supplement for the dietary management of tyrosinaemia in children over 8 years.
- POWDER, protein equivalent (essential and non-essential amino acids except tyrosine and phenylalanine) 20 g, carbohydrate 4.7 g, fat less than 100 mg, energy 416 kJ (99 kcal)/34 g, with vitamins, minerals, and trace elements. To flavour unflavoured products, see FlavourPac p. 1441.

**TYR express 20 oral powder 34g sachets** (Vitaflo International Ltd)
- 30 sachet (ACBS) · NHS indicative price = £434.31

**TYR Gel®**
- Nutritional supplement for the dietary management of tyrosinaemia in children 1–10 years.
- GEL, protein equivalent (essential and non-essential amino acids except tyrosine and phenylalanine) 10 g, carbohydrate 10.3 g, fat less than 100 mg, energy 339 kJ (81 kcal)/24 g, with vitamins, minerals, and trace elements. To flavour unflavoured products, see FlavourPac p. 1441.

**TYR gel oral powder 24g sachets** (Vitaflo International Ltd)
- 30 sachet (ACBS) · NHS indicative price = £216.42

**TYR Lophlex® LQ 20**
- Nutritional supplement for the dietary management of tyrosinaemia in children over 5 years and adults.
- LIQUID, protein equivalent (essential and non-essential amino acids except phenylalanine and tyrosine) 20 g, carbohydrate 8.8 g, fat less than 500 mg, fibre 500 mg, energy 509 kJ (120 kcal)/125 mL, with vitamins, minerals, and trace elements.

**TYR Lophlex LQ 20 liquid** (Nutricia Ltd)
- 125ml (ACBS) · NHS indicative price = £16.27

**TYR Maxamaid®**
- Nutritional supplement for the dietary management of tyrosinaemia in children 1–8 years.
- POWDER, protein equivalent (essential and non-essential amino acids except phenylalanine and tyrosine) 25 g, carbohydrate 51 g, fat less than 500 mg, energy 1311 kJ (309 kcal)/100 g, with vitamins, minerals, and trace elements.

**TYR Maxamaid powder** (Nutricia Ltd)
- 500 gram (ACBS) · NHS indicative price = £39.61

**XPHEN TYR Tyrosidon®**
- Nutritional supplement for the management of tyrosinaemia in children and adults where plasma-methionine concentrations are normal.
- POWDER, protein equivalent (essential and non-essential amino acids except phenylalanine and tyrosine) 77 g, carbohydrate 4.5 g, fat nil, energy 1386 kJ (326 kcal)/100 g.

**XPHEN TYR Tyrosidon Free AA Mix powder** (Nutricia Ltd)
- 500 gram (ACBS) · NHS indicative price = £188.69

**XPTM Tyrosidon®**
- Nutritional supplement for the dietary management of tyrosinaemia type I in children and adults where plasma-methionine concentrations are above normal.
- POWDER, protein equivalent (essential and non-essential amino acids except methionine, phenylalanine, and tyrosine) 77 g, carbohydrate 4.5 g, fat nil, energy 1586 kJ (326 kcal)/100 g.

**XPTM Tyrosidon powder** (Nutricia Ltd)
- 500 gram · NHS indicative price = £91.31
Appendix 3
Cautionary and advisory labels for dispensed medicines

Guidance for cautionary and advisory labels
Medicinal forms within BNF publications include code numbers of the cautionary labels that pharmacists are recommended to add when dispensing. It is also expected that pharmacists will counsel patients and carers when necessary. Counselling needs to be related to the age, experience, background, and understanding of the individual patient or carer. The pharmacist should ensure understanding of how to take or use the medicine and how to follow the correct dosage schedule. Any effects of the medicine on co-ordination, performance of skilled tasks (e.g. driving or work), any foods or medicines to be avoided, and what to do if a dose is missed should also be explained. Other matters, such as the possibility of staining of the clothes or skin, or discolouration of urine or stools by a medicine should also be mentioned.

For some medicines there is a special need for counselling, such as an unusual method or time of administration or a potential interaction with a common food or domestic remedy, and this should be mentioned where necessary.

Original packs
Most preparations are dispensed in unbroken original packs that include further advice for the patient in the form of patient information leaflets. Label 10 may be of value where appropriate. More general leaflets advising on the administration of preparations such as eye drops, eye ointments, inhalers, and suppositories are also available.

Scope of labels
In general no label recommendations have been made for injections on the assumption that they will be administered by a healthcare professional or a well-instructed patient. The labelling is not exhaustive and pharmacists are recommended to use their professional discretion in labelling new preparations and those for which no labels are shown.

Individual labelling advice is not given on the administration of the large variety of antacids. In the absence of instructions from the prescriber, and if on enquiry the patient has had no verbal instructions, the directions given under 'Dose' should be used on the label.

It is recognised that there may be occasions when pharmacists will use their knowledge and professional discretion and decide to omit one or more of the recommended labels for a particular patient. In this case counselling is of the utmost importance. There may also be an occasion when a prescriber does not wish additional cautionary labels to be used, in which case the prescription should be endorsed 'NCL.' (no cautionary labels). The exact wording that is required instead should then be specified on the prescription.

Pharmacists label medicines with various wordings in addition to those directions specified on the prescription. Such labels include 'Shake the bottle', 'For external use only', and 'Store in a cool place', as well as 'Discard..... days after opening' and 'Do not use after.....', which apply particularly to antibiotic mixtures, diluted liquid and topical preparations, and to eye drops. Although not listed in the BNF these labels should continue to be used when appropriate; indeed, 'For external use only' is a legal requirement on external liquid preparations, while 'Keep out of the reach of children' is a legal requirement on all dispensed medicines. Care should be taken not to obscure other relevant information with adhesive labelling.

It is the usual practice for patients to take standard tablets with water or other liquid and for this reason no separate label has been recommended.

The label wordings recommended by the BNF apply to medicines dispensed against a prescription. Patients should be aware that a dispensed medicine should never be taken by, or shared with, anyone other than for whom the prescriber intended it. Therefore, the BNF does not include warnings against the use of a dispensed medicine by persons other than for whom it was specifically prescribed.

The label or labels for each preparation are recommended after careful consideration of the information available. However, it is recognised that in some cases this information may be either incomplete or open to a different interpretation. The BNF will therefore be grateful to receive any constructive comments on the labelling suggested for any preparation.

Recommended label wordings
For BNF 61 (March 2011), a revised set of cautionary and advisory labels were introduced. All of the existing labels were user-tested, and the revised wording selected reflects terminology that is better understood by patients.

Wordings which can be given as separate warnings are labels 1–19, 29–30, and 32. Wordings which can be incorporated in an appropriate position in the directions for dosage or administration are labels 21–28. A label has been omitted for number 20; labels 31 and 33 no longer apply to any medicines in the BNF and have therefore been deleted.

If separate labels are used it is recommended that the wordings be used without modification. If changes are made to suit computer requirements, care should be taken to retain the sense of the original.

Welsh labels
Comprehensive Welsh translations are available for each cautionary and advisory label. These appear directly under the English label.

Labels
1 Warning: This medicine may make you sleepy
Rhybudd: Gall y fedyginiaeth hon eich gwneud yn gysglyd
To be used on preparations for children containing antihistamines, or other preparations given to children where the warnings of label 2 on driving or alcohol would not be appropriate.

2 Warning: This medicine may make you sleepy. If this happens, do not drive or use tools or machines. Do not drink alcohol
Rhybudd: Gall y fedyginiaeth hon eich gwneud yn gysglyd. Peidwch á gyrru, defnyddio offer llaw neu beiriannau os yw hyn yn digwydd. Peidwch ag yfed alchohol
To be used on preparations for adults that can cause drowsiness, thereby affecting coordination and the ability to drive and operate hazardous machinery; label 1 is more appropriate for children. *It is an offence to drive while under the influence of drink or drugs.*

Some of these preparations only cause drowsiness in the first few days of treatment and some only cause drowsiness in higher doses.

In such cases the patient should be told that the advice applies until the effects have worn off. However many of these preparations can produce a slowing of reaction time and a loss of mental concentration that can have the same effects as drowsiness.

Avoidance of alcoholic drink is recommended because the effects of CNS depressants are enhanced by alcohol. Strict prohibition however could lead to some patients not taking...
the medicine. Pharmacists should therefore explain the risk and encourage compliance, particularly in patients who may think they already tolerate the effects of alcohol (see also label 3). Queries from patients with epilepsy regarding fitness to drive should be referred back to the patient’s doctor.

Side-effects unrelated to drowsiness that may affect a patient’s ability to drive or operate machinery safely include blurred vision, dizziness, or nausea. In general, no label has been recommended to cover these cases, but the patient should be suitably counselled.

3 Warning: This medicine may make you sleepy. If this happens, do not drive or use tools or machines

Rhybudd: Gall y feddygyniaeth hon eich gwneud yn gysglyd. Peidiwch â gyruf, defnyddio offer llaw neu beiriannau os yw hyn yn digwydd

To be used on preparations containing monoamine-oxidase inhibitors; the warning to avoid alcohol and deacoholised (low alcohol) drink is covered by the patient information leaflet.

Also to be used as for label 2 but where alcohol is not an issue.

4 Warning: Do not drink alcohol

Rhybudd: Peidiwch ag yfed alcohol

To be used on preparations where a reaction such as flushing may occur if alcohol is taken (e.g. metronidazole). Alcohol may also enhance the hypoglycaemia produced by some oral antidiabetic drugs but routine application of a warning label is not considered necessary.

Patients should be advised not to drink alcohol for as long as they are receiving/using a course of medication, and in some cases for a period of time after the course is finished.

5 Do not take indigestion remedies 2 hours before or after you take this medicine

Peidiwch â chymryd meddygyniaethau camdrueliad 2 awr cyn neu ar ôl y feddygyniaeth hon

To be used with label 25 on preparations coated to resist gastric acid (e.g. enteric-coated tablets). This is to avoid the possibility of premature dissolution of the coating in the presence of an alkaline pH.

Label 5 also applies to drugs such as gabapentin where the absorption is significantly affected by antacids. Pharmacists will be aware (from a knowledge of physiology) that the usual time during which indigestion remedies should be avoided is at least 2 hours before and after the majority of medicines have been taken; when a manufacturer advises a different time period, this can be followed, and should be explained to the patient.

6 Do not take indigestion remedies, or medicines containing iron or zinc, 2 hours before or after you take this medicine

Peidiwch â chymryd meddygyniaethau camdrueliad neu feddygyniaethau sy’n cynnwys haearn neu sinc, 2 awr cyn neu ar ôl y feddygyniaeth hon

To be used on preparations containing olsxacin and some other quinolones, doxycycline, lymecycline, minocycline, and penicillamine. These drugs chelate calcium, iron, and zinc and are less well absorbed when taken with calcium-containing antacids or preparations containing iron or zinc. Pharmacists will be aware (from a knowledge of physiology) that these incompatible preparations should be taken at least 2 hours apart for the majority of medicines; when a manufacturer advises a different time period, this can be followed, and should be explained to the patient.

7 Do not take milk, indigestion remedies, or medicines containing iron or zinc, 2 hours before or after you take this medicine

Peidiwch â chymryd laeth, meddygyniaethau camdrueliad, neu feddygyniaeth sy’n cynnwys haearn neu sinc, 2 awr cyn neu ar ôl cymryd y feddygyniaeth hon

To be used on preparations containing ciprofloxacín, norfloxacín, or tetracyclines that chelate calcium, iron, magnesium, and zinc, and are thus less available for absorption. Pharmacists will be aware (from a knowledge of physiology) that these incompatible preparations should be taken at least 2 hours apart for the majority of medicines; when a manufacturer advises a different time period, this can be followed, and should be explained to the patient.

Doxycycline, lymecycline, and minocycline are less liable to form chelates and therefore only require label 6 (see above).

8 Warning: Do not stop taking this medicine unless your doctor tells you to stop

Rhybudd: Peidiwch â stopio cymryd y feddygyniaeth hon, oni bai fodi eich meddyg yn dweud wrthych am stopio

To be used on preparations that contain a drug which is required to be taken over long periods without the patient necessarily perceiving any benefit (e.g. antituberculous drugs). Also to be used on preparations that contain a drug whose withdrawal is likely to be a particular hazard (e.g. clonidine for hypertension). Label 10 (see below) is more appropriate for corticosteroids.

9 Space the doses evenly throughout the day. Keep taking this medicine until the course is finished, unless you are told to stop

Gadewch yr un faint o amser rhwng pob dôs yn ystod y dydd. Parhewch i gymryd y feddygyniaeth hon esbod y cyfan wedi’i orffen, oni bai eich bod yn cael cyngor i stopio

To be used on preparations where a course of treatment should be completed to reduce the incidence of relapse or failure of treatment.

The preparations are antimicrobial drugs given by mouth. Very occasionally, some may have severe side-effects (e.g. diarrhoea in patients receiving clindamycin) and in such cases the patient may need to be advised of reasons for stopping treatment quickly and returning to the doctor.

10 Warning: Read the additional information given with this medicine

Rhybudd: Darlennwch y wybodaeth ychwanegol gyda’r feddygyniaeth hon

To be used particularly on preparations containing anticoagulants, lithium, and oral corticosteroids. The appropriate treatment card should be given to the patient and any necessary explanations given. This label may also be used on other preparations to remind the patient of the instructions that have been given.

11 Protect your skin from sunlight—even on a bright but cloudy day. Do not use sunbeds

Diolgelwch eich croen rhag golau’r haul, hyd yn oed ar ddiwrnod braf ond cymylog. Peidiwch â defnyddio gwely haul

To be used on preparations that may cause phototoxic or photoallergic reactions if the patient is exposed to ultraviolet radiation. Many drugs other than those listed in Appendix 3 (e.g. phenothiazines and sulfonamides) may, on rare occasions, cause reactions in susceptible patients. Exposure to high intensity ultraviolet radiation from sunray lamps and sunbeds is particularly likely to cause reactions.

12 Do not take anything containing aspirin while taking this medicine

Peidiwch â chymryd unrhyw beth sy’n cynnwys aspirin gyda’r feddygyniaeth hon

To be used on preparations containing anticoagulants, lithium, and oral corticosteroids. This label may also be used on other preparations to remind the patient of the instructions that have been given.

Label 12 should not be used for anticoagulants since label 10 is more appropriate.

13 Dissolve or mix with water before taking

Gadewch i doddi mewn dŵr cyn ei gymryd

To be used on preparations that are intended to be dissolved in water (e.g. soluble tablets) or mixed with water (e.g. powders, granules) before use. In a few cases other liquids such as fruit juice or milk may be used.
14 This medicine may colour your urine. This is harmless
Gall y feddyginiaeth hon liwio eich dŵr. Nid yw hyn yn arwydd o ddrwgy
To be used on preparations that may cause the patient’s urine to turn an unusual colour. These include triamterene (blue under some lights), levodopa (dark reddish), and rifampicin (red).

15 Caution: flammable. Keep your body away from fire or flames
Rhybudd: Fflamadwy. Ar ôl rohi’r feddyginiaeth ymlaen, cadwch yn glir o dân neu ffilmaw
To be used on preparations containing sufficient flammable solvent to render them flammable if exposed to a naked flame.

16 Dissolve the tablet under your tongue—do not swallow. Store the tablets in this bottle with the cap tightly closed. Get a new supply 8 weeks after opening
Rhôwch y dabledd i doddi dan eich tafod - peidiwch â’i lyncu. Cadwch y tabledi yn y botel yma gyda’r weddi’i gau yn dynn. Gofynnwch am dabledi newyd 8 wythnos ar ôl ei hagor
To be used on glyceryl trinitrate tablets to remind the patient not to transfer the tablets to plastic or less suitable containers.

17 Do not take more than... in 24 hours
Peidiwch â chymryd mwy na... mewn 24 awr
To be used on preparations for the treatment of acute migraine except those containing ergotamine, for which label 18 is used. The dose form should be specified, e.g. tablets or capsules.
It may also be used on preparations for which no dose has been specified by the prescriber.

18 Do not take more than... in 24 hours. Also, do not take more than... in any one week
Peidiwch â chymryd mwy na... mewn 24 awr. Hefyd, peidiwch â chymryd mwy na... mewn wythnos
To be used on preparations containing ergotamine. The dose form should be specified, e.g. tablets or suppositories.

19 Warning: This medicine makes you sleepy. If you still feel sleepy the next day, do not drive or use tools or machines. Do not drink alcohol
Rhûbudd: Bydd y feddyginiaeth hon yn eich gwneud yn gysglyd. Os ydych yn dal i deimlo’n gysglyd drannoeth, peidiwch â gyrru, defnyddio offer llaw neu beiriannau. Peidiwch ag yfed alcohol
To be used on preparations containing hypnotics (or some other drugs with sedative effects) prescribed to be taken at night. On the rare occasions when hypnotics are prescribed for daytime administration (e.g. nitrazepam in epilepsy), this label would clearly not be appropriate. Also to be used as an alternative to the label 2 wording (the choice being at the discretion of the pharmacist) for anxioalytics prescribed to be taken at night.
It is hoped that this wording will convey adequately the problem of residual morning sedation after taking ‘sleeping tablets’.

20 Take with or just after food, or a meal
Cymerwch gyda neu ar ôl bwyd
To be used on preparations that are liable to cause gastric irritation, or those that are better absorbed with food.
Patients should be advised that a small amount of food is sufficient.

21 Take with or just after food, or a meal
Cymerwch gyda neu ar ôl bwyd
To be used on preparations that are liable to cause gastric irritation, or those that are better absorbed with food.
Patients should be advised that a small amount of food is sufficient.

22 Take 30 to 60 minutes before food
Cymerwch 30 i 60 munud cyn bwyd
To be used on some preparations whose absorption is thereby improved.
Most oral antibacterials require label 25 instead (see below).

23 Take this medicine when your stomach is empty. This means an hour before food or 2 hours after food
Cymerwch y feddyginiaeth hon ar stumog wag. Mae hyn yn gogygu awr cyn, neu 2 awr ar ôl bwyd
To be used on oral antibacterials whose absorption may be reduced by the presence of food and acid in the stomach.

24 Suck or chew this medicine
Bydd angen cni neu sugnro’r feddyginiaeth hon
To be used on preparations that should be sucked or chewed.
The pharmacist should use discretion as to which of these words is appropriate.

25 Swallow this medicine whole. Do not chew or crush
Llynchwch yn gyfan. Peidiwch â chni neu falu’n fân
To be used on preparations that are enteric-coated or designed for modified-release.
Also to be used on preparations that taste very unpleasant or may damage the mouth if not swallowed whole.
Patients should be advised (where relevant) that some modified-release preparations can be broken in half, but that the halved tablet should still be swallowed whole, and not chewed or crushed.

26 Dissolve this medicine under your tongue
Gadwch i’r feddyginiaeth hon doddi o dan y tafod
To be used on preparations designed for sublingual use.
Patients should be advised to hold under the tongue and avoid swallowing until dissolved. The buccal mucosa between the gum and cheek is occasionally specified by the prescriber.

27 Take with a full glass of water
Cymerwch gyda llond gwyrdd o dŵr
To be used on preparations that should be well diluted (e.g. chloral hydrate), where a high fluid intake is required (e.g. sulfonamides), or where water is required to aid the action (e.g. methylcellulose).
The patient should be advised that ‘a full glass’ means at least 150 mL. In most cases fruit juice, tea, or coffee may be used.

28 Spread thinly on the affected skin only
Taeu this medicine as appropriate. Yn unig
To be used on external preparations that should be applied sparingly (e.g. corticosteroids, dithranol).

29 Do not take more than 2 at any one time. Do not take more than 8 in 24 hours
Peidiwch â chymryd mwy na 2 ar un rhwym un adeg. Peidiwch â chymryd mwy nag 8 mewn 24 awr
To be used on containers of dispensed solid dose preparations containing paracetamol for adults when the instruction on the label indicates that the dose can be taken on an ‘as required’ basis.
The dose form should be specified, e.g. tablets or capsules.
This label has been introduced because of the serious consequences of overdosage with paracetamol.

30 Contains paracetamol. Do not take anything else containing paracetamol while taking this medicine. Talk to a doctor at once if you take too much of this medicine, even if you feel well
Yn cynnwys paracetamol. Peidiwch â chymryd unrhyw beth arall sy’n cynnwys paracetamol tra’n cymryd y feddyginiaeth hon. Siaradwch gyda’r meddyg ar unwaith os ydych yn cymryd gormod, hyd yw oed os ydych yn teimlo’n iawn
To be used on all containers of dispensed preparations containing paracetamol.

32 Contains aspirin. Do not take anything else containing aspirin while taking this medicine
Yn cynnwys aspirin. Peidiwch â chymryd unrhyw beth arall sy’n cynnwys aspirin tra’n cymryd y feddyginiaeth hon
To be used on containers of dispensed preparations containing aspirin when the name on the label does not include the word ‘aspirin’.

25 Swallow this medicine whole. Do not chew or crush
Llynchwch yn gyfan. Peidiwch â chni neu falu’n fân
To be used on preparations that are enteric-coated or designed for modified-release.
Also to be used on preparations that taste very unpleasant or may damage the mouth if not swallowed whole.
Patients should be advised (where relevant) that some modified-release preparations can be broken in half, but that the halved tablet should still be swallowed whole, and not chewed or crushed.

26 Dissolve this medicine under your tongue
Gadwch i’r feddyginiaeth hon doddi o dan y tafod
To be used on preparations designed for sublingual use.
Patients should be advised to hold under the tongue and avoid swallowing until dissolved. The buccal mucosa between the gum and cheek is occasionally specified by the prescriber.

27 Take with a full glass of water
Cymerwch gyda llond gwyrdd o dŵr
To be used on preparations that should be well diluted (e.g. chloral hydrate), where a high fluid intake is required (e.g. sulfonamides), or where water is required to aid the action (e.g. methylcellulose).
The patient should be advised that ‘a full glass’ means at least 150 mL. In most cases fruit juice, tea, or coffee may be used.

28 Spread thinly on the affected skin only
Taeu this medicine as appropriate. Yn unig
To be used on external preparations that should be applied sparingly (e.g. corticosteroids, dithranol).

29 Do not take more than 2 at any one time. Do not take more than 8 in 24 hours
Peidiwch â chymryd mwy na 2 ar un rhwym un adeg. Peidiwch â chymryd mwy nag 8 mewn 24 awr
To be used on containers of dispensed solid dose preparations containing paracetamol for adults when the instruction on the label indicates that the dose can be taken on an ‘as required’ basis.
The dose form should be specified, e.g. tablets or capsules.
This label has been introduced because of the serious consequences of overdosage with paracetamol.

30 Contains paracetamol. Do not take anything else containing paracetamol while taking this medicine. Talk to a doctor at once if you take too much of this medicine, even if you feel well
Yn cynnwys paracetamol. Peidiwch â chymryd unrhyw beth arall sy’n cynnwys paracetamol tra’n cymryd y feddyginiaeth hon. Siaradwch gyda’r meddyg ar unwaith os ydych yn cymryd gormod, hyd yw oed os ydych yn teimlo’n iawn
To be used on all containers of dispensed preparations containing paracetamol.

32 Contains aspirin. Do not take anything else containing aspirin while taking this medicine
Yn cynnwys aspirin. Peidiwch â chymryd unrhyw beth arall sy’n cynnwys aspirin tra’n cymryd y feddyginiaeth hon
To be used on containers of dispensed preparations containing aspirin when the name on the label does not include the word ‘aspirin’.
Appendix 4

Wound management products and elasticated garments

CONTENTS

Basic wound contact dressings .......................................................... 1457
Low adherence dressing ................................................................. 1457
Absorbent dressings ........................................................................ 1459
Advanced wound dressings ............................................................... 1460
Hydrogel dressings ........................................................................... 1460
Vapour-permeable films and membranes ........................................ 1461
Soft polymer dressings ................................................................... 1463
Hydrocolloid dressings .................................................................... 1464
Foam dressings ................................................................................ 1465
Alginate dressings ........................................................................... 1467
Capillary-acting dressings ................................................................. 1468
Odour absorbent dressings ............................................................... 1468
Antimicrobial dressings ................................................................... 1468
Honey ................................................................................................. 1468
Iodine ................................................................................................. 1469
Silver ................................................................................................. 1469
Other antimicrobials ....................................................................... 1471
Specialised dressings ...................................................................... 1472
Protease-modulating matrix dressings ........................................... 1472
Silicone keloid dressings ................................................................. 1472
Adjunct dressings and appliances .................................................... 1472
Surgical absorbents ......................................................................... 1472
Wound drainage pouches ............................................................... 1473

Physical debridement pads ................................................................. 1473
Complex adjunct therapies ................................................................. 1473
Topical negative pressure therapy .................................................... 1473
Wound care accessories ................................................................... 1474
Dressing packs ................................................................................ 1474
Woven and fabric swabs ................................................................ 1474
Surgical adhesive tapes .................................................................. 1475
Skin closure dressings ...................................................................... 1476
Bandages ............................................................................................. 1476
Non-extensible bandages ................................................................. 1476
Light-weight conforming bandages ................................................ 1476
Tubular bandages and garments ...................................................... 1477
Support bandages ........................................................................... 1478
Adhesive bandages ......................................................................... 1479
Cohesive bandages ......................................................................... 1479
Compression bandages .................................................................. 1479
Multi-layer compression bandaging ................................................ 1480
Medicated bandages ....................................................................... 1480
Medicated stocking ......................................................................... 1481
Compression hosiery and garments .................................................. 1481
Graduated compression hosiery ......................................................... 1481
Lymphoedema garments .................................................................. 1481

The correct dressing for wound management depends not only on the type of wound but also on the stage of the healing process. The principal stages of healing are: cleansing, removal of debris; granulation, vascularisation; epithelialisation. The ideal dressing for moist wound healing needs to ensure that the wound remains: moist with the volume and viscosity of exudate changes as the wound heals. There are certain circumstances where moist wound healing is not appropriate (e.g. gangrenous toes associated with vascular disease).

Advanced wound dressings are designed to control the environment for wound healing, for example to donate fluid (hydrogels), maintain hydration (hydrocolloids), or to absorb wound exudate (alginites, foams).

Practices such as the use of irritant cleansers and desloughing agents may be harmful and are largely obsolete; removal of debris and dressing remnants should need minimal irrigation with lukewarm sterile sodium chloride 0.9% solution or water.

Hydrogel, hydrocolloid, and medical grade honey dressings can be used to deslough wounds by promoting autolytic debridement; there is insufficient evidence to support any particular method of debridement for difficult-to-heal surgical wounds. Sterile larvae (maggots) are also available for biosurgical removal of wound debris.

There have been few clinical trials able to establish a clear advantage for any particular product. The choice between different dressings depends not only on the type and stage of the wound, but also on patient preference or tolerance, site of the wound, and cost. For further information, see Buyers’ Guide: Advanced wound dressings (October 2008); NHS Purchasing and Supply Agency, Centre for Evidence-based Purchasing.

Prices quoted in Appendix 4 are basic NHS net prices; for further information see Prices in the BNF under How to use the BNF.

The table below gives suggestions for choices of primary dressing depending on the type of wound (a secondary dressing may be needed in some cases).

Basic wound contact dressings

Low adherence dressing

Low adherence dressings are used as interface layers under secondary absorbent dressings. Placed directly on the wound bed, non-absorbent, low adherence dressings are suitable for clean, granulating, lightly exuding wounds without necrosis, and protect the wound bed from direct contact with secondary dressings. Care must be taken to avoid granulation tissue growing into the weave of these dressings.
1458  Basic wound contact dressings

**Wound contact material for different types of wounds**

**Wound PINK (epithelialising)**

<table>
<thead>
<tr>
<th>Low Exudate</th>
<th>Moderate Exudate</th>
<th>Heavy Exudate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low adherence p. 1457</td>
<td>Soft ploymer p. 1463</td>
<td>Foam with extra absorbency p. 1466</td>
</tr>
<tr>
<td>Vapour-permeable film p. 1461</td>
<td>Foam, low absorbent p. 1465</td>
<td>Hydrocolloid-fibrous p. 1464</td>
</tr>
<tr>
<td>Soft polymer p. 1463</td>
<td>Alginate p. 1467</td>
<td>Alginate p. 1467</td>
</tr>
<tr>
<td>Hydrocolloid p. 1464</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Wound RED (granulating)**

Symptoms or signs of infection, see Wounds with signs of infection

<table>
<thead>
<tr>
<th>Low Exudate</th>
<th>Moderate Exudate</th>
<th>Heavy Exudate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low adherence p. 1457</td>
<td>Hydrocolloid-fibrous p. 1464</td>
<td>Foam with extra absorbency p. 1466</td>
</tr>
<tr>
<td>Soft polymer p. 1463</td>
<td>Foam p. 1465</td>
<td>Hydrocolloid-fibrous p. 1464</td>
</tr>
<tr>
<td>Hydrocolloid p. 1464</td>
<td>Alginate p. 1467</td>
<td>Alginate p. 1467</td>
</tr>
<tr>
<td>Foam, low absorbent p. 1465</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Wound YELLOW (Sloughy) (granulating)**

Symptoms or signs of infection, see Wounds with signs of infection

<table>
<thead>
<tr>
<th>Low Exudate</th>
<th>Moderate Exudate</th>
<th>Heavy Exudate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low adherence p. 1457</td>
<td>Hydrocolloid-fibrous p. 1464</td>
<td>Hydrocolloid-fibrous p. 1464</td>
</tr>
<tr>
<td>Hydrogel p. 1460</td>
<td>Alginate p. 1467</td>
<td>Capillary-action p. 1468</td>
</tr>
<tr>
<td>Hydrocolloid p. 1464</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Wound BLACK (Necrotic/ Eschar)**

Consider mechanical debridement alongside autolytic debridement

<table>
<thead>
<tr>
<th>Low Exudate</th>
<th>Moderate Exudate</th>
<th>Heavy Exudate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydrogel p. 1464</td>
<td>Hydrocolloid p. 1464</td>
<td>Hydrocolloid-fibrous p. 1464</td>
</tr>
<tr>
<td>Hydrocolloid p. 1464</td>
<td>Hydrocolloid-fibrous p. 1464</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Foam p. 1465</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alginate p. 1467</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Seek advice from wound care specialist</td>
<td></td>
</tr>
</tbody>
</table>

**Wounds with signs of infection**

Consider systemic antibacterials if appropriate; also consider odour-absorbent dressings. For malodorous wounds with slough or necrotic tissue, consider mechanical or autolytic debridement

<table>
<thead>
<tr>
<th>Low Exudate</th>
<th>Moderate Exudate</th>
<th>Heavy Exudate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low adherence with honey p. 1468</td>
<td>Hydrocolloid-fibrous with silver p. 1470</td>
<td>Hydrocolloid-fibrous with silver p. 1470</td>
</tr>
<tr>
<td>Low adherence with iodine p. 1469</td>
<td>Foam with silver p. 1470</td>
<td>Foam extra absorbent, with silver p. 1470</td>
</tr>
<tr>
<td>Low adherence with silver p. 1471</td>
<td>Alginate with silver p. 1470</td>
<td>Alginate with honey p. 1469</td>
</tr>
<tr>
<td>Hydrocolloid with silver p. 1470</td>
<td>Honey-topical p. 1468</td>
<td>Alginate with silver p. 1470</td>
</tr>
<tr>
<td>Honey-topical p. 1468</td>
<td>Cadexomer-iodine p. 1469</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Seek advice from wound care specialist</td>
<td></td>
</tr>
</tbody>
</table>

**N-A Ultra dressing** (Systagenix Wound Management Ltd) 19cm × 9.5cm= £0.67, 9.5cm × 9.5cm= £0.35

**Atrauman dressing** (Paul Hartmann Ltd) 10cm × 20cm= £0.63, 20cm × 30cm= £0.74, 5cm × 5cm= £0.27, 7.5cm × 10cm= £0.28

**N-A Ultra** Warp knitted fabric manufactured from a bright viscose monofilament.

Tulle dressings are manufactured from cotton or viscose fibres which are impregnated with white or yellow soft paraffin to prevent the fibres from sticking, but this is only partly successful and it may be necessary to change the dressings frequently. The paraffin reduces absorbency of the dressing. Dressings with a reduced content (light loading) of soft paraffin are less liable to interfere with absorption; dressings with ‘normal loading’ (such as Jelonet®) have been used for skin graft transfer. Knitted viscose primary dressing is an alternative to tulle dressings for exuding wounds; it can be used as the initial layer of multi-layer compression bandaging in the treatment of venous leg ulcers.

**Knitted polyester primary dressing**

**Atrauman dressing** (Paul Hartmann Ltd) 10cm × 20cm= £0.63, 20cm × 30cm= £1.74, 5cm × 5cm= £0.27, 7.5cm × 10cm= £0.28

**N-A Ultra dressing** (Systagenix Wound Management Ltd) 19cm × 9.5cm= £0.67, 9.5cm × 9.5cm= £0.35

**N-A Ultra** Warp knitted fabric manufactured from a bright viscose monofilament.

**N-A Ultra dressing** (Systagenix Wound Management Ltd) 19cm × 9.5cm= £0.67, 9.5cm × 9.5cm= £0.35

**Profore** Warp knitted fabric manufactured from a bright viscose monofilament.

**Tricotex dressing** (Smith & Nephew Healthcare Ltd) 9.5cm × 9.5cm= £0.34

**Cuticell** (Tulle Gras). Fabric of leno weave, weft and warp threads of cotton and/or viscose yarn, impregnated with white or yellow soft paraffin; for light or normal loading

**Jelonet dressing** (Smith & Nephew Healthcare Ltd) 10cm × 10cm= £0.41

**Paraffin Gauze Dressing**

**Cuticell** (Tulle Gras). Fabric of leno weave, weft and warp threads of cotton and/or viscose yarn, impregnated with white or yellow soft paraffin; for light or normal loading

**Jelonet** (Tulle Gras). Fabric of leno weave, weft and warp threads of cotton and/or viscose yarn, impregnated with white or yellow soft paraffin; for light or normal loading

**Cuticell** (BSN medical Ltd) Classic dressing 10cm × 10cm= £0.29
Neotulle (Tulle Gras). Fabric of leno weave, weft and warp threads of cotton and/or viscose yarn, impregnated with white or yellow soft paraffin; for light or normal loading

Neotulle (Neomedic Ltd) dressing 10cm x 10cm= £0.29

Paragaue (Tulle Gras). Fabric of leno weave, weft and warp threads of cotton and/or viscose yarn, impregnated with white or yellow soft paraffin; for light or normal loading

Paragaue (C D Medical Ltd) dressing 10cm x 10cm= £0.28

Paranet (Tulle Gras). Fabric of leno weave, weft and warp threads of cotton and/or viscose yarn, impregnated with white or yellow soft paraffin; for light or normal loading

Paranet (Synergy Health Plc) dressing 10cm x 10cm= £0.25

Absorbent dressings

Perforated film absorbent dressings are suitable only for wounds with mild to moderate amounts of exudate; they are not appropriate for leg ulcers or for other lesions that produce large quantities of viscous exudate. Dressings with an absorbent cellulose or polymer wadding layer are suitable for use on moderately to heavily exuding wounds.

Absorbent cellulose dressing

CelluDress

CelluDress Dressing (Medicareplus International Ltd) 10cm x 10cm= £0.19, 10cm x 15cm= £0.20, 10cm x 20cm= £0.22, 15cm x 20cm= £0.30, 20cm x 25cm= £0.40, 20cm x 30cm= £0.85

Eclipsy

Absorbent Cellulose Dressing with Fluid Repellent Backing

Eclipsy (Advancis Medical) Boot dressing 60cm x 70cm= £13.78, dressing 15cm x 15cm= £0.97, 20cm x 30cm= £2.14, 60cm x 40cm= £8.15

Exu-Dry

Absorbent Cellulose Dressing with Fluid Repellent Backing

Exu-Dry dressing (Smith & Nephew Healthcare Ltd) 10cm x 15cm= £1.14, 15cm x 23cm= £2.32, 23cm x 38cm= £5.40

Mesorb

Cellulose wadding pad with gauze wound contact layer and non-woven repellent backing

Mesorb dressing (Mohlycke Health Care Ltd) 10cm x 10cm= £0.62, 10cm x 15cm= £0.81, 10cm x 20cm= £1.00, 15cm x 20cm= £1.43, 20cm x 25cm= £2.25, 20cm x 30cm= £2.55

Telfa Max

Absorbent Cellulose Dressing with Fluid Repellent Backing

Zetuvit E

Absorbent Cellulose Dressing with Fluid Repellent Backing; sterile or non-sterile

Zetuvit E (Paul Hartmann Ltd) non-sterile dressing 10cm x 10cm= £0.07, 10cm x 20cm= £0.09, 20cm x 20cm= £0.14, 20cm x 40cm= £0.28, sterile dressing 10cm x 10cm= £0.21, 10cm x 20cm= £0.25, 20cm x 20cm= £0.39, 20cm x 40cm= £1.11

Absorbent perforated dressing

Adpore

Low-adherence primary dressing consisting of viscose and rayon absorbent pad with adhesive border.

Adpore dressing (Medicareplus International Ltd) 10cm x 10cm= £0.10, 10cm x 15cm= £0.16, 10cm x 20cm= £0.30, 10cm x 25cm= £0.34, 10cm x 30cm= £0.42, 10cm x 35cm= £0.50, 7cm x 8cm= £0.08

Cosmopore E

Low-adherence primary dressing consisting of viscose and rayon absorbent pad with adhesive border.

Cosmopore E dressing (Paul Hartmann Ltd) 10cm x 20cm= £0.46, 10cm x 25cm= £0.56, 10cm x 35cm= £0.78, 5cm x 7.2cm= £0.08, 8cm x 10cm= £0.18, 8cm x 15cm= £0.28

Cutiplast Steril

Low-adherence primary dressing consisting of viscose and rayon absorbent pad with adhesive border.

Cutiplast Steril dressing (Smith & Nephew Healthcare Ltd) 10cm x 20cm= £0.31, 10cm x 25cm= £0.32, 10cm x 30cm= £0.43, 8cm x 10cm= £0.11, 8cm x 15cm= £0.25

Leukomed

Low-adherence primary dressing consisting of viscose and rayon absorbent pad with adhesive border.

Leukomed dressing (BSM medical Ltd) 10cm x 20cm= £0.44, 10cm x 25cm= £0.49, 10cm x 30cm= £0.63, 10cm x 35cm= £0.73, 5cm x 7.2cm= £0.09, 8cm x 10cm= £0.19, 8cm x 15cm= £0.33

Medipore + Pad

Low-adherence primary dressing consisting of viscose and rayon absorbent pad with adhesive border.

Medipore + Pads dressing (3M Health Care Ltd) 10cm x 10cm= £0.15, 10cm x 15cm= £0.25, 10cm x 20cm= £0.37, 10cm x 25cm= £0.46, 10cm x 35cm= £0.64, 5cm x 7.2cm= £0.07

Medisafe

Low-adherence primary dressing consisting of viscose and rayon absorbent pad with adhesive border.

Medisafe dressing (Neomedic Ltd) 6cm x 8cm= £0.08, 8cm x 10cm= £0.13, 8cm x 12cm= £0.23, 9cm x 15cm= £0.29, 9cm x 20cm= £0.34, 9cm x 25cm= £0.36

Mepore

Low-adherence primary dressing consisting of viscose and rayon absorbent pad with adhesive border.

Mepore dressing (Mohlycke Health Care Ltd) 10cm x 11cm= £0.22, 11cm x 15cm= £0.36, 7cm x 8cm= £0.11, 9cm x 20cm= £0.44, 9cm x 25cm= £0.61, 9cm x 30cm= £0.70, 9cm x 35cm= £0.76

PremierPore

Low-adherence primary dressing consisting of viscose and rayon absorbent pad with adhesive border.

PremierPore dressing (Shermond) 10cm x 10cm= £0.12, 10cm x 15cm= £0.18, 10cm x 20cm= £0.32, 10cm x 25cm= £0.36, 10cm x 30cm= £0.45, 10cm x 35cm= £0.52, 5cm x 7cm= £0.05

Primapore

Low-adherence primary dressing consisting of viscose and rayon absorbent pad with adhesive border.

Primapore dressing (Smith & Nephew Healthcare Ltd) 10cm x 20cm= £0.44, 10cm x 25cm= £0.50, 10cm x 30cm= £0.63, 10cm x 35cm= £0.97, 6cm x 8.3cm= £0.18, 8cm x 10cm= £0.19, 8cm x 15cm= £0.34

Softpore

Low-adherence primary dressing consisting of viscose and rayon absorbent pad with adhesive border.

Softpore dressing (Richardson Healthcare Ltd) 10cm x 10cm= £0.13, 10cm x 15cm= £0.20, 10cm x 20cm= £0.35, 10cm x 25cm= £0.40, 10cm x 30cm= £0.49, 10cm x 35cm= £0.58, 6cm x 7cm= £0.06

Sterifix

Low-adherence primary dressing consisting of viscose and rayon absorbent pad with adhesive border.

Telfa Island

Low-adherence primary dressing consisting of viscose and rayon absorbent pad with adhesive border.

Telfa Island dressing (Aria Medical Ltd) 10cm x 12.5cm= £0.27, 10cm x 20cm= £0.35, 10cm x 25.5cm= £0.45, 10cm x 35cm= £0.62, 5cm x 10cm= £0.08

Absorbent perforated plastic film faced dressing

Absopad

Low-adherence primary dressing consisting of 3 layers—perforated polyester film wound contact layer, absorbent cotton pad, and hydrophobic backing.

Absopad dressing (Medicareplus International Ltd) 10cm x 10cm= £0.13, 20cm x 10cm= £0.28

Askina Pad

Low-adherence primary dressing consisting of 3 layers—perforated polyester film wound contact layer, absorbent cotton pad, and hydrophobic backing.

Askina (B.Braun Medical Ltd) Pad dressing 10cm x 10cm= £0.21
Low-adherence primary dressing consisting of 3 layers—perforated polyester film wound contact layer, absorbent cotton pad, and hydrophobic backing.

Interpose
Low-adherence primary dressing consisting of 3 layers—perforated polyester film wound contact layer, absorbent cotton pad, and hydrophobic backing.

Melolin
Low-adherence primary dressing consisting of 3 layers—perforated polyester film wound contact layer, absorbent cotton pad, and hydrophobic backing.

Melolin dressing (Smith & Nephew Healthcare Ltd) 10cm × 10cm= £0.28, 20cm × 10cm= £0.54, 5cm × 5cm= £0.17

Skintact
Low-adherence primary dressing consisting of 3 layers—perforated polyester film wound contact layer, absorbent cotton pad, and hydrophobic backing.

Skintact dressing (Robinson Healthcare) 10cm × 10cm= £0.17, 20cm × 10cm= £0.34, 5cm × 5cm= £0.10

Solviline N
Low-adherence primary dressing consisting of 3 layers—perforated polyester film wound contact layer, absorbent cotton pad, and hydrophobic backing.

Solviline N dressing (Lohmann & Rauscher (UK) Ltd) 10cm × 10cm= £0.18, 20cm × 10cm= £0.36, 5cm × 5cm= £0.10

Telfa
Low-adherence primary dressing consisting of 3 layers—perforated polyester film wound contact layer, absorbent cotton pad, and hydrophobic backing.

Telfa dressing (Aria Medical Ltd) 10cm × 7.5cm= £0.16, 15cm × 7.5cm= £0.18, 20cm × 7.5cm= £0.29, 7.5cm × 5cm= £0.10

Super absorbent cellulose and polymer primary dressing

Curea PI
Super absorbent cellulose and polymer primary dressing

Curea PI dressing (Charles S. Bullen Stomacare Ltd) 10cm × 10cm square= £2.15, 10cm × 30cm rectangular= £3.64, 10cm × 30cm rectangular= £5.20, 12cm × 12cm square= £2.65, 20cm × 20cm square= £6.89, 20cm × 30cm rectangular= £10.03, 7.5cm × 7.5cm square= £1.72

Curea P2
Super absorbent cellulose and polymer primary dressing (non-adherent)

Curea P2 dressing (Charles S. Bullen Stomacare Ltd) 10cm × 20cm rectangular= £4.49, 11cm × 11cm square= £2.47, 20cm × 20cm square= £7.82, 20cm × 30cm rectangular= £10.60

Cutisorb Ultra
Super absorbent cellulose and polymer primary dressing

Cutisorb Ultra dressing (BSN medical Ltd) 10cm × 10cm square= £2.13, 10cm × 20cm rectangular= £3.56, 20cm × 20cm square= £6.66, 20cm × 30cm rectangular= £10.06

DryMax Extra
Super absorbent cellulose and polymer primary dressing

DryMax Extra dressing (Aspen Medical Europe Ltd) 10cm × 10cm square= £0.87, 10cm × 20cm rectangular= £1.04, 20cm × 20cm square= £1.84, 20cm × 30cm rectangular= £2.33

ELECT Superabosorber
Super absorbent cellulose and polymer primary dressing

ELECT Superabosorber dressing (Smith & Nephew Healthcare Ltd) 10cm × 10cm square= £0.96, 10cm × 20cm rectangular= £1.13, 20cm × 20cm square= £2.01, 20cm × 30cm rectangular= £2.54

Zetuvit Plus
Super absorbent cellulose primary dressing

Zetuvit Plus dressing (Paul Hartmann Ltd) 10cm × 10cm= £0.64, 10cm × 20cm= £0.88, 15cm × 20cm= £1.01, 20cm × 25cm= £1.38, 20cm × 40cm= £2.13

Super absorbent hydroconductive dressing

Dartex dressing (Martindale Pharmaceuticals Ltd) 10cm × 1.3m= £16.00, 10cm × 10cm= £2.24, 10cm × 1m= £16.00, 20cm × 20cm= £6.00, 20cm × 1m= £25.00, 20cm × 20cm= £6.98, 5cm × 5cm= £0.95, 7.5cm × 1m= £15.50, 7.5cm × 7.5cm= £1.77

Advanced wound dressings

Hydrogel dressings
Hydrogel dressings are most commonly supplied as an amorphous, cohesive topical application that can take up the shape of a wound. A secondary, non-absorbing dressing is needed. These dressings are generally used to donate liquid to dry sloughy wounds and facilitate autolytic debridement of necrotic tissue; some also have the ability to absorb very small amounts of exudate. Hydrogel products that do not contain propylene glycol should be used if the wound is to be treated with larval therapy. Hydrogel sheets have a fixed structure and limited fluid-handling capacity; hydrogel sheet dressings are best avoided in the presence of infection, and are unsuitable for heavily exuding wounds.

Hydrogel application (amorphous)

ActivHeal Hydrogel
Hydrogel containing guar gum and propylene glycol

ActivHeal (Advanced Medical Solutions Ltd) Hydrogel dressing= £1.41

Aquaform
Hydrogel containing modified starch copolymer

AquaForm (Aspen Medical Europe Ltd) Hydrogel dressing= £2.02

Askina Gel
Hydrogel containing modified starch and glycerol

Askina (B.Braun Medical Ltd) Gel dressing= £2.03

Cutimed
Hydrogel

Cutimed (BSN medical Ltd) Gel dressing= £3.05

Flexigran
Hydrogel containing modified starch and glycerol

Flexigran (A1 Pharmaceuticals) Gel dressing= £1.90

GranuGel
Hydrogel containing carboxymethylcellulose, pectin and propylene glycol

GranuGel (Convatec Ltd) Hydrocolloid Gel dressing= £2.35

Intraseal Gel
Hydrogel containing modified carmellose polymer and propylene glycol

IntraSite (Smith & Nephew Healthcare Ltd) Gel dressing= £3.63

Nu-Gel
Hydrogel containing alginate and propylene glycol

Nu-Gel (Systagenix Wound Management Ltd) dressing= £2.09

Purilon Gel
Hydrogel containing carboxymethylcellulose and calcium alginate

Purilon (Coloplast Ltd) Gel dressing= £2.30

Hydrogel sheet dressings

ActiFormCool
Hydrogel dressing

ActiFormCool sheet (Activa Healthcare Ltd) 10cm × 10cm square= £2.66, 10cm × 15cm rectangular= £3.83, 20cm × 20cm square= £8.01, 5cm × 6.5cm rectangular= £1.81

Aquaflo
Hydrogel dressing

Aquaflo (Covidien (UK) Commercial Ltd) sheet 7.5cm discs= £2.60

Coolie
Hydrogel dressing (without adhesive border)

Coolie (Zederbraun Ltd) sheet 7cm discs= £1.96
Vapour-permeable films and membranes

**Gel FX**
Hydrogel dressing (without adhesive border)
**Gel FX sheet** (Synergy Health Plc) 10cm x 10cm square = £1.60, 15cm x 15cm square = £3.20

**Geliperm**
Hydrogel sheets
**Geliperm** (Geistlich Sons Ltd) sheet 10cm x 10cm square = £2.53

**Hydrosorb**
Absorbent, transparent, hydrogel sheets containing polyurethane polymers covered with a semi-permeable film
**Hydrosorb sheet** (Paul Hartmann Ltd) 10cm x 10cm square = £2.26, 20cm x 20cm square = £6.77, 5cm x 7.5cm rectangular = £1.58

**Hydrosorb Comfort**
Absorbent, transparent, hydrogel sheets containing polyurethane polymers covered with a semi-permeable film (with adhesive border, waterproof)
**Hydrosorb Comfort sheet** (Paul Hartmann Ltd) 12.5cm x 12.5cm square = £3.61, 4.5cm x 6.5cm rectangular = £1.87, 7.5cm x 10cm rectangular = £2.48

**Intrasite Conformable**
Soft non-woven dressing impregnated with Intrasite® gel
**IntraSite Conformable dressing** (Smith & Nephew Healthcare Ltd) 10cm x 10cm square = £1.82, 10cm x 20cm rectangular = £2.46, 10cm x 40cm rectangular = £4.40

**Novogel**
Glycerol-based hydrogel sheets (standard or thin)
**Novogel sheet** (Ford Medical Associates Ltd) 10cm x 10cm square = £3.18, 15cm x 20cm rectangular = £6.07, 20cm x 40cm rectangular = £11.56, 30cm x 30cm (0.15cm thickness) square = £12.71, (0.30cm thickness) square = £13.47, 5cm x 7.5cm rectangular = £1.99, 7.5cm diameter circular = £2.89

**SanoSkin NET**
Hydrogel sheet (without adhesive border)
**SanoSkin** (Ideal Medical Solutions Ltd) NET sheet 8.5cm x 12cm rectangular = £2.28

**Vacunet**
Non-adherent, hydrogel coated polyester net dressing
**Vacunet dressing** (Proxet Healthcare Ltd) 10cm x 10cm square = £1.93, 10cm x 15cm rectangular = £2.86

**Sodium hyaluronate dressings**
The hydrating properties of sodium hyaluronate promote wound healing, and dressings can be applied directly to the wound, or to a primary dressing (a secondary dressing should also be applied). The iodine and potassium iodide in these dressings prevent the bacterial decay of sodium hyaluronate in the wound. 
**Hyiodine** should be used with caution in thyroid disorders.

**Hyiodine**
Sodium hyaluronate 1.5%, potassium iodide 0.15%, iodine 0.1%, in a viscous solution
**Hyiodine** (H & R Healthcare Ltd) dressing = £35.00

**Vapour-permeable films and membranes**
Vapour-permeable films and membranes allow the passage of water vapour and oxygen but are impermeable to water and micro-organisms, and are suitable for lightly exuding wounds. They are highly conformable, provide protection, and a moist healing environment; transparent film dressings permit constant observation of the wound. Water vapour loss can occur at a slower rate than exudate is generated, so that fluid accumulates under the dressing, which can lead to tissue maceration and to wrinkling at the adhesive contact site (with risk of bacterial entry). Newer versions of these dressings have increased moisture vapour permeability. Despite these advances, vapour-permeable films and membranes are unsuitable for infected, large heavily exuding wounds, and chronic leg ulcers. Vapour-permeable films and membranes are suitable for partial-thickness wounds with minimal exudate, or wounds with eschar. Most commonly, they are used as a secondary dressing over alginates or hydrogels; film dressings can also be used to protect the fragile skin of patients at risk of developing minor skin damage caused by friction or pressure.

**Non-woven fabric dressing with viscose-rayon pad.**

**Niko Fix**
For intravenous and subcutaneous catheter sites
**Niko** (Unomedical Ltd) Fix dressing 7cm x 8.5cm = £0.19

**Vapour-permeable Adhesive Film Dressing (Semi-permeable Adhesive Dressing)**
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces.

**Askina Derm**
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces
**Askina Derm dressing** (B.Braun Medical Ltd) 10cm x 12cm = £1.10, 10cm x 20cm = £2.08, 15cm x 20cm = £2.52, 20cm x 30cm = £4.51, 6cm x 7cm = £0.38

**C-View**
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces
**C-View dressing** (Aspen Medical Europe Ltd) 10cm x 12cm = £1.02, 12cm x 12cm = £1.09, 15cm x 20cm = £2.36, 6cm x 7cm = £0.38

**Dressfilm**
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces
**Dressfilm** (St Georges Medical Ltd) dressing 15cm x 20cm = £1.90

**Hydrolfilm**
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces
**Hydrolfilm dressing** (Paul Hartmann Ltd) 10cm x 12.5cm = £0.42, 10cm x 15cm = £0.53, 10cm x 25cm = £0.82, 12cm x 25cm = £0.87, 15cm x 20cm = £0.97, 20cm x 30cm = £1.61, 6cm x 7cm = £0.23

**Hypafix Transparent**
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces
**Hypafix Transparent** (BSN medical Ltd) dressing 10cm x 2m = £8.88

**Leukomed T**
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces
**Leukomed T dressing** (BSN medical Ltd) 10cm x 12.5cm = £1.04, 11cm x 14cm = £1.25, 15cm x 20cm = £2.40, 15cm x 25cm = £2.56, 7.2cm x 5cm = £0.38, 8cm x 10cm = £0.71

**Mepitel Film**
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces
**Mepitel Film dressing** (Molnlycke Health Care Ltd) 10.5cm x 12cm = £1.31, 10.5cm x 25cm = £2.55, 15.5cm x 20cm = £3.24, 6.5cm x 7cm = £0.49

**Mepore Film**
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces
**Mepore Film dressing** (Molnlycke Health Care Ltd) 10cm x 12cm = £1.23, 10cm x 25cm = £2.39, 15cm x 20cm = £3.04, 6cm x 7cm = £0.46

**OpSite Flexifix**
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces
**OpSite Flexifix dressing** (Smith & Nephew Healthcare Ltd) 10cm x 1m = £6.67, 5cm x 1m = £3.95
OpSite Flexigrid
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces

OpSite Flexigrid dressing (Smith & Nephew Healthcare Ltd) 12cm × 12cm = £1.14, 15cm × 20cm = £2.88, 6cm × 7cm = £0.40

Polyskin II
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces

Kendall Film dressing (Aria Medical Ltd) 10cm × 12cm = £1.03, 15cm × 20cm = £2.04, 15cm × 20cm = £2.35, 20cm × 25cm = £4.11, 4cm × 4cm = £0.36, 5cm × 7cm = £0.40

ProtectFilm
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces

ProtectFilm dressing (Wallace, Cameron & Company Ltd) 10cm × 12cm = £0.20, 15cm × 20cm = £0.40, 6cm × 7cm = £0.11

Suprasorb F
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces

Suprasorb F dressing (Lohmann & Rauscher (UK) Ltd) 10cm × 12cm = £0.81, 15cm × 20cm = £2.52, 5cm × 7cm = £0.34

Tegaderm
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces

Tegaderm Film dressing (3M Health Care Ltd) 10cm × 12cm = £1.11, 15cm × 20cm = £2.41, 6cm × 7cm = £0.39

Tegaderm diamond
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces

Tegaderm Diamond dressing (3M Health Care Ltd) 10cm × 12cm = £1.21, 6cm × 7cm = £0.45

Vellafilm
Extensible, waterproof, water vapour-permeable polyurethane film coated with synthetic adhesive mass; transparent. Supplied in single-use pieces

Vellafilm dressing (Advancis Medical) 12cm × 12cm = £1.10, 12cm × 35cm = £0.75, 15cm × 20cm = £2.10

Vapour-permeable Adhesive Film Dressing with absorbent pad

Adapore Ultra
Film dressing with absorbent pad

Adapore Ultra dressing (Mediceplus International Ltd) 10cm × 10cm = £0.14, 10cm × 15cm = £0.22, 10cm × 20cm = £0.33, 10cm × 25cm = £0.35, 15cm × 20cm = £0.52, 7cm × 8cm = £0.12

Vapour-permeable Adhesive Film Dressing with absorbent pad

Alldress
Film dressing with absorbent pad

Alldress dressing (Molynxe Health Care Ltd) 10cm × 10cm = £0.96, 15cm × 15cm = £2.10, 15cm × 20cm = £2.59

C-View Post-Op
Film dressing with absorbent pad

C-View Post-Op dressing (Aspen Medical Europe Ltd) 10cm × 12cm = £1.10, 10cm × 25cm = £1.60, 10cm × 35cm = £2.60, 6cm × 7cm = £0.40

Clearpore
Film dressing with absorbent pad

Clearpore dressing (Richardsioneer Healthcare Ltd) 10cm × 10cm = £0.20, 10cm × 15cm = £0.24, 10cm × 20cm = £0.36, 10cm × 25cm = £0.40, 10cm × 30cm = £0.65, 6cm × 10cm = £0.15, 6cm × 7cm = £0.12

Hydrolfilm Plus
Film dressing with absorbent pad

Hydrolfilm Plus dressing (Paul Hartmann Ltd) 10cm × 20cm = £0.46, 10cm × 25cm = £0.61, 10cm × 30cm = £0.69, 7.2cm × 5cm = £0.18, 9cm × 10cm = £0.27, 9cm × 15cm = £0.30

Leukomed T Plus
Film dressing with absorbent pad

Leukomed T plus dressing (BSN medical Ltd) 10cm × 20cm = £1.36, 10cm × 25cm = £1.53, 10cm × 30cm = £2.56, 10cm × 35cm = £3.11, 7.2cm × 5cm = £0.27, 8cm × 10cm = £0.54, 8cm × 15cm = £0.82

Mepore Film & Pad
Film dressing with absorbent pad

Mepore Film & Pad dressing (Molynxe Health Care Ltd) 4cm × 5cm = £0.24, 5cm × 7cm = £0.24, 9cm × 10cm = £0.62, 9cm × 15cm = £0.92, 9cm × 20cm = £1.36, 9cm × 25cm = £1.50, 9cm × 30cm = £2.01, 9cm × 35cm = £2.50

Mepore Ultra
Film dressing with absorbent pad

Mepore Ultra dressing (Molynxe Health Care Ltd) 10cm × 11cm = £0.80, 11cm × 15cm = £1.18, 7cm × 8cm = £0.40, 9cm × 20cm = £1.51, 9cm × 25cm = £1.67, 9cm × 30cm = £2.75

OpSite Plus
Film dressing with absorbent pad

OpSite Plus dressing (Smith & Nephew Healthcare Ltd) 10cm × 12cm = £1.21, 10cm × 20cm = £0.94, 10cm × 35cm = £3.38, 6.5cm × 5cm = £0.33, 8.5cm × 9.5cm = £0.89

OpSite Post-op
Film dressing with absorbent pad

OpSite Post-op dressing (Smith & Nephew Healthcare Ltd) 10cm × 12cm = £1.19, 10cm × 20cm = £2.00, 10cm × 25cm = £2.52, 10cm × 30cm = £2.98, 10cm × 35cm = £3.32, 8.5cm × 15.5cm = £1.21, 8.5cm × 9.5cm = £0.87

Pharmapore-PU
Film dressing with absorbent pad

Pharmapore-PU dressing (Wallace, Cameron & Company Ltd) 10cm × 25cm = £0.38, 10cm × 30cm = £0.58, 8.5cm × 15.5cm = £0.20

PremierPore VP
Film dressing with absorbent pad

PremierPore VP dressing (Shermond) 10cm × 10cm = £0.16, 10cm × 15cm = £0.24, 10cm × 20cm = £0.36, 10cm × 25cm = £0.38, 10cm × 30cm = £0.57, 10cm × 35cm = £0.69, 5cm × 7cm = £0.13

Tegaderm
Film dressing with absorbent pad

Tegaderm + Pad dressing (3M Health Care Ltd) 5cm × 7cm = £0.26, 9cm × 10cm = £0.65, 9cm × 15cm = £0.95, 9cm × 20cm = £1.40, 9cm × 25cm = £1.57, 9cm × 35cm = £2.60

Tegaderm Absorbent Clear
Film dressing with clear acrylic polymer oval-shaped pad or rectangular-shaped pad

Tegaderm Absorbent Clear Acrylic dressing (3M Health Care Ltd) 11.1cm × 12.7cm oval = £4.11, 14.2cm × 15.8cm oval = £5.78, 14.9cm × 15.2cm rectangular = £8.66, 16.8cm × 19cm sacral = £10.37, 20cm × 20.3cm rectangular = £13.91, 7.6cm × 9.5cm oval = £3.17

Vapour-permeable transparent film dressing with adhesive foam border.

Central Gard
For intravenous and subcutaneous catheter sites

Central Gard dressing (Unomedical Ltd) 16cm × 7cm = £0.96, 16cm × 8.8cm = £1.05

Easi-V
For intravenous and subcutaneous catheter sites

Easi-V (ConvaTec Ltd) dressing 7cm × 7.5cm = £0.38

Vapour-permeable transparent, adhesive film dressing.

Hydrofilm I.V. Control
For intravenous and subcutaneous catheter sites

Hydrofilm (Paul Hartmann Ltd) I.V. Control dressing 7cm × 9cm = £0.31

Vapour-permeable, transparent, adhesive film dressing.

IV3000
For intravenous and subcutaneous catheter sites

IV3000 dressing (Smith & Nephew Healthcare Ltd) 10cm × 12cm = £1.41, 5cm × 6cm = £0.43, 6cm × 7cm = £0.56, 7cm × 9cm = £0.74, 9cm × 12cm = £1.47
Mepore IV
For intravenous and subcutaneous catheter sites
Mepore IV dressing (Molyncke Health Care Ltd) 10cm × 11cm = £1.07, 5cm × 5.5cm = £0.31, 8cm × 9cm = £0.40

Pharmapore-PU IV
For intravenous and subcutaneous catheter sites
Pharmapore-PU IV dressing (Wallace, Cameron & Company Ltd) 6cm × 7cm = £0.08, 7cm × 8.5cm = £0.07, 7cm × 9cm = £0.17

Tegaderm IV
For intravenous and subcutaneous catheter sites
Tegaderm IV dressing with securing tapes (3M Health Care Ltd) 10cm × 15.5cm = £1.67, 7cm × 8.5cm = £0.99, 8.5cm × 10.5cm = £1.16

Soft polymer dressings
Dressings with soft polymer, often a soft silicone polymer, in a non-adherent or gently adherent layer are suitable for use on lightly to moderately exuding wounds. For moderately to heavily exuding wounds, an absorbent secondary dressing can be added, or a soft polymer dressing with an absorbent pad can be used. Wound contact dressings coated with soft silicone have gentle adhesive properties and can be used on fragile skin areas or where it is beneficial to reduce the frequency of primary dressing changes. Soft polymer dressings should not be used on heavily bleeding wounds; blood clots can cause the dressing to adhere to the wound surface. For silicone keloid dressings see under Specialised dressings.

Cellulose dressings
Sorbion Sachet Border
Absorbent polymers in cellulose matrix, hypoallergenic polypropylene envelope, with adhesive border
Cutimed Sorbion Sachet Border dressing (BSN medical Ltd) 10cm × 10cm square= £2.98, 15cm × 15cm square= £4.54, 25cm × 15cm rectangular= £7.06

Sorbion Sachet EXTRA
Absorbent polymers in cellulose matrix, hypoallergenic polypropylene envelope
Cutimed Sorbion Sachet Extra dressing (BSN medical Ltd) 10cm × 10cm= £2.27, 20cm × 10cm= £3.77, 20cm × 20cm= £7.08, 30cm × 20cm= £10.09, 5cm × 5cm= £1.47, 7.5cm × 7.5cm= £1.80

Sorbion Sachet Multi Star
Absorbent polymers in cellulose matrix, hypoallergenic polypropylene envelope
Cutimed Sorbion Sachet Multi Star dressing (BSN medical Ltd) 14cm × 14cm = £4.94, 8cm × 8cm = £3.02

Sorbion Sachet S Drainage
Absorbent polymers in cellulose matrix, hypoallergenic polypropylene envelope (‘Y’ shaped dressing)
Cutimed (BSN medical Ltd) Sorbion Sachet S drainage dressing 10cm × 10cm = £2.67

Suprasorb X
Biosynthetic cellulose fibre dressing
Suprasorb X dressing (Lohmann & Rauscher (UK) Ltd) 14cm × 20cm rectangular= £8.46, 2cm × 21cm roller= £6.58, 5cm × 5cm square= £2.05, 9cm × 9cm square= £4.27

With absorbent pad
Advazorb Border
Soft silicone wound contact dressing with polyurethane foam film backing and adhesive border
Advazorb Border dressing (Advancis Medical) 10cm × 10cm= £2.10, 10cm × 20cm= £2.90, 10cm × 30cm= £4.25, 12.5cm × 12.5cm= £2.58, 15cm × 15cm= £3.15, 20cm × 20cm= £5.46, 7.5cm × 7.5cm = £1.19

Advazorb Border Lite
Soft silicone wound contact dressing with polyurethane foam film backing and adhesive border
Advazorb Border Lite dressing (Advancis Medical) 10cm × 10cm = £1.89, 10cm × 20cm= £2.61, 10cm × 30cm= £3.83, 12.5cm × 12.5cm= £2.32, 15cm × 15cm= £2.84, 20cm × 20cm= £4.91, 7.5cm × 7.5cm= £1.07

Advazorb Silfix
Soft silicone wound contact dressing with polyurethane foam film backing
Advazorb Silfix dressing (Advancis Medical) 10cm × 10cm= £1.85, 10cm × 20cm= £3.18, 12.5cm × 12.5cm= £2.59, 15cm × 15cm= £3.36, 20cm × 20cm= £4.98, 7.5cm × 7.5cm= £0.99

Advazorb Silfix Lite
Soft silicone wound contact dressing with polyurethane foam film backing
Advazorb Silfix Lite dressing (Advancis Medical) 10cm × 10cm= £1.67, 10cm × 20cm= £2.86, 12.5cm × 12.5cm= £2.33, 15cm × 15cm= £3.02, 20cm × 20cm= £4.48, 7.5cm × 7.5cm= £0.89

Allevyn Gentle
Soft gel wound contact dressing, with polyurethane foam film backing
Allevyn Gentle dressing (Smith & Nephew Healthcare Ltd) 10cm × 10cm= £2.53, 10cm × 20cm= £4.07, 15cm × 15cm= £4.25, 20cm × 20cm= £6.78, 5cm × 5cm= £1.27

Allevyn Gentle Border
Silicone gel wound contact dressing, with polyurethane foam film backing
Allevyn Gentle Border dressing (Smith & Nephew Healthcare Ltd) Heel dressing 23cm × 23.2cm= £9.74, dressing 10cm × 10cm= £2.21, 12.5cm × 12.5cm= £2.71, 17.5cm × 17.5cm= £5.34, 7.5cm × 7.5cm= £1.51,

Allevyn Gentle Border Lite
Silicone gel wound contact dressing, with polyurethane foam film backing
Allevyn Gentle Border Lite dressing (Smith & Nephew Healthcare Ltd) 10cm × 10cm= £2.18, 15cm × 15cm= £3.85, 5.5cm × 12cm= £1.86, 5cm × 5cm= £0.91, 8cm × 15cm= £3.47

Allevyn Life
Soft silicone wound contact dressing, with central mesh screen, polyurethane foam film backing and adhesive border
Allevyn Life dressing (Smith & Nephew Healthcare Ltd) 10.3cm × 10.3cm= £1.71, 12.9cm × 12.9cm= £2.51, 15.4cm × 15.4cm= £3.06, 21cm × 21cm= £6.04

Cutimed Siltec
Soft silicone wound contact dressing, with polyurethane foam film backing
Cutimed Siltec (BSN medical Ltd) Heel dressing 16cm × 24cm= £7.29, Sacrum dressing 17.5cm × 17.5cm= £4.64, 23cm × 23cm= £7.43, dressing 10cm × 10cm= £2.51, 10cm × 20cm= £4.14, 15cm × 15cm= £4.69, 20cm × 20cm= £7.11, 5cm × 6cm= £1.34,

Cutimed Siltec B
Soft silicone wound contact dressing, with polyurethane foam film backing, with adhesive border, for lightly to moderately exuding wounds
Cutimed Siltec B dressing (BSN medical Ltd) 12.5cm × 12.5cm= £3.30, 15cm × 15cm= £5.08, 17.5cm × 17.5cm= £5.35, 22.5cm × 22.5cm= £8.64, 7.5cm × 7.5cm= £1.56

Cutimed Siltec L
Soft silicone wound contact dressing, with polyurethane foam film backing, for lightly to moderately exuding wounds
Cutimed Siltec L dressing (BSN medical Ltd) 10cm × 10cm = £2.16, 15cm × 15cm = £3.55, 5cm × 6cm = £1.07

Eclypse Adherent
Soft silicone wound contact layer with absorbent pad and film backing
Eclypse Adherent dressing (Advancis Medical) 10cm × 10cm= £2.99, 10cm × 20cm= £3.75, 15cm × 15cm= £4.99, 20cm × 20cm= £9.99, 17cm × 19cm sacral= £3.76, 22cm × 23cm sacral= £6.23

Flivasorb
Absorbent polymer dressing with non-adherent wound contact layer
Flivasorb dressing (Lohmann & Rauscher (UK) Ltd) 10cm × 10cm square= £0.89, 10cm × 20cm rectangular= £1.06, 20cm × 20cm square= £1.88, 20cm × 30cm rectangular= £2.37

downloaded from www.medicalbr.com
### 1464 Advanced wound dressings

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Description</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Flivasorb Adhesive</strong></td>
<td>Absorbent polymer dressing with non-adherent wound contact layer and adhesive border</td>
<td>£5.41</td>
</tr>
<tr>
<td><strong>Flivasorb Adhesive dressing</strong></td>
<td>(Loehmann &amp; Rauscher (UK) Ltd) 12cm × 12cm square= £3.35, 15cm × 15cm square= £4.58</td>
<td></td>
</tr>
<tr>
<td><strong>Mepitel</strong></td>
<td>Absorbent soft silicone dressing with polyurethane foam film backing</td>
<td></td>
</tr>
<tr>
<td><strong>Mepitel</strong></td>
<td>(Molnlycke Health Care Ltd) Heel dressing 12cm × 20cm= £2.22, XT dressing 10cm × 11cm= £2.66, 11cm × 20cm= £4.39, 15cm × 16cm= £4.82, 20cm × 21cm= £7.28, dressing 5cm × 5cm= £1.24</td>
<td></td>
</tr>
<tr>
<td><strong>Mepitel Border</strong></td>
<td>Absorbent soft silicone dressing with polyurethane foam film backing and adhesive border</td>
<td></td>
</tr>
<tr>
<td><strong>Mepitel Border Lite</strong></td>
<td>Thin absorbent soft silicone dressing with polyurethane foam film backing and adhesive border</td>
<td></td>
</tr>
<tr>
<td><strong>Mepitel Lite</strong></td>
<td>Thin absorbent soft silicone dressing with polyurethane foam film backing</td>
<td></td>
</tr>
<tr>
<td><strong>Mepitel Lite dressing</strong></td>
<td>(Molnlycke Health Care Ltd) 10cm × 10cm= £1.97, 15cm × 15cm= £3.94, 4cm × 5cm= £0.92, 5cm × 12.5cm= £2.01, 7.5cm × 7.5cm= £1.35</td>
<td></td>
</tr>
<tr>
<td><strong>Mepitel Transfer</strong></td>
<td>Soft silicone exudate transfer dressing</td>
<td></td>
</tr>
<tr>
<td><strong>Mepitel Transfer dressing</strong></td>
<td>(Molnlycke Health Care Ltd) 10cm × 12cm= £3.51, 15cm × 20cm= £10.64, 20cm × 50cm= £27.20, 7.5cm × 8.5cm= £2.23</td>
<td></td>
</tr>
<tr>
<td><strong>Sorbion Sana</strong></td>
<td>Non-adherent polyethylene wound contact dressing with absorbent core</td>
<td></td>
</tr>
<tr>
<td><strong>Cutimed Sorbion Sana Gentle dressing</strong></td>
<td>(BSN medical Ltd) 12cm × 12cm= £2.52, 12cm × 22cm= £4.54, 22cm × 22cm= £8.07, 8.5cm × 8.5cm= £2.01</td>
<td></td>
</tr>
<tr>
<td><strong>Urgotul Duo</strong></td>
<td>Non-adherent polymer wound contact dressing with absorbent pad</td>
<td></td>
</tr>
<tr>
<td><strong>Urgotul Duo dressing</strong></td>
<td>(Urgo Ltd) 10cm × 12cm= £3.87, 15cm × 20cm= £8.98, 5cm × 10cm= £2.50</td>
<td></td>
</tr>
<tr>
<td><strong>Without absorbent pad</strong></td>
<td>Adaptic Touch</td>
<td></td>
</tr>
<tr>
<td><strong>Adaptic Touch dressing</strong></td>
<td>Non-adherent soft silicone wound contact dressing</td>
<td></td>
</tr>
<tr>
<td><strong>Ashina SilNet</strong></td>
<td>Soft silicone-coated wound contact dressing</td>
<td></td>
</tr>
<tr>
<td><strong>Ashina SilNet dressing</strong></td>
<td>(B.Braun Medical Ltd) 10cm × 18cm= £5.03, 20cm × 30cm= £12.32, 5cm × 7.5cm= £1.14, 7.5cm × 11cm= £2.25</td>
<td></td>
</tr>
<tr>
<td><strong>Mepitel</strong></td>
<td>Soft silicone, semi-transparent wound contact dressing</td>
<td></td>
</tr>
<tr>
<td><strong>Mepitel dressing</strong></td>
<td>(Molnlycke Health Care Ltd) 12cm × 15cm= £5.60, 5cm × 7cm= £1.40, 8cm × 10cm= £2.80</td>
<td></td>
</tr>
<tr>
<td><strong>Mepitel One</strong></td>
<td>Soft silicone, thin, transparent wound contact dressing</td>
<td></td>
</tr>
<tr>
<td><strong>Mepitel One dressing</strong></td>
<td>(Molnlycke Health Care Ltd) 13cm × 15cm= £4.98, 24cm × 27.5cm= £14.25, 6cm × 7cm= £1.22, 9cm × 10cm= £2.41</td>
<td></td>
</tr>
<tr>
<td><strong>Physiotulle</strong></td>
<td>Non-adherent soft polymer wound contact dressing</td>
<td></td>
</tr>
<tr>
<td><strong>Physiotulle dressing</strong></td>
<td>(Coloplast Ltd) 10cm × 10cm= £2.28, 15cm × 20cm= £6.96</td>
<td></td>
</tr>
<tr>
<td><strong>Silflex</strong></td>
<td>Soft silicone-coated polyester wound contact dressing</td>
<td></td>
</tr>
<tr>
<td><strong>Silflex dressing</strong></td>
<td>(Advancis Medical) 12cm × 15cm= £4.58, 20cm × 30cm= £11.79, 35cm × 60cm= £39.54, 5cm × 7cm= £11.11, 8cm × 10cm= £2.27</td>
<td></td>
</tr>
<tr>
<td><strong>Silon-TSR</strong></td>
<td>Soft silicone polymer wound contact dressing</td>
<td></td>
</tr>
<tr>
<td><strong>Silon-TSR dressing</strong></td>
<td>(Bio Med Sciences) 13cm × 13cm= £3.52, 13cm × 25cm= £5.47, 28cm × 30cm= £7.37</td>
<td></td>
</tr>
<tr>
<td><strong>Sobion Contact</strong></td>
<td>Non-adherent soft polymer wound contact dressing</td>
<td></td>
</tr>
<tr>
<td><strong>Cutimed Sorbion Contact dressing</strong></td>
<td>(BSN medical Ltd) 10cm × 10cm= £2.01, 10cm × 20cm= £4.03, 20cm × 20cm= £7.06, 20cm × 30cm= £10.09, 7.5cm × 7.5cm= £1.51</td>
<td></td>
</tr>
<tr>
<td><strong>Tegaderm Contact</strong></td>
<td>Non-adherent polymer wound contact dressing</td>
<td></td>
</tr>
<tr>
<td><strong>Tegaderm Contact dressing</strong></td>
<td>(3M Health Care Ltd) 20cm × 25cm= £10.86, 7.5cm × 10cm= £2.27</td>
<td></td>
</tr>
<tr>
<td><strong>Urgotul</strong></td>
<td>Non-adherent soft polymer wound contact dressing</td>
<td></td>
</tr>
<tr>
<td><strong>Urgotul dressing</strong></td>
<td>(Urgo Ltd) 10cm × 10cm= £3.11, 10cm × 40cm= £10.44, 15cm × 15cm= £6.60, 15cm × 20cm= £8.79, 20cm × 30cm= £14.13, 5cm × 5cm= £1.55</td>
<td></td>
</tr>
<tr>
<td><strong>Hydrocolloid dressings</strong></td>
<td>Hydrocolloid dressings are usually presented as a hydrocolloid layer on a vapour-permeable film or foam pad. Semi-permeable to water vapour and oxygen, these dressings form a gel in the presence of exudate to facilitate rehydration in lightly to moderately exuding wounds and promote autolytic debridement of dry, sloughy, or necrotic wounds; they are also suitable for promoting granulation. Hydrocolloid-fibrous dressings made from modified carmellose fibres resemble alginate dressings; hydrocolloid-fibrous dressings are more absorptive and suitable for moderately to heavily exuding wounds.</td>
<td></td>
</tr>
<tr>
<td><strong>Hydrocolloid-fibrous dressings</strong></td>
<td>Aquacel</td>
<td></td>
</tr>
<tr>
<td><strong>Aqualoc</strong></td>
<td>Soft non-woven pad containing hydrocolloid-fibres</td>
<td></td>
</tr>
<tr>
<td><strong>Aqualoc</strong></td>
<td>(ConvaTec Ltd) Ribbon dressing 1cm × 45cm= £1.86, 2cm × 45cm= £2.48, dressing 10cm × 10cm square= £2.45, 15cm × 15cm square= £4.60, 4cm × 10cm rectangular= £1.32, 4cm × 20cm rectangular= £1.94, 4cm × 30cm rectangular= £2.92, 5cm × 5cm square= £1.03</td>
<td></td>
</tr>
<tr>
<td><strong>Aqualoc Foam</strong></td>
<td>Soft non-woven pad containing hydrocolloid-fibres with foam layer; with or without adhesive border</td>
<td></td>
</tr>
<tr>
<td><strong>Aqualoc Foam dressing (adhesive)</strong></td>
<td>(ConvaTec Ltd) 10cm × 10cm= £2.16, 12.5cm × 12.5cm= £2.68, 17.5cm × 17.5cm= £5.36, 19.8cm × 19.8cm heel= £5.48, 20cm × 16.9cm sacrals= £4.92, 21cm × 21cm= £7.84, 25cm × 30cm= £10.15, 8cm × 8cm (non-adhesive) 10cm × 10cm= £2.56, 15cm × 15cm= £4.30, 15cm × 20cm= £5.88, 20cm × 20cm= £7.01</td>
<td></td>
</tr>
<tr>
<td><strong>UrgoClean Pad</strong></td>
<td>Pad, hydrocolloid fibres coated with soft-adherent liopo-iodial wound contact layer</td>
<td></td>
</tr>
<tr>
<td><strong>UrgoClean Pad dressing</strong></td>
<td>(Urgo Ltd) 10cm × 10cm square= £2.14, 20cm × 15cm rectangular= £4.02, 6cm × 6cm square= £0.96</td>
<td></td>
</tr>
<tr>
<td><strong>UrgoClean Rope</strong></td>
<td>Rope, non-woven rope containing hydrocolloid fibres</td>
<td></td>
</tr>
<tr>
<td><strong>UrgoClean rope dressing</strong></td>
<td>(Urgo Ltd) 2.5cm × 40cm= £2.41, 5cm × 40cm= £3.18</td>
<td></td>
</tr>
<tr>
<td><strong>Polyurethane matrix dressing</strong></td>
<td>Cutinova Hydro</td>
<td></td>
</tr>
<tr>
<td><strong>Polyurethane matrix with absorbent particles and waterproof polyurethane film</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cutinova Hydro dressing</strong></td>
<td>(Smith &amp; Nephew Healthcare Ltd) 10cm × 10cm square= £2.57, 15cm × 20cm rectangular= £5.44, 5cm × 6cm rectangular= £1.28</td>
<td></td>
</tr>
</tbody>
</table>
With adhesive border

**Biatain Super**
Semi-permeable hydrocolloid dressing; without adhesive border

**Biatain Super dressing (adhesive)** (Coloplast Ltd) 10cm × 10cm square= £2.18, 12.5cm × 12.5cm square= £3.60, 15cm × 15cm rectangular= £3.61, 15cm × 15cm square= £4.35, 20cm × 20cm square= £6.78

**Granuflex Bordered**
Hydrocolloid wound contact layer bonded to plastic foam layer, with outer semi-permeable polyurethane film

**Granuflex Bordering dressing** (Convatec Ltd) 10cm × 10cm square= £3.37, 10cm × 13cm triangular= £3.97, 15cm × 15cm square= £6.43, 15cm × 18cm triangular= £6.19, 6cm × 6cm square= £1.78

**Hydocoll Border**
Hydrocolloid dressing with adhesive border and absorbent wound contact pad

**Hydocoll Border (bevelled edge) dressing** (Paul Hartmann Ltd) 10cm × 10cm square= £4.75, 12cm × 12cm square= £5.64, 15cm × 15cm square= £8.57, 5cm × 5cm square= £1.01, 7.5cm × 7.5cm square= £1.67, 6cm × 12cm concave= £2.14

**Tegaderm Hydrocolloid**
Hydrocolloid dressing with adhesive border; normal or thin

**Tegaderm Hydrocolloid (3M Health Care Ltd) Thin dressing** 10cm × 12cm oval= £1.55, 13cm × 15cm oval= £2.89, dressing 10cm × 12cm oval= £2.33, 13cm × 15cm oval= £4.34, 17.1cm × 16.1cm sacral= £4.85

**Ultec Pro**
Semi-permeable hydrocolloid dressing with adhesive border

**Ultec Pro dressing (adhesive)** (Covidien (UK) Commercial Ltd) 15cm × 18cm sacral= £3.30, 19.5cm × 23cm sacral= £4.98, 21cm × 21cm square= £4.67

**Without adhesive border**

**ActivHeal Hydrocolloid**
Semi-permeable polyurethane film backing, hydrocolloid wound contact layer, with or without polyurethane foam later

**ActivHeal Hydrocolloid** (Advanced Medical Solutions Ltd) dressing 10cm × 10cm square= £1.58, 15cm × 15cm square= £3.43, 15cm × 18cm sacral= £3.98, 5cm × 7.5cm rectangular= £0.78, foam backed dressing 10cm × 10cm square= £1.55, 15cm × 15cm square= £2.91, 15cm × 18cm sacral= £3.36, 5cm × 7.5cm rectangular= £0.97

**Askina Biofilm Transparent**
Semi-permeable, polyurethane film dressing with hydrocolloid adhesive

**Askina Biofilm Transparent dressing** (B.Braun Medical Ltd) 10cm × 10cm square= £1.08, 20cm × 20cm square= £3.20

**Biatain Super**
Semi-permeable, hydrocolloid film dressing without adhesive border

**Biatain Super dressing (non-adhesive)** (Coloplast Ltd) 10cm × 10cm square= £2.18, 12.5cm × 12.5cm square= £3.60, 15cm × 15cm rectangular= £3.61, 15cm × 15cm square= £4.35, 20cm × 20cm square= £6.78

**Comfeel Plus Contour**
Hydrocolloid dressings containing carmelllose sodium and calcium alginate

**Comfeel Plus Contour dressing** (Coloplast Ltd) 6cm × 8cm= £2.23, 9cm × 11cm= £3.87

**Comfeel Plus Pressure Relieving**
Hydrocolloid dressings containing carmelllose sodium and calcium alginate

**Comfeel Plus Pressure Relieving dressing** (Coloplast Ltd) 10cm diameter circular= £4.66, 15cm diameter circular= £7.01, 7cm diameter circular= £3.48

**Comfeel Plus Transparent**
Hydrocolloid dressings containing carmelllose sodium and calcium alginate

**Comfeel Plus Transparent dressing** (Coloplast Ltd) 10cm × 10cm square= £1.28, 15cm × 15cm square= £3.35, 15cm × 20cm rectangular= £3.40, 20cm × 20cm square= £3.42, 5cm × 15cm rectangular= £1.59, 5cm × 25cm rectangular= £2.59, 9cm × 7cm rectangular= £0.67, 9cm × 14cm rectangular= £2.44, 9cm × 25cm rectangular= £3.47

**Comfeel Plus Ulcer**
Hydrocolloid dressings containing carmelllose sodium and calcium alginate

**Comfeel Plus Ulcer (bevelled edge) dressing** (Coloplast Ltd) 10cm × 10cm square= £2.46, 18cm × 20cm triangular= £5.73, 20cm × 20cm square= £7.59, 4cm × 6cm rectangular= £0.96

**DuoDERM Extra Thin**
Semi-permeable hydrocolloid dressing

**DuoDERM Extra Thin dressing** (Convatec Ltd) 10cm × 10cm square= £1.33, 15cm × 15cm square= £2.88, 5cm × 10cm rectangular= £0.77, 7.5cm × 7.5cm square= £0.81, 9cm × 15cm rectangular= £1.78, 9cm × 25cm rectangular= £2.85, 9cm × 35cm rectangular= £3.98

**DuoDERM Signal**
Semi-permeable hydrocolloid dressing with ‘Time to change’ indicator

**DuoDERM Signal dressing** (Convatec Ltd) 10cm × 10cm square= £2.14, 11cm × 19cm oval= £3.28, 14cm × 14cm square= £3.75, 18.5cm × 19.5cm heel= £5.25, 20cm × 20cm square= £7.46, 22.5cm × 20cm sacral= £6.13

**Flexigran**
Semi-permeable hydrocolloid dressing without adhesive border; normal or thin

**Flexigran (A1 Pharmaceuticals) Thin dressing** 10cm × 10cm square= £1.08, dressing 10cm × 10cm square= £2.19

**Granuflex**
Hydrocolloid wound contact layer bonded to plastic foam layer, with outer semi-permeable polyurethane film

**Granuflex (modified dressing)** (Convatec Ltd) 10cm × 10cm square= £2.83, 15cm × 15cm square= £5.36, 15cm × 20cm rectangular= £5.81, 20cm × 20cm square= £8.07

**Hydocoll Basic**
Hydrocolloid dressing with absorbent wound contact pad

**Hydocoll (Paul Hartmann Ltd) Basic dressing** 10cm × 10cm square= £2.47

**Hydocoll Thin Film**
Thin hydrocolloid dressing with absorbent wound contact pad

**Hydocoll Thin Film dressing** (Paul Hartmann Ltd) 10cm × 10cm square= £1.16, 15cm × 15cm square= £2.61, 7.5cm × 7.5cm square= £0.70

**Nu-Derm**
Semi-permeable hydrocolloid dressing (normal and thin)

**Nu-Derm dressing** (Systagenix Wound Management Ltd) 10cm × 10cm square= £1.56, 15cm × 15cm square= £3.18, 15cm × 18cm sacral= £4.45, 20cm × 20cm square= £6.36, 5cm × 5cm square= £0.85, 8cm × 12cm heel/elbow= £3.18, thin 10cm × 10cm square= £1.06

**Tegaderm Hydrocolloid**
Hydrocolloid dressing without adhesive border; normal and thin

**Tegaderm Hydrocolloid** (3M Health Care Ltd) Thin dressing 10cm × 10cm square= £1.55, dressing 10cm × 10cm square= £2.37

**Ultec Pro**
Semi-permeable hydrocolloid dressing; without adhesive border

**Ultec Pro dressing** (Covidien (UK) Commercial Ltd) 10cm × 10cm square= £2.28, 15cm × 15cm square= £4.44, 20cm × 20cm square= £6.69

**Foam dressings**
Dressings containing hydrophilic polyurethane foam (adhesive or non-adhesive), with or without plastic film-backing, are suitable for all types of exuding wounds, but not for dry wounds; some foam dressings have a moisture-sensitive film backing with variable permeability dependant
on the level of exudate. Foam dressings vary in their ability to absorb exudate; some are suitable only for lightly to moderately exuding wounds, others have greater fluid-handling capacity and are suitable for heavily exuding wounds. Saturated foam dressings can cause maceration of healthy skin if left in contact with the wound. Foam dressings can be used in combination with other primary wound contact dressings. If used under compression bandaging or compression garments, the fluid-handling capacity of the foam dressing may be reduced. Foam dressings can also be used to provide a protective cushion for fragile skin. A foam dressing containing ibuprofen is available and may be useful for treating painful exuding wounds.

**Cavi-Care**
Soft, conforming cavity wound dressing prepared by mixing thoroughly for 15 seconds immediately before use and allowing to expand its volume within the cavity

**Polymem Foam Dressing**

<table>
<thead>
<tr>
<th>Dimension</th>
<th>Brand Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>4x4 cm square</td>
<td>PolyMem dressing (Aspen Medical Europe Ltd)</td>
</tr>
<tr>
<td>5x5 cm square</td>
<td>PolyMem dressing (Aspen Medical Europe Ltd)</td>
</tr>
<tr>
<td>6x6 cm square</td>
<td>PolyMem dressing (Aspen Medical Europe Ltd)</td>
</tr>
<tr>
<td>10x10 cm rectangular</td>
<td>PermaFoam Comfort dressing (Paul Hartmann Ltd)</td>
</tr>
</tbody>
</table>

**Tegaderm Foam Adhesive**

<table>
<thead>
<tr>
<th>Dimension</th>
<th>Brand Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>3x3 cm square</td>
<td>Tegaderm Foam dressing (3M Health Care Ltd)</td>
</tr>
<tr>
<td>5x5 cm square</td>
<td>Tegaderm Foam dressing (3M Health Care Ltd)</td>
</tr>
<tr>
<td>8x8 cm square</td>
<td>Tegaderm Foam dressing (3M Health Care Ltd)</td>
</tr>
</tbody>
</table>

**PermaFoam Dressing**

<table>
<thead>
<tr>
<th>Dimension</th>
<th>Brand Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>2x2 in square</td>
<td>PermaFoam dressing (Paul Hartmann Ltd)</td>
</tr>
<tr>
<td>3x3 in square</td>
<td>PermaFoam dressing (Paul Hartmann Ltd)</td>
</tr>
<tr>
<td>4x4 in square</td>
<td>PermaFoam dressing (Paul Hartmann Ltd)</td>
</tr>
</tbody>
</table>

**Biatain Silicone**

<table>
<thead>
<tr>
<th>Dimension</th>
<th>Brand Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>4x4 cm square</td>
<td>Biatain Silicone dressing (Coloplast Ltd)</td>
</tr>
<tr>
<td>5x5 cm square</td>
<td>Biatain Silicone dressing (Coloplast Ltd)</td>
</tr>
<tr>
<td>6x6 cm square</td>
<td>Biatain Silicone dressing (Coloplast Ltd)</td>
</tr>
</tbody>
</table>

**Advazorb**

<table>
<thead>
<tr>
<th>Dimension</th>
<th>Brand Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>3x3 cm square</td>
<td>Advazorb dressing (Coloplast Ltd)</td>
</tr>
<tr>
<td>5x5 cm square</td>
<td>Advazorb dressing (Coloplast Ltd)</td>
</tr>
<tr>
<td>8x8 cm square</td>
<td>Advazorb dressing (Coloplast Ltd)</td>
</tr>
</tbody>
</table>

**Biatain -Ibu Soft-Hold**

<table>
<thead>
<tr>
<th>Dimension</th>
<th>Brand Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>4x4 cm square</td>
<td>Biatain -Ibu Soft-Hold dressing (Coloplast Ltd)</td>
</tr>
<tr>
<td>5x5 cm square</td>
<td>Biatain -Ibu Soft-Hold dressing (Coloplast Ltd)</td>
</tr>
<tr>
<td>6x6 cm square</td>
<td>Biatain -Ibu Soft-Hold dressing (Coloplast Ltd)</td>
</tr>
</tbody>
</table>

**Biatain Adhesive**

<table>
<thead>
<tr>
<th>Dimension</th>
<th>Brand Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1x1 cm square</td>
<td>Biatain Adhesive dressing (Coloplast Ltd)</td>
</tr>
<tr>
<td>2x2 cm square</td>
<td>Biatain Adhesive dressing (Coloplast Ltd)</td>
</tr>
<tr>
<td>3x3 cm square</td>
<td>Biatain Adhesive dressing (Coloplast Ltd)</td>
</tr>
</tbody>
</table>

**Kendall Foam Island**

<table>
<thead>
<tr>
<th>Dimension</th>
<th>Brand Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>3x3 cm square</td>
<td>Kendall Foam Island dressing (Aria Medical Ltd)</td>
</tr>
<tr>
<td>5x5 cm square</td>
<td>Kendall Foam Island dressing (Aria Medical Ltd)</td>
</tr>
<tr>
<td>7x7 cm square</td>
<td>Kendall Foam Island dressing (Aria Medical Ltd)</td>
</tr>
</tbody>
</table>

**Biatain -Ibu Non-Adhesive**

<table>
<thead>
<tr>
<th>Dimension</th>
<th>Brand Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>4x4 cm square</td>
<td>Biatain -Ibu Non-Adhesive dressing (Coloplast Ltd)</td>
</tr>
<tr>
<td>5x5 cm square</td>
<td>Biatain -Ibu Non-Adhesive dressing (Coloplast Ltd)</td>
</tr>
<tr>
<td>8x8 cm square</td>
<td>Biatain -Ibu Non-Adhesive dressing (Coloplast Ltd)</td>
</tr>
</tbody>
</table>

**PermaFoam Comfort dressing**

<table>
<thead>
<tr>
<th>Dimension</th>
<th>Brand Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>2x2 in square</td>
<td>PermaFoam Comfort dressing (Paul Hartmann Ltd)</td>
</tr>
<tr>
<td>3x3 in square</td>
<td>PermaFoam Comfort dressing (Paul Hartmann Ltd)</td>
</tr>
<tr>
<td>4x4 in square</td>
<td>PermaFoam Comfort dressing (Paul Hartmann Ltd)</td>
</tr>
</tbody>
</table>

**Askina Foam**

<table>
<thead>
<tr>
<th>Dimension</th>
<th>Brand Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>4x4 cm square</td>
<td>Askina Foam (Braun Medical Ltd)</td>
</tr>
<tr>
<td>5x5 cm square</td>
<td>Askina Foam (Braun Medical Ltd)</td>
</tr>
<tr>
<td>6x6 cm square</td>
<td>Askina Foam (Braun Medical Ltd)</td>
</tr>
</tbody>
</table>

**Kendall Foam Plus dressing**

<table>
<thead>
<tr>
<th>Dimension</th>
<th>Brand Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>3x3 cm square</td>
<td>Kendall Foam Plus dressing (Aria Medical Ltd)</td>
</tr>
<tr>
<td>5x5 cm square</td>
<td>Kendall Foam Plus dressing (Aria Medical Ltd)</td>
</tr>
<tr>
<td>8x8 cm square</td>
<td>Kendall Foam Plus dressing (Aria Medical Ltd)</td>
</tr>
</tbody>
</table>

**Advazorb**

<table>
<thead>
<tr>
<th>Dimension</th>
<th>Brand Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>3x3 cm square</td>
<td>Advazorb dressing (Coloplast Ltd)</td>
</tr>
<tr>
<td>5x5 cm square</td>
<td>Advazorb dressing (Coloplast Ltd)</td>
</tr>
<tr>
<td>8x8 cm square</td>
<td>Advazorb dressing (Coloplast Ltd)</td>
</tr>
</tbody>
</table>

**Biatain -Ibu Non-Adhesive**

<table>
<thead>
<tr>
<th>Dimension</th>
<th>Brand Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>4x4 cm square</td>
<td>Biatain -Ibu Non-Adhesive dressing (Coloplast Ltd)</td>
</tr>
<tr>
<td>5x5 cm square</td>
<td>Biatain -Ibu Non-Adhesive dressing (Coloplast Ltd)</td>
</tr>
<tr>
<td>8x8 cm square</td>
<td>Biatain -Ibu Non-Adhesive dressing (Coloplast Ltd)</td>
</tr>
</tbody>
</table>

**Biatain Adhesive**

<table>
<thead>
<tr>
<th>Dimension</th>
<th>Brand Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1x1 cm square</td>
<td>Biatain Adhesive dressing (Coloplast Ltd)</td>
</tr>
<tr>
<td>2x2 cm square</td>
<td>Biatain Adhesive dressing (Coloplast Ltd)</td>
</tr>
<tr>
<td>3x3 cm square</td>
<td>Biatain Adhesive dressing (Coloplast Ltd)</td>
</tr>
</tbody>
</table>

**Biatain Silicone**

<table>
<thead>
<tr>
<th>Dimension</th>
<th>Brand Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1x1 cm square</td>
<td>Biatain Silicone dressing (Coloplast Ltd)</td>
</tr>
<tr>
<td>2x2 cm square</td>
<td>Biatain Silicone dressing (Coloplast Ltd)</td>
</tr>
<tr>
<td>3x3 cm square</td>
<td>Biatain Silicone dressing (Coloplast Ltd)</td>
</tr>
</tbody>
</table>

**Biatain -Ibu Non-Adhesive**

<table>
<thead>
<tr>
<th>Dimension</th>
<th>Brand Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>4x4 cm square</td>
<td>Biatain -Ibu Non-Adhesive dressing (Coloplast Ltd)</td>
</tr>
<tr>
<td>5x5 cm square</td>
<td>Biatain -Ibu Non-Adhesive dressing (Coloplast Ltd)</td>
</tr>
<tr>
<td>8x8 cm square</td>
<td>Biatain -Ibu Non-Adhesive dressing (Coloplast Ltd)</td>
</tr>
</tbody>
</table>

**Biatain -Ibu Soft-Hold**

<table>
<thead>
<tr>
<th>Dimension</th>
<th>Brand Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>2x2 cm square</td>
<td>Biatain -Ibu Soft-Hold dressing (Coloplast Ltd)</td>
</tr>
<tr>
<td>3x3 cm square</td>
<td>Biatain -Ibu Soft-Hold dressing (Coloplast Ltd)</td>
</tr>
<tr>
<td>4x4 cm square</td>
<td>Biatain -Ibu Soft-Hold dressing (Coloplast Ltd)</td>
</tr>
</tbody>
</table>

**Biatain -Ibu Non-Adhesive**

<table>
<thead>
<tr>
<th>Dimension</th>
<th>Brand Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>4x4 cm square</td>
<td>Biatain -Ibu Non-Adhesive dressing (Coloplast Ltd)</td>
</tr>
<tr>
<td>5x5 cm square</td>
<td>Biatain -Ibu Non-Adhesive dressing (Coloplast Ltd)</td>
</tr>
<tr>
<td>8x8 cm square</td>
<td>Biatain -Ibu Non-Adhesive dressing (Coloplast Ltd)</td>
</tr>
</tbody>
</table>

**Kendall Plus**

<table>
<thead>
<tr>
<th>Dimension</th>
<th>Brand Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>3x3 cm square</td>
<td>Kendall Plus dressing (Aria Medical Ltd)</td>
</tr>
<tr>
<td>5x5 cm square</td>
<td>Kendall Plus dressing (Aria Medical Ltd)</td>
</tr>
<tr>
<td>8x8 cm square</td>
<td>Kendall Plus dressing (Aria Medical Ltd)</td>
</tr>
</tbody>
</table>
Kerraheel
  *Kerraheel* (Crawford Healthcare Ltd) dressing 12cm × 20cm heel= £4.65

Lyfoam Max
  *Lyfoam Max dressing* (Molnycke Health Care Ltd) 10cm × 10cm square= £1.14, 10cm × 20cm rectangular= £2.01, 15cm × 15cm square= £2.15, 15cm × 20cm rectangular= £2.71, 20cm × 20cm square= £3.99, 7.5cm × 8.5cm rectangular= £1.09

PermaFoam
  *PermaFoam* (Paul Hartmann Ltd) Cavity dressing 10cm × 10cm= £2.03, dressing (non-adhesive) 10cm × 10cm square= £2.14, 10cm × 20cm rectangular= £3.67, 15cm × 15cm square= £4.06, 20cm × 20cm square= £6.20, 6cm diameter circular= £1.11, 8cm × 8cm square (fenestrated)= £1.26

PolyMem
  *PolyMem dressing* (Aspen Medical Europe Ltd) 7cm × 7cm tube= £1.72, 9cm × 9cm tube= £2.17, finger/toe size 1= £2.50, 2= £2.50, 3= £2.50

PolyMem
  *PolyMem dressing* (Aspen Medical Europe Ltd) 10cm × 10cm square= £2.47, 10cm × 61cm rectangular= £13.10, 13cm × 13cm square= £4.12, 17cm × 19cm rectangular= £6.08, 20cm × 60cm rectangular= £30.90, 8cm × 8cm square= £1.59

PolyMem Max
  *PolyMem Max dressing* (Aspen Medical Europe Ltd) 11cm × 11cm square= £2.97, 20cm × 20cm square= £11.68

PolyMem WIC
  *PolyMem* (Aspen Medical Europe Ltd) WIC dressing 8cm × 8cm= £3.69

Tegaderm Foam
  *Tegaderm Foam dressing* (3M Health Care Ltd) 10cm × 10cm square= £2.19, 10cm × 20cm rectangular= £3.71, 10cm × 60cm rectangular= £12.54, 20cm × 20cm square= £5.92, 8.8cm × 8.8cm square (fenestrated)= £2.23

Tielie Xtra
  *Tielie Xtra dressing* (Systagenix Wound Management Ltd) 11cm × 11cm square= £2.24, 15cm × 15cm square= £3.37, 15cm × 20cm rectangular= £5.51

Transorbent
  *Transorbent dressing (adhesive)* (B.Braun Medical Ltd) 10cm × 10cm square= £1.98, 15cm × 15cm square= £3.65, 20cm × 20cm square= £5.53, 5cm × 7cm rectangular= £1.05

UrgoCell TLC
  *UrgoTul Absorb dressing* (Urgo Ltd) 10cm × 10cm= £2.38, 15cm × 20cm= £4.20, 6cm × 6cm= £1.21, 12cm × 15cm heel= £4.80.

Alginate dressings
  Non-woven or fibrous, non-occlusive, alginate dressings, made from calcium alginate, or calcium sodium alginate, derived from brown seaweed, form a soft gel in contact with wound exudate. Alginate dressings are highly absorbent and suitable for use on exuding wounds, and for the promotion of autolytic debridement of debris in very moist wounds. Alginate dressings also act as a haemostatic, but caution is needed because blood clots can cause the dressing to adhere to the wound surface. Alginate dressings should not be used if bleeding is heavy and extreme caution is needed if used for tumours with friable tissue. Alginate sheets are suitable for use as a wound contact dressing for moderately to heavily exuding wounds and can be layered into deep wounds; alginate rope can be used in sinus and cavity wounds to improve absorption of exudate and prevent maceration. If the dressing does not have an adhesive border or integral adhesive plastic film backing, a secondary dressing will be required.

ActivHeal Alginate
  Calcium sodium alginate dressing

ActivHeal Alginate dressing
  *ActivHeal Alginate dressing* (Advanced Medical Solutions Ltd) 10cm × 10cm= £1.15, 10cm × 20cm= £2.83, 5cm × 5cm= £0.59

ActivHeal Aquafiber
  Non-woven, calcium sodium alginate dressing

ActivHeal Aquafiber
  *ActivHeal Aquafiber* (Advanced Medical Solutions Ltd) Rope dressing 2cm × 42cm= £1.81, dressing 10cm × 10cm= £1.80, 15cm × 15cm= £3.40, 5cm × 5cm= £0.76

Algite M
  Calcium alginate fibre, non-woven dressing

Algite M
  *Algite M* (Smith & Nephew Healthcare Ltd) Rope dressing 2cm × 30cm= £3.50, dressing 10cm × 10cm= £1.93, 15cm × 20cm= £5.19, 5cm × 5cm= £0.93

Algostier
  Calcium alginate dressing

Algostier
  *Algostier* (Smith & Nephew Healthcare Ltd) Rope dressing 2g= £3.83, dressing 10cm × 10cm= £2.12, 10cm × 20cm= £3.58, 5cm × 5cm= £0.93

Biatain Alginate
  Alginate and carboxymethylcellulose dressing, highly absorbent, gelling dressing

Biatain Alginate dressing
  *Biatain Alginate dressing* (Coloplast Ltd) 10cm × 10cm= £2.33, 15cm × 15cm= £4.43, 44cm= £2.75, 5cm × 5cm= £0.98

Cutimed Alginate
  Calcium sodium alginate dressing

Cutimed Alginate dressing
  *Cutimed Alginate dressing* (BSN medical Ltd) 10cm × 10cm= £1.58, 10cm × 20cm= £2.97, 5cm × 5cm= £0.75

Kaltostat
  Calcium alginate fibre, non-woven

Kaltostat dressing
  *Kaltostat dressing* (Convatec Ltd) 10cm × 20cm= £4.12, 15cm × 25cm= £7.08, 2g= £3.86, 5cm × 5cm= £0.96, 7.5cm × 12cm= £2.10

Kendall
  Calcium alginate dressing

Kendall Calcium Alginate
  *Kendall Calcium Alginate* (Aria Medical Ltd) Rope dressing 30cm= £2.89, 61cm= £5.07, 91cm= £5.46, dressing 10cm × 10cm= £1.52, 10cm × 14cm= £2.45, 10cm × 20cm= £2.98, 15cm × 25cm= £5.25, 30cm × 61cm= £27.56, 5cm × 5cm= £0.72

Kendall Plus
  Calcium alginate dressing

Kendall
  *Kendall* (Aria Medical Ltd) Foam Plus dressing 10cm × 10cm square= £1.47

Melgisorb
  Calcium sodium alginate fibre, highly absorbent, gelling dressing, non-woven

Melgisorb
  *Melgisorb* (Molnycke Health Care Ltd) Cavity dressing 2.2cm × 32cm= £3.55, dressing 10cm × 10cm= £1.88, 10cm × 20cm= £3.52, 5cm × 5cm= £0.90

Sorbalgon
  Calcium alginate dressing

Sorbalgon
  *Sorbalgon* (Paul Hartmann Ltd) T dressing 2g= £3.51, dressing 10cm × 10cm= £1.72, 5cm × 5cm= £0.82

Sorbsan Flat
  Calcium alginate fibre, highly absorbent, flat non-woven pads

Sorbsan Flat dressing
  *Sorbsan Flat dressing* (Aspen Medical Europe Ltd) 10cm × 10cm= £1.71, 10cm × 20cm= £3.20, 5cm × 5cm= £0.81

Sorbsan Plus
  Alginate dressing bonded to a secondary absorbent viscose pad

Sorbsan Plus dressing
  *Sorbsan Plus dressing* (Aspen Medical Europe Ltd) 10cm × 15cm= £3.10, 10cm × 20cm= £3.96, 15cm × 20cm= £5.49, 7.5cm × 10cm= £1.76

Sorbsan Ribbon
  Alginate dressing bonded to a secondary absorbent viscose pad

Sorbsan
  *Sorbsan* (Aspen Medical Europe Ltd) Ribbon dressing 40cm= £2.04

Sorbsan Surgical Packing
  Alginate dressing bonded to a secondary absorbent viscose pad

Sorbsan
  *Sorbsan* (Aspen Medical Europe Ltd) Packing dressing 2g= £3.47
**Suprasorb A**
Calcium alginate dressing

**Suprasorb A** (Lohmann & Rauscher (UK) Ltd) alginate dressing 10 cm × 10 cm = £1.23, 5 cm × 5 cm = £0.63, cavity dressing 2g = £2.28

**Tegaderm Alginate**
Calcium alginate dressing

**Tegaderm Alginate dressing** (3M Health Care Ltd) 10 cm × 10 cm = £1.72, 2 cm × 3.4 cm = £2.87, 5 cm × 5 cm = £0.81

**Urgosorb**
Alginate and carboxymethylcellulose dressing without adhesive layer

**Urgosorb** (Urgo Ltd) Pad dressing 10 cm × 10 cm = £2.13, 10 cm × 20 cm = £3.91, 5 cm × 5 cm = £0.89, Rope dressing 30 cm = £2.79

**Capillary-acting dressings**

**Advadraw**
Non-adherent dressing consisting of a soft viscose and polyester absorbent pad with central wicking layer between two perforated permeable wound contact layers

**Advadraw dressing** (Advancis Medical) 10 cm × 10 cm = £0.88, 10 cm × 15 cm = £1.19, 15 cm × 20 cm = £1.57, 5 cm × 7.5 cm = £0.57

**Advadraw Spiral**

**Advadraw** (Advancis Medical) Spiral dressing 0.5 cm × 40 cm = £0.82

**Cerdak Aerocloth**
Non-adhesive wound contact sachet containing ceramic spheres, with non-woven fabric adhesive backing

**Cerdak Aerocloth dressing** (Apollo Medical Products Ltd) 5 cm × 10 cm = £1.94, 5 cm × 5 cm = £1.37

**Cerdak Aerofilim**
Non-adhesive wound contact sachet containing ceramic spheres, with waterproof transparent adhesive film backing

**Cerdak Aerofilim dressing** (Apollo Medical Products Ltd) 5 cm × 10 cm = £2.07, 5 cm × 5 cm = £1.51

**Cerdak Basic**
Non-adhesive wound contact sachet containing ceramic spheres

**Cerdak Basic dressing** (Apollo Medical Products Ltd) 10 cm × 10 cm = £1.56, 10 cm × 15 cm = £2.08, 5 cm × 5 cm = £0.70

**Sumar Life**

**Sumar Life dressing** (Lantor (UK) Ltd) 10 cm × 10 cm = £1.59, 10 cm × 15 cm = £2.12, 5 cm × 5 cm = £0.93

**Sumar Max**

**Sumar Max dressing** (Lantor (UK) Ltd) 10 cm × 10 cm = £1.61, 10 cm × 15 cm = £2.15, 5 cm × 5 cm = £0.95

**Sumar Spiral**

**Sumar** (Lantor (UK) Ltd) Spiral dressing 0.5 cm × 40 cm = £1.57

**Vacutex**
Low-adherent dressing consisting of two external polyester wound contact layers with central wicking polyester/cotton mix absorbent layer

**Vacutex dressing** (Haddenham Healthcare Ltd) 10 cm × 10 cm = £1.68, 10 cm × 15 cm = £2.25, 10 cm × 20 cm = £2.70, 5 cm × 5 cm = £0.95

**Odour absorbent dressings**

Dressings containing activated charcoal are used to absorb odour from wounds. The underlying cause of wound odour should be identified. Wound odour is most effectively reduced by debridement of slough, reduction in bacterial levels, and frequent dressing changes. Fungating wounds and chronic infected wounds produce high volumes of exudate which can reduce the effectiveness of odour absorbent dressings. Many odour absorbent dressings are intended for use in combination with other dressings; odour absorbent dressings with a suitable wound contact layer can be used as a primary dressing.

**Askina Carbosorb**
Activated charcoal and non-woven viscose rayon dressing

**Askina Carbosorb dressing** (B.Braun Medical Ltd) 10 cm × 10 cm = £2.92, 10 cm × 20 cm = £5.64

**CarboFLEX**
Dressing in 5 layers: wound-facing absorbent layer containing alginate and hydrocollod; water-resistant second layer; third layer containing activated charcoal; non-woven absorbent fourth layer; water-resistant backing layer

**CarboFlex dressing** (ConvaTec Ltd) 10 cm × 10 cm = £3.24, 15 cm × 20 cm = £7.38, 8 cm × 15 cm = £3.89

**Carbopad VC**
Activated charcoal non-absorbent dressing

**Carbopad VC dressing** (Synergy Health Plc) 10 cm × 10 cm = £1.62, 10 cm × 20 cm = £2.19

**Clinisorb Odour Control Dressings**
Activated charcoal cloth enclosed in viscose rayon with outer polyamide coating

**Clinisorb dressing** (Climed Ltd) 10 cm × 10 cm = £1.91, 10 cm × 20 cm = £2.54, 15 cm × 25 cm = £4.09

**Antimicrobial dressings**

Spreading infection at the wound site requires treatment with systemic antibacterials. For local wound infection, a topical antimicrobial dressing can be used to reduce the level of bacteria at the wound surface but will not eliminate a spreading infection. Some dressings are designed to release the antimicrobial into the wound, others act upon the bacteria after absorption from the wound. The amount of exudate present and the level of infection should be taken into account when selecting an antimicrobial dressing. Medical grade honey has antimicrobial and anti-inflammatory properties. Dressings impregnated with iodine can be used to treat clinically infected wounds. Dressings containing silver should be used only when clinical signs or symptoms of infection are present. Dressings containing other antimicrobials such as polihexanide (polyhexamethylene biguanide) or dialkylcarnamol chloride are available for use on infected wounds. Although hypersensitivity is unlikely with chlorhexidine impregnated tulle dressing, the antibacterial efficacy of these dressings has not been established.

**Honey**
Medical grade honey has antimicrobial and anti-inflammatory properties and can be used for acute or chronic wounds. Medical grade honey has osmotic properties, producing an environment that promotes autolytic debridement; it can help control wound malodour. Honey dressings should not be used on patients with extreme sensitivity to honey, bee stings or bee products. Patients with diabetes should be monitored for changes in blood-glucose concentrations during treatment with topical honey or honey-impregnated dressings.

For **Activon Tulle**®, where no size is stated by the prescriber the 5 cm size is to be supplied. **Medihoney® Antimicrobial Wound Gel** is not recommended for use in deep wounds or body cavities where removal of waxes may be difficult.

**Honey-based topical application**

**Activon Honey**
Medical grade manuka honey

**L-Mesitran SOFT ointment dressing**

Honey (medical grade) 40%

**L-Mesitran** (Aspen Medical Europe Ltd) SOFT ointment dressing= £3.59

**MANUKApil Honey**
Medical grade manuka honey

**MANUKApil** (Manuka Medical Ltd) dressing= £5.90

**Medihoney Antimicrobial Medical Honey**
Medical grade, Leptospermum sp.

**Medihoney** (Derma Sciences Europe, Ltd) Antimicrobial Medical Honey dressing= £9.90

**Medihoney Antimicrobial Wound Gel**
Medical grade, Leptospermum sp. 80% in natural waxes and oils

**Medihoney** (Derma Sciences Europe, Ltd) Antimicrobial Wound Gel dressing= £4.02
**Mesitran Ointment**
Honey (medical grade) 47%

**Excipients** include lanolin

Mesitran (Aspen Medical Europe Ltd) ointment dressing= £9.90

**Sheet dressing**

**Actilite**
Knitted viscose impregnated with medical grade manuka honey and manuka oil

Actilite gauze dressing (Advancis Medical) 10cm x 10cm= £0.98, 10cm x 20cm= £1.90, 5cm x 5cm= £0.57

**Activon Tulle**
Knitted viscose impregnated with medical grade manuka honey

Activon Tulle gauze dressing (Advancis Medical) 10cm x 10cm= £2.97, 5cm x 5cm= £1.80

**Algivon**
Absorbent, non-adherent calcium alginate dressing impregnated with medical grade manuka honey

Algivon dressing (Advancis Medical) 10cm x 10cm= £3.40, 5cm x 5cm= £1.98

**Algivon Plus**
Reinforced calcium alginate dressing impregnated with medical grade manuka honey

Algivon Plus (Advancis Medical) Ribbon dressing 2.5cm x 20cm= £3.36, dressing 10cm x 10cm= £3.36, 5cm x 5cm= £1.96

**L-Mesitran Border**
Hydrogel, semi-permeable dressing impregnated with medical grade honey, with adhesive border

L-Mesitran (Aspen Medical Europe Ltd) Border sheet 10cm x 10cm square= £2.74

**L-Mesitran Hydro**
Hydrogel, semi-permeable dressing impregnated with medical grade honey, without adhesive border

L-Mesitran Hydro sheet (Aspen Medical Europe Ltd) 10cm x 10cm square= £2.63, 15cm x 20cm rectangular= £5.48

**L-Mesitran Net**
Hydrogel, non-adherent wound contact layer, without adhesive border

L-Mesitran (Aspen Medical Europe Ltd) Net sheet 10cm x 10cm square= £2.53

**Medihoney Antimicrobial Honey Apinate**
Non-adherent calcium alginate dressing, impregnated with medical grade honey

Medihoney Antibacterial Honey Apinate (Derma Sciences Europe, Ltd) dressing 10cm x 10cm square= £3.40, 5cm x 5cm square= £2.00, rope dressing 1.9cm x 30cm= £4.20

**Medihoney Antibacterial Honey Tulle**
Woven fabric impregnated with medical grade manuka honey

Medihoney (Derma Sciences Europe, Ltd) Tulle dressing 10cm x 10cm= £2.98

**Medihoney Gel Sheet**
Sodium alginate dressing impregnated with medical grade honey

Medihoney Gel Sheet dressing (Derma Sciences Europe, Ltd) 10cm x 10cm= £4.20, 5cm x 5cm= £1.75

**MelMax**
Acetate wound contact layer impregnated with buckwheat honey 75% in ointment basis

MelMax dressing (CliniMed Ltd) 5cm x 6cm rectangular= £4.82, 8cm x 10cm rectangular= £9.90, 8cm x 20cm rectangular= £19.79

**Melladerm Plus Tulle**
Knitted viscose impregnated with medical grade honey (Bulgarian, mountain flower) 45% in a basis containing polyethylene glycol

Melladerm (SanoMed Manufacturing BV) Plus Tulle dressing 10cm x 10cm= £2.10

**Iodine**

Cadeoxem–iodine, like povidone–iodine, releases free iodine when exposed to wound exudate. The free iodine acts as an antiseptic on the wound surface, the cadexomer absorbs wound exudate and encourages de-sloughing. Two-component hydrogel dressings containing glucose oxidase and iodide ions generate a low level of free iodine in the presence of moisture and oxygen. Povidone–iodine fabric dressing is a knitted viscose dressing with povidone–iodine incorporated in a hydrophilic polyethylene glycol basis; this facilitates diffusion of the iodine into the wound and permits removal of the dressing by irrigation. The iodine has a wide spectrum of antimicrobial activity but it is rapidly deactivated by wound exudate. Systemic absorption of iodine may occur, particularly from large wounds or with prolonged use.

Iodosorb® and Iodosette® are used for the treatment of chronic exuding wounds; max. single application 50 g, max. weekly application 150 g; max. duration up to 3 months in any single course of treatment. They are contra-indicated in patients receiving lithium, in thyroid disorders, in pregnancy and breast feeding, and in children; they should be used with caution in patients with severe renal impairment or history of thyroid disorder.

Iodoxyme® is an antimicrobial dressing used for moderately exuding wounds. It is contra-indicated in thyroid disorders and in patients receiving lithium; it should be used with caution in children and in women who are pregnant or breast-feeding.

Oxyzyme® is used for non-infected, dry to moderately exuding wounds. It is contra-indicated in thyroid disorders and in patients receiving lithium; it should be used with caution in children and in women who are pregnant or breast-feeding.

Povidone–iodine Fabric Dressing is used as a wound contact layer for abrasions and superficial burns. It is contra-indicated in patients with severe renal impairment and in women who are pregnant or breast-feeding; it should be used with caution in patients with thyroid disease and in children under 6 months.

**Iodoflex Paste**
Iodine 0.9% as cadeoxem–iodine in a paste basis with gauze backing

**Iodosorb Ointment**
Iodine 0.9% as cadeoxem–iodine in an ointment basis

**Iodosorb Powder**
Iodine 0.9% as cadeoxem–iodine microbeads; 3-g sachet

**Iodosource Powder**
(Iodosorb (Smith & Nephew Healthcare Ltd) powder dressing sachets= £1.95

**Iodoxyme Hydrogel**
Hydrogel (two-component dressing containing glucose oxidase and iodide ions)

Iodoxyme dressing (Crawford Healthcare Ltd) 10cm x 10cm square= £12.62, 6.5cm x 5cm rectangular= £7.57

**Oxyzyme Hydrogel**
Hydrogel (two-component dressing containing glucose oxidase and iodide ions)

Oxyzyme dressing (Crawford Healthcare Ltd) 10cm x 10cm square= £10.10, 6.5cm x 5cm rectangular= £6.06

**Povidone–iodine fabric dressing**

**Inadine**

(Drug Tariff specification 43). Knitted viscose primary dressing impregnated with povidone–iodine ointment 10%

**Inadine dressing** (Systagenix Wound Management Ltd) 5cm x 5cm= £0.33, 9.5cm x 9.5cm= £0.49

**Silver**

Antimicrobial dressings containing silver should be used only when infection is suspected as a result of clinical signs or symptoms (see also notes above). Silver ions exert an antimicrobial effect in the presence of wound exudate; the
volume of wound exudate as well as the presence of infection should be considered when selecting a silver-containing dressing. Silver-impregnated dressings should not be used routinely for the management of uncomplicated ulcers. It is recommended that these dressings should not be used on acute wounds as there is some evidence to suggest they delay wound healing. Dressings impregnated with silver sulfadiazine have broad antimicrobial activity; if silver sulfadiazine is applied to large areas, or used for prolonged periods, there is a risk of blood disorders and skin discoloration. The use of silver sulfadiazine-impregnated dressings is contra-indicated in neonates, in pregnancy, and in patients with significant renal or hepatic impairment, sensitivity to sulfonamides, or G6PD deficiency. Large amounts of silver sulfadiazine applied topically may interact with other drugs—see Appendix 1 (sulfonamides).

**Calcium alginate dressing, with silver**

*Sorbsan Silver Plus dressing* (Aspen Medical Europe Ltd) 10cm x 15cm = £5.56, 10cm x 20cm = £6.77, 15cm x 20cm = £9.08, 7.5cm x 10cm = £3.35

*Sorbsan Silver Ribbon* With silver

*Sorbsan* (Aspen Medical Europe Ltd) Silver Ribbon dressing 1g = £4.15

*Sorbsan Silver Surgical Packing* With silver

*Sorbsan* (Aspen Medical Europe Ltd) Silver Packing dressing 2g = £5.76

**Suprasorb A + Ag**

Calcium alginate dressing, with silver

**Suprasorb A + Ag** (Lohmann & Rauscher (UK) Ltd) dressing 10cm x 10cm = £4.11, 10cm x 20cm = £7.59, 5cm x 5cm = £1.63, rope dressing 2g = £6.08.

**Tegaderm Alginate Ag**

Calcium alginate and carboxymethylcellulose dressing, with silver

**Tegaderm Alginate Ag dressing** (3M Health Care Ltd) 10cm x 10cm = £3.24, 3cm x 30cm = £3.70, 5cm x 5cm = £1.39

**Urgosorb Silver**

Alginate and carboxymethylcellulose dressing, impregnated with silver

**Urgosorb Silver** (Urgo Ltd) Rope dressing 2.5cm x 30cm = £3.71, dressing 10cm x 10cm = £6.95, 10cm x 20cm = £5.94, 5cm x 5cm = £1.54

**Foam dressings**

**Acticoat Moisture Control**

Three layer polyurethane dressing consisting of a silver coated layer, a foam layer, and a waterproof layer

**Acticoat Moisture Control dressing** (Smith & Nephew Healthcare Ltd) 10cm x 10cm square = £16.95, 10cm x 20cm rectangular = £33.04, 5cm x 5cm square = £7.25

**Allevyn Ag**

Silver sulfadiazine impregnated polyurethane foam film dressing with or without adhesive border

**Allevyn Ag** (Smith & Nephew Healthcare Ltd) Adhesive dressing 10cm x 10cm square = £5.55, 12.5cm x 12.5cm square = £7.30, 17.5cm x 17.5cm square = £14.04, 17cm x 17cm sacral = £10.96, 22cm x 22cm sacral = £14.69, 7.5cm x 7.5cm square = £3.53, Heel Non-Adhesive dressing 10.5cm x 13.5cm = £10.87, Non-Adhesive dressing 10cm x 10cm square = £6.20, 15cm x 15cm square = £11.76, 20cm x 20cm square = £17.22, 5cm x 5cm square = £3.29

**Biatain Ag**

Silver impregnated polyurethane foam film dressing, with or without adhesive border

**Biatain Ag** (Coloplast Ltd) cavity dressing 5cm x 8cm = £4.07, dressing 10cm x 10cm square = £8.16, 10cm x 20cm rectangular = £15.00, 12.5cm x 12.5cm square = £9.34, 15cm x 15cm square = £16.38, 18cm x 18cm square = £18.73, 19cm x 20cm heel = £18.47, 20cm x 20cm square = £23.11, 23cm x 23cm sacral = £19.63, 5cm x 7cm rectangular = £3.35

**PolyMem Silver**

Silver impregnated polyurethane foam film dressing, with or without adhesive border

**PolyMem Silver** (Aspen Medical Europe Ltd) WIC dressing 8cm x 8cm = £7.05, dressing 10.8cm x 10.8cm square = £8.86, 12.7cm x 8.8cm oval = £5.60, 17cm x 19cm rectangular = £17.76, 5cm x 7.6cm oval = £2.27

**UrgoCell Silver**

Non-adherent, polyurethane foam film dressing with silver in wound contact layer

**UrgoCell Silver dressing** (Urgo Ltd) 10cm x 10cm = £5.95, 15cm x 20cm = £10.90, 6cm x 6cm = £4.33

**Hydrocolloid dressings**

**Aquacel Ag**

Soft non-woven pad containing hydrocolloid fibres, (silver impregnated)

**Aquacel Ag** (Convatec Ltd) Ribbon dressing 1cm x 45cm = £3.12, 2cm x 45cm = £4.76, dressing 10cm x 10cm square = £4.74, 15cm x 15cm square = £8.92, 20cm x 30cm rectangular = £22.12, 4cm x 10cm rectangular = £2.88, 4cm x 20cm rectangular = £3.76, 4cm x 30cm rectangular = £5.63

**Physiotulle Ag**

Non-adherent polyester fabric with hydrocolloid and silver sulfadiazine

**Physiotulle** (Coloplast Ltd) dressing 10cm x 10cm = £2.28
Low adherence dressing

**Acticoat**
Three-layer antimicrobial barrier dressing consisting of a polyurethane foam dressing with acetate fabric coated with dialkylcarbamoyl chloride, with adhesive border

**Acticoat dressing** (Smith & Nephew Healthcare Ltd) 10cm × 10cm rectangular= £8.65, 10cm × 20cm rectangular= £13.53, 20cm × 40cm rectangular= £46.28, 5cm × 5cm square= £3.54

**Acticoat 7**
Five-layer antimicrobial barrier dressing consisting of a polyester core between low adherent silver-coated high density polyethylene mesh (for 7-day wear)

**Acticoat 7 dressing** (Smith & Nephew Healthcare Ltd) 10cm × 12.5 cm rectangular= £18.34, 15cm × 15cm square= £32.97, 5cm × 5cm square= £6.16

**Acticoat Flex 3**
Conformable antimicrobial barrier dressing consisting of a polyester core between low adherent silver-coated high density polyethylene mesh (for 3-day wear)

**Acticoat Flex 3 dressing** (Smith & Nephew Healthcare Ltd) 10cm × 10cm square= £8.73, 10cm × 20cm rectangular= £13.64, 20cm × 40cm rectangular= £46.69, 5cm × 5cm square= £3.57

**Acticoat Flex 7**
Conformable antimicrobial barrier dressing consisting of a polyester core between low adherent silver-coated high density polyethylene mesh (for 7-day wear)

**Acticoat Flex 7 dressing** (Smith & Nephew Healthcare Ltd) 10cm × 12.5cm rectangular= £18.50, 15cm × 15cm square= £33.27, 5cm × 5cm square= £6.21

**Atrauma Ag**
Non-adherent polyamide fabric impregnated with silver and neutral triglycerides

**Atrauma Ag dressing** (Paul Hartmann Ltd) 10cm × 10cm= £1.26, 10cm × 20cm= £2.47, 5cm × 5cm= £0.52

**Soft polymer dressings**

**Allevyn Ag Gentle**
Soft polymer wound contact dressing, with silver sulfadiazine impregnated polyurethane foam layer, with or without adhesive border

**Allevyn Ag Gentle** (Smith & Nephew Healthcare Ltd) Border dressing 10cm × 10cm= £6.43, 12.5cm × 12.5cm= £8.26, 17.5cm × 17.5cm= £15.75, 7.5cm × 7.5cm= £4.28, dressing 10cm × 10cm= £5.24, 10cm × 20cm= £10.31, 15cm × 15cm= £11.61, 20cm × 20cm= £12.19, 5cm × 5cm= £3.35

**Mepilex**
Soft silicone wound contact dressing with polyurethane foam film backing, with silver, with or without adhesive border

**Mepilex** (Molnlycke Health Care Ltd) Ag dressing 10cm × 10cm= £6.12, 10cm × 20cm= £10.09, 15cm × 15cm= £11.36, 20cm × 20cm= £16.84, 20cm × 50cm= £63.20, Border Ag dressing 10cm × 12.5cm= £6.16, 10cm × 20cm= £8.97, 10cm × 30cm= £13.46, 15cm × 17.5cm= £11.31, 17cm × 20cm= £14.66, 7cm × 7.5cm= £3.41, Border Sacrum Ag dressing 18cm × 18cm= £11.83, 20cm × 20cm= £14.58, 23cm × 23cm= £18.69, Heel Ag dressing 13cm × 20cm= £12.78, 15cm × 22cm= £14.32

**Urgotol Silver**
Non-adherent soft polymer wound contact dressing, with silver

**Urgotol Silver dressing** (Urgo Ltd) 10cm × 12cm= £3.58, 15cm × 20cm= £9.75

**Urgotol Duo Silver**
Non-adherent soft polymer wound contact dressing, with silver and charcoal

**With charcoal**

**Actisorb Silver 220**
Knitted fabric of activated charcoal, with one-way stretch, with silver residues, within spun-bonded nylon sleeve

**Actisorb Silver 220 dressing** (Systagenix Wound Management Ltd) 10.5cm × 10.5cm= £2.58, 10.5cm × 19cm= £4.70, 6.5cm × 9.5cm= £1.64

**Other antimicrobials**

**Cutimed Siltec Sorbact**
Polyurethane foam dressing with acetate fabric coated with dialkylcarbamoyl chloride, with adhesive border

**Cutimed Siltec Sorbact dressing** (BSN medical Ltd) 12.5cm × 12.5cm= £6.51, 15cm × 15cm= £8.07, 17.5cm × 17.5cm= £11.29, 22.5cm × 22.5cm= £17.17, 7.5cm × 7.5cm= £2.54, 17.5cm × 17.5cm sacral= £8.16, 23cm × 23cm sacral= £12.26

**Cutimed Sorbact**
Low adherence acetate tissue impregnated with dialkylcarbamoyl chloride; dressing pad, swabs, round swabs or ribbon gauze, cotton

**Cutimed Sorbact** (BSN medical Ltd) Ribbon dressing 2cm × 50cm= £4.08, 5cm × 200cm= £8.03, Round swab 3cm= £3.33, dressing pad 10cm × 10cm= £5.55, 10cm × 20cm= £8.67, 7cm × 9cm= £3.56, swab 4cm × 6cm= £1.67, 7cm × 9cm= £2.78

**Cutimed Sorbact Gel**
Hydrogel dressing impregnated with dialkylcarbamoyl chloride

**Cutimed Sorbact Gel dressing** (BSN medical Ltd) 7.5cm × 15cm rectangular= £4.52, 7.5cm × 7.5cm square= £2.68

**Cutimed Sorbact Hydroactive**
Non-adhesive gel dressing with hydropolymer matrix and acetate fabric coated with dialkylcarbamoyl chloride

**Cutimed Sorbact Hydroactive dressing** (BSN medical Ltd) 14cm × 14cm= £5.42, 14cm × 24cm= £8.69, 15cm × 19cm= £10.21, 24cm × 24cm= £15.47, 7cm × 8.5cm= £3.71

**Cutimed Sorbact Hydroactive B**
Gel dressing with hydropolymer matrix and acetate fabric coated with dialkylcarbamoyl chloride, with adhesive border

**Cutimed Sorbact Hydroactive B dressing** (BSN medical Ltd) 10cm × 10cm= £7.16, 10cm × 20cm= £11.47, 15cm × 15cm= £13.48, 5cm × 6.5cm= £4.02

**Flaminal Forte gel**
Alginate with glucose oxidase and lactoperoxidase, for moderately to heavily exuding wounds

**Flaminal Forte dressing** (Flenn Health UK Ltd) 15g= £7.73, 50g= £25.60

**Flaminal Hydro gel**
Alginate with glucose oxidase and lactoperoxidase, for lightly to moderately exuding wounds

**Flaminal Hydro gel dressing** (Flenn Health UK Ltd) 15g= £7.73, 50g= £25.60

**Kendall AMD**
Foam dressing with polyhexamidine, without adhesive border

**Kendall AMD Antimicrobial foam dressing** (Aria Medical Ltd) 10cm × 10cm square= £4.71, 10cm × 20cm rectangular= £8.92, 15cm × 15cm= £8.92, 20cm × 20cm square= £13.07, 5cm × 5cm square= £2.50, 8.8cm × 7.5cm rectangular (fenestrated)= £4.23

**Kendall AMD Plus**
Foam dressing with polyhexamidine, without adhesive border

**Kendall AMD Antimicrobial Plus foam dressing** (Aria Medical Ltd) 10cm × 10cm square= £4.94, 8.8cm × 7.5cm rectangular (fenestrated)= £4.43

**Oncolin Wound gel**
Wound gel, hydroxyethylcellulose and propylene glycol, with octenidine hydrochloride

**Oncolin Wound gel dressing** (Schulke & Mayr Ltd) 20ml= £4.78

**Prontosan Wound Gel**
Hydrogel containing betaine surfactant and polihexanide

**Prontosan Wound Gel dressing** (B. Braun Medical Ltd) 30ml= £6.44

**Suprasorb X + PHMB**
Biosynthetic cellulose fibre dressing with polyhexanide

**Suprasorb X + PHMB dressing** (Lohmann & Rauscher (UK) Ltd) 14cm × 20cm rectangular= £11.64, 2cm × 21cm rope= £7.25, 5cm × 5cm square= £2.57, 5cm × 9cm square= £5.12
Specialised dressings

Protease-modulating matrix dressings
Cadesorb Ointment
Cadesorb (Smith & Nephew Healthcare Ltd) ointment = £9.32

Catrix dressing (Crangane Healthcare Ltd) sachets = £3.80

Promogran
Collagen and oxidised regenerated cellulose matrix, applied directly to wound and covered with suitable dressing

Promogran dressing (Systagenix Wound Management Ltd) 123 square cm = £15.62, 28 square cm = £5.19

Promogran Prisma Matrix
Collagen, silver and oxidised regenerated cellulose matrix, applied directly to wound and covered with suitable dressing

Promogran Prisma dressing (Systagenix Wound Management Ltd) 123 square cm = £17.98, 28 square cm = £6.31

UrgoStart
Soft adherent polymer matrix containing nano-oligosaccharide factor (NOSF), with polyurethane foam film backing

UrgoStart dressing (Urgo Ltd) 10cm × 10cm = £6.16, 15cm × 20cm = £11.08, 6cm × 6cm = £4.45, 12cm × 19cm heel = £8.49

UrgoStart Contact
Non-adherent soft polymer wound contact dressing containing nano-oligosaccharide factor (NOSF)

UrgoStart (Urgo Ltd) Contact dressing 5cm × 7cm = £3.00

Silicone keloid dressings
Silicone gel and gel sheets are used to reduce or prevent hypertrophic and keloid scarring. They should not be used on open wounds. Application times should be increased gradually. Silicone sheets can be washed and reused.

Silicone gel

Bapscarcare
Silicone gel

Bapscarcare (BAP Medical UK Ltd) gel = £17.00

Clitech
Silicone gel

Clitech (Su-Med International (UK) Ltd) gel = £50.00

Dermatix
Silicone gel

Dermatix gel (Meda Pharmaceuticals Ltd) = £60.53

Kelo-cote UV
Silicone gel with SPF 30 UV protection

Kelo-cote (Sinclair IS Pharma Plc) UV gel = £17.88

Kelo-cote gel
Silicone gel

Kelo-cote (Sinclair IS Pharma Plc) gel = £51.00

Kelo-cote spray
Silicone spray

Kelo-cote (Sinclair IS Pharma Plc) spray = £51.00

NewGel+E
Silicone gel with vitamin E

NewGel+E (Advantedge Surgical Ltd) gel = £17.70

ScarSil
Silicone gel

ScarSil (Jobskin Ltd) gel = £15.19

Silgel STC-SE
Silicone gel

Silgel (Nagor Ltd) STC-SE gel = £19.00

Silicone sheets

Advisal Conform
Self-adhesive silicone gel sheet with polyurethane film backing

Advisal Conform sheet (Advancis Medical) 10cm × 10cm square = £5.20, 15cm × 10cm rectangular = £9.17

Bapscarcare T
Self-adhesive silicone gel sheet

Bapscarcare T sheet (BAP Medical UK Ltd) 10cm × 15cm rectangular = £9.00, 5cm × 30cm rectangular = £9.00, 5cm × 7cm rectangular = £3.15

Cica-Care
Soft, self-adhesive, semi-occlusive silicone gel sheet with backing

Cica-Care sheet (Smith & Nephew Healthcare Ltd) 15cm × 12cm rectangular = £28.82, 5cm × 12cm rectangular = £14.79

Clitech
Silicone gel sheet

Clitech sheet (Su-Med International (UK) Ltd) 10cm × 10cm square = £7.50, 10cm × 20cm rectangular = £12.50, 15cm × 15cm square = £14.00

Dermatix
Self-adhesive silicone gel sheet (clear- or fabric-backed)

Dermatix (Meda Pharmaceuticals Ltd) Clear sheet 13cm × 13cm square = £15.79, 13cm × 25cm rectangular = £28.53, 20cm × 30cm rectangular = £51.97, 4cm × 13cm rectangular = £6.88, Fabric sheet 13cm × 13cm square = £15.79, 13cm × 25cm rectangular = £28.53, 20cm × 30cm rectangular = £51.97, 4cm × 13cm rectangular = £6.88

Mepiform
Self-adhesive silicone gel sheet with polyurethane film backing

Mepiform sheet (Mohlycke Health Care Ltd) 4cm × 31cm rectangular = £11.02, 5cm × 7cm rectangular = £3.49, 9cm × 18cm rectangular = £13.64

Scar FX
Self-adhesive, transparent, silicone gel sheet

Scar FX sheet (Jobskin Ltd) 10cm × 20cm rectangular = £16.00, 22.5cm × 14.5cm shaped = £12.00, 25.5cm × 30.5cm rectangular = £60.00, 3.75cm × 22.5cm rectangular = £12.00, 7.5cm diameter shaped = £8.50

Silgel
Silicone gel sheet

Silgel sheet (Nagor Ltd) 10cm × 10cm square = £13.50, 10cm × 30cm rectangular = £31.50, 10cm × 5cm rectangular = £7.50, 15cm × 10cm rectangular = £19.50, 20cm × 20cm square = £40.00, 25cm × 15cm shaped = £21.12, 30cm × 5cm rectangular = £19.50, 40cm × 40cm square = £144.00, 46cm × 8.5cm shaped = £39.46, 5.5cm diameter shaped = £4.00

Adjunct dressings and appliances

Surgical absorbents
Surgical absorbents applied directly to the wound have many disadvantages—dehydration of and adherence to the wound,
shredding of fibres, and the leakage of exudate ('strike through') with an associated risk of infection. Gauze and cotton absorbent dressings can be used as secondary layers in the management of heavily exuding wounds (but see also Capillary-action dressings). Absorbent cotton gauze fabric can be used for swabbing and cleaning skin. Ribbon gauze can be used post-operatively to pack wound cavities, whereas adherence to the wound bed will cause bleeding and tissue damage on removal of the dressing—an advanced wound dressing (e.g. hydrocolloid-fibrous, foam, or alginate) layered into the cavity is often more suitable.

Cotton

**Absorbent Cotton, BP**
Carded cotton fibres of not less than 10 mm average staple length, available in rolls and balls

**Absorbent** (Robert Bailey & Son Plc) cotton BP 1988

**Absorbent Cotton, Hospital Quality**
As for absorbent cotton but lower quality materials, shorter staple length etc.

**Absorbent** (Robert Bailey & Son Plc) cotton hospital quality

**Gauze and cotton tissue**

**Gamgee Tissue (blue)**
Consists of absorbent cotton enclosed in absorbent cotton gauze type 12 or absorbent cotton and viscose gauze type 2 Gamgee (Robinson Healthcare) tissue blue label

**Gamgee Tissue (pink)**
Consists of absorbent cotton enclosed in absorbent cotton gauze type 12 or absorbent cotton and viscose gauze type 2 Gamgee (Robinson Healthcare) tissue pink label DT

**Gauze and tissue**

**Absorbent Cotton Gauze, BP 1988**
Cotton fabric of plain weave, in rolls and as swabs (see below), usually Type 13 light, sterile

**Absorbent** (Robert Bailey & Son Plc) cotton BP 1988

**Alvita** (Alliance Healthcare (Distribution) Ltd) absorbent cotton BP 1988

**Clini** (CliniSupplies Ltd) absorbent cotton BP 1988

**Vernaid** (Synergy Health Plc) absorbent cotton BP 1988

**Absorbent Cotton and Viscose Ribbon Gauze, BP 1988**
Woven fabric in ribbon form with fast selvedge edges, warp threads of cotton, weft threads of viscose or combined cotton and viscose yarn, sterile

**Vernaid Fast Edge ribbon gauze sterile** (Synergy Health Plc) 1.25cm, 2.5cm

**Lint**

**Absorbent Lint, BPC**
Cotton cloth of plain weave with nap raised on one side from warp yarns

**Absorbent** (Robinson Healthcare) lint

**Alvita** (Alliance Healthcare (Distribution) Ltd) absorbent lint BPC

**Clini** (CliniSupplies Ltd) absorbent lint BPC

**Pads**

**Drisorb**
Absorbent Dressing Pads, Sterile

**Drisorb** (Synergy Health Plc) dressing pad 10cm × 20cm= £0.17

**PremierPad**
Absorbent Dressing Pads, Sterile

**PremierPad dressing pad** (Shermond) 10cm × 20cm= £0.18, 20cm × 20cm= £0.25

**XuPad**
Absorbent Dressing Pads, Sterile

**Xupad dressing pad** (Richardson Healthcare Ltd) 10cm × 20cm= £0.17, 20cm × 20cm= £0.28, 20cm × 40cm= £0.40

**Wound drainage pouches**
Wound drainage pouches can be used in the management of wounds and fistulas with significant levels of exudate.

**Biotrol Draina 5**
Wound drainage pouch

**Biotrol Draina 5 wound drainage bag** (B.Braun Medical Ltd) large (Transparent)= £96.45, medium (Transparent)= £78.43, mini (Transparent)= £78.66

**Biotrol Draina 5 Vision**
Wound drainage pouch

**Draina 5 Vision** (B.Braun Medical Ltd) 100 wound drainage bag= £125, 24, 50 wound drainage bag= £102.17, 75 wound drainage bag= £107.94

**Eakin Access window**
For use with Eakin® pouches

**Eakin** (Pelican Healthcare Ltd) access window large= £38.14

**Eakin Wound pouch, bung closure**
Wound pouch, bung closure

**Eakin wound drainage bag with bung closure** (Pelican Healthcare Ltd) large= £103.52, medium= £76.28, small= £54.49, and access window for horizontal wounds, extra large= £103.52, for horizontal wounds, extra large= £92.63, for vertical incision wounds, extra large= £92.63, wounds, extra large= £92.63

**Eakin Wound pouch, fold and tuck closure**
Wound pouch, fold and tuck closure

**Eakin wound drainage bag with fold and tuck closure** (Pelican Healthcare Ltd) large= £92.63, medium= £70.83, small= £49.04, extra large= £81.73

**Option Wound Manager**
Wound drainage bag

**Option wound manager bag** (Oakmed Ltd) large= £160.22, medium= £134.42, small= £131.50, square= £140.27, extra small= £118.23

**Option Wound Manager with access port**
Wound drainage bag, with access port

**Option wound manager bag with access port** (Oakmed Ltd) large= £171.27, medium= £140.27, small= £137.34, square= £146.11, extra small= £129.28

**Option Wound Manager, cut to fit**
Wound drainage bag, cut to fit

**Option wound manager bag** (Oakmed Ltd) large= £84.23, medium= £80.42, small= £72.59

**Welland Fistula bag**
Wound drainage bag, cut-to-fit

**Welland (Welland Medical Ltd) Fistula wound drainage bag= £82.93**

**Physical debridement pads**
DebiSoft® is a pad that is used for the debridement of superfi cial wounds containing loose slough and debris, and for the removal of hyperkeratosis from the skin. DebiSoft® must be fully moistened with a wound cleansing solution before use and is not appropriate for use as a wound dressing.

**DebiSoft Pad**
Polyester fibres with bound edges and knitted outer surface coated with polyacrylate

DebiSoft (Lohmann & Rauscher (UK) Ltd) pad 10cm × 10cm= £6.45

**Complex adjunct therapies**

**Topical negative pressure therapy**

**Accessories**

**Renasy**
Soft port and connector

**Renasy** (Smith & Nephew Healthcare Ltd) Soft Port= £11.21, connector for use with soft port= £3.29

**V.A.C.**
Drape, gel for canister, Sensa T.R.A.C. Pad

Sensa T.R.A.C.® (KCI Medical Ltd) pad= £10.95

T.R.A.C.® (KCI Medical Ltd) connector= £3.13

V.A.C.® (KCI Medical Ltd) drape= £9.39, gel strips= £3.76

**Venturi**
Gel patches, adhesive, and connector

**Venturi** (Talley Group Ltd) adhesive gel patch= £15.00, connector= £15.00

**WoundASSIST gel strip**
WoundASSIST (Huntleigh Healthcare Ltd) TNP gel strip= £3.37
Vacuum assisted closure products

**Exsu-Fast kit 1**
Dressing Kit
Exsu-Fast (Synergy Health Plc) dressing kit 1= £28.04

**Exsu-Fast kit 2**
Dressing Kit
Exsu-Fast (Synergy Health Plc) dressing kit 2= £35.83

**Exsu-Fast kit 3**
Dressing Kit
Exsu-Fast (Synergy Health Plc) dressing kit 3= £35.83

**Exsu-Fast kit 4**
Dressing Kit
Exsu-Fast (Synergy Health Plc) dressing kit 4= £28.04

**V.A.C. GranuFoam**
Polyurethane foam dressing (with adhesive drapes and pad connector); with or without silver
V.A.C. GranuFoam (KCI Medical Ltd) dressing kit= £32.04, Small/medium= £28.04, medium= £28.79, dressing kit large= £31.70, medium= £27.32, small= £22.95

**V.A.C. Simplace**
Spiral-cut polyurethane foam dressings, vapour-permeable adhesive film dressings (with adhesive drapes and pad connector)
V.A.C. Simplace EX dressing kit (KCI Medical Ltd) medium= £30.58, small= £26.60

**V.A.C. WhiteFoam**
Polyvinyl alcohol foam dressing or dressing kit
V.A.C. WhiteFoam dressing (KCI Medical Ltd) large= £17.04, small= £10.64, kit large= £33.54, small= £25.91

**Venturi**
Wound sealing kit, flat drain; with or without channel drain
Venturi wound sealing kit with (Talley Group Ltd) channel drain= £15.00, flat drain, large= £17.50, standard= £15.00

**WoundASSIST**
Wound pack and channel drain
WoundASSIST TNP dressing pack (Huntleigh Healthcare Ltd) medium= £23.85, small/medium= £20.81, channel drain medium/large= £23.85, small/medium= £20.81, extra large= £34.05

**Wound drainage collection devices**

**ActiV.A.C.**
Canister with gel
ActiV.A.C. (KCI Medical Ltd) canister with gel= £28.42

**S-Canister**
Canister kit
S-Canister (Smith & Nephew Healthcare Ltd) kit= £19.00

**V.A.C. Freedom**
Canister with gel
V.A.C. (KCI Medical Ltd) Freedom Canister with gel= £28.85

**Venturi**
Canister kit with solidifier
Venturi (Talley Group Ltd) Compact canister kit= £12.50, canister kit= £12.50

**WoundASSIST wound pack**
Canister
WoundASSIST (Huntleigh Healthcare Ltd) TNP canister= £20.30

Wound care accessories

**Dressing packs**
The role of dressing packs is very limited. They are used to provide a clean or sterile working surface; some packs shown below include cotton wool balls, which are not recommended for use on wounds.

**Multiple Pack Dressing No. 1**
Contains absorbent cotton, absorbent cotton gauze type 13 light (sterile), open-wove bandages (banded)
Vernaid (Synergy Health Plc) multiple pack dressing

**Non-drug tariff specification sterile dressing packs**

**Dressit**
Vitrex gloves, large apron, disposable bag, paper towel, soft swabs, adsorbent pad, sterile field
Dressit sterile dressing pack (Richardson Healthcare Ltd) with medium/large gloves= £0.60, small/medium gloves= £0.60

**Nurse It**
Contains latex-free, powder-free nitrite gloves, sterile laminated paper sheet, large apron, non-woven swabs, paper towel, disposable bag, compartmented tray, disposable forceps, paper measuring tape
Nurse It sterile dressing pack (Medicareplus International Ltd) with medium/large gloves= £0.55, small/medium gloves= £0.55

**Polyfield Nitrile Patient Pack**
Contains powder-free nitrite gloves, laminated sheet, non-woven swabs, towel, polyethylene disposable bag, apron
Polyfield Nitrile Patient Pack (Shemond) with large gloves= £0.52, medium gloves= £0.52, small gloves= £0.52

**Sterile Dressing Pack with Non-Woven Pads**

**Vernaid**
Vernaid (Synergy Health Plc) sterile dressing pack with non-woven pads

**Sterile dressing packs**

**Vernaid**
(Drug Tariff specification 10). Contains gauze and cotton tissue pad, gauze swabs, absorbent cotton wool balls, absorbent paper towel, water repellent inner wrapper
Vernaid (Synergy Health Plc) sterile dressing pack

Woven and fabric swabs

**Gauze Swab, PB 1988**
Consists of absorbent cotton gauze type 13 light or absorbent cotton and viscose gauze type 1 folded into squares or rectangles of 8-ply with no cut edges exposed, sterile or non-sterile
Alvita gauze swab 8ply (Alliance Healthcare (Distribution) Ltd) non-sterile 10cm × 10cm, sterile 7.5cm × 7.5cm
CS (CliniSupplies Ltd) gauze swab 8ply non-sterile 10cm × 10cm
Clini gauze swab 8ply (CliniSupplies Ltd) non-sterile 10cm × 10cm, sterile 7.5cm × 7.5cm
Gauze (Robert Bailey & Son Plc) swab 8ply non-sterile 10cm × 10cm
MeCoBo gauze swab 8ply (MeCoBo Ltd) non-sterile 10cm × 10cm, sterile 7.5cm × 7.5cm
Propax gauze (BSN medical Ltd) swab 8ply sterile 7.5cm × 7.5cm
Sovereign (Waymade Healthcare Plc) gauze swab 8ply sterile 7.5cm × 7.5cm
Steraid (Robert Bailey & Son Plc) gauze swab 8ply sterile 7.5cm × 7.5cm
Vernaid gauze swab 8ply (Synergy Health Plc) non-sterile 10cm × 10cm, sterile 7.5cm × 7.5cm

**Non-woven Fabric Swab**
(Drug Tariff specification 28). Consists of non-woven fabric folded 4-ply; alternative to gauze swabs, type 13 light, sterile or non-sterile
CS (CliniSupplies Ltd) non-woven fabric swab 4ply non-sterile 10cm × 10cm
Clini non-woven fabric swab 4ply (CliniSupplies Ltd) non-sterile 10cm × 10cm, sterile 7.5cm × 7.5cm
CliniMed (CliniMed Ltd) non-woven fabric swab 4ply non-sterile 10cm × 10cm
MeCoBo (MeCoBo Ltd) non-woven fabric swab 4ply non-sterile 10cm × 10cm
Multisorb (BSN medical Ltd) non-woven fabric swab 4ply sterile 7.5cm × 7.5cm
Sofsort non-woven fabric swab 4ply (Synergy Health Plc) non-sterile 10cm × 10cm
Softswab non-woven fabric swab 4ply (Richardson Healthcare Ltd) non-sterile 10cm × 10cm, sterile 7.5cm × 7.5cm
Topper 8 non-woven fabric swab 4ply (Systagenic Wound Management Ltd) non-sterile 10cm × 10cm, sterile 7.5cm × 7.5cm
Filmed non-woven Fabric Swab

Regal
(Drug Tariff specification 29). Film of viscose fibres enclosed within non-woven viscose fabric folded 8-ply, non-sterile Regal (Systagenix Wound Management Ltd) filmed swab 8ply 10cm x 10cm

Surgical adhesive tapes
Adhesive tapes are useful for retaining dressings on joints or awkward body parts. These tapes, particularly those containing rubber, can cause irritant and allergic reactions in susceptible patients; synthetic adhesives have been developed to overcome this problem, but they, too, may sometimes be associated with reactions. Synthetic adhesive, or silicon adhesive, tapes can be used for patients with skin reactions to plasters and restraining containing rubber, or undergoing prolonged treatment.

Adhesive tapes that are occlusive may cause skin maceration. Care is needed not to apply these tapes under tension, to avoid creating a tourniquet effect. If applied over joints they need to be orientated so that the area of movement of the limb.

Occlusive adhesive tapes
Blenderm
(Impermeable Plastic Adhesive Tape, BP 1988). Extensible water-impermeable plastic film spread with a polymeric adhesive mass
Blenderm tape (3M Health Care Ltd) 2.5cm= £1.77, 5cm= £3.37

Sleek
(Impermeable Plastic Adhesive Tape, BP 1988). Extensible water-impermeable plastic film spread with an adhesive mass
Leukoplast Sleek tape (BSN medical Ltd) 2.5cm, 5cm, 7.5cm

Permeable adhesive tapes
3M Kind Removal Silicone Tape
Soft silicone, water-resistant, knitted fabric, polyurethane film adhesive tape
3M Micropore Silicone tape (3M Health Care Ltd) 2.5cm= £3.58, 5cm= £6.48

Chemifix
Chemifix tape (Medicareplus International Ltd) 10cm= £2.10, 2.5cm= £0.90, 5cm= £1.40

Chempore
(Permeeable Non-Woven Synthetic Adhesive Tape, BP 1988). Backing of paper-based or non-woven textile material spread with a polymeric adhesive mass
Chempore tape (Medicareplus International Ltd) 1.25cm= £0.27, 2.5cm= £0.70, 5cm= £0.95

Clinipore
(Permeeable Non-Woven Synthetic Adhesive Tape, BP 1988). Backing of paper-based or non-woven textile material spread with a polymeric adhesive mass
Clinipore tape (CliniSupplies Ltd) 1.25cm= £0.35, 2.5cm= £0.73, 5cm= £0.99

Elastoplast
(Elastic Adhesive Tape, BP 1988). Woven fabric, elastic in warp (crepe-twisted cotton threads), weft of cotton and/or viscose threads, spread with adhesive mass containing zinc oxide
Tensoplast (BSN medical Ltd) elastic adhesive tape 2.5cm

Hypafix
Hypafix tape (BSN medical Ltd) 10cm= £4.72, 15cm= £6.99, 2.5cm= £1.70, 20cm= £9.28, 30cm= £13.41, 5cm= £2.71

Insil
Soft silicone, water-resistant, knitted fabric, polyurethane film adhesive tape
Insil tape (Insight Medical Products Ltd) 2cm= £5.77, 4cm= £5.77

Leukofix
(Permeeable Non-Woven Synthetic Adhesive Tape, BP 1988). Backing of paper-based or non-woven textile material spread with a polymeric adhesive mass
Leukofix tape (BNF medical Ltd) 1.25cm= £0.56, 2.5cm= £0.91, 5cm= £1.18

Leukopor
(Permeeable Non-Woven Synthetic Adhesive Tape, BP 1988). Backing of paper-based or non-woven textile material spread with a polymeric adhesive mass
Leukopor tape (BNF medical Ltd) 1.25cm= £0.50, 2.5cm= £0.78, 5cm= £1.37

Mediplast
(Permeeable Non-Woven Synthetic Adhesive Tape, BP 1988). Backing of paper-based or non-woven textile material spread with a polymeric adhesive mass
Mediplast tape (Neomedic Ltd) 1.25cm= £0.30, 2.5cm= £0.50

Mediplast
Fabric, plain weave, warp and weft of cotton and/or viscose, spread with an adhesive containing zinc oxide
Mediplast Zinc Oxide plaster (Neomedic Ltd) 1.25cm= £0.82, 2.5cm= £1.19, 5cm= £1.99, 7.5cm= £2.99

Mefix
Mefix tape (Molnlycke Health Care Ltd) 10cm= £2.90, 15cm= £3.95, 2.5cm= £1.03, 20cm= £5.07, 30cm= £7.25, 5cm= £1.81

Mepitac
Soft silicone, water-resistant, knitted fabric, polyurethane film adhesive tape
Mepitac tape (Molnlycke Health Care Ltd) 2cm= £6.96, 4cm= £6.96

Micropore
(Permeeable Non-Woven Synthetic Adhesive Tape, BP 1988). Backing of paper-based or non-woven textile material spread with a polymeric adhesive mass
Micropore tape (3M Health Care Ltd) 1.25cm= £0.62, 2.5cm= £0.92, 5cm= £1.62

Omnifix
Omnifix tape (Paul Hartmann Ltd) 10cm= £4.08, 15cm= £6.02, 5cm= £2.42

OpSite Flexifix Gentle
Soft silicone, water-resistant, knitted fabric, polyurethane film adhesive tape
OpSite Flexifix Gentle tape (Smith & Nephew Healthcare Ltd) 2.5cm= £10.41, 5cm= £19.51

Primafix
Primafix tape (Smith & Nephew Healthcare Ltd) 10cm= £2.36, 15cm= £3.48, 20cm= £4.29, 5cm= £1.61

Scanpor
(Permeeable Non-Woven Synthetic Adhesive Tape, BP 1988). Backing of paper-based or non-woven textile material spread with a polymeric adhesive mass
Scanpor tape (Bio-Diagnostics Ltd) 1.25cm= £0.55, 2.5cm= £0.92, 5cm= £1.75, 7.5cm= £2.56

Siltape
Soft silicone, water-resistant, knitted fabric, polyurethane film adhesive tape
Siltape (Advancis Medical) 2cm= £5.60, 4cm= £5.60

1475
Surgical adhesive tapes

BNF 74

Wound management | Appendix 4
Strapal
Fabric, plain weave, warp and weft of cotton and/or viscose, spread with an adhesive containing zinc oxide
*Strapal adhesive tape* (BSN medical Ltd) 2.5cm= £1.40, 5cm= £2.37, 7.5cm= £3.56

Transpore
(Permeable Non-Woven Synthetic Adhesive Tape, BP 1988). Backing of paper-based or non-woven textile material spread with a polymeric adhesive mass
*Transpore tape* (3M Health Care Ltd) 2.5cm= £0.84, 5cm= £1.48

Zinc Oxide Adhesive Tape, BP 1988
Fabric, plain weave, warp and weft of cotton and/or viscose, spread with an adhesive containing zinc oxide
*Fast Aid zinc oxide adhesive tape* (Robinson Healthcare) 1.25cm, 2.5cm, 5cm, 7.5cm

Skin closure dressings
Skin closure strips are used as an alternative to sutures for minor cuts and lacerations. Skin tissue adhesive (section 13.10.5) can be used for closure of minor skin wounds and for additional suture support.

*Skin closure strips, sterile*

**Leukostrip**
Drug Tariff specifies that these are specifically for personal administration by the prescriber
*Leukostrip* (Smith & Nephew Healthcare Ltd) skin closure strips 6.4mm × 76mm= £6.38

**Omnistrip**
Drug Tariff specifies that these are specifically for personal administration by the prescriber
*Omnistrip* (Paul Hartmann Ltd) skin closure strips sterile 6mm × 76mm= £24.34

**Steri-strip**
Drug Tariff specifies that these are specifically for personal administration by the prescriber
*Steri-strip* (3M Health Care Ltd) skin closure strips 6mm × 75mm= £8.77

**Bandages**

Non-extensible bandages
Skin closure strips are used as an alternative to sutures for minor cuts and lacerations. Skin tissue adhesive can be used for closure of minor skin wounds and for additional suture support.

**Open-wove Bandage, Type 1 BP 1988**
Cotton cloth, plain weave, warp of cotton, weft of cotton, viscose, or combination, one continuous length
*Clini open wove bandage Type 1 BP 1988* (CliniSupplies Ltd) 10cm × 5m, 2.5cm × 5m, 5cm × 5m, 7.5cm × 5m
*Vernaid white open wove bandage* (Synergy Health Plc) 10cm × 5m, 2.5cm × 5m, 5cm × 5m, 7.5cm × 5m
*White open wove bandage* (Robert Bailey & Son Plc) 10cm × 5m, 2.5cm × 5m, 5cm × 5m, 7.5cm × 5m

**Triangular Calico Bandage, BP 1980**
Unbleached calico right-angled triangle
*Clini* (CliniSupplies Ltd) triangular calico bandage BP 1980 90cm × 127cm
*Triangular* (BSN medical Ltd) calico bandage 90cm × 127cm

Light-weight conforming bandages
Lightweight conforming bandages are used for dressing retention, with the aim of keeping the dressing close to the wound without inhibiting movement or restricting blood flow. The elasticity of conforming-stretch bandages (also termed contour bandages) is greater than that of cotton conforming bandages.

**Acti-Wrap**
Fabric, plain weave, warp of polyamide filament, weft of cotton or viscose, fast edges, one continuous length, 4m stretched (all)
*Acti-Wrap (cohesive/latex free) bandage* (Activa Healthcare Ltd) 10cm × 4m= £0.81, 6cm × 4m= £0.47, 8cm × 4m= £0.69

**Cotton Conforming Bandage, BP 1988**
Cotton fabric, plain weave, treated to impart some elasticity to warp and weft
*Easifix Crinx bandage* (BSN medical Ltd) 10cm × 3.5m= £1.04, 15cm × 3.5m= £1.42, 5cm × 3.5m= £0.69, 7.5cm × 3.5m= £0.84

**Easifix**
Fabric, plain weave, warp of polyamide filament, weft of cotton or viscose, fast edges, one continuous length, 4m stretched (all)
*Easifix bandage* (BSN medical Ltd) 10cm × 4m= £0.51, 15cm × 4m= £0.67, 5cm × 4m= £0.36, 7.5cm × 4m= £0.43

**Easifix K**
Fabric, knitted warp of polyamide filament, weft of cotton or viscose, fast edges, one continuous length. 4m stretched
*Easifix K bandage* (BSN medical Ltd) 10cm × 4m= £0.19, 15cm × 4m= £0.33, 2.5cm × 4m= £0.10, 5cm × 4m= £0.11, 7.5cm × 4m= £0.16

**Hospiform**
Fabric, plain weave, warp of polyamide, weft of viscose
*Hospiform bandage* (Paul Hartmann Ltd) 10cm × 4m= £0.19, 12cm × 4m= £0.59, 7cm × 4m= £0.17

**K-Band**
Fabric, knitted warp of polyamide filament, weft of cotton or viscose, fast edges, one continuous length. 4m stretched
*K-Band bandage* (Urgo Ltd) 10cm × 4m= £0.28, 15cm × 4m= £0.50, 5cm × 4m= £0.20, 7cm × 4m= £0.26

**Knit Fix**
Fabric, knitted warp of polyamide filament, weft of cotton or viscose, fast edges, one continuous length. 4m stretched
*Knit Fix bandage* (Robert Bailey & Son Plc) 10cm × 4m= £0.17, 15cm × 4m= £0.33, 5cm × 4m= £0.12, 7cm × 4m= £0.17

**Knit-Band**
Fabric, knitted warp of polyamide filament, weft of cotton or viscose, fast edges, one continuous length. 4m stretched
*Knit-Band bandage* (CliniSupplies Ltd) 10cm × 4m= £0.17, 15cm × 4m= £0.30, 5cm × 4m= £0.10, 7cm × 4m= £0.15

**Kontour**
Fabric, plain weave, warp of polyamide filament, weft of cotton or viscose, fast edges, one continuous length, 4m stretched (all)
*Kontour bandage* (Easigrip Ltd) 10cm × 4m= £0.40, 15cm × 4m= £0.66, 5cm × 4m= £0.28, 7.5cm × 4m= £0.35

**Mollelast**
Fabric, plain weave, warp of polyamide filament, weft of cotton or viscose, fast edges, one continuous length, 4m stretched (all)
*Mollelast* (Lohmann & Rauscher (UK) Ltd) bandage 4cm × 4m= £0.30

**Peha-haft**
Polyamide and Cellulose Contour Bandage, cohesive, latex-free
*Peha-haft bandage* (Paul Hartmann Ltd) 10cm × 4m= £0.77, 12cm × 4m= £0.91, 2.5cm × 4m= £0.74, 4cm × 4m= £0.48, 6cm × 4m= £0.56, 8cm × 4m= £0.67

**PremierBand**
Polyamide and Cellulose Contour Bandage
PremierBand bandage (Shermond) 10cm × 4m= £0.17, 15cm × 4m= £0.25, 5cm × 4m= £0.12, 7.5cm × 4m= £0.14

**Slinky**
Fabric, plain weave, warp of polyamide filament, weft of cotton or viscose, fast edges, one continuous length, 4m stretched (all)
*Slinky bandage* (Molnlycke Health Care Ltd) 10cm × 4m= £0.72, 15cm × 4m= £1.04, 7.5cm × 4m= £0.59

**Stayform**
Fabric, plain weave, warp of polyamide filament, weft of cotton or viscose, fast edges, one continuous length, 4m stretched (all)
*Stayform bandage* (Robinson Healthcare) 10cm × 4m= £0.40, 15cm × 4m= £0.68, 5cm × 4m= £0.29, 7.5cm × 4m= £0.36
Tubular bandages and garments

Tubular bandages are available in different forms, according to the function required of them. Some are used under orthopaedic casts and some are suitable for protecting areas to which creams or ointments (other than those containing potent corticosteroids) have been applied. The conformability of the elasticated versions makes them particularly suitable for retaining dressings on difficult parts of the body or for soft tissue injury, but their use as the only means of applying pressure to an oedematous limb or to a varicose ulcer is not appropriate, since the pressure they exert is inadequate. Compression hosiery reduces the recurrence of venous leg ulcers and should be considered for use after wound healing. Silk clothing is available as an alternative to elasticated viscose stockinette garments, for use in the management of severe eczema and allergic skin conditions.

Elasticated Surgical Tubular Stockinette, Foam padded is used for relief of pressure and elimination of friction in relevant area; porosity of foam lining allows normal water loss from skin surface.

For Elasticated Tubular Bandage, BP 1993, where no size stated by the prescriber, the 50 cm length should be supplied and widend exposed.

Non-elasticated Cotton Stockinette, Bleached, BP 1988 1m lengths is used as basis (with wadding) for Plaster of Paris bandages etc.; 6 m length, compression bandage. For Non-elasticated Ribbed Cotton and Viscose Surgical Tubular Stockinette, BP 1988, the Drug Tariff specifies various combinations of sizes to provide sufficient material for part or full body coverage. It is used as protective dressings with tar-based and other steroid ointments.

Elasticated Acti-Fast

(Drug Tariff specification 46). Lightweight plain-knitted elasticated tubular bandage

Acti-Fast 2-way stretch stockinette (Activa Healthcare Ltd) 10.75cm= £6.04, 17.5cm= £1.83, 20cm= £3.20, 3.5cm= £0.56, 5cm= £0.58, 7.5cm= £0.77

Clinifast

(Drug Tariff specification 46). Lightweight plain-knitted elasticated tubular bandage; various colours and sizes

Clinifast stockinette (Clinisupplies Ltd) 10.75cm= £6.04, 17.5cm= £1.83, 3.5cm= £0.56, 5cm= £0.58, 7.5cm= £0.77, clava 5-14 years= £6.75, 6 months-5 years= £5.85, cycle shorts large adult= £16.25, medium adult= £14.25, small adult= £12.50, gloves large adult= £4.99, child/small adult= £4.99, gloves medium adult= £4.99, child= £4.99, gloves small child= £4.99, leggings (Blue, Pink, White) 11-14 years= £11.88, 2-5 years= £9.50, 5-8 years= £10.69, 8-11 years= £11.88, mittens 2-8 years= £2.97, 9-14 years= £2.97, up to 24 months= £2.97, socks 8-14 years= £2.97, up to 8 years= £2.97, tights (Blue, Pink, White) 6-24 months= £7.13, vest long sleeve (Blue, Pink, White) 11-14 years= £11.88, 2-5 years= £9.50, 5-8 years= £10.69, 8-11 years= £11.88, mittens 2-8 years= £2.97, 9-14 years= £2.97, up to 24 months= £2.97, socks 8-14 years= £2.97, up to 8 years= £2.97, tights 6-24 months= £7.13, vest long sleeve 11-14 years= £11.88, 2-5 years= £9.50, 5-8 years= £10.69, 6-24 months= £7.13, 8-11 years= £11.88

Comfifast Multistretch (Drug Tariff specification 46). Lightweight plain-knitted elasticated tubular bandage; various colours and sizes

Comfifast Multistretch 2-way stretch stockinette (Synergy Health Plc) 10.75cm= £6.45, 17.5cm= £2.49, 3.5cm= £0.61, 5cm= £0.63, 7.5cm= £0.83

Coverflex

(Drug Tariff specification 46). Lightweight plain-knitted elasticated tubular bandage; various colours and sizes

Coverflex stockinette (Paul Hartmann Ltd) 10.75cm= £9.59, 17.5cm= £2.53, 3.5cm= £0.83, 5cm= £0.86, 7.5cm= £5.68

Easifast

(Drug Tariff specification 46). Lightweight plain-knitted elasticated tubular bandage; various colours and sizes

Easifast stockinette (Easigrip Ltd) 10.75cm= £7.23, 17.5cm= £1.91, 3.5cm= £0.65, 5cm= £0.69, 7.5cm= £0.94

Elasticated Surgical Tubular Stockinette, Foam padded or Tupipad (Drug Tariff specification 25). Fabric as for Elasticated Tubular Bandage with polyurethane foam lining.

Elasticated Tubular Bandage, BP 1993

(Drug Tariff specification 25). Fabric as for Elasticated Tubular Bandage with polyurethane foam lining; lengths 50 cm and 1 m

CliniGrip bandage (Clinisupplies Ltd) 10cm size F= £0.74, 12cm size G= £0.77, 6.25cm size B= £0.61, 6.75cm size C= £0.65, 7.5cm size D= £0.66, 8.75cm size E= £0.74

Easigrip bandage (Synergy Health Plc) 10cm size F= £0.74, 12cm size G= £0.77, 6.25cm size B= £0.61, 6.75cm size C= £0.65, 7.5cm size D= £0.66, 8.75cm size E= £0.74

Essential ESTS Bandage (E Sallis Ltd) 10cm size F= £1.80, 12cm size G= £2.09, 6.25cm size B= £0.87, 6.75cm size C= £1.88, 7.5cm size D= £1.88, 8.75cm size E= £2.04

Tubigrip bandage (Molynex Healthcare Ltd) 10cm size F= £2.04, 12cm size G= £2.35, 6.25cm size B= £0.99, 6.75cm size C= £1.94, 7.5cm size D= £1.94, 8.75cm size E= £2.80

Easigrip bandage (Easigrip Ltd) 10cm size F= £0.75, 12cm size G= £0.78, 6.25cm size B= £0.80, 6.75cm size C= £0.80, 7.5cm size D= £0.80, 8.75cm size E= £0.80

Skinny (Drug Tariff specification 46). Lightweight plain-knitted elasticated tubular bandage; various colours and sizes

Skinny Stockinette (Dermacea Ltd) body suit (Blue, Ecru, Pink) 3-6 months= £16.18, 6-12 months= £18.21, premature= £16.18, up to 3 months= £16.18, clava (Blue, Ecru, Pink) 5-14 years= £7.73, 6 months-5 years= £6.74, gloves large (Beige, Blue, Ecru, Grey, Pink) adult= £5.34, child= £5.34, gloves medium (Beige, Blue, Ecru, Grey, Pink) adult= £5.34, child= £5.34, gloves small (Blue, Ecru, Grey, Pink) adult= £5.29, child= £5.29, knee socks extra (Black, Natural, White) large adult 11+= £13.94, knee socks large (Black, Natural, White) adult 8-11= £13.94, child 2-4= £13.94, knee socks medium (Black, Natural, White) adult 6-8= £13.94, child 1-2= £13.94, knee socks small (Black, Natural, White) adult 4-6= £13.94, child 0-1= £13.94, leggings (Beige, Blue, Ecru, Grey, Pink) 11-14 years= £17.20, 2-5 years= £13.74, 5-8 years= £15.52, 6-24 months= £10.48, 8-11 years= £17.20, large adult= £25.13, medium adult= £23.20, small adult= £21.27, mittens (Blue, Ecru, Pink) 2-8 years= £3.87, 8-14 years= £3.87, up to 24 months= £3.87, socks (Blue, Ecru, Pink) 6 months-8 years= £4.27, 8-14 years= £4.27, vest long sleeve (Blue, Ecru, Grey, Pink) 11-14 years= £17.20, 2-5 years= £13.74, 5-8 years= £15.52, 6-24 months= £10.48, 8-11 years= £17.20, large adult= £25.13, medium adult= £23.20, small adult= £21.27, vest short sleeve (White) 11-14 years= £17.09, 2-5 years= £13.63, 5-8 years= £15.36, 6-24 months= £10.38, 8-11 years= £17.09, large adult= £25.03, medium adult= £23.10, small adult= £21.16
Tubfast 2-way stretch
(Drug Tariff specification 46). Lightweight plain-knitted elasticated tubular bandage; various colours and sizes
Tubfast 2-way stretch stockinette
(Mohnlycke Health Care Ltd)
10.75cm= £6.45, 20cm= £3.42, 3.5cm= £0.61, 5cm= £0.63, 7.5cm= £0.83, gloves extra small child= £5.69, medium/large adult= £5.69, small child= £5.69, small medium/adult medium/large child= £5.69, leggings 2-5 years= £15.14, 5-8 years= £17.04, 8-11 years= £18.93, socks (one size)= £4.79, tights 6-24 months= £11.36, vest long sleeve 11-14 years= £18.93, 2-5 years= £15.14, 5-8 years= £17.04, 6-24 months= £11.36, 8-11 years= £18.93
Non-elasticated
Cotton Stockinette, Bleached, BP 1988
Knitted fabric, cotton yarn, tubular length, 1m
Cotton stockinette bleached heavyweight (E Sallis Ltd) 10cm, 2.5cm, 5cm, 7.5cm
Silk Clothing
DermaSilk
Knitted silk fabric, hypoallergenic, sericin-free
DermaSilk (Esperance Healthcare Ltd) medium/large= £42.07, medium= £31.30, body suit 0-3 months= £38.53, 12-18 months= £40.82, 18-24 months= £41.85, 24-36 months= £41.93, 3-6 months= £38.61, 6-9 months= £39.72, 9-12 months= £40.74, boxer shorts male adult extra large/XX large= £42.07, small/medium= £42.07, briefs female adult extra large/XX large= £31.30, small/medium= £31.30, facial mask adult= £21.13, child= £16.57, infant= £16.57, teen= £21.13, gloves large adult= £20.89, gloves large adult= £20.94, gloves medium adult= £20.94, child= £14.92, gloves small adult= £20.94, child= £14.92, leggings 0-3 months= £27.51, leggings 12-18 months= £29.78, leggings 18-24 months= £30.83, leggings 3-4 years= £31.99, leggings 3-6 months= £27.57, leggings 6-9 months= £28.67, leggings 9-12 months= £29.72, leggings adult female XX large= £79.14, extra large= £79.14, large= £79.14, medium= £79.14, small= £79.14, leggings adult male XX large= £79.14, extra large= £79.14, large= £79.14, medium= £79.14, small= £79.14, pyjamas 10-12 years= £82.81, 3-4 years= £71.76, 5-6 years= £76.18, 7-8 years= £79.49, roll neck shirt 10-12 years= £54.99, 3-4 years= £47.58, 5-6 years= £50.76, 7-8 years= £52.88, round neck shirt adult female XX large= £78.21, extra large= £78.21, large= £78.21, medium= £78.21, small= £78.21, round neck shirt adult male XX large= £78.21, extra large= £78.21, large= £78.21, medium= £78.21, small= £78.21, tubular sleeves= £34.02, sleeves= £77.57, undersocks adult 11-13= £18.61, 1-2= £18.61, 1-2= £18.61, 9-10= £18.61, undersocks child 2-5= £18.61, 3-8= £18.61, 9-11= £18.61, unisex roll neck shirt adult female XX large= £78.21, extra large= £78.21, large= £78.21, medium= £78.21, small= £78.21
DreamSkin
Knitted silk fabric, hypoallergenic, sericin-free, with methacrylate copolymer and zinc-based antibacterial
DreamSkin (DreamSkin Health Ltd) baby leggings with foldaway feet
3-0 months= £25.45, 12-18 months= £28.37, 18-24 months= £28.85, 3-4 years= £30.47, 3-6 months= £25.96, 6-9 months= £27.31, polo neck shirt small= £7.84, body suit 0-3 months= £35.86, 12-18 months= £38.89, 18-24 months= £39.42, 3-4 years= £40.99, 3-6 months= £36.37, 6-9 months= £37.84, 9-12 months= £38.38, boxer shorts 11-12 years= £21.62, boxer shorts 3-4 years= £21.62, boxer shorts 5-6 years= £21.62, boxer shorts 7-8 years= £21.62, boxer shorts 9-10 years= £21.62, boxer shorts male adult XX large= £34.00, extra large= £34.00, large= £34.00, medium= £34.00, small= £34.00, briefs female adults 11-13= £21.62, briefs 3-4 years= £21.62, briefs 5-6 years= £21.62, briefs 7-8 years= £21.62, briefs 9-10 female adult XX large= £31.94, extra large= £31.94, large= £31.94, medium= £31.94, small= £31.94, eye mask= £10.27, footless leggings 11-12 years= £33.52, footless leggings 3-4 years= £30.47, footless leggings 5-6 years= £31.98, footless leggings 7-8 years= £32.49, footless leggings 9-10 years= £33.01, footless leggings adult female XX large= £77.12, extra large= £77.12, large= £77.12, medium= £77.12, small= £77.12, footless leggings adult male XX large= £77.12, extra large= £77.12, large= £77.12, medium= £77.12, small= £77.12, gloves large adult= £20.24, gloves medium adult= £20.24, child= £14.42, gloves
Elset
Knit fabric, viscose and elastomer yarn. Type 2 (light support bandage)
Elset (Molynex Health Care Ltd) S bandage 15 cm × 12 m = £5.60, bandage 10 cm × 6 m = £2.61, 10 cm × 8 m = £3.34, 15 cm × 6 m = £2.80.

Hospicrepe 233 Fabric, plain weave, warp of crepe-twisted cotton threads, weft of cotton threads; stretch bandage, lighter than cotton crepe, 4.5 m stretched (all)
Hospicrepe 233 bandage (Paul Hartmann Ltd) 10 cm × 4.5 m= £0.96, 15 cm × 4.5 m= £1.36, 5 cm × 4.5 m= £0.52, 7.5 cm × 4.5 m= £0.72

Hospilite Fabric, cotton, polyamide, and elastane; light support bandage (Type 2), 4.5 m stretched (all)
Hospilite bandage (Paul Hartmann Ltd) 10 cm × 4.5 m= £0.62, 15 cm × 4.5 m= £0.91, 5 cm × 4.5 m= £0.37, 7.5 cm × 4.5 m= £0.51

K-Lite Knit fabric, viscose and elastomer yarn. Type 2 (light support bandage)
K-Lite (Urgo Ltd) Long bandage 10 cm × 5.25 m= £1.16, bandage 10 cm × 4.5 m= £1.01, 15 cm × 4.5 m= £1.46, 5 cm × 4.5 m= £0.55, 7 cm × 4.5 m= £0.77

K-Plus Knit fabric, viscose and elastomer yarn. Type 2 (light support bandage)
K-Plus (Urgo Ltd) Long bandage 10 cm × 10.25 m= £2.65, bandage 10 cm × 8.7 m= £2.29

K-Firm Knit fabric, viscose and elastomer yarn. Type 2 (light support bandage)
K-Firm bandage (Millepedge Healthcare) 10 cm × 4.5 m= £0.66, 15 cm × 4.5 m= £0.96, 5 cm × 4.5 m= £0.36, 7.5 cm × 4.5 m= £0.51

L3 Knit fabric, viscose and elastomer yarn. Type 2 (light support bandage)
L3 (Smith & Nephew Healthcare Ltd) bandage 10 cm × 8.6 m= £2.22

Neosport Fabric, cotton, polyamide, and elastane; light support bandage (Type 2), 4.5 m stretched (all)
Neosport bandage (Neomedic Ltd) 10 cm × 4.5 m= £0.91, 15 cm × 4.5 m= £1.12, 5 cm × 4.5 m= £0.54, 7.5 cm × 4.5 m= £0.73

PremierBand Fabric, plain weave, warp of crepe-twisted cotton threads, weft of cotton threads; stretch bandage, lighter than cotton crepe, 4.5 m stretched (all)
PremierBand bandage (Shermond) 10 cm × 4.5 m= £0.79, 15 cm × 4.5 m= £1.18, 5 cm × 4.5 m= £0.45, 7.5 cm × 4.5 m= £0.63

Profore #2 Fabric, cotton, polyamide, and elastane; light support bandage (Type 2), 4.5 m stretched (all)
Profore #2 (Smith & Nephew Healthcare Ltd) bandage 10 cm × 4.5 m= £1.36, latex free bandage 10 cm × 4.5 m= £1.44

Profore #3 Knit fabric, viscose and elastomer yarn. Type 2 (light support bandage)
Profore #3 (Smith & Nephew Healthcare Ltd) bandage 10 cm × 8.7 m= £3.96, latex free bandage 10 cm × 8.7 m= £4.31

Setocrepe Fabric, cotton, polyamide, and elastane; light support bandage (Type 2), 4.5 m stretched (all)
Setocrepe (Molynex Health Care Ltd) bandage 10 cm × 4.5 m= £1.20

Soffcrepe Fabric, cotton, polyamide, and elastane; light support bandage (Type 2), 4.5 m stretched (all)
Soffcrepe bandage (BSN medical Ltd) 10 cm × 4.5 m= £1.25, 15 cm × 4.5 m= £1.82, 5 cm × 4.5 m= £0.70, 7.5 cm × 4.5 m= £0.99

Adhesive bandages Elastic adhesive bandages are used to provide compression in the treatment of varicose veins and for the support of injured joints; they should no longer be used for the support of fractured ribs and clavicles. They have also been used with zinc paste bandage in the treatment of venous ulcers, but they can cause skin reactions in susceptible patients and may not produce sufficient pressures for healing (significantly lower than those provided by other compression bandages).

Elastic Adhesive Bandage, BP 1993 Woven fabric, elastic in warp (crepe-twisted cotton threads), weft of cotton and/or viscose threads spread with adhesive mass containing zinc oxide. 4.5 m stretched

Tensoplast bandage (BSN medical Ltd) 10 cm × 4.5 m, 5 cm × 4.5 m, 7.5 cm × 4.5 m

Cohesive bandages Cohesive bandages adhere to themselves, but not to the skin, and are useful for providing support for sports use where ordinary stretch bandages might become displaced and adhesive bandages are inappropriate. Care is needed in their application, however, since the loss of ability for movement between turns of the bandage to equalise local areas of high tension carries the potential for creating a tourniquet effect. Cohesive bandages can be used to support sprained joints and as an outer layer for multi-layer compression bandaging; they should not be used if arterial disease is suspected.

Cohesive extensible bandages
Coban Bandage Coban (3M Health Care Ltd) self-adherent bandage 10 cm × 6 m= £2.93
K Press Bandage K Press bandage (Urgo Ltd) 10 cm × 6.5 m= £2.93, 10 cm × 7.5 m= £3.42, 12 cm × 7.5 m= £4.31, 8 cm × 7.5 m= £3.22

Profore #4 Bandage Profore #4 (Smith & Nephew Healthcare Ltd) bandage 10 cm × 2.5 m= £3.28, latex free bandage 10 cm × 2.5 m= £3.56

Ultra Fast Bandage Ultra (Robinson Healthcare) Fast cohesive bandage 10 cm × 6.3 m= £2.59

Compression bandages High compression products are used to provide the high compression needed for the management of gross varices, post-thrombotic venous insufficiency, venous leg ulcers, and gross oedema in average-sized limbs. Their use calls for an expert knowledge of the elastic properties of the products and experience in the technique of providing careful graduated compression. Incorrect application can lead to uneven and inadequate pressures or to hazardous levels of pressure. In particular, injudicious use of compression in limbs with arterial disease has been reported to cause severe skin and tissue necrosis (in some instances calling for amputation). Doppler testing is required before treatment with compression. Oral pentoxifylline p. 227 can be used as adjunct therapy if a chronic venous leg ulcer does not respond to compression bandaging [unlicensed indication].

High compression bandages

High Compression Bandage Cotton, viscose, nylon, and Lycra® extensible bandage, 3 m (unstretched)
KThreec (Urgo Ltd) bandage 10 cm × 3 m= £2.85
SurePress (Convatec Ltd) bandage 10 cm × 3 m= £3.65
PEC High Compression Bandages Polyamide, elastane, and cotton compression (high) extensible bandage, 3.5 m unstretched
Setopress (Molynex Health Care Ltd) bandage 10 cm × 3.5 m= £3.55
1480 Bandages

**Viscose, elastane, and cotton compression (high) extensible bandage,** 3 m unstretched (both)

**Tensopress bandage** (BSN medical Ltd) 10cm × 3m = £3.49, 7.5cm × 3m = £2.71

**Short stretch compression bandages**

**Actico** Bandage

**Actico bandage** (Activia Healthcare Ltd) 10cm × 6m = £3.38, 12cm × 6m = £4.31, 4cm × 6m = £2.42, 6cm × 6m = £2.83, 8cm × 6m = £3.25

**Comprilan** Bandage

**Comprilan bandage** (BSN medical Ltd) 10cm × 5m = £3.41, 12cm × 5m = £4.15, 6cm × 5m = £2.70, 8cm × 5m = £3.17

**Rosalid K** Bandage

**Rosalid K bandage** (Lohmann & Rauscher (UK) Ltd) 10cm × 10m = £6.02, 10cm × 5m = £3.46, 12cm × 5m = £4.20, 6cm × 5m = £2.65, 8cm × 5m = £3.17

**Silkolan** Bandage

**Sub-compression wadding bandage**

**Cellona Undercast Padding** Padding

**Cellona Undercast padding bandage** (Lohmann & Rauscher (UK) Ltd) 10cm × 2.75m = £0.47, 15cm × 2.75m = £0.60, 5cm × 2.75m = £0.31, 7.5cm × 2.75m = £0.38

**Flexi-Ban** Padding

**Flexi-Ban** (Activia Healthcare Ltd) bandage 10cm × 3.5m = £0.50

**K Tech Reduced** Padding

**K Tech Reduced bandage 10cm** × (Urgo Ltd) 6m = £4.75, 7.3m = £5.18

**K-Soft** Padding

**K-Soft** (Urgo Ltd) Long bandage 10cm × 4.5m = £0.57, bandage 10cm × 3.5m = £0.46

**K-Tech (K Tech in DMD)** Padding

**K-Tech** (Urgo Ltd) Reduced bandage 10cm × 7.3m = £5.18, bandage 10cm × 5m = £3.96, 10cm × 6m = £4.75, 12cm × 6m = £5.99, 12cm × 7.3m = £6.54, 8cm × 6m = £4.49, 8cm × 7.3m = £4.89

**Ortho-Band Plus** Padding

**Ortho-Band** (Millpledge Healthcare) Plus bandage 10cm × 3.5m = £0.37

**Profore #1** Padding

**Profore #1** (Smith & Nephew Healthcare Ltd) bandage 10cm × 3.5m = £0.71, latex free bandage 10cm × 3.5m = £0.77

**Softexe** Padding

**Softexe** (Molhycke Health Care Ltd) bandage 10cm × 3.5m = £0.62

**SurePres** Padding

**SurePres** (Convatec Ltd) bandage 10cm × 3m = £3.65

**Ultra Soft** Padding

**Ultra** (Robinson Healthcare) Soft wadding bandage 10cm × 3.5m = £0.39

**Velband** Padding

**Velband** (BSN medical Ltd) absorbent padding bandage 10cm × 4.5m = £0.73

**Multi-layer compression bandaging**

Multi-layer compression bandaging systems are an alternative to High Compression Bandages for the treatment of venous leg ulcers. Compression is achieved by the combined effects of two or three extensible bandages applied over a layer of orthopaedic wadding and a wound contact dressing.

**Four layer systems**

**K-Four** Padding

**K-Four** Multi-layer compression bandaging kit, four layer system

**K-Four** (Urgo Ltd) Reduced Compression multi-layer compression bandage kit 18cm ankle circumference = £4.51, multi-layer compression bandage kit 18cm-25cm ankle circumference = £6.90, 25cm-30cm ankle circumference = £6.90, greater than 30cm ankle circumference = £9.50, less than 18cm ankle circumference = £7.21

**Profore** Wound contact layer

**Profore** Multi-layer compression bandaging kit, four layer system

**Profore** (Smith & Nephew Healthcare Ltd) Lite latex free multi-layer compression bandage kit = £6.00, multi-layer compression bandage kit = £5.52, latex free multi-layer compression bandage kit 18cm-25cm ankle circumference = £10.22, multi-layer compression bandage kit 18cm-25cm ankle circumference = £9.57, 25cm-30cm ankle circumference = £7.94, above 30cm ankle circumference = £11.89, up to 18cm ankle circumference = £10.26

**Ultra Four** Wound contact layer

**Ultra Four** Multi-layer compression bandaging kit, four layer system

**Ultra Four** (Robinson Healthcare) Reduced Compression multi-layer compression bandage kit = £4.14, multi-layer compression bandage kit 18cm-25cm ankle circumference = £5.67, up to 18cm ankle circumference = £6.41

**Two layer systems**

**Coban 2** Multi-layer compression bandaging kit, two layer system (latex-free, foam bandage and cohesive compression bandage)

**Coban 2** (3M Health Care Ltd) Lite multi-layer compression bandage kit = £8.24, multi-layer compression bandage kit = £8.24

**K Two** Multi-layer compression bandaging kit, two layer system

**UrgoKTwo** (Urgo Ltd) Reduced latex free multi-layer compression bandage kit (10cm) 18cm-25cm ankle circumference = £8.68, 25cm-32cm ankle circumference = £9.48, Reduced multi-layer compression bandage kit 18cm-25cm ankle circumference = £8.18, 25cm-32cm ankle circumference = £8.93, latex free multi-layer compression bandage kit (10cm) 18cm-25cm ankle circumference = £8.68, 25cm-32cm ankle circumference = £9.48, multi-layer compression bandage kit (10cm) 18cm-25cm ankle circumference = £8.17, 25cm-32cm ankle circumference = £8.93, multi-layer compression bandage kit (12cm) 18cm-25cm ankle circumference = £10.30, 25cm-32cm ankle circumference = £11.26, multi-layer compression bandage kit size 0 short 18cm-25cm ankle circumference = £6.90, with UrgoStart multi-layer compression bandage kit 18cm-25cm ankle circumference = £10.19, 25cm-32cm ankle circumference = £10.96

**Medicated bandages**

Zinc Paste Bandage has been used with compression bandaging for the treatment of venous leg ulcers. However, paste bandages are associated with hypersensitivity reactions and should be used with caution. Zinc paste bandages are also used with coal tar or ichthammol in chronic lichenified skin conditions such as chronic eczema (ichthammol often being preferred since its action is considered to be milder). They are also used with calamine in milder eczematous skin conditions.

Downloaded from www.medicalbr.com
Zipzoc® can be used under appropriate compression bandages or hosiery in chronic venous insufficiency.

**Zinc Paste Bandage, BP 1993**
Cotton fabric, plain weave, impregnated with suitable paste containing zinc oxide; requires additional bandaging

*Excipients: may include* cetostearyl alcohol, hydroxybenzoates

**Viscopaste** (Smith & Nephew Healthcare Ltd) PB7 bandage 7.5cm × 6m= £3.69

**Zinc Paste and Ichthammol Bandage, BP 1993**
Cotton fabric, plain weave, impregnated with suitable paste containing zinc oxide and ichthammol; requires additional bandaging

*Excipients: may include* cetostearyl alcohol

**Ichthopaste** (Smith & Nephew Healthcare Ltd) bandage 7.5cm × 6m= £3.72

**Medicated stocking**

*Zipzoc*
Sterile rayon stocking impregnated with ointment containing zinc oxide 20%

*Zipzoc* (Smith & Nephew Healthcare Ltd) stockings= £31.26

**Compression hosiery and garments**

Compression (elastic) hosiery is used to treat conditions associated with chronic venous insufficiency, to prevent recurrence of thrombosis, or to reduce the risk of further venous ulceration after treatment with compression bandaging. Doppler testing to confirm arterial sufficiency is required before recommending the use of compression hosiery.

Before elastic hosiery can be dispensed, the quantity (single or pair), article (including accessories), and compression class must be specified by the prescriber. There are different compression values for graduated compression hosiery and lymphoedema garments (see table below). All dispensed elastic hosiery articles must state on the packaging that they conform with Drug Tariff technical specification No. 40, for further details see Drug Tariff.

**Graduated Compression hosiery, Class 1 Light Support** is used for superficial or early varices, varicosis during pregnancy.

**Graduated Compression hosiery, Class 2 Medium Support** is used for varices of medium severity, ulcer treatment and prophylaxis, mild oedema, varicosis during pregnancy.

**Graduated Compression hosiery, Class 3 Strong Support** is used for gross varices, post thrombotic venous insufficiency, gross oedema, ulcer treatment and prophylaxis.

**Compression values for hosiery and lymphoedema garments**

**Class 1:** Compression hosiery (British standard) 14–17 mmHg, lymphoedema garments (European classification) 18–21 mmHg; **Class 2** Compression hosiery (British standard) 18–24 mmHg, lymphoedema garments (European classification) 23–32 mmHg; **Class 3** Compression hosiery (British standard) 25–35 mmHg, lymphoedema garments (European classification) 34–46 mmHg; **Class 4** Compression hosiery (British standard)—not available, lymphoedema garments (European classification) 49–70 mmHg; **Class 4 super** Compression hosiery (British standard)—not available, lymphoedema garments (European classification) 60–90 mmHg.

**Graduated compression hosiery**

**Class 1 Light Support**
Hosiery, compression at ankle 14–17 mmHg, thigh length or below knee with knitted in heel

**Class 2 Light Support**
Hosiery, compression at ankle 14–17 mmHg, thigh length or below knee with knitted in heel

**Accessories**

**Suspender**
Suspender, for thigh stockings

Anklets

**Class 2 Medium Support**
Anklets, compression 18–24 mmHg, circular knit (standard and made-to-measure)

**Class 3 Strong Support**
Anklets, compression 18–24 mmHg, circular knit (standard and made-to-measure)

**Knee caps**

**Class 2 Medium Support**
Kneecaps, compression 18–24 mmHg, circular knit (standard and made-to-measure)

**Class 3 Strong Support**
Kneecaps, compression 18–24 mmHg, circular knit (standard and made-to-measure)

**Lymphoedema garments**

Lymphoedema compression garments are used to maintain limb shape and prevent additional fluid retention. Either flat-bed or circular knitting methods are used in the manufacture of elasticated compression garments. Seamless, circular-knitted garments (in standard sizes) can be used to prevent swelling if the lymphoedema is well controlled and if the limb is in good shape and without skin folds. Flat-knitted garments (usually made-to-measure) with a seam, provide greater rigidity and stiffness to maintain reduction of lymphoedema following treatment with compression bandages. A standard range of light, medium, or high compression garments are available, as well as low compression (12–16 mmHg) arm sleeves, made-to-measure garments up to compression 90 mmHg, and accessories—see Drug Tariff for details. Note There are different compression values for lymphoedema garments and graduated compression hosiery, see Compression hosiery and garments above.
Dental Practitioners’ Formulary

List of Dental Preparations

The following list has been approved by the appropriate Secretaries of State, and the preparations therein may be prescribed by dental practitioners on form FP10D (GP14 in Scotland, WP10D in Wales).

Licensed sugar-free versions, where available, are preferred. Licensed alcohol-free mouthwashes, where available, are preferred.

Amoxicillin Oral Suspension, BP
Amoxicillin Oral Powder, DPF
Amoxicillin Capsules, BP
Aciclovir Tablets, BP, Aciclovir Oral Suspension, BP, Aciclovir Cream, BP
Licensed alcohol-free

Benzydamine Mouthwash, BP
Aspirin Tablets, Dispersible, BP
Artificial Saliva Gel, DPFP
Artificial Saliva Oral Spray, DPFP
Artificial Saliva Pastilles, DPFP
Artificial Saliva Protective Spray, DPFP
Artificial Saliva Substitutes as listed below (to be prescribed only for indications approved by ACBS (patients suffering from dry mouth as a result of having or, having undergone, radiotherapy or sicca syndrome):

BioXtra® Gel Mouthwash
Glandsone® Moisturising Gel
Saliveze®

Artificial Saliva Substitute Spray, DPFP
Aspirin Tablets, Dispersible, BP
Azithromycin Capsules, 250 mg, DPFP
Azithromycin Oral Suspension, 200 mg/5 mL, DPFP
Azithromycin Tablets, 250 mg, DPFP
Azithromycin Tablets, 500 mg, DPFP
Beclomethasone Pressurised Inhalation, BP, 50 micrograms/ metered inhalation, CFC-free, as: Clenil Modulate®
Benzydamine Mouthwash, BP 0.15%
Benzydamine Oromucosal Spray, BP 0.15%
Betamethasone Soluble Tablets, 500 micrograms, DPFP
Carbamazepine Tablets, BP
Cefalexin Capsules, BP
Cefalexin Oral Suspension, BP
Cefalexin Tablets, BP
Cefradine Capsules, BP
Cetirizine Oral Solution, BP, 5 mg/5 mL
Cetirizine Tablets, BP, 10 mg
Chlorhexidine Gluconate Gel, BP
Chlorhexidine Mouthwash, BP
Chlorhexidine Oral Spray, DPFP
Chlorphenamine Tablets, BP
Choline Salicylate Dental Gel, BP
Clarithromycin Oral Suspension, 125 mg/5 mL, DPFP
Clarithromycin Oral Suspension, 250 mg/5 mL, DPFP
Clarithromycin Tablets, BP
Clindamycin Capsules, BP
Co-amoxiclav Tablets, BP, 250/125 (amoxicillin 250 mg as trihydrate, clavulanic acid 125 mg as potassium salt)
Co-amoxiclav Oral Suspension, BP, 125/31 (amoxicillin 125 mg as trihydrate, clavulanic acid 31.25 mg as potassium salt)/5 mL
Co-amoxiclav Oral Suspension, BP, 250/62 (amoxicillin 250 mg as trihydrate, clavulanic acid 62.5 mg as potassium salt)/5 mL
Diazepam Oral Solution, BP, 2 mg/5 mL
Diazepam Tablets, BP
Diclofenac Sodium Tablets, Gastro-resistant, BP
Dihydrocodeine Tablets, BP, 30 mg
Doxycycline Tablets, Dispersible, BP
Doxycycline Capsules, BP, 100 mg
Doxycycline Tablets, 20 mg, DPFP
Ephedrine Nasal Drops, BP
Erythromycin Ethyl Succinate Oral Suspension, BP
Erythromycin Ethyl Succinate Tablets, BP
Erythromycin Stearate Tablets, BP
Erythromycin Tablets, Gastro-resistant, BP
Fluconazole Capsules, 50 mg, DPFP
Fluconazole Oral Suspension, 50 mg/5 mL, DPFP
Hydrocortisone Cream, BP, 1%
Hydrocortisone Oromucosal Tablets, BP
Hydrogen Peroxide Mouthwash, BP, 6%
Ibuprofen Oral Suspension, BP, sugar-free
Ibuprofen Tablets, BP
Lansoprazole Capsules, Gastro-resistant, BP
Lidocaine Ointment, BP
Lidocaine Spray 10%, DPFP
Loratadine Syrup, 5 mg/5 mL, DPFP
Loratadine Tablets, BP, 10 mg
Menthol and Eucalyptus Inhalation, BP 1980
Metronidazole Oral Suspension, BP
Metronidazole Tablets, BP
Miconazole Cream, BP
Miconazole Oromucosal Gel, BP
Miconazole and Hydrocortisone Cream, BP
Miconazole and Hydrocortisone Ointment, BP
Nystatin Oral Suspension, BP
Omeprazole Capsules, Gastro-resistant, BP
Oxytetracycline Tablets, BP
Paracetamol Oral Suspension, BP
Paracetamol Tablets, BP
Paracetamol Tablets, Soluble, BP
Phenoxybenzylpenicillin Oral Solution, BP
Phenoxybenzylpenicillin Tablets, BP
Promethazine Hydrochloride Tablets, BP
Promethazine Oral Solution, BP
Saliva Stimulating Tablets, DPFP
Sodium Chloride Mouthwash, Compound, BP
Sodium Fluoride Oral Drops, BP
Sodium Fluoride Tablets, BP
Sodium Fluoride Toothpaste 0.619%, DPFP
Sodium Fluoride Toothpaste 1.1%, DPFP
Sodium Fusidate Ointment, BP
Temazepam Tablets, BP
TMazepam Oral Solution, BP
Temazepam Tablets, BP
Tetracycline Tablets, BP

Preparations in this list which are not included in the BP or BPC are described under Details of DPF preparations.

For details of preparations that can be prescribed, see individual entries under the relevant drug monographs throughout the BNF publications.

Details of DPF preparations

Preparations on the List of Dental Preparations which are specified as DPF are described as follows in the DPF. Although brand names may occur for identification no modifications are required.

Amoxicillin Oral Powder
amoxicillin (as trihydrate) 3 g sachet
Artificial Saliva Gel
(proprietary product: Biotene Oralbalance), lactoperoxidase, lactoferrin, lysozyme, glucose oxidase, xylitol in a gel basis

Artificial Saliva Oral Spray
(proprietary product: Xerolin) consists of water, sorbitol, carmellose (carboxymethylcellulose), potassium chloride, sodium chloride, potassium phosphate, magnesium chloride, calcium chloride and other ingredients, pH neutral

Artificial Saliva Pastilles
(proprietary product: Salivix), consists of acacia, malic acid, and other ingredients

Artificial Saliva Protective Spray
(proprietary product: Aquoral) consists of oxidised glycerol triesters, silicon dioxide, flavouring agents, aspartame

Artificial Saliva Substitute Spray
(proprietary product: AS Saliva Orthana Spray) consists of mucin, methylparaben, benzalkonium chloride, EDTA, xylitol, peppermint oil, spearmint oil, mineral salts

Azithromycin Capsules
azithromycin 250 mg

Azithromycin Oral Suspension 200 mg/5 mL
azithromycin 200 mg/5 mL when reconstituted with water

Azithromycin Tablets
azithromycin 250 mg and 500 mg

Betamethasone Soluble Tablets 500 micrograms
betamethasone (as sodium phosphate) 500 micrograms

Chlorhexidine Oral Spray
(proprietary product: Corsodyl Oral Spray), chlorhexidine gluconate 0.2%

Clarithromycin Oral Suspension 125 mg/5 mL
clarithromycin 125 mg/5 mL when reconstituted with water

Clarithromycin Oral Suspension 250 mg/5 mL
clarithromycin 250 mg/5 mL when reconstituted with water

Doxycycline Tablets 20 mg
(proprietary product: Periostat), doxycycline (as hyclate) 20 mg

Fluconazole Capsules 50 mg
fluconazole 50 mg

Fluconazole Oral Suspension 50 mg/5 mL
(proprietary product: Diflucan), fluconazole 50 mg/5 mL when reconstituted with water

Lidocaine Spray 10%
(proprietary product: Xylocaine Spray), lidocaine 10% supplying 10 mg lidocaine/spray

Loratadine Syrup 5 mg/5 mL
loratadine 5 mg/5 mL

Saliva Stimulating Tablets
(proprietary product: SST), citric acid, malic acid and other ingredients in a sorbitol base

Sodium Fluoride Toothpaste 0.619%
(proprietary product: Duraphat '2800 ppm' Toothpaste), sodium fluoride 0.619%

Sodium Fluoride Toothpaste 1.1%
(proprietary product: Duraphat '5000 ppm' Toothpaste), sodium fluoride 1.1%
Nurse Prescribers’ Formulary for Community Practitioners

List of preparations approved by the Secretary of State which may be prescribed on form FP10P (form HS21(N) in Northern Ireland, form GP10(N) in Scotland, forms WP10CN and WP10PN in Wales) by Nurses for National Health Service patients.

Community practitioners who have completed the necessary training may only prescribe items appearing in the nurse prescribers’ list set out below. Community Practitioner Nurse Prescribers are recommended to prescribe generically, except where this would not be clinically appropriate or where there is no approved generic name.

Medicinal Preparations

Preparations on this list which are not included in the BP or BPC are described under Details of NPF preparations.

Almond Oil Ear Drops, BP
Arachis Oil Enema, NPF
Aspirin Tablets, Dispersible, 300 mg, BP (max. 96 tablets; max. pack size 32 tablets)
Bisacodyl Suppositories, BP (includes 5-mg and 10-mg strengths)
Bisacodyl Tablets, BP
Catheter Maintenance Solution, Sodium Chloride, NPF
Catheter Maintenance Solution, ‘Solution G’, NPF
Catheter Maintenance Solution, ‘Solution R’, NPF
Chlorhexidine Gluconate Alcoholic Solutions containing at least 0.05%
Chlorhexidine Gluconate Aqueous Solutions containing at least 0.05%
Choline Salicylate Dental Gel, BP
Clotrimazole Cream 1%, BP
Co-danthramer Capsules, NPF
Co-danthramer Capsules, Strong, NPF
Co-danthramer Oral Suspension, NPF
Co-danthramer Oral Suspension, Strong, NPF
Co-danthusate Capsules, BP
Co-danthusate Oral Suspension, NPF
Crotamiton Cream, BP
Crotamiton Lotion, BP
Dimeticone barrier creams containing at least 10%
Dimeticone Lotion, NPF
Docucate Capsules, BP
Docucate Enema, NPF
Docucate Oral Solution, BP
Docucate Oral Solution, Paediatric, BP
Econazole Cream 1%, BP
Emollients as listed below:
Aquadrate ® 10% w/w Cream
Arachis Oil, BP
Balneum ® Plus Cream
Cetramen ® Emollient Cream
Dermamist ®
Diprobase ® Cream
Diprobase ® Ointment
Doublebase
Doublebase ® Dayleve Gel
E45 ® Cream
E45 ® Itch Relief Cream
Emulsifying Ointment, BP
Eucerin ® Intensive 10% w/w Urea Treatment Cream
Eucerin ® Intensive 10% w/w Urea Treatment Lotion
Hydromol ® Cream
Hydromol ® Intensive
Hydrous Ointment, BP
Lipobase ®
Liquid and White Soft Paraffin Ointment, NPF
Neutrogena ® Norwegian Formula Dermatological Cream
Nutraplus ® Cream
Oiatum ® Cream
Oiatum ® Junior Cream
Paraffin, White Soft, BP
Paraffin, Yellow Soft, BP
Ultrabase ®
Unguentum M ®
Emollient Bath and Shower Preparations as listed below:
Aquadream, BP
Balneum ® (except pack sizes that are not to be prescribed under the NHS (see Part XVIII of the Drug Tariff, Part XI of the Northern Ireland Drug Tariff))
Balneum Plus ® Bath Oil (except pack sizes that are not to be prescribed under the NHS (see Part XVIII of the Drug Tariff, Part XI of the Northern Ireland Drug Tariff))
Cetramen ® Emollient Bath Additive
Dermal ® Bath Emollient
Doublebase ® Emollient Bath Additive
Doublebase ® Emollient Shower Gel
Doublebase ® Emollient Wash Gel
Hydromol ® Bath and Shower Emollient
Oiatum ® Emollient
Oiatum ® Gel
Oiatum ® Junior Bath Additive
Zerolatum ® Emollient Medicinal Bath Oil
Folic Acid Tablets 400 micrograms, BP
Glycerol Suppositories, BP
Ibuprofen Oral Suspension, BP (except for indications and doses that are prescription-only)
Ibuprofen Tablets, BP (except for indications and doses that are prescription-only)
Ispaghula Husk Granules, BP
Ispaghula Husk Granules, Effervescent, BP
Ispaghula Husk Oral Powder, BP
Lactulose Solution, BP
Lidocaine Ointment, BP
Lidocaine and Chlorhexidine Gel, BP
Macrogl Oral Liquid, Compound, NPF
Macrogl Oral Powder, Compound, NPF
Macrogl Oral Powder, Compound, Half-strength, NPF
Magnesium Hydroxide Mixture, BP
Magnesium Sulfate Paste, BP
Malathion aqueous lotions containing at least 0.5%
Mebendazole Oral Suspension, NPF
Mebendazole Tablets, NPF
Methylcellulose Tablets, BP
Miconazole Cream 2%, BP
Miconazole Oromucosal Gel, BP
Mouthwash Solution-tablets, NPF
Nicotine Inhalation Cartridge for Oromucosal Use, NPF
Nicotine Lozenge, NPF
Nicotine Medicated Chewing Gum, NPF
Nicotine Nasal Spray, NPF
Nicotine Oral Spray, NPF
Nicotine Sublingual Tablets, NPF
Nicotine Transdermal Patches, NPF
Nystatin Oral Suspension, BP
Paracetamol Oral Suspension, BP (includes 120 mg/5 mL and 250 mg/5 mL strengths—both of which are available as sugar-free formulations)
Paracetamol Tablets, BP (max. 96 tablets; max. pack size 32 tablets)
Paracetamol Tablets, Soluble, BP (includes 120-mg and 500-mg tablets; max. 96 tablets; max. pack size 32 tablets)
Permethrin Cream, NPF
Phosphates Enema, BP
Povidone–Iodine Solution, BP
Senna Oral Solution, NPF
Senna Tablets, BP
Senna and Ispaghula Granules, NPF
Sodium Chloride Solution, Sterile, BP
Sodium Citrate Compound Enema, NPF
Sodium Picosulfate Capsules, NPF
Sodium Picosulfate Elixir, NPF
Spermoidal contraceptives as listed below:
   Gygel® Contraceptive Jelly
Sterculia Granules, NPF
Sterculia and Frangula Granules, NPF
Titanium Ointment, BP
Water for Injections, BP
Zinc and Castor Oil Ointment, BP
Zinc Oxide and Dimeticone Spray, NPF
Zinc Oxide Impregnated Medicated Bandage, NPF
Zinc Oxide Impregnated Medicated Stocking, NPF
Zinc Paste Bandage, BP 1993
Zinc Paste and Ichthammol Bandage, BP 1993

Appliances and Reagents (including Wound Management Products)

Community Practitioner Nurse Prescribers in England, Wales and Northern Ireland can prescribe any appliance or reagent in the relevant Drug Tariff. In the Scottish Drug Tariff, Appliances and Reagents which may not be prescribed by Nurses are annotated Nx.

Appliances (including Contraceptive Devices) as listed in Part IXA of the Drug Tariff (Part III of the Northern Ireland Drug Tariff, Part 3 (Appliances) and Part 2 (Dressings) of the Scottish Drug Tariff). (Where it is not appropriate for nurse prescribers in family planning clinics to prescribe contraceptive devices using form FP10(P) (forms WP10CN and WP10PN in Wales), they may prescribe using the same system as doctors in the clinic.)

Incontinence Appliances as listed in Part IXB of the Drug Tariff (Part III of the Northern Ireland Drug Tariff, Part 5 of the Scottish Drug Tariff).

Stoma Appliances and Associated Products as listed in Part IXC of the Drug Tariff (Part III of the Northern Ireland Drug Tariff, Part 6 of the Scottish Drug Tariff).

Chemical Reagents as listed in Part IXR of the Drug Tariff (Part II of the Northern Ireland Drug Tariff, Part 9 of the Scottish Drug Tariff).

The Drug Tariffs can be accessed online at:
National Health Service Drug Tariff for England and Wales: www.ppa.org.uk/ppa/edt_intro.htm
Health and Personal Social Services for Northern Ireland Drug Tariff: www.hscbusiness.hscni.net/services/2034.htm
Scottish Drug Tariff: www.isdscotland.org/Health-topics/Prescribing-and-Medicines/Scottish-Drug-Tariff/

Details of NPF preparations

Preparations on the Nurse Prescribers’ Formulary which are not included in the BP or BPC are described as follows in the Nurse Prescribers’ Formulary. Although brand names have sometimes been included for identification purposes, it is recommended that non–proprietary names should be used for prescribing medicinal preparations in the NPF except where a non–proprietary name is not available.

Arachis Oil Enema
arachis oil 100%

Catheter Maintenance Solution, Sodium Chloride
(proprietary products: OptiFlo S; Uro-Tainer Sodium Chloride; Uriflex-S), sodium chloride 0.9%

Catheter Maintenance Solution, ‘Solution G’
(proprietary products: OptiFlo G; Uro-Tainer Suby G; Uriflex G), citric acid 3.23%, magnesium oxide 0.38%, sodium bicarbonate 0.7%, disodium edetate 0.01%

Catheter Maintenance Solution, ‘Solution R’
(proproprietary products: OptiFlo R; Uro-Tainer Solution R; Uriflex R), citric acid 6%, gluconolactone 0.6%, magnesium carbonate 2.8%, disodium edetate 0.01%

Chlorhexidine gluconate alcoholic solutions
(proprietary products: ChloralPrep; Hydrex Solution; Hydrex spray), chlorhexidine gluconate in alcoholic solution

Chlorhexidine gluconate aqueous solutions
(proproprietary product: Unisept), chlorhexidine gluconate in aqueous solution

Co-danthramer Capsules (proprietary product: Codalax), co-danthramer 5/200 mg (dantron 25 mg, poloxamer 188’ 200 mg)

Co-danthramer Capsules, Strong (proprietary product: Codalax), co-danthramer 37.5/500 mg (dantron 37.5 mg, poloxamer 188’ 500 mg)

Co-danthramer Oral Suspension (proprietary product: Codalax Forte), co-danthramer 25/200 in 5 mL (dantron 25 mg, poloxamer 188’ 200 mg/5 mL)

Co-danthrusate Oral Suspension (proprietary product: Normax), co-danthrusate 50/60 (dantron 50 mg, docusate sodium 60 mg/5 mL)

Dimeticone barrier creams
(proproprietary products Conotrane Cream, dimeticone ‘350’ 22%, Slopex Barrier Cream, dimeticone ‘1000’ 10%), dimeticone 10–22%

Dimeticone Lotion
(proproprietary product: Hedrin), dimeticone 4%

Docusate Enema
(proproprietary product: Norgalax Micro-encema), docusate sodium 120 mg in 10 g

Liquid and White Soft Paraffin Ointment
liquid paraffin 50%, white soft paraffin 50%

Macrogol Oral Liquid, Compound
(proproprietary product: Movicol Liquid), macrogol ‘3350’ (polyethylene glycol ‘3350’) 13.125 g, sodium bicarbonate 178.5 mg, sodium chloride 350.7 mg, potassium chloride 46.6 mg/25 mL

Macrogol Oral Powder, Compound
(proproprietary products: Laxido Orange, Molaxole, Movicol), macrogol ‘3350’ (polyethylene glycol ‘3350’) 13.125 g, sodium bicarbonate 178.5 mg, sodium chloride 350.7 mg, potassium chloride 46.6 mg/sachet; (amount of potassium chloride varies according to flavour of Movicol® as follows: plain-flavour (sugar-free) = 50.2 mg/sachet; lime and lemon flavour = 46.6 mg/sachet; chocolate flavour = 31.7 mg/sachet. 1 sachet when reconstituted with 125 mL water provides K+ 5.4 mmol/litre)

Macrogol Oral Powder, Compound, Half-strength
(proproprietary product: Movicol-Half), macrogol ‘3350’ (polyethylene glycol ‘3350’) 6.563 g, sodium bicarbonate 89.3 g, sodium chloride 175.4 mg, potassium chloride 23.3 mg/sachet

Melatonian aqueous lotions
(proproprietary products: Derbac-M Liquid), melatonin 0.5% in an aqueous basis

Mebendazole Oral Suspension (proprietary product: Vermox), mebendazole 100 mg/5 mL

Mebendazole Tablets (proprietary products: Ovex, Vermox), mebendazole 100 mg (can be supplied for oral use in the treatment of enterobiasis in adults and children over 2 years provided its container or package is labelled to show...
a max. single dose of 100 mg and it is supplied in a container or package containing not more than 800 mg)

**Mouthwash Solution-tablets**

consist of tablets which may contain antimicrobial, colouring and flavouring agents in a suitable soluble effervescent basis to make a mouthwash

**Nicotine Inhalation Cartridge for Oromucosal Use**

(proprietary products: NicAssist Inhalator, Nicorette Inhalator), nicotine 15 mg (for use with inhalation mouthpiece; to be prescribed as either a starter pack (6 cartridges with inhalator device and holder) or refill pack (42 cartridges with inhalator device)

**Nicotine Lozenge**

nicotine (as bitartrate) 1 mg or 2 mg (proprietary product: Nicorette Mint Lozenge, Nicotinell Mint Lozenge), or nicotine (as resinate) 1.5 mg, 2 mg, or 4 mg (proprietary product: NiQuitin Lozenges, NiQuitin Minis, NiQuitin Pre-quit)

**Nicotine Medicated Chewing Gum**

(proprietary products: NicAssist Gum, Nicorette Gum, Nicotinell Gum, NiQuitin Gum), nicotine 2 mg or 4 mg

**Nicotine Nasal Spray**

(proprietary product: NicAssist Nasal Spray, Nicorette Nasal Spray), nicotine 500 micrograms/metered spray

**Nicotine Oral Spray**

(proprietary product: Nicorette Quickmist), nicotine 1 mg/metered spray

**Nicotine Sublingual Tablets**

(proprietary product: NicAssist Microtab, Nicorette Microtab), nicotine (as a cyclodextrin complex) 2 mg (to be prescribed as either a starter pack (2 × 15-tablet discs with dispenser) or refill pack (7 × 15-tablet discs))

**Nicotine Transdermal Patches**

releasing in each 16 hours, nicotine approx. 5 mg, 10 mg, or 15 mg (proprietary products: Boots NicAssist Patch, Nicorette Patch), or releasing in each 16 hours approx. 10 mg, 15 mg, or 25 mg (proprietary products: NicAssist Translucent Patch, Nicorette Invisi Patch), or releasing in each 24 hours nicotine approx. 7 mg, 14 mg, or 21 mg (proprietary products: Nicopatch, Nicotinell TTS, NiQuitin, NiQuitin Clear)

(prescriber should specify the brand to be dispensed)

**Permethrin Cream**

(proprietary product: Lyclear Dermal Cream), permethrin 5%

**Senna Oral Solution**

(proprietary product: Senokot Syrup), sennosides 7.5 mg/5 mL

**Senna and Ispaghula Granules**

(proprietary product: Manevac Granules), senna fruit 12.4%, ispaghula 54.2%

**Sodium Citrate Compound Enema**

(proprietary products: Micolette Micro-enema; Micralax Micro-enema; Relaxit Micro-enema), sodium citrate 450 mg with glycerol, sorbitol and an anionic surfactant

**Sodium Picosulfate Capsules**

(proprietary products: Dulcolax Perles), sodium picosulfate 2.5 mg

**Sodium Picosulfate Elixir**

(proprietary product: Dulcolax Liquid), sodium picosulfate 5 mg/5 mL

**Sterculia Granules**

(proprietary product: Normacol Granules), sterculia 62%

**Sterculia and Frangula Granules**

(proprietary product: Normacol Plus Granules), sterculia 62%, frangula (standardised) 8%

**Zinc Oxide and Dimeticone Spray**

(proprietary product: Sprilon), dimeticone 1.04%, zinc oxide 12.5% in a pressurised aerosol unit

**Zinc Oxide Impregnated Medicated Bandage**

(proprietary product: Steripaste), sterile cotton bandage impregnated with paste containing zinc oxide 15%

**Zinc Oxide Impregnated Medicated Stocking**

(proprietary product: Zipzoc), sterile rayon stocking impregnated with ointment containing zinc oxide 20%
Non-medical prescribing

Overview
A range of non-medical healthcare professionals can prescribe medicines for patients as either Independent or Supplementary Prescribers.

Independent prescribers are practitioners responsible and accountable for the assessment of patients with previously undiagnosed or diagnosed conditions and for decisions about the clinical management required, including prescribing. They are recommended to prescribe generically, except where this would not be clinically appropriate or where there is no approved non-proprietary name.

Supplementary prescribing is a partnership between an independent prescriber (a doctor or a dentist) and a supplementary prescriber to implement an agreed Clinical Management Plan for an individual patient with that patient’s agreement.

Independent and Supplementary Prescribers are identified by an annotation next to their name in the relevant professional register.

Information and guidance on non-medical prescribing is available on the Department of Health website at www.dh.gov.uk/health/2012/04/prescribing-change.


For information on the supply and administration of medicines to groups of patients using Patient Group Directions see Guidance on prescribing p. 1.

Nurses
Nurse Independent Prescribers (formerly known as Extended Formulary Nurse Prescribers) are able to prescribe any medicine for any medical condition.

Nurse Independent Prescribers are able to prescribe, administer, and give directions for the administration of Schedule 2, 3, 4, and 5 Controlled Drugs. This extends to diamorphine, dipipanone, or cocaine for treating organic disease or injury, but not for treating addiction.

Nurse Independent Prescribers must work within their own level of professional competence and expertise.

The Nurse Prescribers’ Formulary p. 1484 for Community Practitioners provides information on prescribing.

Pharmacists
Pharmacist Independent Prescribers can prescribe any medicine for any medical condition.

They are also able to prescribe, administer, and give directions for the administration of Schedule 2, 3, 4, and 5 Controlled Drugs. This extends to diamorphine, dipipanone, or cocaine for treating organic disease or injury, but not for treating addiction.

Pharmacist Independent Prescribers must work within their own level of professional competence and expertise.

Optometrists
Optometrist Independent Prescribers can prescribe any licensed medicine for ocular conditions affecting the eye and the tissues surrounding the eye, except Controlled Drugs or medicines for parenteral administration. Optometrist
Index of proprietary manufacturers

The following is an alphabetical list of manufacturers and other companies referenced in the BNF, with their medicines information or general contact details. For information on ‘special-order’ manufacturers and specialist importing companies see ‘Special-order manufacturers’.

3M Health Care Ltd, Tel: (01509) 611 611
Allen & Hanburys Ltd, Tel: 0800 221 441, customercontactuk@skk.com
A1 Pharmaceuticals Plc, Tel: (01708) 528 900, sales@alplic.com
Abbott, Tel: (01628) 773 355
Abbott Healthcare Products Ltd, Tel: (01628) 773 355, medinfo.shl@abbott.com
AbbVie Ltd, Tel: (01628) 561 090, ukmedinfo@abbvie.com
Abaxis BioScience Ltd, Tel: (020) 7081 0850, abaxismedical@idisharma.com
Acuros Therapeutics Ltd, Tel: (01244) 625 152
Actavis UK Ltd, a subsidiary of Accord Healthcare Ltd, Tel: (01271) 385 267, medinfo@accord-healthcare.com
Actelion Pharmaceuticals UK Ltd, Tel: (020) 8987 3333, medinfo.uk@actelion.com
Adicin Healthcare, Tel: 0845 060 6707, adicinmedical.co.uk
Adienne Pharma and Biotech, Tel: 0039 (0) 335 873 8731
ADI Medical UK, Tel: (01628) 485159, info@adimedicall.co.uk
Advanced Medical Solutions Group Plc, Tel: (01606) 863 500
Advancis Medical Ltd, Tel: (01623) 751 500, info@advancis.co.uk
Advantech Surgical Ltd, Tel: 0845 130 5866, customerservice@newgpl.co.uk
Aegerion Pharmaceuticals Ltd, Tel: 00800 234 7466, medinfo.europe@aegerion.com
AgMaxtra Europe Ltd, Tel: (01235) 838 639, info@wavesense.co.uk
Agepha GmbH, Tel: (020) 3239 6241, uk@agepha.com
Agugtatt Ltd, Tel: (01275) 463 691, info@agugtatt.co.uk
Air Products plc, Tel: 0800 373 580
Alan Pharmaceuticals, Tel: (020) 7284 2887, info@alanpharmaceuticals.co.uk
Alcon Laboratories (UK) Ltd, Tel: 0345 266 9363, gmbmedicaldepartment@alcon.com
Alexion Pharma UK Ltd, Tel: (01932) 359 220, alexion.uk@alexion.com
Alliema Sciences Limited, Tel: 0800 019 1253, medicalinformation@alliemas.com
Allissa Healthcare, Tel: (01489) 80 759, enquiries@allissahc.com
ALK-Abelló (UK) Ltd, Tel: (0118) 903 7940, info@uk.alk-abello.com
Alkopharma Sarl, Tel: (0041) 277 206 969, regulatory@alkopharma.com
Allergan Ltd, Tel: (01628) 494 026
Allergy Therapeutics Ltd, Tel: (01903) 844 702
Alliance Pharmaceuticals Ltd, Tel: (01249) 466 966, info@alliancepharma.co.uk
Almirall Ltd, Tel: 0800 008 7399, medinfouk@almirall.com
Altacor Ltd, Tel: (01223) 421 411, info@altacor-pharma.com
Amidpharm Mercury Company Ltd, Tel: 08700 70 30 33, medicalinformation@amcolimited.com
Amen Ltd, Tel: (01223) 420 305, gbinfoline@amen.com
Abbott Medical Optics, Tel: 0800 376 7950
Amred Healthcare Ltd, Tel: (0330) 333 0079, info@amredhealthcare.co.uk
Amryt Pharma, Tel: 008000 234 7466, medinfo@amrytpharma.com
Apollo Medical Technologies Ltd, Tel: 831 201, supercheck2@btinternet.com
Archimed, Tel: 0800 756 9951, enquiries@archimed.com
Archimedes Pharma UK Ltd, Tel: (0118) 931 5094, medicalinformationuk@archimedespharma.com
Arctic Medical Ltd, Tel: (01303) 277 751, sales@arcticmedical.co.uk
Ardana Bioscience Ltd, Tel: (0121) 226 8550
ARIAD Pharma UK Ltd, Tel: 0800 0002 7423, eumedinfo@ariad.com
Ark Therapeutics Group Plc, Tel: (020) 7338 7722, info@arktherapeutics.com
Aspen, Tel: 0800 008 7392, aspenmedicalinfo@professionalinformation.co.uk
Aspen Medical Europe Ltd, Tel: (01527) 587 725, customerservice@aspenmedicaleurope.com
AS Pharma Ltd, Tel: 0870 066 4117, info@asperiapharma.co.uk
Aspíre Pharma Ltd, Tel: (01730) 231 148, info@aspirepharma.co.uk
Astellas Pharma Ltd, Tel: (020) 3379 8000, medinfo.gb@astellas.com
AstraZeneca UK Ltd, Tel: 0800 783 0033, medicalinformationuk@astrazeneca.com
Aude Mckenzie (Pharma Division) Ltd, Tel: (01895) 627 420
Auxilium, Tel: 0845 017 2315, auxilium@pilglobal.com
Axcan Pharma SA, Tel: (0033) 130 461 900
AYMES International Ltd, Tel: 0845 6805 496, info@aymes.com
Ayrton Saunders Ltd, Tel: (0151) 709 2074, info@ayrtons.com
BAP Medical UK Ltd, Tel: 0844 879 7689
Barclays, Tel: (0203) 527 888
Balsema Pharmaceuticals Ltd, Tel: (01483) 790 023, ukmedinfo@balsema.com
Bausch & Lomb UK Ltd, Tel: (01748) 828 864, medicalinformationuk@bausch.com
Baxalta UK Limited, Tel: (01635) 798 777, medinfo.emea@baxalta.com
Baxter Healthcare Ltd, Tel: (01635) 206 345, surecall@baxter.com
Bayer Healthcare Pharmaceuticals, Tel: (01635) 563 000, medicalinformation@bayer.co.uk
Bayer Healthcare Pharmaceuticals, Tel: (01635) 563 000, medicalinformation@bayer.co.uk
Bayer Healthcare Pharmaceuticals, Tel: (01635) 563 000, medicalinformation@bayer.co.uk
Bayer Healthcare Pharmaceuticals, Tel: (01635) 563 000, medicalinformation@bayer.co.uk
BBI Healthcare, Tel: (01792) 229 333, info@bbihealthcare.com
B. Braun Medical Ltd, Tel: (0114) 225 9000, info.bbmuk@bbruan.com
Beacon Pharmaceuticals Ltd, Tel: (01892) 600 930, info@beaconpharma.co.uk
Beiersdorf UK Ltd, Tel: (0121) 329 8800
Bensis Healthcare (UK) Ltd, Tel: (01748) 828 789, information@bensis-healthcare.com
BGP Products Ltd, Tel: (01707) 853 000, medinfo.shl@mylan.com
BHR Pharmaceuticals Ltd, Tel: (024) 7637 7210, info@bhr.co.uk
Bial Pharma UK Ltd, Tel: 01763 916 010, medinfo.uk@bial.com
Biogen Idec Ltd, Tel: 0800 008 7401
Biolitec Pharma Ltd, Tel: (00353) 1463 7415
BioMarin Europe Ltd, Tel: (020) 7420 8000, biofarro.com@bm.com
Biomonde, Tel: 0845 230 1810, info@biomonde.com
Biotest (UK) Ltd, Tel: (0121) 733 3393, medicinesinformation@biotestuk.com
Blackwell Supplies Ltd, Tel: (01634) 877 620
BOC Medical, Tel: 0800 111 333
Boehringer Ingelheim Ltd, Tel: (01344) 424 600, medinfo@bra.boehringer-ingelheim.com
The Boots Company PLC, Tel: (0115) 959 5165
BPC 100 Ltd, Tel: 01942 852085
Bio Products Laboratory Ltd, Tel: (020) 8957 2255, medinfo@bpl.co.uk
Brancaster Pharma Ltd, Tel: (01737) 243 407, enquiries@brancasterpharma.com
Bray Healthcare, Tel: (01367) 240 736, info@bray-healthcare.com
Bristol Laboratories Ltd, Tel: (0) 1442 200 922, info@bristol-labs.co.uk
Bristol-Myers Squibb Pharmaceuticals Ltd, Tel: (01995) 523 000, medicalinformation@bms.com
Britannia Pharmaceuticals, Tel: 0870 851 0207, enquiries@medinformation.co.uk
BSN Medical Ltd, Tel: 0845 122 3600
BTG International Ltd, Tel: (0207) 575 0000, medical.services@btgplc.com
Bullen Healthcare, Tel: 0800 269 327
Cambridge Medical Aesthetics Ltd, Tel: (01733) 326171, info@cambridgemedicalaesthetics.com
Cambridge Sensors Ltd, Tel: (01480) 482 920, sales-orders@cs-limited.co.uk
<table>
<thead>
<tr>
<th>Company Name</th>
<th>Telephone Number</th>
<th>Email Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tillomed Laboratories Ltd</td>
<td>(01480) 402 400</td>
<td><a href="mailto:info@tillomed.co.uk">info@tillomed.co.uk</a></td>
</tr>
<tr>
<td>Tillotts Pharma UK Ltd</td>
<td>01522 813 500</td>
<td><a href="mailto:ukmedinfo@tillotts.com">ukmedinfo@tillotts.com</a></td>
</tr>
<tr>
<td>TMC Pharma Services Ltd</td>
<td>(01252) 842 255</td>
<td><a href="mailto:info@tmcpharma.com">info@tmcpharma.com</a></td>
</tr>
<tr>
<td>Tobia Teff UK Ltd</td>
<td>(020) 7328 2045</td>
<td><a href="mailto:info@tobiateff.co.uk">info@tobiateff.co.uk</a></td>
</tr>
<tr>
<td>Torbet Laboratories Ltd</td>
<td>(01953) 607 856</td>
<td><a href="mailto:customerservices@cambridge-healthcare.co.uk">customerservices@cambridge-healthcare.co.uk</a></td>
</tr>
<tr>
<td>Transdermal Ltd</td>
<td>(020) 8654 2251</td>
<td><a href="mailto:info@transdermal.co.uk">info@transdermal.co.uk</a></td>
</tr>
<tr>
<td>TRB Chemedica (UK) Ltd</td>
<td>0845 330 7556</td>
<td></td>
</tr>
<tr>
<td>Typharm Ltd</td>
<td>(01603) 722 480</td>
<td><a href="mailto:customerservices@typharm.com">customerservices@typharm.com</a></td>
</tr>
<tr>
<td>UCB Pharma Ltd</td>
<td>(01753) 534 655</td>
<td><a href="mailto:medicalinformationuk@ucb.com">medicalinformationuk@ucb.com</a></td>
</tr>
<tr>
<td>Ultrapharm Ltd</td>
<td>(01491) 578 016</td>
<td></td>
</tr>
<tr>
<td>Univar Ltd</td>
<td>(01908) 362 200</td>
<td><a href="mailto:trientine@univareurope.com">trientine@univareurope.com</a></td>
</tr>
<tr>
<td>Unomedical Ltd</td>
<td>(01527) 587 700</td>
<td></td>
</tr>
<tr>
<td>Urgo Ltd</td>
<td>(01509) 502 051</td>
<td><a href="mailto:woundcare@uk.urgo.com">woundcare@uk.urgo.com</a></td>
</tr>
<tr>
<td>Vegenat c/o Archelis Ltd</td>
<td>0870 803 2484</td>
<td></td>
</tr>
<tr>
<td>Vertex Pharmaceuticals (UK) Ltd</td>
<td>0800 028 2616</td>
<td><a href="mailto:eumedicalinfo@vrtx.com">eumedicalinfo@vrtx.com</a></td>
</tr>
<tr>
<td>Vifor Pharma UK Ltd</td>
<td>(01276) 853 633</td>
<td><a href="mailto:medicalinfo.uk@viforpharma.com">medicalinfo.uk@viforpharma.com</a></td>
</tr>
<tr>
<td>Viiv Healthcare UK Ltd</td>
<td>0800221441</td>
<td></td>
</tr>
<tr>
<td>Viridian Pharma Ltd</td>
<td>(01633) 400 335</td>
<td><a href="mailto:customercontactuk@gsk.com">customercontactuk@gsk.com</a></td>
</tr>
<tr>
<td>ViroPharma Ltd</td>
<td>(020) 7572 1222</td>
<td></td>
</tr>
<tr>
<td>Vitaflo International Ltd</td>
<td>(0151) 709 9020</td>
<td><a href="mailto:vitaflo@vitaflo.co.uk">vitaflo@vitaflo.co.uk</a></td>
</tr>
<tr>
<td>Vitalograph Ltd</td>
<td>(01280) 827 110</td>
<td><a href="mailto:sales@vitalograph.co.uk">sales@vitalograph.co.uk</a></td>
</tr>
<tr>
<td>Wallace Cameron Ltd</td>
<td>(01698) 354 600</td>
<td><a href="mailto:sales@wallacecameron.com">sales@wallacecameron.com</a></td>
</tr>
<tr>
<td>Wallace Manufacturing Chemists Ltd</td>
<td>(01235) 538 700</td>
<td><a href="mailto:info@alinter.co.uk">info@alinter.co.uk</a></td>
</tr>
<tr>
<td>Warburtons</td>
<td>(01204) 513 004</td>
<td></td>
</tr>
<tr>
<td>Warner Chilcott UK Ltd</td>
<td>(01932) 824 700</td>
<td></td>
</tr>
<tr>
<td>Welsh Blood Service</td>
<td>(01443) 622 000</td>
<td><a href="mailto:donor.care@wales.nhs.uk">donor.care@wales.nhs.uk</a></td>
</tr>
<tr>
<td>Wellfoods Ltd</td>
<td>(01226) 381 712</td>
<td><a href="mailto:wellfoods@wellfoods.co.uk">wellfoods@wellfoods.co.uk</a></td>
</tr>
<tr>
<td>Williams Medical Supplies Ltd</td>
<td>(01685) 844 739</td>
<td></td>
</tr>
<tr>
<td>Wockhardt UK Ltd</td>
<td>(01978) 661 261</td>
<td></td>
</tr>
<tr>
<td>Wyeth Pharmaceuticals</td>
<td>(01628) 604 377</td>
<td><a href="mailto:eumedinfo@pfizer.com">eumedinfo@pfizer.com</a></td>
</tr>
<tr>
<td>Wynlit Laboratories</td>
<td>(07903) 370 130</td>
<td></td>
</tr>
<tr>
<td>Wyvern Medical Ltd</td>
<td>(01531) 631 105</td>
<td></td>
</tr>
<tr>
<td>Zentiva</td>
<td>(01483) 554 101</td>
<td><a href="mailto:gb-zentivamedicalinformation@sanofi.com">gb-zentivamedicalinformation@sanofi.com</a></td>
</tr>
<tr>
<td>Zeroderma Ltd</td>
<td>(01858) 525 643</td>
<td></td>
</tr>
</tbody>
</table>

*Downloaded from www.medicalbr.com*
Special-order manufacturers

Unlicensed medicines are available from ‘special-order’ manufacturers and specialist-importing companies; the MHRA maintains a register of these companies at tinyurl.com/cdsiks.

Licensed hospital manufacturing units also manufacture ‘special-order’ products as unlicensed medicines, the principal NHS units are listed below. A database (Pro-File; www.pro-file.nhs.uk) provides information on medicines manufactured in the NHS; access is restricted to NHS pharmacy staff.

The Association of Pharmaceutical Specials Manufacturers may also be able to provide further information about commercial companies (www.apsm-uk.com).

The MHRA recommends that an unlicensed medicine should only be used when a patient has special requirements that cannot be met by use of a licensed medicine.

As well as being available direct from the hospital manufacturer(s) concerned, many NHS-manufactured Specials may be bought from the Oxford Pharmacy Store, owned and operated by Oxford Health NHS Foundation Trust.

England

London

Barts and the London NHS Trust
Mr J. A. Rickard, Head of Barts Health Pharmaceuticals
Barts Health NHS Trust
The Royal London Hospital
Pathology and Pharmacy Building
80 Newark St
Whitechapel
London
E1 2ES
(020) 3246 0394 (order/enquiry)
barts.pharmaceuticals@bartshealth.nhs.uk

Guy’s and St. Thomas’ NHS Foundation Trust
Mr P. Forsey, Associate Chief Pharmacist
Guy’s and St. Thomas’ NHS Foundation Trust
Guy’s Hospital
Pharmacy Department
Great Maze Pond
London
SE1 9RT
(020) 7188 4992 (order)
(020) 7188 5003 (enquiry)
Fax: (020) 7188 5013
paulforsey@gstt.nhs.uk

Moorfields Pharmaceuticals
Mr. T. Record, Technical Director
Moorfields Pharmaceuticals
25 Provost St
London
N1 7NH
(020) 7684 9090 (order/enquiry)
Fax: (020) 7502 2332

London North West Healthcare NHS Trust
Mr. K. Wong
London North West Healthcare NHS Trust
Northwick Park Hospital
Watford Rd
Harrow
Middlesex
HA1 3UJ
(020) 8869 2295 (order)
(020) 8869 2204/2223 (enquiry)
kwong@nhs.net

Royal Free Hampstead NHS Trust
Ms C. Trehane, Production Manager
Royal Free Hampstead NHS Trust
Pond St
London
NW3 2QG
(020) 7830 2424 (order)
(020) 7830 2282 (enquiry)
Fax: (020) 7794 1875
christine.trehane@nhs.net

St George’s Healthcare NHS Trust
Mr. V. Kumar, Assistant Chief Pharmacist
St George’s Hospital
Technical Services
Blackshaw Rd
Tooting
London
SW17 0QT
(020) 8725 1770/1768
Fax: (020) 8725 3947
vinodh.kumar@stgeorges.nhs.uk

University College Hospital NHS Foundation Trust
Mr T. Murphy, Production Manager
University College Hospital
235 Euston Rd
London
NW1 2BU
(020) 7380 9723 (order)
(020) 7380 9726
tony.murphy@uclh.nhs.uk

Midlands and Eastern

Barking, Havering and Redbridge University Trust
Mr N. Fisher, Senior Principal Pharmacist
Queen’s Hospital
Pharmacy Department
Romford
Essex
RM7 0AG
(01708) 435 463 (order)
(01708) 435 042 (enquiry)
neil.fisher@bbrhospitals.nhs.uk

Burton Hospitals NHS Foundation Trust
Mr. D. Raynor, Head of Pharmacy Manufacturing Unit
Burton Hospitals NHS Foundation Trust
Pharmacy Manufacturing Unit
Belvedere Rd
Burton-on-Trent
DE13 0RB
(01283) 511 511 ext: 5275 (order/enquiry)
Fax: (01283) 593 036
david.raynor@burtonft.nhs.uk

Colchester Hospital University NHS Foundation Trust
Mr. S. Pullen, Pharmacy Production Manager
Colchester General Hospital
Main Pharmacy
Turner Rd
Colchester
Essex
CO4 5JL
(01206) 742 007 (order)
(01206) 744 208 (enquiry)
Fax: (01206) 841 249
pharmacy.stores@colchesterhospital.nhs.uk
(01206) psu.enquiries@colchesterhospital.nhs.uk
(enquiry)

Ipswich Hospital NHS Trust
Dr. J. Harwood, Production Manager
Ipswich Hospital NHS Trust
Pharmacy Manufacturing Unit
Health Rd
Ipswich
IP4 5PD
(01473) 703 440 (order)
(01473) 703 603 (enquiry)
Fax: (01473) 703 609
john.harwood@ipswichhospital.nhs.uk

Nottingham University Hospitals NHS Trust
Mr. I. Graham, Senior Pharmacist, Production Nottingham University Hospitals NHS Trust
Pharmacy Production Unit
Queens Medical Centre Campus
Nottingham
NG7 2UH
(0115) 924 9924 ext: 66521 (enquiry/order)
Fax: (0115) 970 9780
jeff.graham@nuh.nhs.uk

University Hospital of North Staffordshire NHS Trust
Ms K. Ferguson, Chief Technician
University Hospital of North Staffordshire NHS Trust
Pharmacy Technical Services
City General Site
Stoke-on-Trent
ST4 6SG
(01782) 674 568 (order)
(01782) 674 568 (enquiry)
Fax: (01782) 674 575
caroline.ferguson@uhns.nhs.uk

North East

The Newcastle upon Tyne Hospitals NHS Foundation Trust
Mr Y. Hunter-Blair, Production Manager
Royal Victoria Infirmary
Newcastle Specials
Pharmacy Production Unit
Queen Victoria Rd
Newcastle-upon-Tyne
NE1 4LP
(0191) 282 0395 (order)
(0191) 282 0389 (enquiry)
Fax: (0191) 282 0469
yan.hunter-blair@nuth.nhs.uk

Special-order manufacturers
North West
Preston Pharmaceuticals
Ms A. Bolch, Deputy Chief Pharmacist (PMU)
Preston Pharmaceuticals
Royal Preston Hospital
Fulwood
Preston
PR2 9HT
(01772) 523 617 (order)
(01772) 522 593 (enquiry)
Fax: (01772) 523 645
angela.bolch@lthtr.nhs.uk

Stockport Pharmaceuticals
Mr A. Singleton, Head of Production
Stepping Hill Hospital
Stockport NHS Foundation Trust
Stockport Pharmaceuticals
Stockport
SK2 7JE
(0161) 419 5666 (order)
(0161) 419 5657 (enquiry)
Fax: (0161) 419 5426
andrew.singleton@stockport.nhs.uk

South
Portsmouth Hospitals NHS Trust
Mr R. Lucas, Product Development Manager
Portsmouth Hospitals NHS Trust
Pharmacy Manufacturing Unit
Unit D2, Railway Triangle Industrial Estate
Walton Road
Farlington
Portsmouth
PO6 1TF
(02392) 389 078 (order)
(02392) 316 312 (enquiry)
Fax: (02392) 316 316
robert.lucas@porthosp.nhs.uk

South East
East Sussex Healthcare NHS Trust
Mr P. Keen, Business Manager
Eastbourne District General Hospital
East Sussex Hospitals NHS Trust
Eastbourne Pharmaceuticals
Kings Drive
Eastbourne
BN21 2UD
(01323) 414 906 (order)
(01323) 417 400 ext: 3076 (enquiry)
Fax: (01323) 414 931
paul.keen@esht.nhs.uk

South West
Torbay Pharmaceuticals
Ms J. Bamby, Pharmacy Manufacturing Services Manager
South Devon Healthcare NHS Foundation Trust
Torbay Pharmaceuticals
Kemmings Close, Long Rd
Paignton
TQ4 7TW
(01803) 664 707
Fax: (01803) 664 354
jane.bamby@nhs.net

Yorkshire
Calderdale and Huddersfield NHS Foundation Trust
Dr B. Grewal, Managing Director
Calderdale and Huddersfield NHS Foundation Trust
Huddersfield Pharmacy Specials
Gate 2 - Acre Mills, School St West
Huddersfield
HD3 3ET
(01484) 355 388 (order/enquiry)
info.hps@cht.nhs.uk

Northern Ireland
Victoria Pharmaceuticals
Mr S. Cameron, Production Manager - Pharmacy
Victoria Pharmaceuticals
Royal Hospitals
Plenum Building
Grosvenor Road
Belfast
BT12 6BA
(028) 9063 0070 (order/enquiry)
Fax: (028) 9063 5282 (order/enquiry)
samuel.cameron@belfasttrust.hscni.net

Scotland
NHS Greater Glasgow and Clyde
Ms K. Pollock, Acting Production Manager
Pharmacy Production Unit
University Place
Glasgow
G12 8TA
(0141) 451 5820 (order)
(0141) 451 5822 (enquiry)
Fax: (0141) 334 9137
pharmacyproductionunit@ggc.scot.nhs.uk

Tayside Pharmaceuticals
Mr S. Bath, Production Manager
Ninewells Hospital
Tayside Pharmaceuticals
Dundee
DD1 9SY
(01382) 632 052 (order)
(01382) 632 273 (enquiry)
Fax: (01382) 632 060
sbath@nhs.net

Wales
Cardiff and Vale University Health Board
Mr P. Spark, Principal Pharmacist (Production)
Cardiff and Vale University Health Board
20 Fieldway
Cardiff
CF14 4HY
(029) 2074 8120
Fax: (029) 2074 8130
paul.spark@wales.nhs.uk
A2A Spacer, 265
Abacavir, 610
  ▶ With dolutegravir and lamivudine, 611
  ▶ With lamivudine, 611
  ▶ With lamivudine and zidovudine, 611
Abasaglar preparations, 672
Abatacept, 1007
Abciximab, 203
Abelcet, 562
Abilify preparations, 377
Abiraterone acetate, 873
Able Spacer, 265
Abraxane, 856
Absence seizures, 294
Absopad, 1459
Absorbent cotton products, 1473
Absorbent dressings, 1459
Absorbent Lin, 1473
Abstral, 437
Abtard, 443
Acamprosate calcium, 469, 471
Acarbbose, 651
Acocif, 943
Acocol, 259
Accrete D5, 994
Accupro, 167
Accuretic, 168
Acoza, 1128
Acebutolol, 146
Aceclofenac, 1030
Acemetacin, 1030
Acenocoumarol, 134
Acetaminophen, see Paracetamol
Acetazolamide, 1080
Acetylcysteine chloride, 1074
Acetylcysteine-release enhancers, 1023
Acetylsalicylase inhibitors and memantine, 288
Acetylecysteine
  ▶ Eye, 1065
  ▶ Paracetamol toxicity, 1251, 1260
Acetylsalicylic Acid, see Aspirin
Aciclovir
  ▶ Viral eye infection, 1073
  ▶ Viral infection, 599
  ▶ Viral skin infection, 1135
Aciclovir preparations, 68
Acipimox, 194
Acitretin, 1156
Aclasta, 689
Acclidinium bromide, 238
  ▶ With formoterol, 238
Acronym MRT, 535
Acne, 1162
Acenecide, 1164
Acondro, 752
Acravin, 267
Acetarsol HCT, 174
Actico, 1480
Acticoat products, 1470
Actidose-Aqua Advance, 1256
Acti-Fast, 1477
ActiFormCool, 1460
Actikerall, 1178
Actilite, 1469
Actylse preparations, 211
Actiq, 438
Actisorb Silver 220, 1471
ActiV.A.C., 171
Activated dimeticone, see Simeticone
Active, 676
Active elimination techniques, 1250
Active immunity, 1190
ActivHeal preparations, 1460, 1465
Actixon, 1469
Acti-Wrap, 1476
Actonel preparations, 687
Actos, 668
Actrapid preparations, 673
Acular, 1077
Acumor XL, 289
Acute alcohol withdrawal, 468
Acute angle-closure glaucoma, 1078
Acute gout, 1019
Acute coronary syndromes, 206
  ▶ Initial management, 207
  ▶ Long-term management, 207
  ▶ STEMI, 207
  ▶ NSTEMI, 206
  ▶ Unstable angina, 206
Acute diarrhoea, 64
Acute erythematous candidiasis, 1115
Acute otitis media, 1093
Acute porphyrias, 969
Acute urinary retention, 736
Acyclovir, see Aciclovir
Adalat preparations, 158
Adalimumab, 1008
Adapalene, 1165
  ▶ With benzoyl peroxide, 1166
Adapatic Touch, 1464
Adartrel, 405
Adasuve, 370
Adcal preparations, 958, 994
Adcetris, 810
Adcirca, 768
Add Ins, 1450
Additrace, 985
Adefovir dipivoxil, 589
Adempas, 181
Adenocor, 105
Adenoscan, 105
Adenosine, 104
Adenuric, 1022
Adepend, 473
Adhesive bandages, 1479
Adipine preparations, 158
Adizem preparations, 153
Adjunct dressings and appliances, 1472
Adiport, 794
Adipor products, 1459, 1462
Adrenaline/epinephrine
  ▶ CPR and Anaphylaxis, 216
  ▶ Priapism, 771
  ▶ With articaine hydrochloride, 1238
  ▶ With bupivacaine, see Bupivacaine with adrenaline
  ▶ With lidocaine, see Lidocaine with adrenaline
Adrenal insufficiency, 30
Adrenergic neurone blocking drugs, 138
Adrenoceptor agonists
  (sympathomimetics), 233
Adrenocortical function testing, 700
Adsorbents and bulk-forming drugs, 64
ADVadraw products, 1468
Advagraf, 794
Advanced wound dressings, 1460
Advasil Conform, 1472
Advate, 109
Advacor preparations, 1463, 1466
Adverse reactions to drugs, 12
Adverse reactions to medical devices, 13
Advocate Redi-Code+, 676
AeroChamber Plus, 265
AErrane, 1222
Afatinib, 892
Afinitor, 901
Aflibercept
  ▶ Malignancy, 921
  ▶ Eye, 1087
Aglalsidase alfa, 972
Aglalsidase beta, 972
Aggrastat, 204
Agomelatine, 344
Agrippal, 1213
Aidulan, 753
Aindem, 742
AirFluSal Forspiro, 255
Airomir preparations, 246
AirSalb, 246
Airways disease, use of corticosteroids, 248
AirZone, 264
Aizena, 759
Akomem, 535
Akomemycin Plus, 1168
Akyzene, 416
Alateris, 1001
Albendazole, 571
Albiglutide, 657
Albumin solution, 960
Albunorm, 960
Alburex, 960
Albustix, 680
Albuterol, see Salbutamol
Alclometasone dipropionate, 1140
Alcohol, 460, 643, 1172, 1250
Alcohol dependence, 468
Alcohol disinfectants, 1172
Aldactide, 184
Aldactone, 196
Aldara, 1182
Alddehyde dehydrogenase inhibitors, 471
Aldesleukin, 883
Aldomet, 140
Aldosterone antagonists, 219
Aldurazyme, 975
Alemuzumab, 804
Alendronate, see Alendronic acid
Alendronic acid, 683
  ▶ With colecaciferol, 684
INDEX

1496 Alenini - Antibacterial therapy

Alenini, 752
Alenvona, 752
Alfacalcidol, 991
Alfentanil, 1232
Alfuzosin hydrochloride, 737
Alginic acid, 67
Algisite products, 1467, 1470
Algivon preparations, 1469
Alglucosidase alfa, 976
Algosteril products, 995
Alglucosidase alfa, 666
Amaryl, 666
Ambrolir, 1209
AmBisome, 562
Ambrisentan, 179
Amethocaine, see Tetracaine
Ametop, 1248
Amefbutamone hydrochloride, see Bupropion hydrochloride
Amfexa, 334
Amias, 170
Amifampridine, 1025
Amikacin, 491
Amikin, 518
Amilamont, 224
Amiloride hydrochloride, 223
> With bumetanide, 224
> With cyclophosphamide, 160
> With furosemide, see Co-amilofruse
> With hydrochlorothiazide and timolol, see Timolol with amiloride and hydrochlorothiazide
> With hydrochlorothiazide, see Co-amiloizide
Amino acid formula, 1423
Amino acids and derivatives, 48, 971, 975, 977
Aminophylline, 261
Aminosalicylates, 36, 97
Aminosalicylic acid, 552
Amiodarone hydrochloride, 102
Amisulpride, 376
Amizina, 55
Amitriptyline hydrochloride, 355
> With perphenazine, 356
Amlodipine, 150
> With hydrochlorothiazide and olmesartan, see Olmesartan with amlodipine and hydrochlorothiazide
> With olmesartan, see Olmesartan with amlodipine
> With valsartan, 151
Ammonaps, 978
Amoxicillin, 572
Amoxicillin, 490
Amoxicillin and hydrochloride, 35, 36
Amoxycillin, 1131
Amoxicillin, 518
Amoxicillin with clavulanic acid, see Co-amoxiclav
Anoxil, 519
Amoxicillin, see Amoxicillin
Amphotericin B, 561
Amphotericin B, see Amphotericin
Ampicillin, 520
> With fluocxacillin, see Co-fluampicil
Ampres, 1241
Amsacrine, 860
Anidulafungin, 55
Amyotrophic lateral sclerosis, 386
Anabact, 1128
Anabolic steroids, 723
Anaemia, iron deficiency, 930
Anaemia, megaloblastic, 936
Anaemias, other, 922
Anaesthetics, general
> Intravenous anaesthetics, 1220
> Volatile liquid anaesthetics, 1221
Anagrelide, 945
Anakinra, 1004
Anal fissure, 89
Analgesics, 420
> Analgesics, non-opioid, 422, 451
> Compound analgesic preparations, 421
> Dental and orofacial pain, 420
> Dysmenorrhea, 420
> Opioid analgesics, 421
> Postoperative analgesia, 422
Anamix preparations, 1447
Anaphylaxis, 30, 266
Anastrozole, 880
Ancylostoma, 568
Androcur, 726
Androgenetic alopecia, 1170
Androgens, 723, 724
Anectine, 1227
Anethol with borneol, camphene, cineole, fenchone and pinene, 743
Angeliq, 717
Angina, 141
Angiotensin-converting enzyme inhibitors, 138
Angiotensin-II receptor antagonists, 139
Angioxx, 131
Angitil preparations, 154
Angular cheilitis, 1115, 1126
Anhydrol, 1160
Anidulafungin, 560
Anogenital warts, 1179
Anoro Ellipta, 241
Anquil, 363
Antacids, 67
Antazoline with xylometazoline, 1059
Anterior pituitary hormones, 700
Anterior uveitis, 1064
Anthelmintics, 571, 1169
Anticholinergic drugs, see Anticholinergic agents, peripherally acting, 177
Antianginal drugs, 202
Antiarhythmics
> Antiarhythmics, class I a, 99
> Antiarhythmics, class I b, 100
> Antiarhythmics, class I c, 100
> Antiarhythmics, class III, 102
> Antiarhythmics, other, 104
Antibacterial drugs, 490
> Aminoglycosides, 490
> Carbapenems, 494
> Cephalosporins, 496,
> Glycopeptide, 504
> Lincosamides, 506
> Macrolides, 507
> Monobactams, 511
> Nitroimidazole derivatives, 512
> Penicillins, 514
> Polymyxins, 525
> Quinolones, 526
> Sulfonamides, 531
> Tetracyclines and related drugs, 533
Antibacterials, principles of therapy, 479
Antibacterials, prophylaxis for procedures, 481
Antibacterial therapy
> Animal and human bites, 489
> Bacterial vaginosis, 486
> Biliary-tract infection, 486

downloaded from www.medicalbr.com
Urinary-tract infections,
▶ Otitis media,
Throat infections,
▶ Pneumonia,
Osteomyelitis,
Suicidal behaviour and antidepressant
Shigellosis,
▶ Haemophilus in
▶ Erysipelas,
▶ Gastric-entitis,
▶ Gingivitis: acute necrotising
溃疡率, 1114
▶ Gonorrhea: uncomplicated, 487
Impetigo: small areas of skin infected, 489
Haemophilus influenzae epiglotitis,
▶ Mastitis during breast-feeding, 490
Meningitis caused by Listeria, 485
Osteomyelitis, 487
Otis externa, 485
Otis media, 486
Pelvic inflammatory disease, 487
Periapical or periodontal abscess, 1114
Pericoronitis, 1114
Periodontitis, 1114
Peritonitis, 486
Pneumonia, 489
Prosthetic valve endocarditis caused by staphylococci, 484
Purulent conjunctivitis, 486
Salmonea (non-typoid), 486
Septicaemia, 484
Septic arthritis, 487
Shigellosis, 486
Sinusitis, 487
Syphilis, 487
Throat infections, 1114
Typhoid fever, 486
Urinary-tract infections, 556
Anticoagulants
▶ Oral, 114
▶ Parenteral, 115
Antidepressant drugs, 342
▶ Anxiety disorders and obsessive-compulsive disorder, 343
▶ Hyponatraemia and antidepressant therapy, 342
▶ Serotonin syndrome, 342
▶ Suicidal behaviour and antidepressant therapy, 342
Antidiabetic drugs, 647
Antidiarrhoeal drugs, 64, 94
Antidiuretic hormone disorders, 627
Anti-d (RhD) immunoglobulin, 1185
Antiemetics and anti-nauseants, 450
▶ Antihistamines, 409
▶ Cannabinoids, 410
▶ Dopamine receptor antagonists, 410
▶ Neurokinin receptor antagonists, 412
▶ Serotonin (5HT3) receptor antagonists, 413
Antiepileptic drugs, 295
Antiepileptic hypersensitivity syndrome, 293
Antifibrinolytic drugs and haemostatics, 107
Antifibrinotics, 285
Antifoaming drugs, 70
Antifungals, systemic use, 558
▶ Aspergillosis, 558
▶ Candidiasis, 558
▶ Cryptococcosis, 558
▶ Histoplasmosis, 558
▶ Skin and nail infections, 559
Antigiardias, 573
Antihistamines, allergen immunotherapy and allergic emergencies, 265
▶ Allergen immunotherapy, 266
▶ Anaphylaxis, 266
Antihypertensive drugs, 137
Antimalarials, 574
▶ Artemether with lumefantrine, 574
▶ Chloroquine, 574
▶ Mefloquine, 574
▶ Piperaquine with arteminol, 574
▶ Primaquine, 574
▶ Proguanil, 574
▶ Pyrimethamine, 574
▶ Quinine, 574
▶ Tetracyclines, 574
Antimetabolites, 827
Antimicrobial dressings, 1468
Antimotility drugs, 47, 64
Antimuscarinics, 732
▶ Bronchodilators, 238
▶ In parkinsonism, 391
▶ Urinary, 732
Antimuscarinics (systemic), 732
Antineoplastic drugs
▶ Alkylating agents, 828
▶ Anthracyclines and related drugs, 835
▶ Anti-androgens, 873
▶ Antifibrinotics, 918
▶ Antimetabolites, 838
▶ Anti-oestrogens, 878
▶ Cytotoxic antibiotics and related substances, 849
▶ Plant alkaloids, 851
▶ Platinum compounds, 851
▶ Podophyllotoxin derivatives, 853
▶ Proteasome inhibitors, 889
▶ Protein kinase inhibitors, 892
▶ Taxanes, 853
▶ Topoisomerase I inhibitors, 856
▶ Vinca alkaloids, 858
Anti-oestrogens, 723
Antiprotocoal drugs, 572
Antipruritics, 1161
Antipsychotic depot injections, 366
Antipsychotic drugs, 366
Antisecretory drugs, 47, 94
Antiseptic mouthwashes, 1111
Antiseptics and disinfectants, 1172
Antithymocyte immunoglobulin (rabbit), 786
Antithyroid drugs, 726
Antituberculosis drugs, 549
Antivaccella-zoster Immunoglobulin, see Varicella-zoster immunoglobulin
Antivirals, 1158
Anisul-He, 90
Anxiety, 325
Anxiolytics, 460
Apremilast, 121
Apixaban, 121
Apo-preparations, 399
Apomorphine hydrochloride, 398
Apraclonidine, 1086
Apremilast, 1018
Aprepitant, 412
Apresoline, 176
Aprinox, 161
Aprokan, 1070
Aprovel preparations, 171
Artivis, 622
Aquadrate, 1125
Aquaflo, 1460
Aquaform Hydrogel, 1460
Aquamax, 1121, 1123
Aquanol, 1123
AquaSothe, 1161
Arachis oil, 58
▶ With chlorobutanol, 1098
▶ With extract of coal tar, see Extract of coal tar with arachis oil
Aragam, 1187
Aranesp preparations, 925
Arava, 1002
Arcocix, 1038
Argatroban monohydrate, 116, 130
Aricept preparations, 288
Arinindex, 880
Ariniprazole, 376
Aristra, 123
Arjuna, 1098, 1162
Arjever, 417
Aromasin, 881
Aromatic inhalations, 282
Arrhythmias, 32, 96, 142, 962
▶ Arrhythmias after myocardial infarction, 98
▶ Atrial fibrillation, 96
▶ Atrial flutter, 97
▶ Cardioversion, 96
▶ Ecotopic beats, 96
▶ Paroxysmal atrial fibrillation, 97
▶ Paroxysmal supraventricular tachycardia, 97
▶ Stroke prevention, 97
▶ Supraventricular and ventricular arrhythmias, 98
▶ Supraventricular arrhythmias, 98
▶ Torsade de pointes, 98
▶ Ventricular arrhythmias, 99
▶ Ventricular tachycardia, 98
Arsenic trioxide, 861
Artelac preparations, 1066
Artemether with lumefantrine, 574, 581
Arteminol with piperaquine phosphate, 581
Arthritis, 998
Arthrotec, 1037
Articaine hydrochloride with adrenaline, see Adrenaline with articaine hydrochloride
Artificial saliva products, 1106
Artificial tears, 1066
Arythmol, 102
Arzerra, 816
Asacol preparations, 41
Ascariasis (common roundworm infections), 570
downloaded from www.medicalbr.com
With betamethasone, see Betamethasone with clotrimazole
Clozapine, 377
Clozaril, 378
Cluster headache and the trigeminal autonomic cephalalgias, 450
Coagulation factor deficiencies, 108
Coal tar, 1152
With arachis oil extract of coal tar, cade oil, light liquid paraffin and tar, 1152
With calamine, 1153
With coconut oil and salicylic acid, 1153
With dithranol and salicylic acid, 1153
With lecithin, 1153
With salicylic acid, 1153
With salicylic acid and precipitated sulfur, 1154
With zinc oxide, 1154
Co-amilofruse, 220
Co-amilozide, 161
Co-amoxiclav, 521
Cobalin, 939
Coban products, 1479
Co-bendeldopa, 394
Cobicistat, 622
With elvitegravir, emtricitabine and tenofovir, see Elvitegravir with cobicistat, emtricitabine and tenofovir disoproxil
Cobimetinib, 895
Cocaine, 1254
Co-careldopa, 396
Coelcomfort and Gault, 20
Co-codamol, 430
Cocois, 1154
Co-cyprindiol, 1163
Co-danthramer, 60
Co-danthrusate, 60
Codaine phosphate, 431
With buclizine hydrochloride and paracetamol, see Paracetamol with buclizine hydrochloride and codeine phosphate
With paracetamol, see Co-codamol
With aspirin, see Aspirin with codeine
Codipar, 431
Codis, 425
Co-dydramol, 433
Coeliac disease, 35, 986
Co-fluampicil, 520
Co-flumacetone, 184
Cohesive bandages, 1479
Colazide, 39
Colchicine, 1020
Colecalciferol, 992
With alendronic acid, see Alendronic acid with colecalciferol
With calcium carbonate, 993
With calcium carbonate and risendronate, see Risedronate with calcium carbonate and colecalciferol
With calcium phosphate, 994
Colesevamel hydrochloride, 190
Colestid, 190
Colestipol hydrochloride, 190
Colestyramine, 47, 191
Colgate preparations, 1110
Colief, 1440
ColiFin, 526
Colifoam, 638
Colistimethate sodium, 525
Colistin sulmethate sodium, see Colistimethate sodium
Colobreathe, 526
Collagenase, 1056
Colloidon with castor oil and coloholony, see Castor oil with colloidon and coloholony
Colofac preparations, 85
Colomycin, 526
Colpermin, 46
Co-magaldrox, 68
Combigan, 1087
Combined hormonal contraceptives, 745, 749
Interactions, 748
Combivent, 240
Combivir, 618
Combodart, 740
Cometrig, 894
Comfeel preparations, 1465
Comfigrip products, 1477
Comifast products, 1477
Compact, 676
Competact, 668
Complan Shake, 1430
Complementary and alternative medicine, 2
Compression bandages, 1479
Compression hosiery and garments, 1481
Comprilan products, 1480
Comtess, 392
Concerta XL, 333
Condyline, 1180
Conestat alfa, 279
Confusion and restlessness, 26
Congenital abnormalities, 13
Congescor, 148
Conjugated oestrogens (equine), 710
Conjugated oestrogens with bazedoxifene acetate, 711
Conjugated oestrogens with medroxyprogesterone, 717
Conotrate, 1119
Conscious sedation for clinical procedures, 1234
Consion XL, 289
Constella, 47
Constipation, 24, 51
Bowel cleansing preparations, 52
Children, 52
Faecal impaction, 52
Pregnancy and breast-feeding, 52
Contact lenses and drug treatment, 1058
Contiflo XL, 740
Continuous subcutaneous insulin infusion (insulin pump), 644
Contour, 676
Contour Next, 676
Contour TS, 676
Contraception, 745
Combined, 749
Devices, 749, 756
Emergency, 757
Hormonal, 745
Interactions, 747
Oral progestogen-only, 758
Parenteral progestogen-only, 762
Spermicidal, 764
Controlled drugs and drug dependence, 8
Conversion of units, 1536
Convules, 338
Convulsive status epilepticus, 296
Coolie, 1460
Copaxone, 801
Capegus, 594
Co-phenotrope, 64
Coracten preparations, 159
Cordarone X, 103
Corgard, 144
Corfottolipin alfa, 702
Coronary artery disease, 32
Corsodyl preparations, 1108
Corticosteroid combinations with anti-infectives, 1063, 1096, 1147
Corticosteroid-induced osteoporosis, 682
Corticosteroid responsive conditions, 631
Corticosteroids and other immunosuppressants, 785
Corticosteroids, general use, 631
Glucocorticoid side effects, 632
Managing side-effects, 632
Mineralocorticoid side effects, 632
Side-effects, 632
Corticosteroids, inflammatory disorders, 1053
Local corticosteroid injections, 1053
Systemic corticosteroids, 1053
Corticosteroids (inhaled), 249
Corticosteroids (intranasal), 1102
Corticosteroids, replacement therapy, 632
Corticosteroids (systemic), 633
Corticosteroids (topical), 1140
Corticotrophins, 700
Cortiment, 44
Cosentyx, 1005
Co-simalcette, 68
Cositam XL, 740
Cosmofa, 932
Cosmopor preparations, 1459
Cosopt, 1082
Cotellic, 896
Co-tenidone, 148
Co-triamterzide, 225
Co-trimoxazole, 531
Cotton Stockinette preparations, 1478
Cough and congestion, 282
Coumarins and phenindione, 114
Coverflex products, 1477
Covermark preparations, 1176, 1420, 1491
Coversyl preparations, 166
Cozaar preparations, 171
Co-zidocapt, 163
Crab lice, 1127
Creon, 94
Crepe products, 1478
Crescomb, 564
Crestor, 198
Crinone, 722
Crisantasapase, 862
Crixivan, 620
Crizotinib, 896
Crohn’s disease, 36
Fistulating Crohn’s disease, 37
Cromoglicate and related therapy, 259
Cromolyn, 1060
Crotamiton, 1161
Croup, 235
Cryptococcosis, 558
Crystacide, 1175
CS products, 1474
CS Spray, 1255
Cubicin, 538
Cuplex, 1182
Cuprelon preparations, 1049
Curasept, 1108
Curatoderm, 1159
Carea products, 1460
Cushing's Syndrome, 641
Cuticell, 1458
Cutimed preparations, 1460, 1463, 1466, 1471
Cutina products, 1464
Cutiplast Sterilproducts, 1459
Cutisorb products, 1460
Cyclizine, 442
Cyclimorph, 434
Cyclizine, 409
Cyclophosphamide, 830
Cycloplegics, 1073
 Cyclo- Progynova, 720
Cycloserine, 553
Cyclosporin, see Ciclosporin
Cyclokapron, 108
Cymbalta, 351
Cymevene, 603
Cyprophosphate hydrochloride, 273
Cyprostat, 726
Cyproterone acetate, 723, 725
Cyproterone acetate, see Amiloride with cyclophosphamide
Cyclophosphamide hydrochloride, 1065
 Cyclophosphamide, see Calcitriol
Dabigatran etexilate, 591
Dacarbazine, 831
Dacarbazine, 835
Dacarbazin, 125
Dacenberg, 938
Dacine, 635
Dacron, 938
Darmorubicin, 835
Dapsone, 545
Dapoxetine, 773
Dapson, 545
Daptomycin, 537
Daxas, 835
Dbuks, 261
Danofloxacin, 752
Dapagliflozin, 662
Dapoxetine, 663
Darbeprido, 924
Darifenacin, 732
Dariparinux, 676
Daritox, 676
Darunavir, 619
Danazol, 1131
Dasatinib, 898
Daotrix, 841
Ddeferoxamine mesilate, 619
Dexitrem, 898
Davonex, 835
Dexamethasone, 752
Decapetyl SR, 699
Decitabine, 841
Deferasirox, 939
Deferiprone, 940
Deferoxamine Mesilate, 827
Deflazocort, 635
Degarelix, 875
Delamanid, 533
Delmosart, 333
Deltocortril Enteric, 640
Deltosterol, 640, 1054
Deltodyne, 554
Demeclocycline hydrochloride, 533
Dementia, 287
Demulcent and expectorant cough preparations, 283
Denel, 1244
Denosumab, 691
Denosumab, 1170
Dental anaesthesia, 1237
Dental and orofacial pain, 30, 420, 1029
Dental caries, 1109
Dental practice (prescribing), 30
Dental Practitioners' Formulary, 1482
Dentinox preparations, 70
Denver stomatitis, 1115
Denzapine, 378
Depakote, 338
Depexyl, 352
Depirol preparations, 368, 374
Depocyst, 841
Depontin, 213
Deprescribing, 1
Depression, 342
Dequingluon chloride, 780
Derbac-M, 1135
Dermabond preparations, 1176, 1420
Dermabol preparation, 1176
Dermacolor preparations, 1176, 1420
Dermacol, 1162
Derma-Flex, 1176
Dermauro, 1121
Dermastem, 1123
DermaSilk products, 1478
Dermatix preparations, 1472
Dermatronics Once, 1125
Dermatophytes, 1126
Dermax, 1170
Dermal preparations, 1119
Dermovate preparations, 1142
Descovy, 615
Desflurane, 941
Dexferoxamine mesilate, 941
INDEX
Desflurane, **1222**
Desitrend, 306
Desloratadine, **269**
Deslounging agents, 1172
DesmoMelt, 630
Desmopressin, **628**
Desmospray, 629
Desmotabs, 629
Desogestrel, **758**
Desogestrel with ethinylestradiol, see Ethinylestradiol with desogestrel
Desomono, 759
Desox, 759
Destrilt, 87
Desunin, **992**
Detrinorm preparations, 735
Detrusitol preparations, 735
Dexafree, 1062,
Dexamethasone
   - Eye, **1061**
   - Joints and soft tissues, **1053**
   - Systemic use, **635**
   - With ciprofloxacin, **1096**
   - With framycetin sulfate and polymyxin B sulfate, **1097**
   - With glucic acid acid and neomycin sulfate, **1097**
   - With hydrocortisone, **1060**
   - With tobramycin, **1064**
Dexamethasone sulfate, **333**
Dexamethasone, **759**
Dexil, 1235
Dexamethasone, **334**
Dexibuprofen, **1032**
Dexamethasone, **790**
Dexketoprofen, **1033**
Dexmedetomidine, **1235**
Dexrazoxane, **868**
Dexsol, 636
Dextran 70 with hypromellose, **333**
Dextran 70 with sodium chloride, **1222**
Dextrose, **955**
Dextrose Monohydrate, see Glucose
DF 118, **434**
D-Gam, **1186**
DHC Continus, **434**
Diabact UBT, **82**
Diabetes, **643**
   - During medical illness, **651**
   - HbA1c measurement, **643**
   - Management during surgery, **649**
   - Oral glucose tolerance tests, **643**
Diabetes insipidus, **627**
Diabetes mellitus, **643**
Diabetes mellitus, diagnostic and monitoring devices, **675**
   - Blood monitoring, **675**
   - Urinalysis, **675**
Diabetes, pregnancy and breast-feeding, **649**
Diabetic complications, **648**
   - Cardiovascular disease, **648**
   - Diabetic nephropathy, **649**
   - Diabetic neuropathy, **649**
Diabetic ketoacidosis, **651**
Diabion, **668**
Diafer, **932**
Diaglumet XL, **653**
Diamecine, **1437**
Diamicron preparations, **666**
Diamorphine hydrochloride, **433**
Diadox preparations, **1080**
Dianette, **1164**
Diarrhoea, **64**
   - Acute diarrhoea, **64**
   - High output stomas, **47**
Diastix, **676, 680**
Diazemuls, **329**
Diazepam, **327**
Diazoxide, **681**
Diclofenac potassium, **1033**
Diclofenac sodium
   - Actinic keratosis, **1177**
   - Eye, **1077**
   - Pain and inflammation, **1034**
   - With misoprostol, **1036**
Diclofenac preparations, **1036**
Dicobalt edetate, **1257**
Dicyclomine hydrochloride, see Dicycloverine hydrochloride
Dicyclomine hydrochloride, **82**
   - With aluminium hydroxide, **83**
Diflunisal, **612**
Dienogest with estradiol valerate, **751**
Diethylcarbamazine, **571**
Diethyl phthalate with methyl salicylate, **571**
Diethylcarbamazine
   - With dithranol and salicylic acid, **571**
   - With tobramycin, **571**
Dexamethasone, **571**
Dexedrine preparations, **334**
Dextrin, **1032**
Dexamethasone, **790**
Dexketoprofen, **1033**
Dexametamidone, **1235**
Dexrazoxane, **868**
Dexsol, 636
Dextran 70 with hypromellose, see Hypromellose with dextran 70
Dextran 70 with sodium chloride, **960**
Dextrose, **955**
Dextrose Monohydrate, see Glucose
DF 118, **434**
D-Gam, **1186**
DHC Continus, **434**
Diabact UBT, **82**
Diabetes, **643**
   - During medical illness, **651**
   - HbA1c measurement, **643**
   - Management during surgery, **649**
   - Oral glucose tolerance tests, **643**
Diabetes insipidus, **627**
Diabetes mellitus, **643**
Diabetes mellitus, diagnostic and monitoring devices, **675**
   - Blood monitoring, **675**
   - Urinalysis, **675**
Diabetes, pregnancy and breast-feeding, **649**
Diabetic complications, **648**
   - Cardiovascular disease, **648**
   - Diabetic nephropathy, **649**
   - Diabetic neuropathy, **649**
Diabetic ketoacidosis, **651**
Diabion, **668**
Diafer, **932**

**1504** Desflurane – Dopaminergic drugs used in Parkinson’s disease

BNF 74

Diphtheria with pertussis, poliomyelitis vaccine and tetanus, **1203**
Diphtheria with poliomyelitis and tetanus vaccine, **1203**
Dipipanone hydrochloride with cyclizine, **434**
Dipiruvan, **1221**
Diprobase, **1123**
Diprogesic, **1148**
Dip/Ser, see Dipherthera antitoxin
Dipyridamole, **120**
   - With aspirin, **120**
   - Disease-modifying anti-rheumatic drugs, **1001**
Disodium hydrogen carbonate with glucose, potassium chloride and sodium chloride, **956**
Disopyramide, **99**
Disprin preparations, **119**
Dissolution of blood clots, **744**
Distaclor preparations, **498**
Distantine, **1003**
Disulfiram, **469, 471**
Dithranol, **1151**
   - With salicylic acid and zinc oxide, **1152**
   - With coal tar and salicylic acid, see Coal tar with dithranol and salicylic acid
Dithrocream, **1152**
Ditropan preparations, **734**
Diumide-K Continus, **222**
Diuress, **221**
Diuretics, **218**
Diucrex, **225**
Diverticular disease and diverticulitis, **35**
Dixarit, **140**
Dobutamine, **215**
Docetaxel, **854**
DocOmega, **1449**
Docusate sodium
   - Constipation, **58**
   - Ear wax, **1098**
   - Docusate sodium with diantran, see Diantran
Docusol, **59**
Dolenio, **372**
Dolutegravir, **606**
   - With abacavir and lamivudine, see Abacavir with dolutegravir and lamivudine
Domiciliary oxygen, **236**
Dopamine, **410**
Dopamine hydrochloride, **412**
Dopamine hydrochloride, **389**
Dopamine hydrochloride, **410**
Dopamine hydrochloride, **288**
Dopacard, **187**
Dopamine hydrochloride, **181**
Dopamine-receptor agonists, **389**
Dopamine responsive conditions, **692**
Dopaminergic drugs
   - catechol-O-methyltransferase inhibitors, **392**
   - Dopamine precursors, **394**
   - Dopamine receptor agonists, **397, 692**
   - Monoamine-oxidase B inhibitors, **406**
   - Monoamine-oxidase inhibitors, **343**
   - NMDA receptor antagonists, **291, 1234**
Dopaminergic drugs used in Parkinson’s disease, **389**
Dopamine hydrochloride, 187
Doralese Tiltab, 739
Dorisin XL, 197
Dornase alfa, 280
Dorzolamide, 1081
  ⇒ With timolol, 1082
Dostinex, 401
Dosulepin hydrochloride, 357
Dothiepin hydrochloride, see Dosulepin hydrochloride

Doublebase preparations, 1121
Dovobet, 1142
Droxia, 1159
Doxadura preparations, 738
Doxapram hydrochloride, 286
Doxazosin, 738
Doxepin
  ⇒ Depressive illness, 358
  ⇒ Pruritus, 1161
Doxorubicin hydrochloride, 835
Doxorubicin, 836

Doxyccycline
  ⇒ Aphthous ulceration, 1114
  ⇒ Systemic use, 534
Drain products, 1473
Drapelone, 1119
Drawtex products, 1460
DreamSkin products, 1478
Dressfilin, 1461
Dressing packs, 1474
Dressings, see Wound management
Dressit products, 1474
Dretine, 752
Drictol, 1160
Dried prothrombin complex, 108
Drisorb, 1473
Dronedarone, 103
Droperidol, 418
Dropodex, 1062,
Drospirenone with estradiol, see Estradiol with drospirenone
Drospirenone with ethinylestradiol, see Ethinylestradiol with drospirenone

Droxia, 863

Drug allergy (suspected or confirmed), 13
Drugs acting on the renin-angiotensin system
  ⇒ ACE inhibitors, 162
  ⇒ Angiotensin II receptor antagonists, 169, 186
  ⇒ Renin inhibitors, 175
Drugs affecting gonadotrophins, 693
Dry and scaling skin disorders, 1118
Dry eye, 1065
DryMax Extra, 1460
Dry mouth, 25, 1105
Drytec saline, 954
D4T, see Stavudine
Duac, 1165
Duaktlr, 238
Duallis, 202
Duvive, 711
Ducilitia, 351
Dukoral, 1205
Dulaglutide, 657
DulcoEase, 59
Dulco-Lax preparations, 60, 62
Duloxetine, 350
Ducal preparations, 1436
DuoDERM preparations, 1465

DuoDopa, 397
Duofilm, 1182
DuoResp Spiramox, 253
DuoTrav, 1086
Dupalac, 55
Durogesic preparations, 438
Dutasteride, 723, 741
  ⇒ With tamsulosin, see Tamsulosin with dutasteride
Dyazide, 225
Dydrogesterone with estradiol, see Estradiol with dydrogesterone
Dynista, 1104
Dynastat, 1232
Dysmenorrhoea, 420
Dyspepsia, 67
Dysphagia, 25
Dyspnoea, 25
Dysport, 388
Dystonias and other involuntary movements, 386


E
EAA®, 1450
Eakin products, 1473
Ear conditions, 1093
Ear infections, bacterial, 485
Earol, 1098
Easifast products, 1477
Easifix K products, 1476
Easifix products, 1476
EasigrIP products, 1477
Easilphen, 1450
Easil-V, 1462
Easylhaier preparations, 243, 246, 250, 252
EbChek, 679
Ebesque XL, 383
Ebola, 292
Ecaltu, 560
E-Caps, 996
Ecxocolat, 1037
Echinocandin antifungals, 559
Eferol, 995
Eclampsia and pre-eclampsia, 962
Ecypele preparations, 1459, 1463
Econoc preparations, 1036
Econazole nitrate
  ⇒ Skin and nail infections, 1130
  ⇒ Vaginal and vulval candidiasis, 781
Ecopace, 163
Ecstasy, 1254
Ecotopic beats, 96
Ecuziluzumab, 930
Eczcema, 1136
Eczemol, 1123
Edarbi, 170
Edicil MR, 666
Edoxaban, 113, 122
Eldronax, 346
Edurant, 610
Efavirenz, 608
  ⇒ With emtricitabine and tenofovir disopropil, 612
  ⇒ With emtricitabine and tenofovir, see Efavirenz with emtricitabine and tenofovir disopropil
Efexor preparations, 352
Effentora, 437
Efflsomyl XL, 736
Effient, 209
Efllornithine, 1171
Efomterol fumarate, see Formoterol fumarate
Efracone, 535
Efudix, 1178
Ekirra, 238
Elantan preparations, 215
Elaprase, 975
Elbasvir with grazoprevir, 591
Eldepryl, 408
Elderly (prescribing), 28
Elisdine, 859
Elycylates, see Fluids and electrolytes
Electrolyte replacement therapy, 947
Electrolytes and minerals
  ⇒ Aluminium, 964
  ⇒ Calcium, 958, 964
  ⇒ Magnesium, 962
  ⇒ Potassium, 968
  ⇒ Sodium chloride, 953
  ⇒ Zinc, 979
Elct Superabsorber products, 1460
Element, 676
Elemental preparations, 1423
Eletiptan, 453
Elekin, 754
Ellied, 1155
Ellquis, 122
Ellunite, 752
Elluone, 758
Elluste preparations, 714, 719
Elmindo, 289
Elcon, 1146
Elcosta, 109
ElOINE, 752
Elonva, 702
Elosulfase alfa, 974
Elotuzumab, 812
Elset products, 1479
Eltrombopag, 945
Eltroxin, 729
Elvanse, 335
Elvitegravir, 607
  ⇒ With cobicistat, emtricitabine and tenofovir alafenamide, 613
  ⇒ With cobicistat, emtricitabine and tenofovir disopropil, 613
  ⇒ With cobicistat, emtricitabine and tenofovir, see Elvitegravir with cobicistat, emtricitabine and tenofovir disopropil
Emadine, 1059
Emedastine, 1059
Emepin, 1124
Emend, 413
Emerade, 218
Emergency contraception, 747
Emergency supply of medicines, 7
Emergency treatment of poisoning, 1249
  ⇒ Alcohol, 1250
  ⇒ Antidepressants, 1253
  ⇒ Antimalarials, 1253
  ⇒ Antipsychotics, 1253
  ⇒ Aspin, 1250
  ⇒ Benzodiazepines, 1253
  ⇒ Beta blockers, 1253
  ⇒ Calcium antagonists, 1254
  ⇒ Carbon monoxide, 1255
  ⇒ Cocaine, 1254
  ⇒ CS Spray, 1255

Downloaded from www.medicalbr.com
Emtricitabine, 613

With tenofovir, see Emtricitabine with tenofovir disoproxil

With cobicistat, elvitegravir and tenofovir, see Elvitegravir with cobicistat, emtricitabine and tenofovir disoproxil

With efavirenz and tenofovir, see Efavirenz with emtricitabine and tenofovir disoproxil

With rilpivirine and tenofovir alafenamide, 614

With rilpivirine and tenofovir disoproxil, 614

With rilpivirine and tenofovir, see Emtricitabine with rilpivirine and tenofovir disoproxil

With tenofovir alafenamide, 615

With tenofovir disoproxil, 615

Emtriva, 614

Emulsiderm, 1119

Emustil, 1069

Enalapril maleate, 164

With hydrochlorothiazide, 164

Enbrel, 1014

Endekay, 1110

Endosporic retrograde cholangiopancreatoscopy, 482

Endothelin receptor antagonists, 179

Energivit, 1436

Ener-G products, 1441

Enfuvirtide, 606

Enferix B, 1211

Enkaphalinase inhibitors, 64

Enopen, 1123

Enoxaparin sodium, 127

Enoximone, 186

Enshake, 1438

Enstilar, 1142

Ensure products, 1429

Entacapone, 392

With carbidopa and levodopa, see Carbidopa with entacapone and levodopa

Entecavir, 1506

Enteral nutrition, 588

Epclusa, 597

Epiderm, 874

Ergoloid, 661

Enalapril maleate, 994

With calcium lactate and calcium phosphate, 995

Ergometrine maleate, 776

With oxytocin, 777

Ergorat, 995

Ergotalkoids, 450, 452

Ergotamine tartrate, 452

With caffeine hydrate and cyclizine hydrochloride, 453

Eribulin, 862

Erivedge, 920

Erlibelle, 754

Erlotinib, 899

Ertapenem, 511

Ertapenem, 494

Erwinase, 862

Erymax, 511

Erythrocit preparations, 511

Erythrolar, 511

Erythromycin, 510

With isotretnoin, see Isotretnoin with erythromycin

With tretinoin, see Tretinoin with erythromycin

With zinc acetate, 1164

Erythromed preparations, 511

Erythropsietins, 923

Esbriet, 285

Eschar (wound), see Wound management

Esicalopram, 348

Elicarbazepine acetate, 299

Esmiror, 1229

Esmolol hydrochloride, 149

Esnyna, 758

Esomeprazole, 76

With naproxen, see Naproxen with esomeprazole

Essential thrombocythaemia, 944

Estimating renal function, 20

Estracyt, 832

Estraderm preparations

Estimating renal function, 1253

Equivalent anti-inflammatory doses of corticosteroids, 632

Equivalent doses of opioid analgesics, 24

Equivalent doses of oral antipsychotics, 366

Erbitalus, 811

Erdosteine, 280

Erdotin, 280

Epilepsy, 976

Epiduo

Epileptic and tonic seizures, 294

Driving, 294

Focal seizures with or without secondary generalisation, 294

Generalised seizures, 294

Myoclonic seizures, 295

Non-convulsive status epilepticus, 296

Pregnancy, 294

Status epilepticus, 296

Tonic-clonic seizures, 294

Epileptiform preparations, 314

Epinaistine hydrochloride, 1059

EpiPen, 218

Epirubicin hydrochloride, 836

Episenta, 314

Epithelialising wound, see Wound management

Epival CR, 314

Epivir, 616

Epolenone, 185

Epoetin alfa, 925

Epoetin beta, 927

Epoetins, 924

Epoetin zeta, 928

Epoprostenol, 112, 116

Eposin, 853

Eppinix XL, 405

E64 preparations, 1121, 1123

Eprex, 927

Eprosartan, 170

Eptacog alfa (activated), see Factor VIIa (recombinant)

Epitifibatide, 203

Equasym preparations, 333

Equivalents of corticosteroids, 632

Equivalents of opioid analgesics, 24

Equivalent doses of oral antipsychotics, 366

Erythromycin, 776

With oxytocin, 777

Ergorat, 995

Ergotalkoids, 450, 452

Ergotamine tartrate, 452

With caffeine hydrate and cyclizine hydrochloride, 453

Eribulin, 862

Erivedge, 920

Erlibelle, 754

Erlotinib, 899

Ertapenem, 494

Erwinase, 862

Erymax, 511

Erythrocit preparations, 511

Erythrolar, 511

Erythromycin, 510

With isotretnoin, see Isotretnoin with erythromycin

With tretinoin, see Tretinoin with erythromycin

With zinc acetate, 1164

Erythromed preparations, 511

Erythropsietins, 923

Esbriet, 285

Eschar (wound), see Wound management

Esicalopram, 348

Elicarbazepine acetate, 299

Esmiror, 1229

Esmolol hydrochloride, 149

Esnyna, 758

Esomeprazole, 76

With naproxen, see Naproxen with esomeprazole

Essential thrombocythaemia, 944

Estimating renal function, 20

Estracyt, 832

Estraderm preparations

Estimating renal function, 1253

Equivalent anti-inflammatory doses of corticosteroids, 632

Equivalent doses of opioid analgesics, 24

Equivalent doses of oral antipsychotics, 366

Erbitalus, 811

Erdosteine, 280

Erdotin, 280

Epilepsy, 976

Epiduo

Epileptic and tonic seizures, 294

Driving, 294

Focal seizures with or without secondary generalisation, 294

Generalised seizures, 294

Myoclonic seizures, 295

Non-convulsive status epilepticus, 296

Pregnancy, 294

Status epilepticus, 296

Tonic-clonic seizures, 294

Epileptiform preparations, 314

Epinaistine hydrochloride, 1059

EpiPen, 218

Epirubicin hydrochloride, 836

Episenta, 314

Epithelialising wound, see Wound management

Epival CR, 314

Epivir, 616

Epolenone, 185

Epoetin alfa, 925

Epoetin beta, 927

Epoetins, 924

Epoetin zeta, 928

Epoprostenol, 112, 116

Eposin, 853

Eppinix XL, 405

E64 preparations, 1121, 1123

Eprex, 927

Eprosartan, 170

Eptacog alfa (activated), see Factor VIIa (recombinant)

Epitifibatide, 203

Equasym preparations, 333

Equivalent anti-inflammatory doses of corticosteroids, 632

Equivalent doses of opioid analgesics, 24

Equivalent doses of oral antipsychotics, 366

Erbitalus, 811

Erdosteine, 280

Erdotin, 280

Epilepsy, 976

Epiduo

Epileptic and tonic seizures, 294

Driving, 294

Focal seizures with or without secondary generalisation, 294

Generalised seizures, 294

Myoclonic seizures, 295

Non-convulsive status epilepticus, 296

Pregnancy, 294

Status epilepticus, 296

Tonic-clonic seizures, 294

Epileptiform preparations, 314

Epinaistine hydrochloride, 1059

EpiPen, 218

Epirubicin hydrochloride, 836

Episenta, 314

Epithelialising wound, see Wound management
Estradiol
- Sex hormone responsive conditions, 707
- Vaginal atrophy, 782
- With drospirenone, 717
- With dydrogesterone, 717
- With estril and estrone, 714
- With levonorgestrel, 718
- With medroxyprogesterone, 718
- With nomegestrol, 751
- With norethisterone, 718
- With norgestrel, 720
- Estradiol valerate with dienogest, see Dienogest with estradiol valerate
- Estradot, 734
- Estramustine phosphate, 831
- Estrin, 783
- Estril, 783
  - With estrone and estradiol, see Estradiol with estril and estrone
- Estrone with estradiol and estrone
- Estradiol with estril and estrone
- E-Tabs, 996
- Etamsylate, 108
- Etanercept, 1012
- Ethambutol hydrochloride, 554
- Ethambutol with isoniazid, pyrazinamide and rifampicin, see Rifampicin with ethambutol, isoniazid and pyrazinamide
- Ethamsylate, see Etamsylate
- Ethinylestradiol, 709, 715
  - With cyproterone acetate, see Co-cyprindiol
  - With desogestrel, 751
  - With drospirenone, 752
  - With etonogestrel, 752
  - With gestodene, 753
  - With levonorgestrel, 753
  - With norelgestromin, 754
  - With norethisterone, 755
  - With norgestimate, 755
- Ethinylestradiol, see Ethinylestradiol
- Ethosuximide, 295, 300
- Ethylene glycol and methanol, 1255
- Etodolac, 1037
- Etofylline, 1037
- Etomidate, 1220
- Etomidate-Lipuro, 1220
- Etonogestrel, 762
- Etonogestrel with ethinylestradiol, see Ethinylestradiol with etonogestrel
- Etopan XL, 1037
- Etopophos, 853
- Etofoside, 853
- Etoricoxib, 1038
- Etravirine, 608
- Etravirin, 1142
- Eucalyptus with menthol, 284
- Eucerin preparations, 1125
- Eucresam, 657
- Eudemine, 681
- Eumovate, 1143
- Eumarine, 582
- European viper snake venom antiserum, 1261
- Evacal D5, 994
- Everolimus, 900
- Evidence grading, x
- Eviplera, 615
- Evirex, 710
- Evista, 710
- Evolocumab, 189
- Evolva, 841
- Evolve HA, 1068
- Evorel preparations, 714, 720
- Evotaz, 619
- Evokal, 529
- Evora, 755
- Excipients, 3
- Exelon, 291
- Exemol, 130
- Exemestane, 880
- Exenatide, 658
- Exercise-induced asthma, 232
- Exforge, 151
- Exjade, 940
- Ex-Lax Senna, 62
- Exocin, 1072
- Exocrine pancreatic insufficiency, 92
- Exorex preparations, 1152
- Exsu-Fast products, 1474
- Estavox, 800
- Extemporaneous preparation, 3
- Extrelol, 1098
- Extracorporeal circuits, 113
- Extract of coal tar with arachis oil, 1154
- Extrapulmonary tuberculosis, 548
- Extrapyramidal side-effects, 365
- Extravasation, 826, 1055
- Exudate (wound), see Wound management
- Ex-U-Dry products, 1459
- Exiviera, 598
- Eye, 1057
- Eye, allergy and inflammation, 1058
- Eye drops and eye ointments, 1057
- Eye infections, 1069
- Eye infections, bacterial, 486
- Eye lotions, 1057
- Eye, surgical and peri-operative drug use, 1075
- Eylea, 1088
- Eyetazox, 1080
- Ezetimibe, 191
  - With simvastatin, see Simvastatin with ezetimibe
- Ezetrol, 192
- Ezinelle, 762

F
- Fabrazyme, 972
- Fabric Swab, 1474
- Fabry’s disease, 972
- Factor IX fraction, dried, 108
- Factor VIIa (recombinant), 109
- Factor VIII fraction, dried, 109
- Factor VIII inhibitor bypassing fraction, 110
- Factor XIII fraction, dried, 110
- Faecal impaction, 52
- Faecal softeners, 51
- Falciparum malaria (treatment), 580
- Famciclovir, 601
- Familial breast cancer, 871
- Famotidine, 73
- Fampridine, 799
- Fampyra, 799
- Fanvir, 602
- Fanhdi, 110
- Faramsil, 740
- Fareston, 880
- Farydak, 865
- Fasigyn, 514
- Faslodex, 879
- Fast Aid, 1476
- Fasturttec, 870
- Fate, 1446
- F bevorin, 349
- Fearoll, 759
- Febrile convulsions, 296
- Febuxostat, 1021
- Feed additives, 1440
- Feed supplements, 1434
- Feed thickeners and pre-thickened drinks, 1440
- Fefol Sponsules, 936
- FEIBA Imuno, 111
- Felbinac, 1038
- Feldene preparations, 1050
- Felodipine, 154
  - With ramipril, see Ramipril with felodipine
- Feloters XL, 155
- Felypressin with prilocaine, see Prilocaine with felypressin
- Femara, 881
- FemCap, 757
- Fenodene preparations, 753
- Fenodette, 753
- Fenostar preparations, 718
- FenSeven preparations, 714, 718
- Fenbital preparations, 1043
- Fenclomax, 438
- Fenclid, 1211
- Fenofibrate, 193
- Fenoprofen, 1039
- Fenpropanol, 1040
- Fenitals, 438
- Fentanyll, 434
  - With bupivacaine, see Bupivacaine with fentanyl
- Fenticonazole nitrate, 782
- Fosanox Sponsules, 935
- Feracru, 933
- Ferinjekt, 932
- Ferric carboxymaltose, 931
- Ferric maltol, 933
- Ferrin, 941
- Ferrograd preparations, 935
- Ferrous fumarate, 934
  - With ascorbic acid, 935
  - With folic acid, 935
- Fesoterodine fumarate, 732
- Fexofenadine hydrochloride, 269
- Fiasp preparations, 674
- Fibrates, 190
- Fibrazate XL, 192
- Fibrinogen, dried, 110
- Fibrogastrin P, 110
- Fibro-Vein, 228
- Fidaxomicin, 538
- Fifty:50, 1124
- Filicicides, 570
- Filigrastim, 942
- Finance, 1165
- Finasteride, 742

Downloaded from www.medicalbr.com
Flunthixol Decanoate, see Flunthixol decanoate
Flunthixol, see Flunthixol
Flunthixol, 368
Flupentixol decanoate, 373
Fluphenazine decanoate, 374
Flurandrenolone, see Fluoroxycortide
Flurazepam, 461
Flurbiprofen
• Eye procedures, 1077
• Pain and inflammation, 1040
• Sore throat, 1113
Flutamide, 875
Fluticasone
• Asthma, 253
• Nasal, 1103
• Skin, 1145
• With azelastine, 1104
• With formoterol, 254
• With salmeterol, 255
Fluticasone furoate with vilanterol, 254
Flutiform, 254
Fluvastatin, 196
Fluvoxamine maleate, 349
FML Liquifilm, 1062
Focal seizures, 294
Folic acid, 937
• With ferrous fumarate, see Ferrous fumarate with folic acid
• With ferrous sulphate, see Ferrous sulphate with folic acid
Folinic acid, 869
Folvipil, 154
Follitropin alfa, 702
• With lutropin alfa, 703
• Follitropin beta, 703
Fomipt, 539
Fondaparinux sodium, 116, 123
Food allergy, 82
Food hygine, 1201
Foodlink Complete, 1430
Foods for special diets, 1441
Foradil, 243
Forceval preparations, 990
Formaldehyde, 1180
Formoterol fumarate, 242
• With aclimium bromide, see Aclidinium bromide with formoterol
• With beclometasone, see Beclomethasone with formoterol
• With budesonide, see Budesonide with formoterol
• With fluticasone, see Fluticasone with formoterol
Formulas (specialised, infant and child), see Specialised formulas
Forsteo, 691
Forticare, 1432
Forticreme preparations, 1430
Fortijuce, 1427
Fortipine LA, 158
Fortisip preparations, 1428, 1429, 1430, 1431
Fortum, 501
Forxiga, 663
Fosamax, 684
Fosaprepitant, 413
Fosavance, 685
Foscan, 889
Foscarnet sodium, 604
Foscavir, 604
Fosfomycin, 538
Fosinopril sodium, 164
Fosphenytoin sodium, 300
Fosrenol, 966
Fostair preparations, 251
Fostimon, 704
Fragnin, 127
Framycetin sulfate, 1094
• With dexamethasone and gramicidin, see Dexamethasone with framycetin sulfate and gramicidin
Frangula with sterculia, see Sterculia with frangula
FreeStyle products, 676
Fresh frozen plasma, 111
Fresubin preparations, 1422
Friars’ Balsam, see Benzoin tincture
Frisium, 320
Frovatriptan, 454
Fructose-based formula, 1440
Fruitivits, 1439
Frusemide, see Furosemide
Frusene, 222
Frusol, 221
FTC, see Emtricitabine
Fucibet, 1147
Fucidin preparations, 540, 1150
Fultium preparations, 993
Fulvestrant, 878
Fungal infection, 558, 779
Fungal skin infections, 1130
Fungating tumours, 25
Fungizone, 562
Furosemide, 221
• With amiloride hydrochloride, see Co-amilorfruse
• With potassium chloride, 222
• With spironolactone, see Spironolactone with furosemide
• With triamterene, 222
Fusidic acid, 539
• Eye, 1072
• With betamethasone, see Betamethasone with fusidic acid
• With hydrocortisone, see Hydrocortisone with fusidic acid
Fuzatal XL, 737
Fuzone, 606
Fybogel preparations, 46, 53
Fycompa, 308
Fyne Dynamics Pinnacle, 265
G
G6PD deficiency, 922
Gabapentin, 295, 301
Gabitril, 315
GA gel, 1447
Galantamine, 289
Galantex XL, 289
Galcode, 432
Galebon, 740
Galenphol, 284
Galfur preparations, 934
Gallstones, 85
Galpseud preparations, 1100
Galsulfase, 974
Galsya XL, 289
Galvas, 656
Gamgee products, 1473
Gamma-amino butyric acid analogues and derivatives, 471
Gammagard S/D, 1188
Gammanorm, 1187
Gammarex, 1187
Ganunex, 1188
Ganciclovir
  • Ophthalmic herpes simplex, 1073
  • Systemic use, 603
Ganfort, 1083
Ganirelix, 694
Gardasil preparations, 1212
Gastric and duodenal ulceration, 70
Gastro-intestinal pain, 25
Gastro-intestinal smooth muscle spasm, 82
Gastro-intestinal system infections, bacterial, 486
Gastro-oesophageal reflux disease, 81
Gastroprotective complexes and chelators, 71
Gatalin XL, 289
Gaucher’s disease, 972
Gaze, 1474
Gaze swab, 1474
Gaviscon preparations, 68
Gazylan XL, 290
Gazyvaro, 815
G-CSF, see Filgrastim
Gedarel, 752
Gefitinib, 902
Gelaspam, 961
Gelatin, 961
Gel FX, 1461
Gelperm, 1461
Gelofusine, 961
Geloplasma, 961
GelTears, 1066
Gemcitabine, 843
Gemeprost, 778
Gemfibrozil, 193
Gemzar, 844
General anaesthesia, 1218
Generalised seizures, 294
Gentane, 558
Genital system infections, bacterial, 486
Genius products, 1441
Genotropin preparations, 706
Gentamicin
  • Ear, 1094
  • Eye, 1070
  • Systemic, 491
  • With hydrocortisone, 1095
Genvoya, 613
Gestodene with ethinylestradiol, see Ethinylestradiol with gestodene
Gestone, 722
Gielism, 84
Gilenya, 803
Gimeracil with oteracil and tegafur, see Tegafur with gimeracil and oteracil
Giotrif, 892
Glascosamine, 1000
Glucose, 955
  • With disodium hydrogen citrate with potassium chloride and sodium chloride, see Disodium hydrogen citrate with glucose, potassium chloride and sodium chloride
  • With sodium chloride, see Sodium chloride with glucose
Glucone, 676
Glucone products – Helicobacter Test INFAI 1509
Glucone, 666
Gliclazide, 666
Glicerol, 61
  • With magnesium sulfate and phenol, 1175
Glycercyline, 212
Glycine, 744
Glycogenolytic hormones, 681
Glycogen storage disease, 1447
Glycophylin A recombinant methionyl human granulocyte-colony stimulating factor, see Lipoglyfilm
Glycoprolate, see Glycoprotein bromide
Glycoprotein bromide
  • Airways disease, 238
  • Anaesthetic adjuvant, 1225
  • Hyperhidrosis, 1160
  • With neostigmine, see Neostigmine with glycoprotein bromide
  • With indacaterol, 239
Glycosidase, 1447
Glypressin, 87
Glytrin, 214
GnRH, see Gonadorelin
Gold, 999
Golimumab, 1014
Gonadorelin, 701
Gonadorelin analogues, 693
Gonadotrophin-releasing hormone, see Gonadorelin
Gonadotrophin replacement therapy, 701
Gonadotrophin responsive conditions, 693
Gonal-f, 703
Gonapex Depot, 699
Goserelin, 695
Gout, 1019
Graduated compression hosiery, 1481
Granisetron, 413
Granocyte, 943
Granuflex preparations, 1465
GranuGel, 1460
Granulating wound, see Wound management
Granupas, 552
Grass pollen extract, 277
Grazax, 277
Grepid, 119
Grifols, 960
Griseofulvin
  • Skin, 1132
  • Systemic use, 568
Grisol AF, 1132
Growth factors, 47
Growth hormone, 700
Growth hormone disorders, 705
Guanethidine monosulfate, 177
Guanfacine, 335
Guanylcylic cyclase stimulators, 180
Gygel, 764
Gyno-Daktarin, 782
Gyno-Pevaryl, 781
Gynoxin, 782
H
Haemarginate, 971
Haemoglobin, 110
Haemorrhage, 113
Haemorrhoids, 803
Halaven, 89
Halaven preparations, 369, 375
Haleraid preparations, 265
Haloperidol, 368
Haloperidol decanoate, 375
Hapoctasin, 430
Harvoni, 596
Havrix, 1209
Hayleve, 273
HbA1c measurement, 643
HBVAXPRO, 1211
HCG, see Chorionic gonadotrophin
HCU preparations, 1448
Headache, 449
Head lice, 1127
Heart failure, 138, 142, 184
Heavy menstrual bleeding, 709
Heavy metals, 1255
Hedrin preparations, 1134
Helicobacter pylori diagnosis, 81
Helicobacter pylori infection, 70
Helicobacter Test INFAI, 82
downloaded from www.medicalbr.com
Helixate NexGen, 110
Helinth infections, 570
Hemabate, 776
Heparin, 116
Heparinoid, 1179
Heparin toxicity, 1258
Heparin (unfractionated), 128
Heparon Junior, 1432
Hepatect CP, 1186
Hepatic impairment (prescribing), 1258
Heparon Junior, 1108
Hepatic impairment, 1109
Hepatic encephalopathy, 19
Hepatitis, 587
* Chronic hepatitis B, 587
* Chronic hepatitis C, 588
Hepatitis A and B vaccine, 1208
Hepatitis A vaccine, 1194, 1209
Hepatitis A with typhoid vaccine, 1209
Hepatitis B and A vaccine, see Hepatitis A and B vaccine
Hepatitis B immunoglobulin, 1186
Hepatitis B vaccine, 1194, 1210
Hepatotoxic drugs, 19
Hepatyrax, 1210
Hepsera, 590
Herceptin, 824
Hereditary angioedema, 267, 699
Heroin hydrochloride, see Diamorphine hydrochloride
Heron Foods, 1443
Herpes labialis, 1126
Herpes simplex (ophthalmic), 1073
Herpesvirus infections, 598
* Cytomegalovirus infection, 599
* Herpes simplex infections, 598
* Varicella-zoster infections, 598
Hexamine hippurate, see Methenamine hippurate
Hexitol, 1108
Hexapal, 227
Hibi, 1174
Hibiscrub, 1174
Hibitane preparations, 1123, 1174
Hiccup, 25
Hidroscie, 66
High-energy supplements, 1434
High-fibre supplements, 1439
Hiperx, 557
Hirsutism, 1170
Hirudins, 116
Hirudoid, 1179
Histamine analogues, 419
Histamine dihydrochloride, 884
Histocryl preparations, 1176
Histoplasmosis, 558
HIV infection, 604
* Postexposure prophylaxis, 605
* Pre-exposure prophylaxis, 605
Hizentra, 1188
H2-receptor antagonists, 72
Homatropine hydrobromide, 1065
Homocystinuria, 973
Homocystinuria or hypermethioninaemia, 1447
Honey dressings, see Antimicrobial dressings
Hormone replacement therapy, 709
Hormonin, 714
Hospicare products, 1478
Hospiform, 1476
Hospilite, 1479
HRT, 708
H2-receptor antagonists, 72
Humalog preparations, 670, 675
Human Albumin Solution, see Albumin solution
Human chorigonadotropin, see Chorionic gonadotropin
Human chorigonadotropin, see Chorionicgonadotropin alfa
Human coagulation factor VIII, dried, see Factor VIII fraction, dried
Human fibrin-stabilising factor, dried, see Factor XIII fraction, dried
Human hemin, see Haem arginate
Human papillomavirus vaccine, 1195, 1212
Human prothrombin complex, see Dried prothrombin complex
HumPen Luxura HD, 680
Humatrope, 707
Humira, 1010
Humulin preparations, 669, 673
Hybak, 1068
Hyaluronidase, 1056
Hyctamin, 857
Hycosan preparations, 1069
Hydatid disease, 570
Hydralazine hydrochloride, 175
Hydramed preparations, 1069
Hydra, 863
Hydrex, 1174
Hydrochlorothiazide, 162
* With amiloride and timolol, see Timolol with amiloride and hydrochlorothiazide
* With amiloride hydrochloride, see Co-amilozide
* With amlopidine and olmesartan, see Olmesartan with amlopidine and hydrochlorothiazide
* With captorpril, see Co-ziidocapt
* With enalapril, see Enalapril with hydrochlorothiazide
* With irbesartan, see Ibesartan with hydrochlorothiazide
* With losartan, see Losartan with hydrochlorothiazide
* With losartan, see Losartan with hydrochlorothiazide
* With olmesartan, see Olmesartan with hydrochlorothiazide
* With quinapril, see Quinapril with hydrochlorothiazide
* With telmisartan, see Telmisartan with hydrochlorothiazide
* With triamterene, see Co-triamterzide
* With valsartan, see Valsartan with hydrochlorothiazide
Hydrolcoll preparations, 1465
Hydrocortisone
* Oral and perioral lesions, 1113
* Skin, 1145
* Soft tissue and joints, 1054
* Systemic use, 637
* With benzalkonium chloride, dimeticone and nystatin, 1149
* With chlorhexidine hydrochloride and nystatin, 1150
* With clotrimazole, 1150
* With fusidic acid, 1150
* With miconazole, 1150
* With oxytetracycline, 1151
* With urea, 1146
* With benzyl benzoate, bismuth oxide, bismuth subgallate, peru balsam and zinc oxide, see Benzyl benzoate with bismuth oxide, bismuth subgallate, hydrocortisone acetate, peru balsam and zinc oxide
* With benzyl benzoate, bismuth oxide, peru balsam, promacaine hydrochloride and zinc oxide, see Benzyl benzoate with bismuth oxide, hydrocortisone acetate, peru balsam, promacaine hydrochloride and zinc oxide
Hydrocortisone butyrate, 1146
* With cinchocaine, see Cinchocaine with hydrocortisone
* With gentamicin, see Gentamicin with hydrocortisone
* With lidocaine, 91
* With promacaine, 92
Hydrocortistab, 638, 1054
Hydrofil preparations, 1461
Hydrofluemethasone with spiranolactone, see Co-flumactone
Hydrogel dressings, 1460
Hydrogen peroxide
* Oral hygiene, 1109
* Skin, 1174
Hydromel preparations, 1121, 1123, 1124, 1125
Hydromoor, 1067
Hydromorphine hydrochloride, 439
Hydrosorb products, 1461
Hydralacte with simeticone, see Cosimalcide
Hydroxocobalamin, 938
Hydroxybenzamide, 863
Hydroxychlorquine sulfate, 1001
Hydroxyethylcellulose, 1066
Hydroxypropyl guar with polyethylene glycol and propylene glycol, 1066
Hydroxyzine hydrochloride, 274
Hydron, 1461
Hylo-Comod, 1069
Hylo-fresh, 1069
Hy-opt, 1068
Hyoscyne butylbromide, 83
Hyoscyne hydrobromide, 417
* With papaveretum, see Papaveretum with hyoscyne hydrobromide
Hyphax, 1461, 1475
Hyperalcaemia, 957
Hypercalcium, 957
Hyperhidrosis, 1159
Hyperkalaemia, 967
Hyperlipidaemia, 188
Hyperlysinaemia, 967
Hyperphosphataemia, 957
Hyperparathyroidism, 957
Hyperparotidism, 957
Hyperprolactinemia, 365
Hypersal, 1068
Hypertension, 135
Hypertension associated with phaeochromocytoma, 176
Hypertensive crises, 137, 177
Hyperthyroidism, 726
Invanz, 494
Invasive Haemophilus influenzae type b disease, 1194
Invega, 381
Invicorp preparations, 773
Invirase, 622
InVita D3, 993
Invnodol SR, 448
Invokana, 962
Iodide with iodine, 728
Iodine dressings, see Antimicrobial dressings
Iodine products, 1172
Iodine with iodide, see Iodide with iodine
Iodosorb, 1469
Iodozyme, 1476
Ipratropium bromide
▶ Airways disease, 239
▶ Nasal, 1102
Ipratropium with salbutamol, 239
Irbesartan, 170
▶ With hydrochlorothiazide, 171
Iressa, 902
Irinotecan hydrochloride, 856
Iron deficiency anaemia, 930
Iron dextran, 932
Iron isomaltoside 1000, 932
Ironorm, 935
Iron overload, 939
Iron preparations, 95
Iron salts, 1254
Iron sucrose, 933
Iriclens, 1175
Irrigation solutions, 744, 1175
Irripod, 1175
Irritable bowel syndrome, 45
Isavuconazole, 563
Ischaemic stroke, 113
Isentress, 608
Isis XI, 215
Ismo preparations, 215
Isocarboxazid, 345
Isodur XI, 215
Isoflurane, 1222
Isoket preparations, 214
Isoleucine50, 1450
Isometheptene with paracetamol, see Paracetamol with isometheptene
Isoniazid, 554
▶ With rifampicin, see Rifampicin with isoniazid
▶ With ethambutol with pyrazinamide and rifampicin, see Rifampicin with ethambutol, isoniazid and pyrazinamide
▶ With pyrazinamide and rifampicin, see Rifampicin with isoniazid and pyrazinamide
Ispaghula, 53
Ispaghula husk
▶ With mebeverine, see Mebeverine with ispaghula husk
▶ With senna, see Senna with ispaghula husk
Ispiral, 155
Istin, 151
Itraconazole, 564
IV3000, 1462
Ivabradine, 205
Ivacaftor, 1086
IVD50, 1469
IVF50, 1476
Ivermectin
Ivermectin granules
Ivimpex, 215
Ivinox, 860
Ivix, 1213
J
Jakavi, 913
Janumet, 656
Januvia, 655
Japanese encephalitis vaccine, 1195, 1213
Jardiance, 665
Javel, 860
Jaydiss, 762
Jelonet, 1458
Jentadueto, 654
Jet nebulisers, 230
Jetrea, 1092
Jevity preparations, 1422, 1424
Jevista, 854
Jext, 218
Finaric, 631
Joint prosthesis, 33
Joint prostheses and dental treatment, 483
Joint replacement, 482
Joy-Rides, 418
Juliperla, 753
Juvela products, 1442
Juvenile idiopathic arthritis, 999
K
Kadcyla, 824
Kalcripos-D, 994
Kaletro, 621
Kalspare, 224
Kaltostat, 1467
Kalyltech, 281
Koalin, 66
▶ With morphine, 65
Kapake preparations, 431
Katyca, 753
Kay-Cee-L, 969
K-Band, 1476
Keflex, 497
Kefid, 498
Kelo-cote preparations, 1472
Kemadrin, 391
Kenalog, 641, 1055
Kendall AMD products, 1471
Kendall Products, 1466
Kengreval, 203
Kentera, 734
Keppara, 306
Keral, 1033
Ketalar, 1235
Ketamine, 1234
KetoCal, 1432
Ketocanazole
▶ Cushing’s syndrome, 641
▶ Skin, 1130
▶ Vaginal and vulval infections, 782
Ketoprofen, 1044
▶ With omeprazole, 1045
Ketorolac trometamol
▶ Eye, 1077
▶ Systemic use, 1231
Ketotix, 680
Ketotifen
▶ Eye, 1059
▶ Systemic use, 275
Ketovite, 990
KeyOmega, 1450
Keytruda, 818
K-Four, 1480
Kindergen, 1433
Kineret, 1004
Kivioig, 1188
Kisplyx, 907
Kivexa, 611
Klaricid preparations, 509
Klean-Prep, 50
Klofem, 719
Klovan, 719
KL lite, 1479
Klorafect, 1072
Knit-Band, 1476
Knit-Firm, 1479
Knit Fix, 1476
Kagenate, 110
Kolantic, 83
Kolbam, 86
Komboglyze, 655
Konakion preparations, 997
Kontour, 1476
K-Plus, 1479
K Print, 1479
K-Soft, 1480
K Tech products, 1480
K Two products, 1480
Kuvan, 986
Kwells, 418
Kyprolis, 891
Kytril, 414
L
L3, 1479
Laaglyda MR, 666
Labetalol hydrochloride, 143
Labyrinth disorders, 408
Lacidipine, 155
Lacosamide, 1004
Lacidipine, 155
Lactoamid, 302
Lacri-Lube, 1067

downloaded from www.medicalbr.com
Lactic acid, 780
  - With salicylic acid, see Salicylic acid with lactic acid

Lactugal, 55

Lactulose, 55

Lambert–eaton myasthenic syndrome, 1024

Lamictal, 305

Lamisil, 1133

Lamivudine, 615
  - With abacavir and dolutegravir, see Abacavir with dolutegravir and lamivudine
  - With abacavir and zidovudine, see Abacavir with lamivudine and zidovudine
  - With abacavir, see Abacavir with lamivudine
  - With zidovudine, see Zidovudine with lamivudine

Lamotrigine, 295, 303

Lanoxin, 107

Lanreotide, 876

Lansoprazole, 77

Lanthanum, 965

Lantus preparations

Larafen CR, 1045

Larbx XL, 738

Largactil, 368

Larium, 584

Laronidase, 975

Lasalactone, 223

Latanoprost, 1083
  - With timolol, 1084

Latent tuberculosis, 548

Latuda, 379

Laxatives, 51

Leandra, 754

Lecaent, 311

Leflunomide, 1002

Leishmaniicides, 573

Leishmaniasis, 573

Leptomtra, 805

Lenalidomide, 885

Lenogastrim, 943

Lenvatinib, 906

Lenvima, 907

Leprosy, 544

Lercanidipine hydrochloride, 156

Lescol preparations, 197

Lestrany, 752

Letrozole, 881

Leucine100, 1450

Leukof, 1475

Leukomed preparations, 1459, 1461

Leukopor, 1475

Leukostrip, 1476

Leukotriene receptor antagonists, 258

Leuprolrelin acetate, 696

Leustat, 840

Lovastatin, 828

Levamisole, 571

Leverim preparations, 671

Leveraxo, 443

Levest, 754

Levetiracetam, 295, 305

Levitra, 769

Levocabupolol hydrochloride, 1078

Levobupivacaine, 1241

Levocarnitine, 971

Levocetirizine hydrochloride, 270

Levodopa, 390

Levodopa with benserazide, see Co-beneldopa

Levodopa with carbidopa and entacapone, see Carbidopa with entacapone and levodopa

Levodopa with carbidopa, see Co-careldopa

Levofloxacin
  - Eye, 1071
  - Systemic use, 528

Levofolinic acid, 870

Levoment

Levomepromazine, 971

Levofolinic acid, 975

Levodopa with carbidopa, see Co-beneldopa

Levodopa with benserazide, see Co-beneldopa

Levoret, 762

Levophenylalanine, 1244

Levalbuterol, 1244

Levurocobic, 1245

Lifestyle Products, 1441

Lignocaine hydrochloride, see Lidocaine hydrochloride

Lignospan Special

Lifestyle Products

Lido Male

Lido Male

Lidocaine and Fluorescein, 1074

Lidocaine hydrochloride
  - Arrhythmias, 100
  - Oropharyngeal use, 1111
  - With adrenaline, 1243
  - With chlorhexidine, see Chlorhexidine with lidocaine
  - With fluosurf, see Fluosurf with lidocaine
  - With hydrocortisone, see Hydrocortisone with lidocaine
  - With methylprednisolone, see Methylprednisolone with lidocaine
  - With phenylephrine, 1244
  - With prilocaine, 1244
  - With tetracaine, 1245

Lifestyle Products, 1441

Lignocaine hydrochloride, see Lidocaine hydrochloride

Lignospan Special, 1244

Li-Liquid, 342

Linclotide, 47

Linagliptin, 654

Lipid-regulating drugs, 188

Liptor, 196

Liposome, 1123

LiquaMag GP, 963

LiquiBand, 1176

Liquid paraffin, 59
  - With magnesium hydroxide, 59
  - With retinol palmitate with white soft paraffin with light liquid paraffin and wool, see Retinol palmitate with white soft paraffin and light liquid paraffin and liquid paraffin and wool fat
  - With white soft paraffin and wool alcohols, 1067

Liquifilm Tears, 1068

Liquigen, 1435

Liquivisc, 1066

Liraglutide, 659
  - With insulin degludec, see Insulin degludec with liraglutide

Lisdexametamisef, 334

Lisinopril, 165
  - With hydrochlorothiazide, 166

Lison, 341

Liptak, 840

Lithium, 337, 1254

Lithium carbonate, 340

Lithium citrate, 341

Liver disease, 34, 85

Livial, 716

Lixiana, 122

Lixisenatide, 659

Lizina, 755

L-Mesitran Products, 1469

LMX 4, 1243

Local anaesthesia, 1236
  - Dental anaesthesia, 1237
  - Toxicity, 1237
  - Use of vasoconstrictors, 1237

Local anaesthetics, 1076

Local analgesics, 1111

Local corticosteroid injections, 1053

Local inflammation of joints and soft tissue, 1053

Loceryl, 1132

Locoid preparations, 1446

Lodine SR, 1037

Lodotra, 641

Lodoxamide, 1070

Loestrin preparations, 755

Lofepamine, 360

Lofexidine hydrochloride, 471, 478

Lojuxta, 201

Lomipitapide, 190, 201

Lomustine, 832

Long-acting beta agonists, 234

Long-acting insulin, 646

Longtec, 443

Long-term oxygen therapy, 237

Loniten, 176

Longue, 943

Longsurf, 849

Loop diuretics, 219

Loperamide hydrochloride, 65
  - With simeticon, 66

Lophex preparations, 1450

Lopid, 194

Lopinavir with ritonavir, 620

Loprazolam, 461

Lopresor preparations, 149

Lopropin products, 1445, 1450

Loradine, 270

Lorazepam, 322

Lornetazepam, 462

Loron, 688

Losartan potassium, 171
  - With hydrochlorothiazide, 174

Losec, 79

Losinate MR, 740

Lotemax, 1077

Lopredrol etabonate, 1077

Lotprosin XL, 290

Lotriderm, 1147

Low back pain and sciatica, 1028
Low molecular weight heparins, 116
Low-protein foods, 1445
Loxapine, 370
LPL, 1121
L-Triiodothyronine sodium, see Liothyronine sodium
L-Tyrosine, 1450
Lubion, 722
Lubiprostone, 54
Lubristil, 1069
Lucentis, 752
Lumactofor with ivacaftor, 557
Lumacaftor with ivacaftor, 962
Lucentis, 54
Lubristil, 1066
Lumefantrine with artemether, 569
Lumefantrine with artemether, 981
Magnaspartate, 963
Magnesium hydroxide, 1046
Magnesium glycerophosphate, 479
Magnesium citrate with sodium bicarbonate, see Magnesium trisilicate with sodium bicarbonate
Magnesium carbonate, 1089
Magnesium trisilicate, 1087
Magnesium aspartate, 557
Magnesium carbonate, 69
With calcium acetate, see Calcium acetate with magnesium carbonate
With citric acid, see Citric acid with magnesium carbonate
Measles, mumps and rubella vaccine, live, 1196, 1213
Medications, 479
Medications, 572
Medication bandages, 1480
Medication packing, 1481
Medication preparations, 1468
Medication products, 1469
Medication preparations, 333
Medication preparations, 1475
Medications with aluminium, 1459
Medications with aluminium, 468
Medication preparations, 639, 1054
Medication preparations, 763
Medication preparations with conjugated oestrogens, see Conjugated oestrogens with medroxyprogesterone
Medication preparations with estradiol, see Estradiol with medroxyprogesterone
Mefenamic acid, 1046
Mefloquine, 475
Mefloquine, 574, 584
Megace, 878
Megaloblastic anaemia, 936
Menogestrol acetate, 878
Menopause, 464
Menopause, 467
Menopause, 310
Menopause, 734
Menopause, 822
Menopause, 1046
Menopause, 1459
Menopause, 1460
Menopause, 1067
Menopause, 292
Menopause, 291
Menopause, 293
Menopause, 996
Mepacrine hydrochloride, 885
Mepacrine hydrochloride, 1207
Mepacrine hydrochloride, 704
Mepacrine hydrochloride, 1206
Mepacrine hydrochloride, 1207
Mepacrine hydrochloride, 736
Mepacrine hydrochloride, 1048
Mepacrine hydrochloride, 1206
Mepacrine hydrochloride, 1207
Mepacrine hydrochloride, 704
Mepacrine hydrochloride, 1206
Mepacrine hydrochloride, 1207
Mepacrine hydrochloride, 704
Mepacrine hydrochloride, 1206
Mepacrine hydrochloride, 1207
Mepacrine hydrochloride, 704
Mepacrine hydrochloride, 1206
Mepacrine hydrochloride, 1207
Mepacrine hydrochloride, 704
Mepacrine hydrochloride, 1206
Mepacrine hydrochloride, 1207
Mepacrine hydrochloride, 704
Mepacrine hydrochloride, 1206
Mepacrine hydrochloride, 1207
Mepacrine hydrochloride, 704
Mepacrine hydrochloride, 1206
Mepacrine hydrochloride, 1207
Mepacrine hydrochloride, 704
Mepacrine hydrochloride, 1206
Mepacrine hydrochloride, 1207
Mepacrine hydrochloride, 704
Monoclonal antibodies for ulcerative colitis – Neutrogena preparations

Monoclonal antibodies for ulcerative colitis, 38
Monfer, 932
Monomax preparations, 215
Monomil XL, 215
Mononine, 109
Monopost, 1084
Monosorb XL, 215
Monotrim, 542
Montelukast, 258
Mornil, 539
Morphgesic SR, 441
Morphint, 439
  » With cyclizine, 442
  » With kaolin, see Kaolin with morphine
Motens, 155
Motifene, 1036
Motilium preparations, 411
Motion sickness, 409
Motor neurone disease, 385
  » Amyotrophic lateral sclerosis, 393
Mouthwashes and other preparations for oropharyngeal use, 1107, 1117
Movement disorders, 385
Moventig, 63
Movicol, 56
Moviprep preparations, 49
Moxifloxacin
  » Eye, 1071
  » Systemic use, 529
Moxisylyte, 227
Moxivi, 1072
Moxonidine, 140
Mozobil, 944
MRSA, 545
Mrs Crimbles products, 1443
MST Continus, 441
MSUD preparations, 1448
Mucoclear, 264
Mucodyne, 280
Mucogel, 68
Mucolytics, 280
Mucopolysaccharidosis, 974
Multaq, 104
Multimorbidity, 1
Multiple sclerosis, 797
  » Emotional lability, 798
  » Fatigue and impaired mobility, 798
  » Oscillopsia, 798
  » Spasticity, 798
Multi-thick, 1440
Munalea, 752
Mupirocin
  » Nasal, 1101
  » Skin, 1129
Muscular dystrophy, 1024
Musculoskeletal system infections, bacterial, 487
Muse, 771
MXL, 441
Myasthenia gravis, 1024
Mycame, 561
Mycobutin, 543
Mycohenolate moefitil, 796
Myco preparations, 1133
Mydriacyl, 1074
Mydriaser, 1075
Mydriatics and cycloplegics, 1073
Mydrilate, 1065
Myfenax, 797
Myfortic, 796
Myglucohealth, 676
Mylafent, 438
Mylatrip, 454
Mylife preparations, 676
Myocardial infarction, 142, 962
Myocardial ischaemia, 202
Myocet, 836
Myoclonic seizures, 295
Myocin, 1084
Myometrial relaxants, 774
Myotonia, 741
Myozyme, 976

N
Naboline, 410
Nabumetone, 1047
Nacrez, 759
Nadolol, 144
Nafarelin, 697
Nafldofuryl oxalate, 227
Naglazyme, 974
Nairnes products, 1442
Nalcrom, 260
Nalidixic acid, 530
Nalmefene, 469, 472
Nalorex, 473
Naloxegol, 63
Naloxone hydrochloride, 1259
  » With buprenorphine, see Buprenorphine with naloxone
  » With oxycodone, see Oxycodone with naloxone
Naltrexone hydrochloride, 469, 472
Nandovan XL, 197
Nandrolone, 682
Nappy rash, 1118
N-A preparations, 1458
Naprosyn preparations, 1049
Naproxen, 1048
  » With esomeprazole, 1049
  » With misoprostol, 1049
Naramig, 455
Naratraiptan, 454
Narcolepsy, 466
Nardil, 345
Naropin, 1248
Nasacort, 1105
Nasal congestion, 1099
Nasal infection, 1101
Nasal inflammation and rhinitis, 1102
Nasal polyps, 1099
Nasal staphylococci, 1099
Naseptin, 1101
Nasobec, 1107
Nasonex, 1109
Natalizumab, 805
Natcel, 994
Nateglinide, 660
Natrium preparations, 162
Natzon, 429
Nausea and labyrinth disorders, 408
Nausea (cytotoxic drugs), 826
Navelbine, 860
Navidrex, 225
Navigare, 160
Nazdol MR, 666
Nebcin, 494
Nebido, 725
Nebilet, 150
Nebivolol, 149
Nebulisers, 229
Nebuliser solutions, 264
Nebusal, 264
Necitumumab, 813
Necrotic wound, see Wound management
Neditol XL, 736
Nedocromil sodium
  » Eye, 1060
  » Respiratory, 259
Nefopam hydrochloride, 424
Nebaban, 525
Neis Vac-C, 1206
Nelarabine, 846
Nedatine, 292
Neclarityn, 269
Neo-Cytamen, 939
Neoef XL, 155
Neomycin sulfate
  » Eye, 1095
  » Skin, 1127
  » Systemic use, 492
  » With clobetasol propionate and nystatin, see Clobetasol propionate with neomycin sulfate and nystatin
  » With dexamethasone and glacial acetic acid, see Dexamethasone with glacial acetic acid and neomycin sulfate
Neomycin with betamethasone, see Betamethasone with neomycin
Neomycin with chlorhexidine, see Chlorhexidine with neomycin
Neomycin with dexamethasone, hyproemullosel and polymyxin B sulfate, see Dexamethasone with hyproemullosel, neomycin and polymyxin B sulfate
Neomycin with fluocinolone, see Fluocinolone acetonide with neomycin
Neo-Nucleus preparations, 161
Neoral, 790
Neorecormon, 928
Neospor, 1478
Neostigmine, 1024
  » With glycopyrronium bromide, 1229
Neostigmine methylsulfate, see Neostigmine
Neotigason, 1157
Neotulle, 1458
Neovent, 244
Nepafenac, 1061
Nephropathic cystinosis, 975
Nephrotoxic drugs, 20
Nerison, 1143
Nerve agents, 1255
Nesulast, 944
Neupogen preparations, 943
Neupro, 406
Neural tube defects (prevention in pregnancy), 997
NeuroBloc, 389
Neuroleptic malignant syndrome, 365
Neuromuscular blockade, 1225
Neuromuscular blockade reversal, 1229
Neuromuscular disorders, 1022
Neurontin, 302
Neuropathic pain, 457
Neuroprotective drugs, 389, 1023
Neutral Insulin, see Insulin
Neutrogena preparations, 1198
Neutropenia and stem cell mobilisation, 941
Nevanac, 1061
Nevirapine, 609
NewGel-E, 1472
Nexavar, 914
Nexum, 77
Nexplanon, 763
Nicam, 1169
Nicardipine hydrochloride, 156
Nicif, 498
Nicorandil, 206
Nicotinamide, 1168
Nicotine, 473
Nicotine dependence, 469, 473
Nicotinic acid, 190, 194
Nicotinic receptor agonists, 473
Nicoumalone, see Acenocoumarol
Niemann–pick type c disease, 976
Nifedipine, 157
  ▶ With atenolol, see Atenolol with nifedipine
Nifedipress MR, 158
Niferex, 936
Niko Fix, 1461
Nilotinib, 907
Nimbox, 1228
Nimenrix, 1207
Nimodipine, 111
Nimotop, 112
Nimvastat, 291
Ninlaro, 267
Nipent, 850
Nitisinone, 977
Nitarets, 212
Nitrazepam, 462
Nitroceine, 213
Nitro-Dur, 213
Nitrofurantoin, 557
Nitrofurantoin, 214
Nitromin, 214
Nitroval, 213
Nitrous oxide, 1219, 1222
Nivestim, 943
Nivolumab, 814
Nizatidine, 73
Nizoral, 782, 1131
Nocturnal enuresis in children, 731
Nocturnal leg cramps, 1025
Nomegestrol with estradiol, see Estradiol with nomegestrol
Non-depolarising neuromuscular blocking drugs, 1225
Non-falciparum malaria (treatment), 580
Non-medical prescribing, 1487
Nonoxinol, 764
Non-steroidal anti-inflammatory drugs, 1028
  ▶ Dental and orofacial pain, 1053
Nootropil, 387
Noqdirna, 630
Noradrenaline/norepinephrine, 183
Norcuron, 1229
Nordimet, 846
Nortryptiline preparations, 361
Norelgestromin with ethinylenestradiol, see Ethinylenestradiol with norelgestromin
Norethisterone, 720
  ▶ With estradiol, see Estradiol with norethisterone
  ▶ With ethinylenestradiol, see Ethinylenestradiol with norethisterone
  ▶ With mestranol, 755
Norfloxacin, 530
Norgalax, 59
Norvigo, see Norvalgo
Noridazol, 721
Noristerat, 721
Norvasc preformulations, 54
Normal immunoglobulin, 1186
Normasol, 1175
Normosang, 971
Norprolac, 693
Norntriptyline, 361
Norvir, 621
Nose, 1098
Nose infections, bacterial, 487
Notifiable diseases, 480
Novofem, 719
Novogel, 1461
NovoMix preparations, 670
NovoPen 4, 680
NovoRapid preparations, 674
NovoSeven, 109
Novafi, 566
Noxious gases, 1255
Noyada, 163
Nozinan, 419
Nplate, 947
NSPire Piko-I, 264
NSPire Pocket Peak, 264
NTBC, see Nitisinone
Nucala, 256
NU DERM, 1465
Nuelin preparations, 264
Nu-Gel, 1460
Nulojix, 797
Nurofen preparations, 1042, 1044
Nurse It, 1474
Nurse Prescribers’ Formulary, 1548
Nu-Seals, 118
Nutils preparations, 1429, 1440
Nutraphus, 1125
Nutricrem, 1431
Nutriplas preparations, 1430
Nutrition and metabolic disorders, 947, 1509
Nutrition in special diets, 986
  ▶ Coeliac disease, 986
  ▶ Phenylketonuria, 986
Nutrition (intravenous), 979
Nutrition (oral), 985
Nutritional supplements for metabolic diseases, 1447
Nutritional supplements (non-disease specific), 1427
Nutrizym preparations, 94
NutropinAQ, 706
NuvaRing, 753
Nouvella preparations, 719
Nuvig, 110
Nystaform preparations, 1133, 1150
Nystan, 1116
Nystatin, 1116
  ▶ With benzalkonium chloride, dimeticon and hydrocortisone, see Hyroocortisone with benzalkonium chloride, dimeticon and nystatin
  ▶ With chlorhexidine hydrochloride and hydrocortisone, see Hydrocortisone with chlorhexidine hydrochloride and nystatin
  ▶ With chlorhexidine, see Chlorhexidine with nystatin
  ▶ With clobetasol propionate and neomycin sulfate, see Clobetasol propionate with neomycin sulfate and nystatin
  ▶ With cloretasone butyrate and oxytetracycline, see Clobetasone butyrate with nystatin and oxytetracycline
O
Oakmed products, 1473
Obesity, 88
Obinutuzumab, 815
Obsessive–compulsive disorder, 343
Obstetrics, 773
Oculus, 1182
Ocriplasmin, 1092
Octagam, 1188
Octasa MR, 41
OctaplasLG, 111
Octaplex, 108
Ocentinil Wound Gel, 1471
Ocentinil Wound Irrigation Solution, 1472
Octin, 629
Octotrode, 877
Ocufer, 1077
Ocular lubricants, 1065
Ocular peri-operative drugs, 1075
Ocu-Lube, 1067
Ocusan, 1069
Odefsey, 614
ODMS, 1068
Odour absorbent dressings, 1468
Oedema, 218
Oesophageal varices, 87
Oestrogel, 714
Oestrogens, 710, 782, 875
Oestrogens and HRT, 707
Oestrogens combined with progestogens, 717, 749
Ofatumumab, 816
Ofram PR, 120
Oferv, 918
Oflaxacin
  ▶ Eye, 1072
  ▶ Systemic use, 530
Oftaquix, 1071
Oflatum, 1121, 1123
Oflatum Plus, 1119
Olanzapine, 379
Olanzapine embonate, 384
Olanzapine pamoate, see Olanzapine embonate
Olaparib, 919
Olbetam, 194
PK Foods products, 1445
PKU products, 1451
Plaque, 1002
Plasma substitutes, 950, 960
Platelet disorders, 944
- Essential thrombocytopenia, 944
- Idiopathic thrombocytopenic purpura, 944
Plavix, 119
Plegridy, 801
Plenalex, 993
Plendil, 155
Periactin, 944
Pletal, 227
Phagis, 1245
Pneumococcal polysaccharide conjugate vaccine (adsorbed), 1197, 1207
Pneumococcal polysaccharide vaccine, 1197, 1207
Pneumocystis pneumonia,
Pneumococcal polysaccharide vaccine,
Poliomyelitis vaccine, 1249
Podophyllotoxin,
Pollenase preparations
Plaquenil
PKU products
Pneumococcal polysaccharide
Platelet disorders,
Pollenshield
Polycal
Polyacrylic acid,
Polio
Polyethylene glycols,
Polycystic ovary syndrome,
Polyethylene glycol with hydroxypropyl guar and propylene glycol,
Polyethylene glycol with hydroxypropyl guar and propylene glycol,
Polylex, 1129
Polyfield dressing packs, 1474
Polymer products, 1466, 1470
Polyvinyl alcohol, 1068
Polmalodimide, 886
Pompe disease, 976
Ponatinib, 911
Ponstan, 1046
Porcine insulin, 888
Portrazza, 814
Posaconazole, 565
Posterior pituitary hormones, 627
Postmenopausal osteoporosis, 682
Postoperative analgesia, 422
Postoperative nausea and vomiting, 408
Post operative pain and inflammation, 1075
Postpartum haemorrhage, 776
Potaba, 588
Potactasol, 857
Potassium aminobenzoate, 988
Potassium bicarbonate with potassium acid tartrate, 968
Potassium bicarbonate with potassium chloride, see Potassium chloride with potassium bicarbonate
Potassium bicarbonate with sodium alginate, see Sodium alginate with potassium bicarbonate
Potassium chloride, 968
- With calcium chloride and sodium chloride and sodium lactate, 951
- With calcium chloride dihydrate and sodium chloride, 951
- With calcium chloride dihydrate and sodium chloride, see Potassium chloride with calcium chloride dihydrate and sodium chloride
- With disodium hydrogen citrate with glucose and sodium chloride, see Disodium hydrogen citrate with glucose, potassium chloride and sodium chloride
- With furosemide, see Furosemide with potassium chloride
- With glucose, 951
- With glucose and sodium chloride, 952
- With potassium bicarbonate, 952
- With rice powder, sodium chloride and sodium citrate, 956
- With sodium ascorbate, sodium chloride, macrogl 3550, anhydrous sodium sulfate and ascorbic acid, see Macrogl 3550 with anhydrous sodium sulfate, ascorbic acid, potassium chloride, sodium ascorbate and sodium chloride
- With sodium chloride, 953
Potassium citrate with citric acid, see Citric acid with potassium citrate
Potassium permanganate, 1172
Potassium-sparing diuretics and aldosterone antagonists, 219
Potassium supplements, 95
Povidone iodine, 1074
Povidone-iodine
- Eye, 1074
- Skin, 1172
Powergel, 1045
Pradaax, 133
Pradlixone chloride, 1257
Pralone, 200
Pramipexole, 402
Pramocaine with hydrocortisone, see Hydrocortisone with pramocaine
Prandin, 661
Prasugrel, 208
Pravastatin sodium, 197
Praxbind, 116
Praxilene, 228
Praziquantel, 572
Prazosin, 739
Preblazon XL, 736
Preconceive, 937
Pred Forte, 1063
Prednisolone
- Ear, 1096
- Eye, 1062
- Joint and soft tissue, 1054
- Systemic use, 639
- With cinchocaine, see Cinchocaine with prednisolone
Prednisone, 641
Predsol preparations, 641, 1063, 1096
Pre-eclampsia, 962
Prefilin, 429
Pregabalin, 310
Pregaday, 934
Pregnancy (prescribing), 22
Pregnyl, 702
Premarin, 711
Premature ejaculation, 773
Premature labour, 777
Pre-medications and peri-operative drugs, 1223
PremierBand products, 1478
PremierPad, 1473
PremierPore preparations, 1459, 1462
Premique preparations, 717
Pretrix, 430
Prinapad, 1260
Prescription writing, 18
Preservatives and sensitisers, 1057
Preservex, 1030
Prestylon, 202
Preterm birth, 1190
Prevenar, 1207
Prezista, 619
Priadel preparations, 341
Priapism, 765
Priligy, 773
Prilocaine hydrochloride, 1246
- With felypressin, 1247
- With lidocaine, see Lidocaine with prilocaine
Priloketel, 1246
Prima, 187
Primacor, 1475
Primafix, 1475
Primapore, 1459
Primazine, 574, 585
Primary biliary cholangitis, 86
Primaquin preparations, 495
Primidon, 319
Primidol N, 721
Priorix, 1214
Privigen, 1188
Pro-Banthine, 84
Procarbazine, 866
Proceli products, 1442
Prochlorperazine, 371
Procoralan, 206
Proctofoam HC, 92
Proctosedi, 91
Procyshin, 976
Pro-Epanutin, 301
Proflavine, 1175
Profore products, 1458, 1478
Progestosterone, 721
Progestogen—only contraceptives, 747
Progestogens and progesterone receptor modulators, 709
Prograf, 794
Proguanil hydrochloride, 574, 585
- With atovaquone, see Atovaquone with proguanil hydrochloride
- With chloroquine, see Chloroquine with proguanil
Prognova preparations, 714
Proleukin, 894
Probi, 692
Promazine hydrochloride, 386
Prometax, 291
Promethazine hydrochloride, 275
Promethazine tooclate, 417
Promin products, 1445
Promixin, 526
Promogran products, 1472
Prontosan irrigation, 1472
Prontosan Wound Gel, 1471
Propafenone hydrochloride, 101
Promapmidine isionate, 1073
Propantheline bromide, 84
Propeca, 742
Propess, 775
Propiverine hydrochloride, 735
Propofol, 1220
Propofol-Lipuro, 1221
Propranolol hydrochloride, 145
Propylene glycol with hydroxypropyl guar and polyethylene glycol, see Hydroxypropyl guar with polyethylene glycol and propylene glycol
Propylthiouracil, 728
Provart, 742
ProSource preparations, 1436
Prostacyclin, see Epoprostenol
Prostaglandin analogues and prostamides, 1078, 1082
Prostaglandins, erectile dysfunction, 769
Prostaglandins, gastrointestinal, 75
Prostaglandins and oxytocics, 773, 776, 778
Prostat preparations, 697
Prostate Cancer, 872
Prostatic hyperplasia, 138
Prostin preparations, 775
ProSure, 1433
Prosurin XL, 740
Protamine sulfate, 1258
Protamine zinc insulin, 672
Protamine zinc insulin injection—long acting, see Protamine zinc insulin
Protase-modulating matrix dressings, 1472
ProTectFilm, 1461
Protein C concentrate, 110
Protein kinase C activators, 1178
Protelos, 690
Prothiaden, 358
Protifir, 1436
Protium, 80
Proton pump inhibitors, 76
Protopic, 1155
Protozoal infection, 572
Provera preparations, 764
Providal, 468
Pro-Viron, 724
Prozyometacin, 1076
Prozyometacin hydrochloride, 1076
Prozac, 349
Prozep, 349
ProZero, 1450
Prucalopride, 58
Pruritus, 1160
Pseudoephedrine hydrochloride, 1100
Psoriasis, 1137
Psoriderm, 1122, 1152
Psychoses and related disorders, 364
- Antipsychotic depot injections, 366
- Equivalent doses of oral antipsychotics, 366
Psyquet XL, 383
Psytiol, 374
Pulmicort preparations, 252
Pulmonary hypertension, 178
Pulmozyme, 281
Pure Products, 1501
Purgon, 703
Purilon, 1460
PVA, 1068
Pylabactell, 82
Pyralvex, 1114
Pyrazinamide, 555
- With ethambutol with isoniazid and rifampicin, see Rifampicin with ethambutol, isoniazid and pyrazinamide
- With rifampicin and isoniazid, see Rifampicin with isoniazid and pyrazinamide
Pyrid, 589
Pyridostigmine bromide, 1025
Pyridoxine hydrochloride, 988
Pyrimethamine, 574, 586
- With sulfadoxine, 586
Q
Quair, 751
Quenestra preparations, 191
Quetiapine, 382
Quinagolide, 693
Quinapril, 167
- With hydrochlorothiazide, 168
Quinidine, 574, 586, 1025
Quinoric, 1002
Quoderox, 685
Quenzena, 458
QV, 1121, 1123
Qvar preparations, 250
QV Gentle, 1121
R
5Z-reductase inhibitors, 741
Rabeprazole sodium, 80
Rabies immunoglobulin, 1188
Rabies vaccine, 1198, 1214
Rabipur, 1215
Racedadotril, 66
Rahnea XL, 405
Raloxifene hydrochloride, 709
Raltegravir, 607
Raltitrexed, 866
Rahu, 1243
Ramipril, 168
- With felodipine, 169
Ramucirumab, 819
Ranexa, 205
Ranibizumab, 1089
Ranitidine, 74
Ranitil, 75
Ranolazine, 205
Rapamune, 791
Rapid-acting insulin, 646
Rapifen, 1233
Rapilose preparations, 955
Rapatil, 1060
Raperon XL, 405
Raposin XL, 738
Rasagiline, 406
Rashuricase, 870
Rasiliz, 175
Ravel XL, 162
Raxone, 1092
Razylan, 710
Rebetol, 594
Rebif, 800
Reboxetine, 346
Recovit, 438
Recombinant proteolytic enzymes, 1092
Rectal and anal disorders, 80
Rectogesic, 213
Reduced clotting, 19
Refolinin, 869
Refresh preparations, 1086
Regal, 1475
Regorafenib, 912
Reguarin preparations, 735
Relactogel, 781
Relapsing-remitting multiple sclerosis, 798
Relaxit, 743
Relenza, 626
Relextendat, 1059
Reltevax, 430
Reltevct, 430
Relifex, 1048
Relistor, 63
Relpax, 454
Reltevon, 444
Relvar Ellipta, 254
Remicade, 1018
Remifentanil, 1233
Reminyl preparations, 289
Removab, 810
Remisina, 1018
Renacet, 965
Renagel, 966
Renal impairment (prescribing), 19
Renamil, 1433
Renapro preparations, 1434
Renastart, 1434
Renasys products, 1473
Renovit, 1439
Renil, 1432
Renin inhibitor, 139
Renvela, 966
ReoPro, 203
Repaglinide, 660
Repevax, 1203
Rephoren, 965
Rexinol, 405
Replagel, 972
Repelene-VF, 109
ReQuip preparations, 405
RescueFlow, 961
Rilpivirine with Rilpivirine, Rigevidon
Ribavirin, Ripastat
RHuG-CSF, RhTSH, see
Rheumatoid arthritis and other
Respiratory system, drug delivery, Respiratory stimulants,
Restandol, 725
Restlessness and confusion, 25
Retacr, 929
Retapamulin, 1129
Reteplase, 211
Retinal disorders, 1087
Retinol palmitate with white soft paraffin and light liquid paraffin and liquid paraffin and wool fat, 1068
Retinol, see Vitamin A
Retrovir, 618
Revatio, 767
Revaxis, 1204
Revestive, 48
Revlimid, 886
Revocon, 387
Revolade, 946
Rewisca, 311
Rexocaine, 1244
Reyataz, 618
Rezolsta, 620
Rheumatoid arthritis and other inflammatory disorders, 998
Rhinitis and bacterial sinusitis, 1098
Rhinocort, 1103
Rhophylac, 1186
RtTSH, see Thyrotropin alfa
RHuG-CSF, see Lenograstim
Riamet, 581
Riastap, 111
Ribavirin, 593
Ribafutin, 543
Rifadin, 551
Rifampicin, ▶
- With ethambutol, isoniazid and pyrazinamide, ▶
- With isoniazid, ▶
- With isoniazid and pyrazinamide, ▶
Rifater, 552
Rifaximin, 543
Rifinah, 551
Rigevidon, 754
Rilpivirine, 610
Rilpivirine with emtricitabine and tenofovir, see Emtricitabine with rilpivirine and tenofovir disoproxil
Rilutek, 1023
Riluzole, 1023
Rimactane, 551
Rimexolone, 1063
Rinatec, 1102
Ringer-Lactate Solution for Injection, see Potassium chloride with calcium chloride and sodium chloride and sodium lactate
Ringer’s solution, see Potassium chloride with calcium chloride dihydrate and sodium chloride
Riociguat, 180
Risedronate sodium, 686
- With calcium carbonate and colecalciferol, 687
Risperdal preparations, 384
Risperidone, 383
Ritonavir, 621
- With lopinavir, see Lopinavir with ritonavir
Rituximab, 820
Rivaroxaban, 123
Rivastigmine, 290
Rivate, 291
Rizatriptan, 455
Rizopia products, 1444
Roaccutane, 1167
RoActemra, 1006
Roxaban, 1027
Rocaltrol, 992
Rocephin, 502
Rocuronium bromide, 1228
Rodomel XL, 352
Roferon-A, 883
Rolfumilast, 260
Romiplobastim, 947
Ropilynz XL, 404
Ropinirole, 404
Ropivacaine hydrochloride, 1247
Rosacea and acne, 1162
Rosiced, 1128
Rosidal K, 1480
Rosuvastatin, 197
Rotarix, 1215
Rotavirus vaccine, 1199, 1215
Rotigotine, 406
Rowachol, 87
Rowatinex, 743
Rozen, 1128
Rt-PA, see Alteplase
Rubeferciantis, topical NSAIDs, capsaicin, and poullices, 1056
Ruconest, 279
Rufinamide, 295, 311
Ruxolitinib, 912
Rythmodan preparations, 99
Salicylic acid with rhubarb extract, see Salicylic acid with rhubarb extract
Salicylic acid, 1182
- With benzoic acid, see Benzoic acid with salicylic acid
- With betamethasone, see Betamethasone with salicylic acid
- With boric acid and tannic acid, see Boric acid with salicylic acid and tannic acid
- With coal tar and coconut oil, see Coal tar with coconut oil salicylic acid
- With coal tar and dithranol, see Coal tar with dithranol and salicylic acid
- With coal tar and precipitated sulfur, see Coal tar with salicylic acid and precipitated sulfur
- With coal tar, see Coal tar with salicylic acid
- With dithranol and zinc oxide, see Dithranol with salicylic acid and zinc oxide
- With fluorouracil, see Fluorouracil with salicylic acid
- With lactic acid, 1182
- With rhubarb extract, 1114
- With zinc oxide, 1158
Saline, 1068
Salipraneh, 240
Saliva preparations, 385
Saliveze, 1107
Salivix preparations, 1107
Salmeterol, 243
- With fluticasone, see Fluticasone with salmeterol
Salmofalk, 41
Salvacyl, 699
Samsca, 631
Sancuso, 414
Sandimmun, 790
Sandocal preparations, 959
Sando-K, 952
Sandostatin preparations, 877
Sandrena, 714
SanoSkin, 1461
Santizor XL, 736
Sapropoterin dihydrochloride, 986
Saquinavir, 621
Sativex, 1026
Savene, 688
Savlon preparations, 1174
Saxagliptin, 654
- With metformin, 655
Saxenda, 659
Sayara Press, 764
Schaibes, 1126
Scalp and hair conditions, 1170
- Androgenetic alopecia, 1170
- Hirsutism, 1170
Scandishake, 1438
Scandonest preparations, 1245
Scanhaf, 1475
Scar FX, 1472
Scarsil, 1472
Scheriproct, 91
Schistosomicides (bilharziasis), 570
Schizophrinia, 364
Sciatrica, 1028
Sclerosants, 92, 228
Scopoderm, 418
Scopolamine hydrobromide, see Hyoscine hydrobromide
SD CodeFree, 679
Sebeco, 1154
Sebivo, 589
Seborrhoeic dermatitis, 1136
Sectral, 147
Secukinumab, 1004
Securon preparations, 160
Sedation, anaesthesia, and resuscitation in dental practice, 1219
Sedative drugs, 1223
Sebri Breezhaler, 238
Selective beta-agonists (long-acting), 241
Selective beta-agonists (short-acting), 244
Selective serotonin re-uptake inhibitors (SSRIs), 1253
Selective sinus node I, inhibitors, 205
Selegiline hydrochloride, 407
SelenaSe, 979
Selenium
- Deficiency, 979
- Scalp and hair conditions, 1170
SelenaPrecise, 979
Seleni, 523
Selexipag, 178
Selinico, 472
Selsun preparations, 1171
Senna, 61
- With ispaghula husk, 62
Senokot preparations, 62
Senocard, 679
Sepais, 480
Septanest, 1013
Septicaemia related to vascular catheter, 484
Seprin, 532
Sercasil, 1033
Seravit, 1439
Serc, 420
Sereflex, 255
Serenate, 369
Seretide preparations, 255
Serentec preparations, 244
Seroquel preparations, 383
Serotonin syndrome, 342
Seroxat, 350
Sertraline, 350
Setocone, 1479
Setofilm, 415
Sevelamer, 966
Sevikar preparations, 172
Sevodyne, 430
Sevoflurane, 1223
Sevedol, 441
Sex hormones, 707
- Cancer, 709
- Heavy menstrual bleeding, 709
- Hormone replacement therapy, 709
- Oral contraception, 707
Sexual dysfunction, 365
Short-acting beta2 agonists, 234
Short-acting insulins, 646
Short bowel syndrome, 47
Shortec, 444
Sickle-cell anaemia, 922
Signior, 878
Siklos, 863
Sildenafil, 766
Silflex, 1464
Silgel, 1472
Silicone keloid dressings, 1472
Silik, 1159
Silon-TSR, 1464
Siltape, 1475
Silutiximal, 822
Sivercel preparations, 1470
Silver dressings, see Antimicrobial dressings
Silver nitrate, 1181
Silver sulfadiazine, 1128
Simbrinza, 1081
Simprevir, 597
Simeticone, 67, 70
- With aluminium hydroxide and magnesium hydroxide, 69
- With aluminium hydroxide, dicycloverine hydrochloride and magnesium oxide, see Dicycloverine hydrochloride with aluminium hydroxide, magnesium oxide and simeticone
- With hydrotalcite, see Co-simialcine
- With loperamide, see Loperamide with simeticone
Simponi, 1016
Simulect, 795
Simvastatin, 199
Simvastatin, 198
- With ezetimibe, 199
- With fenofibrate, 199
Simnet preparations, 397
Singular, 258
Sinbrine, 134
Sinusitis and oral pain, 1099
Siogel, 1119
Siromilus, 790
Sirturo, 553
Sitagliptin, 655
- With metformin, 656
Silveto, 542
Skeletal muscle relaxants, 1023
Skin adhesives, 1176
Skin and nail infections, 559
Skin cleansers, antiseptics and desloughing agents, 1172
Skin closure strips, sterile, 1476
Skin conditions, management, 1117
Skin disfigurement, 1176
Skin infections, 489, 1125
- Angular cheilitis, 1126
- Candidiasis, 1126
- Crab lice, 1127
- Dermatophytoses, 1126
- Head lice, 1127
- Herpes labialis, 1126
- Itching, 1127
- Pityriasis versicolor, 1126
- Scabies, 1126
Skin infections, bacterial, 489
Skinnees, 1477
Skinorex, 1165
Skintract, 1460
Sleek, 1475
Sleep disorders, 459
Slinky, 1476
Slocinx XL, 738
SLO Drink preparations, 1440
Slo-Phyllin, 264
Sloughy wound, see Wound management
Slow Sodium, 953
Slozem, 154
Smallpox vaccine, 1199
Snake bites and animal stings, 1256, 1261
Sno-Pro, 1450
Sno Tears, 1068
Sodiofolin, 869
Sodium acid phosphate with sodium phosphate, 57
Sodium alginate with calcium carbonate and sodium bicarbonate, 81
Sodium alginate with potassium bicarbonate, 68
Sodium aurothiomalate, 1003
Sodium bicarbonate
- Electrolyte imbalances, 950
- Ear wax, 1097
- With calcium carbonate and sodium alginate, see Sodium alginate with calcium carbonate and sodium bicarbonate
- With magnesium carbonate and magnesium trisilicate, see Magnesium trisilicate with magnesium carbonate and sodium bicarbonate
- With sodium chloride, 1109
Sodium carbonate
- Eye, 1068
- Fluid and electrolytes, 953
- Oral hygiene, 1109
- With glucose, 954
- With calcium carbonate and potassium chloride, see Potassium chloride with calcium carbonate, dihydrate and sodium chloride
- With dextran 70, see Dextran 70 with sodium chloride
- With sodium bicarbonate, see Sodium bicarbonate with sodium chloride
Sodium citrate, 743
Sodium citrate with potassium chloride, rice powder and sodium chloride, see Potassium chloride with rice powder, sodium chloride and sodium citrate
Sodium clodronate, 688
Sodium cromoglicate
- Allergic rhinitis, 1105
- Asthma, 260
- Conjunctivitis, 1060
Sodium cromoglicate, see Sodium cromoglicate
Sodium feredetate, 936
Sodium fluoride, 1110
Sodium hyaluronate, 1068
Sodium ironedetate, see Sodium feredetate
Sodium Lactate Intravenous Infusion, Compound, see Potassium chloride with calcium chloride and sodium chloride and sodium lactate
Sodium lactate with calcium chloride, potassium chloride and sodium chloride, see Potassium chloride with calcium chloride and sodium chloride and sodium lactate
Sodium nitrite, 1257
Sodium nitroprusside, 177
Sodium oxybate, 466

Downloaded from www.medicalbr.com
Sodium phenylbutyrate, 977
Sodium phosphate with sodium acid phosphate, see Sodium acid phosphate with sodium phosphate
Sodium picosulfate, 62
  » With magnesium citrate, see Magnesium citrate with sodium picosulfate
Sodium picosulfate, see Sodium picosulfate
Sodium polystyrene sulfonate, 968
Sodium sitobugluconate, 573
Sodium tetradecyl sulfate, 228
Sodium thiosulfate, 1257
Sodium valproate, 312
Softcrepe, 1479
Soffen, 1123
Soffperla, 753
Sofosbuvir, 1436
Soffen, 1123
Soffperla, 753
Sodium acid phosphate, see
  » Hyaluronidase,
  » Collagenase,
  » Capsaicin,
Syntocinon, 776
Syntometrine, 777
Syringe drivers, 26
Systane, 1067
Sytrin, 936

T
Tabryn MR, 740
Tacalcitol, 1159
Tacrolimus
- Immunosuppression, 791
- Skin, 1155
Tadalafil, 767
Taenicidus, 570
Tafamidis, 389
Tafinlar, 898
Tafluprost, 1084
- With timolol, 1085
Tagamet, 73
Tagrisso, 909
Talimogene laherparevvec, 881
Taltz, 1156
Tambocor preparations, 101
Tamfex XL, 740
Tamiflu, 624
Tamoxifen, 879
Tamsulosin hydrochloride, 589
- With dutasteride, 740
- With solifenacin, 740
Tamurex, 740
Tanatril, 165
Tapclob, 320
Tapentadol, 446
Taptiqlum, 1085
Taransis products, 1445, 1447
Tarceva, 900
Targaxan, 544
Targeted therapy responsive malignancy, 889
Targinact, 445
Targocid, 504
Targretin, 867
Tarsil, 531
Tasigna, 908
Tasmar, 393
Tavanic, 529
Tavelg, 273
Tavexus, 855
Taxotere, 855
Tazarotene, 1158
Tazobactam with piperacillin, see Piperacillin with tazobactam
Tazocin, 516
3TC, see Lamivudine
Tear deficiency, ocular lubricants, and astringents, 1065
Tear-Lac, 1067
Tears Naturale, 1067
Tecfidera, 802
Tedizolid, 541
Teduglutide, 48
TEEZ, 679
Teegaderm products, 1462, 1463, 1464, 1465, 1466, 1467, 1468, 1470
Tegafur with gimeracil and oteracil, 848
Tegfutik, 1023
Tegretol preparations, 299
Teicoplanin, 504
Telavancin, 504
Telbivudine, 589
Telfa products, 1459, 1460, 1472
Telfast, 270
Telmisartan, 173
- With hydrochlorothiazide, 173
Telzir, 620
Temazepam, 463
Temgesic, 429
Temocillin, 524
Temodal, 834
Temomodac, 834
Temoparin, 889
Temozolomide, 833
Temosirilom, 915
Tencetaplast, 211
Tenif, 148
Tenofovir disoproxil, 616
Tenerit, 149
Teneritex, 149
Tenormin, 147
Tenoxicam, 1051
Tenprolide XL, 383
Tensaid XL, 149
Tenprolide XL, 1051
Tenretic preparations, 101
Tenretic preparations, 536
Tenifed, 909
Teniprodol, 909
Tensipine MR, 909
Tensoplast preparations
- With timolol, 1085
Tengion, 936
Temptazepam, 463
Temosirilom, 915
Tencetaplast, 211
Tenif, 148
Tenofovir disoproxil, 616
Tenerit, 149
Teneritex, 149
Tenormin, 147
Tenoxicam, 1051
Tenprolide XL, 383
Tensaid XL, 162
Tensipine MR, 158
Tensoplast preparations, 1475, 1479
Tensopress, 1480
Teoptic, 834
Tepadin, 849
Tephrine, 429
Terasezza, 1164
Terazosin, 741
Terbinafine, 1132
Terbutaline sulfate, 246
Teriflunomide, 806
Teriparatide, 690
Terlipressin acetate, 87
Termination of pregnancy, 483, 777
Teromeg, 202
Terpenes, 87
Terra-Contril preparations, 1151
Test for Helicobacter pylori, 71
Testim, 725
Testogel, 725
Testosterone, 724
Testosterone decanoate, isocaproate, phenylpropionate and propionate, 725
Testosterone enantate, 725
Testosterone propionate, 725
Testosterone undecanoate, 725
Tetanus and diphtheria with poliomyelitis, see Diphtheria with poliomyelitis and tetanus vaccine
Tetanus immunoglobulin, 1188
Tetanus vaccine, 1199
Tetanus with diphtheria with haemophilus influenza with pertussis and poliomyelitis, see Diphtheria with haemophilus influenza type b vaccine, pertussis, poliomyelitis and tetanus
Tetanus with diphtheria with pertussis and diphtheria, see Diphtheria with pertussis, poliomyelitis vaccine and tetanus
Tetrabenzine, 387
Tetracaine
- Anaesthesia, 1248
- Eye, 1076
- With lidocaine, see Lidocaine with tetracaine
Tetracosactide, 700
Tetracosactrin, see Tetracosactide
Tetracycline, 536
Tetracyclines, 488, 574
Tetrydsal, 535
Tetrastarch, 961
Teveten, 170
Teysono, 848
Thalidomide, 887
Thiamin, 951
TheCal-D5, 994
Theophylline, 234, 263, 1254
Thiamine, 989
Thiazides and related diuretics, 219
Thick & Easy preparations, 1440
Thicken Aid
- With timolol, 1085
TheraCal, 994
Thiopentone, see Thiopentone sodium
Thiopentone sodium, 516
Tick-borne encephalitis vaccine, 1200, 1216
TiCoVac, 1216
Tigecycline, 536
Tilade preparations, 259
Tildiem preparations, 153
Tilorol SR, 448
Tilofyl, 438
Tiloket preparations
- With amiloride and timolol, 1079
- With amiloride and hydrochlorothiazide, 146
- With bendroflumethiazide, 146
- With bimatoprost, see Bimatoprost with timolol
- With brimonidine, see Brimonidine with timolol
- With brinzolamide, see Brinzolamide with timolol
- With dorzolamide, see Dorzolamide with timolol
- With lantanolprost, see Lantanoprost with timolol
- With travoprost, see Travoprost with timolol
Timoptol preparations, 1079

Downloaded from www.medicalbr.com
Tinazepine, 488, 514
Tinzaparin sodium, 129
Tioconazole, 1131
Tioconazole, 1131
Tioconazole, 1131
Tiopex, 1079
Tiotropium, 240
Tramadol hydrochloride, 447
Trimetopen, 915
Tramquil SR, 449
Tramulief SR, 448
Trandate, 144
Trandolapril, 169
Transeamic acid, 107
Tranquilyn, 333
Transderm-Nitro, 213
Transient ischaemic attack, 113
Transtarla, 1024
Transorbent, 1467
Transpore, 1476
Travact, 430
Transeural resection of prostate, 482
Tranlycypromine, 345
Trophic preparations, 144
Trastuzumab, 823
Trastuzumab emtansine, 824
Travatan, 1085
Travel, see Vaccines for travel
Travel Calm, 418
Travoprost, 1085
With timolol, 1086
Traxon, 1039
Trazodone hydrochloride, 352
Trecin, 1168
Tree pollen extract, 278
Trental, 228
Tresulturn, 834
Tresiba preparations, 671
Tretinoin, 867
With clindamycin, 1168
With erythromycin, 1168
Trevicta, 381
Triamcinolone acetonide
Inflammation and allergy, 641
Soft tissue and joints, 1054
Rhinitis, 1104
Triamcinolone hexacetonide, 1055
Triamcinolone with chlortetracycline, see Chlortetracycline with triamcinolone
Triamterene, 224
With chlortalidone, 224
With furosemide, see Furosemide with triamterene
Triamterene with hydrochlorothiazide, see Co-trimaterterzide
Triapin, 169
Triazole antifungals, 559
Triflubin, see Rifliblin
Trichomonacides, 573
Tricocces, 1458
Tricycl and related antidepressant drugs, 343
Triestral, 718
Trientine dihydrochloride, 978
Trifluperoxazine, 372
Trifluridine with tipiracil, 849
Trigeminal neuralgia, 458
Trihexyphenidyl hydrochloride, 392
Tripletal, 307
Trimepazine tartrate, see Alimemazine tartrate
Trimethoprim, 542
With sulfamethoxazole, see Co-trimoxazole
Trimipranime, 352
Trimovate, 1149
Triptafen preparations, 356
Triptans, 453
Triptorelin, 689
Trisenox, 861
Trisequens preparations, 719
Triate, 168
Tritamyl products, 1443
Triumeq, 611
Trizinir, 611
Trolactin, 120
Tropicamide, 1074
Tropicamide with phenylephrine, see Phenylephrine with tropicamide
Tropium chloride, 734
Trosyl, 1131
TRUEresult, 679
TrueTrack System, 679
TRUEyou, 679
Trudil, 655
Trusopt, 1081
Truvada, 615
Trypapacoids, 573
Tuberculin PPD, see Tuberculin purified protein derivative
Tuberculin purified protein derivative, 1190
Tuberculosis, 546
Extrapulmonary tuberculosis, 548
Latent tuberculosis, 548
Treatment failure, 548
Treatment interruptions, 548
Tuberculosis diagnostic test, 1190
Tubifast products, 1478
Tubigrip, 1477
Tubular bandages and garments, 1477
Tumour lysis syndrome, 826
Twinrix, 1209
TwoCal preparations, 1426
Tybost, 623
Tygacil, 537
Tylex, 431
Tymbrinbe, 494
Type 1 diabetes, 644
Type 2 diabetes, 646
Typhexis, 1208
Typhim Vi, 1208
Typhoid vaccine, 1200, 1208
Typhoid with hepatitis A vaccine, see Hepatitis A with typhoid vaccine
TYR Anamix Junior LQ, 1453
TYR Lophex LQ, 1453
Tyrosinaemia, 1452
Tyrosinaemia type I, 977
Tyrosine 1000, 1450
TYR preparations, 1453
Tysabri, 971
Tyaera, 989
Tyverb, 906
U
Ulcerative colitis, 73
Ulpirstin acetate, 75
Ultec Pro, 1465
Ultibro Breezhaler, 239
Ultiva, 1234
Ultra bandages, 1479
Ultraproct, 90
Ultrasonic nebulisers, 230
Undecenoic acid

Unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI), 206

Upostelle, 762

Upravi, 178

Urarex, 735

Urea (15C), 81

Urea cycle disorders, 977

Urea hydrogen peroxide, 1098

Urea with hydrocortisone, see Hydrocortisone with urea

UrgoCell preparations, 1470

UrgoClean, 1464

Urgosorb preparations, 1468, 1470

UrgoSTART preparations, 1472

Urotidis preparations, 1464, 1467, 1471

Uricosurics, 1020

Uricto, 1021

Urinalysis, 675, 693

Urinary frequency, enuresis and incontinence, 731

Urinary retention, 736

Urinary-tract infections, 556

Urispas, 733

Urofollitropin, 704

Urokinese, 133

Urological anti-inflammatory drugs, 744

Urological pain, 742

Urological surgery, 744

Uro-Tainer products, 744

Urothelial toxicity, 827

Ursodeoxycholic acid, 86

Ursofalk, 87

Ustekinumab, 1006

Utovlan, 721

Utrogestan, 722

Vaccines, 1190, 1201

- Anthrax vaccine, 1192

- BCG vaccine, 1192

- Botulism antitoxin, 1193

- Cholera vaccine, 1193

- Diphtheria vaccine, 1193

- Haemophilus influenzae type B conjugate vaccine, 1193

- Hepatitis A vaccine, 1194

- Hepatitis B vaccine, 1194

- Human papillomavirus vaccine, 1195

- Immunisation schedule, 1190

- Influenza vaccine, 1195

- Invasive Haemophilus influenzae type b disease, 1194

- Japanese encephalitis vaccine, 1195

- Measles, Mumps and Rubella vaccine, 1196

- Meningococcal vaccines, 1196

- Pertussis vaccine, 1197

- Pneumococcal vaccine, 1197

- Poliomyelitis vaccine, 1198

- Rabies vaccine, 1198

- Rotavirus vaccine, 1199

- Smallpox vaccine, 1199

- Tetanus vaccine, 1199

- Tick-borne encephalitis vaccine, 1200

- Typhoid vaccine, 1200

- Varicella-zoster vaccine, 1200

- Yellow fever vaccine, 1200

- Vaccines for travel, 1200

- V.A.C. products, 1473

- Vacufet, 1461

- Vacutex, 1468

- Vagifem, 783

- Vaginal and vulval conditions, 779

- Vaginal atrophy, 782

- Valaciclovir, 602

- Valcyte, 604

- Valdoxan, 344

- Valganciclovir, 603

- Valine50, 1450

- Valios, 292

- Valket Retard, 1045

- Valproate, 296

- Valproic acid, 337

- Valsartan, 174

  - With amlopidine, see Amlopidine with valsartan

  - With hydrochlorothiazide, 174

  - With sacubitril, 186

- Valtrex, 603

- Vamju, 666

- Vancin preparations, 506

- Vancomycin, 505

- Vandetanib, 916

- Vaniqua, 1171

- Vanquoral, 790

- Vantobra, 494

- Vapour-permeable films and membranes, 1461

- VAQTA, 1209

- Vardenafil, 768

- Varenicline, 475

- Vargatef, 918

- Varicella-zoster, 1189

- Varicella-zoster immunoglobulin, 1189

- Varicella-zoster infections, 598

- Varicella-zoster vaccine, 1200, 1216

- Varilrix, 1217

- Variquel, 87

- Varivax, 1217

- Vascalpha, 155

- Vascular disease, 226

- Vaseline, 1124

- Vasoconstrictor sympathomimetics, 181

- Vasodilator antihypertensive drugs, 137

- Vasopressin, 630

- Vasant XL, 737

- Vectibix, 817

- Vecuronium bromide, 1229

- Vedolizumab, 44

- Vedrop, 996

- Vehicles, 1117

- Vein malformations, 228

- Velaglucerase alfa, 973

- Velband, 1480

- Velcade, 890

- Velletri, 112

- Vellaflum products, 1462

- Velpropho, 967

- Venmrufenib, 917

- Venaxa XL, 352

- Vencar XL, 352

- Vencylyto, 920

- Venetoc lax, 919

- Venlalblue XL, 352

- Venlaidex XL, 352

- Venlafaxine, 351

- Venlallic XL, 352

- Venofer, 933

- Venous thromboembolism, 112

- Vensir XL, 352

- Ventavis, 179

- Ventra, 77

- Ventricular arrhythmias, 99

- Ventricular tachycardia, 98

- Venturi products, 1473

- Vepesid, 853

- Veracur, 1180

- Verapamil hydrochloride, 159

- Verapress MR, 160

- Veromox, 572

- Vernafl, 1473, 1476, 1478

- Verrugon, 1182

- Versatsi, 1243

- Vertab SR, 160

- Verteporfin, 1090

- Verte, 244

- Vescicare, 734

- Vesanmi, 740

- VFEND, 567

- Viagra, 767

- VIA TIM, 1210

- Viabe XM, 154

- Vibativ, 505

- Vibramycin preparations, 535, 1115

- Victaryl, 438

- Victoz, 659

- Vidaza, 839

- Videne preparations, 1173

- Videx preparations, 612

- Viekirax, 593

- ViePax preparations, 352

- Vigabatrin, 316

- Vigam preparations, 1188

- Vilanterol with fluticasone, see Fluticasone furoate with vilanterol

- Vilanterol with umecilminium, see Umeclidinium with vilanterol

- Umeclidinium with vilanterol

- Vildagliptin, 656

  - With metformin, 656

- Vinizin, 974

- Vinmo, 1049

- Vintup, 303

- Vincristine sulfate, 858

- Vinca alkaloids, 827

- Vincristine sulfate, 858

- Vindesine sulfate, 859

- Vinflunine, 859

- Vinorelbin, 860

- Vipemtot, 654

- Vipidina, 653

- Virafeon preparations, 590

- Viral eye infection, 1073

- Viral infection, 587

- Viral skin infections, 1135

- Viral vaccines, 1208

- Viramune, 610
Vivalvoginal candidiasis in pregnancy, 779

W

Wakix, 467
Warburtons products, 1442
Warfarin sodium, 135
Warticon, 1180
Warts and calluses, 1179
\(\text{\textbullet\ }\) Anogenital warts, 1179
Wasp Venom, 278
Wasp venom extract, 278
WaveSense JAZZ, 679
Waxsol, 1098
Weak opioids, 422
Welland, 1473
Wellfoods products, 1442
Wellvone, 569
White soft paraffin with liquid paraffin and wool alcohols, see Liquid paraffin with white soft paraffin and wool alcohols
White soft paraffin with retinol palmitate with light liquid with liquid paraffin and wool, see Retinol palmitate with white soft paraffin and liquid paraffin and liquid paraffin and wool fat
Wilson’s disease, 978
Wilton, 978
WoundASSIST products, 1473
Wounds, 1457
\(\text{\textbullet\ }\) Adjunct dressings and appliances, 1472
\(\text{\textbullet\ }\) Advanced wound dressings, 1460
\(\text{\textbullet\ }\) Antimicrobial dressings, 1468
\(\text{\textbullet\ }\) Bandages, 1476
\(\text{\textbullet\ }\) Basic wound contact dressings, 1457
\(\text{\textbullet\ }\) Compression hosiery and garments, 1481
\(\text{\textbullet\ }\) Specialised dressings, 1472
\(\text{\textbullet\ }\) Topical negative pressure therapy, 1473
\(\text{\textbullet\ }\) Wound care accessories, 1474

X

Xadago, 407
Xagrid, 945
Xalilin preparations, 1066
Xalacom, 1084
Xalatan, 1084
Xalkori, 897
Xaluprine, 844
Xanax, 326
Xanthine oxidase inhibitors, 1021
Xanhines, 261
Xarelto, 125
Xatral preparations, 737
Xeloda, 840
Xemacort, 1147
Xenazine, 387
Xenical, 89
Xeomim, 388
Xepin, 1161
Xeplon, 381
Xerolin, 1107
Xetinin XL, 509
Xgeva, 692
Xiapex, 1056
Xifaxantu, 544
Xigduo, 664
Xipamide, 225
XLYS TRY Glutaridon, 1447
XMET preparations, 1448
XMTVI preparations, 1449
Xolair, 257
Xomolix, 419
XPHEN TYR preparations, 1453
XPTM preparations, 1453
Xtandi, 874
Xitlophy, 671
Xipad, 1473
Xylolaine preparations, 1243
Xylometazoline hydrochloride, 1100
\(\text{\textbullet\ }\) With antazoline, see Antazoline with xylometazoline
Xyloproct, 91
Xyrem, 467
Xyzal, 270

Y

Yacella, 752
Yasmin, 752
Yellow card scheme, 12
Yellow fever vaccine, 1200, 1217
Yellox, 1076
Yemex, 438
Yentreve, 351
Yervoy, 813
Yiznell, 752
Yondelis, 851

Z

Zacrin, 458
Zaditen, 275, 1060
Zafirlukast, 259
Zalasta, 380
Zaleplon, 460, 465
Zaltrap, 921
Zaluron XL, 383
Zalviso, 446
Zamadol preparations, 448
Zanamivir, 625
Zanidip, 156
Zantac, 75
Zapatin, 431
Zaponex, 378
Zarzio, 943
Zavedos, 837
Zavesca, 976
Zebini, 300
Zedbal, 508
Zeffix, 616
Zelapar, 408
Zelboraf, 918
Zelleta, 759
Zemom XL, 215
Zemplar, 995
Zemtard XL, 154
Zenalb, 960
Zepatier, 591
Zerbaxa, 503
Zeridame SR, 448
Zerit, 616
ZeroAQS, 1123
Zerobase, 1123
Zerocream, 1123
Zeroguent, 1124
Zerolatum preparations, 1121
Zeroneum, 1122
Zestoretic preparations, 166
Zestril, 165
Zetuvit preparations, 1459
Zetvera, 503
Ziagen, 611
Ziclas, 666
Zicron preparations, 666
Zidovudine, 514
Zidovudine, 611
Ziclaseg, 666
Zidovudine, 666
Zidovudine, 514
Zidovudine, 617
▶ With abacavir and lamivudine, see Abacavir with lamivudine and zidovudine
▶ With lamivudine, 618
Zimovane, 466
Zinacef, 499
Zinamide, 556
Zinbryta, 804
Zinc, 979
Zinc acetate, 978
▶ With erythromycin, see Erythromycin with zinc acetate
Zinc deficiency, 979
Zinc oxide
▶ With benzyl benzoate, bismuth oxide, bismuth subgallate, hydrocortisone acetate and peru balsam, see Benzyl benzoate with bismuth oxide, bismuth subgallate, hydrocortisone acetate, peru balsam and zinc oxide
▶ With benzyl benzoate, bismuth oxide, hydrocortisone acetate, peru balsam and pramocaine hydrochloride, see Benzyl benzoate with bismuth oxide, hydrocortisone acetate, peru balsam, pramocaine hydrochloride and zinc oxide
▶ With calamine, see Calamine with zinc oxide
▶ With coal tar, see Coal tar with zinc oxide
▶ With dithranol and salicylic acid, see Dithranol with salicylic acid and zinc oxide
▶ With ichthammol, see Ichthammol with zinc oxide
▶ With salicylic acid, see Salicylic acid with zinc oxide
Zinc sulfate, 979
Zinc undecenoate with undecenoic acid, see Undecenoic acid with zinc undecenoate
Zindacclin, 1164
Zinert, 1164
Zinforo, 503
Zinmat, 499
Zipotec, 1481
Zispin preparations, 355
Zithromax, 508
Zitral, 846
Zocor, 199
Zoely, 751
Zofran preparations, 415
Zoladex preparations, 696
Zoledronic acid, 688
Zolmitriptan, 456
Zolpidem tartrate, 460, 465
Zomacton, 707
Zomacton, 444
Zonesta, 689
Zonig preparations, 457
Zomorph, 442
REPORT OF SUSPECTED ADVERSE DRUG REACTIONS

If you suspect an adverse reaction may be related to one or more drugs/vaccines/complementary remedies, please complete this Yellow Card. See 'Adverse reactions to drugs' section in BNF or www.mhra.gov.uk/yellowcard for guidance. Do not be put off reporting because some details are not known.

**PATIENT DETAILS**

Patient Initials: ____________  Sex: M / F  Age (at time of reaction): ____________  Weight (kg): ____________  Is the patient pregnant? Y / N  Ethnicity: ____________  Identification number (e.g. Practice or Hospital Ref): ____________

**SUSPECTED DRUG(S)/VACCINE(S)**

<table>
<thead>
<tr>
<th>Drug/Vaccine (Brand if known)</th>
<th>Batch</th>
<th>Route</th>
<th>Dosage</th>
<th>Date started</th>
<th>Date stopped</th>
<th>Prescribed for</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SUSPECTED REACTION(S)**

Please describe the reaction(s) and any treatment given. (Please attach additional pages if necessary):

<table>
<thead>
<tr>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recovered</td>
</tr>
<tr>
<td>Recovering</td>
</tr>
<tr>
<td>Continuing</td>
</tr>
<tr>
<td>Other</td>
</tr>
</tbody>
</table>

Date reaction(s) started: ____________  Date reaction(s) stopped: ____________

Do you consider the reactions to be serious?  Yes / No

If yes, please indicate why the reaction is considered to be serious (please tick all that apply):

- Patient died due to reaction
- Life threatening
- Congenital abnormality
- Involved or prolonged inpatient hospitalisation
- Involved persistent or significant disability or incapacity
- Medically significant; please give details: ____________

If the reactions were not serious according to the categories above, how bad was the suspected reaction?

- Mild
- Unpleasant, but did not affect everyday activities
- Bad enough to affect everyday activities
It's easy to report online: www.mhra.gov.uk/yellowcard

OTHER DRUG(S) (including self-medication and complementary remedies)
Did the patient take any other medicines/vaccines/complementary remedies in the last 3 months prior to the reaction? Yes / No
If yes, please give the following information if known:

<table>
<thead>
<tr>
<th>Drug/Vaccine (Brand if known)</th>
<th>Batch</th>
<th>Route</th>
<th>Dosage</th>
<th>Date started</th>
<th>Date stopped</th>
<th>Prescribed for</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Additional relevant information e.g. medical history, test results, known allergies, rechallenge (if performed). For reactions relating to use of a medicine during pregnancy please state all other drugs taken during pregnancy, the last menstrual period, information on previous pregnancies, ultrasound scans, any delivery complications, birth defects or developmental concerns.

Please list any medicines obtained from the internet:

REPORTER DETAILS
Name and Professional Address:

______________________________

________

Postcode: _______________________ Tel No: _______________________

Email: _______________________

Speciality: _______________________

Signature: ______________________ Date: _______________________

CLINICIAN (if not the reporter)
Name and Professional Address:

______________________________

________

Postcode: _______________________ Tel No: _______________________

Email: _______________________

Speciality: _______________________

Signature: ______________________ Date: _______________________

Information on adverse drug reactions received by the MHRA can be downloaded at www.mhra.gov.uk/daps
Stay up-to-date on the latest advice for the safe use of medicines with our monthly bulletin Drug Safety Update at: www.mhra.gov.uk/drugsafetyupdate

Please attach additional pages if necessary. Send to: FREEPOST YELLOW CARD (no other address details required)
REPORT OF SUSPECTED ADVERSE DRUG REACTIONS

If you suspect an adverse reaction may be related to one or more drugs/vaccines/complementary remedies, please complete this Yellow Card. See "Adverse reactions to drugs" section in BNF or www.mhra.gov.uk/yellowcard for guidance. Do not be put off reporting because some details are not known.

**PATIENT DETAILS**
Patient Initials: ___________  Sex: M / F  Is the patient pregnant? Y / N  Ethnicity: ___________
Age (at time of reaction): ___________  Weight (kg): ___________  Identification number (e.g. Practice or Hospital Ref): ___________

**SUSPECTED DRUG(S)/VACCINE(S)**
<table>
<thead>
<tr>
<th>Drug/Vaccine (Brand if known)</th>
<th>Batch</th>
<th>Route</th>
<th>Dosage</th>
<th>Date started</th>
<th>Date stopped</th>
<th>Prescribed for</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SUSPECTED REACTION(S)** Please describe the reaction(s) and any treatment given. (Please attach additional pages if necessary):

Date reaction(s) started: ___________  Date reaction(s) stopped: ___________

Do you consider the reactions to be serious?  Yes / No
If yes, please indicate why the reaction is considered to be serious (please tick all that apply):

- [ ] Patient died due to reaction
- [ ] Life threatening
- [ ] Congenital abnormality
- [ ] Involved or prolonged inpatient hospitalisation
- [ ] Involved persistent or significant disability or incapacity
- [ ] Medically significant; please give details: ___________

If the reactions were not serious according to the categories above, how bad was the suspected reaction?

- [ ] Mild
- [ ] Unpleasant, but did not affect everyday activities
- [ ] Bad enough to affect everyday activities

Outcome:  
- [ ] Recovered
- [ ] Recovering
- [ ] Continuing
- [ ] Other

---
It’s easy to report online: www.mhra.gov.uk/yellowcard

**OTHER DRUG(S) (including self-medication and complementary remedies)**
Did the patient take any other medicines/vaccines/complementary remedies in the last 3 months prior to the reaction? Yes / No
If yes, please give the following information if known:

<table>
<thead>
<tr>
<th>Drug/Vaccine (Brand if known)</th>
<th>Batch</th>
<th>Route</th>
<th>Dosage</th>
<th>Date started</th>
<th>Date stopped</th>
<th>Prescribed for</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Additional relevant information** e.g. medical history, test results, known allergies, rechallenge (if performed). For reactions relating to use of a medicine during pregnancy please state all other drugs taken during pregnancy, the last menstrual period, information on previous pregnancies, ultrasound scans, any delivery complications, birth defects or developmental concerns.

**REPORTER DETAILS**
Name and Professional Address:
__________________________________________
__________________________________________
__________________________________________
Postcode: ___________________________ Tel No: ___________________________
Email: ________________________________
Speciality: ____________________________
Signature: ____________________________ Date: ____________________________

**CLINICIAN (if not the reporter)**
Name and Professional Address:
__________________________________________
__________________________________________
__________________________________________
Postcode: ___________________________ Tel No: ___________________________
Email: ________________________________
Speciality: ____________________________
Date: ____________________________

Information on adverse drug reactions received by the MHRA can be downloaded at [www.mhra.gov.uk/daps](http://www.mhra.gov.uk/daps)
Stay up-to-date on the latest advice for the safe use of medicines with our monthly bulletin *Drug Safety Update* at: [www.mhra.gov.uk/drugsafetyupdate](http://www.mhra.gov.uk/drugsafetyupdate)

Please attach additional pages if necessary. Send to: FREEPOST YELLOW CARD (no other address details required)
Adult Advanced Life Support Algorithm

Unresponsive and not breathing normally

- Call resuscitation team

CPR 30:2
Attach defibrillator/monitor
Minimise interruptions

Assess rhythm

Shockable (VF/Pulseless VT)

- 1 Shock
  - Minimise interruptions

Immediate post cardiac arrest treatment
- Use ABCDE approach
- Aim for SpO2 of 94-96%
- Aim for normal PaCO2
- 12-lead ECG
- Treat precipitating cause
- Targeted temperature management

Immediately resume CPR for 2 min
Minimise interruptions

Return of spontaneous circulation

Non-shockable (PEA/Asystole)

- Immediately resume CPR for 2 min
  - Minimise interruptions

During CPR
- Ensure high quality chest compressions
- Minimise interruptions to compressions
- Give oxygen
- Use waveform capnography
- Continuous compressions when advanced airway in place
- Vascular access (intravenous or intraosseous)
- Give adrenaline every 3-5 min
- Give amiodarone after 3 shocks

Treat Reversible Causes
- Hypoxia
- Hypovolaemia
- Hypoa/hyperkalaemia/metabolic
- Hypothermia
- Thrombosis - coronary or pulmonary
- Tension pneumothorax
- Tamponade – cardiac
- Toxins

Consider
- Ultrasound imaging
- Mechanical chest compressions to facilitate transfer/treatment
- Coronary angiography and percutaneous coronary intervention
- Extracorporeal CPR

Reproduced with the kind permission of the Resuscitation Council (UK) from Resuscitation Guidelines, 2015

downloaded from www.medicalbr.com
Medical emergencies in the community

Overview
Drug treatment outlined below is intended for use by appropriately qualified healthcare professionals. Only drugs that are used for immediate relief are shown; advice on supporting care is not given. Where the patient’s condition requires investigation and further treatment, the patient should be transferred to hospital promptly.

Acute coronary syndromes

▶ ANGINA: UNSTABLE
Aspirin dispersible tablets p. 117 (75 mg, 300 mg)
BY MOUTH (DISPERSED IN WATER OR CHEWED)
» Adult: 300 mg

▶ PLUS
▶ EITHER Glyceryl trinitrate aerosol spray p. 212
(400 micrograms/metered dose)
SUBLINGUALLY
» Adult: 1–2 sprays, repeated as required
▶ OR Glyceryl trinitrate tablets (300 micrograms, 500 micrograms, 600 micrograms)
SUBLINGUALLY
» Adult: 0.3–1 mg, repeated as required

▶ MYOCARDIAL INFARCTION: NON-ST-SEGMENT ELEVATION
Treat as for Angina: unstable

▶ MYOCARDIAL INFARCTION: ST-SEGMENT ELEVATION
Aspirin dispersible tablets (75 mg, 300 mg)
BY MOUTH (DISPERSED IN WATER OR CHEWED)
» Adult: 300 mg
Glyceryl trinitrate aerosol spray (400 micrograms/metered dose)
SUBLINGUALLY
» Adult: 1–2 sprays, repeated as required
▶ OR Glyceryl trinitrate tablets (300 micrograms, 500 micrograms, 600 micrograms)
SUBLINGUALLY
» Adult: 0.3–1 mg, repeated as required

Acute asthma

ásthma: acute

Regard each emergency consultation as being for severe acute asthma until shown otherwise; failure to respond adequately at any time requires immediate transfer to hospital

▶ EITHER Salbutamol aerosol inhaler p. 244
(100 micrograms/metered inhalation)
BY AEROSOL INHALATION VIA LARGE-VOLUME SPACER
AND A CLOSE-FITTING FACE MASK IF CHILD UNDER 3 YEARS
» Adult and Child: 2–10 puffs each inhaled separately, repeated every 10–20 minutes or as necessary
▶ OR Salbutamol nebuliser solution (1 mg/mL, 2 mg/mL)
BY INHALATION OF NEBULISED SOLUTION (VIA OXYGEN-DRIVEN NEBULISER IF AVAILABLE)
» Child 4 years and below: 2.5 mg every 20–30 minutes or as necessary
» Child 5–11 years: 2.5–5 mg every 20–30 minutes or as necessary
» Child 12–17 years: 5 mg every 20–30 minutes or as necessary
» Adult: 5 mg every 20–30 minutes or as necessary
▶ OR Terbutaline sulfate nebuliser solution p. 246 (2.5 mg/mL)
BY INHALATION OF NEBULISED SOLUTION (VIA OXYGEN-DRIVEN NEBULISER IF AVAILABLE)
» Child 4 years and below: 5 mg every 20–30 minutes or as necessary
» Child 5–11 years: 5–10 mg every 20–30 minutes or as necessary
» Child 12–17 years: 10 mg every 20–30 minutes or as necessary
» Adult: 10 mg every 20–30 minutes or as necessary

▶ PLUS (in all cases)
▶ EITHER Prednisolone tablets p. 639 (or prednisolone soluble tablets) (5 mg)
BY MOUTH
» Child 11 years and below: 1–2 mg/kg (max. 40 mg) once daily for up to 3 days or longer if necessary; if child has been taking an oral corticosteroid for more than a few days, give prednisolone 2 mg/kg (max. 60 mg) once daily
» Child 12–17 years: 40–50 mg once daily for at least 5 days
» Adult: 40–50 mg once daily for at least 5 days
▶ OR Hydrocortisone p. 637 (preferably as sodium succinate)
BY INTRAVENOUS INJECTION
» Child 17 years and below: 4 mg/kg (max. 100 mg) every 6 hours until conversion to oral prednisolone is possible; alternative dose if weight unavailable:
» Child 1 year and below: 25 mg
» Child 2–4 years: 50 mg
» Child 5–17 years: 100 mg
» Adult: 100 mg every 6 hours until conversion to oral prednisolone is possible

High-flow oxygen should be given if available (via face mask in children)
Monitor response 15 to 30 minutes after nebulisation; if any signs of acute asthma persist, arrange hospital admission. While awaiting ambulance, repeat nebulised beta₂ agonist (as above) and give with
Ipratropium bromide nebuliser solution p. 239
(250 micrograms/mL)
BY INHALATION OF NEBULISED SOLUTION (VIA OXYGEN-DRIVEN NEBULISER IF AVAILABLE)
▶ Child 11 years and below: 250 micrograms, repeated every 20–30 minutes for the first 2 hours, then every 4–6 hours as necessary
▶ Child 12–17 years: 500 micrograms every 4–6 hours as necessary
▶ Adult: 500 micrograms every 4–6 hours as necessary

▶ CROUP
Dexamethasone oral solution p. 635 (2 mg/5 mL)
BY MOUTH
▶ Child 1 month–2 years: 150 micrograms/kg as a single dose

▶ ANAPHYLAXIS
Adrenaline/epinephrine injection p. 216 (1 mg/mL (1 in 1000))
BY INTRAMUSCULAR INJECTION
▶ Child 5 years and below: 150 micrograms (0.15 mL), repeated every 5 minutes if necessary
▶ Child 6–11 years: 300 micrograms (0.3 mL), repeated every 5 minutes if necessary
▶ Child 12–17 years: 500 micrograms (0.5 mL), repeated every 5 minutes if necessary; 300 micrograms (0.3 mL) should be given if child is small or prepubertal
▶ Adult: 500 micrograms (0.5 mL), repeated every 5 minutes if necessary

High-flow oxygen and intravenous fluids should be given as soon as available.

Chlorphenamine maleate injection p. 272
BY INTRAMUSCULAR OR INTRavenous INJECTION
May help counter histamine-mediated vasodilation and bronchoconstriction.

Hydrocortisone (preferably as sodium succinate)
BY INTRAVENOUS INJECTION
Has delayed action but should be given to severely affected patients to prevent further deterioration.

Bacterial infection
▶ MENINGOCOCCAL DISEASE
Benzylenicillin sodium injection p. 517 (600 mg, 1.2 g)
BY INTRAVENOUS INJECTION (OR BY INTRAMUSCULAR INJECTION IF VENOUS ACCESS NOT AVAILABLE)
▶ Neonate: 300 mg
▶ Child 1 month–11 months: 300 mg
▶ Child 1–9 years: 600 mg
▶ Child 10–17 years: 1.2 g
▶ Adult: 1.2 g

NOTE A single dose should be given before urgent transfer to hospital, so long as this does not delay the transfer.

▶ OR if history of allergy to penicillin
Cefotaxime injection p. 500 (1 g)
BY INTRAVENOUS INJECTION (OR BY INTRAMUSCULAR INJECTION IF VENOUS ACCESS NOT AVAILABLE)
▶ Neonate: 50 mg/kg
▶ Child 1 month–11 years: 50 mg/kg (max. 1 g)
▶ Child 12–17 years: 1 g
▶ Adult: 1 g

NOTE A single dose can be given before urgent transfer to hospital, so long as this does not delay the transfer.

▶ OR if history of immediate hypersensitivity reaction (including anaphylaxis, angioedema, urticaria, or rash immediately after administration) to penicillin or to cephalosporins
Chloramphenicol injection p. 537 (1 g)
BY INTRavenous INJECTION
▶ Child: 12.5–25 mg/kg
▶ Adult: 12.5–25 mg/kg

NOTE A single dose can be given before urgent transfer to hospital, so long as this does not delay the transfer.
See also Central nervous system infections, bacterial p. 485.

Seizures
▶ CONVULSIVE (INCLUDING FEBRILE) SEIZURES LASTING LONGER THAN 5 MINUTES
▶ EITHER Diazepam rectal solution p. 327 (2 mg/mL, 4 mg/mL)
BY RECTUM
▶ Neonate: 1.25–2.5 mg, repeated once after 10–15 minutes if necessary
▶ Child 1 month–1 year: 5 mg, repeated once after 10–15 minutes if necessary
▶ Child 2–11 years: 5–10 mg, repeated once after 10–15 minutes if necessary
▶ Child 12–17 years: 10–20 mg, repeated once after 10–15 minutes if necessary
▶ Adult: 10–20 mg, repeated once after 10–15 minutes if necessary
▶ Elderly: 10 mg, repeated once after 10–15 minutes if necessary

▶ OR Midazolam oromucosal solution p. 323
BY BUCCAL ADMINISTRATION, REPEATED ONCE AFTER 10 MINUTES IF NECESSARY
▶ Neonate: 300 micrograms/kg [unlicensed]
▶ Child 1–2 months: 300 micrograms/kg (max. 2.5 mg) [unlicensed]
▶ Child 3 months–11 months: 2.5 mg
▶ Child 1–4 years: 5 mg
▶ Child 5–9 years: 7.5 mg
▶ Child 10–17 years: 10 mg
▶ Adult: 10 mg [unlicensed]

Hypoglycaemia
▶ DIABETIC HYPOGLYCAEMIA
Glucose or sucrose
BY MOUTH
▶ Adult and Child over 2 years: approx. 10–20 g (55–110 mL Lucozade ® Energy Original or 100–200 mL Coca-Cola ®—both non-diet versions or 2–4 teaspoonfuls of sugar or 3–6 sugar lumps) repeated after 10–15 minutes if necessary

▶ OR if hypoglycaemia unresponsive or if oral route cannot be used
Glucagon injection p. 681 (1 mg/mL)
BY SUBCUTANEOUS OR INTRAMUSCULAR INJECTION
▶ Child body-weight up to 25 kg: 500 micrograms (0.5 mL)
▶ Child body-weight 25 kg and over: 1 mg (1 mL)
▶ Adult: 1 mg (1 mL)

▶ OR if hypoglycaemia prolonged or unresponsive to glucagon after 10 minutes
Glucose intravenous infusion p. 955 (10%)
BY INTRAVENOUS INJECTION INTO LARGE VEIN
▶ Child: 5 mL/kg (glucose 500 mg/kg)

Glucose intravenous infusion (20%)
BY INTRAVENOUS INJECTION INTO LARGE VEIN
▶ Adult: 50 mL

Downloaded from www.medicalbr.com
Approximate Conversions and Units

Conversion of pounds to kilograms

<table>
<thead>
<tr>
<th>lb</th>
<th>kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.45</td>
</tr>
<tr>
<td>2</td>
<td>0.91</td>
</tr>
<tr>
<td>3</td>
<td>1.36</td>
</tr>
<tr>
<td>4</td>
<td>1.81</td>
</tr>
<tr>
<td>5</td>
<td>2.27</td>
</tr>
<tr>
<td>6</td>
<td>2.72</td>
</tr>
<tr>
<td>7</td>
<td>3.18</td>
</tr>
<tr>
<td>8</td>
<td>3.63</td>
</tr>
<tr>
<td>9</td>
<td>4.08</td>
</tr>
<tr>
<td>10</td>
<td>4.54</td>
</tr>
<tr>
<td>11</td>
<td>4.99</td>
</tr>
<tr>
<td>12</td>
<td>5.44</td>
</tr>
<tr>
<td>13</td>
<td>5.90</td>
</tr>
<tr>
<td>14</td>
<td>6.35</td>
</tr>
</tbody>
</table>

Conversion of stones to kilograms

<table>
<thead>
<tr>
<th>stones</th>
<th>kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>6.35</td>
</tr>
<tr>
<td>2</td>
<td>12.70</td>
</tr>
<tr>
<td>3</td>
<td>19.05</td>
</tr>
<tr>
<td>4</td>
<td>25.40</td>
</tr>
<tr>
<td>5</td>
<td>31.75</td>
</tr>
<tr>
<td>6</td>
<td>38.10</td>
</tr>
<tr>
<td>7</td>
<td>44.45</td>
</tr>
<tr>
<td>8</td>
<td>50.80</td>
</tr>
<tr>
<td>9</td>
<td>57.15</td>
</tr>
<tr>
<td>10</td>
<td>63.50</td>
</tr>
<tr>
<td>11</td>
<td>69.85</td>
</tr>
<tr>
<td>12</td>
<td>76.20</td>
</tr>
<tr>
<td>13</td>
<td>82.55</td>
</tr>
<tr>
<td>14</td>
<td>88.90</td>
</tr>
<tr>
<td>15</td>
<td>95.25</td>
</tr>
</tbody>
</table>

Conversion from millilitres to fluid ounces

<table>
<thead>
<tr>
<th>mL</th>
<th>fl oz</th>
</tr>
</thead>
<tbody>
<tr>
<td>50</td>
<td>1.8</td>
</tr>
<tr>
<td>100</td>
<td>3.5</td>
</tr>
<tr>
<td>150</td>
<td>5.3</td>
</tr>
<tr>
<td>200</td>
<td>7.0</td>
</tr>
<tr>
<td>500</td>
<td>17.6</td>
</tr>
<tr>
<td>1000</td>
<td>35.2</td>
</tr>
</tbody>
</table>

Length

1 metre (m) = 1000 millimetres (mm)
1 centimetre (cm) = 10 mm
1 inch (in) = 25.4 mm
1 foot (ft) = 12 inches
12 inches = 304.8 mm

Mass

1 kilogram (kg) = 1000 grams (g)
1 gram (g) = 1000 milligrams (mg)
1 milligram (mg) = 1000 micrograms
1 microgram = 1000 nanograms
1 nanogram = 1000 picograms

Volume

1 litre = 1000 millilitres (mL)
1 millilitre (1 mL) = 1000 microlitres
1 pint = 568 mL

Other units

1 kilocalorie (kcal) = 4186.8 joules (J)
1000 kilocalories (kcal) = 4.1868 megajoules (MJ)
1 megajoule (MJ) = 238.8 kilocalories (kcal)
1 millimetre of mercury (mmHg) = 133.3 pascals (Pa)
1 kilopascal (kPa) = 7.5 mmHg (pressure)

Plasma-drug concentrations

Plasma-drug concentrations in BNF publications are expressed in mass units per litre (e.g. mg/litre). The approximate equivalent in terms of amount of substance units (e.g. micromol/litre) is given in brackets.

Prescribing for children: weight, height, and gender

The table below shows the mean values for weight, height, and gender by age; these values have been derived from the UK-WHO growth charts 2009 and UK1990 standard centile charts, by extrapolating the 50th centile, and may be used to calculate doses in the absence of measurements. However, an individual’s weight and height might vary considerably from the values in the table and it is important to ensure that the value chosen is appropriate. In most cases the actual measurement should be obtained as soon as possible and the dose re-calculated.

<table>
<thead>
<tr>
<th>Age</th>
<th>Weight (kg)</th>
<th>Height (cm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full-term neonate</td>
<td>3.5</td>
<td>51</td>
</tr>
<tr>
<td>1 month</td>
<td>4.3</td>
<td>55</td>
</tr>
<tr>
<td>2 months</td>
<td>5.4</td>
<td>58</td>
</tr>
<tr>
<td>3 months</td>
<td>6.1</td>
<td>61</td>
</tr>
<tr>
<td>4 months</td>
<td>6.7</td>
<td>63</td>
</tr>
<tr>
<td>6 months</td>
<td>7.6</td>
<td>67</td>
</tr>
<tr>
<td>1 year</td>
<td>9</td>
<td>75</td>
</tr>
<tr>
<td>3 years</td>
<td>14</td>
<td>96</td>
</tr>
<tr>
<td>5 years</td>
<td>18</td>
<td>109</td>
</tr>
<tr>
<td>7 years</td>
<td>23</td>
<td>122</td>
</tr>
<tr>
<td>10 years</td>
<td>32</td>
<td>138</td>
</tr>
<tr>
<td>12 years</td>
<td>39</td>
<td>149</td>
</tr>
<tr>
<td>14 year old boy</td>
<td>49</td>
<td>163</td>
</tr>
<tr>
<td>14 year old girl</td>
<td>54</td>
<td>159</td>
</tr>
<tr>
<td>Adult male</td>
<td>68</td>
<td>176</td>
</tr>
<tr>
<td>Adult female</td>
<td>58</td>
<td>164</td>
</tr>
</tbody>
</table>
Recommended wording of cautionary and advisory labels

For details including Welsh Language translation see p. 1454

1. Warning: This medicine may make you sleepy
2. Warning: This medicine may make you sleepy. If this happens, do not drive or use tools or machines. Do not drink alcohol
3. Warning: This medicine may make you sleepy. If this happens, do not drive or use tools or machines
4. Warning: Do not drink alcohol
5. Do not take indigestion remedies 2 hours before or after you take this medicine
6. Do not take indigestion remedies, or medicines containing iron or zinc, 2 hours before or after you take this medicine
7. Do not take milk, indigestion remedies, or medicines containing iron or zinc, 2 hours before or after you take this medicine
8. Warning: Do not stop taking this medicine unless your doctor tells you to stop
9. Space the doses evenly throughout the day. Keep taking this medicine until the course is finished, unless you are told to stop
10. Warning: Read the additional information given with this medicine
11. Protect your skin from sunlight—even on a bright but cloudy day. Do not use sunbeds
12. Do not take anything containing aspirin while taking this medicine
13. Dissolve or mix with water before taking
14. This medicine may colour your urine. This is harmless
15. Caution: flammable. Keep your body away from fire or flames after you have put on the medicine
16. Dissolve the tablet under your tongue—do not swallow. Store the tablets in this bottle with the cap tightly closed. Get a new supply 8 weeks after opening
17. Do not take more than... in 24 hours
18. Do not take more than... in 24 hours. Also, do not take more than... in any one week
19. Warning: This medicine makes you sleepy. If you still feel sleepy the next day, do not drive or use tools or machines. Do not drink alcohol
20. Take with or just after food, or a meal
21. Take 30 to 60 minutes before food
22. Take this medicine when your stomach is empty. This means an hour before food or 2 hours after food
23. Suck or chew this medicine
24. Swallow this medicine whole. Do not chew or crush
25. Dissolve this medicine under your tongue
26. Take with a full glass of water
27. Spread thinly on the affected skin only
28. Do not take more than 2 at any one time. Do not take more than 8 in 24 hours
29. Contains paracetamol. Do not take anything else containing paracetamol while taking this medicine. Talk to a doctor at once if you take too much of this medicine, even if you feel well
30. Contains aspirin. Do not take anything else containing aspirin while taking this medicine
### Abbreviations and Symbols

Internationally recognised units and symbols are used in the BNF publications where possible.

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACBS</td>
<td>Advisory Committee on Borderline Substances, see Borderline Substances</td>
</tr>
<tr>
<td>ACE</td>
<td>Angiotensin-converting enzyme</td>
</tr>
<tr>
<td>ADHD</td>
<td>Attention deficit hyperactivity disorder</td>
</tr>
<tr>
<td>AIDS</td>
<td>Acquired immunodeficiency syndrome</td>
</tr>
<tr>
<td>approx.</td>
<td>approximately</td>
</tr>
<tr>
<td>AV</td>
<td>atrioventricular</td>
</tr>
<tr>
<td>AWMSG</td>
<td>All Wales Medicines Strategy Group</td>
</tr>
<tr>
<td>BAN</td>
<td>British Approved Name</td>
</tr>
<tr>
<td>BMI</td>
<td>body mass index</td>
</tr>
<tr>
<td>BP</td>
<td>British Pharmacopoeia 2013, unless otherwise stated</td>
</tr>
<tr>
<td>BPC</td>
<td>British Pharmaceutical Codex 1973 and Supplement 1976, unless otherwise stated</td>
</tr>
<tr>
<td>BRCA</td>
<td>breast cancer gene</td>
</tr>
<tr>
<td>CD</td>
<td>preparation in Schedule 1 of the Misuse of Drugs Regulations 2001 (and subsequent amendments). For regulations see Controlled drugs and drug dependence p. 8.</td>
</tr>
<tr>
<td>CDPD</td>
<td>Continuous ambulatory peritoneal dialysis</td>
</tr>
<tr>
<td>CHM</td>
<td>Commission on Human Medicines</td>
</tr>
<tr>
<td>CHMP</td>
<td>Committee for Medicinal Products for Human Use</td>
</tr>
<tr>
<td>CNS</td>
<td>central nervous system</td>
</tr>
<tr>
<td>CSM</td>
<td>Committee on Safety of Medicines (now subsumed under Commission on Human Medicines)</td>
</tr>
<tr>
<td>d. c.</td>
<td>direct current</td>
</tr>
<tr>
<td>DMARD</td>
<td>Disease-modifying antirheumatic drug</td>
</tr>
<tr>
<td>DPF</td>
<td>Dental Practitioners’ Formulary</td>
</tr>
<tr>
<td>e/c</td>
<td>enteric-coated (term gastro-resistant in BP)</td>
</tr>
<tr>
<td>ECG</td>
<td>electrocardiogram</td>
</tr>
<tr>
<td>EEG</td>
<td>electro-encephalogram</td>
</tr>
<tr>
<td>eGFR</td>
<td>estimated glomerular filtration rate, see Prescribing in renal impairment p. 19</td>
</tr>
<tr>
<td>f/c</td>
<td>film-coated</td>
</tr>
<tr>
<td>G6PD</td>
<td>glucose 6-phosphate dehydrogenase</td>
</tr>
<tr>
<td>HIV</td>
<td>Human immunodeficiency virus</td>
</tr>
<tr>
<td>HRT</td>
<td>Hormone replacement therapy</td>
</tr>
<tr>
<td>i/m</td>
<td>intramuscular</td>
</tr>
<tr>
<td>i/v</td>
<td>intravenous</td>
</tr>
<tr>
<td>INR</td>
<td>international normalised ratio</td>
</tr>
<tr>
<td>MAOI</td>
<td>Monoamine-oxidase inhibitor</td>
</tr>
<tr>
<td>max.</td>
<td>maximum</td>
</tr>
<tr>
<td>MHRA</td>
<td>Medicines and Healthcare products Regulatory Agency</td>
</tr>
<tr>
<td>m/r</td>
<td>modified-release</td>
</tr>
<tr>
<td>NCL</td>
<td>no cautionary labels (prescription endorsement made by prescriber when recommended cautionary labels are not required)</td>
</tr>
<tr>
<td>NHS</td>
<td>National Health Service</td>
</tr>
<tr>
<td>NICE</td>
<td>National Institute for Health and Care Excellence</td>
</tr>
<tr>
<td>NPF</td>
<td>Nurse Prescribers’ Formulary</td>
</tr>
<tr>
<td>NSAID</td>
<td>Non-steroidal anti-inflammatory drug</td>
</tr>
<tr>
<td>NSTEMI</td>
<td>non-ST-segment elevation myocardial infarction</td>
</tr>
<tr>
<td>PARP</td>
<td>poly (ADP-ribose) polymerase</td>
</tr>
<tr>
<td>PGD</td>
<td>patient group direction</td>
</tr>
<tr>
<td>PHE</td>
<td>Public Health England (formerly Health Protection Agency (HPA))</td>
</tr>
<tr>
<td>PoM</td>
<td>prescription-only medicine, see Fig. 1 How to use BNF publications</td>
</tr>
<tr>
<td>C</td>
<td>trade mark</td>
</tr>
<tr>
<td>rINN</td>
<td>Recommended International Non-Proprietary Name</td>
</tr>
<tr>
<td>RSV</td>
<td>respiratory syncytial virus</td>
</tr>
<tr>
<td>s/c</td>
<td>sugar-coated</td>
</tr>
<tr>
<td>SLS</td>
<td>Selected List Scheme</td>
</tr>
<tr>
<td>SMC</td>
<td>Scottish Medicines Consortium</td>
</tr>
<tr>
<td>SPC</td>
<td>Summary of Product Characteristics</td>
</tr>
<tr>
<td>spp.</td>
<td>species</td>
</tr>
<tr>
<td>SSRI</td>
<td>Selective serotonin reuptake inhibitor</td>
</tr>
<tr>
<td>STEMI</td>
<td>ST-segment elevation myocardial infarction</td>
</tr>
<tr>
<td>UK</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Units</td>
<td>for SI units see Prescription writing p. 5</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>

Limited experience of the use of this product and the MHRA requests that all suspected adverse reactions should be reported, see Adverse reactions to drugs p. 12 general sales list pharmacy only medicine drug-class monograph, see How to use BNF Publications, p. xii precedes evidence graded content, see How BNF Publications are constructed p. ix

Symbols will be displayed - grades reflect the strengths of recommendations in evidence graded content, see How BNF Publications are constructed p. ix

### Latin abbreviations

Directions should be in English without abbreviation. However, Latin abbreviations have been used when prescribing.

The following is a list of appropriate abbreviations. It should be noted that the English version is not always an exact translation.

- a. c. = ante cibum (before food)
- b. d. = bis die (twice daily)
- d. v. = omni nocte (every night)
- d. m. = omni die (every day)
- xii
- i. m. = omni mane (every morning)
- q. d. s. = quarta die sumendum (to be taken four times daily)
- q. c. = post cibum (after food)
- p. r. = pro re nata (when required)
- q. d. s. = quarta quaque hora (every four hours)
- stat = immediately
- t. d. s. = ter die sumendum (to be taken three times daily)
- t. i. d. = ter in die (three times daily)

### E numbers

The following is a list of common E numbers and the inactive ingredients to which they correspond.

<table>
<thead>
<tr>
<th>E number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>E102</td>
<td>Tartrazine</td>
</tr>
<tr>
<td>E211</td>
<td>Sodium Benzoate</td>
</tr>
<tr>
<td>E104</td>
<td>Quinoline Yellow</td>
</tr>
<tr>
<td>E223</td>
<td>Sodium Metabisulfite</td>
</tr>
<tr>
<td>E110</td>
<td>Sunset Yellow FCF</td>
</tr>
<tr>
<td>E320</td>
<td>Butylated Hydroxyanisole</td>
</tr>
<tr>
<td>E123</td>
<td>Amaranth</td>
</tr>
<tr>
<td>E321</td>
<td>Butylated Hydroxytoluene</td>
</tr>
<tr>
<td>E124</td>
<td>Ponceau 4R</td>
</tr>
<tr>
<td>E322</td>
<td>Leichthins</td>
</tr>
<tr>
<td>E127</td>
<td>Erythrosine BS</td>
</tr>
<tr>
<td>E420</td>
<td>Sorbitol</td>
</tr>
<tr>
<td>E132</td>
<td>Indigo Carmine</td>
</tr>
<tr>
<td>E421</td>
<td>Mannitol</td>
</tr>
<tr>
<td>E142</td>
<td>Green S</td>
</tr>
<tr>
<td>E422</td>
<td>Glycerol</td>
</tr>
<tr>
<td>E171</td>
<td>Titanium Dioxide</td>
</tr>
<tr>
<td>E901</td>
<td>Beeswax (white and yellow)</td>
</tr>
<tr>
<td>E172</td>
<td>Iron oxides, iron hydroxides</td>
</tr>
<tr>
<td>E1520</td>
<td>Propylene Glycol</td>
</tr>
<tr>
<td>E200</td>
<td>Sorbic Acid</td>
</tr>
</tbody>
</table>